NCT_ID|DOWNLOAD_DATE|DOWNLOAD_DATE_DT|ORG_STUDY_ID|BRIEF_TITLE|OFFICIAL_TITLE|ACRONYM|SOURCE|HAS_DMC|OVERALL_STATUS|START_DATE|COMPLETION_DATE|COMPLETION_DATE_TYPE|PRIMARY_COMPLETION_DATE|PRIMARY_COMPLETION_DATE_TYPE|PHASE|STUDY_TYPE|STUDY_DESIGN|NUMBER_OF_ARMS|NUMBER_OF_GROUPS|ENROLLMENT_TYPE|ENROLLMENT|BIOSPEC_RETENTION|BIOSPEC_DESCR|GENDER|MINIMUM_AGE|MAXIMUM_AGE|HEALTHY_VOLUNTEERS|SAMPLING_METHOD|STUDY_POP|VERIFICATION_DATE|LASTCHANGED_DATE|FIRSTRECEIVED_DATE|IS_SECTION_801|IS_FDA_REGULATED|WHY_STOPPED|HAS_EXPANDED_ACCESS|FIRSTRECEIVED_RESULTS_DATE|URL|TARGET_DURATION|STUDY_RANK|LIMITATIONS_AND_CAVEATS
NCT00000105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002LS032|Vaccination With Tetanus and KLH to Assess Immune Responses.|Vaccination With Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses||Masonic Cancer Center, University of Minnesota|Yes|Terminated|July 2002|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|112|Samples With DNA|analysis of blood samples before and 4 weeks postvaccination|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|-  Normal volunteers          -  Patients with Cancer (breast, melanoma, hematologic)          -  Transplant patients (umbilical cord blood transplant, autologous transplant)          -  Patients receiving other cancer vaccines|November 2012|November 6, 2012|November 3, 1999|Yes|Yes|Replaced by another study.|No||https://clinicaltrials.gov/show/NCT00000105||211435|
NCT00000106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR03186-9943|41.8 Degree Centigrade Whole Body Hyperthermia for the Treatment of Rheumatoid Diseases|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||November 2000|June 23, 2005|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000106||211434|
NCT00000107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0737|Body Water Content in Cyanotic Congenital Heart Disease|||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Case Control|||||||Both|17 Years|60 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000107||211433|
NCT00000108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1647|Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||||||Female|50 Years|65 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000108||211432|
NCT00000102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR01070-0506|Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets|||National Center for Research Resources (NCRR)||Completed||||||Phase 1/Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|14 Years|35 Years|No|||January 2004|June 23, 2005|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000102||211437|
NCT00000104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00400-0587|Does Lead Burden Alter Neuropsychological Development?|||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2003|June 23, 2005|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000104||211436|
NCT00000117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-13|Intravenous Immunoglobulin Therapy in Optic Neuritis|||National Eye Institute (NEI)||Completed|August 1995|December 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|50 Years||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000117||211424|
NCT00000118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-14|Ganciclovir Implant Study for Cytomegalovirus Retinitis|||National Eye Institute (NEI)||Completed|October 1992|December 1993|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|N/A|N/A||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000118||211423|
NCT00000119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-15|Safety and Efficacy of a Heparin-Coated Intraocular Lens in Uveitis|||National Eye Institute (NEI)||Active, not recruiting|March 1994|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||September 1999|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000119||211422|
NCT00000120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-19|Clinical Trial of Eye Prophylaxis in the Newborn|||National Eye Institute (NEI)||Completed|January 1985|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|1 Year||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000120||211421|
NCT00000132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-31|Early Manifest Glaucoma Trial (EMGT)|||National Eye Institute (NEI)||Active, not recruiting|October 1992|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|50 Years|80 Years||||October 2001|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000132||211409|
NCT00000133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-32|Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity|||National Eye Institute (NEI)||Completed|January 1986|August 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study|||||||Both|N/A|1 Year|No|||October 2003|February 3, 2014|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000133||211408|
NCT00000115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-11|Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema|||National Eye Institute (NEI)||Completed|December 1990|June 1994|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|8 Years|N/A||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000115||211426|
NCT00000110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00032-0855|Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000110||211431|
NCT00000111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1620|Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2000|June 23, 2005|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000111||211430|
NCT00000112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR06022-0029|Prevalence of Carbohydrate Intolerance in Lean and Obese Children|||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|8 Years|18 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000112||211429|
NCT00000113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-9|Correction of Myopia Evaluation Trial (COMET)|Correction of Myopia Evaluation Trial (COMET)||National Eye Institute (NEI)||Completed|September 1997|September 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|6 Years|12 Years|No|||September 2009|March 23, 2010|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000113||211428|
NCT00000114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-10|Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa|||National Eye Institute (NEI)||Completed|May 1984|June 1987|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|49 Years||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000114||211427|
NCT00000116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-12|Randomized Trial for Retinitis Pigmentosa|Randomized Trial for Retinitis Pigmentosa||National Eye Institute (NEI)||Completed|May 1996|September 1997||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|56 Years||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000116||211425|
NCT00000130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-29|Endophthalmitis Vitrectomy Study (EVS)|||National Eye Institute (NEI)||Completed|February 1990|January 1995|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000130||211411|
NCT00000131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-30|Central Vein Occlusion Study (CVOS)|||National Eye Institute (NEI)||Completed|August 1988|February 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000131||211410|
NCT00000149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-50|Collaborative Initial Glaucoma Treatment Study (CIGTS)|||National Eye Institute (NEI)||Active, not recruiting|October 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|25 Years|75 Years|No|||June 2002|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000149||211394|
NCT00000135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-34|Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)|Monoclonal Antibody CMV Retinitis Trial (MACRT)|MACRT|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|September 1995|August 1996|Actual|August 1996|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|209|||Both|13 Years|N/A|No|||July 2015|October 14, 2015|September 23, 1999|No|Yes||No|June 12, 2015|https://clinicaltrials.gov/show/NCT00000135||211406|
NCT00000134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-33|Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)|Cytomegalovirus Retinitis Retreatment Trial|CRRT|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|December 1992|March 1995|Actual|March 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|279|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|September 23, 1999|Yes|Yes||No|June 15, 2015|https://clinicaltrials.gov/show/NCT00000134||211407|
NCT00000121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-20|The Prism Adaptation Study (PAS)|||National Eye Institute (NEI)||Completed|March 1984|May 1989|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|3 Years|N/A||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000121||211420|
NCT00000122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-21|Fluorouracil Filtering Surgery Study (FFSS)|||National Eye Institute (NEI)||Completed|September 1985|June 1988|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000122||211419|
NCT00000123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-22|The Berkeley Orthokeratology Study|||National Eye Institute (NEI)||Completed|January 1978|February 1979|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|35 Years||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000123||211418|
NCT00000124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-23|Collaborative Ocular Melanoma Study (COMS)|||National Eye Institute (NEI)||Active, not recruiting|November 1986|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||June 2002|June 1, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000124||211417|
NCT00000125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-24|Ocular Hypertension Treatment Study (OHTS)|Ocular Hypertension Treatment Study (OHTS)|OHTS|Washington University School of Medicine|Yes|Completed|February 1994|March 2009|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1636|||Both|40 Years|80 Years|No|||April 2015|April 17, 2015|September 23, 1999||No||No|March 6, 2015|https://clinicaltrials.gov/show/NCT00000125||211416|
NCT00000126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-25|Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)|||National Eye Institute (NEI)||Active, not recruiting|October 1994|||||N/A|Observational|Time Perspective: Longitudinal|||||||Both|50 Years|N/A|No|||October 2003|May 25, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000126||211415|
NCT00000127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-26|Ischemic Optic Neuropathy Decompression Trial (IONDT)|||National Eye Institute (NEI)||Completed|October 1992|October 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||September 2009|March 23, 2010|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000127||211414|
NCT00000128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-27|A Trial of Bifocals in Myopic Children With Esophoria|||National Eye Institute (NEI)||Active, not recruiting|June 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|6 Years|12 Years||||June 2002|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000128||211413|
NCT00000129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-28|Prospective Evaluation of Radial Keratotomy (PERK) Study|||National Eye Institute (NEI)||Completed|April 1981|October 1983|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000129||211412|
NCT00000162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-64|Branch Vein Occlusion Study|||National Eye Institute (NEI)||Completed|July 1977|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 1999|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000162||211381|
NCT00000150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-52|Submacular Surgery Trials (SST)|Submacular Surgery Trials (SST)||National Eye Institute (NEI)||Completed|January 1999|September 2001||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000150||211393|
NCT00000173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0011|Memory Impairment Study (Mild Cognitive Impairment Study)|A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)||National Institute on Aging (NIA)||Completed|March 1999|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|55 Years|90 Years|No|||June 2009|December 10, 2009|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000173||211373|
NCT00000174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0012|Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)|||National Institute on Aging (NIA)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|55 Years|85 Years|No|||January 2000|December 8, 2005|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000174||211372|
NCT00000136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-35|Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)|Foscarnet-Ganciclovir CMV Retinitis Trial|FGCRT|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|March 1990|October 1991|Actual|October 1991|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|234|||Both|13 Years|N/A|No|||July 2015|September 22, 2015|September 23, 1999||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT00000136||211405|
NCT00000137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-36|Collaborative Corneal Transplantation Studies (CCTS)|||National Eye Institute (NEI)||Completed|May 1986|September 1989|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|10 Years|N/A||||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000137||211404|
NCT00000138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-37|Herpetic Eye Disease Study (HEDS) I|||National Eye Institute (NEI)||Active, not recruiting|May 1989|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000138||211403|
NCT00000139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-38|Herpetic Eye Disease Study (HEDS) II|||National Eye Institute (NEI)||Completed|October 1992|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|March 23, 2010|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000139||211402|
NCT00000140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-39|The Silicone Study|||National Eye Institute (NEI)||Completed|September 1985|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 1999|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000140||211401|
NCT00000142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-41|Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)|Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)|HPCRT|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|April 1994|February 1996|Actual|February 1996|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|13 Years|N/A|No|||July 2015|October 14, 2015|September 23, 1999||No||No|June 2, 2015|https://clinicaltrials.gov/show/NCT00000142||211400|
NCT00000143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-42|Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)|Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)|GCCRT|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|May 1997|June 2000|Actual|June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|13 Years|N/A|No|||July 2015|February 18, 2016|September 23, 1999||No||No|July 1, 2015|https://clinicaltrials.gov/show/NCT00000143||211399|
NCT00000144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-43|Glaucoma Laser Trial (GLT) Glaucoma Laser Trial Followup Study (GLTFS)|||National Eye Institute (NEI)||Completed|January 1984|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|35 Years|N/A|No|||October 2003|June 2, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000144||211398|
NCT00000146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-47|Optic Neuritis Treatment Trial (ONTT)|||National Eye Institute (NEI)||Active, not recruiting|July 1988|||||Phase 3|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|46 Years|No|||October 2003|June 2, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000146||211397|
NCT00000147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-48|Longitudinal Optic Neuritis Study (LONS)|||National Eye Institute (NEI)||Active, not recruiting|July 1988|||||N/A|Interventional|Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|46 Years|No|||October 1999|May 26, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000147||211396|
NCT00000148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-49|Advanced Glaucoma Intervention Study (AGIS)|||National Eye Institute (NEI)||Active, not recruiting|April 1988|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|35 Years|80 Years|No|||October 2003|June 2, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000148||211395|
NCT00000159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-61|Sorbinil Retinopathy Trial (SRT)|||National Eye Institute (NEI)||Completed|August 1983|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|56 Years|No|||October 1999|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000159||211384|
NCT00000160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-62|Diabetic Retinopathy Study (DRS)|||National Eye Institute (NEI)||Completed|January 1972|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||October 2003|June 1, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000160||211383|
NCT00000161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-63|Randomized Trials of Vitamin Supplements and Eye Disease|||National Eye Institute (NEI)||Active, not recruiting|August 1993|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|45 Years|N/A|Accepts Healthy Volunteers|||September 2001|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000161||211382|
NCT00000163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-65|Congenital Esotropia Observational Study (CEOS)|||National Eye Institute (NEI)||Completed|December 1997|July 2000||||N/A|Observational|N/A|||||||Both|N/A|20 Weeks|No|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000163||211380|
NCT00000167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-70|Complications of Age-Related Macular Degeneration Prevention Trial|Complications of Age-Related Macular Degeneration Prevention Trial (CAPT)|CAPT|National Eye Institute (NEI)|Yes|Completed|May 1999|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|1052|||Both|50 Years|N/A|No|||December 2007|March 23, 2010|September 23, 1999||No||No||https://clinicaltrials.gov/show/NCT00000167||211379|
NCT00000212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06234-1|IV Cocaine Abuse: A Laboratory Model - 1|IV Cocaine Abuse: A Laboratory Model||New York State Psychiatric Institute||Completed|July 1987|July 1988|Actual|July 1988|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|45 Years|No|||December 2012|August 27, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000212||211340|
NCT00000213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06234-2|IV Cocaine Abuse: A Laboratory Model - 2|IV Cocaine Abuse: A Laboratory Model||New York State Psychiatric Institute||Completed|April 1990|April 1991|Actual|April 1991|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|45 Years|No|||December 2012|August 27, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000213||211339|
NCT00000151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-53|Early Treatment Diabetic Retinopathy Study (ETDRS)|||National Eye Institute (NEI)||Completed|December 1979|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||October 2003|September 1, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000151||211392|
NCT00000152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-54|Randomized Trial of Beta-Carotene and Macular Degeneration|||National Eye Institute (NEI)||Active, not recruiting|April 1982|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Male|40 Years|84 Years|Accepts Healthy Volunteers|||September 2001|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000152||211391|
NCT00000153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-55|Krypton-Argon Regression of Neovascularization Study (KARNS)|||National Eye Institute (NEI)||Completed|December 1984|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|79 Years|No|||October 1999|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000153||211390|
NCT00000154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-56|Diabetic Retinopathy Vitrectomy Study (DRVS)|||National Eye Institute (NEI)||Completed|October 1976|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||October 1999|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000154||211389|
NCT00000155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-57|The Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study|||National Eye Institute (NEI)||Active, not recruiting|June 1995|||||N/A|Observational|Time Perspective: Prospective|||||||Both|12 Years|N/A|No|||November 2001|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000155||211388|
NCT00000156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-58|The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)|||National Eye Institute (NEI)||Completed|July 1995|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|1 Day||||October 2003|June 2, 2006|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000156||211387|
NCT00000157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-59|Randomized Trial of Aspirin and Cataracts in U.S. Physicians|||National Eye Institute (NEI)||Terminated|April 1982|January 1988|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Male|40 Years|84 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000157||211386|
NCT00000158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-60|Macular Photocoagulation Study (MPS)|||National Eye Institute (NEI)||Active, not recruiting|February 1979|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000158||211385|
NCT00000214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06234-3|IV Cocaine Abuse: A Laboratory Model - 3|IV Cocaine Abuse: A Laboratory Model||New York State Psychiatric Institute||Completed|January 1992|January 1993|Actual|January 1993|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|45 Years|No|||December 2012|August 27, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000214||211338|
NCT00000215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06234-4|IV Cocaine Abuse: A Laboratory Model - 4|IV Cocaine Abuse: A Laboratory Model||National Institute on Drug Abuse (NIDA)||Completed||December 2001||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|45 Years|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000215||211337|
NCT00000216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06266-1|Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1|Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000216||211336|
NCT00000175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0016|The Effects of Sex Hormones on Cognition and Mood in Older Adults|||National Institute on Aging (NIA)||Terminated||June 2005|Anticipated|June 2005|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|65 Years|90 Years|Accepts Healthy Volunteers|||March 2004|December 10, 2009|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000175||211371|
NCT00000176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0018|Alzheimer's Disease Prevention Trial|Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.||National Institute on Aging (NIA)||Completed||September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|65 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 3, 2010|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000176||211370|
NCT00000244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08067-1|Effects of Dynorphin 1-13 on Heroin Addiction - 1|Effects of Dynorphin 1-13 on Heroin Addiction||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|August 1994|March 1997|Actual|March 1997|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|55 Years|No|||May 2015|May 26, 2015|September 20, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000244||211308|
NCT00000245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08082-1|Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1|Evaluation of a Desipramine Ceiling in Cocaine Abuse||National Institute on Drug Abuse (NIDA)||Completed|May 1994|December 2001||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||May 1994|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000245||211307|
NCT00000246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08265-1|Rapid Benzodiazepine Detoxification Using Flumazenil - 1|Rapid Benzodiazepine Detoxification Using Flumazenil||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000246||211306|
NCT00000248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08355-1|Dose Response Trial of Pergolide for Cocaine Dependence - 1|Dose Response Trial of Pergolide for Cocaine Dependence||Medical University of South Carolina||Completed|February 1996|||||Phase 3|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||May 1997|September 11, 2012|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000248||211305|
NCT00000249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-1|Effects of Subanesthetic Concentrations of Nitrous Oxide - 1|Effects of Subanesthetic Concentrations of Nitrous Oxide||University of Chicago||Completed|September 1993|June 1995|Actual|June 1995|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|10|||Both|21 Years|37 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000249||211304|
NCT00000168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-71|Longitudinal Study of Ocular Complications of AIDS (LSOCA)|Studies of Ocular Complications of AIDS (SOCA)|LSOCA|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|August 1998|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2392|Samples With DNA|Laboratory studies will include hematology serum chemistry and lymphocyte subset analysis      for all patients. The amount of blood for hematology, serum chemistry, and lymphocyte subset      analysis is restricted to no more than a total of 17 mL per draw. Data existing on HIV viral      load analysis at the clinic will be collected. If HIV data are not available from medical      records within the visit time window, blood should be collected for local HIV viral load      determination.|Both|13 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of AIDS according to the 1993 CDC diagnostic criteria for AIDS        and diagnosed on or after 01 January 2001 will be eligible for enrollment.|June 2015|June 10, 2015|September 23, 1999||No||No||https://clinicaltrials.gov/show/NCT00000168||211378|
NCT00000169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-72|The Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study|||National Eye Institute (NEI)||Recruiting|April 1999|||||N/A|Observational|N/A|||||||Both|6 Years|14 Years|Accepts Healthy Volunteers|||June 2001|June 23, 2005|September 23, 1999||||No||https://clinicaltrials.gov/show/NCT00000169||211377|
NCT00000170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-73|Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia|Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia||Jaeb Center for Health Research|Yes|Completed|April 1999|August 2013|Actual|November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|419|||Both|N/A|6 Years|No|||March 2014|March 5, 2014|September 23, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000170||211376|
NCT00000171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0006|Study of Melatonin: Sleep Problems in Alzheimer's Disease|||National Institute on Aging (NIA)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|55 Years|N/A|No|||March 2005|June 23, 2005|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000171||211375|
NCT00000172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0009|Evaluation of Galantamine in the Treatment of Alzheimer's Disease|Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration Regimen||National Institute on Aging (NIA)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2002|June 23, 2005|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000172||211374|
NCT00000177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0001|Estrogen Hormone Protocol|||National Institute on Aging (NIA)||Completed|October 1995|January 1999|Actual|January 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Female|60 Years|N/A|No|||September 2009|December 10, 2009|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000177||211369|
NCT00000178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0002|Multicenter Trial of Prednisone in Alzheimer's Disease|Multicenter Trial of Prednisone in Alzheimer's Disease||National Institute on Aging (NIA)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||February 2005|June 23, 2005|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000178||211368|
NCT00000208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06082-4|Methadone/Buprenorphine Cross-Over Study - 4|Methadone/Buprenorphine Cross-Over Study||National Institute on Drug Abuse (NIDA)||Completed|February 1992|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||September 1993|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000208||211344|
NCT00000209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06082-5|Buprenorphine Dosing Interval - 5|Buprenorphine Dosing Interval||National Institute on Drug Abuse (NIDA)||Completed|November 1992|||||Phase 2|Interventional|Masking: Single Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||September 1994|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000209||211343|
NCT00000210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06116-1|Treatment Efficacy for Drug Abuse and AIDS Prevention - 1|Treatment Efficacy for Drug Abuse and AIDS Prevention||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Male|26 Years|41 Years|No|||December 2002|June 2, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000210||211342|
NCT00000211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06116-2|Treatment Efficacy for Drug Abuse and AIDS Prevention - 2|Treatment Efficacy for Drug Abuse and AIDS Prevention||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Male|26 Years|41 Years|No|||December 2002|June 2, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000211||211341|
NCT00000253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-5|Effects of Nitrous Oxide: A Dose-Response Analysis - 5|Effects of Nitrous Oxide: A Dose-Response Analysis||University of Chicago||Completed|November 1994|March 1996|Actual|March 1996|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|16|||Both|21 Years|37 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000253||211300|
NCT00000217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06954-1|Pharmacotherapy and Intensive Treatment of Drug Abuse - 1|Pharmacotherapy and Intensive Treatment of Drug Abuse||University of Kansas Medical Center||Completed|September 1990|||October 1996|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||April 2015|April 15, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000217||211335|
NCT00000218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06954-2|Pharmacotherapy and Intensive Treatment - 2|Pharmacotherapy and Intensive Treatment||National Institute on Drug Abuse (NIDA)||Completed||June 2005|Actual|||Phase 4|Interventional|Primary Purpose: Treatment||||353|||Female|18 Years|60 Years|No|||March 2009|March 23, 2009|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000218||211334|
NCT00000219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-1|Buprenorphine Dose Alteration Study - 1|Buprenorphine Dose Alteration Study||National Institute on Drug Abuse (NIDA)||Completed|December 1991|July 2001||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Male|19 Years|41 Years|No|||April 1992|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000219||211333|
NCT00000220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-2|Gradual Vs. Rapid Buprenorphine Detoxification - 2|Gradual Vs. Rapid Buprenorphine Detoxification||National Institute on Drug Abuse (NIDA)||Completed|June 1991|July 2001||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|33 Years|43 Years|No|||September 1991|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000220||211332|
NCT00000179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0003|Agitation in Alzheimer's Disease|||National Institute on Aging (NIA)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||March 2005|June 23, 2005|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000179||211367|
NCT00000180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0008|AIT-082 Phase 1B Study|||National Institute on Aging (NIA)||Completed||June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2005|December 10, 2009|October 29, 1999||||No||https://clinicaltrials.gov/show/NCT00000180||211366|
NCT00000187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00144-1|Ritanserin in Treatment of Cocaine Dependence - 1|Ritanserin in Treatment of Cocaine Dependence||University of Pennsylvania||Completed|July 1992|||June 1994|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|80|||Male|28 Years|47 Years|No|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000187||211365|
NCT00000188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00144-2|Selegiline in Treatment of Cocaine Dependence - 2|Selegiline in Treatment of Cocaine Dependence||University of Pennsylvania||Completed|September 1994|October 1995|Actual|October 1995|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000188||211364|
NCT00000189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00144-3|Gepirone vs Placebo in Treatment of Cocaine Dependence - 3|Gepirone vs Placebo in Treatment of Cocaine Dependence||University of Pennsylvania||Completed|January 1990|February 1991|Actual|February 1991|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|41|||Male|N/A|N/A|No|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000189||211363|
NCT00000190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00144-4|Cocaine in Parotid Saliva, Blood and Urine - 4|Cocaine in Parotid Saliva, Blood and Urine||University of Pennsylvania||Completed|January 1991|February 1992|Actual|February 1992|Actual|Phase 1|Interventional|Primary Purpose: Diagnostic||||0|||Male|N/A|N/A|No|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000190||211362|
NCT00000191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00144-5|Carbamazepine Treatment for Cocaine Dependence - 5|Carbamazepine Treatment for Cocaine Dependence||University of Pennsylvania||Completed|January 1991|February 1994|Actual|February 1994|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|51 Years|No|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000191||211361|
NCT00000192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00191-1|Neurobiology of Opioid Dependence: 1 - 1|Neurobiology of Opioid Dependence: 1||Yale University||Withdrawn|January 1993|January 1998|Actual|January 1998|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||August 2015|August 5, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000192||211360|
NCT00000193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00191-2|Neurobiology of Opioid Dependence: 2 - 2|Neurobiology of Opioid Dependence: 2||Yale University||Withdrawn|January 1993|January 1998|Actual|January 1998|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Male|N/A|N/A|No|||August 2015|August 5, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000193||211359|
NCT00000194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00191-3|Neurobiology of Opioid Dependence: 3 - 3|Neurobiology of Opioid Dependence: 3||Yale University||Withdrawn|January 1993|January 1998|Actual|January 1998|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Male|N/A|N/A|No|||August 2015|August 5, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000194||211358|
NCT00000195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00191-4|Neurobiology of Opioid Dependence: 4 - 4|Neurobiology of Opioid Dependence: 4||Yale University||Withdrawn|January 1993|January 1998|Actual|January 1998|Actual|Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||August 2015|August 5, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000195||211357|
NCT00000196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00191-5|Neurobiology of Opioid Dependence: 5 - 5|Neurobiology of Opioid Dependence: 5||Yale University||Withdrawn|January 1993|January 1998|Actual|January 1998|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||September 2013|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000196||211356|
NCT00000197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00238-2|Propranolol for Treatment of Cocaine Addiction - 2|Propranolol for Treatment of Cocaine Addiction||National Institute on Drug Abuse (NIDA)|No|Completed|January 1987|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|25 Years|49 Years|No|||February 2010|February 3, 2010|September 20, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00000197||211355|
NCT00000198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00238-3|Piracetam for Treatment of Cocaine Addiction - 3|Piracetam for Treatment of Cocaine Addiction||University of Pennsylvania||Completed|October 1996|October 1997|Actual|October 1997|Actual|Phase 1|Interventional|Primary Purpose: Treatment||||0|||Male|21 Years|45 Years|No|||December 2013|October 5, 2015|September 20, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00000198||211354|
NCT00000199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00238-4|Piracetam for Treatment of Cocaine Addiction, Phase II - 4|Piracetam for Treatment of Cocaine Addiction, Phase II||University of Pennsylvania||Withdrawn||||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||July 2013|October 7, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000199||211353|
NCT00000200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-03818-1|Cocaine Effects in Humans: Physiology and Behavior - 1|Cocaine Effects in Humans: Physiology and Behavior||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 1997|January 1998|Actual|January 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|45 Years|No|||September 2008|September 10, 2008|September 20, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000200||211352|
NCT00000201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-05196-1|Pharmacological Modulation of Cocaine Effects - 1|Pharmacological Modulation of Cocaine Effects||National Institute on Drug Abuse (NIDA)||Completed||December 2001||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Female|N/A|N/A|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000201||211351|
NCT00000202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-05626-1|Buprenorphine Maintenance for Opioid Addicts - 1|Buprenorphine Maintenance for Opioid Addicts||Yale University||Completed|August 1988|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||December 2002|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000202||211350|
NCT00000203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-05626-2|Buprenorphine Maintenance for Opioid Addicts - 2|Buprenorphine Maintenance for Opioid Addicts||Yale University||Completed|August 1988|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||August 2005|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000203||211349|
NCT00000204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-05626-3|Buprenorphine Maintenance for Opioid Addicts - 3|Buprenorphine Maintenance for Opioid Addicts||Yale University||Completed|August 1988|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||August 2005|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000204||211348|
NCT00000205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06082-1|Buprenorphine Maintenance Protocol - 1|Buprenorphine Maintenance Protocol||University of California, Los Angeles||Completed|October 1990|||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||October 1992|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000205||211347|
NCT00000206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06082-2|Clinical Rescue Protocol - 2|Clinical Rescue Protocol||National Institute on Drug Abuse (NIDA)||Completed|April 1991|||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||November 1993|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000206||211346|
NCT00000207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06082-3|Multicenter Clinical Trial of Buprenorphine - 3|Multicenter Clinical Trial of Buprenorphine||National Institute on Drug Abuse (NIDA)||Completed|May 1992|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||June 1993|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000207||211345|
NCT00000243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-1|Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone|Transitioning Patients From Methadone to Buprenorphine/Naloxone for Treating Opioid Dependence||National Institute on Drug Abuse (NIDA)||Terminated|September 2002|January 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2007|March 15, 2007|September 20, 1999||||||https://clinicaltrials.gov/show/NCT00000243||211309|
NCT00000221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-3|Alternate-Day Buprenorphine Administration. Phase I - 3|Alternate-Day Buprenorphine Administration. Phase I||National Institute on Drug Abuse (NIDA)||Completed|April 1992|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|28 Years|45 Years|No|||November 1993|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000221||211331|
NCT00000222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-4|Alternate-Day Buprenorphine Administration. Phase II - 4|Alternate-Day Buprenorphine Administration. Phase II||National Institute on Drug Abuse (NIDA)||Completed|July 1992|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||0|||Both|28 Years|45 Years|No|||December 1993|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000222||211330|
NCT00000223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-5|Alternate-Day Buprenorphine Administration. Phase IV - 5|Alternate-Day Buprenorphine Administration. Phase IV||National Institute on Drug Abuse (NIDA)||Completed|June 1993|||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|20 Years|49 Years|No|||September 1994|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000223||211329|
NCT00000252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-4|Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4|Lack of Acute Tolerance Development to Effects of Nitrous Oxide||University of Chicago||Completed|June 1994|June 1996|Actual|June 1996|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|11|||Both|21 Years|29 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000252||211301|
NCT00000284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-1|Role of Metabolites in Nicotine Dependence (1) - 1|Role of Metabolites in Nicotine Dependence (1)||National Institute on Drug Abuse (NIDA)||Completed|February 1995|December 2001||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|45 Years|No|||March 1996|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000284||211270|
NCT00000285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-2|Effects of Phenytoin on Cocaine Use in Humans - 2|Effects of Phenytoin on Cocaine Use in Humans||National Institute on Drug Abuse (NIDA)||Completed|May 1996|December 2001||||Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|20 Years|45 Years|No|||May 1997|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000285||211269|
NCT00000257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-9|Effects of Alcohol History on Effects of Nitrous Oxide - 9|Effects of Alcohol History on Effects of Nitrous Oxide||University of Chicago||Completed|September 1995|April 1997|Actual|April 1997|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|19|||Both|21 Years|37 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000257||211296|
NCT00000224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-6|Alternate-Day Buprenorphine. Phase V - 6|Alternate-Day Buprenorphine. Phase V||National Institute on Drug Abuse (NIDA)||Completed|February 1993|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|30 Years|49 Years|No|||April 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000224||211328|
NCT00000225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-7|Alternate-Day Buprenorphine Administration. Phase VI - 7|Alternate-Day Buprenorphine Administration. Phase VI||National Institute on Drug Abuse (NIDA)||Completed|December 1992|||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|51 Years|No|||June 2004|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000225||211327|
NCT00000226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-8|Alternate-Day Buprenorphine Administration. Phase VII - 8|Alternate-Day Buprenorphine Administration. Phase VII||National Institute on Drug Abuse (NIDA)||Completed|November 1994|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|48 Years|No|||July 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000226||211326|
NCT00000227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-9|Alternate-Day Buprenorphine Administration. Phase VIII - 9|Alternate-Day Buprenorphine Administration. Phase VIII||National Institute on Drug Abuse (NIDA)||Completed|August 1994|||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||0|||Both|25 Years|48 Years|No|||July 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000227||211325|
NCT00000228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-10|Buprenorphine Detox With Two Types of Treatment. BBD I - 10|Buprenorphine Detox With Two Types of Treatment. BBD I||National Institute on Drug Abuse (NIDA)||Completed|August 1994|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||July 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000228||211324|
NCT00000229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-11|Buprenorphine Detox With Two Types of Treatment. BBD II - 11|Buprenorphine Detox With Two Types of Treatment. BBD II||National Institute on Drug Abuse (NIDA)||Completed|October 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||September 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000229||211323|
NCT00000230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-12|Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12|Buprenorphine Detoxification With Two Types of Treatment. BBD III||National Institute on Drug Abuse (NIDA)||Completed|January 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||August 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000230||211322|
NCT00000231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-13|Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13|Buprenorphine Detoxification With Two Types of Treatment. BBD IV||National Institute on Drug Abuse (NIDA)||Completed|February 1992|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||March 1994|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000231||211321|
NCT00000232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-14|Alternate Day Buprenorphine Administration, Phase IX - 14|Alternate Day Buprenorphine Administration, Phase IX||National Institute on Drug Abuse (NIDA)||Completed|March 1992|||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|22 Years|51 Years|No|||April 1994|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000232||211320|
NCT00000233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-15|Alternate Day Buprenorphine Administration, Phase X - 15|Alternate Day Buprenorphine Administration, Phase X||National Institute on Drug Abuse (NIDA)||Completed|May 1993|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|34 Years|51 Years|No|||September 1995|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000233||211319|
NCT00000234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-16|Alternate Day Buprenorphine Administration, Phase XI - 16|Alternate Day Buprenorphine Administration, Phase XI||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||0|||Both|25 Years|51 Years|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000234||211318|
NCT00000235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-17|Alternate Day Buprenorphine Administration, Phase XII - 17|Alternate Day Buprenorphine Administration, Phase XII||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000235||211317|
NCT00000236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-18|Buprenorphine Pharmacology Related to Addiction Treatment - 18|Buprenorphine Pharmacology Related to Addiction Treatment||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000236||211316|
NCT00000237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-19|Buprenorphine Detoxification - BBDVI - 19|Buprenorphine Detoxification - BBDVI||National Institute on Drug Abuse (NIDA)||Completed|May 1997|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||May 1997|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000237||211315|
NCT00000238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-20|Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20|Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients||National Institute on Drug Abuse (NIDA)||Completed|August 1997|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|47 Years|No|||November 2008|November 19, 2008|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000238||211314|
NCT00000239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-21|Buprenorphine Pharmacology Related to Addiction Treatment - 21|Buprenorphine Pharmacology Related to Addiction Treatment||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000239||211313|
NCT00000240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-06969-22|Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22|Combined Buprenorphine and Behavioral Treatment Without Contingent Reinforcement||University of Vermont||Completed|April 1999|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|23 Years|47 Years|No|||April 1999|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000240||211312|
NCT00000241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-07200-1|Flupenthixol Decanoate in Methamphetamine Smoking - 1|Flupenthixol Decanoate in Methamphetamine Smoking||National Institute on Drug Abuse (NIDA)||Completed|February 1994|May 1996||||Phase 2|Interventional|Primary Purpose: Treatment||||58|||Both|22 Years|45 Years|No|||February 1994|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000241||211311|
NCT00000242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-07761-1|Carbamazepine Treatment of Cocaine Dependence - 1|Carbamazepine Treatment of Cocaine Dependence||Medical University of South Carolina||Completed|October 1992|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||July 1996|October 8, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000242||211310|
NCT00000254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-6|Isoflurane at Subanesthetic Concentrations - 6|Isoflurane at Subanesthetic Concentrations||University of Chicago||Completed|January 1995|September 1995|Actual|September 1995|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|10|||Male|21 Years|34 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000254||211299|
NCT00000255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-7|Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7|Differential Acute Tolerance Development to Effects of Nitrous Oxide||University of Chicago||Completed|April 1995|May 1996|Actual|May 1996|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|10|||Both|21 Years|37 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000255||211298|
NCT00000256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-8|Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8|Reinforcing Effects of Brief Exposures to Nitrous Oxide||University of Chicago||Completed|August 1995|November 1996|Actual|November 1996|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|11|||Both|22 Years|34 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000256||211297|
NCT00000250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-2|Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2|Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide||University of Chicago||Completed|December 1993|May 1995|Actual|May 1995|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|32 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000250||211303|
NCT00000251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-3|Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3|Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide||University of Chicago||Completed|April 1994|January 1996|Actual|January 1996|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|10|||Both|21 Years|32 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000251||211302|
NCT00000294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-11|Effects of Carvedilol on Cocaine Use in Humans - 11|Effects of Carvedilol on Cocaine Use in Humans||National Institute on Drug Abuse (NIDA)||Completed|September 1998|December 2001||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|20 Years|55 Years|No|||March 1999|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000294||211260|
NCT00000291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-8|Effects of Labetalol on Human Cocaine Use - 8|Effects of Labetalol on Human Cocaine Use||National Institute on Drug Abuse (NIDA)||Completed|October 1997|December 2001||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|20 Years|45 Years|No|||August 1998|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000291||211263|
NCT00000308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-5|Dextroamphetamine-Cocaine Behavioral Intervention - 5|D-Amphetamine-Cocaine Behavioral Intervention||National Institute on Drug Abuse (NIDA)|Yes|Completed|September 1995|September 2000|Actual|September 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|45 Years|No|||August 2008|August 18, 2008|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000308||211246|
NCT00000309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09330-1|Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1|Serotonin/Dopamine Antagonism of Cocaine Effect||Butler Hospital||Terminated|August 1994|January 2000|Actual|January 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|50 Years|No|||July 2015|July 23, 2015|September 20, 1999|Yes|Yes|Unable to recruit adequate number of subjects|No||https://clinicaltrials.gov/show/NCT00000309||211245|
NCT00000258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-10|Role of Instructions in Nitrous Oxide Effects and Choice - 10|Role of Instructions in Nitrous Oxide Effects and Choice||University of Chicago||Completed|April 1996|November 1997|Actual|November 1997|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|22|||Both|21 Years|32 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000258||211295|
NCT00000259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-11|Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11|Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations||University of Chicago||Completed|August 1996|November 1997|Actual|November 1997|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|12|||Both|21 Years|39 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000259||211294|
NCT00000260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-12|Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12|Effects of Behavioral Contingencies on Effects of Nitrous Oxide||University of Chicago||Completed|June 1997|January 1998|Actual|January 1998|Actual|N/A|Interventional|N/A|||Actual|18|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000260||211293|
NCT00000261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-13|Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13|Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide||University of Chicago||Completed|November 1997|October 1998|Actual|October 1998|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver)|1||Actual|14|||Both|N/A|N/A|No|||May 2015|May 26, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000261||211292|
NCT00000262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-14|Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14|Effects of Combined Sevoflurane and Nitrous Oxide Inhalation||University of Chicago||Completed|November 1996|February 1999|Actual|February 1999|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|20|||Both|N/A|N/A|No|||May 2015|May 26, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000262||211291|
NCT00000263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-15|Effects of Combined Alcohol and Nitrous Oxide Intake - 15|Effects of Combined Alcohol and Nitrous Oxide Intake||University of Chicago||Completed|January 1997|October 1998|Actual|October 1998|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|3||Actual|11|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000263||211290|
NCT00000264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-16|Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16|Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide||University of Chicago||Completed|September 1997|October 1999|Actual|October 1999|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|3||Actual|8|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000264||211289|
NCT00000265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08391-17|Subjective Effects of Nitrous Oxide in Dental Patients - 17|Subjective Effects of Nitrous Oxide in Dental Patients||University of Chicago||Completed|July 1997|January 2002|Actual|January 2002|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000265||211288|
NCT00000266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-1|Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1|Flupenthixol Treatment in Schizophrenic Cocaine Abusers||National Institute on Drug Abuse (NIDA)||Completed|August 1994|December 2001||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||April 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000266||211287|
NCT00000267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-2|Risperidone Treatment in Dually-Diagnosed Individuals - 2|Risperidone Treatment in Dually-Diagnosed Individuals||National Institute on Drug Abuse (NIDA)||Completed||December 2001||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|60 Years|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000267||211286|
NCT00000268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-3|Cocaine Abuse and Attention Deficit Disorder - 3|Cocaine Abuse and Attention Deficit Disorder||National Institute on Drug Abuse (NIDA)||Completed|May 1995|November 1998||||N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment||||32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 1995|November 3, 2005|September 20, 1999||||||https://clinicaltrials.gov/show/NCT00000268||211285|
NCT00000269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-4|Pergolide Treatment for Substance Abusers - 4|Pergolide Treatment for Substance Abusers||National Institute on Drug Abuse (NIDA)||Completed|October 1995|December 2001||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Male|18 Years|55 Years|No|||October 1995|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000269||211284|
NCT00000270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-5|Brain Imaging: Cocaine Effects & Medication Development - 5|Brain Imaging: Cocaine Effects & Medication Development||National Institute on Drug Abuse (NIDA)||Completed|May 1995|||||Phase 4|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|48 Years|No|||May 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000270||211283|
NCT00000271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-6|New Approaches to Cocaine Abuse Medications (A) - 6|New Approaches to Cocaine Abuse Medications (A)||National Institute on Drug Abuse (NIDA)||Completed|January 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|60 Years|No|||January 1995|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000271||211282|
NCT00000272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-7|New Approaches to Cocaine Abuse Medications (B) - 7|New Approaches to Cocaine Abuse Medications (B)||National Institute on Drug Abuse (NIDA)||Completed|March 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|60 Years|No|||March 1995|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000272||211281|
NCT00000273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4857|A Laboratory Model for Heroin Abuse Medications - 8|A Laboratory Model for Heroin Abuse Medications||New York State Psychiatric Institute|Yes|Completed|August 1995|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|45 Years|No|||November 2013|November 4, 2013|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000273||211280|
NCT00000274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-9|Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9|Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics||National Institute on Drug Abuse (NIDA)||Completed|March 1997|May 1999||||Phase 2|Interventional|Primary Purpose: Treatment||||60|||Both|18 Years|45 Years|No|||March 1997|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000274||211279|
NCT00000275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09236-10|Cocaine Abuse and ADHD - 10|Cocaine Abuse and ADHD||National Institute on Drug Abuse (NIDA)||Completed|November 1996|March 1998||||Phase 2|Interventional|Primary Purpose: Treatment||||16|||Both|18 Years|55 Years|No|||November 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000275||211278|
NCT00000276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09250-1|Dopamine Reuptake Inhibitors of Cocaine Abuse - 1|Dopamine Reuptake Inhibitors of Cocaine Abuse||Yale University||Terminated|September 1994|August 1999|Actual|August 1999|Actual|Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|45 Years|No|||December 2008|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000276||211277|
NCT00000277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09250-2|Mazindol for Cocaine Abuse - 2|Mazindol for Cocaine Abuse||Yale University||Completed|September 1994|August 1999|Actual|August 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||December 2002|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000277||211276|
NCT00000278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09250-3|Disulfiram for Cocaine-Alcohol Abuse - 3|Disulfiram for Cocaine-Alcohol Abuse||Yale University||Completed|September 1994|August 1999|Actual|August 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|50 Years|No|||December 2002|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000278||211275|
NCT00000279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09250-4|Novel Medications for Opiate Detoxification - 4|Novel Medications for Opiate Detoxification||Yale University||Completed|September 1994|August 1999|Actual|August 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||December 2002|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000279||211274|
NCT00000280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09250-5|Glutaminergic Agents for Cocaine Abuse - 5|Glutaminergic Agents for Cocaine Abuse||Yale University||Completed|September 1994|August 1999|Actual|August 1999|Actual|Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|45 Years|No|||December 2002|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000280||211273|
NCT00000281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09250-6|Pharmacotherapy for Schizophrenic Drug Users - 6|Pharmacotherapy for Schizophrenic Drug Users||Yale University||Completed|September 1994|August 1999|Actual|August 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|55 Years|No|||December 2002|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000281||211272|
NCT00000282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09250-7|Pemoline for Cocaine Abuse - 7|Pemoline for Cocaine Abuse||Yale University||Completed|September 1994|August 1999|Actual|August 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||December 2002|July 24, 2013|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000282||211271|
NCT00000293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-10|Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10|Effect of Nefazodone on Relapse in Females With Cocaine Abuse||National Institute on Drug Abuse (NIDA)||Completed|January 1999|December 2001||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Female|18 Years|55 Years|No|||January 1999|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000293||211261|
NCT00000286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-3|Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3|Effects of Nefazodone on Treatment of Female Cocaine Abusers||National Institute on Drug Abuse (NIDA)||Completed|December 1996|December 2001||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Female|18 Years|55 Years|No|||December 1998|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000286||211268|
NCT00000287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-4|Relapse Patterns in Female Cocaine Users - 4|Relapse Patterns in Female Cocaine Users||National Institute on Drug Abuse (NIDA)||Completed|February 1995|December 2001||||Phase 4|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||0|||Female|18 Years|60 Years|No|||November 1995|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000287||211267|
NCT00000306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-3|Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3|Dextroamphetamine as an Adjunct in Cocaine/Opiate Dependent Patients||National Institute on Drug Abuse (NIDA)||Completed|September 1994|September 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 11, 2008|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000306||211248|
NCT00000307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-4|Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4|Naltrexone as an Adjunct in Alcoholic Cocaine Dependent Patients||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2003|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|50 Years|No|||August 2008|August 11, 2008|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000307||211247|
NCT00000310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09330-2|Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2|Serotonin/Dopamine Antagonism of Cocaine Effect||National Institute on Drug Abuse (NIDA)||Terminated|January 1996|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|50 Years|No|||January 1996|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000310||211244|
NCT00000311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09413-1|Combining Behavioral Treatment With Agonist Maintenance - 1|Combining Behavioral Treatment With Agonist Maintenance||National Institute on Drug Abuse (NIDA)||Active, not recruiting|September 1999|||||Phase 3|Interventional|Primary Purpose: Treatment|2|||168|||Both|N/A|N/A|No|||October 2008|October 27, 2008|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000311||211243|
NCT00000288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-5|Role of Metabolites in Nicotine Dependence (2) - 5|Role of Metabolites in Nicotine Dependence (2)||National Institute on Drug Abuse (NIDA)||Completed|December 1995|December 2002||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|45 Years|No|||December 1996|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000288||211266|
NCT00000289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-6|Role of Metabolites in Nicotine Dependence (3) - 6|Role of Metabolites in Nicotine Dependence (3)||National Institute on Drug Abuse (NIDA)||Completed|May 1998|December 2001||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|45 Years|No|||December 1998|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000289||211265|
NCT00000290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-7|Stress Hormones and Human Cocaine Use - 7|Stress Hormones and Human Cocaine Use||National Institute on Drug Abuse (NIDA)||Completed|May 1997|December 2001||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Male|20 Years|45 Years|No|||January 1998|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000290||211264|
NCT00000292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-9|Acute Withdrawal From Smoked Cocaine - 9|Acute Withdrawal From Smoked Cocaine||National Institute on Drug Abuse (NIDA)||Completed|April 1996|December 2001||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|45 Years|No|||April 1996|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000292||211262|
NCT00000295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-12|Progesterone Treatment in Female Smokers - 12|Progesterone Treatment in Female Smokers||National Institute on Drug Abuse (NIDA)||Completed|April 1999|December 2001||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Female|21 Years|45 Years|No|||April 1999|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000295||211259|
NCT00000329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11160-4|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1||University of Colorado, Denver||Completed|April 1999|August 1999|Actual|August 1999|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||December 2013|June 2, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000329||211225|
NCT00000330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11160-5|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2||University of Colorado, Denver||Terminated|October 1999|November 1999|Actual|November 1999|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||December 2013|June 2, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000330||211224|
NCT00000312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09468-1|Alterations in Serotonergic Functions in Cocaine Addicts - 1|Alterations in Serotonergic Functions in Cocaine Addicts||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Male|25 Years|50 Years|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000312||211242|
NCT00000325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-10757-1|Psychostimulant Abuse - Novel Treatment Approaches - 1|Psychostimulant Abuse - Novel Treatment Approaches||National Institute on Drug Abuse (NIDA)||Completed||December 2001||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Male|N/A|N/A|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000325||211229|
NCT00000326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11160-1|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1(1)||University of Colorado, Denver||Completed|April 1997|August 1997|Actual|August 1997|Actual|Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|64 Years|No|||March 2014|May 26, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000326||211228|
NCT00000313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09468-2|Predictive Values of Serotonergic Alterations for Outcome - 2|Predictive Values of Serotonergic Alterations for Outcome||National Institute on Drug Abuse (NIDA)||Terminated||||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Male|25 Years|50 Years|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000313||211241|
NCT00000314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09468-3|M-CPP and Fenfluramine in Cocaine Addicts - 3|To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Male|25 Years|50 Years|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000314||211240|
NCT00000296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-13|Role of Metabolites in Nicotine Dependence (4) - 13|Role of Metabolites in Nicotine Dependence (4)||National Institute on Drug Abuse (NIDA)||Completed|November 1997|December 2001||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|45 Years|No|||February 1999|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000296||211258|
NCT00000297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09259-14|Effects of Labetalol on Nicotine Administration in Humans - 14|Effects of Labetalol on Nicotine Administration in Humans||National Institute on Drug Abuse (NIDA)||Completed|October 1998|December 2001||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|55 Years|No|||October 1998|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000297||211257|
NCT00000298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09260-1|Buprenorphine Combination Tablet Feasibility - 1|Buprenorphine Combination Tablet Feasibility||National Institute on Drug Abuse (NIDA)||Completed|August 1995|||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||January 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000298||211256|
NCT00000299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09260-2|Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2|Rapid Opiate Detoxification & Naltrexone Induction Using Bup.||University of California, Los Angeles||Completed|October 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|50 Years|No|||January 2016|January 27, 2016|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000299||211255|
NCT00000300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09260-3|Feasibility Study of Take-Home LAAM Medication - 3|Feasibility Study of Take-Home LAAM Medication||National Institute on Drug Abuse (NIDA)||Completed|March 1995|||||Phase 4|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||March 1995|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000300||211254|
NCT00000301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09260-4|Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4|Rapid Evaluation of Cocaine Pharmacotherapies (Amantadine)||National Institute on Drug Abuse (NIDA)||Completed|March 1996|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||December 1997|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000301||211253|
NCT00000302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09260-5|Study Comparing Liquid and Tablet Buprenorphine Formulations - 5|Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||December 2002|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000302||211252|
NCT00000303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09260-6|Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6|Rapid Evaluation of Cocaine Pharmacotherapies (Baclofen)||National Institute on Drug Abuse (NIDA)||Completed|October 1997|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||October 1997|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000303||211251|
NCT00000304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-1|Dextroamphetamine as an Adjunct in Cocaine Treatment - 1|Dextroamphetamine as an Adjunct in Cocaine Treatment||National Institute on Drug Abuse (NIDA)|Yes|Completed|August 1997|August 2001|Actual|August 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|45 Years|No|||August 2008|August 14, 2008|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000304||211250|
NCT00000305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-2|Amphetamine Cocaine Interaction Study - 2|Amphetamine Cocaine Interaction Study||The University of Texas Health Science Center, Houston|Yes|Terminated||||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Male|18 Years|45 Years|No|||May 2012|May 17, 2012|September 20, 1999||No|Original P.I. left the institution|No||https://clinicaltrials.gov/show/NCT00000305||211249|
NCT00000315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09482-1|Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1|Human Dopamine Transported Imaging in Cocaine Abuse: 1||National Institute on Drug Abuse (NIDA)||Completed|November 1996|December 2001||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Male|21 Years|45 Years|No|||November 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000315||211239|
NCT00000316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09482-2|Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2|Human Dopamine Transported Imaging in Cocaine Abuse: 2||National Institute on Drug Abuse (NIDA)||Completed|August 1996|December 2001||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Male|21 Years|45 Years|No|||August 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000316||211238|
NCT00000347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-12|Risperidone for Treatment of Cocaine Dependence in Outpatients - 12|Risperidone for Treatment of Cocaine Dependence in Outpatients||National Institute on Drug Abuse (NIDA)||Completed|July 1997|||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||March 1998|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000347||211207|
NCT00000348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-13|Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13|Infusion Laboratory: Protocol 4 (Dihydrexidine)||National Institute on Drug Abuse (NIDA)||Active, not recruiting||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000348||211206|
NCT00000349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-14|Infusion Laboratory: Protocol 5 (Flupenthixol) - 14|Infusion Laboratory: Protocol 5 (Flupenthixol)||National Institute on Drug Abuse (NIDA)||Active, not recruiting||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||December 2002|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000349||211205|
NCT00000350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-15|Effects of Stimulant Dependence on Human Striatal Dopamine System - 15|Effects of Stimulant Dependence on Human Striatal Dopamine System||National Institute on Drug Abuse (NIDA)||Active, not recruiting|March 1999|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||March 1999|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000350||211204|
NCT00000351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-16|Cognitive Correlates of Substance Abuse, Part 2 - 16|Cognitive Correlates of Substance Abuse, Part 2||National Institute on Drug Abuse (NIDA)||Active, not recruiting||||||Phase 4|Observational|Time Perspective: Cross-Sectional||||43|||Both|N/A|N/A|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000351||211203|
NCT00000317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3124|Early Phase II Trials for Cocaine Medication Development - 1|Early Phase II Trials for Cocaine Medication Development||New York State Psychiatric Institute|No|Completed|August 1996|July 1999|Actual|July 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|60 Years|No|||October 2012|October 24, 2012|September 20, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000317||211237|
NCT00000318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09803-1|Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1|Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot||National Institute on Drug Abuse (NIDA)|No|Completed|December 1994|August 2007|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Both|21 Years|55 Years|No|||December 2008|December 17, 2008|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000318||211236|
NCT00000319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09803-2|Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2|Buprenorphine Maintenance Dose Schedule and Treatment Setting||National Institute on Drug Abuse (NIDA)||Completed|June 1996|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|55 Years|No|||June 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000319||211235|
NCT00000320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-10068-1|Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1|Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution||National Institute on Drug Abuse (NIDA)|No|Completed|October 1997|August 1999|Actual|August 1999|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||January 2009|January 5, 2009|September 20, 1999||No||No||https://clinicaltrials.gov/show/NCT00000320||211234|
NCT00000321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-10643-1|Methamphetamine Abuse Treatment in Patients With AIDS - 1|Methamphetamine Abuse Pharmacology in Patients With AIDS||National Institute on Drug Abuse (NIDA)||Completed|October 1996|December 2001||||Phase 4|Interventional|Primary Purpose: Treatment||||0|||Male|N/A|N/A|No|||October 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000321||211233|
NCT00000322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-10739-1|Tyrosine for Methamphetamine Dependence - 1|Tyrosine for Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)||Completed|April 1997|December 2001||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||89|||Both|18 Years|65 Years|No|||April 1997|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000322||211232|
NCT00000323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-10753-1|Therapeutic Potential of Kappa-Opioids Against Cocaine - 1|Therapeutic Potential of Kappa-Opioids Against Cocaine||National Institute on Drug Abuse (NIDA)||Completed|July 1996|December 1998||||Phase 1|Observational|Primary Purpose: Screening||||10|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||May 2004|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000323||211231|
NCT00000324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-10754-1|Tryptophan and Behavior Therapy for Cocaine Abuse - 1|Tryptophan and Behavior Therapy for Cocaine Abuse||National Institute on Drug Abuse (NIDA)||Completed|March 1997|April 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|55 Years|No|||August 2005|June 2, 2015|September 20, 1999||||||https://clinicaltrials.gov/show/NCT00000324||211230|
NCT00000327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11160-2|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2)||University of Colorado, Denver||Completed|June 1997|August 1997|Actual|August 1997|Actual|Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|62 Years|No|||December 2013|May 26, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000327||211227|
NCT00000328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11160-3|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III||University of Colorado, Denver||Completed|July 1997|August 1997|Actual|August 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||December 2013|May 26, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000328||211226|
NCT00000331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11160-6|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3||University of Colorado, Denver||Terminated|December 2002|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|2|||0|||Both|18 Years|65 Years|No|||December 2013|June 2, 2015|September 20, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000331||211223|
NCT00000332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0009-1|High Dose Nimodipine Treatment Adjunct - 1|High Dose Nimodipine Pharmacotherapy Adjunct||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|22 Years|45 Years|No|||December 2002|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000332||211222|
NCT00000333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0009-2|Evaluation of Benztropine for Cocaine Craving - 2|Evaluation of Efficacy of Benztropine for Cocaine Craving||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|22 Years|48 Years|No|||December 2002|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000333||211221|
NCT00000334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0009-3|Comparison of Buprenorphine and Methadone - 3|Pharmacological Comparison of Buprenorphine and Methadone||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Male|23 Years|45 Years|No|||December 2002|June 2, 2015|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000334||211220|
NCT00000368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH045964|Treatment of Panic Disorder: Long Term Strategies|Treatment of Panic Disorder: Long Term Strategies||New York State Psychiatric Institute|Yes|Completed|February 1999|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|379|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000368||211190|
NCT00000352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0012-1|Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1|Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients||National Institute on Drug Abuse (NIDA)||Completed|December 1996|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|55 Years|No|||August 1997|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000352||211202|
NCT00000353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0012-2|Trial of Buprenorphine/Naloxone for Opiate Dependence - 2|Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|19 Years|57 Years|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000353||211201|
NCT00000335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0009-4|Activity Monitoring Assessment of Opiate Withdrawal - 4|Activity Monitoring Assessment of Opiate Withdrawal||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Male|21 Years|55 Years|No|||December 2002|March 20, 2013|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000335||211219|
NCT00000336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-1|Selegiline in Outpatient Treatment for Cocaine Dependence - 1|Safety and Efficacy of Selegiline in Outpatient Treatment for Cocaine||National Institute on Drug Abuse (NIDA)||Completed|January 1995|||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||January 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000336||211218|
NCT00000337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-2|Infusion Laboratory: Protocol 1 - Selegeline - 2|Infusion Laboratory: Protocol 1 - Selegeline||National Institute on Drug Abuse (NIDA)||Completed|November 1994|||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|31 Years|47 Years|No|||August 1996|November 3, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000337||211217|
NCT00000338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-3|Infusion Laboratory: Protocol 2 (Lisuride) - 3|Infusion Laboratory: Protocol 2 (Lisuride)||National Institute on Drug Abuse (NIDA)||Active, not recruiting|March 1996|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||2|||Both|21 Years|50 Years|No|||March 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000338||211216|
NCT00000339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-4|Infusion Laboratory: Protocol 3 (Risperidone) - 4|Infusion Laboratory: Protocol 3 (Risperidone)||National Institute on Drug Abuse (NIDA)||Active, not recruiting|June 1996|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||13|||Both|21 Years|50 Years|No|||June 1996|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000339||211215|
NCT00000340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-5|Pemoline in the Treatment of Stimulant Dependence - 5|Pemoline in the Treatment of Stimulant Dependence||National Institute on Drug Abuse (NIDA)||Withdrawn|June 1996|||||Phase 2|Interventional|Primary Purpose: Treatment||||1|||Both|21 Years|50 Years|No|||August 2008|August 25, 2008|September 20, 1999|||Study was never funded.|No||https://clinicaltrials.gov/show/NCT00000340||211214|
NCT00000341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-6|Evaluation of Liquid vs. Tablet Buprenorphine - 6|Pharmacokinetics and Bioavailability of Liquid vs Tablet Buprenorphine||National Institute on Drug Abuse (NIDA)||Completed|August 1996|August 2000|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1|||Both|21 Years|50 Years|No|||August 2008|August 26, 2008|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000341||211213|
NCT00000342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-7|Risperidone for the Treatment of Cocaine Dependence - 7|Risperidone for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|July 1996|||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||June 1997|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000342||211212|
NCT00000343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-8|Brain Changes in Stimulant Dependent Subjects - 8|Brain Changes in Stimulant Dependent Subjects||National Institute on Drug Abuse (NIDA)||Active, not recruiting|April 1996|||||Phase 4|Interventional|Primary Purpose: Treatment||||90|||Both|21 Years|50 Years|No|||April 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000343||211211|
NCT00000344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-9|Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9|Trial of Buprenorphine/Naloxone for Treatment of Opiate Dependence||National Institute on Drug Abuse (NIDA)||Completed||August 2000|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|21 Years|50 Years|No|||August 2008|August 26, 2008|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000344||211210|
NCT00000345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-10|Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10|Evaluation of Lofexidine for Treatment of Opiate Withdrawal||National Institute on Drug Abuse (NIDA)||Completed|April 1996|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||September 1997|August 16, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000345||211209|
NCT00000346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0010-11|Cognitive Correlates of Substance Abuse - 11|Cognitive Correlates of Substance Abuse, Part 1||National Institute on Drug Abuse (NIDA)||Active, not recruiting||||||Phase 4|Interventional|Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000346||211208|
NCT00000363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCD-1160|Acute Otitis Media: Adjuvant Therapy to Improve Outcome|||National Institute on Deafness and Other Communication Disorders (NIDCD)||Completed||June 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|2 Months|1 Year|No|||April 2006|April 21, 2006|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000363||211192|
NCT00000367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059366|Prevention of Suicide in the Elderly|||Weill Medical College of Cornell University||Completed|September 1998|August 2003||||N/A|Interventional|Primary Purpose: Prevention|||||||Both|60 Years|N/A|No|||October 2013|October 25, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000367||211191|
NCT00000374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060004-01|Treatment for First-Episode Schizophrenia|Preventing Morbidity in First-Episode Schizophrenia||Northwell Health|Yes|Completed|September 1998|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|125|||Both|16 Years|40 Years|No|||January 2012|January 12, 2012|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000374||211184|
NCT00000375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH55495|Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder|Continuation ECT Vs Pharmacotherapy--Efficacy And Safety||National Institute of Mental Health (NIMH)||Completed|February 1997|||||Phase 4|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||December 2005|December 19, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000375||211183|
NCT00000354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0012-3|Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3|Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal||National Institute on Drug Abuse (NIDA)||Completed|July 1996|||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|59 Years|No|||July 1996|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000354||211200|
NCT00000355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0012-4|Effects of Buprenorphine and Naloxone in Opiate Addicts - 4|Effects of Buprenophine and Naloxone in Opiate Addicts||National Institute on Drug Abuse (NIDA)||Completed|November 1994|||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|59 Years|No|||May 1995|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000355||211199|
NCT00000356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0012-5|Evaluation of L-Alpha-Acetylmethadol (LAAM) in Methadone Patients - 5|Pharmacokinetics of LAAM in Methadone Patients||National Institute on Drug Abuse (NIDA)||Completed|June 1991|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||February 1992|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000356||211198|
NCT00000357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0012-6|Buprenorphine Maintenance for Opiate Dependence - 6|Buprenorphine Maintenance for Opiate Dependence||National Institute on Drug Abuse (NIDA)||Completed|June 1992|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Male|N/A|N/A|No|||December 1993|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000357||211197|
NCT00000358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-3-0012-7|Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7|Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|59 Years|No|||December 2002|June 23, 2005|September 20, 1999||||No||https://clinicaltrials.gov/show/NCT00000358||211196|
NCT00000359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCD-1156|Treatments for Benign Paroxysmal Positional Vertigo (BPPV)|Treatments for Benign Paroxysmal Positional Vertigo (BPPV)||Baylor College of Medicine|No|Completed|October 1998|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|150|||Both|21 Years|N/A|No|||July 2012|July 25, 2012|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000359||211195|
NCT00000361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCD-1158|Autoimmunity in Inner Ear Disease|||National Institute on Deafness and Other Communication Disorders (NIDCD)||Terminated|March 1998|November 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||April 2006|April 21, 2006|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000361||211194|
NCT00000362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCD-1159|Randomized Study of Two Interventions for Liquid Aspiration: Short-Term and Long-Term Effects|||National Institute on Deafness and Other Communication Disorders (NIDCD)||Terminated||January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||600|||Both|50 Years|95 Years|No|||April 2006|April 21, 2006|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000362||211193|
NCT00000369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R37MH029618|Maintenance Therapies in Bipolar Disorders|||University of Pittsburgh||Completed|June 1997|December 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||February 2008|June 21, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000369||211189|
NCT00000462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51|Bypass Angioplasty Revascularization Investigation (BARI)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1987|November 2004||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2005|February 23, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000462||211097|
NCT00000463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52|Post Coronary Artery Bypass Graft (CABG) Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1987|December 1998||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||August 2004|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000463||211096|
NCT00000464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no record in DORA|Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)|||University of Washington||Completed|April 1987|||December 1992|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||July 2013|July 26, 2013|October 27, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000464||211095|
NCT00000465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54|Emory Angioplasty Versus Surgery Trial (EAST)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1987|August 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||September 2002|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000465||211094|
NCT00000370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29MH057326|Treatment of Social Phobia|Treatment of Social Phobia: Mediators And Moderators||Boston University||Completed|May 1998|February 2003||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2013|August 5, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000370||211188|
NCT00000371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH054245-01A2|Trial of D-Cycloserine in Schizophrenia|A Six Month, Placebo-Controlled Trial of D-Cycloserine Co-Administered With Conventional Antipsychotics in Schizophrenia Patients||Massachusetts General Hospital||Completed|August 1996|April 2002|Actual|April 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||September 2014|September 3, 2014|November 2, 1999||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT00000371||211187|A biased sample may have been produced by restricting the analysis to patients with prominent negative symptoms receiving conventional agents (less compliant with study medication). Additionally, Adverse Event data was lost for the study.
NCT00000372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH057708-02|Glycine and D-Cycloserine in Schizophrenia|A Placebo Controlled Trial of Glycine Added to Clozapine in Schizophrenia||Massachusetts General Hospital||Withdrawn|March 1998|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||June 2014|June 11, 2014|November 2, 1999|||Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients    with Schizophrenia, so the study was suspended.|No||https://clinicaltrials.gov/show/NCT00000372||211186|
NCT00000373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH045802|Treatment of Obsessive-Compulsive Disorder|Neurobiology/Treatment of Obsessive-Compulsive Disorder||University of Florida|No|Completed|September 1992|July 2003|Actual|January 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|74|||Both|14 Years|70 Years|No|||November 2013|November 26, 2013|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000373||211185|
NCT00000376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH052737|Cognitive and Drug Therapy for Drug-Resistant Depression|||University of Pennsylvania||Completed|March 1996|February 1999||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|60 Years||||December 2005|October 9, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000376||211182|
NCT00000678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 119|Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.|Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||July 1992|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||320|||Both|13 Years|N/A|No|||September 1992|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000678||210883|
NCT00000443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAJOH10522|Ondansetron Treatment for Alcoholism|Pharmacological Treatment for Alcoholism||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||April 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|25 Years|60 Years|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000443||211115|
NCT00000430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92237|Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis|Clinical Trial of Continuous Low-Dose Hormone Replacement Therapy Combined With Alendronate in Postmenopausal Women With Low Bone Density||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Terminated|October 1999|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Female|60 Years|N/A|Accepts Healthy Volunteers|||February 2004|January 2, 2007|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000430||211128|
NCT00000377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH043832|Preventing the Return of Depression in Elderly Patients|Maintenance Therapies in Late-Life Depression||University of Pittsburgh||Completed|March 1989|April 2000|Actual|April 2000|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|60 Years|80 Years||||June 2013|June 20, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000377||211181|
NCT00000378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3105|Antidepressant Treatment of Melancholia in Late Life|Antidepressant Treatment of Melancholia in Late :Ife||New York State Psychiatric Institute|No|Completed|July 1997|June 2002|Actual|June 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|60 Years|95 Years|No|||September 2008|October 6, 2015|November 2, 1999||No||No|April 2, 2015|https://clinicaltrials.gov/show/NCT00000378||211180|
NCT00000379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH058363|Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)|Treatment of Outcomes of Fluoxetine vs EMDR in PTSD||Boston University||Completed|January 1999|December 2003||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||February 2014|February 19, 2014|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000379||211179|
NCT00000380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10537-A|Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances|Age-Related Sleep Impairment - Treatment w/GHRH||University of Washington||Completed|June 1996|July 2007||July 2007|Actual|N/A|Interventional|Primary Purpose: Treatment|2||||||Both|N/A|N/A||||December 2015|December 1, 2015|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000380||211178|
NCT00000381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH053681|Fluoxetine for Anxious Children|||University of Pittsburgh||Completed|June 1997|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|8 Years|17 Years||||December 2005|January 7, 2014|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000381||211177|
NCT00000382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH054643|Preventing Child Abuse in Infants|Preventive Intervention for Maltreated Infants||University of Rochester|Yes|Completed|July 1998|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|12 Months|12 Months||||November 2013|November 5, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000382||211176|
NCT00000473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62|Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty?|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1989|June 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||April 2012|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000473||211086|
NCT00000474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63|Prevention and Treatment of Hypertension Study (PATHS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1989|September 1994||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||June 2001|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000474||211085|
NCT00000543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86|Oral Calcium in Pregnant Women With Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1993|July 1999|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|18 Years|40 Years|No|||April 2002|February 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000543||211016|
NCT00000544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87|Dietary Approaches to Stop Hypertension (DASH)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1993|July 1997||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|22 Years|100 Years|No|||October 2005|March 22, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000544||211015|
NCT00000617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120|Azithromycin and Coronary Events Study (ACES)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|January 2005||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||May 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000617||210942|
NCT00000628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 184|A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine|A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||October 1994|July 29, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000628||210933|
NCT00000472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61|Thrombolysis in Myocardial Ischemia Trial (TIMI III)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|June 1995|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|76 Years|No|||July 2000|March 15, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000472||211087|
NCT00000498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17|Control of Hypertension by Non-Pharmacologic Means|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1980|March 1983|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|40 Years|100 Years|No|||January 2000|March 23, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000498||211061|
NCT00000554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98|Women's Ischemia Syndrome Evaluation (WISE)|||University of Pittsburgh||Completed|May 2001|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Primary Purpose: Diagnostic|||||||Female|15 Years|N/A|No|||April 2014|April 3, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000554||211005|
NCT00000555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99|Women's Angiographic Vitamin and Estrogen Trial (WAVE)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1996|May 2003||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|38 Years|86 Years|No|||August 2005|August 8, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000555||211004|
NCT00000574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212|Ibuprofen in Sepsis Study|||Vanderbilt University||Completed|September 1990|July 1995||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000574||210985|
NCT00000513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32|Trial of Antihypertensive Intervention Management|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1984|November 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|65 Years|No|||April 2012|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000513||211046|
NCT00000566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204|Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1983|December 1989||||Phase 3|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|75 Years|No|||June 2002|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000566||210993|
NCT00000567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205|High Frequency Ventilation in Premature Infants (HIFI)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1984|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||December 2005|December 21, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000567||210992|
NCT00000826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 283|Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites|Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|65 Years|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000826||210736|
NCT00000827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 273|A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children|A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||45|||Both|2 Years|12 Years|No|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000827||210735|
NCT00000499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18|Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1980|May 1983|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|60 Years|N/A|No|||April 2012|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000499||211060|
NCT00000519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38|Exercise Training and Plasma Lipoproteins in Man|||Stanford University||Completed|July 1982|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|25 Years|49 Years|No|||June 2013|June 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000519||211040|
NCT00000475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64|Prevention of Early Readmission in Elderly Congestive Heart Failure Patients|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1990|March 1995|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|70 Years|100 Years|No|||December 2005|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000475||211084|
NCT00000476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65|Digitalis Investigation Group (DIG)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1990|June 1998||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|75 Years|No|||November 2005|December 1, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000476||211083|
NCT00000568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206|Lung Health Study (LHS) I and III|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1984|January 2005||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|35 Years|60 Years|No|||August 2005|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000568||210991|
NCT00000569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207|Lung Health Study II|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 2000||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|40 Years|69 Years|No|||March 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000569||210990|
NCT00000575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213|Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)|Childhood Asthma Management Program|CAMP|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|September 1991|March 2012|Actual|October 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1041|||Both|5 Years|12 Years|No|||February 2014|February 20, 2014|October 27, 1999|No|Yes||No|October 16, 2013|https://clinicaltrials.gov/show/NCT00000575||210984|
NCT00000576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214|Inhaled Beclomethasone to Prevent Chronic Lung Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1993|April 1999|Actual|||Phase 3|Interventional|Allocation: Randomized|||||||Both|N/A|1 Year|No|||May 2001|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000576||210983|
NCT00000406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR20582 Substudy EEHSR3|Effects of Strength Training on Knee Osteoarthritis|Effects of Strength Training on Knee Osteoarthritis (OA)||Indiana University||Completed|September 1977|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||280|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 29, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000406||211152|
NCT00000520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39|Prevention of Coronary Aneurysms in Kawasaki Syndrome|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1985|November 1989|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||||||Both|1 Year|17 Years|No|||April 2012|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000520||211039|
NCT00000538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81|Dietary Effects on Lipoproteins and Thrombogenic Activity (DELTA)|||University of North Carolina, Chapel Hill||Completed|September 1992|May 1995|Actual|May 1995|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|189|||Both|18 Years|75 Years|No|||August 2014|August 11, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000538||211021|
NCT00000527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46|Recurrent Carotid Stenosis|||Emory University||Completed|August 1986|November 1998|Actual|November 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||December 2013|December 9, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000527||211032|
NCT00000508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27|Stanford Coronary Risk Intervention Project (SCRIP)|||Stanford University||Completed|September 1983|March 1993||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||March 1993|January 8, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000508||211051|
NCT00000577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215|Asthma Clinical Research Network (ACRN)|Asthma Clinical Research Network (ACRN)||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|July 2008||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||August 2006|August 24, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000577||210982|
NCT00000491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10|Aspirin-Myocardial Infarction Study (AMIS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|October 1974|August 1979|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|30 Years|69 Years|No|||April 2012|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000491||211068|
NCT00000492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11|Beta-Blocker Heart Attack Trial (BHAT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1977|October 1981||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|30 Years|69 Years|No|||October 1981|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000492||211067|
NCT00000557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101|Enhancing Recovery in Coronary Heart Disease (ENRICHD) Patients|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||January 2008|January 15, 2008|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000557||211002|
NCT00000516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35|Studies of Left Ventricular Dysfunction (SOLVD)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1985|May 1990|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|21 Years|80 Years|No|||April 2012|April 26, 2012|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000516||211043|
NCT00000528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47|Trials of Hypertension Prevention (TOHP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1986|June 1998|Actual|||Phase 3|Interventional|Intervention Model: Factorial Assignment, Primary Purpose: Prevention|||||||Both|30 Years|54 Years|No|||December 2005|March 15, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000528||211031|
NCT00000548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92|Inhaled NO in Prevention of Chronic Lung Disease|||University of California, San Francisco||Completed|March 2000|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|1 Year|No|||March 2015|March 3, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000548||211011|
NCT00000484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Treatment of Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1966|January 1979|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|21 Years|55 Years|No|||January 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000484||211075|
NCT00000541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84|Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)|Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)|WAFACS|Brigham and Women's Hospital|Yes|Completed|May 1993|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Prevention|||||||Female|40 Years|N/A|No|||January 2016|January 7, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000541||211018|
NCT00000542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85|Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1993|March 2002|Actual|March 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|55 Years|N/A|No|||February 2009|February 4, 2009|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000542||211017|
NCT00000564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202|Nocturnal Oxygen Therapy|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1976|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|35 Years|70 Years|No|||May 2002|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000564||210995|
NCT00000514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33|Systolic Hypertension in the Elderly Program (SHEP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1984|October 1996||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|60 Years|100 Years|No|||January 2005|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000514||211045|
NCT00000494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13|Management of Patent Ductus in Premature Infants|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1978|March 1982|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||April 2012|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000494||211065|
NCT00000485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4|Hypertension Detection and Follow-up Program (HDFP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1971|May 1982||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|30 Years|69 Years|No|||December 2005|December 21, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000485||211074|
NCT00000486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5|Unstable Angina Pectoris Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1972|January 1980|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|65 Years|No|||January 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000486||211073|
NCT00000551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95|Activity Counseling Trial (ACT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1994|September 2002||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|35 Years|75 Years|No|||August 2007|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000551||211008|
NCT00000552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96|Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.|||New England Research Institutes||Completed|September 1994|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2014|March 3, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000552||211007|
NCT00000524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43|Myocarditis Treatment Trial|||University of Utah||Completed|July 1986|March 1994|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||November 2013|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000524||211035|
NCT00000545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88|Pathways|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|July 2002||||Phase 2|Interventional|Primary Purpose: Prevention|||||||Both|7 Years|11 Years|No|||December 2005|January 3, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000545||211014|
NCT00000546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90|Stress Reduction and Atherosclerotic CVD in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1994|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||October 2005|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000546||211013|
NCT00000483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Coronary Drug Project Mortality Surveillance|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1981|March 1985|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Male|30 Years|64 Years|No|||April 2004|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000483||211076|
NCT00000517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36|Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)|||Massachusetts General Hospital||Completed|July 1985|June 1991|Actual|June 1991|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||April 2014|April 9, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000517||211042|
NCT00000518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37|Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)|||University of Utah||Completed|July 1985|December 1992||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000518||211041|
NCT00000500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19|Physicians' Health Study|||Brigham and Women's Hospital||Completed|September 1981|December 1996|Actual|December 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Male|40 Years|84 Years|No|||January 2014|January 24, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000500||211059|
NCT00000501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20|Hypertension Prevention Trial (HPT) Feasibility Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1981|August 1986|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|25 Years|49 Years|No|||April 2012|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000501||211058|
NCT00000487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6|Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)|||University of Minnesota - Clinical and Translational Science Institute||Completed|June 1972|July 1998||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Male|35 Years|57 Years|No|||February 2016|February 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000487||211072|
NCT00000488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7|Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1973|October 1989|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Male|35 Years|59 Years|No|||April 2012|November 9, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000488||211071|
NCT00000489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8|Coronary Artery Surgery Study (CASS)|||University of Washington||Completed|June 1973|December 1996||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|66 Years|No|||December 2005|February 16, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000489||211070|
NCT00000490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9|Program on Surgical Control of Hyperlipidemias (POSCH)|||University of Minnesota - Clinical and Translational Science Institute||Completed|June 1973|December 1997||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|30 Years|64 Years|No|||February 2016|February 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000490||211069|
NCT00000452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAVOL07517|Naltrexone Treatment of Alcohol Dependence|||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||January 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|75 Years|No|||November 2004|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000452||211106|
NCT00000466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55|Postmenopausal Estrogen/Progestin Interventions (PEPI)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1987|October 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|45 Years|64 Years|No|||July 2005|February 25, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000466||211093|
NCT00000454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAACOO11197|Smoking Cessation in Alcoholism Treatment|Field Study of Smoking Cessation in Alcoholism Treatment||Yale University|No|Completed||August 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||112|||Both|21 Years|N/A|No|||May 2010|May 18, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000454||211105|
NCT00000539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82|Arterial Disease Multifactorial Intervention Trial (ADMIT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|March 1999||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2006|January 10, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000539||211020|
NCT00000540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83|Coronary Artery Bypass Graft (CABG) Patch Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1992|December 1998||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||August 2004|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000540||211019|
NCT00000562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200|Extracorporeal Support for Respiratory Insufficiency (ECMO)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1974|November 1979|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|12 Years|65 Years|No|||January 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000562||210997|
NCT00000549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93|Estrogen Replacement and Atherosclerosis (ERA) in Older Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1994|July 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|45 Years|75 Years|No|||December 2005|March 15, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000549||211010|
NCT00000550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94|Rapid Early Action for Coronary Treatment (REACT)|||New England Research Institutes||Completed|August 1994|May 2000|Actual|May 2000|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2014|March 3, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000550||211009|
NCT00000509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28|Potassium and Sodium to Control Blood Pressure in Hypertensives|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1983|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Male|45 Years|68 Years|No|||January 2000|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000509||211050|
NCT00000391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89 MH-SF|A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.|||National Institute of Mental Health (NIMH)||Completed|January 1988|||January 1990|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2002|March 2, 2015|January 17, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00000391||211167|
NCT00000392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH00013|Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.|Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.||National Institute of Mental Health (NIMH)||Completed|January 1990|August 1996|Actual|August 1996|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|60 Years|No|||October 2013|July 29, 2015|January 17, 2000||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT00000392||211166|
NCT00000495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14|Prevention of Hypertension: A Randomized Trial|||Northwestern University||Completed|December 1978|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||||||Both|30 Years|44 Years|No|||January 2000|November 21, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000495||211064|
NCT00000477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66|Cholesterol Reduction in Seniors Program (CRISP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|June 1992|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|65 Years|100 Years|No|||June 1992|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000477||211082|
NCT00000496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15|Platelet Drug Trial in Coronary Disease Progression|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1979|December 1982|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|65 Years|No|||April 2012|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000496||211063|
NCT00000502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21|Evaluation of SC-V Versus Conventional CPR|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1981|June 1985|Actual|||Phase 3|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000502||211057|
NCT00000565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203|Clinical Study of Intermittent Positive Pressure Breathing (IPPB)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1976|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|30 Years|74 Years|No|||May 2002|December 8, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000565||210994|
NCT00000515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34|Randomized Trial of Dietary Intervention Therapy in Obese Hypertensives (DITOH)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1984|September 1992|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||||||Both|25 Years|55 Years|No|||February 2005|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000515||211044|
NCT00000570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208|Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1986|June 1990|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|N/A|1 Year|No|||January 2000|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000570||210989|
NCT00000478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67|Asymptomatic Cardiac Ischemia Pilot (ACIP) Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1990|June 1997||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||February 2002|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000478||211081|
NCT00000479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69|Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer|Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women|WHS|Brigham and Women's Hospital|Yes|Completed|September 1992|February 2005|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|39876|||Female|45 Years|N/A|No|||June 2012|June 12, 2012|October 27, 1999||No||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00000479||211080|
NCT00000480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70|Multicenter Unsustained Tachycardia Trial (MUSTT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|September 1997||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||August 2004|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000480||211079|
NCT00000503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22|Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1982|October 1987|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|77 Years|No|||January 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000503||211056|
NCT00000504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23|Cardiac Arrhythmia Pilot Study (CAPS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1982|September 1985|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||April 2012|April 26, 2012|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000504||211055|
NCT00000505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24|Thrombolysis in Myocardial Infarction (TIMI)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1983|December 1990|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||July 2000|March 15, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000505||211054|
NCT00000506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25|Cardiovascular System in Obesity: Effect of Treatment|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1983|April 1988|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||January 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000506||211053|
NCT00000580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300|Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1975|June 1986|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|3 Years|No|||January 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000580||210979|
NCT00000531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74|Antiarrhythmics Versus Implantable Defibrillators (AVID)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|August 2002||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2005|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000531||211028|
NCT00000571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209|Trial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease|||McGill University||Completed|February 1986|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|30 Years|75 Years|No|||April 2001|December 28, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000571||210988|
NCT00000525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44|Diuretics, Hypertension, and Arrhythmias Clinical Trial|||University of California, San Francisco||Completed|July 1986|||September 1989|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind|||Actual|233|||Male|35 Years|70 Years|No|||September 2013|September 18, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000525||211034|
NCT00000536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79|Sodium Sensitivity in African Americans|||University of Minnesota - Clinical and Translational Science Institute||Completed|July 1992|June 1997||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|25 Years|64 Years|No|||February 2016|February 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000536||211023|
NCT00000537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80|Stress Reduction & CVD Morbidity and Mortality in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1992|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|55 Years|80 Years|No|||July 2008|July 23, 2008|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000537||211022|
NCT00000563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201|Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1976|August 1983|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|1 Year|No|||April 2012|April 26, 2012|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000563||210996|
NCT00000497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16|Dietary Intervention Study for Hypertension (DISH)|||University of Mississippi Medical Center||Completed|January 1980|September 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|40 Years|N/A|No|||January 2000|April 14, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000497||211062|
NCT00000824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRAT 2|A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients|A Pilot Study of HIV Specific Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients With CD4+ T Cells 100-350 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000824||210738|
NCT00000547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91|Enalapril After Anthracycline Cardiotoxicity|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1994|February 2001||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Year|17 Years|No|||December 2005|January 3, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000547||211012|
NCT00000572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210|Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome|Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome||Intermountain Health Care, Inc.|No|Completed|June 1987|January 1993|Actual|April 1991|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||April 2015|April 8, 2015|October 27, 1999||No||No||https://clinicaltrials.gov/show/NCT00000572||210987|
NCT00000573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211|Emphysema: Physiologic Effects of Nutritional Support|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|November 2005|Actual|||Phase 2|Interventional|Allocation: Randomized|||||||Both|18 Years|75 Years|No|||April 2002|February 23, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000573||210986|
NCT00000510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29|Platelet-Inhibitor Drug Trial in Coronary Angioplasty|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1983|September 1988|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|80 Years|No|||March 2005|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000510||211049|
NCT00000511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30|Polyunsaturates and KCL to Control Mild Hypertension|||Brigham and Women's Hospital||Completed|December 1983|November 1994|Actual|November 1994|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|1||||||Both|21 Years|70 Years|No|||December 2013|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000511||211048|
NCT00000655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 167|A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients|A Randomized, Double-Blind Study of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||January 1992|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||300|||Both|13 Years|N/A|No|||February 2011|February 25, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000655||210906|
NCT00000455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAKRA11062|Naltrexone for Early Problem Drinkers|Targeted Naltrexone for Early Problem Drinkers||University of Connecticut Health Center|No|Completed||September 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||160|||Both|18 Years|60 Years|No|||June 2011|June 17, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000455||211104|
NCT00000456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAANT09568|Behavioral Therapy Plus Naltrexone for Alcoholism|Comparison of Cognitive Behavioral Therapy and Motivational Enhancement Therapy Plus Naltrexone for Alcoholism||Medical University of South Carolina||Completed|September 1992|August 2002|Actual|August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|21 Years|70 Years|No|||October 2010|October 1, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000456||211103|
NCT00000457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|972-95|Pharmacologic Relapse Prevention for Alcoholic Smokers|Pharmacologic Relapse Prevention for Alcoholic Smokers||Mayo Clinic|No|Completed|June 1998|August 2007|Actual|April 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000457||211102|
NCT00000523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42|Optimal Exercise Regimens for Persons at Increased Risk|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1986|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|50 Years|65 Years|No|||January 2000|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000523||211036|
NCT00000532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75|Women's Healthy Lifestyle Project: Cardiovascular Risk Factors and Menopause|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1992|January 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|45 Years|50 Years|No|||April 2002|February 23, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000532||211027|
NCT00000672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 118|An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex|An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||February 1993|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||660|||Both|12 Years|N/A|No|||October 1994|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000672||210889|
NCT00000586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306|Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)|Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1992|June 1994|Actual|June 1994|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|No|||January 2009|November 9, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000586||210973|
NCT00000493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12|Multicenter Investigation of Limitation of Infarct Size (MILIS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1977|December 1985||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|74 Years|No|||December 1985|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000493||211066|
NCT00000558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102|Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1995|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|50 Years|N/A|No|||January 2008|January 15, 2008|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000558||211001|
NCT00000507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26|Intravenous Streptokinase in Acute Myocardial Infarction|||University of Washington||Completed|August 1983|October 1994||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|74 Years|No|||October 1994|February 8, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000507||211052|
NCT00000533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76|Montreal Heart Attack Readjustment Trial (M-HART)|Montreal Heart Attack Readjustment Trial (M-HART)||McGill University||Completed|February 1992|December 1996||||Phase 3|Interventional|N/A|||||||Both|18 Years|75 Years|No|||March 2005|December 28, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000533||211026|
NCT00000534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77|Calcium for Pre-Eclampsia Prevention (CPEP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1991|June 2000||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|18 Years|40 Years|No|||February 2002|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000534||211025|
NCT00000553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97|HDL-Atherosclerosis Treatment Study (HATS)|||University of Washington||Completed|September 1994|February 2001||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Prevention|||||||Both|35 Years|68 Years|No|||March 2005|February 8, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000553||211006|
NCT00000458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMOA10476|Sertraline and Cognitive Therapy in Depressed Alcoholics|Sertraline and Cognitive Therapy in Depressed Alcoholics||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||January 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000458||211101|
NCT00000603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316|Cord Blood Stem Cell Transplantation Study (COBLT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|55 Years|No|||January 2008|January 18, 2008|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000603||210956|
NCT00000615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118|Girls Health Enrichment Multi-Site Studies (GEMS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1999|November 2006||||Phase 2|Interventional|Primary Purpose: Prevention|||||||Female|8 Years|10 Years|No|||April 2005|October 2, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000615||210944|
NCT00000616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119|PREMIER: Lifestyle Interventions for Blood Pressure Control|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|25 Years|100 Years|No|||November 2005|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000616||210943|
NCT00000559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103|Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1995|August 2001||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|45 Years|75 Years|No|||May 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000559||211000|
NCT00000560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104|Beta-Blocker Evaluation in Survival Trial (BEST)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1994|September 1999||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind|||||||Both|18 Years|N/A|No|||April 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000560||210999|
NCT00000561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105|Mode Selection Trial in Sinus Node Dysfunction (MOST)|||Mt. Sinai Medical Center, Miami||Completed|June 1995|May 2002||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2005|February 22, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000561||210998|
NCT00000578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216|NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1994|October 2000||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|40 Years|No|||February 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000578||210981|
NCT00000521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40|Sodium-Potassium Blood Pressure Trial in Children|Sodium-Potassium Blood Pressure Trial in Children||University of Minnesota - Clinical and Translational Science Institute||Completed|August 1985|December 1990|Actual|July 1990|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|285|||Both|10 Years|13 Years|No|||May 2014|May 27, 2014|October 27, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000521||211038|
NCT00000522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41|Treatment of Mild Hypertension Study (TOMHS)|||University of Minnesota - Clinical and Translational Science Institute||Completed|August 1985|May 1994||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|45 Years|69 Years|No|||February 2016|February 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000522||211037|
NCT00000459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48|Dietary Intervention Study in Children (DISC)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1986|January 1999||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|8 Years|10 Years|No|||March 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000459||211100|
NCT00000460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49|Training Levels Comparison Trial|Training Levels Comparison (TLC) Trial in Patients With Coronary Heart Disease||University of Alabama at Birmingham||Withdrawn|December 1986|March 1991|Actual|March 1991|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Male|30 Years|67 Years|No|Non-Probability Sample|Men between the ages of 30 and 67 who respond to an advertisement for research        participants.|November 2013|January 5, 2016|October 27, 1999||No|due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT00000460||211099|
NCT00000461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50|Harvard Atherosclerosis Reversibility Project (HARP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1986|November 1992|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2005|March 15, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000461||211098|
NCT00000825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 021C|The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3|A Randomized, Open-Label Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 1998|||March 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000825||210737|
NCT00000579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217|Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)|Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1994|July 2004|Actual|||Phase 3|Interventional|Intervention Model: Factorial Assignment, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||August 2006|March 22, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000579||210980|
NCT00000471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60|Lifestyle Heart Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|March 1993|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|35 Years|75 Years|No|||January 2000|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000471||211088|
NCT00000529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72|Tamoxifen Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1992|November 1995||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|35 Years|75 Years|No|||August 2001|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000529||211030|
NCT00000530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73|Raynaud's Treatment Study (RTS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|June 1998||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||August 2004|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000530||211029|
NCT00000512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28764-W|Familial Atherosclerosis Treatment Study|Familial Atherosclerosis Treatment Study|FATS|University of Washington|Yes|Completed|January 1984|August 1989|Actual|August 1989|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|146|||Male|18 Years|62 Years|No|||December 2015|December 1, 2015|October 27, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000512||211047|
NCT00000650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 166|An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients|An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|50 Years|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000650||210911|
NCT00000661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 124|The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient|The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|18 Years|N/A|No|||December 1994|August 1, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000661||210900|
NCT00000481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71|Women's Health Trial: Feasibility Study in Minority Populations|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|January 1996||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|50 Years|69 Years|No|||February 2001|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000481||211078|
NCT00000469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58|Asymptomatic Carotid Artery Plaque Study (ACAPS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1988|August 1998|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|40 Years|79 Years|No|||April 2000|February 25, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000469||211090|
NCT00000412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR046124|Osteoporosis Prevention After Heart Transplant|Prevention of Osteoporosis After Cardiac Transplantation||Columbia University||Completed|September 1997|April 2002|Actual|April 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|149|||Both|20 Years|70 Years|No|||July 2015|July 2, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000412||211146|
NCT00000425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01 AR43584 Substudy 0003|Toward Better Outcomes in Osteoarthritis|Toward Better Outcomes in Osteoarthritis (OA): Finding the Appropriate Role for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)||Stanford University||Completed|July 1996|April 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||900|||Both|50 Years|85 Years|No|||April 2013|April 30, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000425||211133|
NCT00000426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR042155|Treatment of Calcium Deficiency in Young Women|Treatment of Calcium Deficiency in Young Women||Creighton University||Completed|January 1995|June 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Female|19 Years|27 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000426||211132|
NCT00000436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR038520|Improving Functional Recovery After Hip Fracture|Self-Efficacy and High-Intensity Strength Training to Improve Postoperative Rehabilitation of Hip Fracture Patients||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|July 1993|June 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|65 Years|N/A|No|||March 2001|January 2, 2007|January 29, 2000||||No||https://clinicaltrials.gov/show/NCT00000436||211122|
NCT00000447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-SCHMITZ-11216-04|Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch)|Behavioral/Pharmacological Treatments for Alcohol-Nicotine Dependence||The University of Texas Health Science Center, Houston||Completed|September 1998|May 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|50 Years|No|||September 2010|September 30, 2010|November 2, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00000447||211111|
NCT00000470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59|Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1988|December 2002||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||March 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000470||211089|
NCT00000482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Coronary Drug Project|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1965|March 1985|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Male|30 Years|64 Years|No|||July 2004|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000482||211077|
NCT00000440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAFAR11222|Sertraline and Naltrexone for Alcohol Dependence|Sertraline and Naltrexone for Alcohol Dependents||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||September 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||124|||Both|18 Years|55 Years|No|||November 2004|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000440||211118|
NCT00000441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMAL10761|Drug Therapy for Alcohol Detoxification|Carbamazepine and Lorazepam in Outpatient Detoxification||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||December 2000||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|70 Years|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000441||211117|
NCT00000433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92244|Blocking Tumor Necrosis Factor in Ankylosing Spondylitis|Anti-Tumor Necrosis Factor (TNFR:Fc) in Ankylosing Spondylitis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|October 1999|March 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|80 Years|No|||February 2003|January 2, 2007|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000433||211125|
NCT00000407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR020614|Improving Vocational Outcomes in Arthritis|Improving Vocational Outcomes in Arthritis||University of Alabama at Birmingham||Completed|January 1997|December 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|326|||Both|18 Years|55 Years|No|||September 2015|January 5, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000407||211151|
NCT00000684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 105|Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals|Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1991|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||10|||Both|19 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000684||210877|
NCT00000685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 088|A Study of Zidovudine in HIV-Infected Patients With Kidney Problems|Evaluation of Zidovudine Pharmacokinetics in Patients With Human Immunodeficiency Virus and Varying Degrees of Renal Insufficiency||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||February 1990|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000685||210876|
NCT00000403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR043348|Doxycycline and OA Progression|Effect of Doxycycline on Osteoarthritis (OA) Progression||Indiana University||Completed|September 1996|July 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||432|||Female|45 Years|64 Years|No|||April 2013|April 29, 2013|November 3, 1999||||||https://clinicaltrials.gov/show/NCT00000403||211155|
NCT00000410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AR45444 NIAMS-004C|Spine Patient Outcomes Research Trial (SPORT) - Intervertebral Disc Herniation|Spine Patient Outcomes Research Trial (SPORT): A Multicenter Randomized Trial for Intervertebral Disc Herniation (IDH)|SPORT|Dartmouth-Hitchcock Medical Center|Yes|Completed|March 2000|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|501|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000410||211148|
NCT00000405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR045655|Effects of Jumping on Growing Bones|The Effects of Jumping on Growing Bones||Oregon State University||Completed|September 1998|November 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||February 2003|December 13, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000405||211153|
NCT00000424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR042165|Tidal Lavage in Knee Osteoarthritis|Tidal Lavage vs. Sham Lavage in Knee Osteoarthritis (OA)||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|July 1995|June 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|40 Years|N/A|No|||March 2001|December 28, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000424||211134|
NCT00000413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR020618|Osteoporosis Prevention in Preadolescent Girls|Osteoporosis Prevention in Preadolescent Girls||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|July 1998|June 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||340|||Female|9 Years|13 Years|Accepts Healthy Volunteers|||February 2003|December 28, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000413||211145|
NCT00000417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR36308 NIAMS-014|Psychoeducational Approach to Improve Health in Lupus|A Randomized Controlled Trial of a Psychoeducational Intervention to Improve Outcomes in Systemic Lupus Erythematosus (SLE)||Brigham and Women's Hospital||Completed|April 1997|March 2001|Actual|March 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|75 Years|No|||December 2013|December 23, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000417||211141|
NCT00000421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR044690|Serologically Active, Clinically Stable Systemic Lupus Erythematosus|Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)|SACS-SLE|New York University School of Medicine|No|Completed|September 1997|August 2003|Actual|August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|154|||Female|13 Years|65 Years|No|||March 2016|March 2, 2016|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000421||211137|
NCT00000439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASAL10523|Drug Treatment for Alcoholics With Bipolar Disorder|Efficacy of Valproate Maintenance in Bipolar Alcoholics||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|No|Completed|October 2000|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|65 Years|No|||February 2009|February 24, 2009|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000439||211119|
NCT00000435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92241|dnaJ Peptide for Relieving Rheumatoid Arthritis|A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis (RA)||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|September 1999|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|85 Years|No|||July 2007|July 30, 2007|January 21, 2000||||||https://clinicaltrials.gov/show/NCT00000435||211123|
NCT00000446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAABRA10761|Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder|Sertraline Treatment in Comorbid Post-Traumatic Stress Disorder and Alcoholism||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||December 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000446||211112|
NCT00000429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR044059|Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis|Calcium Supplementation for Bone Mineralization in Juvenile Rheumatoid Arthritis (JRA)||Children's Hospital Medical Center, Cincinnati||Completed|June 1996|May 2001||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||192|||Both|6 Years|18 Years|No|||July 2013|July 31, 2013|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000429||211129|
NCT00000449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMON7850|Behavior and Naltrexone Treatment for Alcoholics|Coping, Exposure, and Naltrexone Treatment With Alcoholics||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||March 2000||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Primary Purpose: Treatment||||160|||Both|18 Years|65 Years|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000449||211109|
NCT00000432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR36308 NIAMS-017|Lyme Disease Prevention Program|A Controlled Trial of a Primary and Secondary Program for Lyme Disease||Brigham and Women's Hospital||Completed|April 1997|March 2001|Actual|March 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention||||20000|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 23, 2013|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00000432||211126|
NCT00000389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH60005|Treatment for Anxiety in Children|Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study||National Institute of Mental Health (NIMH)||Completed|October 1996|November 1999||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|6 Years|17 Years|No|||November 2005|June 13, 2007|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000389||211169|
NCT00000385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29MH057093|Long-Term Lithium Treatment for Aggressive Conduct Disorder|Long-Term Lithium for Aggressive Conduct Disorder||Drexel University|No|Completed|September 1997|June 2005|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|9 Years|17 Years|No|||November 2013|November 25, 2013|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000385||211173|
NCT00000401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR045255|Oral Collagen for Rheumatoid Arthritis|Open Label Multicenter Induction of CII Tolerance in Patients With Rheumatoid Arthritis||University of Tennessee|Yes|Completed|July 1999|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|80 Years|No|||May 2013|May 28, 2013|November 3, 1999|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00000401||211157|
NCT00000402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR040736|Calcium and Bone Mass in Young Females|Long Term Effects of Calcium on Bone Mass in Young Females||Ohio State University||Completed|August 1991|December 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||354|||Female|8 Years|13 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000402||211156|
NCT00000409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AR45444 NIAMS-004A|Spine Patient Outcomes Research Trial (SPORT): Degenerative Spondylolisthesis With Spinal Stenosis|Spine Patient Outcomes Research Trial (SPORT): A Multicenter Randomized Trial for Degenerative Spondylolisthesis (DS) With Spinal Stenosis (SpS) at L4/L5 Level.|SPORT|Dartmouth-Hitchcock Medical Center|Yes|Completed|March 2000|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000409||211149|
NCT00000418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR20582 Substudy EEHSR4|Psychosocial Treatment for Acute Low Back Pain|Psychosocial Intervention for Acute Low Back Pain (ALBP)||Indiana University||Completed|September 1977|March 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||211|||Both|18 Years|N/A|No|||June 1999|June 4, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000418||211140|
NCT00000411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AR45444 NIAMS-004B|Spine Patient Outcomes Research Trial (SPORT): Spinal Stenosis|Spine Patient Outcomes Research Trial (SPORT): A Multicenter Trial for Spinal Stenosis (SpS)||Dartmouth-Hitchcock Medical Center|Yes|Completed|March 2000|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|289|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000411||211147|
NCT00000692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 100|Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex|Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||March 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000692||210869|
NCT00000414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01 AR43584 Substudy 004|Patient Education in Rheumatoid Arthritis and Osteoarthritis|Patient Education Strategies for Better Outcomes in Rheumatoid Arthritis (RA) and Osteoarthritis (OA)||Stanford University|No|Completed|July 1996|April 2001|Actual|April 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1200|||Both|18 Years|N/A|No|||November 2004|June 19, 2013|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000414||211144|
NCT00000428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR045416|Combining N-of-1 Trials to Assess Fibromyalgia Treatments|Combining N-of-1 Trials to Assess Fibromyalgia Therapies||Tufts Medical Center|Yes|Completed|September 2000|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|60 Years|No|||July 2013|July 31, 2013|January 18, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00000428||211130|
NCT00000422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14866-D|Tailored Treatments of Fibromyalgia|Subgroups of FMS: Symptoms, Beliefs and Tailored Treatments||University of Washington||Completed|July 1998|May 2004|Actual|May 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||312|||Female|21 Years|65 Years|No|||October 2013|October 29, 2013|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000422||211136|
NCT00000450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMAS10518|Naltrexone Maintenance Treatment of Alcoholism|Nalmefene Maintenance Treatment of Alcoholism||The Scripps Research Institute||Completed||April 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||184|||Both|18 Years|65 Years|No|||July 2010|July 21, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000450||211108|
NCT00000445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAABRA11747|Use of Naltrexone in a Clinical Setting|Effectiveness of Naltrexone in a Community Setting||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||September 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||July 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000445||211113|
NCT00000438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMCC11855|Naltrexone Treatment for Alcoholism|Naltrexone Treatment for Alcoholism: Predicting Outcome||Johns Hopkins University|No|Completed||March 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||192|||Both|30 Years|55 Years|No|||May 2010|May 13, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000438||211120|
NCT00000408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR044939|Low Back Pain Patient Education Evaluation|Evaluation of a Low Back Pain Patient Education Program||Stanford University|No|Completed|February 1998|February 2002|Actual|February 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|580|||Both|18 Years|N/A|No|||February 2003|April 30, 2013|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000408||211150|
NCT00000442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAKRA3510|Naltrexone for Relapse Prevention|Etiology and Treatment of Alcohol Dependence||University of Connecticut Health Center||Completed||December 2002||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||57|||Both|18 Years|60 Years|No|||June 2011|June 17, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000442||211116|
NCT00000383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10MH055963|Treatment of Post-Traumatic Stress Disorder (PTSD) in Sexually Abused Children|Treatment of PTSD in Sexually Abused Children||Allegheny Singer Research Institute|Yes|Completed|September 1997|September 2002|Actual|September 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|229|||Both|8 Years|14 Years|No|||March 2015|March 27, 2015|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000383||211175|
NCT00000384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10MH055126|Treatment of Obsessive-Compulsive Disorder (OCD) in Children|Treatment of Pediatric Obsessive-Compulsive Disorder||National Institute of Mental Health (NIMH)||Completed|May 1997|April 2002||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|8 Years|16 Years|No|||November 2005|November 18, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000384||211174|
NCT00000395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29AR042674|Antifolate Effectiveness in Arthritis|Mechanisms of Antifolate Efficacy in Arthritis||University of Alabama at Birmingham||Completed|September 1996|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|85 Years|No|||June 2013|January 5, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000395||211163|
NCT00000396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR020557|Arthritis Patient Education for Urban African Americans|Evaluating/Reinforcing Arthritis Patient Education for Urban African Americans||University of Michigan|No|Completed|September 1997|October 2002|Actual|March 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|90|||Both|18 Years|N/A|No|||June 2013|June 8, 2013|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000396||211162|
NCT00000696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 068|A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease|A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||48|||Both|12 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000696||210865|
NCT00000697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 092|A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir|A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|0|||Both|13 Years|65 Years|No|||May 2012|May 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000697||210864|
NCT00000387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH056580|Self-Management Therapy for Youth With Schizophrenia|Self-Management Therapy for Youth With Schizophrenia|FamCent|National Institute of Mental Health (NIMH)|No|Completed|April 1998|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|19 Years|No|||December 2007|December 26, 2007|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000387||211171|
NCT00000388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH050453|Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)|Multimodal Treatment Study of Children With ADHD|MTA|New York University School of Medicine||Completed|September 1998|November 1999||||Phase 4|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|7 Years|9 Years||||September 2015|September 28, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000388||211170|
NCT00000419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AR42540 NIAMS-028A|Safety of Estrogens in Lupus: Hormone Replacement Therapy|Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Hormone Replacement Therapy||New York University School of Medicine||Terminated|April 1996|August 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Female|18 Years|85 Years|No|||May 2013|May 1, 2013|November 3, 1999||||||https://clinicaltrials.gov/show/NCT00000419||211139|
NCT00000390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH042952|Antidepressant Treatment of AIDS Related Depression.|||National Institute of Mental Health (NIMH)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||April 2000|April 22, 2015|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00000390||211168|
NCT00000415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR045310|Physical Activity, Calcium, and Bone in Children|Calcium Modifies Bone Response to Activity in Children||South Dakota State University||Completed|April 1998|March 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||224|||Both|3 Years|4 Years|Accepts Healthy Volunteers|||June 2013|June 3, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000415||211143|
NCT00000437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMAS11210|Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)|Nalmefene in Nicotine and Alcohol Dependence||The Scripps Research Institute||Completed||December 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||166|||Both|18 Years|65 Years|No|||July 2010|July 21, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000437||211121|
NCT00000423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR044020|Support, Health, and Fibromyalgia|Social Support and Health in Fibromyalgia||San Diego State University||Completed|September 1996|February 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label||||600|||Both|21 Years|N/A|No|||March 2001|December 3, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000423||211135|
NCT00000434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR030692|Impact of Exercise on Older Persons With Osteoarthritis|Impact of Exercise on Older Persons With Osteoarthritis (OA)||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|No|Completed|December 1983|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|217|||Both|60 Years|N/A|No|||December 2007|December 20, 2007|January 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00000434||211124|
NCT00000444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAJOS11124|Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)|Timing of Smoking Intervention in Alcohol Treatment||Minneapolis Veterans Affairs Medical Center||Completed|September 1997|January 2004|Actual|January 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|21 Years|75 Years|No|||January 2008|February 10, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000444||211114|
NCT00000427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AR044855|Effects of Parathyroid Hormone in Men With Osteoporosis|Anabolic Actions of Parathyroid Hormone in Osteoporotic Men||Massachusetts General Hospital||Completed|September 1999|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||81|||Male|46 Years|85 Years|No|||December 2013|December 6, 2013|January 18, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000427||211131|
NCT00000393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89 MH-28|A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).|||National Institute of Mental Health (NIMH)||Completed|January 1988|||January 1990|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Both|18 Years|N/A|No|||April 2002|February 26, 2015|January 17, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00000393||211165|
NCT00000394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR045894|Acupuncture for Carpal Tunnel Syndrome|A Controlled Trial of Acupuncture for Carpal Tunnel Syndrome||George Washington University||Completed|May 1999|January 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||144|||Both|18 Years|70 Years|No|||June 2000|May 14, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000394||211164|
NCT00000448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAOMA10225|Naltrexone Treatment for Alcoholic Women|Naltrexone: Consummatory Behaviors in Alcoholic Women||Yale University|No|Completed|October 1995|December 2000|Actual|December 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|50 Years|No|||May 2014|May 6, 2014|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000448||211110|
NCT00000526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45|Cardiac Arrhythmia Suppression Trial (CAST)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1986|March 1998||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||August 2004|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000526||211033|
NCT00000431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92238|Preliminary Testing of New Treatment for Chronic Leg Wounds|Phase I Trial to Evaluate the Safety of Platelet Derived Growth Factor B (PDGF-B) and a Limb Compression Bandage in Venous Leg Ulcers||University of Pennsylvania|Yes|Completed|January 2005|March 2011|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|90 Years|No|||March 2009|May 8, 2013|January 18, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00000431||211127|
NCT00000451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAOMA12028|Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)|Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives||Yale University||Completed|January 2003|November 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|65 Years|No|||January 2013|January 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000451||211107|
NCT00000467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56|Child and Adolescent Trial for Cardiovascular Health (CATCH)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1987|March 1991|Actual|March 1991|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||||||Both|7 Years|11 Years|No|||January 2008|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000467||211092|
NCT00000468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57|Myocardial Infarction Triage and Intervention Project (MITI)|||University of Washington||Completed|April 1988|March 1992||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|35 Years|71 Years|No|||June 2001|February 8, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000468||211091|
NCT00000386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH058459|Behavior Therapy for Children and Adolescents With Obsessive-Compulsive Disorder (OCD)|Behavior Therapy for Childhood OCD||National Institute of Mental Health (NIMH)||Completed|December 1998|November 2003||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|8 Years|17 Years|No|||February 2008|February 8, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000386||211172|
NCT00000397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008633|Behavioral Insomnia Therapy for Fibromyalgia|Behavioral Insomnia Therapy for Fibromyalgia Patients||Duke University||Completed|July 1999|September 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|106|||Both|21 Years|65 Years|No|||December 2005|July 18, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000397||211161|
NCT00000404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR20582 Substudy: EEHSR 2|Effects of Comprehensive Care for Knee OA|Effects of Comprehensive Care for Knee Osteoarthritis (OA)||Indiana University||Completed|April 1997|March 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|40 Years|N/A|No|||April 2013|April 29, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000404||211154|
NCT00000398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR044064|Behavioral Treatment of Fibromyalgia|Behavioral Treatment of Fibromyalgia||Ohio University||Completed|July 1996|June 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|21 Years|N/A|No|||June 2000|November 26, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000398||211160|
NCT00000399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR039559|Bone Estrogen Strength Training|Bone Estrogen Strength Training (BEST)||University of Arizona||Completed|August 1995|January 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000399||211159|
NCT00000400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AR44855 NIAMS-023|Alendronate and/or Parathyroid Hormone for Osteoporosis|Bone Formation-Resorption Coupling and Osteoporosis||Massachusetts General Hospital|Yes|Completed|August 1999|June 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|176|||Both|45 Years|85 Years|No|||December 2013|December 6, 2013|November 3, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000400||211158|
NCT00000416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR020613|Prevention of Arthritis-Related Work Disability|Prevention of Arthritis-Related Work Disability: A Trial of Job Retention Services Provided to Employed Persons With Arthritis||Boston University|No|Completed|September 1997|August 2001|Actual|August 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|242|||Both|18 Years|65 Years|No|||July 2013|July 31, 2013|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00000416||211142|
NCT00000420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AR42540 NIAMS-028B|Safety of Estrogens in Lupus: Birth Control Pills|Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Oral Contraceptives||New York University School of Medicine||Completed|June 1997|August 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Female|18 Years|39 Years|No|||May 2013|May 1, 2013|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00000420||211138|
NCT00000535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78|Trial of Nonpharmacologic Interventions in Elderly (TONE)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|March 1997||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Treatment|||||||Both|60 Years|80 Years|No|||October 2002|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000535||211024|
NCT00000556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100|Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1995|September 2002||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|65 Years|100 Years|No|||November 2005|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000556||211003|
NCT00000713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 038|A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects|A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1992|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000713||210848|
NCT00000714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 039|An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies|An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2004|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000714||210847|
NCT00000607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC ID unknown (110)|Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)|The REMATCH Trial: Rationale, Design, and End Points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure||Columbia University|No|Completed|October 1997|March 1999|Actual|March 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|72 Years|No|||December 2015|December 22, 2015|October 27, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000607||210952|
NCT00000608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111|Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1997|July 2002|Actual|July 2002|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||||||Both|22 Years|N/A|No|||January 2008|January 15, 2008|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000608||210951|
NCT00000609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112|Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1997|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|19 Years|90 Years|No|||November 2005|February 25, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000609||210950|
NCT00000610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113|Magnesium in Coronaries (MAGIC)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1998|November 2003||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000610||210949|
NCT00000793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 242|A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection|A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1997|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000793||210769|
NCT00000722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 041|Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy|Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1991|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||45|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000722||210839|
NCT00000727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 021|A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)|A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1991|Actual|||Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||322|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000727||210834|
NCT00000686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 111|A Study of d4T in Patients With AIDS or AIDS-Related Complex Who Cannot Take AZT|A Phase I Safety Study of BMY-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [d4T]) Administered Four Times Daily to AZT-Intolerant Patients With AIDS or AIDS-Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||May 1999|August 25, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000686||210875|
NCT00000717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 044|The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS|The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1991|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||50|||Both|13 Years|N/A|No|||October 2012|October 18, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000717||210844|
NCT00000715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 040|A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS|A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Pneumonia in AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1991|Actual|||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||240|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000715||210846|
NCT00000625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 175|A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3|A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1995|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||2100|||Both|12 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000625||210936|
NCT00000721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 066|An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive|An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1991|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||85|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000721||210840|
NCT00000690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 078|Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers|Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1989|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||6|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000690||210871|
NCT00000709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 061|An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts|An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1990|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||50|||Both|12 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000709||210852|
NCT00000716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 043|A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection|A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||January 1991|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||70|||Both|3 Months|12 Years|No|||May 1990|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000716||210845|
NCT00000703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 008|Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members|Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1990|Actual|||N/A|Interventional|Primary Purpose: Treatment||||45|||Both|19 Years|69 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000703||210858|
NCT00000726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 015|Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome|Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1992|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||53|||Both|13 Years|65 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000726||210835|
NCT00000683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 002|A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus|A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1993|Actual|||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Prevention||||54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000683||210878|
NCT00000724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS 401|A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia|A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2004|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||December 2012|December 18, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000724||210837|
NCT00000961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 131|The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants|A Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HIVIG) and of Zidovudine (ZDV) in Infants With Documented HIV Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||May 1991|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||112|||Both|N/A|3 Months|No|||March 1998|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000961||210602|
NCT00000689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 074|Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma|Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1991|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||18|||Both|13 Years|N/A|No|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000689||210872|
NCT00000730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 030|Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients|A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to Conventional Drugs||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||March 1989|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||240|||Both|12 Years|N/A|No|||May 2012|May 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000730||210831|
NCT00000707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 048|Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms|Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1991|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||20|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000707||210854|
NCT00000962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 164|The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients|An Open Label, Staggered Rising Dose Cohort Study Assessing Safety, Tolerance, and Activity of BI-RG-587 in Patients With HIV Infection (CD4+ Cell Count < 400 Cells/mm3)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 1994|August 1, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000962||210601|
NCT00000736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 019|Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals|Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||3200|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000736||210825|
NCT00000734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 037|Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine|Evaluation of the Interaction Between High Dose Trimethoprim/Sulfamethoxazole and Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|50 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000734||210827|
NCT00000775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 011|A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)|A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000775||210786|
NCT00000698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX 303|A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis|A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2007|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Months|N/A|No|||April 1992|September 26, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000698||210863|
NCT00000699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS 403|A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients|A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|No|||April 2003|August 25, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000699||210862|
NCT00000704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 012|A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.|A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1990|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||64|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000704||210857|
NCT00000691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 093|A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure|A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1992|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||156|||Both|13 Years|65 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000691||210870|
NCT00000780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 220|A "Pre-Enrollment" Protocol for HIV-Infected Adolescents|A "Pre-Enrollment" Protocol for HIV-Infected Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||250|||Both|13 Years|20 Years|No|||March 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000780||210781|
NCT00000729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 028|A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease|A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1992|Actual|||Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||10|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000729||210832|
NCT00000712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 063|A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3|A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1994|Actual|||Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000712||210849|
NCT00000708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 059|Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||July 1991|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||July 1991|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000708||210853|
NCT00000757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 003A|A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1992|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000757||210804|
NCT00000725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 013|A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma|A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1990|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000725||210836|
NCT00000718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 047|A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC|A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1991|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||112|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000718||210843|
NCT00000963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 144|A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine|A Randomized Comparative Trial of Two Doses of 2',3'-Dideoxyinosine (ddI) in Children With Symptomatic HIV Infection Who Are Either Unresponsive to Zidovudine and/or Who Are Intolerant to Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1995|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||300|||Both|3 Months|18 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000963||210600|
NCT00000676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 981|Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)|Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1993|Actual|||Phase 3|Interventional|Primary Purpose: Prevention||||500|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000676||210885|
NCT00000723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 009|The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer|Chemotherapy, Radiotherapy, and Azidothymidine for AIDS-Related Primary CNS Lymphoma||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||March 1990|Actual|||N/A|Interventional|Primary Purpose: Treatment||||45|||Both|18 Years|70 Years|No|||May 2012|May 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000723||210838|
NCT00000737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 004|A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome|A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||January 1994|August 22, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000737||210824|
NCT00000700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 002|A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP|A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||482|||Both|12 Years|N/A|No|||February 2012|February 15, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000700||210861|
NCT00000701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 003|A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)|A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1990|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|3 Months|12 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000701||210860|
NCT00000694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 090|A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma|A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1992|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000694||210867|
NCT00000695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 057|Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma|Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1991|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||36|||Both|12 Years|N/A|No|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000695||210866|
NCT00000594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400|NHLBI Type II Coronary Intervention Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1971|November 1976|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|21 Years|55 Years|No|||April 2012|April 26, 2012|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000594||210965|
NCT00000595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401|Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1978|September 1994|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|5 Years|N/A|No|||May 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000595||210964|
NCT00000596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402|Diffuse Fibrotic Lung Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1978|January 1983|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2002|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000596||210963|
NCT00000740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 173|Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects|Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1993|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||44|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000740||210821|
NCT00000711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 065|Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC|Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||60|||Both|12 Years|N/A|No|||April 2012|April 25, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000711||210850|
NCT00000705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 017|Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia|A Phase I Trial to Evaluate Azidothymidine (AZT) in the Treatment of HIV Infections in Patients With Hemophilia||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1989|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|12 Years|N/A|No|||August 2014|August 4, 2014|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000705||210856|
NCT00000719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 050|A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease|A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||96|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000719||210842|
NCT00000964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 136|The Effect of Stomach Acid on Foscarnet|The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1990|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||6|||Male|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000964||210599|
NCT00000733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 035|Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients|Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1991|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000733||210828|
NCT00000731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 032|Evaluation of the Interaction Between Acetaminophen and Zidovudine|Evaluation of the Interaction Between Acetaminophen and Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|50 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000731||210830|
NCT00000732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 033|Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine|Evaluation of the Interaction Between Low Dose Trimethoprim/Sulfamethoxazole and Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|50 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000732||210829|
NCT00000682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 112|A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002|A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1992|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||120|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000682||210879|
NCT00000677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 125|SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy|SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||50|||Both|13 Years|N/A|No|||December 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000677||210884|
NCT00000783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HATS COUPLES|Heterosexual HIV Transmission Study (HATS)|Heterosexual HIV Transmission Study (HATS)||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|June 1994|||November 1999|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||Samples With DNA|Seminal and cervico-vaginal fluids will be collected as well as blood and urine samples.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sexually active HIV-infected concordant and discordant couples|October 2012|October 29, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000783||210778|
NCT00000743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 201|A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons|A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||64|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000743||210818|
NCT00000702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 005|A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection|A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1990|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||315|||Both|12 Years|N/A|No|||February 2012|February 15, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000702||210859|
NCT00000706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 027|Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine|Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1988|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000706||210855|
NCT00000673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 085|A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy|A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||38|||Both|13 Years|65 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000673||210888|
NCT00000679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 114|(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC|(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||February 1994|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||December 1994|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000679||210882|
NCT00000965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 161|The Effects of Zidovudine on the Blood of HIV-Infected Patients|Pharmacokinetics of Total Phosphorylated Zidovudine in Mononuclear Cells From HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||August 1993|Actual|N/A|Interventional|Primary Purpose: Treatment||||20|||Both|13 Years|N/A|No|||February 2011|February 25, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000965||210598|
NCT00000710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 064|A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex|A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000710||210851|
NCT00000629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 191|The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.|The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||6|||Male|18 Years|50 Years|No|||October 2003|July 29, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000629||210932|
NCT00000589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309|Trial to Reduce Alloimmunization to Platelets (TRAP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1989|July 1997||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|15 Years|75 Years|No|||May 2000|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000589||210970|
NCT00000640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 108|A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS|A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1994|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||290|||Both|13 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000640||210921|
NCT00000627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 174|Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome|Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1994|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||90|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000627||210934|
NCT00000585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305|Penicillin Prophylaxis in Sickle Cell Disease (PROPS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1983|October 1994||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|5 Years|No|||October 1994|March 24, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000585||210974|
NCT00000681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 094|A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma|A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||24|||Both|14 Years|N/A|No|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000681||210880|
NCT00000636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 004|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1997|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||2000|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000636||210925|
NCT00000669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 091|A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection|A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|3 Months|12 Years|No|||October 1996|August 25, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000669||210892|
NCT00000823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 276|A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection|A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 2000|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||85|||Both|13 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000823||210739|
NCT00000657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 140|Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex|Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1992|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000657||210904|
NCT00000626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 149|Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease|Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1999|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||27|||Both|12 Years|N/A|No|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000626||210935|
NCT00000583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303|Hepatitis B Vaccine Clinical Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1978|June 1980|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Male|18 Years|36 Years|No|||April 2012|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000583||210976|
NCT00000665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 129|Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component|Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||April 1992|Actual|N/A|Interventional|Primary Purpose: Treatment||||240|||Both|13 Years|N/A|No|||December 1994|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000665||210896|
NCT00000666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 001|A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection|A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1992|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||600|||Both|13 Years|N/A|No|||October 2012|October 26, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000666||210895|
NCT00000652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 176|A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection|A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1995|Actual|||Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||85|||Both|3 Months|18 Years|No|||October 2012|October 31, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000652||210909|
NCT00000653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 138|A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT|A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1995|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||140|||Both|3 Months|18 Years|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000653||210908|
NCT00000593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|313|Viral Activation Transfusion Study (VATS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1994|March 2001||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||December 2005|January 3, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000593||210966|
NCT00000643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 154|Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients|Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1994|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|13 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000643||210918|
NCT00000644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 157|A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS|A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||November 1997|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||February 2011|February 24, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000644||210917|
NCT00000662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX 304|A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease|A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|3 Months|12 Years|No|||April 1992|August 1, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000662||210899|
NCT00000590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310|Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|December 1996||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|40 Years|No|||March 2005|June 23, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000590||210969|
NCT00000591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311|T-Cell Depletion in Unrelated Donor Marrow Transplantation|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 1993|February 2005||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|1 Year|55 Years|No|||November 2005|November 10, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000591||210968|
NCT00000592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|312|Stroke Prevention in Sickle Cell Anemia (STOP 1)|||Georgia Regents University||Completed|July 1994|August 2000||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|2 Years|16 Years|No|||November 2005|December 21, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000592||210967|
NCT00000641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 135|A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.|A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1994|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||90|||Both|13 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000641||210920|
NCT00000660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 110|Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma|Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1992|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000660||210901|
NCT00000587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307|Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 2005|January 3, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000587||210972|
NCT00000588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308|Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone|||Case Western Reserve University||Completed|June 1989|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||February 2002|February 10, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000588||210971|
NCT00000637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 152|A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children|A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||819|||Both|3 Months|17 Years|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000637||210924|
NCT00000648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 145|A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals|A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1996|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||October 2012|October 24, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000648||210913|
NCT00000735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 054|A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC|A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1990|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||12|||Both|12 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000735||210826|
NCT00000828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 255|Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine|Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||250|||Female|13 Years|60 Years|No|||October 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000828||210734|
NCT00000668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 127|A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir|A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||48|||Both|13 Years|60 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000668||210893|
NCT00000584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304|Transfusion-Transmitted Cytomegalovirus Prevention in Neonates|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1983|June 1988|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|1 Year|No|||December 2005|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000584||210975|
NCT00000599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502|Cholesterol-Lowering Atherosclerosis Study (CLAS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1980|November 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|40 Years|59 Years|No|||May 2000|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000599||210960|
NCT00000674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 077P|A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS|A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1992|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000674||210887|
NCT00000645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 150|A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes|A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1994|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000645||210916|
NCT00000581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301|Granulocyte Transfusion Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1976|September 1981|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|12 Years|N/A|No|||January 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000581||210978|
NCT00000582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302|Cooperative Study of Factor VIII Inhibitors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1978|July 1979|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|75 Years|No|||April 2012|April 26, 2012|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000582||210977|
NCT00000802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 277|A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides|A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1997|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||700|||Both|13 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000802||210760|
NCT00000631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 002B|A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)|A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1992|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Prevention||||13|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000631||210930|
NCT00000671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 117|A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment|A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||March 1992|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|12 Years|N/A|No|||August 1992|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000671||210890|
NCT00000605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109|Estrogen and Graft Atherosclerosis Research Trial (EAGER)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1996|July 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|45 Years|75 Years|No|||April 2005|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000605||210954|
NCT00000606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218|National Emphysema Treatment Trial (NETT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1996|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||April 2009|April 13, 2009|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000606||210953|
NCT00000642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 146|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|N/A|60 Years|No|||October 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000642||210919|
NCT00000720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 051|A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine|A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1993|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|3 Months|12 Years|No|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000720||210841|
NCT00000604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108|Influence of CPB Temperature on CABG Morbidity|||Baystate Medical Center||Completed|January 1994|December 1996||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||December 2015|December 11, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000604||210955|
NCT00000638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 177|Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1999|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||2000|||Both|13 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000638||210923|
NCT00000659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 133|A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)|A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||July 1990|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||80|||Both|13 Years|N/A|No|||July 1990|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000659||210902|
NCT00000600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106|Vitamin E and C to Slow Progression of Common Carotid Artery Plaque Build-Up|Antioxidants and Prevention of Early Atherosclerosis||National Heart, Lung, and Blood Institute (NHLBI)||Terminated|June 1995|May 2000|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|35 Years|59 Years|No|||October 2006|December 12, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000600||210959|
NCT00000601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107|Postmenopausal Hormone Therapy in Unstable Angina|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1995|June 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|45 Years|75 Years|No|||February 2005|February 17, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000601||210958|
NCT00000602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|315|Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1994|March 1997||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|18 Years|No|||October 2005|October 26, 2005|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000602||210957|
NCT00000680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 080|A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC|A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000680||210881|
NCT00000687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 096|Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma|Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1993|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||60|||Both|12 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000687||210874|
NCT00000634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 165|A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children|A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||June 1995|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||6|||Both|2 Months|13 Years|No|||February 2011|February 25, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000634||210927|
NCT00000656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 143|A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease|A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||116|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000656||210905|
NCT00000647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 011|An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection|An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1994|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|60 Years|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000647||210914|
NCT00000811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 254|A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children|A Randomized, Phase II/III, Double-Blind, Two-Armed Study of Micronized Atovaquone and Azithromycin (AT/AZ) as Compared to Trimethoprim-Sulfamethoxazole (TMP/SMX) in the Prevention of Serious Bacterial Infections When Used in Children Aged 3 Months to 19 Years With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2001|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||690|||Both|3 Months|18 Months|No|||April 2012|April 2, 2012|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00000811||210751|
NCT00000651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 155|A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy|A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1993|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000651||210910|
NCT00000597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403|Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1982|December 1988|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2000|November 25, 2013|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000597||210962|
NCT00000598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501|Diet and Exercise for Elevated Risk (DEER)|||Stanford University||Completed|August 1991|August 1996||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Prevention|||||||Both|30 Years|64 Years|No|||March 2005|January 8, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000598||210961|
NCT00000654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 122 FIAU|The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU|The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1993|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||78|||Both|13 Years|65 Years|No|||December 2012|December 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000654||210907|
NCT00000693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 070|Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS|Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1992|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||25|||Both|13 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000693||210868|
NCT00000632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 005C|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1992|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Prevention|||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 27, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000632||210929|
NCT00000619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122|Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||January 2008|January 15, 2008|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000619||210941|
NCT00000620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123|Action to Control Cardiovascular Risk in Diabetes (ACCORD)|Action to Control Cardiovascular Risk in Diabetes (ACCORD)|ACCORD|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 1999|December 2012|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|10251|||Both|40 Years|79 Years|No|||November 2014|November 12, 2014|October 27, 1999|Yes|Yes||No|September 5, 2014|https://clinicaltrials.gov/show/NCT00000620||210940|
NCT00000621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124|Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|45 Years|N/A|No|||January 2008|January 15, 2008|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000621||210939|
NCT00000622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219|Childhood Asthma Research and Education (CARE) Network|Childhood Asthma Research and Education (CARE) Network||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|18 Years|No|||August 2006|August 24, 2006|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000622||210938|
NCT00000623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|317|Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)|Thalassemia Clinical Research Network (TCRN)||New England Research Institutes||Completed|July 2000|July 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|1 Year|75 Years|No|||July 2006|March 3, 2014|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000623||210937|
NCT00000670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 107|Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks|Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1989|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000670||210891|
NCT00000728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 024|Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy|Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1990|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000728||210833|
NCT00000635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 172|Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine|Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1992|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|13 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000635||210926|
NCT00000639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 159|A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis|A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1997|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000639||210922|
NCT00000613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116|CVD Risk and Health in Postmenopausal Phytoestrogen Users|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1997|December 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|45 Years|74 Years|No|||December 2005|February 26, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000613||210946|
NCT00000614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117|Prevention of Recurrent Venous Thromboembolism (PREVENT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|30 Years|75 Years|No|||September 2005|March 15, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000614||210945|
NCT00000688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 071|A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS|A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||February 1995|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||180|||Both|13 Years|N/A|No|||October 1990|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000688||210873|
NCT00000667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 148|A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells|A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Prevention||||20|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000667||210894|
NCT00000646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 160|Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS|Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1993|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||54|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000646||210915|
NCT00000658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 142|A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma|A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1996|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||250|||Both|12 Years|N/A|No|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000658||210903|
NCT00000611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114|Women's Health Initiative (WHI)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed||||March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|50 Years|79 Years|No|||January 2006|November 24, 2015|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000611||210948|
NCT00000822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 246/946|A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells|A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||46|||Both|13 Years|N/A|No|||May 2012|May 8, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000822||210740|
NCT00000675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 121|A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex|A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||January 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000675||210886|
NCT00000663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 139|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||18|||Both|N/A|5 Years|No|||October 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000663||210898|
NCT00000664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 141|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||26|||Both|18 Years|N/A|No|||December 1994|August 1, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000664||210897|
NCT00000612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115|Soy Estrogen Alternative Study (SEA)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1996|December 1998|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|45 Years|55 Years|No|||November 2000|February 25, 2016|October 27, 1999||||No||https://clinicaltrials.gov/show/NCT00000612||210947|
NCT00000630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 002A|Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)|Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1992|Actual|||Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Prevention||||35|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000630||210931|
NCT00000649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 168|An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)|An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 1993|July 29, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000649||210912|
NCT00000633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 205|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||55|||Both|18 Years|60 Years|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000633||210928|
NCT00000817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 022|The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients|The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 1994|May 1997|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|260|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000817||210745|
NCT00000818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 012|Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.|Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||May 1996|July 28, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000818||210744|
NCT00000836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 294|A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)|A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||300|||Both|13 Years|N/A|No|||October 2012|October 24, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000836||210726|
NCT00000853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 016B|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|37|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000853||210709|
NCT00000764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 216|Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.|Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1996|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||98|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000764||210797|
NCT00000918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 400|A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure|A Phase II, Randomized, Open-Label Comparative Trial of Salvage Antiretroviral Therapies for HIV-Infected Individuals With Virological Evidence of Nelfinavir Treatment Failure as Reflected by Plasma HIV RNA Concentration of >= 1,000 Copies/ml||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 2002|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||300|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000918||210644|
NCT00000919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 384|A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection|Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2002|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|13 Years|N/A|No|||June 2012|June 5, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000919||210643|
NCT00000815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 225|A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group|A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|6 Months|7 Months|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00000815||210747|
NCT00000816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 268|Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis|Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 4|Interventional|Primary Purpose: Treatment||||370|||Both|13 Years|N/A|No|||April 2012|April 13, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000816||210746|
NCT00000819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 271|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||54|||Both|18 Years|N/A|No|||April 2012|April 13, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000819||210743|
NCT00000847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 022A|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000847||210715|
NCT00000848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 333|The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year|The Antiviral Effect of Switching From Hard Capsule Saquinavir (SQVhc) to the Soft Gelatin Capsule of Saquinavir (SQVsc) Versus Switching to Indinavir (IDV) After 1 Year of Saquinavir Use||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|144|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000848||210714|
NCT00000864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 321|A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women|Phase I Study of Safety, Tolerance, and Pharmacokinetics of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy In Neonates Born to HIV-1 Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||60|||Both|N/A|28 Days|No|||May 2012|May 17, 2012|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00000864||210698|
NCT00000834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 013|A Phase I Study of Methotrexate for HIV Infection|A Phase I Study of Methotrexate for HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2002|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000834||210728|
NCT00000760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 213|A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection|A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||96|||Both|12 Years|N/A|No|||November 1998|July 31, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000760||210801|
NCT00000842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 291|A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy|A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1999|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|18 Years|70 Years|No|||May 2012|May 9, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000842||210720|
NCT00000801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 252|Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma|Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1998|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||33|||Both|16 Years|N/A|No|||October 2012|October 31, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000801||210761|
NCT00000809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 279|Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women|A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 1|Interventional|Primary Purpose: Prevention|||Actual|0|||Both|N/A|3 Days|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000809||210753|
NCT00000839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 249|A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women|A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||12|||Female|13 Years|N/A|No|||August 2004|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000839||210723|
NCT00000835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 025|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000835||210727|
NCT00000845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 021|A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000845||210717|
NCT00001100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID ARB-AL-91-CMV|A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.|A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|N/A|1 Month|No|||November 2005|August 26, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001100||210466|
NCT00000803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 261|A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy|A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1997|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||471|||Both|13 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000803||210759|
NCT00000804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L DRUG|A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)|A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|July 11, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000804||210758|
NCT00000926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 016 Pilot|A Study of Nonoxynol-9 (N-9) and HIV Infection|Phase III Nonoxynol-9 and HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 2001|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Prevention||||4400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000926||210636|
NCT00000829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 292|A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants|A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1999|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2|||60|||Both|2 Months|6 Months|No|||May 2012|May 8, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000829||210733|
NCT00000830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 296|Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.|Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||24|||Female|18 Years|N/A|No|||March 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000830||210732|
NCT00000742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 199|A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)|A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1993|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||15|||Male|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000742||210819|
NCT00000851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 327|Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children|Trial of Stavudine (d4T) Plus Didanosine (ddI) in Children on Long-Term Stavudine Monotherapy, and Stavudine Versus Stavudine Plus Didanosine in Children on Long-Term Zidovudine Monotherapy: A Rollover Protocol for ACTG 240 Participants and Children Receiving Prescription Zidovudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||198|||Both|6 Months|10 Years|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000851||210711|
NCT00000852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 016|A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection|A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Interventional|Primary Purpose: Treatment||||12|||Both|18 Years|50 Years|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000852||210710|
NCT00000878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 332|A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants|A Phase I/II, Open-Label Study to Evaluate the Safety, Tolerance and Pharmacokinetics of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Infected Pregnant Women and Their Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||26|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000878||210684|
NCT00000838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 306|Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine|A Phase II, Randomized Study of the Antiviral Activity and Resistance Interactions of Lamivudine (3TC) in Combination With Zidovudine (AZT), Stavudine (d4T), or Didanosine (ddI) Versus Monotherapy With ddI or d4T in HIV-Infected Individuals With 200 - 600 CD4+ Cells/mm3 and No Previous Nucleoside Experience||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||256|||Both|12 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000838||210724|
NCT00000861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 041|The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients|A Randomized Trial of Immediate Versus Deferred Indinavir in Addition to Background Antiretroviral Therapy in HIV-Infected Patients With CD4+ Cell Counts Between 200 and 500/mm3 and Plasma HIV RNA Levels >= 10,000 Copies/ml||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1997|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||1900|||Both|16 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000861||210701|
NCT00000798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 018|A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000798||210764|
NCT00000876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG 351|Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children|Phase I/II Trial of CD4-IgG2 in HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2006|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|2 Years|12 Years|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||||https://clinicaltrials.gov/show/NCT00000876||210686|
NCT00000855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 331|A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.|The Safety, Tolerance, and Pharmacokinetics of Zidovudine in Premature Infants Exposed to HIV.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 2000|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|N/A|5 Days|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000855||210707|
NCT00000812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 267|A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection|A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000812||210750|
NCT00000761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 211|Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children|Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1997|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|1 Year|17 Years|No|||April 2012|April 27, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000761||210800|
NCT00001110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 723|Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients|Effect of Highly Active Antiretroviral Therapy (HAART) on Viral Burden and Immune Function in the Lungs of HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 1999|April 2003|Actual|||N/A|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001110||210456|
NCT00000810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 260|Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)|Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1996|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000810||210752|
NCT00000753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 187|A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC|A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000753||210808|
NCT00000846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 023|A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.|A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000846||210716|
NCT00000910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 367|A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies|Medical Chart Abstraction of HIV-Infected Pregnant Women and Their Infants Receiving Care or Consultation at Study Sites||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2004|Actual|||N/A|Observational|Time Perspective: Prospective||||2000|||Female|N/A|N/A|No|||October 2013|October 4, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000910||210652|
NCT00000831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 302|Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy|Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||280|||Both|12 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000831||210731|
NCT00000863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 314|A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients|A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||45|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000863||210699|
NCT00000886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 020|A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)|A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000886||210676|
NCT00000850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5041|The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy|The Effects of GM-CSF on Plasma HIV-1 RNA and Chemokine Receptor Expression in HIV-1 Infected Subjects Receiving Concomitant Potent Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2003|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||108|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000850||210712|
NCT00000843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 310|The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children|A Phase IA Single Dose Pharmacokinetics and Safety Study of the Oral Antiviral Compound, 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) (Adefovir Dipivoxil) in Children With HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|N/A|17 Years|No|||April 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000843||210719|
NCT00000844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 022|A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3|A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2002|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||560|||Both|13 Years|N/A|No|||May 2012|May 21, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000844||210718|
NCT00000805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 226|A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease|A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|N/A|20 Years|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000805||210757|
NCT00000806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 282|A Phase I Randomized Dose/Formulation Comparison Study of SC-52151|A Phase I Randomized Dose/Formulation Comparison Study of SC-52151||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||48|||Both|21 Years|N/A|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000806||210756|
NCT00000883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 362|Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy|Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Complications In Subjects With Past CD4 Cells/mm3 Below 50 Who Increased CD4 Cells/mm3 to Above 100 on HAART||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1997|April 2007|Actual|||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||636|||Both|13 Years|N/A|No|||October 2012|October 24, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000883||210679|
NCT00000832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 024|A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers|A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000832||210730|
NCT00000833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 274|A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.|A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|3 Months|12 Years|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000833||210729|
NCT00000840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 304|A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA|A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||70|||Both|13 Years|N/A|No|||April 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000840||210722|
NCT00000762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 218|A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection|A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1996|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|1 Month|18 Years|No|||May 2012|May 22, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000762||210799|
NCT00000866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 014C|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1999|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000866||210696|
NCT00000860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 853|The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients|Effects of Treatment for MAC Infection on Cytokine Expression in HIV-Infected Persons.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||24|||Both|13 Years|N/A|No|||July 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000860||210702|
NCT00000759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 188|Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials|Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||675|||Both|3 Months|8 Years|No|||June 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000759||210802|
NCT00000857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 325|A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3|A Phase I, Double-Blind, Randomized, Placebo-Controlled Trial of Recombinant Human Interleukin-12 (rhIL-12) in HIV-Infected Subjects With Less Than 50 CD4+ T Cells and Subjects With 300-500 CD4+ T Cells||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||65|||Both|18 Years|60 Years|No|||May 2012|June 2, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000857||210705|
NCT00000841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 320|A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months|A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <= 200 Cells/mm3 and >= 6 Months of Prior AZT Experience||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1997|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||1750|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000841||210721|
NCT00000870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 328|A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone|A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2007|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000870||210692|
NCT00000856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 305|A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.|A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|0|||Both|13 Years|N/A|No|||May 2012|May 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000856||210706|
NCT00000813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 012A|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000813||210749|
NCT00000862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 324|A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women|A Phase I Trial of the Pharmacokinetics and Tolerance of Oral Zidovudine Administered to HIV-1 Infected Pregnant Women During Labor and Delivery||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2003|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||36|||Female|N/A|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000862||210700|
NCT00000797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIHS|Women's Interagency HIV Study (WIHS)|Women's Interagency HIV Study (WIHS)||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|August 2004|||November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4176|Samples With DNA|Blood and bodily fluid collection|Female|30 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|HIV-infected women and women at risk of HIV infection|October 2012|October 30, 2012|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000797||210765|
NCT00000763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 215|A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma|A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1997|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||42|||Both|12 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000763||210798|
NCT00001089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 360|A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients|Human Immunodeficiency Virus (HIV) and Cytomegalovirus (CMV) Viral Burden and Development of CMV End-Organ Disease: A Prospective Study in HIV-Infected Individuals.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||400|||Both|13 Years|N/A|No|||February 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001089||210475|
NCT00001101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 97-002|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2001|Actual|March 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||194|||Both|18 Years|N/A|No|||March 2010|August 26, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001101||210465|
NCT00000937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 96-182|Study and Treatment of Post Lyme Disease (STOP-LD)|Study and Treatment of Post Lyme Disease (STOP-LD)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||55|||Both|18 Years|65 Years|No|||November 2005|August 26, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000937||210626|
NCT00000957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 004B|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1993|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000957||210606|
NCT00000774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 230|A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers|A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1999|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|156|||Both|N/A|3 Days|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000774||210787|
NCT00000792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 258|A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects|A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000792||210770|
NCT00000858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 009|Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections|Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||350|||Female|18 Years|45 Years|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000858||210704|
NCT00000859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 042|A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3|A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2001|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||1300|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000859||210703|
NCT00000772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 231|A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals|A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000772||210789|
NCT00000790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 251|Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection|Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||164|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000790||210772|
NCT00000746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 008|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1994|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000746||210815|
NCT00000777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 234|Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)|Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1998|Actual|||Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||24|||Female|16 Years|40 Years|No|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000777||210784|
NCT00000787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HATS PROSPECTIVE|Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study|Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Interventional|Primary Purpose: Treatment||||1000|||Female|18 Years|49 Years|No|||April 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000787||210775|
NCT00000796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 238|A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.|A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||525|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000796||210766|
NCT00000752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 186|Preventing Frequent Sinus Infections in HIV-Infected Patients|Management of HIV-Infected Patients at Risk of Recurrent Purulent Sinusitis: Role of Anti-Inflammatory, Antibacterial, and Decongestant Prophylaxis||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||February 1993|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|12 Years|N/A|No|||October 2012|May 14, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000752||210809|
NCT00000744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 010|A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women|A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1995|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Female|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000744||210817|
NCT00000750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 182|A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection|A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||400|||Both|N/A|9 Months|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000750||210811|
NCT00000854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 329|A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss|A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Trial of Nandrolone Decanoate in Women With HIV-Associated Weight Loss||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2003|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||38|||Female|13 Years|N/A|No|||February 2012|February 13, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000854||210708|
NCT00000768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 183|A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients|A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1998|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||24|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000768||210793|
NCT00000950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 309|Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis|Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||May 2002|Actual|N/A|Interventional|Primary Purpose: Treatment||||50|||Both|13 Years|N/A|No|||March 2011|March 1, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000950||210613|
NCT00000779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 214|A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3|A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Prevention||||130|||Both|13 Years|N/A|No|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000779||210782|
NCT00000799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 281|HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol|HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1996|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||October 2012|October 31, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000799||210763|
NCT00000776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 202|Dexamethasone in Cryptococcal Meningitis|Dexamethasone in Cryptococcal Meningitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000776||210785|
NCT00000781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 193A|A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)|A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||1292|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000781||210780|
NCT00000756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 006|Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3|Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000756||210805|
NCT00000765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 002|Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)|Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2002|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||80|||Both|13 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000765||210796|
NCT00000785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 017|A Registry of Tuberculosis Cases in the CPCRA|A Registry of Tuberculosis Cases in the CPCRA||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 1992|June 1994|Actual|June 1994|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1509|Samples With DNA|Any sample that can be used to test for M.tuberculosis|Both|N/A|N/A|No|Non-Probability Sample|All eligible CPCRA subjects|September 2013|September 28, 2013|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000785||210776|
NCT00000837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG 265|A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children|Phase I/II Study of the Safety and Immunogenicity of Live-Attenuated Varicella Vaccine (Varivax) in HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||127|||Both|12 Months|8 Years|No|||February 2015|February 11, 2015|November 2, 1999|No|Yes||||https://clinicaltrials.gov/show/NCT00000837||210725|
NCT00000747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 208|An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3|An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||December 1994|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||February 2011|February 28, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000747||210814|
NCT00000748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 006|A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients|A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1996|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||2500|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000748||210813|
NCT00000749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 007C|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000749||210812|
NCT00000958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 103|A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)|A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1995|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||8|||Both|18 Years|50 Years|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000958||210605|
NCT00000807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 269|Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy|Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2000|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||41|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000807||210755|
NCT00000758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 200|A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women|A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1998|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||158|||Female|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000758||210803|
NCT00000955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 008|Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection|Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1992|Actual|December 1992|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|864|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000955||210608|
NCT00000800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 262|Methadone Effects on Zidovudine (ZDV, AZT) Disposition|Methadone Effects on Zidovudine (ZDV, AZT) Disposition||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000800||210762|
NCT00000769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 224|A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma|A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|13 Years|N/A|No|||April 2012|April 27, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000769||210792|
NCT00000789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 240|A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection|A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1998|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||230|||Both|3 Months|6 Years|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000789||210773|
NCT00000782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 221|A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen|A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1996|Actual|||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000782||210779|
NCT00000791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 259|A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV|A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1995|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|13 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000791||210771|
NCT00000766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 228|CMV Retinitis Retreatment Trial|CMV Retinitis Retreatment Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||September 1995|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||February 2011|February 28, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000766||210795|
NCT00000784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 012|A Study of Psychosocial and Behavioral Determinants of Differential Rates of Participant Compliance in CPCRA Protocols|A Study of Psychosocial and Behavioral Determinants of Differential Rates of Participant Compliance in CPCRA Protocols||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1994|September 1996|Actual|September 1996|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|557|||Both|13 Years|N/A|No|Non-Probability Sample|Consenting patients newly enrolled in either CPCRA 007 or CPCRA 006|September 2013|September 28, 2013|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000784||210777|
NCT00000755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 209|A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3|A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1993|Actual|||Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||168|||Both|13 Years|N/A|No|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000755||210806|
NCT00000788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 030|A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone|A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1994|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000788||210774|
NCT00000849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 299|A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children|Phase I/II Trial of Recombinant Interleukin-2 In Symptomatic Human Immunodeficiency Virus-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2001|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||27|||Both|3 Years|12 Years|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000849||210713|
NCT00000754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 197|A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3|A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000754||210807|
NCT00000956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 003B|A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1993|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000956||210607|
NCT00000959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 005|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1996|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||600|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000959||210604|
NCT00000814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 245|A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease|A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1998|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||390|||Both|6 Months|20 Years|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000814||210748|
NCT00000741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 170|The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS|A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|0|||Both|N/A|2 Years|No|||October 2012|October 24, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000741||210820|
NCT00000773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 227|Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children|Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Prevention||||24|||Both|1 Month|12 Years|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000773||210788|
NCT00000808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 250|A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers|A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||49|||Female|13 Years|60 Years|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000808||210754|
NCT00000770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 241|A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine|A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1994|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000770||210791|
NCT00000771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 192|A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3|A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||68|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000771||210790|
NCT00000739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 179|Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection|Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||96|||Both|1 Month|12 Years|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000739||210822|
NCT00000751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 185|A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)|A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2007|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||1600|||Female|13 Years|60 Years|No|||May 2006|September 26, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000751||210810|
NCT00000767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 014A|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1996|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000767||210794|
NCT00000794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 237|Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis|Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1998|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000794||210768|
NCT00000795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 017|A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2002|September 8, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000795||210767|
NCT00000778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 008|A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin|A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||44|||Both|18 Years|N/A|No|||June 1995|August 6, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000778||210783|
NCT00000960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 076|The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants|A Phase III Randomized Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerance of Oral Zidovudine (AZT) in Pregnant HIV Infected Women and Their Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1994|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||1496|||Both|N/A|60 Years|No|||March 2012|May 15, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000960||210603|
NCT00000820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 248|A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy|A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2002|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||104|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000820||210742|
NCT00000738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 162|Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1|Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1994|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000738||210823|
NCT00000745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 003|A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1991|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000745||210816|
NCT00000821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 015|Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients|Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2002|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||78|||Both|18 Years|N/A|No|||October 2012|November 1, 2012|November 2, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00000821||210741|
NCT00000935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT IG02|An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens|Evaluation of Intravenous Gamma Globulin (IVIG) As an Agent to Lower Allosensitization and Improve Allograft Survival in Highly-Sensitized Adult End-Stage Renal Disease (ESRD) Patients (IG02)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed||June 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|N/A|No|||February 2013|February 1, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000935||210628|
NCT00001012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 022|A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes|An Open Label, Multiple Dose Ranging Trial of AL721 in Patients With Persistent Generalized Lymphadenopathy and Symptomatic HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|60 Years|No|||September 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001012||210551|
NCT00000979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 116|Comparison of ddI Versus Zidovudine in HIV-Infected Patients|Comparison of 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine in Therapy of Patients With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||October 1992|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||1500|||Both|12 Years|N/A|No|||January 2003|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000979||210584|
NCT00000901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 395|Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children|A Multicenter, Open-Labeled, 96-Week Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Indinavir in Combination With Stavudine and Lamivudine in Pediatric Patients With HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Both|3 Years|15 Years|No|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000901||210661|
NCT00000938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 97-003|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|18 Years|N/A|No|||November 2005|August 26, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000938||210625|
NCT00001215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860096|Genetic Studies of Lysosomal Storage Disorders|Studies of Genetic Heterogeneity in Patients With Lysosomal Storage Disorders||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 1986|||||N/A|Observational|N/A|||Actual|424|||Both|N/A|99 Years|No|||February 2016|March 9, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001215||210364|
NCT00000893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 382|Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children|A Phase I/II, Open-Label, AUC-Controlled Study to Determine the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1997|December 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||Actual|103|||Both|3 Months|16 Years|No|||June 2015|June 2, 2015|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00000893||210669|
NCT00000986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 067|The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex|A Safety, Tolerance, and Immunological Study of a Combination of Recombinant Interleukin 2 and Zidovudine in Patients With AIDS or AIDS Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1994|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|50 Years|No|||April 2012|April 25, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000986||210577|
NCT00001237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890041|Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas|Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|March 1989|April 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001237||210345|
NCT00001238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890086|Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders|Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|April 1989|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Both|2 Years|N/A|No|||April 2015|April 30, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001238||210344|
NCT00000966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 156|A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS|A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||45|||Both|13 Years|N/A|No|||October 1994|August 25, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000966||210597|
NCT00000984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 101|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|18 Years|No|||October 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000984||210579|
NCT00000939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5039|A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible|Phase II Randomized, Open-Label Study of Maintenance of HIV RNA Suppression After Switching to ddI/d4T/HU vs. ddI/d4T/EFV vs. Continuing the Pre-Entry Protease Inhibitor Regimen||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2000|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||150|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000939||210624|
NCT00000940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 371|Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV|A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 1999|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|121|||Both|16 Years|N/A|No|||January 2016|January 5, 2016|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00000940||210623|
NCT00001040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 229|Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC|Double-Blind, Randomized, Phase II Study of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus Ro 31-8959 Plus AZT Plus ddC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||May 1994|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||300|||Both|13 Years|N/A|No|||February 2011|February 28, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001040||210523|
NCT00000978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 106|A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)|An Open-Label, Randomized, Dose-Finding, Multicenter Trial of Dideoxycytidine (ddC) Administered Concurrently With Zidovudine (AZT) in the Treatment of AIDS or Advanced ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||68|||Both|18 Years|N/A|No|||August 1992|August 6, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000978||210585|
NCT00000988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 089|A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex|A Phase I Safety and Pharmacokinetics Study of BMY-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily to Patients With AIDS or AIDS Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 1994|August 25, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000988||210575|
NCT00000989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 073|The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS|A Controlled, Randomized Phase II Study of the Safety and Efficacy of Combined Therapy With Ganciclovir and Granulocyte-Macrophage Colony Stimulating Factor Versus Ganciclovir Alone for the Treatment of Sight-Threatening Cytomegalovirus Retinitis in AIDS Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1992|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||50|||Both|13 Years|65 Years|No|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000989||210574|
NCT00000897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 317|A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women|The Effect of Oral and Injectable Contraceptives (Norethindrone/Ethinyl Estradiol, Medroxyprogesterone Acetate) and Gender on Plasma and Intracellular Zidovudine Pharmacokinetics||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||October 2005|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||42|||Both|18 Years|45 Years|No|||March 2011|March 1, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000897||210665|
NCT00001011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 016|The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex|The Safety and Efficacy of Zidovudine in the Treatment of Patients With Early AIDS Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||538|||Both|12 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001011||210552|
NCT00000884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 027|A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers|A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2000|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000884||210678|
NCT00000885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 372|Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320|A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2003|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|16 Years|N/A|No|||August 2012|August 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000885||210677|
NCT00000985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 095|Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir|Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1990|Actual|||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||26|||Both|13 Years|65 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000985||210578|
NCT00001208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850195|Botulinum Toxin for the Treatment of Involuntary Movement Disorders|A Training Protocol for the Use of Botulinum Toxin in the Treatment of Neurological Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|November 1985|October 2019|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|4 Years|N/A|No|||May 2015|May 20, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001208||210371|
NCT00000983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 128|The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children|A Randomized Blinded Trial To Evaluate the Safety and Tolerance of High Versus Low Dose Zidovudine Administered to Children With Human Immunodeficiency Virus||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1994|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||400|||Both|3 Months|12 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000983||210580|
NCT00000951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 323|A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush|A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2002|Actual|||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||948|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000951||210612|
NCT00000952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 345|A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children|A Phase I/II Study of Ritonavir Therapy in HIV-1 Infected Infants and Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2004|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|1 Month|2 Years|No|||October 2014|October 28, 2014|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000952||210611|
NCT00001250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900044|Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial|Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial||National Institutes of Health Clinical Center (CC)||Completed|December 1989|October 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||130|||Female|N/A|N/A|No|||October 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001250||210332|
NCT00000991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 081|A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients|A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1994|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||600|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000991||210572|
NCT00000894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 350|Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis|Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||June 2000|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||300|||Both|13 Years|N/A|No|||June 2003|February 22, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000894||210668|
NCT00000972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 005A/B|A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59|A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1992|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Prevention|||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 27, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000972||210591|
NCT00001048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 243|Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients|A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1997|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||90|||Both|18 Years|65 Years|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001048||210515|
NCT00000980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 113|A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea|Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||25|||Both|13 Years|N/A|No|||October 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000980||210583|
NCT00000947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 048|A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients|A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylaxis for Disseminated Mycobacterium Avium Complex Disease and Bacterial Pneumonia Versus Deferred Prophylaxis in HIV-Infected Patients Who Experience Rebound in CD4+ Cell Count Due to Active Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2000|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||850|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000947||210616|
NCT00000995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 004|A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection|Phase I Studies of the Combination of AZT and DHPG (Ganciclovir) in Patients With AIDS and Cytomegalovirus Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1990|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000995||210568|
NCT00000931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 015|HIV Prevention Counseling for Men Who Have Sex With Men|A Randomized Clinical Trial of the Efficacy of a Behavioral Intervention to Prevent Acquisition of HIV Among Men Who Have Sex With Men||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||4350|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|September 8, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000931||210631|
NCT00000932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 060|A Study of the Long-Term Outcomes of HIV-Positive Patients|A Prospective Study of Long-Term Clinical, Virologic, and Immunologic Outcomes in HIV-Infected Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 1999|September 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3669|||Both|13 Years|N/A|No|Probability Sample|HIV infected individuals|April 2014|April 14, 2014|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000932||210630|
NCT00000933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 054|Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048|Effects of Prophylaxis for Disseminated Mycobacterium Avium Complex (MAC) Disease With Azithromycin Versus Deferred Prophylaxis on Carriage of Antibiotic-Resistant Streptococcus Pneumoniae: A Substudy of the CR-MAC Protocol (CPCRA 048)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2000|Actual|||N/A|Observational|N/A||||326|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000933||210629|
NCT00000898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 378|The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir|A Prototype Study to Test the Effect of Staggered Dosing on the Pharmacokinetic Interactions Between Paired Combinations of Nelfinavir (NFV), Ritonavir (RTV), and Soft Gelatin Capsule of Saquinavir (SQVsgc)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2000|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000898||210664|
NCT00000899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 380|A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients|Effect of Cytoreductive Chemotherapy Combined With Highly Active Antiretroviral Therapy on Lymph Node HIV DNA in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||10|||Both|18 Years|50 Years|No|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000899||210663|
NCT00001213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860062|Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis|Trial of Topical Cysteamine in the Treatment of Corneal Cystine Crystal Accumulation in Cystinosis||National Institutes of Health Clinical Center (CC)|No|Completed|April 1986|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|328|||Both|2 Years|N/A|No|||June 2014|June 20, 2014|November 3, 1999|Yes|Yes||No|June 20, 2014|https://clinicaltrials.gov/show/NCT00001213||210366|Due to the progressive nature of the drug's development, this protocol reflects the culmination of cysteamine studies performed at NIH. The combined analyses of the data is presented and not the data or analyses of one individual protocol.
NCT00000971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 178|The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS|A Phase I/II Dose-Ranging, Pharmacokinetic, Drug Interaction, Safety and Preliminary Efficacy Study of Oral Clarithromycin Granules for Suspension, in Combination With Zidovudine or Dideoxyinosine, in the Treatment of Disseminated Mycobacterium Avium Complex Infections in Pediatric Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||24|||Both|3 Months|18 Years|No|||October 1996|July 31, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000971||210592|
NCT00000895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 341|A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection|Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2001|Actual|||N/A|Interventional|Primary Purpose: Treatment||||85|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000895||210667|
NCT00000968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 004|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1993|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000968||210595|
NCT00001226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870207|Lipoprotein Metabolism in Normal Volunteers and Patients With Abnormal Levels of Lipoproteins|Lipoprotein Metabolism in Normal Volunteers and Dyslipoproteinemic Patients (Stable Isotopes)||National Institutes of Health Clinical Center (CC)||Completed|December 1987|March 2002||||N/A|Observational|N/A||||90|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001226||210354|
NCT00000946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 032|A Study to Test the Safety of Three Experimental HIV Vaccines|A Phase I Trial to Evaluate the HIV-1 SF-2 Recombinant p24 Subunit Vaccine [Chiron Vaccines] Administered as a Novel Boost in "Prime-Boost" Vaccination Regimens With ALVAC-HIV vCP205 [Pasteur Merieux Connaught] and HIV-1 SF-2 rgp120 in MF59 [Chiron Vaccines]||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000946||210617|
NCT00000981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 122 FIAC|The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS|Efficacy and Safety of Oral FIAC in AIDS Patients With Cytomegalovirus Infection: A Dose Ranging Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1993|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||78|||Both|13 Years|65 Years|No|||December 2012|December 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000981||210582|
NCT00001007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 049|A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth|A Multicenter Phase I Trial To Evaluate the Safety and Pharmacokinetics of Intravenous and Oral Zidovudine in Infants With Perinatal Human Immunodeficiency Virus (HIV) Exposure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|N/A|3 Months|Accepts Healthy Volunteers|||January 2003|July 11, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001007||210556|
NCT00000967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 153|The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children|Safety and Tolerance of Zidovudine and Interferon-Alpha in HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||52|||Both|3 Months|17 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000967||210596|
NCT00000953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 169|Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients|Evaluation of Brovavir ( BV-ara-U; SQ 32,756 ) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||September 1996|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||February 2011|February 25, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000953||210610|
NCT00001214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860088|Collection of Blood From Patients With Pancytopenia|Lymphocytapheresis of Patients With Pancytopenia||National Institutes of Health Clinical Center (CC)||Completed|April 1986|||||N/A|Observational|Time Perspective: Prospective|||Actual|38|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001214||210365|
NCT00000890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 892|A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients|Effect of Highly Active Antiretroviral Therapy (HAART) on Lean Body Mass||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||200|||Both|18 Years|N/A|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000890||210672|
NCT00000891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 375|Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315|Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2004|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||34|||Both|16 Years|N/A|No|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000891||210671|
NCT00000892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 359|A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir|Activity of the Soft Gelatin Capsule of Saquinavir (SQVsgc) in Combination With Ritonavir or Nelfinavir and Combinations of Delavirdine and/or Adefovir Dipivoxil in HIV-Infected Subjects With Prior Indinavir Use and Viral Loads From 2,000 to 200,000 Copies HIV RNA/ml||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1999|Actual|||N/A|Interventional|Primary Purpose: Treatment||||300|||Both|16 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000892||210670|
NCT00000992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 084|A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS|Pilot Study to Determine the Feasibility of Itraconazole for Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1992|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||March 2012|May 15, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000992||210571|
NCT00000900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 891|The Effects of Illnesses on HIV Levels in the Body|The Impact of Intercurrent Illness on HIV Viral Load||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||26|||Both|13 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000900||210662|
NCT00001239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890119|Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer|Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|July 1989|January 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001239||210343|
NCT00001240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890005|Evaluating Patients With Abnormal Levels of Gastric Acid|Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion||National Institutes of Health Clinical Center (CC)||Completed|January 1989|January 2004||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2004|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001240||210342|
NCT00000896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 387|A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients|A Randomized Controlled Trial to Compare the Efficacy of a Four Drug Antiretroviral Regimen Alone or in Combination With GM-CSF or IL-12 Administered to HIV-1 Infected Subjects as Measured by the Characteristics of Viral Decay||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2000|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000896||210666|
NCT00000976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 134|A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex|A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 1994|August 5, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000976||210587|
NCT00000974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 115|A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia|A Phase I Study of the Safety, Tolerance, and Study of the Pharmacokinetics of Aerosolized Pentamidine and Parenteral Pentamidine in Children With HIV Infection and Suspected Pneumocystis Carinii Pneumonia||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|2 Months|13 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000974||210589|
NCT00000975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 120|A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS|Pilot Study To Determine the Feasibility of Itraconazole for Primary Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1994|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000975||210588|
NCT00000990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 052|The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms|A Multicenter Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Oral Zidovudine in the Treatment of Children Infected With Human Immunodeficiency Virus With Mild to Moderate Symptoms (Including LIP)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1992|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||224|||Both|3 Months|12 Years|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000990||210573|
NCT00001031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 201|A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults|A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1997|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|296|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001031||210532|
NCT00001032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 190|A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT|A Phase II Study to Evaluate Pharmacokinetics, Safety, Tolerance and Activity of Dideoxycytidine (ddC) Administered in Combination With Zidovudine (AZT) in Stable, AZT-Treated Pediatric Patients With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1995|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||180|||Both|3 Months|12 Years|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001032||210531|
NCT00000944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 358|A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants|A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Indinavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women During Gestation and Post Partum, and in Their Infants Post Maternal Dosing||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2003|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||24|||Female|13 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00000944||210619|
NCT00000945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 363|A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients|A Pilot Study of the Effect of Cidofovir for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Subjects With Acquired Immunodeficiency Syndrome (AIDS)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2001|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000945||210618|
NCT00001077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 038|A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements|An Open-Label, Randomized, Three-Arm, Comparative Trial of a Caloric Supplement With Peptides and Medium-Chain Triglycerides Versus a Caloric Supplement With Whole Protein and Long-Chain Triglycerides Versus No Caloric Supplement for the Prevention of Weight Loss in Individuals With AIDS Who Take a Daily Multivitamin and Mineral Supplement||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 1996|April 1998|Actual|April 1998|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|536|Samples With DNA|Blood collection|Both|13 Years|N/A|No|Non-Probability Sample|HIV-infected participants who take a daily multivitamin and mineral supplement|September 2013|September 28, 2013|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00001077||210487|
NCT00000921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 349|The Effects of Prednisone on HIV Levels and the Immune System|A Phase II, Randomized, Placebo-Controlled Study of the Immunologic and Virologic Effects of Prednisone on HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 1996|||June 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||118|||Both|18 Years|N/A|No|||June 2003|February 22, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000921||210641|
NCT00000873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 247|A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants|A Randomized, Double-Blind, Controlled Study of an Increased Caloric Density Infant Formula and Its Effect on Growth and Nutritional Status in HIV-Infected Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2005|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||2400|||Both|N/A|17 Days|Accepts Healthy Volunteers|||October 2013|October 4, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000873||210689|
NCT00000877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 365|Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults|Steady-State Pharmacokinetic Interaction Study of Indinavir and Rifabutin||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||31|||Both|18 Years|60 Years|No|||May 2012|May 21, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000877||210685|
NCT00000912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 398|A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients|A Phase II, Randomized Trial of Amprenavir as Part of Dual Protease Inhibitor Regimens (Placebo-Controlled) in Combination With Abacavir, Efavirenz, and Adefovir Dipivoxil Versus Amprenavir Alone in HIV-Infected Subjects With Prior Exposure to Approved Protease Inhibitors and Loss of Virologic Suppression as Reflected by a Plasma HIV-1 RNA Concentration >= 1,000 Copies/ml||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2000|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||475|||Both|13 Years|N/A|No|||July 2013|June 2, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000912||210650|
NCT00000941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5047|A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood|Evaluation of Potential Pharmacokinetic Interactions Between Protease Inhibitors and Lipid Lowering Agents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000941||210622|
NCT00000874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 046|A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART|A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 1997|March 1999|Actual|January 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|148|Samples With DNA|Blood collection|Both|13 Years|N/A|No|Non-Probability Sample|HIV-infected participants currently failing their antiretroviral regimens|September 2013|September 28, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000874||210688|
NCT00000880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 334|A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease|Phase II Study of Cyclosporin (Neoral) in Immune Activation and HIV Expression in Early HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2000|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000880||210682|
NCT00000875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRAT 3|Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection|Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||April 2003|August 4, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000875||210687|
NCT00001084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 343|A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients|A Prospective Randomized Double-Blind Trial of Three Maintenance Regimens for HIV-Infected Subjects Receiving Induction Therapy With Zidovudine, Lamivudine and Indinavir||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1997|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001084||210480|
NCT00000902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 366|A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment|RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||217|||Both|6 Months|21 Years|No|||October 2012|September 30, 2014|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000902||210660|
NCT00001057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 275|The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of the Virologic Effect of Two Different Nucleoside Treatment Strategies (Zidovudine Versus Zidovudine in Combination With Didanosine) for HIV Infection in Subjects With CD4+ Counts >= 550 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1995|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||105|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001057||210507|
NCT00001078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG P1008|A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications|An Observational Study of the Rate of Opportunistic Infection Events in HIV-Infected Children Who Have Demonstrated Immunologic Reconstitution and Who Have Discontinued OI Prophylaxis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||May 2005|Actual|N/A|Interventional|Primary Purpose: Treatment||||200|||Both|2 Years|21 Years|No|||July 2005|March 1, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001078||210486|
NCT00000969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 002|A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy|A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1992|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000969||210594|
NCT00000924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 403|A Study to Compare Two Different Anti-HIV Drug Regimens|A Phase II Randomized, Multicenter Protocol Evaluating Two Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs, and an NNRTI||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2001|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||120|||Both|4 Months|21 Years|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000924||210638|
NCT00000908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 888|A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts|Impact of Discontinuing PCP Prophylaxis in Subjects Receiving Antiretroviral Therapies Who Have Had Increases in CD4 Counts to > 200 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Natural History||||250|||Both|13 Years|N/A|No|||February 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000908||210654|
NCT00000948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 021B|Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3|A Randomized, Open Label Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 1998|||March 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||72|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000948||210615|
NCT00000904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 034|Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults|A Phase I Trial to Compare the Safety and Immunogenicity of the Live Recombinant Canarypox ALVAC-HIV Vaccines, vCP205, vCP1433, and vCP1452, in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000904||210658|
NCT00000905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 379|A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy|Discontinuation of Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Immune Reconstitution by Potent Antiretroviral Therapy: Safety, Virology, and Immunology Profiles||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||75|||Both|13 Years|N/A|No|||June 2003|July 28, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000905||210657|
NCT00000914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 057|A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks|A Randomized Study of the Virologic Efficacy of Different Antiretroviral (AR) Treatment Strategies in HIV-Infected Individuals With Detectable Plasma HIV RNA Measurements After at Least 16 Weeks on Their Initial Protease Inhibitor-Containing AR Regimens||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2000|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||March 2012|March 26, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000914||210648|
NCT00000915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET D01|An HIV Vaccine Preparedness Study|HIV Vaccine Preparedness Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Interventional|Primary Purpose: Treatment||||4892|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000915||210647|
NCT00000930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 019|A Study of HIV in Newly Infected Individuals|Infected Participants Protocol: Evaluation of Natural History of HIV Infection in Newly HIV-Infected Persons in HIVNET Target Populations||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|||Samples With DNA|Specimens appropriate for clinical and laboratory assessments and necessary for evaluation      of study outcome measures|Both|18 Years|N/A|No|Non-Probability Sample||October 2012|October 29, 2012|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00000930||210632|
NCT00000942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 316A|A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies|A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2001|Actual|||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||1244|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000942||210621|
NCT00000943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5046s|A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328|A Controlled, Pilot Study of the Immunogenicity of Remune in HIV-Infected Subjects Receiving Either Highly Active Antiretroviral Therapy (HAART) Alone or HAART and Interleukin-2 (IL-2): A Nested Substudy of ACTG 328||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005|Actual|||N/A|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000943||210620|
NCT00000927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 009|A Study of BufferGel in Women|Phase I Vaginal Microbicide Study of BufferGel||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Prevention||||40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 1999|January 8, 2007|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000927||210635|
NCT00000888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 354|Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies|A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Ritonavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women and Their Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||14|||Female|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000888||210674|
NCT00000881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 352|A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease|A Phase I/II Study of Cidofovir for HIV-Infected Children With Invasive CMV (Cytomegalovirus) Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||Actual|0|||Both|3 Months|13 Years|No|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000881||210681|
NCT00000882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 370|Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects|Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||May 1999|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||300|||Both|12 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000882||210680|
NCT00000903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 388|Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen|A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/mm3 or Greater Than or Equal to 80,000 HIV RNA Copies/ml in Plasma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2001|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||444|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000903||210659|
NCT00000879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 326|A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers|A Phase I/II Study to Evaluate the Safety and Immunogenicity of ALVAC HIV Vaccines Alone and With AIDSVAX B/B in Children Born to HIV-Infected Mothers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2005|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||48|||Both|N/A|3 Days|No|||May 2012|May 16, 2012|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00000879||210683|
NCT00000922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 058|A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)|A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2006|Actual|January 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1710|||Both|13 Years|N/A|No|||April 2014|April 16, 2014|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000922||210640|
NCT00001079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 313|A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss|Double-Blind Randomized Comparison Phase II Trial of Megestrol Acetate and Testosterone Enanthate in Combination Versus Megestrol Acetate Plus Testosterone Enanthate Placebo in Human Immunodeficiency Virus (HIV)-Associated Wasting.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2002|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001079||210485|
NCT00001085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 347|A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients|A Randomized, Double-Blind, Phase II Study of 141W94 (VX-478) Monotherapy vs. 141W94 (VX-478) Plus ZDV Plus 3TC in HIV Infected Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||94|||Both|13 Years|N/A|No|||February 2012|February 14, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001085||210479|
NCT00000977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 137|Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity|Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1993|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||52|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000977||210586|
NCT00000923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5051|Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328|Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2004|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000923||210639|
NCT00000907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 393|A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients|A Study of Discontinuing Maintenance Therapy in Subjects With Disseminated Mycobacterium Avium Complex (DMAC)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||50|||Both|13 Years|N/A|No|||June 2003|July 29, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000907||210655|
NCT00000917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 385|Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants|Establishment of a Cord Blood Bank for Gene Therapy in HIV-Infected Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|September 1997|||||N/A|Observational|N/A||||200|||Both|N/A|6 Months|No|||June 2003|July 30, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000917||210645|
NCT00000954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 163|A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma|Phase I/II Study of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) and Dideoxyinosine (ddI) or Dideoxycytidine (ddC) in the Treatment of AIDS-Related Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||72|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000954||210609|
NCT00000911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-05-001|A Study to Monitor Patients With Primary or Early HIV Infection|An Observational Study of Subjects With Primary HIV Infection: A Study of the UCSD Acute/Early HIV Infection (AEHIV) Clinical Studies Unit||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1999|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Blood, lymph node tissue, CSF, and semen or vaginal secretion specimens|Both|13 Years|N/A|No|Non-Probability Sample|Patients who have recently been infected with HIV|October 2015|October 21, 2015|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000911||210651|
NCT00000889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 021A|A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3|A Randomized, Open-Label, Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1997|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000889||210673|
NCT00000949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 059|A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3|A Randomized, Open-Label, Study of the Impact of Two Doses of Subcutaneous Recombinant IL-2 (Proleukin) on Viral Burden and CD4+ Cell Count in Patients With HIV-1 Infection and CD4+ Cell Counts Greater Than or Equal to 300/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2000|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||460|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000949||210614|
NCT00000887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 353|A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants|A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Nelfinavir (Viracept) Co-Administered With Zidovudine (ZDV) and Lamivudine (3TC) in HIV Infected Pregnant Women and Their Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2004|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Female|13 Years|N/A|No|||May 2012|May 21, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000887||210675|
NCT00000920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 386|Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns|A Phase I Trial of the Safety and Pharmacokinetics of Fortovase (Saquinavir-SGC) Co-Administered With Low Dose (Ritonavir) RTV, ZDV and 3TC in HIV Seropositive Pregnant Women During Gestation and Postpartum, and in Their Infant's Post-Maternal Dosing||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2003|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||24|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00000920||210642|
NCT00001086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 368|A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients|A Randomized, Phase II, Placebo Controlled Trial of Abacavir (ABC, 1592U89) in Combination With Open-Label Indinavir Sulfate (IDV) and Efavirenz (EFV, DMP-266) in HIV-Infected Subjects With Nucleoside Analog Experience: A Rollover Study for ACTG 320||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1999|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|16 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001086||210478|
NCT00001087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 364|The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs|Comparison of the Virologic Efficacy of Nelfinavir and/or DMP 266 (Efavirenz, EFV) in Combination With One or Two New Nucleoside Analogs in Nucleoside Experienced Subjects: A Roll-Over Study to ACTG 302/303||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2000|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|12 Years|N/A|No|||May 2012|May 21, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001087||210477|
NCT00000987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 075|A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS|A Phase I Study of Combination Chemotherapy (Adriamycin, Bleomycin, and Vincristine) and Azidothymidine in the Treatment of AIDS Related Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1992|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||36|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000987||210576|
NCT00000868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 028|A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers|A Phase I Safety and Immunogenicity Trial of Orally Administered Live Attenuated Recombinant Salmonella Typhi CVD 908 Delta-asd (pW57-asd+) Expressing HIV-1 LAI gp120 (VVG 203) and Parenterally Administered HIV-1 MN rgp120 in Alum in HIV-1-Uninfected Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||27|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000868||210694|
NCT00000925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 392|A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss|Evaluation of High Protein Supplementation in HIV-1-Positive Subjects With Stable Weight Loss||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 1999|||June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000925||210637|
NCT00000936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT IN01/OLN-359|A Study To Test An Anti-Rejection Therapy After Kidney Transplantation|Controlled Trial of Induction Therapy in Renal Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|November 1999|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|292|||Both|N/A|20 Years|No|||January 2013|January 24, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000936||210627|
NCT00001062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 278|A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes|A Phase I Study of a Fixed-Schedule Regimen of Alternating Oral and Intravenous Ganciclovir for Treatment of Cytomegalovirus Retinitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1998|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||25|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001062||210502|
NCT00001076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 029|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1997|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||34|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001076||210488|
NCT00001080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 340|Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals|Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999|||as of 4/23/97|No||https://clinicaltrials.gov/show/NCT00001080||210484|
NCT00001081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 336|A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium|A Phase II/III Placebo-Controlled Study of Nitazoxanide (NTZ) For Persons With AIDS and Cryptosporidiosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1998|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||February 2012|February 14, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001081||210483|
NCT00000871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 202/HIVNET 014|A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers|A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2000|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||420|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000871||210691|
NCT00000872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 356|Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection|Early Intensive Antiretroviral Combination Therapy in HIV-1 Infected Infants and Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Both|N/A|2 Years|No|||May 2012|May 17, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000872||210690|
NCT00000906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 401|Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients|The Effect of HIV Protease Inhibitors on the Stereospecific Metabolism of Methadone in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000906||210656|
NCT00000916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5025|A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood|A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||399|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000916||210646|
NCT00000913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 397|A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children|A Randomized Trial of Two Saquinavir-Containing Combination Treatment Regimens in Children With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2001|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||50|||Both|3 Years|16 Years|No|||March 2012|March 26, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000913||210649|
NCT00000865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 330|The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children|A Phase I Safety and Pharmacokinetic Study of 1592U89 Alone and In Combination With Other Antiretroviral Agents in Infants and Children With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|3 Months|13 Years|No|||February 2012|February 14, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000865||210697|
NCT00000973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 102|A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients|Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||26|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000973||210590|
NCT00000982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 103|A Study of Azidothymidine in HIV-Infected Children|A Randomized Trial To Evaluate the Impact of Maintaining Steady-State Concentrations of Azidothymidine (AZT) Versus an Intermittent Schedule of AZT Delivery in Children With Symptomatic HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||September 1996|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||75|||Both|3 Months|12 Years|No|||October 1996|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000982||210581|
NCT00000929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 008|A Study of the Effects of Advantage 24 on the Rectum|Phase I Rectal Microbicide Study||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed||July 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||70|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 21, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000929||210633|
NCT00000928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 013|Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples|Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting||||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 29, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000928||210634|
NCT00000869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 316|A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies|A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2001|Actual|||Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||2009|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000869||210693|
NCT00001088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 031|A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 1997|February 2001|Actual|February 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2008|September 26, 2008|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001088||210476|
NCT00000970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 151|A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir|A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1993|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000970||210593|
NCT00000867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 301|A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)|A Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Memantine for AIDS Dementia Complex (ADC) as Concurrent Treatment With Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 1996|July 2001|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000867||210695|
NCT00001082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 039|The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (Bis-POM PMEA) in Prolonging Survival of HIV-Infected Individuals With a CD4+ Cell Count of <= 100/mm3 or With a CD4+ Cell Count Both > 100 and <= 200/mm3 and a Nadir CD4+ Cell Count of <= 50/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 1996|August 1999|Actual|January 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|505|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001082||210482|
NCT00001083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 338|Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs|A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV- Infected Children; PRAM-1: ZDV+3TC vs. d4T+Ritonavir vs. ZDV+3TC+Ritonavir; PRAM-1, Step 2: d4T+Nevirapine+Ritonavir; PRAM-1, Step 3: d4T+Indinavir vs. ZDV+3TC+Indinavir||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2001|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||240|||Both|2 Years|17 Years|No|||February 2012|February 14, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001083||210481|
NCT00000909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 021D|A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy|A Randomized, Open Label Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Alone vs No Therapy in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3 Who Do Not Wish to Receive Treatment With Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000909||210653|
NCT00001066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 300|A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children|A Randomized Comparative Study of Combined Zidovudine-Lamivudine (3TC) vs. the Better of ddI Monotherapy vs. Zidovudine Plus Ddl in Symptomatic HIV-1 Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||January 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||740|||Both|3 Months|15 Years|No|||March 2011|March 1, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001066||210498|
NCT00001114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 206|The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma|A Randomized Phase II Trial to Determine the Safety, Tolerance, and Efficacy of Two Doses of Interferon Alfa-2b Combined With Didanosine in Patients With Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2000|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||90|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001114||210452|
NCT00001128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIDS R001|Treatment of Chronic Cryptosporidiosis in AIDS Patients|A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||June 2003|September 8, 2008|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00001128||210439|
NCT00001129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 062|A Study of Two Adherence Plans to Help HIV-Positive Patients Take Their Medications Correctly|Adherence Strategies Using a Medication Manager and an Electronic Medication Reminder System for HIV-Infected Patients Receiving HAART||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2003|Actual|||N/A|Interventional|Intervention Model: Factorial Assignment, Primary Purpose: Treatment||||1248|||Both|N/A|N/A|No|||September 2013|September 28, 2013|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00001129||210438|
NCT00001387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940204|Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy|Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy||National Institutes of Health Clinical Center (CC)||Completed|September 1994|July 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001387||210218|
NCT00001365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930183|Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System|NMDA Receptor Antagonist Treatment of Neurodegenerative Disease||National Institutes of Health Clinical Center (CC)||Completed|July 1993|June 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||42|||Both|N/A|N/A|No|||July 2000|July 12, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001365||210236|
NCT00001021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 009|A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)|A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||57|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001021||210542|
NCT00001069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 036|A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment|A Randomized Study of the Clinical Effects of Initiating or Changing Antiretroviral Therapy Based on Plasma HIV RNA Quantitation Compared With Initiating or Changing Therapy Based on Current Clinical Practice Alone||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||N/A|Observational|Observational Model: Natural History||||1100|||Both|13 Years|N/A|No|||January 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001069||210495|
NCT00001070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 017|The Safety and Effectiveness of Different Doses of Vitamin C in HIV-Infected Patients|A Dose Escalation Study to Evaluate Tolerance and Antiviral Effect of Oral Vitamin C in Two Groups of HIV-Infected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001070||210494|
NCT00001071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 285|A Study of Stem Cells and Filgrastim|A Pilot Study of Stem Cell Mobilization and Harvesting From the Peripheral Blood Using Filgrastim||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||N/A|Interventional|Primary Purpose: Treatment||||24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001071||210493|
NCT00001072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 026|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||140|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001072||210492|
NCT00001166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|780001|Gyrate Atrophy of the Choroid and Retina|The Diagnosis, Pathogenesis and Treatment of Gyrate Atrophy of the Choroid and Retina||National Institutes of Health Clinical Center (CC)||Completed|January 1978|March 2004||||N/A|Observational|N/A||||65|||Both|N/A|N/A|No|||March 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001166||210407|
NCT00001064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRAT 1|A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3|A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001064||210500|
NCT00001103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 736|HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs|Cerebrospinal Fluid Human Immunodeficiency Virus-1 (HIV-1) and Cognitive Function in Individuals Receiving Potent Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||May 2006|July 28, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001103||210463|
NCT00001025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 194|Evaluation of Patients Who Have Not Had Success With Zidovudine|A Study to Evaluate the Short-Term Clinical and Virologic Significance of Zidovudine Resistance||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1995|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||120|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001025||210538|
NCT00001065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 295|A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole|A Phase II Trial of Amphotericin B Oral Suspension for Fluconazole-Resistant Oral Candidiasis in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||70|||Both|13 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001065||210499|
NCT00001074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 307|The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients|A Phase I/II Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone and in Combination With ddI Compared With ddI Alone in Subjects With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2000|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001074||210490|
NCT00001143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000005|Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye|Ocular Motor Development During the First Seven Months of Life in Infants With and Without a Family History of Strabismus||National Institutes of Health Clinical Center (CC)||Completed|October 1999|October 2002||||N/A|Observational|N/A||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001143||210429|
NCT00001019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 007A/B|Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant|A Phase I Clinical Trial to Evaluate:Part A. The Safety and Immunogenicity of Two Dose Levels of SF-2 gp120 (CHO) With or Without MTP-PE Adjuvant in the MF59 Emulsion Part B. The Safety and Immunogenicity of Five Monthly Doses of 50 mcg gp120 Protein in MF59 Emulsion (Without MTP-PE) Versus the Emulsion Control||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001019||210544|
NCT00001022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 007|A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients|A Randomized, Comparative Trial of Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus Dideoxycytidine (ddC) in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1995|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||1200|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001022||210541|
NCT00001113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 014|A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma|A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1990|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001113||210453|
NCT00001362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930060|Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders|Structural and Functional Imaging of Neurologically Impaired Patients and Normal Volunteers With 1.5 and 3.0 Tesla MRI||National Institutes of Health Clinical Center (CC)||Completed|December 1992|July 2003||||N/A|Observational|N/A||||830|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001362||210239|
NCT00001102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 061|The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients|Metabolic Consequences of Highly Active Antiretroviral Therapy (HAART) in HIV-Positive Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2006|Actual|||N/A|Observational|N/A||||460|||Both|13 Years|N/A|No|||April 2014|April 16, 2014|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001102||210464|
NCT00001092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-05-007|The Biology of HIV Transmission|The Determinants of the Biology of HIV Transmission to Determine the Immunologic and Virologic Characteristics of Those Who May Have Transmitted HIV to Another Individual||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1999|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood, genital fluids, and saliva collection|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected adults with recent seroconversion|October 2015|October 21, 2015|November 2, 1999||No||No||https://clinicaltrials.gov/show/NCT00001092||210472|
NCT00001058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 223|A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS|A Phase II/III Prospective, Multicenter, Randomized, Controlled Trial Comparing the Safety and Efficacy of Three Clarithromycin-Containing Combination Drug Regimens for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Disease in Persons With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1999|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||246|||Both|13 Years|N/A|No|||April 2012|April 2, 2012|November 2, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00001058||210506|
NCT00001399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940033|Gene Therapy for the Treatment of Fanconi's Anemia Type C|Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients||National Institutes of Health Clinical Center (CC)||Completed|December 1993|February 2009||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||9|||Both|5 Years|N/A|No|||February 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001399||210208|
NCT00001115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 020|The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood|A Pilot Study to Determine the Effect of Acyclovir Treatment for Herpes Simplex Virus (HSV) Infection on Peripheral Blood HIV Viral Load.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|13 Years|N/A|No|||June 1998|July 28, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001115||210451|
NCT00001075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 315|The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients|A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2007|Actual|||N/A|Interventional|Primary Purpose: Treatment||||55|||Both|16 Years|N/A|No|||February 2012|February 13, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001075||210489|
NCT00001178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810010|Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders|Regional Cerebral Utilization of Glucose in Patients With a Diagnosis of Frontal Lobe Dementia, Atypical Parkinsonian Disorder, and Other Basal Ganglia Disorders||National Institutes of Health Clinical Center (CC)||Terminated|January 1981|December 2012||||N/A|Observational|N/A|||Actual|597|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|August 20, 2013|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001178||210396|
NCT00001073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 293|Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors|A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2001|Actual|||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||150|||Female|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001073||210491|
NCT00001096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 036|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001096||210468|
NCT00001097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 381|Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems|Establishment and Maintenance of Long-Term Undetectable Plasma HIV-1 RNA: Correlation With Immunologic Reconstitution and Viral Dynamics||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 1997|||||N/A|Observational|N/A||||120|||Both|8 Years|22 Years|No|||November 2005|April 23, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001097||210467|
NCT00001034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 023|The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV|A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1995|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||850|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001034||210529|
NCT00001121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 014A|A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1|Evaluation of Virologic, Immunologic, and Clinical Parameters of Participants in HIVNET 014 Who Become Infected With HIV-1||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 1999|||||N/A|Observational|N/A|||||||Both|18 Years|60 Years|No|||June 2003|September 11, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001121||210445|
NCT00001112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 072|The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine|A Phase I Study To Determine the Safety of the Optimal Monocyte Activating Administration Schedule of Subcutaneous Human Recombinant Interferon-gamma in ZDV-Treated Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|65 Years|No|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001112||210454|
NCT00001055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 022|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1997|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||76|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001055||210509|
NCT00001093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-05-005|Outcomes of Anti-HIV Therapy During Early HIV Infection|Outcomes of Antiretroviral Therapy During Primary HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1999|June 2007|Actual|||N/A|Observational|N/A||||48|||Both|13 Years|N/A|No|||October 2012|October 26, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001093||210471|
NCT00001363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930077|PET Scan to Map the Areas of the Brain Involved in Planning|Functional Brain Mapping of Planning Activities With [015] Water PET Blood Flow Technique||National Institutes of Health Clinical Center (CC)||Completed|January 1993|March 2001||||N/A|Observational|N/A||||230|||Both|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001363||210238|
NCT00001108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1007|A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses|Multi-Drug Antiretroviral Therapy for Heavily Pretreated Pediatric AIDS Patients: A Phase I Proof of Concept Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||6|||Both|4 Years|22 Years|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001108||210458|
NCT00001023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 001|The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients|Evaluation of the Safety, Tolerance and Pharmacokinetics of Rifabutin/Clarithromycin Combination and Rifabutin/Azithromycin Combination in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1998|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||91|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|November 2, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00001023||210540|
NCT00001063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 290|The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks|A Phase II Randomized Study of the Virologic and Immunologic Effects of d4T vs Zidovudine Plus d4T vs Zidovudine Plus Ddl in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and Greater Than 12 Weeks Zidovudine Experience||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1997|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||200|||Both|12 Years|N/A|No|||April 2012|April 13, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001063||210501|
NCT00001376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940196|Steroid Hormones, TH1/TH2 Cytokines and Reproductive Status|Steroid Hormones, TH1/TH2 Cytokines and Reproductive Status||National Institutes of Health Clinical Center (CC)||Completed|August 1994|June 2000||||N/A|Observational|N/A||||209|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001376||210228|
NCT00001054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 253|The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children|A Phase I Trial to Evaluate the Pharmacokinetics, Safety, and Tolerance of Valacyclovir HCl in HIV-1 Infected Children With Herpes Simplex Infections or Varicella/Zoster Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||January 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|4 Years|12 Years|No|||April 2012|April 2, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001054||210510|
NCT00001104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 036|A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia|A Placebo Controlled Trial To Evaluate Zidovudine (ZDV) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Hemophilic Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1990|Actual|||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||538|||Both|12 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001104||210462|
NCT00001056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 004A|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1994|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001056||210508|
NCT00001189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830227|The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors|The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 1983|April 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||150|||Both|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001189||210387|
NCT00001109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG P1009|A Blood Test to Look at Cells of the Immune System in Healthy Children|Mononuclear Cell Phenotyping in Normal Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||630|||Both|N/A|18 Years|Accepts Healthy Volunteers|||October 2004|July 29, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001109||210457|
NCT00001042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 015|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1996|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|112|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001042||210521|
NCT00001364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930151|Evaluation and Treatment of Patients Spinal Blood Vessel Abnormalities|Evaluation and Treatment of Patients With Spinal Vascular Abnormalities||National Institutes of Health Clinical Center (CC)||Completed|June 1993|December 2007||||N/A|Observational|N/A||||120|||Both|4 Years|N/A|No|||December 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001364||210237|
NCT00001020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 006X|A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)|A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001020||210543|
NCT00001091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 377|Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens|A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs and an NNRTI||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2000|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||200|||Both|4 Months|17 Years|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001091||210473|
NCT00001061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 266|Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS|A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||167|||Both|13 Years|N/A|No|||May 2012|May 8, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001061||210503|
NCT00001105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 232|The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV|A Phase I Clinical Trial to Study the Toxicity, Pharmacokinetics, and Efficacy of Human Monoclonal Antibody, F105, for Treating Human Immunodeficiency Virus Infection.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1996|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||8|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001105||210461|
NCT00001390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940018|Salivary Evaluation in Normal Volunteers|Salivary Evaluation in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|October 1993|||||N/A|Observational|N/A|||Anticipated|250|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001390||210217|
NCT00001117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 383|A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection|Dynamics of Hepatitis C Infection in Subjects With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Receiving Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 2|Observational|N/A||||60|||Both|13 Years|N/A|No|||June 2003|July 30, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001117||210449|
NCT00001024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 003|The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS|A Multicenter, Open-Label Study of Viral Burden in Peripheral Blood Versus Lymphoid Tissue Before and After Antiretroviral Therapy in HIV-Infected Individuals Without AIDS (NOTE: One Arm Receives no Treatment)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2002|Actual|||N/A|Interventional|Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001024||210539|
NCT00001067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 298|The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs|A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 1997|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||105|||Both|12 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001067||210497|
NCT00001068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 303|A Study of Disease Progression and Anti-HIV Treatments|Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-up Study to ACTG 175||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||210|||Both|12 Years|N/A|No|||May 2012|May 1, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001068||210496|
NCT00001167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790101|Ultrasound Evaluation of Tongue Movements in Speech and Swallowing|Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx||National Institutes of Health Clinical Center (CC)||Completed|August 1979|November 2004||||N/A|Observational|N/A||||570|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001167||210406|
NCT00001060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 101|A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons|A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|50 Years|No|||May 2013|May 3, 2013|November 2, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00001060||210504|
NCT00001052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 016A|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1997|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|110|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001052||210512|
NCT00001035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 203P|The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections|A Phase I Pilot Study of the Safety and Efficacy of Interferon Alfa-2b (IFN Alfa-2b) in Combination With Nucleoside Analog Therapy in Patients With Combined Hepatitis C (HCV) and Advanced Human Immunodeficiency Virus (HIV) Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||10|||Both|13 Years|N/A|No|||April 2012|April 27, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001035||210528|
NCT00001090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 033|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205, Combined With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Healthy, HIV-1 Uninfected Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1999|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001090||210474|
NCT00000997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 011|A Study of Dideoxycytidine in HIV-Infected Patients|Pharmacokinetics and Bioavailability of Dideoxycytidine in Patients With Human Immunodeficiency Virus Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1988|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000997||210566|
NCT00001014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 031|Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1991|Actual|||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||302|||Both|12 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001014||210549|
NCT00001053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 019|A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects|A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1996|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 8, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001053||210511|
NCT00000999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 020|The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC|A Multicenter Uncontrolled Trial To Evaluate the Long Term Safety and Tolerance of Zidovudine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS and Advanced ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1989|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000999||210564|
NCT00001107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 98-014|Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants|Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 4|Interventional|Masking: Double-Blind, Primary Purpose: Prevention||||500|||Both|N/A|N/A|No|||November 2005|August 26, 2010|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001107||210459|
NCT00001219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870091|Comparing Magnetic Resonance Imaging/Spectroscopy Techniques|Magnetic Resonance Imaging at 1.5 and 3.0 Tesla||National Institutes of Health Clinical Center (CC)||Recruiting|June 1987|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|June 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001219||210360|
NCT00001224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870104|Analysis of Eye Tissue|Immunologic Analysis of Intra-Ocular Tissue||National Institutes of Health Clinical Center (CC)||Completed|July 1987|September 2002||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||September 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001224||210356|
NCT00001043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 013B|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1997|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention|||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001043||210520|
NCT00001036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 236|The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine and Thymosin Alpha 1 in HIV-Positive, Asymptomatic and Symptomatic Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||October 1996|July 29, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001036||210527|
NCT00001028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 013|A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides|A Randomized, Comparative, Prospective Study of Monthly Aerosolized Pentamidine and Thrice Weekly Dapsone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant to Trimethoprim and/or Sulfonamides||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1994|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001028||210535|
NCT00001039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATRI 007|Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients|The Effect of Therapy on the Tissue Burden of Disseminated MAC Infection as Measured by Quantitative Bone Marrow Culture and Correlation With Quantitative Blood Culture in HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2002|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||24|||Both|13 Years|N/A|No|||October 2012|October 29, 2012|November 2, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00001039||210524|
NCT00001094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 374|A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients|A Phase II, Randomized, Controlled, Open-Label Trial of Combination Therapy With Nelfinavir (NFV) and Saquinavir (SQV)Sgc With Delavirdine (DLV) or 3TC/ZDV Versus Nelfinavir (NFV) and 3TC/ZDV in Subjects With HIV Infection and > 5,000 HIV RNA Copies/ML||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|13 Years|N/A|No|||March 2015|March 5, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001094||210470|
NCT00000996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 006|A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma|Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1990|Actual|||Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000996||210567|
NCT00001033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 222|The Treatment of Tuberculosis in HIV-Infected Patients|The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1997|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||650|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001033||210530|
NCT00000994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 001|A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma|A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||240|||Male|18 Years|N/A|No|||February 2012|February 15, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00000994||210569|
NCT00001004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 025|A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex|A Randomized Multicenter Phase II Trial of Recombinant Tumor Necrosis Factor and Recombinant Human Interferon-gamma in Patients With AIDS Related Complex||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1990|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|70 Years|No|||May 2012|May 21, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001004||210559|
NCT00001216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860020|Non-Invasive Electrical Stimulation of the Human Brain|Non-Invasive Stimulation of the Human Central Nervous System (Digitimer)||National Institutes of Health Clinical Center (CC)||Completed|February 1986|February 2001||||N/A|Observational|N/A||||175|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001216||210363|
NCT00001003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 079|A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia|Aerosols in the Treatment of Pneumocystis Carinii Pneumonia: A Nested Study Quantitating the Delivery of Aerosolized Pentamidine for Prophylaxis of PCP in Protocols ACTG 021 and ACTG 081||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1992|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||20|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001003||210560|
NCT00000998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 018|A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP|Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1989|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|60 Years|No|||December 2012|December 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000998||210565|
NCT00001016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX 301|A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies|A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2007|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||July 1993|September 26, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001016||210547|
NCT00001044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 016|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001044||210519|
NCT00001220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870160|Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders|Comparison of Ultrasound and Videofluoroscopic Imaging Techniques in Diagnosing Oropharyngeal Dysphagia in Neurologically Impaired Subjects||National Institutes of Health Clinical Center (CC)||Completed|October 1987|November 2005||||N/A|Observational|N/A||||750|||Both|N/A|N/A|No|||November 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001220||210359|
NCT00001235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880029|Genetic Studies in Alzheimer's Disease|Biochemical and Genetic Studies in Familial Alzheimer's Disease||National Institutes of Health Clinical Center (CC)||Completed|February 1988|February 2004||||N/A|Observational|N/A||||1500|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001235||210346|
NCT00001106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 082|A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children|A Phase I Trial To Evaluate Zidovudine (ZDV) in HIV-1 Infected Pregnant Women and Their Offspring||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1994|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|50 Years|No|||March 2012|June 2, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001106||210460|
NCT00000993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS 402|A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus|An Open Protocol for the Use of Zidovudine for Prophylactic Treatment of Individuals After Accidental Massive Exposure to the Human Immunodeficiency Virus (HIV)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Prevention|||||||Both|13 Years|N/A|Accepts Healthy Volunteers|||April 1991|August 25, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00000993||210570|
NCT00001047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 027|Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS|An Open-Label, Randomized Trial of Four Treatment Regimens for Patients With Disseminated Mycobacterium Avium Complex Disease and Acquired Immunodeficiency Syndrome (AIDS)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1996|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001047||210516|
NCT00001009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 060|A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)|A Phase I/II Dose Ranging Trial of Oral Dextran Sulfate (UA001) in HIV Infected Individuals and in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS Related Complex (ARC)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 1990|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||60|||Both|12 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001009||210554|
NCT00001041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 235|Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)|Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 1998|Actual|||Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||24|||Female|16 Years|40 Years|No|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001041||210522|
NCT00001221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870152|Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome|A Double-Blind, Randomized, Placebo-Controlled Trial of the Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome||National Institutes of Health Clinical Center (CC)||Completed|September 1987|September 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||160|||Female|N/A|N/A|No|||September 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001221||210358|
NCT00001194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840058|NMR Scanning on Patients|NMR Scanning on Patients||National Institutes of Health Clinical Center (CC)||Completed|April 1984|February 2001||||N/A|Observational|N/A||||99999|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001194||210382|
NCT00001017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 026|Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS|Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||July 1991|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||330|||Both|18 Years|N/A|No|||September 2002|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001017||210546|
NCT00001217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870068|Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study|Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study||National Institutes of Health Clinical Center (CC)||Completed|May 1987|December 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||260|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001217||210362|
NCT00001249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900043|Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac|Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac||National Institutes of Health Clinical Center (CC)||Completed|December 1989|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001249||210333|
NCT00001027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 189|A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole|A Phase I/II Trial of Parenteral Pentamidine for PCP Prophylaxis in HIV-Infected Children Who Are Intolerant to Oral Trimethoprim-Sulfamethoxazole||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1996|Actual|||Phase 1|Interventional|Primary Purpose: Treatment||||32|||Both|1 Month|6 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001027||210536|
NCT00001037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 013A|A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules|A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention|||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001037||210526|
NCT00001038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 204|A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients|A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||May 1996|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||1200|||Both|13 Years|N/A|No|||February 2011|February 28, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001038||210525|
NCT00001026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 010|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 1994|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001026||210537|
NCT00001005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 042|A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes|Interleukin-2 Augmentation of Specific Anti-HIV Immune Responses: Phase I Trial of the Combination of 3'-Azido-3'-Deoxythymidine (Zidovudine) and Recombinant Interleukin-2 in Patients With Asymptomatic HIV Infection Associated With Lymphadenopathy (Walter Reed Stage II)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 1995|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001005||210558|
NCT00001000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 056|A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection|Immunologic Effect After Single Dose Atvogen in Healthy Volunteers and Asymptomatic HIV-Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 1990|Actual|||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001000||210563|
NCT00001001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 062|A Study of Zidovudine in HIV-Infected Patients With Liver Disease|A Clinical Study Examining the Pharmacokinetics and Bioavailability of Azidothymidine (AZT, Zidovudine) in Patients With Human Immunodeficiency Virus (HIV) Infection and Hepatic Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1990|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||39|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001001||210562|
NCT00001015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 034|A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems|A Multicenter Phase I Clinical Trial of Ribavirin in the Treatment of Patients With AIDS and Advanced AIDS Related Illnesses||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1990|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||96|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001015||210548|
NCT00001002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 053|A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time|Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1991|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001002||210561|
NCT00001013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 029|Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 1991|Actual|||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||364|||Both|12 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001013||210550|
NCT00001202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850016|Treatment of Boys With Precocious Puberty|Spironolactone and Testolactone Treatment of Boys With Familial Isosexual Precocious Puberty||National Institutes of Health Clinical Center (CC)||Completed|January 1985|January 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||80|||Male|N/A|N/A|No|||January 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001202||210376|
NCT00001018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 198|A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea|Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics and Dose Escalation, Efficacy, and Safety Study of Letrazuril for AIDS-Related Cryptosporidial Diarrhea||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||32|||Both|13 Years|N/A|No|||October 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001018||210545|
NCT00001218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870016|Development of Normative Ultrasound Databases of Tongue Surface Configuration|Development of Normative Ultrasound Databases of Tongue Surface Configuration||National Institutes of Health Clinical Center (CC)||Completed|February 1987|January 2001||||N/A|Observational|N/A||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001218||210361|
NCT00001008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 055|A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)|Pharmacokinetic Study of the Interaction of Azidothymidine and Methadone in Patients With AIDS and ARC||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||March 1991|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||August 1991|March 11, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001008||210555|
NCT00001225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870057|Family Studies of Inherited Heart Disease|Family Studies of Hypertrophic Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|April 1987|August 2002||||N/A|Observational|N/A||||5880|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001225||210355|
NCT00001111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 180|A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children|Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||June 1995|Actual|N/A|Interventional|Primary Purpose: Treatment||||35|||Both|N/A|17 Years|No|||February 2011|February 28, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001111||210455|
NCT00001045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 244|Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease|A Double-Blinded, Randomized Trial Comparing Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus ddI Plus Nevirapine in Asymptomatic Patients on AZT Monotherapy Who Develop a Mutation at Codon 215 of HIV Reverse Transcriptase in Serum/Plasma Viral RNA||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||300|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001045||210518|
NCT00001223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870029|Studying Patients With Cystic Fibrosis and Other Pulmonary and Pancreatic Disorders|Diagnosis and Treatment of Patients With Cystic Fibrosis and Other Disorders of the Respiratory System and Pancreas||National Institutes of Health Clinical Center (CC)||Recruiting|February 1987|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|4 Years|N/A|No|||July 2015|July 25, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001223||210357|
NCT00001046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 233|Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)|Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||Actual|0|||Female|16 Years|40 Years|No|||May 2012|May 23, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001046||210517|
NCT00001029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 193|A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past|A Randomized, Double-Blind, Three-Arm Study Comparing Combination to Monthly Alternating Nucleoside Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) With a Prior History of Nucleoside Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1993|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||654|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001029||210534|
NCT00001030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 196|The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients|A Prospective, Randomized, Comparative Study of the Safety and Efficacy of Clarithromycin Versus Rifabutin Versus the Combination of Clarithromycin Plus Rifabutin for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia or Disseminated MAC Disease in HIV-Infected Patients With CD4 Lymphocyte Counts <= 100 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1996|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||1100|||Both|12 Years|N/A|No|||March 2012|June 2, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001030||210533|
NCT00001116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 928|A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients|Effect of Recombinant Human Soluble Tumor Necrosis Factor Receptor (TNFR:Fc) on Interleukin-6 (IL-6), Tumor Necrosis Factor-Alpha (TNF-alpha) and Markers of Immune Activation in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2000|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001116||210450|
NCT00001095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 373|A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir|A Phase II Study of 1) Amprenavir (141W94/VX478) Plus 3TC Plus ZDV (or d4T) or 2) IDV Plus NVP Plus 3TC Plus d4T in Subjects Previously Treated With Amprenavir and 3) Other Treatment Regimens (Observational ARM) in Subjects Previously Treated With Amprenavir||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1999|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||94|||Both|13 Years|N/A|No|||February 2012|February 16, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001095||210469|
NCT00001049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 239|A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV|A Phase I Evaluation of the Safety and Toxicity of Zidovudine and Didanosine in Combination in HIV-Infected or Exposed Infants and a Phase II Study of the Effect of Didanosine vs. Combination Therapy With Zidovudine and Didanosine on HIV-1 RNA in Infants With HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 1998|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|N/A|3 Months|No|||March 2012|March 29, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001049||210514|
NCT00001050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WACS|Study of Women Who Have AIDS|Women's AIDS Cohort Study (WACS)||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||N/A|Observational|Observational Model: Natural History||||1250|||Both|18 Years|N/A|No|||March 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001050||210513|
NCT00001010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 010|A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients|An Uncontrolled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Zidovudine (AZT) and Acyclovir (ACV) Given Concomitantly to Patients With Human Immunodeficiency Virus Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 1990|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|19 Years|N/A|No|||March 2012|March 15, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001010||210553|
NCT00001006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 046|A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)|A Phase One Study of AS-101 in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 1993|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|No|||March 2012|March 28, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001006||210557|
NCT00001059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 286|Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS|Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2012|April 13, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001059||210505|
NCT00001182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820057|Evaluation of Patients With Unusual Diagnostic or Treatment Considerations|General Dental Diagnostic and Therapeutic Study: A Pilot Program for Evaluating the Research Potential of Referred Subjects||National Institutes of Health Clinical Center (CC)||Completed|April 1982|June 2002||||N/A|Interventional|N/A||||300|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001182||210393|
NCT00001265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910196|Study and Treatment of Inflammatory Muscle Diseases|Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|August 1991|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001265||210319|
NCT00001234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880019|Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells|Retroviral-Mediated Transfer and Expression of Glucocerebrosidase and Ceramidtrihexosidase (a-Galactosidase A) cDNA's in Human Hematopoietic Progenitor Cells||National Institutes of Health Clinical Center (CC)||Completed|January 1988|April 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001234||210347|
NCT00001539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960052|Evaluation of Lyme Disease: Clinical, Microbiological and Immunological Characteristics|A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Chronic Lyme Infection and Selected Control Populations||National Institutes of Health Clinical Center (CC)||Recruiting|March 1996|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|13 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 24, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001539||210095|
NCT00001549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960009|Diagnosis and Natural History Study of Patients With Neurological Conditions|Diagnosis and Natural History Protocol for Patients With Neurological Conditions||National Institutes of Health Clinical Center (CC)||Completed|October 1995|January 2006||||N/A|Observational|N/A||||600|||Both|N/A|N/A|No|||January 2006|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001549||210085|
NCT00001533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960142|Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine|Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine||National Institutes of Health Clinical Center (CC)||Completed|September 1996|September 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||October 1999|July 14, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001533||210100|
NCT00001205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850127|Treatment of Patients With Cysticercosis With Praziquantel or Albendazole|Treatment of Cysticercosis Including Neurocysticercosis With Praziquantel, Albendazole and Other Novel Treatment Modalities||National Institutes of Health Clinical Center (CC)||Recruiting|July 1985|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|2 Years|75 Years|No|||December 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001205||210373|
NCT00001203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850087|Deferoxamine for the Treatment of Hemochromatosis|Clinical Course of Patients With Transfusional Hemochromatosis on Deferoxamine||National Institutes of Health Clinical Center (CC)||Completed|April 1985|November 2015||||N/A|Observational|N/A|||Actual|151|||Both|4 Years|N/A|No|||November 2015|November 10, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001203||210375|
NCT00001210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860199|Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines|Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines||National Institutes of Health Clinical Center (CC)||Completed|November 1986|September 2000||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001210||210369|
NCT00001228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880194|Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer|Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm||National Institutes of Health Clinical Center (CC)||Completed|October 1988|September 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||September 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001228||210353|
NCT00001155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760042|Treatment of Wegener's Granulomatosis With Cyclophosphamide|Treatment of Wegener's Granulomatosis With Cyclophosphamide||National Institutes of Health Clinical Center (CC)||Completed|February 1976|February 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||February 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001155||210417|
NCT00001168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790100|Evaluation of Lipoproteins|Teaching Protocol for the Evaluation of Plasma Lipoproteins||National Institutes of Health Clinical Center (CC)||Recruiting|August 1979|||||N/A|Observational|N/A|||Anticipated|2000|||Both|N/A|N/A|No|||March 2016|March 11, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001168||210405|
NCT00001169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790144|Clinical Investigation of Infections Due to Leishmanial Parasites|Clinical Investigation of Infections Due to Leishmanial Parasites||National Institutes of Health Clinical Center (CC)||Completed|December 1979|February 2001||||N/A|Observational|N/A||||250|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001169||210404|
NCT00001314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920195|Investigation of Heart Function in Patients With Heart Valve Defects|Investigation of Myocardial Contractile Reserve by Dobutamine Stress Transesophageal Echocardiography in Aortic and Mitral Regurgitation||National Institutes of Health Clinical Center (CC)||Completed|May 1992|March 2001||||N/A|Observational|N/A||||200|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001314||210280|
NCT00001316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920125|Viral Load in Blood and Lymph Tissues of HIV-Infected Individuals|A Study of Viral Burden in Peripheral Blood Versus Lymphoid and Bone Marrow Tissue in HIV-Infected Individuals||National Institutes of Health Clinical Center (CC)||Recruiting|March 1992|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 24, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001316||210279|
NCT00001233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880217|Study of Children at Risk for Disruptive Behavior Disorders|A Longitudinal Study of Children at Risk for Disruptive Behavior Disorders: Transitions From Early Childhood to Middle Childhood and Adolescence||National Institutes of Health Clinical Center (CC)||Completed|December 1988|December 2000||||N/A|Observational|N/A||||900|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001233||210348|
NCT00001242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890173|Resistance to Vitamin D or Parathyroid Hormone|Studies of States With Resistance to Vitamin D and Parathyroid Hormone||National Institutes of Health Clinical Center (CC)||Recruiting|September 1989|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|1 Year|N/A|No|||March 2015|April 7, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001242||210340|
NCT00001277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910085|Studies of Elevated Parathyroid Activity|Studies of Hyperparathyroidism and Related Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|March 1991|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|N/A|N/A|No|||September 2015|January 22, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001277||210310|
NCT00001204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850105|Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers|Cardiovascular Evaluation of Homozygous Familial Hypercholesterolemia||National Institutes of Health Clinical Center (CC)||Completed|May 1985|||||N/A|Observational|N/A|||Actual|73|||Both|2 Years|70 Years|No|||February 2016|March 3, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001204||210374|
NCT00001248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890045|Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)|Evaluation of Progression in Multiple Sclerosis by Magnetic Resonance Imaging (MRI)||National Institutes of Health Clinical Center (CC)||Recruiting|March 1989|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|920|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 8, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001248||210334|
NCT00001253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900123|The Effects of Estrogen on Cognition in Girls With Turner Syndrome|Estrogen Effects on Cognition in Girls With Turner Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 1990|March 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||950|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001253||210329|
NCT00001254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900137|Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome|Evaluation of the Gastrinoma in Patients With Zollinger-Ellison Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 1990|||||N/A|Observational|N/A|||Actual|273|||Both|18 Years|N/A|No|||February 2016|March 2, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001254||210328|
NCT00001151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760081|Studies With 1,25-Dihydroxycholecalciferol|Studies With 1,25-Dihydroxycholecalciferol||National Institutes of Health Clinical Center (CC)|No|Terminated|March 1976|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||June 2013|November 21, 2013|November 3, 1999||No|Terminated because of lack of drug supply|No|November 12, 2010|https://clinicaltrials.gov/show/NCT00001151||210421|
NCT00001152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760189|Pigment Dispersion Syndrome With and Without Glaucoma|Pigment Dispersion Syndrome With and Without Glaucoma||National Institutes of Health Clinical Center (CC)||Completed|June 1976|June 2000||||N/A|Observational|N/A||||175|||Both|N/A|N/A|No|||May 1998|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001152||210420|
NCT00001212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860204|Drug Therapy in Lupus Nephropathy|Immunosuppressive Drug Therapy in Membranous Lupus Nephropathy||National Institutes of Health Clinical Center (CC)||Completed|November 1986|September 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||45|||Both|N/A|N/A|No|||April 2008|April 8, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001212||210367|
NCT00001527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960016|Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension|Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension||National Institutes of Health Clinical Center (CC)||Completed|November 1995|September 2000||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001527||210106|
NCT00001528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960031|Analysis of Heart Muscle Function Following Exercise in Patients With Heart Disease|Post-Stress Left Ventricular Contractile Dysfunction: Does It Represent Persistent Myocardial Ischemia or Stunning?||National Institutes of Health Clinical Center (CC)||Completed|February 1996|March 2001||||N/A|Observational|N/A||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001528||210105|
NCT00001529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960049|Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives|Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation||National Institutes of Health Clinical Center (CC)||Recruiting|March 1996|May 2040|Anticipated|May 2026|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99999999|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|January 22, 2016|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001529||210104|
NCT00001241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890015|Treatment of Zollinger-Ellison Syndrome|Medical Therapy of Zollinger-Ellison Syndrome||National Institutes of Health Clinical Center (CC)||Completed|January 1989|December 2007||||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||December 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001241||210341|
NCT00001156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760021|Assessment of Patients With Multiple Sclerosis (MS)|Combined Clinical, Immunological and Virological Assessment of Patients With Multiple Sclerosis (MS)||National Institutes of Health Clinical Center (CC)||Completed|January 1976|February 2010||||N/A|Observational|N/A|||Actual|1388|||Both|18 Years|75 Years|No|||February 2010|February 2, 2010|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001156||210416|
NCT00001191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830018|The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid|The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid||National Institutes of Health Clinical Center (CC)||Completed|February 1983|December 2007||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001191||210385|
NCT00001564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970050|A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas|A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas||National Institutes of Health Clinical Center (CC)||Completed|December 1996|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|30|||Both|N/A|30 Years|No|||September 2014|September 5, 2014|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001564||210076|
NCT00001246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890006|Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Children|Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Controls||National Institutes of Health Clinical Center (CC)||Recruiting|January 1989|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|6000|||Both|3 Years|N/A|Accepts Healthy Volunteers|||December 2015|January 5, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001246||210336|
NCT00001247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890160|Inpatient Evaluation of Adults With Schizophrenia|Inpatient Evaluation of Neuropsychiatric Patients||National Institutes of Health Clinical Center (CC)||Recruiting|September 1989|||||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|January 6, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001247||210335|
NCT00001230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880083|Host Response to Infection and Treatment in Filarial Diseases|Host Response to Infection and Treatment in the Filarial Diseases of Humans||National Institutes of Health Clinical Center (CC)||Recruiting|May 1988|||||N/A|Observational|N/A|||Anticipated|500|||Both|1 Year|100 Years|No|||October 2015|January 22, 2016|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001230||210351|
NCT00001206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850115|Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)|Biological Markers in Childhood Psychiatric Disorders||National Institutes of Health Clinical Center (CC)||Completed|June 1985|||||N/A|Observational|N/A|||Actual|347|||Both|6 Years|17 Years|No|||December 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001206||210372|
NCT00001125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG 391|Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox|Use of a Live-Attenuated Varicella-Zoster Virus (VZV) Vaccine to Boost Immunity to VZV in HIV-Infected Children Previously Infected With Varicella||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2004|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Prevention||||60|||Both|2 Years|18 Years|No|||October 2014|October 28, 2014|January 17, 2000|No|Yes||||https://clinicaltrials.gov/show/NCT00001125||210442|
NCT00001259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900088|A Treatment Study for Premenstrual Syndrome (PMS)|The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)||National Institutes of Health Clinical Center (CC)||Recruiting|March 1990|||||N/A|Observational|N/A|||Anticipated|100|||Female|18 Years|50 Years|No|||June 2015|June 20, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001259||210323|
NCT00001269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910121|Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer|Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|May 1991|February 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001269||210316|
NCT00001211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860015|Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects|Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects||National Institutes of Health Clinical Center (CC)||Completed|January 1986|December 2000||||N/A|Observational|N/A||||160|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001211||210368|
NCT00001195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840169|Endocrine Studies of Healthy Children|Endocrine Studies of Healthy Children||National Institutes of Health Clinical Center (CC)||Completed|August 1984|October 2014||||N/A|Observational|N/A|||Actual|1247|||Both|2 Years|18 Years|No|||October 2014|October 21, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001195||210381|
NCT00001181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820165|Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty|Testolactone Treatment of Girls With LHRH Analog-Resistant Precocious Puberty Due to Autonomous, Non-Neoplastic Ovarian Estrogen Secretion||National Institutes of Health Clinical Center (CC)||Completed|October 1982|May 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Female|N/A|N/A|No|||May 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001181||210394|
NCT00001292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920106|Study of Scaling Disorders and Other Inherited Skin Diseases|Clinical and Genetic Studies of the Scaling Disorders and Other Selected Genodermatoses||National Institutes of Health Clinical Center (CC)||Completed|February 1992|April 2001||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2000|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001292||210299|
NCT00001153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760207|Visual Function and Ocular Pigmentation in Albinism|Visual Function and Ocular Pigmentation in Albinism||National Institutes of Health Clinical Center (CC)||Completed|June 1976|May 2000||||N/A|Observational|N/A||||130|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001153||210419|
NCT00001158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770066|Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System|Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System||National Institutes of Health Clinical Center (CC)||Completed|April 1977|March 2000||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||April 1999|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001158||210415|
NCT00001159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770002|Evaluation of Patients With Thyroid Disorders|Evaluation of Patients With Thyroid Function Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|January 1977|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|99999999|||Both|N/A|N/A|No|||May 2015|June 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001159||210414|
NCT00001231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880131|Perimenopause-Related Mood and Behavioral Disorders|The Evaluation of Women With Perimenopause-Related Mood and Behavioral Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|July 1988|||||N/A|Observational|N/A|||Anticipated|1900|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||April 2015|January 7, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001231||210350|
NCT00001530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960059|Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy|Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|April 1996|May 2000||||N/A|Observational|N/A||||120|||Both|N/A|N/A|No|||April 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001530||210103|
NCT00001252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900168|Human Movement Database|A Rigid Body Database on Human Movement||National Institutes of Health Clinical Center (CC)||Recruiting|July 1990|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|999999999|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|November 13, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001252||210330|
NCT00001243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890035|Effects of HIV on the Development and Function of Bone Marrow Cells|Effects of Infection With the Human Immunodeficiency Virus on the Development and Function of Bone Marrow Cells||National Institutes of Health Clinical Center (CC)||Completed|February 1989|December 2005||||N/A|Observational|N/A||||300|||Both|N/A|N/A|No|||December 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001243||210339|
NCT00001196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840056|Evaluation of Salivary Gland Dysfunction|Evaluation of Salivary Gland Dysfunction||National Institutes of Health Clinical Center (CC)||Terminated|March 1984|September 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|1740|||Both|12 Years|N/A|No|||September 2015|September 30, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001196||210380|
NCT00001540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960058|The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo|The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo||National Institutes of Health Clinical Center (CC)||Completed|April 1996|March 2000||||N/A|Observational|N/A||||52|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 1999|March 3, 2008|April 1, 2000||||No||https://clinicaltrials.gov/show/NCT00001540||210094|
NCT00001258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900014|Studies of Frontal Lobe Brain Functioning in Schizophrenia|Studies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|October 1989|||||N/A|Observational|N/A|||Anticipated|1070|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001258||210324|
NCT00001209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860169|A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors|A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors||National Institutes of Health Clinical Center (CC)||Completed|October 1986|August 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||September 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001209||210370|
NCT00001131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-06-001|Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients|Procedure for Initiation, Administration, and Discontinuation of Interleukin-2 (IL-2) Therapy in Conjunction With Highly Active Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|N/A|N/A|No|||September 2013|May 14, 2015|January 17, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00001131||210436|
NCT00001270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910156|Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma|Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|June 1991|March 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||85|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001270||210315|
NCT00001531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960099|Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction|Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction||National Institutes of Health Clinical Center (CC)||Completed|June 1996|September 2000||||N/A|Observational|N/A||||355|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001531||210102|
NCT00001198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840050|Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia|Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients||National Institutes of Health Clinical Center (CC)||Recruiting|March 1984|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1975|||Both|6 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001198||210378|
NCT00001170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790123|Study of the Psychological Development of Children of Parents With and Without Affective Disorders|Affective Disorders and Affective Development: A Study of Child Rearing and Child Development in Normal Families and Families With Affective Disorders||National Institutes of Health Clinical Center (CC)||Completed|October 1979|February 2005||||N/A|Observational|N/A||||1045|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001170||210403|
NCT00001532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960100|Role of Genetic Factors in the Development of Lung Disease|Role of Genetic Factors in the Pathogenesis of Lung Disease||National Institutes of Health Clinical Center (CC)||Recruiting|June 1996|||||N/A|Observational|N/A|||Anticipated|3600|||Both|8 Years|90 Years|Accepts Healthy Volunteers|||July 2015|September 12, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001532||210101|
NCT00001565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970051|Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy|Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy||National Institutes of Health Clinical Center (CC)||Completed|December 1996|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001565||210075|
NCT00001154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760051|Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins|Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients||National Institutes of Health Clinical Center (CC)||Recruiting|March 1976|||||N/A|Observational|N/A|||Anticipated|900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001154||210418|
NCT00001193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840216|A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer|A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|November 1984|September 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001193||210383|
NCT00001244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890158|Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes|Studies of Immune Regulation in Patients With Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes||National Institutes of Health Clinical Center (CC)||Recruiting|September 1989|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|2 Years|N/A|No|||December 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001244||210338|
NCT00001280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910064|Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease|Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Completed|January 1991|March 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001280||210308|
NCT00001229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880189|Diagnosis and Treatment of Pheochromocytoma|Diagnosis and Treatment of Pheochromocytoma||National Institutes of Health Clinical Center (CC)||Completed|October 1988|January 2001||||N/A|Observational|N/A||||240|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001229||210352|
NCT00001201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840203|Evaluation of Neuromuscular Disease|Evaluation of Neuromuscular Diseases||National Institutes of Health Clinical Center (CC)||Completed|October 1984|November 2002||||N/A|Observational|N/A||||1500|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001201||210377|
NCT00001137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5001|Long-Term Data Collection From Participants in Adult AIDS Clinical Trials|Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) Protocol||AIDS Clinical Trials Group||Completed|January 2000|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5982|||Both|13 Years|N/A|No|Non-Probability Sample|Participants in this study will be HIV-infected men and women who are enrolled in an ACTG        parent study and are receiving HAART.|December 2013|December 5, 2013|January 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00001137||210431|
NCT00001262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900149|Copper Histidine Therapy for Menkes Diseases|Early Copper Histidine Therapy in Menkes Disease||National Institutes of Health Clinical Center (CC)|Yes|Completed|June 1990|July 2013|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|N/A|No|||September 2015|September 29, 2015|November 3, 1999|Yes|Yes||No|August 5, 2014|https://clinicaltrials.gov/show/NCT00001262||210320|
NCT00001197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|840029|Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia|Effect of Hydroxyurea on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia||National Institutes of Health Clinical Center (CC)||Completed|February 1984|May 2015|Actual|December 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2015|October 10, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001197||210379|
NCT00001353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930110|Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin Pairs|A Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-Infected Identical Twins||National Institutes of Health Clinical Center (CC)||Completed|March 1993|March 2002||||N/A|Observational|N/A||||24|||Both|N/A|N/A|No|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001353||210247|
NCT00001150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760293|Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers|Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 1976|March 2004||||N/A|Observational|N/A||||2000|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001150||210422|
NCT00001368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930220|Potential Risk Factors for Stroke|Cytokine and Leukocyte Activation Profile as a Risk Factor for Cerebral Vascular Disease and Stroke||National Institutes of Health Clinical Center (CC)||Completed|October 1993|November 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||500|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001368||210233|
NCT00001384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940145|A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients|A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|May 1994|February 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001384||210221|
NCT00001397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940010|Evaluation, Treatment, and Training for Patients With Blood Disorders|Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|October 1993|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|2 Years|N/A|No|||November 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001397||210210|
NCT00001257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900120|Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses|Comparison of Inflammatory Responses in Normal Volunteers and Patients With Abnormal Phagocyte Function Using the Suction Blister Technique||National Institutes of Health Clinical Center (CC)||Recruiting|April 1990|||||N/A|Observational|N/A|||Anticipated|200|||Both|6 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001257||210325|
NCT00001183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820032|Evaluation of the Causes and Disease Processes of Chronic Lung Disease|Comprehensive Evaluation of the Etiology and Pathogenesis of Chronic Lung Disease (Screening Protocol)||National Institutes of Health Clinical Center (CC)||Recruiting|March 1982|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|9 Years|90 Years|No|||February 2016|March 8, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001183||210392|
NCT00001163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|780039|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|March 1978|||||N/A|Observational|N/A|||Anticipated|7500|||Both|1 Year|N/A|Accepts Healthy Volunteers|||April 2015|May 8, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001163||210410|
NCT00001176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810081|Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure|The Function of Dopaminergic and Noradrenergic Systems in Salt-Sensitive Hypertension: The Effects of Changes in Sodium Intake||National Institutes of Health Clinical Center (CC)||Completed|May 1981|December 2001||||N/A|Observational|N/A||||110|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001176||210398|
NCT00001180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820045|Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency|Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency||National Institutes of Health Clinical Center (CC)||Completed|March 1982|June 2005||||N/A|Observational|N/A||||2250|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001180||210395|
NCT00001126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 97-023|Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)|A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|2 Years|17 Years|No|||November 2005|August 26, 2010|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00001126||210441|
NCT00001133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5055|Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir|A Phase I/II, Randomized, Open-Label Study of the Safety and Pharmacokinetics of Indinavir + Ritonavir Therapy in HIV-Infected Subjects Failing Amprenavir, Nelfinavir, Saquinavir, or Nelfinavir/Saquinavir Combination Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2006|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|January 17, 2000||||||https://clinicaltrials.gov/show/NCT00001133||210434|
NCT00001145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000006|Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome|Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome||National Institutes of Health Clinical Center (CC)||Completed|October 1999|October 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||October 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001145||210427|
NCT00001144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000001|Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia|Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML||National Institutes of Health Clinical Center (CC)||Completed|October 1999|October 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||October 2002|October 6, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001144||210428|
NCT00001396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940001|Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...|Obstructive Hypertrophic Cardiomyopathy (HCM) in Children: Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy||National Institutes of Health Clinical Center (CC)||Completed|October 1993|July 2008||||Phase 1|Interventional|Primary Purpose: Treatment|1|||100|||Both|5 Years|20 Years|No|||July 2008|July 24, 2008|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001396||210211|
NCT00001359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930122|Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)|A Trial of Prophylaxis for the PANDAS Subgroup||National Institutes of Health Clinical Center (CC)||Completed|April 1993|January 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||January 2006|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001359||210242|
NCT00001147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000008|Blood Sampling for Neurochemical and Genetic Testing|Blood Sampling for Neurochemical and Genetic Testing||National Institutes of Health Clinical Center (CC)||Completed|October 1999|March 2004||||N/A|Observational|N/A||||500|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001147||210425|
NCT00001366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930191|Mapping the Areas of the Brain Associated With Language in Children With Epilepsy|MRI-Based Functional Language Mapping in Children With Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|August 1993|September 2002||||N/A|Observational|N/A||||230|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001366||210235|
NCT00001173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800070|Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization|Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization||National Institutes of Health Clinical Center (CC)||Completed|June 1980|June 2000||||N/A|Observational|N/A||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001173||210400|
NCT00001372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940066|Study of Systemic Lupus Erythematosus|Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)||National Institutes of Health Clinical Center (CC)||Recruiting|February 1994|||||N/A|Observational|N/A|||Anticipated|100000|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|March 11, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001372||210231|
NCT00001373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940105|Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics|Genetics and Pathophysiology of Familial Mediterranean Fever and Related Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|March 1994|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|March 4, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001373||210230|
NCT00001162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770094|Parasitic Infections of the Gastrointestinal Tract|Study of Patients With Parasitic Infections of the Gastrointestinal Tract||National Institutes of Health Clinical Center (CC)||Recruiting|May 1977|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|3 Years|N/A|No|||July 2015|August 5, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001162||210411|
NCT00001132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5064|Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination|A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 1999|April 2001||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|13 Years|N/A|No|||June 2003|September 8, 2008|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00001132||210435|
NCT00001142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000010|Metabolism and Body Shape of Healthy Children and Children With Chronic Infections|Metabolism and Body Composition of Healthy Children and Children With Chronic Infections||National Institutes of Health Clinical Center (CC)||Completed|October 1999|December 2000||||N/A|Observational|N/A||||185|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001142||210430|
NCT00001186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830022|Psychological Benefits of a Normalized Camping Experience for Children With Cancer|Psychological Benefits of a Normalized Camping Experience for Children With Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|February 1983|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|9999|||Both|7 Years|17 Years|No|||December 2015|January 1, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001186||210389|
NCT00001188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830212|The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities|The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities||National Institutes of Health Clinical Center (CC)||Completed|December 1983|September 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001188||210388|
NCT00001160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770096|Studies on Tumors of the Thyroid|Studies on Thyroid Nodules and Thyroid Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|May 1977|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|99999|||Both|N/A|N/A|No|||October 2015|October 8, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001160||210413|
NCT00001161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770119|Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens|Anomalies of the Anterior Chamber, Angle, Iris, Cornea and Lens With or Without Glaucoma or Ocular Hypertension||National Institutes of Health Clinical Center (CC)||Completed|July 1977|August 2002||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001161||210412|
NCT00001130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-05-009|Identifying Emergency Room Patients Who Have Recently Been Infected With HIV|Increasing Identification of Patients With Primary HIV Infection (PHI) Through a Questionnaire Intervention in an Emergency Department (ED) Setting||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||200|||Both|18 Years|N/A|No|||January 2005|September 8, 2008|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00001130||210437|
NCT00001120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5035|A Study of Patients With AIDS Syndrome|Oncogenic Viral Pathogenesis and Cancer Risk Factors Among Patients With the Acquired Immunodeficiency Syndrome: A Prospective Cohort Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||5000|||Both|18 Years|N/A|No|||May 2006|September 11, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001120||210446|
NCT00001232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880132|The Effect of GnRH on Pitutitary Hormones in Menstrual-Cycle Mood Related Disorders|Pituitary Gonadotropin Response to GnRH Stimulation in Menstrual, Climacteric and, Menopause-Related Mood and Behavioral Disorders||National Institutes of Health Clinical Center (CC)||Completed|July 1988|June 2000||||N/A|Observational|N/A||||140|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001232||210349|
NCT00001367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930202|Diagnosis and History Study of Patients With Different Neurological Conditions|Diagnosis and Natural History Protocol for Patients With Different Neurological Conditions||National Institutes of Health Clinical Center (CC)||Recruiting|August 1993|||||N/A|Observational|N/A|||Anticipated|3000|||Both|2 Years|N/A|No|||May 2015|May 29, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001367||210234|
NCT00001122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-05-003|A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly|A Phase II, Randomized, Open-Label Study of Maximally Assisted Therapy (MAT) Compared to Self-Administered Therapy (SAT) for the Treatment of HIV Infection in Antiretroviral Naive Subjects With CD4 Greater Than or Equal to 200 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||October 2003|Actual|Phase 2|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||74|||Both|13 Years|N/A|No|||January 2005|March 1, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001122||210444|
NCT00001123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-066|A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome|A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|12 Years|N/A|No|||November 2005|August 26, 2010|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00001123||210443|
NCT00001386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940159|Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection|Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection||National Institutes of Health Clinical Center (CC)||Completed|June 1994|January 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||31|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001386||210219|
NCT00001398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940016|Stem Cell Factor Medication for Aplastic Anemia|A Phase I/II Trial of Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) in Patients Diagnosed With Acquired Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Completed|October 1993|June 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001398||210209|
NCT00001148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000009|Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor|Detection of Glioblastoma or Anaplastic Astrocytoma Cells in the Circulation During Surgical Resection||National Institutes of Health Clinical Center (CC)||Completed|October 1999|January 2005||||N/A|Observational|N/A||||25|||Both|N/A|N/A|No|||January 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001148||210424|
NCT00001172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800093|Visual Stimulus and Eye Movement|Visual Motor Coordination in Man||National Institutes of Health Clinical Center (CC)||Completed|August 1980|August 2008||||N/A|Observational|N/A||||225|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||August 2008|August 7, 2008|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001172||210401|
NCT00001371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940048|A Pilot Study of Topical Antiflammin-2 for Psoriasis|A Pilot Study of Topical Antiflammin-2 for Psoriasis||National Institutes of Health Clinical Center (CC)||Completed|December 1993|December 2000||||N/A|Observational|N/A||||24|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001371||210232|
NCT00001165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|780133|Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas|Evaluation of Chemotherapy With Streptozotocin Combined With 5-Fluorouracil and Adriamycin in Patients With Zollinger-Ellison Syndrome and Metastatic Non-Beta-Islet Cell Neoplasm||National Institutes of Health Clinical Center (CC)||Completed|September 1978|August 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||999|||Both|N/A|N/A|No|||August 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001165||210408|
NCT00001171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790089|Evaluation of Factors in Human Brain Tumors|Evaluation of Biological, Immunological and Therapeutic Parameters in Brain Tumor Patients||National Institutes of Health Clinical Center (CC)||Completed|July 1979|September 2005||||N/A|Observational|N/A||||800|||Both|N/A|N/A|No|||September 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001171||210402|
NCT00001185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820083|Study of "Post-Polio Syndrome"|Post-Polio Motor Neuron Disease: Clinical, Virological, and Immunological Studies||National Institutes of Health Clinical Center (CC)||Completed|June 1982|May 2003||||N/A|Observational|N/A||||360|||Both|N/A|N/A|No|||May 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001185||210390|
NCT00001135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 316B|A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants|A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2001|Actual|||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||2009|||Both|13 Years|N/A|No|||March 2012|March 30, 2012|January 23, 2000||||No||https://clinicaltrials.gov/show/NCT00001135||210433|
NCT00001245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890174|Study of Patients With Strongyloides Stercoralis Infection|Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis||National Institutes of Health Clinical Center (CC)||Completed|August 1989|||May 2009|Actual|N/A|Observational|N/A||||650|||Both|8 Years|80 Years|No|||May 2009|August 24, 2009|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001245||210337|
NCT00001190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830199|Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature|A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature||National Institutes of Health Clinical Center (CC)||Completed|November 1983|October 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||October 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001190||210386|
NCT00001119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-02-001|Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV|A Study of the Effects of Combination Antiretroviral Therapy in Acute HIV-1 Infection With an Emphasis on Immunological Responses||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1999|||June 2004|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||288|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2005|March 1, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001119||210447|
NCT00001184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820183|Immune Regulation in Ulcerative Colitis or Crohn s Disease|Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut||National Institutes of Health Clinical Center (CC)||Recruiting|November 1982|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|8 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001184||210391|
NCT00001342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930020|Study of Glycogen Storage Disease and Associated Disorders|A Study of Collateral Disorders of Glycogen Storage Disease||National Institutes of Health Clinical Center (CC)||Completed|November 1992|April 2001||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001342||210257|
NCT00001360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930170|Studies of Blood Flow to the Brain During Thought|Regional Cerebral Blood Flow Studies of Object Perception, Identification, Localization, and Memory||National Institutes of Health Clinical Center (CC)||Recruiting|July 1993|||||N/A|Observational|N/A|||Anticipated|4100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 20, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001360||210241|
NCT00001361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930010|Magnetic Resonance Imaging Studies of Motor and Thought Processes|Central Nervous System Motor and Cognitive Processes: Nuclear Magnetic Resonance Imaging at 1.5 to 4 Tesla||National Institutes of Health Clinical Center (CC)||Completed|October 1992|January 2002||||N/A|Observational|N/A||||610|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001361||210240|
NCT00001146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000004|Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial|Omega-3 Fatty Acids in the Treatment of Major Depression and Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial||National Institutes of Health Clinical Center (CC)||Completed|October 1999|August 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||240|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001146||210426|
NCT00001118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1005|Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children|A Phase I/II Study of T-20, a Fusion Inhibitor, in HIV-1 Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||24|||Both|3 Years|12 Years|No|||May 2012|May 17, 2012|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001118||210448|
NCT00001385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940151|Positron Emission Tomography in Patients With Breast Cancer|Positron Emission Tomography in Patients With Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|May 1994|April 2000||||N/A|Observational|N/A||||75|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001385||210220|
NCT00001375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940194|The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis|The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis||National Institutes of Health Clinical Center (CC)||Completed|August 1994|June 2000||||N/A|Observational|N/A||||500|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001375||210229|
NCT00001149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|750124|Monitoring Patients With Uncontrolled Epilepsy|Monitoring of Seizures, EEG and Serum Antiepileptic Drug Concentrations in Patients With Uncontrolled Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|November 1975|January 2002||||N/A|Observational|N/A||||900|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001149||210423|
NCT00001164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|780099|Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers|Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers||National Institutes of Health Clinical Center (CC)||Completed|July 1978|June 2000||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2000|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001164||210409|
NCT00001174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800083|Evaluation of the Genetics of Bipolar Disorder|Bipolar Genetics: A Collaborative Study||National Institutes of Health Clinical Center (CC)||Recruiting|August 1980|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|4000|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|January 12, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001174||210399|
NCT00001177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810126|Study of Premenstrual Syndrome and Premenstrual Dysphoria|The Evaluation of Women With Menstrually Regulated Mood and Behavioral Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|August 1981|||||N/A|Observational|N/A|||Anticipated|1600|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|May 2, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001177||210397|
NCT00001251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900095|Phase I Study of Intrathecal Mafosfamide|Phase I Study of Intrathecal Mafosfamide||National Institutes of Health Clinical Center (CC)||Completed|November 1989|November 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||65|||Both|N/A|N/A|No|||November 2003|August 16, 2013|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00001251||210331|
NCT00001255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900195|Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study|Treatment of Severe Combined Immunodeficiency Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency With Autologous Lymphocytes of CD34+ Cells Transduced With a Human ADA Gene: A Natural History Study||National Institutes of Health Clinical Center (CC)||Completed|September 1990|July 2002||||N/A|Observational|N/A||||10|||Both|N/A|N/A|No|||July 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001255||210327|
NCT00001136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 038|A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine|A Multi-Centered Phase 1 Trial to Evaluate the Memory Responses to a Single Boosting Vaccination With ALVAC-HIV vCP205 in Volunteers Who Have Previously Received Poxvirus-Based Vaccines||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention|||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 11, 2012|January 25, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00001136||210432|
NCT00001127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 99-021|Study of a Flu Vaccine in Children|Study of the Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in a Community-Based, Non-Randomized, Open-Label Trial in Children to Assess Safety and Herd Immunity for the Control of Epidemic Influenza||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Prevention||||15000|||Both|18 Months|18 Years|Accepts Healthy Volunteers|||November 2005|August 26, 2010|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00001127||210440|
NCT00001192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830176|Neuropsychological Evaluation of Psychiatric and Neurological Patients|Neuropsychological Evaluation of Psychiatric and Neurological Patients||National Institutes of Health Clinical Center (CC)||Completed|October 1983|December 2006||||N/A|Observational|N/A||||4300|||Both|N/A|95 Years|Accepts Healthy Volunteers|||December 2006|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001192||210384|
NCT00001256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900086|Steroids and Methotrexate to Treat Systemic Vasculitis|An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis||National Institutes of Health Clinical Center (CC)||Completed|March 1990|February 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||February 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001256||210326|
NCT00001294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920078|Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens|Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens||National Institutes of Health Clinical Center (CC)||Completed|January 1992|April 2005||||N/A|Observational|N/A||||2000|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001294||210298|
NCT00001330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930035|Study of Silicone-Associated Connective Tissue Diseases|Epidemiologic, Immunologic, and Immunogenetic Factors in Silicone-Associated Connective Tissue Diseases||National Institutes of Health Clinical Center (CC)||Completed|November 1992|October 2000||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001330||210267|
NCT00001705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980142|Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence|Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence||National Institutes of Health Clinical Center (CC)||Completed|July 1998|June 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||141|||Both|N/A|N/A|No|||July 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001705||209964|
NCT00001381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940098|A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder|A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder||National Institutes of Health Clinical Center (CC)||Completed|March 1994|December 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||18|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001381||210224|
NCT00001345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930127|Studies of Inherited Diseases of Metabolism|Family Studies in Metabolic Diseases and Mineral Metabolism||National Institutes of Health Clinical Center (CC)||Recruiting|April 1993|||||N/A|Observational|N/A|||Anticipated|2000|||Both|N/A|N/A|No|||November 2015|December 2, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001345||210254|
NCT00001696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980099|A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor|A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor||National Institutes of Health Clinical Center (CC)||Completed|April 1998|March 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001696||209970|
NCT00001698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980118|Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR|Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR||National Institutes of Health Clinical Center (CC)||Completed|June 1998|June 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||57|||Both|N/A|N/A|No|||June 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001698||209969|
NCT00001477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950176|Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy|Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy||National Institutes of Health Clinical Center (CC)||Completed|August 1995|October 2000||||N/A|Observational|N/A||||300|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001477||210143|
NCT00001349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930057|Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies|Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies||National Institutes of Health Clinical Center (CC)||Recruiting|December 1992|||||N/A|Observational|N/A|||Anticipated|300|||Both|7 Years|N/A|No|||February 2016|March 19, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001349||210251|
NCT00001424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950025|Evaluation and Natural History of Children With Cancer and AIDS|Evaluation and Natural History of Children With Cancer and AIDS||National Institutes of Health Clinical Center (CC)||Completed|November 1994|August 2000||||N/A|Observational|N/A||||110|||Both|N/A|N/A|No|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001424||210187|
NCT00001306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920223|Steroid Therapy in Autoimmune Premature Ovarian Failure|Autoimmune Premature Ovarian Failure: A Controlled Trial of Alternate-Day Prednisone Therapy||National Institutes of Health Clinical Center (CC)||Completed|July 1992|December 2011||||N/A|Observational|N/A|||Actual|33|||Female|18 Years|39 Years|No|||December 2011|December 13, 2011|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001306||210288|
NCT00001307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920243|Positron Emission Tomography to Measure Pain and Pain Control|Somatosensory Studies of Pain and Pain Control Measured With Oxygen-15 Water Positron Emission Tomography and Functional MRI in Normals and Patients With Neuropathic or Chronic Pain Conditions||National Institutes of Health Clinical Center (CC)||Completed|August 1992|August 2005||||N/A|Observational|N/A||||273|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001307||210287|
NCT00001278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910139|Study of Eye Tissue for Sarcoidosis|Immunologic Assay of Conjunctiva and Lacrimal Gland for Sarcoidosis||National Institutes of Health Clinical Center (CC)||Completed|May 1991|April 2001||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001278||210309|
NCT00001319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920256|Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts|Evaluation of the Epidemiology, Clinical Manifestations, Etiologies, and Immunology of Human Immunodeficiency Virus (HIV) Negative CD4 T Lymphocyte Deficient Patients||National Institutes of Health Clinical Center (CC)||Completed|September 1992|July 2003||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||July 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001319||210276|
NCT00001391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940188|Bone Regeneration Using Bone Marrow Stromal Cells|Bone Regeneration Using Bone Marrow Stromal Cells||National Institutes of Health Clinical Center (CC)||Completed|August 1994|October 2010||||N/A|Observational|N/A|||Actual|54|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2010|October 5, 2010|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001391||210216|
NCT00001648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970166|Structure of the Herpes Simplex Virus Receptor|Polymorphism of the Herpes Simplex Virus Receptor||National Institutes of Health Clinical Center (CC)||Completed|August 1997|April 2010||||N/A|Observational|N/A|||Actual|60|||Both|18 Years|N/A|No|||April 2010|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001648||210006|
NCT00001649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970168|Valaciclovir to Prevent Transmission of Herpes Simplex Virus|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples||National Institutes of Health Clinical Center (CC)||Completed|August 1997|August 2003||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||180|||Both|N/A|N/A|No|||August 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001649||210005|
NCT00001317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920186|A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood|A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood||National Institutes of Health Clinical Center (CC)||Completed|May 1992|July 2001||||Phase 4|Interventional|Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001317||210278|
NCT00001318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920255|Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma|Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma||National Institutes of Health Clinical Center (CC)||Completed|August 1992|November 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001318||210277|
NCT00001344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930114|Dextromethorphan Versus Placebo for Neuropathic Pain|Dextromethorphan Versus Placebo for Neuropathic Pain||National Institutes of Health Clinical Center (CC)||Completed|March 1993|February 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||129|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001344||210255|
NCT00001350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930063|Study of Autoimmune Lymphoproliferative Syndrome (ALPS)|Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated With an Expansion of CD4-8-/TCR Alpha/Beta+ T Cells||National Institutes of Health Clinical Center (CC)||Recruiting|December 1992|||||N/A|Observational|N/A|||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|March 14, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001350||210250|
NCT00001689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980053|A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia|A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia||National Institutes of Health Clinical Center (CC)||Completed|January 1998|November 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||November 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001689||209973|
NCT00001347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930161|Study of Usher Syndromes, Type 1 and Type 2|Usher Syndrome - Clinical and Molecular Studies||National Institutes of Health Clinical Center (CC)||Completed|June 1993|August 2002||||N/A|Observational|N/A||||200|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001347||210252|
NCT00001394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940195|Using X-Ray Dye to Locate Hidden Parathyroid Tumors|Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas||National Institutes of Health Clinical Center (CC)||Completed|August 1994|July 2005||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||July 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001394||210213|
NCT00001295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920094|Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease|Continuing Treatment for Children and Adults in the Center for Cancer Research||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 1992|||||N/A|Observational|Time Perspective: Prospective|||Actual|2145|||Both|N/A|99 Years|No|||September 2015|October 6, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001295||210297|
NCT00001713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980067|Treatment for Blood Clots in the Veins of the Legs|Treatment of Acute Deep Vein Thrombosis of the Lower Extremity With Intraclot, Pulse-Sprayed Recombinant Tissue Plasminogen Activator, Plus Heparin and Warfarin: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|February 1998|January 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2006|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001713||209961|
NCT00001346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930037|Diabetic Retinopathy and Visual Function Study|Diabetic Retinopathy and Visual Function Study||National Institutes of Health Clinical Center (CC)||Completed|November 1992|October 2000||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001346||210253|
NCT00001355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930119|Detection and Characterization of Host Defense Defects|Detection and Characterization of Host Defense Defects||National Institutes of Health Clinical Center (CC)||Recruiting|April 1993|||||N/A|Observational|N/A|||Anticipated|2000|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 20, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001355||210245|
NCT00001320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920024|Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients|I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 1991|July 2003||||N/A|Observational|N/A||||265|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001320||210275|
NCT00001416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940050|Bone Response to Enzyme Replacement in Gaucher's Disease|Skeletal Responses to Macrophage-Targeted Glucocerebrosidase in Patients With Type 1 Gaucher's Disease||National Institutes of Health Clinical Center (CC)||Completed|December 1993|November 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001416||210193|
NCT00001328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920246|Gene Therapy for the Treatment of Brain Tumors|Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction With the Thymidine Kinase Gene and Intravenous Ganciclovir||National Institutes of Health Clinical Center (CC)||Completed|August 1992|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|15|||Both|19 Years|N/A|No|||April 2010|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001328||210269|
NCT00001329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920259|Study of Norepinephrine Levels and Sympathetic Nervous System Activity|Plasma Catecholamine Kinetics||National Institutes of Health Clinical Center (CC)||Completed|September 1992|September 2002||||N/A|Observational|N/A||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001329||210268|
NCT00001703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980139|Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma|Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma||National Institutes of Health Clinical Center (CC)|No|Terminated|August 1998|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|November 3, 1999||No|Due to poor accrual and lack of peptide vaccine|No|May 17, 2011|https://clinicaltrials.gov/show/NCT00001703||209965|Patients were enrolled to Arm A only due to poor accrual and the lack of peptide vaccine.
NCT00001379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940074|Treatment and Natural History Study of Lymphomatoid Granulomatosis|Treatment and Natural History Study of Lymphomatoid Granulomatosis||National Institutes of Health Clinical Center (CC)||Recruiting|February 1994|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|12 Years|120 Years|No|||October 2015|November 4, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001379||210225|
NCT00001392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940127|Pathogenesis of Glomerulosclerosis|Pathogenesis of Glomerulosclerosis||National Institutes of Health Clinical Center (CC)||Recruiting|April 1994|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|4 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 3, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001392||210215|
NCT00001338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930153|A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer|A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|June 1993|January 2001||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||65|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001338||210260|
NCT00001404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940193|Phenotype and Etiology of Pallister-Hall Syndrome|Genetic and Clinical Studies of Congenital Anomaly Syndromes||National Institutes of Health Clinical Center (CC)||Completed|August 1994|January 2016||||N/A|Observational|N/A|||Actual|1170|||Both|N/A|N/A|No|||January 2016|January 8, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001404||210204|
NCT00001405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940073|Use of G-CSF to Obtain Blood Cell Precursors|Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells||National Institutes of Health Clinical Center (CC)||Recruiting|February 1994|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|450|||Both|2 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001405||210203|
NCT00001406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940079|Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia|Eosinophil Activation and Function in Parasitic Infections and Other Conditions With Increased Tissue or Peripheral Blood Eosinophilia in Humans||National Institutes of Health Clinical Center (CC)||Recruiting|February 1994|||||N/A|Observational|N/A|||Anticipated|500|||Both|1 Year|100 Years|No|||July 2015|October 6, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001406||210202|
NCT00001683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980015|A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer|A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer||National Institutes of Health Clinical Center (CC)||Completed|October 1997|August 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||August 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001683||209977|
NCT00001354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930113|Interleukin-2 Therapy for HIV Infection - Supplemental Procedures|A Randomized Trial of Interleukin-2 Therapy in HIV-Infected Patients||National Institutes of Health Clinical Center (CC)||Completed|March 1993|March 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001354||210246|
NCT00001356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930136|Characteristics of Mast Cells in Mastocytosis|Culture and Characteristics of Mastocytosis Mast Cells||National Institutes of Health Clinical Center (CC)||Completed|May 1993|May 2002||||N/A|Observational|N/A||||300|||Both|N/A|N/A|No|||May 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001356||210244|
NCT00001426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950055|A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer|A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 1995|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|47|||Female|N/A|N/A|No|||November 2013|October 4, 2014|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001426||210186|
NCT00001427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950056|A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin|A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin||National Institutes of Health Clinical Center (CC)||Completed|January 1995|April 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Female|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001427||210185|
NCT00001428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950067|A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer|A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 1995|December 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||65|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001428||210184|
NCT00001352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930106|Evaluation and Follow-up of Patients With Cryptococcosis|Cryptococcosis in Previously Healthy Adults||National Institutes of Health Clinical Center (CC)||Recruiting|March 1993|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|December 24, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001352||210248|
NCT00001266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910014|A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma|A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma||National Institutes of Health Clinical Center (CC)||Completed|October 1990|August 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||70|||Male|N/A|N/A|No|||August 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001266||210318|
NCT00001287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910039|Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)||National Institutes of Health Clinical Center (CC)||Completed|December 1990|January 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001287||210303|
NCT00001296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920105|A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma|A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma||National Institutes of Health Clinical Center (CC)||Completed|February 1992|October 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||122|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001296||210296|
NCT00001308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920178|Central Mechanisms in Speech Motor Control Studied With H215O PET|Multimodal Studies of Language Production and Comprehension in Normal Volunteers and Patients With Neurologically-Based Language Impairments||National Institutes of Health Clinical Center (CC)||Completed|April 1992|||||N/A|Observational|N/A|||Actual|1163|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2015|September 12, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001308||210286|
NCT00001309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920033|The Body's Affect on Vitamin C|Pharmacokinetics and Biodistribution of Ascorbic Acid in Healthy Human Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|October 1991|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001309||210285|
NCT00001383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940119|A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833|A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833||National Institutes of Health Clinical Center (CC)||Completed|March 1994|January 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||52|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001383||210222|
NCT00001654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970116|The Role of Emotion in the Development of Psychopathology|The Role of Emotion in the Development of Psychopathology||National Institutes of Health Clinical Center (CC)||Completed|May 1997|May 2003||||N/A|Observational|N/A||||1200|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001654||210001|
NCT00001393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940133|Genetic Markers for Focal Segmental Glomerulosclerosis|Genetic Markers for Focal Segmental Glomerulosclerosis||National Institutes of Health Clinical Center (CC)||Recruiting|April 1994|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|19 Months|N/A|Accepts Healthy Volunteers|||December 2015|January 29, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001393||210214|
NCT00001339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930200|A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection|A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection||National Institutes of Health Clinical Center (CC)||Completed|August 1993|August 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||42|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001339||210259|
NCT00001693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980087|Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers|Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers||National Institutes of Health Clinical Center (CC)||Completed|March 1998|January 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001693||209972|
NCT00001337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930133|Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma|Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma||National Institutes of Health Clinical Center (CC)||Recruiting|April 1993|March 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|338|||Both|12 Years|100 Years|No|||January 2016|February 10, 2016|November 3, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00001337||210261|
NCT00001402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940054|PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers|Assessment of Metabolic Function and Perfusion Using Positron Emission Tomography: An Analysis of Patients With Congestive Cardiomyopathy Before and After Beta-Blockers||National Institutes of Health Clinical Center (CC)||Completed|January 1994|March 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||130|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001402||210206|
NCT00001298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920134|A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction|A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction||National Institutes of Health Clinical Center (CC)||Completed|March 1992|January 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001298||210295|
NCT00001716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980129|Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia|Physiologic Effects of Inhaled Nitric Oxide, Nitroglycerin, and Placebo in Study Subjects With Sickle Cell Anemia||National Institutes of Health Clinical Center (CC)||Completed|July 1998|July 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||58|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001716||209958|
NCT00001267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910018|A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine|A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine||National Institutes of Health Clinical Center (CC)||Completed|October 1990|April 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||42|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001267||210317|
NCT00001382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940118|A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate|A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate||National Institutes of Health Clinical Center (CC)||Completed|March 1994|March 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001382||210223|
NCT00001661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970048|Mechanisms of Human Plasticity in the Human System|Mechanisms of Plasticity in the Human Motor System||National Institutes of Health Clinical Center (CC)||Completed|December 1996|March 2002||||N/A|Observational|N/A||||260|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001661||209996|
NCT00001341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930210|A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease|A Phase I Trial of ZD1694 (TOMUDEX® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease||National Institutes of Health Clinical Center (CC)||Completed|September 1993|June 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||August 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001341||210258|
NCT00001519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960098|Oxygen Uptake Kinetics During Recovery From Maximal and Submaximal Exercise|Oxygen Uptake Kinetics During Recovery From Maximal and Submaximal Exercise||National Institutes of Health Clinical Center (CC)||Completed|June 1996|April 2001||||N/A|Observational|N/A||||5|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001519||210113|
NCT00001536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960123|Issues Surrounding Prenatal Genetic Testing for Achondroplasia|Issues Surrounding Prenatal Genetic Testing for Achondroplasia||National Institutes of Health Clinical Center (CC)||Completed|August 1996|July 2000||||N/A|Observational|N/A||||2000|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001536||210097|
NCT00001535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960051|Twins Study of Gene Therapy for HIV Infection|Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Anti-Sense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV-1 Infected Identical Twins||National Institutes of Health Clinical Center (CC)||Completed|March 1996|March 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||48|||Both|N/A|N/A|No|||March 2002|February 7, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001535||210098|
NCT00001560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970028|Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers|Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers||National Institutes of Health Clinical Center (CC)||Completed|December 1996|October 2011||||N/A|Observational|N/A|||Actual|24|||Both|N/A|65 Years|No|||October 2011|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001560||210079|
NCT00001538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960050|Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers|Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers||National Institutes of Health Clinical Center (CC)||Completed|March 1996|April 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||41|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001538||210096|
NCT00001395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940106|Long Term Follow-Up of Diabetic Retinopathy|Long Term Follow-Up of Diabetic Retinopathy||National Institutes of Health Clinical Center (CC)||Completed|March 1994|August 2000||||N/A|Observational|N/A||||75|||Both|N/A|N/A|No|||March 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001395||210212|
NCT00001311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920157|Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients|Evaluation of the Efficacy of a Surface Modified Intraocular Lens in Reducing Post-Operative Inflammatory Signs Following Extracapsular Surgery in Uveitis Patients With Cataracts||National Institutes of Health Clinical Center (CC)||Completed|April 1992|February 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001311||210283|
NCT00001324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920119|PET Scan to Study Brain Control of Human Movement|CNS Control of Human Movement: H215O PET Studies||National Institutes of Health Clinical Center (CC)||Completed|March 1992|July 2001||||N/A|Observational|N/A||||510|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001324||210272|
NCT00001332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930048|Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis|Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis||National Institutes of Health Clinical Center (CC)||Completed|December 1992|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001332||210265|
NCT00001301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920242|Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors|Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors||National Institutes of Health Clinical Center (CC)||Completed|August 1992|April 2000||||N/A|Observational|N/A||||107|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001301||210293|
NCT00001288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910134|Brain Blood Flow Studies of Language and Memory|Cerebral Blood Flow Studies of Language and Memory||National Institutes of Health Clinical Center (CC)||Completed|May 1991|June 2003||||N/A|Observational|N/A||||303|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001288||210302|
NCT00001275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910127|Ovarian Follicle Function in Patients With Primary Ovarian Failure|Ovarian Follicle Function in Patients With Primary Ovarian Insufficiency||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 1991|||||N/A|Observational|N/A|||Actual|1134|||Female|18 Years|42 Years|No|||August 2015|September 9, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001275||210312|
NCT00001548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960124|Genetics of Obsessive-Compulsive Disorder|Genetics of Obsessive-Compulsive Disorder: A Collaborative Study||National Institutes of Health Clinical Center (CC)||Completed|August 1996|September 2015||||N/A|Observational|N/A|||Actual|1067|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001548||210086|
NCT00001303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920141|Effects of Endotoxin in Normal Human Volunteers|The Cardiopulmonary Effects of Endotoxin in Normal Human Volunteers||National Institutes of Health Clinical Center (CC)||Completed|April 1992|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|198|||Both|18 Years|45 Years|No|||August 2015|August 12, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001303||210291|
NCT00001500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960061|Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits|Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits||National Institutes of Health Clinical Center (CC)||Completed|April 1996|July 2004||||N/A|Observational|N/A||||4500|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001500||210125|
NCT00001333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930085|Phase I Study of Intrathecal Topotecan|Phase I Study of Intrathecal Topotecan||National Institutes of Health Clinical Center (CC)||Completed|February 1993|December 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001333||210264|
NCT00001282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910143|A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients|A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients||National Institutes of Health Clinical Center (CC)||Completed|July 1991|April 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||73|||Both|N/A|N/A|No|||April 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001282||210306|
NCT00001327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920226|Establishing the Physiology of Syringomyelia|Establishing the Physiology of Syringomyelia||National Institutes of Health Clinical Center (CC)||Completed|July 1992|March 2011||||N/A|Observational|N/A|||Actual|120|||Both|18 Years|N/A|No|||March 2011|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001327||210270|
NCT00001534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960144|Long Term Effects of Enalapril and Losartan on Genetic Heart Disease|Double-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCM||National Institutes of Health Clinical Center (CC)||Completed|September 1996|April 2003||||N/A|Observational|N/A||||112|||Both|N/A|N/A|No|||April 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001534||210099|
NCT00001284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910124|Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers|Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 1.5 Tesla MRI||National Institutes of Health Clinical Center (CC)||Completed|May 1991|||||N/A|Observational|Time Perspective: Prospective|||Actual|2802|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001284||210305|
NCT00001310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920113|Tissue Studies of Human Eye Diseases|Immunopathology and Molecular Pathology of Ocular Diseases in Humans||National Institutes of Health Clinical Center (CC)||Terminated|March 1992|September 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|3797|||Both|N/A|N/A|No|||September 2015|September 17, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001310||210284|
NCT00001323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920262|Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia|Neuropsychiatric Evaluation of Normal Subjects and Psychiatric and Neurologic Contrast Groups||National Institutes of Health Clinical Center (CC)||Completed|August 1992|August 2005||||N/A|Observational|N/A||||810|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001323||210273|
NCT00001522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960101|Metabolic Differences of Overweight Children and Children of Overweight Parents|Population Differences in the Insulin Sensitivity, Resting Energy Expenditure, and Body Composition of Overweight Children and Children of Overweight Parents||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 1996|||||N/A|Observational|Time Perspective: Prospective|||Actual|246|||Both|6 Years|N/A|No|||July 2015|August 5, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001522||210110|
NCT00001261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900139|Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies|The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over||National Institutes of Health Clinical Center (CC)||Completed|May 1990|July 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||July 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001261||210321|
NCT00001276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910066|Diagnosing and Treating Low Blood Sugar Levels|Fasting Hypoglycemia: Diagnosis and Treatment||National Institutes of Health Clinical Center (CC)||Recruiting|January 1991|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|10 Years|N/A|No|||August 2015|August 28, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001276||210311|
NCT00001403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940132|Study of Proteus Syndrome and Related Congenital Disorders|The Phenotype and Etiology of Proteus Syndrome and Related Overgrowth Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|April 1994|||||N/A|Observational|N/A|||Anticipated|1500|||Both|N/A|N/A|No|||August 2015|September 18, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001403||210205|
NCT00001260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900142|Brain Tissue Collection for Neuropathological Studies|Brain Procurement for the Human Brain Collection Core||National Institutes of Health Clinical Center (CC)||Recruiting|May 1990|||||N/A|Observational|N/A|||Anticipated|2500|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001260||210322|
NCT00001304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920011|Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34|Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34||National Institutes of Health Clinical Center (CC)|Yes|Completed|October 1991|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|17 Years|69 Years|No|||November 2015|November 10, 2015|November 3, 1999|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT00001304||210290|Study reported here was the primary long-term study for adults with hypoparathyroidism. Subsequent studies included additional patients.
NCT00001507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960104|Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer|A Multi-Center Study of Paclitaxel/Cyclophosphamide and High Dose Melphalan/Etoposide With Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|July 1996|June 2014|Actual|June 1998|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||June 2014|November 4, 2014|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001507||210119|
NCT00001547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960103|Neuropsychiatric Effects of Interferon-Alpha and Ribavirin|A Magnetic Resonance Spectroscopy Study of Neuropsychiatric Effects Associated With Cytokines||National Institutes of Health Clinical Center (CC)||Completed|June 1996|June 2002||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001547||210087|
NCT00001524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960095|Thalidomide to Treat Oral Lesions in HIV-Infected Patients|Evaluation of a TNF-Alpha Modulator for the Treatment of Oral Lesions in HIV/AIDS Patients||National Institutes of Health Clinical Center (CC)||Completed|June 1996|December 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||110|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001524||210108|
NCT00001526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960096|ANTI-TAC THERAPY FOR UVEITIS|Trial of Treatment of Non-Infectious Intermediate and Posterior Uveitis With Humanized Anti-Tac Antibody Therapy||National Institutes of Health Clinical Center (CC)||Completed|June 1996|September 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||September 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001526||210107|
NCT00001322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920174|The Effects of Reproductive Hormones on Mood and Behavior|The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Estrogen and Progesterone Replacement||National Institutes of Health Clinical Center (CC)||Recruiting|April 1992|||||N/A|Observational|N/A|||Anticipated|140|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|September 17, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001322||210274|
NCT00001546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960087|Circadian Regulation of Sleep in Habitual Short Sleepers and Long Sleepers|Circadian Regulation of Sleep in Habitual Short Sleepers and Long Sleepers||National Institutes of Health Clinical Center (CC)||Completed|May 1996|June 2000||||N/A|Observational|N/A||||38|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001546||210088|
NCT00001271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910176|A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma|A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|July 1991|April 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||June 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001271||210314|
NCT00001313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920189|Evaluation of Patients With Known or Suspected Heart Disease|Evaluation of Patients With Known or Suspected Heart Disease (Screening Protocol)||National Institutes of Health Clinical Center (CC)||Completed|May 1992|January 2009||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001313||210281|
NCT00001335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930125|New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma|New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma||National Institutes of Health Clinical Center (CC)||Completed|April 1993|January 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001335||210263|
NCT00001336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930129|In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients|In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients||National Institutes of Health Clinical Center (CC)||Completed|April 1993|February 2003||||N/A|Observational|N/A||||1000|||Both|N/A|N/A|No|||February 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001336||210262|
NCT00001272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910232|A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients|A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|September 1991|May 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Female|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001272||210313|
NCT00001325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920175|Metabolic Abnormalities in Children With Epilepsy|Natural History of Metabolic Abnormalities in Children With Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|April 1992|June 2004||||N/A|Observational|N/A||||80|||Both|N/A|N/A|No|||June 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001325||210271|
NCT00001285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910206|Effects of Sex Hormones on Circadian Rhythm in Men and Women|Chronobiologic Effects of Gonadal Steroid Manipulations in Volunteer Subjects||National Institutes of Health Clinical Center (CC)||Completed|August 1991|June 2000||||N/A|Observational|N/A||||73|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001285||210304|
NCT00001554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960093|Infrared Camera for Brain Mapping During Surgery|Intraoperative Infrared Functional Brain Mapping||National Institutes of Health Clinical Center (CC)||Completed|June 1996|June 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001554||210080|
NCT00001561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970030|Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation|Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation||National Institutes of Health Clinical Center (CC)||Completed|November 1996|September 2005||||Phase 3|Interventional|Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|No|||September 2005|September 21, 2007|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001561||210078|
NCT00001302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920268|A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833|A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833||National Institutes of Health Clinical Center (CC)||Completed|September 1992|June 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001302||210292|
NCT00001305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920034|Growth Hormone Therapy in Osteogenesis Imperfecta|Studies of Growth Deficiency and Growth Hormone Treatment in Children With Osteogenesis Imperfecta Types III and IV||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 1991|March 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|3 Years|16 Years|No|||May 2015|July 7, 2015|November 3, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00001305||210289|
NCT00001289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910225|Effects of Enzyme Replacement in Gaucher's Disease|Clinical and Biochemical Effects of Macrophage-Targeted Glucocerebrosidase on Neurological Involvement in Neuronopathic Gaucher's Disease||National Institutes of Health Clinical Center (CC)||Completed|September 1991|March 2008||||N/A|Observational|N/A||||70|||Both|N/A|N/A|No|||March 2008|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001289||210301|
NCT00001563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970040|EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma|EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|December 1996|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||August 2015|August 15, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001563||210077|
NCT00001400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940045|Outpatient Evaluation of Patients With Known or Suspected Heart Disease|Outpatient Evaluation of Patients With Known or Suspected Heart Disease (Screening Protocol)||National Institutes of Health Clinical Center (CC)||Completed|December 1993|December 2001||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||December 2001|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001400||210207|
NCT00001377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940041|Familial Prostate Cancer|Familial Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|December 1993|December 2000||||N/A|Observational|N/A||||200|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001377||210227|
NCT00001331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930143|Genetic and Family Studies of Inherited Muscle Diseases|Genetic and Family Studies of Inherited Muscle Diseases||National Institutes of Health Clinical Center (CC)||Completed|May 1993|March 2002||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2002|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001331||210266|
NCT00001312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920250|Age-Related Macular Degeneration and Cataract|Age-Related Eye Disease Study - Follow-Up||National Institutes of Health Clinical Center (CC)||Completed|August 1992|||March 2008|Actual|N/A|Interventional|Primary Purpose: Treatment||||200|||Both|55 Years|80 Years|No|||March 2008|January 28, 2010|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001312||210282|
NCT00001291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920065|Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions|Investigations of Blood, Synovial Tissue and Synovial Fluids From Patients With Rheumatoid Arthritis and Related Conditions||National Institutes of Health Clinical Center (CC)||Completed|December 1991|January 2001||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||December 1999|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001291||210300|
NCT00001343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930054|The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome|The Relative Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate, GH Binding Protein, IGF-I, and Cognitive Function in Growth Hormone-Treated Girls With Turner Syndrome||National Institutes of Health Clinical Center (CC)||Completed|December 1992|October 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||80|||Female|10 Years|14 Years|No|||October 2007|November 25, 2009|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001343||210256|
NCT00001281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910140|Studies of Blood and Reproductive Fluids in HIV-Infected and Non-HIV-Infected Persons|Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Reproductive Fluids in HIV-Infected and HIV-Uninfected Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|May 1991|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001281||210307|
NCT00001523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960082|Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation|Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation||National Institutes of Health Clinical Center (CC)||Completed|May 1996|March 2000||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001523||210109|
NCT00001351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930086|Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders|Evaluation and Long Term Follow Up of Patients With Acute or Chronic Inflammatory Disorders||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 1993|||||N/A|Observational|Time Perspective: Prospective|||Actual|289|||Both|2 Years|N/A|No|||September 2015|October 6, 2015|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00001351||210249|
NCT00001357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930205|Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients|Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients||National Institutes of Health Clinical Center (CC)||Completed|August 1993|April 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||April 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001357||210243|
NCT00001300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920210|A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma|A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma||National Institutes of Health Clinical Center (CC)||Completed|June 1992|March 2001||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||150|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001300||210294|
NCT00001378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940056|A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer|A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|January 1994|November 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001378||210226|
NCT00001568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970068|Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities|Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities||National Institutes of Health Clinical Center (CC)||Completed|February 1997|October 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||October 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001568||210072|
NCT00001574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970093|A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors|A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors||National Institutes of Health Clinical Center (CC)||Completed|March 1997|||||N/A|Observational|Time Perspective: Prospective|||Actual|40|||Both|N/A|21 Years|No|||August 2015|September 10, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001574||210066|
NCT00001598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970123|DHEA Treatment for Sjogren's Syndrome|Dehydroepiandrosterone (DHEA) Treatment for Sjogren's Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 1997|June 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||28|||Female|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001598||210050|
NCT00001599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970133|Pilot Study of Thalidomide to Treat Sjogren's Syndrome|Pilot Study of Thalidomide for Sjogren's Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 1997|June 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||28|||Female|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001599||210049|
NCT00001566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970052|A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas|A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas||National Institutes of Health Clinical Center (CC)|No|Completed|December 1996|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|5 Years|35 Years|No|||June 2012|June 12, 2012|November 3, 1999||No||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00001566||210074|
NCT00001597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970104|Pain Measurement in Healthy Volunteers|Pain Measurement in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|March 1997|June 2002||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001597||210051|
NCT00001844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990163|Study of New Magnetic Resonance Methods|Functional and Metabolic Imaging Using Magnetic Resonance at 3.0 Tesla||National Institutes of Health Clinical Center (CC)||Terminated|September 1999|September 2012||||N/A|Observational|N/A|||Actual|99|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|May 7, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001844||209873|
NCT00001504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960080|A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients|A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|May 1996|January 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||18|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001504||210122|
NCT00001446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950178|A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer|A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|September 1995|July 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||64|||Male|N/A|N/A|No|||August 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001446||210170|
NCT00001810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990094|An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections|An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections||National Institutes of Health Clinical Center (CC)||Completed|April 1999|October 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||300|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001810||209891|
NCT00001866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990152|Eye Muscle Surgery to Treat Congenital Nystagmus|Horizontal Rectus Tenotomy in the Treatment of Congenital Nystagmus||National Institutes of Health Clinical Center (CC)||Completed|August 1999|November 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001866||209853|
NCT00001550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960062|Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)|The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial||National Institutes of Health Clinical Center (CC)||Completed|April 1996|May 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||May 2002|July 13, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001550||210084|
NCT00001483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950129|Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression|Acute Efficacy of Bupropion, Sertraline, and Venlafaxine as Adjuvant Treatment to Mood Stabilizers in Bipolar Depression: A Randomized, Double-Blind, Comparative Study||National Institutes of Health Clinical Center (CC)||Completed|June 1995|May 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|No|||May 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001483||210137|
NCT00001505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960097|The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic Diseases|The Acquisition of Blood and Skin Samples From Patient Volunteers to Support Research Activities on Dermatologic and Other Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|June 1996|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001505||210121|
NCT00001515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960021|Diagnostic Effectiveness of Virtual Bronchoscopy|Diagnostic Efficacy of Virtual Bronchoscopy||National Institutes of Health Clinical Center (CC)||Completed|December 1995|November 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001515||210116|
NCT00001544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960060|Genetic Aspects of Neurologic and Psychiatric Disorders|Genetic Aspects of Neurologic and Psychiatric Disorders||National Institutes of Health Clinical Center (CC)||Completed|April 1996|March 2004||||N/A|Observational|N/A||||1227|||Both|N/A|N/A|No|||March 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001544||210090|
NCT00001450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950198|Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC|Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC||National Institutes of Health Clinical Center (CC)||Completed|September 1995|June 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||58|||Both|N/A|N/A|No|||July 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001450||210167|
NCT00001451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950123|Evaluation of Healthy Volunteer Marrow Donors Participating in the National Marrow Donor Program (NMDP)|Evaluation of Healthy Volunteer Marrow Donors Participating in the National Marrow Donor Program (NMDP)||National Institutes of Health Clinical Center (CC)||Completed|March 1995|February 2011||||N/A|Observational|N/A|||Actual|57|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 2, 2011|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001451||210166|
NCT00001886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990074|Real Time 3-Dimensional Stress Echocardiography|Real Time 3-Dimensional Stress Echocardiography||National Institutes of Health Clinical Center (CC)||Completed|March 1999|March 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||150|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001886||209836|
NCT00001442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950162|A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer|A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer||National Institutes of Health Clinical Center (CC)||Completed|July 1995|June 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||June 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001442||210174|
NCT00001443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950163|A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection|A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection||National Institutes of Health Clinical Center (CC)||Completed|July 1995|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||63|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001443||210173|
NCT00001516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960040|Evaluating the Personal Computer as a Treatment Activity in Occupational Therapy|Linking Occupational Therapy Process and Patient Performance: The Personal Computer Activity in Occupational Interventions||National Institutes of Health Clinical Center (CC)||Completed|January 1996|May 2003||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||May 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001516||210115|
NCT00001475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950133|Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist|A Randomized Trial of Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist in Patients With HIV-1 Infection||National Institutes of Health Clinical Center (CC)||Completed|June 1995|June 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||85|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001475||210145|
NCT00001826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990134|Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor|A Long-Term Observational Study of Immunologic Reconstitution in HIV-1 Infected Children Who Are Receiving Combination Protease Inhibitor and Reverse Transcriptase Inhibitors||National Institutes of Health Clinical Center (CC)||Completed|July 1999|May 2006||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||May 2006|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001826||209884|
NCT00001482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950115|New Drugs in the Treatment of Mood Disorders|Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders||National Institutes of Health Clinical Center (CC)||Completed|May 1995|May 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||June 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001482||210138|
NCT00001474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950114|Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients|Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients||National Institutes of Health Clinical Center (CC)||Completed|May 1995|March 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||36|||Both|N/A|N/A|No|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001474||210146|
NCT00001545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960086|Evaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Mood Disorders|Evaluation of rTMS in the Treatment of Mood Disorders||National Institutes of Health Clinical Center (CC)||Completed|May 1996|July 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||91|||Both|18 Years|90 Years|No|||July 2006|July 12, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001545||210089|
NCT00001542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960108|Fluconazole Prophylaxis of Thrush in AIDS|Fluconazole Prophylaxis of Thrush in AIDS||National Institutes of Health Clinical Center (CC)||Completed|July 1996|November 2001||||Phase 4|Interventional|Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001542||210092|
NCT00001543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960048|Dynamics of Leptin and Endocrine Function|Dynamics of Leptin and Endocrine Function||National Institutes of Health Clinical Center (CC)||Completed|March 1996|June 2002||||N/A|Observational|N/A||||230|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001543||210091|
NCT00001552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960089|Characteristics of Idiopathic Familial Voice Disorders|Characteristics of Idiopathic Familial Voice Disorders||National Institutes of Health Clinical Center (CC)||Completed|May 1996|||November 2009|Actual|N/A|Observational|N/A||||270|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001552||210082|
NCT00001518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960053|A Randomized Evaluation of the Effect of Routine Normal Saline Flush Versus Heparinized Saline Solution in Groshong and Groshong PICC Catheters|A Randomized Evaluation of the Effect of Routine Normal Saline Flush Versus Heparinized Saline Solution in Groshong and Groshong PICC Catheters||National Institutes of Health Clinical Center (CC)||Completed|January 1996|November 2000||||N/A|Observational|N/A||||132|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001518||210114|
NCT00001452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950059|Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex|Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions||National Institutes of Health Clinical Center (CC)||Recruiting|January 1995|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|3 Years|N/A|No|||November 2015|December 2, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001452||210165|
NCT00001862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990047|TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis|The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Completed|February 1999|March 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||March 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001862||209857|
NCT00001444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950171|A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms|A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms||National Institutes of Health Clinical Center (CC)||Completed|August 1995|May 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||51|||Both|N/A|N/A|No|||May 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001444||210172|
NCT00001460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950051|Evaluation and Treatment of Heart Disease in Patients Not Participating in Research|Evaluation and Therapy of Heart Disease in Patients Not Participating in Research (Teaching Protocol)||National Institutes of Health Clinical Center (CC)||Completed|January 1995|April 2002||||N/A|Interventional|N/A|||||||Both|N/A|N/A|No|||April 2002|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001460||210157|
NCT00001521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960033|Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia|An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 1996|June 2016|Anticipated|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|62|||Both|2 Years|20 Years|No|||January 2016|January 26, 2016|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001521||210111|
NCT00001453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950104|Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome|Internal Jugular Vein Sampling for ACTH Levels for the Differential Diagnosis of Cushing Syndrome||National Institutes of Health Clinical Center (CC)||Completed|April 1995|October 2014||||N/A|Observational|N/A|||Actual|98|||Both|18 Years|75 Years|No|||October 2014|January 22, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001453||210164|
NCT00001553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960090|Motor Changes Associated With Recovery From Stroke After Therapy|Functional Changes Associated With Recovery of Motor Function in Chronic Ischemic Subcortical Stroke After a Therapeutic Intervention||National Institutes of Health Clinical Center (CC)||Completed|May 1996|March 2001||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001553||210081|
NCT00001551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960088|Characteristics of Idiopathic Familial Speech Disorders|Characteristics of Idiopathic Familial Speech Disorders||National Institutes of Health Clinical Center (CC)||Completed|May 1996|||November 2009|Actual|N/A|Observational|N/A||||375|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001551||210083|
NCT00001499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960054|Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer|Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)||Completed|March 1996|June 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001499||210126|
NCT00001570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970074|A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer|A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 1997|January 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||46|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001570||210070|
NCT00001448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950185|The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection|The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection||National Institutes of Health Clinical Center (CC)||Completed|August 1995|June 2000||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||July 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001448||210169|
NCT00001454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950110|Hormonal Effects on the Uterus and Endometrium|Endometrial Mediators of Gonadal Steroid Action||National Institutes of Health Clinical Center (CC)||Completed|April 1995|July 2015||||N/A|Observational|N/A|||Actual|129|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||July 2015|January 22, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001454||210163|
NCT00001520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960122|The Early Reversibility of Rocuronium After Different Doses of Neostigmine|The Early Reversibility of Rocuronium After Different Doses of Neostigmine||National Institutes of Health Clinical Center (CC)||Completed|September 1996|August 2000||||Phase 4|Interventional|Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||September 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001520||210112|
NCT00001498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960032|A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer|A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 1996|December 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||55|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001498||210127|
NCT00001858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990119|Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants|Monitoring for Donor-Specific Hyporesponsiveness Following Renal and Pancreatic Allotransplantation||National Institutes of Health Clinical Center (CC)||Completed|June 1999|May 2014||||N/A|Observational|N/A|||Actual|294|||Both|N/A|N/A|No|||May 2014|May 31, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001858||209861|
NCT00001496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960026|Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer|Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|January 1996|November 2001||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001496||210129|
NCT00001497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960030|Assessment of Attentional Functioning in Children With HIV-1 Infection|Assessment of Attentional Functioning in Children With HIV-1 Infection||National Institutes of Health Clinical Center (CC)||Completed|December 1995|October 2000||||N/A|Observational|N/A||||90|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001497||210128|
NCT00001449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950197|A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients|A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|September 1995|April 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||September 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001449||210168|
NCT00001485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950149|Effects of Season on Melatonin Secretion in Healthy Men and Women and Patients With Seasonal Affective Disorder|Gender Differences in the Effects of Season on Patterns of Nocturnal Melatonin Secretion in Healthy Volunteers and Patients With Seasonal Affective Disorder (SAD)||National Institutes of Health Clinical Center (CC)||Completed|June 1995|April 2000||||N/A|Observational|N/A||||116|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001485||210136|
NCT00001486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950150|Genetic Study of Schizophrenia|A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings||National Institutes of Health Clinical Center (CC)||Recruiting|June 1995|||||N/A|Observational|N/A|||Anticipated|6150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|February 20, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001486||210135|
NCT00001579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970136|A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors|A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|June 1997|March 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||May 2000|July 14, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001579||210062|
NCT00001567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970060|A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia|A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia||National Institutes of Health Clinical Center (CC)||Completed|January 1997|April 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||56|||Both|N/A|N/A|No|||April 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001567||210073|
NCT00001445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950172|Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection|Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection||National Institutes of Health Clinical Center (CC)||Completed|August 1995|July 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||32|||Both|N/A|N/A|No|||August 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001445||210171|
NCT00001461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950099|Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme|Investigation of the Interaction Between the Vascular Endothelium and Angiotensin-Converting Enzyme||National Institutes of Health Clinical Center (CC)||Completed|March 1995|April 2001||||N/A|Observational|N/A||||209|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001461||210156|
NCT00001462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950116|Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals|Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals||National Institutes of Health Clinical Center (CC)||Completed|May 1995|April 2000||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001462||210155|
NCT00001506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960102|Evaluation and Treatment of Patients With Dermatologic Diseases|Evaluation and Treatment of Subjects With Dermatologic Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|June 1996|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|N/A|100 Years|No|||December 2015|December 31, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001506||210120|
NCT00001842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990141|G-CSF for Granulocyte Donation|Kinetics of Intravenous G-CSF-Induced Granulocyte Mobilization in Healthy Apheresis Donors||National Institutes of Health Clinical Center (CC)||Completed|July 1999|June 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||16|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00001842||209874|
NCT00001471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950027|Tissue Biopsy and Imaging Studies in HIV-Infected Patients|Virologic and Immunologic Evaluation of Lymph Node, Tonsillar, and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid||National Institutes of Health Clinical Center (CC)||Recruiting|November 1994|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|635|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001471||210148|
NCT00001473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950091|Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides|A Staged Therapeutic Approach Using Cyclophosphamide and Methotrexate in the Treatment of Wegener's Granulomatosis and Related Vasculitides||National Institutes of Health Clinical Center (CC)||Completed|March 1995|March 2004||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||March 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001473||210147|
NCT00001872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990037|Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease|Apheresis of Family Members of Patients Undergoing Allogeneic Bone Marrow Transplantation. A Pre-Clinical Study of Selective Depletion of Donor Lymphocytes to Prevent Acute Graft-Versus-Host Disease||National Institutes of Health Clinical Center (CC)||Recruiting|February 1999|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|May 20, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001872||209848|
NCT00001587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970200|A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver|A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver||National Institutes of Health Clinical Center (CC)||Completed|September 1997|March 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001587||210057|
NCT00001620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970041|Screening for Hematology Branch Protocols|Screening Protocol for Subjects Being Evaluated for Hematology Branch Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|December 1996|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|2 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001620||210031|
NCT00001469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950158|Genetic Analysis of Hereditary Prostate Cancer|Genetic Analysis of Hereditary Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|July 1995|||||N/A|Observational|N/A|||Anticipated|70000|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001469||210149|
NCT00001491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950121|Analysis of the Nervous System in Patients With Fabry's Disease|The Natural History and Pathogenesis of Fabry Disease||National Institutes of Health Clinical Center (CC)||Completed|May 1995|March 2008||||N/A|Observational|N/A||||325|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2008|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001491||210132|
NCT00001456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950193|Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome|Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|September 1995|||||N/A|Observational|N/A|||Anticipated|400|||Both|1 Year|80 Years|No|||February 2016|March 16, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001456||210161|
NCT00001439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950145|A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant|A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant||National Institutes of Health Clinical Center (CC)||Completed|June 1995|April 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||255|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001439||210176|
NCT00001430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950073|A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas|A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|February 1995|January 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||49|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001430||210183|
NCT00001431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950075|A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas|A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas||National Institutes of Health Clinical Center (CC)||Completed|February 1995|November 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||November 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001431||210182|
NCT00001432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950086|The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies|The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies||National Institutes of Health Clinical Center (CC)||Completed|March 1995|November 2003||||N/A|Observational|N/A||||75|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001432||210181|
NCT00001458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950047|Evaluation of Patients With Heart Disease Not Eligible for Research Protocols|Diagnosis and Treatment of Patients With Heart and Vascular Disease (Training Protocol)||National Institutes of Health Clinical Center (CC)||Recruiting|January 1995|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|N/A|N/A|No|||May 2015|May 27, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001458||210159|
NCT00001675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980056|The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics|Functional Neuroanatomy of Positive and Negative Affect in Alcoholics and Non-Alcoholics||National Institutes of Health Clinical Center (CC)||Completed|January 1998|December 2015||||N/A|Observational|N/A|||Actual|1194|||Both|12 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001675||209984|
NCT00001476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950134|Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up|Gene Therapy Approach for Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Completed|June 1995|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|14|||Both|5 Years|N/A|No|||December 2010|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001476||210144|
NCT00001489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950008|Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism|The Effect of Vigabatrin on Cerebral Blood Flow and Glucose Metabolism||National Institutes of Health Clinical Center (CC)||Completed|October 1994|August 2000||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001489||210133|
NCT00001437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950138|Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis|Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis||National Institutes of Health Clinical Center (CC)||Completed|June 1995|March 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001437||210178|
NCT00001438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950144|A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes|A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes||National Institutes of Health Clinical Center (CC)||Completed|June 1995|December 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001438||210177|
NCT00001695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980098|Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trials|Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trials||National Institutes of Health Clinical Center (CC)||Completed|April 1998|January 2002||||N/A|Observational|N/A||||125|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001695||209971|
NCT00001502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960068|A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors|Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors||National Institutes of Health Clinical Center (CC)||Completed|April 1996|March 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001502||210124|
NCT00001666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970092|Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy|Drug Refractory Partial Epilepsy, A Therapeutic Trial With Transcranial Magnetic Stimulation||National Institutes of Health Clinical Center (CC)||Completed|March 1997|June 2002||||N/A|Observational|N/A||||32|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001666||209991|
NCT00001467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950066|Genetic Analysis of Immune Disorders|Genetic Analysis of Immune Disorders||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|January 1995|||||N/A|Observational|N/A|||Actual|2945|||Both|N/A|N/A|No|||May 2015|May 22, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001467||210151|
NCT00001712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980066|Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan|Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan||National Institutes of Health Clinical Center (CC)||Completed|February 1998|October 2005||||N/A|Observational|N/A||||3400|||Both|N/A|N/A|No|||October 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001712||209962|
NCT00001457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950199|Lamivudine for Chronic Hepatitis B|Lamivudine for Chronic Hepatitis B||National Institutes of Health Clinical Center (CC)||Completed|September 1995|September 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||September 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001457||210160|
NCT00001487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950151|Treatment of Mid-Life-Related Mood Disorders|Dehydroepiandrosterone Treatment of Mid-Life-Related Mood Disorders in Women and Men||National Institutes of Health Clinical Center (CC)||Completed|June 1995|April 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||April 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001487||210134|
NCT00001667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970097|Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases|Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases||National Institutes of Health Clinical Center (CC)||Completed|March 1997|April 2000||||N/A|Observational|N/A||||300|||Both|N/A|N/A|No|||February 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001667||209990|
NCT00001410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940014|PEG-Glucocerebrosidase for the Treatment of Gaucher Disease|A Phase I and II Study of PEG-Glucocerebrosidase in Patients With Type 1 or Type 3 Gaucher Disease||National Institutes of Health Clinical Center (CC)||Completed|October 1993|December 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||18|||Both|N/A|N/A|No|||December 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001410||210198|
NCT00001436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950119|A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma|A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma||National Institutes of Health Clinical Center (CC)||Completed|May 1995|September 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001436||210179|
NCT00001481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950097|The Role of Hormones in Postpartum Mood Disorders|An Endocrine Model for Postpartum Mood Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|March 1995|||||N/A|Observational|N/A|||Anticipated|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001481||210139|
NCT00001440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950146|Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy|Pilot Study of Autologous T Cells and/or IL-2 for the Enhancement of Immune Reconstitution After Dose-Intensive Chemotherapy for Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|July 1995|January 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||51|||Both|N/A|N/A|No|||January 2002|March 3, 2008|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00001440||210175|
NCT00001465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950186|Study of the Disease Process of Lymphangioleiomyomatosis|Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)||National Institutes of Health Clinical Center (CC)||Recruiting|September 1995|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|16 Years|80 Years|No|||November 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001465||210153|
NCT00001678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980124|Genetics of Rheumatoid Arthritis|Genetics of Rheumatoid Arthritis: The North American Rheumatoid Arthritis Consortium||National Institutes of Health Clinical Center (CC)||Completed|July 1998|June 2014||||N/A|Observational|N/A|||Actual|39|||Both|18 Years|N/A|No|||June 2014|June 21, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001678||209981|
NCT00001671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970170|The Classification and Cause of Leukodystrophies of Unknown Cause|The Nosology and Etiology of Leukodystrophies of Unknown Cause||National Institutes of Health Clinical Center (CC)||Completed|September 1997|December 2008||||N/A|Observational|N/A||||400|||Both|N/A|N/A|No|||December 2008|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001671||209987|
NCT00001676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980055|Cyclophosphamide and Fludarabine to Treat Lupus Nephritis|Combination of Cyclophosphamide and Fludarabine for Lupus Nephritis: Tolerance, Toxicity, Efficacy and Effects on B and T Lymphocyte Regeneration||National Institutes of Health Clinical Center (CC)||Completed|January 1998|November 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||November 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001676||209983|
NCT00001509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960117|A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor|A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor||National Institutes of Health Clinical Center (CC)||Completed|July 1996|May 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001509||210118|
NCT00001512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960133|Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines|Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines||National Institutes of Health Clinical Center (CC)||Completed|September 1996|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||March 2010|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001512||210117|
NCT00001466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950010|Study of Clinical and Molecular Manifestations of Genetic Disorders|Clinical and Molecular Manifestations of Six Categories of Genetic Disorders||National Institutes of Health Clinical Center (CC)||Completed|October 1994|October 2000||||N/A|Observational|N/A||||1200|||Both|N/A|N/A|No|||September 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001466||210152|
NCT00001407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940149|Interferon Gamma for Drug Resistant Tuberculosis|Treatment of Multiply Drug Resistant Tuberculosis With Interferon Gamma: A Phase I/II Dose Escalation Trial||National Institutes of Health Clinical Center (CC)||Completed|May 1994|May 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||May 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001407||210201|
NCT00001681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980011|A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations|A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations||National Institutes of Health Clinical Center (CC)||Completed|October 1997|September 2000||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001681||209978|
NCT00001408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940203|Role of T-Cells in Asthma|Cytokine Expression in Allergic Asthma||National Institutes of Health Clinical Center (CC)||Completed|September 1994|October 1995|Actual|October 1995|Actual|N/A|Observational|N/A||||250|||Both|18 Years|65 Years|No|||June 2009|August 27, 2009|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001408||210200|
NCT00001468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950085|Outcomes of Education and Counseling for BRCA1 Testing|Outcomes of Education and Counseling for BRCA1 or BRCA2 Testing||National Institutes of Health Clinical Center (CC)||Completed|March 1995|February 2001||||N/A|Observational|N/A||||1500|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001468||210150|
NCT00001480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950096|The Evaluation and Follow-up of Individuals With Memory Disorder|The Evaluation and Follow-up of Patients With Memory Disorder and Normal Controls||National Institutes of Health Clinical Center (CC)||Completed|March 1995|March 2007||||N/A|Observational|N/A||||750|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2007|March 5, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001480||210140|
NCT00001418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940186|PET Scan in Patients With Neurocardiologic Disorders|Positron Emission Tomographic (PET) Scanning of Sympathetic Innervation and Function in Patients With Neurocardiologic Disorders||National Institutes of Health Clinical Center (CC)||Completed|July 1994|August 2004||||N/A|Observational|N/A||||335|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001418||210191|
NCT00001412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940037|Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement|The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement||National Institutes of Health Clinical Center (CC)||Completed|December 1993|November 2001||||N/A|Observational|N/A||||70|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001412||210197|
NCT00001459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950048|Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers|Tomographic Myocardial Wall Motion Analysis in Patients With Myocardial Ischemia and in Normal Subjects||National Institutes of Health Clinical Center (CC)||Completed|January 1995|March 2001||||N/A|Observational|N/A||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001459||210158|
NCT00001409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940206|Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications|A Phase I/II Pilot Study of the Safety of the Adoptive Transfer of Syngeneic Gene-Modified Cytotoxic T Lymphocytes in HIV Infected Identical Twins||National Institutes of Health Clinical Center (CC)||Completed|September 1994|June 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001409||210199|
NCT00001672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970175|Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy|Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|September 1997|March 2000||||N/A|Observational|N/A||||40|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001672||209986|
NCT00001677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980117|Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy|Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy||National Institutes of Health Clinical Center (CC)||Completed|June 1998|April 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001677||209982|
NCT00001541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960065|Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis|Analysis of Bronchial and Bronchoalveolar Lavage Fluid and Bronchial Mucosal Biopsies in Patients With Wegener's Granulomatosis||National Institutes of Health Clinical Center (CC)||Completed|April 1996|January 2003||||N/A|Observational|N/A||||25|||Both|N/A|N/A|No|||January 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001541||210093|
NCT00001668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970102|Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors|Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors||National Institutes of Health Clinical Center (CC)||Completed|April 1997|April 2000||||N/A|Observational|N/A||||75|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001668||209989|
NCT00001415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940146|Glucocorticoid Effects on Cellular Cytokine Release|Glucocorticoid Effects on Cellular Cytokine Release||National Institutes of Health Clinical Center (CC)||Completed|May 1994|July 2000||||N/A|Observational|N/A||||130|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001415||210194|
NCT00001495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960013|A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors|A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|November 1995|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||September 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001495||210130|
NCT00001711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980019|Magnetic Resonance Imaging (MRI) Ofl Volunteers|Volunteer Scanning on MR||National Institutes of Health Clinical Center (CC)||Recruiting|October 1997|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|18 Years|N/A|No|||September 2015|December 16, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001711||209963|
NCT00001679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980150|Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients|Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients||National Institutes of Health Clinical Center (CC)||Completed|August 1998|June 2000||||N/A|Observational|N/A||||250|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001679||209980|
NCT00001680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980008|A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus|A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus||National Institutes of Health Clinical Center (CC)||Completed|October 1997|July 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||17|||Both|N/A|N/A|No|||September 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001680||209979|
NCT00001413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940121|Bone Mineral Density in Women With Major Depression|Bone Mineral Density in Patients With Major Depression With Melancholic and Atypical Features: Relation to Stress-System Neurohormonal Function||National Institutes of Health Clinical Center (CC)||Completed|April 1994|January 2007||||N/A|Observational|N/A||||585|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001413||210196|
NCT00001420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950082|Study of Psoriatic Arthritis|Studies of the Pathogenesis and Natural History of Psoriatic Arthritis||National Institutes of Health Clinical Center (CC)||Completed|March 1995|January 2006||||N/A|Observational|N/A||||999|||Both|N/A|N/A|No|||January 2006|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001420||210190|
NCT00001421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950139|Methimazole to Treat Polymyositis and Dermatomyositis|A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis||National Institutes of Health Clinical Center (CC)||Completed|June 1995|April 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001421||210189|
NCT00001478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950016|Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders|Regional Cerebral Blood Flow Correlates of Spontaneous and Drug-Induced Clinical Changes in Mood Disorders||National Institutes of Health Clinical Center (CC)||Completed|October 1994|January 2001||||N/A|Observational|N/A||||170|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001478||210142|
NCT00001479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950044|Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression|Intensively Sampled Dynamics of ACTH and Cortisol Affective Disorders||National Institutes of Health Clinical Center (CC)||Completed|January 1995|May 2000||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001479||210141|
NCT00001414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940122|Mapping Personality Traits to Genes|Mapping Personality Traits to Genes||National Institutes of Health Clinical Center (CC)||Completed|April 1994|June 2002||||N/A|Observational|N/A||||2400|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001414||210195|
NCT00001455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950142|Iron Overload in African Americans|Iron Overload in African Americans||National Institutes of Health Clinical Center (CC)||Completed|June 1995|June 2000||||N/A|Observational|N/A||||500|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001455||210162|
NCT00001503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960071|Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease|Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|May 1996|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1500|||Both|7 Years|100 Years|No|||November 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001503||210123|
NCT00001417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940158|Direct Injection of Alcohol for the Treatment of Spinal Tumors|Study of the Efficacy of Direct Intratumoral Injection of Absolute Ethanol in Treating Symptomatic Spinal Tumors||National Institutes of Health Clinical Center (CC)||Completed|June 1994|May 2002||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||May 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001417||210192|
NCT00001673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980009|Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Screening Evaluation for NIAAA Protocols||National Institutes of Health Clinical Center (CC)||Completed|October 1997|December 2015||||N/A|Observational|N/A|||Actual|2220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001673||209985|
NCT00001464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950167|Effect of High Levels of Oxygen and Smoking on the Lungs in Human Volunteers|Effect of Hypoxia and Smoking on Oxidation of Proteins and Nucleic Acids in Human Volunteers||National Institutes of Health Clinical Center (CC)||Completed|July 1995|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|77|||Both|N/A|N/A|No|||December 2015|December 15, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001464||210154|
NCT00001435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950112|Psychosocial Correlates and Coping Strategies Associated With Long-Term Survival of HIV-Infected Children|Psychosocial Correlates and Coping Strategies Associated With Long-Term Survival of HIV-Infected Children||National Institutes of Health Clinical Center (CC)||Completed|April 1995|December 2000||||N/A|Observational|N/A||||110|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001435||210180|
NCT00001669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970148|A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients|A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients||National Institutes of Health Clinical Center (CC)||Completed|July 1997|April 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||April 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001669||209988|
NCT00001422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950140|A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis|A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis||National Institutes of Health Clinical Center (CC)||Completed|June 1995|April 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001422||210188|
NCT00001493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960007|Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer|Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cance||National Institutes of Health Clinical Center (CC)||Completed|October 1995|June 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||42|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001493||210131|
NCT00001659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970157|Consequences of Conjugal Bereavement in Adults|Conjugal Bereavement in Older Adults: Biological, Functional, and Psychological Consequences||National Institutes of Health Clinical Center (CC)||Completed|July 1997|May 2002||||N/A|Observational|N/A||||210|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001659||209997|
NCT00001985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000063|Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus|Multi-Center Study to Determine Whether CD 152 Gene Polymorphisms Associated With Susceptibility to Type-1-Diabetes Mellitus (T1DM) Correspond With Abnormalities in T Cell Function||National Institutes of Health Clinical Center (CC)||Completed|January 2000|February 2003||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2003|March 4, 2008|January 26, 2000||||No||https://clinicaltrials.gov/show/NCT00001985||209755|
NCT00001724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980035|Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction|Evaluation of the Analgesic Effects of Locally Applied Flurbiprofen and Bupivacaine in the Oral Surgery Model||National Institutes of Health Clinical Center (CC)||Completed|November 1997|November 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001724||209950|
NCT00001688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980041|A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine|A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine||National Institutes of Health Clinical Center (CC)||Completed|January 1998|November 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001688||209974|
NCT00002041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001A|Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients|Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002041||209700|
NCT00002042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004F|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002042||209699|
NCT00001986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000062|1-Octanol to Treat Essential Tremor|Double-Blind, Placebo-Controlled, Single-Dose Trial of 1-Octanol in Essential Tremor||National Institutes of Health Clinical Center (CC)||Completed|January 2000|January 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||12|||Both|N/A|N/A|No|||January 2000|March 3, 2008|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00001986||209754|
NCT00001992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075A|A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers|A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||August 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001992||209749|
NCT00001993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057A|Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3|Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||February 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001993||209748|
NCT00002051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015E|Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection|Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002051||209690|
NCT00002014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052A|A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)|A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002014||209727|
NCT00002003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055A|Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas|Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002003||209738|
NCT00002025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029D|Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient|Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Months|N/A|No|||September 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002025||209716|
NCT00001652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970039|The Evaluation and Follow-up of Patients With Bipolar Disorder|The Evaluation and Naturalistic Follow-up of Patients With Bipolar Disorder||National Institutes of Health Clinical Center (CC)||Completed|December 1996|December 2002||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||December 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001652||210002|
NCT00001611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970081|Immune Activity Against CVM Retinitis|Efficacy of Elevated CD4 Cell Counts on CMV Retinitis||National Institutes of Health Clinical Center (CC)||Completed|February 1997|April 2004||||N/A|Observational|N/A||||15|||Both|N/A|N/A|No|||April 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001611||210039|
NCT00002015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029G|An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children|An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|3 Months|12 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002015||209726|
NCT00002016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071B|A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis|A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002016||209725|
NCT00001657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970128|Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Chronic Posttraumatic Stress Disorder (PTSD)|Controlled Studies of Repetitive Transcranial Magnetic Stimulation (rTMS) in Chronic Posttraumatic Stress Disorder (PTSD)||National Institutes of Health Clinical Center (CC)||Completed|June 1997|May 2000||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001657||209999|
NCT00001650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970189|Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients|Studies of Lymphocyte Kinetics Using Bromodeoxyuridine||National Institutes of Health Clinical Center (CC)||Completed|September 1997|May 2011||||N/A|Observational|N/A|||Actual|56|||Both|18 Years|N/A|No|||May 2011|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001650||210004|
NCT00001686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980037|Evaluation, Treatment, and Natural History of Children With Cancer|Treatment of Children With Cancer||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|December 1997|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|355|||Both|3 Months|40 Years|No|||December 2015|January 14, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001686||209975|
NCT00001606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970180|Genetic Analysis of Human Hereditary Hearing Impairment|Genetic Analysis of Human Hereditary Hearing Impairment||National Institutes of Health Clinical Center (CC)||Terminated|September 1997|April 2015||||N/A|Observational|N/A|||Actual|404|||Both|N/A|N/A|No|||April 2015|April 8, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001606||210042|
NCT00001575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970110|Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia|||National Institutes of Health Clinical Center (CC)|No|Completed|April 1997|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|80 Years|No|||October 2015|October 30, 2015|November 3, 1999|No|Yes||No|May 14, 2015|https://clinicaltrials.gov/show/NCT00001575||210065|
NCT00001736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980109|New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis|Safety and Efficacy Trial of a Proposed NDA Formulation of Topical Cysteamine in the Treatment of Corneal Cystine Crystal Accumulation in Cystinosis||National Institutes of Health Clinical Center (CC)||Completed|May 1998|March 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||51|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001736||209938|
NCT00001737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980110|Cyclosporin Implant to Treat Uveitis|A Pilot Study of a Sustained-Release Cyclosporine A Implant for Uveitis||National Institutes of Health Clinical Center (CC)||Completed|May 1998|March 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||March 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001737||209937|
NCT00001664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970070|Sleep Disorders of Patients With Diseases of the Nervous System|Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders||National Institutes of Health Clinical Center (CC)||Completed|December 1996|September 2011||||N/A|Observational|N/A|||Actual|83|||Both|5 Years|N/A|No|||September 2011|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001664||209993|
NCT00001626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970117|Comparing Therapies for the Treatment of Severe Aplastic Anemia|A Randomized Trial of Antithymocyte Globulin and Cyclosporine Versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Completed|May 1997|March 2008|Actual|September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|15 Years|N/A|No|||October 2015|October 17, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001626||210025|
NCT00001612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970120|Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)|Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)||National Institutes of Health Clinical Center (CC)||Completed|May 1997|August 2000||||N/A|Observational|N/A||||170|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001612||210038|
NCT00001987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760006|Genetic Studies of Insulin and Diabetes|Natural History of Disorders of Insulin Resistance||National Institutes of Health Clinical Center (CC)||Recruiting|January 1976|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|6 Months|N/A|No|||October 2015|November 3, 2015|January 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00001987||209753|
NCT00001989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106A|A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin|A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||October 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001989||209752|
NCT00001702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980138|Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection|Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection||National Institutes of Health Clinical Center (CC)||Completed|July 1998|||June 2007|Actual|N/A|Observational|N/A||||400|||Both|N/A|N/A|No|||October 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001702||209966|
NCT00002026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033A|Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)|Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002026||209715|
NCT00001604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970057|Genetic Linkage Studies of Stuttering|Genetic Studies of Stuttering||National Institutes of Health Clinical Center (CC)||Recruiting|January 1997|||||N/A|Observational|N/A|||Anticipated|4000|||Both|6 Years|N/A|Accepts Healthy Volunteers|||June 2015|February 12, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001604||210044|
NCT00001658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970145|Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections|A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections||National Institutes of Health Clinical Center (CC)||Completed|July 1997|June 2001||||Phase 4|Interventional|Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||August 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001658||209998|
NCT00001639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970045|Evaluation of Patients With Unresolved Chromosome Abnormalities|Evaluation of Patients With Unresolved Chromosome Aberrations||National Institutes of Health Clinical Center (CC)||Completed|December 1996|October 2000||||N/A|Observational|N/A||||263|||Both|N/A|N/A|No|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001639||210015|
NCT00001609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970009|Studies of Families With Hereditary Cataracts|Clinical and Molecular Studies in Families With Congenital or Hereditary Cataracts||National Institutes of Health Clinical Center (CC)||Completed|October 1996|March 2003||||N/A|Observational|N/A||||1200|||Both|N/A|N/A|No|||March 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001609||210041|
NCT00001662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970049|Treatment of Alzheimer's Disease With CX516 (Ampalex)|Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease||National Institutes of Health Clinical Center (CC)||Completed|December 1996|November 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||November 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001662||209995|
NCT00001778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980047|Evaluation of Patients With HAM/TSP|Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)||National Institutes of Health Clinical Center (CC)||Recruiting|December 1997|||||N/A|Observational|N/A|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001778||209906|
NCT00001990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053D|An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine|An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||April 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001990||209751|
NCT00001625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970105|Methods for Measuring Insulin Sensitivity|Methods for Assessing Insulin Sensitivity In Vivo||National Institutes of Health Clinical Center (CC)||Completed|April 1997|April 2007||||N/A|Observational|N/A||||480|||Both|21 Years|65 Years|No|||April 2007|March 5, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001625||210026|
NCT00001637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970202|Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults|Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults||National Institutes of Health Clinical Center (CC)||Completed|September 1997|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|55 Years|71 Years|No|||January 2016|January 23, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001637||210017|
NCT00001618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970022|Segmental Bronchoalveolar Lavage|Bronchoscopy in Patients With Pulmonary Diseases and Research Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|November 1996|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|18 Years|65 Years|No|||December 2015|December 24, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001618||210033|
NCT00001584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970158|Determination of HIV-1 Production by the Prostate|Determination of HIV-1 Production by the Prostate||National Institutes of Health Clinical Center (CC)||Completed|July 1997|April 2001||||N/A|Observational|N/A||||35|||Male|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001584||210059|
NCT00002043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007B|Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)|Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002043||209698|
NCT00002044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014D|A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases|A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002044||209697|
NCT00001701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980137|Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection|Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection||National Institutes of Health Clinical Center (CC)||Completed|July 1998|||June 2007|Actual|N/A|Observational|N/A||||300|||Both|N/A|N/A|No|||October 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001701||209967|
NCT00001715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980090|Evaluation of Patients With Blood Disorders|Evaluation of Hematologic Patients - Training Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|April 1998|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|N/A|N/A|No|||October 2015|October 17, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001715||209959|
NCT00002010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012P|Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis|Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002010||209731|
NCT00002011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|049A|The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex|The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||July 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002011||209730|
NCT00002012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|069A|Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients|Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||March 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002012||209729|
NCT00002013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045C|A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients|A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||December 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002013||209728|
NCT00001788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990004|Genetic Basis of Primary Immunodeficiencies|Molecular Basis of Primary Immunodeficiencies||National Institutes of Health Clinical Center (CC)||Recruiting|October 1998|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|February 9, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001788||209899|
NCT00001647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970165|White Blood Cell Infusions to Treat HIV Infection|Effects of Repeated Infusions of Adoptively Transferred Syngeneic Lymphocytes on the Immune Systems of HIV-1 Infected Identical Twins||National Institutes of Health Clinical Center (CC)||Completed|August 1997|August 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001647||210007|
NCT00001665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970073|Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease|Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?||National Institutes of Health Clinical Center (CC)||Completed|January 1997|September 2000||||N/A|Observational|N/A||||12|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001665||209992|
NCT00001730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980038|Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.|A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal||National Institutes of Health Clinical Center (CC)||Completed|December 1997|April 2000||||Phase 4|Interventional|Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001730||209944|
NCT00001605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970114|Vaccination for Middle Ear Infection|Phase I Study to Evaluate the Safety and Immunogenicity of a Nontypeable Haemophilus Influenzae Vaccine for Otitis Media||National Institutes of Health Clinical Center (CC)||Completed|May 1997|April 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001605||210043|
NCT00001638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970204|Magnetic Resonance Imaging of the Blood Vessels of the Heart|Cardiovascular Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Completed|September 1997|August 2009|Actual|August 2009|Actual|N/A|Observational|N/A||||99999999|||Both|18 Years|N/A|No|||August 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001638||210016|
NCT00001610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970080|Normal Human Electro-Oculogram|Normal Human Electro-Oculogram||National Institutes of Health Clinical Center (CC)||Completed|February 1997|March 2003||||N/A|Observational|N/A||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001610||210040|
NCT00001972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940205|PET Scan of Brain Metabolism in Relation to Age and Disease|Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and Disease||National Institutes of Health Clinical Center (CC)||Completed|September 1994|August 2002||||N/A|Observational|N/A||||123|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2002|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001972||209766|
NCT00001719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980148|Magnetic Resonance Imaging of Blood Flow in the Liver and Abdomen|Examination of the Hemodynamics of the Portal Venous System in Normal Volunteers Using Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Completed|August 1998|August 2002||||N/A|Observational|N/A||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001719||209955|
NCT00001991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107A|A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia|A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||April 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001991||209750|
NCT00001717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980131|Influences on HIV Infected Subjects' Willingness to Participate in Research and Ability to Give Informed Consent|Influences on HIV Infected Subjects' Willingness to Participate in Research and Ability to Give Informed Consent||National Institutes of Health Clinical Center (CC)||Completed|July 1998|July 2000||||N/A|Observational|N/A||||225|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001717||209957|
NCT00001627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970130|Collection of Blood and Bone Marrow From Healthy Volunteers and Patients for Research Purposes|Collection of Blood and Bone Marrow From Healthy Volunteers and Patients for Research Purposes||National Institutes of Health Clinical Center (CC)||Completed|June 1997|||||N/A|Observational|N/A|||Actual|154|||Both|2 Years|N/A|No|||November 2015|November 17, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001627||210024|
NCT00002023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014C|An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2|An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002023||209718|
NCT00002024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029B|Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections|Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002024||209717|
NCT00002036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060A|Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)|Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)||Abbott||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002036||209705|
NCT00002004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064A|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002004||209737|
NCT00002027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|038A|Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)|Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment||||60|||Both|12 Years|65 Years|No|||June 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002027||209714|
NCT00001617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970183|Test of QLS Device to Detect Early Cataracts|Feasibility Study - Use of Quasielastic Light Scattering (QLS) Device in a Study of the Human Lens and Lens Opacities||National Institutes of Health Clinical Center (CC)||Completed|September 1997|August 2000||||N/A|Observational|N/A||||10|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001617||210034|
NCT00001643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970173|Gene Analysis of Parkinson's Disease|Gene Analysis in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|August 1997|||August 2009|Actual|N/A|Observational|N/A||||320|||Both|18 Years|N/A|No|||August 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001643||210011|
NCT00001731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980032|Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops|A Double-Masked, Randomized, Vehicle-Controlled Pilot Study of the Treatment of Keratoconjunctivitis Sicca With Topical Cyclosporin A 0.1% Emulsion||National Institutes of Health Clinical Center (CC)||Completed|November 1997|October 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001731||209943|
NCT00001615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970151|Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration|Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Completed|July 1997|May 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||180|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001615||210035|
NCT00001849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990055|New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome|New Imaging Modalities in the Evaluation of Patients With Ectopic Cushing's Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|February 1999|December 2019|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|202|||Both|18 Years|90 Years|No|||June 2015|January 22, 2016|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001849||209869|
NCT00001582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970143|Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer|Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection||National Institutes of Health Clinical Center (CC)||Recruiting|July 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|1 Year|99 Years|No|||April 2015|March 24, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001582||210060|
NCT00001622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970098|Study of the Response of Human Small Blood Vessels|Study of the Relation Between In Vivo and In Vitro Response of Human Small Vessels||National Institutes of Health Clinical Center (CC)||Completed|March 1997|March 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||87|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001622||210029|
NCT00001623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970099|Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia|HLA-Matched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies||National Institutes of Health Clinical Center (CC)||Completed|March 1997|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|10 Years|55 Years|No|||August 2015|August 27, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001623||210028|
NCT00001714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980084|Magnetization Transfer Quantitation and Characterization for Clinical Scanners|Magnetization Transfer Quantitation and Characterization for Clinical Scanners||National Institutes of Health Clinical Center (CC)||Completed|March 1998|July 2001||||N/A|Observational|N/A||||100|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001714||209960|
NCT00001880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990064|Stem Cell Transplantation for Metastatic Solid Tumors|Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy||National Institutes of Health Clinical Center (CC)||Completed|March 1999|||||N/A|Observational|N/A|||Actual|84|||Both|10 Years|80 Years|No|||September 2015|September 12, 2015|July 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00001880||209841|
NCT00001881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990065|Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease|Clinical Manifestations of Mutations in Genes Linked to Familial Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|March 1999|April 2001||||N/A|Observational|N/A||||9999|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001881||209840|
NCT00001857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990109|Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation|A Multicenter, Open-Label, Study to Determine the Safety of BG9588 (Anti-CD40L Antibody) Therapy Compared to Standard Treatment in Renal Allograft Transplantation||National Institutes of Health Clinical Center (CC)||Completed|May 1999|April 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001857||209862|
NCT00001641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970089|Study of Heritable Connective Tissue Disorders|Clinical and Molecular Manifestations of Heritable Connective Tissue Disorders||National Institutes of Health Clinical Center (CC)||Completed|March 1997|June 2002||||N/A|Observational|N/A||||900|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001641||210013|
NCT00001642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970122|Positional Cloning of the Gene(s) Responsible for Alagille Syndrome|Positional Cloning of the Gene(s) Responsible for Alagille Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 1997|March 2000||||N/A|Observational|N/A||||225|||Both|N/A|N/A|No|||May 1999|March 3, 2008|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00001642||210012|
NCT00001871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990036|Study of Muscle Abnormalities in Patients With Specific Genetic Mutations|An Exploratory Study of Skeletal Muscle Abnormalities in Patients With Mutations in Alpha-Tropomyosin and PABP2 Genes||National Institutes of Health Clinical Center (CC)||Completed|January 1999|March 2001||||N/A|Observational|N/A||||80|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001871||209849|
NCT00001631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970177|Study of Blood Flow in Heart Muscle|Study of Myocardial Perfusion by MRI||National Institutes of Health Clinical Center (CC)||Completed|August 1997|January 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||249|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001631||210020|
NCT00001878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990058|Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts|Contribution of Insulin-Like Growth Factor-I (IGF-I) and Its Binding Protein (IGFBP3) to Increased Left Ventricular Mass in Familial Hypertrophic Cardiomyopathy Caused by Distinct Sarcomeric Mutations||National Institutes of Health Clinical Center (CC)||Completed|February 1999|August 2002||||N/A|Observational|N/A||||175|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001878||209843|
NCT00001879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990060|Collections of Blood and Stool Samples in Patients With Acute Hepatitis|Collection of Blood and Stool Samples in Patients With Acute Hepatitis||National Institutes of Health Clinical Center (CC)||Completed|March 1999|March 2001||||N/A|Observational|N/A||||200|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001879||209842|
NCT00001596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970085|Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome|Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome||National Institutes of Health Clinical Center (CC)|Yes|Active, not recruiting|September 2005|September 2020|Anticipated|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|November 3, 1999|Yes|Yes||No|December 12, 2011|https://clinicaltrials.gov/show/NCT00001596||210052|Study enrollment progressed more slowly than anticipated (spanning >3 years instead of one). The Data Safety and Monitoring Board performed an interim analysis one year after 30 subjects enrolled and directed the study to stop due to futility.
NCT00001629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970142|The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function|The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function||National Institutes of Health Clinical Center (CC)||Completed|July 1997|September 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||49|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001629||210022|
NCT00001589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970113|Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors|Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors||National Institutes of Health Clinical Center (CC)||Completed|April 1997|May 2002||||N/A|Observational|N/A||||120|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001589||210056|
NCT00001591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970152|Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy|Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy||National Institutes of Health Clinical Center (CC)||Completed|July 1997|July 2003||||N/A|Observational|N/A||||450|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001591||210055|
NCT00001614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970146|The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis|The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Completed|July 1997|May 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||13|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001614||210036|
NCT00001845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990164|Study of Brain Blood Flow During Induced Hypercapnia (Excess Blood Carbon Dioxide)|MR Perfusion Imaging in Hypercapnia: Development of Technical Protocols||National Institutes of Health Clinical Center (CC)||Completed|September 1999|August 2004||||N/A|Observational|N/A||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001845||209872|
NCT00001850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990103|Evaluation of Women With Endocrine and Reproductive-Related Conditions|Evaluation of Women With Endocrine and Reproductive-Related Conditions||National Institutes of Health Clinical Center (CC)||Recruiting|May 1999|||||N/A|Observational|N/A|||Anticipated|900|||Both|1 Year|80 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001850||209868|
NCT00001877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990057|Treatment of Pulmonary Sarcoidosis With Pentoxifylline|Treatment of Pulmonary Sarcoidosis With Pentoxifylline||National Institutes of Health Clinical Center (CC)||Completed|February 1999|May 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||May 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001877||209844|
NCT00001685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980023|Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase|Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase||National Institutes of Health Clinical Center (CC)||Completed|November 1997|September 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||114|||Both|N/A|N/A|No|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001685||209976|
NCT00001859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990120|Screening for Patients Needing Kidney, Kidney-Pancreas, or Islet-Cell Transplant|Screening Protocol for Patients Needing a Kidney, Kidney-Pancreas, or Islet Cell Transplant||National Institutes of Health Clinical Center (CC)||Completed|June 1999|May 2014||||N/A|Observational|N/A|||Actual|621|||Both|N/A|N/A|No|||May 2014|May 31, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001859||209860|
NCT00001860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990162|Sandostatin LAR Depot vs. Surgery for Treating Acromegaly|Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma||National Institutes of Health Clinical Center (CC)||Completed|August 1999|July 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||July 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001860||209859|
NCT00001884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990068|Specimen Collection for Individuals With Lung Disease Associated With Rheumatoid Arthritis|Specimen Procurement for Individuals With Pulmonary Fibrosis Associated With Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Completed|March 1999|December 2007||||N/A|Observational|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001884||209838|
NCT00001640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970078|Genetic Analysis of Parkinson's Disease|Genetic Analysis of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|February 1997|February 2009||||N/A|Observational|N/A||||500|||Both|18 Years|N/A|No|||February 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001640||210014|
NCT00001569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970072|Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis|Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis||National Institutes of Health Clinical Center (CC)||Completed|January 1997|December 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||74|||Both|N/A|N/A|No|||December 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001569||210071|
NCT00001577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970131|Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity|Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity||National Institutes of Health Clinical Center (CC)||Completed|June 1997|March 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||April 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001577||210063|
NCT00001656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970126|Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders|Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics||National Institutes of Health Clinical Center (CC)|No|Completed|June 1997|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|7 Years|18 Years|No|||March 2011|March 11, 2011|November 3, 1999||No||No|March 2, 2011|https://clinicaltrials.gov/show/NCT00001656||210000|
NCT00001663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970053|Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation|Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation||National Institutes of Health Clinical Center (CC)||Completed|January 1997|January 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001663||209994|
NCT00001600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970163|Diagnosis and Evaluation of Patients Needing Third Molar (Wisdom Tooth) Extraction and Patients With Chronic Facial Pain|Diagnosis and Evaluation of Patients in Need of Third Molar Removal or Suffering From Chronic Facial Pain||National Institutes of Health Clinical Center (CC)||Completed|August 1997|August 2005||||N/A|Observational|N/A||||4000|||Both|N/A|N/A|No|||August 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001600||210048|
NCT00001601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970169|Evaluation and Treatment of Oral Soft Tissue Diseases|Patient Evaluation and Treatment of Oral Soft Tissue Diseases According to Generally Available, Standard Procedures and Therapeutic Modalities||National Institutes of Health Clinical Center (CC)||Completed|August 1997|August 2002||||N/A|Interventional|N/A||||999|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001601||210047|
NCT00001594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970064|Evaluation and Intervention for the Effects of Osteogenesis Imperfecta|Evaluation and Intervention for Ambulation, Growth, and Basilar Invagination in Osteogenesis Imperfecta||National Institutes of Health Clinical Center (CC)||Recruiting|January 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|N/A|25 Years|No|||September 2015|October 6, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001594||210054|
NCT00001595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970076|An Investigation of Pituitary Tumors and Related Hypothalmic Disorders|A Clinical and Genetic Investigation of Pituitary Tumors and Related Hypothalmic Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|February 1997|||||N/A|Observational|N/A|||Anticipated|1500|||Both|3 Years|70 Years|No|||February 2016|February 19, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001595||210053|
NCT00001645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970096|Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection|Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection||National Institutes of Health Clinical Center (CC)||Recruiting|March 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|1 Year|N/A|No|||August 2015|January 22, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001645||210009|
NCT00001646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970164|Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis|Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis||National Institutes of Health Clinical Center (CC)||Completed|August 1997|August 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||September 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001646||210008|
NCT00001571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970075|A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines|A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines||National Institutes of Health Clinical Center (CC)||Completed|February 1997|December 2000||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001571||210069|
NCT00001846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990168|Whole Blood and Blood Component Collection for Research|Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use||National Institutes of Health Clinical Center (CC)||Recruiting|August 1999|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001846||209871|
NCT00001851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990003|Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome|Evaluation and Treatment to Improve Bone Quality and Prevent Fractures by the Percutaneous Replacement of Diseased Tissue in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome||National Institutes of Health Clinical Center (CC)||Completed|December 1998|April 2002|Actual|April 2002|Actual|N/A|Observational|N/A||||50|||Both|4 Years|N/A|No|||June 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001851||209867|
NCT00001852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990070|Natural History of Salivary Gland Dysfunction and Sj(SqrRoot)(Delta)Gren s Syndrome|Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome||National Institutes of Health Clinical Center (CC)||Completed|April 1999|||||N/A|Observational|N/A|||Actual|560|||Both|4 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001852||209866|
NCT00001853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990002|Diabetes and Heart Disease Risk in Blacks|Diabetes and Heart Disease Risk in Blacks||National Institutes of Health Clinical Center (CC)||Recruiting|October 1998|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1132|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001853||209865|
NCT00001854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990042|Long-Term Therapy With Ribavirin for Chronic Hepatitis C|Long-Term Therapy With Ribavirin for Chronic Hepatitis C||National Institutes of Health Clinical Center (CC)||Completed|February 1999|January 2008|Actual|October 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||January 2008|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001854||209864|
NCT00001613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970121|Cataract Surgery to Obtain Human Lens Material for the Study of Nuclear Cataracts|Use of Human Lens Material for the Study of Nuclear Cataracts||National Institutes of Health Clinical Center (CC)||Completed|May 1997|May 2002||||N/A|Observational|N/A||||96|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001613||210037|
NCT00001621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970061|Evaluation and Treatment of Patients With Lung Disease Not Participating in Research|Evaluation and Treatment of Pulmonary Patients Not Participating in Research (Training Protocol)||National Institutes of Health Clinical Center (CC)||Recruiting|January 1997|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|8 Years|N/A|No|||January 2016|February 6, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001621||210030|
NCT00001870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990033|Study of the Effects of Vitamin C on Patients With Type 2 Diabetes|An Exploratory Study of the Effects of Oral Vitamin C Administration on Insulin Sensitivity and Vascular Reactivity in Subjects With Type 2 Diabetes||National Institutes of Health Clinical Center (CC)||Completed|January 1999|December 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001870||209850|
NCT00001883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990067|Quality Control of Cardiopulmonary Exercise Equipment|Quality Control of P-CCMB Cardiopulmonary Exercise Equipment||National Institutes of Health Clinical Center (CC)||Completed|March 1999|October 2002||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2002|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001883||209839|
NCT00001619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970026|Magnetic Resonance Imaging at Different Levels of Magnetic Intensity|Magnetic Resonance at 1.5 and 3 Tesla||National Institutes of Health Clinical Center (CC)||Completed|November 1996|July 2011||||N/A|Observational|N/A|||Actual|497|||Both|18 Years|80 Years|No|||July 2011|July 21, 2011|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001619||210032|
NCT00001602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970002|Genetic Factors Related to Stuttering|Genetic Linkage Analysis in Developmental Stuttering: Gene Mapping in Extended Kindreds and Candidate Gene Analyses||National Institutes of Health Clinical Center (CC)||Completed|October 1996|February 2005||||N/A|Observational|N/A||||500|||Both|N/A|N/A|No|||February 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001602||210046|
NCT00001580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970138|Tissue Acquisition for Molecular Diagnostics|Tissue Acquisition for Molecular Diagnostics||National Institutes of Health Clinical Center (CC)||Completed|June 1997|March 2003||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||March 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001580||210061|
NCT00001576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970111|A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver|A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver||National Institutes of Health Clinical Center (CC)||Completed|July 1997|March 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||28|||Both|N/A|N/A|No|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001576||210064|
NCT00001572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970077|Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype|Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype||National Institutes of Health Clinical Center (CC)||Completed|January 1997|November 2010|Actual|July 1999|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2010|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001572||210068|
NCT00001644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970082|Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection|Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication||National Institutes of Health Clinical Center (CC)||Completed|March 1997|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||February 2010|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001644||210010|
NCT00001848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990012|The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis|The Safety and Effectiveness of Surgery With or Without Raloxifene (Evista (Trademark), Lilly) for the Treatment of Pelvic Pain Caused by Endometriosis||National Institutes of Health Clinical Center (CC)||Completed|November 1998|January 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||612|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001848||209870|
NCT00001573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970087|A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy|A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy||National Institutes of Health Clinical Center (CC)||Completed|March 1997|May 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001573||210067|
NCT00001624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970100|Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation|Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation||National Institutes of Health Clinical Center (CC)||Completed|March 1997|March 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||16|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001624||210027|
NCT00001632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970188|Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease|Myocardial Ultrasonic Tissue Characterization in Patients With a Genetic Predisposition for the Development of Hypertrophic Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|September 1997|August 2002||||N/A|Observational|N/A||||195|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001632||210019|
NCT00001633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970193|Safety and Effectiveness of Coronary Magnetic Resonance Angiography (CMRA) Imaging|A Phase II Feasibility Study of the Safety and Efficacy of Coronary Magnetic Resonance Angiography (CMRA) Imaging||National Institutes of Health Clinical Center (CC)||Completed|September 1997|December 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001633||210018|
NCT00001856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990107|Live Donors for Kidney Transplants|Live Donor Renal Donation for Allotransplantation||National Institutes of Health Clinical Center (CC)||Completed|May 1999|May 2014||||N/A|Observational|N/A|||Actual|260|||Both|18 Years|N/A|No|||May 2014|May 31, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001856||209863|
NCT00001628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970140|The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function|The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function||National Institutes of Health Clinical Center (CC)||Completed|July 1997|September 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||36|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001628||210023|
NCT00001867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990179|Effect of Pregnancy on Uveitis|Effect of Pregnancy on Uveitis||National Institutes of Health Clinical Center (CC)||Completed|September 1999|September 2000||||N/A|Observational|N/A||||10|||Female|N/A|N/A|No|||September 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001867||209852|
NCT00001869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990020|Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)|Lymphangioleiomyomatosis (LAM) Registry||National Institutes of Health Clinical Center (CC)||Completed|December 1998|April 2003||||N/A|Observational|N/A||||400|||Both|N/A|N/A|No|||April 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001869||209851|
NCT00001861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990035|Screening for Studies on Nystagmus and Strabismus|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Nystagmus or Strabismus||National Institutes of Health Clinical Center (CC)||Completed|January 1999|December 2007||||N/A|Observational|N/A||||1500|||Both|N/A|N/A|No|||December 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001861||209858|
NCT00001651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970191|Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients|Studies of Lymphocyte Kinetics Using Stable Isotopes||National Institutes of Health Clinical Center (CC)||Recruiting|September 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 17, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001651||210003|
NCT00001699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980121|A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers|A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers||National Institutes of Health Clinical Center (CC)||Completed|June 1998|March 2000||||N/A|Observational|N/A||||45|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001699||209968|
NCT00001630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970154|Treatment of Autoimmune Thrombocytopenia (AITP)|High-Dose Cyclophosphamide With CD34+ Selected Autologous Hematopoietic Cell Support for Treatment of Refractory Chronic Autoimmune Thrombocytopenia||National Institutes of Health Clinical Center (CC)||Completed|July 1997|June 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|65 Years|No|||March 2011|June 2, 2011|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001630||210021|
NCT00001586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970178|Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis|Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis||National Institutes of Health Clinical Center (CC)|No|Completed|September 1997|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|November 3, 1999||No||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00001586||210058|
NCT00001603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970044|The Effects of Upper Airway and Digestive Tract Tumors on the Immune System|A Pilot Study of Immunoregulatory Factor Expression and Immune Responses in Patients With Squamous Cell Carcinoma or Papilloma of the Upper Aerodigestive Tract||National Institutes of Health Clinical Center (CC)||Completed|December 1996|December 2004||||N/A|Observational|N/A||||93|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001603||210045|
NCT00001836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990001|Detection of Coronary Artery Calcification: Comparison of Volumetric and Electron Beam Computed Tomography|Detection of Coronary Artery Calcification: Comparison of Volumetric and Electron Beam Computed Tomography||National Institutes of Health Clinical Center (CC)||Completed|October 1998|November 2001||||N/A|Observational|N/A||||213|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001836||209879|
NCT00001890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990100|Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections|Immunomodulatory Effects of Hormone Therapy in Postmenopausal Women With Chronic Chlamydia Pneumoniae or Cytomegalovirus Infection||National Institutes of Health Clinical Center (CC)||Completed|May 1999|March 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||80|||Female|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001890||209832|
NCT00002187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251D|A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis|A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002187||209554|
NCT00002219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232H|Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children|A Phase I/II, Open-Label, Multi-Center Study of the Pharmacokinetics, Safety, Tolerance and Activity of Two Dose Levels of Adefovir Dipivoxil (ADF) and Nelfinavir When Added to Antiretroviral Therapy for the Treatment of HIV-Infected Pediatric Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||36|||Both|3 Months|16 Years|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002219||209522|
NCT00001749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980144|Medical Treatment for Diamond Blackfan Anemia|Treatment of Diamond Blackfan Anemia With Antithymocyte Globulin and Cyclosporine A||National Institutes of Health Clinical Center (CC)||Completed|July 1998|July 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||July 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001749||209929|
NCT00001750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980154|Comparing Treatments for Multiple Myeloma|Randomized Trial of Autologous Transplantation With Filgrastim Versus Stem Cell Factor/Filgrastim-Primed CD34-Enriched Peripheral Blood Cells for Multiple Myeloma||National Institutes of Health Clinical Center (CC)||Completed|September 1998|August 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||32|||Both|N/A|N/A|No|||August 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001750||209928|
NCT00002188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271A|A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma|Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002188||209553|
NCT00002233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264K|A Study of a Combination of Four Drugs in Patients With Recent HIV Infection|A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Quadruple Antiretroviral Therapy (EPIVIR, Abacavir, Amprenavir, and Indinavir) in Subjects Acutely Infected With HIV-1||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|15 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002233||209508|
NCT00002224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039G|Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)|Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric Coated or Didanosine Formulations Each Administered Once Daily||Bristol-Myers Squibb||Completed|March 1999|March 1999|Actual|March 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2011|April 13, 2011|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002224||209517|
NCT00002225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281D|A Study of Efavirenz in Combination With Stavudine and Didanosine|A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Didanosine in Antiretroviral Therapy-Naive HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002225||209516|
NCT00001910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990146|Mechanisms of Allergen Immunotherapy|Immunologic Mechanism of Allergen Immunotherapy||National Institutes of Health Clinical Center (CC)||Completed|July 1999|August 2003||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||August 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001910||209818|
NCT00002203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280A|A Study of Two Anti-HIV Drug Combinations|A Randomized, Multicenter Study of Epivir 150 Mg Bid, Retrovir 200 Mg Tid and a Protease Inhibitor Vs 3TC 150 Mg/ZDV 300 Mg Fixed Dose Tablet Given Bid With a Protease Inhibitor in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002203||209538|
NCT00001898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990130|Microarray Analysis for Human Genetic Disease|Microarray Analysis for Human Genetic Disease||National Institutes of Health Clinical Center (CC)||Completed|June 1999|May 2008||||N/A|Observational|N/A||||1500|||Both|N/A|N/A|No|||May 2008|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001898||209827|
NCT00001784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980130|Mexiletine for the Treatment of Focal Dystonia|Mexiletine for the Treatment of Focal Dystonia||National Institutes of Health Clinical Center (CC)||Completed|July 1998|July 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||July 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001784||209901|
NCT00001837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990013|Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients|Sonographic Evaluation of the Effects of Raloxifene on the Uterus and Ovaries in Premenopausal Patients at High Risk for Developing Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|November 1998|October 2005||||N/A|Observational|N/A||||60|||Female|N/A|N/A|No|||October 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001837||209878|
NCT00002189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273A|Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals|Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002189||209552|
NCT00001806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990081|Methods in Education for Breast Cancer Genetics|Methods in Education for Breast Cancer Genetics||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 1999|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|170|||Both|18 Years|100 Years|No|||October 2015|October 14, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001806||209893|
NCT00001827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990137|p53 Vaccine for Ovarian Cancer|Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary||National Institutes of Health Clinical Center (CC)||Terminated|July 1999|January 2013|Actual|December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|N/A|No|||January 2013|February 19, 2014|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001827||209883|
NCT00001756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980027|Study of Mast Cell Precursors|The Characterization of CD34+ Derived Mast Cell Precursors Mobilized by Administration of Granulocyte Colony Stimulating Factor and Plerixafor||National Institutes of Health Clinical Center (CC)||Recruiting|November 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001756||209924|
NCT00002204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095|A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults|A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002204||209537|
NCT00002218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278B|A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients|A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002218||209523|
NCT00001747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980112|Racial Differences in Control of Blood Vessel Tone and Blood Flow|Racial Differences in Flow Mediated Vasodilator Function||National Institutes of Health Clinical Center (CC)||Completed|May 1998|March 2001||||N/A|Observational|N/A||||108|||Both|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001747||209931|
NCT00001807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990088|(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy|(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 1999|||||N/A|Observational|Time Perspective: Prospective|||Actual|50|||Both|4 Years|20 Years|No|||September 2015|October 10, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001807||209892|
NCT00001785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980160|Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)|Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a||National Institutes of Health Clinical Center (CC)||Completed|September 1998|September 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||12|||Both|N/A|N/A|No|||September 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001785||209900|
NCT00001959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000042|Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)|Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study||National Institutes of Health Clinical Center (CC)|No|Completed|December 1999|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2012|May 16, 2014|January 18, 2000|No|Yes||No|June 16, 2010|https://clinicaltrials.gov/show/NCT00001959||209778|No control group, measurement imprecision, results may not applicable to all patients with FSGS, needs histologic evidence to support our findings, Optimal dosage needs to be identified.
NCT00001864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990110|Amblyopia (Lazy Eye) Treatment Study|Amblyopia Treatment Study||National Institutes of Health Clinical Center (CC)||Completed|May 1999|November 2001||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001864||209855|
NCT00001865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990135|HAT in Eye Complications of Behcet's Disease|A Study to Investigate the Safety and Efficacy of HAT to Treat the Ocular Complications Related to Behcet's Disease||National Institutes of Health Clinical Center (CC)||Completed|July 1999|June 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||26|||Both|N/A|N/A|No|||June 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001865||209854|
NCT00001765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980104|Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease|Low Intensity Preparative Regimen Followed by HLA-Matched, Mobilized Peripheral Blood Stem Cell Transplantation for Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Completed|April 1998|February 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||February 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001765||209915|
NCT00001909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990115|Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma|Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma||National Institutes of Health Clinical Center (CC)||Completed|May 1999|May 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||May 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001909||209819|
NCT00001818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990118|Combination Drug Treatment of Pediatric HIV Infection|A Pilot Study of Hydroxyurea in Combination With Stavudine, Didanosine and Efavirenz in Pediatric Patients With HIV-1 Infection||National Institutes of Health Clinical Center (CC)||Completed|June 1999|November 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||November 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001818||209886|
NCT00001823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990128|Evaluation for NCI Surgery Branch Clinical Studies|Evaluation for NCI Surgery Branch Clinical Research Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|June 1999|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|6000|||Both|16 Years|80 Years|No|||March 2016|March 22, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001823||209885|
NCT00001797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990027|Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis|Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis||National Institutes of Health Clinical Center (CC)||Completed|January 1999|September 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||36|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001797||209896|
NCT00001803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990053|Von Hippel-Lindau Disease Genetic Epidemiology Study|Von Hippel-Lindau (VHL) Disease Genetic Epidemiology Study||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 1999|||||N/A|Observational|Time Perspective: Retrospective|||Actual|546|||Both|13 Years|100 Years|No|||November 2015|November 19, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001803||209895|
NCT00001805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990071|A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab|A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab||National Institutes of Health Clinical Center (CC)||Completed|March 1999|June 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001805||209894|
NCT00002223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|245E|A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients|Ritonavir (ABT-538)/Indinavir Combination Treatment in HIV-Infected Patients Previously Receiving Indinavir 800 mg TID||Abbott||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002223||209518|
NCT00002190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229N|A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients|A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002190||209551|
NCT00002191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274A|A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis|A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002191||209550|
NCT00001748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980122|HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies|HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies||National Institutes of Health Clinical Center (CC)||Completed|June 1998|May 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001748||209930|
NCT00002234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232J|Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients|A Phase II, 48 Week, Open-Label Study Designed to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Simplified Dosing Regimen of Preveon (Adefovir Dipivoxil; bis-POM PMEA), Videx (Didanosine; ddI), Sustiva (Efavirenz; DMP-266), and Epivir (Lamivudine; 3TC) Administered Once Daily for the Treatment of HIV-1 Infection||Bristol-Myers Squibb||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||25|||Both|13 Years|N/A|No|||November 2004|June 23, 2005|August 30, 2001||||||https://clinicaltrials.gov/show/NCT00002234||209507|
NCT00001752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980158|Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women|Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women||National Institutes of Health Clinical Center (CC)||Completed|September 1998|July 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001752||209927|
NCT00001753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980166|Study of the Effects of Temperature on Metabolism in Human Muscle|Study of Temperature Effects on Skeletal Muscle Aerobic Energy Metabolism||National Institutes of Health Clinical Center (CC)||Completed|September 1998|November 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||17|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001753||209926|
NCT00001913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990008|The Impact of Familiarity and Emotional Attachment on the Visual Processing of Faces|The Impact of Familiarity and Emotional Attachment on the Visual Processing of Faces||National Institutes of Health Clinical Center (CC)||Completed|October 1998|October 2003||||N/A|Observational|N/A||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001913||209815|
NCT00002185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259F|A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3|A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||20|||Both|13 Years|N/A|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002185||209556|
NCT00001937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000014|Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients|A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant||National Institutes of Health Clinical Center (CC)||Completed|November 1999|December 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||800|||Both|N/A|N/A|No|||November 1999|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001937||209794|
NCT00001888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990076|Sample Collections From the Airways of Asthmatic Patients|Fiberoptic Bronchoscopy in Patients With Asthma||National Institutes of Health Clinical Center (CC)||Recruiting|March 1999|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|18 Years|75 Years|No|||July 2015|September 19, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001888||209834|
NCT00001783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980115|Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy|Neuroanatomical and Neurophysiological Basis of Motor Recovery Associated With Treatment of Recent Stroke Using Amphetamine and Physical Therapy||National Institutes of Health Clinical Center (CC)||Completed|April 1998|June 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||34|||Both|N/A|N/A|No|||June 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001783||209902|
NCT00001764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980092|Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions|Mycophenolate Mofetil in the Treatment of Wegener's Granulomatosis and Related Vasculitides||National Institutes of Health Clinical Center (CC)||Completed|April 1998|June 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||June 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001764||209916|
NCT00002200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238M|A Study of 1592U89 in HIV-Infected Adults|A 1592U89 Open-Label Protocol for Adult Patients With HIV-1 Infection.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002200||209541|
NCT00002201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|245D|A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients|Safety and Efficacy of Ritonavir (ABT-538) in Combination With Nelfinavir in HIV-Infected Subjects.||Abbott||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002201||209540|
NCT00002202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264E|A Comparison of 141W94 and Indinavir in HIV-Infected Patients|A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 With Indinavir in Combination With Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy, in NRTI-Experienced, Protease Inhibitor (PI)-Naive, HIV-1-Infected Patients.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||460|||Both|18 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002202||209539|
NCT00001915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990034|Study of Attention Deficit/Hyperactivity Disorder Using Transcranial Magnetic Stimulation|Cortical Correlates of Subtle Motor Signs in Attention-Deficit/Hyperactivity Disorder and Healthy Controls||National Institutes of Health Clinical Center (CC)||Completed|January 1999|February 2004||||N/A|Observational|N/A||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001915||209814|
NCT00001876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990056|Lung Disease Associated With Rheumatoid Arthritis|Pulmonary Fibrosis Associated With Rheumatoid Arthritis: Definition of the Natural History of Disease||National Institutes of Health Clinical Center (CC)||Completed|February 1999|||||N/A|Observational|N/A|||Actual|132|||Both|21 Years|N/A|No|||July 2015|August 5, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001876||209845|
NCT00001839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990021|A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome|A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome||National Institutes of Health Clinical Center (CC)||Completed|December 1998|May 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||182|||Both|N/A|N/A|No|||December 1998|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001839||209877|
NCT00002239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T20-206|A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults|A Controlled Phase 2 Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-1 Infected Adults||Hoffmann-La Roche||Completed|May 1999|||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||68|||Both|18 Years|N/A|No|||November 2005|November 14, 2005|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002239||209502|
NCT00002192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|275A|Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.|Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002192||209549|
NCT00001812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990097|A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2|A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2||National Institutes of Health Clinical Center (CC)||Completed|April 1999|August 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||84|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001812||209890|
NCT00001754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980119|Study of Skeletal Disorders and Short Stature|Clinical and Molecular Manifestations of Human Skeletal Dysplasias and Short Stature||National Institutes of Health Clinical Center (CC)||Completed|June 1998|May 2001||||N/A|Observational|N/A||||600|||Both|N/A|N/A|No|||June 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001754||209925|
NCT00002186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270A|Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)|Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||February 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002186||209555|
NCT00002205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264H|An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen|An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002205||209536|
NCT00002206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232F|A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs|A Phase I/II, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 60 Mg Daily Dose of Adefovir Dipivoxil in HIV-Infected Patients Naive to Anti-Retroviral Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|60 Years|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002206||209535|
NCT00002217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280D|A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs|Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002217||209524|
NCT00002232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|A Study of GENEVAX-HIV, a Possible Vaccine|GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular or Intradermal Administration in HIV Seronegative Volunteers||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002232||209509|
NCT00001894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990150|A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy|A Randomized Prospective Comparison of DDD Chamber Pacing and Percutaneous Transluminal Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Associated With Severe Drug-Refractory Symptoms||National Institutes of Health Clinical Center (CC)||Completed|August 1999|September 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||70|||Both|N/A|N/A|No|||September 2002|July 3, 2006|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001894||209829|
NCT00001899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990015|Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy|Immunologic and Virologic Characterization of HIV-Infected Patients After Cessation of Highly Active Antiretroviral Therapy (HAART)||National Institutes of Health Clinical Center (CC)||Completed|December 1998|April 2013||||N/A|Observational|N/A|||Actual|38|||Both|18 Years|N/A|No|||April 2013|January 14, 2014|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001899||209826|
NCT00001841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990061|Magnetic Resonance Angiography (MRA) for the Diagnosis of Atherosclerosis|Contrast Enhanced Resonance Angiography (MRA) in the Diagnosis of Atherosclerotic Disease: A Pilot Technical Development Study||National Institutes of Health Clinical Center (CC)||Completed|March 1999|December 2004||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||December 2004|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001841||209875|
NCT00001777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980046|Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)|A Controlled, Randomized, Double-Blind Trial of Sertraline in Patients With Frontal Lobe Dementia (FLD)||National Institutes of Health Clinical Center (CC)||Completed|December 1997|May 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||November 1998|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001777||209907|
NCT00002213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264F|The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors|A Phase II Study Evaluating the Safety and Antiviral Activity of Combination Therapy With 1592U89, 141W94 and DMP 266 in HIV-1 Infected Subjects With Detectable HIV-1 Plasma RNA Despite Treatment With a Protease Inhibitor Containing Regimen||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||80|||Both|13 Years|N/A|No|||March 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002213||209528|
NCT00001901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990040|Etanercept to Treat Wegener's Granulomatosis|Phase I/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatosis||National Institutes of Health Clinical Center (CC)||Completed|February 1999|March 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||March 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001901||209825|
NCT00002193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264C|Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors|A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of 141W94 Plus Current Nucleoside Therapy Versus Current Nucleoside Therapy Alone in Protease-Naive, HIV-Infected Children||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||210|||Both|6 Months|18 Years|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002193||209548|
NCT00002194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200G|An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.|An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||36|||Both|18 Years|65 Years|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002194||209547|
NCT00001776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980025|Effects of Brain Stimulation on Learning and Reasoning|Can Stimulation of Frontal Cortical Regions Facilitate Performance on Tests of Procedural Implicit Learning and Analogical Reasoning?||National Institutes of Health Clinical Center (CC)||Completed|October 1997|December 2003||||N/A|Observational|N/A||||122|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001776||209908|
NCT00001720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980077|Treatment of Childhood Osteoporosis With Alendronate (Fosamax)|Alendronate Versus Placebo for Idiopathic Juvenile Osteoporosis||National Institutes of Health Clinical Center (CC)||Completed|March 1998|June 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||June 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001720||209954|
NCT00002002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056A|A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome|A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002002||209739|
NCT00002022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004G|Treatment Program for Anemia in AIDS Patients|Treatment Program for Anemia in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||February 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002022||209719|
NCT00001816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990105|The Impact of Starbright World on Children Being Treated at the NIH|The Impact of Starbright World on Children Being Treated at the NIH||National Institutes of Health Clinical Center (CC)||Completed|May 1999|February 2001||||N/A|Observational|N/A||||35|||Both|N/A|N/A|No|||May 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001816||209887|
NCT00001887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990075|Factors Involved in Asthma and Airway Inflammation|The Role of a Novel Aminopeptidase-Like Protein in Asthma||National Institutes of Health Clinical Center (CC)||Completed|March 1999|February 2001||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001887||209835|
NCT00001999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079A|A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS|A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001999||209742|
NCT00002007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067C|A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia|A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002007||209734|
NCT00002054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022C|A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients|A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002054||209687|
NCT00002055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022D|A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP|A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002055||209686|
NCT00001781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980069|Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)|Open-Label Baseline vs. Treatment Trial Evaluating the Safety, Tolerability and Effect on MRI Lesion and Immunology Parameters of CGP 77116 in Patients With Multiple Sclerosis Mark||National Institutes of Health Clinical Center (CC)||Completed|February 1998|March 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001781||209904|
NCT00002028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040A|A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)|A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||August 2007|August 15, 2007|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002028||209713|
NCT00002045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014E|A Prospective Double-Blind Study of Retrovir in Early HIV Infection|A Prospective Double-Blind Study of Retrovir in Early HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002045||209696|
NCT00002046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014G|A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC|A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||May 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002046||209695|
NCT00002047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014H|Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure|Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002047||209694|
NCT00002031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|047A|Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)|Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002031||209710|
NCT00001782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980082|Areas of Brain Responsible for Understanding American Sign Language|Hemispheric Lateralization of Language Receptive Function in the Deaf and in Hearing Individuals Who Learned ASL as First Language||National Institutes of Health Clinical Center (CC)||Completed|March 1998|December 2000||||N/A|Observational|N/A||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001782||209903|
NCT00001718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980135|Facilitation of Oral Bolus Propulsion Using Electropalatography in Patients With Dysphagia|Facilitation of Oral Bolus Propulsion Using Electropalatography in Patients With Dysphagia||National Institutes of Health Clinical Center (CC)||Completed|July 1998|June 2000||||N/A|Interventional|N/A||||10|||Both|N/A|N/A|No|||July 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001718||209956|
NCT00001723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980111|Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases|Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions||National Institutes of Health Clinical Center (CC)|Yes|Completed|May 1998|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|12 Years|17 Years|No|||November 2012|November 15, 2012|November 3, 1999|Yes|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT00001723||209951|
NCT00001873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990046|The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine||National Institutes of Health Clinical Center (CC)||Completed|February 1999|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|10 Years|55 Years|No|||July 2015|August 5, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001873||209847|
NCT00001768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980014|Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)|Childhood Onset Psychiatric Disorders: A Placebo Controlled Double-Blind Crossover Trial of Intravenous Immunoglobulin (IVIg)||National Institutes of Health Clinical Center (CC)||Completed|October 1997|June 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001768||209913|
NCT00001780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980065|Magnetic Stimulation of the Human Nervous System|Stimulation of the Human Central and Peripheral Nervous System With a Magnetic Stimulator||National Institutes of Health Clinical Center (CC)||Completed|February 1998|November 2005||||N/A|Observational|N/A||||450|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001780||209905|
NCT00001722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980103|Fat Tissue Microperfusion to Measure Leptin Secretion and Its Relations With Fat Breakdown in Humans|Adipose Tissue Microperfusion to Assess Leptin Secretion and Its Relations With Lipolysis in Humans||National Institutes of Health Clinical Center (CC)||Completed|April 1998|July 2003||||N/A|Observational|N/A||||70|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001722||209952|
NCT00001728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980146|Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome|A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome||National Institutes of Health Clinical Center (CC)||Completed|August 1998|May 2011|Actual|August 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|40|||Both|6 Years|N/A|No|||May 2011|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001728||209946|
NCT00001835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990171|Oxaliplatin in Cancer Patients With Impaired Kidney Function|A Phase I Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function||National Institutes of Health Clinical Center (CC)||Completed|September 1999|December 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||December 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001835||209880|
NCT00001732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980072|Screening for Studies on Inherited Eye Diseases|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Inherited Ophthalmic Diseases||National Institutes of Health Clinical Center (CC)||Completed|February 1998|May 2008||||N/A|Observational|N/A||||800|||Both|N/A|N/A|No|||May 2008|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001732||209942|
NCT00001725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980042|Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain|Clinical Trials in Orofacial Neuralgias||National Institutes of Health Clinical Center (CC)||Completed|December 1997|January 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001725||209949|
NCT00001726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980116|Study of the Composition of Dental Plaque|Spatial Organization of Viridans Streptococci in Oral Biofilms||National Institutes of Health Clinical Center (CC)||Completed|June 1998|August 2009|Actual|August 2009|Actual|N/A|Observational|N/A||||50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|October 26, 2010|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001726||209948|
NCT00001965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000034|Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)|Double Blind Placebo Controlled Study of Cyclosporin A in Patients With Left Ventricular Hypertrophy Caused by Sarcomeric Gene Mutations||National Institutes of Health Clinical Center (CC)||Completed|December 1999|February 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||32|||Both|N/A|N/A|No|||November 1999|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001965||209772|
NCT00001734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980085|Screening for NEI Clinical Studies|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Ocular Inflammatory or Immunologic Diseases||National Institutes of Health Clinical Center (CC)||Completed|March 1998|October 2008||||N/A|Observational|N/A||||3000|||Both|2 Years|N/A|No|||October 2008|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001734||209940|
NCT00001994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101A|A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine|A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||March 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001994||209747|
NCT00001995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|048C|A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS|A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||November 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001995||209746|
NCT00002000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104A|A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients|A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002000||209741|
NCT00002001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052B|The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease|The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||September 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002001||209740|
NCT00001761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980059|Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis|Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis||National Institutes of Health Clinical Center (CC)||Completed|February 1998|April 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||January 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001761||209919|
NCT00002048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014J|The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)|The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||September 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002048||209693|
NCT00002005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064B|A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex|A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002005||209736|
NCT00001790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990007|Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia|Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia||National Institutes of Health Clinical Center (CC)||Completed|October 1998|September 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||October 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001790||209897|
NCT00002032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|048A|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|18 Years|N/A|No|||January 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002032||209709|
NCT00002050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015D|A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients|A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002050||209691|
NCT00001721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980081|Study of Smith-Lemli-Opitz Syndrome|Clinical and Basic Investigations Into Smith-Lemli-Opitz Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|March 1998|||||N/A|Observational|N/A|||Anticipated|200|||Both|N/A|N/A|No|||September 2015|September 18, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001721||209953|
NCT00001727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980145|Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome|Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|August 1998|||||N/A|Observational|N/A|||Anticipated|300|||Both|N/A|105 Years|No|||August 2015|March 24, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001727||209947|
NCT00001885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990069|Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis|Pulmonary Fibrosis Associated With Rheumatoid Arthritis: Identification of Genetic Polymorphisms||National Institutes of Health Clinical Center (CC)||Completed|March 1999|December 2007||||N/A|Observational|N/A||||400|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2007|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001885||209837|
NCT00001738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980152|Vascular Endothelial Growth Factor (VEGF) in Uveitis|A Pilot Study to Demonstrate the Presence of Vascular Endothelial Growth Factor (VEGF) in Uveitic Cystoid Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|August 1998|June 2000||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001738||209936|
NCT00001729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980003|Combination Drug Therapy for Patients With Hepatitis C|Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C||National Institutes of Health Clinical Center (CC)||Completed|October 1997|September 2002||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||September 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001729||209945|
NCT00001757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980028|An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections|An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections||National Institutes of Health Clinical Center (CC)||Completed|November 1997|July 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||December 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001757||209923|
NCT00001758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980031|Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz|Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz||National Institutes of Health Clinical Center (CC)||Completed|November 1997|August 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||August 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001758||209922|
NCT00001741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980029|Study of Inherited Changes of Receptors Located on Blood Vessels|Study of Vascular Responsiveness in Subjects With Polymorphisms of the Angiotensin II Type I Receptor Gene||National Institutes of Health Clinical Center (CC)||Completed|November 1997|April 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001741||209934|
NCT00001996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053B|A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole|A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||May 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001996||209745|
NCT00001997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072B|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001997||209744|
NCT00001733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980076|Screening for Studies on Retinovascular Diseases|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Retinovascular Diseases||National Institutes of Health Clinical Center (CC)||Completed|March 1998|July 2008||||N/A|Observational|N/A||||2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|September 26, 2015|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001733||209941|
NCT00001766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980147|Drug Interactions Among Anti-HIV Agents|Pharmacokinetic Interactions Between Ritonavir, Amprenavir and Efavirenz and Nelfinavir, Amprenavir, and Efavirenz in People Infected With HIV||National Institutes of Health Clinical Center (CC)||Completed|August 1998|August 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||22|||Both|N/A|N/A|No|||August 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001766||209914|
NCT00001813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990099|Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy|Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy||National Institutes of Health Clinical Center (CC)||Recruiting|April 1999|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|700|||Both|1 Year|99 Years|Accepts Healthy Volunteers|||January 2016|February 10, 2016|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001813||209889|
NCT00001774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980013|Vasodilation in Patients With Fabry's Disease|An Investigation of Endothelium-Derived Vasodilation in Patients With Fabry's Disease||National Institutes of Health Clinical Center (CC)||Completed|October 1997|October 2000||||N/A|Observational|N/A||||48|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001774||209909|
NCT00002006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067A|A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility|A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002006||209735|
NCT00002029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041A|Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent|Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent||Abbott||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002029||209712|
NCT00002019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051A|Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome|Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002019||209722|
NCT00002020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014L|Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC|Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002020||209721|
NCT00002021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020F|An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies|An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||October 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002021||209720|
NCT00001830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990143|Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants|Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Completed|July 1999|May 2015|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|110|||Both|12 Years|75 Years|No|||May 2015|May 20, 2015|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001830||209882|
NCT00001759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980044|Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography|Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography||National Institutes of Health Clinical Center (CC)||Completed|December 1997|January 2001||||N/A|Observational|N/A||||95|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001759||209921|
NCT00001863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990059|Leflunomide to Treat Uveitis|Pilot Study of Leflunomide for the Treatment of Uveitis||National Institutes of Health Clinical Center (CC)||Completed|March 1999|February 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||16|||Both|N/A|N/A|No|||February 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001863||209856|
NCT00002008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067D|An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia|An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|50 Years|No|||January 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002008||209733|
NCT00002009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067E|A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia|A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Male|18 Years|50 Years|No|||June 1988|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002009||209732|
NCT00001760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980049|Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals|Determination of Cytokine Production Patterns in the Skin of Patients With Systemic Mastocytosis and Atopic Dermatitis Using the Suction Blister Technique||National Institutes of Health Clinical Center (CC)||Completed|January 1998|December 2001||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2001|December 12, 2007|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001760||209920|
NCT00001770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980079|Progestin (Progesterone-Like Hormones) Induced Dysphoria (Depressed Mood, Irritability, Anxiety)|The Phenomenology and Biophysiology of Progestin-Induced Dysphoria||National Institutes of Health Clinical Center (CC)||Completed|March 1998|March 2003||||N/A|Observational|N/A||||50|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001770||209912|
NCT00001735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980088|Gene Therapy for Gyrate Atrophy|Phase I Study in the Safety and Efficacy of Transduced Keratinocytes for Possible Treatment of Gyrate Atrophy||National Institutes of Health Clinical Center (CC)||Completed|April 1998|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001735||209939|
NCT00001789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990133|BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis|An Open-Label, Multiple-Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BG9588 (Anti-CD40L Antibody) in Subjects With Proliferative Lupus Glomerulonephritis (SLE-GN)||National Institutes of Health Clinical Center (CC)||Completed|June 1999|May 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001789||209898|
NCT00001840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990041|Evaluation of Treated and Untreated Stroke|Evaluation of Treated and Untreated Stroke||National Institutes of Health Clinical Center (CC)||Completed|February 1999|July 2001||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||January 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001840||209876|
NCT00001762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980070|Magnetic Resonance Imaging of the Face and Bones|Magnetic Resonance Imaging to Study Avascular Necrosis in HIV-Infected Subjects||National Institutes of Health Clinical Center (CC)||Completed|February 1998|July 2013||||N/A|Observational|N/A|||Actual|532|||Both|18 Years|N/A|No|||July 2013|August 20, 2013|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001762||209918|
NCT00001763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980091|Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection|Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection||National Institutes of Health Clinical Center (CC)||Completed|April 1998|March 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||April 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001763||209917|
NCT00001998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103A|Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)|Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00001998||209743|
NCT00002030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022E|An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients|An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002030||209711|
NCT00001740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980016|Evaluation of Left Ventricular Volumes by Real-Time 3-Dimensional Echocardiography|Evaluation of Left Ventricular Volumes by Real-Time 3-Dimensional Echocardiography||National Institutes of Health Clinical Center (CC)||Completed|October 1997|October 2000||||N/A|Observational|N/A||||240|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001740||209935|
NCT00001832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990158|Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma Using Cloned Lymphocytes Following the Administration of a Non-Myeloablative But Lymphocyte Depleting Regimen||National Institutes of Health Clinical Center (CC)|Yes|Completed|August 1999|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|15||Actual|170|||Both|7 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 19, 2012|November 3, 1999|Yes|Yes||No|November 7, 2012|https://clinicaltrials.gov/show/NCT00001832||209881|
NCT00001814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990101|Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples|Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples||National Institutes of Health Clinical Center (CC)||Completed|April 1999|January 2001||||N/A|Observational|N/A||||600|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001814||209888|
NCT00001874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990048|Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy|Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy||National Institutes of Health Clinical Center (CC)||Completed|February 1999|August 2009|Actual|August 2009|Actual|N/A|Observational|N/A||||400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001874||209846|
NCT00002049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015B|Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients|Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002049||209692|
NCT00002039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020A|An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients|An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002039||209702|
NCT00002040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012L|Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002040||209701|
NCT00001771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980094|I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers|I-123 Beta-CIT SPECT Studies of Dopamine and Serotonin Transporters in Neuropsychiatric Patients and Normal Volunteers||National Institutes of Health Clinical Center (CC)||Completed|May 1998|May 2003||||N/A|Observational|N/A||||112|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001771||209911|
NCT00002033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045A|A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease|A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|70 Years|No|||February 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002033||209708|
NCT00002034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029F|A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS|A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||January 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002034||209707|
NCT00002035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039B|Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine|Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine||Bristol-Myers Squibb||Completed||April 1992|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|12 Years|N/A|No|||August 2011|August 4, 2011|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002035||209706|
NCT00001772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980156|Evaluation of Patients With Rapid Cycling Bipolar Disorder (RCBD)|Evaluation of Patients With Rapid Cycling Bipolar Disorder||National Institutes of Health Clinical Center (CC)||Completed|September 1998|July 2001||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||August 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001772||209910|
NCT00001742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980064|The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients|The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients||National Institutes of Health Clinical Center (CC)||Completed|February 1998|January 2001||||N/A|Observational|N/A||||75|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001742||209933|
NCT00001746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980102|Screening for Inherited Heart Disease|Evaluation of Patients With Known or Suspected Inherited Heart Disease (Screening Protocol)||National Institutes of Health Clinical Center (CC)||Completed|April 1998|April 2003||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2003|March 4, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001746||209932|
NCT00002062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011A|Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients|Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002062||209679|
NCT00002388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238G|A Study of 1592U89 in HIV-Infected Patients|A Study to Evaluate the Single-Dose and Steady-State Pharmacokinetics/Dynamics of 1592U89 and Its Active Moiety, 1144U88 5'-Triphosphate (1144U88-TP) Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002388||209354|
NCT00002424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300B|A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine|A Multicenter, Double-Blind, Randomized Pilot Study to Compare the Safety and Activity of L-756423/Indinavir, 1600/800 Mg Qd or 800/400 Mg Bid Versus Indinavir, 800 Mg q8h, All in Combination With Stavudine and Lamivudine||NIH AIDS Clinical Trials Information Service||Suspended||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||186|||Both|18 Years|N/A|No|||April 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002424||209319|
NCT00001948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000046|A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy|A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Completed|December 1999|February 2002||||N/A|Observational|N/A||||70|||Both|N/A|N/A|No|||February 2002|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001948||209788|
NCT00002389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238D|The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs|A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination With Lamivudine (3TC) and Zidovudine (ZDV) Versus 3TC/ZDV in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects With CD4+ Counts >= 100 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||210|||Both|13 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002389||209353|
NCT00002348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241A|A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma|Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002348||209394|
NCT00002070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005A|Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis|Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002070||209671|
NCT00002413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292B|A Study of MKC-442 in HIV-Positive Patients|An Open Label Study of MKC-442 in at Least Triple Drug Combination in Patients Previously Treated With Nucleoside Reverse Transcriptase and Protease Inhibitors and Who Are Naive to Non-Nucleoside Reverse Transcriptase Inhibitors||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002413||209329|
NCT00002073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004E|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002073||209668|
NCT00002074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012D|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002074||209667|
NCT00001922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990009|Sensory Function in Idiopathic Voice Disorders|Sensory Function in Idiopathic Voice Disorders||National Institutes of Health Clinical Center (CC)||Completed|November 1998|||September 2009|Actual|N/A|Observational|N/A||||370|||Both|20 Years|80 Years|No|||September 2009|March 15, 2011|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001922||209807|
NCT00001978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890152|Determination of Kidney Function|Determination of Glomerular Filtration Rate, Effective Renal Plasma Flow and Glomerular Capillary Wall Permselectivity||National Institutes of Health Clinical Center (CC)||Recruiting|August 1989|||||N/A|Observational|N/A|||Anticipated|9999999|||Both|7 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 20, 2000||No||No||https://clinicaltrials.gov/show/NCT00001978||209761|
NCT00001979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920156|Immune System Related Kidney Disease|Studies of Immunologically-Mediated Kidney Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|April 1992|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|N/A|N/A|No|||September 2015|October 6, 2015|January 20, 2000||No||No||https://clinicaltrials.gov/show/NCT00001979||209760|
NCT00001938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000018|A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)|A Pilot Study of Proteomic Evaluation of Epithelial Ovarian Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile Associated With Relapse||National Institutes of Health Clinical Center (CC)||Completed|November 1999|||||N/A|Observational|Time Perspective: Prospective|||Actual|26|||Female|18 Years|N/A|No|||June 2015|June 27, 2015|January 18, 2000||No||No||https://clinicaltrials.gov/show/NCT00001938||209793|
NCT00002390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238H|A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients|A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002390||209352|
NCT00002391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238L|The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs|A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|3 Months|12 Years|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002391||209351|
NCT00001983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000066|Eligibility Screening for National Institute of Dental and Craniofacial Research Studies|Screening Protocol to Evaluate Patients for Approved Studies||National Institutes of Health Clinical Center (CC)||Completed|January 2000|December 2003||||N/A|Observational|N/A||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2003|March 3, 2008|January 26, 2000||||No||https://clinicaltrials.gov/show/NCT00001983||209757|
NCT00001984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000013|Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys|Tolerance Induction Following Human Renal Transplantation Using Treatment With a Humanized Monoclonal Antibody Against CD52 (Campath-1H)||National Institutes of Health Clinical Center (CC)|Yes|Completed|November 1999|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||September 2010|September 13, 2010|January 26, 2000||||No|September 13, 2010|https://clinicaltrials.gov/show/NCT00001984||209756|
NCT00001893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990140|Study of TNFR:Fc (Enbrel) in the Treatment of Asthma|A Clinical Trial of TNFR:Fc in a Segmental Allergen Challenge Model of Asthma||National Institutes of Health Clinical Center (CC)||Completed|August 1999|||December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years|No|||June 2008|June 25, 2010|November 3, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00001893||209830|
NCT00001960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000007|Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle|Controlled Cross-Over Study of DDD Pacemaker Therapy in Symptomatic Children With Obstructive Hypertrophic Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|November 1999|December 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||December 2002|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001960||209777|
NCT00002423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264M|A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir|A Phase II, Open-Label Trial for Treatment of HIV Infection in Subjects Who Have Failed Initial Combination Therapy With Regimens Containing Indinavir or Nelfinavir: Combination Therapy With 3TC (150 Mg BID), Abacavir (300 Mg BID) and Amprenavir (1200 Mg BID) Plus Either Nelfinavir (1250 Mg BID) or Indinavir (800 Mg TID) for 48 Weeks||NIH AIDS Clinical Trials Information Service||Completed|March 1999|||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||December 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002423||209320|
NCT00001927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990045|Study of Abnormal Blood Clotting in Children With Stroke|Study of Abnormal Acquired and Genetic Coagulation Factors in Children With Porencephaly and Stroke||National Institutes of Health Clinical Center (CC)||Completed|February 1999|May 2011||||N/A|Observational|N/A|||Actual|130|||Both|N/A|45 Years|No|||May 2011|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001927||209803|
NCT00002080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109A|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||April 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002080||209661|
NCT00002081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031E|Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease|Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002081||209660|
NCT00002082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058F|Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study|Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002082||209659|
NCT00002083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115A|Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS|Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002083||209658|
NCT00001946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000028|Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis|A Comparison of Contrast Enhanced Magnetic Resonance Angiography (MRA) and Conventional Angiography in the Diagnosis of Atherosclerotic Disease: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|December 1999|September 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||September 2002|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001946||209789|
NCT00001911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990147|Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections|Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections||National Institutes of Health Clinical Center (CC)||Completed|July 1999|July 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||July 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001911||209817|
NCT00001973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970055|Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome|Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues||National Institutes of Health Clinical Center (CC)||Completed|December 1996|December 2008||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||December 2008|September 26, 2015|January 18, 2000||No||No||https://clinicaltrials.gov/show/NCT00001973||209765|
NCT00001981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850082|The Treatment and Natural History of Acromegaly|Acromegaly Treatment and Natural History||National Institutes of Health Clinical Center (CC)||Recruiting|April 1985|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|January 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00001981||209759|
NCT00002088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|083A|Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial|Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002088||209653|
NCT00002096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|059E|A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine|A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||November 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002096||209645|
NCT00001928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990072|Intravenous Levodopa for the Diagnosis of Parkinson's Disease|Intravenous Levodopa in Parkinsonism||National Institutes of Health Clinical Center (CC)||Completed|March 1999|July 2000||||N/A|Observational|N/A||||25|||Both|N/A|N/A|No|||March 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001928||209802|
NCT00002404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291A|The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients|The Effect of Treatment With Valacyclovir 500 mg BID on the Detection of HIV From Genital HSV Lesions in HIV-Infected Patients: A Double-Blind Crossover Study||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 1999|January 24, 2008|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002404||209338|
NCT00002392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279A|A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART|A Study to Investigate the Potential of Thalidomide Treatment to Enhance Immune Responses in HIV-Infected Individuals Who Are Receiving Highly Active Antiretroviral Therapy.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002392||209350|
NCT00002393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281A|A Study of Indinavir Taken With or Without DMP 266|A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||300|||Both|13 Years|60 Years|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002393||209349|
NCT00001961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000025|MRI Evaluation of Chest Pain|MRI Evaluation of Chest Pain Compatible With Myocardial Ischemia||National Institutes of Health Clinical Center (CC)||Completed|December 1999|January 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||360|||Both|N/A|N/A|No|||January 2005|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001961||209776|
NCT00001962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000029|A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure|A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia||National Institutes of Health Clinical Center (CC)|Yes|Terminated|November 1999|September 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|2 Years|N/A|No|||April 2015|April 28, 2015|January 18, 2000||No|DSMB recommended closing the study and publishing the results|No|April 20, 2011|https://clinicaltrials.gov/show/NCT00001962||209775|
NCT00002086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052C|A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection|A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||256|||Both|13 Years|N/A|No|||October 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002086||209655|
NCT00002087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084A|Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals|Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002087||209654|
NCT00002398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232G|Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations|A Randomized, Open-Label Expanded Access Program to Evaluate the Safety of Preveon (Adefovir Dipivoxil) at Two Dose Levels When Used in Combination With Other Antiretroviral Agents for the Treatment of Patients With HIV Infection Who Have Failed Other Antiretroviral Therapy and Have Limited Treatment Options||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||December 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002398||209344|
NCT00002399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288A|A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients|A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 Versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|65 Years|No|||January 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002399||209343|
NCT00001971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910214|Evaluation of Patients With Liver Disease|Evaluation of Patients With Liver Disease||National Institutes of Health Clinical Center (CC)||Recruiting|September 1991|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|2 Years|N/A|No|||May 2015|May 23, 2015|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00001971||209767|
NCT00001958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000040|Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)|Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia||National Institutes of Health Clinical Center (CC)||Completed|December 1999|February 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||February 2002|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001958||209779|
NCT00002386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246J|Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia|A Multiclinic, Open Pilot Study to Investigate the Effect of Combination Antiretroviral Therapy Including Indinavir Sulfate on Coagulation Factors, on Platelet Aggregation, and on Factor VIII/IX Half-Life in HIV-1 Seropositive Patients With Hemophilia A or B||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Primary Purpose: Treatment||||55|||Male|16 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002386||209356|
NCT00002090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058H|An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)|An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002090||209651|
NCT00002091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118A|An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent|An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||October 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002091||209650|
NCT00002422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303A|A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy|A Phase I/II, Open-Label Study of the Safety, Tolerance, Pharmacokinetics, Drug-Interaction and Anti-HIV Activity of Intramuscularly Administered Alpha-Epi-Br (HE2000) in HIV-Infected Patients on Salvage Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||April 2002|June 24, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002422||209321|
NCT00002097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103B|A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.|A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002097||209644|
NCT00002063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|016A|Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)|Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002063||209678|
NCT00001923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990022|Transcranial Magnetic Stimulation for the Treatment of Phantom Pain|Phantom Pain: A Therapeutic Trial Using Transcranial Magnetic Stimulation||National Institutes of Health Clinical Center (CC)||Completed|December 1998|December 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||December 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001923||209806|
NCT00001966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000054|Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome|A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome||National Institutes of Health Clinical Center (CC)||Completed|January 2000|January 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||January 2000|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001966||209771|
NCT00002095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|059D|A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus|A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||700|||Both|13 Years|N/A|No|||November 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002095||209646|
NCT00002405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264G|A Study of Amprenavir in HIV-Infected Patients|Amprenavir (141W94) Open Label Protocol for Subjects With HIV-1 Infection Who Have Experienced Treatment Failure or Are Intolerant to Previous Protease Inhibitor Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|4 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002405||209337|
NCT00001933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990139|Nefiracetam in the Treatment of Alzheimer's Disease|Nefiracetam Therapy of Alzheimer's Type Dementia||National Institutes of Health Clinical Center (CC)||Completed|July 1999|January 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001933||209797|
NCT00001967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000020|Intermittent Versus Continuous Medication in the Treatment of HIV|Immunologic and Virologic Studies of Intermittent Versus Continuous HAART in the Treatment of HIV Disease||National Institutes of Health Clinical Center (CC)||Completed|November 1999|November 2004||||Phase 4|Interventional|Primary Purpose: Treatment||||123|||Both|N/A|N/A|No|||November 2004|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001967||209770|
NCT00002387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246K|The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz|A Multicenter, Open, Randomized, Forty-Eight-Week, Pilot Study to Evaluate the Activity, Safety, and Pharmacokinetics of Indinavir Sulfate, 1200 Mg q 12h and DMP 266, 300 Mg q 12h Versus Indinavir Sulfate, 1000 Mg q 8h and DMP 266, 600 Mg q.h.s.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002387||209355|
NCT00002414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|289B|Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia|Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002414||209328|
NCT00001977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000056|The Effect of Acetylcholine on Memory and Attention|Cholinergic Modulation of Human Memory and Attention: Functional Neuroimaging Studies||National Institutes of Health Clinical Center (CC)||Completed|January 2000|April 2001||||N/A|Observational|N/A||||70|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|January 20, 2000||||No||https://clinicaltrials.gov/show/NCT00001977||209762|
NCT00001934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990169|Zenapax to Treat Multiple Sclerosis|Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II Trial||National Institutes of Health Clinical Center (CC)||Completed|September 1999|September 2008|Actual|August 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|65 Years|No|||August 2011|August 4, 2011|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001934||209796|
NCT00002397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229P|A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease|An Exploratory Study of Fortovase (Saquinavir) Soft Gelatin Capsules (SGC) Plus d4T and 3TC or Fortovase (Saquinavir) SGC Plus Nelfinavir and d4T in Patients With HIV-1 Associated Nephropathy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002397||209345|
NCT00002412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292C|A Study of MKC-442 in Combination With Other Anti-HIV Drugs|A Randomized, Double-Blind Study of MKC-442 Combined With Stavudine, Didanosine, and Hydroxyurea in HIV-Infected Patients Who Are Protease Inhibitor Experienced and Non-Nucleoside Reverse Transcriptase Inhibitor Naive||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002412||209330|
NCT00002059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008E|A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers|A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002059||209682|
NCT00002064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021A|Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse|Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002064||209677|
NCT00002354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246D|A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients|One Year Study in HIV-1 Seropositive, AZT-Experienced Patients to Evaluate the Safety and Efficacy of MK-639 Administered Concomitantly With Stavudine (d4T)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||540|||Both|18 Years|60 Years|No|||January 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002354||209388|
NCT00001925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990030|Effect of Alcohol on Tremors|Effect of Alcohol on Physiologic and Pathologic Tremors||National Institutes of Health Clinical Center (CC)||Completed|January 1999|July 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||23|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001925||209805|
NCT00001926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990031|The Connection Between Areas in the Brain of Blind Patients|Connectivity of Occipital and Somatosensory Cortical Areas in Blind Subjects||National Institutes of Health Clinical Center (CC)||Completed|April 1999|November 2003||||N/A|Observational|N/A||||45|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2003|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001926||209804|
NCT00001916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990049|Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression|Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression||National Institutes of Health Clinical Center (CC)||Completed|March 1999|August 2000||||N/A|Observational|N/A||||17|||Both|N/A|N/A|No|||February 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001916||209813|
NCT00002417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264J|A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications|An Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who Are Intolerant (Hyperlipidemia With or Without Lipodystrophy) But Not Failing Their Current Protease Inhibitor Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention|||||||Both|13 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002417||209325|
NCT00002426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232K|A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Adefovir Dipivoxil as Intensification Therapy in Combination With Highly Active Antiretroviral Therapy (HAART) in HIV Infected Patients With HIV-1 RNA > 50 and <= 400 Copies/Ml||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||390|||Both|N/A|N/A|No|||December 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002426||209317|
NCT00002418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292D|The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors|A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Transcriptase Inhibitor Naive Patients Who Failed Previous Protease Inhibitor Treatment||Bristol-Myers Squibb||Terminated||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||March 2000|August 13, 2008|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002418||209324|
NCT00002052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019A|Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients|Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002052||209689|
NCT00002053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022B|A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP|A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002053||209688|
NCT00002238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002A|Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen|Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002238||209503|
NCT00002222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268B|A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS|An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002222||209519|
NCT00002037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062B|Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study|Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||May 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002037||209704|
NCT00002056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023A|A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS|A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002056||209685|
NCT00001976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000059|Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection|CMV Real-Time PCR Versus PP65 Antigenemia in Diagnosing Cytomegalovirus Disease in Hematopoietic Stem Cell Transplant Patients||National Institutes of Health Clinical Center (CC)||Completed|January 2000|February 2003||||N/A|Observational|N/A||||180|||Both|N/A|N/A|No|||February 2003|March 3, 2008|January 20, 2000||||No||https://clinicaltrials.gov/show/NCT00001976||209763|
NCT00002165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259B|Viracept Expanded Access Program|Viracept Expanded Access Program||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||October 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002165||209576|
NCT00002184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232E|A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient|A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 100/mm3 and HIV-1 RNA Copy Numbers >= 5,000 Copies/Ml and Prior RTI Therapy But No Prior PI Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|16 Years|N/A|No|||October 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002184||209557|
NCT00001975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000051|Study of Skin Tumors in Tuberous Sclerosis|Cutaneous Tumorigenesis in Patients With Tuberous Sclerosis||National Institutes of Health Clinical Center (CC)||Recruiting|January 2000|||||N/A|Observational|N/A|||Anticipated|130|||Both|18 Years|90 Years|No|||February 2016|February 19, 2016|January 20, 2000||No||No||https://clinicaltrials.gov/show/NCT00001975||209764|
NCT00002195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264D|A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients|A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination With Retrovir and Epivir Compared to Retrovir and Epivir Alone in Patients With HIV Infection.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||290|||Both|18 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002195||209546|
NCT00002215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292A|A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive|A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002215||209526|
NCT00002228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295A|A Study of T-20 in HIV-Positive Adults|A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||78|||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002228||209513|
NCT00001918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990136|L-5-HTP-Related EMS|L-5-Hydroxy-Tryptophan-Related Eosinophilia-Myalgia Syndrome (EMS): Clinical Patient Evaluation||National Institutes of Health Clinical Center (CC)||Completed|July 1999|August 2000||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||June 1999|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001918||209811|
NCT00002235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259G|A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors|A Phase II, 48-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of a Simplified Dosing Regimen of Viracept (Nelfinavir Mesylate) 1250 Mg BID, Crixivan (Indinavir Sulfate) 1200mg q12h, and Sustiva (Efavirenz; DMP-266) 600 Mg q24h for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Transcriptase Inhibitor and Protease Inhibitor Naive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|13 Years|N/A|No|||March 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002235||209506|
NCT00002207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039D|A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients|A Randomized, Double-Blind Study of the Antiviral Activity of Once-Daily and Twice-Daily Dosing of Didanosine in Combination With Twice-Daily Dosing of Stavudine in HIV-Infected Subjects||Bristol-Myers Squibb||Completed|February 2004|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 13, 2011|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002207||209534|
NCT00002209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|289A|Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy|Multiple Ascending Dose Pharmacokinetics of CPI-1189 (LU 02-584) in Fasted, HIV Infected, Male Volunteers on Combined Reverse Transcriptase and Protease Inhibitor Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Male|18 Years|50 Years|No|||December 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002209||209532|
NCT00002210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228D|A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies|Phase II Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Effect of Delavirdine Mesylate (Rescriptor), in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1-Infected Neonates, Infants, and Children||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment||||24|||Both|1 Month|15 Years|No|||January 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002210||209531|
NCT00001917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990073|Brain Imaging in Elderly People and Individuals With Alzheimer's Disease|M2 Receptor Measurements in Aging and in Alzheimer's Disease||National Institutes of Health Clinical Center (CC)||Completed|April 1999|April 2005||||N/A|Observational|N/A||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2005|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001917||209812|
NCT00001956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000055|Influence of Genetics in Pain Sensitivity|||National Institutes of Health Clinical Center (CC)||Completed|January 2000|February 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||800|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2005|June 29, 2006|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001956||209781|
NCT00001936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990178|Electrical Muscle Stimulation to Aid Swallowing in Dysphagia|Feasibility of Neuromuscular Stimulation for Laryngeal Elevation During Swallowing||National Institutes of Health Clinical Center (CC)||Completed|September 1999|||August 2009|Actual|N/A|Observational|N/A||||155|||Both|N/A|90 Years|Accepts Healthy Volunteers|||August 2009|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001936||209795|
NCT00002057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026A|Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC|Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002057||209684|
NCT00001903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990083|Prevention of RSV Infections in Bone Marrow Transplant Recipients|Prevention of RSV Infections in Bone Marrow Transplant Recipients||National Institutes of Health Clinical Center (CC)||Completed|April 1999|May 2001||||Phase 4|Interventional|Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001903||209824|
NCT00001904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990085|Assessment of a B-Mode Ultrasound Technique for the Measurement of Carotid Artery Intima-Media Thickness|Assessment of a B-Mode Ultrasound Technique for the Measurement of Carotid Artery Intima-Media Thickness||National Institutes of Health Clinical Center (CC)||Completed|April 1999|September 2000||||N/A|Observational|N/A||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001904||209823|
NCT00001889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990077|Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease|Comparison of Myocardial Contrast Echo With Dobutamine Echo in Diagnosis of Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|March 1999|March 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||150|||Both|N/A|N/A|No|||February 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001889||209833|
NCT00002174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262A|Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients|Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002174||209567|
NCT00001982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930159|History of Hepatitis C in Volunteer Blood Donors|Natural History of Chronic Hepatitis C Among Volunteer Blood Donors||National Institutes of Health Clinical Center (CC)||Completed|June 1993|April 2000||||N/A|Observational|N/A||||60|||Both|N/A|N/A|No|||May 1999|March 3, 2008|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00001982||209758|
NCT00002214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286A|Phase I Trial of S-1153 in Patients With HIV Infection|Phase I Trial of S-1153 in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002214||209527|
NCT00002229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229Q|Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients|A Phase IV, Non-Comparative Study to Evaluate FORTOVASE (Saquinavir) Soft Gel Capsule (SGC) TID Regimen in Combination With Two NRTI's in HIV-1 Infected Women and Men||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|16 Years|64 Years|No|||December 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002229||209512|
NCT00002198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238F|A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients|A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 1592U89 and Ethanol Following Their Co-Administration to HIV-Infected Subjects.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002198||209543|
NCT00001952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000017|Using a Narcotic to Enhance the Numbing Effect of the Local Anesthetic Lidocaine on Inflamed Molar Teeth|Analgesic Effects of Peripherally Administered Opioids in a Clinical Model of Chronic Inflammation||National Institutes of Health Clinical Center (CC)||Completed|November 1999|December 2002||||N/A|Observational|N/A||||275|||Both|N/A|N/A|No|||December 2002|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001952||209785|
NCT00001953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000022|The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers|Basal and Stimulated Somatostatin Plasma Levels in Patients With Primary Sjogren's Syndrome and in Control Subjects||National Institutes of Health Clinical Center (CC)||Completed|November 1999|December 2001||||N/A|Observational|N/A||||32|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2001|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001953||209784|
NCT00001919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990151|Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects|Serotonin Transporter Availability and Mood State in Normal Volunteers Taking Hypericum Perforatum (St. John's Wort)||National Institutes of Health Clinical Center (CC)||Completed|September 1999|June 2002||||N/A|Observational|N/A||||13|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001919||209810|
NCT00002208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246M|A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC|A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||400|||Both|16 Years|N/A|No|||February 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002208||209533|
NCT00002221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY 2|Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma|High Dose Chemotherapy and Autologous Peripheral Stem Cell Transplantation for HIV Lymphomas: A Phase IIA Study of Comparative Marking Using a Ribozyme Gene and a Neutral Gene||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||5|||Both|18 Years|60 Years|No|||June 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002221||209520|
NCT00001930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990098|Treatment of Huntington's Chorea With Amantadine|NMDA-Receptor Blockade in Huntington's Chorea||National Institutes of Health Clinical Center (CC)||Completed|April 1999|February 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001930||209800|
NCT00001931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990104|Treatment of Parkinson's Disease With a Transdermal Skin Patch|Transdermal Application of Dopamine Agonist N-0923 in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|May 1999|January 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||June 2000|March 3, 2008|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00001931||209799|
NCT00001912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990149|Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis|Analysis of the Occurrence of Perilesional Edema and Seizures in Patients With Inactive Cysticercosis||National Institutes of Health Clinical Center (CC)||Completed|August 1999|April 2012||||N/A|Observational|N/A|||Actual|6|||Both|18 Years|N/A|No|||April 2012|September 26, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001912||209816|
NCT00002017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072A|Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2|Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002017||209724|
NCT00002018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|069B|Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects|Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002018||209723|
NCT00001895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990153|Electromechanical Mapping to Evaluate Heart Muscle|Evaluation of Electromechanical Endocardial Mapping for Assessment of Myocardial Ischemia and Viability||National Institutes of Health Clinical Center (CC)||Completed|August 1999|December 2001||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||71|||Both|N/A|N/A|No|||December 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001895||209828|
NCT00001963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000031|Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects|Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Completed|December 1999|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||28|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 1999|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001963||209774|
NCT00001929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990078|Treatment of Parkinson's Disease With Eliprodil|NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|March 1999|January 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001929||209801|
NCT00001964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000032|Combination Therapy of Severe Aplastic Anemia|Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)||National Institutes of Health Clinical Center (CC)||Completed|December 1999|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|1 Year|N/A|No|||May 2015|May 14, 2015|January 18, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00001964||209773|
NCT00001891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990108|Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle|Assessment of Myocardial Viability Utilizing Myocardial Contrast Echocardiography||National Institutes of Health Clinical Center (CC)||Completed|May 1999|March 2001||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||March 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001891||209831|
NCT00002182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266A|A Study of Megestrol Acetate in HIV-Infected Children|Megestrol Acetate For Failure To Thrive In Pediatric HIV||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|6 Months|18 Years|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002182||209559|
NCT00002199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238K|A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.|A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||550|||Both|16 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002199||209542|
NCT00001920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990166|Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia|Investigation of Brain Function During Eyeblink Responding in Normal Volunteers and Patients With Schizophrenia (A Study of Behavior and Evoked Potentials)||National Institutes of Health Clinical Center (CC)||Completed|August 1999|June 2010||||N/A|Observational|N/A|||Actual|112|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2010|June 4, 2010|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001920||209809|
NCT00002226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|294A|Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma|A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002226||209515|
NCT00002227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281C|A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002227||209514|
NCT00002216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280C|A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment|A Comparison of a Four-Drug Regimen Comprised of 141W94, 1592U89, and Combivir With a Three-Drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naive HIV-Infected Patients.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002216||209525|
NCT00002236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228G|A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients|An Open-Label, Parallel Group, Pilot Study of Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of BID and TID Regimens of Delavirdine Mesylate, Zidovudine, and Indinavir Sulfate in HIV-1 Infected Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|14 Years|N/A|No|||April 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002236||209505|
NCT00001950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000035|The Development of Categorization|The Development of Categorization||National Institutes of Health Clinical Center (CC)||Completed|December 1999|May 2012||||N/A|Observational|N/A|||Actual|219|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||May 2012|February 19, 2014|January 18, 2000||No||No||https://clinicaltrials.gov/show/NCT00001950||209787|
NCT00001951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000045|Hormone Replacement in Young Women With Premature Ovarian Failure|Hormone Replacement in Young Women With Premature Ovarian Failure||National Institutes of Health Clinical Center (CC)||Completed|December 1999|October 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||250|||Female|18 Years|32 Years|Accepts Healthy Volunteers|||October 2006|February 24, 2007|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001951||209786|
NCT00001957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000016|Testing a Possible Cause of Reduced Ability of Children to Process Speech in Noise|TEOAE Suppression in Children With Auditory Processing Difficulty||National Institutes of Health Clinical Center (CC)||Completed|November 1999|November 2003||||N/A|Observational|N/A||||100|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2003|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001957||209780|
NCT00002220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246N|Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir|Multi-Center, Open-Label Study of the Effect of Indinavir, Efavirenz, and Adefovir Dipivoxil Combination Therapy in Patients Who Have Failed Nelfinavir||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||120|||Both|16 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002220||209521|
NCT00002211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228E|Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients|An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||April 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002211||209530|
NCT00001968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000053|Once-Daily Drug Regimen for HIV-Infected Patients|A Pilot Study of Once-Daily Therapy With Amprenavir, Ritonavir, Lamivudine and Abacavir in HIV-Infected, Antiretroviral-Naive Patients||National Institutes of Health Clinical Center (CC)||Completed|January 2000|November 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||December 1999|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001968||209769|
NCT00002038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012C|Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy|Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002038||209703|
NCT00001905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990089|Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I|Interferon Gamma Administration in Leukocyte Adhesion Deficiency Type I||National Institutes of Health Clinical Center (CC)||Completed|April 1999|March 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||March 2002|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001905||209822|
NCT00001906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990091|Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants|Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants||National Institutes of Health Clinical Center (CC)||Completed|April 1999|May 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2000|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001906||209821|
NCT00001908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990114|T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma|T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma||National Institutes of Health Clinical Center (CC)||Completed|June 1999|July 2001||||N/A|Observational|N/A||||40|||Both|N/A|N/A|No|||July 2001|March 3, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001908||209820|
NCT00001954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000026|Etanercept Therapy for Sjogren's Syndrome|Etanercept Therapy for Sjogren's Syndrome||National Institutes of Health Clinical Center (CC)||Completed|December 1999|November 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||28|||Both|N/A|N/A|No|||November 2003|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001954||209783|
NCT00001955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000037|Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)|The Role of Cytokines as Inflammatory Mediators in Painful Temporomandibular Joints||National Institutes of Health Clinical Center (CC)||Completed|December 1999|February 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||150|||Both|N/A|N/A|No|||February 2004|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001955||209782|
NCT00001969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000049|Heart Disease Risk Factors in Major Depression|Factors in Susceptibility to Ischemic Heart Disease in Major Depression: Documentation of Insulin Resistance in Patients With Major Depression Utilizing the Hyperinsulinemic Euglycemic Glucose Clamp||National Institutes of Health Clinical Center (CC)||Completed|December 1999|January 2007||||N/A|Observational|N/A||||160|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2007|March 5, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001969||209768|
NCT00002158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253B|A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis|Open-Label Compassionate Use of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|3 Years|65 Years|No|||July 2007|July 9, 2007|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002158||209583|
NCT00002183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264B|A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection|A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002183||209558|
NCT00002230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|296A|A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients|A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002230||209511|
NCT00001921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990172|Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings|Integrating EEG/MEG and fMRI: Activity Correlation Between Frontal and Temporal Lobe Structures in Schizophrenic Patients, Their Siblings and Unrelated Normal Volunteers||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|September 1999|||||N/A|Observational|N/A|||Actual|1280|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 20, 2015|November 3, 1999||No||No||https://clinicaltrials.gov/show/NCT00001921||209808|
NCT00002196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278A|A Study of CI-1012 in HIV-Infected Patients|A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||32|||Both|18 Years|60 Years|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002196||209545|
NCT00002197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238E|A Study of 1592U89 in HIV-Infected Children|1592U89 Open-Label Protocol for Pediatric Patients With HIV Infection.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|6 Months|13 Years|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002197||209544|
NCT00002231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers|GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002231||209510|
NCT00002212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287A|A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma|Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002212||209529|
NCT00001940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000024|Voriconazole to Treat Fungal Infections|An Open Label, Non-Comparative, Multi-Center Phase III Trial of the Efficacy, Safety, and Toleration of Extended Voriconazole in the Treatment of Invasive Fungal Infections||National Institutes of Health Clinical Center (CC)||Completed|December 1999|July 2001||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||November 2000|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001940||209792|
NCT00001941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000030|Anti-Tac for Treatment of Leukemia|A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia||National Institutes of Health Clinical Center (CC)|No|Completed|December 1999|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|34|||Both|10 Years|N/A|No|||August 2012|August 13, 2012|January 18, 2000|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00001941||209791|Study was closed to accrual since the cessation of the production of daclizumab.
NCT00001944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000044|Vinorelbine and XR9576 to Treat Cancer|A Clinical Trial of the P-Glycoprotein Antagonist, XR9576, in Combination With Vinorelbine in Patients With Cancer: Analysis of the Interaction Between XR9576 and Vinorelbine||National Institutes of Health Clinical Center (CC)||Completed|December 1999|June 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||December 2000|March 3, 2008|January 18, 2000||||No||https://clinicaltrials.gov/show/NCT00001944||209790|
NCT00001932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990122|Serotonin Receptors in Seizure Disorders|PET Imaging of Serotonin Receptors in Seizure Disorders||National Institutes of Health Clinical Center (CC)||Completed|June 1999|August 2007||||N/A|Observational|N/A||||95|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2007|March 5, 2008|November 3, 1999||||No||https://clinicaltrials.gov/show/NCT00001932||209798|
NCT00002140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226B|A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients|A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002140||209601|
NCT00002511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22911|Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer|PHASE III STUDY OF POST-OPERATIVE EXTERNAL RADIOTHERAPY IN PATHOLOGICAL STAGE T3 N0 PROSTATIC CARCINOMA||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1992|||December 2001|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|1005|||Both|N/A|75 Years|No|||October 2012|October 15, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002511||209242|
NCT00002585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063706|Pyrazoloacridine in Treating Women With Metastatic Breast Cancer|PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH METASTATIC BREAST CANCER||Barbara Ann Karmanos Cancer Institute|No|Completed|February 1994|January 2001|Actual|October 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|N/A|No|||March 2012|March 9, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002585||209175|
NCT00002586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-0382|13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer|ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13-CIS RETINOIC ACID WITH OR WITHOUT ALPHA TOCOPHEROL OR OBSERVATION|13-Cis|University of Colorado, Denver|Yes|Completed|January 1993|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|96|||Both|18 Years|90 Years|No|||May 2014|May 5, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002586||209174|
NCT00002178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229J|A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients|A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||375|||Both|16 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002178||209563|
NCT00002527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078380|Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed|COLORECTAL ADENOMA CHEMOPREVENTION TRIAL USING ASPIRIN: A PHASE III STUDY||Alliance for Clinical Trials in Oncology|Yes|Completed|May 1993|January 2006|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|719|||Both|30 Years|74 Years|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002527||209229|
NCT00002563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063515|SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease|Health Status and Quality of Life in Patients With Early Stage Hodgkin's Disease: A Companion Study to SWOG-9133||Southwest Oncology Group|Yes|Completed|April 1994|May 2005|Actual|September 2003|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|263|||Both|18 Years|N/A|No|Non-Probability Sample|Community Sample|April 2013|April 8, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002563||209195|
NCT00002272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020G|An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies|An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||September 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002272||209470|
NCT00002275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041B|A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)|Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations||Abbott||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002275||209467|
NCT00002099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126B|Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients|Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||July 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002099||209642|
NCT00002556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02445|Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma|The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma||National Cancer Institute (NCI)||Completed|July 1994|||January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002556||209202|
NCT00002273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029C|A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS|Double-Blind, Placebo-Controlled Study of Intravenous Ganciclovir (DHPG) for Cytomegalovirus Colitis in Patients With Acquired Immune Deficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|21 Years|N/A|No|||September 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002273||209469|
NCT00002274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039A|A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine|An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002274||209468|
NCT00002124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228B|A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3|A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||1250|||Both|14 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002124||209617|
NCT00002132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236A|Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.|Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002132||209609|
NCT00002179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246G|The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection|A Multiclinic, Open Study to Evaluate the Ability of the Combination of Indinavir, Zidovudine and Lamivudine to Result in Sustained Suppression of HIV-1 in Asymptomatic HIV-1 Seropositive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002179||209562|
NCT00002180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269A|A Study of PMPA in HIV-Infected Patients|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, and Pharmacokinetics, and Antiviral Activity of 9-[(R)-2-(Phosphonomethoxy)Propyl] Adenine (PMPA) in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002180||209561|
NCT00002535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STLMC-BRM-93004|Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma|TUMOR INFILTRATING LYMPHOCYTE THERAPY FOR ADVANCED MELANOMA USING IMMUNOMODULATION, A PHASE II STUDY||National Cancer Institute (NCI)||Completed|July 1993|July 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|17 Years|N/A|No|||August 2000|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002535||209222|
NCT00002152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222B|A Study of WF 10 IV Solution in Patients With Advanced HIV Disease|Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of WF 10 IV Solution ( TCDO ) in the Management of Patients With Advanced HIV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002152||209589|
NCT00002153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247A|Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders|Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||25|||Both|21 Years|N/A|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002153||209588|
NCT00002075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012G|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002075||209666|
NCT00002139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226D|Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.|Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002139||209602|
NCT00002103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132C|A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia|A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||January 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002103||209638|
NCT00002522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078283|Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (CEP) WITH RESCUE BY AUTOLOGOUS BONE MARROW OR AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN'S DISEASE||Temple University||Completed|February 1993|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|70 Years|No|||September 2010|September 30, 2010|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002522||209234|
NCT00002568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063600|Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer|A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA||Gynecologic Oncology Group||Completed|June 1994|||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|470|||Female|N/A|N/A|No|||May 2010|July 8, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002568||209190|
NCT00002076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012J|Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002076||209665|
NCT00002077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012K|An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002077||209664|
NCT00002078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082A|Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection|Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002078||209663|
NCT00002079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057B|Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)|Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002079||209662|
NCT00002154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250A|A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia|Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002154||209587|
NCT00002279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031B|A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)|Dideoxycytidine (Ro 24-2027). An Open-Label, Safety Study of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine (AZT) Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||October 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002279||209463|
NCT00002280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039C|A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine|An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Children With Acquired Immunodeficiency Syndrome (AIDS) Who Have Demonstrated Significant Deterioration or Intolerance to Zidovudine (Retrovir)||Bristol-Myers Squibb||Completed||November 1994|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Months|12 Years|No|||August 2011|August 4, 2011|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002280||209462|
NCT00002574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02233|Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia|PHASE II STUDY OF SIMULTANEOUS HOMOHARRINGTONINE (NSC 141633) AND ALPHA INTERFERON (IFN-A) THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA (CML)||National Cancer Institute (NCI)||Completed|September 1994|||June 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|15 Years|N/A|No|||October 2001|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002574||209185|
NCT00002113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213A|A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.|A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||64|||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002113||209628|
NCT00002100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127A|Phase I/II Study of Curdlan Sulfate|Phase I/II Study of Curdlan Sulfate||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||April 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002100||209641|
NCT00002567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-161|High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission|PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS||Memorial Sloan Kettering Cancer Center||Completed|March 1994|November 2000|Actual|November 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|16 Years|65 Years|No|||June 2013|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002567||209191|
NCT00002243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297A|A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment|A Phase 1B Dose-Range Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-Calanolide A on Surrogate Markers in HIV-Positive Patients With No Previous Antiretroviral Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||July 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002243||209499|
NCT00002138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088D|A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.|A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002138||209603|
NCT00002148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242A|Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia|Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002148||209593|
NCT00002572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-0426.cc|Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors|Intracavitary Allogenic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2 Therapy for Recurrent Primary Brain Tumors||University of Colorado, Denver||Completed|November 1994|December 1999|Actual|December 1999|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||July 2000|May 28, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002572||209186|
NCT00002540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01755|Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial||National Cancer Institute (NCI)||Active, not recruiting|November 1993|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|76685|||Male|55 Years|74 Years|No|||February 2016|February 23, 2016|November 1, 1999|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00002540||209217|
NCT00002542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA12|Tamoxifen in Treating Women With High-Risk Breast Cancer|DOUBLE-BLIND RANDOMIZED TRIAL OF TAMOXIFEN VERSUS PLACEBO IN PATIENTS WITH NODE POSITIVE BREAST CANCER WHO HAVE COMPLETED CMF, CEF OR AC ADJUVANT CHEMOTHERAPY||Canadian Cancer Trials Group||Completed|July 1993|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|800|||Female|N/A|120 Years|No|||January 2011|March 21, 2016|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002542||209216|
NCT00002160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|256A|A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain|A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||March 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002160||209581|
NCT00002167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261A|Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.|Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||78|||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002167||209574|
NCT00002161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232C|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||May 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002161||209580|
NCT00002528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078383|Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer|Surgical Therapy With or Without Axillary Node Clearance for Breast Cancer in the Elderly Who Receive Adjuvant Therapy With Tamoxifen.|10-93|International Breast Cancer Study Group|Yes|Completed|May 1993|August 2010|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|473|||Female|60 Years|N/A|No|||July 2012|April 3, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002528||209228|
NCT00002579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063694|Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer|PROTOCOL FOR THE SCOTTISH CHEMO-ENDOCRINE TRIAL D||National Cancer Institute (NCI)||Completed|March 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Female|N/A|N/A|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002579||209180|
NCT00002089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058C|An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy|An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002089||209652|
NCT00002101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|048D|A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo|A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|13 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002101||209640|
NCT00002246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244E|A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex|A Pilot Open Label, Multicenter Study to Evaluate the Role of Stavudine (d4T) in the Treatment of AIDS Dementia Complex||Bristol-Myers Squibb||Completed|October 1997|March 1999|Actual|March 1999|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||20|||Both|13 Years|N/A|No|||April 2011|April 28, 2011|November 2, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00002246||209496|
NCT00002564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063537|Nutrition Intervention in Treating Women With Breast Cancer|A CLINICAL TRIAL TO DETERMINE THE EFFICACY OF A DIETARY FAT REDUCTION PROGRAM PROVIDED IN ADDITION TO SYSTEMIC ADJUVANT THERAPY IN THE MANAGEMENT OF PATIENTS WITH PRIMARY INVASIVE BREAST CANCER||National Cancer Institute (NCI)||Completed|April 1994|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2500|||Female|48 Years|78 Years|No|||February 2010|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002564||209194|
NCT00002130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234C|A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons|A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002130||209611|
NCT00002131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234D|A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma|A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002131||209610|
NCT00002536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078470|Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer|TREATMENT OF PATIENTS WITH SUBOPTIMAL ('BULKY') STAGE IB CARCINOMA OF THE CERVIX: A RANDOMIZED COMPARISON OF RADICAL HYSTERECTOMY AND PELVIC AND PARA-AORTIC LYMPHADENECTOMY WITH OR WITHOUT NEOADJUVANT VINCRISTINE AND CISPLATIN CHEMOTHERAPY, PHASE III||Gynecologic Oncology Group||Completed|December 1996|||August 2007|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||March 2008|July 8, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002536||209221|
NCT00002251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|059A|A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir|A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||20|||Both|13 Years|60 Years|No|||May 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002251||209491|
NCT00002252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102A|A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea|A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002252||209490|
NCT00002149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243A|Acupuncture and Herbal Treatment of Chronic HIV Sinusitis|Acupuncture and Herbal Treatment of Chronic HIV Sinusitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||40|||Both|18 Years|60 Years|No|||September 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002149||209592|
NCT00002141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238A|A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89|A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89||NIH AIDS Clinical Trials Information Service||Completed|July 1994|||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Both|13 Years|55 Years|No|||October 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002141||209600|
NCT00002142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216B|An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS|An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||October 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002142||209599|
NCT00002143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239A|Treatment of Psoriasis Using Acitretin in HIV-Positive Patients|Treatment of Psoriasis Using Acitretin in HIV-Positive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002143||209598|
NCT00002520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078281|Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer|Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings||Eastern Cooperative Oncology Group|No|Completed|June 1992|||February 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|434|||Both|19 Years|120 Years|No|||October 2015|October 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002520||209236|
NCT00002521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078282|Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (CEP) WITH RESCUE BY AUTOLOGOUS BONE MARROW OR AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA (INTERMEDIATE AND HIGH-GRADE HISTOLOGIES)||Temple University||Completed|February 1993|February 2000|Actual|February 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|70 Years|No|||September 2010|September 30, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002521||209235|
NCT00002543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCW-ARRC-22393|Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors|GALLIUM NITRATE FOR THE TREATMENT OF MALIGNANT TUMORS, A PHASE I STUDY||National Cancer Institute (NCI)||Completed|February 1995|October 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|3|||Both|N/A|21 Years|No|||May 2007|July 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002543||209215|
NCT00002544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-AIO-01/92|Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer|MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS||National Cancer Institute (NCI)||Completed|May 1993|November 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Female|N/A|80 Years|No|||April 2001|August 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002544||209214|
NCT00002168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260B|A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients|An Open Label, Randomized, Comparative Study of Zerit (d4T) + Videx (ddI) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700/mm3 and HIV RNA Baseline Copy Number of >= 10,000 Copies/ml||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||200|||Both|16 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002168||209573|
NCT00002169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259A|A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis|A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002169||209572|
NCT00002126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087A|A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.|A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||250|||Both|13 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002126||209615|
NCT00002557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063440|Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides|PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME||National Cancer Institute (NCI)||Active, not recruiting|June 1993|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|3|||Both|N/A|N/A|No|||August 2000|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002557||209201|
NCT00002098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126A|Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients|Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||50|||Both|18 Years|60 Years|No|||March 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002098||209643|
NCT00002170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259C|A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)|A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Disseminated Mycobacterium Avium Complex Disease (MAC) in AIDS Patients Who Are Receiving Standard Acute Treatment for This Opportunistic Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002170||209571|
NCT00002171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259D|A Study of Viracept in HIV-Positive Women|A Phase II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Viracept in Combination With Antiretroviral Therapy in HIV Positive Women With <= 1 Month of Prior Treatment With d4T and/or 3TC||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Female|13 Years|N/A|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002171||209570|
NCT00002577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9311|Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer|A PHASE I/II DOSE ESCALATION STUDY USING THREE DIMENSIONAL CONFORMAL RADIATION THERAPY POST INDUCTION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE, NON-SMALL CELL LUNG CANCER||Radiation Therapy Oncology Group|Yes|Completed|July 1995|||January 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002577||209182|
NCT00002578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 96-26|Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma|Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome||Roswell Park Cancer Institute||Completed|August 1994|||January 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|120 Years|No|||October 2015|October 5, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002578||209181|
NCT00002575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-934653|Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer|A PHASE III PROSPECTIVE RANDOMIZED TRIAL COMPARING LAPAROSCOPIC-ASSISTED COLECTOMY VERSUS OPEN COLECTOMY FOR COLON CANCER||Alliance for Clinical Trials in Oncology|Yes|Completed|August 1994|November 2009|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|810|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002575||209184|
NCT00002261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063A|A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers|A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers||Bristol-Myers Squibb||Completed||||||Phase 1|Interventional|Primary Purpose: Prevention|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2007|September 24, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002261||209481|
NCT00002114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215A|A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides|A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides||NIH AIDS Clinical Trials Information Service||Completed||January 1994||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Both|18 Years|N/A|No|||January 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002114||209627|
NCT00002115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217A|A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.|A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||November 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002115||209626|
NCT00002116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218A|A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS|A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||December 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002116||209625|
NCT00002102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132B|A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.|A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002102||209639|
NCT00002117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220A|A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection|A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||528|||Both|18 Years|N/A|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002117||209624|
NCT00002545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9305|Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme|A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME||Radiation Therapy Oncology Group|Yes|Completed|February 1994|||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002545||209213|
NCT00002125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020H|A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)|A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Primary Purpose: Treatment||||112|||Both|18 Years|N/A|No|||June 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002125||209616|
NCT00002118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031F|An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies|An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|3 Months|11 Years|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002118||209623|
NCT00002582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRI-ABC|Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer|UKCCCR RANDOMISED TRIAL OF ADJUVANT ENDOCRINE THERAPY AND CHEMOTHERAPY IN WOMEN WITH EARLY BREAST CANCER, THE ADJUVANT BREAST CANCER (ABC) TRIAL||National Cancer Institute (NCI)||Completed|June 1993|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|6000|||Female|N/A|N/A|No|||May 2007|August 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002582||209177|
NCT00002583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR10|Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed|A PHASE III PROSPECTIVE RANDOMIZED STUDY OF ADJUVANT CHEMOTHERAPY WITH VINORELBINE AND CISPLATIN IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER WITH COMPANION TUMOUR MARKER EVALUATION||Canadian Cancer Trials Group||Completed|July 1994|December 2009|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|482|||Both|18 Years|N/A|No|||March 2012|September 20, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002583||209176|
NCT00002569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9402|Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma|Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas||Radiation Therapy Oncology Group|Yes|Completed|July 1994|||February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002569||209189|
NCT00002065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|024A|Depot Disulfiram for AIDS and ARC|Depot Disulfiram for AIDS and ARC||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002065||209676|
NCT00002066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015A|Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection|Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002066||209675|
NCT00002071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004A|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002071||209670|
NCT00002072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004C|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002072||209669|
NCT00002237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301A|A Study of Peldesine (BCX-34) in HIV-Infected Patients|Phase I Placebo-Controlled Study of Oral BCX-34 (Peldesine) in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002237||209504|
NCT00002111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212A|A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.|A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||May 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002111||209630|
NCT00002112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012Q|Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome|Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002112||209629|
NCT00002380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229K|The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children|A Phase I/II Pharmacokinetic and Safety Study of Saquinavir Soft Gelatin Capsules and Pediatric Pellet Formulations in Combination With Nucleoside Antiretroviral Agents With or Without Nelfinavir, in HIV-Infected Infants and Children||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|6 Months|13 Years|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002380||209362|
NCT00002385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|277A|The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients|Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314).||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002385||209357|
NCT00002181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218B|Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS|Open-Label Study of Cidofovir Gel for Acyclovir-Unresponsive Mucocutaneous Herpes Simplex Disease in Patients With AIDS.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||November 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002181||209560|
NCT00002156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251B|A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )|A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||194|||Both|18 Years|N/A|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002156||209585|
NCT00002361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246S|Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors|A Multicenter, Open-Label, 24-Week Study to Evaluate the Safety and Activity of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 200 Mg b.i.d. and Two NRTIs in HIV-1 Infected Patients Who Failed PI Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||February 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002361||209381|
NCT00002408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293A|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002408||209334|
NCT00002409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280B|The Effect of Teaching HIV-Infected Patients About HIV and Treatment|A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virological Outcomes, Adherence, Immunological Outcome, and Health Outcomes in HIV-Infected Subjects From Under-Represented Populations Treated With Triple Nucleoside Therapy (Combivir, Lamivudine 150 Mg/Zidovudine 300 Mg PO BID Plus Abacavir 300 Mg PO BID) for Twenty-Four Weeks||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002409||209333|
NCT00002104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133A|Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV|Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002104||209637|
NCT00002105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134B|Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma|Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||220|||Both|18 Years|N/A|No|||January 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002105||209636|
NCT00002106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135A|A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3|A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||104|||Both|18 Years|N/A|No|||May 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002106||209635|
NCT00002394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|282A|Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment|A Four-Week, Open-Label, Non-Randomized, Multicenter, Dose-Finding, Pilot Study to Evaluate the Safety and Efficacy of Two Daily Doses of Lamisil (1500 Mg and 2000 Mg), Administered for a Maximum of 4 Weeks in HIV-Positive Subjects With Oral Mucosal Candidiasis Not Having Responded to a Minimum of 200 Mg Fluconazole Monotherapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002394||209348|
NCT00002416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298A|Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination|A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment||||390|||Both|18 Years|N/A|No|||March 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002416||209326|
NCT00002133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236B|An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.|An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002133||209608|
NCT00002146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020J|Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study|Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||January 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002146||209595|
NCT00002400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228C|A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients|An Open-Label Randomized Study of Delavirdine Mesylate (Rescriptor) in Combination With Zidovudine (Retrovir) and Two Doses of Indinavir (Crixivan) Versus Zidovudine, Lamivudine (Epivir), and Indinavir in HIV-1-Infected Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||January 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002400||209342|
NCT00002084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104B|A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients|A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002084||209657|
NCT00002085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058D|A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy|A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002085||209656|
NCT00002150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221B|A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients|A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002150||209591|
NCT00002127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230A|A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome|A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002127||209614|
NCT00002151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221C|A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients|A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002151||209590|
NCT00002092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119A|A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection|A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002092||209649|
NCT00002372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264A|A Study of 141W94 in Combination With Other Anti-HIV Drugs|A Phase I/II Screening Trial to Identify Potential Partner Compounds to Use in Combination With 141W94||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002372||209370|
NCT00002381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200F|The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1 Infected Adults Treated With Stavudine [d4T] (Zerit)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002381||209361|
NCT00002155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246E|A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC|A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||June 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002155||209586|
NCT00002157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230B|Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome|Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002157||209584|
NCT00002107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|085A|A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients|A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002107||209634|
NCT00002406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246P|A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients|A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulphate, 800 Mg q 8h Versus 1,200 Mg q 12h in HIV-Infected Individuals Having Plasma Viral RNA Less Than 400 Copies/Ml, on Concomitant Therapy With 2 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||350|||Both|16 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002406||209336|
NCT00002407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLANTIC STUDY|A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs|A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002407||209335|
NCT00002420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292E|The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors|A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Rescriptor (Delavirdine Mesylate), and MKC-442 (With or Without Hydroxyurea) for the Treatment of HIV-1- Infected Patients Who Failed Previous Protease Inhibitor Treatment||Bristol-Myers Squibb||Terminated||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002420||209322|
NCT00002144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240A|The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment|The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||12|||Both|13 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002144||209597|
NCT00002108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129D|3TC (Lamivudine; GR109714X) Open-Label Program|3TC (Lamivudine; GR109714X) Open-Label Program||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Years|N/A|No|||November 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002108||209633|
NCT00002415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283B|Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Antiviral Activity of the Addition of PMPA Prodrug to Combination Antiretroviral Regimens in Treatment-Experienced HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||175|||Both|18 Years|65 Years|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002415||209327|
NCT00002425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229E|The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs|A Multicenter, Open-Label Study of the Safety and Activity of Saquinavir Soft Gelatin Capsule Formulation (Saquinavir SGC) in Combination With Other Antiretroviral Drugs||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||December 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002425||209318|
NCT00002145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020I|Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease|Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||145|||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002145||209596|
NCT00002128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232A|Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients|Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||15|||Both|18 Years|60 Years|No|||July 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002128||209613|
NCT00002122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226A|A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients|A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||720|||Both|12 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002122||209619|
NCT00002093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121A|A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.|A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002093||209648|
NCT00002094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117A|Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E|Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|45 Years|No|||February 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002094||209647|
NCT00002129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234A|A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3|A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002129||209612|
NCT00002058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|027A|A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease|A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002058||209683|
NCT00002159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254A|A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis|A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||December 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002159||209582|
NCT00002419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|299A|Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment|A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of Novel Quadruple-Combination Therapy With Preveon (Adefovir Dipivoxil; Bis-POM PMEA), Abacavir (1592U89), Sustiva (Efavirenz; DMP-266), and Amprenavir (141W94) for the Treatment of HIV-1 Infection in Patients Who Have Failed Previous Protease Inhibitor Treatment||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||25|||Both|13 Years|N/A|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002419||209323|
NCT00002382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229L|A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients|An Open Label International Compassionate Treatment Program for the Use of Saquinavir (R0 31-8959) Either As Monotherapy or in Combination With Other Anti-Retroviral Drugs in Patients With Proven HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||4000|||Both|13 Years|N/A|No|||June 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002382||209360|
NCT00002162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229D|A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs|A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||140|||Both|13 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002162||209579|
NCT00002163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238B|A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex|A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002163||209578|
NCT00002164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259E|Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants|Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||24|||Both|N/A|13 Years|No|||May 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002164||209577|
NCT00002427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304A|Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults|A Phase I/II Study of the Safety and Antiretroviral Activity of Nine Hydroxyurea Regimens in Combination With ddI and d4T in Subjects With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed|May 1999|||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Primary Purpose: Treatment||||225|||Both|18 Years|N/A|No|||August 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002427||209316|
NCT00002396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283A|The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients|A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Activity of 9-[2-(R)-[[Bis[[(Isopropoxycarbonyl)- Oxy]Methoxy]Phosphinoyl]Methoxy]Propyl]Adenine Fumarate (PMPA Prodrug) in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|60 Years|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002396||209346|
NCT00002119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222A|A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection|A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002119||209622|
NCT00002120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224A|Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia|Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|13 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002120||209621|
NCT00002109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015H|Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy|Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002109||209632|
NCT00002137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088B|A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4|A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002137||209604|
NCT00002060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008D|A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)|A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|75 Years|No|||June 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002060||209681|
NCT00002403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290A|Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients|A Phase I/II Multiple Dose Study to Evaluate the Safety, Pharmacokinetic Profile and Virologic/Immunologic Activity of Zintevir (AR177) in HIV-1 Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||December 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002403||209339|
NCT00002121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223A|Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea|Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002121||209620|
NCT00002067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025B|A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia|Phase III Randomized Double-Blind Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia||Bristol-Myers Squibb||Completed||||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002067||209674|
NCT00002166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200D|An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease|An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002166||209575|
NCT00002061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008B|A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy|A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|50 Years|No|||June 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002061||209680|
NCT00002068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012H|A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002068||209673|
NCT00002069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010A|A Study of DTC in Patients With AIDS and AIDS Related Complex|A Study of DTC in Patients With AIDS and AIDS Related Complex||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002069||209672|
NCT00002173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094|An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.|An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002173||209568|
NCT00002378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229H|A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients|A Randomized Phase IIIB Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) TID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) BID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) BID Plus Nelfinavir BID Plus a NRTI in HIV-1 Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||825|||Both|16 Years|N/A|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002378||209364|
NCT00002379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232D|The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs|A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination With Zidovudine, Lamivudine, or Stavudine for the Treatment of Therapy Naive HIV-Infected Patients With CD4 Cell Counts >= 100 Cells/mm3 and HIV-1 RNA Copy Numbers >= 5,000 Copies/Ml||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|16 Years|N/A|No|||October 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002379||209363|
NCT00002383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229M|A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients|A Randomized, Parallel, Open-Label Study Comparing Saquinavir (Hard Gelatin Formulation, 600 Mg Tid) to Saquinavir Soft Gelatin Formulation [(400 Mg, 800 Mg, 1200 Mg) Tid} x 4 Weeks in HIV Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002383||209359|
NCT00002384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|276A|A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|Vistide (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002384||209358|
NCT00002172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093|An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml|An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002172||209569|
NCT00002134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037B|A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis|A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||450|||Both|13 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002134||209607|
NCT00002110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211A|A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease|A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|13 Years|N/A|No|||October 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002110||209631|
NCT00002395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|284A|Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)|An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|18 Years|N/A|No|||July 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002395||209347|
NCT00002410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281B|A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients|A Phase III, Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens (DMP 266 + Indinavir, DMP 266 + Zidovudine + Lamivudine, Indinavir + Zidovudine + Lamivudine) in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|60 Years|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002410||209332|
NCT00002411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039E|A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs|A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects||Bristol-Myers Squibb||Completed|March 1998|September 1999|Actual|September 1999|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||April 2011|April 13, 2011|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002411||209331|
NCT00002135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037C|An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access|An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||November 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002135||209606|
NCT00002147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134D|Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.|Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002147||209594|
NCT00002123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228A|A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3|A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|14 Years|N/A|No|||November 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002123||209618|
NCT00002401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228F|A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients|An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) in Triple and Quadruple Combinations With Zidovudine (ZDV), Indinavir (IDV), and Lamivudine (3TC) in HIV-1 Infected Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||160|||Both|14 Years|N/A|No|||January 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002401||209341|
NCT00002402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX 002|A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines|Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAX B/B and B/E Vaccines in the United States||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002402||209340|
NCT00002428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091|A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects|A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002428||209315|
NCT00002136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088A|A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days|A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002136||209605|
NCT00002175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265A|Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.|Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||46|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002175||209566|
NCT00002176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244C|A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection|A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection||Bristol-Myers Squibb||Completed|May 1997|March 2000|Actual|March 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2011|April 13, 2011|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002176||209565|
NCT00002177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244D|A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection|A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection||Bristol-Myers Squibb||Completed|May 1997|March 2000|Actual|March 2000|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2011|April 13, 2011|November 2, 1999|No|Yes||||https://clinicaltrials.gov/show/NCT00002177||209564|
NCT00002760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064708|Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer|A PHASE III TWO-ARM RANDOMIZED STUDY COMPARING ANTIANDROGEN WITHDRAWAL ALONE VERSUS ANTIANDROGEN WITHDRAWAL COMBINED WITH KETOCONAZOLE AND HYDROCORTISON IN PATIENTS WITH ADVANCED PROSTAGE CANCER||Alliance for Clinical Trials in Oncology|Yes|Completed|August 1996|April 2009|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Male|N/A|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002760||209041|
NCT00002725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02239|Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|PHASE II EVALUATION OF BRYOSTATIN-1 (NSC 339555) IN NON-HODGKIN'S LYMPHOMA||National Cancer Institute (NCI)||Completed|August 1996|||April 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|N/A|No|||October 2000|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002725||209066|
NCT00002456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267.01|Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation|Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease||Fred Hutchinson Cancer Research Center||Completed|May 1986|April 2002|Actual|||Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||November 2011|November 28, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002456||209287|
NCT00002292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023B|A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|Inhaled Versus Intravenous Pentamidine in Pneumocystis Carinii Pneumonia in the Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002292||209450|
NCT00002336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124A|The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients|A Prospective, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Clarithromycin for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients With CD4 Counts <= 100 Cells/mm3||Abbott||Completed|November 1992|November 1994|Actual|November 1994|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||February 2009|January 15, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002336||209406|
NCT00002337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234B|A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease|A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002337||209405|
NCT00002757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5961|TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma|FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study||Children's Oncology Group|Yes|Completed|June 2001|October 2009|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Actual|1148|||Both|N/A|20 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002757||209043|
NCT00002717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064554|Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer|A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|March 1996|||October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|324|||Female|18 Years|N/A|No|||January 2010|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002717||209073|
NCT00002718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-084|T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia|A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor||Memorial Sloan Kettering Cancer Center||Completed|November 1995|October 2008|Actual|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|49 Years|No|||December 2015|December 21, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002718||209072|
NCT00002338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237A|The Safety and Effectiveness of 935U83 in HIV-Infected Patients|A Phase I Trial to Evaluate the Safety, Tolerance, and Pharmacokinetics of 935U83 After Multiple Dosing in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||40|||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002338||209404|
NCT00002455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG-CO/BR-1|Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma|Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts||National Cancer Institute (NCI)||Active, not recruiting|April 1971|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|20 Years|80 Years|No|||November 1998|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002455||209288|
NCT00002711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-073|Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus|A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL||Memorial Sloan Kettering Cancer Center||Completed|October 1995|October 2000|Actual|October 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002711||209077|
NCT00002744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1952|Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia|Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia||Children's Oncology Group|Yes|Completed|May 1996|March 2007|Actual|February 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|1970|||Both|1 Year|9 Years|No|||July 2014|July 23, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002744||209056|
NCT00002316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131A|The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis|Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002316||209426|
NCT00002248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081A|A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients|A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002248||209494|
NCT00002705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01833|Topotecan in Treating Children With Refractory Leukemia|TOPOTECAN FOR CHILDREN WITH REFRACTORY LEUKEMIA, A PEDIATRIC ONCOLOGY GROUP PHASE I COOPERATIVE AGREEMENT STUDY||National Cancer Institute (NCI)||Completed|April 1996|||January 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|20 Years|No|||May 2001|January 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002705||209081|
NCT00002749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064682|Carboplatin in Patients With Progressive Gliomas|PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS||Duke University||Completed|February 1993|March 2000|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|N/A|N/A|No|||October 2009|October 12, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002749||209051|
NCT00002375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246H|Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients|A Multicenter, 24-Week Study of the Safety, Pharmacokinetics, and Activity of the Coadministration of Indinavir and Nelfinavir in HIV-1 Seropositive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||February 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002375||209367|
NCT00002287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014I|A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus|A Placebo-Controlled Trial to Evaluate Retrovir in Preventing Infection With the Human Immunodeficiency Virus (HIV) in Health Care Workers After Accidental Exposure||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|Accepts Healthy Volunteers|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002287||209455|
NCT00002293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026B|A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes|Nystatin Pastille for the Prophylaxis of Oral Candidiasis in Patients With AIDS or AIDS Related Syndromes||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002293||209449|
NCT00002294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012A|A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS|Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002294||209448|
NCT00002703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064503|Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer|A PHASE III TRIAL EMPLOYING CONFORMAL PHOTONS WITH PROTON BOOST IN EARLY STAGE PROSTATE CANCER: CONVENTIONAL DOSE COMPARED TO HIGH DOSE IRRADIATION||National Cancer Institute (NCI)||Completed|January 1996|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|390|||Male|N/A|N/A|No|||April 2012|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002703||209083|
NCT00002434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132A|A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)|A Study of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Years|N/A|No|||January 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002434||209309|
NCT00002435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136A|A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients|Study of the Activity of Thymic Humoral Factor (THF Gamma 2) on HIV Load in HIV-Positive Individuals With CD4+ Cell Counts in the Range of 200-500 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002435||209308|
NCT00002288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014K|The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System|Safety and Efficacy of Retrovir in HIV Infected Patients Having Neuropsychological Impairments||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|50 Years|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002288||209454|
NCT00002335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233A|The Safety and Effectiveness of 524W91|A Phase I, Randomized, Single-Dose, Placebo-Controlled Trial to Evaluate the Safety and Pharmacokinetics of 524W91||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||18|||Both|18 Years|55 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002335||209407|
NCT00002306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012I|A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B|Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002306||209436|
NCT00002307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116A|A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients|A Double-Blind Comparison of Zidovudine (AZT) Versus Stavudine (d4T; BMY 27857) for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between 50 and 500 Cells/mm3||Bristol-Myers Squibb||Completed||December 1994|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||August 2011|August 4, 2011|November 2, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002307||209435|
NCT00002308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116B|A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs|A Randomized Blinded Evaluation of Two Doses of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; d4T) to Make Treatment Available to Severely Immunocompromised Patients With HIV Infection Who Have Failed or Are Intolerant of Alternative Antiretroviral Therapy||Bristol-Myers Squibb||Completed||November 1991|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||August 2011|August 4, 2011|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002308||209434|
NCT00002752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004635|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers|PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS||Duke University||Completed|February 1993|March 2010|Actual|January 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|3 Years|N/A|No|||February 2013|July 15, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002752||209048|
NCT00002723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02788|Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer|A PHASE III STUDY OF THREE DIFFERENT DOSES OF SURAMIN (NSC #34936) ADMINISTERED WITH A FIXED DOSING SCHEDULE IN PATIENTS WITH ADVANCED PROSTATE CANCER||National Cancer Institute (NCI)|Yes|Completed|January 1996|March 2008|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|390|||Male|18 Years|N/A|No|||February 2013|February 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002723||209067|
NCT00002714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC-G4|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease|A PHASE II TRIAL OF EIGHT-WEEK STANFORD V CHEMOTHERAPY PLUS MODIFIED INVOLVED FIELD RADIOTHERAPY IN FAVORABLE, LIMITED STAGE HODGKIN'S DISEASE||National Cancer Institute (NCI)||Completed|April 1995|September 2001|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|60 Years|No|||September 2001|May 14, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002714||209076|
NCT00002332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015I|A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs|Double-Blind Study of the Effect of Timunox (Thymopentin) on Lymphoproliferative Responses and Virus Load in HIV-Infected Subjects Receiving Nucleoside Analog Antiretroviral Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002332||209410|
NCT00002346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232B|The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients|A Phase I/II Study of Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) and Placebo in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|60 Years|No|||March 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002346||209396|
NCT00002259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055B|Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma|Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002259||209483|
NCT00002742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064660|Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer|A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS||National Cancer Institute (NCI)||Completed|January 1996|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|2 Years|N/A|No|||July 2007|March 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002742||209057|
NCT00002745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02791|Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma|PHASE II STUDY OF 9-AMINOCAMPTOTHECIN (9-AC/DMA, NSC# 603071) IN PREVIOUSLY TREATED HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA: IWF GRADES A-H||National Cancer Institute (NCI)|No|Completed|April 1996|January 2008|Actual|April 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2013|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002745||209055|
NCT00002357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252A|The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms|A Multicenter, Randomized, Double-Blinded, Dose-Escalation Study Evaluating the Safety and Antiretroviral Activity of HBY 097 Versus HBY 097 Plus AZT in Patients With Asymptomatic or Mildly Symptomatic HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||144|||Both|13 Years|N/A|No|||May 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002357||209385|
NCT00002358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|255A|A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV|Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy||Bristol-Myers Squibb||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Years|17 Years|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002358||209384|
NCT00002444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253A|A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea|Phase I/II Open Label Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed|October 1995|February 1996||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||28|||Both|18 Years|65 Years|No|||February 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002444||209299|
NCT00002289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015C|The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients|Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002289||209453|
NCT00002350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|089|A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients|A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002350||209392|
NCT00002351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246A|A Study of L-735,524 in HIV-Positive Children and Adolescents|An Open-Labeled, Multiple Dose, Multicenter Study to Investigate the Safety, Tolerability, and Plasma Concentration Profile of L-735,524 Capsules in HIV-Seropositive Older Children and Adolescent Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||12|||Both|10 Years|18 Years|No|||October 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002351||209391|
NCT00002733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064631|Biological Therapy in Treating Patients With Metastatic Cancer|ALPHA INTERFERON, TUMOR INFILTRATING LYMPHOCYTES, AND INTERLEUKIN-2 IN THE TREATMENT OF CANCER||Hoag Memorial Hospital Presbyterian||Completed|January 1996|January 2000|Actual|January 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002733||209063|
NCT00002734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02240|Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer|PHASE I STUDY OF INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNO-CHEMOTHERAPY FOR OVARIAN CANCER||National Cancer Institute (NCI)||Completed|March 1996|||April 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||February 2001|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002734||209062|
NCT00002715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064551|Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma|A PHASE II PILOT STUDY OF SHORT TERM (12 WEEK) COMBINATION CHEMOTHERAPY (STANFORD V) IN UNFAVORABLE HODGKIN'S DISEASE||National Cancer Institute (NCI)||Active, not recruiting|April 1989|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|60 Years|No|||June 2009|July 1, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002715||209075|
NCT00002304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012B|A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems|A Randomized Comparative Multicenter Trial of Fluconazole and Ketoconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|70 Years|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002304||209438|
NCT00002305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012F|A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002305||209437|
NCT00002295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008F|A Study of Isoprinosine in Patients With Severe AIDS|A Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Severe Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002295||209447|
NCT00002323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200B|A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell|A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002323||209419|
NCT00002347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229C|The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection|A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection: Retrovir/HIVID/Nevirapine and Retrovir/HIVID/Invirase||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||225|||Both|13 Years|N/A|No|||June 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002347||209395|
NCT00002317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132D|A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia|A Study of Neutrexin (Trimetrexate Glucuronate) With Leucovorin Protection for Pediatric Patients (Ages 2-12) With Pneumocystis Carinii Pneumonia||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Years|12 Years|No|||July 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002317||209425|
NCT00002324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200C|The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease|A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety, and Tolerance of 1) 400 Mg Nevirapine in Combination With 500-600 Mg Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 3-24 Months of Prior Zidovudine Therapy and 200-500 CD4 Cells/mm3 and 2) 400 Mg Nevirapine Versus Nevirapine Placebo in Asymptomatic HIV-1 Nucleoside Naive Patients With 200-500 CD4 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|13 Years|N/A|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002324||209418|
NCT00002269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|073A|A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen|A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002269||209473|
NCT00002677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064322|Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors|PHASE I STUDY OF THE ORALLY ADMINISTERED BUTYRATE PRODRUG, TRIBUTYRIN, IN PATIENTS WITH SOLID TUMORS||National Cancer Institute (NCI)||Completed|August 1995|||January 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2001|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002677||209102|
NCT00002678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MY7|Combination Chemotherapy in Treating Patients With Multiple Myeloma|A COMPARATIVE STUDY OF DEXAMETHASONE VERSUS PREDNISONE (BOTH IN COMBINATION WITH MELPHALAN) AS INDUCTION THERAPY IN UNTREATED SYMPTOMATIC MYELOMA WITH AN ADDITIONAL ASSESSMENT OF DEXAMETHASONE VERSUS NO ADDITIONAL TREATMENT AS MAINTENANCE THERAPY IN NON-PROGRESSING PATIENTS||Canadian Cancer Trials Group|Yes|Completed|May 1995|December 2009|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|595|||Both|18 Years|N/A|No|||September 2011|September 20, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002678||209101|
NCT00002735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064634|SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue|Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II||Southwest Oncology Group|Yes|Terminated|April 1996|March 2005|Actual|April 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|120 Years|No|||September 2015|September 28, 2015|November 1, 1999|Yes|Yes|Terminated due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00002735||209061|
NCT00002737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30951|Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer|A RANDOMIZED PHASE II TRIAL OF INTERFERON ALPHA-2A WITH AND WITHOUT 13-CIS RETINOIC ACID IN PATIENTS WITH PROGRESSIVE MEASURABLE METASTATIC RENAL CELL CARCINOMA. Amendment Protocol: Extension to a Randomized Phase III Trial||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 1996|||January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|320|||Both|18 Years|75 Years|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002737||209060|
NCT00002364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238C|A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs|An Exploratory Study of the Antiretroviral Activity of 1592U89 When Administered in Combination With Other Specific Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in NRTI Experienced Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|13 Years|N/A|No|||April 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002364||209378|
NCT00002365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258A|A Study of LXR015-1 in HIV-Infected Patients|A Randomized, Parallel, Open-Label Phase I Study of LXR015-1 in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002365||209377|
NCT00002366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|245C|The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma|A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma||Abbott||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002366||209376|
NCT00002270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074A|A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection|A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002270||209472|
NCT00002679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064337|Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer|Sequential Adjuvant Chemotherapy With Doxorubicin, Taxol, and Cyclophosphamide for Stage II or III Resectable Breast Cancer With Four or More Involved Axillary Lymph Nodes||Yale University|No|Completed|February 1994|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|89|||Both|18 Years|N/A|No|||August 2009|August 24, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002679||209100|
NCT00002450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283D|Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Tenofovir Disoproxil Fumarate in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|65 Years|No|||July 2000|June 23, 2005|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00002450||209293|
NCT00002290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018A|The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection|A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002290||209452|
NCT00002359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092|A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega|A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Regardless of Concomitant HIV Therapies||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||3000|||Both|18 Years|N/A|No|||June 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002359||209383|
NCT00002716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9481|Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer|PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER||Alliance for Clinical Trials in Oncology|No|Completed|January 1996|August 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002716||209074|
NCT00002322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210A|A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients|Randomized, Double-Blind, Placebo-Controlled Comparative Dose-Response Study of Two Doses of Atevirdine Mesylate (U-87201E) in Combination With Fixed Doses of Zidovudine (AZT) in HIV+ Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||November 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002322||209420|
NCT00002296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008C|The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease|A Multi-Center Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|50 Years|No|||June 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002296||209446|
NCT00002708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9508|Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases|A PHASE III TRIAL COMPARING WHOLE BRAIN IRRADIATION WITH VERSUS WITHOUT STEREOTACTIC RADIOSURGERY BOOST FOR PATIENTS WITH ONE TO THREE UNRESECTED BRAIN METASTASES||Radiation Therapy Oncology Group|Yes|Completed|January 1996|December 2004|Actual|January 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|333|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002708||209078|
NCT00002753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064689|Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas|PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS||Duke University||Completed|November 1991|April 2001|Actual|April 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|6|||Both|3 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002753||209047|
NCT00002318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134A|A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma|Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||225|||Both|18 Years|N/A|No|||January 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002318||209424|
NCT00002240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302A|Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs|Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen||Bristol-Myers Squibb||Completed|March 1999|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 28, 2011|November 2, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00002240||209501|
NCT00002696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOCS-08-BR-95-III|Combination Chemotherapy in Treating Women With Stage III Breast Cancer|MULTIMODALITY TREATMENT STRATEGY FOR STAGE III BREAST CANCER||National Cancer Institute (NCI)||Suspended|October 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|21 Years|75 Years|No|||April 2008|August 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002696||209088|
NCT00002693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064447|Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia|PHASE I STUDY OF CONTINUOUS INFUSION CARBOPLATIN AND TOPOTECAN IN THE TREATMENT OF RELAPSED ACUTE LEUKEMIA AND BLAST CRISIS CHRONIC MYELOGENOUS LEUKEMIA||Mayo Clinic|Yes|Completed|October 1995|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2011|August 2, 2011|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002693||209090|
NCT00002748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064681|Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma|Phase I Study of Cytokine-Gene Modified Autologous or Partially Matched Allogeneic Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma||St. Jude Children's Research Hospital||Completed|December 1991|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|38|||Both|N/A|21 Years|No|||October 2011|October 3, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002748||209052|
NCT00002754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064690|Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors|PHASE I STUDY OF MONOCLONAL ANTIBODY FRAGMENT 131I MEL-14 F(AB')2 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT MELANOMA AND OTHER BRAIN TUMORS||Duke University||Completed|February 1993|April 2001|Actual|April 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|6|||Both|3 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002754||209046|
NCT00002376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246F|The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients|A Randomized Controlled Clinical Study to Determine If the Addition of HIV RNA Viral Load Is an Effective Tool in Determining Treatment Regimens for HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||540|||Both|18 Years|N/A|No|||June 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002376||209366|
NCT00002377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV15376|A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes|||Hoffmann-La Roche||Completed||||||Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|14 Years|N/A|No|||July 2005|July 1, 2005|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002377||209365|
NCT00002291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022A|The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP Before|A Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002291||209451|
NCT00002740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3951|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma|Phase I Pilot Study of Multiple Cycles of High Dose Chemotherapy With Peripheral Blood Stem Cell Infusions In Advanced Stage Neuroblastoma||Children's Oncology Group|Yes|Completed|May 1996|September 2005|Actual|March 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|21 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002740||209058|
NCT00002449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B007|Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy|A Bridging Dose-Escalation Study of the Safety, Pharmacokinetic Properties, and Immunologic Effect of Subcutaneous L2-7001 (Recombinant Human Interleukin-2) in Patients Infected With HIV With CD4+ T-Cell Counts of 300 to 500 Cells/mm3 and Viral Burden Under 10,000 Copies/Ml on Active Antiretroviral Therapy (ART)||NIH AIDS Clinical Trials Information Service||Active, not recruiting|August 1999|||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||212|||Both|18 Years|N/A|No|||July 2001|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002449||209294|
NCT00002750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2117|Melphalan in Patients With Neoplastic Meningitis|Phase I of Intrathecal Melphalan in Patients With Recurrent Neoplastic Meningitis||Duke University||Completed|December 1992|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|6|||Both|3 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002750||209050|
NCT00002284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014A|A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant|A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|50 Years|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002284||209458|
NCT00002285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014B|A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS|A Phase I/II Pilot Trial To Evaluate Zidovudine (AZT) and T Lymphocyte Transfer in the Treatment of Human Immunodeficiency Virus Type-III (HIV) Infection in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002285||209457|
NCT00002286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014F|A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients|Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients: A Pilot Study||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002286||209456|
NCT00002588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2994|Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia|Phase I Trial of Sequential Topotecan(NSC 609699)and Etoposide for Patients With Relapsed, Refractory,or High Risk Acute Myeloid or Lymphoid Leukemia||Case Comprehensive Cancer Center|Yes|Completed|August 1994|January 2001|Actual|July 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002588||209172|
NCT00002589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063744|Lymphocyte Therapy in Treating Patients With Kidney Cancer|Adjuvant Autolymphocyte Therapy (ALT) For Patients With Non-Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|July 1994|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|90|||Both|16 Years|N/A|No|||December 2005|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002589||209171|
NCT00002241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246T|Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily|A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 100 Mg/d4T/3TC b.i.d. in HIV-Infected Individuals||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||80|||Both|16 Years|N/A|No|||July 2001|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002241||209500|
NCT00002362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298B|A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients||NIH AIDS Clinical Trials Information Service||Suspended|August 1999|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002362||209380|
NCT00002321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|086A|A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis|A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002321||209421|
NCT00002276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044A|The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia|Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||June 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002276||209466|
NCT00002277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012N|A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections|Fluconazole Versus Amphotericin B: A Prospective, Randomized, Multicenter Study for Therapy of Fungal Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||December 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002277||209465|
NCT00002278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|038B|A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS|28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|65 Years|No|||July 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002278||209464|
NCT00002367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229F|A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs|An Open-Label, Non-Comparative Study of Saquinavir-SGC in Combination With Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients With No Previous Anti-Retroviral Drug Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||40|||Both|16 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002367||209375|
NCT00002368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200E|The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs|An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS Progression Events or Death When Used in Combination With Lamivudine (3TC) and Stable (>= 4 Weeks) Background Nucleoside Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||2000|||Both|13 Years|N/A|No|||August 2002|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002368||209374|
NCT00002247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|059C|A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy|A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||225|||Both|13 Years|N/A|No|||March 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002247||209495|
NCT00002301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020B|A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir|Foscarnet Treatment of Cytomegalovirus (CMV) Retinitis in AIDS Patients Not Eligible for Ganciclovir Therapy and Ganciclovir Treatment Failures||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002301||209441|
NCT00002546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0150|Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus|A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus||Gynecologic Oncology Group||Completed|December 1993|||September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|216|||Female|21 Years|120 Years|No|||February 2016|February 10, 2016|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002546||209212|
NCT00002547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063305|Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome|ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA||Barbara Ann Karmanos Cancer Institute||Completed|August 1987|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|N/A|60 Years|No|||August 2012|August 6, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002547||209211|
NCT00002553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160.06|Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer|TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MARROW TRANSPLANTATION FROM UNRELATED DONORS MATCHED FOR HLA OR INCOMPATIBLE FOR ONE HLA LOCUS ANTIGEN||Fred Hutchinson Cancer Research Center||Completed|August 1990|June 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|55 Years|No|||November 2011|November 28, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002553||209205|
NCT00002309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058I|A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients|A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Azithromycin as Prophylaxis Against the Development of Mycobacterium Avium Complex Disease in HIV-Infected People||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002309||209433|
NCT00002325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012R|A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common|A Double-Blind, Placebo-Controlled Study of Fluconazole in the Prevention of Active Coccidioidomycosis and Other Systemic Fungal Infections in HIV-Infected Patients Living in the Coccidioidal Endemic Area||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002325||209417|
NCT00002326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217B|The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients|A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of Combination Zidovudine (AZT) and 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA; Adefovir) Treatment in HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||October 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002326||209416|
NCT00002302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004B|The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002302||209440|
NCT00002580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063695|Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer|PROTOCOL FOR THE SCOTTISH PREMENOPAUSAL CHEMO-ENDOCRINE TRIAL||National Cancer Institute (NCI)||Completed|June 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Female|N/A|70 Years|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002580||209179|
NCT00002560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-018|Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma|PHASE II TRIAL OF MONOCLONAL ANTIBODY 3F8 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) FOR NEUROBLASTOMA||Memorial Sloan Kettering Cancer Center||Completed|February 1994|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|2 Years|21 Years|No|||June 2013|June 27, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002560||209198|
NCT00002561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD6|Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease|A PHASE III STUDY OF RADIOTHERAPY OR ABVD PLUS RADIOTHERAPY VERSUS ABVD ALONE IN THE TREATMENT OF EARLY STAGE HODGKIN'S DISEASE||Canadian Cancer Trials Group|Yes|Completed|January 1994|January 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|405|||Both|16 Years|N/A|No|||January 2012|October 5, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002561||209197|
NCT00002327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219A|The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients|A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Condyloma Acuminatum in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002327||209415|
NCT00002344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226C|A Study of Azithromycin in HIV-Infected Patients|Double-Blind Crossover Study Assessing the Dose Proportionality of Azithromycin Tablets in HIV-Infected Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||12|||Both|18 Years|65 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002344||209398|
NCT00002345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025C|The Safety and Effectiveness of Megace in HIV-Infected Women|Phase IV Study on the Safety and Efficacy of Megace Oral Suspension in HIV-Positive Females||Bristol-Myers Squibb||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Female|18 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002345||209397|
NCT00002565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063574|Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma|RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY ("ATT") VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5||M.D. Anderson Cancer Center|No|Completed|May 1994|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|15 Years|N/A|No|||October 2012|October 5, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002565||209193|
NCT00002566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063579|Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors|INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS||National Cancer Institute (NCI)||Active, not recruiting|February 1994|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|280|||Male|16 Years|N/A|No|||May 2007|November 2, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002566||209192|
NCT00002249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105A/B|A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection|A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||September 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002249||209493|
NCT00002250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|076A|A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura|A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002250||209492|
NCT00002373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263A|The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients|A Phase I/II Trial to Evaluate the Tolerability, Anti-CMV Activity and Pharmacokinetics of 1263W94 Following Multiple Oral Administration of Escalating Doses in HIV-Infected Patients With Asymptomatic CMV Shedding||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||56|||Male|18 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002373||209369|
NCT00002374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229G|A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients|A Phase IIIB Open-Label Trial Replacing Saquinavir HGC (Ro 31-8959) With Saquinavir SGC (Ro 31-8959) in Combination With Other Antiretroviral Drugs in Patients With HIV-1 Infection||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||120|||Both|16 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002374||209368|
NCT00002244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222C|A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pivotal Clinical Study Evaluating the Safety and Efficacy of WF10 (TCDO) Intravenous Solution in the Management of Patients With Late-Stage HIV Disease||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||March 2001|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002244||209498|
NCT00002245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264L|A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients|Effect of Amprenavir on Carbohydrate and Lipid Metabolism in Patients With HIV Infection||NIH AIDS Clinical Trials Information Service||Completed|April 1999|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002245||209497|
NCT00002255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|077A|An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)|An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002255||209487|
NCT00002352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248A|A Study of Lobucavir in Patients With AIDS|Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002352||209390|
NCT00002353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090|A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||July 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002353||209389|
NCT00002257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|059B|A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS|A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||150|||Both|13 Years|N/A|No|||July 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002257||209485|
NCT00002258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080A|A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia|A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002258||209484|
NCT00002266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045B|An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients|An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||December 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002266||209476|
NCT00002548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWOG-9321|SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma|Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study||Southwest Oncology Group|Yes|Completed|January 1994|November 2006|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|899|||Both|18 Years|70 Years|No|||March 2015|March 5, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002548||209210|
NCT00002549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063311|Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia|RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL||National Cancer Institute (NCI)||Active, not recruiting|November 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1520|||Both|15 Years|60 Years|No|||December 2009|December 22, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002549||209209|
NCT00002571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063620|SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma|Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II||Southwest Oncology Group|No|Completed|June 1994|July 2011|Actual|November 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002571||209187|
NCT00002341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236C|A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole|An Open-Label Extension Study of Maintenance Therapy in HIV-Positive Subjects With Fluconazole-Refractory Oropharyngeal Candidiasis Who Have Responded to Itraconazole Oral Solution||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002341||209401|
NCT00002319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134C|A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma|Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002319||209423|
NCT00002320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129B|A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past|A Randomized, Double-Blind Multicenter Trial to Compare the Safety and Efficacy of Lamivudine (3TC; GR109714X) Monotherapy Versus Zidovudine (AZT) Monotherapy Versus 3TC Administered With AZT in the Treatment of HIV-1 Infected Patients Who Are AZT Naive (< 4 Weeks) With CD4 Cell Counts of 200-500 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|12 Years|N/A|No|||May 1994|December 8, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002320||209422|
NCT00002558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-162|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors|PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES||Memorial Sloan Kettering Cancer Center||Completed|January 1994|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|15 Years|N/A|No|||October 2015|October 28, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002558||209200|
NCT00002559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-012|Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin|PHASE I/II TRIAL OF TAXOL, IFOSFAMIDE, AND CISPLATIN FOR CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH FAVORABLE PROGNOSTIC FEATURES||Memorial Sloan Kettering Cancer Center||Completed|January 1994|January 2003|Actual|January 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|43|||Both|15 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002559||209199|
NCT00002587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02235|Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors|A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH PACLITAXEL (TAXOL)||National Cancer Institute (NCI)||Completed|September 1994|December 2000|Actual|December 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2001|May 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002587||209173|
NCT00002256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031D|Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.|Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||August 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002256||209486|
NCT00002342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088C|A Study of Tecogalan Sodium|A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Twice Weekly for 21 Days||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002342||209400|
NCT00002313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103C|A Study of Nystatin in HIV-Infected Patients|Extended Maintenance Protocol for Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection (NOTE: Continuation Study Intended Only for Patients Who Have Completed FDA 103B)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002313||209429|
NCT00002314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128A|A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma|A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002314||209428|
NCT00002315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130A|A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems|A Double-Blind, Multicenter Study Comparing Oral 882C87 With Oral Acyclovir for Treatment of Localized Herpes Zoster in Immunocompromised Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||May 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002315||209427|
NCT00002576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-TU-NH3003|Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma|A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER)||National Cancer Institute (NCI)||Completed|November 1992|January 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|65 Years|N/A|No|||May 2007|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002576||209183|
NCT00002264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068A|The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea|Efficacy of Cow's Milk Immune Globulin in the Treatment of Chronic Intestinal Cryptosporidiosis in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002264||209478|
NCT00002260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054C|An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects|An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002260||209482|
NCT00002271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054A|An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects|An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002271||209471|
NCT00002349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244A|A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.|A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.||Bristol-Myers Squibb||Completed|January 1995|May 1999|Actual|May 1999|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2011|April 13, 2011|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002349||209393|
NCT00002267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|048B|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|18 Years|N/A|No|||March 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002267||209475|
NCT00002253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102B|A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.|A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1992|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002253||209489|
NCT00002254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054B|A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)|A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002254||209488|
NCT00002360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039H|A Study Comparing Two Forms of Didanosine in HIV-infected Patients|Pivotal Bioequivalence Study of Videx Chewable/Dispersible Buffered Tablets and an Encapsulated Enteric Coated Bead Formulation of Didanosine in HIV-Infected Subjects||Bristol-Myers Squibb||Completed|March 1999|March 1999|Actual|March 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|50 Years|No|||April 2011|April 13, 2011|November 2, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002360||209382|
NCT00002268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071A|A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria|A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1991|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002268||209474|
NCT00002281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061A|A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex|An Open Label Phase I/II Study of Recombinant Granulocyte Colony-Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With AIDS or ARC||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002281||209461|
NCT00002333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229A|A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine|A Randomized, Double-Blind, Multicenter, Parallel Study of Ro 31-8959 (Saquinavir; HIV Proteinase Inhibitor) Alone, HIVID (Dideoxycytidine; Zalcitabine, ddC) Alone, and Both in Combination, as Treatment for Advanced HIV Infection (CD4 50-300 Cells/mm3) in Patients Discontinuing or Unable to Take Retrovir (Zidovudine; AZT) Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|18 Years|N/A|No|||February 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002333||209409|
NCT00002550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9309|Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|March 1994|November 2013|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|429|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002550||209208|
NCT00002551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063349|SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed|Postoperative Evaluation of 5-FU by Bolus Injection vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT Plus Bolus 5-FU Plus Leucovorin in Patients With Rectal Cancer, Phase III||Southwest Oncology Group|Yes|Completed|March 1994|October 2008|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1917|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002551||209207|
NCT00002554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|832.00|Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse|RADIOLABELED BC8 (ANTI-CD45) ANTIBODY COMBINED WITH BUSULFAN AND CYCLOPHOSPHAMIDE AS TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA IN FIRST OR SECOND REMISSION OR UNTREATED FIRST RELAPSE FOLLOWED BY HLA-IDENTICAL RELATED MARROW TRANSPLANTATION||Fred Hutchinson Cancer Research Center||Completed|November 1993|December 1999|Actual|December 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|16 Years|55 Years|No|||March 2010|March 29, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002554||209204|
NCT00002562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063506|Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer|EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA||National Cancer Institute (NCI)||Completed|March 1994|August 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Female|N/A|N/A|No|||December 2005|June 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002562||209196|
NCT00002310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120A|SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir|A Pilot Study to Determine the Safety and Efficacy of Topically Applied SP-303T in Patients With Acquired Immunodeficiency Syndrome and Concomitant Herpes Simplex Virus (HSV) Infection Unresponsive to Acyclovir||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002310||209432|
NCT00002334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229B|A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment|A Randomized, Multicenter, Double-Blind, Phase III, Parallel Study of Zidovudine (AZT) Alone Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus AZT Plus Saquinavir Mesylate (Ro 31-8959 ; HIV Proteinase Inhibitor) Versus AZT Plus ddC Plus Ro 31-8959 in Previously Untreated or Minimally Pretreated HIV-Infected Patients With CD4 Lymphocyte Counts From 50 to <= 350 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||3000|||Both|18 Years|N/A|No|||September 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002334||209408|
NCT00002330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|059F|A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|A Randomized Study Comparing the Safety and Efficacy of Three Doses of Oral Ganciclovir to Intravenous Ganciclovir for the Maintenance Treatment of Cytomegalovirus Retinitis in People With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||280|||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002330||209412|
NCT00002331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214A|The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS|A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS||Abbott||Completed|January 1994|March 1995|Actual|March 1995|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 2009|January 15, 2015|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002331||209411|
NCT00002570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO10|Immediate Compared With Delayed Chemotherapy in Treating Patients With Advanced Colorectal Cancer Without Signs or Symptoms of Disease|A PHASE III STUDY OF IMMEDIATE VERSUS DELAYED CHEMOTHERAPY FOR ASYMPTOMATIC ADVANCED COLORECTAL CANCER||Canadian Cancer Trials Group|Yes|Completed|July 1994|February 2009|Actual|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|79 Years|No|||September 2011|September 20, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002570||209188|
NCT00002510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078066|Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY RESCUE WITH MOBILIZED AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH LOW-GRADE, TRANSFORMED, OR FOLLICULAR LARGE CELL NON-HODGKIN'S LYMPHOMA||Temple University||Completed|April 1992|June 2001|Actual|June 2001|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|65 Years|No|||September 2010|September 30, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002510||209243|
NCT00002311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122A|The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients|A Phase I-II Dose Escalation Study to Examine the Safety of Four Doses of Wobenzym in HIV Seropositive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002311||209431|
NCT00002312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125A|The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine|Open-Label Escalating Multiple-Dose Study of the Safety, Tolerance, and Pharmacokinetics of Oral U-90152 in HIV-1 Infected Males and Females With CD4 Counts of 200 - 500 Cells/mm3 Who Are Maintained on a Stable Dose of Zidovudine (AZT)||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002312||209430|
NCT00002356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251C|The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes|An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002356||209386|
NCT00002262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066A|A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma|A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|70 Years|No|||December 1988|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002262||209480|
NCT00002263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067B|A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine|A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|6 Months|12 Years|No|||January 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002263||209479|
NCT00002265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031C|An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492|An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002265||209477|
NCT00002355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251A|A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes|A Randomized Comparison of Immediate Versus Delayed Treatment With Intravitreal Injections of ISIS 2922 in Patients With Peripheral Cytomegalovirus (CMV) Retinitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002355||209387|
NCT00002369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260A|A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|An Open Label, Randomized, Comparative Study of Zerit (d4T) + Epivir (3TC) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700 Cells/mm3 and HIV RNA Baseline Copy Number of >= 10,000 Copies/ml||Bristol-Myers Squibb||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||200|||Both|16 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002369||209373|
NCT00002282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012M|A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS|A Randomized Multicenter Study of the Efficacy, Safety, and Toleration of Fluconazole or Clotrimazole Troches in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||February 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002282||209460|
NCT00002283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007A|A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002283||209459|
NCT00002552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063370|Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma|AUTOLOGOUS, ALLOGENEIC, OR SYNGENEIC BONE MARROW TRANSPLANTATION IN HODGKIN'S DISEASE, NON-HODGKIN'S LYMPHOMA, AND MULTIPLE MYELOMA||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 1993|October 2003|Actual|September 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|70 Years|No|||April 2013|April 5, 2013|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002552||209206|
NCT00002555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22931|High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer|A PHASE III RANDOMIZED STUDY ON POSTOPERATIVE RADIO- AND CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CARCINOMAS||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 1994|||October 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|338|||Both|18 Years|70 Years|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002555||209203|
NCT00002370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254B|Study of Itraconazole in Patients With Advanced HIV Infection|Pharmacokinetics Study of Intravenous Itraconazole Followed by Oral Dosing at 200 Mg Twice Daily in Patients With Advanced HIV Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002370||209372|
NCT00002371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244B|The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine|A Randomized Double-Blind Study of Safety, Virologic and Immunological Effects of Stavudine Plus Lamivudine (3TC) Versus Zidovudine Plus Lamivudine in HIV-Infected Subjects Following At Least Six Months of Zidovudine Therapy||Bristol-Myers Squibb||Completed|June 1996|December 1997|Actual|December 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|November 2, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00002371||209371|
NCT00002303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004D|The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in Patients With AIDS or Advanced ARC and Anemia||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002303||209439|
NCT00002581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063696|Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer|PROTOCOL FOR THE SCOTTISH POSTMENOPAUSAL CHEMO-ENDOCRINE TRIAL||National Cancer Institute (NCI)||Completed|June 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Female|N/A|70 Years|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002581||209178|
NCT00002297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008A|A Study of Isoprinosine in Patients With Lymph Node Disease|A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 1989|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002297||209445|
NCT00002298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013A|The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection|Long-Term Efficacy and Tolerance of Oral Ribavirin Compared to Placebo as a Preventative in Early Stages of Human Immunodeficiency Virus Infection - United States||NIH AIDS Clinical Trials Information Service||Terminated||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||March 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002298||209444|
NCT00002299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017A|The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|Combination Therapy With 9-(1,3-Dihydroxy-2-Propoxymethyl) Guanine (DHPG) and Interferon Beta for the Prevention of Relapse of Cytomegalovirus Retinitis in Patients With the Acquired Immunodeficiency Syndrome||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||April 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002299||209443|
NCT00002300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025A|A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition|Phase II-III Randomized Double-Blind Study Comparing Megestrol Acetate at 100, 400, and 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia||Bristol-Myers Squibb||Completed||||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2007|October 1, 2007|November 2, 1999||||||https://clinicaltrials.gov/show/NCT00002300||209442|
NCT00002343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|048E|A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS|An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts <= 100 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||June 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002343||209399|
NCT00002339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120|A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems|An Open Multicenter Trial of Fluconazole Oral Suspension in the Treatment of Esophageal Candidiasis in Immunocompromised Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|13 Years|70 Years|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002339||209403|
NCT00002340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|227B|A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX|A Randomized, Open-Label Trial of High Dose Atovaquone Versus Low Dose Atovaquone Versus Aerosolized Pentamidine for Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With HIV Infection Who Are Intolerant of TMP/SMX||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||615|||Both|13 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002340||209402|
NCT00002328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058J|Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs|Oral/Intravenous Azithromycin in the Treatment of Cryptosporidiosis in Patients Whose Disease Has Not Been Controlled by Conventional Therapy||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002328||209414|
NCT00002329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221A|A Study of MDL 28,574A in HIV-Infected Patients|A Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Oral Dose-Tolerance Study of Oral MDL 28,574A Solution in HIV-Positive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|No|||May 1995|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002329||209413|
NCT00002363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257A|The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients|Study of the Safety and Effects of Two Doses of SPC3, Administered Daily Intravenously in HIV-1 Seropositive Patients||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||April 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002363||209379|
NCT00002873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9517|Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer|A PHASE I/II TRIAL TO EVALUATE BRACHYTHERAPY AS THE SOLE METHOD OF RADIATION THERAPY FOR STAGE I AND II BREAST CARCINOMA||Radiation Therapy Oncology Group|Yes|Completed|May 1997|||June 2007|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||February 2008|July 17, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002873||208950|
NCT00002874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9601|Radiation Therapy With or Without Bicalutamide in Treating Patients With Stage II, Stage III, or Recurrent Prostate Cancer|A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE||Radiation Therapy Oncology Group|Yes|Active, not recruiting|February 1998|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|840|||Male|N/A|N/A|No|||March 2015|March 26, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002874||208949|
NCT00002898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065228|Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma|MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood||National Cancer Institute (NCI)||Completed|January 1995|December 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|N/A|17 Years|No|||May 1999|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002898||208929|
NCT00002904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16951|Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors|PHASE I CLINICAL AND PHARMACOKINETIC STUDY TO DETERMINE THE SAFETY OF ECTEINASCIDIN-743 (ET-743) ADMINISTERED AS A SINGLE INTRAVENOUS INFUSION OVER 60 MINUTES EVERY 21 DAYS IN PATIENTS WITH SOLID TUMORS||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002904||208923|
NCT00002519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC LUN65|Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer|PH I Continuous Infusion Taxol in Combination With Thoracic Radiation Therapy in Untreated Locally Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)|Yes|Completed|January 1997|January 2000|Actual|January 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|6|||Both|18 Years|N/A|No|||April 2011|May 1, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002519||209237|
NCT00002903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16945T|Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer|PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 1995|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002903||208924|
NCT00002880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065180|Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|PHASE II STUDY OF ORAL ETOPOSIDE WITH PHARMACODYNAMIC MODELING IN RELAPSED NON-HODGKIN'S LYMPHOMA (IWF GRADES A-H)||Alliance for Clinical Trials in Oncology|No|Completed|November 1996|January 2008|Actual|January 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|N/A|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002880||208944|
NCT00002909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02250|Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma|A PHASE I CLINICAL AND PHARMACOLOGIC EVALUATION OF PHENYLBUTYRATE IN PATIENTS WITH REFRACTORY SOLID TUMORS: STUDY OF CONTINUOUS EXPOSURE ORAL PHENYLBUTYRATE ON A THREE TIMES DAILY SCHEDULE||National Cancer Institute (NCI)||Completed|February 1997|||October 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2001|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002909||208919|
NCT00002839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-24954|Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx|PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 1996|||May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|564|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002839||208975|
NCT00002846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065085|Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer|TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH LOW-DOSE INTRAVENOUS RECOMBINANT INTERLEUKIN-2||National Cancer Institute (NCI)||Active, not recruiting|September 1995|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|14|||Both|18 Years|N/A|No|||December 2003|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002846||208970|
NCT00002473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30904|Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer|A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 1992|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 11, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002473||209275|
NCT00002622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063982|Talc in Treating Patients With Malignant Pleural Effusion|Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study||Alliance for Clinical Trials in Oncology|Yes|Completed|December 1994|January 2006|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|501|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002622||209147|
NCT00002623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08941|Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1994|||December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|640|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002623||209146|
NCT00002838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM95-194|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia|Phase I/II Pilot Study of Allogeneic Peripheral Blood Stem Cell Infusion For Patients With High Risk Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|December 1995|July 2002|Actual|July 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|65 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002838||208976|
NCT00002441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX 004|Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection|A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1 Infection in North America||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||5000|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002441||209302|
NCT00002493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0122|Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer|WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III||Gynecologic Oncology Group|Yes|Completed|May 1992|||April 2001|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||February 2014|February 12, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002493||209258|
NCT00002494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077643|Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia|HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN||Alliance for Clinical Trials in Oncology|No|Completed|May 1992|January 2006|Actual|March 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|134|||Both|15 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002494||209257|
NCT00002908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065273|Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA AND CLL||Barbara Ann Karmanos Cancer Institute|Yes|Completed|December 1996|November 2001|Actual|February 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002908||208920|
NCT00002595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGH-1011|Toremifene in Treating Patients With Desmoid Tumors|PHASE II STUDY OF THE SAFETY AND EFFICACY OF TOREMIFENE IN THE THERAPY OF DESMOID TUMORS||National Cancer Institute (NCI)||Completed|July 1991|September 2010|Actual|May 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|72|||Both|16 Years|N/A|No|||August 2010|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002595||209166|
NCT00002516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078196|Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma|EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92]||National Cancer Institute (NCI)||Active, not recruiting|July 1992|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|N/A|35 Years|No|||January 2010|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002516||209239|
NCT00002517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078212|Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome|IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY||National Cancer Institute (NCI)||Completed|March 1993|||May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|14 Years|No|||December 2002|June 19, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002517||209238|
NCT00002442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225C|A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs|A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of Epivir 150 Mg BID Versus Epivir 300 Mg Once-Daily When Administered for 24 Weeks in Combination With FDA-Approved Dosage Regimens of Zerit and Either Crixivan or Viracept in Subjects With HIV-1 Infection||NIH AIDS Clinical Trials Information Service||Completed|June 1999|||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002442||209301|
NCT00002893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065216|Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer|CHEMOTHERAPY CHOICES IN ADVANCED COLORECTAL CANCER: A RANDOMISED TRIAL COMPARING 2 DURATIONS AND 3 SYSTEMIC CHEMOTHERAPY REGIMENS IN THE PALLIATIVE TREATMENT OF ADVANCED COLORECTAL CANCER||National Cancer Institute (NCI)||Active, not recruiting|June 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|900|||Both|N/A|N/A|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002893||208934|
NCT00002881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065185|Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer|PHASE III TRIAL OF ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE + SURAMIN + HYDROCORTISONE VS ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE IN PATIENTS WITH METASTATIC PROSTATE CANCER||National Cancer Institute (NCI)||Completed|October 1996|||April 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||May 2007|November 6, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002881||208943|
NCT00002882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID95-196|Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma|Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2||M.D. Anderson Cancer Center|No|Completed|November 1995|April 2006|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|140|||Both|10 Years|70 Years|No|||December 2011|December 12, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002882||208942|
NCT00002470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAOP-5190|Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors|A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid||National Cancer Institute (NCI)||Completed|September 1990|January 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|May 14, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002470||209278|
NCT00002474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMC-3007|Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer|Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma||National Cancer Institute (NCI)||Completed|February 1991|October 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|64 Years|No|||March 2003|May 29, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002474||209274|
NCT00002889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065212|Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer|PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY||Alliance for Clinical Trials in Oncology|No|Completed|May 1997|June 2009|Actual|January 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Male|30 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002889||208937|
NCT00002480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-022|Radiation Therapy in Treating Patients With Prostate Cancer|Phase I Study of 3-Dimensional Conformal Radiotherapy in Patients With Locally Advanced (Stage T2c and T3) Adenocarcinoma of the Prostate||Memorial Sloan Kettering Cancer Center||Completed|February 1991|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002480||209268|
NCT00002840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26951|Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma|PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 1996|||March 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|350|||Both|16 Years|69 Years|No|||July 2012|July 6, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002840||208974|
NCT00002849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9628|S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis|Phase II Study of Dexamethasone/Alpha-Interferon in AL Amyloidosis||Southwest Oncology Group|Yes|Completed|November 1996|July 2000|Actual|December 1998|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002849||208967|
NCT00002845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065084|Interleukin-2 in Treating Patients With Metastatic Melanoma|TREATMENT OF METASTATIC MELANOMA WITH RECOMBINANT INTERLEUKIN-2||National Cancer Institute (NCI)||Active, not recruiting|September 1995|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||May 2000|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002845||208971|
NCT00002490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077404|Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer|A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER||National Cancer Institute (NCI)||Completed|September 1991|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2001|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002490||209260|
NCT00002492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-89253|Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma|CLINICAL AND PHARMACOLOGICAL STUDY OF CHEMOTHERAPY IN SOFT TISSUE SARCOMA||University of Miami Sylvester Comprehensive Cancer Center||Completed|November 1991|February 2000|Actual|February 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|July 25, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002492||209259|
NCT00002448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229S|A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients|Evaluation of Immune Reconstitution in HIV Infected Patients Treated With Fortovase (Saquinavir) SGC QD Plus Ritonavir QD Plus 2 NRTIs Vs Efavirenz QD Plus 2 NRTIs||NIH AIDS Clinical Trials Information Service||Completed|October 1999|||||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||40|||Both|16 Years|N/A|No|||January 2001|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002448||209295|
NCT00002875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9961|Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma|Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA||Children's Oncology Group|Yes|Completed|December 1996|January 2011|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|421|||Both|3 Years|22 Years|No|||July 2014|July 31, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002875||208948|
NCT00002602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-3D/OG-9406|Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer|A PHASE I/II DOSE ESCALATION STUDY USING THREE DIMENSIONAL CONFORMAL RADIATION THERAPY FOR ADENOCARCINOMA OF THE PROSTATE||Radiation Therapy Oncology Group|Yes|Completed|May 1994|November 2013|Actual|March 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1084|||Male|18 Years|N/A|No|||March 2015|March 26, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002602||209159|
NCT00002447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229R|A Study to Compare Two Anti-HIV Drug Combinations|An Open Label, Randomized, Multicenter Study to Evaluate Fortovase (Saquinavir) SGC QD, Norvir (Ritonavir) QD Plus Two NRTIs Vs Sustiva (Efavirenz) QD Plus Two NRTIs in HIV Infected Patients||NIH AIDS Clinical Trials Information Service||Completed|October 1999|||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||146|||Both|18 Years|N/A|No|||January 2001|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002447||209296|
NCT00002902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065242|Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors|PHASE I TRIAL OF IRINOTECAN AND TOMUDEX IN COMBINATION ON AN EVERY THREE WEEK SCHEDULE||National Cancer Institute (NCI)||Completed|April 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2002|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002902||208925|
NCT00002899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22952-26001|Adjuvant Radiation Therapy in Treating Patients With Brain Metastases|Phase III Trial on Convergent Beam Irradiation of Cerebral Metastases||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|November 1996|||November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|340|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999|||Low accrual|No||https://clinicaltrials.gov/show/NCT00002899||208928|
NCT00002533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-19920577|Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer|A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|February 1993|August 2006|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||August 2013|July 25, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002533||209224|
NCT00002525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078337|Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed|PHASE III INTERGROUP PROSPECTIVELY RANDOMIZED TRIAL OF PERI-OPERATIVE 5-FU AFTER CURATIVE RESECTION, FOLLOWED BY 5-FU/LEVAMISOLE FOR PATIENTS WITH COLON CANCER||Eastern Cooperative Oncology Group||Active, not recruiting|August 1993|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2001|April 2, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002525||209231|
NCT00002526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 57/93|Chemotherapy in Treating Patients With Advanced Sarcoma|Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma||Swiss Group for Clinical Cancer Research|Yes|Completed|January 1993|September 1995|Actual|September 1995|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002526||209230|
NCT00002860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065130|SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma|A Phase II Trial of Complete Surgical Resection For Stage IV Melanoma -- Surgical Resection With Biological Evaluation and Clinical Follow-Up||Southwest Oncology Group|No|Completed|November 1996|December 2010|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||January 2012|January 11, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002860||208960|
NCT00002852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02967|Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer|A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG||National Cancer Institute (NCI)||Completed|October 1996|||July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002852||208964|
NCT00002471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-013|Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|February 1990|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002471||209277|
NCT00002475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVMC-ONC-222|Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer|A Trial of Active Intralymphatic Immunotherapy With Interferon-Treated Cells and Cyclophosphamide||National Cancer Institute (NCI)||Completed|April 1991|June 2009|Actual|December 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2008|July 9, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002475||209273|
NCT00002876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065162|Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas|A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS||Mayo Clinic||Completed|October 1991|January 2005|Actual|April 1998|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002876||208947|
NCT00002615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063914|Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer|A RANDOMISED, CONTROLLED TRIAL OF PRE- AND POST-OPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER||National Cancer Institute (NCI)||Completed|June 1994|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|N/A|N/A|No|||August 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002615||209153|
NCT00002616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063925|Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer|A PILOT TRIAL OF INTERLEUKIN-2 WITH G-CSF AS PRIMING THERAPY FOR PERIPHERAL BLOOD STEM CELL HARVESTING IN PATIENTS WITH ADVANCED BREAST CANCER: STAMP V HIGH DOSE CHEMOTHERAPY, STEM CELL INFUSION AND POST-INFUSION G-CSF AND INTERLEUKIN-2||National Cancer Institute (NCI)||Active, not recruiting|February 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|N/A|64 Years|No|||September 2000|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002616||209152|
NCT00002504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077942|Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer|OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER||Hoag Memorial Hospital Presbyterian|No|Completed|August 1992|February 1999|Actual|February 1998|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002504||209249|
NCT00002453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283C|A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection|An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients||NIH AIDS Clinical Trials Information Service||Completed|December 1999|||||N/A|Interventional|Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||May 2000|June 23, 2005|January 24, 2000||||No||https://clinicaltrials.gov/show/NCT00002453||209290|
NCT00002866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA15|Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer|A PHASE I/II STUDY OF DOCETAXEL AND EPIRUBICIN AS FIRST LINE THERAPY FOR METASTATIC BREAST CANCER||Canadian Cancer Trials Group||Completed|August 1996|December 2009|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Female|16 Years|N/A|No|||November 2010|November 7, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002866||208955|
NCT00002539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-80931|Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma|A RANDOMISED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT GRANULOCYTE COLONY-STIMULATING FACTOR IN OPERABLE OSTEOSARCOMA||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 1993|||October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|214|||Both|N/A|40 Years|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002539||209218|
NCT00002872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065154|Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions|A PROSPECTIVE RANDOMIZED TRIAL OF BLEOMYCIN VS. DOXYCYCLINE VS. TALC FOR THE INTRAPLEURAL TREATMENT OF MALIGNANT PLEURAL EFFUSIONS||Eastern Cooperative Oncology Group||Completed|November 1996|||February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|480|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002872||208951|
NCT00002887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065207|Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer|PHASE I TRIAL OF HYDROXYUREA FOR SALVAGE OF INCURABLE NON-SMALL CELL LUNG CANCER||National Cancer Institute (NCI)||Active, not recruiting|July 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||October 2001|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002887||208939|
NCT00002888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065210|Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer|A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER||National Cancer Institute (NCI)||Completed|March 1997|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002888||208938|
NCT00002883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065190|Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus|A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION||National Cancer Institute (NCI)||Active, not recruiting|October 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|250|||Both|N/A|75 Years|No|||April 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002883||208941|
NCT00002472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000076756|Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors|Phase II Pre-Irradiation Chemotherapy for Central Nervous System Germ Cell Malignancies||Mayo Clinic||Completed|March 1991|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|3 Years|N/A|No|||March 2011|March 14, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002472||209276|
NCT00002897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065226|Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus|RANDOMIZED STUDY OF PREOPERATIVE CHEMOTHERAPY VERSUS SURGERY ALONE IN ESOPHAGUS CANCER||National Cancer Institute (NCI)||Completed|July 1992|June 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|75 Years|No|||May 2007|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002897||208930|
NCT00002894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065217|Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer|A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER||National Cancer Institute (NCI)||Completed|March 1996|June 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Female|N/A|N/A|No|||February 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002894||208933|
NCT00002890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-010|Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia|PHASE I DOSE-ESCALATION TRIAL OF YTTRIUM-90-LABELED HuM195 (HUMANIZED ANTI-CD33) IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES||Memorial Sloan Kettering Cancer Center||Completed|October 1996|January 2001|Actual|January 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|16 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002890||208936|
NCT00002479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI T91-0136|Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome|Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome||Northwestern University|Yes|Completed|October 1991|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 17, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002479||209269|
NCT00002611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9440|Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer|NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY||Children's Oncology Group|Yes|Completed|July 1995|August 2003|Actual|June 2002|Actual|Phase 3|Interventional|Primary Purpose: Treatment|9||Actual|3031|||Both|N/A|15 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002611||209154|
NCT00002864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA14|Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer|A RANDOMIZED TRIAL OF ANTIESTROGEN THERAPY VERSUS COMBINED ANTIESTROGEN AND OCTREOTIDE LAR THERAPY IN THE ADJUVANT TREATMENT OF BREAST CANCER IN POST-MENOPAUSAL WOMEN||Canadian Cancer Trials Group|Yes|Completed|August 1996|April 2010|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|667|||Female|N/A|N/A|No|||September 2011|September 20, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002864||208957|
NCT00002430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246R|A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations|A Multicenter, Open-Label, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate/d4T/3TC Versus Indinavir Sulfate/Nelfinavir Mesylate/d4T/3TC in HIV-Infected Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||220|||Both|16 Years|N/A|No|||February 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002430||209313|
NCT00002431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050A|The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients|A Multi-Center Trial to Evaluate the Safety and Effectiveness of Peridex Dosed Twice or Three Times Daily for Preventing or Delaying the Occurrence of Lesions Due to Oral Candidiasis in HIV-Positive Individuals||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|13 Years|75 Years|No|||November 1993|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002431||209312|
NCT00002911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065284|Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer|A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MARIMASTAT IN PATIENTS WITH MINIMAL DISEASE STAGE III NON-SMALL CELL LUNG CANCER||National Cancer Institute (NCI)||Completed|December 1996|May 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002911||208918|
NCT00002912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01835|Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia|A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA||National Cancer Institute (NCI)||Completed|January 1997|||March 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|21 Years|No|||August 2010|January 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002912||208917|
NCT00002878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065178|Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma|A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA||Eastern Cooperative Oncology Group||Completed|March 1997|||April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 28, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002878||208946|
NCT00002879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-958053|Cladribine in Patients With Mantle Cell Lymphoma|A PHASE II TRIAL OF 2-CDA IN PREVIOUSLY TREATED OR UNTREATED PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)||Alliance for Clinical Trials in Oncology|Yes|Completed|November 1996|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002879||208945|
NCT00002624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9335|Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function|VIDEO ASSISTED WEDGE RESECTION (VAR) AND RADIOTHERAPY FOR HIGH RISK T1 NON-SMALL CELL LUNG CANCER: A PHASE II STUDY||Alliance for Clinical Trials in Oncology|No|Completed|December 1994|August 2005|Actual|April 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002624||209145|
NCT00002596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWOG-9442|Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors|RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS||National Cancer Institute (NCI)||Completed|September 1994|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|270|||Male|12 Years|N/A|No|||October 2003|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002596||209165|
NCT00002538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9302|Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers|LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY||Gynecologic Oncology Group|Yes|Completed|September 1993|||March 2010|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||August 2013|August 19, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002538||209219|
NCT00002738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-093|Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma|Phase II Trial of Trimetrexate and Leucovorin in The Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia||Memorial Sloan Kettering Cancer Center||Completed|January 1996|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|N/A|21 Years|No|||March 2013|March 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002738||209059|
NCT00002446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305A|Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients|Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients||NIH AIDS Clinical Trials Information Service||Completed|August 1998|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||February 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002446||209297|
NCT00002514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078099|Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission|Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission||Eastern Cooperative Oncology Group|Yes|Completed|April 1993|||December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1929|||Both|15 Years|65 Years|No|||August 2007|November 21, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002514||209241|
NCT00002515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-148|Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer|Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers||Memorial Sloan Kettering Cancer Center||Completed|October 1992|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002515||209240|
NCT00002466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-062|Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer|Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma||Memorial Sloan Kettering Cancer Center||Completed|May 1990|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002466||209279|
NCT00002461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000075725|Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma|Phase II Study of Intensive Carmustine and Etoposide With Cisplatin or Cyclophosphamide, Followed By Rescue With Autologous Bone Marrow Treated In Vitro With Etoposide and/or Peripheral Blood Stem Cells Mobilized With Filgrastim (G-CSF) or Sargramostim (GM-CSF) With or Without Radiotherapy in Patients With Resistant Hodgkin's Disease or Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|April 1988|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|65 Years|No|||October 2006|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002461||209283|
NCT00002489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-119|Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors|PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS||Memorial Sloan Kettering Cancer Center||Completed|October 1991|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|20 Years|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002489||209261|
NCT00002759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02242|Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma|A PHASE I STUDY OF IRINOTECAN (CPT-11) WITH PHARMACOKINETIC MODULATION BY CYCLOSPORINE A AND PHENOBARBITAL||National Cancer Institute (NCI)||Completed|June 1996|||April 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||May 2006|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002759||209042|
NCT00002755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064692|Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer|PROSPECTIVE RANDOMISED EVALUATION OF HIGH-INTENSITY CHEMOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR SUPPORT IN PATIENTS WITH HIGH RISK BREAST CANCER||National Cancer Institute (NCI)||Completed|November 1995|June 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|600|||Female|18 Years|N/A|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002755||209045|
NCT00002756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9407|Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia|Induction Intensification in Infant ALL: A Children's Oncology Group Study||Children's Oncology Group|Yes|Completed|June 1996|March 2012|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Both|N/A|1 Year|No|||February 2014|February 12, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002756||209044|
NCT00002505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077951|Tumor Cell Vaccine in Treating Patients With Advanced Cancer|RANDOMIZED PHASE II TRIAL OF AUTOLOGOUS TUMOR CELL VACCINE||Hoag Memorial Hospital Presbyterian|No|Completed|August 1992|May 2006|Actual|August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002505||209248|
NCT00002506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077957|Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer|ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS||Hoag Memorial Hospital Presbyterian|No|Completed|August 1992|February 1999|Actual|January 1996|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002506||209247|
NCT00002481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077128|Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase II Study of High-Dose Cytarabine, Cisplatin, and Dexamethasone Followed By Cyclophosphamide, Etoposide, Total Body Irradiation, and Autologous Bone Marrow Rescue in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|March 1990|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||May 2001|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002481||209267|
NCT00002502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-103|Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome|BUSULFAN AND CYCLOPHOSPHAMIDE FOR CYTOREDUCTION OF PATIENTS WITH ACUTE AND CHRONIC LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION WHO CANNOT BE TREATED WITH TOTAL BODY IRRADIATION||Memorial Sloan Kettering Cancer Center||Completed|July 1992|May 2000|Actual|May 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|55 Years|No|||June 2013|June 26, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002502||209251|
NCT00002436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129C|The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT|A Randomized Lamivudine (3TC)/Dideoxycytidine (ddC) Double-Blind Multicenter Trial (With Open-Label AZT) to Evaluate the Safety and Efficacy of Low Dose 3TC Administered Concurrently With AZT Versus High Dose 3TC Administered Concurrently With AZT Versus ddC Administered Concurrently With AZT in the Treatment of HIV-1 Infected, AZT-Experienced (>= 24 Weeks) Patients With CD4 Counts of 100-300 Cells/mm3||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||325|||Both|18 Years|N/A|No|||May 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002436||209307|
NCT00002437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216A|The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||48|||Both|13 Years|60 Years|No|||November 1994|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002437||209306|
NCT00002704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01528|Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia|TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY||National Cancer Institute (NCI)||Completed|January 1996|||June 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|N/A|20 Years|No|||November 2007|January 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002704||209082|
NCT00002508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078063|Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors|INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY GERM CELL TUMORS EMPLOYING HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND THIOTEPA WITH AUTOLOGOUS BONE MARROW RESCUE FOR PATIENTS 15 TO 60 YEARS OF AGE||Temple University||Completed|November 1990|September 2001|Actual|September 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|60 Years|No|||September 2010|September 30, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002508||209245|
NCT00002485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9284|Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer|Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment||Children's Oncology Group||Completed|February 1992|September 2005|Actual|July 2003|Actual|N/A|Observational|N/A||2|Actual|359|||Both|N/A|21 Years|No|||February 2014|February 12, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002485||209264|
NCT00002499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077835|Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia|TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS||National Cancer Institute (NCI)||Active, not recruiting|January 1990|||||Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|N/A|19 Years|No|||May 2000|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002499||209253|
NCT00002719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06954|Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia|RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1995|||November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|61 Years|80 Years|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002719||209071|
NCT00002438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|235B|A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients|Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||April 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002438||209305|
NCT00002443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246B|The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|Twelve-Month Study in HIV-1 Seropositive Retroviral-Naive Patients to Compare the Safety and Efficacy of MK-639 and Zidovudine (AZT) Administered Concomitantly to MK-639 Alone and Zidovudine (AZT) Alone||NIH AIDS Clinical Trials Information Service||Completed||January 1996||||N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||780|||Both|18 Years|N/A|No|||September 1996|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002443||209300|
NCT00002462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20884|RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease|Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|September 1989|||May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|615|||Both|15 Years|70 Years|No|||February 2016|February 3, 2016|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002462||209282|
NCT00002751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1193|Monoclonal Antibody Therapy in Treating Patients With Brain Metastases|PROTOCOL FOR A PHASE I STUDY OF INTRATHECAL MONOCLONAL ANTIBODY FRAGMENT 131I Me1-14 F(ab')2 IN PATIENTS WITH NEOPLASMS METASTATIC TO THE LEPTOMENINGES||Duke University||Completed|July 1989|May 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|6|||Both|3 Years|N/A|No|||October 2009|June 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002751||209049|
NCT00002452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300A|A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir|A Multicenter, Open-Label, Pilot Study to Evaluate the Safety and Activity of L-756423/Indinavir Sulfate, 800/400 Mg b.i.d. in Combination With Two nRTIs in HIV-Infected Patients Who Failed an Indinavir Containing Regimen||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||February 2000|June 23, 2005|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00002452||209291|
NCT00002477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077026|Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer|Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 1991|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||July 2007|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002477||209271|
NCT00002727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9512|Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord|A RANDOMIZED STUDY OF HYPERFRACTIONATION VERSUS CONVENTIONAL FRACTIONATION IN T2 SQUAMOUS CELL CARCINOMA OF THE VOCAL CORD||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 1996|||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002727||209065|
NCT00002730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064620|Chemotherapy in Treating Children With Neuroblastoma|PILOT STUDY OF BUTHIONINE SULFOXIMINE (BSO) IN COMBINATION WITH MELPHALAN FOR HIGH RISK NEUROBLASTOMA PATIENTS||National Cancer Institute (NCI)||Completed|June 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||February 2002|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002730||209064|
NCT00002747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064678|Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer|RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY||National Cancer Institute (NCI)||Active, not recruiting|September 1992|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|240|||Both|N/A|70 Years|No|||May 2007|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002747||209053|
NCT00002482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077247|Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer|A PHASE I-II TRIAL OF MUROMONAB (OKT-3) WITH LOW-DOSE CYCLOPHOSPHAMIDE||National Cancer Institute (NCI)||Active, not recruiting|June 1991|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002482||209266|
NCT00002509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078064|High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer|HIGH-DOSE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CARBOPLATIN FOLLOWED BY RESCUE WITH AUTOLOGOUS BONE MARROW AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH POOR PROGNOSIS BREAST CANCER||Temple University||Completed|November 1991|December 2003|Actual|December 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|15 Years|60 Years|No|||September 2010|September 30, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002509||209244|
NCT00002676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-937351|Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma|PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL)||Alliance for Clinical Trials in Oncology|No|Completed|July 1995|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|70 Years|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002676||209103|
NCT00002687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064412|Interleukin-2 in Treating Patients With Mycosis Fungoides|Phase 1 Trial of Subcutaneous [SC]; Outpatient Interleukin-2 for Patients With Advanced Mycosis Fungoides [Stage IIb, III, IV]||University of Washington||Completed|February 1995|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|80 Years|No|||November 2012|November 30, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002687||209095|
NCT00002484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-121|Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer|A PHASE I TRIAL OF DOSE ESCALATION OF EXTERNAL BEAM RADIATION THERAPY USING CONFORMAL 3-DIMENSIONAL TREATMENT PLANNING FOR NON-SMALL CELL LUNG CANCER||Memorial Sloan Kettering Cancer Center||Completed|October 1991|||July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002484||209265|
NCT00002529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078385|Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer|Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.|12-93|International Breast Cancer Study Group|Yes|Completed|May 1993|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|452|||Female|N/A|70 Years|No|||July 2012|April 3, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002529||209227|
NCT00002445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306A|Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients|A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002445||209298|
NCT00002682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPPDM95-084|Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach|CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA||M.D. Anderson Cancer Center|No|Completed|August 1995|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002682||209097|
NCT00002531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078421|Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia|MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93)||National Cancer Institute (NCI)||Active, not recruiting|January 1993|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|65 Years|No|||December 2006|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002531||209226|
NCT00002523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078308|Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed|FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY||National Cancer Institute (NCI)||Active, not recruiting|April 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|80 Years|No|||September 2002|July 20, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002523||209233|
NCT00002524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM93-058|Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma|Pilot Study in AIDS-Related Lymphomas||M.D. Anderson Cancer Center|No|Completed|June 1993|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|15 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002524||209232|
NCT00002720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064573|Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer|QUADRANTECTOMY PLUS AXILLARY DISSECTION VERSUS QUADRANTECTOMY ALONE IN MAMMOGRAPHIC STAGE T1N0 BREAST CANCER PATIENTS AGED OVER 65 YEARS||National Cancer Institute (NCI)||Completed|December 1995|December 2012|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|642|||Female|65 Years|80 Years|No|||August 2000|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002720||209070|
NCT00002722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40953|High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer|RANDOMIZED PHASE II STUDY OF A WEEKLY 24H-INFUSION OF HIGH-DOSE 5-FU PLUS OR MINUS FOLINIC ACID (HD-FU/FA) VERSUS HD-FU/FA PLUS BIWEEKLY CISPLATIN VERSUS FAMTX (5-FU/ADRIAMYCIN/METHOTREXATE) IN ADVANCED GASTRIC CANCER, AN EORTC/AIO INTERGROUP TRIAL||European Organisation for Research and Treatment of Cancer - EORTC||Completed|January 1996|||August 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|135|||Both|N/A|75 Years|No|||March 2012|March 2, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002722||209068|
NCT00002459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55874|Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus|Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1988|||August 2001|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|224|||Female|N/A|N/A|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002459||209285|
NCT00002463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P88-006|Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors|Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma||M.D. Anderson Cancer Center|No|Completed|February 1989|January 2008|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|3 Years|No|||February 2013|February 14, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002463||209281|
NCT00002746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064671|Interleukin-2 in Treating Patients With Myelodysplastic Syndrome|A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)||University of Washington||Completed|January 1996|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|15 Years|N/A|No|||December 2012|December 12, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002746||209054|
NCT00002488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077375|Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy|INTENSIFICATION WITH HIGH DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN FOR INTERMEDIATE OR HIGH GRADE LYMPHOMA PATIENTS WHO FAILED PRIMARY COMBINATION CHEMOTHERAPY||National Cancer Institute (NCI)||Active, not recruiting|December 1991|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|64 Years|No|||April 2000|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002488||209262|
NCT00002501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077861|Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma|PHASE II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE PLUS RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR (rhG-CSF) IN THE TREATMENT OF FOLLICULAR LOW-GRADE NON-HODGKIN'S LYMPHOMA||Alliance for Clinical Trials in Oncology|No|Completed|October 1992|January 2006|Actual|July 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|55 Years|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002501||209252|
NCT00002503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30921|Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases|A PROSPECTIVE MULTICENTER RANDOMIZED STUDY COMPARING STRONTIUM-89 CHLORIDE AND PALLIATIVE LOCAL FIELD RADIOTHERAPY IN PATIENTS WITH HORMONAL ESCAPED ADVANCED PROSTATIC CANCER||European Organisation for Research and Treatment of Cancer - EORTC||Completed|October 1992|||November 2000|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|204|||Male|N/A|N/A|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002503||209250|
NCT00002684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-031|Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer|Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors||Memorial Sloan Kettering Cancer Center||Completed|May 1995|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002684||209096|
NCT00002495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077691|SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease|Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin, Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease||Southwest Oncology Group|Yes|Active, not recruiting|September 1992|December 2015|Anticipated|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|348|||Both|16 Years|N/A|No|||September 2015|September 15, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002495||209256|
NCT00002454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000071657|Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx|Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx||National Cancer Institute (NCI)||Active, not recruiting|December 1971|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|N/A|No|||January 2002|July 23, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002454||209289|
NCT00002498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077804|Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer|CMF AND MITOXANTRONE IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER, A RANDOMIZED PHASE II STUDY||National Cancer Institute (NCI)||Active, not recruiting|July 1992|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|70 Years|N/A|No|||May 2000|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002498||209254|
NCT00002487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077374|Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer|INTRAPERITONEAL METHOTREXATE AND DIPYRIDAMOLE AS SALVAGE TREATMENT FOR ADVANCED OVARIAN CARCINOMA||National Cancer Institute (NCI)||Active, not recruiting|July 1991|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2000|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002487||209263|
NCT00002451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246U|Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs|A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Activity of Indinavir Sulfate 1200 Mg q.d. and Ritonavir 200 Mg q.d. in Combination With Stavudine and Lamivudine in Treatment Naive HIV-1 Infected Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||8|||Both|18 Years|N/A|No|||July 2002|June 23, 2005|January 17, 2000||||No||https://clinicaltrials.gov/show/NCT00002451||209292|
NCT00002432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020E|A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|An Open Study of Foscarnet Treatment of CMV-Retinitis in AIDS Patients||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 1990|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002432||209311|
NCT00002534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-045|Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission|A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS||Memorial Sloan Kettering Cancer Center||Completed|May 1993|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002534||209223|
NCT00002439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272A|A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma|Randomized Phase III Vehicle Controlled Trial of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 1997|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002439||209304|
NCT00002537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02487|Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer|A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH CHEST IRRADIATION||National Cancer Institute (NCI)||Completed|September 1993|||March 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||May 2006|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002537||209220|
NCT00002532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-ALL-REZ-02/92|Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia|TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL||National Cancer Institute (NCI)||Active, not recruiting|January 1993|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|65 Years|No|||March 2002|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002532||209225|
NCT00002721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM-2394C|Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|A PHASE I TRIAL OF ESTRAMUSTINE PHOSPHATE AND DOXORUBICIN IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER||University of New Mexico|No|Completed|March 1995|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002721||209069|
NCT00002440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238J|A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|An Open-Label, Phase II Trial to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of 1592U89 in Combination With Selected HIV-1 Protease Inhibitors in Antiretroviral-Naive, HIV-1-Infected Patients.||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||80|||Both|16 Years|N/A|No|||November 1998|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002440||209303|
NCT00002460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-PHASE-III-88002|Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer|Phase III Randomized Study of Adjuvant Therapy With Tamoxifen vs Endocrine Ablation vs Tamoxifen Plus Endocrine Ablation vs No Adjuvant Therapy in Patients Under Age 50 With Operable Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1987|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|49 Years|No|||December 2006|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002460||209284|
NCT00002465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000076422|High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma|Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma||National Cancer Institute (NCI)||Active, not recruiting|December 1987|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002465||209280|
NCT00002695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064467|Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck|CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA||National Cancer Institute (NCI)||Active, not recruiting|January 1996|||||N/A|Observational|N/A|||Anticipated|530|||Both|18 Years|N/A|No|||January 2002|September 24, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002695||209089|
NCT00002496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9111|Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx|PHASE III TRIAL TO PRESERVE THE LARYNX: INDUCTION CHEMOTHERAPY AND RADIATION THERAPY VERSUS CONCOMITANT CHEMOTHERAPY AND RADIATION THERAPY VERSUS RADIATION THERAPY||Radiation Therapy Oncology Group|Yes|Completed|August 1992|November 2013|Actual|August 2002|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2014|January 23, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002496||209255|
NCT00002476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-PHASE-III-91001|Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer|Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer||National Cancer Institute (NCI)||Completed|January 1990|January 2010|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|August 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002476||209272|
NCT00002478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077078|Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer|Phase II Study of Prolonged Oral VP-16 for Advanced Ovarian Epithelial and Cervical Cancer||Gynecologic Oncology Group||Terminated|June 1993|||October 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||November 2000|June 7, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002478||209270|
NCT00002458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-118|Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission|Phase II Study of Adjuvant Therapy With Antiganglioside GD2-Specific Mouse Monoclonal Antibody 3F8 for Metastatic Neuroblastoma in Second Remission||Memorial Sloan Kettering Cancer Center||Completed|November 1987|September 2001|Actual|September 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|18 Years|No|||June 2013|June 4, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002458||209286|
NCT00002433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062A|The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS|Activation of Alveolar Macrophages by Aerosolized r-metHuIFN-Gamma (IFN-Gamma) in Patients With AIDS||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||12|||Both|18 Years|65 Years|No|||November 1999|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00002433||209310|
NCT00002507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078021|Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer|RADIATION WITH MITOMYCIN C OR PORFIROMYCIN IN THE TREATMENT OF CANCER OF THE HEAD AND NECK AREA||Yale University||Completed|November 1992|October 2002|Actual|October 2002|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|20 Years|80 Years|No|||June 2000|July 24, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002507||209246|
NCT00002429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039F|Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen|Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen||Bristol-Myers Squibb||Completed|July 1999|January 2001|Actual|January 2001|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|November 2, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00002429||209314|
NCT00003015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065595|Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma|Ultimate Low Grade Glioma Study||National Cancer Institute (NCI)||Active, not recruiting|January 1997|||||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|200|||Both|N/A|15 Years|No|||January 2001|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003015||208828|
NCT00003049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065689|Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas|A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer\||Mayo Clinic|Yes|Completed|May 1997|July 2007|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003049||208800|
NCT00003056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAXTER-302302|Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation|Peripheral Blood Stem Cell Transplantation in Patients With Advanced Malignancies Eligible for Allogeneic Transplantation From Matched Related Donors: A Randomized Study of Cyclosporine/Methotrexate or Cyclosporine/T-Cell Depletion (CD34 Cell Selection) for GVHD Prophylaxis||Baxalta US Inc.|Yes|Terminated|April 1997|June 2003||June 2003||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Actual|105|||Both|18 Years|55 Years|No|||May 2013|June 26, 2015|November 1, 1999|No|Yes|Interim analysis indicated study should be terminated|||https://clinicaltrials.gov/show/NCT00003056||208794|
NCT00002625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063990|Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma|PHASE I STUDY OF TOPOTECAN AND THORACIC RADIATION||National Cancer Institute (NCI)||Completed|March 1995|September 2000|Actual|April 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2013|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002625||209144|
NCT00003012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065590|Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer|A Prospective Randomized Comparison of CMF Versus Sequential Epirubicin Followed by SMF as Adjuvant Chemotherapy for Women With Early Breast Cancer||National Cancer Institute (NCI)||Completed|October 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Female|N/A|N/A|No|||November 2008|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003012||208831|
NCT00003028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16969|MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors|Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every 3 Weeks||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|5|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003028||208816|
NCT00003061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20962|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma|Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 1997|||March 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|16 Years|60 Years|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003061||208790|
NCT00002766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-015|Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma|A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone ("ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol||Memorial Sloan Kettering Cancer Center||Completed|March 1996|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|120 Years|No|||January 2016|January 25, 2016|November 1, 1999|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00002766||209035|
NCT00003063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065728|Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer|Adjuvant Chemoimmunotherapy for Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|November 1991|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1050|||Both|N/A|75 Years|No|||November 2005|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003063||208788|
NCT00002654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 10/94|Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer|Phase III Study of Hyperfractionated Radiation Therapy With or Without Simultaneaous Application of CIS-Platinum in Patients With Moderately Advanced to Advanced Cancers of the Head and Neck||Swiss Group for Clinical Cancer Research|No|Completed|April 1994|July 2000|Actual|March 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Actual|224|||Both|20 Years|75 Years|No|||March 2013|March 6, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002654||209121|
NCT00002655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-0092.cc|Cryosurgery in Treating Patients With Liver Cancer or Liver Metastases|Cryosurgical Destruction of Surgically Incurable Liver Tumors||University of Colorado, Denver|Yes|Completed|March 1995|September 1999|Actual|September 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||July 2013|July 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002655||209120|
NCT00003035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065642|Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer|A Pilot Trial Comparing Doxorubicin and Paclitaxel Induced Apoptosis in Locally Advanced Breast Cancer||Georgetown University|No|Completed|March 1997|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||December 2006|March 22, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003035||208811|
NCT00002996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065544|Flecainide in Treating Patients With Chronic Neuropathic Pain|Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial||Eastern Cooperative Oncology Group|No|Completed|February 1998|||April 2006|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||Anticipated|20|||Both|19 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002996||208847|
NCT00002608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-OTT-9401|Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors|Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies||National Cancer Institute (NCI)||Completed|May 1994|April 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|65 Years|No|||May 2005|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002608||209157|
NCT00002609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-088|Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission|PHASE II TRIAL OF POST-REMISSION THERAPY WITH HuM195 AND CYTOTOXIC CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA||Memorial Sloan Kettering Cancer Center||Completed|August 1994|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|40|||Both|12 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002609||209156|
NCT00002691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-065|Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma|LSA5 PROTOCOL FOR THE TREATMENT OF ADVANCED PEDIATRIC AND ADOLESCENT NON-HODGKIN'S LYMPHOMA (NHL)||Memorial Sloan Kettering Cancer Center||Completed|August 1995|June 2000|Actual|June 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002691||209092|
NCT00002664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064248|Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer|PHASE II STUDY OF MONOCLONAL ANTIBODY 17-1A WITH GM-CSF IN TREATMENT OF 5-FU RESISTANT COLORECTAL CANCER||National Cancer Institute (NCI)||Completed|July 1995|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002664||209113|
NCT00003001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065561|Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer|Phase I/II Study of 5-Fluorouracil/Folinic Acid/Gemcitabine in Patients With Advanced Colorectal Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 1997|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|63|||Both|N/A|N/A|No|||April 2002|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003001||208842|
NCT00003000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065555|Morphine for the Treatment of Pain in Patients With Breast Cancer|Peripheral Effects of Opioid Analgesia in Patients Undergoing Axillary Node Dissection||Roswell Park Cancer Institute|Yes|Completed|May 1992|June 2001|Actual|January 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|||Both|N/A|120 Years|No|Probability Sample|Breast Cancer Patients|October 2015|October 12, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003000||208843|
NCT00002692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064434|Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver|A RANDOMISED TRIAL OF INTRAVENOUS VERSUS INTRAHEPATIC ARTERIAL 5-FU AND LEUCOVORIN FOR COLORECTAL LIVER METASTASES||National Cancer Institute (NCI)||Active, not recruiting|December 1994|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|312|||Both|N/A|N/A|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002692||209091|
NCT00002600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063839|Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer|A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA||National Cancer Institute (NCI)||Completed|September 1994|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Female|18 Years|65 Years|No|||September 2001|April 23, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002600||209161|
NCT00002999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065552|S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx|S9715, Study of Patients With Advanced Nasopharyngeal Cancers Treated With Chemo-Radiotherapy, Phase II||Southwest Oncology Group|No|Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||May 2015|May 22, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002999||208844|
NCT00003044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065675|Chemotherapy in Treating Patients With Liver Cancer|A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010) Administered to Patients With Unresectable Primary Hepatocellular Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|September 1996|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|N/A|No|||April 2000|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003044||208804|
NCT00002649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03072|Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|May 1995|||November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|16 Years|60 Years|No|||February 2013|February 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002649||209126|
NCT00002627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064016|Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer|PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH HIGH RISK STAGE II AND III BREAST CANCER||National Cancer Institute (NCI)||Active, not recruiting|November 1994|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|65 Years|No|||July 2000|January 9, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002627||209143|
NCT00003002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065564|HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer|A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers||University of Washington||Completed|April 1996|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|N/A|No|||December 2012|December 12, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003002||208841|
NCT00002702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064500|Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx|Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx||National Cancer Institute (NCI)||Recruiting|September 1992|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|260|||Both|N/A|75 Years|No|||February 2011|August 23, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002702||209084|
NCT00002604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1994|O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors|Phase I Trial of O6 Benzylguanine and BCNU; A Biochemical Modulation Trial Based Upon Depletion of O6 Alkylguanine DNA Alkyltransferase Directed DNA Repair||Case Comprehensive Cancer Center|Yes|Completed|January 1996|February 2004|Actual|July 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||July 2010|July 7, 2010|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002604||209158|
NCT00002644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064151|Tamoxifen for the Prevention of Breast Cancer in High-Risk Women|INTERNATIONAL BREAST CANCER INTERVENTION STUDY: A MULTICENTRE TRIAL OF TAMOXIFEN TO PREVENT BREAST CANCER||National Cancer Institute (NCI)||Completed|January 1994|May 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|7000|||Female|35 Years|70 Years|No|||July 2011|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002644||209129|
NCT00003026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22961|Hormone Therapy in Treating Patients With Advanced Prostate Cancer|Long Term Adjuvant Hormonal Treatment With LHRH Analogue Versus No Further Treatment in Locally Advanced Prostatic Carcinoma Treated by External Irradiation and a Six Months Combined Androgen Blockade - A Phase III Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1997|||September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|966|||Both|N/A|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003026||208818|
NCT00003027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065617|Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma|A Randomized Phase III Trial of Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon A-2B Versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients With Metastatic Malignant Melanoma||Eastern Cooperative Oncology Group|Yes|Completed|October 1997|||July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|482|||Both|18 Years|N/A|No|||January 2010|January 28, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003027||208817|
NCT00003011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR12|Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer|A Phase III Study of Marimastat in Patients With Small Cell Lung Cancer Following a Response to First Line Chemotherapy||Canadian Cancer Trials Group|Yes|Completed|March 1997|December 2008|Actual|January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|555|||Both|16 Years|N/A|No|||January 2012|May 30, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003011||208832|
NCT00002674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|928.00|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia|CYTOREDUCTIVE CHEMOTHERAPY WITH MITOXANTRONE, CYTOSINE ARABINOSIDE AND ETOPOSIDE FOLLOWED BY RECOMBINANT HUMAN G-CSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA||Fred Hutchinson Cancer Research Center||Completed|October 1994|March 2000|Actual|March 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|17 Years|65 Years|No|||March 2010|March 31, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002674||209105|
NCT00003060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065722|Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma|Pilot Study for Matched-Related Allogeneic Bone Marrow Transplantation for Metastatic Malignant Melanoma||National Cancer Institute (NCI)||Active, not recruiting|March 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|6|||Both|16 Years|44 Years|No|||June 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003060||208791|
NCT00003055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-060|Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer|Phase II Trial of Cisplatin and Irinotecan in Patients With Advanced Esophageal Cancer||Memorial Sloan Kettering Cancer Center||Completed|June 1997|April 2001|Actual|April 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003055||208795|
NCT00002667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064256|Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer|EARLY DETECTION OF SECOND PRIMARY LUNG CANCERS BY SPUTUM CYTOLOGY IMMUNOSTAINING||National Cancer Institute (NCI)||Active, not recruiting|July 1995|||||N/A|Interventional|Primary Purpose: Screening|||Anticipated|1100|||Both|18 Years|N/A|No|||May 2006|February 23, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002667||209111|
NCT00002643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01832|Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor|INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY||National Cancer Institute (NCI)||Completed|April 1995|||June 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|N/A|30 Years|No|||March 2007|January 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002643||209130|
NCT00002610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9444|Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors|National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study||Children's Oncology Group|Yes|Completed|January 1996|February 2006|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|4||Actual|203|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002610||209155|
NCT00003005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065572|Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia|A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia||Boston Medical Center|Yes|Completed|December 1997|March 2001|Actual|March 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2000|June 12, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003005||208838|
NCT00002662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVENTIS-56976-TAX-311|Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer|PHASE III COMPARISON OF TAXOTERE (DOCETAXEL) AND TAXOL (PACLITAXEL) IN PATIENTS WITH ADVANCED BREAST CANCER||National Cancer Institute (NCI)||Completed|August 1994|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2004|August 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002662||209115|
NCT00002663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-024|Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies|An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune (EBV)-Immune T-Lymphocytes Derived From Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases||Atara Biotherapeutics||Recruiting|March 1995|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|N/A|N/A|No|||July 2015|July 27, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002663||209114|
NCT00002656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064199|Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer|PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA||Barbara Ann Karmanos Cancer Institute|No|Completed|October 1995|February 2008|Actual|December 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002656||209119|
NCT00003041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065670|Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer|Phase II Evaluation of Pyrazoloacridine (NSC #366140) in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|July 1997|January 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|16 Years|N/A|No|||January 2002|January 30, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003041||208806|
NCT00003042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96139|Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer|Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma||City of Hope Medical Center||Active, not recruiting|May 1997|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|60 Years|No|||December 2015|December 30, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003042||208805|
NCT00003037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-040|Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|Phase I/II Trial of the Combination of Docetaxel, Gemcitabine and Cisplatin (DGP) as Induction Chemotherapy in Patients With Stage III Non-Small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 1997|March 2002|Actual|March 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003037||208810|
NCT00003038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065661|Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors||Mayo Clinic|Yes|Completed|October 1997|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2011|August 2, 2011|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003038||208809|
NCT00003009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065584 (0I-95-1)|Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer|A Phase I Study of Inhalation of Interleukin-2 (IL-2) in Patients With Metastatic or Unresectable Cancer||University of Southern California|Yes|Terminated|February 1996|August 2000|Actual|August 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|16|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes|Insufficient Accrual|No||https://clinicaltrials.gov/show/NCT00003009||208834|
NCT00003007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTENNM-BCG-5889|Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma|Interferon Maintenance in Advanced Multiple Myeloma After Using High-Dose Melphalan as Myeloablative Chemotherapy: A Pilot Study||National Cancer Institute (NCI)||Completed|July 1996|January 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|19 Years|64 Years|No|||September 2002|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003007||208836|
NCT00002619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063964|Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors|A TRIAL OF INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RECONSTITUTION FOR PATIENTS BETWEEN SIX AND SIXTY YEARS OF AGE, WITH NON-PROGRESSIVE GLIOBLASTOMA MULTIFORME OR DIFFUSE INTRINSIC BRAINSTEM TUMORS, FOLLOWING INITIAL LOCAL-FIELD IRRADIATION||New York University School of Medicine||Completed|September 1994|||April 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|6 Years|59 Years|No|||June 2000|November 8, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002619||209150|
NCT00002620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26882|Radiation Therapy in Treating Patients With Brain Cancer|EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 1994|||June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|212|||Both|16 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002620||209149|
NCT00003025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-034|Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer|A Phase I Pilot Trial of Immunotherapy With Autologous Tumor-Derived gp96 Heat Shock Protein - Peptide Complex (HSPPC-96) in Patients With Resected Pancreatic Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Completed|March 1997|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|16|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003025||208819|
NCT00003006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065576|Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer|Detection of Occult Micrometastases in Patients With Clinical Stage I NSCLC: A Prosepective Analysis||Alliance for Clinical Trials in Oncology|No|Completed|May 1997|June 2010|Actual|March 2002|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Actual|501|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003006||208837|
NCT00003016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065596|Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer|Reliable Assessment of the Efficacy and Safety of Prolonging the Use of Adjuvant Tamoxifen: A Large, Simple, Randomised Study||National Cancer Institute (NCI)||Active, not recruiting|October 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|20000|||Both|N/A|N/A|No|||October 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003016||208827|
NCT00002618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9315|Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma|A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin||Children's Oncology Group|Yes|Completed|December 1994|September 2006|Actual|September 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|242|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002618||209151|
NCT00002788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|962.00|High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia|A PILOT STUDY OF TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS TRANSPLANTATION WITH CD34 SELECTED PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA||Fred Hutchinson Cancer Research Center||Completed|October 1995|September 2002||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|17 Years|65 Years|No|||September 2010|September 13, 2010|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00002788||209017|
NCT00003045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065679|Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer|A Phase II Trial of Hyperthermia and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Active, not recruiting|April 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|65|||Male|18 Years|N/A|No|||November 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003045||208803|
NCT00002671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064290|Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer|PHASE II STUDY OF 9-20-S-AMINO-CAMPTOTHECIN (9-AC) AS SECOND LINE THERAPY IN ADVANCED OVARIAN CARCINOMA||New York University School of Medicine||Completed|December 1995|||February 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2006|November 8, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002671||209107|
NCT00003057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065713|Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer|Randomized Trial of High-Dose Versus Conventional Dose Octreotide Acetate Versus Loperamide in the Treatment of Chemotherpay-Related Diarrhea in Patients With Colorectal Cancer||National Cancer Institute (NCI)||Completed|November 1996|||May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|500|||Both|18 Years|N/A|No|||January 2009|May 9, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003057||208793|
NCT00003058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065717|Troglitazone in Treating Patients With Liposarcoma|Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma||National Cancer Institute (NCI)||Active, not recruiting|June 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||June 2000|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003058||208792|
NCT00003054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065702|Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus|Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||Gynecologic Oncology Group||Terminated|August 1997|||April 2003||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||May 2003|April 10, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003054||208796|
NCT00003050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065692 (1B-97-2)|Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer|Weekly Paclitaxel During Radiation Therapy for Locally Advanced Breat Cancer||University of Southern California|Yes|Completed|April 1997|March 2000|Actual|March 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|46|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003050||208799|
NCT00002593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063773|S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed|Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer||Southwest Oncology Group|Yes|Completed|December 1994|March 2005|Actual|December 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1135|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002593||209168|
NCT00002995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9602|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma|Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol||Children's Oncology Group|Yes|Completed|August 1997|January 2011|Actual|September 2006|Actual|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|483|||Both|N/A|49 Years|No|||February 2014|February 12, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002995||208848|
NCT00003013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065593|Chemotherapy Plus Surgery in Treating Women With Breast Cancer|European Cooperative Study of Chemotherapy and Surgery Comparing Adjuvant Doxorubicin Followed by CMF vs. Adjuvant Doxorubicin/Paclitaxel Followed by CMF vs. Primary Doxorubicin/Paclitaxel Followed by CMF in Women With Operable Breast Cancer and T>2 cm||National Cancer Institute (NCI)||Completed|October 1996|March 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|450|||Female|18 Years|70 Years|No|||June 2000|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003013||208830|
NCT00003017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065597|Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix|Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix||National Cancer Institute (NCI)||Completed|July 1997|August 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2004|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003017||208826|
NCT00002642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064135|SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer|Induction Chemoradiotherapy Followed by Surgical Resection for Non-small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors): A Phase II Trial||Southwest Oncology Group|Yes|Completed|April 1995|July 2004|Actual|January 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002642||209131|
NCT00002848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065087|Group Therapy Compared With Educational Materials in Patients With Prostate Cancer|SUPPORTIVE-EXPRESSIVE GROUP THERAPY FOR MEN WITH PRIMARY PROSTATE CANCER||University of Rochester|No|Completed|April 1997|September 2004|Actual|September 2004|Actual|N/A|Interventional|N/A|||Anticipated|480|||Male|N/A|N/A|No|||March 2013|March 4, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002848||208968|
NCT00002665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWOG-9400|SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia|TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FIRST COMPLETE REMISSION||Southwest Oncology Group||Completed|July 1995|December 2003|Actual|December 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|15 Years|65 Years|No|||March 2015|March 5, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002665||209112|
NCT00002670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9501|Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery|Phase III Intergroup Trial of Surgery Followed by (1) Radiotherapy vs. (2) Radiochemotherapy For Resectable High Risk Squamous Cell Carcinoma of the Head and Neck||Radiation Therapy Oncology Group|Yes|Completed|September 1995|November 2013|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|459|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002670||209108|
NCT00002869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065147|Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia|PROSPECTIVE RANDOMISED STUDY TO COMPARE LOW-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA VS HIGH-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA IN PATIENTS WITH NEWLY DIAGONISED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA||National Cancer Institute (NCI)||Active, not recruiting|April 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Both|N/A|N/A|No|||February 2008|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002869||208953|
NCT00002675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-040|Chemotherapy in Treating Patients With Retinoblastoma|A TRIAL OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH INTRAOCULAR RETINOBLASTOMA||Memorial Sloan Kettering Cancer Center||Completed|May 1995|January 2001|Actual|January 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|17 Years|No|||June 2013|June 26, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002675||209104|
NCT00002597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9408|Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer|A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE||Radiation Therapy Oncology Group|Yes|Completed|October 1994|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2028|||Male|N/A|N/A|No|||November 2015|November 14, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002597||209164|
NCT00002598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-070|Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia|A PHASE II STUDY OF MITOXANTRONE AND HIGH-DOSE ARA-C FOLLOWED BY INTENSIVE CONSOLIDATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE FOR MYELOID BLAST CRISIS OF CHRONIC MYELOGENOUS LEUKEMIA (CML)||Memorial Sloan Kettering Cancer Center||Completed|June 1994|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|16 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002598||209163|
NCT00002601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94072|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma|High-Dose Doxorubicin and Ifosfamide Followed by Melphalan and Cisplatin for Patients With High-Risk and Recurrent Sarcoma||City of Hope Medical Center|No|Completed|September 1994|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|10 Years|55 Years|No|||December 2015|December 30, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002601||209160|
NCT00002680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064338|Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer|Phase II Trial of Sequential High-Dose Alkylating Agents in Metastatic Breast Cancer||Yale University|No|Completed|February 1994|December 2000|Actual|December 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|40|||Both|18 Years|N/A|No|||August 2009|July 23, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002680||209099|
NCT00002913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02251|Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer|PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES||National Cancer Institute (NCI)||Completed|December 1996|||July 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|N/A|N/A|No|||January 2013|January 23, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002913||208916|
NCT00002914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065289|Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract|PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM||Eastern Cooperative Oncology Group|No|Completed|May 1997|March 2004|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||January 2010|January 25, 2010|November 1, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00002914||208915|
NCT00002884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRE-CURIE-HDD|Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus|A PROSPECTIVE RANDOMISED NON SURGICAL TREATMENT OF OESOPHAGEAL CANCER WITH COMBINED CHEMOTHERAPY AND EXTERNAL BEAM IRRADIATION WITH VS WITHOUT HIGH-DOSE BRACHYTHERAPY||National Cancer Institute (NCI)||Active, not recruiting|March 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|326|||Both|18 Years|74 Years|No|||May 2007|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002884||208940|
NCT00002631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9405|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus|A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY||Radiation Therapy Oncology Group|Yes|Completed|June 1995|||September 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|298|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002631||209140|
NCT00002847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065086|Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND INTERFERON ALPHA||National Cancer Institute (NCI)||Active, not recruiting|September 1995|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|14|||Both|18 Years|N/A|No|||December 2003|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002847||208969|
NCT00002854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94098|High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer|PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT||City of Hope Medical Center|Yes|Completed|December 1994|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|55 Years|No|||August 2015|August 24, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002854||208963|
NCT00002896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065222|Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer|RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA||National Cancer Institute (NCI)||Active, not recruiting|September 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|774|||Both|N/A|75 Years|No|||February 2008|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002896||208931|
NCT00002673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011.01|Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation|A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION||Fred Hutchinson Cancer Research Center||Completed|June 1995|February 2002|Actual|||Phase 2|Interventional|Primary Purpose: Supportive Care|||Anticipated|30|||Both|12 Years|60 Years|No|||June 2010|June 15, 2010|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002673||209106|
NCT00002669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-18951|Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma|TREATMENT OF METASTATIC MELANOMA WITH DTIC, CDDP AND IFN ALPHA WITH OR WITHOUT IL-2: A RANDOMIZED PHASE III TRIAL||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 1995|||August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|70 Years|No|||June 2012|June 29, 2012|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00002669||209109|
NCT00002858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065122|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer|PHASE III STUDY COMPARING TWO DOSES OF INDUCTION CHEMOTHERAPY FOLLOWED BY ALTERNATION OF CHEMOTHERAPY AND RADIOTHERAPY IN LIMITED SMALL CELL LUNG CANCER||National Cancer Institute (NCI)||Active, not recruiting|March 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|280|||Both|N/A|69 Years|No|||May 2007|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002858||208961|
NCT00002653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064187|Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma|VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE||National Cancer Institute (NCI)||Active, not recruiting|September 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Both|65 Years|74 Years|No|||October 2002|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002653||209122|
NCT00002592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063772|Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia|AUTOLOGOUS BONE MARROW TRANSPLANTATION USING C-MYB (LR-3001) ANTISENSE OLIGODEOXYNUCLEOTIDE TREATED BONE MARROW IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC OR ACCELERATED PHASE||Abramson Cancer Center of the University of Pennsylvania||Completed|June 1993|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|60 Years|No|||January 2015|January 13, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002592||209169|
NCT00002842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94080|Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer|Hepatic Resection Followed by Concurrent Adjuvant Portal Vein Infusion of Fluorodeoxyuridine and Systemic 5-Fluorouracil and Folinic Acid for Metastatic Colorectal Carcinoma||City of Hope Medical Center||Completed|September 1994|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|70 Years|No|||June 2015|June 3, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002842||208973|
NCT00002844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM90-106|Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia|Bone Marrow Transplantation for Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|March 1991|June 2002|Actual|July 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|16 Years|65 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002844||208972|
NCT00002870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGASE03|High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer|A RANDOMIZED, MULTI-CENTRE PHASE III TRIAL TO EVALUATE THE ROLE OF INTENSIFIED THERAPY WITH AUTOLOGOUS TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN ADVANCED OR METASTATIC BREAST CANCER RESPONDING TO INDUCTION CHEMOTHERAPY||UNICANCER|Yes|Completed|December 1994|January 2002|Actual|January 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|180|||Female|18 Years|59 Years|No|||December 2014|December 14, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002870||208952|
NCT00002688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064413|Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY||National Cancer Institute (NCI)||Active, not recruiting|February 1995|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002688||209094|
NCT00002689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMM-95079|Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer|Phase II Interstitial Colloidal 32P Integrated in The Treatment of Non-Resectable Pancreatic Cancer||National Cancer Institute (NCI)||Completed|September 1995|June 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||June 2007|July 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002689||209093|
NCT00002907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065272|Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma|PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 1997|November 2000|Actual|January 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002907||208921|
NCT00002632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064057|Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer|PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES||Eastern Cooperative Oncology Group||Completed|March 1995|||May 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002632||209139|
NCT00002895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065218|Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer|A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators||National Cancer Institute (NCI)||Completed|June 1996|October 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1400|||Female|N/A|N/A|No|||September 2005|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002895||208932|
NCT00002892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065215|Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma|A RANDOMISED STUDY OF OBSERVATION VERSUS ADJUVANT LOW DOSE EXTENDED DURATION INTERFERON ALPHA-2A IN COMPLETELY RESECTED HIGH RISK MALIGNANT MELANOMA||National Cancer Institute (NCI)||Completed|October 1995|December 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Both|N/A|N/A|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002892||208935|
NCT00002621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9362|Interferon Alfa in Treating Children With HIV-Related Cancer|A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study||Children's Oncology Group|Yes|Completed|December 1994|September 2005|Actual|July 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002621||209148|
NCT00002637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-134|Biological Therapy in Treating Patients With Prostate Cancer|PHASE I/II STUDY OF IMMUNIZATION WITH MHC CLASS I MATCHED ALLOGENEIC HUMAN PROSTATIC CARCINOMA CELLS ENGINEERED TO SECRETE INTERLEUKIN-2 AND INTERFERON-GAMMA||Memorial Sloan Kettering Cancer Center||Completed|January 1995|February 2001|Actual|February 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Male|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002637||209135|
NCT00002855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM95-231|Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer|A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate||M.D. Anderson Cancer Center|No|Completed|August 1996|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|306|||Male|N/A|N/A|No|||July 2012|July 27, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002855||208962|
NCT00002668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064257|Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer|PATIENT SKILLS FOR CANCER PAIN CONTROL IN PATIENTS WITH METASTATIC BREAST OR PROSTATE CANCER||Eastern Cooperative Oncology Group|No|Terminated|October 1995|September 1998|Actual|September 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|13|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|November 1, 1999|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00002668||209110|
NCT00002646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064156|Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer|PHASE III DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE RANDOMIZED COMPARISON OF ADJUVANT THERAPY WITH TAMOXIFEN VS. TAMOXIFEN AND FENRETINIDE IN POSTMENOPAUSAL WOMEN WITH INVOLVED AXILLARY LYMPH NODES AND POSITIVE RECEPTORS||National Cancer Institute (NCI)||Completed|October 1995|||February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1500|||Female|N/A|N/A|No|||October 2010|January 4, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002646||209128|
NCT00002647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064165|Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors|Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study||National Cancer Institute (NCI)||Recruiting|May 1994|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|3 Years|70 Years|No|||June 2009|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002647||209127|
NCT00002851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065094|Lymph Node Radiation Therapy in Patients With Stage I, Stage II, or Stage III Breast Cancer That Has Been Surgically Removed|PHASE III RANDOMISED TRIAL INVESTIGATING THE ROLE OF INTERNAL MAMMARY AND MEDIAL SUPRACLAVICULAR (IM-MS) LYMPH NODE CHAIN IRRADIATION IN STAGE I-III BREAST CANCER||National Cancer Institute (NCI)||Active, not recruiting|July 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|4000|||Female|N/A|75 Years|No|||December 2004|January 28, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002851||208965|
NCT00002628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064017|Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer|PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO THE HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH BREAST CANCER||National Cancer Institute (NCI)||Active, not recruiting|November 1994|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|65 Years|No|||April 2000|January 9, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002628||209142|
NCT00002590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5941|Combination Chemotherapy in Treating Children With Lymphoma|A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma||Children's Oncology Group|Yes|Completed|July 1994|March 2007|Actual|March 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Both|N/A|20 Years|No|||July 2014|July 23, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002590||209170|
NCT00002697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-072|Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|HIGH DOSE CHEMORADIOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR PATIENTS WITH PRIMARY REFRACTORY, RELAPSED AND POOR PROGNOSIS NON-HODGKIN'S LYMPHOMA||Memorial Sloan Kettering Cancer Center||Completed|September 1995|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002697||209087|
NCT00002599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063834|Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma|MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL||National Cancer Institute (NCI)||Active, not recruiting|September 1994|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|750|||Both|N/A|64 Years|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002599||209162|
NCT00002905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065256|Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|PROSPECTIVE NON-RANDOMIZED STUDY WITH CHEMOTHERAPY FOR RELAPSED OR REFRACTORY HIV-RELATED NON-HODGKIN'S LYMPHOMA: VMP REGIMEN FOR RELAPSED PATIENTS, CDE REGIMEN FOR REFRACTORY PATIENTS||National Cancer Institute (NCI)||Active, not recruiting|June 1995|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||September 2011|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002905||208922|
NCT00002700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06951|Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia|A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 1995|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|392|||Both|15 Years|60 Years|No|||June 2013|June 11, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002700||209086|
NCT00002701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064499|Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia|INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA||National Cancer Institute (NCI)||Active, not recruiting|October 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|750|||Both|16 Years|74 Years|No|||November 2006|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002701||209085|
NCT00002865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065137|High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia|HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN||Comprehensive Cancer Center of Wake Forest University|No|Completed|April 1995|August 2001|Actual|June 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|120 Years|No|||September 2015|September 29, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002865||208956|
NCT00002650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064180|High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed|PHASE II DOUBLE-BLIND CHEMOPREVENTION TRIAL OF HIGH DOSE FOLIC ACID VERSUS PLACEBO IN PATIENTS WITH RESECTED COLORECTAL POLYPS||National Cancer Institute (NCI)||Active, not recruiting|April 1995|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|80|||Both|21 Years|N/A|No|||May 2007|November 6, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002650||209125|
NCT00002651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064184|Hormone Therapy in Treating Men With Stage IV Prostate Cancer|Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III||National Cancer Institute (NCI)||Recruiting|May 1995|||June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1512|||Male|18 Years|N/A|No|||April 2009|October 23, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002651||209124|
NCT00002633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR3|Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer|Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate||Canadian Cancer Trials Group|Yes|Completed|March 1995|January 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|361|||Male|N/A|79 Years|No|||January 2012|January 31, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002633||209138|
NCT00002634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-011|Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma|N7: EVALUATION OF MAXIMAL CHEMOTHERAPY DOSE INTENSITY PLUS MONOCLONAL ANTIBODY 3F8 IN THE TREATMENT OF NEUROBLASTOMA||Memorial Sloan Kettering Cancer Center||Completed|February 1995|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|1 Year|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002634||209137|
NCT00002863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065134|Cryosurgery in Treating Patients With Soft Tissue Sarcoma|PHASE I FEASIBILITY TRIAL OF CRYOSURGICAL ABLATION OF SOFT TISSUE SARCOMAS OF THE EXTREMETY||University of Southern California|Yes|Terminated|June 1996|July 2000|Actual|July 2000|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes|Insufficient Accrual|No||https://clinicaltrials.gov/show/NCT00002863||208958|
NCT00002652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064185|Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease|A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE||National Cancer Institute (NCI)||Completed|May 1995|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2002|February 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002652||209123|
NCT00002657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064200|SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant|Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and Promace-Cytabom For Treatment of Post-Cardiac Transplant Lymphoproliferation.||Southwest Oncology Group|No|Completed|May 1995|July 2011|Actual|November 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|15 Years|N/A|No|||January 2013|January 22, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002657||209118|
NCT00002658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064208|Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia|ACUTE MYELOID LEUKAEMIA TRIAL 12||National Cancer Institute (NCI)||Active, not recruiting|January 1994|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Both|15 Years|N/A|No|||October 2002|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002658||209117|
NCT00002638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMC-06695|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia|HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR CHILDREN WITH RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA||National Cancer Institute (NCI)||Completed|March 1995|March 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|1 Year|19 Years|No|||September 2002|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002638||209134|
NCT00002639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064118|Suramin in Treating Patients With Recurrent Primary Brain Tumors|ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS||National Cancer Institute (NCI)||Completed|July 1995|May 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|N/A|No|||February 2001|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002639||209133|
NCT00002641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62931|Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma|RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 1995|June 2012|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|350|||Both|16 Years|69 Years|No|||July 2002|August 7, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002641||209132|
NCT00002594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9430|Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors|Dose-Intensive Melphalan and Cyclophosphamide With Autologous Bone Marrow Rescue for Recurrent Medulloblastoma and Germ Cell Tumors||Children's Oncology Group|Yes|Completed|September 1994|March 2007|Actual|September 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|2 Years|25 Years|No|||July 2014|July 23, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002594||209167|
NCT00002706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-LAP2|Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus|A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III||Gynecologic Oncology Group||Completed|April 1996|||March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2616|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002706||209080|
NCT00002659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064225|Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer|A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK||National Cancer Institute (NCI)||Active, not recruiting|May 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002659||209116|
NCT00002707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-27|Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed|A RANDOMIZED TRIAL COMPARING PREOPERATIVE DOXORUBICIN (ADRIAMYCIN)/CYCLOPHOSPHAMIDE (AC) TO PREOPERATIVE AC FOLLOWED BY PREOPERATIVE DOCETAXEL (TAXOTERE) AND TO PREOPERATIVE AC FOLLOWED BY POSTOPERATIVE DOCETAXEL IN PATIENTS WITH OPERABLE CARCINOMA OF THE BREAST||NSABP Foundation Inc|Yes|Completed|December 1995|February 2010|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2411|||Female|N/A|N/A|No|||February 2010|February 2, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002707||209079|
NCT00002900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065237|SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial|A STUDY OF THE LATE CARDIAC EFFECTS OF TWO DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENTS IN WOMEN WITH NODE NEGATIVE BREAST CANCER TREATED ON SWOG-8897||Southwest Oncology Group||Completed|February 1997|||March 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|180|||Female|18 Years|120 Years|No|Non-Probability Sample|Patients with histologically proven invasive adenocarcinoma of the breast with negative        axillary lymph nodes|October 2015|October 15, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002900||208927|
NCT00002901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065241|Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function|PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION||City of Hope Medical Center||Completed|December 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 11, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002901||208926|
NCT00002630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064030|High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse|HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA||Mayo Clinic|Yes|Completed|June 1993|May 2001|Actual|February 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|65 Years|No|||May 2011|May 10, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002630||209141|
NCT00002635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064085|Aminocamptothecin in Treating Patients With T-cell Lymphoma|PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA||Yale University|No|Completed|May 1995|April 2000|Actual|April 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2001|July 24, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002635||209136|
NCT00002681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064351|Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma|Humanized Anti-Tac Antibody Therapy In Hodgkin's Disease, A Phase Ib/II Trial||Roger Williams Medical Center||Completed|July 1995|December 2003|Actual|September 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002681||209098|
NCT00003213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 90/95|Drugs to Reduce the Side Effects of Chemotherapy|A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis||Swiss Group for Clinical Cancer Research|No|Completed|May 1996|August 1999|Actual|April 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|267|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003213||208657|
NCT00003183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066007|Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer|A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 1997|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|64|||Male|N/A|N/A|No|||April 2001|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003183||208683|
NCT00002813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064956|Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer|A LIMITED ACCESS PHASE II TRIAL OF CISPLATIN AND NAVELBINE (VINORELBINE) IN ADVANCED AND RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX||Gynecologic Oncology Group||Completed|August 1997|||October 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|62|||Female|N/A|N/A|No|||March 2008|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002813||208996|
NCT00003156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065948|Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus|Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus||Gynecologic Oncology Group||Terminated|June 1998|||October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||January 2006|April 10, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00003156||208704|
NCT00003190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02793|Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia|Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML &gt;60 Years||National Cancer Institute (NCI)||Completed|January 1998|||August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|640|||Both|60 Years|N/A|No|||June 2013|June 3, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003190||208678|
NCT00003202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066052|Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|Alternating Phase I/II Trials of Twice-Weekly Infusion Gemcitabine (2'2'-Difluoro-2'-Deoxycytidine) and Concurrent Thoracic Radiation Alone - Or Following 2 Cycles of Cisplatin/Gemcitabine Induction Chemotherapy for the Treatment of Stage IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)||Comprehensive Cancer Center of Wake Forest University|No|Completed|January 1998|July 2006|Actual|April 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||July 2012|July 11, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003202||208667|
NCT00003145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209.00|Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia|Induction of Mixed Hematopoietic Chimerism Using Fludarabine, Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion In Patients With Chronic Myeloid Leukemia in Chronic and Accelerated Phases: A Multi-center Study||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|August 1997|||March 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|74 Years|No|||January 2016|January 5, 2016|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003145||208714|
NCT00002780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064792|Biological Therapy in Treating Women With Metastatic Breast Cancer|INFUSION OF ACTIVATED T CELLS AND LOW DOSE INTERLEUKIN 2 COMBINED WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR THE TREATMENT OF WOMEN WITH METASTATIC BREAST CANCER: PHASE I/II||National Cancer Institute (NCI)||Active, not recruiting|May 1996|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Female|18 Years|N/A|No|||February 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002780||209024|
NCT00003207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066062|Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers|Phase I Study on Doxil and SDZ PSC 833 in the Treatment of AIDS-Associated Kaposi's Sarcoma and Other Advanced Malignancies||Washington University School of Medicine|No|Completed|March 1998|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003207||208662|
NCT00003163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065959|Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers|Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies||National Cancer Institute (NCI)||Active, not recruiting|September 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||October 2002|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003163||208698|
NCT00002828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-021|Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer|PHASE I TRIAL OF SEQUENTIAL TOMUDEX AND 5-FLUOROURACIL IN SUBJECTS WITH ADVANCED COLORECTAL CARCINOMA||Memorial Sloan Kettering Cancer Center||Completed|April 1995|November 2001|Actual|November 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002828||208984|
NCT00002793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064871|Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer|PALLIATIVE LOCAL CHEMOTHERAPY FOR NON-RESECTABLE LIVER METASTASES FROM COLORECTAL CARCINOMA, A RANDOMISED PHASE III STUDY||National Cancer Institute (NCI)||Active, not recruiting|January 1991|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|336|||Both|18 Years|76 Years|No|||May 2007|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002793||209012|
NCT00003178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9720|Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia|Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study||Children's Oncology Group|Yes|Completed|March 1998|March 2007|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|N/A|21 Years|No|||July 2014|July 24, 2014|June 2, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00003178||208687|
NCT00003179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065999|Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer|A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera||Gynecologic Oncology Group||Terminated|November 1998|||February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|360|||Female|N/A|N/A|No|||July 2006|June 7, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003179||208686|
NCT00002812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1961|Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia|Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study||Children's Oncology Group|Yes|Completed|September 1996|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2078|||Both|1 Year|21 Years|No|||August 2013|August 23, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002812||208997|
NCT00002806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-937202|Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma|PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS||Alliance for Clinical Trials in Oncology|No|Completed|July 1996|July 2004|Actual|January 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002806||209002|
NCT00003212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62971|Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma|Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|January 1998|||November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|780|||Both|15 Years|65 Years|No|||January 2012|January 19, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003212||208658|
NCT00003152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20963|Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma|Marrow-Ablative Chemo-Radiotherapy and Autologous Stem Cell Transplantation Followed by Interferon-Alpha Maintenance Treatment Versus Interferon-Alpha Maintenance Treatment Alone After a Chemotherapy-Induced Remission in Patients With Stages III or IV Follicular Non-Hodgkin's Lymphoma. A Prospective, Randomized, Phase III Clinical Trial.||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|March 1997|||November 1999|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|469|||Both|18 Years|65 Years|No|||June 2012|June 29, 2012|November 1, 1999|||low accrual|No||https://clinicaltrials.gov/show/NCT00003152||208707|
NCT00003153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065938|Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation|Phase II Study of Salvage Cellular Immunotherapy for Patients With Persistent or Recurrent Multiple Myeloma After Allogeneic Bone Marrow Transplantation From an HLA-Matched Sibling Donor||National Cancer Institute (NCI)||Completed|February 1998|||February 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|22|||Both|18 Years|N/A|No|||July 2004|February 25, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003153||208706|
NCT00002787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104.00|Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation|Phase I Trial of Post Transplant Immunization With Autologous Myeloma Idiotype-KLH/GM-CSF In Myeloma Patients Following Autologous or Allogeneic Marrow or Stem Cell Transplantation||Fred Hutchinson Cancer Research Center||Active, not recruiting|March 1996|||December 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||May 2015|May 1, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002787||209018|
NCT00002765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064729|Immunotoxin in Treating Patients With Leukemia or Lymphoma|PHASE I STUDY OF ANTI-TAC(Fv)-PE38 (LMB-2), A RECOMBINANT SINGLE-CHAIN IMMUNOTOXIN FOR TREATMENT OF TAC-EXPRESSING MALIGNANCIES||National Cancer Institute (NCI)||Completed|April 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|April 28, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002765||209036|
NCT00003143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065926|Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation|A Randomized Study of Ethyol (Amifostine) With Platinum Based Salvage Chemotherapy in Patients With Lymphoma Undergoing Autologous Stem Cell Transplantation||Jonsson Comprehensive Cancer Center|No|Completed|November 1997|||December 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003143||208716|
NCT00003182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066004|Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck|A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma)||National Cancer Institute (NCI)||Active, not recruiting|March 1997|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||July 2000|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003182||208684|
NCT00002790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1096.00|Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant|A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS) IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FROM RELATED DONORS MISMATCHED FOR ONE HLA ANTIGEN IN THE DIRECTION OF GRAFT-VERSUS-HOST DISEASE (GVHD)||Fred Hutchinson Cancer Research Center||Withdrawn|March 1996|||||Phase 1/Phase 2|Interventional|Primary Purpose: Supportive Care|||Actual|0|||Both|13 Years|N/A|No|||March 2015|March 4, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002790||209015|
NCT00002794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064874|Carboplatin Plus Vincristine in Treating Children With Retinoblastoma|Evaluation of Chemotherapy as Initial Treatment for Retinoblastoma||St. Jude Children's Research Hospital||Completed|February 1996|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|25|||Both|N/A|10 Years|No|||October 2011|October 3, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002794||209011|
NCT00003089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJUH-969139|Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer|A Phase II Trial of Induction Paclitaxel Plus Carboplatin Followed by Thoracic Radiation Therapy With Concurrent Weekly Low-Dose Paclitaxel and Twice Weekly Amifostine for Patients With Unresectable Locally Advanced or Partially Resected Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|July 1997|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003089||208766|
NCT00003216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9704|Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas|A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma||Radiation Therapy Oncology Group|Yes|Completed|July 1998|||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|518|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003216||208654|
NCT00002805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2951|Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|Acute Myeloid Leukemia Salvage Therapy for Patients in First Relapse or Who Fail to Achieve an Initial Remission or Who Develop AML as a Second Malignant Neoplasm||Children's Oncology Group|Yes|Completed|August 1997|June 2008|Actual|May 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002805||209003|
NCT00002819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064983|Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer|A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY||Gynecologic Oncology Group||Terminated|November 1996|||February 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|N/A|65 Years|No|||May 2007|April 10, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002819||208991|
NCT00003181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066003|Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Using Low Dose Subcutaneous IL-2, Vinblastine and GM-CSF in the Treatment of Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|May 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||May 2001|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003181||208685|
NCT00003144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065927|Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors|Phase I Study of Amifostine (Ethyol) as a Cytoprotector of Gemcitabine/Cisplatin Combination||New York University School of Medicine||Completed|August 1997|||April 2001|Actual|Phase 1|Interventional|Primary Purpose: Supportive Care|||Anticipated|44|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003144||208715|
NCT00002764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62933|Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma|METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1996|||November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|340|||Both|16 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002764||209037|
NCT00003146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204.00|Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase II Trial of Thiotepa, Busulfan, and Melphalan Followed by Autologous or Syngeneic Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma||Fred Hutchinson Cancer Research Center||Completed|November 1997|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||June 2011|June 21, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003146||208713|
NCT00003186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 96-57|Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer|Dynamic In Vivo Lymphography and Sentinel Node Biopsy in Colorectal Cancer: A Feasibility Study||Roswell Park Cancer Institute||Completed|April 1997|||March 2005|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|75 Years|No|||February 2013|February 4, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003186||208680|
NCT00003187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066016|Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma|The Unrelated Donor Marrow Transplantation Trial||Virginia Commonwealth University|No|Completed|May 1995|February 2005|Actual|February 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|19|||Both|N/A|55 Years|No|||February 2010|February 23, 2010|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00003187||208679|
NCT00003160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065955|Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum|A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Patients With Taxol/Platinum-Refractory Stage III and IV Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|N/A|No|||January 2001|April 19, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003160||208700|
NCT00002791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9514|Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma|A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL||Radiation Therapy Oncology Group|Yes|Completed|February 1997|November 2013|Actual|May 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2014|January 23, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002791||209014|
NCT00003176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065986|Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma|A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas||National Cancer Institute (NCI)||Active, not recruiting|January 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|82|||Both|18 Years|N/A|No|||January 2007|December 13, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003176||208688|
NCT00002922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065327|Paclitaxel in Treating Patients With Advanced Head and Neck Cancer|Phase II Evaluation of Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck||Eastern Cooperative Oncology Group||Completed|January 1997|||September 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 28, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002922||208908|
NCT00003195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1272.00|Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma|A Phase II Study of Total Marrow Irradiation, Busulfan, and Alpha-Interferon Followed by Allogeneic Peripheral Blood Stem Cell or Marrow Transplantation for Treatment of Patients With Advanced Multiple Myeloma.||Fred Hutchinson Cancer Research Center||Completed|December 1997|November 2000|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||November 2011|November 15, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003195||208673|
NCT00002818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064976|High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies|Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia||Virginia Commonwealth University|No|Completed|February 1995|February 2001|Actual|February 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|120 Years|No|||December 2015|December 10, 2015|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00002818||208992|
NCT00003185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066013|Biological Therapy in Treating Patients With Glioblastoma Multiforme|Adoptive Immunotherapy of Glioblastoma Multiforme With Tumor-Sensitized, Ex Vivo Activated T Lymphocytes||National Cancer Institute (NCI)||Completed|August 1997|July 1998|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||December 2008|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003185||208681|
NCT00003199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 1605|Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer|A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF||Fred Hutchinson Cancer Research Center|No|Completed|November 1997|||December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|19 Years|65 Years|No|||July 2011|July 8, 2011|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003199||208669|
NCT00003200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066044|Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck|Taxotere Plus Concurrent Radiotherapy After Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck (TAXT-XRT)||National Cancer Institute (NCI)||Active, not recruiting|October 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||June 2000|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003200||208668|
NCT00003203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9971|Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors|An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed by Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors||Children's Oncology Group|Yes|Completed|March 1998|March 2012|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|3 Years|21 Years|No|||August 2013|August 22, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003203||208666|
NCT00003154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1597|Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase II Trial of 9-Aminocamptothecin (9-AC) Colloidal Dispersion (CD) 120-Hour Continuous Intravenous Infusion in Advanced Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|January 1998|June 2001|Actual|April 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003154||208705|
NCT00003150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065935|Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma|Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|December 1997|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|630|||Both|60 Years|N/A|No|||August 2010|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003150||208709|
NCT00003167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02261|Gene Therapy in Treating Patients With Advanced Bladder Cancer|A Phase I Trial of Intravesical Ad-p53 Treatment in Locally Advanced and Metastatic Bladder Cancer||National Cancer Institute (NCI)||Completed|May 1998|||December 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003167||208695|
NCT00002833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM94-078|Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia|Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis||M.D. Anderson Cancer Center|No|Completed|October 1994|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|55 Years|70 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002833||208980|
NCT00002835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA DM95-121|Combination Chemotherapy in Treating Patients With Lymphoma|A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma||M.D. Anderson Cancer Center|No|Completed|July 1995|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|15 Years|59 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002835||208979|
NCT00003159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065952|Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer|Randomized Trial of Surgical Resection With or Without Pre-Operative Chemotherapy in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) of Any Stage||National Cancer Institute (NCI)||Completed|August 1997|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|600|||Both|N/A|N/A|No|||May 2005|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003159||208701|
NCT00003148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06964|Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia|Phase II Study of the Efficacy of rH Interleukin-2 in Patients With Slowly Progressing Acute Myelogenous Leukemia (AML) and With Limited Bone Marrow Blastosis After Autologous Stem Cell Transplantation or Chemotherapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|October 1997|||April 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|86|||Both|18 Years|60 Years|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003148||208711|
NCT00003149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065934|Interleukin-12 in Treating Patients With Multiple Myeloma|Phase II of Interleukin-12 for Plateau Phase Multiple Myeloma||National Cancer Institute (NCI)||Completed|December 1997|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||March 2009|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003149||208710|
NCT00003209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55954|Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer|A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1997|||December 1999|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|700|||Female|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003209||208661|
NCT00002773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVMC-ONC-222P|Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer|A CLINICAL TRIAL FOR PANCREAS CANCER USING ACTIVE INTRALYMPHATIC IMMUNOTHERAPY WITH INTERFERON-TREATED PANCREAS CANCER TISSUE CULTURE CELLS, GMCSF, AND LOW-DOSE CYCLOPHOSPHAMIDE||National Cancer Institute (NCI)||Completed|May 1996|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2007|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002773||209030|
NCT00003198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-120|Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors|A Phase I Dose-Escalation Study of Topotecan and Ifosfamide in Patients With Refractory Non-Hematologic Malignancies.||Memorial Sloan Kettering Cancer Center||Completed|November 1997|May 2000|Actual|May 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003198||208670|
NCT00003147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02259|Gene Therapy in Treating Patients With Cancer of The Liver|Phase I Study of Percutaneous Injections of Adeno-Virus p53 Construct (ADENO-p53) for Hepatocellular Carcinoma||National Cancer Institute (NCI)||Terminated|February 1998|||June 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2000|February 4, 2013|April 6, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00003147||208712|
NCT00003214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 45/94|Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer|Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III)||Swiss Group for Clinical Cancer Research||Completed|July 1996|April 2000|Actual|April 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Female|N/A|80 Years|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003214||208656|
NCT00002792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1032.01|Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders|ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS||Fred Hutchinson Cancer Research Center||Completed|June 1996|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|65 Years|No|||March 2010|March 31, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002792||209013|
NCT00003162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9714|Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer|Randomized Trial of Palliative Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life||Radiation Therapy Oncology Group|Yes|Completed|February 1998|||July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|949|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003162||208699|
NCT00003165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065966|Doxorubicin in Treating Women With Advanced Breast Cancer|A Phase II Trial of PK1 in Women With Advanced Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Female|18 Years|N/A|No|||April 2010|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003165||208697|
NCT00002829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM94-009|Bone Marrow Transplantation in Treating Patients With Lymphoma|Autologous and Allogeneic Bone Marrow Transplantation for Low Grade Lymphoma||M.D. Anderson Cancer Center|No|Completed|February 1994|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|15 Years|60 Years|No|||July 2012|July 26, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002829||208983|
NCT00003082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065781|Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer|A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients||University of Arizona||Completed|December 1997|February 2001|Actual|February 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|27|||Both|18 Years|N/A|No|||May 2007|March 12, 2010|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003082||208772|
NCT00003193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066028|Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Phase I/II Study of Escalating Doses of Taxol Used Concurrently With Ethyol and Accelerated Hyperfractionated Radiotherapy in the Treatment of Stage III and IV Carcinoma of the Head and Neck||Massachusetts General Hospital||Completed|January 1998|September 2005|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003193||208675|
NCT00003194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066029|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of Thiotepa in Combination With Carboplatin and Topotecan With Peripheral Blood Progenitor Cell Support for the Treatment of Children With Recurrent or Refractory Solid Tumors.||National Cancer Institute (NCI)||Active, not recruiting|July 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|1 Year|30 Years|No|||March 2003|February 6, 2009|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00003194||208674|
NCT00003170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-969256|Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer|Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy||Alliance for Clinical Trials in Oncology|Yes|Completed|February 1998|June 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|129|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003170||208694|
NCT00003034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065639|ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen|ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen||National Cancer Institute (NCI)||Active, not recruiting|May 1997|||February 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||October 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003034||208812|
NCT00002781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064811|Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma|PROCEDURES FOR BNCT PHASE-I STUDY OF MELANOMA IN THE EXTREMITIES||National Cancer Institute (NCI)||Active, not recruiting|April 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||April 2000|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002781||209023|
NCT00002768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064734|Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission|AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY||Alliance for Clinical Trials in Oncology|No|Completed|June 1996|March 2009|Actual|February 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|15 Years|69 Years|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002768||209033|
NCT00002771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-CML-3|Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia|PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML||National Cancer Institute (NCI)||Active, not recruiting|January 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|750|||Both|N/A|N/A|No|||July 2000|August 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002771||209032|
NCT00002789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1092.00|Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia|A PHASE III RANDOMIZED STUDY COMPARING G-CSF MOBILIZED PERIPHERAL BLOOD STEM CELLS WITH MARROW AS THE SOURCE OF STEM CELLS FOR ALLOGENEIC TRANSPLANTS FROM HLA IDENTICAL, RELATED DONORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA||Fred Hutchinson Cancer Research Center||Completed|May 1996|September 2001|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|100|||Both|15 Years|65 Years|No|||March 2010|March 29, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002789||209016|
NCT00003040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065668|S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx|A Phase II Study to Evaluate Transoral CO2 Laser Supraglottic Laryngectomy and Irradiation in Stage I, II and III Squamous Cell Carcinoma of the Supraglottic Larynx||Southwest Oncology Group|No|Terminated|September 1997|December 2007|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|November 1, 1999||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00003040||208807|
NCT00002798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01834|Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)||National Cancer Institute (NCI)||Completed|August 1996|||September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|880|||Both|N/A|21 Years|No|||January 2013|January 15, 2013|November 24, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00002798||209009|
NCT00002767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064732|Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma|PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA||National Cancer Institute (NCI)||Active, not recruiting|January 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||May 2007|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002767||209034|
NCT00002997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065545|Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer|Phase II Trial of Cryoablation for Treatment of Unresectable Colorectal Hepatic Metastases||National Cancer Institute (NCI)||Completed|August 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002997||208846|
NCT00002998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-963251|Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer|Phase II Study of Gemcitabine (GEMZAR) and Cisplatin (CDDP) in Advanced Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|August 1997|May 2006|Actual|April 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002998||208845|
NCT00002814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9607|Combination Chemotherapy for Patients With Brain Cancer|A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma||Dartmouth-Hitchcock Medical Center|Yes|Completed|August 1996|December 2001|Actual|April 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002814||208995|
NCT00002816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1951|Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia|EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY||Children's Oncology Group|Yes|Completed|December 1996|April 2006|Actual|November 2002|Actual|Phase 3|Interventional|Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|20 Years|No|||August 2013|August 21, 2013|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002816||208994|
NCT00003018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065599|S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer|A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma||Southwest Oncology Group|Yes|Completed|September 1997|January 2007|Actual|January 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003018||208825|
NCT00003022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-021|Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer|Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms||Memorial Sloan Kettering Cancer Center||Completed|April 1997|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|3 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003022||208821|
NCT00002784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064834|High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer|Randomized Trial of High-dose Epirubicin and Cyclophosphamide x 3 Supported by Peripheral Blood Progenitor Cells Versus Anthracycline and Cyclophosphamide x 4 Followed by Cyclophosphamide, Methotrexate, and 5-fluorouracil x 3 as Adjuvant Treatment for High Risk Operable Stage ii and Stage Iii Breast Cancer in Premenopausal and Young Postmenopausal (Less Than or Equal to 65 Yrs) Patients.|15-95|International Breast Cancer Study Group|Yes|Completed|June 1996|December 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|344|||Female|16 Years|65 Years|No|||July 2012|April 3, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002784||209021|
NCT00002778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064783|Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia|GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (Rhu-GM-CSF) FOR REDUCTION OF LEUKEMIC RELAPSE AFTER T-LYMPHOCYTE DEPLETED ALLOGENEIC BMT FOR CHRONIC MYELOID LEUKEMIA||Sidney Kimmel Comprehensive Cancer Center||Terminated|February 1995|July 2010|Actual|February 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||April 2011|July 19, 2011|November 1, 1999|||subject accrual and data analysis is completed.|No||https://clinicaltrials.gov/show/NCT00002778||209026|
NCT00003039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02253|Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma|A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients With Previously Treated Intermediate and High Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma||National Cancer Institute (NCI)||Completed|September 1997|||April 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2000|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003039||208808|
NCT00003048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-041|Amifostine in Treating Patients With Myelodysplastic Syndrome|Phase II Study of Intravenous Amifostine in Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Completed|May 1997|February 2001|Actual|February 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003048||208801|
NCT00002800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-044|Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome|PHASE II STUDY OF HIGH DOSE CYTARABINE COMBINED WITH A SINGLE HIGH DOSE OF IDARUBICIN FOR NEWLY DIAGNOSED PATIENTS WITH AML: THE AML-3 PROTOCOL||Memorial Sloan Kettering Cancer Center||Completed|July 1996|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002800||209008|
NCT00002775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064755|Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|PHASE I/II STUDY OF DOCETAXEL (TAXOTERE) AND ESTRAMUSTINE COMBINATION CHEMOTHERAPY IN PATIENTS WITH PROSTATE CANCER||National Cancer Institute (NCI)||Active, not recruiting|February 1998|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|37|||Male|18 Years|N/A|No|||April 2000|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002775||209028|
NCT00003003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065565|Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia|A Pilot Clinical Trial of Mitomycin C Modulation of Multidrug Resistance Proteins and a Phase I Evaluation of Mitomycin C and Mitoxantrone in Patients With Acute Myelogenous Leukemia||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 1996|August 2000|Actual|August 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|29|||Both|18 Years|N/A|No|||June 2000|March 1, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003003||208840|
NCT00003053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065700|Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed|Adjuvant Treatment of Non Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 1994|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|750|||Both|N/A|70 Years|No|||January 2008|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003053||208797|
NCT00003062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08965|Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer|A Phase II Study of TEMOZOLOMIDE in Advanced Non-Small Cell Lung Cancer With and Without Brain Metastases||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 1997|||January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|70|||Both|N/A|69 Years|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003062||208789|
NCT00002868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065146|Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia|PROSPECTIVE RANDOMISED STUDY TO COMPARE INTERFERON-ALPHA-n1 (WELLFERON) VS 'IDAC' CHEMOTHERAPY AND AUTOGRAFTING FOLLOWED BY INTERFERON ALPHA-n1 (WELLFERON) IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA||Eastern Cooperative Oncology Group||Completed|January 1996|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|744|||Both|15 Years|65 Years|No|||June 2005|February 9, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002868||208954|
NCT00002827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9426|Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease|RESPONSE DEPENDENT TREATMENT OF STAGES IA, IIA AND IIIA HODGKIN'S DISEASE WITH DBVE AND LOW DOSE INVOLVED FIELD IRRADIATION WITH OR WITHOUT ZINECARD: A PEDIATRIC ONCOLOGY GROUP PHASE III STUDY||Children's Oncology Group|Yes|Completed|October 1996|June 2008|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|294|||Both|N/A|21 Years|No|||August 2013|August 22, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002827||208985|
NCT00003019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9650|Vinblastine and Methotrexate in Treating Children With Desmoid Tumors|Vinblastine and Methotrexate in Children With Desmoid Tumor (Aggressive Fibromatosis) Which is Recurrent or Not Amenable to Surgical Resection or Irradiation - A Pediatric Oncology Group Phase II Study||Children's Oncology Group|Yes|Completed|August 1997|September 2006|Actual|July 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|N/A|21 Years|No|||July 2014|July 24, 2014|August 3, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00003019||208824|
NCT00003004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-077|Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors|An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Flavopiridol Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|July 1997|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|73|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003004||208839|
NCT00002809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064937|Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer|Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States||Temple University||Completed|August 1996|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|17 Years|60 Years|No|||September 2010|September 30, 2010|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002809||209000|
NCT00003023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-024|Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer|Phase I Trial of A1G4 Anti-Idiotypic Monoclonal Antibody With Bacille-Calmette-Guerin (BCG) Adjuvant in High Risk Patients With GD2 Positive Tumors||Memorial Sloan Kettering Cancer Center||Completed|March 1997|||January 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|N/A|N/A|No|||January 2013|January 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003023||208820|
NCT00002822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064998|Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer|RANDOMISED CLINICAL TRIAL OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE WITH MID-CYCLE VINCRISTINE (VICE) VERSUS STANDARD PRACTICE CHEMOTHERAPY IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER (SCLC) AND GOOD PERFORMANCE STATUS||National Cancer Institute (NCI)||Completed|March 1996|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|N/A|N/A|No|||December 2000|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002822||208990|
NCT00002811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064945|T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum|A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES||National Cancer Institute (NCI)||Active, not recruiting|July 1996|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|30|||Both|2 Years|60 Years|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002811||208998|
NCT00003029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-05962|Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas|Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial.||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 1997|||July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|200|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003029||208815|
NCT00003031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-19961|Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis|An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 1997|||October 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|212|||Both|12 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003031||208814|
NCT00002831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM94-064|Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia|A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies||M.D. Anderson Cancer Center|No|Completed|July 1994|December 2002|Actual|December 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|15 Years|55 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002831||208982|
NCT00002807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN5|Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery|A Phase III Randomized Trial Comparing TAH BSO Versus TAH BSO Plus Adjuvant Pelvic Irradiation in Intermediate Risk Carcinoma of the Endometrium||Canadian Cancer Trials Group|Yes|Completed|July 1996|December 2009|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Female|N/A|N/A|No|||April 2012|September 20, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002807||209001|
NCT00002762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9431|Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer|MENSTRUAL CYCLE AND SURGICAL TREATMENT OF BREAST CANCER||Alliance for Clinical Trials in Oncology|Yes|Completed|June 1996|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1118|||Female|18 Years|55 Years|No|Non-Probability Sample|This trial enrolled premenopausal women age 18 to 55 years who had regular menstrual        cycles of 21- to 35-days duration and pathologic stages I to II breast cancer, in whom all        gross disease—including ductal carcinoma in situ—was surgically removed either in a        one-stage or two-stage procedure. Surgical treatment consisted of an open biopsy followed        by a mastectomy or breast-conserving surgery with or without sentinel node biopsy and/or        axillary nodal dissection. Fine needle aspirates and core or stereotactic needle biopsies        were allowed before the definitive procedure. Chemotherapy and/or radiotherapy were        allowed in accordance with internationally accepted criteria, as per investigator's        discretion. Eligibility required serum be drawn within 1 calendar day of the        lumpectomy/mastectomy for women who underwent a one-stage procedure and within 1 calendar        day of each stage for women who underwent a two-stage procedure.|July 2015|July 3, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002762||209039|
NCT00002850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065093|Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy|Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma||University of Rochester|Yes|Completed|March 1997|January 2012|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|212|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|November 1, 1999||No||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00002850||208966|
NCT00002785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1953|Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia|Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age.||Children's Oncology Group|Yes|Completed|July 1996|March 2007|Actual|August 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002785||209020|
NCT00002786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1017.01|Biological Therapy in Treating Patients With Metastatic Melanoma|PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY USING GENETICALLY MODIFIED AND UNMODIFIED AUTOLOGOUS CD8+ TYROSINASE-SPECIFIC T CELLS FOR PATIENTS WITH METASTATIC MELANOMA||Fred Hutchinson Cancer Research Center||Completed|October 1995|March 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|75 Years|No|||May 2010|May 6, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002786||209019|
NCT00003052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065699|Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma|Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults||National Cancer Institute (NCI)||Completed|July 1997|June 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|340|||Both|18 Years|70 Years|No|||November 2006|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003052||208798|
NCT00002783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-027|Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer|A PHASE II TRIAL OF NEOADJUVANT CISPLATIN-FLUOROURACIL CHEMOTHERAPY, SURGERY, AND INTRAPERITONEAL (IP) FLOXURIDINE (FUdR) PLUS LEUCOVORIN IN PATIENTS WITH GASTRIC CANCER||Memorial Sloan Kettering Cancer Center||Completed|May 1996|January 2001|Actual|January 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002783||209022|
NCT00003008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065583|Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma|Pilot Study to Evaluate the Potential Interactions Between Paclitaxel and Protease Inhibitors in Patients With AIDS-Related Kaposi's Sarcoma||Eastern Cooperative Oncology Group|No|Completed|June 1997|||June 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003008||208835|
NCT00002824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065004|Gene Therapy in Treating Patients With Primary Brain Tumors|A PHASE I TRIAL OF HSV-TK ADENOVIRUS GENE THERAPY FOR PRIMARY BRAIN TUMORS||National Cancer Institute (NCI)||Completed|February 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2000|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002824||208988|
NCT00002825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02247|Docetaxel in Treating Children With Recurrent Solid Tumors|A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS||National Cancer Institute (NCI)||Completed|January 1997|||December 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|21 Years|No|||May 2006|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002825||208987|
NCT00002826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065011|Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer|A PILOT PHASE II TRIAL OF PSC 833 MODULATION OF MULTIDRUG RESISTANCE TO PACLITAXEL IN THE TREATMENT OF METASTATIC CARCINOMA OF THE BREAST||Eastern Cooperative Oncology Group||Completed|June 1997|||November 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Female|18 Years|N/A|No|||August 2013|August 28, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002826||208986|
NCT00002801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064898|Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer|PHASE I TRIAL OF POST-OPERATIVE COMBINED ORAL UFT PLUS LEUCOVORIN AND RADIATION THERAPY FOR RECTAL CANCER||National Cancer Institute (NCI)||Completed|April 1996|December 2009|Actual|December 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||December 2009|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002801||209007|
NCT00002802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064902|Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma|PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS||National Cancer Institute (NCI)||Completed|July 1990|September 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|N/A|20 Years|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002802||209006|
NCT00002804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9553|Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma|Phase II Study of Neoadjuvant Vincristine, Ifosfamide, Doxorubicin, and AND G-CSF in Children With Advanced Stage Non-Rhabdomyosarcoma Soft Tissue Sarcomas||Children's Oncology Group|Yes|Completed|September 1996|April 2006|Actual|June 2000|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|N/A|21 Years|No|||July 2014|July 24, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002804||209004|
NCT00003020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065605|LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases|Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms||Duke University||Completed|September 1997|September 2000|Actual|September 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003020||208823|
NCT00002774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-12503|Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer||Stanford University||Completed|June 1996|June 2005|Actual|June 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|63|||Both|17 Years|N/A|No|||June 2014|June 19, 2014|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00002774||209029|
NCT00002832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM94-077|Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia|Phase I/II Trial of Decitabine and Allogeneic Peripheral Blood Stem Cells Transplantation for Treatment of Relapse Post Allogeneic Bone Marrow Transplantation||M.D. Anderson Cancer Center|No|Completed|August 1995|March 2002|Actual|March 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|60 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002832||208981|
NCT00002823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065002|Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer|A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER||Gustave Roussy, Cancer Campus, Grand Paris||Completed|February 1995|||January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|3300|||Both|18 Years|75 Years|No|||April 2011|March 26, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002823||208989|
NCT00003046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID97-027|Interleukin-12 in Treating Patients With Cancer in the Abdomen|Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas||M.D. Anderson Cancer Center|No|Completed|August 1997|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003046||208802|
NCT00003032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA16|High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer|A Randomized Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy Versus Standard Therapy in Women With Metastatic Breast Cancer Who Have Responded to Anthracycline or Taxane-Based Induction Chemotherapy||Canadian Cancer Trials Group||Completed|April 1997|December 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|192|||Female|16 Years|60 Years|No|||November 2010|November 7, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003032||208813|
NCT00002796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00038|Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer|Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate, Indomethacin and Recombinant Human Interferon-Gamma in Advanced Colorectal Cancer||National Cancer Institute (NCI)||Terminated|May 1997|||December 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|N/A|N/A|No|||January 2013|January 31, 2013|November 1, 1999|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00002796||209010|
NCT00002862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065133|Perillyl Alcohol in Treating Patients With Refractory Cancer|A PHASE I STUDY OF PERILLYL ALCOHOL IN PATIENTS WITH REFRACTORY MALIGNANCIES (NSC #641066)||National Cancer Institute (NCI)||Completed|October 1996|||April 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2000|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002862||208959|
NCT00002763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064718|High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma|POST-OPERATIVE ADJUVANT INTERFERON-ALFA-2B (INTRON-A) TREATMENT AFTER RESECTION OF THICK PRIMARY MELANOMA AND/OR REGIONAL LYMPHNODE METASTASES 'INTERMEDIATE-HIGH DOSE' VS INTERMEDIATE-LOW DOSE' IFN-ALFA VS OBSERVATION: A 3-ARM MULTICENTER RANDOMIZED PHASE III TRIAL||National Cancer Institute (NCI)||Active, not recruiting|April 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Both|16 Years|75 Years|No|||November 2011|November 15, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002763||209038|
NCT00002772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064747|S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer|A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin Plus Paclitaxel Plus Cyclophosphamide With High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women With 4-9 Involved Axillary Lymph Nodes||Southwest Oncology Group|Yes|Terminated|July 1996|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|602|||Female|18 Years|N/A|No|||January 2013|January 22, 2013|November 1, 1999|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00002772||209031|
NCT00003064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065734|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer|Phase I-II Study of Tandem Cycles of High Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Support in Women With Persistent, Refractory or Recurrent Advanced (Stage III or IV), Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 1997|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||December 2002|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003064||208787|
NCT00002837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM95-156|High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer|Phase I-II Study of Dose Intense Doxorubicin, Paclitaxel And Cyclophosphamide With Peripheral Blood Progenitor Cells (PBPC) And Cytokine Support In Patients With Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Completed|September 1995|January 2002|Actual|January 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|15 Years|60 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002837||208977|
NCT00002803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064903|Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma|COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA||National Cancer Institute (NCI)||Completed|July 1995|February 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|44|||Both|N/A|1 Year|No|||April 2008|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002803||209005|
NCT00002817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064975|Vaccine Therapy in Treating Patients With Metastatic Melanoma|INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA||National Cancer Institute (NCI)||Active, not recruiting|April 1996|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2002|January 9, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002817||208993|
NCT00003014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065594|Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer|Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy||National Cancer Institute (NCI)||Completed|April 1998|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Male|16 Years|N/A|No|||March 2011|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003014||208829|
NCT00002810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064938|High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis|Autologous Peripheral Blood Stem Cell Transplantation With High Dose Melphalan For Treatment Of Primary Amyloidosis (AL)||Temple University||Completed|May 1996|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|65 Years|No|||September 2010|September 30, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002810||208999|
NCT00002836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM95-047|Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer|A Phase III Randomized Comparison of High Dose Chemotherapy G-CSF To G-CSF For Mobilization of Peripheral Blood Stem Cells For Autologous Transplantation For Patients With Responsive Metastatic Breast Cancer Or High Risk Stage II-III Patients||M.D. Anderson Cancer Center|No|Completed|May 1995|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|65 Years|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002836||208978|
NCT00003021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065606|Bizelesin in Treating Patients With Advanced Cancer|A Phase I Trial of Bizelesin (NSC 615291) Using a Single Bolus Infusion Given Every Twenty-eight (28) Days in Patients With Advanced Cancer||The University of Texas Health Science Center at San Antonio||Completed|August 1997|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2012|November 2, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003021||208822|
NCT00002761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA7158|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia|CAMP-010: PHASE I/II STUDY OF IN VIVO PURGING FOLLOWED BY HIGH DOSE CHEMOTHERAPY, AUTOLOGOUS HEMATOPOIETIC STEM CELL INFUSION AND IMMUNOTHERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA||Columbia University||Withdrawn|February 1996|October 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|60 Years|No|||November 2012|November 16, 2012|November 1, 1999|Yes|Yes|PI left institution|No||https://clinicaltrials.gov/show/NCT00002761||209040|
NCT00002777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10951|Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer|RANDOMIZED PHASE II STUDY IN FIRST LINE HORMONAL TREATMENT FOR METASTATIC BREAST CANCER WITH EXEMESTANE OR TAMOXIFEN IN POSTMENOPAUSAL PATIENTS||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 1996|||December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|342|||Female|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002777||209027|
NCT00002779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-947851|Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma|PHASE II TRIAL OF FLUDARABINE AND SANDOSTATIN FOR RELAPSED LOW-GRADE NON-HODGKIN'S LYMPHOMA||Alliance for Clinical Trials in Oncology|No|Completed|February 1998|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002779||209025|
NCT00003353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066334|High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis|A Phase II Study of High-Dose Melphalan With Hematopoietic Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis||Eastern Cooperative Oncology Group||Completed|July 1998|||December 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003353||208545|
NCT00003350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03149|Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma|Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma||National Cancer Institute (NCI)||Completed|March 1999|||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003350||208548|
NCT00003332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066296|Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer|Phase I/II Study of Induction Chemotherapy With Gemcitabine and Cisplatin Followed by Combined Chemo-radiation and/or Surgical Resection for Locally Advanced Pancreatic Cancer||New York University School of Medicine||Completed|July 1997|||October 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003332||208563|
NCT00002950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065420|Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer|Phase I/II Study of Topotecan (SKF 104864) With Recombinant GM-CSF (Sargramostim) Used as a Priming Agent in Advanced Malignancies||National Cancer Institute (NCI)||Active, not recruiting|September 1996|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||October 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002950||208882|
NCT00003344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066321|Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer|Phase I-II Study of Weekly CPT-11 and Radiation Therapy for Unresectable or Locally Recurrent Large Bowel Cancer||Medical University of South Carolina|Yes|Completed|August 1998|January 2000|Actual|January 2000|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|49|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003344||208552|
NCT00003342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-114|Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer|Phase I Trial of Dose-Dense Gemcitabine, Doxorubicin, Then Paclitaxel Plus Carboplatin In Patients With Transitional Cell Carcinoma of the Urothelium and Impaired Renal Function||Memorial Sloan Kettering Cancer Center||Completed|December 1997|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003342||208554|
NCT00003326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066278|Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus|A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Patients With Advanced Esophageal Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||April 2001|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003326||208569|
NCT00003327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066279|Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer|A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||November 2001|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003327||208568|
NCT00002987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065522|Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease|Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy||National Cancer Institute (NCI)||Active, not recruiting|January 1997|||||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|400|||Both|16 Years|75 Years|No|||March 2005|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002987||208854|
NCT00003299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066238|Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Phase III Study Comparing Etoposide and Cisplatin With Etoposide, Cisplatin and Paclitaxel in Patients With Extensive Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|April 1998|January 2006|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|587|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003299||208589|
NCT00003352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP BP-58|Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer|A Phase II Study in Patients With Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)||NSABP Foundation Inc|Yes|Completed|June 1998|December 2002|Actual|September 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Female|18 Years|N/A|No|||December 2012|December 10, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003352||208546|
NCT00002920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065314|S9630, Medroxyprogesterone in Treating Women With Breast Cancer|A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III||Southwest Oncology Group|Yes|Completed|March 1997|December 2009|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|313|||Female|18 Years|N/A|No|||October 2012|October 30, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002920||208910|
NCT00002994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065541|Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors|A Pilot Study of Low-Dose Interleukin-2 Plus Recombinant Human Anti-HER2 Monoclonal Antibody in Solid Tumors||Alliance for Clinical Trials in Oncology|Yes|Completed|July 1997|April 2002|Actual|March 2000|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|355|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002994||208849|
NCT00003320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066270|Radiation Therapy Following Surgery to Remove Brain Metastases|Pilot Study of Adjuvant Fractionated Stereotactic Radiotherapy Following Surgical Removal of Cerebral Metastases||Jonsson Comprehensive Cancer Center|Yes|Completed|March 1997|||August 2006|Actual|N/A|Interventional|Primary Purpose: Treatment|||Actual|20|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003320||208575|
NCT00003307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066254|Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer|A Phase II Open Label Trial of Amifostine Plus Fractionated Radiotherapy for Primary Prostate Adenocarcinoma (T1a-T3b, NoMo, PSA>10 ng/ml) to Estimate Acute Grade 2 Genitourinary and Gastrointestinal Toxicity||University of Arizona||Completed|March 1998|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Male|18 Years|N/A|No|||May 2006|March 12, 2010|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003307||208584|
NCT00002947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065414|Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer|A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors||Yale University|No|Terminated|October 1996|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002947||208885|
NCT00002921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065324|S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery|Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II||Southwest Oncology Group|No|Terminated|March 1997|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|November 1, 1999|Yes|Yes|Permanently Closed Due to Lack of Accrual|No||https://clinicaltrials.gov/show/NCT00002921||208909|
NCT00003252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066134|Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy|A Phase IV Open Label Study of the Effects of a Five Minute Infusion Time for Ethyol (Amifostine) in Patients Undergoing Chemotherapy||National Cancer Institute (NCI)||Completed|December 1997|September 2004|Actual|||Phase 4|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||April 2000|March 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003252||208627|
NCT00002986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0224|Chemotherapy in Treating Patients With Recurrent Malignant Glioma|Phase I Treatment of Adults With Primary Malignant Glioma With Topotecan (NSC #609699) Plus BCNU (NSC #409962)||Duke University||Completed|February 1997|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002986||208855|
NCT00002951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8176|Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer|Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck||University of Chicago|No|Completed|June 1996|July 2006|Actual|June 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|N/A|N/A|No|||September 2013|September 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002951||208881|
NCT00003341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-125|Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy|The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial||Memorial Sloan Kettering Cancer Center||Completed|December 1997|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|275|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003341||208555|
NCT00003354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066336|Conventional Surgery Compared With Laparoscopic-Assisted Surgery in Treating Patients With Colorectal Cancer|Conventional Versus Laparoscopic-Assisted Surgery in Colorectal Cancer||National Cancer Institute (NCI)||Completed|July 1996|December 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1200|||Both|18 Years|N/A|No|||January 2001|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003354||208544|
NCT00003356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066338|Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma|A Phase II Study of Rituxan and IL-2 in Patients With Low Grade or Follicular B-Cell Lymphoma||University of Rochester||Completed|November 1997|May 2002|Actual|May 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|75 Years|No|||October 2013|October 14, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003356||208543|
NCT00002981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-007|PET Scan in Treating Patients With Metastatic Prostate Cancer|11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 1997|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|173|||Male|N/A|120 Years|No|||February 2016|February 2, 2016|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002981||208859|
NCT00002964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 94-10|Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer|Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light||Roswell Park Cancer Institute||Completed|February 1995|||April 2004|Actual|Phase 2|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||February 2013|February 4, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002964||208873|
NCT00003323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9782|Hormone Therapy in Treating Patients With Prostate Cancer|A Phase II Trial of Potency-Sparing Hormonal Therapy in Patients With Elevated Serum PSA After Radiation Therapy or Radical Prostatectomy for Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|May 1998|March 2010|Actual|May 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Male|N/A|N/A|No|||June 2015|June 23, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003323||208572|
NCT00003313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9801|Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer|A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitaxel and Carboplatin||Radiation Therapy Oncology Group|Yes|Completed|September 1998|June 2010|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|243|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003313||208579|
NCT00002928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-070|Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer|A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 1997|August 2001|Actual|August 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002928||208903|
NCT00003241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCCC-H-5057|Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors|Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors||National Cancer Institute (NCI)||Completed|May 1998|September 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|2 Years|21 Years|No|||April 2000|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003241||208635|
NCT00002948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065416|High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer|A Phase I Study of High Dose Topotecan With Filgrastim and Peripheral Blood Stem Cell Support for Patients With Refractory Malignancies||Yale University|No|Terminated|October 1996|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2014|July 1, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002948||208884|
NCT00003337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066308|Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma|The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|March 1997|||||Phase 3|Interventional|Primary Purpose: Diagnostic|||Anticipated|100|||Both|16 Years|N/A|No|||December 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003337||208559|
NCT00003328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066281|Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase III Double-Blind, Randomised, Placebo-Controlled Study of Porfiromycin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Cancer||National Cancer Institute (NCI)||Completed|December 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|N/A|No|||May 2010|May 20, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003328||208567|
NCT00003329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066283|Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer|ECOG Laboratory Study: Mapping Interactive Cancer Susceptibility Loci||Eastern Cooperative Oncology Group||Completed|January 1998|||December 2007|Actual|N/A|Observational|N/A|||Anticipated|4000|||Both|N/A|N/A|No|||March 2008|April 2, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003329||208566|
NCT00003330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066286|Interleukin-12 in Treating Patients With Advanced Cancer|Phase I Clinical Trials of IV rhIL-12 With or Without a Test-Dose in Patients With Advanced Malignancies (rhIL-12 NSC# 672423)||National Cancer Institute (NCI)||Completed|July 1998|||April 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||May 2001|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003330||208565|
NCT00002963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 92-42|Photodynamic Therapy in Treating Patients With Skin Cancer|Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy||Roswell Park Cancer Institute|Yes|Completed|November 1993|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 30, 2013|November 1, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00002963||208874|
NCT00003343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-3340-009|Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor AG3340 in Combination With Mitoxantrone and Prednisone With Provision for Subsequent Change in Therapy in Patients Having Hormone-Refractory Prostate Cancer||Pfizer||Completed|March 1998|||January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|525|||Male|18 Years|N/A|No|||August 2012|August 7, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003343||208553|
NCT00003250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066130|Fenretinide in Treating Patients With Solid Tumors|Phase I Evaluation of Fenretinide (NSC# 374551)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 1998|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|15 Years|N/A|No|||April 2014|April 9, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003250||208629|
NCT00003351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-963255|Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer|Randomized Phase II Trial of Irinotecan (CPT-11) In Patients With Refractory Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|August 1998|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003351||208547|
NCT00003345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-121|Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer|Phase II Trial of Cisplatin and Irinotecan in Patients With Suboptimally Debulked, Incompletely Responding Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Completed|October 1997|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Female|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003345||208551|
NCT00002990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30962|Surgery and BCG in Treating Patients With Bladder Cancer|Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 1997|||April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1288|||Both|N/A|85 Years|No|||June 2013|June 11, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002990||208851|
NCT00002935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 93-23|Photodynamic Therapy in Treating Patients With Early Esophageal Cancer|A Phase II Study of the Safety and Efficacy of Photodynamic Therapy in Carcinoma in Situ of the Esophagus||Roswell Park Cancer Institute|Yes|Completed|October 1995|September 2007|Actual|August 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002935||208897|
NCT00003339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066310 (10M-97-3)|Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma|A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma||University of Southern California|Yes|Completed|November 1998|September 2004|Actual|November 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003339||208557|
NCT00003340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J9736 CDR0000066314|Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia|A Phase II Study of Cyclophosphamide Followed by Topotecan in Patients With Refractory or Relapsed Acute Myelogenous Leukemia||Sidney Kimmel Comprehensive Cancer Center||Completed|November 1997|February 2000|Actual|February 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2014|May 1, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003340||208556|
NCT00003298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066237|Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer|A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer||Eastern Cooperative Oncology Group|No|Completed|February 1999|May 2011|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 1, 1999|Yes|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT00003298||208590|
NCT00003305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066248|Aminopterin in Treating Patients With Refractory Leukemia|A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia||National Cancer Institute (NCI)||Completed|July 1997|September 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|75|||Both|N/A|N/A|No|||August 2008|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003305||208585|
NCT00003362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-012|Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma|Pilot Trial of Multi-Epitope Melanoma Peptide Vaccine Using GM-CSF, Montanide and QS-21 as Adjuvants||Memorial Sloan Kettering Cancer Center||Completed|May 1998|February 2001|Actual|February 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003362||208537|
NCT00003361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-98017|Decitabine in Treating Patients With Myelodysplastic Syndrome|Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes||National Cancer Institute (NCI)||Completed|April 1998|December 2009|Actual|September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|75|||Both|15 Years|N/A|No|||December 2009|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003361||208538|
NCT00002949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8270|Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis|Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies||University of Chicago|No|Completed|July 1996|May 2001|Actual|November 2000|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002949||208883|
NCT00003324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066275|Radiation Therapy With or Without Surgery in Treating Patients Who Have Brain Metastases|Prognostic Factors Associated With Successful Omission of Whole Brain Radiotherapy in Patients With 4 or Less Cerebral Metastases Treated With Focal Radiation or Surgery||Jonsson Comprehensive Cancer Center|Yes|Completed|December 1997|||July 2006|Actual|N/A|Interventional|Primary Purpose: Treatment|||Actual|61|||Both|18 Years|N/A|No|||July 2012|September 30, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003324||208571|
NCT00003331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066292|Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies||New York University School of Medicine||Completed|January 1998|||November 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003331||208564|
NCT00002975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065494|Photodynamic Therapy in Treating Patients With Skin Cancer|A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses||Roswell Park Cancer Institute|Yes|Completed|February 1997|April 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|N/A|N/A|No|||August 2013|August 2, 2013|November 1, 1999|Yes|Yes||No|June 28, 2013|https://clinicaltrials.gov/show/NCT00002975||208863|Study was activated prior to RPCI putting a system in place to centralize data entry and data management. Data entry was done by PI's staff. PI died and left incomplete data. Efficay and safety data were not analyzed.
NCT00003311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066258|Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|Phase II CCOP Trial of High Dose Methotrexate/ARA-C and HCVAD for Newly Diagnosed Nodular and Diffuse Mantle Cell Lymphoma and Their Blastic Variants||M.D. Anderson Cancer Center|No|Completed|March 1999|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|16 Years|N/A|No|||October 2012|October 5, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003311||208581|
NCT00003360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-011|Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer|Phase I Study of 131I-Labeled Humanized Antibody A33 in Patients With Advanced Colorectal Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|April 1998|||August 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003360||208539|
NCT00003357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-123|Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease|Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate Plus the Immunological Adjuvant QS21||Memorial Sloan Kettering Cancer Center||Completed|January 1998|November 2001|Actual|November 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|9|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003357||208542|
NCT00002970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01836|506U78 in Treating Patients With Refractory Hematologic Cancer|A Phase II Study of Compound 506U78 in Patients With Refractory T-Cell Malignancies-POG/CCG Intergroup Study||National Cancer Institute (NCI)||Completed|June 1997|||January 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Both|N/A|21 Years|No|||July 2013|July 1, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002970||208868|
NCT00002982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-004|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma|A Phase II Trial of ICE Chemotherapy Followed by High Dose BEAM Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients >= 60 Years Old With Refractory or Relapsed Intermediate Grade Non-Hodgkin's Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|January 1997|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|60 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002982||208858|
NCT00003251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066133|Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer|A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1997|||||Phase 1/Phase 2|Interventional|Primary Purpose: Supportive Care|||Anticipated|46|||Both|18 Years|N/A|No|||June 2000|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003251||208628|
NCT00003312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9805|Brachytherapy in Treating Patients With Prostate Cancer|Phase II Trial of Transrectal Ultrasound Guided Permanent Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate||Radiation Therapy Oncology Group|Yes|Completed|September 1998|November 2013|Actual|January 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|95|||Male|N/A|N/A|No|||January 2014|January 23, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003312||208580|
NCT00002941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5962|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma|A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, BCNU, and Etoposide (CBV) for Recurrent and Primarily Refractory Hodgkin's and Non-Hodgkin's Lymphoma||Children's Oncology Group|Yes|Completed|April 1998|March 2007|Actual|November 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|1 Year|21 Years|No|||July 2014|July 31, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002941||208891|
NCT00003325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0173|Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva|Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva||Gynecologic Oncology Group|No|Completed|December 1999|||July 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|515|||Female|N/A|N/A|No|||May 2015|May 27, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003325||208570|
NCT00003321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-15961-40973|Quality-of-Life Assessment of Patients Who Have Cancer of the Esophagus|An International Field Study of the Reliability and Validity of the EORTC-QLQ-C30 and a Disease Specific Questionnaire Module (the EORTC OES-24) in Assessing the Quality of Life of Patients With Oesophageal Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 1998|||August 2001|Actual|N/A|Observational|N/A|||Anticipated|370|||Both|N/A|N/A|No|||June 2013|June 11, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003321||208574|
NCT00003322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066273|Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer|A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|March 1998|||January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|384|||Female|N/A|N/A|No|||August 2012|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003322||208573|
NCT00002974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065489|Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma|A Phase II Study of Whole Blood Hyperthermia and Ice Chemotherapy in Sarcoma Patients||University of Wisconsin, Madison|No|Completed|July 1996|April 2003|Actual|July 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|34|||Both|18 Years|65 Years|No|||May 2011|September 30, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002974||208864|
NCT00003174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065984|Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|Phase I Clinical Evaluation of Bryostatin 1 in Combination With 2-CdA in Patients With Relapsed CLL||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 1998|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003174||208690|
NCT00002942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065391|Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer|Randomized Phase III Trial of G-CSF Primed Autologous Bone Marrow Versus Peripheral Blood Progenitor Cells (PBPC) as Hematopoietic Support for High-Dose Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Therapy in Poor Prognosis Breast Cancer||Comprehensive Cancer Center of Wake Forest University|No|Completed|June 1996|December 2003|Actual|January 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|60 Years|No|||July 2012|July 12, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002942||208890|
NCT00002937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065380|Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer|A Phase II Randomized Study of Paclitaxel Versus Paclitaxel + PSC833 for Advanced Breast Cancer (Recurring Less Than 6 Months Since Adjuvant or as Second Line for Advanced Disease||City of Hope Medical Center||Completed|June 1996|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|70|||Both|N/A|N/A|No|||January 2010|January 4, 2010|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002937||208895|
NCT00002969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065476|S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)||Southwest Oncology Group|Yes|Completed|May 1997|January 2007|Actual|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00002969||208869|
NCT00003197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-128|Green Tea Extract in Treating Patients With Advanced Solid Tumors|Phase I Evaluation of Green Tea Extract in Adults With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|December 1997|June 2000|Actual|June 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003197||208671|
NCT00002955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065428 (3P-95-1)|Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas|Modulation of 5-Fluorouracil With Trimetrexate and Leucovorin in Advanced Pancreatic Cancer||University of Southern California|Yes|Completed|August 1995|June 2006|Actual|May 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|21|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002955||208878|
NCT00002960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C95084|SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)|A Phase I Study in Patients With Peritoneal Carcinomatosis Using SCH 58500 (rAd/p53) Administered by Single Intraperitoneal Instillation||Merck Sharp & Dohme Corp.||Completed|June 1999|July 2000|Actual|July 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|59|||Female|18 Years|120 Years|No|||February 2016|February 3, 2016|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002960||208876|
NCT00003171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065975|Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome|Phase II Clinical Evaluation of Bryostatin 1 in Patients With Myelodysplastic Syndrome||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 1998|June 2003|Actual|July 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003171||208693|
NCT00003215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 38/97|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma|Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL)||Swiss Group for Clinical Cancer Research||Completed|April 1997|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|60 Years|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003215||208655|
NCT00003140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA17|Letrozole After Tamoxifen in Treating Women With Breast Cancer|A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen||Canadian Cancer Trials Group|Yes|Completed|August 1998|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5187|||Female|N/A|N/A|No|||March 2012|September 18, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003140||208718|
NCT00003141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99703|Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors|A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors||Children's Oncology Group|Yes|Completed|March 1998|October 2011|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|N/A|2 Years|No|||March 2014|March 27, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003141||208717|
NCT00002924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9663|Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy|Androgen Receptor Mutations in Hormone Refractory Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|January 1997|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|184|Samples With DNA|Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20      patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).|Male|N/A|N/A|No|Non-Probability Sample|Eligible men enrolled on a trial of antiandrogen withdrawal had a minimum        prostate-specific antigen (PSA) level of 5 ng/dL that was increasing on castration therapy        including an antiandrogen. Marrow biopsies were obtained to collect prostate tumor.        Additional samples were obtained from men enrolled on chemotherapy trials.|July 2015|July 7, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002924||208906|
NCT00002989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065526|Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome|A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse||National Cancer Institute (NCI)||Active, not recruiting|March 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|207|||Both|16 Years|60 Years|No|||July 2007|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002989||208852|
NCT00002967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065472|Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer|A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients With Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer||National Cancer Institute (NCI)||Completed|May 1997|March 2006|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||June 2012|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002967||208871|
NCT00003196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1225.00|Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma|Induction of Mixed Hematopoietic Chimerism in Older Patients With B-Cell Malignancies and in Selected Other Diseases, Using Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion: A Pilot Study.||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|September 1997|||April 2002|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|50 Years|65 Years|No|||October 2015|October 30, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003196||208672|
NCT00003166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03120|Bryostatin and Vincristine in B-Cell Malignancies|A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies||National Cancer Institute (NCI)||Completed|May 1998|||July 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003166||208696|
NCT00002917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU-13707-OSP-97-092|Paclitaxel in Treating Patients With Early-Stage Bladder Cancer|A PHASE I/II INSTITUTIONAL STUDY OF INTRAVESICAL TAXOL (PACLITAXEL) INSTILLATION FOR THE TREATMENT OF SUPERFICIAL BLADDER CANCER||National Cancer Institute (NCI)||Completed|November 1996|May 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2001|May 14, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002917||208912|
NCT00002926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065336|Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia|Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration||National Cancer Institute (NCI)||Active, not recruiting|December 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|80|||Both|16 Years|60 Years|No|||May 2001|May 26, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002926||208904|
NCT00003175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065985|Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer|A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract||National Cancer Institute (NCI)||Completed|December 1997|March 2009|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|N/A|N/A|No|||February 2010|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003175||208689|
NCT00003010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065585|Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy|A Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After Induction Chemotherapy||Eastern Cooperative Oncology Group|Yes|Completed|September 1997|||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|334|||Female|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003010||208833|
NCT00002943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065392|Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer|High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study||Comprehensive Cancer Center of Wake Forest University|No|Completed|February 1993|August 2007|Actual|October 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002943||208889|
NCT00003191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02262|Fenretinide in Treating Children With Solid Tumors|A Phase I Study of Fenretinide (NSC #374551) in Children With High Risk Solid Tumors||National Cancer Institute (NCI)||Completed|March 1998|||March 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|21 Years|No|||August 2006|February 6, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003191||208677|
NCT00003192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9025|Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus|A Phase II Trial of 9-Aminocamptothecin (NSC 603071) Administered as a 120-Hour Continuous Infusion in Patients With Previously Untreated Gastric Cancer||University of Chicago|No|Completed|March 1998|August 2003|Actual|February 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003192||208676|
NCT00003211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066069|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor|Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support||St. Jude Children's Research Hospital|No|Completed|October 1996|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|94|||Both|3 Years|20 Years|No|||November 2012|November 6, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003211||208659|
NCT00002956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065433|Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants|A Phase I Pilot Trial to Evaluate the Toxicity of Allogeneic Epstein-Barr Virus Specific T-Lymphocytes for the Treatment of EBV-Associated Lymphoproliferative Diseases in Organ Transplant Recipients||University of Alabama at Birmingham|Yes|Withdrawn|November 1996|February 2002|Actual|February 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||November 2012|March 18, 2016|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002956||208877|
NCT00002973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065487|Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma|Phase II Evaluation of IV Melphalan (L-PAM) and Whole Body Hyperthermia (WBH) for Malignant Melanoma||University of Wisconsin, Madison||Completed|December 1995|December 2000|Actual|May 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|34|||Both|16 Years|120 Years|No|||September 2015|September 30, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002973||208865|
NCT00002968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02826|Edrecolomab in Treating Patients With Stage II Colon Cancer|Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon||National Cancer Institute (NCI)||Completed|May 1997|||July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2100|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002968||208870|
NCT00003204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02972|Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma|Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy||National Cancer Institute (NCI)||Completed|March 1998|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|515|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00003204||208665|
NCT00002976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065498|Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer|A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma||Gynecologic Oncology Group||Terminated|June 1997|||July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2108|||Female|N/A|N/A|No|||April 2003|April 10, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002976||208862|
NCT00002988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0564|Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma|Phase I Treatment of Adults With Primary Malignant Glioma With Irinotecan (CPT-11) (NSC #6616348) Plus BCNU (NSC #409962)||Duke University||Completed|April 1997|November 2000|Actual|November 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||February 2013|June 19, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002988||208853|
NCT00002944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9952|Combination Chemotherapy in Treating Children With Progressive Brain Tumors|Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old||Children's Oncology Group|Yes|Completed|April 1997|April 2012|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|428|||Both|N/A|9 Years|No|||September 2013|September 6, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002944||208888|
NCT00003151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20961|Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma|A Phase II Clinical Trial of Anti-Helicobacter Pylori Treatment in Endoscopically Diagnosed Low-Grade Localized Gastric Lymphoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 1997|||October 1998|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|96|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003151||208708|
NCT00002971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065479|O(6)-Benzylguanine in Treating Patients With Malignant Glioma|A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma||National Cancer Institute (NCI)||Completed|April 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|December 13, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002971||208867|
NCT00002925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065333|Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia|Phase I Study of MDR Modulation With PSC-833 (NSC# 648265) With a Pilot Study of Cytogenetic Risk-Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy With RIL-2 (NSC # 373364) in Previously Untreated Patients With AML< 60 Years||National Cancer Institute (NCI)|No|Completed|February 1997|June 2010|Actual|November 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|15 Years|59 Years|No|||March 2011|November 29, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002925||208905|
NCT00002985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 96-28|Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma|Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome||Roswell Park Cancer Institute||Completed|November 1996|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||February 2013|February 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002985||208856|
NCT00003172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065978|Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer|Randomized Phase II Trial of Either 5-Fluorouracil, Recombinant Alfa-2a-Interferon and Intravenous Hydroxyurea With Filgrastim Support (FHIG) or Doxorubicin/Docetaxel (Dd) in Patients With Advanced Gastric Cancer||National Cancer Institute (NCI)||Completed|December 1997|September 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003172||208692|
NCT00002930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-079|PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery|Whole-Body 18F-Fluorodeoxyglucose Positron Emission Tomography to Measure the Response to Induction Chemotherapy of Potentially Resectable Lung and Esophageal Carcinomas||Memorial Sloan Kettering Cancer Center||Completed|December 1996|||October 2002|Actual|Phase 2/Phase 3|Interventional|Primary Purpose: Diagnostic|||Anticipated|75|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002930||208902|
NCT00002923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065328|KRN5500 in Treating Patients With Metastatic Solid Tumors|Phase I Evaluation of KRN5500 (NSC650426)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 1997|October 2000|Actual|January 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|15 Years|N/A|No|||April 2014|April 24, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002923||208907|
NCT00002980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065502|Decitabine in Treating Patients With Melanoma or Other Advanced Cancer|A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|May 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|February 13, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002980||208860|
NCT00003210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02264|Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease||National Cancer Institute (NCI)||Completed|February 1998|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|16 Years|N/A|No|||January 2013|April 14, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003210||208660|
NCT00002952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9018|Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma|Phase I/II Study of Immunization With MAGE-3 Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients With Metastatic Melanoma||University of Chicago|No|Completed|January 1997|November 2002|Actual|August 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||September 2013|September 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002952||208880|
NCT00002972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08956|Paclitaxel in Treating Patients With Lung Cancer|Phase II Study on TAXOL in Bronchioalveolar Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|January 1997|||August 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|75 Years|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002972||208866|
NCT00003205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-0751.cc|Bryostatin 1 in Treating Patients With Stage IV Breast Cancer|A Phase II Trial of Bryostatin-1 for the Treatment of Stage IV Breast Cancer||University of Colorado, Denver|Yes|Completed|April 1998|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|May 28, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003205||208664|
NCT00003217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9517|Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia|A Pilot Study of Dose Intensification of Methotrexate and Cyclophosphamide in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Non-Hodgkins Lymphoma and B-Cell All- A Limited Institution Phase III Pilot Study||Children's Oncology Group|Yes|Completed|March 1998|September 2006|Actual|October 2004|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003217||208653|
NCT00002932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9615|Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck|Phase II Multi-Institutional Trial of Targeted Supradose Cisplatin Chemoradiation for Stage IV Squamous Cell Carcinoma of the Head and Neck||Radiation Therapy Oncology Group|Yes|Completed|May 1997|March 2005|Actual|March 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002932||208900|
NCT00002965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM96-296|Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas|Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas||M.D. Anderson Cancer Center|No|Completed|January 1997|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|N/A|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002965||208872|
NCT00002933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1296|Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer|CWRU 1296: Biochemical and Pharmacokinetic Predictors of Colon Cancer Response to a Topoisomerase I Directed Treatment With Irinotecan||Case Comprehensive Cancer Center|Yes|Completed|September 1996|January 2001|Actual|July 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002933||208899|
NCT00002934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065370|Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ|Local Excision Alone for Selected Patients With DCIS of the Breast||Eastern Cooperative Oncology Group|No|Terminated|April 1997|October 2012|Actual|December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|711|||Female|18 Years|120 Years|No|||October 2015|October 6, 2015|November 1, 1999||No|This study was terminated when the accrual goal for the low/intermediate grade stratum was    reached. The high grade stratum was closed due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00002934||208898|
NCT00003173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-089|High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors|High-Dose Thiotepa With Autologous Stem Cell Rescue in Patients With Malignancies Refractory to Conventional Chemotherapy||Memorial Sloan Kettering Cancer Center||Completed|September 1997|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|N/A|N/A|No|||March 2013|March 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003173||208691|
NCT00002936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 95-05|Altretamine and Etoposide in Treating Patients With HIV-Related Cancer|Hexamethylamine and VP-16 an Oral Regimin for HIV Malignancies: A Phase I/II Trial||Roswell Park Cancer Institute||Completed|July 1996|||January 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002936||208896|
NCT00002939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8380|Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer|A Phase I Trial of Dose Escalated Irinotecan (CPT-11) With Paclitaxel in Patients With Metastatic or Recurrent Malignancies||University of Chicago|No|Completed|November 1996|April 2002|Actual|February 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002939||208893|
NCT00002945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065406|High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia|High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia||Roswell Park Cancer Institute|Yes|Completed|December 1996|August 2011|Actual|August 2001|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|25 Years|N/A|No|||April 2012|April 12, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002945||208887|
NCT00003184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066010|Vaccine Therapy in Treating Women With Metastatic Breast Cancer|Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer||National Cancer Institute (NCI)||Completed|August 1996|July 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||November 2000|April 2, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003184||208682|
NCT00002953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065426|Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer|A Radomized Trial of Epirubicin & Cyclophosphamide vs. Epirubicin & Paclitaxel in the Treatment of Women With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|December 1996|November 2005|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|704|||Female|N/A|N/A|No|||December 2005|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002953||208879|
NCT00002931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96126|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer|Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer||City of Hope Medical Center||Completed|February 1997|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|16 Years|N/A|No|||December 2014|December 3, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00002931||208901|
NCT00002961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1995-9-1013|Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia|Randomized Trial of Busulfan or Total Body Irradiation Conditioning Regimens for Children With Acute Lymphoblastic Leukemia||Children's Hospital of Philadelphia|No|Terminated|October 1995|February 2001|Actual|February 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|2||Actual|43|||Both|N/A|21 Years|No|||October 2013|October 14, 2013|November 1, 1999|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00002961||208875|
NCT00003206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066059|Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer|A Phase II Trial of Carboplatin Plus Paclitaxel in the Treatment of Locally Recurrent or Metastatic Nasopharyngeal Carcinoma||Eastern Cooperative Oncology Group||Completed|April 1998|||July 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003206||208663|
NCT00002984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9622|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus|Paclitaxel Combined With 5-FU and Cisplatin Concomitant With Radiotherapy in the Management of Locally Advanced or Metastatic Esophageal Cancer (Adenocarcinoma and Squamous Histologies) - A Phase I/Modified Phase II Trial||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|March 1997|January 2007|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002984||208857|
NCT00002993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065540|Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus|Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas||Gynecologic Oncology Group||Terminated|August 1997|||January 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Female|N/A|N/A|No|||May 2006|July 8, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002993||208850|
NCT00002915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065290|Penclomedine in Treating Patients With Advanced Solid Tumors|A PHASE I AND PHARMACOLOGICAL STUDY OF PENCLOMEDINE (NSC#338720, IND#43409) ADMINISTERED DAILY BY MOUTH FOR FIVE CONSECUTIVE DAYS IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES||Sidney Kimmel Comprehensive Cancer Center||Completed|December 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|19 Years|N/A|No|||August 2010|August 5, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002915||208914|
NCT00002916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-13961|Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer|A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 1996|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|44|||Female|19 Years|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002916||208913|
NCT00002977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1181.00|Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission|A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer||Fred Hutchinson Cancer Research Center||Completed|January 1997|||November 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Female|18 Years|60 Years|No|||September 2010|September 13, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002977||208861|
NCT00002940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065389|Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS|Hydroxyurea Treatment of EBV-Associated Primary CNS Lymphoma in Children and Adults With AIDS||St. Jude Children's Research Hospital|No|Completed|October 1996|March 2002|Actual|March 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2002|October 18, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002940||208892|
NCT00003157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-964352|Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas or Stomach|A Phase I Study of Gemcitabine, Cisplatin, and Radiation Therapy in Patients With Locally Advanced Pancreatic and Gastric Cancer||Alliance for Clinical Trials in Oncology|No|Completed|February 1998|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003157||208703|
NCT00003158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065951|S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer|A Phase II Trial of Concurrent Carboplatin/VP-16 and Radiation Followed by Paclitaxel (Taxol) for Poor-Risk Stage III Non-Small Cell Lung Cancer||Southwest Oncology Group|Yes|Completed|February 1998|December 2007|Actual|December 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003158||208702|
NCT00002938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9687|Surgery in Treating Patients With Prostate Cancer|The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial||Alliance for Clinical Trials in Oncology|No|Completed|May 1997|January 2010|Actual|February 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Male|N/A|75 Years|No|||July 2015|July 30, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00002938||208894|
NCT00002919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-066|Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer|PHASE II TRIAL OF THE COMBINATION OF TRANSURETHRAL RESECTION AND NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH INVASIVE UROTHELIAL TRACT TUMORS SELECTED BY STAGE AND P53 NUCLEAR EXPRESSION||Memorial Sloan Kettering Cancer Center||Completed|November 1996|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00002919||208911|
NCT00002946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065413|Penclomedine in Treating Patients With Solid Tumors or Lymphoma|A Phase I Trial of Oral Penclomedine||National Cancer Institute (NCI)||Completed|October 1997|||April 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00002946||208886|
NCT00003404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066410|Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast|A Prospective Study of Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|January 1998|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|120 Years|No|||October 2015|November 25, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003404||208502|
NCT00003459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066491|Antineoplaston Therapy in Treating Patients With Brain Stem Glioma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Brain Stem Glioma||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||April 2007|May 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003459||208450|
NCT00003460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066492|Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors|Phase II Study of Antineoplastons A10 and AS2-1 In Children With Primitive Neuroectodermal Tumors||National Cancer Institute (NCI)||Active, not recruiting|September 1995|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||June 2009|July 14, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003460||208449|
NCT00003528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01839|Raltitrexed in Treating Children With Refractory Acute Leukemia|A Phase I Trial of Tomudex in Children With Leukemia||National Cancer Institute (NCI)||Completed|September 1998|||June 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|21 Years|No|||January 2013|January 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003528||208391|
NCT00003472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066509|Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Oligodendroglioma||National Cancer Institute (NCI)||Active, not recruiting|May 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|July 14, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003472||208437|
NCT00003473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066510|Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Mixed Glioma||National Cancer Institute (NCI)||Recruiting|March 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003473||208436|
NCT00003437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066464|Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia|Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial||National Cancer Institute (NCI)||Active, not recruiting|January 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1800|||Both|1 Year|18 Years|No|||February 2003|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003437||208469|
NCT00003439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02272|Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer|A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis||National Cancer Institute (NCI)||Completed|August 1998|||May 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||April 2007|February 6, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003439||208468|
NCT00003440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02792|Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic|A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hour Infusion Every 3 Weeks With Herceptin (Trastuzumab) (NSC #688097) in the Treatment of Patients With/Without HER-2/Neu-Overexpressing Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|July 1998|||July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|580|||Female|18 Years|N/A|No|||June 2013|June 3, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003440||208467|
NCT00003124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065883|Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer|Phase II Trial of Maximal Androgen Deprivation Followed by Conformal External Beam Radiotherapy With Continued Androgen Deprivation for Clinically Localized Prostate Cancer||National Cancer Institute (NCI)||Completed|May 1997|January 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|105|||Male|N/A|N/A|No|||December 2002|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003124||208734|
NCT00003125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065885|Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors|A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 and GM-CSF in Patients With CEA Expressing Tumors||Georgetown University|No|Completed|January 1998|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||May 2007|March 22, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003125||208733|
NCT00003501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066541|Antineoplaston Therapy in Treating Patients With Recurrent or Refractory High-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma, High Grade||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003501||208412|
NCT00003502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-LY-9|Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage II, III, or IV Mantle Cell Lymphoma||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003502||208411|
NCT00003435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066461|Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer|A Pilot Study Involving Administration of Combination Anti-Retroviral Therapy and Transplantation of HLA-Matched Sibling Peripheral Blood Stem Cells or Partially HLA-Matched Unrelated Umbilical Cord Blood In Adults With HIV Infection and Hematologic Malignancies||Duke University||Withdrawn|May 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|55 Years|No|||December 2000|March 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003435||208471|
NCT00003139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9709|Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer|A Phase III Study to Test the Efficacy of the Prophylactic Use of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated With Curative Radiation Therapy in Head and Neck Cancer Patients||Radiation Therapy Oncology Group|Yes|Completed|March 1998|October 2002|Actual|January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|249|||Both|18 Years|120 Years|No|||November 2015|November 14, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003139||208719|
NCT00003126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065887|Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer|A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma||Loyola University|No|Completed|June 1997|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|68|||Both|16 Years|N/A|No|||August 2010|August 16, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003126||208732|
NCT00003514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-NE-2|Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003514||208404|
NCT00003515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066558|Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Primitive Neuroectodermal Tumor Outside the Central Nervous System||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003515||208403|
NCT00003474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066511|Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Glioblastoma Multiforme||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||February 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003474||208435|
NCT00003475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066512|Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors||National Cancer Institute (NCI)||Recruiting|February 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003475||208434|
NCT00003081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.00|Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma|A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarcoma||Fred Hutchinson Cancer Research Center||Completed|March 1998|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|16|||Both|N/A|49 Years|No|||September 2010|September 16, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003081||208773|
NCT00003088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9741|Combination Chemotherapy in Treating Patients With Breast Cancer|A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|September 1997|June 2003|Actual|April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2005|||Female|18 Years|N/A|No|||June 2015|June 23, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003088||208767|
NCT00003519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066563|Combination Chemotherapy in Treating Women With Breast Cancer|Phase III Study of Adriamycin/Taxotere Versus Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer||Eastern Cooperative Oncology Group|Yes|Completed|August 1998|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2778|||Female|18 Years|N/A|No|||January 2010|January 27, 2010|November 1, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00003519||208399|
NCT00003434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1259|Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer|A Pilot Study of Active Immunotherapy With Carcinoembryonic Antigen Peptide-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Resected, Stage I, II and III Pancreatic Adenocarcinoma Expressing Carcinoembryonic Antigen||Duke University|No|Terminated|June 1998|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003434||208472|
NCT00003523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066567|Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum|Evaluation of Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|January 1999|October 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|13 Years|N/A|No|||June 2005|June 20, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00003523||208395|
NCT00003104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-064|Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer|A Phase II Study Using High Dose Three Dimensional Conformal Radiation Therapy in Intermediate Prognostic Risk Patients With Adenocarcinoma of the Prostate||Memorial Sloan Kettering Cancer Center||Completed|June 1997|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Male|N/A|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003104||208751|
NCT00003512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066555|Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|November 16, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003512||208406|
NCT00003513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066556|Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Neuroblastoma||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003513||208405|
NCT00003467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1706|Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma|Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers||Duke University||Completed|January 1998|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|68|||Both|18 Years|N/A|No|||October 2009|June 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003467||208442|
NCT00003446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOCS-12-CR-97|Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer|Phase II Trial of Trimetrexate (Neutrexin), 5-Fluorouracil and Leucovorin in Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|December 1997|August 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|74 Years|No|||September 2001|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003446||208462|
NCT00003134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-967251|Irinotecan in Treating Patients With Recurrent Glioma|A Phase II Trial of Irinotecan in Recurrent Glioma||Alliance for Clinical Trials in Oncology|Yes|Completed|January 1998|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003134||208724|
NCT00003441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-308|Irofulven in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of MGI-114 (NSC# 683863) Administered Intravenously for Five Days Every 28 Days to Patients With Metastatic Colorectal Cancer||M.D. Anderson Cancer Center|No|Completed|August 1998|November 2000|Actual|November 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003441||208466|
NCT00003451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01397|Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer|Phase I Trial of Interleukin-12 Followed by Interferon-Alpha||National Cancer Institute (NCI)||Completed|August 1998|||December 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|13 Years|N/A|No|||July 2007|January 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003451||208458|
NCT00003375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9802|Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma|A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|October 1998|||August 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|370|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003375||208529|
NCT00003065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065736|Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix|Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix||National Cancer Institute (NCI)||Completed|January 1997|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Female|18 Years|60 Years|No|||September 2003|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003065||208786|
NCT00003484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008915|Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors|Phase I Study of Anti-Tenascin Monoclonal Antibody I-Labeled 81C6 Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary Brain Tumors After External Beam Radiotherapy||Duke University||Completed|September 1997|March 2010|Actual|November 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003484||208428|
NCT00003485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066523|Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Colon||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003485||208427|
NCT00003476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066513|Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Children With Primary Malignant Brain Tumors||National Cancer Institute (NCI)||Recruiting|March 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003476||208433|
NCT00003477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066514|Antineoplaston Therapy in Treating Children With Visual Pathway Glioma|Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Children With Visual Pathway Glioma||National Cancer Institute (NCI)||Recruiting|June 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003477||208432|
NCT00003094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-960928|Carotenoid Rich Diet in Treating Cervical Dysplasia|Carotenoid-Rich Diet Trial to Reverse CIN II||University of California, San Diego||Withdrawn|October 1997|||||Phase 2|Interventional|Primary Purpose: Prevention|||Actual|0|||Female|18 Years|55 Years|No|||August 2007|May 19, 2014|November 1, 1999|||Study was halted prematurely, prior to enrollment of first participant|No||https://clinicaltrials.gov/show/NCT00003094||208761|
NCT00003073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065754|Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors|A Phase I Dose Escalation Study of Intrathecal DepoFoam Encapsulated Cytarabine (DTC 101) in Pediatric Patients With Advanced Meningeal Malignancies||National Cancer Institute (NCI)||Active, not recruiting|February 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|1 Year|21 Years|No|||April 2002|March 22, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003073||208780|
NCT00003401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066405|Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma|Autologous Transplantation With Gemcitabine and High Dose BCNU Plus Melphalan Followed by Consolidation With DCEP Plus Gemcitabine and Taxol/Cisplatin in Patients With Multiple Myeloma and >12 Months of Standard Therapy||National Cancer Institute (NCI)||Completed|January 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003401||208505|
NCT00003402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066407|Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Autologous Transplantation With and High Dose BCNU and Melphalan Followed by Consolidation With DCEP Plus Taxol/Cisplatin in Patients With Poor Prognosis Low Grade Non-Hodgkin's Lymphoma and Chronic Lymphocyte Leukemia, Who Have Received < or = 12 Months of Standard Therapy||University of Maryland||Completed|January 1999|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|70 Years|No|||September 2009|September 23, 2009|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003402||208504|
NCT00003526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066570|Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of Unknown Primary||National Cancer Institute (NCI)||Active, not recruiting|March 1996|||February 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||October 2008|October 24, 2008|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003526||208392|
NCT00003443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-042|Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|A Phase II Trial of Bryostatin-1 In Patients With Metastatic or Recurrent Squamos Cell Carcinoma of the Head and Neck||Memorial Sloan Kettering Cancer Center||Completed|July 1998|May 2001|Actual|May 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003443||208465|
NCT00003489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066527|Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|16 Years|N/A|No|||July 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003489||208424|
NCT00003505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-LY-12|Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Primary Central Nervous System Lymphoma||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||October 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003505||208410|
NCT00003113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU4496|Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas|Oral Combination Chemotherapy in Conjunction With G-CSF in the Treatment of Elderly Patients With Intermediate and High Grade Non-Hodgkin's Lymphoma||Case Comprehensive Cancer Center|Yes|Terminated|July 1997|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|60 Years|N/A|No|||January 2011|January 13, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003113||208744|
NCT00003499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066538|Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma Low Grade||National Cancer Institute (NCI)||Active, not recruiting|March 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|August 12, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003499||208414|
NCT00003520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066564|Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Kidney||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003520||208398|
NCT00003468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066504|Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Children With Low Grade Astrocytoma||National Cancer Institute (NCI)||Recruiting|May 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003468||208441|
NCT00003469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066505|Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System|Phase II Study of Antineoplastons A10 and AS2-1 in Children With Rhabdoid Tumor of the Central Nervous System||National Cancer Institute (NCI)||Active, not recruiting|February 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||June 2009|July 14, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003469||208440|
NCT00003454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066486|Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Breast||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003454||208455|
NCT00003455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-BR-14|Antineoplaston Therapy in Treating Women With Advanced Breast Cancer|Phase II Study of Oral Antineoplastons A10 and AS2-1 in Women With Advanced Breast Cancer||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003455||208454|
NCT00003075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID92-027|Fenretinide in Treating Patients With Cervical Neoplasia|A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3||M.D. Anderson Cancer Center|No|Completed|September 1992|May 2001|Actual|September 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|39|||Female|18 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003075||208779|
NCT00003530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066577|Antineoplaston Therapy in Treating Patients With Primary Liver Cancer|Phase II Study of Antineoplaston A10 in Patients With Primary Liver Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|14 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003530||208390|
NCT00003531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066578|Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Pancreas||National Cancer Institute (NCI)||Active, not recruiting|April 1996|||January 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|January 21, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003531||208389|
NCT00003500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066540|Antineoplaston Therapy in Treating Patients With Refractory or Recurrent Intermediate-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma, Intermediate Grade||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003500||208413|
NCT00003522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066566|Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Small Intestine||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003522||208396|
NCT00003388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066385|Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma|A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma||Eastern Cooperative Oncology Group|No|Completed|February 1999|||April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|38|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003388||208517|
NCT00003389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066386|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma|A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease||Eastern Cooperative Oncology Group|Yes|Active, not recruiting|April 1999|May 2016|Anticipated|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|854|||Both|16 Years|N/A|No|||September 2015|September 25, 2015|November 1, 1999|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT00003389||208516|
NCT00003449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066478 (5O-98-1)|Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer|Phase II Study of Weekly Paclitaxel and Gemcitabine in Platinum-Resistant Ovarian Cancer||University of Southern California|Yes|Completed|May 1998|February 2004|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|35|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003449||208460|
NCT00003450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066481|Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer|Phase I Trial of Intraperitoneal Adenoviral p53 Gene Therapy in Patients With Advanced Recurrent or Persistent Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|N/A|No|||June 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003450||208459|
NCT00003495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066534|Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Squamos Cell Carcinoma of the Lung||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003495||208418|
NCT00003496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066535|Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Small Cell Carcinoma of the Lung||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003496||208417|
NCT00003105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-095|Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer|Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium||Memorial Sloan Kettering Cancer Center||Completed|September 1997|August 2004|Actual|August 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003105||208750|
NCT00003107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9708-05; T97-0027|Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors|A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support||Indiana University||Completed|October 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2014|September 9, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003107||208749|
NCT00003403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066409|GPX-100 in Treating Patients With Solid Tumors|Phase I Safety and Efficacy Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer||Gem Pharmaceuticals||Completed|August 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2001|April 22, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003403||208503|
NCT00003470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066507|Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma||National Cancer Institute (NCI)||Recruiting|March 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003470||208439|
NCT00003471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066508|Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Low Grade Astrocytoma||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003471||208438|
NCT00003508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066551|Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Mesothelioma||National Cancer Institute (NCI)||Terminated|March 1996|||December 2011|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|40|||Both|1 Year|N/A|No|||June 2009|December 17, 2013|November 1, 1999|Yes|Yes|Withdrawn due to slow enrollment|No||https://clinicaltrials.gov/show/NCT00003508||208409|
NCT00003521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066565|Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Soft Tissue Sarcoma||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003521||208397|
NCT00003493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF-IRB-2006|Combination Chemotherapy in Treating Patients With Multiple Myeloma|Phase II Trial of Doxil, Vincristine and Decadron in Multiple Myeloma||National Cancer Institute (NCI)||Completed|November 1998|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2001|July 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003493||208420|
NCT00003486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-CO-3|Antineoplaston Therapy in Treating Patients With Colon Cancer|Phase II Study of Antineoplastons A10 and AS2-1 Capsules in Patients With Adenocarcinoma of the Colon||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003486||208426|
NCT00003487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066525|Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Esophagus||National Cancer Institute (NCI)||Terminated|May 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|December 17, 2013|November 1, 1999|Yes|Yes|Withdrawn due to slow enrollment|No||https://clinicaltrials.gov/show/NCT00003487||208425|
NCT00003432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2030|Immunotherapy in Treating Patients With Metastatic Breast Cancer|A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Cultured Dendritic Cells for Patients With Breast Cancer Who Achieve a Complete Response After High Dose Chemotherapy and Stem Cell Support||Duke University|No|Terminated|June 1998|November 2002|Actual|November 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|November 1, 1999|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00003432||208474|
NCT00003076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065763|Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus|Phase IIb Chemoprevention Trial of Difluoromethylornithine (DFMO) in Human Subjects With Intestinal-type Barrett's Esophagus||University of Michigan Cancer Center||Completed|October 1995|October 2005|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Prevention|||Anticipated|152|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003076||208778|
NCT00003494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066533|Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Bronchial Alveolar Carcinoma of the Lung||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003494||208419|
NCT00003457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066489|Antineoplaston Therapy in Treating Patients With Brain Tumors|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Brain Tumors||National Cancer Institute (NCI)||Recruiting|July 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003457||208452|
NCT00003396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066397|Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Evaluation of Allogeneic Peripheral Blood Stem Cell Transplants From a Related Donor Without Graft-Versus-Host Prophylaxis in Patients With High Risk of Relapse||University of Maryland||Completed|September 1998|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|42|||Both|N/A|N/A|No|||September 2009|September 23, 2009|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003396||208510|
NCT00003108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMC-97166|Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer|A Phase I Study of Bryostatin and Cisplatin in Patients With Advanced Cancer||National Cancer Institute (NCI)||Completed|October 1997|October 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|July 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003108||208748|
NCT00003458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066490|Antineoplaston Therapy in Treating Children With Brain Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Children Wtih Brain Tumors||National Cancer Institute (NCI)||Recruiting|September 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003458||208451|
NCT00003429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-047|PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery|A Pilot Study of 18F-Flourodeoxyglucose Positron Emission Tomography in the Diagnosis of Primary and Recurrent Cervical Cancer||Memorial Sloan Kettering Cancer Center||Completed|May 1998|October 2002|Actual|October 2002|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Female|18 Years|120 Years|No|||December 2015|December 17, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003429||208477|
NCT00003430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-033|L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors|A Pharmacokinetic Study Evaluating the Safety, Tolerability and Maximally Tolerated Dose of 7-Day Continuous Infusions of L-778,123 in Patients With Recurrent of Refractory Solid Malignancies||Memorial Sloan Kettering Cancer Center||Completed|April 1998|April 2000|Actual|April 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003430||208476|
NCT00003431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066457|Flt3L in Treating Patients With Metastatic Colorectal Cancer|Pilot Study of FLT3 Ligand Prior to Resection of Hepatic Metastases of Colorectal Cancer||Duke University||Completed|June 1998|May 2001|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2013|March 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003431||208475|
NCT00003516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066559|Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer|Phase II Study of Antineoplaston A10 and AS2-1 Capsules In Patients With Incurable, Stage C or D Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003516||208402|
NCT00003517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-PR-6|Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer|Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003517||208401|
NCT00003103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-096|Chemotherapy in Treating Patients With Solid Tumors|A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies||Memorial Sloan Kettering Cancer Center||Completed|August 1997|August 2002|Actual|August 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|57|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003103||208752|
NCT00003359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-004|T138067 Sodium in Treating Patients With Advanced Refractory Cancer|Phase I Dose Escalation Study to Evaluate the Safety of T138067-Sodium in Patients With Advanced Refractory Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 1998|January 2001|Actual|January 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003359||208540|
NCT00003095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065813|S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer|S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623||Southwest Oncology Group|No|Completed|November 1997|February 2001|Actual|February 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|26|Samples With DNA|tissue and blood|Female|18 Years|120 Years|No|Non-Probability Sample|Must be enrolled in SWOG-9623 at time of registration to this study, but must not have        started treatment Hormone receptor status: Not specified|October 2015|October 23, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003095||208760|
NCT00003110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU5496|Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Trial of 72-Hour Continuous Infusion Bleomycin as Salvage Therapy in AIDS-Related and Immunocompetent Non-Hodgkin's Lymphoma||Case Comprehensive Cancer Center|Yes|Completed|July 1997|December 2002|Actual|August 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||June 2010|June 10, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003110||208746|
NCT00003111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065855|Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|Phase II Clinical and Laboratory Study of Irinotecan/Cisplatin Chemotherapy Followed by Surgery in Stage III NSCLC||Yale University|No|Completed|April 1997|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|10|||Both|18 Years|N/A|No|||August 2009|July 23, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003111||208745|
NCT00003135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065903|Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer|A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy||National Cancer Institute (NCI)||Recruiting|November 1997|||September 2009|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|34|||Female|18 Years|N/A|No|||December 2008|April 29, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003135||208723|
NCT00003120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065875|S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission|Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy||Southwest Oncology Group|Yes|Completed|November 1997|November 2012|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|308|||Female|18 Years|N/A|No|||October 2014|October 7, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003120||208737|
NCT00003115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065866|Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy|Spinal Effects of Epidural Hydromorphone||Roswell Park Cancer Institute|Yes|Completed|June 1996|February 2004|Actual|January 2003|Actual|Phase 3|Interventional|Primary Purpose: Supportive Care|||Anticipated|40|||Male|18 Years|70 Years|No|||February 2011|February 22, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003115||208742|
NCT00003297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066235|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer|Phase I/II Study of High Dose Topotecan, Mitoxantrone and Thiotepa (TMT) Followed by Autologous Stem Cell Transplant in Patients With Recurrent Platinum Resistant Ovarian Cancer||Georgetown University|No|Completed|December 1997|January 2001|Actual|January 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|N/A|No|||September 2000|March 22, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003297||208591|
NCT00003308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066255|Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma|A Phase II Trial of Radiosurgery for 1 to 3 Newly Diagnosed Brain Metastases From Renal Cell, Melanoma and Sarcoma||Eastern Cooperative Oncology Group||Completed|July 1998|||September 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003308||208583|
NCT00003084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-022|Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer|A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|December 1997|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Male|18 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003084||208771|
NCT00003114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2496|Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease|Oral Combination Chemotherapy in the Treatment of AIDS-Associated Hodgkin's Disease||Case Comprehensive Cancer Center|Yes|Completed|July 1997|February 2003|Actual|June 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||June 2010|June 9, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003114||208743|
NCT00003079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065773|Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma|Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-Beta-D-Arabinofuranosylcytosine (HiDAC) in Patients With Refractory Leukemia||Virginia Commonwealth University|No|Completed|September 1997|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|N/A|No|||February 2010|February 15, 2010|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00003079||208775|
NCT00003080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1144.00|Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer|A Phase I Trial of Sequential High Dose Chemotherapy Regimens Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With Persistent Stage III/IV Ovarian Cancer||Fred Hutchinson Cancer Research Center||Completed|September 1996|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|60 Years|No|||September 2010|September 13, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003080||208774|
NCT00003334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066300|Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract|Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin||New York University School of Medicine||Completed|March 1997|||December 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|120 Years|No|||March 2016|March 10, 2016|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003334||208562|
NCT00003078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065771|Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix|A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes||Gynecologic Oncology Group||Completed|October 1997|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|870|||Female|N/A|N/A|No|||April 2011|July 8, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003078||208776|
NCT00003301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066241|Irinotecan in Treating Patients With Recurrent Malignant Glioma|A Dose Finding and Safety/Efficacy Trial of CPT-11 (Irinotecan) in Patients With Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|July 1998|April 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2005|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003301||208588|
NCT00003096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B971|Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors|Molecular Biology of Pediatric Brain Tumors||Children's Oncology Group|No|Completed|December 1996|March 2007|Actual|March 2006|Actual|N/A|Observational|N/A|||Actual|88|||Both|N/A|20 Years|No|Non-Probability Sample|Children with primitive neuroectodermal tumors / medulloblastoma (PNET/Mb).|August 2014|August 5, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003096||208759|
NCT00003099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID94-029|Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer|Phase II Clinical Trial of N-(4-hydroxyphenyl) Retinamide (4-HPR) and Tamoxifen in Breast Neoplasia, Administration During the Period Between the Diagnostic Core Biopsy and Definitive Surgery||M.D. Anderson Cancer Center|No|Completed|May 1996|January 2003|Actual|June 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Female|18 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003099||208756|
NCT00003100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065832|Dietary Soy Isoflavones for the Prevention of Cancer|Metabolic Fate and Plasma Kinetics of Dietary Soy Isoflavones||National Cancer Institute (NCI)||Active, not recruiting|October 1996|||||N/A|Interventional|Primary Purpose: Prevention|||Anticipated|90|||Both|18 Years|N/A|No|||June 2000|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003100||208755|
NCT00003338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066309|Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma|The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|March 1997|||||Phase 2/Phase 3|Interventional|Primary Purpose: Diagnostic|||Anticipated|60|||Both|16 Years|N/A|No|||December 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003338||208558|
NCT00003346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-124|Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma|Phase I-II Trial of High-Dose Acetaminophen With Carmustine in Patients With Metastatic Melanoma||Memorial Sloan Kettering Cancer Center||Completed|November 1997|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003346||208550|
NCT00003090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065794|Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer|Phase II Trial of Bolus Interleukin-2 in Previously Treated Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 1996|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|N/A|No|||July 2000|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003090||208765|
NCT00003131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-AR-0903B1-201-US|CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse|A Study of the Efficacy and Safety of CMA-676 as Single Agent Treatment of Patients With Acute Myeloid Leukemia (AML) in First Relapse||Pfizer||Completed|February 1997|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003131||208727|
NCT00003123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065882|Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome|A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes||National Cancer Institute (NCI)||Active, not recruiting|August 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|17 Years|N/A|No|||January 2004|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003123||208735|
NCT00003302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066242|MRI to Detect Breast Tumors in Women|Breast MRI Protocol||National Cancer Institute (NCI)||Active, not recruiting|May 1998|||||N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|1500|||Female|18 Years|79 Years|No|||February 2006|May 9, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003302||208587|
NCT00003085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065784 (3P-94-1A)|Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer|Minimal Access Surgery for Pancreas Cancer: A Phase II Trial Study I: Staging of Pancreas Cancer||University of Southern California|Yes|Terminated|September 1996|July 2000|Actual|July 2000|Actual|Phase 2|Interventional|Primary Purpose: Diagnostic|||Actual|28|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes|Insufficient Accrual|No||https://clinicaltrials.gov/show/NCT00003085||208770|
NCT00003127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065890|S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer|Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma||Southwest Oncology Group|No|Completed|February 1998|July 2004|Actual|April 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Female|16 Years|N/A|No|||June 2012|June 13, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003127||208731|
NCT00003128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065891|Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus|A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus||Gynecologic Oncology Group||Completed|November 1997|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|166|||Female|18 Years|N/A|No|||May 2004|July 8, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003128||208730|
NCT00003315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066264|Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection|Supplementary Protocol for Patients With Invasive Fungal Infection, Entered Into AML 11, AML 12 and UKALL XII (Or Their Successors)||National Cancer Institute (NCI)||Completed|July 1997|December 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|200|||Both|15 Years|N/A|No|||May 2007|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003315||208578|
NCT00003309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066256|Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer|A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma||Eastern Cooperative Oncology Group|No|Completed|July 1998|||March 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003309||208582|
NCT00003086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065786|Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer|Phase I/II Study of Samarium 153 as Part of a Double (Sequential) Autologous Bone Marrow Transplant (ABMT) for Patients With Stage IV Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 1997|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Female|21 Years|65 Years|No|||December 2006|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003086||208769|
NCT00003087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-088|Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus|Phase II Trial of Preoperative Combined Modality Therapy for Localized Esophageal Carcinoma: Cisplatin-Paclitaxel Followed by Radiation Therapy With Concurrent Cisplatin and Paclitaxel||Memorial Sloan Kettering Cancer Center||Completed|August 1997|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003087||208768|
NCT00003335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU4Y97|Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|January 1998|January 2012|Actual|November 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|N/A|54 Years|No|||March 2012|March 14, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003335||208561|
NCT00003097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065820|Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer|Skin Cancer Prophylaxis by Low-Fat Dietary Intervention||National Cancer Institute (NCI)||Active, not recruiting|April 1989|||||Phase 2|Interventional|Primary Purpose: Prevention|||Anticipated|175|||Both|15 Years|N/A|No|||October 2007|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003097||208758|
NCT00003101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-077|Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma|A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma||Memorial Sloan Kettering Cancer Center||Completed|August 1997|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003101||208754|
NCT00003358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-129|Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Phase I Trial Intraperitoneal Cisplatin With Intraperitoneal Gemcitabine in Patients With Epithelial Ovarian Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|January 1998|||January 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Female|N/A|N/A|No|||January 2013|January 15, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003358||208541|
NCT00003117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065871|Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer|Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness||Alliance for Clinical Trials in Oncology|Yes|Completed|October 1997|January 2006|Actual|December 2004|Actual|Phase 3|Interventional|Primary Purpose: Treatment|2||Actual|584|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003117||208740|
NCT00003118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065873|Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus|A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer||Alliance for Clinical Trials in Oncology|Yes|Terminated|October 1997|March 2000|Actual|March 2000||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes|completed administratively due to poor acrual|No||https://clinicaltrials.gov/show/NCT00003118||208739|
NCT00003092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9762|Paclitaxel in Treating Older Patients With Solid Tumors|Clinical Pharmacology of Paclitaxel in Relation to Patient Age||Alliance for Clinical Trials in Oncology|No|Completed|September 1997|June 2006|Actual|March 2006|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|55 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003092||208763|
NCT00003116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1995T|High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|May 1997|June 2009|Actual|March 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|4 Years|55 Years|No|||June 2010|June 9, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003116||208741|
NCT00003317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9734|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|A Phase III Study of Surgical Resection and Chemotherapy (Paclitaxel and Carboplatin) With or Without Adjuvant Radiotherapy for Resected Stage IIIA Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|May 1998|August 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003317||208576|
NCT00003066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065737|Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer|Phase II Evaluation of Docetaxel Combined With Estramustine Phosphate in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||December 2006|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003066||208785|
NCT00003098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065828|Diet and Estrogen Metabolism in Postmenopausal Women|Diet and Estrogen Metabolism in Postmenopausal Women||Jonsson Comprehensive Cancer Center|No|Completed|August 1997|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|12|||Female|50 Years|69 Years|No|||January 2016|January 29, 2016|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003098||208757|
NCT00003093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3961|Combination Chemotherapy in Treating Children With Neuroblastoma|Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study||Children's Oncology Group|Yes|Completed|March 1988|January 2011|Actual|September 2006|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|573|||Both|N/A|20 Years|No|||July 2014|July 31, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003093||208762|
NCT00003225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066087|Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer|Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer||Jonsson Comprehensive Cancer Center|No|Completed|July 1997|June 2001|Actual|March 2000|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2012|September 30, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003225||208647|
NCT00003091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065795|High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma|Treatment of Metastatic Renal Cell Carcinoma and Melanoma With Subsequential High-Dose Subcutaneous Interferon Alfa-2b and High-Dose Bolus and Continuous Intravenous Interleukin-2||Hoag Memorial Hospital Presbyterian|No|Completed|January 1996|January 2000|Actual|January 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003091||208764|
NCT00003109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065851|Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors|Phase I Pharmacokinetic and Pharmacodynamic Trial of Irinotecan in Combination With Tomudex in Patients With Refractory Solid Malignancies||Fox Chase Cancer Center|No|Completed|December 1997|January 2001|Actual|October 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|39|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003109||208747|
NCT00003102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065834|Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer|Phase I/II Study of 131-I-Labeled Chimeric Antibody G250 (131-I-cG250) in Patients With Advanced Renal Carcinoma||National Cancer Institute (NCI)||Completed|July 1997|||August 2000|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Both|16 Years|N/A|No|||December 2009|December 2, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003102||208753|
NCT00003336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU5Y97|Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders||Case Comprehensive Cancer Center|Yes|Completed|January 1998|February 2006|Actual|December 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|55 Years|No|||June 2010|June 10, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003336||208560|
NCT00003316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066265|Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus|Evaluation of Gemcitabine in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||Gynecologic Oncology Group||Terminated|August 1998|||April 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2004|April 10, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00003316||208577|
NCT00003122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065880|Surgery in Treating Patients With Neuroblastoma|Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma||National Cancer Institute (NCI)||Recruiting|December 1994|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|210|||Both|N/A|20 Years|No|||July 2007|August 23, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003122||208736|
NCT00003348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066327|Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain|Phase I Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent, Persistent or Progressive Cerebral Anaplastic Gliomas||Duke University||Completed|May 1998|August 2000|Actual|August 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003348||208549|
NCT00003130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065893|Paclitaxel in Treating Women With Recurrent Solid Tumors|Prospective Evaluation of Body Surface Area (BSA) as a Determinant of Paclitaxel Pharmacokinetics/Pharmacodynamics in Women With Solid Tumors||Alliance for Clinical Trials in Oncology|No|Completed|November 1997|January 2006|Actual|January 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003130||208728|
NCT00003119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9641|Surgery in Treating Children With Neuroblastoma|Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study||Children's Oncology Group|No|Active, not recruiting|March 1998|||March 2006|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|968|||Both|N/A|21 Years|No|||February 2016|February 29, 2016|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003119||208738|
NCT00003132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065897|Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer|Phase I Study of Bryostatin-1 (NSC 339555) and Cisplatin in Advanced Malignancies||New York University School of Medicine||Completed|January 1998|||November 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2009|November 8, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003132||208726|
NCT00003133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-106|Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer|Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy After Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium||Memorial Sloan Kettering Cancer Center||Completed|September 1997|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003133||208725|
NCT00003304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26972|Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors|Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1998|||March 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|29|||Both|18 Years|69 Years|No|||March 2012|March 5, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003304||208586|
NCT00003077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9473|Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss|Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia||Alliance for Clinical Trials in Oncology|No|Completed|October 1995|November 2004|Actual|July 2004|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|63|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003077||208777|
NCT00003136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8433|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer|A Phase I/II Dose Escalation Trial of Carboplatin With Amifostine Pretreatment to Augment High Dose Cyclophosphamide With Autologous Peripheral Blood Stem Cell Support for the Treatment of Patients With Epithelial Ovarian Cancer||University of Chicago|No|Completed|December 1996|October 2001|Actual|December 2000|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|N/A|65 Years|No|||February 2013|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003136||208722|
NCT00003137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-964152|Irinotecan in Treating Patients With Advanced Cancer of the Stomach|A Phase II Trial of CPT-11 in Patients With Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Incorporating Pretreatment and Posttreatment Biopsies for Evaluation of Tumor Thymidylate Synthase, MIB-1, Topoisomerase I, and p53||Alliance for Clinical Trials in Oncology|Yes|Completed|December 1997|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003137||208721|
NCT00003138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065907|Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes|Phase III Evaluation of EPO With or Without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes||Eastern Cooperative Oncology Group|Yes|Completed|December 1997|May 2014|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|November 1, 1999|Yes|Yes||No|September 11, 2013|https://clinicaltrials.gov/show/NCT00003138||208720|
NCT00003129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065892|Chemotherapy in Treating Patients With Early-Stage Bladder Cancer|Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin||National Cancer Institute (NCI)||Completed|July 1998|||November 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||January 2002|June 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003129||208729|
NCT00003235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066107|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed|A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer||Eastern Cooperative Oncology Group|Yes|Completed|April 1998|||August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|294|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003235||208641|
NCT00003067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065739|Biological Therapy in Treating Patients With Primary or Advanced Glioma|Intracavitary Interleukin-2 (IL-2) and Lymphokine-Activated Killer (LAK) Cell Therapy for Malignant Gliomas||National Cancer Institute (NCI)||Suspended|July 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2008|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003067||208784|
NCT00003068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065742|High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer|An Out Patient Dose Escalation Trial of High Dose Mitoxantrone, Thiotepa and Cyclophosphamide Plus Autologous Blood Cell Rescue and Amifostine Cytoprotection||National Cancer Institute (NCI)||Completed|June 1997|November 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|16 Years|70 Years|No|||May 2006|January 30, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003068||208783|
NCT00003070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9480|Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer|Afterload Reduction Therapy for Late Anthracycline Cardiotoxicity: A Pediatric Oncology Group Cancer Control Study||Children's Oncology Group|Yes|Completed|September 2000|March 2007|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|8||Actual|13|||Both|8 Years|N/A|No|||August 2014|August 4, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003070||208782|
NCT00003072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065752|Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer|Amifostine (Ethyol) as a Protectant in Metastatic Ovarian and Non-Small Cell Lung Cancer in Paclitaxel/Carboplatin-Treated Patients: A Comparative Trial||University of California, San Francisco||Completed|May 1997|October 1998|Actual|October 1998|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||Anticipated|80|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003072||208781|
NCT00003555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY-HSC-3732|Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors|Use of Weekly One Hour Paclitaxel Infusion With Dose Escalation for Recurrent and Resistant Cancers, Using Amifostine as a Cytoprotector||National Cancer Institute (NCI)||Completed|July 1998|May 2003|Actual|||Phase 1|Interventional|Primary Purpose: Supportive Care|||Anticipated|20|||Both|18 Years|N/A|No|||May 2006|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003555||208367|
NCT00003571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9865|Gene Testing in Patients With Colon Cancer|Tumor Replication Error (RER) Status and Outcome in a Colon Cancer Adjuvant Chemotherapy Trial||Alliance for Clinical Trials in Oncology|No|Completed|August 1998|January 2006|Actual|January 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|Samples With DNA|Samples of tumor and normal tissue|Both|N/A|N/A|No|Non-Probability Sample|Patients previously enrolled on CALGB-8896.|July 2015|July 3, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003571||208353|
NCT00003627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066710|Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx|Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|70 Years|No|||January 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003627||208303|
NCT00003607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066684|Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer|Phase III Randomized Study of Radiotherapy to the Prostate With or Without Radiotherapy to the Pelvis in Patients With Stage I, II, or III Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Active, not recruiting|December 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|450|||Male|N/A|75 Years|No|||December 2004|February 18, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003607||208320|
NCT00003650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066742|Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma|Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|June 1998|||||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|200|||Both|N/A|18 Years|No|||March 2001|January 20, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003650||208282|
NCT00003652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066744|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer|Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|350|||Both|N/A|80 Years|No|||May 2005|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003652||208281|
NCT00003654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066746|Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer|Diagnostic Study of Patent Blue V Dye to Identify Sentinel Lymph Nodes in Patients With Stage I or IIA Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1997|||||N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|200|||Female|N/A|N/A|No|||December 2006|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003654||208279|
NCT00003573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9631|Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma|A Phase I/II Feasibility Study of Oral Etoposide Given Concurrently With Radiotherapy Followed With Dose Intensive Adjuvant Chemotherapy for Children With Newly Diagnosed High Stage Medulloblastoma||Children's Oncology Group|Yes|Completed|November 1998|March 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|3 Years|21 Years|No|||July 2014|July 24, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003573||208351|
NCT00003647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066736|Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma|Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma||Vical|Yes|Completed|July 1998|September 2002|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||July 2008|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003647||208285|
NCT00003662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066755|Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases||Roswell Park Cancer Institute|Yes|Completed|August 1998|January 2001|Actual|January 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|90|||Both|N/A|N/A|No|||March 2011|March 3, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003662||208273|
NCT00003564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-050|Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas|Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas||M.D. Anderson Cancer Center|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|N/A|No|||February 2012|February 17, 2012|November 1, 1999||No|Study withdrawn.|No||https://clinicaltrials.gov/show/NCT00003564||208359|
NCT00003616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066694|Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma|Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)||Completed|September 1998|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2006|December 13, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003616||208313|
NCT00003274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066176 (10M-97-1)|Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery|A Randomized Phase II Trial of a Vaccine Combining Tyrosinase /gp100 Peptides Emulsified With Montanide ISA 51 Alone or With a Block Co-Polymer CRL 1005 or With GM-CSF for Patients With Resected Stages IIA and IIB Melanoma Grant Application Title: MART-1/gp100 Immune Responses to a Melanoma Vaccine||University of Southern California|Yes|Completed|March 1998|November 2002|Actual|September 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003274||208609|
NCT00003605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066680|Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma|Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma||Hoag Memorial Hospital Presbyterian|No|Withdrawn|May 1998|January 2000|Actual|January 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||August 2015|August 17, 2015|November 1, 1999||No|no patient accrual|No||https://clinicaltrials.gov/show/NCT00003605||208322|
NCT00003656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066748|Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of Atragen and Interferon Alfa-2b in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|43|||Both|18 Years|N/A|No|||May 2006|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003656||208278|
NCT00003565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066631|Docetaxel in Treating Patients With Solid Tumors|A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients||Alliance for Clinical Trials in Oncology|No|Completed|September 1998|January 2008|Actual|January 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|109|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003565||208358|
NCT00003282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02266|EF5 in Treating Patients With Solid Tumors|Phase I Trial of EF5, an Agent for the Detection of Hypoxia||National Cancer Institute (NCI)||Completed|March 1998|||May 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003282||208603|
NCT00003619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-MCP-70612-01|Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia|A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid||National Cancer Institute (NCI)||Completed|February 1998|April 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|19 Years|90 Years|No|||February 2008|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003619||208311|
NCT00003615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066692|Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma||Eastern Cooperative Oncology Group|No|Completed|March 1999|||August 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|77|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00003615||208314|
NCT00003237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066109|Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach|Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia||Eastern Cooperative Oncology Group|No|Completed|March 1998|||October 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003237||208639|
NCT00003574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066641|Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors|A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima GliaSite RTS, a Radiation Delivery System, in Patients With Recurrent Malignant Brain Tumors Undergoing Surgical Resection||National Cancer Institute (NCI)||Completed|April 1999|June 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2000|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003574||208350|
NCT00003562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066626|Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin||National Cancer Institute (NCI)||Active, not recruiting|July 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|38|||Both|18 Years|N/A|No|||March 2001|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003562||208361|
NCT00003667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-074|Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma|Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane With and Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma||Memorial Sloan Kettering Cancer Center||Completed|September 1998|August 2000|Actual|August 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|3 Years|60 Years|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003667||208268|
NCT00003669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2141|Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer|Phase II Nonrandomized Study of LY353381-HC1 in Patients With Recurrent or Advanced Endometrial Cancer||Eli Lilly and Company||Completed|November 1998|April 2001|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2008|June 6, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003669||208267|
NCT00003452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066483|Antineoplaston Therapy in Treating Patients With Stage IV Bladder Cancer or Stage IV Newly Diagnosed, Incurable Bladder Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder||National Cancer Institute (NCI)||Active, not recruiting|May 1996|||August 2005|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|October 22, 2008|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003452||208457|
NCT00003453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066485|Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland||National Cancer Institute (NCI)||Recruiting|August 1996|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003453||208456|
NCT00003674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-979251|Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer|Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|December 1998|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003674||208263|
NCT00003665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02292|Vaccine Therapy in Treating Patients With Stage IV Melanoma|Phase I Trial of a Dendritic Cell Vaccine for Melanoma||National Cancer Institute (NCI)||Completed|April 1999|November 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003665||208270|
NCT00003287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-05963|Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer|First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 1998|||March 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|554|||Both|18 Years|75 Years|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003287||208600|
NCT00003288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01837|Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors|A Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|August 1998|||June 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|21 Years|No|||April 2000|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003288||208599|
NCT00003614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066691|Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|Phase II Study of Weekly Paclitaxel by 1-HR Infusion Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma||Eastern Cooperative Oncology Group||Completed|December 1998|||April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||August 2013|August 22, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00003614||208315|
NCT00003648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-974655|Genetic Study of Patients and Families With a History of Colorectal Cancer|The Familial Colorectal Neoplasia Collaborative Group||Alliance for Clinical Trials in Oncology|No|Completed|July 1998|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1500|Samples With DNA|blood and tumor samples|Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with colorectal cancer previously enrolled on NCCTG-784852,        NCCTG-794751, NCCTG-844652, NCCTG-874651, NCCTG-894651, or NCCTG-914653.|July 2015|July 14, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003648||208284|
NCT00003649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066741|Gene Therapy in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Surgically Removed|Phase I Pilot Trial of Adenovirus p53 in Bronchioloalveolar Cell Lung Carcinoma (BAC) Administered by Bronchoalveolar Lavage||National Cancer Institute (NCI)||Completed|November 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003649||208283|
NCT00003623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-979252|High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer|Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder||Alliance for Clinical Trials in Oncology|Yes|Completed|October 1999|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|21|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003623||208307|
NCT00003625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9879|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma|Vincristine, Etoposide and Cyclosporine A in Concert With Standard Dose Radiation Therapy in Diffuse Intrinsic Brain Stem Glioma - A Phase I Study of Dose Escalation of Vincristine||Children's Oncology Group|Yes|Completed|December 1998|April 2006|Actual|February 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|3 Years|21 Years|No|||July 2014|July 25, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003625||208305|
NCT00003622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066701|Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy|Phase II Study of Vinorelbine With Paclitaxel in the Treatment of Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|January 1999|||May 2008|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Male|18 Years|N/A|No|||May 2008|February 26, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003622||208308|
NCT00003566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066632|Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer|Pre-Resection Minimally Invasive Surgical Restaging of Stage III (Mediastinal Node Positive) Non-Small Cell Lung Cancer (NSCLC)||Alliance for Clinical Trials in Oncology|No|Completed|September 1998|March 2006|Actual|March 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment|||Actual|75|||Both|18 Years|N/A|No|||September 2013|October 16, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003566||208357|
NCT00003294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066227|Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer|Initial Clinical Evaluation of the Combination of Paclitaxel and Carboplatin With Modulation of Toxicity With GCSF and Amifostine||Roswell Park Cancer Institute|Yes|Completed|May 1997|May 2004|Actual|April 1999|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|N/A|N/A|No|||March 2011|March 3, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003294||208593|
NCT00003296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066230|Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer|Phase II Study of TLC D-99 for Hepatobiliary Carcinomas||National Cancer Institute (NCI)||Active, not recruiting|January 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|26|||Both|18 Years|N/A|No|||September 2000|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003296||208592|
NCT00003584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066653|Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer|A Phase II Trial of Combination Vinorelbine-Estramustine With or Without Prednisone for High Risk and Recurrent, Advanced and Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|July 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|N/A|N/A|No|||December 2000|February 26, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003584||208342|
NCT00003659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-080|Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia|A Phase II Study of Fludarabine Induction With Sequential High Dose Cyclophosphamide and Rituximab as Consolidation Therapy for Previously Untreated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia||Memorial Sloan Kettering Cancer Center||Completed|September 1998|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|75 Years|No|||November 2012|November 28, 2012|November 1, 1999|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT00003659||208275|
NCT00003663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066756|Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma|Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma||Hoag Memorial Hospital Presbyterian|No|Withdrawn|June 1998|January 2000|Actual|January 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|November 1, 1999||No|no patient accrual|No||https://clinicaltrials.gov/show/NCT00003663||208272|
NCT00003642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22971|Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer|A Phase II Feasibility Study of Combined Accelerated External Radiation and Chemotherapy With 5FU and CDDP Following Transurethral Resection in Patients With Muscle Invasive Transitional Carcinoma of the Bladder - T2-T3, N0, M0 (UICC 1992)||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|October 1998|||July 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|43|||Both|N/A|75 Years|No|||March 2012|March 5, 2012|November 1, 1999|||low accrual|No||https://clinicaltrials.gov/show/NCT00003642||208290|
NCT00003643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30983|Combination Chemotherapy in Treating Men With Germ Cell Cancer|Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|October 1998|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|498|||Male|16 Years|50 Years|No|||March 2012|March 5, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003643||208289|
NCT00003644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0175|Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer|A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma||Gynecologic Oncology Group|Yes|Completed|October 1998|||March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|571|||Female|N/A|120 Years|No|||March 2016|March 17, 2016|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003644||208288|
NCT00003677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-071|Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer|Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma||M.D. Anderson Cancer Center|No|Completed|March 1999|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003677||208261|
NCT00003242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-139|Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors|An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Bryostatin-1 Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|February 1998|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003242||208634|
NCT00003243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066119, J9743|Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer|A Phase I Trial of Combined Chemotherapy and Donor Lymphocyte Infusion for Aggressive Hematologic Malignancies in Relapse After Allogeneic Bone Marrow Transplantation||Sidney Kimmel Comprehensive Cancer Center||Completed|January 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2010|March 9, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003243||208633|
NCT00003621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-987251|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma|Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma)||Alliance for Clinical Trials in Oncology|No|Completed|February 1999|July 2005|Actual|February 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003621||208309|
NCT00003664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066757|Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically|Combination Chemobiotherapy With Gemcitabine, 5-Fluorouracil, Interleukin-2 and Alpha Interferon in Patients With Metastatic or Unresectable Renal Cell Cancer. A Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|70 Years|No|||September 2000|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003664||208271|
NCT00003630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-046|Arsenic Trioxide in Treating Patients With Advanced Solid Tumors|Phase I Study of Arsenic Trioxide||Memorial Sloan Kettering Cancer Center||Completed|August 1998|August 2000|Actual|August 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003630||208302|
NCT00003548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066605|Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity|Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity||New York University School of Medicine||Completed|August 1998|||December 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00003548||208373|
NCT00003567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2Y97|Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Mutant MGMT Gene Transfer Into Human Hematopoietic Progenitors to Protect Hematopoiesis During O6-Benzylguanine (BG, NSC 637037) and Carmustine Followed by Temozolomide Therapy of Advanced Solid Tumors||Case Comprehensive Cancer Center|Yes|Terminated|May 1999|February 2007|Actual|January 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||June 2010|June 9, 2010|November 1, 1999|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00003567||208356|
NCT00003568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWG-UIC-T98-0027|Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma|A Randomized Phase II Trial of a Mutated gp100 Melanoma Peptide (g209-217(210M) With Hight Dose Interleukin-2 (IL-2) in HLA-A2.1+Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|November 1998|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||November 2005|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003568||208355|
NCT00003569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 97-39|Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel|Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol||Roswell Park Cancer Institute||Completed|March 1998|||June 2003|Actual|Phase 1|Observational|N/A|||Actual|2|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003569||208354|
NCT00003461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2237|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors|Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors||Duke University||Completed|February 1998|February 2005|Actual|February 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||February 2013|August 20, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003461||208448|
NCT00003462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0672|Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors|Phase I Study of Intrathecal Spartaject-Busulfan in Patients With Neoplastic Meningitis||Duke University||Completed|April 1998|February 2001|Actual|February 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003462||208447|
NCT00003596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9811|Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer|A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal||Radiation Therapy Oncology Group|Yes|Completed|October 1998|||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|650|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003596||208331|
NCT00003563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066627|Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases|Phase III Randomized Trial of Gadolinium Texaphyrin (PCI-0120) Injection as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases||Pharmacyclics||Completed|August 1998|June 2005|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|N/A|No|||June 2008|October 29, 2013|November 1, 1999|No|Yes||||https://clinicaltrials.gov/show/NCT00003563||208360|
NCT00003657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066750|Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable Cancer|High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection||National Cancer Institute (NCI)||Active, not recruiting|July 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|55 Years|No|||May 2006|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003657||208277|
NCT00003670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2145|Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer|Phase II Study of LY353381-HC1 Administered to Women With Refractory Ovarian Cancer||Eli Lilly and Company||Completed|October 1998|January 2001|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2008|June 6, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003670||208266|
NCT00003671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9705|Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia|Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study||Children's Oncology Group|Yes|Completed|December 1998|February 2009|Actual|November 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|N/A|18 Years|No|||July 2014|July 24, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003671||208265|
NCT00003675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066776|Topotecan in Treating Patients With Myelodysplastic Syndrome|A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)||Alliance for Clinical Trials in Oncology|No|Completed|March 1999|April 2009|Actual|January 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|15 Years|N/A|No|||September 2013|September 28, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003675||208262|
NCT00003658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-083|Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers|A Phase I-II Study of Pentostatin With Cyclophosphamide for Previously Treated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia||Memorial Sloan Kettering Cancer Center||Completed|September 1998|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003658||208276|
NCT00003653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR7|Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer|A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer||Canadian Cancer Trials Group|Yes|Completed|January 1999|January 2013|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1386|||Male|16 Years|N/A|No|||August 2012|January 10, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003653||208280|
NCT00003262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066154|Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection|Prospective Non Randomized Study With Chemotherapy in Patients With Hodgkin's Disease and HIV Infection: "Stanford V Regimen" For "Low Risk" Patients, "EBVP Regimen" For "High Risk" Patients||National Cancer Institute (NCI)||Active, not recruiting|May 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||October 2002|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003262||208618|
NCT00003263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066157|Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma|Phase I Combined Modality Protocol for Malignant Mesothelioma: Cisplatin & rIFN-alpha-2b Followed by Surgical Resection (Debulking), and Post-Op Concurrent Chemoradiotherapy With Cisplatin, +/- rIFN-alpha-2b||Fox Chase Cancer Center||Completed|August 1996|November 2000|Actual|December 1999|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003263||208617|
NCT00003276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-964252|Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer|A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors||Alliance for Clinical Trials in Oncology|No|Completed|March 1998|March 2001|Actual|March 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003276||208608|
NCT00003606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066683|Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer|Phase III Randomized Study of Cisplatin and Etoposide With or Without Epirubicin and Cyclophosphamide for Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|216|||Both|18 Years|75 Years|No|||May 2007|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003606||208321|
NCT00003679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066780|Combination Chemotherapy in Treating Women With Breast Cancer|A Randomised Comparative Trial of Adriamycin + Taxotere vs. Adriamycin + Cyclophosphamide as Primary Medical Therapy for Patients With Potentially Operable Breast Cancer Greater Than or Equal to 3 cm Diameter, Locally Advanced, or Inflammatory Disease||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|350|||Female|18 Years|60 Years|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003679||208259|
NCT00003610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-969257|Capsaicin Lozenges in Treating Patients With Mucositis Caused by Radiation Therapy|Phase III Comparison of Oral Capsaicin Lozenge Versus Placebo Lozenge for Radiation-Induced Mucositis||Alliance for Clinical Trials in Oncology|No|Completed|October 1998|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003610||208319|
NCT00003219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066080|Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer|A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily in Patients With Metastatic Breast Cancer||University of Wisconsin, Madison||Completed|May 1998|May 1998|Actual|May 1998|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2012|October 8, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003219||208652|
NCT00003444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066472|Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin|A Prospective Randomized Phase III Clinical Trial Assessing the Role of Post-Operative Radiotherapy Plus Adjuvant Interferon Alpha-2b in Patients With Cervical, Axillary, and Inguinal Nodal Metastasis From Cutaneous Melanoma||Eastern Cooperative Oncology Group|Yes|Completed|October 1998|||September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|167|||Female|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003444||208464|
NCT00003445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOCS-04-CC-97|Docetaxel in Treating Patients With Advanced Cancer of the Cervix|Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma||National Cancer Institute (NCI)||Completed|December 1997|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||September 2001|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003445||208463|
NCT00003268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJUH-980407|Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Study of Cytosine Arabinoside, Idarubicin, and Amifostine as Induction Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia||National Cancer Institute (NCI)||Completed|January 1998|December 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2003|August 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003268||208613|
NCT00003222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7621|Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma|Phase II Trial for the Evaluation of the Efficacy of Vaccination With Synthetic Melanoma Peptides Either Pulsed on Dendritic Cells, or Administered With GM-CSF-in-Adjuvant, Plus Administration of Sustemic IL-2, in Patients With Advanced Melanoma.||University of Virginia|Yes|Completed|April 1998|||September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|79 Years|No|||December 2014|December 18, 2014|November 1, 1999|No|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00003222||208650|
NCT00003253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066135|Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer|Assessment of the Predictive Value of the Extreme Drug Resistance (EDR) Assay in Patients Receiving Paclitaxel for Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 1997|||||Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|100|||Both|18 Years|N/A|No|||May 2006|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003253||208626|
NCT00003257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066148|Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer|A Phase II, Multicenter, Open Label Study to Evaluate Effectiveness and Safety of AdCMV-p53 Administered by Intra-Tumoral Injections in 39 Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)||National Cancer Institute (NCI)||Active, not recruiting|January 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|N/A|No|||April 2000|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003257||208622|
NCT00003397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066399|Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Autologous Stem Cell Transplantation for Poor Prognosis, Relapsed, or Refractory Intermediate-High Grade B-Cell Lymphoma Using Gemcitabine Plus High Dose BCNU and Melphalan Followed by Anti-CD20 Moab (IDEC C2B8, Rituximab, Rituxan) and Consolidative Chemotherapy||University of Maryland||Completed|September 1998|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|75 Years|No|||September 2009|September 23, 2009|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003397||208509|
NCT00003478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1529|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors|Phase I Study of Intra-Tumoral, Radiolabeled, Anti-Tenascin Monoclonal Antibody 81C6 in the Treatment of Patients With Malignant Primary Brain Tumors||Duke University||Completed|October 1997|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003478||208431|
NCT00003463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901|Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas|Phase I Treatment of Adults With Recurrent Supratentorial High Grade Glioma With Gliadel Wafers Plus Irinotecan (CPT-11)||Duke University||Completed|July 1998|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003463||208446|
NCT00003267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55962|Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer|A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 1998|||July 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|214|||Both|N/A|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003267||208614|
NCT00003479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066516|Antineoplaston Therapy in Treating Patients With Ependymoma|Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Patients With Ependymoma||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||September 2006|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003479||208430|
NCT00003289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J9814, CDR0000066221|UCN-01 in Treating Patients With Advanced Cancer|A Phase I and Pharmacologic Study of UCN-01 (NSC638850)||Sidney Kimmel Comprehensive Cancer Center||Completed|June 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2010|August 5, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003289||208598|
NCT00003264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066159|Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer|Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck||Fox Chase Cancer Center|No|Completed|October 1997|June 2002|Actual|February 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003264||208616|
NCT00003279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08971|Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG|SILVA|European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 1998|||January 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003279||208606|
NCT00003229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066097|Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal|A Phase I-II Trial of Antigen-Pulsed Autologous Dendritic Cells for Induction of Anti-Tumor Immunity in Patients Completing Lymphadenectomy for Metastatic Melanoma||Duke University||Completed|July 1997|February 2005|Actual|April 2000|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2013|March 22, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003229||208646|
NCT00003490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066529|Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma|Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF||National Cancer Institute (NCI)||Completed|October 1998|August 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|16 Years|N/A|No|||March 2001|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003490||208423|
NCT00003231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 16/96|Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer|Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2)||Swiss Group for Clinical Cancer Research||Completed|April 1997|September 2000|Actual|September 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003231||208644|
NCT00003269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066165|Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors|A Phase II, Open-Label, Trial Evaluating the Efficacy of Amifostine in Patients With Cancers Receiving Outpatient Dose-intensive Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Chemotherapy||Scripps Health|No|Completed|February 1998|January 2001|Actual|January 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|70 Years|No|||January 2011|January 6, 2011|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003269||208612|
NCT00003447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066476|Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Vinorelbine Versus Gemcitabine Versus Gemcitabine and Vinorelbine in Elderly Patients With Stage IIIB-IV Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|630|||Both|70 Years|N/A|No|||September 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003447||208461|
NCT00003223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066085|SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth|A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia||Southwest Oncology Group|No|Terminated|December 1997|March 2000|Actual|March 2000|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|5|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|November 1, 1999|Yes|Yes|Closed due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00003223||208649|
NCT00003234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A09705|Vinorelbine in Treating Children With Recurrent or Refractory Cancers|A Phase II Study of Navelbine (Vinorelbine) In Children With Recurrent Or Refractory Malignancies||Children's Oncology Group|Yes|Completed|May 1998|March 2007|Actual|March 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|3||Actual|50|||Both|N/A|21 Years|No|||July 2014|July 25, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003234||208642|
NCT00003224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6346|Vaccine Therapy in Treating Patients With Metastatic Melanoma|Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With a Synthetic Melanoma Peptide in Patients With High Risk Melanoma||University of Virginia|Yes|Completed|February 1996|||August 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|22|||Both|18 Years|79 Years|No|||November 2014|November 18, 2014|November 1, 1999|No|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00003224||208648|
NCT00003398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066400|Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor||University of Maryland||Completed|September 1998|May 2000|Actual|May 2000|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|N/A|50 Years|No|||September 2009|September 23, 2009|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003398||208508|
NCT00003464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1171|Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme|Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal||Duke University||Completed|September 1997|August 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||October 2009|June 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003464||208445|
NCT00003465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1534|Temozolomide in Treating Patients With Anaplastic Oligodendroglioma|Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal||Duke University||Completed|March 1998|February 2001|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||October 2009|June 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003465||208444|
NCT00003291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B969|Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia|Molecular Genetic Lesions and Clinical Outcome in Pediatric ALL Patients||Children's Oncology Group|No|Completed|March 1998|||March 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective|||Anticipated|200|||Both|N/A|17 Years|No|||August 2014|August 7, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003291||208596|
NCT00003259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/97|Vinorelbine in Treating Patients With Metastatic Prostate Cancer|Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma Phase II Trials Protocol 4: Vinorelbine||Swiss Group for Clinical Cancer Research||Completed|October 1997|September 1999|Actual|September 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|85 Years|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003259||208621|
NCT00003497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066536|Antineoplaston Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 Capsules In Patients With Non Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003497||208416|
NCT00003518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066562|Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors|Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors||Eastern Cooperative Oncology Group|No|Completed|January 1999|||July 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|44|||Both|15 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003518||208400|
NCT00003278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-967351|Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma|Primary Central Nervous System Non-Hodgkins's Lymphoma (PCNSL): A Phase II Clinical Trial of Radiation Therapy and High Dose Corticosteroids for Elderly Patients (70 Years of Age and Older)||Alliance for Clinical Trials in Oncology|No|Completed|March 1998|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|70 Years|N/A|No|||July 2015|July 14, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003278||208607|
NCT00003284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066206|High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer|Tandem Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) After High Dose Paclitaxel Followed by Ifosfamide, Carboplatin, and Etoposide (ICE) for the Treatment of Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|N/A|No|||June 2000|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003284||208601|
NCT00003236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066108|Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer|Randomized Phase II Study of Human C-raf Kinase Antisense Oligonucleotide Isis 5132 (CGP 69846A) or Human Pkc-Alpha Antisence Oligonucleotide ISIS 3521 (CGP 64128A) in Women With Previously Treated Matastatic Breast Cancer||Eastern Cooperative Oncology Group||Completed|May 1998|||June 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003236||208640|
NCT00003509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066552|Antineoplaston Therapy in Treating Patients With Stage IV Melanoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Malignant Melanoma||National Cancer Institute (NCI)||Completed|March 1996|||February 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2009|May 23, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003509||208408|
NCT00003511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066554|Antineoplaston Therapy in Treating Patients With Multiple Myeloma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|April 1996|||January 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|January 21, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003511||208407|
NCT00003238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066113|Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer||University of Wisconsin, Madison||Completed|February 1998|||October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||August 2013|August 15, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003238||208638|
NCT00003240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066115|Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|A Major Randomised Trial to Determine the Value of Cisplatin-Based Chemotherapy For All Patients With Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1800|||Both|18 Years|N/A|No|||May 2007|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003240||208636|
NCT00003436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066463|Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia|Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12||National Cancer Institute (NCI)||Completed|July 1998|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Both|N/A|15 Years|No|||December 2000|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003436||208470|
NCT00003456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066488|Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Glioblastoma Multiforme||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003456||208453|
NCT00003232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR6|Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer|Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain||Canadian Cancer Trials Group||Completed|November 1997|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|204|||Male|N/A|N/A|No|||November 2010|November 7, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003232||208643|
NCT00003254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066138|SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil|A Phase II Trial of 5-Fluorouracil Plus 776C85 in Patients With Advanced Resistant Colorectal Cancer||Southwest Oncology Group|No|Completed|April 1998|October 2003|Actual|November 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003254||208625|
NCT00003399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066402|Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma|Autologous Transplantation With High Dose BCNU and Melphalan Followed by Consolidation With DCEP and Taxol/Cisplatin in Patients With Multiple Myeloma and < or = 12 Months of Standard Therapy||National Cancer Institute (NCI)||Completed|September 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003399||208507|
NCT00003466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1703 (CDR0000066502)|Temozolomide in Treating Patients With Progressive Low-Grade Glioma|Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal||Duke University|No|Completed|March 1998|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|100|||Both|4 Years|N/A|No|||February 2013|July 7, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003466||208443|
NCT00003255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-968151|Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia|Phase II Study of Continuous Infusion Carboplatin and Topotecan in the Treamtment of Relapsed Acute Myelogenous Leukemia (AML)||Alliance for Clinical Trials in Oncology|No|Completed|November 1999|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|74 Years|No|||July 2015|July 9, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003255||208624|
NCT00003280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 35/98|Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma|A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4||Swiss Group for Clinical Cancer Research||Completed|January 1998|March 2002|Actual|March 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003280||208605|
NCT00003281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-972051|Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer|Phase II Trial of Topotecan and Paclitaxel in Previously Treated Patients With Relapsed Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|April 1998|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003281||208604|
NCT00003483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066521|Antineoplaston Therapy in Treating Patients With Meningioma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Meningioma||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003483||208429|
NCT00003524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066568|Antineoplaston Therapy in Treating Patients With Stomach Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Stomach||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003524||208394|
NCT00003290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066222|Radiation Therapy in Treating Patients With Prostate Cancer|A Randomised Trial of High Dose Therapy in Localised Cancer of the Prostate Using Conformal Radiotherapy Techniques||National Cancer Institute (NCI)||Completed|January 1998|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Male|N/A|N/A|No|||July 2001|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003290||208597|
NCT00003266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066161|Methylphenidate in Treating Patients With Melanoma|Double-Blind Randomized Trial of Methylphenidate for Alleviation of Fatigue and Lethargy Associated With Interferon Alpha 2b||National Cancer Institute (NCI)||Completed|June 1999|||May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|200|||Both|18 Years|N/A|No|||March 2008|May 6, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003266||208615|
NCT00003220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066081|Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of Bryostatin 1 in Patients With Metastatic Colo-Rectal Adenocarcinoma||Barbara Ann Karmanos Cancer Institute|Yes|Completed|February 1998|June 2001|Actual|November 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||April 2013|April 3, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003220||208651|
NCT00003525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066569|Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Uterine Cervix and/or Vulva||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003525||208393|
NCT00003433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066459|Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer|A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous, Cultured Dendritic Cells After Complete Resection of Hepatic Metastases of Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|June 1998|August 2003|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003433||208473|
NCT00003245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066124|Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma|Phase II Study of Irinotecan for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Completed|February 1998|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|15 Years|75 Years|No|||October 2012|October 5, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003245||208632|
NCT00003270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 97-26|Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer|Cord Blood Transplantation for Hematologic Malignancies and Bone Marrow Failure Syndromes||Roswell Park Cancer Institute|Yes|Active, not recruiting|September 1997|||August 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|5 Years|50 Years|No|||June 2015|June 24, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003270||208611|
NCT00003273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066174|Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor|Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue||New York University School of Medicine||Withdrawn|November 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|10 Years|No|||November 2015|November 30, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003273||208610|
NCT00003400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066404|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer|High Dose Chemotherapy With Stem Cell Rescue Followed By Consolidation Treatment in Patients With Metastatic Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Male|18 Years|70 Years|No|||June 2000|February 26, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003400||208506|
NCT00003239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-229|Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT)||M.D. Anderson Cancer Center|No|Completed|March 1998|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|12 Years|N/A|No|||July 2012|July 27, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003239||208637|
NCT00003249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02265|Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers|A Phase I Investigation of Carboxyamido-triazole (CAI) Modulated by Ketoconozole In Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|May 1998|||December 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003249||208630|
NCT00003260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066151|Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer|Multicentre Phase III Comparing To Therapeutic Sequence: Folfiri Following of Folfox6 (Group A) and Folfox6 Following Of (Group B) For Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|109|||Both|18 Years|75 Years|No|||May 2007|January 10, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003260||208620|
NCT00003261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066153|Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma|Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy||National Cancer Institute (NCI)||Active, not recruiting|May 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|14|||Both|18 Years|N/A|No|||October 2001|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003261||208619|
NCT00003498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066537|Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|December 1996|||January 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|January 21, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003498||208415|
NCT00003283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066197|Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma|Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma||Eastern Cooperative Oncology Group|No|Completed|July 1998|||September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|38|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003283||208602|
NCT00003256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066145|Flavopiridol in Treating Patients With Recurrent Prostate Cancer|A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|May 1998|April 2004|Actual|July 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|N/A|N/A|No|||January 2013|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003256||208623|
NCT00003293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUGEN-SU101.015|SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme|A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse||Pfizer||Completed|February 1998|May 2001|Actual|May 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2012|September 10, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003293||208594|
NCT00003491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066530|Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Lung||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003491||208422|
NCT00003492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066531|Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung||National Cancer Institute (NCI)||Active, not recruiting|April 1996|||January 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|January 21, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003492||208421|
NCT00003248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066128|Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia|A Randomized Phase II Study of Concurrent Fludarabine + Chimeric Anti-CD20 Monoclonal Antibody IDEC-C2B8 (Rituximab) [NSC# 687451] Induction Followed By Rituximab Consolidation In Untreated Patients With B-Cell Chronic Lymphocytic Leukemia||Alliance for Clinical Trials in Oncology||Completed|March 1998|June 2010|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|104|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003248||208631|
NCT00003292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066225|S9624 Ifosfamide in Treating Patients With Meningeal Tumors|S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors||Southwest Oncology Group|Yes|Terminated|July 1998|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|November 1, 1999|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00003292||208595|
NCT00003230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 34/95|Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia|Paclitaxol (Taxol) for Refractory or Relapsed Acute Leukemia in Elderly Patients, and Blast Crisis of Chronic Myelogenous Leukemia: A Multicenter Phase I/II Study||Swiss Group for Clinical Cancer Research||Completed|January 1998|July 2000|Actual|July 2000|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003230||208645|
NCT00003808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066953|Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia|Phase II Study of Theophylline in Chronic Lymphocytic Leukemia||Eastern Cooperative Oncology Group||Completed|May 1999|||September 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003808||208142|
NCT00003821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066974|Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer|Phase II Trial of Aminopterin in Patients With Persistent or Recurrent Endometrial Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|January 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Female|N/A|N/A|No|||July 2000|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003821||208131|
NCT00003715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066824|Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma|A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b||AVAX Technologies||Terminated|December 1998|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|425|||Both|18 Years|120 Years|No|||December 2015|December 2, 2015|November 1, 1999|Yes|Yes|Terminated: recruiting or enrolling participants has halted prematurely and will not resume;    participants are no longer being examined or treated|No||https://clinicaltrials.gov/show/NCT00003715||208225|
NCT00003794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066937|Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer|Quality of Life in Ovarian Germ Cell Cancer Survivors||Gynecologic Oncology Group||Terminated|April 1999|||July 2005|Actual|N/A|Observational|N/A|||||||Female|18 Years|N/A|No|||November 2005|June 7, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003794||208154|
NCT00003758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066882|Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia|Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|15 Years|60 Years|No|||January 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003758||208185|
NCT00003712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066820|CCI-779 in Treating Patients With Advanced Solid Tumors|A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous CCI-779 Given Once Daily for 5 Days Every 2 Weeks to Patients With Advanced Solid Tumors||The University of Texas Health Science Center at San Antonio|Yes|Completed|January 2001|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003712||208228|
NCT00003718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066827|Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma|Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas||National Cancer Institute (NCI)||Active, not recruiting|September 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||August 2001|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003718||208222|
NCT00003719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066828|Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma|Phase II Evaluation of Irinotecan (CPT-11) in Previously Treated Advanced Sarcomas||National Cancer Institute (NCI)||Active, not recruiting|July 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|27|||Both|18 Years|N/A|No|||August 2001|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003719||208221|
NCT00003759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066883|AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer|Intravesical Treatment of Superficial Bladder Cancer Characterized on the Basis of the Tumor Markers p53 and pRb||National Cancer Institute (NCI)||Completed|November 1998|November 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|January 30, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003759||208184|
NCT00003760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066884|Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer|A Phase II Trial of MGI 114 in Patients With Advanced Pancreatic Adenocarcinoma||The University of Texas Health Science Center at San Antonio|Yes|Completed|November 1998|May 2000|Actual|May 2000|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003760||208183|
NCT00003815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066967|Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma|A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups||National Cancer Institute (NCI)||Active, not recruiting|June 1994|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|15 Years|65 Years|No|||July 2001|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003815||208136|
NCT00003805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-46971|Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count|Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 1997|||June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Actual|859|||Both|2 Years|N/A|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003805||208143|
NCT00003765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01842|O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors|A Trial of 06-BG and BCNU in Children With CNS Tumors||National Cancer Institute (NCI)||Completed|May 1999|||March 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|21 Years|No|||October 2007|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003765||208178|
NCT00003750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0018|Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors|A Phase I/IB Intergroup Trial of the HU14.18-IL2 Fusion Protein in Children With Refractory Neuroblastoma and Other GD2 Positive Tumors||Children's Oncology Group|Yes|Completed|October 2001|September 2005|Actual|January 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|N/A|21 Years|No|||August 2014|August 6, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003750||208192|
NCT00003408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066418|Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer|Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation||National Cancer Institute (NCI)||Completed|April 1998|March 2000|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||April 2003|March 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003408||208498|
NCT00003415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066429|Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome|Phase I/II Study of Combined Treatment With Amifostine (Ethyol) and Topotecan (Hycamtin MS) in Patients With Myelodysplastic Syndrome||National Cancer Institute (NCI)||Completed|September 1998|November 2002|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|26|||Both|18 Years|N/A|No|||July 2000|January 30, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003415||208491|
NCT00003764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066890|Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia|Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia||Eastern Cooperative Oncology Group|Yes|Completed|December 1999|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|280|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003764||208179|
NCT00003708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066816|Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Study of Cyclic Oral Administration of SCH 52365 for 21 of 28 Days in Patients With Advanced Solid Malignancies||The University of Texas Health Science Center at San Antonio|Yes|Completed|July 1998|May 2000|Actual|May 2000|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003708||208232|
NCT00003766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9523|O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery|Determination of Optimal O6-Benzylguanine Dose to Achieve O6-Alkylguanine-DNA Alkyltransferase Depletion in Patients With Surgically Resectable Solid Tumors||University of Chicago|No|Completed|October 1999|November 2001|Actual|November 2001|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|N/A|No|||March 2014|March 5, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003766||208177|
NCT00003824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066978|S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer|The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder||Southwest Oncology Group|Yes|Terminated|April 1999|January 2007|Actual|July 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|November 1, 1999|Yes|Yes|Permanently Closed Due to Poor Accrual|No||https://clinicaltrials.gov/show/NCT00003824||208129|
NCT00003713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066821|Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I, Pharmacokinetic, and Treatment Duration and Escalation Study of Intravenous Intoplicine Administered as a 5 to 21-Day Continuous Infusion Every 4 Weeks||National Cancer Institute (NCI)||Active, not recruiting|August 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||May 2001|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003713||208227|
NCT00003391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066389|Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Phase I Trial of Monoclonal Antibody muJ591 in Patients With Hormone-Independent Prostate Cancer||Weill Medical College of Cornell University||Completed|June 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Male|21 Years|N/A|No|||October 2009|October 9, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003391||208514|
NCT00003392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9727|High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer|Multiple Cycles of High Dose Chemotherapy Supported With Filgrastim and Peripheral Blood Progenitor Cells in Patients With Metastatic Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|September 1997|January 2003|Actual|August 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|61|||Both|18 Years|65 Years|No|||February 2012|February 19, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003392||208513|
NCT00003698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066805|Chemotherapy in Treating Patients With Solid Tumors|A Phase I Trial of Combretastatin A4 Phosphate in Patients With Solid Tumours Given by Weekly Intravenous Infusion||National Cancer Institute (NCI)||Completed|July 1998|December 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||February 2008|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003698||208241|
NCT00003700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-19802|Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia|Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradiation||Alliance for Clinical Trials in Oncology|No|Completed|January 1999|January 2010|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|15 Years|N/A|No|||June 2015|June 23, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003700||208240|
NCT00003775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUGEN-SU101.021|Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse|A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse||Pfizer||Completed|December 1998|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003775||208171|
NCT00003793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB9804|Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma|Clinical and Biological Predictors of Therapy-Related Leukemia||Children's Oncology Group|No|Completed|December 1998|March 2007|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|294|Samples With DNA|blood|Both|N/A|17 Years|No|Non-Probability Sample|Children receiving high dose chemotherapy for sarcomas.|August 2014|August 4, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003793||208155|
NCT00003638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066723|Vaccine Therapy in Treating Women With Metastatic Breast Cancer|A Multi-Center Phase III Randomized, Controlled Study of Theratope Vaccine for Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|January 1999|December 2008|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|950|||Female|18 Years|N/A|No|||December 2008|March 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003638||208294|
NCT00003416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9805|S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia|S9805, Phase II Study of Tandem High Dose Melphalan Supported by Peripheral Blood Stem Cell Support in Waldenstrom's Macroglobulinemia (WM)||Southwest Oncology Group|Yes|Completed|September 1998|January 2004|Actual|August 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|69 Years|No|||March 2015|March 5, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003416||208490|
NCT00003731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26971|Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors|First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1998|||January 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|39|||Both|18 Years|70 Years|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003731||208210|
NCT00003709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066817|Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetic Study of FB-642 Administered Orally on a Weekly Schedule to Patients With Advanced Solid Tumors||The University of Texas Health Science Center at San Antonio|Yes|Completed|October 1998|November 2000|Actual|November 2000|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003709||208231|
NCT00003776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-102|Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma|A Phase II Window Study of Trimetrexate With Simultaneous Leucovorin Protection in the Treatment of Newly Diagnosed Patients With Metastatic Osteosarcoma||Memorial Sloan Kettering Cancer Center||Completed|December 1998|March 2000|Actual|March 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|30 Years|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003776||208170|
NCT00003819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-048|Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer|Vaccination of Prostate Cancer Patients With Thompson-Friedenreich [TF(c)]-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Comparing TF(c)-KLH Doses||Memorial Sloan Kettering Cancer Center||Completed|June 1998|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||March 2013|March 18, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003819||208133|
NCT00003820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMHD0003|Rituximab in Treating Patients With Hodgkin's Lymphoma|Phase II Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease||Stanford University|No|Completed|January 1999|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|3 Years|N/A|No|||June 2012|June 5, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003820||208132|
NCT00003714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-107|Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer|Phase II Trial of Pyrazoloacridine (PZA) in Previously Untreated Hepatocellular Carcinoma (HCC) Patients||M.D. Anderson Cancer Center|No|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||February 2012|February 20, 2012|November 1, 1999||No|Withdrawn|No||https://clinicaltrials.gov/show/NCT00003714||208226|
NCT00003411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-97-108|Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer|Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers||University of Pittsburgh|Yes|Completed|November 1998|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||January 2016|January 15, 2016|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003411||208495|
NCT00003412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066424|Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation|Phase I Study of Post Transplant rhIL-12 High Dose Cyclophosphamide, Thiotepa, and Carboplatin in the Treatment of Metastatic Breast Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|June 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Female|18 Years|60 Years|No|||October 2001|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003412||208494|
NCT00003773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066900 (5O-98-4)|IM-862 in Treating Patients With Recurrent Ovarian Cancer|Phase I Study of Escalating Doses of IM-862 in Patients With Ovarian Cancer||University of Southern California|Yes|Completed|February 1999|August 2001|Actual|July 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|43|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003773||208172|
NCT00003812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066958|Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Topotecan/Paclitaxel Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer: A Phase II Study||Alliance for Clinical Trials in Oncology||Completed|March 1999|March 2006|Actual|June 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|75|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003812||208138|
NCT00003814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066966|Eflornithine in Treating Patients With Bladder Cancer|Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer||National Cancer Institute (NCI)||Completed|February 1999|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|450|||Both|18 Years|N/A|No|||May 2007|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003814||208137|
NCT00003803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08972-22973|Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed|A Randomized Phase III Study Comparing Induction Chemotherapy to Daily Low Dose Cisplatin Both Combined With High Dose Radiotherapy Using Concomitant Boost Technique in Patients With Inoperable Non-Small Cell Lung Cancer Stage I, II, and Low Volume Stage III||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|February 1999|||March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|158|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|November 1, 1999|||low accrual|No||https://clinicaltrials.gov/show/NCT00003803||208145|
NCT00003717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066826|Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|A Phase II Trial of Weekly Paclitaxel Plus Oral Estramustine in Patients With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|17|||Male|N/A|N/A|No|||August 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003717||208223|
NCT00003706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066814|LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function|A Phase I Pharmacokinetic Trial of LY231514 Administered Intravenously Every 3 Weeks in Advanced Cancer Patients With Varying Degrees of Renal Function||The University of Texas Health Science Center at San Antonio|Yes|Completed|April 1998|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003706||208234|
NCT00003797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066940|Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas|Herceptin (NSC #688097) and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/NEU||National Cancer Institute (NCI)||Active, not recruiting|March 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|41|||Both|18 Years|N/A|No|||December 2002|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003797||208151|
NCT00003822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066975|SR-45023A in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetic Study of SR-45023A During a 14-Day Treatment Schedule||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2001|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003822||208130|
NCT00003796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066939|Irofulven in Treating Patients With Metastatic Breast Cancer|Phase II Study of MGI-114 in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|May 1999|||December 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||March 2003|February 8, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003796||208152|
NCT00003753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-072|Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer|A Phase I-II Study of Hepatic Arterial Therapy Via Pump (Protocol D97-063) With Floxuridine (FUDR) and Dexamethasone (DEX) in Combination With Intravenous Irinotecan as Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|September 1998|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003753||208189|
NCT00003755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-099|Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor|Phase I Study of R031-7453, a Novell Cell Cycle Inhibitor, Administered as Escalating Oral Doses in Adults With Solid Tumors: 4-Day Schedule||Memorial Sloan Kettering Cancer Center||Completed|October 1998|August 2001|Actual|August 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003755||208187|
NCT00003757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 31/98|Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy|Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA)||Swiss Group for Clinical Cancer Research||Completed|February 1998|July 2007|Actual|July 2002|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003757||208186|
NCT00003751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-9704 CDR0000066872|Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma|Phase II Study of Penicillamine and Reduction of Copper for Angiosuppressive Therapy of Adults With Newly Diagnosed Glioblastoma||Sidney Kimmel Comprehensive Cancer Center||Completed|March 1999|July 2005|Actual|June 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003751||208191|
NCT00003752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIGAND-L1069-34|Bexarotene in Treating Patients With Metastatic Breast Cancer|A Multicenter Phase II Evaluation of Targretin (Bexarotene) Capsules in Patients With Advanced Breast Cancer||National Cancer Institute (NCI)||Completed|October 1998|March 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|180|||Both|18 Years|N/A|No|||May 2007|May 29, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003752||208190|
NCT00003710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066818|Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetic Study of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Solid Tumors||The University of Texas Health Science Center at San Antonio|Yes|Completed|August 1998|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2012|August 7, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003710||208230|
NCT00003754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-088|Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers|A Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent or Refractory Malignancies||Memorial Sloan Kettering Cancer Center||Completed|September 1998|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003754||208188|
NCT00003685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC15|Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer|A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer||Canadian Cancer Trials Group||Completed|December 1998|February 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|210|||Both|16 Years|N/A|No|||March 2010|November 7, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003685||208253|
NCT00003707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066815|Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer||The University of Texas Health Science Center at San Antonio|Yes|Completed|October 1998|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003707||208233|
NCT00003792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAYUMC-098004|Vaccine Therapy in Treating Patients With Metastatic Melanoma|Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial||National Cancer Institute (NCI)||Completed|April 1999|October 2006|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||October 2006|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003792||208156|
NCT00003816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066968|Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer|Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia||Roswell Park Cancer Institute|Yes|Active, not recruiting|October 1998|||March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|362|||Both|4 Years|70 Years|No|||November 2015|November 19, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003816||208135|
NCT00003817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066969|Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy|A Randomized Phase II Trial of Acupressure and Acustimulation Wrist Bands for the Prevention of Chemotherapy-Induced Nausea and Vomiting||University of Rochester||Completed|October 1999|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|700|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003817||208134|
NCT00003730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-05971|Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer|A Multicenter Randomized Trial, With Direct Individual Benefit, to Determine the Optimal Circadian Time of Vinorelbine Administration Combined With Chronomodulated Infusion of 5-Fluorouracil in Previously Treated Patients With Metastatic Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1998|||November 2004|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|80|||Female|N/A|N/A|No|||June 2012|June 29, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003730||208211|
NCT00003740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-085|Trastuzumab in Treating Patients With Prostate Cancer|Phase II Study of Herceptin (Recombinant Humanized Anti-p185HER2 Monoclonal Antibody) for the Treatment of Androgen Independent Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|October 1998|September 2002|Actual|September 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003740||208202|
NCT00003809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066954|Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck||Eastern Cooperative Oncology Group||Completed|June 1999|||September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003809||208141|
NCT00003761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066886|Vaccine Therapy in Treating Patients With Metastatic Breast Cancer|A Phase I Trial of Recombinant Vaccinia Virus That Expresses DF3/MUC1 in Patients With Metastatic Adnocarcinoma of the Breast||National Cancer Institute (NCI)||Active, not recruiting|February 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||June 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003761||208182|
NCT00003795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066938|Quality of Life in Survivors of Gynecologic Cancer|Quality of Life of Gynecologic Cancer Survivors||Gynecologic Oncology Group||Completed|April 1999|||March 2002|Actual|N/A|Observational|N/A|||Anticipated|311|||Female|N/A|N/A|No|||March 2009|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003795||208153|
NCT00003800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066944|Diagnostic Study of Patients With Stage I Testicular Cancer|Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor||Eastern Cooperative Oncology Group|No|Active, not recruiting|May 1999|||December 2004|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|76|||Male|15 Years|N/A|No|||November 2012|November 30, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003800||208148|
NCT00003801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066945|Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma|Intergroup Rhabdomyosarcoma Study Group: Late Effects After Treatment for Rhabdomyosarcoma||National Cancer Institute (NCI)||Completed||||||N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|5 Years|N/A|No|||February 2000|August 19, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003801||208147|
NCT00003711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LILLY-H3E-MC-JMAX(a)|Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors|A Phase I Trial of LY231514 With Irinotecan Administered Intravenously Every 21 Days in Patients With Metastatic Cancer||National Cancer Institute (NCI)||Completed|September 1997|September 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2000|May 29, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003711||208229|
NCT00003802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J9875, CDR0000066946|Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma|A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma||Sidney Kimmel Comprehensive Cancer Center||Completed|February 1999|October 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2012|December 12, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003802||208146|
NCT00003427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-034|Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer|Phase I Study to Evaluate the Combination Chemotherapy Regimen of Oxaliplatin Plus Irinotecan in Previously Treated Patients With Metastatic Gastrointestinal Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 1998|April 2002|Actual|April 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003427||208479|
NCT00003378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066372|Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer|A Phase I Feasibility Trial of Carboplatin, Paclitaxel, and Gemcitabine in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Terminated|August 1998|||February 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Female|18 Years|80 Years|No|||December 2011|July 8, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003378||208526|
NCT00003409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066421|Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I Dose Escalating Study of the Safety and Tolerability of Gadolinium Texaphyrin as a Radiation Sensitizer in Patients With Primary Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|July 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003409||208497|
NCT00003418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066434|Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer|Randomized Double-Blind Trial in Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen||National Cancer Institute (NCI)||Active, not recruiting|February 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|4400|||Female|N/A|N/A|No|||March 2008|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003418||208488|
NCT00003637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066722|Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx|Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|N/A|N/A|No|||January 2006|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003637||208295|
NCT00003379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066374|Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer|A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis||Gynecologic Oncology Group||Completed|November 1999|||January 2007|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||November 2004|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003379||208525|
NCT00003380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066375|Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma||Gynecologic Oncology Group||Terminated|May 1998|||July 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||October 2002|June 7, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003380||208524|
NCT00003390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066388|6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer|A Phase II Trial of 6-Hydroxymethylacylfulvene (MGI-114) in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|June 1998|August 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2000|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003390||208515|
NCT00003410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-HSPC-970904303|Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas|Pilot Trial of Gadolium Texaphyrin for Magnetic Resonance Imaging-Guided Resection of High Grade Gliomas||National Cancer Institute (NCI)||Completed|July 1998|June 2004|Actual|||Phase 1|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||May 2006|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003410||208496|
NCT00003617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066695|Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach|Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|March 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|16 Years|N/A|No|||April 2009|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003617||208312|
NCT00003386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066382|Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer|Treatment of Ovarian Carcinoma With DNP-Modified Autologous Tumor Vaccine||Gynecologic Oncology Group||Terminated|July 1999|||April 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2008|April 10, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003386||208519|
NCT00003419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066438|Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma|Treatment of HIV-Related Kaposi's Sarcoma and Stage I-III Slow-Proliferative Disease With Highly Active Antiretroviral Therapy (HAART)||National Cancer Institute (NCI)||Active, not recruiting|June 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||November 2001|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003419||208487|
NCT00003384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-171|Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer|Expression of the MN Protein in Atypical Glandular Cells of Undetermined Significance (Agus or Agcus) As a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia||Gynecologic Oncology Group||Completed|September 1998|||January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|684|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003384||208521|
NCT00003387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066383|Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery|Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial||Alliance for Clinical Trials in Oncology|Yes|Completed|July 1998|April 2009|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|366|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003387||208518|
NCT00003633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066717|Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer|Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Male|18 Years|N/A|No|||March 2005|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003633||208299|
NCT00003645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID97-077|Hormone Therapy in Treating Patients Who Have Stage I or Stage II Prostate Cancer|A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence||M.D. Anderson Cancer Center|No|Active, not recruiting|June 1999|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|496|||Male|N/A|N/A|No|||June 2015|June 25, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003645||208287|
NCT00003646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066735|Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma|Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma||Vical|Yes|Completed|August 1998|May 2002|Actual|March 2002|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003646||208286|
NCT00003611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-969251|Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation|Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers||Alliance for Clinical Trials in Oncology|No|Completed|May 2000|June 2003|Actual|February 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|129|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003611||208318|
NCT00003612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-983252|Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer|Randomized Phase II Trial of Paclitaxel, Carboplatin and rhuMAb Her-2 (Herceptin) as First-Line Chemotherapy in Patients With Metastatic Breast Cancer Who Overexpress Her-2||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|April 1999|||December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003612||208317|
NCT00003613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03119|O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma|Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma||National Cancer Institute (NCI)||Terminated|April 1999|||May 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||January 2013|January 10, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003613||208316|
NCT00003624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066705|Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer|A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity||Gynecologic Oncology Group||Terminated|December 1998|||January 2004|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Female|N/A|N/A|No|||May 2006|April 10, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003624||208306|
NCT00003640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30971|Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer|A Feasibility Study of Thorough Transurethral Resection (TURB) and Escalated Dose M-VAC Chemotherapy as Primary Treatment of T2-T3a, N0-Nx, M0 Transitional Cell Carcinoma of the Bladder, With the Intention of Bladder Preservation||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|September 1998|||November 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|73|||Both|N/A|N/A|No|||March 2012|March 5, 2012|November 1, 1999|||low accrual|No||https://clinicaltrials.gov/show/NCT00003640||208292|
NCT00003641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066727|High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma|Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage TN ,TN, TN, and T, N (Microscopic) Melanoma||National Cancer Institute (NCI)||Suspended|December 1998|||July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|1420|||Both|18 Years|N/A|No|||July 2011|July 11, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003641||208291|
NCT00003422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066442|Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed|A Randomised Trial Comparing Pre-Operative Radiotherapy and Selective Post-Operative Chemoradiotherapy in Rectal Cancer||National Cancer Institute (NCI)||Completed|January 1998|June 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1800|||Both|N/A|75 Years|No|||March 2007|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003422||208484|
NCT00003423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066443|Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma T Cell Protocol||National Cancer Institute (NCI)||Active, not recruiting|May 1995|||||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|100|||Both|N/A|14 Years|No|||April 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003423||208483|
NCT00003407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066416|Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia|Protocol for Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantron Followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin and Decadron||National Cancer Institute (NCI)||Active, not recruiting|April 1998|||||Phase 2|Interventional|Primary Purpose: Supportive Care|||Anticipated|50|||Both|18 Years|N/A|No|||May 2006|May 9, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003407||208499|
NCT00003420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066440|CT Scans in Treating Patients With Stage I Testicular Cancer After Undergoing Orchiectomy|A Study of CT Scan Frequency in Patients With Stage I Testicular Teratoma||National Cancer Institute (NCI)||Completed|July 1997|April 2010|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|||Anticipated|900|||Male|N/A|N/A|No|||December 2002|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003420||208486|
NCT00003572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066639, J9845|Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers|Non-Myeloablative Allogeneic Bone Marrow Transplant for Hematologic Malignancies||Sidney Kimmel Comprehensive Cancer Center||Completed|August 1998|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|70 Years|No|||May 2014|May 1, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003572||208352|
NCT00003425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKMC-97BMT72|Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect|Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients||University of Kentucky|Yes|Completed|December 1997|||July 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|14 Years|70 Years|No|||April 2013|April 25, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003425||208481|
NCT00003394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-032|Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer|Phase I/II Study of Weekly Intravenous Estramustine Phosphate in Combination With Paclitaxel and Carboplatin in Patients With Advanced Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 1998|April 2003|Actual|April 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Male|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003394||208512|
NCT00003368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066357|Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis|Phase I Study of Irinotecan for Patients With Abnormal Liver or Renal Function or With Prior Pelvic Radiation Therapy||National Cancer Institute (NCI)||Completed|June 1998|July 2006|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|March 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003368||208533|
NCT00003661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066754|Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children and Adults With Hematologic Malignancies||Roswell Park Cancer Institute|Yes|Completed|June 1998|March 2006|Actual|November 1999|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|54 Years|No|||March 2011|March 3, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003661||208274|
NCT00003370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01838|Irofulven in Treating Children With Recurrent or Refractory Solid Tumors|A Trial of MGI 114 in Children With Solid Tumors: A Pediatric Oncology Group Phase I Cooperative Agreement Study||National Cancer Institute (NCI)||Completed|August 1998|||March 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|21 Years|No|||May 2006|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003370||208531|
NCT00003364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066349|Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer|A Randomised Study of Timing of Thoracic Irradiation in Small Cell Lung Cancer (Study 8)||National Cancer Institute (NCI)||Completed|January 1993|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|398|||Both|N/A|74 Years|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003364||208536|
NCT00003365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066350|Sulindac and Plant Compounds in Preventing Colon Cancer|The Effect of Plant Phenolic Compounds on Human Colon Epithelial Cells||Rutgers, The State University of New Jersey|No|Terminated|August 1996|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||January 2011|January 26, 2011|November 1, 1999||No|Study completed|No||https://clinicaltrials.gov/show/NCT00003365||208535|
NCT00003367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-014|Diet and PSA Levels in Patients With Prostate Cancer|The Effect of a Low Fat Diet, High in Soy, Fruits, Vegetables, Green Tea, Vitamin E and Fiber on the PSA in Patients With Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 1998|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|154|||Male|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003367||208534|
NCT00003414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J9726 CDR0000066427|Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease|Randomized Trial of Autologous GVHD for Refractory Lymphoma||Sidney Kimmel Comprehensive Cancer Center||Completed|October 1997|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|N/A|No|||July 2015|July 16, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003414||208492|
NCT00003395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-023|Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer|Dose-Ranging Study of Arsenic Trioxide in Advanced Hematologic Cancers||Memorial Sloan Kettering Cancer Center||Completed|April 1998|March 2000|Actual|March 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|17 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003395||208511|
NCT00003620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02280|Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia|A PHASE II STUDY OF FLAVOPIRIDOL (NSC # 649890) IN PATIENTS WITH PREVIOUSLY TREATED BCELL CHRONIC LYMPHOCYTIC LEUKEMIA||National Cancer Institute (NCI)||Completed|June 1999|||June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003620||208310|
NCT00003428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-038|Hormone Therapy in Treating Women With Breast Cancer|Phase II Randomized Double-Blind Evaluation of Two Dose Levels of LY353381 Hydrochloride Administered to Women With Locally Advanced or Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|May 1998|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|114|||Female|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003428||208478|
NCT00003666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066761|Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer|Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|November 1998|January 2006|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003666||208269|
NCT00003631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-071|Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma|High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease||Memorial Sloan Kettering Cancer Center||Completed|August 1998|||April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|118|||Both|N/A|120 Years|No|||December 2015|December 17, 2015|November 1, 1999|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00003631||208301|
NCT00003405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066413|Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia|Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon||National Cancer Institute (NCI)||Active, not recruiting|April 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|N/A|70 Years|No|||February 2001|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003405||208501|
NCT00003377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066371|Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix|A Phase I Study of Extended Field Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes||Gynecologic Oncology Group|Yes|Completed|November 1999|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||December 2012|December 27, 2012|November 1, 1999|Yes|Yes||No|November 23, 2012|https://clinicaltrials.gov/show/NCT00003377||208527|
NCT00003673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-AR-0903B1-203-US|CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse|A Study of the Safety of CMA-676 in Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) in First Relapse||Pfizer||Completed|March 1998|March 1999|Actual|March 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|55|||Both|60 Years|N/A|No|||August 2012|August 21, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003673||208264|
NCT00003426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-019|Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer|A Phase I Trial of Combined Modality Gemcitabine Plus Radiation Therapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Completed|April 1998|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003426||208480|
NCT00003626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066708|Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy|Phase II Evaluation of Dolastatin-10 in Patients With Hormone Refractory Prostate Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 1998|May 2000|Actual|December 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||April 2013|April 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003626||208304|
NCT00003678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066779|Tamoxifen in Treating Women With Breast Cancer|A Large, Uniquely Simple, Randomised Study to Assess Much More Reliably the Balance of Benefits and Risks of Prolonging Adjuvant Tamoxifen Treatment in Early Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 1991|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|20000|||Female|N/A|N/A|No|||March 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003678||208260|
NCT00003381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9870|Quality of Life Assessment of Patients Receiving Treatment for Esophageal Cancer [Companion to CALGB-9781]|Quality of Life and Cost Analysis of a Prospective Randomized Phase III Trial Comparing Trimodality Therapy to Surgery Alone for Esophageal Cancer [Companion to CALGB-9781]||Alliance for Clinical Trials in Oncology|No|Terminated|July 1998|January 2005|Actual|January 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with esophageal cancer eligible to participate in C9781.|June 2015|June 23, 2015|November 1, 1999||No|companion study to CALGB-9781 which closed administratively due to poor accrual|No||https://clinicaltrials.gov/show/NCT00003381||208523|
NCT00003382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066377|Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer|A Phase I Study of Gemcitabine/Topotecan in Combination in Refractory Ovarian Cancer or Cancer of the Fallopian Tube||Gynecologic Oncology Group||Terminated|May 1998|||April 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2006|June 7, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003382||208522|
NCT00003634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066718|Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy|A Double-Blind Placebo Controlled Trial of Intravenous OvaRex MAb-B43.13 as Post Chemotherapy Consolidation for Ovarian Tubal and Peritoneal Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 1998|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Female|18 Years|N/A|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003634||208298|
NCT00003635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW-PGAA2003|506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents|A Multicenter Study to Assess the Efficacy of 506U78 in Patients With Chronic Lymphocytic Leukemia Who Are Refractory to Fludarabine and Alkylator Therapy||National Cancer Institute (NCI)||Completed|January 1999|March 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2002|July 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003635||208297|
NCT00003369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066358|S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer|Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer||Southwest Oncology Group|No|Completed|August 1998|July 2004|Actual|October 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|18 Years|N/A|No|||June 2012|June 13, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003369||208532|
NCT00003372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I109|Topotecan in Treating Patients With Recurrent Brain Tumors|A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma||Canadian Cancer Trials Group||Completed|December 1997|December 2009||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||November 2010|November 7, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003372||208530|
NCT00003413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066426|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer|High Dose Chemotherapy With Stem Cell Rescue in Recently Diagnosed Patients With Advanced (Stage III and IV) Ovarian Cancer With > 1 cm Residual Disease After Debulking Surgery||University of Maryland||Completed|September 1998|February 2001|Actual|February 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|32|||Female|18 Years|70 Years|No|||September 2009|September 23, 2009|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003413||208493|
NCT00003424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC-AHCC01|Tamoxifen in Treating Patients With Primary Liver Cancer|Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|April 1997|August 2009|Actual|June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Both|10 Years|90 Years|No|||August 2009|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003424||208482|
NCT00003639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066724|Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma|Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction||National Cancer Institute (NCI)||Active, not recruiting|November 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|15 Years|70 Years|No|||May 2007|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003639||208293|
NCT00003406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066415|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer|A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies||National Cancer Institute (NCI)||Completed|October 1997|March 2000|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|65 Years|No|||July 2007|March 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003406||208500|
NCT00003421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066441|Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease|A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease||National Cancer Institute (NCI)||Completed|June 1998|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Both|N/A|N/A|No|||May 2007|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003421||208485|
NCT00003417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9803|Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme|Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme||Radiation Therapy Oncology Group|Yes|Completed|September 1998|||May 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003417||208489|
NCT00003376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066368|Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium|Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium||Eastern Cooperative Oncology Group|Yes|Completed|September 1998|||September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|330|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003376||208528|
NCT00003632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-086|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma|A Phase II Study of Intensive Methotrexate and Cytarabine Followed by High Dose Beam Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|September 1998|||July 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|N/A|No|||January 2013|January 15, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003632||208300|
NCT00003385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066381|Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma||Gynecologic Oncology Group||Completed|March 1999|||January 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Female|N/A|N/A|No|||September 2003|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003385||208520|
NCT00003636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55971|Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer|A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 1998|||January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|704|||Female|N/A|N/A|No|||August 2013|August 4, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003636||208296|
NCT00003864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067028|Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus|A Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus||Eastern Cooperative Oncology Group||Completed|July 1999|||January 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003864||208096|
NCT00003929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3496|Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Combined Modality Therapy of AIDS-Related and Immunocompetent Primary CNS Lymphoma (PCL) Using Filgrastim (G-CSF)||Case Comprehensive Cancer Center|Yes|Withdrawn|June 1998|||March 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||March 2012|March 16, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003929||208042|
NCT00003874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1345.00|Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia|A Phase I/II Study of Combined Enrichment of CD34+ Cells and Depletion of B-Cells From Peripheral Blood Stem Cell Components for Patients With B-Lymphoid Malignancies||Fred Hutchinson Cancer Research Center||Completed|February 1999|September 2001||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||November 2011|November 28, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003874||208088|
NCT00003927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99002|Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer|High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer||City of Hope Medical Center||Active, not recruiting|March 1999|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|59 Years|No|||July 2015|July 22, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003927||208044|
NCT00003969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-PHASE-I-PH1/074|Geldanamycin Analogue in Treating Patients With Advanced Cancer|A Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) (NSC 330507) Via Intravenous Administration in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|August 1998|January 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 2000|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003969||208010|
NCT00003924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELA-LY302|Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma|A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease)||National Cancer Institute (NCI)||Active, not recruiting|October 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|360|||Both|18 Years|64 Years|No|||May 2007|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003924||208047|
NCT00003930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9906|Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer|A Phase I/II Trial in Patients With Muscle-Invading Bladder Cancer of Transurethral Surgery Plus Taxol, Cisplatin and Bid Irradiation Followed by Either Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy||Radiation Therapy Oncology Group|Yes|Completed|September 1999|November 2013|Actual|July 2003|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003930||208041|
NCT00003960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J9828 CDR0000067159|Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies||Sidney Kimmel Comprehensive Cancer Center||Completed|April 1998|September 2001|Actual|September 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|19 Years|55 Years|No|||May 2014|May 1, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003960||208017|
NCT00003869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02898|Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer|Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|April 1999|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|N/A|No|||December 2012|May 2, 2014|November 1, 1999|Yes|Yes||No|November 24, 2010|https://clinicaltrials.gov/show/NCT00003869||208092|
NCT00003833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-984654|Genetic Study in Patients With Stage II or Stage III Colon Cancer|The Clinical and Pathological Significance of Allelic Imbalance of 8p in Patients With Colorectal Cancer||Alliance for Clinical Trials in Oncology|No|Completed|February 1999|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|598|Samples With DNA|Normal and tumor tissue|Both|N/A|69 Years|No|Non-Probability Sample|Patients with advanced colon cancer previously participating in NCCTG-914653.|July 2015|July 7, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003833||208121|
NCT00003799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03145|Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer|Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma||National Cancer Institute (NCI)||Completed|May 1999|||September 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003799||208149|
NCT00003931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9769|Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia|Assessment of the Partial Tandem Duplication of ALL1 (MLL) in Patients With Acute Myeloid Leukemia- A CALGB Leukemia Tissue Bank Project||Alliance for Clinical Trials in Oncology|No|Completed|February 1999|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9769|Samples With DNA|blood or bone marrow samples|Both|15 Years|N/A|No|Non-Probability Sample|Patients previously enrolled on CALGB-9665.|July 2015|July 3, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003931||208040|
NCT00003955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9802|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma|A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study||Children's Oncology Group||Completed|September 1999|October 2009|Actual|January 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|77|||Both|N/A|49 Years|No|||February 2014|February 12, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003955||208022|
NCT00003956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067155|Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I Study of Continuous Oral Administration of SCH 66336 and 5-Fluorouracil/Leucovorin (5FU/LV) in Patients With Advanced Cancer||National Cancer Institute (NCI)||Completed|April 1999|December 2009|Actual|January 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||December 2009|April 2, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003956||208021|
NCT00003982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16970|MEN-10755 in Treating Patients With Solid Tumors|Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every Week for 3 Consecutive Weeks, Followed by One Week's Rest||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003982||208001|
NCT00003861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067025|Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia|Molecular Genetic Features of Acute Lymphoblastic Leukemia||Alliance for Clinical Trials in Oncology||Withdrawn|April 1999|||||N/A|Interventional|Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003861||208099|
NCT00003976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16973|E7070 in Treating Patients With Solid Tumors|Phase I Study to Determine the Safety of E7070 in Patients With a Solid Tumor on a Single IV Infusion Repeated Every 3 Weeks||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|70 Years|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003976||208006|
NCT00003600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-979253|Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy|A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy||Alliance for Clinical Trials in Oncology|Yes|Completed|December 1998|January 2010|Actual|December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|344|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003600||208327|
NCT00003601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066674|Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome|A Phase II Double-Blind Study of Topical Tretinoin With or Without Oral 4-HPR (Fenretinide) in Patients With the Dysplastic Nevus Syndrome||National Cancer Institute (NCI)||Completed|September 1998|||March 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|38|||Both|18 Years|N/A|No|||March 2008|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003601||208326|
NCT00003885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067053|Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma|Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia||National Cancer Institute (NCI)||Active, not recruiting|November 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||June 2000|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003885||208078|
NCT00003865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067029|Toremifene in Treating Patients With Ovarian Cancer|Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary||National Cancer Institute (NCI)||Completed|July 1999|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2003|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003865||208095|
NCT00003907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067083|Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver|Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial||Eastern Cooperative Oncology Group|No|Completed|August 1999|August 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|November 1, 1999|Yes|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT00003907||208060|
NCT00003908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067086|S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Evaluation of the Combination of Docetaxel (Taxotere)/ Carboplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Southwest Oncology Group|Yes|Completed|November 1999|January 2007|Actual|June 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003908||208059|
NCT00003535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066582|Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma|Phase II Study of Antineoplastons A10 and AS2-1 in Children With High Grade Glioma||National Cancer Institute (NCI)||Active, not recruiting|August 1993|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||June 2009|July 14, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003535||208385|
NCT00003974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067177|Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma|An Evaluation of the Immunological Parameters Associated With a Skin-Test and Immunization of Lung and Mesothelioma Cancer Patients With Autologous Lung Tumor Associated Antigen: Characterization of the Patients' Cytolytic and Helper T Cell Reactivity for Identification of the Specific Antigen(s): A Pilot Study||Roswell Park Cancer Institute|Yes|Completed|August 1997|November 2000|Actual|June 1998|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|20 Years|70 Years|No|||March 2011|March 3, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003974||208007|
NCT00003968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02303|Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer|Phase II Study of Bryostatin-1 in Metastatic Renal Cell Carcinoma(Summary Last Modified 8/1999)||National Cancer Institute (NCI)||Completed|June 1999|||December 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2004|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003968||208011|
NCT00003842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067001|IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma|A Phase I Study of a Recombinant Chimeric Protein Composed of Circularly Permuted IL-4 and a Mutated Form of the Pseudomonas Exotoxin Termed IL-4(38-37)-PE38KDEL (IL-4 Toxin) for the Treatment of Recurrent Malignant Astrocytoma||National Cancer Institute (NCI)||Active, not recruiting|March 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 1999|December 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003842||208115|
NCT00003884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067052|Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer||Novartis||Completed|August 1998|January 2001|Actual|January 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|600|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003884||208079|
NCT00003916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22972-26991|Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma|Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1999|||December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|65 Years|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003916||208051|
NCT00003962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J9825 CDR0000067162|Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Dose Finding Study of Toxicity and Immunomodulatory Effects of Interleukin-2 Following Allogeneic Bone Marrow Transplantation in Patients at High Risk for Relapse||Sidney Kimmel Comprehensive Cancer Center||Completed|April 1998|June 2000|Actual|June 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||May 2014|May 1, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003962||208015|
NCT00003862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9904|Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer|A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach||Radiation Therapy Oncology Group|Yes|Completed|November 1999|||November 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2003|July 17, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003862||208098|
NCT00003870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1298.00|Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia|Radiolabeled BC8 (Anti-CD45) Antibody Combined With Cyclophosphamide and Total Body Irradiation Followed by HLA-matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Lymphocytic Leukemia||Fred Hutchinson Cancer Research Center||Completed|February 1999|November 2001|Actual|November 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|2 Years|55 Years|No|||March 2010|March 31, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003870||208091|
NCT00003871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067036|PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer|Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer||Eastern Cooperative Oncology Group|No|Completed|August 1999|||June 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|60|||Male|18 Years|N/A|No|||January 2010|January 26, 2010|November 1, 1999|Yes|Yes||||https://clinicaltrials.gov/show/NCT00003871||208090|
NCT00003970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02304|Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma|A Phase I Clinical Trial to Investigate the Correlation Between UGT1A1 Genotype and Irinotecan (CPT-11) Pharmacokinetics and Toxicity in Cancer Patients||National Cancer Institute (NCI)||Completed|January 1999|||October 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003970||208009|
NCT00003972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1316.00|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer|A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast Cancer||Fred Hutchinson Cancer Research Center||Completed|July 1998|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|280|||Both|18 Years|65 Years|No|||March 2010|March 31, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003972||208008|
NCT00003967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067168|Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma||Gynecologic Oncology Group||Completed|September 1999|||April 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Female|18 Years|N/A|No|||March 2008|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003967||208012|
NCT00003910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067089|Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia|A Phase II Study of Initial Treatment With Methotrexate in Large Granular Lymphocytic (LGL) Leukemia||Eastern Cooperative Oncology Group|No|Terminated|July 1999|March 2012|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||October 2012|October 6, 2015|November 1, 1999|Yes|Yes||No|October 16, 2012|https://clinicaltrials.gov/show/NCT00003910||208057|
NCT00003911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067090|S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases|A Phase II Pilot Study of Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases||Southwest Oncology Group|No|Terminated|July 1999|August 2007|Actual|August 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||January 2013|January 30, 2013|November 1, 1999|Yes|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00003911||208056|
NCT00003958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9803|Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma|Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma||Children's Oncology Group|Yes|Completed|September 2002|||October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|702|||Both|N/A|49 Years|No|||June 2013|June 13, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003958||208019|
NCT00003915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067095|Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer|Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment||University of Massachusetts, Worcester|Yes|Active, not recruiting|May 1999|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Male|N/A|120 Years|No|||February 2016|February 25, 2016|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003915||208052|
NCT00003985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-13972|KRN7000 in Treating Patients With Solid Tumors|Phase I Study of KRN7000 in Patients With Solid Tumor Treated With a Weekly Intravenous Administration Schedule||European Organisation for Research and Treatment of Cancer - EORTC||Withdrawn|September 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003985||207999|
NCT00003867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067031|Irinotecan and Capecitabine in Treating Patients With Solid Tumors|Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies||National Cancer Institute (NCI)||Active, not recruiting|March 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||April 2007|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003867||208094|
NCT00003914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067094|Dolastatin 10 in Treating Patients With Advanced Kidney Cancer|Phase II Study of Dolastatin-10 in Patients With Advanced Renal Cell Carcinoma||Mayo Clinic|Yes|Completed|August 1999|May 2009|Actual|August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003914||208053|
NCT00003859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067022|Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS|Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood||National Cancer Institute (NCI)||Completed|April 1992|April 2003|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|230|||Both|3 Years|16 Years|No|||April 2009|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003859||208101|
NCT00003926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997LS053|Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors|A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors||Masonic Cancer Center, University of Minnesota|Yes|Terminated|November 1998|August 2003|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Both|1 Year|45 Years|No|||August 2010|August 20, 2010|November 1, 1999|No|Yes|Withdrawn due to slow accrual|No||https://clinicaltrials.gov/show/NCT00003926||208045|
NCT00003981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16975|E7070 in Treating Patients With Solid Tumors|Phase I Study to Determine the Safety of E7070 in Patients With a Solid Tumor as a Single IV Infusion Weekly X 4, Repeated Every 6 Weeks||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003981||208002|
NCT00003989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16977|ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma|Phase II Trial With ISIS 3521/CGP 64128A in Patients With Malignant Melanoma and Non Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003989||207998|
NCT00003852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067015|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors|Phase II Study of Intensive Chemotherapy With Autologous Peripheral Blood Stem Cell Support in Patients With Cisplatin Resistant Germ Cell Tumors||National Cancer Institute (NCI)||Active, not recruiting|March 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|15 Years|N/A|No|||May 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003852||208108|
NCT00003898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067069|Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation|The Use of Supplemental Oral Glutamine (GLN) to Decrease Morbidity in Patients Undergoing Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Study||Roswell Park Cancer Institute|Yes|Completed|January 1999|January 2004|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|120|||Both|1 Year|21 Years|No|||February 2011|February 25, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003898||208067|
NCT00003863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9764|Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma|Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma||Alliance for Clinical Trials in Oncology|No|Completed|June 1999|May 2005|Actual|May 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|391|Samples With DNA|Tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with non-Hodgkin's lymphoma and previously enrolled on CALGB 59903,        59909, 10002 and 50103.|July 2015|July 14, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003863||208097|
NCT00003913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1330.00|Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease|A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation||Fred Hutchinson Cancer Research Center||Completed|December 1998|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|390|||Both|N/A|18 Years|No|||March 2010|March 31, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003913||208054|
NCT00003917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKF1598|Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer|An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy||Case Comprehensive Cancer Center|Yes|Completed|March 1999|November 2001|Actual|November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003917||208050|
NCT00003883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1322.00|Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation|A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients||Fred Hutchinson Cancer Research Center||Completed|October 1998|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|578|||Both|13 Years|N/A|No|||March 2010|March 31, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003883||208080|
NCT00003991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067196|Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia|Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission (CR)||National Cancer Institute (NCI)||Completed|July 1998|August 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|360|||Both|18 Years|N/A|No|||December 2011|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003991||207997|
NCT00003980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16981|BIBX 1382 in Treating Patients With Solid Tumors|Phase I and Pharmacokinetics Study to Determine the Safety of BIBX 1382 in Patients With a Solid Tumor on a Continuous Daily Oral Administration Schedule and After Single Oral and Intravenous Doses||European Organisation for Research and Treatment of Cancer - EORTC||Suspended|February 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003980||208003|
NCT00003920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD-986545|Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer|Pharmacokinetic/Dosimetry/MTNTD Study of 111In/90Y-2IT-BAD-m170 for Therapy in Metastatic Breast Cancer Patients With Post Therapy Support of Autologous Pretherapy Apheresed Peripheral Blood Stem Cells and Cyclosporin A Given for Suppression of HAMA Response||National Cancer Institute (NCI)||Active, not recruiting|April 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|55 Years|No|||November 2000|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003920||208049|
NCT00003984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-13981|Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome|Phase II Trial With a Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients With High Risk Primary Myelodysplastic Syndromes||European Organisation for Research and Treatment of Cancer - EORTC||Withdrawn|February 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003984||208000|
NCT00003925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067112|Combination Chemotherapy In Treating Patients With Advanced Cancer|Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 1998|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003925||208046|
NCT00003961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067160, J9852|Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes||Sidney Kimmel Comprehensive Cancer Center||Completed|April 1999|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||April 2014|April 16, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003961||208016|
NCT00003868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297.00|Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia|Radiolabeled BC8 (Anti-CD45) Antibody Combined With Cyclophosphamide and Total Body Irradiation Followed by HLA-matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome||Fred Hutchinson Cancer Research Center||Completed|February 1999|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|2 Years|55 Years|No|||August 2010|August 20, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003868||208093|
NCT00003897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO98601|Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma|Phase I Trial of Immunization Using Particle-Mediated Transfer of Genes for GP-100 and GM-CSF Into Uninvolved Skin of Patients With Melanoma (Summary Last Modified 7/1999)||University of Wisconsin, Madison||Completed|May 1999|December 2006|Actual|March 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003897||208068|
NCT00003860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067023|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer|Intensive Chemotherapy With Peripheral Blood Stem Cell Support for Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|60 Years|No|||December 1999|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003860||208100|
NCT00003933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9805|Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia|The Incidence and Prognostic Significance of P16 INK4A/ P15 INK4B Gene Alterations in Children With Relapsed ALL Treated on CCG-1941||Children's Oncology Group|No|Completed|April 1999|||April 2006|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|N/A|17 Years|No|||August 2014|August 6, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003933||208039|
NCT00003957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067156|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|A Phase II Trial of Multiple Cycles of Sequential High Dose Chemotherapy for Patients With Chemotherapy Sensitive Relapsed Non-Hodgkin's Lymphoma||Fox Chase Cancer Center||Completed|December 1998|August 2001|Actual|September 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|3|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003957||208020|
NCT00003959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-037|Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome|Vaccination of Patients With Myelodysplastic Syndrome Against Mutated RAS Proteins: A Pilot Trial||Memorial Sloan Kettering Cancer Center||Completed|June 1999|||December 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|1|||Both|17 Years|N/A|No|||January 2013|January 15, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003959||208018|
NCT00003556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02274|Vaccine Therapy in Treating Patients With Melanoma|Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) or a Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With Surgically Incurable Melanoma||National Cancer Institute (NCI)||Completed|January 1999|||May 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003556||208366|
NCT00003534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066581|Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003534||208386|
NCT00003778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02295|Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma|Phase II Trial of Dolastatin-10 in Patients With Previously Untreated Recurrent/Metastatic Sarcoma||National Cancer Institute (NCI)||Completed|April 1999|||July 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||September 2000|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003778||208168|
NCT00003532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066579|Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003532||208388|
NCT00003533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066580|Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|N/A|No|||April 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003533||208387|
NCT00003546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066601|Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer|Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas||Alliance for Clinical Trials in Oncology||Completed|September 1998|January 2006|Actual|December 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|43|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003546||208374|
NCT00003790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B942|Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome|Detection of Minimal Residual Disease in Children Receiving Therapy for AML or MDS||Children's Oncology Group|No|Completed|February 1995|September 2006|Actual|April 2002|Actual|N/A|Observational|N/A|||Actual|496|||Both|N/A|21 Years|No|Non-Probability Sample|Patients with acute myeloid leukemia or myelodysplastic syndrome (MDS) enrolled on the CCG        2961 AML treatment protocol.|August 2014|August 5, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003790||208157|
NCT00003585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM-0996C|Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer|A Phase I/II Pilot Study of a Novel Four Drug Regimen for the Treatment of Advanced Renal Cell Carcinoma: FUNIL-cRA||University of New Mexico|No|Completed|August 1996|August 2002|Actual|August 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|N/A|N/A|No|||December 2013|December 9, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003585||208341|
NCT00003587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066656|S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Randomized Phase II Trial of Carboplatin/Gemcitabine Followed By Paclitaxel or Cisplatin/Vinorelbine Followed by Docetaxel in Advanced Non-Small Cell Lung Cancer||Southwest Oncology Group|Yes|Completed|October 1998|January 2007|Actual|January 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003587||208340|
NCT00003545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01840|506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL)||National Cancer Institute (NCI)||Completed|August 1998|||March 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|16 Years|N/A|No|||April 2007|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003545||208375|
NCT00003762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-982452|Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Randomized Phase II Study of Docetaxel and Gemcitabine for Stage IIIB/IV Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|February 1999|May 2008|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00003762||208181|
NCT00003763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066889|Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer|A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors||National Cancer Institute (NCI)||Completed|January 1999|||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Female|18 Years|N/A|No|||April 1999|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003763||208180|
NCT00003769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9710-07; T98-0046|Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer|A Phase II Trial of Perillyl Alcohol in Patients With Resectable Pancreatic Cancer||Indiana University||Completed|February 1999|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2014|September 9, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003769||208175|
NCT00003582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-88191|Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer|Phase I/II Study to Evaluate Combined Hyperfractionated Radiation Therapy and 5-Fluorouracil, Cisplatin and Paclitaxel (Taxol) and Amifostine (WR 2721, Ethyol) in Stage III and IV Inoperable Head and Neck Carcinomas||University of Miami Sylvester Comprehensive Cancer Center||Completed|May 1988|December 1996|Actual|December 1996|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003582||208344|
NCT00003787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-980919|Women's Healthy Eating and Living Study|Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study||University of California, San Diego|Yes|Active, not recruiting|March 1995|July 2016|Anticipated|March 2007|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|3000|Samples With DNA|Serum, plasma, buffy coat, RBC, DNA at five time periods|Female|18 Years|70 Years|No|Non-Probability Sample|Women who were diagnosed with early-stage breast cancer within the previous 4 years, and        are between the ages of 18-74|May 2014|May 20, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003787||208160|
NCT00003768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILEX1Y98|Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors|A Phase I Pharmacokinetic Study of Single Dose Intravenous CA4P in Patients With Advanced Cancer||Case Comprehensive Cancer Center|Yes|Completed|September 1998|July 2001|Actual|July 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00003768||208176|
NCT00003575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02276|Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma|A Randomized Pre-Phase II Trial of Interleukin-2, Interleukin-12, or No Additional Therapy Following Response to Ifosfamide/Etoposide Chemotherapy for Refractory HIV-Associated Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|January 1999|||April 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||October 2002|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003575||208349|
NCT00003544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-057|Irinotecan in Treating Patients With Metastatic Colorectal Cancer|A Phase II Trial of Preoperative Irinotecan (CPT-11) in Patients With High-Risk Resectable Metastatic Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|June 1998|March 2001|Actual|March 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003544||208376|
NCT00003589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08975|Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|Randomized Study With New Combination Chemotherapies in Advanced Non-Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 1998|||July 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|450|||Both|18 Years|75 Years|No|||March 2012|March 5, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003589||208338|
NCT00003716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066825|Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy|Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression||National Cancer Institute (NCI)||Active, not recruiting|March 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|3 Years|70 Years|No|||June 2002|March 17, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003716||208224|
NCT00003781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066913|Docetaxel in Treating Patients With Stage IV Prostate Cancer|Phase II Study of Weekly Docetaxel (Taxotere) in Hormone Refractory Metastatic Prostate Cancer||OHSU Knight Cancer Institute|Yes|Completed|December 1998|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|25|||Male|18 Years|N/A|No|||May 2012|May 24, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003781||208165|
NCT00003553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066610|Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation for Metastatic Renal Cell Carcinoma Followed by Allogeneic T-Cell Infusion as Adoptive Immunotherapy||National Cancer Institute (NCI)||Recruiting|January 1999|||December 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|80|||Both|18 Years|80 Years|No|||June 2009|June 23, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003553||208369|
NCT00003804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066948|Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor|Nephroblastoma Clinical Trial and Study||National Cancer Institute (NCI)||Active, not recruiting|July 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|350|||Both|N/A|17 Years|No|||April 2012|June 23, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003804||208144|
NCT00003602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066675|Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia|A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission||National Cancer Institute (NCI)||Active, not recruiting|March 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|55 Years|N/A|No|||January 2001|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003602||208325|
NCT00003603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066676|Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma|A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|March 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|660|||Both|18 Years|N/A|No|||February 2001|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003603||208324|
NCT00003598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066670|UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia|Retinoids and Intermediate Biomarkers for CIN II and III: Pilot Trial|IRB 1996-0189|University of Michigan Cancer Center|Yes|Completed|January 1999|November 2009|Actual|March 2001|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|180|||Female|14 Years|N/A|No|||September 2010|September 20, 2010|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003598||208329|
NCT00003798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066941, J9840|Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery|Phase I Study Involving Gadolinium Texaphyrin (NSC 695238) in Patients With Pancreatic and Periampullary Adenocarcinoma Receiving Radiotherapy for Unresectable Disease||Sidney Kimmel Comprehensive Cancer Center||Completed|April 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003798||208150|
NCT00003771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066897|Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer|Protocol for Randomized Clinical Study Concerning Hormonal Replacement Therapy (HRT) After Previous Radical Breast Cancer Treatment||National Cancer Institute (NCI)||Completed|September 1997|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|1300|||Female|N/A|N/A|No|||July 2001|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003771||208174|
NCT00003772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-15982|Quality-of-Life Assessment in Patients With Ovarian Cancer|An International Field Study of the Reliability and Validity of a Disease-Specific Questionnaire Module (the QLQ-OV28) in Assessing the Quality of Life of Patients With Ovarian Cancer||European Organisation for Research and Treatment of Cancer - EORTC|No|Completed|January 1999|February 2003|Actual|August 2001|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|372|||Female|18 Years|N/A|No|Non-Probability Sample|ovarian cancer|August 2012|August 24, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003772||208173|
NCT00003551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066608|Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer|A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|August 1998|September 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2000|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003551||208371|
NCT00003594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9741|Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum||Alliance for Clinical Trials in Oncology|No|Completed|October 1998|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1691|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003594||208333|
NCT00003595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02279|Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma|Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|January 1999|||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||May 2007|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003595||208332|
NCT00003543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-056|Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|Phase I Study of Combination Immunochemotherapy in Patients With Advanced Colorectal Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|June 1998|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003543||208377|
NCT00003552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066609|Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma|Phase I/II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation Followed by Allogeneic T-cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Terminated|January 1999|October 2002|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|60 Years||||December 2001|April 27, 2015|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00003552||208370|
NCT00003782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-30|Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes|A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes||NSABP Foundation Inc|Yes|Completed|March 1999|December 2012|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5351|||Female|18 Years|N/A|No|||January 2013|January 11, 2013|November 1, 1999|Yes|Yes||No|August 24, 2012|https://clinicaltrials.gov/show/NCT00003782||208164|
NCT00003541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-045|Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma|High Dose Combined Modality Therapy With Peripheral Blood Progenitor Cell Transplantation as Primary Treatment for Patients With Mantle Cell Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|June 1998|July 2006|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003541||208379|
NCT00003542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-052|Interferon Alfa in Treating Patients With Advanced Kidney Cancer|Phase I/II Study of Subcutaneous Administration of Pegylated-Interferon Alpha-2A (RO 25-8310) in Previously Untreated Patients With Locally Advanced or Metastatic Renal Cell Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|May 1998|April 2004|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003542||208378|
NCT00003554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF-IRB-2603|Rituximab in Treating Patients With Multiple Myeloma|Rituxan in the Management of Multiple Myeloma||National Cancer Institute (NCI)||Completed|November 1998|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2008|July 17, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003554||208368|
NCT00003779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 06/98|Biological Therapy in Treating Patients With Bladder Cancer|A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ||Swiss Group for Clinical Cancer Research|Yes|Completed|November 1998|June 2010|Actual|June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||May 2013|May 16, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003779||208167|
NCT00003783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9806|Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia|ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study||Children's Oncology Group|Yes|Completed|March 1999|March 2007|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|N/A|17 Years|No|||July 2014|July 24, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003783||208163|
NCT00003604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066679|Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery|A Multi-Center Adjuvant Trial of Outpatient Moderate-Dose Bolus Interleukin-2 for Renal Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|N/A|No|||September 2000|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003604||208323|
NCT00003560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066624|Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|May 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||September 2003|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003560||208363|
NCT00003811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9749|Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors|High-Dose Cisplatin, Etoposide and Bleomycin (HD-PEB) Combined With Amifostine in Children With High-Risk Malignant Germ Cell Tumors - A POG Pilot Study||Children's Oncology Group||Completed|April 2000|September 2007|Actual|October 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|27|||Both|N/A|14 Years|No|||July 2013|July 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003811||208139|
NCT00003597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09717|Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors|A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors||Children's Oncology Group||Completed|November 1998|September 2005|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Both|1 Year|21 Years|No|||July 2014|July 23, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003597||208330|
NCT00003558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT-KWF-CKVO-9801|Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin|A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|140|||Both|18 Years|N/A|No|||February 2003|August 6, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003558||208364|
NCT00003810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066955|Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas|A Phase II Study of Gemcitabine and Docetaxel in Pancreatic Adenocarcinoma||Eastern Cooperative Oncology Group||Completed|April 1999|||May 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 22, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003810||208140|
NCT00003578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066645|High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma|A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL||National Cancer Institute (NCI)||Active, not recruiting|January 1993|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|16 Years|65 Years|No|||May 2007|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003578||208346|
NCT00003580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTENN-6507|Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer|Phase II Study - Efficacy of Amifostine in Alleviating Toxicity Associated With Targeted Supradose Cisplatin and Concomitant Radiation Therapy (RADPLAT) in Head and Neck Cancer||National Cancer Institute (NCI)||Completed|June 1998|May 2004|Actual|||Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2006|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003580||208345|
NCT00003784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066917|S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas||Southwest Oncology Group|Yes|Completed|May 1999|||January 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003784||208162|
NCT00003561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066625|Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|Granulocyte-Macrophage Colony Stimulating Factor (Rhu-GM-CSF) With Interferon-Alpha (IFN-alpha) for Chronic Myeloid Leukemia||Sidney Kimmel Comprehensive Cancer Center||Terminated|February 1998|August 2010|Actual|October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||April 2011|July 19, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003561||208362|
NCT00003557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9409|Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer|A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer||University of Chicago|No|Completed|January 1999|August 2003|Actual|June 2000|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003557||208365|
NCT00003577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066644|Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer|National Breast Cancer Study of Epirubicin + CMF v Classical CMF Adjuvant Therapy||National Cancer Institute (NCI)||Completed|March 1996|September 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Female|N/A|N/A|No|||February 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003577||208347|
NCT00003777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066906|Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer|A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||November 2002|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003777||208169|
NCT00003592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066662|Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer|Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|September 1998|||August 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|230|||Both|18 Years|N/A|No|||January 2009|January 28, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003592||208335|
NCT00003593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2971|Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome|Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study||Children's Oncology Group|Yes|Completed|June 1999|April 2012|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Both|N/A|21 Years|No|||June 2013|June 26, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003593||208334|
NCT00003576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066643|Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery|Surgery and Adjuvant Radiotherapy Versus Concurrent Chemo-Radiotherapy for Resectable (Non-Metastatic) Stage III/IV Head and Neck Squamous Cell Cancer||National Cancer Institute (NCI)||Completed|January 1997|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|N/A|N/A|No|||April 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003576||208348|
NCT00003588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02277|Gene Therapy in Treating Patients With Ovarian Cancer|A Phase I Study of Ad-p53 (NSC# 683550) for Patients With Platinum- and Paclitaxel-Resistant Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Completed|September 1998|||March 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||June 2002|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003588||208339|
NCT00003590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066659|S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma|Phase II Study of Hydroxyurea for Unresectable Meningioma||Southwest Oncology Group|No|Completed|November 1998|July 2011|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|120 Years|No|||September 2015|September 28, 2015|November 1, 1999|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00003590||208337|Early termination leading to fewer than expected subjects analyzed. With 28 eligible patients estimate of response probability can be estimated to within +/- 19%.
NCT00003789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01843|Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg|A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion and Melphalan With and Without Tumor Necrosis Factor in Patients With Localized Advanced Extremity Melanoma||National Cancer Institute (NCI)||Completed|March 1999|||January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||June 2013|July 15, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003789||208158|
NCT00003536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-BR-10|Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer|Phase II Randomized Study of Methotrexate With or Without Antineoplaston A10 Capsules in Women With Advanced Breast Cancer||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||December 2006|July 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003536||208384|
NCT00003583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066651|Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer|A Phase II Trial Using Amifostine as a Chemo/Radio Protective Agent in the Treatment of Limited Stage Small-Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 1997|||||Phase 2|Interventional|Primary Purpose: Supportive Care|||Anticipated|20|||Both|18 Years|N/A|No|||May 2006|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003583||208343|
NCT00003549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066606|S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer|A Phase II Trial of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)||Southwest Oncology Group|Yes|Completed|October 1998|January 2003|Actual|September 2001|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003549||208372|
NCT00003591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9812|Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer|A Phase II Trial of External Irradiation (50.4 GY) and Weekly Paclitaxel (Taxol) for Non-Metastatic, Unresectable Pancreatic Cancer||Radiation Therapy Oncology Group|Yes|Completed|November 1998|October 2005|Actual|June 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003591||208336|
NCT00003537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066585|Antineoplaston Therapy in Treating Patients With Residual or Recurrent Anaplastic Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Anaplastic Astrocytoma||National Cancer Institute (NCI)||Recruiting|April 1995|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003537||208383|
NCT00003786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9635|Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase II Trial of MGI-114 (NSC# 683863) Administered as a 5-Minute Infusion Daily for Five Days Every 4 Weeks in Patients With Previously Untreated Advanced Colorectal Cancer||University of Chicago|No|Withdrawn|April 1999|November 2000|Actual|November 2000|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|November 1, 1999|No|Yes|NO participants|No||https://clinicaltrials.gov/show/NCT00003786||208161|
NCT00003538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066589, J9711|Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation|Stem Cell Augmented, Elutriated Grafts for Allogeneic Bone Marrow Transplantation||Sidney Kimmel Comprehensive Cancer Center||Completed|March 1997|May 2004|Actual|May 2004|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|N/A|65 Years|No|||May 2014|May 1, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003538||208382|
NCT00003539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-028|Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer|Phase II Study of Weekly 1-Hour Paclitaxel (Taxol) Plus Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in the Treatment of Patients With Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 1998|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003539||208381|
NCT00003540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-030|Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel|Phase II Study of Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer Previously Treated With Adriamycin and Taxol||Memorial Sloan Kettering Cancer Center||Completed|June 1998|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003540||208380|
NCT00003780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066912|Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas|An Open Label Randomized Trial Comparing the Safety and Efficacy of Systemic Chemotherapy (Gemcitabine) to Immunotherapy (CYTOIMPLANT - Intra Tumor Implants of Allogeneic Peripheral Blood Mononuclear Cells Sensitized Against Patient Alloantigens by Mixed Lymphocyte Culture) as First Line Therapy for Patients With Unresectable Locally Advanced, and Metastatic Pancreatic Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||May 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003780||208166|
NCT00003599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-078|Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer|A Randomized Study of the Effect of Alpha-tocopherol (AT) on 13-cis-retinoic Acid (13-cRA) Toxicity in a Preliminary Chemoprevention Trial in Former and Current Smokers||M.D. Anderson Cancer Center|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|November 1, 1999||No|Withdrawn study.|No||https://clinicaltrials.gov/show/NCT00003599||208328|
NCT00003788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066927|Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas|Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors||National Cancer Institute (NCI)||Active, not recruiting|April 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|270|||Both|18 Years|N/A|No|||September 2003|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003788||208159|
NCT00004022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067241|Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma|Immunotherapy for Malignant Melanoma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 1997|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004022||207973|
NCT00004028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065129|Carmustine in Treating Patients With Recurrent Malignant Glioma|PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA||National Cancer Institute (NCI)||Completed|September 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 1999|February 6, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004028||207969|
NCT00004041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066871|Gene Therapy in Treating Patients With Recurrent Malignant Gliomas|Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas||National Cancer Institute (NCI)||Completed|March 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|February 6, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004041||207958|
NCT00004146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03011|Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM|Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme||National Cancer Institute (NCI)|Yes|Completed|March 2000|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||April 2015|May 5, 2015|December 10, 1999|Yes|Yes||No|March 13, 2015|https://clinicaltrials.gov/show/NCT00004146||207869|
NCT00004050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCL-1102-202|Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer|Phase II Study Evaluating the Safety and Efficacy of Neoadjuvant Leuvectin Immunotherapy for the Treatment of Prostate Cancer||Vical|No|Terminated|June 1999|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||July 2014|July 25, 2014|December 10, 1999|Yes|Yes|Development in prostate cancer indication halted|No||https://clinicaltrials.gov/show/NCT00004050||207950|
NCT00004136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID97-328|Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer|A Phase II Study of Radiofrequency Ablation of Unresectable Liver Tumors||M.D. Anderson Cancer Center|No|Completed|November 1999|January 2006|Actual|April 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|N/A|N/A|No|||July 2012|July 27, 2012|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004136||207878|
NCT00004058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5986; CDR0000067255|12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder|Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders||Rutgers, The State University of New Jersey|Yes|Terminated|December 1998|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 25, 2010|December 10, 1999|||At this time it is felt that we will not gain further information from an additional patients.|No||https://clinicaltrials.gov/show/NCT00004058||207943|
NCT00004059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-024|Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors|A Phase I Study of the Cyclin-Dependent Kinase (CDK)/Protein Kinase C (PKC) Inhibitor UCN-01 (NSC 638850) in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|July 1999|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004059||207942|
NCT00004084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067295|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immu-LL2: Treatment With 90Y-hLL2 IgG||Garden State Cancer Center at the Center for Molecular Medicine and Immunology||Completed|April 1998|||May 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004084||207918|
NCT00003701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066808|Combination Chemotherapy in Treating Patients With Bladder Cancer|A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse||National Cancer Institute (NCI)||Completed|March 1999|||August 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|490|||Both|N/A|N/A|No|||February 2009|November 2, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003701||208239|
NCT00004080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067291|Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors|Assessment of the Safety and Transduction Efficiency of SCH58500, An Adenoviral Vector p53 Delivery System, to Patients With Recurrent Malignant Brain Tumors||National Cancer Institute (NCI)||Completed|December 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2001|February 6, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004080||207922|
NCT00004109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID97-335|Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma|A Phase I Study of Preoperative Concurrent Chemoradiation for High-Risk Extremity and Trunk Soft Tissue Sarcomas||M.D. Anderson Cancer Center|No|Completed|March 1998|April 2011|Actual|September 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|16 Years|N/A|No|||August 2012|August 1, 2012|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004109||207894|
NCT00004110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-IRB-99033|Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma|Monoclonal Antibody 3F8 and Oral Etoposide for the Treatment of Neuroblastoma||Memorial Sloan Kettering Cancer Center||Completed|August 1999|||September 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2013|October 30, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004110||207893|
NCT00004032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02255|Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer|Intraperitoneal (IP) Autologous Therapeutic Tumor Vaccine AUT-OV-ALVAC-h.B7.1 Plus IP rIFN-gamma for Patients With Ovarian Cancer. A Pilot Study||National Cancer Institute (NCI)||Completed|October 1997|||April 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|N/A|N/A|No|||January 2013|January 22, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004032||207965|
NCT00004089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU V96N3|Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer|A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer||National Cancer Institute (NCI)||Completed|August 1999|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|80 Years|No|||January 2011|July 9, 2013|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004089||207913|
NCT00004024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067243|Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma|Immunotherapy for Malignant Glioma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 1997|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004024||207972|
NCT00003704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-984652|Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer|Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis||Alliance for Clinical Trials in Oncology|No|Completed|April 1999|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003704||208236|
NCT00003705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066813|BMS-184476 in Treating Patients With Advanced Solid Tumors|Phase I Study of BMS-184476 in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|November 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2007|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003705||208235|
NCT00004054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9902|Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer|A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer||Radiation Therapy Oncology Group|Yes|Completed|January 2000|November 2013|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Male|18 Years|N/A|No|||December 2014|December 24, 2014|December 10, 1999|Yes|Yes||No|December 24, 2014|https://clinicaltrials.gov/show/NCT00004054||207947|
NCT00004128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067356|Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia|The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP||National Cancer Institute (NCI)||Active, not recruiting|September 1999|||January 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Both|15 Years|60 Years|No|||April 2008|December 22, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004128||207882|
NCT00004090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU CINJ98X1|Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors|Gemcitabine (10 mg/m2/Min) and Cisplatin: A Phase I Study||National Cancer Institute (NCI)||Completed|August 1999|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2011|July 9, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004090||207912|
NCT00003951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067147|DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Carcinoma of the Pancreas||Daiichi Sankyo Inc.||Completed|June 1999|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|37|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003951||208025|
NCT00003688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066791|Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia|Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia||Gynecologic Oncology Group||Completed|October 1999|||September 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|12 Years|50 Years|No|||December 2003|June 7, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003688||208250|
NCT00004145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9581|Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Allogeneic Peripheral Blood Stem Cell Transplantation Using a Non-Myeloablative Preparative Regimen for Patients With Hematologic Malignancies||University of Chicago|No|Completed|November 1998|August 2011|Actual|November 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|60 Years|No|||March 2014|March 6, 2014|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004145||207870|
NCT00004025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067245|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma|Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of Autologous Dendritic Cells Transduced With Adenoviruses Encoding the MART-1 and gp100 Melanoma Antigens Administered With or Without Low Dose Recombinant Interleukin-2 (rIL-2) in Patients With Stage IV Melanoma||National Cancer Institute (NCI)||Active, not recruiting|March 1999|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||July 2002|January 3, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004025||207971|
NCT00003690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066793|Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of Flavopiridol in Combination With Cisplatin in Patients With Advanced Malignancies||Mayo Clinic|Yes|Completed|December 1998|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003690||208249|
NCT00004087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067300|Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer|Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 in Advanced Metastatic Colorectal Cancer and Pancreatic Cancers Using Autologous Peripheral Blood Stem Cell Rescue (PBSCR) to Control Myelotoxicity||Garden State Cancer Center at the Center for Molecular Medicine and Immunology|No|Completed|March 1997|||May 2001|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||June 2011|June 21, 2011|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004087||207915|
NCT00004013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1338.00|Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer|Treatment of Refractory Stage IV Metastatic Breast Cancer With Weekly Paclitaxel or Weekly Paclitaxel and Herceptin Following Autologous/Syngeneic Stem Cell Transplant||Fred Hutchinson Cancer Research Center||Completed|January 1999|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|N/A|No|||March 2010|March 31, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004013||207978|
NCT00004040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066763|Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy|Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma Whose Disease Has Been Controlled With Chemotherapy: Rituximab Anti-CD20 Monoclonal Antibody or Interferon Alpha 2-b as Maintenance Therapy||Hoag Memorial Hospital Presbyterian|No|Withdrawn|June 1998|June 1999|Actual|June 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||August 2015|August 17, 2015|December 10, 1999||No|no patient accruals|No||https://clinicaltrials.gov/show/NCT00004040||207959|
NCT00004033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066141|Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma|Phase II Clinical Study of a Liposome Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally in Patients With Malignant Pleural Mesothelioma||New York University School of Medicine||Completed|September 1998|||May 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004033||207964|
NCT00004038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02273|Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer|Pilot Study of p53 Intralesional Gene Therapy With Chemotherapy in Breast Cancer||National Cancer Institute (NCI)||Completed|January 1999|||May 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2001|February 6, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004038||207961|
NCT00004049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067233|SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I and Pharmacokinetic Study of SR-45023A Administered Once Every 7 Days||National Cancer Institute (NCI)||Active, not recruiting|April 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||May 2001|July 23, 2008|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004049||207951|
NCT00004060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067258|Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane and Topotecan||Daiichi Sankyo Inc.||Completed|July 1999|September 2000|Actual|September 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2012|May 15, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004060||207941|
NCT00004147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067379|COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors|A Phase I/II Study of Col-3 Administered on a Continuous Daily Oral Schedule in Patients With Recurrent High-Grade Astrocytoma||National Cancer Institute (NCI)||Completed|July 2000|November 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2003|June 20, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004147||207868|
NCT00004142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID98-035|Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver|Phase II Study of Radiofrequency Ablation of Colorectal Cancer Liver Metastases Combined With Post-Ablation Hepatic Arterial Infusion of Floxuridine Alternating With 5-Fluorouracil||M.D. Anderson Cancer Center|No|Completed|September 1999|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004142||207873|
NCT00004047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067149|Chemotherapy in Treating Patients Who Have Hematologic Cancer|A Phase I Study of Intravenous DX-8951f in Patients With Advanced Myelodysplastic Syndromes, Refractory Acute Leukemia, Refractory or Transformed Chronic Lymphocytic Leukemia, and Chronic Myelogenous Leukemia in Blastic Phase||Daiichi Sankyo Inc.||Completed|June 1999|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2012|May 15, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004047||207953|
NCT00004048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067172|Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer|Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin||Garden State Cancer Center at the Center for Molecular Medicine and Immunology||Completed|September 1998|May 2002|Actual|May 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|16 Years|80 Years|No|||June 2011|June 21, 2011|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004048||207952|
NCT00004079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00028|Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Trial of Sarcosinamide Nitrosourea (SarCNU) in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|August 1999|||September 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004079||207923|
NCT00004086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067298|Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer|A Phase I Trial of a Combined Regimen of Chemotherapy and 90Y-Labeled, Humanized LL2 (Anti-CD22) Antibody With Peripheral Stem Cell Rescue for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|June 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2001|June 6, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004086||207916|
NCT00004076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067285|PNU 166148 in Treating Patients With Metastatic Solid Tumors|A Phase I Study to Evaluate MAG-CPT (PNU 166148) Given as One Single Intravenous Administration Every 4 Weeks in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|June 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||November 2000|December 18, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004076||207926|
NCT00004143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008771|Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes|Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes||Duke University|Yes|Completed|September 1999|June 2009|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|December 10, 1999|Yes|Yes||No|September 6, 2013|https://clinicaltrials.gov/show/NCT00004143||207872|Small number of subjects analyzed
NCT00004112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|447-97|Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma|A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma||University of Nebraska|No|Completed|September 1999|March 2003|Actual|December 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|19 Years|N/A|No|||April 2010|April 13, 2010|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004112||207892|
NCT00004113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-019|Temozolomide in Treating Patients With Recurrent Malignant Glioma|A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma||Memorial Sloan Kettering Cancer Center||Completed|June 1999|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004113||207891|
NCT00004132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMGEN-KGF-980231-03|Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Patients With Hematologic Malignancies Undergoing Total Body Irradiation (TBI) and High-Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation||National Cancer Institute (NCI)||Completed|January 2000|May 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|12 Years|65 Years|No|||June 2007|June 25, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004132||207880|
NCT00004051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067246|Irinotecan in Treating Patients With Advanced Solid Tumors|A Phase I Study to Evaluate Orally Administered Irinotecan HCL (CPT-11) Given as a Powder-Filled Capsule Formulation Daily for 14 Days Every Three Weeks in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|August 1998|December 2009|Actual|July 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||December 2009|December 18, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004051||207949|
NCT00004052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-012|Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia|Phase II, Multicenter Vaccination of Patients With Chronic Myelogenous Leukemia With a Multivalent Tumor Specific Breakpoint Peptide Vaccine||Memorial Sloan Kettering Cancer Center||Completed|March 1999|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|16 Years|N/A|No|||June 2013|June 24, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004052||207948|
NCT00003998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067208|Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer|A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Completed|October 1998|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1050|||Female|18 Years|N/A|No|||October 2007|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003998||207990|
NCT00004072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1A96|O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma|Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU in Patients With Multiple Myeloma||Case Comprehensive Cancer Center|Yes|Completed|September 1999|September 2004|Actual|August 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|N/A|No|||June 2010|June 9, 2010|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004072||207930|
NCT00004078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9761|Irinotecan in Treating Children With Refractory Solid Tumors|Phase II Trial of Irinotecan in Children With Refractory Solid Tumors||Children's Oncology Group|Yes|Completed|October 1999|||October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|181|||Both|1 Year|21 Years|No|||June 2013|June 13, 2013|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004078||207924|
NCT00004115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067341|Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy|Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2003|September 16, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004115||207889|
NCT00004036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066347|Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer|Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells||National Cancer Institute (NCI)||Active, not recruiting|November 1997|||||Phase 1|Interventional|Primary Purpose: Supportive Care|||Anticipated|30|||Both|18 Years|N/A|No|||May 2007|December 18, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004036||207963|
NCT00004068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067271|Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor|Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide||St. Jude Children's Research Hospital||Completed|March 1999|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|53|||Both|3 Years|21 Years|No|||October 2011|October 3, 2011|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004068||207933|
NCT00004070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067274|Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer|A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)||National Cancer Institute (NCI)||Active, not recruiting|July 1999|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|34|||Both|18 Years|N/A|No|||January 2001|February 6, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004070||207932|
NCT00004071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUGEN-SU101.035|Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer|A Randomized, Open-Label Phase II/III Study of SU101 Plus Mitoxantrone/Prednisone Compared to Mitoxantrone/Prednisone Alone in Patients With Hormone-Refractory Prostate Cancer||Pfizer||Completed|August 1999|September 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||September 2012|September 10, 2012|December 10, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00004071||207931|
NCT00004026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067257|CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy|A Phase II Study of CT-2584 Mesylate in Patients With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|80|||Male|18 Years|N/A|No|||June 2007|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004026||207970|
NCT00004074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01398|Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu|A Phase I Trial of Herceptin and Interleukin-12||National Cancer Institute (NCI)||Completed|August 1999|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004074||207928|
NCT00004083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067294|Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer|A Phase II Pilot Study of SPI-77 (Stealth Liposomal Cisplatin) in Patients With Recurrent Platinum-Sensitive Ovarian Cancer||New York University School of Medicine||Completed|February 1999|||December 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2011|March 25, 2011|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004083||207919|
NCT00004129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067357|Phosphorus 32 in Treating Patients With Glioblastoma Multiforme|Phase I/II Study of Interstitial Colloidal 32P for the Treatment of Recurrent Malignant Central Nervous System Tumors and Primary Central Nervous System Tumors With Poor Prognostic Factors||National Cancer Institute (NCI)||Recruiting|September 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||April 2008|September 16, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004129||207881|
NCT00004039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066762|Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma|Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma||Hoag Memorial Hospital Presbyterian|No|Withdrawn|June 1998|January 2000|Actual|January 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||August 2015|August 17, 2015|December 10, 1999||No|No patient accruals|No||https://clinicaltrials.gov/show/NCT00004039||207960|
NCT00004006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067217|Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma|Treatment for Extrachoroidal or Metastatic Retinoblastoma||St. Jude Children's Research Hospital||Completed|November 1997|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|4|||Both|N/A|15 Years|No|||October 2011|October 3, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004006||207984|
NCT00004077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067286|Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer|A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors||National Cancer Institute (NCI)||Completed|May 1996|July 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Male|16 Years|64 Years|No|||January 2001|December 18, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004077||207925|
NCT00004144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067375|Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer|Phase I Study of Bryostatin 1 and Gemcitabine (Gemzar)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 2000|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004144||207871|
NCT00004030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065641|VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin|A Phase I/II Study of the Pharmacokinetics, Tolerability and Safety of Administration of VX-853 to Patients Receiving Single Agent Therapy With Doxorubicin HCI||Georgetown University|No|Completed|March 1996|January 2001|Actual|January 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||January 2001|March 22, 2011|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004030||207967|
NCT00004031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065658|SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma|SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups||Southwest Oncology Group|Yes|Completed|July 1997|||July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Both|15 Years|65 Years|No|||May 2013|May 22, 2013|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004031||207966|
NCT00004037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066369|Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer|Evaluation of Docetaxel in Recurrent, Platinum Resistant, Refractory and Paclitaxel Refractory Ovarian Cancer and Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Terminated|June 1998|||April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2003|April 10, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004037||207962|
NCT00004085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067297|Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer|Phase I/II Trial of High-Dose Radioimmunotherapy With a 90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody for the Treatment of Stage IV Breast Cancer||Garden State Cancer Center at the Center for Molecular Medicine and Immunology||Completed|May 1998|||May 2002|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004085||207917|
NCT00003977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067180|Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer|A Phase I Study of Immunization With Alternating Human Papillomavirus E7 Lipopeptide Epitope Vaccine and Dendritic Cells Presenting the E7 Epitope for the Treatment of Recurrent or Persistent Cervical Cancer||National Cancer Institute (NCI)||Completed|November 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2003|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003977||208005|
NCT00003950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9824|Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer|A Phase II Trial of Irinotecan (CPT-11) and Cyclosporine in Patients With 5-FU Refractory Advanced Colorectal Cancer||University of Chicago|No|Completed|January 2000|January 2005|Actual|December 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003950||208026|
NCT00003935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9836|Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma|Treatment of Children With Diffuse Intrinsic Brain Stem Glioma With Standard Dose Irradiation and Vincristine Plus Oral VP-16, A POG Pilot Study||Children's Oncology Group|Yes|Completed|September 1999|March 2007|Actual|October 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|3 Years|21 Years|No|||July 2014|July 25, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003935||208037|
NCT00003941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30974|Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer|A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1999|||June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|222|||Male|16 Years|50 Years|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003941||208032|
NCT00003723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066832|S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery|Phase II Study of Gemcitabine and Cisplatin in Unresectable Malignant Mesothelioma||Southwest Oncology Group|Yes|Completed|February 1999|December 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003723||208218|
NCT00003746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 32/98|Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia|Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia||Swiss Group for Clinical Cancer Research|Yes|Completed|September 1998|November 2010|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003746||208196|
NCT00003953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2198|Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer|A Phase II Study of Preoperative Dose-Dense Chemotherapy With Sequential Doxorubicin and Docetaxel for Initial Treatment of Operable and Inoperable Stage II-IIIB Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|February 1999|January 2013|Actual|November 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||January 2013|January 25, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003953||208024|
NCT00003954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1383.00|Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma|Allogeneic Stem Cell Transplantation For Multiple Myeloma: A Two Step Approach To Reduce Toxicity Involving High Dose Melphalan and Autologous Stem Cell Transplant Followed By PBSC Allografting After Low Dose TBI||Fred Hutchinson Cancer Research Center||Active, not recruiting|March 1999|||December 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|65 Years|No|||May 2015|May 19, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003954||208023|
NCT00003742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-100|Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Trial of Paclitaxel, Cisplatin, and Irinotecan in Patients With Advanced Solid Tumor Malignancies||Memorial Sloan Kettering Cancer Center||Completed|October 1998|August 2001|Actual|August 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003742||208200|
NCT00003748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066868|Irinotecan in Treating Patients With Esophageal or Stomach Cancer|Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia||Jonsson Comprehensive Cancer Center|No|Completed|August 1998|January 2005|Actual|June 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003748||208194|
NCT00003727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066839|Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia|Autotransplantation for Chronic Myelogenous Leukemia (CML) Followed by Immunotherapy With Ex-Vivo Expanded Autologous T Cells||University of Maryland||Completed|March 1999|February 2008|Actual|March 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|22|||Both|N/A|N/A|No|||September 2009|September 23, 2009|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003727||208214|
NCT00003728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066840|Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma|The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||May 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1500|||Both|N/A|17 Years|No|||June 2009|January 20, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003728||208213|
NCT00003696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066803|Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer|Phase III Study of Cyclophosphamide, Doxorubicin and Etoposide Compared to Carboplatin and Taxol in Patients With Extensive Disease Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|250|||Both|18 Years|N/A|No|||November 2001|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003696||208243|
NCT00003697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066804|Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors|A Phase I Trial of 5, 6 Dimethyl Xanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors||National Cancer Institute (NCI)||Completed|October 1995|December 1998|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|3|||Both|18 Years|75 Years|No|||June 2009|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003697||208242|
NCT00003857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-98-04|Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ|Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast||Radiation Therapy Oncology Group|Yes|Active, not recruiting|December 1999|||February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|636|||Female|26 Years|120 Years|No|||November 2015|November 14, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003857||208103|
NCT00003858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-99801|Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence|A Phase II Trial of Adjuvant Mitoxantrone (NSC #301739) for High Risk Patients Following Radical Prostatectomy||Alliance for Clinical Trials in Oncology||Withdrawn||||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999||No|The study was not activated.|No||https://clinicaltrials.gov/show/NCT00003858||208102|
NCT00003928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3897|Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Utilizing Gemcitabine and Cisplatinum in Patients With Renal Cell Carcinoma||Case Comprehensive Cancer Center|Yes|Completed|January 1999|April 2006|Actual|February 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003928||208043|
NCT00003703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066810|Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetics Study of SarCNU in Patients With Advanced Cancers||National Cancer Institute (NCI)||Completed|January 1999|March 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|March 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003703||208237|
NCT00003946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067139|Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer|Phase II Study of Danazol in Advanced or Recurrent Endometrial Cancer||Gynecologic Oncology Group||Completed|August 1999|||June 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||July 2004|June 7, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003946||208027|
NCT00003873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02300|Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer|Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer||National Cancer Institute (NCI)||Completed|April 1999|||July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|950|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003873||208089|
NCT00003936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067128|Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease|Phase II Clinical Evaluation of Bryostatin 1 in Patients With Hodgkin's Disease||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 1999|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2014|April 9, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003936||208036|
NCT00003721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066830|Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I, Pharmacologic and Biologic Study of Col-3 (NSC683551) Administered on a 28-Day Oral Dosing Schedule in Patients With Advanced Solid Tumors||The University of Texas Health Science Center at San Antonio|Yes|Completed|November 1998|April 2002|Actual|April 2002|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003721||208219|
NCT00003734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066849|Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer|A Randomised Comparison of Short and Protracted Neoadjuvant Hormonal Therapy Prior to Radiation Therapy of High Risk Localized Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|276|||Male|18 Years|N/A|No|||December 2011|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003734||208207|
NCT00003909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01845|Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma|A Phase I Study of Motexafin Gadolinium (Xcytrin, NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood||National Cancer Institute (NCI)||Completed|August 1999|||March 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|21 Years|No|||January 2013|January 15, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003909||208058|
NCT00003741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDMC-97127|Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma|HeFi-1 Antibody Therapy in Ki-1 and Hodgkin's Lymphomas, a Phase I Study||National Cancer Institute (NCI)||Completed|February 1999|December 2007|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2005|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003741||208201|
NCT00003739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS973|Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy|Randomized Comparison Between Antibiotics Alone and Antibiotics Plus Granulocyte-Colony Stimulating Factor in Pediatric Patients With Chemotherapy Induced Febrile Neutropenia||Children's Oncology Group|Yes|Completed|March 1999|September 2006|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Actual|67|||Both|N/A|21 Years|No|||February 2014|February 12, 2014|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003739||208203|
NCT00003695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066799|Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer|A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery||National Cancer Institute (NCI)||Completed|May 1998|January 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Female|N/A|N/A|No|||May 2007|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003695||208244|
NCT00003726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9815|Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer|A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy||Dartmouth-Hitchcock Medical Center|Yes|Completed|November 1998|July 2001|Actual|July 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003726||208215|
NCT00003682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066784|Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer|Treatment of Metastatic Prostate Cancer That is Hormone-Independent: Evaluation of the Role of Chemotherapy on the Quality of Life of Patients. Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|160|||Male|18 Years|N/A|No|||May 2007|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003682||208256|
NCT00003680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066782|Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer|A Randomised Comparative Trial of Highly Intensive Chemotherapy With Stem Cell Support vs. Relatively Intensive Chemotherapy (CMF 8 Cycles) in Breast Cancer Patients Node Positive Surgery, Having Received Primary Medical Therapy With an Anthracycline Regimen||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Female|18 Years|60 Years|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003680||208258|
NCT00003686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC16|Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids|A Double Blind Phase III Study of Oral Pilocarpine for Opioid-Induced Dry Mouth||Canadian Cancer Trials Group|Yes|Terminated|August 1998|November 1999|Actual|October 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|4|||Both|16 Years|N/A|No|||January 2012|May 30, 2013|November 1, 1999||No|Terminated due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00003686||208252|
NCT00003684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC14|Theophylline in Treating Cancer Patients With Shortness of Breath|A Phase III Double-Blind Study of Theophylline Versus Placebo for the Treatment of Dyspnea in Cancer Patients||Canadian Cancer Trials Group||Completed|March 1998|December 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|60|||Both|16 Years|N/A|No|||March 2010|November 11, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003684||208254|
NCT00003702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0174|Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia|A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia||Gynecologic Oncology Group||Completed|June 1999|||July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Female|N/A|N/A|No|||February 2016|February 9, 2016|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003702||208238|
NCT00003683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066785|Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer|Treatment of Sarcomatous Kidney Cancer That is Metastatic in Adults With Doxorubicin and Ifosfamide. Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|March 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||May 2002|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003683||208255|
NCT00003966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067166|Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation|Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose||National Cancer Institute (NCI)||Active, not recruiting|March 1999|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|140|||Both|N/A|N/A|No|||May 2006|May 9, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003966||208013|
NCT00003937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9754|Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma|Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study||Children's Oncology Group|Yes|Completed|September 1999|June 2008|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|253|||Both|N/A|30 Years|No|||August 2014|August 4, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003937||208035|
NCT00003942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067135|Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||August 2000|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003942||208031|
NCT00003943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067136|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.|A Phase II Trial of High Dose Paclitaxel, Carboplatin and Topotecan With Peripheral Blood Stem Cell Support in Extensive Stage Small Cell Cancer||Fox Chase Cancer Center|No|Completed|September 1998|February 2003|Actual|November 2000|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003943||208030|
NCT00003963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067163|Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation|Treatment of B-Cell NHL Relapsing After Transplant With a Rituxan Vinorelbine Combination||Jonsson Comprehensive Cancer Center|Yes|Completed|May 1999|February 2005|Actual|September 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2012|September 30, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003963||208014|
NCT00003720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUGEN-SU5416.003|SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma|A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma||Pfizer||Completed|July 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2012|August 22, 2012|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003720||208220|
NCT00003733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066848|Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer|A Phase II Study of Sequential Carboplatin, Paclitaxel and Hycamtin in Patients With Previously Untreated Advanced Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||December 2000|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003733||208208|
NCT00003744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066863|Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery|Gemcitabine for Advanced Salivary Cancer: A Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||August 2004|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003744||208198|
NCT00003745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01841|Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas|A Phase II Study of Continuous 21 Day Infusion of Topotecan (NSC # 609699) in Children With Relapsed Solid Tumors||National Cancer Institute (NCI)||Completed|May 1999|||June 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|N/A|21 Years|No|||April 2003|February 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003745||208197|
NCT00003724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-39804|Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases|Phase III Randomized Prospective Trial of Open Versus Minimally Invasive, Video-Assisted Resection of Pulmonary Metastases||Alliance for Clinical Trials in Oncology|No|Completed|February 1999|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|530|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003724||208217|
NCT00003725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066837|Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer|Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors||National Cancer Institute (NCI)||Active, not recruiting|December 1996|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||May 2007|November 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003725||208216|
NCT00003737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-095|Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma|A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma||Memorial Sloan Kettering Cancer Center||Completed|January 1999|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|18 Years|No|||June 2013|June 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003737||208204|
NCT00003749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066869|Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer|A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer||National Cancer Institute (NCI)||Completed|April 1998|December 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2300|||Female|N/A|N/A|No|||April 1999|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003749||208193|
NCT00003687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC17|Treatment for Chronic Pain in Patients With Advanced Cancer|A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients||Canadian Cancer Trials Group||Completed|December 1998|February 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|16 Years|N/A|No|||March 2010|November 7, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003687||208251|
NCT00003912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067091|Chemotherapy in Treating Children With Liver Cancer|Liver Tumour Studies - Hepatoblastoma and Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|June 1998|October 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|260|||Both|N/A|16 Years|No|||December 2000|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003912||208055|
NCT00003938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-19951|Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients|A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 1999|||May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Actual|115|||Both|N/A|N/A|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003938||208034|
NCT00003939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62982-16993|Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma|Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult||European Organisation for Research and Treatment of Cancer - EORTC||Completed||||November 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|132|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003939||208033|
NCT00003692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066795|Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer|Video-Assisted Lobectomy for Peripheral (no Greater Than 3 cm), N0, Non-Small Cell Lung Cancer: A Phase II Feasibility Study||Alliance for Clinical Trials in Oncology|No|Completed|December 1998|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|128|||Both|N/A|N/A|No|||September 2013|September 27, 2013|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003692||208247|
NCT00003693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-187|Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia|Phase I Study of Dolastatin-10 in Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase||M.D. Anderson Cancer Center|No|Completed|March 1999|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||August 2012|August 1, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003693||208246|
NCT00003934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02811|Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia|Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia||National Cancer Institute (NCI)||Completed|June 1999|||November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|420|||Both|N/A|N/A|No|||June 2013|June 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003934||208038|
NCT00003732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN-104864/373|Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer|A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered Every 21 Days to Patients With Epithelial Ovarian Cancer Stages IIb, IIc, III and IV||National Cancer Institute (NCI)||Completed|September 1998|September 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|80|||Female|18 Years|N/A|No|||July 2002|August 9, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003732||208209|
NCT00003944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067137|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||Fox Chase Cancer Center|No|Completed|August 1998|February 2003|Actual|December 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|3|||Female|18 Years|N/A|No|||April 2013|April 16, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003944||208029|
NCT00003735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09714|Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia|A Phase II Study of Oral Topotecan in Children With Relapsed Acute Leukemia||Children's Oncology Group||Completed|December 1998|September 2006|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003735||208206|
NCT00003979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16985|CHS 828 in Treating Patients With Solid Tumors|Phase I and Pharmacokinetics Study to Determine the Safety of CHS 828 in Patients With a Solid Tumor on a Single Oral Dose Repeated Every 3 Weeks||European Organisation for Research and Treatment of Cancer - EORTC||Withdrawn|April 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003979||208004|
NCT00003747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066867|Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma|Phase I (Tumour Site Specific) Study of Carboplatin and Temozolomide in Patients With Advanced Melanoma||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2001|September 19, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003747||208195|
NCT00003743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066861|Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation|Multicenter Observer-Blind Randomized Phase II Parallel Study Comparing Three Doses of Subcutaneous Interleukin 2 After Megatherapy and Peripheral Stem Cell Reinfusion in Stage 4 Neuroblastoma in Patients Over 1 Year of Age||National Cancer Institute (NCI)||Active, not recruiting|March 1997|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|25|||Both|1 Year|21 Years|No|||May 2007|September 16, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003743||208199|
NCT00003736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066851|MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer|Pilot Study: High Risk Breast Cancer Screening Pilot Study||National Cancer Institute (NCI)||Active, not recruiting|June 1999|||||N/A|Interventional|Primary Purpose: Screening|||Anticipated|200|||Female|25 Years|N/A|No|||June 2007|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003736||208205|
NCT00003729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-58953|Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia|Phase II Study of Fludarabine + Idarubicin + Aracytine in Refractory or Relapsed ALL in Children||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|December 1998|||April 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|13|||Both|N/A|17 Years|No|||September 2012|September 20, 2012|November 1, 1999|||low accrual|No||https://clinicaltrials.gov/show/NCT00003729||208212|
NCT00003694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02786|Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase|A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine||National Cancer Institute (NCI)||Completed|March 1999|||August 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|16 Years|N/A|No|||June 2013|June 4, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003694||208245|
NCT00003923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-015|Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas|Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction||Memorial Sloan Kettering Cancer Center||Completed|March 1999|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|4|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003923||208048|
NCT00003681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066783|Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome|Phase II Multicenter Study of Amifostine in Patients With Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||July 2000|May 9, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003681||208257|
NCT00003691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066794|Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|A Randomized Study of Doxorubicin Plus Cisplatin Versus Doxorubicin Plus Cisplatin Plus 3-Hour Paclitaxel With G-CSF Support in Patients With Primary Stage III & IV or Recurrent Endometrial Carcinoma||Gynecologic Oncology Group||Completed|December 1998|||June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|240|||Female|18 Years|N/A|No|||September 2010|July 8, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003691||208248|
NCT00003945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067138|Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer|A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix||Gynecologic Oncology Group||Completed|June 1999|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Female|18 Years|N/A|No|||September 2004|May 24, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003945||208028|
NCT00004244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067489|Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma|Phase I Trial of rhIL-12 and rHuIFN-a2b in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma||National Cancer Institute (NCI)||Completed|March 2000|September 2008|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||June 2005|March 19, 2013|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004244||207780|
NCT00004294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11727|Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease|||National Center for Research Resources (NCRR)||Completed|November 1999|||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004294||207747|
NCT00004206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067452|Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer|Phase II Study of Oxaliplatin and 5 Fluorouracil in the Treatment of Advanced Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2002|June 23, 2014|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004206||207815|
NCT00004190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-984351|Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer|A Phase I(Limited)/Phase II Study of Oxaliplatin (OXAL) and Gemcitabine (GEMZAR) in Patients With Metastatic Pancreatic Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|October 1999|June 2003|Actual|April 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004190||207830|
NCT00004228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5971|Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma|Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma||Children's Oncology Group|Yes|Active, not recruiting|June 2000|||August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|393|||Both|1 Year|30 Years|No|||November 2015|November 25, 2015|January 28, 2000|Yes|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00004228||207795|
NCT00004216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-005|VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy|A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intratumoral Injection||National Cancer Institute (NCI)||Completed|August 1999|January 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|July 17, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004216||207806|
NCT00004242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067487|Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors|Phase I Study of Oxaliplatin in Combination With 5-Fluorouracil and Gemcitabine in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|October 1999|||December 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2002|February 8, 2013|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004242||207782|
NCT00004186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067427|Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer|Phase I/IIA Study of Sequential Ifosfamide and Topotecan in Patients With Small Cell Lung Cancer||University of Alabama at Birmingham|Yes|Completed|December 1996|December 2004|Actual|December 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Both|N/A|N/A|No|||April 2013|April 10, 2013|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004186||207834|
NCT00004314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11823|Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease|||Office of Rare Diseases (ORD)||Completed|February 1996|||||Phase 2|Interventional|Primary Purpose: Treatment||||2|||Male|N/A|N/A|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004314||207736|
NCT00004315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11827|Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease|||National Center for Research Resources (NCRR)||Active, not recruiting|November 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|4 Months|N/A|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004315||207735|
NCT00004093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99L1|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|A Phase I-II Study of Induction Chemotherapy With Carboplatin and Gemcitabine, Followed by Chemoradiotherapy With Paclitaxel and Vinorelbine for Patients With Locally Advanced Non-Small Cell Lung Cancer||Northwestern University||Terminated|August 1999|March 2002|Actual|February 2002|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|December 10, 1999|Yes|Yes|Original Principal Investigator left the institution.|No||https://clinicaltrials.gov/show/NCT00004093||207909|
NCT00004094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU C98N1|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx|A Phase II Study of Induction Chemotherapy Followed by Concomitant Paclitaxel (1 Hour Infusion), Fluorouracil, Hydroxyurea and Hyperfractionated Radiotherapy for Advanced Oral, Pharynx and Larynx Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|80 Years|No|||December 2002|January 3, 2014|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004094||207908|
NCT00004108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067329|DX-8951f in Treating Patients With Liver Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hepatocellular Carcinoma||Daiichi Sankyo Inc.||Completed|September 1999|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||May 2012|May 15, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004108||207895|
NCT00004217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9918|S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older||Southwest Oncology Group||Completed|February 2000|March 2006|Actual|May 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|56 Years|N/A|No|||March 2015|March 5, 2015|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004217||207805|
NCT00004218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067454|Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide||National Cancer Institute (NCI)||Completed|October 1999|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 2006|December 17, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004218||207804|
NCT00004181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 92H3T|Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia|Allogeneic Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in the Chronic Phase or Multiple Myeloma||Northwestern University|Yes|Completed|October 1999|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|55 Years|No|||June 2012|June 8, 2012|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004181||207838|
NCT00004234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN3|Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx|A Comparison of Acute Oral Mucositis Between Morning and Afternoon Radiotherapy in Patients Receiving Radiation Treatment for Cancer of the Head and Neck||Canadian Cancer Trials Group||Completed|August 1999|February 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|16 Years|N/A|No|||March 2010|November 11, 2013|January 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00004234||207789|
NCT00003880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C98102|Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer|A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery||Merck Sharp & Dohme Corp.||Terminated|February 1999|August 2001|Actual|August 2001|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|132|||Female|18 Years|N/A|No|||April 2015|April 15, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003880||208083|
NCT00004232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA96H4|Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies||Northwestern University|Yes|Completed|October 1999|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Primary Purpose: Supportive Care|||||||Both|10 Years|65 Years|No|||May 2012|May 31, 2012|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004232||207791|
NCT00004215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-055|Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia|Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin "7+3" Regimen||Memorial Sloan Kettering Cancer Center||Completed|August 1999|August 2000|Actual|August 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|55 Years|N/A|No|||June 2013|June 18, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004215||207807|
NCT00004187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/99|Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer|A Phase I-II Study of Capecitabine and Oxaliplatin in Chemotherapy-Naive and Thymidylate Synthase Inhibitor Pretreated Advanced or Metastatic Colorectal Cancer||Swiss Group for Clinical Cancer Research||Completed|June 1999|April 2004|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|January 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00004187||207833|
NCT00003837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066994|506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma||National Cancer Institute (NCI)||Completed|September 1999|November 2007|Actual|||N/A|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|16 Years|N/A|No|||December 2005|June 18, 2013|November 1, 1999||||||https://clinicaltrials.gov/show/NCT00003837||208118|
NCT00003838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990050|Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow|Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|February 1999|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|214|||Both|2 Years|80 Years|No|||August 2015|March 11, 2016|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003838||208117|
NCT00004177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067299|Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer|Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 in Advanced Ovarian Cancer Using Autologous Peripheral Blood Stem Cell Rescue (PBSCR) to Control Myelotoxicity||Garden State Cancer Center at the Center for Molecular Medicine and Immunology||Completed|August 1999|||May 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|80 Years|No|||June 2011|June 21, 2011|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004177||207842|
NCT00004312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00827-1196|Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis|||National Center for Research Resources (NCRR)||Completed|October 1999|||||N/A|Observational|Primary Purpose: Screening||||400|||Both|N/A|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004312||207738|
NCT00004313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11822|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency|||Office of Rare Diseases (ORD)||Completed|August 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004313||207737|
NCT00004194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067435|Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease|A Phase I-II Study for the Treatment of Steroid Resistant GVHD With Fludarabine||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 1/Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||April 2000|December 17, 2013|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004194||207827|
NCT00004219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMBEC-RD526/21494|Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma|A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|150|||Male|18 Years|70 Years|No|||June 2007|August 1, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004219||207803|
NCT00004196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067439|Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis|A Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients With Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy||University of Alabama at Birmingham|Yes|Completed|October 1999|November 2007|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|3000|||Both|18 Years|70 Years|No|||April 2013|January 16, 2014|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004196||207825|
NCT00004201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067444|Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer|A Randomized Phase II Trial of Cisplatin or Carboplatin With Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed||August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|February 1, 2013|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004201||207820|
NCT00004226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067467|Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy|Phase I/II Study of High Dose Limited Volume Postoperative Reirradiation in Recurrent or Second Primary Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Active, not recruiting|May 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|December 3, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004226||207797|
NCT00004227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067468|Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx|Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck||University of Alabama at Birmingham|Yes|Terminated|April 1999|May 2008|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||November 2012|February 5, 2014|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004227||207796|
NCT00004221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9903|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer|A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Terminated|November 1999|||March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004221||207801|
NCT00004223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067464|Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer|Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium||Eastern Cooperative Oncology Group|No|Completed|December 1999|||October 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 26, 2010|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004223||207800|
NCT00004224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067465|Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma|SIOP Study of Combined Modality Treatment in Childhood Ependymoma||National Cancer Institute (NCI)||Completed|January 1999|March 2008|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|65|||Both|3 Years|20 Years|No|||April 2008|August 23, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004224||207799|
NCT00004178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067388|Gene Therapy in Treating Patients With Cancer|Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma||Roger Williams Medical Center||Completed|April 1998|December 2001|Actual|December 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2006|June 9, 2011|January 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00004178||207841|
NCT00004182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98B3|Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer|Phase II Study for the Evaluation of CPT-11 (Irinotecan, Camptosar) in Patients With Metastatic or Recurrent Breast Cancer||Northwestern University|Yes|Completed|October 1999|April 2000|Actual|April 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004182||207837|
NCT00004239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-69803|506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment|A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment||Alliance for Clinical Trials in Oncology|No|Terminated|December 1999|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|January 28, 2000|No|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00004239||207784|
NCT00004174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 96B1|Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer|High Dose Paclitaxel Added to Cyclophosphamide and Thiotepa Followed by Autologous Stem Cell Rescue: A Phase I Trial in Advanced Breast Cancer||Northwestern University|Yes|Completed|October 1999|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|30|||Both|N/A|60 Years|No|||July 2013|July 9, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004174||207845|
NCT00004213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-001-2|3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors|An Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in Cancer Patients Using a Single Daily Dose for Five Days||National Cancer Institute (NCI)||Completed|May 1998|January 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|July 17, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004213||207808|
NCT00004265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067524|Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer|Phase II Study of Weekly Paclitaxel as Second-Line Therapy in Patients With Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|December 3, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004265||207760|
NCT00004199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-3340-017|Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor Prinomastat (AG3340) in Combination With Gemcitabine and Cisplatin in Patients Having Advanced Non-Small Cell Lung Cancer||Pfizer||Completed|March 1999|||July 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2012|August 7, 2012|January 21, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004199||207822|
NCT00004210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067459|Study of the Results of Education and Counseling for Persons Undergoing Genetic Testing for Hereditary Nonpolyposis Colon Cancer|Outcomes in Education and Counseling for HNPCC Testing||National Cancer Institute (NCI)||Completed|February 2000|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|900|||Both|18 Years|N/A|No|||July 2009|October 23, 2014|January 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00004210||207811|
NCT00004200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-3340-019|Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in Combination With Temozolomide Following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme||Pfizer||Completed|October 1999|||January 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||August 2012|August 7, 2012|January 21, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004200||207821|
NCT00004233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067477|S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach|A Phase II Study of PN-401, 5-FU and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach||Southwest Oncology Group|No|Completed|February 2001|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||May 2010|July 21, 2011|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004233||207790|
NCT00004183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067422|Capecitabine in Treating Patients With Malignant Mesothelioma|Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study||Alliance for Clinical Trials in Oncology|No|Completed|November 2000|January 2006|Actual|December 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|27|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004183||207836|
NCT00004205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067451|Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer|A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors|BIG 1-98|International Breast Cancer Study Group|Yes|Active, not recruiting|March 1998|||December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|8028|||Female|30 Years|N/A|No|||August 2015|August 31, 2015|January 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00004205||207816|
NCT00004207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067453|Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer|A Phase I Study to Determine the Maximum Tolerated Dose of Daunoxome as Therapy for the Treatment of Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2000|June 23, 2014|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004207||207814|
NCT00004208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 33/99|Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome|Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care||Swiss Group for Clinical Cancer Research|Yes|Completed|August 2000|October 2011|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|January 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00004208||207813|
NCT00004263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM99-165|Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Phase I Study of UCN-01 and Cytarabine (ARA-C) in Patients With Acute Myelogenous Leukemia, and Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Completed|December 1999|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||July 2012|July 27, 2012|January 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00004263||207762|
NCT00004264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067523|Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase I/II Trial of Amifostine, High-Dose Cisplatin and Docetaxel in Patients With Advanced Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 1997|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|December 3, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004264||207761|
NCT00004230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98CC1|Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation|Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation||Northwestern University|Yes|Completed|October 1999|March 2002|Actual|March 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Actual|35|||Both|N/A|N/A|No|||May 2012|May 31, 2012|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004230||207793|
NCT00004231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 96H3|Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma|Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma||Northwestern University|Yes|Completed|October 1999|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004231||207792|
NCT00004243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067488|Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor|A Phase I Study of Oxaliplatin in Combination With Docetaxel (Taxotere) Metastatic/Recurrent Solid Tumors||City of Hope Medical Center||Completed|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 11, 2010|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004243||207781|
NCT00004192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272-99|Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma|A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma||University of Nebraska||Completed|May 2000|March 2001|Actual|February 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|60|||Both|18 Years|N/A|No|||June 2010|June 23, 2010|January 21, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004192||207829|
NCT00004193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067434|ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer|Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Patients With Advanced Colorectal Cancer||University of Alabama at Birmingham|Yes|Terminated|January 1999|November 2000|Actual|November 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004193||207828|
NCT00004154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067387|Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer|Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer||M.D. Anderson Cancer Center|Yes|Completed|June 2000|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004154||207861|
NCT00004156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-023|Vaccine Therapy in Treating Patients With Breast Cancer|Vaccination of High Risk Breast Cancer Patients With MUC-1 (Glycosylated) Keyhole Limpet Hemocyanin Conjugates Plus the Immunological Adjuvant QS21||Memorial Sloan Kettering Cancer Center||Completed|May 1999|||June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004156||207860|
NCT00004175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98B1|Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer|Phase II Study of Taxotere, Doxorubicin and Cyclophosphamide (TAC) Primary Therapy in Stage III Breast Cancer||Northwestern University|Yes|Completed|November 1998|June 2005|Actual|September 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2012|May 31, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004175||207844|
NCT00004237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067481|Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer|A Randomized Phase II Trial of Navelbine/Epirubicin Versus Navelbine/Mitozantrone Versus Cyclophosphamide/Adriamycin as Preoperative Chemotherapy in Patients With > or = 3cm Diameter Early Breast Cancer||National Cancer Institute (NCI)||Completed|October 1998|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|70 Years|No|||May 2005|November 5, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004237||207786|
NCT00004293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11725|Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease|||National Center for Research Resources (NCRR)||Recruiting|November 1999|||||Phase 2|Interventional|Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004293||207748|
NCT00004317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11837|Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis|Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis||Office of Rare Diseases (ORD)|Yes|Recruiting|July 2000|December 2030|Anticipated|December 2030|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|N/A|N/A|No|||May 2009|May 13, 2009|October 18, 1999||No||No||https://clinicaltrials.gov/show/NCT00004317||207733|
NCT00004211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408|Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer|A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With RNA Encoding Prostate Specific Antigen, PSA||Duke University||Completed|July 1999|January 2002|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|17|||Male|18 Years|N/A|No|||January 2005|March 19, 2013|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004211||207810|
NCT00004188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3973|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma|A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma||Children's Oncology Group|Yes|Completed|February 2001|||October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|495|||Both|N/A|30 Years|No|||May 2013|May 16, 2013|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004188||207832|
NCT00004212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067330|DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas|A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas||Daiichi Sankyo Inc.||Completed|September 1999|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||May 2012|May 15, 2012|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004212||207809|
NCT00004179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20981|Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkin's Lymphoma: A Phase III Randomized Clinical Trial - Intergroup Collaborative Study||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|May 1999|||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|475|||Both|18 Years|120 Years|No|||February 2016|February 3, 2016|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004179||207840|
NCT00004180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067406|Rosiglitazone in Treating Patients With Liposarcoma|Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma||Dana-Farber Cancer Institute|No|Active, not recruiting|October 1999|July 2016|Anticipated|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004180||207839|
NCT00004238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-053|10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Patients With Advanced Non-Small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|July 1999|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004238||207785|
NCT00004245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-057|Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia|A Phase I Study of Salicylate for Adult Patients With Advanced Myelodysplastic Disorders or Acute Myelogenous Leukemia||Memorial Sloan Kettering Cancer Center||Completed|August 1999|||September 2004|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 17, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004245||207779|
NCT00004195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067438|Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer|Evaluation of Dihydropyrimidine Dehydrogenase (DPD) Activity in Surgically Resected Primary and Metastatic Colorectal Cancer After 48 hr Pretreatment With Eniluracil||University of Alabama at Birmingham|Yes|Completed|September 1998|May 2001|Actual|October 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|19 Years|80 Years|No|||June 2015|June 12, 2015|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004195||207826|
NCT00004225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067466|Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Phase I Pilot Trial of Adenovirus p53 and Radiotherapy on Nonsmall Cell Lung Cancer||National Cancer Institute (NCI)||Completed|January 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|July 3, 2010|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004225||207798|
NCT00004202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067445|Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer|A Phase II Study of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Radiation Therapy With RSR13 for Locally Advanced Inoperable Non-Small Cell Lung Cancer||Spectrum Pharmaceuticals, Inc||Completed|October 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2013|May 8, 2013|January 21, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004202||207819|
NCT00004184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067424|Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase I/II Trial of a Human Anti-Idiotypic Monoclonal Antibody Vaccine (4B5) Which Mimics the GD2 Antigen, in Patients With Melanoma||University of Alabama at Birmingham|Yes|Completed|August 1998|June 2001|Actual|June 2001|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2013|April 11, 2013|January 21, 2000|No|Yes||||https://clinicaltrials.gov/show/NCT00004184||207835|
NCT00004236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067480|Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer|A Phase II Study of Caelyx in the Treatment of Advanced Gastric Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2000|June 23, 2014|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004236||207787|
NCT00004176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067202|Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|A Phase II Evaluation of Ethyol as an Esophageal Mucosal Protectant in the Treatment of Limited Disease Small Cell Lung Cancer With Chemotherapy and Twice-Daily Radiation||Washington University School of Medicine|No|Completed|October 1998|February 2001|Actual|February 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|34|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004176||207843|
NCT00004287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11715|Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis|||Office of Rare Diseases (ORD)||Completed|November 1995|||||Phase 1|Interventional|Primary Purpose: Treatment||||14|||Both|18 Years|N/A|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004287||207750|
NCT00004288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11716|Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis|||Office of Rare Diseases (ORD)||Completed|May 1996|December 1999||||Phase 2|Interventional|Primary Purpose: Treatment||||4|||Male|18 Years|65 Years|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004288||207749|
NCT00004203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10020|Oxaliplatin in Treating Patients With Metastatic Bladder Cancer|A Phase II Study of Oxaliplatin in Urothelial Cancer||University of Chicago|No|Completed|February 2000|April 2005|Actual|February 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004203||207818|
NCT00004204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067449|Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma|A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Active, not recruiting|February 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2006|January 3, 2014|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004204||207817|
NCT00004189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067430|Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer|A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin Without and With Granulocyte Colony-Stimulating Factor Support Every 21 Days||National Cancer Institute (NCI)||Completed|October 1999|||July 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2003|February 8, 2013|January 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004189||207831|
NCT00003828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066983|S9804: Vinorelbine in Treating Patients With Stage IV Melanoma|Evaluation of Vinorelbine Tartrate (Navelbine) in Patients With Disseminated Malignant Melanoma and One Prior Systemic Therapy||Southwest Oncology Group|No|Completed|May 1999|March 2004|Actual|December 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|N/A|No|||August 2012|August 20, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003828||208126|
NCT00004100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067316|Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Gemcitabine and Vinorelbine vs Standard Chemotherapy Containing Cisplatin for Stage IIIB/IV Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|69 Years|No|||June 2008|December 17, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004100||207903|
NCT00003832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02297|Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer|Cell Kinetic Study of Bromodeoxyuridine (BrdU) in Prostate Cancer||National Cancer Institute (NCI)||Completed|July 1999|||June 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Male|N/A|N/A|No|||January 2013|January 24, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003832||208122|
NCT00004127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10015|Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach|A Phase II Study of Oxaliplatin in Combination With Fluorouracil and Leucovorin in Carcinoma of the Esophagus and Gastric Cardia||University of Chicago|No|Completed|February 2000|August 2003|Actual|October 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004127||207883|
NCT00003899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1343.00|Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors|High-Dose Consolidation With Escalating Doses of Melphalan and Thiotepa for Stage IV Breast Cancer||Fred Hutchinson Cancer Research Center||Completed|January 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||September 2010|September 16, 2010|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003899||208066|
NCT00003876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMC-98724|Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma|A Phase I Study of Concurrent Multi-modality Treatment for Patients With Relapsed Malignant Glioma Using Permanent I-125 Interstitial Seeds and Dose Escalation of Gliadel 3.85% Carmustine (BCNU) Polymer Wafers||National Cancer Institute (NCI)||Completed|April 1999|May 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2001|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003876||208086|
NCT00004138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0050|Positron Emission Tomography for Detecting Non-small Cell Lung Cancer|The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Non-Small Cell Lung Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|September 1999|December 2002|Actual|December 2002|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|303|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004138||207876|
NCT00003901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0040|Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery|A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|July 1999|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1310|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003901||208064|
NCT00004114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067340|Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer|Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study||Jonsson Comprehensive Cancer Center||Withdrawn||||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2012|September 30, 2015|December 10, 1999|||Study never opened|No||https://clinicaltrials.gov/show/NCT00004114||207890|
NCT00003881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067048|Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC||National Cancer Institute (NCI)||Completed|May 1999|July 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003881||208082|
NCT00003825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9809|Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy|Phase III Study of Pentosanpolysulfate (PPS) in Treatment of GI Tract Sequelae of Radiotherapy||Radiation Therapy Oncology Group|Yes|Completed|June 1999|||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|174|||Both|N/A|N/A|No|||August 2013|August 9, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003825||208128|
NCT00003827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066982|Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome|Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|16 Years|N/A|No|||July 2007|December 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003827||208127|
NCT00004091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99G3|Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results|Development of Antibody-Based Diagnostic Markers for Abnormal Cervical Cells||Northwestern University||Completed|August 1999|February 2001|Actual|February 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|Patients must have a diagnosis of an abnormal Pap test, performed as part of standard of        care screening in the clinic. The patient's informed consent will be obtained during their        initial interview with the clinic physician.|January 2011|January 27, 2011|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004091||207911|
NCT00004092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98096|Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer|Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer||City of Hope Medical Center||Completed|May 1999|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|N/A|60 Years|No|||July 2015|July 7, 2015|December 10, 1999|Yes|Yes||No|July 7, 2015|https://clinicaltrials.gov/show/NCT00004092||207910|
NCT00004075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067283|17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery|A Phase I Trial of 17-Allylaminogeldanamycin (17-AAG) in Solid Tumor and Lymphoma Patients||Mayo Clinic|Yes|Completed|August 1999|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2011|August 2, 2011|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004075||207927|
NCT00004029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065275|Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer|A PHASE I TRIAL OF RECOMBINANT VACCINIA VIRUS THAT EXPRESSES PSA IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE||National Cancer Institute (NCI)||Completed|December 1996|||May 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Male|18 Years|N/A|No|||June 2006|February 8, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004029||207968|
NCT00004097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU C97N2|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer|A Phase I Study of Concomitant Chemoradiotherapy With Gemcitabine, Paclitaxel, and 5-FU for Patients With Advanced and/or Recurrent Cancer of the Head and Neck||National Cancer Institute (NCI)||Active, not recruiting|August 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2001|September 19, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004097||207905|
NCT00003856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067019|Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy|A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||January 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003856||208104|
NCT00003831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0030|Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer|Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma||Alliance for Clinical Trials in Oncology|Yes|Completed|July 1999|January 2011|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1023|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003831||208123|
NCT00003835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01844|Combination Chemotherapy in Treating Patients With Stage III Colon Cancer|Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer||National Cancer Institute (NCI)||Completed|May 1999|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1260|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003835||208119|
NCT00004061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMGEN-KGF-980231-04|Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer|A Randomized Double-Blind, Placebo-Controlled Trial of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Patients With Hematologic Malignancies Undergoing Total Body Irradiation (TBI) and High-Dose Chemotherapy With Autologous Peripheral Blood||National Cancer Institute (NCI)||Completed|May 1999|December 2009|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|111|||Both|18 Years|65 Years|No|||December 2009|June 25, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004061||207940|
NCT00004101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067318|Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|Phase I Trial of Humanized 1D10 Monoclonal Antibody (Hu1D10) In Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)||National Cancer Institute (NCI)||Completed|November 1999|||June 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||May 2001|February 8, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004101||207902|
NCT00004122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067348|BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer|A National Phase II Trial of Intron (Interferon-alfa 2b) Plus BCG for Treatment of Superficial Bladder Cancer||Roswell Park Cancer Institute||Completed|July 1999|||April 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 31, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004122||207888|
NCT00004081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067292|Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Trial of Weekly, Low-Dose Docetaxel (Taxotere) in Patients With Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Serous Cancer||Dana-Farber Cancer Institute|No|Completed|July 1999|March 2003|Actual|January 2002|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Female|18 Years|N/A|No|||August 2012|August 9, 2012|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004081||207921|
NCT00004082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIH-99-1285|Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors|A Phase I Study of Docetaxel (Taxotere), Carboplatin, and Gemcitabine (DoCaGem) as First-Line Therapy for Patients With High-Risk Epithelial Tumors of Mullerian Origin||National Cancer Institute (NCI)||Completed|July 1999|December 2010|Actual|September 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2010|June 25, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004082||207920|
NCT00004135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9672|Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer|Allogeneic Stem Cell Transplantation of Renal Cell Cancer and Metastatic Melanoma After Non-Myeloablative Chemotherapy||University of Chicago|No|Completed|February 1999|August 2007|Actual|October 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||March 2014|March 6, 2014|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004135||207879|
NCT00003875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1315.00|Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia|Treatment of Acute Myelogenous Leukemia With Busulfan and Etoposide Followed by Autologous or Syngeneic Stem Cell Rescue and Low-Dose Interleukin 2 (IL-2) Immunotherapy||Fred Hutchinson Cancer Research Center|No|Completed|November 1998|||April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|N/A|65 Years|No|||August 2015|August 4, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003875||208087|
NCT00003888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-24971|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer|A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 1999|March 2015|Actual|March 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|359|||Both|18 Years|70 Years|No|||July 2015|July 16, 2015|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003888||208076|
NCT00004073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-9808 CDR0000067281|Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center||Completed|December 1999|June 2004|Actual|May 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|54|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004073||207929|
NCT00003896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067066|S9912 Combination Chemo in Stage III Ovarian Cancer,|Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women With Optimally-Debulked Stage III Epithelial Ovarian Cancer||Southwest Oncology Group|No|Completed|September 1999|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Female|N/A|N/A|No|||January 2013|January 2, 2013|November 1, 1999|Yes|Yes||No|October 30, 2012|https://clinicaltrials.gov/show/NCT00003896||208069|
NCT00003834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-974651|Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer|A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver||Alliance for Clinical Trials in Oncology|Yes|Completed|March 1999|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003834||208120|
NCT00004105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067324|Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I/II Study of Paclitaxel, Estramustine Phosphate, and Vinorelbine (PaclEVin)||New York University School of Medicine||Completed|September 1998|||April 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 25, 2011|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004105||207898|
NCT00004106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA97H3|Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome|Phase II Trial of Temozolomide for the Treatment of Mycosis Fungoides and the Sezary Syndrome||Northwestern University||Terminated|May 1998|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|December 10, 1999|Yes|Yes|Per Data Monitoring Committee given the poor/inadequate accrual.|No||https://clinicaltrials.gov/show/NCT00004106||207897|
NCT00004107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067327|Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With High-Dose 90Y-Labeled Humanized LL2 Anti-CD-22 Antibody and Peripheral Blood Stem Cell Rescue||Garden State Cancer Center at the Center for Molecular Medicine and Immunology||Completed|February 1998|||May 2001|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|80 Years|No|||June 2011|June 21, 2011|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004107||207896|
NCT00003849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-987851|Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Phase II Trial of C2B8 in Patients With Asymptomatic CD20+ B-Cell Follicular Small Cleaved Low-Grade Non-Hodgkin's Lymphoma or Relapsed CD20+ Hodgkin's Disease||Alliance for Clinical Trials in Oncology|No|Completed|July 1999|February 2008|Actual|February 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||July 2015|July 4, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003849||208111|
NCT00003829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-978151|Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia|A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL||Alliance for Clinical Trials in Oncology|No|Completed|August 1999|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003829||208125|
NCT00003830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-32|Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer|A Randomized, Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node-Negative Breast Cancer Patients||NSABP Foundation Inc|Yes|Completed|May 1999|February 2014|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5611|||Female|18 Years|N/A|No|||March 2014|March 6, 2014|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003830||208124|
NCT00004137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067367|S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Paclitaxel, Carboplatin and Topotecan With G-CSF in Untreated Patients With Extensive Small Cell Lung Cancer||Southwest Oncology Group|No|Completed|October 1999|November 2008|Actual|March 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004137||207877|
NCT00004095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98X3|Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors|Phase I Trial of Irinotecan (CPT-11) and Gemcitabine in Patients With Solid Tumors||Northwestern University||Completed|August 1999|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2011|January 28, 2011|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004095||207907|
NCT00004102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067321|Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma||New York University School of Medicine||Completed|January 1999|||November 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 25, 2011|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004102||207901|
NCT00003900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-982453|Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer|A Phase II Study of Irinotecan (CPT-11) and Docetaxel (Taxotere) in Patients With Recurrent Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|October 1999|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003900||208065|
NCT00003877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067043|Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer|A Phase I/II Study in Metastatic Breast Cancer Patients Infused With Stromagen and Isolated, Mobilized, Autologous Peripheral Blood CD34+ Progenitor Cells After High-Dose Chemotherapy||Roswell Park Cancer Institute|Yes|Completed|September 1998|December 2000|Actual|February 2000|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|64 Years|No|||March 2011|March 3, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003877||208085|
NCT00003878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067044|Carmustine Implants in Treating Patients With Brain Metastases|The Treatment of One or Two Supratentorial Brain Metastases With Surgical Resection and BCNU-Polymer Wafers||National Cancer Institute (NCI)||Completed|April 2002|April 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2003|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003878||208084|
NCT00004126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10014|Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer|A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Non-Small Cell Lung Cancer||University of Chicago|No|Completed|November 1999|August 2003|Actual|January 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004126||207884|
NCT00003887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600.03|Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation|Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation||Fred Hutchinson Cancer Research Center||Completed|August 1998|February 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|70 Years|No|||November 2011|November 28, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003887||208077|
NCT00003843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067003|Irinotecan in Treating Patients With Colorectal Cancer|UGT1A1 Polymorphism in Patients With Colorectal Cancer Treated With CPT-11 (Irinotecan)||California Cancer Consortium||Terminated|October 1998|February 2001|Actual|February 2001|Actual|Phase 2|Observational|N/A|||Anticipated|28|||Both|18 Years|N/A|No|||September 2013|February 13, 2015|November 1, 1999|Yes|Yes|Study terminated due to poor accrual|||https://clinicaltrials.gov/show/NCT00003843||208114|
NCT00003846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99702|Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors|Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support||Children's Oncology Group|Yes|Completed|July 1999|March 2007|Actual|October 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|3 Years|21 Years|No|||July 2014|July 25, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00003846||208113|
NCT00003847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067008|VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer|A Phase II Study of the Safety, Efficacy and Pharmacokinetics of VX-710 in Combination With Doxorubicin and Vincristine in Patients With Small Cell Lung Cancer (SCLC)||Vertex Pharmaceuticals Incorporated||Terminated|December 1998|||February 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003847||208112|
NCT00003894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067064|Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant|Thalidomide vs. Placebo for Steroid Dependent or Refractory Chronic Graft vs. Host Disease (cGVHD) IND #42782||Roswell Park Cancer Institute|Yes|Completed|March 1999|June 2002|Actual|January 2000|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|1||Actual|36|||Both|3 Years|N/A|No|||March 2011|March 3, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003894||208071|
NCT00003895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02096|Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma|A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients With a &gt;1mm Melanoma on Initial Biopsy||National Cancer Institute (NCI)||Completed|April 1999|||September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|17 Years|N/A|No|||November 2013|January 28, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003895||208070|
NCT00003906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP P-2|Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women|Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer||NSABP Foundation Inc|Yes|Completed|May 1999|August 2012|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|19747|||Female|35 Years|N/A|No|||October 2015|October 5, 2015|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003906||208061|
NCT00004088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99021|Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma|Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma||City of Hope Medical Center||Active, not recruiting|April 1999|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|65 Years|No|||July 2015|July 22, 2015|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004088||207914|
NCT00004124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067352|S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer|Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High-Risk Prostate Cancer Patients Following Radical Prostatectomy||Southwest Oncology Group|Yes|Terminated|October 1999|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|983|||Male|18 Years|N/A|No|||October 2012|October 3, 2012|December 10, 1999|Yes|Yes|Permanently Closed Due to Safety Issue|No||https://clinicaltrials.gov/show/NCT00004124||207886|
NCT00004096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99L2|Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase I/II Study of Carboplatin and Navelbine for Advanced Non-Small Cell Lung Cancer||Northwestern University|Yes|Completed|August 1999|March 2002|Actual|March 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004096||207906|
NCT00003850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02299|Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of Thalidomide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|April 1999|||June 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2001|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003850||208110|
NCT00003840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-22300|DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia|A Phase I Study of DTGM Fusion Protein (IND BB#8153) in Relapsed and Refractory Adult Acute Myeloid Leukemia (AML)||Comprehensive Cancer Center of Wake Forest University||Completed|October 2000|July 2005|Actual|September 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|November 1, 1999||||||https://clinicaltrials.gov/show/NCT00003840||208116|
NCT00003851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA8471|Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer|Evaluation of Intensive Pancreatic Proteolytic Enzyme Therapy With Ancillary Nutritional Support Versus Gemcitabine Chemotherapy in the Treatment of Inoperable Pancreatic Adenocarcinoma||Columbia University|No|Terminated|March 1999|July 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||February 2013|February 13, 2013|November 1, 1999||No|Approval lapse|No||https://clinicaltrials.gov/show/NCT00003851||208109|
NCT00004125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067353|Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes|A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer||Eastern Cooperative Oncology Group|Yes|Completed|October 1999|||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2010|January 28, 2010|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004125||207885|
NCT00003892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I116|ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer|Phase II Study of CGP 69846A (ISIS 5132) in Recurrent Epithelial Ovarian Cancer||Canadian Cancer Trials Group|No|Completed|February 1999|September 2008|Actual|October 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||July 2012|September 20, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003892||208073|
NCT00004099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40954|Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer|Randomized Phase III Study of Preoperative Chemotherapy Followed by Surgery Versus Surgery Alone in Locally Advanced Gastric Cancer (cT3 and cT4NxM0)||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|July 1999|||February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|144|||Both|18 Years|69 Years|No|||September 2012|September 20, 2012|December 10, 1999|||low accrual|No||https://clinicaltrials.gov/show/NCT00004099||207904|
NCT00004103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067322|Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer|A Phase II Study of Systemic Therapy With CPT-11 (Camptosar HCl) and Cisplatin in Patients With Advanced Gastric Cancer to be Followed by Surgical Resection and Postoperative Intraperitoneal Chemotherapy||New York University School of Medicine||Completed|July 1998|June 2009|Actual|March 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 5, 2011|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004103||207900|
NCT00004123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID95-225|Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma|A Phase I Study of Preoperative Chemoradiation and Intraoperative Radiation Therapy in the Treatment of Retroperitoneal Sarcoma||M.D. Anderson Cancer Center|No|Completed|July 1997|October 2009|Actual|July 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004123||207887|
NCT00003893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067062|Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer|Sequencing of Chemotherapy and Radiotherapy in Adjuvant Breast Cancer||National Cancer Institute (NCI)||Completed|July 1998|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2250|||Female|N/A|N/A|No|||November 2001|December 18, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003893||208072|
NCT00003855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0011|Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer|A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node||Alliance for Clinical Trials in Oncology|No|Completed|April 1999|February 2011|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|605|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003855||208105|
NCT00004141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9372|Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma|Phase II Study of Outpatient CDDP and DTIC Followed by GM-CSF, IFN-a2b, and IL-2 in Patients With Advanced Melanoma||University of Chicago|No|Completed|August 1998|April 2006|Actual|January 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|N/A|N/A|No|||September 2013|September 4, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004141||207874|
NCT00003882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067049|Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors|Phase I Dose Finding Study of Anhydrovinblastine Administered as a 1-Hour Infusion Every 3 Weeks to Patients With Advanced Solid Tumors||Roswell Park Cancer Institute|Yes|Completed|March 1999|September 2000|Actual|April 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003882||208081|
NCT00003890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I125|MG98 in Treating Patients With Advanced Solid Tumors|A Phase I Study of MG98 Given as a 2 Hour Twice Weekly IV Infusion in Patients With Advanced Cancer||Canadian Cancer Trials Group||Completed|February 1999|September 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||March 2010|November 7, 2010|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00003890||208075|
NCT00003891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I123|Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors|A Phase I Study of NX211 Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors||Canadian Cancer Trials Group||Completed|February 1999|September 2009|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||March 2010|November 7, 2010|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00003891||208074|
NCT00004139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067369|Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Phase II Randomized Trial of Gemcitabine/Docetaxel and Gemcitabine/Irinotecan in Stage IIIB/IV Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|September 1999|January 2006|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004139||207875|
NCT00003902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 25/99|Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement|Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement||Swiss Group for Clinical Cancer Research||Completed|March 1999|September 2005|Actual|December 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|110|||Female|65 Years|N/A|No|||May 2012|May 14, 2012|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003902||208063|
NCT00004104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067323|Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma|Phase II Trial of the Effects of Interferon Alfa-2b on the Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Patients With Stage III Malignant Melanoma||New York University School of Medicine||Completed|June 1998|||July 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||June 2007|November 8, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004104||207899|
NCT00003853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067016|4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis|Phase II Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL)||National Cancer Institute (NCI)||Completed|April 1999|August 2001|Actual|August 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||May 2011|November 9, 2012|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003853||208107|
NCT00003854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0010|Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer|A Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Clinical T1-2 N0 Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|April 1999|July 2011|Actual|August 2006|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4590|||Female|18 Years|N/A|No|||July 2015|July 6, 2015|November 1, 1999||No||No||https://clinicaltrials.gov/show/NCT00003854||208106|
NCT00003903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067078|Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer|An Evaluation of the Effect of Androgen Ablation on Bone Resorption in Prostate Cancer Patients||University of Rochester||Completed|July 1999|August 2007|Actual|August 2007|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||Anticipated|150|||Male|N/A|N/A|No|||October 2013|October 14, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00003903||208062|
NCT00004408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13296|Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease|||Mast Therapeutics, Inc.||Completed|November 1997|November 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|10 Years|65 Years|No|||March 2012|March 5, 2012|October 18, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004408||207667|
NCT00004454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13577|Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)|||Office of Rare Diseases (ORD)||Completed|October 1996|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||2|||Both|18 Years|N/A|No|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004454||207633|
NCT00004399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13249|Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia|||FDA Office of Orphan Products Development||Completed|September 1995|August 2000||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention||||2000|||Female|N/A|N/A|No|||January 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004399||207675|
NCT00004400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13251|Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women|||FDA Office of Orphan Products Development||Completed|April 1997|September 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|56|||Female|18 Years|50 Years|No|||May 1998|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004400||207674|
NCT00004373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11960|Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety|||Office of Rare Diseases (ORD)||Completed|March 1997|March 2001||||Phase 2|Interventional|Primary Purpose: Treatment||||80|||Both|18 Years|50 Years|No|||May 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004373||207691|
NCT00004403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13286|Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis|||FDA Office of Orphan Products Development||Completed|May 2000|March 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|16 Years|65 Years|No|||January 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004403||207671|
NCT00004420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13314|Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis|||FDA Office of Orphan Products Development||Completed|September 1994|August 1999||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|1 Year|15 Years|No|||January 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004420||207658|
NCT00004475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14042|Genetic Linkage Study for Hereditary Pancreatitis|||Office of Rare Diseases (ORD)||Recruiting|December 1998|||||N/A|Observational|Observational Model: Natural History|||||||Both|N/A|N/A|No|||September 2006|September 5, 2006|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004475||207623|
NCT00004334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1781|Study of Depression, Peptides, and Steroids in Cushing's Syndrome|||National Center for Research Resources (NCRR)||Recruiting|July 1994|||||N/A|Observational|Primary Purpose: Screening||||8|||Both|20 Years|60 Years|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004334||207721|
NCT00004346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00334-0067|Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis|Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)||National Center for Research Resources (NCRR)||Recruiting|January 1996|||||Phase 2|Interventional|Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004346||207710|
NCT00004423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13352|Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease|||FDA Office of Orphan Products Development||Completed|December 1995|March 1998||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||80|||Both|18 Years|80 Years|No|||January 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004423||207655|
NCT00004471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13941|Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer|||University of Alabama at Birmingham||Completed|August 1995|||May 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment||||9|||Both|16 Years|N/A|No|||March 2011|March 28, 2011|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004471||207625|
NCT00004474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14004|Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia|Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia||Office of Rare Diseases (ORD)|Yes|Completed|September 1998|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2|||224|||Both|N/A|59 Years|No|||October 2008|October 1, 2008|October 18, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004474||207624|
NCT00004285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11704|Phase II Randomized Study of Standard Vs High Amount of Hemodialysis Using Low Vs High Flux Dialyzer Membranes for End Stage Renal Disease|||Office of Rare Diseases (ORD)||Completed|October 1992|December 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||900|||Both|18 Years|80 Years|No|||July 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004285||207752|
NCT00004480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14182|Study of Botulinum Toxin in Patients With Primary Hyperhidrosis|||Office of Rare Diseases (ORD)||Completed|July 1999|||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||July 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004480||207620|
NCT00004481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR01070-0470|Genetic Study of Sitosterolemia|||National Center for Research Resources (NCRR)||Completed|November 1999|||||N/A|Observational|Observational Model: Natural History|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004481||207619|
NCT00004429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13377|Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis|||FDA Office of Orphan Products Development||Completed|December 1999|February 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||October 2007|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004429||207651|
NCT00004374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00750-0062|Study of Systemic Amyloidosis Presentation and Prognosis|Study of Systemic Amyloidosis Presentation and Prognosis||National Center for Research Resources (NCRR)||Recruiting|January 1979|||||N/A|Observational|Primary Purpose: Screening||||100|||Both|N/A|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004374||207690|
NCT00004375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR05096-0002|Ultraviolet Light Therapy for Systemic Lupus Erythematosus|||National Center for Research Resources (NCRR)||Recruiting|September 1991|||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||January 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004375||207689|
NCT00003996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-987252|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Trial of Pre-irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 4 Astrocytoma (Glioblastoma)||Alliance for Clinical Trials in Oncology|No|Completed|May 1999|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003996||207992|
NCT00004392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12190|Incidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for Sudden Infant Death Syndrome (SIDS)|||Office of Rare Diseases (ORD)||Completed|May 1994|August 1999||||N/A|Observational|Primary Purpose: Screening||||900|||Both|N/A|1 Year|Accepts Healthy Volunteers|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004392||207680|
NCT00004468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13927|Study of Topical Calcitriol or Oral Calcitriol in Patients With Psoriasis|||Office of Rare Diseases (ORD)||Completed|October 1998|||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||500|||Both|N/A|N/A|No|||July 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004468||207626|
NCT00004398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13191|Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria|||Office of Rare Diseases (ORD)||Completed|January 1998|May 2000||||Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||June 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004398||207676|
NCT00004433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13395|Randomized Study of Pergolide in Children With Tourette Syndrome|||FDA Office of Orphan Products Development||Completed|December 1994|September 2002||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||74|||Both|7 Years|17 Years|No|||March 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004433||207648|
NCT00004414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13306|Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis|||FDA Office of Orphan Products Development||Completed|September 1997|June 2002||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||252|||Both|N/A|30 Days|No|||May 1999|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004414||207663|
NCT00004332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11890|Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly|||Office of Rare Diseases (ORD)||Completed|May 1993|||||N/A|Observational|Primary Purpose: Screening||||148|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004332||207723|
NCT00004333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11892|Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I|||Office of Rare Diseases (ORD)||Completed|November 1994|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004333||207722|
NCT00004419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13313|Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance|||FDA Office of Orphan Products Development||Completed|April 1998|September 2000||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|14 Years|65 Years|No|||June 1999|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004419||207659|
NCT00004440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13438|Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis|||FDA Office of Orphan Products Development||Completed|August 1996|June 1999||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|5 Years|N/A|Accepts Healthy Volunteers|||April 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004440||207644|
NCT00004421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13315|Deep Brain Stimulation in Treating Patients With Dystonia|Phase II/III Study of Deep Brain Stimulation in Patients With Dystonia||FDA Office of Orphan Products Development||Completed|September 1997|September 2000||||Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|75 Years|No|||March 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004421||207657|
NCT00004422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13322|Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection|||FDA Office of Orphan Products Development||Completed|August 1997|September 2002||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||174|||Both|N/A|5 Years|No|||June 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004422||207656|
NCT00004438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13402|Leuprolide in Treating Adults With Hypogonadotropism|Study of Leuprolide in Adults With Hypogonadotropism||FDA Office of Orphan Products Development||Completed|September 1997|September 2002||||N/A|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|35 Years|No|||June 1998|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004438||207645|
NCT00004386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12054|Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency|||Office of Rare Diseases (ORD)||Terminated|October 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004386||207683|
NCT00004575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000077|Effects of Miconazole on Blood Flow|Investigation of Miconazole as an Inhibitor of Endothelium-Derived Hyperpolarizing Factor||National Institutes of Health Clinical Center (CC)||Completed|February 2000|October 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2001|March 3, 2008|February 17, 2000||||No||https://clinicaltrials.gov/show/NCT00004575||207575|
NCT00004402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13284|Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis|||FDA Office of Orphan Products Development||Completed|November 1999|June 2000||||Phase 3|Interventional|Primary Purpose: Treatment||||30|||Both|N/A|10 Years|No|||January 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004402||207672|
NCT00004376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11979|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder|||Office of Rare Diseases (ORD)||Completed|September 1994|June 2000||||Phase 3|Interventional|Primary Purpose: Treatment||||35|||Both|7 Years|16 Years|No|||March 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004376||207688|
NCT00004412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13302|Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers|Phase II Trial of Arginine Butyrate for Treatment of Refractory Leg Ulcers in Sickle Cell Disease or Beta Thalassemia||Boston University|No|Completed|September 1997|February 2005|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|16 Years|60 Years|No|||March 2015|March 18, 2015|October 18, 1999|Yes|Yes||No|July 22, 2013|https://clinicaltrials.gov/show/NCT00004412||207664|
NCT00004441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13439|Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis|||FDA Office of Orphan Products Development||Completed|September 1997|September 2001||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Anticipated|39|||Both|N/A|N/A|No|||July 1998|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004441||207643|
NCT00004437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13400|Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2|||FDA Office of Orphan Products Development||Completed|October 1999|October 2000||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||January 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004437||207646|
NCT00004344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11903|Purification of Testis-Stimulating Factor in Precocious Puberty|||Office of Rare Diseases (ORD)||Completed|January 1997|||||N/A|Observational|Primary Purpose: Screening||||4|||Male|18 Years|N/A|No|||February 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004344||207712|
NCT00004410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13299|Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants|||FDA Office of Orphan Products Development||Completed|June 1998|March 2002||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|20 Days|No|||August 1998|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004410||207665|
NCT00004406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13293|Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis|||FDA Office of Orphan Products Development||Completed|October 1999|July 2004||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Male|29 Years|67 Years|No|||January 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004406||207669|
NCT00004407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13294|Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy|||FDA Office of Orphan Products Development||Terminated|February 1998|March 2000||||N/A|Interventional|Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||January 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004407||207668|
NCT00004393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12217|Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome|||Office of Rare Diseases (ORD)||Completed|July 1997|September 2000||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|7 Years|60 Years|No|||March 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004393||207679|
NCT00004345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11904|Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome|||National Center for Research Resources (NCRR)||Terminated|October 1999|||||N/A|Observational|Primary Purpose: Screening||||100|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004345||207711|
NCT00004430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13380|Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization|||FDA Office of Orphan Products Development||Completed|September 1994|September 1998||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|150|||Both|12 Years|N/A|No|||August 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004430||207650|
NCT00004448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13463|Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy|||Office of Rare Diseases (ORD)||Completed|November 1997|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||123|||Both|N/A|40 Years|No|||September 2008|September 8, 2008|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004448||207637|
NCT00004428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13364|Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis|||FDA Office of Orphan Products Development||Completed|September 1997|October 1999||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||January 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004428||207652|
NCT00004401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13253|Study of Human Botulism Immunoglobulin in Infants With Botulism|||FDA Office of Orphan Products Development||Completed|January 1998|June 1998||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|N/A|1 Year|No|||March 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004401||207673|
NCT00004397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13187|Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria|||Office of Rare Diseases (ORD)||Completed|January 1998|May 2000||||Phase 1|Interventional|Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||June 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004397||207677|
NCT00004446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13456|Study of Fluoxetine in Patients With Depersonalization Disorder|||National Institute of Mental Health (NIMH)||Completed|April 1998|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|65 Years|No|||March 2005|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004446||207638|
NCT00004387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12102|Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease|||Office of Rare Diseases (ORD)||Completed|January 1996|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||34|||Both|35 Years|75 Years|No|||July 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004387||207682|
NCT00004436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13399|Randomized Study of Hormonal Regulation of Infantile Hemangioma|||FDA Office of Orphan Products Development||Completed|July 1993|June 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|1 Month|8 Months|No|||August 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004436||207647|
NCT00004444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13445|Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis|||FDA Office of Orphan Products Development||Completed|November 1994|January 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||February 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004444||207640|
NCT00004416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13308|Randomized Study of Botulinum Toxin Type A for Achalasia|||FDA Office of Orphan Products Development||Completed|January 1997|March 2002||||N/A|Interventional|Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||April 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004416||207661|
NCT00004418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13312|Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy|Study of Glyceryl Trierucate and Glyceryl Trioleate (Lorenzo's Oil) Therapy in Male Children With Adrenoleukodystrophy||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Suspended|April 1998|November 2014|Anticipated|November 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Months|6 Years|No|||September 2014|September 17, 2014|October 18, 1999|Yes|Yes|No funding and moved to expanded access|No||https://clinicaltrials.gov/show/NCT00004418||207660|
NCT00004378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11981|Stem Cell Transplantation (SCT) for Genetic Diseases|||National Center for Research Resources (NCRR)||Completed|January 1995|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|N/A|17 Years|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004378||207687|
NCT00004426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13361|Leuprolide in Determining the Cause of Gonadotropin Deficiency|Study of Gonadotropin Releasing Hormone Agonist Test Using Leuprolide Acetate in Patients With Gonadotropin Deficiency||FDA Office of Orphan Products Development||Completed|August 1994|September 1998||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|9 Years|18 Years|No|||January 2000|March 25, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004426||207653|
NCT00004449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH048863|Randomized Study of Intensive One-on-one Behavioral Treatment for Preschool Aged Children With Autism|Randomized Study of Intensive One-on-one Behavioral Treatment Versus Individualized Parent Training in Preschool Aged Children With Autism||University of California, Los Angeles|No|Completed|May 1998|April 2006|Actual|September 2004|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|2 Years|3 Years|No|||May 2015|May 26, 2015|October 18, 1999||No||No||https://clinicaltrials.gov/show/NCT00004449||207636|
NCT00004445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13455|Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord Injuries|||Case Western Reserve University||Completed|September 1996|||September 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|October 18, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004445||207639|
NCT00004424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13353|Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy|||FDA Office of Orphan Products Development||Completed|July 1996|March 2000||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|N/A|18 Years|No|||April 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004424||207654|
NCT00004323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11863|Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia|||National Center for Research Resources (NCRR)||Completed|February 1995|||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|55 Years|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004323||207732|
NCT00004324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR06022-5099|Developmental Phenomenology of Obsessive Compulsive Disorder and Tourette Syndrome in Children and Adolescents|||National Center for Research Resources (NCRR)||Completed|December 1989|||||N/A|Observational|Primary Purpose: Screening||||90|||Both|5 Years|17 Years|No|||January 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004324||207731|
NCT00004396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13185|Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias|||National Center for Research Resources (NCRR)||Completed|September 1997|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004396||207678|
NCT00004358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11925|Phase II Study of Calcitonin for Tumoral Calcinosis|||National Center for Research Resources (NCRR)||Completed|November 1992|||||Phase 2|Interventional|Primary Purpose: Treatment||||9|||Both|N/A|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004358||207701|
NCT00004359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11928|Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita|||Office of Rare Diseases (ORD)||Completed|February 1996|||||Phase 2|Interventional|Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004359||207700|
NCT00004368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11947|Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis|||Office of Rare Diseases (ORD)||Active, not recruiting|May 1990|||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|N/A|17 Years|No|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004368||207692|
NCT00004404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13288|Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes|||FDA Office of Orphan Products Development||Completed|April 1997|September 2002||||N/A|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||May 1998|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004404||207670|
NCT00004457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13650|Determinants of Disease Severity in Amyotrophic Lateral Sclerosis|||Office of Rare Diseases (ORD)||Active, not recruiting|March 1998|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Prospective||||75|||Both|18 Years|N/A|No|||January 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004457||207632|
NCT00004464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13895|Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria|||Office of Rare Diseases (ORD)||Active, not recruiting|February 1996|||||N/A|Interventional|Primary Purpose: Treatment||||25|||Both|N/A|70 Years|No|||March 2007|March 28, 2007|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004464||207630|
NCT00004479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14181|Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope|||Office of Rare Diseases (ORD)||Completed|March 1999|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||July 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004479||207621|
NCT00004415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13307|Study of Combined Intercostal and Diaphragm Pacing for Artificial Respiration in Quadriplegic Patients|||FDA Office of Orphan Products Development||Terminated|May 1991|September 2000||||N/A|Interventional|Primary Purpose: Treatment||||5|||Both|18 Years|49 Years|No|||September 2002|April 6, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004415||207662|
NCT00004451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13548|Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients|||National Institute of Mental Health (NIMH)||Completed|March 1998|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2005|November 29, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004451||207634|
NCT00004409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13297|Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease|||FDA Office of Orphan Products Development||Completed|August 1995|April 2004||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||May 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004409||207666|
NCT00004458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13682|Longitudinal and Biological Study of Childhood Disintegrative Disorder|||Office of Rare Diseases (ORD)||Terminated|May 1997|||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||220|||Both|2 Years|9 Years|No|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004458||207631|
NCT00004380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12015|Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis|||Office of Rare Diseases (ORD)||Completed|December 1991|December 1997||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment||||1|||Both|N/A|N/A|No|||July 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004380||207686|
NCT00004390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12133|Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia|||Office of Rare Diseases (ORD)||Completed|February 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|90 Years|No|||February 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004390||207681|
NCT00004467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13925 DK52827 (completed)|Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|June 1998|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|173|||Both|18 Years|70 Years|No|||January 2010|January 12, 2010|October 18, 1999|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00004467||207627|
NCT00004465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13923|Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome|||Office of Rare Diseases (ORD)||Completed|July 1998|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||204|||Both|6 Months|18 Years|No|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004465||207629|
NCT00004431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13391|Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia|||FDA Office of Orphan Products Development||Completed|June 1998|September 1999||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|80 Years|No|||April 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004431||207649|
NCT00004381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12021|Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia|||Office of Rare Diseases (ORD)||Completed|December 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|24 Hours|No|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004381||207685|
NCT00004012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-112|Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|December 1998|December 2000|Actual|December 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||June 2013|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004012||207979|
NCT00004017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067235|Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma|Phase II Open-Label, Non-Randomized, Multicenter Study of Interstitial 131I-chTNT-1/B for the Treatment of Newly Diagnosed or Recurrent Malignant Glioma||National Cancer Institute (NCI)||Completed|February 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||March 2003|February 6, 2009|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004017||207974|
NCT00004010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59704|Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease|Pilot Study for the Treatment of Children With Newly Diagnosed Advanced Stage Hodgkin's Disease: Upfront Dose Intensive Chemotherapy||Children's Oncology Group|Yes|Completed|October 1999|June 2008|Actual|October 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|N/A|21 Years|No|||February 2014|February 25, 2014|November 1, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00004010||207981|
NCT00004256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067503|Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer|Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer||National Cancer Institute (NCI)||Completed|October 1997|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|20 Years|80 Years|No|||August 2006|November 5, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004256||207769|
NCT00004266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11643|Study of Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes at High Risk of Kidney or Heart Disease|Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease||Office of Rare Diseases (ORD)||Completed|August 1993|July 1999||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||160|||Both|18 Years|N/A|No|||December 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004266||207759|
NCT00004268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11645|Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension|||National Center for Research Resources (NCRR)||Completed|April 2001|||||Phase 2|Interventional|Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004268||207758|
NCT00004246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID95-038|Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx|A Phase I Study of Fludarabine With Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck||M.D. Anderson Cancer Center|No|Completed|May 2000|December 2002|Actual|February 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|January 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00004246||207778|
NCT00004250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-047|Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery|A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity||Memorial Sloan Kettering Cancer Center||Completed|August 1999|||June 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004250||207775|
NCT00004251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I126|Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer|A Phase II Study of Letrozole in Patients With Advanced or Recurrent Endometrial Cancer||Canadian Cancer Trials Group||Completed|January 2000|January 2011|Actual|September 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||July 2012|September 20, 2012|January 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00004251||207774|
NCT00004297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11733|Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus|||Office of Rare Diseases (ORD)||Completed|November 1995|February 1999||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|18 Years|N/A|No|||December 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004297||207745|
NCT00004300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11754|Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis|Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis||Office of Rare Diseases (ORD)||Suspended||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2006|October 5, 2010|October 18, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004300||207744|
NCT00004284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11703|Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria|||Office of Rare Diseases (ORD)||Completed|April 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||June 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004284||207753|
NCT00004172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 92B3T|Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer|Peripheral Stem Cell Transplantation Protocol for Patients With Previously Treated Advanced Breast Cancer - A Phase II Pilot Study||Northwestern University|Yes|Completed|October 1999|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||June 2012|June 8, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004172||207847|
NCT00004173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-99H0284|Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer|A Phase I Study of Oxaliplatin in Combination With Paclitaxel||National Cancer Institute (NCI)||Active, not recruiting|October 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2003|May 14, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004173||207846|
NCT00004014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO1898|Liposomal Doxorubicin in Treating Patients With Prostate Cancer|Liposome-Encapsulated Doxorubicin (LED) in Hormone Refractory Prostate Carcinoma, Phase II||Case Comprehensive Cancer Center|Yes|Completed|April 1999|November 2001|Actual|January 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|N/A|N/A|No|||August 2010|August 13, 2010|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004014||207977|
NCT00004015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-11961|Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery|Postoperative Treatment of Glioblastoma With BNCT at the Petten Irradiation Facility||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 2002|||July 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|50 Years|N/A|No|||July 2012|July 17, 2012|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004015||207976|
NCT00004057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-116|Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas|A Phase I and Pharmacokinetic Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of Combination Therapy With Paclitaxel and L-778,123 in Patients With Recurrent or Refractory Solid Malignancies||Memorial Sloan Kettering Cancer Center||Completed|December 1998|December 2000|Actual|December 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004057||207944|
NCT00004005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067216|Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin|Irinotecan and 5-Fluorouracil/Leucovorin for Patients With Colorectal Carcinoma and Other Refractory Tumors||St. Jude Children's Research Hospital||Completed|September 1998|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|N/A|24 Years|No|||October 2011|October 3, 2011|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004005||207985|
NCT00003997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02309|6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia|Phase I Study of MGI-114 (NSC#683863) in Patients With Refractory Myelodysplastic Syndromes, Acute Leukemia and Chronic Myelogenous Leukemia in Blastic Phase (CML-BP)||National Cancer Institute (NCI)||Completed|July 1999|||October 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2001|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003997||207991|
NCT00004248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067494|Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Low Dose Schedule of Adriamycin and Protracted Infusion of Recombinant Interleukin-2: A Phase II Study of Immunotherapy in Unresectable Hepatocellular Carcinoma||Roswell Park Cancer Institute|Yes|Completed|July 1999|May 2001|Actual|June 2000|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004248||207777|
NCT00004016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067234|Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors|Phase I Trial of Immunotherapy With Adenovirus-Interferon- Gamma (TG1041) in Patients With Malignant Melanoma||University of Rochester||Completed|April 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 5, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004016||207975|
NCT00004257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067504|Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer|A Phase I Study of Oxaliplatin in Combination With Continuous Infusion 5-Fluorouracil and Radiation in Esophageal Cancer||National Cancer Institute (NCI)||Completed|January 2000|January 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|March 25, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004257||207768|
NCT00004261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067516|EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma|A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas||National Cancer Institute (NCI)||Active, not recruiting|December 1999|||||Phase 1|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||June 2002|February 18, 2011|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004261||207764|
NCT00004252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUGEN-SU5416.031|Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer|A Randomized, Open-Label, Multicenter Phase III Study of 5-FU/Leucovorin With or Without Concomitant SU5416 in Patients With Metastatic Colorectal Cancer||Pfizer||Completed|November 1999|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2012|September 10, 2012|January 28, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004252||207773|
NCT00004310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11812|Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder|||National Center for Research Resources (NCRR)||Active, not recruiting|October 1999|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||76|||Both|18 Years|55 Years|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004310||207740|
NCT00004311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11816|Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome|||Office of Rare Diseases (ORD)||Completed|July 1989|January 1996||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||May 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004311||207739|
NCT00004062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067262|Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer|Restoration of Radioiodine Uptake in Thyroid Carcinoma: A Clinical Trial||National Cancer Institute (NCI)||Completed|July 1999|August 2006|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2004|December 18, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004062||207939|
NCT00004063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067264|Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer|A Phase I-II Clinical Trial of Cisplatin (Platinol) Followed by Gemcitabine HCl (Gemzar) in Combination With Mild, Fever-Range Whole Body Hyperthermia (LL-WBH) at 40C in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Recruiting|August 1999|||November 2011|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2008|April 29, 2009|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004063||207938|
NCT00004307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00188-0606|Study of Treatment and Metabolism in Patients With Urea Cycle Disorders|Therapeutic and Metabolic Studies of Urea Cycle Disorders: Part A: Nitrogen Flux and Ureagenesis; Part B (Closed): Phase I Adenovirus Vector-Mediated Gene Therapy for Ornithine Transcarbamylase Deficiency||National Center for Research Resources (NCRR)||Recruiting|December 1999|||||Phase 1|Interventional|Primary Purpose: Treatment||||66|||Both|6 Months|64 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004307||207741|
NCT00003993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067198|Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma|A Phase lb Trial of the Combination of Bryostatin-1 and Low Dose Interleukin-2: Evaluation of the Functional and Molecular Status of Human Monocytes as Antigen Presenting Cells||National Cancer Institute (NCI)||Completed|September 1999|||July 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||May 2006|April 28, 2015|November 1, 1999||||||https://clinicaltrials.gov/show/NCT00003993||207995|
NCT00004042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOEH-1152.1|Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer|A Phase I Dose-Escalation Study of BIBH-1 in Patients With Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer||National Cancer Institute (NCI)||Completed|November 1998|December 2009|Actual|July 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||December 2009|July 17, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004042||207957|
NCT00004056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9822|Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia|Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequential Remission Induction and Consolidation Followed by Single Dose Melphalan With Peripheral Stem Cell Rescue: A POG Pilot Study||Children's Oncology Group|Yes|Completed|October 1999|March 2007|Actual|October 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|21 Years|No|||July 2014|July 24, 2014|December 10, 1999||Yes||No||https://clinicaltrials.gov/show/NCT00004056||207945|
NCT00004065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-037|Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer|A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol||Memorial Sloan Kettering Cancer Center||Completed|July 1999|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 20, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004065||207936|
NCT00003992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02305|Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2|Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer||National Cancer Institute (NCI)||Completed|August 1999|March 2009|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|N/A|No|||March 2013|May 31, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003992||207996|
NCT00004229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02314|Endostatin in Treating Patients With Advanced Solid Tumors|A Phase I Surrogate Endpoint Trial of Human Recombinant Endostatin in Patients With Advanced Solid Tumors Amenable to Biopsy||National Cancer Institute (NCI)||Completed|October 1999|||October 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2002|February 8, 2013|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004229||207794|
NCT00004235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9941|Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach|A Phase II Study of Taxotere and Irinotecan (CPT-11) in Patients With Advanced Adenocarcinoma of the Lower Esophagus, Esophagogastric Junction, and Gastric Cardia||Alliance for Clinical Trials in Oncology|No|Completed|January 2000|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004235||207788|
NCT00003994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9645|Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer|Intergroup Protocol for Treatment of Children With Hepatoblastoma||Children's Oncology Group|Yes|Completed|March 1999|||October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|277|||Both|N/A|21 Years|No|||June 2013|June 13, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00003994||207994|
NCT00003995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02307|Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2|Phase II and Pharmacokinetic Study of CPT-11 and Trastuzumab (RhuMab HER2, Herceptin) in Advanced Colo-Rectal Cancer With p185 HER 2 Overexpression||National Cancer Institute (NCI)||Completed|September 1999|||March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||June 2007|February 7, 2013|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00003995||207993|
NCT00004258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9909-40; T99-0076|EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer|A Phase I Trial of EMD 121974 in Patients With Advanced or Metastatic Cancer||Indiana University||Completed|December 1999|September 2001|Actual|August 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004258||207767|
NCT00004259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9813|Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas|A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)||Radiation Therapy Oncology Group|Yes|Active, not recruiting|June 2000|||March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|230|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|January 28, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004259||207766|
NCT00004249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-065|Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy|Immunization Using Polysialic Acid-KLH or N-Propionylated Polysialic Acid-KLH Conjugate Plus the Immunological Adjuvant QS-21 in Patients With Small Cell Lung Cancer Who Have Achieved a Major Response to Initial Therapy||Memorial Sloan Kettering Cancer Center||Completed|August 1998|November 2001|Actual|November 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004249||207776|
NCT00004253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067500|Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase II Study of 3-Dimensional Conformal Hyperfractionation Radiation Therapy (3D-CHRT) With Dose Escalation and Amifostine Mucosal Protection for Patients With Favorable Prognosis Inoperable Stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC) Receiving Paclitaxel and Carboplatin||National Cancer Institute (NCI)||Active, not recruiting|March 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|December 17, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004253||207772|
NCT00004296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11731|Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients|||Office of Rare Diseases (ORD)||Completed|September 1995|||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||1000|||Both|10 Years|N/A|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004296||207746|
NCT00004260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067514|Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|Phase I Study of Interleukin-12 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma||Mayo Clinic|Yes|Completed|October 1999|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2011|August 2, 2011|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004260||207765|
NCT00004278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11689|Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection|||Office of Rare Diseases (ORD)||Completed|December 1991|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||130|||Both|N/A|1 Month|No|||July 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004278||207754|
NCT00004305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11791|Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis|||National Center for Research Resources (NCRR)||Completed|January 1998|||||N/A|Observational|Primary Purpose: Screening||||105|||Both|N/A|N/A|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004305||207743|
NCT00004045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067146|Chemotherapy in Treating Patients With Prostate Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hormone-Refractory Prostate Cancer||Daiichi Sankyo Inc.||Completed|June 1999|August 2001|Actual|August 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||May 2012|May 15, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004045||207955|
NCT00004046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067148|Chemotherapy in Treating Women With Metastatic Breast Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Adenocarcinoma of the Breast||Daiichi Sankyo Inc.||Completed|June 1999|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2012|May 15, 2012|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004046||207954|
NCT00004286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11713|Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy|||Office of Rare Diseases (ORD)||Completed|February 1996|November 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|12 Years|N/A|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004286||207751|
NCT00004055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-982052|Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|November 1999|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004055||207946|
NCT00004066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-027|Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma|A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma||Memorial Sloan Kettering Cancer Center||Completed|June 1999|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|82|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004066||207935|
NCT00004004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067214|Procarbazine in Treating Patients With Recurrent Brain Tumor|A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas||National Cancer Institute (NCI)||Completed|July 1999|August 2003|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|June 20, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004004||207986|
NCT00004001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067211|S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy|Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer||Southwest Oncology Group|Yes|Completed|October 1999|January 2007|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|770|||Male|18 Years|N/A|No|||February 2014|February 21, 2014|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004001||207989|
NCT00004002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067212|PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma|Phase I Trial of PS-341 in Advanced Cancers||New York University School of Medicine||Completed|July 1999|||October 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2005|November 8, 2012|November 1, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004002||207988|
NCT00004003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067213|Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery|A Study of Gemcitabine, Cisplatin, and 5-Fluorouracil in the Treatment of Advanced Pancreatic Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|April 1999|August 2003|Actual|November 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004003||207987|
NCT00004254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08992|Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed|Phase II Study on Tomusex in Malignant Mesothelioma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 1999|||June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004254||207771|
NCT00004255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIMERIC-HM01|Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation|A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia||National Cancer Institute (NCI)||Completed|March 2000|May 2003|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|50 Years|No|||February 2002|July 9, 2013|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004255||207770|
NCT00004274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11680|Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome|Controlled Study of Estrogen Effects on Cognitive and Social Function in Girls With Turner's Syndrome||Office of Rare Diseases (ORD)||Completed|February 1990|||||N/A|Interventional|Primary Purpose: Treatment||||260|||Female|8 Years|12 Years|Accepts Healthy Volunteers|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004274||207757|
NCT00004275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11681|Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome|Phase II Randomized Study of Oxandrolone vs Placebo for Growth Hormone-Treated Girls With Turner's Syndrome||Office of Rare Diseases (ORD)||Completed|October 1999|||August 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||80|||Female|10 Years|14 Years|No|||September 2008|September 8, 2008|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004275||207756|
NCT00004241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02315|17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma|A Phase I Trial of Weekly 17-Allylamino-17 Demethoxygeldanamycin||National Cancer Institute (NCI)||Completed|October 1999|||May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004241||207783|
NCT00004306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11796|Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)|Pathogenic Mechanism of Spinocerebellar Ataxia Type 10 (SCA10)||Office of Rare Diseases (ORD)|No|Completed|November 1999|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|Samples With DNA|DNA from blood and skin and muscle biopsy samples.|Both|3 Years|N/A|No|Non-Probability Sample|Patients with inherited ataxia|March 2012|March 5, 2012|October 18, 1999||No||No||https://clinicaltrials.gov/show/NCT00004306||207742|
NCT00004316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11835|Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis|||Office of Rare Diseases (ORD)||Completed|June 1995|||August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||139|||Female|18 Years|N/A|No|||September 2008|September 8, 2008|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004316||207734|
NCT00004276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11682|Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections|||Office of Rare Diseases (ORD)||Completed|September 1990|June 1999||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004276||207755|
NCT00004043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067041|Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer|Phase II Study of Pulse Calcitriol in Patients With Rising PSA After Definitive Treatment for Prostate Cancer||OHSU Knight Cancer Institute|Yes|Completed|February 1999|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|N/A|No|||September 2009|May 24, 2012|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004043||207956|
NCT00004262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01400|Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme|PHASE I TRIAL OF GADOLINIUM TEXAPHYRIN (PCI -0120) AS A RADIOSENSITIZER DURING STEREOTACTIC RADIOSURGERY BOOST FOR GLIOBLASTOMA MULTIFORME||National Cancer Institute (NCI)||Completed|November 1999|||May 2005|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|January 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004262||207763|
NCT00004008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-PHASE-II-PH2/039|Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer|A Phase II Trial of Bryostatin 1 in Ovarian Cancer Administered by Weekly 24 Hour Intravenous Infusion||National Cancer Institute (NCI)||Completed|July 1999|May 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||November 1999|June 25, 2013|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004008||207983|
NCT00004009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067221|R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia|A Phase I Study to Determine Biological Endpoints of Up to 21 Day Dosing of the Farnesyltransferase Inhibitor R115777 (IND# 52,302) for Refractory and Relapsed Adult Leukemias (Summary Last Modified 9/1999)||National Cancer Institute (NCI)||Completed|June 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|July 23, 2008|November 1, 1999||||No||https://clinicaltrials.gov/show/NCT00004009||207982|
NCT00004064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067265|Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX MabB43.13 in Ovarian Cancer Patients With an Elevated Serum CA 125 But Without Other Evidence of Disease||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|102|||Female|18 Years|N/A|No|||June 2007|November 5, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004064||207937|
NCT00004011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067223|S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC)||Southwest Oncology Group|Yes|Completed|October 1999|November 2012|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|354|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|November 1, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004011||207980|
NCT00004067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-31|Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2|A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2||NSABP Foundation Inc|Yes|Active, not recruiting|February 2000|March 2020|Anticipated|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2130|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004067||207934|
NCT00004735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1006|The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV|The Effects of Highly Active Antiretroviral Therapy (HAART) on the Recovery of Immune Function in HIV-Infected Children and Young Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2000|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|81|||Both|2 Years|24 Years|No|||October 2013|October 4, 2013|February 25, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004735||207513|
NCT00004791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11912|Study of the Nutritional, Metabolic, and Body Composition Profile in Children and Adolescents With Epidermolysis Bullosa|||Office of Rare Diseases (ORD)||Completed|August 1995|||||N/A|Observational|Primary Purpose: Screening||||15|||Both|N/A|18 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004791||207477|
NCT00004793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11923|Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children|||Office of Rare Diseases (ORD)||Completed|June 1995|||||N/A|Observational|Primary Purpose: Screening||||4|||Both|N/A|18 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004793||207476|
NCT00004804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11964|Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C|||Office of Rare Diseases (ORD)||Completed|August 1993|||||Phase 3|Interventional|Primary Purpose: Treatment||||57|||Both|N/A|N/A|No|||February 1997|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004804||207467|
NCT00004772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11794|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy|||Office of Rare Diseases (ORD)||Completed|September 1992|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|15 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004772||207489|
NCT00004767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11753|Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders|||Office of Rare Diseases (ORD)||Completed|January 1985|||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004767||207493|
NCT00004689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13311|Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease|||FDA Office of Orphan Products Development||Completed|January 1991|September 1998||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||February 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004689||207530|
NCT00004578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285A|ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects|Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naive HIV-Infected Patients||Abbott|No|Completed|November 1997|April 2005|Actual|April 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2008|April 2, 2008|November 2, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004578||207572|
NCT00004366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11944|Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction|||Office of Rare Diseases (ORD)||Completed|August 1995|May 2000||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Educational/Counseling/Training||||20|||Both|N/A|N/A|No|||June 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004366||207694|
NCT00004797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11941|Pilot Study of Fructose for Sickle Cell Crisis|||Office of Rare Diseases (ORD)||Completed|August 1995|||||N/A|Interventional|Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004797||207472|
NCT00004747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11663|Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis|||Office of Rare Diseases (ORD)||Completed|July 1995|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||170|||Both|6 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004747||207507|
NCT00004760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11694|Study of Axial Mobility Exercises in Parkinson Disease|||Office of Rare Diseases (ORD)||Completed|May 1995|December 1997||||N/A|Interventional|Primary Purpose: Educational/Counseling/Training||||80|||Both|50 Years|90 Years|No|||April 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004760||207497|
NCT00004800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11954|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines|||Office of Rare Diseases (ORD)||Completed|September 1992|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||13250|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||February 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004800||207470|
NCT00004697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13360|Randomized Study of the Use of Intravenous Choline Supplementation in Long Term Total Parenteral Nutrition|||FDA Office of Orphan Products Development||Completed|November 1997|March 1999||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|16 Years|74 Years|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004697||207525|
NCT00004664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11931|Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting|||Office of Rare Diseases (ORD)||Completed|June 1995|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||69|||Both|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004664||207539|
NCT00004799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11953|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines|||Office of Rare Diseases (ORD)||Completed|April 1991|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||10000|||Both|2 Months|3 Months|Accepts Healthy Volunteers|||January 1997|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004799||207471|
NCT00004690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13316|Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis|||FDA Office of Orphan Products Development||Completed|September 1996|September 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|2 Years|N/A|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004690||207529|
NCT00004694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13356|Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations|||FDA Office of Orphan Products Development||Completed|January 1994|September 1998||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Both|8 Years|N/A|No|||April 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004694||207528|
NCT00004762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11707|Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis|||Office of Rare Diseases (ORD)||Completed|December 1994|||||Phase 2|Interventional|Primary Purpose: Treatment||||5|||Both|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004762||207495|
NCT00004699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13381|Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism|||FDA Office of Orphan Products Development||Completed|August 1995|January 1999||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||8|||Both|N/A|3 Months|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004699||207524|
NCT00004700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13382|Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism|||FDA Office of Orphan Products Development||Completed|August 1995|January 1999||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|3 Months|18 Years|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004700||207523|
NCT00004685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13285|Randomized Study of Albuterol in Patients With Facioscapulohumeral Muscular Dystrophy|||FDA Office of Orphan Products Development||Completed|January 1998|September 2000||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|80 Years|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004685||207533|
NCT00004761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11706|Establishment of the National Epidermolysis Bullosa Registry|||Office of Rare Diseases (ORD)||Completed|September 1986|||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||July 2004|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004761||207496|
NCT00004730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS019643|Magnesium Sulfate For Brain Injury|Magnesium Sulfate for Neuroprotection After Brain Trauma||University of Washington|Yes|Completed|August 1998|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|14 Years|N/A|No|||October 2011|October 26, 2011|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004730||207518|
NCT00004635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000080|Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer|A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation||National Institutes of Health Clinical Center (CC)|No|Completed|February 2000|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|159|||Male|18 Years|N/A|No|||August 2012|August 13, 2012|February 19, 2000||No||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00004635||207563|A total of 159 participants were accrued beginning in March 2000 until January 2005. Accrual rates were less than anticipated and the study was closed to further entry by the Independent Data Safety and Monitoring Board for the NCI CCR.
NCT00004637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00069-0611|Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy|||National Center for Research Resources (NCRR)||Completed||||||Phase 4|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Year|18 Years|No|||December 2003|June 23, 2005|February 23, 2000||||No||https://clinicaltrials.gov/show/NCT00004637||207562|
NCT00004734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS034447|Vitamin Therapy for Prevention of Stroke|Vitamin Intervention for Stroke Prevention||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|September 1996|February 2004||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|35 Years|N/A|No|||April 2004|June 23, 2005|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004734||207514|
NCT00004604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065619|Biological Therapy in Treating Patients With Metastatic Cancer|A Phase I Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Metastatic Malignancies Expressing Carcinoembryonic Antigen||Duke University|No|Completed|February 1997|July 2002|Actual|June 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004604||207564|
NCT00004641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11640|A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis|Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis||Office of Rare Diseases (ORD)||Completed|May 1993|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||212|||Both|18 Years|74 Years|No|||September 2008|September 8, 2008|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004641||207558|
NCT00004650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11726|Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss|||Office of Rare Diseases (ORD)||Completed|August 1993|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Female|N/A|N/A|No|||June 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004650||207549|
NCT00004805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11973|Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death|||Office of Rare Diseases (ORD)||Completed|September 1991|August 1997||||N/A|Interventional|Primary Purpose: Educational/Counseling/Training||||500|||Both|N/A|N/A|No|||February 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004805||207466|
NCT00004740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11642|Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users|||Office of Rare Diseases (ORD)||Active, not recruiting|February 1995|||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|18 Years|N/A|No|||January 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004740||207509|
NCT00004744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11660|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis|||Office of Rare Diseases (ORD)||Completed|February 1993|||September 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||76|||Both|18 Years|60 Years|No|||September 2008|September 8, 2008|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004744||207508|
NCT00004807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12009|Study of the Pathogenesis of Rett Syndrome|||Office of Rare Diseases (ORD)||Completed|January 1995|||||N/A|Interventional|Primary Purpose: Treatment||||120|||Both|N/A|45 Years|No|||December 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004807||207464|
NCT00004784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11873|Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis|||Office of Rare Diseases (ORD)||Completed|January 1994|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||315|||Both|20 Years|69 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004784||207483|
NCT00004732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0119970017|Carotid Revascularization Endarterectomy Versus Stenting Trial|Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)|CREST|Rutgers, The State University of New Jersey|Yes|Active, not recruiting|December 2000|December 2016|Anticipated|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2502|||Both|18 Years|N/A|No|||October 2015|January 4, 2016|February 25, 2000|Yes|Yes||No|September 26, 2013|https://clinicaltrials.gov/show/NCT00004732||207516|
NCT00004733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS034796|Timing of Levodopa Treatment in Parkinson's Disease|Earlier Versus Later L-Dopa in Parkinson's Disease||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|January 1998|February 2004||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|N/A|No|||February 2004|June 23, 2005|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004733||207515|
NCT00004665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11935|Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus|||Office of Rare Diseases (ORD)||Completed|June 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Female|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004665||207538|
NCT00004667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11955|Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease|||Office of Rare Diseases (ORD)||Completed|October 1993|||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004667||207537|
NCT00004755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11679|Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil|Phase II Randomized Study of Allopurinol Versus Glucantime Versus Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil||Office of Rare Diseases (ORD)||Completed|September 1995|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||375|||Both|12 Years|N/A|No|||January 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004755||207502|
NCT00004695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13358|Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency|||FDA Office of Orphan Products Development||Completed|September 1997|March 2000||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|2 Years|N/A|No|||May 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004695||207527|
NCT00004731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS036714|Parkinson's Disease Treatment With Coenzyme Q10|Effects of Coenzyme Q10 in Early Parkinson's Disease||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|September 1998|October 2003||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|N/A|No|||December 2003|June 23, 2005|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004731||207517|
NCT00004643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11685|Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus|||Office of Rare Diseases (ORD)||Completed|February 1995|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|64 Years|No|||March 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004643||207556|
NCT00004661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11909|Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism|||Office of Rare Diseases (ORD)||Completed|May 1993|||||N/A|Observational|Primary Purpose: Screening||||20|||Both|12 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004661||207542|
NCT00004758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11691|Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment|||Office of Rare Diseases (ORD)||Completed|November 1993|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||30|||Both|N/A|2 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004758||207499|
NCT00004806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11983|Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis|||University of Alabama at Birmingham|No|Completed|June 1995|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment||||9|||Both|18 Years|N/A|No|||March 2011|March 29, 2011|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004806||207465|
NCT00004642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11673|Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease|Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease||Office of Rare Diseases (ORD)||Completed|February 1995|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|29 Days|No|||March 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004642||207557|
NCT00004662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11918|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus|||Office of Rare Diseases (ORD)||Completed|March 1996|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Female|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004662||207541|
NCT00004753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11677|Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease|||Office of Rare Diseases (ORD)||Completed|August 1993|||||N/A|Observational|Primary Purpose: Screening||||90|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004753||207504|
NCT00004754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11678|Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension|||Office of Rare Diseases (ORD)||Completed|August 1993|||||Phase 4|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004754||207503|
NCT00004686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13298|Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis|||FDA Office of Orphan Products Development||Completed|February 1994|September 1999||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|50 Years|N/A|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004686||207532|
NCT00004785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11874|Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia|||Office of Rare Diseases (ORD)||Completed|November 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||54|||Both|N/A|2 Weeks|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004785||207482|
NCT00004776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11821|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome|||Office of Rare Diseases (ORD)||Completed|November 1993|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|4 Years|30 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004776||207487|
NCT00004778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11826|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery|||Office of Rare Diseases (ORD)||Completed|August 1993|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||1090|||Female|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004778||207486|
NCT00004759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11692|Methylprednisolone Given by 24-Hour or 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury|Phase III Randomized, Double-Blind Study of Methylprednisolone by 24- Versus 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury||Office of Rare Diseases (ORD)||Completed|December 1991|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||497|||Both|14 Years|N/A|No|||September 2008|September 8, 2008|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004759||207498|
NCT00004696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13359|Study of Morphine in Postoperative Infants to Allow Normal Ventilation|||FDA Office of Orphan Products Development||Completed|August 1994|July 1998||||N/A|Interventional|Allocation: Randomized||||100|||Both|N/A|1 Year|No|||May 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004696||207526|
NCT00004738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000089|Genetic Analysis of the Chiari I Malformation|Genetic Analysis of the Chiari I Malformation||National Institutes of Health Clinical Center (CC)||Recruiting|February 2000|||||N/A|Observational|N/A|||Anticipated|200|||Both|1 Year|N/A|No|||September 2015|September 26, 2015|February 26, 2000||No||No||https://clinicaltrials.gov/show/NCT00004738||207511|
NCT00004739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0130|The Metabolic Effects of Protease Inhibitors in HIV Infected Children|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Primary Purpose: Prevention|||||||Both|7 Years|18 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|February 29, 2000||||No||https://clinicaltrials.gov/show/NCT00004739||207510|
NCT00004669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12016|Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia|||Office of Rare Diseases (ORD)||Completed|June 1996|||||Phase 2|Interventional|Primary Purpose: Prevention||||40|||Both|N/A|1 Year|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004669||207536|
NCT00004769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11770|Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy|Myotonic Dystrophy:Muscle Wasting and Altered Metabolism||University of Rochester|No|Completed|December 1993|March 2000|Actual|March 2000|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|130|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|National sample|January 2013|January 25, 2013|February 24, 2000||No||No||https://clinicaltrials.gov/show/NCT00004769||207492|
NCT00004748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11664|Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis||Office of Rare Diseases (ORD)||Completed|November 1989|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004748||207506|
NCT00004751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11667|Phase II Randomized Study of Selective Dorsal Rhizotomy and Physiotherapy Vs Physiotherapy Alone for Spastic Diplegia|||Office of Rare Diseases (ORD)||Active, not recruiting|October 1991|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|3 Years|18 Years|No|||February 1997|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004751||207505|
NCT00004705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13446|Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis|||FDA Office of Orphan Products Development||Completed|September 1996|January 1999||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|4 Years|N/A|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004705||207522|
NCT00004727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS033430|Antiplatelet Therapy to Prevent Stroke in African Americans|African American Antiplatelet Stroke Prevention Study||National Institute of Neurological Disorders and Stroke (NINDS)||Completed||||||Phase 4|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|29 Years|85 Years|No|||June 2003|June 23, 2005|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004727||207521|
NCT00004779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11829|Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis|||Office of Rare Diseases (ORD)||Completed|January 1993|||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||12|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004779||207485|
NCT00004781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11861|Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups|||Office of Rare Diseases (ORD)||Completed|September 1989|||||N/A|Observational|Primary Purpose: Screening||||250|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 1997|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004781||207484|
NCT00004652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11760|Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome|||Office of Rare Diseases (ORD)||Completed|February 1993|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||20|||Both|5 Years|11 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004652||207548|
NCT00004654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11799|Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia|||Office of Rare Diseases (ORD)||Completed|January 1996|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||60|||Both|15 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004654||207547|
NCT00004763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11717|Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism|||Office of Rare Diseases (ORD)||Completed|January 1993|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||45|||Female|15 Years|40 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004763||207494|
NCT00004688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13310|Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms|||FDA Office of Orphan Products Development||Completed|August 1996|July 1998||||Phase 2|Interventional|Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004688||207531|
NCT00004728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS036643|Aspirin Or Warfarin To Prevent Stroke|Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study||National Institute of Neurological Disorders and Stroke (NINDS)||Terminated||July 2003||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|40 Years|N/A|No|||June 2006|June 5, 2006|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004728||207520|
NCT00004794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11927|Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis|||Office of Rare Diseases (ORD)||Completed|March 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||90|||Both|13 Years|60 Years|No|||January 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004794||207475|
NCT00004801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11956|Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency|||Office of Rare Diseases (ORD)||Completed|March 1992|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||3|||Both|12 Years|N/A|No|||January 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004801||207469|
NCT00004663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11926|Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus Erythematosus|||Office of Rare Diseases (ORD)||Completed|February 1994|||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||480|||Female|18 Years|50 Years|No|||July 2004|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004663||207540|
NCT00004789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11887|Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria|||Office of Rare Diseases (ORD)||Completed|July 1993|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||59|||Both|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004789||207478|
NCT00004729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS035980|Ketogenic Diet for Child Epilepsy and Seizure Control|Efficacy of the Ketogenic Diet -- a Blinded Study||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|July 1997|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Year|10 Years|No|||December 2006|December 21, 2006|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004729||207519|
NCT00004756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11686|Study of Individualized Instruction Versus Pamphlet in Systemic Lupus Erythematosus|Randomized Study of Individualized Instruction Versus Pamphlet in Systemic Lupus Erythematosus||Office of Rare Diseases (ORD)||Completed|December 1994|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Educational/Counseling/Training||||150|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004756||207501|
NCT00004757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11687|Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth|||Office of Rare Diseases (ORD)||Completed|August 1992|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|29 Days|No|||January 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004757||207500|
NCT00004670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12083|Phase II Study of Pallidotomy for Parkinson Disease|||Office of Rare Diseases (ORD)||Completed|October 1994|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||60|||Both|30 Years|75 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004670||207535|
NCT00004682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13250|Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis|||FDA Office of Orphan Products Development||Terminated|March 1995|March 1999||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||100|||Both|15 Years|N/A|No|||March 1999|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004682||207534|
NCT00004736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5062|Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis|Viral and Immune Dynamics in HIV-Infected Patients With Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||44|||Both|18 Years|N/A|No|||June 2003|September 10, 2008|February 25, 2000||||No||https://clinicaltrials.gov/show/NCT00004736||207512|
NCT00004825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13283|Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism|||FDA Office of Orphan Products Development||Completed|May 1998|May 1998||||N/A|Interventional|Primary Purpose: Treatment||||10|||Both|1 Month|18 Years|No|||July 1998|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004825||207454|
NCT00004579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV124|A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection|A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults||NIH AIDS Clinical Trials Information Service||Completed|April 1998|||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2003|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00004579||207571|
NCT00004580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285B|A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors|Phase I/II Study of ABT-378/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients||Abbott||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00004580||207570|
NCT00004151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16991N|Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer|Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Advanced Non Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 1999|||November 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004151||207864|
NCT00004152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-004|PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma|A Pilot Study to Compare 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) Scanning in Addition to CT Scanning With CT Scanning Alone in the Pre-Operative Evaluation of Patients With Stage III and IV Melanoma||Memorial Sloan Kettering Cancer Center||Completed|February 1999|||December 2002|Actual|Phase 2|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||January 2013|January 15, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004152||207863|
NCT00004550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000067|Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions|The Evaluation and Follow-up of Patients With Obsessive-Compulsive Disorder and OC Spectrum Disorders||National Institutes of Health Clinical Center (CC)||Completed|January 2000|April 2008||||N/A|Observational|N/A||||400|||Both|18 Years|N/A|No|||April 2008|September 26, 2015|February 3, 2000||||No||https://clinicaltrials.gov/show/NCT00004550||207599|
NCT00004551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|934-97|Behavioral Counseling for Alcohol Dependent Smokers (Nicotine Patch)|Mood Management Training for Alcohol Dependent Smokers||Mayo Clinic||Completed|February 1999|January 2003|Actual|January 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|144|||Both|18 Years|N/A|No|||September 2010|September 28, 2010|February 3, 2000||No||No||https://clinicaltrials.gov/show/NCT00004551||207598|
NCT00004552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAOMA03510|Acamprosate Treatment: Mechanisms of Action|Etiology and Treatment of Alcohol Dependence||Yale University||Completed||December 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||120|||Both|21 Years|55 Years|No|||June 2015|June 30, 2015|February 3, 2000||||No||https://clinicaltrials.gov/show/NCT00004552||207597|
NCT00004585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307A|A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults|A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy With Combivir (Lamivudine 150mg/Zidovudine 300mg) BID, Ziagen (Abacavir) 300mg BID, and Sustiva (Efavirenz) 600mg QD for 24 Weeks, Followed by the Triple Nucleoside Combination Tablet (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) BID Plus Sustiva (Efavirenz) 600mg QD for 24 Weeks in HIV-Infected Adults||NIH AIDS Clinical Trials Information Service||Completed|October 1999|||||Phase 4|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||November 2000|June 23, 2005|February 15, 2000||||No||https://clinicaltrials.gov/show/NCT00004585||207565|
NCT00004486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14266|Randomized Study of Fluoxetine in Children and Adolescents With Autism|||FDA Office of Orphan Products Development||Completed|September 1998|December 2002||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|5 Years|17 Years|No|||December 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004486||207615|
NCT00004490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14271|Phase III Randomized Study of Sodium Dichloroacetate in Children With Congenital Lactic Acidosis|||FDA Office of Orphan Products Development||Completed|October 1998|September 2002||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|3 Months|18 Years|No|||April 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004490||207611|
NCT00004478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14180|Droxidopa in Treating Patients With Neurogenic Hypotension|Study of Droxidopa in Patients With Neurologic Hypotension||Office of Rare Diseases (ORD)||Completed|March 1999|March 2006|Actual|March 2006|Actual|N/A|Interventional|Primary Purpose: Treatment|||||||Both|20 Years|N/A|No|||September 2008|September 17, 2008|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004478||207622|
NCT00004558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126|Antiarrhythmic Effects of N-3 Fatty Acids|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1999|January 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||December 2005|February 17, 2016|February 9, 2000||||No||https://clinicaltrials.gov/show/NCT00004558||207592|
NCT00004574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000076|Vitamin Replacement in Abetalipoproteinemia|Vitamin Replacement in Abetalipoproteinemia||National Institutes of Health Clinical Center (CC)||Completed|February 2000|May 2001||||N/A|Observational|N/A||||1|||Both|N/A|N/A|No|||December 1999|March 3, 2008|February 17, 2000||||No||https://clinicaltrials.gov/show/NCT00004574||207576|
NCT00004165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 97H6T|Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma||Northwestern University|Yes|Completed|October 1999|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2012|May 31, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004165||207851|
NCT00004149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067382|Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy|A Phase II Trial of Arsenic Trioxide in Advanced Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|September 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||July 2004|July 7, 2011|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004149||207866|
NCT00004382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12022|Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns|||Office of Rare Diseases (ORD)||Completed|December 1999|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||80|||Both|N/A|24 Hours|No|||September 2008|September 8, 2008|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004382||207684|
NCT00004220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067461|Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer|A Phase I Study of Oxaliplatin in Combination With Gemcitabine||City of Hope Medical Center||Completed|October 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 11, 2010|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004220||207802|
NCT00004157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1365.00|Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors|Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC)||Fred Hutchinson Cancer Research Center||Completed|August 2000|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||March 2010|March 31, 2010|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004157||207859|
NCT00004450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13532|Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy|||FDA Office of Orphan Products Development||Completed|August 1998|November 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Male|4 Years|N/A|No|||January 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004450||207635|
NCT00004485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14243|Bone Marrow Transplantation in Treating Children With Sickle Cell Disease|Phase I/II Study of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation From HLA-Identical Donors in Children With Sickle Cell Disease||Office of Rare Diseases (ORD)||Completed|December 1999|||August 2007|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||50|||Both|N/A|16 Years|No|||September 2008|September 8, 2008|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004485||207616|
NCT00004487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14267|Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux|||FDA Office of Orphan Products Development||Active, not recruiting|May 1999|||||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|6 Months|18 Years|No|||April 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004487||207614|
NCT00004492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14273|Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia|||FDA Office of Orphan Products Development||Completed|October 1999|September 2001||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||January 2001|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004492||207610|
NCT00004562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130|Occluded Artery Trial (OAT)|Occluded Artery Trial (OAT) - Randomized Comparative Effectiveness Trial of PCI and Medical Therapy Only Post MI|OAT|New York University School of Medicine|Yes|Completed|September 1999|June 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2201|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|February 9, 2000|Yes|Yes||No|May 7, 2010|https://clinicaltrials.gov/show/NCT00004562||207588|
NCT00004496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14286|Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure|||FDA Office of Orphan Products Development||Completed|February 1999|September 2003||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|80 Years|No|||August 1999|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004496||207606|
NCT00004497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14287|Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension|||FDA Office of Orphan Products Development||Completed|October 1998|September 2000||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|8 Years|75 Years|No|||September 1999|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004497||207605|
NCT00004498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14290|Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency|||FDA Office of Orphan Products Development||Terminated|July 1998|September 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||21|||Both|18 Years|69 Years|No|||February 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004498||207604|
NCT00004573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0728|Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||November 2001|June 23, 2005|February 18, 2000||||No||https://clinicaltrials.gov/show/NCT00004573||207577|
NCT00004563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220|Scleroderma Lung Disease|Cyclophosphamide Versus Placebo in Scleroderma Lung Study|SLS|The University of Texas Health Science Center, Houston|No|Completed|August 1999|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|158|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|February 9, 2000|Yes|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT00004563||207587|
NCT00004564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1659|The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A|||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 2003|June 23, 2005|February 11, 2000||||No||https://clinicaltrials.gov/show/NCT00004564||207586|
NCT00004577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000082|Study of New Magnetic Resonance Imaging Methods of the Brain|Characterization of Brain Morphology and Activity Using Functional and Anatomical MRI Contrast||National Institutes of Health Clinical Center (CC)||Recruiting|February 2000|||||N/A|Observational|N/A|||Anticipated|650|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 10, 2015|February 18, 2000||No||No||https://clinicaltrials.gov/show/NCT00004577||207573|
NCT00004161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067401|Fenretinide in Treating Patients With Leukoplakia of the Mouth|A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia||University of Alabama at Birmingham|Yes|Completed|June 1997|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004161||207855|
NCT00004570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000073|Hereditary Deficits in Auditory Processing Leading to Language Impairment|Identification of Hereditary Auditory Temporal Processing Deficits||National Institutes of Health Clinical Center (CC)||Completed|February 2000|||||N/A|Observational|N/A|||Actual|875|||Both|6 Years|85 Years|No|||September 2015|October 6, 2015|February 14, 2000||No||No||https://clinicaltrials.gov/show/NCT00004570||207580|
NCT00004162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067402|Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma|Phase I Trial of Liposomal Doxorubicin (Doxil) Based Combination Chemotherapy Regimen in AIDS-Associated Non-Hodgkin's Lymphoma||University of Alabama at Birmingham|Yes|Completed|June 1997|January 2001|Actual|January 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|48|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004162||207854|
NCT00004163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067405|Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer|Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2001|February 6, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004163||207853|
NCT00004159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067399|Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor|Biweekly Gemcitabine and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer and Solid Tumors: A Phase I/IIa Study||University of Alabama at Birmingham||Terminated|February 2000|February 2000|Actual|February 2000|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|54|||Both|18 Years|N/A|No|||March 2013|November 18, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004159||207857|
NCT00004164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067408|Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx|A Phase II Trial of Docetaxel, Cisplatin, 5-FU, and Leucovorin for Carcinoma of the Nasopharnyx||National Cancer Institute (NCI)||Active, not recruiting|August 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2000|February 6, 2009|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004164||207852|
NCT00004466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13924|Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome|||Office of Rare Diseases (ORD)||Completed|October 1998|December 1999||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|6 Years|17 Years|No|||June 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004466||207628|
NCT00004488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14269|Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease|||FDA Office of Orphan Products Development||Completed|October 1998|September 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|82|||Both|18 Years|50 Years|No|||March 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004488||207613|
NCT00004493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14274|Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia|||FDA Office of Orphan Products Development||Completed|September 1998|September 2003||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|75|||Both|3 Months|N/A|No|||May 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004493||207609|
NCT00004494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14275|Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis|||Stony Brook University||Recruiting|September 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||August 1999|March 7, 2013|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004494||207608|
NCT00004553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000072|Electromyography to Diagnose Neuromuscular Disorders|Diagnosis of Neuromuscular Disorders With Specialized Electromyographic Studies||National Institutes of Health Clinical Center (CC)||Completed|February 2000|November 2005||||N/A|Interventional|N/A||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|February 4, 2000||||No||https://clinicaltrials.gov/show/NCT00004553||207596|
NCT00004557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920075|Models of Disordered Knowledge and Memory Systems in Dementia and Related Disorders|Models of Disordered Knowledge and Memory Systems in Dementia and Related Disorders||National Institutes of Health Clinical Center (CC)||Completed|January 1992|April 2000||||N/A|Observational|N/A||||650|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 1999|March 3, 2008|February 8, 2000||||No||https://clinicaltrials.gov/show/NCT00004557||207593|
NCT00004571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000085|Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers|Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 3.0 Tesla MRI and Magnetoencephalography||National Institutes of Health Clinical Center (CC)||Recruiting|February 2000|||||N/A|Observational|N/A|||Anticipated|2920|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 5, 2015|February 15, 2000||No||No||https://clinicaltrials.gov/show/NCT00004571||207579|
NCT00004549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000065|Magnetic Resonance Imaging to Detect Blood Vessel Inflammation in Patients Undergoing Peripheral Balloon Angioplasty|MRI Detection of Vascular Inflammation in Patients Undergoing Peripheral Angioplasty||National Institutes of Health Clinical Center (CC)||Completed|January 2000|January 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2002|March 3, 2008|February 3, 2000||||No||https://clinicaltrials.gov/show/NCT00004549||207600|
NCT00004576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000084|Study of LY300164 for the Treatment of Parkinson's Disease|AMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|February 2000|August 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||February 2000|March 3, 2008|February 17, 2000||||No||https://clinicaltrials.gov/show/NCT00004576||207574|
NCT00004166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 97CC4|Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy|Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial||Northwestern University|Yes|Completed|October 1999|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||May 2012|May 31, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004166||207850|
NCT00004554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAPET09544|Sertraline for Alcohol Dependence and Depression|Sertraline for Alcohol Dependence and Depression||University of Pennsylvania|No|Completed|January 2000|February 2006|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|171|||Both|21 Years|65 Years|No|||September 2013|October 2, 2015|February 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004554||207595|
NCT00004567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000075|Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes|A Randomized Trial Comparing Methotrexate Versus Mycophenolate Mofetil for Remission Maintenance in Wegener's Granulomatosis and Related Vasculitides||National Institutes of Health Clinical Center (CC)||Completed|February 2000|June 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|No|||June 2004|March 3, 2008|February 11, 2000||||No||https://clinicaltrials.gov/show/NCT00004567||207583|
NCT00004482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14209|Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis|||Mayo Clinic|Yes|Completed|December 1999|July 2006|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2010|September 8, 2010|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004482||207618|
NCT00004197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-99|Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma|A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma||University of Nebraska||Completed|June 1999|November 2003|Actual|January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2010|June 23, 2010|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004197||207824|
NCT00004198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196-99|Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma|A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Indolent B Cell Lymphoma||University of Nebraska|No|Completed|June 1999|November 2003|Actual|January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2010|June 23, 2010|January 21, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004198||207823|
NCT00004160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067400|Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed|Sequential and Concomitant Chemoradiotherapy With Gemcitabine-Based Chemotherapy for Inoperable Stage IIIa and IIIb Non-Small Cell Lung Cancer: A Phase I/IIa Study||University of Alabama at Birmingham|Yes|Completed|February 2000|May 2004|Actual|May 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|72|||Both|N/A|N/A|No|||October 2005|November 25, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004160||207856|
NCT00004153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9308|Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma|Sensitive RT-PCR Analysis for Melanoma Markers From Lymph Nodes and Peripheral Blood in Patients With Melanoma||University of Chicago|No|Completed|June 1998|January 2005|Actual|March 2004|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|106|||Both|N/A|N/A|No|||September 2013|September 4, 2013|December 10, 1999||No||No||https://clinicaltrials.gov/show/NCT00004153||207862|
NCT00004158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1442.00|Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase I/II Study of Targeted Radiotherapy Using Holmium-166-DOTMP With Melphalan and Peripheral Blood Stem Cell Transplantation for Treatment of Multiple Myeloma||Fred Hutchinson Cancer Research Center||Completed|June 1999|January 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||September 2010|September 17, 2010|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004158||207858|
NCT00004500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL4-MAS-03|Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome|A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Bronchoalveolar Lavage With Lucinactant to Standard Care for the Treatment of the Meconium Aspriation Syndrome (MAS) in Newborn Infants||Discovery Laboratories, Inc.|Yes|Terminated|March 2000|November 2004|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|N/A|48 Hours|No|||May 2012|May 1, 2012|October 18, 1999|Yes|Yes|Slow enrollment and administrative reasons|No|April 2, 2012|https://clinicaltrials.gov/show/NCT00004500||207603|Early termination led to a small number of subjects analyzed. Results should be interpreted with caution.
NCT00004572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0129|Identification and Therapy Efficacy of Type 2 Diabetes in Hispanic Patients|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Observational|Observational Model: Defined Population|||||||Both|10 Years|18 Years|No|||April 2000|June 23, 2005|February 16, 2000||||No||https://clinicaltrials.gov/show/NCT00004572||207578|
NCT00004171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 87H6T|Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma|Autologous Blood Stem Cell Transplantation in Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma Who Have Had Prior Radiation Therapy||Northwestern University|Yes|Completed|October 1999|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||June 2012|June 8, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004171||207848|
NCT00004495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14276|Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis|||FDA Office of Orphan Products Development||Completed|June 1999|September 2000||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Anticipated|84|||Both|21 Years|89 Years|No|||August 1999|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004495||207607|
NCT00004556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910230|The Effects of Dextroamphetamine on Brain Function|Mechanisms of Individual Variation of Dextroamphetamine Effects in Normal Human Subjects||National Institutes of Health Clinical Center (CC)||Completed|September 1991|||||N/A|Observational|N/A|||Actual|108|||Both|18 Years|45 Years|No|||June 2015|June 19, 2015|February 8, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004556||207594|
NCT00004569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00096-0938|Incorporating Flow Limitation Into the Diagnosis and Quantification of Sleep Disordered Breathing|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||January 2004|June 23, 2005|February 12, 2000||||No||https://clinicaltrials.gov/show/NCT00004569||207581|
NCT00004169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 93H2|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease|High-Dose Chemoradiotherapy With Stem Cell Support in Patients With Relapsed or Refractory Hodgkin's Disease||Northwestern University|Yes|Completed|November 1993|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||June 2012|June 21, 2012|December 10, 1999|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004169||207849|
NCT00004489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14270|Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis|||FDA Office of Orphan Products Development||Completed|October 1998|September 2002||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|45 Years|No|||January 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004489||207612|
NCT00004442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13442|Study of Bile Acids in Patients With Peroxisomal Disorders|||FDA Office of Orphan Products Development||Terminated||April 1999||||N/A|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|N/A|5 Years|No|||November 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004442||207642|
NCT00004443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13443|Study of NTBC for Tyrosinemia I|||FDA Office of Orphan Products Development||Completed|October 1998|September 2006||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|17 Years|No|||April 2000|March 24, 2015|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004443||207641|
NCT00004565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000079|Susceptibility to Breast Cancer|Susceptibility to Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2000|May 2012||||N/A|Observational|N/A|||Actual|49|||Female|N/A|N/A|No|||May 2012|October 9, 2014|February 11, 2000||No||No||https://clinicaltrials.gov/show/NCT00004565||207585|
NCT00004566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000081|Study of Fetal Swallowing|Pilot Study: Ultrasonic Evaluation of the Development of the Fetal Upper Aerodigestive Tract: Establishing Clinical Indicators of Deglutitive Function||National Institutes of Health Clinical Center (CC)||Completed|February 2000|May 2004||||N/A|Observational|N/A||||120|||Both|N/A|N/A|No|||May 2004|March 3, 2008|February 11, 2000||||No||https://clinicaltrials.gov/show/NCT00004566||207584|
NCT00004533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14137|Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis|||Office of Rare Diseases (ORD)||Active, not recruiting|August 1999|||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||19|||Both|15 Years|N/A|No|||February 2001|June 23, 2005|January 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004533||207602|
NCT00004547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000069|Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy|Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis||National Institutes of Health Clinical Center (CC)|No|Completed|January 2000|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|188|||Both|18 Years|N/A|No|||September 2015|October 19, 2015|February 3, 2000||No||No|August 30, 2011|https://clinicaltrials.gov/show/NCT00004547||207601|
NCT00004559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127|Fatty Acid Antiarrhythmia Trial (FAAT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1999|February 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||November 2005|March 15, 2016|February 9, 2000||||No||https://clinicaltrials.gov/show/NCT00004559||207591|
NCT00004560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128|Public Access Defibrillation (PAD) Community Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|February 2004||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||November 2005|December 1, 2005|February 9, 2000||||No||https://clinicaltrials.gov/show/NCT00004560||207590|
NCT00004561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129|Treatment of Hypertension With Two Exercise Intensities|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1997|May 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|75 Years|No|||August 2004|February 25, 2016|February 9, 2000||||No||https://clinicaltrials.gov/show/NCT00004561||207589|
NCT00004568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000043|Study of Inherited Neurological Disorders|Clinical and Molecular Manifestations of Inherited Neurological Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|February 2000|||||N/A|Observational|N/A|||Anticipated|2500|||Both|N/A|N/A|No|||January 2016|February 3, 2016|February 11, 2000||No||No||https://clinicaltrials.gov/show/NCT00004568||207582|
NCT00004150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067383|High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer|Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid||National Cancer Institute (NCI)||Completed|March 1999|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2001|November 5, 2013|December 10, 1999||||No||https://clinicaltrials.gov/show/NCT00004150||207865|
NCT00004209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICRF-95.240|Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Randomized Study of MVP 3 Versus 6 Cycles in Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|August 6, 2013|January 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004209||207812|
NCT00004148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067380|Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma|A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma||National Cancer Institute (NCI)||Completed|October 1999|||April 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2006|February 8, 2013|December 10, 1999|No|Yes||No||https://clinicaltrials.gov/show/NCT00004148||207867|
NCT00004483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14226|NF2 Natural History Consortium|||Office of Rare Diseases (ORD)||Active, not recruiting|January 2002|||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|5 Years|N/A|No|||September 2005|September 27, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004483||207617|
NCT00005005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 AR92245|PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis|Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis||University of California, San Francisco||Completed|October 1999|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|238|||Female|55 Years|85 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|March 24, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005005||207322|
NCT00004916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98H2|Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|Phase I/II Study of Mesna, Ifosfamide, Teniposide and Weekly Taxol (MITTen) in Relapsed Lymphoma||Northwestern University|Yes|Completed|February 1999|October 2002|Actual|October 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004916||207373|
NCT00004917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9903|Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer|A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiotherapy for Carcinoma of the Head and Neck||Radiation Therapy Oncology Group|Yes|Completed|June 2000|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2015|November 14, 2015|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004917||207372|
NCT00005006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AR039191|Parathyroid Hormone (PTH) With Alendronate for Osteoporosis|Cyclical vs Daily Continuous PTH in Combination With Alendronate vs Alendronate Alone||Helen Hayes Hospital|No|Completed|September 1987|December 2006|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|140|||Female|50 Years|N/A|No|||August 2015|August 17, 2015|March 24, 2000||No||No||https://clinicaltrials.gov/show/NCT00005006||207321|
NCT00004903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067582|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase II Study of High Dose Late Intensification Therapy in Patients With Chemotherapy Sensitive Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|October 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||June 2001|January 3, 2014|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004903||207386|
NCT00004935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 22/99|Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2|Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.||Swiss Group for Clinical Cancer Research|Yes|Active, not recruiting|August 1999|June 2018|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Female|18 Years|70 Years|No|||September 2015|September 28, 2015|March 7, 2000||No||No||https://clinicaltrials.gov/show/NCT00004935||207354|
NCT00004893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067570|Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer|Evaluation of Novel Therapeutic Agents Against Breast Cancer: An Innovative Randomized Phase II Trial Design||Alliance for Clinical Trials in Oncology|No|Terminated|December 1999|February 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||September 2013|October 16, 2013|March 7, 2000|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00004893||207395|
NCT00004912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA98CC6|Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss|Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss||Northwestern University|Yes|Completed|January 2000|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2012|May 17, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004912||207377|
NCT00005023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067339|Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer|A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers||University of Washington||Completed|March 1999|January 2001|Actual|January 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2012|December 12, 2012|April 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005023||207306|
NCT00004936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067622|MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients|Role of Radiology in the Pretreatment Evaluation of Invasive Cervical Cancer|ACRIN 6651|American College of Radiology Imaging Network|Yes|Completed|April 2000|October 2002|Actual|May 2001|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Female|N/A|N/A|No|||January 2013|January 25, 2013|March 7, 2000||No||No||https://clinicaltrials.gov/show/NCT00004936||207353|
NCT00004919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01846|Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy|A Trial of Irinotecan and Cisplatin in Children With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|December 1999|||March 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|1 Year|21 Years|No|||July 2013|July 1, 2013|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004919||207370|
NCT00004877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067537|BMS-214662 in Treating Patients With Advanced Solid Tumors|Phase I Study of BMS-214662 Oral Dosing in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|July 1999|||April 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|December 2, 2009|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004877||207410|
NCT00004878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067538|Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia|A Study to Determine the Safety and Efficacy of Using CD8-High Density Microparticles (CD8-HDM) to Deplete CD8+ Cells From Donor Lymphocyte Infusion in Order to Reduce Graft-versus-Host Disease (GvHD) Without Compromising an Anti-Leukemia Effect in Patients With Chronic Myeloid Leukemia Given HLA-Identical Sibling Peripheral Blood Stem Cell Transplants After Non-Myeloablative Conditioning||Jonsson Comprehensive Cancer Center||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Actual|0|||Both|50 Years|70 Years|No|||July 2012|July 27, 2012|March 7, 2000|||study never opened|No||https://clinicaltrials.gov/show/NCT00004878||207409|
NCT00004929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-056|Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer|Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Examining the Immunogenicity of Glycosylated MUC-2-KLH Peptide Conjugate Vaccine||Memorial Sloan Kettering Cancer Center||Completed|September 1999|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|No|||January 2013|January 30, 2013|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004929||207360|
NCT00004940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13376|Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria|||FDA Office of Orphan Products Development||Completed|May 1996|September 2001||||Phase 3|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||April 2000|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004940||207349|
NCT00004900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-HAC98B2|Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer|A Phase II Pilot Study of Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support Without Conventional-Dose Induction Chemotherapy for Women With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|October 1999|August 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|65 Years|No|||October 2007|May 29, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004900||207389|
NCT00004920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08983|Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura|Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 1999|||January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|256|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004920||207369|
NCT00004908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 87H5T|Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma|Autologous Blood Stem Cell Transplantation in Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma With High-Dose Cyclophosphamide, Total Body Irradiation and Involved-Field Radiation Therapy||Northwestern University|Yes|Completed|November 1999|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||August 2011|August 25, 2011|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004908||207381|
NCT00004872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067532|Endostatin in Treating Patients With Advanced Refractory Solid Tumors|Phase I Study of Endostatin in Advanced Cancer Patients||University of Wisconsin, Madison||Completed|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||September 2015|September 30, 2015|March 7, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004872||207415|
NCT00004934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067620|Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer||National Cancer Institute (NCI)||Completed|August 1999|May 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2003|February 1, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004934||207355|
NCT00004985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286D|Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy|A Phase II, Single-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen||NIH AIDS Clinical Trials Information Service||Completed|January 2000|||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||March 2001|June 23, 2005|March 15, 2000||||No||https://clinicaltrials.gov/show/NCT00004985||207340|
NCT00004928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-073|Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer|A Phase I Study of 1,25 Dihydroxy-Vitamin D3 (Calcitriol) in Patients With Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|October 1999|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2013|June 18, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004928||207361|
NCT00004938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11815|Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis|||Office of Rare Diseases (ORD)||Completed|August 1996|August 1996||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||30|||Both|12 Years|N/A|No|||April 2000|June 8, 2006|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004938||207351|
NCT00004922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-041|Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors|A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors||Memorial Sloan Kettering Cancer Center||Completed|June 1999|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004922||207367|
NCT00004941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13447|Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease|||FDA Office of Orphan Products Development||Completed|July 1996|July 1996||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||94|||Both|18 Years|65 Years|No|||April 2000|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004941||207348|
NCT00004904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA97H1|Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 "Veto" Cells||Northwestern University|Yes|Completed|October 1999|July 2000|Actual|July 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|45 Years|No|||May 2012|May 31, 2012|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004904||207385|
NCT00004986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253C|Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients|Open Label, Multi-Center Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in Subjects With AIDS in the United States||NIH AIDS Clinical Trials Information Service||Terminated|February 2000|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||August 2000|June 23, 2005|March 16, 2000||||No||https://clinicaltrials.gov/show/NCT00004986||207339|
NCT00004930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-049|Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases|Phase I and Clinical Pharmacologic Study of Inhaled Doxorubicin in Adults With Advanced Solid Tumors Affecting the Lungs||Memorial Sloan Kettering Cancer Center||Completed|July 1999|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004930||207359|
NCT00004918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03086|Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome|A Phase I/II Study of PR1 (NSC 698102) Human Leukemia Peptide Vaccine With Montanide ISA 51 (NSC 675756) or Montanide ISA 51 VG (NSC 737063) Adjuvant||National Cancer Institute (NCI)||Completed|December 1999|||December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|69|||Both|19 Years|N/A|No|||January 2013|January 4, 2013|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004918||207371|
NCT00004915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98G1|Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer|Phase II Study of Raloxifene in Recurrent Endometrial Cancer||Northwestern University|Yes|Completed|November 1998|February 2000|Actual|February 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2012|May 31, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004915||207374|
NCT00004909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98Q3|Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer|The Impact of Oral Chemotherapy on Quality of Life in Patients With Recurrent Epithelial Ovarian Cancer||Northwestern University|Yes|Completed|November 1999|November 2002|Actual|November 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|40|||Female|18 Years|N/A|No|Non-Probability Sample|Patients determined to have recurrent, persistent, or progressive cancer and scheduled to        undergo either oral or parenteral chemotherapy as prescribed by the treating physician.|February 2011|February 18, 2011|March 7, 2000||No||No||https://clinicaltrials.gov/show/NCT00004909||207380|
NCT00004880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067542|Vaccine Therapy in Treating Patients With Advanced Kidney Cancer|A Phase I Pilot Trial of a Multi-Antigen Loaded Dendritic Cell Vaccine for the Treatment of Advanced Renal Cell Carcinoma||Jonsson Comprehensive Cancer Center|No|Completed|June 1997|||April 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|14|||Both|18 Years|N/A|No|||July 2012|October 1, 2015|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004880||207407|
NCT00004873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 42/99|Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer|Taxotere-Cisplatin-5FU (TCF) Versus Taxotere-Cisplatin (TC) Versus Epirubicin-Cisplatin-5FU (ECF) as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial||Swiss Group for Clinical Cancer Research||Completed|August 1999|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||May 2012|May 14, 2012|March 7, 2000||No||No||https://clinicaltrials.gov/show/NCT00004873||207414|
NCT00004932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9973|STI571 in Treating Patients With Recurrent Leukemia|A Phase I Study of STI571 in Ph+ Leukemia||Children's Oncology Group|Yes|Completed|January 2002|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|31|||Both|N/A|21 Years|No|||February 2014|February 20, 2014|March 7, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004932||207357|
NCT00004939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11963|Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy|||Office of Rare Diseases (ORD)||Completed|August 1996|August 1996||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||34|||Both|20 Years|80 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004939||207350|
NCT00004901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-V95N4|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer|A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer||National Cancer Institute (NCI)||Completed|October 1999|July 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|June 25, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004901||207388|
NCT00004993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANENE (completed)|Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis|Can PTH Reverse Glucocorticoid-induced Osteoporosis||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 1999|August 2001||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||March 2010|March 1, 2010|March 17, 2000||||No||https://clinicaltrials.gov/show/NCT00004993||207333|
NCT00004885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40986|Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer|CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 1999|||July 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|430|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004885||207403|
NCT00004886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16992|MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Study to Determine the Safety of MS-209 in Combination With Docetaxel in Patients With a Solid Progressive Tumor||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1999|||June 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004886||207402|
NCT00004914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98CC7|Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue|A Phase II Trial of Progressive Resistance Training (PRT) Plus Procrit for the Treatment of Anemia-Related Fatigue in Cancer Patients||Northwestern University|Yes|Completed|January 2000|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004914||207375|
NCT00004905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMC-5892|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia|Pilot Study of Intensive Chemotherapy Followed by Peripheral Blood Stem Cell Harvesting for Autotransplantation of Adults With Chronic Myelogenous Leukemia and High Risk Acute Leukemia||National Cancer Institute (NCI)||Completed|October 1999|September 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||February 2001|May 29, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004905||207384|
NCT00004906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-H97B1|Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer|A Phase II Multi-Institution Study of Docetaxel and Doxorubicin as Induction Therapy Followed by Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support for Women With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|October 1999|June 2001|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|65 Years|No|||November 2007|May 29, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004906||207383|
NCT00004870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067529|Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase I/II, Pharmacokinetic, and Biologic Correlative Study of G3139, NSC # 683428 (Phosphorothioate Antisense Oligonucleotide Directed to Bcl-2) and Irinotecan in Patients With Metastatic Colorectal Cancer||The University of Texas Health Science Center at San Antonio||Completed|June 2000|September 2002|Actual|September 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 19, 2013|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004870||207417|
NCT00004871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067531, J9950|Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate (PB, NSC 657802) in Combination With 5-Azacytidine (5-AZA, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)||Sidney Kimmel Comprehensive Cancer Center||Completed|May 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|March 9, 2010|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004871||207416|
NCT00004933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-19807|Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa|A Phase III Study of Interferon-Refractory Patients With BCR/ABL(+) Chronic Myelogenous Leukemia (CML) Treated With Homoharringtonine (NSC #141633) vs. Hydroxyurea||Alliance for Clinical Trials in Oncology|Yes|Terminated|January 2000|May 2001|Actual|May 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|16 Years|N/A|No|||June 2015|June 23, 2015|March 7, 2000|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00004933||207356|
NCT00004931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03165|Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer|A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon||National Cancer Institute (NCI)||Completed|February 2000|||September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2472|||Both|N/A|N/A|No|||January 2013|January 10, 2013|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004931||207358|
NCT00004881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSGENE-TG4010.01|Vaccine Therapy in Treating Patients With Advanced Cancer|Phase I Bridging Trial of TG4010 as Antigen-Specific Immunotherapy in Patients With MUC-1 Positive Advanced Cancer||National Cancer Institute (NCI)||Completed|April 2000|May 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2001|June 25, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004881||207406|
NCT00004926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-99078|ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy|A Phase I Study of Oral ILX23-7553 in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|October 1999|December 2009|Actual|August 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|May 29, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004926||207363|
NCT00004927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS-CA163-001|BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy|Phase I Study of BMS-247550 Given Every Three Weeks in Patients With Advanced Malignancies||Bristol-Myers Squibb||Completed|July 1999|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2014|March 7, 2014|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004927||207362|
NCT00004994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000002|Comparison of Quality of Life in Patients Undergoing More Intensive Versus Less Intensive Chemotherapy and Radiation Preceding a Bone Marrow Transplant|A Study Comparing Quality of Life in Patients Undergoing a Non-Myeloablative Versus a Myeloablative Peripheral Blood Stem Cell Transplant for Hematological Diseases||National Institutes of Health Clinical Center (CC)||Completed|October 1999|October 2004||||N/A|Observational|N/A||||106|||Both|N/A|N/A|No|||October 2004|March 3, 2008|March 22, 2000||||No||https://clinicaltrials.gov/show/NCT00004994||207332|
NCT00004979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067543|Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors|Phase I/II Study of Oral Topotecan and Intravenous Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (Phases I and II) and Other Advanced Solid Tumors (Phase I Only)||National Cancer Institute (NCI)||Completed||September 2000|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2001|January 3, 2014|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004979||207346|
NCT00004883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02318|Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2|A Phase II Trial of Trastuzumab (Herceptin) for Advanced Stage (IIIB, IV), HER2 Overexpressing, Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|February 2000|||August 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004883||207405|
NCT00004980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063326|Repetitive Transcranial Magnetic Stimulation for "Voices"|Repetitive Transcranial Magnetic Stimulation of Speech Processing Brain Areas in Schizophrenic Patients Who Hear "Voices"||Yale University|Yes|Completed|December 1999|June 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||August 2013|August 5, 2013|March 10, 2000||No||No|November 25, 2008|https://clinicaltrials.gov/show/NCT00004980||207345|
NCT00004910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98CC2|Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction|A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy||Northwestern University|Yes|Completed|January 2000|February 2003|Actual|February 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004910||207379|
NCT00004892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067569|O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma|Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)||Completed|April 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2007|February 6, 2009|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004892||207396|
NCT00004902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA97H4|Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma|Phase II Pilot Evaluation of Infusional 8 Cl-cAMP in the Treatment of Relapsed or Refractory Multiple Myeloma||Northwestern University|Yes|Completed|January 1998|November 1999|Actual|November 1999|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 17, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004902||207387|
NCT00004999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286C|Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients|A Randomized, Double-Blind, Placebo-Controlled Study of AG1549 in Combination With Viracept (Nelfinavir Mesylate) and Combivir (Zidovudine + Lamivudine) in Treatment-Naive HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Suspended|August 1999|||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||March 2001|June 23, 2005|March 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004999||207328|
NCT00004879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067539|Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer|An Open Label, Multiple Dose, Dose-Rising Clinical Trial of the Safety of ABX-EGF in Patients With Renal, Prostate, Pancreatic, Non-Small-Cell Lung, Colorectal, or Esophageal Cancer||Jonsson Comprehensive Cancer Center||Completed|April 2000|||July 2005|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 7, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004879||207408|
NCT00004913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98X2|Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Study of Docetaxel Plus 5-FU, Cisplatin and Leucovorin in Patients With Advanced Solid Tumors||Northwestern University||Completed|January 2000|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004913||207376|
NCT00004924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067608|Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase II Trial of Irinotecan Plus Paclitaxel in Patients With Advanced Nonsmall Cell Lung Cancer||Yale University|No|Completed|March 1999|February 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|28|||Both|18 Years|N/A|No|||August 2009|August 21, 2009|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004924||207365|
NCT00004925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-054|Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer|Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|August 1999|August 2003|Actual|August 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 18, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004925||207364|
NCT00004907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 95H4T|Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma|High-Dose Chemoradiotherapy With Stem Cell Allogeneic Cellular Rescue in Patients With Relapsed or Refractory Hematologic Malignancy - A Phase I/II Study||Northwestern University|Yes|Completed|October 1999|August 2004|Actual|August 2004|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|60 Years|No|||June 2012|June 8, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004907||207382|
NCT00005000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259H|Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs|A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting|December 1999|||||Phase 4|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||July 2002|June 23, 2005|March 21, 2000||||No||https://clinicaltrials.gov/show/NCT00005000||207327|
NCT00005030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067553|SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver|A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Colorectal Carcinoma Metastatic to the Liver Scheduled for Exploratory Laparotomy and/or Resection||M.D. Anderson Cancer Center|No|Withdrawn|June 2000|September 2000|Actual|September 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|April 6, 2000||No|No enrollment.|No||https://clinicaltrials.gov/show/NCT00005030||207299|
NCT00005035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067571|Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer|A Phase II Study of Oxaliplatin in Patients With Advanced Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|December 1999|March 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2002|January 30, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005035||207295|
NCT00004978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPRIT 001|An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy|A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mm^3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial|ESPRIT|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2000|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4150|||Both|18 Years|N/A|No|||October 2012|May 1, 2013|March 10, 2000|Yes|Yes||No|January 20, 2011|https://clinicaltrials.gov/show/NCT00004978||207347|
NCT00004937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16991G|Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme|Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme||European Organisation for Research and Treatment of Cancer - EORTC||Completed|October 1999|||May 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2012|July 10, 2012|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004937||207352|
NCT00004911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98CC3|Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction|A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy||Northwestern University|Yes|Completed|January 2000|February 2003|Actual|February 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004911||207378|
NCT00005052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067645|Vaccine Therapy in Treating Patients With Primary Stage II Melanoma|Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation||National Cancer Institute (NCI)||Active, not recruiting|December 1999|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||January 2006|February 6, 2009|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005052||207279|
NCT00005004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000096|Brain Processing of Language Meanings|Investigations in Discourse Processes||National Institutes of Health Clinical Center (CC)||Completed|March 2000|March 2005||||N/A|Observational|N/A||||500|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2005|March 3, 2008|March 23, 2000||||No||https://clinicaltrials.gov/show/NCT00005004||207323|
NCT00004921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067604|High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery|A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer||National Cancer Institute (NCI)||Completed|September 1998|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|65 Years|No|||July 2002|September 16, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004921||207368|
NCT00004984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPT-1 (completed)|The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 1994|June 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|3 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|March 13, 2000||||||https://clinicaltrials.gov/show/NCT00004984||207341|
NCT00004923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067606|Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors|Dose Escalation Trial of Docetaxel Plus Irinotecan in Patients With Advanced Cancer||Yale University|No|Completed|April 1999|May 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|47|||Both|18 Years|N/A|No|||August 2009|August 21, 2009|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004923||207366|
NCT00004851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990090|Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies|Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies||National Institutes of Health Clinical Center (CC)||Completed|April 1999|May 2001||||N/A|Observational|N/A||||1|||Both|N/A|N/A|No|||March 2000|March 3, 2008|March 2, 2000||||No||https://clinicaltrials.gov/show/NCT00004851||207435|
NCT00004866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067525|DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix||Daiichi Sankyo Inc.||Completed|January 2000|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2012|May 15, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004866||207420|
NCT00004802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11958|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders|||Office of Rare Diseases (ORD)||Completed|June 1992|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|10 Years|75 Years|No|||January 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004802||207468|
NCT00004812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12017|Phase II Randomized Pilot Study of Body Weight Support and Treadmill Training for Chronic Thoracic Spinal Cord Injury|||Office of Rare Diseases (ORD)||Completed|July 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||26|||Both|16 Years|60 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004812||207459|
NCT00004895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 97X1|Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery|Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study||Northwestern University|Yes|Completed|October 1999|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004895||207394|
NCT00004360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11929|Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus|||Office of Rare Diseases (ORD)||Completed|September 1995|||||N/A|Observational|Primary Purpose: Screening|||||||Both|6 Months|70 Years|Accepts Healthy Volunteers|||December 1999|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004360||207699|
NCT00004361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11936|Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects|||Office of Rare Diseases (ORD)||Completed|July 1995|||||N/A|Observational|Primary Purpose: Screening||||150|||Both|18 Years|N/A|No|||January 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004361||207698|
NCT00004829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13390|Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis|||FDA Office of Orphan Products Development||Completed|June 1995|May 1998||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|6 Years|N/A|No|||June 1998|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004829||207450|
NCT00004832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13441|Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome|||FDA Office of Orphan Products Development||Completed|August 1994|June 1998||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||26|||Both|18 Years|N/A|No|||July 1998|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004832||207448|
NCT00004367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11945|Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia|||National Center for Research Resources (NCRR)||Completed|May 2000|||||N/A|Interventional|Primary Purpose: Diagnostic||||165|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004367||207693|
NCT00004853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000092|Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy|A Randomized Trial of Filgrastim-SD/01 vs. Filgrastim in Newly Diagnosed Children and Young Adults With Sarcoma Treated With Dose-Intensive Chemotherapy||National Institutes of Health Clinical Center (CC)||Completed|March 2000|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|N/A|25 Years|No|||January 2016|January 28, 2016|March 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004853||207433|
NCT00004770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11774|Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy|||Office of Rare Diseases (ORD)||Completed|October 1995|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||1|||Male|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004770||207491|
NCT00004771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11792|Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease|||Office of Rare Diseases (ORD)||Completed|October 1992|||||Phase 2|Interventional|Primary Purpose: Treatment||||40|||Male|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004771||207490|
NCT00004848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810110|A Controlled Prospective Study of Transfusion-Associated Hepatitis|A Controlled Prospective Study of Transfusion-Associated Hepatitis||National Institutes of Health Clinical Center (CC)||Completed|July 1981|May 2000||||N/A|Observational|N/A||||2000|||Both|N/A|N/A|No|||July 1999|March 3, 2008|March 2, 2000||||No||https://clinicaltrials.gov/show/NCT00004848||207437|
NCT00004827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13351|Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa|||FDA Office of Orphan Products Development||Completed|March 1996|June 2002||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||46|||Male|N/A|N/A|No|||May 1998|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004827||207452|
NCT00004867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0060|Positron Emission Tomography in Determining Stage of Esophageal Cancer|The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Carcinoma of the Thoracic Esophagus||Alliance for Clinical Trials in Oncology|No|Completed|November 1999|January 2009|Actual|January 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|235|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004867||207419|
NCT00004326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11872|Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome|||National Center for Research Resources (NCRR)||Completed|August 1994|||||N/A|Observational|Primary Purpose: Screening||||12|||Both|15 Years|80 Years|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004326||207729|
NCT00004327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11875|Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia|||Office of Rare Diseases (ORD)||Completed|January 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||8|||Both|N/A|N/A|No|||June 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004327||207728|
NCT00004328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11883|Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I|||Office of Rare Diseases (ORD)||Completed|December 1992|||||Phase 2|Interventional|Primary Purpose: Treatment||||1|||Both|N/A|N/A|No|||May 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004328||207727|
NCT00004329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11884|Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy|||National Center for Research Resources (NCRR)||Completed|November 1999|||||N/A|Observational|Primary Purpose: Screening||||12|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004329||207726|
NCT00004850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910117|Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection|Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population||National Institutes of Health Clinical Center (CC)||Recruiting|April 1991|||||N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|March 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00004850||207436|
NCT00004868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067527|SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy|A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas||National Cancer Institute (NCI)||Completed|February 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|November 22, 2008|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004868||207418|
NCT00004842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13922|Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis|||Office of Rare Diseases (ORD)||Active, not recruiting|October 1998|||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|18 Years|70 Years|No|||December 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004842||207443|
NCT00004808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12010|Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis|||Office of Rare Diseases (ORD)||Completed|September 1991|||||Phase 2|Interventional|Primary Purpose: Treatment||||78|||Both|12 Years|N/A|No|||December 2001|June 8, 2006|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004808||207463|
NCT00004814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12023|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis|||Office of Rare Diseases (ORD)||Completed|October 1991|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||250|||Both|18 Years|45 Years|No|||January 1997|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004814||207458|
NCT00004815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12024|Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome|||Office of Rare Diseases (ORD)||Completed|May 1992|||||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment||||1|||Both|N/A|N/A|No|||July 2004|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004815||207457|
NCT00004773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11798|Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome|||Office of Rare Diseases (ORD)||Completed|August 1995|June 1997||||N/A|Observational|Primary Purpose: Screening||||95|||Female|N/A|N/A|No|||January 1997|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004773||207488|
NCT00004325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11866|Study of the Neurobiology of Tourette Syndrome and Related Disorders|||National Center for Research Resources (NCRR)||Completed|December 1988|||||N/A|Observational|Primary Purpose: Screening||||200|||Both|12 Years|45 Years|No|||January 2004|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004325||207730|
NCT00004846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000048|Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV|Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV||National Institutes of Health Clinical Center (CC)||Completed|December 1999|October 2002||||N/A|Observational|N/A||||30000|||Both|N/A|N/A|No|||October 2002|March 3, 2008|March 2, 2000||||No||https://clinicaltrials.gov/show/NCT00004846||207439|
NCT00004858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067509|Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|A Phase I Study of B43-Genistein Immunoconjugate in Recurrent B-Lineage Acute Lymphoblastic Leukemia and Non Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|80 Years|No|||July 2007|September 19, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004858||207428|
NCT00004859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02943|Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer|A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)|Yes|Terminated|January 2000|March 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|589|||Both|18 Years|N/A|No|||February 2013|May 29, 2014|March 7, 2000|Yes|Yes|Trial was stopped early for futility|No|February 16, 2012|https://clinicaltrials.gov/show/NCT00004859||207427|
NCT00004330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11885|Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks|||National Center for Research Resources (NCRR)||Completed|March 1987|||||N/A|Interventional|Primary Purpose: Prevention|||||||Female|18 Years|55 Years|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004330||207725|
NCT00004331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11888|Studies in Porphyria I: Characterization of Enzyme Defects|||National Center for Research Resources (NCRR)||Recruiting|November 1992|||||N/A|Observational|Primary Purpose: Screening||||25|||Both|N/A|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004331||207724|
NCT00004828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13357|Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure|||FDA Office of Orphan Products Development||Completed|December 1994|December 1997||||Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||28|||Both|N/A|17 Years|No|||June 1998|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004828||207451|
NCT00004844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13940|Randomized Study of Fetal Neurotransplantation for the Treatment of Parkinson's Disease|||Office of Rare Diseases (ORD)||Active, not recruiting|July 1998|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|40 Years|75 Years|No|||January 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004844||207441|
NCT00004787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11877|Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes|||Office of Rare Diseases (ORD)||Completed|December 1994|||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004787||207480|
NCT00004860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067511|Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer|A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer||Eastern Cooperative Oncology Group||Completed|June 2000|||October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|75 Years|N/A|No|||August 2013|August 22, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004860||207426|
NCT00004852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225D|Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs|A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily Vs. Lamivudine 150mg BID in Combination With Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretroviral-Naive Adults With HIV-1 Infection||NIH AIDS Clinical Trials Information Service||Completed|September 1999|||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|June 23, 2005|March 2, 2000||||No||https://clinicaltrials.gov/show/NCT00004852||207434|
NCT00004338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11897|Study of Zinc for Wilson Disease|||National Center for Research Resources (NCRR)||Completed|October 1993|||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||300|||Both|N/A|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004338||207718|
NCT00004339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1850|Study of Tetrathiomolybdate in Patients With Wilson Disease|||National Center for Research Resources (NCRR)||Completed|January 1994|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||December 2003|May 8, 2006|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004339||207717|
NCT00004340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11899|Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis|||National Center for Research Resources (NCRR)||Completed|June 1995|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||109|||Both|1 Year|18 Years|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004340||207716|
NCT00004341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11900|Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders|||Office of Rare Diseases (ORD)||Active, not recruiting|July 1995|||||N/A|Observational|Primary Purpose: Screening|||||||Both|N/A|N/A|No|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004341||207715|
NCT00004861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-994-011|Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion in the Treatment of Patients With Advanced Pancreatic Cancer||Pfizer||Completed|October 1999|September 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2012|August 8, 2012|March 7, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00004861||207425|
NCT00004862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01399|Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I Study of G3139 (NSC 683428) in Combination With Salvage Chemotherapy for Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)||National Cancer Institute (NCI)||Completed|October 1999|||December 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|16 Years|N/A|No|||May 2002|January 31, 2013|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004862||207424|
NCT00004335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11894|Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle|||National Center for Research Resources (NCRR)||Completed|April 1993|||||N/A|Observational|Primary Purpose: Screening|||||||Both|7 Years|35 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004335||207720|
NCT00004336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11895|Pilot Study of Familial Nonsyndromal Mondini Dysplasia|||National Center for Research Resources (NCRR)||Completed|October 1995|||||N/A|Observational|Primary Purpose: Screening||||2|||Both|N/A|N/A|No|||April 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004336||207719|
NCT00004809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12011|Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia|||Office of Rare Diseases (ORD)||Completed|June 1992|||||Phase 1|Interventional|Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004809||207462|
NCT00004810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12012|Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis|||Office of Rare Diseases (ORD)||Completed|June 1996|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004810||207461|
NCT00004816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12050|A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis|||Office of Rare Diseases (ORD)||Completed|July 1995|||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|21 Years|75 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004816||207456|
NCT00004788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11886|Study of Nutritional Factors in Porphyria|||Office of Rare Diseases (ORD)||Completed|May 1988|||||N/A|Observational|Primary Purpose: Screening||||30|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004788||207479|
NCT00004786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11876|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis|||Office of Rare Diseases (ORD)||Completed|December 1995|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004786||207481|
NCT00004856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02046|Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium|A Phase II Trial of Trastuzumab (Herceptin; NSC #688097, IND #6667) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma||National Cancer Institute (NCI)|Yes|Terminated|July 2002|||July 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004856||207430|
NCT00004831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13413|Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria|||FDA Office of Orphan Products Development||Completed|October 1996|July 1998||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||August 1998|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004831||207449|
NCT00004833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13444|Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome|||FDA Office of Orphan Products Development||Terminated|July 1995|November 2002||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||170|||Both|N/A|17 Years|No|||September 2002|April 6, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004833||207447|
NCT00004342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11901|International Registry for Severe Chronic Neutropenia|||National Center for Research Resources (NCRR)||Recruiting|June 1994|||||N/A|Observational|Observational Model: Natural History||||1000|||Both|3 Months|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004342||207714|
NCT00004343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00334-0028|Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome|||National Center for Research Resources (NCRR)||Active, not recruiting|October 1999|||||N/A|Observational|Primary Purpose: Screening||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004343||207713|
NCT00004845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0021|A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)|A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease||National Institute on Aging (NIA)||Completed||December 2001|Actual|December 2001|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|55 Years|N/A|No|||June 2009|December 10, 2009|February 28, 2000||||No||https://clinicaltrials.gov/show/NCT00004845||207440|
NCT00004854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-5073|The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure|||National Center for Research Resources (NCRR)||Completed||||||Phase 1|Interventional|Primary Purpose: Diagnostic|||||||Both|3 Months|17 Years|No|||December 2003|June 23, 2005|March 8, 2000||||No||https://clinicaltrials.gov/show/NCT00004854||207432|
NCT00004796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11934|Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis|||Office of Rare Diseases (ORD)||Completed|November 1994|February 1997||||Phase 2|Interventional|Primary Purpose: Treatment||||16|||Both|N/A|64 Years|No|||February 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004796||207473|
NCT00004354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11917|Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism|||National Center for Research Resources (NCRR)||Completed|June 1999|||||N/A|Observational|Primary Purpose: Screening|||||||Both|N/A|N/A|No|||May 2002|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004354||207704|
NCT00004834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13462|Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder|||Northwell Health||Completed|May 1998|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||326|||Both|18 Years|64 Years|No|||February 2013|February 20, 2013|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004834||207446|
NCT00004863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067518|Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Open-Label Safety Study of Escalating Doses of Taxol in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors||Montefiore Medical Center||Completed|July 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2010|October 25, 2010|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004863||207423|
NCT00004348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11907|Study of Protein Translocation in Patients With Beta-Oxidation Disorders|||Office of Rare Diseases (ORD)||Active, not recruiting|September 1995|||||N/A|Observational|Primary Purpose: Screening||||20|||Both|N/A|N/A|No|||January 2000|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004348||207708|
NCT00004351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11914|Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes|||Office of Rare Diseases (ORD)||Completed|September 1999|||||N/A|Observational|Primary Purpose: Screening||||20|||Both|N/A|N/A|No|||October 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004351||207706|
NCT00004353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00827-0071|Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia|||National Center for Research Resources (NCRR)||Completed|December 1978|||||N/A|Observational|N/A|||Anticipated|35|||Both|N/A|N/A|No|||April 2002|July 9, 2008|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004353||207705|
NCT00004356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11920|Study of Homocysteine Metabolism in Homocystinuria|||Office of Rare Diseases (ORD)||Completed|February 1995|October 2000||||N/A|Observational|Primary Purpose: Screening||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2001|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004356||207703|
NCT00004838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13576|Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children|||Office of Rare Diseases (ORD)||Completed|September 1997|July 1998||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||175|||Both|N/A|6 Years|No|||September 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004838||207445|
NCT00004840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13784|Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants|||Office of Rare Diseases (ORD)||Completed|May 1998|June 1998||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||996|||Female|20 Years|36 Years|No|||October 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004840||207444|
NCT00004350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11911|Evaluation of Fanconi Syndrome and Cystinosis|||Office of Rare Diseases (ORD)||Completed|October 1999|||||N/A|Observational|Primary Purpose: Screening||||12|||Both|N/A|N/A|No|||December 1999|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004350||207707|
NCT00004795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11930|Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus|||Office of Rare Diseases (ORD)||Completed|August 1994|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||190|||Female|18 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004795||207474|
NCT00004811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12013|Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis|||Office of Rare Diseases (ORD)||Completed|March 1985|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||7|||Both|18 Years|N/A|No|||December 2001|June 8, 2006|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004811||207460|
NCT00004847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000093|Diagnosis of Pheochromocytoma|Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma||National Institutes of Health Clinical Center (CC)||Recruiting|February 2000|||||N/A|Observational|N/A|||Anticipated|2400|||Both|7 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 23, 2016|March 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004847||207438|
NCT00004817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/12249|Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures|||Office of Rare Diseases (ORD)||Completed|February 1991|||||Phase 3|Interventional|Primary Purpose: Treatment||||385|||Both|14 Years|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004817||207455|
NCT00004347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00334-0068|Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome|The Effects of Dietary Cholesterol in the Smith-Lemli-Opitz Syndrome||National Center for Research Resources (NCRR)||Recruiting|November 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004347||207709|
NCT00004855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5014|Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs|A Randomized, Open-Label, Pilot Treatment Trial Evaluating Cellular Dynamics and Immune Restoration in Treatment-Naive HIV-Infected Subjects Receiving Either the Protease Inhibitor LPV/r or the Nucleoside Analogue Reverse Transcriptase Inhibitors d4T/3TC/Abacavir With the Non-Nucleoside Reverse Transcriptase Inhibitor Nevirapine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2005|Actual|||N/A|Interventional|Primary Purpose: Treatment||||55|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|February 29, 2000||||No||https://clinicaltrials.gov/show/NCT00004855||207431|
NCT00004857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-19901|Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Fludarabine Induction Followed by CAMPATH-1H Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia||Alliance for Clinical Trials in Oncology|No|Completed|January 2000|February 2010|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|March 7, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00004857||207429|
NCT00004357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11924|Absorption of Corticosteroids in Children With Juvenile Dermatomyositis|Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis||Northwestern University|No|Completed|September 1997|February 2008|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|4 Years|21 Years|No|||July 2011|July 20, 2011|October 18, 1999||No||No||https://clinicaltrials.gov/show/NCT00004357||207702|
NCT00004843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13926|A Randomized Study of Surgery Vs No Surgery in Patients With Mild Asymptomatic Primary Hyperparathyroidism|||Office of Rare Diseases (ORD)||Active, not recruiting|June 1994|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||100|||Both|50 Years|75 Years|No|||December 1998|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004843||207442|
NCT00004864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067520|Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Open-Label Safety Study of Escalating Doses of Taxotere in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors||Montefiore Medical Center||Completed|July 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2008|December 29, 2011|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004864||207422|
NCT00004865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067521|Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy|Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Combination With Chemotherapy in Patients With Metastatic or Recurrent Squamous Cell Head and Neck Carcinoma||National Cancer Institute (NCI)||Completed|November 1999|||January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2009|March 6, 2009|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004865||207421|
NCT00004887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067562|Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery|A Randomized Phase III Comparative Study of Paclitaxel With Carboplatin Versus Mitomycin, Ifosfamide, Cisplatin (MIC) Chemotherapy in Inoperable Advanced Stage Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2000|September 19, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004887||207401|
NCT00004888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02949|Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer|A Safety and Efficacy Study of Doxil and Taxotere ± Herceptin in Advanced Breast Cancer||National Cancer Institute (NCI)||Completed|January 2001|May 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|18 Years|N/A|No|||December 2012|May 7, 2014|March 7, 2000|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00004888||207400|
NCT00004826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/13295|Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease|||FDA Office of Orphan Products Development||Completed|October 1993|November 1997||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||May 1998|March 24, 2015|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004826||207453|
NCT00004363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00048-0568|Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus|||National Center for Research Resources (NCRR)||Completed|December 1995|||||N/A|Observational|Primary Purpose: Screening|||||||Both|6 Months|70 Years|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004363||207697|
NCT00004364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11939|Study of Novel Types of Familial Diabetes Insipidus|||Office of Rare Diseases (ORD)||Active, not recruiting|December 1995|||||N/A|Observational|Primary Purpose: Screening||||5|||Both|6 Months|70 Years|No|||February 2006|February 21, 2006|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004364||207696|
NCT00004365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11940|Study of Pituitary Size and Function in Familial Dwarfism of Sindh|||Office of Rare Diseases (ORD)||Completed|September 1995|February 2000||||N/A|Observational|Primary Purpose: Screening||||4|||Both|10 Years|60 Years|No|||December 2003|June 23, 2005|October 18, 1999||||No||https://clinicaltrials.gov/show/NCT00004365||207695|
NCT00004899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 91H1T|Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study||Northwestern University|Yes|Completed|October 1999|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||June 2012|June 8, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004899||207390|
NCT00005165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1038|Charleston Heart Study - Predictors of Coronary Disease in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1984|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005165||207171|
NCT00005166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040|Sodium Transport: Genetics and Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1984|March 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005166||207170|
NCT00005167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1041|Diet Modification and Blood Pressure in Young People|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1984|December 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005167||207169|
NCT00005186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1064|Epidemiology of Cardiovascular Diseases in The Elderly|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1986|June 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005186||207150|
NCT00005187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1065|Cardiovascular Risk Profile Among Mexican-Americans|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1986|March 1991||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005187||207149|
NCT00005111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000106|PET Scans in Normal Volunteers and Patients With Fabry Disease|(18)Fluorodeoxyglucose Positron Emission Tomography in Patients With Fabry Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2000|March 2001||||N/A|Observational|N/A||||24|||Male|N/A|N/A|Accepts Healthy Volunteers|||March 2000|March 3, 2008|April 13, 2000||||No||https://clinicaltrials.gov/show/NCT00005111||207223|
NCT00005234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1114|Cardiovascular Disease in Black Versus White Physicians|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|August 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005234||207102|
NCT00005235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC ID unknown (1116)|Heart Rate Variability and Sudden Cardiac Death|The Ability of Several Short-term Measures of RR Variability to Predict Mortality After Myocardial Infarction||Columbia University|No|Completed|December 1988|September 1993|Actual|September 1993|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|715|||Both|18 Years|N/A|No|Non-Probability Sample|Participants in the Multicenter Post Infarction Program (MPIP), a natural history study|December 2015|December 22, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005235||207101|
NCT00005236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1117|Atherosclerosis and Omega-3 Fatty Acids in Alaskan Natives|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1988|November 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005236||207100|
NCT00005161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033|Longitudinal Twin Study - Cohort Study of Blood Pressure|||Virginia Commonwealth University||Completed|August 1983|July 1993||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2016|March 4, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005161||207175|
NCT00005162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1034|Epidemiology of Decline in Heart Disease Mortality|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1983|November 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005162||207174|
NCT00005084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067693|Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma|Pediatric Low Grade Astrocytoma: Treatment Guidance||National Cancer Institute (NCI)||Active, not recruiting|February 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|N/A|12 Years|No|||February 2008|December 17, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005084||207248|
NCT00005055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16994N|Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer|Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|January 2000|||March 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005055||207276|
NCT00005105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14924|Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation|||National Center for Research Resources (NCRR)||Recruiting|January 1997|||||N/A|Observational|Primary Purpose: Screening||||75|||Both|18 Months|18 Years|No|||December 2003|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005105||207228|
NCT00005129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|908|Bogalusa Heart Study|||Tulane University|No|Active, not recruiting|June 1972|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12000|||Both|N/A|N/A|No|Non-Probability Sample|12000 individuals who have been examined as children and adults for over 40 years for        heart disease risk factors.|September 2015|September 24, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005129||207207|
NCT00005130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000|Coronary Artery Risk Development in Young Adults (CARDIA)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1984|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|Black and white males and females 18 to 30 years of age at baseline.|April 2009|September 21, 2010|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005130||207206|
NCT00005270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1154|Family Blood Pressure Program - SAPPHIRe Network|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||August 2008|August 20, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005270||207066|
NCT00005271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1155|INTERMAP: International Population Study on Macronutrients and BP|INTERMAP: International Population Study on Macronutrients and BP||Northwestern University|No|Completed|July 1995|May 2015|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|4680|Samples Without DNA|24 hour urine collection among all participants|Both|40 Years|59 Years|No|Probability Sample|The INTERMAP study population includes 4,680 men and women ages 40-59 who were recruited        from 17 population samples of diverse ethnicity/ SES/ eating practices in four countries        (China, Japan, UK, USA).|January 2016|January 11, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005271||207065|
NCT00005272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1157|Smoking and Body Weight: Analysis of HHANES|||University of Memphis||Completed|September 1990|September 1992||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|January 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005272||207064|
NCT00005108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000111|Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls|Effects of Hormone Therapy on Vascular Inflammation and Compliance||National Institutes of Health Clinical Center (CC)||Completed|April 2000|January 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Female|N/A|N/A|No|||January 2002|March 3, 2008|April 11, 2000||||No||https://clinicaltrials.gov/show/NCT00005108||207225|
NCT00005067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02323|Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer|A Phase I Trial of Photodynamic Therapy With Lutetium Texaphyrin in Patients With Locally Recurrent Prostate Carcinoma||National Cancer Institute (NCI)||Terminated|February 2000|||January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|N/A|No|||January 2013|January 15, 2013|April 6, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00005067||207265|
NCT00005131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|Atherosclerosis Risk in Communities (ARIC)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1985|January 2007|Actual|January 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2009|April 13, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005131||207205|
NCT00005132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002|National Growth and Health Study (NGHS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1985|March 2000||||N/A|Observational|N/A|||||||Female|9 Years|19 Years|No|||January 2006|January 27, 2006|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005132||207204|
NCT00005119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHYS-JACOBS (completed)|Altered Calcium and Vitamin D in PMDD or Severe PMS|Altered Calcium And Vitamin D Metabolism in PMDD||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|May 2000|October 2003||||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Diagnostic|||||||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|April 19, 2000||||No||https://clinicaltrials.gov/show/NCT00005119||207217|
NCT00005137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007|Heritage Study--Genetics, Exercise and Risk Factors|Health, Risk Factors, Exercise Training, and Genetics|HERITAGE|Washington University School of Medicine||Completed|July 1992|August 2005|Actual|August 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|||||||Both|N/A|N/A|No|||May 2014|May 27, 2014|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005137||207199|
NCT00005103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14875|Study of the Pathogenesis of Porphyria Cutanea Tarda|||National Center for Research Resources (NCRR)||Completed|November 2000|||||N/A|Observational|Primary Purpose: Screening||||120|||Both|N/A|N/A|No|||December 2003|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005103||207230|
NCT00005110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-5074|A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis|||National Center for Research Resources (NCRR)||Suspended||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|5 Years|45 Years|No|||November 2001|June 23, 2005|April 13, 2000||||No||https://clinicaltrials.gov/show/NCT00005110||207224|
NCT00005073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVARTIS-CZOL4460704|Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms|A Randomized Double-Blind Placebo Controlled Phase III Trial Evaluating Zoledronate Plus Standard Therapy Versus Placebo Plus Standard Therapy in Patients With Recurrent Carcinoma of the Prostate Who Are Asymptomatic With Castrate Levels of Testosterone and Have Rising PSA Levels Without Radiologically-Evident Metastatic Disease||Novartis||Terminated|September 1999|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|544|||Male|18 Years|N/A|No|||April 2013|April 30, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005073||207259|
NCT00005138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009|High Blood Pressure in the Young|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1976|June 1989|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005138||207198|
NCT00005139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010|Characterization Of Coronary Prone Pedigrees|||University of Utah||Completed|July 1977|December 1991||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 19, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005139||207197|
NCT00005140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011|Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1977|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2008|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005140||207196|
NCT00005141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012|Minneapolis Children's Blood Pressure Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1977|May 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005141||207195|
NCT00005181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1059|Blood Pressure Control in Juveniles - Longitudinal Study|||Indiana University||Completed|July 2000|June 2003|Actual|June 2003|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||February 2014|February 24, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005181||207155|
NCT00005182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1060|Health Professionals Follow-up Study|||Harvard School of Public Health||Completed|December 1985|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50000|Samples With DNA|plasma, RBC, WBC|Male|N/A|N/A|No|Non-Probability Sample|Male Health Professionals|March 2013|March 30, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005182||207154|
NCT00005183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1061|Apolipoprotein A-I Gene Polymorphism and Atherosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1985|November 1988||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005183||207153|
NCT00005184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1062|Immunogenetic Factors of Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1985|November 1989|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005184||207152|
NCT00005185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1063|Myocardial Infarction and Non-contraceptive Estrogen Use|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1986|March 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005185||207151|
NCT00005054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067649|Temozolomide in Treating Women With Advanced Breast Cancer|Phase II Trial of Temodal 4 Hourly in Progressive Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2001|September 19, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005054||207277|
NCT00005188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1066|Quantitative Genetic Analysis of Lipid Research Clinic Family Data|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1986|June 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005188||207148|
NCT00005118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246V|The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment|A Multicenter, Open-Label, 24-Week Study to Evaluate the Efficacy and Safety of Indinavir Sulfate 800 Mg and Ritonavir 200 Mg b.i.d. Plus 2 NRTIs b.i.d. in HIV-1 Infected Individuals Who Require Early Treatment Intervention||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||July 2001|June 23, 2005|April 7, 2000||||No||https://clinicaltrials.gov/show/NCT00005118||207218|
NCT00005094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02327|Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps|Prevention of Sporadic Colorectal Adenomas With Celecoxib||National Cancer Institute (NCI)||Completed|March 2000|||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|1170|||Both|30 Years|N/A|No|||April 2013|April 11, 2013|April 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005094||207238|
NCT00005085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067695|Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer|A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)||National Cancer Institute (NCI)||Completed|February 2000|||June 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2002|February 8, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005085||207247|
NCT00005086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11203|Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer|A Phase II Trial of "Sequential Doublets" Chemotherapy in Patients With Locally Advanced or Metastatic Bladder Cancer||University of Chicago|No|Completed|August 1999|April 2005|Actual|August 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005086||207246|
NCT00005189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1067|Carotid Atherosclerosis Follow-up Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1986|April 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2002|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005189||207147|
NCT00005190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1068|Reproduction and Survival After Cardiac Defect Repair|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1986|December 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005190||207146|
NCT00005100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00645-2525|Measurement of Outcome of Surgical Treatment in Patients With Acromegaly|||National Center for Research Resources (NCRR)||Recruiting|September 1999|||||N/A|Observational|Primary Purpose: Screening||||165|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005100||207233|
NCT00005112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0111|Growth Hormone Use in Cystic Fibrosis - a Multicenter Study|||National Center for Research Resources (NCRR)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|5 Years|12 Years|No|||December 2003|June 23, 2005|April 15, 2000||||No||https://clinicaltrials.gov/show/NCT00005112||207222|
NCT00005101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00645-2738|Study of Low Bone Mass in Premenopausal or Perimenopausal Women|||National Center for Research Resources (NCRR)||Completed|February 1998|||||N/A|Observational|Primary Purpose: Screening|||||||Female|16 Years|54 Years|No|||December 2003|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005101||207232|
NCT00005102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1571|Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome|Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome||National Center for Research Resources (NCRR)||Recruiting|January 1995|||||N/A|Observational|Observational Model: Natural History||||11|||Both|N/A|N/A|No|||December 2003|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005102||207231|
NCT00005122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901|Evans County Studies|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1958|August 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005122||207214|
NCT00005123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|902|Honolulu Heart Program|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1965|September 2002||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||September 2004|March 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005123||207213|
NCT00005124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|903|National Heart, Lung, and Blood Institute Twin Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1969|November 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005124||207212|
NCT00005125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|904|NAS-NRC Twin Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1970|September 1988||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||June 2001|June 2, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005125||207211|
NCT00005117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00051-1162|Effect of Pravastatin on Endothelial Dysfunction Following a Single High Fat Meal|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2001|June 23, 2005|April 18, 2000||||No||https://clinicaltrials.gov/show/NCT00005117||207219|
NCT00005089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067707|S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma|Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized Aggressive Histologies of Non-Hodgkin's Lymphoma||Southwest Oncology Group|No|Active, not recruiting|April 2000|January 2017|Anticipated|November 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005089||207243|
NCT00005068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067673|Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors||Mayo Clinic|Yes|Completed|January 2000|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2011|August 2, 2011|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005068||207264|
NCT00005069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-107|Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of Arsenic Trioxide (NSC #706363) in Patients With Advanced Renal Cell Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|January 2000|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 18, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005069||207263|
NCT00005062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067664|Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission|A Phase III Trial Comparing High Versus Standard Dose of Prophylactic Cranial Irradiation (PCI) in Limited Small Cell Lung Cancer Complete Responders||Gustave Roussy, Cancer Campus, Grand Paris||Completed|September 1999|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||March 2014|March 12, 2014|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005062||207269|
NCT00005064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02322|PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome|Phase I Study of PS-341 in Acute Myeloid Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase||National Cancer Institute (NCI)||Completed|February 2000|||October 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005064||207268|
NCT00005207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1086|Renin and Prorenin in Pregnancy|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1987|July 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005207||207129|
NCT00005222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101|Decline in Cardiovascular Mortality: Framingham 1950-1984|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1988|March 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005222||207114|
NCT00005223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102|Epidemiology of APO- and Lipoproteins in Elderly Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1988|March 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2001|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005223||207113|
NCT00005090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067708|S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease|A Randomized Phase III Trial Comparing Early High Dose Chemotherapy and an Autologous Stem Cell Transplant to Conventional Dose ABVD Chemotherapy for Patients With Advanced Stage Poor Prognosis Hodgkin's Disease as Defined by the International Prognostic Factors Project on Advanced Hodgkin's Disease||Southwest Oncology Group|Yes|Terminated|April 2000|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|15 Years|65 Years|No|||January 2013|January 22, 2013|April 6, 2000|No|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00005090||207242|
NCT00005093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-994-013|Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer|A Randomized Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion as Second-Line Treatment of Patients With Advanced Nonsmall Cell Lung Cancer||Pfizer||Completed|December 1999|May 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2012|August 8, 2012|April 6, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00005093||207239|
NCT00005087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9911|Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer|Phase II Study of Paclitaxel and Cisplatin in Combination With Split Course Concomitant Hyperfractionated Re-Irradiation in Patients With Recurrent Squamous Cell Cancer of the Head and Neck||Radiation Therapy Oncology Group|Yes|Completed|March 2000|November 2013|Actual|November 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005087||207245|
NCT00005126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905|Vietnam Era Twin (VET) Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|March 1991||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005126||207210|
NCT00005127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|906|Muscatine Heart Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1971|November 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 19, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005127||207209|
NCT00005128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|907|Lipid Research Clinics Population Studies|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1972|December 1994||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005128||207208|
NCT00005258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1141|Family Study of Congenital Cardiovascular Malformations|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1990|May 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005258||207078|
NCT00005259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1142|Polyunsaturated Fats and Risk of Primary Cardiac Arrest|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|March 2007|Actual|March 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005259||207077|
NCT00005260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1143|Mechanisms Underlying Psychosocial Associations With Ischemic Heart Disease (Kuopio)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|August 2002|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2005|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005260||207076|
NCT00005082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067691|Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma|Magnetic Resonance Correlates of Glioma Tumor Burden||Jonsson Comprehensive Cancer Center||Completed|November 1998|||November 2000|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Actual|1|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005082||207250|
NCT00005107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00051-1123|Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia|||National Center for Research Resources (NCRR)||Recruiting||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|April 11, 2000||||No||https://clinicaltrials.gov/show/NCT00005107||207226|
NCT00005142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1013|Etiology and Prevalence of Peripheral Arterial Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1978|March 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005142||207194|
NCT00005224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103|Gender Response To Coronary Risk|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1988|March 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005224||207112|
NCT00005061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-13992|Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase I, Open Label Multiple Dose, Safety and Pharmacokinetic Study of Intravenously Administered Humanized Anti-VEGF Monoclonal Antibody (HuMV833) to Patients With Relapsed or Refractory Solid Tumors||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1999|||June 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005061||207270|
NCT00005294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2017|Developmental Sequelae of Severe Chronic Lung Disorders|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1989|June 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005294||207042|
NCT00005295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2018|Idiopathic Pulmonary Fibrosis: a Case-control Study|||University of New Mexico||Completed|July 1989|June 1995||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005295||207041|
NCT00005116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOVACSM (completed)|Depression In Juvenile Diabetics|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|8 Years|16 Years|No|||March 2010|March 1, 2010|April 13, 2000||||No||https://clinicaltrials.gov/show/NCT00005116||207220|
NCT00005133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003|Cardiovascular Health Study (CHS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1988|May 2009|Actual|May 2009|Actual|N/A|Observational|N/A|||||||Both|65 Years|N/A|No|||May 2009|May 1, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005133||207203|
NCT00005134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004|Strong Heart Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|December 2005|Actual|December 2005|Actual|N/A|Observational|N/A|||||||Both|45 Years|74 Years|No|||May 2009|May 1, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005134||207202|
NCT00005225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104|Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease|||University of Utah||Completed|April 1988|March 1991||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 19, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005225||207111|
NCT00005226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106|Epidemiology of Plasma Fatty Acids and Atherosclerosis|||University of Minnesota - Clinical and Translational Science Institute||Completed|July 1988|June 1992||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005226||207110|
NCT00005227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107|AIDS-Associated Cardiomyopathy|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1988|June 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005227||207109|
NCT00005163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1035|Validation and Field Test for Risk Appraisal Instruments|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1983|May 1989|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005163||207173|
NCT00005164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1036|Insulin Resistance and Blood Pressure Regulation in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1983|August 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005164||207172|
NCT00005208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1087|Regulation of Placental Vascular Reactivity in Pregnancy-induced Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1987|July 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005208||207128|
NCT00005209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1088|Genetic Epidemiology of Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1987|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2008|March 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005209||207127|
NCT00005210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1089|Sex Steroids, Obesity and Lipids in Adolescent Females|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1987|September 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005210||207126|
NCT00005156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1028|Mortality Surveillance of MRFIT Screenees|||University of Minnesota - Clinical and Translational Science Institute||Completed|April 1982|July 1996||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 29, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005156||207180|
NCT00005157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1029|Speech Characteristics in Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1982|November 1989|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005157||207179|
NCT00005158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030|Segregation/Linkage Analysis for Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1982|June 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005158||207178|
NCT00005229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109|HIV-Associated Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1988|June 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005229||207107|
NCT00005230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110|Epidemiology of Carotid Disease in Elderly Adults|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1988|June 2003|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005230||207106|
NCT00005220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1099|Postmenopausal Progestins, MI and Stroke|||University of Washington||Completed|April 1988|January 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005220||207116|
NCT00005221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100|Analysis of Longitudinal Cardiopulmonary Data|||Brigham and Women's Hospital||Completed|April 1988|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|60000|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric Task Force, combination of 11 different studies collecting pediatric blood        pressure data.|May 2012|May 15, 2012|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005221||207115|
NCT00005088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9914|Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer|A Phase II Trial of Concomitant Boost Radiation and Concurrent Cisplatin for Advanced Head and Neck Carcinomas||Radiation Therapy Oncology Group|Yes|Completed|April 2000|||January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2013|November 18, 2013|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005088||207244|
NCT00005091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIICHI-8951E-PRT017|DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer as First Line Therapy||National Cancer Institute (NCI)||Completed|February 1999|August 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2008|July 9, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005091||207241|
NCT00005231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111|Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1988|June 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005231||207105|
NCT00005232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112|Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1988|July 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005232||207104|
NCT00005233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1113|Patterns of Fatty Acids in Framingham Offspring|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|August 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2002|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005233||207103|
NCT00005329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4128|Protein S and Myocardial Infarction|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1992|March 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005329||207008|
NCT00005330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4148|Framingham Children's Study - Food and Exercise Habits in Framingham Study Descendents|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1985|April 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005330||207007|
NCT00005083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067692|Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors|Defining Functional Tissue in Brain Tumors With Integrated Neuroimaging (Pilot Study)||Jonsson Comprehensive Cancer Center||Withdrawn|March 1998|||||Phase 2|Interventional|Primary Purpose: Diagnostic|||Actual|0|||Both|18 Years|55 Years|No|||October 2012|October 2, 2012|April 6, 2000|||no participants enrolled|No||https://clinicaltrials.gov/show/NCT00005083||207249|
NCT00005097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067798|Green Tea Extract in Treating Patients With Actinic Keratosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology||University of California, Irvine|Yes|Terminated|August 1999|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|88|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|April 6, 2000||No|terminated due to the low conditional power for a positive study|No||https://clinicaltrials.gov/show/NCT00005097||207235|
NCT00005098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14810|Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency|||National Center for Research Resources (NCRR)||Terminated|March 1999|||||N/A|Observational|Primary Purpose: Screening||||160|||Both|N/A|N/A|No|||May 2002|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005098||207234|
NCT00005331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4152|Providers for Smoking Prevention Programs|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|February 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005331||207006|
NCT00005332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4183|Antihypertensive Drug/Gene Interactions and CV Events|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|August 2007|Actual|August 2007|Actual|N/A|Observational|N/A|||||||Both|30 Years|79 Years|No|||January 2008|January 25, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005332||207005|
NCT00005333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4188|Epidemic Hypertension in Nigerian Workers|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1991|August 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005333||207004|
NCT00005334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4189|Effects of Personality and Context on Recovery From Coronary Artery Bypass|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1991|June 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005334||207003|
NCT00005120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297B|The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Phase IB Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-Calanolide A on Surrogate Markers in HIV-Positive Patients With No Previous Antiretroviral Therapy||NIH AIDS Clinical Trials Information Service||Active, not recruiting|April 2000|||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|April 20, 2000||||No||https://clinicaltrials.gov/show/NCT00005120||207216|
NCT00005121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900|Framingham Heart Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1948|September 2008|Actual|September 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2009|June 2, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005121||207215|
NCT00005095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99G8|Specimen and Data Study for Ovarian Cancer Early Detection and Prevention|Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study||Northwestern University|Yes|Recruiting|March 2000|||December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|Subjects blood and other specimens are collected their follow-up clinic appointments.|Female|18 Years|80 Years|No|Non-Probability Sample|Women at high risk of ovarian cancer due to family or personal medical history, or a        gynecologic abnormality.|July 2015|July 7, 2015|April 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005095||207237|
NCT00005096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067764|Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer|Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|85 Years|No|||January 2002|July 23, 2008|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005096||207236|
NCT00005074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I127|Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma|A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Untreated or Relapsed Mantle Cell Lymphoma||Canadian Cancer Trials Group||Completed|January 2000|September 2008|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005074||207258|
NCT00005075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067682|Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer|Evaluation of the Ablatherm High Intensity Focused Ultrasound Device After Failed Radiation Therapy for Localized Prostate Cancer||National Cancer Institute (NCI)||Terminated|July 1999|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Male|50 Years|N/A|No|||May 2009|November 5, 2013|April 6, 2000|||Withdrawn because Ablatherm devices were not available anymore at trial centers|No||https://clinicaltrials.gov/show/NCT00005075||207257|
NCT00005324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4105|Genetic and Epidemiologic Studies of Premature Coronary Artery Disease - SCOR in Arteriosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1992|November 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005324||207013|
NCT00005325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4109|Identifying Genes Involved in Abnormal Blood Pressure - Hypertension SCOR|||Boston University||Completed|February 1996|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2014|July 15, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005325||207012|
NCT00005326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4111|Cerebrovascular Involvement in Sickle Cell Disease - Comprehensive Sickle Cell Center|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1988|March 2004|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005326||207011|
NCT00005135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005|Insulin Resistance Atherosclerosis Study (IRAS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2009|April 13, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005135||207201|
NCT00005136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006|Family Heart Study (FHS)|||University of Minnesota - Clinical and Translational Science Institute||Completed|June 1992|August 2005|Actual|August 2005|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||March 2014|March 14, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005136||207200|
NCT00005159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1031|National Longitudinal Mortality Study (NLMS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1983|December 2009|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2012|November 9, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005159||207177|
NCT00005160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1032|Epidemiology of Cardiovascular Risk Factors in Women (Healthy Women Study)|Epidemiology of Cardiovascular Risk Factors in Women (Healthy Women Study)||University of Pittsburgh|Yes|Completed|April 1983|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|532|Samples Without DNA|Plasma and serum samples from baseline and follow up exams stored at -80 degrees Celsius in      the Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh.|Female|20 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|The study began in 1983-84, baseline age was 48, median age was 47. The first EBT        examination was added to the study at the approximate time of the 8th postmenopausal visit        in 1992-93. 249 women in this grant period.|January 2016|January 12, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005160||207176|
NCT00005104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14915|Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome|||National Center for Research Resources (NCRR)||Completed|January 2000|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||99|||Female|18 Years|40 Years|No|||December 2003|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005104||207229|
NCT00005060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 43/99|Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer|A Phase III Trial of Preoperative vs. Postoperative Chemotherapy With Taxotere-Cisplatin-5FU (TCF) in Patients With Locally Advanced Operable Gastric Carcinoma||Swiss Group for Clinical Cancer Research|Yes|Completed|November 1999|March 2006|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|April 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005060||207271|
NCT00005092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-283|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Completed|March 1999|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|49 Years|No|||July 2012|July 27, 2012|April 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005092||207240|
NCT00005179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1057|Diet, Exercise and Cardiovascular Health Among Ethnic Children|||Georgia Regents University||Completed|September 1985|June 1990||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|December 21, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005179||207157|
NCT00005180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1058|End-organ Pathology in Childhood Essential Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1985|June 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005180||207156|
NCT00005056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-PHASE-I/II-PH2/034|Bryostatin 1 In Treating Patients With Progressive Kidney Cancer|A Phase II Trial of Bryostatin-1 in Hypernephroma||National Cancer Institute (NCI)||Completed|March 1999|July 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2006|June 25, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005056||207275|
NCT00004645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11693|Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone|||Office of Rare Diseases (ORD)||Active, not recruiting|January 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||22|||Both|18 Years|60 Years|No|||March 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004645||207554|
NCT00004656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11814|Nutritional Aspects of Rett Syndrome|||Office of Rare Diseases (ORD)||Completed|May 1993|||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Female|5 Years|18 Years|Accepts Healthy Volunteers|||February 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004656||207546|
NCT00005048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067640|Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Safety and Efficacy of One Hour Weekly Taxol Infusion and Estramustine in Hormone Refractory Prostate Cancer||New York University School of Medicine||Completed|April 1997|||August 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||November 2000|November 8, 2012|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005048||207283|
NCT00004991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000095|Study of Brain Activity During Speech Production and Speech Perception|Brain Activation During Developmental Speech Production and Speech Perception||National Institutes of Health Clinical Center (CC)||Completed|March 2000|||August 2009|Actual|N/A|Observational|N/A||||411|||Both|6 Years|65 Years|Accepts Healthy Volunteers|||August 2009|September 2, 2009|March 18, 2000||No||No||https://clinicaltrials.gov/show/NCT00004991||207335|
NCT00005081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0059|Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma|Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas||Duke University||Completed|August 2000|April 2001|Actual|April 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|August 20, 2014|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005081||207251|
NCT00005012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B010|Safety and Effectiveness of PEG-Intron in HIV-Infected Patients|Antiviral Activity and Tolerability of PEG-Intron in HIV-Infected Subjects Failing HAART||NIH AIDS Clinical Trials Information Service||Completed|March 2000|September 2000||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||250|||Both|N/A|N/A|No|||August 2000|June 23, 2005|March 29, 2000||||No||https://clinicaltrials.gov/show/NCT00005012||207316|
NCT00004583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285C|A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy|A Randomized, Double-Blind, Phase III Study of ABT-378/Ritonavir Plus Stavudine and Lamivudine vs Nelfinavir Plus Stavudine and Lamivudine in Antiretroviral Naive HIV-Infected Subjects||Abbott||Completed|March 1999|||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||660|||Both|12 Years|N/A|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00004583||207567|
NCT00004584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302B|Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment|Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination Regimen(s) as Compared to a Reference Combination Regimen(s) in Antiretroviral-Experienced HIV-Infected Subjects||Bristol-Myers Squibb||Completed|December 1999|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 28, 2011|February 10, 2000|Yes|Yes||||https://clinicaltrials.gov/show/NCT00004584||207566|
NCT00005037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067626|Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer|Temozolomide in the Treatment of Advanced Non-Small Cell Lung Carcinoma: Phase II Evaluation in Previously Treated and Chemo-Naive Patients||Fox Chase Cancer Center||Completed|January 2000|April 2008|Actual|October 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005037||207293|
NCT00005016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000104|Study of the Experiences and Needs of Parents Continuing a Pregnancy Following a Prenatal Diagnosis of Holopresencephaly|The Experiences and Needs of Parents Continuing a Pregnancy Following Abnormal Prenatal Results: The Case of Holoprosencephaly||National Institutes of Health Clinical Center (CC)||Completed|March 2000|February 2001||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||March 2000|March 3, 2008|April 4, 2000||||No||https://clinicaltrials.gov/show/NCT00005016||207312|
NCT00005018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238R|Safety and Effectiveness of a Combination Anti-HIV Drug Treatment|A Phase IV 48-Week, Randomized, Open-Label, Multicenter Trial of Abacavir (300mg BID)/Efavirenz (600mg QD)/Didanosine (400mg QD) +/- Hydroxyurea (500mg BID) in HIV-1 Infected Subjects Failing Initial Therapy With 3TC/ZDV (or d4T) +/- Protease Inhibitor(s)||NIH AIDS Clinical Trials Information Service||Completed|July 1999|October 2000||||Phase 4|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||150|||Both|13 Years|N/A|No|||August 2000|June 23, 2005|April 4, 2000||||No||https://clinicaltrials.gov/show/NCT00005018||207310|
NCT00005027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067548|Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer|A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 2000|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005027||207302|
NCT00004992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(IND) - DPP (completed)|Diabetes Prevention Program|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 1996|April 2001||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention||||3819|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2011|February 3, 2011|March 17, 2000||||||https://clinicaltrials.gov/show/NCT00004992||207334|
NCT00005007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92240|Etanercept for Wegener's Granulomatosis|Wegener's Granulomatosis Etanercept Trial (WGET)||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|June 2000|March 2003|Actual|March 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||181|||Both|11 Years|N/A|No|||December 2007|December 19, 2007|March 24, 2000||Yes||||https://clinicaltrials.gov/show/NCT00005007||207320|
NCT00005020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-05-008|Observing Patients With Early HIV Infection|An Observational Study of Viral and Immune Dynamics in Subjects With Acute HIV Infection: A Study of the UCSD Acute/Early HIV Infection (AEHIV) Clinical Studies Unit||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||10|||Both|13 Years|N/A|No|||December 2004|March 24, 2010|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005020||207309|
NCT00005031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067554|Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer|A Phase II Evaluation of MGI-114 in the Treatment of Recurrent or Persistent Endometrial Carcinoma||Gynecologic Oncology Group||Completed|August 2000|||October 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2008|May 24, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005031||207298|
NCT00004997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980101|Leucovorin for the Treatment of 5 q Minus Syndrome|The Experimental Treatment of Transfusion Dependent 5q Minus Syndrome With Leucovorin||National Institutes of Health Clinical Center (CC)||Completed|April 1998|July 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||14|||Both|N/A|N/A|No|||July 2002|March 3, 2008|March 22, 2000||||No||https://clinicaltrials.gov/show/NCT00004997||207330|
NCT00005036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01847|Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU||National Cancer Institute (NCI)||Completed|November 1999|||December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|560|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005036||207294|
NCT00004996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000099|Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections|Langherhans' Cell Function and Inflammatory Responses in Skin of Volunteers Using the Suction Blister Technique||National Institutes of Health Clinical Center (CC)||Completed|March 2000|April 2015||||N/A|Observational|N/A|||Actual|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|January 22, 2016|March 22, 2000||No||No||https://clinicaltrials.gov/show/NCT00004996||207331|
NCT00004987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309A|Treatment of Advanced AIDS Patients With Dextrin Sulfate|Intraperitoneal Dextrin Sulfate in Patients With Advanced HIV Disease: A Phase I Trial||NIH AIDS Clinical Trials Information Service||Active, not recruiting|October 1999|||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2001|June 23, 2005|March 16, 2000||||No||https://clinicaltrials.gov/show/NCT00004987||207338|
NCT00004988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000098|Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria|A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration||National Institutes of Health Clinical Center (CC)||Completed|March 2000|October 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||45|||Both|N/A|N/A|No|||October 2002|March 3, 2008|March 18, 2000||||No||https://clinicaltrials.gov/show/NCT00004988||207337|
NCT00005053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16994P|Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer|Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Pancreatic Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 1999|||March 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005053||207278|
NCT00005050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067642|Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer|A Phase I/II Study of Eniluracil Plus Oral 5-Fluorouracil Combined With Oxaliplatin (FOX-E) in Patients With Previously-Treated Colorectal Cancer||New York University School of Medicine||Completed|August 1999|||June 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 25, 2011|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005050||207281|
NCT00005051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067644|Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer|Phase II Study of First-Line Therapy of Ovarian Cancer With Sequential Regimens: Cisplatin-Prolonged Oral Topotecan (C-PORT) Followed by Paclitaxel/Carboplatin (PC)||New York University School of Medicine||Completed|August 1999|||March 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2003|November 8, 2012|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005051||207280|
NCT00004640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-008|"Clinical Trials to Enhance Elders' Oral Health" ("TEETH")|Trials to Enhance Elders' Teeth and Oral Health||University of Washington|Yes|Completed|May 1998|October 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|1101|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|September 17, 1999||No||No||https://clinicaltrials.gov/show/NCT00004640||207559|
NCT00005028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067549|Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer|Phase II Study of Weekly Paclitaxel and Bryostatin-1 in Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|May 2000|||July 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Male|18 Years|N/A|No|||November 2005|February 8, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005028||207301|
NCT00005042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-022|SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma|A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma||AIDS Malignancy Consortium|No|Completed|January 2000|November 2000|Actual|November 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2014|August 28, 2014|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005042||207288|
NCT00004998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286B|Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients|A Phase II, Open-Label Study of AG1549 in Combination With Other Antiretroviral Agents in Treatment-Naive HIV-Infected Patients||NIH AIDS Clinical Trials Information Service||Suspended|November 1999|||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||March 2001|June 23, 2005|March 21, 2000||||No||https://clinicaltrials.gov/show/NCT00004998||207329|
NCT00004658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11828|Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity|||Office of Rare Diseases (ORD)||Completed|March 1995|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004658||207545|
NCT00004582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285E|ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past|A Phase II Study of ABT-378/Ritonavir and Efavirenz in Multiple Protease Inhibitor-Experienced Subjects||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2000|June 23, 2005|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00004582||207568|
NCT00005017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264N|Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment|A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 4|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|April 3, 2000||||No||https://clinicaltrials.gov/show/NCT00005017||207311|
NCT00005009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT VZV|A Study of the Safety and Effectiveness of Varivax (the Chicken Pox Vaccine) in Children Who Have Received Kidney Transplants|Evaluation of the Safety and Immunogenicity of Varivax (Live-Attenuated Varicella-Zoster Virus Vaccine) in Pediatric Renal Transplant Recipients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 1998|June 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||50|||Both|2 Years|21 Years|No|||January 2013|January 16, 2013|March 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005009||207319|
NCT00005013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH70007|Treatment of Major Depression With St. John's Wort (Hypericum)|A Placebo Controlled Clinical Trial of a Standardized Extract of Hypericum Perforatum in Major Depressive Disorder||National Institute of Mental Health (NIMH)||Completed|December 1998|July 2001|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2006|April 7, 2014|March 31, 2000||||No||https://clinicaltrials.gov/show/NCT00005013||207315|
NCT00005022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9712|Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer|A Phase I/II Escalation Study of Thoracic Irradiation With Concurrent Chemotherapy for Patients With Limited Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|February 1998|June 2010|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|64|||Both|18 Years|80 Years|No|||October 2013|October 31, 2013|April 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005022||207307|
NCT00005024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067540|Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease|A Double-blind, Multicenter, Parallel Study Comparing the Efficacy and Safety of Kytril Tablets With Placebo, in the Prevention of Nausea and Vomiting During the Days Following Administration of IV Cyclophosphamide-based or Carboplatin-based Chemotherapy in Patients With Malignant Disease||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||June 2007|January 3, 2014|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005024||207305|
NCT00005046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067638|Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer|A Phase I Open Label Assessment of the Safety and Pharmacokinetics of Intraperitoneal PACLIMER Microspheres (Polilactofate/Paclitaxel) in Patients With Ovarian Cancer||Gynecologic Oncology Group||Completed|April 2000|||January 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|21 Years|N/A|No|||July 2008|May 24, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005046||207285|
NCT00005021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-96004|Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma|Phase I Evaluation of Topotecan in Combination With Paclitaxel and Carboplatin||Fox Chase Cancer Center|Yes|Completed|July 1996|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005021||207308|
NCT00005002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B009|Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)|A Randomized, Double-Blind, Adjuvant-Controlled, Multicenter Study to Compare the Virologic and Immunologic Effect of Highly Active Antiretroviral Therapy (HAART) Plus Remune Versus HAART Plus Incomplete Freund's Adjuvant (IFA) in Antiretroviral-Naive Patients Infected With Human Immunodeficiency Virus Type 1 (HIV-1)||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||688|||Both|13 Years|N/A|No|||August 2001|June 23, 2005|March 21, 2000||||No||https://clinicaltrials.gov/show/NCT00005002||207325|
NCT00005003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000094|Genetic Component of Handedness|Mapping the Genetic Component of Hand-Use Preference||National Institutes of Health Clinical Center (CC)||Completed|March 2000|April 2006||||N/A|Observational|N/A||||1400|||Both|N/A|N/A|No|||April 2006|March 3, 2008|March 23, 2000||||No||https://clinicaltrials.gov/show/NCT00005003||207324|
NCT00005025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067546|Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2003|November 5, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005025||207304|
NCT00004981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308A|Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)|A Phase IIIB Randomized, Multicenter Study of the Efficacy and Safety of Combivir 1 Tablet Po Bid Plus Ziagen 300mg Po Bid Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet Po Bid, Administered for 24 Weeks in Subjects With HIV-1 Infection||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||230|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|March 13, 2000||||No||https://clinicaltrials.gov/show/NCT00004981||207344|
NCT00004648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11711|Studies of Hereditary Hemorrhagic Telangiectasia|Studies of Hereditary Hemorrhagic Telangiectasia: Screening Methods for Pulmonary Arteriovenous Malformations; Prevalence of Pulmonary and Cerebral Arteriovenous Malformations; Prevalence of Cardiac Valve Abnormalities; and Identification of Modifier Genes||Office of Rare Diseases (ORD)||Completed|May 1996|||||N/A|Observational|Primary Purpose: Screening||||65|||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004648||207551|
NCT00004649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11712|Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients|||Office of Rare Diseases (ORD)||Completed|May 1995|||||N/A|Observational|Primary Purpose: Screening|||||||Both|N/A|N/A|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004649||207550|
NCT00005001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B008|Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)|A Pilot, Phase II, Double-Blind Study to Assess the Virologic Effect of Remune Versus Incomplete Freund's Adjuvant (IFA) in Patients Who Are Infected With Human Immunodeficiency Virus Type I (HIV-1), Have a Plasma HIV-1 RNA Level Less Than 50 Copies/Ml, Are Receiving Highly Active Antiretroviral Therapy (HAART), and Who Subsequently Discontinue Their HAART Regimen||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|13 Years|N/A|No|||March 2001|June 23, 2005|March 21, 2000||||No||https://clinicaltrials.gov/show/NCT00005001||207326|
NCT00004581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285D|A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment|A Randomized, Open-Label, Phase III Study of ABT-378/Ritonavir in Combination With Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination With Nevirapine and Two NRTIs in Antiretroviral-Experienced HIV-Infected Subjects||Abbott||Completed||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||300|||Both|12 Years|N/A|No|||February 2009|February 19, 2009|November 2, 1999||||No||https://clinicaltrials.gov/show/NCT00004581||207569|
NCT00004639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-010|Cleft Palate Surgery and Speech Development|Velopharyngeal Function for Speech After Palatal Surgery||University of Florida|Yes|Completed|February 1996|April 2007|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|475|||Both|N/A|N/A|No|||June 2011|September 16, 2011|September 17, 1999||No||No||https://clinicaltrials.gov/show/NCT00004639||207560|
NCT00004646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11695|Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy|||Office of Rare Diseases (ORD)||Completed|April 1995|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Male|5 Years|15 Years|No|||December 2001|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004646||207553|
NCT00005026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067547|Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer|A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|February 2000|||January 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||July 2008|May 24, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005026||207303|
NCT00005044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9910|Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer|A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|February 2000|||May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1579|||Male|18 Years|120 Years|No|||November 2015|November 14, 2015|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005044||207287|
NCT00005029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067550|Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer||Gynecologic Oncology Group||Terminated|February 2000|||January 2004||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||July 2004|April 10, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005029||207300|
NCT00005010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CR01|Prevention of Kidney Transplant Rejection|An Interventional Trial in Established Chronic Renal Allograft Rejection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed||March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 23, 2013|March 28, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005010||207318|
NCT00005032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10117|Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer|A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer||University of Chicago|No|Completed|April 2000|September 2001|Actual|January 2001|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005032||207297|
NCT00005047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067639|4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer|MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) in Organ-Confined Bladder Cancer Based on p53 Status||Southwest Oncology Group|Yes|Active, not recruiting|September 1998|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|800|||Both|N/A|N/A|No|||June 2011|July 21, 2011|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005047||207284|
NCT00005033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067558|Trastuzumab in Treating Patients With Recurrent Osteosarcoma|Phase II Study of Recombinant Humanized Monoclonal Antibody Against HER2 for the Treatment of Recurrent Osteosarcoma||National Cancer Institute (NCI)||Completed|December 1999|August 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2004|June 20, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005033||207296|
NCT00005076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067683|Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer|Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Chemotherapy in Patients With Advanced Colorectal Carcinoma||University of Alabama at Birmingham|Yes|Completed|October 1999|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005076||207256|
NCT00005045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067636|Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer|Phase II Study of Carboxyamidotriazole (CAI, NSC #609974) in Patients With Advanced Renal Cell Carcinoma Refractory to Immunotherapy||National Cancer Institute (NCI)||Completed|March 2000|June 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|June 20, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005045||207286|
NCT00004990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000100|Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis|Pulse Dexamethasone in Focal Segmental Glomerulosclerosis||National Institutes of Health Clinical Center (CC)||Completed|March 2000|December 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||December 2004|March 3, 2008|March 18, 2000||||No||https://clinicaltrials.gov/show/NCT00004990||207336|
NCT00004647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11702|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy|||Office of Rare Diseases (ORD)||Completed|March 1993|February 1999||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|21 Years|60 Years|No|||March 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004647||207552|
NCT00004982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHELATION (completed)|Combination Iron Chelation Therapy|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 1998|November 2002||||Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|7 Years|N/A|No|||January 2010|January 12, 2010|March 13, 2000||||No||https://clinicaltrials.gov/show/NCT00004982||207343|
NCT00004983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BROWNS (completed)|Education and Group Support for Diabetic Hispanics|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 1999|December 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Prevention|||||||Both|35 Years|70 Years|No|||February 2010|February 12, 2010|March 13, 2000||||No||https://clinicaltrials.gov/show/NCT00004983||207342|
NCT00005038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067627|Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer|A Randomized Phase II Study to Evaluate the Efficacy of Combined Immunotherapy With Subcutaneous Interleukin-2 and Maxamine in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|June 1999|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||June 2001|September 19, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005038||207292|
NCT00005039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02319|Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)|A Phase II Randomized Trial of Recombinant Fowlpox and Recombinant Vaccinia Virus Expressing PSA in Patients With Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Terminated|January 2000|||March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Male|18 Years|N/A|No|||January 2013|January 23, 2013|April 6, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00005039||207291|
NCT00004659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11858|Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors|||Office of Rare Diseases (ORD)||Active, not recruiting|November 1994|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||March 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004659||207544|
NCT00004660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11860|Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy|||Office of Rare Diseases (ORD)||Active, not recruiting|June 1993|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||42|||Both|30 Years|N/A|No|||January 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004660||207543|
NCT00005079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-9810046|Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer|Timing of Breast Cancer Surgery, Menstrual Cycle and Prognosis||National Cancer Institute (NCI)||Completed|January 1999|October 2004|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||April 2003|May 14, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005079||207253|
NCT00005080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02324|506U78 in Treating Patients With Lymphoma|A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL)||National Cancer Institute (NCI)||Completed|May 2000|||January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|N/A|69 Years|No|||January 2013|January 15, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005080||207252|
NCT00004638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00069-0609|Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|N/A|18 Years|Accepts Healthy Volunteers|||November 2001|June 23, 2005|February 23, 2000||||No||https://clinicaltrials.gov/show/NCT00004638||207561|
NCT00004644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/11690|Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection|||Office of Rare Diseases (ORD)||Completed|February 1995|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||25|||Both|N/A|28 Days|No|||March 1999|June 23, 2005|February 24, 2000||||No||https://clinicaltrials.gov/show/NCT00004644||207555|
NCT00005040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-051|Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma|Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|January 2000|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|17 Years|N/A|No|||June 2013|June 18, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005040||207290|
NCT00005041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067632|R115777 in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study to Determine the Antitumor Activity of Farnesyltransferase Inhibitor R115777 in Subjects With Relapsed Small Cell Lung Cancer||New York University School of Medicine||Completed|September 1999|||May 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2000|November 8, 2012|April 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005041||207289|
NCT00005106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264P|A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients|A 96-Week, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Tolerability of the Antiretroviral Activity of Stavudine (40mg BID) Plus Lamivudine (150mg BID) Plus Nelfinavir (1250mg BID) Versus Abacavir (300mg BID) Plus Combivir (3TC 150mg/ZDV 300mg BID) Versus Combivir (3TC 150mg/ZDV 300mg BID) Plus Nelfinavir (1250mg BID) in HIV-1 Infected Subjects||NIH AIDS Clinical Trials Information Service||Completed|September 1999|||||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||230|||Both|18 Years|N/A|No|||November 2000|June 23, 2005|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005106||207227|
NCT00005011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000103|Combined Hormone Replacement in Menstrually-Related Mood Disorders|The Treatment of Menstrually-Related Mood Disorders With Continuous Gonadal Steroid Replacement||National Institutes of Health Clinical Center (CC)||Completed|March 2000|||||N/A|Observational|N/A|||Actual|22|||Female|18 Years|50 Years|No|||June 2015|July 11, 2015|March 29, 2000||No||No||https://clinicaltrials.gov/show/NCT00005011||207317|
NCT00005014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH70001|Treatment of Autism in Children and Adolescents|Placebo-Controlled Study of Risperidone for the Treatment of Children and Adolescents With Autism and Negative Behavioral Symptoms||National Institute of Mental Health (NIMH)||Completed|October 1997|February 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|101|||Both|5 Years|17 Years|No|||August 2010|April 16, 2014|March 31, 2000||||No||https://clinicaltrials.gov/show/NCT00005014||207314|
NCT00005015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH70008|Treatment of Depression in Youth With Bipolar Disorders|Fluoxetine for the Treatment of Major Depression in Youth With Bipolar Disorder _||National Institute of Mental Health (NIMH)||Terminated||September 2000||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|8 Years|18 Years||||November 2000|November 17, 2005|March 31, 2000||||No||https://clinicaltrials.gov/show/NCT00005015||207313|
NCT00005049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067641|Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer|Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies||New York University School of Medicine||Completed|May 1997|||November 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|45|||Both|18 Years|N/A|No|||April 2011|April 4, 2011|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005049||207282|
NCT00005113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT SRL1|A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant|An Open-Label, Comparative Study of the Effect of Sirolimus Versus Standard Treatment on Clinical Outcomes and Histologic Progression of Allograft Nephropathy in High Risk Pediatric Renal Transplant Patients||Children's Hospital Boston|Yes|Terminated|July 1999|March 2006|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|N/A|20 Years|No|||March 2012|March 12, 2012|April 14, 2000|No|Yes|Inability to meet the accrual target of 213.|No||https://clinicaltrials.gov/show/NCT00005113||207221|
NCT00005386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4292|Biobehavioral Determinants of Obesity in Black Women|||University of Memphis||Completed|September 1995|August 1998||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|January 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005386||206951|
NCT00005387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4293|Genetics of Hypertension in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||December 2008|December 3, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005387||206950|
NCT00005428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4346|Familial Aggregation of Stress Response|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1993|July 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005428||206909|
NCT00005429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4347|Clinical Cardiovascular Outcomes of African-Americans|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|March 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005429||206908|
NCT00005430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4348|Low Cholesterol and Mortality in Blacks and Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|September 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005430||206907|
NCT00005579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC-9802|Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia|Phase II Trial of Dolastin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|June 1998|February 2003|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|June 25, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005579||206765|
NCT00005504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5022|Epidemiology of Venous Thrombosis and Pulmonary Embolism|Longitudinal Investigation of Thromboembolism Etiology|LITE|University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|February 1998|December 2006||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21680|Samples With DNA|DNA, serum, plasma|Both|45 Years|N/A|No|Probability Sample|ARIC and CHS cohorts|January 2015|January 29, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005504||206835|
NCT00005505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5023|Neighborhood Environments and Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1997|November 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005505||206834|
NCT00005485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5001|Environmental and Genetic Factors That Influence Cardiovascular Disease in African Americans|Jackson Heart Study (JHS)||National Heart, Lung, and Blood Institute (NHLBI)||Recruiting|October 1996|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5307|||Both|35 Years|84 Years|No|||April 2006|April 27, 2006|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005485||206853|
NCT00005486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5002|Lymphangioleiomyomatosis (LAM) Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1997|June 2003|Actual|||N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||December 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005486||206852|
NCT00005406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4323|Change in Coronary Heart Disease Risk Factors in Young Adults|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1991|April 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005406||206931|
NCT00005513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5031|Framingham Nutrition Studies|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|July 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005513||206826|
NCT00005514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5032|Dietary Patterns and Risk of Cardiovascular Disease|||Harvard School of Public Health||Completed|August 1998|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120000|Samples With DNA|Plasma and buffy coat|Both|N/A|N/A|No|Non-Probability Sample|Nurses' Health Study and Health Professionals' Follow-up Study|March 2013|March 18, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005514||206825|
NCT00005420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4338|Prediction of Quality of Life in Cardiovascular Disease|||University of Texas at Austin||Completed|April 1992|March 1995||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 13, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005420||206917|
NCT00005421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4339|Blood Pressure Tracking--Childhood to Young Adulthood|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005421||206916|
NCT00005422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4340|Longitudinal Analysis of Spirometry in Black Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005422||206915|
NCT00005423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4341|Dietary Quality and Subsequent Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1992|December 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005423||206914|
NCT00005424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4342|Prospective Analysis of the Effect of Widowhood on CVD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|February 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005424||206913|
NCT00005389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4295|Effect of Drug Therapy on Reinfarction Risk in Women|||University of Washington||Completed|September 1995|August 1998||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2001|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005389||206948|
NCT00005390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4296|Family Process, Adherence, and Child Asthma Outcome|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1996|July 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005390||206947|
NCT00005391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4297|Pediatric Cardiomyopathy Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|May 2010|Actual|||N/A|Observational|N/A|||||||Both|N/A|18 Years|No|||January 2014|January 7, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005391||206946|
NCT00005451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4384|WINCATI Software Tool for Survey Research|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|July 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005451||206886|
NCT00005452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4385|Ti PC Software for Analyzing Longitudinal Data|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|April 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005452||206885|
NCT00005445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4374|Epidemiology of Pediatric Asthma Hospitalization|||Dartmouth-Hitchcock Medical Center||Completed|April 1994|February 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 5, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005445||206892|
NCT00005338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4200|Homocysteine and Progression of Atherosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|August 2004|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|100 Years|No|||December 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005338||206999|
NCT00005339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4201|Risk of Post Transfusion Hepatitis C Virus Infection|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1992|April 2004|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005339||206998|
NCT00005340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4202|Hypertension in Blacks of West African Origin|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|August 2005|Actual|August 2005|Actual|N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2008|March 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005340||206997|
NCT00005436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4364|Lupus Cohort--Thrombotic Events and Coronary Artery Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|August 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005436||206901|
NCT00005461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4905|Epidemiology of Symptom Perception in Childhood Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1991|June 2002|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005461||206877|
NCT00005462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4906|Genetics of Atherosclerosis in Mexican Americans|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|May 2008|Actual|May 2008|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||July 2008|July 1, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005462||206876|
NCT00005378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4276|Impact of Sleep Disordered Breathing in Older Adults|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1994|May 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005378||206959|
NCT00005379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4283|Tuberculosis in a Multiethnic Inner City Population|Tuberculosis in a Multiethnic Inner City Population||New York University School of Medicine||Completed|August 1994|July 1999|Actual|July 1999|Actual|N/A|Observational|Observational Model: Case Control||3|||||Both|N/A|100 Years|No|Non-Probability Sample|The study population will be made up of three cohorts: (1) intravenous drug users and        their sexual contacts in an already-recruited cohort; (2) children who receive their        primary care at Bellevue Hospital Medical Center; and (3) Bellevue Hospital Center        inpatients with TB and outpatients undergoing prophylactic treatment|December 2015|December 28, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005379||206958|
NCT00005441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4370|Lifestyle Management for Women With CHD and NIDDM|||Oregon Research Institute|No|Completed|April 1993|March 1998|Actual|October 1997|Actual|N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||February 2016|February 4, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005441||206896|
NCT00005442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4371|Re-evaluating Triglycerides in Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1994|May 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005442||206895|
NCT00005443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4372|Race, Class, and Gender--Studies of Health Effects|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1994|December 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005443||206894|
NCT00005347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4216|Framingham Cycle V Offspring-Spouse Nutrition Studies|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1992|January 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005347||206990|
NCT00005341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4204|Blood Donation--Immune Sequelae and Recruitment|||University of New Mexico||Completed|February 1992|January 1997||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005341||206996|
NCT00005342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4205|Weight Set-Point and HDL Concentration in Runners|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1993|April 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005342||206995|
NCT00005427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4345|Cohort Study of Respiratory Illness in Early Childhood|||University of New Mexico||Completed|March 1993|February 1995||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005427||206910|
NCT00005449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4378|Social Support and Myocardial Ischemia|||University of Florida||Completed|August 1996|June 2001||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 7, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005449||206888|
NCT00005346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4215|Mechanisms Underlying Abnormal Ambulatory BP Patterns|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1993|December 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005346||206991|
NCT00005415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4333|Physical Activity Effects on Health Care Utilization|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|September 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005415||206922|
NCT00005416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4334|Diet, Exercise, and Cardiovascular Health Among Ethnic Children|||Georgia Regents University||Completed|July 1992|June 1995||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|December 21, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005416||206921|
NCT00005515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5033|Mutations, Hormone Therapy (HRT) and Venous Thromboembolism|||University of Washington||Completed|September 1998|August 2003||||N/A|Observational|N/A|||||||Female|30 Years|89 Years|No|||July 2005|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005515||206824|
NCT00005516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5035|Epidemiology of Sleep Disordered Breathing in Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1998|June 2002|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005516||206823|
NCT00005487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5003|Multi-Ethnic Study of Atherosclerosis (MESA)|Multi-Ethnic Study of Atherosclerosis (MESA)||National Heart, Lung, and Blood Institute (NHLBI)||Active, not recruiting|January 1999|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|45 Years|84 Years|No|Non-Probability Sample|Participants were recruited from the MESA Study Field Centers.|April 2012|June 2, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005487||206851|
NCT00005488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5004|Common Variants in Candidate Genes and Premature MI Risk|||University of Washington||Completed|July 1998|August 2002||||N/A|Observational|N/A|||||||Both|18 Years|59 Years|No|||January 2005|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005488||206850|
NCT00005489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5005|Salt Sensitivity, Cardiovascular and Metabolic Disease|||Indiana University||Completed|January 1998|December 2001||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2015|December 28, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005489||206849|
NCT00005407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4324|Statistical Analysis of Pediatric Task Force Data Base|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1991|January 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005407||206930|
NCT00005473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4956|Cardiovascular Disease Trends 1980-91--A Gender Specific Perspective|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1996|June 2001|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||September 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005473||206865|
NCT00005474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4958|Markers and Mechanisms of Macrovascular Disease in IDDM|||Medical University of South Carolina||Completed|September 1996|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1063|Samples Without DNA|Both DNA samples as well as plasma, serum and urine samples were collected from the      DCCT/EDIC cohort.|Both|N/A|N/A|No|Non-Probability Sample|Patients with type 1 diabetes enrolled in the DCCT/EDIC cohort who agreed to participate        in our sub-study were enrolled|August 2008|April 13, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005474||206864|
NCT00005434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4361|Opioid Compromise in Hypertension--Modulating Factors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|March 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005434||206903|
NCT00005435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4362|Hostility and Pathogenic Mechanisms of Coronary Heart Disease in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1991|June 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005435||206902|
NCT00005458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4902|Suppressed Anger, Blood Pressure and Mortality Follow-up|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1991|December 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005458||206880|
NCT00005425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4343|Statistical Analysis of Vlagtwedde-Vlaardingen Data Set|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|February 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005425||206912|
NCT00005426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4344|Effects of CHD Prevention on Lipoprotein Subclasses|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1993|December 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005426||206911|
NCT00005343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4206|Social Support and CHD Risk Factors--A Community Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1993|December 1995||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005343||206994|
NCT00005344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4209|Mediators of Social Support in Coronary Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1992|April 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005344||206993|
NCT00005345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4212|Genetic Epidemiology of Blood Lipids and Obesity - Ancillary to NGHS|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1993|July 2000|Actual|||N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005345||206992|
NCT00005475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4959|Longitudinal Study of Asthma From Birth to Adulthood|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1996|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|22 Years|No|||May 2009|May 1, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005475||206863|
NCT00005476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4960|Sociodemographic Regulation of Cardiovascular Function and Structure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|November 2005|Actual|November 2005|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2009|May 1, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005476||206862|
NCT00005477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4961|Hispanic and White Women's Cardiovascular Health|||Stanford University||Completed|September 1996|August 1998||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|January 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005477||206861|
NCT00005352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4231|Chronic Stress as a Risk Factor in the Etiology of Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|August 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005352||206985|
NCT00005353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4236|Cardiac Autonomic Control in Children of HIV Positive Mothers|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1992|May 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005353||206984|
NCT00005354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4237|Computed Tomography (CT)--An Epidemiologic Study in the Young|||University of Iowa||Completed|April 1992|May 2007|Actual|May 2007|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|March 26, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005354||206983|
NCT00005483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4970|Plasma Homocysteine Distribution in the United States|||Tufts University||Completed|December 1994|July 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 6, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005483||206855|
NCT00005484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5000|Predictors of Hospital-Based Care in Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|March 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005484||206854|
NCT00005400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4317|Angiotensinogen Variants and Adverse Pregnancy Outcomes|||University of Utah||Completed|August 1995|July 2003||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 19, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005400||206937|
NCT00005401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4318|Validation and Exploration of Sleep and Mood Predictors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1995|July 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005401||206936|
NCT00005525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5053|Sleep Apnea in Elderly Male Twins|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1998|July 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005525||206814|
NCT00005526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5058|Genetic Basis of Abdominal Aortic Aneurysm|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|November 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005526||206813|
NCT00005355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4241|Gender Differences in Familial Risk|||Virginia Commonwealth University||Completed|February 1993|January 1996||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 29, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005355||206982|
NCT00005356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4242|Novel Hemostatic Cardiac Risk Factors in Framingham|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1994|May 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005356||206981|
NCT00005450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4380|Health Promotion in the Elderly--Prevention of Cardiovascular Disorders|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1991|November 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005450||206887|
NCT00005439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4367|Evaluation of Childhood Blood Pressure and Lipid Screening|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|March 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005439||206898|
NCT00005581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067266|Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer|Epirubicin Plus Paclitaxel Versus Cyclophosphamide, Epirubicin and 5-Fluorouracil as Adjuvant Treatment of Node Positive Breast Cancer Patients: A Controlled Randomized Phase III Study||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Female|N/A|70 Years|No|||June 2007|December 17, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005581||206763|
NCT00005583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSGO-EC9501|Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer|A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|January 2000|July 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Female|N/A|N/A|No|||November 2006|August 1, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005583||206762|
NCT00005417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4335|Fifteen Year Follow-up of 5,500 Black and 5,500 Other Hypertensives|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|September 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005417||206920|
NCT00005459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4903|Risk of Coronary Heart Disease in Women With Polycystic Ovary Syndrome|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|January 25, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005459||206879|
NCT00005528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5060|Genetics of CVD Risk Factors in Samoans|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1995|February 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005528||206812|
NCT00005529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5062|Self-Scored Cardiovascular Disease Risk Appraisal|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005529||206811|
NCT00005530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5063|Diet, Insulin Resistance, and Cardiovascular Risk|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1994|April 2000||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005530||206810|
NCT00005349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4218|Epidemiology of Coronary Artery Calcification||ECAC|University of Michigan||Completed|April 1991|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1736|||Both|20 Years|91 Years|Accepts Healthy Volunteers|Non-Probability Sample|817 men and 830 women ages 20 and older recruited from Rochester, MN.|June 2013|June 18, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005349||206988|
NCT00005350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4219|Evaluating Strategies to Control Hypercholesterolemia|||National Bureau of Economic Research, Inc.||Completed|April 1991|January 1993||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2015|December 21, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005350||206987|
NCT00005440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4369|Disability Among Adults With Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|January 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005440||206897|
NCT00005357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4243|Pulmonary Hypertension--Mechanisms and Family Registry|Pulmonary Hypertension--Mechanisms and Family Registry||Vanderbilt University||Completed|April 1994|March 1999|Actual|March 1999|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||February 2016|February 9, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005357||206980|
NCT00005597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067710|S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors|Phase II Study of Temozolomide in Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)||Southwest Oncology Group|Yes|Completed|April 2000|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005597||206748|
NCT00005460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4904|Predictors of Cardiovascular Disease in the Elderly|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1991|December 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005460||206878|
NCT00005480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4964|Cardiovascular Disease Knowledge/Morbidity--Socioeconomic Cohort Outcomes|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|August 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005480||206858|
NCT00005446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4375|Endogenous Estrogen and Coronary Heart Disease in Women|||New York University School of Medicine||Completed|April 1994|||March 1999|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|||||Female|N/A|100 Years|No|||December 2015|December 30, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005446||206891|
NCT00005447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4376|Physical Activity and Cardiovascular Disease Prevention|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1995|July 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005447||206890|
NCT00005448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4377|Adverse Events With Magnesium Sulfate|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1996|June 2002||||N/A|Observational|N/A|||||||Female|N/A|N/A|No|||March 2005|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005448||206889|
NCT00005358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4245|Thrombogenic Factors and Recurrent Coronary Events|||University of Rochester||Completed|April 1994|March 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005358||206979|
NCT00005359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4246|Genetics of Asthma and Bronchial Hyperresponsiveness|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1994|May 2008|Actual|May 2008|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||July 2008|July 1, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005359||206978|
NCT00005540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5080|Physical Fitness and Cardiovascular Mortality in Firefighters|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1999|May 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Male|N/A|N/A|No|||November 2002|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005540||206800|
NCT00005541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5083|Hemochromatosis and Iron Overload Screening Study (HEIRS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 2000|January 2006|Actual|January 2006|Actual|N/A|Observational|N/A|||||||Both|25 Years|N/A|No|||April 2009|April 13, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005541||206799|
NCT00005365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4252|Central Obesity and Disease Risk in Japanese Americans|||University of Washington||Completed|February 1993|January 1998||||N/A|Observational|N/A|||||||Both|45 Years|74 Years|No|||August 2004|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005365||206972|
NCT00005366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4253|Biobehavioral Mechanisms of Blood Pressure Regulation|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1998|Actual|||N/A|Observational|N/A|||||||Both|25 Years|39 Years|No|||April 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005366||206971|
NCT00005367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4254|Epidemiology of Long QTand Asian Sudden Death in Sleep|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1993|January 1995||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||March 2005|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005367||206970|
NCT00005437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4365|Physical Activity and Cardiovascular Risk in Black Girls|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1992|January 1998||||N/A|Observational|Observational Model: Natural History|||||||Female|11 Years|17 Years|No|||August 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005437||206900|
NCT00005438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4366|Neuropsychological Studies of Children With Sickle Cell|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1993|January 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005438||206899|
NCT00005402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4319|Transfusion Associated HCV in a Pediatric Population|||Children's Research Institute||Completed|May 1996|April 2001|Actual|April 2001|Actual|N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|December 16, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005402||206935|
NCT00005403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4320|Heart Disease and the Black Health Disadvantage|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1991|January 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005403||206934|
NCT00005404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4321|Compliance in the Physicians' Health Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1991|January 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005404||206933|
NCT00005545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5088|Arterial Endothelial Function--An Epidemiologic Study|Arterial Endothelial Function--An Epidemiologic Study||University of Iowa||Completed|December 1998|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|Samples With DNA|Stored plasma and DNA samples|Both|35 Years|60 Years|No|Non-Probability Sample|Muscatine Study Longitudinal Adult Cohort - representative sample of childhood        participants from the 1970s|December 2013|December 10, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005545||206795|
NCT00005546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5090|Molecular Genetic Epidemiology of Three Cardiac Defects -SCOR in Pediatric Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1999|December 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||December 2004|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005546||206794|
NCT00005547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5091|Infection and Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1999|June 2003|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005547||206793|
NCT00005542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5084|Sarcoid Genetic Analysis (SAGA)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1999|April 2005|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005542||206798|
NCT00005543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|962-98|Genetic Epidemiology of Venous Thromboembolism|||Mayo Clinic||Completed|April 1999|June 2005|Actual|June 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3135|||Male|N/A|100 Years|No|||December 2015|December 29, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005543||206797|
NCT00005544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5087|Community Based Study of Adult Onset Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1999|January 2005|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||May 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005544||206796|
NCT00005368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4255|Genetic Epidemiology of Hypertriglyceridemia|||University of Washington||Completed|July 1993|August 2003||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2005|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005368||206969|
NCT00005369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4260|Coronary Artery Disease Mechanisms in High Risk Families--Racial Difference|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|August 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005369||206968|
NCT00005385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4290|Seasonal Variation of Blood Cholesterol Levels|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1994|July 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005385||206952|
NCT00005351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4226|Incidence and Outcomes of Venous Thromboembolism|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|July 1994||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||September 2002|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005351||206986|
NCT00005471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4953|Anxiety and Cardiovascular Autonomic Control|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|January 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005471||206867|
NCT00005472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4954|Job Strain, Ambulatory Blood Pressure and Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|August 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005472||206866|
NCT00005578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9425|Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease|Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study||Children's Oncology Group|Yes|Completed|March 1997|June 2008|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|219|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|May 2, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00005578||206766|
NCT00005418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4336|Epidemiology of Cardiotoxicity in Children With Cancer|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|March 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||September 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005418||206919|
NCT00005419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4337|Physical Activity, Hypertension, Diabetes, and Coronary Heart Disease|||Stanford University||Completed|March 1992|February 1994||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005419||206918|
NCT00005364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4251|Genetic Epidemiology of CHD Risk Factors in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1994|March 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005364||206973|
NCT00005464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4908|DISH Data Analysis Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1991|January 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005464||206874|
NCT00005465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4909|Genetic Mapping of Atherogenic Lipoprotein Phenotypes|||University of Washington||Completed|August 1991|July 1996||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2001|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005465||206873|
NCT00005466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4910|Stroke and MI in Users of Estrogen/Progestogen|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|July 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005466||206872|
NCT00005600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067713|Axillary Drainage Following Lymph Node Dissection in Women With Stage I or Stage II Breast Cancer|Optimum Drainage of the Axilla After Lymph Node Dissection: A Randomized Prospective Study||National Cancer Institute (NCI)||Active, not recruiting|November 1997|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||December 2005|November 5, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005600||206745|
NCT00005500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5018|Collaborative Studies on the Genetics of Asthma (CSGA)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|August 2002|Actual|August 2002|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|January 25, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005500||206839|
NCT00005481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4965|Epidemiology of Impaired Coagulant Balance in Diabetes|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|July 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005481||206857|
NCT00005482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4969|Homocyst(e)Ine, Vitamin Status, and CVD Risk|||University of Washington||Completed|September 1995|March 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005482||206856|
NCT00005380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4284|Insulin, Androgen, and Risk in African-American Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1998|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005380||206957|
NCT00005381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4286|Prevalence of Sleep Apnea in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1994|February 2000||||N/A|Observational|Observational Model: Natural History|||||||Both|20 Years|N/A|No|||June 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005381||206956|
NCT00005469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4914|Maturational Changes in Cardiac Structures -- Blood Pressure Relationship -- SCOR in Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1990|November 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005469||206869|
NCT00005470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4952|Divergence of Blood Pressure By Race in Adolescent Girls|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|August 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005470||206868|
NCT00005370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4261|Longitudinal Study of Cortisol and Pulmonary Function|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1993|March 1999|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||November 2001|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005370||206967|
NCT00005388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4294|Visceral Fat, Metabolic Rate, and CHD Risk in Young Adults|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|March 2004|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005388||206949|
NCT00005501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5019|Hypertensive Treatment and Epidemiological Analyses|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|August 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005501||206838|
NCT00005502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|632-01|Coronary Disease Morbidity and Mortality in a Population|Coronary Disease Morbidity and Mortality in a Population||Mayo Clinic|No|Completed|October 2002|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5476|Samples Without DNA|plasma, serum and white blood cells are stored for future research projects|Both|18 Years|N/A|No|Probability Sample|All residents of Olmsted County, MN who are hospitalized and have an elevated Troponin        level.Non-residenst of Olmsted County are excluded.|May 2013|May 13, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005502||206837|
NCT00005503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5021|Epidemiology of Cardiac Development in Youth|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1997|August 1999|Actual|||N/A|Observational|N/A|||||||Both|8 Years|17 Years|No|||October 2002|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005503||206836|
NCT00005382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4287|Sources of Variability in Peak Expiratory Flow|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1995|May 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005382||206955|
NCT00005383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4288|Anger and Cardiovascular Risk in Urban Youth|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1995|December 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||September 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005383||206954|
NCT00005384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4289|Diet/Activity of Mexican American and Anglo Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1995|December 2002|Actual|||N/A|Observational|N/A|||||||Both|4 Years|11 Years|No|||August 2004|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005384||206953|
NCT00005463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4907|Population-Based Modeling of Cholesterol Lowering in the United States|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|May 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||September 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005463||206875|
NCT00005405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4322|Parity and Serum Lipids in White and Hispanic Women|||University of Pennsylvania||Completed|September 1991|September 1993|Actual|September 1993|Actual|N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 19, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005405||206932|
NCT00005548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5092|Green Tea Consumption and Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1999|March 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005548||206792|
NCT00005412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4330|Dietary Antioxidants and Atherosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1992|June 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005412||206925|
NCT00005413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4331|Stroke Risk in the NAS-NRC Twin Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|September 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005413||206924|
NCT00005414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4332|Validation of a Historical Physical Activity Survey|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|September 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005414||206923|
NCT00005249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1131|Epidemiology of Blood Pressure, Insulin, Salt Transport|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1989|August 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005249||207087|
NCT00005262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1146|Epidemiology of Idiopathic Dilated Cardiomyopathy (Washington, DC Dilated Cardiomyopathy Study)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|June 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005262||207074|
NCT00005263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC ID unknown (1147)|Postprandial Lipoproteins and Atherosclerosis|Association of Postprandial Triglyceride and Retinyl Palmitate Responses With Newly Diagnosed Exercise-induced Myocardial Ischemia in Middle-aged Men and Women||Columbia University|No|Completed|July 1990|November 1995|Actual|November 1995|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|205|||Both|18 Years|N/A|No|Non-Probability Sample|Populations undergoing diagnostic exercise electrocardiographic or thallium stress tests        at our medical centers.|December 2015|December 22, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005263||207073|
NCT00005264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1148|Pediatric Epidemiology of Cardiovascular Disease Risk Factors (Project Heartbeat)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1990|September 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2002|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005264||207072|
NCT00005286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007|Epidemiology of Sleep Apnea Syndrome|||University of New Mexico||Completed|April 1986|March 1989||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005286||207050|
NCT00005290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012|Epidemiology of Interstitial Lung Disease|||University of New Mexico||Completed|April 1988|June 1997||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005290||207046|
NCT00005317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4090|Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1986|November 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005317||207020|
NCT00005318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4091|ARDS - Clinical Epidemiology and the Role of the Inflammatory Response - SCOR in Acute Lung Injury|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1994|November 2004||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||December 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005318||207019|
NCT00005323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4104|Epidemiology of Persistent Pulmonary Hypertension of the Newborn - SCOR in Lung Biology and Diseases in Infants and Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1991|November 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005323||207014|
NCT00005203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1082|Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia|||University of Washington||Completed|July 1987|June 1992||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005203||207133|
NCT00005204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1083|Blood Pressure and Diurnal Variation in Sodium, Potassium, and Water Excretion|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1987|July 1989|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005204||207132|
NCT00005479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC ID unknown (4963)|Diabetes, Lipoproteins and Accelerated Vascular Disease|Measures of Postprandial Lipoproteins Are Not Associated With Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus||Columbia University|No|Completed|September 1996|September 2009|Actual|August 2001|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|164|||Both|35 Years|75 Years|No|Non-Probability Sample|Individuals with type 2 diabetes mellitus (DM) with or without coronary artery disease        (CAD)|December 2015|December 23, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005479||206859|
NCT00005307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009|Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|March 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005307||207029|
NCT00005197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1076|Predictors of Perioperative Cardiac Morbidity|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1986|November 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005197||207139|
NCT00005198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1077|Survival After Myocardial Infarction in A Biethnic Texas Community (Corpus Christi Heart Project)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1987|March 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005198||207138|
NCT00005199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1078|Balloon Valvuloplasty Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1987|November 1994||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005199||207137|
NCT00005200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1079|Adolescent Blood Pressure Variation and Ventricular Mass|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1987|June 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005200||207136|
NCT00005205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1084|Incidence of Diabetes and Cardiovascular Disease in Mexican Americans|Incidence of Diabetes and Cardiovascular Disease in Mexican Americans||The University of Texas Health Science Center at San Antonio|No|Completed|August 1987|July 2003||||N/A|Observational|N/A|||||||Both|24 Years|64 Years|No|||March 2016|March 7, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005205||207131|
NCT00005192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1071|Psychophysiology of Cardiovascular Reactivity|||University of Miami||Completed|July 1986|June 2006|Actual|June 2006|Actual|N/A|Observational|N/A|||||||Male|25 Years|54 Years|No|Non-Probability Sample||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005192||207144|
NCT00005193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1072|Prospective Study of Diabetes-related Vascular Disease in Oklahoma Indians|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1986|August 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||September 2002|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005193||207143|
NCT00005194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1073|Insulin and Biogenic Amines in Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1986|August 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005194||207142|
NCT00005195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1074|Catheter Ablation Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1986|August 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||September 2002|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005195||207141|
NCT00005273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300|Pulmonary Complications of HIV Infection Study (PACS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1987|May 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005273||207063|
NCT00005299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2022|Familial Aggregation and Natural History of Sleep Apnea|||Brigham and Women's Hospital||Completed|August 1990|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|726|Samples With DNA|Samples stored deidentified|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Probands with sleep apnea and family members; neighborhood control families|July 2013|July 29, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005299||207037|
NCT00005300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001|Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|October 1988|June 1995||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005300||207036|
NCT00004884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40984|Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer|Randomized Phase II Study of Docetaxel/Gemcitabine vs. Docetaxel/Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 1999|||March 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|96|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004884||207404|
NCT00004891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-99048|PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery|Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|September 1999|||March 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|149|||Both|18 Years|120 Years|No|||December 2015|December 21, 2015|March 7, 2000||No||No||https://clinicaltrials.gov/show/NCT00004891||207397|
NCT00005196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1075|Worcester Heart Attack Community Surveillance Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1986|March 2006|Actual|March 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||May 2009|March 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005196||207140|
NCT00005211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1090|Cardiovascular Mortality Among Tunnel and Bridge Workers Exposed To Carbon Monoxide|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|October 1987|September 1990||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||November 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005211||207125|
NCT00005278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501|Retrovirus Epidemiology Donor Study I (REDS I)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1989|October 2007|Actual|October 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 24, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005278||207058|
NCT00005279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000|Tucson Epidemiology Study of Chronic Obstructive Lung Diseases|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1971|November 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005279||207057|
NCT00005206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1085|Calcium Intake, Metabolism, and Gestational Blood Pressure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1987|August 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005206||207130|
NCT00005237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118|Epidemiology of Symptomatic Arrhythmias|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1988|November 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005237||207099|
NCT00005238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1119|Antecedents of Hypertension: Role of Race and Stress|||Georgia Regents University||Completed|December 1988|December 2001||||N/A|Observational|N/A|||||||Both|7 Years|14 Years|No|||December 2004|December 21, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005238||207098|
NCT00005250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1132|Linkage Study of Long QT Syndrome In An Amish Kindred|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|December 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005250||207086|
NCT00005287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008|Late Sequelae of Bronchopulmonary Dysplasia|||Stanford University||Completed|July 1986|June 1989||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005287||207049|
NCT00005256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138|Coronary Screening in a High Risk Subset|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1990|August 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005256||207080|
NCT00005275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302|Sleep Heart Health Study (SHHS) Data Coordinating Center|The Sleep Heart Health Study (SHHS) Was a Multi-site Prospective Cohort Study to Investigate Obstructive Sleep Apnea (OSA) and Other Sleep-disordered Breathing (SDB) as Risk Factors for Cardiovascular Diseases and Hypertension|SHHS|Johns Hopkins Bloomberg School of Public Health|No|Completed|September 1994|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6441|||Both|40 Years|N/A|No|Non-Probability Sample|Participants in SHHS were recruited from NHLBI cohort studies already in progress. Parent        cohort studies and recruitment targets for these cohorts were as follows:          -  Atherosclerosis Risk in Communities Study (ARIC) - 1,750 participants          -  Cardiovascular Health Study (CHS) - 1,350 participants          -  Framingham Heart Study (FHS) - 1,000 participants          -  Strong Heart Study (SHS) - 600 participants          -  New York Hypertension Cohorts - 1,000 participants          -  Tucson Epidemiologic Study of Airways Obstructive Diseases and the Health and             Environment Study - 900 participants|May 2013|May 19, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005275||207061|
NCT00005280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001|Specialized Center of Research in Occupational and Immunologic Lung Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1972|November 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005280||207056|
NCT00005267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1151|Family Blood Pressure Program - HyperGEN|||University of Alabama at Birmingham||Completed|September 1995|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|3604|Samples With DNA|Tissue suitable for DNA extraction|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|(A) sample of hypertensive sibships with at least two members diagnosed with hypertension        before the age of 60 (probands); (B) random sample of age-matched persons from the same        base populations, from which normotensive controls could be drawn; (C) unmedicated,        normotensive adult offspring of one of the hypertensive siblings.|June 2012|October 6, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005267||207069|
NCT00005268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1152|Family Blood Pressure Program - GenNet Network|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2008|August 20, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005268||207068|
NCT00005239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120|Genetic Epidemiology of Coronary Heart Disease Risk in Women Twins|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1989|December 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005239||207097|
NCT00005296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2019|Sleep Apnea: Age Effects On Prevalence and Natural History|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|December 1994||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005296||207040|
NCT00005297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2020|Age-related Prevalence of Sleep Respiratory Disturbances|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1990|June 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005297||207039|
NCT00005288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009|Epidemiology and Pulmonary Response To Organic Dust Exposure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1986|November 1991||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||April 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005288||207048|
NCT00005327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4117|Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center|||University of Southern California||Completed|April 1993|March 1998||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|January 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005327||207010|
NCT00005319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4093|Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1985|December 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005319||207018|
NCT00005320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4097|Regulation of Pharyngeal Muscle Contraction - SCOR in Cardiopulmonary Disorders of Sleep|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|August 1998||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal|||||||Male|N/A|N/A|No|||March 2005|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005320||207017|
NCT00005321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4099|Epidemiology of Sleep Disordered Breathing - SCOR in Cardiopulmonary Disorders of Sleep|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|August 1999||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005321||207016|
NCT00005217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1096|Intermittent ST Depression and Prognosis After Myocardial Infarction|||New York University School of Medicine||Completed|April 1988|March 1991||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 27, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005217||207119|
NCT00005269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1153|Family Blood Pressure Program - GENOA|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||August 2008|August 20, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005269||207067|
NCT00005219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1098|Predicting Physical Activity Change: an Epidemiologic Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1988|March 1990||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005219||207117|
NCT00005153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1025|Etiologic Risk Factors of Cardiovascular Malformations|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1980|November 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2001|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005153||207183|
NCT00005298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2021|Inflammation, Autonomic Dysfunction and Airway Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|June 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005298||207038|
NCT00005301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3002|Transfusion Safety Study (TSS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1984|February 1998||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005301||207035|
NCT00005302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3003|Drug Etiology of Aplastic Anemia and Related Dyscrasias|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1985|June 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005302||207034|
NCT00005303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3004|Effectiveness of AIDS Antibody Screening|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1986|September 1995||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||December 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005303||207033|
NCT00005304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005|Delta Hepatitis and Liver Disease in Hemophiliacs|||Baylor College of Medicine||Completed|September 1986|September 1991||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2015|December 8, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005304||207032|
NCT00005328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4124|Antecedents of the Type A Behavior Pattern|||University of Pittsburgh||Completed|April 1980|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|184|||Both|9 Years|16 Years|No|Non-Probability Sample|Adolescents from one high school in Pittsburgh|January 2013|January 16, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005328||207009|
NCT00005218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1097|Epidemiological Tool To Detect Angina Pectoris in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1988|March 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005218||207118|
NCT00005148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1019|Coronary Heart Disease Incidence, Mortality, and Risk Factor Relationships|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1979|August 1991||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005148||207188|
NCT00005149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020|Genetic and Environmental Determinants of Hypertension|||University of Utah||Completed|February 1980|November 1992||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 19, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005149||207187|
NCT00005154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1026|National Health and Nutrition Examination Survey IV (NHANES (IV)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1981|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2009|April 13, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005154||207182|
NCT00005155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1027|Physiological and Psychosocial Correlates of Type A Behavior|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1982|January 1989|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005155||207181|
NCT00005212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1091|Work Organization and Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1988|February 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005212||207124|
NCT00005213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1092|Lithium Countertransport and Blood Pressure In CARDIA and TOMHS|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1988|February 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005213||207123|
NCT00005214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1093|Epidemiology of Genetic Factors in Lipid Metabolism|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1988|March 1993||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005214||207122|
NCT00005215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1094|Lipoprotein Subfractions and Coronary Heart Disease During 25 Year Follow-up|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1988|March 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005215||207121|
NCT00005335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4192|Genetic Epidemiology of Lipoprotein-Lipid Levels|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1991|March 2002|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005335||207002|
NCT00004890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067566|Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer|Phase IB Open-Label Rising-Dose Study of Biomed 101 in Patients Treated With Interleukin-2 for Malignancy||National Cancer Institute (NCI)||Completed|December 2000|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2008|March 25, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004890||207398|
NCT00004898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 91H5T|Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia|Dose Escalation of VP-16 With Cyclophosphamide and Total Body Irradiation as Preparative Regimen for Autologous Transplantation for High-Grade Lymphoma and Acute Lymphoblastic Leukemia||Northwestern University|Yes|Completed|October 1999|July 2003|Actual|July 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|6|||Both|N/A|65 Years|No|||June 2012|June 8, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004898||207391|
NCT00005216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095|Multicenter Study of Silent Myocardial Ischemia (MSSMI)|||University of Rochester||Completed|April 1988|December 1994||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005216||207120|
NCT00005228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108|AIDS-Associated Heart Disease -- Incidence and Etiology|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1988|June 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005228||207108|
NCT00005312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4068|International Programs Collaborative Studies Coordinating Center|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|August 2002||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||July 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005312||207025|
NCT00004889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067565|Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia||Jonsson Comprehensive Cancer Center|No|Completed|December 1999|July 2005|Actual|January 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||July 2012|September 30, 2015|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004889||207399|
NCT00005251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1133|Genetic Analysis of Familial Hypertrophic Cardiomyopathy|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005251||207085|
NCT00005252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1134|Physicians' Health Study: Study of Low Cardiovascular Disease Mortality|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|December 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005252||207084|
NCT00005276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1303|A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1995|March 2003||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||December 2005|March 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005276||207060|
NCT00005277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1500|Cooperative Study of The Clinical Course of Sickle Cell Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1977|December 2000||||N/A|Observational|N/A|||||||Both|N/A|25 Years|No|||August 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005277||207059|
NCT00005308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3011|Anemia and Surgery: Indications For Transfusion|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1990|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005308||207028|
NCT00005360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4247|HIV Diversity and Pathogenesis in Donor-Recipient Clusters|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1992|July 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005360||206977|
NCT00005361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4248|Determinants of Respiratory Health in Young Adults|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1993|March 1998|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||June 2000|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005361||206976|
NCT00005240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC ID unknown (1121)|Epidemiology of Hypertensive Emergency|Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population||Columbia University|No|Completed|October 1989|December 1992|Actual|June 1991|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|210|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects were enrolled in a case-control study of hypertensive emergency and urgency.        Cases were patients with incidents of hypertensive emergency or hypertensive urgency, and        controls were hypertensive patients with other acute conditions who were admitted to the        hospital or were treated in the emergency room and released.|December 2015|December 22, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005240||207096|
NCT00005241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1122|Myocardial Infarction and Current Oral Contraceptive Use|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|December 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005241||207095|
NCT00005314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008338|Behavioral Factors in Coronary Heart Disease|||Duke University|No|Completed|July 1986|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|694|Samples With DNA|Urine and plasma samples and extracted DNA are retained|Both|22 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normal volunteers|February 2015|March 12, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005314||207023|
NCT00005315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4078|Psychosocial Factors and Cardiovascular Disease|Psychosocial Factors and Cardiovascular Disease||Columbia University|No|Completed|September 1993|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2008|March 7, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005315||207022|
NCT00005316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4086|White Coat Hypertension and Antihypertensive Treatment Effect - SCOR in Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1985|November 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005316||207021|
NCT00005266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1150|Cardiovascular Disease Mortality in The NAS-NRC Twin Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1990|September 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005266||207070|
NCT00005150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1021|Minnesota Heart Health Program|||University of Minnesota - Clinical and Translational Science Institute||Completed|July 1980|June 1993||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005150||207186|
NCT00005408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4326|Reanalysis of CVD Risk Factors Via Likelihood Methods|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1992|April 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005408||206929|
NCT00005409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4327|Longitudinal Studies of Blood Pressure in the Elderly|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1991|April 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005409||206928|
NCT00005281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002|Early Risk Predictors For Chronic Pulmonary Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1977|November 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005281||207055|
NCT00005282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003|Prospective Evaluation of Airways Reactivity|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1981|November 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005282||207054|
NCT00005283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004|Risk Factors For Asthma in Laboratory Animal Allergy|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1983|June 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005283||207053|
NCT00005284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005|Epidemiology of Airway Responsiveness|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1985|March 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005284||207052|
NCT00005285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006|Effect of Maternal Smoking On Neonatal Lung Function|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1985|November 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005285||207051|
NCT00005143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1014|Stanford Five-City Multifactor Risk Reduction Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1978|February 1998||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||March 2005|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005143||207193|
NCT00005144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1015|Coronary-Prone Behavior and Cardiovascular Reactivity|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1978|June 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005144||207192|
NCT00005145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1016|Minnesota Heart Survey - Risk Factor Survey|Study of Trends in Cardiovascular Risk Factors in an Urban Population.|MHS|University of Minnesota - Clinical and Translational Science Institute||Completed|April 1979|February 2005|Actual|February 2005|Actual|N/A|Observational|N/A||1|||||Both|8 Years|84 Years|No|||February 2016|February 3, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005145||207191|
NCT00005146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1017|Diabetes and Cardiovascular Risk In Mexico City (San Antonio Heart Study)|Diabetes and Cardiovascular Risk In Mexico City (San Antonio Heart Study)||The University of Texas Health Science Center at San Antonio|No|Completed|May 1979|August 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2016|March 7, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005146||207190|
NCT00005147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1018|Epidemiology of Atherosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1979|June 1991||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005147||207189|
NCT00005151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1022|Pawtucket Heart Health Program|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1980|July 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005151||207185|
NCT00005152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024|Nurses' Health Study (Cardiovascular Component)|Nurses' Health Study (Cardiovascular Component)||Brigham and Women's Hospital|No|Completed|August 1980|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|121700|||Female|N/A|N/A|No|Probability Sample|See "Detailed Description"|January 2016|January 7, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005152||207184|
NCT00005175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1052|Coronary Heart Disease Risk Factors in Upwardly Mobile Blacks and Whites|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1985|June 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005175||207161|
NCT00005431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4349|Coronary Heart Disease Risk Factors in Blacks Vs Whites|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1994|February 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005431||206906|
NCT00005432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4350|Impact of Surfactant's Availability on Newborns|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1995|December 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005432||206905|
NCT00005433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4351|Correlates of Angiographic Changes and Coronary Events|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1996|March 1998||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2002|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005433||206904|
NCT00005453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4441|Adherence in Clinical Trials-Induction Strategies|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|June 1997|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|100 Years|No|||September 2002|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005453||206884|
NCT00005336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4195|Dietary Treatment of Hyperlipidemia in Women vs. Men|||University of Washington||Completed|April 1991|September 1996||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005336||207001|
NCT00005337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4196|Hostility and Coronary Risk--Role of Weak Vagal Function|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1991|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005337||207000|
NCT00004897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 94I1|Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer|PFL-Alpha Chemotherapy Followed by Surgery or FHX for Early Stage Esophageal Cancer - A Pilot Project||Northwestern University||Terminated|October 1999|November 2007|Actual|July 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2012|June 8, 2012|March 7, 2000|Yes|Yes|Institutional Review Board requested termination - all patients deceased and no new accrual.|No||https://clinicaltrials.gov/show/NCT00004897||207392|
NCT00005253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1135|Proarrhythmic Medicines and Primary Cardiac Arrest|||University of Washington||Completed|January 1990|January 2000||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2006|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005253||207083|
NCT00004876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067536|Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer|A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer||National Cancer Institute (NCI)||Completed|August 1999|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||November 2011|August 23, 2013|March 7, 2000||||No||https://clinicaltrials.gov/show/NCT00004876||207411|
NCT00005168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042|Hyperapo B and Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1984|December 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005168||207168|
NCT00005467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4912|Indices of Severity and Prognosis for Sickle Cell Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|December 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005467||206871|
NCT00005468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4913|Lipid Variability--Influence of Stress|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|December 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005468||206870|
NCT00004896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 91H4T|Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia||Northwestern University|Yes|Completed|October 1999|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|60 Years|No|||June 2012|June 8, 2012|March 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00004896||207393|
NCT00005242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123|Childhood Passive Smoking: Cohort Study of Cardiac Risk|||Virginia Commonwealth University||Completed|April 1989|June 1994||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005242||207094|
NCT00005243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1124|Triggers of Ventricular Arrhythmias (TOVA) Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|August 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||December 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005243||207093|
NCT00005254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1136|Natural History of Peripheral Arterial Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1990|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005254||207082|
NCT00005309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3012|Prospective Study of HIV Infection in Hemophiliacs|||Puget Sound Blood Center||Completed|July 1990|March 1995||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 5, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005309||207027|
NCT00005311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4047|Hypertension in Minorities Database-Workshop and Publication|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|March 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||June 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005311||207026|
NCT00005371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4262|Epidemiology of Acute Phase Protein and CHD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1993|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005371||206966|
NCT00005372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4264|Intimal Thickening and Antioxidants in Hispanics and Anglos (Los Angeles Atherosclerosis Study)|||University of Southern California||Completed|January 1994|February 2005||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005372||206965|
NCT00005373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4267|Racial Differences in the Coronary Microcirculation|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|August 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005373||206964|
NCT00005392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4298|Epidemiology of Venous Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|July 2000|Actual|||N/A|Observational|N/A|||||||Both|29 Years|91 Years|No|||July 2005|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005392||206945|
NCT00005244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1125|Anger Expression, Self-focus and Coronary Heart Disease Risk Factors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|March 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005244||207092|
NCT00005245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1126|Community Structure and Cardiovascular Mortality Trends|Community Structure and Cardiovascular Mortality Trends||University of North Carolina, Chapel Hill||Completed|June 1989|May 1993|Actual|May 1993|Actual|N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 4, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005245||207091|
NCT00005265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1149|Natural History of Coronary Heart Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1990|May 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005265||207071|
NCT00005289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010|Risk Factors in Bronchopulmonary Dysplasia (Newborn Lung Project)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1987|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||July 2008|July 23, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005289||207047|
NCT00005291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013|Clinical Epidemiology of Asthma in An HMO|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1988|April 2003|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005291||207045|
NCT00005292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014|Alpha1-antitrypsin Deficiency Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|November 1999||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|March 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005292||207044|
NCT00005293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015|Antecedents of Bronchopulmonary Dysplasia|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1988|November 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005293||207043|
NCT00005410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4328|Epidemiology of Coronary Heart Disease in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1991|May 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005410||206927|
NCT00005411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4329|Study of Children's Activity and Nutrition (SCAN)--Extended Analyses|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1991|September 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005411||206926|
NCT00005313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10927-B|Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia|Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia||University of Washington|No|Completed|April 2001|March 2003|Actual|March 2003|Actual|N/A|Observational|Observational Model: Family-Based||1|Actual|450|||Both|18 Years|N/A|No|Non-Probability Sample|Relatives of patients with familial combined hyperlipidemia|December 2014|December 9, 2014|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005313||207024|
NCT00005261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1145|Urinary Kallikrein and Hypertension: A Prospective Study|||University of Utah||Completed|July 1990|June 1993||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 19, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005261||207075|
NCT00005173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1048|Myocardial Infarction and Past Oral Contraceptive Use|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1985|April 1989|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005173||207163|
NCT00005174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1051|Western Collaborative Group Study (WCGS): 25-Year Follow-up of Cardiovascular Disease Morbidity and Mortality|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1985|June 1990|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005174||207162|
NCT00005176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1053|Long QT Syndrome-Population Genetics and Cardiac Studies|Long QT Syndrome-Population Genetics and Cardiac Studies|LQTS|University of Rochester|No|Completed|August 1985|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|2125|Samples With DNA|DNA|Both|N/A|100 Years|No|Non-Probability Sample|As of the 2013 closeout report, 1329 probands with clinical dx of LQTS and members of        their extended families have been enrolled in the LQTS Registry. By ECG classification,        this includes 3420 probands and affected family members, 3533 unaffected family members,        and 2105 family members with borderline QTc. Of those, 2125 have had mutations identified.|October 2015|October 20, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005176||207160|
NCT00005177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1055|Reno Diet Heart Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1985|November 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005177||207159|
NCT00005178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1056|Study of Children's Activity and Nutrition (SCAN)|||Georgia Regents University||Completed|September 1985|August 1991||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2000|December 21, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005178||207158|
NCT00005201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1080|Idiopathic Dilated Cardiomyopathy|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1987|June 1992||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005201||207135|
NCT00005202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1081|Identifying High Risk Patients With Syncope|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1987|June 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005202||207134|
NCT00005455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4488|Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1993|December 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|March 10, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005455||206883|
NCT00005456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4900|Hypertensive and Normal Pregnancy--Calcium Metabolism and Renin-Angiotensin - SCOR in Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1990|November 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005456||206882|
NCT00005457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4901|Model-Free Time Curves for Longitudinal Data Analysis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1991|June 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005457||206881|
NCT00005478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4962|Precursors of CVD Risk Factors--Project Heartbeat|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|September 1998|Actual|||N/A|Observational|N/A|||||||Both|8 Years|14 Years|No|||March 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005478||206860|
NCT00005274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301|Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1989|March 2003||||Phase 3|Observational|N/A|||||||Male|N/A|N/A|No|||October 2005|October 26, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005274||207062|
NCT00005305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3006|Hepatitis Delta Infections in Hemophiliacs|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1986|September 1991||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||June 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005305||207031|
NCT00005306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3007|Natural History of Post-Transfusion Non-A, Non-B Hepatitis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1988|September 2001||||N/A|Observational|Observational Model: Natural History|||||||Both|N/A|N/A|No|||August 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005306||207030|
NCT00004875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 96X2|Heparin or Enoxaparin in Patients With Cancer|Release of TFPI by Anticoagulants in Cancer Patients by Standard or LMW Heparin||Northwestern University|Yes|Completed|July 1996|March 1999|Actual|March 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|6|||Both|18 Years|N/A|No|Probability Sample|A group of cancer patients representing a large variety of different tumor types will be        observed after receiving standard heparin or enoxaprin to determine risk for        thromboembolic disease.|February 2011|February 18, 2011|March 7, 2000||No||No||https://clinicaltrials.gov/show/NCT00004875||207412|
NCT00005169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1043|Lifestyle and Chronic Disease in College Alumni (Harvard Alumni Health Study)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1984|June 2000||||N/A|Observational|N/A|||||||Both|65 Years|N/A|No|||October 2002|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005169||207167|
NCT00005170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1044|Ambulatory Blood Pressure and Behavior|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1984|February 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005170||207166|
NCT00005171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1046|Cardiovascular Risk Factors in United States Adolescents and Adults|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1984|March 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005171||207165|
NCT00005172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1047|Socioeconomic Status, John Henryism and Hypertension Risk in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1984|April 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005172||207164|
NCT00005191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1069|Clinical Course of Coronary Artery Disease Among Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1986|March 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005191||207145|
NCT00005490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5007|Modeling DNA Diversity in Cardiovascular Health/Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1997|June 2003||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||February 2005|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005490||206848|
NCT00005492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5009|Pooled Analysis of NHANES I/II--Race, Gender, and CHD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1997|July 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005492||206847|
NCT00005444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4373|Hypertension in Families of African Origin|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1995|July 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005444||206893|
NCT00004874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259-98|Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma||University of Nebraska||Terminated|November 1998|November 2012|Actual|April 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|19 Years|N/A|No|||April 2013|April 17, 2013|March 7, 2000|No|Yes|lack of FDA approval|No||https://clinicaltrials.gov/show/NCT00004874||207413|
NCT00005246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1128|Epidemiology of Insulin and Dehydroepiandrosterone Sulfate and Coronary Heart Disease Mortality|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1989|July 1991|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005246||207090|
NCT00005247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1129|Nutritional Determinants of Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1989|July 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005247||207089|
NCT00005248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1130|Adiposity and Fat Patterning in Black Americans|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1989|July 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005248||207088|
NCT00005255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1137|Ischemic Heart Disease Incidence and Indices of Body-fat Distribution|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1990|April 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005255||207081|
NCT00005257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139|Diet and Plasma Cholesterol - Secular Trend Analysis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1990|April 1992|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005257||207079|
NCT00005322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4100|Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1990|December 1998||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005322||207015|
NCT00005393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4299|Epidemiology: Oxidative Stress and Early Atherosclerosis|Epidemiology: Oxidative Stress and Early Atherosclerosis||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|August 1996|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5115|Samples With DNA|blood and urine samples and DNA|Both|17 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study sample was selected from residents of Minneapolis, MN, Birmingham, AL, Chicago,        IL and Oakland, CA in 1985-86 as a community based sample.|December 2015|December 2, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005393||206944|
NCT00005394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4300|Diagnosis/Pathophysiology of Glucocorticoid Remediable Aldosteronism Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1995|July 2000|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005394||206943|
NCT00005648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003976|Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer|A Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 in Patients With Advanced Pancreatic Cancer||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 1999|November 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|688|||Both|18 Years|N/A|No|||October 2010|May 17, 2011|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005648||206699|
NCT00005622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11282|Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders|Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|May 1996|July 2009|Actual|September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|15 Years|50 Years|No|||October 2012|October 24, 2012|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005622||206725|
NCT00005629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067782|Vaccine Therapy in Treating Patients With Liver Cancer|Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma||Jonsson Comprehensive Cancer Center|Yes|Completed|July 1999|June 2002|Actual|May 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||July 2012|September 30, 2015|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005629||206718|
NCT00005717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4926|Medication Adherence in COPD--A Self-Regulation Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1990|July 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005717||206638|
NCT00005718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4927|Evaluation of Cholesterol Education for At-Risk Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1990|March 1993|Actual|||N/A|Observational|N/A|||||||Both|4 Years|10 Years|No|||July 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005718||206637|
NCT00005654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14914|Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome|||Office of Rare Diseases (ORD)||Completed|January 2000|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||88|||Female|18 Years|40 Years|No|||April 2000|June 23, 2005|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005654||206695|
NCT00005655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000121|Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer|A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|April 2000|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|99 Years|No|||March 2016|March 16, 2016|May 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005655||206694|
NCT00005641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11587|Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation|T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|September 1997|September 2000|Actual|September 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|60 Years|No|||December 2012|December 10, 2012|May 2, 2000|Yes|Yes|low study accrual|No||https://clinicaltrials.gov/show/NCT00005641||206706|
NCT00005610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9975|Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung|Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung||Alliance for Clinical Trials in Oncology|Yes|Completed|September 2000|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005610||206735|
NCT00005362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4249|Dose Estimation for Studies of Acute Respiratory Effects|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|August 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005362||206975|
NCT00005363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4250|Ambulatory Blood Pressure and Prognosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1992|July 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005363||206974|
NCT00005627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI-98238|Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase I Study of Estramustine, Taxotere and Carboplatin (ETP) in Patients With Horomone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|March 1999|April 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|85 Years|No|||April 2003|July 17, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005627||206720|
NCT00005666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1662|Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2001|June 23, 2005|May 19, 2000||||No||https://clinicaltrials.gov/show/NCT00005666||206687|
NCT00005667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1658|Vancomycin Resistant Enterococci in Patients Awaiting Liver Transplantation at the University of Michigan: Prevalence, Risk Factors, Natural History and Outcome of Colonization|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|No|||November 2001|June 23, 2005|May 19, 2000||||No||https://clinicaltrials.gov/show/NCT00005667||206686|
NCT00005630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-028|Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer|Vaccination of Non-Small Cell Lung Cancer Patients Against Mutated K-Ras: A Pilot Trial||Memorial Sloan Kettering Cancer Center||Completed|July 1999|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|17 Years|N/A|No|||June 2013|June 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005630||206717|
NCT00005680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1070|Whitehall II - Social and Occupational Influences On Health and Illness|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 2007|Actual|August 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005680||206675|
NCT00005681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1127|Vascular Basis for the Treatment of Ischemia|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1989|July 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||October 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005681||206674|
NCT00005674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0745|Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]|||National Center for Research Resources (NCRR)||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||December 2003|June 23, 2005|May 26, 2000||||No||https://clinicaltrials.gov/show/NCT00005674||206681|
NCT00005634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-059|Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy|Phase I Clinical and Pharmacological Study of Suberoylanilide Hydroxamic Acid- SAHA (MSK390) in Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|January 2000|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005634||206713|
NCT00005700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4281|Fat Reduction Intervention Trial in African-Americans|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005700||206655|
NCT00005701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4301|Acute Cardiac Ischemia in Women in the ACI/TIPI Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1994|June 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005701||206654|
NCT00005702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4302|Promoting Smoking Cessation in Hospital Patients|||University of Minnesota - Clinical and Translational Science Institute||Completed|May 1996|April 2000||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||February 2016|February 29, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005702||206653|
NCT00005703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4310|Hemostasis in Sickle Cell Disease--Infancy to Adulthood|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1995|July 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005703||206652|
NCT00005682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3008|Aplastic Anemia Epidemiology: Incidence and Case-control|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1988|August 1994|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005682||206673|
NCT00005683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4094|Clinical Interventions in Respiratory Distress Syndrome and Neonatal Lung Injury - SCOR in Lung Biology and Diseases in Infants and Children|||University of Rochester||Completed|December 1986|November 1997||||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005683||206672|
NCT00005684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4108|Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1996|January 2001|Actual|||Phase 3|Observational|Time Perspective: Retrospective|||||||Both|N/A|100 Years|No|||February 2005|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005684||206671|
NCT00005652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15038|Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura|||Office of Rare Diseases (ORD)||Completed|December 2000|||August 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2008|September 8, 2008|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005652||206696|
NCT00005671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000131|Quality of Life in Patients With Chronic Ischemic Heart Disease|Quality of Life in Chronic Ischemic Heart Disease With Left Ventricular Dysfunction||National Institutes of Health Clinical Center (CC)||Completed|May 2000|May 2002||||N/A|Observational|N/A||||105|||Both|N/A|N/A|No|||May 2002|March 3, 2008|May 24, 2000||||No||https://clinicaltrials.gov/show/NCT00005671||206683|
NCT00005691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4213|Psychosocial Risk Factors for Coronary Heart Disease in Swedish Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|August 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2001|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005691||206664|
NCT00005628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-077|Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma|A Phase II Trial of Active Specific Immunotherapy in Patients With Recurrent Soft Tissue Sarcoma Using Autologous Tumor-derived Heat Shock Protein-Peptide Complex (HSPPC-96)||Memorial Sloan Kettering Cancer Center||Completed|November 1999|August 2001|Actual|August 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005628||206719|
NCT00005794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-355|Perifosine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Perifosine on a Loading Dose/Maintenance Dose Schedule in Patients With Advanced Cancer||University of Wisconsin, Madison||Completed|February 2000|July 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||October 2015|October 15, 2015|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005794||206564|
NCT00005602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0012|Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas|Phase I Study of Concurrent Cereport and Carboplatin With Radiation Therapy for Children With Newly-Diagnosed Brain Stem Gliomas||Children's Oncology Group|Yes|Completed|February 2001|September 2005|Actual|January 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|4||Actual|13|||Both|3 Years|21 Years|No|||February 2014|February 19, 2014|May 2, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00005602||206743|
NCT00005603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9906|Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia|ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study||Children's Oncology Group|Yes|Completed|March 2000|||September 2005|Actual|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|276|||Both|1 Year|21 Years|No|||February 2014|February 18, 2014|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005603||206742|
NCT00005604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00049|Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors|Phase I Trial of Twice Weekly IV IL-12 Plus Low-Dose Subcutaneous IL-2 in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|March 2000|||July 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005604||206741|
NCT00005638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-081|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer|Phase I Trial of Combined Modality Irinotecan, Cisplatin, and Concurrent Radiation Therapy for Patients With Locally Advanced Esophageal Cancer||Memorial Sloan Kettering Cancer Center||Completed|October 1999|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005638||206709|
NCT00005743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4967|Exercise Adherence in a Behavioral Weight Loss Program|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1996|April 2001|Actual|||N/A|Interventional|Allocation: Randomized|||||||Male|N/A|100 Years|No|||August 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005743||206612|
NCT00005646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067826|Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive Stage Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|April 2000|February 2008|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005646||206701|
NCT00005635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067790|Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2|A Phase II Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of Herceptin Administered Subcutaneously in Combination With Paclitaxel in Women With HER2 Overexpressing Metastatic Breast Cancer||Genentech, Inc.||Completed|January 2000|||November 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||August 2013|August 16, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005635||206712|
NCT00005665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0135|Ingested Interferon Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Type 1 Diabetes Mellitus|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|3 Years|25 Years|No|||December 2003|June 23, 2005|May 19, 2000||||No||https://clinicaltrials.gov/show/NCT00005665||206688|
NCT00005677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1023|Percutaneous Transluminal Coronary Angioplasty (PTCA) Registries I, II, and III and the Dynamic Registry|Dynamic Evaluation of Coronary Intervention||University of Pittsburgh|Yes|Completed|August 1980|January 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4290|||Both|N/A|N/A|No|Non-Probability Sample|Patients with coronary heart disease who have undergone percutaneous transluminal coronary        angioplasty (PTCA) and have alternative angioplasty devices|January 2016|January 12, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005677||206678|
NCT00005804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1467.00|Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen||Fred Hutchinson Cancer Research Center||Completed|October 1999|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|50 Years|No|||March 2010|March 31, 2010|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005804||206554|
NCT00005669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000134|Metformin to Treat Obesity in Children With Insulin Resistance|Effects of Metformin on Energy Intake, Energy Expenditure, and Body Weight in Overweight Children With Insulin Resistance||National Institutes of Health Clinical Center (CC)|Yes|Completed|May 2000|May 2011|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|6 Years|12 Years|No|||April 2015|April 21, 2015|May 19, 2000|Yes|Yes||No|April 7, 2010|https://clinicaltrials.gov/show/NCT00005669||206684|
NCT00005696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4263|Early Atherosclerosis Change in Two Clinical Trials|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1994|December 1996|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|100 Years|No|||May 2005|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005696||206659|
NCT00005605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 95B2|Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer|Does Tamoxifen Prevent the Skeletal and Cardiovascular Morbidity of Chemotherapy in Premenopausal Women?||Northwestern University||Completed|February 2000|October 2005|Actual|October 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|79|||Female|35 Years|50 Years|No|Non-Probability Sample|Patients with stage I or II breast cancer currently undergoing treatment with either        chemotherapy or tamoxifen.|February 2011|February 18, 2011|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005605||206740|
NCT00005745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5006|Consequences and Correlates of Weight Fluctuations|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1998|December 2002|Actual|||N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||September 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005745||206610|
NCT00005746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5012|Community Site Coronary Risk Control in Black Families|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1998|March 2003|Actual|||N/A|Observational|N/A|||||||Both|30 Years|59 Years|No|||May 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005746||206609|
NCT00005611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067740|BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment|Phase I Study of BMS-188797 in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2000|July 23, 2008|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005611||206734|
NCT00005612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12085|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer|A Phase I/II Study of Intensive-Dose Etoposide, Topotecan and Carboplatin (ETC) Followed by Autologous Stem Cell Rescue in Chemosensitive Ovarian Cancer Patients With Either Minimal Residual Disease or at First Relapse|ETC|H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|August 1999|February 2004|Actual|February 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|65 Years|No|||September 2012|September 24, 2012|May 2, 2000|Yes|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00005612||206733|
NCT00005663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104C|A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients|An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects||NIH AIDS Clinical Trials Information Service||Active, not recruiting|June 1999|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2001|June 23, 2005|May 11, 2000||||No||https://clinicaltrials.gov/show/NCT00005663||206690|
NCT00005664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000127|Evaluation of Patients With Endocrine-Related Conditions|Evaluation of Patients With Endocrine-Related Conditions||National Institutes of Health Clinical Center (CC)||Recruiting|May 2000|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|1 Month|100 Years|No|||September 2015|January 22, 2016|May 17, 2000||No||No||https://clinicaltrials.gov/show/NCT00005664||206689|
NCT00005639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067799|Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment|A Phase I Dose Escalation to Maximally Tolerated Dose Trial of 5-Azacytidine (5 AC, NSC 102816) in Combination With Sodium Phenylbutyrate (PB, NSC 657802) in Patients With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|June 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|March 13, 2010|May 2, 2000||||||https://clinicaltrials.gov/show/NCT00005639||206708|
NCT00005609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067738|Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia|Rituximab for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated or Previously Treated Patients||National Cancer Institute (NCI)||Completed|April 2000|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|August 14, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005609||206736|
NCT00005692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4222|Inflammation Markers Over Time in Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|November 2002|Actual|||N/A|Observational|N/A|||||||Both|65 Years|100 Years|No|||March 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005692||206663|
NCT00005693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4238|Computer Assisted Instruction Weight Management for Low Literacy Populations|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1992|March 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005693||206662|
NCT00005694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4244|Worksites, Occupational Nurses and Cholesterol Change|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1992|June 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005694||206661|
NCT00005695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4258|Physical Training and Blood Pressure in High Risk Youths|||Georgia Regents University||Completed|January 1995|December 1997||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|December 21, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005695||206660|
NCT00005678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1037|Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1984|April 1996||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005678||206677|
NCT00005679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1049|Pathobiological Determinants of Atherosclerosis in Youth (PDAY)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1985|July 1993|Actual|July 1993|Actual|N/A|Observational|N/A|||||||Both|15 Years|34 Years|No|||January 2008|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005679||206676|
NCT00005631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-092|Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma|Cytoreduction and Stem Cell Mobilization With Rituximab and ICE for Patients With Refractory or Relapsed CD20+ B-Cell IGL Eligible for ASCT: The RICE Protocol||Memorial Sloan Kettering Cancer Center||Completed|November 1999|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|72 Years|No|||June 2013|June 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005631||206716|
NCT00005632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-040|Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer|Vaccination of Prostate Cancer Patients With MUC-1-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Examining the Immunogenicity of MUC-1 Glycopeptide Conjugate||Memorial Sloan Kettering Cancer Center||Completed|June 1999|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|N/A|No|||January 2013|January 30, 2013|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005632||206715|
NCT00005613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11306|Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Prospective, Comparative Trial of Allogeneic Versus Autologous Stem Cell Transplantation for High Risk Lymphoma|CBV|H. Lee Moffitt Cancer Center and Research Institute|No|Completed|March 1996|June 2010|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|15 Years|55 Years|No|||June 2013|June 3, 2013|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005613||206732|
NCT00005772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0021|Whole-Body Cooling for Birth Asphyxia in Term Infants|Randomized Controlled Trial of Hypothermia for Hypoxic-Ischemic Encephalopathy in Term Infants||NICHD Neonatal Research Network|Yes|Completed|October 1999|July 2010|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|N/A|6 Hours|No|||June 2015|June 3, 2015|June 1, 2000||No||No||https://clinicaltrials.gov/show/NCT00005772||206585|
NCT00005704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4359|Pharmacologic Intervention for Postcessation Weight Gain|||University of Memphis||Completed|July 1991|June 1997||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|January 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005704||206651|
NCT00005675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92242|Oral Type I Collagen for Relieving Scleroderma|Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Completed|April 2000|||May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||March 2008|May 24, 2010|May 26, 2000|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00005675||206680|
NCT00005636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-085|Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery|A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma||Memorial Sloan Kettering Cancer Center||Completed|November 1999|November 2000|Actual|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005636||206711|
NCT00005657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000125|Genetics of Hepatitis C Virus Infection|Immunogenetics of Hepatitis C Virus Infection||National Institutes of Health Clinical Center (CC)||Completed|May 2000|April 2011||||N/A|Observational|N/A|||Actual|870|||Both|2 Years|N/A|No|||April 2011|September 26, 2015|May 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005657||206693|
NCT00005658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000122|Glycine to Treat Psychotic Disorders in Children|Childhood Onset Psychotic Disorders: An Open Trial With the Amino Acid Glycine||National Institutes of Health Clinical Center (CC)||Completed|May 2000|January 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||January 2002|March 3, 2008|May 9, 2000||||No||https://clinicaltrials.gov/show/NCT00005658||206692|
NCT00005716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4925|Asthma Partnership for Minority Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1994|July 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005716||206639|
NCT00005697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4272|Intervention for Resistant Pregnant Smokers|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1993|December 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005697||206658|
NCT00005676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|909|High Density Lipoprotein Subspecies and Coronary Disease|High Density Lipoprotein Subspecies and Coronary Disease||Tufts University|No|Completed|April 2000|August 2005|Actual|August 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|2700|||Male|41 Years|90 Years|No|Probability Sample|men with CHD and low HDL-C men without CHD|March 2014|March 3, 2014|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005676||206679|
NCT00005614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11909|Management of Metastatic Breast Cancer in Frail Patients|Management of Metastatic Breast Cancer in Frail Patients||H. Lee Moffitt Cancer Center and Research Institute|No|Withdrawn|August 1999|June 2000|Actual|June 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|65 Years|N/A|No|||September 2012|September 21, 2012|May 2, 2000|Yes|Yes|no accrual|No||https://clinicaltrials.gov/show/NCT00005614||206731|
NCT00005705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4489|Adherence in the Childhood Asthma Management Program|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1992|June 1996|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|100 Years|No|||September 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005705||206650|
NCT00005706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4915|Urban African-American Community Hypertension Control|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005706||206649|
NCT00005618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067755|Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia|Phase II Study of Arsenic Trioxide, NSC 706363, in Relapsed of Refractory Chronic Myelogenous Leukemia||National Cancer Institute (NCI)||Completed|February 2000|March 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2001|June 20, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005618||206727|
NCT00005673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000129|Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs|Safety and Pharmacokinetic Study of Capravirine. Part I. Pharmacokinetics of Capravirine in HIV-Negative Volunteers. Part II. Antiviral Activity of Capravirine, Efavirenz, and Abacavir in HIV-Infected Patients||National Institutes of Health Clinical Center (CC)||Completed|May 2000|May 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||46|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2002|March 3, 2008|May 24, 2000||||No||https://clinicaltrials.gov/show/NCT00005673||206682|
NCT00005698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4277|IN CONTROL--Hypertension Reduction in Inner City Seattle|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005698||206657|
NCT00005699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4278|Improving Hypertension Control in the Inner City|Improving Hypertension Control in the Inner City||Medical College of Wisconsin|No|Completed|September 1993|February 2005|Actual|February 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2000|||Male|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|African-Americans with or without hypertension|February 2016|February 10, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005699||206656|
NCT00005640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11785|Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer|Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer: A Feasibility Study||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|June 1999|February 2002|Actual|February 2002|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005640||206707|
NCT00005624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11560|CI-994 in Treating Patients With Advanced Myeloma|A Multicenter Phase 2 Study of Oral N-Acetyl Dinaline (CI-994) in the Treatment of Patients With Advanced Myeloma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|August 1997|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005624||206723|
NCT00005633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-036|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Vaccination of Melanoma Patients With Tyrosinase YMD and gp100 IMD-Javelin Fusion Peptides/HSP70 Complexes: A Trial Comparing the Immunogenicity of Three Doses||Memorial Sloan Kettering Cancer Center||Completed|June 1999|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005633||206714|
NCT00005619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 97Z3|Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia|Detection of Hairy Cell Leukemia Minimal Residual Disease: Detection by Flow Cytometry||Northwestern University||Completed|February 2000|August 2001|Actual|August 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a documented diagnosis of hairy cell leukemia who are undergoing routine        bone marrow boipsy/aspiration and peripheral blood collection.|February 2011|February 18, 2011|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005619||206726|
NCT00005649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067869|Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer|An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|July 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|75 Years|No|||December 2006|July 23, 2008|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005649||206698|
NCT00005773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0019|Early Inhaled Nitric Oxide for Respiratory Failure in Newborns|Early Inhaled Nitric Oxide Therapy in Term and Near Term Infants With Respiratory Failure|Early iNO|NICHD Neonatal Research Network|Yes|Terminated|August 1998|August 2003|Actual|May 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|302|||Both|N/A|14 Days|No|||June 2015|June 3, 2015|June 1, 2000|No|Yes|Halted after 3 years because of a persistent decline in enrollment|No||https://clinicaltrials.gov/show/NCT00005773||206584|
NCT00005647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1399|SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck|A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck||Case Comprehensive Cancer Center|Yes|Completed|May 2000|October 2003|Actual|December 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005647||206700|
NCT00005637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067793|Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma|A Phase I Study of Extended Low Dose Temozolomide (SCH 52365, Temodar (R)) and Carmustine (BCNU) in the Treatment of Malignant Gliomas After Radiation Therapy||National Cancer Institute (NCI)||Completed|December 1999|December 2009|Actual|June 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|April 2, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005637||206710|
NCT00005601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9981|Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|A Phase II Trial of Cisplatinum, Cytosine Arabinoside, Dexamethasone (DHAP) With Rituxan in Patients With Relapsed CD20+ B-Cell Non-Hodgkin's Lymphoma||Alliance for Clinical Trials in Oncology|No|Completed|October 2000|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005601||206744|
NCT00005731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4940|Develop and Implement Asthma Controlling Strategies|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|May 1997||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||April 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005731||206624|
NCT00005732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4941|Develop and Implement Asthma Controlling Strategies (1)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|January 1997||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||August 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005732||206623|
NCT00005660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770172|The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases|The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases||National Institutes of Health Clinical Center (CC)||Completed|October 1977|November 2001||||N/A|Observational|N/A||||130|||Both|N/A|N/A|No|||November 2001|March 3, 2008|May 12, 2000||||No||https://clinicaltrials.gov/show/NCT00005660||206691|
NCT00005687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4182|Recycling Attempters and Relapsers in Smoking Cessation|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1989|April 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005687||206668|
NCT00005688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4184|Cardiac Arrhythmias and the Perception of Symptoms|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1989|February 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005688||206667|
NCT00005689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4185|Trial of Smoking Cessation Programs in Black Churches|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1991|June 1995||||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|N/A|No|||March 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005689||206666|
NCT00005690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4194|Improving Outcomes and Quality of Life After CABG|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|November 2000|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Male|N/A|100 Years|No|||January 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005690||206665|
NCT00005508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5026|Determinants of Coronary Disease in High Risk Families|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1998|June 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005508||206831|
NCT00005509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5027|Cardiovascular Risk Factors in a Cohort of Latina Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1998|March 2002|Actual|||N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||December 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005509||206830|
NCT00005510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5028|Strong Heart Study Analyses Obesity and Lipoproteins|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1998|March 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005510||206829|
NCT00005511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5029|SCOR in Neurobiology of Sleep--Intermediate Traits for Sleep Apnea|||University of Pennsylvania||Completed|September 1998|||August 2003|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2016|January 19, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005511||206828|
NCT00005512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5030|Genetic Epidemiology--Development of Cardiovascular Risk|||Virginia Commonwealth University||Completed|August 1998|July 2002||||N/A|Observational|N/A|||||||Both|10 Years|18 Years|No|||February 2016|February 29, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005512||206827|
NCT00005626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11586|Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)|Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|February 1998|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005626||206721|
NCT00005608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99B3|Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer|Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer||Northwestern University||Terminated|February 2000|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2012|May 31, 2012|May 2, 2000|Yes|Yes|Drug was pulled from the market.|No||https://clinicaltrials.gov/show/NCT00005608||206737|
NCT00005564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5113|Impact of Adult Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1997|June 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005564||206778|
NCT00005517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5036|Community Surveillance of Congestive Heart Failure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1998|June 2004|Actual|||N/A|Observational|N/A|||||||Both|35 Years|84 Years|No|||November 2005|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005517||206822|
NCT00005549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5093|Isocyanate Antigens and T Cells That Cause Asthma|||Yale University||Completed|January 1999|April 2007|Actual|April 2007|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||March 2014|March 13, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005549||206791|
NCT00005550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5094|Endotoxin and Bronchial Inflammation in Asthma|||University of North Carolina, Chapel Hill||Completed|January 1999|December 2006|Actual|December 2006|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2014|August 8, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005550||206790|
NCT00005551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5095|Sleep Apnea in a Non-Clinical Population|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1999|March 2002|Actual|||N/A|Observational|N/A|||||||Male|30 Years|60 Years|No|||August 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005551||206789|
NCT00005065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01401|Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|A Phase I Study of Induction Carboplatin / Paclitaxel Chemotherapy, Pre-operative Radiotherapy With Gadolinium Texaphyrin (Gd-Tex), and Surgical Resection in Stage IIIA (N2) Non-small Cell Lung Carcinoma.||National Cancer Institute (NCI)||Completed|January 2000|||December 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005065||207267|
NCT00005066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10227|O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma|A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Advanced Soft Tissue Sarcoma||University of Chicago|No|Completed|June 2000|October 2002|Actual|September 2001|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005066||207266|
NCT00005572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5067|A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection|Study of Pathogen-Specific Immune Responses and General Immune Competence in Opportunistic Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||90|||Both|13 Years|N/A|Accepts Healthy Volunteers|||June 2003|July 31, 2008|April 28, 2000||||No||https://clinicaltrials.gov/show/NCT00005572||206771|
NCT00005574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000083|Gentamicin Treatment of Muscular Dystrophy|Gentamicin Treatment of Patients With Muscular Dystrophy Due to Nonsense Mutations in Dystrophin||National Institutes of Health Clinical Center (CC)||Completed|February 2000|January 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||4|||Both|N/A|N/A|No|||January 2000|March 3, 2008|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005574||206770|
NCT00005570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000120|An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers|An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers||National Institutes of Health Clinical Center (CC)||Completed|April 2000|July 2000||||N/A|Observational|N/A||||200|||Both|N/A|N/A|No|||April 2000|March 3, 2008|April 22, 2000||||No||https://clinicaltrials.gov/show/NCT00005570||206773|
NCT00005577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02246|Gemcitabine in Treating Children With Refractory Solid Tumors|A PEDIATRIC PHASE I STUDY OF GEMCITABINE (NSC# 613327) IN SOLID TUMORS||National Cancer Institute (NCI)||Completed|August 1996|||September 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|1 Year|21 Years|No|||December 2002|February 4, 2013|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005577||206767|
NCT00005588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067662|Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer|Standardization of Breast Radiotherapy: Trial A - A Randomized Comparison of Fractionation Regimens After Local Excision or Mastectomy in Women With Early Stage Breast Cancer||National Cancer Institute (NCI)||Completed|January 1999|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2000|December 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005588||206757|
NCT00005589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067665|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy||National Cancer Institute (NCI)||Completed|October 1999|April 2013|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|460|||Both|18 Years|N/A|No|||March 2007|September 16, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005589||206756|
NCT00005518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5038|Epidemiology and Immunology of Hemophilia A Inhibitors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1998|August 2003|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005518||206821|
NCT00005519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5039|Prospective Study of Diet and Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|August 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005519||206820|
NCT00005533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016441|Hostility, Depression, Social Environment and CHD Risk|Hostility, Depression, Social Environment and CHD Risk||Duke University||Completed|February 1997|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|592|||Both|N/A|N/A|No|Non-Probability Sample|coronary heart disease patients --- undergoing angiography|February 2013|July 14, 2014|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005533||206807|
NCT00005586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067660|Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed|A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer||National Cancer Institute (NCI)||Completed|October 1997|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|2500|||Both|18 Years|N/A|No|||March 2007|December 17, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005586||206759|
NCT00005523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5050|Home Based Environmental Adherence Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1998|December 2003|Actual|||N/A|Observational|N/A|||||||Both|6 Years|17 Years|No|||January 2006|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005523||206816|
NCT00005524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5051|Mental Stress, Autonomic Function, and Heart Disease|||Hebrew Rehabilitation Center, Boston||Completed|September 1998|August 2003||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2005|January 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005524||206815|
NCT00005590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-TU-SIGNIFICANT|Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma|A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors||National Cancer Institute (NCI)||Completed|August 1999|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|16 Years|N/A|No|||July 2002|August 1, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005590||206755|
NCT00005520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004017|Genetic Epidemiology of Responses to Antihypertensives|Genetic Epidemiology of Responses to Antihypertensives|GERA|Mayo Clinic|No|Completed|February 1997|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1200|Samples With DNA|Serum, plasma, buffy coat, urine.|Both|18 Years|60 Years|No|Non-Probability Sample|Adult African American men and women with previously diagnosed primary hypertension were        recruited from Atlanta, Georgia; and adult European American man and women with previously        diagnosed primary hypertension were recruited from Rochester, Minnesota.|January 2013|January 15, 2013|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005520||206819|
NCT00005521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5048|Exercise and Blood Pressure in Children: A Meta-Analysis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1998|July 2004|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|100 Years|No|||December 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005521||206818|
NCT00005522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5049|Social Dominance, Gender, and Cardiovascular Reactivity|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1998|April 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||October 2005|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005522||206817|
NCT00005531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5064|Genetic Epidemiology of Sarcoidosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1996|November 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005531||206809|
NCT00005532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5065|Dietary Fat, Plasma Lipids, and Other CHD Risk Factors|||Tufts University||Completed|May 1996|August 2005||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 6, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005532||206808|
NCT00005070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-072|Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer|A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|January 2000|May 2001|Actual|May 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||June 2013|June 18, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005070||207262|
NCT00005552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5096|Isocyanate Dermal Exposures in Autobody Shops|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1999|December 2001|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005552||206788|
NCT00005077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067684|Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction|Phase I Study of Oxaliplatin in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction (Summary Last Modified 04/2000)||City of Hope Medical Center||Completed|February 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 4, 2010|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005077||207255|
NCT00005078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99139|Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors|Phase I Dose Escalation Study of Tirapazamine (NSC 130181) in Combination With Carboplatin and Paclitaxel in Advanced Malignant Solid Tumors||City of Hope Medical Center||Completed|March 2000|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005078||207254|
NCT00005072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCL-1102-203|Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer|Phase I/II Study Evaluating the Safety and Efficacy of Leuvectin Immunotherapy for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy (Summary Last Updated: 02/2001)||Vical|No|Terminated|November 2000|April 2003|Actual|April 2003|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|N/A|No|||July 2014|July 25, 2014|April 6, 2000|Yes|Yes|Development in prostate cancer indication halted|No||https://clinicaltrials.gov/show/NCT00005072||207260|
NCT00005606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 98H1|Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation|Adoptive Immunotherapy of Epstein Barr Virus Induced Lymhoproliferative Disease. A Comparison of Allogeneic and Autologous Lymphocyte Responses ex Vivo and Use of Highly Selected Reactive Cells as an Alternative to Chemotherapy in Vivo.||Northwestern University|Yes|Completed|February 2000|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2012|May 31, 2012|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005606||206739|
NCT00005553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5097|Prospective Assessment After Pediatric Cardiac Ablation (PAPCA)|||Stanford University||Completed|May 1998|April 2004||||N/A|Observational|N/A|||||||Both|N/A|16 Years|No|||October 2005|January 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005553||206787|
NCT00005554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5098|Biobehavioral Predictors of Coronary Angioplasty Outcome|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1999|January 2004|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005554||206786|
NCT00005555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5099|Dose Response to Exercise and Cardiovascular Health|||University of Florida||Completed|May 1998|April 2003||||N/A|Interventional|Primary Purpose: Prevention|||||||Both|30 Years|65 Years|No|||January 2016|January 7, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005555||206785|
NCT00005556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5101|Retention of Bone Marrow Donors in a National Registry|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1997|April 2003|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005556||206784|
NCT00005565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5114|Mechanisms of Low Levels of Apolipoprotein B|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1997|June 2002|Actual|June 2002|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|January 25, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005565||206777|
NCT00005566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR06022-0021|Cognitive Aspects of Adolescent Suicide|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|10 Years|16 Years|No|||November 2001|June 23, 2005|April 22, 2000||||No||https://clinicaltrials.gov/show/NCT00005566||206776|
NCT00005580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066433|Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma|Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma||Virginia Commonwealth University|No|Completed|September 1998|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|54|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005580||206764|
NCT00005593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1998|Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome|Phase I Study of Fludarabine, Carboplatin, and Topotecan for Patients With Relapsed/Refractory Acute Leukemia and Advanced Myelodysplastic Syndromes||Case Comprehensive Cancer Center|Yes|Completed|September 1998|March 2003|Actual|April 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|12 Years|N/A|No|||June 2010|June 9, 2010|May 2, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00005593||206752|
NCT00005584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20982|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma|Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|October 1998|||May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1649|||Both|15 Years|70 Years|No|||February 2016|February 3, 2016|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005584||206761|
NCT00005585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9904|Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia|ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study||Children's Oncology Group|Yes|Completed|April 2000|||July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|838|||Both|1 Year|9 Years|No|||June 2013|June 7, 2013|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005585||206760|
NCT00005534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1577-00|Prevalence of Asymptomatic Ventricular Dysfunction|||Mayo Clinic||Completed|January 1997|March 2006|Actual|March 2006|Actual|N/A|Observational|N/A|||||||Both|45 Years|N/A|No|||March 2014|March 5, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005534||206806|
NCT00005596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9905|Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia|ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study||Children's Oncology Group|Yes|Active, not recruiting|April 2000|||July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1076|||Both|1 Year|21 Years|No|||May 2015|May 6, 2015|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005596||206749|
NCT00005576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01527|Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma|A PHASE I STUDY OF CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY (ch14.18) WITH GM-CSF AND INTERLEUKIN-2 (IL-2) IN CHILDREN WITH NEUROBLASTOMA IMMEDIATELY POST AUTOLOGOUS BMT OR PBSC RESCUE||National Cancer Institute (NCI)||Completed|January 2001|||March 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|21 Years|No|||January 2013|January 15, 2013|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005576||206768|
NCT00005642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2Y99|SU5416 in Treating Patients With Advanced Solid Tumors|A Phase I Pharmacodynamic Trial of SU5416 (NSC 696819)||Case Comprehensive Cancer Center|Yes|Completed|May 2000|November 2005|Actual|December 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|May 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005642||206705|
NCT00005598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067711|Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome|A Phase II Trial of 5-Azacytidine (NSC #102816) and Ethyol (Amifostine) in the Treatment of Adults With Myelodysplastic Syndromes||University of Michigan Cancer Center|Yes|Completed|October 2000|March 2002|Actual|December 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2012|December 19, 2012|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005598||206747|
NCT00005535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5068|Gene Mapping for Quantitative Traits|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2000|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||October 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005535||206805|
NCT00005536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5069|Genetic Analysis of Human Hypertensive End Stage Renal Disease (H-ESRD)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1997|June 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2005|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005536||206804|
NCT00005537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5071|Genetics of Airway Responsiveness and Lung Function|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1997|June 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005537||206803|
NCT00005538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5075|CHD Risk, Behavioral Stress and Reproductive Hormones|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1987|June 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005538||206802|
NCT00005539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998-496|Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes|Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes|WESCID|University of Wisconsin, Madison||Completed|February 1999|January 2003|Actual|January 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Both|N/A|100 Years|No|Non-Probability Sample||February 2016|February 5, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005539||206801|
NCT00005497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5015|Risk Factors for Pulmonary Hypertension of the Newborn|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1998|March 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||October 2005|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005497||206842|
NCT00005498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5016|Do Hostility and Stress Predict Cardiovascular Mortality in MRFIT?|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1998|October 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005498||206841|
NCT00005643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067809|Chemotherapy in Treating Patients With Sarcoma of the Uterus|Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus||Gynecologic Oncology Group||Completed|May 2000|||March 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|21 Years|N/A|No|||November 2005|June 7, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005643||206704|
NCT00005057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067654|Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma|A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma||National Cancer Institute (NCI)||Completed|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|April 28, 2015|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005057||207274|
NCT00005058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067655|Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer|A Direct Comparison of Contrast Enhanced Power Doppler Ultrasound in Primary Breast Cancer and Axillary Nodal Status With Histopathological Variables and Clinical Outcome||National Cancer Institute (NCI)||Active, not recruiting|August 1997|||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Female|18 Years|N/A|No|||April 2005|November 5, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005058||207273|
NCT00005059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9921|Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer|A Phase II Study of Carboplatin and Paclitaxel in Elderly Patients With Metastatic or Recurrent Unresectable Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|January 2000|April 2006|Actual|July 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|65 Years|N/A|No|||July 2015|July 7, 2015|April 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005059||207272|
NCT00005650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00046-1395|Genetic Study of Patients With Primary Ciliary Dyskinesia|Genetic Study of Patients With Primary Ciliary Dyskinesia||National Center for Research Resources (NCRR)||Completed|February 2000|||||N/A|Observational|Observational Model: Natural History||||180|||Both|N/A|N/A|No|||December 2003|June 23, 2005|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005650||206697|
NCT00005615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11543|Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa|The Florida Melanoma Trial: A Phase I/II Trial of Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa in the Treatment of Advanced Stage III Melanoma: Study Site & Coordinating Center||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 1997|December 2005|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005615||206730|
NCT00005557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0084|Epidemiology of Sleep-Disordered Breathing in Adults|Epidemiology of Sleep-Disordered Breathing in Adults||University of Wisconsin, Madison||Active, not recruiting|April 1999|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1545|||Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|In 1988, employees of 4 Wisconsin state agencies, ages 30-60 years, were surveyed        regarding sleep habits and problems by mail. From these data, a sampling frame was        constructed and 2884 randomly-selected men and women (of 4896 survey respondents) were        invited to participate in the WSC Study. Recruitment for baseline sleep studies occurred        from 1989 to 2004.|December 2012|December 11, 2012|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005557||206783|
NCT00005559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5104|Statistical Basis for Hemochromatosis Screening|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1997|June 2000|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005559||206782|
NCT00005567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR06022-0038|Parental Knowledge and Beliefs About Infant Sleep Position|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|2 Weeks|Accepts Healthy Volunteers|||April 2000|June 23, 2005|April 22, 2000||||No||https://clinicaltrials.gov/show/NCT00005567||206775|
NCT00005591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067696|Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas|Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody C225 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer||University of Alabama at Birmingham|Yes|Withdrawn|October 1999|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2007|December 11, 2013|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005591||206754|
NCT00005571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000117|Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis|A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients||National Institutes of Health Clinical Center (CC)||Completed|April 2000|December 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||17|||Both|N/A|N/A|No|||December 2001|March 3, 2008|April 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005571||206772|
NCT00005644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067810|Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function|Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency||National Cancer Institute (NCI)||Completed|May 2000|||February 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2002|September 29, 2012|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005644||206703|
NCT00005645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067825|ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment|Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2001|January 3, 2014|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005645||206702|
NCT00005594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067701|ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas|Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-Ras, in Patients With Advanced Pancreatic Cancer||University of Alabama at Birmingham|Yes|Completed|July 2000|||December 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2010|December 30, 2010|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005594||206751|
NCT00005595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 99H5|Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease|Multicenter Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Hodgkin's Disease||Northwestern University|Yes|Terminated|June 2000|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|2|||Both|16 Years|N/A|No|||June 2012|June 7, 2012|May 2, 2000|Yes|Yes|Unable to accrue subjects in a timely fashion.|No||https://clinicaltrials.gov/show/NCT00005595||206750|
NCT00005587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067661|Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer|Standardization of Breast Radiotherapy: Trial B - A Randomized Comparison of Fractionation Regimens After Local Excision or Mastectomy in Women With Early Stage Breast Cancer||National Cancer Institute (NCI)||Completed|January 1999|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2001|December 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005587||206758|
NCT00005668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID MSG 37|A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma|A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|18 Years|N/A|No|||November 2005|August 26, 2010|May 18, 2000||||No||https://clinicaltrials.gov/show/NCT00005668||206685|
NCT00005685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4131|Blood Pressure Control--Racial and Psychosocial Influences|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1983|July 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2006|February 23, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005685||206670|
NCT00005686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4171|Dietary Intervention Methods for Clinical Trials|||University of Minnesota - Clinical and Translational Science Institute||Completed|April 1989|April 2003||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 29, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005686||206669|
NCT00005493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010|Observational Aspirin Use and CVD in the Physicians' Health Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1998|March 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005493||206846|
NCT00005494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5011|Prospective Study of Health in Runners and Walkers|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1998|May 2004|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2005|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005494||206845|
NCT00005495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5013|Primary Prevention of CHD Risk Factors Occurring in US|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1998|June 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2002|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005495||206844|
NCT00005496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5014|Inflammation, Infection, and Future Cardiovascular Risk|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|August 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2005|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005496||206843|
NCT00005499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5017|Congestive Heart Failure Trends in the Elderly 1970-94|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1998|June 2001|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005499||206840|
NCT00005071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067676|Diagnosis and Treatment Planning in Patients Suspected of Having Lung Cancer|A Pilot Study Leading to a Randomized Trial Comparing Outcomes in Patients With Suspected Lung Cancer Investigated in the Conventional Locally (LO) Based (BA) Chest Clinic Compared With a Centralized 2 Stop Pathway (LOBA 2STOP)||National Cancer Institute (NCI)||Active, not recruiting|October 1998|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||June 2007|November 5, 2013|April 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005071||207261|
NCT00005560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5106|Prevalence and Correlates of Childhood Sleep Apnea|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1999|December 2003|Actual|December 2003|Actual|N/A|Observational|N/A|||||||Both|6 Years|12 Years|No|||January 2008|January 25, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005560||206781|
NCT00005569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000116|Effects of Topical SLPI on Skin Wounds|Effects of Topical Anti-Inflammatory Agents on Cutaneous Wound Healing||National Institutes of Health Clinical Center (CC)||Completed|April 2000|July 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2003|March 3, 2008|April 22, 2000||||No||https://clinicaltrials.gov/show/NCT00005569||206774|
NCT00005506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5024|Vascular Disease--Structure/Function|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1998|June 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005506||206833|
NCT00005507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5025|Race and the Use of Cardiovascular Surgical Procedures|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1998|March 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005507||206832|
NCT00005616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-035A|Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer|A Phase I Single Dose-Escalation Study of BIBH-1 in Patients With Colorectal Cancer Scheduled for Surgical Resection||Memorial Sloan Kettering Cancer Center||Completed|September 1999|August 2000|Actual|August 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005616||206729|
NCT00005617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067754|Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma|A Phase I Trial Testing Mart-1 Peptide Immunization in Malignant Melanoma||Jonsson Comprehensive Cancer Center|Yes|Completed|July 1997|||June 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|6||||||Both|18 Years|N/A|No|||July 2012|October 28, 2015|May 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005617||206728|
NCT00005625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-098|Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma|Phase II Study of ET-743 Therapy in Metastatic Osteosarcoma||Memorial Sloan Kettering Cancer Center||Completed|December 1999|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||June 2013|June 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005625||206722|
NCT00005562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5108|Coronary Artery Calcium, Exercise Tests, and CHD Outcome|||The Cooper Institute||Completed|September 1999|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||March 2014|March 12, 2014|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005562||206780|
NCT00005563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110|Multicenter Asthma Research Collaboration|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1999|June 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||September 2002|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005563||206779|
NCT00005575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCP (completed)|Treatment of Non-Cardiac Chest Pain With Imipramine or Cognitive-Behavioral Therapy|Psychophysiological Interactions in Non-Cardiac Chest Pain||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 1999|December 2002||||Phase 3|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 2010|January 12, 2010|May 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005575||206769|
NCT00005592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067697|Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multicenter, Open-Label, Trial to Evaluate the Efficacy and Safety of IDEC-Y2B8 Radioimmunotherapy of Relapsed or Refractory Low-Grade or Follicular Transformed B-Cell Non-Hodgkin's Lymphoma||University of Alabama at Birmingham|Yes|Completed|November 1999|November 2005|Actual|March 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|May 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005592||206753|
NCT00005599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067712|Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer|Phase II Trail of Bryostatin-1 and Paclitaxel in Patients With Advanced Esophageal Cancer||National Cancer Institute (NCI)||Completed|February 2000|August 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|June 20, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005599||206746|
NCT00005623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067765|Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer|A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients||National Cancer Institute (NCI)||Completed|December 1999|January 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Male|18 Years|N/A|No|||December 2003|March 25, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005623||206724|
NCT00005607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067731|Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus|A Phase II Study of CPT-11 and 5-FU/LCV in Patients With Previously Untreated Gastric Adenocarcinoma||National Cancer Institute (NCI)||Active, not recruiting|February 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2000|December 18, 2013|May 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005607||206738|
NCT00005825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067837|Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2003|December 17, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005825||206533|
NCT00005844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067860|Oxaliplatin in Treating Children With Advanced Solid Tumors|A Phase I Study of Oxaliplatin in Children With Solid Tumors||St. Jude Children's Research Hospital|No|Completed|April 2000|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|26|||Both|N/A|21 Years|No|||October 2012|October 22, 2012|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005844||206514|
NCT00005845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01158|Tipifarnib in Treating Patients With Myelodysplastic Syndromes|Phase I Study of the Farnesyl Transferase Inhibitor R115777 (NSC #702818) in Patients With Myelodysplastic Syndrome||National Cancer Institute (NCI)||Completed|June 2002|||September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005845||206513|
NCT00005934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000166|5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia|A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia||National Institutes of Health Clinical Center (CC)||Completed|June 2000|June 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||June 2003|March 3, 2008|July 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005934||206434|
NCT00005935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000157|Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia|A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA)||National Institutes of Health Clinical Center (CC)||Completed|June 2000|March 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||130|||Both|N/A|N/A|No|||March 2002|March 3, 2008|July 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005935||206433|
NCT00005837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067852|Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer|Phase II Evaluation of Oxaliplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix||National Cancer Institute (NCI)||Completed|February 2000|June 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||July 2004|June 20, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005837||206521|
NCT00005863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067895|Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia|Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML||National Cancer Institute (NCI)||Completed|August 1998|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 2006|December 18, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005863||206495|
NCT00005832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067846|S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer||Southwest Oncology Group|Yes|Completed|June 2000|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005832||206526|
NCT00005846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067864|Tipifarnib in Treating Patients With Myeloproliferative Disorders|Phase I/II Study of the Farnesyltransferase Inhibitor R115777 (NSC 702818) in Patients With Myeloproliferative Disorders||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||July 2005|June 4, 2011|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005846||206512|
NCT00005891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15099|Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia|||Office of Rare Diseases (ORD)||Completed|March 2000|||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|54 Years|No|||July 2004|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005891||206468|
NCT00005892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15100|Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia|||Office of Rare Diseases (ORD)||Completed|March 2000|||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|54 Years|No|||July 2004|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005892||206467|
NCT00005861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067891|Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer|Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma||Gynecologic Oncology Group||Completed|May 2000|||August 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||August 2002|June 7, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005861||206497|
NCT00005822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU5199|SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer|A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|April 2000|October 2003|Actual|December 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005822||206536|
NCT00005847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067865|Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients With Metatstatic Hormone Refractory Prostate Cancer||Eastern Cooperative Oncology Group|No|Completed|January 2001|||July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||January 2010|January 26, 2010|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005847||206511|
NCT00005854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1457.00|Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Transplantation of HLA Haploidentical Marrow Cells After Ex Vivo Exposure to Recipient Alloantigen in Presence of CTLA4-Ig - A Phase II Study of Tolerance Induction in Donor T Cells by Blockade of the CD80/CD86:CD28 Costimulatory Signal||Fred Hutchinson Cancer Research Center||Completed|December 1999|October 2000|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|50 Years|No|||November 2011|November 28, 2011|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005854||206504|
NCT00005841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067857 (10M-99-3)|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 With ProGP for Patients With Resected Stages III and IV Melanoma||University of Southern California|Yes|Terminated|June 2000|October 2002|Actual|December 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|June 2, 2000|Yes|Yes|Toxicity/Side Effects|No||https://clinicaltrials.gov/show/NCT00005841||206517|
NCT00005872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067908|Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer|Phase II Study of RFS 2000 in Relapsed NSCLC||National Cancer Institute (NCI)||Completed|May 1999|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2001|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005872||206486|
NCT00005823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067831|Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over||National Cancer Institute (NCI)||Completed|December 1998|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Both|60 Years|N/A|No|||September 2006|December 17, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005823||206535|
NCT00005866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9920|S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia|A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study)||Southwest Oncology Group||Completed|February 2000|March 2006|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|16 Years|55 Years|No|||March 2015|March 5, 2015|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005866||206492|
NCT00005862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067893|SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas|A Phase II Trial of SU5416 (NSC #696819) in Previously Treated Patients With Advanced, Metastatic and/or Locally Recurrent Soft Tissue Sarcomas||National Cancer Institute (NCI)||Completed|October 2000|||July 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||April 2002|February 8, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005862||206496|
NCT00005925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000158|Brain Infusion of Muscimol to Treat Epilepsy|Trial of Intracerebral Infusion in Patients With Medically Intractable Epilepsy||National Institutes of Health Clinical Center (CC)||Terminated|June 2000|March 2020|Anticipated|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||December 2014|December 25, 2014|June 24, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005925||206440|
NCT00005950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02339|506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma|Phase II Study of 506U78 (NSC #686673) for Patients With Relapsed or Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma||National Cancer Institute (NCI)||Terminated|April 2000|||October 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|16 Years|N/A|No|||January 2013|January 22, 2013|July 5, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00005950||206418|
NCT00005834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9922|S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma|A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients With Refractory Multiple Myeloma||Southwest Oncology Group|Yes|Terminated|April 2000|November 2007|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|June 2, 2000|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00005834||206524|
NCT00005830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9908|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer|Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma||Gynecologic Oncology Group||Completed|July 2000|||July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005830||206528|
NCT00005808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02328|Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia|Phase I Study Photodynamic Therapy Using Lutrin (Lutetium Texaphyrin) in the Treatment of Patients With Cervical Intraepithelial Neoplasia||National Cancer Institute (NCI)||Terminated|December 2000|||April 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Female|18 Years|65 Years|No|||February 2013|February 6, 2013|June 2, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00005808||206550|
NCT00005951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1087|Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma|Phase I Treatment of Adults With Primary Malignant Glioma With Irinotecan (CPT-11) (NSC- #6616348) Plus Temodar (NSC #362856)||Duke University||Completed|August 2000|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|August 20, 2014|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005951||206417|
NCT00005849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10337|Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer|Phase II Study of Bryostatin-1 in Combination With Paclitaxel for Non-Small Cell Lung Cancer||University of Chicago|No|Completed|April 2000|November 2003|Actual|September 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005849||206509|
NCT00005838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02725|Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery|Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|March 2000|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|756|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005838||206520|
NCT00005831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03187|Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer|Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer||National Cancer Institute (NCI)||Completed|March 2000|||August 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||January 2013|January 11, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005831||206527|
NCT00005821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067828|Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer|Sentinel Lymph Node Biopsy in the Assessment of Axillary Nodal Status in Operable Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2003|November 5, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005821||206537|
NCT00005873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067909|Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Relapsed Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|September 1999|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2001|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005873||206485|
NCT00005875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067911|Nitrocamptothecin in Treating Patients With Metastatic Melanoma|Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma||National Cancer Institute (NCI)||Completed|January 1999|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||September 2001|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005875||206483|
NCT00005871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067907|Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer|Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005871||206487|
NCT00005876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067912|Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery|A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005876||206482|
NCT00005877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067914|Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer|Phase II and Pharmacokinetic Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Colorectal Cancer Who Have Failed Previous 5-FU Based Chemotherapy||National Cancer Institute (NCI)||Active, not recruiting|September 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||April 2002|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005877||206481|
NCT00005829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-98-81-52|Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia|Phase II Study of Gemcitabine for Relapsed B-Cell Chronic Lymphocytic Leukemia||Alliance for Clinical Trials in Oncology|No|Completed|February 2000|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005829||206529|
NCT00005810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-99813|Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of Estramustine, Docetaxel, and Carboplatin With G-CSF Support in Men With Hormone Refractory Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|March 2000|June 2006|Actual|December 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005810||206548|
NCT00005811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01848|Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment|A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies||National Cancer Institute (NCI)||Completed|April 2000|February 2009|Actual|April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|1 Year|21 Years|No|||February 2013|February 20, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005811||206547|
NCT00005812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9812|Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma|A Pilot Phase II Trial of Temozolomide in Leptomeningeal Metastases||Dartmouth-Hitchcock Medical Center|Yes|Terminated|January 2000|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|June 2, 2000|Yes|Yes|No objective response documented, protocol terminated after 12 patients.|No||https://clinicaltrials.gov/show/NCT00005812||206546|
NCT00005878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J9932, CDR0000067917|Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus|Chemoprevention for Barrett's Esophagus Trial (CBET)||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2000|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||May 2013|May 3, 2013|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005878||206480|
NCT00005860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067890|Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum|A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity||National Cancer Institute (NCI)||Completed|April 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|April 23, 2011|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005860||206498|
NCT00005839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067854|Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor|A Phase I Study of Oxaliplatin in Combination With Capecitabine in Metastatic/Recurrent Solid Tumors||City of Hope Medical Center||Completed|August 2000|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005839||206519|
NCT00005827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9711|Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer|Phase I Single and Multiple-Dose Safety and Pharmacokinetic Clinical Study of Genistein in Normal Volunteers and in Prostate Neoplasia (Multiple Dose Safety and Pharmacokinetic Clinical Study of Genistein in Prostate Neoplasia)||UNC Lineberger Comprehensive Cancer Center|Yes|Withdrawn|December 1999|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|40 Years|N/A|No|||April 2012|April 20, 2012|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005827||206531|
NCT00005855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067881|Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma|A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered With a Fixed Dose of BCNU Every Six Weeks in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)||Completed|July 2000|October 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||December 2003|June 20, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005855||206503|
NCT00005842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067858|Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer|A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer||National Cancer Institute (NCI)||Completed|June 2000|||February 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2007|February 8, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005842||206516|
NCT00005818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02330|SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer|A Phase I/II Study of Escalating Doses of SU5416 (NSC 696819) in Combination With CPT-11 in Patients With Advanced Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|March 2000|||March 2003|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005818||206540|
NCT00005869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067905|Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer|Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients||National Cancer Institute (NCI)||Active, not recruiting|November 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005869||206489|
NCT00005870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067906|Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas|Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients||National Cancer Institute (NCI)||Active, not recruiting|March 1999|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005870||206488|
NCT00005843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02335|R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer|Phase II Trial of R115777 (NSC-702818), an Inhibitor of Farnesyl Protein Transferase, in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma||National Cancer Institute (NCI)||Completed|May 2000|||September 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2007|February 8, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005843||206515|
NCT00005917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000153|Study of Chediak-Higashi Syndrome|Investigations Into Chediak-Higashi Syndrome and Related Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|June 2000|||||N/A|Observational|N/A|||Anticipated|60|||Both|1 Month|N/A|No|||October 2015|October 20, 2015|June 16, 2000||No||No||https://clinicaltrials.gov/show/NCT00005917||206448|
NCT00005856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02336|Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults With Newly Diagnosed Glioblastoma Multiforme||National Cancer Institute (NCI)||Terminated|December 2000|||January 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|June 2, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00005856||206502|
NCT00005852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11309|Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant|Allogeneic Bone Marrow Transplantation for Marrow Failure States||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|June 1996|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|55 Years|No|||December 2012|December 10, 2012|June 2, 2000|||low accrual|No||https://clinicaltrials.gov/show/NCT00005852||206506|
NCT00005918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244F|Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients|The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy||Bristol-Myers Squibb||Completed|June 2000|April 2002|Actual|April 2002|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||730|||Both|12 Years|N/A|No|||April 2011|April 28, 2011|June 15, 2000|Yes|Yes||||https://clinicaltrials.gov/show/NCT00005918||206447|
NCT00005835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067849|N99-02: Melphalan and Buthionine Sulfoximine|Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)|BSO|New Approaches to Neuroblastoma Therapy Consortium|Yes|Active, not recruiting|August 2001|March 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|30 Years|No|||December 2015|December 11, 2015|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005835||206523|
NCT00005836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067851|Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy|Phase II Evaluation of Oxaliplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer||National Cancer Institute (NCI)||Completed|February 2000|July 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||March 2003|June 20, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005836||206522|
NCT00005819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3Y99|Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Fenretinide in Combination With Paclitaxel and Cisplatin||Case Comprehensive Cancer Center|Yes|Completed|April 2000|August 2006|Actual|May 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005819||206539|
NCT00005883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067923|Phenethyl Isothiocyanate in Preventing Lung Cancer in People Who Smoke|A Phase I - Part B Multiple Dose Trial of Phenethyl Isothiocyanate||New York University School of Medicine||Completed||||April 2001|Actual|Phase 1|Interventional|Primary Purpose: Prevention|||||||Both|N/A|N/A|No|||March 2011|March 25, 2011|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005883||206475|
NCT00005850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067871|Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|Fluoxetine in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A Phase II Pilot Study to Improve Quality of Life During Chemotherapy||Alliance for Clinical Trials in Oncology||Terminated|August 2001|||September 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||September 2013|September 18, 2013|June 2, 2000|No|Yes|Lack of sufficient accrual|No||https://clinicaltrials.gov/show/NCT00005850||206508|
NCT00005840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9907|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer|Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy||Gynecologic Oncology Group||Completed|July 2000|||July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005840||206518|
NCT00005814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-095|Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer|Phase II Study of C225 in Combination With Cisplatin and Standard/Delayed Accelerated Hyperfractionated Radiation Therapy in Patients With Advanced Head & Neck Cancer||Memorial Sloan Kettering Cancer Center||Completed|December 1999|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005814||206544|
NCT00005815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-103|Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma|A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma||Memorial Sloan Kettering Cancer Center||Completed|December 1999|August 2004|Actual|August 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005815||206543|
NCT00005884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067928|Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer|Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial||University of Wisconsin, Madison||Completed||||December 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|21 Years|120 Years|No|||September 2015|September 30, 2015|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005884||206474|
NCT00005824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-020|Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma|Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma||AIDS Malignancy Consortium||Completed|November 2000|April 2006|Actual|July 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||February 2016|February 1, 2016|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005824||206534|
NCT00005851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1495.00|Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer|Phase I/II Study of HLA-Matched Non-Myeloablative Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation as Treatment for Patients With Metastatic Renal Cell Carcinoma. A Multi-Center Trial.||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|February 2000|||July 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|74 Years|No|||July 2015|July 6, 2015|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005851||206507|
NCT00005820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-99901|Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|May 2000|September 2006|Actual|September 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|N/A|N/A|No|||July 2015|July 7, 2015|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005820||206538|
NCT00005826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16996G|Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme|Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 2000|||September 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|17|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005826||206532|
NCT00005833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067847|S9923 R115777 in Treating Patients With Advanced Colorectal Cancer|A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Colorectal Cancer||Southwest Oncology Group|Yes|Completed|June 2000|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005833||206525|
NCT00006048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068064|ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer|A Randomized, Double Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Gemcitabine and Cisplatin Versus Placebo in Combination With Gemcitabine and Cisplatin in Chemotherapy Naive Patients With Advanced (Stage III or IV) Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2001|December 18, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006048||206321|
NCT00005719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4928|Sustaining Women's Smoking Cessation Postpartum|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|June 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||July 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005719||206636|
NCT00005720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4929|Lay-Led Smoking Cessation Approach for Southeast Asian Men|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1990|August 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005720||206635|
NCT00005791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067737|Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies||National Cancer Institute (NCI)||Completed|October 1999|December 2009|Actual|July 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|December 18, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005791||206567|
NCT00005792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11752|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Study of Intensive-Dose Melphalan, Topotecan, and VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|June 1998|December 2016|Anticipated|September 2001|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|15 Years|69 Years|No|||February 2016|February 29, 2016|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005792||206566|
NCT00005793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11941|A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide|A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 1999|November 2006|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|16 Years|59 Years|No|||September 2012|September 24, 2012|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005793||206565|
NCT00005859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067888|Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma|Phase I/II Trial of R115777 in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)||Completed|August 2000|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|July 23, 2008|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005859||206499|
NCT00005868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08984|Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer|Taxotere and Cisplatin as Induction Chemotherapy in Patients With Stage IIIa N2 Non Small Cell Lung Cancer (NSCLC)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 2000|||August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|47|||Both|19 Years|N/A|No|||July 2012|July 17, 2012|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005868||206490|
NCT00005713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC ID unknown (4922)|Childhood Asthma Program in NYC Health Department Clinics|Improving Care for Minority Children With Asthma: Professional Education in Public Health Clinics||Columbia University|No|Completed|August 1990|February 1997|Actual|February 1997|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|1 Month|21 Years|No|Non-Probability Sample|Children with asthma in New York City|December 2015|December 22, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005713||206642|
NCT00005714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4923|Development and Evaluation of Community Asthma Program|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1990|July 1996|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005714||206641|
NCT00005715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4924|Community Intervention for Minority Children With Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1990|July 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005715||206640|
NCT00005726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4935|Evaluation of Low Literacy CVD Nutrition Education|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|May 1995|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005726||206629|
NCT00005721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4930|Retaining Donors and Increasing Donation Frequency|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1990|August 1993||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||March 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005721||206634|
NCT00005722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4931|Stroke Belt Initiative|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1990|September 1996||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005722||206633|
NCT00005763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1045|INTERSALT: International Study of Sodium, Potassium, and Blood Pressure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1984|April 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2000|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005763||206594|
NCT00005723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4932|Worksite Issues in Organizational Health Promotion (Take Heart)|||Oregon Research Institute|No|Completed|January 1991|September 1996|Actual|January 1996|Actual|N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2016|February 4, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005723||206632|
NCT00005724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4933|CVD Nutrition Modules Tailored to Low Literacy Skills|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|May 1997||||N/A|Observational|Observational Model: Natural History|||||||Male|N/A|N/A|No|||July 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005724||206631|
NCT00005725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4934|Low Literacy CVD Diet Education for Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|May 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005725||206630|
NCT00005774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0024|Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants|Early Surfactant Followed by Nasal CPAP to Reduce the Use of Mechanical Ventilation Without Additional Morbidity in Infants 1250- 2000 Grams With RDS|Surfactant 2|NICHD Neonatal Research Network|Yes|Terminated|May 2000|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|N/A|12 Hours|No|||June 2015|June 3, 2015|June 1, 2000||No|The trial was stopped after 7 months for lack of recruitment.|No||https://clinicaltrials.gov/show/NCT00005774||206583|
NCT00005795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 99H6|Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia|Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old||Northwestern University|Yes|Completed|February 2000|July 2002|Actual|July 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|11|||Both|16 Years|N/A|No|||June 2012|June 7, 2012|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005795||206563|
NCT00005764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238T|A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients|Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)||NIH AIDS Clinical Trials Information Service||Completed|May 2000|||||Phase 4|Interventional|Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|May 30, 2000||||No||https://clinicaltrials.gov/show/NCT00005764||206593|
NCT00005765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0747|Behavioral Economics of Human Drug Self-Administration|||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||||||Both|21 Years|50 Years|No|||December 2003|June 23, 2005|June 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005765||206592|
NCT00005771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0746|The Use of Real Time Ultrasound Feedback in Teaching Abdominal Hollowing Exercises|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2001|June 23, 2005|June 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005771||206586|
NCT00005777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0018|Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)|Randomized Trial of Minimal Ventilator Support and Early Corticosteroid Therapy to Increase Survival Without Chronic Lung Disease in Extremely-Low-Birth-Weight Infants|SAVE|NICHD Neonatal Research Network|Yes|Terminated|February 1998|September 2002|Actual|September 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|220|||Both|N/A|10 Days|No|||June 2015|June 3, 2015|June 1, 2000||No|The trial was halted because of unanticipated nonrespiratory adverse events related to    dexamethasone therapy.|No||https://clinicaltrials.gov/show/NCT00005777||206580|
NCT00005779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5049|Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy|A Phase I, Limited-Center, Sequential Cohort Trial of HIV Vaccine (Polyvalent Peptide Vaccine C4-V3) in Conjunction With Interleukin-12 in Subjects With Maximal Suppression of HIV Replication and CD4 Count > 400 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2004|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|June 3, 2000||||No||https://clinicaltrials.gov/show/NCT00005779||206578|
NCT00005787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99Z1|Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma|Ex Vivo Expanded Peripheral Blood Mononuclear Cells for the Elimination of Neutropenia Associated With High Dose Chemotherapy||Northwestern University|Yes|Terminated|September 1999|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Primary Purpose: Supportive Care|||Actual|3|||Both|17 Years|65 Years|No|||May 2012|May 31, 2012|June 2, 2000||No|Per PI due to poor/inadequate accrual.|No||https://clinicaltrials.gov/show/NCT00005787||206570|
NCT00005788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 96H7|Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome|Phase II Trial of Subcutaneous Injections of Interleukin-2 for the Treatment of Mycosis Fungoides or the Sezary Syndrome||Northwestern University|Yes|Terminated|April 1997|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 31, 2012|June 2, 2000|Yes|Yes|Low/inadequate rate of accrual.|No||https://clinicaltrials.gov/show/NCT00005788||206569|
NCT00005733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4942|Develop and Implement Asthma Controlling Strategies (2)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|March 1997||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||September 2002|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005733||206622|
NCT00005780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000133|Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma|Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2000|June 2018|Anticipated|August 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|99 Years|No|||November 2015|December 2, 2015|June 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005780||206577|
NCT00005805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-102|St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer|Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial||Memorial Sloan Kettering Cancer Center||Completed|December 1999|||June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||January 2013|January 17, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005805||206553|
NCT00005806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-069|Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Pilot Trial of Daily Oral ZD1839 (Iressa) With Standard Doses of Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|September 1999|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005806||206552|
NCT00005807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067800|BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer|A Phase I Scientific Exploratory Study of Epothilone B Analog (BMS-247550; NSC #710428) in Patients With Solid Tumors and Gynecological Malignancies||National Cancer Institute (NCI)||Completed|July 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|July 23, 2008|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005807||206551|
NCT00005739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC ID unknown (4948)|Behavioral Interventions for Control of TB|Behavioral Interventions for Control of Tuberculosis||Columbia University|No|Completed|September 1995|December 2015|Actual|December 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|145|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected and confirmed TB|December 2015|December 21, 2015|May 25, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005739||206616|
NCT00005740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4949|TB Contact Investigation: Behavioral Intervention|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005740||206615|
NCT00005741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4950|Indigenous Outreach Among Injection Drug Users to Treat and Control TB|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2001|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005741||206614|
NCT00005742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4951|Behavioral Interventions for Control of Tuberculosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 2001|Actual|||N/A|Observational|N/A|||||||Both|11 Years|19 Years|No|||May 2005|February 26, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005742||206613|
NCT00005813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9705|Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme|A Phase I Trial of Intratumoral Bispecific Antibody and Activated Monocytes in Patients With Recurrent or Refractory Glioblastoma Multiforme||Dartmouth-Hitchcock Medical Center|Yes|Completed|March 1997|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2011|October 26, 2011|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005813||206545|
NCT00005734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4943|Intervention to Improve Asthma Management/Prevention|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|September 2002||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||March 2005|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005734||206621|
NCT00005735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4944|Controlling Asthma at School|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|October 2002|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2004|February 22, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005735||206620|
NCT00005748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5056|Stress Reduction and Prevention of Hypertension in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1998|April 2004|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||March 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005748||206608|
NCT00005749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5061|Project Andale--Increasing Exercise in Hispanic Women|||San Diego State University||Completed|July 1996|December 2002||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||August 2004|January 11, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005749||206607|
NCT00005374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4268|Genetics of the Metabolic Syndrome in Japanese Americans|||University of Washington||Completed|January 1994|May 2004||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2005|February 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005374||206963|
NCT00005375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4271|Smoking Onset in a Biethnic Population|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|January 2006|Actual|January 2006|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|January 25, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005375||206962|
NCT00005736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4945|Interventions to Improve Asthma Management/Prevention at School|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|September 2002||||N/A|Observational|Observational Model: Natural History|||||||Both|N/A|N/A|No|||July 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005736||206619|
NCT00005737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4946|Tuberculosis Prophylaxis in the Homeless--A Controlled Trial|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|August 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2004|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005737||206618|
NCT00005738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4947|Promoting Adherence to TB Regimens in Latino Adolescents|||San Diego State University||Completed|September 1995|August 2001||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||May 2002|January 11, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005738||206617|
NCT00005766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0750|Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis|||National Center for Research Resources (NCRR)||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||December 2003|June 23, 2005|June 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005766||206591|
NCT00005767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0740|Dynamic Aspects of Amino Acid Metabolism|||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|June 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005767||206590|
NCT00005857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99118|Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy|Randomized Phase II Trial of Herceptin (NSC 688097) and Weekly Docetaxel (NSC 628503) in Androgen-Independent (Horomone Refractory) Adenocarcinoma of the Prostate (CaP)||City of Hope Medical Center||Completed|August 2000|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||October 2011|October 18, 2011|June 2, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00005857||206501|
NCT00005376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4273|Premature Birth and Its Sequelae in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||November 2001|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005376||206961|
NCT00005377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4275|Molecular Epidemiology of Essential Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1994|May 2009|Actual|May 2009|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2009|May 1, 2009|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005377||206960|
NCT00005395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4303|Honolulu Heart Program-Study of Stroke and Dementia|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|July 2000|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||February 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005395||206942|
NCT00005727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4936|CVD Nutrition Education|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1991|May 1996||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2000|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005727||206628|
NCT00005728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4937|Nutrition Education|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1992|April 1996|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005728||206627|
NCT00005729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4938|CVD Nutrition Education for Low Literacy ESL Students|||San Diego State University||Completed|August 1992|December 1996||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|January 11, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005729||206626|
NCT00005730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4939|National Marrow Donor Program (NMDP)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1989|December 1995||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||March 2005|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005730||206625|
NCT00005786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00040|Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia|A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas||National Cancer Institute (NCI)||Terminated|January 2001|||November 2004|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|June 2, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00005786||206571|
NCT00005797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11281|Bone Marrow Transplant in Treating Patients With Hematologic Cancers|Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|March 1993|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|15 Years|55 Years|No|||October 2012|October 24, 2012|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005797||206561|
NCT00005853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1478.00|Biological Therapy in Treating Patients With Myelodysplastic Syndrome|Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc||Fred Hutchinson Cancer Research Center||Completed|December 1999|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2010|March 31, 2010|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005853||206505|
NCT00005775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0020|Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants|Randomized Controlled Trial of Parenteral Glutamine Supplementation for Extremely-Low-Birth-Weight (ELBW) Infants|Glutamine|NICHD Neonatal Research Network|Yes|Completed|July 1999|August 2001|Actual|December 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1433|||Both|N/A|72 Hours|No|||June 2015|June 3, 2015|June 1, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005775||206582|
NCT00005776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0014|Inhaled Nitric Oxide Study for Respiratory Failure in Newborns|The Randomized Inhaled Nitric Oxide Study (NINOS) in Full-Term and Nearly Full-Term Infants With Hypoxic Respiratory Failure|NINOS|NICHD Neonatal Research Network|Yes|Terminated|October 1995|May 1998|Actual|May 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|235|||Both|N/A|14 Days|No|||June 2015|June 3, 2015|June 1, 2000|Yes|Yes|Results showed statistically significant benefit in the experimental group|No||https://clinicaltrials.gov/show/NCT00005776||206581|
NCT00005828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9951|Green Tea Extract in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Green Tea Extract in the Treatment of Androgen-Independent Metastatic Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|December 2000|June 2008|Actual|March 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005828||206530|
NCT00005800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11971|Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer|A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|April 1999|May 2012|Actual|January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|70 Years|No|||September 2012|September 24, 2012|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005800||206558|
NCT00005750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5078|School and Family-Based Obesity Prevention for Children|||Stanford University||Completed|April 1996|March 2001||||N/A|Observational|N/A|||||||Both|8 Years|12 Years|No|||July 2001|January 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005750||206606|
NCT00005781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000138|Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles|Digital Imaging as a Tool for Assessing the Prevalence of Atypical Nevi, Psoriasis and Hand Dermatitis: A Validation Study in Preparation for NHANES IV, Dermatology Section||National Institutes of Health Clinical Center (CC)||Completed|May 2000|September 2000||||N/A|Observational|N/A||||600|||Both|N/A|N/A|No|||May 2000|March 3, 2008|June 3, 2000||||No||https://clinicaltrials.gov/show/NCT00005781||206576|
NCT00005801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0119|Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil||University of Colorado, Denver||Completed|November 1999|September 2001|Actual|September 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|55 Years|74 Years|No|||September 2001|November 14, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005801||206557|
NCT00005802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1380.00|Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia|Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant||Fred Hutchinson Cancer Research Center||Completed|June 1999|March 2005|Actual|March 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2010|March 31, 2010|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005802||206556|
NCT00005803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409.00|Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma|A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|September 1999|||January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|75 Years|No|||February 2016|February 23, 2016|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005803||206555|
NCT00005756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5111|Epidemiology of Coronary Calcification in the Elderly|||University of Pittsburgh|Yes|Completed|August 1999|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Both|65 Years|100 Years|No|Non-Probability Sample|614 older adults aged, on average, 80 years (range, 67 to 99 years); 367 (60%) were women,        and 143 (23%) were black.|January 2016|January 12, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005756||206600|
NCT00006035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068050|Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma|An Open Label Lesion Controlled Study of Electroporation Therapy (EPT) for the Treatment of Cutaneous Metastatic Melanoma Using the Genetronics, Inc. Medpulser System and Bleomycin||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2000|September 16, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006035||206334|
NCT00005751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5081|Endothelial Vasomotor Function in the Framingham Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1998|November 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2004|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005751||206605|
NCT00005752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5086|Overweight Adults--Ethnic, SES and Behavioral Influences|||Stanford University||Completed|April 1999|March 2002||||N/A|Observational|N/A|||||||Both|25 Years|64 Years|No|||August 2004|January 8, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005752||206604|
NCT00005707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4916|Improving Hypertension Care for Inner City Minorities|||Baylor College of Medicine||Completed|September 1993|August 1998||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2015|December 8, 2015|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005707||206648|
NCT00005708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4917|Improving Adherence to Interventions for Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1997|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||July 2000|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005708||206647|
NCT00005396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4304|Motivating Smokers--Reduce Child Environmental Tobacco Smoke Exposure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1994|August 1999|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2002|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005396||206941|
NCT00005397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305|Epidemiology of Carotid Artery Atherosclerosis in Youth|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1995|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A|||||||Both|11 Years|50 Years|No|||December 2008|December 3, 2008|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005397||206940|
NCT00005753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100|Pharmacological and Behavioral Treatment of Insomnia|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1997|May 2002|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||February 2005|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005753||206603|
NCT00005754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-661|Coronary Artery Calcification in Type 1 Diabetes|||University of Colorado, Denver|No|Completed|September 1999|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1420|||Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|656 IDDM patients aged 20-55 years and 764 of their non-diabetic spouse/partner controls|June 2015|June 8, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005754||206602|
NCT00005755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5109|Community Based Study on Occupational Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1999|April 2003|Actual|||N/A|Observational|N/A|||||||Both|20 Years|44 Years|No|||January 2006|March 15, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005755||206601|
NCT00005757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5115|Racial Variation in ACE--Genetic and Physiologic Bases|||Vanderbilt University||Completed|September 1997|August 2001||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 28, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005757||206599|
NCT00005758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5057|Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination|A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of Immunization With an HIV Immunogen on the Time to Virologic Relapse in Individuals Receiving Potent, Suppressive Antiretroviral Therapies||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2005|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||472|||Both|14 Years|N/A|No|||May 2012|May 21, 2012|May 23, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005758||206598|
NCT00005867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNLI-CHOPVPMITCEBO-GOODRISK|Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma|Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|January 1998|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|310|||Both|18 Years|59 Years|No|||March 2007|June 25, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005867||206491|
NCT00005398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013233|University of North Carolina Alumni Heart Study|University of North Carolina Alumni Heart Study||Duke University|No|Active, not recruiting|May 1996|||May 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6340|||Both|N/A|N/A|No|Non-Probability Sample|participants in the University of North Carolina Alumni Heart Study|September 2015|September 30, 2015|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005398||206939|
NCT00005399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4313|Cohort Study of Heart Rate Variability|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1996|June 2001||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||August 2004|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005399||206938|
NCT00005744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4968|Increased Physical Activity in African-American Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1996|August 2001|Actual|||N/A|Observational|N/A|||||||Female|50 Years|70 Years|No|||August 2004|February 17, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005744||206611|
NCT00005760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000115|Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes|A Pilot Study of the Metabolic Effects of Large Volume Liposuction in Overweight Women With Hyperinsulinemia, Impaired Glucose Tolerance and/or Type 2 Diabetes||National Institutes of Health Clinical Center (CC)||Completed|May 2000|January 2002||||N/A|Observational|N/A||||10|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2002|March 3, 2008|May 26, 2000||||No||https://clinicaltrials.gov/show/NCT00005760||206597|
NCT00005768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0741|Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women|||National Center for Research Resources (NCRR)||Recruiting||||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|50 Years|N/A|No|||December 2003|June 23, 2005|June 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005768||206589|
NCT00005769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0744|Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|45 Years|55 Years|No|||November 2001|June 23, 2005|June 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005769||206588|
NCT00005864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067896|Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer|A Phase II Study of Chloroquinoxaline Sulfonamide (CQS) in Colorectal Cancer Stage IV||National Cancer Institute (NCI)||Completed|April 2000|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|January 30, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005864||206494|
NCT00005865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067897|Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Research Study Evaluating Oral and Intravenous NAVELBINE as a Single Agent for the Treatment of Chemotherapy-Naive Subjects With Inoperable Stage IIIb or Stage IV Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|April 2000|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|January 3, 2014|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005865||206493|
NCT00005790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 95C1|Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors|Perfusion Magnetic Resonance Imaging of Brain Tumors: Correlation With Indicators of Angiogenesis||Northwestern University||Withdrawn|April 1996|May 1999||May 1999||N/A|Interventional|Primary Purpose: Diagnostic|||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|June 2, 2000|No|Yes|Unable to accrue subjects.|No||https://clinicaltrials.gov/show/NCT00005790||206568|
NCT00005784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000139|Evaluation and Treatment of Patients With Retinal Disease|Evaluation and Treatment Protocol for Patients With Retinal Disease||National Institutes of Health Clinical Center (CC)||Completed|May 2000|August 2008||||N/A|Observational|N/A||||1000|||Both|10 Years|N/A|No|||August 2008|September 26, 2015|June 3, 2000||No||No||https://clinicaltrials.gov/show/NCT00005784||206573|
NCT00005785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990167|Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer|Low Intensity Non-Myeloablative Preparative Conditioning Followed by Transplantation of Genetically Modified HLA-Matched Peripheral Blood Hematopoietic Precursor Cells (PBPC) for Hematologic Malignancies in HIV Positive Adults||National Institutes of Health Clinical Center (CC)||Completed|September 1999|November 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||November 2001|March 3, 2008|June 3, 2000||||No||https://clinicaltrials.gov/show/NCT00005785||206572|
NCT00005798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11072|Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer|A Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin (CTC) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Breast Cancer|CTC|H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 1995|July 2007|Actual|August 2001|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|209|||Female|15 Years|64 Years|No|||October 2012|October 24, 2012|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005798||206560|
NCT00005778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92243|High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide|Randomized Trial of High-Dose IV Cyclophosphamide Versus Monthly IV Cyclophosphamide||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|January 2000|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||November 2008|November 5, 2008|June 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005778||206579|
NCT00005809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067802|Computerized Tomographic Colonography Compared With Standard Diagnostic Procedures in Detecting Colorectal Neoplasia|Computerized Tomographic Colonography: Performance Evaluation in a Multicenter Setting|ACRIN 6656|American College of Radiology Imaging Network|Yes|Completed|July 2000|January 2003|Actual|October 2000|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||February 2013|February 1, 2013|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005809||206549|
NCT00005709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4918|Lipoprotein Metabolism in Hypertensive African-Americans|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1993|August 1998|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||June 2001|February 24, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005709||206646|
NCT00005710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4919|Recycling of Chronic Smokers to Sustained Abstinence|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1990|June 1995||||N/A|Observational|N/A|||||||Male|N/A|N/A|No|||July 2001|June 23, 2005|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005710||206645|
NCT00005711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4920|Intervention for Hispanic Children With Asthma|Intervention for Hispanic Children With Asthma||The University of Texas Health Science Center at San Antonio|No|Completed|August 1990|July 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|145|||Both|N/A|17 Years|No|||February 2016|February 19, 2016|May 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00005711||206644|
NCT00005782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000060|Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait|Leukapheresis of Volunteers With Sickle Cell Trait to Evaluate Mobilization of Stem Cells With Granulocyte Colony-Stimulating Factor and Stem Cell Collection and Storage for Allogeneic Transplantation||National Institutes of Health Clinical Center (CC)||Completed|January 2000|July 2002||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||12|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2002|March 3, 2008|June 3, 2000||||No||https://clinicaltrials.gov/show/NCT00005782||206575|
NCT00006041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-121|Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer|Vaccination of Patients Who Have Ovarian, Fallopian Tube or Peritoneal Cancer With Glycosylated MUC-1-KLH Conjugate Plus the Immunological Adjuvant QS-21||Memorial Sloan Kettering Cancer Center||Completed|February 2000|February 2002|Actual|February 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 17, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006041||206328|
NCT00005348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4217|Adipose Distribution and Atherosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1991|March 1993|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||April 2000|February 25, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005348||206989|
NCT00005761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000135|Blood Factors and Diabetic Retinopathy|Study of Association of Serum Factors With Diabetic Retinopathy||National Institutes of Health Clinical Center (CC)||Completed|May 2000|December 2010||||N/A|Observational|N/A|||Actual|173|||Both|10 Years|N/A|No|||December 2010|September 26, 2015|May 26, 2000||No||No||https://clinicaltrials.gov/show/NCT00005761||206596|
NCT00005762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5043|Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers|Pharmacokinetic Interaction Studies of Amprenavir (APV), Efavirenz (EFV), and a Second Protease Inhibitor in HIV-Seronegative Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2001|May 2004|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 19, 2013|May 25, 2000||||||https://clinicaltrials.gov/show/NCT00005762||206595|
NCT00005712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4921|Self Management Education Asthma|||University of New Mexico||Completed|August 1990|July 1996||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|May 25, 2000||||No||https://clinicaltrials.gov/show/NCT00005712||206643|
NCT00005848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-99031|R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Phase II Trial of R115777 (NSC 702818) an Inhibitor of Farnesyl Protein Transferase, in Patients With Hormone Refractory Prostate Cancer||Fox Chase Cancer Center|No|Completed|April 2000|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|7|||Male|18 Years|N/A|No|||July 2013|July 10, 2013|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005848||206510|
NCT00005858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067885|LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer|Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin Admistered by Continuous Infusion||National Cancer Institute (NCI)||Completed|April 2000|||April 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2003|February 8, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005858||206500|
NCT00005796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9607-22|Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors|A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltransferase||Indiana University|Yes|Completed|February 2000|December 2011|Actual|June 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|5 Years|N/A|No|||March 2015|March 23, 2015|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005796||206562|
NCT00005770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0745|Investigation of the Effect of Acupuncture Needling on Connective Tissue Using Ultrasound Elastography|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2001|June 23, 2005|June 1, 2000||||No||https://clinicaltrials.gov/show/NCT00005770||206587|
NCT00005874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067910|Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas|Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas||National Cancer Institute (NCI)||Completed|June 1999|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2001|December 3, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005874||206484|
NCT00005783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000087|A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders|A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders||National Institutes of Health Clinical Center (CC)||Completed|March 2000|October 2000||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||February 2000|March 3, 2008|June 3, 2000||||No||https://clinicaltrials.gov/show/NCT00005783||206574|
NCT00005799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1463.00|Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer|Low-Dose TBI and Fludarabine Followed by Unrelated Donor Stem Cell Transplantation for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|November 1999|||July 2002|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||October 2015|October 13, 2015|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005799||206559|
NCT00005816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1716|Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer|Active Immunotherapy of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA||Duke University||Completed|February 2000|August 2002|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||December 2008|March 19, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005816||206542|
NCT00005817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00031|Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer|A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer||National Cancer Institute (NCI)||Completed|March 2000|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|June 2, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005817||206541|
NCT00005978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067966|N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma|Dose Escalation Study of 131 I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma - A Phase I Study||New Approaches to Neuroblastoma Therapy Consortium|Yes|Completed|May 2000|||December 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|21 Years|No|||May 2009|October 14, 2010|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005978||206391|
NCT00005996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068000|SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I Study of SU5416 in Combination With Gemcitabine/Cisplatin in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2000|December 18, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005996||206373|
NCT00006005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068013|Thalidomide in Treating Patients With Gynecologic Sarcomas|Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin||National Cancer Institute (NCI)||Completed|September 2000|August 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||August 2004|June 20, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006005||206364|
NCT00006006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02347|Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed|Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression||National Cancer Institute (NCI)||Completed|August 2000|||March 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||September 2003|February 8, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006006||206363|
NCT00006071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000175|Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol|Effects of Rosiglitazone on Endothelium-Dependent Vasodilation and on Endothelin Activity in Patients With Essential Hypertension and in Patients With Hypercholesterolemia||National Institutes of Health Clinical Center (CC)||Completed|July 2000|March 2001||||N/A|Observational|N/A||||120|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2000|March 3, 2008|July 21, 2000||||No||https://clinicaltrials.gov/show/NCT00006071||206301|
NCT00005968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0468.cc|Irofulven in Treating Patients With Stage IV Melanoma|A Multicenter Phase II Trial of MGI-114 in Patients With Stage IV Malignant Melanoma||University of Colorado, Denver|No|Completed|November 1999|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|May 28, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005968||206401|
NCT00005973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02343|BMS-214662 in Treating Patients With Solid Tumors|Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors||National Cancer Institute (NCI)||Completed|April 2000|||July 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|N/A|No|||January 2013|January 22, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005973||206396|
NCT00005974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I136|Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma|A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Previously Untreated Metastatic or Locally Advanced Soft Tissue Sarcoma||Canadian Cancer Trials Group|No|Completed|July 2000|September 2008|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2011|September 27, 2011|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00005974||206395|
NCT00005999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068003|Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer|A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma||National Cancer Institute (NCI)||Completed|April 2000|May 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|17 Years|N/A|No|||March 2002|June 20, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005999||206370|
NCT00006018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU4Y99|Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors|Phase I Study of BMS-214662 and Paclitaxel in Patients With Advanced Malignancies||Case Comprehensive Cancer Center|Yes|Completed|July 2000|April 2002|Actual|December 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00006018||206351|
NCT00006099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068107|Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer|Pilot Trial of Humanized 3S193 Monoclonal Antibody (hu3S193) in Presurgical Patients With Ovarian Cancer||National Cancer Institute (NCI)||Completed|May 2000|||||Phase 1|Interventional|Primary Purpose: Diagnostic|||||||Female|18 Years|N/A|No|||June 2002|February 6, 2009|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006099||206274|
NCT00005992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-9909056-02B|Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Phase I Clinical Trial of Recombinant Prostate Specific Membrane Antigen (rPSMA)-Loaded Mature Autologous Dendritic Cells (CapPVax) for the Treatment of Metastatic Horomone Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||May 2002|August 6, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005992||206377|
NCT00006188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000204|Evaluation and Treatment of Patients With Inflammatory Eye Diseases|Evaluation and Treatment Protocol for Patients With Intraocular Inflammatory Disease (Uveitis)||National Institutes of Health Clinical Center (CC)||Completed|August 2000|July 2008||||N/A|Observational|N/A||||300|||Both|4 Years|N/A|No|||July 2008|September 26, 2015|August 26, 2000||No||No||https://clinicaltrials.gov/show/NCT00006188||206192|
NCT00006021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20000156|Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma|Phase I/II Trial of Arsenic Trioxide (As2O3) With Ascorbic Acid in the Treatment of Relapsed/Refractory Multiple Myeloma||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|June 2000|March 2007|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|July 5, 2000||Yes||||https://clinicaltrials.gov/show/NCT00006021||206348|
NCT00006087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068079|Chest X-Ray or Chest CT Scan in Patients at High Risk of Developing Lung Cancer|A Randomized Prospective Study Comparing Annual Chest X-Rays to Annual Spiral Chest CT Scanning in Patients at High-Risk for the Development of Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|November 1999|||||N/A|Interventional|Primary Purpose: Screening|||||||Both|40 Years|70 Years|No|||December 2007|February 6, 2009|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006087||206286|
NCT00006088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068080|Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors|A Phase I Absolute Bioavailability Study of Oral NAVELBINE (Vinorelbine Tartrate) in Patients With Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||November 2000|September 19, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006088||206285|
NCT00005975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067962|S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer|A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626||Southwest Oncology Group|Yes|Completed|April 1998|March 2002|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|288|||Female|N/A|120 Years|No|||November 2015|November 17, 2015|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005975||206394|
NCT00005976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01850|Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma|Phase I/II Trial of Pyrazoloacridine and Carboplatin in Patients With Recurrent Glioma||National Cancer Institute (NCI)||Completed|May 2000|April 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||September 2003|May 31, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005976||206393|
NCT00006024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0011|Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma|A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas||Children's Oncology Group|Yes|Completed|November 2000|September 2006|Actual|January 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|3 Years|21 Years|No|||February 2014|February 11, 2014|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006024||206345|
NCT00006004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068012|Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer|A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients||Eastern Cooperative Oncology Group||Completed|May 2000|||January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 16, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006004||206365|
NCT00006042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068057, J9966|Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Non-Myeloablative Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Using Haploidentical Donors: A Phase I Trial of Pre-Transplant Cyclophosphamide||Sidney Kimmel Comprehensive Cancer Center||Completed|December 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||March 2010|March 9, 2010|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006042||206327|
NCT00005989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067978|R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer|A Phase II Study of Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small Cell Lung Cancer||Mayo Clinic|Yes|Completed|November 2002|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2011|August 2, 2011|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005989||206380|
NCT00005956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309|Biological Therapy in Treating Patients With Advanced Cancer|A Pilot Study of Active Immunotherapy With HER2/Neu Intracellular Domain (ICD) Protein-Pulsed, Autologous, Cultured Dendritic Cells in Patients With No Evidence of Disease After Standard Treatment for HER2/Neu Expressing Malignancies||Duke University|No|Completed|February 2000|July 2002|Actual|August 2001|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2013|July 7, 2014|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005956||206413|
NCT00005957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA20|Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer|A Phase III Study of Regional Radiation Therapy in Early Breast Cancer||Canadian Cancer Trials Group|Yes|Active, not recruiting|April 2000|December 2016|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1832|||Female|16 Years|120 Years|No|||March 2016|March 11, 2016|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00005957||206412|
NCT00005986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067974|Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia|Autologous Transplantation for Chronic Myelogenous Leukemia Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming||Masonic Cancer Center, University of Minnesota||Terminated|August 2000|||September 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|65 Years|No|||July 2011|July 13, 2011|July 5, 2000||Yes|Principal investigator left the university.|No||https://clinicaltrials.gov/show/NCT00005986||206383|
NCT00005977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9917|Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia|A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All||Children's Oncology Group|Yes|Completed|September 2000|September 2006|Actual|March 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|83|||Both|N/A|22 Years|No|||August 2013|August 19, 2013|July 5, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00005977||206392|
NCT00005979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067967|Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer|Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence||National Cancer Institute (NCI)||Active, not recruiting|February 1998|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||September 2000|February 3, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005979||206390|
NCT00005980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10993-16998|Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer|A Randomized Phase II Study of Two Different Schedules of Caelyx in Metastatic Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 2000|||July 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|116|||Female|N/A|N/A|No|||July 2012|July 17, 2012|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005980||206389|
NCT00006070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000168|Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction|Safety and Efficacy of a TNF Receptor Fusion Protein for Injury-Induced Inflammation and Sequelae||National Institutes of Health Clinical Center (CC)||Completed|July 2000|May 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||86|||Both|N/A|N/A|No|||May 2004|March 3, 2008|July 18, 2000||||No||https://clinicaltrials.gov/show/NCT00006070||206302|
NCT00006022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068034|Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer|Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)||Virginia Commonwealth University|Yes|Completed|September 2000|January 2004|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|120 Years|No|||December 2015|December 10, 2015|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006022||206347|
NCT00006023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/00|Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma - Phase II Trials - Protocol 5: Capecitabine||Swiss Group for Clinical Cancer Research|Yes|Completed|March 2000|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|85 Years|No|||May 2012|May 14, 2012|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00006023||206346|
NCT00006003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02346|SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated|A Phase II Trial of SU5416 (NSC #696819) in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Terminated|July 2000|||July 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|July 5, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00006003||206366|
NCT00005997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2299|Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer|Phase II and Pharmacokinetic Trial of Rebeccamycin Analog in Hepatobiliary Cancers||Case Comprehensive Cancer Center|Yes|Terminated|April 1999|November 2005|Actual|April 2005|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|July 5, 2000|Yes|Yes|slow accrual for Cohort II|No||https://clinicaltrials.gov/show/NCT00005997||206372|
NCT00006031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12114|Comparison of Two Types of Biopsy in Patients With Breast Lesions|Randomized Prospective Trial Comparing Radioactive Seed Localized Breast Biopsy to Needle Localized Breast Biopsy||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|November 1999|July 2006|Actual|July 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|117|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006031||206338|
NCT00006008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068016|Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase II Trial of Arsenic Trioxide (NSC #706363) for Relapsed or Refractory Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Completed|June 2000|September 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2002|June 20, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006008||206361|
NCT00006020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0010|S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia|A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-cell Acute Lymphoblastic Leukemia (ALL)||Southwest Oncology Group||Completed|July 2000|July 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|16 Years|N/A|No|||March 2015|March 5, 2015|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006020||206349|
NCT00005965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTS-99-1113-ME|Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix|Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix||National Cancer Institute (NCI)||Completed|August 2000|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2004|July 9, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005965||206404|
NCT00006017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1599|Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer|A Randomized Phase II Trial of Two Different Schedules of Administration of Rebeccamycin Analog in Patients With Advanced Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|May 2000|January 2005|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|N/A|N/A|No|||June 2010|June 9, 2010|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006017||206352|
NCT00005987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1996LS137|Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma|Autologous Transplantation for Multiple Myeloma: A Research Study of Multiple Myeloma Using Chemotherapy Plus Growth Factor Primed Peripheral Blood Stem Cells Followed by Autologous Transplantation and Post-Transplant Immunotherapy||Masonic Cancer Center, University of Minnesota|Yes|Terminated|August 2000|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|87|||Both|N/A|70 Years|No|||October 2012|October 9, 2012|July 5, 2000|Yes|Yes|Withdrawn because treatment guidelines changed|No||https://clinicaltrials.gov/show/NCT00005987||206382|
NCT00006082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16996SL|Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer|Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On - 2 Days Off" Oral Treatment in Advanced Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2000|||August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|38|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006082||206291|
NCT00005983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067971|S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer|Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes Phase III||Southwest Oncology Group|Yes|Terminated|June 2000|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Female|21 Years|N/A|No|||January 2013|January 22, 2013|July 5, 2000|No|Yes|due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00005983||206386|
NCT00005961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02340|O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma|A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Metatstatic Melanoma||National Cancer Institute (NCI)||Completed|June 2000|||December 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2003|February 8, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005961||206408|
NCT00005962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067944|Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia|A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia||Eastern Cooperative Oncology Group||Completed|July 2000|June 2007|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 16, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005962||206407|
NCT00005958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067939|Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer|Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim||National Cancer Institute (NCI)||Active, not recruiting|October 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2001|December 3, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005958||206411|
NCT00006037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068052 (3C-99-3)|Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer|Phase II Randomized Placebo-Controlled Double-Blinded Study With 5-FU vs. 5-FU With IM862 With Cross-Over to CPT-11 vs. CPT-11 With IM862||University of Southern California|Yes|Terminated|November 1999|November 2001|Actual|November 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|18|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|July 5, 2000|Yes|Yes|Drug not available|No||https://clinicaltrials.gov/show/NCT00006037||206332|
NCT00005990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067979|R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetic Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan||New York University School of Medicine||Completed|August 2000|||September 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2006|November 8, 2012|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005990||206379|
NCT00006002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10428|SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of SU5416 (NSC# 686819) in Patients With Hormone Refractory Prostate Cancer||University of Chicago|No|Completed|June 2000|January 2006|Actual|September 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|N/A|No|||September 2013|September 4, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006002||206367|
NCT00005993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999LS022|Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer|Immunotherapy With Subcutaneous Il-2 and Stem Cell Factor (SCF) for Patients With Lymphoma or Breast Cancer After Autologous Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Terminated|May 1999|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||October 2012|October 9, 2012|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005993||206376|
NCT00005994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067996|Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy|Patient Information and Antiemetic Drug Efficacy||University of Rochester||Completed|August 2000|July 2001|Actual|July 2001|Actual|N/A|Interventional|Allocation: Randomized|||||||Both|18 Years|N/A|No|||March 2013|March 4, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005994||206375|
NCT00005984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1996LS183|Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia|Autologous Marrow Transplantation for Chronic Myelogenous Leukemia Using Stem Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming||Masonic Cancer Center, University of Minnesota|Yes|Terminated|August 2000|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|70 Years|No|||May 2011|May 25, 2011|July 5, 2000|Yes|Yes|Study terminated as principal investigator [PI] left the university.|No||https://clinicaltrials.gov/show/NCT00005984||206385|
NCT00005985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1996LS155|Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma|Primed Peripheral Blood Stem Cell Autologous Transplantation for Lymphoma and Hodgkin's Disease||Masonic Cancer Center, University of Minnesota|Yes|Completed|August 2000|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|213|||Both|N/A|70 Years|No|||October 2012|October 16, 2012|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00005985||206384|
NCT00006049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068065|ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer|A Randomized, Double-Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Paclitaxel and Carboplatin Versus Placebo in Combination With Paclitaxel and Carboplatin in Chemotherapy-Naive Patients With Advanced (Stage III or IV) Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2001|December 18, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006049||206320|
NCT00006050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068072|Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver|Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|75 Years|No|||September 2005|February 6, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006050||206319|
NCT00006029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-59804|Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase I/II Study of Gemcitabine (GEMZAR)/Vinorelbine (NAVELBINE)/Liposomal Doxorubicin (DOXIL) in Relapsed/Refractory Hodgkin's Disease||Alliance for Clinical Trials in Oncology|Yes|Completed|July 2000|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|N/A|N/A|No|||July 2015|July 7, 2015|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006029||206340|
NCT00006016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02352|Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery|An Evaluation of Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer||National Cancer Institute (NCI)||Completed|May 2000|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||January 2013|April 14, 2015|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006016||206353|
NCT00005998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999LS080|Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease|Autologous Transplantation for Non-Hodgkin's Lymphoma and Hodgkin's Disease Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Mobilization Using Hematopoietic Cytokines Plus Chemotherapy||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|January 2000|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|70 Years|No|||October 2012|October 9, 2012|July 5, 2000|Yes|Yes|Withdrawn because study never enrolled patients|No||https://clinicaltrials.gov/show/NCT00005998||206371|
NCT00005988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067977|Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy|A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies||National Cancer Institute (NCI)||Active, not recruiting|February 2000|||||Phase 1|Interventional|Primary Purpose: Supportive Care|||||||Both|N/A|40 Years|No|||May 2009|May 16, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005988||206381|
NCT00005960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067942|Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of Doxorubicin and Cyclophosphamide With Sequential Docetaxel in Patients With Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||January 2001|December 3, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005960||206409|
NCT00005972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067959|Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer|Phase II Trial of Gemcitabine/Irinotecan as Second Line Therapy for Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|May 2000|February 2008|Actual|October 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|73|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005972||206397|
NCT00006026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16996U|Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract|Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2000|||October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|21|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006026||206343|
NCT00006093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068098|EMD 121974 in Treating Patients With Progressive or Recurrent Glioma|A Phase I/II Trial of EMD 121974 for Treatment of Patients With Recurrent Anaplastic Gliomas||National Cancer Institute (NCI)||Completed|September 2000|October 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|June 20, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006093||206280|
NCT00005991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067980|Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer|Phase I/II Study of Gemcitabine and Doxil Combination Chemotherapy in Patients With Advanced Solid Tumors (Phase I)/Breast Cancer (Phase II)||M.D. Anderson Cancer Center|No|Completed|April 2000|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Female|18 Years|N/A|No|||October 2012|October 5, 2012|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00005991||206378|
NCT00005969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-255|Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease|Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients With Relapsed or Refractory Hodgkin's Disease||M.D. Anderson Cancer Center|No|Withdrawn|September 1999|||January 2001|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|N/A|No|||February 2012|February 17, 2012|July 5, 2000||No|Study withdrawn.|No||https://clinicaltrials.gov/show/NCT00005969||206400|
NCT00005966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067949|Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer|Phase III Randomized Trial of Interferon-Alfa2b Alone Versus Interferon-Alfa2b Plus Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|October 2000|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|February 4, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005966||206403|
NCT00006043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-010|Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin|Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors||Memorial Sloan Kettering Cancer Center||Completed|February 2000|November 2001|Actual|November 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||June 2013|June 4, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006043||206326|
NCT00006015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068024|Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer|Phase II Study Evaluating the Combination of 5-Fluorouracil, Leucovorin, Oxaliplatin, and Herceptin in the Treatment of Patients With Metastatic Colorectal Cancer Who Have Progressed After 5-FU and/or Irinotecan-Containing Therapy||National Cancer Institute (NCI)|Yes|Terminated|May 2000|February 2003|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2011|May 1, 2013|July 5, 2000|No|Yes|lack of sufficient accrual|No||https://clinicaltrials.gov/show/NCT00006015||206354|
NCT00005995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067999|AE-941 in Treating Patients With Metastatic Kidney Cancer|AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy||AEterna Zentaris||Completed|October 2000|||March 2007|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2008|March 4, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005995||206374|
NCT00005963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9932|Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer|Phase II Trial of Docetaxel and Carboplatin as First-Line Therapy for Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|November 2000|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005963||206406|
NCT00006177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000198|Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study|The Phenomenology and Neurophysiology of Affective Dysregulation in Children and Adolescents With Bipolar Disorder||National Institutes of Health Clinical Center (CC)||Recruiting|August 2000|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2200|||Both|42 Months|17 Years|Accepts Healthy Volunteers|||July 2015|August 13, 2015|August 12, 2000||No||No||https://clinicaltrials.gov/show/NCT00006177||206202|
NCT00006178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000196|Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection|Sirolimus Monotherapy to Optimize Activation Induced Cell Death (AICD) in Renal Transplants Following Lymphocyte Depletion Induction With Thymoglobulin||National Institutes of Health Clinical Center (CC)||Completed|August 2000|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||June 2010|June 16, 2010|August 15, 2000||No||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00006178||206201|Optimal dose of RATG remains to be determined. Whether other depleting agents are as effective as RATG is unclear.
NCT00006032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12220|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer|A Phase II Study of Intensive-Dose Topotecan, Ifosfamide/Mesna and Etoposide (TIME) Followed by Autologous Stem Cell Rescue in Metastatic Breast Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|March 2000|April 2001|Actual|April 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|64 Years|No|||December 2012|December 10, 2012|July 5, 2000||No|low accrual|No||https://clinicaltrials.gov/show/NCT00006032||206337|
NCT00006009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC-NCI-102|Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma|A Phase I, Multiple Dose Escalation Trial of Intravenous Humanized Anti-CD3 Antibody (HuM291) in Patients With CD3+ T-cell Lymphomas||National Cancer Institute (NCI)||Completed|April 2001|October 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|May 14, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006009||206360|
NCT00006010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0041|Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer|Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable or Metastatic Hepatocellular Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|September 2001|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006010||206359|
NCT00006025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068037|Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma|Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)||Completed|November 2000|||May 2008|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|November 22, 2008|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006025||206344|
NCT00006011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0184|Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer|A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma||Gynecologic Oncology Group||Completed|July 2000|||March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|659|||Female|N/A|N/A|No|||April 2015|April 30, 2015|July 5, 2000|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00006011||206358|
NCT00006054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15104|Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies|||Office of Rare Diseases (ORD)||Terminated|March 2000|December 2002|Actual|December 2002|Actual|N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|35 Years|No|||October 2003|October 14, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006054||206315|
NCT00006205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAJOH1052207A1|Alcohol Dependency Study: Combining Medication Treatment for Alcoholism|Combining Medications Treatment for Alcoholism||University of Virginia|Yes|Recruiting|March 2005|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006205||206178|
NCT00005928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000162|Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation|Effects of Angiotensin Converting Enzyme Inhibitor Therapy on Vascular Inflammation and Compliance||National Institutes of Health Clinical Center (CC)||Completed|June 2000|February 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||February 2002|March 3, 2008|June 28, 2000||||No||https://clinicaltrials.gov/show/NCT00005928||206437|
NCT00006027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9905|Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer|A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer||Radiation Therapy Oncology Group|Yes|Completed|August 2000|||June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||August 2013|August 9, 2013|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006027||206342|
NCT00005886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067956|Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer|A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2000|||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2008|July 23, 2008|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005886||206473|
NCT00005948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1455.00|Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia|A Pilot Study of High Dose Busulfan Combined With IL2/GM-CSF Activated Autologous/Syngeneic PBSC, Sequential IL2/GM-CSF Therapy and Alpha Interferon Maintenance Therapy as Treatment of CML||Fred Hutchinson Cancer Research Center||Completed|January 2000|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||March 2010|March 31, 2010|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005948||206420|
NCT00005949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02337|Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma|Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma||National Cancer Institute (NCI)||Completed|March 2001|||March 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005949||206419|
NCT00005898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15109|Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia|||Office of Rare Diseases (ORD)||Completed|February 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||30|||Both|N/A|34 Years|No|||July 2004|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005898||206464|
NCT00005900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15111|Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|||Office of Rare Diseases (ORD)||Active, not recruiting|August 1999|||||N/A|Observational|Primary Purpose: Screening||||10|||Both|N/A|N/A|No|||October 2003|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005900||206463|
NCT00005893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15101|Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders|||Office of Rare Diseases (ORD)||Completed|June 2000|||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2004|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005893||206466|
NCT00005911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000151|Magnetic Resonance Imaging to Study the Normal Eye|Refinement of the Magnetic Resonance Imaging Technique for the Study of the Normal Eye, Particularly the Lens and Cataract||National Institutes of Health Clinical Center (CC)||Completed|June 2000|August 2002||||N/A|Observational|N/A||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2002|March 3, 2008|June 13, 2000||||No||https://clinicaltrials.gov/show/NCT00005911||206453|
NCT00005916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000154|PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer|A Randomized Phase II Study of a PSA-Based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy||National Institutes of Health Clinical Center (CC)||Completed|June 2000|December 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|48|||Male|18 Years|N/A|No|||December 2005|September 26, 2015|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00005916||206449|
NCT00005882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067922|Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps|A Phase II Clinical Trial of a Randomized, Double-Blind, Placebo Controlled Clinical Trial of DFMO and Sulindac Against Various Endpoints of Colorectal Pathobiology in a Cohort of Individuals at Increased Risk of Colorectal Carcinoma||University of California, Irvine|Yes|Completed|June 2000|December 2011|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|324|||Both|40 Years|80 Years|No|||January 2013|January 28, 2013|June 2, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005882||206476|
NCT00005906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000147|Treatment With Octreotide in Patients With Lymphangioleiomyomatosis|Treatment With Octreotide in Patients With Lymphangioleiomyomatosis||National Institutes of Health Clinical Center (CC)|Yes|Completed|June 2000|||April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|65 Years|No|||April 2010|April 29, 2010|June 9, 2000||No||No|February 26, 2010|https://clinicaltrials.gov/show/NCT00005906||206458|
NCT00005907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000144|Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers|Evaluation of Hepatitis B Surface Antigen-Specific and Tetanus Toxoid-Specific Lymphocytes||National Institutes of Health Clinical Center (CC)||Completed|June 2000|May 2002||||N/A|Observational|N/A||||55|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2002|March 3, 2008|June 9, 2000||||No||https://clinicaltrials.gov/show/NCT00005907||206457|
NCT00005939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067749|Brachytherapy in Treating Patients With Recurrent Prostate Cancer|Phase I/II Study of Interstitial Colloidal 32P for Locally Recurrent Prostate Cancer Failing Radiation||National Cancer Institute (NCI)||Active, not recruiting|November 1999|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|21 Years|N/A|No|||February 2001|November 5, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005939||206429|
NCT00005890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR08084-0043|Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock|||National Center for Research Resources (NCRR)||Completed|March 1996|||||N/A|Interventional|Primary Purpose: Diagnostic||||56|||Both|1 Month|18 Years|No|||December 2003|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005890||206469|
NCT00005945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1991|Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia|Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia||Children's Oncology Group|Yes|Completed|June 2000|June 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|3054|||Both|1 Year|9 Years|No|||February 2016|February 19, 2016|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005945||206423|
NCT00005931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310B|SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment|A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2000|June 23, 2005|June 30, 2000||||No||https://clinicaltrials.gov/show/NCT00005931||206436|
NCT00005947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9901 CDR0000067868|Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge) for Asymptomatic Metastatic Hormome-Refractory Prostate Cancer||Dendreon||Completed|November 1999|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Male|18 Years|N/A|No|||October 2010|October 8, 2010|July 5, 2000||Yes||No|May 28, 2010|https://clinicaltrials.gov/show/NCT00005947||206421|
NCT00005924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000163|Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus|Persistence of Epstein-Barr Virus in Vivo||National Institutes of Health Clinical Center (CC)||Completed|June 2000|February 2010||||N/A|Observational|N/A|||Actual|41|||Both|18 Years|N/A|No|||February 2010|September 26, 2015|June 24, 2000||No||No||https://clinicaltrials.gov/show/NCT00005924||206441|
NCT00005896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15107|Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia|||Office of Rare Diseases (ORD)||Active, not recruiting|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment||||6|||Both|5 Years|N/A|No|||March 2001|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005896||206465|
NCT00006198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00096-0958|Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|June 23, 2005|September 9, 2000||||No||https://clinicaltrials.gov/show/NCT00006198||206184|
NCT00005943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-0526.cc|Gene Therapy in Treating Patients With Metastatic Melanoma|A Phase I Study Using Direct Combination DNA Injections for the Immunotherapy of Metastatic Melanoma||University of Colorado, Denver|Yes|Completed|February 2000|September 2001|Actual|September 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2001|May 28, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005943||206425|
NCT00005944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067833|Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer|Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence||National Cancer Institute (NCI)||Active, not recruiting|November 1999|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|70 Years|No|||June 2007|April 23, 2011|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005944||206424|
NCT00005908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000149|Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer|A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression||National Institutes of Health Clinical Center (CC)|No|Completed|June 2000|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|June 13, 2000|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00005908||206456|
NCT00005880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067919|Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia|A Phase II Trial of Inhaled Budesonide (Pulmicort Turbuhaler) in Persons With Dysplasia of the Bronchial Epithelium||National Cancer Institute (NCI)||Completed|July 2000|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|40 Years|74 Years|No|||July 2007|July 23, 2008|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005880||206478|
NCT00005881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS972|Quality of Life in Children Treated for Cancer|Assessment of Health/Quality of Life in Survivors of Childhood Cancer||Children's Oncology Group|No|Completed|April 2000|September 2006|Actual|March 2003|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|538|||Both|8 Years|20 Years|No|Probability Sample|Previous treatment for cancer or currently undergoing treatment for cancer.|August 2013|August 22, 2013|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005881||206477|
NCT00006000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068008|SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of SU5416 in Combination With CPT-11 and Cisplatin in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|August 2000|March 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2002|January 30, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006000||206369|
NCT00006012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9923|Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase I-II Study of Topotecan and Paclitaxel Followed by High-Dose Thoracic Radiation Therapy With Concomitant Cisplatin/Etoposide and Amifostine in Limited-Stage Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|February 2001|May 2006|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006012||206357|
NCT00005920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267B|Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole|A Multiclinic, Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety, Tolerability, and Efficacy of L-743,872 in the Treatment of Fluconazole-Unresponsive Oropharyngeal Candidiasis in Adults||NIH AIDS Clinical Trials Information Service||Terminated||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||70|||Both|18 Years|65 Years|No|||June 2000|June 23, 2005|June 19, 2000||||No||https://clinicaltrials.gov/show/NCT00005920||206445|
NCT00005921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267A|A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis|An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis||NIH AIDS Clinical Trials Information Service||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||18|||Male|18 Years|65 Years|No|||June 2000|June 23, 2005|June 19, 2000||||No||https://clinicaltrials.gov/show/NCT00005921||206444|
NCT00005912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000150|Voriconazole to Prevent Systemic Fungal Infections in Children|An Open Intravenous Multiple Dose, Multi-Center Study to Investigate the Pharmacokinetics, Safety and Toleration of Voriconazole in Children Aged 2-12 Years Who Require Treatment for the Prevention of Systemic Fungal Infection||National Institutes of Health Clinical Center (CC)||Completed|June 2000|January 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||48|||Both|N/A|N/A|No|||June 2000|March 3, 2008|June 14, 2000||||No||https://clinicaltrials.gov/show/NCT00005912||206452|
NCT00006028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068041|Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy|Evaluation of Gemcitabine and Cisplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer||Gynecologic Oncology Group||Completed|January 2001|||January 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||March 2003|May 24, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006028||206341|
NCT00005940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1470.00|Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission|Phase II Study of Radiolabeled BC8 (Anti-CD45) Antibody Combined With Busulfan and Cyclophosphamide as Treatment for Acute Myelogenous Leukemia in First Remission Followed by HLA-Identical Related Peripheral Blood Stem Cell Transplantation||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|October 1999|||January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|16 Years|55 Years|No|||November 2015|November 16, 2015|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005940||206428|
NCT00005926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000161|Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas|A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas||National Institutes of Health Clinical Center (CC)||Completed|June 2000|December 2000||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||June 2000|March 3, 2008|June 28, 2000||||No||https://clinicaltrials.gov/show/NCT00005926||206439|
NCT00005927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000160|Study of Adrenal Gland Tumors|Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue||National Institutes of Health Clinical Center (CC)||Recruiting|June 2000|||||N/A|Observational|N/A|||Anticipated|2000|||Both|3 Years|70 Years|No|||July 2015|July 25, 2015|June 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00005927||206438|
NCT00005942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02329|Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy|Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy||National Cancer Institute (NCI)||Completed|March 2000|||December 2000|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005942||206426|
NCT00005954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2114|Temozolomide in Treating Patients With Brain Metastases|Phase II Treatment of Adults With Brain Metastases With Temodar||Duke University||Completed|August 2000|June 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2009|June 19, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005954||206415|
NCT00005981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1298|Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Trial of O6Benzylguanine and BCNU in Patients With Colon and Rectal Carcinoma||Case Comprehensive Cancer Center|Yes|Completed|June 2000|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005981||206388|
NCT00005982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02344|506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma|Phase II Study of 506U78 (NSC #686673) in Patients With Previously Treated Cutaneous T-Cell Lymphoma||National Cancer Institute (NCI)||Terminated|April 2000|||July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|16 Years|N/A|No|||January 2013|January 22, 2013|July 5, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00005982||206387|
NCT00005941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1477.00|Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer|Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy||Fred Hutchinson Cancer Research Center||Completed|November 1999|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|64 Years|No|||March 2010|March 31, 2010|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005941||206427|
NCT00005888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15024|Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants|||National Center for Research Resources (NCRR)||Completed|January 1997|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|N/A|96 Hours|No|||April 2002|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005888||206471|
NCT00005889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00188-0667|Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion|Study of Gluconeogenesis in Very Low Birth Weight Infants Receiving Total Parenteral Nutrition||National Center for Research Resources (NCRR)||Recruiting|October 1999|||||N/A|Interventional|Primary Purpose: Treatment||||96|||Both|N/A|6 Days|No|||December 2003|June 23, 2005|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005889||206470|
NCT00006203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMON0785011A1|Naltrexone, Craving, and Drinking|Naltrexone, Craving, and Drinking: Ecological Assessment||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||186|||Both|21 Years|N/A|No|||October 2006|October 20, 2006|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006203||206180|
NCT00006013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-00009|SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma|Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma||Fox Chase Cancer Center|Yes|Completed|June 2000|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006013||206356|
NCT00005902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000140|Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease|A Prospective Natural History Study of VHL Patients With CNS Hemangioblastomas||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2000|||||N/A|Observational|N/A|||Actual|250|||Both|8 Years|75 Years|No|||September 2015|September 18, 2015|June 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00005902||206461|
NCT00005903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000145|Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy|Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP||National Institutes of Health Clinical Center (CC)||Completed|June 2000|May 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||May 2005|March 3, 2008|June 7, 2000||||No||https://clinicaltrials.gov/show/NCT00005903||206460|
NCT00005905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000146|Leptin to Treat Lipodystrophy|Efficacy of Leptin Replacement in Treatment of Lipodystrophy||National Institutes of Health Clinical Center (CC)||Completed|June 2000|April 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||April 2003|March 3, 2008|June 9, 2000||||No||https://clinicaltrials.gov/show/NCT00005905||206459|
NCT00005914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061686-01|Genetics of Recurrent Early-Onset Depression|||National Institute of Mental Health (NIMH)||Completed|October 1999|September 2003||||N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2009|December 16, 2009|June 15, 2000||||No||https://clinicaltrials.gov/show/NCT00005914||206451|
NCT00006001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02345|SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer|Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced Colorectal Cancer||National Cancer Institute (NCI)||Terminated|August 2000|August 2009|Actual|February 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2009|May 31, 2013|July 5, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00006001||206368|
NCT00006007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-983253|LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer|A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|December 2000|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Female|18 Years|N/A|No|||July 2015|July 13, 2015|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006007||206362|
NCT00005901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000136|Pamidronate to Treat Osteogenesis Imperfecta in Children|A Trial of Pamidronate in Children With Osteogenesis Imperfecta||National Institutes of Health Clinical Center (CC)|Yes|Completed|June 2000|March 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|N/A|16 Years|No|||February 2016|February 1, 2016|June 6, 2000|Yes|Yes||No|November 24, 2015|https://clinicaltrials.gov/show/NCT00005901||206462|
NCT00005909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000141|Study of Alkaptonuria|Clinical, Biochemical, and Molecular Investigations Into Alkaptonuria||National Institutes of Health Clinical Center (CC)||Recruiting|June 2000|||||N/A|Observational|N/A|||Anticipated|200|||Both|2 Years|90 Years|No|||September 2015|October 6, 2015|June 13, 2000||No||No||https://clinicaltrials.gov/show/NCT00005909||206455|
NCT00005959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067940|Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma|Phase II Trial of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated Intermediate or High Grade Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|December 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|December 3, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005959||206410|
NCT00005919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000155|Cause of Pigment Dispersion Syndrome|Etiology of Pigment Dispersion Syndrome (PDS)||National Institutes of Health Clinical Center (CC)||Completed|June 2000|August 2003||||N/A|Observational|N/A||||90|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2003|March 3, 2008|June 17, 2000||||No||https://clinicaltrials.gov/show/NCT00005919||206446|
NCT00005937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000169|Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia|A Phase II Study of Antithymocyte Globulin (ATG) and Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)||National Institutes of Health Clinical Center (CC)|Yes|Completed|June 2000|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|July 6, 2000||No||No|April 2, 2010|https://clinicaltrials.gov/show/NCT00005937||206431|
NCT00005938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067736|DX-8951f in Treating Patients With Biliary Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer)||Daiichi Sankyo Inc.||Completed|March 2000|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||May 2012|May 15, 2012|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005938||206430|
NCT00005922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR046825|Conditioning, the Placebo Effect, and Psoriasis|Role of Conditioning in the Pharmacotherapy of Psoriasis||University of Rochester|Yes|Completed|August 2000|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|138|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 20, 2013|June 22, 2000||No||No||https://clinicaltrials.gov/show/NCT00005922||206443|
NCT00005923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00109-0749|The Effect of Estrogen and Progesterone Levels on Knee and Ankle Joint Laxity|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Observational|Observational Model: Natural History|||||||Both|15 Years|23 Years|Accepts Healthy Volunteers|||November 2001|June 23, 2005|June 23, 2000||||No||https://clinicaltrials.gov/show/NCT00005923||206442|
NCT00006204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASAL11929|Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)|Combined Pharmacotherapy in Depressed Alcoholics||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|March 2000|January 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||106|||Both|18 Years|65 Years|No|||December 2007|December 7, 2007|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006204||206179|
NCT00005952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1735|Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors|A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors||Duke University|No|Completed|August 2000|November 2005|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|18 Years|No|||February 2013|June 19, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005952||206416|
NCT00005887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067957|Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases|A Phase III, Randomized, Open-Label, Comparative Study of Standard Whole Brain Radiation Therapy With or Without RSR13 in Patients With Brain Metastases||Spectrum Pharmaceuticals, Inc||Completed|February 2000|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2013|May 8, 2013|June 2, 2000||||No||https://clinicaltrials.gov/show/NCT00005887||206472|
NCT00005955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0931|Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors|Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy||Duke University||Completed|August 2000|September 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|4 Years|21 Years|No|||October 2009|June 19, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005955||206414|
NCT00006014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02351|SU5416 in Treating Patients With Malignant Mesothelioma|A Phase II Trial of SU5416 (NSC# 696819) in Patients With Malignant Mesothelioma||National Cancer Institute (NCI)||Completed|August 2000|February 2009|Actual|February 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2009|May 31, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006014||206355|
NCT00005879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMC-HSC-7264-97|LY353381 in Preventing Breast Cancer in Women With Hyperplasia|A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia||University of Kansas Medical Center|No|Completed|August 2000|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|199|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|June 2, 2000||No||No||https://clinicaltrials.gov/show/NCT00005879||206479|
NCT00005910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000152|Laparoscopy to Remove Pancreatic Tumors (Insulinomas)|Use of Laparoscopy for Localization and Resection of Insulinomas of the Pancreas||National Institutes of Health Clinical Center (CC)||Completed|June 2000|May 2006||||N/A|Interventional|N/A||||23|||Both|N/A|N/A|No|||May 2006|March 3, 2008|June 13, 2000||||No||https://clinicaltrials.gov/show/NCT00005910||206454|
NCT00005915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 064|A Comparison of Two Anti-HIV Treatment Plans|A Randomized Study of a Prescribed 4-Month Structured Treatment Interruption (STI) Followed by Initiation of a New Antiretroviral Regimen Versus Immediate Initiation of a New Antiretroviral Regimen in HIV-Infected Patients With Multidrug Resistant (MDR) Virus||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2004|Actual|||N/A|Observational|N/A||||480|||Both|13 Years|N/A|No|||September 2013|September 28, 2013|June 15, 2000||||No||https://clinicaltrials.gov/show/NCT00005915||206450|
NCT00006019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068030|Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer|Pilot Study of Sodium Phenylbutyrate Plus Azacytidine||National Cancer Institute (NCI)||Completed|May 2000|August 2003|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2002|June 20, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006019||206350|
NCT00005936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000167|Collection of Liver Tissue for Virologic Studies|Collection of Liver Tissue for Virologic Studies||National Institutes of Health Clinical Center (CC)||Completed|June 2000|March 2002||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||March 2002|March 3, 2008|July 6, 2000||||No||https://clinicaltrials.gov/show/NCT00005936||206432|
NCT00005946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067863|Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation|A Pilot Study of Combined Chemotherapy and Donor Lymphocyte Infusion for Hematologic Malignancies in Relapse After Allogeneic Bone Marrow Transplantation||National Cancer Institute (NCI)||Active, not recruiting|October 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2007|February 6, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005946||206422|
NCT00005933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000164|Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders|Cognitive Function in Leukocyte Disorders||National Institutes of Health Clinical Center (CC)||Completed|June 2000|July 2005||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||July 2005|March 3, 2008|July 4, 2000||||No||https://clinicaltrials.gov/show/NCT00005933||206435|
NCT00005967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02342|Tipifarnib in Treating Patients With Advanced Hematologic Cancer|A Dose Finding Study of R115777 (NSC 702818) in Patients With Advanced Hematologic Malignancies||National Cancer Institute (NCI)||Completed|August 2000|||April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2004|February 8, 2013|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005967||206402|
NCT00006153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-05-006|Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination|A Multicenter, Double-Blind, Phase I, Adjuvant Controlled Study to Evaluate the Effect of Remune (HIV-1 Immunogen) Compared to IFA, in Combination With Fully Suppressive Antiviral Drug Therapy on HIV-1-Specific Immunogenicity in Subjects With Acute or Primary HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|16 Years|N/A|No|||June 2003|July 29, 2008|August 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006153||206226|
NCT00006161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVERT (completed)|Decompression Intervention of Variceal Rebleeding Trial (DIVERT)|Decompression Intervention of Variceal Rebleeding Trial||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 1996|December 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006161||206218|
NCT00006162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fujimotow (completed)|Lifestyle Interventions to Reduce Diabetes Risk|Interventions to Reduce Diabetic Risk in Japanese Americans||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|October 1994|April 1999||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|40 Years|N/A|No|||March 2010|March 1, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006162||206217|
NCT00006250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068182|Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma|Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|May 2000|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|70 Years|No|||March 2007|September 19, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006250||206137|
NCT00006137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15244|Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy|||Office of Rare Diseases (ORD)||Completed|May 2000|||||N/A|Interventional|Primary Purpose: Treatment||||43|||Both|13 Years|60 Years|Accepts Healthy Volunteers|||September 2000|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006137||206237|
NCT00006138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15314|Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia Major|||Office of Rare Diseases (ORD)||Completed|June 1998|August 2000||||N/A|Observational|Primary Purpose: Screening||||35|||Both|6 Years|N/A|No|||October 2000|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006138||206236|
NCT00006200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00096-1000|Thalidomide and Dacarbazine for Metastatic Melanoma|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|June 23, 2005|September 9, 2000||||No||https://clinicaltrials.gov/show/NCT00006200||206182|
NCT00006218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-009|3-AP in Treating Patients With Advanced Cancer|A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion||National Cancer Institute (NCI)||Completed|May 2000|January 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|July 17, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006218||206167|
NCT00006219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068084|Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma|A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance||Mayo Clinic|Yes|Completed|August 2000|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||August 2011|August 2, 2011|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006219||206166|
NCT00006225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 97B2|Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer|Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study||Northwestern University||Completed|November 1999|January 2004|Actual|January 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||May 2012|May 31, 2012|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006225||206160|
NCT00006226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01852|Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|A Phase II Trial of Thalidomide in Patients With Relapsed Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|September 2000|||December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006226||206159|
NCT00006227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0187|Paclitaxel in Treating Patients With Ovarian Stromal Cancer|Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy||Gynecologic Oncology Group||Active, not recruiting|November 2000|||July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|N/A|N/A|No|||March 2016|March 16, 2016|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006227||206158|
NCT00006102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01851|Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma|A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors||National Cancer Institute (NCI)||Completed|July 2000|||June 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|21 Years|No|||November 2010|February 4, 2013|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006102||206271|
NCT00006130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR01271-5715|Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease|Randomized Study of Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease||National Center for Research Resources (NCRR)||Active, not recruiting|June 1999|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||50|||Both|10 Years|N/A|No|||May 2002|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006130||206244|
NCT00006134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15328|Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture|||National Center for Research Resources (NCRR)||Completed|September 1993|||||N/A|Observational|Primary Purpose: Screening||||300|||Both|N/A|N/A|No|||December 2003|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006134||206240|
NCT00006126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99H2|Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery|Allogeneic Peripheral Blood Progenitor Cell Transplantation in Patients With Incurable Solid Tumors: A Phase I Study||Northwestern University||Withdrawn|September 1999|April 2001||April 2001||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|59 Years|No|||November 2015|November 10, 2015|August 3, 2000|No|Yes|Unable to accrue subjects.|No||https://clinicaltrials.gov/show/NCT00006126||206248|
NCT00006106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI-98320|ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer|Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck||National Cancer Institute (NCI)||Withdrawn|July 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|79 Years|No|||December 2006|July 9, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006106||206267|
NCT00006103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9864|Combination Chemotherapy in Treating Patients With Colorectal Cancer|Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11||Alliance for Clinical Trials in Oncology|No|Completed|July 2000|April 2002|Actual|April 2002|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|N/A|N/A|No|||July 2015|July 13, 2015|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006103||206270|
NCT00006181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR045901|Promoting Healthy Lifestyles Among Firefighters|PHLAME: Promoting Healthy Lifestyles: Alternative Models' Effects|PHLAME|Oregon Health and Science University||Completed|April 1999|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||600|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2003|January 6, 2014|August 19, 2000||No||No||https://clinicaltrials.gov/show/NCT00006181||206199|
NCT00006182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68|Stroke Prevention in Sickle Cell Anemia (STOP 2)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2000|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|2 Years|20 Years|No|||October 2005|February 17, 2016|August 21, 2000||||No||https://clinicaltrials.gov/show/NCT00006182||206198|
NCT00006183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131|Comparison of Hematocrit Levels in Infant Heart Surgery|Hematocrit Strategy in Infant Heart Surgery||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2000|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||120|||Both|N/A|1 Year|No|||March 2008|March 6, 2008|August 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00006183||206197|
NCT00006184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000201|Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma|Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)|No|Completed|August 2000|July 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||March 2014|March 24, 2014|August 23, 2000|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00006184||206196|
NCT00006167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAW (completed)|Nutrition Intervention in AIDS Wasting|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 1998|August 2000||||Phase 4|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006167||206212|
NCT00006168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMPS (completed)|Ursodiol-Methotrexate for Primary Biliary Cirrhosis|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 1994|March 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|69 Years|No|||January 2010|January 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006168||206211|
NCT00006142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15326|Study of a Phenylalanine Restricted Diet During Pregnancy to Prevent Symptoms in Offspring of Patients With Phenylketonuria|||Office of Rare Diseases (ORD)||Completed|December 1983|||||N/A|Interventional|Primary Purpose: Prevention|||||||Female|N/A|N/A|No|||August 2000|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006142||206235|
NCT00006131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15324|Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster|||National Center for Research Resources (NCRR)||Completed|January 1997|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|66|||Both|18 Years|N/A|No|||December 2003|May 22, 2007|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006131||206243|
NCT00006364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02360|Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|Phase I and Pilot Study of Subcutaneous Homoharringtonine in Chronic Myelogenous Leukemia||National Cancer Institute (NCI)||Completed|November 1999|||September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|12 Years|N/A|No|||January 2013|January 22, 2013|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006364||206036|
NCT00006232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSLG-H31|Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma|A Randomized Trial Comparing Z-Dex With VAD as Induction Therapy for Patients With Multiple Myeloma||National Cancer Institute (NCI)||Completed|October 1996|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|N/A|75 Years|No|||March 2007|May 14, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006232||206153|
NCT00006108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9904|Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer|A Phase II Trial of Xeloda, Every Three Week Taxol and Herceptin in Metastatic Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|August 1999|July 2002|Actual|September 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|59 Years|No|||February 2012|February 3, 2012|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006108||206265|
NCT00006110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9818|Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer|Nonrandomized Ph II Study of Multimodality Therapy for Stg IIB, IIIA/B, or Initially Presenting Stg IV Breast Cancer w/ Four Cycles of AC Followed by 12 Weeks of Single Agent Paclitaxel w/ or w/o Herceptin Followed by Local Therapy Followed by Weekly Herceptin or No Additional Therapy|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|December 1998|April 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|85|||Female|N/A|120 Years|No|||January 2016|January 20, 2016|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006110||206264|
NCT00006156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000189|Feasibility Study for Development of an Early Test for Ovarian Failure|FSH-Stimulated Inhibin B as a Marker for Early Ovarian Insufficiency||National Institutes of Health Clinical Center (CC)||Completed|August 2000|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|49|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 28, 2013|August 9, 2000||No||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00006156||206223|
NCT00006169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stark (completed)|Behavioral Treatment of Weight Gain in CF|Behavioral Treatment of Weight Gain in CF||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 1996|November 1999||||Phase 3|Interventional|Primary Purpose: Prevention|||||||Both|4 Years|12 Years|No|||March 2010|March 1, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006169||206210|
NCT00006369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068242|ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase II, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the Treatment of Metastatic Breast Cancer in Postmenopausal Women Who Have Failed Tamoxifen Therapy||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||October 2001|November 5, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006369||206031|
NCT00006105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9193|Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer|Phase II Trial of Adjuvant Gemcitabine Plus Cisplatin With Amifostine Cytoprotection in Patients With Locally Advanced Bladder Cancer||University of Chicago|No|Completed|June 2000|September 2006|Actual|November 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006105||206268|
NCT00006111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068123|Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract|Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy||National Cancer Institute (NCI)||Active, not recruiting|April 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||May 2002|February 6, 2009|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006111||206263|
NCT00006144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5015|A Study of HIV-Disease Development in Aging|A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-Disease Progression Associated With Aging||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2000|April 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||90|||Both|13 Years|N/A|No|||November 2013|November 6, 2013|August 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006144||206233|
NCT00006173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000195|Magnetic Resonance Imaging for Evaluating Kidney Function|Assessment of Renal Artery Stenosis and Renovascular Hypertension by Contrast Enhanced Magnetic Resonance Imaging: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|August 2000|January 2004||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2004|March 3, 2008|August 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006173||206206|
NCT00006174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000183|Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome|Effects of the Aromatase Inhibitor Letrozole on Pubertal Progression and Indices of Bone Turnover in Girls With Precocious Puberty and McCune-Albright Syndrome (MAS)||National Institutes of Health Clinical Center (CC)||Completed|August 2000|May 2009||||Phase 1|Interventional|Primary Purpose: Treatment|1|||25|||Female|1 Year|8 Years|No|||May 2009|May 19, 2009|August 11, 2000||No||No||https://clinicaltrials.gov/show/NCT00006174||206205|
NCT00006135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15334|Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth|||National Center for Research Resources (NCRR)||Completed|June 1997|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|N/A|28 Days|No|||December 2003|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006135||206239|
NCT00006107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068118|Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)||National Cancer Institute (NCI)||Active, not recruiting|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|February 6, 2009|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006107||206266|
NCT00006193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0761|Effectiveness of Atkins Diet for Weight Loss|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||November 2001|June 23, 2005|September 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006193||206188|
NCT00006194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0764|Effects of Exercise on Markers of Inflammation in Skeletal Muscle in Elderly Hip Fracture Patients|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||||||Both|65 Years|N/A|No|||December 2003|June 23, 2005|September 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006194||206187|
NCT00006116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068129|Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine||National Cancer Institute (NCI)||Active, not recruiting|April 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||November 2000|July 23, 2008|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006116||206258|
NCT00006143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1011|Growth Hormone Treatment of Children With HIV-Associated Growth Failure|A Randomized, Open-Label Study of Recombinant Human Growth Hormone (r-hGH) in Children With HIV-Associated Growth Failure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2002|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||102|||Both|4 Years|13 Years|No|||May 2012|May 17, 2012|August 7, 2000||||||https://clinicaltrials.gov/show/NCT00006143||206234|
NCT00006157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBD (completed)|Treatment of Functional Bowel Disorders|Multicenter Trial of Functional Bowel Disorders||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 1996|March 2001||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Female|18 Years|65 Years|No|||January 2010|January 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006157||206222|
NCT00006158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anabole (completed)|AIDS Wasting in Women: Anabolic Effects of Testosterone|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 1998|December 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|45 Years|No|||February 2010|February 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006158||206221|
NCT00006132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15325|Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System|||National Center for Research Resources (NCRR)||Recruiting|June 1997|||||Phase 3|Interventional|Primary Purpose: Treatment||||132|||Both|N/A|28 Days|No|||December 2003|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006132||206242|
NCT00006114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068126|Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine||National Cancer Institute (NCI)||Active, not recruiting|May 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|80 Years|No|||September 2000|February 26, 2011|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006114||206260|
NCT00006150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000159|Study of Clinical Features and Genetics of Hyperimmunoglobulin E Recurrent Infection|Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)||National Institutes of Health Clinical Center (CC)||Recruiting|August 2000|||||N/A|Observational|N/A|||Anticipated|600|||Both|N/A|105 Years|No|||December 2015|December 24, 2015|August 8, 2000||No||No||https://clinicaltrials.gov/show/NCT00006150||206229|
NCT00006112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068124|Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer|Randomized Therapeutic Study Comparing Tumor Resection Followed Immediately by Intraperitoneal Chemotherapy and Systemic Chemotherapy VS Systemic Chemotherapy Alone for the Treatment of Colorectal Cancer Metastatic to the Peritoneum||National Cancer Institute (NCI)||Active, not recruiting|January 1996|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2001|April 23, 2011|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006112||206262|
NCT00006246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068178|Busulfan in Treating Children and Adolescents With Refractory CNS Cancer|Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis||Pediatric Brain Tumor Consortium|Yes|Completed|November 2000|||May 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|28|||Both|3 Years|21 Years|No|||October 2009|October 6, 2009|September 11, 2000|No|Yes||||https://clinicaltrials.gov/show/NCT00006246||206141|
NCT00006185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hivtzd (completed)|Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome|Cellular Mechanisms for Metabolic Dysfunction in HIV||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 1999|August 2003||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|55 Years|No|||March 2010|March 1, 2010|August 22, 2000||||No||https://clinicaltrials.gov/show/NCT00006185||206195|
NCT00006136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15337|Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia|||Office of Rare Diseases (ORD)||Completed|March 1999|||||Phase 2|Interventional|Primary Purpose: Treatment||||15|||Both|3 Years|N/A|No|||July 2004|November 4, 2005|August 3, 2000||||||https://clinicaltrials.gov/show/NCT00006136||206238|
NCT00006117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068130|Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase II Study of Gemcitabine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Pancreatic Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||October 2009|October 29, 2009|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006117||206257|
NCT00006370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVARTIS-CSMT-487A0103|Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer|A Phase II, Open-label, Multi-Center Study to Evaluate the Efficacy of 90Y-SMT 487 Administered Intravenously to Patients With Refractory Small Cell Lung or Advanced Metastatic Breast Cancer Expressing Somatostatin Receptors as Determined by OctreoScan Scintigraphy||Novartis||Completed|July 2000|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|275|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006370||206030|
NCT00006163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|glasgowr (completed)|Computer-assisted Diabetes Self-management Interventions|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 1997|June 1999||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment|||||||Both|30 Years|N/A|No|||March 2010|March 1, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006163||206216|
NCT00006186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00069-0621|Autologous Fresh Whole Blood and Coagulation Following Cardiopulmonary Bypass in Infants|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|1 Month|N/A|No|||December 2003|June 23, 2005|August 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006186||206194|
NCT00006206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAComb|COMBINE (Acamprosate/Naltrexone)|COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions||University of North Carolina, Chapel Hill||Completed|August 1997|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1375|||Both|18 Years|N/A|No|||November 2007|April 30, 2010|September 11, 2000||||||https://clinicaltrials.gov/show/NCT00006206||206177|
NCT00006352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08971B|Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer|The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 1999|||October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|453|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006352||206048|
NCT00006170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-04174-1|Bupropion and Weight Control for Smoking Cessation - 1|Bupropion and Weight Control for Smoking Cessation||University of Pittsburgh|No|Completed|September 2000|September 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|349|||Female|18 Years|65 Years|No|||January 2016|February 3, 2016|August 9, 2000||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00006170||206209|
NCT00006207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 020|Safety and Tolerability of the Vaginal Gel PRO 2000/5|A Phase I Multicenter Dose Escalation Safety and Acceptability Study of the Investigational Vaginal Microbicide Agent PRO 2000/5 Gel (P)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2003|July 29, 2008|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006207||206176|
NCT00006148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000192|Spleen Size in Peripheral Blood Stem Cell Donors|Spleen Size in Peripheral Blood Stem Cell Donors||National Institutes of Health Clinical Center (CC)||Completed|August 2000|June 2004||||N/A|Observational|N/A||||49|||Both|N/A|N/A|No|||June 2004|March 3, 2008|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006148||206230|
NCT00006151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11645-1|Combining a Smoke Ending Aid With Behavioral Treatment - 1|Combining a Smoke Ending Aid With Behavioral Treatment||University of Pennsylvania|No|Completed|May 1999|February 2002|Actual|February 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 8, 2000||No||No|June 24, 2013|https://clinicaltrials.gov/show/NCT00006151||206228|
NCT00006118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068131|Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer|First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine||National Cancer Institute (NCI)||Active, not recruiting|July 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||November 2001|July 23, 2008|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006118||206256|
NCT00006220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068108|Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy|Arsenic Trioxide Alone or With ATRA (Vesanoid) for Resistant Hematologic Malignancy||Washington University School of Medicine||Terminated|June 1999|February 2002|Actual|November 2000|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|3||Actual|5|||Both|15 Years|N/A|No|||February 2013|February 4, 2013|September 11, 2000|No|Yes|Study drug became commercially available.|No||https://clinicaltrials.gov/show/NCT00006220||206165|
NCT00006122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06993|Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia|Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 2000|||January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|106|||Both|61 Years|N/A|No|||July 2012|July 13, 2012|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006122||206252|
NCT00006123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068138|Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer|Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|65 Years|No|||December 2006|February 6, 2009|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006123||206251|
NCT00006371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12219|A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer|A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|May 2000|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Male|N/A|N/A|No|||September 2012|September 25, 2012|October 4, 2000|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00006371||206029|
NCT00006195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0752|Glucose Regulation During Risperidone and Olanzapine Treatment|||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2003|October 11, 2006|September 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006195||206186|
NCT00006208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298C|A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs|A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting|August 2000|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2006|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006208||206175|
NCT00006120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068134|Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer|Phase II Randomized Study of Two Different Schedules of Docetaxel or Paclitaxel for Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 2000|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|75 Years|No|||March 2006|July 23, 2008|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006120||206254|
NCT00006152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5061|A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment|A Phase II, Restrictively Randomized, Open-Label, Pilot Study of Treatment Intensification of Early Virologic Failure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2002|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||42|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|August 7, 2000||||||https://clinicaltrials.gov/show/NCT00006152||206227|
NCT00006247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068179|SU5416 in Treating Children With Recurrent or Progressive Brain Tumors|A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors||Pediatric Brain Tumor Consortium|Yes|Terminated|August 2000|March 2006|Actual|July 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|33|||Both|N/A|21 Years|No|||October 2009|October 13, 2009|September 11, 2000|No|Yes|The pharmaceutical company discontinued further development of SU5416.|No||https://clinicaltrials.gov/show/NCT00006247||206140|
NCT00006133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15327|Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus|||National Center for Research Resources (NCRR)||Completed|June 2000|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||970|||Female|N/A|N/A|No|||December 2003|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006133||206241|
NCT00006165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|maum (completed)|Native Hawaiian Diabetes Intervention Program|Cultural-based Diabetes Program for Native Hawaiians||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Interventional|Primary Purpose: Prevention|||||||Both|30 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 1, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006165||206214|
NCT00006084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068076|Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia|Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301||National Cancer Institute (NCI)||Active, not recruiting|February 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2001|December 18, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006084||206289|
NCT00006040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-126|Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia|Phase I Study of Yttrium-90 Labeled HuM195 Combined With Etoposide as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients With Advanced Myelodysplastic Syndrome and Refractory Leukemia||Memorial Sloan Kettering Cancer Center||Completed|April 2000|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006040||206329|
NCT00006166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASTRA (completed)|North American Study for the Treatment of Refractory Ascites (NASTRA)|The North American Study for the Treatment of Refractory Ascites (NASTRA) Clinical Trial||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 1997|October 2001||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2010|January 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006166||206213|
NCT00006125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-59906|Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma|A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)||Alliance for Clinical Trials in Oncology|No|Completed|July 2000|||August 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||July 2015|July 7, 2015|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006125||206249|
NCT00006090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068092|Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia|Phase II Study of Arsenic Trioxide (NSC #706363) Therapy for Fludarabine Refractory or Relapsed Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Withdrawn|June 2000|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|N/A|No|||October 2012|October 5, 2012|August 3, 2000||No|No enrollment.|No||https://clinicaltrials.gov/show/NCT00006090||206283|
NCT00006039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-101|Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma|Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|December 1999|March 2001|Actual|March 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006039||206330|
NCT00006064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1010|The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children|Effect of Antiretroviral Therapy on Body Composition in HIV-Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2000|February 2005|Actual|||N/A|Observational|N/A||||100|||Both|1 Month|12 Years|No|||October 2014|October 28, 2014|June 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006064||206305|
NCT00006154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-07-001|A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection|Randomized, Controlled, Open Label, Multi-Center Phase III Trial Comparing the Safety and Antiviral Activity of a Protease-Containing Regimen (d4T/ddI/IDV/RTV) Versus a Protease-Sparing Regimen (d4T/ddI/EFV) and the Ability of Interleukin-2 to Purge HIV From Latent Stores in Patients With Acute/Early HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|August 7, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006154||206225|
NCT00006164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALT C|Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment|Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)|HALT-C|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|June 2000|October 2009|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1050|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|August 8, 2000|Yes|Yes||No|June 9, 2009|https://clinicaltrials.gov/show/NCT00006164||206215|
NCT00006038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-066|Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer|A Phase II Trial of Neoadjuvant Cisplatin-Fluorouracil-Docetaxel Chemotherapy, Surgery, and Intraperitoneal (IP) Floxuridine (FUdR) Plus Leucovorin in Patients With Locally Advanced Gastric Cancer||Memorial Sloan Kettering Cancer Center||Completed|February 2000|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 17, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006038||206331|
NCT00006059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00645-2635|Genetic Study of Familial Epilepsy|||National Center for Research Resources (NCRR)||Completed|January 1997|||||N/A|Observational|Primary Purpose: Screening||||898|||Both|N/A|N/A|No|||December 2003|June 23, 2005|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006059||206310|
NCT00006075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 025|A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies|Phase IIA Study of Tolerance and Safety of Differing Concentrations of Chlorhexidine, for Peripartum Vaginal and Infant Washes, to Prevent Mother to Infant HIV-1 Transmission||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2007|Actual|||Phase 2|Interventional|Primary Purpose: Prevention||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2004|September 26, 2008|July 27, 2000||||No||https://clinicaltrials.gov/show/NCT00006075||206298|
NCT00006159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|carterj (completed)|Family-Centered Diabetes Project|Family-Centered Diabetes Project for Pueblo Native Americans||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 1994|January 2004|Actual|||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|February 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006159||206220|
NCT00006160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dahmsw (completed)|African-American Diabetes Intervention Project|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|6 Years|17 Years|No|||February 2010|February 12, 2010|August 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006160||206219|
NCT00006055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15105|Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases|||Office of Rare Diseases (ORD)||Active, not recruiting|March 2000|||||N/A|Interventional|Primary Purpose: Treatment||||10|||Both|1 Year|55 Years|No|||October 2003|June 23, 2005|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006055||206314|
NCT00006095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9971|Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy|A Trial of Irinotecan (NSC# 616348) Plus Vincristine in Children With Solid Tumors||Children's Oncology Group|Yes|Completed|July 2000|September 2005|Actual|January 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|1 Year|21 Years|No|||February 2014|February 20, 2014|August 3, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00006095||206278|
NCT00006124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00869|Celecoxib in Treating Patients With Bladder Cancer|Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer||National Cancer Institute (NCI)|No|Completed|June 2000|April 2008|Actual|March 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|152|||Both|18 Years|N/A|No|||January 2013|February 12, 2013|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006124||206250|
NCT00006083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068075|Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter|A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters||Jonsson Comprehensive Cancer Center|Yes|Completed|April 2000|November 2000|Actual|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||||||Both|18 Years|N/A|No|||July 2012|October 1, 2015|August 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006083||206290|
NCT00006077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000187|Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease|Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2000|July 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||July 2003|March 3, 2008|August 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006077||206296|
NCT00006100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068109|Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma|A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease||National Cancer Institute (NCI)||Active, not recruiting|April 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2005|December 17, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006100||206273|
NCT00006098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-031|PS-341 in Treating Patients With Hematologic Cancer|A Phase I Study of PS-341 in Patients With Hematologic Malignancies||Memorial Sloan Kettering Cancer Center||Completed|April 2000|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006098||206275|
NCT00006047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12177|Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide|Phase I Study of Combination Therapy With Oral 9-Nitrocamptothecin and Oral Etoposide||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|June 2000|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006047||206322|
NCT00006373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12246|Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|A Phase II Study of Intensive-Dose Topotecan, Ifosfamide/Mesna and Etoposide (Vepesid)(TIME) Followed by Autologous Stem Cell Rescue in High Risk Lymphoma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|February 2000|December 2011|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|64 Years|No|||June 2013|June 3, 2013|October 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006373||206027|
NCT00006078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-H-99-058|Lycopene In Preventing of Prostate Cancer|Single Dose Pharmacokinetic Study of Lycopene Delivered in a Well Defined Food-Based Lycopene Delivery System (Tomato Paste-oil Mixture) in Healthy Male Volunteers Between 18 and 45 Years of Age||National Cancer Institute (NCI)||Completed|June 2000|January 2005|Actual|||Phase 1|Interventional|Primary Purpose: Prevention|||||||Male|18 Years|45 Years|No|||December 2004|June 25, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006078||206295|
NCT00006046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068062|Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer|Phase I Study of Humanized 3S193 (Anti-Lewis-Y) Antibody in Patients With Advanced Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|January 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|February 6, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006046||206323|
NCT00006066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 402|Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems|Phase I/II Trial of Subcutaneous IL-2 With Highly Active Antiretroviral Therapy in HIV-Infected Children With Immunosuppression||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2006|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||92|||Both|2 Years|18 Years|No|||May 2012|May 17, 2012|July 14, 2000|No|Yes||||https://clinicaltrials.gov/show/NCT00006066||206304|
NCT00006104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 9823|Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer|A Multi-Institutional Phase II Pilot Trial With Weekly Docetaxel and Herceptin as First or Second Line Therapy for HER2/Neu Overexpressing Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|September 1998|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|46|||Female|18 Years|N/A|No|||August 2012|August 10, 2012|August 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006104||206269|
NCT00006044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-115|Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy|A Phase I Trial of Testosterone in Patients With Progressive Androgen-Independent Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|February 2000|||February 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||January 2013|January 17, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006044||206325|
NCT00006045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068061|Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia|Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML)||National Cancer Institute (NCI)||Active, not recruiting|March 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|November 5, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006045||206324|
NCT00006060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15245|Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis|||Office of Rare Diseases (ORD)|Yes|Recruiting|April 1999|||||N/A|Observational|N/A||||100|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 10, 2009|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00006060||206309|
NCT00006086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068078|BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer|Phase I Study of BMS-188797 in Combination With Carboplatin in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|June 2000|||February 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|September 8, 2010|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006086||206287|
NCT00006374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKF2598|Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized, Phase II Study of Topotecan/Paclitaxel vs Etoposide/Cisplatin as First-Line Therapy for Patients With Extensive Disease Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Withdrawn|October 1999|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|October 4, 2000|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00006374||206026|
NCT00006056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15106|Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders|||Office of Rare Diseases (ORD)||Active, not recruiting|March 2000|||||N/A|Interventional|Primary Purpose: Treatment||||40|||Both|N/A|55 Years|No|||October 2003|June 23, 2005|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006056||206313|
NCT00006073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000180|Endocrine Studies in Health and Disease|Endocrine Studies in Health and Disease||National Institutes of Health Clinical Center (CC)||Recruiting|July 2000|||||N/A|Observational|N/A|||Anticipated|3500|||Both|N/A|99 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|July 25, 2000||No||No||https://clinicaltrials.gov/show/NCT00006073||206299|
NCT00006030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASO-BREAST-BASO-II|Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer|Protocol of a Randomized Trial for the Management of Small Well-Differentiated and Special Type Carcinomas of the Breast||National Cancer Institute (NCI)||Active, not recruiting|January 1992|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|70 Years|No|||December 2006|August 6, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006030||206339|
NCT00006094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02357|Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum|A Phase I/II Study of Preoperative Oxaliplatin (NSC# 266046), 5-Fluorouracil, and External Beam Radiation Therapy in Locally Advanced Rectal Cancer||National Cancer Institute (NCI)||Completed|July 2000|||October 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|August 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006094||206279|
NCT00006080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068068|Fenretinide in Treating Patients With Recurrent Malignant Glioma|Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)||Completed|November 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2005|November 22, 2008|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006080||206293|
NCT00006052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068087|STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia|A Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Accelerated Phase||Novartis|No|Completed|June 2000|||June 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2014|January 30, 2014|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006052||206317|
NCT00005964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-C59910|Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|Randomized Phase II Study of Dose-Adjusted EPOCH vs. NHL-15 Chemotherapy for Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NHL)||Alliance for Clinical Trials in Oncology|No|Completed|May 2000|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|N/A|N/A|No|||July 2015|July 6, 2015|July 5, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00005964||206405|
NCT00005970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01849|Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer|Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|May 2000|||May 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3000|||Female|18 Years|N/A|No|||December 2014|March 11, 2016|July 5, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00005970||206399|
NCT00006145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5030|Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV|A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2000|February 2006|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||350|||Both|13 Years|N/A|No|||July 2013|July 8, 2013|August 7, 2000||||||https://clinicaltrials.gov/show/NCT00006145||206232|
NCT00006146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 00-009|Half-Dose Flu Vaccine Study in Healthy Adults|Evaluation of the Immunogenicity of Low Dose Trivalent Inactivated Influenza Vaccine in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2000|September 2000||||Phase 2|Interventional|Primary Purpose: Prevention||||840|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2005|August 26, 2010|August 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006146||206231|
NCT00006089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02356|Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy||National Cancer Institute (NCI)||Completed|March 2001|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Female|18 Years|N/A|No|||January 2014|January 10, 2014|August 3, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006089||206284|
NCT00006053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068088|STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa|A Study to Determine the Safety and Efficacy of STI571 in Patients With Chronic Myeloid Leukemia Who Are Hematologically or Cytogenetically Resistant or Refractory to Interferon-Alpha, or Intolerant of, Interferon-Alpha||Novartis|No|Completed|June 2000|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 16, 2013|July 5, 2000||No||No||https://clinicaltrials.gov/show/NCT00006053||206316|
NCT00006061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15077|Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency|||Office of Rare Diseases (ORD)||Completed|January 2000|January 2000||||N/A|Interventional|Primary Purpose: Treatment||||1|||Female|20 Years|20 Years|No|||July 2000|June 23, 2005|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006061||206308|
NCT00006081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-203|Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer|A Phase II Study of Bryostatin-1 (NSC 339555) Plus Paclitaxel in Patients With Metastatic or Unresectable Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction||M.D. Anderson Cancer Center|No|Completed|June 2000|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|August 3, 2000||No||No||https://clinicaltrials.gov/show/NCT00006081||206292|
NCT00006051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068073|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer|Combination Chemotherapy Concurrent With Postoperative Radiotherapy Epidermoid Carcinoma of the Head and Neck at High Risk of Recurrence - Study of Feasibility||National Cancer Institute (NCI)||Active, not recruiting|February 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||November 2001|February 6, 2009|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006051||206318|
NCT00006062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000172|Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction|Phase I Study of Oxaliplatin in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction||National Institutes of Health Clinical Center (CC)||Completed|July 2000|May 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||June 2000|March 3, 2008|July 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006062||206307|
NCT00006097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068104|Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia|CC-1088 Therapy for Chronic Lymphocytic Leukemia: A Phase I/II Trial||Boston Medical Center|Yes|Completed|August 1999|July 2005|Actual|July 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2001|September 21, 2010|August 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006097||206276|
NCT00006171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000193|Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma|A Study of the Effects of Potent Anti-HIV Therapy on Parameters Hypothesized to be Related to the Pathogenesis of Kaposi's Sarcoma (KS) in HIV-Infected Individuals||National Institutes of Health Clinical Center (CC)||Completed|August 2000|June 2012||||N/A|Observational|N/A|||Actual|24|||Both|13 Years|N/A|No|||June 2012|February 19, 2014|August 10, 2000||No||No||https://clinicaltrials.gov/show/NCT00006171||206208|
NCT00006057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15151|Diagnostic and Screening Study of Genetic Disorders|||National Center for Research Resources (NCRR)||Completed|December 1999|||||N/A|Observational|Primary Purpose: Screening||||50|||Both|N/A|N/A|No|||April 2002|June 23, 2005|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006057||206312|
NCT00006085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068077|CP-609,754 in Treating Patients With Advanced Solid Tumors|Phase I Open-Label Study of the Safety, Toleration and Pharmacokinetics of CP-609,754, a Farnesyl Transferase Inhibitor, in Subjects With Advanced Malignant Tumors||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2001|December 18, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006085||206288|
NCT00006036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I133|Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Study of NX 211 in Combination With Cisplatin Given as an IV Infusion Days 1, 2, and 3 Every 3 Weeks in Patients With Solid Tumors||Canadian Cancer Trials Group||Completed|April 2000|December 2009||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006036||206333|
NCT00006113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068125 (10M-99-1)|Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase II Trial of a MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Treated With CD40 Ligand/Gamma Interferon With Subcutaneous IL-2 for Patients With Metastatic Melanoma||University of Southern California|Yes|Terminated|June 1999|April 2006|Actual|May 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|August 3, 2000|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00006113||206261|
NCT00006072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0690|A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2000|June 23, 2005|July 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006072||206300|
NCT00006091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068094|Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment|Arsenic Trioxide Therapy for Interferon Alpha Refractory or Intolerant Chronic Phase Chronic Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Withdrawn|June 2000|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|N/A|No|||October 2012|October 5, 2012|August 3, 2000||No|No enrollment.|No||https://clinicaltrials.gov/show/NCT00006091||206282|
NCT00005971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I137|Flavopiridol in Treating Patients With Metastatic Malignant Melanoma|A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Previously Untreated Metastatic Malignant Melanoma||Canadian Cancer Trials Group||Completed|July 2000|December 2009|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00005971||206398|
NCT00006092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12395|Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia|A Phase II Study of Arsenic Trioxide for Induction Therapy of Adult Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Previously Untreated Chronic Myeloid Leukemia With Blast Crisis||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|August 2000|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|August 3, 2000|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00006092||206281|
NCT00006375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-076|LY293111 in Treating Patients With Advanced Solid Tumors|A Phase I Clinical and Pharmacokinetic Evaluation of LY293111 in Patients With Solid Tumors (Protocol H6H-MC-JEAI)||Memorial Sloan Kettering Cancer Center||Completed|June 2000|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006375||206025|
NCT00006079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID92-026|Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia|A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3||M.D. Anderson Cancer Center|No|Completed|June 2000|April 2004|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|150|||Female|18 Years|N/A|No|||July 2012|July 27, 2012|August 3, 2000||No||No||https://clinicaltrials.gov/show/NCT00006079||206294|
NCT00006034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRACEL-BCI-9804-04|Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer|A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer||National Cancer Institute (NCI)||Completed|June 1998|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||January 2006|May 14, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006034||206335|
NCT00006068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0746|Does Islet Transplantation Eliminate Hypoglycemia?|||National Center for Research Resources (NCRR)||Not yet recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2001|June 23, 2005|July 18, 2000||||No||https://clinicaltrials.gov/show/NCT00006068||206303|
NCT00006155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000197|SU5416 and Carboplatin to Treat Ovarian Cancer|A Phase I Study of SU5416, an Antiangiogenesis Agent, in Combination With Carboplatin in Patients With Platinum-Refractory Ovarian Cancer||National Institutes of Health Clinical Center (CC)||Completed|August 2000|April 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||33|||Female|N/A|N/A|No|||June 2000|March 3, 2008|August 9, 2000||||No||https://clinicaltrials.gov/show/NCT00006155||206224|
NCT00006033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALENTIS-IL2-2001|Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer|Protocol IL-2001: A Multi-Center, Open-Label, Randomized Study of the Efficacy and Safety of Multiple Intratumoral Injections of hIl-2 Plasmid (1.8 mg) Formulated With DOTMA/Cholesterol [Ratio 1:0.5(-/+)] Liposomes in Patients With Unresctable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|June 2000|June 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2001|May 29, 2013|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006033||206336|
NCT00006063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15154|Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis|||Office of Rare Diseases (ORD)||Completed|July 1999|August 1999||||N/A|Interventional|Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||July 2000|June 23, 2005|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006063||206306|
NCT00006076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000176|Genetic Studies of Tone Deafness|Genetic Studies of Tune Deafness||National Institutes of Health Clinical Center (CC)||Completed|July 2000|June 2010||||N/A|Observational|N/A|||Actual|968|||Both|15 Years|N/A|No|||June 2010|September 26, 2015|July 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00006076||206297|
NCT00006101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068110|Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer|Randomized Placebo-Controlled, Double-Blind Phase IIb Chemoprevention Trial of Difluoromethylornithine in Brothers and First Cousin Males of Familial Prostate Cancer Probands||University of California, Irvine|Yes|Completed|October 1998|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|140|||Male|35 Years|70 Years|No|||March 2016|March 23, 2016|August 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006101||206272|
NCT00006058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1630|Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns|Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns||National Center for Research Resources (NCRR)||Completed|September 1996|||||N/A|Observational|Primary Purpose: Screening||||200|||Both|N/A|N/A|No|||December 2003|June 23, 2005|July 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006058||206311|
NCT00006096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068103|Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva|A Randomized Study of Adjuvant Radiation Treatment Versus Radiation and Chemotherapy in Patients With Vulvar Cancer and Involved Nodes||Gynecologic Oncology Group||Terminated|March 2001|||January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||June 2007|June 7, 2013|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006096||206277|
NCT00006372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1Y99|Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I Trial of Combination Pegylated Liposomal Doxorubicin (Doxil), Vinorelbine, and Gemcitabine||Case Comprehensive Cancer Center|Yes|Completed|February 2000|February 2005|Actual|April 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006372||206028|
NCT00006119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068132|Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma|Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma||National Cancer Institute (NCI)||Active, not recruiting|July 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||December 2004|July 23, 2008|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006119||206255|
NCT00006344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068152|Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer|A Randomized, Phase III Dose Response Study of Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Lung||Virginia Commonwealth University|No|Withdrawn|May 2000|December 2000|Actual|December 2000|Actual|Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||May 2015|May 15, 2015|October 4, 2000||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00006344||206056|
NCT00006378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMP1598|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|Phase II Randomized Study of Taxol (PACLITAXEL), Paraplatin (Carboplatin), and Radiation Therapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|December 1999|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|5|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|October 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006378||206022|
NCT00006334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000219|Turner Syndrome: Genotype and Phenotype|Turner Syndrome: Genotype and Phenotype||National Institutes of Health Clinical Center (CC)||Completed|September 2000|July 2014||||N/A|Observational|N/A|||Actual|1017|||Both|10 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 9, 2014|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006334||206065|
NCT00006299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000027|Celebrex for Pain Relief After Oral Surgery|In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model||National Institutes of Health Clinical Center (CC)||Completed|December 1999|February 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||February 2004|March 3, 2008|September 27, 2000||||No||https://clinicaltrials.gov/show/NCT00006299||206097|
NCT00006413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010010|Stem Cell Transplantation to Treat Systemic Mastocytosis|Low Intensity Preparative Regimen Followed by HLA-Matched, Mobilized Peripheral Blood Stem Cell Transplantation for Systemic Mastocytosis||National Institutes of Health Clinical Center (CC)||Completed|October 2000|December 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||25|||Both|2 Years|80 Years|No|||December 2006|February 24, 2007|October 17, 2000||||No||https://clinicaltrials.gov/show/NCT00006413||205988|
NCT00006415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-08-004|A Study of Patients Who Recently Have Been Infected With HIV|Evaluation of Subjects With Primary or Early Human Immunodeficiency Virus (HIV) Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|October 19, 2000||||No||https://clinicaltrials.gov/show/NCT00006415||205986|
NCT00006278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000178|Study of Cushing's Syndrome Not Related to ACTH Production|The Molecular and Cellular Etiology of ACTH-Independent Adrenal Disease||National Institutes of Health Clinical Center (CC)||Completed|September 2000|September 2002||||N/A|Observational|N/A||||18|||Both|N/A|N/A|No|||September 2002|March 3, 2008|September 14, 2000||||No||https://clinicaltrials.gov/show/NCT00006278||206111|
NCT00006383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068259|Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma|Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B-Cell Non-Hodgkin's Lymphoma That is Refractory or Relapsed After Second-Line Combination Chemotherapy Revised Title Per 03/01 SR Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Aggressive Non-Hodgkin's Lymphoma That is Refractory to or Relapsed After Second-Line Combination Chemotherapy||National Cancer Institute (NCI)||Completed|June 2000|August 2009|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|November 5, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006383||206017|
NCT00006366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-R-0012|Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum|Randomized Phase II Trial of Preoperative Combined Modality Chemoradiation for Distal Rectal Cancer||Radiation Therapy Oncology Group|Yes|Completed|February 2001|||December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|July 17, 2013|October 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006366||206034|
NCT00006367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006.00|Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis|Autologous Peripheral Blood Stem Cell Mobilization and Transplantation for Myelofibrosis||Fred Hutchinson Cancer Research Center||Completed|May 2000|January 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|75 Years|No|||June 2010|June 15, 2010|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006367||206033|
NCT00006285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000177|Use of Transcranial Magnetic Stimulation (TMS) and Magnetic Resonance Imaging (MRI) to Study Visual Attention|Transcranial Magnetic Stimulation Studies of Visual Attention||National Institutes of Health Clinical Center (CC)||Completed|September 2000|April 2002|Actual|April 2002|Actual|N/A|Observational|N/A||||30|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2009|August 27, 2009|September 16, 2000||No||No||https://clinicaltrials.gov/show/NCT00006285||206108|
NCT00006306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134|Effects of Chronic Ozone Exposure on Lung Function|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2004|Actual|||N/A|Observational|N/A|||||||Both|18 Years|21 Years|No|||January 2006|February 26, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006306||206092|
NCT00006312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920|Hemochromatosis--Genetic Prevalence and Penetrance|||University of Rochester||Completed|July 1999|May 2003||||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2016|January 14, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006312||206086|
NCT00006327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX 003|Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand|A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand||NIH AIDS Clinical Trials Information Service||Completed|March 1999|August 2000||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||2500|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2003|June 23, 2005|October 2, 2000||||No||https://clinicaltrials.gov/show/NCT00006327||206072|
NCT00006279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 023|The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months|Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2005|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||75|||Both|N/A|N/A|No|||February 2012|February 13, 2012|September 14, 2000||||No||https://clinicaltrials.gov/show/NCT00006279||206110|
NCT00006363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02824|Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia|Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML &lt; 60 Years||National Cancer Institute (NCI)||Completed|November 2000|||June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|720|||Both|15 Years|59 Years|No|||June 2013|June 3, 2013|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006363||206037|
NCT00006307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|915|Epidemiology of Body Mass Index Rebound|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2000|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Both|3 Years|7 Years|No|||January 2008|February 17, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006307||206091|
NCT00006308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|916|Observational Cohort Study of Sodium, Weight and Cardiovascular Disease|Observational Cohort Study of Sodium, Weight and Cardiovascular Disease||Brigham and Women's Hospital|No|Completed|September 1999|August 2004|Actual|August 2004|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||May 2014|May 7, 2014|September 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00006308||206090|
NCT00006345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIGAND-L4389-MR-9901|Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma|An Evaluation of Corticosteroid Pretreatment in Cutaneous T-Cell Lymphoma Patients Receiving Ontak (Denileukin Difitox)||National Cancer Institute (NCI)||Completed|November 1999|March 2004|Actual|||Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||November 2001|May 29, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006345||206055|
NCT00006300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000113|Oral Manifestations of Aplastic Anemia|Oral Manifestations of Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Completed|April 2000|April 2002||||N/A|Observational|N/A||||146|||Both|N/A|N/A|No|||April 2002|March 3, 2008|September 27, 2000||||No||https://clinicaltrials.gov/show/NCT00006300||206096|
NCT00006343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068089|STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia|A Phase III Study of STI571 Versus Interferon-a (IFN-a) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||Novartis|No|Completed|June 2000|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||December 2012|December 30, 2012|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006343||206057|
NCT00006255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2Y00|Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases|A Phase II Study of Magnetic Resonance Guided and Monitored Interstitial Thermal Radiofrequency Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases||Case Comprehensive Cancer Center|Yes|Completed|April 2000|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|September 11, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00006255||206132|
NCT00006256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2199|Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer|Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy||Case Comprehensive Cancer Center|Yes|Active, not recruiting|June 2000|July 2016|Anticipated|November 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||July 2015|July 24, 2015|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006256||206131|
NCT00006708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068320|S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT||Southwest Oncology Group|Yes|Terminated|October 2000|November 2006|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|December 6, 2000|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00006708||205870|
NCT00006721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068321|S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma|A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas||Southwest Oncology Group|Yes|Active, not recruiting|March 2001|||September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|571|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|December 6, 2000|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT00006721||205869|
NCT00006734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS0031|Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor|Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors||Children's Oncology Group|Yes|Completed|May 2001|||August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|587|||Both|N/A|50 Years|No|||May 2013|May 16, 2013|December 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006734||205868|
NCT00006414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010002|Hand Exercise and Upper Arm Anesthesia to Improvements Hand Function in Chronic Stroke Patients|Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia||National Institutes of Health Clinical Center (CC)||Completed|October 2000|March 2006||||N/A|Observational|N/A||||12|||Both|N/A|N/A|No|||March 2006|March 3, 2008|October 17, 2000||||No||https://clinicaltrials.gov/show/NCT00006414||205987|
NCT00006326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228H|Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir|A Randomized, Open-Label Study to Evaluate 3 Salvage Regimens in HIV-Infected Subjects Experiencing Virologic Failure on an Initial HAART Regimen Containing Nelfinavir||NIH AIDS Clinical Trials Information Service||Terminated|August 2000|||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||July 2002|June 23, 2005|October 2, 2000||||No||https://clinicaltrials.gov/show/NCT00006326||206073|
NCT00006337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010001|KW-6002 to Treat Parkinson's Disease|Adenosine A2A Blockade With KW-6002 in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2000|January 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||16|||Both|N/A|N/A|No|||January 2002|March 3, 2008|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006337||206062|
NCT00006316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5038|Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs|Discontinuation of Antifungal Therapy for Histoplasmosis Following Immunologic Response to Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||50|||Both|13 Years|N/A|No|||February 2004|July 30, 2008|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006316||206082|
NCT00006318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000226|Role of Prostaglandins in the Regulation of Brain Blood Flow|Role of Prostaglandins in the Control of Cerebral Blood Flow During Hypercapnia and Functional Activation in Humans||National Institutes of Health Clinical Center (CC)||Completed|September 2000|December 2003||||N/A|Observational|N/A||||125|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2003|March 3, 2008|September 30, 2000||||No||https://clinicaltrials.gov/show/NCT00006318||206081|
NCT00006350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068212|Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies After a Non-Myeloablative Conditioning Regimen From HLA-Matched Sibling Donors||National Cancer Institute (NCI)||Active, not recruiting|April 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2002|February 6, 2009|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006350||206050|
NCT00006263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068203|Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma|Phase II Trial of Temozolomide, Carboplatin and Neupogen in High-Grade Gliomas, Both Newly-Diagnosed and Recurrent||New York University School of Medicine||Withdrawn|November 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|64 Years|No|||August 2015|August 3, 2015|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006263||206124|
NCT00006578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5072|Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication|Evaluation of the Relationship Between Immunologic Recovery After Highly Active Antiretroviral Therapy and the Ability to Mobilize CD34+ Stem Cells Following G-CSF Administration||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||June 2003|March 5, 2015|December 1, 2000||||No||https://clinicaltrials.gov/show/NCT00006578||205880|
NCT00006591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|313A|Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment|The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2004|June 23, 2005|December 1, 2000||||No||https://clinicaltrials.gov/show/NCT00006591||205879|
NCT00006324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 021|Hormonal Birth Control and the Risk of Acquiring HIV|Hormonal Contraception and the Risk of HIV Acquisition||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 1999|December 2002||||N/A|Interventional|Primary Purpose: Treatment||||6360|||Female|16 Years|35 Years|Accepts Healthy Volunteers|||November 2006|August 6, 2008|October 2, 2000||||No||https://clinicaltrials.gov/show/NCT00006324||206075|
NCT00006368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVARTIS-SMT-B151|Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer|A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors||Novartis||Completed|January 1998|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006368||206032|
NCT00006340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064947|Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus|A PHASE I TRIAL OF BUTYRATE AND GANCICLOVIR IN EBV-ASSOCIATED MALIGNANCIES||Boston Medical Center||Completed|December 1994|July 2000|Actual|July 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|3 Years|N/A|No|||July 2013|July 25, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006340||206060|
NCT00006313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921|Hormone Therapy Effects on CVD Risk Factors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1999|June 2000|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|100 Years|No|||September 2002|February 25, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006313||206085|
NCT00006257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068191|SU5416 and Paclitaxel in Treating Patients With Advanced Cancer|Phase I Trial of SU5416 in Combination With Weekly Paclitaxel in Patients With Advanced Malignancies||City of Hope Medical Center||Completed|November 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 11, 2010|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006257||206130|
NCT00006376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068250|R115777 in Treating Patients With Advanced Bladder Cancer|A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma||National Cancer Institute (NCI)||Completed|March 2000|May 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2005|December 3, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006376||206024|
NCT00006258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLA-NYU-0002H|Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma|Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation||National Cancer Institute (NCI)||Completed|November 1997|January 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|10 Years|65 Years|No|||December 2004|July 17, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006258||206129|
NCT00006259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3399|Stereotactic Radiation Therapy in Treating Patients With Brain Metastases|A Phase II Trial of Radiosurgery Alone for Brain Metastases in Elderly Patients or Patients With Poor Performance Status||Case Comprehensive Cancer Center|Yes|Completed|January 2000|February 2005|Actual|November 2001|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006259||206128|
NCT00006323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|926|Neurobehavioral Consequences of Sleep Apnea in Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|July 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2005|February 24, 2016|October 2, 2000||||No||https://clinicaltrials.gov/show/NCT00006323||206076|
NCT00006747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068324|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma|Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma||Alliance for Clinical Trials in Oncology|No|Terminated|November 2000|||January 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|59 Years|No|||September 2013|September 25, 2013|December 6, 2000|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00006747||205867|
NCT00006399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0023|Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease|Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease||National Institute on Aging (NIA)||Completed|September 1999|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||45|||Female|45 Years|85 Years|No|||January 2009|January 13, 2009|August 18, 2000||||No||https://clinicaltrials.gov/show/NCT00006399||206001|
NCT00006339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-03-001|Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection|A Prospective Randomized Open-Label Clinical Trial to Evaluate the Comparative Efficacy and Safety of a Potent Antiretroviral Treatment Regimen With or Without Hydroxyurea for Subjects With Acute HIV-1 Infection or Recent HIV-1 Seroconversion||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|0|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006339||206061|
NCT00006264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-019|Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma|A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma||AIDS Malignancy Consortium||Completed|July 2000|July 2003|Actual|March 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||February 2016|February 1, 2016|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006264||206123|
NCT00006330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1693|Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2001|June 23, 2005|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006330||206069|
NCT00006351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16997|SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract|Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 2000|||December 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|34|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006351||206049|
NCT00006656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068207|Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||August 2003|November 5, 2013|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006656||205874|
NCT00006336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000227|Sensory Training to Treat Focal Dystonia|Sensory Training for Treatment of Focal Dystonia||National Institutes of Health Clinical Center (CC)||Completed|September 2000|November 2001||||N/A|Observational|N/A||||22|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2001|March 3, 2008|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006336||206063|
NCT00006377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-073|Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer|Phase II Study of Sequential Administration of Doxorubicin, Paclitaxel, and Carboplatin in Patients With Advanced and Recurrent Endometrial Cancer||Memorial Sloan Kettering Cancer Center||Completed|June 2000|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 17, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006377||206023|
NCT00006320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000213|Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women|Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women||National Institutes of Health Clinical Center (CC)||Completed|September 2000|July 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Female|N/A|N/A|No|||July 2004|March 3, 2008|September 30, 2000||||No||https://clinicaltrials.gov/show/NCT00006320||206079|
NCT00006321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|924|Neurocognitive Function in Snoring Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A|||||||Both|6 Years|10 Years|No|||July 2008|July 23, 2008|October 2, 2000||||No||https://clinicaltrials.gov/show/NCT00006321||206078|
NCT00006322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|925|Birth Weight Effect on Blood Pressure in Late Childhood|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1999|June 2003|Actual|||N/A|Observational|N/A|||||||Both|11 Years|13 Years|No|||March 2005|March 15, 2016|October 2, 2000||||No||https://clinicaltrials.gov/show/NCT00006322||206077|
NCT00006314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|922|Cytomegalovirus Spread and Reactivation in Blood Cells|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1999|June 2004|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2006|February 23, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006314||206084|
NCT00006315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|923|Dose/Response of Exercise on Long Term Weight Loss|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2004|Actual|||N/A|Observational|N/A|||||||Female|25 Years|45 Years|No|||May 2005|February 23, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006315||206083|
NCT00006389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02361|Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer|A Phase II Combination Trial of Bryostatin-1 and Cisplatin in the Treatment of Metastatic Gastric Cancer||National Cancer Institute (NCI)||Completed|October 2000|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2013|September 26, 2014|October 4, 2000|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00006389||206011|Of 12 pts accrued\treated, none responded. The initial phase accrual goal was 15, but given the 12 non-responders, we determined the probability of 3 future pts all responding (stochastic curtailed sampling) at 2.7%. Decided to terminate the trial.
NCT00006270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15376|Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury|||National Center for Research Resources (NCRR)||Active, not recruiting|February 1998|||||N/A|Observational|Primary Purpose: Screening||||32|||Both|20 Years|35 Years|No|||December 2003|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006270||206118|
NCT00006335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000223|Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID|Decisions of Female Adolescents About Carrier Testing in Families With X-Linked Severe Combined Immunodeficiency (XSCID)||National Institutes of Health Clinical Center (CC)||Completed|September 2000|||September 2008|Actual|N/A|Observational|N/A||||40|||Female|13 Years|17 Years|No|||September 2009|September 24, 2009|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006335||206064|
NCT00006362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068233|PS-341 in Treating Patients With Advanced Cancer|A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Patients With Advanced Solid Tumors and B-cell Lymphoproliferative Disorders||Mayo Clinic|Yes|Completed|November 1999|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2011|August 1, 2011|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006362||206038|
NCT00006394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15433|Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency|||National Center for Research Resources (NCRR)||Completed|April 1997|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||December 2003|June 23, 2005|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006394||206006|
NCT00006395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010005|Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers|Evaluation of the Effect of St. John's Wort on Single Dose Carbamazepine Pharmacokinetics in Normal Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 2000|April 2001||||Phase 4|Interventional|Primary Purpose: Treatment||||12|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2000|March 3, 2008|October 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006395||206005|
NCT00006517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3032/R01 MH42931-01|Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)|Light and Ion Therapy for Seasonal Affective Disorder||New York State Psychiatric Institute|No|Completed|September 1998|April 2004|Actual|June 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|150|||Both|18 Years|70 Years|No|||November 2005|June 2, 2015|November 22, 2000||No||No||https://clinicaltrials.gov/show/NCT00006517||205887|
NCT00006309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|917|Pooling of Cohort Studies on Diet & Coronary Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2002|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2004|February 17, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006309||206089|
NCT00006271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15377|Phase I/II Study of Neuroendocrine Dysfunction in Patients With Closed Head Injuries|||National Center for Research Resources (NCRR)||Active, not recruiting|January 1997|||||N/A|Observational|Primary Purpose: Screening||||100|||Both|18 Years|N/A|No|||December 2003|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006271||206117|
NCT00006412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5087|Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids|A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2003|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||630|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|October 13, 2000||||No||https://clinicaltrials.gov/show/NCT00006412||205989|
NCT00006418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059571|Molecular Genetics of Schizophrenia|||NorthShore University HealthSystem||Completed|September 2003|August 2007||||N/A|Observational|N/A|||Anticipated|10800|||Both|18 Years|N/A|No|||November 2005|April 1, 2014|October 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006418||205984|
NCT00006419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|935|Diet and Chronic Obstructive Pulmonary Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2000|June 2004|Actual|||N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||May 2005|March 15, 2016|October 26, 2000||||No||https://clinicaltrials.gov/show/NCT00006419||205983|
NCT00006310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|918|KSHV Infection in Blood Donors From Texas|KSHV Seroprevalence in Hospital Patients From San Antonio||The University of Texas Health Science Center at San Antonio|No|Completed|April 1999|March 2004||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2016|March 8, 2016|September 28, 2000||No||No||https://clinicaltrials.gov/show/NCT00006310||206088|
NCT00006311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|919|Anxiety and Vagal Control of the Heart in Coronary Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 1999|May 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2006|February 17, 2016|September 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006311||206087|
NCT00006328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1678|Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy|||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Retrospective|||||||Both|18 Years|N/A|No|||December 2003|June 23, 2005|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006328||206071|
NCT00006329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1660|Comparison of Two Methods of Parathyroidectomy for Primary Hyperparathyroidism|||National Center for Research Resources (NCRR)||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||November 2001|June 23, 2005|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006329||206070|
NCT00006356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55963|Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer|A Randomized Phase III Study for the Treatment of Recurrent Epithelial Ovarian Cancer: Chemotherapy Alone Versus Chemotherapy Followed by Secondary Cytoreductive Surgery in Patients With a Treatment-Free Interval of More Than 12 Months||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|August 2000|||October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|38|||Female|18 Years|N/A|No|||September 2012|September 20, 2012|October 4, 2000|||low accrual|No||https://clinicaltrials.gov/show/NCT00006356||206044|
NCT00006357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62001-16003|STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma|Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 2000|||April 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|91|||Both|15 Years|N/A|No|||September 2012|September 20, 2012|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006357||206043|
NCT00006358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068227|Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor|Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|May 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2006|July 23, 2008|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006358||206042|
NCT00006333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000222|Study of Arthritis and Related Conditions|Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions||National Institutes of Health Clinical Center (CC)||Recruiting|September 2000|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|N/A|N/A|No|||January 2016|February 3, 2016|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006333||206066|
NCT00006248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068180|S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Evaluation of Three Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Southwest Oncology Group|Yes|Completed|November 2000|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006248||206139|
NCT00006223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068143|flt3L in Treating Patients With Acute Myeloid Leukemia|A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission||National Cancer Institute (NCI)||Completed|July 2000|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2006|June 20, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006223||206162|
NCT00006224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068144|Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix|Evaluation of Gemcitabine in Persistent or Recurrent Non-Squamous Cell Carcinoma of the Cervix||Gynecologic Oncology Group||Terminated|September 2000|||April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2005|April 10, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006224||206161|
NCT00006275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15372|Study of Topical Calcitriol in Children With Psoriasis|||Office of Rare Diseases (ORD)||Completed|July 2000|July 2000||||N/A|Interventional|Primary Purpose: Treatment||||20|||Both|4 Years|18 Years|No|||September 2000|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006275||206113|
NCT00006276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000211|Micellar Paclitaxel to Treat Severe Psoriasis|A Pilot Open-Label Single-Dose Study Using Intravenous Micellar Paclitaxel for Patients With Severe Psoriasis||National Institutes of Health Clinical Center (CC)||Completed|September 2000|October 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||October 2002|March 3, 2008|September 14, 2000||||No||https://clinicaltrials.gov/show/NCT00006276||206112|
NCT00006243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02359|Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma|Melanoma Vaccines: Differentiation Antigen Peptides (MART-1:27-35, Tyrosinase and Gp-100) as Immune Targets||National Cancer Institute (NCI)||Completed|October 2000|||May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006243||206144|
NCT00006190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lipod (completed)|A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy|The Study of Mechanisms of Lipodystrophy in HIV-Infected Patients||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|November 2000|November 2001||||Phase 4|Interventional|Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|70 Years|No|||March 2010|March 1, 2010|August 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006190||206191|
NCT00006341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066588|Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer|Efficacy of Implant-Supported Maxillofacial Prostheses||Jonsson Comprehensive Cancer Center|No|Completed|June 1997|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|46|||Both|35 Years|80 Years|No|||January 2016|January 29, 2016|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006341||206059|
NCT00006325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1017|Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children|Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of PEG-Intron in HIV-1 Infected Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2004|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||54|||Both|3 Months|16 Years|No|||May 2012|May 18, 2012|October 2, 2000||||||https://clinicaltrials.gov/show/NCT00006325||206074|
NCT00006209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311A|A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs|A Phase I Open-Label Dose Escalation Trial of Tucaresol in HIV-1 Infected Subjects Taking Potent Antiretroviral Therapy||NIH AIDS Clinical Trials Information Service||Active, not recruiting|June 2000|||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006209||206174|
NCT00006187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0025|The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease|||National Institute on Aging (NIA)||Terminated||June 2005|Anticipated|June 2005|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||October 2003|December 10, 2009|August 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006187||206193|
NCT00006127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15281|Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia|||Office of Rare Diseases (ORD)||Active, not recruiting|April 2000|||||Phase 1|Interventional|Primary Purpose: Treatment||||21|||Both|2 Years|N/A|No|||October 2003|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006127||206247|
NCT00006272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00750-9045|Study of Energy Expenditure in Infants With Ventricular Septal Defects|Study of Energy Expenditure in Infants With Ventricular Septal Defects||National Center for Research Resources (NCRR)||Recruiting|August 1994|||||N/A|Observational|Observational Model: Natural History||||20|||Both|3 Months|4 Months|Accepts Healthy Volunteers|||December 2003|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006272||206116|
NCT00006221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068141|BMS-247550 in Treating Patients With Advanced Cancers|A Phase I Study of BMS-247550 (NSC 710428) Given Weekly X 3 Every 4 Weeks in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|November 2000|||June 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||July 2004|February 8, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006221||206164|
NCT00006241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1488.00|Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma|A Pivotal Study to Determine the Safety and Efficacy of Using B-Cell High Density Microparticles (BCell-HDM) to Deplete B-Cells From Peripheral Blood Stem Cell Collections Without Compromising the Time to Neutrophil and Platelet Engraftment in Patients With Relapsed Low or Intermediate Grade B-Cell Non-Hodgkin's Lymphoma Given Autologous Peripheral Blood Stem Cell Transplants After High-Dose Chemotherapy||Fred Hutchinson Cancer Research Center||Completed|March 2000|October 2000|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||November 2011|November 28, 2011|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006241||206146|
NCT00006214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-959257|Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate|Short-Term Chemoprevention Trial in Men With Prostatic Intraepithelial Neoplasia Using Flutamide as an Androgen Deprivation Agent||Alliance for Clinical Trials in Oncology|No|Completed|August 2000|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|63|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006214||206170|
NCT00006216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068049|Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma|Treatment of Malignant Pleural Mesothelioma With Gene Modified Cancer Cell Lines||National Cancer Institute (NCI)||Active, not recruiting|August 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2001|September 19, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006216||206168|
NCT00006786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068328|Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer|Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer||National Cancer Institute (NCI)||Completed|November 2000|September 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2006|June 20, 2013|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006786||205864|
NCT00006242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00032|BMS-214662 in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Farnesyltransferase Inhibitor BMS-214662 (NSC 710086) Escalating to a 24 Hour Continuous Intravenous Infusion in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|July 2000|||September 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006242||206145|
NCT00006222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02358|EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase I Trial of EMD 121974 in Patients With HIV Related Kaposi's Sarcoma||National Cancer Institute (NCI)||Terminated|September 2000|March 2001|Actual|March 2001|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2001|May 31, 2013|September 11, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00006222||206163|
NCT00006239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068164, J9879|Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer|A Phase I, Dose-Finding Trial of Sodium Phenylbutrate (NSC 657802) in Combination With All Trans-retinoic Acid (ATRA, NSC 122758) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)||Sidney Kimmel Comprehensive Cancer Center||Completed|December 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|March 9, 2010|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006239||206148|
NCT00006319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000209|Molecular and Clinical Studies of Primary Immunodeficiency Diseases|Molecular and Clinical Studies of Primary Immunodeficiency Diseases||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|September 2000|||||N/A|Observational|N/A|||Actual|246|||Both|N/A|N/A|No|||February 2016|February 19, 2016|September 30, 2000||No||No||https://clinicaltrials.gov/show/NCT00006319||206080|
NCT00006251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1533.00|Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer|Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|May 2000|||September 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|74 Years|No|||August 2015|August 3, 2015|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006251||206136|
NCT00006199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00096-1001|Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)|||National Center for Research Resources (NCRR)||Recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|June 23, 2005|September 9, 2000||||No||https://clinicaltrials.gov/show/NCT00006199||206183|
NCT00006191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000207|Effect of Levetiracetam on Brain Excitability|Effects of Levetiracetam on Cortical Excitability in Humans||National Institutes of Health Clinical Center (CC)||Completed|August 2000|June 2001||||N/A|Observational|N/A||||14|||Both|N/A|N/A|No|||August 2000|March 3, 2008|August 29, 2000||||No||https://clinicaltrials.gov/show/NCT00006191||206190|
NCT00006254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-008|VNP20009 in Treating Patients With Advanced Solid Tumors|A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration||National Cancer Institute (NCI)||Completed|May 2000|January 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|July 17, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006254||206133|
NCT00006202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000208|Lutein for Age-Related Macular Degeneration|Dose Ranging Study of Lutein Supplementation in Persons Over Age 60||National Institutes of Health Clinical Center (CC)||Completed|September 2000|August 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||45|||Both|N/A|N/A|No|||August 2003|March 3, 2008|September 9, 2000||||No||https://clinicaltrials.gov/show/NCT00006202||206181|
NCT00006196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0754|The Relationship Between Vitamin D, Fingernail Thickness and Bone Density|||National Center for Research Resources (NCRR)||Completed||||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Female|25 Years|75 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|September 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006196||206185|
NCT00006128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15289|Study of Neurobehavioral Outcome in Children or Adolescents With Closed Head Injuries|||National Center for Research Resources (NCRR)||Recruiting|July 1998|||||N/A|Observational|Primary Purpose: Screening||||374|||Both|N/A|12 Years|No|||December 2003|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006128||206246|
NCT00006280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inhaled Tobramycin (completed)|A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis|A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2000|February 2002||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||98|||Both|6 Months|5 Years|No|||March 2010|March 1, 2010|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006280||206109|
NCT00006211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286E|A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments|A Double-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With VIRACEPT and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen||NIH AIDS Clinical Trials Information Service||Completed|February 2000|April 2001||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||March 2001|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006211||206173|
NCT00006215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067941|Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|October 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2001|December 18, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006215||206169|
NCT00006231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068155|Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma|A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma||National Cancer Institute (NCI)||Completed|February 1998|December 2002|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|44|||Both|N/A|N/A|No|||October 2000|December 18, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006231||206154|
NCT00006799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068329|Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer|A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy||Wake Forest Baptist Health||Completed|October 2000|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006799||205863|
NCT00006812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068330|Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer|Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer||Gynecologic Oncology Group||Terminated|March 2001|||July 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||November 2005|April 10, 2013|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006812||205862|
NCT00006253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA079280|Pain and Fatigue Study|Family Home Care for Cancer - A Community-Based Model||Michigan State University|No|Completed|March 2003|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|350|||Both|21 Years|N/A|No|||December 2011|December 6, 2011|September 11, 2000||No||No||https://clinicaltrials.gov/show/NCT00006253||206134|
NCT00006235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068160|Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I Trial of Combination Carboplatin and Lipsomal Doxorubicin (Doxil) In Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Gynecologic Oncology Group||Completed||||February 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||February 2006|July 8, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006235||206150|
NCT00006237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0008|S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma|Phase III Trial of High Dose Interferon Alfa 2-b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma||Southwest Oncology Group|Yes|Completed|August 2000|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|432|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|September 11, 2000|Yes|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00006237||206149|
NCT00006252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068185|Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma|Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells||Alliance for Clinical Trials in Oncology|No|Completed|February 2001|October 2011|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|N/A|69 Years|No|||April 2011|September 25, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006252||206135|
NCT00006331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1699|Prospective Controlled Study of Posttransplant Diabetes|||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|No|||December 2003|June 27, 2005|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006331||206068|
NCT00006332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1707|Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate|||National Center for Research Resources (NCRR)||Completed||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|June 23, 2005|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006332||206067|
NCT00006212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067812|Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer|Phase I Study of Interstitial Colloidal 32P Integrated With External Radiation Therapy and Chemotherapy in the Treatment of Non-Resectable or Medically Inoperable Non-Small Cell Carcinoma of the Lung||National Cancer Institute (NCI)||Active, not recruiting|November 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2001|September 16, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006212||206172|
NCT00006172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3554/R01 MH42931-02|Clinical Trials of Two Non-drug Treatments for Chronic Depression|Light and Negative Ion Treatment for Chronic Depression||New York State Psychiatric Institute|No|Completed|April 2000|February 2004|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|65 Years|No|||March 2008|September 30, 2014|August 11, 2000||No||No||https://clinicaltrials.gov/show/NCT00006172||206207|
NCT00006192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910|Genetics of Coronary Artery Disease in Alaskan Natives (GOCADAN)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2000|December 2005|Actual|December 2005|Actual|N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||May 2009|May 1, 2009|August 31, 2000||||No||https://clinicaltrials.gov/show/NCT00006192||206189|
NCT00006262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 00G1|Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer|A Phase 2 Study of BMY-27557-14 (a Rebeccamycin Analog) in Patients With Ovarian Cancer||Northwestern University|Yes|Terminated|July 2000|September 2001|Actual|September 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|21 Years|N/A|No|||June 2012|June 7, 2012|September 11, 2000|Yes|Yes|Unable to accrue patients to the study.|No||https://clinicaltrials.gov/show/NCT00006262||206125|
NCT00006115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068128|Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|Alternation of FOLFOX6 (Oxaliplatin - Leucovorin - Fluorouracil) and FOLFIRI (Irinotecan - Leucovorin - Fluorouracil) as Second Line Treatment of Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||January 2002|January 10, 2009|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006115||206259|
NCT00006129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15290|Randomized Study of Testosterone and Progressive Resistance Exercise in Men With Burn Injury|||National Center for Research Resources (NCRR)||Recruiting|June 2000|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||60|||Male|18 Years|50 Years|No|||December 2003|June 23, 2005|August 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006129||206245|
NCT00006267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068210|Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of 9-Nitro-Camptothecin In The Third-Line Treatment Of Recurrent Ovarian Or Primary Peritoneal Cancer||Gynecologic Oncology Group||Withdrawn||||May 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Female|N/A|N/A|No|||May 2004|July 8, 2013|September 11, 2000|||Never activated.|No||https://clinicaltrials.gov/show/NCT00006267||206121|
NCT00006233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1462.00|Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma|Phase II Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low-Dose TBI, and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil (MMF) Followed by Donor Lymphocyte Infusion in Selected Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center||Completed|January 2000|December 2003|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|64 Years|No|||November 2011|November 28, 2011|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006233||206152|
NCT00006234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1474.00|Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone|A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease||Fred Hutchinson Cancer Research Center||Completed|November 2001|March 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||November 2011|November 30, 2011|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006234||206151|
NCT00006229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR18|Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer|A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer||Canadian Cancer Trials Group|Yes|Completed|April 2000|February 2009|Actual|December 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|774|||Both|18 Years|N/A|No|||August 2011|November 11, 2013|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006229||206156|
NCT00006230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16996O|Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer|Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced Ovarian Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2000|||April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|51|||Female|18 Years|N/A|No|||September 2012|September 20, 2012|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006230||206155|
NCT00006245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068176|Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel|Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer||National Cancer Institute (NCI)||Completed|July 2000|August 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|June 20, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006245||206142|
NCT00006301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000221|Immune Response to Hepatitis C Virus|Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus||National Institutes of Health Clinical Center (CC)||Completed|September 2000|March 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|46|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 27, 2000||No||No||https://clinicaltrials.gov/show/NCT00006301||206095|
NCT00006228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01402|Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Anti-HER-2 Monoclonal Antibody Trastuzumab (Herceptin) in Combination With Low Dose Interleukin-2 (Proleukin) in Metastatic Breast Cancer Patients Who Have Previously Failed Trastuzumab||National Cancer Institute (NCI)||Completed|July 2000|||July 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|N/A|N/A|No|||October 2013|October 7, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006228||206157|
NCT00006249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-18991|Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma|PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|June 2000|||August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1258|||Both|18 Years|70 Years|No|||February 2015|February 9, 2015|September 11, 2000||No||No||https://clinicaltrials.gov/show/NCT00006249||206138|
NCT00006240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068165|Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia|A Pilot Study of Phenylbutyrate, Dexamethasone and GM-CSF in Refractory or Relapsed t(8;21) Acute Myeloid Leukemia||National Cancer Institute (NCI)||Completed|October 2000|August 2001|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|April 27, 2015|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006240||206147|
NCT00006760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD00P1|Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma|A Pilot Study of Re-Induction Chemotherapy With Ifosfamide, and Vinorelbine (IV) in Children With Refractory/Relapsed Hodgkin's Disease||Children's Oncology Group|Yes|Completed|May 2001|March 2012|Actual|July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|N/A|30 Years|No|||July 2013|July 25, 2013|December 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006760||205866|
NCT00006342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067681|Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor|Analyses of Mutations Associated With Secondary Leukemia or Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease or Childhood Brain Tumors||Duke University||Completed|January 1997|January 2001|Actual|September 2000|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|||Both|N/A|N/A|No|||June 2013|October 13, 2015|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006342||206058|
NCT00006180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000203|Bone Loss in Premenopausal Women With Depression|The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression)||National Institutes of Health Clinical Center (CC)||Completed|August 2000|January 2007||||Phase 4|Interventional|Primary Purpose: Treatment||||220|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||January 2007|February 24, 2007|August 17, 2000||||No||https://clinicaltrials.gov/show/NCT00006180||206200|
NCT00006346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHCH-TM1|Stress Reduction in Older Women With Stage II, Stage III, or Stage IV Breast Cancer|Stress Reduction For Breast Cancer in Women 55 Years of Age or Older: Enhancing Quality of Life and Survival||National Cancer Institute (NCI)||Completed|August 2000|September 2003|Actual|||N/A|Interventional|N/A|||||||Female|55 Years|N/A|No|||March 2010|July 9, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006346||206054|
NCT00006269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068215|Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer|A Prospective, Randomized Trial of Sandostatin LAR Depot for the Prevention of Irinotecan-Induced Diarrhea in Patients With Metastatic Colorectal Cancer||Novartis||Terminated|December 1999|||December 1999|Actual|Phase 3|Interventional|Primary Purpose: Supportive Care|||Actual|89|||Both|18 Years|N/A|No|||May 2012|May 24, 2012|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006269||206119|
NCT00006175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000190|Cyclooxygenase Levels Following Surgery to Remove Third Molars (Wisdom Teeth)|Cytokine Responses to Acute Inflammation in the Oral Surgery Model||National Institutes of Health Clinical Center (CC)||Completed|August 2000|October 2005||||N/A|Observational|N/A||||160|||Both|N/A|N/A|No|||October 2005|March 3, 2008|August 12, 2000||||No||https://clinicaltrials.gov/show/NCT00006175||206204|
NCT00006176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000191|Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies|Clinical, Molecular and Biochemical Characterization of Familial Encephalopathy With Neuroserpin Inclusion Bodies||National Institutes of Health Clinical Center (CC)||Completed|August 2000|August 2009|Actual|August 2009|Actual|N/A|Observational|N/A||||100|||Both|10 Years|N/A|No|||August 2009|September 26, 2015|August 12, 2000||No||No||https://clinicaltrials.gov/show/NCT00006176||206203|
NCT00006121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16001-10005|Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy|Phase II Study of Oxaliplatin Single Agent in Patients With Metastatic Breast Cancer After Failure of Anthracycline/Taxane Based Chemotherapy||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|May 2000|||May 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|18|||Female|18 Years|N/A|No|||July 2012|July 23, 2012|August 3, 2000|||low accrual|No||https://clinicaltrials.gov/show/NCT00006121||206253|
NCT00006265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068208|Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Dose Escalation And Phase II Study Of Gemtuzumab Ozogamicin (CMA-676; Mylotarg) With High-Dose Cytarabine For Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML)||Alliance for Clinical Trials in Oncology|No|Completed|March 2001|May 2005|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|17 Years|N/A|No|||September 2013|September 27, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006265||206122|
NCT00006273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00750-9040|Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis|Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis||National Center for Research Resources (NCRR)||Active, not recruiting|June 1996|||||N/A|Observational|Observational Model: Natural History||||60|||Both|N/A|10 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006273||206115|
NCT00006213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02338|BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia|Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086) in Acute Leukemias, Myelodysplastic Syndromes (RAEB and RAEB-T) and Chronic Myeloid Leukemia in Blast Phase||National Cancer Institute (NCI)||Completed|April 2000|||October 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|15 Years|N/A|No|||January 2013|January 22, 2013|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006213||206171|
NCT00006244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1461.00|Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma|Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|February 2000|||June 2060|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|69 Years|No|||February 2016|February 9, 2016|September 11, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006244||206143|
NCT00006773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02367|Bortezomib in Treating Patients With Recurrent Glioma|Phase I Evaluation of the Safety of PS 341 in the Treatment of Recurrent Gliomas||National Cancer Institute (NCI)||Terminated|May 2001|||June 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|December 6, 2000|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00006773||205865|
NCT00006304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 219C|Long-Term Effects of HIV Exposure and Infection in Children|Pediatric Late Outcomes Protocol||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2002|Actual|||N/A|Observational|N/A||||4150|||Both|N/A|21 Years|Accepts Healthy Volunteers|||October 2013|October 4, 2013|September 27, 2000||||No||https://clinicaltrials.gov/show/NCT00006304||206094|
NCT00006305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133|Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes|Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes|BARI2D|University of Pittsburgh|Yes|Completed|September 2000|March 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2368|||Both|25 Years|N/A|No|||January 2016|January 12, 2016|September 28, 2000||No||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00006305||206093|
NCT00006469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068288|Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer|Phase II Trial of Concurrent Paclitaxel, Carboplatin and External Beam Radiotherapy Followed by Surgical Resection in Stage IIIA (N2) Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2006|February 6, 2009|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006469||205934|
NCT00006968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068349|Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer|Non-Myeloablative Chemotherapy Followed By Related Allogeneic Stem Cell Rescue In Patients With Advanced Renal Cell Carcinoma||Jonsson Comprehensive Cancer Center||Completed|September 2000|||September 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|4|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006968||205853|
NCT00006981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068351|Immunotoxin Therapy in Treating Patients With Advanced Cancer|Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days||National Cancer Institute (NCI)||Completed|December 2000|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|April 29, 2015|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006981||205852|
NCT00007072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15578|Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major|||Office of Rare Diseases (ORD)||Terminated|November 2000|||||Phase 2|Interventional|Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||October 2003|June 23, 2005|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00007072||205845|
NCT00006474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1388|Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma|Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas||Duke University|No|Completed|March 2001|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|June 19, 2013|November 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006474||205929|
NCT00006464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068274|UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors|Phase I Dose Escalation Study of UCN-01 (NSC 638850) Plus Cisplatin in Advanced Malignant Solid Tumors||City of Hope Medical Center||Completed|March 2001|June 2008|Actual|January 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 13, 2010|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006464||205939|
NCT00006440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 029|A Test of Behavioral Intervention for Women at High Risk for HIV Infection|Feasibility Study of a Behavioral Intervention for Women at Persistent High Risk for HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|March 2000|||||N/A|Observational|N/A||||180|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 29, 2012|November 3, 2000||No||No||https://clinicaltrials.gov/show/NCT00006440||205963|
NCT00006443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-08-002|Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection|Evaluating Responses to Antiretroviral Drugs in Cells and Tissues (The ERADICATE Study): Comprehensive Comparisons of Viral and Cellular Dynamics Among Previously-Untreated Subjects With Acute HIV Infection (Seroconversion Syndrome) or Recently Acquired HIV Infection Versus the Early, Middle, and Advanced Stages of Seropositive HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||October 2003|Actual|N/A|Interventional|Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||January 2005|March 1, 2011|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006443||205960|
NCT00006617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-04-008|Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients|An Open-Label, Single Center Trial to Evaluate the Efficacy and Safety of Quadruple Chemotherapy (Zidovudine, EPIVIR, 1592U89, and 141W94) in Subjects Infected With HIV-1 (GW QUAD)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2007|Actual|June 2007|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||December 2004|May 14, 2015|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006617||205877|
NCT00006695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-00|Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|BEAM Plus Iodine-131 Anti-B1 Antibody and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma||University of Nebraska||Completed|April 2000|December 2014|Actual|September 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|19 Years|70 Years|No|||May 2015|May 26, 2015|December 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006695||205871|
NCT00006552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|953|Adherence to Antihypertensive Therapy--Data Analyses|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2002|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|100 Years|No|||May 2005|March 15, 2016|November 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006552||205882|
NCT00006565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136|Randomized Trial to Reduce Environmental Tobacco Smoke in Children With Asthma|Randomized Trial to Reduce Environmental Tobacco Smoke in Children With Asthma||National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|September 2000|April 2004|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|225|||Both|6 Years|12 Years|No|||October 2008|February 17, 2016|December 1, 2000||No||No||https://clinicaltrials.gov/show/NCT00006565||205881|
NCT00006467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0043|Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas|Phase II Trial of Gemcitabine and ISIS 2503 in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma||Alliance for Clinical Trials in Oncology|No|Completed|February 2001|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|November 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006467||205936|
NCT00008866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5069|Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy|A Phase II, Double-Blind, Randomized Study to Determine the Effect of Adding Delayed Versus Immediate Hydroxyurea to a Genotypic Based, ddI-Containing, Three-Drug Antiretroviral Regimen on the Recovery of Total CD4+ T-Cell Counts and Suppression of Plasma Viral Load in Advanced HIV-1 Infected Subjects Failing a First or Second Triple Combination Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|January 18, 2001||||No||https://clinicaltrials.gov/show/NCT00008866||205723|
NCT00006489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAFOA12428|Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)|Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder||University of Pennsylvania|Yes|Completed|December 2000|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|167|||Both|18 Years|65 Years|No|||February 2011|July 3, 2012|November 8, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006489||205914|
NCT00006442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AI-08-003|The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients|Quantitative Assessment of Viral and Lymphocyte Dynamics in Blood and Lymphoreticular Tissues of HIV-1 Infected Patients Treated With Antiretroviral Agents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||60|||Both|18 Years|N/A|No|||January 2005|July 29, 2008|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006442||205961|
NCT00006468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068282|Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer|Phase III Study of An Optimized LV-5FU-Oxaliplatin Regimen in Metastatic Colorectal Cancer. C99-1.||National Cancer Institute (NCI)||Active, not recruiting|January 2000|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||December 2000|January 10, 2009|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006468||205935|
NCT00006438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0118|How Shoes With Rocker Soles Affect Walking|Rocker Sole Kinetics and Kinematics||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|January 1997|December 1999||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||March 2000|June 23, 2005|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006438||205965|
NCT00006515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010037|Late Effects of Treatment for Sarcomas in Children|Late Effects of Treatment in Survivors of Pediatric Sarcomas||National Institutes of Health Clinical Center (CC)||Completed|November 2000|November 2011||||N/A|Observational|N/A|||Actual|39|||Both|7 Years|N/A|No|||November 2011|September 26, 2015|November 21, 2000||No||No||https://clinicaltrials.gov/show/NCT00006515||205889|
NCT00006516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0115|Home Stimulation for Brain-Asphyxiated Infants|Neuroplasticity of Brain-Asphyxiated Infants: Efficacy of Intervention||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|September 1999|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|N/A|1 Month|No|||May 2011|May 20, 2011|November 21, 2000|||Study terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00006516||205888|
NCT00006480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1524.00|Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma|Phase I Study to Evaluate the Safety of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Genetically-Modified Autologous CD8+ T Cell Clones||Fred Hutchinson Cancer Research Center||Completed|May 2000|March 2005|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|17 Years|No|||September 2010|September 17, 2010|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006480||205923|
NCT00006481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9913|Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer|A Phase III Comparison of Biafine to Declared Institutional Preference for Radiation Induced Skin Toxicity in Patients Undergoing Radiation Therapy for Advanced Squamous Cell Carcinomas of the Head and Neck||Radiation Therapy Oncology Group|Yes|Completed|October 2000|||August 2002|Actual|Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||November 2013|November 18, 2013|November 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006481||205922|
NCT00006488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00096-0968|Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease|||National Center for Research Resources (NCRR)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2004|June 23, 2005|November 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006488||205915|
NCT00006503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|944|Prevalence & Progression of Subclinical Atherosclerosis|||Rush University Medical Center||Completed|August 2000|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Female|N/A|N/A|No|||April 2008|April 29, 2014|November 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006503||205901|
NCT00006504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945|Flavonoids and Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2000|July 2002|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|March 15, 2016|November 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006504||205900|
NCT00009217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4051R|Treatment of Behavioral Symptoms in Alzheimer's Disease|Treatment of Behavioral Symptoms in Alzheimer's Disease||New York State Psychiatric Institute|No|Completed|January 1999|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|95 Years|No|||February 2012|February 27, 2012|January 23, 2001||No||No||https://clinicaltrials.gov/show/NCT00009217||205714|
NCT00006465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU5Y99|Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I Study of Oxaliplatin (NSC# 266046), Irinotecan, and Capecitabine in Patients With Solid Tumors||Case Comprehensive Cancer Center|Yes|Completed|December 2000|April 2005|Actual|November 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|November 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00006465||205938|
NCT00006449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAADAV12696|Post-Treatment Effects of Naltrexone|Post-Treatment Effects of Naltrexone||Indiana University||Completed|September 2000|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|21 Years|65 Years|No|||May 2010|May 11, 2010|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006449||205954|
NCT00006450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010028|Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors|Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Progressive or Recurrent CNS Malignancy||National Institutes of Health Clinical Center (CC)||Completed|November 2000|July 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||July 2002|March 3, 2008|November 7, 2000||||No||https://clinicaltrials.gov/show/NCT00006450||205953|
NCT00006484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068315|Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|November 2000|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2002|June 20, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006484||205919|
NCT00006486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02364|Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer|A Phase II Randomized Discontinuation Trial Of Carboxyaminoimidazole (CAI, NSC 609974) In Metastatic Renal Carcinoma||National Cancer Institute (NCI)||Completed|October 2000|||October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|335|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|November 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006486||205917|
NCT00006487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068318|S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer|A Phase I Study Of Tirapazamine/Cisplatin/Etoposide And Concurrent Thoracic Radiotherapy For Limited Stage Small Cell Lung Cancer||Southwest Oncology Group|Yes|Completed|October 2000|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|November 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006487||205916|
NCT00009191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH056511|The Depression in Alzheimer's Disease Study (DIADS)|||Johns Hopkins University||Completed|November 2005|November 2007|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2013|September 17, 2013|January 23, 2001||||No||https://clinicaltrials.gov/show/NCT00009191||205716|
NCT00006507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0104|Occupational Therapy to Treat Children Who Over or Under React to Their Environment|Occupational Therapy (OT) Outcomes: Children With Sensory Modulation Disorders||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|March 1999|February 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|54 Months|11 Years|No|||December 2004|January 16, 2007|November 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006507||205897|
NCT00006508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0770|Disorders of Systemic Glucose Balance|||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2003|June 23, 2005|November 18, 2000||||No||https://clinicaltrials.gov/show/NCT00006508||205896|
NCT00007189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0026|Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)|Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)||National Institute on Aging (NIA)||Completed|January 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2625|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 20, 2007|December 14, 2000||||No||https://clinicaltrials.gov/show/NCT00007189||205837|
NCT00007202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-03-005|Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients|A Pilot Open-Label Phase II Clinical Trial to Evaluate the Safety and Efficacy of a Compact Three Drug Antiretroviral Treatment Regimen for Subjects With Acute HIV-1 Infection or Recent HIV-1 Seroconversion||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2006|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|December 15, 2000||||||https://clinicaltrials.gov/show/NCT00007202||205836|
NCT00006448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0108|Treatment of Chronic Pain After Spinal Cord Injury (SCI) or Amputation|Spinal Cord Injury (SCI) and Amputation Pain Prevention and Treatment||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|August 1996|July 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|75 Years|No|||March 2003|May 20, 2011|November 4, 2000|||terminated/suspended|No||https://clinicaltrials.gov/show/NCT00006448||205955|
NCT00006482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068313|Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix|A Phase II Evaluation Of Gemcitabine And Cisplatin In Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix||Gynecologic Oncology Group||Terminated|October 2000|||April 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||May 2004|April 10, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006482||205921|
NCT00006483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9953|Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung|A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung||Alliance for Clinical Trials in Oncology|No|Completed|October 2000|January 2013|Actual|January 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006483||205920|
NCT00006451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1996LS142|Bone Marrow Transplantation in Treating Patients With Leukemia|T-cell Depletion In Unrelated Donor Marrow Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|April 1996|November 2000|Actual|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|0|||Both|N/A|45 Years|No|||November 2012|November 6, 2012|November 6, 2000|Yes|Yes|Withdrawn due to no accrual|No||https://clinicaltrials.gov/show/NCT00006451||205952|
NCT00006630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVEG 801|Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection|Open-Label, Multi-Site Study for the Administration of Vaccinia Immune Globulin (Human) To Subjects Who Experience Complications From Vaccinia Virus Vaccinations or To Unprotected Individuals Accidentally Exposed To Vaccinia Virus or Related Orthopox Viruses [During HIV Vaccine Research]||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||May 2012|May 11, 2012|December 6, 2000||||||https://clinicaltrials.gov/show/NCT00006630||205876|
NCT00006505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010036|Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression|Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2000|June 2020|Anticipated|June 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||July 2015|July 25, 2015|November 17, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006505||205899|
NCT00009230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0015|Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial|||University of California, Los Angeles||Suspended|June 2000|||June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|90 Years|No|||December 2015|December 2, 2015|January 23, 2001||No|Funding|No||https://clinicaltrials.gov/show/NCT00009230||205713|
NCT00006643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5096|Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus|Use of Single Photon Emission Computed Tomography (SPECT) as a Noninvasive Alternative to Liver Biopsies in Assessing Liver Involvement in Subjects Coinfected With HIV and Hepatitis C Virus (HCV)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||44|||Both|N/A|N/A|No|||June 2003|July 29, 2008|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006643||205875|
NCT00008502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010062|Genetic Analysis of Familial Keloids|Genetic Analysis of Familial Keloids||National Institutes of Health Clinical Center (CC)||Recruiting|January 2001|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|500|||Both|N/A|N/A|No|||June 2015|December 24, 2015|January 12, 2001||No||No||https://clinicaltrials.gov/show/NCT00008502||205739|
NCT00008515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010058|Fluocinolone Implant to Treat Macular Degeneration|A Randomized, Prospective Study of Sustained-Release Fluocinolone Acetonide Implant for Choroidal Neovascularization Associated With Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Completed|January 2001|December 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||16|||Both|N/A|N/A|No|||December 2001|March 3, 2008|January 12, 2001||||No||https://clinicaltrials.gov/show/NCT00008515||205738|
NCT00006493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00096-1006|Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia|||National Center for Research Resources (NCRR)||Completed||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2004|June 23, 2005|November 14, 2000||||No||https://clinicaltrials.gov/show/NCT00006493||205911|
NCT00006494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010004|Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs|An Assessment of the Relationship Between Antiretroviral Drug Genotype/Phenotype (IC50) and Antiretroviral Activity in HIV-Infected, Drug-Experienced Patients With Suboptimal Suppression of Plasma Viral Load||National Institutes of Health Clinical Center (CC)||Completed|November 2000|September 2011||||N/A|Observational|N/A|||Actual|14|||Both|18 Years|N/A|No|||September 2011|September 26, 2015|November 14, 2000||No||No||https://clinicaltrials.gov/show/NCT00006494||205910|
NCT00006495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5058s|Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452|Augmentation of HIV-Specific Helper and CTL Responses Through Therapeutic Vaccination in Individuals Receiving Potent Suppressive Antiretroviral Therapies||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2004|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|November 15, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006495||205909|
NCT00006825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068331|Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer|A Safety Study Of Doxil And Herceptin In Patients With Advanced Her-2 Overexpressing Breast Cancer||New York University School of Medicine||Completed|July 2000|||July 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2011|March 25, 2011|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006825||205861|
NCT00006864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIR1899|Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin||Case Comprehensive Cancer Center|Yes|Completed|July 2000|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2014|January 8, 2014|December 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006864||205860|
NCT00006506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010031|Data Distribution Procedures for NHLBI Data Repository|National Heart, Lung, and Blood Institute Data Repository||National Institutes of Health Clinical Center (CC)||Completed|November 2000|||||N/A|Observational|N/A||||0|||Both|N/A|N/A|No|||June 2012|June 13, 2012|November 17, 2000||No||No||https://clinicaltrials.gov/show/NCT00006506||205898|
NCT00006475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068302|STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis|An Open-Label Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Blast Crisis||Novartis||Completed|September 2000|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 20, 2013|November 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00006475||205928|
NCT00006476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-PHASE I/II-PH1/073|Suramin in Treating Patients With Recurrent Bladder Cancer|A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer||National Cancer Institute (NCI)||Completed|October 2000|October 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||March 2007|June 25, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006476||205927|
NCT00006477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-13001|Mistletoe Lectin in Treating Patients With Refractory Advanced Solid Tumors|Phase I Clinical Trial of Recombinant Viscumin (rVISCUMIN, rMISTLETOE LECTIN, rML) Administered Twice Weekly by the Subcutanous Route in Patients With Solid Tumors After Failure of Standard Therapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2000|||June 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|26|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006477||205926|
NCT00007449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314A|Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors|A Phase II, Open Label, Multicenter Study to Assess the Safety and Efficacy of 100 Mg DPC 083 Once Daily in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Subjects Who Are Failing Treatment With a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimen||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2002|June 23, 2005|December 19, 2000||||No||https://clinicaltrials.gov/show/NCT00007449||205817|
NCT00007475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010053|Permeability Factor in Focal Segmental Glomerulosclerosis|Permeability Factor in Focal Segmental Glomerulosclerosis||National Institutes of Health Clinical Center (CC)|No|Completed|December 2000|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|December 22, 2000|Yes|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT00007475||205816|Note: definitive FSGS Permeability Factor (FPF) assays still in development. Data/samples transferred to the NIH-CC Glomerulosclerosis Consolidation protocol: focus on cardiotrophin like cytokine 1 & antibodies to a panel of podocyte proteins as FPF.
NCT00006437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010026|Pathophysiology of Chronic Wounds|Pathophysiology of Chronic Wounds: Collection of Blood From Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 2000|October 2002||||N/A|Observational|N/A||||999|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2002|March 3, 2008|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006437||205966|
NCT00006434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1694|Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma|||National Center for Research Resources (NCRR)||Completed||||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|10 Years|70 Years|No|||December 2003|June 23, 2005|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006434||205969|
NCT00008762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1742|Bone Health of People With Cystic Fibrosis|Bone Health of People With Cystic Fibrosis||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|8 Years|N/A|No|||December 2003|June 23, 2005|January 16, 2001||||No||https://clinicaltrials.gov/show/NCT00008762||205731|
NCT00006430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00030-0177|A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||February 2002|June 23, 2005|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006430||205973|
NCT00006431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00030-0153|Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA|||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2001|June 23, 2005|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006431||205972|
NCT00007241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44AR045153|Muscle Strengthening Device for Knee Osteoarthritis|Osteoarthritic Knee Isometric Exerciser for Home Use||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|September 2001|July 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||92|||Both|18 Years|N/A|No|||February 2003|January 2, 2007|December 16, 2000||||No||https://clinicaltrials.gov/show/NCT00007241||205833|
NCT00007254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR045506|Morphine Gel for Bedsores|Morphine-Infused Gel for Pressure Ulcer Analgesia||University of Kansas Medical Center||Completed|March 2000|February 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|December 16, 2000||||No||https://clinicaltrials.gov/show/NCT00007254||205832|
NCT00006877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH1500|Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer|A Phase II Study Of Temozolomide In The Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|July 2000|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||February 2001|January 6, 2014|December 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006877||205859|
NCT00006463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9972|Ecteinascidin 743 in Treating Children With Refractory Solid Tumors|Phase I Study of ET-743 in Pediatric Refractory Solid Tumors||Children's Oncology Group|No|Completed|October 2000|September 2005|Actual|January 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|1 Year|17 Years|No|||February 2014|February 19, 2014|November 6, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00006463||205940|
NCT00006490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5076|A Comparison of Two Tests for Anti-HIV Drug Resistance|HIV-1 Resistance Testing During Antiretroviral Failure: Comparison of Sequencing Versus Phenotyping||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||600|||Both|14 Years|N/A|No|||July 2004|September 24, 2008|November 8, 2000||||No||https://clinicaltrials.gov/show/NCT00006490||205913|
NCT00006492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010003|Gluten-Free Diet in Patients With Gluten Sensitivity and Cerebellar Ataxia|Open Label Controlled Trial of Gluten-Free Diet in Patients With Gluten-Sensitivity and Cerebellar Ataxia||National Institutes of Health Clinical Center (CC)||Completed|November 2000|December 2002||||N/A|Observational|N/A||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2002|March 3, 2008|November 9, 2000||||No||https://clinicaltrials.gov/show/NCT00006492||205912|
NCT00009204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059666-01|Serotonergic Pharmacotherapy for Agitation of Dementia|Serotonergic Pharmacotherapy for Agitation of Dementia|SPAD|University of Pittsburgh||Completed|September 1995|April 2002|Actual|April 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 18, 2013|January 23, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00009204||205715|
NCT00007319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5078|Carotid Artery Thickness in HIV Infected and Uninfected Adults|Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults: A Pilot Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Time Perspective: Prospective||||132|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|September 16, 2008|December 16, 2000||||No||https://clinicaltrials.gov/show/NCT00007319||205827|
NCT00007332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 203|Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B|A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a Combined Regimen Using ALVAC vCP1452 and AIDSVAX B/B||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2003|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||330|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|December 16, 2000||||No||https://clinicaltrials.gov/show/NCT00007332||205826|
NCT00006436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010030|EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection|Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas||National Institutes of Health Clinical Center (CC)||Recruiting|October 2000|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2015|August 21, 2015|November 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006436||205967|
NCT00006387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-98026|Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer|A Phase I Study of RAS Peptide Vaccination in Patients With Advanced Pancreatic or Colorectal Adenocarcinoma||Fox Chase Cancer Center|No|Completed|October 2000|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|October 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006387||206013|
NCT00006388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-BR-0021|Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme|A Phase II Trial of High Dose Tamoxifen For The Treatment of Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM)||Radiation Therapy Oncology Group|Yes|Completed|December 2000|||October 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|October 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006388||206012|
NCT00006439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00069-0622|Effects of Home Visits on Medication Adherence in Children and Youth With HIV|||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|24 Years|No|||November 2001|June 23, 2005|November 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006439||205964|
NCT00006497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|938|Long-Term Effects of Subclinical CAD on Cardiac Function|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Both|48 Years|N/A|No|||August 2008|August 20, 2008|November 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006497||205907|
NCT00006433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00030-0156|Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer|||National Center for Research Resources (NCRR)||Recruiting|January 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|90 Years|No|||November 2001|June 23, 2005|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006433||205970|
NCT00006348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-989201|Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment|Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer||Alliance for Clinical Trials in Oncology|No|Completed|October 2000|September 2001|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|N/A|N/A|No|||July 2015|July 14, 2015|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006348||206052|
NCT00006349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N99C5|Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer|An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)||Alliance for Clinical Trials in Oncology|No|Completed|February 2001|January 2007|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|9|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006349||206051|
NCT00006498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|939|Chronic Life Stress and Incident Asthma in Adult Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|August 2005|Actual|||N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||January 2006|March 15, 2016|November 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006498||205906|
NCT00006347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068199|Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Small Cell Lung Cancer (SCLC)||National Cancer Institute (NCI)||Active, not recruiting|August 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|February 28, 2009|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006347||206053|
NCT00006289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000200|Neurotropin to Treat Chronic Neuropathic Pain|Neurotropin for Acute Dental Pain and for Chronic Neuropathic Pain||National Institutes of Health Clinical Center (CC)||Terminated|September 2000|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||June 2012|May 3, 2013|September 21, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006289||206106|
NCT00006295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|912|Molecular & Clinical Evaluation of Low HDL Syndromes|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2000|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|January 18, 2008|September 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006295||206101|
NCT00006296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|913|CV Risk Factors at Age 25-64 & Long-Term Medicare Costs|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|July 2005|Actual|July 2005|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||April 2009|February 17, 2016|September 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006296||206100|
NCT00006297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|914|Risk Factors for CV Disease in a Dialysis Cohort|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|July 2005|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||October 2005|February 17, 2016|September 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006297||206099|
NCT00006441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-01-001|Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV|A Single Center, Randomized Open Label Study of Initial Interleukin-2 Compared to Delayed Interleukin-2 When Added to Zidovudine, 3TC and Nelfinavir In Order to Modulate Immune Function and to Sustain Suppression of HIV-1 Replication Among Those Persons With Primary or Early HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2003|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|398|||Both|18 Years|N/A|No|||April 2014|March 5, 2015|November 3, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006441||205962|
NCT00006260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU4196|Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer|A Phase II Study Of An OutPatient Three Day VIP Regimen With Oral Mesna For Metastatic Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|May 1997|||January 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|N/A|No|||June 2010|June 9, 2010|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006260||206127|
NCT00006261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1199|Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer|Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer||Case Comprehensive Cancer Center|Yes|Withdrawn|May 2000|||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|60 Years|No|||June 2010|June 9, 2010|September 11, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006261||206126|
NCT00006391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068275|Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I Dose-Finding Study of Oxaliplatin (NSC #266046) Combined With Continuous Infusion Topotecan Hydrochloride as Chemotherapy for Patients With Previously Treated Ovarian Cancer||New York University School of Medicine||Completed|August 2000|||November 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2011|April 4, 2011|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006391||206009|
NCT00006409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|934|Trial of Activity for Adolescent Girls (TAAG)|Trial of Activity for Adolescent Girls (TAAG)|TAAG|University of North Carolina, Chapel Hill|Yes|Completed|September 2000|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8727|||Female|12 Years|14 Years|No|||June 2015|June 29, 2015|October 12, 2000||No||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00006409||205991|
NCT00006411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-80|Cornea Donor Study|Cornea Donor Study|CDS|National Eye Institute (NEI)|Yes|Active, not recruiting|July 2002|July 2013|Anticipated|December 2007|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|1101|||Both|40 Years|80 Years|No|||April 2008|March 23, 2010|October 13, 2000||No||No||https://clinicaltrials.gov/show/NCT00006411||205990|
NCT00006379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3Y00|Non-Ablative Allo HSCT For Hematologic Malignancies or SAA|Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia||Case Comprehensive Cancer Center|Yes|Completed|June 2000|October 2011|Actual|January 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|N/A|70 Years|No|||December 2011|December 7, 2011|October 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006379||206021|
NCT00006290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5089|Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs|Perceived Changes in Body Habitus and Body Image Among HIV+ Persons Currently Receiving or Recently Discontinuing Combination Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||60|||Both|18 Years|N/A|No|||June 2003|September 24, 2008|September 21, 2000||||No||https://clinicaltrials.gov/show/NCT00006290||206105|
NCT00006291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5024|Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination|A Phase II, Randomized, Partially Blinded Trial of Combinations of Potent Antiretroviral Therapy, HIV-Specific Immunizations, and Cycles of Interleukin-2 to Promote Efficient Control of Viral Replication||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|September 22, 2000|No|Yes||||https://clinicaltrials.gov/show/NCT00006291||206104|
NCT00006398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Timolol (completed)|Prevention of Esophageal Varices by Beta-Adrenergic Blockers|Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 1993|March 1998||||Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||January 2010|January 12, 2010|October 5, 2000||||No||https://clinicaltrials.gov/show/NCT00006398||206002|
NCT00009542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010059|Effects of Kava on the Body's Elimination of Caffeine and Dextromethorphan|Evaluation of the Effect of Kava on Drug Metabolism Enzymes and EEG Measured Beta Amplitude||National Institutes of Health Clinical Center (CC)||Completed|January 2001|April 2001||||Phase 4|Interventional|Primary Purpose: Treatment||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2001|March 3, 2008|January 27, 2001||||No||https://clinicaltrials.gov/show/NCT00009542||205709|
NCT00006268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068211|Immunotoxin Therapy in Treating Patients With Malignant Glioma|Interstitial Infusion of IL 13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study||National Cancer Institute (NCI)||Completed|October 2000|March 2005|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2005|June 20, 2013|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006268||206120|
NCT00006404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|929|Nutrition in Pregnancy, Birth Weight, and Childhood Asthma|||Harvard Pilgrim Health Care||Completed|September 2000|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||May 2009|March 25, 2014|October 12, 2000||||No||https://clinicaltrials.gov/show/NCT00006404||205996|
NCT00006405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930|APEX: Adiposity Prevention by Exercise in Black Girls|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2002|March 2007|Actual|March 2007|Actual|N/A|Observational|N/A|||||||Female|8 Years|10 Years|No|||January 2008|January 18, 2008|October 12, 2000||||No||https://clinicaltrials.gov/show/NCT00006405||205995|
NCT00006406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931|Amino Acids in Urine, Diet, and Blood Pressure: International Population Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2000|July 2005|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||December 2005|March 15, 2016|October 12, 2000||||No||https://clinicaltrials.gov/show/NCT00006406||205994|
NCT00006407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|932|Sex Steroid Hormones and Risk of CHD in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|July 2004|Actual|||N/A|Observational|N/A|||||||Female|50 Years|79 Years|No|||March 2005|March 15, 2016|October 12, 2000||||No||https://clinicaltrials.gov/show/NCT00006407||205993|
NCT00006355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-9804 CDR0000068223|Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme|Phase I/II Study of Pyrazoloacridine (PZA) in Adults With Newly Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center||Completed|May 2000|October 2006|Actual|October 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 1, 2012|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006355||206045|
NCT00006361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068232|SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck|A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|December 2000|||January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|December 3, 2009|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006361||206039|
NCT00009555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5079|Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat|A Prospective, Multicenter, Randomized, Placebo-Controlled Trial of Physiologic Testosterone Supplementation for HIV-Positive Men With Mildly to Moderately Reduced Serum Testosterone Levels and Abdominal Obesity||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2006|Actual|||Phase 4|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||86|||Male|18 Years|70 Years|No|||May 2012|May 17, 2012|February 1, 2001||||||https://clinicaltrials.gov/show/NCT00009555||205708|
NCT00006390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068272|Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia|Phase II Study of Campath-1H (NSC #950010) and Peripheral Blood Stem Cell Transplant for Patients With Chronic Lymphocytic Leukemia||Eastern Cooperative Oncology Group|No|Completed|February 2001|||December 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 2010|January 26, 2010|October 4, 2000|Yes|Yes||||https://clinicaltrials.gov/show/NCT00006390||206010|
NCT00006400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89|Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia|Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|August 2000|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|191|||Both|9 Months|18 Months|No|||April 2011|April 15, 2011|October 12, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006400||206000|
NCT00006298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 028|Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa|Virological and Immunological Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||125|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2004|September 24, 2008|September 26, 2000||||No||https://clinicaltrials.gov/show/NCT00006298||206098|
NCT00006471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-334|Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of Fenretinide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck||M.D. Anderson Cancer Center|Yes|Completed|September 2000|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|November 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006471||205932|
NCT00006472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068295|Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer|Esophageal Cancer: A Phase II Study of Paclitaxel, Carboplatin and 5-Fluorouracil With Simultaneous Radiotherapy Followed by Surgical Resection||National Cancer Institute (NCI)||Active, not recruiting|January 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||February 2002|February 6, 2009|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006472||205931|
NCT00006396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 012|Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns|A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||1500|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 13, 2012|October 10, 2000||||No||https://clinicaltrials.gov/show/NCT00006396||206004|
NCT00006397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|312A|Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs|A Study of the Combination of Indinavir, Ritonavir, Enteric-Coated ddI and d4T In Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitor Experienced Patients: An Open-Label Study Investigating Differences Between Women and Men||NIH AIDS Clinical Trials Information Service||Active, not recruiting|August 2000|||||Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|October 10, 2000||||No||https://clinicaltrials.gov/show/NCT00006397||206003|
NCT00006382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068258|Lung Screening Study|Lung Screening Study||National Cancer Institute (NCI)||Completed|August 2000|December 2002|Actual|||N/A|Interventional|Primary Purpose: Screening|||||||Both|55 Years|74 Years|No|||June 2010|May 1, 2015|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006382||206018|
NCT00006424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010012|Study of Brain Changes Shaped by Experience|fMRI and Spectroscopy Studies of Cortical Plasticity at 1.5 and 3 Tesla||National Institutes of Health Clinical Center (CC)||Completed|October 2000|January 2002||||N/A|Observational|N/A||||153|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2002|March 3, 2008|October 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006424||205979|
NCT00006447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0106|Supporting Traumatic Brain Injury (TBI) Caregivers|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|September 1997|August 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||64|||Female|18 Years|N/A|No|||May 2011|May 20, 2011|November 4, 2000|||Study terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00006447||205956|
NCT00006384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00041|SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer|Phase II Trial of SU5416 and Interferon Alfa 2B in Unresectable or Metastatic Renal Cell Carcinoma||City of Hope Medical Center||Completed|November 2000|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2011|October 18, 2011|October 4, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00006384||206016|
NCT00006385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068263|Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma|Phase II Evaluation of Immunization With an HLA-A2 Multi-Epitope Peptide Vaccine Containing MART-1 (NSC #672643), gp100 (NSC #683472), and Tyrosinase (NSC #699048) Peptides Alone or in Combination With GM-CSF, IFN Alpha-2b, or GM-CSF + IFN Alpha-2b in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|September 2000|||October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|November 5, 2011|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006385||206015|
NCT00006386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-BR-0023|Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme|A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boosts For Supratentorial Glioblastoma Multiforme||Radiation Therapy Oncology Group|Yes|Completed|March 2001|February 2009|Actual|November 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|N/A|No|||November 2015|November 14, 2015|October 4, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006386||206014|
NCT00006425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010008|Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study|Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|October 2000|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|20|||Female|18 Years|100 Years|No|||November 2015|December 15, 2015|October 31, 2000||No||No||https://clinicaltrials.gov/show/NCT00006425||205978|
NCT00006426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0109|Achilles Tendon Lengthening in Patients With Diabetes to Prevent Foot Ulcers|Controlled Clinical Trial Comparing the Effect of an Achilles Tendon Lengthening Procedure and Casting to Casting Alone for the Treatment of Neuropathic Forefoot Plantar Ulcers in Patients With Diabetes Mellitus||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 1998|May 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||March 2003|June 23, 2005|November 1, 2000||||No||https://clinicaltrials.gov/show/NCT00006426||205977|
NCT00006353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26981-22981|Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 2000|||March 2002|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|575|||Both|18 Years|70 Years|No|||September 2012|September 20, 2012|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006353||206047|
NCT00006354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16002|Mistletoe Lectin in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy|Phase I Clinical Trial of Recombinant Viscumin (rViscumin, rMistletoe Lectin, rML) Administered Twice Weekly By The Intravenous Route In Patients With Solid Tumors After Failure of Standard Therapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 2000|||March 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|41|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006354||206046|
NCT00009243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010007|Natural History of Stroke: Cause and Development|Evaluation, Pathogenesis, and Treatment of Patients With or at Risk for Cerebrovascular Disease (A Natural History/Disease Pathogenesis Protocol)||National Institutes of Health Clinical Center (CC)||Recruiting|January 2001|||||N/A|Observational|N/A|||Anticipated|3000|||Both|18 Years|N/A|No|||June 2015|February 10, 2016|January 24, 2001||No||No||https://clinicaltrials.gov/show/NCT00009243||205712|
NCT00006444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5029|The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women|Assessment of Prevalence and Persistence of Human Papillomavirus (HPV) DNA in HIV-Infected Women Who Are Antiretroviral Naive and Have Initiated HAART||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2000|August 2005|Actual|||N/A|Observational|N/A||||160|||Female|13 Years|N/A|No|||November 2013|November 19, 2013|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006444||205959|
NCT00006445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0511|Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters|First and 2nd Trimester Evaluation of the Risk of Aneuploidy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||38000|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||March 2003|February 21, 2007|November 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006445||205958|
NCT00006359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068228|Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer|Phase II Trial of Androgen Suppression for 6 Months Combined With External Beam Radiotherapy (EBRT) With Brachytherapy (BT) Boost for Intermediate Risk Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|September 2000|March 2012|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Male|18 Years|N/A|No|||September 2013|September 25, 2013|October 4, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006359||206041|
NCT00006274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00750-9044|Study of Energy Requirements in Critically Ill Newborns|Study of Energy Requirements in Critically Ill Newborns||National Center for Research Resources (NCRR)||Recruiting|March 1997|||||N/A|Observational|Observational Model: Natural History||||60|||Both|N/A|120 Hours|Accepts Healthy Volunteers|||December 2003|June 23, 2005|September 11, 2000||||No||https://clinicaltrials.gov/show/NCT00006274||206114|
NCT00006292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000220|Infliximab for the Treatment of Early Rheumatoid Arthritis|Randomized Double Blind Active Treatment Controlled Trial of the Anti-TNF-Alpha Antibody Infliximab in Patients With Erosive Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Completed|September 2000|September 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||September 2005|March 3, 2008|September 23, 2000||||No||https://clinicaltrials.gov/show/NCT00006292||206103|
NCT00006470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9909|Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery|Phase II Study of Postoperative Adjuvant Immunotherapy and Radiation in Patients With Completely Resected Stage II and Stage IIIA Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|March 2001|||December 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 9, 2013|November 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00006470||205933|
NCT00006466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068280|Beta Alethine in Treating Patients With Myeloma|Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma||National Cancer Institute (NCI)||Active, not recruiting|August 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|December 17, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006466||205937|
NCT00006499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940|Genetics of Hypertension and Its Intermediate Phenotypes|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 2000|April 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2004|March 15, 2016|November 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006499||205905|
NCT00006500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941|Trends in Trans-Fatty Acid Intake Between 1980 and 1997|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2000|March 2002||||N/A|Observational|Observational Model: Defined Population|||||||Male|N/A|N/A|No|||April 2004|June 23, 2005|November 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006500||205904|
NCT00006401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-233|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants|Inhaled NO for the Prevention of Chronic Lung Disease||University of Colorado, Denver||Completed|September 2000|October 2007|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|793|||Both|N/A|1 Year|No|||October 2015|October 5, 2015|October 12, 2000||No||No||https://clinicaltrials.gov/show/NCT00006401||205999|
NCT00006402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|927|Lifestyle, Adiposity and Cardiovascular Health in Youths|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2000|July 2004|Actual|July 2004|Actual|N/A|Observational|N/A|||||||Both|15 Years|18 Years|No|||January 2008|January 18, 2008|October 12, 2000||||No||https://clinicaltrials.gov/show/NCT00006402||205998|
NCT00006403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|928|Inflammation: Correlates and Prognosis in Framingham|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2000|June 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||March 2005|February 25, 2016|October 12, 2000||||No||https://clinicaltrials.gov/show/NCT00006403||205997|
NCT00006420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|936|Minnesota Heart Survey - Mortality and Morbidity|Study of Trends of Cardiovascular Disease in a Metropolitan Area.|MHS|University of Minnesota - Clinical and Translational Science Institute||Completed|August 2000|June 2006|Actual|June 2006|Actual|N/A|Observational|N/A||1|||||Both|30 Years|84 Years|No|||February 2016|February 3, 2016|October 26, 2000||No||No||https://clinicaltrials.gov/show/NCT00006420||205982|
NCT00006381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068255|Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer|Phase II Study of Celecoxib in HER-2/Neu Overexpressing Metastatic Breast Cancer Patients Who Have Failed Recombinant Humanized Anti-p 185HER Monoclonal Antibody Trastuzumab (HERCEPTIN)||National Cancer Institute (NCI)||Completed|June 2000|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2003|December 18, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006381||206019|
NCT00006392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068277|S0000 Selenium and Vitamin E in Preventing Prostate Cancer|Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer|SELECT|Southwest Oncology Group|Yes|Completed|July 2001|September 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|35533|||Male|50 Years|120 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|October 4, 2000|Yes|Yes||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00006392||206008|
NCT00006427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0121|Chronic Pain After Amputation|Management of Chronic Pain in Rehabilitation Project II Management of Chronic Pain in Persons With Amputation||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|August 1996|July 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Both|18 Years|65 Years|No|||May 2011|May 20, 2011|November 1, 2000|||Terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00006427||205976|
NCT00006428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0120|Chronic Pain in Spinal Cord Injury|Management of Chronic Pain in Rehabilitation Project I - Management of Chronic Pain in Persons With Spinal Cord Injury||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 1996|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||March 2003|December 14, 2012|November 1, 2000||No||No||https://clinicaltrials.gov/show/NCT00006428||205975|
NCT00006501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1399|Prognostic Significance of T Wave Alternans|The Prevalence and Prognostic Significance of T Wave Alternans in Patients With Severe Congestive Heart Failture||Columbia University|No|Completed|January 2003|February 2012|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|549|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with left ventricular dusfunction or non-ischemic cardiomyopathy, and are at high        risk for sudden cardiac death.|December 2015|December 21, 2015|November 16, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006501||205903|
NCT00006502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|943|Myocardial Perfusion, Risk Factors, and Coronary Calcium|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|June 2005|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2005|February 26, 2016|November 16, 2000||||No||https://clinicaltrials.gov/show/NCT00006502||205902|
NCT00006421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010009|Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study|Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study||National Institutes of Health Clinical Center (CC)||Completed|October 2000|||||N/A|Observational|Time Perspective: Prospective|||Actual|200|||Female|18 Years|N/A|No|||July 2015|July 29, 2015|October 27, 2000||No||No||https://clinicaltrials.gov/show/NCT00006421||205981|
NCT00006422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010023|Evaluation and Treatment of Pediatric Eye Diseases|Evaluation and Treatment Protocol for Patients With Pediatric Eye Diseases and Strabismus||National Institutes of Health Clinical Center (CC)||Completed|October 2000|October 2002||||N/A|Interventional|N/A||||150|||Both|N/A|N/A|No|||October 2002|March 3, 2008|October 27, 2000||||No||https://clinicaltrials.gov/show/NCT00006422||205980|
NCT00006417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010013|Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease|HLA-Matched, Peripheral Blood Stem Cell Transplantation Using Low Intensity Conditioning to Treat Patients With Chronic Granulomatous Disease Who Are Actively Infected||National Institutes of Health Clinical Center (CC)||Completed|October 2000|November 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||November 2004|March 3, 2008|October 24, 2000||||No||https://clinicaltrials.gov/show/NCT00006417||205985|
NCT00006432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00030-0152|Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes|||National Center for Research Resources (NCRR)||Completed|January 2000|||||N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|45 Years|N/A|No|||June 2007|June 22, 2007|November 3, 2000||||No||https://clinicaltrials.gov/show/NCT00006432||205971|
NCT00006429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0103|Treadmill Training for Spinal Cord Injury|Locomotor Therapy Trial for Spinal Cord Injury||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|March 1999|February 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||200|||Both|16 Years|65 Years|No|||May 2011|May 20, 2011|November 1, 2000|||Study Terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00006429||205974|
NCT00006365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-P-0019|External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer|A Phase II Study of External Beam Radiation Therapy Combined With Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate||Radiation Therapy Oncology Group|Yes|Completed|November 2000|November 2013|Actual|December 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Male|18 Years|N/A|No|||January 2014|January 23, 2014|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006365||206035|
NCT00006360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0022|Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer|Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer||Radiation Therapy Oncology Group|Yes|Completed|February 2001|||November 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2005|July 17, 2013|October 4, 2000||No||No||https://clinicaltrials.gov/show/NCT00006360||206040|
NCT00009256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000110|Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy|Analysis of HIV Genetic Variation in Patients Prior to Initiation of Highly Active Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Completed|April 2000|March 2009||||N/A|Observational|N/A||||65|||Both|18 Years|N/A|No|||March 2009|September 26, 2015|January 25, 2001||No||No||https://clinicaltrials.gov/show/NCT00009256||205711|
NCT00009529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-81|The Contact Lens and Myopia Progression (CLAMP) Study|||National Eye Institute (NEI)||Completed||||||N/A|Observational|N/A|||||||Both|8 Years|11 Years|No|||October 2009|October 15, 2009|January 27, 2001||||No||https://clinicaltrials.gov/show/NCT00009529||205710|
NCT00006452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-9712 CDR0000066986|Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme|A Phase I Trial to Evaluate Repetitive Intravenous Doses of Gadolinium-Texaphyrin as a Radiosensitizer in Patients With Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center||Completed|April 1999|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006452||205951|
NCT00006286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH80008|Treatment for Adolescents With Depression Study (TADS)|Treatment for Adolescents With Depression Study (TADS)||National Institute of Mental Health (NIMH)||Completed|September 1998|March 2004||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||432|||Both|12 Years|17 Years|No|||November 2005|April 16, 2014|September 14, 2000||||No||https://clinicaltrials.gov/show/NCT00006286||206107|
NCT00006294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911|GenHAT--Genetics of Hypertension Associated Treatments|||University of Minnesota - Clinical and Translational Science Institute||Completed|September 1999|August 2005|Actual|August 2005|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||March 2014|March 14, 2014|September 25, 2000||||No||https://clinicaltrials.gov/show/NCT00006294||206102|
NCT00006485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068316|Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study Of Flavopiridol Administered With Irinotecan (CPT-11) In Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|September 2000|||December 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2003|December 13, 2009|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006485||205918|
NCT00006496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|937|Molecular Epidemiology of ARDS|||Massachusetts General Hospital|No|Recruiting|February 2000|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|80 Years|No|Non-Probability Sample|All patients admitted to ICU with risk factors for ARDS|April 2014|April 18, 2014|November 16, 2000||No||No||https://clinicaltrials.gov/show/NCT00006496||205908|
NCT00006478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260-00|Vaccine Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|Pilot Trial to Evaluate Immune Response Using Idiotype Vaccines Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Follicular Lymphoma||University of Nebraska||Terminated|September 2000|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|19 Years|N/A|No|||March 2011|March 1, 2011|November 6, 2000|Yes|Yes|Genitope suspend development of MyVax in light of the decision made by the Food and Drug    Administration (FDA) March 6, 2008|No|October 19, 2010|https://clinicaltrials.gov/show/NCT00006478||205925|The Sponsor Genitope suspend development of MyVax in light of the decision made by the FDA March 6, 2008, therefore this trial was halted prematurely leaving insufficient data to analyze.
NCT00006479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068309|Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer|Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study||National Cancer Institute (NCI)||Active, not recruiting|September 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||December 2000|April 15, 2011|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006479||205924|
NCT00006380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-061|Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer|Phase I Evaluation of 131I-J591 Murine Monoclonal Antibody in Patients With Progressive Androgen-Independent Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|September 2000|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2013|June 17, 2013|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006380||206020|
NCT00006393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0104|Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis|Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis||National Center for Research Resources (NCRR)||Recruiting|July 1998|||||N/A|Observational|Primary Purpose: Screening||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2003|June 23, 2005|October 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006393||206007|
NCT00006408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|933|Hypertension in Black Americans: A Life Course Approach|||Duke University|No|Completed|August 2000|January 2006|Actual|January 2006|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|25 Years|50 Years|No|||March 2014|March 27, 2014|October 12, 2000||No||No||https://clinicaltrials.gov/show/NCT00006408||205992|
NCT00006435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010027|Study of Plexiform Neurofibromas in Neurofibromatosis Type 1|Natural History of Plexiform in Neurofibromatosis Type I||National Institutes of Health Clinical Center (CC)||Completed|October 2000|||||N/A|Observational|Time Perspective: Prospective|||Actual|24|||Both|N/A|N/A|No|||July 2015|August 5, 2015|November 3, 2000||No||No||https://clinicaltrials.gov/show/NCT00006435||205968|
NCT00006473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02363|Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|September 2000|||February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|November 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006473||205930|
NCT00012142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068487|CCI-779 in Treating Patients With Prostate Cancer|Randomized, Double-Blind, Placebo-Controlled, Phase II Study Of Intravenous CCI-779 Administered Weekly To Patients With Androgen-Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|September 2000|March 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||May 2002|June 20, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012142||205530|
NCT00008333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0022|Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Oral Vinorelbine For The Treatment Of Metastatic Non-Small Cell Lung Cancer In Patients More Than Or Equal To 65 Years Of Age: A Phase II Trial of Efficacy and Patients Perceived Preference for Oral Therapy||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2001|July 2007|Actual|March 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|65 Years|N/A|No|||July 2015|July 7, 2015|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008333||205752|
NCT00009841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-98025|Gene Therapy in Treating Patients With Advanced Head and Neck Cancer|Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma||University of Pittsburgh||Completed|March 1999|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|13|||Both|18 Years|120 Years|No|||June 2002|February 11, 2016|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009841||205688|
NCT00008138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068380|S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer|Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer|S0009|Southwest Oncology Group|No|Completed|March 2001|November 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|18 Years|120 Years|No|||December 2015|December 8, 2015|January 6, 2001|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00008138||205767|
NCT00009984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02393|Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer|Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine||National Cancer Institute (NCI)||Terminated|March 2002|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009984||205677|
NCT00007943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068355|Gemcitabine in Treating Patients With Advanced Colorectal Cancer|A Phase II Study Of Twenty-Four Hour Infusion Gemcitabine For Advanced Colorectal Cancer||Wake Forest Baptist Health||Completed|September 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007943||205782|
NCT00008112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT-KWF-CKVO-2000-02|Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer|Feasibility Study of the Combination of Radiotherapy, Chemotherapy and Hyperthermia for the Treatment of Stage IIB-III-IVA Cervical Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||October 2002|August 6, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008112||205769|
NCT00008463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5071|A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)|A Prospective, Multicenter, Phase II/III, Open-Label, Controlled, Randomized Trial Evaluating the Efficacy, Safety, and Tolerability of Interferon-alfa-2a Plus Ribavirin Versus PEG-interferon-alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus (HCV) Infection in Individuals Co-Infected With Human Immunodeficiency Virus-1 (HIV-1)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2000|August 2006||||Phase 2|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||132|||Both|18 Years|65 Years|No|||June 2013|June 7, 2013|January 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008463||205742|
NCT00007670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|428|Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.|CSP #428 - Treatment of Seizures in the Elderly Population||VA Office of Research and Development||Completed|January 1998|March 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||720|||Both|60 Years|N/A|No|||February 2007|January 20, 2009|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007670||205803|
NCT00007644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407|Prostate Cancer Intervention Versus Observation Trial (PIVOT)|CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer|PIVOT|VA Office of Research and Development|Yes|Completed|November 1994|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|731|||Male|N/A|75 Years|No|||April 2014|April 24, 2014|December 29, 2000||No||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00007644||205805|
NCT00009646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0011|Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)|Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)|TIPP|NICHD Neonatal Research Network|Yes|Completed|November 1993|March 2001|Actual|March 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1202|||Both|N/A|6 Hours|No|||June 2015|June 3, 2015|February 1, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009646||205702|
NCT00009659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010081|Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause|Biologic Activity of a Selective Progesterone Receptor Modulator, CDB-2914, in Post-Menopausal Women||National Institutes of Health Clinical Center (CC)||Completed|January 2001|December 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||58|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2001|March 3, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009659||205701|
NCT00008125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-97-093|Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors|Phase I Study Of Gemcitabine, Docetaxel And Carboplatin, With And Without Filrastim Support, Combination Chemotherapy In Patients With Advanced Non-Hematological Malignancies||University of Pittsburgh||Completed|March 1998|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|25|||Both|18 Years|120 Years|No|||January 2016|January 14, 2016|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008125||205768|
NCT00007904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1100|Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes|A Phase II Study Of Safety And Tolerability Of Adjuvant Chemotherapy With Continuous Infusion Paclitaxel And Dose Intense Cyclophosphamide And Hematopoietic Growth Factor Support Followed By Doxorubicin For Stage II-IIIA Breast Cancer Involving Greater Than or Equal to 10 Lymph Nodes||Case Comprehensive Cancer Center|Yes|Completed|July 2000|September 2012|Actual|June 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|January 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00007904||205785|
NCT00008268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-067|Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma|A Phase II Study Of Blood Stem Cell Mobilization With Intravenous Melphalan (60 MG/M2) + G-CSF In Patients With Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Completed|August 2000|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008268||205757|
NCT00007774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|451|To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia|CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia||VA Office of Research and Development|No|Completed|March 1998|||June 2001|Actual|Phase 4|Interventional|Masking: Double-Blind|2||Anticipated|600|||Both|N/A|N/A|No|||February 2009|February 3, 2009|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007774||205795|
NCT00007956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068356|Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma|A Phase I Study Of Therapy With Mono-dgA-RFB4 In Patients With Relapsed And Refractory CD22+ B-Cell Lymphoma||National Cancer Institute (NCI)||Completed|November 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2002|April 29, 2015|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007956||205781|
NCT00008437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068417|MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer|Pilot Study of MR-Guided Focused Ultrasound for Tissue Coagulation in Women With Breast Cancer: MR Imaging and Histopathic Correlation, An Assessment or Target Accuracy and Patient Acceptance||InSightec|No|Completed|December 2000|December 2000|Actual|December 2000|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2012|June 29, 2012|January 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00008437||205744|
NCT00011921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068379|Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer|Phase III Randomized Trial of Sequential High-Dose Chemotherapy Versus Standard Chemotherapy for the Treatment of Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|430|||Both|N/A|65 Years|No|||March 2003|September 16, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00011921||205545|
NCT00007631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402|Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer|CSP #402 - VA Topical Tretinoin Chemoprevention Trial||VA Office of Research and Development|Yes|Completed|March 1998|July 2006|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1131|||Both|N/A|N/A|No|||January 2009|January 29, 2009|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007631||205806|
NCT00009815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-013|Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I Study Of Oral Etoposide In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies||University of Pittsburgh||Withdrawn|December 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009815||205690|
NCT00009828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-012|Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors|Phase I Study Of Weekly Paclitaxel In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies||University of Pittsburgh||Withdrawn|December 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009828||205689|
NCT00007722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500|Amyotrophic Lateral Sclerosis (ALS) Gulf War Study|CSP #500 - An Epidemiological Investigation Into the Occurrence of Amyotrophic Lateral Sclerosis (ALS) Among Gulf War Veterans||VA Office of Research and Development|No|Completed|July 2000|March 2003|Actual|March 2003|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|135|Samples With DNA|DNA samples of blood or mouthwash were collected in veterans' homes by nurses.|Both|18 Years|N/A|No|Non-Probability Sample|Living and deceased veterans with an ALS diagnosis who served in the military between        8/2/1990 and 7/31/1991.|October 2009|October 7, 2009|December 29, 2000||No||No||https://clinicaltrials.gov/show/NCT00007722||205799|
NCT00007735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|475|Antibiotic Treatment of Gulf War Veterans' Illnesses|CSP #475 - Persian Gulf - Antibiotic Treatment Trial of Gulf War Veterans' Illnesses||VA Office of Research and Development||Completed|January 1999|October 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||450|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2007|January 20, 2009|December 29, 2000||||||https://clinicaltrials.gov/show/NCT00007735||205798|
NCT00008255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-00092|INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer|Evaluation Of Uridine 5-Triphosphate Solution For Inhalation (UTP) As An Adjunct In The Diagnosis Of Lung Cancer By Sputum Cytology||National Cancer Institute (NCI)||Completed|August 2000|May 2004|Actual|||Phase 2|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||May 2001|June 25, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008255||205758|
NCT00012324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZARIX-ZX101-301|Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer|A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin||National Cancer Institute (NCI)||Completed|September 2000|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2005|June 25, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012324||205519|
NCT00008528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295C|T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs|A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Therapy Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each of the Three Classes of Approved Antiretrovirals (Nucleoside Reverse Transcriptase, Non-Nucleoside Reverse Transcriptase and Protease Inhibitors)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||525|||Both|16 Years|N/A|No|||June 2001|June 23, 2005|January 12, 2001||||No||https://clinicaltrials.gov/show/NCT00008528||205737|
NCT00007787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT DG01|Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants|Evaluation of Antibody Plus Delayed CSA vs CSA in Determining Delayed Graft Function in Cadaver Transplant Recipients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2000|March 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|21 Years|N/A|No|||January 2013|January 18, 2013|January 4, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00007787||205794|
NCT00008398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9901|Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer|A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients||Radiation Therapy Oncology Group|Yes|Completed|October 2000|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||November 2013|November 18, 2013|January 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00008398||205747|
NCT00007969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068358|Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase 1/2 Uncontrolled, Open Label Study Of Photodynamic Vaccination In Patients With Stage III/IV Malignant Melanoma||National Cancer Institute (NCI)||Completed|October 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|November 5, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007969||205780|
NCT00011843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010094|Molecular Analysis of Microphthalmia/Anophthalmia|Molecular Analysis of Microphthalmia/Anophthalmia and Related Disorders||National Institutes of Health Clinical Center (CC)||Completed|February 2001|February 2009||||N/A|Observational|N/A||||450|||Both|N/A|N/A|No|||February 2009|September 26, 2015|February 28, 2001||No||No||https://clinicaltrials.gov/show/NCT00011843||205549|
NCT00007605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|399|Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm|CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation||VA Office of Research and Development|No|Completed|April 1998|December 2003|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|706|||Both|N/A|N/A|No|||June 2011|June 13, 2011|December 29, 2000||No||No||https://clinicaltrials.gov/show/NCT00007605||205808|
NCT00007618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|707D|The Identification of Prognostic Factors of Late Stage Disease, Particularly Those That Are Modifiable, That Might Explain the Worsened Prognosis With Colorectal Cancer Among Veterans.|CSP #707D - Colorectal Cancer-Risk Factors for Advanced Disease||VA Office of Research and Development|No|Completed|January 1998|||||N/A|Observational|N/A||1|||||Both|40 Years|79 Years|No|||February 2011|February 2, 2011|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007618||205807|
NCT00008242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-077|Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma|A Phase II Clinical Trial Of Thalidomide, Adramycin And Dexamethasone (TAD) As Initial Therapy For The Treatment Of Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Completed|August 2000|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2013|March 6, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008242||205759|
NCT00011934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068460, J9833|Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia|Granulocyte-Macrophage Colony Stimulating Factor (Rhu-GM-CSF) and Autologous Bone Marrow Transplantation for Chronic Myeloid Leukemia||Sidney Kimmel Comprehensive Cancer Center||Completed|May 1998|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|70 Years|No|||April 2014|April 16, 2014|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00011934||205544|
NCT00007488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5077|HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs|Virologic Studies in Compartmental Samples From HIV-Infected Subjects Changing or Initiating Potent Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2000|August 2004|Actual|||N/A|Observational|N/A||||164|||Both|13 Years|N/A|No|||November 2013|November 19, 2013|December 23, 2000||||No||https://clinicaltrials.gov/show/NCT00007488||205815|
NCT00009568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010077|Platelet Function in Patients Treated With SSRI and Non-SSRI Antidepressants|Platelet Dysfunction in Patients Treated With SSRI Versus Non-SSRI Antidepressants||National Institutes of Health Clinical Center (CC)||Completed|January 2001|January 2005||||N/A|Observational|N/A||||70|||Both|N/A|N/A|No|||January 2005|March 3, 2008|February 1, 2001||||No||https://clinicaltrials.gov/show/NCT00009568||205707|
NCT00009737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M66001|A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer|A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer||Hoffmann-La Roche||Completed|November 1998|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3348|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00009737||205696|
NCT00011856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010101|Genetic Analysis of Familial Brain Aneurysms|Linkage Analysis of Familial Intracranial Aneurysms||National Institutes of Health Clinical Center (CC)||Completed|February 2001|March 2002||||N/A|Observational|N/A||||300|||Both|N/A|N/A|No|||March 2002|March 3, 2008|March 1, 2001||||No||https://clinicaltrials.gov/show/NCT00011856||205548|
NCT00008385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068402|Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer|Phase III Chemoprevention Trial Of Selenium Supplementation In Persons With Resected Stage I Non-Small Cell Lung Cancer||Eastern Cooperative Oncology Group||Completed|October 2000|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|1960|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|January 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00008385||205748|
NCT00007501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403|Shingles Prevention Study|CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications|SPS|VA Office of Research and Development|Yes|Completed|November 1998|February 2011|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38456|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 2, 2013|December 29, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00007501||205814|
NCT00009997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068430|Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer|Herceptin and Paclitaxel in Locally Advanced Breast Cancer With Her-2 Overexpression||New York University School of Medicine||Completed|March 1999|||January 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2011|March 25, 2011|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009997||205676|
NCT00008372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00104|Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer|Phase II Trial Of CQS (NSC 339004) In Platinum-Refractory Small Cell Lung Cancer||City of Hope Medical Center||Completed|December 2000|September 2002|Actual|September 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2011|October 18, 2011|January 6, 2001||Yes||No||https://clinicaltrials.gov/show/NCT00008372||205749|
NCT00007748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|470|Exercise and Behavioral Therapy Trial (EBT).|CSP#470 - A Randomized, Multi-Center, Controlled Trial of Multi-Modal Therapy in Veterans With Gulf War Illnesses||VA Office of Research and Development||Completed|March 1999|August 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||1064|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007748||205797|
NCT00007761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|430|Does Bipolar Disease Program (BDP) Intervention Improve Long Term Manic and Depressive Symptoms.|CSP #430 - Reducing The Efficacy-Effectiveness Gap In Bipolar Disorder||VA Office of Research and Development|No|Completed|July 1997|||December 2003|Actual|Phase 3|Interventional|N/A|2||Anticipated|382|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|December 29, 2000||No||No||https://clinicaltrials.gov/show/NCT00007761||205796|
NCT00008450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1227.00|Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant|Induction of Mixed Hematopoietic Chimerism in Patients With Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|August 1997|||October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||July 2015|July 6, 2015|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008450||205743|
NCT00008775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00400-0654|Pressure Support Ventilation During CF Exacerbations|Pressure Support Ventilation During CF Exacerbations: A Randomized, Controlled Trial||National Center for Research Resources (NCRR)||Suspended||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|60 Years|No|||November 2001|June 23, 2005|January 16, 2001||||No||https://clinicaltrials.gov/show/NCT00008775||205730|
NCT00008788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00400-0664|Osteoporosis in Children and Adults Following Liver Transplantation|Osteoporosis in Children and Adults Following Liver Transplantation||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||40|||Both|16 Years|40 Years|No|||December 2003|June 23, 2005|January 16, 2001||||No||https://clinicaltrials.gov/show/NCT00008788||205729|
NCT00011960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-G-0114|Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery|A Randomized Phase II Comparison Of Two Cisplatin-Paclitaxel Containing Chemoradiation Regimens In Resected Gastric Cancers||Radiation Therapy Oncology Group|Yes|Completed|May 2001|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2015|November 14, 2015|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00011960||205543|
NCT00011973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068465|Chemotherapy in Treating Patients With Advanced Kidney Cancer|A Phase Two Study Of Fenretinide In Renal Cell Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|December 2000|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00011973||205542|
NCT00011986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0182|Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|January 2001|||March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|3882|||Female|N/A|N/A|No|||January 2014|January 9, 2014|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00011986||205541|
NCT00009178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walsh (completed)|Treatment of Bulimia Nervosa in a Primary Care Setting|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 1998|December 2001||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|60 Years|No|||January 2010|January 12, 2010|January 23, 2001||||No||https://clinicaltrials.gov/show/NCT00009178||205717|
NCT00008736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1724|Electrogastrography (EGC) in Premature Infants With Feeding Intolerance|Electrogastrography (EGC) in Premature Infants With Feeding Intolerance: The Effect of Metoclopramide||National Center for Research Resources (NCRR)||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||||||Both|N/A|1 Month|Accepts Healthy Volunteers|||December 2003|June 23, 2005|January 16, 2001||||No||https://clinicaltrials.gov/show/NCT00008736||205733|
NCT00007982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068360|Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer|CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor||National Cancer Institute (NCI)||Completed|April 1999|May 2008|Actual|February 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2007|February 1, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007982||205779|
NCT00008190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068386|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia|High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia||National Cancer Institute (NCI)||Completed|March 1999|May 2008|Actual|November 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||April 2004|February 1, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008190||205763|
NCT00007657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|424|Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation|CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation||VA Office of Research and Development|No|Completed|December 1998|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|3260|||Both|N/A|N/A|No|||June 2009|June 12, 2009|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007657||205804|
NCT00008151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1555.00|Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome|Gemtuzumab Ozogamicin (GO), Fludarabine, And Low-Dose TBI Followed By Donor Stem Cell Transplantation For Patients With Advanced Acute Myeloid Leukemia Or Myelodysplastic Syndrome||Fred Hutchinson Cancer Research Center||Completed|October 2000|July 2002|Actual|July 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2010|March 31, 2010|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008151||205766|
NCT00008099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-97-046|Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer|Phase I Dose Escalation Trial of a 100 aa Synthetic Mucin Peptide Admixed With SB-AS2 as Adjuvant in Locally Advanced and Resected Pancreatic Cancer||University of Pittsburgh|Yes|Completed|May 1998|February 2004|Actual|March 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008099||205770|
NCT00009750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068364|Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Combined Modality Radioimmunotherapy For Hormone Refractory Metastatic Prostate Cancer With Two Cycles Of Escalating Dose 90Y-DOTA-Peptide-m170 And Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression||National Cancer Institute (NCI)||Active, not recruiting|March 2001|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||November 2003|September 19, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009750||205695|
NCT00009672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010076|Pain Treatment for Sciatica|Morphine, Nortriptyline and Their Combination in Sciatica Treatment||National Institutes of Health Clinical Center (CC)||Completed|January 2001|December 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||80|||Both|19 Years|N/A|No|||December 2006|September 26, 2015|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009672||205700|
NCT00009802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-019|Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of Oral Calcitriol [1,25-(OH)2D3] And Paclitaxel In Advanced Solid Tumors||University of Pittsburgh||Completed|June 1998|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|45|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009802||205691|
NCT00008892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010064|Brain Imaging in Children With AD/HD|Anatomic MRI Brain Imaging of White Matter in Children||National Institutes of Health Clinical Center (CC)||Completed|January 2001|January 2007||||N/A|Observational|N/A||||120|||Both|6 Years|21 Years|No|||January 2007|March 5, 2008|January 18, 2001||||No||https://clinicaltrials.gov/show/NCT00008892||205722|
NCT00009009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010061|Kidney Transplant for HIV-Infected Patients in Renal Failure|Renal Allotransplantation for Treatment of End Stage Renal Disease in the Setting of Human Immunodeficiency Virus (HIV) Infection||National Institutes of Health Clinical Center (CC)||Completed|January 2001|December 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||December 2002|March 3, 2008|January 20, 2001||||No||https://clinicaltrials.gov/show/NCT00009009||205721|
NCT00009035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010070|Natural History of Patients With Brain and Spinal Cord Tumors|Evaluation of the Natural History of Patients With Tumors of the Central Nervous System||National Institutes of Health Clinical Center (CC)||Recruiting|January 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|6000|||Both|1 Year|100 Years|No|||September 2015|February 18, 2016|January 23, 2001||No||No||https://clinicaltrials.gov/show/NCT00009035||205720|
NCT00007826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068071|Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase I/II Trial of an Allogeneic Cell Based Vaccine and an Anti-Idiotypic Antibody Vaccine Approach for Metastatic Adenocarcinoma of the Colon or Rectum||National Cancer Institute (NCI)||Active, not recruiting|April 2000|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2005|September 19, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007826||205791|
NCT00007852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-00|Rituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Lymphoma||University of Nebraska|No|Completed|September 2000|January 2011|Actual|January 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|19 Years|N/A|No|||March 2012|March 23, 2012|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00007852||205789|
NCT00007865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032-00|Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial of Ifosfamide, Carboplatin, and Etoposide (ICE) Chemotherapy in Combination With Rituximab as Salvage Therapy||University of Nebraska|No|Completed|September 2000|April 2008|Actual|March 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|19 Years|N/A|No|||June 2010|June 25, 2010|January 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00007865||205788|
NCT00008749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1736|Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus|Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Observational Model: Case Control|||||||Both|13 Years|N/A|Accepts Healthy Volunteers|||December 2003|June 23, 2005|January 16, 2001||||No||https://clinicaltrials.gov/show/NCT00008749||205732|
NCT00008853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 97-004|Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines|Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Prevention||||65|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2005|August 26, 2010|January 18, 2001||||No||https://clinicaltrials.gov/show/NCT00008853||205724|
NCT00007995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068361|Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis|Phase 2 Study Of High Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support In Patients With Multiple Myeloma And Primary Light Chain Amyloidosis||National Cancer Institute (NCI)||Completed|July 1999|May 2008|Actual|November 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||July 2007|February 1, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007995||205778|
NCT00011895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308B|Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects||NIH AIDS Clinical Trials Information Service||Active, not recruiting|February 2001|||||Phase 4|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||400|||Both|13 Years|N/A|No|||March 2002|June 23, 2005|March 2, 2001||||No||https://clinicaltrials.gov/show/NCT00011895||205547|
NCT00011908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010108|Humanized LL2IGG to Treat Systemic Lupus Erythematosus|A Phase I Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Systemic Lupus Erythematosus||National Institutes of Health Clinical Center (CC)||Completed|February 2001|January 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2003|March 3, 2008|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00011908||205546|
NCT00007839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068279|Beta Alethine in Treating Patients With Low-Grade Lymphoma|Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|August 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2010|December 17, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007839||205790|
NCT00007917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-166|Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of Gemcitabine Followed By Flavopiridol In Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|January 2001|October 2010|Actual|September 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00007917||205784|
NCT00007930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068354|Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer|Randomized Trial of Wide Mesorectal Excision Versus Total Mesorectal Excision for Mid Rectal Cancer||National Cancer Institute (NCI)||Recruiting|August 1999|||||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|800|||Both|18 Years|N/A|No|||December 2006|August 23, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007930||205783|
NCT00009893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0042|Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer|Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|May 2001|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00009893||205684|
NCT00008307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068396|Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders|Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation||National Cancer Institute (NCI)||Active, not recruiting|April 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|52|||Both|1 Year|80 Years|No|||April 2006|January 3, 2014|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008307||205754|
NCT00006455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068133|Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma|International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|December 1999|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|N/A|21 Years|No|||August 2011|August 25, 2011|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006455||205948|
NCT00007280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR046557|Bioengineered Skin and Wound Healing|Mechanisms of Bioengineered Skin in Human Wounds||Roger Williams Medical Center||Completed|October 2000|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2008|August 1, 2013|December 16, 2000||||No||https://clinicaltrials.gov/show/NCT00007280||205830|
NCT00008424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9871|Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants|A Phase I Study of Irinotecan in Patients With Refractory Solid Tumors Who Are Concomitantly Receiving Anticonvulsants||Children's Oncology Group|Yes|Completed|October 2000|September 2006|Actual|September 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|7|||Both|1 Year|21 Years|No|||May 2014|May 2, 2014|January 6, 2001||Yes||No||https://clinicaltrials.gov/show/NCT00008424||205745|
NCT00007540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|709D|Study of Prostate Cancer in Black and White U.S. Veterans|Study of Prostate Cancer in Black and White U.S. Veterans||VA Office of Research and Development||Completed|April 1998|September 2000||||N/A|Observational|N/A|||||||Male|18 Years|N/A|No|||February 2003|January 20, 2009|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007540||205811|
NCT00007579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708D|To Explore Racial Differences in Potential Risk Factors for Developing Prostate Cancer in the VA Population.|Prostate Cancer Case-Control Study: Black Versus White: VA Versus Private Sector||VA Office of Research and Development|No|Completed|February 1998|||||N/A|Observational|N/A||1|||||Male|40 Years|74 Years|No|||February 2003|October 16, 2008|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007579||205810|
NCT00007592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|324|Hypertension Screening and Treatment Program|VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY)||VA Office of Research and Development||Completed|June 1989|||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|No|||February 2003|January 20, 2009|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007592||205809|
NCT00007020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAC-91-10-10|Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid|Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism." This Study Was Previously Registered by the NCRR and Identified as NCRR-M01RR08084-0009||Retrophin, Inc.|No|Completed|January 1992|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|N/A|N/A|No|||April 2015|April 15, 2015|December 6, 2000|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00007020||205849|
NCT00006669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068283|Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma|Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|September 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2001|February 6, 2009|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006669||205873|
NCT00006682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068284|Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer|An Open-Label Phase II Study of Navelbine (Vinorelbine Tartrate) and Taxotere (Docetaxel) as First-Line Therapy for Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2001|July 23, 2008|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006682||205872|
NCT00006514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950|Multivariate Risk of CVD in Diverse Populations|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|August 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2005|February 17, 2016|November 20, 2000||||No||https://clinicaltrials.gov/show/NCT00006514||205890|
NCT00007878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03190|Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Phase I Study of PS-341 in Combination With 5-FU/LV in Solid Tumors||National Cancer Institute (NCI)||Completed|September 2000|||January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00007878||205787|
NCT00006890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MY9|Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Randomized Phase II Dose Finding Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant In Patients With Multiple Myeloma||Canadian Cancer Trials Group|Yes|Completed|July 2000|December 2008|Actual|May 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|16 Years|N/A|No|||September 2011|September 27, 2011|December 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00006890||205858|
NCT00006513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|949|Assessing the Occupation Burden in COPD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|August 2004|Actual|||N/A|Observational|N/A|||||||Both|55 Years|75 Years|No|||January 2006|March 15, 2016|November 20, 2000||||No||https://clinicaltrials.gov/show/NCT00006513||205891|
NCT00006461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9934|Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor|Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children &gt;/= to 8 Months and &lt;3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study||Children's Oncology Group|Yes|Completed|October 2000|||September 2007|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|N/A|3 Years|No|||August 2013|August 7, 2013|November 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00006461||205942|
NCT00011765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010098|Effect of Fluoxetine (Prozac) on Domestic Violence|The Effect of Fluoxetine on Measures of Domestic Violence||National Institutes of Health Clinical Center (CC)||Completed|February 2001|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||June 2010|September 26, 2015|February 28, 2001||No||No||https://clinicaltrials.gov/show/NCT00011765||205555|
NCT00011778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010104|PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck|A Phase I Study of Concomitant Therapy With Proteasome Inhibitor PS-341 and Radiation in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||National Institutes of Health Clinical Center (CC)||Completed|February 2001|February 2013|Actual|August 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2013|February 19, 2014|February 28, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00011778||205554|
NCT00007267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR047219|Psychological Treatments for Scleroderma|Psychosocial Interventions for Scleroderma||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|No|Completed|June 2001|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|89|||Both|18 Years|85 Years|No|||February 2008|February 29, 2008|December 16, 2000||No||No||https://clinicaltrials.gov/show/NCT00007267||205831|
NCT00006456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068151|Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors|Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors||Virginia Commonwealth University|No|Completed|February 1999|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|N/A|N/A|No|||February 2010|February 23, 2010|November 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00006456||205947|
NCT00007306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43AR046653|Treatment of Psoriasis With Parathyroid Hormone|Evaluation of the Therapeutic Efficacy & Safety of Topical Administration of Parathyroid Hormone (PTH) in Psoriasis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|January 2000|April 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||March 2003|January 2, 2007|December 16, 2000||||||https://clinicaltrials.gov/show/NCT00007306||205828|
NCT00012012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0116|Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer|A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes||Radiation Therapy Oncology Group|Yes|Completed|August 2001|June 2010|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|N/A|No|||December 2014|December 24, 2014|March 3, 2001|Yes|Yes||No|December 24, 2014|https://clinicaltrials.gov/show/NCT00012012||205539|
NCT00006446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0500|Preventing Problems in Children's Social Behavior|John F. Kennedy Center for Mental Retardation at Vanderbilt University: Preventing Problems in Children's Social Behavior||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 1996|June 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|3 Years|6 Years|No|||April 2003|February 21, 2007|November 4, 2000||||No||https://clinicaltrials.gov/show/NCT00006446||205957|
NCT00006903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0188|Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer|Phase II Study of Faslodex In Recurrent/Metastatic Endometrial Cancer||Gynecologic Oncology Group|Yes|Active, not recruiting|August 2004|||November 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Female|N/A|N/A|No|||May 2015|May 29, 2015|December 6, 2000|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00006903||205857|Accrual was discontinued after completion of the first stage of accrual due to lack of study drug activity.
NCT00006942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02831|Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Bryostatin in Combination With Cisplatin in Patients With Recurrent or Persistent Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Completed|October 2000|||March 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|December 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006942||205854|
NCT00007124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010042|Ketogenic Diet in Lafora Disease|A Trial of Ketogenic Diet in Lafora Disease||National Institutes of Health Clinical Center (CC)||Completed|December 2000|November 2002||||N/A|Observational|N/A||||15|||Both|N/A|N/A|No|||November 2002|March 3, 2008|December 7, 2000||||No||https://clinicaltrials.gov/show/NCT00007124||205841|
NCT00007059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00046-1404|Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation|Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation||National Center for Research Resources (NCRR)||Completed|June 1998|||||N/A|Interventional|Primary Purpose: Treatment||||20|||Both|19 Years|N/A|No|||December 2003|June 23, 2005|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00007059||205846|
NCT00008177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1432.00|Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|A Phase I Study Combining Escalating Doses of Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to Establish Mixed or Full Donor Chimerism for Elderly Patients With Advanced Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|July 1999|||March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|50 Years|N/A|No|||November 2015|November 16, 2015|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008177||205764|
NCT00007514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|723D|Investigate Olfactory Functioning as a Possible Proxy for Neurotoxic Exposure in Cohorts of Deployed and Non-Deployed Gulf War-Era Veterans.|Olfactory Functioning in Gulf War Veterans||VA Office of Research and Development||Completed|March 2000|February 2001||||N/A|Observational|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2003|January 20, 2009|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007514||205813|
NCT00007228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010052|Heart and Skeletal Muscle Problems in Neuroacanthocytosis|Characterization of Cardiac and Skeletal Myopathy, Risk Evaluation, and Phenotype-Genotype Correlation in Patients With Neuroacanthocytosis||National Institutes of Health Clinical Center (CC)||Completed|December 2000|April 2003||||N/A|Observational|N/A||||120|||Both|N/A|N/A|No|||April 2003|March 3, 2008|December 15, 2000||||No||https://clinicaltrials.gov/show/NCT00007228||205834|
NCT00006457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 00L1|Oltipraz in the Prevention of Lung Cancer in People Who Smoke|Clinical Phase I Multiple-Dose Safety Research Study of Oltipraz in Smokers||Northwestern University||Completed|August 2000|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||June 2012|June 7, 2012|November 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006457||205946|
NCT00006519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010025|Capravirine to Treat Children With HIV Infection|A Phase I Study of Capravirine (AG 1549), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor in Children With HIV Infection||National Institutes of Health Clinical Center (CC)||Completed|November 2000|October 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||96|||Both|N/A|N/A|No|||October 2004|July 10, 2006|November 23, 2000||||No||https://clinicaltrials.gov/show/NCT00006519||205885|
NCT00006526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|951|Coronary Calcification Progression Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1999|May 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|March 15, 2016|November 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006526||205884|
NCT00006539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|952|Thrombotic, Inflammatory & Gene Markers of CVD in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2004|Actual|||N/A|Observational|N/A|||||||Female|50 Years|79 Years|No|||March 2005|March 15, 2016|November 28, 2000||||No||https://clinicaltrials.gov/show/NCT00006539||205883|
NCT00007527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1018|Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice|A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence||VA Office of Research and Development||Completed|August 1999|January 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|15 Years|N/A|No|||February 2003|January 20, 2009|December 29, 2000||||||https://clinicaltrials.gov/show/NCT00007527||205812|
NCT00006994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068353|S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat|S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III||Southwest Oncology Group|Yes|Terminated|November 2001|April 2006|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|23|||Both|18 Years|90 Years|No|||November 2015|November 17, 2015|December 6, 2000|Yes|Yes|Withdrawn due to drug availability and funding|No||https://clinicaltrials.gov/show/NCT00006994||205851|
NCT00007007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-BR-0018|Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases|A Feasibility Study of Neurocognitive Evaluation in Patients Treated for Brain Metastases||Radiation Therapy Oncology Group|Yes|Completed|November 2000|December 2004|Actual|December 2004|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Both|N/A|N/A|No|||March 2015|March 26, 2015|December 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00007007||205850|
NCT00006458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068198|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer|Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Active, not recruiting|August 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2001|February 28, 2009|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006458||205945|
NCT00006462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0022|Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia|A Phase II Study of Gemcitabine (NSC #613327) in Children With Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia||Children's Oncology Group|Yes|Completed|April 2001|September 2006|Actual|August 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|21 Years|No|||February 2014|February 18, 2014|November 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006462||205941|
NCT00011791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010096|Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia|Catecholamine Reserve and Exercise Tolerance in Subjects With Congenital Adrenal Hyperplasia and Healthy Controls||National Institutes of Health Clinical Center (CC)||Completed|February 2001|May 2011||||N/A|Observational|N/A|||Actual|61|||Both|9 Years|40 Years|No|||May 2011|May 11, 2011|February 28, 2001||No||No||https://clinicaltrials.gov/show/NCT00011791||205553|
NCT00007423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 007|Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda|A Phase I Study of the Safety and Immunogenicity of Live Recombinant ALVAC-HIV vCP205 in HIV-1 Uninfected Adult Volunteers in Uganda||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2001|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|December 19, 2000||||No||https://clinicaltrials.gov/show/NCT00007423||205819|
NCT00007137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010044|Structure and Function of the Human Tongue|Task-Induced Physiological and Biomechanical Changes of the In Vivo Human Tongue||National Institutes of Health Clinical Center (CC)||Completed|December 2000|April 2007||||N/A|Observational|N/A||||165|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||April 2007|March 5, 2008|December 9, 2000||||No||https://clinicaltrials.gov/show/NCT00007137||205840|
NCT00011999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-H-0024|Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer|Phase II Early Postoperative Paclitaxel Followed By Paclitaxel And Cisplatin Concurrent With Radiation Therapy For Resected, High Risk Squamous Carcinoma Of The Head And Neck||Radiation Therapy Oncology Group|Yes|Completed|March 2001|June 2010|Actual|February 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|21 Years|N/A|No|||November 2015|November 14, 2015|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00011999||205540|
NCT00008294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-009|Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer|A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|August 2000|||May 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 17, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008294||205755|
NCT00006453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067993|Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy|A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy||AGO Study Group|Yes|Completed|September 1999|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|120 Years|No|||December 2015|December 22, 2015|November 6, 2000||Yes||No||https://clinicaltrials.gov/show/NCT00006453||205950|
NCT00007436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283F|The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients|A Phase 3, Open-Label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2001|June 23, 2005|December 19, 2000||||No||https://clinicaltrials.gov/show/NCT00007436||205818|
NCT00007033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15488|Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease|||National Center for Research Resources (NCRR)||Completed|October 2000|||||N/A|Interventional|Primary Purpose: Treatment||||25|||Both|3 Years|18 Years|No|||April 2002|January 21, 2009|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00007033||205848|
NCT00008164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068384|Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia|Transplantation Using Umbilical Cord And Placental Blood||National Cancer Institute (NCI)||Active, not recruiting|January 1997|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|60 Years|No|||January 2007|December 17, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008164||205765|
NCT00007709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706D|To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI).|CSP #706D - HIV Seroprevalence and Risks in Veterans With Severe Mental Illness||VA Office of Research and Development|No|Completed|January 1998|||||N/A|Observational|N/A||1|||||Both|18 Years|N/A|No|||February 2011|February 2, 2011|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007709||205800|
NCT00006916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-BR-0013|Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme|A Phase II Trial Of Conventional Radiation Therapy Followed By Intratumoral Bleomycin Delivered Using A Refillable, Sustained Release Device (IND# 46,592) For The Treatment Of Supratentorial Glioblastoma||Radiation Therapy Oncology Group|Yes|Terminated|June 2001|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|December 6, 2000|Yes|Yes|Low accrual|No|June 12, 2013|https://clinicaltrials.gov/show/NCT00006916||205856|This study stopped accrual early due unmet targeted accrual goals with 19 subjects accrued out of 72 planned. No efficacy analyses were performed since the small number of patients would not have provided meaningful results.
NCT00006929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01403|Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase I/II Study of Carboplatin / Paclitaxel / Suramin Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|September 2000|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|December 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006929||205855|
NCT00007683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|442|Warfarin and Antiplatelet Therapy in Chronic Heart Failure|CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)||VA Office of Research and Development|Yes|Completed|October 1998|December 2004|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1587|||Both|18 Years|N/A|No|||June 2011|June 14, 2011|December 29, 2000||No||No||https://clinicaltrials.gov/show/NCT00007683||205802|
NCT00007696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|705D|Finding Diabetes Mellitus Among Veterans|CSP #705D - Screening for Diabetes Mellitus in Veterans||VA Office of Research and Development|No|Completed|April 1998|||||N/A|Observational|N/A||1|Anticipated|1276|||Both|45 Years|64 Years|Accepts Healthy Volunteers|||February 2011|February 2, 2011|December 29, 2000||||No||https://clinicaltrials.gov/show/NCT00007696||205801|
NCT00011804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010105|Topiramate in the Treatment of Sciatica|Topiramate in the Treatment of Sciatica||National Institutes of Health Clinical Center (CC)||Completed|February 2001|February 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||65|||Both|N/A|N/A|No|||February 2005|March 3, 2008|February 28, 2001||||No||https://clinicaltrials.gov/show/NCT00011804||205552|
NCT00007215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010051|Dynamic Light Scattering Device (DLS) Study of Age-Related Changes in the Lens and Cataracts|A Study of Age-Related Changes in the Human Lens and Cataracts In Vivo Using Dynamic Light Scattering Device (DLS) Combined With Keratoscopy||National Institutes of Health Clinical Center (CC)||Completed|December 2000|February 2004||||N/A|Observational|N/A||||24|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2004|March 3, 2008|December 15, 2000||||No||https://clinicaltrials.gov/show/NCT00007215||205835|
NCT00006518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010038|Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer|Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|November 2000|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|9999|||Both|18 Years|99 Years|No|||March 2016|March 10, 2016|November 22, 2000||No||No||https://clinicaltrials.gov/show/NCT00006518||205886|
NCT00006459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2017|Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer|Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer||Eli Lilly and Company||Completed|July 2000|October 2005|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2002|June 6, 2012|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006459||205944|
NCT00011388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8324-CP-001|Reproductive Effects of Pesticide, PCB and Mercury Exposure in Laotian Immigrants|Organochlorine Compounds and Menstrual Cycle Function||National Institute of Environmental Health Sciences (NIEHS)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|February 16, 2001||||No||https://clinicaltrials.gov/show/NCT00011388||205582|
NCT00011414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010091|Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors|Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors||National Institutes of Health Clinical Center (CC)||Completed|February 2001|January 2016|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|2 Years|18 Years|No|||January 2016|January 14, 2016|February 17, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00011414||205581|
NCT00008216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5571|Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer|The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation||Columbia University|No|Terminated|July 1996|January 2009|Actual|January 2009|Actual|Phase 2|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|Samples Without DNA|Standard bloodwork that would be required for transplantation patients|Both|18 Years|65 Years|No|Non-Probability Sample|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).|June 2014|June 5, 2014|January 6, 2001|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00008216|36 Months|205761|
NCT00006509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-04-006|A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years|A Phase I/II Safety and Immunogenicity Evaluation of a Prime/Boost Vaccine Using ALVAC-HIV (vCP 1452) With Recombinant gp160 LAI/MN-2 in HIV-Infected Subjects Treated With Antiretroviral Therapy for a Minimum of 2 Years||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2007|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|19 Years|N/A|No|||March 2015|March 5, 2015|November 17, 2000||||||https://clinicaltrials.gov/show/NCT00006509||205895|
NCT00006510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|946|Identification of an Asthma Susceptibility Gene on 3P|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|November 20, 2000||||No||https://clinicaltrials.gov/show/NCT00006510||205894|
NCT00007293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44AR044449|Scalp Psoriasis Treatment With a Fiber Optic Comb|Phototherapy of Psoriasis of the Scalp With a UV-B Emitting Fiber Optic Comb||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|August 2000|July 2002||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||February 2003|January 2, 2007|December 16, 2000||||No||https://clinicaltrials.gov/show/NCT00007293||205829|
NCT00012155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-00022|Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver|A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver||National Cancer Institute (NCI)||Completed|October 2000|December 2009|Actual|November 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|June 25, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012155||205529|
NCT00008229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1542.00|Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma||Fred Hutchinson Cancer Research Center||Completed|August 2000|September 2001|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||September 2010|September 17, 2010|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008229||205760|
NCT00006454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067994|Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer|Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan||AGO Study Group|Yes|Completed|December 1999|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|120 Years|No|||December 2015|December 22, 2015|November 6, 2000||No||No||https://clinicaltrials.gov/show/NCT00006454||205949|
NCT00007046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15489|Genetic Study of Patients and Families With Diaphyseal Medullary Stenosis With Malignant Fibrous Histiocytoma of the Bone|||National Center for Research Resources (NCRR)||Completed|August 2000|||||N/A|Observational|Primary Purpose: Screening|||||||Both|N/A|90 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|December 6, 2000||||No||https://clinicaltrials.gov/show/NCT00007046||205847|
NCT00007384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|957|Longitudinal LDL-C Studies in Black and White Families|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2000|June 2006|Actual|June 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2008|February 17, 2016|December 19, 2000||||No||https://clinicaltrials.gov/show/NCT00007384||205822|
NCT00008281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068394|Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer|A Multicenter, Open-Label, Randomized, Three-Arm Study Of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) Or Oxaliplatin Or A Combination Of (5-Fu) LV + Oxaliplatin As Second-Line Treatment Of Metastatic Colorectal Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|October 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2002|January 3, 2014|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008281||205756|
NCT00008411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-242|Docetaxel in Treating Patients With Metastatic Breast Cancer|Phase III Study Comparing the Use of Docetaxel on a Every Three-Week vs. Weekly Schedule in the Treatment of Patients With Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Completed|December 1999|January 2007|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|N/A|No|||July 2012|July 27, 2012|January 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00008411||205746|
NCT00007085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132|Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED II)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|December 2004|Actual|December 2004|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||January 2008|January 18, 2008|December 7, 2000||||No||https://clinicaltrials.gov/show/NCT00007085||205844|
NCT00007098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|955|Influence of Insulin on BP Change During Adolescence|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 1995|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A|||||||Both|10 Years|20 Years|No|||July 2008|July 23, 2008|December 7, 2000||||No||https://clinicaltrials.gov/show/NCT00007098||205843|
NCT00007111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|956|Children's Activity and Nutrition III|||Georgia Regents University||Completed|April 1992|April 2002||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2005|December 21, 2015|December 7, 2000||||No||https://clinicaltrials.gov/show/NCT00007111||205842|
NCT00006460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068256|Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma||National Cancer Institute (NCI)||Active, not recruiting|August 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|December 3, 2013|November 6, 2000||||No||https://clinicaltrials.gov/show/NCT00006460||205943|
NCT00007800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smith-West (completed)|NEW DAY: Nutrition, Exercise, Weight Loss, Diabetes And You|Obesity Treatment and NIDDM in Black and White Women||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|May 2000|May 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||218|||Female|19 Years|N/A|No|||January 2010|January 12, 2010|January 5, 2001||||No||https://clinicaltrials.gov/show/NCT00007800||205793|
NCT00007813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064263|Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors|TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY||National Cancer Institute (NCI)||Active, not recruiting|May 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|N/A|35 Years|No|||December 2007|February 6, 2009|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007813||205792|
NCT00007891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRICC-BB-IND-7186|Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer|Phase I Study of 90-Y-Humanized-BrE-3 Followed by Autologous Hematopoietic Progenitor Cell Support in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|June 1997|October 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2004|May 14, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00007891||205786|
NCT00007345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010049|Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma|Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|December 2000|December 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 16, 2000|Yes|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT00007345||205825|7 cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.
NCT00007358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR046265|Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus|Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block||New York University School of Medicine||Completed|October 2000|October 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|December 19, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00007358||205824|
NCT00007371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|954|Hepatitis C in Clinically Discordant Hemophilic Siblings|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2004||||N/A|Observational|Observational Model: Defined Population|||||||Male|N/A|N/A|No|||January 2005|June 23, 2005|December 19, 2000||||No||https://clinicaltrials.gov/show/NCT00007371||205823|
NCT00007150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010045|Treatment of Hemochromatosis|Studies of Phlebotomy Therapy in Hereditary Hemochromatosis||National Institutes of Health Clinical Center (CC)||Recruiting|December 2000|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|15 Years|N/A|No|||November 2015|December 2, 2015|December 9, 2000||No||No||https://clinicaltrials.gov/show/NCT00007150||205839|
NCT00007163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010040|Monoclonal Antibody Treatment of Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Levels of Subcutaneously Administered Human Monoclonal Antibody to Interleukin-12 (J695) in Patients With Active Crohn's Disease||National Institutes of Health Clinical Center (CC)||Completed|December 2000|November 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||November 2002|March 3, 2008|December 9, 2000||||No||https://clinicaltrials.gov/show/NCT00007163||205838|
NCT00011531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2108R|Investigation of Subatmospheric Pressure Dressing on Pressure Ulcer Healing|Investigation of Subatmospheric Pressure Dressing on Pressure Ulcer Healing||VA Office of Research and Development||Completed|January 2000|December 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2001|February 5, 2009|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011531||205573|
NCT00011544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1751R|Physical Performance Measures for Manual Wheelchair Users|Physical Performance Measures for Manual Wheelchair Users||VA Office of Research and Development||Completed|January 1998|December 2000|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||120|||Both|20 Years|79 Years|Accepts Healthy Volunteers|||January 2001|January 20, 2009|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011544||205572|
NCT00011817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010102|Evaluation and Treatment of Patients With Inherited Eye Diseases|Evaluation and Treatment Protocol for Potential Research Subjects With Inherited Ophthalmic Diseases||National Institutes of Health Clinical Center (CC)||Completed|February 2001|March 2007||||N/A|Observational|N/A||||300|||Both|6 Months|N/A|No|||March 2007|September 26, 2015|February 28, 2001||||No||https://clinicaltrials.gov/show/NCT00011817||205551|
NCT00011830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010083|Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission|A Pilot Study of G-CSF Induced Stem Cell Mobilization Potential in Patients With Relapsed Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Completed|February 2001|February 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||February 2006|March 3, 2008|February 28, 2001||||No||https://clinicaltrials.gov/show/NCT00011830||205550|
NCT00006604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1020A|Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents|Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2000|September 2014|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|195|||Both|91 Days|21 Years|No|||October 2015|October 12, 2015|December 6, 2000|No|Yes||No||https://clinicaltrials.gov/show/NCT00006604||205878|
NCT00006511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|947|Chromosome 5Q Gene Variants and Asthma-Related Traits|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|August 2005|Actual|||N/A|Observational|N/A|||||||Male|N/A|100 Years|No|||January 2006|February 17, 2016|November 20, 2000||||No||https://clinicaltrials.gov/show/NCT00006511||205893|
NCT00006512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|948|Characterizing a 5P-Linked BHR Susceptibility Locus|||University of Chicago||Completed|September 2000|August 2005|Actual|August 2005|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2016|January 19, 2016|November 20, 2000||||No||https://clinicaltrials.gov/show/NCT00006512||205892|
NCT00007397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|958|Age, Risk Factors for CVD and Cognitive Functioning|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 2000|January 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||December 2005|February 24, 2016|December 19, 2000||||No||https://clinicaltrials.gov/show/NCT00007397||205821|
NCT00007410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|959|Genetic Architecture of Plasma T-PA and PAI-1|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|December 19, 2000||||No||https://clinicaltrials.gov/show/NCT00007410||205820|
NCT00012337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068507|ZD 1839 in Treating Patients With Metastatic Kidney Cancer|A Trial of ZD1839 (Iressa) in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|January 2001|March 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2002|June 20, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012337||205518|
NCT00008346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068399|Screening and Diagnostic Trial to Compare the Effectiveness of Two Types of Mammography in Detecting Breast Cancer in Women|Digital VS. Screen-Film Mammography||National Cancer Institute (NCI)||Completed|October 2001|||||N/A|Interventional|Primary Purpose: Screening|||||||Female|N/A|N/A|No|||December 2003|April 26, 2011|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008346||205751|
NCT00008359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-085|Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment|A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia||Memorial Sloan Kettering Cancer Center||Completed|August 2000|||March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|16 Years|N/A|No|||January 2013|January 17, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008359||205750|
NCT00011050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5099|Effects of Storage on Lactate in Blood Samples|Effects of Storage on Plasma Lactate Determinations||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2001|||||N/A|Observational|N/A||||13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2004|July 29, 2008|February 9, 2001||||No||https://clinicaltrials.gov/show/NCT00011050||205605|
NCT00010491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT000146-01M|Acupuncture and Moxa: A Randomized Clinical Trial for Chronic Diarrhea in HIV Patients|Acupuncture and Moxa: A Randomized Clinical Trial for Chronic Diarrhea in HIV Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|August 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2008|March 5, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010491||205639|
NCT00012038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068474|Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors|A Phase I/II Trial Of MGI114 For Treatment Of Patients With Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|July 2001|October 2003|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|June 20, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012038||205537|
NCT00010842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000066-01P1|Natural Antioxidants in the Treatment of Multiple Sclerosis|Natural Antioxidants in the Treatment of Multiple Sclerosis||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|December 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010842||205620|
NCT00010855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000002|Nonpharmacologic Analgesia for Invasive Procedures|Nonpharmacologic Analgesia for Invasive Procedures||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1997|April 2007|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||390|||Both|18 Years|90 Years|No|||August 2008|August 4, 2008|February 2, 2001||No||No||https://clinicaltrials.gov/show/NCT00010855||205619|
NCT00010530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000082-01P1|Basic Mechanisms of Meditation and Cardiovascular Disease in Older Blacks|Basic Mechanisms of Meditation and Cardiovascular Disease in Older Blacks||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|September 1999|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|65 Years|N/A|No|||December 2009|December 4, 2009|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010530||205636|
NCT00012129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068486|Chemotherapy in Treating Patients With Breast Cancer|Phase I/II Clinical and Pharmacological Study of Liposomal Annamycin in Anthracycline-Resistant Breast Cancer||New York University School of Medicine||Completed|September 1998|||May 2001|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||March 2016|March 10, 2016|March 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00012129||205531|
NCT00011245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010085|Study and Surgical Treatment of Syringomyelia|Establishing the Pathophysiology of Primary Spinal Syringomyelia||National Institutes of Health Clinical Center (CC)||Completed|February 2001|May 2011||||N/A|Observational|N/A|||Actual|50|||Both|18 Years|N/A|No|||May 2011|September 26, 2015|February 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00011245||205592|
NCT00011258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S006|Paraoxonase and LDL Oxidation in Carotid Artery Disease|Paraoxonase and LDL Oxidation in Carotid Artery Disease||VA Office of Research and Development||Completed|March 1997|September 2003||||N/A|Observational|N/A||||1000|||Both|N/A|N/A|No|||January 2004|January 20, 2009|February 14, 2001||||No||https://clinicaltrials.gov/show/NCT00011258||205591|
NCT00010101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068445|Genetic Study of Brain Tumors in Young Children|INI1 Mutation Analysis and Expression Profiling of Embryonal CNS Tumors||Pediatric Brain Tumor Consortium|No|Terminated|March 2001|August 2004|Actual|August 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|38|Samples With DNA|Tumor samples|Both|N/A|3 Years|No|Non-Probability Sample|Tissue samples from infants (< 3 years old) with histologically confirmed primary        intracranial CNS medulloblastoma/PNET, atypical teratoid/rhabdoid tumor, or choroid plexus        carcinoma and with no prior chemotherapy, radiotherapy, or treatment from any other        investigational agent will be used for this research study. Patients who meet the        eligibility criteria, are treated at a PBTC institution that has IRB approval of this        study, and consent to the usage of stored tumor specimens for the study objectives        constitute the study population.|July 2011|July 19, 2011|February 2, 2001||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00010101||205668|
NCT00012168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068489|Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat|Lymphoscintigraphy Assisted Molecular Staging of Head and Neck Cancer||New York University School of Medicine||Completed|May 1999|||July 2003|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|March 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00012168||205528|
NCT00011479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1018|Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents|Single Dose Pharmacokinetic Study of Abacavir in HIV-Infected Children and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||24|||Both|9 Years|18 Years|No|||May 2012|May 17, 2012|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011479||205577|
NCT00011492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010099|Patient Evaluation for Head and Neck Surgery Branch Studies|Evaluation for NIDCD Head & Neck Surgery Branch Clinical Research Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|February 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|4 Years|99 Years|No|||January 2016|February 13, 2016|February 22, 2001||No||No||https://clinicaltrials.gov/show/NCT00011492||205576|
NCT00010153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10963|ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer|A Double-Blind Phase III Clinical Trial to Compare the Effects of a Pre-Operatively Administered Single Dose of "Faslodex" (Long-Acting ICI 182.780) With Placebo on Tumor Recurrence in Pre- and Postmenopausal Women Treated for Operable First Primary Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|November 2000|||October 2001|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||July 2012|July 18, 2012|February 2, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00010153||205664|
NCT00010231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-99044|Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Phase I Study Of Oral, 1,25 Dihydroxycholecalciferol (Calcitriol) + Dexamethasone In Hormone-refractory Prostate Cancer||University of Pittsburgh|Yes|Completed|June 1999|November 2002|Actual|August 2002|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|N/A|No|||March 2015|March 27, 2015|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00010231||205658|
NCT00010608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000082-01P2|Clinical Trial of Meditation for Cardiovascular Disease in Older Black Women|Clinical Trial of Meditation for Cardiovascular Disease in Older Black Women||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|October 1999|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|196|||Female|60 Years|N/A|No|||December 2009|December 4, 2009|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010608||205635|
NCT00014521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068552|Karenitecin in Treating Patients With Recurrent Malignant Glioma|Phase I Evaluation Of The Safety Of Karenitecin In The Treatment Of Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|January 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2005|July 23, 2008|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014521||205358|
NCT00014066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 92-40|Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer|A Phase I Study of Photodynamic Therapy (PDT) Combined With High Dose Rate (HDR) Brachytherapy for Patients With Obstructive Bronchogenic Carcinoma||Roswell Park Cancer Institute||Completed|March 1993|||February 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 4, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014066||205391|
NCT00014248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068522|Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors|A Phase I Study And Pharmacokinetics Of Adenosine 5'- Triphosphate (ATP) When Administered By Intravenous Infusion On A Multiple Weekly Dose Schedule To Patients With Advanced Malignancies (Solid Tumors)||Dartmouth-Hitchcock Medical Center||Completed|October 2000|||November 2002|Actual|Phase 1|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||March 2013|March 15, 2013|April 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00014248||205378|
NCT00011310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9860-CP-001|Cardiopulmonary Effects of Particulate Exposure|||National Institute of Environmental Health Sciences (NIEHS)||Completed|March 1999|February 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 1, 2006|February 15, 2001||||No||https://clinicaltrials.gov/show/NCT00011310||205588|
NCT00011323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|714B|Determining the Risk Factors Such as Smoking, Alcohol, and Caffeine and Their Association With Osteoporosis in Men|Prevalence and Determinants of Osteoporosis in Male Veterans||VA Office of Research and Development||Completed|June 1998|January 2001||||N/A|Observational|N/A||||1000|||Male|50 Years|N/A|No|||February 2003|January 20, 2009|February 15, 2001||||No||https://clinicaltrials.gov/show/NCT00011323||205587|
NCT00012350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12516|Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma|Phase II Evaluation of FTI (R115777) (NSC 702818) in Treatment of Advanced Multiple Myeloma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|January 2001|January 2010|Actual|September 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00012350||205517|
NCT00012363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068515|S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus|Gemcitabine Plus Irinotecan in Patients With Esophageal Cancer, Phase II||Southwest Oncology Group|Yes|Completed|April 2001|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00012363||205516|
NCT00010816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000009-02P3|Herbal Treatment of Hepatitis C in Methadone Maintained Patients|Herbal Treatment of Hepatitis C in Methadone Maintained Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1998|June 2003||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010816||205622|
NCT00010829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000090-01P1|Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors|Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2001|December 2005||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|50 Years|72 Years|Accepts Healthy Volunteers|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010829||205621|
NCT00011037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 026/HIVNET 026|ALVAC-HIV vCP1452 Alone and Combined With MN rgp120|A Multisite Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of ALVAC-HIV vCP1452 Alone and Combined With MN rgp120||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|160|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|February 8, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00011037||205606|
NCT00010426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15704|Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis|||FDA Office of Orphan Products Development||Completed|December 1999|February 2001||||N/A|Interventional|Primary Purpose: Treatment||||30|||Both|1 Year|50 Years|No|||April 2001|March 24, 2015|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010426||205644|
NCT00010439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15705|Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis|A Non-Randomized, Open-Label, Prospective, Non-Controlled, 12-Month Clinical Trial to Determine the Effects of Alendronate 35 or 70 mg/Week Depending Upon Body Weight, in Children and Adolescent With IJO||Medical University of South Carolina|Yes|Completed|September 2000|November 2008|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|5 Years|14 Years|No|||October 2010|October 21, 2010|February 2, 2001|Yes|Yes||No|June 3, 2009|https://clinicaltrials.gov/show/NCT00010439||205643|
NCT00012311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068504|Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer|Multi-Cycle High-Dose Chemotherapy Versus Optimized Conventionally-Dosed Chemotherapy in Patients With Metastatic Breast Cancer: A Phase II Prospective Randomized Trial||National Cancer Institute (NCI)||Active, not recruiting|January 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|59 Years|No|||September 2001|January 3, 2014|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012311||205520|
NCT00010088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068440|Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct|Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas||National Cancer Institute (NCI)||Active, not recruiting|January 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||April 2007|February 6, 2009|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010088||205669|
NCT00010218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068456|Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer|Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|April 2001|January 2006|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|55|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00010218||205659|
NCT00011102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klem (completed)|Prevention of Weight Gain|Prevention of Weight Gain in Women Aged 25 Through 44||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2001|December 2001||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|25 Years|44 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|February 9, 2001||||No||https://clinicaltrials.gov/show/NCT00011102||205601|
NCT00011115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klem-Motivation (completed)|Motivations for Weight Loss|Weight Loss Motivations and Long-term Weight Loss||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2001|May 2003||||N/A|Interventional|Intervention Model: Factorial Assignment, Primary Purpose: Treatment|||||||Female|18 Years|55 Years|No|||January 2010|January 12, 2010|February 9, 2001||||No||https://clinicaltrials.gov/show/NCT00011115||205600|
NCT00011609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2311T|Clinical Evaluation of a Wheelchair Mounted Robotic Arm|Clinical Evaluation of a Wheelchair Mounted Robotic Arm||VA Office of Research and Development||Completed|August 2000|November 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011609||205567|
NCT00011700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9742-CP-001|Stachybotrys Induced Hemorrhage in the Developing Lung|||National Institute of Environmental Health Sciences (NIEHS)||Completed|January 1999|January 2009|Actual|January 2009|Actual|N/A|Observational|N/A|||Anticipated|50|||Both|N/A|12 Months|No|||April 2015|April 13, 2015|February 26, 2001||No||No||https://clinicaltrials.gov/show/NCT00011700||205560|
NCT00014235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1596.00|Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies|Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine and/or Low Dose TBI With Disease-Risk Based Immunosuppression||Fred Hutchinson Cancer Research Center||Active, not recruiting|December 2000|||February 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|74 Years|No|||December 2015|December 1, 2015|April 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00014235||205379|
NCT00014079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-934655|Genetic Markers in Patients With Colorectal Cancer|Clinical Significance of Genetic Markers in Colon Cancer||Alliance for Clinical Trials in Oncology|No|Completed|September 1997|May 2005|Actual|July 2003|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|675|||Both|N/A|N/A|No|Non-Probability Sample|Patients have resectable adenocarcinoma of the colon or rectum and has been previously        enrolled on N784852, N794604, N844652, N864751, N874651, and N894651.|July 2015|July 4, 2015|April 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00014079||205390|
NCT00012103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068484|Computed Tomography for Early Detection of Cancer in Women Who Are at Risk for Lung Cancer|Prevention and Early Detection of Lung Cancer in Women||New York University School of Medicine||Completed|September 1999|||December 2001|Actual|N/A|Interventional|Primary Purpose: Screening|||||||Female|18 Years|N/A|No|||March 2011|March 25, 2011|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012103||205533|
NCT00010621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000076-01P1|Complementary Medicine Approaches to TMD Pain Management|Complementary Medicine Approaches to TMD Pain Management||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|July 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010621||205634|
NCT00010634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000076-01P3|Complementary Naturopathic Medicine for Periodontitis|Complementary Naturopathic Medicine for Periodontitis||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|July 2004||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|35 Years|N/A|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010634||205633|
NCT00011024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000008-01P3|Prospective Studies of the Use of Self Hypnosis, Acupuncture and Osteopathic Manipulation on Muscle Tension in Children With Spastic Cerebral Palsy|Prospective Studies of the Use of Self Hypnosis, Acupuncture and Osteopathic Manipulation on Muscle Tension in Children With Spastic Cerebral Palsy||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1998|June 2004||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|4 Years|21 Years|No|||August 2006|August 17, 2006|February 8, 2001||||No||https://clinicaltrials.gov/show/NCT00011024||205607|
NCT00014391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1379.00|Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation|A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT)||Fred Hutchinson Cancer Research Center||Completed|February 1999|October 2001|Actual|October 2001|Actual|Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||March 2010|March 31, 2010|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014391||205367|
NCT00010452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15706|Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations|Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial||FDA Office of Orphan Products Development||Completed|April 2000|November 2007|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|6 Months|18 Years|No|||January 2008|March 24, 2015|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00010452||205642|
NCT00012025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0032|ICI 182780 in Treating Women With Metastatic Breast Cancer|Phase II Trial Of Fulvestrant (Faslodex) In Women With Metastatic Breast Cancer And Failure on Aromatase Inhibitor Therapy||Alliance for Clinical Trials in Oncology|No|Completed|May 2001|August 2008|Actual|March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Female|18 Years|N/A|No|||July 2015|July 9, 2015|March 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00012025||205538|
NCT00012181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01854|Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas|A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS||National Cancer Institute (NCI)||Completed|April 2001|||January 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|21 Years|No|||July 2013|July 1, 2013|March 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00012181||205527|
NCT00010192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01404|Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer|A Phase I Trial Of Rituximab And Interleukin-2||National Cancer Institute (NCI)||Completed|December 2000|||January 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00010192||205661|
NCT00010205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02375|Benzoylphenylurea in Treating Patients With Advanced Cancer|Phase I Trial Of Benzoylphenylurea (NSC#639829) In Advanced Malignancy||National Cancer Institute (NCI)||Terminated|December 2000|||January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|February 2, 2001|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00010205||205660|
NCT00011180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|864-98|Risk Factors for Venous Thromboembolism in the Community|Subtherapeutic Heparin Anticoagulation as a Predictor of Recurrent Venous Thromboembolism: A Population-Based Cohort Study||Mayo Clinic|No|Completed|April 2001|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|385|Samples With DNA|Plasma and genomic DNA|Both|N/A|N/A|No|Probability Sample|Using the data resouces of the Rochester Epidemiology Project, we will update the        1966-1995 inception cohort to include Olmsted County, Minnesota residents with with a        first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year        period, 1996-2000. All subjects will be followed forward in time through their linked        medical records in the community (retrospective cohort study), until death or the most        recent clinical contact. For each subject, all inpatient and outpatient medical records of        any local health care provider will be searched for vital status at last clinical contact.        For deceased patients, all death certificates will be reviewed regardless of the patient        location at death.        We also identified two Olmsted County residents (controls) without VTE matched by age and        gender to each definite or probable case within the 1996-2000 cohort to perform a        case-control study.|December 2012|December 5, 2012|February 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00011180||205595|
NCT00010504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT000004-01M|Acupuncture in Fibromyalgia|Pilot Study of Acupuncture in Fibromyalgia||National Center for Complementary and Integrative Health (NCCIH)||Completed|August 2000|July 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 2008|March 5, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010504||205638|
NCT00011713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES 009718|Environment and Reproductive Health; Human Exposure to Bisphenol A, Phthalates and Fertility and Pregnancy Outcomes|Human Exposure to Bisphenol A, Phthalates and Fertility, Pregnancy Outcomes.|EARTH|National Institute of Environmental Health Sciences (NIEHS)|No|Recruiting|October 1999|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2401|Samples With DNA|Whole blood, urine, semen, follicular fluid, amniotic fluid|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects will be recruited from couples seeking treatment of infertility at the MGH        IVF Clinic. Men and women must be at least 18 years old to participate in the study.|March 2016|March 9, 2016|February 27, 2001||No||No||https://clinicaltrials.gov/show/NCT00011713||205559|
NCT00011336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|717B|Determine the Association Between the Level of SCI With Chronic Respiratory Symptoms, Measures of Pulmonary Function, and Respiratory Illness.|Prospective Cohort Study of Respiratory Function and Illness in Chronic SCI||VA Office of Research and Development||Completed|July 1998|June 2002||||N/A|Observational|N/A||||400|||Both|N/A|N/A|No|||February 2003|January 20, 2009|February 15, 2001||||No||https://clinicaltrials.gov/show/NCT00011336||205586|
NCT00010387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15672|Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease|||Office of Rare Diseases (ORD)||Completed|March 1999|||August 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment||||32|||Both|N/A|N/A|No|||September 2008|September 8, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010387||205647|
NCT00012259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHIRE-BCH-4556-214|Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Study Of Troxatyl In Patients With CML Blastic Phase Disease||Shire||Completed|October 2000|||February 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|16 Years|N/A|No|||May 2013|May 30, 2013|March 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00012259||205522|
NCT00010647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000084-01P1|Cost-Effectiveness of and Long-Term Outcomes Following Acupuncture Treatment for Osteoarthritis of the Knee|Cost-Effectiveness of and Long-Term Outcomes Following Acupuncture Treatment for Osteoarthritis of the Knee||National Center for Complementary and Integrative Health (NCCIH)||Completed|August 1999|July 2004||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2006|August 16, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010647||205632|
NCT00010686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000090-01P2|Dietary Phytoestrogens and Bone Metabolism|Dietary Phytoestrogens and Bone Metabolism||National Center for Complementary and Integrative Health (NCCIH)||Completed||December 2005||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|50 Years|72 Years|Accepts Healthy Volunteers|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010686||205631|
NCT00013910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00042-1749|NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes|NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes||National Center for Research Resources (NCRR)||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||November 2001|June 23, 2005|April 2, 2001||||No||https://clinicaltrials.gov/show/NCT00013910||205402|
NCT00013923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0027|Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease|A Nutritional Brain Metabolic Enhancer for Alzheimer Disease||National Institute on Aging (NIA)||Completed||June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|50 Years|N/A|No|||August 2003|December 10, 2009|April 2, 2001||||No||https://clinicaltrials.gov/show/NCT00013923||205401|
NCT00014001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH090001-06|CATIE- Schizophrenia Trial|Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)||National Institute of Mental Health (NIMH)||Completed|December 2000|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1600|||Both|18 Years|65 Years|No|||October 2006|June 16, 2015|April 6, 2001||||No||https://clinicaltrials.gov/show/NCT00014001||205396|
NCT00014092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067958|Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery|Treatment of Patients With Metastatic Malignant Melanoma With Chemobiotherapy With Temozolomide, GM-CSF, IL2, and Interferon Alfa-2b Phase II Trial||National Cancer Institute (NCI)||Completed|December 1999|December 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|March 25, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014092||205389|
NCT00010465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000008-01P1|Nervous System Manipulation and Botanicals for the Treatment of Recurrent Ear Infections in Children|Osteopathic Manipulation and Echinacea for the Treatment of Recurrent Ear Infections in Children||National Center for Complementary and Integrative Health (NCCIH)||Completed||December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|12 Months|60 Months|No|||March 2013|March 21, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010465||205641|
NCT00010478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000129-02|Acupuncture and Hypertension|Acupuncture and Hypertension-Efficacy and Mechanisms||National Center for Complementary and Integrative Health (NCCIH)||Completed||||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010478||205640|
NCT00012376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03159|Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer|Dose Finding Study of Bryostatin-1 and GM-CSF in Refractory Myeloid Malignancies||National Cancer Institute (NCI)||Completed|March 2001|||January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|March 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00012376||205515|
NCT00014378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-061|Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors|A Phase I Study Of The Chinese Herb Huanglian (Coptis Chinesis) In Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|October 2000|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|120 Years|No|||December 2015|December 17, 2015|April 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00014378||205368|
NCT00014547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068555|BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment|Phase II Study Of BBR 3464 As Treatment In Patients With Sensitive Or Refractory Small Cell Lung Cancer After One Prior Chemotherapy Regimen||National Cancer Institute (NCI)||Active, not recruiting|November 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2002|July 23, 2008|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014547||205356|
NCT00010868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000161-02|Omega-3 Fatty Acids in Bipolar Disorder|Omega-3 Fatty Acids in Bipolar Disorder Prophylaxis||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2000|July 2004||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010868||205618|
NCT00010517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT000001-01M|Acupuncture in the Treatment of Depression|Acupuncture in the Treatment of Depression||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1997|April 2002||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||March 2008|March 5, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010517||205637|
NCT00011154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8150-CP-001|Exogenous Toxicants and Genetic Susceptibility in ALS|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1996|August 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||525|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 22, 2006|February 12, 2001||||No||https://clinicaltrials.gov/show/NCT00011154||205597|
NCT00010881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000066-01M|Oregon Center for Complementary and Alternative Medicine in Neurological Disorders|Oregon Center for Complementary and Alternative Medicine in Neurological Disorders||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|December 2004||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|65 Years|N/A|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010881||205617|
NCT00012454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010110|E-Selectin Nasal Spray to Prevent Stroke Recurrence|Induction of Mucosal Tolerance to E-Selectin for the Secondary Prevention of Stroke||National Institutes of Health Clinical Center (CC)||Terminated|March 2001|February 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2010|May 3, 2010|March 9, 2001||||No||https://clinicaltrials.gov/show/NCT00012454||205511|
NCT00012467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B013|Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis||InterMune||Completed|January 2000|July 2001|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||May 2009|May 29, 2009|March 9, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00012467||205510|
NCT00012480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6100-CP-001|Effect of Environmental Exposures on the Egg Fertilizing Ability of Human Sperm|Human Sperm Zona Acceptor: Environmental Effects||National Institute of Environmental Health Sciences (NIEHS)||Completed|August 2002|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||Anticipated|400|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|March 9, 2001||No||No||https://clinicaltrials.gov/show/NCT00012480||205509|
NCT00010283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1500.00|Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon|Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy||Fred Hutchinson Cancer Research Center||Completed|July 2000|July 2002|Actual|July 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|5 Years|75 Years|No|||March 2010|March 31, 2010|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010283||205654|
NCT00010374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN 20-0000-0009|Electrical Activation of The Diaphragm for Ventilatory Assist|Multi-Center Pivotal Study of NeuRx RA/4 Ventilatory Assist Device||Synapse Biomedical||Active, not recruiting|February 2000|October 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2008|September 15, 2008|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00010374||205648|
NCT00010114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068446|Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children|Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis||Pediatric Brain Tumor Consortium|No|Completed|March 2001|March 2003|Actual|March 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|83|||Both|N/A|2 Years|No|Non-Probability Sample|The participants in this study are infants (< 3 years of age) with newly diagnosed        medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical        teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who        have received no prior therapy with the exception of steroids and have consented to allow        research studies on banked tissue specimens|July 2011|July 19, 2011|February 2, 2001||No||No||https://clinicaltrials.gov/show/NCT00010114||205667|
NCT00010777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000084-01P2|Fibromyalgia: A Randomized Controlled Trial of a Mind/Body Intervention|Fibromyalgia: A Randomized Controlled Trial of a Mind/Body Intervention||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|March 2004||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010777||205624|
NCT00010972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT000010-01M|Use of Acupuncture for Dental Pain: Testing a Model|Use of Acupuncture for Dental Pain: Testing a Model||National Center for Complementary and Integrative Health (NCCIH)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|40 Years|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010972||205611|
NCT00011349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|719B|Early Stage Prostate Cancer Cohort|CSP #719B - Prospective Cohort of Early Stage Prostate Cancer||VA Office of Research and Development|No|Completed|January 2001|January 2010|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1116|||Male|N/A|N/A|No|Non-Probability Sample|We propose to establish an observational cohort of 1000 US male veterans from 10-12 VAMC        with early stage prostate cancer with no known distant metastases.|April 2013|April 11, 2013|February 15, 2001||No||No||https://clinicaltrials.gov/show/NCT00011349||205585|
NCT00011505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010097|Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia|Investigation of G-CSF-Induced Stem Cell Mobilization Potential in Patients With Diamond-Blackfan Anemia||National Institutes of Health Clinical Center (CC)||Completed|February 2001|April 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||April 2006|March 3, 2008|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011505||205575|
NCT00014534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068554|Combination Chemotherapy in Treating Patients With Bladder Cancer|Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder||Alliance for Clinical Trials in Oncology|Yes|Terminated|March 2004|April 2009|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|April 10, 2001|No|Yes|insufficient accrual|No||https://clinicaltrials.gov/show/NCT00014534||205357|
NCT00014261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068523|Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors|A Phase-I Study Of Cyclical Oral Administration Of Temozolomide In Combination With PEG12000-Interferon Alfa-2B In Patients With Refractory And/Or Advanced Solid Tumors||Dartmouth-Hitchcock Medical Center||Completed|October 2000|||November 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2013|March 15, 2013|April 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00014261||205377|
NCT00014274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30986|Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium|Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|January 2001|||March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|238|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014274||205376|
NCT00012116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068485|Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain|Temozolomide For Patients With Cerebral Metastases Who Have Failed Radiation Therapy||Jonsson Comprehensive Cancer Center|No|Completed|October 2000|April 2002|Actual|April 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00012116||205532|
NCT00012298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00008|Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of Two Sequential Doses of IDEC-Y2B8 in Patients With Relapsed Low-Grade and Follicular Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Terminated|April 2001|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||December 2012|November 4, 2015|March 3, 2001|Yes|Yes|Trial completed prematurely.|No|November 4, 2015|https://clinicaltrials.gov/show/NCT00012298||205521|
NCT00010699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000005-02|Effect of High Dose Vitamin E on Carotid Atherosclerosis|Effect of High Dose Vitamin E on Carotid Atherosclerosis||National Center for Complementary and Integrative Health (NCCIH)||Completed||April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||March 2013|March 21, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010699||205630|
NCT00010712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000090-01P3|Effects of Black Cohosh on Menopausal Hot Flashes|Effects of Black Cohosh on Menopausal Hot Flashes||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|July 2005||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|45 Years|70 Years|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010712||205629|
NCT00010998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000066-01P3|Yoga: Effect on Attention in Aging & Multiple Sclerosis|Yoga: Effect on Attention in Aging & Multiple Sclerosis||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|December 2004||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|65 Years|85 Years|Accepts Healthy Volunteers|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010998||205609|
NCT00011011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5068|Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV|A Randomized Phase I/II Pilot Study of Intermittent Withdrawal of Antiretroviral Therapy as an Immunization Strategy and Double-Blinded Immunization With ALVAC-HIV vCP1452 in Subjects With Persistent CD4+ Cell Counts Greater Than 400 Cells/mm3 and Plasma HIV-1 RNA Levels Less Than 50 Copies/ml||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2001|October 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|94|||Both|13 Years|N/A|No|||July 2013|July 30, 2013|February 8, 2001|No|Yes||||https://clinicaltrials.gov/show/NCT00011011||205608|
NCT00011141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR06020-0165|Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency|Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Year|95 Years|No|||December 2003|June 23, 2005|February 12, 2001||||No||https://clinicaltrials.gov/show/NCT00011141||205598|
NCT00009698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9674|Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia|IL-2 Infusion in AML Patients After Autologous Bone Marrow Transplant: A Pediatric Oncology Group Wide Phase I Trial||Children's Oncology Group|Yes|Completed|March 1998|September 2005|Actual|June 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|21 Years|No|||June 2013|June 27, 2013|February 2, 2001||Yes||No||https://clinicaltrials.gov/show/NCT00009698||205698|
NCT00008840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID MSG 42|A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia|A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2005||||N/A|Observational|N/A||||866|||Both|12 Years|N/A|No|||November 2005|August 26, 2010|January 18, 2001||||No||https://clinicaltrials.gov/show/NCT00008840||205725|
NCT00014170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01855|Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma)||National Cancer Institute (NCI)||Completed|March 2001|||July 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||June 2013|July 15, 2013|April 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00014170||205384|
NCT00010361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15577|Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders|||Office of Rare Diseases (ORD)||Completed|November 2000|||April 2007|Actual|N/A|Interventional|Primary Purpose: Treatment||||20|||Both|N/A|55 Years|No|||August 2006|December 8, 2014|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010361||205649|
NCT00008476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010056|Capsaicin to Control Pain Following Third Molar Extraction|Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia||National Institutes of Health Clinical Center (CC)||Completed|January 2001|January 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||162|||Both|N/A|N/A|No|||January 2004|March 3, 2008|January 9, 2001||||No||https://clinicaltrials.gov/show/NCT00008476||205741|
NCT00008320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0031|Ceramide Cream in Treating Women With Cutaneous Breast Cancer|A Phase II Study Of Topical Ceramide Lipids As Treatment For Cutaneous Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|January 2001|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|January 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00008320||205753|
NCT00014430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068543|Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer|Phase I Clinical Trial Of Vinorelbine (Navelbine) And Trastuzumab (Herceptin) In Patients With Carcinoma Of The Breast Or Non-Small Cell Lung Cancer And HER-2/NEU Overexpression||Dartmouth-Hitchcock Medical Center||Completed|November 1999|||September 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2002|March 12, 2013|April 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00014430||205365|
NCT00008008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068362|Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma|CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy||National Cancer Institute (NCI)||Completed|September 1997|May 2008|Actual|June 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||July 2007|February 1, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008008||205777|
NCT00008060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068372|Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer|Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer||National Cancer Institute (NCI)||Completed|May 2000|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2002|December 18, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008060||205773|
NCT00009633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0007|Follow-up Visit of High Risk Infants|Follow-up Visit of High Risk Infants|FU|NICHD Neonatal Research Network|No|Recruiting|January 1993|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|68000|||Both|18 Months|26 Months|No|Probability Sample|Infants born at 401-1000 grams birth weight and/or <29 weeks gestational age|June 2015|June 3, 2015|February 1, 2001||No||No||https://clinicaltrials.gov/show/NCT00009633||205703|
NCT00010920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000066-01P2|Preventing Cognitive Decline With Alternative Therapies|Preventing Cognitive Decline With Alternative Therapies||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|December 2004||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|85 Years|N/A|Accepts Healthy Volunteers|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010920||205615|
NCT00009581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010078|Nitric Oxide to Improve Blood Flow in Sickle Cell Disease|Targeted Delivery of Nitric Oxide by Hemoglobin to Improve Regional Blood Flow in Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2001|January 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||65|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2003|March 3, 2008|February 1, 2001||||No||https://clinicaltrials.gov/show/NCT00009581||205706|
NCT00009620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0006|Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage|Randomized Clinical Trial of Antenatal Phenobarbital in the Prevention of Neonatal Intracranial Hemorrhage|Phenobarbital|NICHD Neonatal Research Network|Yes|Completed|February 1993|February 1997|Actual|February 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|610|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|February 1, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009620||205704|
NCT00010023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068434|Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System||New York University School of Medicine||Completed|August 2000|||August 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 4, 2011|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010023||205674|
NCT00010127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0759|Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer|A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA||Duke University||Terminated|November 2000|March 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|3|||Male|18 Years|N/A|No|||December 2008|March 19, 2013|February 2, 2001|No|Yes||||https://clinicaltrials.gov/show/NCT00010127||205666|
NCT00010140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068450|Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer|A Multicenter Randomized Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin in Node Positive Postmenopausal Breast Cancer Patients||National Cancer Institute (NCI)||Active, not recruiting|August 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||September 2005|December 17, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010140||205665|
NCT00010036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068435|Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme|A Phase I/II Trial of CPT-11 With Carboplatin in Patients With Glioblastoma Multiforme Prior to Radiation Therapy||New York University School of Medicine||Completed|May 1999|||October 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 25, 2011|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010036||205673|
NCT00010049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068437|Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma|Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|November 2002|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|July 31, 2010|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010049||205672|
NCT00009867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02789|Arsenic Trioxide in Treating Patients With Urothelial Cancer|A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER||National Cancer Institute (NCI)||Completed|December 2000|||June 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009867||205686|
NCT00014404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-111|Celecoxib in Treating Patients With Precancerous Lesions of the Mouth|Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions||Memorial Sloan Kettering Cancer Center||Completed|October 2000|||January 2006|Actual|Phase 2|Interventional|Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||January 2013|January 15, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014404||205366|
NCT00011167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-112|Retinal Arteriolar Abnormalities and CV Mortality|||University of Wisconsin, Madison|No|Completed|March 2001|February 2003|Actual|February 2003|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1380|||Both|43 Years|86 Years|No|Non-Probability Sample|The Beaver Dam Eye Study cohort was first identified by a private census of the city of        Beaver Dam, Wisconsin from September 15, 1987 to May 4, 1988, was examined from 1988-90        (baseline examination), and re-examined in 1993-95 and 1998-2000. The baseline examination        formed the population for both cases and controls. Cases were defined as study        participants who had died since the baseline examination from stroke or ischemic heart        disease. Three participants per case were selected from the entire cohort at baseline as        controls, age and sex matched to cases, irrespective of vital status. No participants were        recruited specifically for this study.|February 2016|February 5, 2016|February 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00011167||205596|
NCT00014183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068512|ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer|A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent||University of Maryland||Completed|January 2001|August 2005|Actual|May 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|September 23, 2009|April 10, 2001||Yes||No||https://clinicaltrials.gov/show/NCT00014183||205383|
NCT00010985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT000144-01M|Usual Care Vs Choice of Alternative Rx: Low Back Pain|Usual Care Vs Choice of Alternative Rx: Low Back Pain||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|August 2003||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2008|March 5, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010985||205610|
NCT00008541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010046|Evaluation and Treatment of Patients With Corneal and External Diseases|Evaluation and Treatment of Corneal and External Diseases and Anterior Segment Disorders||National Institutes of Health Clinical Center (CC)||Completed|January 2001|March 2009||||N/A|Observational|N/A||||600|||Both|2 Years|N/A|No|||March 2009|September 26, 2015|January 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00008541||205736|
NCT00008554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316A|Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy|A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults||NIH AIDS Clinical Trials Information Service||Active, not recruiting|November 2000|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||210|||Both|13 Years|N/A|No|||July 2001|June 23, 2005|January 13, 2001||||No||https://clinicaltrials.gov/show/NCT00008554||205735|
NCT00008827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HarveyBerinoInternet (cmpltd)|The Use of the Internet to Facilitate Weight Loss and Maintenance.|The Use of the Internet to Facilitate Weight Loss and Maintenance.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2000|April 2001||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 12, 2010|January 17, 2001||||No||https://clinicaltrials.gov/show/NCT00008827||205726|
NCT00010907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT00009-02P1|Preliminary Human Trial of NPI-028|||National Center for Complementary and Integrative Health (NCCIH)||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|80 Years|No|||March 2013|March 21, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010907||205616|
NCT00010075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068439|Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer|Study Of The Survival Without Degradation To The Quality Of Life During Chemotherapy For Metastatic Breast Cancer In Women||National Cancer Institute (NCI)||Active, not recruiting|January 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|75 Years|90 Years|No|||June 2003|July 23, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010075||205670|
NCT00008021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD-991860|Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma|A Phase I Study of 90Y-DOTA-Peptide-Lym-1 With Peripheral Blood Stem Cell Support, Paclitaxel And Cyclosporin A In Patients With Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|February 2001|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|August 6, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008021||205776|
NCT00008073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-088|Octreotide and Doxorubicin in Treating Patients With Advanced Cancer|Phase I Study Of Octreotide Acetate (Sandostatin) (SMS) As A Biomodulator Of Doxorubicin (DOX)||University of Pittsburgh||Completed|January 1996|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2013|December 18, 2013|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008073||205772|
NCT00010244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068458|Comparison of Radiation Therapy Regimens in Treating Patients With Localized Prostate Cancer|Conformational, Curative Ratiotherapy For Prostate Cancer (NO, N-): Phase III Multicenter Study Of The Contribution To Survival Without Clinical Or Biological Change With A Dose Variation Of 15% (80 Gy VS 70 Gy)||National Cancer Institute (NCI)||Active, not recruiting|September 1999|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Male|N/A|74 Years|No|||January 2011|February 18, 2011|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010244||205657|
NCT00009763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068369|Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer|Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression||National Cancer Institute (NCI)||Active, not recruiting|March 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2003|September 19, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009763||205694|
NCT00010062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068438|Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer|Study Of Post-Operative Concomitant Radio-Chemotherapy With A Continuous Infusion Of Flourouracil For Adjuvant Treatment Of Resected Pancreatic Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||April 2007|February 6, 2009|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010062||205671|
NCT00014105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068432|Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I/II Trial of Temozolomide and Carboplatin in Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Active, not recruiting|December 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|December 3, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014105||205388|
NCT00014118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068468|Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer|A Phase II Trial OF Chemoradiation For Organ Preservation In Resectable Stage III or IV Squamous Cell Carcinomas Of The Larynx Or Oropharynx||Eastern Cooperative Oncology Group||Completed|March 2001|May 2009|Actual|March 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|120 Years|No|||October 2015|October 6, 2015|April 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00014118||205387|
NCT00014131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068493|Vaccine Therapy in Treating Patients With Kidney Cancer|Vaccine Biotherapy Of Cancer: Autologous Tumor Cells And Dendritic Cells As Active Specific Immunotherapy In Patients With Stage IV Renal Cell Carcinoma||Caladrius Biosciences, Inc.|No|Active, not recruiting|November 2001|December 2015|Anticipated|December 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|16 Years|N/A|No|||June 2014|June 30, 2014|April 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00014131||205386|
NCT00014196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068516|S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer|Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer||Southwest Oncology Group|No|Terminated|March 2001|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|April 10, 2001|Yes|Yes|This study was closed early due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00014196||205382|
NCT00009685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010079|HIV-1 Vaccine Test in Uninfected Adult Volunteers|Evaluation of an HIV-1 DNA Vaccine Encoding a Modified Gag-Pol Protein in Uninfected Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|January 2001|March 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||21|||Both|N/A|N/A|No|||March 2005|March 3, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009685||205699|
NCT00009061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316B|Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs|A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination With Abacavir and Lamivudine for 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Subjects||NIH AIDS Clinical Trials Information Service||Active, not recruiting|November 2000|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||624|||Both|13 Years|N/A|No|||March 2002|June 23, 2005|January 23, 2001||||No||https://clinicaltrials.gov/show/NCT00009061||205718|
NCT00008489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|315A|Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults|A Randomized Open-Label Trial Comparing the Tolerability of Videx EC Capsules to Videx Tablets in Adults With HIV Infection||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 3|Interventional|Primary Purpose: Treatment||||200|||Both|16 Years|N/A|No|||January 2002|December 8, 2005|August 30, 2001||||No||https://clinicaltrials.gov/show/NCT00008489||205740|
NCT00008086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-004|Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carboplatin in Advanced Solid Tumors||University of Pittsburgh||Completed|January 1996|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2013|December 18, 2013|January 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008086||205771|
NCT00014560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068556|Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)||Dartmouth-Hitchcock Medical Center||Terminated|September 2000|||February 2003||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|120 Years|No|||April 2013|October 12, 2015|April 10, 2001|Yes|Yes|Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on    unrelated trials halting manufacturing of BsAb|No|April 2, 2013|https://clinicaltrials.gov/show/NCT00014560||205355|This study was prematurely ended by the sponsor Medarex (supplier of BsAb) due to toxicities experienced at other sites on unrelated trials leading to the decision that Medarex would not be manufacturing the investigational product (BsAb).
NCT00014573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068559|Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer|Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors||Barbara Ann Karmanos Cancer Institute|No|Completed|August 1998|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|N/A|65 Years|No|||April 2013|April 5, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014573||205354|
NCT00011128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5086|Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment|Phase III Evaluation of the Role of Temporary Cessation of Antiretroviral Treatment and Resistance Testing-Based Selection of Antiretroviral Drugs in the Virologic Response to Salvage Therapy for Heavily Treatment-Experienced HIV-Infected Individuals Failing Current Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2004|May 15, 2015|February 10, 2001||||No||https://clinicaltrials.gov/show/NCT00011128||205599|
NCT00008801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00400-0672|hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure|hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|60 Years|No|||December 2003|October 31, 2005|January 16, 2001||||No||https://clinicaltrials.gov/show/NCT00008801||205728|
NCT00008814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00400-0680|Functional Magnetic Resonance Imaging in Infants|Functional Magnetic Resonance Imaging (fMRI) in Infants||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||||||Both|N/A|4 Months|Accepts Healthy Volunteers|||December 2003|June 23, 2005|January 16, 2001||||No||https://clinicaltrials.gov/show/NCT00008814||205727|
NCT00011063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010080|Effect of Ginkgo Biloba on Phenytoin Elimination|Evaluation of the Effect of Ginkgo Biloba on Phenytoin Pharmacokinetics||National Institutes of Health Clinical Center (CC)||Completed|February 2001|April 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||12|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2001|March 3, 2008|February 9, 2001||||No||https://clinicaltrials.gov/show/NCT00011063||205604|
NCT00010179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I138|Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer|Randomized Phase II Study Of NX 211 Given By Two Different Intravenous Schedules In Advanced And/Or Recurrent Epithelial Ovarian Cancer||Canadian Cancer Trials Group||Completed|June 2000|September 2008|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2010|November 7, 2010|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010179||205662|
NCT00008034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10991|Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer|A Phase I Study Of Cyclophoshamide And Epirubicin In Combination With Capecitabine (XELODA) (CEX) As Primary Treatment Of Locally Advanced/Inflammatory Or Large Operable Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2000|||December 2000|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|15|||Female|18 Years|70 Years|No|||July 2012|July 17, 2012|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008034||205775|
NCT00009776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068371|Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma|Combined Modality Radioimmunotherapy For Non-Hodgkin's Lymphoma With Three Cycles Of 90Y-DOTA-peptide-Lym-1, Paclitaxel and Cyclosporin A||National Cancer Institute (NCI)||Active, not recruiting|March 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2001|September 19, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009776||205693|
NCT00009789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068409|Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction|Accelerated Conformal Radiotherapy for Stage I Non-Small Cell Lung Cancer in Patients With Pulmonary Dysfunction: A Phase I Study||Alliance for Clinical Trials in Oncology|No|Completed|December 2000|June 2010|Actual|June 2007|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009789||205692|
NCT00010335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1353.00|Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders|A Pilot Study of High-Dose Immunosuppression Followed by Infusion of CD34-Selected Autologous or Syngeneic Peripheral Blood Stem Cells for Treatment of Refractory Autoimmune Disorders||Fred Hutchinson Cancer Research Center|Yes|Completed|November 2000|May 2011|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|18 Years|No|||March 2015|March 4, 2015|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00010335||205651|
NCT00009906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02372|Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor|Phase III Randomized, Intergroup Trial Assessing the Clinical Activity Of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the Kit Receptor Tyrosine Kinase (CD117)||National Cancer Institute (NCI)||Terminated|December 2000|November 2014|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|748|||Both|15 Years|N/A|No|||June 2014|December 19, 2014|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00009906||205683|
NCT00009594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000076-01P2|Alternative Medicine Approaches for Women With Temporomandibular Disorders|Alternative Medicine Approaches for Women With Temporomandibular Disorders||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|July 2004||||Phase 2|Interventional|Primary Purpose: Diagnostic|||||||Female|25 Years|55 Years|No|||August 2006|August 17, 2006|February 1, 2001||||No||https://clinicaltrials.gov/show/NCT00009594||205705|
NCT00009711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1097.00|Study of Lung Function in Children Who Have Undergone Bone Marrow Transplantation|The Impact of Pediatric Marrow Transplantation on Late Pulmonary Function||Fred Hutchinson Cancer Research Center||Completed|March 1996|August 2005|Actual|August 2004|Actual|N/A|Observational|N/A|||Anticipated|280|||Both|N/A|17 Years|No|||April 2013|April 29, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009711||205697|
NCT00010309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068478|Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma|Phase I/II Trial Investigating The Safety And Immunogenicity Of Adenoviruses Encoding The Melan-A/MART-1 And gp 100 Melanoma Antigens Administered Intradermally To Patients With Stage II-IV Melanoma||National Cancer Institute (NCI)||Active, not recruiting|November 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2002|January 3, 2014|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010309||205653|
NCT00010322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068480|Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer|Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer||Intarcia Therapeutics|No|Terminated|October 2000|May 2001|Actual|May 2001|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2014|March 24, 2014|February 2, 2001|Yes|Yes|Withdrawn due to change in standard of care - new protocol required|No||https://clinicaltrials.gov/show/NCT00010322||205652|
NCT00014209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY10|Combination Chemotherapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma That Has Not Responded to Previous Treatment|A Phase II Study Of Gemcitabine, Dexamethasone, And Cisplatin (GDP) In Patients With Either Hodgkin's Disease Or Aggressive Histology Non-Hodgkin's Lymphoma Which Is Relapsed Or Refractory||Canadian Cancer Trials Group||Completed|December 2000|February 2009|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||March 2010|November 7, 2010|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014209||205381|
NCT00014222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA21|Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer|A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer||Canadian Cancer Trials Group|Yes|Completed|December 2000|March 2014|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2104|||Female|N/A|60 Years|No|||March 2014|March 17, 2014|April 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00014222||205380|
NCT00009854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068416|Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm|Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain||National Cancer Institute (NCI)||Active, not recruiting|June 2000|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2003|November 5, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009854||205687|
NCT00010010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068431|Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer|A Phase II Study of the Combination of Exemestane and Goserelin in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer||New York University School of Medicine||Completed|June 2000|||May 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|120 Years|No|||March 2016|March 10, 2016|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00010010||205675|
NCT00008697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066617|Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia|A Phase I/II Trial of Infusional Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia||Washington University School of Medicine|No|Completed|November 1998|April 2002|Actual|April 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|13|||Both|N/A|N/A|No|||April 2013|April 11, 2013|January 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00008697||205734|
NCT00014144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068509|S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract|Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II||Southwest Oncology Group|No|Completed|February 2001|December 2007|Actual|May 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|N/A|No|||October 2012|October 5, 2012|April 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00014144||205385|
NCT00010803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AT000162-01M|Ginkgo Biloba Prevention Trial in Older Individuals|Ginkgo Biloba Prevention Trial in Older Individuals||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|October 2000|July 2011|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3069|||Both|75 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|February 2, 2001|Yes|Yes||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00010803||205623|
NCT00009048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010071|EMD 128130 for the Treatment of Parkinson's Disease|Effect of Serotoninergic Treatment in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2001|December 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||December 2003|March 3, 2008|January 23, 2001||||No||https://clinicaltrials.gov/show/NCT00009048||205719|
NCT00008203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068387|Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer|High-Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support And One Of Two Regimens Aimed At Modifying Immune Reconstitution In Women With High Risk Stage 2 And Stage 3 Breast Cancer||National Cancer Institute (NCI)||Completed|May 1996|May 2008|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|65 Years|No|||May 2003|February 1, 2013|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008203||205762|
NCT00014287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-039|Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer|Intravesical Gemcitabine Therapy for BCG-Refractory Superficial Bladder Cancer: A Phase I and Pharmacokinetic Study||University of Pittsburgh||Withdrawn|September 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|April 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00014287||205375|
NCT00010270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068462|LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer|A Phase I Study Of LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin Administered By 5-Days Continuous Infusion For Patients With Colorectal Adenocarcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||January 2007|December 18, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010270||205655|
NCT00008047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068368|Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus|Multicentre Phase II Study Of Concomitant Radio-Chemotherapy Associating Continuous Infusion 5-FU With Hydroxyuree Via Bone Marrow With Or Without Paclitaxel In Treatment Of Inoperable Epidermoid Carcinoma Of Esophagus||National Cancer Institute (NCI)||Active, not recruiting|August 1999|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||February 2001|February 6, 2009|January 6, 2001||||No||https://clinicaltrials.gov/show/NCT00008047||205774|
NCT00009945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-34|Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer|A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy||NSABP Foundation Inc|Yes|Completed|January 2001|December 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3323|||Female|18 Years|N/A|No|||April 2014|April 2, 2014|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00009945||205680|
NCT00009958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03151|Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer|A Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM (B7.1/ICAM/LFA-3) Alone, and in Combination With Vaccinia-CEA(6D)-TRICOM, and the Role of GM-CSF, in Patients With CEA Expressing Carcinomas||National Cancer Institute (NCI)||Terminated|November 2000|||April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009958||205679|
NCT00009971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068428|Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer|Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|November 2000|||September 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||October 2003|February 8, 2013|February 2, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00009971||205678|
NCT00011193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL66262|Dose-Response to Exercise in Women Aged 45-75 Years (DREW)|Dose-response to Exercise in Women Aged 45-75 Years (DREW)|DREW|Pennington Biomedical Research Center|Yes|Completed|January 2001|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|464|Samples With DNA|whole blood|Female|45 Years|75 Years|No|Non-Probability Sample|Postmenopausal women aged 45 to 75 years who are overweight|May 2012|May 25, 2012|February 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00011193||205594|
NCT00011206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|963|Mortality Follow-Up and Analyses of Men in the MRFIT|||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2001|June 2006|Actual|June 2006|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|N/A|No|||March 2014|March 14, 2014|February 13, 2001||||No||https://clinicaltrials.gov/show/NCT00011206||205593|
NCT00010413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15674|Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus|||Office of Rare Diseases (ORD)||Completed|April 1999|||August 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||35|||Both|18 Years|70 Years|No|||October 2008|October 1, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010413||205645|
NCT00009919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02373|SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment|Phase II Study of SU5416 (NSC 696819) for Patients With Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or 5-Fluorouracil Containing Regimens||National Cancer Institute (NCI)||Terminated|December 2000|||June 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|16 Years|N/A|No|||January 2013|January 22, 2013|February 2, 2001|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00009919||205682|
NCT00009932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-00H0186|Combination Chemotherapy in Treating Patients With Solid Tumors|A Phase I Study Of Fenretinide Combined With Paclitaxel And Cisplatin For The Treatment Of Refractory Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2002|May 14, 2013|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00009932||205681|
NCT00009880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0113|Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach|Non-Operative Therapy Of Local-Regional Carcinoma Of The Esophagus: A Randomizd Phase II Study Of Two Paclitaxel-Based Chemoradiotherapy Regimens||Radiation Therapy Oncology Group|Yes|Completed|April 2001|||July 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2004|July 17, 2013|February 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00009880||205685|
NCT00010400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15673|Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome|||Office of Rare Diseases (ORD)||Completed|April 1997|||||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment||||35|||Both|18 Years|70 Years|No|||July 2004|June 23, 2005|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010400||205646|
NCT00014365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-118|Ro 31-7453 in Treating Patients With Metastatic Solid Tumors|The Food-Effect Bioavailability Study of Ro 31-7453, a Novel Cell Cycle Inhibitor, in Stable Patient Volunteers With Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|October 2000|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014365||205369|
NCT00013247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 99-277|Facilitating Shared Decisionmaking About Prostate Cancer Screening|Facilitating Shared Decisionmaking About Prostate Cancer Screening||VA Office of Research and Development|No|Completed||December 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|1152|||Male|50 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013247||205452|
NCT00014040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010140|Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease|Nitric Oxide Inhalation Therapy for Myocardial Ischemia in Patients With Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2001|April 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||April 2003|March 3, 2008|April 7, 2001||||No||https://clinicaltrials.gov/show/NCT00014040||205393|
NCT00013208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 97-077|Proactive Diabetes Case Management|Proactive Diabetes Case Management||VA Office of Research and Development|No|Completed||August 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|260|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013208||205455|
NCT00012922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI 99-158|Low Literacy Intervention for Colorectal Cancer Screening|Low Literacy Intervention for Colorectal Cancer Screening||VA Office of Research and Development|No|Completed||April 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|2400|||Male|50 Years|N/A|Accepts Healthy Volunteers|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012922||205477|
NCT00014053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5113|A Study of Immune System Activity in Healthy Adults|A Study of Immune Function in Healthy Adults Aged 18-30 and 45 and Older||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2003|July 29, 2008|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014053||205392|
NCT00014443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068544|Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma|A Pilot Study Of Hycamtin (Topotecan) And Thalomid (Thalidomide) In Patients With Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Active, not recruiting|August 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||January 2006|July 23, 2008|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014443||205364|
NCT00014456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9933|Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors|A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors||Dartmouth-Hitchcock Medical Center|Yes|Completed|March 2000|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|April 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00014456||205363|
NCT00016445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15806|Phase II Study of Growth Hormone in Children With Cystic Fibrosis|||Office of Rare Diseases (ORD)||Completed|February 2001|||August 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||40|||Both|5 Years|12 Years|No|||September 2008|September 8, 2008|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016445||205237|
NCT00016458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15818|Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis|||Office of Rare Diseases (ORD)||Completed|June 2000|||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|N/A|64 Years|No|||September 2008|September 2, 2008|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016458||205236|
NCT00013182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRM 95-184|Effect of Activity on Sleep of Cognitively-Impaired Veterans|Effect of Activity on Sleep of Cognitively-Impaired Veterans||VA Office of Research and Development|No|Completed||June 2001|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Male|55 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013182||205457|
NCT00013832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010135|Study of Tongue Pressures|Effect of Task on Oral Pressure Dynamics During Swallowing||National Institutes of Health Clinical Center (CC)||Completed|March 2001|April 2007||||N/A|Observational|N/A||||160|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2007|September 26, 2015|March 30, 2001||||No||https://clinicaltrials.gov/show/NCT00013832||205408|
NCT00013325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2140R|Cardiac Disease and the Electrocardiogram in SCI Patients|Cardiac Disease and the Electrocardiogram in SCI Patients||VA Office of Research and Development||Completed|October 1999|September 2002|Actual|||Phase 2|Observational|Time Perspective: Prospective||||800|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013325||205446|
NCT00014352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-113|Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer|Phase II Trial Of Sequential Estramustine/Paclitaxel Followed By Doxorubicin/Ketoconazole In Patients With Androgen-Independent Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|September 2000|||March 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||January 2013|January 15, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014352||205370|
NCT00013078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 94-003|Safe-Grip Fall/Injuries Intervention: A Randomized Trial|Safe-Grip Fall/Injuries Intervention: A Randomized Trial||VA Office of Research and Development|No|Completed||June 2001|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|210|||Both|65 Years|N/A|No|||June 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013078||205465|
NCT00013195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRM 95-022|Nurse Counseling for Physical Activity in Primary Care Patients|Nurse Counseling for Physical Activity in Primary Care Patients||VA Office of Research and Development|No|Completed||June 2000|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|1||Anticipated|210|||Both|60 Years|80 Years|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013195||205456|
NCT00016978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01859|Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan|A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients With Metastatic Colorectal Carcinoma Previously Treated With Irinotecan (CPT-11)||National Cancer Institute (NCI)||Completed|April 2001|||June 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||August 2007|February 4, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016978||205205|
NCT00016991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2421|ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse|A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme||Duke University||Completed|June 2001|April 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2009|June 19, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016991||205204|
NCT00013091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 95-074|Treatment of Depression in Patients With PTSD|Treatment of Depression in Patients With PTSD||VA Office of Research and Development|No|Completed|October 1997|September 2002|Actual|September 2002|Actual|N/A|Interventional|Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|120|||Both|21 Years|N/A|No|||May 2009|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013091||205464|
NCT00012519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1013|Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment|A Phase I/II Trial of Ritonavir and Indinavir in Children Failing Other Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|2 Years|17 Years|No|||May 2012|May 17, 2012|March 10, 2001||||||https://clinicaltrials.gov/show/NCT00012519||205506|
NCT00012545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010122|Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease|Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|March 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|March 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00012545||205505|
NCT00013585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5090|Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients|Phase II, Placebo-Controlled, Double-Blind Study of the Selegiline Transdermal System (STS) in the Treatment of HIV-Associated Cognitive Impairment||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|127|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|March 22, 2001||||||https://clinicaltrials.gov/show/NCT00013585||205426|
NCT00013143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF 99-144|Patient Profiling and Provider Feedback to Reduce Adverse Drug Events|Patient Profiling and Provider Feedback to Reduce Adverse Drug Events||VA Office of Research and Development|No|Completed|June 2001|January 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind|1||Anticipated|1200|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013143||205460|
NCT00013845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010139|Evaluation and Treatment of Patients With Epilepsy|Evaluation and Treatment of Patients With Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|March 2001|||||N/A|Observational|N/A|||Anticipated|21500|||Both|2 Years|N/A|No|||September 2015|March 22, 2016|March 30, 2001||No||No||https://clinicaltrials.gov/show/NCT00013845||205407|
NCT00013858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7902-CP-001|Environmental Contaminants and Infant Development|||National Institute of Environmental Health Sciences (NIEHS)||Completed|January 1997|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|280|||Both|N/A|1 Day|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 30, 2001||No||No||https://clinicaltrials.gov/show/NCT00013858||205406|
NCT00013403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1998R|The Impact of Rehabilitation on Quality of Life in Visually Impaired|The Impact of Rehabilitation on Quality of Life in Visually Impaired||VA Office of Research and Development||Completed|April 1999|March 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013403||205440|
NCT00016393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068629|BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|June 2001|April 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||February 2004|June 20, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016393||205241|
NCT00016406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068630|S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer|A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer||Southwest Oncology Group|Yes|Completed|May 2001|February 2012|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|399|||Female|18 Years|N/A|No|||January 2013|January 23, 2013|May 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00016406||205240|
NCT00012558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH80001|Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)|Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)||National Institute of Mental Health (NIMH)||Completed|September 1998|September 2005||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||5000|||Both|15 Years|N/A|No|||April 2007|May 3, 2007|March 13, 2001||||||https://clinicaltrials.gov/show/NCT00012558||205504|
NCT00012584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH12012|Treatment of Youth With ADHD and Anxiety|A Treatment Study of Youth With Comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Anxiety Disorders||National Institute of Mental Health (NIMH)||Completed|November 2000|May 2002|Actual|May 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|6 Years|17 Years|No|||June 2009|June 23, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012584||205503|
NCT00013507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2226R|Effects of Functional Incidental Training in VA NHCU Residents|Effects of Functional Incidental Training in VA NHCU Residents||VA Office of Research and Development||Completed|January 1999|December 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|24|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013507||205432|
NCT00013416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2002R|Measurement and Prediction of Outcomes of Amplification|Measurement and Prediction of Outcomes of Amplification||VA Office of Research and Development||Completed|October 1999|September 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|60 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013416||205439|
NCT00013429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2102R|Evaluation of Eye Movement Tracking Systems for Visual Rehabilitation|Evaluation of Eye Movement Tracking Systems for Visual Rehabilitation||VA Office of Research and Development||Completed|January 2000|September 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013429||205438|
NCT00016653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC0599|Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy|A Multicenter Randomized Placebo-controlled Double-blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy||Cooperative International Neuromuscular Research Group||Completed|June 2000|December 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Male|5 Years|9 Years|No|||October 2011|October 26, 2011|May 21, 2001||||||https://clinicaltrials.gov/show/NCT00016653||205225|
NCT00016471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00071-0374|A Genetic Analysis of Usher Syndrome in Ashkenazi Jews|A Genetic Analysis of Usher Syndrome in Ashkenazi Jews||National Center for Research Resources (NCRR)||Completed|March 2001|February 2002||||N/A|Observational|Observational Model: Defined Population|||||||Both|N/A|N/A|No|||November 2003|June 23, 2005|May 7, 2001||||No||https://clinicaltrials.gov/show/NCT00016471||205235|
NCT00014495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-117|Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer|Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies||Memorial Sloan Kettering Cancer Center||Completed|November 2000|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|120 Years|No|||December 2015|December 17, 2015|April 10, 2001|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00014495||205360|
NCT00014508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068551|Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma||National Cancer Institute (NCI)||Completed|April 2001|||February 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||November 2005|February 25, 2009|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014508||205359|
NCT00013572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B011|HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults|A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 1|Interventional|Primary Purpose: Prevention||||36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2003|June 23, 2005|March 21, 2001||||No||https://clinicaltrials.gov/show/NCT00013572||205427|
NCT00016666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010175|Clinical Trial of Propranolol for Seasonal Affective Disorder|Treatment of Winter Depression With Pharmacological Suppression of Melatonin Secretion||National Institutes of Health Clinical Center (CC)||Completed|May 2001|January 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2007|February 24, 2007|May 23, 2001||||No||https://clinicaltrials.gov/show/NCT00016666||205224|
NCT00013104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCR 99-014|Implementation of Ischemic Heart Disease Clinical Practice Guidelines|Implementation of Ischemic Heart Disease Clinical Practice Guidelines||VA Office of Research and Development|No|Completed||September 2002|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|||January 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013104||205463|
NCT00013117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCR 99-008|Computer-Assisted Access to Specialist Expertise|Computer-Assisted Access to Specialist Expertise||VA Office of Research and Development|No|Completed||December 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10000|||Both|N/A|N/A|No|||November 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013117||205462|
NCT00014586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30991|Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer|Randomized Phase III Step-Up Study On Initial Antiandrogen Monotherapy In Comparison With Watchful Waiting In Asymptomatic T1-3 Any G (Any Gleason) NO or Nx M0 Prostate Cancer Patients Without Local Treatment With Curative Intent||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|January 2001|||February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|110|||Male|N/A|80 Years|No|||September 2012|September 20, 2012|April 10, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00014586||205353|
NCT00012701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIS 99-042|Measuring HIV Quality of Care|Measuring HIV Quality of Care||VA Office of Research and Development|No|Completed||June 2003|Actual|||N/A|Observational|N/A||1|Anticipated|1600|||Both|N/A|N/A|No|||July 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012701||205494|
NCT00013754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9601-CP-001|Pesticide Exposure Pathways for Farmworker Children|Child Environmental Health Center--Reducing Pesticide Exposure in Children of Farmworkers (UW IRB 96-6567-C02, FENSKE, 6/15/00-6/14/01)||National Institute of Environmental Health Sciences (NIEHS)||Completed|March 2001|October 2003|Actual|October 2003|Actual|N/A|Observational|N/A|||Anticipated|40|||Both|2 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 29, 2001||No||No||https://clinicaltrials.gov/show/NCT00013754||205414|
NCT00012714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 94-125|Evaluation of Subacute Rehabilitative Care|Evaluation of Subacute Rehabilitative Care||VA Office of Research and Development|No|Completed||June 2000|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|55 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012714||205493|
NCT00013156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 96-024|Cost-Effectiveness of Lung Volume Reduction Surgery|Cost-Effectiveness of Lung Volume Reduction Surgery||VA Office of Research and Development|No|Completed||March 2000|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Male|N/A|75 Years|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013156||205459|
NCT00013936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010136|A Novel Acuity Testing Method|A Novel Acuity Testing Method||National Institutes of Health Clinical Center (CC)||Completed|March 2001|October 2002||||N/A|Observational|N/A||||500|||Both|N/A|N/A|No|||October 2002|March 3, 2008|April 3, 2001||||No||https://clinicaltrials.gov/show/NCT00013936||205400|
NCT00016419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0020|S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome|A Phase II Study of Anti-Thymocyte Globulin and Cyclosporine for Patients With Myelodysplastic Syndrome (MDS)||Southwest Oncology Group||Completed|August 2001|January 2007|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|15 Years|N/A|No|||March 2015|March 5, 2015|May 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00016419||205239|
NCT00012831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 95-143|Nurse Managed Clinic for Dementia Patients and Family Caregivers|Nurse Managed Clinic for Dementia Patients and Family Caregivers||VA Office of Research and Development|No|Completed||June 2001|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Male|N/A|N/A|No|||December 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012831||205484|
NCT00013689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010132|Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome|Pilot Study of Pyrimethamine and Sulfadoxine (Fansidar) for the Treatment of Individuals With the Autoimmune Lymphoproliferative Syndrome (ALPS)||National Institutes of Health Clinical Center (CC)||Completed|March 2001|March 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||8|||Both|N/A|N/A|No|||March 2003|March 3, 2008|March 28, 2001||||No||https://clinicaltrials.gov/show/NCT00013689||205419|
NCT00013702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010134|Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients|Adefovir Dipivoxil for the Treatment of Hepatitis B in Human Immunodeficiency Virus Infected Patients With Decompensated Hepatitis B Liver Disease and a Hepatitis B Viral Load of at Least 1.0 X 10(6) (Copies/mL) Despite 52 Weeks of Lamivudine Therapy||National Institutes of Health Clinical Center (CC)||Completed|March 2001|February 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||February 2004|March 3, 2008|March 28, 2001||||No||https://clinicaltrials.gov/show/NCT00013702||205418|
NCT00016848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010183|Effects of Dietary Carbohydrate and Fat on Hormones|The Effects of Dietary Carbohydrate and Fat on Hormone Regulators of Body Composition and Reproduction||National Institutes of Health Clinical Center (CC)||Completed|June 2001|May 2003||||N/A|Observational|N/A||||80|||Both|N/A|N/A|No|||May 2003|March 3, 2008|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016848||205215|
NCT00016497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCD1RO1DC035-04|Adenoidectomy for Otitis Media in 2-3 Year Old Children|Adenoidectomy for Otitis Media in 2-3 Year Old Children||National Institute on Deafness and Other Communication Disorders (NIDCD)||Terminated|February 1997|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|24 Months|47 Months|No|||April 2006|April 21, 2006|May 10, 2001||||No||https://clinicaltrials.gov/show/NCT00016497||205234|
NCT00014625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16005-18002|E7070 in Treating Patients With Stage IV Melanoma|Open Label Phase II Study Of E7070 In Patients With Metastatic Melanoma (Stage IV)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2001|||November 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|28|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014625||205350|
NCT00014638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068583|Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer|Open Label, Multicenter Trial Of Femera (Letrozole) 2.5 mg As First-line Therapy In Postmenopausal Women With Metastatic Breast Cancer Relapsing Following Adjuvant Tamoxifen Therapy||Novartis||Completed|January 2001|March 2002|Actual|March 2002|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2013|February 20, 2013|April 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00014638||205349|
NCT00013130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 96-002|Ambulatory Care Quality Improvement (ACQUIP)|Ambulatory Care Quality Improvement (ACQUIP)||VA Office of Research and Development|No|Completed||February 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|62487|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013130||205461|
NCT00013975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010119|Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease|Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|March 2001|March 2003||||N/A|Observational|N/A||||120|||Both|N/A|N/A|No|||March 2003|March 3, 2008|April 4, 2001||||No||https://clinicaltrials.gov/show/NCT00013975||205397|
NCT00012636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPG 97-006|Guidelines for Drug Therapy of Hypertension: Closing the Loop|Guidelines for Drug Therapy of Hypertension: Closing the Loop||VA Office of Research and Development|No|Completed||September 2000|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|1||Anticipated|36|||Both|N/A|N/A||||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012636||205499|
NCT00013728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6214-CP-001|Asthma & Exposure to Peaks in Particulate Air Pollution|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 2000|October 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||24|||Both|9 Years|18 Years|No|||March 2006|March 22, 2006|March 28, 2001||||No||https://clinicaltrials.gov/show/NCT00013728||205416|
NCT00016861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCCC-H-6957|Irinotecan in Treating Children With Refractory or Progressive Solid Tumors|Pediatric Phase I and Pharmacokinetic Study of Irinotecan||National Cancer Institute (NCI)||Completed|September 1998|January 2005|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|21 Years|No|||November 2004|June 25, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016861||205214|
NCT00013169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC 98-051|Patient-Centered Alternative to Psychiatric Hospitalization for Veterans|Patient-Centered Alternative to Psychiatric Hospitalization for Veterans||VA Office of Research and Development|No|Completed||September 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013169||205458|
NCT00013598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010130|Treatment of Nonalcoholic Steatohepatitis With Pioglitazone|Treatment of Nonalcoholic Steatohepatitis With Pioglitazone||National Institutes of Health Clinical Center (CC)||Completed|March 2001|March 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||March 2004|March 3, 2008|March 24, 2001||||No||https://clinicaltrials.gov/show/NCT00013598||205425|
NCT00012818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 99-241|Efficacy and Cost Effectiveness of Relaxation and Response to CHF|Efficacy and Cost Effectiveness of Relaxation and Response to CHF||VA Office of Research and Development|No|Completed||September 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012818||205485|
NCT00013377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1982R|Predictors of Driving Performance and Successful Mobility - Rehabilitation in Patients With Medical Eye Condition|Predictors of Driving Performance and Successful Mobility - Rehabilitation in Patients With Medical Eye Condition||VA Office of Research and Development||Completed|April 1999|March 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013377||205442|
NCT00013390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1995R|Evaluation of Treatment Methods for Clinically Significant Tinnitus|Evaluation of Treatment Methods for Clinically Significant Tinnitus||VA Office of Research and Development|No|Completed|October 1999|September 2002|Actual|September 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2011|May 17, 2011|March 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00013390||205441|
NCT00014300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16994G-26002|Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme|Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme||European Organisation for Research and Treatment of Cancer - EORTC||Completed|January 2001|||September 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|32|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014300||205374|
NCT00014313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62993|Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor|A Phase II Study to Evaluate the Role of Weekly Cisplatin With Oral Etoposide in Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) With Bone and/or Bone Marrow Metatstatic Disease||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|January 2001|||December 2002|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|3|||Both|15 Years|65 Years|No|||September 2012|September 20, 2012|April 10, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00014313||205373|
NCT00016432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-33|Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen|A Randomized Trial Evaluating The Effect Of Exemestane In Clinical Stage T1-3 N0-1 M0 Postmenopausal Breast Cancer Patients Completing At Least Five Years Of Tamoxifen Therapy||NSABP Foundation Inc||Completed|May 2001|February 2011|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1598|||Female|18 Years|N/A|No|||April 2011|April 18, 2011|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016432||205238|
NCT00012935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI 99-159|Treatment Decision Intervention for Veterans With Prostate Cancer|Treatment Decision Intervention for Veterans With Prostate Cancer||VA Office of Research and Development|No|Completed||December 2001|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Male|50 Years|80 Years|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012935||205476|
NCT00012948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUI 99-101|Centralized Telephone Outreach to Assist Smoking Cessation Among Veterans|Centralized Telephone Outreach to Assist Smoking Cessation Among Veterans||VA Office of Research and Development|No|Completed||September 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|800|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012948||205475|
NCT00013767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9601-CP-002|Community Based Prevention/Control Project|Child Environmental Health Center--Reducing Pesticide Exposure in Children of Farmworkers||National Institute of Environmental Health Sciences (NIEHS)||Completed|June 1999|October 2003|Actual|October 2003|Actual|N/A|Interventional|Primary Purpose: Prevention||||400|||Both|1 Year|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 29, 2001||No||No||https://clinicaltrials.gov/show/NCT00013767||205413|
NCT00014014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1012|Zidovudine and Lamivudine Given Once Versus Twice Daily|A Phase I Pharmacokinetic Study of Once Versus Twice Daily Dosing With Zidovudine and Lamivudine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||20|||Both|12 Years|24 Years|No|||October 2013|October 4, 2013|April 7, 2001||||No||https://clinicaltrials.gov/show/NCT00014014||205395|
NCT00013338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2142R|Supported Treadmill Ambulation Training After Spinal Cord Injury|Supported Treadmill Ambulation Training After Spinal Cord Injury||VA Office of Research and Development||Completed|January 2000|December 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||40|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013338||205445|
NCT00013351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1830R|Restricted Useful Field View as a Risk Factor in Older Adults|Restricted Useful Field View as a Risk Factor in Older Adults||VA Office of Research and Development||Completed|April 1998|March 2001|Actual|||Phase 2|Observational|Time Perspective: Prospective||||150|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013351||205444|
NCT00013364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1850R|Effects of Stimulus Validity on Speech Recognition|Effects of Stimulus Validity on Speech Recognition||VA Office of Research and Development||Completed|April 1998|March 2001|Actual|||Phase 2|Observational|Time Perspective: Prospective||||80|||Both|18 Years|85 Years|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013364||205443|
NCT00013065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HII 99-054|A Medication Adherence Intervention for HIV Infected Veterans|A Medication Adherence Intervention for HIV Infected Veterans||VA Office of Research and Development|No|Completed||December 2003|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|210|||Both|18 Years|65 Years|No|||January 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013065||205466|
NCT00012649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DII 99-187|Improving Diabetes Care Via Telephone Assessment and Patient Education|Improving Diabetes Care Via Telephone Assessment and Patient Education||VA Office of Research and Development|No|Completed||May 2003|Actual|||N/A|Observational|N/A||1|Actual|480|||Both|N/A|N/A|No|||January 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012649||205498|
NCT00012753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 95-084|Automated Calls With Nurse Follow-Up to Improve Diabetes Ambulatory Care|Automated Calls With Nurse Follow-Up to Improve Diabetes Ambulatory Care||VA Office of Research and Development|No|Completed||December 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|272|||Both|18 Years|75 Years|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012753||205490|
NCT00016367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM99-015|Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Completed|May 2001|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|May 6, 2001||No||No||https://clinicaltrials.gov/show/NCT00016367||205243|
NCT00016380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC19|Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen|A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis||Canadian Cancer Trials Group||Completed|February 2001|February 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|16 Years|N/A|No|||March 2010|November 7, 2010|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016380||205242|
NCT00011648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010088|Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia|Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients With Sickle Cell Anemia||National Institutes of Health Clinical Center (CC)||Recruiting|February 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|February 24, 2001||No||No||https://clinicaltrials.gov/show/NCT00011648||205564|
NCT00011661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8755-CP-001|Social Network Based Intervention to Reduce Lead Exposure Among Native American Children|||National Institute of Environmental Health Sciences (NIEHS)||Completed|June 2000|August 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|February 26, 2001||||No||https://clinicaltrials.gov/show/NCT00011661||205563|
NCT00011674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8158-CP-001|Early Exposure to Lead and Adolescent Development|||National Institute of Environmental Health Sciences (NIEHS)||Completed|May 1997|May 2001||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2006|March 22, 2006|February 26, 2001||||No||https://clinicaltrials.gov/show/NCT00011674||205562|
NCT00011687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9916-CP-001|Study for Future Families|US Study of Semen Quality in Partners of Pregnant Women||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1999|September 2003||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||2400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 22, 2006|February 26, 2001||||No||https://clinicaltrials.gov/show/NCT00011687||205561|
NCT00016783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1015|Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV|Intensification of HIV-Specific CD4 and CD8 Activity by Cycling Highly Active Antiretroviral Therapy (HAART) in Pediatric/Adolescent Patients With Less Than 50 HIV RNA Copies/ml||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||39|||Both|2 Years|21 Years|No|||October 2013|October 4, 2013|June 2, 2001||||No||https://clinicaltrials.gov/show/NCT00016783||205218|
NCT00016835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-03|Treating Periodontal Infection: Effects on Glycemic Control in People With Type 2 Diabetes|Treating Periodontal Infection: Effects on Glycemic Control||National Institute of Dental and Craniofacial Research (NIDCR)|Yes|Active, not recruiting|April 2001|October 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||October 2007|October 5, 2007|June 5, 2001||||No||https://clinicaltrials.gov/show/NCT00016835||205216|
NCT00013312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1862R|Effects of Acute SCI on Colonic Motility & Tone|Effects of Acute SCI on Colonic Motility & Tone||VA Office of Research and Development||Completed|April 1999|March 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||12|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013312||205447|
NCT00011635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010054|The Effect of Milk Thistle on the Pharmacokinetics of Indinavir|The Effect of Milk Thistle on the Pharmacokinetics of Indinavir||National Institutes of Health Clinical Center (CC)||Completed|February 2001|June 2001||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2000|March 3, 2008|February 24, 2001||||No||https://clinicaltrials.gov/show/NCT00011635||205565|
NCT00017004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0191|Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia|Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer||Gynecologic Oncology Group||Completed|August 2001|||January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|114|||Female|N/A|N/A|No|||December 2014|December 29, 2014|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017004||205203|
NCT00013260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC 97-010|An Integrated Model of Primary Care in Mental Health|An Integrated Model of Primary Care in Mental Health||VA Office of Research and Development|No|Completed||July 2000|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|271|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013260||205451|
NCT00013520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5095|Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection|Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2005|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||1125|||Both|16 Years|N/A|No|||May 2012|May 17, 2012|March 16, 2001||||||https://clinicaltrials.gov/show/NCT00013520||205431|
NCT00011622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0158|Maternal Glucose Measurement in Pregnancy Using a Continuous Ambulatory Subcutaneous Monitor|Maternal Glucose Measurement in Pregnancy Using a Continuous Ambulatory Subcutaneous Monitor||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011622||205566|
NCT00010751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000011-1|Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors|Chronic Diabetic Painful Neuropathy and Cardiovascular Risk Factors in NIDDM: An Alternative Approach.||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1998|June 2004||||Phase 2|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|20 Years|80 Years|No|||August 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010751||205626|
NCT00010764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000003-01|Efficacy of Acupuncture in the Treatment of Fibromyalgia|Efficacy of Acupuncture in the Treatment of Fibromyalgia||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|July 2002||||Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2008|March 5, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010764||205625|
NCT00012597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC 97-013|Pressure Ulcer Assessment Via Telemedicine|Pressure Ulcer Assessment Via Telemedicine||VA Office of Research and Development|No|Completed||September 2000|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|128|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012597||205502|
NCT00012883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 96-031|Home Walking Exercise Training in Advanced Heart Failure|Home Walking Exercise Training in Advanced Heart Failure||VA Office of Research and Development|No|Completed||December 2001|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012883||205480|
NCT00012896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 97-026|Improving Cancer Pain Management Using AHCPR Cancer Pain Guidelines|Improving Cancer Pain Management Using AHCPR Cancer Pain Guidelines||VA Office of Research and Development|No|Completed||September 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind|1||Anticipated|320|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012896||205479|
NCT00010725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000082-01P3|Effects of Herbal Antioxidants on Cardiovascular Disease in Older Blacks|Effects of Herbal Antioxidants on Cardiovascular Disease in Older Blacks||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|September 1999|August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||138|||Both|60 Years|N/A|No|||January 2010|January 11, 2010|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010725||205628|
NCT00012194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03129|7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors|Phase I Dose Escalation Study of UCN-01 (NSC 638850) Plus Cisplatin in Advanced Malignant Solid Tumors||National Cancer Institute (NCI)||Terminated|March 2001|||January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|March 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00012194||205526|
NCT00012441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0781|Comparison of Daily Nocturnal Hemodialysis With Daily Hemodialysis|Comparison of Daily Nocturnal Hemodialysis With Daily Hemodialysis||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|21 Years|75 Years|No|||December 2003|June 23, 2005|March 6, 2001||||No||https://clinicaltrials.gov/show/NCT00012441||205512|
NCT00016510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010165|Differences in Brain Processing of First and Second Languages (Korean and English)|Differences of Verbal Working Memory and Translation Systems Between First and Second Languages: a Functional MRI Study||National Institutes of Health Clinical Center (CC)||Completed|May 2001|May 2002||||N/A|Observational|N/A||||63|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2002|March 3, 2008|May 12, 2001||||No||https://clinicaltrials.gov/show/NCT00016510||205233|
NCT00012610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC 97-034|Efficacy of Telepsychiatry in the Treatment of Depression|Efficacy of Telepsychiatry in the Treatment of Depression||VA Office of Research and Development|No|Completed||September 2000|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|119|||Both|N/A|N/A|No|||April 2015|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012610||205501|
NCT00012623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC 97-068|Improving Service Delivery Through Access Points|Improving Service Delivery Through Access Points||VA Office of Research and Development|No|Completed||March 2002|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|39481|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012623||205500|
NCT00012207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1503.00|Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Study To Evaluate The Safety Of Cellular Immunotherapy Using Genetically Modified Autologous Cd20-Specific Cd8+ T Cell Clones For Patients With Relapsed Cd20+ Indolent Lymphomas||Fred Hutchinson Cancer Research Center|Yes|Completed|September 2000|July 2010|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|N/A|N/A|No|||August 2010|August 20, 2010|March 3, 2001|No|Yes||||https://clinicaltrials.gov/show/NCT00012207||205525|
NCT00011440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8077-CP-001|Pollutant Altered Allergic Responses|Markers of Pollutant Altered Allergic Responses||National Institute of Environmental Health Sciences (NIEHS)||Completed|December 1998|August 2002||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|February 20, 2001||||No||https://clinicaltrials.gov/show/NCT00011440||205580|
NCT00011453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9554-CP-001|Protection Against Benzene Toxicity|NQO1 in Protection Against Benzene Toxicity||National Institute of Environmental Health Sciences (NIEHS)||Completed|July 1998|June 2001||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Prospective|||||||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2002|June 23, 2005|February 21, 2001||||No||https://clinicaltrials.gov/show/NCT00011453||205579|
NCT00011284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6091-CP-001|Mechanisms of Inflammatory Liver Injury|||National Institute of Environmental Health Sciences (NIEHS)||Completed||November 2001||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||50|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2002|June 23, 2005|February 15, 2001||||No||https://clinicaltrials.gov/show/NCT00011284||205590|
NCT00011297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMAL1076106|Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal|Alcohol Research Center - Treatment and Implications||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed||December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|70 Years|No|||October 2006|October 20, 2006|February 15, 2001||||No||https://clinicaltrials.gov/show/NCT00011297||205589|
NCT00016679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010178|1-Octanol to Treat Essential Tremor|Dose Finding Study of 1-Octanol in Essential Tremor||National Institutes of Health Clinical Center (CC)||Completed|May 2001|March 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||42|||Both|N/A|N/A|No|||March 2004|March 3, 2008|May 24, 2001||||No||https://clinicaltrials.gov/show/NCT00016679||205223|
NCT00016952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0048|Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer|Phase II Study in Patients With Metastatic Colorectal Carcinoma Previously Treated With Oxaliplatin (OXAL) or a Combination of Irinotecan (CPT-11) and OXAL||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2001|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00016952||205207|
NCT00013533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010125|Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies|Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies||National Institutes of Health Clinical Center (CC)||Completed|March 2001|May 2015|Actual|March 2008|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|4 Years|20 Years|No|||May 2015|May 8, 2015|March 20, 2001||No||No||https://clinicaltrials.gov/show/NCT00013533||205430|
NCT00011726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7437-CP-001|Lead Mobilization & Bone Turnover in Pregnancy/Lactation|||National Institute of Environmental Health Sciences (NIEHS)||Completed|August 1996|December 2002||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||1000|||Female|12 Years|35 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|February 27, 2001||||No||https://clinicaltrials.gov/show/NCT00011726||205558|
NCT00011739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S002|A Prospective Cohort Study of MR Abnormalities and Back Pain Risk|A Prospective Cohort Study of MR Abnormalities and Back Pain Risk||VA Office of Research and Development||Completed|November 1997|September 2001||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||February 2003|January 20, 2009|February 27, 2001||||No||https://clinicaltrials.gov/show/NCT00011739||205557|
NCT00011752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010090|Serotonin in Alcoholism|Effects of Acute Plasma Tryptophan Depletion on Serotonin Receptor Occupancy and Binding Affinity Using PET in Healthy and Alcoholic Human Subjects||National Institutes of Health Clinical Center (CC)||Completed|February 2001|September 2005||||N/A|Observational|N/A||||75|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|February 28, 2001||||No||https://clinicaltrials.gov/show/NCT00011752||205556|
NCT00010166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068452|Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas|Phase II Trial Of Adjuvant 2'2'-Difluoro-2'-Deoxycytidine (Gemcitabine) And External Beam Radiation For The Treatment Of Resectable Pancreatic Cancer||Wake Forest Baptist Health||Completed|December 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010166||205663|
NCT00013715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9004-CP-001|Ozone and Rhinovirus-Induced Disease in Asthmatics|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1999|August 2003||||N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 8, 2008|March 28, 2001||||No||https://clinicaltrials.gov/show/NCT00013715||205417|
NCT00012675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DII 99-205|Developing and Implementing a Quality Measure for Glycemic Control|Developing and Implementing a Quality Measure for Glycemic Control||VA Office of Research and Development|No|Withdrawn||December 2003|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|March 14, 2001|||This study was withdrawn prior to enrollment.|No||https://clinicaltrials.gov/show/NCT00012675||205496|
NCT00010738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT000226-01M|Effects of Meditation on Mechanism of Coronary Heart Disease|Effects of Meditation on Mechanism of Coronary Heart Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|August 2002||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||145|||Both|18 Years|N/A|No|||July 2006|August 17, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010738||205627|
NCT00010946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AT000171-01M|Acupuncture Safety/Efficacy in Knee Osteoarthritis|Acupuncture Safety/Efficacy in Knee Osteoarthritis||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1998|August 2003||||Phase 3|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||March 2008|March 5, 2008|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010946||205613|
NCT00012506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-82|The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis|||National Eye Institute (NEI)||Recruiting||||||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|2 Years|18 Years|No|||March 2001|June 23, 2005|March 10, 2001||||No||https://clinicaltrials.gov/show/NCT00012506||205507|
NCT00012688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DII 99-206|Periodontal Care and Glycemic Control in Diabetes|Periodontal Care and Glycemic Control in Diabetes||VA Office of Research and Development|No|Completed||September 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012688||205495|
NCT00016146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-062|Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer|Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates: A Dose-Escalating Trial Studying The Immunogenicity And Safety Of The Immunological Adjuvant GPI-0100||Memorial Sloan Kettering Cancer Center||Completed|July 2000|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Male|18 Years|N/A|No|||March 2013|March 18, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016146||205260|
NCT00012389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068524|Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer|A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|December 2000|October 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2002|December 18, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012389||205514|
NCT00012428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9815-CP-001|Prenatal PCB Exposure|Prenatal PCB Exposure and Cognitive Development||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1999|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||||224|||Female|16 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 6, 2001||No||No||https://clinicaltrials.gov/show/NCT00012428||205513|
NCT00012090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-054|Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum|A Phase II Trial Of Oral Bicalutamide With Subcutaneous Goserelin In Patients With Epithelial Ovarian, Fallopian Tube, Or Peritoneal Carcinoma In Second Or Greater Remission||Memorial Sloan Kettering Cancer Center||Completed|September 2000|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 17, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012090||205534|
NCT00012727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 95-011|Matching, Outcomes and Costs in Substance Abuse/Psychiatric Treatment|Matching, Outcomes and Costs in Substance Abuse/Psychiatric Treatment||VA Office of Research and Development|No|Completed||August 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|236|||Both|N/A|N/A|No|||July 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012727||205492|
NCT00012740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 95-050|A Casefinding and Referral System for Older Veterans Within Primary Care|A Casefinding and Referral System for Older Veterans Within Primary Care||VA Office of Research and Development|No|Completed||September 2001|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|792|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012740||205491|
NCT00016562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010174|Cause and Pathogenesis of Neurometabolic Disorders|The Etiology and Pathogenesis of Neurometabolic Disorders||National Institutes of Health Clinical Center (CC)||Completed|May 2001|March 2008||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||March 2008|September 26, 2015|May 16, 2001||||No||https://clinicaltrials.gov/show/NCT00016562||205229|
NCT00016588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283H|Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs|An Open-Label Study to Assess the Anti-HIV-1 Activity of Tenofovir Disoproxil Fumarate (TDF) in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1||NIH AIDS Clinical Trials Information Service||Completed|May 2001|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||May 2002|June 23, 2005|May 17, 2001||||No||https://clinicaltrials.gov/show/NCT00016588||205228|
NCT00011557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1747R|Functional Magnetic Micturition in Patients w/SCI|Functional Magnetic Micturition in Patients w/SCI||VA Office of Research and Development||Completed|January 1998|December 2000|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011557||205571|
NCT00011570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1770R|Electrical Control of Bladder in Spinal Cord Injury Patients|Electrical Control of Bladder in Spinal Cord Injury Patients||VA Office of Research and Development||Completed|April 1998|November 2007|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||April 2008|April 25, 2008|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011570||205570|
NCT00011466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1738|Nutrient Intake in Children With Attention Deficit Hyperactivity Disorder|Nutrient Intake in Children With Attention Deficit Hyperactivity Disorder||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|5 Years|13 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|February 21, 2001||||No||https://clinicaltrials.gov/show/NCT00011466||205578|
NCT00016523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0026|Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure|Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure|Preemie iNO|NICHD Neonatal Research Network|Yes|Terminated|January 2001|May 2006|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|420|||Both|N/A|120 Hours|No|||June 2015|June 3, 2015|May 14, 2001|No|Yes|Preliminary results showed increased intraventricular hemorrhage (IVH) in experimental arm|No||https://clinicaltrials.gov/show/NCT00016523||205232|
NCT00013273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1792R|Physical Conditioning in Management of Chronic Venous Insufficiency|Physical Conditioning in Management of Chronic Venous Insufficiency||VA Office of Research and Development||Completed|January 1999|December 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013273||205450|
NCT00013286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2016R|A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk|A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk||VA Office of Research and Development||Completed|October 1999|September 2002|Actual|||Phase 2|Observational|Time Perspective: Prospective||||750|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013286||205449|
NCT00011362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0005|Dexamethasone Therapy in VLBW Infants at Risk of CLD|Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD)|Dexamethasone|NICHD Neonatal Research Network|Yes|Completed|September 1992|April 1994|Actual|January 1994|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|371|||Both|N/A|15 Days|No|||June 2015|June 3, 2015|February 15, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00011362||205584|
NCT00011375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010089|Rolipram to Treat Multiple Sclerosis|Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure||National Institutes of Health Clinical Center (CC)||Completed|February 2001|April 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||52|||Both|N/A|N/A|No|||April 2004|March 3, 2008|February 16, 2001||||No||https://clinicaltrials.gov/show/NCT00011375||205583|
NCT00010257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068461|Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma|Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma||Eastern Cooperative Oncology Group|No|Completed|February 2001|August 2012|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||June 2013|October 7, 2015|February 2, 2001|Yes|Yes||No|September 17, 2012|https://clinicaltrials.gov/show/NCT00010257||205656|
NCT00016874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-015|3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer|A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer||National Cancer Institute (NCI)||Completed|December 2000|January 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|July 17, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016874||205213|
NCT00012805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 97-022|Effectiveness and Cost Impact of a Telecommunications System in COPD|Effectiveness and Cost Impact of a Telecommunications System in COPD||VA Office of Research and Development|No|Completed||March 2001|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Male|N/A|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012805||205486|
NCT00010933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000008-01P2|Treatment of Functional Abdominal Pain in Children: Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities|Treatment of Functional Abdominal Pain in Children: Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1998|June 2004||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|20 Years|No|||August 2006|August 16, 2006|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010933||205614|
NCT00011089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283G|Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations|US Expanded Access Program of Tenofovir Disoproxil Fumarate in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options||NIH AIDS Clinical Trials Information Service||Active, not recruiting|February 2001|||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2001|June 23, 2005|February 9, 2001||||No||https://clinicaltrials.gov/show/NCT00011089||205602|
NCT00012662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DII 99-188|Disease Management and Educational Intervention Outcomes in High-Risk Diabetics|Disease Management and Educational Intervention Outcomes in High-Risk Diabetics||VA Office of Research and Development|No|Completed||December 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1800|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012662||205497|
NCT00016211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22993-08993|Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer|Prophylactic Cranial Irradiation In Extensive Disease Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2001|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|287|||Both|18 Years|75 Years|No|||September 2012|September 20, 2012|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016211||205255|
NCT00012051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKTO-2000-06|Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY)||National Cancer Institute (NCI)||Completed|September 2000|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|340|||Both|18 Years|65 Years|No|||March 2007|August 9, 2013|March 3, 2001||||No||https://clinicaltrials.gov/show/NCT00012051||205536|
NCT00012064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068481|Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma|Vaccine Biotherapy of Cancer: Tumor Cells and Dendritic Cells as Active Specific Immunotherapy of Patients With Metastatic Melanoma||Caladrius Biosciences, Inc.|No|Completed|July 2000|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|16 Years|N/A|No|||August 2013|January 27, 2014|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00012064||205535|
NCT00012246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068497|Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract|A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin||The University of Texas Medical Branch, Galveston||Terminated|July 2002|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|March 3, 2001|Yes|Yes|Administratively Terminated|No||https://clinicaltrials.gov/show/NCT00012246||205523|
NCT00012844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 95-150|Redesigning Patient Handling Tasks to Prevent Nursing Back Injuries|Redesigning Patient Handling Tasks to Prevent Nursing Back Injuries||VA Office of Research and Development|No|Completed||December 1999|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|134|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012844||205483|
NCT00016796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010181|Language Stimuli Screening in Children|Language Stimuli Screening in Children||National Institutes of Health Clinical Center (CC)||Completed|May 2001|March 2005||||N/A|Observational|N/A||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2005|March 3, 2008|June 2, 2001||||No||https://clinicaltrials.gov/show/NCT00016796||205217|
NCT00016965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068636|BMS-247550 in Treating Patients With Advanced Pancreatic Cancer|A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer||National Cancer Institute (NCI)||Completed|July 2001|April 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|June 20, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016965||205206|
NCT00011518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7459-CP-001|Bladder Cancer Case Control Study of Arsenic in Water|||National Institute of Environmental Health Sciences (NIEHS)||Completed|October 1997|July 2001||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||600|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011518||205574|
NCT00011583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2156|Robot Assisted Upper Limb Neuro-Rehabilitation|Robot Assisted Upper Limb Neuro-Rehabilitation||VA Office of Research and Development||Completed|January 2000|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2008|March 10, 2008|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011583||205569|
NCT00011596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2226R|FNS and Weight Support Treadmill Training for Gait Component Restoration|FNS and Weight Support Treadmill Training for Gait Component Restoration||VA Office of Research and Development||Completed|August 2000|August 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|February 22, 2001||||No||https://clinicaltrials.gov/show/NCT00011596||205568|
NCT00016536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 032|Effects of BufferGel and PRO 2000/5 Gel in Men|Male Tolerance Study of BufferGel and PRO 2000/5 Gel (P)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 1997|Actual|||Phase 1|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Prevention||||24|||Male|18 Years|N/A|No|||April 2012|April 3, 2012|May 16, 2001||||||https://clinicaltrials.gov/show/NCT00016536||205231|
NCT00016549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010173|Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer|A Pilot Study to Evaluate Angiogenesis After Treatment With Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) in Previously Untreated Patients With Inflammatory Breast Cancer or Locally Advanced Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|May 2001|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2012|September 26, 2015|May 16, 2001||No||No||https://clinicaltrials.gov/show/NCT00016549||205230|
NCT00013546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010114|Hormone Replacement Therapy to Treat Turner Syndrome|Turner Syndrome: Hormone Replacement Therapy||National Institutes of Health Clinical Center (CC)||Completed|March 2001|December 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||92|||Female|N/A|N/A|No|||December 2002|March 3, 2008|March 20, 2001||||No||https://clinicaltrials.gov/show/NCT00013546||205429|
NCT00013559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010109|Natural History Study of Smith-Magenis Syndrome|Natural History Study of the Clinical and Molecular Manifestations of Smith-Magenis Syndrome (SMS)||National Institutes of Health Clinical Center (CC)||Recruiting|March 2001|||||N/A|Observational|N/A|||Anticipated|700|||Both|N/A|N/A|No|||June 2015|July 15, 2015|March 20, 2001||No||No||https://clinicaltrials.gov/show/NCT00013559||205428|
NCT00011076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010066|Pirfenidone to Treat Hypertrophic Cardiomyopathy|Double-Blind Placebo-Controlled Study of Pirfenidone, A Novel Anti-Fibrotic Drug in Symptomatic Patients With Hypertrophic Cardiomyopathy (HCM) Associated With Left Ventricular Diastolic Function||National Institutes of Health Clinical Center (CC)||Completed|February 2001|April 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||April 2003|March 3, 2008|February 9, 2001||||No||https://clinicaltrials.gov/show/NCT00011076||205603|
NCT00010348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15576|Study of Total Body Irradiation in Combination With Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation Followed By Cyclosporine and Mycophenolate Mofetil in High Risk-Patients With Human Immunodeficiency Virus-1|Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil||Office of Rare Diseases (ORD)|Yes|Recruiting|November 2000|December 2015|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|64 Years|No|||May 2009|May 13, 2009|February 2, 2001||No||No||https://clinicaltrials.gov/show/NCT00010348||205650|
NCT00017017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-1071|CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer|A Phase I/II Trial fo Intravenous CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|February 2001|December 2009|Actual|February 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||December 2009|May 29, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017017||205202|
NCT00017030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMAR-ET-B-022-00|Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma|Phase II Study of ET-743 Given as a Three Hour Intravenous Infusion in Patients With Advanced and/or Metastatic Soft Tissue Sarcoma Previously Treated With Chemotherapy||National Cancer Institute (NCI)||Completed|February 2001|December 2009|Actual|January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|June 25, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017030||205201|
NCT00012909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC 98-039|Development and Evaluation of a Hormone Replacement Therapy Decision-Aid|Development and Evaluation of a Hormone Replacement Therapy Decision-Aid||VA Office of Research and Development|No|Completed||March 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|150|||Female|45 Years|74 Years|Accepts Healthy Volunteers|||November 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012909||205478|
NCT00016601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5093|Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women|An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) and Selected Protease Inhibitor (PI) and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapies Among HIV-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2001|May 2004|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||76|||Female|13 Years|N/A|No|||October 2012|October 31, 2012|May 18, 2001||||No||https://clinicaltrials.gov/show/NCT00016601||205227|
NCT00016627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|969|Linkage Study in Familial Pulmonary Fibrosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2000|July 2005|Actual|||N/A|Observational|N/A|||||||Both|20 Years|90 Years|No|||November 2005|February 17, 2016|May 19, 2001||||No||https://clinicaltrials.gov/show/NCT00016627||205226|
NCT00012220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068495|Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas|A Randomized Phase II Study Of Gemcitabine/Cisplatin, Gemcitabine/Docetaxel, Gemcitabine/Irinotecan, Or Fixed Dose Rate Infusion Gemcitabine In Patients With Metastic Pancreatic Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|January 2001|April 2009|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|259|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|March 3, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00012220||205524|
NCT00010959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000155-01P4|Single-Dose Study of Black Cohosh and Red Clover|A Phase I Single-Dose Pharmacokinetic Study of Black Cohosh and Red Clover in Healthy Menopausal Women 45-59 Years of Age||National Center for Complementary and Integrative Health (NCCIH)|No|Completed|February 2001|February 2002||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|45 Years|59 Years|Accepts Healthy Volunteers|||March 2007|March 1, 2007|February 2, 2001||||No||https://clinicaltrials.gov/show/NCT00010959||205612|
NCT00012779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 95-118|Effectiveness of a Health Education Program in a Primary Care Setting|Effectiveness of a Health Education Program in a Primary Care Setting||VA Office of Research and Development|No|Completed||March 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|288|||Both|55 Years|N/A|No|||June 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012779||205488|
NCT00012792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 96-015|Randomized Controlled Trial of Exercise Training in Patients With COPD|Randomized Controlled Trial of Exercise Training in Patients With COPD||VA Office of Research and Development|No|Completed||December 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|130|||Male|50 Years|79 Years|No|||December 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012792||205487|
NCT00013741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9511|The MI-HEART Project|||National Library of Medicine (NLM)||Completed||||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind||||55|||Both|30 Years|N/A|No|||February 2003|May 23, 2012|March 28, 2001||||No||https://clinicaltrials.gov/show/NCT00013741||205415|
NCT00013299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2443R|Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3|Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3||VA Office of Research and Development||Completed|October 2000|April 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||427|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013299||205448|
NCT00012493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9825-CP-001|Cardiac Vulnerability in Potentially Susceptible Patients|||National Institute of Environmental Health Sciences (NIEHS)||Completed|October 1999|December 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|45 Years|74 Years|No|||September 2006|September 1, 2006|March 9, 2001||||No||https://clinicaltrials.gov/show/NCT00012493||205508|
NCT00012961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCR 99-012|Improving Health Services for Veterans With Schizophrenia|Improving Health Services for Veterans With Schizophrenia||VA Office of Research and Development|No|Completed||March 2003|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|||January 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012961||205474|
NCT00015860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068444|STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia|A Phase I/II Trial of STI-571 and Chemotherapy in Lymphoid Blast Crisis of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoid Leukemia||National Cancer Institute (NCI)||Completed|May 2001|October 2003|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|June 20, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00015860||205280|
NCT00015808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010167|Safety Study of Idebenone to Treat Friedreich's Ataxia|Phase I Clinical Trial to Establish the Maximum Tolerated Dose of Idebenone in Children, Adolescents, and Adults With Friedreich's Ataxia||National Institutes of Health Clinical Center (CC)||Completed|May 2001|April 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||April 2006|July 11, 2006|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00015808||205284|
NCT00015223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-5|Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5|Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD||National Institute on Drug Abuse (NIDA)||Completed|June 1997|||||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||October 2012|June 2, 2015|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015223||205314|
NCT00015236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-6|Modeling Impaired Judgement in Cocaine Abusers - 6|Modeling Impaired Judgement in Cocaine Abusers||National Institute on Drug Abuse (NIDA)||Completed|March 1997|||||Phase 4|Interventional|Masking: Open Label, Primary Purpose: Prevention||||0|||Both|18 Years|60 Years|No|||June 1998|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015236||205313|
NCT00015249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-7|Prepulse Inhibition of Startle in Cocaine Dependence - 7|Prepulse Inhibition of Startle in Cocaine Dependence (Human)||National Institute on Drug Abuse (NIDA)||Completed|February 1997|||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Diagnostic||||0|||Male|18 Years|60 Years|No|||June 1998|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015249||205312|
NCT00014742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15764|Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease|||FDA Office of Orphan Products Development||Completed||April 2004||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|N/A|No|||April 2001|March 24, 2015|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014742||205343|
NCT00014885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9006-CP-001|Bone Lead Levels and College Achievement Scores|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1998|August 2001||||N/A|Observational|Time Perspective: Retrospective||||750|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|April 12, 2001||||No||https://clinicaltrials.gov/show/NCT00014885||205333|
NCT00014898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5015-CP-001|Attention Deficit Disorder and Exposure to Lead|||National Institute of Environmental Health Sciences (NIEHS)||Completed|June 1999|May 2002||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||||500|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||March 2001|June 23, 2005|April 12, 2001||||No||https://clinicaltrials.gov/show/NCT00014898||205332|
NCT00016887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068609|Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma|Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination||National Cancer Institute (NCI)||Active, not recruiting|December 2000|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||August 2003|September 16, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016887||205212|
NCT00017082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROLOGUE-EFC4759|Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer|A Multicenter, Phase II Study Of Oxaliplatin Single Agent As Third-Line Treatment Of Metastatic Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|April 2001|December 2010|Actual|June 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2010|June 25, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017082||205197|
NCT00015951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068576|Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers|A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Refractory and Relapsed Acute Myelogenous Leukemias (AMLs)||University of Maryland||Completed|April 2001|March 2004|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|September 23, 2009|May 6, 2001||Yes||No||https://clinicaltrials.gov/show/NCT00015951||205273|
NCT00019019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950015|Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas|A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA||National Institutes of Health Clinical Center (CC)||Completed|October 1994|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00019019||205058|
NCT00015938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068575|S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer|Docetaxel And Vinorelbine Plus Filgrastim For HER-2 Negative, Stage IV Breast Cancer||Southwest Oncology Group|Yes|Completed|May 2001|November 2012|Actual|February 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Female|18 Years|N/A|No|||January 2013|January 23, 2013|May 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00015938||205274|
NCT00015769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010168|Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness|Pilot Evaluation of Levetiracetam (Keppra® (Registered Trademark)) in Bipolar Illness||National Institutes of Health Clinical Center (CC)||Completed|April 2001|April 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||April 2003|March 3, 2008|May 4, 2001||||No||https://clinicaltrials.gov/show/NCT00015769||205287|
NCT00019097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064244|Vaccine Therapy in Treating Patients With Multiple Myeloma|Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation||National Cancer Institute (NCI)||Completed|July 1995|March 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||May 2006|June 19, 2013|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019097||205053|
NCT00019110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064330|Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer|VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER||National Cancer Institute (NCI)||Completed|November 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||November 1999|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019110||205052|
NCT00016224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-006|Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer|Phase II Trial of Thalidomide in Patients With Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 2001|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 17, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016224||205254|
NCT00016159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-072|Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia|Phase II Study Of Combined Modality Postremission Therapy As Determined By Molecular Response (Adaptive Regulation) In The Treatment Of Acute Promyelocytic Leukemia (APL)||Memorial Sloan Kettering Cancer Center||Completed|November 2000|||March 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|N/A|N/A|No|||January 2013|January 15, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016159||205259|
NCT00014989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0800|Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)|Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)|BEAM|The George Washington University Biostatistics Center|Yes|Completed|December 1997|June 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|2136|||Female|N/A|N/A|No|||October 2015|October 19, 2015|April 17, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00014989||205326|
NCT00014677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-3001-0001|NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme|A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|March 2001|July 2008|Actual|September 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|July 17, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014677||205346|
NCT00015548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH090001-05|CATIE-Alzheimer's Disease Trial|Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)||National Institute of Mental Health (NIMH)||Completed|March 2001|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|N/A|N/A|No|||February 2009|June 16, 2015|April 20, 2001||||No||https://clinicaltrials.gov/show/NCT00015548||205302|
NCT00015561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8161-CP-001|Pesticides--Health Fertility and Reproductive Risk|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1996|August 2001||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||1803|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|April 20, 2001||||No||https://clinicaltrials.gov/show/NCT00015561||205301|
NCT00018954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077227|Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma|PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA||National Institutes of Health Clinical Center (CC)||Completed|October 1992|October 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||February 2012|February 16, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00018954||205061|
NCT00015002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-0801|Repeat Antenatal Steroids Trial|A Randomized Placebo-Controlled Trial of Antenatal Corticosteroid Regimens|BEARS|The George Washington University Biostatistics Center|Yes|Terminated|March 2000|March 2007|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|486|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|April 17, 2001|Yes|Yes|Concerns regarding neonatal data|No||https://clinicaltrials.gov/show/NCT00015002||205325|
NCT00015015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7355-CP-001|Dichloroacetate Kinetics, Metabolism and Toxicology|||National Institute of Environmental Health Sciences (NIEHS)||Completed|December 1994|October 2002||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||100|||Both|3 Months|65 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|April 17, 2001||||No||https://clinicaltrials.gov/show/NCT00015015||205324|
NCT00015613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9867-CP-001|Farm Work & Preterm Low Birthweight Among Hispanic Women|Study of Hispanic Acculturation Reproduction and the Environment (SHARE)||National Institute of Environmental Health Sciences (NIEHS)||Completed|August 1998|September 2001||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||1500|||Female|12 Years|40 Years|Accepts Healthy Volunteers|||September 2002|November 2, 2005|April 23, 2001||||No||https://clinicaltrials.gov/show/NCT00015613||205297|
NCT00015626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR06020-0057|A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)|A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)||National Center for Research Resources (NCRR)||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|5 Years|N/A|No|||December 2003|June 23, 2005|April 24, 2001||||No||https://clinicaltrials.gov/show/NCT00015626||205296|
NCT00014755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15796|Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis|||Office of Rare Diseases (ORD)||Completed|December 1997|||||Phase 1|Interventional|Primary Purpose: Treatment||||35|||Both|18 Years|60 Years|No|||April 2001|June 23, 2005|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014755||205342|
NCT00014768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15797|Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis|||National Center for Research Resources (NCRR)||Terminated|February 2001|||||N/A|Observational|Observational Model: Natural History||||36|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2002|June 23, 2005|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014768||205341|
NCT00019084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064192|Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer|VACCINE THERAPY WITH TUMOR SPECIFIC MUTATED P53 OR RAS PEPTIDES ALONE OR IN COMBINATION WITH CELLULAR IMMUNOTHERAPY WITH PEPTIDE ACTIVATED LYMPHOCYTES (PAL CELLS) ALONG WITH SUBCUTANEOUS IL-2||National Cancer Institute (NCI)||Completed|February 1996|May 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2007|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019084||205054|
NCT00019201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065062|Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer|PILOT STUDY OF THE CORRELATION BETWEEN THE FINDINGS OF ATYPICAL/MALIGNANT CELLS IN SPUTUM AND FLUORESCENCE BRONCHOSCOPY IN PATIENTS AT RISK FOR LUNG CANCER OF THE LIFE IMAGING SYSTEM AND WHITE LIGHT BRONCHOSCOPY||National Cancer Institute (NCI)||Completed|August 1996|||||N/A|Interventional|Primary Purpose: Screening|||||||Both|18 Years|N/A|No|||February 2000|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019201||205047|
NCT00015990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01856|Thalidomide in Treating Patients With Myelodysplastic Syndrome|Phase II Study of Thalidomide in the Treatment of Myelodysplastic Syndromes in Adults: A Clinical and Biologic Study||National Cancer Institute (NCI)||Completed|April 2001|||February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00015990||205270|
NCT00016900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-124|PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus|A Phase II Multicenter Study of the Efficacy and Safety Study of PNU-93914 (Liposome Encapsulated Paclitaxel) in Patients With Advanced Esophageal Cancer Previously Exposed to Chemotherapy||Memorial Sloan Kettering Cancer Center||Completed|December 2000|June 2001|Actual|June 2001|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016900||205211|
NCT00017043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068644|BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy|A Phase II Study of Epothilone Analog BMS-247550 in Patients With Metastatic Gastric Adenocarcinoma Previously Treated With a Taxane||Bristol-Myers Squibb||Completed|February 2001|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017043||205200|
NCT00015899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068571|SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors|Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors||Pediatric Brain Tumor Consortium|Yes|Completed|January 2002|March 2007|Actual|September 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|53|||Both|N/A|21 Years|No|||October 2009|October 13, 2009|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00015899||205277|
NCT00019331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065656|Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors|Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|October 1997|May 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019331||205042|
NCT00015574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9825-CP-002|Air Pollution and Implantable Cardioverter Defibrillators|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1998|September 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||500|||Both|N/A|90 Years|No|||September 2006|September 1, 2006|April 20, 2001||||No||https://clinicaltrials.gov/show/NCT00015574||205300|
NCT00016237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068612|Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment|Phase I Dose-Escalation Study of the Pharmacokinetic, Safety, Tolerability, and Biologic Activity of huKS-IL-2 Administered Daily as a 1-Hour Intravenous Infusion for Five Consecutive Days for Treatment of Refractory Epithelial Cancer||EMD Serono||Completed|December 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|October 22, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016237||205253|
NCT00014911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN005CT (DAIT NIS01)|Islet Transplantation for Type 1 Diabetes|Islet Transplantation for Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression (ITN005CT)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2001|August 2010|Actual|June 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|No|||June 2014|June 4, 2014|April 13, 2001|No|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00014911||205331|
NCT00015106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0012-7|Resperine, Gabapentin, or Lamotrigine for the Treatment of Cocaine Dependence: 2 - 7|CREST-I: Resperine, Gabapentin, or Lamotrigine Vs. Placebo||National Institute on Drug Abuse (NIDA)||Completed|November 1997|||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||0|||Both|18 Years|59 Years|No|||February 1999|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015106||205318|
NCT00014781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15802|Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis|||Office of Rare Diseases (ORD)|Yes|Completed|February 2001|||||N/A|Observational|N/A|||Anticipated|39|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2009|March 10, 2009|April 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00014781||205340|
NCT00015795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010169|Study of Air Stream in Voice Production|Laryngeal Resistance in Abductor Spasmodic Dysphonia||National Institutes of Health Clinical Center (CC)||Completed|May 2001|June 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2003|March 3, 2008|May 4, 2001||||No||https://clinicaltrials.gov/show/NCT00015795||205285|
NCT00015912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02379|Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Clinical And Biologic Study Of The Combination Of Low Dose Interferon-Alpha And Thalidomide (NSC #66847) For Patients With Relapsed Or Refractory Low-Grade Follicular Lymphoma||National Cancer Institute (NCI)||Terminated|July 2001|||September 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|May 6, 2001|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00015912||205276|
NCT00015028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0012-1|Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1|CS1008A Efficacy/Safety Trial of Buprenorphine/Naloxone||National Institute on Drug Abuse (NIDA)||Completed|November 1996|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|23 Years|59 Years|No|||November 1996|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015028||205323|
NCT00018967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077521|Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate|A Trial of Carboxypeptidase-G2 (CPDG2) For The Management of Patients With Intrathecal Methotrexate Overdose||National Cancer Institute (NCI)||Completed|November 1993|||April 2007|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|10|||Both|N/A|N/A|No|||April 2007|April 29, 2015|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00018967||205060|
NCT00015132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0012-9|Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9|CREST-II: Tiagabine, Sertraline, or Donepezil Vs. Unmatched Placebo||National Institute on Drug Abuse (NIDA)||Completed|March 1999|||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||0|||Both|18 Years|60 Years|No|||March 1999|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015132||205317|
NCT00015171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-1|Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1|CS1008 A&B Eff/Safety Trial of BUP/NX for the Treatment of Opiate Dependence||National Institute on Drug Abuse (NIDA)||Completed|April 1996|||||Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|59 Years|No|||January 1999|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015171||205316|
NCT00015717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010146|Magnetic Resonance Imaging to Investigate Silent Strokes During Neck and Skull Angioplasty|Silent Cerebral Ischemia After Cervico-Cranial Angioplasty Detected by Diffusion-Weighted MRI||National Institutes of Health Clinical Center (CC)||Completed|April 2001|March 2004||||N/A|Observational|N/A||||24|||Both|N/A|N/A|No|||March 2004|March 3, 2008|May 2, 2001||||No||https://clinicaltrials.gov/show/NCT00015717||205289|
NCT00019318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065653|Depsipeptide in Treating Patients With Solid Tumors|Phase I Trial of a Four Hour Infusion of Depsipeptide (NSC630176) Given on Days 1 and 5 of a 21 Day Cycle in Patients With Refractory Neoplasms||National Cancer Institute (NCI)||Completed|August 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2001|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019318||205043|
NCT00019396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065997|flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer|Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer||National Cancer Institute (NCI)||Completed|February 1998|March 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A||||May 2006|June 19, 2013|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019396||205038|
NCT00015639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010156|Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus|Identification of Donors of CD36-Deficient Platelets Among Individuals on the NIH Campus||National Institutes of Health Clinical Center (CC)||Completed|April 2001|February 2004||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||February 2004|March 3, 2008|April 25, 2001||||No||https://clinicaltrials.gov/show/NCT00015639||205295|
NCT00016042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068588|Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer|Interleukin 12-Primed Activated T Cells For Patients With Metastatic Renal Cell Carcinoma Or Colorectal Carcinoma (Phase I)||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2001|September 19, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016042||205267|
NCT00019474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066253|Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer|Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filigrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||April 2007|February 6, 2009|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019474||205032|
NCT00019487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066287|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma Using Cloned Peripheral Blood Lymphocytes Sensitized In Vitro to the gp209-2M Immunodominant Peptide||National Cancer Institute (NCI)||Completed|November 1998|May 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019487||205031|
NCT00016289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02381|Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Phase II Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis (Residual Disease < 1cm) Associated With Ovarian Epithelial Cancer or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|July 2001|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||January 2013|January 22, 2013|May 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00016289||205249|
NCT00015652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5088|Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection|A Pilot Study of Low Dose Interleukin-2 (IL-2) With the Addition of Pegylated Interferon (PEG-IFN Alfa-2b) and Ribavirin (RBV) for the Treatment of Hepatitis C Infection in Subjects With HIV Coinfection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2005|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|No|||May 2012|May 21, 2012|April 26, 2001|No|Yes||||https://clinicaltrials.gov/show/NCT00015652||205294|
NCT00019006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000063475|Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer|Phase I Pilot Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in the Adjuvant Setting in Patients With Colorectal, Pancreatic, or Lung Cancer||National Cancer Institute (NCI)||Completed|March 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||May 2005|April 27, 2015|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019006||205059|
NCT00014937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5116|Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen|A Randomized, Controlled Trial of Two Potent, Simplified Regimens Utilizing A Protease Inhibitor-Sparing Regimen Versus A Nucleoside-Sparing Regimen for HIV-Infected Subjects Who Participated in ACTG 388 or Who Responded to A First Potent Combination Regimen and Have 200 or Less HIV-1 RNA Copies/ml||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|13 Years|N/A|No|||July 2013|July 26, 2013|April 14, 2001||||No||https://clinicaltrials.gov/show/NCT00014937||205330|
NCT00014950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Farrell (completed)|Benefits and Risks of Newborn Screening for Cystic Fibrosis|Pulmonary Benefits of Cystic Fibrosis Neonatal Screening||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||||||Both|1 Month|21 Years|No|||March 2010|March 1, 2010|April 14, 2001||||No||https://clinicaltrials.gov/show/NCT00014950||205329|
NCT00015587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9137-CP-001|Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)|Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure|CCLS|National Institute of Environmental Health Sciences (NIEHS)|No|Recruiting|April 1995|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1320|Samples With DNA|pre-treatment peripheral blood and bone marrow saliva|Both|N/A|14 Years|No|Non-Probability Sample|Children diagnosed with leukemia and matched controls|October 2014|October 14, 2014|April 23, 2001||No||No||https://clinicaltrials.gov/show/NCT00015587||205299|
NCT00015600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8766-CP-001|Community-Based Environmental Health Intervention|Community-Based Environmental Health Intervention||National Institute of Environmental Health Sciences (NIEHS)||Completed|October 1997|September 2002||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 22, 2006|April 23, 2001||||No||https://clinicaltrials.gov/show/NCT00015600||205298|
NCT00017056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-015|BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy|A Phase II Study Of Epothilone Analog BMS-247550 In Patients With Metastatic Gastric Adenocarcinoma Previously Treated With A Fluoropyrimidine And/Or Platinum||Memorial Sloan Kettering Cancer Center||Completed|February 2001|January 2002|Actual|January 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017056||205199|
NCT00019448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066215|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma||National Cancer Institute (NCI)||Completed|September 1998|March 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A||||September 2001|June 19, 2013|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019448||205034|
NCT00019461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066216|Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|April 1998|October 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2003|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019461||205033|
NCT00018356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-007-98S|Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly|Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly||VA Office of Research and Development||Completed|January 1999|August 2006|Actual|July 2006|Actual|Phase 4|Interventional|N/A|1||Anticipated|88|||Male|65 Years|N/A|No|||June 2011|June 22, 2011|July 3, 2001||No||No||https://clinicaltrials.gov/show/NCT00018356||205105|
NCT00018369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-009-99F|Age-Related Changes in Stress Hormone Regulation|Mechanism of Aging-Related Changes in (HPA) Hydrocortisone Corticotropin Feedback Function||VA Office of Research and Development||Completed|December 2000|April 2004||||Phase 4|Observational|Time Perspective: Prospective|||||||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||||https://clinicaltrials.gov/show/NCT00018369||205104|
NCT00018382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-012-98S|Insulin, Neurogenetics and Memory in Alzheimer's Disease|Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach||VA Office of Research and Development||Completed|October 1999|March 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|55 Years|80 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018382||205103|
NCT00018395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADE-AI|Cardiovascular Mortality Associated With Abnormal Calcium Metabolism|Cardiovascular Mortality Associated With Abnormal Calcium Metabolism||VA Office of Research and Development||Completed|August 1997|June 2002||||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018395||205102|
NCT00015925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068574, J0253|MS-275 in Treating Patients With Hematologic Cancer|Phase I Clinical-Labratory Study of the Histone Deacetylase (HDA) Inhibitor MS-275 in Adults With Refractory and Relapsed Hematologic Malignancies||Sidney Kimmel Comprehensive Cancer Center||Completed|February 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|March 9, 2010|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00015925||205275|
NCT00016692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B014|Safety and Tolerability of Z-100 in Patients With Early HIV Infection|A Phase 1b Multicenter Double-Blind, Placebo-Controlled, Randomized Study on the Safety and Tolerability of Z-100 in Early HIV-1 Infected Patients||Zeria Pharmaceutical||Terminated||||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2001|April 26, 2006|May 24, 2001||||||https://clinicaltrials.gov/show/NCT00016692||205222|
NCT00016302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01857|Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia||National Cancer Institute (NCI)||Completed|April 2001|||July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|100|||Both|1 Year|21 Years|No|||January 2013|January 15, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016302||205248|
NCT00015782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010166|The Natural History and Pathogenesis of Mucolipidosis Type IV|The Natural History and Pathogenesis of Mucolipidosis Type IV||National Institutes of Health Clinical Center (CC)||Completed|April 2001|March 2008||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||March 2008|September 26, 2015|May 4, 2001||||No||https://clinicaltrials.gov/show/NCT00015782||205286|
NCT00016198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROLOGUE-EFC4760|Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer|A Randomized, Multicenter, Phase II Study Of Bolus/Infusion 5-FU/LV (de Gramont Regimen) Versus Oxaliplatin And Bolus/Infusion 5-FU/LV (de Gramont Regimen) As Third-Line Treatment Of Patients With Metastatic Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|May 2001|December 2010|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2010|June 25, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016198||205256|
NCT00016081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1290.00|Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation|A Randomized Phase III Study To Evaluate The Safety And Efficacy Or Ribavirin Inhaled Solution In Preventing Progression Of Upper Respiratory Tract Respiratory Syncytial Virus (RSV) Infection To RSV Pneumonia In Blood And Bone Marrow Transplant (BMT) Recipients||Fred Hutchinson Cancer Research Center||Completed|March 1998|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|2 Years|N/A|No|||March 2010|March 26, 2010|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016081||205264|
NCT00015041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0012-2|Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2|PK 0396 - Buprenorphine Dose Escalation Trial||National Institute on Drug Abuse (NIDA)||Completed|November 1996|||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|21 Years|45 Years|No|||July 1998|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015041||205322|
NCT00015210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-4|Nefazodone in the Treatment of Cocaine Dependence and Depression - 4|Efficacy of Nefazodone in Cocaine Dependent Subjects||Boston Medical Center||Completed|February 1997|||May 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|21 Years|55 Years|No|||July 2015|July 29, 2015|April 18, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00015210||205315|
NCT00015483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5020-CP-001|Hematotoxic Effects of Particulate Exposure|Hematotoxic Effects of Benzene and Doxorubicin||National Institute of Environmental Health Sciences (NIEHS)||Completed||||||N/A|Observational|Allocation: Random Sample|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|April 20, 2001||||No||https://clinicaltrials.gov/show/NCT00015483||205303|
NCT00016276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02380|Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer|A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ STAGE IIIA, IIIB OR REGIONAL STAGE IV BREAST CANCER||National Cancer Institute (NCI)||Terminated|May 2001|||March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|396|||Female|18 Years|N/A|No|||January 2013|January 15, 2013|May 6, 2001|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00016276||205250|
NCT00015821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01853|Thalidomide in Treating Patients With Myelofibrosis|A Pilot Study of Thalidomide as an Inhibitor of Angiogenesis in the Treatment of Myelofibrosis With Myeloid Metaplasia (MMM)||National Cancer Institute (NCI)||Completed|May 2000|||December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00015821||205283|
NCT00016094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03039|S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma|Bevacizumab (rhuMab VEGF) (NSC-704865) Therapy for Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|April 2001|September 2008|Actual|August 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|19 Years|N/A|No|||January 2013|January 28, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016094||205263|
NCT00018941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000076799|Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|April 1991|May 2003|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|June 14, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00018941||205062|
NCT00014339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068535|Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma|A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|March 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2007|December 17, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014339||205371|
NCT00018499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPID-030-98S|Genotype Influence on Recovery After Traumatic Brain Injury|The Influence of APOE Genotype on Recovery After Traumatic Brain Injury||VA Office of Research and Development||Completed|October 1998|October 2001||||N/A|Observational|N/A|||||||Both|17 Years|55 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018499||205094|
NCT00019435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066180|LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors|Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Immunotoxin for Advanced Carcinomas That Express Lewis Y Antigen||National Cancer Institute (NCI)||Completed|May 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2007|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019435||205035|
NCT00013793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0153|Ultrasound and Motivational Enhancement for Prenatal Smoking Cessation|Ultrasound and Motivational Enhancement for Prenatal Smoking Cessation||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||30|||Female|16 Years|N/A|Accepts Healthy Volunteers|||December 2003|June 23, 2005|March 29, 2001||||No||https://clinicaltrials.gov/show/NCT00013793||205411|
NCT00019032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064038|Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia|PHASE I STUDY OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA USING THE MIK-BETA 1 MONOCLONAL ANTIBODY DIRECTED TOWARD THE IL-2R BETA SUBUNIT||National Cancer Institute (NCI)||Completed|March 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||April 2004|April 27, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019032||205057|
NCT00019214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065234|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Phase I/II Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From The Melanoma Associated Antigens MART-1 and gp 100||National Cancer Institute (NCI)||Completed|April 1997|July 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2005|June 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019214||205046|
NCT00019227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065240|Monoclonal Antibody Therapy in Treating Patients With Leukemia|PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA||National Cancer Institute (NCI)||Completed|October 1996|July 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019227||205045|
NCT00013780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6075-CP-001|Ozone Exposure and Dose Delivered to Human Lungs|||National Institute of Environmental Health Sciences (NIEHS)||Completed|July 1998|June 2003||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||||50|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|March 29, 2001||||No||https://clinicaltrials.gov/show/NCT00013780||205412|
NCT00012766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 95-097|Effectiveness of Team Treatment of Depression in Primary Care|Effectiveness of Team Treatment of Depression in Primary Care||VA Office of Research and Development|No|Completed||March 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|18 Years|N/A|No|||December 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012766||205489|
NCT00013013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPG 97-039|A Randomized Trial to Implement the AHCPR Smoking Cessation Guideline|A Randomized Trial to Implement the AHCPR Smoking Cessation Guideline||VA Office of Research and Development|No|Completed||August 2001|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|4000|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013013||205470|
NCT00019539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066669|Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer|Phase II Randomized Study of Monoclonal Antibody VEGF in Patients With Unresectable Advanced Renal Cell Cancer||National Cancer Institute (NCI)||Completed|November 1998|November 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||October 2004|June 19, 2013|January 9, 2009||||No||https://clinicaltrials.gov/show/NCT00019539||205028|
NCT00016029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0866|Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer|Prospective Comparison of Air Contrast Barium Enema (ACBE), Computed Tomographic Colonography (Virtual Colonoscopy) and Colonoscopy for Evaluation of the Colon in Patients With Fecal Occult Blood||Duke University||Terminated|August 2000|August 2005|Actual|||N/A|Interventional|Primary Purpose: Diagnostic|||Actual|775|||Both|18 Years|N/A|No|||September 2003|March 20, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016029||205268|
NCT00012857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 95-192|Pain Management and Behavioral Outcomes in Patients With Dementia|Pain Management and Behavioral Outcomes in Patients With Dementia||VA Office of Research and Development|No|Completed||March 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|66|||Both|55 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012857||205482|
NCT00013442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2133R|AERs in Aphasia: Severity and Improvement|AERs in Aphasia: Severity and Improvement||VA Office of Research and Development||Completed|January 2000|December 2002|Actual|||Phase 2|Observational|Time Perspective: Prospective||||20|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013442||205437|
NCT00013650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010128|Effects of an Anti-Inflammatory Drug in Alzheimer's Disease|Pilot Study of Immunomodulatory Versus Antiinflammatory Therapy in Alzheimer's Disease||National Institutes of Health Clinical Center (CC)||Completed|March 2001|April 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||60|||Both|50 Years|95 Years|No|||April 2008|April 22, 2008|March 27, 2001||||No||https://clinicaltrials.gov/show/NCT00013650||205421|
NCT00014690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZENECA-9331IL/0024|ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II, Open, Randomized Multicenter Trial to Assess the Efficacy and Tolerability of Intravenous ZD9331 Given as Monotherapy (at Two Doses) or in Combination With Topotecan, in Patients With Ovarian Cancer Refractory or Recurrent After Failing Platinum and Paclitaxel in Combination||National Cancer Institute (NCI)||Completed|March 2001|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2004|August 1, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014690||205345|
NCT00014729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15738|Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa|||FDA Office of Orphan Products Development||Completed|October 2000|September 2002||||Phase 1|Interventional|Primary Purpose: Treatment||||20|||Both|15 Years|N/A|No|||May 2001|March 24, 2015|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014729||205344|
NCT00014807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8707-CP-001|Reducing Pesticide Exposure in Minority Families|Reducing Pesticide Exposure in Minority Families||National Institute of Environmental Health Sciences (NIEHS)||Completed|July 2000|June 2005||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Prevention||||1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2006|September 1, 2006|April 11, 2001||||No||https://clinicaltrials.gov/show/NCT00014807||205338|
NCT00013455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2236R|Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting|Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting||VA Office of Research and Development||Completed|August 2000|August 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|48|||Both|18 Years|N/A|No|||May 2002|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013455||205436|
NCT00014482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-134|Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation|Music Therapy for Distress During Autologous Stem Cell Transplantation: A Randomized Trial||Memorial Sloan Kettering Cancer Center||Completed|December 2000|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014482||205361|
NCT00018655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-041-99S|Integrated Intervention for Substance Abusers With Depressive Disorders|Integrated Intervention for Substance Abusers With Depressive Disorders||VA Office of Research and Development|Yes|Terminated|April 2000|September 2012|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|July 3, 2001||No|PI has been contacted numerous times for an update, with no response. ORD requested a close    out of this project. 10/2011|No||https://clinicaltrials.gov/show/NCT00018655||205082|
NCT00018668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-041-00S|Antipsychotic Response in Schizophrenia|Psychopharmacologic Aspects of Motor Slowing in Schizophrenia||VA Office of Research and Development||Completed|October 2000|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|21 Years|70 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018668||205081|
NCT00018876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AR047121|Low-Dose Radiation to Prevent Complications of Back Surgery|Radiotherapy to Prevent Fibrosis After Lumbar Laminectomy||University of Pittsburgh||Completed|October 2000|October 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||46|||Both|18 Years|80 Years|No|||March 2006|June 6, 2013|July 5, 2001||||No||https://clinicaltrials.gov/show/NCT00018876||205065|
NCT00014326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20971-22997|Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma|A Phase III Randomized Study On Low-Dose Total Body Irradiation And Involved Field Radiotherapy In Patients With Localized, Stages I and II, Low Grade Non-Hodgkin's Lymphoma||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|January 2001|||March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|204|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|April 10, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00014326||205372|
NCT00013884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010133|HIV Maintenance Therapy With T-20 During HAART Interruption|A Pilot Study to Evaluate the Ability of Maintenance Therapy With the HIV Fusion Inhibitor T20 to Prevent Rebound of Plasma HIV RNA Following an Interruption of HAART||National Institutes of Health Clinical Center (CC)||Completed|March 2001|April 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||April 2003|March 3, 2008|March 31, 2001||||No||https://clinicaltrials.gov/show/NCT00013884||205404|
NCT00013962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR01070-0562|Vitamin D Metabolism and the Williams Syndrome|Vitamin D Metabolism and the Williams Syndrome||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Case Control|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|April 3, 2001||||No||https://clinicaltrials.gov/show/NCT00013962||205398|
NCT00019409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998007|Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia|A Randomized Study of Two Methods of CNS Prophylaxis in Patients With Acute Lymphoblastic Leukemia||National Institutes of Health Clinical Center (CC)||Withdrawn|October 1999|July 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|0|||Both|1 Year|20 Years|No|||March 2012|March 21, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019409||205037|
NCT00019422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066169|Lobradimil and Carboplatin in Treating Children With Brain Tumors|A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors||National Cancer Institute (NCI)||Completed|March 1998|April 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||April 2003|August 14, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019422||205036|
NCT00013871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1024|Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs|Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Treated With Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2004|Actual|||N/A|Interventional|Primary Purpose: Prevention||||300|||Both|2 Years|18 Years|No|||November 2013|November 25, 2013|March 31, 2001||||||https://clinicaltrials.gov/show/NCT00013871||205405|
NCT00013026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI 99-124|Trial of a Tailored Message Program to Implement CHF Guidelines|Trial of a Tailored Message Program to Implement CHF Guidelines||VA Office of Research and Development|No|Completed||March 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|1||Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013026||205469|
NCT00013039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPG 97-001|Computerized Guidelines Enhanced by Symptoms and History: Clinical Effects|Computerized Guidelines Enhanced by Symptoms and History: Clinical Effects||VA Office of Research and Development|No|Completed||February 2001|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1000|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013039||205468|
NCT00019136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064488|Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer|TREATMENT OF PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER USING ANTI-CD3 STIMULATED PERIPHERAL BLOOD LYMPHOCYTES TRANSDUCED WITH A GENE ENCODING A CHIMERIC T-CELL RECEPTOR REACTIVE WITH FOLATE BINDING PROTEIN||National Cancer Institute (NCI)||Completed|February 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2003|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019136||205050|
NCT00015756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010163|Tissue Collection From People With Cystic Fibrosis|Tissue Collection Protocol for Individuals With Cystic Fibrosis||National Institutes of Health Clinical Center (CC)||Completed|May 2001|April 2008||||N/A|Observational|N/A||||100|||Both|9 Years|65 Years|No|||April 2008|August 24, 2009|May 4, 2001||||No||https://clinicaltrials.gov/show/NCT00015756||205288|
NCT00012870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 95-244|Effect of Behavioral Management on Quality of Life in Heart Failure|Effect of Behavioral Management on Quality of Life in Heart Failure||VA Office of Research and Development|No|Completed||March 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|116|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012870||205481|
NCT00013611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0303M44961|Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)|A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)|SILCAAT|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2001|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1695|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|March 24, 2001||No||No|November 8, 2010|https://clinicaltrials.gov/show/NCT00013611||205424|
NCT00013624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010118|Riluzole to Treat Parkinson's Disease|Effect of Antiglutamatergic Treatment in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|March 2001|March 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||March 2005|March 3, 2008|March 24, 2001||||No||https://clinicaltrials.gov/show/NCT00013624||205423|
NCT00013234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 98-159|Health Services Implications of a Teledermatology Consult System|Health Services Implications of a Teledermatology Consult System||VA Office of Research and Development|No|Completed||September 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|260|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013234||205453|
NCT00013494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2169T|Video-Based Functional Performance and Assessment Following Stroke|Video-Based Functional Performance and Assessment Following Stroke||VA Office of Research and Development||Completed|July 1999|June 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||30|||Both|18 Years|N/A|No|||March 2006|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013494||205433|
NCT00014794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010151|Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients|H215O Positron Emission Tomography (PET) in the Assessment of Synovial Blood Flow in Rheumatoid Arthritis Patients||National Institutes of Health Clinical Center (CC)||Completed|April 2001|March 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||March 2003|March 3, 2008|April 11, 2001||||No||https://clinicaltrials.gov/show/NCT00014794||205339|
NCT00014820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7953|Occupation and Asthma in an Urban Low Income Population|Occupation and Asthma in an Urban Low Income Population||New York University School of Medicine||Completed|March 2001|February 2005|Actual|February 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|800|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients at Bellevue Hospital who were given a diagnosis between the dates of 1/1/1996 and        6/30/2003.|December 2015|December 17, 2015|April 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00014820||205337|
NCT00014833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|965|Life Course Socioeconomic Status, Social Context and Cardiovascular Disease|||University of North Carolina, Chapel Hill|No|Completed|March 2001|February 2006|Actual|February 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||November 2015|November 30, 2015|April 11, 2001||||No||https://clinicaltrials.gov/show/NCT00014833||205336|
NCT00013637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8074-CP-001|Lead Exposure, Genetics, and Osteoporosis Epidemiology|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1998|August 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||650|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2006|September 1, 2006|March 26, 2001||||No||https://clinicaltrials.gov/show/NCT00013637||205422|
NCT00014469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-126|Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer|A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies||Memorial Sloan Kettering Cancer Center||Completed|December 2000|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2013|March 6, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014469||205362|
NCT00013806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1748|CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study|CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||December 2003|June 23, 2005|March 29, 2001||||No||https://clinicaltrials.gov/show/NCT00013806||205410|
NCT00013819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7198-CP-001|Exposure, Dose, Body Burden and Health Effects of Lead|Exposure, Dose, Body Burden and Health Effects of Lead||National Institute of Environmental Health Sciences (NIEHS)||Completed|February 1997|February 2001|Actual|February 2001|Actual|N/A|Observational|Time Perspective: Prospective||||944|||Both|17 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 29, 2001||No||No||https://clinicaltrials.gov/show/NCT00013819||205409|
NCT00018811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-001-99S2|Psychological Assessment and Treatment of Chronic Benign Headache|Psychological Assessment and Treatment of Chronic Benign Headache||VA Office of Research and Development||Completed|April 1999|March 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2003|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018811||205070|
NCT00018889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010206|Phenotype/Genotype Correlations in Movement Disorders|Phenotype/Genotype Correlations in Movement Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|July 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1500|||Both|2 Years|N/A|No|||September 2015|October 2, 2015|July 7, 2001||No||No||https://clinicaltrials.gov/show/NCT00018889||205064|
NCT00013949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9825-CP-003|Cardiovascular Vulnerability to Particulate Exposure|Active Elderly Study||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 1998|September 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||200|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|April 3, 2001||||No||https://clinicaltrials.gov/show/NCT00013949||205399|
NCT00013052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DII 99-097|Improving Health Outcomes of Diabetic Veterans: A Diabetic Self-Management Program|Improving Health Outcomes of Diabetic Veterans: A Diabetic Self-Management Program||VA Office of Research and Development|No|Completed||September 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|2068|||Both|40 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013052||205467|
NCT00019058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064077|Radiation Therapy in Treating Patients With Glioblastoma|A PHASE I STUDY OF COMBINED RADIATION RESPONSE MODIFIERS EMPLOYING HYDROXYUREA AND PENTOXIFYLLINE FOR TREATMENT OF GLIOBLASTOMA||National Cancer Institute (NCI)||Completed|April 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|34|||Both|18 Years|N/A|No|||December 2001|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019058||205056|
NCT00019071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064153|Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma|A PHASE I STUDY OF 2-CHLORODEOXYADENOSINE AND RADIATION FOR THE TREATMENT OF HIGH GRADE GLIOMA (CDX)||National Cancer Institute (NCI)||Completed|March 1995|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019071||205055|
NCT00012974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHI 99-063|Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas|Innovative Strategies for Implementing New CHF Guideline Recommendations||VA Office of Research and Development|No|Completed|November 2005|May 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2005|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012974||205473|
NCT00013663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B012|Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load|A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2006|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||92|||Both|19 Years|N/A|No|||June 2006|November 1, 2012|March 27, 2001||||No||https://clinicaltrials.gov/show/NCT00013663||205420|
NCT00019357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065811|Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy|Cellular Immunotherapy With Autologous T Lymphocytes Stimulated With the Patient's Tumor-Specific Mutated Ras Peptides||National Cancer Institute (NCI)||Completed|June 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2001|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019357||205040|
NCT00015886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068567|Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery|Docetaxel (Taxotere) and 5-Fluorouracil As Second- Or Third-Line Chemotherapy In Women With Metastatic Breast Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|January 1997|July 2009|Actual|May 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||July 2012|July 12, 2012|May 6, 2001||No||No||https://clinicaltrials.gov/show/NCT00015886||205278|
NCT00013221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 95-213|Exercise Effect on Aerobic Capacity and QOL in Heart Failure|Exercise Effect on Aerobic Capacity and QOL in Heart Failure||VA Office of Research and Development|No|Completed||March 2000|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013221||205454|
NCT00013468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2299R|Early Diagnosis of Steroid-Responsive & No-Responsive Hearing Loss|Early Diagnosis of Steroid-Responsive & No-Responsive Hearing Loss||VA Office of Research and Development||Completed|August 2000|August 2003|Actual|||Phase 2|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|N/A|No|||January 2001|January 20, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013468||205435|
NCT00014963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7780-CP-001|Biomarkers of Benzene Exposure in Inner City Residents|||National Institute of Environmental Health Sciences (NIEHS)||Completed||||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||90|||Both|3 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 22, 2006|April 16, 2001||||No||https://clinicaltrials.gov/show/NCT00014963||205328|
NCT00014976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010148|Physiologic Studies of Spasticity|Spasticity: Physiologic Studies||National Institutes of Health Clinical Center (CC)||Completed|April 2001|November 2010||||N/A|Observational|N/A|||Actual|48|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||November 2010|November 2, 2010|April 17, 2001||No||No||https://clinicaltrials.gov/show/NCT00014976||205327|
NCT00015080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0012-5|Naltrexone in Treatment of Cocaine Dependence - 5|Naltrexone in Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|May 1995|||||Phase 2|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|65 Years|No|||December 1996|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015080||205319|
NCT00014599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55985|Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva|Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2001|||February 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Female|18 Years|N/A|No|||September 2012|September 20, 2012|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014599||205352|
NCT00014612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10981-22023|Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer|After Mapping Of The Axilla: Radiotherapy Or Surgery|AMAROS|European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2001|March 2013|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4813|||Female|N/A|N/A|No|||October 2013|October 28, 2013|April 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00014612||205351|
NCT00014651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068584|Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection|Vapreotide in Pancreas Surgery: A Double-Blind, Placebo-Controlled, Randomized Study of Vapreotide to Prevent Post-Surgical Complications in Patients Undergoing Elective Pancreatic Resection Grant Application Title: Vapreotide to Prevent Complications of Pancreatic Resection||Mayo Clinic||Terminated|March 2001|April 2002|Actual|March 2001|Actual|Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|90 Years|No|||August 2010|August 6, 2010|April 10, 2001|||Teminated by the DSMB because there are no differences between the control group and the    Vapreotide group|No||https://clinicaltrials.gov/show/NCT00014651||205348|
NCT00014664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068585|Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II, Open-Label, Randomized, Multicenter Trial To Evaluate The Preliminary Safety And Efficacy of Hu1D10 In Patients With Relapsed Or Refractory Grades I, II, or III B-Cell Non-Hodgkin's Lymphoma (Including Follicular, Small Lymphocytic And Marginal Zone/MALT)||National Cancer Institute (NCI)||Active, not recruiting|October 2000|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|December 17, 2013|April 10, 2001||||No||https://clinicaltrials.gov/show/NCT00014664||205347|
NCT00018824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-009-98S|Treating Alcohol Use In Older Adults With Depression|The Treatment of Late Life Major Depression Complication by Alcohol||VA Office of Research and Development||Completed|October 1999|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|55 Years|N/A|No|||September 2009|September 21, 2009|July 3, 2001||No||No||https://clinicaltrials.gov/show/NCT00018824||205069|
NCT00018837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-010-98S|Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome|Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome||VA Office of Research and Development||Completed|April 1998|March 2001||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment|||||||Both|18 Years|65 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018837||205068|
NCT00018902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH061835|Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)|Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)|TORDIA|University of Pittsburgh|Yes|Completed|January 2001|March 2007|Actual|March 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|334|||Both|12 Years|18 Years|No|||March 2014|March 11, 2014|July 10, 2001|Yes|Yes||||https://clinicaltrials.gov/show/NCT00018902||205063|
NCT00014027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010141|Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress|Polyunsaturated Fatty Acids and the Neurochemistry of Cardiovascular and Behavioral Responses in Aggressive Alcoholics||National Institutes of Health Clinical Center (CC)||Completed|April 2001|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||July 2010|September 26, 2015|April 7, 2001||No||No||https://clinicaltrials.gov/show/NCT00014027||205394|
NCT00013897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302C|A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine|A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine||Bristol-Myers Squibb||Completed|February 2001|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2011|April 28, 2011|March 31, 2001|Yes|Yes||||https://clinicaltrials.gov/show/NCT00013897||205403|
NCT00015873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068529|Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia|International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia||Dutch Childhood Oncology Group|Yes|Completed|May 1999|December 2009|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|N/A|1 Year|No|||February 2014|February 14, 2014|May 6, 2001||No||No||https://clinicaltrials.gov/show/NCT00015873||205279|
NCT00019240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065260|Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection|PHASE II PROTOCOL WITH LABORATORY CORRELATES OF 1-[(S)-3-HYDROXY-2-(PHOSPHOMETHOXY)PROPYL]CYTOSINE DIHYDRATE(CIDOFOVIR) IN PATIENTS WITH KAPOSI'S SARCOMA (KS)||National Cancer Institute (NCI)||Completed|November 1996|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2007|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019240||205044|
NCT00012987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPG 97-002|Implementing Guidelines for Smoking Cessation: A Randomized Trial of Evidence-Based Quality Improvement|Implementing Guidelines for Smoking Cessation: A Randomized Trial of Evidence-Based Quality Improvement||VA Office of Research and Development|No|Completed||December 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2500|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00012987||205472|
NCT00013000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPG 97-027|A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines|A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines||VA Office of Research and Development|No|Completed||September 2000|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|65 Years|No|||February 2007|April 6, 2015|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013000||205471|
NCT00019123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064453|Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma|A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA||National Cancer Institute (NCI)||Completed|April 1996|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2007|August 14, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019123||205051|
NCT00019344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065779|Flavopiridol in Treating Patients With Refractory Cancer|A Phase I Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Refractory Neoplasms||National Cancer Institute (NCI)||Completed|August 1997|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019344||205041|
NCT00015067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0012-4|Cocaine-Methylphendidate Interaction Study - 4|Cocaine-Methylphendidate Interaction Study||National Institute on Drug Abuse (NIDA)||Completed|December 1997|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment||||8|||Both|21 Years|45 Years|No|||October 1998|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015067||205320|
NCT00016016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03153|Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia|A Phase I/II Study of Flavopiridol (NSC 649890, IND 46,211) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Poor-Risk Acute Leukemias||National Cancer Institute (NCI)||Completed|February 2001|||November 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016016||205269|
NCT00014859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|967|Epidemiology of Surfactant Protein-B Deficiency|Epidemiology of Surfactant Protein-B Deficiency||Washington University School of Medicine|No|Recruiting|June 2001|June 2019|Anticipated|June 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|5000|Samples With DNA|DNA and tracheal aspirate samples|Both|N/A|1 Year|Accepts Healthy Volunteers|Non-Probability Sample|Cohort I is a population-based cohort from Missouri. Cohort II is a case-control cohort        from the Neonatal Intensive Care Unit at St. Louis Children's Hospital and from patients        referred from other centers.|June 2015|June 1, 2015|April 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00014859|4 Weeks|205335|
NCT00013481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2116|Coordination of Hemiparetic Movement After Post-Stroke Rehabilitation|Coordination of Hemiparetic Movement After Post-Stroke Rehabilitation||VA Office of Research and Development||Completed|January 2000|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||November 2009|November 9, 2009|March 14, 2001||||No||https://clinicaltrials.gov/show/NCT00013481||205434|
NCT00015054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0012-3|Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3|MPD04961-Methylphendidate Treatment of Cocaine Dependent ADHD Patients||National Institute on Drug Abuse (NIDA)||Completed|September 1998|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||20|||Both|21 Years|50 Years|No|||February 1999|November 3, 2005|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015054||205321|
NCT00018850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-013-99F|5HT3 Antagonism and Auditory Gating in Schizophrenia|5HT3 Antagonism and Auditory Gating in Schizophrenia||VA Office of Research and Development||Completed|June 1998|June 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018850||205067|
NCT00018863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3761|Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)|Methylphenidate Efficacy and Safety in ADHD Preschoolers||New York State Psychiatric Institute||Active, not recruiting|April 2001|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||165|||Both|3 Years|5 Years|No|||October 2006|November 1, 2013|July 5, 2001||||||https://clinicaltrials.gov/show/NCT00018863||205066|
NCT00014872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|968|Genetic Epidemiology and Energy Metabolism in Black Girls|||University of New Mexico||Completed|May 2001|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Female|12 Years|15 Years|No|Probability Sample|12-15 years old black girl with Cardiovascular Diseases Obesity|January 2014|January 9, 2014|April 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00014872||205334|
NCT00017966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010199|Brain Excitability During Self-Paced Voluntary Movements|Cortical Excitability During Self-Paced Voluntary Movements||National Institutes of Health Clinical Center (CC)||Completed|June 2001|June 2002||||N/A|Observational|N/A||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|June 23, 2001||||No||https://clinicaltrials.gov/show/NCT00017966||205135|
NCT00019175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064960|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma|PHASE I TRIAL IN PATIENTS WITH METASTATIC MELANOMA OF IMMUNIZATION WITH A RECOMBINANT FOWLPOX VIRUS ENCODING THE GP100 MELANOMA ANTIGEN||National Cancer Institute (NCI)||Completed|August 1996|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019175||205049|
NCT00018486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPID-018-98F|Epidemiology of Hearing Loss in Diabetic and Non-Diabetic Veterans|Epidemiology of Hearing Loss in Diabetic and Non-Diabetic Veterans||VA Office of Research and Development||Completed|April 1999|March 2004||||N/A|Observational|N/A|||||||Both|21 Years|80 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018486||205095|
NCT00018629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-043-99S|Cognitive - Behavioral Therapy|Rehabilitation of Older Patients With Schizophrenia||VA Office of Research and Development||Completed|May 2000|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|1||Actual|76|||Both|45 Years|N/A|No|||September 2008|January 5, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018629||205084|
NCT00017823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9941|Acupressure to Treat Nausea and Vomiting in HIV/AIDS Patients|The Acupressure Study||National Institute of Nursing Research (NINR)||Completed||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2001|April 20, 2010|June 13, 2001||||No||https://clinicaltrials.gov/show/NCT00017823||205143|
NCT00017160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-S-0124|Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma|Phase II Study of Neoadjuvant Doxorubicin and Ifosfamide, Radiotherapy, and Surgical Resection in Patients With Primary or Recurrent Retroperitoneal Sarcoma||Radiation Therapy Oncology Group|Yes|Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||June 2013|June 25, 2013|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017160||205191|
NCT00018473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPID-006-98F|Gene-Environment Interactions in Alzheimer's Disease|Gene-Environment Interactions in Alzheimer's Disease||VA Office of Research and Development||Completed|April 1999|March 2004||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018473||205096|
NCT00018135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0795|Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals|Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||December 2003|June 23, 2005|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018135||205122|
NCT00017836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024823|Mechanisms Linking Depression to Cardiovascular Risk|||Emory University||Completed|June 2001|May 2006|Actual|May 2006|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||May 2014|May 28, 2014|June 15, 2001||||No||https://clinicaltrials.gov/show/NCT00017836||205142|
NCT00018005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137|A Self-Management Intervention for Mild to Moderate Heart Failure|Heart Failure Adherence and Retention Trial (HART)|HART|Rush University Medical Center|Yes|Completed|June 2001|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|902|||Both|N/A|N/A|No|||October 2012|October 19, 2012|June 26, 2001||No||No||https://clinicaltrials.gov/show/NCT00018005||205132|
NCT00021697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-AVR-102|Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS|A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis||Avanir Pharmaceuticals||Completed|January 2001|March 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|80 Years|No|||April 2014|April 10, 2014|August 1, 2001||||||https://clinicaltrials.gov/show/NCT00021697||204900|
NCT00017628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14975|Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis|||Office of Rare Diseases (ORD)||Completed|April 2001|||||Phase 1|Interventional|Primary Purpose: Treatment||||20|||Both|N/A|59 Years|No|||July 2004|June 23, 2005|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017628||205157|
NCT00019552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066696|Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase II Study of MGI-114 in Patients With Recurrent or Persistent Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Completed|September 1998|April 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2002|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019552||205027|
NCT00019188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000064977|Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma|Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma||National Cancer Institute (NCI)||Completed|January 1997|March 2007|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||April 2004|June 19, 2013|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019188||205048|
NCT00021827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTHrP and Osteo (completed)|PTHrP and Osteoporosis|Pathophysiology of PTH-related Protein in Humans.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 1999|December 2001||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|50 Years|75 Years|No|||March 2010|March 1, 2010|August 4, 2001||||No||https://clinicaltrials.gov/show/NCT00021827||204890|
NCT00021489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5105|Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment|A Phase I/II Study of the Safety, Tolerability, and Antiretroviral Activity of Mycophenolate Mofetil As an Adjunct to Abacavir Therapy in HIV-Infected Subjects With Treatment Failure and Extensive Prior Antiretroviral Exposure||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|July 18, 2001||||No||https://clinicaltrials.gov/show/NCT00021489||204911|
NCT00018590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0087|Center for the Study of Vascular Disease in Hispanic and Native Americans|Center for the Study of Vascular Disease in Hispanic and Native Americans||VA Office of Research and Development||Completed|January 2001|||||N/A|Observational|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018590||205087|
NCT00018603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-047-99F|Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)|Guanfacine for the Treatment of PTSD||VA Office of Research and Development||Completed|November 1999|October 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018603||205086|
NCT00018616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-047-98F|Improving Compliance With Metformin|Improving Compliance With Metformin||VA Office of Research and Development||Completed|October 1999|January 2005|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|79|||Both|18 Years|N/A|No|||September 2009|September 21, 2009|July 3, 2001||No||No||https://clinicaltrials.gov/show/NCT00018616||205085|
NCT00017147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068656|S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma|A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma||Southwest Oncology Group|Yes|Completed|September 2001|November 2012|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017147||205192|
NCT00022009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068683|Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase I/II Randomized Trial Comparing Two Treatment Schedules Of Gemcitabine In Poor Prognosis Status Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2001|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2002|September 19, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022009||204876|
NCT00022022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068702|Docetaxel in Treating Patients With Non-Small Cell Lung Cancer|Docetaxel In Second-Line Treatment Of Advanced Non-Small-Cell Lung Cancer - The Distal Study||National Cancer Institute (NCI)||Active, not recruiting|December 2000|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|75 Years|No|||April 2006|December 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022022||204875|
NCT00017875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010188|Transcranial Magnetic Stimulation (TMS) Studies of Dystonia|Neurophysiological Studies of Focal and Generalized Forms of Dystonia Using Transcranial Magnetic Stimulation (TMS)||National Institutes of Health Clinical Center (CC)||Completed|June 2001|July 2005||||N/A|Observational|N/A||||120|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2005|March 3, 2008|June 15, 2001||||No||https://clinicaltrials.gov/show/NCT00017875||205140|
NCT00017914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940165|Adult and Juvenile Myositis|Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies||National Institutes of Health Clinical Center (CC)||Recruiting|June 1994|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1200|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|December 15, 2015|June 19, 2001||No||No||https://clinicaltrials.gov/show/NCT00017914||205139|
NCT00017108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068650|Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia|Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3)||National Cancer Institute (NCI)||Active, not recruiting|March 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||June 2004|July 23, 2008|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017108||205195|
NCT00017641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14976|Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus|||Office of Rare Diseases (ORD)||Active, not recruiting|April 2001|||||Phase 1|Interventional|Primary Purpose: Treatment||||10|||Both|N/A|59 Years|No|||November 2003|June 23, 2005|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017641||205156|
NCT00021294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068767|Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis|Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms||University of Arizona||Completed|May 2001|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|March 23, 2010|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00021294||204925|
NCT00018551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCO-021-98S|Chemoprevention With Folic Acid|3389 Colorectal Adenoma: Chemoprevention With Folic Acid||VA Office of Research and Development||Completed|October 1998|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||||https://clinicaltrials.gov/show/NCT00018551||205090|
NCT00018564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUD-048-00S|Novel Therapies for Essential Tremor|Novel Therapies for Essential Tremor||VA Office of Research and Development||Completed|October 2000|September 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018564||205089|
NCT00018577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUD-024-99S|The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men|The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men||VA Office of Research and Development||Completed|October 2000|September 2002||||N/A|Observational|Time Perspective: Prospective|||||||Male|81 Years|N/A|Accepts Healthy Volunteers|||December 2004|April 2, 2008|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018577||205088|
NCT00017797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5084|Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women|Evaluation of Metabolic Complications Associated With Antiretroviral Medications in HIV-1-Infected Pregnant Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Observational Model: Case Control||||160|||Female|13 Years|N/A|No|||August 2006|August 3, 2006|June 12, 2001||||No||https://clinicaltrials.gov/show/NCT00017797||205145|
NCT00017810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6510|The Healthy Life Choices Project in HIV-Positive Patients|||National Institute of Nursing Research (NINR)||Recruiting||||||Phase 1|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|18 Years|N/A|No|||April 2001|December 8, 2005|June 13, 2001||||No||https://clinicaltrials.gov/show/NCT00017810||205144|
NCT00021671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET 024|Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission|Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||3720|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 13, 2012|July 31, 2001||||No||https://clinicaltrials.gov/show/NCT00021671||204901|
NCT00021320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068769|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer|Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer||Fox Chase Cancer Center||Completed|May 2000|April 2009|Actual|January 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|21|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00021320||204923|
NCT00021333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068770|Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer|Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung||Fox Chase Cancer Center||Completed|September 1999|May 2008|Actual|April 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|29|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00021333||204922|
NCT00018109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-5083|A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)|A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)||National Center for Research Resources (NCRR)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|5 Years|10 Years|No|||December 2003|June 23, 2005|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018109||205124|
NCT00018772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMA-013-98F|Risk Factors for Venous Thromboembolism|2779 Epidemiology of Genetic and Acquired Risk Factors for Venous Thrombosis||VA Office of Research and Development||Completed|April 1999|April 2003||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018772||205073|
NCT00018785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMU-035-98S|Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants|Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants||VA Office of Research and Development||Completed|October 1998|September 2003||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018785||205072|
NCT00018798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-001-99F|Post-Traumatic Stress Disorder (PTSD) Symptom Study|Longitudinal Evaluation of Chronic Combat-Related PTSD||VA Office of Research and Development||Completed|April 2000|April 2003||||N/A|Observational|N/A|||||||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018798||205071|
NCT00021853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010217|Motor Training to Treat Hand Dystonia|Motor Training as Treatment of Focal Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|August 2001|August 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||August 2002|March 3, 2008|August 8, 2001||||No||https://clinicaltrials.gov/show/NCT00021853||204888|
NCT00018122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0779|Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls|Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls (Project 2 of JDFI Washington University Center for Islet Transplantation, KS Polonsky, PI)||National Center for Research Resources (NCRR)||Active, not recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Female|18 Years|65 Years|No|||December 2003|June 27, 2005|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018122||205123|
NCT00017121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0071|Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung|Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung||Alliance for Clinical Trials in Oncology|No|Completed|May 2002|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017121||205194|
NCT00017654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/14983|Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia|||Office of Rare Diseases (ORD)||Active, not recruiting|April 2001|||||N/A|Interventional|Primary Purpose: Treatment||||3|||Both|15 Years|55 Years|No|||October 2003|June 23, 2005|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017654||205155|
NCT00021567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010205|A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections|A Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterial in Previously Treated or Moderate to Severe Pulmonary Mycobacterium Avium Complex (MAC) Infection||National Institutes of Health Clinical Center (CC)||Completed|July 2001|June 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||June 2002|March 3, 2008|July 24, 2001||||No||https://clinicaltrials.gov/show/NCT00021567||204906|
NCT00021580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0775|Modification of the "Edmonton Protocol" to Allow for Successful Islet Transplantation From a Single Pancreas and Extension of the "Edmonton Protocol" to Kidney Transplant Recipients|Modification of the "Edmonton Protocol" to Allow for Successful Islet Transplantation From a Single Pancreas and Extension of the "Edmonton Protocol" to Kidney Transplant Recipients (Project 1 of JDFI Washington University Center for Islet Transplantation)||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||April 2004|June 23, 2005|July 24, 2001||||No||https://clinicaltrials.gov/show/NCT00021580||204905|
NCT00017225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPOH-GERMANY-NB97|Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma|Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma||National Cancer Institute (NCI)||Completed|May 1997|February 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|20 Years|No|||August 2002|August 1, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017225||205186|
NCT00018746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-037-98S|Transcranial Magnetic Stimulation in Depression|Efficacy of Threshold vs. Subthreshold TMS in the Treatment of Depression||VA Office of Research and Development||Completed|July 1999|July 2001||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2004|January 20, 2009|July 3, 2001||||||https://clinicaltrials.gov/show/NCT00018746||205075|
NCT00017992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298D|Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV|An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV-Infected Pediatric Patients||NIH AIDS Clinical Trials Information Service||Recruiting||||||Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Primary Purpose: Treatment||||100|||Both|3 Months|17 Years|No|||March 2003|June 23, 2005|June 23, 2001||||No||https://clinicaltrials.gov/show/NCT00017992||205133|
NCT00017342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068679|Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia|Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia||Virginia Commonwealth University|Yes|Completed|July 2001|June 2005|Actual|September 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|February 26, 2010|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017342||205177|
NCT00018759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-023-00S|Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients|Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients||VA Office of Research and Development||Completed|March 2001|October 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|25 Years|65 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018759||205074|
NCT00021840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971|Genetic Epidemiology of Asthma in Costa Rica|Genetic Epidemiology of Asthma in Costa Rica||Brigham and Women's Hospital|No|Completed|July 2001|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|4245|Samples With DNA|Blood (and its components, e.g., serum, WBC, etc.)|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Homogeneous Hispanic population from the Central Valley of Costa Rica|August 2014|August 1, 2014|August 7, 2001||No||No||https://clinicaltrials.gov/show/NCT00021840||204889|
NCT00017251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02387|Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer|A Phase I Study Of Genasense, A Bcl-2 Antisense Oligonucleotide, Combined With Carboplatin And Etoposide In Patients With Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|April 2001|||January 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017251||205184|
NCT00017264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068668|Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma|A Phase I Evaluation of the Safety and Pharmacokinetics of ABT-627 in Adults With Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|June 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|January 10, 2009|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017264||205183|
NCT00017771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5117|Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs|A Pathophysiologic Study of Development of Distal Symmetrical Polyneuropathy in Individuals With Advanced HIV-1 Infection and Prior Antiretroviral Exposure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2001|July 2004|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|Samples With DNA|Blood collection|Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected individuals who have previously undergone HIV treatment. HIV-uninfected to be        used as controls.|July 2013|July 26, 2013|June 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00017771||205147|
NCT00019383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000065915|Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using Immunodominant Peptides From the Tyrosinase Protein or Tyrosinase Related Protein-1 (TRP1)||National Cancer Institute (NCI)||Completed|January 1998|June 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||June 2003|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019383||205039|
NCT00021775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 033|HIV Prevention Preparedness Study in Russia, China, and India|HIV Prevention Preparedness Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2002|February 2004|Actual|||N/A|Observational|N/A||||2000|||Both|14 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 31, 2013|August 4, 2001||No||No||https://clinicaltrials.gov/show/NCT00021775||204894|
NCT00021346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068771|Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors|Phase I Evaluation Of Carboplatin And Gemcitabine||Fox Chase Cancer Center||Completed|November 1997|March 2002|Actual|July 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|8|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021346||204921|
NCT00017784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268C|Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection|Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment||NIH AIDS Clinical Trials Information Service||Active, not recruiting||||||Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||June 2001|June 23, 2005|June 11, 2001||||No||https://clinicaltrials.gov/show/NCT00017784||205146|
NCT00019513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980143|Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas|A Phase I Study of Weekly Gemcitabine in Combination With Infusional 5-Fluorouracil and Oral Calcium Leucovorin in Adult Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|August 1998|June 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|108|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019513||205029|
NCT00017446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068689|CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma|Phase II Evaluation Of CP4071 In Previously Treated Advanced Sarcomas||National Cancer Institute (NCI)||Active, not recruiting|October 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2002|January 3, 2014|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017446||205170|
NCT00017576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068720|Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy|Phase II Study of Calcitrol Enhanced Carboplatin in Hormone Refractory Prostate Cancer||OHSU Knight Cancer Institute|Yes|Completed|December 2000|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||September 2009|May 24, 2012|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017576||205160|
NCT00019500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066428|Raloxifene in Preventing Breast Cancer in Premenopausal Women|A Randomized Phase II Trial of Two Doses of Raloxifene in Pre-Menopausal Women at High Risk For Developing Invasive Breast Cancer||National Cancer Institute (NCI)||Completed|December 1998|June 2005|Actual|||Phase 2|Interventional|Primary Purpose: Prevention|||||||Female|23 Years|47 Years|No|||April 2009|June 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019500||205030|
NCT00018330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-006-98F|Genetics, Metabolism and Weight Loss in Older, Obese Veterans|Genetics, Metabolism and Weight Loss in Older, Obese Veterans||VA Office of Research and Development||Completed|April 1999|March 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||||||Both|50 Years|65 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018330||205107|
NCT00018343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-007-97F|Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen|Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen||VA Office of Research and Development||Completed|April 1998|March 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|50 Years|90 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018343||205106|
NCT00017745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010187|Phenotype/Genotype Correlations in Neuromuscular Disorders|Phenotype/Genotype Correlations in Inherited Myopathies||National Institutes of Health Clinical Center (CC)||Completed|June 2001|May 2007||||N/A|Observational|N/A||||1000|||Both|N/A|N/A|No|||May 2007|September 26, 2015|June 8, 2001||||No||https://clinicaltrials.gov/show/NCT00017745||205149|
NCT00017758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5108|The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs|The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2004|March 13, 2006|June 11, 2001||||No||https://clinicaltrials.gov/show/NCT00017758||205148|
NCT00018317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-005-99F|Resistance Training and Diet in Patients With Chronic Renal Failure|Resistance Training and Diet in Patients With Chronic Renal Failure||VA Office of Research and Development||Completed|October 2000|December 2005||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|50 Years|89 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018317||205108|
NCT00017680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/15927|Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis|Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in||Office of Rare Diseases (ORD)||Completed|July 1999|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||25|||Both|18 Years|70 Years|No|||June 2008|June 6, 2008|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017680||205154|
NCT00021307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-01004|Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I/II Trial Of Temozolomide And Carboplatin In Recurrent Glioblastoma Multiforme||Fox Chase Cancer Center|No|Withdrawn||April 2002|Actual|April 2002|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|July 11, 2001|Yes|Yes|Study not activated.|No||https://clinicaltrials.gov/show/NCT00021307||204924|
NCT00018304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-005-98S|Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow|Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow||VA Office of Research and Development||Completed||||||Phase 1|Observational|N/A|||||||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018304||205109|
NCT00018460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epid-004-98F|Anticoagulation, Vitamins, and Endothelial Function|Anticoagulation, Vitamins, and Endothelial Function||VA Office of Research and Development||Completed|April 1999|March 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|50 Years|95 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018460||205097|
NCT00017589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068721|Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia|Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia||National Cancer Institute (NCI)||Completed|December 2000|May 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|60 Years|N/A|No|||April 2003|January 3, 2014|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017589||205159|
NCT00017602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068722|Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma|Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|December 2000|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2003|January 3, 2014|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017602||205158|
NCT00018148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-006-97F|Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation|Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation||VA Office of Research and Development|Yes|Completed|April 1998|January 2003|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|70 Years|No|||September 2010|September 14, 2010|July 3, 2001||No||No||https://clinicaltrials.gov/show/NCT00018148||205121|
NCT00018161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-008-97F|Treatment to Quit Smoking|Combined Pharmacologic/Behavioral Treatment for Smoking Cessation||VA Office of Research and Development||Completed|January 1997|June 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||September 2007|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018161||205120|
NCT00021502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APX-PHP 99-004|Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)|A Phase 3, Multi-Center, Randomized, Placebo Controlled Study of PHP When Administered by Continuous Infusion in Patients With Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)||Apex Bioscience||Completed|March 2001|May 2004|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|18 Years|N/A|No|||August 2009|August 13, 2009|July 18, 2001||||||https://clinicaltrials.gov/show/NCT00021502||204910|
NCT00017953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHOW|Look AHEAD: Action for Health in Diabetes|Look AHEAD: Action for Health in Diabetes|Look AHEAD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|June 2001|August 2016|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5145|||Both|55 Years|76 Years|No|||February 2015|February 5, 2015|June 21, 2001||No||No||https://clinicaltrials.gov/show/NCT00017953||205136|
NCT00017979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010200|Study of Brain Control of Movement|Effect of Volitional Inhibition on Cortical Inhibitory Mechanisms||National Institutes of Health Clinical Center (CC)||Completed|June 2001|June 2002||||N/A|Observational|N/A||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|June 23, 2001||||No||https://clinicaltrials.gov/show/NCT00017979||205134|
NCT00018252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-003-96F|The Effect of Exercise Training on Mental Stress-Induced Silent Ischemia|The Effect of Exercise Training on Mental Stress-Induced Silent Ischemia||VA Office of Research and Development||Completed|April 1997|March 2000||||N/A|Interventional|Allocation: Randomized|||||||Both|60 Years|N/A|Accepts Healthy Volunteers|||June 2001|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018252||205113|
NCT00018408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADE-ARCD1|Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)|Genetic Mechanisms of Chronic Obstructive Pulmonary Disease||VA Office of Research and Development||Completed|October 1998|September 2001||||N/A|Observational|Time Perspective: Retrospective|||||||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018408||205101|
NCT00017433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068688|Arsenic Trioxide in Treating Patients With Multiple Myeloma|Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|November 16, 2008|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017433||205171|
NCT00021996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI-N91-00-02-040|Valdecoxib in Treating Chronic Pain in Cancer Patients|Clinical Protocol for a Randomized Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib (SC-65872) 40mg BID as Add-On Therapy to Opioid Medication in Patients With Chronic Cancer Pain||National Cancer Institute (NCI)||Completed|January 2001|February 2004|Actual|||N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||February 2002|July 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021996||204877|
NCT00017407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068686|Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer|A Prospective, Randomized, Open-Label, Phase III Trial of Chemotherapy With Carboplatin And Paclitaxel, Versus Carboplatin And Paclitaxel In Combination With ISIS-3521, An Antisense Inhibitor Of Protein Kinase C Alpha In Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|October 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2006|February 6, 2009|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017407||205172|
NCT00021138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICS-R44-CA80525|Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking|Computerized Scheduling of Nicotine Inhaler Use||National Cancer Institute (NCI)||Completed|April 2001|March 2004|Actual|||N/A|Interventional|Primary Purpose: Prevention|||||||Both|18 Years|67 Years|No|||March 2011|May 14, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021138||204934|
NCT00015444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010145|Screening and Natural History: Primary Lateral Sclerosis and Related Disorders|Screening and Natural History: Primary Lateral Sclerosis and Related Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|April 2001|||||N/A|Observational|N/A|||Anticipated|240|||Both|18 Years|N/A|No|||July 2015|February 10, 2016|April 18, 2001||No||No||https://clinicaltrials.gov/show/NCT00015444||205306|
NCT00016926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068633|Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial Of Capecitabine In Advanced, Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix||Gynecologic Oncology Group||Completed|April 2001|||July 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||May 2004|May 24, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016926||205209|
NCT00017459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SANOFI-EFC3675|Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|The International Tirazone Triple Trial (i3T): A Phase III, Randomized Efficacy And Safety Study Of The Combination Chemotherapy With Tirapazamine+Cisplatin+Vinorelbine Versus Cisplatin+Vinorelbine In Subjects With Inoperable, Previously Untreated, Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|July 2000|February 2004|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|August 1, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017459||205169|
NCT00017472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01405|Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia|Phase I Study of Thrice Weekly Hu1D10*in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Acute Leukemia||National Cancer Institute (NCI)||Completed|April 2001|||April 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017472||205168|
NCT00017485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068696|Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer|A Phase I Study Of Photodynamic Therapy (PDT) For The Treatment Of Basal Cell Carcinoma (BCC): A Drug/Light Dose Finding Study Utilizing 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A (HPPH-PHOTOCLOR)||Roswell Park Cancer Institute|Yes|Completed|January 2000|January 2007|Actual|December 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017485||205167|
NCT00016939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068634|Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase II Study of Flavopiridol 1 Hour Bolus Days 1-3 Q 21 Days in Patients With Advanced Renal Cell Cancer||National Cancer Institute (NCI)||Completed|May 2001|April 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 2008|June 20, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016939||205208|
NCT00021372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068773|Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase II Study of Paclitaxel and Estramustine Phosphate in Patients With Relapsed Non-Hodgkin's Lymphoma||Fox Chase Cancer Center||Completed|February 1996|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00021372||204919|
NCT00021385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068774|Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer|A Phase IIA Trial of Continuous Five Day Infusions of MSI-1256F (Squalamine Lactate) Plus Carboplatin for Therapy of Refractory and Resistant Stage III and IV Ovarian Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2002|December 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021385||204918|
NCT00021814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTOPS (completed)|Medical Therapy of Prostatic Symptoms (MTOPS)|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 1995|March 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2931|||Male|50 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 4, 2001||||||https://clinicaltrials.gov/show/NCT00021814||204891|
NCT00021892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|973|Ventricular Matrix Remodeling: Correlates and Prognosis|||Boston University||Completed|June 2001|May 2006|Actual|May 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||February 2014|February 20, 2014|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021892||204885|
NCT00021905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|974|Atrial Fibrillation Incidence, Risk Factors and Genetics|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2002|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 23, 2008|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021905||204884|
NCT00016718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1021|Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs|An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2001|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|90 Days|21 Years|No|||May 2013|May 3, 2013|May 31, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00016718||205221|
NCT00016731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010152|Adolescence, Puberty, and Emotion Regulation|Adolescence, Puberty, Hormones, and Emotion Regulation: An fMRI Study||National Institutes of Health Clinical Center (CC)||Completed|May 2001|||||N/A|Observational|Time Perspective: Retrospective|||Actual|300|||Both|8 Years|55 Years|No|||January 2016|January 20, 2016|May 31, 2001||No||No||https://clinicaltrials.gov/show/NCT00016731||205220|
NCT00016263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068616|Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma|Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma||National Cancer Institute (NCI)||Completed|July 2000|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2002|January 3, 2014|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016263||205251|
NCT00021710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010220|Motor Learning in Stroke Patients and Healthy Volunteers|Motor Learning: Behavioral and Physiologic Studies in Normal Volunteers and Stroke Patients||National Institutes of Health Clinical Center (CC)||Completed|July 2001|June 2005||||N/A|Observational|N/A||||78|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|March 3, 2008|August 2, 2001||||No||https://clinicaltrials.gov/show/NCT00021710||204899|
NCT00021918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|975|Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|June 2004|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|30 Years|70 Years|No|||October 2005|February 17, 2016|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021918||204883|
NCT00021931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|976|Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|March 2005|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|100 Years|No|||July 2005|March 15, 2016|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021931||204882|
NCT00021944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|977|Non-Traditional Cardiovascular Risk Factors in Type 2 Diabetes Mellitus - Ancillary to VA Study of Glycemic Control|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|November 2005|Actual|November 2005|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021944||204881|
NCT00021957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|978|ESCAPE Mechanistic Substudies - Ancillary to ESCAPE|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|March 2005|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|16 Years|100 Years|No|||May 2005|February 17, 2016|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021957||204880|
NCT00016250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-139|Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer|A Randomized Phase II Study of Two Shcedules of Ro 31-7453 in Patients With Metastatic (Dukes' D) Colorectal Carcinoma (CRC) Who Have Failed Both Fluoropyrimidine and Irinotecan Chemotherapy||Memorial Sloan Kettering Cancer Center||Completed|December 2000|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016250||205252|
NCT00016315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0017|Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer|A Phase I Study of Gemcitabine, Carboplatin or Gemcitabine, Paclitaxel and Radiation Therapy Followed by Adjuvant Chemotherapy for Patients With Favorable Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)||Radiation Therapy Oncology Group|Yes|Completed|May 2001|June 2010|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|13||Actual|35|||Both|N/A|N/A|No|||November 2015|November 14, 2015|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016315||205247|
NCT00015457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010147|Amlodipine Plus Botulinum Toxin for Focal Dystonia|Trial of Amlodipine Combined With Botulinum Toxin Injections for Focal Dystonia||National Institutes of Health Clinical Center (CC)||Completed|April 2001|||April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|April 18, 2001||No||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00015457||205305|
NCT00020839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-18981|Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain|Temozolomide Versus Temozolomide + Whole Brain Radiation In Stage IV Melanoma Patients With Asymptomatic Brain Metastases||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|April 2001|||May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|July 11, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00020839||204954|
NCT00017134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068655|Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk|An Exploratory Evaluation of Fenretinide (4-HPR) as a Chemopreventive Agent for Ovarian Carcinoma||Gynecologic Oncology Group||Terminated|September 2002|||December 2006|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|71|||Female|18 Years|N/A|No|||November 2006|June 7, 2013|June 6, 2001|||Withdrawn due to poor accrual|||https://clinicaltrials.gov/show/NCT00017134||205193|
NCT00015275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-9|Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9|Pathophysiological Subtyping of Abnormalities in Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 4|Interventional|Masking: Open Label, Primary Purpose: Diagnostic||||0|||Male|N/A|N/A|No|||December 2002|June 2, 2015|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015275||205311|
NCT00015288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-10|Buprenorphine and Naloxone Combination Study - 10|PK0496 Pharmacokinetics of Buprenorphine||National Institute on Drug Abuse (NIDA)||Completed|November 1996|||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|21 Years|50 Years|No|||August 1998|June 2, 2015|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015288||205310|
NCT00015301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-11|Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11|Methylphenidate Raclopride PET Test||National Institute on Drug Abuse (NIDA)||Completed||||||Phase 4|Interventional|Masking: Double-Blind, Primary Purpose: Diagnostic||||0|||Both|18 Years|75 Years|No|||December 2002|June 2, 2015|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015301||205309|
NCT00017173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068658|S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat|Phase II Trial Of Surgery With Perioperative RPR/INGN 201 (Ad5CMV-p53) Gene Therapy Followed By Chemoradiotherapy For Advanced, Resectable Squamous Cell Carcinoma Of The Oral Cavity, Oropharynx, Larynx, and Pharynx||Southwest Oncology Group|No|Terminated|February 2003|July 2011|Actual|May 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 6, 2001|Yes|Yes|Terminated for poor accrual.|No||https://clinicaltrials.gov/show/NCT00017173||205190|
NCT00017186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0021|Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma|Phase II Study of Gemcitabine and Epirubicin for the Treatment of Mesothelioma||Alliance for Clinical Trials in Oncology|Yes|Completed|July 2001|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017186||205189|
NCT00015665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010150|Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections|Open-Label, Non-Comparative Protocol for the Emergency Use of Voriconazole in Patients With Life Threatening, Invasive Mycoses Who Are Failing on Currently Available Antifungal Agents||National Institutes of Health Clinical Center (CC)||Completed|April 2001|March 2003||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||March 2003|March 3, 2008|April 28, 2001||||No||https://clinicaltrials.gov/show/NCT00015665||205293|
NCT00015834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02374|STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia|A Phase I/II Trial of STI571 and High-Dose Cytarabine in Myeloid Blast Crisis of Chronic Myeloid Leukemia||National Cancer Institute (NCI)||Completed|May 2001|||April 2003|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|May 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00015834||205282|
NCT00015847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068443|Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia|A Phase I/II Dose-Finding Study to Determine the Safety, Tolerability, and Anti-Leukemic Effects of STI571 (NSC 716051) in Combination With Interferon-alpha in Patients With Chronic Myelogenous Leukemia in Chronic Phase||OHSU Knight Cancer Institute|Yes|Terminated|April 2001|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2012|July 12, 2012|May 6, 2001|Yes|Yes||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00015847||205281|Early termination; 12 month follow-up was not carried out.
NCT00015977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9845|Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Phase II Study of Immunization With PSMA Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients With Metastatic Prostate Cancer||University of Chicago|No|Completed|November 2001|January 2005|Actual|March 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||March 2014|March 6, 2014|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00015977||205271|
NCT00021398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068776|Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer|Phase II Study: Hyperfractionated Pre-Op Chemo-Radiation for Locally Advanced Rectal Cancer||Fox Chase Cancer Center|No|Active, not recruiting|July 1996|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00021398||204917|
NCT00021424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068782|Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer|Phase I/Pilot Study of Intralesional Immunotherapy With A Recombinant Avipox Virus Engineered To Express A Triad Of Co-Stimulatory Molecules In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck||National Cancer Institute (NCI)||Completed|June 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2002|April 29, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021424||204916|
NCT00021554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295D|T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs|A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Regimen Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each of the Three Classes of Approved Antiretrovirals (Nucleoside Reverse Transcriptase, Non-Nucleoside Reverse Transcriptase and Protease Inhibitors)||NIH AIDS Clinical Trials Information Service||Completed||||||Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||525|||Both|16 Years|N/A|No|||May 2002|June 23, 2005|July 21, 2001||||No||https://clinicaltrials.gov/show/NCT00021554||204907|
NCT00021749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL208|Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia|Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia||Genta Incorporated|No|Completed|January 2001|||January 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||November 2009|November 10, 2009|August 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00021749||204896|
NCT00016913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-99811|Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer|Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|May 2001|May 2008|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Male|18 Years|N/A|No|||December 2015|December 28, 2015|June 6, 2001|No|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT00016913||205210|
NCT00017069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068646|Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma|CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|February 2001|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|November 16, 2008|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017069||205198|
NCT00016341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068624|Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer|Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients With Stage III & IV or Recurrent Endometrial Cancer||Gynecologic Oncology Group||Terminated|May 2001|||October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||June 2007|April 10, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016341||205245|
NCT00021866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0334-2001|Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy|Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study||Emory University|Yes|Completed|September 2000|August 2012|Actual|August 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||4|Actual|331|Samples With DNA|Venous blood for AED levels Cord Blood for G6PD, Homocysteine Saliva for drug metabolizing      enzymes, antioxidant enzymes, DNA repair enzymes, drug membrane transporter proteins and      folate-related genes|Female|N/A|N/A|No|Non-Probability Sample|Mothers and their child(ren) who were exposed to one of the following monotherapies in        utero- Lamotrigine, Carbamazepine, Phenytoin, or Valproate. Fathers of the children and a        first degree materal relative of the mother are also invited to have IQ testing and        medical history|September 2013|November 8, 2013|August 8, 2001||No||No||https://clinicaltrials.gov/show/NCT00021866||204887|
NCT00021879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|972|Visceral Adiposity and CVD Risk in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 2001|February 2006|Actual|February 2006|Actual|N/A|Observational|N/A|||||||Female|23 Years|25 Years|No|||January 2008|February 17, 2016|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021879||204886|
NCT00017238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03132|KRN5500 in Treating Patients With Solid Tumors|A Phase I Trial of KRN5500 (NSC 650426) Given as a 72 Hour Continuous IV Infusion Every 21 Days in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|February 2002|||November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017238||205185|
NCT00016328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01858|CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|May 2001|||August 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2013|July 17, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016328||205246|
NCT00016107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02962|Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer|A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab (IND # 7921, NSC # 704865) In Men With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|June 2001|||February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Male|N/A|N/A|No|||June 2013|June 4, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00016107||205262|
NCT00016354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0072 CDR0000068625|Benzoylphenylurea in Treating Patients With Advanced Solid Tumors|Phase I Study of Continuous Weekly Dosing of Dimethyl Benzoylphenylurea (BPU) in Patients With Solid Tumors Not Responding to Conventional Therapy||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|March 2001|September 2006|Actual|August 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|May 6, 2001|No|Yes||No|June 11, 2012|https://clinicaltrials.gov/show/NCT00016354||205244|
NCT00020930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068731|Cetuximab in Treating Patients With Stage IV Colorectal Cancer|Phase II Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Patients With Irinotecan-Refractory, Stage IV Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|March 2001|||August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|December 3, 2009|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020930||204947|
NCT00020943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068732|Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma|A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma||Alliance for Clinical Trials in Oncology|No|Completed|June 2001|September 2009|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|69 Years|No|||September 2013|September 25, 2013|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00020943||204946|
NCT00020904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-031|BMS-247550 in Treating Women With Metastatic Breast Cancer|A Phase II Study of Epothilone B Analog BMS-247550 in Patients With Taxane-Resistant Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|February 2001|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020904||204949|
NCT00020917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-037|Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer|Pilot Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Combination With Irinotecan, Fluorouracil, and Leucovorin, and in Patients With Newly Diagnosed Stage IV Colorectal Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|February 2001|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020917||204948|
NCT00015340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5-0013-14|Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14|Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study||National Institute on Drug Abuse (NIDA)||Completed|November 1997|||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|18 Years|59 Years|No|||August 2008|August 26, 2008|April 18, 2001||||No||https://clinicaltrials.gov/show/NCT00015340||205308|
NCT00015431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010153|Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms|The Immune Basis for the Gastrointestinal Complications of Common Variable Immunodeficiency||National Institutes of Health Clinical Center (CC)||Completed|April 2001|July 2013||||N/A|Observational|N/A|||Actual|30|||Both|10 Years|N/A|No|||July 2013|February 19, 2014|April 18, 2001||No||No||https://clinicaltrials.gov/show/NCT00015431||205307|
NCT00015470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010149|Diagnostic Evaluation of Patients With Neuromuscular Disease|Diagnostic Evaluation of Patients With Neuromuscular Diseases||National Institutes of Health Clinical Center (CC)||Completed|April 2001|May 2007||||N/A|Observational|N/A||||500|||Both|N/A|N/A|No|||May 2007|September 26, 2015|April 19, 2001||||No||https://clinicaltrials.gov/show/NCT00015470||205304|
NCT00017277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22996-24002|Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer|A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|March 2001|||April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|75 Years|No|||September 2012|September 20, 2012|June 6, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00017277||205182|
NCT00015964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10869A|ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck|A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck||University of Chicago|No|Completed|March 2001|July 2005|Actual|September 2001|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|May 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00015964||205272|
NCT00015704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5102|Effect of Interleukin-2 on HIV Treatment Interruption|An Open-Label, Pilot Study Utilizing CD4 T-Cell Counts Lower Than 350 Cells/mm3 as the Threshold for Restarting Therapy With Potent Antiretroviral Therapy With or Without Interleukin-2 to Determine the Effect of Pulse Therapy on the Characteristics of Treatment Interruptions||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|May 1, 2001|No|Yes||||https://clinicaltrials.gov/show/NCT00015704||205290|
NCT00016055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068590|Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma|Interleukin 12-Primed Activated T Cells As Therapy For Patients With Metastatic Melanoma (Phase I)||National Cancer Institute (NCI)||Active, not recruiting|November 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||November 2006|September 19, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016055||205266|
NCT00021437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR06020-0060|Biological Significance of the Bloom's Syndrome Protein|Biological Significance of the Bloom's Syndrome Protein||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|2 Years|55 Years|No|||December 2003|June 23, 2005|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021437||204915|
NCT00021450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068749|Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer|Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy Alone Vs Three Dimensional Conformal Therapy / Intensity Modulated Radiotherapy Plus Adjuvant Hormonal Therapy In Localized T1b-c, T2a, N0, M0 Prostatic Carcinoma. A Phase III Randomized Study||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Male|N/A|80 Years|No|||April 2008|February 18, 2011|July 13, 2001||||No||https://clinicaltrials.gov/show/NCT00021450||204914|
NCT00021463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5103|Changing to Nonprotease Inhibitor Treatment to Improve Side Effects|Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||February 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||342|||Both|13 Years|N/A|No|||January 2003|February 24, 2011|July 14, 2001||||No||https://clinicaltrials.gov/show/NCT00021463||204913|
NCT00021476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR047298|Preventing Chronic Whiplash Pain|Preventing Chronic Whiplash Pain: Biobehavioral Approach||University of Washington||Completed|May 2001|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||300|||Both|20 Years|65 Years|No|||August 2013|August 9, 2013|July 16, 2001||No||No||https://clinicaltrials.gov/show/NCT00021476||204912|
NCT00017095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10994-p53|Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer|First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 2001|||November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1856|||Female|N/A|70 Years|No|||October 2013|October 23, 2013|June 6, 2001||No||No||https://clinicaltrials.gov/show/NCT00017095||205196|
NCT00016068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1577.00|Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation|A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation||Fred Hutchinson Cancer Research Center||Completed|January 2001|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|184|||Both|16 Years|N/A|No|||May 2010|May 14, 2010|May 6, 2001|Yes|Yes||||https://clinicaltrials.gov/show/NCT00016068||205265|
NCT00016133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRACEL-ASI-2002|Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery|A Non-Randomized Multicenter Phase I/II Study Of Active Specific Immunotherapy In Patients With Stage II and Stage III Colon Cancer||National Cancer Institute (NCI)||Completed|March 2001|August 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|21 Years|85 Years|No|||July 2004|May 29, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016133||205261|
NCT00021541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010222|R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas|A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas||National Institutes of Health Clinical Center (CC)|Yes|Completed|July 2001|November 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|62|||Both|3 Years|25 Years|No|||September 2012|September 24, 2012|June 19, 2006||No||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00021541||204908|
NCT00021762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5120|Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV|A Pilot Phase II Evaluation of the Effects on HIV Replication of Immunization With a gp120-Depleted, Inactivated Whole Virus Vaccine Combined With Exposures to Replicating Autologous HIV by Scheduled Treatment Interruptions, a Rollover Study of A5057||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||May 2012|May 17, 2012|August 4, 2001|No|Yes||||https://clinicaltrials.gov/show/NCT00021762||204895|
NCT00015678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010164|Effects of Flumazenil on Brain Excitability|Effects of Flumazenil on Cortical Excitability in Humans||National Institutes of Health Clinical Center (CC)||Completed|April 2001|April 2002||||N/A|Observational|N/A||||7|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2002|March 3, 2008|April 28, 2001||||No||https://clinicaltrials.gov/show/NCT00015678||205292|
NCT00015691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5082|Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities|A Randomized, Double-Blind, Placebo-Controlled Study of Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Subjects With Hyperinsulinemia and Elevated Waist/Hip Ratio||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||January 2006|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||105|||Both|18 Years|65 Years|No|||July 2013|July 19, 2013|May 1, 2001||||No||https://clinicaltrials.gov/show/NCT00015691||205291|
NCT00021788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK55347 (completed)|Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression|Immunomodulation for Islet Transplantation in Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 2000|December 2001||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 2010|July 7, 2010|August 4, 2001||||No||https://clinicaltrials.gov/show/NCT00021788||204893|
NCT00021801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dk56953 (completed)|Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen|Pathways to Tolerance in Human Islet Transplantation||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 2000|September 2000||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|No|||March 2010|March 1, 2010|August 4, 2001||||No||https://clinicaltrials.gov/show/NCT00021801||204892|
NCT00017316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068677|Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma|A Phase II, Pharmacologic and Biologic Study of Escalating Doses of Thalidomide (NSC #66847) Administered Orally Once a Day in Combination With a Fixed Dose of SU5416 (NSC #696819) in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|March 2001|||September 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||August 2002|February 8, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017316||205179|
NCT00017329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068678|PS-341 in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of PS341 (NSC 681239) in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|April 2001|||April 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||December 2009|December 13, 2009|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017329||205178|
NCT00016744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1765|Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)|A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous Cystic Fibrosis Patients||Children's Hospital of Philadelphia|Yes|Completed|September 2001|October 2005|Actual|October 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|N/A|No|||January 2009|January 8, 2009|May 31, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00016744||205219|
NCT00017355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068680|Vaccine Therapy in Treating Patients With Metastatic Melanoma|Mature Dendritic Cell Immunotherapy Of Metastatic Melanoma- A Phase I Trial||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||March 2003|September 16, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017355||205176|
NCT00017368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL00P1|Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma|A Pilot Study Of Tandem High Dose Chemotherapy With Stem Cell Rescue Following Induction Therapy In Children With High Risk Neuroblastoma||Children's Oncology Group|Yes|Completed|April 2001|January 2012|Actual|September 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|N/A|30 Years|No|||February 2014|February 12, 2014|June 6, 2001||Yes||No||https://clinicaltrials.gov/show/NCT00017368||205175|
NCT00017381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03156|Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma|Dose Finding Study of IDEC-Y2B8 With Autologous Stem Cell Support||National Cancer Institute (NCI)||Completed|April 2001|||December 2007|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2013|January 8, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017381||205174|
NCT00021047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010172|Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor|A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|July 2001|June 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 7, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021047||204940|
NCT00021359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068772|Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma|A Phase II Trial of Dexamethasone and 13-cis-Retinoic Acid as First-Line Treatment for Multiple Myeloma||Fox Chase Cancer Center||Completed|August 1999|October 2005|Actual|July 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|July 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00021359||204920|
NCT00021632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5092s|Effects of Ribavirin on Zidovudine or Stavudine|Pharmacokinetic Evaluation of the Effects of Ribavirin (RBV) on Zidovudine (ZDV) or Stavudine (d4T) Triphosphate (TP) Formation||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||32|||Both|13 Years|N/A|No|||July 2013|May 15, 2015|July 26, 2001||||No||https://clinicaltrials.gov/show/NCT00021632||204904|
NCT00021645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010214|Vitamin E to Treat Uveitis-Associated Macular Edema|Randomized Masked Study to Evaluate the Use of Vitamin E in the Treatment of Uveitis-Associated Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|July 2001|June 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||June 2004|March 3, 2008|July 26, 2001||||No||https://clinicaltrials.gov/show/NCT00021645||204903|
NCT00021658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9605-CP-001|Effects of Pesticide Exposure on Neurodevelopment/Growth/Respiratory Health|||National Institute of Environmental Health Sciences (NIEHS)||Completed|October 1999|September 2003||||N/A|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Prevention||||550|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|September 26, 2014|July 30, 2001||No||No||https://clinicaltrials.gov/show/NCT00021658||204902|
NCT00021970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|979|Modifying Oxidative Damage in WAVE - Ancillary to WAVE|||University of Minnesota - Clinical and Translational Science Institute||Completed|April 2001|March 2005||||N/A|Observational|Time Perspective: Retrospective|||||||Female|38 Years|86 Years|No|||February 2016|February 29, 2016|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021970||204879|
NCT00016172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-044|ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of ZD0473 and Doxil in Patients With Advanced Refractory Cancer||Memorial Sloan Kettering Cancer Center||Completed|November 2000|April 2002|Actual|April 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016172||205258|
NCT00016185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068605|Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Study Of Flavopiridol And Docetaxel (Taxotere) In Patients With Advanced Cancers||Barbara Ann Karmanos Cancer Institute|Yes|Completed|March 2001|December 2005|Actual|February 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|May 6, 2001||||No||https://clinicaltrials.gov/show/NCT00016185||205257|
NCT00021528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH90003|Sequenced Treatment Alternatives to Relieve Depression (STAR*D)|Sequenced Treatment Alternatives to Relieve Depression||National Institute of Mental Health (NIMH)||Completed|July 2001|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||4000|||Both|18 Years|75 Years|No|||September 2006|September 24, 2009|July 20, 2001||||No||https://clinicaltrials.gov/show/NCT00021528||204909|
NCT00021723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-1792-201|Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease|||JANSSEN Alzheimer Immunotherapy Research & Development, LLC||Terminated|September 2001|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||375|||Both|50 Years|85 Years|No|||November 2001|September 22, 2009|August 2, 2001||||||https://clinicaltrials.gov/show/NCT00021723||204898|
NCT00021736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1004B|Phase II/III Study of Anti-VEGF in Neovascular AMD|Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD).||Eyetech Pharmaceuticals||Completed|July 2001|July 2002||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||540|||Both|50 Years|N/A|No|||July 2002|June 23, 2005|August 3, 2001||||||https://clinicaltrials.gov/show/NCT00021736||204897|
NCT00021983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066835|Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia|Phase I Study of BL22, a Recombinant Immunotoxin for Treatment of CD22+ Leukemias and Lymphomas||National Cancer Institute (NCI)||Completed|December 1998|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2006|April 28, 2015|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00021983||204878|
NCT00020462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068505|Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma|Active Specific Immunotherapy for Follicular Lymphomas With Liposomes Containing Tumor-Derived Antigen and IL-2||National Cancer Institute (NCI)||Completed|February 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2008|April 29, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020462||204980|
NCT00019643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990026|Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer|Prospective Study of Potential Factors Affecting Weight in Breast Cancer Patients Receiving Adjuvant Chemotherapy||National Institutes of Health Clinical Center (CC)||Terminated|August 1999|April 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|26|||Both|18 Years|80 Years||||March 2012|March 28, 2012|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00019643||205021|
NCT00020787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068713|Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer|An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV)||Jonsson Comprehensive Cancer Center|Yes|Completed|July 2001|December 2002|Actual|January 2002|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||July 2012|September 30, 2015|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00020787||204957|
NCT00020501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010093|Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver|A Phase III Prospective Random Assignment Trial of Regional and Systemic Chemotherapy With or Without Initial Isolated Hepatic Perfusion for Patients With Metastatic Unresectable Colorectal Cancers of the Liver||National Institutes of Health Clinical Center (CC)||Completed|March 2001|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 7, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020501||204977|
NCT00024193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-NB-1999-02|Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma|A Study Of The Treatment Of Metastatic Neuroblastoma In Children More Than One Year Of Age At Diagnosis||National Cancer Institute (NCI)||Active, not recruiting|April 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|N/A|No|||November 2001|August 6, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024193||204719|
NCT00024206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02412|SU6668 in Treating Patients With Advanced Solid Tumors|A Phase I Surrogate Endpoint Trial of SU6668 in Patients With Incurable Solid Tumors||National Cancer Institute (NCI)||Completed|July 2001|||July 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00024206||204718|
NCT00020254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068106|Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer|A Randomized Phase II Study of Either Immunotherapy With a Regimen of Recombinant Pox Viruses That Express PSA/B7.1 Plus Adjuvant GM-CSF and IL2 or Hormone Therapy With Nilutamide in Patients With Hormone Refractory Prostate Cancer and No Radiographic Evidence of Disease||National Cancer Institute (NCI)||Completed|June 2000|||October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||April 2003|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020254||204989|
NCT00020852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-9908076|Cryosurgery in Treating Women With Breast Lesions|Evaluation of Freezing Tumors in the Treatment of Breast Cancer Safety Study - 1-Probe CRYOcare Surgical System for Breast Tumor Ablation||National Cancer Institute (NCI)||Completed|May 2001|July 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||May 2004|May 29, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020852||204953|
NCT00020995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068737|Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer|Effects of a Low Fat Diet on Serum Factors and Prostate Cancer||National Cancer Institute (NCI)||Completed|August 2001|January 2010|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Male|40 Years|80 Years|No|||May 2004|September 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020995||204944|
NCT00023894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068874|Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Flavopiridol (NSC# 649890) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|July 2001|February 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||May 2004|June 20, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023894||204742|
NCT00020475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068514|Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye|Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma||National Cancer Institute (NCI)||Completed|February 2001|March 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A||||July 2002|August 14, 2013|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00020475||204979|
NCT00019734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067075|Vaccine Therapy in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen||National Cancer Institute (NCI)||Completed|July 1999|May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||May 2007|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019734||205014|
NCT00019747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990102|Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer||National Institutes of Health Clinical Center (CC)|Yes|Terminated|August 1999|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|July 11, 2001|Yes|Yes|DSMB recommended closure of the protocol due to slow accrual.|No|September 25, 2012|https://clinicaltrials.gov/show/NCT00019747||205013|
NCT00023582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 036|HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru|HIV Prevalence, Incidence and HSV-2 Prevalence Among High-Risk MSM in Lima, Peru||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||250|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|August 7, 2008|September 10, 2001||||No||https://clinicaltrials.gov/show/NCT00023582||204764|
NCT00019812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990121|Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2|Study of Trastuzumab (Herceptin) and Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|August 1999|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|N/A|No|||April 2003|March 21, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019812||205009|
NCT00019760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990093|Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver|Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver||National Institutes of Health Clinical Center (CC)||Completed|April 1999|March 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A||||March 2012|March 21, 2012|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00019760||205012|
NCT00020267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068173|Vaccine Therapy in Treating Patients With Metastatic Cancer|Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen||National Cancer Institute (NCI)||Completed|July 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A||||May 2002|April 27, 2015|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00020267||204988|
NCT00020332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068292|Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase I/II Trial of Docetaxel Followed by Infusional Flavopiridol Over 72 Hours in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|October 2000|March 2003|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2002|June 14, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020332||204987|
NCT00024076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068889|Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer|Radiofrequency Ablation of Pulmonary Malignancy||Jonsson Comprehensive Cancer Center|Yes|Completed|May 2000|||December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||July 2012|October 28, 2015|September 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00024076||204728|
NCT00023660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-C-0128|Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer|A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer||Radiation Therapy Oncology Group|Yes|Completed|August 2001|||January 2005|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Female|18 Years|85 Years|No|||November 2013|November 18, 2013|September 13, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00023660||204759|
NCT00020891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-022|CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy|The Use Of Multiple CT Scans To Reduce Target Positioning Errors In Patients Undergoing External Beam Radiotherapy Treatment For Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2001|||June 2006|Actual|Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|25|||Male|N/A|N/A|No|||January 2013|January 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020891||204950|
NCT00020644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGH-3000|Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer|Phase I Study of Continuous Infusion Gemcitabine||National Cancer Institute (NCI)||Active, not recruiting|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|August 6, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020644||204968|
NCT00023881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068872|Bortezomib in Treating Patients With Chronic Myelogenous Leukemia|Phase II Study of a Proteasome Inhibitor, PS-341 (NSC 681239) in Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase||M.D. Anderson Cancer Center|No|Completed|July 2001|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|September 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00023881||204743|
NCT00019786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990123|Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases|A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver||National Institutes of Health Clinical Center (CC)||Completed|August 1999|January 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|67|||Both|N/A|N/A|No|||March 2012|March 21, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019786||205010|
NCT00023816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068867|Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma|Third Phase I and Pharmacokinetic Study Of FB-642 Administered Orally To Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2001|September 19, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023816||204748|
NCT00023907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068875|Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum and Paclitaxel-Resistant Ovarian or Primary Peritoneal Cancer||Gynecologic Oncology Group||Terminated|July 2001|||April 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||May 2004|April 10, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023907||204741|
NCT00020449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068502|Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma|A Phase II Study of Liposomal Doxorubicin and Interleukin-12 in AIDS-Associated Kaposi's Sarcoma Followed by Chronic Administration of Interleukin-12||National Cancer Institute (NCI)||Completed|January 2001|May 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|June 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020449||204981|
NCT00020969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068734|Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes|Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes||National Cancer Institute (NCI)||Active, not recruiting|March 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2004|May 12, 2011|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020969||204945|
NCT00023595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018940|Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease|Surgical Treatment for Ischemic Heart Failure (STICH)|STICH|Duke University|Yes|Active, not recruiting|January 2002|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2136|||Both|18 Years|100 Years|No|||September 2015|October 6, 2015|September 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00023595||204763|
NCT00023621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-U19-CA81888-BC|Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome||National Cancer Institute (NCI)||Completed|February 2001|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|60|||Both|18 Years|75 Years|No|||July 2007|June 25, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023621||204762|
NCT00019929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067284|Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|Phase II Trial of Individualized Mutant p53 Peptide-Pulsed Cultured Autologous Dendritic Cells in the Adjuvant Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer After Standard Therapy||National Cancer Institute (NCI)||Completed|August 2000|December 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2005|June 18, 2013|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00019929||205003|
NCT00023673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG L-0117|Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group||Completed|July 2001|November 2013|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|63|||Both|N/A|N/A|No|||November 2015|November 14, 2015|September 13, 2001|Yes|Yes||No|February 12, 2014|https://clinicaltrials.gov/show/NCT00023673||204758|This study was originally designed to escalate 3DRT via increasing doses per fraction. However, due to excessive toxicity at dose level 1 (75.25 Gy, 2.15 Gy/fraction), the protocol was amended in January 2003 to de-escalate 3DRT dose.
NCT00019864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067263|Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma|Osteosarcoma: Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma.||National Cancer Institute (NCI)||Terminated|March 2000|October 2011|Actual|December 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|25 Years|No|||October 2007|June 4, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019864||205006|
NCT00019838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067252|UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia|Phase I and Pharmacokinetic Study of UCN-01 and Fludarabine in Relapsed or Refractory Low-Grade Lymphoid Malignancies||National Cancer Institute (NCI)||Completed|July 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2005|April 28, 2015|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00019838||205007|
NCT00023790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1Y97|Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin|Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies||Case Comprehensive Cancer Center|Yes|Terminated|August 2001|February 2006|Actual|December 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|September 13, 2001|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00023790||204749|
NCT00023686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0070|Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer|A Randomized Trial of Radical Prostatectomy Versus Brachytherapy for Patients With T1c or T2a N0 M0 Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|October 2001|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Male|N/A|75 Years|No|||July 2015|July 14, 2015|September 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00023686||204757|
NCT00021034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-020|Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Phase I Trial of Taurolidine After Positive Second Look Surgery for Recurrent Ovarian Epithelial, Fallopian Tube and Primary Peritoneal Cancers||Memorial Sloan Kettering Cancer Center||Completed|March 2001|August 2001|Actual|August 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021034||204941|
NCT00020553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068602|Video Support Program For Families With a Parent Newly Diagnosed With Cancer|We Can Cope: Family Support When A Parent Has Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 2000|||||N/A|Interventional|N/A|||||||Both|N/A|N/A|No|||October 2006|September 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020553||204974|
NCT00024024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02410|BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma||National Cancer Institute (NCI)||Completed|August 2001|||August 2003|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|16 Years|N/A|No|||April 2008|February 8, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00024024||204732|
NCT00023972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068880|Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Randomized, Open-Label, Multicenter Phase III Study Comparing the Efficacy and Safety of a Combination of Intravenous DX-8951f (Exatecan Mesylate) Plus Gemcitabine to Gemcitabine Alone in Patients With Locally Advanced or Metastatic Cancer of the Exocrine Pancreas Who Have Not Received Prior Chemotherapy||Daiichi Sankyo Inc.||Completed|July 2001|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 15, 2012|September 13, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00023972||204736|
NCT00020748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068710|Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer|A Phase I Study of Epirubicin in Combination With Irinotecan in Patients With Advanced Cancer||Georgetown University|No|Completed|August 2000|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2005|March 23, 2011|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00020748||204960|
NCT00020800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068714|Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)||Jonsson Comprehensive Cancer Center||Completed|September 2001|||April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020800||204956|
NCT00019916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067279|Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer|Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Adenocarcinoma of the Breast or Ovary||National Cancer Institute (NCI)||Completed|June 2000|July 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2005|June 19, 2013|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00019916||205004|
NCT00024037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001.00|Laser Therapy in Preventing Oral Mucositis in Patients Undergoing Bone Marrow Transplantation|A Phase II/III Blinded Randomized Trial to Determine the Efficacy of Low Energy Diode Laser Therapy (650 nm or 780 nm) to Prevent Oral Mucositis Following Bone Marrow Transplantation||Fred Hutchinson Cancer Research Center||Completed|April 1995|December 2002|Actual|||Phase 2/Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|12 Years|N/A|No|||June 2010|June 15, 2010|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024037||204731|
NCT00021216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01860|Bortezomib in Treating Children With Advanced Solid Tumors|A Phase I Study Of PS-341 In Pediatric Patients With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|November 2001|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|21 Years|No|||December 2013|April 14, 2015|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00021216||204931|
NCT00021229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03019|Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma|A Phase I/II Trial Of STI571 In Children With Newly Diagnosed Poor Prognosis Brainstem Gliomas And Recurrent Intracranial Malignant Gliomas||National Cancer Institute (NCI)|Yes|Terminated|May 2001|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|3 Years|21 Years|No|||February 2013|July 25, 2014|July 11, 2001|Yes|Yes|Poor accrual|No|February 9, 2010|https://clinicaltrials.gov/show/NCT00021229||204930|The phase II component of the trial was terminated because of poor accrual. Only one patient enrolled to the phase II component and did not receive the investigational drug.
NCT00023634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0114|S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer|An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers||Southwest Oncology Group|Yes|Terminated|June 2001|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|80 Years|No|||March 2015|March 5, 2015|September 13, 2001|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00023634||204761|
NCT00023699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068852|Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|August 2001|May 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||August 2003|June 20, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023699||204756|
NCT00023712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02404|Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Bortezomib (Velcade™, PS-341, NSC #681239, IND #58443) in the Treatment of Persistent or Recurrent Platinum-Sensitive Epithelial Ovarian or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|July 2004|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Female|N/A|N/A|No|||December 2012|April 29, 2014|September 13, 2001|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00023712||204755|
NCT00020618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI-MOR-00-01|Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain|An Open Label, Randomized, Multicenter, Crossover, Phase II Study to Compare Pain Relief Following Morphine Administration Via AERxPMS vs Orally in Cancer Patients Experiencing Opioid-Sensitive Breakthrough Pain||National Cancer Institute (NCI)||Completed|March 2001|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||February 2002|July 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020618||204970|
NCT00020631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068675|Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer|A Pilot Study Of Pirfenidone For The Treatment Of Radiation-Induced Fibrosis||National Cancer Institute (NCI)||Completed|October 2001|October 2007|Actual|||N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||April 2004|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020631||204969|
NCT00019968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990145|Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg|Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity||National Institutes of Health Clinical Center (CC)||Completed|August 1999|March 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|N/A||||March 2012|March 14, 2012|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00019968||205001|
NCT00023959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02408|Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer|A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer||National Cancer Institute (NCI)||Completed|July 2001|||March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00023959||204737|
NCT00020176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067899|Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer|Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|June 2000|August 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||November 2004|June 18, 2013|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00020176||204992|
NCT00021060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02947|Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer|Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC||National Cancer Institute (NCI)||Completed|August 2002|||September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|842|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00021060||204939|
NCT00020683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02924|A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma|A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma||National Cancer Institute (NCI)||Terminated|March 2003|||November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00020683||204965|
NCT00019708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00819|Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|A Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (AAG, NSC 330507) in Adult Patients With Solid Tumors||National Cancer Institute (NCI)||Terminated|June 1999|||April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|19 Years|N/A|No|||December 2013|December 13, 2013|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00019708||205016|
NCT00020605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068671|Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-Malignant Pain or Malignant Pain||National Cancer Institute (NCI)||Active, not recruiting|May 2000|||||Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||October 2001|May 9, 2009|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020605||204971|
NCT00021125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-CH03|Radiation Therapy in Treating Patients With Head and Neck Cancer|A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients||National Cancer Institute (NCI)||Completed|July 2000|June 2007|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|460|||Both|N/A|N/A|No|||December 2002|June 25, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021125||204935|
NCT00020488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068548|Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors|A Phase I & Pharmacologic Trial Of Sequential Irinotecan As A 24-Hour IV Infusion, Leucovorin, & Flurouracil As A 48-Hour IV Infusion In Adult Cancer Patients||National Cancer Institute (NCI)||Completed|February 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|April 29, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020488||204978|
NCT00023647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068847|Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients||Mannkind Corporation|No|Completed|July 2000|November 2002|Actual|April 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00023647||204760|
NCT00024089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068890|Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase II Study of ZD 1839 (Iressa) in Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck||National Cancer Institute (NCI)||Completed|July 2001|||March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2005|February 8, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00024089||204727|
NCT00019656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066960|Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer|A Phase I Trial of Oral Perifosine With Different Loading Schedules in Patients With Refractory Neoplasms||National Cancer Institute (NCI)||Completed|August 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019656||205020|
NCT00019669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066961|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using a Recombinant Fowlpox Virus Encoding a GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence||National Cancer Institute (NCI)||Completed|October 1999|October 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||August 2004|June 19, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019669||205019|
NCT00020189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068028|Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||National Cancer Institute (NCI)||Completed|June 2000|August 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020189||204991|
NCT00020202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068031|FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer|Phase II Study of FR901228 in Patients With Refractory or Progressive Small Cell or Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|June 2000|March 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||June 2006|August 14, 2013|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00020202||204990|
NCT00020865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068726|Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia|Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB||National Cancer Institute (NCI)||Active, not recruiting|September 2001|||||Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2007|December 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020865||204952|
NCT00024102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-49907|Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer|A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|September 2001|November 2012|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|633|||Female|65 Years|N/A|No|||June 2015|June 23, 2015|September 13, 2001|Yes|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00024102||204726|
NCT00021268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICN-2000-1|Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer|Phase I Study Of Tocladesine In Patients With Colorectal Carcinoma Following Therapy With 5-FU And Irinotecan||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||October 2002|August 1, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021268||204927|
NCT00021281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068766|Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer|A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 2000|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2001|December 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021281||204926|
NCT00020761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068711|Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach|A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract||Jonsson Comprehensive Cancer Center|Yes|Completed|April 2000|August 2005|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00020761||204959|
NCT00020774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068712|SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer|A Phase IB Clinical Study Of The Farnesyltransferase Inhibitor SCH 66336 And Gemcitabine In Patients With Resectable Primary Liver Neoplasms||Jonsson Comprehensive Cancer Center|Yes|Withdrawn|October 1998|||January 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00020774||204958|
NCT00019994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067391|Vaccine Therapy in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using a Class II Restricted Peptide From the GP100 Antigen and Class I Restricted Peptides From the GP100 and MART-1 Antigens||National Cancer Institute (NCI)||Completed|October 1999|October 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||March 2003|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019994||205000|
NCT00020722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068707|Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer|Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II)||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|August 2007|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|120 Years|No|||February 2016|February 15, 2016|July 11, 2001|Yes|Yes|Lack of funding to continue study.|No|February 9, 2015|https://clinicaltrials.gov/show/NCT00020722||204962|Not enough funding to finish study, cost of immunotherapy infusions for the stem cell transplant portion & of infusions for targeted T cell therapy were limited due to lack of funding, trial was converted into a proof-of-principle or concept trial.
NCT00020735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-00-105|Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer|A Phase II Randomized Controlled Clinical Trial Of The Antiestrogen GTx-006 In Subjects With Prostate Cancer||University of Pittsburgh|Yes|Completed|April 2001|June 2009|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|45|||Male|18 Years|120 Years|No|||December 2015|December 1, 2015|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00020735||204961|
NCT00021151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILEX1999|Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia|CAMPATH-1H Compassionate Treatment In Patients With PLL Who Have Failed At Least One Prior Regimen And CLL Patients Who Have Failed Fludarabine Therapy||Case Comprehensive Cancer Center|Yes|Completed|January 2000|May 2002|Actual|April 2001|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00021151||204933|
NCT00021164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068756|Vaccine Therapy in Treating Patients With Metastatic Cancer|Immunization of HLA-A*0201 Patients With Metastatic Cancer Using a Peptide Epitope From the Telomerase Antigen||National Cancer Institute (NCI)||Completed|May 2001|May 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2004|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021164||204932|
NCT00020345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000218|Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas|Phase II Study of Neoadjuvant Intraperitoneal Gemcitabine and Intravenous Gemcitabine With Radiotherapy Followed by Surgery and Adjuvant Intraperitoneal Gemcitabine, Intravenous Gemcitabine, and Fluorouracil in Patients With Advanced Adenocarcinoma of the Pancreas||National Institutes of Health Clinical Center (CC)||Completed|September 2000|March 2002|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||March 2012|March 7, 2012|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00020345||204986|
NCT00020358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068299|Vaccine Therapy in Treating Patients With Melanoma|Randomized Comparison of Three Schedules of Peptide Immunization in Patients With Stage II or III, or Completely Resected Metastatic Melanoma||National Cancer Institute (NCI)||Completed|September 2000|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||March 2003|June 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020358||204985|
NCT00024154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02411|Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer|A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2)||National Cancer Institute (NCI)||Completed|February 2002|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00024154||204722|
NCT00023868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068871|Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver|A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum||National Cancer Institute (NCI)||Completed|November 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|January 3, 2009|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023868||204744|
NCT00017511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068698|Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region||Daiichi Sankyo Inc.||Completed|June 2001|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2012|May 15, 2012|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017511||205165|
NCT00023725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068854|Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma|A Randomized Phase I/II Study Of Preoperative Radiotherapy With/Without SUGEN 5416 (NSC # 696819; A TK Inhibitor Anti-Angiogenesis Compound) In The Management Of Low To Intermediate Grade Soft Tissue Sarcoma Of The Trunk or Extremity||National Cancer Institute (NCI)||Completed|August 2001|October 2003|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2007|June 20, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023725||204754|
NCT00023933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02406|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer|Phase I Trial of 131I-HuCC49^CH2 for Colon Cancer||National Cancer Institute (NCI)||Completed|October 2001|||July 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|19 Years|N/A|No|||January 2013|January 24, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00023933||204739|
NCT00019695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066964|Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer|Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate||National Cancer Institute (NCI)||Terminated|March 1999|March 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||March 2004|April 21, 2014|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019695||205017|
NCT00018083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00030-0162|Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen|Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2001|June 23, 2005|July 2, 2001||||No||https://clinicaltrials.gov/show/NCT00018083||205126|
NCT00018187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-011-98S|Combinations of Pharmacologic Smoking Cessation Treatments|Combinations of Pharmacologic Smoking Cessation Treatments||VA Office of Research and Development||Completed|November 1998|June 2001||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|40 Years|No|||May 2007|January 20, 2009|July 3, 2001||||||https://clinicaltrials.gov/show/NCT00018187||205118|
NCT00024115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068892|BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Withdrawn||||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|April 27, 2015|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024115||204725|
NCT00023842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30993|BCG With or Without Mitomycin in Treating Patients With Bladder Cancer|A Randomized Phase II Trial of Sequential Chemo-Immunotherapy Versus Immunotherapy Alone in Carcinoma in Situ of the Urinary Bladder||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 2001|||February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|97|||Both|N/A|N/A|No|||September 2012|September 20, 2012|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023842||204746|
NCT00018421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADE-RA|Effects of Exercise on Patients With Hemiparetic Stroke|Effects of Exercise on Patients With Hemiparetic Stroke||VA Office of Research and Development||Completed|July 1997|June 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|40 Years|80 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018421||205100|
NCT00018434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADE-RCD2|The Epidemiology of Infection With Vancomycin-Resistant Enterococci|The Epidemiology of Infection With Vancomycin-Resistant Enterococci||VA Office of Research and Development||Completed|July 1998|June 2001||||N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|90 Years|No|||June 2015|June 25, 2015|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018434||205099|
NCT00018200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-018-98F|Effect of Antidepressants on Back Pain|Efficacy of Antidepressants in Chronic Back Pain||VA Office of Research and Development|Yes|Completed|April 1999|March 2004|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|130|||Both|21 Years|65 Years|No|||June 2012|June 4, 2012|July 3, 2001||No||No||https://clinicaltrials.gov/show/NCT00018200||205117|
NCT00023192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010242|Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care|Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care||National Institutes of Health Clinical Center (CC)||Completed|August 2001|June 2004||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||June 2004|March 3, 2008|August 29, 2001||||No||https://clinicaltrials.gov/show/NCT00023192||204790|
NCT00019682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02897|Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma|A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma||National Cancer Institute (NCI)|Yes|Completed|December 1999|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|N/A|No|||December 2012|December 5, 2014|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00019682||205018|
NCT00018642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-042-96F|Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder|Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia||VA Office of Research and Development||Completed|April 1997|March 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018642||205083|
NCT00017199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068660|PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors|Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors||National Cancer Institute (NCI)||Completed|April 2001|May 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|January 30, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017199||205188|
NCT00018447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-022-98S|Combination Osteogenic Therapy in Established Osteoporosis|Combination Osteogenic Therapy in Established Osteoporosis||VA Office of Research and Development||Completed|November 1998|October 2003||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Female|60 Years|80 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||||https://clinicaltrials.gov/show/NCT00018447||205098|
NCT00019721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067051|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using MART-1 and GP100 Peptides Modified to Increase Binding to HLA-0201||National Cancer Institute (NCI)||Completed|April 1999|June 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||August 2002|June 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019721||205015|
NCT00023140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9401-CP-001|Collaborative Study of 1,3 Butadiene Biomarkers|Collaborative Study of 1,3 Butadiene Biomarkers||National Institute of Environmental Health Sciences (NIEHS)||Completed|July 1999|June 2002|Actual|May 2002|Actual|N/A|Observational|Time Perspective: Prospective||||80|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|August 22, 2001||||No||https://clinicaltrials.gov/show/NCT00023140||204793|
NCT00023153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010239|Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection|Studies of the Addition of Adefovir Dipivoxil to Lamivudine for the Treatment of Chronic Hepatitis B: A Randomized, Double-Blind, Placebo Controlled Study in HIV-Infected Patients and an Open-Label Study in HIV-Negative Subjects||National Institutes of Health Clinical Center (CC)||Completed|August 2001|October 2004||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||October 2004|March 3, 2008|August 24, 2001||||No||https://clinicaltrials.gov/show/NCT00023153||204792|
NCT00023166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTX-5001|Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas|Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas||Enzon Pharmaceuticals, Inc.||Terminated|May 2001|May 2002||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|June 23, 2005|August 24, 2001||||||https://clinicaltrials.gov/show/NCT00023166||204791|
NCT00017524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068699|AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors|A Phase I Dose-Escalation Study of AG2037 Administered Once Weekly for Three Weeks to Patients With Advanced Cancer||University of Alabama at Birmingham|Yes|Completed|March 2001|November 2004|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|No|||November 2012|December 12, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017524||205164|
NCT00017537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068700|Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer|Phase IB Trial of Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer Adjuvant in Patients With Metastatic Cancer||University of Alabama at Birmingham|Yes|Withdrawn|March 2000|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||November 2012|August 2, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017537||205163|
NCT00023738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068855|Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma|A Phase I/II Study Of Neoadjuvant Chemotherapy, Angiogenesis Inhibitor SU5416 (NSC # 696819; A TK Inhibitor Anti-Angionesises Compound), And Radiation Therapy In The Management Of High Risk, High-Grade, Soft Tissue Sarcomas Of The Extremities And Body Wall||National Cancer Institute (NCI)||Completed|August 2001|October 2003|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2010|June 20, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023738||204753|
NCT00023751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-80002|Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer|A Phase II Study of Local Excision Alone or Local Excision Plus Adjuvant Chemoradiation Therapy for Small Distal Rectal Cancers||Alliance for Clinical Trials in Oncology|No|Completed|July 2001|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|320|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|September 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00023751||204752|
NCT00023998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01863|Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma|A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2||National Cancer Institute (NCI)||Completed|July 2001|May 2007||November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|30 Years|No|||January 2013|February 1, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00023998||204734|
NCT00017693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT Asthma 013.0014|Recombinant Human IL-4 Receptor Used in Treatment of Asthma|Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 1998|February 2000|Actual|February 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|62|||Both|12 Years|85 Years|No|||March 2016|March 3, 2016|June 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017693||205153|
NCT00017706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simkin-Silverman (completed)|Effectiveness of Primary Care Physicians in Delivering Weight Control Counseling|Treatment of Obesity in the Primary Care Setting||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||May 2001||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|21 Years|70 Years|No|||January 2010|January 12, 2010|June 7, 2001||||No||https://clinicaltrials.gov/show/NCT00017706||205152|
NCT00017732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010191|Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans|Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans||National Institutes of Health Clinical Center (CC)||Completed|June 2001|March 2003||||N/A|Observational|N/A||||2000|||Both|N/A|N/A|No|||March 2003|March 3, 2008|June 8, 2001||||No||https://clinicaltrials.gov/show/NCT00017732||205150|
NCT00023829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-P-0011|Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer|Phase III Randomized Study of Adjuvant Therapy for High Risk pT3N0 Prostate Cancer||Radiation Therapy Oncology Group|Yes|Completed|August 2001|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|67|||Male|N/A|N/A|No|||November 2013|November 12, 2013|September 13, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00023829||204747|
NCT00019773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067201|Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer|Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients||National Cancer Institute (NCI)||Completed|July 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019773||205011|
NCT00018018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010189|Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency|Treatment of SCID Due to ADA Deficiency With Autologous Cord Blood or Bone Marrow CD34+ Cells Transduced With a Human ADA Gene||National Institutes of Health Clinical Center (CC)||Completed|June 2001|September 2014|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|8|||Both|1 Month|N/A|No|||September 2014|October 4, 2014|June 27, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00018018||205131|
NCT00018213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-020-97F|Naltrexone and Patch for Smokers|Naltrexone and Nicotine Replacement Effects on Cue Reactivity of Smokers||VA Office of Research and Development||Completed|April 1998|March 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2007|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018213||205116|
NCT00018044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010202|Study of Mycobacterial Infections|Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections||National Institutes of Health Clinical Center (CC)||Recruiting|June 2001|||||N/A|Observational|N/A|||Anticipated|700|||Both|N/A|N/A|No|||June 2015|June 19, 2015|June 28, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00018044||205129|
NCT00018057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010192|Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes|Fluoxetine's Effects on Attention and Emotional Memory in Anxious and Depressed Youth and Adults||National Institutes of Health Clinical Center (CC)||Recruiting|June 2001|||||N/A|Observational|N/A|||Anticipated|2330|||Both|8 Years|40 Years|Accepts Healthy Volunteers|||October 2015|January 29, 2016|June 29, 2001||No||No||https://clinicaltrials.gov/show/NCT00018057||205128|
NCT00018070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010208|Identification and Treatment of Feeder Vessels in Macular Degeneration|Feasibility Study of the Identification and Treatment of Feeder-Vessels of Choroidal Neovascularization in Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Completed|June 2001|August 2006||||Phase 1|Interventional|Primary Purpose: Treatment||||20|||Both|50 Years|N/A|No|||August 2006|September 26, 2015|June 30, 2001||||No||https://clinicaltrials.gov/show/NCT00018070||205127|
NCT00023348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2173|TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB|TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in USPHS Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen||Centers for Disease Control and Prevention||Completed|July 1999|November 2002||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2005|September 9, 2005|September 6, 2001||||||https://clinicaltrials.gov/show/NCT00023348||204780|
NCT00023335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-1427|TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis|TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis||Centers for Disease Control and Prevention||Completed|April 1995|March 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|18 Years|N/A|No|||September 2005|September 1, 2005|September 6, 2001||||||https://clinicaltrials.gov/show/NCT00023335||204781|
NCT00023452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3041|Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection|TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection|PREVENT TB|Centers for Disease Control and Prevention|Yes|Completed|June 2001|September 2013|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8595|||Both|2 Years|N/A|No|||July 2015|July 30, 2015|September 6, 2001|No|Yes||No|August 15, 2012|https://clinicaltrials.gov/show/NCT00023452||204772|
NCT00018512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURG-030-99S|Biological Specifications for Denture Designs|Biological Specifications for Denture Designs||VA Office of Research and Development||Completed|October 1999|September 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|35 Years|80 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018512||205093|
NCT00018681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAST-005-98S|Regulation of Human Intestinal Bile Acid Transport in Health and Disease|Regulation of Human Intestinal Bile Acid Transport in Health and Disease||VA Office of Research and Development||Completed|April 1998|January 2002||||Phase 1|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018681||205080|
NCT00018525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURG-014-00S|Lung Volume Reductions Surgery (LVRS) Study|Effects of Lung Volume Reduction Surgery in the Treatment of Severe Emphysema||VA Office of Research and Development||Completed|October 2000|September 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Male|N/A|75 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018525||205092|
NCT00018538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCO-09-99S|Calcifidol Therapy in Men With Cancer|Calcifidol Therapy in Men With Cancer||VA Office of Research and Development||Completed|October 1999|September 2002||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018538||205091|
NCT00019825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067228|Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura|Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Lung Cancer Patients||National Cancer Institute (NCI)||Completed|October 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019825||205008|
NCT00017212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068663|DX-8951f in Treating Patients With Metastatic Stomach Cancer|A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer||Daiichi Sankyo Inc.||Completed|April 2001|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 15, 2012|June 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00017212||205187|
NCT00017290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068673|Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma|A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|November 2000|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2002|December 3, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017290||205181|
NCT00017550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068709|Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome|An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS)||National Cancer Institute (NCI)||Active, not recruiting|August 2001|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|February 6, 2009|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017550||205162|
NCT00023920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02405|Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia|A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase||National Cancer Institute (NCI)||Terminated|July 2001|||September 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|September 13, 2001|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00023920||204740|
NCT00024050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1536.00|Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome|Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for the Treatment of "Less Advanced" Myelodysplasi||Fred Hutchinson Cancer Research Center||Completed|February 2001|August 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||May 2010|May 12, 2010|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024050||204730|
NCT00024063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068888|SU006668 in Treating Patients With Advanced Solid Tumors|A Phase I Study Of SU006668 Via Twice Daily Oral Administration Under Fed Conditions In Patients With Advanced Malignancies||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2007|December 18, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024063||204729|
NCT00017719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1022|Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy|Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2002|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||440|||Female|14 Years|N/A|No|||November 2013|November 25, 2013|June 8, 2001||||||https://clinicaltrials.gov/show/NCT00017719||205151|
NCT00017940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0029|Gene Therapy for Alzheimer's Disease Clinical Trial|A Phase I Study of Ex Vivo Nerve Growth Factor Gene Therapy for Alzheimer's Disease||National Institute on Aging (NIA)||Completed||November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|50 Years|N/A|No|||July 2005|December 10, 2009|June 20, 2001||||||https://clinicaltrials.gov/show/NCT00017940||205137|
NCT00018096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00030-0183|The Genetics of Environmental Asthma|The Genetics of Environmental Asthma||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|June 2001|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|176|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2008|May 5, 2008|July 2, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00018096||205125|
NCT00023985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068881|Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer|Vaccination With Autologous Tumor Lysate-Pulsed Dendritic Cells - Phase I||Roswell Park Cancer Institute|Yes|Completed|January 2001|August 2003|Actual|July 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2011|March 3, 2011|September 13, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00023985||204735|
NCT00023855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068870|PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacodynamic Study of Proteasome Inhibitor, PS-341, in Combination With Doxorubicin in Patients With Advanced Solid Tumors||University of Wisconsin, Madison||Completed|June 2001|||October 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||September 2015|September 30, 2015|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00023855||204745|
NCT00018226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-022-97S|Effect Of Case Management Following Discharge From Methadone Treatment|Enhanced Outreach Counseling Following Methadone Treatment Discharge||VA Office of Research and Development||Completed|April 1998|March 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018226||205115|
NCT00017862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010155|Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome|A Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional Therapy||National Institutes of Health Clinical Center (CC)||Completed|June 2001|June 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||June 2003|March 3, 2008|June 15, 2001||||No||https://clinicaltrials.gov/show/NCT00017862||205141|
NCT00018239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-001-99S|Aging and Cellular Mechanism for Insulin Action After Exercise Training|Aging and Cellular Mechanism for Insulin Action After Exercise Training||VA Office of Research and Development||Completed|October 1999|September 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||||||Both|50 Years|80 Years|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018239||205114|
NCT00023465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-MO1RR00036-0798|Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging|Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||10|||Female|18 Years|N/A|No|||December 2003|June 23, 2005|September 6, 2001||||No||https://clinicaltrials.gov/show/NCT00023465||204771|
NCT00019890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067277|Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma|Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma||National Cancer Institute (NCI)||Completed||March 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A||||June 2001|June 19, 2013|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00019890||205005|
NCT00018694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAST-007-99S|Cholestanol in Humans|Biologic Significance of Cholestanol in Man||VA Office of Research and Development||Withdrawn|October 1999|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label|1||Actual|0|||Both|5 Years|80 Years|No|||October 2013|October 11, 2013|July 3, 2001||No||No||https://clinicaltrials.gov/show/NCT00018694||205079|
NCT00018265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-003-99S|Fitness and Daily Function in Adults|Oxygen Kinetics, Mobility Task Performance, and Task Training in Older Adults||VA Office of Research and Development||Completed|October 1999|September 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||140|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018265||205112|
NCT00018707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-033-98F|Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress|Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress||VA Office of Research and Development||Completed|April 1999|March 2003||||N/A|Observational|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018707||205078|
NCT00018720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAST-026-95F|Regulation of Sterol Homeostasis|Regulation of Sterol Homeostasis||VA Office of Research and Development||Completed|April 1996|December 2000||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018720||205077|
NCT00018733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-031-99F|Biological Aspects of Depression and Antidepressant Drugs|Biological Aspects of Depression and Antidepressant Drugs||VA Office of Research and Development||Completed|September 1996|December 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|69 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018733||205076|
NCT00019955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067334|Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)|A Phase II Study to Evaluate Radiofrequency Ablation of Renal Cancer||National Cancer Institute (NCI)||Completed|March 2000|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2005|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00019955||205002|
NCT00023543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|981|Reduction of Triglycerides in Women on Hormone Replacement Therapy|Reduction of Triglycerides in Women on HRT||University of Pittsburgh||Completed|September 2001|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|508|||Female|52 Years|60 Years|No|||June 2013|June 18, 2013|September 7, 2001||No||No||https://clinicaltrials.gov/show/NCT00023543||204767|
NCT00023556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|982|Genetic Architecture of Heart Disease in Rural Brazil|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||August 2008|August 20, 2008|September 7, 2001||||No||https://clinicaltrials.gov/show/NCT00023556||204766|
NCT00017303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068674|Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer|A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2002|November 5, 2013|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017303||205180|
NCT00017394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02388|Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer|A Phase II Study of Bevacizumab in Combination With Vinorelbine in Stage IV Breast Cancer||National Cancer Institute (NCI)||Completed|March 2001|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|June 6, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00017394||205173|
NCT00017563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068719|Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer|Phase I/II Study of Neoadjuvant Weekly Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients With High Risk Localized Prostate Cancer||OHSU Knight Cancer Institute|Yes|Completed|September 2000|||May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Male|18 Years|120 Years|No|||February 2016|February 11, 2016|June 6, 2001|Yes|Yes||No|May 31, 2011|https://clinicaltrials.gov/show/NCT00017563||205161|
NCT00024167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-156|Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer|A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer||M.D. Anderson Cancer Center|Yes|Terminated|April 2002|||September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|265|||Male|18 Years|N/A|No|||February 2016|February 19, 2016|September 13, 2001|Yes|Yes|Terminated due to slow accrual|No|January 22, 2016|https://clinicaltrials.gov/show/NCT00024167||204721|
NCT00023764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01406|Bortezomib in Treating Patients With Lymphoproliferative Disorders|Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders||National Cancer Institute (NCI)||Completed|June 2001|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||December 2012|November 2, 2015|September 13, 2001|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00023764||204751|
NCT00023777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0112|S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older||Southwest Oncology Group||Completed|August 2001|April 2008|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|56 Years|N/A|No|||March 2015|March 5, 2015|September 13, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00023777||204750|
NCT00017927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010197|A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome|A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome||National Institutes of Health Clinical Center (CC)||Completed|June 2001|June 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||June 2005|March 3, 2008|June 20, 2001||||No||https://clinicaltrials.gov/show/NCT00017927||205138|
NCT00024180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068898|FR901228 in Treating Patients With Hematologic Cancer|A Phase I Study of Depsipeptide in Selected Hematologic Malignancies (NSC 630176)||National Cancer Institute (NCI)||Completed|January 2002|August 2006|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|January 30, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024180||204720|
NCT00024128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-028|Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma|Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD)||AIDS Malignancy Consortium||Withdrawn|August 2001|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|65 Years|No|||February 2016|February 1, 2016|September 13, 2001|No|Yes|Withdrawn prior to initiation.|No||https://clinicaltrials.gov/show/NCT00024128||204724|
NCT00024011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02409|PS-341 in Treating Patients With Metastatic Malignant Melanoma|A Phase II Study of PS-341 in the Treatment of Metastatic Malignant Melanoma||National Cancer Institute (NCI)||Completed|July 2001|||September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00024011||204733|
NCT00024141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068895|Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors|5-Flourouracil Preceded by Irinotecan In Patients With Advanced Solid Tumors: A Pilot Study||Roswell Park Cancer Institute|Yes|Completed|May 2001|January 2003|Actual|September 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 3, 2011|September 13, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00024141||204723|
NCT00018031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010194|Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients|A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin|HEPCPR|National Institutes of Health Clinical Center (CC)||Completed|June 2001|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|June 27, 2001||No||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00018031||205130|
NCT00018174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-011-97S|Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers|Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers||VA Office of Research and Development||Completed|February 1998|January 2005|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 26, 2009|July 3, 2001||No||No||https://clinicaltrials.gov/show/NCT00018174||205119|
NCT00019578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990011|Stereotactic Radiosurgery in Treating Patients With Brain Tumors|Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms||National Institutes of Health Clinical Center (CC)||Completed|November 1998|May 2002|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||March 2012|March 21, 2012|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019578||205025|
NCT00019591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066874|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase I/II Trial of Vaccination With Mutant Ras Peptide-Pulsed Dendritic Cells in the Treatment of HLA A2.1 Positive Patients With Colorectal Cancer||National Cancer Institute (NCI)||Completed|March 1999|November 2005|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2005|June 19, 2013|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00019591||205024|
NCT00018278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-004-98S|Electrophysiologic Measures of Treatment Response in Alzheimer Disease|Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease||VA Office of Research and Development||Completed|October 1998|September 2001||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|55 Years|85 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018278||205111|
NCT00018291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-005-00S|Specific Interventions for Agitation in Alzheimer's Disease|Specific Interventions for Agitation in Alzheimer's Disease||VA Office of Research and Development||Completed|January 2001|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||December 2004|January 20, 2009|July 3, 2001||||No||https://clinicaltrials.gov/show/NCT00018291||205110|
NCT00017498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-24982|Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck|Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2001|||April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|21|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|June 6, 2001||||No||https://clinicaltrials.gov/show/NCT00017498||205166|
NCT00019604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990025|Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer|The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms||National Institutes of Health Clinical Center (CC)|No|Terminated|August 1998|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|July 11, 2001|Yes|Yes|Principal investigator left the institution.|No|April 1, 2014|https://clinicaltrials.gov/show/NCT00019604||205023|Adverse event data is available but the format is uninterpretable.
NCT00019630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000066924|Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors|Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|July 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years||||June 2002|April 27, 2015|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00019630||205022|
NCT00023127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9142-CP-001|Reducing Indoor Allergen Exposures in Northern Manhattan and the South Bronx|||National Institute of Environmental Health Sciences (NIEHS)||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|6 Years|18 Years|No|||March 2006|March 22, 2006|August 22, 2001||||No||https://clinicaltrials.gov/show/NCT00023127||204794|
NCT00023569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010248|Electrical Stimulation to Improve Hand Function in Patients With Chronic Stroke|Cortical Motor Reorganization in Chronic Stroke Following EMG Triggered NMES Therapy||National Institutes of Health Clinical Center (CC)||Completed|September 2001|September 2003||||N/A|Observational|N/A||||16|||Both|N/A|N/A|No|||September 2003|March 3, 2008|September 8, 2001||||No||https://clinicaltrials.gov/show/NCT00023569||204765|
NCT00023946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02407|BMS-247550 in Treating Patients With Liver or Gallbladder Cancer|A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer||National Cancer Institute (NCI)||Terminated|August 2001|November 2009|Actual|July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2012|May 13, 2014|September 13, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00023946||204738|
NCT00022841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR002161|Prevention of Steroid-Induced Osteoporosis in Children|Prevention of Steroid-Induced Osteoporosis in Children||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Terminated||September 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|5 Years|N/A|No|||December 2007|December 14, 2007|August 14, 2001||Yes|Inadequate eligible subjects to expect sufficient numbers to analyse outcomes.|||https://clinicaltrials.gov/show/NCT00022841||204816|
NCT00023205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR47782 NIAMS-068|Impact of Literacy Level on Patient Education and Health Among People With Arthritis|Literacy in Arthritis Management: A Randomized Controlled Clinical Trial of a Novel Education Intervention||Brigham and Women's Hospital||Completed|November 2002|December 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|134|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|August 29, 2001||No||No||https://clinicaltrials.gov/show/NCT00023205||204789|
NCT00022776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AR45633|Surgical Versus Nonsurgical Treatment for Spinal Stenosis|Randomized Clinical Trial of Treatment for Spinal Stenosis||University of Pittsburgh|Yes|Completed|September 2000|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|178|||Both|50 Years|N/A|No|||February 2013|February 26, 2013|August 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00022776||204821|
NCT00022308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068803|Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Phase I Trial of Radical Thoracic Radiation, Weekly CPT-11 (Irinotecan) and Cisplatin in Locally Advanced Non-Small Cell Lung Carcinoma||Fox Chase Cancer Center||Completed|January 1999|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 30, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022308||204856|
NCT00022321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068805|Gemtuzumab in Treating Patients With Myelodysplastic Syndrome|A Randomized Study Of The Safety And Efficacy Of Two Dose Schedules Of Gemcituzumab Ozogamicin In Patients With Intermediate-2 Or High-Risk Myelodysplastic Syndromes||National Cancer Institute (NCI)||Active, not recruiting|September 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|December 18, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022321||204855|
NCT00022347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK-286.2003|TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Completed|May 2001|December 2009|Actual|April 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2009|June 25, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022347||204853|
NCT00022360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-01057|Taurolidine in Treating Patients With Recurrent or Progressive Glioma|An Open-Label Dose-Ranging Study of the Safety of Taurolidine 2% Solution Administered Intravenously to Patients With Recurrent or Progressive High Grade Glioma||Memorial Sloan Kettering Cancer Center||Completed|May 2001|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||June 2013|June 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022360||204852|
NCT00023023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010231|Study of Transfusion-Transmitted Infections|A Prospective Study of Transfusion-Transmitted Infections||National Institutes of Health Clinical Center (CC)||Recruiting|August 2001|||||N/A|Observational|N/A|||Anticipated|2800|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|August 18, 2001||No||No||https://clinicaltrials.gov/show/NCT00023023||204802|
NCT00023374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2340|TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance|TBTC Study 24: A Non-Comparative Study of the Efficacy of a Largely-Intermittent, Six-Month Tuberculosis Treatment Regimen Among Patients Who Will Not Receive Isoniazid Due to Initial Isoniazid Resistance or Intolerance||Centers for Disease Control and Prevention|Yes|Completed|August 2000|December 2010|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||June 2011|August 2, 2011|September 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00023374||204778|
NCT00023387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2558|TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine|Intensive Pharmacokinetic Study of Three Doses of Rifapentine (600, 900 and 1200mg) During Continuation Phase Therapy of Tuberculosis in HIV-Negative Adults||Centers for Disease Control and Prevention||Completed|March 2000|May 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||September 2005|September 9, 2005|September 6, 2001||||||https://clinicaltrials.gov/show/NCT00023387||204777|
NCT00025818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192371-011-01|Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome|||Allergan||Completed|May 2001|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|290|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|October 26, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025818||204609|
NCT00026169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03115|Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure|A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group||National Cancer Institute (NCI)||Completed|September 2001|||April 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|16 Years|N/A|No|||January 2013|January 9, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026169||204584|
NCT00022802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AR44759|Image Guided System for Orthopaedic Surgery|Image Guided Surgical System for Orthopaedic Trauma||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Terminated|December 2002|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2009|April 7, 2009|August 14, 2001|No|Yes|Grant expired|No||https://clinicaltrials.gov/show/NCT00022802||204819|
NCT00023361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2174|TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen|TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen||Centers for Disease Control and Prevention||Completed|February 1999|February 2003||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||215|||Both|18 Years|N/A|No|||September 2005|September 1, 2005|September 6, 2001||||||https://clinicaltrials.gov/show/NCT00023361||204779|
NCT00026091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00457|Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|September 2001|||March 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|N/A|N/A|No|||February 2013|March 22, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026091||204590|
NCT00026182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01865|Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|October 2001|||February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026182||204583|
NCT00022997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010230|Study of Taste Deficits|Studies of Deficits in the Sense of Taste||National Institutes of Health Clinical Center (CC)||Recruiting|August 2001|||||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|June 10, 2015|August 17, 2001||No||No||https://clinicaltrials.gov/show/NCT00022997||204804|
NCT00022451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010196|Tipifarnib in Treating Young Patients With Refractory Leukemia|A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients With Refractory Leukemia||National Institutes of Health Clinical Center (CC)||Completed|June 2001|March 2005|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||March 2012|March 14, 2012|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022451||204845|
NCT00022464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068820|CCI-779 in Treating Patients With Metastatic Melanoma|A Phase II Study Of CCI-779 (NSC 683864) In Metastatic Melanoma||City of Hope Medical Center||Completed|June 2001|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2015|June 3, 2015|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022464||204844|
NCT00022399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068812|Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer|A Randomized, Placebo-Controlled Trial Of Celecoxib In Men Pre-Prostatectomy For Clinically Localized Adenocarcinoma Of The Prostate: Evaluation Of Drug-Specific Biomarker Modulation||National Cancer Institute (NCI)||Completed|September 2001|||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Male|18 Years|N/A|No|||October 2004|February 18, 2011|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022399||204849|
NCT00022412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-595|Doxercalciferol Before Surgery in Treating Localized Prostate Cancer|Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN||University of Wisconsin, Madison|No|Active, not recruiting|August 2001|||February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|21 Years|120 Years|No|||October 2015|October 9, 2015|August 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00022412||204848|
NCT00022165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068791|Selenium in the Prevention of Cancer|Prevention Of Cancer By Intervention With Selenium||University of Surrey|No|Completed|October 1999|January 2002|Actual|January 2002|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|501|||Both|60 Years|74 Years|No|||August 2015|August 10, 2015|August 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00022165||204866|
NCT00022932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-99-032|Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP|Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-Line CHOP||Corixa Corporation||Active, not recruiting|January 2000|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||September 2004|June 23, 2005|August 16, 2001||||||https://clinicaltrials.gov/show/NCT00022932||204809|
NCT00022750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK48117 (completed)|Randomized Trial of Health Events Costs in Diabetic Blacks|Project Sugar 2: Health Events Costs in Diabetic Blacks||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|October 2000|May 2005||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention||||800|||Both|30 Years|N/A|No|||January 2010|January 14, 2010|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022750||204823|
NCT00025753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0823|Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution|Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||December 2003|June 23, 2005|October 19, 2001||||No||https://clinicaltrials.gov/show/NCT00025753||204614|
NCT00026351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069021|Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase II Multicenter Trial Of Pentostatin and Rituximab In Patients With Previously Treated and Untreated Low Grade B-Cell Non-Hodgkin's Lymphoma (NHL) Including Chronic Lymphocytic Leukemia (CLL)||National Cancer Institute (NCI)||Completed|December 2000|June 2003|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2002|February 1, 2013|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026351||204571|
NCT00026013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000836-01|Effects of St. John's Wort on the Effectiveness of Oral Contraceptives|Effects of Hypericum Perforatum on Effectiveness of Oral Contraceptives||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2002|January 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||25|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|November 5, 2001||||No||https://clinicaltrials.gov/show/NCT00026013||204596|
NCT00023439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2530|TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment|Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB||Centers for Disease Control and Prevention||Completed|May 2000|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|pulmonary TB suspects|June 2011|August 2, 2011|September 6, 2001||No||No||https://clinicaltrials.gov/show/NCT00023439||204773|
NCT00022763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV16056|T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents|A Phase I/II Pharmacokinetic and Safety Study of T-20 in Combination With an Optimized Background in HIV Infected Children and Adolescents||Hoffmann-La Roche||Completed|August 2001|||December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|3 Years|16 Years|No|||January 2016|January 19, 2016|August 11, 2001|||||December 4, 2015|https://clinicaltrials.gov/show/NCT00022763||204822|
NCT00026143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02816|Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma|Phase II Trial of Interleukin-12 (NSC #672423, IND #6798) Followed by Interferon Alfa-2B in Patients With Metastatic Malignant Melanoma||National Cancer Institute (NCI)||Completed|October 2001|||July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026143||204586|
NCT00026156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068991|S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or With Performance Status 2||Southwest Oncology Group|No|Completed|November 2001|November 2008|Actual|July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|November 9, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00026156||204585|
NCT00022984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010237|Technology Dependency and Health-Related Quality of Life|Toward a Theory of Technology Dependency and Health Related Quality of Life (HRQL): A Test of a Model in Patients With an Implantable Cardioverter Defibrillator||National Institutes of Health Clinical Center (CC)||Completed|August 2001|August 2004||||N/A|Observational|N/A||||125|||Both|N/A|N/A|No|||August 2004|March 3, 2008|August 17, 2001||||No||https://clinicaltrials.gov/show/NCT00022984||204805|
NCT00023491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010234|Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells|Assessment of the Potential of Hematopoietic Stem Cells to Transdifferentiate Into Salivary Gland and Oral Mucosal Epithelial Cells in Adult Bone Marrow Transplant Patients||National Institutes of Health Clinical Center (CC)||Completed|September 2001|October 2004||||N/A|Observational|N/A||||10|||Female|N/A|N/A|No|||October 2004|March 3, 2008|September 7, 2001||||No||https://clinicaltrials.gov/show/NCT00023491||204770|
NCT00026234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01866|Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver|A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Liver||National Cancer Institute (NCI)||Completed|February 2002|||January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|N/A|N/A|No|||June 2013|July 15, 2013|November 9, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00026234||204579|
NCT00026104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02423|Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer|A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC #702818) for Locally Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|November 2001|||August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|N/A|N/A|No|||June 2013|June 5, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026104||204589|
NCT00026273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP 4174B-307|Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer|Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer||Pfizer||Completed|January 2001|||September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||August 2012|August 6, 2012|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026273||204576|
NCT00022113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02392|EMD 121974 in Treating Patients With Advanced Solid Tumors|A Phase I Study of EMD 121974 in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|May 2001|||May 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022113||204870|
NCT00022737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01862|Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia|A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051)||National Cancer Institute (NCI)||Completed|October 2002|||October 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|220|||Both|1 Year|21 Years|No|||November 2012|February 26, 2014|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022737||204824|
NCT00022477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11003B|BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Study Of Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Advanced Colorectal Carcinoma||University of Chicago|No|Completed|September 2001|December 2004|Actual|October 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022477||204843|
NCT00022659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02400|Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|April 2002|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Female|18 Years|N/A|No|||December 2012|April 23, 2015|August 10, 2001|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT00022659||204830|
NCT00022087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068781|Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer|Phase III Trial of Intravenous Zoledronic Acid (Zometa) in the Prevention of Bone Loss in Localized Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure||Alliance for Clinical Trials in Oncology|Yes|Completed|December 2001|February 2009|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|439|||Female|40 Years|N/A|No|||September 2013|September 26, 2013|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022087||204871|
NCT00025766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|989|Angioplasty and Heart Stents to Treat Individuals With an Occluded Artery Following a Heart Attack|TOSCA-2: An Angiographic Substudy (Ancillary) of the Occluded Artery Trial (OAT)|TOSCA-2|University Health Network, Toronto|Yes|Completed|September 2001|December 2011|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|October 22, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025766||204613|
NCT00022139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0044|Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer||Alliance for Clinical Trials in Oncology|No|Completed|January 2002|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|August 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00022139||204868|
NCT00022880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-98-018|Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia|A Phase I, Dose-Escalation, Open-Label, Multicenter Study of Iodine-131, Anti-B1 Antibody for Intermediate- and High-Risk B-Cell Chronic Lymphocytic Leukemia||Corixa Corporation||Active, not recruiting|July 1999|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||August 2004|June 23, 2005|August 15, 2001||||||https://clinicaltrials.gov/show/NCT00022880||204813|
NCT00022893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-98-021|Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma|Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti-B1 Antibody.||Corixa Corporation||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|June 23, 2005|August 15, 2001||||||https://clinicaltrials.gov/show/NCT00022893||204812|
NCT00025779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01MH70009|Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders|Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders||National Institute of Mental Health (NIMH)||Completed|October 2001|||November 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|5 Years|14 Years|No|||August 2008|July 24, 2009|October 23, 2001||||No||https://clinicaltrials.gov/show/NCT00025779||204612|
NCT00026312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01064|Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma|Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue||National Cancer Institute (NCI)|Yes|Active, not recruiting|October 2001|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1660|||Both|N/A|30 Years|No|||January 2016|March 24, 2016|November 9, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00026312||204573|
NCT00025831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020017|Biological Specimen Collection for Laboratory Methods Development and Training Purposes|Biological Specimen Collection for Laboratory Methods Development and for Training Purposes||National Institutes of Health Clinical Center (CC)||Completed|October 2001|September 2005||||N/A|Observational|N/A||||200|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|October 26, 2001||||No||https://clinicaltrials.gov/show/NCT00025831||204608|
NCT00022620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55961|Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer|Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 2001|||October 2002|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|75 Years|No|||September 2012|September 20, 2012|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022620||204833|
NCT00022711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-01020|Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer|A Phase II Study of Temozolomide (SCH 52365) in the Treatment of Patients With Relapsed Small Cell Lung Cancer||Fox Chase Cancer Center|No|Completed|January 2002|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|August 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00022711||204826|
NCT00022633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068837|S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract|Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years)||Southwest Oncology Group|No|Terminated|July 2001|July 2011|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|N/A|120 Years|No|||January 2016|January 26, 2016|August 10, 2001|Yes|Yes|Permanently Closed Due to Poor Accrual|No|November 26, 2012|https://clinicaltrials.gov/show/NCT00022633||204832|
NCT00023075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010241|Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis|Nuclear Magnetic Spectroscopy for the Evaluation of Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis||National Institutes of Health Clinical Center (CC)||Completed|August 2001|August 2003||||N/A|Observational|N/A||||55|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2003|March 3, 2008|August 22, 2001||||No||https://clinicaltrials.gov/show/NCT00023075||204798|
NCT00026338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA3|Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer|A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer||Canadian Cancer Trials Group|Yes|Completed|August 2001|February 2009|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|569|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|November 9, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00026338||204572|
NCT00026247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069012|Radiofrequency Ablation in Treating Patients With Bone Metastases|A Phase I/II Study of Percutaneous Radiofrequency Ablation of Bone Metastases Using CT Guidance||National Cancer Institute (NCI)||Completed|November 2001|||February 2011|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Both|21 Years|N/A|No|||March 2006|April 7, 2011|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026247||204578|
NCT00022243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068798|T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy|A Phase II, Open Label Study Of T138067-Sodium In A Second-Line Setting In Non-Small-Cell Lung Cancer Patients With Locally Advanced Or Metastatic Disease Who Have Failed First-Line Therapy With a Taxane||National Cancer Institute (NCI)||Active, not recruiting|October 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|January 3, 2014|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022243||204860|
NCT00023114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8408-CP-001|p450 Mediated Lung Toxicity|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 2000|September 2001||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening||||10|||Both|N/A|N/A|No|||September 2006|September 1, 2006|August 22, 2001||||No||https://clinicaltrials.gov/show/NCT00023114||204795|
NCT00022490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068822|Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase||OHSU Knight Cancer Institute|Yes|Terminated|June 2001|July 2011|Actual|May 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|120 Years|No|||December 2015|December 8, 2015|August 10, 2001|Yes|Yes||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00022490||204842|Study was terminated, therefore the 12 month response data was not analyzed.
NCT00026260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069013|SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of SU5416 (NSC 696819) in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix||National Cancer Institute (NCI)||Completed||October 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||June 2007|June 20, 2013|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026260||204577|
NCT00023283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-9803-1|Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1|Counseling Conditions for Thrice Weekly Buprenorphine in a Primary Care Clinic||National Institute on Drug Abuse (NIDA)||Not yet recruiting||||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|0|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2008|December 30, 2008|August 30, 2001||No||No||https://clinicaltrials.gov/show/NCT00023283||204785|
NCT00023049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010229|Genetic Analysis of Hereditary Disorders of Hearing and Balance|Genetic Analysis of Hereditary Disorders of Hearing and Balance||National Institutes of Health Clinical Center (CC)||Recruiting|August 2001|||||N/A|Observational|N/A|||Anticipated|750|||Both|N/A|99 Years|No|||September 2015|January 15, 2016|August 21, 2001||No||No||https://clinicaltrials.gov/show/NCT00023049||204800|
NCT00023062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010240|Transcranial Magnetic Stimulation in Parkinson's Disease|TMS Measures in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2001|August 2003||||N/A|Observational|N/A||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2003|March 3, 2008|August 22, 2001||||No||https://clinicaltrials.gov/show/NCT00023062||204799|
NCT00022815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44AR044591|Management of Compartment Syndrome With Ultrafiltration|Management of Compartment Syndrome With Ultrafiltration||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|June 2002|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|14 Years|80 Years|No|||April 2008|April 11, 2008|August 14, 2001||||No||https://clinicaltrials.gov/show/NCT00022815||204818|
NCT00022191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30987|Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer|Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2001|||June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|608|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022191||204864|
NCT00022724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068848|CCI-779 in Treating Patients With Malignant Glioma|Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma||National Cancer Institute (NCI)||Completed|December 2001|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2005|November 22, 2008|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022724||204825|
NCT00022217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068796|Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer|A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse||National Cancer Institute (NCI)||Active, not recruiting|November 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2002|December 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022217||204862|
NCT00022230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068797|Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer|Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II)||Roger Williams Medical Center|Yes|Withdrawn|January 2000|January 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||May 2015|May 4, 2015|August 10, 2001|No|Yes|PI left Institution|No||https://clinicaltrials.gov/show/NCT00022230||204861|
NCT00023010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010236|Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)|Follow-Up of a Phase-I Gene Therapy Trial of Patients With Leukocyte Adherence Deficiency||National Institutes of Health Clinical Center (CC)||Completed|August 2001|December 2010||||N/A|Observational|N/A|||Actual|2|||Both|N/A|N/A|No|||December 2010|September 26, 2015|August 18, 2001||No||No||https://clinicaltrials.gov/show/NCT00023010||204803|
NCT00025792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020018|Clinical Trial of Pramipexole in Bipolar Depression|An Investigation of the Antidepressant Efficacy of a Dopamine Agonist With Neurotrophic Properties in Bipolar Disorder||National Institutes of Health Clinical Center (CC)||Completed|October 2001|November 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|October 24, 2001||||No||https://clinicaltrials.gov/show/NCT00025792||204611|
NCT00025805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020019|G-CSF to Treat Crohn's Disease|Granulocyte-Colony Stimulating Factor Treatment for Crohn's Disease: A Pilot Study Assessing Immune and Clinical Response||National Institutes of Health Clinical Center (CC)||Completed|October 2001|June 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||23|||Both|18 Years|N/A|No|||June 2008|September 26, 2015|October 25, 2001||||No||https://clinicaltrials.gov/show/NCT00025805||204610|
NCT00022048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC-MDA-ID-01152|Bevacizumab in Treating Patients With Myelodysplastic Syndrome|Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS)||National Cancer Institute (NCI)||Completed|August 2001|November 2004|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2004|May 14, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022048||204873|
NCT00023296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010223|Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension|Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension||National Institutes of Health Clinical Center (CC)||Completed|July 2001|November 2015|Actual|November 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|September 3, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00023296||204784|
NCT00023309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010246|Lamivudine and Adefovir to Treat Chronic Hepatitis B|Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B||National Institutes of Health Clinical Center (CC)|No|Completed|August 2001|August 2013|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|September 3, 2001|No|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00023309||204783|
NCT00023322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010247|Pegylated Interferon to Treat Chronic Hepatitis D|Treatment of Chronic Delta Hepatitis With Pegylated Interferon||National Institutes of Health Clinical Center (CC)|No|Completed|August 2001|October 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|September 3, 2001|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT00023322||204782|
NCT00022646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0026|Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Clinical Trial Evaluating Three Schedules Of ALIMTA Plus Gemcitabine As Frontline Chemotherapy For Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|August 2001|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|157|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|August 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00022646||204831|
NCT00023218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5133|Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis|Effect of Change to a Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimen of Efavirenz (EFV) and Lopinavir/Ritonavir (LPV/r) on Liver Histology in HIV-1-Infected Individuals With Lactic Acidemia and Persistent Alanine Aminotransferase (ALT) Elevations on NRTI-Containing Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|13 Years|N/A|No|||June 2003|March 5, 2015|August 29, 2001||||No||https://clinicaltrials.gov/show/NCT00023218||204788|
NCT00023231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CN01|Pediatric Kidney Transplant Without Calcineurin Inhibitors|Calcineurin Inhibitor Sparing Protocol in Living Donor Pediatric Kidney Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2001|August 2006|Actual|August 2004|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|21 Years|No|||October 2012|October 31, 2012|August 29, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00023231||204787|
NCT00026000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020027|Brain Activation in Vocal and Motor Tics|Brain Activation in Motor and Vocal Tics in Patients With Tourette's Syndrome or Chronic Motor or Vocal Tic Disorder Using Blood Oxygenation Level Dependent Functional MRI||National Institutes of Health Clinical Center (CC)||Completed|November 2001|January 2005||||N/A|Observational|N/A||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2005|March 3, 2008|November 2, 2001||||No||https://clinicaltrials.gov/show/NCT00026000||204597|
NCT00023426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2404|TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis|TBTC Study 25:A Prospective, Randomized, Double-Blind Study of the Tolerability of Higher Doses of Rifapentine||Centers for Disease Control and Prevention||Completed|July 1999|February 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2005|September 9, 2005|September 6, 2001||||||https://clinicaltrials.gov/show/NCT00023426||204774|
NCT00022854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR047631|Pain Relief Results After Anterior Cruciate Ligament (ACL) Reconstruction|Outcomes After ACL Reconstruction: The Effect of Femoral Nerve Block Analgesia||University of Pittsburgh|Yes|Completed|May 2001|January 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|270|||Both|14 Years|65 Years|No|||May 2013|May 2, 2013|August 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00022854||204815|
NCT00022516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068827|Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer|Low-dose Cytotoxics as "Anti-angiogenesis Treatment" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer|22-00|International Breast Cancer Study Group|Yes|Active, not recruiting|November 2000|December 2020|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1086|||Both|18 Years|120 Years|No|||November 2015|November 6, 2015|August 10, 2001||No||No|November 6, 2015|https://clinicaltrials.gov/show/NCT00022516||204841|This trial collected only Grade 3 or higher Adverse Events.
NCT00026442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069030|Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer|A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|November 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2004|December 17, 2013|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026442||204565|
NCT00026468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069032|Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis|Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis||University of Utah||Withdrawn|July 1999|July 1999|Actual|July 1999|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|80 Years|No|||July 2013|July 23, 2013|November 9, 2001||No|Principle Investigator has left the University.|No||https://clinicaltrials.gov/show/NCT00026468||204564|
NCT00022867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR043740|Encouraging Calcium Absorption and Bone Formation During Early Puberty|Optimization of Calcium Absorption and Bone Formation During Early Puberty||Baylor College of Medicine|Yes|Completed|May 2001|November 2006|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|August 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00022867||204814|
NCT00022945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-99-037|Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma|Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma||Corixa Corporation||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2005|June 23, 2005|August 16, 2001||||||https://clinicaltrials.gov/show/NCT00022945||204808|
NCT00022958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-98-020|Expanded Access Study of Iodine-131 Anti-B1 Antibody|Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma||Corixa Corporation||Active, not recruiting|September 1998|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|June 23, 2005|August 16, 2001||||||https://clinicaltrials.gov/show/NCT00022958||204807|
NCT00025740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020015|Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder|Combined Treatment With a Benzodiazepine (Clonazepam) and a Selective Serotonin Reuptake Inhibitor (Paroxetine) for Rapid Treatment of Posttraumatic Stress Disorder (PTSD)||National Institutes of Health Clinical Center (CC)||Completed|October 2001|August 2004||||Phase 4|Interventional|Primary Purpose: Treatment||||78|||Both|N/A|N/A|No|||August 2004|March 3, 2008|October 16, 2001||||No||https://clinicaltrials.gov/show/NCT00025740||204615|
NCT00020878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068727|Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers|Celecoxib for Chemoprevention of Primary Lung Cancer||Jonsson Comprehensive Cancer Center|Yes|Completed|March 2001|May 2009|Actual|November 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Both|45 Years|N/A|No|||March 2016|March 2, 2016|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00020878||204951|
NCT00025844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020003|Fear Conditioning Using Computer-Generated Virtual Reality|Fear Conditioning Using Computer-Generated Virtual Reality||National Institutes of Health Clinical Center (CC)||Completed|October 2001|April 2012||||N/A|Observational|N/A|||Actual|202|||Both|7 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2012|October 26, 2001||No||No||https://clinicaltrials.gov/show/NCT00025844||204607|
NCT00025857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020007|Brain Function in Mentally Ill Adolescents|Adolescent Medial Temporal Lobe Function in Health and Illness||National Institutes of Health Clinical Center (CC)||Completed|October 2001|June 2012||||N/A|Observational|N/A|||Actual|105|||Both|7 Years|18 Years|No|||June 2012|October 9, 2014|October 26, 2001||No||No||https://clinicaltrials.gov/show/NCT00025857||204606|
NCT00026286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069015|Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer|A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen||National Cancer Institute (NCI)||Completed|September 2000|||August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||March 2008|May 9, 2009|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026286||204575|
NCT00025987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020025|Temperature Response to a Head-Neck Cooling System|Thermal Responses In Normal Volunteers To Head-Neck Cooling||National Institutes of Health Clinical Center (CC)||Completed|November 2001|April 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2003|March 3, 2008|November 2, 2001||||No||https://clinicaltrials.gov/show/NCT00025987||204598|
NCT00020111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067717|Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma|Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients With Refractory Leukemia or Lymphoma||National Cancer Institute (NCI)||Completed|March 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|2 Years|21 Years|No|||February 2005|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020111||204995|
NCT00025870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020023|Studies of Children With Metabolic and Other Genetic Disorders|Studies of Pediatric Patients With Metabolic or Other Genetic Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|October 2001|||||N/A|Observational|N/A|||Anticipated|2500|||Both|N/A|18 Years|No|||May 2015|May 13, 2015|October 27, 2001||No||No||https://clinicaltrials.gov/show/NCT00025870||204605|
NCT00026377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11193A|SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer|A Phase I Study Of SU5416 With Androgen Ablation And Radiation In Patients With Intermediate and Advanced Stage Prostate Cancer||University of Chicago|No|Completed|November 2001|April 2003|Actual|March 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|N/A|N/A|No|||September 2013|September 4, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026377||204569|
NCT00020007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067490|Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery|A Phase I Study of Isolated Lung Perfusion With Paclitaxel and Moderate Hyperthermia in Patients With Unresectable Pulmonary Malignancies||National Cancer Institute (NCI)||Completed|December 1999|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2006|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020007||204999|
NCT00020709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03041|Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|June 2001|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|840|||Both|N/A|N/A|No|||February 2013|February 26, 2013|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00020709||204963|
NCT00026195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-60001|Irinotecan in Treating Aging Patients With Solid Tumors|Clinical Pharmacology In The Elderly: Prospective Evaluation Of The Pharmacokinetics, Pharmacogenetics And Pharmacodynamics Of CPT-11 And Aging||Alliance for Clinical Trials in Oncology|No|Completed|September 2001|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026195||204582|
NCT00020566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068608|Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma|European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)||National Cancer Institute (NCI)||Recruiting|February 2001|||December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|1200|||Both|N/A|49 Years|No|||June 2012|June 23, 2014|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00020566||204973|
NCT00020540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068601|Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer|Treatment Of Patients With Metastatic Melanoma And Renal Cancer With A Combination Of Flt3L And CD40L||National Cancer Institute (NCI)||Completed|March 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2002|April 29, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020540||204975|
NCT00025415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02418|Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction|A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction||National Cancer Institute (NCI)||Completed|August 2001|||January 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|15 Years|N/A|No|||February 2013|February 6, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025415||204640|
NCT00022373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068810|Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer|A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy||National Cancer Institute (NCI)||Active, not recruiting|December 2000|||||Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||November 2001|October 14, 2014|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022373||204851|
NCT00022386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO-PR-00-27-012|Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer|An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer||National Cancer Institute (NCI)||Completed||April 2004|Actual|||Phase 4|Interventional|Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||May 2002|July 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022386||204850|
NCT00020527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068564|Caspofungin Acetate in Treating Children With Fever and Neutropenia|A Multicenter, Open, Non-Comparative, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Separate Doses of MK-0991 in Children With New Onset Fever and Neutropenia||National Cancer Institute (NCI)||Completed|March 2001|June 2003|Actual|||N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|2 Years|17 Years|No|||March 2003|June 17, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020527||204976|
NCT00020696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068705|Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation of Tirapazamine (NSC #130181, IND #46,525) in Combination With Cisplatin in Recurrent Platinum Sensitive Ovarian or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|June 2001|||April 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||March 2008|January 7, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020696||204964|
NCT00021008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068738|ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer|A Phase II Open, Multicenter Trial to Assess the Activity and Tolerability of ZD0473 Given Intravenously as Second-line Therapy to Patients With Non-Small Lung Cancer Who Have Failed One Prior Platinum Based Chemotherapy Regimen||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2001|December 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021008||204943|
NCT00021021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068739|RPI.4610 in Treating Patients With Metastatic Kidney Cancer|A Phase II, Open-Label, Multicenter Trial of Angiozyme in Subjects With Metastatic Renal Cell Cancer||National Cancer Institute (NCI)||Completed|September 2001|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|March 25, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00021021||204942|
NCT00022425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068816|Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy|Multiple-Dose Phase I and Pharmacokinetic Trial of Perillyl Alcohol||National Cancer Institute (NCI)||Active, not recruiting|June 2001|||||Phase 1|Interventional|Primary Purpose: Prevention|||||||Female|18 Years|N/A|No|||September 2003|December 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022425||204847|
NCT00022438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068818|Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment|Immunization of HLA-0201 Positive Patients With Metastatic Melanoma Using a Peptide From Tyrosinase-related Protein 2 (TRP-2)||National Cancer Institute (NCI)||Completed|June 2001|August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||July 2004|June 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022438||204846|
NCT00025883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020022|Leptin to Treat Lipodystrophy|Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy||National Institutes of Health Clinical Center (CC)||Completed|October 2001|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|6 Months|N/A|No|||May 2015|May 23, 2015|October 27, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025883||204604|
NCT00025584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02422|PS-341 in Treating Women With Metastatic Breast Cancer|Phase II Trial Of PS-341 In Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|August 2001|||August 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||January 2013|January 22, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025584||204627|
NCT00025597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068977|Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.|European Infant Neuroblastoma Study - Unresectable Tumors (MYCN Not Amplified)||National Cancer Institute (NCI)||Completed|July 1999|February 2011|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||November 2001|September 16, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025597||204626|
NCT00020124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000088|Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs|Phase I and Clinical Pharmacologic Study of Inhaled Doxorubicin in Adults With Advanced Solid Tumors Affecting the Lungs||National Institutes of Health Clinical Center (CC)||Completed|June 2000|December 2002|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 14, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020124||204994|
NCT00020397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068403|Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma|Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen||National Cancer Institute (NCI)||Completed|November 2000|July 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||January 2005|June 18, 2013|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020397||204983|
NCT00025896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU-001-00|Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease|A Prospective Multinational, Multicenter, Clinical Trial of the Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) in Cross-Reacting Immunologic Material-Positive Patients With Classical Infantile Pompe Disease||Sanofi||Completed|May 2001|September 2002|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|N/A|N/A|No|||November 2014|November 12, 2014|October 31, 2001||||||https://clinicaltrials.gov/show/NCT00025896||204603|
NCT00025974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020002|Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder|Serotonin 1A Receptor Imaging and Benzodiazepine Receptor Imaging in Panic Disorder and Posttraumatic Stress Disorder||National Institutes of Health Clinical Center (CC)||Completed|October 2001|July 2008||||N/A|Observational|N/A||||230|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2008|July 22, 2008|November 2, 2001||No||No||https://clinicaltrials.gov/show/NCT00025974||204599|
NCT00021073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02389|Combination Chemotherapy in Treating Patients With Advanced Cancer|Phase I Study of Flavopiridol in Combination With 5-Fluorouracil, Leucovorin and Irinotecan in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|May 2001|||April 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00021073||204938|
NCT00021099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02390|Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer|A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium||National Cancer Institute (NCI)||Completed|June 2001|||August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|July 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00021099||204937|
NCT00021242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0023|Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia|A Phase II Study of Docetaxel (Taxotere) (NSC# 628503, IND# 59,761) in Children With Refractory Leukemias||Children's Oncology Group|Yes|Completed|August 2002|September 2006|Actual|March 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|21 Years|No|||August 2014|August 7, 2014|July 11, 2001||Yes||No||https://clinicaltrials.gov/show/NCT00021242||204929|
NCT00020410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068405|Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer|Phase I Study Of Yttrium 90-labeled Monoclonal Antibody B3 With Autologous Stem Cell Support For Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|February 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|April 29, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020410||204982|
NCT00026364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02425|ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer|A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer||National Cancer Institute (NCI)||Completed|November 2001|||December 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||September 2002|March 19, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026364||204570|
NCT00026065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000310-02|Hypertension: Prediction of Biofeedback Success|Hypertension: Prediction of Biofeedback Success||National Center for Complementary and Integrative Health (NCCIH)||Completed|February 2000|March 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2006|September 28, 2007|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026065||204592|
NCT00026078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOCS-02-BR-01|Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer|Docetaxel (DTX) - Ifosfamide (IFX) As First Line Chemotherapy In Metastatic Breast Cancer||National Cancer Institute (NCI)||Recruiting|March 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|42|||Female|21 Years|75 Years|No|||November 2006|August 6, 2013|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026078||204591|
NCT00019565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980163|PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy|The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature||National Institutes of Health Clinical Center (CC)||Completed|October 1998|||August 2008|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|145|||Both|18 Years|N/A|No|||September 2007|April 23, 2012|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00019565||205026|
NCT00025506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02421|Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus|A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus||National Cancer Institute (NCI)|Yes|Completed|September 2001|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|N/A|N/A|No|||December 2013|May 7, 2015|October 11, 2001|Yes|Yes||No|May 7, 2015|https://clinicaltrials.gov/show/NCT00025506||204633|
NCT00025519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-01006|Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer|Submyeloablative Allogeneic Blood Stem Cell Transplantation With HLA Identical Donor Lymphocyte Infusions From Matched Related and Matched Unrelated Donors for Treatment of Metastatic Renal Cell Carcinoma||Fox Chase Cancer Center|No|Withdrawn|June 2001|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||July 2013|July 10, 2013|October 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025519||204632|
NCT00022074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068780|Gabapentin For the Control of Hot Flashes in Women With Breast Cancer|Control of Vasomotor Symptoms in Women Treated for Breast Cancer||University of Rochester||Completed|July 2001|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||||||Female|N/A|120 Years|No|||October 2015|October 13, 2015|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022074||204872|
NCT00020046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000033|Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer|Phase II Randomized Study of Docetaxel With or Without Thalidomide in Patients With Androgen-Independent Metastatic Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|December 1999|September 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||March 2012|March 14, 2012|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00020046||204998|
NCT00020072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067694|Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells|Gene Expression Analysis in Cutaneous T-Cell Lymphoma||National Cancer Institute (NCI)||Completed|March 2000|||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|85 Years|No|||March 2003|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020072||204997|
NCT00021112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08981|Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer|Surgical Treatment Of Stage IIIB Non-Small Cell Lung Cancer After Induction-Chemoradiotherapy||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|April 2001|||October 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|5|||Both|18 Years|75 Years|No|||July 2012|July 17, 2012|July 11, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00021112||204936|
NCT00022126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL01P1|Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia|A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia||Children's Oncology Group|Yes|Completed|November 2002|April 2006|Actual|January 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|1 Year|No|||February 2014|February 18, 2014|August 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00022126||204869|
NCT00025688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068992|Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer|A Randomized, Phase II Trial of Weekly Taxol (Paclitaxel) Versus Weekly Taxol Plus Paraplatin (Carboplatin) as First-Line Chemotherapy in Patients Age 65 Years or Older With Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2006|July 23, 2008|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025688||204619|
NCT00020371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068319|BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy|Phase I Study of BMS-247550 in Patients With Refractory Neoplasms||National Cancer Institute (NCI)||Completed|September 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A||||May 2005|April 27, 2015|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00020371||204984|
NCT00020150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067880|Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors|Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors||National Cancer Institute (NCI)||Completed|June 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|21 Years|No|||August 2004|April 28, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020150||204993|
NCT00025909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020013|Intermittent vs. Continuous HAART to Treat Chronic HIV Infection|A Randomized, Controlled Trial of Short Cycle Intermittent Versus Continuous HAART for the Treatment of Chronic HIV Infection||National Institutes of Health Clinical Center (CC)||Completed|October 2001|January 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||January 2005|March 3, 2008|October 31, 2001||||No||https://clinicaltrials.gov/show/NCT00025909||204602|
NCT00025922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020026|Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load|Influenza Vaccine in HIV Infection: Immunologic Responses and Effect on HIV Viral Load||National Institutes of Health Clinical Center (CC)||Completed|October 2001|October 2003||||N/A|Observational|N/A||||240|||Both|N/A|N/A|No|||October 2003|March 3, 2008|October 31, 2001||||No||https://clinicaltrials.gov/show/NCT00025922||204601|
NCT00025935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020021|Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder|Characterization and Pathophysiology of Severe Mood and Behavioral Dysregulation in Children and Youth||National Institutes of Health Clinical Center (CC)||Recruiting|October 2001|||||Phase 4|Observational|N/A|||Anticipated|850|||Both|7 Years|25 Years|Accepts Healthy Volunteers|||October 2015|February 17, 2016|October 31, 2001||No||No||https://clinicaltrials.gov/show/NCT00025935||204600|
NCT00026130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068988|Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer|A Phase II Trial of Gemcitabine, 5-Fluorouracil and Radiation Therapy in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma||Alliance for Clinical Trials in Oncology|No|Completed|September 2001|June 2010|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026130||204587|
NCT00022204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068794|Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer|Double-Blind, Placebo-Controlled, Randomised Trial Of Alpha-Tocopherol And Oxpentifylline In Patients With Radiation Fibrosis||National Cancer Institute (NCI)||Completed|January 2000|||||Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||May 2007|November 5, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022204||204863|
NCT00026039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS031251|Women's Estrogen for Stroke Trial (WEST)|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|December 1993|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind|||||||||||||November 2005|May 12, 2006|November 7, 2001||||No||https://clinicaltrials.gov/show/NCT00026039||204594|
NCT00026052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020034|Riluzole to Treat Major Depression|An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent With Neurotrophic Properties in Major Depression||National Institutes of Health Clinical Center (CC)||Completed|November 2001|April 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||31|||Both|N/A|N/A|No|||April 2003|March 3, 2008|November 8, 2001||||No||https://clinicaltrials.gov/show/NCT00026052||204593|
NCT00026221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00006|Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma|A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma||National Cancer Institute (NCI)||Completed|November 2001|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|November 9, 2001|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00026221||204580|
NCT00020657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068694|Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer|Treatment of Delayed Nausea: What Works Best?||University of Rochester||Completed|July 2001|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020657||204967|
NCT00020670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068701|Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia|A Phase I Study of Vaccination With Autologous CD40-Activated Acute Lymphoblastic Leukemia Cells||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2003|February 6, 2009|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020670||204966|
NCT00026026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0173|Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders|Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|5 Years|80 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|November 6, 2001||||No||https://clinicaltrials.gov/show/NCT00026026||204595|
NCT00022256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-01051|Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|An Open-Label Phase II Trial to Evaluate the Safety and Pharmacokinetics of Motexafin Gadolinium and Cranial Irradiation in the Treatment of Newly Diagnosed Glioblastoma Multiforme||Memorial Sloan Kettering Cancer Center||Completed|April 2001|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022256||204859|
NCT00022178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068792|Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin|An Open Label Prospective Randomised Study Comparing The Use Of Vincristine, Adriamycin And Cyclophosphamide (VAC) Versus Epirubicin, Cisplatin And Continuous 5-Flourouracil (ECF) In Patients With Unknown Primary Carcinoma (UPC)||National Cancer Institute (NCI)||Active, not recruiting|December 1998|||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2002|September 19, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022178||204865|
NCT00021255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_GMA_302|Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer|Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration||Sanofi||Completed|April 2001|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3222|||Female|18 Years|70 Years|No|||March 2015|March 2, 2015|July 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00021255||204928|
NCT00026117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-971151|Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer|Phase III Evaluation Of Benefin Shark Cartilage In Patients With Advanced Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|August 2001|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026117||204588|
NCT00026299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11089A|Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer|A Phase I/ Randomized Phase II Trial Of Oxaliplatin (NSC #266046) With Or Without ZD 1839 (NSC # 715055) In Patients With Advanced Colorectal Carcinoma||University of Chicago|No|Completed|September 2001|February 2005|Actual|December 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026299||204574|
NCT00020098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000039|Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer|Use of Complementary or Alternative Medicine Practices by Women at Increased Risk for Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|June 2000|September 2001|Actual|||N/A|Interventional|Primary Purpose: Prevention|||||||Female|18 Years|N/A|No|||March 2012|March 28, 2012|July 11, 2001||||No||https://clinicaltrials.gov/show/NCT00020098||204996|
NCT00026403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9942|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer|A Phase II Study of Gemcitabine, Cisplatin and Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer||Alliance for Clinical Trials in Oncology|No|Completed|September 2001|July 2009|Actual|June 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026403||204568|
NCT00026416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069028|Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma|Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2003|January 3, 2014|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026416||204567|
NCT00026208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMHD0002|Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma|Risk Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study||Stanford University||Active, not recruiting|June 2001|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|70 Years|No|||August 2013|August 2, 2013|November 9, 2001||No||No||https://clinicaltrials.gov/show/NCT00026208||204581|
NCT00026429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069029|Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma|A Multicenter Phase II Evaluation Of ONTAK (DENILEUKINDIFTITOX) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2002|December 17, 2013|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026429||204566|
NCT00022282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068801|AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma|Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients||AEterna Zentaris||Completed|April 2001|||March 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2008|February 27, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022282||204858|
NCT00020579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010124|MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|March 2001|October 2008|Actual|April 2008|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|July 11, 2001||||||https://clinicaltrials.gov/show/NCT00020579||204972|
NCT00022334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068806|Vaccine Therapy in Treating Patients With Liver Cancer|A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma||Jonsson Comprehensive Cancer Center|Yes|Completed|January 2001|October 2008|Actual|December 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|August 10, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00022334||204854|
NCT00022295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068802|Phenoxodiol in Treating Patients With Refractory Solid Tumors|Phase IB Study of Phenoxodiol Given by Constant Intravenous Infusion in Patients With Solid Neoplasms (With the Exception of Breast Cancer) Whose Tumors Are Refractory to Standard Therapy||National Cancer Institute (NCI)||Completed|August 2001|October 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||March 2007|March 25, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022295||204857|
NCT00020826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-15001-40003|Assessing Quality of Life of Patients With Stomach Cancer|An International Field Study Of The Reliability And Validity Of The EORTC QLQ-C30 And A Disease-Specific Questionnaire Module (The QLQ-STO22) In Assessing The Quality Of Life Of Patients With Gastric Cancer||European Organisation for Research and Treatment of Cancer - EORTC|No|Completed|April 2001|January 2004|Actual|May 2003|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|267|||Both|18 Years|N/A|No|Non-Probability Sample|The study sample will be composed of a consecutive series of patients with gastric cancer        meeting the eligibility criteria in each participating centre. The definition of gastric        cancer is adenocarcinoma of the stomach, and includes all tumours of the fundus, body and        antrum, linitis plastica and tumours of the cardia that infiltrate the gastro-oesophageal        junction and distal oesophagus from below; classified as type III according to Siewert        (1998. The study sample will be stratified by treatment - potentially curative and purely        palliative.|August 2012|August 24, 2012|July 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00020826||204955|
NCT00025480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068965|Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|August 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||April 2007|February 6, 2009|October 11, 2001||||||https://clinicaltrials.gov/show/NCT00025480||204635|
NCT00025493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068966|S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer|Single Agent Docetaxel for Metastatic Breast Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger Than 60 Years)||Southwest Oncology Group|Yes|Terminated|October 2001|June 2008|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||January 2013|January 22, 2013|October 11, 2001|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00025493||204634|
NCT00025350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068952|Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer|A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma||National Cancer Institute (NCI)||Completed|October 2001|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2006|June 20, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025350||204645|
NCT00025363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01864|Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma|A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors||National Cancer Institute (NCI)||Completed|November 2001|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|N/A|20 Years|No|||January 2013|January 16, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025363||204644|
NCT00024635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010254|Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers|The Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|September 2001|||||N/A|Observational|N/A|||Anticipated|16000|||Both|3 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 23, 2001||No||No||https://clinicaltrials.gov/show/NCT00024635||204687|
NCT00025298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-24981|Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx|A Feasibility Study Of Primary Chemotherapy Followed By Concomitant Chemoradiation With And Without Amifostine In Patients With Locally Advanced Undifferentiated Nasopharyngeal Cancer (UNPC)||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|July 2001|||October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|5|||Both|15 Years|70 Years|No|||September 2012|September 20, 2012|October 11, 2001|||low accrual|No||https://clinicaltrials.gov/show/NCT00025298||204649|
NCT00028353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211|A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)|||GTx||Completed|April 2001|July 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Male|30 Years|N/A|No|||November 2013|November 13, 2013|December 22, 2001||||||https://clinicaltrials.gov/show/NCT00028353||204429|
NCT00025025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-MC9944|Screening Tests in Detecting Colorectal Cancer|Colorectal Cancer Screening: Fecal Blood vs. DNA||Alliance for Clinical Trials in Oncology|No|Completed|October 2001|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|4482|||Both|65 Years|80 Years|No|Non-Probability Sample|Patients aged 65 -80 years|September 2015|September 2, 2015|October 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00025025||204670|
NCT00025090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068911|Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer|Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer||National Cancer Institute (NCI)||Completed|March 2001|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|600|||Both|N/A|N/A|No|||March 2007|August 23, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025090||204665|
NCT00025103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-UKWR|Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney|Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK)||National Cancer Institute (NCI)||Active, not recruiting|May 2001|||November 2008|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|75|||Both|N/A|17 Years|No|||June 2009|August 1, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025103||204664|
NCT00024232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-01030|Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer|Pilot Trial of Humanized Monoclonal Antibody J591 in Patients With Progressive Androgen-Independent Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|June 2001|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2013|June 17, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024232||204717|
NCT00027677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16007|Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors|Phase I Study To Determine The Safety Of Halofuginone In Patients With A Solid Progressive Tumor||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 2001|||February 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027677||204476|
NCT00024648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LErafAON-001|Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies|Phase I Study to Determine the Maximum Tolerated Dose of LErafAON in Combination With Radiotherapy in Patients With Advanced Malignancies||INSYS Therapeutics Inc||Completed|March 2001|December 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|September 24, 2001||||||https://clinicaltrials.gov/show/NCT00024648||204686|
NCT00024596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|985|Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)|||Washington University School of Medicine||Completed|September 2001|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Actual|3389|Samples With DNA|Stored DNA, lymphoblasts|Both|N/A|100 Years|No|||December 2015|December 21, 2015|September 21, 2001||||No||https://clinicaltrials.gov/show/NCT00024596||204689|
NCT00027911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2273|Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma|A Pilot Study of NY-ESO-1 Immunization in Patients With NY-ESO-1/LAGE Antigen Expressing Cancer||Columbia University||Terminated|April 2001|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 13, 2013|December 7, 2001|Yes|Yes|Departure of PI|No||https://clinicaltrials.gov/show/NCT00027911||204459|
NCT00024622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010232|PET Scanning in Parkinson s Disease|Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia||National Institutes of Health Clinical Center (CC)||Recruiting|September 2001|||||N/A|Observational|N/A|||Anticipated|460|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|September 23, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00024622||204688|
NCT00025389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12653A|Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer||University of Chicago|No|Completed|November 2001|August 2007|Actual|December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025389||204642|
NCT00025155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02413|Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy|A Phase II Evaluation of Epothilone-B BMS 247550 (NSC # 710428) in the Treatment of Recurrent or Persistent Platinum and Paclitaxel Refractory Ovarian or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|July 2002|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|N/A|N/A|No|||December 2012|June 17, 2015|October 11, 2001|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT00025155||204660|
NCT00025285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068946|Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer||Wake Forest Baptist Health||Completed|November 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 21, 2009|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025285||204650|
NCT00028327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5141|Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care|Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy for HIV-Infected Subjects With CD4 Cell Counts Less Than 350 Cells/mm3 Admitted to Intensive Care Areas With an AIDS-Defining Illness, Pneumonia, or Sepsis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||July 2004|February 28, 2011|December 20, 2001||||No||https://clinicaltrials.gov/show/NCT00028327||204431|
NCT00028340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020077|High-Risk Breast Duct Epithelium|Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile||National Institutes of Health Clinical Center (CC)||Recruiting|December 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|155|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|November 5, 2015|December 21, 2001||No||No||https://clinicaltrials.gov/show/NCT00028340||204430|
NCT00028418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1972-01|Clofarabine in Chronic Lymphocytic Leukemia|Phase I Study of CL-F-ARA-A in Solid and Hematologic Malignancies||FDA Office of Orphan Products Development||Completed|February 1999|March 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||November 2001|March 24, 2015|January 4, 2002||||||https://clinicaltrials.gov/show/NCT00028418||204425|
NCT00025610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068979|Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma|European Infant Neuroblastoma Study - Stage 4S and Stage 4 (No Bone, Lung, Pleura or CNS); MYCN Not Amplified||National Cancer Institute (NCI)||Completed|July 1999|March 2009|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||November 2001|September 16, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025610||204625|
NCT00025246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03079|Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery|A Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST)||National Cancer Institute (NCI)||Completed|September 2001|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|16 Years|N/A|No|||January 2013|February 19, 2013|October 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025246||204653|
NCT00025259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD0031|Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease|A Phase III Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease||Children's Oncology Group|Yes|Active, not recruiting|September 2002|||August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|1734|||Both|N/A|21 Years|No|||September 2015|September 11, 2015|October 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025259||204652|
NCT00028548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069103|XK469 in Treating Patients With Advanced Solid Tumors|Phase I Study of R(+)-XK469 (NSC 698215) Given Daily, Days 1-5, Repeated Every Three Weeks in Patients With Advanced Malignancies||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 2002|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|16 Years|N/A|No|||April 2014|April 24, 2014|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028548||204418|
NCT00025194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068935|Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer|A Phase I And Randomized Phase 2 Trial Of Epothilone B Analogue BMS 247550 (NSC # 710428) Administered Every 21 Days With Or Without Oral Estramustine Phosphate In Patients With Androgen Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|July 2001|July 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||November 2005|June 20, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025194||204657|
NCT00024427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068931|Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer|An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer||Wellstat Therapeutics|No|Completed|February 2001|||February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|18 Years|N/A|No|||May 2010|June 27, 2012|September 13, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00024427||204702|
NCT00024297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-WARP|Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters|A Multicenter Prospective Randomized Controlled Trial of Thrombosis Prophylaxis With Warfarin in Cancer Patients With Central Venous Catheters||National Cancer Institute (NCI)||Completed|October 1999|February 2009|Actual|||N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|16 Years|N/A|No|||December 2002|August 6, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024297||204712|
NCT00025571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068974|Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer|A Phase I Study of Photodynamic Therapy (PDT) Using 2-(1-hexyloxyethyl)-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Early Stage Lung Cancer - A Dose Ranging Study||Roswell Park Cancer Institute|Yes|Completed|June 2001|October 2004|Actual|October 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 3, 2011|October 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025571||204628|
NCT00025701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020010|EEG and EMG Studies of Hand Dystonia|EEG Study of Movement-Related Center-Surround Organization in Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|October 2001|October 2010||||N/A|Observational|N/A|||Actual|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2010|October 5, 2010|October 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00025701||204618|
NCT00027924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1519.00|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome|Fludarabine And Busulfan As Conditioning For Patients With Chronic Myeloid Leukemia Or Myelodysplastic Syndrome Transplanted With Hematopoietic Stem Cells From HLA-Compatible Related Or Unrelated Donors||Fred Hutchinson Cancer Research Center||Completed|October 2001|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||March 2010|March 31, 2010|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027924||204458|
NCT00025337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02417|Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated|Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer||National Cancer Institute (NCI)||Completed|September 2001|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|880|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025337||204646|
NCT00024999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020011|EEG and EMG Analysis of Ideomotor Apraxia|EEG Analysis of Ideomotor Apraxia||National Institutes of Health Clinical Center (CC)||Completed|October 2001|September 2005||||N/A|Observational|N/A||||60|||Both|N/A|N/A|No|||September 2005|March 3, 2008|October 10, 2001||||No||https://clinicaltrials.gov/show/NCT00024999||204672|
NCT00025012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000076973|Isotretinoin in Preventing Skin Cancer|Use Of Isotretinion For Prevention Of Skin Cancer In Patients With Xeroderma Pigmentosum Or Nevoid Basal Cell Carcinoma Syndrome||National Cancer Institute (NCI)||Completed|June 1991|February 2004|Actual|||N/A|Interventional|Primary Purpose: Prevention|||||||Both|2 Years|N/A|No|||November 2007|June 17, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025012||204671|
NCT00025038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01861|Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia|Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia||National Cancer Institute (NCI)||Completed|June 2001|||October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|18 Years|No|||January 2013|April 10, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025038||204669|
NCT00028509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL0131|Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201|Assessment of Clinical and Neuroradiologic Evidence of Methotrexate Leukoencephalopathy in Children Treated on POG 9605 and 9201||Children's Oncology Group|No|Completed|July 2002|||July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|66|||Both|1 Year|9 Years|No|Non-Probability Sample|Previously enrolled on POG-9201 or POG-9605|February 2014|February 11, 2014|January 4, 2002||No||No||https://clinicaltrials.gov/show/NCT00028509||204421|
NCT00025233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02416|Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix|A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)||National Cancer Institute (NCI)||Completed|April 2002|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||January 2013|June 10, 2015|October 11, 2001|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT00025233||204654|
NCT00025402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068957|Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia|Randomized Multicenter Treatment Optimization Study In Chronic Myeloid Leukemia (CML) Interferon-a Vs. Allogeneic Stem Cell Transplantation Vs. High-Dose Chemotherapy Followed By Autografting And Interferon-a Maintainance In Early Chronic Phase||National Cancer Institute (NCI)||Active, not recruiting|July 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Both|N/A|N/A|No|||July 2002|December 17, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025402||204641|
NCT00027469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020059|MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery|Evidence of Procedural Embolism Complicating Renal Artery Stenting||National Institutes of Health Clinical Center (CC)||Completed|December 2001|December 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||December 2005|March 3, 2008|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027469||204491|
NCT00024518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010249|Interferon-Alpha for Diabetes Mellitus Type 1|Ingested Interferon-Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Diabetes Mellitus||The University of Texas Health Science Center, Houston|No|Completed|September 2001|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|57|||Both|3 Years|25 Years|No|||November 2013|November 18, 2013|September 19, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00024518||204695|
NCT00024531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0031|Lipitor as a Treatment for Alzheimer's Disease|Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease||National Institute on Aging (NIA)||Completed|October 2000|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||98|||Both|50 Years|N/A|No|||November 2006|November 8, 2006|September 19, 2001||||No||https://clinicaltrials.gov/show/NCT00024531||204694|
NCT00024544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|683-803|Pilot Study in Patients With Symptomatic Steroid-Naive Asthma|A Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of SB 240683 in Patients With Symptomatic Steroid-Naive Asthma||Facet Biotech||Completed|August 2001|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|70 Years|No|||March 2012|March 6, 2012|September 19, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00024544||204693|
NCT00025428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068960|Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma|Treatment Of Children Over The Age Of 1 Year With Unresectable Localized Neuroblastoma Without MYCN Amplification||National Cancer Institute (NCI)||Completed|December 2000|November 2013|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||Anticipated|100|||Both|1 Year|18 Years|No|||November 2006|December 3, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025428||204639|
NCT00025441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068961|Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors|MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood||National Cancer Institute (NCI)||Completed|November 1998|March 2010|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|6 Years|17 Years|No|||November 2001|December 3, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025441||204638|
NCT00024401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068929|DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer|Phase II Open-Label Study of Taxoperxin (DHA-Paclitacel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Cancer of the Colon/Rectum||National Cancer Institute (NCI)||Active, not recruiting|May 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|July 23, 2008|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024401||204704|
NCT00024414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068930|DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer|Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||March 2003|July 23, 2008|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024414||204703|
NCT00025675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTC-0001 CDR0000068984|Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors|ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2002|||June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|October 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025675||204620|
NCT00024505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|983|Multidisciplinary Study of Right Ventricular Dysplasia|Multidisciplinary Study of Right Ventricular Dysplasia||University of Arizona|Yes|Completed|September 2001|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|320|Samples With DNA|Blood|Both|12 Years|90 Years|No|Non-Probability Sample|Referals to enrolling centers from communities|January 2013|January 15, 2013|September 18, 2001||No||No||https://clinicaltrials.gov/show/NCT00024505||204696|
NCT00025129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-011|VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial of VNP4010M, A Novel Alkylating Agent for Patients With Advanced or Metastatic Cancer||National Cancer Institute (NCI)||Completed|March 2001|May 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|July 17, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025129||204662|
NCT00027937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1595.00|Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma|A Phase II Study Of Mobilization Chemotherapy With GMCSF And GCSF Followed By High Dose Therapy Combined With IL2 Activated Autologous Peripheral Blood Stem Cells Followed By Sequential IL2 Therapy As Treatment For Solid Tumors And Lymphoma||Fred Hutchinson Cancer Research Center||Completed|August 2001|November 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|56 Years|No|||May 2010|May 12, 2010|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027937||204457|
NCT00025207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02414|Gefitinib in Treating Patients With Malignant Mesothelioma|A Phase II Study Of ZD 1839 (NSC 715055, IND 61187) In Patients With Malignant Mesothelioma||National Cancer Institute (NCI)||Completed|September 2001|||February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025207||204656|
NCT00025142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC-670|Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer|A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)||National Cancer Institute (NCI)||Completed|July 2001|November 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2005|May 14, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025142||204661|
NCT00025376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11049A|PS-341 in Treating Patients With Metastatic Kidney Cancer|A Phase II Trial of PS-341 in Patients With Renal Cell Cancer||University of Chicago|No|Completed|October 2001|March 2006|Actual|September 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025376||204643|
NCT00024661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LErafAON-002|Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors|Study to Determine the Maximum Tolerated Dose of Liposome-Encapsulated C-RAF Antisense Oligodeoxynucleotide (LErafAON) in Patients With Advanced Solid Tumors||INSYS Therapeutics Inc||Completed|March 2001|October 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|September 24, 2001||||||https://clinicaltrials.gov/show/NCT00024661||204685|
NCT00028080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020055|Evaluation, Treatment, and Follow-up of Patients With Lyme Disease|Evaluation, Treatment and Follow up of Patients With Lyme Disease||National Institutes of Health Clinical Center (CC)||Recruiting|November 2001|||||N/A|Observational|N/A|||Anticipated|400|||Both|N/A|N/A|No|||January 2016|February 4, 2016|December 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00028080||204449|
NCT00028093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020065|Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease|Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease||National Institutes of Health Clinical Center (CC)|No|Completed|December 2001|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||May 2013|September 4, 2013|December 11, 2001||No||No|May 26, 2011|https://clinicaltrials.gov/show/NCT00028093||204448|
NCT00025532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068971|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer|A Pre-Phase I Biodistribution Study Of hCC^CH2 Labeled With 131 Iodine In Patients With Gastrointestinal Adenocarcinomas||University of California, San Francisco||Withdrawn|April 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|19 Years|N/A|No|||September 2012|September 13, 2012|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025532||204631|
NCT00025168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068933|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer|Phase II Trial Of Induction Gemcitabine/CPT-11 Followed By Twice-Weekly Infusion Gemcitabine And Concurrent External Beam Radiation For The Treatment Of Locally Advanced Pancreatic Cancer||Wake Forest Baptist Health||Completed|November 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025168||204659|
NCT00027560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-092|Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer|Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphohematopoietic Malignancies||Memorial Sloan Kettering Cancer Center||Completed|July 2001|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|N/A|70 Years|No|||December 2012|December 3, 2012|December 7, 2001|Yes|Yes||No|November 27, 2012|https://clinicaltrials.gov/show/NCT00027560||204484|
NCT00025077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-CNS-2000-01|Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors|Treatment Of Recurrent Central Nervous System Primitive Neuroectodermal Tumors (PNETs) In Children And Adolescents A Strategy Including The Use Of High Dose Thiotepa And High Dose Carboplatin||National Cancer Institute (NCI)||Completed|January 2000|April 2011|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|20 Years|No|||June 2007|August 1, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025077||204666|
NCT00025220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02415|Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus|A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||National Cancer Institute (NCI)||Completed|September 2001|July 2008|Actual|April 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|N/A|N/A|No|||December 2012|March 13, 2015|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025220||204655|
NCT00025272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068945|Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Study of Sequential Topotecan-Carboplatin-Etoposide in Patients With Extensive Stage Small Cell Lung Cancer||Wake Forest Baptist Health||Completed|November 2001|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025272||204651|
NCT00025116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I140|ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Randomized Phase II Study Of ZD1839 (IRESSA) In Patients With Hormone Refractory Prostate Cancer||Canadian Cancer Trials Group||Completed|April 2001|September 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|16 Years|N/A|No|||March 2010|November 7, 2010|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025116||204663|
NCT00024492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEM-001|Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer|||INSYS Therapeutics Inc||Completed|August 2001|June 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2004|June 2, 2011|September 17, 2001||||||https://clinicaltrials.gov/show/NCT00024492||204697|
NCT00024271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068907|Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer|Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma||National Cancer Institute (NCI)||Active, not recruiting|May 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|January 3, 2014|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024271||204714|
NCT00025623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068980|Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma|European Infant Neuroblastoma Study - Stage 4 With Bone, Lung, Pleura or CNS Involvement; MYCN Not Amplified||National Cancer Institute (NCI)||Completed|July 1999|March 2009|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||December 2002|September 16, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025623||204624|
NCT00025545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1099.00|Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>|A Phase II Trial to Evaluate the Use of G-CSF-Mobilized Peripheral Blood Progenitor Cells as Hematopoietic Rescue in Patients With Acute Leukemia Undergoing Allografting From an Unrelated Donor||Fred Hutchinson Cancer Research Center||Completed|March 1996|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|55 Years|No|||May 2010|May 12, 2010|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025545||204630|
NCT00025636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068981|Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma|A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease||National Cancer Institute (NCI)||Active, not recruiting|July 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|220|||Both|18 Years|60 Years|No|||June 2007|September 16, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025636||204623|
NCT00027963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N00C3|Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy|The Efficacy Of Gabapentin In The Management Of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial||Alliance for Clinical Trials in Oncology|No|Completed|February 2002|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027963||204456|
NCT00024323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-021|Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin||National Cancer Institute (NCI)||Completed|March 2001|June 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|July 17, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024323||204710|
NCT00024674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS1PE-001|Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days|||INSYS Therapeutics Inc||Withdrawn|February 2001|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|September 24, 2001|||Support withdrawn - Study continued by NCI - see record NCT00006981|||https://clinicaltrials.gov/show/NCT00024674||204684|
NCT00028028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03146|CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized, Phase II ECOG Trial of Two Dose Levels of CCI-779 in Patients With Extensive-Stage Small Cell Lung Cancer Who Have Responding or Stable Disease After Induction Chemotherapy||National Cancer Institute (NCI)||Completed|February 2002|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00028028||204451|
NCT00028067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302F|A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor|A Phase III Study Comparing the Antiviral Efficacy and Safety of Atazanavir With Nelfinavir: Each in Combination With Dual Nucleoside Therapy in HIV-Infected Subjects Who Have Failed a Regimen Not Containing a Protease Inhibitor||Bristol-Myers Squibb||Terminated|August 2001|April 2002|Actual|April 2002|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||500|||Both|16 Years|N/A|No|||April 2011|April 28, 2011|December 10, 2001|Yes|Yes||||https://clinicaltrials.gov/show/NCT00028067||204450|
NCT00023400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2587|TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB|TBTC Study 23B:Intensive Pharmacokinetics of the Nelfinavir Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen||Centers for Disease Control and Prevention||Completed|February 2000|February 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||September 2005|September 1, 2005|September 6, 2001||||||https://clinicaltrials.gov/show/NCT00023400||204776|
NCT00023413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2588|TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz|TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections||Centers for Disease Control and Prevention||Completed|November 1999|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|September 6, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00023413||204775|
NCT00027846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0121|Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma|A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma||Children's Oncology Group|Yes|Active, not recruiting|August 2003|||January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|378|||Both|1 Year|21 Years|No|||March 2015|March 3, 2015|December 7, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027846||204464|
NCT00028405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSC-OL001|Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors|A Multicenter Phase I Safety and Tolerability Study of the Oncolux System for Intratumoral Delivery of Non-Coherent Light for the Photoactivation of LS 11 in Patients With Refractory Solid Tumors||Light Sciences LLC||Completed|November 2001|December 2002||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||March 2003|June 23, 2005|January 4, 2002||||||https://clinicaltrials.gov/show/NCT00028405||204426|
NCT00024583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|984|Prenatal Nutrition and Adult Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Both|55 Years|60 Years|No|||January 2008|February 17, 2016|September 21, 2001||||No||https://clinicaltrials.gov/show/NCT00024583||204690|
NCT00022594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16008|Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer|Phase II Study Of NX 211 (Liposomal Lurtotecan) Given As An IV Bolus Injection On Days 1 and 8 Every 3 Weeks In Patients With Metastatic Or Loco-Regional Recurrent Squamous Cell Carcinoma Of The Head and Neck With Target Lesions Within Previously Irradiated Fields Or Outside Previously Irradiated Fields||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2001|||August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022594||204835|
NCT00028197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020068|Comparison of Externally and Self-Initiated Movements|Comparison of Externally and Self-Initiated Movements||National Institutes of Health Clinical Center (CC)||Completed|December 2001|November 2005||||N/A|Observational|N/A||||55|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|December 17, 2001||||No||https://clinicaltrials.gov/show/NCT00028197||204440|
NCT00028210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020067|Enhanced Tactile (Touch) Spatial Acuity in Upper Limb Amputees|Enhancement of Tactile Spatial Acuity in Upper Limb Amputees||National Institutes of Health Clinical Center (CC)||Completed|December 2001|March 2004||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|March 3, 2008|December 17, 2001||||No||https://clinicaltrials.gov/show/NCT00028210||204439|
NCT00028236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020057|Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)|Ex Vivo Retroviral Gene Transfer For Treatment of X-Linked Severe Combined Immunodeficiency (XSCID)||National Institutes of Health Clinical Center (CC)||Completed|December 2001|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|3|||Both|18 Months|20 Years|No|||July 2011|July 26, 2011|December 17, 2001||No||No||https://clinicaltrials.gov/show/NCT00028236||204438|
NCT00028483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069079|Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer|A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma||Seattle Genetics, Inc.||Terminated|October 2000|April 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||October 2011|October 21, 2011|January 4, 2002||Yes||||https://clinicaltrials.gov/show/NCT00028483||204423|
NCT00022529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02396|BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors|Phase I Study of Intravenous BMS-214662 FTI (NSC# 710086) and Herceptin (NSC# 688097) Weekly in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|July 2001|||January 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022529||204840|
NCT00028366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5143|Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People|A Randomized, Comparative Study of Lopinavir/Ritonavir Versus GW433908 and Ritonavir Versus Lopinavir/Ritonavir and GW433908 (In Combination With Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase Inhibitors) in HIV-1-Infected Subjects With Virologic Treatment Failure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2005|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||August 2012|August 15, 2012|December 27, 2001||||||https://clinicaltrials.gov/show/NCT00028366||204428|
NCT00028158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG1-003|Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer|An Open-Label Phase Ib/II Study of the Safety, Tolerability and Efficacy of G207, a Genetically Engineered Herpes Simplex Type-1 Virus, Administered Intracerebrally to Patients With Recurrent Malignant Glioma||MediGene||Completed|December 2001|October 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|19 Years|N/A|No|||December 2001|June 23, 2005|December 17, 2001||||||https://clinicaltrials.gov/show/NCT00028158||204443|
NCT00024557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL13PEI-002|Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients|Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma||INSYS Therapeutics Inc||Completed|June 2001|July 2007|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|September 20, 2001||||||https://clinicaltrials.gov/show/NCT00024557||204692|
NCT00022672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO16216|A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer|A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer||Hoffmann-La Roche||Completed|January 2001|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Female|18 Years|N/A|No|||June 2013|June 7, 2013|August 10, 2001|Yes|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT00022672||204829|
NCT00022685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068842|Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab)||National Cancer Institute (NCI)||Active, not recruiting|September 2001|||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|December 18, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022685||204828|
NCT00022971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010235|Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia|Combination Antibody Therapy With Apolizumab (1D10) and Rituximab (CD20) in Relapsed Lymphoma and CLL||National Institutes of Health Clinical Center (CC)||Completed|August 2001|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|August 17, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022971||204806|
NCT00027690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02429|Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer|A Phase II Trial of ZD 1839 (IRESSA) (NSC #715055) in the Treatment of Persistent or Recurrent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|June 2002|July 2013|Actual|September 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|18 Years|N/A|No|||December 2012|March 13, 2015|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027690||204475|
NCT00024570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL13PEI-001|Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma|Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study||INSYS Therapeutics Inc||Completed|November 2000|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|September 20, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00024570||204691|
NCT00022906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-98-028|Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement|Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody For Patients With Previously Treated Non-Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement||Corixa Corporation||Active, not recruiting|May 1999|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||August 2004|June 23, 2005|August 15, 2001||||||https://clinicaltrials.gov/show/NCT00022906||204811|
NCT00022919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010212|Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods|Analysis of Prostate Cancer Short-Term Cultures Utilizing Molecular Cytogenetic Methods||National Institutes of Health Clinical Center (CC)||Completed|August 2001|August 2004||||N/A|Observational|N/A||||150|||Male|N/A|N/A|No|||August 2004|March 3, 2008|August 16, 2001||||No||https://clinicaltrials.gov/show/NCT00022919||204810|
NCT00022152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N003A|Vinorelbine in Treating Older Women With Stage IV Breast Cancer|Phase II Trial of Oral Vinorelbine for the Treatment of Metastatic Breast Cancer in Patients >65 Years of Age: A Trial of Efficacy, Toxicity, and Patients' Perceived Preference for Oral Therapy||Alliance for Clinical Trials in Oncology|No|Completed|November 2001|August 2007|Actual|March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|65 Years|N/A|No|||July 2015|July 9, 2015|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022152||204867|
NCT00023530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139|Blood and Marrow Transplant Clinical Research Network|Blood and Marrow Transplant Clinical Research Network||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|2 Years|N/A|No|||July 2006|February 17, 2016|September 7, 2001||||No||https://clinicaltrials.gov/show/NCT00023530||204768|
NCT00027742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-005|Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma|A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma||Memorial Sloan Kettering Cancer Center||Completed|May 2001|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027742||204471|
NCT00027859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069088|Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer|A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy for Prostate Cancer||Eastern Cooperative Oncology Group|Yes|Completed|May 2003|||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||January 2010|January 26, 2010|December 7, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027859||204463|
NCT00028002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02437|Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor|A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117)||National Cancer Institute (NCI)||Completed|February 2002|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||November 2012|May 7, 2014|December 7, 2001|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00028002||204453|
NCT00023504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010226|Antibody Production in Immune Disorders|Evaluation of Immune Response to Vaccines in Primary Immune Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|September 2001|||||N/A|Observational|N/A|||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 13, 2016|September 7, 2001||No||No||https://clinicaltrials.gov/show/NCT00023504||204769|
NCT00023101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8337-CP-001|Lead, Endocrine Disruption and Reproductive Outcomes|||National Institute of Environmental Health Sciences (NIEHS)||Completed|August 1996|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||800|||Both|20 Years|34 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|August 22, 2001||||No||https://clinicaltrials.gov/show/NCT00023101||204796|
NCT00028431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1975-01|Novel Adjuvants for Peptide-Based Melanoma Vaccines|An Open Label Study of MDX-CTLA4 in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 in the Treatment of Patients With Resected Stage III or IV Melanoma||University of Southern California||Completed|August 2001|June 2005|Actual|January 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|January 4, 2002||||||https://clinicaltrials.gov/show/NCT00028431||204424|
NCT00028015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I146|SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer||Canadian Cancer Trials Group||Completed|October 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00028015||204452|
NCT00024284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068908|Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors|A Phase I Study Of Carboplatin And Irinotecan In Patients 1-21 Years Of Age With Refractory Solid Tumors||Bristol-Myers Squibb||Completed|June 2001|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|21 Years|No|||April 2013|April 3, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024284||204713|
NCT00022542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02397|BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma|A Phase II Study of Epothilone B Analog (BMS-247550) in Advanced Soft Tissue Sarcomas||National Cancer Institute (NCI)||Terminated|June 2001|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||December 2012|April 14, 2015|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022542||204839|
NCT00022607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068834|Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|January 2002|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2004|June 20, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022607||204834|
NCT00028561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02726|BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of Epothilone B Analog BMS 247550 in Combination With Carboplatin in Recurrent and/or Refractory Solid Tumors||National Cancer Institute (NCI)||Terminated|October 2001|||February 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|January 4, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00028561||204417|
NCT00024375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068926|DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer|Phase II Open-Label Study of Taxoperxin (DHA-Paclitaxel) Injection by 2 Hour Intravenous Infusion in Patients With Metastatic Cancer of the Pancreas||National Cancer Institute (NCI)||Active, not recruiting|June 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|February 17, 2009|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024375||204706|
NCT00028288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC-1003|Study of Daclizumab in Patients With Chronic, Persistent Asthma|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma||Facet Biotech||Completed|September 2001|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|70 Years|No|||March 2012|March 9, 2012|December 19, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028288||204434|
NCT00022828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15AR047296|3-D Laser Imaging to Analyze Neck Movement|3-D Laser Imaging for Cervical Spine Motion Analysis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Active, not recruiting|January 2003|January 2006||||Phase 1|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||134|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|January 2, 2007|August 14, 2001||||No||https://clinicaltrials.gov/show/NCT00022828||204817|
NCT00027768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069066|Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer|Randomised Trial of Adjuvant Hepatic Intra-Arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|June 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Both|17 Years|N/A|No|||June 2007|September 19, 2013|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027768||204470|
NCT00027820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1641.00|Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer|Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|August 2001|||September 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|N/A|N/A|No|||December 2015|December 14, 2015|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027820||204466|
NCT00028301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302D|Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)|A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus Lopinavir/Ritonavir(LPV/RTV), Each in Combination With Two Nucleosides in Subjects Who Have Experienced Virologic Failure With Prior Protease Inhibitor-Containing HAART Regimen(s)||Bristol-Myers Squibb||Completed|February 2001|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||September 2010|September 10, 2010|December 20, 2001||||||https://clinicaltrials.gov/show/NCT00028301||204433|
NCT00028314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5110|Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients|A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2002|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|13 Years|N/A|No|||July 2013|July 26, 2013|December 20, 2001||||No||https://clinicaltrials.gov/show/NCT00028314||204432|
NCT00023036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010228|Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts|Clinical and Molecular Analysis of Enlarged Vestibular Aqueducts||National Institutes of Health Clinical Center (CC)||Recruiting|August 2001|||||N/A|Observational|N/A|||Anticipated|500|||Both|N/A|99 Years|No|||August 2015|December 31, 2015|August 21, 2001||No||No||https://clinicaltrials.gov/show/NCT00023036||204801|
NCT00024310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068917|Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Trial of Lometrexol Sodium and Paclitaxel Adminsitered Intravenously Every 21 Days in Conjunction With Oral Folic Acid in Patients With Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|September 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|September 16, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024310||204711|
NCT00027989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069104|Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer|An Open-Label, Single-Arm, Phase II Study of Liposomal Doxorubicin (Doxil) and Gemcitabine in the Treatment of Women With Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2004|December 17, 2013|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027989||204454|
NCT00028132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 050|Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel|Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2005|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|December 13, 2001||||||https://clinicaltrials.gov/show/NCT00028132||204445|
NCT00023088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940130|Screening Study for the Department of Rehabilitation Medicine|Rehabilitation Medicine Screening Protocol||National Institutes of Health Clinical Center (CC)||Completed|April 1994|July 2008||||N/A|Observational|N/A||||600|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2008|September 26, 2015|August 22, 2001||No||No||https://clinicaltrials.gov/show/NCT00023088||204797|
NCT00027976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069099|Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses|A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses||University of Alabama at Birmingham|Yes|Withdrawn|December 2001|December 2005|Actual|December 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|N/A|No|||November 2012|August 1, 2013|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027976||204455|
NCT00028145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1025|Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission|Perinatal Core Protocol||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Completed|October 2002|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3090|Samples With DNA|Blood and amniotic fluid|Female|14 Years|N/A|No|Probability Sample|Primary care clinics|October 2014|October 8, 2014|December 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00028145||204444|
NCT00028379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020082|Enhancement of Use-Dependent Plasticity by Somatosensory Stimulation in Chronic Stroke|Enhancement of Use-Dependent Plasticity by Somatosensory Stimulation in Chronic Stroke||National Institutes of Health Clinical Center (CC)||Completed|December 2001|November 2005||||N/A|Interventional|N/A||||52|||Both|N/A|N/A|No|||November 2005|March 3, 2008|December 27, 2001||||No||https://clinicaltrials.gov/show/NCT00028379||204427|
NCT00024388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068928|Chemotherapy in Treating Patients With Metastatic Kidney Cancer|Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion In Patients With Metastatic, Locally Advanced, or Unresectable Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|July 23, 2008|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024388||204705|
NCT00022555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02398|Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma|A Phase I Trial of Combination Bryostatin-1 and Vincristine in HIV-Related B-cell Neoplasms||National Cancer Institute (NCI)||Completed|November 2001|||July 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022555||204838|
NCT00028522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00013|R(+)XK469 in Treating Patients With Advanced Neuroblastoma|Phase I Study Of R(+)XK469 In Patients With Advanced Neuroblastoma||National Cancer Institute (NCI)||Completed|December 2001|||September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|5 Years|20 Years|No|||December 2013|December 13, 2013|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028522||204420|
NCT00028106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020032|131MIBG to Treat Malignant Pheochromocytoma|(131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma||National Institutes of Health Clinical Center (CC)||Completed|December 2001|January 2007||||Phase 2|Interventional|Primary Purpose: Treatment|1|||32|||Both|18 Years|70 Years|No|||August 2008|December 17, 2009|December 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00028106||204447|
NCT00022698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068843|Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer|A Phase II Study of Oral Xeloda in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|March 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2005|July 23, 2008|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022698||204827|
NCT00027482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020066|Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers|Studies of Specific Immune Responses in HIV-Infected and HIV-Uninfected Volunteers||National Institutes of Health Clinical Center (CC)||Completed|December 2001|August 2008||||N/A|Observational|N/A||||2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|September 26, 2015|December 7, 2001||No||No||https://clinicaltrials.gov/show/NCT00027482||204490|
NCT00024349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068921|Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer|2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer||National Cancer Institute (NCI)||Completed|June 2001|April 2012|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|350|||Both|18 Years|N/A|No|||May 2007|December 17, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024349||204708|
NCT00024362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068924|BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery|A Phase II Trial of BBR 3464 as First Line Treatment in Patients With Inoperable, Locally Advanced or Metastatic Adenocarcinoma of the Pancreas||National Cancer Institute (NCI)||Active, not recruiting|May 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2007|July 23, 2008|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024362||204707|
NCT00027872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02980|Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia||National Cancer Institute (NCI)||Completed|October 2001|January 2009|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|65 Years|N/A|No|||March 2013|March 22, 2013|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027872||204462|
NCT00027885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3100|Phase II Bevacizumab + Tax In Advanced Breast Cancer|A Randomized Phase II Study of Bevacizumab in Combination With Docetaxel in Locally Advanced Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|November 2001|August 2010|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|December 7, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027885||204461|
NCT00022789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980|Prevalence of Sleep-Disordered Breathing in Children|Prevalence of Sleep Disordered Breathing in Children||Milton S. Hershey Medical Center|No|Completed|August 2001|November 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|700|||Both|5 Years|12 Years|No|Probability Sample|Random representative population sample of children in elementary school (K-5)|March 2014|March 12, 2014|August 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00022789||204820|
NCT00027534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2840|Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer|A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA||Duke University|No|Completed|January 2002|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027534||204486|
NCT00027547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1586.00|Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia|Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Sibling Donors For Treatment Of Patients With High Risk Acute Lymphocytic Leukemia In Complete Remission||Fred Hutchinson Cancer Research Center||Completed|July 2001|July 2004|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|75 Years|No|||November 2011|November 28, 2011|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027547||204485|
NCT00027833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069082|Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer|Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma||National Cancer Institute (NCI)||Active, not recruiting|December 2001|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|January 3, 2014|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027833||204465|
NCT00028496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02433|Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer|Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas||National Cancer Institute (NCI)||Completed|November 2001|||November 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028496||204422|
NCT00023244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT SW01|Steroid Withdrawal in Pediatric Kidney Transplant Recipients|A Double-Blind Randomized Trial of Steroid Withdrawal in Sirolimus- and Cyclosporine-Treated Primary Transplant Recipients||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|January 2001|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|274|||Both|N/A|20 Years|No|||October 2012|October 26, 2012|August 29, 2001|No|Yes|Effective August 13, 2004: Due to an unanticipated high incidence of post-transplant    lymphoproliferative disorder|No||https://clinicaltrials.gov/show/NCT00023244||204786|
NCT00028119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 034|HIV Incidence and Participation Retention in Pune, India|HPTN HIV Incidence and Participant Retention Protocol, Pune, India||HIV Prevention Trials Network||Completed|August 2002|August 2005|Actual|August 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2||1070|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-uninfected non-sex worker women and HIV-discordant heterosexual couples attending STD        clinics in Pune, India|August 2010|August 18, 2014|December 13, 2001||No||No||https://clinicaltrials.gov/show/NCT00028119||204446|
NCT00027573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-90003|Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer|Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A Phase II Study||Alliance for Clinical Trials in Oncology|No|Completed|October 2001|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|60 Years|No|||July 2015|July 7, 2015|December 7, 2001||No||No||https://clinicaltrials.gov/show/NCT00027573||204483|
NCT00028249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020053|Process and Outcomes of Pain Management|A Randomized Study Evaluating the Process and Outcomes of the Pain and Palliative Care Team Intervention||National Institutes of Health Clinical Center (CC)||Completed|December 2001|December 2005||||N/A|Observational|N/A||||298|||Both|N/A|N/A|No|||December 2005|March 3, 2008|December 17, 2001||||No||https://clinicaltrials.gov/show/NCT00028249||204437|
NCT00028262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010086|Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis|A Combination Therapy With Cystagon and N-Acetylcysteine for INCL Patients||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2001|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Months|3 Years|No|||November 2013|January 16, 2015|December 17, 2001|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00028262||204436|
NCT00028275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020072|Gamma Interferon Therapy for Chronic Hepatitis C|Pilot Studies of Gamma Interferon Therapy for Chronic Hepatitis C||National Institutes of Health Clinical Center (CC)||Completed|December 2001|November 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||November 2003|March 3, 2008|December 18, 2001||||No||https://clinicaltrials.gov/show/NCT00028275||204435|
NCT00028171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0824|Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing|Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|June 23, 2005|December 17, 2001||||No||https://clinicaltrials.gov/show/NCT00028171||204442|
NCT00028184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020078|Role of the Intact Hemisphere in Recovery of Motor Function After Stroke|Role of the Intact Hemisphere in Recovery of Motor Function After Stroke||National Institutes of Health Clinical Center (CC)||Completed|December 2001|December 2004||||N/A|Observational|N/A||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|March 3, 2008|December 17, 2001||||No||https://clinicaltrials.gov/show/NCT00028184||204441|
NCT00022568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068831|Vaccine Therapy in Treating Patients With Metastatic Melanoma|A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma||National Cancer Institute (NCI)||Active, not recruiting|August 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|December 17, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022568||204837|
NCT00022581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03081|Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial of Thalidomide (NSC #66847, IND #48832) for Patients With Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|July 2001|||December 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|August 10, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00022581||204836|
NCT00027586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-284|Imatinib Mesylate in Treating Patients With Metastatic Melanoma|Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma||M.D. Anderson Cancer Center|No|Completed|September 2001|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|N/A|No|||July 2012|July 27, 2012|December 7, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027586||204482|
NCT00028535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01407|Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors|Phase I Trial of Interleukin-12 in Combination With Paclitaxel Plus Herceptin in Patients With Her2-positive Malignancies||National Cancer Institute (NCI)||Completed|November 2001|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028535||204419|
NCT00024479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010227|Natural History of Rheumatic Diseases in Minority Communities|Studies of the Natural History of Rheumatic Disease in Minority Communities||National Institutes of Health Clinical Center (CC)||Recruiting|September 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100000|||Both|18 Years|N/A|No|||January 2016|March 12, 2016|September 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00024479||204698|
NCT00022035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 99-12|Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia|Influenza Vaccine Immunogenicity in Children During and After Therapy for Acute Lymphoblastic Leukemia||Roswell Park Cancer Institute||Completed|August 2000|||November 2002|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|1 Year|20 Years|No|||January 2013|January 30, 2013|August 10, 2001||||No||https://clinicaltrials.gov/show/NCT00022035||204874|
NCT00027664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICRF-C00.204|Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer|Interferon Alpha In Combination With Thalidomide In The Treatment Of Metastatic Renal Cell Carcinoma A Randomized Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|February 2001|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|N/A|No|||March 2002|August 6, 2013|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027664||204477|
NCT00024466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0115 CDR0000068953|Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma|Vaccination In Peripheral Stem Cell Transplant Setting For Multiple Myeloma: The Use Of Autologous Tumor Cells/An Allo PSCT||Sidney Kimmel Comprehensive Cancer Center||Completed|March 2001|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||May 2014|May 1, 2014|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024466||204699|
NCT00027898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02432|Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Study of PS-341 (NSC 681239), Carboplatin, and Etoposide in Patients With Advanced Solid Tumors Refractory to Standard Therapy||National Cancer Institute (NCI)||Completed|January 2002|||January 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|16 Years|N/A|No|||February 2013|February 6, 2013|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027898||204460|
NCT00027599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02427|APC8015 and Bevacizumab in Treating Patients With Prostate Cancer|A Phase II Study Of Prostatic Acid Phosphatase-Pulsed Dendritic Cells (Provenge) In Combination With Bevacizumab In Patients With Serologic Progression Of Prostate Cancer After Definitive Local Therapy||National Cancer Institute (NCI)||Completed|December 2001|||July 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|N/A|N/A|No|||December 2003|February 8, 2013|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027599||204481|
NCT00026494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-088|Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases|A Phase I/II Trial Of Temozolomide And Vinorelbine For Patients With Recurrent Brain Metastases||Memorial Sloan Kettering Cancer Center||Completed|July 2001|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 9, 2001|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00026494||204563|
NCT00027521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069037|Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer|Phase I Study: Electroporation Therapy With Bleomycin For The Treatment Of Pancreatic Cancer||Ichor Medical Systems Incorporated||Withdrawn|December 2000|||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||September 2012|September 17, 2012|December 7, 2001|||Program terminated|No||https://clinicaltrials.gov/show/NCT00027521||204487|
NCT00027105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020044|Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer|Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center||National Institutes of Health Clinical Center (CC)||Completed|November 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|165|||Both|18 Years|85 Years|No|||January 2016|January 13, 2016|November 20, 2001||No||No||https://clinicaltrials.gov/show/NCT00027105||204518|
NCT00026910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980136|Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma|Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|July 1998|May 2002||||N/A|Observational|N/A||||200|||Both|N/A|N/A|No|||May 2002|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026910||204533|
NCT00026975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 AT000428-01P1|Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients|Clinical Outcomes Modeling for Laryngectomy Surgery Patients and Efficacy of Hyperbaric Oxygen Therapy||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||August 2006|August 17, 2006|November 15, 2001||||No||https://clinicaltrials.gov/show/NCT00026975||204528|
NCT00026767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010144|Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients|Surveillance of Invasive Fungal Infections in Bone Marrow/Stem Cell and Solid Organ Transplantation Recipients and Other Immunocompromised Patients: A Prospective Study||National Institutes of Health Clinical Center (CC)||Completed|April 2001|July 2012||||N/A|Observational|N/A|||Actual|217|||Both|N/A|N/A|No|||July 2012|February 19, 2014|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026767||204544|
NCT00027495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000067916|Curcumin for the Prevention of Colon Cancer|Phase I Pharmacokinetic Trial of Curcuminoids Administered in a Capsule Formulation||University of Michigan Cancer Center|Yes|Completed|December 2001|September 2007|Actual|February 2004|Actual|Phase 1|Interventional|Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||December 2012|December 19, 2012|December 7, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027495||204489|
NCT00027508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-01084|Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma|Phase II Study Of ET-743 In Patients With Unresectable Malignant Pleural Mesothelioma||PharmaMar||Terminated|July 2001|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|February 23, 2015|December 7, 2001||Yes|Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained.|No||https://clinicaltrials.gov/show/NCT00027508||204488|
NCT00027066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS028371|Warfarin Versus Aspirin Recurrent Stroke Study|A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke||Columbia University|No|Completed|June 1993|November 2001|Actual|June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2|||2206|||Both|30 Years|85 Years|No|||June 2011|June 16, 2011|November 20, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027066||204521|
NCT00027079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAJOH12964|Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)|||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|September 2001|August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|18 Years|65 Years|No|||December 2007|December 7, 2007|November 20, 2001||||No||https://clinicaltrials.gov/show/NCT00027079||204520|
NCT00029809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000612-01|Chinese Exercise Modalities in Parkinson's Disease|Chinese Exercise Modalities in Parkinson's Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||40|||Both|40 Years|85 Years|No|||July 2006|August 17, 2006|January 23, 2002||||No||https://clinicaltrials.gov/show/NCT00029809||204334|
NCT00026819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020046|Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction|Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model||National Institutes of Health Clinical Center (CC)||Completed|November 2001|November 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||150|||Both|N/A|N/A|No|||November 2003|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026819||204540|
NCT00027261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 039|Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults|A Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of High-Dose Live Recombinant Canarypox ALVAC-HIV Vaccine (vCP1452) in Healthy, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2005|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|110|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|November 29, 2001|No|Yes||||https://clinicaltrials.gov/show/NCT00027261||204506|
NCT00026858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950003|Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts|Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts||National Institutes of Health Clinical Center (CC)||Completed|October 1994|November 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||November 2002|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026858||204537|
NCT00026624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5130|Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC|A Phase I/II Study to Evaluate the Safety and Immunogenicity of the Subcutaneous Administration of ALVAC-HIV vCP1452 Infected Autologous Dendritic Cells Versus the Subcutaneous Administration of ALVAC-HIV vCP1452 To HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2006|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 16, 2012|November 12, 2001||||||https://clinicaltrials.gov/show/NCT00026624||204555|
NCT00030264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2339|Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas|Vinblastine/Methotrexate For Severe Progressive Plexiform Neurofibromas: A Phase II Study||Children's Hospital of Philadelphia|Yes|Active, not recruiting|February 2001|December 2015|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|25 Years|No|||September 2015|September 30, 2015|February 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030264||204302|
NCT00029822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4485|Clinical Trial in Males With BPH (Enlarged Prostate)|Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.||Sanofi||Completed|May 2001|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|1522|||Male|55 Years|N/A|No|||June 2008|June 6, 2008|January 23, 2002||||||https://clinicaltrials.gov/show/NCT00029822||204333|
NCT00027274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020052|Cancer in Inherited Bone Marrow Failure Syndromes|Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study||National Institutes of Health Clinical Center (CC)||Recruiting|November 2001|||||N/A|Observational|N/A|||Anticipated|4000|||Both|N/A|120 Years|Accepts Healthy Volunteers|||December 2015|January 1, 2016|November 29, 2001||No||No||https://clinicaltrials.gov/show/NCT00027274||204505|
NCT00027287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020063|Laser and Medical Treatment of Diabetic Macular Edema|Preliminary Assessment of Laser and Medical Treatment of Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|November 2001|December 2002||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||December 2002|March 3, 2008|November 29, 2001||||No||https://clinicaltrials.gov/show/NCT00027287||204504|
NCT00027430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1981-01|Androgen Replacement Therapy in Women With Hypopituitarism|TheraDerm Administration in Women With Hypopituitarism||FDA Office of Orphan Products Development||Completed|September 2001|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|50 Years|No|||November 2001|March 24, 2015|December 5, 2001||||||https://clinicaltrials.gov/show/NCT00027430||204494|
NCT00027157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000118|Determination of Variances in Exhaled Nitric Oxide Output in Normal Healthy Male Volunteers Consuming High and Low Nitrate/Nitrite Diets|The Determination of Variances in Exhaled Nitric Oxide Output in Normal Healthy Male Volunteers Consuming High and Low Nitrate/Nitrite Diets||National Institutes of Health Clinical Center (CC)||Completed|April 2000|April 2003||||N/A|Observational|N/A||||18|||Male|N/A|N/A|Accepts Healthy Volunteers|||April 2003|March 3, 2008|November 27, 2001||||No||https://clinicaltrials.gov/show/NCT00027157||204514|
NCT00027612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N997D|Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme|Pilot And Phase II Trial Of Irinotecan And Radiation Followed By Irinotecan And BCNU In Glioblastoma Multiforme Patients||Alliance for Clinical Trials in Oncology|No|Completed|July 2002|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027612||204480|
NCT00029835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4735|Obese Patients With Untreated Dyslipidemias|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias|RIO-Lipids|Sanofi||Completed|September 2001|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1033|||Both|18 Years|70 Years|No|||April 2009|April 17, 2009|January 23, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00029835||204332|
NCT00026780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010157|Eligibility Screening for a NCI Pediatric Oncology Branch Research Study|Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI), Pediatric Oncology Branch (POB) Clinical Research Protocols||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2001|||||N/A|Observational|Time Perspective: Prospective|||Actual|1347|||Both|N/A|35 Years|No|||December 2015|March 2, 2016|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026780||204543|
NCT00026793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010158|Assessment of Blood Vessel Density in Kaposi s Sarcoma Lesions|Protocol to Assess Vascularity in Kaposi's Sarcoma Lesions Utilizing Non-Invasive Imaging Techniques||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2001|||||N/A|Observational|Time Perspective: Prospective|||Actual|29|||Both|18 Years|100 Years|No|||September 2015|October 6, 2015|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026793||204542|
NCT00027703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02430|Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma|A Double Blind, Placebo Controlled Randomized Phase II Trial Of Gemcitabine And Cisplatin With Or Without The VEGF Inhibitor Bevacizumab (NSC #704865) In Patients With Malignant Mesotheloma||National Cancer Institute (NCI)||Completed|October 2001|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||December 2012|February 10, 2014|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027703||204474|
NCT00026923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990028|A Phase II Evaluation of Telesurgery Systems|A Phase II Evaluation of Telesurgery Systems||National Institutes of Health Clinical Center (CC)||Completed|January 1999|December 2001||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||December 2001|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026923||204532|
NCT00026936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990116|A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning|A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning||National Institutes of Health Clinical Center (CC)||Completed|May 1999|January 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||140|||Both|N/A|N/A|No|||January 2005|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026936||204531|
NCT00026598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020024|Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease|Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2001|November 2003||||N/A|Observational|N/A||||90|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2003|March 3, 2008|November 10, 2001||||No||https://clinicaltrials.gov/show/NCT00026598||204557|
NCT00027235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0829|Popcorn Lung: the Discovery of a New Disease|Popcorn Lung: the Discovery of a New Disease||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|65 Years|No|||December 2003|June 23, 2005|November 28, 2001||||No||https://clinicaltrials.gov/show/NCT00027235||204508|
NCT00030433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069165|S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial Of Gemcitabine (NSC-613327) And Irinotecan (NSC-616348) In Patients With Untreated Extensive Stage Small Cell Lung Cancer (SCLC)||Southwest Oncology Group|No|Completed|January 2002|November 2008|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|February 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030433||204291|
NCT00026663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000078|Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance|Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer or Normal Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|February 2000|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|March 5, 2016|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026663||204552|
NCT00026728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010073|Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States|The Seroprevalence of Kaposi's Sarcoma Herpesvirus in the United States||National Institutes of Health Clinical Center (CC)||Completed|February 2001|December 2005||||N/A|Observational|N/A||||20169|||Both|N/A|N/A|No|||December 2005|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026728||204547|
NCT00026741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010112|Research in Skin Inflammation|Expression of Chemokine and Chemokine Receptors in Skin in a Model of Delayed-Type Hypersensitivity||National Institutes of Health Clinical Center (CC)||Completed|March 2001|January 2002||||N/A|Observational|N/A||||10|||Both|N/A|N/A|No|||January 2002|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026741||204546|
NCT00027339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5126|Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV|A Phase II Study of the Predictive Value of Pharmacokinetic-Adjusted Phenotypic Susceptibility (C12h/IC50) on Antiretroviral Response to Ritonavir-Enhanced Protease Inhibitors in Subjects With Failure of Previous Protease Inhibitor-Based Regimens||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|53|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|December 4, 2001||||||https://clinicaltrials.gov/show/NCT00027339||204501|
NCT00027716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-073|Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma|A Multi-Institutional, Open-Label, Two-Group, Phase II Study of PS-341 (LDP-341, NSC #681239) in Patients With Advanced or Metastatic Sarcoma||Memorial Sloan Kettering Cancer Center||Completed|October 2001|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027716||204473|
NCT00027391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-2029-01|Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)|Clinical Trials of Albuterol and Oxandrolone in FSH Dystrophy||FDA Office of Orphan Products Development||Completed|September 2001|August 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|80 Years|No|||November 2001|March 24, 2015|December 5, 2001||||||https://clinicaltrials.gov/show/NCT00027391||204497|
NCT00027404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-2026-01|Study of Fluoxetine in Adults With Autistic Disorder|Fluoxetine vs Placebo in Adult Autistic Disorder||FDA Office of Orphan Products Development||Completed|September 2001|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|65 Years|No|||November 2002|March 24, 2015|December 5, 2001||||||https://clinicaltrials.gov/show/NCT00027404||204496|
NCT00027326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020064|Collection of Blood and Urine From Patients Undergoing Radiation Therapy|Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|December 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|450|||Both|18 Years|90 Years|No|||June 2015|December 19, 2015|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00027326||204502|
NCT00026949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990161|Study of Etoposide in Breast Cancer Patients|Pharmacokinetics of Etoposide in Patients With Breast Cancer Receiving High-Dose Etoposide||National Institutes of Health Clinical Center (CC)||Completed|August 1999|August 2004||||N/A|Observational|N/A||||33|||Female|N/A|N/A|No|||August 2004|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026949||204530|
NCT00030628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0300|Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase III Randomized Trial Of The Role Of Whole Brain Radiation Therapy In Addition To Radiosurgery In The Management Of Patients With One To Three Cerebral Metastases||Alliance for Clinical Trials in Oncology|No|Completed|December 2001|||October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030628||204276|
NCT00030641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069185|Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer|Randomized Study of Docetaxel Versus Docetaxel Plus Genasense™ (G3139; Bcl-2 Antisense Oligonucleotide) in Patients With Previously Treated Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|January 3, 2014|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030641||204275|
NCT00030654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-P-0014|Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer|A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy||Radiation Therapy Oncology Group|Yes|Active, not recruiting|October 2002|||February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|120 Years|No|||December 2015|December 11, 2015|February 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030654||204274|
NCT00027144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-117|Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase|A Feasibility and Toxicity Study of Vaccination With HSP70 for the Treatment of Chronic Myelogenous Leukemia in the Chronic Phase||University of Connecticut Health Center||Completed|December 2000|October 2002||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||November 2001|June 23, 2005|November 27, 2001||||||https://clinicaltrials.gov/show/NCT00027144||204515|
NCT00026832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020047|Examination of Brain Serotonin Receptors in Patients With Mood Disorders|Serotonin1A Receptor and Serotonin Transporter Imaging In Mood Disorders||National Institutes of Health Clinical Center (CC)||Completed|October 2001|November 2012||||N/A|Observational|N/A|||Actual|214|||Both|18 Years|60 Years|No|||November 2012|August 20, 2013|November 14, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026832||204539|
NCT00027794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30001|Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer|Radical Prostatectomy for Locally Advanced Prostate Cancer. A Feasibility Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2001|||January 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Male|N/A|70 Years|No|||September 2012|September 20, 2012|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027794||204468|
NCT00029939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020109|Brain Activity During Production of Movement|Real-Time Analysis of Scalp Electroencephalography and Magnetoencephalography During Production of Human Voluntary Movement||National Institutes of Health Clinical Center (CC)||Completed|January 2002|November 2010||||N/A|Observational|N/A|||Actual|140|||Both|18 Years|N/A|No|||November 2010|September 26, 2015|January 26, 2002||No||No||https://clinicaltrials.gov/show/NCT00029939||204325|
NCT00027118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020045|Morbidity After Diagnosis and Treatment of Breast Cancer Patients|A Prospective (Cohort) Study to Identify Factors Affecting Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center (BCC)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|February 2, 2016|November 20, 2001||No||No||https://clinicaltrials.gov/show/NCT00027118||204517|
NCT00027131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-062|Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70|Vaccination Against High Risk Breast Cancer With Autologous Tumor-Derived Heat Shock Protein 70-Peptide Complexes (HSP70)||University of Connecticut Health Center||Terminated|December 2000|October 2002||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Female|18 Years|N/A|No|||October 2008|October 7, 2008|November 27, 2001|||difficulty with accrual|||https://clinicaltrials.gov/show/NCT00027131||204516|
NCT00026676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000130|Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine|Retrospective Analysis of HIV-1 RNA Levels in Pediatric HIV-Infected Patients Treated With Didanosine||National Institutes of Health Clinical Center (CC)||Completed|May 2000|April 2003||||N/A|Observational|N/A||||82|||Both|N/A|N/A|No|||April 2003|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026676||204551|
NCT00029796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000205-01A1|Isoflavones and Acute-phase Response in Chronic Renal Failure|Isoflavones and Acute-phase Response in Chronic Renal Failure||National Center for Complementary and Integrative Health (NCCIH)||Completed||September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|70 Years|No|||March 2013|March 21, 2013|January 23, 2002||||No||https://clinicaltrials.gov/show/NCT00029796||204335|
NCT00027300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1801|Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis||Biogen|Yes|Completed|November 2001|January 2005|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|900|||Both|18 Years|50 Years|No|||June 2009|June 15, 2009|November 30, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027300||204503|
NCT00026871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970129|Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System|Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System||National Institutes of Health Clinical Center (CC)||Completed|July 1997|May 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||May 2006|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026871||204536|
NCT00026884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970147|Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease|Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease||National Institutes of Health Clinical Center (CC)||Recruiting|July 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Both|1 Year|65 Years|Accepts Healthy Volunteers|||April 2015|January 8, 2016|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026884||204535|
NCT00027807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069072|Biological Therapy in Treating Women With Stage IV Breast Cancer|Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 2001|March 2013|Actual|September 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|120 Years|No|||February 2016|February 15, 2016|December 7, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00027807||204467|
NCT00030576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069178 (PHL-002)|Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase I/II Study Of OSI-774 In Combination With Cisplatin In Patients With Recurrent Or Metastatic Squamous Cell Cancer Of The Head And Neck||University Health Network, Toronto|Yes|Completed|November 2001|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|February 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030576||204280|
NCT00027781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16006-30005|MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy|Open Label Phase II Study of MEN-10755 Administered Every 3 Weeks in Patients With Progressive Hormone Refractory Prostate Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 2001|||March 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|37|||Male|18 Years|N/A|No|||July 2012|July 23, 2012|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027781||204469|
NCT00027053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAFRI13243|Trazodone for Sleep Disturbance in Early Alcohol Recovery|Trazodone for Sleep Disturbance - Early Alcohol Recovery|SIESTA|Rhode Island Hospital|No|Completed|June 2002|June 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|65 Years|No|||March 2006|May 11, 2010|November 19, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027053||204522|
NCT00026962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990180|Effects of Raloxifene on Hormone Levels|Assessment of the Effects of Raloxifene on Salivary Estradiol and Progesterone Levels||National Institutes of Health Clinical Center (CC)||Completed|September 1999|August 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Female|N/A|N/A|No|||August 2003|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026962||204529|
NCT00030381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02443|Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis|Phase I Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL)||National Cancer Institute (NCI)||Terminated|December 2001|||January 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|February 14, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00030381||204295|
NCT00030043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-001969-01|An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors|Penetrating Auditory Brainstem Implant for Neurofibromatosis 2||FDA Office of Orphan Products Development||Completed|September 2001|August 2003||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||January 2002|March 24, 2015|January 30, 2002||||No||https://clinicaltrials.gov/show/NCT00030043||204318|
NCT00026845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790111, CDR0000256918|Comparison of Surgeries, With or Without Radiation Therapy, in Treating Women With Stage I or Stage II Breast Cancer|The Treatment Of Clinical Stage I And II Carcinoma Of The Breast With Mastectomy And Axillary Dissection Versus Excisional Biopsy, Axillary Dissection And Definitive Irradiation||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 1979|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|237|||Female|N/A|N/A|No|||September 2011|September 29, 2011|November 14, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00026845||204538|
NCT00027443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1986-01|Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis|Giant Cell Myocarditis Treatment Trial Pilot Study||FDA Office of Orphan Products Development||Completed|August 2001|July 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||October 2001|March 24, 2015|December 5, 2001||||||https://clinicaltrials.gov/show/NCT00027443||204493|
NCT00027456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020060|Leptin to Treat Severe Insulin Resistance - Pilot Study|Efficacy of Leptin in Severe Insulin Resistance: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|November 2001|December 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||2|||Both|N/A|N/A|No|||December 2002|March 3, 2008|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027456||204492|
NCT00030277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOCUS-G000280|High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer|Feasibility Study for Locally Recurrent Prostate Cancer Treatment With HIFU Using the SONABLATE System||National Cancer Institute (NCI)||Completed|October 2001|December 2008|Actual|October 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Male|40 Years|80 Years|No|||December 2008|July 9, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030277||204301|
NCT00030290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOCUS-G000276|Ultrasound in Treating Patients With Prostate Cancer Confined to the Prostate|Feasibility Study for Organ Confined Prostate Cancer Treatment With HIFU Using SONABLATE System||National Cancer Institute (NCI)||Completed|October 2001|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|40 Years|80 Years|No|||December 2008|July 9, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030290||204300|
NCT00027196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980100|Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease|Clinical Correlates of Molecular Defects in Familial Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|April 1998|April 2003||||N/A|Observational|N/A||||9999999|||Both|N/A|N/A|No|||April 2003|March 3, 2008|November 27, 2001||||No||https://clinicaltrials.gov/show/NCT00027196||204511|
NCT00026897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980033|Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer|Trafficking of Indium-111-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer||National Institutes of Health Clinical Center (CC)||Completed|December 1997|December 2002||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||December 2002|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026897||204534|
NCT00027352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 065|A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)|A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Time Perspective: Prospective||||6000|||Both|13 Years|N/A|No|||December 2008|November 24, 2009|December 4, 2001||||No||https://clinicaltrials.gov/show/NCT00027352||204500|
NCT00027365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 041|An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV|A Phase I Safety and Immunogenicity Trial of a Combination Vaccine (NefTat and gp120w61d) Formulated With AS02A (GlaxoSmithKline Biologicals) Given Intramuscularly in HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2003|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||84|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|December 4, 2001||||||https://clinicaltrials.gov/show/NCT00027365||204499|
NCT00027040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5114s|A Study of Decreased Mental Function Associated With HIV|HIV-Associated Cognitive Impairment and Oxidative Stress: An In Vivo Proton Magnetic Resonance Spectroscopy Study of Cerebral Injury||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2005|Actual|||N/A|Interventional|Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||October 2012|January 15, 2015|November 16, 2001||||No||https://clinicaltrials.gov/show/NCT00027040||204523|
NCT00027417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1971-01|Study of Triostat in Infants During Heart Surgery|Triostat in Children During CardioPulmonary Bypass (CPB)||Seattle Children's Hospital|Yes|Completed|April 2001|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|195|||Both|N/A|2 Years|No|||August 2013|August 1, 2013|December 5, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00027417||204495|
NCT00027209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS038473|Hormone Replacement in Menopausal Women With Epilepsy|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed||||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Female|N/A|N/A|No|||November 2005|May 12, 2006|November 28, 2001||||No||https://clinicaltrials.gov/show/NCT00027209||204510|
NCT00027222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-83|The Early Treatment for Retinopathy of Prematurity Study (ETROP)|The Early Treatment for Retinopathy of Prematurity Study (ETROP)||National Eye Institute (NEI)||Active, not recruiting|October 2001|||||Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|N/A|42 Days|No|||December 2003|June 23, 2005|November 28, 2001||||No||https://clinicaltrials.gov/show/NCT00027222||204509|
NCT00027170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020050|Technical Development of Cardiovascular Magnetic Resonance Imaging|Technical Development of Cardiovascular Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Recruiting|November 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|7560|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 9, 2015|November 27, 2001||No||No||https://clinicaltrials.gov/show/NCT00027170||204513|
NCT00026754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010129|Screening Patients for NCI Protocol Eligibility|Eligibility Screening and Tissue Procurement for the National Cancer Institute Center for Cancer Research Clinical Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|March 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|15000|||Both|N/A|100 Years|No|||November 2015|December 15, 2015|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026754||204545|
NCT00030238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020100|Supplemental Calcium in Overweight People|Supplemental Calcium in Overweight Out-Patients||National Institutes of Health Clinical Center (CC)||Completed|February 2002|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|540|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|February 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030238||204303|
NCT00025064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-HD-2000-02|Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma|Protocol For The Treatment Of Children And Adolescents With Hodgkin's Disease||National Cancer Institute (NCI)||Active, not recruiting|January 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|260|||Both|N/A|17 Years|No|||December 2002|August 6, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025064||204667|
NCT00030056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-002016|GM-CSF in Patients With Pulmonary Alveolar Proteinosis|Trial of GM-CSF for Alveolar Proteinosis||FDA Office of Orphan Products Development||Terminated|September 2001|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|70 Years|No|||January 2002|March 24, 2015|January 30, 2002||||||https://clinicaltrials.gov/show/NCT00030056||204317|
NCT00030173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOS-101|A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors|A Phase 1, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Epothilone D in Patients With Advanced Solid Tumors||Bristol-Myers Squibb||Completed|October 2001|June 2003|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|85 Years|No|||January 2009|January 7, 2009|February 7, 2002||||||https://clinicaltrials.gov/show/NCT00030173||204308|
NCT00030511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-05991|Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer|A Phase II Study of Chronomodulated Preoperative Infusional Chemoradiation for Biliary Tract Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|October 2001|||July 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2012|July 13, 2012|February 14, 2002|||low accrual|No||https://clinicaltrials.gov/show/NCT00030511||204285|
NCT00029718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020104|Interhemispheric Interactions Associated With Performance of Voluntary Movements in Patients With Stroke Motor Disability|Interhemispheric Interactions Associated With Performance of Voluntary Movements in Patients With Stroke Motor Disability||National Institutes of Health Clinical Center (CC)||Completed|January 2002|November 2011||||N/A|Observational|N/A|||Actual|57|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2011|September 26, 2015|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00029718||204341|
NCT00024453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-SC-1999-01|Teicoplanin in Treating Septicemia in Patients Who Are Receiving Chemotherapy Through a Central Venous Catheter|The Use of Teicoplanin in the Treatment of Septicaemia Caused by Coagulase-Negative Staphylococci - A Randomized Study Comparing Bolus Injection With Infused and/or Line-Locked Teicoplanin||National Cancer Institute (NCI)||Active, not recruiting|February 1999|||December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|1360|||Both|N/A|N/A|No|||June 2009|August 6, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024453||204700|
NCT00030121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-001|Carperitide in Acute Respiratory Distress Syndrome (ARDS)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Evaluation of the Safety and Efficacy of Carperitide Infusion in Patients With ARDS||Suntory Pharmaceutical||Completed|December 1999|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2008|February 19, 2008|January 31, 2002||||||https://clinicaltrials.gov/show/NCT00030121||204312|
NCT00025649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068982|Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma|European Infant Neuroblastoma Study - Stage 2, 3, 4, and 4S; MYCN Amplified Tumors||National Cancer Institute (NCI)||Completed|July 1999|March 2009|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||December 2001|September 16, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025649||204622|
NCT00025662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010162|Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS|Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using RFT5-SMPT-dgA,Specific Anti-IL-2 Receptor Immunotoxin: Reducing GVHD Risk Associated With HLA-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in Older Adults||National Institutes of Health Clinical Center (CC)|Yes|Completed|May 2001|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|No|||December 2011|December 9, 2011|October 11, 2001|No|Yes||No|April 20, 2011|https://clinicaltrials.gov/show/NCT00025662||204621|
NCT00025727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316C|Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure|A Phase III, Randomized, Multicenter, Parallel Group, Open-Label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/Ritonavir (700mg/100mg Twice Daily or 1400mg/200mg Once Daily) Versus Lopinavir/Ritonavir (400mg/100mg Twice Daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure||NIH AIDS Clinical Trials Information Service||Active, not recruiting|May 2001|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||330|||Both|13 Years|N/A|No|||June 2002|June 23, 2005|October 15, 2001||||No||https://clinicaltrials.gov/show/NCT00025727||204616|
NCT00030342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STLMC-IMM-0104|Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer|A Phase I/II Study Of Interleukin-12-Primed Activated T Cells In Combination With 5FU, GM-CSF And Interferon Alfa-2b In Metastatic Renal Cell Carcinoma Or Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|November 2001|January 2008|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2008|June 25, 2013|February 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030342||204298|
NCT00030602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069181|Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer|A Phase 2 Study Of Prostate Specific Antigen-3 (PSA-3) (NSC # 694155) With Montanide (NSC #675756) Vaccination In Patients With Prostate Cancer Recurrent||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||March 2002|February 6, 2009|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030602||204278|
NCT00030615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02727|Decitabine in Treating Patients With Advanced Solid Tumors|A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|December 2001|||September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|February 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030615||204277|
NCT00024687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS1PE-002|Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses|||INSYS Therapeutics Inc||Withdrawn|November 2000|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|September 24, 2001|||Support withdrawn - Study continued by NCI - see record NCT00006981|||https://clinicaltrials.gov/show/NCT00024687||204683|
NCT00024921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0805|The Genetics of Kidneys in Diabetes (GoKinD) Study|The Genetics of Kidneys in Diabetes (GoKinD) Study||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|N/A|||Anticipated|2100|||Both|18 Years|54 Years|No|||December 2003|September 5, 2013|October 5, 2001||||No||https://clinicaltrials.gov/show/NCT00024921||204676|
NCT00024934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020009|B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency|A Phase I Dose Escalation Study of B-Lymphocyte Stimulator (BLyS) Administered Subcutaneously in Patients With Selective IgA Deficiency||National Institutes of Health Clinical Center (CC)||Completed|October 2001|August 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||August 2004|July 10, 2006|October 9, 2001||||No||https://clinicaltrials.gov/show/NCT00024934||204675|
NCT00024960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020008|Dopamine Function in Developmental Stuttering|Assessment of Pre- and Post-Synaptic Dopamine Function in Developmental Stuttering Using 11C-Raclopride and Positron Emission Tomography||National Institutes of Health Clinical Center (CC)||Completed|October 2001|October 2010||||N/A|Observational|N/A|||Actual|12|||Both|18 Years|55 Years|No|||October 2010|October 30, 2010|October 9, 2001||No||No||https://clinicaltrials.gov/show/NCT00024960||204674|
NCT00024986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020006|Tenofovir Disoproxil Fumarate to Treat Pediatric HIV|A Phase I Study of Tenofovir Disoproxil Fumarate (PMPA Prodrug), A Novel Nucleotide Analog Reverse Transcriptase Inhibitor in Children With HIV Infection||National Institutes of Health Clinical Center (CC)||Completed|October 2001|September 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||September 2005|March 3, 2008|October 10, 2001||||No||https://clinicaltrials.gov/show/NCT00024986||204673|
NCT00030537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069175|Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Pilot Study to Evaluate Epidermal Growth Factor Receptor Signaling After Treatment With Oral OSI-774 in Patients With Locally Advanced or Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|November 2001|March 2003|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2002|June 17, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030537||204283|
NCT00030719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069191|Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma|High Risk Neuroblastoma Study 1 Of Siop-Europe||National Cancer Institute (NCI)||Recruiting|December 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|175|||Both|1 Year|20 Years|No|||August 2010|June 23, 2014|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030719||204269|
NCT00025051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068840|Celecoxib in Preventing Skin Cancer|A Phase II, Double-Blind, Placebo-Controlled Clinical Trial To Assess Celecoxib As A Chemopreventive Agent Inhibiting UV-Induced Erythema And Cutaneous Carcinogenesis As Assessed Through Surrogate Biological Markers In Biopsied Skin After Exposure Of Skin In Normal Volunteers Ages 20-60 Years Old With Fitzpatrick Type I, II, III And IV Skin To UV-Radiation From Artificial Light Sources||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|0|||Both|20 Years|60 Years|No|||December 2006|March 21, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025051||204668|
NCT00029731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1978-01|Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients|Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease||FDA Office of Orphan Products Development||Completed|August 2001|July 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Anticipated|30|||Both|5 Years|N/A|No|||January 2002|March 24, 2015|January 21, 2002||||||https://clinicaltrials.gov/show/NCT00029731||204340|
NCT00029848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4736|Obese Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes|RIO-Diabetes|Sanofi||Completed|October 2001|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1045|||Both|18 Years|70 Years|No|||April 2009|April 17, 2009|January 23, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00029848||204331|
NCT00026806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010203|Long-Term Survival With HIV: Psychological and Behavioral Factors Associated With the Transition From Adolescence to Young Adulthood|Long-Term Survival With HIV: A Study of the Psychological and Behavioral Factors Associated With the Transition From Adolescence To Young Adulthood||National Institutes of Health Clinical Center (CC)||Completed|July 2001|June 2005||||N/A|Observational|N/A||||55|||Both|N/A|N/A|No|||June 2005|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026806||204541|
NCT00024336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-CNS-1999-06|Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma|Treatment of Children With Newly Diagnosed Diffuse Pontine Gliomas Using Conventional Radiotherapy and High Dose Tamoxifen||National Cancer Institute (NCI)||Active, not recruiting|August 1999|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|19 Years|No|||December 2006|August 6, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024336||204709|
NCT00026546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020036|Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers|A Behavioral and Functional Neuroimaging Study of Inhibitory Motor Control||National Institutes of Health Clinical Center (CC)||Completed|November 2001|||||N/A|Observational|N/A|||Actual|189|||Both|8 Years|17 Years|No|||June 2015|June 19, 2015|November 9, 2001||No||No||https://clinicaltrials.gov/show/NCT00026546||204560|
NCT00030134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020116|Data Collection in Women With Fabry Disease|A Study to Collect Normative Data in Female Patients With Fabry Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2002|February 2003||||N/A|Observational|N/A||||60|||Female|N/A|N/A|No|||February 2003|March 3, 2008|February 2, 2002||||No||https://clinicaltrials.gov/show/NCT00030134||204311|
NCT00030667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01869|Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood|A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors||National Cancer Institute (NCI)||Completed|May 2002|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|30 Years|No|||December 2013|April 14, 2015|February 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030667||204273|
NCT00030186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0701a/202/ON/US|Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation|An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations||Teva Pharmaceutical Industries||Completed|January 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|February 7, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030186||204307|
NCT00025714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020014|Study of Specimens Obtained During Epilepsy Surgery|Research Study of Specimens Obtained During Epilepsy Surgery||National Institutes of Health Clinical Center (CC)||Recruiting|October 2001|||||N/A|Observational|N/A|||Anticipated|120|||Both|4 Years|N/A|No|||February 2016|March 10, 2016|October 11, 2001||No||No||https://clinicaltrials.gov/show/NCT00025714||204617|
NCT00029913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 403|A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials|A Multi-Site Evaluation of Virologic, Immunologic, and Clinical Natural History of Participants Enrolled in Phase I and Phase II HIV-1 Vaccine Protocols or HIV-1 Vaccine Preparedness Cohorts Who Develop HIV-1 Infection Subsequent to Trial Enrollment||HIV Vaccine Trials Network||Completed|April 2002|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|54|||Both|N/A|N/A|No|Non-Probability Sample|Participants who were enrolled in HIV preventive vaccine clinical trials and became HIV        infected as a result of the vaccine.|August 2010|August 31, 2010|January 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00029913||204327|
NCT00029926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020114|Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity|A Pilot Study of F-18FDG Positron Emission Tomography (PET) to Assess the Distribution of Activated Lymphocytes in Systemic Lupus Erythematosus (SLE)||National Institutes of Health Clinical Center (CC)||Completed|January 2002|November 2002||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||November 2002|March 3, 2008|January 26, 2002||||No||https://clinicaltrials.gov/show/NCT00029926||204326|
NCT00030355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069158|Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia|A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia||National Cancer Institute (NCI)||Withdrawn||||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|12 Years|N/A|No|||September 2007|March 21, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030355||204297|
NCT00024791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010260|Eye-Hand Coordination in Children With Spastic Diplegia|Neurophysiology of Motor Disorders in Spastic Diplegia||National Institutes of Health Clinical Center (CC)||Completed|September 2001|September 2005||||N/A|Observational|N/A||||144|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|September 27, 2001||||No||https://clinicaltrials.gov/show/NCT00024791||204682|
NCT00030446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I149|Erlotinib and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Study Of OSI-774 (NSC 718781) Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer||Canadian Cancer Trials Group||Completed|January 2002|December 2009|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2010|November 7, 2010|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030446||204290|
NCT00026650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000074|Follow Up of Patients Treated With Radiotherapy|Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy||National Institutes of Health Clinical Center (CC)||Recruiting|February 2000|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|June 5, 2015|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026650||204553|
NCT00030420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069164|Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer|Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 2001|February 2008|Actual|May 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|February 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030420||204292|
NCT00025181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068934 (10M-00-4)|Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery|An Open-label Study Of MDX-CTLA4 In Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Resected Stage III Or Stage IV Melanoma||University of Southern California|Yes|Completed|October 2001|June 2005|Actual|January 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|19|||Both|N/A|N/A|No|||May 2014|May 20, 2014|October 11, 2001|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00025181||204658|
NCT00030524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069174|ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients With Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy||The University of Texas Health Science Center at San Antonio||Completed|January 2002|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2012|October 26, 2012|February 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030524||204284|
NCT00030693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02455|Vaccine Therapy in Treating Patients With Metastatic Solid Tumors|Intra-Lesional rF-B7.1 Versus rF-Tricom Vaccine In The Treatment Of Metastatic Cancer||National Cancer Institute (NCI)||Terminated|December 2001|||April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|February 14, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00030693||204271|
NCT00030147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020120|Raloxifene and Rimostil for Perimenopause-Related Depression|The Efficacy of Phytoestrogens and Selective Estrogen Receptor Modulators in Perimenopause-Related Depression||National Institutes of Health Clinical Center (CC)||Completed|February 2002|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|65|||Female|40 Years|60 Years|No|||May 2015|June 24, 2015|February 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030147||204310|
NCT00030199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020119|Brain Control of Blinking|Cortical Control of Voluntary Blinking||National Institutes of Health Clinical Center (CC)||Completed|February 2002|February 2004||||N/A|Observational|N/A||||10|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2004|March 3, 2008|February 7, 2002||||No||https://clinicaltrials.gov/show/NCT00030199||204306|
NCT00024440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068932|Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|July 2001|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2003|January 3, 2014|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024440||204701|
NCT00029861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4743|Obese Patients With or Without Comorbidities (RIO-North America)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities||Sanofi||Completed|August 2001|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|3045|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|January 23, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00029861||204330|
NCT00030004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000121-01|Pilot Study of Spinal Manipulation for Chronic Neck Pain|Pilot Study of Spinal Manipulation for Chronic Neck Pain||National Center for Complementary and Integrative Health (NCCIH)||Terminated|May 2000|April 2001||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||July 2006|August 17, 2006|January 29, 2002||||No||https://clinicaltrials.gov/show/NCT00030004||204320|
NCT00030498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01868|Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction|Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction||National Cancer Institute (NCI)||Completed|December 2001|||July 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|February 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030498||204286|
NCT00025454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068963|R115777 in Treating Patients With Advanced Solid Tumors|Phase I Trial of R115777 (NSA 702818) in Advanced Malignant Solid Tumors||City of Hope Medical Center||Completed|August 2001|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|February 5, 2010|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025454||204637|
NCT00025467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02420|Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|September 2001|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|N/A|N/A|No|||January 2013|January 23, 2013|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025467||204636|
NCT00030030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000277-01|Evaluating Silymarin for Chronic Hepatitis C|Evaluating Silymarin for Chronic Hepatitis C||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2000|June 2002||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||||||||July 2006|August 17, 2006|January 30, 2002||||No||https://clinicaltrials.gov/show/NCT00030030||204319|
NCT00030589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069179|Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma|A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|February 2001|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2003|December 17, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030589||204279|
NCT00030459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS-MESO-1|Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma|Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma||National Cancer Institute (NCI)||Active, not recruiting|November 2000|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2003|August 6, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030459||204289|
NCT00030472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069168|Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix|A Phase II Evaluation of Liposomal Doxorubicin (Doxil) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix||Gynecologic Oncology Group||Terminated|December 2001|||October 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||September 2004|April 10, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030472||204288|
NCT00030485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I148|Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer|A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium||National Cancer Institute (NCI)||Completed|January 2002|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2011|January 24, 2014|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030485||204287|
NCT00030563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069177|Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver|A Phase II Study Of Adjuvant Intravenous Irinotecan Following Resection With Or Without Radiofrequency Ablation (RFA), Of Hepatic Metastases From Colorectal Carcinoma||University of Washington||Completed|May 2001|October 2005|Actual|October 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2012|November 28, 2012|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030563||204281|
NCT00024804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010184|Evaluation and Treatment of Skeletal Diseases|Evaluation and Treatment of Bone and Mineral Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|September 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|2 Months|N/A|No|||August 2015|August 28, 2015|September 28, 2001||No||No||https://clinicaltrials.gov/show/NCT00024804||204681|
NCT00024817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|986|Energy Expenditure, Diet and Body Fat in Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2002|Actual|||N/A|Observational|N/A|||||||Both|8 Years|15 Years|No|||August 2004|March 10, 2016|September 28, 2001||||No||https://clinicaltrials.gov/show/NCT00024817||204680|
NCT00030706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069190|Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Study Of Epothilone B Analogue BMS-247550 In Relapse And/Or Refractory Stage III Or IV Ovarian Epithelial Cancer, Following Front-Line Treatment With Platinum Plus Taxane-Based Chemotherapy||National Cancer Institute (NCI)||Active, not recruiting|November 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|75 Years|No|||February 2006|July 23, 2008|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030706||204270|
NCT00030407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069163|Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer|Evaluation Of Celecoxib In Combination With Weekly Docetaxel In Elderly (70 Years) Or Poor Performance Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Barbara Ann Karmanos Cancer Institute|No|Completed|October 2001|April 2009|Actual|September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|February 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030407||204293|
NCT00025311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068949|Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain|A Phase I Study Of Seven Day Continuous Intrathecal/Intraventricular Infusion Of Topotecan For Patients With Recurrent, Progressive Or Refractory Leptomingeal Disease||New York University School of Medicine||Completed|May 2001|||October 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||March 2003|November 8, 2012|October 11, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00025311||204648|
NCT00025324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068950|Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors|Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol||National Cancer Institute (NCI)||Active, not recruiting|December 2000|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||December 2004|December 17, 2013|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025324||204647|
NCT00029952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930169|Long Term Post Operative Follow-Up of Cushing Syndrome|Long-Term Post-Operative Follow-Up of Cushing Syndrome||National Institutes of Health Clinical Center (CC)||Completed|July 1993|September 2004||||N/A|Observational|N/A||||500|||Both|N/A|N/A|No|||September 2004|March 3, 2008|January 26, 2002||||No||https://clinicaltrials.gov/show/NCT00029952||204324|
NCT00030160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schmitzm (completed)|Strength Training for Obesity Prevention|Strength Training for Obesity Prevention||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2002|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||160|||Female|25 Years|44 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|February 7, 2002||||No||https://clinicaltrials.gov/show/NCT00030160||204309|
NCT00026559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010185|Effects of Arousal and Stress in Anxiety|Effects of Arousal and Stress on Classical Conditioning||National Institutes of Health Clinical Center (CC)||Recruiting|June 2001|||||N/A|Observational|N/A|||Anticipated|1387|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|December 17, 2015|November 10, 2001||No||No||https://clinicaltrials.gov/show/NCT00026559||204559|
NCT00026585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020037|Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder|A Double-Blind Study Examining the Efficacy of the Protein Kinase C Inhibitor Tamoxifen in the Treatment of Acute Mania||National Institutes of Health Clinical Center (CC)||Completed|November 2001|November 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||50|||Male|18 Years|65 Years|No|||May 2008|October 31, 2009|November 10, 2001||||No||https://clinicaltrials.gov/show/NCT00026585||204558|
NCT00030212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020121|Immune Abnormalities in Sporadic Inclusion Body Myositis|Study of Immune Dysregulation in Patients With Sporadic Inclusion Body Myositis (s-IBM)||National Institutes of Health Clinical Center (CC)||Completed|February 2002|December 2007||||N/A|Observational|N/A||||80|||Both|25 Years|80 Years|No|||December 2007|March 5, 2008|February 7, 2002||||No||https://clinicaltrials.gov/show/NCT00030212||204305|
NCT00024245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-01014|10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors|Phase I and Clinical Pharamcologic Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Combination With Probenecid in Adults With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|May 2001|April 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|June 25, 2013|September 13, 2001||||No||https://clinicaltrials.gov/show/NCT00024245||204716|
NCT00024258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-042|Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors|Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|March 2001|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|40 Years|No|||October 2015|October 22, 2015|September 13, 2001|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00024258||204715|
NCT00030095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069022|2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of 2-Methoxyestradiol (2ME2), (NSC-659853) An Angiogenesis Inhibitor, In Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|September 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|April 29, 2015|January 30, 2002||||||https://clinicaltrials.gov/show/NCT00030095||204314|
NCT00030108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020031|Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy|Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias||National Institutes of Health Clinical Center (CC)||Completed|November 2001|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|2 Years|21 Years|No|||March 2012|March 14, 2012|January 30, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00030108||204313|
NCT00030550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 01-16|Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes||Roswell Park Cancer Institute||Completed|September 2001|||June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 30, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030550||204282|
NCT00030225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-202|Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure|Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure||Vital Therapies, Inc.|Yes|Completed|January 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|50 Years|No|||July 2012|July 24, 2012|February 11, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030225||204304|
NCT00030368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01408|Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Study of PS-341 in Combination With Paclitaxel in Metastatic Solid Tumors||National Cancer Institute (NCI)||Completed|November 2001|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|February 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030368||204296|
NCT00025558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068973|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer|Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease||New York University School of Medicine||Completed|October 2000|||May 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|1 Year|49 Years|No|||March 2011|March 25, 2011|October 11, 2001||||No||https://clinicaltrials.gov/show/NCT00025558||204629|
NCT00024830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|987|Peer-Based Skills Training to Enhance Teen Weight Loss|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2002|Actual|||N/A|Observational|N/A|||||||Both|13 Years|16 Years|No|||October 2005|March 15, 2016|September 28, 2001||||No||https://clinicaltrials.gov/show/NCT00024830||204679|
NCT00030303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069127|Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia|A Feasibility And Toxicity Study Of Vaccination With HSP70 For The Treatment Of Chronic Myelogenous Leukemia In Chronic Phase||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|June 4, 2011|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030303||204299|
NCT00030680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62991-22998|Radiation Therapy in Treating Patients With Aggressive Fibromatoses|Phase II Pilot Study Of Moderate Dose Radiotherapy For Inoperable Aggressive Fibromatoses||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 2001|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|44|||Both|16 Years|N/A|No|||August 2013|August 26, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030680||204272|
NCT00024843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|988|Family Based Interventions: Preschool Children and Parent|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|August 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|February 23, 2016|September 28, 2001||||No||https://clinicaltrials.gov/show/NCT00024843||204678|
NCT00024908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020001|Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex|Testing A Model of the Representational Knowledge Stored in the Human Prefrontal Cortex||National Institutes of Health Clinical Center (CC)||Completed|October 2001|April 2010||||N/A|Observational|N/A|||Actual|949|||Both|6 Years|90 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|October 4, 2001||No||No||https://clinicaltrials.gov/show/NCT00024908||204677|
NCT00030394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01867|Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia||National Cancer Institute (NCI)||Completed|September 2002|||October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|N/A|21 Years|No|||January 2013|January 16, 2013|February 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030394||204294|
NCT00026702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000107|Search for New Methods to Detect Acute Renal Failure|Search for Novel Methods to Detect Acute Renal Failure||National Institutes of Health Clinical Center (CC)||Recruiting|April 2000|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|640|||Both|3 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026702||204549|
NCT00026715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000148|Evaluation of New Test Method to Measure Kidney Function|Validation of Fast Methods to Measure Glomerular Filtration Rate||National Institutes of Health Clinical Center (CC)||Completed|June 2000|June 2002||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||June 2002|March 3, 2008|November 14, 2001||||No||https://clinicaltrials.gov/show/NCT00026715||204548|
NCT00029874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1968-01|Minocycline in Patients With Huntington's Disease|Minocycline Dosing and Safety in Huntington's Disease||FDA Office of Orphan Products Development||Completed|September 2001|August 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||63|||Both|18 Years|N/A|No|||December 2004|March 24, 2015|January 24, 2002||||||https://clinicaltrials.gov/show/NCT00029874||204329|
NCT00029120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020095|Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder|MRI Contrast Imaging in the Evaluation and Follow-up of Patients With Memory Disorder and Healthy Controls||National Institutes of Health Clinical Center (CC)||Completed|December 2001|April 2008||||N/A|Observational|N/A||||450|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|January 5, 2002||||No||https://clinicaltrials.gov/show/NCT00029120||204379|
NCT00028847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069141|Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia|A Dose-ranging Phase I/II Study of STI571 in Combination With Cytarabin in Patients With First Chronic Phase Chronic Myeloid Leukemia||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|65 Years|No|||August 2011|September 16, 2013|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028847||204396|
NCT00028860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TULCC-RM-002|Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer|A Phase II Trial Of Adjuvant Chemotherapy For High Risk Transitional Cell Carcinoma Of The Urothelium||National Cancer Institute (NCI)||Completed|October 2001|October 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2004|July 9, 2013|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028860||204395|
NCT00028574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069107|Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer|A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Management of Hot Flashes in Men||Alliance for Clinical Trials in Oncology|Yes|Completed|December 2001|April 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|223|||Male|18 Years|N/A|No|||September 2013|September 26, 2013|January 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028574||204416|
NCT00028587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02436|PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|December 2001|||April 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028587||204415|
NCT00029042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020081|Infliximab to Treat Children With Juvenile Rheumatoid Arthritis|A Randomized Double Blind Controlled Intra-Patient Dose Escalation Phase II Trial of Infliximab in Pediatric Patients With Refractory Juvenile Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Terminated|January 2002|October 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||48|||Both|N/A|N/A|No|||August 2008|August 26, 2008|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00029042||204382|
NCT00028717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069122|Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma|A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|February 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|65 Years|N/A|No|||November 2007|September 16, 2013|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028717||204405|
NCT00029211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000114-01|A Trial of Echinacea in Children|A Randomized Controlled Trial of Echinacea in Children||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2000|March 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||August 2006|August 17, 2006|January 9, 2002||||No||https://clinicaltrials.gov/show/NCT00029211||204372|
NCT00029900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-2003-01|ADI-PEG in Patients With Metastatic Melanoma|Phase I Testing of ADI-PEG in Metastatic Melanoma||FDA Office of Orphan Products Development||Completed|September 2001|August 2003||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||January 2002|March 24, 2015|January 24, 2002||||||https://clinicaltrials.gov/show/NCT00029900||204328|
NCT00029315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-2018-01|Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage|Intraventricular Rt-PA Pharmacokinetic and Pharmacodynamic Study||FDA Office of Orphan Products Development||Completed|September 2001|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|75 Years|No|||December 2001|March 24, 2015|January 10, 2002||||||https://clinicaltrials.gov/show/NCT00029315||204364|
NCT00032773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-NIP-010|Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD|A Sequentially Adaptive, Open Label, Dose-finding, Phase I/II Trial of Pentostatin in the Treatment of Steroid-refractory Acute Graft Versus Host Disease (aGvHD)||Astex Pharmaceuticals||Terminated||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|6 Months|N/A|No|||June 2005|October 12, 2009|April 2, 2002||||||https://clinicaltrials.gov/show/NCT00032773||204123|
NCT00032435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|453|Homocysteine Study (HOST)|CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)||VA Office of Research and Development|No|Completed|May 2001|September 2006|Actual|August 2006|Actual|Phase 3|Interventional|Masking: Double-Blind|2||Anticipated|2003|||Both|21 Years|N/A|No|||October 2010|October 14, 2010|March 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00032435||204148|
NCT00029224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS16|Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions|A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions||Novartis||Completed|October 2001|November 2002|Actual|November 2002|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|January 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00029224||204371|
NCT00029406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990|Transfusion Infections Pediatric Prospective Study (TRIPPS)|Transfusion Infections Pediatric Prospective Study (TRIPPS)|TRIPPS|Children's Research Institute|No|Completed|April 2001|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|Samples Without DNA|Whole blood and plasma samples|Both|6 Months|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric recipients of allogeneic blood transfusion and linked blood donors|December 2015|December 15, 2015|January 10, 2002||No||No||https://clinicaltrials.gov/show/NCT00029406||204359|
NCT00029445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020086|Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors|Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity||National Institutes of Health Clinical Center (CC)||Recruiting|January 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|18 Years|N/A|No|||April 2015|September 24, 2015|January 11, 2002||No||No||https://clinicaltrials.gov/show/NCT00029445||204358|
NCT00028977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069155|Herbal Therapy in Treating Women With Metastatic Breast Cancer|A Pilot Safety, Feasibility, Efficacy And Correlative (Phase I/II) Study Assessing Herba Scutellaria Barbatae (HSB) For Metastatic Breast Cancer||University of California, San Francisco||Completed|August 2001|April 2006|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|21|||Female|18 Years|N/A|No|||September 2012|September 13, 2012|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028977||204386|
NCT00029536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P-0001408|Progesterone vs Placebo Therapy for Women With Epilepsy|Phase 3 Study of Progesterone vs Placebo Therapy||Beth Israel Deaconess Medical Center|Yes|Completed|October 2000|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|462|||Female|13 Years|45 Years|No|||July 2010|July 20, 2010|January 15, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00029536||204352|
NCT00028704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10974-22002|Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy|Conservative Local Treatment Versus Mastectomy After Induction Chemotherapy In Locally Advanced Breast Cancer: A Randomized Phase III Study||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|October 2001|||December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|26|||Female|N/A|N/A|No|||July 2012|July 17, 2012|January 4, 2002|||low accrual|No||https://clinicaltrials.gov/show/NCT00028704||204406|
NCT00032539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|476CC|EQUIC-CC: Enhancing Quality of Informed Consent - Customized Consent|CSP #476CC - Enhancing Quality of Informed Consent (EQUIC-CC) Customized Consent||VA Office of Research and Development|No|Completed|April 1999|April 1999|Actual|April 1999|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Anticipated|240|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Veterans in selected clinical trials conducted by VA|March 2012|March 14, 2012|March 27, 2002||No||No||https://clinicaltrials.gov/show/NCT00032539||204140|
NCT00032552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|476DP|Enhancing Quality of Informed Consent (EQUIC-DP) Developmental Phase|CSP #476DP - Enhancing Quality of Informed Consent (EQUIC-DP) Developmental Phase||VA Office of Research and Development|No|Completed|April 1999|February 2006|Actual|February 2006|Actual|N/A|Observational|N/A||1|Actual|632|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Veterans|March 2010|March 23, 2010|March 27, 2002||No||No||https://clinicaltrials.gov/show/NCT00032552||204139|
NCT00028730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-105|Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer|Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders||Memorial Sloan Kettering Cancer Center||Completed|August 2001|June 2008|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|18 Years|No|||December 2015|December 21, 2015|January 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028730||204404|
NCT00028743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OV16|Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer||Canadian Cancer Trials Group|Yes|Completed|August 2001|January 2013|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|819|||Female|18 Years|75 Years|No|||December 2012|October 31, 2013|January 4, 2002||No||No||https://clinicaltrials.gov/show/NCT00028743||204403|
NCT00029172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9903-06|Treatment for Post-Stroke Depression|Treatment for Post-Stroke Depression||Indiana University|Yes|Completed|May 1999|December 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|188|||Both|N/A|N/A|No|||December 2009|December 31, 2009|January 8, 2002||No||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00029172||204375|
NCT00029666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020105|Study of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease|Placebo Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2002|March 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||March 2005|March 3, 2008|January 17, 2002||||No||https://clinicaltrials.gov/show/NCT00029666||204344|
NCT00029978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000287-01|Transfer of Neural Energy Between Humans|Transfer of Neural Energy Between Human Subjects||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|January 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|January 29, 2002||||No||https://clinicaltrials.gov/show/NCT00029978||204322|
NCT00032019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069249|Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Phase II Study Of Dose-Adjusted Epoch-Rituximab (EPOCH-R) Chemotherapy For Patients With Previously Untreated Aggressive CD20+ B-Cell Non-Hodgkin's Lymphoma (NHL)||Alliance for Clinical Trials in Oncology|No|Completed|February 2002|April 2009|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|N/A|N/A|No|||September 2013|September 25, 2013|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00032019||204175|
NCT00028925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0027|Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF (Filgrastim) Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|November 2001|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 4, 2002||No||No||https://clinicaltrials.gov/show/NCT00028925||204390|
NCT00028938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069148|Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer|A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer||Wake Forest Baptist Health||Completed|January 2002|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028938||204389|
NCT00029679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000637-02|Borage Oil and Ginkgo Biloba (EGb 761) in Asthma|Borage Oil and Ginkgo Biloba (EGb 761) in Asthma||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|July 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||280|||Both|16 Years|75 Years|No|||August 2006|August 16, 2006|January 18, 2002||||No||https://clinicaltrials.gov/show/NCT00029679||204343|
NCT00029692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000842-01|Effects of Ginseng and Ginkgo on Drug Disposition in Man|Effects of Ginseng and Ginkgo on Drug Disposition in Man||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2002|March 2005||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|20 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 24, 2006|January 18, 2002||||No||https://clinicaltrials.gov/show/NCT00029692||204342|
NCT00029601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020088|Surround Inhibition in Patients With Dystonia|The Study of Surround Inhibition in Patients With Dystonia||National Institutes of Health Clinical Center (CC)||Completed|January 2002|July 2002||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2002|March 3, 2008|January 15, 2002||||No||https://clinicaltrials.gov/show/NCT00029601||204349|
NCT00032084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069256|S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery|Smoking Cessation Intervention (Including Bupropion-Zyban Versus Placebo) for Completely Resected Stage I and II Non-Small Cell Lung Cancer Survivors Who Are Current Smokers||Southwest Oncology Group|Yes|Terminated|January 2002|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|No|||March 2013|March 8, 2013|March 8, 2002|Yes|Yes|This study was closed early due to poor accrual|No||https://clinicaltrials.gov/show/NCT00032084||204171|
NCT00029393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142|Induction of Stable Chimerism for Sickle Cell Anemia|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2001|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|January 10, 2002||||No||https://clinicaltrials.gov/show/NCT00029393||204360|
NCT00029965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020107|Nervous System Degeneration in Glycosphingolipid Storage Disorders|Investigation of Neurodegeneration in the Glycosphingolipid Storage Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|January 2002|||||N/A|Observational|N/A|||Anticipated|150|||Both|6 Months|N/A|No|||June 2015|June 13, 2015|January 27, 2002||No||No||https://clinicaltrials.gov/show/NCT00029965||204323|
NCT00028782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02438|EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer|The Detection of Tumor Hypoxia and Vascularity in Patients Undergoing Intraperitoneal Photodynamic Therapy||National Cancer Institute (NCI)||Terminated|October 2001|||September 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 4, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00028782||204400|
NCT00032448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|456|Does Tension-Free Herniorrhaphy or Laparoscopic Herniorrhaphy Achieve Equal or Better Recurrence Rates and Lower Costs While Achieving Equivalent Outcomes for Hernia Patients?|CSP #456 - Tension Free Inguinal Hernia Repair: Comparison of Open and Laparoscopic Surgical Techniques||VA Office of Research and Development|No|Completed|October 1998|June 2004|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|2200|||Male|18 Years|N/A|No|||April 2011|April 13, 2011|March 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00032448||204147|
NCT00032786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD303|Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease|A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease||Elan Pharmaceuticals||Completed|March 2002|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 6, 2012|April 3, 2002||||||https://clinicaltrials.gov/show/NCT00032786||204122|
NCT00029640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020108|The Treatment of Children and Adolescents With Treatment-Resistant Depression|Clinical and Neurochemical Effects of Pharmacologic Treatment in Pediatric Depression||National Institutes of Health Clinical Center (CC)||Completed|January 2002|March 2004||||N/A|Observational|N/A||||90|||Both|N/A|N/A|No|||March 2004|March 3, 2008|January 16, 2002||||No||https://clinicaltrials.gov/show/NCT00029640||204346|
NCT00028990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069156|Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer||Eastern Cooperative Oncology Group|Yes|Completed|December 2001|May 2009|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|722|||Both|18 Years|N/A|No|||January 2010|March 8, 2012|January 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028990||204385|
NCT00030082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068941|Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer|A Phase I Study of Hepatic Arterial Infusion of Escalating Dose Melphalan With Venous Filtration for Metastatic Unresectable Cancers of the Liver||National Cancer Institute (NCI)||Completed|July 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|14 Years|N/A|No|||July 2004|April 29, 2015|January 30, 2002||||No||https://clinicaltrials.gov/show/NCT00030082||204315|
NCT00032695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS035745|Treatment of AIDS Vacuolar Myelopathy With Methionine|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|80 Years|No|||November 2005|May 12, 2006|March 28, 2002||||No||https://clinicaltrials.gov/show/NCT00032695||204129|
NCT00032708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-651|Dryvax Dilution-Prev Vacc Adults|A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2004|November 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||90|||Both|N/A|N/A||||May 2006|August 26, 2010|March 28, 2002||||||https://clinicaltrials.gov/show/NCT00032708||204128|
NCT00028821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02439|2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacologic Study of 2-Methoxyestradiol in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|January 2002|||April 2006|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028821||204398|
NCT00028639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 00B11|PS-341 in Treating Women With Metastatic Breast Cancer|A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer||Northwestern University|Yes|Completed|August 2001|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2011|July 1, 2011|January 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028639||204411|
NCT00029302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020069|Brain Control of Bimanual (Both Hands) Movements|Brain Areas Involved in Temporal Linkage of Bilateral Movements||National Institutes of Health Clinical Center (CC)||Completed|December 2001|December 2008||||N/A|Observational|N/A||||40|||Both|21 Years|75 Years|No|||December 2008|December 25, 2008|January 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00029302||204365|
NCT00032110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02459|Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Study of OSI-774 in Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|January 2002|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|April 14, 2015|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00032110||204169|
NCT00028951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069149|Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva|A Phase III Clinical Trial Use of TISSEEL VH Fibrin Sealant to Reduce Lymphedema Incidence After Inguinal Lymph Node Dissection Performed in the Management of Vulvar Malignancies||Gynecologic Oncology Group||Completed|January 2003|||December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||December 2005|July 8, 2013|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028951||204388|
NCT00029250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000328-01|Garlic in Hyperlipidemia Caused by HAART|Phase II, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study on the Effects of Garlic on Hyperlipidemia Induced by HAART in HIV-positive Individuals||National Center for Complementary and Integrative Health (NCCIH)||Withdrawn|November 2001|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||March 2013|March 21, 2013|January 9, 2002||||No||https://clinicaltrials.gov/show/NCT00029250||204369|
NCT00029068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020076|Cortical Excitability in Obsessive-Compulsive and Related Disorders|Studies of Cortical Excitability in Obsessive-Compulsive Disorder, Related Disorder and Healthy Volunteers Using Paired-Pulse Transcranial Magnetic Stimulation||National Institutes of Health Clinical Center (CC)||Completed|January 2002|December 2003||||N/A|Observational|N/A||||145|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2003|March 3, 2008|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00029068||204381|
NCT00032149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069261|Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2007|September 19, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00032149||204166|
NCT00029653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020101|Effect of Transcranial Magnetic Stimulation on Free Will|The Effect of Transcranial Magnetic Stimulation on Free Will||National Institutes of Health Clinical Center (CC)||Completed|January 2002|June 2002||||N/A|Observational|N/A||||10|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2002|March 3, 2008|January 16, 2002||||No||https://clinicaltrials.gov/show/NCT00029653||204345|
NCT00030069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 01-020|Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes|Calcitriol and Dexamethasone for Myelodysplastic Syndromes||University of Pittsburgh||Completed|September 2001|May 2009|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|N/A|N/A|No|||January 2016|January 14, 2016|January 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030069||204316|
NCT00029328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-2020-01|Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation|Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation||FDA Office of Orphan Products Development||Completed|September 2001|September 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|12 Months|N/A|No|||November 2001|March 24, 2015|January 10, 2002||||||https://clinicaltrials.gov/show/NCT00029328||204363|
NCT00032799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD301|Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease|A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease||Elan Pharmaceuticals||Completed|December 2001|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 6, 2012|April 3, 2002||||||https://clinicaltrials.gov/show/NCT00032799||204121|
NCT00032812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020153|The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease|Motor Memory: Study of the Role of Dopamine in Healthy Subjects and Patients With Parkinson's Disease Using PET and EEG||National Institutes of Health Clinical Center (CC)||Completed|March 2002|April 2004||||N/A|Observational|N/A||||64|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2004|March 3, 2008|April 3, 2002||||No||https://clinicaltrials.gov/show/NCT00032812||204120|
NCT00032461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458|Compare the Medical Conditions of Gulf War Veterans to Non-Deployed Veterans|National Health Survey of Gulf War Era Veterans and Their Families - Phase III Physical Examinations||VA Office of Research and Development||Completed|November 1998|April 2001||||N/A|Observational|Time Perspective: Retrospective||||2000|||Both|N/A|N/A||||March 2007|January 20, 2009|March 20, 2002||||No||https://clinicaltrials.gov/show/NCT00032461||204146|
NCT00029146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS042167|Carotid Occlusion Surgery Study|Carotid Occlusion Surgery Study|COSS|University of North Carolina, Chapel Hill|Yes|Terminated|July 2002|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|700|||Both|18 Years|85 Years|No|||March 2012|March 24, 2012|January 8, 2002|Yes|Yes|Pre-specified futility boundary was reached.|No|January 17, 2012|https://clinicaltrials.gov/show/NCT00029146||204377|
NCT00029237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000331|Alternative Stress Management Approaches in HIV Disease|Alternative Stress Management Approaches in HIV Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||392|||Both|18 Years|N/A|No|||August 2006|August 17, 2006|January 9, 2002||||No||https://clinicaltrials.gov/show/NCT00029237||204370|
NCT00029003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03073|Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)||National Cancer Institute (NCI)||Completed|December 2001|||December 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|N/A|N/A|No|||February 2013|February 27, 2013|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00029003||204384|
NCT00028873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10003-16004|R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy|An EORTC-IDBBC/ECSG Phase II Study Evaluating The Role Of The Multi-Drug Resistance (MDR) Reversor, R101933, In Patients With Taxane Refractory Metastatic Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2001|||June 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|35|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028873||204394|
NCT00028600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-100001|Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma|Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma||Alliance for Clinical Trials in Oncology|No|Completed|November 2001|February 2010|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|64 Years|No|||July 2015|July 30, 2015|January 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028600||204414|
NCT00029159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS032531|The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome|The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome||Thomas Jefferson University|Yes|Completed|November 1992|June 2012|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|200|||Female|10 Years|14 Years|No|||June 2012|June 4, 2012|January 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00029159||204376|
NCT00029744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 903|A Study to Prepare for Future HIV Vaccine Studies|An HIV Vaccine Preparedness Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2003|May 2007|Actual|||N/A|Observational|N/A|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|January 21, 2002||No||No||https://clinicaltrials.gov/show/NCT00029744||204339|
NCT00029575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020071|Magnetic Resonance Imaging of Narrowed Arteries|Intravascular Narrow Field Magnetic Resonance Arterial Wall Imaging||National Institutes of Health Clinical Center (CC)||Completed|January 2002|December 2003||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||December 2003|March 3, 2008|January 15, 2002||||No||https://clinicaltrials.gov/show/NCT00029575||204351|
NCT00029588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020092|Reward-Related Processes and Brain Function|Reward-Related Processes and Brain Function||National Institutes of Health Clinical Center (CC)||Completed|January 2002|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|247|||Both|9 Years|40 Years|No|||July 2015|November 3, 2015|January 15, 2002||No||No||https://clinicaltrials.gov/show/NCT00029588||204350|
NCT00029770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000707-01|Chiropractic Care, Medication, and Self-Care for Neck Pain|Chiropractic Care, Medication, and Self-Care for Neck Pain||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2001|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||270|||Both|18 Years|65 Years|No|||January 2008|January 23, 2008|January 23, 2002||No||No||https://clinicaltrials.gov/show/NCT00029770||204337|
NCT00029783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000644-03|Efficacy of Distant Healing in Glioblastoma Treatment|Efficacy of Distant Healing in Glioblastoma Treatment||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|June 2005||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||150|||Both|18 Years|75 Years|No|||July 2006|August 17, 2006|January 23, 2002||||No||https://clinicaltrials.gov/show/NCT00029783||204336|
NCT00029627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020089|Brain Receptors in Sympathetic Nervous System Regulation|Alpha(2)-Adrenoreceptor (AR) Subtype Polymorphisms and Physiological Responses to Alpha(2)-AR Agonist and Antagonist Drugs||National Institutes of Health Clinical Center (CC)||Completed|January 2002|December 2004||||N/A|Observational|N/A||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|March 3, 2008|January 16, 2002||||No||https://clinicaltrials.gov/show/NCT00029627||204347|
NCT00028964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069154|Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer|A Randomized, Double Blind, Pacebo-Controlled Study to Assess The Feasibility, Toxicity And Efficacy (Phase I/II) Of A Chinese Herbal Therapy (CHT) For Symptom Management In Women Undergoing Chemotherapy For Stage I/II/III Breast Cancer||University of California, San Francisco||Completed|February 2001|February 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||February 2011|February 20, 2011|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028964||204387|
NCT00029757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-1056|Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women|Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Female|35 Years|75 Years|Accepts Healthy Volunteers|||December 2003|November 4, 2005|January 22, 2002||||No||https://clinicaltrials.gov/show/NCT00029757||204338|
NCT00029107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020096|Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis|Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis||National Institutes of Health Clinical Center (CC)|No|Completed|December 2001|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|75 Years|No|||April 2012|April 10, 2012|January 5, 2002|No|Yes||No|October 26, 2011|https://clinicaltrials.gov/show/NCT00029107||204380|The study was not blinded. In addition, the study was limited to patients who had failed antiviral therapy.
NCT00028626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-113|Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer|Clinical Efficacy And Biologic Effects Of Preoperative Portal Vein Embolization In Patients With Colorectal Liver Metastases||Memorial Sloan Kettering Cancer Center||Completed|August 2001|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028626||204412|
NCT00029276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000610-01|Magnetic Stimulation for Parkinson Disease|Transcranial Magnetic Stimulation For Treatment Of Depression In Parkinson's Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|August 2000|April 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|40 Years|75 Years|No|||August 2006|August 16, 2006|January 9, 2002||||No||https://clinicaltrials.gov/show/NCT00029276||204367|
NCT00029289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000292-01|Effects of Lutein in Retinitis Pigmentosa|Effects of Lutein in Retinitis Pigmentosa||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2001|October 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||||||||August 2006|August 16, 2006|January 9, 2002||||No||https://clinicaltrials.gov/show/NCT00029289||204366|
NCT00029029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069180|Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases|RF Ablation of Painful Metastases Involving Bone||Mayo Clinic||Active, not recruiting|October 2000|||October 2002|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|120 Years|No|||January 2016|January 7, 2016|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00029029||204383|
NCT00029614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAABUK00301|Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD|Psychopharmacology of Adolescents With AUD and ADHD||University of Pittsburgh||Completed|May 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|13 Years|18 Years|No|||April 2010|April 27, 2010|January 16, 2002||||No||https://clinicaltrials.gov/show/NCT00029614||204348|
NCT00028613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRLX1400|Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma|Phase I Safety Study Of 131I-Lym-1 For The Treatment Of Previously Treated Diffuse Large B-Cell Lymphoma||Case Comprehensive Cancer Center|Yes|Completed|March 2001|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028613||204413|
NCT00029458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020085|Clozapine for Treatment-Resistant Mania|A Double Blind Study Examining the Efficacy of Clozapine and a Study of the Pathophysiology in Treatment Resistant Mania||National Institutes of Health Clinical Center (CC)||Completed|January 2002|October 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||42|||Both|N/A|N/A|No|||October 2005|March 3, 2008|January 11, 2002||||No||https://clinicaltrials.gov/show/NCT00029458||204357|
NCT00029484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000255-01|Tai Chi Chih and Varicella Zoster Immunity|Tai Chi Chih and Varicella Zoster Immunity||National Center for Complementary and Integrative Health (NCCIH)||Completed||||||Phase 2|Interventional|Allocation: Randomized||||70|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|January 11, 2002||||No||https://clinicaltrials.gov/show/NCT00029484||204356|
NCT00029497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000402-01|Sham Device, Pill Placebo or Treatment For Arm Pain|Sham Device, Pill Placebo or Treatment For Arm Pain||National Center for Complementary and Integrative Health (NCCIH)||Completed||June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|January 14, 2002||||No||https://clinicaltrials.gov/show/NCT00029497||204355|
NCT00029185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1984-01|Study of Dehydrex in Patients With Corneal Erosion|Topical Dehydrex in Treating Recurrent Corneal Erosion||FDA Office of Orphan Products Development||Completed|September 2001|September 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||October 2001|March 24, 2015|January 8, 2002||||||https://clinicaltrials.gov/show/NCT00029185||204374|
NCT00029991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000204-02|Extract of Ginkgo Biloba (EGB 761) and Vascular Function|Extract of Ginkgo Biloba (Egb 761) and Vascular Function||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|July 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||July 2006|August 17, 2006|January 29, 2002||||||https://clinicaltrials.gov/show/NCT00029991||204321|
NCT00031915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069239|Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma|Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society||National Cancer Institute (NCI)||Completed|June 2002|May 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|10 Years|N/A|No|||October 2003|June 17, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00031915||204183|
NCT00031928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069240|Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors|Phase I Study of Intrathecal Mafosfamide||National Cancer Institute (NCI)||Completed|January 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|3000|||Both|3 Years|N/A|No|||November 2003|April 29, 2015|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00031928||204182|
NCT00031941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020083|CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy|A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer||National Institutes of Health Clinical Center (CC)||Completed|April 2002|April 2009|Actual|September 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 14, 2012|March 8, 2002||||||https://clinicaltrials.gov/show/NCT00031941||204181|
NCT00032838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020155|Effects of Stress Hormones on Emotion and Cognition|The Effects of Cortisol and Norepinephrine Modulation on Emotional and Nonemotional Processing||National Institutes of Health Clinical Center (CC)||Completed|March 2002|January 2006||||N/A|Observational|N/A||||170|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|April 3, 2002||||No||https://clinicaltrials.gov/show/NCT00032838||204118|
NCT00031902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069238|Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|Rituxumab Combined With Chemotherapy (PVB) For Poor Prognosis HIV-Related Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2003|September 19, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00031902||204184|
NCT00031980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-10003|Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer|Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia||Alliance for Clinical Trials in Oncology|No|Completed|March 2002|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|March 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031980||204178|
NCT00032175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-GEM-CAP|Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|April 2002|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|508|||Both|18 Years|N/A|No|||April 2007|June 25, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00032175||204164|
NCT00032955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0001-1|Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1|Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification||National Institute on Drug Abuse (NIDA)|Yes|Completed|February 2001|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||163|||Both|15 Years|N/A|No|||April 2010|April 13, 2010|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00032955||204110|
NCT00032409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000895-01|The Effects of Music Therapy-Based Stress Reduction on Bone Marrow Transplant Recipients|The Effects of Music Therapy-Based Stress Reduction on Bone Marrow Transplant Recipients||National Center for Complementary and Integrative Health (NCCIH)||Completed|August 2001|June 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||July 2006|August 17, 2006|March 20, 2002||||No||https://clinicaltrials.gov/show/NCT00032409||204150|
NCT00027092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5112s|Use of a Test That Evaluates How the Body Handles Insulin and Glucose|AACTG Modified Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT) for the Assessment of Insulin Sensitivity: A Substudy of A5079||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||50|||Male|18 Years|N/A|No|||February 2004|August 6, 2008|November 20, 2001||||No||https://clinicaltrials.gov/show/NCT00027092||204519|
NCT00028834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02440|Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer|A Phase II Trial Of Bevacizumab (NSC#704865) Plus Gemcitabine In Patients With Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|February 2002|||December 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|January 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00028834||204397|
NCT00032279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1589|Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease|A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease||Facet Biotech||Active, not recruiting|March 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||October 2003|June 23, 2005|March 15, 2002||||||https://clinicaltrials.gov/show/NCT00032279||204159|
NCT00026520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069046|Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma|Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II||National Cancer Institute (NCI)||Completed|November 2001|April 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|June 20, 2013|November 9, 2001||||No||https://clinicaltrials.gov/show/NCT00026520||204562|
NCT00026533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069053|Thalidomide in Treating Patients With Thyroid Cancer|Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas||University of Kentucky|No|Completed|June 2001|December 2005|Actual|November 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2011|July 7, 2011|November 9, 2001|No|Yes||No||https://clinicaltrials.gov/show/NCT00026533||204561|
NCT00032617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|494|A Randomized Clinical Trial of Cognitive-Behavioral Treatment for Post-Traumatic Stress Disorders in Women|CSP #494 - A Randomized Clinical Trial of Cognitive-Behavioral Treatment for PTSD in Women (PTSD)||VA Office of Research and Development|Yes|Completed|August 2002|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|284|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 22, 2010|March 27, 2002||No||No||https://clinicaltrials.gov/show/NCT00032617||204135|
NCT00032825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020149|Ketoconazole Plus Docetaxel to Treat Prostate Cancer|A Phase I Trial of High Dose Ketoconazole Plus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|March 2002|June 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|480|||Male|18 Years|N/A|No|||May 2012|December 16, 2015|April 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00032825||204119|
NCT00032292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-405|Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease|A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation||Facet Biotech||Completed|March 2002|August 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||34|||Both|N/A|N/A|No|||March 2012|March 9, 2012|March 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00032292||204158|
NCT00032643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526|A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)|CSP #526 - A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)||VA Office of Research and Development|No|Terminated|June 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Masking: Double-Blind|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|March 27, 2002||No|Funding support withdrawn (much slower than expected enrollment)|No||https://clinicaltrials.gov/show/NCT00032643||204133|
NCT00032656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000407-01|Adolescents' Use of Complementary and Alternative Medicine|Adolescents' Use of Complementary and Alternative Medicine||National Center for Complementary and Integrative Health (NCCIH)||Completed|February 2001|December 2003||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||1400|||Both|14 Years|19 Years|No|||July 2006|August 17, 2006|March 27, 2002||||No||https://clinicaltrials.gov/show/NCT00032656||204132|
NCT00032669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020150|Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children|Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children||National Institutes of Health Clinical Center (CC)||Completed|March 2002|April 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||34|||Both|N/A|N/A|No|||April 2006|March 3, 2008|March 27, 2002||||No||https://clinicaltrials.gov/show/NCT00032669||204131|
NCT00027625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069049|Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma|A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas||National Cancer Institute (NCI)||Completed|January 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|December 13, 2008|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027625||204479|
NCT00027638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-01027|Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors|Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers)||Memorial Sloan Kettering Cancer Center||Completed|March 2001|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 17, 2013|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027638||204478|
NCT00032487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465|Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)|CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)|VADT|VA Office of Research and Development|Yes|Completed|December 2000|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1791|||Both|40 Years|N/A|No|||March 2014|March 7, 2014|March 21, 2002|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00032487||204144|Our study had several limitations. Since we were studying veterans, the patients were predominantly men, and extrapolation of our findings to women must be done with caution.Changes in therapeutic agents have occurred since the design of our protocol
NCT00031993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02457|Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix|A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix||National Cancer Institute (NCI)||Completed|March 2002|||November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|18 Years|N/A|No|||January 2013|January 16, 2013|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031993||204177|
NCT00032006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0052|Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer|A Trial Of Neoadjuvant Androgen Supression And Dose Escalation Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy||Alliance for Clinical Trials in Oncology|No|Completed|February 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00032006||204176|
NCT00026988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000613-01|Creatine Therapy for Huntington's Disease|Creatine Therapy for Huntington's Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|October 2001|June 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|18 Years|N/A|No|||July 2006|August 17, 2006|November 15, 2001||||No||https://clinicaltrials.gov/show/NCT00026988||204527|
NCT00027001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000291-01|Qigong Therapy For Heart Device Patients|Qigong Therapy for Heart Device Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|June 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||July 2006|August 17, 2006|November 15, 2001||||No||https://clinicaltrials.gov/show/NCT00027001||204526|
NCT00032877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020148|Genetic Analysis of Fraser Syndrome and Fryns Syndrome|Molecular Genetic Analysis of Fraser Syndrome and Fryns Syndrome||National Institutes of Health Clinical Center (CC)||Completed|April 2002|February 2003||||N/A|Observational|N/A||||400|||Both|N/A|N/A|No|||February 2003|March 3, 2008|April 4, 2002||||No||https://clinicaltrials.gov/show/NCT00032877||204116|
NCT00032890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIT|Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)|Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)||VA Office of Research and Development||Completed|April 2000|February 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1588|||Both|40 Years|N/A|No|||November 2006|January 20, 2009|April 5, 2002||||||https://clinicaltrials.gov/show/NCT00032890||204115|
NCT00032734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI4488|Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion.||Sanofi||Completed|June 2001|July 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|N/A|No|||June 2008|June 16, 2008|March 29, 2002||||||https://clinicaltrials.gov/show/NCT00032734||204126|
NCT00032747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI4510|Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Effects of Vasopressin V2 Receptor Antagonist on Clinical Improvement in Patients With Severe Chronic Heart Failure||Sanofi||Completed|August 2001|February 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|338|||Both|18 Years|80 Years|No|||June 2008|June 16, 2008|March 29, 2002||||||https://clinicaltrials.gov/show/NCT00032747||204125|
NCT00027248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226-98-002|Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections|Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization||BioWest Therapeutics Inc||Completed|September 2000|July 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1400|||Both|16 Years|N/A|No|||September 2005|September 12, 2005|November 29, 2001||||||https://clinicaltrials.gov/show/NCT00027248||204507|
NCT00032032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0028|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm||Alliance for Clinical Trials in Oncology|Yes|Completed|May 2002|January 2010|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||July 2015|July 4, 2015|March 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00032032||204174|
NCT00032305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-406|Research Study in Patients With Severe Ulcerative Colitis|A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids||Facet Biotech||Completed|March 2002|November 2005|Actual|November 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|70 Years|No|||March 2012|March 6, 2012|March 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00032305||204157|
NCT00032331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27|(PET) Imaging in the Management of Patients With Solitary Pulmonary Nodules|18/F-FLUORODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN THE MANAGEMENT OF PATIENTS WITH SOLITARY PULMONARY NODULES||VA Office of Research and Development||Completed|January 1999|June 2003||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||500|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2004|January 20, 2009|March 18, 2002||||No||https://clinicaltrials.gov/show/NCT00032331||204156|
NCT00028756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC 30994|Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium|Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder||European Organisation for Research and Treatment of Cancer - EORTC||Completed|October 2001|July 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Both|N/A|N/A|No|||September 2014|September 16, 2014|January 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028756||204402|
NCT00026637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1084|Depression and Health Outcomes in Refractory Epilepsy|Depression and Health Outcomes in Refractory Epilepsy||Columbia University|Yes|Terminated|August 2001|June 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|21 Years|75 Years|No|||January 2012|January 12, 2012|November 14, 2001|Yes|Yes|The PI left Columbia in 2008. No research related activity has taken place since then.|No||https://clinicaltrials.gov/show/NCT00026637||204554|
NCT00032188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02460|Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer|A Randomized Phase II Study Of Interluekin-2 In Combination With Three Different Doses Of Bryostatin In Patients With Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|January 2002|||June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00032188||204163|
NCT00032864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S003|Clinical Trial of Footwear in Patients With Diabetes|Clinical Trial of Footwear in Patients With Diabetes||VA Office of Research and Development||Completed|January 1997|September 2000||||N/A|Observational|N/A|||||||||||||February 2003|January 20, 2009|April 4, 2002||||No||https://clinicaltrials.gov/show/NCT00032864||204117|
NCT00032903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST 01-402|This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.|Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial||Sigma-Tau Research, Inc.||Completed|March 2002|October 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|59|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|April 5, 2002||||||https://clinicaltrials.gov/show/NCT00032903||204114|
NCT00032422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000671-01|Acupuncture in Cardiovascular Disease|Acupuncture in Cardiovascular Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2001|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|March 20, 2002||||No||https://clinicaltrials.gov/show/NCT00032422||204149|
NCT00032513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020147|Genetic Studies of Chronic Active Epstein-Barr Disease|Genetic Studies of Chronic Active Epstein-Barr Virus Infection||National Institutes of Health Clinical Center (CC)||Recruiting|March 2002|||||N/A|Observational|N/A|||Anticipated|300|||Both|2 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|March 22, 2002||No||No||https://clinicaltrials.gov/show/NCT00032513||204142|
NCT00032526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0180|Classical Conditioning to Treat Allergic Airway Diseases|Classical Conditioning to Treat Allergic Airway Diseases||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|March 25, 2002||||No||https://clinicaltrials.gov/show/NCT00032526||204141|
NCT00027729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-078|Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer|Phase I/II Study of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|June 2001|November 2004|Actual|November 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|December 7, 2001||||No||https://clinicaltrials.gov/show/NCT00027729||204472|
NCT00032474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000832-01|Ginkgo Biloba Extract and the Insulin Resistance Syndrome|Ginkgo Biloba Extract and the Insulin Resistance Syndrome||National Center for Complementary and Integrative Health (NCCIH)||Completed|December 2001|May 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|20 Years|80 Years|No|||July 2006|August 17, 2006|March 21, 2002||||No||https://clinicaltrials.gov/show/NCT00032474||204145|
NCT00032565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|476SM|EQUIC-SM: Enhancing Quality of Informed Consent|CSP #476SM - Enhancing Quality of Informed Consent (EQUIC-SM) Self-Monitoring|EQUIC|VA Office of Research and Development|No|Completed|November 2002|March 2008|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|836|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in various VA clinics|September 2010|September 22, 2010|March 27, 2002||No||No||https://clinicaltrials.gov/show/NCT00032565||204138|
NCT00032916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-2359-02-1|Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1|Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers||National Institute on Drug Abuse (NIDA)||Active, not recruiting|June 2001|December 2002||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|45 Years|No|||April 2004|October 23, 2007|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00032916||204113|
NCT00032097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069257|Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain|A Phase I Trial To Evaluate Repetitive Intravenous Doses Of Gadolinium-Texaphyrin As A Radiosensitizer In Patients With Glioblastoma Multi Forme||National Cancer Institute (NCI)||Completed|April 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|February 6, 2009|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00032097||204170|
NCT00027014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000864-01|Herb-Opioid Interactions|Herb-Opioid Interactions||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2001|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||54|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||July 2006|February 7, 2007|November 15, 2001||||No||https://clinicaltrials.gov/show/NCT00027014||204525|
NCT00027027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC2297g|Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors|A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies||Genentech, Inc.||Completed|November 2001|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|21|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|November 15, 2001|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT00027027||204524|
NCT00032578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|478Fe|VA Genetic Tissue Banking|CSP #478 (FeAST-DNA), Genetic Tissue Banking in VA Clinical Research: A Cooperative Studies Program Demonstration Project||VA Office of Research and Development||Completed|January 2000|||||N/A|Observational|N/A||||1000|||Both|18 Years|N/A|No|||June 2006|January 20, 2009|March 27, 2002||||No||https://clinicaltrials.gov/show/NCT00032578||204137|
NCT00028912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069146|Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|Phase I Trial of Bortezomib (NSC 681239, IND#58443) and Carboplatin in Recurrent or Progressive Epithelial Ovarian Cancer or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|November 2001|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||April 2004|April 23, 2011|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028912||204391|
NCT00027378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAACOR13370|Pharmacological Intervention Project (Fluoxetine)|Pharmacological Intervention Project (Fluoxetine)|FIDAA|University of Pittsburgh|No|Completed|July 2001|June 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|15 Years|20 Years|No|||June 2013|June 17, 2013|December 4, 2001|Yes|Yes||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00027378||204498|Limited sample size; efficacy of CBT/MET Therapy
NCT00032123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069259|Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer|A Phase II Study Of OSI-774 (NSC 718781) In Unresectable Or Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction||National Cancer Institute (NCI)||Completed|June 2002|May 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2003|June 21, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00032123||204168|
NCT00028899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML00P2|Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes|A Dose Finding Study of the Safety of Gemtuzumab Ozogamicin Combined With Conventional Chemotherapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia||Children's Oncology Group|Yes|Completed|July 2002|March 2012|Actual|September 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|47|||Both|N/A|21 Years|No|||February 2014|February 18, 2014|January 4, 2002||Yes||||https://clinicaltrials.gov/show/NCT00028899||204392|
NCT00032344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380|Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps|CSP #380 - Prospective Evaluation of Risk Factors for Large (> 1 CM) Colonic Adenomas in Asymptomatic Subjects||VA Office of Research and Development|Yes|Completed|October 1993|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3200|||Both|50 Years|75 Years|No|||November 2010|November 19, 2010|March 18, 2002||No||No||https://clinicaltrials.gov/show/NCT00032344||204155|
NCT00032682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020146|Constipation in Pediatric Cancer Patients Receiving Vinca Alkaloids or Narcotics|A Pilot Study Evaluating the Assessment Process for Constipation in Pediatric Oncology Patients Who Are Receiving Vinca Alkaloids and/or Narcotics||National Institutes of Health Clinical Center (CC)||Completed|March 2002|April 2006||||N/A|Observational|N/A||||34|||Both|N/A|N/A|No|||April 2006|March 3, 2008|March 27, 2002||||No||https://clinicaltrials.gov/show/NCT00032682||204130|
NCT00026689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000181|Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols|Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|July 2000|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1000|||Both|N/A|90 Years|No|||November 2015|December 15, 2015|November 14, 2001||No||No||https://clinicaltrials.gov/show/NCT00026689||204550|
NCT00032201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020144|Cell Lines From High-Risk Breast Tissue|Establishment of Normal High Risk Breast Epithelial Cell Cultures, and A High Risk Cell Line and Tissue Repository From Breast Tissue From Women at High Risk of Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|March 2002|December 2014||||N/A|Observational|N/A|||Actual|45|||Female|20 Years|80 Years|No|||December 2014|December 5, 2014|March 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00032201||204162|
NCT00032357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410|Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD?|CSP #410 - The Iron (Fe) and Atherosclerosis Study (FeAST)|FeAST|VA Office of Research and Development|Yes|Completed|May 1999|September 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1277|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 18, 2013|March 19, 2002||No||No||https://clinicaltrials.gov/show/NCT00032357||204154|
NCT00032370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|411|Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality|CSP #411 - The Coronary Artery Revascularization Prophylaxis (CARP) Trial|CARP|VA Office of Research and Development|No|Completed|August 1997|May 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|510|||Both|N/A|N/A|No|||June 2015|June 25, 2015|March 19, 2002||No||No||https://clinicaltrials.gov/show/NCT00032370||204153|
NCT00031837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069232|Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer|A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer||University of Rochester||Terminated|October 2002|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|March 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00031837||204189|
NCT00026611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 01-632|A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults|A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|32 Years|Accepts Healthy Volunteers|||March 2010|August 26, 2010|November 12, 2001||||No||https://clinicaltrials.gov/show/NCT00026611||204556|
NCT00032630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|517|Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass|CSP #517 - Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass|ROOBY|VA Office of Research and Development|Yes|Completed|April 2002|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2203|||Both|N/A|N/A|No|||April 2014|April 18, 2014|March 27, 2002||No||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00032630||204134|
NCT00032500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001146-01|Evaluation of Echinacea for the Common Cold|Evaluation of Echinacea in a Human Rhinovirus Challenge||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2001|May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||||||||July 2006|August 17, 2006|March 22, 2002||||No||https://clinicaltrials.gov/show/NCT00032500||204143|
NCT00031889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 09/01|Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer|A Randomized Phase II Trial of Exemestane With and Without Bicalutamide as Second Line Therapy After Failure of Androgen Suppression in Advanced Prostate Cancer||Swiss Group for Clinical Cancer Research|Yes|Completed|August 2001|June 2002|Actual|June 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Male|18 Years|N/A|No|||May 2012|May 14, 2012|March 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00031889||204185|
NCT00027183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980062|Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa|Role of Exotoxins in the Pathogenesis of Pseudomonas Aeruginosa||National Institutes of Health Clinical Center (CC)||Recruiting|February 1998|||||N/A|Observational|N/A|||Anticipated|225|||Both|9 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 11, 2016|November 27, 2001||No||No||https://clinicaltrials.gov/show/NCT00027183||204512|
NCT00032721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001012-01|The Use of Reiki for Patients With Advanced AIDS|The Use of Reiki for Patients With Advanced AIDS||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2002|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||146|||Both|21 Years|N/A|No|||July 2006|August 17, 2006|March 29, 2002||||No||https://clinicaltrials.gov/show/NCT00032721||204127|
NCT00031811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069229|Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer|Breast Cancer Survivors: Exercise and Raloxifene||OHSU Knight Cancer Institute||Completed|March 2001|April 2003|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Actual|80|||Female|N/A|N/A|No|||June 2010|May 24, 2012|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031811||204191|
NCT00031824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCT0031|Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease|Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease||Children's Oncology Group|Yes|Completed|April 2002|January 2011|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|||Actual|82|||Both|1 Year|29 Years|No|||February 2014|February 12, 2014|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031824||204190|
NCT00031850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRI-IBIS-RAZOR|Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer|A Randomized Trial Of Raloxifene Plus Zoladex For Prevention Of Breast Cancer||National Cancer Institute (NCI)||Completed|March 2000|May 2007|Actual|||N/A|Interventional|Primary Purpose: Prevention|||Anticipated|150|||Female|30 Years|45 Years|No|||May 2007|June 25, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00031850||204188|
NCT00028652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069115|Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases|Treament of Spontaneous Tumor Metastases With IL-12 DNA (NSC #709933): A Phase IB Trial||University of Wisconsin, Madison||Terminated|January 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||September 2015|September 30, 2015|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028652||204410|
NCT00028665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1499|Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma|Randomized Phase II Trial of B-Lymphocyte Purging of Autologous Peripheral Blood Progenitor Cells in Patients With B-Cell Non-Hodgkin's Lymphoma||Case Comprehensive Cancer Center|Yes|Completed|June 2000|||March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|12 Years|65 Years|No|||June 2010|June 9, 2010|January 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00028665||204409|
NCT00028678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069119|Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme|A Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients With Newly Diagnosed Glioblastoma Multiforme||Eastern Cooperative Oncology Group|No|Completed|May 2002|||July 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2010|January 26, 2010|January 4, 2002|Yes|Yes||||https://clinicaltrials.gov/show/NCT00028678||204408|
NCT00032591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481|The Home INR Study|CSP #481 - The Home INR Study (THINRS)|THINRS|VA Office of Research and Development|Yes|Completed|August 2003|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2922|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|March 27, 2002||No||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00032591||204136|
NCT00032760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000416-01|Meditation-Based Treatment for Binge Eating Disorder|Meditation-Based Treatment for Binge Eating Disorder||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2002|March 2004|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||September 2007|September 28, 2007|April 1, 2002||||No||https://clinicaltrials.gov/show/NCT00032760||204124|
NCT00032162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069262|Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer|Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors||AGO Study Group|Yes|Completed|August 2001|||May 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Female|18 Years|N/A|No|||May 2012|May 29, 2012|March 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00032162||204165|
NCT00032227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR048093|Carpal Tunnel Syndrome: Diagnosis and Treatment Trial|Carpal Tunnel Syndrome: Diagnosis and Treatment Trial||University of Washington||Completed|August 2002|April 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||May 2013|May 4, 2013|March 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00032227||204161|
NCT00032240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR047785|Shoe Inserts for Treating Osteoarthritis of the Knee|Randomized Trial of a Wedged Insole for Treatment of Osteoarthritis of the Knee||Boston University||Completed|February 2002|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|45 Years|85 Years|No|||June 2013|June 2, 2013|March 12, 2002||||No||https://clinicaltrials.gov/show/NCT00032240||204160|
NCT00032383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000553-01|Complementary/Alternative Medicine for Abnormality in the Vestibular (Balance) System|Complementary/Alternative Medicine for Vestibulopathy||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2001|April 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||July 2006|January 19, 2007|March 20, 2002||||No||https://clinicaltrials.gov/show/NCT00032383||204152|
NCT00032396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS FL-004|A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration|||Control Delivery Systems||Active, not recruiting|November 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|55 Years|N/A|No|||December 2002|May 25, 2006|March 20, 2002||||||https://clinicaltrials.gov/show/NCT00032396||204151|
NCT00032929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CSP-1019-1|Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1|Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|March 2001|||December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|April 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00032929||204112|
NCT00032942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CSP-1020-1|Lofexidine for Opiate Withdrawal - 1|A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal||National Institute on Drug Abuse (NIDA)||Completed|April 2001|||October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|18 Years|N/A|No|||July 2008|July 21, 2008|April 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00032942||204111|
NCT00031278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C005|Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer|A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin® In Patients With Metastatic Breast Cancer||Pfizer||Completed|October 2001|June 2003|Actual|June 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Female|18 Years|N/A|No|||May 2011|May 26, 2011|February 28, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00031278||204228|
NCT00031291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020137|Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin|Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin||National Institutes of Health Clinical Center (CC)||Completed|February 2002|March 2004||||N/A|Observational|N/A||||400|||Both|N/A|N/A|No|||March 2004|March 3, 2008|February 28, 2002||||No||https://clinicaltrials.gov/show/NCT00031291||204227|
NCT00032058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069254|Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer|MR Imaging And MR Spectroscopic Imaging Of Prostate Cancer Prior To Radical Prostatectomy: A Prospective Multi-Institutional Clinicopathological Study||National Cancer Institute (NCI)||Completed|June 2003|||June 2006|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||||||Male|18 Years|N/A|No|||April 2005|February 18, 2011|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00032058||204172|
NCT00031395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS039087|Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children|Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT)||University of Cincinnati|Yes|Completed|September 1999|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|122|||Both|7 Years|12 Years|No|||May 2009|May 20, 2009|March 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031395||204221|
NCT00031408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5128|Consent for Use of Stored Patient Specimens for Future Testing|Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses||AIDS Clinical Trials Group|Yes|Recruiting|March 2002|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|Samples With DNA|Blood and tissue samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected individuals|August 2015|August 5, 2015|March 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00031408||204220|
NCT00031668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY8|Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation|A Phase III Study of Involved Field Radiation Therapy (IFRT) in Patients With Histologically Aggressive Non-Hodgkin's Lymphoma Following High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT)||Canadian Cancer Trials Group||Completed|January 2001|February 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 11, 2013|March 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00031668||204202|
NCT00031798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069227|Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors|A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy||Wake Forest Baptist Health||Terminated|April 2002|May 2006|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|March 8, 2002|No|Yes|low accrual; loss of funding|No||https://clinicaltrials.gov/show/NCT00031798||204192|
NCT00031447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-006|Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth|A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to the Skin, Eye, and Mouth||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 1999|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|N/A|28 Days|No|||November 2009|May 10, 2012|March 6, 2002|Yes|Yes||No|April 1, 2009|https://clinicaltrials.gov/show/NCT00031447||204217|
NCT00031642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|535-00|Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation|Phase I/II Study of IDEC-Y2B8 (Zevalin) for Post Transplant Relapses of B-Cell Non-Hodgkin's Lymphoma||University of Nebraska|No|Completed|January 2002|March 2008|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|19 Years|N/A|No|||December 2013|December 13, 2013|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031642||204204|
NCT00030992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020130|BMS 247550 to Treat Kidney Cancer|A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma||National Institutes of Health Clinical Center (CC)|No|Completed|February 2002|June 2012|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||June 2012|August 13, 2012|February 20, 2002|Yes|Yes||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00030992||204250|
NCT00031083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1502|Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas|A Multi-center, Open Label, Two Part, Dose Escalation Study to Determine the Tolerability of Interferon-Beta Gene Transfer (BG00001) in the Treatment of Recurrent or Progressive Grade III and Grade IV Gliomas||Biogen||Suspended|January 2002|March 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||November 2004|June 7, 2012|February 20, 2002||||||https://clinicaltrials.gov/show/NCT00031083||204243|
NCT00031369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020132|Brain Anatomy in Dystonia|In Vivo Mapping Of Structural and Biochemical Abnormalities In Patients With Primary Focal Dystonia||National Institutes of Health Clinical Center (CC)||Terminated|February 2002|March 2015||||N/A|Observational|N/A|||Actual|189|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 11, 2015|March 2, 2002||No||No||https://clinicaltrials.gov/show/NCT00031369||204223|
NCT00030810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 16/01|Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC|Preoperative Chemoradiotherapy In Non-Small Cell Lung Cancer (NSCLC) Patients With Operable Stage IIIB Disease: A Prospective Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|September 2001|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030810||204262|
NCT00035360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00738|Phase III PEG-Intron in HIV-infected Patients (Study P00738)|Phase 3 Study of PEG-Intron in Heavily Treatment-experienced, HIV-infected Patients||Merck Sharp & Dohme Corp.||Completed|March 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|49|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035360||203936|
NCT00031187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG0001-015|Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer|Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma||Seattle Genetics, Inc.||Completed|October 2000|July 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Male|18 Years|N/A|No|||October 2011|October 21, 2011|February 27, 2002||||||https://clinicaltrials.gov/show/NCT00031187||204235|
NCT00031746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069221|Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels|Effects of Dietary Soy on Biomarkers of Prostate Cancer: A Prospective Phase II Study||Alliance for Clinical Trials in Oncology|No|Terminated|February 2000|||June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|26|||Male|50 Years|N/A|No|||September 2013|September 25, 2013|March 8, 2002||No|Insufficient accrual|No||https://clinicaltrials.gov/show/NCT00031746||204196|
NCT00031551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020133|Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury|Evaluation of Efficacy and Mechanisms of an Anti-Inflammatory Intervention for Chemotherapy Related Mucosal Injury||National Institutes of Health Clinical Center (CC)|Yes|Terminated|March 2002|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|27|||Both|16 Years|N/A|No|||November 2015|November 24, 2015|March 7, 2002||No|It was not feasible to recruit required sample size from two clinical sites.|No|November 24, 2015|https://clinicaltrials.gov/show/NCT00031551||204210|
NCT00034398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020181|Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome|Evaluation of Density and Pattern of Distribution of GABA A Receptors in Brain of Patients With Tourette's Syndrome Studied With PET Using [11C] Flumazenil||National Institutes of Health Clinical Center (CC)||Completed|April 2002|March 2010||||N/A|Observational|N/A|||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 12, 2010|April 26, 2002||No||No||https://clinicaltrials.gov/show/NCT00034398||204007|
NCT00031512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-018|Pleconaril Enteroviral Sepsis Syndrome|A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates With Enteroviral Sepsis Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2001|September 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|N/A|15 Days|No|||August 2012|February 28, 2013|March 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031512||204212|
NCT00031681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00019|7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)|A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)||National Cancer Institute (NCI)||Completed|December 2001|||January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031681||204201|
NCT00030953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020128|Magnetic Resonance Spectroscopy to Evaluate Tourette s Syndrome|Evaluation of Tourette's Syndrome With Multimetabolite H-Magnetic Resonance Spectroscopy at 3T||National Institutes of Health Clinical Center (CC)||Completed|February 2002|February 2015||||N/A|Observational|N/A|||Actual|100|||Both|14 Years|65 Years|No|||February 2015|February 4, 2015|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030953||204253|
NCT00031629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0131G|Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus|A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||Gynecologic Oncology Group||Completed|January 2005|||January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|March 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031629||204205|
NCT00034632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02095|Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)|Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections||Merck Sharp & Dohme Corp.||Completed|April 2001|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|65 Years|No|||August 2015|August 11, 2015|May 1, 2002||||No||https://clinicaltrials.gov/show/NCT00034632||203990|
NCT00031538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020140|Genetic Analysis of Brain Tumors|A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative||National Institutes of Health Clinical Center (CC)||Terminated|March 2002|April 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|480|||Both|1 Year|99 Years|No|||April 2015|December 16, 2015|March 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00031538||204211|
NCT00032136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-TU-TEAM|Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer|An Open Label, Randomized Multicenter Comparative Trial Of 5 Years Adjuvant Exemestane Treatment Versus 5 Years Adjuvant Tamoxifen Treatment In Postmenopausal Women With Early Breast Cancer||National Cancer Institute (NCI)||Completed|December 2001|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|4400|||Female|N/A|N/A|No|||March 2007|August 1, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00032136||204167|
NCT00031863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-TU-VICTOR|Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer|Phase III, Randomized, Double Blind, Placebo Controlled Study of Rofecoxib in Colorectal Cancer Patients Following Adjuvant Chemotherapy||National Cancer Institute (NCI)||Completed|February 2001|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2002|August 1, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00031863||204187|
NCT00031200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|991|MRI Derived Organ & Tissue Mass Changes With Weight Loss - Ancillary to Look AHEAD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|February 2007|Actual|February 2007|Actual|N/A|Observational|N/A|||||||Both|45 Years|75 Years|No|||January 2008|January 18, 2008|February 27, 2002||||No||https://clinicaltrials.gov/show/NCT00031200||204234|
NCT00031304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020127|Screening Protocol for HIV Vaccine Studies|Screening Subjects for HIV Vaccine Research Studies||National Institutes of Health Clinical Center (CC)||Completed|February 2002|April 2013||||N/A|Observational|N/A|||Actual|1324|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2013|August 20, 2013|February 28, 2002||No||No||https://clinicaltrials.gov/show/NCT00031304||204226|
NCT00030745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 17/00|Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung|Preoperative Chemotherapy Of Potentially Resectable Mesothelioma Of The Pleura||Swiss Group for Clinical Cancer Research|Yes|Completed|June 2000|August 2003|Actual|May 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030745||204267|
NCT00030758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCOG-SCTN-BR0101|Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer|G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 4|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|816|||Female|18 Years|N/A|No|||June 2007|August 6, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030758||204266|
NCT00035230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003232|A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Topiramate in Patients With Acute Manic or Mixed Episodes of Bipolar I Disorder With an Optional Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2001|November 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|338|||Both|16 Years|N/A|No|||January 2011|June 6, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035230||203946|
NCT00035243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2207|EPO906 Therapy in Patients With Advanced Kidney Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer||Novartis||Completed|April 2002|||August 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|85 Years|No|||April 2012|April 16, 2012|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035243||203945|
NCT00031213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|992|Heavy Metals, Obesity and Cardiovascular Risk - Ancillary to Look AHEAD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2007|Actual|August 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|February 27, 2002||||No||https://clinicaltrials.gov/show/NCT00031213||204233|
NCT00031226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|993|Biomarkers of Oxidative Stress in LOOK AHEAD - Ancillary to LOOK AHEAD|||Arizona State University||Completed|September 2004|August 2007|Actual|August 2007|Actual|N/A|Observational|N/A|||||||Both|45 Years|75 Years|No|||March 2014|March 12, 2014|February 27, 2002||||No||https://clinicaltrials.gov/show/NCT00031226||204232|
NCT00031239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|994|Sleep Apnea in Look AHEAD Participants - Ancillary to Look AHEAD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Both|45 Years|75 Years|No|||May 2009|May 1, 2009|February 27, 2002||||No||https://clinicaltrials.gov/show/NCT00031239||204231|
NCT00031252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|995|Neighborhood-Level Influences on All-Cause Mortality|||Stanford University||Completed|January 2001|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||June 2013|June 24, 2013|February 27, 2002||||No||https://clinicaltrials.gov/show/NCT00031252||204230|
NCT00031031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KN-001-01|Kanglaite Injection Phase I Study|Phase I Study of KLT in Patients With Solid Tumors Refractory to Standard Therapy||KangLaiTe USA||Completed|June 2001|November 2002|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|N/A|No|||November 2007|November 26, 2007|February 20, 2002||||||https://clinicaltrials.gov/show/NCT00031031||204247|
NCT00031044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5118|Adding New Drugs for HIV Infected Patients Failing Current Therapy|A Randomized Phase I/II Placebo-controlled Study of Amdoxovir (DAPD) Versus Placebo Together With Enfuvirtide (T-20) Plus Optimized Background Therapy for HIV-Infected Subjects Failing Current Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|February 20, 2002||||||https://clinicaltrials.gov/show/NCT00031044||204246|
NCT00030940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020122|Cause, Development, and Progression of Stiff-Person Syndrome|Natural History and Immunopathogenesis of Stiff Person Syndrome (SPS)||National Institutes of Health Clinical Center (CC)||Completed|February 2002|December 2007||||N/A|Observational|N/A||||40|||Both|25 Years|80 Years|No|||December 2007|March 5, 2008|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030940||204254|
NCT00031876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 26/00|Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer|Phase I/II Trial of Capecitabine With Weekly Paclitaxel for Advanced Breast Cancer||Swiss Group for Clinical Cancer Research|Yes|Completed|May 2000|September 2004|Actual|September 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|64 Years|No|||May 2012|May 14, 2012|March 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00031876||204186|
NCT00031707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-989255|Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite|Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Megestrol Acetate (Megace) Versus an N-3 Fatty Acid (EPA) Enriched Nutritional Supplement Versus Both for the Treatment of Cancer Cachexia and Anorexia||Alliance for Clinical Trials in Oncology|Yes|Completed|March 2000|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|429|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031707||204199|
NCT00031772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069225|S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer|Enhancing Well-Being During Breast Cancer Recurrence. SWOG Study S9832.||Southwest Oncology Group|Yes|Completed|July 1998|November 2003|Actual|November 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|322|||Female|18 Years|N/A|No|||February 2013|February 12, 2013|March 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00031772||204194|
NCT00031785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069226|Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer|A Phase III, Double-Blind, Randomized Study of the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer Patients Receiving Thoracic Radiation Therapy||Wake Forest Baptist Health||Completed|September 2000|||||Phase 3|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00031785||204193|
NCT00031720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069219|Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease|Phase II Study of Soy Protein to Treat Vasomotor Symptoms in Postmenopausal Women Taking Tamoxifen||Alliance for Clinical Trials in Oncology|Yes|Completed|March 2002|November 2013|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|112|||Female|18 Years|N/A|No|||May 2014|May 15, 2014|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031720||204198|
NCT00031733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069220 (10M-01-1)|Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma|A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma||University of Southern California|Yes|Completed|February 2002|November 2007|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|March 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031733||204197|
NCT00031421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-489|Neonatal CMV-Ganciclovir Follow-up Study|A Follow-up Assessment of Subjects Who Received Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) During the Phase I/II Study to Evaluate the Safety and Efficacy of Ganciclovir Treatment for Congenital Cytomegalovirus (CMV) Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2001|November 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2||8|||Both|9 Years|14 Years|No|Probability Sample|Children of both genders that previously enrolled in "Evaluation of Ganciclovir (DHPG) for        the Treatment of Symptomatice Congenital Cytomegalovirus Infections."|July 2008|August 11, 2011|March 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00031421||204219|
NCT00030875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I150|Bortezomib in Treating Patients With Mantle Cell Lymphoma|A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Mantle Cell Lymphoma||Canadian Cancer Trials Group||Completed|July 2002|December 2009|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030875||204258|
NCT00030888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069208|UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer|A Phase 2 Study Of UCN-01 In Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|December 2002|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|January 3, 2014|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030888||204257|
NCT00030771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 16/00|Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients|Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial||Swiss Group for Clinical Cancer Research|Yes|Active, not recruiting|April 2001|December 2020|Anticipated|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|75 Years|No|||January 2015|January 13, 2015|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030771||204265|
NCT00030732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 44/00|Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer|Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|June 2001|April 2008|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030732||204268|
NCT00031434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-595|Valganciclovir in Congenital CMV Infants|A Phase I/II Pharmacokinetic and Pharmacodynamic Evaluation of Oral Valganciclovir in Neonates With Symptomatic Congenital Cytomegalovirus (CMV) Infection (CASG 109)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2002|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|30 Days|No|||July 2009|February 3, 2011|March 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031434||204218|
NCT00031018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0120|Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha|Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha||National Center for Research Resources (NCRR)||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||February 2008|February 4, 2008|February 20, 2002||||No||https://clinicaltrials.gov/show/NCT00031018||204248|
NCT00031486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-022|Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir|A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2000|February 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|12 Years|N/A|No|||October 2011|May 10, 2012|March 6, 2002|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00031486||204214|
NCT00031499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-005|Azithromycin/Bicillin Syphilis|A Phase III Equivalence Trial of Azithromycin vs. Benzathine Penicillin for the Treatment of Early Syphilis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2000|March 2009|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|593|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|March 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031499||204213|
NCT00031954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 8|Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|A Phase II Study Of Paclitaxel, Carboplatin And Gemcitabine In Previously Untreated Patients With Epithelial Ovarian Carcinoma FIGO Stage IIB-IV||AGO Study Group||Completed|August 2001|||April 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Female|18 Years|120 Years|No|||December 2015|December 22, 2015|March 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00031954||204180|
NCT00030862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-123|Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus|Phase II Single-Arm Trial Of CPT-11 (Irinotecan HC1; Camptosar Injection)/Cisplatin In Patients With Advanced Esophageal Cancer||Memorial Sloan Kettering Cancer Center||Completed|October 2001|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030862||204259|
NCT00031382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020135|Imaging Study of Automatic Movements|A Neuroimaging Study of Automatic Movements||National Institutes of Health Clinical Center (CC)||Completed|February 2002|March 2005||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2005|March 3, 2008|March 2, 2002||||No||https://clinicaltrials.gov/show/NCT00031382||204222|
NCT00031694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03003|Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer|A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients With Advanced Pancreatic Cancer||National Cancer Institute (NCI)|Yes|Completed|January 2002|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|19 Years|N/A|No|||May 2013|April 8, 2015|March 8, 2002|No|Yes||No|April 8, 2015|https://clinicaltrials.gov/show/NCT00031694||204200|
NCT00031265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS037840|Efficacy of a Family Telephone Intervention for Stroke|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|October 1998|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||290|||Both|36 Years|N/A|No|||October 2005|October 11, 2005|February 28, 2002||||No||https://clinicaltrials.gov/show/NCT00031265||204229|
NCT00031967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-BR-0119|Melatonin and Radiation Therapy in Treating Patients With Brain Metastases|A Randomized Phase II Study of A.M. and P.M. Melatonin for Brain Metastasis in RPA Class II Patients||Radiation Therapy Oncology Group|Yes|Completed|May 2002|||March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2013|November 18, 2013|March 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031967||204179|
NCT00030901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069210|S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate|L-Selenium-Based Chemoprevention Of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia||Southwest Oncology Group|Yes|Completed|February 2000|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|619|||Male|40 Years|N/A|No|||January 2013|January 2, 2013|February 14, 2002|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00030901||204256|
NCT00031590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-002301|Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma|Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)||Children's Hospital of Philadelphia|Yes|Terminated|April 2001|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|3 Years|30 Years|No|||September 2015|September 30, 2015|March 8, 2002|Yes|Yes|The study was terminated prematurely due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00031590||204207|
NCT00031317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020136|Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression|Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression||National Institutes of Health Clinical Center (CC)||Completed|February 2002|June 2005||||Phase 4|Interventional|Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||June 2005|March 3, 2008|February 28, 2002||||No||https://clinicaltrials.gov/show/NCT00031317||204225|
NCT00031759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-989251|Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia|Phase II Topical Immunomodulatory Therapy With Imiquimod for the Chemoprevention of Recurrent and High-Grade Cervical Intraepithelial Neoplasia (CIN)||Alliance for Clinical Trials in Oncology|No|Completed|June 1999|February 2010|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|57|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031759||204195|
NCT00031460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-007|Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates|A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Involving the Central Nervous System||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 1997|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|N/A|28 Days|No|||October 2009|May 10, 2012|March 6, 2002|Yes|Yes||No|April 2, 2009|https://clinicaltrials.gov/show/NCT00031460||204216|
NCT00031473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-038|Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients|A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|November 1997|March 2003||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||90|||Both|5 Years|60 Years|No|||December 2003|August 26, 2010|March 6, 2002||||||https://clinicaltrials.gov/show/NCT00031473||204215|
NCT00030823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-019|Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence|Vaccination Of High Risk Breast Cancer Patients With Heptavalent Antigen - Keyhole Limpet Hemocyanin Conjugate Plus The Immunological Adjuvant QS21||Memorial Sloan Kettering Cancer Center||Completed|March 2001|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|120 Years|No|||November 2015|November 24, 2015|February 14, 2002|No|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT00030823||204261|
NCT00030849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069202|Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma|Phase II Trial Of Oral Bexarotene (Targretin) Combined With Interferon Alfa-2b (Intron-A) For Patients With Cutaneous T-Cell Lymphoma||National Cancer Institute (NCI)||Completed|October 2001|December 2009|Actual|September 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|April 2, 2013|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030849||204260|
NCT00031343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020139|The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin|A Randomized, Controlled Study to Assess the Impact of Highly Active Antiretroviral Therapy to Hepatitis C Therapy in Patients Coinfected With HIV-1 and Treated With Peginterferon Alpha-2b and Ribavirin||National Institutes of Health Clinical Center (CC)||Completed|February 2002|April 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||128|||Both|N/A|N/A|No|||April 2004|March 3, 2008|March 2, 2002||||No||https://clinicaltrials.gov/show/NCT00031343||204224|
NCT00031616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069205|NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers||National Cancer Institute (NCI)||Active, not recruiting|December 2001|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|December 17, 2013|March 8, 2002||||No||https://clinicaltrials.gov/show/NCT00031616||204206|
NCT00030979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020115|Donepezil to Treat Dementia in Parkinson's Disease|Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial||National Institutes of Health Clinical Center (CC)||Completed|February 2002|March 2005||||Phase 4|Interventional|Primary Purpose: Treatment||||28|||Both|N/A|N/A|No|||March 2005|March 3, 2008|February 15, 2002||||No||https://clinicaltrials.gov/show/NCT00030979||204251|
NCT00031161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-2013-01|Prevention of Dichloroacetate Toxicity|Prevention of Dichloroacetate Toxicity||FDA Office of Orphan Products Development||Completed|September 2001|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|30|||Both|3 Months|21 Years|No|||January 2002|March 24, 2015|February 26, 2002||||||https://clinicaltrials.gov/show/NCT00031161||204237|
NCT00031174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020131|Blood Component Collection From Patients With Rheumatic Disease and Healthy Volunteers|Collection Of Blood Components Using Apheresis From Patients With Rheumatic Diseases and Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|February 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100000|||Both|18 Years|N/A|No|||May 2015|June 6, 2015|February 26, 2002||No||No||https://clinicaltrials.gov/show/NCT00031174||204236|
NCT00031655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1623.00|Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission|Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Unrelated Donors for Treatment of Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission - A Multicenter Trial||Fred Hutchinson Cancer Research Center|Yes|Completed|September 2001|November 2012|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|75 Years|No|||December 2012|December 5, 2012|March 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031655||204203|
NCT00032045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069251|Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma|An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma||National Cancer Institute (NCI)||Completed|January 2002|August 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||March 2003|June 18, 2013|March 8, 2002||||||https://clinicaltrials.gov/show/NCT00032045||204173|
NCT00030966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1802|Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis||Biogen|Yes|Completed|January 2002|December 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1200|||Both|18 Years|55 Years|No|||June 2009|June 17, 2009|February 15, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00030966||204252|
NCT00031122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD039195-01|Study of Genetic Risk Factors for Spina Bifida and Anencephaly|The Spina Bifida Research Resource|SBRR|Office of Rare Diseases (ORD)|No|Active, not recruiting|September 2000|September 2012|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Anticipated|1100|Samples With DNA|DNA extracted from whole blood, saliva, buccal swab, and/or amniocytes|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteer participants recruited through support groups, clinics, and Web site responses|May 2009|October 4, 2010|February 26, 2002||No||No||https://clinicaltrials.gov/show/NCT00031122||204240|
NCT00035009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-059|Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)|A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder With Melancholic Features||Merck Sharp & Dohme Corp.||Completed|September 2001|March 2004|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|468|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035009||203963|
NCT00035139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1783|Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery|Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery||National Center for Research Resources (NCRR)||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||||||Both|6 Years|16 Years|No|||December 2003|June 23, 2005|May 2, 2002||||No||https://clinicaltrials.gov/show/NCT00035139||203953|
NCT00034190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-8184-1066|Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma|A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma||OncoGenex Technologies||Completed|March 2002|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|April 23, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034190||204022|
NCT00034203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HURA501|Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.|||XOMA (US) LLC||Completed|April 2002|August 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||September 2004|June 23, 2005|April 23, 2002||||||https://clinicaltrials.gov/show/NCT00034203||204021|
NCT00035295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-061|Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)|A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|November 2001|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|584|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035295||203941|
NCT00034827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040-000-002|A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer|A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer, or Pancreatic Cancer||Pfizer||Completed|January 2002|May 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||172|||Both|18 Years|N/A|No|||July 2006|May 3, 2007|May 2, 2002||||No||https://clinicaltrials.gov/show/NCT00034827||203975|
NCT00034957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196-ONC-0100-005|Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)|||Pfizer||Completed||October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2012|February 14, 2012|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034957||203966|
NCT00035204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002002|A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease|A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||May 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|63|||Both|60 Years|N/A|No|||April 2010|June 6, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035204||203948|
NCT00035217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0838|Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program|Follow-Up Study for Men Diagnoses With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Male|40 Years|N/A|No|||December 2003|June 23, 2005|May 2, 2002||||No||https://clinicaltrials.gov/show/NCT00035217||203947|
NCT00034268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6428|A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer|A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|March 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|April 24, 2002||||||https://clinicaltrials.gov/show/NCT00034268||204016|
NCT00034619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5142|A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.|||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034619||203991|
NCT00034658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00041|Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)|Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections||Merck Sharp & Dohme Corp.||Completed|December 1998|March 2002|Actual|March 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|336|||Both|13 Years|N/A|No|||September 2015|September 10, 2015|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034658||203988|
NCT00034866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI 1182.52|Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals|Double-Blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-Experienced Subjects.||Boehringer Ingelheim||Completed|April 2002|October 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||165|||Both|18 Years|N/A|No|||September 2005|September 19, 2005|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034866||203972|
NCT00029133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS038554|Hypothermia During Intracranial Aneurysm Surgery Trial|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|February 2000|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||1000|||Both|19 Years|N/A|No|||August 2003|June 23, 2005|January 8, 2002||||No||https://clinicaltrials.gov/show/NCT00029133||204378|
NCT00035022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-01-02|Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas|Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies||BioCryst Pharmaceuticals||Completed|August 2001|March 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||71|||Both|N/A|N/A|No|||February 2005|January 12, 2006|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035022||203962|
NCT00034242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020185|High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration|The Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With Cerebellar Degeneration: A Double Blind, Placebo Controlled Trial||National Institutes of Health Clinical Center (CC)||Completed|April 2002|February 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||February 2004|March 3, 2008|April 24, 2002||||No||https://clinicaltrials.gov/show/NCT00034242||204018|
NCT00034255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INGAP-01-001|Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients|Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients||GMP Endotherapeutics||Completed|December 2001|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||62|||Both|18 Years|70 Years|No|||June 2003|June 23, 2005|April 24, 2002||||||https://clinicaltrials.gov/show/NCT00034255||204017|
NCT00035152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS TAX/MEN.12|Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer|A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.||Bristol-Myers Squibb||Completed|June 2000|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||444|||Both|18 Years|N/A|No|||August 2007|June 27, 2008|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035152||203952|
NCT00035165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2206|EPO906 Therapy in Patients With Advanced Melanoma|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Melanoma||Novartis||Completed|March 2002|||May 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|85 Years|No|||April 2012|April 24, 2012|May 2, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00035165||203951|
NCT00035178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG-402|Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis|Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis||Encysive Pharmaceuticals||Completed|May 2002|November 2002||||Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|21 Years|75 Years|No|||December 2003|June 23, 2005|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035178||203950|
NCT00030914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N99C7|Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women|Phase III Comparison of Depomedroxyprogesterone Acetate (DPROV) to Venlafaxine for Managing Hot Flashes||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2002|September 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|227|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|February 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00030914||204255|
NCT00034450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001025-01|Developmental Study on Fatigue in Cancer|Developmental Study on Fatigue in Cancer||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2002|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||March 2006|August 17, 2006|April 29, 2002||||No||https://clinicaltrials.gov/show/NCT00034450||204004|
NCT00034463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310|ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer|A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer||Eli Lilly and Company||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|April 29, 2002||||||https://clinicaltrials.gov/show/NCT00034463||204003|
NCT00029198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000370-01|Preterm Infants' Weight Gain Following Massage Therapy|Preterm Infants' Weight Gain Following Massage Therapy||University of Miami|Yes|Completed|April 2003|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|139|||Both|28 Weeks|32 Weeks|No|||April 2014|April 9, 2014|January 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00029198||204373|
NCT00034281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-01-TL-165-001|Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2|A Phase I, Open-Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose and Pharmacokinetics of Oral TAK-165 Administered Once Daily to Subjects With Tumors Known to Express HER2.||Takeda|No|Completed|June 2002|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|April 24, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00034281||204015|
NCT00034294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC-80-203|A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea|A Randomized, Double-Blind Study of GT160-246 Versus Vancomycin in Patients With C. Difficile-Associated Diarrhea||Sanofi||Completed|February 2002|July 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|April 24, 2002||||||https://clinicaltrials.gov/show/NCT00034294||204014|
NCT00035191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002011|A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia|A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2001|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|254|||Both|40 Years|N/A|No|||November 2010|June 6, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035191||203949|
NCT00034749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003361|The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia|The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2001|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|279|||Both|13 Years|17 Years|No|||March 2010|June 6, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034749||203981|
NCT00028795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0126|Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma|A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma||Children's Oncology Group|Yes|Completed|December 2002|March 2012|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|3 Years|21 Years|No|||February 2014|February 19, 2014|January 4, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00028795||204399|
NCT00034671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01893|PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)|Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts||Merck Sharp & Dohme Corp.||Completed|January 2001|March 2002|Actual|November 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|98|||Both|13 Years|65 Years|No|||December 2015|December 30, 2015|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034671||203987|
NCT00034840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.327|Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose|A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDIS® (Telmisartan 80 mg p.o. Once Daily) and Diovan® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Hypertension After Missing One Dose||Boehringer Ingelheim||Completed|October 2001|August 2002||August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||490|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034840||203974|
NCT00035061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4698|A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium|||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035061||203959|
NCT00035100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2203|EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer||Novartis||Completed|September 2001|||June 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||April 2012|April 13, 2012|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035100||203956|
NCT00035113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2204|EPO906 Therapy in Patients With Prostate Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Androgen-independent Prostate Cancer||Novartis||Suspended|January 2002|||January 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Male|18 Years|85 Years|No|||November 2009|November 18, 2009|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035113||203955|
NCT00035256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5490|Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis|Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis||Eli Lilly and Company||Completed|October 2001|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Female|55 Years|80 Years|No|||May 2007|May 11, 2007|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035256||203944|
NCT00035269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12600071|New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)|Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study||Pfizer||Completed|December 2001|May 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|230|||Both|13 Years|N/A|No|||April 2011|April 25, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035269||203943|
NCT00034359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-003|Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection|A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults||Achillion Pharmaceuticals||Completed|February 2002|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|79|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|April 26, 2002||Yes||||https://clinicaltrials.gov/show/NCT00034359||204010|
NCT00034372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVA-Gy-15|Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma|||Unither Pharmaceuticals||Terminated|September 2000|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||102|||Female|18 Years|N/A|No|||December 2007|December 13, 2007|April 26, 2002|||closed by sponser|||https://clinicaltrials.gov/show/NCT00034372||204009|
NCT00034385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020168|Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients|Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients||National Institutes of Health Clinical Center (CC)||Completed|April 2002|October 2009|Actual|January 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment|1|||12|||Both|18 Years|N/A|No|||August 2008|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00034385||204008|
NCT00028691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069120|Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma|Chlorambucil Versus 2x2 Gy Involved Field Radiotherapy in Stage III/IV Previously Untreated Follicular Lymphoma Patients. A Prospective, Randomized Phase III Clinical Trial||National Cancer Institute (NCI)||Active, not recruiting|December 2002|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2002|September 16, 2013|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028691||204407|
NCT00028769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069132|S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer|Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate||Southwest Oncology Group|No|Completed|December 2001|July 2011|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Male|18 Years|N/A|No|||June 2013|June 12, 2013|January 4, 2002|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00028769||204401|
NCT00035334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-503004|Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis|A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis||Bellus Health Inc||Completed|October 2001|December 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||February 2006|February 13, 2006|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035334||203938|
NCT00034424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020178|Cause of Familial Testicular Cancer|Multidisciplinary Etiologic Study of Familial Testicular Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|April 2002|||||N/A|Observational|N/A|||Anticipated|1750|||Both|12 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|April 27, 2002||No||No||https://clinicaltrials.gov/show/NCT00034424||204006|
NCT00031005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020126|Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency|Treatment of Leukocyte Adhesion Deficiency With Allogeneic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Completed|February 2002|February 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||February 2003|March 3, 2008|February 20, 2002||||No||https://clinicaltrials.gov/show/NCT00031005||204249|
NCT00031109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 803|The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys|An Open-Label, Passive Antibody Trial to Assess Efficacy in the Pathogenic SHIV-89.6P Macaque Model of Human Antibodies Generated by a Candidate HIV-1 Vaccine in a Phase I Clinical Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2005|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Prevention||||10|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2012|May 3, 2012|February 25, 2002||||||https://clinicaltrials.gov/show/NCT00031109||204241|
NCT00034554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP09-0001|Study of gp75 Vaccine in Patients With Stage III and IV Melanoma|Phase I Study of gp75 DNA Vaccine in Patients With AJCC Stage III and IV Melanoma||ImClone LLC|No|Completed|March 2002|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|31|||Both|18 Years|N/A|No|||December 2009|April 8, 2010|April 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034554||203996|
NCT00029263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000511-01|Screening Herbs for Drug Interactions|R-21 Project: Screening Herbs for Drug Interference||National Center for Complementary and Integrative Health (NCCIH)||Completed|August 2001|May 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||140|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|January 9, 2002||||No||https://clinicaltrials.gov/show/NCT00029263||204368|
NCT00034541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP02-9932|Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer|Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Carboplatin-Paclitaxel in Patients With Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer||ImClone LLC|No|Completed|December 2000|May 2003|Actual|May 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2010|April 8, 2010|April 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034541||203997|
NCT00035074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00240-1757|A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease|A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease||National Center for Research Resources (NCRR)||Completed||||||N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||December 2003|June 23, 2005|May 2, 2002||||No||https://clinicaltrials.gov/show/NCT00035074||203958|
NCT00035087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2201|EPO906 Therapy in Patients With Advanced Colorectal Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Colorectal Cancer||Novartis||Completed|May 2002|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|62|||Both|18 Years|85 Years|No|||December 2013|December 3, 2013|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035087||203957|
NCT00034970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000683-01|Mindfulness-Based Art Therapy for Cancer Patients|Mindfulness-Based Art Therapy for Cancer Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2002|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||114|||Both|21 Years|N/A|No|||July 2006|August 17, 2006|May 2, 2002||||No||https://clinicaltrials.gov/show/NCT00034970||203965|
NCT00029341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5131|A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body|A Phase II Study to Demonstrate That Therapy With Efavirenz (EFV) and Other Antiretroviral Drugs Can Be Interrupted Without Selecting for EFV-Resistant Virus, and Relation to Kinetics of Drug Elimination||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2005|July 29, 2008|January 10, 2002||||No||https://clinicaltrials.gov/show/NCT00029341||204362|
NCT00029380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141|Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia|Sibling Donor Cord Blood Banking and Transplantation||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1999|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|3 Years|14 Years|No|||September 2008|September 30, 2008|January 10, 2002||No||No||https://clinicaltrials.gov/show/NCT00029380||204361|
NCT00034684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00701|Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)|Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia||Merck Sharp & Dohme Corp.||Completed|July 2001|October 2003|Actual|October 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|132|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034684||203986|
NCT00034801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5529|Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia|A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression||Eli Lilly and Company||Completed|September 2001|March 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||378|||Both|18 Years|60 Years|No|||July 2006|July 18, 2006|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034801||203977|
NCT00034476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1641|A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis|A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis||Eli Lilly and Company||Completed|October 2001|October 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||466|||Both|18 Years|N/A|No|||July 2006|July 18, 2006|April 29, 2002||||||https://clinicaltrials.gov/show/NCT00034476||204002|
NCT00035308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJP 394-90-09|Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease||La Jolla Pharmaceutical Company||Completed||December 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|12 Years|70 Years|No|||December 2002|September 22, 2006|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035308||203940|
NCT00035321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6272|The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression|The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features||Eli Lilly and Company||Completed|April 2002|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|65 Years|No|||July 2006|July 21, 2006|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035321||203939|
NCT00028886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069144|Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma|A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|March 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|450|||Both|18 Years|65 Years|No|||October 2012|September 16, 2013|January 4, 2002||||No||https://clinicaltrials.gov/show/NCT00028886||204393|
NCT00034814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXL-201-14-189|Multicenter Trial for Adults With Partial Seizures|Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients With Partial Seizures: A Phase II Clinical Trial.||Teva Pharmaceutical Industries||Completed|January 2002|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|6||Actual|190|||Both|18 Years|65 Years|No|||March 2011|March 15, 2011|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034814||203976|
NCT00034138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVA-Gy-16|A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma|||Unither Pharmaceuticals||Terminated|March 2002|December 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Female|18 Years|65 Years|No|||December 2007|December 13, 2007|April 23, 2002|||closed by sponser|||https://clinicaltrials.gov/show/NCT00034138||204026|
NCT00030797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/00|Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer|A Randomized Phase II Trial Of Capecitabine And Different Schedules Of Irinotecan As First Line Treatment For Advanced Or Metastatic Colorectal Cancer||Swiss Group for Clinical Cancer Research|Yes|Completed|February 2001|December 2003|Actual|May 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|February 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00030797||204263|
NCT00034489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2245|A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.|A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2006|July 18, 2006|April 29, 2002||||||https://clinicaltrials.gov/show/NCT00034489||204001|
NCT00034502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2927|A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.|||Eli Lilly and Company||Completed||||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|April 29, 2002||||||https://clinicaltrials.gov/show/NCT00034502||204000|
NCT00029510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000652-02|Magnesium and Asthma - Clinical Trials|Magnesium and Asthma - Clinical Trials||National Center for Complementary and Integrative Health (NCCIH)||Completed|May 2002|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|January 14, 2002||||No||https://clinicaltrials.gov/show/NCT00029510||204354|
NCT00029523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0101-010|DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor|A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis||Pacira Pharmaceuticals, Inc||Completed|April 2001|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||February 2007|February 27, 2007|January 15, 2002||||||https://clinicaltrials.gov/show/NCT00029523||204353|
NCT00031096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90905|Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne|A 12-week, Randomized, Double-blind, Multicenter Study Comparing the Clinical Efficacy and Safety of Azelaic Acid 15% Gel (SH H 655 BA) With Its Vehicle (SH H 655 PBA) in Patients With Mild to Moderate Acne.||Bayer||Completed|January 2002|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|879|||Both|12 Years|N/A|No|||February 2014|February 23, 2014|February 21, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00031096||204242|
NCT00034567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0032|Healthy Aging and Memory Study|Alzheimer's Disease Prevention Instrument Protocol||National Institute on Aging (NIA)||Completed||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||650|||Both|75 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 14, 2007|April 30, 2002||||No||https://clinicaltrials.gov/show/NCT00034567||203995|
NCT00034515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-102|A Study in Adult and Pediatric Patients With Cystic Fibrosis|Ph 1b/2a Study to Assess Levels of INS37217 and Placebo Treatment With Maximum Tolerated Dose Administered by Inhalation Via the Pari LC Star Nebulizer in Adult and Pediatric CF Patients||Merck Sharp & Dohme Corp.||Completed|June 2001|August 2002|Actual|August 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|63|||Both|5 Years|N/A|No|||February 2015|February 13, 2015|April 29, 2002||||||https://clinicaltrials.gov/show/NCT00034515||203999|
NCT00034528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT DF/HCC 01-098|Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia|Allogeneic Stem Cell Transplantation Following Nonmyeloablative Chemotherapy in Patients With Hemoglobinopathies||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|September 2001|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|April 30, 2002|No|Yes|Due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00034528||203998|
NCT00034697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02143|Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)|A Phase II Study of Temozolomide (SCH 52365) in Subjects With Brain Metastasis From Non-Small-Cell Lung Cancer||Merck Sharp & Dohme Corp.||Completed|June 2001|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034697||203985|
NCT00034710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C102|Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain|A Double-Blind Controlled Pilot Study of High-Dose Capsaicin Patches in the Treatment of Pain Associated With Postherpetic Neuralgia||NeurogesX||Completed|March 2002|October 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||February 2006|February 6, 2006|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034710||203984|
NCT00034723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020180|MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis|MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)||National Institutes of Health Clinical Center (CC)||Completed|April 2002|March 2004||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|March 3, 2008|May 1, 2002||||No||https://clinicaltrials.gov/show/NCT00034723||203983|
NCT00034736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002392|A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting|A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2002|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|691|||Both|6 Months|16 Years|No|||December 2010|June 6, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034736||203982|
NCT00034762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002764|Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease|Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2000|January 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|473|||Both|55 Years|N/A|No|||January 2011|January 31, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034762||203980|
NCT00034645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C98316|Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease|||Merck Sharp & Dohme Corp.||Completed|January 1999|February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|600|||Both|13 Years|65 Years|No|||July 2015|July 10, 2015|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034645||203989|
NCT00035035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5148|A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.|A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.||Eli Lilly and Company||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00035035||203961|
NCT00035048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-068|Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|November 2001|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|540|||Both|65 Years|N/A|No|||March 2015|March 10, 2015|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035048||203960|
NCT00035282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-060|Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)|A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|September 2001|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|450|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035282||203942|
NCT00035347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661035|Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia|A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia||Pfizer|No|Completed|January 2001|June 2002|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035347||203937|
NCT00034853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.235|Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)|A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis||Boehringer Ingelheim||Completed|December 2000|||June 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Anticipated|180|||Both|2 Years|17 Years|No|||October 2013|October 31, 2013|May 2, 2002||||No||https://clinicaltrials.gov/show/NCT00034853||203973|
NCT00034879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0050|Iressa Expanded Access Program (EAP)|An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||AstraZeneca|No|Completed|August 2000|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 3, 2013|May 2, 2002|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00034879||203971|
NCT00035126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2205|EPO906 Therapy in Patients With Advanced Breast Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer||Novartis||Suspended|January 2002|||November 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|18 Years|85 Years|No|||September 2011|September 23, 2011|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035126||203954|
NCT00034775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002761|A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.|Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2001|October 2002|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|141|||Both|18 Years|N/A|No|||January 2011|January 7, 2011|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034775||203979|
NCT00034788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003238|A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX|A Multicenter Clinical Evaluation of the Efficacy and Safety of REGRANEX Gel in the Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|December 2000|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|84|||Both|18 Years|80 Years|No|||March 2010|June 6, 2011|May 2, 2002|||Slow recruitment; Study did not address safety concern raised by European Medicines Agency|||https://clinicaltrials.gov/show/NCT00034788||203978|
NCT00030784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62002|Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma|Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 2001|||March 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|28|||Both|18 Years|70 Years|No|||September 2012|September 20, 2012|February 14, 2002||||No||https://clinicaltrials.gov/show/NCT00030784||204264|
NCT00034151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-8184-1061|Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer|A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma||OncoGenex Technologies||Completed|March 2002|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|N/A|No|||June 2009|June 2, 2009|April 23, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034151||204025|
NCT00034164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-8184-1063|Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer|A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer||OncoGenex Technologies|No|Completed|April 2002|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|April 23, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034164||204024|
NCT00034177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-8184-1065|Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium|Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium||OncoGenex Technologies||Completed|April 2002|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|April 23, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034177||204023|
NCT00034580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5528|Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder|Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed||Eli Lilly and Company||Completed|August 2001|August 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||326|||Both|18 Years|70 Years|No|||July 2006|July 18, 2006|April 30, 2002||||||https://clinicaltrials.gov/show/NCT00034580||203994|
NCT00034892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077IL/0114|CAFE Comparison of Atypicals in First Episode of Psychosis|Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison||AstraZeneca||Completed|March 2002|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|40 Years|No|||January 2013|January 3, 2013|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034892||203970|
NCT00034905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077US/0043|A Comparison of Seroquel vs. Risperidone in Schizophrenia|||AstraZeneca||Completed|July 2001|September 2002|Actual|September 2002|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034905||203969|
NCT00034918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6474IL/0002|This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer|An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).||AstraZeneca||Completed|May 2002|November 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||44|||Female|18 Years|N/A|No|||January 2013|January 3, 2013|May 2, 2002||||||https://clinicaltrials.gov/show/NCT00034918||203968|
NCT00034944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-063|Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)|A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|January 2002|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|495|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|May 2, 2002|Yes|Yes||||https://clinicaltrials.gov/show/NCT00034944||203967|
NCT00034333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC-DOX-004|Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer|Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients With Unresectable Hepatocellular Carcinoma||FeRx||Terminated|March 2002|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|80 Years|No|||May 2004|June 23, 2005|April 25, 2002||||||https://clinicaltrials.gov/show/NCT00034333||204012|
NCT00034346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20025404|ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)|A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer||Amgen||Completed|January 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||194|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|April 25, 2002||||||https://clinicaltrials.gov/show/NCT00034346||204011|
NCT00034593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4699|A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium|||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|April 30, 2002||||||https://clinicaltrials.gov/show/NCT00034593||203993|
NCT00034606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5115|Comparing 3 Schedules of Alimta Plus Gemzar|||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|May 1, 2002||||||https://clinicaltrials.gov/show/NCT00034606||203992|
NCT00034983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_407|Treatment of Patients With Major Depressive Disorder With MK0869|A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|October 2001|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|900|||Both|18 Years|N/A|No|||July 2008|July 31, 2008|May 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00034983||203964|
NCT00033618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02970|Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck|A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck||National Cancer Institute (NCI)||Completed|November 2002|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|April 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00033618||204061|
NCT00033631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0126|Radiation Therapy in Treating Patients With Stage II Prostate Cancer|A Phase III Randomized Study Of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT In Patients Treated For Localized Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|March 2002|||April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1532|||Male|N/A|120 Years|No|||November 2015|November 19, 2015|April 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00033631||204060|
NCT00033384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069279|CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer|A Multicenter Phase 2 Study of CI-1040 In Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer Or Pancreatic Cancer||University of Alabama at Birmingham|Yes|Completed|February 2002|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2002|April 10, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033384||204077|
NCT00033397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150007|Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery|Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|February 2002|||May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|384|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|April 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00033397||204076|
NCT00033774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020160|Stem Cell Collection for Adult Volunteers|Peripheral Blood Stem Cell Collection From Adult Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|April 2002|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|April 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00033774||204051|
NCT00033787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020162|Serotonin Function During Depression|Tryptophan Depletion PET Study in Remitted Depressed Subjects and Healthy Controls, and GABA MRS Study in Remitted and Currently Depressed Subjects and Healthy Controls||National Institutes of Health Clinical Center (CC)||Completed|April 2002|April 2005|Actual|April 2005|Actual|N/A|Observational|N/A||||450|||Both|18 Years|60 Years|No|||June 2009|August 27, 2009|April 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00033787||204050|
NCT00033046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0002-1|Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1|Safety Evaluation of Cocaine Treatment Medication Modafinil: Interactions With Intravenous Cocaine||National Institute on Drug Abuse (NIDA)||Active, not recruiting|June 2001|April 2002||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|45 Years|No|||May 2004|February 8, 2007|April 5, 2002||||||https://clinicaltrials.gov/show/NCT00033046||204103|
NCT00033813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUL0401|KUL0401: An Open-label Pilot Study of Oxatomide in Steroid-Naive Duchenne Muscular Dystrophy|||Cooperative International Neuromuscular Research Group||Completed|January 2002|||December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Male|5 Years|10 Years|No|||March 2014|March 7, 2014|April 10, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00033813||204049|
NCT00033852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001047-01|Treatment of Depression With Massage in HIV|Treatment of Depression With Massage in HIV||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2002|May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||90|||Both|16 Years|N/A|No|||March 2008|March 5, 2008|April 11, 2002||||No||https://clinicaltrials.gov/show/NCT00033852||204046|
NCT00033865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 AT000066-01A1|Yoga as a Treatment for Insomnia|Yoga as a Treatment for Insomnia||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2001|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|25 Years|59 Years|No|||April 2015|April 27, 2015|April 11, 2002||No||No||https://clinicaltrials.gov/show/NCT00033865||204045|
NCT00033332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069274|Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma|A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma||National Cancer Institute (NCI)||Completed|April 2002|June 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2005|April 2, 2014|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033332||204081|
NCT00033176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000246-01A2|Immune Restoration by Lipoic Acid in AIDS|Immune Restoration by Lipoic Acid in AIDS||National Center for Complementary and Integrative Health (NCCIH)||Completed|February 2002|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||33|||Both|18 Years|N/A|No|||July 2006|August 17, 2006|April 8, 2002||||No||https://clinicaltrials.gov/show/NCT00033176||204093|
NCT00033462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02797|Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer|A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma||National Cancer Institute (NCI)||Completed|March 2002|||November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033462||204071|
NCT00033215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0110P1416|A Phase 1 Study of S-3304 in Patients With Solid Tumors|A Phase 1 Study of S-3304 in Patients With Solid Tumors||Shionogi||Active, not recruiting|November 2001|October 2003||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|85 Years|No|||November 2003|June 23, 2005|April 9, 2002||||||https://clinicaltrials.gov/show/NCT00033215||204090|
NCT00033293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL00P3|Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma|A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone||Children's Oncology Group|Yes|Active, not recruiting|March 2004|||December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|N/A|8 Years|No|||March 2015|March 3, 2015|April 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00033293||204084|
NCT00034086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5136|Study of Anti-HIV Therapy Intensification|Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2006|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|N/A|N/A|No|||May 2012|May 17, 2012|April 22, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00034086||204029|
NCT00033410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069281|Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|A Phase I Study Of Tirapazamine (NSC 130181) Paclitaxel And Carboplatin With Concurrent Radiation Followed By Tirapazamine/Paclitaxel/Carboplatin Consolidation For Stage III Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|March 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||September 2006|February 6, 2009|April 9, 2002||||||https://clinicaltrials.gov/show/NCT00033410||204075|
NCT00037076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1028S|Prevalence of Hepatitis C Virus Infection in HIV-Infected Children|Hepatitis C Prevalence in Perinatally Infected HIV-Positive Children Enrolled in PACTG 219C||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2003|Actual|||N/A|Observational|N/A||||600|||Both|1 Year|20 Years|No|||October 2012|October 30, 2012|May 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00037076||203814|
NCT00033059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0003-1|Assessment of Potential Interactions Between Cocaine and Tolcapone - 1|Assessment of Potential Interactions Between Intravenous Cocaine and Tolcapone||National Institute on Drug Abuse (NIDA)||Active, not recruiting|July 2001|March 2002||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|45 Years|No|||August 2003|February 8, 2007|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00033059||204102|
NCT00033072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0004-1|Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1|Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline||National Institute on Drug Abuse (NIDA)||Active, not recruiting|September 2001|October 2002||||Phase 1|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment||||16|||Both|18 Years|45 Years|No|||November 2003|October 23, 2007|April 5, 2002||||||https://clinicaltrials.gov/show/NCT00033072||204101|
NCT00033527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069297|INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer|A Double-Blinded, Placebo-Controlled, Parallel Group Study Of Uridine 5'-Triphosphate (UTP) Solution For Inhalation As An Adjunct In The Diagnosis Of Lung Cancer By Sputum Cytology||National Cancer Institute (NCI)||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||September 2002|November 5, 2013|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033527||204067|
NCT00033722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069316|Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2002|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2002|January 3, 2014|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033722||204054|
NCT00033995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020175|Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder|Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder With [15O]H2O PET in Awake and in Sleep States||National Institutes of Health Clinical Center (CC)||Completed|April 2002|February 2009||||N/A|Observational|N/A||||46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|April 18, 2002||No||No||https://clinicaltrials.gov/show/NCT00033995||204036|
NCT00033007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0006-1|Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics - 1|Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2001|February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||440|||Both|N/A|N/A|No|||April 2010|April 13, 2010|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00033007||204106|
NCT00037037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069357|Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma|A Phase I Study of Peptide Based Vaccine Therapy in Patients With High-Risk or Metastatic Melanoma||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2004|December 17, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00037037||203817|
NCT00037050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12600080|Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria|Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections||Pfizer||Completed|April 2002|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|739|||Both|13 Years|N/A|No|||September 2009|September 11, 2009|May 14, 2002||||||https://clinicaltrials.gov/show/NCT00037050||203816|
NCT00033540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069299|S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma|A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma||Southwest Oncology Group|Yes|Completed|September 2003|July 2011|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|April 9, 2002|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00033540||204066|
NCT00033306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069272|BMS-247550 in Treating Patients With Metastatic Colorectal Cancer|A Phase II Study Of Epothilone Analog BMS-247550 In Patients With Metastatic Colorectal Cancer Previously Treated With A Fluoropyrimidine And Irinotecan||University of Alabama at Birmingham|Yes|Terminated|February 2002|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033306||204083|
NCT00033319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069273|Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps|UKCAP Trial: A Multi-Center Double Blind Randomised Controlled Trial Of Aspirin And/Or Folate Supplementation For the Prevention Of Recurrent Colorectal Adenomas||National Cancer Institute (NCI)||Active, not recruiting|May 1997|||||N/A|Interventional|Primary Purpose: Prevention|||||||Both|N/A|75 Years|No|||December 2002|September 16, 2013|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033319||204082|
NCT00033020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0007-1|Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1|Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2001|February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||390|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00033020||204105|
NCT00037505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0849|Major Depression and Inflammatory Risk Markers for Coronary Heart Disease|Major Depression and Inflammatory Risk Markers for Coronary Heart Disease||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|15 Years|55 Years|Accepts Healthy Volunteers|||December 2003|June 23, 2005|May 17, 2002||||No||https://clinicaltrials.gov/show/NCT00037505||203781|
NCT00032968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0002-1|Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1|Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2001|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment||||341|||Both|15 Years|N/A|No|||April 2010|April 13, 2010|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00032968||204109|
NCT00033111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0007-1|A Study of Cabergoline for the Treatment of Cocaine Dependence - 1|Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|June 2001|April 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||July 2008|July 21, 2008|April 5, 2002||||||https://clinicaltrials.gov/show/NCT00033111||204098|
NCT00033085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0005-1|Ondansetron for the Treatment of Cocaine Dependence - 1|Double-Blind, Placebo-Controlled Trial of Ondansetron for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|May 2001|December 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||July 2008|July 21, 2008|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00033085||204100|
NCT00033098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0006-1|Cocaine-Metyrapone Interaction Study - 1|Cocaine-Metyrapone Interaction Study||National Institute on Drug Abuse (NIDA)||Active, not recruiting|November 2001|May 2002||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|45 Years|No|||August 2003|October 23, 2007|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00033098||204099|
NCT00033423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069282|Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase I, Multicenter, Open Label, Dose Escalation Of 90Y-Zevalin Radioimmunotherapy Using A Modified Treatment Regimen For Relapsed Or Refractory CD20+ B-Cell (Follicular/Transformed) Non-Hodgkin's Lymphoma||University of Alabama at Birmingham|Yes|Terminated|August 2001|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|18|||Both|19 Years|N/A|No|||December 2013|December 12, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033423||204074|
NCT00037674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003199|A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Two Doses of Topiramate for the Treatment of Acute Manic or Mixed Episodes in Patients With Bipolar I Disorder With an Optional Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2001|May 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|434|||Both|16 Years|N/A|No|||January 2011|May 17, 2011|May 20, 2002||||||https://clinicaltrials.gov/show/NCT00037674||203768|
NCT00032981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0004-1|Motivational Enhancement to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1|Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse||National Institute on Drug Abuse (NIDA)|Yes|Completed|May 2001|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||561|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00032981||204108|
NCT00033826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR047869|Role of Fat Tissue in Vitamin D Metabolism|The Role of Adipose Tissue in Vitamin D Metabolism||Tufts University|No|Completed|April 2002|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|41|||Both|18 Years|65 Years|No|Non-Probability Sample|patients from Obesity Clinic|May 2013|May 23, 2013|April 10, 2002||No||No||https://clinicaltrials.gov/show/NCT00033826||204048|
NCT00033839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-02-02|A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache||Winston Laboratories||Completed|January 2002|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|April 11, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033839||204047|
NCT00033657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069309|Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer|Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus||Eastern Cooperative Oncology Group|No|Completed|May 2002|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|April 9, 2002||No||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00033657||204058|
NCT00033683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069311|Combination Chemotherapy in Treating Women With Resected Breast Cancer|A Randomised Trial Of Standard Anthracycline-Based Chemotherapy With Fluorouracil, Epirubicin And Cyclophosphamide (FEC) Or Epirubicin And CMF (Epi-CMF) Versus FEC Followed By Sequential Docetaxel As Adjuvant Treatment For Women With Early Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2001|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2005|February 6, 2009|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033683||204057|
NCT00034047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000453-01|Endometriosis : Traditional Medicine vs Hormone Therapy|Endometriosis : Traditional Medicine vs Hormone Therapy||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2002|August 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|45 Years|No|||January 2008|January 23, 2008|April 19, 2002||No||No||https://clinicaltrials.gov/show/NCT00034047||204032|
NCT00033709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069314|Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma|A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma||National Cancer Institute (NCI)||Active, not recruiting|March 2002|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|January 3, 2014|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033709||204055|
NCT00034216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020179|Collection of Blood From Patients With Cancer|Biospecimen Acquisition From Human Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|April 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|100 Years|No|||February 2016|February 18, 2016|April 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00034216||204020|
NCT00034229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020176|Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression|A Double-Blind Randomized Placebo-Controlled Trial of Felbamate in Treatment Resistant Bipolar Depression||National Institutes of Health Clinical Center (CC)||Completed|April 2002|March 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||52|||Both|N/A|N/A|No|||March 2006|March 3, 2008|April 24, 2002||||No||https://clinicaltrials.gov/show/NCT00034229||204019|
NCT00033943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP201|Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis|A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Two Dosage Levels of OP2000 (75 Mg and 125 Mg) Administered Once Daily by Subcutaneous Injection for the Treatment of Active Ulcerative Colitis||Incara Pharmaceuticals||Completed|January 2001|September 2002||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|18 Years|60 Years|No|||October 2002|June 23, 2005|April 16, 2002||||||https://clinicaltrials.gov/show/NCT00033943||204040|
NCT00033553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069300|Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer|Induction/Concurrent Chemotherapy and Dose-Escalated Three Dimensional Thoracic Radiation for Patients With Stage III Non Small Cell Lung Cancer: A Randomized Phase II Study||Alliance for Clinical Trials in Oncology|No|Completed|March 2002|June 2010|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033553||204065|
NCT00032994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0005-1|Motivational Interviewing to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1|Motivational Interviewing (MI) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2001|October 2002||October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||422|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00032994||204107|
NCT00034073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020182|Magnetic Resonance Imaging in Children and Adults Using Arterial Spin Tagging Techniques|Quantitative fMRI in Children and Adults Using Arterial Spin Tagging Techniques||National Institutes of Health Clinical Center (CC)||Completed|April 2002|April 2009||||N/A|Observational|N/A||||70|||Both|8 Years|50 Years|No|||April 2009|April 17, 2009|April 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00034073||204030|
NCT00033969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020169|Study of Proteins Associated With Complex Regional Pain Syndrome|Complex Regional Pain Syndrome Proteomics Study||National Institutes of Health Clinical Center (CC)||Terminated|April 2002|October 2014||||N/A|Observational|N/A|||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 24, 2014|April 17, 2002||No||No||https://clinicaltrials.gov/show/NCT00033969||204038|
NCT00033917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS027116|Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial|Randomized Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial||Yale University||Completed|September 1989|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|630|||Both|N/A|6 Hours|Accepts Healthy Volunteers|||February 2013|February 20, 2013|April 12, 2002||No||No|January 8, 2013|https://clinicaltrials.gov/show/NCT00033917||204041|
NCT00033189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC0301|An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy|||Cooperative International Neuromuscular Research Group||Completed|September 2001|January 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Male|5 Years|11 Years|No|||November 2010|November 15, 2010|April 8, 2002||||||https://clinicaltrials.gov/show/NCT00033189||204092|
NCT00033163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5127|A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV|A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|April 8, 2002||||||https://clinicaltrials.gov/show/NCT00033163||204094|
NCT00033137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020159|Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer|The Birt Hogg-Dube Syndrome: Identification of the Disease Gene and Characterization of the Predisposition of Renal Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|April 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|800|||Both|4 Years|65 Years|No|||April 2015|April 22, 2015|April 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00033137||204096|
NCT00033982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020171|Posaconazole to Treat Invasive Fungal Infections|Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections||National Institutes of Health Clinical Center (CC)||Completed|April 2002|February 2007||||Phase 3|Interventional|Primary Purpose: Treatment||||50|||Both|2 Years|N/A|No|||February 2007|September 26, 2015|April 18, 2002||||No||https://clinicaltrials.gov/show/NCT00033982||204037|
NCT00033878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000896-01|Study of Noni in Cancer Patients|Phase I Study of Noni in Cancer Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2001|June 2006|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2007|March 27, 2007|April 11, 2002||||No||https://clinicaltrials.gov/show/NCT00033878||204044|
NCT00033254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02461|Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases|A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC#66847) Versus Conventional Radiation Therapy for Multiple Brain Metastases||National Cancer Institute (NCI)||Completed|March 2002|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033254||204087|
NCT00033267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01870|CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma|A Phase II Study of CCI-779 in Previously Treated Patients With Mantle Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|April 2002|February 2008|Actual|February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2012|April 2, 2014|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033267||204086|
NCT00034307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH01/FPH01-X|Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension|A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension||ICOS-Texas Biotechnology||Active, not recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|16 Years|75 Years|No|||May 2002|June 23, 2005|April 24, 2002||||||https://clinicaltrials.gov/show/NCT00034307||204013|
NCT00033735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069317|Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer|Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma||Eisai Inc.|Yes|Completed|January 2000|||June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|April 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00033735||204053|
NCT00033748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069324|Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver|Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer||Alliance for Clinical Trials in Oncology|No|Completed|December 2001|June 2010|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033748||204052|
NCT00033345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069276|Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer|Multiple Daily Dose Phase I Safety And Pharmacokinetic Clinical Study Of Indole-3-Carbinol||National Cancer Institute (NCI)||Completed|January 2002|||||Phase 1|Interventional|Primary Purpose: Prevention|||||||Female|18 Years|70 Years|No|||March 2003|July 23, 2008|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033345||204080|
NCT00033033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0001-1|Reserpine for the Treatment of Cocaine Dependence - 1|Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|July 2001|May 2003||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||August 2008|August 15, 2008|April 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00033033||204104|
NCT00033488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069292|Screening Women at High Genetic Risk for Ovarian Cancer|The UK Familial Ovarian Cancer Screening Study||National Cancer Institute (NCI)||Completed|September 2000|March 2010|Actual|||N/A|Interventional|Primary Purpose: Screening|||Anticipated|5000|||Female|35 Years|N/A|No|||June 2007|December 17, 2013|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033488||204069|
NCT00034112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000207-01A1|Efficacy of Osteopathic Manipulation in Chronic Obstructive Pulmonary Disease|Efficacy of Osteopathic Manipulation in Chronic Obstructive Pulmonary Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2001|March 2002||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2006|August 17, 2006|April 22, 2002||||No||https://clinicaltrials.gov/show/NCT00034112||204028|
NCT00033566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069301|S-3304 in Treating Patients With Advanced Solid Tumors|A Phase I Study of S-3304 in Patients With Solid Tumors||Roswell Park Cancer Institute|Yes|Completed|October 2001|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 3, 2011|April 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00033566||204064|
NCT00033592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N99C4|Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking|Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention||Alliance for Clinical Trials in Oncology|No|Completed|February 2002|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|15||Actual|1708|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033592||204063|
NCT00033605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N00CA|Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis|Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2002|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|130|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033605||204062|
NCT00033150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UO1 DC 4560|A Comparison of Language Intervention Programs|A Comparison of Language Intervention Programs||National Institute on Deafness and Other Communication Disorders (NIDCD)||Completed|June 2002|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||216|||Both|6 Years|9 Years|No|||April 2006|April 21, 2006|April 8, 2002||||No||https://clinicaltrials.gov/show/NCT00033150||204095|
NCT00034125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3883|Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.|a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.||Eli Lilly and Company||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2006|July 18, 2006|April 23, 2002||||||https://clinicaltrials.gov/show/NCT00034125||204027|
NCT00033124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0009-1|A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1|Behavioral Trial for the Treatment of Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)||Active, not recruiting|July 2001|June 2002||||Phase 2|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||August 2003|February 8, 2007|April 5, 2002||||No||https://clinicaltrials.gov/show/NCT00033124||204097|
NCT00033202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST 01-401|This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor|Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.||Sigma-Tau Research, Inc.||Completed|March 2002|February 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|April 9, 2002||Yes||||https://clinicaltrials.gov/show/NCT00033202||204091|
NCT00034060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020170|The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept|Suppression of the Growth Hormone/ Insulin-Like Growth Factor-1 (GH/IGF-1) Axis in Women With Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Completed|April 2002|December 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||36|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2005|March 3, 2008|April 19, 2002||||No||https://clinicaltrials.gov/show/NCT00034060||204031|
NCT00033280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-BR-0131|Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas|A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas||Radiation Therapy Oncology Group|Yes|Active, not recruiting|July 2002|||April 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|April 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00033280||204085|
NCT00033436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069283|Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer|A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer||National Cancer Institute (NCI)||Completed|October 2000|November 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|330|||Both|18 Years|N/A|No|||December 2002|September 19, 2013|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033436||204073|
NCT00033449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02462|Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase I Study Of ZD 1839 In Combination With Radiation And Chemotherapy In Locally Advanced Squamous Cell Carcinoma Of The Head And Neck||National Cancer Institute (NCI)||Terminated|February 2002|||April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|April 9, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00033449||204072|
NCT00033358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00466|Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer|Modulation Of Putative Surrogate Endpoint Biomarkers In Endometrial Biopsies From Women With HNPCC||National Cancer Institute (NCI)||Completed|February 2002|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Female|25 Years|50 Years|No|||April 2013|May 2, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033358||204079|
NCT00033371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00844|Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis|A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients||National Cancer Institute (NCI)|Yes|Terminated|December 2001|December 2014|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|65 Years|No|||May 2013|January 26, 2015|April 9, 2002|Yes|Yes|Slow recruitment.|No|January 26, 2015|https://clinicaltrials.gov/show/NCT00033371||204078|Following reports of COX-2 inhibitor-associated cardiovascular toxicities, trial suspended from December 17, 2004 to March 18, 2005 pending reevaluation of cardiovascular risks, only two sites resumed the trial.
NCT00033228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069252|Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Phase I/II Pilot Study Of Intranodal Delivery Of A Plasmid DNA (Synchrovax SEM Vaccine) In Stage IV Melanoma Patients||Mannkind Corporation|No|Completed|January 2002|April 2003|Actual|March 2003|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||May 2011|May 11, 2011|April 9, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00033228||204089|
NCT00033644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069308|Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus|A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus||Gynecologic Oncology Group||Terminated|March 2002|||October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2004|April 10, 2013|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033644||204059|
NCT00033956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10-01-12-002|Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2|Phase I/II Open Label Dose Escalation and Double-Blind, Placebo-Controlled Evaluation of M40403, for the Prevention of the Dose Limiting Toxicities of High Dose IV Bolus IL-2 Treatment of Metastatic Melanoma or Renal Cell Carcinoma.||MetaPhore Pharmaceuticals||Suspended|December 2001|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||48|||Both|18 Years|N/A|No|||May 2002|June 23, 2005|April 17, 2002||||||https://clinicaltrials.gov/show/NCT00033956||204039|
NCT00034008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000734-01|Efficacy of Healing Touch in Stressed Neonates|Efficacy of Healing Touch in Stressed Neonates||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2003|July 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||13|||Both|N/A|N/A|No|||July 2006|August 17, 2006|April 19, 2002||||No||https://clinicaltrials.gov/show/NCT00034008||204035|
NCT00034021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000224-01A2|Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction|Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction||National Center for Complementary and Integrative Health (NCCIH)||Completed|June 2002|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|65 Years|No|||July 2006|August 17, 2006|April 19, 2002||||No||https://clinicaltrials.gov/show/NCT00034021||204034|
NCT00033514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069295|Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression|Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression||Jonsson Comprehensive Cancer Center|Yes|Completed|August 2001|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||August 2013|October 29, 2015|April 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00033514||204068|
NCT00034437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020189|Immune Response to Cytomegalovirus|Measurement of Cytomegalovirus (CMV)-Specific T Lymphocytes in CMV-Seropositive Normal Volunteers.||National Institutes of Health Clinical Center (CC)||Completed|April 2002|April 2003||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||April 2003|March 3, 2008|April 27, 2002||||No||https://clinicaltrials.gov/show/NCT00034437||204005|
NCT00033241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-155|Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors|A Phase Ib Multicenter Trial To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Gemcitabine Administered In Combination With Escalating Oral Doses Of OSI-774 To Patient Cohorts With Recently Diagnosed, Gemcitabine-Naive, Advanced Pancreatic Carcinoma Or Other Potentially Responsive Malignancies||Astellas Pharma Inc||Completed|June 2001|April 2004|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2015|June 12, 2015|April 9, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00033241||204088|
NCT00037492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS032324|Families In Recovery From Stroke Trial (F.I.R.S.T.)|Psychological Intervention in Stroke Recovery||National Institute of Neurological Disorders and Stroke (NINDS)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention||||291|||Both|45 Years|N/A|No|||May 2007|May 21, 2007|May 17, 2002||||No||https://clinicaltrials.gov/show/NCT00037492||203782|
NCT00035594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010144|Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy|A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects With Advanced Breast Cancer Treated With Single Agent Docetaxel||Amgen||Completed|February 2002|June 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2|||928|||Both|N/A|N/A|No|||May 2013|May 7, 2013|May 3, 2002||||No||https://clinicaltrials.gov/show/NCT00035594||203918|
NCT00035607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010199|Chemotherapy Related Anemia|A Randomized, Open-label, Multicenter Study of Subcutaneous and Intravenous Administration of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy||Amgen||Completed|December 2001|April 2003|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|May 3, 2002||||No||https://clinicaltrials.gov/show/NCT00035607||203917|
NCT00037570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001K2-201|Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage|A Randomized Study of the Effect of Intravenous Pantoprazole on Gastric pH After Successful Hemostasis in Patients With Bleeding Peptic Ulcer||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2000|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Actual|12|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|May 17, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00037570||203776|
NCT00037583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903B1-206|Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia|A Dose-Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (go) Given in Combination With Cytarabine and Daunorubicin in Relapsed or Refractory Patients and in Younger de Novo Patients With Acute Myeloid Leukemia (AML)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|69|||Both|18 Years|59 Years|No|||August 2009|August 20, 2009|May 17, 2002||||||https://clinicaltrials.gov/show/NCT00037583||203775|
NCT00037375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1166|Physical Activity, Body Composition, and Prevalent Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2001|June 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||February 2005|February 17, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037375||203791|
NCT00037388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1167|Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2004|June 2006|Actual|June 2006|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037388||203790|
NCT00037401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1168|Postprandial Lipemia and Endothelial Function in ACCORD- Ancillary to ACCORD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2005|Actual|August 2005|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|50 Years|75 Years|No|||January 2008|February 17, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037401||203789|
NCT00038090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-070|Thalidomide-Dexamethasone for Multiple Myeloma|Thalidomide-Dexamethasone for Multiple Myeloma||M.D. Anderson Cancer Center|No|Completed|September 2001|May 2005|Actual|May 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|N/A|N/A|No|||July 2012|July 31, 2012|May 28, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038090||203737|
NCT00038012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN97-310|rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin|A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved With Thrombosol and 2% DMSO in Patients With Gynecologic Malignancy Receiving Carboplatin||M.D. Anderson Cancer Center|No|Completed|September 1999|June 2004|Actual|October 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|15 Years|N/A|No|||July 2012|July 31, 2012|May 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038012||203743|
NCT00037973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F2302|Effect of Ventilation-Feedback Training on Exercise Performance in COPD|Effects of Ventilation-Feedback Training on Exercise Performance in COPD||VA Office of Research and Development|No|Completed|August 2000|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|40 Years|N/A|No|||September 2010|September 15, 2010|May 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00037973||203746|
NCT00037739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1175|Chronic Obstructive Pulmonary Disease Gene Localization|||University of Utah||Completed|April 2001|March 2004||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2016|January 19, 2016|May 20, 2002||||No||https://clinicaltrials.gov/show/NCT00037739||203763|
NCT00037752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1176|Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates|Use of Sibutramine in Smoking Cessation|SUCCESS|University of Tennessee|Yes|Completed|September 2002|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|436|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|May 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00037752||203762|
NCT00037882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM00-150|PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron|A Phase II Study of SCH 54031 (Peg Interferon Alpha-2B/PEG-Intron) in Subjects With Interferon-Refractory Chronic Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Terminated|February 2001|December 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|N/A|No|||July 2012|July 31, 2012|May 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00037882||203753|
NCT00037895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2340R|Stroke Rehabilitation Outcomes With Supported Treadmill Ambulation Training|Stroke Rehabilitation Outcomes With Supported Treadmill Ambulation Training||VA Office of Research and Development||Completed|January 2001|December 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||May 2002|January 20, 2009|May 24, 2002||||No||https://clinicaltrials.gov/show/NCT00037895||203752|
NCT00031135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-1994-01|Total Parenteral Nutrition-Associated Liver Disease|Prevention of TPN-Associated Hepatic Steatosis: A Placebo Controlled Trial||FDA Office of Orphan Products Development||Terminated|September 2001|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|48|||Both|21 Years|74 Years|No|||January 2002|March 24, 2015|February 26, 2002||||||https://clinicaltrials.gov/show/NCT00031135||204239|
NCT00037687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAR03|Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis|A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®) for Reducing 28 Day All Cause Mortality in Patients With Severe Sepsis||ICOS Corporation||Terminated|April 2001|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2500|||Both|18 Years|N/A|No|||January 2003|June 23, 2005|May 20, 2002||||||https://clinicaltrials.gov/show/NCT00037687||203767|
NCT00037700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000198|Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis|||Swedish Orphan Biovitrum||Completed|May 2001|December 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|November 25, 2009|May 20, 2002||||||https://clinicaltrials.gov/show/NCT00037700||203766|
NCT00036881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N01C4|Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer|Phase III Double-Blind, Placebo-Controlled Randomized Comparison Of Zinc Sulfate Versus Placebo For The Prevention Of Altered Taste In Patients With Head And Neck Cancer During Radiation||Alliance for Clinical Trials in Oncology|Yes|Completed|May 2002|June 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|173|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|May 13, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036881||203828|
NCT00037999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2419R|The Effect of Testosterone Supplementation on Rehabilitation Outcomes|The Effect of Testosterone Supplementation on Rehabilitation Outcomes||VA Office of Research and Development||Completed|April 2001|March 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Male|65 Years|N/A|No|||May 2002|January 20, 2009|May 24, 2002||||No||https://clinicaltrials.gov/show/NCT00037999||203744|
NCT00036998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069347|Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer|A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast||National Cancer Institute (NCI)||Active, not recruiting|August 2001|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2004|November 5, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036998||203820|
NCT00037011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-075|Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma|Phase I Study of Oral Beta-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma||Memorial Sloan Kettering Cancer Center||Completed|November 2001|||January 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|N/A|49 Years|No|||January 2013|January 17, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00037011||203819|
NCT00037284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1159|Behavioral and Immunological Factors in Coronary Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2001|May 2008|Actual|May 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 1, 2008|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037284||203798|
NCT00037297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160|Epidemiology of Cardiovascular Disease in Diabetes|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2001|June 2007|Actual|June 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037297||203797|
NCT00037024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009493|Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer|Project LEAD: Promoting Health Among Populations With Early Stage Cancers||Duke University|Yes|Completed|April 2002|October 2004|Actual|February 2004|Actual|N/A|Interventional|N/A|||||||Both|65 Years|N/A|No|||November 2012|July 11, 2014|May 13, 2002||No||No||https://clinicaltrials.gov/show/NCT00037024||203818|
NCT00031057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5129|Vitamin B Therapy for Hyperlactatemia|A Pilot Study of Oral B Vitamin Therapy for Asymptomatic or Mildly Symptomatic Hyperlactatemia in Patients on NRTIs||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||March 2003|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||225|||Both|13 Years|N/A|No|||November 2004|February 25, 2011|February 20, 2002||||No||https://clinicaltrials.gov/show/NCT00031057||204245|
NCT00031070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5138|Increasing HAART-Induced Immune Restoration With Cyclosporine|Augmenting the Magnitude of HAART-Induced Immune Restoration With the Use of Cyclosporine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2006|March 5, 2015|February 20, 2002||||No||https://clinicaltrials.gov/show/NCT00031070||204244|
NCT00035789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-027|A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen|||Bristol-Myers Squibb||Completed|November 2001|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||January 2010|April 7, 2011|May 5, 2002||||||https://clinicaltrials.gov/show/NCT00035789||203904|
NCT00035919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-01-2|Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver|Tumor Site Specific Phase I Evaluation of Safety of Hepatic Arterial Infusion of a Matrix-Targeted Retroviral Vector Bearing a Dominant Negative Cyclin G1 Construct as Intervention for Colorectal Carcinoma Metastatic to Liver||University of Southern California||Withdrawn|November 2002|October 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|May 6, 2002|||Never received final IRB approval for amendments, so never opened officially|No||https://clinicaltrials.gov/show/NCT00035919||203894|
NCT00037310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1161|New CVD Risk Factors for Lowered Cognitive Functioning|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|March 2007|Actual|March 2007|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|January 18, 2008|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037310||203796|
NCT00037414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1169|Joint Determinants of Bone Density and CVD Calcification|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 21, 2008|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037414||203788|
NCT00037427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1170|Airway Responses Following Chlorine Gas Exposure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|July 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||May 2005|March 15, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037427||203787|
NCT00037440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1171|Genetic Epidemiology of Change in CVD Risk Factors|Genetic Epidemiology of Change in CVD Risk Factors (HL70568-1)||The University of Texas Health Science Center, Houston|No|Completed|September 2001|August 2005|Actual|August 2005|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|1735|||Both|8 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community study of schoolchildren in Bogalusa, Louisiana, with follow-up into young        adulthood. Both whites and African Americans recruited.|December 2014|December 1, 2014|May 16, 2002||No||No||https://clinicaltrials.gov/show/NCT00037440||203786|
NCT00037453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1172|Analysis of Sex Hormones and Lipoproteins in Young Males|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|March 2003|Actual|||N/A|Observational|N/A|||||||Male|10 Years|15 Years|No|||August 2004|March 15, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037453||203785|
NCT00038051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-342|Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies|Phase I Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies||M.D. Anderson Cancer Center|Yes|Completed|May 1999|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|May 24, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038051||203740|
NCT00031148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-2021-01|Keratinocyte Growth Factor to Prevent Acute GVHD|Phase I/II Trial of Keratinocyte Growth Factor (rHuKGF) to Prevent Acute GVHD in 6/6 HLA=BMT Recipients||FDA Office of Orphan Products Development||Completed|September 2001|August 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||72|||Both|3 Years|65 Years|No|||January 2002|March 24, 2015|February 26, 2002||||||https://clinicaltrials.gov/show/NCT00031148||204238|
NCT00037544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B1-306|Study Evaluating ReFacto AF in Severe Hemophilia A|An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) With Severe Hemophilia A||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||April 2008|April 18, 2008|May 17, 2002||||||https://clinicaltrials.gov/show/NCT00037544||203778|
NCT00037557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A1-301|Study Evaluating rFIX; BeneFIX in Severe Hemophilia B|An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Children Less Than 6 Years of Age With Severe Hemophilia B||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2002|November 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|5 Years|No|||December 2007|December 18, 2007|May 17, 2002||||No||https://clinicaltrials.gov/show/NCT00037557||203777|
NCT00037843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUM88-001|Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening|Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening||M.D. Anderson Cancer Center||Completed|December 1988|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|114|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|May 23, 2002||||No||https://clinicaltrials.gov/show/NCT00037843||203755|
NCT00037869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-063|High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors|High Dose I-131 Metaiodobenzylguanidine (MIBG) Therapy for Metastatic Neuroendocrine Tumors||M.D. Anderson Cancer Center|No|Completed|November 2001|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|2 Years|N/A|No|||July 2012|July 31, 2012|May 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00037869||203754|
NCT00038064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010101|Anemia in Patients With a Non-Myeloid Malignancy|A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulation Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy||Amgen||Completed|January 2002|April 2004|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|707|||Both|18 Years|N/A|No|||September 2008|September 11, 2008|May 28, 2002||||No||https://clinicaltrials.gov/show/NCT00038064||203739|
NCT00037934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2436|Robotic Upper-Limb Neurorehabilitation in Chronic Stroke Patient|Evaluation of Robotic Upper Extremity Neuro-Rehabilitation||VA Office of Research and Development|No|Completed|April 2002|December 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|May 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00037934||203749|
NCT00037947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2568R|Auditory Function in Patients With and Without Multiple Sclerosis|Auditory Function in Patients With and Without Multiple Sclerosis||VA Office of Research and Development||Completed|October 2001|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|May 24, 2002||||No||https://clinicaltrials.gov/show/NCT00037947||203748|
NCT00037960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2480T|Automated Constraint-Induced Therapy for Restoring Movement After Stroke|Automated Constraint-Induced Therapy for Restoring Movement After Stroke||VA Office of Research and Development||Completed|June 2001|June 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2002|January 20, 2009|May 24, 2002||||No||https://clinicaltrials.gov/show/NCT00037960||203747|
NCT00037765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL068890|Gene Modifiers of Cystic Fibrosis Lung Disease|Gene Modifiers of Cystic Fibrosis Lung Disease||University of North Carolina, Chapel Hill|No|Active, not recruiting|September 2001|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|100 Years|No|Non-Probability Sample|CF patients who have the same CFTR genetic background, i.e., homozygous deltaF508, and who        are at the extremes of pulmonary phenotype, i.e., the most severe and mildest lung        disease.|October 2015|October 26, 2015|May 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00037765||203761|
NCT00037986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2439R|Functioning, Disability, and Quality of Life in the Adult Hearing Impaired|Functioning, Disability, and Quality of Life in the Adult Hearing Impaired||VA Office of Research and Development||Completed|July 2001|June 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|330|||Both|18 Years|N/A|No|||February 2009|February 9, 2009|May 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00037986||203745|
NCT00037115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANI-MTX02-001|Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.|An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results.||MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute||Withdrawn|May 2002|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|50 Years|No|||November 2009|November 20, 2009|May 15, 2002|||Lack of funding|||https://clinicaltrials.gov/show/NCT00037115||203811|
NCT00037128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL97-01|Study of GL701 in Men With Systemic Lupus Erythematosus|||Genelabs Technologies||Active, not recruiting|March 1998|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Male|18 Years|N/A|No|||May 2004|December 8, 2005|May 16, 2002||||||https://clinicaltrials.gov/show/NCT00037128||203810|
NCT00031564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12207|Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2|Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 for Patients With Stage IV Renal Cell Carcinoma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|May 2000|June 2012|Actual|June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|March 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00031564||204209|
NCT00031577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-6-1780|Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma|A Phase I Study Of Taxol And Involved Field Radiation Therapy For Newly Diagnosed Intrinsic Gliomas Of Childhood||Children's Hospital of Philadelphia||Terminated|August 1999|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|11|||Both|3 Years|21 Years|No|||January 2014|March 17, 2015|March 8, 2002|No|Yes|Administrative closure 9/22/2006. Decline in enrollment at CHOP. due to competing protocols    with new agents.|No||https://clinicaltrials.gov/show/NCT00031577||204208|
NCT00037089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS-200604|A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer|||Edelman, Martin, M.D.||Active, not recruiting||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|79 Years|No|||January 2005|June 23, 2005|May 14, 2002||||||https://clinicaltrials.gov/show/NCT00037089||203813|
NCT00037102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANI-MTX01-001|Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis|An Open Label Study of the Safety and Efficacy of Combination Therapy With AVONEX and Bi-Monthly High Dose Intravenous Methotrexate With Leucovorin Rescue in the Treatment of Multiple Sclerosis|MTX01|MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute||Completed|July 2001|December 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|60 Years|No|||November 2003|June 16, 2009|May 15, 2002||No||||https://clinicaltrials.gov/show/NCT00037102||203812|
NCT00037466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1173|Relation of Diet to Serum Homocysteine Level in Youths|Relation of Diet to Serum Homocysteine Level in Youths||Children's Hospital Boston|No|Completed|September 2000|November 2002|Actual|August 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2445|||Both|10 Years|18 Years|No|Non-Probability Sample|The CATCH study initially recruited 5,106 third grade students to participate in a risk        factor screening at baseline. Of these, 3645 (71%) participated in risk factor screening        at the end of grade 8 when serum tHcy, folate, vitamin B6 and vitamin B12 were first        assessed and 2909 (57%) students participated in the follow-up risk factor screening in        grade 12. Of these students, 2445, attended both grade 8 and grade 12 examinations and        provided blood at both examinations. This group constituted the study population for this        report.|February 2005|March 1, 2016|May 16, 2002||No||No||https://clinicaltrials.gov/show/NCT00037466||203784|
NCT00037635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000172|A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients|A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis||Amgen||Completed|December 2001|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|May 17, 2002||||No||https://clinicaltrials.gov/show/NCT00037635||203771|
NCT00037648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990758-990779|Juvenile Rheumatoid Arthritis|A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuIL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis||Swedish Orphan Biovitrum||Completed|July 2000|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|2 Years|17 Years|No|||February 2008|November 25, 2009|May 17, 2002||||No||https://clinicaltrials.gov/show/NCT00037648||203770|
NCT00037141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMS002|Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)|Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate)||American Medical Systems||Completed|March 2002|March 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||150|||Male|50 Years|80 Years|No|||June 2004|October 4, 2007|May 15, 2002||||||https://clinicaltrials.gov/show/NCT00037141||203809|
NCT00037154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 R01 DK056199 (completed)|Saw Palmetto Extract in Benign Prostatic Hyperplasia|Saw Palmetto Extract In Benign Prostatic Hyperplasia||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 1999|December 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||224|||Male|50 Years|N/A|No|||January 2010|January 12, 2010|May 16, 2002||||||https://clinicaltrials.gov/show/NCT00037154||203808|
NCT00036946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGENERON-VGFT-ST-0103|VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma|An Open-Label, Sequential Cohort Dose-Escalation Safety, Tolerability And Pharmacokinetic Study Of VEGF Trap In Patients With Incurable, Relapsed Or Refractory Solid Tumors Or Lymphoma||Regeneron Pharmaceuticals||Completed|November 2001|||March 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|25 Years|N/A|No|||April 2005|April 15, 2013|May 13, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036946||203824|
NCT00036959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020141|ABT-751 in Treating Young Patients With Refractory Solid Tumors|Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|March 2002|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Both|N/A|18 Years|No|||March 2012|March 14, 2012|May 13, 2002||||||https://clinicaltrials.gov/show/NCT00036959||203823|
NCT00037323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1162|Framingham Offspring Study: Psychosocial Risk Factors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 2001|October 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||May 2004|March 15, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037323||203795|
NCT00037336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1163|Atherosclerosis in Rheumatoid Arthritis|||Vanderbilt University||Completed|September 2001|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Both|18 Years|N/A|No||people with rheumatoid arthritis|March 2014|March 14, 2014|May 16, 2002||No||No||https://clinicaltrials.gov/show/NCT00037336||203794|
NCT00037349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1164|Heart Rate Recovery and Mortality|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 2001|February 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2005|February 17, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037349||203793|
NCT00037661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-108|Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye|Double-Masked, Randomized, Placebo-Controlled Study of Efficacy Parameter Following Administration of INS365 Ophthalmic Solution or Placebo in a Controlled Adverse Environment (CAE) Chamber in Subjects With Non-Sjogren's Associated Dry Eye||Merck Sharp & Dohme Corp.||Completed|April 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|222|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|May 18, 2002||||||https://clinicaltrials.gov/show/NCT00037661||203769|
NCT00037518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000204|A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer|An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.||Amgen||Completed|April 2001|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||46|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|May 17, 2002||||||https://clinicaltrials.gov/show/NCT00037518||203780|
NCT00037531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E1-306|Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients|An Open-label Extension Study of the Safety of Long-term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study|||Actual|769|||Both|18 Years|N/A|No|||August 2009|August 17, 2009|May 17, 2002||||||https://clinicaltrials.gov/show/NCT00037531||203779|
NCT00037830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS038681|GM1 Ganglioside Effects on Parkinson's Disease|The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication||Thomas Jefferson University|No|Completed|November 1999|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|94|||Both|39 Years|85 Years|No|||December 2012|December 18, 2012|May 22, 2002|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00037830||203756|
NCT00038038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID93-028|Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole|Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole||M.D. Anderson Cancer Center|No|Withdrawn|January 1994|June 2003|Actual|June 2003|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|May 24, 2002|No|Yes|No participants enrolled, study terminated.|No||https://clinicaltrials.gov/show/NCT00038038||203741|
NCT00037921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2410R|UTI Prophylaxis Using Bacterial Interference Following SCI|UTI Prophylaxis Using Bacterial Interference Following SCI||VA Office of Research and Development||Completed|January 2001|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2010|May 5, 2010|May 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00037921||203750|
NCT00038142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID97-198|Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients|Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma||M.D. Anderson Cancer Center|Yes|Terminated|November 1997|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|3 Years|60 Years|No|||March 2016|March 3, 2016|May 29, 2002|Yes|Yes|Low Accrual|No||https://clinicaltrials.gov/show/NCT00038142||203733|
NCT00038155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2805G|Rehabilitation for Older Adults From Acute Medical Conditions|Rehabilitation for Older Adults From Acute Medical Conditions|STAGE|VA Office of Research and Development|No|Completed|May 2002|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|60 Years|N/A|No|||September 2010|September 22, 2010|May 29, 2002||No||No||https://clinicaltrials.gov/show/NCT00038155||203732|
NCT00038168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-268|Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma|Phase I/II Study of Intravenous Estramustine Phosphate Combined With Taxol in Patients With Hormone Refractory Adenocarcinoma of the Prostate||M.D. Anderson Cancer Center|No|Completed|June 2000|January 2003|Actual|January 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|N/A|N/A|No|||July 2012|July 31, 2012|May 29, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038168||203731|
NCT00038116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-0097|Embryonic Dopamine Cell Implants for Parkinson's Disease|Embryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind Study||University of Colorado, Denver||Completed|May 1995|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|75 Years|No|||March 2010|February 4, 2013|May 29, 2002||No||No||https://clinicaltrials.gov/show/NCT00038116||203735|
NCT00038129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR048529|SPRINT - Randomized Trial of Tibial Fracture Fixation|Study to Prospectively Evaluate Reamed Intramedullary Nails in Tibial Shaft Fractures (SPRINT)||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2002|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|16 Years|N/A|No|||June 2013|June 17, 2013|May 29, 2002||No||No||https://clinicaltrials.gov/show/NCT00038129||203734|
NCT00036842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069328|Arsenic Trioxide in Treating Men With Germ Cell Cancer|Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies||National Cancer Institute (NCI)||Completed|April 2002|June 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Male|16 Years|N/A|No|||August 2004|June 21, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036842||203831|
NCT00037180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IQ8-01-02-016|For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy|Phase II, Randomized, Double-Blind, Multicenter Trial Of Celecoxib Vs Placebo For The Prevention Of Diarrhea Associated With CPT-11/5fu/LV Chemotherapy In Patients With Previously Untreated Metastatic Colorectal Cancer||Pfizer||Terminated|April 2002|January 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||212|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|May 16, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00037180||203806|
NCT00037193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00036-0855|Acute Regulation of Parathyroid Hormone by Dietary Phosphate|Acute Regulation of Parathyroid Hormone by Dietary Phosphate||National Center for Research Resources (NCRR)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|21 Years|N/A|No|||December 2003|June 23, 2005|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037193||203805|
NCT00037206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER002-7|A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).|An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis.||Pfizer||Completed|May 2002|February 2003|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||October 2008|October 17, 2008|May 16, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00037206||203804|
NCT00037219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER002-6|The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.|A Phase 2, Open-Label, Randomized, Dose-Ranging Study of the Safety and Efficacy of Intravenous Anidulafungin (VER002) in the Treatment of Patients With Invasive Candidiasis||Pfizer||Completed|August 2001|November 2002|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|N/A|No|||October 2008|October 17, 2008|May 16, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00037219||203803|
NCT00037232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1140|Failure Time Methods for Family Disease Studies|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|March 2005|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||May 2005|March 15, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037232||203802|
NCT00035451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999105|Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.|Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.||Forest Laboratories|No|Completed|February 2001|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|658|||Both|18 Years|80 Years|No|||September 2011|September 30, 2011|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035451||203929|
NCT00037063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5145|A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs|A Pilot Study of the Efficacy of a Combination of Antioxidants and B Vitamins in Preventing the Recurrence of Hyperlactatemia in Subjects Who Have Limited Antiretroviral Options||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Prevention|||Actual|0|||Both|13 Years|N/A|No|||June 2003|June 3, 2015|May 14, 2002||||No||https://clinicaltrials.gov/show/NCT00037063||203815|
NCT00037167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44AR048029|Effects of Exercise Poles on Older Adults During Exercise Walking|Impact of Running Poles on Older Adult Exercise Walking||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|September 2001|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||April 2009|April 8, 2009|May 16, 2002||No||No||https://clinicaltrials.gov/show/NCT00037167||203807|
NCT00037362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1165|Measuring Sensitivity to Nonignorability|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2005|Actual|August 2005|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||January 2008|January 18, 2008|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037362||203792|
NCT00037479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS038636|Brain Imaging and Retreatment Study of Persistent Lyme Disease|PET and MRI Imaging of Persistent Lyme Encephalopathy||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|December 1999|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||65|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2005|December 6, 2005|May 17, 2002||||No||https://clinicaltrials.gov/show/NCT00037479||203783|
NCT00037791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-OTPO-005|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.||Pfizer||Completed|December 1999|September 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||180|||Both|18 Years|N/A|No|||September 2006|November 8, 2006|May 21, 2002||||No||https://clinicaltrials.gov/show/NCT00037791||203759|
NCT00037804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M64750017|Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction|||Pfizer||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 13, 2009|May 21, 2002||||||https://clinicaltrials.gov/show/NCT00037804||203758|
NCT00037817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020205|Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies|Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies||National Institutes of Health Clinical Center (CC)||Completed|May 2002|November 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Both|18 Years|65 Years|No|||December 2015|January 5, 2016|May 21, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00037817||203757|
NCT00038025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM94-026|A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies|A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|September 1994|November 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|16 Years|N/A|No|||August 2012|August 1, 2012|May 24, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038025||203742|
NCT00037596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903B1-205|Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia|A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2000|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 11, 2013|May 17, 2002||Yes||||https://clinicaltrials.gov/show/NCT00037596||203774|
NCT00037609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-049|Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients|Phase I-II Study to Evaluate Safety, Efficacy and Pharmacokinetic Interactions Between Capecitabine (XELODA) and Exisulind (APTOSYN) in Patients With Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Completed|January 2001|February 2003|Actual|February 2003|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|N/A|No|||October 2012|October 22, 2012|May 17, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00037609||203773|
NCT00037622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-901|Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.|An Open-Label Treatment Protocol to Provide Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection||Achillion Pharmaceuticals||Terminated||May 2003|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||August 2009|August 18, 2009|May 17, 2002|||Safety concerns from other studies.|||https://clinicaltrials.gov/show/NCT00037622||203772|
NCT00037908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2405R|Effects of Strength Training on Upper-Limb Function in Post-Stroke Hemiparesis|Effects of Strength Training on Upper-Limb Function in Post-Stroke Hemiparesis||VA Office of Research and Development||Completed|October 2000|September 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||May 2002|January 20, 2009|May 24, 2002||||No||https://clinicaltrials.gov/show/NCT00037908||203751|
NCT00038077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|276|Reversal of Ventricular Remodeling With Toprol-XL|||AstraZeneca||Completed|August 2001|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||November 2010|November 17, 2010|May 28, 2002||||||https://clinicaltrials.gov/show/NCT00038077||203738|
NCT00038103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NQ8-01-02-013|Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen|Open-Label, Multicentre, Controlled Study Of Exemestane (Aromasin®) With Or Without Celecoxib (Celebrex®) In Postmenopausal Women With Advanced Breast Cancer (ABC) Having Progressed On Tamoxifen||Pfizer|No|Completed|January 2002|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Female|18 Years|N/A|No|||February 2010|February 11, 2010|May 29, 2002|Yes|Yes||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00038103||203736|
NCT00037713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILVA EORTC 08971|Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG|The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG||ImClone LLC|No|Completed|September 1998|October 2002|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|515|||Both|18 Years|N/A|No|||April 2010|April 7, 2010|May 20, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00037713||203765|
NCT00037726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1174|Antibiotics in Infancy--Risk Factor for Childhood Asthma|||Georgia Regents University||Completed|April 2001|March 2004||||N/A|Observational|N/A|||||||Both|N/A|7 Years|No|||December 2005|December 21, 2015|May 20, 2002||||No||https://clinicaltrials.gov/show/NCT00037726||203764|
NCT00037778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1178|Genetic Modifiers of Cystic Fibrosis: Sibling Study|Genetic Modifiers of Cystic Fibrosis: Sibling Study||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective|||||||Both|N/A|N/A|No|||April 2012|April 26, 2012|May 20, 2002||||No||https://clinicaltrials.gov/show/NCT00037778||203760|
NCT00036855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01871|Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma|A Phase I Study Of Yttrium-Ibritumomab Tiuxetan (90Y Zevalin, Yttrium (90)-Anti-CD20, NSC # 710085) Preceded By Rituximab In Children With Recurrent/Refractory CD20 Positive Lymphoma||National Cancer Institute (NCI)||Terminated|June 2002|||March 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|N/A|21 Years|No|||January 2013|January 16, 2013|May 13, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00036855||203830|
NCT00036972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOPHARM-IL13PEI-002-R01|Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma|Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma||National Cancer Institute (NCI)||Completed|November 2001|December 2009|Actual|January 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|June 25, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036972||203822|
NCT00036985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069346|Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer|A Randomized Pivotal Clinical Trial To Assess The Efficacy Of Pre-operative Focused Microwave Thermotherapy Treatment Combined With Pre-operative Chemotherapy For Cytoreduction Of Advanced Breast Cacer In Intact Breast||National Cancer Institute (NCI)||Active, not recruiting|August 2001|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2004|December 18, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036985||203821|
NCT00036868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10995-16999|Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer|A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|February 2002|||June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Female|18 Years|N/A|No|||June 2013|June 6, 2013|May 13, 2002||No||No||https://clinicaltrials.gov/show/NCT00036868||203829|
NCT00037245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1144|Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA|||University of Washington||Completed|September 2001|July 2005||||N/A|Observational|N/A|||||||Female|N/A|100 Years|No|||December 2005|February 8, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037245||203801|
NCT00037258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1156|Dyslipidemia and Risk of Cardiovascular Disease in Diabetic Men and Women|||Brigham and Women's Hospital||Completed|September 2001|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||March 2014|March 28, 2014|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037258||203800|
NCT00037271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1158|Genome Scan for Obesity in a Multi-Ethnic Sample|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2001|March 2003|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||August 2004|February 17, 2016|May 16, 2002||||No||https://clinicaltrials.gov/show/NCT00037271||203799|
NCT00036894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069338|CC-5013 in Treating Patients With Recurrent Glioma|A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas||National Cancer Institute (NCI)||Completed|March 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2003|April 29, 2015|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036894||203827|
NCT00036920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK-286.2004|TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|January 2002|December 2009|Actual|August 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|June 25, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036920||203826|
NCT00036933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-140|Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer|Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates Plus The Immunological Adjuvant QS21||Memorial Sloan Kettering Cancer Center||Completed|March 2002|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|No|||March 2013|March 22, 2013|May 13, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036933||203825|
NCT00036023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010162|Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies|A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy||Amgen||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||May 2009|May 7, 2009|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00036023||203887|
NCT00036426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FavId-01|Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma|Phase II Study of FavId (Tumor-Specific Idiotype-KLH) and Soluble GM-CSF Immunotherapy in Patients With Stable or Progressive Grade 1 and 2 Follicular B-Cell Lymphomas||Favrille||Active, not recruiting|March 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|18 Years|N/A|No|||October 2004|June 23, 2005|May 9, 2002||||||https://clinicaltrials.gov/show/NCT00036426||203858|
NCT00036218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|666E-CNS-0075-021|Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.|A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.||Pfizer||Completed|December 2001|April 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|30 Years|N/A|No|||June 2006|June 6, 2006|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036218||203873|
NCT00036231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG1068-03|Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction||Repligen Corporation||Terminated|April 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|32 Months|59 Months|No|||August 2005|November 17, 2005|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036231||203872|
NCT00036244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG1068-04|Synthetic Human Secretin in Children With Autism|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism||Repligen Corporation||Completed|April 2002|January 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|32 Months|59 Months|No|||August 2005|August 4, 2005|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036244||203871|
NCT00035412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000502-01A1|St. John's Wort Versus Placebo in Social Phobia|St. John's Wort Versus Placebo in Social Phobia||National Center for Complementary and Integrative Health (NCCIH)||Completed|December 2001|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||July 2006|August 17, 2006|May 3, 2002||||No||https://clinicaltrials.gov/show/NCT00035412||203932|
NCT00035425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12600079|Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection|A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections||Pfizer|No|Completed|November 2001|November 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|13 Years|N/A|No|||November 2009|November 30, 2009|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035425||203931|
NCT00036686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13021|Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy|A Clinical Trial of the Action of Isoflavones in Breast Neoplasia: Administration Prior to Mastectomy or Lumpectomy-A Pilot Study||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|December 2002|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1|||Female|18 Years|N/A|No|||September 2012|September 21, 2012|May 13, 2002|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00036686||203840|
NCT00036504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4050|Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin|Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients New to Insulin Therapy Who Were Inadequately Controlled on Oral Agents||Eli Lilly and Company||Completed|August 2001|August 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|30 Years|79 Years|No|||October 2010|October 12, 2010|May 10, 2002||||||https://clinicaltrials.gov/show/NCT00036504||203852|
NCT00036712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069293|Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation|A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients||National Cancer Institute (NCI)||Recruiting|January 2002|||August 2009|Anticipated|Phase 2|Interventional|Primary Purpose: Supportive Care|||Anticipated|80|||Both|2 Years|18 Years|No|||June 2009|September 19, 2013|May 13, 2002||No||No||https://clinicaltrials.gov/show/NCT00036712||203839|
NCT00036738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1581.00|Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib|Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia - a Multi-Center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|July 2001|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|70 Years|No|||July 2015|July 20, 2015|May 13, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036738||203838|
NCT00036751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02463|Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Trial Of STI571 For The Treatment Of Platinum And Taxane Refractory Stage III And IV Epithelial Ovarian Cancer And Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|April 2002|||August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|N/A|N/A|No|||January 2013|January 23, 2013|May 13, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036751||203837|
NCT00036140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196-ONC-0100-006|Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma|||Pfizer||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|June 23, 2005|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036140||203879|
NCT00036829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFLEXXION-50|Improving Pain Management in Patients With Nonhematologic Cancer|Improving Pain Management in Cancer Care||National Cancer Institute (NCI)||Completed|March 2002|April 2003|Actual|||N/A|Interventional|N/A|||||||Both|18 Years|N/A|No|||March 2003|July 17, 2013|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036829||203832|
NCT00035802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016867|A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2002|April 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|13 Years|17 Years|No|||June 2011|June 23, 2011|May 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035802||203903|
NCT00035685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|998|Exposure of Children With Asthma to Household Environmental Tobacco Smoke|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 2001|November 2006|Actual|||N/A|Observational|N/A|||||||Both|6 Years|12 Years|No|||January 2008|February 17, 2016|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035685||203912|
NCT00035698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999|Epidemiological and Genetic Studies of Body Mass Index|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 2001|January 2009|Actual|January 2009|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2009|January 30, 2009|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035698||203911|
NCT00035711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008|VA HDL Intervention Trial (VA-HIT) Ancillary Study Data Analysis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2004|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|100 Years|No|||November 2005|March 15, 2016|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035711||203910|
NCT00036465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5115|Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads|A Phase II, Randomized, Controlled, Pilot Study of Antiretroviral Switch at Lower Versus Higher HIV-1 RNA Levels in Subjects Experiencing Virologic Relapse on a Current HAART Regimen||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||July 2013|July 26, 2013|May 10, 2002||||No||https://clinicaltrials.gov/show/NCT00036465||203855|
NCT00035555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-100|Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney|Phase II/III, Open-Label, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 (Belatacept) as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients||Bristol-Myers Squibb||Completed|March 2001|July 2012|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|230|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|May 3, 2002|Yes|Yes||No|September 4, 2013|https://clinicaltrials.gov/show/NCT00035555||203921|
NCT00035568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV138-062|A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes|||Bristol-Myers Squibb||Completed|February 2002|June 2003|Actual|June 2003|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||||||Both|20 Years|75 Years|No|||April 2011|April 7, 2011|May 3, 2002||||||https://clinicaltrials.gov/show/NCT00035568||203920|
NCT00035581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP 719|Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART|A Multi-Center, Randomized, Controlled Study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease||Hemispherx Biopharma|No|Terminated|May 2001|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035581||203919|
NCT00039494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00640|Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors|A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|December 2002|||July 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|171|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039494||203636|
NCT00039611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069434|Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|Oxaliplatin (NSC 266046) in Combination With 5-Fluorouracil and Leucovorin (FOLFOX4) for Patients Who Have Not Received Prior Chemotherapy for Advanced Colorectal Cancer||National Cancer Institute (NCI)||Completed|May 2002|October 2007|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|N/A|No|||July 2002|June 18, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039611||203629|
NCT00035958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR047784|Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis|Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis||Children's Hospital Medical Center, Cincinnati||Terminated|August 2002|August 2002|Actual|August 2002|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|4 Years|16 Years|No|||July 2013|July 31, 2013|May 7, 2002|No|Yes|Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make    the project budget over the limit for this funding mechanism.|||https://clinicaltrials.gov/show/NCT00035958||203891|
NCT00036153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0-103|Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis|A Randomized, Double-Blind Study to Assess the Efficacy of Tacrolimus (Prograf®)+ Methotrexate Vs. Placebo + Methotrexate in the Treatment of Rheumatoid Arthritis in Patients With Partial Response to Methotrexate||Astellas Pharma Inc||Completed|March 2002|January 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|18 Years|N/A|No|||December 2011|March 26, 2012|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036153||203878|
NCT00036166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG463-21-01|Study of FK463 for the Treatment of Invasive Aspergillosis|An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis||Astellas Pharma Inc||Completed|January 1999|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|326|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|May 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036166||203877|
NCT00035672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|997|Genetic Predictors of Incident Cardiovascular Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 2002|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2008|April 22, 2008|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035672||203913|
NCT00039624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020207|Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer|A Phase II Study of MR-Guided High Dose Rate Brachytherapy Boosts For Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|May 2002|June 2010|Actual|July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|90 Years|No|||October 2015|October 29, 2015|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039624||203628|
NCT00036400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002365|Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2001|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|May 9, 2002||||||https://clinicaltrials.gov/show/NCT00036400||203860|
NCT00036413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCH346 0102|A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis|A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Safety and Dose-ranging Study of Three Oral Doses (0.5 mg, 2.5 mg and 10 mg Once Daily) of TCH346 in Patients With Amyotrophic Lateral Sclerosis.||Novartis||Completed|January 2002|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|44|||Both|40 Years|75 Years|No|||November 2011|November 22, 2011|May 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00036413||203859|
NCT00036374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004774|A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis|A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis||Centocor, Inc.||Completed|October 2001|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|123|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||April 2010|May 16, 2011|May 9, 2002||||||https://clinicaltrials.gov/show/NCT00036374||203862|
NCT00039715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020209|Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder|Effect of Hydrocortisone Infusion on Hippocampal Glucose Metabolism, Neuropsychological Test Performance and Reexperiencing Symptoms in Patients With Post-Traumatic Stress Disorder (PTSD)||National Institutes of Health Clinical Center (CC)||Completed|June 2002|September 2004||||N/A|Observational|N/A||||93|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2004|March 3, 2008|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039715||203622|
NCT00036452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5073|A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation|A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|402|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|May 10, 2002||||||https://clinicaltrials.gov/show/NCT00036452||203856|
NCT00036634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-120-1101|A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients|A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1||Gilead Sciences||Completed|March 2002|February 2003|Actual|February 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||January 2014|January 13, 2014|May 13, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00036634||203843|
NCT00035529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-200|A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis|A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis||Bristol-Myers Squibb||Terminated|November 2001|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||||||Both|18 Years|55 Years|No|||December 2010|December 2, 2010|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035529||203923|
NCT00035542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV138-059|A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.|||Bristol-Myers Squibb||Completed|December 2001|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|9 Years|16 Years|No|||April 2011|April 7, 2011|May 3, 2002||||||https://clinicaltrials.gov/show/NCT00035542||203922|
NCT00036439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004777|A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis|A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis||Centocor, Inc.||Completed|February 2002|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|364|||Both|18 Years|N/A|No|||March 2010|May 16, 2011|May 10, 2002||||||https://clinicaltrials.gov/show/NCT00036439||203857|
NCT00036517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHY906-2000-1|Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer|A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose Escalation, Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer||PhytoCeutica||Terminated|February 2002|March 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||September 2004|June 23, 2005|May 10, 2002||||||https://clinicaltrials.gov/show/NCT00036517||203851|
NCT00036543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M00-211|A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer||Abbott||Completed|May 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Male|19 Years|N/A|No|||August 2006|August 10, 2006|May 10, 2002||||||https://clinicaltrials.gov/show/NCT00036543||203850|
NCT00036036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-461-003|Study of CP-461 in Patients With Advanced Renal Cell Cancer|Phase II Study of CP-461 in Patients With Advanced Renal Cell Cancer||Astellas Pharma Inc||Completed|July 2001|July 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|May 7, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00036036||203886|
NCT00036660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I142|SarCNU in Treating Patients With Recurrent Malignant Glioma|A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma||Canadian Cancer Trials Group||Completed|August 2001|September 2008|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036660||203841|
NCT00035737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1050|Vascular Function in the Framingham Third Generation|||Boston University||Completed|May 2002|March 2007|Actual|March 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||February 2014|February 20, 2014|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035737||203908|
NCT00035750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1054|Risk Factors for Atherogenesis in Type 1 Diabetes|||University of Wisconsin, Madison||Completed|September 2001|August 2005||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2016|January 28, 2016|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035750||203907|
NCT00035763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105|Pain in Sickle Cell Epidemiologic Study|Pain in Sickle Cell Epidemiologic Study||Virginia Commonwealth University||Completed|October 2001|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Both|16 Years|100 Years|No|||January 2008|March 23, 2016|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035763||203906|
NCT00035776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1115|Blood Factors and Peripheral Arterial Disease Outcomes|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 2001|December 2005|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2006|March 15, 2016|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035776||203905|
NCT00036595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020199|Functional Coupling of Cortico-Cortical and Cortico-Muscular Connections During Motor Movements: An Electrocorticographic Study of Ipsilateral Motor Control|Functional Coupling Of Cortico-Cortical and Cortico-Muscular Connections During Motor Movements: An Electrocorticographic Study of Ipsilateral Motor Control||National Institutes of Health Clinical Center (CC)||Completed|May 2002|May 2006||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||May 2006|March 3, 2008|May 10, 2002||||No||https://clinicaltrials.gov/show/NCT00036595||203846|
NCT00036608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-026|A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine|||Bristol-Myers Squibb||Completed|January 2002|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||January 2010|April 7, 2011|May 10, 2002||||||https://clinicaltrials.gov/show/NCT00036608||203845|
NCT00036621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA161-006|A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy|||Bristol-Myers Squibb||Terminated||||September 2002|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2007|February 27, 2010|May 11, 2002||||||https://clinicaltrials.gov/show/NCT00036621||203844|
NCT00035841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2008|Phase 2 Study of TLK286 in Metastatic Breast Cancer|Phase 2 Study of TLK286 in Metastatic Breast Cancer||Telik||Completed|April 2002|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2011|July 21, 2011|May 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035841||203900|
NCT00035854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12600082VRE|New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)|Linezolid IV/PO for the Treatment of Vancomycin-Resistant Enterococcus Infections in Children||Pfizer||Completed|February 2002|May 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|N/A|17 Years|No|||August 2009|August 13, 2009|May 6, 2002||||||https://clinicaltrials.gov/show/NCT00035854||203899|
NCT00036335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6353|Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain|Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain||Eli Lilly and Company||Completed|March 2002|January 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||286|||Both|18 Years|N/A|No|||July 2006|July 18, 2006|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036335||203865|
NCT00036556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M00-244|Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer|A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer||Abbott||Completed|June 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|941|||Male|19 Years|N/A|No|||August 2007|August 13, 2007|May 10, 2002||||No||https://clinicaltrials.gov/show/NCT00036556||203849|
NCT00036569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020193|A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas|A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) in Children With Diffuse Pontine Gliomas||National Institutes of Health Clinical Center (CC)|No|Completed|May 2002|January 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|21 Years|No|||January 2012|January 10, 2012|May 10, 2002||No||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00036569||203848|
NCT00036179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG463-21-02|Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis|An Open-Label, Non-Comparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis||Astellas Pharma Inc||Completed|February 1999|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|75|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|May 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036179||203876|
NCT00036192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA-614-0004|Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea|A Randomized, Double-Blind, Placebo-Controlled Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea||Astellas Pharma Inc||Completed|February 2002|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|25 Years|70 Years|No|||December 2011|December 8, 2011|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036192||203875|
NCT00035971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5548|EVA: Evista Alendronate Comparison|||Eli Lilly and Company||Completed||||||Phase 4|Interventional|Primary Purpose: Treatment|||||||Female|50 Years|80 Years|No|||July 2006|July 18, 2006|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00035971||203890|
NCT00035984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-115|Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus|A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea||AstraZeneca|No|Completed|May 2002|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|734|||Both|16 Years|75 Years|No|||January 2015|February 23, 2015|May 7, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035984||203889|
NCT00036582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020198|Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents|Clozapine vs Placebo In Treatment-Refractory Bipolar Disorder In Children And Adolescents||National Institutes of Health Clinical Center (CC)||Completed|May 2002|February 2004||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||116|||Both|N/A|N/A|No|||February 2004|March 3, 2008|May 10, 2002||||No||https://clinicaltrials.gov/show/NCT00036582||203847|
NCT00036491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AC002|Anti-CD20 in Systemic Lupus Erythematosus|An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2001|January 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|May 10, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036491||203853|
NCT00035373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020186|Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols|Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute (NCI) Clinical Research Protocols||National Institutes of Health Clinical Center (CC)||Terminated|April 2002|April 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|767|||Both|18 Years|100 Years|No|||April 2015|December 16, 2015|May 2, 2002||No||No||https://clinicaltrials.gov/show/NCT00035373||203935|
NCT00035815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1461-01|Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial|Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS)||Mayo Clinic|Yes|Completed|June 2003|December 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|80 Years|No|||February 2013|February 13, 2013|May 6, 2002|Yes|Yes||No|November 17, 2009|https://clinicaltrials.gov/show/NCT00035815||203902|
NCT00036647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR.21|OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease||Astellas Pharma Inc||Completed|October 2001|January 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|731|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|May 13, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00036647||203842|
NCT00036296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXL-202-18-189|Effects of Talampanel on Patients With Advanced Parkinson's Disease|Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)||Teva Pharmaceutical Industries||Completed|December 2006|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|40 Years|85 Years|No|||October 2009|April 11, 2011|May 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00036296||203867|
NCT00035724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1039|Monitoring Community Trends in Heart Failure|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2002|March 2007|Actual|March 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||May 2009|May 1, 2009|May 4, 2002||||No||https://clinicaltrials.gov/show/NCT00035724||203909|
NCT00035464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000037|Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.|Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients||Forest Laboratories|No|Completed|December 2000|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|431|||Both|18 Years|N/A|No|||September 2011|September 30, 2011|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035464||203928|
NCT00035828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-0209|A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD|||Abgenix||Completed|December 2001|December 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|50 Years|N/A|No|||July 2003|June 23, 2005|May 6, 2002||||||https://clinicaltrials.gov/show/NCT00035828||203901|
NCT00036257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-461-010|Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia|||Astellas Pharma Inc||Completed|March 2002|April 2003|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|May 8, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00036257||203870|
NCT00036790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069322|Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer|An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies||University of Wisconsin, Madison||Completed|February 2002|||October 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||September 2015|September 30, 2015|May 13, 2002||||No||https://clinicaltrials.gov/show/NCT00036790||203834|
NCT00036816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-18001 -88001|Vaccine Therapy in Treating Patients With Melanoma of the Eye|Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|February 2002|||February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|13|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|May 13, 2002|||low accrual|No||https://clinicaltrials.gov/show/NCT00036816||203833|
NCT00036062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6025|A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury|A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury||Eli Lilly and Company||Completed|August 2001|December 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||July 2006|July 18, 2006|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00036062||203885|
NCT00036075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-461-006|Study Using CP-461 to Treat Advanced Prostate Cancer|||Astellas Pharma Inc||Completed|August 2001|December 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Male|18 Years|N/A|No|||October 2011|October 14, 2011|May 7, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00036075||203884|
NCT00036088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2347|Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia|||Eli Lilly and Company||Completed|August 2001|July 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||530|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2006|July 18, 2006|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00036088||203883|
NCT00035893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP 720|The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART|The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval.||Hemispherx Biopharma|No|Completed|May 2001|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|May 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035893||203896|
NCT00035906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-103-06-03|Research Study in Patients With Persistent Macular Edema|Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome||Allergan||Completed|October 2001|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|315|||Both|12 Years|N/A|No|||May 2011|May 27, 2011|May 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00035906||203895|
NCT00036270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971-ONC-0028-081|Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane|Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients|TEAM|Pfizer|Yes|Completed|August 2001|February 2011|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9779|||Female|50 Years|N/A|No|||October 2015|October 6, 2015|May 8, 2002|Yes|Yes||No|October 30, 2009|https://clinicaltrials.gov/show/NCT00036270||203869|Overall Survival was reported as number of events which otherwise reported as time.
NCT00036283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NQ4-00-02-011|Chemoprevention of Oral Premalignant Lesions|Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND||Pfizer||Completed|November 2000|April 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||42|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|May 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00036283||203868|
NCT00035997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS24|Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis|An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis||Novartis||Completed|April 2002|January 2004|Actual|January 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|261|||Male|18 Years|N/A|No|||November 2009|November 20, 2009|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00035997||203888|
NCT00036348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-010|Study of Aripiprazole in Patients With a History of Bipolar Disorder|||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|March 2000|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2007|November 7, 2013|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036348||203864|
NCT00036361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-087|Broad Effectiveness: Study With Aripiprazole|Broad Effectiveness: Study With Aripiprazole||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2002|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||444|||Both|18 Years|75 Years|No|||September 2007|November 7, 2013|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036361||203863|
NCT00036764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02464|BMS-247550 in Treating Patients With Stage IV Melanoma|A Phase II Study Of Epothilone B Analog BMS 247550 (NSC # 710428) In Stage IV Malignant Melanoma||National Cancer Institute (NCI)||Completed|February 2002|||August 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|May 13, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036764||203836|
NCT00036205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M27600011|Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease|Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.||Pfizer||Terminated|August 2000|December 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||984|||Both|30 Years|N/A|No|||January 2007|January 17, 2007|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036205||203874|
NCT00035477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000038|Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation|Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation||Forest Laboratories|No|Completed|September 2000|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|80 Years|No|||September 2011|September 30, 2011|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035477||203927|
NCT00035659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|996|Longitudinal Study of the Menopause and Fat Patterning|||Rush University Medical Center||Completed|April 2002|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|868|||Female|N/A|N/A|No|Probability Sample|The prospective study will be conducted on an intact biracial cohort of 868 women (419        African Americans; 449 Caucasians) who are participating in a larger study (Women in the        Southside Health [WISH] Project) of women undergoing the menopausal transition.|October 2015|October 26, 2015|May 4, 2002||No||No||https://clinicaltrials.gov/show/NCT00035659||203914|
NCT00036309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4445|Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder|Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder||Eli Lilly and Company||Completed|May 2002|July 2003||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|May 8, 2002||||||https://clinicaltrials.gov/show/NCT00036309||203866|
NCT00036777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00042|UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of UCN-01 in Combination With Carboplatin in Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|March 2002|||October 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|May 13, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00036777||203835|
NCT00035867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.1001|Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome|Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome||Telik||Completed|April 2002|May 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|18 Years|N/A|No|||June 2005|May 30, 2008|May 6, 2002||||||https://clinicaltrials.gov/show/NCT00035867||203898|
NCT00036387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003133|A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.|A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug Background Therapy.||Centocor, Inc.||Completed||November 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|347|||Both|18 Years|N/A|No|||May 2010|May 18, 2011|May 9, 2002||||||https://clinicaltrials.gov/show/NCT00036387||203861|
NCT00035490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000098|Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators|Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators||Forest Laboratories|No|Completed|September 2001|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|633|||Both|18 Years|N/A|No|||September 2011|September 30, 2011|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035490||203926|
NCT00035503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-201-19-166|Multicenter Trial For Patients With Acute Crohn's Disease|||Teva Pharmaceutical Industries||Completed|January 2002|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 20, 2013|May 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00035503||203925|
NCT00035880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-CB-9906|Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease|A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease||Abgenix||Completed|October 1999|June 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||95|||Both|1 Year|N/A|No|||July 2003|June 23, 2005|May 6, 2002||||||https://clinicaltrials.gov/show/NCT00035880||203897|
NCT00036101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-074|Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder|||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|February 2002|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2007|November 7, 2013|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00036101||203882|
NCT00036114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-004|Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type|||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|March 2000|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|55 Years|95 Years|No|||April 2011|November 7, 2013|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00036114||203881|
NCT00036127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-050|Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders|||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|April 2002|January 2003|Actual|January 2003|Actual|Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2007|November 7, 2013|May 7, 2002||||||https://clinicaltrials.gov/show/NCT00036127||203880|
NCT00035620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990130|Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy|A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients||Amgen||Completed|April 2000|April 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|N/A|21 Years|No|||February 2010|February 25, 2010|May 3, 2002||||No||https://clinicaltrials.gov/show/NCT00035620||203916|
NCT00035633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-022|A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen|||Bristol-Myers Squibb||Completed|December 2001|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||January 2010|April 7, 2011|May 4, 2002||||||https://clinicaltrials.gov/show/NCT00035633||203915|
NCT00035932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-045|Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV|Phase III Open Label Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV||Bristol-Myers Squibb|No|Completed|November 2001|March 2009|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|571|||Both|16 Years|N/A|No|||November 2010|November 29, 2010|May 6, 2002|Yes|Yes||Yes|October 14, 2010|https://clinicaltrials.gov/show/NCT00035932||203893|
NCT00035945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 14803-CS2|ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections|||Ionis Pharmaceuticals, Inc.||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2007|October 15, 2007|May 6, 2002||||||https://clinicaltrials.gov/show/NCT00035945||203892|
NCT00035386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020125|Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study|Trans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility Study||National Institutes of Health Clinical Center (CC)||Completed|April 2002|April 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||12|||Both|N/A|N/A|No|||April 2003|March 3, 2008|May 2, 2002||||No||https://clinicaltrials.gov/show/NCT00035386||203934|
NCT00035399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000304-01A1|Efficacy of Acupuncture With Physical Therapy for Knee Osteo-Arthritis|Efficacy of Acupuncture With Physical Therapy for Knee Osteo-Arthritis||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|March 2002|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|40 Years|N/A|No|||August 2008|August 11, 2008|May 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00035399||203933|
NCT00035516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-011|A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy|||R-Pharm||Completed|February 2001|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2016|February 9, 2016|May 3, 2002||||||https://clinicaltrials.gov/show/NCT00035516||203924|
NCT00036478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5144|Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients|Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Suspended||||||N/A|Observational|N/A||||32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2004|August 6, 2008|May 10, 2002||||No||https://clinicaltrials.gov/show/NCT00036478||203854|
NCT00035438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000391-01|St. John’s Wort Vs. Placebo in Obsessive-Compulsive Disorder.|St. John’s Wort Vs. Placebo in Obsessive-Compulsive Disorder.||National Center for Complementary and Integrative Health (NCCIH)||Completed|May 2002|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||August 2006|August 3, 2006|May 3, 2002||||No||https://clinicaltrials.gov/show/NCT00035438||203930|
NCT00040391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440E-ONC-0020-315|A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer|A Phase II, Randomized, Open-Label, Controlled, Dose-Elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer||Celgene||Terminated||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2007|March 13, 2007|June 26, 2002||||||https://clinicaltrials.gov/show/NCT00040391||203576|
NCT00040404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1347c/204/PD/US-CA|Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease||Teva Pharmaceutical Industries|Yes|Terminated|March 2002|August 2005|Actual|August 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|806|||Both|30 Years|N/A|No|||May 2012|May 8, 2012|June 26, 2002|Yes|Yes|Unlikely to provide evidence of significant effect|No||https://clinicaltrials.gov/show/NCT00040404||203575|
NCT00039572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDMC-E-010284FB|Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain|A Phase I/II Trial For Neutron Capture Therapy In Glioblastoma Multiforme And Intracranial Melanoma||National Cancer Institute (NCI)||Completed|May 2002|January 2005|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2002|June 25, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039572||203631|
NCT00039767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020203|Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices|Heparin vs. Lepirudin Flushes in Preventing Withdrawal Occlusion of Tunneled, Open-Ended Venous Access Devices: A Blinded, Randomized, Clinical Trial||National Institutes of Health Clinical Center (CC)||Completed|May 2002|April 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||340|||Both|N/A|N/A|No|||April 2006|March 3, 2008|June 7, 2002||||No||https://clinicaltrials.gov/show/NCT00039767||203619|
NCT00040001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTI-0009/003|Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation|||Aderis Pharmaceuticals||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|85 Years|No|||February 2003|June 23, 2005|June 18, 2002||||||https://clinicaltrials.gov/show/NCT00040001||203604|
NCT00039702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020058|Brain Imaging in Alzheimer's Disease|SPECT Imaging of Alpha4beta2 Nicotinic Acetylcholine Receptors Using [123I]5-I-A-85380 in Alzheimer's Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2002|September 2004||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2004|March 3, 2008|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039702||203623|
NCT00040534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01499|Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)|||Merck Sharp & Dohme Corp.||Terminated|January 2001|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|June 28, 2002||||||https://clinicaltrials.gov/show/NCT00040534||203565|
NCT00038675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-167|Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate|Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With Platelet Derived Growth Factor (PDGF-R) Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)||M.D. Anderson Cancer Center|Yes|Completed|June 2001|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|N/A|N/A|No|||December 2013|December 10, 2013|June 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038675||203693|
NCT00040157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-006|Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.|A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load||Achillion Pharmaceuticals||Terminated||May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|June 21, 2002|||Safety concerns|||https://clinicaltrials.gov/show/NCT00040157||203594|
NCT00040014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971-ONC-0401-003|Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women|Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen.||Pfizer||Terminated|June 2002|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|18 Years|N/A|No|||February 2012|February 14, 2012|June 18, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00040014||203603|
NCT00040521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3067K5-208|Study Evaluating rhIL-11 in Active Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||September 2005|February 7, 2013|June 27, 2002||||||https://clinicaltrials.gov/show/NCT00040521||203566|
NCT00040300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-PSI-004-02-101|A 14-Day Study of Racivir When Used in Combination in HIV-Infected Males|||Pharmasset||Completed|June 2002|December 2002||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||18|||Male|18 Years|45 Years|No|||July 2005|July 18, 2005|June 24, 2002||||||https://clinicaltrials.gov/show/NCT00040300||203583|
NCT00033696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069313|Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Paclitaxel/Topotecan/Etoposide (EtopoTax) Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer: A Phase II Study||Alliance for Clinical Trials in Oncology|No|Completed|September 2001|April 2009|Actual|January 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|65|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|April 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033696||204056|
NCT00033891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020156|Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis|||National Institutes of Health Clinical Center (CC)||Completed|April 2002|May 2010|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|April 11, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00033891||204043|
NCT00040547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01964|Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)|Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors||Merck Sharp & Dohme Corp.||Completed|June 2001|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|65 Years|No|||February 2015|February 16, 2015|June 28, 2002||||||https://clinicaltrials.gov/show/NCT00040547||203564|
NCT00040560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP102|Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer|||Copharos||Active, not recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||January 2003|June 23, 2005|June 28, 2002||||||https://clinicaltrials.gov/show/NCT00040560||203563|
NCT00039416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02895|Imatinib Mesylate in Treating Patients With Myelofibrosis|A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis||National Cancer Institute (NCI)||Completed|April 2002|||August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2012|February 24, 2014|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039416||203642|
NCT00039429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069382|Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer|A Phase II Trial Evaluating Atrasentan In Patients With Advanced Renal Cell Carcinoma||Eastern Cooperative Oncology Group|No|Completed|May 2003|||April 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|180|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|June 6, 2002|Yes|Yes||||https://clinicaltrials.gov/show/NCT00039429||203641|
NCT00039520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069390|Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer|A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenocarcinoma Of The Breast||Fox Chase Cancer Center||Completed|January 2002|July 2008|Actual|June 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||May 2014|May 5, 2014|June 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00039520||203634|
NCT00033475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069288|Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation|Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients||National Cancer Institute (NCI)||Active, not recruiting|March 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|N/A|No|||June 2002|December 18, 2013|April 9, 2002||||No||https://clinicaltrials.gov/show/NCT00033475||204070|
NCT00039468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0134|Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy|A Phase II Study Of Thalidomide And CPT-11 (IRINOTECAN) Following Radiotherapy For Glioblastoma Multiforme||Dartmouth-Hitchcock Medical Center|Yes|Completed|March 2002|February 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|June 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00039468||203638|
NCT00039481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01872|Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors|A Phase I Trial Of G3139 (BCL-2 Antisense, NSC# 683428, IND# 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumors||National Cancer Institute (NCI)||Completed|November 2002|||October 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|1 Year|21 Years|No|||January 2013|January 16, 2013|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039481||203637|
NCT00038389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-460|Study of Vioxx and Radiation Therapy for Brainstem Glioma|Phase I Study of Vioxx and Radiation Therapy for Brainstem Glioma||M.D. Anderson Cancer Center|No|Terminated|January 2002|January 2005|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|3 Years|85 Years|No|||July 2012|July 27, 2012|May 30, 2002|No|Yes|Unavailability of study drug.|No||https://clinicaltrials.gov/show/NCT00038389||203715|
NCT00033904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-12 Part I|Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer|A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma||Agenus, Inc.||Completed|June 2000|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||650|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|April 12, 2002||Yes||||https://clinicaltrials.gov/show/NCT00033904||204042|
NCT00034034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001028-01|Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer|An Intervention to Improve End-of-Life Symptom Distress||National Center for Complementary and Integrative Health (NCCIH)||Completed|June 2002|August 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||105|||Both|18 Years|N/A|No|||January 2007|January 4, 2007|April 19, 2002||||No||https://clinicaltrials.gov/show/NCT00034034||204033|
NCT00039780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS30203R|Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel|BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer||BioNumerik Pharmaceuticals, Inc.|Yes|Completed|September 2001|September 2014|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|764|||Female|18 Years|N/A|No|||October 2015|October 22, 2015|June 10, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00039780||203618|
NCT00038597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM01-072|Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)|Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)||M.D. Anderson Cancer Center|No|Completed|April 2001|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|16 Years|N/A|No|||January 2012|January 20, 2012|June 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038597||203699|
NCT00039845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020223|MRI Language Studies in Young Children|fMRI Languages Studies In Young Children||National Institutes of Health Clinical Center (CC)||Completed|June 2002|April 2009||||N/A|Observational|N/A||||180|||Both|4 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 21, 2009|June 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00039845||203614|
NCT00039858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG-401|Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin|Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin||Encysive Pharmaceuticals||Completed|September 2003|March 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|N/A|16 Years|No|||January 2007|January 10, 2007|June 13, 2002||||||https://clinicaltrials.gov/show/NCT00039858||203613|
NCT00039923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020227|Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria|A Pilot Study to Determine if Transfer of Gpi-Linked Proteins Occurs Following Transfusion of Red Cells to Patients With Paroxysmal Nocturnal Hemoglobinuria||National Institutes of Health Clinical Center (CC)||Completed|June 2002|June 2005||||N/A|Observational|N/A||||7|||Both|N/A|N/A|No|||June 2005|March 3, 2008|June 14, 2002||||No||https://clinicaltrials.gov/show/NCT00039923||203609|
NCT00039936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMitchell (completed)|Treatment of Binge Eating Disorder|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|June 17, 2002||||No||https://clinicaltrials.gov/show/NCT00039936||203608|
NCT00040248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020213|Daclizumab to Treat Wegener's Granulomatosis|A Randomized Trial Examining the Use of Daclizumab in Wegener's Granulomatosis||National Institutes of Health Clinical Center (CC)||Completed|June 2002|May 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|No|||May 2005|March 3, 2008|June 22, 2002||||No||https://clinicaltrials.gov/show/NCT00040248||203587|
NCT00040417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8750|Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies|Allo SCT From HLA Haploidentical Related Donors Using Sub-Myeloablative Conditioning For Patients With High Risk Hemoglobinopathies: Hemo SS, Hemo SC, Hemo SB0/+ Thalassemia, Homozygous B0/+ Thalassemia or Severe B0/+ Thalassemia Variants||Baylor College of Medicine||Terminated|August 2000|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|N/A|65 Years|No|||April 2007|April 9, 2007|June 26, 2002||||||https://clinicaltrials.gov/show/NCT00040417||203574|
NCT00040430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP101|Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer|||Copharos||Active, not recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Female|18 Years|N/A|No|||January 2003|June 23, 2005|June 26, 2002||||||https://clinicaltrials.gov/show/NCT00040430||203573|
NCT00040287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS038441|Theory-Based Interventions for Smoking and Obesity (Challenge) Trial|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|January 1999|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||1778|||Both|18 Years|60 Years|No|||May 2007|May 16, 2007|June 24, 2002||||No||https://clinicaltrials.gov/show/NCT00040287||203584|
NCT00040469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6847|Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies|Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia||Baylor College of Medicine||Terminated|August 2000|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|N/A|64 Years|No|||April 2007|April 9, 2007|June 26, 2002||||||https://clinicaltrials.gov/show/NCT00040469||203570|
NCT00040105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-169|Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia|Phase I Study of Zarnestra (R115777.USA30) and Gleevec (Imatinib Mesylate) in Chronic Phase Chronic Myelogenous Leukemia (CML)||M.D. Anderson Cancer Center|No|Completed|October 2002|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|16 Years|N/A|No|||July 2012|July 31, 2012|June 19, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00040105||203597|
NCT00040339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS43353|Hypothermia to Treat Severe Brain Injury|The National Acute Brain Injury Study: Hypothermia II (NABISH II)||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|May 2002|July 2005|Actual|||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment||||42|||Both|16 Years|45 Years|No|||December 2007|December 26, 2007|June 24, 2002||||No||https://clinicaltrials.gov/show/NCT00040339||203580|
NCT00040170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG4010.03|Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer|Randomized Multicenter Phase II Study Evaluating Two Dosing Schedules of TG4010(MVA-MUC1-IL2) in Patients With Adenocarcinoma of the Prostate||Transgene||Terminated|May 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Male|18 Years|N/A|No|||October 2006|October 31, 2006|June 21, 2002||||||https://clinicaltrials.gov/show/NCT00040170||203593|
NCT00040183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA.3|OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.|A Randomized Placebo Controlled Study of OSI-774 (Tarceva (TM)) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer||Astellas Pharma Inc||Completed|October 2001|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|569|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 21, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00040183||203592|
NCT00040196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020216|How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance|Dopaminergic Modulation of Cerebral Connectivity During Sequential Finger Movements||National Institutes of Health Clinical Center (CC)||Completed|June 2002|July 2009|Actual|July 2009|Actual|N/A|Observational|N/A||||133|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2009|September 26, 2015|June 21, 2002||No||No||https://clinicaltrials.gov/show/NCT00040196||203591|
NCT00039507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069389|Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer|Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer||Fox Chase Cancer Center||Completed|June 2002|February 2004|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|February 11, 2010|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039507||203635|
NCT00039676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020210|Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy||National Institutes of Health Clinical Center (CC)||Recruiting|June 2002|||||N/A|Observational|N/A|||Anticipated|3000|||Both|1 Year|100 Years|Accepts Healthy Volunteers|||March 2016|March 10, 2016|June 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00039676||203625|
NCT00039546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-TU-TANGO|Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery|'tAnGo', A Phase III Randomised Trial Of Gemcitabine In Paclitaxel-Containing, Epirubicin-Based, Adjuvant Chemotherapy For ER/PgR-Poor, Early Stage, Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2005|August 6, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039546||203633|
NCT00039559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069397|Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer|Ovarian Cancer Screening Pilot Trial in High Risk Women||Massachusetts General Hospital|Yes|Active, not recruiting|May 2002|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2430|||Female|30 Years|N/A|No|||June 2013|June 7, 2013|June 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00039559||203632|
NCT00039585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069403|Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor|Phase II Clinical Trial With Proteomic Profiling Of Imatinib Mesylate (Gleevec; STI571), A PDGFR And C-Kit Inhibitor, In Patients With Refractory Or Relapsed Epithelial Ovarian Cancer, Fallopian Tube And Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|May 2002|||February 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||February 2007|April 29, 2015|June 6, 2002||||||https://clinicaltrials.gov/show/NCT00039585||203630|
NCT00039962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ta1-CHC-2K0804|Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin|||SciClone Pharmaceuticals||Completed|May 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|June 17, 2002||||||https://clinicaltrials.gov/show/NCT00039962||203607|
NCT00040209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020236|JP-1730 to Treat Parkinson's Disease|Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2002|July 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||July 2005|March 3, 2008|June 21, 2002||||No||https://clinicaltrials.gov/show/NCT00040209||203590|
NCT00040222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020212|Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer|Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|June 2002|||||N/A|Observational|N/A|||Anticipated|500|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 22, 2002||No||No||https://clinicaltrials.gov/show/NCT00040222||203589|
NCT00038610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-006|Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia|Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|March 2001|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|15 Years|N/A|No|||August 2015|August 19, 2015|June 3, 2002|Yes|Yes||No|August 19, 2015|https://clinicaltrials.gov/show/NCT00038610||203698|
NCT00038623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-541|Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma|A Phase II Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Completed|April 2002|February 2010|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 31, 2011|June 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038623||203697|
NCT00039689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020202|Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Primary and Chronic HIV-Infected Patients|Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-Infected Patients||National Institutes of Health Clinical Center (CC)||Recruiting|May 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|360|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|June 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00039689||203624|
NCT00039793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000348-01|Massage Therapy for Cancer-Related Fatigue|Massage Therapy for Cancer-Related Fatigue||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2001|March 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||July 2006|August 17, 2006|June 11, 2002||||No||https://clinicaltrials.gov/show/NCT00039793||203617|
NCT00039871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02370|PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)|PEG-Intron Plus REBETOL for the Treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Alpha Interferon Treatment in Combination With Ribavirin)||Merck Sharp & Dohme Corp.|Yes|Completed|May 2002|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2333|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|June 13, 2002|No|Yes||No|September 29, 2008|https://clinicaltrials.gov/show/NCT00039871||203612|
NCT00039884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/155A|Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?|Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma.||Mirhashemi, Ramin, M.D.||Active, not recruiting|September 2001|March 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||64|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2002|June 23, 2005|June 13, 2002||||||https://clinicaltrials.gov/show/NCT00039884||203611|
NCT00040066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0013-1|Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1|Development of Human Laboratory Study Model of Cocaine Relapse Prevention||National Institute on Drug Abuse (NIDA)||Active, not recruiting|May 2002|August 2003||||Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|18 Years|55 Years|No|||September 2004|October 23, 2007|June 18, 2002||||||https://clinicaltrials.gov/show/NCT00040066||203599|
NCT00040092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOR/VIR/P03/002|A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer|||Aptose Biosciences Inc.||Completed|July 2002|||July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||January 2008|January 4, 2008|June 19, 2002||||||https://clinicaltrials.gov/show/NCT00040092||203598|
NCT00040352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020211|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma||National Institutes of Health Clinical Center (CC)||Recruiting|June 2002|||||N/A|Observational|N/A|||Anticipated|3000|||Both|1 Year|100 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|June 25, 2002||No||No||https://clinicaltrials.gov/show/NCT00040352||203579|
NCT00040482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7156|High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis|Intensive Immunosuppression Followed by Rescue With CD34 Selected, T Cell Depleted, Leukopheresis Products in Patients With Multiple Sclerosis||Baylor College of Medicine||Completed|April 1999|August 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|60 Years|No|||April 2007|April 9, 2007|June 26, 2002||||||https://clinicaltrials.gov/show/NCT00040482||203569|
NCT00040495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001K2-315|Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage|An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2001|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Prevention|||Actual|149|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|June 26, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00040495||203568|
NCT00039988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AMS01|Treatment of Multiple Sclerosis With Copaxone and Albuterol|Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2001|November 2007|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||May 2012|April 3, 2014|June 18, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039988||203605|
NCT00040456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9251 MG Pidolate|Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate|The Effect of Oral Magnesium Pidolate on Incidence of Painful Crises in Patients With Hemoglobin SC Disease||Baylor College of Medicine|Yes|Terminated|January 2001|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|N/A|N/A|No|||November 2012|November 15, 2012|June 26, 2002|Yes|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00040456||203571|
NCT00039754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102|A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma|A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma||Poniard Pharmaceuticals||Terminated|March 2002|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2009|January 19, 2009|June 7, 2002|||business reasons|||https://clinicaltrials.gov/show/NCT00039754||203620|
NCT00039455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00035|Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer|A Phase I Study of Herceptin/Flavopiridol in HER-2 Positive Metastatic Breast Cancer||National Cancer Institute (NCI)||Terminated|April 2002|||December 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|June 6, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00039455||203639|
NCT00039819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020228|Nerve Stimulation to Modify a Spinal Reflex|Plasticity of Reciprocal Inhibition||National Institutes of Health Clinical Center (CC)||Completed|June 2002|May 2003||||N/A|Observational|N/A||||25|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2003|March 3, 2008|June 11, 2002||||No||https://clinicaltrials.gov/show/NCT00039819||203616|
NCT00039832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020154|ReoPro and Retavase to Restore Brain Blood Flow After Stroke|ReoPro Retavase Reperfusion of Stroke Safety Study - Imaging Evaluation||National Institutes of Health Clinical Center (CC)||Completed|March 2002|May 2008|Actual|April 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|No|||September 2011|September 19, 2011|June 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00039832||203615|
NCT00040274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPC 817-201|A Study of DPC 817 in HIV-Infected Males|A Placebo-Controlled, Dose-Escalation Study in HIV-1 Infected Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of DPC 817||Pharmasset||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||July 2005|July 18, 2005|June 24, 2002||||||https://clinicaltrials.gov/show/NCT00040274||203585|
NCT00039650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020201|Pilot Study: Effects of G-CSF on T Cell Function|Pilot Study of the Effects of G-CSF on T Cell Function||National Institutes of Health Clinical Center (CC)||Completed|May 2002|March 2004||||N/A|Observational|N/A||||15|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|March 3, 2008|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039650||203627|
NCT00039663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020208|Endothelial Dysfunction as a Risk Factor in HIV Study|Endothelial Dysfunction as a Risk Factor in HIV Study||National Institutes of Health Clinical Center (CC)||Completed|May 2002|October 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|No|||October 2005|March 3, 2008|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039663||203626|
NCT00038636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M99-049|A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors|A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors||Abbott||Completed|September 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||August 2006|August 13, 2006|June 3, 2002||||||https://clinicaltrials.gov/show/NCT00038636||203696|
NCT00038649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-151|Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Higher-Dose Gleevec (STI571)||M.D. Anderson Cancer Center|Yes|Terminated|June 2001|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|15 Years|N/A|No|||December 2013|December 6, 2013|June 3, 2002|Yes|Yes|Sponsor discontinued providing study drug.|No||https://clinicaltrials.gov/show/NCT00038649||203695|
NCT00038662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-366|Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure|A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure||Abbott||Completed|May 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Male|19 Years|N/A|No|||August 2006|August 10, 2006|June 3, 2002||||||https://clinicaltrials.gov/show/NCT00038662||203694|
NCT00040443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORX-CX516-012.1|Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.|Efficacy And Safety Of CX516 (900 Mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-Week Study.||RespireRx||Completed|April 2002|March 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|55 Years|85 Years|No|||February 2005|June 23, 2005|June 26, 2002||||||https://clinicaltrials.gov/show/NCT00040443||203572|
NCT00039910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444-ONC-0003-0019|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy||Pfizer||Completed|July 2000|March 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||240|||Both|18 Years|N/A|No|||September 2006|May 3, 2007|June 14, 2002||||No||https://clinicaltrials.gov/show/NCT00039910||203610|
NCT00040027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ta1-CHC-2K0803a|Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin|||SciClone Pharmaceuticals||Completed|April 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|June 18, 2002||||||https://clinicaltrials.gov/show/NCT00040027||203602|
NCT00038480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1030|Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants|A Phase I/II Study of Lopinavir/Ritonavir in HIV-1 Infected Infants Less Than 6 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|N/A|6 Months|No|||May 2012|May 17, 2012|May 31, 2002||||||https://clinicaltrials.gov/show/NCT00038480||203708|
NCT00038493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM01-258|Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme|Phase II Evaluation Temozolomide and Farnesyl Transferase Inhibitor (SCH66336) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Terminated|September 2001|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|May 31, 2002|Yes|Yes|Lack of Accrual|No||https://clinicaltrials.gov/show/NCT00038493||203707|
NCT00040235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020234|Magnesium Effects in Apheresis|Citrate Effects and Role of Prophylactic Magnesium Administration During Large-Volume Leukapheresis||National Institutes of Health Clinical Center (CC)||Completed|June 2002|February 2004||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||52|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2004|March 3, 2008|June 22, 2002||||No||https://clinicaltrials.gov/show/NCT00040235||203588|
NCT00040040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0010-1|Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1|Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion||National Institute on Drug Abuse (NIDA)||Active, not recruiting|June 2002|September 2003||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Diagnostic||||20|||Both|18 Years|45 Years|No|||August 2003|February 8, 2007|June 18, 2002||||No||https://clinicaltrials.gov/show/NCT00040040||203601|
NCT00040053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0011-1|Ondansetron for the Treatment of Methamphetamine Dependence - 1|Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence.||National Institute on Drug Abuse (NIDA)||Completed|June 2002|February 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||154|||Both|18 Years|N/A|No|||July 2008|July 21, 2008|June 18, 2002||||No||https://clinicaltrials.gov/show/NCT00040053||203600|
NCT00040313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1005|Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula|A Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center, Comparative Trial, in Parallel Groups, to Establish the Safety and Preliminary Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer), Given Every 6 Weeks for 12 to 30 Weeks to Patients With Clinically Significant Diabetic Macular Edema (CSME) Involving the Center of the Macula||Eyetech Pharmaceuticals||Completed|October 2002|February 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||May 2006|May 2, 2006|June 24, 2002||||||https://clinicaltrials.gov/show/NCT00040313||203582|
NCT00040326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS42372|Early Surgical Intervention to Treat Epilepsy|Early Randomized Surgical Epilepsy Trial|ERSET|University of California, Los Angeles|Yes|Completed|July 2002|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|N/A|No|||February 2010|February 22, 2010|June 24, 2002||||No||https://clinicaltrials.gov/show/NCT00040326||203581|
NCT00039975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5159|Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers|Evaluation of Potential Pharmacokinetic Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2004|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|June 18, 2002||||No||https://clinicaltrials.gov/show/NCT00039975||203606|
NCT00040261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020231|Clinical Trial of Memantine for Major Depression|An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression||National Institutes of Health Clinical Center (CC)||Completed|June 2002|March 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||112|||Both|N/A|N/A|No|||March 2005|March 3, 2008|June 22, 2002||||No||https://clinicaltrials.gov/show/NCT00040261||203586|
NCT00040365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020215|Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer|Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study||National Institutes of Health Clinical Center (CC)|No|Completed|June 2002|June 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Male|18 Years|N/A|No|||April 2012|April 26, 2012|June 25, 2002|No|Yes||No|January 13, 2012|https://clinicaltrials.gov/show/NCT00040365||203578|
NCT00040378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0033|Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)|Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)||University of Kentucky|Yes|Active, not recruiting|May 2002|August 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|10400|||Male|60 Years|90 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|June 25, 2002||No||No||https://clinicaltrials.gov/show/NCT00040378||203577|
NCT00039741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P390|Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children|A Phase II/III Randomized, Open-Label Study of Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV-1-Infected Antiretroviral Naive Children Between 30 Days and 18 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2002|March 2010|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|266|||Both|N/A|18 Years|No|||November 2014|October 26, 2015|June 7, 2002|Yes|Yes||No|December 19, 2011|https://clinicaltrials.gov/show/NCT00039741||203621|
NCT00039442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0128G|Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix||Gynecologic Oncology Group||Completed|April 2002|||January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|N/A|N/A|No|||December 2014|December 29, 2014|June 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00039442||203640|
NCT00040508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020235|Sirolimus for Focal Segmental Glomerulosclerosis|Sirolimus for Focal Segmental Glomerulosclerosis||National Institutes of Health Clinical Center (CC)||Completed|June 2002|January 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||January 2005|March 3, 2008|June 26, 2002||||No||https://clinicaltrials.gov/show/NCT00040508||203567|
NCT00040131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02580|Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)|||Merck Sharp & Dohme Corp.||Terminated|January 2002|January 2003|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|316|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|June 20, 2002||||||https://clinicaltrials.gov/show/NCT00040131||203596|
NCT00040144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-005|Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B|A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B||Achillion Pharmaceuticals||Terminated|July 2002|May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||85|||Both|18 Years|N/A|No|||August 2009|August 18, 2009|June 21, 2002|||Safety concerns|||https://clinicaltrials.gov/show/NCT00040144||203595|
NCT00038571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-596|Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy|Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy||M.D. Anderson Cancer Center|Yes|Completed|May 2002|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|17 Years|N/A|No|||July 2012|July 27, 2012|May 31, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038571||203701|
NCT00038584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID98-251|A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer|A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy||M.D. Anderson Cancer Center|No|Completed|June 1999|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|May 31, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038584||203700|
NCT00038766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNI-1493 CD-02|CNI-1493 for Treatment of Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease|CD02|Ferring Pharmaceuticals|No|Terminated|June 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|June 5, 2002|Yes|Yes|Unable to enroll into study.|No||https://clinicaltrials.gov/show/NCT00038766||203687|
NCT00042406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-CD4-004|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-alpha Blocker|A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active RA Failing Treatment With Methotrexate and TNF-alpha Blocking Agents||Emergent Product Development Seattle LLC||Terminated|September 2002|||September 2002|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|July 29, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00042406||203435|
NCT00045773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060697|Treatment Outcome of Vascular Depression|Treatment Outcome of Vascular Depression||Washington University School of Medicine|No|Completed|April 2001|April 2006|Actual|April 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|208|||Both|60 Years|N/A|No|Non-Probability Sample|Adults 60+ with major depression.|June 2013|June 19, 2013|September 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045773||203204|
NCT00038870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-075|Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes|Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes||M.D. Anderson Cancer Center|No|Withdrawn|January 2001|January 2003|Actual|January 2003|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||August 2012|August 2, 2012|June 5, 2002|Yes|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00038870||203679|
NCT00039026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-113|Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea|A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone||AstraZeneca|No|Completed|February 2002|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|377|||Both|16 Years|75 Years|No|||January 2015|February 23, 2015|June 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00039026||203667|
NCT00039195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-142|Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma|Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index II or III Diffuse Large B Cell Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|November 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|64 Years|No|||April 2013|April 26, 2013|June 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00039195||203656|
NCT00038285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2830R|Healthy Heart Amputation Rehabilitation Treatment (H.A.R.T)|Healthy Heart Amputation Rehabilitation Treatment (H.A.R.T)||VA Office of Research and Development||Completed|April 2002|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||May 2002|January 20, 2009|May 29, 2002||||No||https://clinicaltrials.gov/show/NCT00038285||203722|
NCT00038298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010238|A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Safety and Tolerability of AMG 719 in Subjects With Rheumatoid Arthritis Receiving Methothrexate||Amgen||Completed|April 2002|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|53|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|May 29, 2002||||No||https://clinicaltrials.gov/show/NCT00038298||203721|
NCT00044798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063405|Magnetic Stimulation Therapy for Treating Vascular Depression|Vascular Depression and Magnetic Stimulation Therapy|rtms|University of Iowa|Yes|Completed|September 2001|August 2008|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|51 Years|89 Years|No|||September 2013|September 26, 2013|September 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044798||203264|
NCT00044031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC4|Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma|Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4)||Cancer Advances Inc.|No|Completed|February 2001|October 2007|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|394|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|August 16, 2002|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00044031||203320|
NCT00038987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-009|Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT|A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2002|August 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||330|||Both|18 Years|32 Years|Accepts Healthy Volunteers|||December 2003|August 26, 2010|June 6, 2002||||||https://clinicaltrials.gov/show/NCT00038987||203670|
NCT00038935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B1-305|Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A|A Single Dose, Randomized, Double-Blind, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Factor VIII (BDDrFVIII) Manufactured by the Current Process (ReFacto) and by an Albumin Free Manufacturing Process (ReFacto AF)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||April 2008|April 18, 2008|June 5, 2002||||||https://clinicaltrials.gov/show/NCT00038935||203674|
NCT00038948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-316|Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients|A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|January 2002|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|830|||Both|13 Years|N/A|No|||April 2010|April 22, 2010|June 5, 2002|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00038948||203673|
NCT00042419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10939-CP-001|Work and Health Disparities Among Rural Women|||National Institute of Environmental Health Sciences (NIEHS)||Completed|March 2002|July 2003||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 1, 2006|July 29, 2002||||No||https://clinicaltrials.gov/show/NCT00042419||203434|
NCT00042432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010239|Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients|A Study of an Investigational Medication for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients||Amgen||Completed|June 2002|August 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|July 29, 2002||||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00042432||203433|
NCT00042445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9723-CP-001|Brain Neoplasms, Leukemia and Petrochemical Exposures|||National Institute of Environmental Health Sciences (NIEHS)||Completed|August 2000|July 2005||||N/A|Observational|Observational Model: Case Control||||1456|||Both|N/A|30 Years|No|||September 2006|September 1, 2006|July 30, 2002||||No||https://clinicaltrials.gov/show/NCT00042445||203432|
NCT00042458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-150|Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control|A Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety of Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by Insulin Dose Optimization in Subjects With Type 1 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Intensive Insulin Therapy||AstraZeneca|No|Completed|April 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|296|||Both|18 Years|N/A|No|||August 2015|September 22, 2015|July 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00042458||203431|
NCT00042536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020262|Effects of Yohimbine and Naltrexone on Sexual Function|Effects of Alpha-2 Adrenergic and Opiate Receptor Blockade on Sexual Function in Healthy Male Volunteers||National Institutes of Health Clinical Center (CC)||Completed|July 2002|April 2004||||N/A|Observational|N/A||||40|||Male|N/A|N/A|Accepts Healthy Volunteers|||April 2004|March 3, 2008|July 31, 2002||||No||https://clinicaltrials.gov/show/NCT00042536||203425|
NCT00042549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-PA-001|Lithotripsy for the Treatment of Gallstones|Biliary Lithotripsy in Combination With Actigall Versus Actigall Monotherapy for the Treatment of Symptomatic Cholesterol Gallstones||Medstone International||Terminated|May 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||184|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2003|June 23, 2005|July 31, 2002||||||https://clinicaltrials.gov/show/NCT00042549||203424|
NCT00038545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM01-008|A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Patients With Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Completed|May 2001|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|May 31, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038545||203703|
NCT00039312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-10-034|Comparison of Screening Tests in Detecting Cervical Neoplasia|Multi-Institutional Prospective Cohort Study For The Comparison Of Different Primary Screening Strategies For The Detection Of Cervical Neoplasia||Jonsson Comprehensive Cancer Center|No|Completed|December 1999|April 2010|Actual|August 2003|Actual|N/A|Interventional|Primary Purpose: Screening|||Actual|15|||Female|18 Years|N/A|No|||July 2012|July 27, 2012|June 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00039312||203650|
NCT00039325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069373|Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma|A Phase I/II Trial Testing Mart-1 Genetic Immunization In Malignant Melanoma||Jonsson Comprehensive Cancer Center|Yes|Completed|March 2002|June 2009|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|28|||Both|18 Years|N/A|No|||July 2012|October 1, 2015|June 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00039325||203649|
NCT00039208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-05011|Combination Chemotherapy in Treating Patients With Colorectal Cancer|Time Finding Study of Chronomodulated Irinotecan, 5 Fluorouracil, Leucovorin and Oxaliplatin as First or Second Chemotherapy Line Against Metastatic Colorectal Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2002|||August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2012|July 12, 2012|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039208||203655|
NCT00038844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-200|Safety and Efficacy of Campath in Nonmyeloablative Transplantation|Safety and Efficacy of Campath in Nonmyeloablative Transplantation||M.D. Anderson Cancer Center|No|Completed|June 2001|September 2010|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|N/A|70 Years|No|||October 2011|October 31, 2011|June 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00038844||203681|
NCT00038857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-220|Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases|Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases||M.D. Anderson Cancer Center|No|Completed|September 2001|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|55 Years|No|||August 2012|August 7, 2012|June 5, 2002|Yes|Yes||No|June 21, 2012|https://clinicaltrials.gov/show/NCT00038857||203680|
NCT00038714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stressgen SGN-00101-0005|A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis|A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis||Nventa Biopharmaceuticals Corporation||Completed|November 2001|January 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|27|||Both|2 Years|18 Years|No|||June 2007|June 26, 2007|June 4, 2002||||||https://clinicaltrials.gov/show/NCT00038714||203690|
NCT00038181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-089|Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer|A Tolerance and Efficacy Trial of Preoperative Thalidomide Treatment Followed by Radical Retropubic Prostatectomy (RRP) in Select Patients With Locally Advanced Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|October 2000|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|N/A|N/A|No|||July 2012|July 31, 2012|May 29, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038181||203730|
NCT00039130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-10002|Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia|Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia||Alliance for Clinical Trials in Oncology|No|Completed|May 2002|October 2014|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|16 Years|N/A|No|||November 2015|November 23, 2015|June 6, 2002|Yes|Yes||No|October 16, 2014|https://clinicaltrials.gov/show/NCT00039130||203660|
NCT00038311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444-ONC-0003-020|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI))||Pfizer||Completed|September 2000|March 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||120|||Both|13 Years|N/A|No|||April 2015|April 30, 2015|May 30, 2002||||No||https://clinicaltrials.gov/show/NCT00038311||203720|
NCT00038337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2569R|Improving Functional Health Literacy in Older Veterans|Improving Functional Health Literacy in Older Veterans||VA Office of Research and Development||Completed|April 2001|May 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|240|||Both|65 Years|N/A|No|||May 2002|January 20, 2009|May 30, 2002||||No||https://clinicaltrials.gov/show/NCT00038337||203719|
NCT00039078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069336|Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery|The Use of TheraSphere® for the Treatment of Unresectable Hepatocellular Carcinoma||National Cancer Institute (NCI)||Recruiting|August 2000|||||Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||December 2008|December 23, 2009|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039078||203664|
NCT00042042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR00030-0199|Screening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic|Screening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic||National Center for Research Resources (NCRR)||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||400|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||July 2002|June 23, 2005|July 22, 2002||||No||https://clinicaltrials.gov/show/NCT00042042||203463|
NCT00038415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM99-412|A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach|A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach||M.D. Anderson Cancer Center|Yes|Terminated|December 2001|January 2005|Actual|July 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|May 30, 2002|Yes|Yes|Vaccine unavailable.|No||https://clinicaltrials.gov/show/NCT00038415||203713|
NCT00038220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M00-154|Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients|A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1||Abbott||Completed|July 2000|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||July 2006|July 26, 2006|May 29, 2002||||||https://clinicaltrials.gov/show/NCT00038220||203727|
NCT00039169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069359|BAY 59-8862 in Treating Patients With Advanced Kidney Cancer|An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 2001|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2008|July 23, 2008|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039169||203658|
NCT00039182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02466|Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung|A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Completed|May 2002|||June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||January 2013|January 23, 2013|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039182||203657|
NCT00038779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM96-122|Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States||M.D. Anderson Cancer Center|No|Terminated|August 1996|September 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|49 Years|No|||August 2012|August 3, 2012|June 5, 2002||Yes|Lack of Accrual|No||https://clinicaltrials.gov/show/NCT00038779||203686|
NCT00038909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082A1-302|Study Evaluating ReFacto in Hemophilia A|Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 1994|May 2001|Actual|May 2001|Actual|N/A|Interventional|Primary Purpose: Treatment|||Actual|103|||Both|N/A|N/A|No|||February 2013|February 7, 2013|June 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038909||203676|
NCT00042471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-153|Evaluation of the Bioavailability of Pramlintide|||AstraZeneca||Completed|June 2002|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|70 Years|No|||August 2015|September 22, 2015|July 30, 2002||||No||https://clinicaltrials.gov/show/NCT00042471||203430|
NCT00042484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10688-CP-001|Community Organizing Network for Environmental Health|||National Institute of Environmental Health Sciences (NIEHS)||Completed||June 2002|Actual|June 2002|Actual|N/A|Interventional|N/A|||||||||||||April 2015|April 13, 2015|July 30, 2002||No||No||https://clinicaltrials.gov/show/NCT00042484||203429|
NCT00042497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2002-04|Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma|A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma||Anosys||Suspended|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2002|June 23, 2005|July 30, 2002||||||https://clinicaltrials.gov/show/NCT00042497||203428|
NCT00042562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6476|Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression|Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression||Eli Lilly and Company||Completed|December 2002|December 2003||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|July 31, 2002||||||https://clinicaltrials.gov/show/NCT00042562||203423|
NCT00038233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM98-359|Thalidomide for Multiple Myeloma|Thalidomide for Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Completed|May 1999|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|N/A|N/A|No|||July 2012|July 27, 2012|May 29, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038233||203726|
NCT00038922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3067K5-114|Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Safety and Exploratory Pharmacogenomic Study of Orally Administered Recombinant Human Interleukin Eleven (rhIL-11) in Patients With Mild to Moderate Left-Sided Ulcerative Colitis||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2006|May 17, 2006|June 5, 2002||||||https://clinicaltrials.gov/show/NCT00038922||203675|
NCT00042159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063326|Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations|TMS Intervention Development for Auditory Hallucinations||Yale University|Yes|Completed|July 2002|June 2004|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|55 Years|No|||August 2013|August 2, 2013|July 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00042159||203454|
NCT00038818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-335|CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation|CD8 Depleted Donor Lymphocyte Infusions for Patients With Relapse Or Residual Disease Following Allogeneic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Terminated|May 2001|December 2002|Actual|December 2002|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||August 2012|August 22, 2012|June 5, 2002|Yes|Yes|Low accrual.|No||https://clinicaltrials.gov/show/NCT00038818||203683|
NCT00038831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-010|Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS|Phase I/II Evaluation of Safety and Activity of Mylotarg Plus Melphalan and Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Completed|May 2001|October 2006|Actual|March 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|12 Years|75 Years|No|||July 2012|July 31, 2012|June 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038831||203682|
NCT00039052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-3001-ST-0101|Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer|An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors||National Cancer Institute (NCI)||Completed|January 2002|July 2008|Actual|May 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2003|July 17, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039052||203665|
NCT00038727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND - DK048489|Diabetes Prevention Program Outcomes Study|Diabetes Prevention Program Outcomes Study|DPPOS|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|September 2002|January 2015|Anticipated|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2776|||Both|25 Years|N/A|No|||June 2014|June 16, 2014|June 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038727||203689|
NCT00039299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCYTE-SPR-080011|Biological Therapy in Treating Patients With Prostate Cancer|A Phase I Safety Study Of Xcellerate In Patients With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|March 2002|June 2003|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||June 2003|April 2, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039299||203651|
NCT00042263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10936-CP-001|Healthy Environments Partnership|Social and Physical Environments and Health Disparities||National Institute of Environmental Health Sciences (NIEHS)||Completed|April 2002|||||N/A|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional||||1000|||Both|25 Years|95 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|July 25, 2002||||No||https://clinicaltrials.gov/show/NCT00042263||203446|
NCT00038792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-036|Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD|A Phase I/II Trial of Recombinant Human Keratinocyte Growth Factor (rHuKFG) for the Treatment of Steroid Refractory Gastrointestinal Acute Graft-versus-host Disease (aGvHD)||M.D. Anderson Cancer Center|Yes|Terminated|October 2000|January 2003|Actual|January 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||August 2012|August 1, 2012|June 5, 2002|Yes|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00038792||203685|
NCT00039377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00436|Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG||National Cancer Institute (NCI)|No|Completed|April 2002|February 2014|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|15 Years|59 Years|No|||June 2014|November 13, 2014|June 6, 2002|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00039377||203645|
NCT00039390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02467|Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of ZD1839 With Capecitabine in Patients With Advanced Solid Tumors (Formerly a Phase I Trial of ZD1839 With Capecitabine and Celecoxib)||National Cancer Institute (NCI)||Completed|April 2002|||May 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039390||203644|
NCT00038428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2003|Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer|||Telik||Completed|June 2001|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||40|||Female|18 Years|N/A|No|||June 2011|July 21, 2011|May 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038428||203712|
NCT00038441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID95-115|Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas|Phase I Trial of Intratumoral Injection of DTI-015 for Recurrent Malignant Gliomas||M.D. Anderson Cancer Center|No|Completed|September 1995|August 2005|Actual|February 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|May 30, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038441||203711|
NCT00038883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-410|Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies|Campath-1H Snd Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|April 2001|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|15 Years|60 Years|No|||July 2012|July 27, 2012|June 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038883||203678|
NCT00039104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02799|Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer|A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|April 2002|||January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|N/A|No|||June 2013|June 4, 2013|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039104||203662|
NCT00039117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01409|Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia|A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)&gt;= 60 Years of Age||National Cancer Institute (NCI)||Completed|April 2002|||September 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|60 Years|N/A|No|||June 2013|December 3, 2015|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039117||203661|
NCT00038519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M00-261|Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor|An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.||Abbott||Completed|April 2001|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||July 2006|July 27, 2006|May 31, 2002||||||https://clinicaltrials.gov/show/NCT00038519||203705|
NCT00042510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC4|Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer|Open-Label,Multicenter Study of G17DT Immunogen in Combination w/ Cisplatin and 5-FU in Subjects w/ Metastatic or Locally Recurrent Gastric or Gastroesophageal Cancer Previously Untreated With Chemotherapy.||Cancer Advances Inc.|No|Completed|August 2000|July 2004|Actual|February 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|July 31, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00042510||203427|
NCT00038350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2641R|Effects of Age and Age-Related Diseases on Swallowing|Effects of Age and Age-Related Diseases on Swallowing||VA Office of Research and Development|No|Completed|January 2002|March 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|65 Years|N/A|No|||May 2008|May 5, 2008|May 30, 2002||No||No||https://clinicaltrials.gov/show/NCT00038350||203718|
NCT00039403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02468|UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer|A Phase I Study Of UCN-01 In Combination With Gemcitabine In Unresectable Or Metastatic Pancreatic Carcinoma||National Cancer Institute (NCI)||Completed|April 2002|||May 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039403||203643|
NCT00042523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020267|Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus|Role of the Antibody Against NR2 Glutamate Receptor in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus||National Institutes of Health Clinical Center (CC)||Completed|July 2002|January 2005||||N/A|Observational|N/A||||61|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2005|March 3, 2008|July 31, 2002||||No||https://clinicaltrials.gov/show/NCT00042523||203426|
NCT00042575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6475|Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression|Protocol F1J-US-HMBY Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression||Eli Lilly and Company||Completed|June 2002|August 2002||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 18, 2006|July 31, 2002||||||https://clinicaltrials.gov/show/NCT00042575||203422|
NCT00042588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN01|A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis||ICOS Corporation||Completed|May 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|June 23, 2005|August 1, 2002||||||https://clinicaltrials.gov/show/NCT00042588||203421|
NCT00038363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O2571R|Comparison of Subacute and Hospital Based Rehabilitation Care|Comparison of Subacute and Hospital Based Rehabilitation Care||VA Office of Research and Development||Completed|April 2001|March 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|260|||Both|18 Years|N/A|No|||May 2002|January 20, 2009|May 30, 2002||||No||https://clinicaltrials.gov/show/NCT00038363||203717|
NCT00038376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM90-007|Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies|Phase II Study of Interferon Alpha and Isotretinoin in Patients With T-Cell Malignancies||M.D. Anderson Cancer Center|No|Terminated|May 1990|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|May 30, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038376||203716|
NCT00038259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5132|Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy|An Exploratory, Open-Label, Randomized Trial to Evaluate the Ability of Interleukin-2 (IL-2) to Enhance HIV-Specific Immunity and Influence the Time to Virologic Relapse Following Withdrawal of Potent Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||21|||Both|N/A|N/A|No|||May 2012|May 9, 2012|May 29, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00038259||203724|
NCT00038272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5165|A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Pilot Study of Beta-D-2,6-diaminopurine Dioxolane (DAPD) Versus DAPD Plus Mycophenolate Mofetil (MMF) in Treatment-Experienced Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|May 29, 2002||||No||https://clinicaltrials.gov/show/NCT00038272||203723|
NCT00038402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-146|Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer|Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer||M.D. Anderson Cancer Center|No|Completed|April 2001|July 2011|Actual|November 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|N/A|N/A|No|||July 2012|July 19, 2012|May 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038402||203714|
NCT00039039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068846|Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer|Phase III Randomized Study of Paclitaxel and Carboplatin or Cisplatin Followed by Radiotherapy With or Without Concurrent Paclitaxel in Patients With Unresectable Stage III Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2000|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|70 Years|No|||August 2006|December 17, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039039||203666|
NCT00039273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069368|Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer|An Open Label Phase II Clinical Trial To Evaluate The Safety And Efficacy Of ABX-EGF In Patients With Metastatic Colorectal Carcinoma||Jonsson Comprehensive Cancer Center||Completed|July 2002|||May 2003|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039273||203653|
NCT00039286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-134|Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer|A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|October 2001|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|118|||Female|N/A|120 Years|No|||December 2015|December 23, 2015|June 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00039286||203652|
NCT00038753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-85|Vision In Preschoolers Study (VIP Study)|||National Eye Institute (NEI)||Active, not recruiting||||||Phase 3|Interventional|Primary Purpose: Diagnostic|||||||Both|36 Months|59 Months|Accepts Healthy Volunteers|||October 2009|October 15, 2009|June 4, 2002||||No||https://clinicaltrials.gov/show/NCT00038753||203688|
NCT00042276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020245|The Natural History of Upper Trapezius Myofascial Trigger Points: Comparison of Local and Remote Tissue Milieu in Normal Muscle, Latent and Active Myofascial Trigger Points Over Time|The Natural History of Upper Trapezius Myofascial Trigger Points: Comparison of Local and Remote Tissue Milieu in Normal Muscle, Latent and Active Myofascial Trigger Points Over Time||National Institutes of Health Clinical Center (CC)||Completed|July 2002|March 2013||||N/A|Observational|N/A|||Actual|88|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2013|January 14, 2014|July 26, 2002||No||No||https://clinicaltrials.gov/show/NCT00042276||203445|
NCT00038961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103414|Safety Study of Fondaparinux Sodium to Prevent Venous Thromboembolic Events (APOLLO)|A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression Versus Intermittent Pneumatic Compression Used Alone for the Prevention of Venous Thromboembolic Events in Patients at Increased Risk Undergoing Major Abdominal Surgery||GlaxoSmithKline||Completed|October 2001|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1309|||Both|40 Years|N/A|No|||August 2011|August 22, 2011|June 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038961||203672|
NCT00038974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Virahep-C (completed)|Hepatitis C Antiviral Resistance in African-Americans|Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 2002|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|70 Years|No|||March 2011|March 15, 2011|June 5, 2002||||||https://clinicaltrials.gov/show/NCT00038974||203671|
NCT00038532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-287|Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART|An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART||Abbott||Completed|April 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||July 2006|March 29, 2008|May 31, 2002||||||https://clinicaltrials.gov/show/NCT00038532||203704|
NCT00038896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B5-353|Study Evaluating Venlafaxine ER in Adults With Panic Disorder|A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|343|||Both|18 Years|N/A|No|||August 2009|August 13, 2009|June 5, 2002||||||https://clinicaltrials.gov/show/NCT00038896||203677|
NCT00039091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03144|Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer|Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (Anti-CTLA-4) Humanized Monoclonal Antibody (MDX-CTLA-4 NSC# 732442, Previously 720801) in Patients Previously Vaccinated With GM-CSF-Based Autologous Tumor Vaccines (CTEP Protocol Number P-5708) and Patients With Acute Myelogenous Leukemia/ Myelodysplasia, and Non-Small Cell Lung Cancer Who Have Not Received a Prior Vaccine||National Cancer Institute (NCI)||Terminated|March 2002|||November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|19 Years|N/A|No|||January 2013|January 9, 2013|June 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00039091||203663|
NCT00038805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-153|Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)|Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Terminated|May 2001|November 2004|Actual|November 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|55 Years|75 Years|No|||July 2012|July 27, 2012|June 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038805||203684|
NCT00039234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069365|Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver|A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis||National Cancer Institute (NCI)||Active, not recruiting|September 2002|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2003|December 17, 2013|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039234||203654|
NCT00038454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLK-213|Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery|A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery||Hemosol||Suspended||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||180|||Both|18 Years|80 Years|No|||April 2003|June 23, 2005|May 30, 2002||||||https://clinicaltrials.gov/show/NCT00038454||203710|
NCT00038467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-OEXE-031|Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer|Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen|IES|Pfizer|Yes|Completed|February 1998|March 2013|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4740|||Female|30 Years|N/A|No|||April 2014|April 21, 2014|May 31, 2002|Yes|Yes||No|March 5, 2014|https://clinicaltrials.gov/show/NCT00038467||203709|Other AEs included both SAEs and AEs. Non-SAE could not be presented separately for this study as AEs were collected in clinical database where SAE flags were not collected.
NCT00039000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-21|Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma|A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus Physician's Choice Including Interleukin-2 and/or Dacarbazine/Temozolomide-based Therapy and/or Complete Tumor Resection in Stage IV Melanoma||Agenus, Inc.||Completed|March 2002|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|June 6, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00039000||203669|
NCT00039013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-112|Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin|A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone||AstraZeneca|No|Completed|March 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|336|||Both|16 Years|75 Years|No|||January 2015|February 23, 2015|June 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00039013||203668|
NCT00039338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55994|Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer|Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Active, not recruiting|March 2002|July 2019|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|686|||Female|18 Years|75 Years|No|||May 2015|May 18, 2015|June 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00039338||203648|
NCT00039156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069358|BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma|An Open Phase II Multi-Center Trial of BAY 59-8862 in Patients With Aggressive Refractory Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|January 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2004|July 23, 2008|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039156||203659|
NCT00039351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20992|Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma|Diffuse Large B Cell And Peripheral T-Cell Non-Hodgkin's Lymphoma In The Frail Elderly. Progressive And Cautious Treatment Strategy In Poor Status Patients. A Phase II Trial With Emphasis On Geriatric Assessment And Quality Of Life||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 2002|||January 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|70 Years|N/A|No|||September 2012|September 20, 2012|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039351||203647|
NCT00044005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050174|Safety and Tolerability Study of Drug to Treat Schizophrenia|A Randomized, Open-Label, Dose-Blinded, Multicenter, 6-Month Study of Safety and Tolerability of 3 Dose Levels of SM-13496 (Lurasidone) in Patients With Schizophrenia||Sunovion|No|Completed|September 2002|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|65 Years|No|||March 2014|March 31, 2014|August 16, 2002|No|Yes||No|February 16, 2011|https://clinicaltrials.gov/show/NCT00044005||203322|
NCT00038688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 037|A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts|A Phase III Randomized Study to Evaluate the Efficacy of a Network-Oriented Peer Education Intervention for the Prevention of HIV Transmission Among Injection Drug Users and Their Network Members||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||2610|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|October 29, 2009|June 4, 2002||||No||https://clinicaltrials.gov/show/NCT00038688||203692|
NCT00038701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID98-248|Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas|Phase II Study of Gemcitabine-Based Chemoradiation and TNP-470 for Patients With Locally Advanced, Nonmetastatic Adenocarcinoma of the Pancreas||M.D. Anderson Cancer Center|No|Terminated|August 2000|May 2004|Actual|July 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|June 4, 2002|Yes|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00038701||203691|
NCT00038558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-087|Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy|Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy||M.D. Anderson Cancer Center|Yes|Completed|November 2001|March 2005|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|16 Years|N/A|No|||July 2012|July 27, 2012|May 31, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038558||203702|
NCT00038246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-087|Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma|Phase I/II Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma (AI-PCa)||M.D. Anderson Cancer Center|Yes|Completed|October 2000|December 2004|Actual|February 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|N/A|N/A|No|||May 2013|May 31, 2013|May 29, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038246||203725|
NCT00038506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESS 30005|Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure|A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)||ViiV Healthcare||Completed|March 2002|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||100|||Both|18 Years|N/A|No|||October 2010|April 6, 2015|May 31, 2002||||||https://clinicaltrials.gov/show/NCT00038506||203706|
NCT00038194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-271|Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer|Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|October 2001|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|N/A|N/A|No|||July 2012|July 31, 2012|May 29, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00038194||203729|
NCT00044018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-007|CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma|An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma||Celgene|No|Completed|April 2002|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|102|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|August 16, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044018||203321|
NCT00038207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P99-401|Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies|Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies||M.D. Anderson Cancer Center|No|Completed|June 2000|September 2005|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|N/A|No|||July 2012|July 27, 2012|May 29, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00038207||203728|
NCT00042146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060413|Behavioral and Pharmacological Treatment for Insomnia|Behavioral and Pharmacological Treatment for Insomnia||Laval University||Completed|December 2001|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|30 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 17, 2013|July 24, 2002||||No||https://clinicaltrials.gov/show/NCT00042146||203455|
NCT00042601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-149|Evaluation of the Effect of Pramlintide on Satiety and Food Intake|A Single Center, Randomized, Double-blind, Placebo-controlled, Two-period, Crossover Study Evaluating the Acute Effect of Pramlintide on Satiety and Food Intake in Normal-weight and Obese Non-diabetic Subjects and in Insulin Treated Subjects With Type 1 and Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|July 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Male|18 Years|70 Years|No|||October 2015|October 20, 2015|August 1, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00042601||203420|
NCT00041015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKF1501|Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment For Chemotherapy-Naive Patients With Extensive Disease - Small Cell Lung||Case Comprehensive Cancer Center|Yes|Completed|September 2001|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041015||203535|
NCT00041132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069445|S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma|Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma||Southwest Oncology Group|No|Completed|September 2002|June 2011|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|69 Years|No|||October 2012|October 3, 2012|July 8, 2002||No||No|March 5, 2012|https://clinicaltrials.gov/show/NCT00041132||203526|
NCT00042614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020266|Study of Heart Transplant Rejection|Acute Cardiac Allograft Cellular Rejection and Cardiac Allograft Vasculopathy: Identification of Diagnostic Biomarkers and Target Pathways for Preventive Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|July 2002|||||N/A|Observational|N/A|||Anticipated|482|||Both|12 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|August 1, 2002||No||No||https://clinicaltrials.gov/show/NCT00042614||203419|
NCT00042627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020255|Prevalence and Risk of Cataracts in Granulocyte Donors|Prevalence and Risks for Posterior Subcapsular Cataracts in Volunteer Granulocytapheresis Donors||National Institutes of Health Clinical Center (CC)||Completed|July 2002|June 2007||||N/A|Observational|N/A||||252|||Both|18 Years|N/A|No|||June 2007|September 26, 2015|August 1, 2002||||No||https://clinicaltrials.gov/show/NCT00042627||203418|
NCT00043069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N01C8|Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer|Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study||Alliance for Clinical Trials in Oncology|Yes|Completed|November 2002|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|71|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|August 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00043069||203388|
NCT00042926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0360|Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer|A Trial Of Lymphatic Mapping And Sentinel Node Lymphadenectomy For Patients With T1 or T2 Clinically N0 Oral Cavity Squamous Cell Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|May 2002|November 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|161|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|August 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00042926||203398|
NCT00043095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256333|BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of BMS 247550 (NSC# 710428) and Gemcitabine in Patients With Advanced Solid Tumor Malignancies||National Cancer Institute (NCI)||Completed|June 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2005|July 23, 2008|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00043095||203386|
NCT00042809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02477|Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors|Phase I Study To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Combined EGFR (erbB1) And HER2 (erbB2) Blockade, With OSI-774 And Trastuzumab, In Combination With Weekly Paclitaxel||National Cancer Institute (NCI)||Completed|May 2002|||December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|August 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042809||203407|
NCT00043004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40004|Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer|CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastases||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|May 2002|||June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|119|||Both|18 Years|80 Years|No|||September 2012|September 20, 2012|August 5, 2002|||low accrual|No||https://clinicaltrials.gov/show/NCT00043004||203392|
NCT00043212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC3-HRPC, October 2001|Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.|A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating DCVax(tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment of Metastatic Hormone Refractory Prostate Cancer||Northwest Biotherapeutics||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Male|18 Years|N/A|No|||April 2013|April 30, 2013|August 6, 2002|Yes|Yes|Redirection of company goals|No||https://clinicaltrials.gov/show/NCT00043212||203379|
NCT00043030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020204|Evaluating Patient Participation in Phase I Clinical Trials|Survey Of Patient's Motivations, Perceptions, And Expectations In Phase I Clinical Trials||National Institutes of Health Clinical Center (CC)||Completed|June 2002|May 2009|Actual|December 2006|Actual|N/A|Interventional|N/A|||Anticipated|120|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00043030||203390|
NCT00041210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069453|Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma|Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|850|||Both|18 Years|60 Years|No|||April 2009|September 19, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041210||203523|
NCT00042796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01873|Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I Study Of Decitabine (DAC) (IND # 50733) In Children With Relapsed Or Refractory Acute Leukemia||National Cancer Institute (NCI)||Terminated|December 2002|||October 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|21 Years|No|||January 2013|January 22, 2013|August 5, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00042796||203408|
NCT00042289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1026s|Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy|Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|March 2003|||June 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|1786|||Female|N/A|N/A|No|||February 2016|February 26, 2016|July 26, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042289||203444|
NCT00042302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TQD LUNG 001|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)|||QLT Inc.||Terminated|June 2002|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind||||540|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|July 26, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042302||203443|
NCT00042315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TQD LUNG 002|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)|||QLT Inc.||Terminated|June 2002|June 2003||June 2003||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind||||490|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|July 26, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042315||203442|
NCT00041951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-1441|Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study|Search for Genes Influencing Childhood Absence Epilepsy Study||Icahn School of Medicine at Mount Sinai|No|Recruiting|December 1998|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|saliva|Both|3 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Whole families with many members affected with epilepsy or both parents and a child with        CAE of families without other affected members (trios) and healthy individuals without        epilepsy|August 2012|August 9, 2012|July 19, 2002||No||No||https://clinicaltrials.gov/show/NCT00041951||203470|
NCT00042341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO212|Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)|A Phase II, Open Label Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia||Sanofi||Completed|May 2002|January 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|21 Years|No|||March 2014|March 17, 2014|July 26, 2002||||||https://clinicaltrials.gov/show/NCT00042341||203440|
NCT00042354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO222|Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients|A Phase II, Open Label Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myelogenous Leukemia||Sanofi||Completed|May 2002|August 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|21 Years|No|||March 2015|March 4, 2015|July 26, 2002||||||https://clinicaltrials.gov/show/NCT00042354||203439|
NCT00042367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8619|Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors|Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants With Brain Tumors|BB'98|Baylor College of Medicine|Yes|Completed|April 2000|June 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|N/A|36 Months|No|||February 2012|February 10, 2012|July 26, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042367||203438|
NCT00043199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-726-01|A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies|A Phase II Study of Aroplatin in Subjects With Recurrent, Unresectable and Metastatic Colorectal Cancer Refractory to 5-Fluorouracil (5-FU)/Leucovorin or Capecitabine, and Irinotecan||Aronex Pharmaceuticals||Active, not recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2004|June 23, 2005|August 6, 2002||||||https://clinicaltrials.gov/show/NCT00043199||203380|
NCT00042237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH060216|Treatment of Depressed Women Who Have Been Sexually Abused|Treatment of Women With Depression and Sexual Abuse||Butler Hospital||Completed|September 2001|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Female|18 Years|65 Years|No|||August 2013|August 20, 2013|July 24, 2002||||No||https://clinicaltrials.gov/show/NCT00042237||203448|
NCT00042250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM91-102|IUdR/BUdR Cell Cycle Labelling|Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling||M.D. Anderson Cancer Center|No|Completed|May 1992|October 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|28|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|July 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00042250||203447|
NCT00041093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0127S|Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix||Gynecologic Oncology Group||Completed|June 2002|||January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|N/A|N/A|No|||February 2016|February 10, 2016|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041093||203529|
NCT00042705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5410-CP-001|Asthma Severity in Children and Environmental Agents|||National Institute of Environmental Health Sciences (NIEHS)||Completed|May 2000|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective|||||||Both|5 Years|11 Years|No|||April 2015|April 13, 2015|August 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00042705||203413|
NCT00041171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-60002|Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery|Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors||Alliance for Clinical Trials in Oncology||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|July 8, 2002|No|Yes|The study was not activated.|No||https://clinicaltrials.gov/show/NCT00041171||203525|
NCT00042211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061331|Preventing Depression in Patients With Macular Degeneration|Preventing Depression in Macular Degeneration||Thomas Jefferson University|Yes|Completed|February 2001|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|206|||Both|65 Years|N/A|No|||February 2008|January 7, 2014|July 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00042211||203450|
NCT00042224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060390|Electroconvulsive Therapy in Clozapine Refractory Schizophrenia|ECT in Clozapine Refractory Schizophrenia||Northwell Health|Yes|Completed|December 2000|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|60 Years|No|||September 2015|September 15, 2015|July 24, 2002||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT00042224||203449|
NCT00042653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000188|A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis|A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)||Amgen||Completed|May 2002|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|August 2, 2002||||No||https://clinicaltrials.gov/show/NCT00042653||203417|
NCT00042666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4849|A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.|A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma||Eli Lilly and Company|No|Completed|June 2002|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||October 2009|October 16, 2009|August 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00042666||203416|
NCT00042718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002650|A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.|||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2001|August 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|659|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|August 5, 2002||||||https://clinicaltrials.gov/show/NCT00042718||203412|
NCT00043225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010198|The Role of Bacteria and Genetic Variations in Cystic Fibrosis|Clinical Course in Cystic Fibrosis: The Effects of Pseudomonas Aeruginosa and Potential Modifier Genes||National Institutes of Health Clinical Center (CC)||Recruiting|June 2001|||||N/A|Observational|N/A|||Anticipated|200|||Both|9 Years|80 Years|No|||September 2015|October 6, 2015|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00043225||203378|
NCT00041223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069454|IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer|Double-Blind, Placebo-Controlled, Randomized Phase II Trial of IH636 Grape Seed Proanthocyanidin Extract (GSPE) in Patients With Adverse Effects of High Dose Breast Radiotherapy||National Cancer Institute (NCI)||Active, not recruiting|September 2002|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||September 2002|November 5, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041223||203522|
NCT00042978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02819|Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer|A Randomized Phase II Study Of Carboplatin And Etoposide With Or Without G3139 (NSC #683428, IND #58842) In Patients With Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|April 2003|||May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|August 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042978||203394|
NCT00042991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03022|Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas|Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors||National Cancer Institute (NCI)||Completed|July 2002|March 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|3 Years|21 Years|No|||December 2012|May 15, 2014|August 5, 2002|Yes|Yes||No|February 9, 2011|https://clinicaltrials.gov/show/NCT00042991||203393|
NCT00042848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069477|Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer|Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of The Effect Of Modafinil On Fatigue In Cancer Patients Receiving Chemotherapy||University of Rochester|Yes|Completed|August 2002|October 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|837|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|August 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00042848||203404|
NCT00041964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5150|A Study of HIV Levels During Pregnancy and After Childbirth|A Prospective Observational Study of Virologic and Immunologic Changes in HIV-Infected Women During the Postpartum Period||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|N/A||||129|||Female|13 Years|N/A|No|||July 2012|July 23, 2012|July 19, 2002||||No||https://clinicaltrials.gov/show/NCT00041964||203469|
NCT00041977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DERM-303|Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea||CollaGenex Pharmaceuticals||Completed|June 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2003|June 23, 2005|July 19, 2002||||||https://clinicaltrials.gov/show/NCT00041977||203468|
NCT00041925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGT003-03|Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures|A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Peripheral Vein Grafts in Patients Undergoing Peripheral Arterial Bypass Graft Procedures||Anesiva, Inc.||Completed|November 2001|November 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1400|||Both|18 Years|N/A|No|||July 2005|July 14, 2005|July 18, 2002||||||https://clinicaltrials.gov/show/NCT00041925||203472|
NCT00042055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-461-012|CP-461 for the Treatment of Crohn's Disease|A Phase II Pilot Study of CP-461 in the Treatment of Moderately to Severely Active Crohn's Disease||Astellas Pharma Inc||Completed|July 2002|September 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|July 22, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00042055||203462|
NCT00041938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1093|Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial|Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial|WARCEF|Columbia University|Yes|Completed|October 2002|July 2014|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2305|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|July 19, 2002||No||No|January 3, 2013|https://clinicaltrials.gov/show/NCT00041938||203471|
NCT00041106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02818|Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer|Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND #61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma||National Cancer Institute (NCI)||Completed|May 2002|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|July 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00041106||203528|
NCT00041197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02930|Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery|A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec™) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)||National Cancer Institute (NCI)||Completed|June 2002|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|732|||Both|18 Years|N/A|No|||June 2013|July 15, 2013|July 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00041197||203524|
NCT00042380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020254|Examination of a Soy-Based Supplement for Major Depression|A Phase 2A Study of Soy Isoflavones in the Treatment of Major Depression||National Institutes of Health Clinical Center (CC)||Completed|July 2002|April 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||April 2005|March 3, 2008|July 26, 2002||||No||https://clinicaltrials.gov/show/NCT00042380||203437|
NCT00042393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-01-550|An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options|A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options||Gilead Sciences||Approved for marketing||||||Phase 3|Expanded Access|N/A|||||||Both|16 Years|N/A|No|||January 2014|January 3, 2014|July 27, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00042393||203436|
NCT00040755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00041|BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|May 2002|||July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Male|N/A|N/A|No|||January 2013|January 31, 2013|July 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00040755||203551|
NCT00042900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-090|Pyroxamide in Treating Patients With Advanced Cancer|A Phase I Clinical And Pharmacological Study Of Pyroxamide (NSC 696085) In Patients With Advanced Malignancies||Memorial Sloan Kettering Cancer Center||Completed|April 2002|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00042900||203400|
NCT00042913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069484|Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase 2 Open Label, Randomized, Dose And Schedule Finding, Clinical Trial Of Immunotherapy With AMG 412 In Subjects With Diffuse Large B-Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|May 2002|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|December 18, 2013|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00042913||203399|
NCT00041236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62006|Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma|Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2002|||December 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|15 Years|75 Years|No|||July 2012|July 17, 2012|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041236||203521|
NCT00041249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62011|Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma|Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2002|||January 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|64|||Both|15 Years|N/A|No|||July 2012|July 17, 2012|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041249||203520|
NCT00042679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6429|A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.|A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.||Eli Lilly and Company||Completed|June 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|August 2, 2002||||||https://clinicaltrials.gov/show/NCT00042679||203415|
NCT00042692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10196-CP-001|Catechol Thioethers in Parkinson's Disease|||National Institute of Environmental Health Sciences (NIEHS)||Completed|March 2001|March 2002||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||||20|||Both|N/A|N/A|No|||March 2006|March 22, 2006|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00042692||203414|
NCT00043017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069496|Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer|Contrast-Enhanced Breast MRI For Evaluation Of Patients Undergoing Neoadjuvant Treatment For Locally-Advanced Breast Cancer (I-SPY 1/ACRIN 6657)|ACRIN 6657|American College of Radiology Imaging Network|Yes|Completed|May 2002|March 2011|Actual|May 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|356|||Female|18 Years|N/A|No|||October 2013|October 7, 2013|August 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00043017||203391|
NCT00043147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTERON-00-02|Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease|A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms||National Cancer Institute (NCI)||Completed|April 2002|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||December 2004|May 29, 2013|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00043147||203382|
NCT00042731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13004|Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy|A Randomized Pilot Clinical Trial Of The Action Of Isoflavones And Lycopene In Localized Prostate Cancer: Administration Prior To Radical Prostatectomy||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 2002|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|79|||Male|45 Years|80 Years|No|||September 2012|September 21, 2012|August 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042731||203411|
NCT00042770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069451|Standard Chest Tube Compared With a Small Catheter in Treating Malignant Pleural Effusion in Patients With Cancer|Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control, OPEC)||Alliance for Clinical Trials in Oncology|Yes|Completed|May 2002|February 2008|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|August 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042770||203410|
NCT00042783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069468|Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Phase II Trial Of A D1/3-MAGE3-HIS Fusion Protein (NSC-719274) With Adjuvant SBAS02B (NSC-719275) For Patients With Stage IV, M1a or M1b Metastatic Melanoma||National Cancer Institute (NCI)||Completed|September 2002|March 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||April 2004|June 21, 2013|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00042783||203409|
NCT00043134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256224|Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome|Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study||National Cancer Institute (NCI)||Active, not recruiting|May 2002|||May 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|220|||Both|60 Years|N/A|No|||April 2008|April 10, 2010|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00043134||203383|
NCT00042874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01410|Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Irinotecan (CPT-11) and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|May 2002|||January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|August 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042874||203402|
NCT00042939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069486|Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer|Phase II Trial of Irinotecan/Docetaxel for Advanced Pancreatic Cancer, With Randomization Between Irinotecan/Docetaxel and Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor (EGF-r)||Eastern Cooperative Oncology Group|No|Completed|July 2003|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||December 2012|April 2, 2013|August 5, 2002|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00042939||203397|
NCT00042952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02481|Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer|A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma||National Cancer Institute (NCI)||Terminated|June 2002|||October 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|15 Years|N/A|No|||January 2013|January 15, 2013|August 5, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00042952||203396|
NCT00042965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-90008|Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|October 2002|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|August 5, 2002||No||No||https://clinicaltrials.gov/show/NCT00042965||203395|
NCT00042185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061957|Eating Disorder Prevention Programs|Austin Body Acceptance Study||University of Texas at Austin||Completed|February 2001|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4|||450|||Female|14 Years|19 Years|Accepts Healthy Volunteers|||September 2013|September 26, 2013|July 24, 2002||||No||https://clinicaltrials.gov/show/NCT00042185||203452|
NCT00042081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGT003-04|Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures|A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures||Anesiva, Inc.||Completed|July 2002|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3000|||Both|18 Years|80 Years|No|||July 2005|May 4, 2006|July 22, 2002||||||https://clinicaltrials.gov/show/NCT00042081||203460|
NCT00042094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMPX-001|Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®|A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®)||DynPort Vaccine Company LLC, A CSC Company||Completed|March 2002|March 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||350|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 29, 2011|July 23, 2002||||||https://clinicaltrials.gov/show/NCT00042094||203459|
NCT00042120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10803-CP-001|Farming and Movement Evaluation Study (FAME)|Pesticides and Risk in the Agricultural Health Study|FAME|National Institute of Environmental Health Sciences (NIEHS)||Completed|April 2001|||July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective|||Actual|520|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|September 26, 2014|July 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00042120||203457|
NCT00042133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10902-CP-001|Socio-economic Status and Age-related Disability in a Biracial Community|||National Institute of Environmental Health Sciences (NIEHS)||Completed|April 2001|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|6000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|July 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00042133||203456|
NCT00042068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.258|A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis|A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis||Boehringer Ingelheim||Completed|June 2002|July 2003||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||1000|||Both|18 Years|80 Years|No|||October 2013|October 31, 2013|July 22, 2002||||No||https://clinicaltrials.gov/show/NCT00042068||203461|
NCT00041990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC-013|Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)|A Phase II, Multicenter Study of Decitabine (5-Aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Accelerated Phase Refractory to Imatinib Mesylate (STI 571)||Astex Pharmaceuticals||Completed|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|2 Years|N/A|No|||December 2007|December 12, 2007|July 19, 2002||||||https://clinicaltrials.gov/show/NCT00041990||203467|
NCT00040859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0149|Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer|A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia||Alliance for Clinical Trials in Oncology|No|Completed|September 2002|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00040859||203543|
NCT00041119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-40101|Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer|Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|May 2002|||April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|4646|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041119||203527|
NCT00043108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256334|Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Trimodality Protocol for the Treatment of Locally Advanced, Potentially Resectable Non-Small Cell Lung Cancer Targeting||Fox Chase Cancer Center||Active, not recruiting|July 2002|September 2016|Anticipated|December 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|57|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00043108||203385|
NCT00042003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC-012|Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)|A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571)||Astex Pharmaceuticals|No|Completed|July 2002|||December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|2 Years|N/A|No|||June 2008|January 22, 2013|July 19, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042003||203466|
NCT00042016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC-014|Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)|A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate (STI 571)||Astex Pharmaceuticals||Completed|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|2 Years|N/A|No|||June 2005|October 12, 2009|July 19, 2002||||||https://clinicaltrials.gov/show/NCT00042016||203465|
NCT00042029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-073|Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)|A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|June 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|324|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|July 22, 2002||||||https://clinicaltrials.gov/show/NCT00042029||203464|
NCT00042887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30004|Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer|Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|May 2002|||May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|58|||Both|N/A|80 Years|No|||September 2012|September 20, 2012|August 5, 2002|||low accrual|No||https://clinicaltrials.gov/show/NCT00042887||203401|
NCT00043082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256331|S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer|A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy||Southwest Oncology Group|Yes|Completed|August 2002|July 2011|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|120 Years|No|||October 2015|October 23, 2015|August 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00043082||203387|
NCT00043186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010223|Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density|A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density||Amgen||Completed|May 2002|June 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|412|||Female|N/A|80 Years|No|||September 2013|September 6, 2013|August 6, 2002||||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00043186||203381|
NCT00043043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069498|Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia|Rectal Abberant Crypt Foci And Other Intermediate Biomarkers For Sporadic Colorectal Neoplasia: Cross-Sectional Prevelance And Modulation By Celecoxib||National Cancer Institute (NCI)||Completed|May 2003|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||November 2004|June 18, 2013|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00043043||203389|
NCT00043121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00004|Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery|A Phase I Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Advanced Malignancy||National Cancer Institute (NCI)||Completed|June 2002|||August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|August 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00043121||203384|
NCT00042822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069473|FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma|A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers||National Cancer Institute (NCI)||Completed|May 2002|||March 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|May 14, 2011|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00042822||203406|
NCT00042835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02478|Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer|A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer||National Cancer Institute (NCI)||Terminated|May 2002|||December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|August 5, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00042835||203405|
NCT00042861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069478|UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Pharmacologic Trial Of Infusional UCN-01 Given With A Weekly Schedule Of 5-Fluorouracil And Leucovorin||National Cancer Institute (NCI)||Completed|August 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|April 29, 2015|August 5, 2002||||No||https://clinicaltrials.gov/show/NCT00042861||203403|
NCT00042107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10751-CP-001|Molecular Epidemiology of Parkinson's Disease|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 2000|June 2005||||N/A|Observational|N/A|||Anticipated|2022|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2002|September 26, 2014|July 24, 2002||||No||https://clinicaltrials.gov/show/NCT00042107||203458|
NCT00039364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16011-26013|Imatinib Mesylate in Treating Patients With Gliomas|Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 2002|||August 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|112|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|June 6, 2002||||No||https://clinicaltrials.gov/show/NCT00039364||203646|
NCT00042172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH061801|Treatment for Early Memory Loss|Cognitive Enhancers Explored With PET Imaging||University of Iowa||Completed|June 2002|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 27, 2014|July 24, 2002||||No||https://clinicaltrials.gov/show/NCT00042172||203453|
NCT00042328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9912|A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients|A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients||Baylor College of Medicine|Yes|Completed|August 2001|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|2 Years|18 Years|No|||August 2015|August 20, 2015|July 26, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00042328||203441|
NCT00042198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060735|Treatment of Depression After Coronary Bypass Surgery|Treatment of Depression After Coronary Bypass Surgery||Washington University School of Medicine|Yes|Completed|December 2001|August 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|123|||Both|21 Years|N/A|No|||July 2013|July 1, 2013|July 24, 2002||No||No||https://clinicaltrials.gov/show/NCT00042198||203451|
NCT00041548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARLW1|Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation|Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation||INO Therapeutics|Yes|Terminated|May 2002|June 2005|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|N/A|120 Hours|No|||June 2010|June 9, 2010|July 10, 2002|Yes|Yes|slow enrollment|No||https://clinicaltrials.gov/show/NCT00041548||203499|
NCT00041860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9676-CP-001|Modulation of Benzene Metabolism by Exposure to Environment|||National Institute of Environmental Health Sciences (NIEHS)||Completed||||||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study|||||||||||||July 2002|June 23, 2005|July 18, 2002||||No||https://clinicaltrials.gov/show/NCT00041860||203475|
NCT00048022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16630|Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma|||Hoffmann-La Roche||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||May 2005|June 23, 2005|October 24, 2002||||||https://clinicaltrials.gov/show/NCT00048022||203047|
NCT00047580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN021-502|Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.|A Multicenter, Open-Label, Randomized, 4-Way Crossover Trial of the Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex (Tizanidine Hydrochloride) Tablets Taken Under Fed and Fasted Conditions in Patients With Moderate to Severe Spasticity||Elan Pharmaceuticals||Completed|June 2002|September 2002||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 8, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00047580||203079|
NCT00041275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069460|Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|May 2002|August 2011|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|20 Years|N/A|No|||September 2002|September 19, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041275||203518|
NCT00040911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL04C2|Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma|A Randomized Study Of Electroacupuncture Treatment For Delayed Chemotherapy-Induced Nausea And Vomiting In Patients With Pediatric Solid Tumors||Children's Oncology Group|Yes|Completed|April 2005|January 2011|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|17|||Both|5 Years|35 Years|No|||May 2013|May 29, 2013|July 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00040911||203539|
NCT00041730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FavId-04|Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma|Phase II Trial of Rituxan(R) Plus FavId(TM) (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients With Grade 1 or 2 Follicular B-Cell Lymphoma||Favrille||Active, not recruiting|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||October 2004|September 29, 2009|July 15, 2002||||||https://clinicaltrials.gov/show/NCT00041730||203485|
NCT00041743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crow (completed)|Treatment of Binge Eating Disorder|Treatment of Binge Eating Disorder||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 2002|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years|No|||January 2010|January 12, 2010|July 16, 2002||||No||https://clinicaltrials.gov/show/NCT00041743||203484|
NCT00047593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-98|Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98|Phase 3 Study to Compare Two Different IOP Lowering Medications for the Treatment of Open Angle Glaucoma or Ocular Hypertension in Japanese Subjects C-01-98.||Alcon Research||Completed|January 2000|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|October 8, 2002||||||https://clinicaltrials.gov/show/NCT00047593||203078|
NCT00047606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-32|Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32|Phase 4 Study to Compare Two Different IOP Lowering Medications for the Treatment of Open Angle Glaucoma or Ocular Hypertension in Caucasian and Japanese Subjects C-02-32.||Alcon Research||Terminated|August 2002|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|84|||Both|18 Years|N/A|No|||August 2008|August 16, 2012|October 8, 2002|Yes|Yes|Management Decision|||https://clinicaltrials.gov/show/NCT00047606||203077|
NCT00047619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2803-R|Enhancement of Pressure Healing With Pulsatile Lavage|Enhancement of Pressure Healing With Pulsatile Lavage||VA Office of Research and Development|No|Completed|June 2002|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|October 9, 2002||No||No|July 8, 2015|https://clinicaltrials.gov/show/NCT00047619||203076|
NCT00046449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|398149|Prevention of Seasonal Affective Disorder|||GlaxoSmithKline||Completed|September 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2015|June 2, 2015|September 30, 2002||||||https://clinicaltrials.gov/show/NCT00046449||203159|
NCT00041600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS035129|Human Epilepsy Genetics--Neuronal Migration Disorders Study|Human Epilepsy Genetics--Neuronal Migration Disorders Study||Harvard University Faculty of Medicine|No|Recruiting|April 1996|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|3500|Samples With DNA|whole blood, DNA|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be selected through collaborations with clinicians.|June 2014|June 27, 2014|July 11, 2002||No||No||https://clinicaltrials.gov/show/NCT00041600||203495|
NCT00045188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02491|Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer|Phase II Trial of STI571 in Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|August 2002|||July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045188||203239|
NCT00045201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00015|Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors|Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|June 2002|||June 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2014|January 11, 2016|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045201||203238|
NCT00045227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256919|Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer|A Pilot Trial of Pox Vector PSA Vaccine With Concurrent Docetaxel Versus Pox Vector Vaccine Followed by Docetaxel in Metastatic Androgen Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|August 2002|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||December 2003|June 18, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045227||203237|
NCT00041457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1183|Epidemiology of Venous Thromboembolism|||Brigham and Women's Hospital||Completed|July 2002|June 2006|Actual|June 2006|Actual|N/A|Observational|N/A||4|||||Both|N/A|N/A|No|||August 2015|August 5, 2015|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041457||203505|
NCT00041080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02475|Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy||National Cancer Institute (NCI)||Completed|February 2003|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Female|N/A|N/A|No|||January 2013|April 29, 2014|July 8, 2002|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00041080||203530|
NCT00040586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100-471|Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2|Phase II Trial of Monoclonal Antibody J591 in Combination With Low-Dose Interleukin-2 in Patients With Recurrent Prostate Cancer||BZL Biologics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|21 Years|N/A|No|||July 2002|January 19, 2007|July 1, 2002||||||https://clinicaltrials.gov/show/NCT00040586||203561|
NCT00041886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020244|Radiofrequency Ablation of Painful Soft Tissue Neoplasms|Radiofrequency Ablation of Painful Soft Tissue Neoplasms||National Institutes of Health Clinical Center (CC)||Completed|July 2002|June 2005||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||June 2005|March 3, 2008|July 18, 2002||||No||https://clinicaltrials.gov/show/NCT00041886||203474|
NCT00041054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-30104|Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients With Extensive Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|June 2002|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041054||203532|
NCT00040651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR92239|Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients|Transplantation With T-Cell Depleted Autologous Peripheral Stem Cells for Severe Systemic Sclerosis: A Phase I Dose Escalation Study||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Terminated|July 2002|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|70 Years|No|||December 2007|December 19, 2007|July 5, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00040651||203557|
NCT00045682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0186C|CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of CT-2103 in the Third-Line Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Cancer||Gynecologic Oncology Group||Completed|September 2002|||January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045682||203211|
NCT00045695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I152|Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia|A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Waldenstrom's Macroglobulinemia||National Cancer Institute (NCI)|No|Completed|August 2002|December 2009|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||September 2011|May 16, 2013|September 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00045695||203210|
NCT00045032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO16348|Trastuzumab in Treating Women With Primary Breast Cancer|HERA: A Randomised Three-Arm Multi-Centre Comparison Of 1 Year And 2 Years Of Herceptin Versus No Herceptin In Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy||Hoffmann-La Roche||Active, not recruiting|December 2001|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5043|||Female|18 Years|N/A|No|||March 2012|June 4, 2012|September 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045032||203248|
NCT00041496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207266082|Prevention Of Recurrence Of Atrial Fibrillation|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)||GlaxoSmithKline||Completed|November 2001|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|520|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|July 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041496||203502|
NCT00045266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGENERON-VGF-ST-0105|VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma|An Open-Label, Long Term, Safety, and Tolerability Study of VEGF Trap in Patients With Incurable, Relapsed or Refractory Solid Tumors or Lymphoma||Regeneron Pharmaceuticals||Completed|April 2002|||February 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|25 Years|N/A|No|||December 2009|April 15, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045266||203236|
NCT00041587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL13PEI-103|Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma|Pre-operative IL13-PE38QQR Infusion in Patients With Recurrent or Progressive Supratentorial Malignant Glioma: A Phase I/II Study||INSYS Therapeutics Inc||Completed|July 2002|July 2007|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|July 10, 2002||Yes||||https://clinicaltrials.gov/show/NCT00041587||203496|
NCT00041782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-078|Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients|Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients||M.D. Anderson Cancer Center|Yes|Terminated|October 2000|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 27, 2012|July 16, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041782||203481|
NCT00041509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|424323/025|ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)|ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty|TEMPEST|GlaxoSmithKline|No|Completed|January 2002|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|343|||Both|35 Years|N/A|No|||June 2011|June 30, 2011|July 9, 2002|Yes|Yes||||https://clinicaltrials.gov/show/NCT00041509||203501|
NCT00041535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020243|OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease|A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease||National Institutes of Health Clinical Center (CC)||Completed|July 2002|March 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||30|||Both|4 Years|N/A|No|||March 2008|September 26, 2015|July 9, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00041535||203500|
NCT00041821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10424-CP-001|Nasal Irritation Study: Individual Factors in Nasal Irritant Sensitivity|Individual Factors in Nasal Irritant Sensitivity||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 2000|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind||||64|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||March 2006|March 22, 2006|July 18, 2002||||No||https://clinicaltrials.gov/show/NCT00041821||203478|
NCT00041028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011318|EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients With Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|May 2002|April 2014|Actual|September 2007|Actual|Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|60|||Both|18 Years|N/A|No|||September 2006|April 30, 2015|July 8, 2002||Yes||||https://clinicaltrials.gov/show/NCT00041028||203534|
NCT00041041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02473|Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of Gleevec (Imatinib Mesylate) (IND #61135, NSC #716051) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|June 2002|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||January 2013|February 19, 2013|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041041||203533|
NCT00041327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-033|Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma|Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma||AIDS Malignancy Consortium||Completed|October 2002|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|120 Years|No|||February 2016|February 1, 2016|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041327||203514|
NCT00040846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1591.00|Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies|Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|November 2001|||December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|74 Years|No|||January 2016|January 5, 2016|July 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00040846||203544|
NCT00041834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10100-CP-001|Geographic Modeling of Traffic and Asthma Rates|||National Institute of Environmental Health Sciences (NIEHS)||Completed|September 2000|August 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||||||||July 2002|June 23, 2005|July 18, 2002||||No||https://clinicaltrials.gov/show/NCT00041834||203477|
NCT00045136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256377|Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma||National Cancer Institute (NCI)||Completed|January 2002|||January 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||April 2009|April 2, 2009|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045136||203243|
NCT00045149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1588.00|Biological Therapy in Treating Patients With Metastatic Melanoma|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen Specific T Cell Clones Targeting Cancer Testis Antigens for Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center||Completed|October 2002|June 2005|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2010|May 5, 2010|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045149||203242|
NCT00041665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000162|Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy|A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Recombinant Human Keratinocyte Growth Factor for Reduction of Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy With Autologous PBPC Transplantation||Amgen||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||May 2013|May 6, 2013|July 11, 2002||||||https://clinicaltrials.gov/show/NCT00041665||203490|
NCT00040729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069394|Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C|Retrospective Analysis Of Promoter Polymorphism Of UGT1A1 Gene In Cancer Patients Enrolled On Clinical Trials With Flavopiridol At National Cancer Institute To Assess The Pharmacokinetics And Pharmacodynamics Of Flavopiridol||National Cancer Institute (NCI)||Completed|March 2002|||||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||May 2003|April 24, 2015|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040729||203553|
NCT00040742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069401|Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer|A Phase II/III Randomized, Controlled Clinical Trial Of Ginger (Zingiber Officinale) For Nausea Caused By Chemotherapy For Cancer||University of Rochester|Yes|Completed|March 2003|December 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|745|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|July 8, 2002||No||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00040742||203552|Two main weaknesses of the study, which should be controlled for in future studies, were not controlling for chemotherapy regimens (i.e., high versus low emetogenic regimens) or the severity level of nausea before enrollment.
NCT00040781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01874|Gefitinib in Treating Children With Refractory Solid Tumors|A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|June 2002|||October 2004|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|N/A|21 Years|No|||January 2013|January 22, 2013|July 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00040781||203549|
NCT00040794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02821|Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer|ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study||National Cancer Institute (NCI)||Completed|May 2002|||March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|July 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00040794||203548|
NCT00041717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-F301|Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury|Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury||Acorda Therapeutics|Yes|Completed|July 2002|May 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|70 Years|No|||April 2013|April 25, 2013|July 12, 2002|No|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT00041717||203486|
NCT00040664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV 20003|A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years|See Detailed Description||GlaxoSmithKline||Completed|July 2002|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|69|||Both|2 Years|18 Years|No|||January 2011|January 24, 2011|July 5, 2002||||No|August 6, 2009|https://clinicaltrials.gov/show/NCT00040664||203556|
NCT00040833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-008|Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer|Acupuncture for the Treatment of Pancreatic Cancer Pain: A Single Arm Phase II Study||Memorial Sloan Kettering Cancer Center||Completed|February 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040833||203545|
NCT00040937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0204|S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase II Trial Of Thalidomide/Dexamethasone Induction Followed By Tandem Melphalan Transplant And Prednisone/Thalidomide Maintenance (A BMT Study)||Southwest Oncology Group|Yes|Active, not recruiting|June 2002|October 2015|Anticipated|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|July 8, 2002|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT00040937||203538|
NCT00045318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIICHI-8951A-PRT026|Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction|A Phase I Study of DX-8951f (Exatecan Mesylate for Injection) in Patients With Renal Dysfunction||National Cancer Institute (NCI)||Completed|May 2002|October 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|July 9, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045318||203232|
NCT00041795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082-2001-005|Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer||NeoTherapeutics||Completed|January 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|80 Years|No|||July 2002|June 23, 2005|July 16, 2002||||||https://clinicaltrials.gov/show/NCT00041795||203480|
NCT00045045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256314|Positron Emission Tomography in Detecting Testicle Cancer|A Study Of 18 FDG PET In The Prediction Of Relapse In Patients With A Clinical Stage I Non-Seminomatous Germ Cell Tumor||National Cancer Institute (NCI)||Completed|May 2002|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Diagnostic|||||||Male|N/A|N/A|No|||September 2002|December 17, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045045||203247|
NCT00041431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1181|Estrogen, Cytokines and Heart Failure in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 2001|December 2003|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind|||||||Female|N/A|100 Years|No|||May 2005|February 23, 2016|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041431||203507|
NCT00041444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-409|Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study|Multi-Ethnic Study of Atherosclerosis-Eye Study|MESA-Eye|University of Wisconsin, Madison||Completed|June 2002|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6176|||Both|45 Years|84 Years|No|||February 2016|February 5, 2016|July 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00041444||203506|
NCT00040599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hMN14-02|Safety Study of 90Y-hMN14 to Treat Colorectal Cancer|A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Metastatic/Recurrent Colorectal Carcinomas||Immunomedics, Inc.||Completed|January 2000|January 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|July 1, 2002||||||https://clinicaltrials.gov/show/NCT00040599||203560|
NCT00045279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-143|PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of PEG-Intron in Patients With Advanced Renal Cell Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|April 2002|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045279||203235|
NCT00045292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1603.00|Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation|A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants||Fred Hutchinson Cancer Research Center||Completed|April 2002|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|12 Years|N/A|No|||September 2010|September 17, 2010|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045292||203234|
NCT00041808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC-DOX-003|Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver|A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver .||FeRx||Completed|July 2001|April 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||February 2003|June 23, 2005|July 17, 2002||||||https://clinicaltrials.gov/show/NCT00041808||203479|
NCT00040989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-0201019|BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer|Phase II Study of BAY 56-3722 in Patients With Recurrent, Unresectable, or Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|July 9, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040989||203536|
NCT00041678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-005|Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type|||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|January 2000|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|55 Years|95 Years|No|||September 2007|November 7, 2013|July 12, 2002||||||https://clinicaltrials.gov/show/NCT00041678||203489|
NCT00041691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hMN14-06|Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery|A Phase I, Single Dose Escalating Study to Investigate the Tolerability, Pharmacokinetics and Dosimetry of 90 Y-Humanized MN-14 IgG in Colorectal Cancer Patients With Limited Residual Disease After Primary or Salvage Surgery||Immunomedics, Inc.||Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2003|June 23, 2005|July 12, 2002||||||https://clinicaltrials.gov/show/NCT00041691||203488|
NCT00041704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER002-11|The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)|A Phase 2 Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis.||Pfizer||Completed|August 2002|August 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|12 Years|N/A|No|||October 2008|October 17, 2008|July 12, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00041704||203487|
NCT00040625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6093|ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.|||Eli Lilly and Company||Approved for marketing||||||Phase 2|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2007|March 14, 2007|July 2, 2002||||||https://clinicaltrials.gov/show/NCT00040625||203559|
NCT00040638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2014|Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer|||Telik||Completed|July 2002|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2011|July 21, 2011|July 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00040638||203558|
NCT00041574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT-31|Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide|Development of a Hospital-Based Home Program for the Use of Inhaled Nitric Oxide in the Chronic Management of Severe Cardiopulmonary Diseases||INO Therapeutics|Yes|Terminated|April 2002|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|5 Years|N/A|No|||January 2009|January 9, 2009|July 10, 2002|Yes|Yes|Closed for lack of enrollment|No||https://clinicaltrials.gov/show/NCT00041574||203497|
NCT00044668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-117|Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination|An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination||AstraZeneca|No|Completed|August 2002|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|20 Years|75 Years|No|||January 2015|February 19, 2015|September 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044668||203274|
NCT00044681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002143|A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression|A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2002|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|258|||Both|18 Years|85 Years|No|||November 2010|May 17, 2011|September 3, 2002||||||https://clinicaltrials.gov/show/NCT00044681||203273|
NCT00041379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069494|Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia|Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia||National Cancer Institute (NCI)||Active, not recruiting|March 2002|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|December 17, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041379||203511|
NCT00041392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007128|Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery|PeriOperative Interventional Neuroprotection Trial (POINT)|POINT|Duke University||Completed|December 2001|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|389|||Both|55 Years|N/A|No|||April 2012|July 25, 2013|July 8, 2002|Yes|Yes||No|August 5, 2012|https://clinicaltrials.gov/show/NCT00041392||203510|
NCT00041405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1179|Mechanisms of Pro-Thrombosis in Diabetes Mellitus -- Ancillary to BARI 2D|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2001|June 2005|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||July 2005|February 24, 2016|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041405||203509|
NCT00041418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180|Cardiac MR of Subclinical CVD: Impact of Age|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 18, 2008|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041418||203508|
NCT00045162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256908|S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer|Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)||Southwest Oncology Group|Yes|Completed|November 2002|December 2009|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|671|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|September 6, 2002|Yes|Yes||No|April 16, 2013|https://clinicaltrials.gov/show/NCT00045162||203241|
NCT00041899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020219|Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914|Pharmacokinetic Comparison of Two Preparations of the Selective Progesterone Receptor Modular CDB2914||National Institutes of Health Clinical Center (CC)||Completed|May 2002|March 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||15|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2005|March 3, 2008|July 18, 2002||||No||https://clinicaltrials.gov/show/NCT00041899||203473|
NCT00040885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N01C9|Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)|Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients||Alliance for Clinical Trials in Oncology|Yes|Completed|October 2002|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|67|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00040885||203541|
NCT00040898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-002|Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed|Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control||Memorial Sloan Kettering Cancer Center||Completed|January 2001|||January 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 17, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040898||203540|
NCT00041314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069467|Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Trial Of Carboplatin And Gemcitabine With Exisulind In Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|August 2002|||July 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2002|June 6, 2009|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041314||203515|
NCT00040950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069423|Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|March 2002|October 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2003|December 18, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040950||203537|
NCT00041262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-OE05|Combination Chemotherapy in Treating Patients With Esophageal Cancer|A Prospective Randomized Trial Comparing Standard Chemotherapy Followed By Resection Versus Infusional Chemotherapy In Patients With Resectable Adenocarcinoma Of The Oesophagus||National Cancer Institute (NCI)||Recruiting|November 2004|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1300|||Both|N/A|N/A|No|||March 2007|August 9, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041262||203519|
NCT00045097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256355|Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase II Clinical Trial Of BMS-247550 (NSC 710428), An Epothilone B Analog, In Patients With Breast Carcinoma||National Cancer Institute (NCI)||Completed|May 2002|July 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2007|June 18, 2013|September 6, 2002||||||https://clinicaltrials.gov/show/NCT00045097||203246|
NCT00041288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069462|Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase II Multicenter Randomized Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL||National Cancer Institute (NCI)||Active, not recruiting|October 2001|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2003|February 6, 2009|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00041288||203517|
NCT00041652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hMN14-04|Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer|A Phase I/II Clinical Trial of Immunotherapy With Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas||Immunomedics, Inc.||Completed|February 2000|June 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2005|October 21, 2005|July 11, 2002||||||https://clinicaltrials.gov/show/NCT00041652||203491|
NCT00041847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11126-CP-001|Gene-Environment Interaction in Prostate Cancer|Gene-Environment Interaction in Prostate Cancer||National Institute of Environmental Health Sciences (NIEHS)||Completed|July 2001|July 2005|Actual|July 2005|Actual|N/A|Observational|Time Perspective: Retrospective|||Actual|881|||Male|N/A|69 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|July 18, 2002||No||No||https://clinicaltrials.gov/show/NCT00041847||203476|
NCT00045305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256928|Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes|A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes||Eastern Cooperative Oncology Group|No|Completed|May 2005|September 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||January 2015|January 15, 2015|September 6, 2002|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00045305||203233|
NCT00041353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-02010|Comparison of Biomarkers Based on Fine-Needle Aspiration in Women at Increased or Normal Risk of Breast Cancer|Breast Cancer Biomarkers Based on Fine Needle Aspirates||Fox Chase Cancer Center|No|Withdrawn||September 2002|Actual|September 2002|Actual|N/A|Interventional|Primary Purpose: Screening|||Actual|0|||Female|30 Years|N/A|No|||July 2013|July 10, 2013|July 8, 2002|Yes|Yes|Study was not activated at Fox Chase Cancer Center|No||https://clinicaltrials.gov/show/NCT00041353||203512|
NCT00041301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-15011-30011|Assessing Quality of Life of Patients With Prostate Cancer|An International Field Study Of The Reliability And Validity Of The EORTC QLQ-C30 And A Disease-Specific Questionnaire Module (QLQ-PR25) For Assessing Quality Of Life Of Patients With Prostate Cancer||European Organisation for Research and Treatment of Cancer - EORTC|No|Completed|March 2002|November 2005|Actual|December 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|625|||Male|18 Years|N/A|No|Non-Probability Sample|Prostate cancer|August 2012|August 24, 2012|July 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00041301||203516|
NCT00041613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T301|Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate|||Introgen Therapeutics||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2008|March 28, 2008|July 11, 2002||||||https://clinicaltrials.gov/show/NCT00041613||203494|
NCT00040807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069408|Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer|Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma||National Cancer Institute (NCI)||Completed|October 2002|||April 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2004|July 29, 2009|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040807||203547|
NCT00040820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069410|Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer|A Treatment Access Program With Oxaliplatin for Previously Treated Colorectal Cancer Patients||Roswell Park Cancer Institute|Yes|Completed|January 2002|March 2004|Actual|August 2003|Actual|N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2011|March 3, 2011|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00040820||203546|
NCT00041756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001065|Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis|Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis||Procter and Gamble|No|Completed|July 2002|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|395|||Both|40 Years|80 Years|No|||November 2011|November 7, 2011|July 16, 2002|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00041756||203483|
NCT00041769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5146|Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor|A Phase II Randomized Controlled Trial Evaluating the Impact of Therapeutic Drug Monitoring (TDM) on Virologic Response to a Salvage Regimen in Subjects With a Normalized Inhibitory Quotient (NIQ) Less Than or Equal to 1 to One or More Protease Inhibitors||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2002|August 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|18 Years|N/A|No|||December 2008|July 12, 2010|July 16, 2002||||No||https://clinicaltrials.gov/show/NCT00041769||203482|
NCT00040872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-065|Multiple Therapies in Treating Patients With Advanced Neuroblastoma|N8: Dose-Intensive Chemotherapy Plus Biologics in the Treatment of Neuroblastoma||Memorial Sloan Kettering Cancer Center||Completed|June 2000|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|50 Years|No|||March 2013|March 6, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040872||203542|
NCT00041626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T302|Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone|||Introgen Therapeutics||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2007|September 10, 2007|July 11, 2002||||||https://clinicaltrials.gov/show/NCT00041626||203493|
NCT00041639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hMN14-03|Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer|A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma||Immunomedics, Inc.||Completed|January 2000|December 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||January 2004|June 23, 2005|July 11, 2002||||||https://clinicaltrials.gov/show/NCT00041639||203492|
NCT00045175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256917|UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|A Phase I Study of UCN-01 in Combination With Topotecan in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|June 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2004|April 23, 2011|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045175||203240|
NCT00041470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-5891|Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial|Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial||University of Washington|No|Completed|March 2001|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|July 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041470||203504|
NCT00041483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-99|Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD|Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD||Alcon Research||Completed|June 2002|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|530|||Both|50 Years|N/A|No|||July 2008|June 30, 2014|July 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00041483||203503|
NCT00044811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455P/3001|Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma|A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma||Sanofi||Completed|March 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1000|||Both|12 Years|80 Years|No|||August 2008|August 20, 2008|September 5, 2002||||||https://clinicaltrials.gov/show/NCT00044811||203263|
NCT00045110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02490|Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma|A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy||National Cancer Institute (NCI)||Active, not recruiting|August 2002|||December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|September 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045110||203245|
NCT00045123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256371|R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence|Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence With Rising PSA Levels After Prostatectomy, Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease||National Cancer Institute (NCI)||Active, not recruiting|February 2002|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||February 2004|December 17, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045123||203244|
NCT00041561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT-11|Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics|The Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) In Pediatrics||INO Therapeutics|Yes|Terminated|January 2002|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|N/A|16 Years|No|||June 2010|June 14, 2010|July 10, 2002|Yes|Yes|Study stopped due to poor enrollment|No||https://clinicaltrials.gov/show/NCT00041561||203498|
NCT00046878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3318|Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme|Phase 2 Trial of BCNU Plus O6-Benzylguanine (NSC 637037) in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme||Duke University||Withdrawn||August 2002|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00046878||203126|
NCT00041340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02479|Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer|Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known As(STI571) (NSC #716051) In Patients With Colorectal Cancer Stage IV||National Cancer Institute (NCI)||Completed|May 2002|||July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|N/A|No|||January 2013|January 22, 2013|July 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00041340||203513|
NCT00045435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1654.00|Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission|Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|April 2002|||June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|55 Years|N/A|No|||January 2016|January 19, 2016|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045435||203226|
NCT00045630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256921|S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium|A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates||Southwest Oncology Group|No|Completed|January 2003|December 2011|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|September 6, 2002|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00045630||203213|
NCT00045864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL2NHL05|Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.|||Chiron Corporation||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|February 2, 2006|September 12, 2002||||||https://clinicaltrials.gov/show/NCT00045864||203199|
NCT00044889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO221|Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia|A Phase II, Open-Label Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia||Sanofi||Completed|May 2002|March 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|September 6, 2002||||||https://clinicaltrials.gov/show/NCT00044889||203258|
NCT00040677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-17043-05|A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.|A Phase II, Multicenter, Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Efficacy and Safety of ICA-17043 With or Without Hydroxyurea Therapy in Patients With Sickle Cell Anemia||Icagen|Yes|Completed|February 2002|January 2004|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|60 Years|No|||July 2011|July 13, 2011|July 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00040677||203555|
NCT00040690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069374|Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia|A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|November 2008|December 2008|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|16 Years|N/A|No|||May 2007|December 18, 2013|July 8, 2002||||No||https://clinicaltrials.gov/show/NCT00040690||203554|
NCT00044837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5119|Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women|A Phase I, Pharmacokinetic Study of Hormone Replacement Therapy in HIV-1-Infected, Postmenopausal Women on Nelfinavir, Lopinavir/Ritonavir, or Efavirenz||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment||||120|||Female|18 Years|N/A|No|||June 2003|June 3, 2015|September 5, 2002||||No||https://clinicaltrials.gov/show/NCT00044837||203261|
NCT00044863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP02-0144|Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma|A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma||ImClone LLC|No|Completed|August 2002|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|18 Years|N/A|No|||February 2011|February 21, 2011|September 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044863||203260|
NCT00044876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020287|Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist|Treatment of Leiomyomata With the Selective Progesterone Receptor Modulator CDB-2914||National Institutes of Health Clinical Center (CC)||Completed|September 2002|October 2015|Actual|June 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|56|||Female|33 Years|50 Years|No|||October 2015|January 22, 2016|September 5, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044876||203259|
NCT00044902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010138|Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)|||Amgen||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|December 20, 2007|September 6, 2002||||||https://clinicaltrials.gov/show/NCT00044902||203257|
NCT00044915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100282|Repinotan in Patients With Acute Ischemic Stroke|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke||Bayer||Completed|December 2000|September 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|782|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044915||203256|
NCT00044044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050049|A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia|A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol in Patients With Schizophrenia Who Are Experiencing an Acute Exacerbation of Symptoms||Sunovion|No|Completed|July 2002|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|356|||Both|18 Years|64 Years|No|||March 2014|March 31, 2014|August 16, 2002|No|Yes||No|February 1, 2011|https://clinicaltrials.gov/show/NCT00044044||203319|
NCT00043654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020251|Clinical Trial of Mifepristone for Bipolar Depression|Antiglucocorticoid Therapy in Bipolar Depression With Mifepristone (RU486)||National Institutes of Health Clinical Center (CC)||Completed|August 2002|June 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||110|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2007|June 26, 2007|August 9, 2002||||No||https://clinicaltrials.gov/show/NCT00043654||203349|
NCT00043836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0214|The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure|A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study||Synvista Therapeutics, Inc||Completed|July 2002|October 2005|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|60 Years|N/A|No|||August 2007|September 1, 2009|August 14, 2002||||||https://clinicaltrials.gov/show/NCT00043836||203335|
NCT00043849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0034|Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)|Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)||National Institute on Aging (NIA)||Completed|July 2002|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|50 Years|N/A|No|||August 2006|December 10, 2009|August 14, 2002||||No||https://clinicaltrials.gov/show/NCT00043849||203334|
NCT00043927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864-A/389|Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults|An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer.||GlaxoSmithKline||Completed|April 2001|||January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||760|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|August 14, 2002||||||https://clinicaltrials.gov/show/NCT00043927||203328|
NCT00045422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-013|Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Open Label Study to Determine Safety and Efficacy of Interferon-alpha in Combination With Imantinib Mesylate (Gleevec) in Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Not Achieved a Complete Cytogenetic Response to Gleevec as a Single Agent||Memorial Sloan Kettering Cancer Center||Completed|April 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 4, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045422||203227|
NCT00045721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257268|Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma|Phase I Trial of GLIADEL and O(6)-Benzylguanine in Pediatric Patients With Recurrent Malignant Gliomas||Pediatric Brain Tumor Consortium|Yes|Terminated|March 2003|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|3|||Both|3 Years|21 Years|No|||October 2009|October 15, 2009|September 6, 2002|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00045721||203208|
NCT00045357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585.00|Biological Therapy in Treating Patients With Metastatic Melanoma|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD4+ Antigen-Specific T Cell Clones for Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center||Completed|November 2001|August 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|75 Years|No|||September 2010|September 20, 2010|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045357||203230|
NCT00045760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7252, 6669|The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis|||Eli Lilly and Company||Completed|September 2002|||||Phase 4|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|September 9, 2002||||||https://clinicaltrials.gov/show/NCT00045760||203205|
NCT00045604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256923|Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I Study of Imatinib (Gleevec) in Combination With Irinotecan and Cisplatin in Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|July 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|July 23, 2008|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045604||203215|
NCT00045617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256922|S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer|A Phase II Trial of Patients With Limited Stage Small Cell Lung Cancer Treated With Thoracic Radiation Therapy and Chemotherapy With Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines||Southwest Oncology Group|Yes|Terminated|January 2003|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2012|June 11, 2012|September 6, 2002|Yes|Yes|Closed due to lack of drug availability.|No||https://clinicaltrials.gov/show/NCT00045617||203214|
NCT00045903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #4734R|Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder|CBT Augmentation for SRI Pharmacotherapy in OCD|Aug1|New York State Psychiatric Institute|Yes|Completed|August 2000|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|70 Years|No|||October 2012|April 22, 2014|September 13, 2002||No||No||https://clinicaltrials.gov/show/NCT00045903||203197|
NCT00044590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10544-CP-001|Parkinson's Diseases Susceptibility Genes and Pesticides|Parkinson's Diseases Susceptibility Genes and Pesticides||National Institute of Environmental Health Sciences (NIEHS)||Recruiting|September 2000|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|N/A|||Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|October 5, 2015|September 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00044590||203280|
NCT00044603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10165-CP-001|Vulnerability of the Fetus/Infant to PAH, PM2.5 AND ETS.|Vulnerability of the Fetus/Infant to PAH, PM2.5 AND ETS||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|February 2000|January 2006|Actual|January 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|505|Samples With DNA|Biologic samples were collected from the mothers and their children as follows: maternal      blood (30-35 ml) within 1 day postpartum and umbilical cord blood (30 - 60 ml) collected by      delivery room staff immediately after the cord was cut. Members of the research staff      transported the samples to the laboratory immediately. The buffy coat, packed red blood      cells, and plasma samples were separated and stored at -70°C and then shipped to Columbia      University. Placental tissue and meconium were also collected. The placental tissue and      meconium were sent to Columbia and stored for future analysis under separate funding.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Only Polish and Caucasian women and their children are included in the study. There are no        race/ethnic minorities included because the Krakow population is ethnically and racially        homogeneous (almost 100% Caucasian).|October 2014|October 14, 2014|September 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00044603||203279|
NCT00044967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0190|Genetic Study of Young Patients With Colorectal Cancer|A Prospective Study Of The Prognostic Significance Of Microsatellite Instability In Patients With Early Age-Of-Onset Colorectal Cancer||Alliance for Clinical Trials in Oncology|No|Completed|May 2002|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|651|||Both|18 Years|49 Years|No|Non-Probability Sample|Patients diagnosed with adenocarcinoma of the colon or rectum.|July 2015|July 14, 2015|September 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00044967||203253|
NCT00044980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008521|Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer|Fresh Start: Promoting Health in Prostate Cancer Survivors||Duke University|Yes|Completed|July 2002|December 2006|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized|||||||Male|18 Years|N/A|No|||November 2012|July 11, 2014|September 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00044980||203252|
NCT00044993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTROGEN-201-010|Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer|Phase II, Single Arm, Single Institution Clinical Trial of Docetaxel and Doxorubicin in Combination With Local Administration of INGN 201 (Ad5CMV-p53) in Locally Advanced Breast Cancer (LABC)||National Cancer Institute (NCI)||Completed|February 2002|August 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|May 29, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00044993||203251|
NCT00045006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-01021|Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer|Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies||National Cancer Institute (NCI)||Completed|July 2001|July 2008|Actual|December 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2003|May 29, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045006||203250|
NCT00045019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-15012|Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care|An International Field-Testing Study Of The Reliability And Validity Of A Patient Satisfaction Module (QLQ-SAT32) Assessing Cancer Patients' Perception Of The Quality Of Care Received Within The Hospital||European Organisation for Research and Treatment of Cancer - EORTC|No|Completed|May 2002|March 2005|Actual|June 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|795|||Both|18 Years|N/A|No|Non-Probability Sample|cancer patients discharged from a surgery or medical ward of oncology institute.|August 2012|August 24, 2012|September 6, 2002||No||No||https://clinicaltrials.gov/show/NCT00045019||203249|
NCT00044928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-101074|Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection|Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2002|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Actual|262|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044928||203255|
NCT00044954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069461|Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study||National Cancer Institute (NCI)||Active, not recruiting|November 2001|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||February 2005|February 6, 2009|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00044954||203254|
NCT00043745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR046922|Bone Response to Soy Isoflavones in Women|Bone Response to Soy Isoflavones in Women|SIRBL|Iowa State University|Yes|Completed|March 2003|||April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|224|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 6, 2013|August 13, 2002||No||No||https://clinicaltrials.gov/show/NCT00043745||203342|
NCT00043758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-01-232|Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients|||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2002|July 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||170|||Both|18 Years|N/A|No|||June 2005|June 23, 2005|August 13, 2002||||||https://clinicaltrials.gov/show/NCT00043758||203341|
NCT00043771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-01-231|Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients|Multi-Center, Double-Blind Study to Compare the Effects of 30mg Qd Versus 15 Mg Bid of Tolvaptan in Congestive Heart Failure Patients||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|May 2002|September 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2002|June 23, 2005|August 13, 2002||||||https://clinicaltrials.gov/show/NCT00043771||203340|
NCT00043862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/535|The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)|A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer|(SCLC)|GlaxoSmithKline|No|Completed|August 2002|||November 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|August 14, 2002||||||https://clinicaltrials.gov/show/NCT00043862||203333|
NCT00043940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-98-10|Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)|Anticoagulant Therapy With Bivalirudin in the Performance of PCI in Patients With Heparin-Induced Thrombocytopenia||The Medicines Company||Completed|April 1999|||February 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||September 2011|September 15, 2011|August 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00043940||203327|
NCT00043953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-384|Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects|A Phase II Study of Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects||Abbott|No|Completed|August 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2007|September 26, 2007|August 15, 2002||||No||https://clinicaltrials.gov/show/NCT00043953||203326|
NCT00044057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|872-CL-004|A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)|A Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients With Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo||Astellas Pharma Inc||Completed|December 2000|January 2003||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2006|March 31, 2006|August 16, 2002||||||https://clinicaltrials.gov/show/NCT00044057||203318|
NCT00045331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256868|Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer|Are the Proteomic Profiles of Serum and Urine Predictivefor Clinical Outcome After Definitive Radiotherapy for Localized Prostate Cancer? A Preliminary Cohort Study||National Cancer Institute (NCI)||Completed|August 2002|October 2007|Actual|||N/A|Interventional|Primary Purpose: Diagnostic|||||||Male|18 Years|N/A|No|||October 2004|June 18, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045331||203231|
NCT00045526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01418|Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer|Phase II Study Of OSI-774 In Advanced Esophageal Cancer||National Cancer Institute (NCI)||Completed|June 2002|||February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|September 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045526||203219|
NCT00045747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257125|UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer|Phase II Study of UCN-01 in Combination With Fluorouracil in Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|July 2002|September 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|June 21, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045747||203206|
NCT00045396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03158|A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)|A Phase II Study of the Farnesyltransferase Inhibitor ZARNESTRA (Tipifarnib, R115777, NSC #702818, IND #58,359) in Complete Remission Following Induction and/or Consolidation Chemotherapy in Adults With Poor-Risk Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplasia (MDS).||National Cancer Institute (NCI)||Completed|June 2002|||October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045396||203228|
NCT00044694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-116|Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|August 2002|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|156|||Both|18 Years|65 Years|No|||January 2015|February 19, 2015|September 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044694||203272|
NCT00045591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-40105|Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer|Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design||Alliance for Clinical Trials in Oncology|Yes|Terminated|February 2003|||January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Female|18 Years|N/A|No|||August 2015|August 28, 2015|September 6, 2002|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00045591||203216|
NCT00045786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-1088-MDS-801-001|Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes|||Celgene||Completed|October 2001|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||39|||Both|18 Years|80 Years|No|||May 2004|June 23, 2005|September 9, 2002||||||https://clinicaltrials.gov/show/NCT00045786||203203|
NCT00045799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSB-IR C03|Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill|Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill||Valeant Pharmaceuticals International, Inc.|No|Completed|May 2002|May 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|354|||Both|16 Years|N/A|No|||April 2014|April 24, 2014|September 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045799||203202|
NCT00045812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010115|SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia||National Institutes of Health Clinical Center (CC)||Completed|March 2001|April 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||April 2004|March 3, 2008|September 10, 2002||||No||https://clinicaltrials.gov/show/NCT00045812||203201|
NCT00045474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256587|Brachytherapy in Treating Patients With Recurrent Malignant Glioma|Phase I Brachytherapy Dose Escalating Study Using the Proxima Therapeutics, Inc. GliaSite RTS in Patients With Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|October 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|February 6, 2009|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045474||203223|
NCT00044707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-154|Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide|||AstraZeneca||Completed|August 2002|September 2002|Actual|September 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||May 2015|May 20, 2015|September 3, 2002||||No||https://clinicaltrials.gov/show/NCT00044707||203271|
NCT00044720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-101164|Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients|An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Masking: Open Label|||Actual|484|||Both|13 Years|N/A|No|||August 2009|August 17, 2009|September 4, 2002||||||https://clinicaltrials.gov/show/NCT00044720||203270|
NCT00044616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060353-01|Relapse Prevention for Bipolar Type-II Disorder|Relapse Prevention of Bipolar Type-II Disorder||University of Pennsylvania||Completed|February 2001|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|100 Years|No|||December 2013|October 2, 2015|September 3, 2002||||No||https://clinicaltrials.gov/show/NCT00044616||203278|
NCT00044629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011850|Combined Behavioral/Pharmacological Therapy for Insomnia|Combined Behavioral/Pharmacological Therapy for Insomnia||Duke University||Completed|September 2001|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|162|||Both|21 Years|75 Years|No|||September 2013|September 12, 2013|September 3, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00044629||203277|
NCT00043784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENO_GMA_301|SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes|A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)||Sanofi||Completed|August 2001|||February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||8000|||Both|18 Years|N/A|No|||September 2008|September 15, 2008|August 13, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00043784||203339|
NCT00044642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059142|Lorazepam-Induced Toxicity in the Aged|Long-Term Lorazepam Use and Acute Toxicity in the Aged||Nathan Kline Institute for Psychiatric Research||Completed|December 2000|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|90|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 5, 2013|September 3, 2002||||No||https://clinicaltrials.gov/show/NCT00044642||203276|
NCT00044655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 98-924|Switching Medication to Treat Schizophrenia|Effectiveness of Switching Antipsychotic Medications||Icahn School of Medicine at Mount Sinai|Yes|Completed|July 2001|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|September 3, 2002|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00044655||203275|
NCT00043355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIMAC-001|Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterials in Previously Treated or Mod-to-Sev Pulmonary Mycobacterium Avium Complex Infection||InterMune||Terminated|December 2000|February 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|August 7, 2002|||Futility|No||https://clinicaltrials.gov/show/NCT00043355||203370|
NCT00043368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C016|PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)|A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy||Pfizer|No|Completed|September 2002|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||March 2009|March 11, 2009|August 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00043368||203369|
NCT00043797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|676/US/2-01|Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy|||The Institute for Diabetes Discovery, LLC||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||December 2002|June 23, 2005|August 13, 2002||||||https://clinicaltrials.gov/show/NCT00043797||203338|
NCT00043875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM20006|Pediatric Epilepsy Trial in Subjects 1-24 Months|A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 Months)||GlaxoSmithKline|No|Completed|May 2000|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|177|||Both|1 Month|24 Months|No|||August 2015|August 19, 2015|August 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00043875||203332|
NCT00043888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZL30006|Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR|A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg Twice Daily or 700mg/100mg Twice Daily) When Used in Combination With a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR Twice Daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.||GlaxoSmithKline||Completed|January 2002|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|13 Years|N/A|No|||February 2013|February 11, 2013|August 14, 2002||||||https://clinicaltrials.gov/show/NCT00043888||203331|
NCT00043966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-418|Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects|A Randomized, Open-Label Study of 800 Mg Lopinavir/200 Mg Ritonavir QD in Combination With Tenofovir and Emtricitabine Vs. 400 Mg Lopinavir /100 Mg Ritonavir BID in Combination With Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects||Abbott||Completed|July 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||July 2006|July 26, 2006|August 15, 2002||||||https://clinicaltrials.gov/show/NCT00043966||203325|
NCT00043979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020259|Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas|Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas||National Institutes of Health Clinical Center (CC)|No|Completed|August 2002|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|35 Years|No|||September 2013|September 12, 2013|August 15, 2002|Yes|Yes||No|April 3, 2013|https://clinicaltrials.gov/show/NCT00043979||203324|
NCT00043992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9744-CP-001|Outdoor Allergen Exposure, Sensitivity, and Acute Asthma|||National Institute of Environmental Health Sciences (NIEHS)||Completed|July 2001|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1000|||Both|15 Years|50 Years|No|||September 2006|September 1, 2006|August 16, 2002||||No||https://clinicaltrials.gov/show/NCT00043992||203323|
NCT00044200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000057|Positron Emission Tomography (PET) to Study Brain Signaling|Positron Emission Tomography Imaging of Activation-Induced Signal Transduction in Human Brain||National Institutes of Health Clinical Center (CC)||Completed|January 2000|June 2015||||N/A|Observational|N/A|||Actual|20|||Both|18 Years|45 Years|No|||June 2015|June 13, 2015|August 21, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044200||203308|
NCT00044408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6204|Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes|LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes||Eli Lilly and Company||Completed|July 2002|October 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|August 28, 2002||||||https://clinicaltrials.gov/show/NCT00044408||203293|
NCT00045513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-006|Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma|Phase I/II Study Of UCN-01 In Combination With Fludarabine In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma||University Health Network, Toronto||Completed|June 2002|||December 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2015|July 22, 2015|September 6, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00045513||203220|
NCT00045370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-023|Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer|A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Intravenous CCI-779 Given in Combination With Escalating Doses of Interferon-Alpha to Patients With Advanced Renal Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 2002|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045370||203229|
NCT00045565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03162|Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma|Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma||National Cancer Institute (NCI)||Completed|October 2002|||November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045565||203217|
NCT00045877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL2NHL03|Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments|||Chiron Corporation||Completed||||||Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|February 2, 2006|September 12, 2002||||||https://clinicaltrials.gov/show/NCT00045877||203198|
NCT00045448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVENTIS-HMR1275A/1501|Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Single Center Open-Label Non-Comparative Phase I Dose Finding Study Of Weekly Flavopiridol In Combination With Weekly Docetaxel In Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|April 2002|December 2009|Actual|January 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|May 29, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045448||203225|
NCT00045461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-DOLPHIN-1|Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY||National Cancer Institute (NCI)||Recruiting|June 2000|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|241|||Female|18 Years|65 Years|No|||October 2002|August 6, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045461||203224|
NCT00045669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257029|Imatinib Mesylate in Treating Patients With Salivary Gland Cancer|A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas||University Health Network, Toronto||Completed|July 2002|January 2005|Actual|January 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2012|June 11, 2012|September 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045669||203212|
NCT00045838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020279|HIV-1 Vaccine Test in Uninfected Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA006-00-VP, In Uninfected Adult Volunteers||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2002|April 2003|Actual|April 2003|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 10, 2002|||The study product was revised. PI withdrew the study without enrolling participants..|No||https://clinicaltrials.gov/show/NCT00045838||203200|
NCT00044824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455P/3002|Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma|A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma||Sanofi||Completed|February 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1000|||Both|12 Years|80 Years|No|||August 2008|August 20, 2008|September 5, 2002||||||https://clinicaltrials.gov/show/NCT00044824||203262|
NCT00044733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903X-100374|Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant|A Dose-Finding Study of the Safety of Gemtuzumab Ozogamicin as Single Agent Treatment of Patients With Relapsed Acute Myelogenous Leukemia After Autologous or Allogenic Hematopoietic Stem Cell Transplant (HSCT)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2000|September 2004||||Phase 2|Interventional|Masking: Open Label||||38|||Both|N/A|N/A|No|||May 2006|May 17, 2006|September 4, 2002||||||https://clinicaltrials.gov/show/NCT00044733||203269|
NCT00044746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-100468|Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections|An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2000|January 2003|Actual|January 2003|Actual|Phase 4|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|314|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|September 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044746||203268|
NCT00044759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910B1-308|Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma|A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||January 2003|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2007|October 8, 2007|September 4, 2002||||||https://clinicaltrials.gov/show/NCT00044759||203267|
NCT00044772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B5-399|Study Evaluating Venlafaxine ER in Patients With Panic Disorder|A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2001|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|653|||Both|18 Years|N/A|No|||August 2009|August 13, 2009|September 4, 2002||||||https://clinicaltrials.gov/show/NCT00044772||203266|
NCT00044785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401.02.001|Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors|A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.||Wellstat Therapeutics||Terminated|August 2002|March 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||May 2005|June 23, 2005|September 4, 2002||||||https://clinicaltrials.gov/show/NCT00044785||203265|
NCT00043901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM40097|Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures||GlaxoSmithKline||Completed|December 2000|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|141|||Both|2 Years|N/A|No|||August 2013|August 20, 2013|August 14, 2002||||No||https://clinicaltrials.gov/show/NCT00043901||203330|
NCT00040573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM601-001|Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.|A Phase I/II Open Label, Single Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients With Recurrent High-Grade Glioma.||TransMolecular||Completed|June 2002|August 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|June 29, 2002||||||https://clinicaltrials.gov/show/NCT00040573||203562|
NCT00040768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02470|Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer|A Phase II Study Of PS-341 In Metastatic Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Terminated|April 2002|||March 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|July 8, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00040768||203550|
NCT00043550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061410|Treatments for Depression: Drug Versus Psychotherapy|Efficacy of Dynamic Therapy Versus Selective Serotonin Reuptake Inhibitor for Depression||University of Pennsylvania|Yes|Completed|November 2001|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|156|||Both|18 Years|70 Years|No|||June 2012|June 12, 2012|August 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00043550||203357|
NCT00043810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-060|Study of Gelonin Purging of Autologous Stem Cells for Transplantation|Dose Finding Study of Gelonin Purging of Autologous Stem Cells for Transplantation of Patients With AML/MDS in First or Subsequent Remission||M.D. Anderson Cancer Center|No|Terminated|July 2002|March 2005|Actual|March 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||July 2012|July 27, 2012|August 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00043810||203337|
NCT00043823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-604|Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer|Safety and Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMAb VEGF and EGFR Tyrosine Kinase Inhibitor OSI-774 for Locally Advanced or Metastatic Non-Squamous Cell NSCLC in Patients Who Have Been Previously Treated||M.D. Anderson Cancer Center|No|Completed|August 2002|May 2006|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|August 14, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00043823||203336|
NCT00043914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM40013|Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy|A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients With Epilepsy||GlaxoSmithKline||Completed|January 2002|January 2003|Actual|January 2003|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|16 Years|N/A|No|||February 2013|February 11, 2013|August 14, 2002||||||https://clinicaltrials.gov/show/NCT00043914||203329|
NCT00041067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069440|S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer|Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer||Southwest Oncology Group|Yes|Completed|September 2002|January 2012|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Female|18 Years|N/A|No|||May 2013|May 20, 2013|July 8, 2002||No||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00041067||203531|
NCT00045500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256599|UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma|A Phase I Trial Of UCN-01 And Prednisone In Patients With Refractory Solid Tumors And Lymphomas||National Cancer Institute (NCI)||Completed|June 2002|||January 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2005|April 29, 2015|September 6, 2002||||||https://clinicaltrials.gov/show/NCT00045500||203221|
NCT00045708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03016|A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas|A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas||National Cancer Institute (NCI)||Completed|October 2002|||November 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|September 6, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045708||203209|
NCT00045734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02495|Imatinib Mesylate in Treating Patients With Recurrent Meningioma|Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma||National Cancer Institute (NCI)||Completed|February 2003|||December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2013|June 11, 2013|September 6, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045734||203207|
NCT00045539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256605|Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma|A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma||National Cancer Institute (NCI)||Completed|October 2002|January 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|June 21, 2013|September 6, 2002||||No||https://clinicaltrials.gov/show/NCT00045539||203218|
NCT00045487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256598|Erlotinib in Treating Patients With Advanced Kidney Cancer|A Phase II, Pharmacokinetic And Biologic Correlative Study of OSI-774, An EGFR Tyrosine Kinase Inhibitor, In Patients With Advanced Renal Cell Carcinoma|OSI-774|The University of Texas Health Science Center at San Antonio|No|Completed|June 2002|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|September 6, 2002|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00045487||203222|The PI/responsible party left this institution. Additional records for completion of results entries is not available at our institution. NCI transferred the PRS record to this institution >4.5 years after the PIs left employment.
NCT00043316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GICF-001|Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis|A Phase I/II Study of Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis||InterMune||Completed|February 2001|October 2002|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|66|||Both|12 Years|N/A|No|||October 2007|October 29, 2007|August 7, 2002||||No||https://clinicaltrials.gov/show/NCT00043316||203373|
NCT00047827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0-125|Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis|A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis||Astellas Pharma Inc|No|Terminated|December 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||August 2014|August 19, 2014|October 18, 2002|No|Yes|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT00047827||203060|
NCT00047905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030009|Pilot Study of the Process of Prenatal Genetic Counseling|The Process of Prenatal Genetic Counseling Using a Simulated Client - A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|October 2002|April 2003||||N/A|Interventional|N/A||||30|||Both|N/A|N/A|No|||April 2003|March 3, 2008|October 22, 2002||||No||https://clinicaltrials.gov/show/NCT00047905||203055|
NCT00049582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02502|Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia|Phase I Study of 5-Aza-2'-Deoxycytidine (Decitabine) as a Biologic Modifier of Retinoid Responsive Genes in Patients With High-Risk Myelodysplastic Syndromes and Acute Myelogenous Leukemia (De-novo, Relapsed or Secondary)||National Cancer Institute (NCI)||Terminated|September 2002|||June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049582||202940|
NCT00049595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20012|Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma|BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|August 2002|||January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|552|||Both|16 Years|60 Years|No|||February 2016|February 5, 2016|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00049595||202939|
NCT00043693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062629|Family Intervention for Mental Illness and Substance Abuse|Family Intervention for SMI and Substance Use Disorder||Dartmouth-Hitchcock Medical Center||Completed|April 2002|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||August 2012|August 7, 2012|August 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00043693||203346|
NCT00044096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020263|Psychopharmacology of Fear-Potentiated Startle in Humans|Psychopharmacology of Fear-Potentiated Startle in Humans||National Institutes of Health Clinical Center (CC)||Completed|August 2002|September 2013||||N/A|Observational|N/A|||Actual|225|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 18, 2013|August 16, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044096||203315|
NCT00043537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH053703|Treatment of Childhood Social Phobia|Treatment of Childhood Social Phobia||University of Central Florida|Yes|Completed|April 2001|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|139|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|August 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00043537||203358|
NCT00049842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02570|Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)|PEG-Intron(TM) Maintenance Therapy vs. an Untreated Control Group for Prevention of Progression of Fibrosis in Adult Subjects With Chronic Hepatitis C With Hepatic Fibrosis (METAVIR Fibrosis Score of F2 or F3), Who Failed Therapy With PEG-Intron Plus REBETOL(R) (in Protocol No. P02370)||Merck Sharp & Dohme Corp.|Yes|Completed|October 2002|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|540|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|November 14, 2002|No|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00049842||202922|
NCT00049855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|536-00|Novel Approaches in Linkage Analysis for Complex Traits|||Mayo Clinic||Completed|September 2002|February 2005|Actual|February 2005|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2014|April 15, 2014|November 14, 2002||||No||https://clinicaltrials.gov/show/NCT00049855||202921|
NCT00050011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS32|Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy|An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy||Novartis|No|Completed|September 2002|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|602|||Female|18 Years|85 Years|No|||February 2014|February 21, 2014|November 18, 2002|Yes|Yes||No|December 4, 2013|https://clinicaltrials.gov/show/NCT00050011||202909|
NCT00047749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN92045-301|Prialt (Ziconotide) In Severe Chronic Pain|A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults With Severe Chronic Pain||Elan Pharmaceuticals||Completed|August 2002|June 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 16, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00047749||203066|
NCT00043264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRR-M01RR02558-0176|Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis|Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis||National Center for Research Resources (NCRR)||Completed||||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||December 2003|June 23, 2005|August 7, 2002||||No||https://clinicaltrials.gov/show/NCT00043264||203376|
NCT00043381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0007|Decitabine Versus Supportive Care in Adults With Advanced-stage MDS|A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome||Astex Pharmaceuticals||Completed|April 2001|April 2003|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||June 2011|January 22, 2013|August 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00043381||203368|
NCT00048113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 2302-CS20|Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease|ISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease||Ionis Pharmaceuticals, Inc.||Completed|September 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|12 Years|N/A|No|||October 2007|October 15, 2007|October 24, 2002||||||https://clinicaltrials.gov/show/NCT00048113||203040|
NCT00048126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO16460|A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer|An Open-label Study of the Effect of Continuous Xeloda Therapy in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|July 2001|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048126||203039|
NCT00047294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257587|Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting||National Cancer Institute (NCI)||Active, not recruiting|April 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|February 6, 2009|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00047294||203098|
NCT00047502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-221|Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia|Phase I Study of Lonafarnib (SCH66336) and Gleevec (Imatinib Mesylate) in Chronic Myelogenous Leukemia (CML)||M.D. Anderson Cancer Center|Yes|Completed|November 2002|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|16 Years|N/A|No|||February 2012|February 20, 2012|October 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047502||203085|
NCT00044434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAGRA13689|Bupropion as a Smoking Cessation Aid in Alcoholics|Bupropion as a Smoking Cessation Aid in Alcoholics||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|May 2002|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|25 Years|75 Years|No|||January 2008|January 25, 2008|August 28, 2002||||No||https://clinicaltrials.gov/show/NCT00044434||203291|
NCT00044447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE490/4033|Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione|A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy||Sanofi||Completed|May 2001|September 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|170|||Both|18 Years|80 Years|No|||June 2008|June 18, 2008|August 28, 2002||||||https://clinicaltrials.gov/show/NCT00044447||203290|
NCT00047840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6474IL/0006|This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.|A Randomized, Double-blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxel (TAXOTERE™) in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-based Chemotherapy.||AstraZeneca||Completed|October 2002|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||129|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|October 18, 2002||||No||https://clinicaltrials.gov/show/NCT00047840||203059|
NCT00044278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM20007|Pediatric Epilepsy Study in Subjects 1-24 Months|An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)||GlaxoSmithKline|No|Completed|September 2000|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|197|||Both|1 Month|24 Months|No|||April 2015|April 14, 2015|August 23, 2002||||||https://clinicaltrials.gov/show/NCT00044278||203302|
NCT00044291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomed 777-CLP-29|Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer|||Intarcia Therapeutics||Completed|June 2002|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|865|||Female|18 Years|N/A|No|||July 2015|July 29, 2015|August 23, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00044291||203301|
NCT00047515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-69|Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69|Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients C-01-69.||Alcon Research||Completed|January 2001|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|October 8, 2002||||||https://clinicaltrials.gov/show/NCT00047515||203084|
NCT00047528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-41|Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41|Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients (C-02-41).||Alcon Research||Completed|January 2001|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|October 8, 2002||||||https://clinicaltrials.gov/show/NCT00047528||203083|
NCT00048412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8714|Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H|Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancy, Using MHC Identical or Near Identical Donors and Sub-Myeloablative Conditioning With CAMPATH 1H (DIMSUM)||Baylor College of Medicine||Completed|June 2000|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|70 Years|No|||April 2007|April 9, 2007|October 30, 2002||||||https://clinicaltrials.gov/show/NCT00048412||203021|
NCT00043394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C015|CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer|A Phase I/II Open Label, Multi-Center, Dose-Escalation Study Of Subcutaneous CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer||Pfizer|No|Completed|September 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Female|18 Years|N/A|No|||March 2009|March 11, 2009|August 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00043394||203367|
NCT00044538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10653|Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients|An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC)||Bayer||Completed|December 2001|June 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||June 2009|June 19, 2009|August 30, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044538||203284|
NCT00044122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020277|Study of Factors Regulating Mast Cell Proliferation|Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells||National Institutes of Health Clinical Center (CC)||Recruiting|August 2002|||||N/A|Observational|N/A|||Anticipated|450|||Both|1 Year|65 Years|No|||August 2015|September 10, 2015|August 17, 2002||No||No||https://clinicaltrials.gov/show/NCT00044122||203313|
NCT00044356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCL-1005-208|Phase II Trial of Allovectin-7® for Metastatic Melanoma|A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma||Vical|No|Completed|February 2001|September 2004|Actual|August 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|133|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|August 26, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044356||203297|
NCT00044083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020239|Clinical Trial of Tolcapone for Cognition in Schizophrenia|Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype||National Institutes of Health Clinical Center (CC)||Completed|August 2002|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|1||Actual|212|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|December 16, 2015|August 16, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044083||203316|
NCT00044239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020281|Characterization of Childhood-Onset Obsessive-Compulsive Disorder|The Characterization of Childhood Onset Obsessive Compulsive Disorder and the PANDAS Subgroup||National Institutes of Health Clinical Center (CC)||Completed|August 2002|May 2010||||N/A|Observational|N/A|||Actual|49|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||May 2010|May 19, 2010|August 22, 2002||No||No||https://clinicaltrials.gov/show/NCT00044239||203305|
NCT00044252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020256|Role of Hormones in Susceptibility to Seizures in Women With Epilepsy|Role of Serum Gonadal and Neuroactive Steroids in the Seizure Susceptibility of Women With Catamenial Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|July 2002|January 2008||||N/A|Observational|N/A||||50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|March 5, 2008|August 22, 2002||||No||https://clinicaltrials.gov/show/NCT00044252||203304|
NCT00044525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10654|Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients|An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer||Bayer||Completed|April 2002|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Female|18 Years|N/A|No|||December 2014|December 18, 2014|August 30, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044525||203285|
NCT00047684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH061319|Brief Integrative Therapy for Post-Traumatic Stress Disorder|Development and Initial Evaluation of Brief Integrative Therapy for PTSD||Dartmouth-Hitchcock Medical Center||Completed|November 2001|November 2002||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|18 Years|65 Years|No|||September 2008|September 9, 2013|October 11, 2002||||No||https://clinicaltrials.gov/show/NCT00047684||203071|
NCT00043303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GILF-001|Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis|A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.||InterMune||Completed|September 2001|November 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|502|||Both|18 Years|75 Years|No|||October 2007|October 29, 2007|August 7, 2002||||No||https://clinicaltrials.gov/show/NCT00043303||203374|
NCT00043459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-607-007|Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.|||Tularik||Terminated|July 2002|March 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||March 2003|June 23, 2005|August 8, 2002||||||https://clinicaltrials.gov/show/NCT00043459||203362|
NCT00043472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020268|Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk|Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer||National Institutes of Health Clinical Center (CC)||Completed|August 2002|||||N/A|Observational|N/A|||Actual|40|||Female|19 Years|100 Years|No|||December 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00043472||203361|
NCT00044382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-501-001|Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome|A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome||Celgene|Yes|Completed|February 2002|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||June 2009|June 16, 2009|August 27, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044382||203295|
NCT00044395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2133|Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes|LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes||Eli Lilly and Company||Completed|July 2002|October 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|August 28, 2002||||||https://clinicaltrials.gov/show/NCT00044395||203294|
NCT00043563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH061457|Cognitive Behavioral Treatment of Pediatric Trichotillomania|Cognitive Behavioral Treatment of Pediatric Trichotillomania||University of Pennsylvania|Yes|Completed|January 2001|October 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|8 Years|17 Years|No|||December 2015|December 15, 2015|August 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00043563||203356|
NCT00043667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020242|Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis|Evaluation of Subcutaneous Daclizumab Treatments in Patients With Non-Infectious Sight-Threatening Uveitis: A Multicenter, Open-Label, Phase II Study||National Institutes of Health Clinical Center (CC)||Completed|August 2002|October 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||October 2004|March 3, 2008|August 10, 2002||||No||https://clinicaltrials.gov/show/NCT00043667||203348|
NCT00043680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020257|Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy|Multi-Center Randomized Phase I/II Trial to Study the Effects of Cyclooxygenase-2 Inhibition on the Response to Photodynamic Therapy in Patients With Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Completed|August 2002|January 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||January 2005|March 3, 2008|August 10, 2002||||No||https://clinicaltrials.gov/show/NCT00043680||203347|
NCT00044343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF20004|GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin|An Open-Label, Multicenter, Phase II Study of Oral Lapatinib (GW572016) as Single Agent, Second-Line Therapy in Subjects With Metastatic Colorectal Cancer Who Have Progressed on First-Line Therapy With 5-Fluorouracil in Combination With Irinotecan or Oxaliplatin||GlaxoSmithKline||Completed|September 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|August 26, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044343||203298|
NCT00047762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI2520g|Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer|Open-Label, Multicenter, Dose-Escalation Study in Subjects w/Advanced Colorectal Cancer to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tarceva in Combination w/5-Fluorouracil, Leucovorin, and Irinotecan and of Bevacizumab in Combination w/Tarceva, 5-Fluorouracil, Leucovorin, and Irinotecan||Genentech, Inc.||Completed|October 2002|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2004|June 23, 2005|October 16, 2002||||||https://clinicaltrials.gov/show/NCT00047762||203065|
NCT00047775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-HeFT|African-American Heart Failure Trial|||Nitromed||Completed|May 2001|August 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1100|||Both|18 Years|N/A|No|||October 2004|June 23, 2005|October 18, 2002||||||https://clinicaltrials.gov/show/NCT00047775||203064|
NCT00047788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6474IL/0004|Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer|A Phase Two Study of ZD6474 in Patients With Relapsed Multiple Myeloma||AstraZeneca||Completed|October 2002|May 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|October 18, 2002||||||https://clinicaltrials.gov/show/NCT00047788||203063|
NCT00043511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 045|Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults|A Phase I Trial to Evaluate the Safety and Immunogenicity of the HIV-1 pGA2/JS2 Plasmid DNA Vaccine Given Intramuscularly (IM) in HIV-1 Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||April 2003|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|August 9, 2002||||||https://clinicaltrials.gov/show/NCT00043511||203359|
NCT00044226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-BPH-01|A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia||Milkhaus Laboratory||Recruiting|April 2002|October 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Male|45 Years|80 Years|Accepts Healthy Volunteers|||August 2002|June 23, 2005|August 22, 2002||||||https://clinicaltrials.gov/show/NCT00044226||203306|
NCT00047853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020321|Brain Changes in Fear|fMRI Investigation of Explicit Cue and Contextual Fear||National Institutes of Health Clinical Center (CC)||Recruiting|October 2002|||||N/A|Observational|N/A|||Anticipated|1430|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|October 22, 2002||No||No||https://clinicaltrials.gov/show/NCT00047853||203058|
NCT00044265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K726-01-4002|Treatment of Pediatric Hypertension With Altace Trial|A Dose Escalation, Randomized, Double-blind Withdrawal Study of the Efficacy, Dose-response, and Safety of Ramipril for the Treatment of Hypertension in Children and Adolescents||Pfizer||Completed|July 2002|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||310|||Both|6 Years|16 Years|No|||June 2012|June 6, 2012|August 23, 2002||||||https://clinicaltrials.gov/show/NCT00044265||203303|
NCT00043615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020258|Collection of Blood, Bone Marrow, Tumor or Tissue Samples|Acquisition of Blood, Bone Marrow, Tumor, or Tissue Samples||National Institutes of Health Clinical Center (CC)||Completed|July 2002|April 2012||||N/A|Observational|N/A|||Actual|74|||Both|18 Years|N/A|No|||April 2012|September 26, 2015|August 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00043615||203352|
NCT00043628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020264|Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease|Stem Cell Mobilization as Therapy for Chronic Myocardial Ischemia in Patients With Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2002|February 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||February 2005|March 3, 2008|August 9, 2002||||No||https://clinicaltrials.gov/show/NCT00043628||203351|
NCT00043641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020232|HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)|HIV Expression in Patients With Viral Loads Suppressed on HAART||National Institutes of Health Clinical Center (CC)||Completed|July 2002|February 2013||||N/A|Observational|N/A|||Actual|73|||Both|18 Years|N/A|No|||February 2013|August 20, 2013|August 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00043641||203350|
NCT00047385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02002|National Lung Screening Trial (NLST) Screening|National Lung Screening Trial A Randomized Trial Comparing Low-dose Helical CT With Chest Xray for Lung Cancer|NLST|National Cancer Institute (NCI)|Yes|Completed|August 2002|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|53454|||Both|55 Years|74 Years|Accepts Healthy Volunteers|||October 2012|May 2, 2014|October 3, 2002||No||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00047385||203093|NLST utilized institutions with special expertise. The "healthy volunteer" effect may apply. Scanners are now more technologically advanced. Ongoing LDCT screening may reduce the rate of lung cancer deaths more than three rounds done in NLST.
NCT00047411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147|Home Use of Automatic External Defibrillators to Treat Sudden Cardiac Arrest|Home Automatic External Defibrillator Trial -- HAT|HAT|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2002|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|7001|||Both|18 Years|N/A|No|||March 2008|March 6, 2008|October 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00047411||203092|
NCT00044369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10496-CP-001|Role of the Toxic Metal Cadmium in the Mechanism Producing Infertility With a Varicocele|Increased Testicular Cd2+ & Infertility With Varicocele ( a Varicose Vein in the Scrotum)||National Institute of Environmental Health Sciences (NIEHS)||Completed|May 2000|April 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||400|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|August 27, 2002||||No||https://clinicaltrials.gov/show/NCT00044369||203296|
NCT00044486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01899|Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)|A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients||Merck Sharp & Dohme Corp.||Completed|July 2002|April 2005|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|602|||Both|13 Years|N/A|No|||August 2015|August 14, 2015|August 29, 2002||||||https://clinicaltrials.gov/show/NCT00044486||203287|
NCT00044577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL30001|New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects|See Detailed Description||GlaxoSmithKline|No|Completed|July 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||166|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|August 30, 2002||||||https://clinicaltrials.gov/show/NCT00044577||203281|
NCT00047697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH064941|Drug Treatment for Autism|Donepezil HCl: Treating Cognitive Deficits in Autism||National Institute of Mental Health (NIMH)||Completed|October 2002|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||40|||Both|8 Years|17 Years|No|||October 2008|October 13, 2008|October 11, 2002||||No||https://clinicaltrials.gov/show/NCT00047697||203070|
NCT00043498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8977-CP-001|Health Effects of Early-Life Exposure to Urban Pollutants in Minority Children|Health Effects of Early-Life Exposure to Urban Pollutants in Minority Children||National Institute of Environmental Health Sciences (NIEHS)|Yes|Completed|August 1997|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|727|Samples With DNA|We collected maternal urine during the third trimester of pregnancy, maternal blood at      delivery, umbilical cord blood, meconium, blood and urine from the child at ages 24, 36, and      60 months.|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The present study enrolled 727 African American and Latino (Dominican) mothers and their        children. The African American and Latino (Dominican) women were initially enrolled into        the parent CCCEH study during pregnancy. Caucasian women are not included because a        central purpose of the research is to evaluate health outcomes in a high risk, minority        population.|October 2014|October 14, 2014|August 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00043498||203360|
NCT00043602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059668|Clinician Managed Interpersonal Psychotherapy|Clinician Managed Interpersonal Psychotherapy||University of Iowa|No|Completed|September 2001|December 2007|Actual|December 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 25, 2013|August 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00043602||203353|
NCT00044174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020278|Dyadic Interactions in Depressed and Non-Depressed Mothers and Their Infants|Dyadic Interactions in Depressed and Non-Depressed Mothers and Their Infants||National Institutes of Health Clinical Center (CC)||Completed|August 2002|||||N/A|Observational|N/A|||Anticipated|850|||Both|N/A|45 Years|No|||February 2016|March 1, 2016|August 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00044174||203310|
NCT00048373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10339|Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL|Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE)||Baylor College of Medicine||Completed|October 2001|April 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|65 Years|No|||August 2006|August 22, 2006|October 30, 2002||||||https://clinicaltrials.gov/show/NCT00048373||203024|
NCT00048386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8354|Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy|A Pilot Study of Gene Modified Autologous Neuroblastoma Vaccine for the Post-Chemotherapy Treatment of High-Risk Neuroblastoma|CYCHE2|Baylor College of Medicine|Yes|Completed|November 1999|October 2009|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|64 Years|No|||July 2012|July 26, 2012|October 30, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00048386||203023|
NCT00048399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9446|Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H|Phase I/II Study of Allogeneic Stem Cell Transplantation For Patients With Graft Failure Following Allogeneic Transplantation Using MHC Identical or Near Identical Donors and Submyeloablative Conditioning With CAMPATH 1H (CAMGRAFT)||Baylor College of Medicine||Terminated|December 2000|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|64 Years|No|||April 2007|April 9, 2007|October 30, 2002||||||https://clinicaltrials.gov/show/NCT00048399||203022|
NCT00044421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2784|Treatment of Peripheral Neuropathy in Patients With Diabetes|LY333531 Treatment of Peripheral Neuropathy in Patients With Diabetes||Eli Lilly and Company||Completed|July 2002|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|August 28, 2002||||||https://clinicaltrials.gov/show/NCT00044421||203292|
NCT00044070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|872-CL-003|A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion, and FLAIR Magnetic Resonance Imaging in Patients With Acute Ischemic Stroke||Astellas Pharma Inc||Completed|December 2000|January 2003||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2006|March 31, 2006|August 16, 2002||||||https://clinicaltrials.gov/show/NCT00044070||203317|
NCT00047801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2012|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer||Telik||Completed|October 2002|September 2004|Actual|September 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||June 2011|July 21, 2011|October 18, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00047801||203062|
NCT00044460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/326|Efficacy and Safety In Poorly Controlled Type 2 Diabetics|A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|May 2002|April 2003|Actual|April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|149|||Both|18 Years|70 Years|No|||June 2011|June 1, 2011|August 29, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044460||203289|
NCT00043719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR048679|Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women|Prevention of Postmenopausal Bone Loss With Nitric Oxide||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|July 2002|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 29, 2009|August 12, 2002|Yes|Yes||||https://clinicaltrials.gov/show/NCT00043719||203344|
NCT00044109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020274|Magnets in the Treatment of Sciatica|Static Magnets In The Treatment of Sciatica||National Institutes of Health Clinical Center (CC)||Completed|August 2002|June 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||75|||Both|30 Years|80 Years|No|||June 2006|June 23, 2006|August 17, 2002||||No||https://clinicaltrials.gov/show/NCT00044109||203314|
NCT00044564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100386|Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma|An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma||Bayer||Completed|December 2001|January 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|August 30, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00044564||203282|
NCT00044473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002389|A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat|An Open-Label Study of Levofloxacin to Evaluate Bacteriologic Outcome in the Treatment of Children Who Are at Risk for Acute Otitis Media That is Difficult to Treat||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2002|July 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|206|||Both|6 Months|5 Years|No|||January 2011|June 6, 2011|August 29, 2002||||||https://clinicaltrials.gov/show/NCT00044473||203288|
NCT00044551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100389|Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma|An Open Phase II, Multi Center Trial of BAY 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma||Bayer||Completed|February 2002|July 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|August 30, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00044551||203283|
NCT00047866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030013|Brain Function in Response to Motivational Stimuli|Brain Activation in Response to Motivational and Affective Stimuli: Pharmacological Manipulations||National Institutes of Health Clinical Center (CC)||Completed|October 2002|June 2010||||N/A|Observational|N/A|||Actual|38|||Both|18 Years|65 Years|No|||June 2010|June 26, 2010|October 22, 2002||No||No||https://clinicaltrials.gov/show/NCT00047866||203057|
NCT00047879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030002|Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas|A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas||National Institutes of Health Clinical Center (CC)|No|Completed|October 2002|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|June 19, 2006||No||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00047879||203056|Registered 7 out of 64 participants and they came off study for progressive disease around 3-4 months after starting the study.
NCT00043277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-02-04|Study Of Angiomax In Infants Under Six Months With Thrombosis|Pilot Dose Finding And Efficacy Study Of Angiomax® (Bivalirudin) As Primary Anticoagulation In Infants Under Six Months With Thrombosis||The Medicines Company||Completed|August 2002|December 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|N/A|6 Months|No|||January 2006|January 31, 2006|August 7, 2002||||||https://clinicaltrials.gov/show/NCT00043277||203375|
NCT00043576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN101-002|ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere|A Phase 2/3 Multicenter, Randomized, Double Blind Study of Docetaxel (Taxotere) Plus DN-101 or Placebo in Androgen Independent Prostate Cancer (AIPC)||Novacea||Active, not recruiting|August 2002|December 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Male|18 Years|N/A|No|||February 2005|March 10, 2009|August 9, 2002||||||https://clinicaltrials.gov/show/NCT00043576||203355|
NCT00043589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH035182|Memory and Mental Health in Aging|Memory and Mental Health in Aging||Stanford University|No|Completed|June 2002|December 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|August 9, 2002||No||No||https://clinicaltrials.gov/show/NCT00043589||203354|
NCT00043706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATGFB1-001-01|Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis|A Phase 1/2 Double Blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic Sclerosis||Sanofi||Completed||September 2003|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2015|March 4, 2015|August 12, 2002||||||https://clinicaltrials.gov/show/NCT00043706||203345|
NCT00044512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10874|A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma|A Phase II Multicenter Uncontrolled Trial of Sorafenib (BAY43-9006) in Patients With Advanced Hepatocellular Carcinoma||Bayer|No|Completed|August 2002|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|August 30, 2002|No|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00044512||203286|Subjects had advanced disease and were heavily pretreated. National Cancer Institute-Common Toxicity Criteria (NCI-CTC) was translated to Medical Dictionary for Regulatory Activities (MedDRA) for System Organ Class (SOC) only.
NCT00049400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0355|S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction|A Phase I Pharmacokinetic Study Of Epothilone B Analogue BMS-247550 (NSC 710428D) In Patients With Advanced Malignancies And Varying Levels Of Liver Dysfunction||Southwest Oncology Group|Yes|Completed|October 2003|December 2007|Actual|September 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 12, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00049400||202951|
NCT00047710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-146|Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer|A Phase I Trial of Concurrent RHUMAB VEGF (BEVACIZUMAB) and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Completed|September 2002|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 31, 2012|October 14, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047710||203069|
NCT00047723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS045294|Minocycline to Treat Amyotrophic Lateral Sclerosis|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|January 2003|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|21 Years|85 Years|No|||December 2007|December 18, 2007|October 16, 2002||||||https://clinicaltrials.gov/show/NCT00047723||203068|
NCT00047736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI2298g|A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer|A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy||Genentech, Inc.||Completed|July 2001|July 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 19, 2013|October 16, 2002||||||https://clinicaltrials.gov/show/NCT00047736||203067|
NCT00047814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA-788-0004|Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection|A Multiple Rising-Dose Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection||Astellas Pharma Inc||Completed|October 2002|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|60 Years|No|||December 2011|December 8, 2011|October 18, 2002||||||https://clinicaltrials.gov/show/NCT00047814||203061|
NCT00044187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5102|The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder|The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder||Eli Lilly and Company||Completed|April 2001|September 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|18 Years|65 Years|No|||July 2006|July 18, 2006|August 21, 2002||||||https://clinicaltrials.gov/show/NCT00044187||203309|
NCT00043238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10904-CP-001|Mohawk Culture, Behavior, Toxicant Exposure and Health|Mohawk Culture, Behavior, Toxicant Exposure and Health||National Institute of Environmental Health Sciences (NIEHS)||Completed||July 2005|Actual|July 2005|Actual|N/A|Observational|N/A|||Anticipated|220|||Both|17 Years|18 Years|No|||April 2015|April 13, 2015|August 7, 2002||No||No||https://clinicaltrials.gov/show/NCT00043238||203377|
NCT00050765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol BMI-US-01-001|Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection|A Phase I Multi-Center Study to Assess the Safety and Cardiovascular Effects of MyoCell™ Implantation in Patients With a Previous MI and Placement of an ICD Requiring De Novo Coronary Artery Bypass Graft Therapy||Bioheart, Inc.||Not yet recruiting|August 2006|August 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|80 Years|No|||March 2006|March 6, 2006|December 18, 2002||||||https://clinicaltrials.gov/show/NCT00050765||202855|
NCT00050882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-611-05|Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis|A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis||Chugai Pharma USA||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2004|June 23, 2005|December 29, 2002||||||https://clinicaltrials.gov/show/NCT00050882||202846|
NCT00049829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2301|HORIZON-PFT: Pivotal Fracture Trial|HORIZON-PFT: Pivotal Fracture Trial||Novartis||Completed|January 2002|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||7700|||Female|65 Years|89 Years|No|||November 2011|November 1, 2011|November 14, 2002||||||https://clinicaltrials.gov/show/NCT00049829||202923|
NCT00044213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654|Trial to Assess Chelation Therapy (TACT)|Trial to Assess Chelation Therapy (TACT)||Mt. Sinai Medical Center, Miami|Yes|Completed|September 2003|August 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1708|||Both|50 Years|N/A|No|||August 2013|August 30, 2013|August 22, 2002|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00044213||203307|
NCT00044135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-102 B|A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.|A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus.||Triangle Pharmaceuticals||Active, not recruiting|August 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|No|||November 2002|June 23, 2005|August 20, 2002||||No||https://clinicaltrials.gov/show/NCT00044135||203312|
NCT00044148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6249|The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes|||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|30 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 18, 2006|August 20, 2002||||||https://clinicaltrials.gov/show/NCT00044148||203311|
NCT00043329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIOS-003|Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis|Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis||InterMune||Completed|January 2002|September 2005|Actual|||Phase 4|Observational|Time Perspective: Retrospective||1|Actual|6|||Both|N/A|N/A|No|Non-Probability Sample|Osteopetrosis patients receiving Actimmune therapy|October 2007|October 30, 2007|August 7, 2002||||No||https://clinicaltrials.gov/show/NCT00043329||203372|
NCT00049309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008602|Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer|Prostate Cancer: Impact Of Fat And Flaxseed - Modified Diets||Duke University|Yes|Completed|January 2003|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|161|||Male|18 Years|N/A|No|||February 2013|April 9, 2013|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00049309||202958|
NCT00048139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO16461|A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer|An Open-label Study of the Effect of Intermittent Xeloda in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|October 2001|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048139||203038|
NCT00048152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M67005|A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients|A Randomized, Open-label Study Comparing the Effects of Low-dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab||Hoffmann-La Roche||Completed|December 2000|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|539|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048152||203037|
NCT00048165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR15880|A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation|A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplatation.||Hoffmann-La Roche||Completed|August 1999|August 2002|Actual|August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|434|||Both|13 Years|N/A|No|||March 2016|March 21, 2016|October 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048165||203036|
NCT00048334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030030|Depsipeptide to Treat Thyroid and Other Advanced Cancers|Phase I Trial of Romidepsin Given on Days One, Three, and Five in Patients With Thyroid and Other Advanced Cancers||National Institutes of Health Clinical Center (CC)||Completed|October 2002|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2014|February 19, 2014|October 29, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00048334||203027|
NCT00048347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030019|Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis|An Open-Label, Pilot Study of Type I Interferon (AVONEX) Treatment of Ulcerative Colitis||National Institutes of Health Clinical Center (CC)|No|Completed|October 2002|May 2010|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2010|August 30, 2010|October 29, 2002|No|Yes||No|July 6, 2010|https://clinicaltrials.gov/show/NCT00048347||203026|While this study was designed as a proof-of-concept pilot trial to correlate changes in IL-13 and other cytokines with clinical response, efficacy was measured. The efficacy estimate is limited by the open-label design.
NCT00048100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-034|Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes|Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy||M.D. Anderson Cancer Center|Yes|Terminated|February 2001|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||August 2012|August 22, 2012|October 24, 2002|No|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00048100||203041|
NCT00047437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017406|Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure|Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)||Duke University|Yes|Completed|April 2003|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2331|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|October 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00047437||203090|
NCT00047541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-70|Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70|Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients C-01-70.||Alcon Research||Completed|February 2001|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|October 8, 2002||||||https://clinicaltrials.gov/show/NCT00047541||203082|
NCT00044304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020286|Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome|Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients With Myeloproliferative and/or Steroid-Refractory Hypereosinophilic Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|August 2002|January 2030|Anticipated|January 2030|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|100 Years|No|||April 2015|December 11, 2015|August 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00044304||203300|
NCT00044317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8391-CP-001|Health Effects of Particulate Acids in Late Adolescence|||National Institute of Environmental Health Sciences (NIEHS)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1500|||Both|16 Years|19 Years|Accepts Healthy Volunteers|||August 2002|June 23, 2005|August 26, 2002||||No||https://clinicaltrials.gov/show/NCT00044317||203299|
NCT00043342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GICF-002|Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis|A Phase I/II Study of Interferon Gamma-1b by Subcutaneous Injection for the Treatment of Patients With Cystic Fibrosis||InterMune||Completed|April 2002|March 2003|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|51|||Both|6 Years|N/A|No|||October 2007|October 29, 2007|August 7, 2002||||No||https://clinicaltrials.gov/show/NCT00043342||203371|
NCT00047632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIOV-001|Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer|Interferon Gamma-1b in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First Line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma.||InterMune||Terminated|October 2001|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|847|||Female|N/A|N/A|No|||October 2007|October 30, 2007|October 9, 2002|||futility|No||https://clinicaltrials.gov/show/NCT00047632||203075|
NCT00047645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPF-001|A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis||InterMune||Completed|April 2000|December 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|330|||Both|20 Years|79 Years|No|||November 2007|November 1, 2007|October 9, 2002||||No||https://clinicaltrials.gov/show/NCT00047645||203074|
NCT00047671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062531|Ethnic Variations in Antidepressant Response|Ethnic Variations in Antidepressant Response||National Institute of Mental Health (NIMH)|Yes|Completed|June 2002|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|70 Years|No|||August 2009|August 3, 2009|October 11, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047671||203072|
NCT00046202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020311|Study of Inborn Errors of Cholesterol Synthesis and Related Disorders|Investigations Into Inborn Errors of Cholesterol Synthesis and Related Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|September 2002|||||N/A|Observational|N/A|||Anticipated|550|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 12, 2016|September 21, 2002||No||No||https://clinicaltrials.gov/show/NCT00046202||203178|
NCT00046462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4022|Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment|Substituting Lantus®(Insulin Glargine[rDNAorigin]Inj) for a Thiazolidinedione vs. a 3rd Oral Agent as add-on Therapy in Patients Failing a Thiazolidinedione & Sulfonylurea or Metformin Combination||Sanofi||Completed|November 2001|December 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|79 Years|No|||January 2011|January 10, 2011|September 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00046462||203158|
NCT00047021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU5Y01|Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma|A Pilot Study Of Cytarabine And High-Dose Mitoxantrone For Relapsed Or Refractory Hematologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|November 2001|September 2005|Actual|August 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|55 Years|No|||June 2010|June 10, 2010|October 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00047021||203117|
NCT00046553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020317|Brain Receptor Function in Post-Traumatic Stress Disorder|Glucocorticoid and Mineralocorticoid Receptor Function in Post Traumatic Stress Disorder||National Institutes of Health Clinical Center (CC)||Completed|September 2002|October 2004||||N/A|Observational|N/A||||97|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2004|March 3, 2008|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046553||203151|
NCT00048009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16631|Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids|||Hoffmann-La Roche||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||May 2005|June 23, 2005|October 24, 2002||||||https://clinicaltrials.gov/show/NCT00048009||203048|
NCT00047034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03076|E7389 in Treating Patients With Advanced Solid Tumors|Phase I Trial of E7389 (Halichondrin B Analog) (NSC# 707389) in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|August 2002|||October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047034||203116|
NCT00046514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA013-0|ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer|A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer||Celgene Corporation||Completed|June 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||July 2007|July 18, 2007|September 30, 2002||||||https://clinicaltrials.gov/show/NCT00046514||203154|
NCT00048204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKD20006|A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder|An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder||GlaxoSmithKline||Completed|November 2002|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|372|||Both|18 Years|65 Years|No|||February 2013|February 11, 2013|October 28, 2002||||No||https://clinicaltrials.gov/show/NCT00048204||203035|
NCT00048217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1249-105|A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102|||Trimeris||Active, not recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|June 23, 2005|October 28, 2002||||||https://clinicaltrials.gov/show/NCT00048217||203034|
NCT00048464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XT003|T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant|A Phase I/II Study of Xcellerated T Cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma||Xcyte Therapies||Active, not recruiting|October 2002|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|70 Years|No|||March 2005|November 6, 2006|October 31, 2002||||||https://clinicaltrials.gov/show/NCT00048464||203017|
NCT00048529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-607-006|Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus|||Tularik||Suspended|September 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||April 2004|June 23, 2005|November 1, 2002||||||https://clinicaltrials.gov/show/NCT00048529||203012|
NCT00047554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-79|Study of TRAVATAN in Subjects With Iris Pigmentation Changes|A Five-Year, Multicenter, Commercial Label Safety Study of TRAVATAN® 0.004% in Patients With TRAVATAN-Induced Iris Pigmentation Changes||Alcon Research||Terminated|May 2003|June 2012|Actual|June 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|336|||Both|N/A|N/A|No|Non-Probability Sample|Patients were identified and enrolled from 23 investigational centers in the US.|May 2013|May 13, 2013|October 8, 2002|No|Yes|Study objectives met|No||https://clinicaltrials.gov/show/NCT00047554||203081|
NCT00047567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN-345-509|Open-label Adjunctive Zonisamide for Bipolar Disorder|||Elan Pharmaceuticals||Terminated|July 2002|July 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|6 Years|17 Years|No|||December 2015|December 10, 2015|October 8, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00047567||203080|
NCT00048321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 104838-CS7|ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis|ISIS 104838-CS7, A Double-Blind, Placebo-Controlled, Randomized Trial of the Safety, Efficacy and Pharmacokinetic Profile of ISIS 104838 (TNF-Alpha Antisense Oligonucleotide) Subcutaneous Injections in Active Rheumatoid Arthritis Patients||Ionis Pharmaceuticals, Inc.||Completed|January 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||October 2007|October 15, 2007|October 29, 2002||||||https://clinicaltrials.gov/show/NCT00048321||203028|
NCT00048230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34101-039|PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Millennium Pharmaceuticals, Inc.||Completed|June 2002|December 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|620|||Both|N/A|N/A|No|||January 2012|January 12, 2012|October 28, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048230||203033|
NCT00048503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004033|Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older|An Open-label, Phase 2 Study of the Farnesyl Transferase Inhibitor ZARNESTRA (R115777) as Post-consolidation Therapy for Acute Myeloid Leukemia (AML) in Patients Age 60 Years and Older.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2002|November 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|88|||Both|60 Years|N/A|No|||April 2010|April 23, 2010|November 1, 2002||||||https://clinicaltrials.gov/show/NCT00048503||203014|
NCT00048542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE038|Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis||Abbott|Yes|Completed|September 2002|June 2010|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|171|||Both|4 Years|17 Years|No|||August 2011|August 18, 2011|November 1, 2002|Yes|Yes||No|December 7, 2009|https://clinicaltrials.gov/show/NCT00048542||203011|
NCT00048555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-21|Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma|A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan® for Patients With Relapsed or Refractory, Follicular Lymphoma||Biogen|No|Completed|November 2002|November 2010|Actual|March 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||January 2011|September 12, 2013|November 1, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048555||203010|
NCT00046306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9520-CP-001|Nevada Environmental Tobacco Smoke and Health Study|||National Institute of Environmental Health Sciences (NIEHS)||Completed||August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||375|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|September 26, 2002||No||No||https://clinicaltrials.gov/show/NCT00046306||203170|
NCT00047242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0173, CDR0000257566|UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors|The Pharmacokinetic and Safety Profile of UCN-01 in Combination With Irinotecan in Solid Tumors (Primarily Lung, Ovarian and GI Cancers)||Sidney Kimmel Comprehensive Cancer Center||Completed|August 2002|||February 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|October 3, 2002||||||https://clinicaltrials.gov/show/NCT00047242||203102|
NCT00047255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257580|Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer|A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification||Jonsson Comprehensive Cancer Center|Yes|Completed|May 2002|April 2010|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|263|||Female|18 Years|75 Years|No|||February 2016|February 11, 2016|October 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00047255||203101|
NCT00048516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-021|Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)|Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)||Abbott||Completed|February 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|18 Years|N/A|No|||July 2006|July 31, 2006|November 1, 2002||||||https://clinicaltrials.gov/show/NCT00048516||203013|
NCT00047268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257581|Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome|Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood||National Cancer Institute (NCI)||Active, not recruiting|July 1998|||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|18 Years|No|||July 2007|September 16, 2013|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00047268||203100|
NCT00047281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257584|Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma|Trial Of Oral Thalidomide, Celecoxib, Etoposide And Cyclophosphamide In Adult Patients With Relapsed Or Progressive Malignant Gliomas||National Cancer Institute (NCI)||Active, not recruiting|March 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2004|November 22, 2008|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00047281||203099|
NCT00046475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20,762-401|A Study for Patients With Neurogenic Orthostatic Hypotension|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Patients With Neurogenic Orthostatic Hypotension||Shire||Completed|January 2002|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|140|||Both|18 Years|N/A|No|||November 2007|May 13, 2015|September 30, 2002|||||April 24, 2015|https://clinicaltrials.gov/show/NCT00046475||203157|
NCT00046488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152-20|Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)|A Phase I Multicenter, Dose-Escalation Study of IDEC-152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Biogen|Yes|Completed|September 2002|March 2010|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|70|||Both|18 Years|N/A|No|||May 2010|September 12, 2013|September 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00046488||203156|
NCT00048425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001069|Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.|Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.||Abbott||Completed|September 2002|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||December 2006|December 14, 2006|October 31, 2002||||||https://clinicaltrials.gov/show/NCT00048425||203020|
NCT00048438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-019|Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)|Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)||Abbott||Completed|February 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|18 Years|N/A|No|||August 2006|August 10, 2006|October 31, 2002||||||https://clinicaltrials.gov/show/NCT00048438||203019|
NCT00046566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145|Protein Supplements to Treat High Blood Pressure|Clinical Trial of Dietary Protein on Blood Pressure||Tulane University Health Sciences Center|Yes|Completed|July 2002|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|280|||Both|22 Years|N/A|No|||November 2013|November 25, 2013|September 30, 2002||No||No||https://clinicaltrials.gov/show/NCT00046566||203150|
NCT00046579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184|Psychosocial Determinants of Nutrient Intake in Girls|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2002|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Female|9 Years|23 Years|No|||January 2008|January 18, 2008|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046579||203149|
NCT00046865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257016|Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer|Treatment of Chemotherapy-Induced Nausea With Acupressure: A Phase III Trial||M.D. Anderson Cancer Center|No|Completed|October 2002|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|57|||Female|18 Years|N/A|No|||October 2012|October 5, 2012|October 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00046865||203127|
NCT00046709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-SF-108|Marijuana for Cancer Pain|Marijuana in Combination With Opioids for Cancer Pain: A Pilot Study||Center for Medicinal Cannabis Research||Terminated|September 2002|October 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|October 1, 2002|||Discontinued due to non-enrollment.|||https://clinicaltrials.gov/show/NCT00046709||203139|
NCT00048061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM16549|MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis|A Randomized, Double-blind Study Comparing the Effect of Monthly Versus Daily Treatment With Oral Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis||Hoffmann-La Roche||Completed|April 2002|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1609|||Female|55 Years|80 Years|No|||October 2015|October 1, 2015|October 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048061||203044|
NCT00048074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM16550|DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis|A Randomized, Double-blind Study Comparing the Effect of Different Treatment Regimens of Intravenous Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis||Hoffmann-La Roche||Completed|June 2002|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|1395|||Female|55 Years|80 Years|No|||January 2016|January 4, 2016|October 24, 2002|Yes|Yes||No|January 4, 2016|https://clinicaltrials.gov/show/NCT00048074||203043|
NCT00047983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ID01|Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients|A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed||April 2004|Actual|||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|4 Years|N/A|No|||January 2013|January 16, 2013|October 23, 2002||No||No||https://clinicaltrials.gov/show/NCT00047983||203049|
NCT00047008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0129|Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer|A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas||Radiation Therapy Oncology Group|Yes|Active, not recruiting|July 2002|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|743|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|October 3, 2002|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00047008||203118|
NCT00048568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-102|A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate||Bristol-Myers Squibb||Completed|December 2002|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1250|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|November 2, 2002|Yes|Yes||No|March 28, 2011|https://clinicaltrials.gov/show/NCT00048568||203009|
NCT00048581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-029|Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy||Bristol-Myers Squibb||Completed|December 2002|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|738|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|November 2, 2002|Yes|Yes||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00048581||203008|
NCT00047346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02499|Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction|A Dose-Finding, Safety, And Pharmacokinetic Study Of The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor OSI-774 (NSC 718781) In Patients With Unresectable Hepatocellular Carcinoma And Moderate Hepatic Dysfunction||National Cancer Institute (NCI)||Completed|August 2002|||December 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047346||203094|
NCT00047203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02496|Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Flavopiridol in Patients With Relapsed and Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|September 2002|||September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047203||203105|
NCT00047216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-007|Tipifarnib in Treating Patients With Recurrent Bladder Cancer|A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder||University Health Network, Toronto||Completed|November 2002|||March 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2015|July 22, 2015|October 3, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00047216||203104|
NCT00048295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 2302-CS21|Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease|ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s Disease||Ionis Pharmaceuticals, Inc.||Active, not recruiting|May 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|12 Years|N/A|No|||April 2004|June 23, 2005|October 29, 2002||||||https://clinicaltrials.gov/show/NCT00048295||203030|
NCT00048308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000099|Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass|||Alexion Pharmaceuticals||Active, not recruiting|January 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3000|||Both|18 Years|N/A|No|||February 2003|September 13, 2010|October 29, 2002||||||https://clinicaltrials.gov/show/NCT00048308||203029|
NCT00047333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02498|Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed|A Phase 2 Open-Label Study Of OSI-774 (NSC 718781) In Unresectable Hepatocellular Carcinoma||National Cancer Institute (NCI)||Terminated|August 2002|||January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|October 3, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00047333||203095|
NCT00046501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4030|Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents|Morning LANTUS v. Intermediate-acting Insulin 2x/Day as Basal Insulin in a Multiple Daily Inj. w/ Humalog in Adolescents w/ Type 1 Diabetes Mellitus: an Active-controlled, Open, Randomized, Gender-stratified, Two-arm, Parallel-group Study||Sanofi||Completed|November 2002|||February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2011|September 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00046501||203155|
NCT00047489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM01-646|Study of ABT-751 in Patients With Refractory Hematologic Malignancies|A Phase I Study of ABT-751 in Patients With Refractory Hematologic Malignancies||M.D. Anderson Cancer Center||Completed|December 2002|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|17 Years|N/A|No|||February 2012|February 20, 2012|October 8, 2002||||||https://clinicaltrials.gov/show/NCT00047489||203086|
NCT00047229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257565|Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)|A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|October 2002|||January 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2005|April 4, 2009|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00047229||203103|
NCT00046891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N00C9|EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer|The Use of Ginkgo Biloba For The Prevention Of Chemotherapy-Related Cognitive Dysfunction||Alliance for Clinical Trials in Oncology|Yes|Completed|December 2002|April 2015|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|226|||Female|18 Years|N/A|No|||November 2015|November 23, 2015|October 3, 2002|Yes|Yes||No|February 25, 2015|https://clinicaltrials.gov/show/NCT00046891||203125|
NCT00046527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA012-0|Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer|A Controlled, Randomized, Phase III, Multicenter, Open Label Study of ABI-007(a Cremophor Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol in Patients With Metastatic Breast Cancer||Celgene Corporation||Completed|June 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||460|||Both|16 Years|N/A|No|||October 2004|July 12, 2006|September 30, 2002||||||https://clinicaltrials.gov/show/NCT00046527||203153|
NCT00046592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1185|Mechanisms of Disability in Peripheral Arterial Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2002|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Both|59 Years|80 Years|No|||January 2008|February 17, 2016|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046592||203148|
NCT00046605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1186|Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2002|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 23, 2008|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046605||203147|
NCT00046618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1187|Mapping Novel Disease Genes for Dilated Cardiomyopathy|||Mayo Clinic||Completed|July 2002|June 2006|Actual|June 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||February 2014|February 19, 2014|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046618||203146|
NCT00046436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1031|Rapid HIV Tests for Women Late in Pregnancy and During Labor|Mother-Infant Rapid Intervention at Delivery (MIRIAD)||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||March 2004|Actual|||N/A|Observational|Time Perspective: Prospective||||7500|||Female|13 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 31, 2013|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046436||203160|
NCT00048035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16285|A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia|A Randomized, Open-label Study of Dose Conversion Factors for Maintenance Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia||Hoffmann-La Roche||Completed|February 2002|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|91|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|October 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048035||203046|
NCT00048048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16528|A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.|A Randomized, Open-label Study of the Effect of Different Dosing Intervals of Subcutaneous Mircera on Hemoglobin Level/Correction in Patients With Chronic Renal Anemia||Hoffmann-La Roche||Completed|March 2002|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|65|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|October 24, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048048||203045|
NCT00047957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030008|Brain Inhibition of Muscle Movement in Normal Volunteers|The Effect of Peripheral Homotopic and Heterotopic Stimulation on Cortical Excitability||National Institutes of Health Clinical Center (CC)||Completed|October 2002|September 2005||||N/A|Observational|N/A||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|October 22, 2002||||No||https://clinicaltrials.gov/show/NCT00047957||203051|
NCT00047970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-E-N-271|The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer|The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|August 2003|April 2015|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|50884|||Female|35 Years|74 Years|Accepts Healthy Volunteers|||November 2012|April 14, 2015|October 23, 2002||No||No||https://clinicaltrials.gov/show/NCT00047970||203050|
NCT00048282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNET/HPTN 055|HIV Prevention Preparedness Study|HIV Prevention Preparedness Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Time Perspective: Prospective||||1200|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2006|May 13, 2010|October 29, 2002||||No||https://clinicaltrials.gov/show/NCT00048282||203031|
NCT00046683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM307|Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia|A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia||Sanofi||Completed|July 2001|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||284|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|October 1, 2002||||||https://clinicaltrials.gov/show/NCT00046683||203141|
NCT00046696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-103|A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.|A Phase I and Pharmacokinetic Study of NM-3 Administered Orally Once or Twice Daily on Five Consecutive Days and Repeated Weekly for Six Weeks Every Eight Weeks in Patients With Advanced Solid Tumors.||Sanofi||Completed|May 2001|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|October 1, 2002||||||https://clinicaltrials.gov/show/NCT00046696||203140|
NCT00047463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB030633|Effects of Treating Obstructive Sleep Apnea in Epilepsy|Effects of Treating Obstructive Sleep Apnea in Epilepsy||Vanderbilt University|Yes|Completed|September 2002|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|October 7, 2002||No||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00047463||203088|Being a pilot study with a relatively small sample size, we were unable to isolate the effects of specific medications or seizure types on the presence of sleep apnea.
NCT00048360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK130934|Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults|An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder||GlaxoSmithKline||Completed|October 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||162|||Both|18 Years|60 Years|No|||February 2013|February 11, 2013|October 30, 2002||||||https://clinicaltrials.gov/show/NCT00048360||203025|
NCT00048594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-065|Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Patients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|January 2002|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|800|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048594||203007|
NCT00048607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-062|Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)|A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder||Merck Sharp & Dohme Corp.||Completed|July 2002|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|600|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048607||203006|
NCT00047307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01430|Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer|A Phase 1 Study of Alvocidib (Flavopiridol) in Combination With Radiation in Locally Advanced, Non-Operable Pancreatic and Extrahepatic Bile Duct Cancers||National Cancer Institute (NCI)||Completed|August 2002|||August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047307||203097|
NCT00047424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148|Stop Atherosclerosis in Native Diabetics Study (SANDS)|Stop Atherosclerosis in Native Diabetics Study (SANDS)||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|40 Years|N/A|No|||August 2008|February 4, 2009|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00047424||203091|
NCT00048490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030024|Transcranial Magnetic Stimulation to Treat Epilepsy|Drug-Refractory Neocortical Epilepsy: rTMS Treatment||National Institutes of Health Clinical Center (CC)||Completed|October 2002|October 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||70|||Both|N/A|N/A|No|||October 2004|March 3, 2008|October 31, 2002||||No||https://clinicaltrials.gov/show/NCT00048490||203015|
NCT00047476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|d-MPH-COG-002|D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients|Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of d-MPH in the Treatment of Fatigue and Neurobehavioral Impairment Related to Chemotherapy in Adult Cancer Patients||Celgene||Completed|June 2002|March 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|70 Years|No|||May 2004|June 23, 2005|October 8, 2002||||||https://clinicaltrials.gov/show/NCT00047476||203087|
NCT00047658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPF-002|A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label Extension||InterMune||Completed|November 2001|May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|20 Years|79 Years|No|||November 2007|November 2, 2007|October 9, 2002||||No||https://clinicaltrials.gov/show/NCT00047658||203073|
NCT00046085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH062135|Online Family Support and Education for Schizophrenia|Online Family Support and Education for Schizophrenia||National Institute of Mental Health (NIMH)||Active, not recruiting|March 2001|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||72|||Both|18 Years|60 Years|No|||December 2005|October 5, 2010|September 19, 2002||||No||https://clinicaltrials.gov/show/NCT00046085||203186|
NCT00046631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188|Community Characteristics and Physical Activity Among Adolescent Girls - Ancillary to TAAG|Community Characteristics and Physical Activity Among Adolescent Girls|TAAG2|RAND|No|Completed|August 2002|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1556|||Female|11 Years|14 Years|No|||March 2014|March 11, 2014|September 30, 2002||No||No||https://clinicaltrials.gov/show/NCT00046631||203145|
NCT00047320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0122|Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors|A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT||Children's Oncology Group|Yes|Active, not recruiting|January 2004|||February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|3 Years|24 Years|No|||September 2015|September 23, 2015|October 3, 2002|Yes|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT00047320||203096|
NCT00047450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063931|Antidepressant Treatment in Older Adults With Schizophrenia|Citalopram Augmentation in Older Patients With Schizophrenia||Veterans Medical Research Foundation|Yes|Completed|September 2001|September 2007|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|212|||Both|40 Years|N/A|No|||August 2013|August 6, 2013|October 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00047450||203089|
NCT00047918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030010|Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing|Investigation of Hematologic Parameters in Mastocytosis and Idiopathic Anaphylaxis||National Institutes of Health Clinical Center (CC)||Completed|October 2002|August 2004||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||August 2004|March 3, 2008|October 22, 2002||||No||https://clinicaltrials.gov/show/NCT00047918||203054|
NCT00047931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030022|HIV-1 Vaccine Test in Uninfected Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in Uninfected Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 2002|May 2009||||Phase 1|Interventional|Primary Purpose: Treatment|1|||50|||Both|18 Years|40 Years|No|||May 2009|May 6, 2009|October 22, 2002||No||No||https://clinicaltrials.gov/show/NCT00047931||203053|
NCT00046540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE-SN38-101|Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer|||INSYS Therapeutics Inc||Completed|October 2002|November 2010|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|September 30, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00046540||203152|
NCT00046644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1189|Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial|||Nemours Children's Clinic||Completed|June 2002|May 2005|Actual|May 2005|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2014|April 16, 2014|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046644||203144|
NCT00046657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1190|Longitudinal Study of Neighborhood Predictors of CVD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2007|Actual|August 2007|Actual|N/A|Observational|N/A|||||||Both|25 Years|N/A|No|||January 2008|January 18, 2008|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046657||203143|
NCT00046670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1191|Sleep Disordered Breathing, APOE, and Lipid Metabolism|||Stanford University||Completed|September 2002|April 2007|Actual|April 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||March 2014|March 4, 2014|September 30, 2002||||No||https://clinicaltrials.gov/show/NCT00046670||203142|
NCT00043407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C010|CPG 7909 in Patients Wih Stage IV Renal Cell Cancer|A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 In Patients With Stage Iv Renal Cell Carcinoma||Pfizer|No|Completed|March 2002|September 2004|Actual|September 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|August 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00043407||203366|
NCT00043420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C014|CPG 7909 in Patients With Cutaneous T-Cell Lymphoma|A Phase I/II Open Label, Multi-Center Study For The Evaluation Of Pf-3512676 (CPG 7909) In Patients With Stage Ib To Iva Cutaneous T-Cell Lymphoma||Pfizer|No|Completed|January 2003|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|42|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|August 8, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00043420||203365|
NCT00043433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-607-004|Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.|||Tularik||Active, not recruiting|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||April 2004|June 23, 2005|August 8, 2002||||||https://clinicaltrials.gov/show/NCT00043433||203364|
NCT00043446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-607-005|Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.|||Tularik||Active, not recruiting|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Female|18 Years|N/A|No|||April 2004|June 23, 2005|August 8, 2002||||||https://clinicaltrials.gov/show/NCT00043446||203363|
NCT00047944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030014|MRI Study of Brain Activity and Risk for Depression in Adolescents|Neural Circuitry and Risk for Depression in Adolescents: A Study Using Functional Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Completed|October 2002|||||N/A|Observational|N/A|||Actual|88|||Both|10 Years|55 Years|No|||January 2016|February 5, 2016|October 22, 2002||No||No||https://clinicaltrials.gov/show/NCT00047944||203052|
NCT00048256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030028|Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates|Exploring the Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates||National Institutes of Health Clinical Center (CC)||Completed|October 2002|September 2005||||N/A|Observational|N/A||||57|||Both|N/A|N/A|No|||September 2005|March 3, 2008|October 28, 2002||||No||https://clinicaltrials.gov/show/NCT00048256||203032|
NCT00048451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-020|Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)|Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)||Abbott||Completed|February 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|18 Years|N/A|No|||July 2006|July 31, 2006|October 31, 2002||||||https://clinicaltrials.gov/show/NCT00048451||203018|
NCT00048087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-004|Iressa/Docetaxel in Non-Small-Cell Lung Cancer|A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Combination With Docetaxel in Patients With Recurrent or Metastatic Advanced Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Withdrawn|August 2002|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||July 2012|July 27, 2012|October 24, 2002|Yes|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00048087||203042|
NCT00048477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030020|Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers|Determination of Nitrite as a Source of Bioactive Nitric Oxide in Human Subjects||National Institutes of Health Clinical Center (CC)||Completed|October 2002|November 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||42|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2003|March 3, 2008|October 31, 2002||||No||https://clinicaltrials.gov/show/NCT00048477||203016|
NCT00043732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005173|Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients in Active Rheumatoid Arthritis Receiving Methotrexate||Scios, Inc.||Completed||September 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|August 12, 2002||||||https://clinicaltrials.gov/show/NCT00043732||203343|
NCT00046319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB-220|Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension|A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Patients With Moderate to Severe Pulmonary Arterial Hypertension||Gilead Sciences||Completed|September 2002|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2009|April 15, 2009|September 26, 2002||||||https://clinicaltrials.gov/show/NCT00046319||203169|
NCT00046332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITG20001|A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients|A Phase II, Randomized, Placebo-controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Doses of S-1360 Versus Placebo Over 10 Days in ART-naive HIV-1 Infected Adults.||GlaxoSmithKline||Completed|June 2002|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|September 26, 2002||||||https://clinicaltrials.gov/show/NCT00046332||203168|
NCT00050648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0336|To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris|Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody and Cyclosporine for the Treatment of Active Psoriasis.||Rockefeller University|No|Completed|October 1997|April 2008|Actual|September 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|December 17, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050648||202863|
NCT00051701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM.NHL232|Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma||Sanofi||Terminated|December 2002|August 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||61|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|January 15, 2003||||||https://clinicaltrials.gov/show/NCT00051701||202786|
NCT00046371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STn-BR-105|Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients|Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex®||Oncothyreon Canada Inc.||Completed|August 2002|August 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2008|January 22, 2008|September 27, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00046371||203165|
NCT00046384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-077|Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder|||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|June 2002|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2007|November 7, 2013|September 27, 2002||||||https://clinicaltrials.gov/show/NCT00046384||203164|
NCT00046397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020316|Phase I Trial of Smallpox Vaccine|A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Dosing Schedule, Immunogenicity and Protective Efficacy Against Dryvax Challenge in Vaccinia-Naive Individuals||National Institutes of Health Clinical Center (CC)||Completed|September 2002|August 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||195|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2005|March 3, 2008|September 27, 2002||||No||https://clinicaltrials.gov/show/NCT00046397||203163|
NCT00047125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-24001-22005|Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor|Randomized Phase III Study On The Selection Of The Target Volume In Postoperative Radiotherapy For Cervical Lymph Node Metastases Of Squamous Cell Carcinoma From And Unknown Primary (CUP)||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Completed|July 2002|||July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Female|18 Years|N/A|No|||June 2012|June 19, 2012|October 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00047125||203110|
NCT00050141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004030|Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer|A Randomised, Blinded, Phase 2 Study of Letrozole Plus the Farnesyl Transferase Inhibitor ZARNESTRA TM (R115777) and Letrozole Plus Placebo in the Treatment of Advanced Breast Cancer After Antiestrogen Therapy.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2002|January 2008|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|121|||Female|50 Years|N/A|No|||January 2013|January 31, 2013|November 22, 2002|Yes|Yes||||https://clinicaltrials.gov/show/NCT00050141||202899|
NCT00051792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001168-01|Yoga for Treating Shortness of Breath in Chronic Obstructive Pulmonary Disease (COPD)|Efficacy of Yoga for Self-Management of Dyspnea in COPD||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2003|July 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|40 Years|N/A|No|||August 2006|August 16, 2006|January 16, 2003||||No||https://clinicaltrials.gov/show/NCT00051792||202779|
NCT00050427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004525|A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer|A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2002|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Female|18 Years|N/A|No|||April 2011|April 26, 2011|December 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050427||202878|
NCT00046345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-900|Atazanavir for HIV Infected Individuals: An Early Access Program|||Bristol-Myers Squibb||No longer available|May 2002|July 2003||||N/A|Expanded Access|N/A|||||||Both|16 Years|N/A|No|||April 2011|April 13, 2011|September 26, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00046345||203167|
NCT00045955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455P/3003|Long-Term Safety Performance of Fexofenadine in Asthma|A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects With Asthma||Sanofi||Completed|February 2002|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1200|||Both|12 Years|80 Years|No|||August 2008|August 20, 2008|September 17, 2002||||||https://clinicaltrials.gov/show/NCT00045955||203194|
NCT00050804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030036|Evaluation of Stress Disorders|Efficacy of an SSRI in Acute Stress Disorder and PTSD||National Institutes of Health Clinical Center (CC)||Completed|December 2002|February 2004||||Phase 4|Interventional|Primary Purpose: Treatment||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2004|March 3, 2008|December 19, 2002||||No||https://clinicaltrials.gov/show/NCT00050804||202852|
NCT00050479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030065|Laser and Medical Treatment of Diabetic Macular Edema|Preliminary Multi-Center Assessment of Laser and Medical Treatment of Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|December 2002|July 2006||||Phase 3|Interventional|Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||July 2006|July 18, 2006|December 9, 2002||||No||https://clinicaltrials.gov/show/NCT00050479||202875|
NCT00047138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257531|Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor|Nephroblastoma (Wilms Tumour) Clinical Trial And Study||National Cancer Institute (NCI)||Recruiting|January 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|350|||Both|N/A|18 Years|No|||June 2009|June 23, 2014|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00047138||203109|
NCT00050297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|598-CL-004|YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer|||Astellas Pharma Inc||Terminated||February 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2012|June 6, 2012|December 3, 2002||||||https://clinicaltrials.gov/show/NCT00050297||202888|
NCT00046904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257027|Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer|Phase III Placebo-Controlled, Randomized, Double-Blind Comparison Of Etanercept (Enbrel) Versus Placebo For The Treatment Of Cancer-Associated Weight Loss And Anorexia||Mayo Clinic|Yes|Completed|May 2003|||September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2011|May 4, 2011|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00046904||203124|
NCT00046423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-005-0|A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies|A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-Hematologic Malignancies||Celgene Corporation||Completed|April 2000|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||August 2006|July 14, 2008|September 30, 2002||||||https://clinicaltrials.gov/show/NCT00046423||203161|
NCT00046813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14009-1|Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1|High-Dose Versus Regular-Dose Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder||National Institute on Drug Abuse (NIDA)||Terminated|August 2001|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||August 2008|August 19, 2008|October 3, 2002|||Interim data analysis showed no effect between treatment groups|No||https://clinicaltrials.gov/show/NCT00046813||203131|
NCT00050310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020110|Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients|Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients||National Institutes of Health Clinical Center (CC)||Recruiting|February 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|N/A|99 Years|Accepts Healthy Volunteers|||October 2015|January 20, 2016|December 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00050310||202887|
NCT00050323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCREN-005-01|Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer|Phase 1/2 Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusion in Patients With AJCC Stage IV Renal Cell Carcinoma||Sanofi||Completed|November 2002|March 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|December 4, 2002||||||https://clinicaltrials.gov/show/NCT00050323||202886|
NCT00045916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3891|Optimizing Electroconvulsive Therapy for Depression|Optimization of Electroconvulsive Therapy||New York State Psychiatric Institute||Completed|February 2001|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|340|||Both|18 Years|N/A|No|||October 2008|August 9, 2013|September 13, 2002||No||No||https://clinicaltrials.gov/show/NCT00045916||203196|
NCT00050635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995AUS38|STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea|||Novartis||Completed|December 2002|July 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|December 17, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050635||202864|
NCT00046150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964/3006|12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.|12-Week, Multinational, Multicenter, Controlled, Open, 1:1 Randomized, Parallel Clinical Trial Comparing the Safety of HMR1964 and Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion (CSII) in Subjects With Type 1 Diabetes Mellitus||Sanofi||Completed|May 2002|December 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|59|||Both|18 Years|N/A|No|||June 2008|June 18, 2008|September 20, 2002||||||https://clinicaltrials.gov/show/NCT00046150||203182|
NCT00046163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD 426-403|A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension|A Phase IV, Multi-Center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled Study to Assess the Clinical Benefit of Three Doses of Midodrine Hydrochloride (ProAmatine®) in Subjects With Neurogenic Orthostatic Hypotension||Shire||Terminated|September 2002|August 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||November 2007|November 2, 2007|September 20, 2002|||Study was terminated due to poor enrollment|||https://clinicaltrials.gov/show/NCT00046163||203181|
NCT00050388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCL-1005-207|Phase II Trial of Allovectin-7® for Head and Neck Cancer|Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx||Vical||Completed||June 2002||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2008|June 20, 2008|December 6, 2002||||||https://clinicaltrials.gov/show/NCT00050388||202881|
NCT00045994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0107-Silver|The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling|Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SILVER Study||Synvista Therapeutics, Inc||Completed|August 2001|June 2003|Actual|January 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|50 Years|N/A|No|||August 2007|July 28, 2009|September 17, 2002||||||https://clinicaltrials.gov/show/NCT00045994||203191|
NCT00046020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B-100469|Study Evaluating Venlafaxine ER in Recurrent Depression|An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2000|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Actual|1096|||Both|18 Years|N/A|No|||August 2009|August 13, 2009|September 18, 2002||||||https://clinicaltrials.gov/show/NCT00046020||203190|
NCT00046033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5135|Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance|A Phase II, Randomized, Open-Label Study Comparing Fixed-Dose Versus Concentration-Adjusted Lopinavir/Ritonavir Therapy in HIV-Infected Subjects on Salvage Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||118|||Both|18 Years|70 Years|No|||May 2005|February 28, 2011|September 18, 2002||||No||https://clinicaltrials.gov/show/NCT00046033||203189|
NCT00047112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257600|Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer|Randomized Study of Pre-Operative Radio-Chemotherapy Versus Surgery Alone in Thoracic Esophageal Cancer Deemed to be Resectable||Federation Francophone de Cancerologie Digestive||Completed|May 2002|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|195|||Both|N/A|74 Years|No|||February 2005|March 3, 2014|October 3, 2002||No||No||https://clinicaltrials.gov/show/NCT00047112||203111|
NCT00050232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-AVR-106|Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients|||Avanir Pharmaceuticals|No|Completed|December 2002|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|18 Years|68 Years|No|||May 2014|May 5, 2014|December 2, 2002||||No||https://clinicaltrials.gov/show/NCT00050232||202892|
NCT00050674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD01-20010120|Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma|Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma||Schwartzberg, Lee, M.D.|No|Completed|November 2001|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2012|December 26, 2012|December 17, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050674||202861|
NCT00050622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062946|Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)|ADHD Treatment: Comparative and Combined Dosage Effects||State University of New York at Buffalo||Completed|September 2001|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||144|||Both|5 Years|12 Years|No|||November 2011|November 3, 2011|December 16, 2002||||No||https://clinicaltrials.gov/show/NCT00050622||202865|
NCT00045942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPKC412A2104|PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3|An Open-label, Phase I/II Trial of PKC412 in Patients With Acute Myeloid Leukemia and Patients With Myelodysplastic Syndrome With Either Wild Type or Mutated FLT3||Novartis|No|Completed|January 2002|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|September 16, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00045942||203195|
NCT00050661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0337|To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris|Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody/ Placebo to Prevent Relapse of Psoriasis Vulgaris Following NBUVB Therapy||Rockefeller University|No|Completed|October 1997|April 2008|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|December 17, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050661||202862|
NCT00046852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000256870|Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma|High-Dose Therapy and Autologous Blood Stem Cell Transplantation (ASCT) Followed by Post-Transplant Immunotherapy With Costimulated Autologous T-Cells in Conjunction With Pneumococcal Conjugate Vaccine Immunization for Patients With Multiple Myeloma||University of Maryland||Completed|December 2001|February 2008|Actual|November 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||September 2009|September 23, 2009|October 3, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00046852||203128|
NCT00047073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257255|Sirolimus in Treating Patients With Glioblastoma Multiforme|A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme||Jonsson Comprehensive Cancer Center|Yes|Completed|July 2002|October 2007|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|October 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00047073||203113|
NCT00047099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-ADEBAR|Combination Chemotherapy in Treating Women With Breast Cancer|A Randomized Phase III Trial Comparing FEC-Chemotherapy vs. EC-Doc-Chemotherapy in Patients With Primary Breast Cancer||National Cancer Institute (NCI)||Completed|August 2001|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|446|||Female|18 Years|70 Years|No|||December 2002|May 29, 2013|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00047099||203112|
NCT00046059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000058|Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)|Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)||National Institutes of Health Clinical Center (CC)||Suspended|February 2000|||||N/A|Observational|N/A|||Actual|3481|||Both|7 Years|N/A|No|||January 2016|February 3, 2016|September 18, 2002||No||No||https://clinicaltrials.gov/show/NCT00046059||203188|
NCT00046072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5564-A001-201|A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis|A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis||Eisai Inc.||Completed|October 2001|April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|85 Years|No|||December 2005|December 8, 2005|September 19, 2002||||||https://clinicaltrials.gov/show/NCT00046072||203187|
NCT00046943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257127|Atrasentan in Treating Patients With Prostate Cancer|A Phase III Extension Study to Evaluate the Safety of 10 mg Atrasentan in Men With Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|September 2002|||June 2007|Actual|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|19 Years|N/A|No|||September 2003|February 18, 2011|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00046943||203121|
NCT00046969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGOSG-OVAR-MO16375-MARCH|Epoetin Beta in Treating Anemia in Patients With Cervical Cancer|Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin)||National Cancer Institute (NCI)||Completed|July 2002|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|450|||Female|18 Years|N/A|No|||March 2007|May 29, 2013|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00046969||203120|
NCT00047164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020284|Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy|A Pilot Study of Ipilimumab (MDX-CTLA4, MDX-010) in Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|September 2002|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||March 2012|April 30, 2012|October 3, 2002|Yes|Yes||||https://clinicaltrials.gov/show/NCT00047164||203108|
NCT00050336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01901|Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)|A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.||Terminated|December 2002|March 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|702|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|December 4, 2002||||||https://clinicaltrials.gov/show/NCT00050336||202885|
NCT00050349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2212|EPO906 in Carcinoid and Other Neuroendocrine Tumors|EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors||Novartis||Completed|July 2002|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|December 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050349||202884|
NCT00046111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864-A/565|A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors|A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors||GlaxoSmithKline||Completed|September 2001|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|September 19, 2002||||No||https://clinicaltrials.gov/show/NCT00046111||203185|
NCT00050791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFN 0357|Effects of Leptin Treatment on Weight Loss|Leptin Treatment for Prevention of the Metabolic and Endocrine Sequelae of a Decreased Caloric Intake: Studies of Patients on a Very Low Calorie Diet||Rockefeller University|No|Completed|March 2001|June 2009|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 18, 2010|December 19, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050791||202853|
NCT00046241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK130930|Prevention of Seasonal Affective Disorder|A 7 Month, Multicenter, Randomized, Double-blind, Placebo-controlled Comparison of 150-300mg/Day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase||GlaxoSmithKline||Completed|September 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|September 24, 2002||||||https://clinicaltrials.gov/show/NCT00046241||203175|
NCT00046254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2310|Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture|||Novartis||Completed|February 2002|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2127|||Both|50 Years|N/A|No|||May 2012|May 1, 2012|September 24, 2002||||||https://clinicaltrials.gov/show/NCT00046254||203174|
NCT00050401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3591IL/0082|Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support|Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia||AstraZeneca||Completed|July 2002|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|December 8, 2002||||||https://clinicaltrials.gov/show/NCT00050401||202880|
NCT00046189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020313|Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum|Cancer Risk in Xeroderma Pigmentosum Heterozygotes||National Institutes of Health Clinical Center (CC)||Recruiting|September 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|800|||Both|1 Year|99 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|September 21, 2002||No||No||https://clinicaltrials.gov/show/NCT00046189||203179|
NCT00046787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-12|Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer|Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer||Astellas Pharma Inc||Completed|September 2002|February 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||47|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|October 3, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00046787||203133|
NCT00046800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-20|Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer|A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer||Astellas Pharma Inc||Completed|September 2002|March 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Female|18 Years|N/A|No|||October 2011|October 18, 2011|October 3, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00046800||203132|
NCT00050245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030057|Rituximab to Treat Neuropathy With Anti-MAG Antibodies|Safety, Tolerability, and Efficacy of Rituximab in Patients With Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy: A Double-Blind Placebo-Controlled Randomized Trial||National Institutes of Health Clinical Center (CC)||Completed|November 2002|October 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||30|||Both|25 Years|80 Years|No|||October 2007|November 25, 2009|December 2, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00050245||202891|
NCT00047047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01429|Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of Gemcitabine, 17-Allylaminogeldanamycin (17-AAG) And Cisplatin In Advanced Solid Tumor Patients||National Cancer Institute (NCI)||Completed|August 2002|||September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047047||203115|
NCT00047060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020250|Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome|A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H||National Institutes of Health Clinical Center (CC)||Recruiting|July 2002|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||April 2015|December 10, 2015|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047060||203114|
NCT00046722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-SF-101|Marijuana for HIV-Related Peripheral Neuropathy|Effects of Marijuana on Neuropathic Pain in HIV-Related Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study.||Center for Medicinal Cannabis Research||Completed|January 2003|April 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|October 1, 2002||||||https://clinicaltrials.gov/show/NCT00046722||203138|
NCT00050778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMMS223|A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis|A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis||Sanofi|Yes|Completed|December 2002|January 2010|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|334|||Both|18 Years|50 Years|No|||January 2015|January 6, 2015|December 19, 2002|Yes|Yes||No|November 3, 2008|https://clinicaltrials.gov/show/NCT00050778||202854|
NCT00046761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2506/INT0104|A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke|A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke||Ono Pharmaceutical Co. Ltd||Terminated|November 2002|||May 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1320|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|October 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00046761||203135|
NCT00046124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8957-CP-001|Organophosphate Pesticides and Human Reproductive Health|||National Institute of Environmental Health Sciences (NIEHS)||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|20 Years|34 Years|Accepts Healthy Volunteers|||September 2006|September 1, 2006|September 20, 2002||||No||https://clinicaltrials.gov/show/NCT00046124||203184|
NCT00046137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6817|Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis|||Eli Lilly and Company||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Female|45 Years|85 Years|No|||July 2006|July 19, 2006|September 20, 2002||||||https://clinicaltrials.gov/show/NCT00046137||203183|
NCT00050817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4505|Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)|A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.||Sanofi||Completed|October 2002|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|15603|||Both|45 Years|N/A|No|||April 2012|April 20, 2012|December 20, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00050817||202851|
NCT00046176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESS30008|A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients|A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients.||GlaxoSmithKline|No|Completed|August 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||May 2011|June 2, 2011|September 20, 2002||||||https://clinicaltrials.gov/show/NCT00046176||203180|
NCT00046267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5148|Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients|A Pilot Study of the Safety, Efficacy, and Tolerability of Extended-Release Niacin (Niaspan) for the Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||May 2006|February 28, 2011|September 24, 2002||||No||https://clinicaltrials.gov/show/NCT00046267||203173|
NCT00046774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020272|Monoclonal Antibody Treatment for Systemic Lupus Erythematosus|A Phase I, Open-Labeled, Dose-Ascending Clinical Trial of Immunotherapy of MRA, A Humanized Anti-IL 6 Receptor Monoclonal Antibody, In Patients With Systemic Lupus Erythematosus||National Institutes of Health Clinical Center (CC)||Completed|September 2002|July 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|October 2, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00046774||203134|
NCT00049998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864-A/387|Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer|An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non Small Cell Lung Cancer||GlaxoSmithKline||Completed|October 2001|||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||760|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|November 18, 2002||||||https://clinicaltrials.gov/show/NCT00049998||202910|
NCT00047177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257562|Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor|A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors||Pediatric Brain Tumor Consortium|Yes|Completed|October 2002|July 2007|Actual|August 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|N/A|21 Years|No|||October 2009|October 14, 2009|October 3, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00047177||203107|
NCT00050414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004057|A Study of Trabectedin in Patients With Advanced Ovarian Cancer|Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2002|September 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Female|18 Years|N/A|No|||January 2013|January 9, 2013|December 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050414||202879|
NCT00046735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-ST-003|Phase 1 Study OF CDC-501 in Patients With Solid Tumors|A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors||Celgene||Completed|June 2002|September 2006|Actual|August 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|October 2, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00046735||203137|
NCT00046215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020312|Transcranial Magnetic Stimulation to Study Imagination of Movement|Effect of Transcranial Magnetic Stimulation to Dorsal Premotor Cortex on Motor Imagination||National Institutes of Health Clinical Center (CC)||Completed|September 2002|November 2003||||N/A|Observational|N/A||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2003|March 3, 2008|September 21, 2002||||No||https://clinicaltrials.gov/show/NCT00046215||203177|
NCT00050466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030012|Dynamic Light Scattering and Keratoscopy for Corneal Examination|A Pilot Study Using the Dynamic Light Scattering Device (DLS) Combined With Keratoscopy on the Cornea in Vivo||National Institutes of Health Clinical Center (CC)||Completed|December 2002|September 2005||||N/A|Observational|N/A||||24|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|December 9, 2002||||No||https://clinicaltrials.gov/show/NCT00050466||202876|
NCT00046358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020305|The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease|The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-Amyloid||National Institutes of Health Clinical Center (CC)||Completed|September 2002|August 2005||||Phase 4|Interventional|Primary Purpose: Treatment||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2005|March 3, 2008|September 26, 2002||||No||https://clinicaltrials.gov/show/NCT00046358||203166|
NCT00046748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2306|Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma|Ph III, 28-wk, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess Efficacy, Safety, Tolerability of SC Omalizumab in Adults and Adolescents w/ Severe Persist. Allergic Asthma & Are Inadequately Controlled Despite GINA (2002) Step 4 Tx||Novartis||Completed|December 2001|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|484|||Both|12 Years|75 Years|No|||October 2011|October 24, 2011|October 2, 2002||||||https://clinicaltrials.gov/show/NCT00046748||203136|
NCT00046280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACS|HIV Infection in Homosexual and Bisexual Men|||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting||||||N/A|Observational|Time Perspective: Prospective||||1100|||Male|18 Years|N/A|No|||November 2005|November 2, 2012|September 24, 2002||||No||https://clinicaltrials.gov/show/NCT00046280||203172|
NCT00046293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020301|ReoPro and Retavase to Treat Acute Stroke|ReoPro Retavase Reperfusion of Stroke Safety Study-Imaging Evaluation With Computed Tomography (ROSIE-CT)||National Institutes of Health Clinical Center (CC)||Completed|September 2002|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|80 Years|No|||April 2011|April 9, 2011|September 25, 2002||No||No||https://clinicaltrials.gov/show/NCT00046293||203171|
NCT00046410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020314|Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting|Assessing the Risk of New Ischemic Brain Lesions With On- Versus Off-Pump Coronary Artery Bypass Grafting||National Institutes of Health Clinical Center (CC)||Completed|September 2002|November 2007||||N/A|Observational|N/A||||340|||Both|18 Years|N/A|No|||November 2007|September 26, 2015|September 27, 2002||||No||https://clinicaltrials.gov/show/NCT00046410||203162|
NCT00046930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257122|Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia|A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts||Eastern Cooperative Oncology Group|Yes|Completed|July 2002|||June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|449|||Both|60 Years|N/A|No|||June 2015|June 1, 2015|October 3, 2002|Yes|Yes||No|August 17, 2010|https://clinicaltrials.gov/show/NCT00046930||203122|
NCT00052156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-MMAIT-4-001|Vaccine Therapy for Patients With Stage IV Melanoma|A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma||CancerVax Corporation||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||670|||Both|18 Years|80 Years|No|||April 2005|June 23, 2005|January 23, 2003||||||https://clinicaltrials.gov/show/NCT00052156||202751|
NCT00052169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-IR-002|Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer|A Phase 2, Multi-Center Trial of ZD1839 (IRESSA) in Combination With Docetaxel as First-Line Treatment in Patients With Advanced Breast Cancer||NSABP Foundation Inc|No|Completed|January 2003|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||December 2007|December 13, 2007|January 24, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00052169||202750|
NCT00050440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004429|Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma|A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2002|July 2004|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||January 2013|January 7, 2013|December 9, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050440||202877|
NCT00046228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005410|A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)|A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.||Centocor, Inc.||Completed|August 2002|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2461|||Both|21 Years|N/A|No|||July 2014|July 25, 2014|September 24, 2002|Yes|Yes||No|March 26, 2009|https://clinicaltrials.gov/show/NCT00046228||203176|Some AEs were collected separately per protocol and are reported as “Other Pre-Specified Outcomes Measures”.
NCT00052520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1655.00|Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation|Phase I/II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant||Fred Hutchinson Cancer Research Center|No|Completed|September 2002|June 2013|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|N/A|No|||July 2013|July 3, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052520||202726|
NCT00046995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257228|Combination Chemotherapy in Treating Patients With Colon Cancer|5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03).||National Cancer Institute (NCI)||Active, not recruiting|May 2001|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Both|18 Years|N/A|No|||November 2002|September 19, 2013|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00046995||203119|
NCT00047190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02804|Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia|A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM)||National Cancer Institute (NCI)||Completed|August 2002|||April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00047190||203106|
NCT00046917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00023|Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Irinotecan (CPT-11) and Cisplatin in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|July 2002|||March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2011|February 21, 2014|October 3, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00046917||203123|
NCT00050076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-MCC135-001|Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.|A Phase II, Double-Blind, Randomized, Exploratory, Placebo-Controlled Study of Efficacy, Safety, and Tolerability of MCC-135 Comparing QD vs BID Doses in Subjects With Congestive Heart Failure, NYHA Class II/III||Takeda|No|Completed|August 2002|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|204|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|November 20, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050076||202904|
NCT00051402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000567-01A1|Phytoestrogens and Memory Decline in Menopause|Phytoestrogens and Cognition in Menopause||National Center for Complementary and Integrative Health (NCCIH)||Completed|December 2002|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Female|62 Years|N/A|No|||October 2007|October 24, 2007|January 9, 2003||||No||https://clinicaltrials.gov/show/NCT00051402||202807|
NCT00051688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEZ101|Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer|||Chiron Corporation||Terminated|June 2003|August 2004||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 10, 2006|January 15, 2003||||||https://clinicaltrials.gov/show/NCT00051688||202787|
NCT00049517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258113|Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia|A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation||Eastern Cooperative Oncology Group|Yes|Active, not recruiting|December 2002|October 2016|Anticipated|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|657|||Both|16 Years|60 Years|No|||October 2015|October 6, 2015|November 12, 2002|Yes|Yes||No|January 10, 2013|https://clinicaltrials.gov/show/NCT00049517||202945|
NCT00049699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-028|VNP40101M in Treating Patients With Advanced or Metastatic Cancer|A Phase I Trial of VNP40101M, a Novel Alkylating Agent, Administered Weekly for Patients With Advanced or Metastatic Cancer||National Cancer Institute (NCI)||Completed|October 2002|January 2008|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2004|July 17, 2013|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049699||202933|
NCT00049725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030046|Daclizumab to Treat Chronic Immune Thrombocytopenia|A Study of Daclizumab in Chronic Immune Thrombocytopenia (ITP)||National Institutes of Health Clinical Center (CC)||Completed|November 2002|December 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||December 2004|March 3, 2008|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049725||202931|
NCT00049374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258058|Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma||University of Maryland||Completed|September 2002|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|September 23, 2009|November 12, 2002||Yes||No||https://clinicaltrials.gov/show/NCT00049374||202953|
NCT00049387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03106|Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|September 2002|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2013|April 14, 2015|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049387||202952|
NCT00050492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030068|Biological Markers in Retinal Vasculitis|Identification of Biological Markers in Retinal Vasculitis||National Institutes of Health Clinical Center (CC)||Completed|December 2002|September 2006||||N/A|Observational|N/A||||200|||Both|10 Years|N/A|No|||September 2006|September 26, 2015|December 9, 2002||||No||https://clinicaltrials.gov/show/NCT00050492||202874|
NCT00050505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-007|Expanded Dryvax Dilution Study in Previously Vaccinated Adults|A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2002|December 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|927|||Both|32 Years|70 Years|Accepts Healthy Volunteers|||July 2009|December 4, 2014|December 10, 2002||||No||https://clinicaltrials.gov/show/NCT00050505||202873|
NCT00050518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-054|APSV in Vaccinia Naive Adults|A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults.||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||444|||Both|18 Years|32 Years|Accepts Healthy Volunteers|||March 2010|August 26, 2010|December 11, 2002||||||https://clinicaltrials.gov/show/NCT00050518||202872|
NCT00050531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-534|High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)|Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia With High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination With Peg-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF)||M.D. Anderson Cancer Center|Yes|Completed|April 2003|||August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|December 12, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050531||202871|
NCT00050700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030001|Brain Imaging in Depression|Muscarinic Cholinergic Receptor Imaging in Depression||National Institutes of Health Clinical Center (CC)||Completed|December 2002|May 2010||||N/A|Observational|N/A|||Actual|107|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 15, 2010|December 17, 2002||No||No||https://clinicaltrials.gov/show/NCT00050700||202859|
NCT00050713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030071|Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy|Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy||National Institutes of Health Clinical Center (CC)||Completed|December 2002|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|13 Years|N/A|No|||July 2015|July 8, 2015|December 17, 2002||No||No||https://clinicaltrials.gov/show/NCT00050713||202858|
NCT00050752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030066|Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer|Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|December 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|800|||Both|4 Years|65 Years|No|||September 2015|October 6, 2015|December 17, 2002||No||No||https://clinicaltrials.gov/show/NCT00050752||202856|
NCT00050102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX010-08|Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma|A Randomized Study Comparing MDX-010 (CTLA-4) Alone or in Combination With DTIC in the Treatment of Patients With Chemotherapy Naїve Metastatic Melanoma.||Bristol-Myers Squibb||Completed|October 2002|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2011|January 20, 2011|November 21, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050102||202902|
NCT00050167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-580|Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer|Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer||M.D. Anderson Cancer Center|No|Completed|November 2002|August 2011|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|603|||Female|N/A|N/A|No|||August 2011|August 25, 2011|November 25, 2002|No|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00050167||202897|
NCT00050180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030052|Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers|Influence of MDR1 Genotype on Indinavir and Saquinavir Pharmacokinetics in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|November 2002|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|60 Years|No|||May 2012|May 4, 2012|November 25, 2002||No||No||https://clinicaltrials.gov/show/NCT00050180||202896|
NCT00050115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030051|Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia|Collection of Blood, Stool, Bone Marrow and/or Tissue Samples From Subjects With Hepatitis-Associated Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Completed|November 2002|||||N/A|Observational|Time Perspective: Prospective|||Actual|9|||Both|2 Years|N/A|No|||April 2015|April 24, 2015|November 21, 2002||No||No||https://clinicaltrials.gov/show/NCT00050115||202901|
NCT00050206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4360|Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder|Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder||Eli Lilly and Company||Completed|November 2002|May 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|13 Years|17 Years|No|||June 2007|June 11, 2007|November 26, 2002||||||https://clinicaltrials.gov/show/NCT00050206||202894|
NCT00050219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030042|Role of Dopamine in Response to Alcohol|Striatal Dopamine and Alcohol Risk||National Institutes of Health Clinical Center (CC)||Completed|November 2002|September 2004||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2004|March 3, 2008|November 29, 2002||||No||https://clinicaltrials.gov/show/NCT00050219||202893|
NCT00050128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030049|Preliminary Study of Transcranial Magnetic Stimulation for Stroke Rehabilitation|Repetitive Transcranial Magnetic Stimulation in Chronic Stroke Patients. Dose Effect on Motor Cortex Excitability, Motor Performance, and Safety Using Different Stimulation Parameters||National Institutes of Health Clinical Center (CC)||Completed|November 2002|October 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||October 2007|September 26, 2015|November 21, 2002||||No||https://clinicaltrials.gov/show/NCT00050128||202900|
NCT00048750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0-124|Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU|A Phase 3, Randomized,Double-Blind, Comparative Study of Micafungin (FK463) Versus Placebo as Preemptive Prophylactic Antifungal Therapy in Patients in the Intensive Care Unit||Astellas Pharma Inc|Yes|Terminated|January 2003|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|16 Years|N/A|No|||March 2008|March 26, 2012|November 6, 2002|No|Yes|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT00048750||202995|
NCT00048763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-01-335|Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon|||Otsuka America Pharmaceutical||Completed|October 2001|June 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|5 Years|16 Years|No|||July 2005|July 14, 2005|November 7, 2002||||||https://clinicaltrials.gov/show/NCT00048763||202994|
NCT00049114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02500|Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer|A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|February 2003|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|18 Years|N/A|No|||June 2013|June 5, 2013|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049114||202970|
NCT00049127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01576|Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor|Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma||National Cancer Institute (NCI)||Active, not recruiting|June 2003|||August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||August 2014|October 1, 2014|November 12, 2002|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00049127||202969|
NCT00049361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258057|Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases|A Phase II Study Of Whole-Brain Radiation Therapy With Thalidomide And Temozolomide In Patients With Newly Diagnosed Brain Metastases||Wake Forest Baptist Health||Completed|January 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049361||202954|
NCT00049257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258050|Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Paclitaxel and Carboplatin in the Treatment of Hormone-Refractory Prostate Cancer (HRPC)||Jonsson Comprehensive Cancer Center|Yes|Completed|October 2002|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Male|18 Years|N/A|No|||August 2012|October 1, 2015|November 12, 2002|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00049257||202961|The major weakness of the study is, it is a single-arm non-comparative study. With the small sample size of 58 participants who received treatment, the study does not have the statistical power to make categorical assessments or statements.
NCT00049283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03113|Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer|A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck||National Cancer Institute (NCI)||Completed|September 2002|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|June 5, 2014|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049283||202960|
NCT00049504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1667.00|Fludarabine Phosphate, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Total-Body Irradiation, and Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer|Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation||Fred Hutchinson Cancer Research Center|No|Completed|January 2002|February 2014|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|N/A|N/A|No|||February 2014|February 27, 2014|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049504||202946|
NCT00049712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257810|Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma|A Phase I Study Of Medi 522 In Patients With Advanced Tumors||University of Wisconsin, Madison||Completed|October 2002|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2015|July 22, 2015|November 12, 2002||Yes||||https://clinicaltrials.gov/show/NCT00049712||202932|
NCT00050570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060453|Reducing Eating Disorder Risk Factors|Interventions to Reduce Eating Disorder Risk Factors||Stanford University||Completed|February 2001|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|206|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|December 16, 2002||No||No||https://clinicaltrials.gov/show/NCT00050570||202869|
NCT00050726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010171|Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2|Substudies of ESPRIT: ESPRIT Influenza Vaccine Substudy (FLUVAC) and ESPRIT Tetanus-Pneumococcal Vaccine Substudy (TEPVAC)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2001|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1|||620|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|December 17, 2002||No||No||https://clinicaltrials.gov/show/NCT00050726||202857|
NCT00049569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01798|Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia|Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse||National Cancer Institute (NCI)||Completed|January 2003|||March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|1 Year|21 Years|No|||October 2013|October 7, 2013|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049569||202941|
NCT00049764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6716|Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis|Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis||Eli Lilly and Company|Yes|Completed|November 2002|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|474|||Both|N/A|17 Years|No|||November 2007|November 15, 2007|November 13, 2002||||No||https://clinicaltrials.gov/show/NCT00049764||202928|
NCT00050687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP-370-01-01|Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies|A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies||Titan Pharmaceuticals||Terminated|June 2001|March 2005|Actual|March 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2006|January 21, 2011|December 17, 2002||||||https://clinicaltrials.gov/show/NCT00050687||202860|
NCT00050193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030041|Cause and Natural Course of Pediatric-Onset Mastocytosis|Determining the Pathogenesis of Systemic Pediatric-Onset Mastocytosis||National Institutes of Health Clinical Center (CC)||Completed|November 2002|March 2014||||N/A|Observational|N/A|||Actual|103|||Both|N/A|21 Years|No|||March 2014|March 11, 2014|November 25, 2002||No||No||https://clinicaltrials.gov/show/NCT00050193||202895|
NCT00049972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB29060.833|Major Depressive Disorder Study In Adults|An Open Label Study Assessing Paxil CR (Paroxetine CR) in Patients With Major Depressive Disorder Who Discontinued Treatment With Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor Due to Intolerability||GlaxoSmithKline||Completed|September 2002|September 2003|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||646|||Both|18 Years|N/A|No|||October 2010|October 4, 2010|November 18, 2002||||||https://clinicaltrials.gov/show/NCT00049972||202912|
NCT00049985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010170|Heart Failure and Anemia|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects With Symptomatic Heart Failure (CHF) and Anemia.||Amgen||Completed|July 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||300|||Both|21 Years|N/A|No|||August 2009|August 6, 2009|November 18, 2002||||||https://clinicaltrials.gov/show/NCT00049985||202911|
NCT00050089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512|CSP #512 - Options in Management With Anti-Retrovirals|CSP #512 - Options in Management With Anti-Retrovirals (OPTIMA), Management of Patients With HIV Infection for Whom First and Second-line Highly Active Anti-Retroviral Therapy Has Failed|OPTIMA|VA Office of Research and Development|No|Completed|January 2001|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|368|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|November 20, 2002||No||No|September 11, 2013|https://clinicaltrials.gov/show/NCT00050089||202903|
NCT00049946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB223412/078|Schizophrenia Study In Adults|A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia||GlaxoSmithKline||Completed|October 2002|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||231|||Both|18 Years|65 Years|No|||February 2013|February 11, 2013|November 15, 2002||||||https://clinicaltrials.gov/show/NCT00049946||202914|
NCT00049296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU4Y01|Thalidomide and Docetaxel in Treating Patients With Advanced Cancer|Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles||Case Comprehensive Cancer Center|Yes|Completed|July 2002|January 2006|Actual|December 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00049296||202959|
NCT00048854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0108012595|Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder|Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder||Yale University|Yes|Completed|September 2001|January 2008|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|18 Years|48 Years|No|||January 2016|January 11, 2016|November 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048854||202987|
NCT00049140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257828|EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer|Pilot Study of the Relationship Between EF5 Uptake and Concentration of Oxygen-Related Metabolites in Head and Neck Cancer||Duke University||Completed|August 2002|||October 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|N/A|No|||February 2013|July 24, 2014|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049140||202968|
NCT00049218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13427|Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I-II Trial Using Dendritic Cells Transduced With An Adenoviral Vector Containing The p53 Gene To Immunize Patients With Extensive Stage Small Cell Lung Cancer After Standard Chemotherapy||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|April 2003|May 2014|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|November 12, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00049218||202964|
NCT00049543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00650|Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery|A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer||National Cancer Institute (NCI)|Yes|Completed|September 2002|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|503|||Both|18 Years|N/A|No|||March 2014|December 19, 2014|November 12, 2002|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00049543||202943|
NCT00049751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-498|Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis|A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis||Abbott||Completed|September 2002|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||3000|||Both|18 Years|N/A|No|||August 2006|August 13, 2006|November 13, 2002||||||https://clinicaltrials.gov/show/NCT00049751||202929|
NCT00049686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-029|VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome|A Phase I Trial Of VNP40101M, A Novel Alkylating Agent, For Patients With Hematologic Malignancies||National Cancer Institute (NCI)||Completed|April 2002|January 2008|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2003|July 17, 2013|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049686||202934|
NCT00049335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258049|S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed|Protocol For Assessment Of Capecitabine For Advanced Colorectal Cancer In Patients Aged 70 Years And Older (And In A Cohort Of Patients Younger Than 60 Years)||Southwest Oncology Group|Yes|Completed|February 2003|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|November 12, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00049335||202956|
NCT00049348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258056|Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Randomized Phase II Study Of Gemcitabine Plus Radiotherapy Vs. Gemcitabine, 5-Fluorouracil And Cisplatin Followed By Radiotherapy And 5-Fluoraracil For Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma||Eastern Cooperative Oncology Group|No|Completed|May 2003|||October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2005|November 12, 2010|November 12, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00049348||202955|
NCT00049556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258117|Gefitinib in Treating Patients With Cervical Cancer|Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or Cervical Cancer||National Cancer Institute (NCI)||Completed|October 2002|August 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2006|June 18, 2013|November 12, 2002||||||https://clinicaltrials.gov/show/NCT00049556||202942|
NCT00049413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258096|Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma|Pentostatin, Cyclophosphamide And Rituximab (PCR) For B-Cell Chronic Lymphocytic Leukemia (CLL) And Small B-Cell Lymphocytic Lymphoma (SLL): Four Phase II Trials With Patient Stratification Based On Prior Therapy||Hoag Memorial Hospital Presbyterian|No|Completed|June 2002|December 2005|Actual|December 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2011|May 10, 2011|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00049413||202950|
NCT00050856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030056|Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection|Multicenter, Open-Label, Early Acces Program of Fuzeon (Enfuvirtide T-20/Ro 29,9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiretroviral Regimen to Assess Serious Adverse Events, Serious AIDS-Defining Events, and Tolerability in Patient||National Institutes of Health Clinical Center (CC)||Completed|November 2002|November 2003||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||November 2003|March 3, 2008|December 23, 2002||||No||https://clinicaltrials.gov/show/NCT00050856||202848|
NCT00049166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03155|Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer|A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV||National Cancer Institute (NCI)||Completed|October 2002|||July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049166||202967|
NCT00050869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030074|Learning a Motor Task Through Observation|Encoding a Motor Memory by Action Observation||National Institutes of Health Clinical Center (CC)||Completed|December 2002|November 2007||||N/A|Observational|N/A||||56|||Both|18 Years|80 Years|No|||November 2007|March 5, 2008|December 27, 2002||||No||https://clinicaltrials.gov/show/NCT00050869||202847|
NCT00050895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5142|Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients|A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||775|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|December 30, 2002||||||https://clinicaltrials.gov/show/NCT00050895||202845|
NCT00050596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX010-07|Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer|A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose of Docetaxel in Patients With Hormone-Refractory Prostate Cancer||Bristol-Myers Squibb||Completed|November 2002|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2011|June 23, 2011|December 16, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00050596||202867|
NCT00050609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4979|Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of IC351 (LY450190) in Patients With Diabetic Gastroparesis||Eli Lilly and Company|No|Completed|February 2003|September 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|69 Years|No|||November 2007|November 16, 2007|December 16, 2002||||No||https://clinicaltrials.gov/show/NCT00050609||202866|
NCT00050154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004027|Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)|An Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of the Farnesyl-Transferase Inhibitor ZARNESTRA(tm) (R115777) in Subjects With High-Risk Myelodysplastic Syndrome (MDS)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2002|May 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|82|||Both|18 Years|N/A|No|||April 2010|April 23, 2010|November 22, 2002||||||https://clinicaltrials.gov/show/NCT00050154||202898|
NCT00049868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203|Enhanced Linkage Maps From Family-Based Genetics Studies|||Rutgers University||Completed|September 2002|August 2005||||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2006|January 11, 2016|November 14, 2002||||No||https://clinicaltrials.gov/show/NCT00049868||202920|
NCT00049179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0117|S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML)||Southwest Oncology Group||Completed|April 2003|October 2010|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00049179||202966|
NCT00049959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFI MBCC 01 and VFI MBCC 02|Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.|A Randomized, Placebo-Controlled, Masked, Multicenter Phase III Study Of Photodynamic Therapy With Verteporfin For Injection (VFI) For The Treatment Of Multiple Basal Cell Carcinoma||QLT Inc.||Terminated||March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|90 Years|No|||March 2011|March 1, 2011|November 15, 2002||||||https://clinicaltrials.gov/show/NCT00049959||202913|
NCT00050063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5172|Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs|A Rollover Study of A5058s: A Phase II Trial to Evaluate the Ability of Vaccine-Induced Helper and CTL Responses to Control Viremia in the Absence of Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2004|Actual|||N/A|Observational|Time Perspective: Prospective||||78|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|November 20, 2002|No|Yes||||https://clinicaltrials.gov/show/NCT00050063||202905|
NCT00048984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS02B1|Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma|A Groupwide Biology and Banking Study for Ewing Sarcoma||Children's Oncology Group|No|Completed|January 2003|||February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|637|Samples With DNA|Paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens|Both|N/A|50 Years|No|Probability Sample|Patients who have Ewing's sarcoma|June 2013|June 20, 2013|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00048984||202979|
NCT00049075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2|Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Oral Fludarabine Phosphate in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia||Canadian Cancer Trials Group||Completed|August 2002|December 2009|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|128|||Both|16 Years|N/A|No|||March 2010|June 20, 2013|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049075||202973|
NCT00049530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258114|PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma|Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor||Eastern Cooperative Oncology Group|No|Completed|September 2003|June 2014|Actual|August 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2014|October 6, 2015|November 12, 2002|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00049530||202944|
NCT00049231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258053|EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer|Evaluation of Hypoxia by EF5 (NSC#684681) Binding in Cervix Cancer||National Cancer Institute (NCI)||Completed|June 2003|August 2005|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||||||Female|18 Years|N/A|No|||June 2005|June 21, 2013|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049231||202963|
NCT00045968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020221|Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer|A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)|GBM|Northwest Biotherapeutics|Yes|Active, not recruiting|December 2006|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|348|||Both|18 Years|70 Years|No|||February 2016|February 25, 2016|September 17, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00045968||203193|
NCT00045981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0107|The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)|Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SAPPHIRE Study||Synvista Therapeutics, Inc||Completed|October 2001|August 2006|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|50 Years|N/A|No|||August 2007|March 25, 2010|September 17, 2002||||||https://clinicaltrials.gov/show/NCT00045981||203192|
NCT00049322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258045|Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery|A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization||Jonsson Comprehensive Cancer Center|Yes|Completed|June 2003|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|November 12, 2002|Yes|Yes||No|January 20, 2016|https://clinicaltrials.gov/show/NCT00049322||202957|Size of study limits any strong conclusions regarding efficacy.Since this study was first designed and implemented, there have been many advances in the field, including confirmation of proof of principal for anti-angiogenic agents in advanced HCC.
NCT00050557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061512|Family Psychoeducation for Children With Mood Disorders|Family Psychoeducation: Efficacy in Child Mood Disorders||Ohio State University|No|Completed|July 2001|December 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|8 Years|11 Years|No|||May 2012|May 2, 2012|December 13, 2002||No||No||https://clinicaltrials.gov/show/NCT00050557||202870|
NCT00049738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030035|Screening for Childhood-Onset Psychotic Disorders|Screening, Evaluation, Diagnosis, Treatment Optimization and Follow-up for Childhood Onset Psychotic Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|October 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|5 Years|N/A|No|||May 2015|May 19, 2015|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00049738||202930|
NCT00050271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5157|Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy|An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27|||Both|13 Years|N/A|No|||May 2012|May 17, 2012|December 3, 2002||||||https://clinicaltrials.gov/show/NCT00050271||202890|
NCT00050830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4161003|A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer|A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer||Pfizer||Completed|January 2003|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||163|||Both|18 Years|N/A|No|||January 2006|November 6, 2006|December 20, 2002||||No||https://clinicaltrials.gov/show/NCT00050830||202850|
NCT00050843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THAL-MDS-001|A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes|||Celgene||Completed|August 2001|February 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|80 Years|No|||May 2004|June 23, 2005|December 23, 2002||||||https://clinicaltrials.gov/show/NCT00050843||202849|
NCT00050583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060265|Treatment of Medically Unexplained Physical Ailments (Somatization Disorder)|Treatment of Somatization in Primary Care||Rutgers, The State University of New Jersey|No|Completed|February 2001|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|70 Years|No|||January 2014|January 10, 2014|December 16, 2002||No||No||https://clinicaltrials.gov/show/NCT00050583||202868|
NCT00046826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069081|Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy|A Phase II Clinical Trial of Taxotere, Emcyt and Thalidomide (TET) for the Treatment of Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|September 2001|October 2009|Actual|June 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||January 2006|April 2, 2013|October 3, 2002||||No||https://clinicaltrials.gov/show/NCT00046826||203130|
NCT00046839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0213|Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer|A Phase I/II Trial of a COX-2 Inhibitor, Celebrex (Celecoxib), [National Screening Committee# 719627] With Limited Field Radiation for Intermediate Prognosis Patients With Locally Advanced Non-Small Cell Lung Cancer, With Analysis of Prognostic Factors||Radiation Therapy Oncology Group|Yes|Completed|July 2002|||September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|October 3, 2002|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT00046839||203129|This study stopped accrual early with 21 subjects accrued out of 128 planned, therefore only the phase I and phase II primary outcomes were reported.
NCT00049881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202|Genetic Determinants:Low HDL, High Triglycerides, Obesity|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2002|March 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2005|February 17, 2016|November 14, 2002||||No||https://clinicaltrials.gov/show/NCT00049881||202919|
NCT00049894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201|Predictors of Recurrent Stroke in the PROGRESS Study|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2004|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|100 Years|No|||October 2005|February 17, 2016|November 14, 2002||||No||https://clinicaltrials.gov/show/NCT00049894||202918|
NCT00049907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200|Cardiac and Renal Disease Study (CARDS)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2004|Actual|||N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2006|February 17, 2016|November 14, 2002||||No||https://clinicaltrials.gov/show/NCT00049907||202917|
NCT00049920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1194|The ARIC MRI Study|The ARIC Neurocognitive Longitudinal Study||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2002|September 2008|Actual|May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1134|Samples With DNA|Plasma and DNA|Both|N/A|N/A|No|Non-Probability Sample|Participants in the ARIC Neurocognitive Longitudinal Study were recruited for a follow-up        brain MR scan and cognitive testing from the subset of the (parent) ARIC cohort that had        an initial MR scan at the third (Visit 3) ARIC examination. Participants included black        and white men and women.|October 2008|October 7, 2008|November 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00049920||202916|
NCT00049933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1193|Hormone Replacement Therapy and Prothrombotic Variants|||University of Washington||Completed|September 2002|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Female|30 Years|79 Years|No|Non-Probability Sample|General|December 2012|December 18, 2012|November 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00049933||202915|
NCT00050024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030048|Transcranial Magnetic Stimulation and Electrical Stimulation of Nerves to Study Focal Dystonia|The Effect of Peripheral Heterotopic Stimulation on Cortical Excitability in Dystonia||National Institutes of Health Clinical Center (CC)||Completed|November 2002|September 2008||||N/A|Observational|N/A||||38|||Both|18 Years|N/A|No|||September 2008|September 26, 2015|November 19, 2002||No||No||https://clinicaltrials.gov/show/NCT00050024||202908|
NCT00050037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH062053|Cognitive Therapy for Binge-Eating Disorder|Cognitive Therapy Via CD-Rom for Binge-Eating Disorder||University of North Carolina, Chapel Hill|No|Completed|April 2001|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|60 Years|No|||April 2013|April 10, 2013|November 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00050037||202907|
NCT00050050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH060940|Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder|CBT for Residual ADHD Symptoms in Adults||Massachusetts General Hospital|No|Completed|September 2001|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|65 Years|No|||May 2014|May 23, 2014|November 20, 2002||No||No||https://clinicaltrials.gov/show/NCT00050050||202906|
NCT00050284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5170|Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection|Predictors of Immunologic and Clinical Progression in Subjects With CD4+ Cell Counts Greater Than 350 Cells/mm3 Who Discontinue Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Time Perspective: Prospective||||158|||Both|13 Years|N/A|No|||November 2010|November 5, 2010|December 3, 2002||||No||https://clinicaltrials.gov/show/NCT00050284||202889|
NCT00049088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02508|Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of PS-341 in Combination With Docetaxel in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Terminated|August 2002|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|November 12, 2002|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00049088||202972|
NCT00049101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257808|Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|A Phase I/II Study Of OSI-774 In Combination With Oxaliplatin, And 5-Fluourouracil In Patients With Metastatic Colorectal Carcinoma||National Cancer Institute (NCI)||Completed|August 2002|August 2004|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|June 21, 2013|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049101||202971|
NCT00049192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02790|Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A PHASE II STUDY OF G3139 (GENASENSE™, NSC # 683428 IND # 58842) + IMATINIB MESYLATE (GLEEVEC®, STI571) IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA||National Cancer Institute (NCI)||Completed|November 2002|||November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|15 Years|N/A|No|||June 2013|June 3, 2013|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049192||202965|
NCT00049244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258052|BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer|A Phase I Study of BMS-247550 in Combination With Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With a Taxane and an Anthracycline||National Cancer Institute (NCI)||Active, not recruiting|September 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2003|July 23, 2008|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049244||202962|
NCT00050362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030055|Rofecoxib and Bupivacaine to Prevent Pain After Third Molar (Wisdom Tooth) Extraction|Evaluation of a Long-Acting Local Anesthesia (Bupivacaine) and a Selective COX-2 Inhibitor (Rofecoxib) in Suppression of Central Sensitization||National Institutes of Health Clinical Center (CC)||Completed|December 2002|October 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||136|||Both|N/A|N/A|No|||October 2004|March 3, 2008|December 4, 2002||||No||https://clinicaltrials.gov/show/NCT00050362||202883|
NCT00050375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVA-Gy-17|Clinical Trial for Ovarian Cancer (OvaRex®)|A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex® MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin||Unither Pharmaceuticals||Terminated|December 2002|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||354|||Female|18 Years|N/A|No|||June 2006|December 13, 2007|December 5, 2002|||Study closed by sponser|||https://clinicaltrials.gov/show/NCT00050375||202882|
NCT00049816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR048768|Aerobic Exercise Intervention for Knee Osteoarthritis|Aerobic Exercise Intervention for Knee Osteoarthritis||Mayo Clinic||Completed|October 2002|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|306|||Both|30 Years|N/A|No|||May 2013|May 16, 2013|November 14, 2002||No||No||https://clinicaltrials.gov/show/NCT00049816||202924|
NCT00048620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB-00-01|Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI|Double-Blind,2 Dose Group Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI||BioMarin Pharmaceutical||Completed|September 2000|November 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2006|November 2, 2006|November 4, 2002||||||https://clinicaltrials.gov/show/NCT00048620||203005|
NCT00048633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TQD BRST 001|Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer|||QLT Inc.||Completed|November 2001|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||30|||Both|N/A|N/A|No|||May 2012|May 22, 2012|November 4, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00048633||203004|
NCT00054522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270758|Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy|Calcitriol + Dexamethasone in Early, Recurrent Prostate Cancer Following Local Therapy, A Phase I/II Trial||Roswell Park Cancer Institute|Yes|Completed|April 2002|March 2006|Actual|January 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|No|||March 2011|March 7, 2011|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054522||202601|
NCT00053209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269302|Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium|Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer||Eastern Cooperative Oncology Group|No|Completed|April 2004|May 2009|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053209||202690|
NCT00048841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61535 (completed)|Prevention of Osteoporosis in Men With Prostate Cancer|Prevention of Osteoporosis in Men With Prostate Cancer||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|May 2002|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||112|||Male|50 Years|85 Years|No|||March 2010|March 1, 2010|November 8, 2002||||No||https://clinicaltrials.gov/show/NCT00048841||202988|
NCT00052715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258685|Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Trial Of Poly-ICLC For Glioblastoma||National Cancer Institute (NCI)||Completed|November 2002|||April 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2005|February 6, 2009|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052715||202716|
NCT00048776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-01-336|Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon|||Otsuka America Pharmaceutical||Completed|October 2001|June 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|5 Years|16 Years|No|||July 2005|July 14, 2005|November 7, 2002||||||https://clinicaltrials.gov/show/NCT00048776||202993|
NCT00048789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030025|Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease|Treatment of Chronic Graft Versus Host Disease With Extracorporeal Photopheresis||National Institutes of Health Clinical Center (CC)||Completed|November 2002|January 2009||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||25|||Both|4 Years|N/A|No|||January 2009|September 26, 2015|November 7, 2002||No||No||https://clinicaltrials.gov/show/NCT00048789||202992|
NCT00053807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30955|Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer|Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 1998|||January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|96|||Both|N/A|75 Years|No|||September 2012|September 20, 2012|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053807||202650|
NCT00049439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU2498|Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma|Dose-Modified Oral Combination Chemotherapy In Patients With Aids-Related Non-Hodgkin's Lymphoma In The United States And Africa||Case Comprehensive Cancer Center|Yes|Completed|March 1998|February 2008|Actual|October 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|16 Years|N/A|No|||June 2010|June 9, 2010|November 12, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00049439||202949|
NCT00052949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01801|Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer|Phase II Trial of STI571 in Patients With Relapsed Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|May 2003|||October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|91|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052949||202705|
NCT00048971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-60102|Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy|A Pharmacogenetic Case-Control Study of Severe Diarrhea and Life-Threatening Neutropenia in Patients Treated With Irinotecan, 5-Fluorouracil and Leucovorin||Alliance for Clinical Trials in Oncology|No|Completed|April 2002|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|308|Samples With DNA|blood specimens|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with adenocarcinoma of the colon and previously enrolled on        CALGB-89803.|July 2015|July 14, 2015|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00048971||202980|
NCT00053157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC 02-01|Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia|Use Of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) To Mobilize Donor Peripheral Blood Stem Cells Along With GM-CSF Administration Post Allogeneic Transplant - A Pilot Study||Roswell Park Cancer Institute||Completed|June 2002|||August 2004|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||Actual|10|||Both|5 Years|60 Years|No|||January 2013|January 30, 2013|January 27, 2003||||No||https://clinicaltrials.gov/show/NCT00053157||202693|
NCT00053183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269300|Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I Brachytherapy Dose Escalation Using The GliaSite RTS In Newly Diagnosed Glioblastoma Multiforme In Conjunction With External Beam Radiation Therapy||National Cancer Institute (NCI)||Completed|October 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|February 6, 2009|January 27, 2003||||No||https://clinicaltrials.gov/show/NCT00053183||202692|
NCT00048932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-031|A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis|||Bristol-Myers Squibb||Completed|December 2002|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1795|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|November 11, 2002|Yes|Yes||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00048932||202983|
NCT00048945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV16240|Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B|||Hoffmann-La Roche||Completed||||||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2005|August 11, 2005|November 12, 2002||||||https://clinicaltrials.gov/show/NCT00048945||202982|
NCT00048958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-8461|Cytogenetic Studies in Acute Leukemia and Multiple Myeloma|Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients||Alliance for Clinical Trials in Oncology|No|Recruiting|June 1984|||January 2100|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|9000|Samples With DNA|Institutions must submit patient samples (eg, bone marrow and peripheral blood) at      diagnosis, at complete remission, and at the time of relapse to the Alliance-Approved      Institutional Cytogeneticist.|Both|18 Years|N/A|No|Non-Probability Sample|Patient population from the clinical oncology research community including academic        institutions, hospitals and clinics.|August 2015|August 6, 2015|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00048958||202981|
NCT00052728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258720|Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer|A Phase II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|December 2002|July 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2005|June 18, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052728||202715|
NCT00052845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258766|Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer||Alliance for Clinical Trials in Oncology|No|Completed|November 2002|April 2009|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Male|18 Years|N/A|No|||September 2013|September 27, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052845||202711|
NCT00052598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1671.00|Therapeutic Autologous Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant|Phase I/II Study of Adoptive Immunotherapy With CD8+ Proteinase 3 (Myeloblastin)-Specific CTL Clones for HLA-A2+ Patients With Relapse or Progression of Disease After Allogeneic Hematopoietic Stem Cell Transplant for High Risk Myeloid Leukemias||Fred Hutchinson Cancer Research Center|No|Terminated|September 2002|June 2011|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|N/A|N/A|No|||July 2011|July 12, 2011|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052598||202722|
NCT00048880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030038|Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein|Phase I Study of HeFi-1 in Refractory CD30-Positive Malignancy||National Institutes of Health Clinical Center (CC)||Completed|November 2002|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2010|September 26, 2015|November 8, 2002||No||No||https://clinicaltrials.gov/show/NCT00048880||202986|
NCT00048893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030040|Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer|A Multicenter Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion||National Institutes of Health Clinical Center (CC)|Yes|Terminated|November 2002|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|November 8, 2002||No|The study was closed to accrual due to very poor enrollment.|No|October 25, 2011|https://clinicaltrials.gov/show/NCT00048893||202985|The study was closed to accrual due to very poor enrollment. No meaningful data analysis was possible on the small number of accrued subjects, so none was done.
NCT00053261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269327|Vaginal Changes and Sexual Function in Patients With Cervical Cancer|Vaginal Length, Elasticity, Lubrication And Sexual Function In Women With Stage IB2 Cervix Carcinoma||Gynecologic Oncology Group||Completed|July 2003|||January 2007|Actual|N/A|Observational|N/A|||||||Female|N/A|69 Years|No|||June 2005|May 24, 2013|January 27, 2003||||No||https://clinicaltrials.gov/show/NCT00053261||202686|
NCT00052884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258785|Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation|A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis||Eastern Cooperative Oncology Group|No|Terminated|October 2003|March 2011|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||November 2012|November 30, 2012|January 24, 2003|Yes|Yes|Slow accrual and changes in clinical practice|No||https://clinicaltrials.gov/show/NCT00052884||202710|
NCT00052637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC B301/01|Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer|An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer||Photocure|No|Completed|September 2001|||May 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||October 2013|October 22, 2013|January 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00052637||202719|
NCT00049062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257752|Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase II And Biologic Correlative Study Investigating ARIMIDEX In Combination With IRESSA (ZD1839) In Post-Menopausal Patients With Estrogen Receptor-Positive Metastatic Breast Carcinoma Who Have Previously Failed Hormonal Therapy||The University of Texas Health Science Center at San Antonio||Completed|September 2002|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2013|February 19, 2013|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049062||202974|
NCT00052832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258754|Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes||University of Wisconsin, Madison||Completed|September 2002|||July 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||September 2015|September 30, 2015|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052832||202712|
NCT00049634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1628.00|Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder|A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies||Fred Hutchinson Cancer Research Center||Completed|January 2002|||February 2007|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||September 2010|September 14, 2010|November 12, 2002|No|Yes||No||https://clinicaltrials.gov/show/NCT00049634||202937|
NCT00052754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62022|Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma|Phase II Study Of Iressa (ZD 1839) In Locally Advanced And/Or Metastatic Synovial Sarcoma Expressing HER1/EGFR1||European Organisation for Research and Treatment of Cancer - EORTC||Completed|October 2002|||October 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052754||202714|
NCT00052780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03174|Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors|Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors||National Cancer Institute (NCI)||Completed|October 2002|||November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|N/A|21 Years|No|||September 2013|September 27, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052780||202713|
NCT00049608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258130|Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors|A Phase I Study Of The Effect Of Mistletoe Extract, A Complementary Medicine Botanical, On Pharmacokinetics, Pharmacodynamics And Safety Of Gemcitabine In Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Terminated|July 2002|August 2011|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|51|||Both|18 Years|N/A|No|||April 2007|June 17, 2013|November 12, 2002|||Principal investigator [PI] has left institution.|No||https://clinicaltrials.gov/show/NCT00049608||202938|
NCT00049010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257230|Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma|Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma||Alliance for Clinical Trials in Oncology|No|Completed|September 2002|October 2009|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Diagnostic|||Actual|314|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 12, 2002||No||No||https://clinicaltrials.gov/show/NCT00049010||202977|
NCT00053118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269284|Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer|High Dose Carboplatin Combined With Oral VP-16 In The Treatment Of Pediatric CNS Malignancies||Roswell Park Cancer Institute|Yes|Completed|March 2002|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|18 Years|No|||February 2011|February 25, 2011|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053118||202696|
NCT00053235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8004|Research Study in Patients With Advanced Ovarian Epithelial Cancer|A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer||Gynecologic Oncology Group||Withdrawn|November 2002|||August 2010|Actual|N/A|Observational|N/A||1|Actual|0|||Female|N/A|N/A|No|Probability Sample||May 2015|May 29, 2015|January 27, 2003||No||No||https://clinicaltrials.gov/show/NCT00053235||202688|
NCT00052611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258562|Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia|Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study||National Cancer Institute (NCI)||Active, not recruiting|June 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||January 2005|July 23, 2008|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052611||202721|
NCT00049023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000257582|Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors|A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors||National Cancer Institute (NCI)||Recruiting|January 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|2 Years|25 Years|No|||April 2008|February 1, 2011|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049023||202976|
NCT00049036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02926|Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|March 2003|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||December 2012|April 28, 2014|November 12, 2002|Yes|Yes||No|May 23, 2011|https://clinicaltrials.gov/show/NCT00049036||202975|
NCT00053131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269285|Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|High Dose Cytarabine And Mitoxantrone Therapy For Relapsed And Refractory Acute Myeloid And Lymphocytic Leukemia: Effects Of GM-CSF Versus G-CSF On Dendritic Cells And Leukemia Associated Antigen-Specific T-Lymphocytes||Roswell Park Cancer Institute|Yes|Completed|January 1999|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|15 Years|N/A|No|||March 2011|March 7, 2011|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053131||202695|
NCT00048646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0433-2001|Progesterone Treatment of Blunt Traumatic Brain Injury|ProTECT: Single Center, Phase II (Pilot), Double Blind, 4:1 Randomized, Placebo Controlled Clinical Trial for Progesterone Treatment of Moderate and Severe Blunt TBI||Emory University|Yes|Completed|May 2002|September 2005|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|November 4, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048646||203003|
NCT00048659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|598-CL-008|YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy|||Astellas Pharma Inc||Terminated||June 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2012|June 6, 2012|November 4, 2002||||||https://clinicaltrials.gov/show/NCT00048659||203002|
NCT00048997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0214|Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer|A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|September 2002|||December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 12, 2002|No|Yes||No|September 30, 2014|https://clinicaltrials.gov/show/NCT00048997||202978|This study stopped accrual early due to unmet accrual goals.
NCT00048672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-015|Therapy of Early Chronic Phase CML With Gleevec|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)||M.D. Anderson Cancer Center|No|Completed|March 2001|August 2013|Actual|November 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|15 Years|N/A|No|||January 2016|January 19, 2016|November 5, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048672||203001|
NCT00053222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11839A|Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine|A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine||University of Chicago|No|Completed|February 2003|July 2007|Actual|January 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|January 27, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053222||202689|
NCT00052897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02507|SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia|A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals||National Cancer Institute (NCI)||Completed|December 2002|||July 2005|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|N/A|No|||April 2004|February 8, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052897||202709|
NCT00052676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRAUSS-FRANSENOD|Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer|French Randomized Sentinel Node Multicentric Study||National Cancer Institute (NCI)||Completed|October 2002|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||September 2007|May 14, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052676||202718|
NCT00048724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02569|Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)|PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin||Merck Sharp & Dohme Corp.|Yes|Completed|June 2002|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|631|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|November 6, 2002|No|Yes||No|April 23, 2009|https://clinicaltrials.gov/show/NCT00048724||202997|
NCT00048737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-233|Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies|Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|October 2002|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|70 Years|No|||June 2013|June 11, 2013|November 6, 2002||No||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00048737||202996|
NCT00052494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-008|Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I Study Of STI 571 (Gleevec) In Combination With Cisplatin/Irinotecan In Patients With Extensive Stage Small Cell Lung Cancer||University Health Network, Toronto||Completed|April 2003|||February 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|N/A|No|||July 2015|July 22, 2015|January 24, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00052494||202728|
NCT00049777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6743|A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)|A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Heparin in Patients With Severe Sepsis and Higher Disease Severity Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)||Eli Lilly and Company||Completed|December 2002|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2000|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|November 13, 2002||||||https://clinicaltrials.gov/show/NCT00049777||202927|
NCT00049660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10001-160010|Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer|A Randomized Phase II-III Trial Evaluating the Efficacy of Capecitabine and Vinorelbine in Anthracycline and Taxane Pre-Treated Metastatic Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|September 2002|||December 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|47|||Female|18 Years|N/A|No|||July 2012|July 17, 2012|November 12, 2002|||low accrual|No||https://clinicaltrials.gov/show/NCT00049660||202936|
NCT00052923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258802|Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma|Randomized Phase III Trial Of Rituximab (NSC #687451) And Autologous Stem Cell Transplantation For B Cell Diffuse Large Cell Lymphoma||National Cancer Institute (NCI)||Completed|March 2003|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|427|||Both|18 Years|70 Years|No|||June 2006|February 6, 2009|January 24, 2003||||||https://clinicaltrials.gov/show/NCT00052923||202707|
NCT00052936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269015|Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma|Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|January 2001|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1580|||Both|61 Years|80 Years|No|||June 2007|March 11, 2010|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052936||202706|
NCT00054067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269821|Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix|Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation||Gynecologic Oncology Group||Terminated|February 2003|||April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2013|April 10, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054067||202631|
NCT00048685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030026|Study of Oral Bacteria in Patients With Dry Mouth|Incidence and Frequency of Cariogenic Microflora in Patients With Clinical Xerostomia and Autoimmune Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2002|August 2004||||N/A|Observational|N/A||||44|||Both|N/A|N/A|No|||August 2004|March 3, 2008|November 5, 2002||||No||https://clinicaltrials.gov/show/NCT00048685||203000|
NCT00054418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N02C1|Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer|A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma||Alliance for Clinical Trials in Oncology||Completed|March 2003|May 2008|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|216|||Female|18 Years|N/A|No|||October 2013|November 12, 2013|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054418||202608|
NCT00053092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269136|Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma|National Mantle Cell Lymphoma Trial - Phase II Randomized Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma||National Cancer Institute (NCI)||Completed|October 2002|February 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|82|||Both|18 Years|N/A|No|||June 2007|December 17, 2013|January 27, 2003||||No||https://clinicaltrials.gov/show/NCT00053092||202698|
NCT00053105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269140|Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|February 2002|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|64 Years|No|||March 2003|July 4, 2009|January 27, 2003||||No||https://clinicaltrials.gov/show/NCT00053105||202697|
NCT00052624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258574|Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma|A Phase I Multicenter Trial Of Intratumoral/Interstitial Therapy With HN66000, NC66000 (TransMID) In Patients Between 5 and 18 Years Of Age With Progressive Or Recurrent Glioblastoma Multiforme Or Anaplastic Astrocytoma||National Cancer Institute (NCI)||Active, not recruiting|July 2002|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|5 Years|18 Years|No|||April 2004|February 6, 2009|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052624||202720|
NCT00049452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258105|Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer|A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer||National Cancer Institute (NCI)||Completed|December 2001|August 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|120|||Female|18 Years|50 Years|No|||April 2007|January 3, 2014|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049452||202948|
NCT00049465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1430.00|Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer|Multi-Site Randomized Clinical Trial Comparing Standard Recovery Preparation to Extended Recovery Preparation to Enhance Long Term Function After Marrow or Stem Cell Transplant||Fred Hutchinson Cancer Research Center||Completed|August 1998|||February 2005|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||September 2010|September 17, 2010|November 12, 2002||||No||https://clinicaltrials.gov/show/NCT00049465||202947|
NCT00053781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I156|Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma|A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma||Canadian Cancer Trials Group||Completed|June 2003|December 2009|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053781||202652|
NCT00053794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I155|Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma|A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma||Canadian Cancer Trials Group||Completed|May 2003|September 2008|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053794||202651|
NCT00049790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG-CL-004|Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer|||CASI Pharmaceuticals, Inc.||Completed||December 2004||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2009|January 8, 2009|November 13, 2002||||||https://clinicaltrials.gov/show/NCT00049790||202926|
NCT00049803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-SXB-15|Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) With Placebo for the Treatment of Narcolepsy||Orphan Medical||Completed|December 2000|April 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|16 Years|N/A|No|||July 2004|June 23, 2005|November 13, 2002||||||https://clinicaltrials.gov/show/NCT00049803||202925|
NCT00052910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-80101|Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer|Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|December 2002|||June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|546|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|January 24, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00052910||202708|
NCT00048698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030017|Effects of Direct Current Brain Stimulation on Cognition|A Phase I Trial of Focal DC Brain Polarization||National Institutes of Health Clinical Center (CC)||Completed|November 2002|October 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||170|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2005|March 3, 2008|November 5, 2002||||No||https://clinicaltrials.gov/show/NCT00048698||202999|
NCT00048711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB-01-04|Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI|Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI||BioMarin Pharmaceutical||Completed|March 2002|June 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|5 Years|N/A|No|||August 2009|August 24, 2009|November 6, 2002||||||https://clinicaltrials.gov/show/NCT00048711||202998|
NCT00048815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061758|Drug Therapy to Treat Minor Depression|Pharmacotherapy for Minor Depression||National Institute of Mental Health (NIMH)||Completed|February 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|85 Years|No|||October 2008|March 10, 2009|November 8, 2002||||No||https://clinicaltrials.gov/show/NCT00048815||202990|
NCT00049673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MY10|Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma||Canadian Cancer Trials Group|Yes|Completed|September 2002|September 2013|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|332|||Both|16 Years|N/A|No|||September 2013|October 5, 2015|November 12, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00049673||202935|
NCT00052689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01799|Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer|A Randomized Phase II Trial of PS-341 and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma||National Cancer Institute (NCI)||Completed|December 2002|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052689||202717|
NCT00053976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269672|Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease|Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo||National Cancer Institute (NCI)||Active, not recruiting|October 2002|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||December 2003|February 6, 2009|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053976||202638|
NCT00053989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269673|Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia|Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Aplastic Anemia||Roswell Park Cancer Institute|Yes|Active, not recruiting|January 2002|||November 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|5 Years|75 Years|No|||December 2015|December 10, 2015|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053989||202637|
NCT00052585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02505|Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer|A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer||National Cancer Institute (NCI)||Terminated|October 2002|||November 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 24, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00052585||202723|
NCT00048828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060229|Treating Drug-Resistant Childhood Schizophrenia|Treating Refractory Childhood Schizophrenia||Northwell Health||Completed|October 2001|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|10 Years|18 Years|No|||July 2013|July 1, 2013|November 8, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00048828||202989|
NCT00053248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269319|Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase I/II Study To Determine The Safety, Tolerability, And Anti-Leukemic Effects of Trisenox (Arsenic Trioxide) In Combination With Gleevec (STI571) In Patients With Resistant Chronic Myelogenous Leukemia In Chronic Phase||OHSU Knight Cancer Institute|Yes|Completed|October 2002|June 2005|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|N/A|No|||June 2010|May 24, 2012|January 27, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053248||202687|
NCT00054223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030063|Study of Decision Making in Patients Participating in Phase I Clinical Trials|Ethics Study To Understand The Decision Making Process Of Phase I Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|January 2003|November 2005|Actual|||N/A|Interventional|Masking: Open Label|||Anticipated|250|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054223||202621|
NCT00048906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030043|Alpha-Galactosidase A Replacement Therapy for Fabry Disease|A Safety and Pharmacokinetic Study of Replagal Enzyme Replacement Therapy in Patients With Fabry Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2002|November 2003||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||3|||Both|N/A|N/A|No|||November 2003|March 3, 2008|November 8, 2002||||No||https://clinicaltrials.gov/show/NCT00048906||202984|
NCT00052052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPF-004|An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)|An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.||InterMune||Completed|September 2002|September 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|20 Years|79 Years|No|||November 2007|November 2, 2007|January 21, 2003||||No||https://clinicaltrials.gov/show/NCT00052052||202759|
NCT00052065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2011|TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer||Telik||Completed|February 2003|March 2006|Actual|March 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Female|18 Years|N/A|No|||June 2011|July 21, 2011|January 21, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00052065||202758|
NCT00051740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061775|Treating Thought Problems in Patients With Schizophrenia|Compensating for Cognitive Deficits in Schizophrenia||The University of Texas Health Science Center at San Antonio||Completed|February 2002|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||April 2013|April 5, 2013|January 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00051740||202783|
NCT00052117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4311006|Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens|A Phase 2, Randomized, Double-Blind, Dose-Ranging Study Of Capravirine (AG1549) In Combination With Kaletra (Trademark) and At Least 2 Nucleoside Reverse Transcriptase Inhibitors in Hiv-Infected Subjects Who Have Failed Antiretroviral Regimens Containing Protease Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase Inhibitors||Pfizer||Completed|January 2003|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||October 2007|October 5, 2007|January 22, 2003||||||https://clinicaltrials.gov/show/NCT00052117||202754|
NCT00052130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-MMAIT-3-001|Vaccine Therapy for Patients With Stage III Melanoma|Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma||CancerVax Corporation||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1118|||Both|18 Years|80 Years|No|||September 2004|June 23, 2005|January 22, 2003||||||https://clinicaltrials.gov/show/NCT00052130||202753|
NCT00052559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02908|Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer|A Phase I Study Of The Antiangiogenic Agent Bevacizumab In Combination With 5-Fluourouracil And External Beam Radiation Therapy In Rectal Cancer||National Cancer Institute (NCI)||Completed|August 2002|||April 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052559||202725|
NCT00052195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI045407-01A2|Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People|DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2001|May 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1975|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00052195||202748|
NCT00052507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-012|Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase II Study Of PS-341 In Patients With Metastatic Colorectal Cancer||University Health Network, Toronto||Completed|January 2003|||August 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 24, 2003||Yes||No||https://clinicaltrials.gov/show/NCT00052507||202727|
NCT00052221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000069409|Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy|A Placebo Controlled Trial Of Short-Term, High-Dose Epoetin Alfa In Advanced Cancer Outpatients With Mild Fatigue||M.D. Anderson Cancer Center|No|Withdrawn|May 2003|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|January 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00052221||202746|
NCT00051480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-001.005|Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer|A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer||GenVec||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2011|May 11, 2011|January 10, 2003||||||https://clinicaltrials.gov/show/NCT00051480||202801|
NCT00051493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6142|ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.|ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.||Eli Lilly and Company||Completed|April 2002|December 2002||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||July 2006|July 18, 2006|January 10, 2003||||||https://clinicaltrials.gov/show/NCT00051493||202800|
NCT00052572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258542|Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders|A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders||National Cancer Institute (NCI)||Completed|October 2002|July 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||April 2006|June 21, 2013|January 24, 2003||||||https://clinicaltrials.gov/show/NCT00052572||202724|
NCT00051558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6484|Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis|Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis||Eli Lilly and Company|No|Completed|November 2002|January 2008|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|428|||Both|21 Years|N/A|No|||February 2009|February 13, 2009|January 13, 2003|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00051558||202795|
NCT00050999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-04-11|Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients|A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25||Eisai Inc.||Completed|June 1995|December 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||195|||Both|18 Years|N/A|No|||February 2008|February 29, 2008|December 31, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050999||202837|
NCT00051116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-008|A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma|A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma||Celgene|No|Completed|May 2002|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|January 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00051116||202829|
NCT00051415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001291-01|Safety and Effectiveness of Flaxseed for Reducing High Cholesterol|A Double Blind, Randomized, Placebo Controlled Trial of Flaxseed in Patients With Hypercholesterolemia||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2003|January 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|45 Years|75 Years|No|||July 2006|August 17, 2006|January 9, 2003||||No||https://clinicaltrials.gov/show/NCT00051415||202806|
NCT00051727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064707|Prevention of School Dropout for Mexican American Adolescents|Preventive Intervention for Mexican American Adolescents||Arizona State University||Completed|October 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||480|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||January 2012|January 6, 2012|January 15, 2003||||No||https://clinicaltrials.gov/show/NCT00051727||202784|
NCT00051571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG0002-015|Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma|A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma||Seattle Genetics, Inc.||Completed||October 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||October 2011|October 21, 2011|January 13, 2003||||||https://clinicaltrials.gov/show/NCT00051571||202794|
NCT00051753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004168|Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media|A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2002|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1643|||Both|6 Months|5 Years|No|||January 2011|January 7, 2011|January 16, 2003||||||https://clinicaltrials.gov/show/NCT00051753||202782|
NCT00051831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5173|Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults|A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2003|May 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|January 16, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00051831||202776|
NCT00051844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4311002|Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen|A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen||Pfizer||Completed|August 2002|November 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|179|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|January 16, 2003||Yes||||https://clinicaltrials.gov/show/NCT00051844||202775|
NCT00052013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787 0144|Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584|A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB)||Novartis||Completed|February 2003|||June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2011|February 16, 2011|January 21, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00052013||202762|
NCT00051883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00450-1|Chemical Dependency and Smoking Cessation: Patient's Views - 1|Chemical Dependency and Smoking Cessation: Patient's Views||National Institute on Drug Abuse (NIDA)|No|Completed|December 1999|February 2005|Actual|||Phase 4|Observational|Time Perspective: Prospective|||Actual|125|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Substance abuse treatment patients|December 2008|December 22, 2008|January 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00051883||202772|
NCT00051779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL-03|An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer|A 24-Week Blinded Study Conducted at Multiple Centers, Evaluating the Safety and Effectiveness of Various Doses of the Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) When Randomly Assigned to Patients With Breast Cancer That Has Metastasized to Bone||Chugai Pharma USA||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2004|June 23, 2005|January 16, 2003||||||https://clinicaltrials.gov/show/NCT00051779||202780|
NCT00051935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU01502|A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II|Open-Label, Pilot Study of the Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Human Acid Alpha-Glucosidase (rhGAA) as Enzyme Replacement Therapy in Siblings With Glycogen Storage Disease Type II (GSD-II).||Sanofi||Completed|January 2003|October 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||February 2014|February 4, 2014|January 17, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00051935||202768|
NCT00053144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269286|Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia|Irinotecan And Cytarabine In Refractory or Relapsed Acute Myeloid Leukemia And In Chronic Myelogenous Leukemia In Myeloid Blast Transformation: Efficacy And In Vitro Correlates||Roswell Park Cancer Institute|Yes|Completed|November 1999|March 2003|Actual|February 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|N/A|No|||March 2011|March 7, 2011|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053144||202694|
NCT00053326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01802|Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma|A Phase II Study of Fenretinide (NSC# 374551, IND# 40294) in Children With Recurrent/Resistant High Risk Neuroblastoma||National Cancer Institute (NCI)||Completed|May 2003|||March 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|21 Years|No|||October 2013|October 7, 2013|January 27, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053326||202683|
NCT00052325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258166|Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy|Iscar For Supplemental Care In Advanced Non-Small Cell Lung Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|October 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2005|December 17, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052325||202741|
NCT00052208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00849|Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme|A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] With Radiation Therapy in Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|March 2002|||June 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|158|||Both|N/A|N/A|No|||May 2013|June 11, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052208||202747|
NCT00051129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-27|Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)|An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration.||Alcon Research||Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|291|||Both|50 Years|N/A|No|||August 2008|November 27, 2012|January 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00051129||202828|
NCT00052351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258196|Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer|A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors||National Cancer Institute (NCI)||Completed|September 2002|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2003|June 17, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052351||202739|
NCT00052364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02830|Oxaliplatin in Treating Patients With Liver Cancer|A Phase II Study of Oxaliplatin in Hepatocellular Cancer||National Cancer Institute (NCI)||Completed|September 2002|||January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052364||202738|
NCT00052273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258138|LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients||Jonsson Comprehensive Cancer Center|Yes|Completed|December 2002|October 2005|Actual|November 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|16|||Both|18 Years|N/A|No|||August 2012|October 28, 2015|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052273||202745|
NCT00052377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02504|Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides|A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12||National Cancer Institute (NCI)||Terminated|September 2002|||June 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 24, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00052377||202737|
NCT00052286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258139|Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer|A Pilot Study of Modafinil for Treatment of Fatigue and Neurobehavioral Dysfunction in Adult Brain Tumor Patients||Jonsson Comprehensive Cancer Center|Yes|Completed|September 2002|August 2010|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|29|||Both|21 Years|65 Years|No|||February 2016|February 5, 2016|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052286||202744|
NCT00052299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06012|Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia|Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP|AML-17|European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2002|February 2012|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|472|||Both|61 Years|75 Years|No|||August 2012|August 24, 2012|January 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00052299||202743|
NCT00051142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-36|A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)|A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|February 2001|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|January 3, 2003||||||https://clinicaltrials.gov/show/NCT00051142||202827|
NCT00051272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK130927|Effects Of Antidepressants On Sexual Functioning In Adults|A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period||GlaxoSmithKline||Completed|January 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|425|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|January 7, 2003||||||https://clinicaltrials.gov/show/NCT00051272||202817|
NCT00051974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34102-048|Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer||Millennium Pharmaceuticals, Inc.||Completed|December 2002|||September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||155|||Both|18 Years|N/A|No|||February 2008|February 7, 2008|January 21, 2003||||||https://clinicaltrials.gov/show/NCT00051974||202765|
NCT00051428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001075-01|The Efficacy of Reiki in the Treatment of Fibromyalgia|The Efficacy of Reiki in the Treatment of Fibromyalgia||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2003|February 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||August 2006|August 16, 2006|January 9, 2003||||No||https://clinicaltrials.gov/show/NCT00051428||202805|
NCT00051506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7210|ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.|||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 18, 2006|January 10, 2003||||||https://clinicaltrials.gov/show/NCT00051506||202799|
NCT00051519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030079|Screening HIV-Infected Patients for Vaccine Studies|Screening HIV-Infected Subjects for Vaccine Research Studies||National Institutes of Health Clinical Center (CC)||Completed|January 2003|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A||||1000|||Both|18 Years|N/A|No|||June 2009|September 26, 2015|January 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00051519||202798|
NCT00051584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG015-0003|Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer|A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer||Seattle Genetics, Inc.||Terminated||May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|18 Years|N/A|No|||October 2011|October 21, 2011|January 13, 2003||||||https://clinicaltrials.gov/show/NCT00051584||202793|
NCT00051597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG030-0002|A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies|A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies||Seattle Genetics, Inc.||Completed||August 2003|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|January 13, 2003||||||https://clinicaltrials.gov/show/NCT00051597||202792|
NCT00051987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34102-049|Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma|A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma||Millennium Pharmaceuticals, Inc.||Completed|December 2002|||March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||175|||Both|18 Years|N/A|No|||February 2008|February 7, 2008|January 21, 2003||||||https://clinicaltrials.gov/show/NCT00051987||202764|
NCT00052000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M59102-042|A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer|A Phase 1 Single Ascending Dose Trial of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen Independent Prostate Cancer||Millennium Pharmaceuticals, Inc.||Completed|November 2002|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||29|||Male|N/A|N/A|No|||February 2007|February 28, 2007|January 21, 2003||||No||https://clinicaltrials.gov/show/NCT00052000||202763|
NCT00052026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB 105517-321|Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure|A Multicenter, Placebo-Controlled, 8-Month Study of the Effect of Twice Daily Carvedilol in Children With Congestive Heart Failure Due to Systemic Ventricular Systolic Dysfunction||Shaddy, Robert, M.D.|Yes|Completed|May 2000|July 2006|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|161|||Both|N/A|17 Years|No|||December 2008|December 24, 2008|January 21, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00052026||202761|
NCT00051714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH055188|Early Prevention of Conduct Problems|Early Primary Prevention of Conduct Problems||New York University School of Medicine||Completed|March 1997|||December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1050|||Both|33 Months|63 Months|Accepts Healthy Volunteers|||July 2013|July 12, 2013|January 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00051714||202785|
NCT00051870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030081|Brain Encoding for Memory|Role of the Prefrontal Cortex in Successful Memory Encoding||National Institutes of Health Clinical Center (CC)||Completed|January 2003|January 2005||||N/A|Observational|N/A||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2005|March 3, 2008|January 16, 2003||||No||https://clinicaltrials.gov/show/NCT00051870||202773|
NCT00051896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0002-1|Assessment of the Potential Interactions Between Cocaine and GBR 12909 - 1|Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers||National Institute on Drug Abuse (NIDA)||Active, not recruiting|August 2002|||||Phase 1|Interventional|Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|45 Years|No|||March 2005|April 25, 2012|January 17, 2003||||||https://clinicaltrials.gov/show/NCT00051896||202771|
NCT00052104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH062561|Telephone-Based Support for Caregivers of Patients With Dementia|A Telephone Intervention for Dementia Caregivers||Rhode Island Hospital||Completed|December 2001|November 2005|Actual|November 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||85|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2008|August 7, 2013|January 22, 2003||||No||https://clinicaltrials.gov/show/NCT00052104||202755|
NCT00051922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AI045142|Development of a New HIV Vaccine|Evaluation of the Safety of a Polyvalent Vaccinia Virus HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1997|June 2009|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|24|||Both|18 Years|32 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|January 17, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00051922||202769|
NCT00052143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HG002449|Prospective Huntington At Risk Observational Study|Prospective Huntington At Risk Observational Study (PHAROS)|PHAROS|Huntington Study Group|Yes|Active, not recruiting|July 1999|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1001|Samples With DNA|Blood sample|Both|26 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|HD Community|February 2008|April 15, 2009|January 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00052143||202752|
NCT00053027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0189|Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma|Phase II Trial of Rituximab and 2-Chlorodeoxyadenosine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL)||Alliance for Clinical Trials in Oncology|No|Completed|February 2003|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053027||202701|
NCT00053040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269073|Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas|Phase I/II Trial Of Intracerebral IL13-PE38QQR Infusions In Pediatric Patients With Recurrent Malignant Glioma||Pediatric Brain Tumor Consortium|Yes|Withdrawn|October 2005|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|3 Years|21 Years|No|||September 2010|September 23, 2010|January 27, 2003|Yes|Yes|Withdrawal of pharmaceutical company support for the investigational drug|No||https://clinicaltrials.gov/show/NCT00053040||202700|
NCT00052403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258300|Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors|Phase I Study of Monoclonal Antibody Anti-Anb3 Integrin in Patients With Advanced Solid Tumors||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|February 2002|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|January 24, 2003|||Study was not successful at recruiting particpants|No||https://clinicaltrials.gov/show/NCT00052403||202735|
NCT00052416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDMC-W-01-0384-FB|Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Thalidomide in Indolent Non-Hodgkin's Lymphoma: A Feasibility Study||National Cancer Institute (NCI)||Completed|October 2002|January 2003|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|June 25, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052416||202734|
NCT00052338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02503|Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|A Phase I Study Of PS-341 In Combination With Gemcitabine And Carbloplatin In Selected Stage IIIB Or IV Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2002|||May 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|January 24, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00052338||202740|
NCT00051441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002491|Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx|A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine HCl 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Mucositis||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed||February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|605|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|January 9, 2003||||||https://clinicaltrials.gov/show/NCT00051441||202804|
NCT00052390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258249|Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma|A Multi-Institutional, Open-Label, Phase II Study Of Doxorubicin And Bevacizumab (Anti-VEFG Monoclonal Antibody, NSC 704865) For Patients With Advanced Or Metastatic Soft-Tissue Sarcoma||National Cancer Institute (NCI)||Completed|October 2002|October 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2004|June 21, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052390||202736|
NCT00051623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004789|A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis|A Multicenter, Randomized, Double-blind Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Patients With Psoriatic Arthritis||Centocor, Inc.||Completed|May 2003|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|70|||Both|18 Years|N/A|No|||March 2010|May 16, 2011|January 14, 2003||||||https://clinicaltrials.gov/show/NCT00051623||202791|
NCT00051285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESSENTIAL: My-021 and My-026|ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"|ESSENTIAL Protocol No. My-021 and Protocol No. My-026, Each Titled: A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects||Gilead Sciences||Terminated|February 2002|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||1800|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|January 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00051285||202816|
NCT00051389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155|ACE Inhibition and Novel Cardiovascular Risk Factors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 2002|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|55 Years|100 Years|No|||January 2008|February 17, 2016|January 9, 2003||||No||https://clinicaltrials.gov/show/NCT00051389||202808|
NCT00051857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030060|MRI Study of Musculoskeletal Function|Virtual Functional Anatomy (VFA)||National Institutes of Health Clinical Center (CC)||Recruiting|January 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|500|||Both|5 Years|N/A|Accepts Healthy Volunteers|||September 2015|December 2, 2015|January 16, 2003||No||No||https://clinicaltrials.gov/show/NCT00051857||202774|
NCT00052039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPF-003|A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone|A Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving Prednisone||InterMune||Terminated|April 2002|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|79 Years|No|||November 2007|November 2, 2007|January 21, 2003|||Study design changes were needed based on GIPF-001 results|No||https://clinicaltrials.gov/show/NCT00052039||202760|
NCT00051532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBC 9801 INT|Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma|Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5ug) or Placebo in the Treatment of Patients With Hepatocellular Carcinoma Not Amenable to Curative Treatment||LEO Pharma||Terminated|September 1999|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||700|||Both|18 Years|75 Years|No|||April 2005|March 5, 2007|January 13, 2003||||||https://clinicaltrials.gov/show/NCT00051532||202797|
NCT00051766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44AI044558-02A1|Computer-Assisted Adherence Program for Patients Taking Anti-HIV Drugs|A Computer-Based HIV Medication Adherence Intervention||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||200|||Both|16 Years|N/A|No|||May 2005|June 23, 2005|January 16, 2003||||No||https://clinicaltrials.gov/show/NCT00051766||202781|
NCT00051909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6764|Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease|Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease||Eli Lilly and Company||Completed|November 2002|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 18, 2006|January 17, 2003||||||https://clinicaltrials.gov/show/NCT00051909||202770|
NCT00052312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55984|Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer|Randomized Trial Of Adriamycin (A) Cisplatin (P) Chemotherapy Versus Paclitaxel (T) Adriamycin (A) And Cisplatin (P) In Patients With Metastatic/Relapsed Or Locally Advanced Inoperable Endometrial Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2002|||September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|141|||Female|18 Years|N/A|No|||September 2012|September 20, 2012|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052312||202742|
NCT00053001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FALLON-PR01-09-010|Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome|A Phase II Study on the Effectiveness of Thalomid (Thalidomide) Combined With Procrit (Erythropoietin) for the Treatment of Anemia in Patients With Low and Intermediate Risk-1 (IPSS Score Less Than or Equal to 1.5) Myelodysplastic Syndromes||National Cancer Institute (NCI)||Completed|June 2001|October 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|21 Years|N/A|No|||October 2007|June 25, 2013|January 27, 2003||||No||https://clinicaltrials.gov/show/NCT00053001||202703|
NCT00053014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0125|S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia|S0125, A Phase II Study Of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation In Older Patients With Acute Myeloid Leukemia (AML) In First Complete Remission (A BMT Study)||Southwest Oncology Group|Yes|Terminated|April 2003|June 2006|Actual|June 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|55 Years|69 Years|No|||March 2015|March 5, 2015|January 27, 2003|Yes|Yes|Poor accrual|No|January 2, 2013|https://clinicaltrials.gov/show/NCT00053014||202702|
NCT00052078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH064089|Child and Adolescent Anxiety Disorders (CAMS)|Child/Adolescent Anxiety Multimodal Treatment Study||National Institute of Mental Health (NIMH)||Active, not recruiting|January 2003|March 2008|Anticipated|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|488|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||October 2008|October 20, 2008|January 22, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00052078||202757|
NCT00052091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063982|Therapy for Depressed Elders With Thought Problems|PST in Geriatric Depression With Executive Dysfunction||University of California, San Francisco||Completed|September 2002|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|60 Years|N/A|No|||September 2013|September 20, 2013|January 22, 2003||No||No||https://clinicaltrials.gov/show/NCT00052091||202756|
NCT00053053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0122|Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer|A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement||Radiation Therapy Oncology Group|Yes|Completed|December 2002|February 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|472|||Both|17 Years|N/A|No|||October 2013|October 8, 2013|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053053||202699|
NCT00053287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1902|Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS|Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes||Case Comprehensive Cancer Center|Yes|Completed|September 2002|March 2007|Actual|January 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053287||202685|
NCT00052429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-077|High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer|Phase I/II Study of Dose-Painting Using Intensity Modulated Radiation Therapy Plus Chemotherapy in Patients With Stage II-IVB Nasopharyngeal Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|September 2002|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|120 Years|No|||January 2016|January 22, 2016|January 24, 2003|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00052429||202733|
NCT00052442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258425|10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomas and Hodgkin's Disease||National Cancer Institute (NCI)||Completed|August 2002|||March 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|December 3, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052442||202732|
NCT00053300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1502|Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Daily Thalidomide in Extensive Stage Small Cell Lung Cancer Patients Achieving a Complete or Partial Response to Induction Chemotherapy||Case Comprehensive Cancer Center|Yes|Completed|August 2002|April 2010|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053300||202684|
NCT00052455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258428|Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma|A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV||National Cancer Institute (NCI)||Completed|October 2002|September 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|N/A|No|||May 2007|December 17, 2013|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052455||202731|
NCT00052468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258429|Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer|A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV|AGO-OVAR9|AGO Study Group|Yes|Completed|August 2002|January 2011|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1742|||Female|18 Years|N/A|No|||June 2014|June 24, 2014|January 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00052468||202730|
NCT00052481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z0071|Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer|Health-Related Quality Of Life In Patients With Low Risk, Localized Prostate Cancer Randomized To Radical Prostatectomy Or Brachytherapy||Alliance for Clinical Trials in Oncology|No|Completed|September 2002|April 2004|Actual|April 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|500|||Male|N/A|75 Years|No|Non-Probability Sample|Patients diagnosed with adenocarcinoma of the prostate and previously enrolled on        ACOSOG-Z0070.|July 2015|July 14, 2015|January 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00052481||202729|
NCT00048802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060845|Treatment and Outcome of Early Onset Bipolar Disorder|Treatment and Outcome of Early Onset Bipolar Disorder||Northwell Health||Completed|August 2002|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|10 Years|18 Years|No|||January 2014|January 21, 2014|November 8, 2002||||No||https://clinicaltrials.gov/show/NCT00048802||202991|
NCT00051454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AI05395|Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults|A Randomised, Placebo-Controlled, Double-Blind, Phase I/IIa Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic DNA Prime-rFPV Boost HIV Vaccination Strategy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2003|February 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2007|August 23, 2007|January 10, 2003||||No||https://clinicaltrials.gov/show/NCT00051454||202803|
NCT00051467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-001.004|A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer|A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer||GenVec||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2011|February 22, 2012|January 10, 2003||||||https://clinicaltrials.gov/show/NCT00051467||202802|
NCT00051545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBC 9802 INT|Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma|Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5 ug) or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Treatment for Hepatocellular Carcinoma||LEO Pharma||Terminated|November 1999|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||608|||Both|18 Years|75 Years|No|||April 2005|February 21, 2007|January 13, 2003||||||https://clinicaltrials.gov/show/NCT00051545||202796|
NCT00051636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2304|Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period|Randomized, Double-blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observational Period||Novartis||Completed|January 2001|April 2011|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|30 Years|N/A|No|||May 2012|May 9, 2012|January 14, 2003|Yes|Yes||No|April 5, 2012|https://clinicaltrials.gov/show/NCT00051636||202790|
NCT00051662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUPA600|Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis||XOMA (US) LLC||Completed||February 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|80 Years|No|||September 2004|June 23, 2005|January 14, 2003||||||https://clinicaltrials.gov/show/NCT00051662||202789|
NCT00051675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA104|Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas|An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas||XOMA (US) LLC||Completed|July 2002|September 2003||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||September 2004|June 23, 2005|January 14, 2003||||||https://clinicaltrials.gov/show/NCT00051675||202788|
NCT00053196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269301|Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer|Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation||Alliance for Clinical Trials in Oncology|No|Completed|December 2002|August 2010|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|N/A|69 Years|No|||September 2013|September 27, 2013|January 27, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053196||202691|
NCT00052962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030085|Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis|A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2003|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|January 26, 2003|Yes|Yes||No|September 4, 2012|https://clinicaltrials.gov/show/NCT00052962||202704|
NCT00051298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4066|Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia|Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia||Eli Lilly and Company||Completed|November 2002|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|107|||Both|13 Years|17 Years|No|||June 2007|June 11, 2007|January 7, 2003||||||https://clinicaltrials.gov/show/NCT00051298||202815|
NCT00051311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030077|Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers|A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies||National Institutes of Health Clinical Center (CC)||Completed|January 2003|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|75 Years|No|||September 2014|November 7, 2014|January 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00051311||202814|
NCT00055159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030113|Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins|Treatment of Jugular, Subclavian, and/or Innominate Vein Thrombosis With Low Dose Recombinant Tissue Plasminogen Activator Plus Anticoagulation||National Institutes of Health Clinical Center (CC)||Completed|February 2003|December 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||December 2007|September 26, 2015|February 20, 2003||||No||https://clinicaltrials.gov/show/NCT00055159||202553|
NCT00056173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L01-1409|Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma|A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)||Aptose Biosciences Inc.||Completed|March 2002|||December 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|43|||Both|18 Years|N/A|No|||January 2008|January 4, 2008|March 6, 2003||||||https://clinicaltrials.gov/show/NCT00056173||202487|
NCT00050960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L1069-48|Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer||Eisai Inc.||Completed|May 2002|March 2005|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|612|||Both|N/A|N/A|No|||July 2012|July 7, 2012|December 31, 2002|Yes|Yes||No|July 23, 2010|https://clinicaltrials.gov/show/NCT00050960||202840|
NCT00055536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD306|Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease|A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission||Elan Pharmaceuticals||Completed|April 2002|July 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|March 4, 2003||||||https://clinicaltrials.gov/show/NCT00055536||202528|
NCT00055549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030119|Dextromethorphan to Treat Patients With Voice Spasms|The Effects of an NMDA-Receptor Antagonist in Idiopathic Voice Disorders||National Institutes of Health Clinical Center (CC)||Completed|March 2003|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1|||65|||Both|18 Years|80 Years|No|||November 2009|November 17, 2009|March 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00055549||202527|
NCT00055562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-5013-MEL-001|Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma|Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy||Celgene||Completed|January 2003|December 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||274|||Both|18 Years|N/A|No|||May 2004|June 23, 2005|March 5, 2003||||||https://clinicaltrials.gov/show/NCT00055562||202526|
NCT00054561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271174|Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With Stages III/IV Head and Neck Squamous Cell Carcinoma||National Cancer Institute (NCI)||Completed|August 2003|||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2004|February 6, 2009|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054561||202598|
NCT00056576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN46046-304|Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy|A Double-Blind, Randomized, Multicenter, Parallel Group Study to Establish Dose-Response, Safety, and Efficacy of Zonegran (Zonisamide) as Monotherapy in Patients With Newly Diagnosed Epilepsy||Eisai Inc.||Completed|February 2002|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||165|||Both|16 Years|N/A|No|||July 2011|July 14, 2011|March 18, 2003||||||https://clinicaltrials.gov/show/NCT00056576||202457|
NCT00055224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030093|Expectation of Unpleasant Events in Anxiety Disorders|Predictability and Aversive Expectancies in Anxiety and Depressive Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|February 2003|||||N/A|Observational|N/A|||Anticipated|1041|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|October 29, 2015|February 21, 2003||No||No||https://clinicaltrials.gov/show/NCT00055224||202549|
NCT00051324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS040068|Neurobiological Predictors of Huntington's Disease (PREDICT-HD)|Neurobiological Predictors of Huntington's Disease Trial|PREDICT-HD|University of Iowa|No|Recruiting|August 2002|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Cerebral spinal fluid acquired and retained since 2012.      Plasma retained from 2000-2007. Urine, plasma and cell lines to be acquired and retained      2008-2013.|Both|18 Years|N/A|No|Non-Probability Sample|People at risk for HD, who have been tested for the HD gene mutation, and who have not        been diagnosed with symptoms of HD.|December 2015|December 1, 2015|January 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00051324||202813|
NCT00055354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001229-01|Acupuncture for the Treatment of Post-Traumatic Stress Disorder (PTSD)|Acupuncture Diagnosis and Treatment of DSM-IV PTSD||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2002|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||90|||Both|18 Years|65 Years|No|||July 2006|August 17, 2006|February 26, 2003||||No||https://clinicaltrials.gov/show/NCT00055354||202540|
NCT00055198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-EAP-02-01|Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria|A Compassionate Use Protocol for Intravenous Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria That Cannot be Adequately Treated With Currently Available Therapy||Cubist Pharmaceuticals LLC||Completed|January 2003|January 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||December 2006|January 30, 2007|February 20, 2003||||||https://clinicaltrials.gov/show/NCT00055198||202550|
NCT00055393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063289|Drug Treatment for Pathological Gambling|Bupropion Versus Placebo in the Treatment of Pathological Gambling||University of Iowa||Completed|July 2002|April 2006|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|February 28, 2003||||No||https://clinicaltrials.gov/show/NCT00055393||202537|
NCT00050908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5152s|Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs|Endothelial Function in HIV-Infected Subjects Prior To and After Starting a Potent Antiretroviral Regimen||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||75|||Both|13 Years|N/A|No|||July 2013|July 26, 2013|December 30, 2002||||No||https://clinicaltrials.gov/show/NCT00050908||202844|
NCT00051376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154|Vascular Interaction With Age in Myocardial Infarction|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|100 Years|No|||November 2005|February 17, 2016|January 9, 2003||||No||https://clinicaltrials.gov/show/NCT00051376||202809|
NCT00055302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033IL/0046|Arimidex in McCune Albright Syndrome|An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome||AstraZeneca||Completed|August 2002|August 2015|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|N/A|10 Years|No|||August 2015|August 31, 2015|February 25, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055302||202544|
NCT00055315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063746|Treatment for Borderline Personality Disorder|A Cognitive Group Treatment for Borderline Outpatients||University of Iowa||Completed|July 2002|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|February 25, 2003||||No||https://clinicaltrials.gov/show/NCT00055315||202543|
NCT00051805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI045403-01A2|Promoting Adherence to Anti-HIV Drug Regimens|Promoting Adherence to Antiretroviral Regimens||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2002|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment||||119|||Both|19 Years|N/A|No|||August 2007|September 17, 2007|January 16, 2003||||No||https://clinicaltrials.gov/show/NCT00051805||202778|
NCT00054912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP2101-102|An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer|An Open Label, Multi-Center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage III Colon Cancer||Epimmune||Completed|February 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||April 2004|April 7, 2008|February 12, 2003||||||https://clinicaltrials.gov/show/NCT00054912||202572|
NCT00054925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013066|Weight Loss Maintenance (WLM)|Weight Loss Maintenance (WLM)|WLM|Duke University|Yes|Completed|January 2003|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1685|||Both|25 Years|N/A|No|||March 2012|March 6, 2012|February 13, 2003||No||No||https://clinicaltrials.gov/show/NCT00054925||202571|
NCT00050934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476E 2340|Pediatric Epilepsy Study|A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.||Novartis||Completed|June 2002|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|132|||Both|1 Month|3 Years|No|||November 2011|November 22, 2011|December 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050934||202842|
NCT00050947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476E2339|Pediatric Epilepsy Study|A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures.||Novartis||Completed|July 2002|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|94|||Both|1 Month|16 Years|No|||November 2011|November 22, 2011|December 30, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050947||202841|
NCT00054821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AR048939|Prevention of Post-Traumatic Osteoarthritis (OA)|Pathogenesis-Prevention of Post-Traumatic Osteoarthritis (OA): Effects of Distraction and Motion on OA||University of Iowa|Yes|Completed|November 2002|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|56|||Both|N/A|60 Years|No|||August 2013|August 2, 2013|February 11, 2003||No||No||https://clinicaltrials.gov/show/NCT00054821||202579|
NCT00054834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hLL2-14|Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma|A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma||Immunomedics, Inc.||Terminated|March 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|February 11, 2003|||lack of accrual|||https://clinicaltrials.gov/show/NCT00054834||202578|
NCT00054847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|474|Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery|CSP #474 - Radial Artery vs. Saphenous Vein Grafts in Coronary Artery Bypass Surgery (Radial Artery)||VA Office of Research and Development|Yes|Completed|February 2003|February 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|733|||Both|N/A|N/A|No|||April 2014|April 18, 2014|February 11, 2003||No||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00054847||202577|There was more disease in the radial artery grafts at 1 week and at 1 year. There is more spasm or string sign in radial artery grafts. Study was conducted predominantly in men. Data show lower vein graft patency when endoscopic harvesting was used.
NCT00055445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000992-01A1|IdB 1016 Treatment for Hepatitis C Disease|IdB 1016 in Hepatitis C||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2003|April 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|65 Years|No|||July 2006|August 17, 2006|March 3, 2003||||||https://clinicaltrials.gov/show/NCT00055445||202534|
NCT00055471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4054IL/0004|A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer|||AstraZeneca||Completed|June 2003|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|3||Actual|22|||Male|18 Years|N/A|No|||October 2012|October 23, 2012|March 3, 2003||||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00055471||202533|One patient received one dose of 22.5 mg and was dose reduced to 15 mg thereafter. This patient was classified into the 15 mg dose group, except for the single dose pharmacokinetic results (not posted).
NCT00054652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030089|Survey of Sensory and Motor Tricks in Focal Dystonia|Survey of Sensory and Motor Tricks in Focal Dystonia||National Institutes of Health Clinical Center (CC)||Completed|February 2003|February 2005||||N/A|Observational|N/A||||80|||Both|N/A|N/A|No|||February 2005|March 3, 2008|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054652||202591|
NCT00054769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI049139-01A1|Diagnosing Tuberculosis in HIV Infected Children in Peru|Diagnostics For AIDS-Related Pediatric TB, Peru||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2002|February 2007|Actual|February 2007|Actual|N/A|Observational|Time Perspective: Prospective||||760|||Both|N/A|12 Years|Accepts Healthy Volunteers|||July 2007|September 16, 2008|February 10, 2003||||No||https://clinicaltrials.gov/show/NCT00054769||202582|
NCT00055419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-041|A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer|A Phase II Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer||ImClone LLC|No|Completed|February 2003|August 2004|Actual|July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|744|||Both|18 Years|N/A|No|||April 2010|April 8, 2010|February 28, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055419||202536|
NCT00055432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7127|Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer|||Eli Lilly and Company||Terminated||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2006|September 13, 2006|March 3, 2003||||||https://clinicaltrials.gov/show/NCT00055432||202535|
NCT00055055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030099|Study of Families With Twins or Siblings Discordant for Rheumatic Disorders|Pathogenic Studies In Families With Twins Or Siblings Discordant For Systemic Rheumatic Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|February 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1550|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|February 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00055055||202561|
NCT00050921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5174|Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs|Improving Immune Reconstitution With Growth Hormone in HIV-infected Subjects With Incomplete CD4+ Lymphocyte Restoration on Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|December 30, 2002||||||https://clinicaltrials.gov/show/NCT00050921||202843|
NCT00056329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0039|Vitamin E in Aging Persons With Down Syndrome|Multicenter Vitamin E Trial in Aging Persons With Down Syndrome||New York State Institute for Basic Research|Yes|Active, not recruiting|April 2002|May 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|50 Years|N/A|No|||May 2012|May 2, 2012|March 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00056329||202475|
NCT00051948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2018|TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer||Telik||Completed|January 2003|January 2005|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Female|18 Years|N/A|No|||February 2007|July 21, 2011|January 17, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00051948||202767|
NCT00051961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030075|Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome|Effects of Dopaminergic Agonist Treatment on Spinal Cord Excitability in Restless Legs Syndrome||National Institutes of Health Clinical Center (CC)||Completed|January 2003|October 2007||||N/A|Observational|N/A||||90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2007|March 5, 2008|January 17, 2003||||No||https://clinicaltrials.gov/show/NCT00051961||202766|
NCT00051012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-04-14|Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients|A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25||Eisai Inc.||Completed|September 1995|December 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||86|||Both|18 Years|N/A|No|||February 2008|February 29, 2008|December 31, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00051012||202836|
NCT00051025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L4389-30|Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)|A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma||Eisai Inc.||Completed|May 2000|September 2006|Actual|January 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|9|||Both|18 Years|N/A|No|||July 2012|July 7, 2012|December 31, 2002||Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00051025||202835|
NCT00051155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-74|A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)|A 6-Week Safety and Efficacy Study of TRAVATAN Compared to XALCOM in Subjects With Open-Angle Glaucoma or Ocular Hypertension.||Alcon Research||Completed|January 2001|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|January 3, 2003||||||https://clinicaltrials.gov/show/NCT00051155||202826|
NCT00050973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L1069-49|Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|Randomized Phase III Trial Comparing Targretin Capsules/Cisplatin/Vinorelbine Versus Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small Cell Lung Cancer||Eisai Inc.||Completed||March 2005|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|623|||Both|N/A|N/A|No|||July 2008|May 13, 2013|December 31, 2002|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00050973||202839|
NCT00050986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-126|Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme|Phase I/II Evaluation Temozolomide and Farnesyl Transferase Inhibitor ZARNESTRA (R115777) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Completed|December 2002|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||July 2012|July 27, 2012|December 31, 2002|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00050986||202838|
NCT00056927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01HD36514-5|Anti-Smoking Program for Parents: Effects on Child Smoking|Preventing Initiation of Smoking by Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 1997|August 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||1007|||Both|8 Years|N/A|Accepts Healthy Volunteers|||July 2005|September 29, 2006|March 26, 2003||||No||https://clinicaltrials.gov/show/NCT00056927||202432|
NCT00051233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063484|Treatment of Schizophrenia Through Internet-Based Psychoeducation|Schizophrenia Patient and Family Continuity of Care||University of Pittsburgh||Completed|January 2003|January 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|14 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|January 7, 2003||||No||https://clinicaltrials.gov/show/NCT00051233||202820|
NCT00054938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR47782 NIAMS-077|Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)|A Randomized Controlled Trial of Strategies for the Prevention of Accelerated Atherosclerosis in Systemic Lupus Erythematosus - A Pilot Study||Brigham and Women's Hospital||Completed|March 2003|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|February 13, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054938||202570|
NCT00056147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-103|Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease|Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects With Mild to Moderate Cystic Fibrosis Lung Disease||Merck Sharp & Dohme Corp.||Completed|April 2003|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|90|||Both|8 Years|50 Years|No|||January 2015|January 28, 2015|March 6, 2003||||||https://clinicaltrials.gov/show/NCT00056147||202489|
NCT00056238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-758003|Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy|A Phase II Pilot Study of the Safety, Tolerability and Pharmacokinetics of Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy||Bellus Health Inc||Completed|February 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|55 Years|N/A|No|||March 2003|June 23, 2005|March 7, 2003||||||https://clinicaltrials.gov/show/NCT00056238||202482|
NCT00054795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0211|Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)|Randomized Phase III Trial of Xcytrin® (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy||Pharmacyclics||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||550|||Both|18 Years|N/A|No|||May 2007|May 4, 2007|February 10, 2003||||||https://clinicaltrials.gov/show/NCT00054795||202581|
NCT00051090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5167|Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV|Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|January 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00051090||202831|
NCT00051103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF 20002|Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.|An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens||GlaxoSmithKline||Completed|October 2002|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||April 2015|April 14, 2015|January 3, 2003||||No||https://clinicaltrials.gov/show/NCT00051103||202830|
NCT00055094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI044656-01|Treatment of Acute HIV Infection to Preserve Immune Function|Immune Control of HIV Replication||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 1999|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||500|||Both|18 Years|N/A|No|||April 2004|June 23, 2005|February 19, 2003||||No||https://clinicaltrials.gov/show/NCT00055094||202558|
NCT00056251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIC01|Interstitial Cystitis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of RTX Topical Solution in Patients With Interstitial Cystitis||ICOS Corporation||Completed|January 2003|August 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|70 Years|No|||January 2004|June 23, 2005|March 7, 2003||||||https://clinicaltrials.gov/show/NCT00056251||202481|
NCT00052182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AI048238-03|Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients|A Single Center Phase I Safety and Immunogenicity Study of Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) for Immunotherapy of HIV-1 Infected Individuals Receiving Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2002|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|59 Years|No|||September 2007|October 22, 2007|January 24, 2003||||No||https://clinicaltrials.gov/show/NCT00052182||202749|
NCT00054860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 048|Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults|A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of the EP HIV-1090 DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||42|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|February 11, 2003||||||https://clinicaltrials.gov/show/NCT00054860||202576|
NCT00054873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEZ001|Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer|||Chiron Corporation||Completed|November 2003|December 2004||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2006|July 10, 2006|February 12, 2003||||||https://clinicaltrials.gov/show/NCT00054873||202575|
NCT00051038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-038|Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients|A Phase II Study of the Safety and Efficacy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Who Have Hepatitis B Viremia While Being Treated With Lamivudine||Bristol-Myers Squibb||Completed|September 2002|October 2005|Actual|October 2005|Actual|Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||August 2007|April 7, 2011|December 31, 2002||||||https://clinicaltrials.gov/show/NCT00051038||202834|
NCT00051051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033-011|A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer|A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer||Pfizer||Completed|December 2002|May 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||168|||Female|18 Years|N/A|No|||September 2006|May 3, 2007|January 2, 2003||||No||https://clinicaltrials.gov/show/NCT00051051||202833|
NCT00055588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030120|Nervous System Function in Normal Volunteers During Cycling Training|Spinal Substrates of Training-Dependent Improvements in Locomotor Function||National Institutes of Health Clinical Center (CC)||Completed|March 2003|May 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|September 26, 2015|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055588||202524|
NCT00051363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150|Apnea Positive Pressure Long-Term Efficacy Study|APPLES: Apnea Positive Pressure Long-Term Efficacy Study||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2002|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1105|||Both|18 Years|N/A|No|||July 2009|February 23, 2010|January 9, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00051363||202810|
NCT00055068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH060669|Family Based Treatment of Early Childhood Obsessive Compulsive Disorder|Family Based Treatment of Early Childhood OCD||Rhode Island Hospital||Completed|March 2002|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|38|||Both|5 Years|8 Years|No|||February 2008|May 6, 2014|February 19, 2003||||No||https://clinicaltrials.gov/show/NCT00055068||202560|
NCT00055081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067148|The Impact of Family CTI on Homeless Children|The Impact of Family CTI on Homeless Children||Nathan Kline Institute for Psychiatric Research|No|Completed|July 2002|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|320|||Both|18 Months|16 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|February 19, 2003||No||No||https://clinicaltrials.gov/show/NCT00055081||202559|
NCT00055237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030110|Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients|Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma||National Institutes of Health Clinical Center (CC)|No|Completed|February 2003|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|February 21, 2003||No||No|June 19, 2012|https://clinicaltrials.gov/show/NCT00055237||202548|
NCT00054951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC-DOX-006|Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads|A Phase I/II, Open Label, Multicenter, Single-Arm, Safety and Efficacy Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery (Via Hepatic Artery Catheterization) for the Treatment of Patients With Unresectable Hepatocellular Carcinoma.||FeRx||Active, not recruiting|June 2001|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||September 2003|June 23, 2005|February 13, 2003||||||https://clinicaltrials.gov/show/NCT00054951||202569|
NCT00056992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206|Testing of ADI-PEG in Hepatocellular Carcinoma|Phase II Testing of ADI-PEG in Hepatocellular Carcinoma||FDA Office of Orphan Products Development||Completed|September 2002|October 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||34|||Both|N/A|N/A|No|||September 2002|March 24, 2015|March 26, 2003||||||https://clinicaltrials.gov/show/NCT00056992||202427|
NCT00054808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genta-GGN202|Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Multicenter Study of Gallium Nitrate in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma||Genta Incorporated||Completed|June 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||February 2006|February 7, 2006|February 10, 2003||||||https://clinicaltrials.gov/show/NCT00054808||202580|
NCT00051168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-20|A Long-term Safety Study of Once-daily Travatan|A Long-term Safety Study of Once-daily TRAVATAN||Alcon Research||Completed|January 2006|||March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|502|||Both|18 Years|N/A|No|||April 2010|October 2, 2011|January 3, 2003|Yes|Yes||No|March 22, 2010|https://clinicaltrials.gov/show/NCT00051168||202825|
NCT00051181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-38|A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma|A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.||Alcon Research||Completed|January 2000|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|January 3, 2003||||||https://clinicaltrials.gov/show/NCT00051181||202824|
NCT00051194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-03|A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension|A 6-week Safety and Efficacy Study of Combination IOP-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension.||Alcon Research||Completed|September 2002|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2006|April 12, 2012|January 3, 2003||||||https://clinicaltrials.gov/show/NCT00051194||202823|
NCT00055289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030112|Brain Use of Sensory Information to Generate Movement|Role of Multimodal Areas for Sensory-To-Motor Processing||National Institutes of Health Clinical Center (CC)||Completed|February 2003|January 2006||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|February 22, 2003||||No||https://clinicaltrials.gov/show/NCT00055289||202545|
NCT00056160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-009|CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma|A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma||Celgene|Yes|Completed|January 2003|October 2008|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|353|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|March 6, 2003|Yes|Yes||No|December 24, 2009|https://clinicaltrials.gov/show/NCT00056160||202488|Analyses for efficacy had data cutoff dates of 07 Jun 2005 and a data cutoff date of 23 Jul 2008 for overall survival. Only safety data were collected for 6 subjects ongoing beyond the 23 Jul 2008 data cutoff date.
NCT00051246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062054|Group Therapy for Postpartum Depression|Relational Group Intervention for Postpartum Depression||University of Wisconsin, Madison|Yes|Completed|January 2002|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Female|18 Years|N/A|No|||January 2014|January 23, 2014|January 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00051246||202819|
NCT00051259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK130926|Effects of Antidepressants on Sexual Functioning|A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period||GlaxoSmithKline||Completed|January 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||420|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|January 7, 2003||||||https://clinicaltrials.gov/show/NCT00051259||202818|
NCT00051207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH061948|Therapy for Depression With Co-occurring Panic or Anxiety Symptoms|Interpersonal Psychotherapy for Depression With Co-occurring Panic and Anxiety Symptoms (IPT-PS)||University of Pittsburgh||Completed|November 2002|August 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|60 Years|No|||December 2007|June 21, 2013|January 7, 2003||||No||https://clinicaltrials.gov/show/NCT00051207||202822|
NCT00056446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787 0133/304946|Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer|A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum||Novartis|No|Completed|January 2003|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|855|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 13, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00056446||202467|
NCT00055003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030102|Effect of Hydrocortisone on the Brain|Effects of Hydrocortisone Infusion on Processing of Facially Expressed Emotion During Functional Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Completed|February 2003|November 2010||||N/A|Observational|N/A|||Actual|80|||Both|18 Years|50 Years|No|||November 2010|November 19, 2010|February 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00055003||202565|
NCT00055016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030106|Registry of Fabry Disease - A Multicenter Observational Study|Registry of Fabry Disease: A Multicenter, Longitudinal Observational Study||National Institutes of Health Clinical Center (CC)||Completed|February 2003|March 2008||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||March 2008|September 26, 2015|February 15, 2003||||No||https://clinicaltrials.gov/show/NCT00055016||202564|
NCT00055029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030033|Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis|X-Linked Juvenile Retinoschisis - Clinical and Molecular Studies||National Institutes of Health Clinical Center (CC)||Recruiting|February 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|9 Months|N/A|No|||July 2015|August 5, 2015|February 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00055029||202563|
NCT00055042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030064|Laser and Antioxidant Treatment of Diabetic Macular Edema|Laser and Antioxidant Treatment of Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|February 2003|January 2004||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||January 2004|March 3, 2008|February 15, 2003||||No||https://clinicaltrials.gov/show/NCT00055042||202562|
NCT00054886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTKC-0511-014|Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer|Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma||Pfizer||Completed|January 2003|August 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||63|||Both|18 Years|N/A|No|||July 2006|May 4, 2007|February 12, 2003||||No||https://clinicaltrials.gov/show/NCT00054886||202574|
NCT00054899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP2101-101|An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer|An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)||Epimmune||Completed|January 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||April 2004|March 23, 2010|February 12, 2003||||||https://clinicaltrials.gov/show/NCT00054899||202573|
NCT00055705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270801|PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer|A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity||National Cancer Institute (NCI)||Completed|January 2003|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|April 23, 2011|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055705||202516|
NCT00051818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI48398-01|Immune and Viral Outcomes of HIV-1 Therapy Interruption|Immune and Viral Outcomes of HIV-1 Therapy Interruption||The Wistar Institute|Yes|Completed|September 2000|July 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|17 Years|N/A|No|||December 2005|February 8, 2016|January 16, 2003||No||No||https://clinicaltrials.gov/show/NCT00051818||202777|
NCT00055250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4840|A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer|A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer||Eli Lilly and Company||Completed|January 2003|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|February 21, 2003||||||https://clinicaltrials.gov/show/NCT00055250||202547|
NCT00055263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-001|A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies|A Phase I, Open Label, Dose Escalation Study of a New Formulation of Calcitriol (DN-101) for Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies||Novacea||Completed|March 2002|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||February 2003|July 24, 2009|February 21, 2003||||||https://clinicaltrials.gov/show/NCT00055263||202546|
NCT00054444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9913|Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer|A PHASE I STUDY OF PELVIC RADIATION THERAPY WITH CONCOMITANT WEEKLY CISPLATIN AND TOPOTECAN CHEMOTHERAPY IN PATIENTS WITH CERVICAL CARCINOMA WITHOUT EXTRA-PELVIC METASTASIS||Gynecologic Oncology Group||Completed|September 2007|||January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|N/A|N/A|No|||December 2014|December 29, 2014|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054444||202606|
NCT00054457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0242|Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction|A Phase II Study Of Docetaxel And Capecitabine In Patients With Measurable Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction||Alliance for Clinical Trials in Oncology|No|Completed|September 2003|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054457||202605|
NCT00056758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AI043664-04|HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs|Randomized Phase I Evaluation of Immunization With Highly Conserved HIV-1 Derived Peptides and Influenza Matrix Peptide in HIV-1-Infected Subjects on Highly Active Antiretroviral Therapy (HAART) Using Autologous Dendritic Cells Derived From Adherent Monocytic Precursors||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||August 2007|August 23, 2007|March 21, 2003||||||https://clinicaltrials.gov/show/NCT00056758||202445|
NCT00051337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030072|Single Photon Emission Computed Tomography (SPECT) to Study Paroxysmal Hyperkinetic Movement Disorders|The Physiology of Paroxysmal Hyperkinetic Movement Disorders: A SPECT Study||National Institutes of Health Clinical Center (CC)||Completed|January 2003|January 2005||||N/A|Observational|N/A||||40|||Both|N/A|N/A|No|||January 2005|March 3, 2008|January 8, 2003||||No||https://clinicaltrials.gov/show/NCT00051337||202812|
NCT00051350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1192|OmniHeart Trial: Macronutrients and Cardiovascular Risk|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 2002|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment|||||||Both|30 Years|N/A|No|||April 2008|April 22, 2008|January 9, 2003||||No||https://clinicaltrials.gov/show/NCT00051350||202811|
NCT00054535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270794|Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2||National Cancer Institute (NCI)||Completed|January 2003|September 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||July 2004|June 18, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054535||202600|
NCT00054119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0186D|Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Karenitecin in the Third-Line Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|January 2003|||July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|N/A|N/A|No|||December 2014|December 29, 2014|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054119||202629|
NCT00054236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU6Y01|Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia|Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia||Case Comprehensive Cancer Center|Yes|Completed|May 2002|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||September 2012|September 11, 2012|February 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00054236||202620|
NCT00054210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269910|Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study||National Cancer Institute (NCI)||Active, not recruiting|January 2003|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|July 23, 2008|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054210||202622|
NCT00054990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030107|Effects of Antiepileptic Drugs on Brain Excitability|The Effects Of Antiepileptic Drugs On Cortical Excitability||National Institutes of Health Clinical Center (CC)||Completed|February 2003|March 2004||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|March 3, 2008|February 15, 2003||||No||https://clinicaltrials.gov/show/NCT00054990||202566|
NCT00053885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269537|PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma|A Phase II Study of PTK787/ZK222584 (NSC#719335) in Patients With Unresectable Malignant Mesothelioma||Alliance for Clinical Trials in Oncology|No|Completed|July 2003|June 2006|Actual|July 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053885||202645|
NCT00053898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-35|Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy|A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy||NSABP Foundation Inc|Yes|Active, not recruiting|January 2003|March 2016|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3104|||Female|N/A|N/A|No|||March 2015|March 9, 2015|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053898||202644|
NCT00054041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02513|Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia|Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3||National Cancer Institute (NCI)||Completed|June 2004|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|17 Years|N/A|No|||January 2013|January 23, 2013|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054041||202633|
NCT00054600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GvHD Prevention|Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease|A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant||Therakos||Completed|June 2002|June 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|60 Years|No|||April 2010|April 7, 2010|February 5, 2003||||||https://clinicaltrials.gov/show/NCT00054600||202595|
NCT00054158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 02-15|Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma|A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM)||Roswell Park Cancer Institute||Completed|August 2004|||April 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054158||202626|
NCT00054301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICC4102|Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer|Intraoperative Radiation Therapy to the Tumor Bed for Boost Treatment After Lumpectomy Prior to Whole Breast Radiation in Breast Conservation Candidates||Case Comprehensive Cancer Center|Yes|Completed|November 2002|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||June 2010|June 10, 2010|February 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00054301||202615|
NCT00054587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0140/0005 - PACS 04|Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer|Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And FISH+) Subjects||UNICANCER|Yes|Completed|June 2001|December 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3010|||Female|18 Years|64 Years|No|||July 2013|July 18, 2013|February 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00054587||202596|
NCT00054665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030096|PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma|PS-341 and PS-341 + Epoch Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas||National Institutes of Health Clinical Center (CC)|No|Completed|February 2003|July 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|February 5, 2003||No||No|June 25, 2012|https://clinicaltrials.gov/show/NCT00054665||202590|
NCT00053742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030087|Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox|A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Immunogenicity and Protective Efficacy Against Dryvax® (Registered Trademark) Challenge in Vaccinia-Immune Individuals||National Institutes of Health Clinical Center (CC)||Completed|February 2003|March 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2006|March 3, 2008|February 4, 2003||||No||https://clinicaltrials.gov/show/NCT00053742||202654|
NCT00054353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1743.00|Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma|Reduced-Intensity Allogeneic HSC Transplantation From HLA-Matched Related and Unrelated Donors for Patients With Multiple Myeloma - A Multi-Center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|October 2002|||October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054353||202611|
NCT00055341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI049508-01|Treatment of Hepatitis C in Hemophilic Patients With HIV|A Prospective Multicenter, Phase II, Open Label, Controlled Trial Evaluating the Response of Hepatitis C Virus (HCV) to Pegylated Interferon Alpha-2A and Ribavirin in Hemophilic Patients With and Without Coinfection With the Human Immunodeficiency Virus (HIV)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2002|June 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|15 Years|N/A|No|||December 2006|July 29, 2008|February 25, 2003||||No||https://clinicaltrials.gov/show/NCT00055341||202541|
NCT00053443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44AI43750-02 A 2|Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens|Compliance Enhancement In HIV/AIDS Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||156|||Both|16 Years|N/A|No|||December 2005|December 22, 2005|January 29, 2003||||No||https://clinicaltrials.gov/show/NCT00053443||202674|
NCT00054327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1Y00|Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors||Case Comprehensive Cancer Center|Yes|Completed|November 2000|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|34|||Both|N/A|55 Years|No|||June 2013|June 19, 2013|February 5, 2003|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00054327||202613|
NCT00054613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GvHD-SK1|Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease|A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft-versus-Host Disease||Therakos||Completed|June 2002|March 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||72|||Both|N/A|N/A|No|||April 2010|April 7, 2010|February 5, 2003||||||https://clinicaltrials.gov/show/NCT00054613||202594|
NCT00054626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258426|Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer|Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 2001|||June 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|700|||Both|18 Years|74 Years|No|||November 2008|December 17, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054626||202593|
NCT00053911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACS03|Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer|Randomized And Multicentric Phase III Study Evaluating The Benefit By Using A Chemotherapy With FEC 100 And Docetaxel In Non Metastatic Breast Cancer Which Has Relapsed After A Conservative Surgery||UNICANCER||Terminated|November 2002|||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|65 Years|No|||December 2014|December 14, 2014|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053911||202643|
NCT00054249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TULA-T-607-006|T900607 in Treating Patients With Gastroesophageal Junction Cancer|A Phase II Study Of Intravenous T900607-Sodium In Subjects With Previously Treated Gastric Carcinoma||National Cancer Institute (NCI)||Completed|September 2002|September 2010|Actual|October 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2010|July 17, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054249||202619|
NCT00053963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01803|FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia|A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS||National Cancer Institute (NCI)||Completed|September 2002|||February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|21 Years|No|||January 2013|January 15, 2013|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053963||202639|
NCT00054691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-282|ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin|A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin||M.D. Anderson Cancer Center|No|Completed|May 2004|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|February 6, 2003||No||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00054691||202588|
NCT00054704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030092|Riluzole to Treat Depression in Bipolar Disorder|An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression||National Institutes of Health Clinical Center (CC)||Completed|February 2003|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|70 Years|No|||December 2014|December 13, 2014|February 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054704||202587|
NCT00054288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270343|Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors|Escalating Irinotecan (CPT-11) Administered 24 Hours Prior To Gemcitabine In Patients With Refractory Solid Tumors||Roswell Park Cancer Institute|Yes|Completed|August 2001|June 2009|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2014|January 10, 2014|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054288||202616|
NCT00053924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-015|Perifosine in Treating Patients With Advanced Pancreatic Cancer|A Phase 2 Study Of Perifosine As Second Line Therapy For Advanced Pancreatic Carcinoma||University Health Network, Toronto||Completed|May 2003|||May 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2015|July 22, 2015|February 5, 2003||Yes||No||https://clinicaltrials.gov/show/NCT00053924||202642|
NCT00054197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269908|Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|CT-2103 vs Gemcitabine or Vinorelbine for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study||National Cancer Institute (NCI)||Active, not recruiting|January 2003|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|February 23, 2011|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054197||202623|
NCT00053768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269371|Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma|Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses||National Cancer Institute (NCI)||Active, not recruiting|April 2002|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|552|||Both|18 Years|60 Years|No|||June 2007|February 6, 2009|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053768||202653|
NCT00054106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I153|Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer|A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer||Canadian Cancer Trials Group||Completed|December 2002|September 2008|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||March 2010|November 7, 2010|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054106||202630|
NCT00054028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01431|Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer|A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|December 2002|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||February 2015|March 3, 2015|February 5, 2003|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00054028||202634|
NCT00054678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMI-US-01-002|MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)|A Phase I, Open-Label, Non-Randomized, Dose Escalation, Multi Center Study to Assess the Safety and Cardiovascular Effects of Autologous Skeletal Myoblast Implantation by a Transendocardial Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s) With Previous Placement of ICD||Bioheart, Inc.||Active, not recruiting|February 2003|October 2007|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|30 Years|80 Years|No|||October 2007|October 11, 2007|February 6, 2003||||No||https://clinicaltrials.gov/show/NCT00054678||202589|
NCT00054756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030098|Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities|Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities||National Institutes of Health Clinical Center (CC)||Recruiting|February 2003|January 2099|Anticipated|January 2099|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|999999|||Both|2 Years|65 Years|No|||August 2015|August 26, 2015|February 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054756||202583|
NCT00054717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.12|Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)|Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.||Boehringer Ingelheim||Completed|January 2003|||September 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|630|||Both|18 Years|N/A|No|||April 2014|June 23, 2014|February 7, 2003||Yes||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00054717||202586|
NCT00055510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO-004|A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.|||Chugai Pharma USA||Completed||||||Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2004|June 23, 2005|March 4, 2003||||||https://clinicaltrials.gov/show/NCT00055510||202530|
NCT00055523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-403|A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease|A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease||Abbott||Completed|April 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|75 Years|No|||August 2006|August 11, 2006|March 4, 2003||||||https://clinicaltrials.gov/show/NCT00055523||202529|
NCT00053612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI343844|Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission|Prevention of HIV Shedding in Women - Trial of Vitamin A||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Female|N/A|N/A|No|||August 2007|September 17, 2007|February 3, 2003||||No||https://clinicaltrials.gov/show/NCT00053612||202662|
NCT00054964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-202-4-167|Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique|Comparison of Single-dose Efficacy of Albuterol-HFA-BOI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability||Teva Pharmaceutical Industries|No|Completed|March 2003|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|February 14, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054964||202568|
NCT00054977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAVFU-001|Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors|A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors||Galectin Therapeutics Inc.|No|Completed|February 2003|September 2006|Actual|April 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2012|March 9, 2012|February 14, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054977||202567|
NCT00054730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORX-CX516-013|Effects of CX516 on Functioning in Fragile X Syndrome and Autism|Effects of Ampakine CX516 (Ampalex®) on Functioning in Fragile X Syndrome and Autism||RespireRx||Completed|June 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|No|||February 2005|June 23, 2005|February 7, 2003||||||https://clinicaltrials.gov/show/NCT00054730||202585|
NCT00054743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030091|Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United States|Global Initiative to Characterize Differences in Antiretroviral Pharmacokinetics in HIV-Infected Populations||National Institutes of Health Clinical Center (CC)||Completed|February 2003|April 2011|Actual|||Phase 4|Interventional|Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2011|September 26, 2015|February 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00054743||202584|
NCT00054132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-02225|Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer|A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer||National Cancer Institute (NCI)|Yes|Completed|December 2002|||April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||December 2015|December 16, 2015|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054132||202628|
NCT00055484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN46046-228|A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache|A Double-Blind, Randomized, Multicenter, Parallel Dose Study to Evaluate the Safety and Efficacy of Zonisamide 150 mg and 300 mg Per Day and Placebo in Subjects With Migraine Headache||Elan Pharmaceuticals||Completed|March 2002|May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||204|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|March 3, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00055484||202532|
NCT00055497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-433|Remission in Subjects With Crohn's Disease, 1 Year Phase|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease|CLASSICII|Abbott|No|Completed|August 2002|December 2008|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|276|||Both|18 Years|75 Years|No|||April 2011|April 7, 2011|March 3, 2003|Yes|Yes||No|December 15, 2009|https://clinicaltrials.gov/show/NCT00055497||202531|
NCT00053820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269480|Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer|A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|July 2002|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|670|||Both|18 Years|81 Years|No|||August 2006|December 18, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053820||202649|
NCT00053833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269486|S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|S0025: Phase II Trial Of Irinotecan (CAMPTOSAR) For Patients With Platinum And Taxane Refractory Ovarian, Peritoneal Or Fallopian Tube Cancer||Southwest Oncology Group|Yes|Terminated|April 2003|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|N/A|N/A|No|||November 2013|November 7, 2013|February 5, 2003|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00053833||202648|
NCT00053937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269598|Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas|Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas||National Cancer Institute (NCI)||Completed|December 2002|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Prevention|||||||Both|3 Years|21 Years|No|||April 2004|April 29, 2015|February 5, 2003||||||https://clinicaltrials.gov/show/NCT00053937||202641|
NCT00054340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1723.00|Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder|Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders||Fred Hutchinson Cancer Research Center||Completed|October 2002|September 2006|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|N/A|65 Years|No|||May 2010|May 12, 2010|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054340||202612|
NCT00054405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00024|Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma|A Phase I Investigation of IL-12 (NSC 672423)/Pulse IL-2 (Aldesleukin) in Children With Persistent and/or Refractory Neuroblastoma (13623)||National Cancer Institute (NCI)||Terminated|December 2002|||May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|3 Years|21 Years|No|||April 2013|April 8, 2013|February 5, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00054405||202609|
NCT00051077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5149|Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)|A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||May 2012|May 16, 2012|January 3, 2003||||No||https://clinicaltrials.gov/show/NCT00051077||202832|
NCT00054002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269674|Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma|Surgery and Intracavitary Photodynamic Therapy (PDT) for the Treatment of Malignant Pleural Mesothelioma; The Use of Light Delivery Fibers With Large Diffusers||Roswell Park Cancer Institute|Yes|Completed|March 1999|December 2010|Actual|June 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2011|February 25, 2011|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054002||202636|
NCT00054015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269675|3-AP in Treating Patients With Advanced Prostate Cancer|A Phase II Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Patients With Advanced Prostate Cancer||National Cancer Institute (NCI)||Completed|December 2002|January 2008|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||April 2004|November 5, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054015||202635|
NCT00054184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-PGT302|Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer|CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study||CTI BioPharma||Active, not recruiting|January 2003|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054184||202624|
NCT00053703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 MH 615218-01A|Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)|Treatment of Schizophrenia and Related Disorders in Children and Adolescents|TEOSS|University of North Carolina, Chapel Hill|Yes|Completed|February 2002|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|116|||Both|8 Years|19 Years|No|||February 2014|February 7, 2014|February 4, 2003|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00053703||202656|The most significant weakness of this study was the sample size, which was sufficient only to detect large differences across the three treatments and limited our ability to identify predictors of response or adverse effects.
NCT00055172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030105|Genetic Basis of Immunodeficiency|The Determination of Genetic Basis Of Immunodeficiency||National Institutes of Health Clinical Center (CC)||Recruiting|February 2003|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|N/A|N/A|No|||June 2015|July 1, 2015|February 20, 2003||No||No||https://clinicaltrials.gov/show/NCT00055172||202552|
NCT00055328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062322|Treatment for Depression in the Primary Care Setting|Problem-Solving Treatment for Primary Care Depression||Dartmouth-Hitchcock Medical Center||Completed|December 2002|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||August 2008|September 6, 2013|February 25, 2003||||No||https://clinicaltrials.gov/show/NCT00055328||202542|
NCT00055575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030108|Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies|Cholinergic Modulation of Cognition and Emotion in Mood Disorders: Functional Neuroimaging Studies||National Institutes of Health Clinical Center (CC)||Terminated|February 2003|February 2015|Actual|February 2015|Actual|N/A|Interventional|Primary Purpose: Treatment|1||Actual|197|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055575||202525|
NCT00054392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPHA-A1-99002L|Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer||Fox Chase Cancer Center||Withdrawn|September 2001|September 2001|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|February 5, 2003|Yes|Yes|Not opened at Fox Chase Cancer Center|No||https://clinicaltrials.gov/show/NCT00054392||202610|
NCT00054262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TULA-TULI-2202|T900607 in Treating Patients With Unresectable Liver Cancer|A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|November 2002|September 2010|Actual|March 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2010|July 17, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054262||202618|
NCT00054145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-014|Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer|A Phase 2 Study Of Perifosine In Metastatic Or Advanced Breast Cancer||University Health Network, Toronto||Completed|June 2003|||April 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2015|July 22, 2015|February 5, 2003||Yes||No||https://clinicaltrials.gov/show/NCT00054145||202627|
NCT00055185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT2001|Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients|||Progenics Pharmaceuticals, Inc.||Completed|April 2003|June 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||24|||Both|18 Years|N/A|No|||October 2008|October 2, 2008|February 20, 2003||||No||https://clinicaltrials.gov/show/NCT00055185||202551|
NCT00054431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02516|Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia|Phase II Study of Imatinib Mesylate (Gleevec, STI-571) (NSC#716051) and Decitabine (5-AZA-2'-Deoxycitidine) (NSC#127716), in Chronic Myelogenous Leukemia in Accelerated and Blastic Phases||National Cancer Institute (NCI)||Completed|January 2003|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|N/A|No|||January 2013|January 22, 2013|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054431||202607|
NCT00054548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00010|Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors|A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|October 2002|||May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054548||202599|
NCT00054054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269781|S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Docetaxel (NSC-628503), Cisplatin (NSC-119875), And 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed By Accelerated Fractionation/Concomitant Boost Radiation And Concurrent Single Agent Cisplatin (NSC-119875), In Patients With Advanced Squamous Cell Head And Neck Cancer||Southwest Oncology Group|No|Completed|April 2003|||November 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2011|July 21, 2011|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054054||202632|
NCT00051220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059308|Treatment for Specific Phobias in Children|One-Session Treatment for Specific Phobias in Children||Virginia Polytechnic Institute and State University||Completed|October 2001|September 2006|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|150|||Both|7 Years|16 Years|No|||June 2013|June 6, 2013|January 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00051220||202821|
NCT00055367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD305|Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease|A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease||Elan Pharmaceuticals||Completed|April 2002|May 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|12 Years|17 Years|No|||March 2012|March 6, 2012|February 26, 2003||||||https://clinicaltrials.gov/show/NCT00055367||202539|
NCT00053846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269487|Buspirone in Reducing Shortness of Breath in Patients With Cancer|Buspirone in Reducing Shortness of Breath in Patients With Cancer||University of Rochester|Yes|Completed|November 2002|January 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|432|||Both|18 Years|120 Years|No|||October 2015|October 27, 2015|February 5, 2003||No||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00053846||202647|
NCT00053872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269521|Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma|A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma||National Cancer Institute (NCI)||Active, not recruiting|February 2003|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|316|||Both|3 Years|21 Years|No|||February 2007|June 23, 2014|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00053872||202646|
NCT00053950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03166|Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma|A Phase I Study of High-dose Pyrazoloacridine (PZA) (NSC 366140) Supported With Autologous Hematopoietic Stem Cell Rescue in Children With Recurrent or Resistant Neuroblastoma (IND # 36325)||National Cancer Institute (NCI)||Terminated|December 2002|||March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|1 Year|30 Years|No|||April 2013|April 8, 2013|February 5, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00053950||202640|
NCT00054483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02917|Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction|A Phase I Pharmacokinetic Study of PS341 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group||National Cancer Institute (NCI)||Completed|January 2003|||September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|69|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054483||202603|
NCT00054496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270723|Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme|Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme||National Cancer Institute (NCI)||Recruiting|August 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||December 2006|January 9, 2014|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054496||202602|
NCT00055380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030115|Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients|Molecular, Genetic, and Biochemical Effects Of Novel Therapies In Buccal Mucosal Cells||National Institutes of Health Clinical Center (CC)||Completed|February 2003|October 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||October 2005|March 3, 2008|February 28, 2003||||No||https://clinicaltrials.gov/show/NCT00055380||202538|
NCT00054171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 97-32|Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia|A Pilot Study of Short (1-2.5 h), Medium (4-6 h) and Long (18-24 h) Applications of 20% Topical ALA-PDT for Photodynamic Therapy of Cutaneous T and B Cell Lymphomas and Cutaneous Infiltrates of Early CLL||Roswell Park Cancer Institute||Completed|February 1999|||July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|1|||Both|N/A|N/A|No|||January 2013|January 30, 2013|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054171||202625|
NCT00054314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS 02-04|BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer|An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC)||Roswell Park Cancer Institute||Completed|March 2002|||April 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 30, 2013|February 5, 2003||||No||https://clinicaltrials.gov/show/NCT00054314||202614|
NCT00054470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270686|Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer|A Phase II Evaluation Of The Efficacy And Safety Of R115777 (NSC702818) A Non-Peptidomimetic Farnesyl Transferase Inhibitor, And Trastuzumab In Patients With Advanced Breast Cancer||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|December 2002|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|February 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00054470||202604|
NCT00053716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV 2002-05|Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease|Phase II, Single Center, Non-Controlled, Open-Label Study of Liposomal Prostaglandin E1 (Liprostin) as Adjunct Therapy With Lower Limb Angioplasty in Patients With Ischemic and Non-Ischemic Peripheral Arterial Occlusive Disease||Endovasc||Recruiting|February 2003|August 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|75 Years|No|||March 2004|March 6, 2007|February 4, 2003||||||https://clinicaltrials.gov/show/NCT00053716||202655|
NCT00055133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-MPRA02|A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis|A Phase 2 Open-Label Clinical Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis||Angiotech Pharmaceuticals||Completed|September 2002|December 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|21 Years|70 Years|No|||July 2008|July 26, 2008|February 19, 2003||||||https://clinicaltrials.gov/show/NCT00055133||202555|
NCT00055146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L4389-34|Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)|A Multicenter, Phase II Study of ONTAK (Denileukin Diftitox) in Patients With Previously-Treated Chronic Lymphocytic Leukemia||Eisai Inc.||Completed|March 2003|May 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|41|||Both|18 Years|N/A|No|||April 2009|April 16, 2009|February 19, 2003||||No||https://clinicaltrials.gov/show/NCT00055146||202554|
NCT00054574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269889|Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer|A Clinical Trial Evaluating The Safety And Efficacy Of ABX-EGF In Patients With Hormone Resistant Prostate Cancer With Elevated PSA Without Metastasis||Jonsson Comprehensive Cancer Center|Yes|Completed|November 2002|February 2004|Actual|September 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||August 2012|August 2, 2012|February 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00054574||202597|
NCT00054639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-00617|Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma|A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas||National Cancer Institute (NCI)||Completed|January 2003|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||March 2013|May 13, 2014|February 5, 2003|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00054639||202592|
NCT00054275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1102|Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer|A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With The Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|December 2002|November 2012|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 5, 2003|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00054275||202617|
NCT00055107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG 369|Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children|A Phase I/II Open Label Study of Nitazoxanide (NTZ) for the Treatment of Cryptosporidium Parvum in HIV Infected Infants, Children, and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Both|3 Months|19 Years|No|||February 2012|February 14, 2012|February 19, 2003||||||https://clinicaltrials.gov/show/NCT00055107||202557|
NCT00055120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5164|When to Start Anti-HIV Drugs in Patients With Opportunistic Infections|A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2003|August 2007|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|283|||Both|13 Years|N/A|No|||October 2014|October 14, 2014|February 19, 2003||||No||https://clinicaltrials.gov/show/NCT00055120||202556|
NCT00057434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI041956-05|Vitamin A Therapy for Tuberculosis|Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 1998|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1140|||Both|18 Years|80 Years|No|||August 2007|September 17, 2007|April 1, 2003||||No||https://clinicaltrials.gov/show/NCT00057434||202393|
NCT00057447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINHL-001|Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients|Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma||InterMune||Terminated|March 2003|June 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||October 2007|October 30, 2007|April 1, 2003|||administrative reasons|No||https://clinicaltrials.gov/show/NCT00057447||202392|
NCT00053560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL02-01|To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids|A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids||Genelabs Technologies||Active, not recruiting|December 2002|August 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||155|||Female|18 Years|N/A|No|||November 2004|December 26, 2007|January 30, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053560||202665|
NCT00053651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH061555|Prevention of Postpartum Depression in Low-Income Women|Depression Intervention for Poor Pregnant Women||Butler Hospital|Yes|Completed|September 2001|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||250|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|February 4, 2003||||No||https://clinicaltrials.gov/show/NCT00053651||202659|
NCT00057785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0225|Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer|A Phase II Study Of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy For Nasopharyngeal Cancer||Radiation Therapy Oncology Group|Yes|Completed|February 2003|||February 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|April 7, 2003|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT00057785||202367|
NCT00057200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 99-345|Evaluating Telehealth Home Care for Elderly Veterans With Congestive Heart Failure|Evaluating Telehealth Home Care for Elderly Veterans With Congestive Heart Failure||VA Office of Research and Development|No|Completed||January 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|198|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057200||202411|
NCT00057213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHB20002|An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.||GlaxoSmithKline|No|Completed|March 2003|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|367|||Both|18 Years|64 Years|No|||April 2015|April 15, 2015|March 27, 2003||||||https://clinicaltrials.gov/show/NCT00057213||202410|
NCT00057109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECI 01-195|Health Values and Spirituality in Veterans With HIV/AIDS|Health Values and Spirituality in Veterans With HIV/AIDS||VA Office of Research and Development|No|Completed||June 2005|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|||December 2005|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057109||202418|
NCT00057577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060713|Prevention of Recurrence in Depression With Drugs and CT|Prevention of Recurrence in Depression With Drugs and CT|CPT3|Vanderbilt University|Yes|Completed|October 2002|March 2014|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|452|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|April 4, 2003|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00057577||202382|
NCT00058188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 02U1|Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation|A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation||Northwestern University|Yes|Active, not recruiting|March 2003|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Male|18 Years|N/A|No|||September 2015|September 28, 2015|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058188||202342|
NCT00057538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001159-01A1|Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIV|Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIV||National Center for Complementary and Integrative Health (NCCIH)||Completed|May 2003|May 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||60|||Both|18 Years|65 Years|No|||August 2006|August 16, 2006|April 4, 2003||||No||https://clinicaltrials.gov/show/NCT00057538||202385|
NCT00057629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH042178|Prolonged Exposure Therapy for Post Traumatic Stress Disorder Following Sexual Assault|Effectiveness of Treatment for PTSD in Community Agencies||University of Pennsylvania|Yes|Completed|January 2002|August 2009|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|187|||Female|18 Years|67 Years|No|||November 2015|November 12, 2015|April 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00057629||202378|
NCT00053404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI052745-01|Immunologic Control of Drug Resistant HIV|Observational Study of HIV Infected Adults With Detectable Plasma HIV-1 RNA Levels Between 200 and 10,000 Copies/mL While Receiving Stable Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|March 2003|December 2008|Anticipated|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Blood collection|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected participants receiving antiretroviral therapy|September 2008|September 25, 2008|January 28, 2003||No||No||https://clinicaltrials.gov/show/NCT00053404||202677|
NCT00057161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 98-154|Homelessness Prevention: Psychiatric Care With Representative Payeeship|Homelessness Prevention: Psychiatric Care With Representative Payeeship||VA Office of Research and Development|No|Completed||June 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057161||202414|
NCT00053625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS037959|Deep Brain Stimulation for Parkinson's Disease Trial|Deep Brain Stimulation for Parkinson's Disease Trial||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|June 1999|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|123|||Both|30 Years|75 Years|No|||April 2015|April 2, 2015|February 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00053625||202661|
NCT00057395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-726-04|A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies|A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies||Aronex Pharmaceuticals||Active, not recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2004|June 23, 2005|April 1, 2003||||||https://clinicaltrials.gov/show/NCT00057395||202396|
NCT00057122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI048526-01A1|Tuberculosis Prevention for HIV Infected Adults|Novel TB Prevention Regimens for HIV-Infected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2002|June 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1148|||Both|18 Years|N/A|No|||October 2012|October 19, 2012|March 27, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057122||202417|
NCT00057135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 01-074|Improving Antipsychotic Adherence Among Patients With Serious Mental Illness|Improving Antipsychotic Adherence Among Patients With Schizophrenia||VA Office of Research and Development|Yes|Completed|November 2002|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||April 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057135||202416|
NCT00056771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030123|Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts|Clinical and Molecular Studies in Families With Congenital or Hereditary Cataracts||National Institutes of Health Clinical Center (CC)||Recruiting|March 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Both|4 Years|N/A|No|||April 2015|April 21, 2015|March 22, 2003||No||No||https://clinicaltrials.gov/show/NCT00056771||202444|
NCT00056784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030132|The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation|The Pathogenesis of Chronic Graft Failure After Kidney Transplantation||National Institutes of Health Clinical Center (CC)||Completed|March 2003|June 2014||||N/A|Observational|N/A|||Actual|134|||Both|4 Years|N/A|No|||June 2014|June 18, 2014|March 22, 2003||No||No||https://clinicaltrials.gov/show/NCT00056784||202443|
NCT00053391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000258491|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Vaccination Of HLA-A1 And/Or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide - Loaded Autologous Dendritic Cells That Are Generated In The Absence Or Presence Of CD40 Ligand||University Hospital Erlangen|No|Completed|October 2002|June 2007|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|62|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|January 27, 2003||No||No||https://clinicaltrials.gov/show/NCT00053391||202678|
NCT00057889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030094|Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer|A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2003|February 2008|Actual|October 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||March 2012|March 14, 2012|April 7, 2003||||||https://clinicaltrials.gov/show/NCT00057889||202360|
NCT00057967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99H8|Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome|Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome||Northwestern University|Yes|Active, not recruiting|July 2000|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057967||202355|
NCT00057499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN012AI|Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics|Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2003|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|35 Years|No|||June 2014|June 4, 2014|April 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057499||202388|
NCT00057512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M4N001|Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck|Open-Label Phase 1 Dose Escalation Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck||Erimos Pharmaceuticals|No|Completed|January 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||January 2006|February 20, 2016|April 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057512||202387|
NCT00057421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI032414|Tuberculosis in HIV Infected Patients in Uganda|Impact of Tuberculosis on HIV Infection in Uganda||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 1998|September 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||190|||Both|18 Years|60 Years|No|||August 2007|September 17, 2007|April 1, 2003||||No||https://clinicaltrials.gov/show/NCT00057421||202394|
NCT00057018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037606|Improving Arm Mobility and Use After Stroke|The Extremity Constraint Induced Therapy Evaluation (EXCITE) Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|April 2000|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||229|||Both|18 Years|80 Years|No|||May 2011|May 20, 2011|March 26, 2003|||Study terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00057018||202425|
NCT00057031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN101-003|Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)|A Phase 2, Multicenter, Open Label Study of the Safety and Efficacy of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome||Novacea||Active, not recruiting|November 2002|March 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||46|||Both|18 Years|N/A|No|||February 2005|October 31, 2006|March 26, 2003||||||https://clinicaltrials.gov/show/NCT00057031||202424|
NCT00057044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX 01-083|From Research to Practice - Lipid Management for Low HDL-Cholesterol|From Research to Practice - Lipid Management for Low HDL-Cholesterol||VA Office of Research and Development|No|Completed|October 2001|September 2003|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11700|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057044||202423|
NCT00058019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00031|Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas||National Cancer Institute (NCI)|Yes|Completed|February 2003|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||October 2011|May 7, 2014|April 7, 2003|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00058019||202351|
NCT00057525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rPA-EC-02|A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults|A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults||DynPort Vaccine Company LLC, A CSC Company|Yes|Completed|April 2003|August 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 29, 2011|April 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057525||202386|
NCT00053456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030086|The Effect of Exercise on Stem Cell Mobilization and Heart Function in Patients Undergoing Cardiac Rehabilitation|Stem Cell Mobilization For Improvement in Vascular Function and Myocardial Perfusion in Patients Undergoing Cardiac Rehabilitation||National Institutes of Health Clinical Center (CC)||Completed|January 2003|January 2006||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||January 2006|March 3, 2008|January 30, 2003||||No||https://clinicaltrials.gov/show/NCT00053456||202673|
NCT00057720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.3017|TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer|Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]||Telik||Completed|June 2003|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||440|||Female|18 Years|N/A|No|||May 2006|July 21, 2011|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057720||202371|
NCT00057343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106-10|Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma|A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL||Biogen||Terminated|March 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||September 2006|September 8, 2006|March 31, 2003||||||https://clinicaltrials.gov/show/NCT00057343||202400|
NCT00057356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-071|Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients With Decompensated Chronic Heart Failure||Cumberland Pharmaceuticals|No|Completed|November 2002|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|170|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|March 31, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057356||202399|
NCT00057616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MEL-002|Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma.|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy||Celgene||Completed|October 2002|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||274|||Both|18 Years|N/A|No|||May 2004|June 23, 2005|April 4, 2003||||||https://clinicaltrials.gov/show/NCT00057616||202379|
NCT00058695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030155|Genetic Factors in Age-Related Macular Degeneration|Evaluation of Single Nucleotide Polymorphism (SNP) in Patients With and Subjects Without Age-Related Macular Degeneration (AMD)||National Institutes of Health Clinical Center (CC)||Terminated|April 2003|October 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|477|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|April 11, 2003||No||No||https://clinicaltrials.gov/show/NCT00058695||202311|
NCT00053365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02512|Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of Irofulven (IND #55804, NSC #683863) In The Treatment Of Recurrent Or Persistent Platinium-Sensitive Ovarian Or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|June 2003|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Female|18 Years|85 Years|No|||January 2013|April 29, 2014|January 27, 2003|Yes|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT00053365||202680|
NCT00053378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-395|A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects|A Placebo-Controlled, Double-Blind Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects||Abbott||Completed|January 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||July 2006|July 31, 2006|January 27, 2003||||||https://clinicaltrials.gov/show/NCT00053378||202679|
NCT00056875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2146|Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants|Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants||FDA Office of Orphan Products Development||Completed|September 2002|June 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|3 Years|65 Years|No|||February 2006|March 24, 2015|March 25, 2003||||||https://clinicaltrials.gov/show/NCT00056875||202436|
NCT00057564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THAL-MM-003|A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma|A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma||Celgene|Yes|Completed|February 2003|August 2013|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|470|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|April 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057564||202383|
NCT00058097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03013|Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study of R115777 for the Treatment of Adults With Newly Diagnosed Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|August 2003|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058097||202345|
NCT00053482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-400-003|Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults|The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination||Sanofi|Yes|Completed|January 2003|October 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|357|||Both|28 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 7, 2012|January 30, 2003|Yes|Yes||No|January 3, 2011|https://clinicaltrials.gov/show/NCT00053482||202671|
NCT00053599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0038|Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease||National Institute on Aging (NIA)||Completed|December 2002|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|50 Years|N/A|No|||June 2009|July 24, 2009|February 3, 2003||||No||https://clinicaltrials.gov/show/NCT00053599||202663|
NCT00056888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030134|Neurophysiological Studies in Patients With Paroxysmal Hyperkinetic Movement Disorders|Neurophysiological Studies in Patients With Psychogenic Movement Disorders||National Institutes of Health Clinical Center (CC)||Completed|March 2003|February 2009||||N/A|Observational|N/A||||115|||Both|8 Years|N/A|Accepts Healthy Volunteers|||February 2009|September 26, 2015|March 26, 2003||No||No||https://clinicaltrials.gov/show/NCT00056888||202435|
NCT00057590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061941|Outreach and Treatment for Depression in the Labor Force|Outreach and Treatment for Depression in the Labor Force||Harvard Medical School||Completed|March 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||590|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|April 4, 2003||||No||https://clinicaltrials.gov/show/NCT00057590||202381|
NCT00057057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHI 99-074|Telephone Intervention in Heart Failure Patients|Randomized Trial of a Telephone Intervention in Heart Failure Patients||VA Office of Research and Development|No|Completed||March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|438|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057057||202422|
NCT00057070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX 01-080|Facilitating Implementation of the PHS Smoking Cessation Guidelines - RESET|Facilitating Implementation of the PHS Smoking Cessation Guidelines - RESET||VA Office of Research and Development|No|Completed|October 2001|September 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|1||Anticipated|1900|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057070||202421|
NCT00057174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 99-238|Economic Impact of Guidelines for Gastroesophageal Reflux Disease|Economic Impact of Guidelines for Gastroesophageal Reflux Disease||VA Office of Research and Development|No|Completed||June 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|484|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057174||202413|
NCT00057603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH064161|Deep Brain Stimulation for Treatment-Resistant Obsessive Compulsive Disorder|Pilot Study of DBS for Treatment-Refractory OCD||University of Florida|No|Completed|January 2001|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|23 Years|65 Years|No|||November 2011|November 8, 2011|April 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00057603||202380|
NCT00057369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER001-4|Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections|Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens||Vicuron Pharmaceuticals||Active, not recruiting|February 2001|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||88|||Both|18 Years|N/A|No|||June 2003|June 23, 2005|March 31, 2003||||||https://clinicaltrials.gov/show/NCT00057369||202398|
NCT00057252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030128|Development of Computer-aided Detection and Diagnosis From Imaging Techniques|Development and Evaluation of Techniques for Computer Aided Detection and Diagnosis From Radiologic Images||National Institutes of Health Clinical Center (CC)||Completed|March 2003|||||N/A|Observational|N/A|||Actual|66169|||Both|N/A|120 Years|Accepts Healthy Volunteers|||April 2015|March 18, 2016|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00057252||202407|
NCT00058591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8216|Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)|Autologous EBV Specific CTLs for Therapy of Severe Chronic EBV Infection|SCAEBV|Baylor College of Medicine|Yes|Completed|January 2000|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|N/A|No|||April 2009|April 9, 2009|April 8, 2003|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00058591||202317|
NCT00058760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD39757-1|Delaying Sexual Activity in African American Adolescent Girls|A Randomized Controlled Trial of the NIA Intervention||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|February 2001|January 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||240|||Female|11 Years|14 Years|Accepts Healthy Volunteers|||March 2003|June 23, 2005|April 11, 2003||||No||https://clinicaltrials.gov/show/NCT00058760||202307|
NCT00057681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH064846-06|Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents|Treatment of Early Age Mania (TEAM) Study|TEAM|Washington University School of Medicine|Yes|Completed|February 2003|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|379|||Both|6 Years|15 Years|No|||March 2013|March 27, 2013|April 4, 2003||No||No|May 29, 2012|https://clinicaltrials.gov/show/NCT00057681||202374|
NCT00053508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-300-002|Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination|The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study||Sanofi|Yes|Terminated|September 2002|September 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|274|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|January 30, 2003|Yes|Yes|CDC's decision to down-select vaccine development to single candidate, ACAM2000|No||https://clinicaltrials.gov/show/NCT00053508||202669|
NCT00057733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-0108|Stress Management Training in Patients Undergoing Radiation Therapy for Cancer|Stress Management Training For Patients Undergoing Radiotherapy||National Cancer Institute (NCI)||Completed|February 2003|June 2006|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized|||||||Both|18 Years|N/A|No|||April 2005|May 29, 2013|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00057733||202370|
NCT00058838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA2APD-0075-031|Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease|A Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease.||Pfizer||Completed|April 2003|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||854|||Both|30 Years|N/A|No|||June 2006|June 6, 2006|April 14, 2003||||||https://clinicaltrials.gov/show/NCT00058838||202301|
NCT00053690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064662-01|Treatment of Post Traumatic Stress Disorder in Patients With Other Mental Illnesses|Cognitive-Behavioral Treatment of PTSD in SMI Clients||Dartmouth-Hitchcock Medical Center||Completed|January 2002|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||88|||Both|18 Years|65 Years|No|||February 2009|September 9, 2013|February 4, 2003||||No||https://clinicaltrials.gov/show/NCT00053690||202657|
NCT00056953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD37350-3|Peer Mentors for Adolescents in HIV Affected Families|Peer Mentors for Early Adolescents in HIV-Affected Families||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 1999|November 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||160|||Both|9 Years|15 Years|Accepts Healthy Volunteers|||July 2005|July 27, 2005|March 26, 2003||||No||https://clinicaltrials.gov/show/NCT00056953||202430|
NCT00057187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 99-282|Improving Substance Abuse Treatment Aftercare Adherence and Outcome|Improving Substance Abuse Treatment Aftercare Adherence and Outcome||VA Office of Research and Development|No|Completed||January 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|157|||Both|N/A|N/A|No|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057187||202412|
NCT00057226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHB20003|An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.||GlaxoSmithKline|No|Completed|March 2003|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|365|||Both|18 Years|64 Years|No|||April 2015|April 15, 2015|March 27, 2003||||||https://clinicaltrials.gov/show/NCT00057226||202409|
NCT00057239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHB20001|An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks||GlaxoSmithKline||Completed|March 2003|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||546|||Both|18 Years|64 Years|No|||October 2010|October 1, 2010|March 27, 2003||||||https://clinicaltrials.gov/show/NCT00057239||202408|
NCT00053469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030069|Infant s Examination and Manipulation of Objects|Early Learning and Development Project||National Institutes of Health Clinical Center (CC)||Completed|January 2003|March 2015||||N/A|Observational|N/A|||Actual|350|||Both|N/A|2 Years|No|||March 2015|March 31, 2015|January 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00053469||202672|
NCT00053521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206|Genetic Epidemiology of CVD Risk Factors|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 2003|November 2007|Actual|November 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2008|November 9, 2015|January 30, 2003||||No||https://clinicaltrials.gov/show/NCT00053521||202668|
NCT00053534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207|Heart Failure in the Community|||Mayo Clinic||Completed|January 2003|December 2006|Actual|December 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||February 2014|February 19, 2014|January 30, 2003||||No||https://clinicaltrials.gov/show/NCT00053534||202667|
NCT00053547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-022|Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis|Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis||Abbott||Completed|January 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||28|||Both|2 Years|20 Years|No|||July 2006|July 31, 2006|January 30, 2003||||||https://clinicaltrials.gov/show/NCT00053547||202666|
NCT00058032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000285690|CA 125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women|United Kingdom Collaborative Trial Of Ovarian Cancer Screening||National Cancer Institute (NCI)||Completed|February 2003|March 2009|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Screening|||||||Female|50 Years|74 Years|Accepts Healthy Volunteers|||September 2005|December 3, 2013|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058032||202350|
NCT00058045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 99-11|Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer|A Phase I Study Of Low-Dose Subcutaneous Interleukin 2 (IL-2) And Stem Cell Factor (r-metHuSCF) For Patients With AIDS And AIDS-Associated Malignancy||Roswell Park Cancer Institute||Completed|August 2002|||November 2003|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|1|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|April 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00058045||202349|
NCT00057330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-643|HerpeVac Trial for Young Women|A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative||GlaxoSmithKline||Completed|January 2003|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8323|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||March 2013|May 9, 2013|March 31, 2003|Yes|Yes||No|September 29, 2011|https://clinicaltrials.gov/show/NCT00057330||202401|Out of the 8323 subjects enrolled and vaccinated, 7850 subjects were followed throughout the study, e. a. for safety and adverse event assessment (4488 in the Herpes Simplex Virus Group and 3662 in the Havrix Group).
NCT00057551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH062475|Research Evaluating the Value of Augmenting Medication With Psychotherapy (REVAMP)|CBASP Augmentation for Treatment of Chronic Depression||Weill Medical College of Cornell University||Active, not recruiting|April 2003|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||909|||Both|18 Years|75 Years|No|||November 2013|November 1, 2013|April 4, 2003||||No||https://clinicaltrials.gov/show/NCT00057551||202384|
NCT00057382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-067-010|T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients|||Tularik||Terminated|March 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||750|||Both|18 Years|N/A|No|||September 2004|June 23, 2005|March 31, 2003||||||https://clinicaltrials.gov/show/NCT00057382||202397|
NCT00057083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEL 20-036|Effect of Telemedicine on Physician-Patient Communication|Effect of Telemedicine on Physician-Patient Communication||VA Office of Research and Development|No|Completed|March 2003|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Both|18 Years|N/A|No|||February 2008|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057083||202420|
NCT00057096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUI 99-109|Onsite Versus Referral Models of Primary Care for Substance Abusing Patients|Onsite Versus Referral Models of Primary Care for Substance Abusing Patients||VA Office of Research and Development|No|Completed||March 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057096||202419|
NCT00058123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTC-0106 CDR0000287012|Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma|A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma||Sidney Kimmel Comprehensive Cancer Center||Completed|March 2003|November 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058123||202344|
NCT00058149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000287015|Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma||National Cancer Institute (NCI)||Completed|March 2003|||July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|September 20, 2011|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058149||202343|
NCT00053638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESS30009|A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy|A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV-1 Infected Subjects.||GlaxoSmithKline||Completed|February 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||345|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|February 4, 2003||||||https://clinicaltrials.gov/show/NCT00053638||202660|
NCT00057460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030147|Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity|Effects of AMPA Receptor Blockade on Human Cortical Excitability - A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|April 2003|May 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2006|March 3, 2008|April 2, 2003||||No||https://clinicaltrials.gov/show/NCT00057460||202391|
NCT00057473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA124-002|A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors|||Bristol-Myers Squibb||Completed|February 2003|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|1 Year|21 Years|No|||April 2011|April 7, 2011|April 2, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057473||202390|
NCT00058370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-088|Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma|A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2003|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|3 Years|N/A|No|||December 2015|December 10, 2015|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058370||202329|
NCT00053495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-400-005|Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination|The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination||Sanofi|Yes|Completed|January 2003|November 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|353|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||May 2012|May 7, 2012|January 30, 2003|Yes|Yes||No|January 3, 2011|https://clinicaltrials.gov/show/NCT00053495||202670|
NCT00053430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI047742-01A1|Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People|Pharmacologic T Cell Costimulation In HIV Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2001|February 2006|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 6, 2009|January 29, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053430||202675|
NCT00057005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12870|Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation|Phase I Study of Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation (ADVL)|ADVL|Baylor College of Medicine|Yes|Completed|February 2003|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|45 Years|No|||November 2009|January 19, 2010|March 26, 2003|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00057005||202426|
NCT00057408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2190|A Controlled Study of Olanzapine in Children With Autism|A Controlled Study of Olanzapine in Children With Autism||FDA Office of Orphan Products Development|Yes|Completed|May 2003|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|3 Years|12 Years|No|||September 2011|March 24, 2015|April 1, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057408||202395|
NCT00058487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI-01281|Epirubicin and Thalidomide in Treating Patients With Liver Cancer|A Phase II Study Of Epirubicin And Thalidomide In Unresectable Or Metastatic Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|December 2001|January 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||October 2006|July 17, 2013|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058487||202322|
NCT00057291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD39017-2|Effect of Improving Caregiving on Early Mental Health|Effect of Improving Caregiving on Early Mental Health||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|April 2000|March 2006|Actual|March 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1521|||Both|N/A|85 Years|No|||December 2004|October 28, 2014|March 31, 2003||No||No||https://clinicaltrials.gov/show/NCT00057291||202404|
NCT00056199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030101|EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome|Pilot Study of Intravitreal Injection of EYE001 (Anti-VEGF Pegylated Aptamer) for Advanced Ocular Disease of Von Hippel-Lindau (VHL) Disease||National Institutes of Health Clinical Center (CC)||Completed|March 2003|November 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||5|||Both|N/A|N/A|No|||November 2005|March 3, 2008|March 7, 2003||||No||https://clinicaltrials.gov/show/NCT00056199||202485|
NCT00056485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063073|Treatment of Depression in Nursing Homes|Behavioral Intervention for Depression in Nursing Homes||University of Louisville||Completed|April 2002|August 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||40|||Both|60 Years|N/A|No|||January 2008|November 5, 2013|March 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00056485||202464|
NCT00056667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR047014|Relaxation Response Training for the Treatment of Rheumatoid Arthritis|Relaxation Response, Somatic Style and Rheumatoid Arthritis||Brigham and Women's Hospital|No|Completed|July 2001|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|168|||Both|18 Years|75 Years|No|||January 2014|January 15, 2014|March 20, 2003||No||No||https://clinicaltrials.gov/show/NCT00056667||202451|
NCT00053339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-49903|Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer|Phase III Randomized Study of Trastuzumab (Herceptin) With or Without Tamoxifen in Women With Progressive, Stage IV, Estrogen or Progesterone Receptor- and HER2/Neu-Positive Breast Cancer||Alliance for Clinical Trials in Oncology|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 27, 2003|No|Yes|The study was not activated.|No||https://clinicaltrials.gov/show/NCT00053339||202682|
NCT00053352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCT0132|Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors|A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors||Children's Oncology Group|Yes|Active, not recruiting|November 2003|||October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|302|||Both|N/A|21 Years|No|||March 2015|March 4, 2015|January 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053352||202681|
NCT00056277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA30924|Bipolar Disorder Study for Men and Women|A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Bipolar Disorder Patients Currently Experiencing a Major Depressive Episode||GlaxoSmithKline|No|Completed|February 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|260|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|March 10, 2003||||||https://clinicaltrials.gov/show/NCT00056277||202479|
NCT00056290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND 11572|VEGF Gene Transfer for Diabetic Neuropathy|p.VGI.1 (VEGF2) Gene Transfer for Diabetic Neuropathy||Losordo, Douglas, M.D.|Yes|Completed|December 2002|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||November 2010|November 10, 2010|March 10, 2003|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00056290||202478|
NCT00056719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030131|Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study|Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study||National Institutes of Health Clinical Center (CC)||Recruiting|March 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2999997|||Both|18 Years|N/A|No|||July 2015|January 21, 2016|March 21, 2003||No||No||https://clinicaltrials.gov/show/NCT00056719||202447|
NCT00056849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030130|Genetic Determinants of Ankylosing Spondylitis Severity|Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study||National Institutes of Health Clinical Center (CC)||Completed|March 2003|||||N/A|Observational|N/A|||Actual|134|||Both|18 Years|N/A|No|||February 2016|March 9, 2016|March 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00056849||202438|
NCT00055822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271308|Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer|A Phase I/II Study of Oblimersen Sodium (G3139, Genasense) in Combination With Oxaliplatin, 5FU and Leucovorin (FOLFOX4) Regimen in Advanced Colorectal Cancer||The University of Texas Health Science Center at San Antonio|Yes|Completed|October 2002|October 2004|Actual|October 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055822||202509|
NCT00055887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271438|Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer||Spectrum Pharmaceuticals, Inc||Withdrawn|November 2002|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|March 6, 2003|||Study never started. No patients were enrolled.|No||https://clinicaltrials.gov/show/NCT00055887||202504|
NCT00055978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271912|Celecoxib in Preventing Lung Cancer in Former Heavy Smokers|Lung Cancer Chemoprevention With Celecoxib In Ex-Smokers||University of California, Los Angeles|Yes|Completed|October 2002|May 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|112|||Both|45 Years|N/A|No|||June 2011|June 16, 2011|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055978||202498|
NCT00056056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-21011|Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides|A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Terminated|January 2003|June 2011|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|March 6, 2003||No|poor accrual|No||https://clinicaltrials.gov/show/NCT00056056||202494|
NCT00056134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270762|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Vaccination of HLA-A1 and/or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide-Loaded Autologous Dendritic Cells With Prior Depletion of CD25-Positive Cells Using Denileukin Difitox (ONTAK)||University Hospital Erlangen|No|Completed|October 2002|May 2012|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|March 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00056134||202490|
NCT00056862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030136|Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3|Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3||National Institutes of Health Clinical Center (CC)|No|Completed|March 2003|June 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|March 25, 2003|No|Yes||No|November 12, 2010|https://clinicaltrials.gov/show/NCT00056862||202437|
NCT00056368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER002-9|The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis|A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications.||Pfizer||Completed|March 2003|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|256|||Both|16 Years|N/A|No|||October 2008|October 17, 2008|March 11, 2003||Yes||||https://clinicaltrials.gov/show/NCT00056368||202473|
NCT00056381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER002-12|Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17|Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia||Pfizer||Completed|July 2003|June 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|2 Years|17 Years|No|||October 2008|October 17, 2008|March 11, 2003||Yes||||https://clinicaltrials.gov/show/NCT00056381||202472|
NCT00056550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC AT III 01002|Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.|A Study to Assess the Incidence of Deep Vein Thrombosis (DVT) Following Prophylactic Intravenous Administration of Recombinant Human Antithrombin(rhAT) to Hereditary Antithrombin (AT) Deficient Patients in High Risk Situations.|rhAT|rEVO Biologics|No|Completed|December 2002|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|70 Years|No|||August 2012|September 17, 2012|March 17, 2003|Yes|Yes||No|March 19, 2012|https://clinicaltrials.gov/show/NCT00056550||202459|
NCT00057148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 01-197|Massage After Surgery To Help Treat Post-Operative Pain|Acute Post-Operative Pain Management Using Massage As Adjuvant Therapy||VA Office of Research and Development|No|Completed|February 2003|June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||March 2006|April 6, 2015|March 27, 2003||||No||https://clinicaltrials.gov/show/NCT00057148||202415|
NCT00057265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-02B-007|A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B|A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B||Novartis||Completed|February 2003|||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|70 Years||||March 2015|March 19, 2015|March 28, 2003||||||https://clinicaltrials.gov/show/NCT00057265||202406|
NCT00056186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030118|Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling|Exploration of Transitional Life Events in Individuals With Friedreich's Ataxia: Implications for Genetic Counseling||National Institutes of Health Clinical Center (CC)||Completed|March 2003|January 2004||||N/A|Observational|N/A||||40|||Both|N/A|N/A|No|||January 2004|March 3, 2008|March 7, 2003||||No||https://clinicaltrials.gov/show/NCT00056186||202486|
NCT00056472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH062624|Study of Pharmacotherapy of Psychotic Depression|Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression|STOP-PD|Weill Medical College of Cornell University|Yes|Completed|January 2003|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|259|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|March 14, 2003|Yes|Yes||No|June 16, 2009|https://clinicaltrials.gov/show/NCT00056472||202465|
NCT00056641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.51|Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients|An Open Label, Randomized, Parallel-group Pharmacokinetics Trial of Tipranavir / Ritonavir (TPV/RTV), Alone or in Combination With RTV-boosted Saquinavir (SQV), Amprenavir (APV), or Lopinavir (LPV), Plus an Optimized Background Regimen, in Multiple Antiretroviral (ARV) Experienced Patients.||Boehringer Ingelheim||Completed|January 2003|||January 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||328|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|March 19, 2003||||No||https://clinicaltrials.gov/show/NCT00056641||202453|
NCT00056602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030133|Clinically Important Changes in Rheumatoid Arthritis|Clinically Important Changes in Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Completed|March 2003|||||N/A|Observational|N/A|||Actual|192|||Both|18 Years|N/A|No|||February 2016|March 5, 2016|March 19, 2003||No||No||https://clinicaltrials.gov/show/NCT00056602||202455|
NCT00056628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0040|COGNIShunt® System for Alzheimer's Disease|Study to Evaluate the Effect of Flow-Regulated Ventriculoperitoneal Shunting on Progression of Alzheimer's Disease: An Investigation of the Safety and Effectiveness of the COGNIShunt® CNS Shunt System||National Institute on Aging (NIA)||Completed|January 2001|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|62 Years|85 Years|No|||October 2004|September 11, 2006|March 19, 2003||||No||https://clinicaltrials.gov/show/NCT00056628||202454|
NCT00057278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR22264|Gabapentin in Fibromyalgia Trial (GIFT)|Gabapentin in Fibromyalgia Trial (GIFT)||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|March 2003|January 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||December 2007|December 14, 2007|March 28, 2003||||||https://clinicaltrials.gov/show/NCT00057278||202405|
NCT00056264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004795|A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group, Dose Finding Study Evaluating the Safety and Efficacy of Infliximab Administration in Symptomatic Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Centocor, Inc.||Completed|December 2002|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|234|||Both|40 Years|N/A|Accepts Healthy Volunteers|||April 2010|May 16, 2011|March 7, 2003||||||https://clinicaltrials.gov/show/NCT00056264||202480|
NCT00056823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF2428g|Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)|A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration||Genentech, Inc.||Completed|March 2003|December 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||168|||Both|50 Years|N/A|No|||June 2013|June 19, 2013|March 24, 2003||||||https://clinicaltrials.gov/show/NCT00056823||202440|
NCT00056836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF2598g|A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration|A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration||Genentech, Inc.||Completed|March 2003|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||720|||Both|50 Years|N/A|No|||May 2014|May 14, 2014|March 24, 2003|Yes|Yes||||https://clinicaltrials.gov/show/NCT00056836||202439|
NCT00056914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030142|Development of Techniques for Use in MRI With a Magnetic Field of 7 Tesla|Development of 7 Tesla MRI Methodology for Anatomical Functional and Spectroscopic Imaging of the Brain||National Institutes of Health Clinical Center (CC)||Completed|March 2003|January 2010||||N/A|Observational|N/A|||Actual|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|September 26, 2015|March 26, 2003||No||No||https://clinicaltrials.gov/show/NCT00056914||202433|
NCT00053573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU01702|rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)|An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of rhGAA Treatment in Patients Greater Than 6 Months and Less Than or Equal to 36 Months Old With Infantile-Onset GSD-II||Sanofi||Completed|February 2003|November 2006|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|6 Months|36 Months|No|||February 2014|February 4, 2014|January 31, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00053573||202664|
NCT00056797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI051181-01A1|Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV|A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy (HAART).||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||92|||Both|18 Years|65 Years|No|||July 2007|June 18, 2010|March 24, 2003||||||https://clinicaltrials.gov/show/NCT00056797||202442|
NCT00056901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030138|Screening Evaluation for Women With Postpartum Depression|A Screening Protocol to Evaluate Women With Postpartum-Related Mood and Behavioral Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|March 2003|||||N/A|Observational|N/A|||Anticipated|650|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|March 26, 2003||No||No||https://clinicaltrials.gov/show/NCT00056901||202434|
NCT00056069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL01P3|Study of the Physical and Emotional Needs of Parents Caring for Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia|Differences in Parental Caregiving Demands in Childhood Acute Lymphoblastic Leukemia by Length of Infusion Therapy||Children's Oncology Group|No|Completed|December 2002|March 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|N/A|N/A|No|||May 2015|May 6, 2015|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00056069||202493|
NCT00057486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01AI041735-04A2|Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients|A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|September 1997|June 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2|||Both|18 Years|N/A|No|||March 2003|June 23, 2005|April 2, 2003||||||https://clinicaltrials.gov/show/NCT00057486||202389|
NCT00056940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD42260-1|Prevention of Violent Behavior Among Children|Randomized Controlled Trial to Prevent Child Violence||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|September 2001|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||6600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 23, 2007|March 26, 2003||||No||https://clinicaltrials.gov/show/NCT00056940||202431|
NCT00055991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271913|Bexarotene in Preventing Breast Cancer in Women at Genetic Risk|A Multicenter Randomized Double-Blind Trial Of Targretin Capsules Modifying Immunophenotypic Markers Related To Breast Cancer Progression In Breast Tissue From Genetically Identified High Risk Patients||Baylor Breast Care Center|Yes|Completed|September 2001|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|87|||Female|18 Years|N/A|No|||February 2013|February 4, 2013|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055991||202497|
NCT00056524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-AVR-107|Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)|An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.||Avanir Pharmaceuticals||Completed|February 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|80 Years|No|||August 2009|August 4, 2009|March 15, 2003||||||https://clinicaltrials.gov/show/NCT00056524||202461|
NCT00056225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0041|VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)|High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL)||National Institute on Aging (NIA)||Completed|January 2003|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|340|||Both|55 Years|N/A|No|||June 2009|June 10, 2009|March 7, 2003||||No||https://clinicaltrials.gov/show/NCT00056225||202483|
NCT00057668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061563|Preventing Behavior Problems in Children With ADHD|Prevention of Behavioral Deficits in Young ADHD Children||Lehigh University||Active, not recruiting|September 2001|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||August 2006|November 18, 2013|April 4, 2003||||No||https://clinicaltrials.gov/show/NCT00057668||202375|
NCT00057304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM17151|Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus|A Phase II Randomized, Double-Blind, Dose-Ranging Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus||Hoffmann-La Roche||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|35 Years|75 Years|No|||November 2004|June 23, 2005|March 31, 2003||||||https://clinicaltrials.gov/show/NCT00057304||202403|
NCT00056355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030117|Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease|A Single Arm Study of Extracorporeal Photoimmune Therapy With Uvadex For Corticosteroid Sparing in Patients With Corticosteroid-Dependent Crohn's Disease Who May Also Be Refractory or Intolerant to Immunosuppressants and/or Anti-Tumor Necrosis Factor Agen||National Institutes of Health Clinical Center (CC)||Completed|March 2003|November 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||November 2005|March 3, 2008|March 10, 2003||||No||https://clinicaltrials.gov/show/NCT00056355||202474|
NCT00056537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01762001|ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer|An Open-Label, Phase I, Repeat Dose-Escalation Study of ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer||Active Biotech AB|No|Completed|April 2003|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|March 16, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00056537||202460|
NCT00056654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-008|Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer|Pharmacokinetic, Safety and Efficacy Study of a Six-Month Depot Formulation of Leuprolide in Subjects With Prostatic Carcinoma||Abbott|No|Completed|March 2003|July 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|164|||Male|N/A|N/A|No|||September 2008|September 16, 2008|March 20, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00056654||202452|
NCT00056316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH061956|Reducing Depression in Dementia Caregivers|Reducing Depression in Dementia Caregivers||University of Missouri, St. Louis|Yes|Completed|January 2002|August 2004|Actual|August 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Female|50 Years|N/A|No|||June 2014|June 4, 2014|March 10, 2003||No||No|October 23, 2008|https://clinicaltrials.gov/show/NCT00056316||202476|
NCT00056459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787 0135/306241|Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.|A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo||Novartis||Completed|February 2003|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1168|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|March 13, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00056459||202466|
NCT00056004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271915|Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia|Phase II Trial Of Zileuton In Persons With Bronchial Dysplasia||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 2003|March 2009|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|38|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00056004||202496|
NCT00056979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11909|Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases|Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases||Baylor College of Medicine||Terminated|June 2002|June 2003|Actual|June 2003|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||September 2015|September 21, 2015|March 26, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00056979||202428|
NCT00057694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030144|The Value of Genetic Information to Adult Adopted Individuals|Genetic Information: Exploring the Value to Adult Adoptees||National Institutes of Health Clinical Center (CC)||Completed|April 2003|January 2004||||N/A|Observational|N/A||||40|||Both|N/A|N/A|No|||January 2004|March 3, 2008|April 5, 2003||||No||https://clinicaltrials.gov/show/NCT00057694||202373|
NCT00056706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030135|Ischemic Nerve Block to Improve Hand Function in Stroke Patients|Improved Function in the Paretic Hand of Chronic Stroke Patients by Transient Deafferentation of the Intact Upper Extremity||National Institutes of Health Clinical Center (CC)||Completed|March 2003|January 2006||||N/A|Observational|N/A||||75|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|March 21, 2003||||No||https://clinicaltrials.gov/show/NCT00056706||202448|
NCT00056212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001215-01|Evaluating Yoga for Chronic Low Back Pain|Evaluating Yoga for Chronic Low Back Pain||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2002|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|20 Years|64 Years|No|||July 2006|August 17, 2006|March 7, 2003||||No||https://clinicaltrials.gov/show/NCT00056212||202484|
NCT00056394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007830|Coping Skills Training for Early Rheumatoid Arthritis|Coping Skills Training for Early Rheumatoid Arthritis||Duke University|Yes|Completed|February 2003|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|105|||Both|18 Years|N/A|No|||November 2013|July 11, 2014|March 11, 2003||No||No||https://clinicaltrials.gov/show/NCT00056394||202471|
NCT00056082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMC-HSC-8919-02|Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women|A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer||University of Kansas Medical Center|No|Completed|January 2003|July 2013|Actual|July 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|March 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00056082||202492|
NCT00057707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030143|Effects of Modafinil on Brain Function in Patients With Schizophrenia|Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype||National Institutes of Health Clinical Center (CC)||Recruiting|March 2003|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|1||Anticipated|210|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|January 6, 2016|April 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057707||202372|
NCT00055692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02518|Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer|Bevacizumab (RhuMAB-VEGF) In Hepatocellular Cancer For Patients With Unresectable Tumor (Without Invasion Of The Main Portal Vein Or Metastatic Disease) A Phase II Study||National Cancer Institute (NCI)|Yes|Completed|February 2003|December 2009|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||December 2012|January 29, 2016|March 6, 2003|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT00055692||202517|
NCT00056303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH052135|Mental Health Services for Foster and Adopted Children|Specialized Mental Health Services for Foster Infants||University of Delaware|Yes|Active, not recruiting|December 2002|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Both|20 Months|36 Months|No|||December 2014|December 31, 2014|March 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00056303||202477|
NCT00056420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030126|Brain Dynamics Involved in Generating Tics and Controlling Voluntary Movement|Spatiotemporal Dynamics of Cortical Connectivity Involved in Tics and Voluntary Movements in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder: An EEG Study||National Institutes of Health Clinical Center (CC)||Completed|March 2003|January 2009||||N/A|Observational|N/A||||54|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 23, 2009|March 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00056420||202469|
NCT00056433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030127|Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia|Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia||National Institutes of Health Clinical Center (CC)||Completed|March 2003|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|39|||Both|16 Years|N/A|No|||December 2015|December 8, 2015|March 12, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00056433||202468|
NCT00053677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH065920|Drug Treatment for Pathologic Gambling Disorder|Naltrexone Treatment in Pathologic Gambling Disorder||University of Chicago||Completed|December 2002|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||156|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|February 4, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00053677||202658|
NCT00056511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001108-01|Comparing Effects of 3 Sources of Garlic on Cholesterol Levels|Comparing Effects of 3 Sources of Garlic on Serum Lipids||National Center for Complementary and Integrative Health (NCCIH)||Completed|May 2002|April 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2006|August 16, 2006|March 14, 2003||||||https://clinicaltrials.gov/show/NCT00056511||202462|
NCT00056498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH045074|Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine|Clozapine Treatment of Schizophrenic Patients||University of Maryland|Yes|Completed|December 2001|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|65 Years|No|||June 2012|April 10, 2015|March 14, 2003|Yes|Yes||No|March 23, 2009|https://clinicaltrials.gov/show/NCT00056498||202463|
NCT00057642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4358|Improving Retention of Hispanics Receiving Antidepressant Therapy|Improving Hispanic Retention in Antidepressant Therapy||New York State Psychiatric Institute|No|Completed|September 2002|August 2006|Actual|August 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||September 2008|August 16, 2013|April 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057642||202377|
NCT00057655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH065384|Behavioral Health Services for Women Receiving Public Assistance|Access to Behavioral Health Services for Women on TANF||University of Pennsylvania|No|Withdrawn|January 2002|February 2002|Actual|February 2002|Actual|N/A|Observational|Time Perspective: Retrospective|||Actual|0|||Female|18 Years|64 Years|No|||December 2015|December 1, 2015|April 4, 2003||No|lack of funding|No||https://clinicaltrials.gov/show/NCT00057655||202376|
NCT00056589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13-1663|Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency|A Phase 1 Escalating Dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor XIII Deficiency||Novo Nordisk A/S|No|Completed|March 2003|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|March 18, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00056589||202456|
NCT00056966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12472|Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases|Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases||Baylor College of Medicine|Yes|Completed|November 2002|December 2006|Actual|May 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|N/A|No|||June 2012|June 27, 2012|March 26, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00056966||202429|
NCT00056745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI050467|Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines|The Role of Immunization Site in Eliciting Mucosal Immunity||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||12|||Both|18 Years|33 Years|Accepts Healthy Volunteers|||July 2007|September 17, 2007|March 21, 2003||||||https://clinicaltrials.gov/show/NCT00056745||202446|
NCT00057317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WM16177|Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus|A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus||Hoffmann-La Roche||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|35 Years|75 Years|No|||April 2005|June 23, 2005|March 31, 2003||||||https://clinicaltrials.gov/show/NCT00057317||202402|
NCT00056680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD38982-1A6|Three-Part Program for Parents With Premature Infants|Adult Attachment and Intervention Efficacy With Preterms||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|July 2001|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|173|||Both|32 Weeks|37 Weeks|No|||May 2007|June 19, 2007|March 20, 2003||||No||https://clinicaltrials.gov/show/NCT00056680||202450|
NCT00056810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2129|Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine|Assessment of Chronic GBS Improvement With Use of 4-AP||FDA Office of Orphan Products Development||Completed|September 2002|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||30|||Both|19 Years|75 Years|No|||May 2006|March 24, 2015|March 24, 2003||||||https://clinicaltrials.gov/show/NCT00056810||202441|
NCT00056030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N014A|Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer|A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|December 2004|||March 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00056030||202495|
NCT00056095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271936|Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer|Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer||National Cancer Institute (NCI)||Recruiting|December 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|170|||Both|18 Years|65 Years|No|||December 2006|February 6, 2009|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00056095||202491|
NCT00056693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTKC-0511-015|Treatment With SU11248 in Patients With Neuroendocrine Tumors|A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor||Pfizer|No|Completed|April 2003|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||July 2008|July 18, 2008|March 20, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00056693||202449|
NCT00055809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02519|Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors|Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors||National Cancer Institute (NCI)||Completed|January 2003|||June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055809||202510|
NCT00056407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI40006|"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer|REDUCE|GlaxoSmithKline||Completed|March 2003|May 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8231|||Male|50 Years|75 Years|No|||July 2014|April 23, 2015|March 11, 2003||||No|February 1, 2010|https://clinicaltrials.gov/show/NCT00056407||202470|
NCT00056563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|468 Phase I|Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial|CSP #468 Phase I - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease||VA Office of Research and Development|Yes|Completed|April 2002|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Both|22 Years|N/A|No|||April 2014|April 24, 2014|March 18, 2003|Yes|Yes||No|May 20, 2013|https://clinicaltrials.gov/show/NCT00056563||202458|A limitation of this study is that the STN and GPi cases are pooled into a single DBS group. When the study was planned, it was thought that differences between STN and GPi at six months would be small, which was tested during the study analysis.
NCT00053417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-F202|Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis|Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis||Acorda Therapeutics||Completed|February 2003|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|206|||Both|18 Years|70 Years|No|||August 2011|August 3, 2011|January 29, 2003|Yes|Yes|||May 16, 2011|https://clinicaltrials.gov/show/NCT00053417||202676|
NCT00059995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX-060-01|MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma|Phase I/II Open Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Patients With Refractory/Relapsed CD30 Lymphoma||National Cancer Institute (NCI)||Completed|January 2003|November 2009|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||November 2009|May 29, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00059995||202225|
NCT00055952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271889|Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor|A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT)||Daiichi Sankyo Inc.||Completed|January 2003|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2012|May 15, 2012|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055952||202500|
NCT00060554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63133 (ASPIRE-Pilot)|A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)|||Schering-Plough||Withdrawn|April 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|21 Years|N/A|No|||November 2009|November 2, 2009|May 7, 2003|||Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have    data.|||https://clinicaltrials.gov/show/NCT00060554||202192|
NCT00060567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7070-A001-106|Dose-Finding Study of E7070 in Combination With Irinotecan|Phase I Dose-Finding Study of E7070 in Combination With Irinotecan||Eisai Inc.||Completed|March 2003|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|88|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|May 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060567||202191|
NCT00060086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000299439|Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer|Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate||Jonsson Comprehensive Cancer Center|No|Active, not recruiting|March 2003|||December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||September 2015|September 30, 2015|May 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00060086||202222|
NCT00059553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01HD001348|Retraining Walking After Spinal Cord Injury|Activity-Dependent Plasticity After Spinal Cord Injury||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|May 2000|January 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|6 Years|65 Years|No|||August 2005|June 17, 2009|April 28, 2003||||No||https://clinicaltrials.gov/show/NCT00059553||202255|
NCT00059319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS037242|Reduced Manipulation of the Aorta and Neurobehavioral Outcome Trial|||National Institute of Neurological Disorders and Stroke (NINDS)||Completed|January 1999|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||300|||Both|50 Years|N/A|No|||May 2007|May 18, 2007|April 23, 2003||||No||https://clinicaltrials.gov/show/NCT00059319||202272|
NCT00060710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-461-013|CP-461 in the Treatment of Patients With Advanced Melanoma|Phase II Study of CP-461 in the Treatment of Patients With Advanced Melanoma||Astellas Pharma Inc||Terminated|January 2003|December 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|May 9, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00060710||202180|
NCT00060723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD38461-3|Behavioral Effects of Obstructive Sleep Apnea in Children|Behavioral Effect of Obstructive Sleep Apnea in Children||University of Michigan|No|Completed|August 1999|January 2004|Actual|January 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|106|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric Otolaryngology surgery practices and primary care or general surgery practices        at University of Michigan and St. Joseph Mercy Health Systems|October 2011|October 21, 2011|May 9, 2003||No||No||https://clinicaltrials.gov/show/NCT00060723||202179|
NCT00061178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2665g|Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma|Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy & Safety of rhuMAb VEGF in Previously Treated Metastatic Renal Cell Carcinoma||Genentech, Inc.||Terminated||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||275|||Both|18 Years|N/A|No|||December 2004|March 1, 2016|May 21, 2003||||||https://clinicaltrials.gov/show/NCT00061178||202145|
NCT00055731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270970|Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse|Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse||National Cancer Institute (NCI)||Active, not recruiting|November 2002|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|250|||Male|N/A|79 Years|No|||April 2008|February 23, 2012|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055731||202514|
NCT00055757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02808|Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Trial of R115777, a Farnesyl Transferase Inhibitor, in Combination With Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|October 2003|||April 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055757||202513|
NCT00060008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-8-2543|Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma|Novel Imaging Modalities For Plexiform Neurofibromas||Children's Hospital of Philadelphia|No|Terminated|April 2002|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|N/A|25 Years|No|||April 2014|April 3, 2014|May 6, 2003||No|Study was closed early due to poor accrual.|No|April 1, 2014|https://clinicaltrials.gov/show/NCT00060008||202224|The sample size was modest. It is possible that with increased sample size, if the correlation estimate holds, it will become statistically significant.
NCT00055666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270747|Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract|Compassionate Use Of Oral Beclomethasone Dipropionate For Treatment Of Gastrointestinal Graft Versus Host Disease||Roswell Park Cancer Institute|Yes|Completed|March 2001|April 2006|Actual|February 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|51|||Both|4 Years|70 Years|No|||March 2011|March 7, 2011|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055666||202519|
NCT00055679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACS05 UC-0140-0106|Combination Chemotherapy in Treating Women With Stage I Breast Cancer|Phase III Randomized Study Of Adjuvant Fluourouracil, Epirubicin And Cyclophosphamide, In Women With Stage I Breast Cancer||UNICANCER|Yes|Completed|August 2002|June 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1512|||Female|18 Years|65 Years|No|||June 2013|June 17, 2013|March 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00055679||202518|
NCT00059618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-114|PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer|A Phase I Study Evaluating the Safety and Tolerability of PS-341(Bortezomib)and Carboplatin in Patients With Platinum- and Taxane-Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer||M.D. Anderson Cancer Center|No|Completed|April 2003|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|N/A|N/A|No|||August 2012|August 1, 2012|April 29, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059618||202251|
NCT00059813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02828|Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer|A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer||National Cancer Institute (NCI)||Completed|August 2003|||June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|19 Years|N/A|No|||August 2013|August 23, 2013|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059813||202237|
NCT00059930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-005|Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer|A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2003|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059930||202228|
NCT00059579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030149|Brain Regulation of Emotions in People With Depression and Anhedonia|Functional MRI Study of Brain Mechanism Mediating Anhedonia in Major Depression||National Institutes of Health Clinical Center (CC)||Completed|April 2003|November 2010||||N/A|Observational|N/A|||Actual|163|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 13, 2010|April 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00059579||202254|
NCT00059631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-227|Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone|Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone in Patients With Advanced Androgen-Independent Prostate Cancer (AI-PCa)||M.D. Anderson Cancer Center|No|Completed|March 2003|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|18 Years|N/A|No|||June 2015|June 19, 2015|April 29, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059631||202250|
NCT00060112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02531|Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma|A Phase I Study of Oblimersen (Genasense™, G3139) in Combination With Gemcitabine in Advanced Malignancies||National Cancer Institute (NCI)||Terminated|March 2003|||December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|May 6, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00060112||202220|
NCT00059761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0241|Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase I Study of Irinotecan and Cisplatin in Combination With Twice Daily Thoracic Radiotherapy (45 Gy) or Once Daily Thoracic Radiotherapy (70 Gy) for Patients With Limited Stage Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|March 2003|November 2013|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00059761||202240|
NCT00060242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICC2302|Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer|Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid||Case Comprehensive Cancer Center|Yes|Completed|February 2003|January 2008|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060242||202215|
NCT00060255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000301587|High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors|Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors||Roswell Park Cancer Institute|Yes|Completed|December 1991|February 2013|Actual|August 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|451|||Both|4 Years|N/A|No|||May 2013|May 7, 2013|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060255||202214|
NCT00055601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0233|Combination Chemotherapy and Radiation Therapy With or Without Surgery In Treating Patients With Stage II or Stage III Bladder Cancer|A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy||Radiation Therapy Oncology Group|Yes|Active, not recruiting|December 2002|||October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|N/A|N/A|No|||March 2015|March 26, 2015|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055601||202523|
NCT00055614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDMC-E-010405FB|Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Phase I Study of Oral Topotecan as Consolidation for Patients With Mullerian Origin Tumors (Ovary, Tube, Peritoneum)||National Cancer Institute (NCI)||Completed|May 2002|October 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|N/A|No|||April 2007|June 25, 2013|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055614||202522|
NCT00055848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150008|Genetic Study of Familial Factors in Patients With Colon Cancer|Familial Factors in the Development of Colon Cancer||Alliance for Clinical Trials in Oncology|No|Completed|December 2001|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|600|||Both|N/A|70 Years|No|Non-Probability Sample|Patients diagnosed with colon cancer or polyps age 70 or under. Specifically, patients        previously enrolled on CLB-9581, CLB-89803 and CLB-80001.|July 2015|July 9, 2015|March 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00055848||202507|
NCT00055640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1402|Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma|Molecular Risk Guided Treatment Of Diffuse Large B-Cell Non-Hodgkin's Lymphoma||Case Comprehensive Cancer Center|Yes|Completed|October 2002|March 2006|Actual|April 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|March 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00055640||202521|
NCT00055653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270487|Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders|Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation||Roswell Park Cancer Institute|Yes|Completed|January 2003|September 2005|Actual|September 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|17 Years|No|||March 2011|March 3, 2011|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055653||202520|
NCT00059449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGFDNE (completed)|Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis|Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|372|||Both|N/A|72 Hours|No|||January 2010|January 12, 2010|April 25, 2003||||No||https://clinicaltrials.gov/show/NCT00059449||202262|
NCT00059462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10630|Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection|Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone.||Bayer||Completed|December 2002|March 2005|Actual|March 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|April 25, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059462||202261|
NCT00060658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030178|Magnetic Resonance Imaging of Calculus Problem Solving|Functional Neuroimaging of Calculus Problem Solving||National Institutes of Health Clinical Center (CC)||Completed|May 2003|March 2005||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2005|March 3, 2008|May 8, 2003||||No||https://clinicaltrials.gov/show/NCT00060658||202184|
NCT00058968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4097|A Study for the Treatment of Painful Diabetic Neuropathy|Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy||Eli Lilly and Company||Completed|October 2002|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||660|||Both|18 Years|N/A|No|||May 2007|May 16, 2007|April 15, 2003||||||https://clinicaltrials.gov/show/NCT00058968||202292|
NCT00058981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|702/PO|Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects||DeveloGen Israel, Ltd.||Terminated|October 2002|May 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|30 Years|65 Years|No|||March 2009|March 18, 2009|April 15, 2003||||||https://clinicaltrials.gov/show/NCT00058981||202291|
NCT00059475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030172|Peptide Vaccination for Patients at High Risk for Recurrent Melanoma|Randomized Comparison of Peptide Immunization in Patients at High Risk for Recurrence of Melanoma||National Institutes of Health Clinical Center (CC)|No|Completed|April 2003|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|138|||Both|7 Years|N/A|No|||October 2012|October 17, 2012|April 26, 2003|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00059475||202260|
NCT00060099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000299462|SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia|Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III||National Cancer Institute (NCI)||Active, not recruiting|May 2003|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2005|November 5, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00060099||202221|
NCT00060970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29HD033738|Evaluating Muscle Function After Ankle Surgery|Restoration of Muscle Function During Rehabilitation||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 1995|August 2000||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2003|June 23, 2005|May 16, 2003||||No||https://clinicaltrials.gov/show/NCT00060970||202161|
NCT00059800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDMC-W-01-0380-FB|Boron Neutron Capture Therapy in Treating Patients With Melanoma|A Phase II Trial For Neutron Capture Therapy In Melanoma||National Cancer Institute (NCI)||Completed|May 2002|January 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|June 25, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00059800||202238|
NCT00059384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01AI033835-08A1|Alternative Dosing Strategy for Anti-HIV Drugs|Concentration-Controlled Antiretroviral Therapy in Persons Experiencing Persistent Viremia||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2003|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Both|18 Years|N/A|No|||July 2007|September 16, 2008|April 23, 2003||||No||https://clinicaltrials.gov/show/NCT00059384||202267|
NCT00059397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 (DK62765) (completed 2007)|Hepatitis C: Grading and Staging by MR|Hepatitis C: Grading and Staging by MR||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|18 Years|75 Years|No|||March 2010|March 17, 2010|April 24, 2003||||No||https://clinicaltrials.gov/show/NCT00059397||202266|
NCT00055770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01432|Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer|A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|October 2002|||December 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055770||202512|
NCT00059501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030165|Postural Control in the Elderly|Cortical Control of Postural Stability in the Elderly||National Institutes of Health Clinical Center (CC)||Completed|April 2003|March 2005||||N/A|Observational|N/A||||45|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2005|March 3, 2008|April 26, 2003||||No||https://clinicaltrials.gov/show/NCT00059501||202259|
NCT00061243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AI05394|Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Multi-Gene, Polyvalent HIV-1 DNA Plasmid Prime/Env Protein Boost Vaccine Formulation, DP6-001 in Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|April 2004|April 2010|Anticipated|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2005|September 25, 2008|May 22, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00061243||202141|
NCT00059748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030173|Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)|Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still s Disease, Behcet s Disease, and Other Undifferentiated Autoinflammatory Diseases)||National Institutes of Health Clinical Center (CC)||Recruiting|April 2003|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|3 Years|N/A|Accepts Healthy Volunteers|||May 2015|January 7, 2016|May 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00059748||202241|
NCT00059410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0045|Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II|Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II||National Institute on Aging (NIA)||Completed|January 2003|September 2005|Actual|September 2005|Actual|N/A|Observational|Time Perspective: Prospective||||210|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2008|December 10, 2009|April 24, 2003||||No||https://clinicaltrials.gov/show/NCT00059410||202265|
NCT00059514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD37498-3|Tobacco Use Among Arab American Youth|Arab American Youth: Tobacco Use and Intervention||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|May 2000|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|4000|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||April 2003|October 8, 2013|April 28, 2003||||No||https://clinicaltrials.gov/show/NCT00059514||202258|
NCT00059527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD37367-3|Healthy Youth Places: A Program to Promote Nutrition and Physical Activity in Adolescents|Youth Environments Promoting Nutrition and Activity||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|March 1999|May 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||2000|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||August 2005|October 28, 2014|April 28, 2003||||No||https://clinicaltrials.gov/show/NCT00059527||202257|
NCT00060372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00042|Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer|CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation||National Cancer Institute (NCI)||Completed|April 2003|||April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060372||202206|
NCT00060385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20991|Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma|Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|March 2003|||August 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|3|||Both|70 Years|N/A|No|||September 2012|September 20, 2012|May 6, 2003|||low accrual|No||https://clinicaltrials.gov/show/NCT00060385||202205|
NCT00055718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270914|Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy|A Pilot Study of Silymarin During Maintenance Therapy in Children With Acute Lymphoblastic Leukemia (ALL)||National Cancer Institute (NCI)||Completed|November 2001|January 2010|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|50|||Both|2 Years|21 Years|No|||May 2006|December 17, 2013|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055718||202515|
NCT00059982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000298994|Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer|Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma||National Cancer Institute (NCI)||Completed|July 2003|August 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|June 21, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00059982||202226|
NCT00060671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA III 02|Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma|An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)||CTI BioPharma||Terminated|January 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||May 2013|January 15, 2015|May 9, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060671||202183|
NCT00059202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URSO (completed)|Trial of High-dose Urso in Primary Sclerosing Cholangitis|Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|75 Years|No|||October 2013|October 31, 2013|April 21, 2003||||No||https://clinicaltrials.gov/show/NCT00059202||202281|
NCT00059293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208|Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A|||||||Both|1 Year|2 Years|No|||July 2008|July 23, 2008|April 22, 2003||||No||https://clinicaltrials.gov/show/NCT00059293||202274|
NCT00059917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-PGC101|Polyglutamate Camptothecin in Treating Patients With Advanced Cancer|Phase I Study of CT-2106 in Patients With Advanced Malignancy||National Cancer Institute (NCI)||Completed|January 2003|May 2005|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2005|May 29, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00059917||202229|
NCT00059670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UESD (completed)|Comparison of Two Therapies for Upper Esophageal Sphincter (UES) Dysphagia|Comparison of Two Therapies for UES Dysphagia||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||204|||Both|21 Years|90 Years|No|||January 2010|January 12, 2010|May 1, 2003||||No||https://clinicaltrials.gov/show/NCT00059670||202247|
NCT00059683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HD039939-01A1|Ultrasound-indicated Cerclage to Prevent Premature Birth in High-risk Women|Vaginal Ultrasound Cerclage Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|January 2003|October 2009|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|16 Years|N/A|No|||September 2014|September 29, 2014|May 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00059683||202246|
NCT00061139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD040692|Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy|Randomized Controlled Trial of Pediatric CI Therapy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|September 2002|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||52|||Both|2 Years|6 Years|No|||April 2003|June 23, 2005|May 21, 2003||||No||https://clinicaltrials.gov/show/NCT00061139||202148|
NCT00061152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C109|Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy|An Open-Label Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy||NeurogesX||Active, not recruiting||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||September 2007|September 12, 2007|May 21, 2003||||||https://clinicaltrials.gov/show/NCT00061152||202147|
NCT00061165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPAASC (completed)|Obesity Prevention in African American School Children|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|900|||Both|8 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|May 21, 2003||||No||https://clinicaltrials.gov/show/NCT00061165||202146|
NCT00059943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-136|Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer|Pharmacokinetics of Weekly Docetaxel in Patients Age 65 and Older With Metastatic Breast or Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|September 2002|||September 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|65 Years|N/A|No|||January 2013|January 15, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00059943||202227|
NCT00059644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFI 01-01|Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM for the Treatment of Critical Leg Ischemia||Mitsubishi Tanabe Pharma Corporation||Terminated|July 2001|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||560|||Both|40 Years|N/A|No|||June 2005|June 23, 2005|April 29, 2003||||||https://clinicaltrials.gov/show/NCT00059644||202249|
NCT00055939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271888|Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma|A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma||Daiichi Sankyo Inc.||Completed|January 2003|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2012|May 15, 2012|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055939||202501|
NCT00058877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FABE|Familial Aggregation of Barrett's Esophagus|Familial Aggregation of Barrett's Esophagus||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Active, not recruiting||||||N/A|Observational|N/A||||650|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2010|March 17, 2010|April 14, 2003||||No||https://clinicaltrials.gov/show/NCT00058877||202298|
NCT00058994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-29|An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD|An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-related Macular Degeneration||Alcon Research|No|Completed|March 2003|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||August 2008|November 28, 2012|April 15, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058994||202290|
NCT00060905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-540|An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder|An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder||Abbott||Completed|January 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||370|||Both|18 Years|65 Years|No|||August 2006|August 2, 2006|May 15, 2003||||||https://clinicaltrials.gov/show/NCT00060905||202166|
NCT00061074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08075-2|Tobacco Cessation in Postmenopausal Women (Part II) - 2|The Effects of ERT on Appetitive Behavior and Withdrawal in Short-term Smoking Cessation in Postmenopausal Females on Transdermal Nicotine Replacement||University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 1993|March 2000|Actual|March 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1|||Female|40 Years|79 Years|No|||December 2015|December 1, 2015|May 21, 2003||No||No||https://clinicaltrials.gov/show/NCT00061074||202153|
NCT00059904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIR-IL2005-A01|Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma|An Open-Labeled, Phase II Study of Rituximab in Combination With Recombinant IL-2 for Relapsed or Refractory Non-Hodgkin's Lymphoma of Intermediate- or High-Grade Histology||National Cancer Institute (NCI)||Completed|January 2003|June 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|July 17, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00059904||202230|
NCT00055835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271309|S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium|Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients With Locally Advanced or Recurrent Urothelial Malignancy||Southwest Oncology Group|No|Completed|November 2002|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|March 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00055835||202508|
NCT00059423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030168|Gene Message (mRNA) Analysis of Granulocytes|Natural History and Molecular Characterization of Benign Ethnic Neutropenia in Individuals of African Descent||National Institutes of Health Clinical Center (CC)||Recruiting|April 2003|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|5 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 12, 2015|April 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00059423||202264|
NCT00055861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01433|Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer|PHASE 2 STUDY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH ADVANCED BREAST CANCER||National Cancer Institute (NCI)||Completed|July 2002|||August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||June 2013|June 3, 2013|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055861||202506|
NCT00060463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD039907|Increased Access to Emergency Contraceptive Pills|Increased Access to Emergency Contraceptive Pills||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|October 2002|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1490|||Female|14 Years|24 Years|Accepts Healthy Volunteers|||October 2004|June 23, 2005|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00060463||202199|
NCT00055926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271533|CP-724,714 in Treating Patients With Metastatic Breast Cancer|A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer||Jonsson Comprehensive Cancer Center|Yes|Completed|January 2003|May 2005|Actual|December 2004|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|9|||Both|18 Years|N/A|No|||August 2012|October 28, 2015|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055926||202502|
NCT00059826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z05031|Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer|A Phase II Study of Interferon-Based Adjuvant Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma||Alliance for Clinical Trials in Oncology|No|Completed|March 2003|February 2011|Actual|November 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|May 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00059826||202236|
NCT00059540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0008|The Maternal Lifestyle Study (MLS)|The Maternal Lifestyle Study|MLS|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|May 1993|March 2011|Anticipated|March 1995|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11811|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mother and baby dyads delivered at the 4 participating centers.|September 2010|January 9, 2011|April 28, 2003||No||No||https://clinicaltrials.gov/show/NCT00059540||202256|
NCT00060684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA I-06|Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma|A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma||CTI BioPharma||Completed|December 2001|May 2007|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||September 2008|January 15, 2015|May 9, 2003||Yes||||https://clinicaltrials.gov/show/NCT00060684||202182|
NCT00060697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD39541-2|A Mother's Role in Delaying Onset of Sexual Activity in Her Children|Family Intervention to Promote Health in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|December 2000|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||1300|||Both|6 Years|85 Years|Accepts Healthy Volunteers|||May 2003|June 23, 2005|May 9, 2003||||No||https://clinicaltrials.gov/show/NCT00060697||202181|
NCT00059306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03016|Secondary Prevention of Small Subcortical Strokes Trial|Secondary Prevention of Small Subcortical Strokes (SPS3) Trial|SPS3|University of British Columbia|Yes|Completed|February 2003|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3020|||Both|30 Years|N/A|No|||April 2013|April 2, 2013|April 23, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00059306||202273|
NCT00060125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02958|Tipifarnib in Treating Patients With Metastatic Malignant Melanoma|PHASE II TRIAL OF R115777 IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA||National Cancer Institute (NCI)||Completed|May 2003|||June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060125||202219|
NCT00059787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00026|Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma|Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)|Yes|Completed|April 2003|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|18 Years|N/A|No|||May 2013|October 29, 2015|May 6, 2003|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT00059787||202239|
NCT00059839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANHL0131|Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma|A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine||Children's Oncology Group|Yes|Completed|November 2003|July 2014|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|N/A|20 Years|No|||September 2014|September 10, 2014|May 6, 2003|Yes|Yes||No|June 28, 2013|https://clinicaltrials.gov/show/NCT00059839||202235|
NCT00060983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K01HD001193-02|Improving Gait in Patients With Spinal Cord Injuries|Effects of Sensory Motor Input on Gait in SCI (Spinal Cord Injured) Subjects||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|May 1998|April 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||36|||Both|18 Years|60 Years|No|||May 2003|June 23, 2005|May 16, 2003||||No||https://clinicaltrials.gov/show/NCT00060983||202160|
NCT00059657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFI 01-02|Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM in Conjunction With Peripheral Revascularization for the Treatment of Critical Leg Ischemia||Mitsubishi Tanabe Pharma Corporation||Completed|August 2001|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|40 Years|N/A|No|||May 2006|May 17, 2006|April 29, 2003||||||https://clinicaltrials.gov/show/NCT00059657||202248|
NCT00059436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD036725|Mental Effort and Muscle Strength|Mental-effort Effect on Large Muscle Strengthening||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|October 1999|May 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 20, 2011|April 25, 2003|||Study terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00059436||202263|
NCT00059215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7145|A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)|A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 Compared With Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention||Eli Lilly and Company|No|Completed|April 2003|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|905|||Both|18 Years|75 Years|No|||May 2010|May 21, 2010|April 21, 2003|No|Yes||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00059215||202280|
NCT00061087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-011444-1,#4184R|Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1|Treatment of Adult ADHD in Methadone Patients||New York State Psychiatric Institute|Yes|Completed|February 1998|October 2004|Actual|October 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|115|||Both|18 Years|60 Years|No|||October 2012|October 24, 2012|May 21, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00061087||202152|
NCT00061269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDIPC (completed)|Videoendoscopic Drainage of Infected Pancreatic Collections|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|May 22, 2003||||No||https://clinicaltrials.gov/show/NCT00061269||202139|
NCT00061282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2202|Clotrimazole Enemas for Pouchitis in Children and Adults|Clotrimazole Enemas for Pouchitis in Children and Adults|CAPTURE|Children's Hospital Boston|Yes|Suspended|September 2002|June 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|2 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 23, 2003|Yes|Yes|Funding Horizon|No||https://clinicaltrials.gov/show/NCT00061282||202138|
NCT00059891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-124|Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer|Total Anorectal Reconstruction With The American Medical Systems, Inc. Acticon Neosphincter Prosthesis After Abdominoperineal Resection||Memorial Sloan Kettering Cancer Center||Completed|January 2003|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|May 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00059891||202231|
NCT00058734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI044628|Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients|Immune Responses to Antigen-Bearing Dendritic Cells in HIV-Infected Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2000|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2007|August 23, 2007|April 11, 2003||||||https://clinicaltrials.gov/show/NCT00058734||202309|
NCT00059267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH HBV-OLT (completed)|Prevention of Recurrent Hepatitis B After Liver Transplantation|Prevention of Recurrent Hepatitis B After Liver Transplantation||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 2001|||||N/A|Observational|N/A||||500|||Both|13 Years|N/A|No|||January 2010|January 12, 2010|April 22, 2003||||No||https://clinicaltrials.gov/show/NCT00059267||202276|
NCT00057759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0215|Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer|Treatment Of Erectile Dysfunction In Patients Treated On RTOG-9910 For Prostate Cancer: Impact On Patient And Partner Quality Of Life||Radiation Therapy Oncology Group|Yes|Completed|January 2003|||December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|115|||Male|18 Years|N/A|No|||November 2015|November 14, 2015|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057759||202368|
NCT00055913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02520|Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck||National Cancer Institute (NCI)||Completed|March 2003|||September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||December 2012|February 11, 2014|March 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00055913||202503|
NCT00059254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMDFA (COMPLETED)|Differential Metabolism of Dietary Fatty Acids|Differential Metabolism of Dietary Fatty Acids||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2000|April 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||44|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|April 22, 2003||||No||https://clinicaltrials.gov/show/NCT00059254||202277|
NCT00058305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03116|Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation|A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant||National Cancer Institute (NCI)||Completed|March 2003|||December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058305||202333|
NCT00059280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU01602|A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease|An Open-label, Multicenter, Multinational Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid Alpha-glucosidase Treatment in Patients Less Than 6 Months Old With Infantile-onset Pompe Disease||Sanofi||Completed|April 2003|September 2005|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|26 Weeks|No|||July 2006|February 4, 2014|April 22, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059280||202275|
NCT00058604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9454|Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).|Autologous EBV Specific CTLs for Prophylaxis and Therapy of EBV Lymphoma Post Solid Organ Transplant|EUCLID|Baylor College of Medicine|Yes|Completed|January 2001|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|N/A|70 Years|No|||April 2009|April 9, 2009|April 8, 2003|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00058604||202316|
NCT00058240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01435|Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma|A Dose-Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)||National Cancer Institute (NCI)||Completed|April 2003|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||November 2012|June 6, 2014|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058240||202338|
NCT00058461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01804|Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia|A Phase II Study of Rituximab (IND #7028) and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy in Children With Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Terminated|November 2003|||March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|N/A|21 Years|No|||October 2013|October 7, 2013|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058461||202324|
NCT00058357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000288824|Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery|The Efficacy Of Lidocaine Patch In The Management Of Postsurgical Neuropathic Pain In Patients With Cancer: A Phase III Double-Blind, Crossover Study||Alliance for Clinical Trials in Oncology|Yes|Completed|May 2004|July 2007|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058357||202330|
NCT00058721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030006|Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease|SPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2003|January 2005||||N/A|Observational|N/A||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2005|March 3, 2008|April 11, 2003||||No||https://clinicaltrials.gov/show/NCT00058721||202310|
NCT00058435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-122|Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|Phase I Trial of the Monoclonal Anti-Idiotype Antibody ACA125 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer||Memorial Sloan Kettering Cancer Center||Completed|December 2002|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 4, 2013|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058435||202326|
NCT00059592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6644|Valacyclovir in Immunocompromised Children|Valacyclovir in Immunocompromised Children||Baylor College of Medicine||Completed|May 1998|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|2 Years|18 Years|No|||May 2005|June 23, 2005|April 29, 2003||||||https://clinicaltrials.gov/show/NCT00059592||202253|
NCT00059605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-123|Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer|Phase I Study Of Intravenous DOTAP:Cholesterol-Fus1 Liposome Complex (DOTAP:Chol-fus1) In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy||M.D. Anderson Cancer Center|No|Completed|March 2003|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||February 2012|February 21, 2012|April 29, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059605||202252|
NCT00059332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS044364|Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial|Field Administration of Stroke Therapy-Magnesium Trial: A Randomized, Double-Blind, Placebo Controlled Trial of Neuroprotective Magnesium Sulfate Therapy for Acute Stroke Initiated Within 2 Hours of Onset by Paramedics in the Field|FAST-MAG|University of California, Los Angeles|Yes|Completed|January 2005|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1700|||Both|40 Years|95 Years|No|||June 2015|July 24, 2015|April 23, 2003|Yes|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT00059332||202271|
NCT00058851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001326-01|Massage Therapy for Breast Cancer Treatment-Related Swelling of the Arms|Massage Therapy for Breast Cancer-Related Lymphedema||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2003|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|88|||Both|N/A|N/A|No|||August 2009|August 17, 2009|April 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00058851||202300|
NCT00058864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0001|The HIP Impact Protection Program (HIP PRO)|Trochanteric Padding to Prevent Hip Fractures||National Institute on Aging (NIA)||Completed|September 2001|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||546|||Both|66 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 26, 2009|April 14, 2003||||No||https://clinicaltrials.gov/show/NCT00058864||202299|
NCT00057850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02523|BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|January 2002|||July 2003|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||April 2003|February 8, 2013|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057850||202363|
NCT00057863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03004|Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer|A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer||National Cancer Institute (NCI)||Completed|January 2003|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2012|October 16, 2015|April 7, 2003|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT00057863||202362|
NCT00057876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000278947|Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer|A Randomized Phase III Study Of Gemcitabine In Combination With Radiation Therapy Versus Gemcitabine Alone In Patients With Localized, Unresectable Pancreatic Cancer||Eastern Cooperative Oncology Group|Yes|Completed|April 2003|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|April 7, 2003||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00057876||202361|
NCT00059696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01HD034273-04|Treatment for Movement Problems in Elderly Stroke Patients|A Treatment for Excess Motor Disability in the Aged||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|December 1999|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|May 1, 2003|||Study withdrawn/terminated|No||https://clinicaltrials.gov/show/NCT00059696||202245|
NCT00058396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEC-152-20|Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I Study Of IDEC-152 (Anti-CD23 Monoclonal Antibody) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|October 2002|||October 2004|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|May 29, 2013|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058396||202328|
NCT00058422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-090|Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma|A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2003|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|60 Years|120 Years|No|||March 2016|March 1, 2016|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058422||202327|
NCT00059345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR049999|Interaction Between Patient and Healthcare Provider: Response to Acupuncture in Knee Osteoarthritis|The Impact of Patient-Provider Interaction on Response to Acupuncture||M.D. Anderson Cancer Center|No|Completed|September 2002|August 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|639|||Both|50 Years|N/A|No|||November 2013|November 15, 2013|April 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00059345||202270|
NCT00059358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI09141-01A1|Zidovudine Levels in HIV Infected Patients Being Treated for HCV|Pharmacological Interactions Between Zidovudine and Ribavirin in HCV-HIV Co-Infected Patients Treated With Rebetron or Peg-Intron Plus Ribavirin||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2001|June 2005|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|21 Years|60 Years|No|||August 2009|August 6, 2009|April 23, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059358||202269|
NCT00059371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01AI050440-02|Male Circumcision and HIV Rates in Kenya|Trial of Male Circumcision to Reduce HIV Incidence||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|February 2002|December 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2887|||Male|18 Years|24 Years|Accepts Healthy Volunteers|||September 2007|May 28, 2008|April 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00059371||202268|
NCT00058890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 --9618 (completed 2005)|Gabapentin to Treat Itch in Patients With Liver Disease|Study of Gabapentin for the Pruritus of Cholestasis||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|November 2000|January 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||March 2010|March 17, 2010|April 14, 2003||||No||https://clinicaltrials.gov/show/NCT00058890||202297|
NCT00058825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8713-HIMSUM|Stem Cell Transplant for Hematologic Diseases|Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H|HIMSUM|Baylor College of Medicine|Yes|Terminated|August 2000|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|N/A|70 Years|No|||September 2015|September 23, 2015|April 11, 2003|Yes|Yes|Slow accrual due to practice changes meant study would take too long to finish|No|September 23, 2015|https://clinicaltrials.gov/show/NCT00058825||202302|
NCT00058253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01436|Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC# 330507) in Combination With Docetaxel in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|February 2003|March 2010|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||December 2012|June 16, 2014|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058253||202337|
NCT00058318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000288820|S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer|A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients With Advanced Renal Cell Cancer||Southwest Oncology Group|Yes|Completed|December 2004|November 2008|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058318||202332|
NCT00055783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC-NCI-1951|Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma|A Phase II Study of Hu1D10 in Recurrent Hodgkin's Disease||National Cancer Institute (NCI)||Completed|July 2002|April 2003|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2003|May 14, 2013|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055783||202511|
NCT00058903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRCPWS (completed)|Treatment of Cholestatic Pruritus With Sertraline|Treatment of Cholestatic Pruritus With Sertraline||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2003|March 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|21 Years|80 Years|No|||January 2010|January 12, 2010|April 14, 2003||||||https://clinicaltrials.gov/show/NCT00058903||202296|
NCT00058929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01:13|A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension|A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutaneous Remodulin® Therapy After Transition From Flolan® in Patients With Pulmonary Arterial Hypertension||United Therapeutics|No|Completed|October 2002|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||39|||Both|18 Years|75 Years|No|||March 2013|March 5, 2013|April 14, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058929||202295|
NCT00058578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7157|Stem Cell Transplant to Treat Patients With Systemic Sclerosis|Autologous T-Cell Depleted Peripheral Blood Stem Cell Transplantation for the Treatment of Selected Patients With Systemic Sclerosis||Baylor College of Medicine||Completed|June 1999|June 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|No|||April 2007|April 9, 2007|April 8, 2003||||||https://clinicaltrials.gov/show/NCT00058578||202318|
NCT00058682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030150|Anidulafungin Versus Fluconazole in the Treatment of Candidemia|A Phase III, Double Blind, Randomized, Multi-Center Study of the Safety and Efficacy of Anidulafungin VS. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications||National Institutes of Health Clinical Center (CC)||Completed|April 2003|January 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||248|||Both|N/A|N/A|No|||January 2005|March 3, 2008|April 11, 2003||||No||https://clinicaltrials.gov/show/NCT00058682||202312|
NCT00059852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0234|Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane|A Phase II Study of OSI-774 (Tarceva) and Gemcitabine for Patients With Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|June 2003|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00059852||202234|
NCT00059709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD38895-2|Learning to Resolve Family Conflict|Understanding and Learning How to Resolve Family Conflict||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 2000|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||360|||Both|4 Years|N/A|Accepts Healthy Volunteers|||January 2006|April 2, 2007|May 2, 2003||||No||https://clinicaltrials.gov/show/NCT00059709||202244|
NCT00058942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0002|A Trial of Tap Water Treatment in the Elderly|A Randomized Trial of Tap Water Treatment in the Elderly||National Institute on Aging (NIA)||Completed|January 2000|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||810|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2006|December 9, 2009|April 15, 2003||||No||https://clinicaltrials.gov/show/NCT00058942||202294|
NCT00058955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-SXB-25|Physiological, Behavioral and Subjective Effects of Drugs (GHB)|Physiological, Behavioral and Subjective Effects of Drugs (GHB)||Orphan Medical|No|Completed|August 2003|March 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 9, 2008|April 15, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058955||202293|
NCT00059020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030160|The Role of Gene Changes in Brain Tumor Formation and Growth|EGF Polymorphisms and Gliomagenesis||National Institutes of Health Clinical Center (CC)||Completed|April 2003|November 2004||||N/A|Observational|N/A||||344|||Both|N/A|N/A|No|||November 2004|March 3, 2008|April 16, 2003||||No||https://clinicaltrials.gov/show/NCT00059020||202289|
NCT00059033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030004|Evaluation of Primary Chronic Autonomic Failure|Clinical Laboratory Evaluation of Primary Chronic Autonomic Failure||National Institutes of Health Clinical Center (CC)||Recruiting|April 2003|||||N/A|Observational|N/A|||Anticipated|435|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|January 28, 2016|April 16, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059033||202288|
NCT00058201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000287023|Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer|European Study Group For Pancreatic Cancer - Trial 3||National Cancer Institute (NCI)||Completed|July 2001|September 2010|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|1030|||Both|18 Years|N/A|No|||May 2008|December 17, 2013|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058201||202341|
NCT00058214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02832|Perifosine in Treating Patients With Recurrent Prostate Cancer|A Phase II Trial of Perifosine (IND 58,156; NSC# 639966) in Biochemically Recurrent, Hormone Sensitive Prostate Cancer||National Cancer Institute (NCI)||Terminated|March 2003|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|N/A|No|||February 2013|February 9, 2015|April 7, 2003|No|Yes|Did not meet interim stopping criteria for continuation to the second stage.|No|February 9, 2015|https://clinicaltrials.gov/show/NCT00058214||202340|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.
NCT00058266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 00U7|Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy|A Phase II Study Of Genistein In Patients With Localized Prostate Cancer (Molecular Correlates of Soy In Humans)||Northwestern University|Yes|Terminated|December 2002|September 2009|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|N/A|No|||July 2012|July 10, 2012|April 7, 2003|Yes|Yes|Data Monitoring Committee cited poor accrual.|No||https://clinicaltrials.gov/show/NCT00058266||202336|
NCT00058331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N02C2|Epoetin Alfa in Treating Anemia in Patients With Solid Tumors|A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|June 2003|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|365|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058331||202331|
NCT00055874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III-MK-CML-IV|Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase||National Cancer Institute (NCI)||Recruiting|June 2002|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1600|||Both|N/A|N/A|No|||November 2011|August 9, 2013|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055874||202505|
NCT00058526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|719125/002|A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer|A Multicenter Phase I Open-label Dose-escalation Vaccine Trial of dHER2 Protein With AS15 Adjuvant in HER2-overexpressing Patients With High-risk Breast Cancer||GlaxoSmithKline||Completed|March 2003|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|61|||Female|40 Years|70 Years|No|||July 2013|July 18, 2013|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058526||202321|
NCT00058539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC2682g|Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer|A Phase II, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Omnitarg (Pertuzumab) in Subjects With Castration-Resistant Prostate Cancer||Genentech, Inc.||Completed|April 2003|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|42|||Male|18 Years|N/A|No|||June 2015|June 2, 2015|April 8, 2003|||||June 2, 2015|https://clinicaltrials.gov/show/NCT00058539||202320|
NCT00058552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC2689g|A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer|A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer||Genentech, Inc.||Completed||July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|129|||Female|18 Years|N/A|No|||June 2015|June 2, 2015|April 8, 2003|||||June 2, 2015|https://clinicaltrials.gov/show/NCT00058552||202319|
NCT00058812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6676-ETNA|Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts|Administration of EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts|ETNA|Baylor College of Medicine|Yes|Completed|May 1993|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|N/A|N/A|No|||January 2015|January 27, 2015|April 11, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058812||202303|
NCT00059722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6474IL/0003|This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.|A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.||AstraZeneca||Completed|May 2003|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|May 2, 2003||||||https://clinicaltrials.gov/show/NCT00059722||202243|
NCT00059046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030159|Brain Imaging of Serotonin Transporters in the Brain|Kinetic Studies in Whole Body and Brain of [11C]DASB PET Imaging of Serotonin Transporters||National Institutes of Health Clinical Center (CC)||Completed|April 2003|January 2005||||N/A|Observational|N/A||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2005|March 3, 2008|April 16, 2003||||No||https://clinicaltrials.gov/show/NCT00059046||202287|
NCT00059098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211|Identification of Genes Predisposing to Atherosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 2003|February 2008|Actual|February 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2008|April 22, 2008|April 17, 2003||||No||https://clinicaltrials.gov/show/NCT00059098||202286|
NCT00059111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212|Mechanisms Mediating Cardiovascular Disease in Children With Obstructive Sleep Apnea|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2003|March 2008|Actual|March 2008|Actual|N/A|Observational|N/A|||||||Both|8 Years|12 Years|No|||April 2008|April 22, 2008|April 17, 2003||||No||https://clinicaltrials.gov/show/NCT00059111||202285|
NCT00059124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1213|Aortic Calcium: Epidemiology and Progression -- Ancillary to MESA|Aortic Calcium: Epidemiology and Progression||University of California, San Diego|No|Completed|March 2003|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1980|||Both|45 Years|84 Years|Accepts Healthy Volunteers|Probability Sample|A random selection of approximately 1/3 of the original MESA participants.|July 2013|July 10, 2013|April 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00059124||202284|
NCT00058617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6423-ANGEL|Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL|Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma||Baylor College of Medicine|Yes|Completed|January 1996|July 2014|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|N/A|No|||August 2014|August 25, 2014|April 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058617||202315|
NCT00058656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XT004|Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients|A Phase I/II Study of Xcellerated T Cells(tm) in Patients With Chronic Lymphocytic Leukemia (CLL)||Xcyte Therapies||Completed|March 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||January 2005|November 20, 2006|April 8, 2003||||||https://clinicaltrials.gov/show/NCT00058656||202314|
NCT00058669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210|CVD Risk Factors and Sexual Identity in Women|CVD Risk Factors and Sexual Identity in Women||University of Pittsburgh|No|Completed|March 2003|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1174|Samples Without DNA|urine, plasma,|Female|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women over 35 Years age without cvd|January 2016|January 4, 2016|April 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00058669||202313|
NCT00060021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000299048|Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation|A Randomized, Placebo-Controlled, Blinded Study Of Acupuncture Therapy In Mucositis-Related Pain In Patients Undergoing Hematopoietic Stem Cell Transplantation||National Cancer Institute (NCI)||Completed|March 2003|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||April 2004|April 29, 2015|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00060021||202223|
NCT00058227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01434|Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma|A Phase I Study of Flavopiridol, Fludarabine and Rituximab in Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma||National Cancer Institute (NCI)||Completed|April 2003|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058227||202339|
NCT00057746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0212|Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer|A Phase II/III Randomized Trial Of Two Dose Schedules For Delivering Prophylactic Cranial Irradiation For Patients With Limited Disease Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|February 2003|November 2013|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|265|||Both|N/A|N/A|No|||January 2014|January 15, 2014|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057746||202369|
NCT00057954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000285659|Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma|A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplantation for the Treatment of Relapsed Non-Hodgkin and Hodgkin Lymphoma||Eastern Cooperative Oncology Group|No|Terminated|June 2005|May 2011|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|April 7, 2003|Yes|Yes|Slow accrual|No|January 7, 2013|https://clinicaltrials.gov/show/NCT00057954||202356|
NCT00059735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7070-A001-206|A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma|A Phase II Study of E7070 in Patients With Progressive Inoperable and/or Metastatic Renal Cell Carcinoma (RCC)||Eisai Inc.||Completed|May 2002|December 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||February 2008|February 29, 2008|May 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00059735||202242|
NCT00059878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000298887|Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections|A Prospective, Randomized, Double-Blind, Multicenter Pilot Study Of The Safety And Efficacy Of Interferon Gamma- 1b (IFN-y 1b) Plus Voriconazole Versus Placebo Plus Voriconazole In The Treatment Of Invasive Aspergillosis And Other Filamentous Fungal Infections||National Cancer Institute (NCI)||Completed|August 2003|January 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|2 Years|N/A|No|||July 2004|June 17, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00059878||202232|
NCT00059137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030166|Breathing Cycle Biofeedback During Computed Tomography Procedures|Respiratory Cycle Biofeedback During CT Guided Procedures||National Institutes of Health Clinical Center (CC)||Completed|April 2003|March 2006||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||March 2006|March 3, 2008|April 18, 2003||||No||https://clinicaltrials.gov/show/NCT00059137||202283|
NCT00058279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000287211|Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma|MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|February 2003|August 2006|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||August 2006|June 18, 2013|April 7, 2003||||||https://clinicaltrials.gov/show/NCT00058279||202335|
NCT00059189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030163|Brain Plasticity of Verbal Memory in the Blind|Cross-Modal Plasticity of Verbal Memory in the Blind||National Institutes of Health Clinical Center (CC)||Completed|April 2003|April 2005||||N/A|Observational|N/A||||85|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2005|March 3, 2008|April 19, 2003||||No||https://clinicaltrials.gov/show/NCT00059189||202282|
NCT00059228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030161|Clinical Trial of Estrogen for Postpartum Depression|The Efficacy of 17Beta-Estradiol in Postpartum-Related Depressive Illness||National Institutes of Health Clinical Center (CC)||Recruiting|April 2003|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Female|20 Years|45 Years|No|||May 2015|January 30, 2016|April 22, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00059228||202279|
NCT00059241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD39537-2|The "Reach For Health" Program: Delaying Sexual Activity in Children|Reach For Health--Middle Childhood Risk Prevention Study||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|July 2000|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1200|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||April 2003|June 23, 2005|April 22, 2003||||No||https://clinicaltrials.gov/show/NCT00059241||202278|
NCT00058773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6422-ANGELA|Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease|Administration of Autologous Neomycin Resistant Gene Marked EBV Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving Autologous Bone Marrow Transplant for Relapsed EBV-Positive Lymphoma.|ANGELA|Baylor College of Medicine|Yes|Terminated|January 1996|August 2006|Actual|April 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||November 2012|November 5, 2012|April 11, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058773||202306|
NCT00058292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 99H11|Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma||Northwestern University||Completed|April 2000|March 2009|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|17 Years|N/A|No|||May 2012|May 31, 2012|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058292||202334|
NCT00058799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6408-Leu Leu|Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine|Treatment of High Risk Acute Leukemia With CD40 Ligand and IL-2 Gene Modified Autologous Skin Fibroblasts and Tumor Cells||Baylor College of Medicine|No|Completed|June 1999|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|75 Years|No|||July 2010|July 27, 2010|April 11, 2003|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00058799||202304|
NCT00058747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-300-01|AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™|Phase II Exploratory Study Of AG-858 Plus Gleevec™ In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec™||Agenus, Inc.||Terminated|March 2003|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|April 11, 2003||Yes|Business decision of the sponsor|||https://clinicaltrials.gov/show/NCT00058747||202308|
NCT00055965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271903|Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin|A Pragmatic, Randomised Study To Compare The Hospitalisation Rates Of Two Platinum-Based Outpatient Regimens (Gemcitabine/Cisplatin vs. Gemcitabine/Carboplatin) In Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Active, not recruiting|November 2002|||August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||January 2009|September 19, 2013|March 6, 2003||||No||https://clinicaltrials.gov/show/NCT00055965||202499|
NCT00058786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11541|Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells|Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells|CLIMAT|Baylor College of Medicine|Yes|Completed|December 2002|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|April 11, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058786||202305|
NCT00058448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000297621|S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)|Phase II Study Of Weekly Docetaxel In Patients With Advanced Epidermoid Carcinoma Of The Penis||Southwest Oncology Group|No|Terminated|October 2004|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|N/A|No|||April 2013|April 16, 2013|April 7, 2003|Yes|Yes|Study terminated due to poor patient recruitment.|No||https://clinicaltrials.gov/show/NCT00058448||202325|
NCT00058474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP R-04|Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer|A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum||NSABP Foundation Inc|Yes|Active, not recruiting|July 2004|May 2016|Anticipated|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1608|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00058474||202323|
NCT00059865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N9943|Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer|Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|January 2004|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00059865||202233|
NCT00061308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/627|Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer|An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer||GlaxoSmithKline||Completed|December 2002|||September 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||75|||Female|18 Years|N/A|No|||March 2013|March 1, 2013|May 23, 2003||||No||https://clinicaltrials.gov/show/NCT00061308||202136|
NCT00062101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02720|Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer|A Phase II Study of OSI 774 (IND Number 63383) in Combination With Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|January 2004|||January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|June 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062101||202080|
NCT00062231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-46001|Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer|Oral Empirical Therapy of Fever in Low-Risk Neutropenic Cancer Patients: A Prospective, Double-Blind, Randomized, Multicenter Trial Comparing Monotherapy (Single Daily Dose Moxifloxacin) With Combination Therapy (Ciprofloxacin Plus Amoxicillin/Clavulanic Acid)||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|April 2002|||October 2006|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Actual|351|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|June 5, 2003|||low accrual|No||https://clinicaltrials.gov/show/NCT00062231||202073|
NCT00062894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBX001-048|Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab|A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma||GlaxoSmithKline||Completed|April 2003|April 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|N/A|No|||September 2007|September 13, 2007|June 17, 2003||||No||https://clinicaltrials.gov/show/NCT00062894||202025|
NCT00063128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6944|Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.|Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|April 2003|April 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|June 20, 2003|Yes|Yes||||https://clinicaltrials.gov/show/NCT00063128||202008|
NCT00057980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 02I6|Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma|Phase I/II Study of Epirubicin and Celecoxib for Hepatocellular Carcinoma||Northwestern University|Yes|Completed|October 2002|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|8|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057980||202354|
NCT00057993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 01B4|Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer|Phase II Study Of Herceptin And Exemestane For Treatment Of Postmenopausal Women With Metastatic Hormone-Responsive, HER2/NEU Positive Breast Cancer||Northwestern University|Yes|Withdrawn|July 2002|August 2004||August 2004||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|N/A|No|||June 2012|June 7, 2012|April 7, 2003|Yes|Yes|Unable to accrue subjects to the study after 2 years - closed per request by Data Monitoring    Committee.|No||https://clinicaltrials.gov/show/NCT00057993||202353|
NCT00061321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI045462-04|Daily Nevirapine to Prevent Mother to Infant Transmission of HIV|Prevention of Maternal to Infant HIV Transmission in India|SWEN|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2002|September 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|770|||Female|18 Years|N/A|No|||August 2007|July 30, 2008|May 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00061321||202135|
NCT00062309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304712|Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer|A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation||Fox Chase Cancer Center|No|Completed|June 2002|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|307|||Male|18 Years|N/A|No|||March 2016|March 1, 2016|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062309||202067|
NCT00063440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1214|Epidemiology of Carotid IMT Progression in MESA - Ancillary Study|||Tufts Medical Center||Completed|June 2003|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5610|||Both|45 Years|84 Years|No|Non-Probability Sample|Participants of the Multi-Ethnic Study of Atherosclerosis, a cross-sectional NIH        population cohort originating from 6 regions in the United States|February 2013|February 6, 2013|June 26, 2003||No||No||https://clinicaltrials.gov/show/NCT00063440||201987|
NCT00063453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151|Supplemental Selenium and Vitamin E and Pulmonary Function|The Respiratory Ancillary Study (RAS) to SELECT||Cornell University|Yes|Completed|August 2003|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2920|||Male|50 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 19, 2013|June 26, 2003||No||No||https://clinicaltrials.gov/show/NCT00063453||201986|
NCT00061815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-014|Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer|A Phase 3 Randomized Multicenter Study of Cetuximab, Oxaliplatin, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and Leucovorin in Subjects With Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma||ImClone LLC|No|Completed|March 2003|November 2005|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||April 2010|April 8, 2010|June 4, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00061815||202100|
NCT00061828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARC - IND|Biliary Atresia Research Consortium|A Prospective Database of Infants With Cholestasis|PROBE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|May 2004|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Samples of blood, urine and liver tissue samples will be collected for research purposes.|Both|N/A|6 Months|No|Non-Probability Sample|This study population will be selected from the patient base of participating speciality        care clinics.|September 2014|September 15, 2014|June 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00061828||202099|
NCT00061438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3591IL/0089|A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died|A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis||AstraZeneca||Completed|February 2003|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||240|||Both|18 Years|N/A|No|||November 2010|November 17, 2010|May 27, 2003||||||https://clinicaltrials.gov/show/NCT00061438||202126|
NCT00062855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6442|Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma|Phase I Study of Chemokine and Cytokine Gene Modified Autologous Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma Using an Adenoviral Vector (CYCHE)|CYCHE|Baylor College of Medicine|Yes|Completed|November 1997|March 2006|Actual|August 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|21 Years|No|||October 2012|October 26, 2012|June 17, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062855||202028|
NCT00062868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9936-ALCI|LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma|Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI)|ALCI|Baylor College of Medicine|Yes|Active, not recruiting|April 2007|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|89|||Both|N/A|N/A|No|||December 2015|December 30, 2015|June 17, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062868||202027|
NCT00062322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304720|Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase I Study of Preoperative Chemo/Radiation (Concurrent Irinotecan/Cisplatin/RT) Followed by Surgery in Limited Stage Small Cell Lung Cancer (SCLC-LS)||Fox Chase Cancer Center||Completed|February 2003|October 2009|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|February 11, 2010|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00062322||202066|
NCT00062036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030162|Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma|Tumor Infiltrating Lymphocytes (TIL Cells) Transduced With An Interleukin-2 (SBIL-2) Gene Following The Administration Of A Nonmyeloablative But Lymphocyte Depleting Regimen in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)||Completed|June 2003|September 2008|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|N/A|No|||March 2012|July 11, 2012|June 5, 2003||||||https://clinicaltrials.gov/show/NCT00062036||202084|
NCT00061958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02534|Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Study of Arsenic Trioxide (NSC 706363) in Patients With Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction||National Cancer Institute (NCI)||Terminated|June 2003|||April 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|June 5, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00061958||202089|
NCT00058006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 02V2|Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer|Pilot Randomized Trial Of Adjuvant Celecoxib In Patients With Early Stage Head And Neck And Non-Small Cell Lung Cancers||Northwestern University||Completed|September 2002|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2012|June 7, 2012|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058006||202352|
NCT00063063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0001|Generic Database of Very Low Birth Weight Infants|Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants|GDB|NICHD Neonatal Research Network|No|Recruiting|January 1987|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80000|||Both|N/A|14 Days|No|Non-Probability Sample|Infants inborn at NICHD NRN centers that are 401-1000 grams birth weight, and/or <29 weeks        gestational age, OR infants enrolled in one or more additional NICHD NRN studies.|March 2016|March 22, 2016|June 19, 2003||No||No||https://clinicaltrials.gov/show/NCT00063063||202013|
NCT00062049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030152|Interleukin-7 in Treating Patients With Refractory Solid Tumors|A Phase I Study of Subcutaneous "CYT 99 007" (Interleukin-7) in Patients With Refractory Non Hematologic Malignancy||National Institutes of Health Clinical Center (CC)||Completed|April 2003|May 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|June 5, 2003||||||https://clinicaltrials.gov/show/NCT00062049||202083|
NCT00061373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030171|Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)|Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)|CATALIST|National Institutes of Health Clinical Center (CC)|Yes|Completed|May 2003|July 2011|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|85 Years|No|||December 2012|December 27, 2012|May 23, 2003|No|Yes||No|December 27, 2012|https://clinicaltrials.gov/show/NCT00061373||202131|All patients enrolled were dosed with aspirin and tinzaparin. None of the patients received iv eptifibatide. The study was closed prior to dosing with eptifibatide due to slow recruitment over the 5-year trial period.
NCT00061906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0239|Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer|Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|January 2003|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00061906||202093|
NCT00062062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0222|Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer|Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age||Alliance for Clinical Trials in Oncology|No|Completed|October 2004|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|65 Years|N/A|No|||July 2015|July 9, 2015|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062062||202082|
NCT00063076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM02-164|Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata|A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata||M.D. Anderson Cancer Center|Yes|Completed|May 2003|May 2007|Actual|October 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 1, 2012|June 19, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063076||202012|
NCT00063089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1407|Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever|Initial Safety and Pharmacokinetics Trial of Immune Globulin to Staphylococcus Aureus Capsule Polysaccharide (Altastaph) in Subjects With S. Aureus Bacteremia and Persistent Fever||Nabi Biopharmaceuticals||Completed|September 2002|September 2004|Actual|September 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|7 Years|N/A|No|||May 2012|May 10, 2012|June 19, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063089||202011|
NCT00058058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000285698|Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer|MRI Evaluation Of The Contralateral Breast In Women With Recent Diagnosis Of Breast Cancer||National Cancer Institute (NCI)||Completed|February 2001|||March 2007|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Female|18 Years|N/A|No|||April 2004|October 23, 2012|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058058||202348|
NCT00057798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000270753|Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery|Molecular And Genetic Changes In Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Vinorelbine And Gemcitabine - Phase II Study||Roswell Park Cancer Institute|Yes|Completed|March 2000|June 2008|Actual|May 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||March 2011|March 7, 2011|April 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00057798||202366|
NCT00058071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000285700|Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer|A Randomized Phase III Trial of Amifostine vs. No Treatment for Platinum Induced Peripheral Neuropathy||Gynecologic Oncology Group||Completed|March 2003|||December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|100|||Both|18 Years|N/A|No|||July 2007|July 8, 2013|April 7, 2003||||No||https://clinicaltrials.gov/show/NCT00058071||202347|
NCT00061841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FITKID (DK63391) (completed)|Medical College of Georgia FitKid Project|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||Anticipated|685|||Both|8 Years|9 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00061841||202098|
NCT00062179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304540|Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer|A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer||Jonsson Comprehensive Cancer Center|Yes|Completed|March 2003|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||August 2012|October 1, 2015|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062179||202075|
NCT00062452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMADAI (completed)|Esophageal Motility and Airway Defenses Among Infants|Esophageal Motility and Airway Defenses Among Infants||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|May 2002|July 2005|Actual|April 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|N/A|6 Months|Accepts Healthy Volunteers|Probability Sample|Premature infants congenital foregut anomalies Perinatal asphyxia|January 2010|January 12, 2010|June 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00062452||202058|
NCT00061776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C108|NGX-4010 for the Treatment of Postherpetic Neuralgia|A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia||NeurogesX||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2008|March 4, 2008|June 3, 2003||||||https://clinicaltrials.gov/show/NCT00061776||202103|
NCT00061854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000301749|Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Study Of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, To Patients With Progressive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) Following Treatment With Platinum-Based Chemotherapy||Daiichi Sankyo Inc.||Completed|April 2003|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 15, 2012|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00061854||202097|
NCT00061386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD37368-4|Improving Health in Low Income Women Following the Birth of a Child|Reducing Disease Risk in Low Income Postpartum Women||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|March 2001|March 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||680|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||September 2005|September 9, 2005|May 27, 2003||||No||https://clinicaltrials.gov/show/NCT00061386||202130|
NCT00062621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN008ST|Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure|Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2003|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||February 2013|February 1, 2013|June 9, 2003||No||No||https://clinicaltrials.gov/show/NCT00062621||202045|
NCT00061945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02807|Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia|A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)||National Cancer Institute (NCI)||Completed|June 2003|October 2012|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|302|||Both|15 Years|N/A|No|||December 2013|March 20, 2014|June 5, 2003|Yes|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00061945||202090|
NCT00062140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1797.00|Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer|A Phase I Trial Of Total Body Irradiation, Cyclophosphamide Dose-Adjustment Based On Its Metabolism, And Hematopoietic Stem Cell Transplantation For Patients With Hematological Malignancy||Fred Hutchinson Cancer Research Center||Completed|April 2003|July 2004|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||September 2010|September 20, 2010|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00062140||202077|
NCT00062166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030145|Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease|Evaluation of the Natural History and Management of Pancreatic Lesions Associated With Von Hippel-Lindau||National Institutes of Health Clinical Center (CC)||Recruiting|April 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|12 Years|80 Years|No|||December 2015|December 31, 2015|June 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00062166||202076|
NCT00058084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02526|Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer|A Randomized Phase II Study Of BMS 247550 Or Mitoxantrone And Prednisone In Patients With Taxane Resistant Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|March 2003|||September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|N/A|No|||January 2013|January 14, 2013|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00058084||202346|
NCT00063102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-447|A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.|A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens||Abbott|No|Completed|November 2002|August 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||40|||Female|18 Years|N/A|No|||November 2007|November 28, 2007|June 19, 2003||||No||https://clinicaltrials.gov/show/NCT00063102||202010|
NCT00062283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALMEDIX-SDX-102-01|Alanosine in Treating Patients With Cancer|A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer||National Cancer Institute (NCI)||Completed|March 2003|December 2009|Actual|December 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||December 2009|June 25, 2013|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00062283||202069|
NCT00057811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANHL01P1|Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma|A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy||Children's Oncology Group|Yes|Completed|June 2004|July 2014|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|1 Year|29 Years|No|||September 2014|September 10, 2014|April 7, 2003|No|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT00057811||202365|
NCT00061451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7213|Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial|ALIMTA Plus Gemcitabine as Front-line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase II Clinical Trial||Eli Lilly and Company||Completed|December 2002|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||December 2010|December 20, 2010|May 28, 2003||||||https://clinicaltrials.gov/show/NCT00061451||202125|
NCT00062075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00034|Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML||National Cancer Institute (NCI)||Completed|May 2003|||March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||April 2013|December 3, 2015|June 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062075||202081|
NCT00062296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-02025|Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase II Study of Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL||Fox Chase Cancer Center|No|Completed|March 2003|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062296||202068|
NCT00061789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030003|Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia|SPECT Imaging of Alpha 4 Beta 2 Nicotinic Acetylcholine Receptors Using [(123)I]5-I-A-85380 in Schizophrenia||National Institutes of Health Clinical Center (CC)||Completed|February 2003|August 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||100|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2004|March 3, 2008|June 4, 2003||||No||https://clinicaltrials.gov/show/NCT00061789||202102|
NCT00061867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELSION-10302101|Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer|A Dose Escalation, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer||National Cancer Institute (NCI)||Completed|March 2003|August 2005|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|40 Years|N/A|No|||July 2005|May 29, 2013|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00061867||202096|
NCT00062374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01438|Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction|An Evaluation of Preoperative Chemotherapy With Irinotecan and Cisplatin for Advanced, But Resectable Gastric Cancer: A Coordinated Multidisciplinary, Multicenter Study Linking Functional Imaging, Genomic Expression Profiles and Histopathology||National Cancer Institute (NCI)||Completed|June 2003|||June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062374||202063|
NCT00063661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030236|Studying Automatic Movements in Patients With Parkinson's Disease|A Neuroimaging Study of Automatic Movements in Patients With Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2003|May 2005||||N/A|Observational|N/A||||30|||Both|N/A|N/A|No|||May 2005|March 3, 2008|July 2, 2003||||No||https://clinicaltrials.gov/show/NCT00063661||201971|
NCT00062127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02537|Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors|A Phase I Pharmacokinetic Interaction Study of Irinotecan (NSC616348) and Thalidomide (NSC66847) in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|April 2003|||May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|June 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062127||202078|
NCT00062348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-11001|Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases|B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 2003|||December 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|27|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00062348||202064|
NCT00061464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7211|Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.|ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial||Eli Lilly and Company||Completed|February 2003|February 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|May 28, 2003||||||https://clinicaltrials.gov/show/NCT00061464||202124|
NCT00061477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7214|Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma|ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial||Eli Lilly and Company||Completed|December 2002|September 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|May 28, 2003||||||https://clinicaltrials.gov/show/NCT00061477||202123|
NCT00063674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2DPPG (completed)|Type 2 Diabetes Primary Prevention for At Risk Girls|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|240|||Female|7 Years|10 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 2, 2003||||No||https://clinicaltrials.gov/show/NCT00063674||201970|
NCT00062400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10002|Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer|A Survey of the Breast International Group (B.I.G.) to Assess the Attitude of Patients Aged Less Than 35 Years, With Early Breast Cancer, Toward the Risk of Loss of Fertility Related to Adjuvant Therapies||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2003|||June 2008|Actual|N/A|Interventional|N/A|||Anticipated|385|||Female|N/A|35 Years|No|||October 2013|October 23, 2013|June 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00062400||202061|
NCT00061607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030203|Measuring Levels of SMN in Blood Samples of SMA Patients|SMN Levels in Peripheral Blood Samples of SMA Patients and the Effects of Pharmacological Compounds In Vitro||National Institutes of Health Clinical Center (CC)||Completed|May 2003|||||N/A|Observational|N/A|||Actual|73|||Both|2 Years|N/A|No|||March 2015|November 3, 2015|May 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00061607||202115|
NCT00061919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000302440|Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer|A Phase III Randomized, Double Blind, Placebo Controlled Trial Of Carboplatin/Etoposide With Or Without Thalidomide In Small Cell Lung Cancer (Study 12)||University College, London|Yes|Completed|April 2003|July 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|724|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|June 5, 2003||No||No||https://clinicaltrials.gov/show/NCT00061919||202092|
NCT00062556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-02-010403|Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication|Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication||Kos Pharmaceuticals||Completed|January 2003|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||366|||Both|40 Years|N/A|No|||October 2006|October 31, 2006|June 9, 2003||||||https://clinicaltrials.gov/show/NCT00062556||202050|
NCT00061802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002890|Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder|A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2003|February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|225|||Both|18 Years|65 Years|No|||February 2012|February 6, 2012|June 4, 2003||||||https://clinicaltrials.gov/show/NCT00061802||202101|
NCT00061997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000302633|Inositol in Preventing Lung Cancer in Patients With Bronchial Epithelial Dysplasia Who Are Current or Former Smokers|A Phase I Study Of The Safety Of Myo-Inositol As A Chemopreventive Agent||National Cancer Institute (NCI)||Completed|May 2003|||||Phase 1|Interventional|Primary Purpose: Prevention|||||||Both|40 Years|74 Years|No|||November 2005|February 1, 2010|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00061997||202087|
NCT00062205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304551|Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor|Phase II Trial of Gleevec (STI571) in Therapy of Ewing's Family of Tumors and Desmoplastic Small Round Cell Tumors||City of Hope Medical Center||Completed|June 2002|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|16 Years|N/A|No|||February 2010|February 5, 2010|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062205||202074|
NCT00062790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI40014|Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels|Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels||GlaxoSmithKline||Completed|October 2003|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Male|50 Years|N/A|No|||October 2010|October 1, 2010|June 16, 2003||||||https://clinicaltrials.gov/show/NCT00062790||202033|
NCT00062335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22994|High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|A Phase I Study On The Feasibility Of High Dose Three Dimensional Conformal Radiotherapy In Patients With Inoperable And Locally Advanced Non Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|April 2003|||February 2006|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|14|||Both|N/A|N/A|No|||September 2012|September 20, 2012|June 5, 2003|||low accrual|No||https://clinicaltrials.gov/show/NCT00062335||202065|
NCT00057928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000285630|S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer|Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix||Southwest Oncology Group|Yes|Withdrawn|April 2003|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|0|||Female|N/A|N/A|No|||June 2012|June 11, 2012|April 7, 2003|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00057928||202358|
NCT00057941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03148|Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer|A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|September 2003|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Female|18 Years|N/A|No|||January 2013|April 22, 2014|April 7, 2003|Yes|Yes||No|April 11, 2011|https://clinicaltrials.gov/show/NCT00057941||202357|
NCT00061620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-168|Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies|Phase I Study of Continuous Infusion Schedule of (E)-2'-Deoxy-2'-(Fluoromethylene) Cytidine (Tezacitabine, FMdC) in Hematologic Malignancies||M.D. Anderson Cancer Center|No|Completed|September 2001|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|15 Years|N/A|No|||July 2012|July 27, 2012|May 30, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00061620||202114|
NCT00063115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030230|Using fMRI to Understand the Roles of Brain Areas for Fine Hand Movements|Event-Related fMRI Analysis of Patients With Ideomotor Apraxia During Transitive and Intransitive Hand Gesturing||National Institutes of Health Clinical Center (CC)||Completed|June 2003|July 2008||||N/A|Observational|N/A||||35|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2008|September 26, 2015|June 19, 2003||||No||https://clinicaltrials.gov/show/NCT00063115||202009|
NCT00061295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HD037460-01|Treadmill Training With Body Weight Support in Patients With Spinal Cord Injury|Body Weight Supported Ambulation Training After Spinal Cord Injury||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|March 1999|February 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|16 Years|70 Years|No|||March 2003|June 23, 2005|May 23, 2003||||No||https://clinicaltrials.gov/show/NCT00061295||202137|
NCT00061880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOCRYST-1777BC-103|BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma|Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL)||National Cancer Institute (NCI)||Completed|February 2003|January 2008|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|May 29, 2013|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00061880||202095|
NCT00061893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS02P1|Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors|A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors||Children's Oncology Group|Yes|Completed|April 2004|December 2013|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|N/A|50 Years|No|||September 2014|September 16, 2014|June 5, 2003|Yes|Yes||No|January 17, 2013|https://clinicaltrials.gov/show/NCT00061893||202094|
NCT00063232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030233|Treating Nonalcoholic Steatohepatitis (NASH) With Metformin|Treatment of Nonalcoholic Steatohepatitis With Metformin||National Institutes of Health Clinical Center (CC)||Completed|June 2003|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|June 23, 2003||||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00063232||202001|
NCT00062673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6091|Study of Duloxetine in Elderly Patients With Major Depressive Disorder|Duloxetine Versus Placebo in the Treatment of Elderly Patients With Major Depressive Disorder||Eli Lilly and Company|No|Completed|March 2003|July 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||311|||Both|65 Years|N/A|No|||May 2007|May 17, 2007|June 10, 2003||||No||https://clinicaltrials.gov/show/NCT00062673||202041|
NCT00061984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62012|Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma|Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 2003|July 2012|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|455|||Both|18 Years|60 Years|No|||October 2014|October 24, 2014|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00061984||202088|
NCT00057837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000276590|Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC): Topotecan Sequenced With Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced With Etoposide||Eastern Cooperative Oncology Group|No|Completed|March 2004|August 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|April 7, 2003|Yes|Yes||No|January 11, 2013|https://clinicaltrials.gov/show/NCT00057837||202364|
NCT00061360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030193|Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia|A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Completed|May 2003|September 2015|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|2 Years|N/A|No|||September 2015|September 18, 2015|May 23, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00061360||202132|
NCT00062686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF20008|GW572016 For Treatment Of Refractory Metastatic Breast Cancer|An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens||GlaxoSmithKline|No|Completed|November 2003|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Female|18 Years|N/A|No|||April 2015|April 14, 2015|June 11, 2003||||||https://clinicaltrials.gov/show/NCT00062686||202040|
NCT00062699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-516|Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis|A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects With Stage V Chronic Kidney Disease on Hemodialysis||Abbott||Terminated|April 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2200|||Both|20 Years|N/A|No|||July 2006|July 31, 2006|June 11, 2003||||||https://clinicaltrials.gov/show/NCT00062699||202039|
NCT00062881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3241|Intrathecal Mafosfamide|Phase I Study of Intrathecal Mafosfamide||Baylor College of Medicine||Completed|June 1990|September 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|3 Years|N/A|No|||April 2005|August 21, 2006|June 17, 2003||||||https://clinicaltrials.gov/show/NCT00062881||202026|
NCT00057915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4180|Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer|A Phase I Study of Active Immunotherapy With CAP-1 (6D) and CMVpp65 Peptide-Pulsed, Autologous Dendritic Cells Produced in the Aastromreplicell Cell Production System in Patients With Stage IV CEA Expressing Malignancies||Duke University|No|Completed|September 2003|September 2006|Actual|August 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|April 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00057915||202359|
NCT00061347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030190|Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment|Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|May 2003|April 2011|Actual|May 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Male|18 Years|90 Years|No|||June 2015|June 26, 2015|May 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00061347||202133|
NCT00060814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00450-2|Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients|Pilot Study Examining the Effects of Combined Pharmacotherapy (Zyban/NRT)/Behavioral Treatment on Smoking Cessation Among MMT Patients.||National Institute on Drug Abuse (NIDA)|No|Completed|June 2002|December 2002|Actual|September 2002|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|No|||December 2008|December 22, 2008|May 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00060814||202172|
NCT00060632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-001|Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies||Merck Sharp & Dohme Corp.||Completed|April 2003|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|46|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|May 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060632||202186|
NCT00060645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-013|Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily x 5 Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies||Merck Sharp & Dohme Corp.||Completed|May 2003|February 2009|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|May 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060645||202185|
NCT00061763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0108|Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias|Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine||Novartis||Completed|May 2003|||November 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|175|||Both|2 Years|N/A|No|||March 2011|March 2, 2011|June 3, 2003||Yes||||https://clinicaltrials.gov/show/NCT00061763||202104|
NCT00062114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50201|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma||Alliance for Clinical Trials in Oncology|No|Completed|April 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|June 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062114||202079|
NCT00060775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030186|The Psychobiology of Childhood Temperament|The Psychobiology of Temperament: An fMRI Study||National Institutes of Health Clinical Center (CC)||Recruiting|May 2003|||||N/A|Observational|N/A|||Anticipated|980|||Both|7 Years|25 Years|Accepts Healthy Volunteers|||September 2015|October 8, 2015|May 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00060775||202175|
NCT00061022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-NXY-0007|Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke|SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke||AstraZeneca||Completed|May 2003|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||3200|||Both|18 Years|N/A|No|||November 2010|November 10, 2010|May 20, 2003||||||https://clinicaltrials.gov/show/NCT00061022||202157|
NCT00061035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLI-CA-TRT-001|Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma|A Phase 1, Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma||Cosmo Bioscience||Completed|April 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Male|18 Years|N/A|No|||August 2008|August 26, 2008|May 20, 2003||||||https://clinicaltrials.gov/show/NCT00061035||202156|
NCT00060827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44HD040743-02|Measuring Head Impacts in Sports|Head Impact Recording Technology for Field Applications||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Withdrawn||||||Phase 2|Observational|N/A|||Actual|0|||Male|18 Years|24 Years|Accepts Healthy Volunteers|||March 2004|October 28, 2014|May 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00060827||202171|
NCT00060918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105517/346|Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension|A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients With Type II Diabetes Mellitus.||GlaxoSmithKline|No|Completed|June 2001|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1210|||Both|30 Years|80 Years|No|||June 2012|April 14, 2015|May 15, 2003||||||https://clinicaltrials.gov/show/NCT00060918||202165|
NCT00060931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105517/347|Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension|A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients With Type II Diabetes Mellitus.||GlaxoSmithKline|No|Completed|June 2001|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|501|||Both|30 Years|80 Years|No|||April 2015|April 13, 2015|May 15, 2003||||||https://clinicaltrials.gov/show/NCT00060931||202164|
NCT00061009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030199|Hypnosis in Autonomic Function|Relationship of Autonomic Function to Hypnotic Susceptibility||National Institutes of Health Clinical Center (CC)||Completed|May 2003|January 2006||||N/A|Observational|N/A||||93|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|May 19, 2003||||No||https://clinicaltrials.gov/show/NCT00061009||202158|
NCT00060359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9914|Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer|A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of CT-2103 and Carboplatin (NSC #214240) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma||Gynecologic Oncology Group||Completed|April 2003|||January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|18 Years|N/A|No|||May 2015|May 7, 2015|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060359||202207|
NCT00061932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03015|Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach|A Phase II Study of PS-341 Alone or in Combination With Irinotecan in Patients With Adenocarcinoma of the Gastroesophageal Junction (GEJ) or Stomach||National Cancer Institute (NCI)|Yes|Completed|April 2003|November 2013|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||June 2013|May 15, 2015|June 5, 2003|Yes|Yes||No|May 15, 2015|https://clinicaltrials.gov/show/NCT00061932||202091|
NCT00061412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P50HD33812-6|Comprehensive Program to Improve Reading and Writing Skills in At-Risk and Dyslexic Children|Learning Disabilities: Links to Schools and Biology||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|December 1995|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||2500|||Both|6 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 27, 2006|May 27, 2003||||No||https://clinicaltrials.gov/show/NCT00061412||202128|
NCT00061516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-00-17|Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension|Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension||Alcon Research||Completed|January 2003|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|5 Years|No|||August 2008|August 4, 2008|May 28, 2003||||||https://clinicaltrials.gov/show/NCT00061516||202120|
NCT00060515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG2133-01|RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease|An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases||Repligen Corporation||Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment||||12|||Both|3 Years|N/A|No|||August 2005|August 4, 2005|May 7, 2003||||||https://clinicaltrials.gov/show/NCT00060515||202195|
NCT00060528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030176|Sequential Vaccinations in Prostate Cancer Patients|A Phase I/II Pilot Study of Sequential Vaccinations With rFowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM) Alone, or in Combination With rVaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), and the Role of GM-CSF, in Men With Prostate Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|May 2003|July 2011|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|N/A|No|||June 2012|June 5, 2012|May 7, 2003|Yes|Yes||No|November 30, 2011|https://clinicaltrials.gov/show/NCT00060528||202194|
NCT00060151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000299531|GW786034 in Treating Patients With Advanced Solid Tumors|A Phase I, Open Label, Multiple Dose, Dose Escalation Study OF GW786034 In Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|December 2002|June 2009|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||April 2006|September 19, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00060151||202217|
NCT00060957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD035750-01|Botulinum Toxin (BOTOX) for Cerebral Palsy|Botulinum Toxin for Spasticity in Cerebral Palsy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|July 1997|June 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|3 Years|12 Years|No|||May 2011|May 20, 2011|May 16, 2003|||Study terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00060957||202162|
NCT00062426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304771|Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer|A Randomized, Prospective Study Comparing Three Regimens Of Eloxatin ™ Plus Fluoropyrimidine For Evaluation Of Safety And Tolerability In First Line Treatment Of Patients With Advanced Colorectal Cancer (Tree Study)||National Cancer Institute (NCI)||Completed|May 2003|February 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|November 5, 2013|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00062426||202060|
NCT00060736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030175|The Effects of Estrogen Withdrawal on Mood Symptoms in Women|The Effects of Acute Withdrawal of Estradiol on Mood Symptoms in Women With Perimenopausal Depression||National Institutes of Health Clinical Center (CC)||Completed|May 2003|||||N/A|Observational|N/A|||Actual|60|||Female|45 Years|65 Years|No|||May 2015|June 4, 2015|May 9, 2003||No||No||https://clinicaltrials.gov/show/NCT00060736||202178|
NCT00061425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hLL2-06-EU|Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG||Immunomedics, Inc.|No|Completed|August 2000|||November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2009|January 8, 2009|May 27, 2003||||No||https://clinicaltrials.gov/show/NCT00061425||202127|
NCT00061256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5163|The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Once-Weekly Alendronate in HIV-Infected Subjects With Decreased Bone Mineral Density Receiving Calcium and Vitamin D||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|25 Years|N/A|No|||August 2009|August 6, 2009|May 22, 2003||||No||https://clinicaltrials.gov/show/NCT00061256||202140|
NCT00061399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD040896|Prospective Memory in Children With Traumatic Brain Injury|Prospective Memory in Normal and Head-Injured Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 2002|December 2006|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Prospective||||178|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||April 2007|October 28, 2014|May 27, 2003||||No||https://clinicaltrials.gov/show/NCT00061399||202129|
NCT00060788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD42259-1|Antisocial Behavior: Passing From Parent to Child to Grandchild|Intergenerational Transmission of Antisocial Behavior||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|September 2001|December 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||663|||Both|36 Months|48 Months|Accepts Healthy Volunteers|||March 2006|March 6, 2006|May 13, 2003||||No||https://clinicaltrials.gov/show/NCT00060788||202174|
NCT00060801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI 543.45|Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult (75 mg, 150 mg) and Pediatric (75 mg) Cystic Fibrosis Patients||Boehringer Ingelheim||Terminated|May 2003|||July 2004|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||420|||Both|6 Years|N/A|No|||October 2013|October 30, 2013|May 13, 2003||||||https://clinicaltrials.gov/show/NCT00060801||202173|
NCT00060450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACIN1|Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation|Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation||INO Therapeutics|No|Terminated|August 2001|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|84|||Both|18 Years|N/A|No|||June 2010|June 14, 2010|May 6, 2003|Yes|Yes|Slow Enrollment|No||https://clinicaltrials.gov/show/NCT00060450||202200|
NCT00061568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030170|Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias|Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-Thalassemia||National Institutes of Health Clinical Center (CC)||Recruiting|May 2003|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|124|||Both|2 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|May 29, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00061568||202117|
NCT00061594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF2587g|A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration|A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration||Genentech, Inc.||Completed|May 2003|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||426|||Both|50 Years|N/A|No|||March 2014|March 18, 2014|May 29, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00061594||202116|
NCT00060840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT 41|The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation|The Effects of Nitric Oxide for Inhalation During Left Ventricular Assist Device (LVAD) Implantation||INO Therapeutics|Yes|Completed|July 2003|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||September 2010|September 17, 2010|May 14, 2003|Yes|Yes||No|August 25, 2010|https://clinicaltrials.gov/show/NCT00060840||202170|
NCT00060996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REM 03:202|Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures|A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures||United Therapeutics||Terminated|February 2003|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|85 Years|No|||March 2013|March 5, 2013|May 19, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060996||202159|
NCT00061230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01HD33988-00606A1|Relaxation Training to Decrease Pain and Improve Function in Adolescents With Cerebral Palsy|Efficacy of Relaxation Training||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|March 2003|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|10 Years|20 Years|No|||April 2003|June 23, 2005|May 22, 2003||||No||https://clinicaltrials.gov/show/NCT00061230||202142|
NCT00060346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000301634|Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia|Phase II Pilot Study Of Rituximab Plus CHOP In Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia||Eastern Cooperative Oncology Group|No|Terminated|June 2004|August 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|May 6, 2003|Yes|Yes|slow accrual|No|January 10, 2013|https://clinicaltrials.gov/show/NCT00060346||202208|
NCT00062244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01437|Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia|Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia||National Cancer Institute (NCI)||Completed|May 2003|||June 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|June 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062244||202072|
NCT00060138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU-080235|Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases|A Phase I-II, 24-Week, Multi-Center, Double-Blind, Randomized, Dose-Ranging Study To Evaluate The Safety And Efficacy Of A Humanized Monoclonal Antibody To PTHrP Versus Zoledronic Acid In Patients With Breast Cancer Metastatic To Bone||Chugai Pharmaceutical||Completed|November 2002|||September 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Female|18 Years|N/A|No|||May 2013|May 13, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00060138||202218|
NCT00061542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-01|Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-Forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension.|Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-Forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension.||Alcon Research||Completed|January 2003|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|N/A|5 Years|No|||August 2008|August 4, 2008|May 28, 2003||||||https://clinicaltrials.gov/show/NCT00061542||202118|
NCT00060307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03059|Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer|A Phase II Study of OSI-774 (NSC-718781) in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer||National Cancer Institute (NCI)||Completed|May 2003|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060307||202211|
NCT00060593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030183|MRI Study of Self-Perception of Postural Stability|Self-Perception of Postural Stability: Event-Related fMRI Study||National Institutes of Health Clinical Center (CC)||Completed|May 2003|May 2005||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2005|March 3, 2008|May 7, 2003||||No||https://clinicaltrials.gov/show/NCT00060593||202189|
NCT00061529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-49|A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|January 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|2 Months|N/A|No|||August 2008|August 4, 2008|May 28, 2003||||||https://clinicaltrials.gov/show/NCT00061529||202119|
NCT00061659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-534|Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma|A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma||Abbott|No|Completed|May 2003|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|June 2, 2003||||No||https://clinicaltrials.gov/show/NCT00061659||202111|
NCT00061672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-457|Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma|A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma||Abbott|No|Completed|April 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||August 2007|August 13, 2007|June 2, 2003||||No||https://clinicaltrials.gov/show/NCT00061672||202110|
NCT00060944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004336|A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer|A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2003|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|May 16, 2003|Yes|Yes||No|January 14, 2014|https://clinicaltrials.gov/show/NCT00060944||202163|
NCT00060606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HD041665|Management of Myelomeningocele Study (MOMS)|Myelomeningocele Repair Randomized Trial|MOMS|The George Washington University Biostatistics Center|Yes|Completed|February 2003|November 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|May 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00060606||202188|
NCT00062010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304430|Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer|Interferon Alpha (NSC# 377523) Plus 13-Cis-Retinoic Acid Modulation Of BCL-2 Plus Paclitaxel For Recurrent Small Cell Lung Cancer||Eastern Cooperative Oncology Group|No|Completed|February 2004|August 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2012|October 6, 2015|June 5, 2003|Yes|Yes||No|December 1, 2012|https://clinicaltrials.gov/show/NCT00062010||202086|
NCT00062023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-454|Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer|Phase II Study Of Colorectal ACF Screening, Regression And Prevention In High Risk Participants||M.D. Anderson Cancer Center|Yes|Terminated|June 2003|May 2006|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|12|||Both|40 Years|80 Years|No|||July 2012|July 27, 2012|June 5, 2003|Yes|Yes|Study closed by the NCI.|No||https://clinicaltrials.gov/show/NCT00062023||202085|
NCT00060749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030179|Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy|Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy||National Institutes of Health Clinical Center (CC)||Completed|May 2003|December 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||22|||Both|N/A|N/A|No|||December 2007|September 26, 2015|May 9, 2003||||No||https://clinicaltrials.gov/show/NCT00060749||202177|
NCT00060437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000301951|Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer|A Phase II Trial Of Oral Perifosine In Patients With Metastatic Androgen Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|October 2003|April 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||April 2004|June 18, 2013|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00060437||202201|
NCT00060320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N01CC|Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer|A Phase III Double-Blind, Randomized, Placebo-Controlled Crossover Trial Of Black Cohosh In The Management Of Hot Flashes||Alliance for Clinical Trials in Oncology|Yes|Completed|October 2003|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|132|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060320||202210|
NCT00061113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13176-1|Substance Dependent Teens - Impact of Treating Depression Study 1 - 1|Substance Dependent Teens - Impact of Treating Depression Study 1||National Institute on Drug Abuse (NIDA)|No|Completed|February 2001|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|13 Years|19 Years|No|||September 2008|September 11, 2008|May 21, 2003||No||No||https://clinicaltrials.gov/show/NCT00061113||202150|
NCT00061490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR002160|The Effect of Weight Loss and Exercise on Knee Osteoarthritis|The Impact of Weight Loss and Exercise on Knee Osteoarthritis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Completed|September 2002|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 29, 2008|May 28, 2003||No||No||https://clinicaltrials.gov/show/NCT00061490||202122|
NCT00061503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-55|Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension|A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension||Alcon Research||Completed|April 2003|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|May 28, 2003||||||https://clinicaltrials.gov/show/NCT00061503||202121|
NCT00060333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0275|Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma|Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|July 2003|||June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060333||202209|
NCT00060411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03157|A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer|A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer||National Cancer Institute (NCI)||Completed|June 2003|||July 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060411||202203|
NCT00060892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-CLI-0202|Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia|A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia||AnGes|Yes|Completed|April 2003|January 2007|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|104|||Both|40 Years|N/A|No|||January 2008|January 9, 2008|May 15, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060892||202167|
NCT00061048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030194|Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma|Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia||National Institutes of Health Clinical Center (CC)|No|Completed|May 2003|July 2012|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|May 20, 2003||No||No|May 17, 2011|https://clinicaltrials.gov/show/NCT00061048||202155|
NCT00061698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063998|Treatment for Depressed Preadolescent Girls|CBT vs CBT Plus Parent Training for Girls With Depression||University of Texas at Austin|No|Completed|April 2002|December 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Female|9 Years|13 Years|No|||June 2015|June 11, 2015|June 3, 2003||No||No||https://clinicaltrials.gov/show/NCT00061698||202109|
NCT00061711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0003|Alternative Therapies for Menopause: A Randomized Trial|||National Institute on Aging (NIA)||Completed|July 2000|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||355|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 9, 2009|June 3, 2003||||No||https://clinicaltrials.gov/show/NCT00061711||202108|
NCT00060762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063863|Effectiveness of Binge Eating Disorder Treatments|Effectiveness of Psychological Treatments for BED||Stanford University|Yes|Completed|April 2002|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|205|||Both|18 Years|65 Years|No|||May 2014|May 14, 2014|May 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00060762||202176|
NCT00061100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3884|HIV Counseling Intervention for Methadone-Maintained Patients - 2|HIV Counseling Intervention for Methadone-Maintained Patients||New York State Psychiatric Institute|No|Completed|October 1999|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|60 Years|No|||March 2015|March 30, 2015|May 21, 2003||No||No||https://clinicaltrials.gov/show/NCT00061100||202151|
NCT00060619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD38647-3|Migraine and Recurrent Abdominal Pain in Children|Treatment of Recurrent Pain Syndromes in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|May 1999|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|180|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||March 2003|June 23, 2005|May 8, 2003||||No||https://clinicaltrials.gov/show/NCT00060619||202187|
NCT00062387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02538|Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study Of Perifosine In Patients With Recurrent Or Metastatic Head And Neck Cancer||National Cancer Institute (NCI)||Terminated|May 2003|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||October 2004|May 31, 2013|June 5, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00062387||202062|
NCT00062257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRG-G15/02|Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer|A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer||National Cancer Institute (NCI)||Completed|June 2003|September 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2005|May 14, 2013|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00062257||202071|
NCT00061126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-0310|ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body|A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis||Abgenix||Completed|April 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Male|18 Years|N/A|No|||September 2004|June 23, 2005|May 21, 2003||||||https://clinicaltrials.gov/show/NCT00061126||202149|
NCT00062270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304674|Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer|Neoadjuvant Chemoradiotherapy (Gemcitabine/Cisplatin and Taxotere) With or Without Co-Administration of ZD 1839 (Iressa) for Stage IIIA (N2) and Selective Stage IIIB Non-Small Cell Lung Cancer: Phase I-II Study||University of Alabama at Birmingham|Yes|Completed|May 2003|September 2004|Actual|September 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|19 Years|120 Years|No|||September 2015|October 6, 2015|June 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062270||202070|
NCT00061633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I6424-202a|Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|FAST|Theravance Biopharma Antibiotics, Inc.|Yes|Completed|June 2003|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||January 2010|January 27, 2010|May 30, 2003|Yes|Yes|||December 2, 2009|https://clinicaltrials.gov/show/NCT00061633||202113|
NCT00061204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030195|Magnetic Resonance Imaging of the Brain in Emotional Processing|Functional Neuroimaging of Social Cognitive and Emotional Processing: Technical and Cognitive Issues||National Institutes of Health Clinical Center (CC)||Completed|May 2003|April 2006||||N/A|Observational|N/A||||38|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2006|March 3, 2008|May 21, 2003||||No||https://clinicaltrials.gov/show/NCT00061204||202144|
NCT00061217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD038919-02|Prosthetic Limbs After Leg Amputation: Alternative Method of Socket Design|Comparison of Rectified and Unrectified Amputee Sockets||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|April 2001|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||59|||Both|18 Years|65 Years|No|||October 2004|June 23, 2005|May 22, 2003||||No||https://clinicaltrials.gov/show/NCT00061217||202143|
NCT00060853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030197|Magnetic Resonance Imaging of the Brain in Social and Emotional Reasoning|Reasoning About Social and Economic Knowledge: Identifying the Role of the Human Prefrontal Cortex Using Functional Neuroimaging||National Institutes of Health Clinical Center (CC)||Completed|May 2003|May 2005||||N/A|Observational|N/A||||330|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2005|March 3, 2008|May 14, 2003||||No||https://clinicaltrials.gov/show/NCT00060853||202169|
NCT00060866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030182|Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance|Propranolol for Syncope With Sympathoadrenal Imbalance||National Institutes of Health Clinical Center (CC)||Completed|May 2003|March 2005||||Phase 4|Interventional|Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||March 2005|March 3, 2008|May 14, 2003||||No||https://clinicaltrials.gov/show/NCT00060866||202168|
NCT00061061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08075-1|Tobacco Cessation in Postmenopausal Women (Part I) - 1|The Effects of ERT on Appetitive Behavior and Withdrawal in Short-term Smoking Cessation Compared to Smoking ad Lib in Postmenopausal Female Smokers.||University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 1997|March 2003|Actual|March 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Female|40 Years|79 Years|No|||December 2015|December 1, 2015|May 21, 2003||No||No||https://clinicaltrials.gov/show/NCT00061061||202154|
NCT00061646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-429|Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)||Abbott|No|Terminated|March 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2007|August 10, 2007|June 2, 2003|||Enrollment suspended based upon interim analysis; subjects allowed to stay on study until    disease progression.|No||https://clinicaltrials.gov/show/NCT00061646||202112|
NCT00061724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSTER (completed)|Medical and Surgical Treatment of Esophageal Reflux|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|175|||Both|18 Years|80 Years|No|||January 2010|January 12, 2010|June 3, 2003||||No||https://clinicaltrials.gov/show/NCT00061724||202107|
NCT00061737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLPIMB (completed)|Quality of Life in Pediatric Inflammatory Bowel Disease|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|350|||Both|8 Years|17 Years|No|||January 2010|January 12, 2010|June 3, 2003||||No||https://clinicaltrials.gov/show/NCT00061737||202106|
NCT00060424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1711.00|Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|March 2003|||September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|N/A|No|||July 2015|July 21, 2015|May 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00060424||202202|
NCT00060203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAR1A02|Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma|A Phase I/II Study of the Safety and Efficacy of Brostallicin (PNU-166196A) in Adult Patients With Multiple Myeloma That Has Progressed on Prior Chemotherapy||Case Comprehensive Cancer Center|Yes|Completed|December 2002|April 2004|Actual|March 2003|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|May 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00060203||202216|
NCT00061750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0107|Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions|A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis||Novartis||Completed|May 2003|||November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|595|||Both|2 Years|N/A|No|||April 2012|April 18, 2012|June 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00061750||202105|
NCT00061334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030196|Investigating the Cognitive Processes That Underlie Social Knowledge and Behavior|Social Knowledge Representation in the Human Prefrontal Cortex||National Institutes of Health Clinical Center (CC)||Completed|May 2003|December 2011||||N/A|Observational|N/A|||Actual|222|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 30, 2011|May 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00061334||202134|
NCT00060502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004798|A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia|A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer.||Centocor, Inc.||Completed|April 2003|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|73|||Both|18 Years|N/A|No|||April 2010|May 16, 2011|May 7, 2003||||||https://clinicaltrials.gov/show/NCT00060502||202196|
NCT00060541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030164|Evaluation and Treatment of Neurosurgical Disorders|Evaluation and Treatment of Neurosurgical Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|May 2003|||||N/A|Observational|N/A|||Anticipated|1600|||Both|4 Years|N/A|No|||October 2015|November 17, 2015|May 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00060541||202193|
NCT00062439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304777|S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors|A Phase II Trial of Induction Chemoradiotherapy With Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)||Southwest Oncology Group|Yes|Completed|July 2003|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|N/A|N/A|No|||October 2013|October 30, 2013|June 5, 2003|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00062439||202059|
NCT00064623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C107|Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy|A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy||NeurogesX||Completed|August 2003|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2008|March 4, 2008|July 10, 2003||||||https://clinicaltrials.gov/show/NCT00064623||201902|
NCT00064636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34101-034|Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|A Phase I, Open Label, Dose Escalation Study of PS-341 Plus Docetaxel in Treatment-Naive or Previously Treated Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors||Millennium Pharmaceuticals, Inc.||Terminated|December 2002|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Both|18 Years|N/A|No|||September 2003|June 23, 2005|July 10, 2003||||||https://clinicaltrials.gov/show/NCT00064636||201901|
NCT00064831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001102-01|Black Cohosh Extract in Postmenopausal Breast Health|The Effect of Black Cohosh Extract on the Human Breast||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|July 2003|February 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||73|||Female|N/A|N/A|No|||December 2007|December 6, 2007|July 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00064831||201886|
NCT00064285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000310175|Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer|Phase I Study Of Flavopiridol In Combination With Imatinib Mesylate (STI571, Gleevec) In Bcr/Abl+ Hematological Malignancies||Virginia Commonwealth University|No|Completed|June 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||April 2010|April 30, 2010|July 8, 2003||Yes||||https://clinicaltrials.gov/show/NCT00064285||201928|
NCT00065767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0049|Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease|Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease||University of Wisconsin, Madison||Completed|September 2001|March 2005|Actual|March 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|55 Years|90 Years|No|||September 2010|October 1, 2015|July 31, 2003||||No||https://clinicaltrials.gov/show/NCT00065767||201820|
NCT00065780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1231|Ventricular Size and Value Calcification Measures by Computed Tomography - Ancillary to MESA|||Los Angeles Biomedical Research Institute||Completed|August 2003|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6814|||Both|45 Years|84 Years|Accepts Healthy Volunteers|Probability Sample|MESA study population - 6814 participants from 6 clinic sites around the US|October 2013|October 25, 2013|July 31, 2003||No||No||https://clinicaltrials.gov/show/NCT00065780||201819|
NCT00063895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03097|Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck|A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|April 2003|||October 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00063895||201954|
NCT00063934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02885|Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer|A Phase 1/2 Study of Bcl-2 Antisense Oligonucleotide G3139 in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer||National Cancer Institute (NCI)||Terminated|May 2003|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2012|May 6, 2014|July 8, 2003|Yes|Yes||No|July 10, 2012|https://clinicaltrials.gov/show/NCT00063934||201953|
NCT00064701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0-158|Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients|A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (Cyclosporine)/MMF in de Novo Kidney Transplant Recipients||Astellas Pharma Inc|Yes|Completed|June 2003|March 2009|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|668|||Both|12 Years|N/A|No|||November 2013|November 12, 2013|July 10, 2003|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT00064701||201896|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00065910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH064927|Improving Attention Skills of Children With Autism|A Joint Attention Intervention With Caregivers and Their Children With Autism||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 2001|January 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|12 Months|36 Months|No|||June 2003|June 28, 2007|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065910||201809|
NCT00065884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30HD002528|Valproate Response in Aggressive Autistic Adolescents|Valproate Response in Aggressive Autistic Adolescents||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|6 Years|21 Years|No|||June 2003|June 23, 2005|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065884||201811|
NCT00064506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224|Gene-Environment Interactions in Complex Disease|Gene-Environment Interactions in Complex Disease||The University of Texas Health Science Center, Houston|No|Completed|July 2003|May 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15792|||Both|45 Years|65 Years|No||Subjects aged 14-65 from four communities.|January 2015|January 13, 2015|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064506||201911|
NCT00064727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030217|Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes|Attenuating Insulin Resistance as a Therapeutic Target in the Management of Heart Failure||National Institutes of Health Clinical Center (CC)||Completed|July 2003|April 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||50|||Both|22 Years|N/A|Accepts Healthy Volunteers|||April 2007|September 26, 2015|July 10, 2003||||No||https://clinicaltrials.gov/show/NCT00064727||201894|
NCT00068666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0274|Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System|A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System||Alliance for Clinical Trials in Oncology|No|Completed|January 2004|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068666||201614|
NCT00066001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-12108|Microbial Associations in Periodontal Health and Disease|The Effect of Systemically Administered Metronidazole Alone and in Combination With Professional Supragingival Plaque Removal on Plaque Composition||The Forsyth Institute|No|Completed|December 2002|December 2009|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|154|||Both|35 Years|N/A|No|||November 2010|November 8, 2010|August 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00066001||201802|
NCT00060398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000301881|Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer|Study Of Epoetin Alfa Vs Epoetin Alfa With Dexamethasone In Hormone Refractory Prostate Cancer Patients: Impact On Fatigue, Anemia, Functional Status And Quality Of Life||National Cancer Institute (NCI)||Completed|June 2004|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|282|||Male|18 Years|N/A|No|||July 2006|May 9, 2009|May 6, 2003||||No||https://clinicaltrials.gov/show/NCT00060398||202204|
NCT00060476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-201|Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)||Merck Sharp & Dohme Corp.||Completed|January 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|15000|||Male|50 Years|75 Years|No|||September 2015|September 15, 2015|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060476||202198|
NCT00064064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000306462|3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Patients With Metastatic Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|January 2003|August 2008|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|November 5, 2013|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064064||201943|
NCT00064181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40015|Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer|Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2003|||January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|86|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064181||201936|
NCT00064896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030250|Technical Development of Cardiovascular Magnetic Resonance Imaging|Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Recruiting|July 2003|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|July 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00064896||201881|
NCT00065377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030251|Effects of Oral Glucosamine on Insulin and Blood Vessel Activity in Normal and Obese People|An Exploratory Study of the Effects of Oral Glucosamine Administration on Insulin Sensitivity and Capillary Recruitment in Normal and Obese Subjects||National Institutes of Health Clinical Center (CC)||Completed|July 2003|June 2006||||Phase 1|Interventional|Primary Purpose: Treatment||||60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2006|June 23, 2006|July 21, 2003||||No||https://clinicaltrials.gov/show/NCT00065377||201846|
NCT00065390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030248|Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome|Pilot (Phase I-II) Study of Pyrimethamine (Daraprim) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)||National Institutes of Health Clinical Center (CC)||Completed|July 2003|June 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||8|||Both|N/A|N/A|No|||June 2005|March 3, 2008|July 21, 2003||||No||https://clinicaltrials.gov/show/NCT00065390||201845|
NCT00065000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63899 (completed)|Impact of Non-Commercialism Policy in Seattle Schools|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||August 2003||||N/A|Interventional|N/A|||||||Both|14 Years|18 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 16, 2003||||No||https://clinicaltrials.gov/show/NCT00065000||201874|
NCT00064363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030207|Talampanel in Treating Patients With Recurrent High-Grade Glioma|A Phase II Trial Of Talampanel In Patients With Recurrent High-Grade Gliomas||National Institutes of Health Clinical Center (CC)||Completed|June 2003|February 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 7, 2012|July 8, 2003||||||https://clinicaltrials.gov/show/NCT00064363||201922|
NCT00064779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL13PEI-105|Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma|Pilot Imaging Study to Assess the Distribution of IL13-PE38QQR Cytotoxin Infusions in Patients With Recurrent, Resectable, Supratentorial Malignant Glioma||INSYS Therapeutics Inc||Completed|July 2003|July 2007|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|July 11, 2003||||||https://clinicaltrials.gov/show/NCT00064779||201890|
NCT00064012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000305974|Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-Label, Phase II Study Of VELCADE Alone Or VELCADE Plus Docetaxel In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer||University of Wisconsin, Madison||Completed|May 2003|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064012||201947|
NCT00068809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 015 v 3.0|4-Day-A-Week Treatment Plan for HIV Infected Adolescents|Short-Cycle Therapy in Adolescents Following Continuous Therapy With Established Viral Suppression: The Impact on Viral Load Suppression||Westat|Yes|Completed|July 2003|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|12 Years|24 Years|No|||February 2016|February 29, 2016|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068809||201606|
NCT00063986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000305866|Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer|Minimally Invasive Esophagectomy (MIE): A Multicenter Feasibility Study||Eastern Cooperative Oncology Group|No|Completed|March 2004|August 2012|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|July 8, 2003|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00063986||201949|
NCT00064246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02721|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder|A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation||National Cancer Institute (NCI)||Completed|July 2003|||September 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064246||201931|
NCT00066027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511-00-FB|Effects of Low-Dose Doxycycline on Oral Bone Loss|Low-Dose Doxycycline Effects on Osteopenic Bone Loss||University of Nebraska|Yes|Completed|June 2002|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Female|45 Years|70 Years|No|||December 2015|December 1, 2015|August 1, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00066027||201800|
NCT00064428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103413|MICHELANGELO OASIS-6 : Fondaparinux in ST Elevation Myocardial Infarction|Safety and Efficacy Trial Evaluating Fondaparinux Use in a Broad Range of Patients With ST Segment Elevation Acute MI||GlaxoSmithKline||Completed|August 2003|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|12092|||Both|21 Years|N/A|No|||August 2011|August 22, 2011|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064428||201917|
NCT00064441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-02-217|FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis|FACTS I: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects With Active Ulcerative Colitis||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|May 2003|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||375|||Both|18 Years|80 Years|No|||May 2012|May 9, 2012|July 8, 2003||||||https://clinicaltrials.gov/show/NCT00064441||201916|
NCT00064454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-02-218|FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis|FACTS II: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects With Active Ulcerative Colitis||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|May 2003|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||375|||Both|18 Years|80 Years|No|||May 2012|May 9, 2012|July 8, 2003||||||https://clinicaltrials.gov/show/NCT00064454||201915|
NCT00064571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DC004681|Surgery for Vocal Cord Paralysis|Medialization Vs Reinnervation for Vocal Cord Paralysis||National Institute on Deafness and Other Communication Disorders (NIDCD)||Terminated|October 2002|October 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||April 2006|April 21, 2006|July 9, 2003||||No||https://clinicaltrials.gov/show/NCT00064571||201906|
NCT00064584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-301|Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)|Tolerability and PK/PD of Multiple Oral Doses of CT53518 in Patients With Acute Myelogenous Leukemia||Millennium Pharmaceuticals, Inc.||Completed|May 2002|July 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 2009|March 23, 2009|July 9, 2003||||||https://clinicaltrials.gov/show/NCT00064584||201905|
NCT00064597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NIFTY|Noninvasive Prenatal Diagnosis: Using Fetal Cells From Maternal Blood|National Institute of Child Health and Human Development Fetal Cell Isolation Study (NIFTY)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|December 1987|December 2003||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||3500|||Female|16 Years|45 Years|No|||June 2003|June 23, 2005|July 10, 2003||||No||https://clinicaltrials.gov/show/NCT00064597||201904|
NCT00064402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-051|Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD|A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease||Sunovion|Yes|Completed|April 2002|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|741|||Both|35 Years|N/A|No|||February 2012|February 21, 2012|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064402||201919|
NCT00064415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-060|To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD|A Multicenter, Open-Label, Randomized, Active-Controlled, Parallel Group Chronic Safety Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease||Sunovion|Yes|Completed|June 2002|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|799|||Both|35 Years|N/A|No|||February 2012|February 21, 2012|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064415||201918|
NCT00064649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIST (terminated)|Minimally Invasive Surgical Therapy for BPH|Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia|MIST|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Terminated|April 2004|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Male|50 Years|N/A|No|||January 2010|January 12, 2010|July 10, 2003|Yes|Yes|Inability to recruit required sample size.|No||https://clinicaltrials.gov/show/NCT00064649||201900|
NCT00066131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104M94001|Obstetrics and Periodontal Therapy (OPT) Study|Effects of Periodontal Therapy on Preterm Birth|OPT|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2003|February 2006|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|823|||Female|16 Years|N/A|No|||July 2015|July 24, 2015|August 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00066131||201793|
NCT00064051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-031|3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Patients With Pancreatic Cancer||National Cancer Institute (NCI)||Completed|January 2003|August 2008|Actual|August 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 1, 2013|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064051||201944|
NCT00060489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077US/0049|Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression|||AstraZeneca||Completed|September 2002|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 2011|January 25, 2011|May 6, 2003||||||https://clinicaltrials.gov/show/NCT00060489||202197|
NCT00064922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13638-3|Incentive Programs for Female Substance Abusers Who Smoke - 3|Incentive Programs for Female Substance Abusers Who Smoke||National Institute on Drug Abuse (NIDA)||Active, not recruiting|January 2002|May 2005||||Phase 2/Phase 3|Interventional|Primary Purpose: Treatment||||90|||Female|15 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 23, 2008|July 15, 2003||||No||https://clinicaltrials.gov/show/NCT00064922||201879|
NCT00064753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAVORIT dk61700 IND|Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)|Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)|FAVORIT|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|May 2002|October 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4110|||Both|35 Years|75 Years|No|||October 2015|October 26, 2015|July 11, 2003|Yes|Yes||No|October 26, 2015|https://clinicaltrials.gov/show/NCT00064753||201892|The B-vitamin pathway for reducing tHcy may not be the optimal one for reducing CVD risk. Also, the duration of follow-up may not have been sufficient to identify a lagged impact on modification of CVD risk.
NCT00065013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STGASB (completed)|Strength Training Following Gastric Bypass for Obesity|Strength Training Following Gastric Bypass for Obesity||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|March 2003|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||January 2010|June 23, 2010|July 16, 2003||No||No||https://clinicaltrials.gov/show/NCT00065013||201873|
NCT00065026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPALLW (completed)|Increasing Physical Activity Levels in Low-Income Women|Environmental Approaches to Reducing Obesity: Increasing Physical Activity Levels in Low-Income Women||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2003|||||N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|150|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 16, 2003||||No||https://clinicaltrials.gov/show/NCT00065026||201872|
NCT00060580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030156|Raman Scattering Spectroscopy to Measure Macular Pigment|Measurement of Macular Pigment With Resonant Raman Backscattering Spectroscopy||National Institutes of Health Clinical Center (CC)||Completed|May 2003|March 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2006|March 3, 2008|May 7, 2003||||No||https://clinicaltrials.gov/show/NCT00060580||202190|
NCT00064194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP1|Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia|A Double-Blind, Placebo-Controlled, Randomized Study Of Combination Vitamin E, Selenium And Soy Protein Product In Subjects With High Grade Prostatic Intraepithelial Neoplasia||Canadian Cancer Trials Group||Completed|November 2001|April 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Male|N/A|N/A|No|||March 2010|November 11, 2013|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064194||201935|
NCT00064207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40013-22012|Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer|Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2003|||January 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|97|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064207||201934|
NCT00068874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR049459|Improving Quality of Life for African American Female Adolescents With Lupus|Predictors of Adaptation and a Cognitive Behavioral Intervention for African American Adolescents With Lupus||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Completed|April 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Female|12 Years|18 Years|No|||April 2009|April 8, 2009|September 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00068874||201601|
NCT00068887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFAMH (DK45343) (withdrawn)|Regional Fatty Acid Metabolism in Humans|Regional Fatty Acid Metabolism in Humans||Mayo Clinic||Withdrawn|September 1999|December 2005||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|September 10, 2003|||NOT A CLINICAL TRIAL|No||https://clinicaltrials.gov/show/NCT00068887||201600|
NCT00068900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFAMET - dk40484 (withdrawn)|FFA Metabolism in Different Types of Human Obesity|FFA Metabolism in Different Types of Human Obesity||Mayo Clinic||Withdrawn|November 2003|February 2004|Actual|January 2004|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|September 10, 2003|||NOT A CLINICAL TRIAL|No||https://clinicaltrials.gov/show/NCT00068900||201599|
NCT00064792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030225|Simvastatin Therapy in Smith-Lemli-Opitz Syndrome|Investigation of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome||National Institutes of Health Clinical Center (CC)|Yes|Completed|July 2003|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|4 Years|18 Years|No|||June 2014|June 4, 2014|July 11, 2003|Yes|Yes||No|July 30, 2012|https://clinicaltrials.gov/show/NCT00064792||201889|
NCT00064103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02541|Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx|Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]||National Cancer Institute (NCI)||Completed|June 2003|||August 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00064103||201940|
NCT00064259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03134|A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer|A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer||National Cancer Institute (NCI)|Yes|Terminated|June 2003|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|19 Years|N/A|No|||May 2013|June 10, 2015|July 8, 2003|No|Yes|Discontinued development of G3139 (oblimersen)|No|June 10, 2015|https://clinicaltrials.gov/show/NCT00064259||201930|
NCT00065741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001376-01A1|Botanical/Drug Interactions in HIV: Glucuronidation|Botanical/Drug Interactions in HIV: Glucuronidation||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2003|March 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2007|March 21, 2007|July 31, 2003||||No||https://clinicaltrials.gov/show/NCT00065741||201822|
NCT00065754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001424-01|Brain Imaging and Pain in Irritable Bowel Syndrome|Brain Imaging and Pain: Analysis of Placebo Analgesia||University of Florida|No|Completed|September 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind||||50|||Both|18 Years|70 Years|No|||August 2011|September 16, 2011|July 31, 2003||No||No||https://clinicaltrials.gov/show/NCT00065754||201821|
NCT00065858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-RFP-2000-16|Effectiveness of BufferGel as a Vaginal Contraceptive|A Randomized, Controlled Trial of the Efficacy, Safety, and Acceptability of BufferGel||Health Decisions||Completed|September 2001|April 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||975|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2006|February 19, 2016|August 1, 2003||Yes||||https://clinicaltrials.gov/show/NCT00065858||201813|
NCT00064467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK130931|Lethargic Depression Study|See Detailed Description||GlaxoSmithKline||Completed|June 2003|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||268|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064467||201914|
NCT00064714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030245 (2993T1-101)|Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes|Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes||AstraZeneca|No|Completed|July 2003|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|60 Years|No|||January 2015|February 23, 2015|July 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064714||201895|
NCT00064805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD036019|Therapy for Reading Problems in Adults After Brain Injury|Cognitively-based Treatments of Acquired Dyslexias||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 2002|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|N/A|No|||April 2014|August 13, 2014|July 14, 2003||||No||https://clinicaltrials.gov/show/NCT00064805||201888|
NCT00064818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000300-01|Acupuncture Needling on Connective Tissue by Ultrasound|Acupuncture Needling on Connective Tissue by Ultrasound||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|September 2003||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||46|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|July 14, 2003||||No||https://clinicaltrials.gov/show/NCT00064818||201887|
NCT00064662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UITN-RCT (completed)|Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence|Randomized Clinical Trial of the Burch Modified Tanagho and Autologous Fascia Sling Procedures for Women With Predominantly Stress Urinary Incontinence|SISTEr|New England Research Institutes|No|Completed|February 2002|March 2010|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|655|||Female|21 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 8, 2013|July 10, 2003||No||No|March 26, 2012|https://clinicaltrials.gov/show/NCT00064662||201899|Patients received care at tertiary care centers which could limit the generalizability of the findings. Patients and providers were aware of treatment assignment which could lead to assessment bias.
NCT00064675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1229|Genetics of Cardiovascular Reactivity in Black Youth|Genetics of Cardiovascular Reactivity in Black Youth||University of Tennessee||Completed|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|500|Samples With DNA|buccal specimens stored at Med Coll Wisconsin|Both|15 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|500 African American youth|April 2013|April 4, 2013|July 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00064675||201898|
NCT00065871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD42427|The Direct Access Study: Access to Hormonal Birth Control Through Community Pharmacies|Improving Contraceptive Practice and Delivery Through Community Pharmacists: The Direct Access Study||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|June 2003|February 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Prevention||||250|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2004|April 5, 2007|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065871||201812|
NCT00064142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02925|Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma||National Cancer Institute (NCI)||Completed|May 2003|||December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|30|||Both|16 Years|N/A|No|||June 2013|June 4, 2013|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00064142||201937|
NCT00064519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1225|Genetics of CRP in Families With Myocardial Infarction|||Medical College of Wisconsin|No|Completed|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1406|Samples With DNA|i.) Blood: A blood sample (30 cc, ~2 tablespoons) will be drawn. This will take place in the      catheterization lab at the end of the catheterization procedure or by using standard      venipuncture technique during a clinic visit or at community outreach events when feasible.      ii.) Buccal Swab: The participant uses specially prepared cotton swabs (called buccal swabs)      to rub in a circular motion on the inside of both cheeks. The swabs collect cheek cells that      can be processed to obtain DNA.      iii.) Saliva: A saliva sample is obtained by having the participant spit in a special vial      specifically designed for genetic testing. The participant will continue to spit into the      vial until it contains 2 ml (about 1 teaspoon) of saliva.|Both|18 Years|100 Years|No|Non-Probability Sample|Individuals having CAD and individuals not having CAD|September 2015|September 22, 2015|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064519||201910|
NCT00063856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-044|Dressing Preparations for Smallpox|A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2003|June 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|102|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2007|February 9, 2012|July 7, 2003||||No||https://clinicaltrials.gov/show/NCT00063856||201957|
NCT00064935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HD038997|Endometrial Biopsy in Infertile Patients|Utility of the Endometrial Biopsy in the Evaluation of the Luteal Phase||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|April 1999|February 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||880|||Female|25 Years|39 Years|Accepts Healthy Volunteers|||May 2003|June 23, 2005|July 15, 2003||||No||https://clinicaltrials.gov/show/NCT00064935||201878|
NCT00065195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001006-01A2|REST: Reducing End-of-Life Symptoms With Touch|Efficacy of Massage at the End of Life||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2003|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||440|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|July 18, 2003||No||No||https://clinicaltrials.gov/show/NCT00065195||201860|
NCT00060294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000301591|Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia|Phase I Study of Zevalin (90Y-Ibritumomab Tiuxetan) in Waldenstrom's Macroglobulinemia (Lymphoplasmacytic Lymphoma)||Jonsson Comprehensive Cancer Center|Yes|Terminated|April 2003|||June 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 7, 2013|May 6, 2003|No|Yes|no accrual|No||https://clinicaltrials.gov/show/NCT00060294||202212|
NCT00063869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A4-203|Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis|A Double-blind, Parallel, Placebo-controlled, Randomized Study of the Efficacy and Safety of Etanercept in Patients With Idiopathic Pulmonary Fibrosis.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|88|||Both|40 Years|80 Years|No|||September 2009|September 3, 2009|July 7, 2003||||||https://clinicaltrials.gov/show/NCT00063869||201956|
NCT00064220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000310138|Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma|A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy||Daiichi Sankyo Inc.||Completed|April 2003|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|N/A|No|||May 2012|May 15, 2012|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064220||201933|
NCT00063882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0232|Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer|A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|June 2003|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|588|||Male|18 Years|120 Years|No|||December 2015|December 11, 2015|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063882||201955|
NCT00068913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01HD032062|Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome|Investigation of Clinical Syndromes Associated With mtDNA Point Mutations: MELAS/DCA Clinical Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|March 2000|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||35|||Both|6 Years|N/A|No|||September 2004|June 23, 2005|September 10, 2003||||||https://clinicaltrials.gov/show/NCT00068913||201598|
NCT00064376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000315451|Paricalcitol in Treating Patients With Myelodysplastic Syndrome|A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes||National Cancer Institute (NCI)||Active, not recruiting|May 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|25 Years|N/A|No|||September 2004|July 23, 2008|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064376||201921|
NCT00064389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-356|Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma|Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma||Sunovion|No|Completed|January 2003|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|746|||Both|12 Years|N/A|No|||February 2012|February 21, 2012|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064389||201920|
NCT00064610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34101-033|Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer|A Phase I/II, Open Label, Dose Escalation Study to Determine the Tolerance and Preliminary Activity of PS-341 Plus Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer Requiring Chemotherapy||Millennium Pharmaceuticals, Inc.||Completed|December 2002|||December 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||102|||Male|18 Years|N/A|No|||February 2008|February 7, 2008|July 10, 2003||||||https://clinicaltrials.gov/show/NCT00064610||201903|
NCT00064272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000310163|UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer|Phase II Trial Of Encapsulized Ginger As A Treatment For Chemotherapy-Induced Nausea and Vomiting AKA IRB 2003-213|IRB 2003-551|University of Michigan Cancer Center||Completed|May 2003|||May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|3||Anticipated|180|||Both|18 Years|N/A|No|||March 2010|March 1, 2010|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064272||201929|
NCT00065923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD042818|Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome|Topiramate Effects on SIB in Prader-Willi Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 2002|||December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||August 2010|April 30, 2013|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065923||201808|
NCT00066040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13534|Prevention of Transmission of Bacteria That Cause Cavities From Mothers to Their Children|Prevention of Transmission of Mutans Streptococci From Mother to Child||New York University|Yes|Completed|January 2001|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|2 Months|35 Years|No|||July 2012|July 16, 2012|August 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00066040||201799|
NCT00064870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0042|Alzheimer's Disease Genetics Study|National Cell Repository for Alzheimer's Disease (NCRAD)|NCRAD|Indiana University|No|Recruiting|June 2002|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|blood samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Families with two or more members with Alzheimer's disease or dementia|February 2016|February 22, 2016|July 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00064870||201883|
NCT00064480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222|Black Pooling Project|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2003|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2008|April 22, 2008|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064480||201913|
NCT00064493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1223|Modeling DNA Diversity in Reverse Cholesterol Transport|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 2003|May 2008|Actual|May 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 1, 2008|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064493||201912|
NCT00064740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001276-01A1|Relaxation Response With Acupuncture for HIV Patients|Relaxation Response With Acupuncture for HIV Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2003|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||August 2006|August 16, 2006|July 11, 2003||||No||https://clinicaltrials.gov/show/NCT00064740||201893|
NCT00064883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030241|Radiation Therapy and the Natural History of Childhood Cancers|The Natural History of Childhood Malignancies Treated With Radiation Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|July 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|6 Months|21 Years|No|||September 2015|October 6, 2015|July 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00064883||201882|
NCT00064844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAACOO11197-05|Combination Nicotine Replacement for Alcoholic Smokers|Combination Nicotine Replacement for Alcoholic Smokers||Yale University|No|Completed|August 2002|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||March 2013|March 8, 2013|July 14, 2003||No||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00064844||201885|
NCT00064688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230|Genomic Dissection of a QTL Affecting the Lipid Profile|Genomic Dissection of a QTL Affecting the Lipid Profile||Medical College of Wisconsin|No|Withdrawn|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|DNA|Both|N/A|N/A|No|||September 2015|September 8, 2015|July 10, 2003||No|This protocol was created to support work as part of an NIH-funded study.|No||https://clinicaltrials.gov/show/NCT00064688||201897|
NCT00066118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10085-A|Health Effects of Silver-Mercury Dental Fillings|The Casa Pia Study of the Health Effects of Dental Amalgam in Children.||University of Washington||Active, not recruiting|August 1996|February 2011|Anticipated|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||507|||Both|8 Years|12 Years|No|||September 2010|September 2, 2010|August 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00066118||201794|
NCT00063843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-003|Anthrax-rPA: Safety, Tolerability, Immunogenicity|A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two Intramuscular Doses to Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2003|August 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||80|||Both|N/A|N/A||||May 2006|August 26, 2010|July 7, 2003||||||https://clinicaltrials.gov/show/NCT00063843||201958|
NCT00064233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000310142|BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate|A Phase I Dose-Escalation Study To Determine The Safety, Pharmacokinetics, And Pharmacodynamics Of BMS-354825 In The Treatment Of Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Hematologic Resistance To Imatinib Mesylate (Gleevec||Jonsson Comprehensive Cancer Center|Yes|Completed|November 2003|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|42|||Both|18 Years|N/A|No|||August 2012|October 1, 2015|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00064233||201932|
NCT00063999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000305940|Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|Randomized Phase III Trial Of Doxorubicin/Cisplatin/Paclitaxel And G-CSF Versus Carboplatin/Paclitaxel In Patients With Stage III & IV Or Recurrent Endometrial Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 2003|||January 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|900|||Female|18 Years|N/A|No|||April 2009|April 23, 2009|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063999||201948|
NCT00065286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD034027|Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation|Movement Dynamic Analyses of Akathisia||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|December 1996|November 1999||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2003|June 23, 2005|July 21, 2003||||No||https://clinicaltrials.gov/show/NCT00065286||201853|
NCT00064350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000315383|Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer|A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens||Eastern Cooperative Oncology Group|Yes|Completed|May 2004|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|342|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|July 8, 2003|Yes|Yes||No|March 8, 2012|https://clinicaltrials.gov/show/NCT00064350||201923|
NCT00063778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 040|Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa|A Phase I Safety and Immunogenicity Trial of an Alphavirus Replicon HIV Subtype C Gag Vaccine (AVX101, Alphavax, Inc.) in Healthy HIV-1 Uninfected Adult Volunteers||AlphaVax, Inc.||Completed|July 2003|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|July 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063778||201963|
NCT00063791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34102-052|A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE|An Open-Labeled, Randomized Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE in Patients With Relapsed Multiple Myeloma Who Have Failed Four or More Lines of Therapy||Millennium Pharmaceuticals, Inc.||No longer available||||||Phase 2|Expanded Access|N/A||||1000|||Both|N/A|N/A|No|||July 2003|February 13, 2007|July 7, 2003||||||https://clinicaltrials.gov/show/NCT00063791||201962|
NCT00063622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH - ADULT (IND)|Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)|Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)|PIVENS|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2005|September 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|247|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|July 1, 2003|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00063622||201974|
NCT00063635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH - PEDIATRICS (IND)|Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)|Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)|TONIC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|September 2005|February 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|173|||Both|8 Years|17 Years|No|||August 2012|August 27, 2012|July 1, 2003|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00063635||201973|
NCT00063648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTLD (completed)|Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|May 2002|December 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|1 Month|21 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 1, 2003||||No||https://clinicaltrials.gov/show/NCT00063648||201972|
NCT00064857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001724-01|Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors|Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|August 2003|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||26|||Both|18 Years|N/A|No|||April 2008|April 21, 2008|July 14, 2003||Yes||||https://clinicaltrials.gov/show/NCT00064857||201884|
NCT00063830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 2302-CS27|ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.|ISIS 2302-CS27, Phase 2, Double-Blinded, Controlled Study of Four Dosing Regimens of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis||Ionis Pharmaceuticals, Inc.||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2007|October 15, 2007|July 7, 2003||||||https://clinicaltrials.gov/show/NCT00063830||201959|
NCT00063973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03175|Cilengitide in Treating Children With Refractory Primary Brain Tumors|Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors||National Cancer Institute (NCI)||Completed|July 2003|||March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|21 Years|No|||September 2013|September 27, 2013|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00063973||201950|
NCT00064038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0232|S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma|Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients With Previously Untreated Multiple Myeloma||Southwest Oncology Group|Yes|Completed|November 2004|May 2012|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 8, 2003|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00064038||201945|
NCT00063284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030220|Investigating the Safety of srTMS in the Treatment of Parkinson's Disease|Safety Study of the Super Rapid Transcranial Magnetic Stimulation in Patients With Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2003|April 2009||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||10|||Both|40 Years|80 Years|No|||April 2009|April 16, 2009|June 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00063284||201998|
NCT00064532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1226|Serum Sex Hormone Levels and Subclinical Atherosclerosis - Ancillary to MESA|||Northwestern University||Completed|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|6173|||Both|45 Years|84 Years|No|Non-Probability Sample|Community sample of African-American, Chinese-American, Caucasian, and Hispanic residents        drawn from six regions in the United States: Baltimore City and Baltimore County,        Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County,        California; New York, New York; and St. Paul, Minnesota.|November 2013|December 2, 2014|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064532||201909|
NCT00062465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030208|Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine|A 24-Week, Double Blind, Randomized Study to Determine the Effects of 24 Weeks of Dosing With Tripterygium Wilfordii Hook F (TwHF) or Sulfasalazine, in Subjects With Active Rheumatoid Arthritis||National Institutes of Health Clinical Center (CC)||Completed|June 2003|March 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||157|||Both|N/A|N/A|No|||March 2006|March 3, 2008|June 5, 2003||||No||https://clinicaltrials.gov/show/NCT00062465||202057|
NCT00062816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 14803-CS3|Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs|||Ionis Pharmaceuticals, Inc.||Completed|May 2004|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||22|||Both|18 Years|65 Years|No|||October 2007|October 15, 2007|June 16, 2003||||||https://clinicaltrials.gov/show/NCT00062816||202031|
NCT00062829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01HD83285|Young Driver Intervention Study: Preventing Motor Vehicle Crashes|Young Driver Intervention Study: Preventing Motor Vehicle Crashes Among Young Drivers||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|September 1998|September 2005|Actual|September 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|3743|||Both|16 Years|16 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|June 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00062829||202030|
NCT00062478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN20405|Study of Karenitecin (BNP1350) in Patients With Brain Tumors|Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin||BioNumerik Pharmaceuticals, Inc.|No|Completed|October 2001|||August 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062478||202056|
NCT00062842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6957|Study of Irinotecan in Children|Pediatric Phase I and Pharmacokinetic Study of Irinotecan||Baylor College of Medicine||Completed|November 1998|May 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|1 Year|21 Years|No|||April 2007|April 9, 2007|June 17, 2003||||||https://clinicaltrials.gov/show/NCT00062842||202029|
NCT00064545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1227|Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC|||University of North Carolina, Chapel Hill|No|Completed|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|1500|||Both|N/A|N/A|No|Probability Sample|ARIC cohort, incident cases of CHD and cohort representative sample.|December 2012|December 11, 2012|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064545||201908|
NCT00064558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1228|Genetic Determinants of Sudden Cardiac Death|Genetic Determinants of Sudden Cardiac Death||Brigham and Women's Hospital|No|Completed|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2500|||Both|30 Years|N/A|No|Probability Sample|Participants previously enrolled in the Physicians' Health Study I (protocol        1999-P-001468), Physicians' Health Study II (protocols 1999-P-003315, 1999-P-003318),        Nurses' Health Study (protocols 1999-P-01114, 1999-P-010982), Women's Health Study        (protocols 1999-P-001304, 1999-P-001478), Women's Antioxidant Cardiovascular Study        (protocols 1999-P-001364, 1999-P-001611), and Health Professional Health Study approved        through the Harvard School of Public Health IRB (protocols 0007PROC, 0103STOR).|June 2015|January 22, 2016|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064558||201907|
NCT00062634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD39118|Education Program to Promote Female Condom Use|Female Condom Intervention Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|June 2003|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||400|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||October 2004|June 23, 2005|June 9, 2003||||No||https://clinicaltrials.gov/show/NCT00062634||202044|
NCT00062647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I6424-203a|Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia|A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia|ASSURE|Theravance Biopharma Antibiotics, Inc.|No|Completed|August 2003|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||March 2011|March 30, 2011|June 9, 2003|Yes|Yes||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00062647||202043|
NCT00062946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030104|PET Imaging of Dopamine in Healthy Study Participants|PET Imaging of Dopamine D2 Receptors and Extracellular Dopamine With (18F)Fallypride, D-Amphetamine, and Alpha-Methyl-Para-Tyrosine in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Completed|June 2003|August 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 16, 2007|June 17, 2003||||No||https://clinicaltrials.gov/show/NCT00062946||202022|
NCT00062959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01HD33207|Preventing Problem Behavior Among Middle School Students|Preventing Problem Behaviors Among Middle School Students||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|June 1994|June 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||2768|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||May 2003|June 23, 2005|June 18, 2003||||No||https://clinicaltrials.gov/show/NCT00062959||202021|
NCT00063024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037743|Program to Prevent Osteoporosis in Girls|Behavioral Strategies to Prevent Osteoporosis in Girls||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|June 1999|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||322|||Female|9 Years|11 Years|Accepts Healthy Volunteers|||May 2003|June 23, 2005|June 19, 2003||||No||https://clinicaltrials.gov/show/NCT00063024||202016|
NCT00064298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFU-60A02|Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer|A Phase II Randomized Placebo Controlled, Double Blinded Trial To Evaluate The Effects Of Fruit And Vegetable Extracts On Intermediate Biomarkers In Head And Neck Cancer Patients||Wake Forest NCORP Research Base|Yes|Completed|January 2004|April 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064298||201927|
NCT00063323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13490-1|Maintenance Treatment for Abstinent Smokers|Maintenance Treatment for Prevention of Smoking Relapse||National Institute on Drug Abuse (NIDA)|Yes|Completed|August 2000|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|589|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||January 2010|January 5, 2010|June 25, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063323||201995|
NCT00063609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GUS45|The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy|The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy||Novartis||Completed|April 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Male|18 Years|N/A|No|||November 2009|November 20, 2009|July 1, 2003||||||https://clinicaltrials.gov/show/NCT00063609||201975|
NCT00063193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS043128|National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial|A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease||University of Rochester|Yes|Completed|May 2003|July 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||195|||Both|30 Years|N/A|No|||January 2016|January 19, 2016|June 23, 2003||||No||https://clinicaltrials.gov/show/NCT00063193||202004|
NCT00064766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD043175|Norplant and Irregular Bleeding/Spotting|A Prospective Randomized Clinical Trial of Doxycycline 20mg Twice a Day Versus Placebo on the Bleeding and Spotting in Women After Insertion of a Levonorgestrel Implant (Norplant) Protocol #2002-1||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|February 2003|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2003|June 23, 2005|July 11, 2003||||||https://clinicaltrials.gov/show/NCT00064766||201891|
NCT00063687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-02-01|Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure|A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure||Cardiome Pharma||Completed|March 2003|June 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|85 Years|No|||July 2003|August 3, 2005|July 2, 2003||||||https://clinicaltrials.gov/show/NCT00063687||201969|
NCT00063700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCPSS (completed)|Impact of Non-Commercialism Policy in Seattle Schools|Impact of Non-Commercialism Policy in Seattle Schools||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2002|July 2005||||N/A|Interventional|Primary Purpose: Prevention|||||||Both|13 Years|18 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 2, 2003||||No||https://clinicaltrials.gov/show/NCT00063700||201968|
NCT00063713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34103-053|VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma|A Phase 2 Study of VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma||Millennium Pharmaceuticals, Inc.||Completed|June 2003|||December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||152|||Both|18 Years|N/A|No|||February 2008|February 7, 2008|July 2, 2003||||No||https://clinicaltrials.gov/show/NCT00063713||201967|
NCT00063258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-327|Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer|Phase II Randomized Open-Label Trial of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Tarceva™) in Combination With Paclitaxel and Carboplatin Prior to Surgery in Resectable Stage IIIA (N2) and IIIB (T4 N2) NSCLC: A Clinical Outcome and Biological Endpoint Trial||M.D. Anderson Cancer Center|Yes|Terminated|June 2003|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|N/A|N/A|No|||May 2011|May 5, 2011|June 24, 2003|No|Yes|Low accrual rate|No|August 25, 2010|https://clinicaltrials.gov/show/NCT00063258||201999|Despite active study recruitment and screening for this study, only 5 subjects were enrolled out of the planned 40 subjects. Of the 5 subjects enrolled, only 1 patient was evaluable for response assessment. The study was subsequently terminated.
NCT00063570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5141|Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy|Phase II Trial of Alimta (Pemetrexed) and Gemzar (Gemcitabine) in Metastatic Breast Cancer Patients Who Have Received Prior Taxane Therapy||Eli Lilly and Company||Completed|July 2003|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||May 2009|May 12, 2009|June 30, 2003|Yes|Yes||No|January 27, 2009|https://clinicaltrials.gov/show/NCT00063570||201978|
NCT00063960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z05032|Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer|A Phase II Trial Of Toxicity Assessment In Two Cohorts Of Patients (Resection Alone Or Ablation With Or Without Resection Of Hepatic Metastases From Colorectal Cancer) Treated With Adjuvant Hepatic Arterial Infusion (HAI) FUDR Plus Systemic CPT-11||Alliance for Clinical Trials in Oncology|No|Completed|August 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00063960||201951|
NCT00062569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0044|Bathing Persons With Alzheimer's Disease aT Home (The BATH Study)|Reminiscence During Bathing Persons With Alzheimer's Disease at Home||National Institute of Nursing Research (NINR)|No|Completed|September 2002|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|90|||Both|60 Years|N/A|No|||March 2009|March 10, 2009|June 9, 2003||No||No||https://clinicaltrials.gov/show/NCT00062569||202049|
NCT00062491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN23106|Study of Karenitecin (BNP1350) to Treat Malignant Melanoma|Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma||BioNumerik Pharmaceuticals, Inc.|No|Completed|May 2002|November 2005|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062491||202055|
NCT00062504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-205-21-189|Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas|A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.||Teva Pharmaceutical Industries||Terminated|July 2003|April 2006|Actual|January 2006|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|June 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00062504||202054|
NCT00062582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-110|Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)|A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 Mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Takeda||Completed|June 2003|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Both|18 Years|N/A|No|||January 2012|May 4, 2012|June 9, 2003||||No||https://clinicaltrials.gov/show/NCT00062582||202048|
NCT00062517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030185|Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning|Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Social Emotional Information and Instrumental Learning||National Institutes of Health Clinical Center (CC)||Recruiting|June 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|508|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|September 15, 2015|June 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00062517||202053|
NCT00062660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.58|Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection|An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options||Boehringer Ingelheim||No longer available|May 2003|April 2014|Actual|April 2014|Actual|N/A|Expanded Access|N/A|||||||Both|2 Years|N/A|No|||July 2014|July 23, 2014|June 10, 2003||||No||https://clinicaltrials.gov/show/NCT00062660||202042|
NCT00063583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-RO1-DK63017-01|Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes|Pirfenidone: A Novel Anti-Scarring Therapy for Diabetic Nephropathy||Sharma, Kumar, M.D.|Yes|Completed|June 2003|March 2009|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|N/A|No|||November 2009|November 3, 2009|June 30, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063583||201977|
NCT00062972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD038107-01|Improving Memory in Patients With Multiple Sclerosis|Interventions to Improve Memory in Patients With Multiple Sclerosis||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|September 1999|August 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|56 Years|No|||May 2011|May 20, 2011|June 18, 2003|||Study terminated/withdrawn|No||https://clinicaltrials.gov/show/NCT00062972||202020|
NCT00063037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037748|Building Better Bones in Children|Building Better Bones in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|June 1999|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||139|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||May 2003|June 23, 2005|June 19, 2003||||No||https://clinicaltrials.gov/show/NCT00063037||202015|
NCT00063388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-012|Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer|A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC)||ImClone LLC|No|Completed|May 2003|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||April 2010|April 8, 2010|June 25, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063388||201991|
NCT00064077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0204|Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix|A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix||Gynecologic Oncology Group||Completed|May 2003|||January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|513|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064077||201942|
NCT00064090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-032|3-AP and Cytarabine in Treating Patients With Hematologic Cancer|A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies||National Cancer Institute (NCI)||Completed|March 2003|January 2008|Actual|September 2004|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|July 17, 2013|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064090||201941|
NCT00063596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD037263|Vitamin A Supplementation in Preterm Infants|Vitamin A Therapy in Preterm Infants: Vaccine Response||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|January 2000|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|N/A|3 Days|No|||November 2004|June 23, 2005|July 1, 2003||||No||https://clinicaltrials.gov/show/NCT00063596||201976|
NCT00063180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030224|Evaluating the Remote Effects of Stroke With MRI and PET Scans|Remote Effects of Stroke on Cerebral Metabolism. Evaluation With Positron Emission Tomography and Proton Magnetic Resonance Spectroscopy||National Institutes of Health Clinical Center (CC)||Completed|June 2003|April 2009||||N/A|Observational|N/A||||70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|September 26, 2015|June 20, 2003||No||No||https://clinicaltrials.gov/show/NCT00063180||202005|
NCT00063401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-009|Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer|A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer||ImClone LLC|No|Completed|September 2003|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||April 2010|April 7, 2010|June 25, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063401||201990|
NCT00064311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030205|Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation|A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Completed|June 2003|September 2004|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||March 2012|March 7, 2012|July 8, 2003||||No||https://clinicaltrials.gov/show/NCT00064311||201926|
NCT00063245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030231|Stimulating Deep Brain Regions With a Magnetic Stimulator|Noninvasive Stimulation of Human Deep Brain Regions With a Magnetic Stimulator||National Institutes of Health Clinical Center (CC)||Completed|June 2003|April 2005||||N/A|Observational|N/A||||18|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2005|March 3, 2008|June 23, 2003||||No||https://clinicaltrials.gov/show/NCT00063245||202000|
NCT00063531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218|Comparison of Two Methods to Diagnose Coronary Artery Disease|Coronary Disease Detection by Thallium SPECT and Fast CT||Johns Hopkins University|No|Completed|June 2003|January 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|650|Samples With DNA|Blood|Both|30 Years|59 Years|No|Probability Sample|Healthy siblings of patients with early onset CAD (<age 60) or the adult offspring of the        siblings or probands, all participants in the GeneSTAR study.|March 2014|March 1, 2014|June 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00063531||201981|
NCT00063544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1219|Physical Activity and Childhood Obesity|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 2003|April 2007|Actual|April 2007|Actual|N/A|Observational|N/A|||||||Both|11 Years|13 Years|No|||May 2009|May 1, 2009|June 30, 2003||||No||https://clinicaltrials.gov/show/NCT00063544||201980|
NCT00063557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220|Neighborhoods and CVD Risk in a Multiethnic Cohort - Ancillary to MESA|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 2003|April 2007|Actual|April 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 24, 2008|June 30, 2003||||No||https://clinicaltrials.gov/show/NCT00063557||201979|
NCT00063804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5191|Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men|A Phase 1, Dose-Rising Study of AMD11070 in HIV-Seronegative Men to Assess the Safety and Pharmacokinetics After Single or Multiple Doses||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|July 7, 2003||||||https://clinicaltrials.gov/show/NCT00063804||201961|
NCT00064909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030247|MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis|Using MR Perfusion Imaging and Hypercapnia to Study Angiogenesis in Multiple Sclerosis Patients||National Institutes of Health Clinical Center (CC)||Completed|July 2003|March 2006||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||March 2006|March 3, 2008|July 14, 2003||||No||https://clinicaltrials.gov/show/NCT00064909||201880|
NCT00062712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030204|Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients|Induction of Donor Specific Immunologic Hyporesponsiveness With Thymoglobulin, Sirolimus and Donor Bone Marrow Infusion||National Institutes of Health Clinical Center (CC)||Completed|June 2003|March 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|12 Years|75 Years|No|||March 2007|March 23, 2007|June 11, 2003||||No||https://clinicaltrials.gov/show/NCT00062712||202038|
NCT00062738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4381|Treatment of Depression in Parkinson's Disease Trial|Treatment of Depression in Patients With Parkinson's Disease||Rutgers, The State University of New Jersey|Yes|Completed|June 2003|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|35 Years|80 Years|No|||October 2015|October 27, 2015|June 12, 2003|Yes|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00062738||202037|This was only an eight week trial with relatively few participants.
NCT00062595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK58363 (completed 2005)|Vitamin K and Bone Turnover in Postmenopausal Women|Vitamin K and Bone Turnover in Postmenopausal Women||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2000|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||375|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2010|March 17, 2010|June 9, 2003||||||https://clinicaltrials.gov/show/NCT00062595||202047|
NCT00062985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBMANC (completed)|Obesity Treatment in a Managed Care Setting|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 1999|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||1801|||Both|18 Years|N/A|No|||November 2010|November 10, 2010|June 18, 2003||||No||https://clinicaltrials.gov/show/NCT00062985||202019|
NCT00062608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTYAP (completed)|Written Self-disclosure for Youth Abdominal Pain|RCT of Written Self-disclosure for Youth Abdominal Pain||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|12 Years|18 Years|No|||January 2010|January 12, 2010|June 9, 2003||||No||https://clinicaltrials.gov/show/NCT00062608||202046|
NCT00064025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0211|Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus|A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus||Gynecologic Oncology Group|Yes|Completed|October 2003|||September 2010|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|75|||Female|18 Years|N/A|No|||July 2014|July 24, 2014|July 8, 2003|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00064025||201946|
NCT00062803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC3484|SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism|The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism||Sanofi||Completed|June 2003|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2009|April 28, 2009|June 16, 2003||||||https://clinicaltrials.gov/show/NCT00062803||202032|
NCT00062998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 (DK62152) (completed 2006)|Free-Living Physical Activity and Energy Expenditure|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Observational|Time Perspective: Prospective||||15|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|June 18, 2003||||No||https://clinicaltrials.gov/show/NCT00062998||202018|
NCT00063362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH062650|Combination Therapy for the Treatment of Bipolar Disorders|Combination Therapy in Bipolar Rapid Cycling||University Hospital Case Medical Center|Yes|Terminated|February 2002|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|16 Years|N/A|No|||December 2013|December 23, 2013|June 25, 2003|Yes|Yes|Funding Expiration|No|November 4, 2013|https://clinicaltrials.gov/show/NCT00063362||201993|
NCT00063050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037749|Osteoporosis Prevention: Changes to Exercise and Diet in Children|Healthy Children Healthy Families||San Diego State University|No|Completed|April 2000|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|155|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||November 2011|November 14, 2011|June 19, 2003||No||No||https://clinicaltrials.gov/show/NCT00063050||202014|
NCT00062543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-167|Hepatic Artery Infusion of CD34+ Cells|Hepatic Artery Infusion of CD34+ Cells, Isolated by the Isolex 300i Device, in Stem Cell Transplant Recipients With Hepatic Failure Due to Veno-occlusive Disease||M.D. Anderson Cancer Center|No|Withdrawn|May 2002|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||August 2012|August 1, 2012|June 9, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062543||202051|
NCT00063141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-006|Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer|Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma||ImClone LLC||Completed|April 2003|October 2007|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1302|||Both|18 Years|N/A|No|||April 2010|April 8, 2010|June 20, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063141||202007|
NCT00063154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC2572g|Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy|A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer||Genentech, Inc.|No|Completed|July 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|June 20, 2003|No|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT00063154||202006|
NCT00063375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH062056|Interactive Computer Treatment for Panic Disorder|Interactive Computer Treatment for Panic Disorder||Florida State University||Completed|January 2002|||February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|65 Years|No|||October 2013|October 24, 2013|June 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00063375||201992|
NCT00063726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34101-040|A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039|An International, Non-Comparative, Open-Label Study of PS-341 Administered to Patients With Multiple Myeloma Who Experienced Relapsed or Progressive Disease After Receiving at Least Four Previous Treatment Regimens or Experienced Progressive Disease After Receiving Dexamethasone in Millennium Protocol M34101-039||Millennium Pharmaceuticals, Inc.||Completed|April 2002|July 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|July 2, 2003||||No||https://clinicaltrials.gov/show/NCT00063726||201966|
NCT00063206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-304|Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|247|||Both|18 Years|75 Years|No|||August 2009|August 18, 2009|June 23, 2003||||||https://clinicaltrials.gov/show/NCT00063206||202003|
NCT00063219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3128K1-201|Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy|A Phase 2, Open-label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Non-small Cell Lung Cancer Refractory to Platinum-based Therapy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|June 23, 2003||||||https://clinicaltrials.gov/show/NCT00063219||202002|
NCT00064324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02798|Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma|A Phase II Study of Perifosine in Soft Tissue Sarcoma||National Cancer Institute (NCI)||Completed|June 2003|||November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00064324||201925|
NCT00064337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0115|S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis|S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study)||Southwest Oncology Group|Yes|Active, not recruiting|January 2004|November 2015|Anticipated|May 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|July 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00064337||201924|
NCT00063479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2202|Bisphosphonate Treatment of Osteogenesis Imperfecta|Bisphosphonate Treatment of Osteogenesis Imperfecta||Novartis||Completed|June 2003|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||158|||Both|3 Months|17 Years|No|||April 2012|April 26, 2012|June 27, 2003||||||https://clinicaltrials.gov/show/NCT00063479||201985|
NCT00063492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1215|Angiotensinogen Gene and Human Hypertension|||University of Utah||Completed|January 2003|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2013|July 23, 2013|June 30, 2003||||No||https://clinicaltrials.gov/show/NCT00063492||201984|
NCT00063505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216|Genes of Hypertension in African Americans|Genes of Hypertension in African Americans||Medical College of Wisconsin|No|Completed|December 2002|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|5000|Samples With DNA|Blood cells and DNA|Both|18 Years|75 Years|No|Non-Probability Sample|African Americans|April 2014|April 22, 2014|June 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00063505||201983|
NCT00063518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10387|Monitoring Trends in Venous Thromboembolism|Incidence Rates, Clinical Profile, and Outcomes of Patients With Venous Thromboembolism||University of Massachusetts, Worcester|No|Completed|April 2003|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||September 2013|September 9, 2013|June 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00063518||201982|
NCT00063752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-001|Safety Study of PI-0824 to Treat Pemphigus Vulgaris|An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy||Peptimmune||Completed|July 2003|March 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||April 2005|June 23, 2005|July 3, 2003||||||https://clinicaltrials.gov/show/NCT00063752||201965|
NCT00063765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030234|Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye|A Phase I Study of NT-501-10 and NT-501-6A.02, Implants of Encapsulated Human NTC-210 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Patients With Retinitis Pigmentosa||National Institutes of Health Clinical Center (CC)||Completed|June 2003|March 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||March 2006|March 3, 2008|July 3, 2003||||No||https://clinicaltrials.gov/show/NCT00063765||201964|
NCT00063297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004342|Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia|||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2003|October 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|60 Years|No|||December 2003|August 27, 2009|June 25, 2003||||||https://clinicaltrials.gov/show/NCT00063297||201997|
NCT00063310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0047|ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation|Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN)||National Institute on Aging (NIA)||Completed|March 2003|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Female|65 Years|N/A|No|||February 2006|December 10, 2009|June 25, 2003||||No||https://clinicaltrials.gov/show/NCT00063310||201996|
NCT00063817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN010ST|Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant|Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2003|July 2009|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|55 Years|No|||February 2016|February 21, 2016|July 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00063817||201960|
NCT00063947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01439|Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer|A Phase I Study of OSI-774 in Combination With Gemcitabine and Radiation in Locally Advanced, Non-Operable Pancreatic Cancer||National Cancer Institute (NCI)||Completed|May 2003|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00063947||201952|
NCT00062907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCL5001-01|Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer|Phase I Open-Label Dose Escalation Trial Evaluating The Safety And Immunogenicity Of Sequential Administration Of Recombinant DNA And Adenovirus Expressing L523S Protein In Patients With Early Stage Non-Small Cell Lung Cancer||Corixa Corporation||Recruiting|May 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||9|||Both|18 Years|N/A|No|||November 2004|December 5, 2006|June 17, 2003||||||https://clinicaltrials.gov/show/NCT00062907||202024|
NCT00062933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030221|A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma|A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma||National Institutes of Health Clinical Center (CC)||Completed|June 2003|March 2008|Actual|September 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2012|August 17, 2012|June 17, 2003||||No||https://clinicaltrials.gov/show/NCT00062933||202023|
NCT00062751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066A1-204|Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms|A Phase 2 Randomized Open-Label Study Of Letrozole In Combination With Two Dose Levels And Schedules Of Oral Temsirolimus (CCI-779), Or Letrozole Alone, In Postmenopausal Women With Locally Advanced Or Metastatic Breast Cancer||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2002|October 2009|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|108|||Female|18 Years|N/A|No|||April 2011|April 13, 2011|June 12, 2003|Yes|Yes||No|October 27, 2010|https://clinicaltrials.gov/show/NCT00062751||202036|Clinical development of oral temsirolimus for treatment of locally advanced or metastatic breast cancer was terminated by Wyeth based on the results of a phase 3 clinical study with the combination temsirolimus and letrozole.
NCT00062764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030212|Treating Nonalcoholic Steatohepatitis With Pioglitazone|Long-Term Treatment of Nonalcoholic Steatohepatitis With Pioglitazone||National Institutes of Health Clinical Center (CC)|No|Completed|June 2003|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2012|December 14, 2012|June 12, 2003|No|Yes||No|March 1, 2011|https://clinicaltrials.gov/show/NCT00062764||202035|A major limitation of this study was the lack of a concurrently followed control group.Another important shortcoming of this study was that patients were treated for 48 weeks only.
NCT00062777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030219|The Framingham Study: Examining DNA Markers and Links to Diseases|A Genome-Wide Scan for Quantitative Trait Loci of Hematocrit - A Framingham Study||National Institutes of Health Clinical Center (CC)||Completed|June 2003|June 2011||||N/A|Observational|N/A|||Actual|330|||Both|N/A|N/A|No|||June 2011|September 26, 2015|June 13, 2003||No||No||https://clinicaltrials.gov/show/NCT00062777||202034|
NCT00064116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY9|Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8)||Canadian Cancer Trials Group|Yes|Completed|May 2001|January 2014|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|824|||Both|18 Years|60 Years|No|||June 2014|June 23, 2014|July 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00064116||201939|
NCT00064129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00036|Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer|A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (Ipilimumab) in Combination With GM-CSF in Patients With Metastatic, Androgen-Independent Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 2003|||January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|18 Years|N/A|No|||December 2015|December 2, 2015|July 8, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00064129||201938|
NCT00063336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH065377|Treatment Response to Rehabilitation in Patients With Schizophrenia|Treatment Response to Rehabilitation in Schizophrenia||Hartford Hospital||Completed|December 2001|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||May 2009|November 7, 2013|June 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00063336||201994|
NCT00063011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD036601|Bone Development in Adolescent Girls: Effects of Calcium and Exercise|Calcium and Exercise Effect on Pubertal Bone Gain||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|May 1998|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||107|||Female|9 Years|10 Years|Accepts Healthy Volunteers|||May 2003|June 23, 2005|June 19, 2003||||No||https://clinicaltrials.gov/show/NCT00063011||202017|
NCT00063414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 2302-CS22|ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis|ISIS 2302-CS22, Phase II, Double-Blinded, Active-Controlled Study of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis (Left-Sided Colitis or Pancolitis With Left Sided Disease Flare)||Ionis Pharmaceuticals, Inc.||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2007|October 15, 2007|June 25, 2003||||||https://clinicaltrials.gov/show/NCT00063414||201989|
NCT00063427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3128K1-200|Study Evaluating MAC-321 in Colorectal Cancer|A Phase 2, Open-Label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Advanced Colorectal Cancer||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|June 26, 2003||||||https://clinicaltrials.gov/show/NCT00063427||201988|
NCT00060268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000301589|Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors|A Phase I/II Trial for Treatment of Obstructive Esophageal Tumors by Photodynamic Therapy (PDT) Using 2-(1-Hydroxyethyl)-2-Devinylpyropheophorbide-a (HPPH)||Roswell Park Cancer Institute|Yes|Completed|January 1997|June 2004|Actual|September 2003|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2011|March 7, 2011|May 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00060268||202213|
NCT00066768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01440|Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer|A Pilot Study of Low Dose Suramin as Modulator of Docetaxel and Gemcitabine in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|July 2003|||March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|August 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00066768||201752|
NCT00066859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-98101|Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression|A Phase III Double-Blind Randomized Trial Comparing Sertraline (Zoloft) And Hypericum Perforatum (St. John's Wort) In Cancer Patients With Mild To Moderate Depression||Wake Forest NCORP Research Base|Yes|Completed|March 2004|November 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|2|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|August 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00066859||201747|
NCT00067483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030275|Pilot Study: Dynamic Light Scattering Device for Studying Early Changes in Cataract|Pilot Study on the Use of the NASA-NEI Dynamic Light Scattering (DLS) Device in Detecting Lens Changes in the Other Eye of Patients With Pre-Senile Cataracts||National Institutes of Health Clinical Center (CC)||Completed|August 2003|December 2007||||N/A|Observational|N/A||||15|||Both|18 Years|55 Years|No|||December 2007|March 5, 2008|August 20, 2003||||No||https://clinicaltrials.gov/show/NCT00067483||201699|
NCT00067795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5181|Evaluating Immune Function Tests in People With HIV|HIV Antigen-Specific Immune Responses - A Comparison of Alternative In Vitro Assays From Subjects Characterized as Either "Stable HAART" or "Efficient Immune Control"||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Time Perspective: Prospective||||54|||Both|18 Years|N/A|No|||November 2010|November 19, 2010|August 27, 2003||||No||https://clinicaltrials.gov/show/NCT00067795||201675|
NCT00070187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD0121|Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma|A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease||Children's Oncology Group|Yes|Completed|November 2003|||June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|30 Years|No|||October 2013|October 16, 2013|October 3, 2003||No||No||https://clinicaltrials.gov/show/NCT00070187||201510|
NCT00067964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHAIO (completed)|Diet and Physical Activity Interactions in Obesity|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention||||90|||Both|25 Years|40 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|September 3, 2003||||No||https://clinicaltrials.gov/show/NCT00067964||201662|
NCT00067977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPKD|Clinical Trial to Slow the Progression of ADPKD|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Not yet recruiting||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|65 Years|No|||November 2005|November 2, 2005|September 3, 2003||||No||https://clinicaltrials.gov/show/NCT00067977||201661|
NCT00067106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI04350|Antiviral Therapy and HIV in the Female Genital Tract|Antiviral Therapy and HIV in the Genital Tract of Women||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|July 2003|March 2009|Actual|March 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|130|Samples With DNA|Blood and genital tract collection|Female|18 Years|70 Years|No|Non-Probability Sample|HIV-infected women who are failing their current antiretroviral regimen and those who are        fully suppressed on antiretroviral therapy|September 2014|May 15, 2015|August 11, 2003||No||No||https://clinicaltrials.gov/show/NCT00067106||201728|
NCT00067119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACTDC (completed)|Vascular Access Clinical Trials Data Coordinating Center|1) Clopidogrel Prevention of Early AV Fistula Thrombosis (IND 64169) 2) Aggrenox Prevention of Access Stenosis (IND 64,202)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2003|February 2008|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|1284|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|August 11, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067119||201727|
NCT00067132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43DK061818 (completed)|Adjuvant Nutrition for Critically Ill Trauma Patients|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|80 Years|No|||January 2010|January 12, 2010|August 11, 2003||||No||https://clinicaltrials.gov/show/NCT00067132||201726|
NCT00066196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP095|Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma|A Phase II, Randomized, Open-Label Study Evaluating The Antitumor Activity Of MEDI-522, A Humanized Monoclonal Antibody Directed Against The Human Alpha V Beta 3 Integrin, ± Dacarbazine In Patients With Metastatic Melanoma||MedImmune LLC|No|Completed|August 2003|June 2007|Actual|April 2007|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||110|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|August 5, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066196||201788|
NCT00070161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000330114|Donepezil or EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases|Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Patients||Wake Forest Baptist Health||Completed|March 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||August 2009|August 20, 2009|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070161||201512|
NCT00070174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML03P1|Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy|Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study||Children's Oncology Group|Yes|Completed|December 2003|December 2013|Actual|September 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|350|||Both|N/A|N/A|No|||February 2014|February 19, 2014|October 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00070174||201511|
NCT00068315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00044|Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|July 2003|||December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068315||201636|
NCT00066573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA27|Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer|A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer||Canadian Cancer Trials Group|Yes|Completed|June 2003|March 2011|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7576|||Female|18 Years|N/A|No|||May 2014|May 14, 2014|August 6, 2003|Yes|Yes||No|April 16, 2014|https://clinicaltrials.gov/show/NCT00066573||201766|
NCT00067002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-407|Randomized Double Cord Blood Transplant Study|Randomized Trial of Unmanipulated Versus Expanded Cord Blood||M.D. Anderson Cancer Center|Yes|Active, not recruiting|April 2003|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|1 Month|80 Years|No|||June 2015|June 4, 2015|August 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067002||201736|
NCT00066326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000315521|Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia|Phase I Study Of The Combination Of 17-AAG And Imatinib Mesylate (Gleevec) In Patients With Blastic Phase, Accelerated Phase Of Chronic Mesylate Leukemia (CML) Or Patients With Chronic Phase CML Who Have Not Achieved A Cytogenetic Response With Imatinib Mesylate||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 2003|September 2005|Actual|October 2004|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 3, 2013|August 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066326||201781|
NCT00067587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 021|Metabolic Abnormalities in HIV Infected and Uninfected Young Women|Prevalence of Morphologic and Metabolic Abnormalities in HIV Infected and Uninfected Young Women||Westat|Yes|Completed|July 2003|June 2005|Actual|June 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|300|||Female|12 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of up to 300 subjects may be enrolled in the study. The number of subjects in each        study group will be as follow: 50 HIV negative subjects; 100 HIV positive subjects with no        exposure to ART; and three groups of up to 50 HIV positive subjects each with different        ART exposure histories.|February 2016|February 29, 2016|August 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00067587||201691|
NCT00066872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000320513|Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer|A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma||National Cancer Institute (NCI)||Completed|October 2002|April 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|N/A|N/A|No|||September 2009|September 16, 2013|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066872||201746|
NCT00066885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN101-004|Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer|A Phase 1/2 Multicenter, Open Label, Dose Ranging Study of DN-101 and Taxotere® in Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Previous Therapy With Platinum-Based Chemotherapy||Novacea||Completed|June 2003|December 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||May 2007|May 3, 2007|August 6, 2003||||||https://clinicaltrials.gov/show/NCT00066885||201745|
NCT00066742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03042|Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer|A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2003|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||December 2012|April 29, 2014|August 6, 2003|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00066742||201753|
NCT00066937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13906|Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)|Pain Management in Temporomandibular Joint Disorders||Johns Hopkins University|Yes|Completed|November 2002|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|214|||Both|18 Years|65 Years|No|||July 2008|June 25, 2010|August 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00066937||201741|
NCT00070538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-034|VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies|A Phase I Study Of VNP40101M And Cytarabine For Patients With Hematologic Malignancies||National Cancer Institute (NCI)||Completed|June 2003|January 2008|Actual|September 2004|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|July 17, 2013|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070538||201491|
NCT00067938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA40917|Bipolar Study in Adults at Least 18 Years of Age|An Open-label Study of Tolerability, Clinical Response, and Satisfaction in Adult Bipolar I Subjects Optimizing Initiation of Therapy Using Administration of Dermatological Precautions and LAMICTAL Titration Packs||GlaxoSmithKline|No|Completed|August 2003|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1200|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|September 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067938||201664|
NCT00067184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV98112004|Fetal Neurobehavioral Development in Methadone Maintained Pregnancies|Methadone, Buprenorphine and Fetal Development||Johns Hopkins University|No|Completed|September 2002|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|157|||Female|18 Years|40 Years|No|Non-Probability Sample|Methadone exposed pregnancies|February 2013|March 30, 2015|August 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00067184||201722|
NCT00066846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000320506|Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy|A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancers That Have Progressed After Standard Chemotherapy||National Cancer Institute (NCI)||Completed|August 2003|July 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2004|June 18, 2013|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066846||201748|
NCT00067015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-040|Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer|Phase III Randomized Trial Study Comparing the Outcome of High-Dose IMRT (86.4 GY) Alone With IMRT to 75.6 GY Plus Neoadjuvant/Adjuvant Androgen Deprivation in Patients With High Grade Intermediate Risk and Unfavorable Risk Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|May 2003|September 2008|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Male|18 Years|120 Years|No|||December 2015|December 21, 2015|August 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067015||201735|
NCT00067028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0181|Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML|A Prospective Randomized Phase I/II Study of Clofarabine (Clo) and Ara-C vs Clo and Ida vs Clo Plus Ida and Ara-C in Patients With First Relapse or First Salvage of Primary Refractory AML; and High-Grade MDS(>/= 10% Blasts); or CML in Myeloid Blasts Phase as Front Line Therapy or in First Salvage.||M.D. Anderson Cancer Center|No|Completed|December 2003|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|166|||Both|18 Years|59 Years|No|||June 2013|June 17, 2013|August 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067028||201734|
NCT00067951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|712753/004|A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics|An Open-label Trial to Evaluate the Safety and Efficacy of Fixed Dose Rosiglitazone/Metformin Combination Therapy in Poorly-controlled Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|October 2003|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|190|||Both|18 Years|70 Years|No|||May 2013|April 10, 2015|September 3, 2003||||||https://clinicaltrials.gov/show/NCT00067951||201663|
NCT00066300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000315460|Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed By T Cell Add-Back For Hematological Malignancies - Effect Of Irradiated Donor Lymphocytes On Chimerism||National Cancer Institute (NCI)||Active, not recruiting|May 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|10 Years|55 Years|No|||April 2004|May 14, 2011|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066300||201783|
NCT00066313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00005|ZD6474 in Treating Patients With Small Cell Lung Cancer|A Phase II Study Of ZD6474 Or Placebo In Small Cell Lung Cancer Patients Who Have Complete Or Partial Response To Induction Chemotherapy +/- Radiation Therapy||AstraZeneca||Completed|May 2003|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2011|April 7, 2011|August 6, 2003||Yes||||https://clinicaltrials.gov/show/NCT00066313||201782|
NCT00066417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000315900|Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia|Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia||National Cancer Institute (NCI)||Terminated||January 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|51|||Both|10 Years|50 Years|No|||November 2006|April 30, 2013|August 6, 2003|||Trial was withdrawn for drug availability issues.|No||https://clinicaltrials.gov/show/NCT00066417||201774|
NCT00066339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10012|Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy|An IDBBC Single Arm Phase II Trial Evaluating The Activity Of Iressa (ZD1839) In Metastatic Breast Cancer Patients Pretreated With An Antiestrogen And A Non-Steroidal Aromatase Inhibitor (Anastrozole Or Letrozole)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2003|||January 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066339||201780|
NCT00066586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP2|Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer|A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer||Canadian Cancer Trials Group||Completed|August 2001|February 2009|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|98|||Female|N/A|N/A|No|||September 2011|May 30, 2013|August 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066586||201765|
NCT00066924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31AT001769-01|Spirituality, Religiosity, and Immune Functioning|||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2003|June 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||120|||Both|21 Years|N/A|No|||May 2005|June 23, 2005|August 7, 2003||||No||https://clinicaltrials.gov/show/NCT00066924||201742|
NCT00068406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000322259|Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva|A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva||National Cancer Institute (NCI)||Completed|January 2005|||December 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Female|N/A|N/A|No|||September 2009|September 2, 2012|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068406||201630|
NCT00068419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST0321|Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor|A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy||Children's Oncology Group|Yes|Active, not recruiting|February 2004|||August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|N/A|18 Years|No|||March 2016|March 21, 2016|September 10, 2003|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00068419||201629|
NCT00067054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030263|Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies|VRC 200: Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies||National Institutes of Health Clinical Center (CC)||Recruiting|August 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|December 9, 2015|August 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00067054||201732|
NCT00066989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1408|Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates|A Double Blind, Randomized, Multicenter Stratified Study to Assess the Safety of an Intravenous Staphylococcus Aureus Immune Globulin (Human) [Altastaph] in Low-Birth-Weight-Neonates||Nabi Biopharmaceuticals||Completed|July 2003|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|N/A|7 Days|No|||May 2012|May 10, 2012|August 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066989||201737|
NCT00066625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02552|Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer|A Phase I and Pharmacokinetic Study of Oxaliplatin (Eloxatin™) in Combination With Bortezomib (PS-341, Velcade™) in Patients With Advanced Malignancy||National Cancer Institute (NCI)||Terminated|July 2003|||April 2007|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|August 6, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00066625||201762|
NCT00066638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03005|FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 2 Study of Depsipeptide in Relapsed/Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|June 2003|March 2011|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2012|March 16, 2015|August 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00066638||201761|
NCT00067249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31AT001401-01|Women's Use of Alternative Medicine: A Multiethnic Study|||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2001|September 2001||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||3200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|February 26, 2007|August 13, 2003||||No||https://clinicaltrials.gov/show/NCT00067249||201717|
NCT00067262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-342|An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents|A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Bipolar Disorder in Children and Adolescents||Abbott||Completed|March 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|10 Years|17 Years|No|||August 2006|August 2, 2006|August 13, 2003||||||https://clinicaltrials.gov/show/NCT00067262||201716|
NCT00067275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030266|The Effect of Dopamine on Motor Skills Training|Dopamine Release in Use-Dependent Plasticity in Health and Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2003|August 2007||||N/A|Observational|N/A||||98|||Both|18 Years|80 Years|No|||August 2007|March 5, 2008|August 13, 2003||||No||https://clinicaltrials.gov/show/NCT00067275||201715|
NCT00067392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14185|Evaluation of Implants Placed Immediately or Delayed Into Extraction Sites|Prospective Evaluation of Immediate Temporized Implants||Louisiana State University Health Sciences Center in New Orleans||Active, not recruiting|November 2003|May 2009|Anticipated|April 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Anticipated|90|||Both|21 Months|65 Years|Accepts Healthy Volunteers|||July 2008|November 8, 2010|August 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00067392||201706|
NCT00066807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000318832|Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer|A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy|PERCHE|International Breast Cancer Study Group|Yes|Terminated|August 2003|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Female|18 Years|65 Years|No|||April 2015|April 28, 2015|August 6, 2003|Yes|Yes|Poor accrual, patients were followed until completion of 5 yrs treatments|No||https://clinicaltrials.gov/show/NCT00066807||201749|
NCT00066976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030258|Studying Fetal Breathing Patterns|Classification of Fetal Breathing Patterns in the Maturing Upper Airway: Spectral Waveform Analysis of Amniotic Fluid Flow Dynamics in Normal Development, Polyhydramnios, and Oligohydramnios||National Institutes of Health Clinical Center (CC)||Completed|August 2003|March 2008||||N/A|Observational|N/A||||0|||Both|18 Years|N/A|No|||March 2008|September 26, 2015|August 7, 2003||||No||https://clinicaltrials.gov/show/NCT00066976||201738|
NCT00066404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000315899|Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions|A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies||National Cancer Institute (NCI)||Active, not recruiting|April 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|August 7, 2010|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066404||201775|
NCT00066508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316254|Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy|A Phase II Study Of PS-341 (VELCADE) In Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Jonsson Comprehensive Cancer Center||Completed|May 2003|||July 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066508||201768|
NCT00067093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC3491|Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)|||Sanofi||Completed|May 2003|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1452|||Both|18 Years|N/A|No|||April 2011|April 5, 2011|August 11, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00067093||201729|
NCT00067145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMINTER (completed)|Computer Intervention for Prevention of Weight Regain|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||300|||Both|20 Years|N/A|No|||January 2010|January 12, 2010|August 11, 2003||||No||https://clinicaltrials.gov/show/NCT00067145||201725|
NCT00070915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000606-01|Massage, Meditation, and Tai Chi for Chronic Lower Back Pain|Relaxation-Related CAM Therapies for Chronic Back Pain||Group Health Cooperative||Completed|September 2000|June 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|October 9, 2003||||No||https://clinicaltrials.gov/show/NCT00070915||201465|
NCT00068172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR88201|Study of PI-88 in Patients With Advanced Melanoma|A Phase I/II Study of PI-88 in Advanced Malignancies (Phase I), and in Advanced Melanoma (Phase II)||Progen Pharmaceuticals||Completed|July 2001|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||88|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|September 9, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068172||201647|
NCT00066391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30992|Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer|Phase II Study of Irinotecan (CPT 11) and Cisplatin (CDDP) in Metastatic or Locally Advanced Penile Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 2003|||January 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|N/A|75 Years|No|||September 2012|September 20, 2012|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066391||201776|
NCT00066599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316329|Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy|An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection||National Cancer Institute (NCI)||Completed|June 2003|June 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|2 Years|11 Years|No|||July 2004|June 18, 2013|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066599||201764|
NCT00067158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0009-1|Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1|Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||585|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|August 12, 2003||||No||https://clinicaltrials.gov/show/NCT00067158||201724|
NCT00067171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0011-1|Telephone Enhancement Procedure for Continuing Care - 1|Telephone Enhancement Procedure (TELE) for Continuing Care||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized||||339|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|August 12, 2003||||No||https://clinicaltrials.gov/show/NCT00067171||201723|
NCT00068185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08AT001315-01A1|A Study of the Pharmacokinetics of Black Cohosh|Interactions Between SERMs, Soy and Black Cohosh||National Center for Complementary and Integrative Health (NCCIH)|Yes|Terminated|August 2003|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2009|December 9, 2009|September 9, 2003|No|Yes|PI left institution, study did not continue, funding stopped|No||https://clinicaltrials.gov/show/NCT00068185||201646|
NCT00067405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000942-01A1|Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia|Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|June 2004|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|No|||April 2008|April 21, 2008|August 18, 2003||No||No||https://clinicaltrials.gov/show/NCT00067405||201705|
NCT00066430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-032|Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia|Infrared Coagulator For Treatment Of High Grade Squamous Intraepithelial Neoplasia (HSIL) in the Anal Canal In HIV Infected Individuals: A Pilot Study||AIDS Malignancy Consortium|No|Completed|September 2003|April 2006|Actual|September 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|August 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00066430||201773|
NCT00066443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA22|Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer|A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer||Canadian Cancer Trials Group|Yes|Completed|February 2003|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Female|16 Years|N/A|No|||January 2014|November 2, 2015|August 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00066443||201772|
NCT00067197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030267|Improving Motor Learning in Stroke Patients|Modulation of Motor Learning in Chronic Stroke Patients by Transcranial DC Stimulation||National Institutes of Health Clinical Center (CC)||Completed|August 2003|July 2008||||N/A|Observational|N/A||||76|||Both|18 Years|N/A|No|||July 2008|September 26, 2015|August 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00067197||201721|
NCT00065104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000512-01|Dehydroepiandrosterone Effects on HIV-1 Replication|Dehydroepiandrosterone Effects on HIV-1 Replication||National Center for Complementary and Integrative Health (NCCIH)||Completed|October 2000|April 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2006|August 16, 2006|July 17, 2003||||||https://clinicaltrials.gov/show/NCT00065104||201867|
NCT00065117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2820C00007|Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.|||AstraZeneca||Terminated|September 2003|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|July 17, 2003||||||https://clinicaltrials.gov/show/NCT00065117||201866|
NCT00067782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-067|A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy|||Bristol-Myers Squibb||Completed|December 2002|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|16 Years|N/A|No|||January 2010|April 7, 2011|August 27, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067782||201676|
NCT00066729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000318803|Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Expressing NY-ESO-1 or LAGE-1||National Cancer Institute (NCI)||Completed|May 2003|||July 2006|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2009|April 23, 2011|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066729||201754|
NCT00066898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGI-1067/042|ARISE – Aggressive Reduction of Inflammation Stops Events|“Reduction of Vascular Inflammation and Coronary Atherosclerosis With AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease”||AtheroGenics||Active, not recruiting|June 2003|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||6000|||Both|18 Years|N/A|No|||September 2006|September 29, 2006|August 6, 2003||||||https://clinicaltrials.gov/show/NCT00066898||201744|
NCT00066209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030240|Investigating Severe Acute Respiratory Syndrome (SARS)|An Investigation of the Inflammatory Response in Severe Acute Respiratory Syndrome (SARS)||National Institutes of Health Clinical Center (CC)||Completed|August 2003|May 2007||||N/A|Observational|N/A||||400|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2007|September 26, 2015|August 5, 2003||||No||https://clinicaltrials.gov/show/NCT00066209||201787|
NCT00066651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316451|Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors|Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing||National Cancer Institute (NCI)||Completed|July 2003|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|April 29, 2015|August 6, 2003||||||https://clinicaltrials.gov/show/NCT00066651||201760|
NCT00068328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-369901|Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer|Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|August 2003|||December 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1360|||Female|65 Years|N/A|No|Non-Probability Sample|Women aged 65 years and older diagnosed with adenocarcinoma of the breast.|July 2015|July 23, 2015|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068328||201635|
NCT00066482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCT01P1|Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors|Pilot Study of Cisplatin, Etoposide, Bleomycin and Escalating Dose Cyclophosphamide Therapy for Children With High Risk Malignant Germ Cell Tumors||Children's Oncology Group|Yes|Completed|July 2004|||April 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|21 Years|No|||October 2013|October 15, 2013|August 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00066482||201769|
NCT00066612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316428|S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy|Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium||Southwest Oncology Group|Yes|Completed|July 2003|May 2010|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|August 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066612||201763|
NCT00066781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N004E|Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary|A Phase II Study Of Gemcitabine (GEMZAR) And Irinotecan (CPT-11) In Previously Untreated Patients With Measurable Disease With Unknown Primary Carcinoma||Alliance for Clinical Trials in Oncology|No|Completed|February 2004|March 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|August 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066781||201751|
NCT00066547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316264|Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy|An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and Taxane Therapy||National Cancer Institute (NCI)||Active, not recruiting|May 2003|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||August 2004|December 3, 2013|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066547||201767|
NCT00068146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020308|Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma|Study of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Evaluation of the Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-Associated Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|September 2002|November 2012||||N/A|Observational|N/A|||Actual|77|||Both|8 Years|N/A|No|||November 2012|July 17, 2015|September 9, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068146||201649|
NCT00068159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030282|Cardiac Function in Patients With Hereditary Hemochromatosis|Characterization of Cardiac Function in Subjects With Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2003|||||N/A|Observational|N/A|||Actual|66|||Both|21 Years|N/A|No|||December 2015|January 6, 2016|September 9, 2003||No||No||https://clinicaltrials.gov/show/NCT00068159||201648|
NCT00068068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSC-OL002|Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases|Safety and Efficacy of Treating Refractory Cancers With the Litx™ System: Phase II Safety and Efficacy Study in Patients With Liver Metastases From Colorectal Cancer That Have Failed Chemotherapy||Light Sciences LLC||Completed|October 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||September 2006|September 18, 2006|September 4, 2003||||||https://clinicaltrials.gov/show/NCT00068068||201655|
NCT00068081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C110|Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia||NeurogesX||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2007|March 4, 2008|September 5, 2003||||||https://clinicaltrials.gov/show/NCT00068081||201654|
NCT00068094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001305|The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics|The Effect of a Probiotic on Hepatic Steatosis||National Center for Complementary and Integrative Health (NCCIH)||Terminated|July 2005|February 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|70 Years|No|||August 2006|August 16, 2006|September 5, 2003||||||https://clinicaltrials.gov/show/NCT00068094||201653|
NCT00066911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030260|Brain Mapping of Voice Control|Functional Brain Mapping of Laryngeal Sensorimotor Control in Voice Disorders||National Institutes of Health Clinical Center (CC)||Completed|August 2003|||November 2009|Actual|N/A|Observational|N/A||||174|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||November 2009|November 10, 2009|August 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00066911||201743|
NCT00067067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030269|Investigating Endothelial Precursor Cells (EPCs)|Circulating Endothelial Progenitor Cells in Gliomas||National Institutes of Health Clinical Center (CC)||Completed|August 2003|October 2004||||N/A|Observational|N/A||||84|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2004|March 3, 2008|August 8, 2003||||No||https://clinicaltrials.gov/show/NCT00067067||201731|
NCT00067080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0109|Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions|A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis||Novartis||Completed|May 2003|||July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|195|||Both|2 Years|N/A|No|||February 2011|February 25, 2011|August 11, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067080||201730|
NCT00068276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-29203|Cholecalciferol in Treating Patients With Myelodysplastic Syndrome|Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial||Comprehensive Cancer Center of Wake Forest University||Completed|July 2003|September 2006|Actual|June 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 4, 2013|September 10, 2003||||No||https://clinicaltrials.gov/show/NCT00068276||201639|
NCT00067496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030276|Modafinil to Treat Fatigue in Post-Polio Syndrome|Modafinil in the Treatment of Fatigue in Post-Polio Syndrome||National Institutes of Health Clinical Center (CC)||Terminated|August 2003|August 2006||||Phase 3|Interventional|Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||May 2005|August 26, 2008|August 20, 2003||||No||https://clinicaltrials.gov/show/NCT00067496||201698|
NCT00066183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030254|Studying Phosphorus Metabolism|Studies in Phosphorus Metabolism||National Institutes of Health Clinical Center (CC)||Completed|August 2003|January 2005||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||January 2005|March 3, 2008|August 4, 2003||||No||https://clinicaltrials.gov/show/NCT00066183||201789|
NCT00065312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5837|An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes|||Eli Lilly and Company||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||July 2006|July 18, 2006|July 21, 2003||||||https://clinicaltrials.gov/show/NCT00065312||201851|
NCT00065416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001584-01|Evaluating Therapeutic Massage for Chronic Neck Pain|||National Center for Complementary and Integrative Health (NCCIH)||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||60|||Both|20 Years|64 Years|No|||October 2004|June 23, 2005|July 22, 2003||||No||https://clinicaltrials.gov/show/NCT00065416||201843|
NCT00065806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006680|Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Efficacy of Lipitor (Atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE||Duke University|Yes|Completed|September 2003|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|221|||Both|10 Years|21 Years|No|||July 2013|July 15, 2013|August 1, 2003|Yes|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00065806||201817|
NCT00065819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR004416|HIV Symptom Management Program for African American Mothers|HIV Symptom Management With African American Mothers||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 1996|August 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||June 2003|June 23, 2005|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065819||201816|
NCT00065832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD30995-9|Reading Problems in Children Living in Urban Areas|Early Interventions for Children With Reading Problems||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 1993|June 2002||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1400|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||October 2004|June 2, 2015|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065832||201815|
NCT00065247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037752|The BONES Project: Building Healthy Bones in Children|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|June 1999|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||1500|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||June 2003|June 23, 2005|July 18, 2003||||No||https://clinicaltrials.gov/show/NCT00065247||201856|
NCT00066222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0239|Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|A Phase II Study Of Accelerated High Dose Thoracic Irradiation With Concurrent Chemotherapy For Patients With Limited Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|June 2003|November 2013|Actual|May 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|August 6, 2003|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT00066222||201786|
NCT00065559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRMTDN (terminated)|Treatment of Diabetic Nephropathy|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Terminated|April 2003|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|July 28, 2003||||No||https://clinicaltrials.gov/show/NCT00065559||201835|
NCT00065572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2820C00018|Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)|||AstraZeneca||Suspended|August 2003|February 2004|Anticipated|February 2004|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2011|January 25, 2011|July 28, 2003||||||https://clinicaltrials.gov/show/NCT00065572||201834|
NCT00066066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14242|Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers|Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers||The Forsyth Institute|No|Completed|July 2003|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|146|||Both|20 Years|N/A|No|||March 2013|March 6, 2013|August 1, 2003||No||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00066066||201797|
NCT00066664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030228|Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin|Characterization of Serum Proteomic Patterns in Neoplastic and Inflammatory Skin Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2003|March 2010|Actual|December 2007|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|423|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2012|March 14, 2012|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066664||201759|
NCT00065403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001414|Acupuncture for Irritable Bowel Syndrome|||National Center for Complementary and Integrative Health (NCCIH)||Completed|February 2004|September 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|18 Years|80 Years|No|||August 2006|August 16, 2006|July 22, 2003||||No||https://clinicaltrials.gov/show/NCT00065403||201844|
NCT00065039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSMIND (completed)|Wise Mind: Environmental Approach for Obesity Prevention|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2003|||||Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 16, 2003||||No||https://clinicaltrials.gov/show/NCT00065039||201871|
NCT00065130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-2067|Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes|Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Basal/Bolus Therapy for Patients With Gestational Diabetes||Novo Nordisk A/S|No|Completed|April 2000|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 21, 2012|July 17, 2003||||No||https://clinicaltrials.gov/show/NCT00065130||201865|
NCT00065143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0139|Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome|A Phase II Study of Clofarabine in Combination With Cytarabine (Ara-C) in Patients >/= 50 Years With Newly Diagnosed and Previously Untreated Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) (>/= 10% Bone Marrow Blasts)||M.D. Anderson Cancer Center|No|Completed|June 2003|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|50 Years|74 Years|No|||January 2012|January 20, 2012|July 17, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00065143||201864|
NCT00065156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-003|Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality|A Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion-dependent Subjects With Myelodysplastic Syndromes Associated With a Del(5q) Cytogenetic Abnormality.||Celgene|No|Completed|June 2003|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Both|18 Years|N/A|No|||October 2011|October 5, 2011|July 17, 2003|Yes|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00065156||201863|
NCT00064961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0004|Obesity Prevention After Smoking Cessation in Menopause|||National Institute on Aging (NIA)||Completed|March 2000|February 2006|Actual|February 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||100|||Female|45 Years|59 Years|Accepts Healthy Volunteers|||December 2009|December 9, 2009|July 16, 2003||||No||https://clinicaltrials.gov/show/NCT00064961||201877|
NCT00064974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-002|Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes|A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes||Celgene|Yes|Completed|June 2003|February 2007|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|215|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|July 16, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00064974||201876|
NCT00064987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HD028138-457|Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism|Role of FSH in Human Gonadal Development||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Terminated|April 2001|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|N/A|No|||April 2014|April 1, 2014|July 16, 2003|No|Yes|Recruitment was at a standstill. We are currently preparing our results for publication.|No||https://clinicaltrials.gov/show/NCT00064987||201875|
NCT00066248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0205|Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment|The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia||University of South Florida|Yes|Completed|June 2003|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|70|||Both|2 Years|20 Years|No|||January 2014|January 31, 2014|August 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00066248||201785|
NCT00066170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-SXB-22|Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy|Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy||Jazz Pharmaceuticals|No|Completed|April 2003|November 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|231|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|August 4, 2003|Yes|Yes||No|October 21, 2011|https://clinicaltrials.gov/show/NCT00066170||201790|
NCT00065429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10/IVB/001|Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer|A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion||ImmunoGen, Inc.|No|Completed|April 2003|December 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|64|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|July 23, 2003|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00065429||201842|
NCT00065442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9902B|Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy|A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma||Dendreon||Completed|July 2003|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|512|||Male|18 Years|N/A|No|||September 2010|September 2, 2010|July 23, 2003|Yes|Yes||No|May 28, 2010|https://clinicaltrials.gov/show/NCT00065442||201841|
NCT00065338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63226 (completed)|Nutritional Restriction and Activity Thermogenesis|Nutritional Restriction and Activity Thermogenesis||Mayo Clinic||Completed|June 2003|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|90|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 1, 2011|July 21, 2003||No||No||https://clinicaltrials.gov/show/NCT00065338||201849|
NCT00065351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-014|Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma|A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma||Celgene|No|Completed|July 2003|March 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|222|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|July 21, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00065351||201848|
NCT00065585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT001110|Efficacy of Acupuncture for Chronic Low Back Pain|Efficacy of Acupuncture for Chronic Low Back Pain||Group Health Cooperative|Yes|Completed|April 2004|June 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4|||640|||Both|18 Years|70 Years|No|||February 2014|February 25, 2014|July 28, 2003||No||No||https://clinicaltrials.gov/show/NCT00065585||201833|
NCT00065676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030256|Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes|Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics||National Institutes of Health Clinical Center (CC)||Recruiting|July 2003|December 2016|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|January 6, 2016|July 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00065676||201827|
NCT00065689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000212-01A1|High Intensity Light Therapy in Alzheimer's Disease|High Intensity Light Therapy in Alzheimer's Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2003|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||107|||Both|55 Years|N/A|No|||July 2006|July 24, 2006|July 31, 2003||||No||https://clinicaltrials.gov/show/NCT00065689||201826|
NCT00066677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316454|Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer|Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma||Fox Chase Cancer Center||Completed|October 2003|April 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||May 2013|June 18, 2013|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066677||201758|
NCT00066690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316456|Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer|A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer|SOFT|International Breast Cancer Study Group|Yes|Active, not recruiting|August 2003|||January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3066|||Female|N/A|N/A|No|||November 2013|November 6, 2013|August 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066690||201757|
NCT00065455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030255|Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa|Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa||National Institutes of Health Clinical Center (CC)||Completed|July 2003|May 2009||||Phase 1|Interventional|Primary Purpose: Treatment|1|||11|||Both|18 Years|N/A|No|||May 2009|September 26, 2015|July 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00065455||201840|
NCT00065468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-304|Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma|A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.|ARCC|Pfizer|Yes|Completed|July 2003|March 2011|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|626|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|July 24, 2003|Yes|Yes||No|March 22, 2012|https://clinicaltrials.gov/show/NCT00065468||201839|Efficacy data was not collected or analyzed after the primary analysis was completed.
NCT00065507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-048|Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation|Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation||Bristol-Myers Squibb|No|Completed|August 2003|May 2013|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|195|||Both|16 Years|N/A|No|||June 2013|June 17, 2013|July 28, 2003|Yes|Yes||No|February 25, 2010|https://clinicaltrials.gov/show/NCT00065507||201838|
NCT00065975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000622-01|Physical CAM Therapies for Chronic Low Back Pain|Physical CAM Therapies for Chronic Low Back Pain||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2002|December 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|20 Years|N/A|No|||August 2006|August 16, 2006|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065975||201804|
NCT00065988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-11886|The Children's Amalgam Trial|Health Effects of Dental Amalgams in Children||New England Research Institutes||Completed|September 1997|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||534|||Both|6 Years|10 Years|No|||August 2005|April 27, 2010|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065988||201803|
NCT00066352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-018|Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter|A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)||University Health Network, Toronto||Completed|September 2003|||September 2003|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2015|July 22, 2015|August 6, 2003||||||https://clinicaltrials.gov/show/NCT00066352||201779|
NCT00066365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST0221|Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma|A Phase II Study of Aerosolized GM-CSF (NSC# 613795, IND# 11042) in Patients With First Pulmonary Recurrence of Osteosarcoma||Children's Oncology Group|Yes|Completed|July 2004|December 2013|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|N/A|39 Years|No|||March 2015|March 17, 2015|August 6, 2003|Yes|Yes||No|February 11, 2015|https://clinicaltrials.gov/show/NCT00066365||201778|
NCT00065936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29HD35862|Self-Injury: Diagnosis and Treatment|Behavioral and Biochemical Mechanisms of Self-Injury||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|July 1997|June 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||37|||Both|4 Years|25 Years|No|||May 2003|June 23, 2005|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065936||201807|
NCT00065949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD21453|Magnesium Sulfate to Prevent Brain Injury in Premature Infants|Magnesium Prevention of Brain Injury in Preterm Infants||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|August 1987|February 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|12 Hours|No|||May 2003|June 23, 2005|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065949||201806|
NCT00065260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030249|Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia|A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment||National Institutes of Health Clinical Center (CC)|Yes|Completed|July 2003|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|2 Years|N/A|No|||February 2016|February 3, 2016|July 18, 2003|Yes|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT00065260||201855|
NCT00065169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH058156|Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs|Anti-Inflammation in AD: PET Imaging Supplement||University of California, Los Angeles||Completed|November 2000|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||138|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|July 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00065169||201862|
NCT00065182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/615|Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized, Phase III Study Comparing Combination IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Advanced (IIIB/IV) Non-Small Cell Lung Cancer (NSCLC)||GlaxoSmithKline|No|Completed|August 2003|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||408|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 17, 2003||||||https://clinicaltrials.gov/show/NCT00065182||201861|
NCT00066274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000315384|Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer|Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|May 2002|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2005|January 10, 2009|August 6, 2003||||No||https://clinicaltrials.gov/show/NCT00066274||201784|
NCT00065052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODHTV (completed)|Modifying the Home Television Watching Environment|Modifying the Home Television Watching Environment||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|September 2002|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|70|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 16, 2003||No||No||https://clinicaltrials.gov/show/NCT00065052||201870|
NCT00065065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSIE|A Trial of Rosiglitazone for Ulcerative Colitis|A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis||University of Pennsylvania|Yes|Completed|September 2002|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|July 16, 2003|No|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00065065||201869|
NCT00065078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD042423|Providing Birth Control Through Home Health Visits|Effectiveness of Nurse Home Contraceptive Dispensing||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|June 2003|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||600|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2005|September 9, 2005|July 16, 2003||||No||https://clinicaltrials.gov/show/NCT00065078||201868|
NCT00066703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBCSG 25-02|Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer|A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer|TEXT|International Breast Cancer Study Group|Yes|Active, not recruiting|August 2003|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2672|||Female|18 Years|N/A|No|||March 2015|March 24, 2015|August 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066703||201756|
NCT00067041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REM03:203|Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft|A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft||United Therapeutics||Terminated|March 2003|December 2003|Actual|December 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|85 Years|No|||March 2013|March 5, 2013|August 8, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067041||201733|
NCT00065533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7491|Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer|Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer||Eli Lilly and Company|No|Completed|May 2003|June 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||June 2007|June 21, 2007|July 28, 2003||||No||https://clinicaltrials.gov/show/NCT00065533||201837|
NCT00065611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030226|Steroid Treatment for Kidney Disease|Pulse Dexamethasone Over 48 Weeks for Podocyte Disease||National Institutes of Health Clinical Center (CC)||Completed|July 2003|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|2 Years|N/A|No|||September 2011|September 20, 2011|July 28, 2003||No||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00065611||201832|
NCT00065624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001062-01A2|Antioxidant Functions of Lipoic Acid|Antioxidant Functions of Lipoic Acid||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2003|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|50 Years|75 Years|No|||September 2007|September 28, 2007|July 29, 2003||||No||https://clinicaltrials.gov/show/NCT00065624||201831|
NCT00065702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000315-01|Biomarkers of Homeopathy in Fibromyalgia|||National Center for Complementary and Integrative Health (NCCIH)||Completed|October 2000|September 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||August 2006|August 17, 2006|July 31, 2003||||No||https://clinicaltrials.gov/show/NCT00065702||201825|
NCT00066456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9915|Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I Study Using Low Dose Abdominal Radiotherapy as A Docetaxel Chemosensitizer for Recurrent , Persistent Or Advanced Ovarian, Peritoneal Or Fallopian Tube Cancer||Gynecologic Oncology Group||Completed|September 2003|||July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|August 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00066456||201771|
NCT00066053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13940|Periodontitis and Cardiovascular Events or "PAVE"|Periodontal Intervention for Cardiac Events: A Pilot Trial||University at Buffalo|Yes|Completed|January 2003|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|N/A|75 Years|No|||May 2007|August 4, 2011|August 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00066053||201798|
NCT00066079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001078-01A1|Home Based Massage and Relaxation for Sickle Cell Pain|Home Based Massage and Relaxation for Sickle Cell Pain||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|August 2003|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|15 Years|65 Years|No|||August 2008|August 4, 2008|August 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00066079||201796|
NCT00066092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020112|Pegfilgrastim PBPC Mobilization Study|Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.||Amgen||Completed|April 2003|October 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|N/A|No|||February 2008|February 20, 2008|August 4, 2003||||No||https://clinicaltrials.gov/show/NCT00066092||201795|
NCT00066378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10021|Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer|An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2003|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Female|N/A|N/A|No|||October 2013|October 23, 2013|August 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00066378||201777|
NCT00065364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD038261|Improving Brain Development in Medically Healthy Premature Infants|Neurodevelopment and Experience: Behavior, Quantitative EEG and MRI||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|May 2000|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||90|||Both|28 Weeks|33 Weeks|Accepts Healthy Volunteers|||October 2004|June 23, 2005|July 21, 2003||||No||https://clinicaltrials.gov/show/NCT00065364||201847|
NCT00065273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P01HD026927|Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay|Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 1998|June 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|6 Years|60 Years|No|||June 2003|June 23, 2005|July 21, 2003||||No||https://clinicaltrials.gov/show/NCT00065273||201854|
NCT00066716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316464|Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus|A Phase II Study Of Preoperative Celecoxib/Paclitaxel/Carboplatin For Squamous Cell And Adenocarcinoma Of The Esophagus||Weill Medical College of Cornell University|No|Completed|June 2003|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||December 2009|December 7, 2009|August 6, 2003||No||No||https://clinicaltrials.gov/show/NCT00066716||201755|
NCT00066014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-12204|Clinical Investigation of Mandibular Implant Overdenture|Clinical Investigation of Mandibular Implant Overdenture||Virginia Commonwealth University|Yes|Completed|November 1998|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|N/A|No|||January 2010|February 21, 2012|August 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00066014||201801|
NCT00066144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AT000155|Use of Black Cohosh and Red Clover for the Relief of Menopausal Symptoms|Black Cohosh and Red Clover Efficacy for the Relief of Menopausal Symptoms||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|April 2003|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|112|||Female|N/A|N/A|No|||October 2007|October 11, 2007|August 4, 2003||||No||https://clinicaltrials.gov/show/NCT00066144||201792|
NCT00065221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001735-01|Ginger Control of Chemotherapy Induced Nausea and Vomiting|Trial of Encapsulated Ginger as a Treatment for Chemotherapy-Induced Nausea and Vomiting||National Center for Complementary and Integrative Health (NCCIH)||Completed|June 2003|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|180|||Both|18 Years|N/A|No|||January 2008|January 24, 2008|July 18, 2003||No||No||https://clinicaltrials.gov/show/NCT00065221||201858|
NCT00068510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000327711|Vaccine Therapy in Treating Patients With Malignant Glioma|Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas||Jonsson Comprehensive Cancer Center|Yes|Completed|June 2003|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2013|September 30, 2015|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068510||201622|
NCT00068523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICC7Y02|Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies|Immunomodulation by Ultraviolet B-Irradiation (UVB) to Facilitate Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|June 2003|||March 2004|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068523||201621|
NCT00066794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0301|S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older||Southwest Oncology Group||Completed|July 2004|January 2010|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|56 Years|N/A|No|||March 2015|March 5, 2015|August 6, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066794||201750|
NCT00065208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001120|Reiki/Energy Healing in Prostate Cancer|Effects of Energy Healing on Prostate Cancer||The Cleveland Clinic|Yes|Completed|April 2005|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|79|||Male|N/A|N/A|No|||September 2012|September 20, 2012|July 18, 2003||No||No||https://clinicaltrials.gov/show/NCT00065208||201859|
NCT00065299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-PKU|Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)|Effects of Maternal Phenylketonuria (PKU) on Pregnancy Outcome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|May 1984|April 2000||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||572|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2000|June 23, 2005|July 21, 2003||||No||https://clinicaltrials.gov/show/NCT00065299||201852|
NCT00065637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR32268|Once Weekly Parathyroid Hormone for Osteoporosis|PTH Once Weekly Research (POWR)||University of California, San Francisco||Completed|December 2003|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||50|||Female|45 Years|70 Years|No|||February 2013|February 4, 2013|July 29, 2003||||No||https://clinicaltrials.gov/show/NCT00065637||201830|
NCT00065650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001324-01|Pilot Study of Vedic Medicine for Type 2 Diabetes|||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2003|January 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|25 Years|80 Years|No|||April 2015|April 14, 2015|July 30, 2003||||No||https://clinicaltrials.gov/show/NCT00065650||201829|
NCT00065715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001428|Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)|Placebo: Physician or Pill? A Randomized Trial in a Common Cold Model Funded by NIH NCCAM Under RFA "The Placebo Effect in Clinical Practice"|PEP|University of Wisconsin, Madison|Yes|Completed|September 2003|April 2013|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|719|||Both|12 Years|N/A|No|||December 2014|December 3, 2014|July 31, 2003||No||No||https://clinicaltrials.gov/show/NCT00065715||201824|
NCT00065728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-03-15|Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD|An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients With Subfoveal Exudative Age-Related Macular Degeneration (AMD)||Alcon Research||Terminated|June 2003|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|50 Years|N/A|No|||May 2009|September 4, 2013|July 31, 2003|Yes|Yes|Management decision|No||https://clinicaltrials.gov/show/NCT00065728||201823|
NCT00066469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANHL0221|Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation|Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT)||Children's Oncology Group|Yes|Active, not recruiting|April 2004|||October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|30 Years|No|||September 2015|September 11, 2015|August 6, 2003|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00066469||201770|
NCT00065546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK55865|Human Requirements for the Nutrient Choline|Human Requirements for the Nutrient Choline||University of North Carolina, Chapel Hill|Yes|Completed|June 2007|January 2012|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|43|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||January 2012|January 5, 2012|July 28, 2003||No||No||https://clinicaltrials.gov/show/NCT00065546||201836|
NCT00065234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001065-01A1|Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)|Acupuncture to Prevent Postoperative Paralytic Ileus||National Center for Complementary and Integrative Health (NCCIH)||Suspended|September 2003|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||100|||Both|18 Years|N/A|No|||August 2006|August 16, 2006|July 18, 2003||||No||https://clinicaltrials.gov/show/NCT00065234||201857|
NCT00065325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238IL/0048|The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer|A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy|EFECT|AstraZeneca||Completed|August 2003|September 2014|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|694|||Female|32 Years|91 Years|No|||February 2015|February 23, 2015|July 21, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00065325||201850|
NCT00065845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HD041249|Colpopexy and Urinary Reduction Efforts (CARE) Protocol|CARE: A Randomized Trial of Colpopexy and Urinary Reduction Efforts|CARE|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|April 2002|April 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|322|||Female|N/A|N/A|No|||October 2010|January 9, 2011|August 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00065845||201814|
NCT00065793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1232|VLDL and LDL Particle Types as Coronary Heart Disease Risk Factors|||Brigham and Women's Hospital||Completed|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1478|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nurses Health Study Health Professionals Follow-up Study|January 2015|January 30, 2015|July 31, 2003||No||No||https://clinicaltrials.gov/show/NCT00065793||201818|
NCT00065962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P01HD035465|Secretin for the Treatment of Autism|Multisite Controlled Secretin Trial in Autism||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|June 1999|May 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||85|||Both|3 Years|12 Years|No|||June 2003|June 23, 2005|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065962||201805|
NCT00065663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-093|Gene Therapy to Improve Wound Healing in Patients With Diabetes|Growth Factor Gene Therapy for Wound Healing||Tissue Repair Company||Completed|August 2002|December 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||21|||Both|18 Years|N/A|No|||November 2007|November 16, 2007|July 30, 2003||||||https://clinicaltrials.gov/show/NCT00065663||201828|
NCT00066950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14251|Prevention Management Model for Early Childhood Caries (MAYA Project)|Prevention Management Model for Early Childhood Caries||University of California, San Francisco|Yes|Completed|March 2003|August 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|361|||Both|18 Years|33 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|August 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00066950||201740|
NCT00062530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AI047490|Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers|Development of an Oral Prime-Boost AIDS Vaccine to Elicit Broadly Neutralizing Antibodies Against HIV-1||National Institute of Allergy and Infectious Diseases (NIAID)||Not yet recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 25, 2008|June 9, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00062530||202052|
NCT00065897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD031991|Prenatal Testing: Amniocentesis Versus Transabdominal Chorionic Villus Sampling (TA CVS)|Randomized Trial of 11-14 Week Amniocentesis and Transabdominal Chorionic Villus Sampling (TA CVS)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 1996|August 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||6400|||Female|34 Years|60 Years|Accepts Healthy Volunteers|||June 2003|June 23, 2005|August 1, 2003||||No||https://clinicaltrials.gov/show/NCT00065897||201810|
NCT00066157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0048|Alzheimer's Disease: Therapeutic Potential of Estrogen|Alzheimer's Disease: Therapeutic Potential of Estrogen||University of Wisconsin, Madison|Yes|Completed|September 2001|January 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|42|||Female|55 Years|90 Years|No|||September 2010|October 1, 2015|August 4, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00066157||201791|
NCT00066963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13058|Fluoride Varnish Randomized Clinical Trial|Comprehensive Oral Health Center for Discovery: New Strategies for Enhancing Tissue Integrity and Repair Early Childhood Caries: Prevention and Treatment Outcomes||University of California, San Francisco|Yes|Completed|October 2002|December 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|376|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||April 2014|April 30, 2014|August 7, 2003||No||No|April 5, 2011|https://clinicaltrials.gov/show/NCT00066963||201739|In a protocol deviation, children received placebo varnish for 10 months; this would be expected to bias the study toward the null of no difference among groups. The study did not address FV efficacy for children with extant or past caries.
NCT00069537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 001|Continuous Glucose Monitors for Children With Diabetes Mellitus|DirecNet Inpatient Study to Test the Accuracy of Continuous Blood Glucose Monitoring Devices in Children With Type 1 Diabetes||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|May 2002|November 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|1 Year|17 Years|No|||September 2005|September 21, 2005|September 29, 2003||||No||https://clinicaltrials.gov/show/NCT00069537||201556|
NCT00090909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000380845|Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study Of Gemcitabine, Cisplatin, and Dexamethasone In Patients With Relapsed Or Refractory Hodgkin Lymphoma||Jonsson Comprehensive Cancer Center||Completed|June 2003|||March 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|September 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090909||200068|
NCT00069914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030310|Immune Response to Influenza Vaccine in HIV-Infected Individuals|Immune Response to Influenza Vaccination in HIV-Infected Individuals||National Institutes of Health Clinical Center (CC)||Completed|September 2003|September 2005||||N/A|Observational|N/A||||165|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|October 2, 2003||||No||https://clinicaltrials.gov/show/NCT00069914||201529|
NCT00070499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00764|Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia|A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2004|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|406|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|October 3, 2003|Yes|Yes||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00070499||201493|
NCT00069030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 044|Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) With the Plasmid Cytokine Adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2003|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|70|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|September 12, 2003||||||https://clinicaltrials.gov/show/NCT00069030||201591|
NCT00069056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030291|Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema|A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|September 2003|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||4|||Both|18 Years|N/A|No|||August 2007|September 26, 2015|September 13, 2003||||No||https://clinicaltrials.gov/show/NCT00069056||201590|
NCT00071071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-CD4-007|Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.|||Emergent Product Development Seattle LLC||Completed|April 2003|||May 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|October 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00071071||201453|
NCT00070889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000147-01|Brain Cell Injury in Patients With A First Episode of Psychosis|Oxidative Cell Injury: First Episode Psychotic Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 1999|August 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||30|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||July 2006|August 17, 2006|October 9, 2003||||No||https://clinicaltrials.gov/show/NCT00070889||201467|
NCT00091234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06031|Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP|AML-19|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|June 2004|||December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|279|||Both|61 Years|N/A|No|||July 2012|July 23, 2012|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00091234||200051|
NCT00070343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000331927|Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301|Continuation Protocol For G3139 (Bcl-2 Antisense Oligonucleotide) And Dacarbazine In Patients With Malignant Melanoma Who Responded To This Combination In Protocol GM301||National Cancer Institute (NCI)||Active, not recruiting|August 2003|||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2004|January 3, 2014|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070343||201500|
NCT00070083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000329985|Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|A Phase I Study Of G3139 Antisense Oligonucleotide (Oblimersen) In Combination With CHOP And Rituximab In Untreated Advanced Stage Diffuse Large B Cell Lymphoma||National Cancer Institute (NCI)||Completed|July 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|19 Years|N/A|No|||June 2005|April 4, 2009|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070083||201518|
NCT00069602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 002|Assessing Continuous Glucose Monitors in Healthy Children|DirecNet Pilot Study to Assess the Accuracy of Continuous Glucose Monitors in Normal Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 2002|November 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||November 2005|November 29, 2005|September 29, 2003||||No||https://clinicaltrials.gov/show/NCT00069602||201551|
NCT00071097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006778|TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients|A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.||Tibotec Pharmaceuticals, Ireland||Completed|December 2004|November 2007|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|330|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|October 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00071097||201451|
NCT00071344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040004|Analysis of Brain Metastasis in Patients With Lung Cancer|Analysis of Brain Metastasis in Patients With Lung Cancer||National Institutes of Health Clinical Center (CC)||Completed|October 2003|October 2004||||N/A|Observational|N/A||||78|||Both|N/A|N/A|No|||October 2004|March 3, 2008|October 20, 2003||||No||https://clinicaltrials.gov/show/NCT00071344||201433|
NCT00069420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH064568|Cognitive Motivational Behavior Therapy for Gamblers|Cognitive-Motivational Behavior Therapy for Gamblers||University at Albany|No|Completed|September 2003|May 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|17 Years|N/A|No|||December 2013|December 30, 2013|September 24, 2003||||No||https://clinicaltrials.gov/show/NCT00069420||201565|
NCT00069316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030306|Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease|A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV)||National Institutes of Health Clinical Center (CC)||Completed|September 2003|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2011|September 26, 2015|September 22, 2003||No||No||https://clinicaltrials.gov/show/NCT00069316||201572|
NCT00069329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030298|Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease|A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease||National Institutes of Health Clinical Center (CC)||Terminated|September 2003|May 2015||||N/A|Observational|N/A|||Actual|70|||Both|N/A|N/A|No|||May 2015|May 8, 2015|September 22, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00069329||201571|
NCT00069654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030312|Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease|Dietary Nitrate/Nitrite as Sources of Bioactive Nitric Oxide in Patients With Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|September 2003|||May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1|||42|||Both|22 Years|N/A|No|||May 2009|September 26, 2015|September 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00069654||201547|
NCT00069212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030292|Psychobiological Mechanisms of Resilience to Trauma|Psychobiological Mechanisms of Resilience to Trauma||National Institutes of Health Clinical Center (CC)||Completed|September 2003|September 2012||||N/A|Observational|N/A|||Actual|210|||Both|18 Years|N/A|No|||September 2012|October 9, 2014|September 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00069212||201579|
NCT00069225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030297|Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder|Cerebral Structure and Function Before and After Pharmacological and Psychological Treatment for PTSD||National Institutes of Health Clinical Center (CC)||Completed|September 2003|September 2005||||N/A|Observational|N/A||||95|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|September 17, 2003||||No||https://clinicaltrials.gov/show/NCT00069225||201578|
NCT00069238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030304|Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas|Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|September 2003|June 2017|Anticipated|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|17 Years|N/A|No|||December 2015|December 15, 2015|September 17, 2003||No||No|October 7, 2015|https://clinicaltrials.gov/show/NCT00069238||201577|
NCT00071383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040005|Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2|Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2||National Institutes of Health Clinical Center (CC)||Completed|October 2003|November 2004||||N/A|Observational|N/A||||78|||Female|N/A|N/A|No|||November 2004|March 3, 2008|October 20, 2003||||No||https://clinicaltrials.gov/show/NCT00071383||201430|
NCT00071396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-368|Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders|Continuous Infusion Followed by Subcutaneous Injection of Campath-1H Plus Rituximab in the Treatment of CD52- and CD20-Positive Refractory or Relapsed Chronic Lymphoid Disorders||M.D. Anderson Cancer Center|No|Completed|October 2002|August 2007|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|15 Years|N/A|No|||August 2012|August 1, 2012|October 21, 2003|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00071396||201429|
NCT00069511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT-231B-02:01|12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.|||Unither Pharmaceuticals||Active, not recruiting|July 2003|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|18 Years|65 Years|No|||June 2004|June 23, 2005|September 29, 2003||||||https://clinicaltrials.gov/show/NCT00069511||201558|
NCT00068497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03171|Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer|Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)||National Cancer Institute (NCI)||Completed|August 2003|||December 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||January 2013|January 11, 2013|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068497||201623|
NCT00069069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030293|E-Selectin Nasal Instillation to Prevent Secondary Stroke|Induction of Mucosal Tolerance to Human E-Selectin for the Secondary Prevention of Stroke||National Institutes of Health Clinical Center (CC)||Not yet recruiting|September 2003|November 2025|Anticipated|November 2025|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|58|||Both|45 Years|N/A|No|||May 2015|June 9, 2015|July 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00069069||201589|
NCT00069082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-02-05|Intranasal Civamide for Episodic Cluster Headache|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache||Winston Laboratories||Completed|August 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|September 15, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00069082||201588|
NCT00068445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N01C3|Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer|The Efficacy of Lamotrigine in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double Blind, Placebo-Controlled Trial||Alliance for Clinical Trials in Oncology|Yes|Completed|February 2004|November 2013|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|131|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068445||201627|
NCT00068458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97301|Survival TRaining for ENhancing Total Health (STRENGTH)|A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer||Wake Forest NCORP Research Base|Yes|Completed|September 2003|January 2005|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|39|||Female|18 Years|N/A|No|||April 2013|April 3, 2013|September 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00068458||201626|
NCT00071136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7221|Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer||Eli Lilly and Company||Completed|December 2003|August 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|October 13, 2003||||||https://clinicaltrials.gov/show/NCT00071136||201448|
NCT00071656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH065927|Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I|Psychosocial Treatment for ADHD Inattentive Type I||University of California, San Francisco||Completed|September 2002|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||60|||Both|7 Years|11 Years|No|||August 2013|August 6, 2013|October 29, 2003||||No||https://clinicaltrials.gov/show/NCT00071656||201409|
NCT00068614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMXA1103|HER-2 Protein Vaccine in Treating Women With Breast Cancer|A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|July 2003|||October 2005|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2014|February 4, 2014|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068614||201616|
NCT00068991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA Project 2|HIV Educational Programs for Villagers of Funan County or Yingzhou District, Anhui Province, China|A Cluster-Randomized Trial to Evaluate the Efficacy of a Combined Individual- and Community-Based Behavioral Intervention to Improve Quality of Life for HIV-Positive Villagers in Rural China (China CIPRA Project 2)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Withdrawn||June 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|May 29, 2015|September 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00068991||201594|
NCT00069199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030294|Optical Coherence Tomography Comparative Study|Optical Coherence Tomography Comparative Study||National Institutes of Health Clinical Center (CC)||Completed|September 2003|August 2005||||N/A|Observational|N/A||||120|||Both|N/A|N/A|No|||August 2005|March 3, 2008|September 17, 2003||||No||https://clinicaltrials.gov/show/NCT00069199||201580|
NCT00067665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(DK62030)|Hypertension in Hemodialysis|Hypertension in Hemodialysis||Indiana University|No|Completed|August 2003|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2011|March 25, 2011|August 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00067665||201685|
NCT00067678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000323-01|Soy Protein in Early Diabetic Nephropathy|Soy Protein in Early Diabetic Nephropathy||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2001|June 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|40 Years|No|||August 2006|August 16, 2006|August 25, 2003||||No||https://clinicaltrials.gov/show/NCT00067678||201684|
NCT00091520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003355|A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure|Follow-up Serial Infusions of Natrecor(Nesiritide) in the Management of Patients With Heart Failure-FUSION II||Scios, Inc.||Completed|April 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|920|||Both|18 Years|N/A|No|||March 2010|May 19, 2011|September 9, 2004||||||https://clinicaltrials.gov/show/NCT00091520||200032|
NCT00069589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-097|Alopecia Areata Registry|Alopecia Areata Registry and Immunogenetic Mechanisms|NAAR|M.D. Anderson Cancer Center|No|Recruiting|November 2001|November 2099|Anticipated|November 2099|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|3100|Samples With DNA|DNA will be analyzed to learn the link between gene markers of traites of alopecia areata.      Sera will be used to analyse cytokins. Lymphocytes will be used for the creation of B-cell      lines.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with alopecia areata (AA), both children and adults, who have been diagnosed by a        physician with alopecia universalis, alopecia totalis, patchy persistent AA, or transient        mild AA. Family members (related by blood) of these patients, preferably sib-pairs plus        parents and multiplex families(persons with at least three family members with AA or        alopecia universalis and alopecia totalis).        Also, healthy individuals who are unaffected, non-blood related individuals and do not        live in the same household with alopecia areata patient are needed as controls.|October 2015|October 27, 2015|September 29, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00069589||201552|
NCT00068432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0288|Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer||M.D. Anderson Cancer Center|No|Completed|December 2003|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|N/A|N/A|No|||January 2012|January 9, 2012|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068432||201628|
NCT00068692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02959|Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery|Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil||National Cancer Institute (NCI)||Terminated|October 2003|||January 2100|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|3000|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|September 10, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00068692||201613|
NCT00069108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO16967|A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer|An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX4") as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy||Hoffmann-La Roche||Completed|July 2003|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|627|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 15, 2003|Yes|Yes||No|January 27, 2016|https://clinicaltrials.gov/show/NCT00069108||201586|
NCT00069121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO16968|A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer|A Randomized, Open-label Study of the Effect of Intermittent Xeloda in Combination With Eloxatin, Versus Fluorouracil/Leucovorin, on Disease-free Survival in Patients Who Have Undergone Surgery for Colon Cancer.||Hoffmann-La Roche||Completed|January 2003|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1886|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|September 15, 2003|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00069121||201585|
NCT00071604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062849|Medication Adherence in Older People With Psychosis|Medication Adherence in Older Psychotic People||Veterans Medical Research Foundation||Active, not recruiting|September 2002|May 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|240|||Both|40 Years|N/A|No|||April 2008|May 3, 2013|October 29, 2003||||No||https://clinicaltrials.gov/show/NCT00071604||201413|
NCT00069693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030314|Evaluation of Chronic Orthostatic Intolerance|Clinical Laboratory Evaluation of Chronic Orthostatic Intolerance||National Institutes of Health Clinical Center (CC)||Completed|September 2003|August 2008||||N/A|Observational|N/A||||200|||Both|10 Years|N/A|Accepts Healthy Volunteers|||August 2008|September 26, 2015|September 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00069693||201545|
NCT00069706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-03-25|Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients|Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients||Alcon Research||Completed|July 2003|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|118|||Both|18 Years|N/A|No|||February 2012|February 11, 2012|September 30, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00069706||201544|
NCT00069485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI047086-03|Resistance to HIV Infection|Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|December 1995|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2007|September 17, 2007|September 26, 2003||||No||https://clinicaltrials.gov/show/NCT00069485||201560|
NCT00067691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001029-01|Acupuncture for Shortness of Breath in Cancer Patients|Acupuncture for Shortness of Breath in Cancer Patients||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2001|November 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2006|August 16, 2006|August 25, 2003||||No||https://clinicaltrials.gov/show/NCT00067691||201683|
NCT00071630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064484|Therapeutic Processes and Treatment Outcome in Adolescents With Anxiety Disorders|Process as a Predictor of Outcomes in CBT for Youth||Temple University||Completed|September 2002|August 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|8 Years|13 Years|No|||September 2008|November 6, 2013|October 29, 2003||||No||https://clinicaltrials.gov/show/NCT00071630||201411|
NCT00071994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02948|Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)|A Phase II Study of ZD1839 (Iressa, Gefitinib, NSC 715055) in Advanced Unresectable Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|February 2004|||May 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00071994||201385|
NCT00068653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000327805|Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer|Phase II Study of the Combination of ZD1839 (Iressa) and Celecoxib in Patients With Platinum Refractory Non-Small Cell Lung Cance||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 2003|May 2008|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068653||201615|
NCT00069186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGI-ALS-III-01|Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis|A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis||The Avicena Group||Active, not recruiting|June 2003|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||107|||Both|21 Years|80 Years|No|||April 2005|June 23, 2005|September 17, 2003||||||https://clinicaltrials.gov/show/NCT00069186||201581|
NCT00067418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030270|Light Scattering Spectroscopy to Determine Brain Tumors|Spectroscopic Determination of Brain Tumor Cells||National Institutes of Health Clinical Center (CC)||Completed|August 2003|October 2004||||N/A|Observational|N/A||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2004|March 3, 2008|August 18, 2003||||No||https://clinicaltrials.gov/show/NCT00067418||201704|
NCT00067431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-552|A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children|A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children||Abbott||Terminated|July 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|3 Years|10 Years|No|||August 2006|August 2, 2006|August 19, 2003||||||https://clinicaltrials.gov/show/NCT00067431||201703|
NCT00067704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020511|Emotional Disclosure in HIV|Efficacy of an Emotional Disclosure Intervention in HIV||University of Miami|No|Completed|February 2004|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|283|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|August 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00067704||201682|
NCT00071669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH061589|Acupuncture as a Supplemental Treatment for Bipolar Depression|Adjunctive Acupuncture as a Treatment for Bipolar Depression||University of Texas Southwestern Medical Center||Completed|November 2001|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|No|||November 2005|April 12, 2013|October 29, 2003||||No||https://clinicaltrials.gov/show/NCT00071669||201408|
NCT00069342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030301|Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases|Health Beliefs and Health Behavior Practices Among Minorities With Rheumatic Diseases||National Institutes of Health Clinical Center (CC)||Completed|September 2003|||||N/A|Observational|Time Perspective: Prospective|||Actual|140|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|September 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00069342||201570|
NCT00069095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO16966|A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer|A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|July 2003|April 2009|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|2035|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|September 15, 2003|Yes|Yes||No|December 11, 2015|https://clinicaltrials.gov/show/NCT00069095||201587|
NCT00069381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062347|Treatment for Women With Post-Traumatic Stress Disorder Related to Childhood Abuse|Skills Training, Exposure, and Their Combination in Childhood Abuse PTSD||New York University School of Medicine||Completed|April 2002|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|144|||Female|22 Years|65 Years|No|||March 2013|March 27, 2013|September 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00069381||201567|
NCT00069550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD024448|Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome|Pathogenesis of Rett Syndrome: Natural History and Treatment||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|September 2004|June 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|1 Year|15 Years|No|||December 2004|June 23, 2005|September 29, 2003||||||https://clinicaltrials.gov/show/NCT00069550||201555|
NCT00071903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040010|The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study|The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study||National Institutes of Health Clinical Center (CC)||Completed|October 2003|July 2008||||N/A|Observational|N/A||||18|||Both|2 Years|50 Years|No|||July 2008|July 19, 2008|November 3, 2003||No||No||https://clinicaltrials.gov/show/NCT00071903||201392|
NCT00068783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03182|S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer|A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)||National Cancer Institute (NCI)||Completed|October 2003|||June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068783||201607|
NCT00069459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100006|Seasonal Affective Depression (SAD) Study|See Detailed Description||GlaxoSmithKline||Completed|September 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||250|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|September 25, 2003||||||https://clinicaltrials.gov/show/NCT00069459||201562|
NCT00069472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-107|Genetic Registry for Rheumatoid Arthritis|Genetics of Rheumatoid Arthritis Registry|NARAC|Northwell Health|No|Completed|October 2002|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|1062|Samples With DNA|DNA, plasma, serum and cells|Both|18 Years|N/A|No|Non-Probability Sample|Persons with RA who have two living biological parents. Parents can be affected or        unaffected with RA. We call the family units "trios".|September 2015|September 9, 2015|September 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00069472||201561|
NCT00069680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030313|Genetic Analysis of Gray Platelet Syndrome|Genetic Analysis of Gray Platelet Syndrome||National Institutes of Health Clinical Center (CC)||Completed|September 2003|||||N/A|Observational|N/A|||Actual|123|||Both|1 Year|80 Years|No|||July 2015|August 7, 2015|September 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00069680||201546|
NCT00071942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03131|Vaccine Therapy in Treating Patients With Metastatic Breast Cancer|A Phase I Trial of An Admixture of Recombinant Vaccinia Virus That Express DF3/MUC1 and rV-TRICOM (B7.ICAM-1, and LFA-3) in Patients With Metastatic Adenocarcinoma of The Breast||National Cancer Institute (NCI)||Terminated|October 2003|||November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00071942||201389|
NCT00068718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1803.00|Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant|Donor Lymphocyte Infusion for the Treatment of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|May 2003|||May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||July 2015|July 31, 2015|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068718||201612|
NCT00067522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD40125|Preventing Unplanned Pregnancies in HIV Infected Zambian Couples|Family Planning Promotion to Prevent Unplanned Pregnancies in HIV Infected Zambian Couples||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|January 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||5000|||Both|16 Years|38 Years|No|||September 2005|June 28, 2007|August 21, 2003||||No||https://clinicaltrials.gov/show/NCT00067522||201696|
NCT00072007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 34/02|Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL|2-CDA and Rituximab as Remission Induction and Rituximab as In Vivo Purging Prior to Peripheral Stem Cell Mobilization in Patients With Chronic Lymphocytic Leukemia (CLL) - A Prospective Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|June 2002|October 2010|Actual|March 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|65 Years|No|||May 2012|May 14, 2012|November 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00072007||201384|
NCT00069862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC-134-102|Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia|Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia||Sanofi||Completed|September 2003|November 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|October 2, 2003||||||https://clinicaltrials.gov/show/NCT00069862||201533|
NCT00069004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1045|A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth|Prevalence of Morphologic and Metabolic Abnormalities in Vertically HIV-Infected and Uninfected Children and Youth||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2003|August 2005|Actual|||N/A|Observational|N/A||||450|||Both|7 Years|25 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|September 12, 2003||||No||https://clinicaltrials.gov/show/NCT00069004||201593|
NCT00069017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP100|Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate|A Phase II, Randomized, Double-Blind Study to Evaluate the Effects of MEDI-522, a Humanized MAb to Integrin Alpha V Beta 3, On Disease Activity and Progression of Joint Damage in Pts With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate||MedImmune LLC||Completed|September 2003|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||November 2007|November 26, 2007|September 12, 2003||||No||https://clinicaltrials.gov/show/NCT00069017||201592|
NCT00067535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0003-1|Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1|Potential Interactions Between IV Cocaine and RPR 102681||National Institute on Drug Abuse (NIDA)||Completed|June 2003|June 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|16|||Both|18 Years|45 Years|No|||February 2009|February 2, 2009|August 21, 2003||||||https://clinicaltrials.gov/show/NCT00067535||201695|
NCT00069355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030296|Propranolol for the Treatment of Acute Stress Disorder|Propranolol For the Treatment of Acute Stress Disorder||National Institutes of Health Clinical Center (CC)||Completed|September 2003|October 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||October 2004|March 3, 2008|September 23, 2003||||No||https://clinicaltrials.gov/show/NCT00069355||201569|
NCT00069368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORSCOR dk64538 (completed)|ORWH:SCOR on Sex and Gender Factors Affecting Women's Incontinence|ORWH:SCOR on Sex and Gender Factors Affecting Women's Incontinence||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|July 2003|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|2161|||Female|44 Years|73 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 40-69 on 1/1/99 who have been Kaiser Permanente members since age 18 and have        had half or more of their deliveries at Kaiser Permanente or are nulliparous and have        diabetes.|September 2014|September 25, 2014|September 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00069368||201568|
NCT00090558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040268|Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease|Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2004|September 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||September 2005|March 3, 2008|August 27, 2004||||No||https://clinicaltrials.gov/show/NCT00090558||200090|
NCT00090571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-102|Juvenile Rheumatoid Arthritis Research Registry|Research Registry for Juvenile Arthritis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|No|Recruiting|October 1994|||September 2009|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|whole blood, serum, Pax gene|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|siblings affected with JIA|June 2009|June 5, 2009|August 27, 2004||No||No||https://clinicaltrials.gov/show/NCT00090571||200089|
NCT00072046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-90206|Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)|A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma||Alliance for Clinical Trials in Oncology|Yes|Completed|October 2003|November 2012|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|732|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|November 4, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072046||201381|
NCT00069433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4339|Enhancing the Outcome of Skills Training for People With Schizophrenia|Skills Training for Schizophrenia: Enhancing Outcomes||New York State Psychiatric Institute|No|Completed|April 2001|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||60|||Both|18 Years|55 Years|No|||September 2013|September 23, 2013|September 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00069433||201564|
NCT00069446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGF2763g|A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers|An Exploratory, Double-Blind, Randomized, Placebo Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers||Genentech, Inc.||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|80 Years|No|||December 2006|December 8, 2006|September 25, 2003||||No||https://clinicaltrials.gov/show/NCT00069446||201563|
NCT00069615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 003|Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children|DirecNet Pilot Study to Evaluate the GlucoWatch G2 Biographer in the Management of Type 1 Diabetes in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|February 2003|June 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||15|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||September 2005|September 21, 2005|September 29, 2003||||No||https://clinicaltrials.gov/show/NCT00069615||201550|
NCT00070824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000960-01A1|Functional Brain Imaging - Acupuncture and Osteoarthritis|Functional Brain Imaging - Acupuncture and Osteoarthritis||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|January 2004|April 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|16|||Both|40 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 6, 2007|October 8, 2003||||No||https://clinicaltrials.gov/show/NCT00070824||201472|
NCT00071058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040011|Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer|A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection||National Institutes of Health Clinical Center (CC)|No|Completed|October 2003|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|October 9, 2003|Yes|Yes||No|August 13, 2012|https://clinicaltrials.gov/show/NCT00071058||201454|
NCT00069784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS6035|The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)|A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)|ORIGIN|Sanofi|Yes|Completed|August 2003|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12537|||Both|50 Years|N/A|No|||January 2013|January 24, 2013|October 1, 2003|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00069784||201539|
NCT00069797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1233|Epidemiology of Coronary Heart Disease in Men Aged 40 and Over|Epidemiology of Coronary Heart Disease in Men Aged 40 and Over||University of Pittsburgh||Completed|September 2003|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1027|Samples With DNA|Blood samples (serum and plasma), buffy coat for DNA|Male|40 Years|49 Years|No|Probability Sample|Male community members from geographically defined areas (Pittsburgh, PA, Honolulu, HI,        and Japan)|January 2013|January 14, 2013|October 1, 2003||No||No||https://clinicaltrials.gov/show/NCT00069797||201538|
NCT00069524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001782-01|Antihyperlipidemic Effects of Oyster Mushrooms|Antihyperlipidemic Effects of Oyster Mushrooms||National Center for Complementary and Integrative Health (NCCIH)||Completed|June 2004|May 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2007|September 25, 2007|September 29, 2003||||||https://clinicaltrials.gov/show/NCT00069524||201557|
NCT00068822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1912-03|Vertebroplasty for the Treatment of Fractures Due to Osteoporosis|Investigational Vertebroplasty Efficacy and Safety Trial (INVEST)||Mayo Clinic|Yes|Completed|April 2003|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|50 Years|N/A|No|||September 2012|September 24, 2012|September 10, 2003|Yes|Yes||No|August 7, 2012|https://clinicaltrials.gov/show/NCT00068822||201605|The possible role of the placebo effect on outcomes remains unclear. Crossover at 1 month was allowed, which complicated the interpretation of between-group outcome differences. Other medical treatments received were not compared to study groups.
NCT00070863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH064562|Treatment for Men Who Are Abusive to Their Partners|Behavior Therapy for Partner Violent Men||University of Maryland, Baltimore County||Active, not recruiting|June 2002|||December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 19, 2013|October 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00070863||201469|
NCT00069823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|157|Study of Acid Reflux in Asthma|The Study of Acid Reflux in Asthma||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|September 2003|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|October 1, 2003|Yes|Yes||No|May 14, 2010|https://clinicaltrials.gov/show/NCT00069823||201536|
NCT00067314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDOABC-4439-001|Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy|A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer||Pfizer||Completed|June 2003|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Female|18 Years|N/A|No|||January 2012|January 13, 2012|August 15, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00067314||201712|
NCT00067639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0164|Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma|Pegfilgrastim (Neulasta) for Mobilization of Peripheral Blood Progenitor Cells (PBPC) in Patients With Multiple Myeloma||M.D. Anderson Cancer Center|No|Completed|December 2003|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|August 25, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00067639||201687|
NCT00067652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BODYIMAGE (completed)|Improving Body Image in Middle Schoolers|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2003|November 2003||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|11 Years|14 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 25, 2003||||No||https://clinicaltrials.gov/show/NCT00067652||201686|
NCT00070486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000334573|Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer|Randomized Phase II Study of Eicosanoid Pathway Modulators and Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|December 2003|May 2011|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|140|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070486||201494|
NCT00069875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4842|A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer|Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined With Two Different Doses of LY293111 or Placebo in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|September 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||195|||Both|18 Years|N/A|No|||December 2007|December 17, 2007|October 2, 2003||||||https://clinicaltrials.gov/show/NCT00069875||201532|
NCT00069901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGT201|Phase II CT-2103/Carboplatin in Ovarian Cancer|CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study||CTI BioPharma||Completed|February 2003|September 2006|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Female|18 Years|N/A|No|||September 2008|September 18, 2008|October 2, 2003||||||https://clinicaltrials.gov/show/NCT00069901||201530|
NCT00068861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-PPCOS|Treatment of Infertility in Women With Polycystic Ovary Syndrome|Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|November 2002|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||678|||Female|18 Years|39 Years|No|||September 2005|September 28, 2007|September 10, 2003||||||https://clinicaltrials.gov/show/NCT00068861||201602|
NCT00068224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030264|Clinical and Molecular Investigations Into Ciliopathies|Clinical and Molecular Investigations Into Ciliopathies||National Institutes of Health Clinical Center (CC)||Recruiting|September 2003|||||N/A|Observational|N/A|||Anticipated|500|||Both|6 Months|80 Years|No|||November 2015|November 17, 2015|September 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00068224||201643|
NCT00067899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSVER (completed)|Oxidative Stress and Vitamin E Requirements|Oxidative Stress and Vitamin E Requirements||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|September 2000|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||99|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|August 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00067899||201667|
NCT00067912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7999|Duloxetine vs. Active Comparator for the Treatment of Depression|Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder||Eli Lilly and Company||Completed|April 2003|March 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|18 Years|N/A|No|||May 2007|May 17, 2007|August 29, 2003||||||https://clinicaltrials.gov/show/NCT00067912||201666|
NCT00068848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD42413|Quick Start Approach to Birth Control Pills|RCT of a Novel Oral Contraceptive Initiation Method||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|February 2003|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||2000|||Female|N/A|24 Years|Accepts Healthy Volunteers|||April 2007|April 9, 2007|September 10, 2003||||No||https://clinicaltrials.gov/show/NCT00068848||201603|
NCT00068978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI047062-03|Analysis of Immune Responses to HIV Vaccines|Flow Cytometry Study of T Cell Responses to HIV Vaccines||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2007|September 17, 2007|September 12, 2003||||No||https://clinicaltrials.gov/show/NCT00068978||201595|
NCT00068042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGA-0435-003|A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly|A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly||Pfizer||Completed|April 2003|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||April 2008|April 3, 2008|September 4, 2003||||||https://clinicaltrials.gov/show/NCT00068042||201657|
NCT00068055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-107|IVIG - West Nile Encephalitis: Safety and Efficacy|A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (OMR-IGG-AM) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2003|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|N/A|No|||July 2009|February 3, 2011|September 4, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068055||201656|
NCT00067743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CRPS-001|A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)|A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)|CRPS|Celgene|Yes|Completed|August 2003|August 2007|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2006|December 28, 2007|August 26, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00067743||201679|
NCT00067756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-2001|4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?|"4 Phenyl Butyrate Mediated Secretion Rescue in Alpha 1-Antitrypsin Deficient Individuals"||University of Florida|Yes|Completed|November 2001|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||April 2013|January 2, 2014|August 26, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00067756||201678|
NCT00067327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001301-01A1|Treatment of Multiple Sclerosis Using Over the Counter Inosine|Treatment of Multiple Sclerosis Using Over the Counter Inosine||National Center for Complementary and Integrative Health (NCCIH)||Completed|February 2002|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|No|||March 2006|March 16, 2006|August 15, 2003||||||https://clinicaltrials.gov/show/NCT00067327||201711|
NCT00067340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19945-C|Caries Transmission Prevention in Alaska Native Infants|Northwest Alaska Center to Reduce Oral Health Disparity Project 2: Caries Transmission Prevention in Alaska Native Infants||University of Washington|Yes|Terminated|April 2003|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2010|May 29, 2015|August 15, 2003||No|Unable to recruit sufficient number of subjects|No||https://clinicaltrials.gov/show/NCT00067340||201710|
NCT00067210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030272|Reducing Seizure Frequency Using Cooling of the Head and Neck|Cooling of the Head and Neck to Reduce Seizure Frequency: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|August 2003|May 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||5|||Both|21 Years|65 Years|No|||June 2008|November 25, 2009|August 12, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00067210||201720|
NCT00067223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030273|Studying Use-Dependent Plasticity|Bi-hemispheric Plasticity Elicited By Unilateral Finger Motor Training||National Institutes of Health Clinical Center (CC)||Completed|August 2003|June 2007||||N/A|Observational|N/A||||28|||Both|18 Years|N/A|No|||June 2007|September 26, 2015|August 12, 2003||||No||https://clinicaltrials.gov/show/NCT00067223||201719|
NCT00067236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002135|Study of Oral PG-116800 Following a Heart Attack|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral PG-116800 Following a Heart Attack||Procter and Gamble|No|Completed|September 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|80 Years|No|||September 2011|September 27, 2011|August 13, 2003|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00067236||201718|
NCT00069160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030284|Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer|A Clinical Trial of the P-Glycoprotein Antagonist, Tariquidar (XR9576), in Combination With Docetaxel in Patients With Lung, Ovarian, Renal and Cervical Cancer: Analysis of the Interaction Between Tariquidar and Docetaxel||National Institutes of Health Clinical Center (CC)|No|Completed|September 2003|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|September 15, 2003||No||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00069160||201583|
NCT00068835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD037890|Using fMRI to Evaluate Instructional Programs for Children With Developmental Dyslexia|Remediation in Developmental Dyslexia||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|June 2000|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||160|||Both|8 Years|12 Years|No|||November 2004|June 23, 2005|September 10, 2003||||No||https://clinicaltrials.gov/show/NCT00068835||201604|
NCT00067600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037744|Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study|Lifestyle Changes to Increase Bone Density in Teen Girls||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 2000|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||228|||Female|14 Years|16 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|August 25, 2003||||No||https://clinicaltrials.gov/show/NCT00067600||201690|
NCT00067301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001077|PUFA Augmentation in Treatment of Major Depression|PUFA Augmentation in Treatment of Major Depression||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2003|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||January 2008|January 23, 2008|August 14, 2003||||||https://clinicaltrials.gov/show/NCT00067301||201713|
NCT00071682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08AT001338-01|Evaulation of Interaction Between Herbal Products and Anticoagulants|Early Identification of Adverse Reactions to Herbs||University of California, San Francisco|No|Withdrawn|October 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 13, 2013|October 29, 2003||||No||https://clinicaltrials.gov/show/NCT00071682||201407|
NCT00071695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6090|Duloxetine vs. Active Comparator in the Treatment of Patients With Depression|Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder||Eli Lilly and Company||Completed|July 2003|May 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|18 Years|N/A|No|||May 2007|May 17, 2007|October 29, 2003||||||https://clinicaltrials.gov/show/NCT00071695||201406|
NCT00068471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000322888|Anidulafungin in Treating Immunocompromised Children With Neutropenia|Phase I-II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Neutropenia||National Cancer Institute (NCI)||Completed|July 2003|October 2007|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|2 Years|17 Years|No|||April 2004|June 18, 2013|September 10, 2003||||No||https://clinicaltrials.gov/show/NCT00068471||201625|
NCT00067808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0180|Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)|Phase II Randomized Study of Three Different Schedules of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Completed|October 2003|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|N/A|N/A|No|||August 2012|August 1, 2012|August 27, 2003|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00067808||201674|
NCT00067821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030278|Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity|A Comparative Study of Pediatric CNS Tumor Activity as Assessed by [18]F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging ([1]H-MRSI)||National Institutes of Health Clinical Center (CC)||Recruiting|August 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|1 Year|21 Years|No|||July 2015|August 28, 2015|August 28, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00067821||201673|
NCT00067873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLKWHT (DK49779) (completed)|Exercise Training in Obesity-prone Black and White Women|Exercise Training in Obesity-prone Black and White Women||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 2000|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention||||231|||Female|21 Years|41 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 29, 2003||||No||https://clinicaltrials.gov/show/NCT00067873||201669|
NCT00067886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK62999|Matrix Metalloproteinases and Diabetic Nephropathy|Matrix Metalloproteinases and Diabetic Nephropathy||Arkansas Children's Hospital Research Institute|No|Completed|March 2003|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|330|||Both|14 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 Diabetes mellitus, ages 14-40 years.|January 2012|January 18, 2012|August 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00067886||201668|
NCT00068133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLTS-589-121|Trial of VLTS-589 in Subjects With Intermittent Claudication|A Phase II Multicenter, Double-Blind, Placebo-Controlled, Trial of VLTS-589 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease||Valentis||Completed|June 2003|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|40 Years|80 Years|No|||May 2005|June 23, 2005|September 8, 2003||||||https://clinicaltrials.gov/show/NCT00068133||201650|
NCT00068302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000321392|Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma|A Phase I Trial Of Sirolimus In Relapsed/Refractory Leukemia And Non-Hodgkin's Lymphoma||Children's Hospital of Philadelphia|Yes|Terminated|January 2003|July 2013|Actual|April 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|21 Years|No|||July 2013|March 11, 2015|September 10, 2003||No|Recruiting/enrolling participants halted prematurely but potentially will resume|No||https://clinicaltrials.gov/show/NCT00068302||201637|
NCT00068484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00044|A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies|A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies||National Cancer Institute (NCI)||Completed|July 2003|||February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068484||201624|
NCT00068198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-067|Human Immune Responses Smallpox|Evaluation of Human Immune Response to Smallpox Vaccine (Vaccinia Virus)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2006|August 26, 2010|September 9, 2003||||||https://clinicaltrials.gov/show/NCT00068198||201645|
NCT00068211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILX651-211|Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma|A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma.||Sanofi||Completed|August 2003|January 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2015|March 4, 2015|September 9, 2003||||||https://clinicaltrials.gov/show/NCT00068211||201644|
NCT00068380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02825|A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer|A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer||National Cancer Institute (NCI)||Completed|March 2004|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|19 Years|N/A|No|||July 2013|October 1, 2014|September 10, 2003|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT00068380||201632|In the first stage none of the 17 patients responded (CR/PR) to treatment. Due to budget constraints and recent reprioritizations, CTEP closed the study to accrual.
NCT00068003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030277|Harvesting Cells for Experimental Cancer Treatments|Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|August 2003|||||N/A|Observational|Time Perspective: Prospective|||Actual|1659|||Both|16 Years|100 Years|Accepts Healthy Volunteers|||April 2015|February 20, 2016|September 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00068003||201659|
NCT00068250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0227|Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|July 2003|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068250||201641|
NCT00068263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0319|3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection|A Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma||Radiation Therapy Oncology Group|Yes|Completed|August 2003|||June 2005|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||November 2015|November 14, 2015|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068263||201640|
NCT00067769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11116|Internet-based Treatment of Early Childhood Fecal Incontinence|Treatment of Early Childhood Constipation/Encopresis||University of Virginia|No|Completed|October 2003|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||June 2014|December 4, 2015|August 27, 2003||No||No||https://clinicaltrials.gov/show/NCT00067769||201677|
NCT00067444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29060/874|Depression Study In Elderly Patients|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed With Major Depressive Disorder||GlaxoSmithKline|No|Completed|June 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|560|||Both|60 Years|N/A|No|||April 2015|April 10, 2015|August 19, 2003||||||https://clinicaltrials.gov/show/NCT00067444||201702|
NCT00067457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S3B30048|Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy|A 12-Week, Randomized, Double-Blind, Placebo- Controlled Study of PRN BID and Fixed Dosing Regimens of Alosetron in Female Subjects With Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy||GlaxoSmithKline|No|Completed|June 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|700|||Female|18 Years|N/A|No|||April 2015|April 15, 2015|August 20, 2003||||||https://clinicaltrials.gov/show/NCT00067457||201701|
NCT00067353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14403|Yakima Head Start Fluoride Varnish Study|Fluoride Varnish Trial in High Caries Preschoolers||University of Washington|Yes|Completed|November 2003|August 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|36 Months|71 Months|Accepts Healthy Volunteers|||May 2010|May 6, 2010|August 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00067353||201709|
NCT00067366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14607|Brief Treatment for Temporomandibular Pain|Brief Focused Treatment for TMD: Mechanisms of Action||University of Connecticut Health Center||Completed|October 2003|September 2011|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|65 Years|No|||September 2011|September 19, 2011|August 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00067366||201708|
NCT00067379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-142542|Early Orthodontic Intervention Under Medicaid|Early Orthodontic Intervention Under Medicaid||University of Washington|Yes|Active, not recruiting|April 2003|June 2009|Anticipated|June 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|8 Years|11 Years|No|||June 2010|June 9, 2010|August 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00067379||201707|
NCT00069407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067201|Comparison of Three Electroconvulsive Therapy (ECT) Techniques for the Treatment of Major Depression|Comparing Three Electrode Placements to Optimize ECT||Rutgers, The State University of New Jersey|Yes|Completed|February 2003|December 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|230|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|September 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00069407||201566|
NCT00067288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001031-01|Meaning-Centered Psychotherapy in Advanced Cancer|Meaning-Centered Psychotherapy in Advanced Cancer||National Center for Complementary and Integrative Health (NCCIH)||Completed|May 2002|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||118|||Both|21 Years|N/A|No|||August 2006|August 16, 2006|August 14, 2003||||No||https://clinicaltrials.gov/show/NCT00067288||201714|
NCT00071149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000590-01|Consistency of Traditional Chinese Medicine Diagnoses and Herbal Prescriptions for Rheumatoid Arthritis|Consistency of Traditional Chinese Medicine Rheumatoid Arthritis Diagnosis and Herbal Prescriptions||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2001|April 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||120|||Both|18 Years|N/A|No|||July 2006|August 17, 2006|October 14, 2003||||No||https://clinicaltrials.gov/show/NCT00071149||201447|
NCT00072059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCHE-NA17101|Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer|An Open Label, Randomized, Multicenter, Phase II Study To Determine Hemoglobin Dose Response, Safety And Pharmacokinetic Profile Of Ro 50-3821 Given Subcutaneously Once Weekly Or Once Every 3 Weeks To Anemic Patients With Stage IIIB or IV Non-Small Cell Lung Carcinoma Receiving Antineoplastic Therapy||National Cancer Institute (NCI)||Completed|July 2003|February 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||January 2005|July 17, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072059||201380|
NCT00068588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02827|GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer|A Phase 2 Study of GTI-2040 (NSC 722929) in Combination With Capecitabine in Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|October 2003|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|October 24, 2014|September 10, 2003|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT00068588||201618|In the first stage of the two stage Optimum design, following the dose escalation step, 3 of 15 patients responded for a response rate of 20%. A response rate of less than 25% would not warrant further study.
NCT00068757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16023-10051|Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer|Phase I Study of Lonafarnib (SCH66336) in Combination With Herceptin Plus Paclitaxel in HER 2 NEU Overexpressing Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 2003|||November 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|September 10, 2003||||No||https://clinicaltrials.gov/show/NCT00068757||201609|
NCT00067834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR32267|Electromagnetic Treatment For Bone Loss After Forearm Fracture|Feasibility and Dosing Study of Bone Density Changes With and Without PEMF Following Immobilization of the Forearm||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|November 2003|October 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|August 28, 2003||||No||https://clinicaltrials.gov/show/NCT00067834||201672|
NCT00068341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000321924|Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer|Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer||Jonsson Comprehensive Cancer Center|Yes|Completed|July 2003|||November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|80|||Female|18 Years|80 Years|No|||June 2014|October 29, 2015|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068341||201634|
NCT00068107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030286|Dosing Study of Replagal in Patients With Fabry Disease|Study of Weekly Dosing Regimens of Replagal in Patients With Fabry Disease With Incomplete Clinical Response to Long-Term Therapy||Baylor Research Institute|No|Completed|September 2003|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|N/A|N/A|No|||March 2015|March 19, 2015|September 6, 2003|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT00068107||201652|Small number of subjects. Single group with comparison to baseline data.
NCT00068120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORWHSCOR-dk64540 (compltd)|ORWH:SCOR - Sex/Gender Factors Affecting Women's Health|ORWH:SCOR - Sex/Gender Factors Affecting Women's Health||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|September 8, 2003||||No||https://clinicaltrials.gov/show/NCT00068120||201651|
NCT00067925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037767|A School-Based Osteoporosis Prevention Program for Adolescent Girls|Incorporating More Physical Activity and Calcium in Teens (IMPACT): A School-Based Osteoporosis Prevention Program for Adolescent Girls||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 2000|June 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||718|||Female|10 Years|13 Years|Accepts Healthy Volunteers|||August 2003|October 18, 2010|September 3, 2003||||No||https://clinicaltrials.gov/show/NCT00067925||201665|
NCT00068601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000327758|S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer|Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|October 2003|September 2016|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|416|||Female|18 Years|49 Years|No|||October 2015|October 15, 2015|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068601||201617|
NCT00068367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000322023|S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor|U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II||Southwest Oncology Group|Yes|Completed|December 2003|August 2009|Actual|July 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|September 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00068367||201633|
NCT00068029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGA-0435-005|Pegvisomant And Sandostatin LAR Combination Study|A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly||Pfizer||Completed|October 2003|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||April 2008|April 3, 2008|September 4, 2003||||||https://clinicaltrials.gov/show/NCT00068029||201658|
NCT00068393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000322258|Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma|Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma With Sarcomatoid Features||Eastern Cooperative Oncology Group|No|Completed|December 2003|May 2011|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|September 10, 2003|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00068393||201631|
NCT00069576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801 - GDM|Gestational Diabetes Mellitus Trial (GDM)|A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus|GDM|The George Washington University Biostatistics Center|Yes|Completed|October 2002|October 2013|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1889|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00069576||201553|
NCT00067548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3095A1-201|Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of EKB-569 in Subjects With Advanced Non-Small Cell Lung Cancer||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|August 21, 2003||||||https://clinicaltrials.gov/show/NCT00067548||201694|
NCT00067470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB-03-05|Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI|||BioMarin Pharmaceutical||Completed|September 2003|March 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|39|||Both|7 Years|N/A|No|||December 2009|December 18, 2009|August 20, 2003|||||February 4, 2009|https://clinicaltrials.gov/show/NCT00067470||201700|
NCT00067561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S3B30040|Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy|A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects With Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy||GlaxoSmithKline||Completed|June 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|702|||Female|18 Years|N/A|No|||April 2015|April 15, 2015|August 21, 2003||||No||https://clinicaltrials.gov/show/NCT00067561||201693|
NCT00069251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0008-1|Bupropion for the Treatment of Methamphetamine Dependence - 1|Bupropion for the Treatment of Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)||Completed|July 2003|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years|No|||July 2008|July 21, 2008|September 18, 2003||||||https://clinicaltrials.gov/show/NCT00069251||201576|
NCT00069264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-101|Study of E7389 in Patients With Advanced Solid Tumors|A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) in Patients With Advanced Solid Tumors||Eisai Inc.||Completed|September 2003|July 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|September 19, 2003|Yes|Yes||No|November 16, 2011|https://clinicaltrials.gov/show/NCT00069264||201575|
NCT00069277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-102|Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors|A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors||Eisai Inc.||Completed|August 2003|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|21|||Both|18 Years|N/A|No|||April 2012|April 6, 2012|September 19, 2003|Yes|Yes||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00069277||201574|
NCT00069303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030305|Natural History of West Nile Virus Infection|Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease||National Institutes of Health Clinical Center (CC)||Completed|September 2003|February 2011||||N/A|Observational|N/A|||Anticipated|110|||Both|18 Years|N/A|No|||February 2011|September 26, 2015|September 22, 2003||No||No||https://clinicaltrials.gov/show/NCT00069303||201573|
NCT00069498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24AI001610-03|Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients|Impact of Co-Receptor and HIV Viral Burden on Gut Mucosa||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 1999|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||14|||Male|18 Years|65 Years|No|||July 2006|May 24, 2007|September 26, 2003||||No||https://clinicaltrials.gov/show/NCT00069498||201559|
NCT00067509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD38515|Emergency Contraception (ECP): Reducing Unintended Pregnancies|A Second Chance With Emergency Contraception (ECP): Reducing Unintended Pregnancy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|June 2001|May 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||1100|||Female|15 Years|39 Years|Accepts Healthy Volunteers|||July 2003|June 23, 2005|August 21, 2003||||No||https://clinicaltrials.gov/show/NCT00067509||201697|
NCT00068289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000320527|Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy|A Phase II Trial of PS-341 (NSC-681239) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2003|July 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|June 21, 2013|September 10, 2003||||No||https://clinicaltrials.gov/show/NCT00068289||201638|
NCT00068770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-2100 CDR0000328117|Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT|A Pharmacokinetic Study of the Interaction Between Celecoxib and Anticonvulsant Drugs in Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Radiation Therapy||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|October 2003|May 2006|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 10, 2003|Yes|Yes|EORTC trail showed TMZ & RT conferred significant survivial in this population|No|November 19, 2012|https://clinicaltrials.gov/show/NCT00068770||201608|Study ended early when results from another study became available documenting Temozolomide (TMZ) and radiation improved survival, we felt it was unethical to continue this study, our study did not include TMZ.
NCT00067847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECSB19PNA (completed)|Evaluation of California's SB 19 Pupil Nutrition Act|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 2003|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||5020|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 28, 2003||||No||https://clinicaltrials.gov/show/NCT00067847||201671|
NCT00068237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0244|Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer|A Phase II Study Of Submandibular Salivary Gland Transfer To The Submental Space Prior To Start Of Radiation Treatment For Prevention Of Radiation-Induced Xerostomia In Head And Neck Cancer Patients||Radiation Therapy Oncology Group|Yes|Completed|August 2003|||January 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|49|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|September 10, 2003||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00068237||201642|
NCT00068549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9912|Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer|A Phase I Study of Whole Pelvic Radiation Therapy With Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis||Gynecologic Oncology Group||Completed|October 2003|||January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|N/A|N/A|No|||December 2014|December 23, 2014|September 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00068549||201620|
NCT00068575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-040|Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer|A Phase II Trial of Pancreaticoduodenectomy Plus Postoperative Cisplatin, Interferon Alfa-2b, and 5-FU Combined With Radiation Treatment for Patients With Resected Pancreatic Adenocarcinoma||M.D. Anderson Cancer Center|No|Completed|May 2002|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|September 10, 2003|Yes|Yes||No|January 23, 2012|https://clinicaltrials.gov/show/NCT00068575||201619|
NCT00067990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGIOB|Angiotensin II Blockade for Chronic Allograft Nephropathy|Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|December 2002|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|153|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|September 3, 2003||No||No||https://clinicaltrials.gov/show/NCT00067990||201660|
NCT00067574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 008|Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents|Structured Treatment Interruption as an Autovaccination Approach to Enhance Immune Based HIV-1 Control in an Adolescent/Young Adult Population||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Terminated|July 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|14 Years|21 Years|No|||November 2003|June 23, 2005|August 25, 2003||||No||https://clinicaltrials.gov/show/NCT00067574||201692|
NCT00067717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001437|Distance Healing in Wound Healing|Placebo Effects in Distance Healing of Wounds||California Pacific Medical Center Research Institute|Yes|Completed|November 2003|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Female|34 Years|64 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|August 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00067717||201681|
NCT00067730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6416|A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation|A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis||Eli Lilly and Company|No|Completed|March 2003|October 2003|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2007|December 3, 2007|August 25, 2003||||No||https://clinicaltrials.gov/show/NCT00067730||201680|
NCT00068926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030285|VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases|VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases||National Institutes of Health Clinical Center (CC)||Completed|September 2003|June 2011||||N/A|Observational|N/A|||Actual|958|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|September 11, 2003||No||No||https://clinicaltrials.gov/show/NCT00068926||201597|
NCT00068952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDOAGL-8725-001|Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme|A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy||Pfizer||Completed|August 2003|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||118|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|September 12, 2003||||No||https://clinicaltrials.gov/show/NCT00068952||201596|
NCT00067613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0025|Benchmarking Initiative to Reduce Bronchopulmonary Dysplasia|Randomized Controlled Trial of Benchmarking to Reduce Bronchopulmonary Dysplasia to Reduce Bronchopulmonary Dysplasia|Benchmarking|NICHD Neonatal Research Network|Yes|Completed|March 2001|May 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4095|||Both|N/A|36 Weeks|Accepts Healthy Volunteers|||June 2015|June 3, 2015|August 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00067613||201689|
NCT00067626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001332|Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes|Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes||Griffin Hospital|Yes|Completed|April 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|August 25, 2003||No||No||https://clinicaltrials.gov/show/NCT00067626||201688|
NCT00069563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P30HD015052|Improving Mental Health Services for Economically Disadvantaged Children: Training Teachers|John F. Kennedy Center for Mental Retardation: Parent Vs. Teacher-Training in Children's Mental Health Services||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 1995|September 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||93|||Both|N/A|N/A|No|||October 2003|June 23, 2005|September 29, 2003||||No||https://clinicaltrials.gov/show/NCT00069563||201554|
NCT00069134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUTH - dk56689|Study of Antioxidants and Oxidants in Malnourished Children|Glutathione Homeostasis and Oxidant Damage in Kwashiorkor||Baylor College of Medicine|Yes|Recruiting|June 2003|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|84|||Both|6 Months|18 Months|No|||January 2015|January 27, 2015|September 15, 2003||No||No||https://clinicaltrials.gov/show/NCT00069134||201584|
NCT00069173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD037746|Preventing Osteoporosis in Adolescent Girls|Prevention of Osteoporosis Among Sedentary Adolescent Females||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|July 2000|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||250|||Female|13 Years|17 Years|Accepts Healthy Volunteers|||June 2003|June 23, 2005|September 16, 2003||||No||https://clinicaltrials.gov/show/NCT00069173||201582|
NCT00067860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035030|Diet/Growth Factor Mechanisms of Gut Adaptation|Diet/Growth Factor Mechanisms of Gut Adaptation||Emory University||Completed|October 1996|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|27|||Both|18 Years|80 Years|No|||December 2013|December 16, 2013|August 29, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00067860||201670|
NCT00071435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040017|Brain Function in Primary Lateral Sclerosis|Movement Related Cortical Potentials in Primary Lateral Sclerosis||National Institutes of Health Clinical Center (CC)||Completed|October 2003|February 2006||||N/A|Observational|N/A||||36|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2006|March 3, 2008|October 22, 2003||||No||https://clinicaltrials.gov/show/NCT00071435||201426|
NCT00071448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-2126|Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population|Basal/Bolus Therapy With Insulin Aspart (NovoLog®) Versus Regular Human Insulin (Novolin® R) or Insulin Lispro (Humalog®) in Combination With NPH: An Open-Label, Randomized, Parallel Group, Multicenter Study in Children and Adolescents With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|June 2002|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|378|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 23, 2003||||No||https://clinicaltrials.gov/show/NCT00071448||201425|
NCT00068731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0351|Lycopene in Treating Patients With Metastatic Prostate Cancer|A Phase II Trial Of Lycopene For Patients With Asymptomatic Androgen-Independent Metastatic Prostate Cancer With PSA Elevation||Alliance for Clinical Trials in Oncology|Yes|Completed|January 2004|October 2009|Actual|February 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|September 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00068731||201611|
NCT00068744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22011-40014|Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer|Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|July 2003|||November 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|88|||Both|18 Years|75 Years|No|||September 2012|September 20, 2012|September 10, 2003|||low accrual|No||https://clinicaltrials.gov/show/NCT00068744||201610|
NCT00069628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 004|Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer|DirecNet Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer in the Management of Type 1 Diabetes in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 2003|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||January 2006|January 5, 2006|September 29, 2003||||No||https://clinicaltrials.gov/show/NCT00069628||201549|
NCT00069641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKT024|Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)|A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II||Shire|Yes|Completed|September 2003|March 2005|Actual|March 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|96|||Male|5 Years|25 Years|No|||January 2014|April 27, 2015|September 29, 2003|No|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00069641||201548|
NCT00070317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0206|Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer|Lymphatic Mapping and Sentinel Node Identification in Patients With Stage1B1 Cervical Carcinoma||Gynecologic Oncology Group||Terminated|June 2004|||January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Female|N/A|N/A|No|||June 2015|June 3, 2015|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070317||201501|
NCT00087334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 17403|Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer|A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus Oxaliplatin (Eloxatin®, Sanofi) Plus ZD 1893 (IRESSA®) in the Treatment of Metastatic Colorectal Cancer||Roswell Park Cancer Institute||Terminated|January 2004|||November 2005|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|18 Years|80 Years|No|||January 2013|January 31, 2013|July 8, 2004|Yes|Yes|Withdrawn due to poor/low accrual|No||https://clinicaltrials.gov/show/NCT00087334||200324|
NCT00089141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1697.00|Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)|A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease||Fred Hutchinson Cancer Research Center|Yes|Terminated|May 2004|September 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|4 Years|N/A|No|||August 2009|May 1, 2013|August 4, 2004|Yes|Yes|Low probability of positive outcome|No|July 15, 2009|https://clinicaltrials.gov/show/NCT00089141||200193|
NCT00070928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000611-01|Valerian to Improve Sleep in Patients With Parkinson's Disease|Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2000|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|30 Years|80 Years|No|||July 2006|July 25, 2006|October 9, 2003||||No||https://clinicaltrials.gov/show/NCT00070928||201464|
NCT00087945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1052|Blood Levels of Abacavir in HIV Infected Adolescents|Abacavir Pharmacokinetics During Chronic Therapy in HIV-1 Infected Adolescents and Young Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2004|December 2004|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|13 Years|25 Years|No|||October 2013|October 4, 2013|July 16, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00087945||200277|
NCT00087893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1261|Epidemiology of Vascular Inflammation & Atherosclerosis|||University of Vermont||Completed|July 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|931|||Both|45 Years|84 Years|No|Probability Sample|1,000 men and women aged 45-84 years|September 2013|September 26, 2013|July 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00087893||200281|
NCT00087906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1262|Disability and Health Outcomes in COPD|Disability and Health Outcomes in COPD||University of California, San Francisco|No|Completed|July 2004|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1589|||Both|N/A|55 Years|No|Probability Sample|We recruited persons with COPD for what we came to term the "FLOW study." The original        project was funded to complete two interviews and a single research clinic evaluation. In        addition to completing this original program of work successfully, we also carried out        follow-up research clinic visits for 667 subjects. These supplemental examinations were        made possible through research funding support from the Flight Attendants Medical Research        Foundation (FAMRI).|December 2015|December 22, 2015|July 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00087906||200280|
NCT00088868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040218|17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma|A Phase I Study Of 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) With Evaluation Of Hsp90 Client Proteins In Subjects With Solid Tumors And Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|June 2004|December 2010|Actual|March 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|August 4, 2004||||||https://clinicaltrials.gov/show/NCT00088868||200213|
NCT00070954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000939-01A1|Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT)|Ginkgo Biloba for ECT-induced Memory Deficits||Medical University of South Carolina||Terminated|February 2003|March 2005|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2008|June 27, 2011|October 9, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00070954||201462|
NCT00087282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000373877|Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer|A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma||National Cancer Institute (NCI)||Completed|June 2004|July 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|June 21, 2013|July 8, 2004||||No||https://clinicaltrials.gov/show/NCT00087282||200326|
NCT00087581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17225|Study of Therapeutic Monitoring of CellCept (Mycophenolate Mofetil) After Kidney Transplantation|A Randomized, Open-label Study of Various Dosing Regimens of CellCept Combined With Various Dosing Regimens of Cyclosporine or Tacrolimus on Treatment Failure in Kidney Transplantation Patients||Hoffmann-La Roche||Completed|July 2004|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|717|||Both|13 Years|75 Years|No|||March 2016|March 1, 2016|July 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087581||200305|
NCT00087594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17251|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.|An Open-Label, Multi-Center, Randomized, Safety, Feasibility and Tolerability Pilot Study of Pegasys® (Peginterferon Alfa-2a) Plus Copegus® (Ribavirin) in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Program.||Hoffmann-La Roche||Completed|November 2003|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 12, 2004|Yes|Yes||No|December 3, 2015|https://clinicaltrials.gov/show/NCT00087594||200304|
NCT00069719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-33|Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients|Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients||Alcon Research||Completed|February 1999|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 4, 2008|September 30, 2003||||||https://clinicaltrials.gov/show/NCT00069719||201543|
NCT00071006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061013|AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)|Phase 2 Study Of AG-013736 In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)||Pfizer|No|Completed|September 2003|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|October 9, 2003|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00071006||201458|
NCT00071019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235|Dietary Fatty Acids, PPAR Activated Genes, and CHD|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 24, 2008|October 9, 2003||||No||https://clinicaltrials.gov/show/NCT00071019||201457|
NCT00070980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001160-01A1|Massage to Increase Well-Being and Immune Function in Dominican Children Infected With HIV|Massage to Enhance Well-Being in HIV-Positive Dominican Children||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2003|November 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||54|||Both|3 Years|7 Years|No|||July 2006|August 17, 2006|October 9, 2003||||No||https://clinicaltrials.gov/show/NCT00070980||201460|
NCT00072111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000335469|Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene|Phase I Study of Anakinra Mediated Tumor Regression and Angiogenesis Inhibition in Subjects With Cancers Producing Interleukin-1||National Cancer Institute (NCI)||Completed|September 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2006|April 29, 2015|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072111||201376|
NCT00087867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005152|Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma|An Open-label Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed, Refractory Patients With Multiple Myeloma||Scios, Inc.||Completed|June 2004|September 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||October 2010|October 15, 2010|July 14, 2004||No||No||https://clinicaltrials.gov/show/NCT00087867||200283|
NCT00071877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040029|An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease|A Clinical Trial of Replagal Enzyme Replacement Therapy in Children Ages 7 - 17 Years With Fabry Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2003|June 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||June 2005|March 3, 2008|November 3, 2003||||No||https://clinicaltrials.gov/show/NCT00071877||201394|
NCT00071890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040018|Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx|Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Anti-Retroviral TX in HIV Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm(3) Who Have Received Anti-Retroviral TX|ILIADE|National Institutes of Health Clinical Center (CC)|Yes|Completed|October 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||September 2010|September 13, 2010|November 3, 2003||No||No|September 13, 2010|https://clinicaltrials.gov/show/NCT00071890||201393|
NCT00072098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000335463|Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer|Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver||National Cancer Institute (NCI)||Recruiting|September 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072098||201377|
NCT00087542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-006|Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug|||ACADIA Pharmaceuticals Inc.||Completed|March 2004|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||December 2005|December 5, 2005|July 9, 2004||||||https://clinicaltrials.gov/show/NCT00087542||200308|
NCT00069927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0201|Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression|Adderall-XR Versus Concerta For Cancer Treatment-Related Neurocognitive Sequelae And Depression In Pediatric Patients: A Randomized Phase II Study||University of South Florida|Yes|Terminated|August 2003|September 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|12|||Both|6 Years|17 Years|No|||January 2014|January 31, 2014|October 3, 2003|No|Yes|Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility|No||https://clinicaltrials.gov/show/NCT00069927||201528|
NCT00069940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-365|Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor|A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF||Dana-Farber Cancer Institute|Yes|Completed|December 2000|August 2008|Actual|August 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Years|N/A|No|||December 2010|December 26, 2010|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00069940||201527|
NCT00069966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000316466|Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse|A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|April 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2004|July 4, 2009|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00069966||201525|
NCT00071175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-103|Lupus Genetics Studies|Lupus Genetic Studies; Lupus Family Registry & Repository|LFRR|Oklahoma Medical Research Foundation|No|Completed|October 1995|November 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Actual|3460|Samples With DNA|DNA, sera, plasma, cell lines|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with SLE Families with living members diagnosed with SLE|October 2015|October 13, 2015|October 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00071175||201445|
NCT00092001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181040|Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer|A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer||Pfizer|No|Completed|January 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|September 21, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00092001||199995|
NCT00092014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-211|A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)|A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis|FACT|Merck Sharp & Dohme Corp.|No|Completed|September 2002|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1053|||Female|25 Years|N/A|No|||December 2013|December 2, 2013|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092014||199994|
NCT00088257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1264|Maternal Fatty Acids, Child Obesity, and Asthma Immunity|Maternal Fatty Acids, Child Obesity, and Asthma Immunity||Harvard Pilgrim Health Care||Completed|August 2004|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|411|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women were recruited in 1999-2002 following their initial prenatal visit at one        of eight obstetric offices of a multi-specialty group practice in eastern MA.|December 2013|December 12, 2013|July 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00088257||200256|
NCT00088270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-904-202|A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer|A Randomized, Open Label, Phase II Study of OSI-7904L Versus 5-FU/LV as First-Line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract||OSI Pharmaceuticals||Completed|August 2004|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||58|||Both|18 Years|N/A|No|||May 2004|February 17, 2006|July 23, 2004||||||https://clinicaltrials.gov/show/NCT00088270||200255|
NCT00087919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1263|Defining an Obesity QTL on Chromosome 3q|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2004|May 2008|Actual|May 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 1, 2008|July 15, 2004||||No||https://clinicaltrials.gov/show/NCT00087919||200279|
NCT00070200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL02P1|Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma|A Pilot Induction Regimen Incorporating Topotecan for Treatment of Newly Diagnosed High Risk Neuroblastoma||Children's Oncology Group|Yes|Completed|March 2004|December 2013|Actual|September 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|30 Years|No|||February 2014|February 12, 2014|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070200||201509|
NCT00070213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000330142|Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer|Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed||National Cancer Institute (NCI)||Active, not recruiting|September 2003|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|460|||Both|N/A|N/A|No|||June 2011|September 16, 2013|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070213||201508|
NCT00071201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-02-526|Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B|A Multi-Center Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Varying Degrees of Renal Impairment||Gilead Sciences||Completed|June 2003|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|65 Years|No|||October 2013|October 14, 2013|October 15, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00071201||201443|
NCT00091325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000387801|Green Tea Extract (Polyphenon E) in Preventing Cancer in Healthy Participants|Phase I Drug Interaction Clinical Study of Polyphenon E||University of Arizona||Completed|October 2004|||March 2005|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 15, 2010|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00091325||200044|
NCT00091962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164|Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery|Treatment of Depression Following Bypass Surgery||University of Pittsburgh|Yes|Completed|August 2003|December 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|455|||Both|N/A|N/A|No|||November 2015|November 30, 2015|September 20, 2004||No||No||https://clinicaltrials.gov/show/NCT00091962||199998|
NCT00087932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000880|Socioeconomic Influences on Complementary and Alternative Medicine Use in Cancer Treatment|Socioeconomic Diversity of CAM Integration in Oncology||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2001|August 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|18 Years|N/A|No|||August 2006|August 17, 2006|July 15, 2004||||No||https://clinicaltrials.gov/show/NCT00087932||200278|
NCT00088218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0183|Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).|Randomized Phase II Study of Clofarabine Alone Versus Clofarabine in Combination With Low-Dose Cytarabine in Previously Untreated Patients >= 60 Years With AML and High-Risk MDS||M.D. Anderson Cancer Center|No|Completed|July 2004|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|95|||Both|60 Years|N/A|No|||April 2011|August 1, 2012|July 22, 2004|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00088218||200258|
NCT00070252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01442|Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer|Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 With Docetaxel and Capecitabine for Patients With Stage IIIA or IIIB Breast Cancer||National Cancer Institute (NCI)||Completed|September 2003|June 2010|Actual|February 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||December 2012|May 1, 2015|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070252||201506|
NCT00071240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI043864|Growth Hormone to Increase Immune Function in People With HIV|The Use of Recombinant Growth Hormone to Enhance T-Cell Production in Adults Infected With HIV-1||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2002|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||August 2009|August 14, 2009|October 16, 2003||No||No||https://clinicaltrials.gov/show/NCT00071240||201440|
NCT00071253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-551|Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness|A Randomized, Double-Blind Study of Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness||Abbott||Terminated|July 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|65 Years|No|||August 2006|August 2, 2006|October 16, 2003||||||https://clinicaltrials.gov/show/NCT00071253||201439|
NCT00091975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-635|Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis|A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis||Abbott||Completed|August 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||78|||Both|18 Years|N/A|No|||July 2006|January 17, 2011|September 20, 2004||||||https://clinicaltrials.gov/show/NCT00091975||199997|
NCT00091624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-011|A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)|A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)||Celgene|No|Completed|March 2003|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|September 13, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00091624||200024|
NCT00091637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003056|Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)|APEX-AMI - Pexelizumab in Conjunction With Angioplasty||Procter and Gamble|Yes|Completed|April 2004|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5745|||Both|18 Years|N/A|No|||August 2011|August 4, 2011|September 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091637||200023|
NCT00087880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15732-1|Maintaining Abstinence in Chronic Cigarette Smokers - 1|Maintaining Abstinence in Chronic Cigarette Smokers||National Institute on Drug Abuse (NIDA)|No|Active, not recruiting|December 2002|September 2009|Anticipated|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|407|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 13, 2008|July 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00087880||200282|
NCT00069758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDX-105-01|Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma|A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab||Teva Pharmaceutical Industries||Completed|September 2003|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|September 30, 2003||||||https://clinicaltrials.gov/show/NCT00069758||201540|
NCT00091650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6257|Olanzapine in Patients With Borderline Personality Disorder|Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo||Eli Lilly and Company||Completed|March 2004|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|15 Years|65 Years|No|||July 2006|July 21, 2006|September 14, 2004||||||https://clinicaltrials.gov/show/NCT00091650||200022|
NCT00087347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000374491|Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer|An NCI-Sponsored Exploratory Study For Determining Optimum Timing For The Imaging Of Intravenous Superparamagnetic Particle Ferumoxytol (Code7228) For The Differentiation of Metastatic and Non Metastatic Lymph Nodes in Patients With Known Primary Cancer Scheduled For Possible Surgical Lymph Node Biopsy/Dissection||Massachusetts General Hospital||Completed|September 2004|||September 2006|Actual|N/A|Observational|N/A|||Anticipated|14|||Both|18 Years|N/A|No|||May 2013|May 12, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087347||200323|
NCT00088556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2023|Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer|Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer||Telik||Completed|August 2004|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||June 2011|May 30, 2012|July 29, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088556||200235|
NCT00069992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-10857-MPDMDSBMT|Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML|Safety And Efficacy of Sub-Myeloablative Allogeneic Stem Cell Transplantation For Patients With Myeloproliferative Disorder (MPD), Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia|MPDMDSBMT|Baylor College of Medicine|Yes|Terminated|December 2001|April 2007|Actual|September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||October 2012|October 5, 2012|October 3, 2003|No|Yes|Closed due to competing protocols|No||https://clinicaltrials.gov/show/NCT00069992||201524|
NCT00070278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-neo-tAnGo|Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer|A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphamide and Paclitaxel + - Gemcitabine in Poor Risk Early Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2005|||September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|800|||Female|N/A|N/A|No|||January 2009|August 6, 2013|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070278||201504|
NCT00071474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000951-01A2|Shamanic Healing for Women With Temporomandibular Joint Disorders (TMDs)|||National Center for Complementary and Integrative Health (NCCIH)||Completed|August 2003|May 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||January 2007|January 22, 2007|October 23, 2003||||No||https://clinicaltrials.gov/show/NCT00071474||201423|
NCT00087607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17756|PEAK Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).|A Randomized, Open-label Study to Compare the Effect of PEGASYS Plus Ribavirin and PEG-Intron Plus Ribavirin on Viral Load Reduction in Interferon-naïve Patients With Chronic Hepatitis C Viral Infection||Hoffmann-La Roche||Completed|December 2003|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|385|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|July 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087607||200303|
NCT00088283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP 1011B|Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)|A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO||Eyetech Pharmaceuticals||Completed|May 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||January 2007|January 17, 2007|July 23, 2004||||||https://clinicaltrials.gov/show/NCT00088283||200254|
NCT00088296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040239|Effects of Osteoarthritis Pain, Morphine, and Placebo on Neuroendocrine Function in Men|Effects of Osteoarthritis Pain, Morphine and Placebo on Neuro-Endocrine Function in Men||National Institutes of Health Clinical Center (CC)||Completed|July 2004|October 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||72|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 19, 2007|July 23, 2004||||No||https://clinicaltrials.gov/show/NCT00088296||200253|
NCT00088309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040234|Effect of Tenofovir DF on Bone Metabolism in Children|Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism||National Institutes of Health Clinical Center (CC)||Completed|June 2004|May 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||May 2006|March 3, 2008|July 23, 2004||||No||https://clinicaltrials.gov/show/NCT00088309||200252|
NCT00071500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43AI052634-01|An Electronic Pillbox for People With HIV|A Novel Technology to Improve HIV Medication Compliance||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|October 2003|June 2009|Anticipated|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|October 24, 2003||No||No||https://clinicaltrials.gov/show/NCT00071500||201421|
NCT00071513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061984|Middle School to High School Transition Project: Depression and Substance Abuse Prevention|Middle School to High School Transition Project||National Institute of Mental Health (NIMH)||Completed|March 2003|June 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||September 2008|September 22, 2008|October 24, 2003||||No||https://clinicaltrials.gov/show/NCT00071513||201420|
NCT00091585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0001|Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.|Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of Intravenous Administration of SNS-595 in Patients With Advanced Malignancies||Sunesis Pharmaceuticals||Completed|June 2004|November 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|May 9, 2007|September 10, 2004||||||https://clinicaltrials.gov/show/NCT00091585||200027|
NCT00088231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0248|PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP|Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients With Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia- Blastic Phase (CML-BP)||M.D. Anderson Cancer Center||Completed|July 2004|October 2006|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|15 Years|N/A|No|||January 2012|January 19, 2012|July 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088231||200257|
NCT00071266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-03-010401|The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC|The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - a Matrix Design||Kos Pharmaceuticals||Completed|October 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||870|||Both|40 Years|N/A|No|||October 2006|October 31, 2006|October 16, 2003||||||https://clinicaltrials.gov/show/NCT00071266||201438|
NCT00071279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5135|SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis|The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006||Sanofi||Completed|November 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind|||Actual|1215|||Both|18 Years|N/A|No|||April 2011|April 5, 2011|October 16, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00071279||201437|
NCT00070031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000329917|Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy|A Phase II Study of Intravenous Edotecarin (PHA-782615) in Patients With Anthracycline- and Taxane-Refractory or Chemoresistant Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|June 2003|December 2009|Actual|April 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2009|December 18, 2013|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070031||201521|
NCT00087295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000373886|S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium|A Phase II Study of Depsipeptide (NSC-630176) In Patients With Advanced Transitional Cell Carcinoma Of The Urinary Tract Who Have Progressed After Receiving One Prior Chemotherapy Regimen For Advanced Disease||Southwest Oncology Group|No|Terminated|June 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||October 2012|October 31, 2012|July 8, 2004|Yes|Yes|Permanently Closed Due to Poor Accrual|No||https://clinicaltrials.gov/show/NCT00087295||200325|
NCT00088829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000368453|Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer|A Pilot Study to Establish a Standardized Protocol for Gene Microarray Analysis in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer: Identifying Factors Predictive of a Response to Paclitaxel||Georgetown University|No|Active, not recruiting|April 2001|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|N/A|No|||August 2014|March 12, 2015|August 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088829||200215|
NCT00088855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01607|Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma|Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|June 2004|||October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||November 2015|January 12, 2016|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088855||200214|
NCT00070551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01443|GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia|A Phase I Study of GTI2040 (NSC 722929; IND 67368) in Combination With High-dose Cytarabine in Refractory or Relapsed Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)||Completed|September 2003|||February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070551||201490|
NCT00071734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040020|Brain Activation During Simple Vocal Behaviors|Brain Activation During Simple Vocal Behaviors||National Institutes of Health Clinical Center (CC)||Completed|October 2003|October 2004||||N/A|Observational|N/A||||37|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2004|March 3, 2008|October 29, 2003||||No||https://clinicaltrials.gov/show/NCT00071734||201403|
NCT00071773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-113|A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema|A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema|Laser|Diabetic Retinopathy Clinical Research Network|No|Completed|July 2003|February 2008|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||March 2011|March 18, 2011|October 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00071773||201400|
NCT00091988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UO1 DK67860 (completed)|Program to Reduce Incontinence by Diet and Exercise (PRIDE)|Program to Reduce Incontinence by Diet and Exercise||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|July 2004|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|330|||Female|30 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 2, 2010|September 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00091988||199996|
NCT00087620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17771|A Study of Capecitabine In Combination With Docetaxel Vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer|||Hoffmann-La Roche||Terminated||||||Phase 4|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2005|December 15, 2005|July 12, 2004||||||https://clinicaltrials.gov/show/NCT00087620||200302|
NCT00088569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040220|Effect of Direct Current Polarization on Brain Function|Measuring the Brain Effects of DC Polarization With O-15 PET||National Institutes of Health Clinical Center (CC)||Completed|July 2004|June 2006||||N/A|Observational|N/A||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2006|March 3, 2008|July 29, 2004||||No||https://clinicaltrials.gov/show/NCT00088569||200234|
NCT00070616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010182|Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support|An Open-label Study of the Pharmacokinetics (PK) of Recombinant Human Keratinocyte Growth Factor (Palifermin; rHuKGF) in Subjects With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy Followed by Peripheral Blood Progenitor Cell (PBPC) Transplantation||Swedish Orphan Biovitrum||Completed|December 2001|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|76 Years|No|||October 2014|October 23, 2014|October 6, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00070616||201486|
NCT00070629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C017|CPG 7909 Injection in Non-Small Cell Lung Cancer|Promune™ (CPG 7909 Injection) In Combination With Chemotherapy In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer, A Randomized, Multi-Center, Controlled, Phase 2 Study||Pfizer||Completed|May 2003|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||February 2009|February 9, 2009|October 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070629||201485|
NCT00071786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030211|Family Study of Affective and Anxiety Spectrum Disorders|Family Study of Affective and Anxiety Spectrum Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|August 2003|||||N/A|Observational|N/A|||Anticipated|3775|||Both|N/A|60 Years|Accepts Healthy Volunteers|||October 2015|October 10, 2015|October 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00071786||201399|
NCT00071799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA PH GL 2003 CL 001|A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care|A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)||Celgene|Yes|Completed|November 2003|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|358|||Both|18 Years|N/A|No|||August 2010|August 24, 2010|October 31, 2003|No|Yes||No|March 2, 2010|https://clinicaltrials.gov/show/NCT00071799||201398|
NCT00087633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18124|PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.|A Randomized, Open-label Study of Prophylactic Administration of PEGASYS Plus Ribavirin After Liver Transplantation on Hepatitis C Recurrence in Patients With Hepatitis C||Hoffmann-La Roche||Completed|October 2004|October 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||December 2010|December 22, 2010|July 12, 2004|Yes|Yes||No|October 14, 2009|https://clinicaltrials.gov/show/NCT00087633||200301|
NCT00070655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5134|Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)|The AMADEUS Trial, A Multicenter, Randomized, Open-label, Assessor Blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Idraparinux (SR34006) With Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patients With Atrial Fibrillation||Sanofi||Completed|September 2003|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|4673|||Both|18 Years|N/A|No|||April 2011|April 5, 2011|October 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070655||201483|
NCT00091949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS044876|Insulin Resistance Intervention After Stroke Trial|Insulin Resistance Intervention After Stroke (IRIS) Trial|IRIS|Yale University|Yes|Completed|February 2005|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3876|||Both|40 Years|N/A|No|||January 2016|January 6, 2016|September 20, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091949||199999|
NCT00087269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02950|Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection|Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Erlotinib) Administered Prior to Surgical Resection in Patients With Early Stage Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Terminated|December 2004|||April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087269||200327|
NCT00088517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040170|Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112|Whole Body Study of [11C]NNC-112 PET Imaging of Dopamine D1 Receptors||National Institutes of Health Clinical Center (CC)||Completed|July 2004|March 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2006|March 3, 2008|July 27, 2004||||No||https://clinicaltrials.gov/show/NCT00088517||200238|
NCT00071565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS039512|Familial Intracranial Aneurysm Study II|Familial Intracranial Aneurysm Study II||University of Cincinnati|No|Completed|September 2002|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|5875|Samples With DNA|blood sample|Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|475 families with multiple affected family members will be selected in this collaborative        research effort of neurologists and neurosurgeons throughout the United States, Canada,        Australia and New Zealand (completed during phase I) 200 Families with multiple affected        family members located in North America, and an additional 1800 subjects with sporadic        aneurysm without a qualifing family history.|August 2015|August 17, 2015|October 28, 2003||No||No||https://clinicaltrials.gov/show/NCT00071565||201416|
NCT00071526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040021|Urinary Vitamin C Loss in Diabetic Subjects|Urinary Vitamin C Loss in Subjects With and Without Diabetes||National Institutes of Health Clinical Center (CC)||Recruiting|October 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|October 27, 2003||No||No||https://clinicaltrials.gov/show/NCT00071526||201419|
NCT00071539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-102-22-188|Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors|||Teva Pharmaceutical Industries||Completed|October 2003|July 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|October 28, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00071539||201418|
NCT00087555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-SXB-26|Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem(R) (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia||Jazz Pharmaceuticals|No|Completed|July 2004|January 2006|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|195|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|July 12, 2004|Yes|Yes||No|October 17, 2011|https://clinicaltrials.gov/show/NCT00087555||200307|
NCT00087568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16965|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin|An Open-label Study of the Safety and Tolerability of PEGASYS Plus Ribavirin in Patients With Chronic Hepatitis C Viral Infection Who Could Not Tolerate or Were Unresponsive to PEG-Intron Plus Ribavirin||Hoffmann-La Roche||Completed|December 2002|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|July 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087568||200306|
NCT00088530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIX301|BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)|Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma: A Randomized, Controlled, Phase III Comparative Trial||CTI BioPharma|Yes|Completed|July 2004|July 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|July 28, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088530||200237|
NCT00088543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-101-1026|Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant|Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-transplant Graft vs. Host Disease (GvHD) Prophylaxis||Sanofi||Completed|March 2004|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|55 Years|No|||March 2015|March 16, 2015|July 29, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088543||200236|
NCT00070304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD0321|Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma|A Phase II Study Of Weekly Gemcitabine And Vinorelbine In Children With Recurrent Or Refractory Hodgkin's Disease||Children's Oncology Group|Yes|Completed|July 2004|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|30 Years|No|||July 2013|July 25, 2013|October 3, 2003||No||No||https://clinicaltrials.gov/show/NCT00070304||201502|
NCT00070720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 01|Improving Perinatal Care in Latin America|Clustered Trial for Improving Perinatal Care in Uruguay/Argentina||NICHD Global Network for Women's and Children's Health|Yes|Completed|September 2003|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||21780|||Both|N/A|N/A|No|||December 2013|December 16, 2013|October 7, 2003||||No||https://clinicaltrials.gov/show/NCT00070720||201478|
NCT00071591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062554|Rehabilitative Training for Older People With Schizophrenia|Functional Skills Training for Late Life Schizophrenia||University of California, San Diego||Completed|July 2001|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||240|||Both|40 Years|N/A|No|||June 2013|June 13, 2013|October 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00071591||201414|
NCT00071357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040003|Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer|Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|October 2003|October 2004||||N/A|Observational|N/A||||78|||Female|N/A|N/A|No|||October 2004|March 3, 2008|October 20, 2003||||No||https://clinicaltrials.gov/show/NCT00071357||201432|
NCT00070122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02556|Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer|A Phase III Trial of Modified FOLFOX6 Versus CAPOX, With Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients With Previously Untreated Advanced Colorectal Cancer||National Cancer Institute (NCI)||Terminated|April 2004|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2200|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|October 3, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00070122||201515|
NCT00070668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237|Inflammatory Genomics in Human Carotid Artery Disease|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||August 2008|August 20, 2008|October 6, 2003||||No||https://clinicaltrials.gov/show/NCT00070668||201482|
NCT00070681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158|Outcomes of Sleep Disorders in Older Men|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|June 2007|Actual|June 2007|Actual|Phase 3|Observational|N/A|||||||Male|65 Years|N/A|No|||April 2009|April 13, 2009|October 6, 2003||||No||https://clinicaltrials.gov/show/NCT00070681||201481|
NCT00070694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030315|An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression|An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907 in Combination With Escitalopram in Treatment Resistant Depression||National Institutes of Health Clinical Center (CC)||Completed|September 2003|October 2004||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||96|||Both|N/A|N/A|No|||October 2004|March 3, 2008|October 6, 2003||||No||https://clinicaltrials.gov/show/NCT00070694||201480|
NCT00070707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03280|Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280)|||Merck Sharp & Dohme Corp.||Terminated|April 2003|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|188|||Both|15 Years|75 Years|No|||June 2015|June 29, 2015|October 7, 2003|||Recruitment challenges.|||https://clinicaltrials.gov/show/NCT00070707||201479|
NCT00072124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000335471|Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma|A Prospective Random Assignment Trial Comparing Complete Metastasectomy to Chemotherapy for Selected Patients With Stage IV Melanoma||National Cancer Institute (NCI)||Completed|September 2003|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||January 2005|June 18, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072124||201375|
NCT00071370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040015|Activating Effects of Sleep Deprivation on Synchronized MEG-EEG Recordings of Epilepsy Patients With Non-Diagnostic EEG|Activating Effects of Sleep Deprivation On Synchronized MEG-EEG Recordings Of Epilepsy Patients With Non-Diagnostic EEG||National Institutes of Health Clinical Center (CC)||Completed|October 2003|November 2005||||N/A|Observational|N/A||||25|||Both|N/A|N/A|No|||November 2005|March 3, 2008|October 20, 2003||||No||https://clinicaltrials.gov/show/NCT00071370||201431|
NCT00071409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003068|Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes|A Randomized, Double-blind, Placebo-controlled, Rising Dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Type I Diabetes Mellitus Patients||Exsulin Corporation|No|Completed|October 2003|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|65 Years|No|||August 2011|July 10, 2014|October 22, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00071409||201428|
NCT00070148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU97102|Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer|A Phase III Randomized Study Comparing The Effects Of Oxandrolone (Oxandrin) And Megestrol Acetate (Megace) On Lean Body Mass, Weight, Body Fat, And Quality Of Life In Patients With Solid Tumors And Weight Loss Receiving Chemotherapy||Wake Forest NCORP Research Base|Yes|Completed|March 2004|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|155|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070148||201513|
NCT00071851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 052|Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults|A Phase IB Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, Administered at 2 Different Dosing Schedules, in HIV-1-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2003|October 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||180|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|November 3, 2003||||||https://clinicaltrials.gov/show/NCT00071851||201395|
NCT00070096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000329992|Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors|A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL||National Cancer Institute (NCI)||Completed|August 2003|June 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|29|||Both|16 Years|N/A|No|||April 2006|June 21, 2013|October 3, 2003||||||https://clinicaltrials.gov/show/NCT00070096||201517|
NCT00071422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003069|Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Rising-dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Insulin-using Type 2 Diabetes Mellitus Patients||Exsulin Corporation||Completed|October 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|126|||Both|35 Years|70 Years|No|||August 2011|July 10, 2014|October 22, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00071422||201427|
NCT00070382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000333213|Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer|A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy||Jonsson Comprehensive Cancer Center|Yes|Completed|August 2003|||November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|14|||Both|18 Years|N/A|No|||August 2012|October 1, 2015|October 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00070382||201499|
NCT00070811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13814|Assessing the Results of Lip Surgery in Patients With Cleft Lip and Palate|Functional Outcomes of Cleft Lip and Lip Revision Surgery||University of North Carolina, Chapel Hill|No|Completed|August 2001|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|127|||Both|3 Months|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited and screened mainly in the UNC Craniofacial Center, the        Graduate Orthodontic Clinic, the Pediatric Dentistry Clinic, and the Orthodontic Faculty        Practice of the University of North Carolina.|July 2013|July 2, 2013|October 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00070811||201473|
NCT00071162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-100|Genetics of Fibromyalgia|Fibromyalgia Family Study Registry||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|No|Active, not recruiting|September 1999|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Actual|560|Samples With DNA|DNA, whole blood|Both|12 Years|N/A|No|Probability Sample|The population of this study is family based and aimed to recruit 160 multic-case FMS        families. We plan to perform a genome scan and evaluate 200-300 linkage markers to FMS and        FMS-related traits. Future plans include establishing a DNA and data repository for        distribution for future studies.|March 2009|March 31, 2009|October 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00071162||201446|
NCT00070135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-100103|Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission|A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|January 2004|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|60 Years|74 Years|No|||July 2015|July 27, 2015|October 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00070135||201514|
NCT00089258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-050|Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment|Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Completed|July 2004|||November 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|74|||Both|N/A|N/A|No|||January 2013|January 15, 2013|August 4, 2004||||No||https://clinicaltrials.gov/show/NCT00089258||200185|
NCT00070447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000334470|Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma|Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients With Previously Untreated Mantle Cell Lymphoma||National Cancer Institute (NCI)||Completed|November 2003|June 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2004|January 27, 2014|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070447||201496|
NCT00070941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000941-01A1|SAM-e for the Treatment of Depression in Patients With Parkinson's Disease|SAM-e Treatment of Depression in Parkinson's Disease||New York University School of Medicine|Yes|Completed|July 2003|October 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|30 Years|80 Years|No|||January 2013|January 17, 2013|October 9, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070941||201463|
NCT00070642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C023|CPG 7909 Injection in Melanoma|ProMune™ (CPG 7909 Injection) With or Without Chemotherapy for the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open Label, Parallel Group, Active-Controlled, Phase II/III Study||Pfizer|No|Completed|December 2003|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|184|||Both|18 Years|N/A|No|||February 2009|February 9, 2009|October 6, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070642||201484|
NCT00070525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01806|Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma|A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma||National Cancer Institute (NCI)||Completed|November 2003|||September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|N/A|21 Years|No|||October 2013|October 7, 2013|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070525||201492|
NCT00070421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFT-NEWORLD|Study of @neWorld: A Virtual Community for Children With Cancer|@neWorld: A Virtual Community For Kids With Cancer||National Cancer Institute (NCI)||Completed|April 2003|January 2005|Actual|||Phase 1/Phase 2|Interventional|N/A|||||||Both|10 Years|15 Years|No|||December 2004|May 14, 2013|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070421||201498|
NCT00071916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-091|Racial Difference in HCV/Host Interactions|African American Response to Therapy for Hepatitis C||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|March 2001|June 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|260|Samples With DNA|Blood. No liver biopsies will be performed specifically for inclusion into the tissue      repository. Only slides or paraffin tissue blocks of previously performed liver biopsies      will be included in the tissue repository.|Both|18 Years|N/A|No|Non-Probability Sample|Adult, male or female, African-Americans or Caucasians, age 18 or older. Serum positive        for hepatitis C.|March 2010|October 28, 2010|November 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00071916||201391|
NCT00071929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000068235|Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer|Phase II Evaluation of Oxaliplatin in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|November 1999|September 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2004|June 20, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00071929||201390|
NCT00070265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02722|Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer|A Multi-Institutional Phase II Trial Of Neoadjuvant Capecitabine (XELODA) And Oxaliplatin (ELOXATIN) For Resectable Colorectal Metastases In The Liver||National Cancer Institute (NCI)||Terminated|August 2003|||September 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|N/A|No|||January 2013|January 23, 2013|October 3, 2003|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00070265||201505|
NCT00069745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPC SAT3-03-01|Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen|A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen||Agennix||Completed|September 2003|March 2007|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||August 2012|August 1, 2012|September 30, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00069745||201541|
NCT00070434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000334469|S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum|A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients With Clinical T4 Rectal Cancer||Southwest Oncology Group|Yes|Withdrawn|August 2004|||February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|October 3, 2003|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00070434||201497|
NCT00070837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M59102-051|MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer|A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer||Millennium Pharmaceuticals, Inc.||Completed|October 2003|October 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Male|18 Years|N/A|No|||July 2007|July 12, 2007|October 8, 2003||||Yes||https://clinicaltrials.gov/show/NCT00070837||201471|
NCT00071617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063881|Youth-Nominated Support Team Intervention for Suicidal Adolescents|Youth Support Team Intervention for Suicidal Adolescents||University of Michigan|Yes|Completed|November 2002|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|448|||Both|13 Years|17 Years|No|||November 2013|November 8, 2013|October 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00071617||201412|
NCT00071955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000269810|Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma|A Phase II Study to Evaluate Safety and Efficacy of Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH and GM-CSF Following the Anti-CD20 Antibody, Rituximab, in Previously Treated Patients With Follicular Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|March 2003|January 2009|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2006|December 18, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00071955||201388|
NCT00071838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040019|Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis|Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System||National Institutes of Health Clinical Center (CC)||Completed|October 2003|August 2011|Actual|October 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||August 2011|August 17, 2011|October 31, 2003||No||No||https://clinicaltrials.gov/show/NCT00071838||201396|
NCT00071461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-320|Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension|BUILD 1|Actelion|Yes|Completed|August 2003|May 2010|Actual|September 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|October 23, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00071461||201424|
NCT00071708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7443|Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial|Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial||Eli Lilly and Company||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||July 2008|July 30, 2008|October 29, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00071708||201405|
NCT00070473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0311|Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors|A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors||Children's Oncology Group|Yes|Completed|October 2003|June 2008|Actual|March 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|33|||Both|1 Year|21 Years|No|||February 2014|February 19, 2014|October 3, 2003|Yes|Yes||||https://clinicaltrials.gov/show/NCT00070473||201495|
NCT00071643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065134|Preventing Post-Stroke Depression|Prevention of Post-Stroke Depression - Treatment Strategy||University of Iowa||Active, not recruiting|September 2002|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|201|||Both|31 Years|89 Years|No|||July 2013|July 1, 2013|October 29, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00071643||201410|
NCT00072020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEFF-AZURE|Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer|Does Adjuvant Zoledronic Acid Reduce Recurrence in Patients With High Risk Localized Breast Cancer?||National Cancer Institute (NCI)||Active, not recruiting|August 2003|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2006|August 1, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072020||201383|
NCT00071032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159|Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease|Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)|FOCUS|Rutgers, The State University of New Jersey|Yes|Completed|July 2003|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2016|||Both|50 Years|N/A|No|||August 2014|August 14, 2014|October 9, 2003||No||No|August 14, 2014|https://clinicaltrials.gov/show/NCT00071032||201456|
NCT00071188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00007|ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)||AstraZeneca||Completed|February 2004|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 7, 2011|October 14, 2003||||No||https://clinicaltrials.gov/show/NCT00071188||201444|
NCT00070902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000123-01|Using MRI Scans to Evaluate Spinal Manipulation|The Effects of Positioning and Adjusting on the Z Joint||National Center for Complementary and Integrative Health (NCCIH)||Completed|June 2000|October 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|21 Years|29 Years|Accepts Healthy Volunteers|||August 2006|August 16, 2006|October 9, 2003||||No||https://clinicaltrials.gov/show/NCT00070902||201466|
NCT00089570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-0401|Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1||Orphan Therapeutics|Yes|Completed|June 2004|September 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|August 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089570||200163|
NCT00089583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV29005|48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection|See Detailed Description||ViiV Healthcare|Yes|Completed|July 2004|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|2 Years|18 Years|No|||April 2014|April 10, 2014|August 6, 2004|Yes|Yes||Yes|February 24, 2012|https://clinicaltrials.gov/show/NCT00089583||200162|
NCT00069953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0246|Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus||Radiation Therapy Oncology Group|Yes|Active, not recruiting|September 2003|||March 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|120 Years|No|||November 2015|November 14, 2015|October 3, 2003|Yes|Yes||No|October 14, 2014|https://clinicaltrials.gov/show/NCT00069953||201526|
NCT00070967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001010-01|Acupuncture to Improve Quality of Life in Patients With Advanced Cancer|Effects of Acupuncture on Pain, Nausea, Quality of Life||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2001|February 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|21 Years|N/A|No|||July 2006|August 17, 2006|October 9, 2003||||No||https://clinicaltrials.gov/show/NCT00070967||201461|
NCT00069810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Role of Chronic Kidney Disease in Cardiovascular Disease|Oxidative Stress in Chronic Kidney Disease||National Heart, Lung, and Blood Institute (NHLBI)|No|Withdrawn|August 2003|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|EDTA tube of whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People with chronic kidney disease and healthy subjects|July 2009|July 16, 2009|October 1, 2003||No|The study is not a clinical trial.|No||https://clinicaltrials.gov/show/NCT00069810||201537|
NCT00071968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000331979|Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse|An Open-Label Study Of Exploratory Pharmacogenomics And Pharmacologic Effects Of Neoadjuvant Oral CCI-779 In Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have A High Risk Of Relapse||Jonsson Comprehensive Cancer Center||Completed|August 2003|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Male|18 Years|N/A|No|||January 2013|January 7, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00071968||201387|
NCT00071981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000335055|Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma|A Randomized Phase II Trial of Multi-Epitope Vaccination With Melanoma Peptides For Cytotoxic T Cells And Helper T Cells For Patients With Metastatic Melanoma||Eastern Cooperative Oncology Group|No|Completed|March 2005|January 2014|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|175|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|November 4, 2003|Yes|Yes||No|November 24, 2012|https://clinicaltrials.gov/show/NCT00071981||201386|
NCT00069732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001190-01A1|Study of Two Complementary and Alternative Medical Treatments for Maintenance of Weight Loss|Pilot of Two CAM Treatments for Maintenance of Weight Loss||Kaiser Permanente||Terminated||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2010|February 11, 2010|September 30, 2003||||No||https://clinicaltrials.gov/show/NCT00069732||201542|
NCT00071721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0043|Valproate in Dementia (VALID)|A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)||Alzheimer's Disease Cooperative Study (ADCS)|Yes|Completed|October 2003|December 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|313|||Both|55 Years|90 Years|No|||September 2014|September 15, 2014|October 29, 2003|Yes|Yes||No|July 6, 2010|https://clinicaltrials.gov/show/NCT00071721||201404|
NCT00070733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD043348-01|The Effect of 5-Alpha Reductase on Testosterone in Men|The Role of 5-Alpha Reductase in Mediating Testosterone Actions||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|August 2003|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||184|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||October 2003|November 4, 2005|October 7, 2003||||No||https://clinicaltrials.gov/show/NCT00070733||201477|
NCT00070746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 09|Perinatal Infections in Pakistan|Perinatal Infections and Pregnancy Outcomes in Pakistan: A Collaborative Research Project in Partnership With the University of Alabama, USA||NICHD Global Network for Women's and Children's Health|Yes|Completed|June 2003|July 2005||||N/A|Observational|Time Perspective: Prospective||||1500|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|October 7, 2003||||No||https://clinicaltrials.gov/show/NCT00070746||201476|
NCT00070759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040006|Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis|Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|October 2003|October 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||6|||Both|18 Years|N/A|No|||October 2006|September 26, 2015|October 7, 2003||||No||https://clinicaltrials.gov/show/NCT00070759||201475|
NCT00070785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040007|Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations|Comprehensive Epitope Mapping of the Epstein-Barr Virus Latent Membrane Protein-2 in Ethnically Diverse Populations||National Institutes of Health Clinical Center (CC)||Completed|October 2003|April 2008||||N/A|Observational|N/A||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|September 26, 2015|October 7, 2003||||No||https://clinicaltrials.gov/show/NCT00070785||201474|
NCT00069836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|712753/009|Study Of AVANDAMET With Or Without Insulin In Type II Diabetes Mellitus Patients|A 24 Week, Randomised, Double Blind, Parallel Study to Compare the Change in HbA1c With AVANDAMET* (8.0 mg / 2.0 g) Plus Insulin to Placebo Plus Insulin, in Subjects With Type 2 Diabetes Starting Insulin Therapy||GlaxoSmithKline|No|Completed|October 2003|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||272|||Both|18 Years|70 Years|No|||November 2011|February 11, 2013|October 1, 2003||||||https://clinicaltrials.gov/show/NCT00069836||201535|
NCT00072033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 75/02|Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer|Docetaxel and Cisplatin Chemo- and Radiochemotherapy Followed by Surgery in Patients With Locally Advanced Esophageal Cancer - A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|March 2003|May 2010|Actual|March 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|70 Years|No|||June 2012|June 2, 2012|November 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00072033||201382|
NCT00070993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000967-01|Creatine for the Treatment of Amyotrophic Lateral Sclerosis|Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis||National Center for Complementary and Integrative Health (NCCIH)||Completed|December 2002|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||110|||Both|21 Years|80 Years|No|||August 2006|August 3, 2006|October 9, 2003||||||https://clinicaltrials.gov/show/NCT00070993||201459|
NCT00071487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBSL02|Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE)||Human Genome Sciences Inc.|Yes|Completed|October 2003|June 2006|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|449|||Both|18 Years|65 Years|No|||August 2013|August 1, 2013|October 24, 2003|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00071487||201422|
NCT00070850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD038940|Prenatal Screening For Smith-Lemli-Opitz Syndrome|The Feasibility of Screening for Smith-Lemli-Opitz Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|April 2001|July 2005||||Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1800|||Female|N/A|N/A|No|||August 2005|June 28, 2007|October 8, 2003||||No||https://clinicaltrials.gov/show/NCT00070850||201470|
NCT00070876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062469|Psychosocial Training for Pediatric Health Care Providers|Trial of Psychosocial Training for Pediatric Generalists||Johns Hopkins Bloomberg School of Public Health|No|Completed|August 2002|August 2008|Actual|August 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||350|||Both|6 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 1, 2013|October 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00070876||201468|
NCT00089921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005167|SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate|A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine||Scios, Inc.||Completed|July 2004|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|302|||Both|18 Years|N/A|No|||October 2010|October 15, 2010|August 17, 2004||No||No||https://clinicaltrials.gov/show/NCT00089921||200137|
NCT00071292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AT000084|Meditation-Based Stress Reduction in Rheumatoid Arthritis|Mindfulness Meditation-Based Stress Reduction in Relieving Symptoms Associated With Rheumatoid Arthritis||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2003|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||80|||Both|18 Years|N/A|No|||March 2008|March 5, 2008|October 17, 2003||||No||https://clinicaltrials.gov/show/NCT00071292||201436|
NCT00071305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040016|Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings|Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings||National Institutes of Health Clinical Center (CC)||Completed|October 2003|||October 2009|Actual|N/A|Observational|N/A||||35|||Both|18 Years|N/A|No|||October 2009|September 26, 2015|October 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00071305||201435|
NCT00071214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1371|Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis|A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis||Nabi Biopharmaceuticals||Completed|September 2003|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3600|||Both|18 Years|N/A|No|||July 2006|July 7, 2006|October 15, 2003||||||https://clinicaltrials.gov/show/NCT00071214||201442|
NCT00071227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040013|Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders|Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders||National Institutes of Health Clinical Center (CC)||Completed|October 2003|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||August 2007|September 26, 2015|October 15, 2003||||No||https://clinicaltrials.gov/show/NCT00071227||201441|
NCT00088738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040189|Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ|Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F] SPA-RQ||National Institutes of Health Clinical Center (CC)||Completed|July 2004|September 2008||||Phase 1|Interventional|Primary Purpose: Treatment|1|||84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 11, 2008|July 30, 2004||No||No||https://clinicaltrials.gov/show/NCT00088738||200222|
NCT00089024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035-04|Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase II Study Of Neo-Adjuvant Chemotherapy And Radiation In Patients With Locally Advanced Pancreatic Cancer||University of Nebraska|Yes|Active, not recruiting|February 2004|||December 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|19 Years|N/A|No|||June 2010|June 1, 2010|August 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089024||200202|
NCT00069849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-614|A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease|A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease||Abbott||Terminated|July 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|50 Years|85 Years|No|||August 2006|August 31, 2006|October 1, 2003||||||https://clinicaltrials.gov/show/NCT00069849||201534|
NCT00070109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0221|Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors|A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas||Children's Oncology Group|Yes|Completed|January 2008|December 2013|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|50|||Both|12 Months|50 Years|No|||September 2014|September 16, 2014|October 3, 2003|Yes|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00070109||201516|
NCT00070239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00039|Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies|A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies||National Cancer Institute (NCI)||Terminated|August 2003|||June 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|October 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00070239||201507|
NCT00071045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040012|Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members|Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members||National Institutes of Health Clinical Center (CC)||Recruiting|October 2003|||||N/A|Observational|N/A|||Anticipated|9999|||Both|2 Years|N/A|Accepts Healthy Volunteers|||October 2015|March 11, 2016|October 9, 2003||No||No||https://clinicaltrials.gov/show/NCT00071045||201455|
NCT00069888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976J_2501|A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy|A Multicenter, Open-Label, Phase II Trial of Adjuvant Taxotere in Patients At High Risk of Relapse Following Prostatectomy||Sanofi||Completed|November 2001|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|83|||Male|18 Years|N/A|No|||June 2011|June 7, 2011|October 2, 2003||||No||https://clinicaltrials.gov/show/NCT00069888||201531|
NCT00070291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000331864|Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma|A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma||Eastern Cooperative Oncology Group|No|Terminated|September 2005|May 2011|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|October 3, 2003|Yes|Yes|Slow accrual.|No|January 7, 2013|https://clinicaltrials.gov/show/NCT00070291||201503|
NCT00070005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKTO-2002-02-POCASTER|J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma|A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2002|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|100|||Both|18 Years|N/A|No|||April 2007|August 6, 2013|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070005||201523|
NCT00070018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000329864|S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma|Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin Lymphoma, Phase II||Southwest Oncology Group|No|Active, not recruiting|February 2004|November 2018|Anticipated|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|October 3, 2003|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT00070018||201522|
NCT00071084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-CD4-008|Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.|||Emergent Product Development Seattle LLC||Completed|May 2003|||June 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2012|December 5, 2012|October 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00071084||201452|
NCT00090285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-020|An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)|An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men||Merck Sharp & Dohme Corp.||Active, not recruiting|September 2004|December 2017|Anticipated|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|4065|||Male|16 Years|26 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|August 25, 2004|Yes|Yes||No|October 14, 2009|https://clinicaltrials.gov/show/NCT00090285||200110|
NCT00071552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-402-4-196|Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients|Evaluation of Clinical Efficacy of HFA-Propelled Beclomethasone Dipropionate Metered-Dose Inhaler Versus Fluticasone Propionate Multidose Dry Powder Inhaler on Small Airways in Poorly Controlled Asthmatic Adolescent and Adult Patients||Teva Pharmaceutical Industries|No|Terminated|January 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|12 Years|70 Years|No|||May 2014|May 9, 2014|October 28, 2003||Yes|Very poor enrollment|No||https://clinicaltrials.gov/show/NCT00071552||201417|
NCT00072072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000335434|Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase I Trial Of A COX-2 Inhibitor (Celecoxib) In Combination With An EGFR Inhibitor (OSI-774) In Metastatic Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|August 2003|January 2006|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||January 2006|September 19, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072072||201379|
NCT00072085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000335441|Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma|Immunization Of Patients With Metastatic Melanoma Using A Recombinant GP100 Protein (184V) And A Class I Restricted Peptide From The GP100 Antigen||National Cancer Institute (NCI)||Completed|September 2003|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||May 2005|June 18, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072085||201378|
NCT00071110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001218-01A1|Electroacupuncture for Major Depression|Electroacupuncture for Major Depression: A Pilot Study||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|80 Years|No|||December 2009|December 4, 2009|October 10, 2003||No||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00071110||201450|Four participants were excluded from the analyses because of a protocol violation. In the Sham Acupuncture group, the acupuncturist placed unelectrified needles in GV-20 and Yin tang points instead of placing them laterally.
NCT00071123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040002|Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder|The Functional Neuroanatomy of Emotion Regulation in Major Depressive Disorder (MDD)||National Institutes of Health Clinical Center (CC)||Completed|October 2003|November 2010||||N/A|Observational|N/A|||Actual|172|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 16, 2010|October 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00071123||201449|
NCT00071578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH066330|Comparing Two Group Therapy Treatments for Binge Eating Disorder|Comparison of Dialectical Behavior Therapy and Supportive Therapy for Binge Eating Disorder||Stanford University|Yes|Completed|October 2003|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|October 29, 2003||No||No||https://clinicaltrials.gov/show/NCT00071578||201415|
NCT00071747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA30926|Clinical Study Of Schizophrenia in Both Men and Women|A Multi-Center, Double Blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine Versus Placebo As Add-On Therapy In Schizophrenia||GlaxoSmithKline||Completed|August 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||176|||Both|18 Years|65 Years|No|||October 2010|October 4, 2010|October 30, 2003||||||https://clinicaltrials.gov/show/NCT00071747||201402|
NCT00071760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV20002|Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects|A 48 Week, Phase II, Open-label, 2-cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-experienced Pediatric Subjects Aged 4 Weeks to <2 Years.||ViiV Healthcare|Yes|Active, not recruiting|October 2003|June 2021|Anticipated|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|N/A|2 Years|No|||May 2014|May 8, 2014|October 30, 2003|Yes|Yes||No|March 2, 2012|https://clinicaltrials.gov/show/NCT00071760||201401|
NCT00089037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1811.00|Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation|A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors||Fred Hutchinson Cancer Research Center||Completed|June 2003|April 2005|Actual|April 2005|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|N/A|N/A|No|||July 2011|July 13, 2011|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089037||200201|
NCT00071331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-03-236|EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan|Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|September 2003|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||3600|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|October 20, 2003||||||https://clinicaltrials.gov/show/NCT00071331||201434|
NCT00070057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01441|Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer|An Exploratory, Open-Label Phase I Pharmacodynamic Study of COX-2 Inhibition With Celecoxib (Celebrex) and Aromatase Activity in Breast Cancer||National Cancer Institute (NCI)||Completed|April 2003|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Female|18 Years|N/A|No|||February 2013|September 12, 2014|October 3, 2003||No||No||https://clinicaltrials.gov/show/NCT00070057||201520|
NCT00070070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000329920|Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder|NY-ESO-1 Protein Immunization of Post-Cystectomy Patients With Transitional Cell Carcinomas Expressing NY-ESO-1 or LAGE-1 Antigen||Ludwig Institute for Cancer Research||Completed|May 2003|||April 2006|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2013|July 18, 2013|October 3, 2003||||No||https://clinicaltrials.gov/show/NCT00070070||201519|
NCT00070564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000334899|S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer|Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|November 2003|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|3250|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|October 3, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00070564||201489|
NCT00070577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030283|Influence of Age and Sex on Alcohol Metabolism and Acute Responses|Influence of Age and Sex on Alcohol Metabolism and Acute Responses||National Institutes of Health Clinical Center (CC)||Completed|September 2003|May 2011||||N/A|Observational|N/A|||Actual|65|||Both|21 Years|65 Years|No|||May 2011|May 4, 2011|October 3, 2003||No||No||https://clinicaltrials.gov/show/NCT00070577||201488|
NCT00070590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-330|Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis||Actelion||Completed|July 2003|September 2005|Actual|September 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||132|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|October 6, 2003||Yes||||https://clinicaltrials.gov/show/NCT00070590||201487|
NCT00071812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBRA01|A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)|A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)||Human Genome Sciences Inc.|Yes|Completed|December 2003|December 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|283|||Both|18 Years|65 Years|No|||August 2013|August 1, 2013|October 31, 2003|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00071812||201397|
NCT00089778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040259|Vaccine Treatment of Kidney Cancer|Immunization of Patients With Renal Cancer Using HLA-A2 and HLA-A3-Binding Peptides From Fibroblast Growth Factors 5 (FGF-5)||National Institutes of Health Clinical Center (CC)|No|Terminated|August 2004|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|16 Years|N/A|No|||September 2012|September 11, 2012|August 12, 2004||No|Finding that fewer tumors than anticipated expressed FGF-5 led to the termination of accrual    to cohorts A and B.|No|June 25, 2012|https://clinicaltrials.gov/show/NCT00089778||200147|
NCT00089791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030216|A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis|A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)||Amgen|Yes|Completed|August 2004|July 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7808|||Female|60 Years|90 Years|No|||February 2016|February 4, 2016|August 13, 2004||Yes||No|July 2, 2010|https://clinicaltrials.gov/show/NCT00089791||200146|
NCT00089804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJP 394-90-14|Study of LJP 394 in Lupus Patients With History of Renal Disease|A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease|ASPEN|La Jolla Pharmaceutical Company|Yes|Terminated|October 2004|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|943|||Both|12 Years|70 Years|No|||March 2009|March 30, 2009|August 13, 2004|Yes|Yes|Interim efficacy analysis indicated it would be futile to continue study.|No||https://clinicaltrials.gov/show/NCT00089804||200145|
NCT00090753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH18387|A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia|An Open-label, Multi-center Study to Document the Efficacy, Safety, and Tolerability of Long-term Administration of RO0503821 in Patients With Chronic Renal Anemia||Hoffmann-La Roche||Completed|October 2004|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1228|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|September 3, 2004|Yes|Yes||No|December 1, 2011|https://clinicaltrials.gov/show/NCT00090753||200077|
NCT00090454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1266|Genetic Markers of CHD Risk in Men and Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 23, 2008|August 26, 2004||||No||https://clinicaltrials.gov/show/NCT00090454||200098|
NCT00091416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 057|Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052|A Phase I Clinical Trial to Evaluate the Safety of a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Administered to Healthy, HIV-1 Uninfected, Adult Participants Who Received DNA Plasmid Vaccine or Placebo in the HVTN 052 Clinical Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|September 8, 2004||||||https://clinicaltrials.gov/show/NCT00091416||200039|
NCT00090363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00006|ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)|Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)||AstraZeneca||Completed|July 2004|August 2011|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|447|||Male|18 Years|N/A|No|||January 2013|January 3, 2013|August 25, 2004|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00090363||200105|‘Final analysis’ results (data cut-off 18th December 2008) should be considered in context with the longevity of the follow-up (median duration approximately 22 months) relative to only approximately 4 months median duration of study treatment.
NCT00090675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00019|Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase IIIb Randomized, Double-Blind Study Comparing Maintenance ZD1839 (IRESSA®) or Placebo Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer|IMAC/Herbst|AstraZeneca||Withdrawn|January 2006|November 2007|Anticipated|November 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|September 2, 2004||Yes|No patients randomised|||https://clinicaltrials.gov/show/NCT00090675||200083|
NCT00090467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1267|Biochemical and Genetic Markers of Hypertension in Women|||Brigham and Women's Hospital||Completed|August 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1600|||Female|50 Years|70 Years|No|Probability Sample|Women's Health Initiative Observational Study (WHI OS)|July 2013|July 26, 2013|August 26, 2004||No||No||https://clinicaltrials.gov/show/NCT00090467||200097|
NCT00090766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV16726|A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients|An Open-label Study of the Safety and Pharmacokinetics of Valcyte Syrup in Pediatric Solid Organ Transplant Patients||Hoffmann-La Roche||Completed|May 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|3 Months|16 Years|No|||March 2016|March 1, 2016|September 3, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090766||200076|
NCT00091715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARLY|Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)||Actelion||Completed|April 2004|February 2011|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|185|||Both|12 Years|N/A|No|||August 2011|August 26, 2011|September 16, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091715||200017|
NCT00087386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01453|Tanespimycin in Treating Patients With Stage III-IV Melanoma|Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients||National Cancer Institute (NCI)||Terminated|June 2004|||February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087386||200320|
NCT00092131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-270|Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 2-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast on Exercise-Induced Bronchospasm||Merck Sharp & Dohme Corp.|No|Completed|June 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|51|||Both|15 Years|45 Years|No|||June 2015|June 22, 2015|September 21, 2004|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00092131||199985|
NCT00089596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB001|Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers|A Safety Study of Infusion of Ex Vivo Selectively Amplified Unrelated Cord Blood Stem Cells in Subjects With Hematological Malignancies Receiving Unrelated Cord Blood Transplantation||ViaCell||Completed|March 2004|October 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|12 Years|60 Years|No|||April 2007|April 11, 2007|August 6, 2004||||No||https://clinicaltrials.gov/show/NCT00089596||200161|
NCT00091702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1057|Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents|A Phase I/II Randomized Trial of the Safety and Immunogenicity of Cold Adapted Influenza Vaccine (FluMist) in HIV-Infected Children and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||300|||Both|5 Years|17 Years|No|||May 2012|May 16, 2012|September 16, 2004||||No||https://clinicaltrials.gov/show/NCT00091702||200018|
NCT00089063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02618|Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma|A Randomized Phase II Continuation Booster Trial After A Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 and ISA 51 VG With Or Without GM-CSF For Patients With Resected Stages IIB/C, III And IV Melanoma||National Cancer Institute (NCI)||Completed|June 2004|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2013|April 14, 2015|August 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089063||200199|
NCT00089960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040110|Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)|An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate||Amgen||Completed|October 2004|June 2008|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|August 18, 2004||||Yes||https://clinicaltrials.gov/show/NCT00089960||200135|
NCT00091130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02623|SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells|An Exploratory Study to Evaluate the Effect of HPV 16 Vaccine on the Reduction of Viral Load in HPV 16 Positive Women With Persistent Viral Infection, But Low Grade Disease (ASCUS/LSIL)||National Cancer Institute (NCI)||Completed|September 2004|||June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|139|||Female|18 Years|50 Years|No|||March 2013|May 31, 2013|September 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091130||200057|
NCT00091442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004120|A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer|A Randomized Controlled Study of Docetaxel Monotherapy or Docetaxel and DOXIL for the Treatment of Advanced Breast Cancer||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|September 2004|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|751|||Female|18 Years|N/A|No|||April 2014|April 2, 2014|September 8, 2004|Yes|Yes||No|December 15, 2009|https://clinicaltrials.gov/show/NCT00091442||200037|
NCT00091468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0060|Nicotine Treatment of Mild Cognitive Impairment (MCI)|Double-Blind Treatment of Mild Cognitive Impairment (MCI) With Transdermal Nicotine or Transdermal Placebo||National Institute on Aging (NIA)|Yes|Active, not recruiting|September 2003|July 2008|Anticipated|July 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|55 Years|90 Years|No|||January 2008|January 7, 2008|September 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091468||200036|
NCT00091481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-367|Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis|A Randomized, Active-Controlled, Double-Blind Multi-Center Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis||Abbott||Completed|June 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|201|||Both|20 Years|N/A|No|||September 2007|September 23, 2007|September 9, 2004||||||https://clinicaltrials.gov/show/NCT00091481||200035|
NCT00087828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31 AT000623-1|Identification of the Cranberry Juice Compounds That Prevent Urinary Tract Infections|Cranberry Juice Metabolites in Urine||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2000|June 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||5|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||August 2006|August 16, 2006|July 14, 2004||||No||https://clinicaltrials.gov/show/NCT00087828||200286|
NCT00089076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02784|MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma|Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Terminated|June 2004|October 2009|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2012|May 22, 2014|August 4, 2004|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00089076||200198|
NCT00090506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001942-01|Yoga for Treating People at Risk for Diabetes or With Both HIV and Depression|Yoga, Health, and Meditation||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2004|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|14 Years|40 Years|No|||January 2008|January 23, 2008|August 26, 2004||No||No||https://clinicaltrials.gov/show/NCT00090506||200094|
NCT00090519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8211|Reduction in the Occurrence of Center-Involved Diabetic Macular Edema|Reduction in the Occurrence of Center-Involved Diabetic Macular Edema||Eli Lilly and Company|No|Completed|February 2004|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|737|||Both|18 Years|N/A|No|||June 2010|February 25, 2011|August 26, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090519||200093|
NCT00092196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004_064|Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)|Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy||Merck Sharp & Dohme Corp.||Completed|December 2002|||February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||820|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092196||199980|
NCT00092209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-302|Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)|A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of the Anti-Hypertensive Efficacy and Safety of Losartan Monotherapy as Compared to HCTZ Monotherapy and to the Combination of Losartan and HCTZ in Japanese Patients With Essential Hypertension||Merck Sharp & Dohme Corp.||Completed|April 2002|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||840|||Both|25 Years|74 Years|No|||March 2015|March 17, 2015|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092209||199979|
NCT00089323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP BP-59|Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer|Bone Marrow Analysis In Early-Stage Breast Cancer||NSABP Foundation Inc|No|Active, not recruiting|January 2007|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1630|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00089323||200180|
NCT00091026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02622|Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer|A Randomized Phase II Study of Bevacizumab (NSC# 704865) and Gemcitabine in Combination With Either Cetuximab (NSC# 714692) or OSI-774 (NSC# 718781) in Patients With Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|July 2004|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||December 2012|April 28, 2014|September 7, 2004|Yes|Yes||No|August 6, 2013|https://clinicaltrials.gov/show/NCT00091026||200064|
NCT00091156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08021|Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa™) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|May 2004|||July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|598|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|September 7, 2004|||low accrual|No||https://clinicaltrials.gov/show/NCT00091156||200055|
NCT00087438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0236|Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer|A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I/II Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|May 2004|||March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|July 8, 2004||No||No|February 25, 2014|https://clinicaltrials.gov/show/NCT00087438||200316|
NCT00088751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040247|Treatment Study of Frontotemporal Dementia|Treatment Study for Frontotemporal Dementia||National Institutes of Health Clinical Center (CC)||Completed|July 2004|June 2009||||N/A|Observational|N/A||||20|||Both|45 Years|95 Years|No|||June 2009|June 3, 2009|July 31, 2004||No||No||https://clinicaltrials.gov/show/NCT00088751||200221|
NCT00089947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-101-1025|A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection|Randomized, Prospective, Phase 2 Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Protocol With Standard Corticosteroid Therapy in Living Donor Renal Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy||Sanofi||Completed|June 2003|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|August 18, 2004||||||https://clinicaltrials.gov/show/NCT00089947||200136|
NCT00090298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-058|Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|April 2004|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|2815|||Both|18 Years|69 Years|No|||October 2015|October 30, 2015|August 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090298||200109|
NCT00090870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378049|PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Of Peg-Intron, GM-CSF And Thalidomide In Metastatic Renal Cell Carcinoma||Medical University of South Carolina|Yes|Completed|April 2002|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|September 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090870||200070|
NCT00091494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268|Socioeconomic Patterning of Inflammation and Hemostasis - Ancillary to MESA|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 23, 2008|September 9, 2004||||No||https://clinicaltrials.gov/show/NCT00091494||200034|
NCT00091754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1269|Atherosclerosis, Plaque and CVD in Communities|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 23, 2008|September 16, 2004||||No||https://clinicaltrials.gov/show/NCT00091754||200014|
NCT00080236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-000006556-PRO-0006|Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation|Safety, Tolerability and Efficacy Study of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation (OLT)||Conatus Pharmaceuticals Inc.|Yes|Completed|November 2003|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|March 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00080236||200802|
NCT00080262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-081|Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)|Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine||Bristol-Myers Squibb||Completed|February 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||125|||Female|18 Years|N/A|No|||April 2011|April 7, 2011|March 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080262||200801|
NCT00089284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 02H8|Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL|A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90-Yttrium- Zevalin and the Redox- Modulating Agent, Motexafin Gadolinium (MGd)||Northwestern University|Yes|Active, not recruiting|September 2003|April 2012|Anticipated|December 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2011|April 11, 2011|August 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089284||200183|
NCT00090324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C00112|Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia|A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets Compared With Placebo in Adolescents With Schizophrenia (Abbreviated)|ANCHOR 112|AstraZeneca||Completed|September 2004|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|249|||Both|13 Years|17 Years|No|||January 2013|January 3, 2013|August 25, 2004||||No||https://clinicaltrials.gov/show/NCT00090324||200107|
NCT00090623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3192g|A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)|A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration||Genentech, Inc.||Completed|August 2004|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|50 Years|N/A|No|||June 2013|June 19, 2013|August 30, 2004||||||https://clinicaltrials.gov/show/NCT00090623||200086|
NCT00091819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0017|Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus|ATLAS1|Theravance Biopharma Antibiotics, Inc.|No|Completed|January 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|862|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|September 17, 2004|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00091819||200009|
NCT00091832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040113|Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer|A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.||Amgen||Completed|September 2004|October 2006|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|6||Actual|255|||Female|18 Years|N/A|No|||December 2013|December 20, 2013|September 17, 2004||||No|December 9, 2010|https://clinicaltrials.gov/show/NCT00091832||200008|
NCT00078078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040127|Clinical and Laboratory Study of Methylmalonic Acidemia|Clinical and Basic Investigations of Methylmalonic Acidemia (MMA) and Related Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|February 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|N/A|N/A|No|||March 2016|March 16, 2016|February 18, 2004||No||No||https://clinicaltrials.gov/show/NCT00078078||200958|
NCT00090779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5217|Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV|The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?||AIDS Clinical Trials Group|Yes|Terminated|January 2005|May 2011|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|September 3, 2004|Yes|Yes|The DSMB concluded that the findings regarding the primary analysis would persist and that no    additional study goals would be achieved by continuing the study.|No|July 2, 2012|https://clinicaltrials.gov/show/NCT00090779||200075|
NCT00091117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00059|Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction|A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEPSponsored Organ Dysfunction Working Group||National Cancer Institute (NCI)||Completed|July 2004|||March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|September 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00091117||200058|
NCT00088179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003141|Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)||Alexion Pharmaceuticals||Active, not recruiting|July 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||4000|||Both|18 Years|N/A|No|||August 2005|August 28, 2005|July 21, 2004||||||https://clinicaltrials.gov/show/NCT00088179||200261|
NCT00089310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378197|Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer|Intraoperative Sentinel Node Mapping In Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|September 2004|April 2009|Actual|February 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|46|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089310||200181|
NCT00078390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0207P1421|Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer|A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer.||Shionogi||Active, not recruiting|February 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|85 Years|No|||December 2004|June 23, 2005|February 24, 2004||||||https://clinicaltrials.gov/show/NCT00078390||200934|
NCT00078403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5178|Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)|Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2004|February 2009|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|338|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|February 24, 2004|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00078403||200933|
NCT00092092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-254|Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)|A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 2-Arm, 2X2 Crossover Study Comparing the Effects of Montelukast, Inhaled Budesonide, and Placebo on Lower Leg Growth in Children (Prepubertal, Tanner Stage I) With Mild Asthma||Merck Sharp & Dohme Corp.|No|Completed|October 2002|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|71|||Both|6 Years|11 Years|No|||June 2015|June 25, 2015|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092092||199988|
NCT00092105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-256|Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)|A Multicenter, Double-Blind, Randomized, Crossover Study Investigating the Clinical Effect of Montelukast in Patients With Concomitant Asthma and Allergic Rhinitis Upon Controlled Exposure to Cat Allergen||Merck Sharp & Dohme Corp.||Completed|April 2002|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|58|||Both|15 Years|55 Years|No|||September 2015|September 2, 2015|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092105||199987|
NCT00089648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181039|SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma|A Phase 2 Study Of SU011248 In The Treatment Of Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma||Pfizer|No|Completed|December 2004|March 2008|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|August 9, 2004|No|Yes||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00089648||200157|
NCT00089661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040135|AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer||Amgen||Completed|October 2004|December 2009|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|252|||Female|18 Years|N/A|No|||July 2013|July 23, 2013|August 9, 2004||Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00089661||200156|
NCT00091299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000386239|Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors|An Open Label, Non Randomized , One Sequence, Add-On Study to Investigate the Effects of PTK787/ZK 222584 on the Pharmacokinetics and Pharmacodynamics of Warfarin at Steady-States in Cancer Patients||Jonsson Comprehensive Cancer Center|Yes|Completed|May 2004|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2012|October 1, 2015|September 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00091299||200046|
NCT00091312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000387797|Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer|Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors||National Cancer Institute (NCI)||Active, not recruiting|June 2004|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1976|||Both|18 Years|75 Years|No|||December 2006|February 6, 2009|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00091312||200045|
NCT00090428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54MH066397|Diet and Behavior in Young Children With Autism|Diet and Behavior in Young Children With Autism||University of Rochester|Yes|Completed|January 2004|February 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|30 Months|54 Months|No|||January 2013|January 31, 2013|August 26, 2004||No||No||https://clinicaltrials.gov/show/NCT00090428||200100|
NCT00090168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-806|Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)|A Multicenter Study to Assess the Cholesterol Lowering Level of Switching to an Investigational Drug Compared to Doubling the Dose of an Investigational Drug in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease||Merck Sharp & Dohme Corp.||Completed|January 2004|November 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|435|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|August 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090168||200119|
NCT00091728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD7034|Hormonal Contraception and Risk of Chlamydia and Gonorrhea|Hormonal Contraception, Cervical Ectopy, and STDs||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Terminated|September 1997|August 2001||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1200|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||September 2004|November 4, 2005|September 16, 2004||||No||https://clinicaltrials.gov/show/NCT00091728||200016|
NCT00092118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-265|The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|October 2003|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1992|||Both|15 Years|85 Years|No|||May 2015|May 25, 2015|September 21, 2004|Yes|Yes||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00092118||199986|
NCT00089050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1820.00|Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia|A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60||Fred Hutchinson Cancer Research Center||Completed|May 2004|March 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|60 Years|N/A|No|||November 2011|November 28, 2011|August 4, 2004||||No||https://clinicaltrials.gov/show/NCT00089050||200200|
NCT00089297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378194|Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer|Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck||Eastern Cooperative Oncology Group|No|Completed|December 2004|February 2011|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||December 2012|February 7, 2013|August 4, 2004|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00089297||200182|
NCT00090311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C00149|Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania|A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbreviated)|ANCHOR 149|AstraZeneca||Completed|July 2004|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|220|||Both|10 Years|17 Years|No|||January 2013|January 3, 2013|August 25, 2004||||||https://clinicaltrials.gov/show/NCT00090311||200108|
NCT00090584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-DRI (completed)|Behavior Enhances Drug Reduction of Incontinence (BE-DRI)|Behavior Enhances Drug Reduction of Incontinence|BE-DRI|New England Research Institutes|Yes|Completed|August 2004|August 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|307|||Female|21 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 8, 2013|August 27, 2004||No||No|August 27, 2012|https://clinicaltrials.gov/show/NCT00090584||200088|Ony 68% of participants completed assigned treatment.
NCT00090181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-806|Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)|A Double-Blind, Parallel-group, 4-Week Trial to Assess the Efficacy and Safety of Etoricoxib 60 mg and Diclofenac 150 mg in Patients With Chronic Low Back Pain||Merck Sharp & Dohme Corp.||Completed|June 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|401|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|August 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090181||200118|
NCT00090441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1265|Risk Burden of Lipoprotein Metabolic Gene Haplotypes|||Intermountain Health Care, Inc.|No|Completed|August 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|4303|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study subjects for the primary association study were selected from Intermountain        Healthcare's ongoing Angiographic Registry and DNA Bank.|December 2012|January 3, 2013|August 26, 2004||No||No||https://clinicaltrials.gov/show/NCT00090441||200099|
NCT00091741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 03-365|Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects|A Phase I Pilot Study to Evaluate Safety and Efficacy of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects Who Are in Virologic Failure and Who Have Failed to Respond to Standard Antiretroviral Therapy||Georgetown University||Completed||October 2004|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|60 Years|No|||September 2004|July 21, 2009|September 16, 2004||||||https://clinicaltrials.gov/show/NCT00091741||200015|
NCT00088504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX03-497-205|Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C|A Phase 2b Study of Merimepodib in Combination With Pegylated Interferon Alfa-2a (Pegasys®) and Ribavirin in Subjects With Chronic Hepatitis C Non-Responsive to Prior Therapy With Pegylated Interferon Alfa and Ribavirin||Vertex Pharmaceuticals Incorporated||Completed|July 2004|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||315|||Both|18 Years|70 Years|No|||December 2007|December 17, 2007|July 27, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088504||200239|
NCT00090649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-309|Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Of DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|369|||Both|18 Years|75 Years|No|||August 2009|August 18, 2009|August 31, 2004||||||https://clinicaltrials.gov/show/NCT00090649||200085|
NCT00091429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 3037|Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day||Gilead Sciences||Completed|August 2004|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|September 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091429||200038|
NCT00090844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000374991|Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer|Preservation of Ovarian Function in Young Women Treated With (Neo) Adjuvant Chemotherapy for Breast Cancer: A Randomized Trial Using the Gonadotropin-releasing Hormone (GnRH) Agonist (Triptorelin) During Chemotherapy||University of South Florida|Yes|Terminated|July 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|49|||Female|N/A|44 Years|No|||January 2013|January 23, 2013|September 7, 2004|No|Yes|Early closure due to low accrual|No|November 30, 2012|https://clinicaltrials.gov/show/NCT00090844||200072|Study closed to accrual early due to futility
NCT00087425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000377250|Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase II Trial Of Bryostatin-1 In Combination With Rituximab In Rituximab-Refractory Indolent B-cell Non Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|July 2004|||October 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2007|April 29, 2015|July 8, 2004||||||https://clinicaltrials.gov/show/NCT00087425||200317|
NCT00089999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF20009|Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer|A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients With Advanced or Metastatic Breast Cancer||GlaxoSmithKline|No|Completed|June 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|138|||Female|18 Years|N/A|No|||September 2014|April 23, 2015|August 18, 2004|Yes|Yes||No|August 18, 2014|https://clinicaltrials.gov/show/NCT00089999||200132|
NCT00090012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8894|Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder|The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder||Eli Lilly and Company||Completed|July 2004|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||340|||Both|18 Years|75 Years|No|||November 2007|November 5, 2007|August 18, 2004||||||https://clinicaltrials.gov/show/NCT00090012||200131|
NCT00089635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030250|ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer|A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy||Amgen||Completed|August 2004|December 2008|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|203|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|August 9, 2004||||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00089635||200158|
NCT00091143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000383908|Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma|A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|July 2004|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||August 2009|April 2, 2013|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00091143||200056|
NCT00091767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1270|Genetic Studies in Difficult to Treat Asthma: TENOR|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A|||||||Both|6 Years|N/A|No|||July 2008|July 23, 2008|September 16, 2004||||No||https://clinicaltrials.gov/show/NCT00091767||200013|
NCT00091780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1271|Epidemiology of Breast Arterial Calcification|||Mayo Clinic||Completed|September 2004|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Female|N/A|N/A|No|||February 2014|February 19, 2014|September 16, 2004||||No||https://clinicaltrials.gov/show/NCT00091780||200012|
NCT00091793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040132|Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis|A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis||Amgen||Completed|August 2004|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|332|||Female|N/A|90 Years|No|||December 2010|December 22, 2010|September 17, 2004||||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00091793||200011|
NCT00078767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K02MH001938|Pharmacologic Treatment of PTSD in Sexually Abused Children|||Allegheny Singer Research Institute||Completed|April 2001|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|10 Years|18 Years|No|||November 2013|November 20, 2013|March 5, 2004||||No||https://clinicaltrials.gov/show/NCT00078767||200909|
NCT00078793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021626|Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis|Phase IV Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis||Amgen||Completed|June 2000|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|2 Years|18 Years|No|Non-Probability Sample|Pediatric subjects age 2 to < or = 18 years of age with polyarticular course or systemic        JRA who have recently started and are currently receiving: etanercept alone or in        combination with methotrexate or other DMARDs; methotrexate alone or in combination with        other DMARDs.The population includes pediatric subjects who completed Immunex protocol        016.0028 and selected other Immunex protocols will be eligible for this study once they        change to marketed etanercept.|May 2013|May 10, 2013|March 5, 2004||||No||https://clinicaltrials.gov/show/NCT00078793||200908|
NCT00089271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02620|17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas|A Phase I Study Of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin, (17-DMAG) (NSC 707545) In Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|July 2004|||June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089271||200184|
NCT00091572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03267|Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)|Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group||Merck Sharp & Dohme Corp.|Yes|Completed|October 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|859|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|September 10, 2004|No|Yes||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00091572||200028|
NCT00091806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030251|Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors|An Open-Label, Clinical Trial Evaluating the Safety and Pharmacokinetics of Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors||Amgen||Completed|August 2004|October 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||July 2009|July 9, 2009|September 17, 2004||||No||https://clinicaltrials.gov/show/NCT00091806||200010|
NCT00092222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040275|Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity|Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity||National Institutes of Health Clinical Center (CC)||Recruiting|September 2004|October 2020|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|55|||Both|12 Years|65 Years|No|||November 2015|December 15, 2015|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092222||199978|
NCT00080678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000354505|Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases|Randomized Double-Blind Phase II Trial of Docetaxel and Imatinib Versus Docetaxel and Placebo in Metastatic Androgen-Independent Prostate Cancer (AIPC) With Bone Metastases||M.D. Anderson Cancer Center|No|Completed|May 2003|March 2008|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|116|||Male|N/A|N/A|No|||October 2012|October 10, 2012|April 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00080678||200772|
NCT00089609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040257|Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer|A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients With Androgen-Independent Prostate Cancer||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|August 2004|January 2017|Anticipated|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Male|18 Years|N/A|No|||February 2016|February 24, 2016|August 6, 2004|Yes|Yes||No|October 12, 2012|https://clinicaltrials.gov/show/NCT00089609||200160|
NCT00089622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040258|Lisuride Patch to Treat Parkinson's Disease|Transcutaneous Lisuride Therapy of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2004|March 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||40|||Both|40 Years|80 Years|No|||March 2007|October 25, 2007|August 6, 2004||||No||https://clinicaltrials.gov/show/NCT00089622||200159|
NCT00090610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008381|Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer|Multicenter, Randomized, Phase II Comparative Study to Compare Efficacy & Safety of Taxotere®/Carboplatin Combination Therapy vs Sequential Therapy w/ Taxotere® Then Carboplatin as Second-line Treatment of Patients w/ Relapsed, Platinum-sensitive Ovarian Cancer||Duke University|Yes|Completed|October 2003|October 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|N/A|No|||December 2012|February 5, 2015|August 27, 2004|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00090610||200087|
NCT00090961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000380928|S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer|A Randomized Trial Assessing the Effects of Exercise on Patients With Locally Advanced Lung Cancer Undergoing Curative Intent Combined Modality Therapy||Southwest Oncology Group|No|Terminated|September 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|2|||Both|N/A|N/A|No|||October 2012|October 31, 2012|September 7, 2004||No|Closed early due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00090961||200067|
NCT00092235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040281|Factors Determining Outcomes in Patients With Graft-Versus-Host Disease|Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease||National Institutes of Health Clinical Center (CC)||Recruiting|September 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|520|||Both|1 Year|75 Years|No|||July 2015|August 18, 2015|September 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00092235||199977|
NCT00078429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1221|Molecular Epidemiology of Myocardial Infarction and Stroke in Older Adults - Ancillary to CHS|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A|||||||Both|65 Years|N/A|No|||July 2008|July 23, 2008|February 25, 2004||||No||https://clinicaltrials.gov/show/NCT00078429||200932|
NCT00088777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9345|Nondrug Treatment Programs for Adults With Fibromyalgia|Behavioral Preparation for Treating Fibromyalgia||University of Utah||Completed|January 2005|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|65 Years|No|||August 2011|August 10, 2011|August 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00088777||200219|
NCT00090974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000380937|Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer|Quality Of Life Companion Study For JMA27 (NCIC-MA.27): A Randomized Phase III Trial Of Exemestane Versus Anastrozole With Or Without Celecoxib In Postmenopausal Women With Receptor Positive Primary Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 2004|||||N/A|Observational|N/A|||||||Female|N/A|N/A|No|||January 2006|August 19, 2009|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00090974||200066|
NCT00078806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021631|Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis|Phase 3 Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis||Amgen||Terminated|June 2001|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|2 Years|18 Years|No|||April 2009|April 30, 2009|March 5, 2004|||the study was terminated because of slow enrollment|No||https://clinicaltrials.gov/show/NCT00078806||200907|
NCT00091091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE04N1|Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma|Health-Related Outcomes For Hodgkin's Disease Survivors||Children's Oncology Group|No|Completed|December 2004|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|530|||Both|N/A|N/A|No|Non-Probability Sample|Treatment for primary Hodgkin disease at any one of the participating institutions 1987 -        onward, or patients otherwise eligible and currently followed at one of the participating        institutions.|February 2016|February 19, 2016|September 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00091091||200060|
NCT00091104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040251|Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma|A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes and Subsequent Peptide Immunization||National Institutes of Health Clinical Center (CC)||Completed|July 2004|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|136|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|September 7, 2004||||||https://clinicaltrials.gov/show/NCT00091104||200059|
NCT00088790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0110C00005|AZD5438 in Patients With Advanced Solid Malignancies|Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies||AstraZeneca||Completed|July 2004|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2011|January 25, 2011|August 4, 2004||||||https://clinicaltrials.gov/show/NCT00088790||200218|
NCT00089089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03096|Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas|Phase I Study of Prolonged Low Dose Decitabine (5-Aza-Deoxycytidine, NSC #127716) in Patients With Biopsiable Advanced Cancers Refractory to Standard Therapy||National Cancer Institute (NCI)||Terminated|September 2004|||March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089089||200197|
NCT00090402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0062|Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease|Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease||Oregon Health and Science University|Yes|Completed|April 2004|February 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|39|||Both|55 Years|N/A|No|||January 2010|February 3, 2010|August 25, 2004||||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00090402||200102|
NCT00091260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000385687|CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis|A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis||Boston Medical Center|Yes|Completed|January 2004|May 2015|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091260||200049|
NCT00089973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSP20001|Study Of Ispinesib In Subjects With Breast Cancer|Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer||GlaxoSmithKline||Completed|June 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|August 18, 2004||||||https://clinicaltrials.gov/show/NCT00089973||200134|
NCT00087217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02610|17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor|Phase I Study of 17- Allylamino-17 Demethoxygeldanamycin (17-AAG) in Combination With Paclitaxel in Advanced Solid Malignancies||National Cancer Institute (NCI)||Completed|May 2004|||June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087217||200329|
NCT00088478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5984|Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia|A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia||Eli Lilly and Company||Completed|June 2004|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|402|||Both|18 Years|75 Years|No|||June 2007|June 11, 2007|July 26, 2004||||||https://clinicaltrials.gov/show/NCT00088478||200241|
NCT00090415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54MH066399|Early Characteristics of Autism|UW STAART Center of Excellence||University of Washington|No|Completed|April 2003|||April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Months|30 Months|Accepts Healthy Volunteers|||June 2012|June 15, 2012|August 26, 2004||No||No||https://clinicaltrials.gov/show/NCT00090415||200101|
NCT00089986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD20001|GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults|A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults||GlaxoSmithKline|No|Completed|September 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1415|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|August 18, 2004||||||https://clinicaltrials.gov/show/NCT00089986||200133|
NCT00091923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-96|Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children|A Randomized Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children 3 to <7 Years Old||Jaeb Center for Health Research||Completed|February 2004|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||268|||Both|3 Years|7 Years|No|||September 2009|March 23, 2010|September 20, 2004||||No||https://clinicaltrials.gov/show/NCT00091923||200001|
NCT00092274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-CD20-001|Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma|An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II||GlaxoSmithKline||Withdrawn|September 2004|January 2005|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2005|April 20, 2015|September 22, 2004|||Acquired asset|||https://clinicaltrials.gov/show/NCT00092274||199976|
NCT00092287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-47-52030-722|Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome|A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome||Ipsen||Terminated|July 2004|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||196|||Both|18 Years|N/A|No|||February 2008|February 25, 2008|September 22, 2004||||||https://clinicaltrials.gov/show/NCT00092287||199975|
NCT00088803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN04B1|DNA Variations in the Gene in Young Patients With Wilms' Tumor|The Incidence, Inheritance, and Prognostic Significance of Polymorphisms in the RASSF1A Gene in Children With Wilms Tumors||Children's Oncology Group|No|Active, not recruiting|August 2004|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|471|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Diagnosis of Wilms' tumor or control participants matched for race, sex, and age.|May 2015|May 6, 2015|August 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00088803||200217|
NCT00090025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL119-001|XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors|A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery||Helsinn Healthcare SA|Yes|Terminated|September 2004|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|August 19, 2004|Yes|Yes|Futility reasons after Independent Data Monitoring Committee interim analysis|No||https://clinicaltrials.gov/show/NCT00090025||200130|
NCT00090038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-12|Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma|A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens||Biogen|No|Completed|October 2003|November 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|40 Years|N/A|No|||October 2009|October 16, 2009|August 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090038||200129|
NCT00091936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA START|Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings|Implementing Anti-Retroviral Therapy in Resource-Constrained Settings: A Randomized Controlled Trial to Assess the Effect of Integrated Tuberculosis and HIV Care on the Incidence of AIDS-Defining Conditions or Mortality in Subjects Co-Infected With Tuberculosis and HIV||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|592|||Both|18 Years|N/A|No|||January 2007|March 26, 2010|September 20, 2004||||No||https://clinicaltrials.gov/show/NCT00091936||200000|
NCT00087464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-08-005|Three Month Course of Anti-HIV Medications for People Recently Infected With HIV|Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection?||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|July 8, 2004|||study was withdrawn before any participants were recruited and enrolled|||https://clinicaltrials.gov/show/NCT00087464||200314|
NCT00088816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000368443|S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer|Phase II Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Advanced Gastric Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2003|||March 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|20 Years|N/A|No|||March 2008|September 16, 2013|August 4, 2004||||No||https://clinicaltrials.gov/show/NCT00088816||200216|
NCT00090389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19AT002022|Acupuncture for Women's Health Conditions|New England School of Acupuncture (NESA) Acupuncture Research Collaborative||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2005|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Female|18 Years|N/A|No|||January 2008|January 23, 2008|August 25, 2004||No||No||https://clinicaltrials.gov/show/NCT00090389||200103|
NCT00090701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4371005|A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer|A Phase 2, Open-Label, Multicenter Study Of The GARFT Inhibitor AG2037 In Patients With MetastatIC Non Small Cell Lung Cancer Who Failed Two Or Three Prior Treatments||Pfizer||Withdrawn|September 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|September 2, 2004||||No||https://clinicaltrials.gov/show/NCT00090701||200081|
NCT00091247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N03CB|Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer|An Exploratory, Placebo-Controlled Trial of Prophylactic Tetracycline for Gefitinib-or Cetuximab-Induced Skin Rash (or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash)||Alliance for Clinical Trials in Oncology|No|Completed|December 2004|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|130|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|September 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091247||200050|
NCT00091884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040223|Efficacy of Elevated CD4 Counts on CMV Retinitis|Efficacy of Elevated CD4 Cell Counts on CMV Retinitis||National Institutes of Health Clinical Center (CC)||Completed|July 2004|April 2005||||N/A|Observational|N/A||||15|||Both|N/A|N/A|No|||April 2005|March 3, 2008|September 17, 2004||||No||https://clinicaltrials.gov/show/NCT00091884||200004|
NCT00089388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02621|Cilengitide in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of EMD 121974 as Maintenance Therapy for Patinets With Acute Myeloid Leukemia in Complete Remission||National Cancer Institute (NCI)||Terminated|July 2004|||June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|50 Years|N/A|No|||January 2013|January 23, 2013|August 4, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00089388||200177|
NCT00090727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-001|Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies||Novacea||Active, not recruiting|August 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||April 2005|October 31, 2006|September 2, 2004||||||https://clinicaltrials.gov/show/NCT00090727||200079|
NCT00090337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-131|Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer|Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial||Memorial Sloan Kettering Cancer Center||Completed|November 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|2||Anticipated|73|||Both|N/A|N/A|No|||March 2013|March 6, 2013|August 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090337||200106|
NCT00087490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951002|Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)|Linezolid in the Treatment of Subjects With Complicated Skin and Soft Tissue Infections Proven to be Due to Methicillin-Resistant Staphylococcus Aureus||Pfizer||Completed|October 2004|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1077|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|July 9, 2004||Yes||No|June 29, 2012|https://clinicaltrials.gov/show/NCT00087490||200312|Comparing duration of intravenous (IV) therapy for linezolid (LZD) and vancomycin (VAN) in study, participants in LZD group had option to switch to oral therapy while those in VAN group had to remain on IV therapy until completion of study treatment.
NCT00087503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDOAGA-6736-001|Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy|A Phase II Efficacy And Safety Study Intravenous Edotecarin In Patients With Advanced Gastric Cancer That Has Progressed Or Recurred After Prior Fluropyrimidine-Based Chemotherapy||Pfizer||Completed|April 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|July 9, 2004||||No||https://clinicaltrials.gov/show/NCT00087503||200311|
NCT00089154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01454|Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of Thrice Weekly Apolizumab in Patients With Chronic Lymphocytic Leukemia : CRC Master Protocol||National Cancer Institute (NCI)||Completed|August 2004|||October 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2013|July 15, 2013|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089154||200192|
NCT00090740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT P01 AI50516|Genetic Risk Factors for Severe Asthma|Genetic Risk Factors for Severe Asthma||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2004|January 2005|Actual|January 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|600|Samples With DNA|40 mL blood|Both|18 Years|44 Years|No|Non-Probability Sample|400 asthmatics and 200 non-asthmatic controls will be recruited. The 200 non-asthmatics        will be matched for age, gender and ethnicity with the asthmatics in the more severe half        of the severity distribution. The participants will be from minority populations (at least        30% African-American and at least 30% Hispanic) and generally of lower socioeconomic        status.|January 2013|January 23, 2013|September 3, 2004||No||No||https://clinicaltrials.gov/show/NCT00090740||200078|
NCT00091273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11276|Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer|Evaluation of Safety and Immunogenicity of a Peptide Vaccine in Patients With Epithelial Ovarian or Primary Peritoneal Cancer||University of Virginia|Yes|Completed|June 2004|June 2007|Actual|February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||May 2014|May 19, 2014|September 7, 2004|No|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00091273||200048|
NCT00091286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000386177|Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer|Evaluation of the Immunogenicity of Vaccination With HER-2/Neu and CEA Derived Synthetic Peptides With GM-CSF-in-Adjuvant, in Patients With Stage IIB, III, or IV Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 2003|||April 2011|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||October 2007|November 13, 2010|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00091286||200047|
NCT00087451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-023|Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)|A Phase I Sequential Ascending Dose Trial of AP23573 in Patients With Progressive or Recurrent Malignant Glioma||Merck Sharp & Dohme Corp.||Completed|July 2004|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087451||200315|
NCT00087789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERE-110-01|CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease|A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild to Moderate Alzheimer's Disease||Ceregene|Yes|Completed|June 2004|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|50 Years|80 Years|No|||June 2010|June 30, 2010|July 13, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087789||200289|
NCT00089102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378044|Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer|Phase II Study of Gemcitabine and CPT-11 (Irinotecan) in Unresectable or Metastatic Renal Cell Carcinoma||Medical University of South Carolina|Yes|Completed|September 2003|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|August 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089102||200196|
NCT00089115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAV-ID-06|Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|Phase III, Randomized, Double Blind, Placebo-Controlled Trial of Favldand GM-CSF Versus Placebo and GM-CSF Following Rituximab in Subjects With Follicular B-Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Terminated|July 2004|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|August 1, 2013|August 4, 2004|||Withdrawn as company has shut down and filed for bankruptcy|No||https://clinicaltrials.gov/show/NCT00089115||200195|
NCT00090376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-0202|Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy|Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3 Arm, 12-Month Study to Evaluate the Effects of GPI 1485 on Erectile Function in Patients Undergoing Bilateral Nerve-Sparing Radical Retropubic Prostatectomy for Prostatic Carcinoma||Eisai Inc.||Completed|December 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Male|40 Years|69 Years|No|||November 2008|November 6, 2008|August 25, 2004||||No||https://clinicaltrials.gov/show/NCT00090376||200104|
NCT00090714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGF2-CAD-CL-007|To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter|||Corautus Genetics||Active, not recruiting|August 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||404|||Both|18 Years|N/A|No|||April 2006|April 18, 2006|September 2, 2004||||||https://clinicaltrials.gov/show/NCT00090714||200080|
NCT00087256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP P-3|Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer|Celecoxib Polyp Prevention Trial in Participants With Resected Stage I Colon Cancer||NSABP Foundation Inc|No|Terminated|July 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|July 8, 2004|Yes|Yes|For scientific, logistic, and administrative reasons.|No||https://clinicaltrials.gov/show/NCT00087256||200328|
NCT00087815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510427|Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain|Complimentary Hyperbaric Oxygen for Brain Radionecrosis||National Cancer Institute (NCI)||Active, not recruiting|September 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Supportive Care|||Anticipated|30|||Both|N/A|N/A|No|||July 2007|December 17, 2013|July 14, 2004||||No||https://clinicaltrials.gov/show/NCT00087815||200287|
NCT00088153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK062249|Effects of Anorexia Nervosa on Bone Mass in Adolescents|Effects of Anorexia Nervosa on Peak Bone Mass||Massachusetts General Hospital|Yes|Completed|July 2003|June 2011|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||September 2011|October 6, 2011|July 20, 2004|Yes|Yes||No|July 6, 2011|https://clinicaltrials.gov/show/NCT00088153||200263|
NCT00089128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378047|Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer|Phase II Study Of Gemcitabine And CPT-11 (Irinotecan) In Locally Advanced Or Metastatic Bladder Cancer||Medical University of South Carolina|Yes|Completed|November 2001|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|August 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089128||200194|
NCT00091052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000383147|Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors|Contrast-Enhanced Radiotherapy With GM-CSF Immune Stimulation - Phase I/II Clinical Center Treatment Trial||National Cancer Institute (NCI)||Completed|July 2004|June 2006|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2006|March 25, 2013|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00091052||200062|
NCT00091533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040278|Neural Correlates of Observation of Tactile Stimulation in Healthy Subjects|Neural Correlates of Observation of Tactile Stimulation in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Completed|September 2004|September 2008||||N/A|Observational|N/A||||30|||Both|18 Years|75 Years|No|||September 2008|September 3, 2008|September 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00091533||200031|
NCT00087841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24AT001074-01|Self-Hypnotic Relaxation Therapy During Invasive Procedures|Midcareer Development of Nonpharmacologic Analgesia||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2002|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||390|||Both|18 Years|90 Years|No|||January 2008|January 15, 2008|July 14, 2004||||No||https://clinicaltrials.gov/show/NCT00087841||200285|
NCT00087854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001A2-200-US|Study of Individualized Amonafide to Treat Prostate Cancer|Dose-Defining Study of a NAT2 Phenotype-Based Dosing Regimen of Intravenous Amonafide L-Malate Administered Weekly in Men With Androgen-Independent Prostate Cancer (AIPC)||Xanthus Pharmaceuticals, Inc.||Completed|March 2004|December 2005|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Male|18 Years|N/A|No|||April 2008|April 21, 2008|July 14, 2004||||||https://clinicaltrials.gov/show/NCT00087854||200284|
NCT00089726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0031|A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)|A Phase II Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) With and Without Low-Dose Cyclophosphamide in Advanced Stage Non-Small Cell Lung Cancer||Cell Genesys||Completed|March 2003|January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||December 2007|December 18, 2007|August 11, 2004||||||https://clinicaltrials.gov/show/NCT00089726||200151|
NCT00091078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02883|Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery|A Phase IIA Study to Determine the Safety and Efficacy of A NCI-Supplied Agent: G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients With Refractory or Relapsed Gastrointestinal Stromal Tumor||National Cancer Institute (NCI)||Terminated|September 2005|||July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|September 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00091078||200061|
NCT00090662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040266|Collection of Peripheral Blood and Bone Marrow From Healthy Donors for Use in In Vitro Research|Collection of Peripheral Blood, Urine, Sputum, and Bone Marrow From Healthy Donors for Use in In Vitro Research||National Institutes of Health Clinical Center (CC)||Recruiting|August 2004|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|September 1, 2004||No||No||https://clinicaltrials.gov/show/NCT00090662||200084|
NCT00087802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9210|Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)|A Phase III Randomized Trial of Gemcitabine/Oxaliplatin (GEMOX) Versus Carboplatin/Paclitaxel (CP) as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Sanofi||Completed|March 2004|||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|383|||Both|18 Years|N/A|No|||April 2009|April 15, 2009|July 13, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087802||200288|
NCT00088101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5312-01|STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors|Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors||Synta Pharmaceuticals Corp.||Completed|February 2004|December 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||December 2008|December 3, 2008|July 20, 2004||||||https://clinicaltrials.gov/show/NCT00088101||200266|
NCT00089401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040229|Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver|A Phase II Trial Of Isolated Hepatic Perfusion (IHP) With Melphalan For Subjects With Metastatic Unresectable Colorectal Cancers Of The Liver With Disease Refractory To First Line Systemic Chemotherapy||National Institutes of Health Clinical Center (CC)||Completed|July 2004|March 2008|Actual|November 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2012|May 11, 2012|August 4, 2004||||No||https://clinicaltrials.gov/show/NCT00089401||200176|
NCT00091377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000389129|Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant||MEI Pharma, Inc.|No|Completed|August 2004|March 2008|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Female|18 Years|N/A|No|||October 2012|October 22, 2012|September 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091377||200041|
NCT00091559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-001|Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)|Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma||Merck Sharp & Dohme Corp.||Completed|February 2005|March 2006|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|74|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|September 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091559||200029|
NCT00091897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040287|Rituximab to Treat Stiff Person Syndrome|Efficacy of Rituximab in Patients With Stiff Person Syndrome With Anti-GAD Antibodies: A Randomized Placebo-Controlled Trial||National Institutes of Health Clinical Center (CC)||Completed|September 2004|May 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|24|||Both|25 Years|80 Years|No|||August 2011|August 30, 2011|September 18, 2004||No||No||https://clinicaltrials.gov/show/NCT00091897||200003|
NCT00088166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI 0303|XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors|A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone||Celtic Pharma Development Services|Yes|Completed|May 2004|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|July 20, 2004|Yes|Yes||No|October 13, 2011|https://clinicaltrials.gov/show/NCT00088166||200262|
NCT00088491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5985|Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia|A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia||Eli Lilly and Company||Completed|June 2004|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1205|||Both|18 Years|75 Years|No|||June 2007|June 20, 2007|July 26, 2004||||||https://clinicaltrials.gov/show/NCT00088491||200240|
NCT00089349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01814|Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia|A Phase II Study of Campath-1H in Children With Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure||National Cancer Institute (NCI)||Completed|July 2004|||September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|30 Years|No|||June 2013|June 4, 2013|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089349||200179|
NCT00090688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1065|Phase 1 meCS6 + LT(R192G) Vaccine Study|Safety and Immunogenicity of Oral Microencapsulated CS6 Vaccine and LT(R192G) Adjuvant in Volunteers||Walter Reed Army Institute of Research (WRAIR)||Completed|August 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2006|January 31, 2006|September 2, 2004||||||https://clinicaltrials.gov/show/NCT00090688||200082|
NCT00087516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-021|Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Completed|June 2004|February 2007|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|741|||Both|18 Years|75 Years|No|||June 2015|June 8, 2015|July 9, 2004|Yes|Yes||No|May 10, 2010|https://clinicaltrials.gov/show/NCT00087516||200310|
NCT00087529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2786g|A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis|A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis|OLYMPUS|Genentech, Inc.||Completed|June 2004|||October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|65 Years|No|||August 2015|August 10, 2015|July 9, 2004|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT00087529||200309|
NCT00089362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01455|Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors|Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors.||National Cancer Institute (NCI)||Completed|July 2004|||January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089362||200178|
NCT00089713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0320|Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)|Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients||Synvista Therapeutics, Inc||Terminated|March 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||392|||Both|45 Years|N/A|No|||June 2005|February 5, 2010|August 10, 2004||||||https://clinicaltrials.gov/show/NCT00089713||200152|
NCT00091338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000387802|Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma|A Study of Subcutaneous "CYT 99 007" (Interleukin-7) in Conjunction With Peptide Immunization in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|August 2004|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2005|April 29, 2015|September 7, 2004||||||https://clinicaltrials.gov/show/NCT00091338||200043|
NCT00091871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040286|A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression|A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression||National Institutes of Health Clinical Center (CC)||Recruiting|September 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|N/A|100 Years|No|||December 2015|December 24, 2015|September 17, 2004||No||No||https://clinicaltrials.gov/show/NCT00091871||200005|
NCT00087191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02607|EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer|Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies||National Cancer Institute (NCI)||Terminated|May 2004|||January 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|July 8, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00087191||200331|
NCT00087204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02609|Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia|A Phase I Study Of XL119 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase||National Cancer Institute (NCI)||Completed|May 2004|||January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087204||200330|
NCT00090090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELSA 2004-001|Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma||Spectrum Pharmaceuticals, Inc|No|Completed|April 2004|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||114|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|August 24, 2004||||No||https://clinicaltrials.gov/show/NCT00090090||200125|
NCT00090103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI40005|Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment|See Detailed Description||GlaxoSmithKline||Completed|November 2003|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|4844|||Male|50 Years|N/A|No|||March 2012|April 11, 2013|August 24, 2004||Yes||No|February 26, 2010|https://clinicaltrials.gov/show/NCT00090103||200124|
NCT00091351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z9031|Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis|A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS)||Alliance for Clinical Trials in Oncology|No|Completed|August 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|370|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|September 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00091351||200042|
NCT00091611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040277|Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer|Phase II Study in Metastatic Renal Cell Cancer Using Cultured, Tumor-Reactive Lymphocytes and Interleukin-2||National Institutes of Health Clinical Center (CC)||Terminated|September 2004|March 2008|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|3|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|September 11, 2004||No|This study was terminated due to low accrual.|No||https://clinicaltrials.gov/show/NCT00091611||200025|
NCT00090987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-042|Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma||AIDS Malignancy Consortium|No|Completed|June 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|September 7, 2004|Yes|Yes||No|May 25, 2011|https://clinicaltrials.gov/show/NCT00090987||200065|
NCT00091910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004114|Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Epoetin Alfa in Critically Ill Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2003|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|1460|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|September 19, 2004||||||https://clinicaltrials.gov/show/NCT00091910||200002|
NCT00088192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1010|Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)|An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD)||Eyetech Pharmaceuticals||Completed|July 2004|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||August 2005|August 29, 2005|July 21, 2004||||||https://clinicaltrials.gov/show/NCT00088192||200260|
NCT00088205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8360|Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma|A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma||Eli Lilly and Company|No|Completed|March 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|July 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088205||200259|
NCT00090116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NER-MD-02|The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease|A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type||Forest Laboratories||Completed|March 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|50 Years|N/A|No|||March 2012|March 1, 2012|August 24, 2004||||||https://clinicaltrials.gov/show/NCT00090116||200123|
NCT00090129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24979|Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis|A Multicentre, Randomised, Double-blind, Placebo Controlled Phase III Study of Subcutaneously Administered Onercept in the Treatment and Re-treatment of Subjects With Moderate to Severe Plaque Psoriasis||EMD Serono||Terminated|September 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|854|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|August 24, 2004|No|Yes|The risk-benefit ratio for the use of onercept in this condition was not sufficiently    favorable to justify continued development|||https://clinicaltrials.gov/show/NCT00090129||200122|
NCT00089674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040138|AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer||Amgen||Completed|August 2004|July 2010|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1468|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|August 9, 2004||||No|July 2, 2010|https://clinicaltrials.gov/show/NCT00089674||200155|
NCT00091663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI3199g|A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients With Advanced Non-Small Cell Lung Cancer||Genentech, Inc.||Completed|August 2004|August 2005|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||5000|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|September 15, 2004||||||https://clinicaltrials.gov/show/NCT00091663||200021|
NCT00091845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4020-14|An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease|An Exploratory Study of the Safety, Tolerability, Pharmacokinetics and Potential Effectiveness of AVI-4020 Injection in Patients Presenting With Presumptive Acute Neuroinvasive West Nile Virus (WNV) Disease||Sarepta Therapeutics||Terminated|November 2004|November 2004|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|75 Years|No|||July 2009|July 6, 2009|September 17, 2004|||Due to limited pool of eligble WNV patients|||https://clinicaltrials.gov/show/NCT00091845||200007|
NCT00091858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010103|Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer||Amgen||Completed|April 2004|December 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2|||1000|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|September 17, 2004||||No||https://clinicaltrials.gov/show/NCT00091858||200006|
NCT00088114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4783-01|STA-4783 and Paclitaxel for Treatment of Solid Tumors|A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors||Synta Pharmaceuticals Corp.||Completed|January 2003|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|July 20, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088114||200265|
NCT00088140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-000006556-PRO-0007|A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients|A Dose Response Study of a Caspase Inhibitor in Hepatitis C Patients||Conatus Pharmaceuticals Inc.|Yes|Completed|July 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|204|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|July 20, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00088140||200264|
NCT00089687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0005-1|GBR 12909 Study in Cocaine Experienced African American Volunteers - 1|GBR 12909 Study in Cocaine Experienced African American Volunteers||National Institute on Drug Abuse (NIDA)||Active, not recruiting|April 2004|May 2005||||Phase 1|Interventional|Primary Purpose: Treatment||||10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2005|October 23, 2007|August 10, 2004||||||https://clinicaltrials.gov/show/NCT00089687||200154|
NCT00089700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-355.03|TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 With Optimized Background Therapy in Treatment-Experienced Subjects Infected With HIV-1||Tanox||Active, not recruiting|March 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||February 2005|June 23, 2005|August 10, 2004||||||https://clinicaltrials.gov/show/NCT00089700||200153|
NCT00090051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-14|FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients|Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL||Hoffmann-La Roche|Yes|Completed|July 2003|June 2012|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|552|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|August 23, 2004|Yes|Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00090051||200128|
NCT00091039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000383146|Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery|A Pilot Trial of a CEA/TRICOM-Based Vaccine in Combination With Combined Chemotherapy/Radiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|August 2004|February 2006|Actual|||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|June 18, 2013|September 7, 2004||||||https://clinicaltrials.gov/show/NCT00091039||200063|
NCT00092300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-181|A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Single Dose Study of the Effect of Rofecoxib 50 mg and Valdecoxib 20 mg in Patients With Postoperative Dental Pain||Merck Sharp & Dohme Corp.||Completed|May 2002|||September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||450|||Both|16 Years|N/A|No|||July 2015|July 31, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092300||199974|
NCT00092313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-182|A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain||Merck Sharp & Dohme Corp.||Completed|June 2002|September 2002|Actual|September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|271|||Both|16 Years|N/A|No|||November 2015|November 24, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092313||199973|
NCT00092326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-183|A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain||Merck Sharp & Dohme Corp.||Completed|June 2002|September 2002|Actual|September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|269|||Both|16 Years|N/A|No|||February 2016|February 19, 2016|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092326||199972|
NCT00088764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-122|Pain and Stress Management for People With Rheumatoid Arthritis|Disclosure and Skills Training for Rheumatoid Arthritis||Wayne State University|Yes|Completed|February 2005|June 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|280|||Both|18 Years|80 Years|No|||August 2013|August 13, 2013|August 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00088764||200220|
NCT00090064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63,384|A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder|Phase II Clinical Trial Testing the Safety and Efficacy of 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Chronic Posttraumatic Stress Disorder||Multidisciplinary Association for Psychedelic Studies|Yes|Completed|March 2004|September 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||February 2014|November 12, 2015|August 24, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090064||200127|
NCT00090077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN210005|Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults|A Phase I, Multicenter, Randomized, Parallel, Double-Blinded Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Dosage Regimens of GW695634G Monotherapy Versus Placebo Over 10 Days in ART-Naive HIV-1 Infected Adults.||GlaxoSmithKline||Completed|April 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||February 2006|February 24, 2006|August 24, 2004||||||https://clinicaltrials.gov/show/NCT00090077||200126|
NCT00091598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIES|ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)|ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension||Gilead Sciences||Completed|January 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||372|||Both|18 Years|N/A|No|||March 2010|March 4, 2010|September 10, 2004|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00091598||200026|
NCT00091546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166|Genetic and Environmental Characteristics of Primary Pulmonary Hypertension|Genetic and Environmental Pathogenesis of PPH||Vanderbilt University|No|Completed|August 2003|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3000|Samples With DNA|Specimens from 100 families affected by PPH|Both|N/A|100 Years|No|Non-Probability Sample|Database and specimen bank developed from 100 families affected by PPH|February 2016|February 1, 2016|September 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00091546||200030|
NCT00087477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIV-800|A Pilot Study of Pivanex in Patients With Malignant Melanoma|A Pilot Study of Pivanex, a Histone Deacetylase Inhibitor, in Patients With Malignant Melanoma||Titan Pharmaceuticals||Terminated|January 2004|August 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Both|18 Years|N/A|No|||August 2005|August 26, 2005|July 8, 2004||||||https://clinicaltrials.gov/show/NCT00087477||200313|
NCT00084734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365571|Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetics Study of Docetaxel in Combination With Capecitabine and Cisplatin in Solid Tumors||Roswell Park Cancer Institute|Yes|Completed|May 2002|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084734||200494|
NCT00084721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 02-24|Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer|A Phase I Study of Irinotecan in Combination With Fixed Dose Celecoxib in Patients With Advanced Colorectal Cancer||Roswell Park Cancer Institute||Completed|March 2005|||October 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|2|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|June 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00084721||200495|
NCT00085384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-115|PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer|A Phase I/II Study to Evaluate the Optimum Dose of Pegylated-Interferon (PEG INTRON) in Patients With Platinum Resistant Ovarian, Peritoneal or Fallopian Tube Cancer||M.D. Anderson Cancer Center|No|Terminated|July 2002|April 2007|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Female|N/A|N/A|No|||August 2012|August 1, 2012|June 10, 2004|Yes|Yes|Terminated due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00085384||200459|
NCT00085696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34103-061|VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma|A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma||Millennium Pharmaceuticals, Inc.||Completed|May 2004|||April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Both|18 Years|N/A|No|||February 2008|February 7, 2008|June 11, 2004||||||https://clinicaltrials.gov/show/NCT00085696||200439|
NCT00085020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000367118|GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu|A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Trastuzumab [Herceptin†]||Jonsson Comprehensive Cancer Center|Yes|Completed|March 2004|February 2005|Actual|December 2004|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|18 Years|N/A|No|||August 2012|October 1, 2015|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085020||200478|
NCT00085735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0331|Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma|A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial||Children's Oncology Group|Yes|Active, not recruiting|April 2004|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|549|||Both|3 Years|21 Years|No|||September 2015|February 9, 2016|June 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085735||200436|
NCT00085059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-11011|Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma|Early Phase II Study On BNCT In Metastatic Malignant Melanoma Using The Boron Carrier BPA||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|April 2004|||October 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|June 10, 2004|||low accrual|No||https://clinicaltrials.gov/show/NCT00085059||200477|
NCT00085098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0232|Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor|Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma||Children's Oncology Group|Yes|Active, not recruiting|January 2007|May 2019|Anticipated|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|3 Years|25 Years|No|||September 2015|September 10, 2015|June 10, 2004|Yes|Yes||No|June 7, 2013|https://clinicaltrials.gov/show/NCT00085098||200476|Study closed early due to slow accrual. Analysis plans were not carried out (lack of statistical precision compromised the ability to draw appropriate conclusions). Reported Primary Outcome Measure data reflects data collection through May 2009.
NCT00089739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040260|Immune Indicators of Uveitis|Use of Immune Cell Markers, Cytokines, Transcription Factors and Surface CD Markers as Markers of Ocular Inflammatory Activity||National Institutes of Health Clinical Center (CC)||Completed|August 2004|October 2008||||N/A|Observational|N/A||||100|||Both|18 Years|N/A|No|||October 2008|September 26, 2015|August 11, 2004||No||No||https://clinicaltrials.gov/show/NCT00089739||200150|
NCT00089752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163|Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea|Impact of CPAP on Functional Outcomes in Milder Obstructive Sleep Apnea (CATNAP)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2003|November 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|272|||Both|18 Years|N/A|No|||May 2009|May 22, 2009|August 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089752||200149|
NCT00089765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040240|Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome|Pilot Study of Intravitreal Injection of Ranibizumab (rhuFAB V2) for Advanced Ocular Disease of Von Hippel-Lindau (VHL) Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2004|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||5|||Both|18 Years|N/A|No|||August 2007|September 26, 2015|August 12, 2004||||No||https://clinicaltrials.gov/show/NCT00089765||200148|
NCT00084747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365583|Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma|Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation With VELCADE Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma||Jonsson Comprehensive Cancer Center|Yes|Completed|June 2004|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|69 Years|No|||February 2016|February 17, 2016|June 10, 2004|Yes|Yes||No|January 20, 2016|https://clinicaltrials.gov/show/NCT00084747||200493|
NCT00085423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000370788|Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma|High Dose Interleukin-2 (IL-2) Therapy In "Lymphodepleted Primed" Patients With Metastatic Melanoma||Dartmouth-Hitchcock Medical Center|Yes|Completed|February 2004|February 2010|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|June 10, 2004|Yes|Yes||No|January 26, 2012|https://clinicaltrials.gov/show/NCT00085423||200456|This was the first stage of a two-stage phase II study and continuation to next stage required 4 of 18 particpant having an objective response. Only 3 objective responses were noted and the study was terminated at stage 1.
NCT00081926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571AUS177|Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|||Novartis||Completed|October 2003|March 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||112|||Both|18 Years|N/A|No|||November 2009|November 20, 2009|April 26, 2004||||||https://clinicaltrials.gov/show/NCT00081926||200692|
NCT00084526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365453|Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer|Evaluation of Daily CT Scans Using CT on Rails for Localization in the Treatment of Prostate Cancer||Fox Chase Cancer Center||Completed|November 2003|February 2007|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|40|||Male|N/A|N/A|No|||February 2010|February 11, 2010|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00084526||200510|
NCT00085761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C112|Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy|An International, Multicenter, Randomized, Double-Blind, 12-Week Controlled Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy||NeurogesX||Terminated||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2008|March 4, 2008|June 14, 2004|||Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes|||https://clinicaltrials.gov/show/NCT00085761||200434|
NCT00085774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-302-4-167|Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma|A Single-Dose Efficacy Comparison of Albuterol Hydrofluoroalkane (HFA) Breath-operated Inhaler (BOI) (Volare Easi-Breathe™) and Albuterol HFA Meter Dose Inhaler (MDI) (Volare™) in Adolescents and Adults With Exercise-Induced Bronchospasm||Teva Pharmaceutical Industries|No|Completed|June 2004|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|12 Years|40 Years|No|||March 2015|March 19, 2015|June 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085774||200433|
NCT00089414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040221|Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives|The Treatment of Menstrually-Related Mood Disorders With Extended Versus Interrupted Oral Contraceptives||National Institutes of Health Clinical Center (CC)||Completed|July 2004|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|5|||Female|N/A|N/A|No|||June 2010|July 7, 2010|August 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00089414||200175|
NCT00089167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-031|Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis|Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic Amyloidosis||Memorial Sloan Kettering Cancer Center||Completed|May 2002|||December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 15, 2013|August 4, 2004||||No||https://clinicaltrials.gov/show/NCT00089167||200191|
NCT00089180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02619|T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant|A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer||National Cancer Institute (NCI)||Completed|March 2004|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|19 Years|N/A|No|||June 2013|December 3, 2015|August 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00089180||200190|
NCT00089427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL13PEI-106-R01|IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma|Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma||INSYS Therapeutics Inc||Completed|July 2004|||July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||April 2011|June 30, 2011|August 5, 2004||||||https://clinicaltrials.gov/show/NCT00089427||200174|
NCT00089440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-MDS-0002-1|Assessment of Interactions Between Methamphetamine and Aripiprazole - 1|Assessment of Interactions Between IV Methamphetamine and Aripiprazole||National Institute on Drug Abuse (NIDA)||Active, not recruiting|June 2004|March 2005||||Phase 1|Interventional|Primary Purpose: Treatment||||17|||Both|18 Years|45 Years|No|||July 2005|October 25, 2007|August 5, 2004||||||https://clinicaltrials.gov/show/NCT00089440||200173|
NCT00085410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00046|Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder|Phase II and Pharmacodynamic Study of PS-341 in Patients With Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder||National Cancer Institute (NCI)|Yes|Completed|January 2004|||April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085410||200457|
NCT00086086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020171|Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Effects of Treatment With 2 Regimens of Subcutaneous Darbepoetin Alfa (Weight-based Dosing and Fixed Dosing) on Hemoglobin Concentration Response in Subjects With Symptomatic CHF and Anaemia||Amgen||Completed|June 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|21 Years|N/A|No|||May 2013|May 10, 2013|June 23, 2004||||||https://clinicaltrials.gov/show/NCT00086086||200410|
NCT00086099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP103|Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia|A Phase IB/II, Randomized, Open-Label, Multicenter Study Evaluating Whether the Addition of Amifostine (Ethyol®) Will Enable the Safe Increase in Dose Intensity of Idarubicin in Combination With Cytosine Arabinoside in Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia||MedImmune LLC||Completed|July 2004|February 2006|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|60 Years|N/A|No|||January 2009|January 28, 2009|June 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086099||200409|
NCT00088907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02956|Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer|Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer||National Cancer Institute (NCI)|Yes|Terminated|August 2004|August 2012|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||July 2013|April 21, 2015|August 4, 2004|Yes|Yes|It was unlikely that the primary endpoint would be reached based on the fifth interim analysis    results.|No|March 20, 2015|https://clinicaltrials.gov/show/NCT00088907||200210|
NCT00088933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00049|Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer|Randomized Single Institution Pilot Study of Vaccinia-CEA(6D)-TRICOM and Fowlpox-CEA(6D)-TRICOM With GM-CSF in Combination With Docetaxel in Patients With CEA-Bearing Cancers||National Cancer Institute (NCI)||Terminated|June 2004|||November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|N/A|No|||March 2013|March 28, 2014|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088933||200209|
NCT00090818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040267|Clinical Research Core Dental Screening Protocol|Clinical Research Core Dental Screening Protocol||National Institutes of Health Clinical Center (CC)||Completed|September 2004|October 2010||||N/A|Observational|N/A|||Actual|441|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2010|September 26, 2015|September 3, 2004||No||No||https://clinicaltrials.gov/show/NCT00090818||200074|
NCT00090831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040270|Investigating the Role of Serotonin in Emotional Processing Through the Use of Tryptophan Depletion|Investigating the Role of Serotonin in Emotional Processing Through the Use of Tryptophan Depletion||National Institutes of Health Clinical Center (CC)||Completed|August 2004|September 2012||||N/A|Observational|N/A|||Actual|91|||Both|20 Years|50 Years|No|||September 2012|February 19, 2014|September 3, 2004||No||No||https://clinicaltrials.gov/show/NCT00090831||200073|
NCT00085124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02805|Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia|A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) &gt; / = 60 Years||National Cancer Institute (NCI)||Completed|December 2003|||June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|60 Years|N/A|No|||June 2013|June 4, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085124||200474|
NCT00086112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004696|Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.|A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|301|||Both|18 Years|65 Years|No|||July 2012|July 19, 2012|June 24, 2004||||||https://clinicaltrials.gov/show/NCT00086112||200408|
NCT00086125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-024|Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)|A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies||Merck Sharp & Dohme Corp.||Completed|June 2004|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|June 24, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086125||200407|
NCT00089830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-1256F-209|A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration|||Genaera Corporation||Terminated|August 2004|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|50 Years|N/A|No|||November 2007|November 27, 2007|August 16, 2004||||||https://clinicaltrials.gov/show/NCT00089830||200144|
NCT00089843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 R01 DK052625 (completed)|Bone Loss in Women With Anorexia Nervosa|IGF-1 and Bone Loss in Women Anorexia Nervosa||Massachusetts General Hospital|Yes|Completed|June 2003|April 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|77|||Female|18 Years|45 Years|No|||May 2012|May 1, 2012|August 16, 2004|Yes|Yes||No|November 9, 2011|https://clinicaltrials.gov/show/NCT00089843||200143|
NCT00089869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8269|A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia|||Eli Lilly and Company||Completed||||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||July 2006|July 18, 2006|August 16, 2004||||||https://clinicaltrials.gov/show/NCT00089869||200141|
NCT00085436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000370794|DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC|A Phase II Study Of Autologous Tumor/DC Vaccine (DC Vaccine) Combined With Interleukin-2 (IL-2) And Interferon-α-2a (IFNα-2a) In Patients With Metastatic Renal Cell Carcinoma (RCC)||Dartmouth-Hitchcock Medical Center|No|Completed|December 2003|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||October 2011|April 24, 2013|June 10, 2004|Yes|Yes||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00085436||200455|
NCT00085488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000370802|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|En Vivo Matured Dendritic Cell Therapy in Patients With Melanoma||Dartmouth-Hitchcock Medical Center||Completed|February 2004|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2005|January 30, 2015|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00085488||200451|
NCT00085501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000370806|S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Selection Design Trial Of Concurrent Chemotherapy + Cetuximab Vs. Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC)||Southwest Oncology Group|Yes|Completed|July 2004|July 2011|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085501||200450|
NCT00090220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-019|A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019)|Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study||Merck Sharp & Dohme Corp.||Completed|June 2004|November 2015|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3819|||Female|24 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|August 25, 2004|Yes|Yes||No|October 30, 2009|https://clinicaltrials.gov/show/NCT00090220||200115|
NCT00090194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT IG03|Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%|Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|June 2003|March 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|56|||Both|1 Year|70 Years|No|||January 2013|January 16, 2013|August 25, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00090194||200117|
NCT00090207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-801|Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)|A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Safety, Tolerability and Efficacy of Aprepitant Regimen Compared to Ondansetron Regimen for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With High Dose Cisplatin in Cycle 1||Merck Sharp & Dohme Corp.||Completed|January 2004|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|477|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|August 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090207||200116|
NCT00085787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRY-0401|A Study of ARRY-142886 in Patients With Advanced Cancer|||Array BioPharma||Completed|June 2004|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|June 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085787||200432|
NCT00085800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1255|Dietary Fiber and Cardiovascular Inflammatory Markers|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 2004|March 2008|Actual|March 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2008|April 22, 2008|June 14, 2004||||No||https://clinicaltrials.gov/show/NCT00085800||200431|
NCT00072813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040033|MRI in Autosomal Dominant Partial Epilepsy With Auditory Features|MRI in Autosomal Dominant Partial Epilepsy With Auditory Features||National Institutes of Health Clinical Center (CC)||Completed|November 2003|||November 2009|Actual|N/A|Observational|N/A||||72|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2009|November 13, 2009|November 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00072813||201330|
NCT00072826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040032|Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease|Atorvastatin Therapy To Improve Endothelial Function in Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2003|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|November 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072826||201329|
NCT00072839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-008-01|Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease|A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects With Moderately Active Crohn's Disease||Shire|No|Completed|October 2003|September 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||January 2015|November 10, 2015|November 11, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072839||201328|
NCT00089895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03684|EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)|Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)||Merck Sharp & Dohme Corp.|Yes|Completed|November 2004|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9406|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 17, 2004|Yes|Yes||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00089895||200139|
NCT00090857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000375585|Letrozole in Preventing Breast Cancer in Postmenopausal Women|A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels||National Cancer Institute (NCI)||Completed|September 2000|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|110|||Female|35 Years|N/A|No|||October 2007|April 10, 2009|September 7, 2004||||No||https://clinicaltrials.gov/show/NCT00090857||200071|
NCT00085813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSP20007|Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer|A Phase II, Open-Label Study of Ispinesib in Subjects With Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer (NSCLC)||GlaxoSmithKline||Completed|December 2003|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|June 14, 2004||||||https://clinicaltrials.gov/show/NCT00085813||200430|
NCT00085826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|028|A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients|A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) Versus Taxotere (Docetaxel) and Placebo in Non-Small Cell Lung Cancer (NSCLC) Patients After Failure of Prior Platinum-Based Chemotherapy||Astellas Pharma Inc||Completed|April 2001|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|N/A|N/A|No|||October 2011|October 18, 2011|June 15, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00085826||200429|
NCT00073866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 01L2|Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase I/II Trial Of Weekly Irinotecan And Docetaxel With The Addition Of Celecoxib In Advanced Non-Small Cell Lung Cancer||Northwestern University|Yes|Completed|June 2003|December 2004|Actual|December 2004|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2012|July 10, 2012|December 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073866||201251|
NCT00082212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-046|A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||ImClone LLC|No|Terminated|November 2004|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||April 2010|April 8, 2010|May 3, 2004|Yes|Yes|Due to lack of sufficient efficacy.|No||https://clinicaltrials.gov/show/NCT00082212||200672|
NCT00082225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14424-ACDAL|LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)|Administration of LMP2a-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma|ACDAL|Baylor College of Medicine|Yes|Terminated|October 2003|January 2008|Actual|February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|No|||February 2014|February 15, 2014|May 3, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082225||200671|
NCT00082238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58603DK (completed)|Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)|Increased Gluconeogenesis is One Cause of CFRD||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 2003|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|May 3, 2004||||No||https://clinicaltrials.gov/show/NCT00082238||200670|
NCT00090545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040262|A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer|A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|August 2004|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Male|18 Years|N/A|No|||August 2012|August 28, 2012|August 27, 2004|Yes|Yes||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00090545||200091|
NCT00090480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0102|Vaccine Treatment for Advanced Breast Cancer|A Phase I/II Study of an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Relapsed or Refractory Breast Cancer||NewLink Genetics Corporation|No|Terminated|August 2004|September 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2009|June 30, 2009|August 26, 2004|Yes|Yes|Enrollment goals unable to be reached.|No||https://clinicaltrials.gov/show/NCT00090480||200096|
NCT00090493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2003-26|Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma|UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma||University of Arkansas|No|Completed|June 2004|May 2012|Actual|July 2007|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|70 Years|No|||May 2013|May 16, 2013|August 26, 2004|Yes|Yes||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00090493||200095|
NCT00091507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165|IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.|Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care Trial|IMMEDIATE|Tufts Medical Center|Yes|Completed|November 2006|August 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|911|||Both|30 Years|N/A|No|||February 2016|February 3, 2016|September 9, 2004|Yes|Yes||No|November 13, 2012|https://clinicaltrials.gov/show/NCT00091507||200033|
NCT00085176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE02C2|Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia|Neurobehavioral Outcomes in Childhood Acute Lymphoblastic Leukemia. A Limited Non-Therapeutic Study||Children's Oncology Group|Yes|Completed|May 2004|January 2011|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|286|||Both|6 Years|16 Years|No|Non-Probability Sample|Children previously randomized to (1) dexamethasone instead of prednisone on COG 1922 and        (2) intrathecal methotrexate, cytarabine, and hydrocortisone (triple therapy) instead of        intrathecal methotrexate alone on COG 1952|January 2014|January 29, 2014|June 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00085176||200471|
NCT00085852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-001|US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation|Phase 1 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Heterogeneous Emphysema||Aeris Therapeutics|Yes|Completed|April 2005|June 2007|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2008|February 27, 2008|June 15, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085852||200427|
NCT00074477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004357|Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 Mg-eq of Paliperidone Palmitate in Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2003|July 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|250|||Both|18 Years|65 Years|No|||April 2010|May 20, 2011|December 12, 2003||||||https://clinicaltrials.gov/show/NCT00074477||201211|
NCT00074490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040055|Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers|Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|December 2003|December 2022|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|510|||Both|11 Years|90 Years|Accepts Healthy Volunteers|||August 2015|September 26, 2015|June 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074490||201210|
NCT00074503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040058|PET Imaging of DHA Metabolism|Positron Emission Tomography Imaging of Incorporation of Docosahexaenoic Acid (DHA) From Plasma Into Human Brain||National Institutes of Health Clinical Center (CC)||Completed|December 2003|July 2010||||N/A|Observational|N/A|||Actual|85|||Both|18 Years|65 Years|No|||July 2010|July 14, 2010|December 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00074503||201209|
NCT00090532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4321001|A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration|A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety an Efficacy of AG-013958 in Subjects With Subfoveal Choroidal Neovascularization Associated With Age-related Macular Degeneration||Pfizer||Terminated|January 2004|August 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||155|||Both|55 Years|N/A|No|||May 2011|May 26, 2011|August 26, 2004|||This study was terminated due to a lack of efficacy.|||https://clinicaltrials.gov/show/NCT00090532||200092|
NCT00090233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-006|Rotavirus Efficacy and Safety Trial (REST)(V260-006)|Safety and Efficacy of Pentavalent (G1, G2, G3, G4 , and P1) Human-Bovine Reassortant Rotavirus Vaccine in Healthy Infants||Merck Sharp & Dohme Corp.||Completed|January 2001|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|69274|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2015|September 18, 2015|August 25, 2004|Yes|Yes||No|June 29, 2009|https://clinicaltrials.gov/show/NCT00090233||200114|70,301 participants randomized, 69,274 evaluated, when DSMB first recommended ending enrollment.
NCT00090246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-091|2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)|A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting||Merck Sharp & Dohme Corp.||Completed|May 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|922|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|August 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090246||200113|
NCT00077675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I6424-202b|Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|FAST2|Theravance Biopharma Antibiotics, Inc.|Yes|Completed|February 2004|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||May 2010|May 13, 2010|February 10, 2004|Yes|Yes||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00077675||200987|
NCT00078065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XT005|Xcellerated T CellsTM in Patients With Multiple Myeloma|A Randomized Phase II Study of Xcellerated T CellsTM With or Without Prior Fludarabine Therapy in Patients With Multiple Myeloma||Xcyte Therapies||Completed|November 2003|June 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||March 2005|November 10, 2005|February 18, 2004||||||https://clinicaltrials.gov/show/NCT00078065||200959|
NCT00072436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00038|Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors|A Phase I Trial of Gemcitabine Followed by a Short Infusion of Flavopiridol in Patients With Solid Tumors||National Cancer Institute (NCI)|Yes|Completed|September 2003|||March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072436||201358|
NCT00074789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065524|Reducing Symptoms of Depression in Low-Income Mothers|Reducing Depressive Symptoms in Low-Income Mothers||University of North Carolina, Chapel Hill|Yes|Completed|June 2003|January 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Female|15 Years|N/A|No|||June 2013|June 20, 2013|December 19, 2003||No||No||https://clinicaltrials.gov/show/NCT00074789||201189|
NCT00090259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-948|Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)|A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment||Merck Sharp & Dohme Corp.||Completed|December 2001|May 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3834|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|August 25, 2004|No|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00090259||200112|
NCT00090142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-275|Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 2-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast on Exercise-Induced Bronchospasm||Merck Sharp & Dohme Corp.|No|Completed|May 2004|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|62|||Both|15 Years|45 Years|No|||July 2015|July 29, 2015|August 24, 2004|Yes|Yes||No|September 22, 2009|https://clinicaltrials.gov/show/NCT00090142||200121|
NCT00090155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-090|2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)|A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting||Merck Sharp & Dohme Corp.||Completed|September 2003|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|805|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|August 24, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090155||200120|
NCT00073541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 72000-030|A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer|An Open-Label Phase II Study in Subjects With Recurrent EGFR-Positive Ovarian Cancer to Investigate the Safety and Efficacy of EMD 72000 Administered as a Single Agent||EMD Serono||Completed|April 2003|August 2004|Actual|March 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|38|||Female|18 Years|N/A|No|||October 2013|October 23, 2013|November 24, 2003||||||https://clinicaltrials.gov/show/NCT00073541||201275|
NCT00073554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA002|Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion|A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion||ARCA Biopharma, Inc.||Completed|June 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||November 2006|December 16, 2009|November 24, 2003||||||https://clinicaltrials.gov/show/NCT00073554||201274|
NCT00084435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365311|S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer|Adjuvant Chemo-RT With Cisplatin (NSC-119875) and Docetaxel (NSC-628503) After Complete Resection of Locally Advanced (Stage III and IV) Squamous Cell Carcinoma of the Head and Neck (SCCHN)|S0217|Southwest Oncology Group|No|Withdrawn|July 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|June 10, 2004||No|Poor accrual and suspension of head and neck committee|No||https://clinicaltrials.gov/show/NCT00084435||200515|
NCT00084682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00027|Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)|Yes|Completed|April 2004|March 2012|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||May 2013|April 29, 2015|June 10, 2004|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT00084682||200498|
NCT00084695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365544|Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases|The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells||National Cancer Institute (NCI)||Recruiting|September 2003|||December 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|25|||Both|N/A|21 Years|No|||October 2008|January 9, 2014|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084695||200497|
NCT00084123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20AT000756-01|Healing Touch and Relaxation Therapies in Cervical Cancer Patients|Healing Touch in Advanced Cervical Cancer Patients: Immune Effects and Mechanisms||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|September 2002|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|N/A|No|||July 2009|July 9, 2009|June 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00084123||200537|
NCT00085306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1604|Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma|Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma||Case Comprehensive Cancer Center|Yes|Completed|April 2004|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085306||200464|
NCT00085332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0129N|Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)|A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||Gynecologic Oncology Group|Yes|Completed|July 2004|||December 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||January 2014|January 10, 2014|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085332||200463|
NCT00091169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000384087|Levocarnitine in Treating Fatigue in Cancer Patients|Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of L-Carnitine Supplementation for Fatigue in Patients With Cancer||National Cancer Institute (NCI)||Completed|November 2005|||July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Anticipated|352|||Both|18 Years|N/A|No|||October 2008|October 26, 2012|September 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091169||200054|
NCT00091182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01815|Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment|A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors||National Cancer Institute (NCI)||Completed|October 2004|||February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|N/A|21 Years|No|||June 2013|June 4, 2013|September 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00091182||200053|
NCT00091195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01036|Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer|A Phase II Study Of Single Agent Depsipeptide (FK228) In Recurrent, Platinum Sensitive Adeno-Carcinoma Of The Ovary Or Peritoneum||National Cancer Institute (NCI)||Terminated|September 2004|||March 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|18 Years|N/A|No|||March 2013|March 18, 2013|September 7, 2004|Yes|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00091195||200052|
NCT00084149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIN501/A5216|Safety of and Immune Response to Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in Adults With Acute HIV Infection|A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|June 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084149||200535|
NCT00084162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040136|Neurocardiac Control in Major Depression|Neurocardiac Control in Major Depression||National Institutes of Health Clinical Center (CC)||Completed|March 2004|March 2010||||N/A|Observational|N/A|||Actual|41|||Both|18 Years|50 Years|No|||March 2010|March 18, 2010|June 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00084162||200534|
NCT00084929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000367101|Computed Tomographic Colonography in Screening Healthy Participants for Colorectal Cancer|National CT Colonography Trial|ACRIN 6664|American College of Radiology Imaging Network|Yes|Completed|February 2005|||September 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|2607|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 7, 2013|June 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00084929||200481|
NCT00084708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365546|Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors|A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA®) in Refractory Solid Tumors||Roswell Park Cancer Institute|Yes|Completed|November 2002|May 2007|Actual|October 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084708||200496|
NCT00077363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02973|Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer|A Phase II Trial of Capecitabine in Combination With the Farnesyltransferase Inhibitor, R115777 (Tipifarnib, Zarnestra) in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|May 2004|||February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|N/A|No|||February 2013|February 26, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077363||201008|
NCT00077662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02303|A Prospective, Observational Study in Patients With Late-Onset Pompe Disease|A Prospective, Observational Study in Patients With Late-Onset Pompe Disease||Sanofi||Completed|March 2004|January 2006|Actual|May 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|8 Years|N/A|No|Non-Probability Sample|Late-Onset Patients diagnosed with Pompe Disease|May 2015|May 4, 2015|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077662||200988|
NCT00084487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02587|Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy|Phase II Trial of XL119 (Rebeccamycin Analogue) in Relapsed "Sensitive" Small Cell Lung Cancer||National Cancer Institute (NCI)||Terminated|April 2004|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2013|May 7, 2014|June 10, 2004|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00084487||200512|
NCT00084461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01449|Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors|Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors||National Cancer Institute (NCI)||Terminated|March 2004|||October 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084461||200513|
NCT00084981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01451|Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer|A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|April 2004|||February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084981||200479|
NCT00089518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5179|Optimal Treatment for Kidney Disease in HIV Infected Adults|A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of an Angiotensin Receptor Blocker (Valsartan) and Highly Active Antiretroviral Therapy (HAART) Versus HAART Alone for the Treatment of HIV-Associated Nephropathy||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||August 2009|March 5, 2015|August 5, 2004||||||https://clinicaltrials.gov/show/NCT00089518||200167|
NCT00089531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040254|Candidate HIV Vaccine|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, in Uninfected Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|August 2004|January 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||January 2008|January 16, 2008|August 5, 2004||||No||https://clinicaltrials.gov/show/NCT00089531||200166|
NCT00088010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8536|Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer|Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.||Eli Lilly and Company|Yes|Completed|June 2004|November 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9369|||Female|60 Years|85 Years|No|||May 2010|May 27, 2010|July 19, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088010||200273|
NCT00087711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2938|A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company|Yes|Completed|July 2004|March 2008|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1713|||Both|18 Years|N/A|No|||May 2009|May 8, 2009|July 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087711||200295|
NCT00088426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040093|Clinical and Genetic Studies on Holoprosencephaly|Clinical and Genetic Studies on Holoprosencephaly||National Institutes of Health Clinical Center (CC)||Recruiting|January 2004|||||N/A|Observational|N/A|||Anticipated|250|||Both|N/A|N/A|No|||April 2015|April 24, 2015|July 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00088426||200244|
NCT00089557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C114|An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain|An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain||NeurogesX||Terminated||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2004|June 23, 2005|August 6, 2004||||||https://clinicaltrials.gov/show/NCT00089557||200164|
NCT00090896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000380840|CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery|A Phase I, Open Label, Study To Evaluate The Safety And Immune Function Effects Of CP-675,206 In Combination With MART-1 Peptide-Pulsed Dendritic Cells In Patients With Advanced Melanoma||Jonsson Comprehensive Cancer Center|Yes|Completed|April 2004|October 2009|Actual|July 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2012|October 28, 2015|September 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00090896||200069|
NCT00087724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0-189|A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease||Astellas Pharma Inc||Terminated|July 2004|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||510|||Both|50 Years|90 Years|No|||June 2012|June 6, 2012|July 12, 2004||||||https://clinicaltrials.gov/show/NCT00087724||200294|
NCT00087750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-MDS-0001-1|Interaction Between Cocaine and Quetiapine - 1|Interaction Between IV Cocaine and Quetiapine||National Institute on Drug Abuse (NIDA)||Active, not recruiting|October 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|45 Years|No|||March 2005|February 8, 2007|July 13, 2004||||||https://clinicaltrials.gov/show/NCT00087750||200292|
NCT00088452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS45911; U01NS045803|Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study|Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|July 2004|November 2014|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|453|||Both|30 Months|13 Years|Accepts Healthy Volunteers|||March 2013|August 12, 2014|July 26, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088452||200243|
NCT00081263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0207|Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia|A RANDOMIZED DOUBLE-BLIND PHASE II TRIAL OF CELECOXIB, A COX-2 INHIBITOR, IN THE TREATMENT OF PATIENTS WITH CERVICAL INTRAEPITHELIAL NEOPLASIA 2/3 or 3 (CIN 2/3 or 3)||Gynecologic Oncology Group|Yes|Active, not recruiting|June 2005|||January 2100|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|130|||Female|18 Years|N/A|No|||August 2014|August 8, 2014|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081263||200740|
NCT00092144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-289|Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral MK0476 Vs Placebo During the Allergy Season in Patients With Seasonal Aeroallergen Sensitivity and Chronic Asthma Which is Also Active During Allergy Season||Merck Sharp & Dohme Corp.||Completed|February 2004|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092144||199984|
NCT00092157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0733-224|Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)|A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patients With Combined Hyperlipidemia-Simvastatin and Fenofibrate Efficacy Trial (SAFARI)||Merck Sharp & Dohme Corp.||Completed|May 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|571|||Both|21 Years|65 Years|No|||December 2014|December 22, 2014|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092157||199983|
NCT00092170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-038|An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)|A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients||Merck Sharp & Dohme Corp.||Completed|March 2002|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|3 Months|17 Years|No|||October 2015|October 16, 2015|September 21, 2004||||No||https://clinicaltrials.gov/show/NCT00092170||199982|
NCT00088049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8047|Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia|A Randomized Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia||Eli Lilly and Company||Completed|October 2003|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||560|||Both|18 Years|65 Years|No|||July 2007|July 16, 2007|July 19, 2004||||||https://clinicaltrials.gov/show/NCT00088049||200270|
NCT00088465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5995|Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder|An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder||Eli Lilly and Company||Completed|August 2004|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|931|||Both|18 Years|76 Years|No|||December 2011|December 9, 2011|July 26, 2004|Yes|Yes||No|October 14, 2011|https://clinicaltrials.gov/show/NCT00088465||200242|
NCT00088699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040222|Rapid Antidepressant Effects of Ketamine in Major Depression|Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist||National Institutes of Health Clinical Center (CC)||Recruiting|July 2004|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Anticipated|324|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|September 15, 2015|July 30, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088699||200224|
NCT00089011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1898.00|Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer|A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|April 2004|||March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|74 Years|No|||January 2016|January 25, 2016|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089011||200203|
NCT00088582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2201|Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients|A Multicenter, Randomized, Crossover, Open Label Dose Finding Study to Compare the Safety, Efficacy and PK/PD Relationship of Multiple Doses of SOM230 and Sandostatin in Acromegalic Patients||Novartis|No|Completed|March 2004|||October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|80 Years|No|||May 2012|May 9, 2012|July 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088582||200233|
NCT00088595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2202|Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors|An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors||Novartis|Yes|Completed|January 2004|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|80 Years|No|||May 2012|May 29, 2012|July 30, 2004|Yes|Yes||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00088595||200232|No formal statistical comparisons were performed for this study. Summary statistics were provided to compare the different doses administered for the primary and secondary endpoints.
NCT00092183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-071|An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)|A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy||Merck Sharp & Dohme Corp.||Completed|October 2002|February 2004|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|866|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092183||199981|
NCT00087763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP 1009|Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)|A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)||Eyetech Pharmaceuticals||Completed|March 2004|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||135|||Both|50 Years|N/A|No|||May 2006|May 2, 2006|July 13, 2004||||||https://clinicaltrials.gov/show/NCT00087763||200291|
NCT00079586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-02-06|Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)|A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)||The Medicines Company||Completed|April 2004|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|March 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00079586||200852|
NCT00079911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100181|A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons|An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons With CD4+ Lymphocyte Count <100 Cells/mm3.||GlaxoSmithKline||Terminated|March 2004|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||162|||Both|18 Years|N/A|No|||September 2010|September 28, 2010|March 18, 2004||||||https://clinicaltrials.gov/show/NCT00079911||200827|
NCT00080639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000353332|CA-125 in Screening Patients at High Risk for Ovarian Cancer|Specialized Program Of Research Excellence (SPORE) In Ovarian Cancer/Cancer Genetics Network Collaborative Ovarian Cancer Screening Pilot Trial In High Risk Women||University of Alabama at Birmingham|Yes|Withdrawn|June 2003|June 2007|Actual|June 2007|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|30 Years|N/A|No|Probability Sample|Women know to be at high risk for ovarian cancer|August 2013|August 1, 2013|April 7, 2004||No|Terminated for administrative reasons and becuase there were no enrollments|No||https://clinicaltrials.gov/show/NCT00080639||200774|
NCT00080665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0214 CDR0000354504|Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Completed|December 2003|January 2011|Actual|January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080665||200773|
NCT00088361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040237|Effect of Respiratory Motion on Positron Emission Tomography Imaging|The Effects of Respiratory Motion on CT Based Attenuation Correction of Positron Emission Tomography Data: Liver and Heart Studies||National Institutes of Health Clinical Center (CC)||Completed|July 2004|June 2006||||N/A|Observational|N/A||||30|||Both|7 Years|N/A|No|||June 2006|March 3, 2008|July 23, 2004||||No||https://clinicaltrials.gov/show/NCT00088361||200249|
NCT00088374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040238|17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease|A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Von Hippel Lindau Disease and Renal Tumors||National Institutes of Health Clinical Center (CC)|No|Completed|July 2004|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|July 23, 2004|No|Yes||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00088374||200248|Study did not meet accrual.
NCT00087776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-02-17|Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma|Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma||Luitpold Pharmaceuticals||Completed|October 2002|||October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|575|||Both|18 Years|N/A|No|||March 2011|March 16, 2011|July 13, 2004||Yes||||https://clinicaltrials.gov/show/NCT00087776||200290|
NCT00079053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN5|Adjuvant Erlotinib After Completing Chemoradiotherapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase I Study of Adjuvant OSI-774 (Tarceva®) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Canadian Cancer Trials Group||Completed|November 2003|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079053||200891|
NCT00079365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355400|Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas|A Randomized Trial Comparing 5-Fluorouracil, External Beam Radiation, and Gemcitabine With or Without P Radiopharmaceutical Therapy As A First Line Therapy in Patients With Locally/Regionally Advanced Non-Resectable Adenocarcinoma of the Pancreas||National Cancer Institute (NCI)||Active, not recruiting|May 2001|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|December 3, 2013|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079365||200869|
NCT00079937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AIA05|Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma|A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma||Novartis||Completed|April 2004|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|628|||Both|6 Years|11 Years|No|||April 2012|April 9, 2012|March 18, 2004|Yes|Yes||No|December 3, 2010|https://clinicaltrials.gov/show/NCT00079937||200825|
NCT00079950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-9009|Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma|||Enzon Pharmaceuticals, Inc.||Suspended|August 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2012|September 5, 2012|March 18, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079950||200824|
NCT00088946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000377681|Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer|Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer||Jonsson Comprehensive Cancer Center|Yes|Completed|May 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|N/A|No|||August 2012|October 28, 2015|August 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088946||200208|
NCT00078819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030211|Etanercept (Enbrel®) in Psoriasis - Pediatrics|Placebo-controlled Multicenter Study With Etanercept to Determine Safety and Efficacy in Pediatric Subjects With Plaque Psoriasis (PEDS)||Amgen||Completed|August 2004|June 2007|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|211|||Both|4 Years|17 Years|No|||July 2013|July 26, 2013|March 5, 2004||||No||https://clinicaltrials.gov/show/NCT00078819||200906|
NCT00092027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-219|A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)|A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women||Merck Sharp & Dohme Corp.||Completed|March 2003|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|454|||Female|25 Years|N/A|No|||June 2015|June 9, 2015|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092027||199993|
NCT00092040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-907|A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)|A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis||Merck Sharp & Dohme Corp.||Completed|March 2003|September 2005|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|936|||Female|40 Years|N/A|No|||February 2015|February 26, 2015|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092040||199992|
NCT00092053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-908|Study of Investigational Drug in Osteoporosis (MK-0217-908)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis||Merck Sharp & Dohme Corp.|No|Completed|December 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|203|||Female|50 Years|N/A|No|||January 2016|January 6, 2016|September 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00092053||199991|
NCT00087646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV17150|REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy|A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy||Hoffmann-La Roche||Completed|September 2003|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|948|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|July 12, 2004|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT00087646||200300|
NCT00087659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GUS63|A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy|||Novartis||Completed|December 2003|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||November 2009|November 20, 2009|July 12, 2004||||||https://clinicaltrials.gov/show/NCT00087659||200299|
NCT00087672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0648|A Phase II Study of CC-5013 in Myelofibrosis|Phase II Study of CC-5013 in Myelofibrosis||M.D. Anderson Cancer Center|No|Completed|July 2004|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|N/A|N/A|No|||August 2012|August 1, 2012|July 12, 2004|Yes|Yes||No|September 15, 2009|https://clinicaltrials.gov/show/NCT00087672||200298|
NCT00091390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0321|Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer|Phase II Trial Of Combined High Dose Rate Brachytherapy And External Beam Radiotherapy For Adenocarcinoma Of The Prostate||Radiation Therapy Oncology Group|Yes|Active, not recruiting|July 2004|||January 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Male|18 Years|120 Years|No|||November 2015|November 14, 2015|September 7, 2004||No||No|October 31, 2014|https://clinicaltrials.gov/show/NCT00091390||200040|
NCT00087373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02615|Vaccine Therapy in Treating Patients With Metastatic Melanoma|Phase II Study of Intratumoral Injection of rF-TRICOMTM in Patients With Metastatic Melanoma Who Have Detectable Tumor Associated T Cells||National Cancer Institute (NCI)||Terminated|June 2004|||February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||December 2012|June 6, 2014|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087373||200321|
NCT00087997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4783-04|A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas|||Synta Pharmaceuticals Corp.||Completed|July 2004|October 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||June 2006|June 19, 2006|July 19, 2004||||||https://clinicaltrials.gov/show/NCT00087997||200274|
NCT00088387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040243|Effect of Lithium and Divalproex in Alzheimer's Disease|Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's Disease||National Institutes of Health Clinical Center (CC)||Completed|July 2004|March 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||March 2005|March 3, 2008|July 23, 2004||||No||https://clinicaltrials.gov/show/NCT00088387||200247|
NCT00089193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10524|Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma|Evaluation of GM-CSF-in-Adjuvant and the Number of Vaccine Sites on Immunization With Multiple Synthetic Melanoma Peptides||University of Virginia|Yes|Completed|September 2003|||February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||December 2014|December 18, 2014|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089193||200189|
NCT00089479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO17629|A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer|A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer||Hoffmann-La Roche||Completed|August 2002|May 2012|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2611|||Female|18 Years|70 Years|No|||December 2012|December 19, 2012|August 5, 2004|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00089479||200170|
NCT00091689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501-852A|Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions|||Pfizer||Completed|September 2004|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2008|October 24, 2008|September 15, 2004||||||https://clinicaltrials.gov/show/NCT00091689||200019|
NCT00088400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040244|Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors|A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme||National Institutes of Health Clinical Center (CC)||Completed|July 2004|November 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||November 2005|March 3, 2008|July 23, 2004||||No||https://clinicaltrials.gov/show/NCT00088400||200246|
NCT00088413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040246|PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer|An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2004|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|100 Years|No|||April 2015|February 5, 2016|July 23, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088413||200245|
NCT00088972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000377698|S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women|Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer||Southwest Oncology Group|Yes|Terminated|November 2004|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|8|||Female|18 Years|120 Years|No|||September 2015|September 28, 2015|August 4, 2004|Yes|Yes|Study closed due to poor accrual.|No|November 9, 2012|https://clinicaltrials.gov/show/NCT00088972||200206|
NCT00089206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10049|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma||University of Virginia|Yes|Completed|August 2002|||November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|12 Years|N/A|No|||December 2014|December 18, 2014|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089206||200188|
NCT00087698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7216|Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma|A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (Alimta) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma||Eli Lilly and Company|No|Completed|September 2003|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||May 2009|May 1, 2009|July 12, 2004|Yes|Yes||No|February 16, 2009|https://clinicaltrials.gov/show/NCT00087698||200296|
NCT00088023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-000|Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness|A Phase I Study of PT-523 in Patients With Solid Tumors||Spectrum Pharmaceuticals, Inc||Terminated|March 2004|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|July 19, 2004||||||https://clinicaltrials.gov/show/NCT00088023||200272|
NCT00088036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6253|Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder|Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo||Eli Lilly and Company||Completed|February 2004|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|18 Years|65 Years|No|||July 2006|July 21, 2006|July 19, 2004||||||https://clinicaltrials.gov/show/NCT00088036||200271|
NCT00088660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBC-PAN-003|PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen|A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen||Therion Biologics Corporation||Active, not recruiting|June 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||February 2006|February 7, 2006|July 30, 2004||||||https://clinicaltrials.gov/show/NCT00088660||200227|
NCT00088673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-758007|Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease|A Phase III Study of the Efficacy and Safety of 3APS in Patients With Mild to Moderate Alzheimer’s Disease||Bellus Health Inc|Yes|Active, not recruiting|June 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||950|||Both|50 Years|N/A|No|||February 2007|February 27, 2007|July 30, 2004||||||https://clinicaltrials.gov/show/NCT00088673||200226|
NCT00089219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10464|Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma|Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma||University of Virginia|Yes|Completed|July 2003|||May 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089219||200187|
NCT00087399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N03C5|Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy|A Phase III Randomized, Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone||Alliance for Clinical Trials in Oncology|Yes|Completed|November 2004|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|118|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087399||200319|
NCT00088062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5326-03|STA-5326 in Crohn's Disease Patients|A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450||Synta Pharmaceuticals Corp.||Completed|February 2004|November 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|65 Years|No|||May 2005|June 23, 2005|July 19, 2004||||||https://clinicaltrials.gov/show/NCT00088062||200269|
NCT00088686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040248|Capsaicin to Control Pain Following Third Molar Extraction|Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia||National Institutes of Health Clinical Center (CC)||Completed|July 2004|October 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|No|||October 2005|March 3, 2008|July 30, 2004||||No||https://clinicaltrials.gov/show/NCT00088686||200225|
NCT00089908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 199|Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults|Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2004|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 17, 2008|August 17, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089908||200138|
NCT00090272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-039|A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)|A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Ertapenem Sodium (MK0826) Versus Cefotetan for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery||Merck Sharp & Dohme Corp.||Completed|April 2002|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|952|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|August 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00090272||200111|
NCT00087412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03060|S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer|Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2||National Cancer Institute (NCI)||Completed|September 2004|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087412||200318|
NCT00087737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-317|Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|369|||Both|18 Years|75 Years|No|||August 2009|August 18, 2009|July 13, 2004||||||https://clinicaltrials.gov/show/NCT00087737||200293|
NCT00088712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040250|Event Related Potentials in Infants and Adults|Event Related Potentials From Infancy to Adulthood||National Institutes of Health Clinical Center (CC)||Recruiting|July 2004|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|500|||Both|3 Months|45 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|July 30, 2004||No||No||https://clinicaltrials.gov/show/NCT00088712||200223|
NCT00089245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-133|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer|Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms||Memorial Sloan Kettering Cancer Center||Recruiting|July 2004|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|N/A|N/A|No|||October 2015|October 28, 2015|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00089245||200186|
NCT00089544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02588|Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall|A Pilot Phase II Study of Pre-Operative Radiation Therapy and Thalidomide (IND 48832; NSC 66847) for Low Grade Primary Soft Tissue Sarcoma or Pre-Operative MAID/Thalidomide/Radiation Therapy for High/Intermediate Grade Primary Soft Tissue Sarcoma of the Extremity or Body Wall||National Cancer Institute (NCI)||Terminated|June 2004|December 2012|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|16 Years|N/A|No|||January 2013|May 29, 2014|August 6, 2004|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00089544||200165|This study closed early due to unacceptably high rate of thromboembolic events in Cohort A and due to low accrual in Cohort B. For this reason efficacy endpoints other than response to pre-operative therapy were not reported.
NCT00081562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-098|Genetics of Ankylosing Spondylitis|Family Studies of the Genetics of Ankylosing Spondylitis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|September 1999|December 2006|Actual|December 2006|Actual|N/A|Observational|N/A||||1600|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2008|February 19, 2008|April 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00081562||200719|
NCT00081575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-313|Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2004|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|434|||Both|18 Years|70 Years|No|||February 2013|February 7, 2013|April 15, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00081575||200718|
NCT00088075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003370|Investigate Risperidone for the Treatment of Schizophrenia in Adolescents|A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2004|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|160|||Both|13 Years|17 Years|No|||January 2011|June 6, 2011|July 19, 2004||||||https://clinicaltrials.gov/show/NCT00088075||200268|
NCT00088088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4783-02|STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Trial of STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC)||Synta Pharmaceuticals Corp.||Completed|March 2004|March 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||86|||Both|18 Years|N/A|No|||December 2008|December 3, 2008|July 20, 2004||||||https://clinicaltrials.gov/show/NCT00088088||200267|
NCT00079924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8141|Effects of Teriparatide in Postmenopausal Women With Osteoporosis|Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene||Eli Lilly and Company||Completed|November 2004|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Female|50 Years|N/A|No|||May 2007|May 23, 2007|March 18, 2004||||||https://clinicaltrials.gov/show/NCT00079924||200826|
NCT00080210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0403|A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy|A Phase II Study of Multiple Doses of Intravenous Puricase in Subjects With Hyperuricemia and Refractory Gout||Savient Pharmaceuticals||Completed|March 2004|February 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|90 Years|No|||May 2013|May 31, 2013|March 24, 2004||||||https://clinicaltrials.gov/show/NCT00080210||200804|
NCT00080223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPF-002|Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis|An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis||Genentech, Inc.|No|Completed|August 2003|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|83|||Both|40 Years|85 Years|No|||February 2016|February 10, 2016|March 24, 2004|Yes|Yes||No|February 10, 2016|https://clinicaltrials.gov/show/NCT00080223||200803|
NCT00080938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000357567|Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer|A Phase II Study of Temozolomide and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)||Eastern Cooperative Oncology Group|No|Completed|October 2005|February 2009|Actual|August 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|April 7, 2004||No||No|December 30, 2010|https://clinicaltrials.gov/show/NCT00080938||200758|
NCT00088335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040236|Biological Markers in Parkinson's Disease|Investigation of Biomarkers in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|July 2004|June 2005||||N/A|Observational|N/A||||90|||Both|N/A|N/A|No|||June 2005|March 3, 2008|July 23, 2004||||No||https://clinicaltrials.gov/show/NCT00088335||200251|
NCT00088881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02957|Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma|A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients With Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)|No|Terminated|December 2004|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|August 4, 2004|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00088881||200212|
NCT00088894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02960|Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|June 2004|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|590|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088894||200211|
NCT00079339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03021|Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma|Phase I/II Trial of R115777 and XRT in Pediatric Patients With Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas||National Cancer Institute (NCI)||Completed|January 2004|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|3 Years|21 Years|No|||December 2012|April 29, 2014|March 8, 2004|Yes|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00079339||200871|
NCT00079352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02580|Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors|A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer||National Cancer Institute (NCI)||Completed|April 2004|||October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079352||200870|
NCT00079599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NR008295-01|L-Carnitine to Treat Fatigue in AIDS Patients|Phase II Developmental Study on Fatigue in AIDS Patients||National Institute of Nursing Research (NINR)|Yes|Completed|November 2002|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||September 2008|September 2, 2008|March 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00079599||200851|
NCT00088348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040241|Screening for Research Subjects With Anterior Segment Diseases|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Anterior Segment Disease||National Institutes of Health Clinical Center (CC)||Completed|July 2004|August 2008||||N/A|Observational|N/A||||600|||Both|N/A|N/A|No|||August 2008|September 26, 2015|July 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00088348||200250|
NCT00087958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6088|Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment|Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine||Sanofi||Completed|August 2004|April 2009|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|168|||Both|18 Years|N/A|No|||April 2009|April 30, 2009|July 16, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087958||200276|
NCT00088608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2208|A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease|A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease||Novartis||Completed|April 2004|||June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|80 Years|No|||November 2011|November 29, 2011|July 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00088608||200231|
NCT00079066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO17|Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer|A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma||Canadian Cancer Trials Group||Completed|August 2003|February 2009|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||March 2010|October 31, 2013|March 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00079066||200890|
NCT00087360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-03030|Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants|Providing Genetic And Environmental Cancer Risk Assessment In Primary Care||Fox Chase Cancer Center|No|Completed|November 2003|May 2007|Actual|May 2007|Actual|N/A|Interventional|Primary Purpose: Screening|||||||Both|50 Years|74 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087360||200322|
NCT00088621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050199|A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia|An Open-Label, Multicenter, Twelve-Month Study of Safety and Tolerability in the Treatment of Schizophrenia||Sunovion|No|Completed|July 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|64 Years|No|||March 2014|March 31, 2014|July 30, 2004|No|Yes||No|February 11, 2011|https://clinicaltrials.gov/show/NCT00088621||200230|
NCT00088634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050196|A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia|A Double-blind Fixed-dose Study of SM-13496 and Placebo in the Treatment of Schizophrenia||Sunovion|No|Completed|May 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|64 Years|No|||March 2014|March 31, 2014|July 30, 2004|No|Yes||No|February 1, 2011|https://clinicaltrials.gov/show/NCT00088634||200229|
NCT00089453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2003-18|Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant|UARK 2003-18, A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma||University of Arkansas|No|Completed|September 2003|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 17, 2012|August 5, 2004||No||No||https://clinicaltrials.gov/show/NCT00089453||200172|
NCT00089466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5210|Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients|Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2004|January 2009|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|6|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|August 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089466||200171|
NCT00091676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BV 301|Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma|Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission|BiovaxID|Biovest International|Yes|Active, not recruiting|January 2000|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|629|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|September 15, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00091676||200020|
NCT00087685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0002|RAD001 in Recurrent Endometrial Cancer Patients|A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer||M.D. Anderson Cancer Center|No|Completed|June 2004|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|N/A|N/A|No|||January 2016|January 6, 2016|July 12, 2004|Yes|Yes||No|December 1, 2015|https://clinicaltrials.gov/show/NCT00087685||200297|
NCT00087984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-002-003|RNA-Loaded Dendritic Cell Cancer Vaccine|A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma||Argos Therapeutics||Completed|January 2004|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|July 16, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087984||200275|
NCT00088985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0310|Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer|Phase II Trial Evaluating The Efficacy Of A Multiepitope Dendritic Cell Vaccine Given With Trastuzumab And Vinorelbine For The Treatment Of Women With Metastatic Breast Cancer That Express HLA-A0201|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|January 2004|||October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|18 Years|120 Years|No|||January 2016|January 20, 2016|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088985||200205|
NCT00089492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV17658|A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients|A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients.||Hoffmann-La Roche||Completed|July 2004|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|16 Years|N/A|No|||March 2016|March 1, 2016|August 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00089492||200169|
NCT00089856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-0029|GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve||Cell Genesys||Terminated|July 2004|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|626|||Male|18 Years|N/A|No|||November 2008|November 3, 2008|August 16, 2004|Yes|Yes|Based on futility analysis showing <30% chance of meeting primary endpoint.|No||https://clinicaltrials.gov/show/NCT00089856||200142|
NCT00092066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-227|A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)|A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporosis||Merck Sharp & Dohme Corp.||Completed|September 2003|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|717|||Both|40 Years|90 Years|No|||November 2014|November 7, 2014|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092066||199990|
NCT00092079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-227 Extension|A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)|A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporosis||Merck Sharp & Dohme Corp.||Completed|January 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|652|||Both|40 Years|90 Years|No|||November 2014|November 7, 2014|September 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092079||199989|
NCT00088647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3161K1-100|Study Evaluating MST-997 in Advanced Malignant Solid Tumors|A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects With Advanced Malignant Solid Tumors||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2006|December 7, 2006|July 30, 2004||||||https://clinicaltrials.gov/show/NCT00088647||200228|
NCT00088959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00886|Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase I Study of Erlotinib and Celecoxib in Former Smokers With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)|No|Completed|December 2003|November 2010|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||April 2013|October 9, 2014|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088959||200207|
NCT00088998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0432|Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer|Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|December 2004|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|August 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00088998||200204|
NCT00089505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5208|NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission|Optimal Combination Therapy After Nevirapine Exposure|OCTANE|AIDS Clinical Trials Group|Yes|Completed|November 2006|February 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|745|||Female|13 Years|N/A|No|||January 2016|January 4, 2016|August 5, 2004|Yes|Yes||No|August 30, 2010|https://clinicaltrials.gov/show/NCT00089505||200168|
NCT00089882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0057|Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II|Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II||National Institute on Aging (NIA)||Completed|May 2003|September 2006|Actual|September 2006|Actual|N/A|Observational|Time Perspective: Prospective||||360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 22, 2009|August 17, 2004||No||No||https://clinicaltrials.gov/show/NCT00089882||200140|
NCT00082615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040188|Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives|Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives||National Institutes of Health Clinical Center (CC)||Completed|May 2004|April 2008||||N/A|Observational|N/A||||210|||Both|18 Years|N/A|No|||April 2008|September 26, 2015|May 13, 2004||||No||https://clinicaltrials.gov/show/NCT00082615||200642|
NCT00076466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040103|Brain Changes Associated With Learning a Motor Task|Changes in Intracortical Inhibitory Processes Are Associated With the Development of Implicit Learning of a Motor Task||National Institutes of Health Clinical Center (CC)||Completed|January 2004|January 2009||||N/A|Observational|N/A||||72|||Both|18 Years|40 Years|No|||January 2009|January 15, 2009|January 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00076466||201070|
NCT00076817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI050467-03|Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm|A Phase I Double Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of the Aventis Pasteur ALVAC-HIV (vCP205) Administered to the Groin Area Versus the Deltoid Area||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2006|September 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 26, 2012|February 3, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00076817||201046|
NCT00084916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02589|CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase|A Phase II Study Of CCI-779 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase||National Cancer Institute (NCI)||Completed|April 2004|||March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084916||200482|
NCT00085293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00033|Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131|Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine||National Cancer Institute (NCI)|No|Completed|May 2004|May 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2014|August 20, 2014|June 10, 2004|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00085293||200465|
NCT00085943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100732|KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks|See Detailed Description||GlaxoSmithKline|No|Completed|May 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||866|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 12, 2011|June 17, 2004||||||https://clinicaltrials.gov/show/NCT00085943||200420|
NCT00085956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8537|Effects of Arzoxifene on Bone Mass and the Uterus|Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women.||Eli Lilly and Company||Completed|April 2004|February 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||March 2007|March 7, 2007|June 18, 2004||||||https://clinicaltrials.gov/show/NCT00085956||200419|
NCT00086229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001938-01|Absorption and Distribution of Glucosamine and Chondroitin|A Pharmacokinetic Study of Glucosamine and Chondroitin||National Center for Complementary and Integrative Health (NCCIH)||Completed|April 2004|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2006|August 16, 2006|June 28, 2004||||No||https://clinicaltrials.gov/show/NCT00086229||200399|
NCT00086879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26034-16031|Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme|Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2004|||March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|110|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|July 8, 2004||||No||https://clinicaltrials.gov/show/NCT00086879||200353|
NCT00086892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0146P|Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240) in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer||Gynecologic Oncology Group|Yes|Completed|June 2004|||April 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||||||Female|18 Years|N/A|No|||February 2014|February 12, 2014|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086892||200352|
NCT00086931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 10803|Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum|A Phase I/II Study of Weekly Intravenous Oxaliplatin in Combination With Oral Daily Capecitabine and Radiation Therapy in the Neoadjuvant Treatment of Rectal Cancer||Roswell Park Cancer Institute|Yes|Completed|September 2003|May 2010|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|75 Years|No|||March 2013|March 7, 2013|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086931||200351|
NCT00082303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32AT001144-01|Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin’s Lymphoma|Music Imagery for Patients in Protected Environments||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2002|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||August 2006|August 16, 2006|May 5, 2004||||No||https://clinicaltrials.gov/show/NCT00082303||200666|
NCT00082628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24380|Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS||EMD Serono||Completed|May 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|569|||Both|18 Years|60 Years|No|||June 2014|June 16, 2014|May 13, 2004||||No||https://clinicaltrials.gov/show/NCT00082628||200641|
NCT00075062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 056|A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials|Characteristics of Baseline Mucosal Indices of Injury and Inflammation in Men For Use in Rectal Microbicide Trials||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||N/A|Observational|Time Perspective: Prospective||||16|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|August 20, 2008|December 31, 2003||||No||https://clinicaltrials.gov/show/NCT00075062||201168|
NCT00086177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-1620-300|Vaginal Progesterone to Reduce the Risk of Another Preterm Birth|A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery||Juniper Pharmaceuticals, Inc.|No|Completed|April 2004|March 2009|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|636|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 18, 2010|June 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086177||200403|
NCT00085969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-120|Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|September 2003|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|99|||Both|18 Years|75 Years|No|||January 2015|February 19, 2015|June 18, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085969||200418|
NCT00086242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510143|Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stage I, Stage II, or Stage III Cervical Cancer|Stress-Immune Response and Cervical Cancer||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 1|Interventional|Allocation: Randomized|||Anticipated|50|||Female|18 Years|N/A|No|||November 2006|July 20, 2009|June 28, 2004||||No||https://clinicaltrials.gov/show/NCT00086242||200398|
NCT00086606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q2788g|A Safety and Efficacy Study of Xolair in Peanut Allergy|A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Oral Food Challenge Trial of Xolair (Omalizumab) in Peanut Allergy||Genentech, Inc.||Terminated|June 2004|April 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||150|||Both|6 Years|75 Years|No|||January 2013|January 17, 2013|July 6, 2004||||No||https://clinicaltrials.gov/show/NCT00086606||200370|
NCT00086944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02600|Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase I/II Study of G3139 (Genasense) in Combination With RICE Chemotherapy in Relapsed B-Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|May 2004|||July 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00086944||200350|
NCT00086593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101464|Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia|A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects With Schizophrenia||GlaxoSmithKline||Completed|May 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|209|||Both|18 Years|65 Years|No|||April 2015|April 16, 2015|July 6, 2004||||No||https://clinicaltrials.gov/show/NCT00086593||200371|
NCT00082316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C111|Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain|A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain||NeurogesX||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2008|January 3, 2008|May 5, 2004||||||https://clinicaltrials.gov/show/NCT00082316||200665|
NCT00083551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5226|UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy|UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy||University of Arkansas|Yes|Completed|August 1998|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|668|||Both|18 Years|75 Years|No|||October 2015|October 21, 2015|May 25, 2004|Yes|Yes||No|August 24, 2015|https://clinicaltrials.gov/show/NCT00083551||200578|
NCT00083564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR 0303|Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma|A Randomized Multicenter Study to Compare the Safety and Efficacy of 166Ho-DOTMP Plus Melphalan to Melphalan Alone as Conditioning for Autologous Peripheral Blood Stem Cell Transplant in Subjects With Primary Refractory Multiple Myeloma||Poniard Pharmaceuticals||Terminated|March 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|70 Years|No|||March 2009|March 30, 2009|May 25, 2004|||For business reasons|||https://clinicaltrials.gov/show/NCT00083564||200577|
NCT00086476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040226|Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles|Investigations of Megakaryocytes From Patients With Abnormal Platelet Vesicles||National Institutes of Health Clinical Center (CC)||Completed|June 2004|June 2011||||N/A|Observational|N/A|||Actual|3|||Both|2 Years|80 Years|No|||June 2011|June 14, 2011|July 1, 2004||No||No||https://clinicaltrials.gov/show/NCT00086476||200380|
NCT00086489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671002|CP-675,206 In Patients With Advanced Melanoma|Phase 1 Open Label, Non-Randomized, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immune Function Effects, And Efficacy Of Multiple Doses Of CP-675,206 In Patients With Advanced Melanoma, And Phase 2, Open Label, Randomized Study To Evaluate the Efficacy, Safety, Tolerability And Pharmacokinetics Of 2 Regimens Of CP-675,206 In Patients With Advanced Melanoma.||AstraZeneca|No|Completed|August 2003|May 2009|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|July 1, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086489||200379|
NCT00085631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005267|Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer|An International Multi Center Phase III Study of Chemoradiotherapy Versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer||Duke University|No|Terminated|March 2003|June 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Female|18 Years|N/A|No|||July 2013|July 10, 2013|June 10, 2004|Yes|Yes|Study was closed because of slow accrual|No|April 10, 2013|https://clinicaltrials.gov/show/NCT00085631||200444|There are integrity issues with the currently available data, involving international institutions, in that several pieces of information relating to patient accrual and outcomes cannot be verified.
NCT00085644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-607|Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis|A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis|ATLAS|Abbott|No|Completed|January 2004|July 2009|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|June 10, 2004|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00085644||200443|Interim results are shown for subjects after 12 weeks for efficacy parameters and 24 weeks for safety parameters. Subjects who discontinued the study before Week 12 and subjects with missing values were classified as nonresponders for efficacy.
NCT00085982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030257|Effect of Leptin Therapy in the Treatment of Severe Insulin Resistance|Effect of Leptin Therapy in the Treatment of Severe Insulin Resistance||National Institutes of Health Clinical Center (CC)||Recruiting|July 2003|January 2030|Anticipated|January 2030|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|20|||Both|5 Years|N/A|No|||November 2015|December 2, 2015|June 18, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085982||200417|
NCT00086255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0012-1|Tiagabine for the Treatment of Cocaine Dependence - 1|Tiagabine for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|October 2002|June 2004||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||August 2008|August 15, 2008|June 29, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086255||200397|
NCT00086268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS75|Non-small Cell Lung Cancer Study US75 (Z-PACT)||ZPACT|Novartis||Completed|April 2004|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|250|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|June 29, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00086268||200396|
NCT00086281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-SXB-23|Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients|Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients||Jazz Pharmaceuticals|No|Completed|November 2003|November 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|June 29, 2004|Yes|Yes||No|November 11, 2011|https://clinicaltrials.gov/show/NCT00086281||200395|
NCT00086619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-123|Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women|Evaluation of Factors That Affect Skeletal Responses to PTH||Massachusetts General Hospital|Yes|Completed|May 2004|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|46 Years|85 Years|No|||September 2013|September 26, 2013|July 7, 2004|Yes|Yes||No|June 7, 2012|https://clinicaltrials.gov/show/NCT00086619||200369|
NCT00086957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03049|Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer|Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma||City of Hope Medical Center|Yes|Completed|January 2004|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086957||200349|
NCT00086970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02601|Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors|A Phase I Study Of BG In Combination With Ifosfamide For Advanced Solid Tumors||National Cancer Institute (NCI)||Terminated|June 2004|||November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|July 8, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00086970||200348|
NCT00082329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040179|G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers|Peripheral Blood Hematopoietic Progenitor Cell Mobilization Using Granulocyte Colony Stimulating Factor (G-CSF) Combined With AMD3100 Mozobil (Plerixafor) in Healthy Volunteers||National Institutes of Health Clinical Center (CC)|No|Completed|May 2004|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|May 6, 2004|Yes|Yes||No|April 1, 2014|https://clinicaltrials.gov/show/NCT00082329||200664|
NCT00083304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-016|Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer|A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Women With Brain Metastases From Breast Cancer|ENRICH|Spectrum Pharmaceuticals, Inc|Yes|Completed|February 2004|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|368|||Female|18 Years|N/A|No|||May 2013|May 8, 2013|May 18, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083304||200597|
NCT00084669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365502|Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer|Targeting Insomnia to Enhance Hot Flush Treatment in Women Receiving Therapy for Breast Cancer or Breast Cancer Risk-Reduction||Massachusetts General Hospital||Completed|May 2004|March 2010|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|119|||Female|18 Years|65 Years|No|||April 2010|April 27, 2010|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00084669||200499|
NCT00085345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCOTHER-MAC001|Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Study of Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients With Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2006|July 9, 2013|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00085345||200462|
NCT00085657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040212|Brain Electrical Stimulation to Enhance Recovery After Stroke|Enhancement of Rehabilitative Treatment-Dependent Functional Recovery After Stroke by Transcranial Direct Current Stimulation (tDCS)||National Institutes of Health Clinical Center (CC)||Completed|June 2004|May 2009||||N/A|Observational|N/A||||150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2009|May 22, 2009|June 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00085657||200442|
NCT00086294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040225|ACP-103 to Treat Parkinson's Disease|5HT2A/C Serotonin Blockade in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2004|November 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||40|||Both|30 Years|80 Years|No|||November 2007|November 16, 2007|June 29, 2004||||No||https://clinicaltrials.gov/show/NCT00086294||200394|
NCT00086632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVA-Gy-18|Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment|An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-Based Front-Line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin||Unither Pharmaceuticals||Terminated|July 2004|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|N/A|80 Years|No|||January 2006|December 13, 2007|July 7, 2004|||closed by sponser|||https://clinicaltrials.gov/show/NCT00086632||200368|
NCT00086645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54MH066398|Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)|Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior||Boston University|Yes|Completed|April 2004|April 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|149|||Both|5 Years|17 Years|No|||July 2014|July 16, 2014|July 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086645||200367|
NCT00086983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03118|Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors|A Phase I Study of XL119 (Rebeccamycin Analogue) in Combination With Oxaliplatin in Patients With Refractory Solid Tumors||National Cancer Institute (NCI)||Terminated|May 2004|||September 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00086983||200347|
NCT00086996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000371963|S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction|Oxaliplatin (NSC-266046) Plus Protracted Infusion 5-Fluorouracil And Radiation For Potentially Curable Esophageal Cancer: A Phase II Trial With Molecular Correlates||Southwest Oncology Group|Yes|Completed|September 2004|August 2011|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|July 8, 2004|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT00086996||200346|
NCT00082342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030116|Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease|Transcranial Direct Current Stimulation for the Treatment of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|March 2003|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|80 Years|No|||November 2012|November 22, 2012|May 6, 2004||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT00082342||200663|
NCT00083616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030167|Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy|A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy||Amgen|Yes|Completed|March 2004|December 2008|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|May 26, 2004||Yes||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00083616||200573|
NCT00084942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000367107|Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder|A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma||Roswell Park Cancer Institute|Yes|Completed|October 2002|November 2006|Actual|May 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2012|January 11, 2012|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084942||200480|
NCT00085358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00619|Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)|A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|May 2004|||May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||March 2013|March 18, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085358||200461|
NCT00085722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0112|Joint Injections for Osteoarthritic Knee Pain|The Efficacy of Prolotherapy in Osteoarthritic Knee Pain||University of Wisconsin, Madison|Yes|Active, not recruiting|July 2004|May 2016|Anticipated|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|111|||Both|40 Years|70 Years|No|||October 2015|October 9, 2015|June 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085722||200437|
NCT00085670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040213|Cytokine Gene Polymorphisms in Bone Marrow Failure|Cytokine Gene Polymorphisms in Bone Marrow Failure||National Institutes of Health Clinical Center (CC)||Completed|June 2004|||||N/A|Observational|N/A|||Actual|79|||Both|2 Years|80 Years|No|||October 2015|October 23, 2015|June 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00085670||200441|
NCT00085683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040209|Herpes Virus-6 and Epilepsy|Human Herpesvirus-6 and Its Effect on the GABA/Glutamate Balance in the Cerebrospinal Fluid and in the Brain From Patients With Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|June 2004|July 2005||||N/A|Observational|N/A||||45|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2005|March 3, 2008|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00085683||200440|
NCT00086307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040227|Lexapro and Pramipexole and to Treat Major Depression|Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study||National Institutes of Health Clinical Center (CC)|No|Completed|June 2004|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|65 Years|No|||January 2013|January 11, 2013|June 29, 2004||No||No|June 7, 2012|https://clinicaltrials.gov/show/NCT00086307||200393|
NCT00086658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100185|Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)|A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES||GlaxoSmithKline||Completed|March 2004|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|86|||Both|18 Years|75 Years|No|||April 2015|April 16, 2015|July 7, 2004||||||https://clinicaltrials.gov/show/NCT00086658||200366|
NCT00087009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-095|Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation|Phase I Study of Oral ß-Glucan and Intravenous Rituximab Among Children and Adolescents With Relapsed CD20-Positive Lymphoma or Leukemia, or Post-Transplant Lymphoproliferative Disease||Memorial Sloan Kettering Cancer Center||Terminated|May 2004|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|N/A|21 Years|No|||March 2013|March 18, 2013|July 8, 2004|No|Yes|Lack of Accrual|No||https://clinicaltrials.gov/show/NCT00087009||200345|
NCT00082368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040177|PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy|A Pilot Study of Tc-94m Sestamibi PET MDR Imaging||National Institutes of Health Clinical Center (CC)|No|Completed|May 2004|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|65 Years|No|||May 2015|May 7, 2015|July 7, 2006|Yes|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT00082368||200661|The lack of flexibility around patient chemotherapy schedules made the protocol difficult to conduct. Future studies should make imaging integral to the treatment protocol .
NCT00082381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWAA|Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin|Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin||AstraZeneca|No|Completed|June 2003|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|551|||Both|30 Years|75 Years|No|||March 2015|March 19, 2015|May 6, 2004|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00082381||200660|
NCT00082654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1639.00|Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients|Emotional Needs of Caregivers and Patient/Spouse Couples During Hematopoietic Stem Cell Transplantation (HSCT)||Fred Hutchinson Cancer Research Center||Completed|March 2002|October 2004|Actual|October 2004|Actual|N/A|Interventional|N/A|||||||Both|21 Years|N/A|No|||September 2010|September 17, 2010|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00082654||200639|
NCT00085371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01452|Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas|A Phase II Study Of Triapine For Advanced Adenocarcinoma Of The Pancreas||National Cancer Institute (NCI)||Completed|July 2004|||July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|116|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085371||200460|
NCT00085709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0106|S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML|A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)||Southwest Oncology Group|Yes|Completed|July 2004|August 2014|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|637|||Both|18 Years|60 Years|No|||September 2015|September 25, 2015|June 14, 2004|Yes|Yes||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00085709||200438|
NCT00087048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000372872|Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer|The Use Of Weekly Topotecan As Second Line Therapy In Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Terminated|April 2004|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 8, 2004|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00087048||200342|
NCT00082420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETEQ (completed)|Retinol Equivalence of Plant Carotenoids in Children|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2004|November 2005|Actual|||N/A|Observational|Observational Model: Case-Only||2|Actual|32|||Both|7 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy children with normal or marginal vitamin A nutrition|January 2010|January 12, 2010|May 6, 2004||||No||https://clinicaltrials.gov/show/NCT00082420||200657|
NCT00086320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004384|A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|111|||Both|18 Years|65 Years|No|||April 2010|June 6, 2011|June 30, 2004||||||https://clinicaltrials.gov/show/NCT00086320||200392|
NCT00086671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-654|Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)|A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase||AbbVie|Yes|Completed|April 2004|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|215|||Both|18 Years|60 Years|No|||January 2013|January 2, 2013|July 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086671||200365|
NCT00087022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX-2003-07-HR|Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer|A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)||Wilex|Yes|Completed|July 2004|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|864|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087022||200344|
NCT00082355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040178|Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins|The Treatment of Deep Vein Thrombosis (DVT) of the Lower Extremities With "Low-Dose" Alteplase: a Pilot Study||National Institutes of Health Clinical Center (CC)|No|Completed|May 2004|October 2014|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|May 6, 2004|No|Yes||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00082355||200662|Small trial of 30 patients does not have statistical power to prove clinical safety (expected to be <1 %)
NCT00082394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100327|A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV|See Detailed Description||GlaxoSmithKline||Completed|April 2004|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|May 6, 2004||||||https://clinicaltrials.gov/show/NCT00082394||200659|
NCT00082407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWAD|Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin|Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin||AstraZeneca|No|Completed|November 2003|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|505|||Both|30 Years|75 Years|No|||March 2015|March 19, 2015|May 6, 2004|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00082407||200658|
NCT00082667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0249|Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast|EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast||Vanderbilt-Ingram Cancer Center|Yes|Terminated|October 2002|June 2005|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|1|||Female|35 Years|N/A|No|||February 2013|February 22, 2013|May 14, 2004|Yes|Yes|PI left VICC|No||https://clinicaltrials.gov/show/NCT00082667||200638|
NCT00085397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000369699|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Randomized Phase II Study of Immunization Against Melanoma Comparing Autologous Dendritic Cells Pulsed With gp100 Peptide to Autologous Dendritic Cells Fused With Autologous Tumor Cells||National Cancer Institute (NCI)||Recruiting|March 2004|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||April 2008|February 6, 2009|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085397||200458|
NCT00086346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-313|Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients|A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Terminated|December 2002|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|607|||Both|13 Years|N/A|No|||April 2010|April 20, 2010|June 30, 2004|Yes|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00086346||200390|
NCT00086359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1039|Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV|A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2004|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|19|||Female|13 Years|N/A|No|||December 2014|December 22, 2014|June 30, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00086359||200389|
NCT00085995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040205|Progression of Spinal Fusion in Ankylosing Spondylitis|Progression of Spinal Fusion in Ankylosing Spondylitis||National Institutes of Health Clinical Center (CC)||Recruiting|June 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|75|||Both|18 Years|N/A|No|||May 2015|February 18, 2016|June 18, 2004||No||No||https://clinicaltrials.gov/show/NCT00085995||200416|
NCT00086021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT001194|Acupuncture for the Treatment of Chronic Daily Headaches|Acupuncture for the Treatment of Chronic Daily Headaches||National Center for Complementary and Integrative Health (NCCIH)||Completed|February 2002|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||74|||Both|18 Years|N/A|No|||June 2007|June 8, 2007|June 21, 2004||||No||https://clinicaltrials.gov/show/NCT00086021||200415|
NCT00087035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000372833|Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer|Phase II Trial Of TAXOTERE + TARCEVA™ To Treat HRPC In Men ≥ 65 Years Of Age||Jonsson Comprehensive Cancer Center|Yes|Completed|May 2004|March 2008|Actual|June 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|65 Years|N/A|No|||August 2012|October 1, 2015|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087035||200343|
NCT00082706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0111|Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant|Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2003|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082706||200637|
NCT00086333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG015-0005|FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma|A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent||Seattle Genetics, Inc.||Completed|July 2004|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2011|October 21, 2011|June 30, 2004||||||https://clinicaltrials.gov/show/NCT00086333||200391|
NCT00086736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000353198|Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy|A Randomized, Placebo-Controlled Phase IIb Clinical Trial of 2-Difluoromethylornithine (DFMO) Versus Bicalutamide (CASODEX) Alone and in Combination in Patients With Prostate Cancer in the Period Prior to Radical Prostatectomy or Brachytherapy: Modulation of Tissue and Molecular Biomarkers in Human Prostate Tissue Serum||University of Alabama at Birmingham|Yes|Completed|November 2001|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|34|||Male|18 Years|N/A|No|||July 2013|November 17, 2013|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086736||200361|
NCT00086034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0221|Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma|Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma||Pharmacyclics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||May 2007|May 11, 2007|June 21, 2004||||||https://clinicaltrials.gov/show/NCT00086034||200414|
NCT00082433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-048|Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer|A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane||R-Pharm|Yes|Completed|November 2003|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1221|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|May 7, 2004|No|Yes||No|May 1, 2009|https://clinicaltrials.gov/show/NCT00082433||200656|
NCT00086684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004576|Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis|Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|September 2003|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|369|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|July 7, 2004|Yes|Yes|Interim Analysis showed that study continuation was futile. No safety concerns were raised    during the trial.|No|May 31, 2012|https://clinicaltrials.gov/show/NCT00086684||200364|
NCT00086710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T20-405|Study of Enfuvirtide in HIV-Positive Subjects|An Open-label, Randomized, Cross-over Study in HIV-Positive Subjects to Determine and Compare the Single-dose Pharmacokinetics of Enfuvirtide after a Single 90 mg SC Administration||Trimeris||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||26|||Both|18 Years|64 Years|No|||April 2004|June 23, 2005|July 8, 2004||||||https://clinicaltrials.gov/show/NCT00086710||200363|
NCT00086723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 00B9|In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer|Phase I/II Trial of In Vivo Angiostatin Generation With Tissue Plasminogen Activator (tPA) and Captopril in Patients With Progressive, Metastatic Cancer||Northwestern University|Yes|Completed|July 2003|January 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2012|June 7, 2012|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086723||200362|
NCT00082732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355833|Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer|Impact of Dietary Intervention in Men With Hormone Refractory Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|July 2002|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|N/A|N/A|No|||October 2012|October 18, 2012|May 14, 2004||No||No||https://clinicaltrials.gov/show/NCT00082732||200635|
NCT00082745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE03N1|Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors|Key Adverse Events After Childhood Cancer||Children's Oncology Group|No|Recruiting|March 2004|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|8100|Samples With DNA|peripheral blood or buccal sample|Both|N/A|21 Years|No|Non-Probability Sample|Patients with a diagnosis of primary cancer at age 21 or younger meeting other criteria|September 2015|September 30, 2015|May 14, 2004||No||No||https://clinicaltrials.gov/show/NCT00082745||200634|
NCT00082446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-017|Combination Study With MVA BN and Dryvax|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of MVA-BN in a Dose Response Regimen Followed by Administration of Dryvax in Healthy Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2004|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|91|||Both|18 Years|32 Years|Accepts Healthy Volunteers|||September 2008|December 18, 2014|May 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082446||200655|
NCT00082758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL0322|hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma|A Phase II Study Of hu14.18-IL2 In Children With Recurrent Or Refractory Neuroblastoma||Children's Oncology Group|Yes|Completed|August 2005|May 2012|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|N/A|21 Years|No|||January 2015|January 27, 2015|May 14, 2004|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00082758||200633|
NCT00083018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000361760|Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer|Evaluation Of The Role Of Nipple Aspiration, Ductal Lavage And Duct Endoscopy At The Time Of Surgery In Patients With Breast Cancer||National Cancer Institute (NCI)||Recruiting|September 2003|||||Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|100|||Female|18 Years|N/A|No|||December 2005|August 23, 2013|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00083018||200618|
NCT00083031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000361807|Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer|Metronomic Chemotherapy in Combination With Bevacizumab for Advanced Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|November 2002|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2005|February 6, 2009|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00083031||200617|
NCT00082719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0172|Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium|Modulation of Death Effector Expression By Short-Term Exposure to Low-Dose Interferon||M.D. Anderson Cancer Center|Yes|Completed|December 2003|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|N/A|N/A|No|||May 2015|May 12, 2015|May 14, 2004||No||No||https://clinicaltrials.gov/show/NCT00082719||200636|
NCT00086060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-121|Pain Management Techniques for Fibromyalgia|Locus of Pain Control: Neural Substrates and Modifiability||University of Michigan|No|Completed|May 2004|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|97|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 6, 2011|June 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00086060||200412|
NCT00082472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dox-2a-07|Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)|Phase I/II Study of Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Locally Advanced or Metastatic Unresectable Non Small Cell Lung Cancer||Zivena||Active, not recruiting|January 2004|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||April 2006|April 14, 2006|May 11, 2004||||||https://clinicaltrials.gov/show/NCT00082472||200653|
NCT00082485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CSP-1021-1|Baclofen for the Treatment of Cocaine Dependence - 1|Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|June 2004|||July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|May 11, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082485||200652|
NCT00087074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02809|CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor|A Trial of CCI-779 in Patients With Soft Tissue Sarcoma.||National Cancer Institute (NCI)||Completed|June 2004|||December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00087074||200340|
NCT00082459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-23|Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma|A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma||Agenus, Inc.||Terminated|July 2002|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|May 10, 2004||Yes|Lack of enrollment|||https://clinicaltrials.gov/show/NCT00082459||200654|
NCT00087061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIGMATAU-ST-01-402|Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma|Oral ST1481 in Adults With Malignant Glioma: A Phase I-II Clinical Trial||National Cancer Institute (NCI)||Completed|May 2004|June 2005|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|July 17, 2013|July 8, 2004||||No||https://clinicaltrials.gov/show/NCT00087061||200341|
NCT00083057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040141|Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck|A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN)||National Institutes of Health Clinical Center (CC)||Completed|May 2004|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|May 14, 2004||||||https://clinicaltrials.gov/show/NCT00083057||200615|
NCT00083044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT P50CA89018|Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy|Surrogate Endpoints in Prevention Studies and Ductal Lavage||Northwestern University|No|Withdrawn|October 2003|July 2008|Actual|July 2008|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|64 Years|No|Non-Probability Sample|Women with early breast cancer or at high risk of developing breast cancer and who are        eligible for tamoxifen therapy|April 2012|April 24, 2012|May 14, 2004||No|Funding ended and will not be renewed|No||https://clinicaltrials.gov/show/NCT00083044||200616|
NCT00086047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR050028|Coping Skills Training for Adolescents With Fibromyalgia|Randomized Clinical Trial in Juvenile Fibromyalgia||Children's Hospital Medical Center, Cincinnati|Yes|Completed|July 2004|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|11 Years|18 Years|No|||October 2013|November 1, 2013|June 22, 2004||No||No|August 12, 2011|https://clinicaltrials.gov/show/NCT00086047||200413|
NCT00086372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP CORE01|Long-term Follow-up of HIV Infected Patients Identified During Early Infection|Acute HIV Infection and Early Disease Research Program (AIEDRP) CORE01 Database||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2003|April 2007|Actual|||N/A|Observational|N/A|||Actual|157|||Both|13 Years|N/A|No|||October 2012|October 26, 2012|June 30, 2004||No||No||https://clinicaltrials.gov/show/NCT00086372||200388|
NCT00086385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-02538-1|Maintaining Nonsmoking: Older Smokers - 1|Maintaining Nonsmoking: Older Smokers||University of California, San Francisco|No|Completed|September 2001|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|403|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 3, 2015|July 1, 2004||No||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00086385||200387|The limitations of this study include generalizability, as the population treated was relatively well-educated, willing to participate in research and to attend treatment sessions.
NCT00082797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000360834|High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Study Of Systemic High-Dose Methotrexate For The Treatment Of Glioblastoma Multiforme In Newly Diagnosed Patients With Measurable Disease||Eastern Cooperative Oncology Group|No|Completed|February 2005|||May 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||January 2010|January 28, 2010|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082797||200631|
NCT00083070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0411|Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia|A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias||Children's Oncology Group|Yes|Completed|March 2004|June 2008|Actual|September 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|1 Year|21 Years|No|||February 2014|February 18, 2014|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083070||200614|
NCT00083083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000362061|Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer|Positron Emission Tomography Pre- and Post-treatment Assessment For Locally Advanced Non-Small Cell Lung Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|March 2005|||June 2006|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||October 2007|February 26, 2011|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083083||200613|
NCT00083330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040172|Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|May 2004|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1|||36|||Both|18 Years|44 Years|No|||October 2009|October 2, 2009|May 20, 2004||No||No||https://clinicaltrials.gov/show/NCT00083330||200595|
NCT00082784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00058|Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms|Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms||National Cancer Institute (NCI)||Completed|March 2004|September 2014|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||October 2014|December 22, 2014|May 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082784||200632|
NCT00083629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040204|Use of [18F]FECNT in Positron Emission Tomography|PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Dopamine Transporter Ligand [18F]FECNT||National Institutes of Health Clinical Center (CC)||Completed|May 2004|September 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|May 27, 2004||||No||https://clinicaltrials.gov/show/NCT00083629||200572|
NCT00083642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040203|Observational Learning in Stroke Patients|Neural Correlates of Observational Motor Learning in Chronic Stroke Patients||National Institutes of Health Clinical Center (CC)||Completed|May 2004|June 2008||||N/A|Observational|N/A||||60|||Both|18 Years|75 Years|No|||June 2008|June 17, 2008|May 27, 2004||||No||https://clinicaltrials.gov/show/NCT00083642||200571|
NCT00083317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040192|Role of the Brain in Making Economic Decisions|The Role of the Prefrontal Cortex in Economic Decision-Making in Reciprocal Trust Games Using Functional Hyperscanning Neuroimaging||National Institutes of Health Clinical Center (CC)||Completed|May 2004|January 2012||||N/A|Observational|N/A|||Actual|127|||Both|21 Years|55 Years|No|||January 2012|January 5, 2012|May 19, 2004||No||No||https://clinicaltrials.gov/show/NCT00083317||200596|
NCT00085748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004381|Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia|A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|114|||Both|65 Years|N/A|No|||November 2010|June 6, 2011|June 14, 2004||||||https://clinicaltrials.gov/show/NCT00085748||200435|
NCT00087087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0126Q|Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation Of Pemetrexed (ALIMTA LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma||Gynecologic Oncology Group|Yes|Completed|July 2004|||December 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|51|||Female|N/A|N/A|No|||February 2014|February 12, 2014|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087087||200339|
NCT00087100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0129O|Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer|A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Endometrial Carcinoma||Gynecologic Oncology Group|Yes|Completed|May 2006|||August 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Female|N/A|N/A|No|||February 2014|February 12, 2014|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087100||200338|
NCT00086749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 00B2|Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer|A Prospective Study Of The Effect Of Tamoxifen On Breast Density In Premenopausal Women||Northwestern University||Completed|February 2003|December 2007|Actual|December 2007|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who are initiating tamoxifen on the advice of their treating physician as the sole        systemic treatment for breast carcinoma or breast cancer risk reduction|July 2012|July 10, 2012|July 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00086749||200360|
NCT00086762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0024|Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors|Chemotherapy and Mindfulness Relaxation: A Randomized Trial at M.D. Anderson Cancer Center and M.D. Anderson Community Clinical Oncology Program||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2004|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|474|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|July 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00086762||200359|
NCT00086450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 02-0163|Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes (FREEDOM)|Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|April 2004|December 2018|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1900|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|July 1, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086450||200382|
NCT00087113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0127T|Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix|A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231517, IND #40061) In the Treatment Of Recurrent Carcinoma Of The Cervix||Gynecologic Oncology Group||Completed|August 2004|||June 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||||||Female|N/A|N/A|No|||February 2014|February 12, 2014|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087113||200337|
NCT00087126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0127U|Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix||Gynecologic Oncology Group|Yes|Completed|February 2005|||January 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087126||200336|
NCT00082498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5211|Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients|Phase II, Randomized, Double-Blind Study of the Safety and Efficacy of Vicriviroc (An Orally Administered HIV-1 Entry Inhibitor) in HIV-Infected, Treatment-Experienced Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2004|January 2011|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|119|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|May 11, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082498||200651|
NCT00082511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL03-01|GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids|A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids||Genelabs Technologies|No|Completed|July 2003|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|114|||Female|18 Years|N/A|No|||January 2008|January 10, 2008|May 11, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082511||200650|
NCT00083343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-045|Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)|A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults With Invasive Candida Infections (Excluding Patients With Candidemia as the Sole Site of Infection)||Merck Sharp & Dohme Corp.||Completed|May 2004|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|May 20, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083343||200594|
NCT00083096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16027-26023|Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas|Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|March 2004|||June 2009|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00083096||200612|
NCT00083356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040182|Bradykinin Receptors and Pain|Bradykinin-1 Receptor and Kinin Induction in a Clinical Model of Tissue Injury||National Institutes of Health Clinical Center (CC)||Completed|May 2004|February 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||February 2006|March 3, 2008|May 21, 2004||||No||https://clinicaltrials.gov/show/NCT00083356||200593|
NCT00083369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1250|Genetic and Environmental Determinants of Triglycerides (GOLDN)|||University of Alabama at Birmingham||Completed|September 2002|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1327|||Both|19 Years|N/A|No|Probability Sample|Subjects meeting entry criteria|November 2013|November 16, 2013|May 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00083369||200592|
NCT00086073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9703-09|Parkinson's Research: The Organized Genetics Initiative|Parkinson's Disease Collaborative Study of Genetic Linkage|PROGENI|Indiana University|No|Completed|August 1998|January 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|Samples With DNA|blood sample|Both|N/A|N/A|No|Non-Probability Sample|families having 2 or more members diagnosed with PD|November 2010|February 15, 2011|June 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00086073||200411|
NCT00086138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH066136|Depression in Alzheimer's Disease-2|Depression in Alzheimer's Disease (DIADS-2)|DIADS-2|Johns Hopkins University|Yes|Completed|July 2004|July 2009|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|June 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086138||200406|
NCT00086151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1258|Identifying Low-Risk Patients With Pulmonary Embolism|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2004|June 2007|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||January 2008|January 24, 2008|June 25, 2004||||No||https://clinicaltrials.gov/show/NCT00086151||200405|
NCT00086164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGT003-05|Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis|A Phase 1/2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene (PTFE) Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis||Anesiva, Inc.||Terminated|May 2004|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|79 Years|No|||July 2005|July 14, 2005|June 25, 2004||||||https://clinicaltrials.gov/show/NCT00086164||200404|
NCT00086463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEP STUDY|Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)|A Safety and Pilot Efficacy Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With PAH||Actelion||Completed|June 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|12 Years|75 Years|No|||March 2011|March 31, 2011|July 1, 2004||||||https://clinicaltrials.gov/show/NCT00086463||200381|
NCT00086775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRLX-FLUCAM106|Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia|Phase II Trial Comparing Combination Treatment With Fludarabine and Alemtuzumab to Fludarabine and Rituximab in Patients With B-Cell Chronic Lymphocytic Leukemia Requiring Treatment After First Line Therapy||National Cancer Institute (NCI)||Completed|July 2003|October 2009|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2009|August 1, 2013|July 8, 2004||||No||https://clinicaltrials.gov/show/NCT00086775||200358|
NCT00087139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00548|Ixabepilone in Treating Patients With Metastatic Prostate Cancer|Phase II Study of a Weekly Schedule of BMS-247550 for Patients With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|September 2004|February 2011|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Male|18 Years|N/A|No|||April 2013|April 21, 2014|July 8, 2004|Yes|Yes||No|November 25, 2012|https://clinicaltrials.gov/show/NCT00087139||200335|
NCT00082524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-043|Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)|A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections||Merck Sharp & Dohme Corp.||Completed|April 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|3 Months|17 Years|No|||December 2014|December 18, 2014|May 11, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082524||200649|
NCT00082810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02982|Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer|A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer||National Cancer Institute (NCI)|Yes|Completed|March 2004|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||October 2013|August 3, 2015|May 14, 2004|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT00082810||200630|
NCT00083109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02586|Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer|Phase I/II Trial Of Low Dose Suramin (CI-1003, NSC#34936) And 5-Fluorouracil In Patients With Metastatic Renal Cell Carcinoma (RCC)||National Cancer Institute (NCI)||Completed|March 2004|March 2008|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||January 2013|May 22, 2015|May 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00083109||200611|
NCT00083382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 98-036|Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide|UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma||University of Arkansas|No|Completed|December 1998|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 21, 2004|Yes|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT00083382||200591|
NCT00086398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14967-1|Psychotherapy Enhancement for Therapeutic Community (TC) Retention - 1|Psychotherapy Enhancement for TC Retention||National Institute on Drug Abuse (NIDA)||Recruiting|September 2001|||||Phase 2|Interventional|Intervention Model: Factorial Assignment, Primary Purpose: Treatment||||100|||Both|15 Years|65 Years|No|||November 2005|November 3, 2005|July 1, 2004||||No||https://clinicaltrials.gov/show/NCT00086398||200386|
NCT00075413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346365|Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer|A Pilot Phase II Protocol Of Arsenic Trioxide (TRISENOX) In Subjects With Advanced Carcinoma Of The Breast||The University of Texas Medical Branch, Galveston||Withdrawn|November 2002|||July 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Female|18 Years|120 Years|No|||September 2015|September 30, 2015|January 9, 2004|||Unable to identify qualified subjects willing to participate in this study|No||https://clinicaltrials.gov/show/NCT00075413||201145|
NCT00075907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1034|Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents|A Comparative Trial of Protease-Containing and Protease-Sparing HAART Regimens in HIV-Infected Adolescents With an Evaluation of Therapeutic Drug Monitoring||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|13 Years|23 Years|No|||October 2013|October 4, 2013|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075907||201109|
NCT00087152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03033|S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer|Phase II Trial Of Imatinib Mesylate (Gleevec®) (NSC-716051) In Combination With Capecitabine (Xeloda®) (NSC-712807) In Metastatic Breast Cancer||National Cancer Institute (NCI)|No|Completed|June 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||February 2013|May 12, 2014|July 8, 2004|No|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00087152||200334|Two-stage design, but did not have enough confirmed responses after the first stage to launch the second stage.
NCT00083395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040194|Isoproterenol Challenge to Detect Arrhythmogenic Right Ventricular Cardiomyopathy|Utility of Isoproterenol Challenge Test to Detect Disease in Patients With Incomplete Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|May 2004|December 2005||||N/A|Observational|N/A||||160|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2005|March 3, 2008|May 22, 2004||||No||https://clinicaltrials.gov/show/NCT00083395||200590|
NCT00082537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-044|MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)|A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in Pediatric Patients With Persistent Fever and Neutropenia||Merck Sharp & Dohme Corp.||Completed|April 2004|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|100|||Both|2 Years|17 Years|No|||September 2015|September 7, 2015|May 11, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082537||200648|
NCT00082823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGENERON-VGFT-ST-0304|Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma|An Open-Label, Long-Term, Safety and Tolerability Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma||Regeneron Pharmaceuticals||Completed|January 2004|||May 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||December 2009|April 15, 2013|May 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082823||200629|
NCT00075621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000347381|Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis|A Phase II Trial of Tandem Transplantation in AL Amyloidosis||Boston Medical Center|No|Active, not recruiting|August 2000|May 2016|Anticipated|June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|65 Years|No|||July 2013|January 29, 2015|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075621||201130|
NCT00076791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P394|Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants|A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2004|March 2011|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|66|||Female|18 Years|N/A|No|||July 2013|July 5, 2013|February 3, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00076791||201048|
NCT00086411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15365-1|Comparing Smoking Treatment Programs for Lighter Smokers - 1|Comparing Smoking Treatment Programs for Lighter Smokers||University of Pennsylvania|Yes|Completed|September 2003|June 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|260|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 24, 2014|July 1, 2004|Yes|Yes||No|June 24, 2013|https://clinicaltrials.gov/show/NCT00086411||200385|Missing data from some early terminations from treatment (i.e., 2 or less visits) may reflect dissatisfaction with counseling assignment or medication effects.
NCT00086424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1259|Epidemiology of Insulin Growth Factor (IGF) and Cardiovascular Events|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2004|April 2008|Actual|April 2008|Actual|N/A|Observational|N/A|||||||Both|65 Years|90 Years|No|||April 2008|April 22, 2008|July 1, 2004||||No||https://clinicaltrials.gov/show/NCT00086424||200384|
NCT00086437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1260|Pharmacogenetics of Hypertriglyceridemia in Hispanics|Pharmacogenetics of Hypertriglyceridemia in Hispanics||University of California, Los Angeles|No|Completed|July 2004|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|274|Samples With DNA|Whole blood|Both|18 Years|100 Years|No|Non-Probability Sample|Hispanics with hypertriglyceridemia|December 2015|December 2, 2015|July 1, 2004||No||No||https://clinicaltrials.gov/show/NCT00086437||200383|
NCT00075647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02567|CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase II Trial of CCI-779 in Locally Advanced or Metastatic Pancreatic Cancer||National Cancer Institute (NCI)||Completed|December 2003|||March 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|January 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00075647||201128|
NCT00075660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I161|3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma|A Phase II Study of Triapine (NSC 663249) in Previously Untreated Patients With Recurrent Renal Cell Carcinoma||Canadian Cancer Trials Group||Completed|January 2004|September 2008|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|November 7, 2010|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075660||201127|
NCT00086801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000370870|Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma|Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma||Alliance for Clinical Trials in Oncology|No|Completed|May 2004|May 2011|Actual|March 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|16 Years|N/A|No|||September 2013|September 28, 2013|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00086801||200357|
NCT00083122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00029|Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Phase II Trial of Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinomas||National Cancer Institute (NCI)||Completed|April 2004|May 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|N/A|No|||April 2013|May 6, 2014|May 14, 2004|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00083122||200610|
NCT00083135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000363631|N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation|I-MIBG Escalating Dose Rapid Sequence Double Infusion Followed By Autologous Stem Cell Infusion For Refractory Neuroblastoma||Children's Hospital Los Angeles|Yes|Completed|March 2004|||February 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|1 Year|30 Years|No|||May 2009|October 14, 2010|May 14, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00083135||200609|
NCT00073827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-353|Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma|An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma||Sunovion|No|Completed|May 2002|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|445|||Both|12 Years|N/A|No|||February 2012|February 21, 2012|December 9, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073827||201254|
NCT00074464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1242|Cholesterol Homeostasis in Framingham Offspring Study|||Tufts University|No|Completed|August 2003|July 2008|Actual|July 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|3378|||Both|25 Years|N/A|No|Probability Sample|Framingham Offspring Study Cycle 6 Participants|May 2013|May 3, 2013|December 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00074464||201212|
NCT00074087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-21012|Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides|Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy||European Organisation for Research and Treatment of Cancer - EORTC||Completed|October 2003|September 2010|Actual|July 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|December 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00074087||201236|
NCT00074438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA17043/U2644g|Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis|Randomized, Multifactorial, Double-blind, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Rituximab (MabThera®/Rituxan®) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis||Genentech, Inc.||Completed|June 2003|July 2011|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|465|||Both|18 Years|80 Years|No|||May 2013|May 7, 2013|December 12, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074438||201214|
NCT00074451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241|Genomewide Search for Loci Underlying Metabolic Syndrome|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Both|40 Years|64 Years|No|||August 2008|August 20, 2008|December 12, 2003||||No||https://clinicaltrials.gov/show/NCT00074451||201213|
NCT00076206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066A3-206|Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy|A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|December 2003|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||||||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|January 15, 2004||Yes||||https://clinicaltrials.gov/show/NCT00076206||201089|
NCT00077103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3302|Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer|Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation]||Case Comprehensive Cancer Center|Yes|Terminated|November 2003|December 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|February 10, 2004|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00077103||201027|
NCT00072410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000339682|Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer|Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized Monoclonal Antibody 3S193 (90Y-hu3S193) in Patients With Advanced Ovarian Cancer||National Cancer Institute (NCI)||Completed|June 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Female|N/A|N/A|No|||August 2005|February 6, 2009|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072410||201359|
NCT00085839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-201|Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2|A Randomized Phase II Study of Single Agent Erlotinib [Tarceva (TM), OSI-774] Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status||Astellas Pharma Inc|No|Completed|February 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|June 15, 2004|No|Yes||No|March 28, 2011|https://clinicaltrials.gov/show/NCT00085839||200428|
NCT00086502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-019|Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy||Merck Sharp & Dohme Corp.||Completed|June 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|353|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 2, 2004|Yes|Yes||No|March 30, 2010|https://clinicaltrials.gov/show/NCT00086502||200378|
NCT00086515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-020|Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy||Merck Sharp & Dohme Corp.||Completed|June 2004|February 2007|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|701|||Both|18 Years|78 Years|No|||April 2015|April 27, 2015|July 2, 2004|Yes|Yes||No|November 19, 2010|https://clinicaltrials.gov/show/NCT00086515||200377|
NCT00082836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-009|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma|A Pilot Study of Radiolabeled Indium-111 and Yttrium-90 Ibritumomab Tiuxetan in Primary CNS Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|December 2004|||May 2007|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00082836||200628|
NCT00083694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 98-032|Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia|UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia||University of Arkansas||Completed|August 1998|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|May 27, 2004||||||https://clinicaltrials.gov/show/NCT00083694||200568|
NCT00073814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-354|Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma|An Efficacy, Safety, and Tolerability Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma||Sunovion|No|Completed|December 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|80|||Both|4 Years|11 Years|No|||February 2012|February 21, 2012|December 9, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073814||201255|
NCT00074750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM03-0130|Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)|A Phase I Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)||M.D. Anderson Cancer Center|Yes|Terminated|December 2003|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|December 19, 2003|No|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00074750||201192|
NCT00075387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-02019-L|Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors|Phase II Clinical Trial of Patients With High-Grade Glioma Treated With Intra-arterial Carboplatin-Based Chemotherapy, Randomized to Treatment With or Without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant Against Severe Thrombocytopenia||OHSU Knight Cancer Institute|Yes|Recruiting|March 2003|December 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075387||201147|
NCT00077116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06013|Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome|Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 2003|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|16 Years|70 Years|No|||July 2012|July 13, 2012|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077116||201026|
NCT00073229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI032391-15|Immune Function of Infants With HIV|Killer Cells and Viral Load in Vertical HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|July 2000|June 2005|Actual|June 2005|Actual|N/A|Observational|N/A|||Anticipated|80|||Both|N/A|24 Months|No|||September 2008|September 25, 2008|November 18, 2003||No||No||https://clinicaltrials.gov/show/NCT00073229||201299|
NCT00073515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA003|Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices|A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters||ARCA Biopharma, Inc.||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||115|||Both|18 Years|N/A|No|||June 2005|February 2, 2010|November 21, 2003||||||https://clinicaltrials.gov/show/NCT00073515||201277|
NCT00074139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU040314|Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer|A Pharmacokinetic Interaction Study Of Docetaxel (Taxotere) 75 mg/mIV On The Combination Therapy Doxorubicin (50 mg/m) And Cyclophosphamide (50 mg/m) In The Treatment Of Advanced Breast Cancer||Case Comprehensive Cancer Center|Yes|Withdrawn|September 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|69 Years|No|||March 2014|March 4, 2014|December 10, 2003|No|Yes|No patients were enrolled|No||https://clinicaltrials.gov/show/NCT00074139||201234|
NCT00074152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000343619|Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer|A Randomized Clinical Trial Of Adjuvant Chemotherapy For Radically Resected Loco-Regional Relapse Of Breast Cancer|CALOR|International Breast Cancer Study Group|Yes|Active, not recruiting|July 2002|June 2016|Anticipated|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Female|18 Years|120 Years|No|||February 2016|February 24, 2016|December 10, 2003||No||No|April 7, 2015|https://clinicaltrials.gov/show/NCT00074152||201233|Small sample size
NCT00082550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040180|Serotonin Transporters in Obsessive-Compulsive-Related Disorders|PET Imaging of Monoamine Transporters in OCD-Related Disorders||National Institutes of Health Clinical Center (CC)||Completed|May 2004|April 2007||||N/A|Observational|N/A||||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2007|March 5, 2008|May 12, 2004||||No||https://clinicaltrials.gov/show/NCT00082550||200647|
NCT00085917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040187|Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients|A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Twice-Weekly Peginterferon Alpha 2a and Ribavirin Induction Therapy for Chronic Hepatitis C in Patients Who Are Coinfected With HIV-1|PIFNPK|National Institutes of Health Clinical Center (CC)|No|Completed|June 2004|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|June 16, 2004||No||No|April 12, 2010|https://clinicaltrials.gov/show/NCT00085917||200422|Small number of enrolled participants
NCT00085930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13149-NESTLES|Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients|Administration of Peripheral Blood T-Cells and EBV Specific CTLs Transduced to Express GD-2 Specific Chimeric T Cell Receptors to Patients With Neuroblastoma|NESTLES|Baylor College of Medicine|Yes|Active, not recruiting|April 2003|December 2021|Anticipated|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|N/A|No|||August 2015|August 26, 2015|June 17, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085930||200421|
NCT00086216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-101|Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma|An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma||Callisto Pharmaceuticals|No|Completed|May 2004|November 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|June 28, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086216||200400|
NCT00086567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040232|Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers|A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse||National Institutes of Health Clinical Center (CC)||Completed|June 2004|||||N/A|Observational|Time Perspective: Prospective|||Actual|8|||Female|18 Years|N/A|No|||April 2015|May 14, 2015|July 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00086567||200373|
NCT00086580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM314|Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients|A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia||Sanofi|Yes|Completed|July 2004|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|335|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|July 6, 2004|Yes|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00086580||200372|
NCT00075881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00652|Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma|Phase II Study of PS-341 for Patients With High-Risk, Newly Diagnosed Multiple Myeloma||National Cancer Institute (NCI)|Yes|Completed|January 2004|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||March 2014|May 29, 2014|January 9, 2004|Yes|Yes||No|March 8, 2012|https://clinicaltrials.gov/show/NCT00075881||201111|
NCT00082290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-046|Massage Therapy in Treating Patients With Cancer Pain|Massage for the Treatment of Pain in Cancer: A Randomized Phase II Study||Memorial Sloan Kettering Cancer Center||Completed|May 2003|||February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|92|||Both|18 Years|120 Years|No|||December 2015|December 17, 2015|May 5, 2004||No||No||https://clinicaltrials.gov/show/NCT00082290||200667|
NCT00098319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 04 Aim III|Oral Cleft Prevention Trial in Brazil|Oral Cleft Prevention Trial in Brazil||NICHD Global Network for Women's and Children's Health||Completed|January 2004|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|2200|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 6, 2004||No||No||https://clinicaltrials.gov/show/NCT00098319||199533|
NCT00098332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOCRYST-BCX1777-C-04-105|Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma|A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma||National Cancer Institute (NCI)||Completed|November 2004|July 2011|Actual|December 2010|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|July 9, 2013|December 7, 2004||||No||https://clinicaltrials.gov/show/NCT00098332||199532|
NCT00098709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-FOX|Fetal Pulse Oximetry Trial (FOX)|A Randomized Clinical Trial of Fetal Pulse Oximetry||The George Washington University Biostatistics Center||Terminated|May 2002|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||10000|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|December 7, 2004||||||https://clinicaltrials.gov/show/NCT00098709||199509|
NCT00109356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-002|Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia|A Phase 1/2, Open Label, Dose Escalation Study of AQ4N for Safety, Tolerability, Pharmacokinetics and Activity in Patients With Lymphoid Neoplasms||Novacea||Active, not recruiting|March 2005|March 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||55|||Both|18 Years|N/A|No|||May 2007|May 4, 2007|April 27, 2005||||||https://clinicaltrials.gov/show/NCT00109356||198732|
NCT00109369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61167 (completed)|Vermont Diabetes Information System|Vermont Diabetes Information System||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|June 2003|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|7500|||Both|18 Years|N/A|No|||January 2011|January 31, 2011|April 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00109369||198731|
NCT00099931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2311|Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes||Novartis||Completed|May 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|254|||Both|18 Years|80 Years||||May 2012|May 4, 2012|December 21, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00099931||199420|
NCT00099944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2305|Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes||Novartis||Completed|May 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|515|||Both|18 Years|80 Years|No|||May 2012|May 3, 2012|December 21, 2004||||No||https://clinicaltrials.gov/show/NCT00099944||199419|
NCT00109876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z4033|Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer|A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|September 2006|||July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|May 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109876||198694|
NCT00110188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-017|Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)|A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)||Merck Sharp & Dohme Corp.|No|Completed|May 2005|August 2007|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Male|18 Years|N/A|No|||November 2015|November 18, 2015|May 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110188||198673|
NCT00110149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000409723|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as First Line Treatment in Indolent Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Recruiting|May 2004|||May 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|May 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110149||198676|
NCT00110162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMCC-VCOG-PR-0103|Androgen Deprivation Therapy in Treating Patients With Prostate Cancer|A Collaborative Randomized Phase III Trial: The Timing of Intervention With Androgen Deprivation in Prostate Cancer Patients With Rising PSA||National Cancer Institute (NCI)||Recruiting|October 2004|||December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Male|N/A|N/A|No|||June 2009|August 6, 2013|May 3, 2005||||No||https://clinicaltrials.gov/show/NCT00110162||198675|
NCT00110682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR 2004-05|Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses|A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up||Derm Research @ 888 Inc.|Yes|Completed|April 2005|December 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2008|April 21, 2008|May 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00110682||198635|
NCT00111592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 00-007|Effectiveness of a Treatment Protocol for Lower Urinary Tract Symptoms in General Practice|Effectiveness of a Treatment Protocol for Lower Urinary Tract Symptoms in General Practice||Maastricht University Medical Center|No|Completed|August 2000|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Male|55 Years|N/A|No|||November 2007|November 21, 2007|May 23, 2005||||No||https://clinicaltrials.gov/show/NCT00111592||198566|
NCT00111566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0359|BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention|Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention||Cardiology Research UBC|No|Completed|December 2004|August 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|624|||Both|N/A|N/A|No|||November 2013|November 27, 2013|May 23, 2005||||No||https://clinicaltrials.gov/show/NCT00111566||198568|
NCT00111579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP123|Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)|A Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With Trivalent Inactivated Vaccine (TIV) in Children 6 to <36 Months of Age||MedImmune LLC|No|Completed|May 2005|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||52|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||July 2008|July 22, 2008|May 23, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00111579||198567|
NCT00111215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-2906|Treatment and Management of Women With Bleeding Disorders|Treatment and Management of Women With Bleeding Disorders||Centers for Disease Control and Prevention||Completed|January 2001|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Female|18 Years|50 Years|No|||June 2006|March 12, 2007|May 18, 2005||||||https://clinicaltrials.gov/show/NCT00111215||198595|
NCT00110942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040166|Treatment for Patients With Osteoarthritis (OA)|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Systemic AMG 108 in Subjects With Osteoarthritis (OA)||Amgen||Completed|February 2005|November 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|30 Years|N/A|No|||June 2008|June 20, 2008|May 16, 2005||||No||https://clinicaltrials.gov/show/NCT00110942||198615|
NCT00111852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSP-MD-01|Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)|A Prospective, Randomized, Double-blind, Placebo-controlled, Single Bolus, Multinational, Multi-center, Parallel Group, Dose-ranging Study of Desmoteplase (INN) in the Indication of Acute Stroke||Forest Laboratories|No|Completed|April 2005|||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|193|||Both|18 Years|85 Years|No|||March 2012|March 19, 2012|May 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111852||198546|
NCT00075426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-402|Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Pilot Phase II Protocol Of Arsenic Trioxide (Trisenox) In Subjects With Advanced Non-Small Cell Carcinoma Of The Lung||The University of Texas Medical Branch, Galveston||Completed|November 2002|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075426||201144|
NCT00076271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040039|Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases|Evaluation and Treatment of Pediatric, Developmental and Genetic Eye Diseases||National Institutes of Health Clinical Center (CC)||Completed|January 2004|October 2008||||N/A|Observational|N/A||||350|||Both|N/A|N/A|No|||October 2008|September 26, 2015|January 16, 2004||No||No||https://clinicaltrials.gov/show/NCT00076271||201084|
NCT00075959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-NXY-0012|Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke|CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage (ICH)||AstraZeneca||Completed|August 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|January 12, 2004||||||https://clinicaltrials.gov/show/NCT00075959||201105|
NCT00108706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCOST|Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)|Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)||City Hospitals Sunderland NHS Foundation Trust||Active, not recruiting|December 2004|September 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||September 2006|September 11, 2006|April 18, 2005||||No||https://clinicaltrials.gov/show/NCT00108706||198779|
NCT00108732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03075|A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer|A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer||National Cancer Institute (NCI)||Completed|February 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|18 Years|N/A|No|||December 2013|June 3, 2015|April 18, 2005|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT00108732||198778|
NCT00108303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-007-03S|Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes|Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes in Individuals Extensively Diagnosed and Genotyped||VA Office of Research and Development|No|Completed|January 2004|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|538|Samples With DNA|dna|Both|1 Year|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons with schizophrenia, their relatives, and controls|December 2015|December 2, 2015|April 14, 2005||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT00108303||198807|Genetic linkage and association do not replicate well across studies. This study should be viewed in this context.
NCT00108628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-018-03S|Cognitive Behavioral Treatments for Post-traumatic Stress Disorder (PTSD) Sleep Disturbance|7857 Cognitive - Behavioral Treatments for PTSD Sleep Disturbance||VA Office of Research and Development|Yes|Completed|April 2004|July 2013|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Both|N/A|N/A|No|||February 2015|February 17, 2015|April 15, 2005||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00108628||198783|
NCT00108654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050140|Vaccine Treatment for HIV-Infection|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects Who Where Previously Immunized With VRC-HIVDNA016-00-VP in VRC 00||National Institutes of Health Clinical Center (CC)||Completed|April 2005|January 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||14|||Both|20 Years|37 Years|Accepts Healthy Volunteers|||January 2008|January 16, 2008|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108654||198782|
NCT00109018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050145|Biomarkers for Cardiovascular Disease|Nitrite as a Marker of Cardiovascular Risk; Development of Novel Biomarkers in Patients With Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2005|April 2009||||N/A|Observational|N/A||||120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2009|September 26, 2015|April 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00109018||198758|
NCT00109382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-100|Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)|Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)||University of Calgary||Completed|May 2003|February 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Anticipated|500|||Both|40 Years|N/A|No|||June 2007|April 7, 2008|April 27, 2005||||No||https://clinicaltrials.gov/show/NCT00109382||198730|
NCT00109616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD044004|Community Trial of Newborn Skin and Umbilical Cord Cleansing on Neonatal Mortality in Nepal|Newborn Antiseptic Washing and Neonatal Mortality-Nepal||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|October 2002|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||17000|||Both|N/A|10 Days|Accepts Healthy Volunteers|||January 2006|April 30, 2013|April 29, 2005||||No||https://clinicaltrials.gov/show/NCT00109616||198713|
NCT00109629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050148|"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection|VRC 008: A Phase I Clinical Trial of a Prime-Boost HIV-1 Vaccination Schedule: Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by Multiclade Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|April 2005|January 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 23, 2008|April 29, 2005||||No||https://clinicaltrials.gov/show/NCT00109629||198712|
NCT00109603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5206|Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy|A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2005|November 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|April 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109603||198714|
NCT00110695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-AX-003|Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer|A Phase 2 Study of Neoadjuvant Chemotherapy With Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane) Followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast Cancer||NSABP Foundation Inc|No|Completed|April 2005|July 2008|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Female|18 Years|N/A|No|||March 2010|March 24, 2010|May 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110695||198634|
NCT00110708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 004|Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism|A Randomized, Placebo-Controlled Phase II Trial Evaluating Safety and Efficacy of Oral Human Immunoglobulin in the Treatment of Gastrointestinal Dysfunction Associated With Autistic Disorder in Pediatric Patients From 2 to 18 Years of Age||PediaMed Pharmaceuticals||Active, not recruiting|April 2005|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|2 Years|18 Years|No|||February 2006|February 20, 2006|May 12, 2005||||||https://clinicaltrials.gov/show/NCT00110708||198633|
NCT00110448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-Kouka(Seikatsu)-025|Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial|Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial||Kumamoto University|Yes|Completed|December 2002|July 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2539|||Both|30 Years|85 Years|No|||August 2008|September 22, 2008|May 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00110448||198653|
NCT00111267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03.0277L|Oral Vitamin B12 Supplementation and Cognitive Performance in Elderly People|The Effect of Oral Vitamin B12 Supplementation on Cognitive Performance in Elderly People: the Brain12 Study||Wageningen University||Completed|May 2003|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||165|||Both|70 Years|N/A|Accepts Healthy Volunteers|||May 2005|June 23, 2005|May 18, 2005||||No||https://clinicaltrials.gov/show/NCT00111267||198591|
NCT00107458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0419|Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors|A Phase I Study of Valproic Acid in Children With Recurrent/Progressive Solid Tumors Including CNS Tumors||Children's Oncology Group|Yes|Completed|May 2005|March 2012|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|26|||Both|2 Years|21 Years|No|||August 2014|August 6, 2014|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107458||198872|
NCT00107471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0224|Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma|A Phase I/II Study of Topotecan With G-CSF and Radiation Therapy in Children With Malignant Intrinsic Pontine Brainstem Gliomas of Childhood||Children's Oncology Group|Yes|Terminated|October 2005|||October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|3 Years|21 Years|No|||December 2013|December 9, 2013|April 5, 2005|Yes|Yes|The unpromising experience of the French group with topotecan given at a dosage of 0.4    mg/m2/day over 30 mins w/in 1 hr of radiation (Cancer 2005; 104: 2792).|No||https://clinicaltrials.gov/show/NCT00107471||198871|
NCT00111930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0019|Biological Effects of Dehydroepiandrosterone (DHEA) in the Elderly|Biological Effects of DHEA in the Elderly||National Institute on Aging (NIA)||Completed|August 2000|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||144|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2009|December 9, 2009|May 26, 2005||||No||https://clinicaltrials.gov/show/NCT00111930||198540|
NCT00111228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU 007_022004|The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-Time Values of Guardian RT|Randomised, Controlled, Multi-Centric, Clinical Study to Assess Whether Type 1 Diabetic Patients in Poor Glycemic Control Can Improve Using the Real-Time Values of Guardian T Versus Conventional Self-Monitoring Blood Glucose||Medtronic||Completed|October 2004|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||162|||Both|8 Years|60 Years|No|||October 2006|October 24, 2006|May 18, 2005||||No||https://clinicaltrials.gov/show/NCT00111228||198594|
NCT00111540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-119|Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes|An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|November 2002|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|456|||Both|18 Years|70 Years|No|||January 2015|February 19, 2015|May 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111540||198570|
NCT00075075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040065|Infliximab to Treat Non-Infectious Scleritis|Pilot Study of the Evaluation of Infliximab in the Treatment of Non-Infectious Scleritis||National Institutes of Health Clinical Center (CC)||Completed|December 2003|September 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||5|||Both|18 Years|N/A|No|||September 2007|September 26, 2015|December 31, 2003||||No||https://clinicaltrials.gov/show/NCT00075075||201167|
NCT00075088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR007881-01A2|Tele-Electrocardiography in Emergency Cardiac Care|Tele-electrocardiography in Emergency Cardiac Care||University of California, San Francisco|Yes|Completed|September 2003|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|794|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|January 2, 2004||No||No|June 8, 2013|https://clinicaltrials.gov/show/NCT00075088||201166|Sample size was not powered to detect a statistically significant difference in survival between patients with and without a prehospital ECG
NCT00075439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02796|Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors|A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors||National Cancer Institute (NCI)||Completed|December 2003|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|January 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00075439||201143|
NCT00075972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|725|Mood and Smoking: A Comparison of Smoking Cessation Treatments|CSP #725 - Mood and Smoking: A Comparison of Smoking Cessation Treatments||VA Office of Research and Development||Completed|March 2003|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||128|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|January 12, 2004||||No||https://clinicaltrials.gov/show/NCT00075972||201104|
NCT00075985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|716B|Following Patients on Warfarin Therapy to See if Differences in Hemorrhagic Complications Exist|CSP #716B - The 80+ Hemorrhagic Cohort Study||VA Office of Research and Development||Completed|May 2000|April 2006||||N/A|Observational|Time Perspective: Prospective||||700|||Both|N/A|N/A|No|||April 2007|January 20, 2009|January 12, 2004||||No||https://clinicaltrials.gov/show/NCT00075985||201103|
NCT00108745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0212|Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer|A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy||Gynecologic Oncology Group|Yes|Active, not recruiting|March 2005|||January 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1100|||Female|N/A|N/A|No|||March 2016|March 17, 2016|April 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00108745||198777|
NCT00108758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1505|Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia|Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors||Novo Nordisk A/S|No|Completed|March 2004|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|23|||Male|2 Years|N/A|No|||October 2013|October 23, 2013|April 18, 2005||||No||https://clinicaltrials.gov/show/NCT00108758||198776|
NCT00109031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040212|Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)|A Randomized, Blinded, Active-control Trial of Palifermin (rHuKGF) to Evaluate Oral Mucositis in Subjects With Hematologic Malignancies Undergoing Fractionated Total Body Irradiation (fTBI) and High Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation||Swedish Orphan Biovitrum|Yes|Completed|January 2005|December 2010|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|47|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|April 22, 2005|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT00109031||198757|
NCT00109395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN275200403367C (contract)|Lorazepam Sedation for Critically Ill Children|A Randomized Controlled Trial Comparing Lorazepam With Midazolam for Sedation of Mechanically Ventilated Pediatric Patients||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|September 2004|September 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|179|||Both|N/A|18 Years|No|||November 2011|December 13, 2011|April 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109395||198729|
NCT00109642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050147|The Role of Norepinephrine in Emotional Processing|Investigating the Role of Norepinephrine in Emotional Processing Through Alpha-2 Adrenergic Receptor Modulation||National Institutes of Health Clinical Center (CC)||Completed|April 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|N/A||||216|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||June 2009|August 27, 2009|April 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00109642||198711|
NCT00109668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-301-4-197|Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids|||Teva Pharmaceutical Industries||Completed|July 2004|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||415|||Both|12 Years|N/A|No|||May 2014|May 9, 2014|May 2, 2005||Yes||||https://clinicaltrials.gov/show/NCT00109668||198709|
NCT00109928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000425643|S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma|Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma||Southwest Oncology Group|No|Completed|September 2005|April 2014|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|May 3, 2005|Yes|Yes||No|June 11, 2014|https://clinicaltrials.gov/show/NCT00109928||198692|
NCT00110201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bnpufl2005|The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure|Prophylactic Use of Nesiritide (Brain Natriuretic Peptide, BNP) for the Prevention of Acute Renal Failure in Thoracic Aortic Aneurysm Surgery Patients||Ejaz, Abulate A, MD||Recruiting|March 2005|December 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||124|||Both|18 Years|N/A|No|||May 2005|June 23, 2005|May 4, 2005||||||https://clinicaltrials.gov/show/NCT00110201||198672|
NCT00109889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000426422|S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma|A Prospective Observational Study of Patients With Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan||Southwest Oncology Group|No|Terminated|April 2005|February 2017|Anticipated|April 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|May 3, 2005||No|poor accrual|No||https://clinicaltrials.gov/show/NCT00109889||198693|
NCT00110175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050149|Motor Performance in Chronic Stroke Patients|Improvement of Motor Performance in Chronic Stroke Patients by Combined Transcranial DC Stimulation and Somatosensory Stimulation||National Institutes of Health Clinical Center (CC)||Completed|April 2005|March 2008||||N/A|Observational|N/A||||50|||Both|18 Years|80 Years|No|||March 2008|March 28, 2008|May 3, 2005||||No||https://clinicaltrials.gov/show/NCT00110175||198674|
NCT00110721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAVFU-003|GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer|A Phase II, Multi-Center, Open-Label Trial to Evaluate the Efficacy and Safety of Intravenous GM-CT-01 in Combination With 5-Fluorouracil When Administered in Monthly Cycles as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer||Galectin Therapeutics Inc.|No|Terminated|May 2005|February 2008|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|May 12, 2005|Yes|Yes|Study protocol amended to a new treatment regimen: study DAVFU-006.|No||https://clinicaltrials.gov/show/NCT00110721||198632|
NCT00110734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-43-05|S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Laser-Assisted Tattoo Removal in Adults|A Randomized, Double-Blind, Placebo Controlled, Paired Study Evaluating S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) for Induction of Local Dermal Anesthesia for Laser-Assisted Tattoo Removal in Adults||ZARS Pharma Inc.||Completed||September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 21, 2005|May 12, 2005||||||https://clinicaltrials.gov/show/NCT00110734||198631|
NCT00111020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11868|Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma|Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma||Bayer|No|Completed|June 2005|October 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2567|||Both|15 Years|N/A|No|||August 2014|August 5, 2014|May 16, 2005|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00111020||198609|
NCT00111280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006742|TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial|HIV-1 Infected Subjects Who Were Randomized in Any Sponsor-selected TMC125 Trial to an Active Control Arm and Either Virologically Failed or Completed the Entire Treatment Period, or to Placebo Arm and Were Treated for at Least 48 Weeks.||Tibotec Pharmaceuticals, Ireland||Completed|September 2004|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|May 18, 2005||||||https://clinicaltrials.gov/show/NCT00111280||198590|
NCT00111293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050157|Attention and Visual Perception|Top-Down Attentional Control of Visual Processing||National Institutes of Health Clinical Center (CC)||Completed|May 2005|May 2010||||N/A|Observational|N/A|||Actual|8|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2010|May 15, 2010|May 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00111293||198589|
NCT00108082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR100216|The CLEVER Study - Coreg And Left Ventricular Mass Regression|A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients With Left Ventricular Hypertrophy (LVH).||GlaxoSmithKline|No|Completed|January 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|287|||Both|18 Years|80 Years|No|||November 2015|November 5, 2015|April 13, 2005|Yes|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00108082||198824|
NCT00107757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR100010|Seasonal Allergic Rhinitis In Pediatric Subjects|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years With Seasonal Allergic Rhinitis (SAR)||GlaxoSmithKline||Completed|March 2005|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||576|||Both|2 Years|12 Years|No|||March 2013|March 1, 2013|April 7, 2005||||||https://clinicaltrials.gov/show/NCT00107757||198849|
NCT00107770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015|Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)|Safety and Dose Escalating Study of Oral Sodium Phenylbutyrate in Subjects With Amyotrophic Lateral Sclerosis||VA Office of Research and Development|No|Completed|April 2005|September 2007|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2008|January 8, 2010|April 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107770||198848|
NCT00107783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050076|Long-Term Study of Nitisinone to Treat Alkaptonuria|Long-Term Clinical Trial of Nitisinone in Alkaptonuria||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2005|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|80 Years|No|||December 2010|December 20, 2010|April 7, 2005||No||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00107783||198847|Small number of patients involved in study and several patients dropped out; primary outcome parameter selection possibly inappropriate because hip joint damage that is already present may be irreversible.
NCT00074802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064481|Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder|CBT Augmentation of Paroxetine for Social Anxiety||Temple University|Yes|Completed|December 2003|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|65 Years|No|||September 2008|March 8, 2016|December 19, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074802||201188|
NCT00075101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR007610-01|Sleep, Fatigue, and Dexamethosone in Children With Leukemia|Sleep, Fatigue, and Dexamethosone in Childhood Cancer||National Institute of Nursing Research (NINR)|No|Completed|September 2000|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|134|||Both|5 Years|21 Years|No|||August 2008|August 14, 2008|January 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00075101||201165|
NCT00075114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR007618-01|Prevent Inability To Control Urination|Promoting Self -Care to Prevent Urinary Incontinence||University of Michigan|Yes|Completed|September 2000|April 2006|Actual|February 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|417|||Female|55 Years|80 Years|No|||January 2015|January 14, 2015|January 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00075114||201164|
NCT00075933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 501-101|ARQ 501 in Subjects With Cancer|A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects With Advanced Solid Tumors||ArQule||Completed|September 2003|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|January 12, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00075933||201107|
NCT00075946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346359|Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma||Eastern Cooperative Oncology Group|Yes|Active, not recruiting|November 2003|September 2023|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|545|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 12, 2004|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00075946||201106|
NCT00075998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPF-007|The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)||InterMune|Yes|Terminated|December 2003|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|826|||Both|40 Years|79 Years|No|||July 2009|July 1, 2009|January 12, 2004|||test drug showed lack of benefit at interim analysis|No||https://clinicaltrials.gov/show/NCT00075998||201102|
NCT00076011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061012|Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma|Phase 2 Study of AG 013736 as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer||Pfizer||Completed|October 2003|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|52|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|January 12, 2004|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00076011||201101|
NCT00109707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2101|A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers|A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies.||Novartis||Completed|May 2004|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|942|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|May 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109707||198707|
NCT00109044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT-MD-35|Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder|Fixed Dose Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder||Forest Laboratories||Completed|March 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||540|||Both|18 Years|80 Years|No|||March 2012|March 1, 2012|April 22, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00109044||198756|
NCT00109057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF0778g|An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study|An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated With rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study||Genentech, Inc.||Completed|February 1998|February 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|56|||Both|N/A|N/A|No|||June 2013|June 19, 2013|April 22, 2005||||||https://clinicaltrials.gov/show/NCT00109057||198755|
NCT00109070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2107g|A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer|A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer||Genentech, Inc.||Completed|September 2000|April 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 19, 2013|April 22, 2005||||||https://clinicaltrials.gov/show/NCT00109070||198754|
NCT00109408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA17824|A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis|A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Monotherapy Versus Methotrexate Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis||Hoffmann-La Roche||Completed|July 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|673|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109408||198728|
NCT00109655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-0046|Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure|A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure||Cell Genesys||Active, not recruiting|April 2005|September 2010|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||October 2008|October 1, 2008|May 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109655||198710|
NCT00109681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIVE C200-003|Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis|A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Pilot Efficacy of Iloprost Inhalation Solution in Adults With Abnormal Pulmonary Arterial Pressure and Exercise Limitation Associated With Idiopathic Pulmonary Fibrosis (IPF)||Actelion|Yes|Completed|April 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|40 Years|85 Years|No|||February 2010|February 11, 2010|May 2, 2005||Yes||||https://clinicaltrials.gov/show/NCT00109681||198708|
NCT00109941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000425404|Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|Treatment of Advanced Pancreatic Cancer With Opioid Growth Factor (OGF): Phase II|OGF|Penn State University|Yes|Completed|October 2003|April 2009|Actual|September 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|No|||March 2013|May 16, 2013|May 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109941||198691|
NCT00110214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02814|Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Doctaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|April 2005|August 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1050|||Male|18 Years|N/A|No|||December 2012|April 21, 2014|May 4, 2005|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00110214||198671|
NCT00110461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-03-240|Aripiprazole in Children and Adolescents With Bipolar I Disorder|A Phase III Trial to Test the Safety and Efficacy of Two Doses of Aripiprazole in Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|March 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|296|||Both|10 Years|17 Years|No|||April 2012|April 19, 2012|May 9, 2005|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00110461||198652|Primary efficacy endpoint is change from baseline in Y-MRS total score. Only randomized subjects with both baseline and 1+ post-baseline were included in primary efficacy analysis so # randomized is different from # included in the efficacy analysis.
NCT00110474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN151198|Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis|Efficacy and Safety of Glucosamine Sulfate Versus a Pure Analgesic (Acetaminophen/Paracetamol) and Placebo in Patients Suffering From Osteoarthritis of the Knee||Rottapharm||Completed|May 2000|December 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|45 Years|75 Years|No|||September 2006|September 18, 2006|May 9, 2005||||No||https://clinicaltrials.gov/show/NCT00110474||198651|
NCT00110760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-40-05|S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face|Randomized, Double-Blind, Placebo Controlled, Paired Study Evaluating S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream)for Induction of Local Dermal Anesthesia for Dermal Filler Injection on the Face of Adults||ZARS Pharma Inc.|No|Completed|June 2005|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|May 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110760||198629|
NCT00111059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Primary Prevention Study: Study on Obesity, Cardiovascular and Psycho-Social Characteristics in the City of Merzig|Cross-Sectional Case-Control Study on Obesity, Cardiovascular and Psycho-Social Characteristics in the City of Merzig||University Hospital, Saarland||Recruiting|January 2005|April 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||600|||Both|18 Years|N/A|No|||May 2005|June 23, 2005|May 16, 2005||||No||https://clinicaltrials.gov/show/NCT00111059||198607|
NCT00111046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2K/261|Pain Relief - Tramadol Versus Ibuprofen|Post-Operative Pain Relief Following Insertion of Radioactive Plaque for Choroidal Melanoma: Randomised Control Trial of Tramadol Vs Ibuprofen: A Pilot Study||Royal Liverpool University Hospital||Active, not recruiting|February 2001|February 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2005|November 9, 2005|May 16, 2005||||No||https://clinicaltrials.gov/show/NCT00111046||198608|
NCT00111605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 060|Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine With or Without IL-12 DNA Adjuvant, Boosted With Homologous Plasmids in Healthy, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|7||Actual|144|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 7, 2012|May 23, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00111605||198565|
NCT00107822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-47-05|Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children|An Open-Label Safety Study to Evaluate the Use of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) in Pediatric Patients Undergoing a Minor or Major Dermal Procedure||ZARS Pharma Inc.||Completed|April 2005|May 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|N/A|17 Years|No|||October 2005|October 5, 2005|April 8, 2005||||||https://clinicaltrials.gov/show/NCT00107822||198844|
NCT00108407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-041-99Sa|Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse|Integrated CBT for Substance Use and Depressive Disorders||VA Office of Research and Development||Completed|October 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|18 Years|70 Years|No|||March 2009|March 4, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108407||198799|
NCT00108095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT102260|A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting|See Detailed Description||GlaxoSmithKline||Completed|October 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|701|||Female|18 Years|55 Years|No|||April 2015|April 14, 2015|April 13, 2005||||No||https://clinicaltrials.gov/show/NCT00108095||198823|
NCT00074815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008097|Treatment of Obsessive Compulsive Disorder in Children|Treatment of Pediatric OCD for SRI Partial Responders||Duke University|Yes|Completed|September 2003|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|124|||Both|7 Years|17 Years|No|||November 2012|July 23, 2014|December 19, 2003||No||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00074815||201187|
NCT00075140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR007970-01|Family Health After Predictive Huntington Disease (HD) Testing|Family Health After Predictive Huntington Disease Testing||National Institute of Nursing Research (NINR)|No|Completed|September 2001|October 2008|Actual|October 2008|Actual|Phase 3|Observational|N/A||1|Actual|422|||Both|N/A|N/A|No|Probability Sample|Family members or significant others, age 14 or older, of persons who 1) have received a        positive result from predictive testing for a mutation in the HD gene, 2) are symptomatic        and living at home, and 3) are symptomatic and are living in a long-term care institution        were the population of interest for this study.|January 2009|January 15, 2009|January 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00075140||201163|
NCT00075478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1813.00|Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|October 2003|||February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|N/A|75 Years|No|||February 2016|February 2, 2016|January 9, 2004|Yes|Yes||No|April 16, 2014|https://clinicaltrials.gov/show/NCT00075478||201140|
NCT00076349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDX-105-02|SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)|A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Combination With Rituximab in Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)||Teva Pharmaceutical Industries||Completed|April 2004|March 2008|Actual|December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|January 20, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00076349||201079|
NCT00109980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001889-01A1|Medicinal Plant Use for Treating Inflammation Among Dominicans in New York City and the Dominican Republic|Dominican Herbal Medicine: Plants Used for Inflammation||New York Botanical Garden|No|Completed|March 2005|||July 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|320|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Dominican community sample in New York City|October 2013|October 30, 2013|May 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00109980||198688|
NCT00109083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333369-MIG-2001|A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine||SK Life Science||Completed|March 2002|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||August 2012|August 1, 2012|April 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109083||198753|
NCT00109096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9710|Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy|A Randomized, Double-Blind Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer||Eli Lilly and Company||Completed|June 2005|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|N/A|No|||May 2007|May 16, 2007|April 22, 2005||||||https://clinicaltrials.gov/show/NCT00109096||198752|
NCT00109421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 034|Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females|PROJECT ÒRÉ: An Innovative Friendship Based HIV/STI Intervention for High Risk African American Females||Westat|No|Completed|November 2004|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|420|||Female|14 Years|21 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|April 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00109421||198727|
NCT00110773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-42-05|S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Pulsed Dye Laser (PDL) Therapy in Adults|A Randomized, Double-Blind, Placebo Controlled, Parallel Study Evaluating the Efficacy of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) to Provide Local Dermal Anesthesia for Pulsed Dye Laser Therapy in Adults||ZARS Pharma Inc.|No|Completed|June 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|May 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110773||198628|
NCT00109954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-04128|Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery|A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)||University of Pittsburgh|Yes|Completed|February 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|120 Years|No|||March 2015|January 15, 2016|May 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109954||198690|
NCT00110227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002454|Tai Chi Mind-Body Therapy for Chronic Heart Failure|Tai Chi Mind-Body Therapy for Chronic Heart Failure|NEXT-Heart|Beth Israel Deaconess Medical Center|Yes|Completed|September 2005|July 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|May 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00110227||198670|
NCT00110487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142A2-200|Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women|A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Effect of ERB-041 in the Reduction of Symptoms Associated With Endometriosis in Reproductive-Age Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2005|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|18 Years|45 Years|No|||December 2007|April 30, 2015|May 9, 2005||||||https://clinicaltrials.gov/show/NCT00110487||198650|
NCT00110500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-509-0401|Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy|A Phase I Dose-Escalation Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy||Sangamo Biosciences||Completed|April 2005|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|65 Years|No|||June 2011|June 6, 2011|May 9, 2005||||||https://clinicaltrials.gov/show/NCT00110500||198649|
NCT00111306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0003 (IMMU-103-03)|Study of Epratuzumab in Systemic Lupus Erythematosus|A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems||UCB Pharma||Terminated|June 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||510|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|May 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00111306||198588|
NCT00111319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-MMY-3002|VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma|An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma||Millennium Pharmaceuticals, Inc.||Completed|December 2004|||July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2009|March 25, 2009|May 19, 2005||Yes||Yes||https://clinicaltrials.gov/show/NCT00111319||198587|
NCT00107809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/3028/AP/MN-OSAHS|Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of PROVIGIL ® (Modafinil) Treatment (100, 200, and 400 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome||Teva Pharmaceutical Industries||Completed|October 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|April 8, 2005||||||https://clinicaltrials.gov/show/NCT00107809||198845|
NCT00109187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q2461g|An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g|Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO)||Genentech, Inc.||Completed|June 2002|April 2003|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||June 2013|June 19, 2013|April 26, 2005||||||https://clinicaltrials.gov/show/NCT00109187||198745|
NCT00074893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-079|Protective Brace to Prevent Hand and Arm Injuries|Shock Absorbing Brace for Study of Upper Extremity Musculoskeletal Disorders||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|November 2003|February 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||15|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2006|March 6, 2006|December 23, 2003||||No||https://clinicaltrials.gov/show/NCT00074893||201181|
NCT00074828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8113|New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery|A Comparison of the Oral Anticoagulant LY517717 Difumarate to Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolic Events (VTE) Post-Total Hip Replacement (THR) and Post-Total Knee Replacement (TKR) Surgery||Eli Lilly and Company||Completed|December 2003|May 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|511|||Both|18 Years|75 Years|No|||March 2008|March 27, 2008|December 19, 2003||||||https://clinicaltrials.gov/show/NCT00074828||201186|
NCT00074841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661120|Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India|A Phase II/III, Randomized, Comparative Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in India||Pfizer||Completed|September 2003|January 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Actual|230|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|December 22, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00074841||201185|
NCT00075491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02566|Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme|A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Terminated|December 2003|||March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|January 9, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00075491||201139|
NCT00075712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCOG-MRC-CHORUS|Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma||National Cancer Institute (NCI)||Completed|September 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|150|||Female|18 Years|N/A|No|||May 2007|August 9, 2013|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075712||201123|
NCT00075725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL0232|Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia|High Risk B-Precursor Acute Lymphoblastic Leukemia||Children's Oncology Group|Yes|Active, not recruiting|December 2003|||June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|3154|||Both|1 Year|30 Years|No|||July 2015|July 10, 2015|January 9, 2004|Yes|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT00075725||201122|
NCT00076037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 056|Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a CTL Multi-Epitope Peptide HIV Vaccine Formulated With RC529-SE, With or Without GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2004|June 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|96|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|January 13, 2004||||||https://clinicaltrials.gov/show/NCT00076037||201099|
NCT00110539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01LM007709|Effectiveness of an Internet-Based Curriculum in Increasing Health Care Providers' Knowledge of Herbs and Dietary Supplements|Internet-Based Curriculum About Herbs and Dietary Supplements||National Library of Medicine (NLM)||Completed|February 2004|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||1500|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2006|May 23, 2012|May 10, 2005||||No||https://clinicaltrials.gov/show/NCT00110539||198646|
NCT00109967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00644|CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study of CCI-779 in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma||National Cancer Institute (NCI)|Yes|Completed|May 2005|March 2012|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||December 2013|March 21, 2014|May 3, 2005|Yes|Yes||No|December 3, 2013|https://clinicaltrials.gov/show/NCT00109967||198689|
NCT00110240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2323|Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|April 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|594|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|May 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110240||198669|
NCT00111111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030190|An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis|A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects With Psoriasis||Amgen||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||May 2009|May 28, 2009|May 17, 2005||||||https://clinicaltrials.gov/show/NCT00111111||198603|
NCT00111332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49302-P2 (completed)|Study of Home-Based Resistance and Strength Training in HIV-Infected Women|Exercise Effects in HIV-Infected Women||Massachusetts General Hospital||Completed|November 2002|July 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|60 Years|No|||April 2010|April 12, 2010|May 19, 2005||||No||https://clinicaltrials.gov/show/NCT00111332||198586|
NCT00111618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1404-203|Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer|An Open Label, Randomized, Phase II Study of AS1404 in Combination With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer||Antisoma Research||Completed|May 2005|August 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Male|18 Years|N/A|No|||January 2009|January 29, 2009|May 24, 2005||||||https://clinicaltrials.gov/show/NCT00111618||198564|
NCT00111631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM18106|A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes|A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin||Hoffmann-La Roche||Completed|May 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|218|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|May 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111631||198563|
NCT00110513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC AT HD 012-04|Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery|A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin Alfa in Hereditary Antithrombin (AT) Deficient Patients in High-Risk Situations for Thrombosis||rEVO Biologics|No|Completed|April 2005|July 2008|Actual|May 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|80 Years|No|||August 2012|August 10, 2012|May 10, 2005|Yes|Yes||No|March 19, 2012|https://clinicaltrials.gov/show/NCT00110513||198648|
NCT00110747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-41-05|S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults|A Randomized, Double-Blind, Placebo Controlled, Paired Study Evaluating the Efficacy of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) in Providing Local Dermal Anesthesia for Non-Ablative Facial Laser Resurfacing in Adults||ZARS Pharma Inc.|No|Completed|June 2005|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|May 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110747||198630|
NCT00111943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 059|Safety and Acceptability of a Vaginal Microbicide|Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|May 26, 2005||||||https://clinicaltrials.gov/show/NCT00111943||198539|
NCT00111956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNF-alpha (completed)|Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2004|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|55 Years|No|||January 2010|January 12, 2010|May 26, 2005||||||https://clinicaltrials.gov/show/NCT00111956||198538|
NCT00111969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0202|ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy|A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of the Celacade™ System on Mortality and Morbidity in Patients With Chronic Heart Failure||Vasogen||Completed|June 2003|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2016|||Both|18 Years|N/A|No|||June 2006|June 28, 2006|May 26, 2005||||||https://clinicaltrials.gov/show/NCT00111969||198537|
NCT00111982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030160|Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin|Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168)||Amgen||Completed|December 2003|February 2006|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|35 Years|70 Years|No|||February 2010|February 25, 2010|May 27, 2005||||No||https://clinicaltrials.gov/show/NCT00111982||198536|
NCT00107484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000420833|Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer|Phase II Study of Combidex in Axillary Node Staging in Breast Cancer||Virginia Commonwealth University|No|Completed|September 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|N/A|No|||April 2010|April 30, 2010|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107484||198870|
NCT00107796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/3027/NA/MN-Narcolepsy|Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of PROVIGIL ® (Modafinil) Treatment (100, 200, and 400 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy||Teva Pharmaceutical Industries||Completed|October 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||May 2006|August 22, 2012|April 8, 2005||||||https://clinicaltrials.gov/show/NCT00107796||198846|
NCT00107497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000417730|Radiation Therapy in Treating Women With Localized Breast Cancer|Prospective Randomised Clinical Trial Testing 5.7 Gy and 6.0 Gy Fractions of Whole Breast Radiotherapy in Terms of Late Normal Tissue Responses and Tumour Control - FAST||National Cancer Institute (NCI)||Completed|January 2005|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|900|||Female|50 Years|N/A|No|||May 2007|February 6, 2009|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107497||198869|
NCT00108459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-002-03F|Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes|Safety and Efficacy of Low Carbohydrate Diet in Obesity and Type 2 DM: RCT||VA Office of Research and Development||Completed|September 2004|December 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|156|||Both|18 Years|N/A|No|||July 2007|January 20, 2009|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108459||198795|
NCT00109200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q2736g|A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma|A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study||Genentech, Inc.||Completed|May 2003|September 2003|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 19, 2013|April 26, 2005||||||https://clinicaltrials.gov/show/NCT00109200||198744|
NCT00074906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY2001/M1-007|Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)|Venticute in Patients With Pneumonia or Aspiration of Gastric Contents Leading to Intubation, Ventilation, and Severe Oxygenation Impairment: A Randomized, Multinational, Multicenter, Parallel Group, Double Blind, Control Group Study||Takeda|Yes|Completed|November 2003|June 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|1200|||Both|12 Years|85 Years|No|||January 2012|May 4, 2012|December 23, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074906||201180|
NCT00074919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02203|Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease|Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease||Sanofi||Approved for marketing|December 2003|February 2007|Actual|February 2007|Actual|N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||February 2014|February 4, 2014|December 23, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00074919||201179|
NCT00075764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000349337|S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer|Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|April 2004|October 2014|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|690|||Female|18 Years|N/A|No|||May 2014|May 8, 2014|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075764||201119|
NCT00075738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000349275|Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer|Phase II Study Of 5FU-Irinotecan-Cisplatin As First-Line Treatment In Patients With Metastatic Carcinoma Of The Esophagus||National Cancer Institute (NCI)||Active, not recruiting|October 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||July 2007|July 23, 2008|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075738||201121|
NCT00077038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040117|Brain Activity in Visual-Motor Behavior|Modulation of the Visual Information Processing in the Human Parieto-Frontal Network as Studied by a Frequency Tagging Technique During Visuomotor Tracking||National Institutes of Health Clinical Center (CC)||Completed|February 2004|March 2007||||N/A|Observational|N/A||||20|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2007|September 26, 2015|February 9, 2004||||No||https://clinicaltrials.gov/show/NCT00077038||201032|
NCT00110292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD040388|Preventing Learning Problems in Young Children: A Public Health and Physician-Based Outreach|An RCT of a Low-Intensity Intervention to Reduce Delay||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|March 2002|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||600|||Both|4 Months|7 Months|Accepts Healthy Volunteers|||May 2005|June 23, 2005|May 5, 2005||||No||https://clinicaltrials.gov/show/NCT00110292||198665|
NCT00110253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-44-05|Duration of Skin Numbing Effect Created by the S-Caine™ Peel|A Randomized, Double-Blind, Paired, Placebo Controlled Study Evaluating the Duration of Anesthetic Effect Produced by the S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) When Applied for 30 and 60 Minutes||ZARS Pharma Inc.|No|Completed|June 2005|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 4, 2012|May 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110253||198668|
NCT00111124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030106|Enbrel® in Psoriatic Arthritis|Enbrel® in Psoriatic Arthritis||Amgen||Completed||||||Phase 4|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2013|May 13, 2013|May 17, 2005||||||https://clinicaltrials.gov/show/NCT00111124||198602|
NCT00110526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 01-0595|Gene Therapy for Prostate Cancer That Returns After Radiation Therapy|Phase I Trial of Adenovirus- Mediated IL-12 Gene Transduction in Patients With Radiorecurrent Prostate Cancer||Icahn School of Medicine at Mount Sinai|Yes|Withdrawn|April 2005|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|40 Years|75 Years|No|||October 2013|October 23, 2013|May 10, 2005|Yes|Yes|No participants met eligibility requirements|No||https://clinicaltrials.gov/show/NCT00110526||198647|
NCT00110786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RagweedMATAMPL204|Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy|A Double Blind Study to Investigate the Clinical Efficacy and Safety of Ragweed MATAMPL (Allergy Therapeutics®), Pollinex®-R (Allergy Therapeutics®) and Placebo in Patients With Seasonal Allergic Rhinitis With Ragweed Allergy, in an Environmental Exposure Chamber (EEC) Model, With Follow-Up During a Natural Ragweed Pollen Season||Allergy Therapeutics||Completed|May 2005|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|65 Years|No|||September 2009|June 16, 2010|May 13, 2005||||No||https://clinicaltrials.gov/show/NCT00110786||198627|
NCT00111670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM18102|A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes|A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes||Hoffmann-La Roche||Completed|June 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|291|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|May 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111670||198560|
NCT00111683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-003|MK0457 in Patients With Leukemia (0457-003)|A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia||Merck Sharp & Dohme Corp.|No|Completed|June 2005|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|May 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111683||198559|
NCT00111345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BfArM 4022064|Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents|Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents||University Hospital Muenster|Yes|Active, not recruiting|March 2004|March 2017|Anticipated|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|550|||Both|N/A|18 Years|No|||March 2012|May 21, 2012|May 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00111345||198585|
NCT00111358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49302-P1 (completed)|Study of Lifestyle Modification in HIV Lipodystrophy|The Effects of a Lifestyle Modification Program (REACH) in Patients With HIV and Metabolic Syndrome||Massachusetts General Hospital|No|Completed|June 2003|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||April 2011|April 15, 2011|May 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00111358||198584|
NCT00111644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI18273|A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia|A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia||Hoffmann-La Roche||Completed|March 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111644||198562|
NCT00111657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006845|Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout|A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout||Duke University|No|Completed|December 2004|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|May 24, 2005|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00111657||198561|
NCT00111995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010125|Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis|A Randomized, Double-Blind Study Comparing Aranesp® (Darbepoetin Alfa) and Recombinant Human Erythropoietin (rHuEPO) in the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis||Amgen||Completed|May 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Both|18 Years|N/A|No|||August 2008|August 7, 2008|May 27, 2005||||||https://clinicaltrials.gov/show/NCT00111995||198535|
NCT00112008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030237|Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis|A Multi-Center, Single-Arm Study Evaluating De Novo Once Every Two Week Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis||Amgen||Completed|May 2004|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2009|July 9, 2009|May 27, 2005||||No||https://clinicaltrials.gov/show/NCT00112008||198534|
NCT00112021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137OB-201|A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects|A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects||AstraZeneca||Completed|May 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|70 Years|No|||April 2015|April 9, 2015|May 27, 2005||||No||https://clinicaltrials.gov/show/NCT00112021||198533|
NCT00108446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-008-02F|Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome|Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome||VA Office of Research and Development||Completed|October 2003|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|January 20, 2009|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108446||198796|
NCT00108836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXBD173A2204|Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder|Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder||Novartis||Completed|March 2005|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|No|||November 2007|May 19, 2010|April 19, 2005||||||https://clinicaltrials.gov/show/NCT00108836||198770|
NCT00108849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG-2195|Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms|A 12 Month Double-blind, Randomized, Parallel-group, Placebo-controlled, Multi-center Trial to Investigate the Efficacy and Safety of Vagifem Low Dose (10 Mcg 17beta-estradiol Vaginal Tablet) for the Treatment of Postmenopausal Atrophic Vaginitis Symptoms||Novo Nordisk A/S|No|Completed|March 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|309|||Female|45 Years|N/A|No|||October 2013|October 21, 2013|April 19, 2005||||No||https://clinicaltrials.gov/show/NCT00108849||198769|
NCT00109252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD2391g|A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g||Genentech, Inc.||Completed|January 2002|April 2003|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||0|||Both|N/A|N/A|No|||June 2013|June 19, 2013|April 26, 2005||||||https://clinicaltrials.gov/show/NCT00109252||198740|
NCT00109265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI2288g|A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy|A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy||Genentech, Inc.||Completed|May 2001|October 2002|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|July 1, 2015|April 26, 2005||Yes||||https://clinicaltrials.gov/show/NCT00109265||198739|
NCT00075205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040072|Rimonabant to Reduce Alcohol Consumption|Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week||National Institutes of Health Clinical Center (CC)||Completed|December 2003|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|54|||Both|21 Years|45 Years|No|||June 2010|June 4, 2010|January 5, 2004||No||No||https://clinicaltrials.gov/show/NCT00075205||201158|
NCT00075218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181004|A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor||Pfizer|Yes|Completed|December 2003|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|361|||Both|18 Years|N/A|No|||August 2009|August 31, 2009|January 6, 2004|Yes|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00075218||201157|Duration of Tumor Response could not be reliably estimated at the time of analysis.
NCT00075452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346480|Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma|Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|November 2003|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2007|July 23, 2008|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075452||201142|
NCT00075465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346617|Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach|Phase II Study of Docetaxel and Epirubicine as First-Line Treatment in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||July 2007|July 23, 2008|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075465||201141|
NCT00075517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346806|Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||July 2007|July 23, 2008|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075517||201137|
NCT00075777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-038|Valproic Acid in Treating Patients With Kaposi's Sarcoma|A Pilot Trial Of Valproic Acid In Patients With Kaposi's Sarcoma||AIDS Malignancy Consortium||Completed|February 2005|February 2008|Actual|July 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075777||201118|
NCT00075751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03183|Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer|A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|January 2004|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|January 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00075751||201120|
NCT00110565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001469-01A2|Effects of Pulsed Magnetic Pads on Rheumatoid Arthritis Symptoms in Postmenopausal Women|Pulsed Electromagnetic Field (PEMF) Efficacy in Reducing Rheumatoid Arthritis Symptoms||National Center for Complementary and Integrative Health (NCCIH)|No|Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||87|||Female|35 Years|N/A|No|||August 2008|August 4, 2008|May 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00110565||198644|
NCT00110799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPL102357|SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C|A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group, Phase II Study to Assess Efficacy, Safety/Tolerability, and Pharmacokinetics of a Thrombopoietin Receptor Agonist, SB-497115-GR, When Administered as 30, 50, and 75 mg Once Daily for 12 Weeks in Subjects With||GlaxoSmithKline||Completed|April 2005|November 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|N/A|No|||March 2011|May 31, 2012|May 13, 2005||||No||https://clinicaltrials.gov/show/NCT00110799||198626|
NCT00110812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPRIT 002|Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People|STALWART: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 With and Without Concomitant Antiretroviral Therapy in Patients With HIV-1 Infection and CD4+ Cell Counts of 300 Cells/mm3 or More|STALWART|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2005|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|267|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|May 13, 2005|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00110812||198625|All randomized patients were followed through 28 Feb 2009. A subset of 222 consenting patients were followed 2 additional years, through 28 Feb 2011.
NCT00111371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL-001; Project on Dyslexia|Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia|Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia)||University Hospital Muenster||Recruiting|January 2005|October 2015|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2006|December 4, 2014|May 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00111371||198583|
NCT00111384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050152|Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)|Variation in Gene Expression in Neurofibromatosis Type 1||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2005|||||N/A|Observational|Time Perspective: Prospective|||Actual|313|||Both|2 Years|100 Years|No|||October 2015|November 17, 2015|May 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00111384||198582|
NCT00111397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050156|Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection|A Study of Adjuvant Cytokine Therapy in Pulmonary Mycobacterium Avium Complex and Other Pulmonary Nontuberculous Mycobacterial Infections||National Institutes of Health Clinical Center (CC)||Completed|May 2005|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||August 2010|September 26, 2015|May 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00111397||198581|
NCT00111410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020101|Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)|A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA)||Swedish Orphan Biovitrum||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|74 Years|No|||September 2011|September 19, 2011|May 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111410||198580|
NCT00111696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP121|Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma|Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Advanced Malignant Melanoma||MedImmune LLC|No|Completed|May 2005|November 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2012|March 13, 2012|May 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00111696||198558|
NCT00111072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050155|Dexamethasone to Treat Oral Lichen Planus|Dexamethasone 0.01% Solution for the Treatment of Oral Lichen Planus||National Institutes of Health Clinical Center (CC)||Completed|May 2005|March 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||70|||Both|N/A|N/A|No|||March 2006|March 3, 2008|May 16, 2005||||No||https://clinicaltrials.gov/show/NCT00111072||198606|
NCT00111085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-054-201|Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)|A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After aSAH by Intravenous Administration of Clazosentan, a Selective ETA Receptor Antagonist|CONSCIOUS-1|Actelion||Completed|January 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|413|||Both|18 Years|70 Years|No|||February 2010|February 11, 2010|May 17, 2005||Yes||||https://clinicaltrials.gov/show/NCT00111085||198605|
NCT00111098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030153|Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis|A Multicenter, Single Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing In Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis||Amgen||Completed|March 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2008|August 7, 2008|May 17, 2005||||No||https://clinicaltrials.gov/show/NCT00111098||198604|
NCT00107510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0338|Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer|Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|August 2005|||September 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|April 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107510||198868|
NCT00107835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-45-05|Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults|An Open-Label Safety Study to Evaluate the Use of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) in Adult Patients Undergoing a Minor or Major Dermal Procedure||ZARS Pharma Inc.|No|Completed|May 2005|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|408|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|April 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107835||198843|
NCT00108121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-002|Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma|A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma||Peplin||Completed|March 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108121||198821|
NCT00108433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951105|Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections|Linezolid vs Vancomycin/Cefazolin in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections||Pfizer||Terminated|September 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|61|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|April 15, 2005|Yes|Yes|See Detailed Description|No|June 28, 2012|https://clinicaltrials.gov/show/NCT00108433||198797|Efficacy results were not reported because the study was prematurely terminated.
NCT00108134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-003|Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Superficial Basal Cell Carcinoma||Peplin||Completed|March 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2008|December 22, 2008|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108134||198820|
NCT00108147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-002-03S|Functional Circuit Training in Older Adults With Congestive Heart Failure|Functional Circuit Training in Older Adults With Congestive Heart Failure||VA Office of Research and Development||Completed|October 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|3||||||Both|60 Years|N/A|No|||March 2009|March 4, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108147||198819|
NCT00108901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60692 (completed)|The Medical College of Georgia PLAY Project: Exercise Dose and Insulin Sensitivity in Obese Children|Exercise Dose and Insulin Sensitivity in Obese Children||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|June 2003|January 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|222|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|April 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00108901||198766|
NCT00108914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR30008|Perennial Allergic Rhinitis Study In Pediatric Subjects|See Detailed Description||GlaxoSmithKline||Completed|February 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|558|||Both|2 Years|12 Years|No|||April 2015|April 14, 2015|April 20, 2005||||No||https://clinicaltrials.gov/show/NCT00108914||198765|
NCT00074958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL-016-01|A Study of Fabrazyme in Pediatric Patients With Fabry Disease|A Multi-center, Phase 2, Open-Label Study of Fabrazyme (Recombinant Human a-Galactosidase A) Replacement Therapy in Pediatric Patients With Fabry Disease||Sanofi||Completed|October 2002|July 2005|Actual|May 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|7 Years|15 Years|No|||March 2015|March 13, 2015|December 24, 2003|No|Yes||No|March 3, 2009|https://clinicaltrials.gov/show/NCT00074958||201176|The trial was not powered to demonstrate clinical benefit.
NCT00075231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-613|A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects|A Randomized, Open-Label Study Exploring a Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects||Abbott||Completed|December 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2006|September 28, 2006|January 6, 2004||||||https://clinicaltrials.gov/show/NCT00075231||201156|
NCT00075179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0562|Natrecor in Pulmonary Hypertension|Phase IV, Open Labeled Study to Test the Effectiveness of Nesiritide in Reversing Pulmonary Hypertension in Patients Who Will be Undergoing CardioThoracic Surgery||M.D. Anderson Cancer Center|No|Terminated|January 2004|March 2006|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|85 Years|No|||July 2012|July 31, 2012|January 5, 2004|Yes|Yes|Low accrual.|No||https://clinicaltrials.gov/show/NCT00075179||201160|
NCT00075543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346887|Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer|Phase I-II Study Of Docetaxel And Oxaliplatine In Patients With Stage III-IV Ovarian Epithelial Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2003|||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|75 Years|No|||July 2007|July 23, 2008|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075543||201136|
NCT00075816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0201|Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)|A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)||Medical College of Wisconsin|Yes|Completed|January 2004|April 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|551|||Both|N/A|66 Years|No|||December 2015|December 28, 2015|January 9, 2004|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT00075816||201116|
NCT00076024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061010|AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer|Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination||Pfizer|Yes|Completed|February 2004|November 2008|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|174|||Female|18 Years|N/A|No|||June 2012|June 21, 2012|January 12, 2004|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00076024||201100|Analysis of TTP (Phase 2, Double-blind) was performed with both discontinuation due to lack of efficacy (LOE) considered a progression and not considered a progression event. Latter was considered primary analysis and former a sensitivity analysis.
NCT00075803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0101|Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)|A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)||Medical College of Wisconsin|Yes|Completed|November 2003|September 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|600|||Both|2 Years|N/A|No|||August 2015|August 5, 2015|January 9, 2004|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00075803||201117|
NCT00076700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040110|Enhanced Tactile Memory in the Blind|Enhanced Tactile Memory in the Blind||National Institutes of Health Clinical Center (CC)||Completed|January 2004|January 2006||||N/A|Observational|N/A||||45|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|January 31, 2004||||No||https://clinicaltrials.gov/show/NCT00076700||201053|
NCT00110838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TME/C-01.07|SOFA: Study on Omega-3 Fatty Acids and Ventricular Arrhythmia|Study on Omega-3 Fatty Acids and Ventricular Arrhythmia, a Parallel, Placebo-Controlled, Double Blind Intervention Study||Wageningen Centre for Food Sciences||Completed|October 2001|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||546|||Both|18 Years|N/A|No|||May 2005|July 20, 2006|May 13, 2005||||No||https://clinicaltrials.gov/show/NCT00110838||198623|
NCT00110552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19AT002656-03|Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients|Effects of a Cognitive Enhancer on Memory and Cognitive Performance||Oregon Health and Science University|Yes|Completed|July 2005|October 2014|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|50 Years|90 Years|No|||October 2014|October 27, 2014|May 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00110552||198645|
NCT00111150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4321|Botswana Tenofovir Oral HIV Prophylaxis Trial|Study of the Safety and Efficacy of Daily Tenofovir Disoproxil Fumarate for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana||Centers for Disease Control and Prevention|Yes|Terminated|September 2005|March 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||March 2007|March 16, 2007|May 17, 2005|||Consenting participants entered tenofovir/emtricitabine oral prophylaxis trial|No||https://clinicaltrials.gov/show/NCT00111150||198600|
NCT00111137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020139|Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy|A Randomized, Open Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients With Non-Myeloid Malignancies Receiving Chemotherapy||Amgen||Completed|February 2003|April 2004|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|718|||Both|18 Years|N/A|No|||February 2008|February 20, 2008|May 17, 2005||||No||https://clinicaltrials.gov/show/NCT00111137||198601|
NCT00111735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-015|Thyroxine Titration Study|What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function||Sir Charles Gairdner Hospital||Active, not recruiting|April 2003|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||55|||Both|18 Years|N/A|No|||May 2005|June 23, 2005|May 24, 2005||||No||https://clinicaltrials.gov/show/NCT00111735||198555|
NCT00111748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29432|UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients|UARK 2005-01, A Phase III Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients||University of Arkansas||Completed|February 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|May 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111748||198554|
NCT00112034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-865|AVONEX® Combination Trial - "ACT"|A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.||Biogen||Completed|June 2003|May 2007|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind||||350|||Both|18 Years|55 Years|No|||May 2008|May 5, 2008|May 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112034||198532|
NCT00112047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-01-934|Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects|A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz||Gilead Sciences|Yes|Completed|July 2003|June 2009|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|517|||Both|18 Years|N/A|No|||October 2010|October 11, 2010|May 27, 2005|Yes|Yes||No|June 22, 2010|https://clinicaltrials.gov/show/NCT00112047||198531|
NCT00111709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-071|Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine||Merck Sharp & Dohme Corp.||Completed|May 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|393|||Female|18 Years|N/A|No|||October 2015|October 9, 2015|May 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111709||198557|
NCT00112060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS101|A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase I/II, Open-Label, Multicenter Study of Single Agent PT-523 in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)||Spectrum Pharmaceuticals, Inc||Withdrawn|April 2008|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|May 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112060||198530|
NCT00107523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1945.00|Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia|A Phase I Trial Evaluating the Effect of the Addition of HMGCoA-Reductase Inhibition With Pravastatin to Salvage Chemotherapy Idarubicin-HDAC in Patients With Relapsed or Refractory Acute Myelogenous Leukemia||Fred Hutchinson Cancer Research Center||Completed|January 2005|October 2005|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2010|September 20, 2010|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107523||198867|
NCT00107536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01464|Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer|A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas||National Cancer Institute (NCI)||Completed|October 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2015|April 8, 2015|April 5, 2005|Yes|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00107536||198866|
NCT00107848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/3029/ES/MN-Open label|PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome|A 1 Year Open Label, Flexible Dosage Extension Study to Assess the Safety and Continued Effectiveness of PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome||Teva Pharmaceutical Industries||Completed|October 2004|September 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment||||280|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|April 8, 2005||||||https://clinicaltrials.gov/show/NCT00107848||198842|
NCT00107861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-20|Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases|A Phase I/II Study of Interferon-Beta Gene Transfer (Ad.hIFN-β) in the Treatment of Refractory Colorectal Carcinoma With Liver Metastases||Biogen||Completed|May 2005|September 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||44|||Both|18 Years|N/A|No|||July 2009|July 10, 2009|April 11, 2005||||||https://clinicaltrials.gov/show/NCT00107861||198841|
NCT00108485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20043224|Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy|Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment||University of Miami|No|Terminated|April 2005|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|April 15, 2005|Yes|Yes|Unable to recruit sufficient study subjects|No||https://clinicaltrials.gov/show/NCT00108485||198794|
NCT00074971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL-005-99|A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease|A Multi-center, Open-Label Extension Study of the Safety and Efficacy of Recombinant Human a-Galactosidase A (r-haGAL) Replacement in Patients With Fabry Disease||Sanofi||Completed|October 1999|December 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||58|||Both|16 Years|N/A|No|||December 2013|December 2, 2013|December 24, 2003||||||https://clinicaltrials.gov/show/NCT00074971||201175|
NCT00075192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671004|CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer|A Phase 1, Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and a Phase 2, Open Label, Randomized Study to Evaluate the Efficacy of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and Androgen Ablation Alone in Patients With High Risk Prostate Cancer||AstraZeneca||Completed|March 2004|March 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|8|||Male|18 Years|N/A|No|||June 2012|June 5, 2012|January 5, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00075192||201159|
NCT00072332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000339607|Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Dose Escalation Study of Edotecarin (PHA-782615) and Cisplatin in Adult Patients With Advanced/Metastatic Solid Tumors||National Cancer Institute (NCI)||Completed|August 2003|December 2009|Actual|December 2005|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|December 18, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072332||201363|
NCT00076375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32101-2-01|Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Two Concentrations of Nanocrystalline Silver Cream (NPI) Applied Twice Daily in Adults With Mild to Moderate Atopic Dermatitis||Nucryst Pharmaceuticals||Completed|November 2003|April 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|65 Years|No|||April 2004|June 23, 2005|January 21, 2004||||||https://clinicaltrials.gov/show/NCT00076375||201077|
NCT00076687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-057|Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function|||Allergan||Completed|October 2003|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|January 29, 2004|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00076687||201054|
NCT00076713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-099|Antiphospholipid Syndrome Collaborative Registry (APSCORE)|Antiphospholipid Syndrome Collaborative Registry (APSCORE)|APSCORE|University of North Carolina, Chapel Hill|No|Completed|April 2000|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|860|Samples With DNA|Serum, plasma, genomic DNA|Both|N/A|N/A|No|Non-Probability Sample|Specialty and subspecialty clinics|February 2013|February 11, 2013|February 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00076713||201052|
NCT00110591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44AI046871-04|Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers|A Phase I, Randomized, Double Blind, Placebo Controlled, Single-Dose, Rising Dose Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO 140 in Healthy Volunteers||CytoDyn, Inc.|No|Completed|April 2004|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|May 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110591||198642|
NCT00110825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17441-1|Behavioral Smoking Cessation Treatment - 1|Behavioral Maintenance Treatment for Smoking Cessation||National Institute on Drug Abuse (NIDA)|Yes|Completed|February 2004|June 2009|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|304|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 2, 2009|May 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00110825||198624|
NCT00111462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010102|Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy|A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) Using Fixed and Weight-Based Dosing for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy||Amgen||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||May 2013|May 6, 2013|May 20, 2005||||||https://clinicaltrials.gov/show/NCT00111462||198576|
NCT00111423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020133|Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA)||Amgen||Completed|August 2002|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||216|||Both|18 Years|N/A|No|||December 2007|March 4, 2009|May 20, 2005||||||https://clinicaltrials.gov/show/NCT00111423||198579|
NCT00111436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030115|Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects|An Open-Label, Long-Term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects||Amgen||Completed|April 2003|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|912|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|May 20, 2005||||No||https://clinicaltrials.gov/show/NCT00111436||198578|
NCT00112086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0206|OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206|Feasibility Study of Neoadjuvant Chemotherapy Followed by Interval Cytoreductive Surgery for Stage III/IV Ovarian, Tubal and Peritoneal Cancers: JCOG0206||Japan Clinical Oncology Group|Yes|Completed|January 2003|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|20 Years|75 Years|No|||February 2008|February 29, 2008|May 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00112086||198528|
NCT00111722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-072|Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine||Merck Sharp & Dohme Corp.||Completed|May 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|393|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|May 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111722||198556|
NCT00107549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1059|Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy|A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of Recombinant HIV-1 Vaccines in HIV-1 Infected Young Adults With Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|24 Years|No|||May 2012|May 17, 2012|April 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107549||198865|
NCT00107562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 032|Adolescent Safer Sex Social Network Intervention|Adolescent Safer Sex Social Network Intervention||Westat|No|Completed|February 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|16 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|April 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00107562||198864|
NCT00107874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M73/99|Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-Scheduled Cesarean Section|Oral Misoprostol as a Second-Line Alternative to Intravenous Oxytocin in Preventing Postoperative Blood Loss After Non-Scheduled Cesarean Section: a Randomized, Double-Blind, Placebo-Controlled Trial||Basel Women’s University Hospital||Completed|January 1999|February 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||56|||Female|18 Years|N/A|No|||April 2005|June 23, 2005|April 11, 2005||||No||https://clinicaltrials.gov/show/NCT00107874||198840|
NCT00108160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-001-04S|Preventing Staphylococcal (Staph) Infection|Intermittent Mupirocin to Prevent Staphylococcal Infection||VA Office of Research and Development|No|Completed|April 2005|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|146|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|April 14, 2005||No||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00108160||198818|The study is underpowered to detect differences between the two treatment arms. We achieved only 75% of target enrollment, and 41.1% dropped out before reaching a primary endpoint. Our re-infection rate was also lower than anticipated (14.4%).
NCT00108875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SuMo-Sec-01|Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer|Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides||Julius-Maximilians University||Recruiting|April 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|19 Years|90 Years|No|||June 2005|July 27, 2006|April 19, 2005||||No||https://clinicaltrials.gov/show/NCT00108875||198767|
NCT00100529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050052|Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations|Stereo Photogrammetry Soft Tissue in Normal Individuals and Patients With Craniofacial Dysmorphologies||National Institutes of Health Clinical Center (CC)||Completed|December 2004|June 2012||||N/A|Observational|N/A|||Actual|1577|||Both|1 Year|80 Years|No|||June 2012|January 14, 2014|December 31, 2004||No||No||https://clinicaltrials.gov/show/NCT00100529||199375|
NCT00076388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791GC00001|Iressa Versus Docetaxel (Taxotere)|A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy||AstraZeneca||Completed|February 2004|October 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1440|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|January 21, 2004||Yes||||https://clinicaltrials.gov/show/NCT00076388||201076|
NCT00075504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03030|Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder||National Cancer Institute (NCI)|Yes|Completed|November 2003|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|August 31, 2015|January 9, 2004|Yes|Yes||No|May 19, 2015|https://clinicaltrials.gov/show/NCT00075504||201138|
NCT00076401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0216|A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)|Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)||Pharmacyclics||Terminated||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|January 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00076401||201075|
NCT00076414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040085|The Effect of Lopinavir/Ritonavir on Endothelial Function|The Effect of Lopinavir/Ritonavir on Endothelial Function in Normal Volunteers||National Institutes of Health Clinical Center (CC)||Completed|January 2004|September 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|March 3, 2008|January 21, 2004||||No||https://clinicaltrials.gov/show/NCT00076414||201074|
NCT00072670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101850|A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer|Phase 2 Study of Yondelis in Men With Advanced Prostate Carcinoma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|January 2004|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|59|||Male|18 Years|N/A|No|||April 2014|April 7, 2014|November 7, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072670||201340|
NCT00076427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040086|Leukapheresis for Research on HCV-Coinfected Patients|Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications||National Institutes of Health Clinical Center (CC)||Completed|January 2004|June 2015||||N/A|Observational|N/A|||Actual|327|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|January 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00076427||201073|
NCT00110877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002794|TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients|A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients||Tibotec Pharmaceuticals, Ireland|Yes|Completed|April 2005|October 2011|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|604|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|May 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110877||198620|
NCT00111163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3606|Intermittent Preventive Treatment With Antimalarials in Kenyan Infants|Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya||Centers for Disease Control and Prevention||Completed|March 2004|March 2008|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1516|||Both|5 Weeks|16 Weeks|Accepts Healthy Volunteers|||September 2012|September 26, 2012|May 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00111163||198599|
NCT00111449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030117|Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis|A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis||Amgen||Completed|June 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|May 20, 2005||||||https://clinicaltrials.gov/show/NCT00111449||198577|
NCT00111176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-536|STARZ-TX2 Clinical Study: Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft|Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft|STARZ-TX2|Cook|Yes|Completed|March 2004|May 2013|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|May 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111176||198598|
NCT00111761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20025409|Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer|A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer||Amgen|Yes|Completed|July 2002|October 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|May 25, 2005|Yes|Yes||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00111761||198553|
NCT00111774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20025405|Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma|An Open Label Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of ABX-EGF in Patients With Metastatic Colorectal Carcinoma||Amgen||Completed|March 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|May 25, 2005||||||https://clinicaltrials.gov/show/NCT00111774||198552|
NCT00111475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000137|Evaluating the Safety and Efficacy of AMG531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura(ITP)|A Dose-Finding Study Evaluating the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)||Amgen||Completed||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||November 2008|November 20, 2008|May 20, 2005||||||https://clinicaltrials.gov/show/NCT00111475||198575|
NCT00111787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF102580|Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer|A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer||GlaxoSmithKline||Completed|April 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||60|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|May 25, 2005||||||https://clinicaltrials.gov/show/NCT00111787||198551|
NCT00111800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPB100925|A New Oral Treatment For Type II Diabetes Mellitus|See Detailed Description||GlaxoSmithKline||Completed|April 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||366|||Both|18 Years|75 Years|No|||October 2010|October 1, 2010|May 25, 2005||||||https://clinicaltrials.gov/show/NCT00111800||198550|
NCT00112073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAB-001-201|AAB-001 in Patients With Mild to Moderate Alzheimer's Disease|A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD||JANSSEN Alzheimer Immunotherapy Research & Development, LLC||Completed|April 2005|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|234|||Both|50 Years|85 Years|No|||March 2012|March 12, 2012|May 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112073||198529|
NCT00107887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19790.01|TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)|Impact of TB Preventive Therapy for HIV/TB Co-infected Patients With Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial||Communicable Disease Program, Brazil|Yes|Completed|June 2005|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17415|||Both|16 Years|N/A|No|||June 2011|June 14, 2011|April 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00107887||198839|
NCT00108173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-018-02S|Brain Reaction to Treatment of Nicotine Dependence|Neural Substrates of Treatment for Nicotine Dependence||VA Office of Research and Development|No|Completed|October 2002|June 2011|Actual|April 2007|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|104|||Both|21 Years|60 Years|No|||April 2013|April 5, 2013|April 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00108173||198817|
NCT00108186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCA-043-04S|Celecoxib Treatment for Lung Cancer|Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer||VA Office of Research and Development|Yes|Withdrawn|October 2004|June 2011|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|April 14, 2005||No|Couldn't accrue patients|No||https://clinicaltrials.gov/show/NCT00108186||198816|
NCT00108199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-001-01S|Generalization of Training in Schizophrenia|Generalization of Training in Schizophrenia||VA Office of Research and Development||Completed|October 2001|September 2004||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|65 Years|No|||May 2007|January 20, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108199||198815|
NCT00108498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP-011-02F|New Pharmacological Treatment for Obstructive Sleep Apnea|New Pharmacological Treatment for Obstructive Sleep Apnea||VA Office of Research and Development||Completed|October 2003|March 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|80 Years|No|||May 2007|January 20, 2009|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108498||198793|
NCT00108511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-009-04S|Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides|Effect of Gemfibrozil on Serum GPI Phospholipase D and Triglycerides||VA Office of Research and Development||Completed|October 2004|September 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|19 Years|74 Years|Accepts Healthy Volunteers|||May 2007|January 20, 2009|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108511||198792|
NCT00108524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-005-03F|A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss|A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss||VA Office of Research and Development|No|Completed|July 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|April 15, 2005||No||No|September 26, 2013|https://clinicaltrials.gov/show/NCT00108524||198791|We provided orlistat at no cost. This could have increased dietary adherence, attendance, and/or retention compared with the LCKD and may lead to different results than what might be seen in patients who must pay for orlistat.
NCT00100542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1055|Psychiatric Problems in Children and Adolescents Infected With HIV at Birth|Psychiatric Co-Morbidity in Perinatally HIV-Infected Children and Adolescents||International Maternal Pediatric Adolescent AIDS Clinical Trials Group||Completed|April 2005|September 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|800|||Both|6 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and their caregivers from specific clinics.|January 2011|January 20, 2011|January 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00100542||199374|
NCT00075569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000347077|SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia|SGN-00101 (HspE7) Immunotherapy Of CIN III||National Cancer Institute (NCI)||Completed|March 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Prevention|||||||Female|18 Years|N/A|No|||January 2006|January 27, 2010|January 9, 2004||||||https://clinicaltrials.gov/show/NCT00075569||201134|
NCT00075244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040073|Alternative Dosing and Regimen of Replagal to Treat Fabry Disease|A Phase I-II Pharmacokinetic/Pharmacodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients With Fabry Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2004|November 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||25|||Male|N/A|N/A|No|||November 2005|March 3, 2008|January 6, 2004||||No||https://clinicaltrials.gov/show/NCT00075244||201155|
NCT00076115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003631|Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents|Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Risperidone for the Treatment of Acute Mania in Bipolar I Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2003|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|13|||Both|10 Years|17 Years|No|||April 2010|June 6, 2011|January 14, 2004||||||https://clinicaltrials.gov/show/NCT00076115||201093|
NCT00076440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0051|Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study|Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study||National Institute on Aging (NIA)||Completed|December 2003|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Male|65 Years|N/A|No|||March 2007|December 10, 2009|January 22, 2004||||||https://clinicaltrials.gov/show/NCT00076440||201072|
NCT00102622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-321|Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer|Phase I of Phase I/II Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer||M.D. Anderson Cancer Center|Yes|Terminated|December 2004|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Female|18 Years|N/A|No|||August 2012|June 4, 2014|January 31, 2005|Yes|Yes|Phase I/II study that did not progress to Phase II due to low accrual.|No||https://clinicaltrials.gov/show/NCT00102622||199220|
NCT00102635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-455|4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer||M.D. Anderson Cancer Center|Yes|Terminated|January 2005|November 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|N/A|No|||July 2012|July 27, 2012|January 31, 2005|No|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00102635||199219|
NCT00102648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0424|Sarasar and Temodar for Glioblastoma Multiforme Patients|Phase I/Ib Study of Sarasar and Temodar in Patients With Recurrent or Temodar-Refractory Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2004|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|January 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102648||199218|
NCT00110851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN2034.05.001|Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) Therapy||Wellstat Therapeutics||Completed|April 2005|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|21 Years|72 Years|No|||August 2007|August 21, 2007|May 13, 2005||||||https://clinicaltrials.gov/show/NCT00110851||198622|
NCT00110864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN2034.05.002|Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes||Wellstat Therapeutics||Completed|May 2005|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|21 Years|65 Years|No|||August 2007|August 21, 2007|May 13, 2005||||||https://clinicaltrials.gov/show/NCT00110864||198621|
NCT00111501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15791-1|LGBT Internet Based Smoking Treatment - 1|LGBT Internet Based Smoking Treatment||University of California, San Francisco|No|Completed|September 2002|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|792|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|May 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00111501||198573|
NCT00111488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR2045885|Guidant Microwave Ablation System for the Treatment of Atrial Fibrillation|Randomized Study of Surgical Ablation With Microwave Energy for the Treatment of Atrial Fibrillation||Boston Scientific Corporation||Terminated|June 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||May 2014|January 5, 2016|May 20, 2005||Yes|Slow enrollment|||https://clinicaltrials.gov/show/NCT00111488||198574|
NCT00112112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP114|Safety Study to Evaluate FluMist in Immunocompromised Children|A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age||MedImmune LLC|Yes|Completed|August 2005|May 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|5 Years|17 Years|No|||July 2012|July 31, 2012|May 27, 2005|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00112112||198526|
NCT00107575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15534-1|Improving Smoking Cessation Outcomes in Heavy Drinkers - 1|Improving Smoking Cessation Outcomes in Heavy Drinkers||National Institute on Drug Abuse (NIDA)|No|Completed|August 2003|April 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|95 Years|No|||May 2010|May 24, 2010|April 5, 2005||No||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00107575||198863|
NCT00107588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-12728-06|Marijuana Treatment Project - 3|Contingency Management for Marijuana Dependence|MTP-3|University of Connecticut Health Center|Yes|Completed|February 2007|August 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|234|||Both|18 Years|80 Years|No|||January 2014|January 7, 2014|April 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00107588||198862|
NCT00107900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-PRT007|Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement|A Phase IIa, Multi-center, Multi-national, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty||Daiichi Sankyo Inc.||Completed|January 2005|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|606|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|April 11, 2005|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00107900||198838|
NCT00107913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOS1|Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura|Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura||Hematology and Oncology Specialists||Recruiting|September 2001|April 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||April 2005|June 23, 2005|April 11, 2005||||No||https://clinicaltrials.gov/show/NCT00107913||198837|
NCT00108212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARD-005-03S|Effect of Diet on Men and Women With Genetic Alterations Associated With Abnormal Blood Tests|Clinical Implications of Genetic Alterations in TG Rich Lipoproteins||VA Office of Research and Development||Completed|January 2005|December 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2007|January 20, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108212||198814|
NCT00108225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03448-A|Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)|2895 Effect of a High Protein Diet on the 24-hr Profile of Ghrelin, GH and IGF-1||VA Office of Research and Development|No|Completed|July 2004|May 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|55 Years|75 Years|No|||June 2014|June 30, 2014|April 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00108225||198813|
NCT00100256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91168|Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy|Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy||Bayer||Completed|January 2004|April 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|21 Years|N/A|No|||December 2014|December 17, 2014|December 27, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00100256||199396|
NCT00100555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2315|A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate|A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate||Novartis||Completed|June 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Female|45 Years|79 Years|No|||April 2012|April 26, 2012|January 3, 2005||||||https://clinicaltrials.gov/show/NCT00100555||199373|
NCT00075582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST0331|Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma|Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma||Children's Oncology Group|Yes|Active, not recruiting|September 2004|||September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|390|||Both|N/A|49 Years|No|||October 2015|October 30, 2015|January 9, 2004|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00075582||201133|
NCT00075595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000347378|Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer|Phase II Study of 5FU/Folinic Acid and Irinotecan as Second or Third Line Treatment in Patients With Metastatic, Unresectable, Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||August 2007|January 3, 2009|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075595||201132|
NCT00075257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-302|Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of DVS-233 SR For Prevention Of Depressive Relapse In Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|603|||Both|18 Years|75 Years|No|||August 2009|August 18, 2009|January 7, 2004||||||https://clinicaltrials.gov/show/NCT00075257||201154|
NCT00075842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N01C5|(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy|The Use Of Valeriana Officinalis (Valerian) In Improving Sleep In Patients Who Are Undergoing Adjuvant Treatment For Cancer" A Phase III Randomized, Placebo-Controlled, Double-Blind Study||Alliance for Clinical Trials in Oncology|Yes|Completed|August 2003|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|227|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075842||201114|
NCT00075855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N02C3|Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors|The Use of Low Dose Testosterone To Enhance Libido In Female Cancer Survivors: A Phase III Randomized, Placebo-Controlled, Double-Blind Crossover Study||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2004|October 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|150|||Female|N/A|N/A|No|||July 2015|July 7, 2015|January 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00075855||201113|
NCT00076141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499A|Relatively Healthy Male Veterans Observed Over Time to See What Types of Diseases Develop|CSP #499A - Selenium and Vitamin E Cancer Prevention Trial - COHORT|ACTIVE Health|VA Office of Research and Development|No|Active, not recruiting|January 2002|January 2016|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|991|Samples With DNA|PE and buffy coat|Male|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  relatively healthy male Veterans          -  at least 50 years old|December 2015|December 22, 2015|January 14, 2004||No||No||https://clinicaltrials.gov/show/NCT00076141||201092|
NCT00076154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500A|National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank|CSP #500A - National Registry of Veterans With Amyotrophic Lateral Sclerosis|ALS Registry|VA Office of Research and Development|No|Completed|January 2003|September 2009|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2121|Samples With DNA|DNA samples or blood or mouthwash were collected in veterans' homes by nurses.|Both|N/A|N/A|No|Probability Sample|Living veterans with an ALS diagnosis verified by medical records.|April 2014|April 18, 2014|January 14, 2004||No||No||https://clinicaltrials.gov/show/NCT00076154||201091|
NCT00076180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040089|Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia|Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia||National Institutes of Health Clinical Center (CC)||Completed|January 2004|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|99 Years|No|||March 2016|March 19, 2016|January 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00076180||201090|
NCT00111826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101|SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes|Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of the Celacade™ System in Improving Walking Distance in Patients With Intermittent Claudication Secondary to Peripheral Arterial Disease||Vasogen||Terminated|January 2003|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|40 Years|N/A|No|||November 2007|March 30, 2010|May 25, 2005||||||https://clinicaltrials.gov/show/NCT00111826||198548|
NCT00111189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004198|A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.|A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2005|February 2008|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|414|||Both|18 Years|65 Years|No|||June 2014|June 19, 2014|May 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111189||198597|
NCT00098280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050048|Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria|A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients||National Institutes of Health Clinical Center (CC)||Completed|December 2004|February 2006||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||75|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2006|March 3, 2008|December 3, 2004||||No||https://clinicaltrials.gov/show/NCT00098280||199536|
NCT00098293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001026|Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine|A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects|MERIT|ViiV Healthcare|Yes|Completed|November 2004|December 2012|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|916|||Both|16 Years|N/A|No|||August 2013|August 7, 2013|December 6, 2004|Yes|Yes||No|July 9, 2012|https://clinicaltrials.gov/show/NCT00098293||199535|Following DSMB decision to discontinue maraviroc 300 mg once daily, inferential statistical analyses was performed between maraviroc 300 mg twice daily and efavirenz 600 mg once daily only. Data at Week 24 was not analyzed as planned in protocol.
NCT00111813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-015|Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))|Phase I Clinical Trial of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma||Merck Sharp & Dohme Corp.||Completed|September 2005|May 2011|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|34|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|May 25, 2005|No|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00111813||198549|
NCT00098943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16041|NGR-TNF in Treating Patients With Advanced Solid Tumors|Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2004|||November 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|70|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00098943||199493|
NCT00099281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB1002 02|DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer|A Phase III Study of DPPE Combined With Epirubicin and Cyclophosphamide vs Epirubicin and Cyclophosphamide Alone as First Line Treatment in Metastatic/Recurrent Breast Cancer||YM BioSciences||Terminated|May 2004|June 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||700|||Female|16 Years|N/A|No|||February 2007|February 27, 2007|December 10, 2004||||||https://clinicaltrials.gov/show/NCT00099281||199469|
NCT00112099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG 0110|GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110|Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110||Japan Clinical Oncology Group|Yes|Active, not recruiting|June 2002|March 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|75 Years|No|||August 2009|August 2, 2009|May 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00112099||198527|
NCT00099242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713D2320|Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease|Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease||Novartis||Completed|November 2003|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1040|||Both|50 Years|85 Years|No|||December 2007|December 17, 2007|December 10, 2004||||||https://clinicaltrials.gov/show/NCT00099242||199472|
NCT00099255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG030-0004|Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma|A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis||Seattle Genetics, Inc.||Completed|September 2004|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|December 10, 2004||||||https://clinicaltrials.gov/show/NCT00099255||199471|
NCT00099268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200A2401|Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy|A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy|STRIDE-PD|Novartis||Completed|September 2004|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|747|||Both|30 Years|70 Years|No|||April 2012|April 19, 2012|December 10, 2004|Yes|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00099268||199470|
NCT00099580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2592-101 (PROCLAIM)|PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure|PROCLAIM: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Examine the Effects of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure||AstraZeneca|No|Completed|March 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||December 2014|January 16, 2015|December 17, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099580||199447|
NCT00099853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2304|Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes||Novartis||Completed|May 2004|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|362|||Both|18 Years|80 Years|No|||January 2013|January 2, 2013|December 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099853||199426|
NCT00099866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2309|Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|January 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|570|||Both|18 Years|75 Years|No|||May 2012|May 4, 2012|December 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099866||199425|
NCT00099606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-003|Phase I (PH I) Mad Refractory Solid Tumor Study|A Phase I Dose-Escalation Study of BMS-354825 in Patients With Refractory Solid Tumors||Bristol-Myers Squibb||Completed|July 2004|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||60|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|December 17, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00099606||199445|
NCT00099619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWAO|Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy|Efficacy of Exenatide Compared With Insulin Glargine in Patients With Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy||AstraZeneca|No|Completed|September 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|30 Years|N/A|No|||January 2015|February 20, 2015|December 17, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099619||199444|
NCT00100230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2543|DHA and X-Linked Retinitis Pigmentosa|Investigation of Effectiveness and Safety of High Dose Docosahexaenoic Acid (DHA) in X-Linked Retinitis Pigmentosa||Retina Foundation of the Southwest|Yes|Completed|September 2004|August 2014|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|78|||Male|7 Years|32 Years|No|||March 2015|March 4, 2015|December 27, 2004|Yes|Yes||No|August 25, 2014|https://clinicaltrials.gov/show/NCT00100230||199398|A lower than expected event rate for the primary outcome measure was the major trial limitation.
NCT00100243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149-04-01|Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy|Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy||PRAECIS Pharmaceuticals Inc.||Completed|May 2004|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Male|18 Years|N/A|No|||September 2006|September 18, 2006|December 27, 2004||||||https://clinicaltrials.gov/show/NCT00100243||199397|
NCT00075374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSMC1503|Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Multicenter, Randomized Phase II Study of Two Schedules of Taxotere (Weekly Versus Every 3 Weeks) in Elderly or Poor Performance (ECOG PS 2), Chemotherapy-Naive Patients With Advanced Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|October 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075374||201148|
NCT00077051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20020154|Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)|Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With a Fixed Dose of Cisplatin Comcomitant With Definitive Radiation in Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity and Oropharynx||University of Miami Sylvester Comprehensive Cancer Center||Completed|April 2004|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|21 Years|N/A|No|||August 2013|July 25, 2014|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077051||201031|
NCT00076076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-023|The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)|The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 Mcg and 500 Mcg Versus Placebo in Patients With Asthma||Takeda||Completed|December 2003|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||822|||Both|18 Years|N/A|No|||January 2012|May 4, 2012|January 13, 2004||||No||https://clinicaltrials.gov/show/NCT00076076||201096|
NCT00075868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0315|Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer|A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer||Radiation Therapy Oncology Group|Yes|Completed|December 2003|||August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|233|||Both|18 Years|120 Years|No|||November 2015|November 14, 2015|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075868||201112|
NCT00111202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLC1012005|Schizophrenia and Genetic Counseling|Schizophrenia and Genetic Counseling: A Survey of People With Schizophrenia and Their Relatives||Sarah Lawrence College||Active, not recruiting|May 2005|June 2006||||Phase 1|Observational|Time Perspective: Cross-Sectional||||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2005|September 28, 2005|May 17, 2005||||No||https://clinicaltrials.gov/show/NCT00111202||198596|
NCT00111514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LMVTC-102|Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine in Combination With Pentavalent Antimony in Treatment of Mucosal Leishmaniasis||IDRI||Completed|July 2004|May 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|60 Years|No|||February 2007|February 13, 2007|May 20, 2005||||||https://clinicaltrials.gov/show/NCT00111514||198572|
NCT00112138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-19|Gabapentin for the Treatment of Hot Flashes in Menopausal Women|Effectiveness and Safety of Gabapentin for the Treatment of Hot Flashes in Menopausal Women: A Randomized Controlled Trial||North Toronto Primary Care Research Network||Completed|March 2004|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 20, 2011|May 27, 2005||||No||https://clinicaltrials.gov/show/NCT00112138||198524|
NCT00101634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003562|Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|518|||Both|18 Years|N/A|No|||January 2011|June 6, 2011|January 12, 2005||||||https://clinicaltrials.gov/show/NCT00101634||199296|
NCT00101647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-005|Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia|A Phase II Study of BMS-354825 in Subjects With Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate||Bristol-Myers Squibb|No|Completed|December 2004|March 2008|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|197|||Both|18 Years|N/A|No|||April 2011|April 13, 2011|January 12, 2005|Yes|Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00101647||199295|
NCT00101959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25277|Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects|An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-ß-1a 30 Mcg qw IM (Avonex®) or Glatiramer Acetate 20 mg qd SC (Copaxone®) to Those Randomized to IFN-ß-1a 44 Mcg Tiw SC (Rebif®), in a Multicenter Study of Subjects With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy||EMD Serono||Withdrawn|November 2004|||||Phase 4|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|60 Years|No|||August 2013|August 4, 2013|January 18, 2005||||||https://clinicaltrials.gov/show/NCT00101959||199271|
NCT00097851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR88202|Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)|Phase II Trial of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer||Progen Pharmaceuticals||Completed|February 2004|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|November 30, 2004||||||https://clinicaltrials.gov/show/NCT00097851||199567|
NCT00097877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-2191|Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes|Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Combination With Metformin in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|January 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|293|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|November 30, 2004||||No||https://clinicaltrials.gov/show/NCT00097877||199566|
NCT00102388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2310|Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|January 2005|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1092|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|January 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102388||199238|
NCT00098670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02812|Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Administered Subcutaneously as Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|October 2004|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||December 2012|May 6, 2014|December 7, 2004|Yes|Yes||No|November 5, 2012|https://clinicaltrials.gov/show/NCT00098670||199511|
NCT00098605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02934|Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases|A Phase 2 Study of GW572016 for Brain Metastases in Patients With HER2-Positive Breast Cancer||National Cancer Institute (NCI)||Completed|October 2004|||September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098605||199514|
NCT00097890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050046|Replagal Enzyme Replacement Therapy for Adults With Fabry Disease|An Open Label Six-Month Maintenance Clinical Trial of Replagal Enzyme Replacement Therapy in Patients With Fabry Disease Who Have Completed TKT027||National Institutes of Health Clinical Center (CC)||Completed|November 2004|December 2005||||Phase 4|Interventional|Primary Purpose: Treatment||||25|||Male|N/A|N/A|No|||December 2005|March 3, 2008|November 30, 2004||||No||https://clinicaltrials.gov/show/NCT00097890||199565|
NCT00107601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-003914-40|Glucontrol Study: Comparing the Effects of Two Glucose Control Regimens by Insulin in Intensive Care Unit Patients|A Multi-Center Study Comparing the Effects of Two Glucose Control Regimens by Insulin in Intensive Care Unit Patients||University Hospital of Liege||Completed|October 2004|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||3500|||Both|18 Years|N/A|No|||February 2006|June 26, 2008|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107601||198861|
NCT00099593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-002545-01|Immunization Against Tumor Cells in Sezary Syndrome|Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells||FDA Office of Orphan Products Development||Completed|September 2004|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|17|||Both|18 Years|N/A|No|||December 2006|March 24, 2015|December 17, 2004||||No||https://clinicaltrials.gov/show/NCT00099593||199446|
NCT00099879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA165-020|Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer|A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer||Bristol-Myers Squibb||Terminated||||March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2007|February 27, 2010|December 21, 2004||||||https://clinicaltrials.gov/show/NCT00099879||199424|
NCT00099892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2303|Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes||Novartis||Completed|May 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|544|||Both|18 Years|78 Years|No|||May 2012|May 1, 2012|December 21, 2004||||No||https://clinicaltrials.gov/show/NCT00099892||199423|
NCT00099905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2301|A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes|A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes||Novartis||Completed|April 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|639|||Both|18 Years|80 Years|No|||May 2012|May 1, 2012|December 21, 2004||||||https://clinicaltrials.gov/show/NCT00099905||199422|
NCT00099918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2327|Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|May 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|717|||Both|18 Years|80 Years|No|||May 2012|May 4, 2012|December 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099918||199421|
NCT00101101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13840|Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma|A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|July 2004|October 2016|Anticipated|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 7, 2005|Yes|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT00101101||199334|With a median follow-up of 67 months, the median overall survival (OS) has not yet been reached.
NCT00101114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03061|Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination With Interferon-Alpha 2B in Patients With Advanced Renal Cancer||National Cancer Institute (NCI)||Completed|September 2004|||May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||February 2013|February 27, 2013|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101114||199333|
NCT00110370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9057|Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes|A Comparison of Prandial Insulin Lispro Mixtures Therapy to Glargine Basal-Bolus Therapy With Insulin Lispro on the Overall Glycemic Control of Patients With Type 2 Diabetes Previously Treated With Oral Agents Combined With Insulin Glargine||Eli Lilly and Company||Completed|April 2004|April 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|30 Years|75 Years|No|||November 2007|November 26, 2007|May 6, 2005||||||https://clinicaltrials.gov/show/NCT00110370||198659|
NCT00110383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174|Comparison of School-Based Supervised Versus Parental Supervised Asthma Therapy|Effectiveness of School Based Supervised Asthma Therapy||University of Alabama at Birmingham|Yes|Completed|May 2004|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|295|||Both|6 Years|12 Years|No|||December 2007|March 2, 2014|May 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110383||198658|
NCT00076089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-111|OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)|Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 Mcg Roflumilast Once Daily Versus Placebo.||Takeda||Completed|December 2003|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1100|||Both|40 Years|N/A|No|||January 2012|May 4, 2012|January 13, 2004||||No||https://clinicaltrials.gov/show/NCT00076089||201095|
NCT00076102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040080|Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas|Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2004|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|3 Years|21 Years|No|||March 2013|March 11, 2013|January 13, 2004||No||No|January 4, 2012|https://clinicaltrials.gov/show/NCT00076102||201094|
NCT00110903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020378|Treatment for Subjects With Active Rheumatoid Arthritis (RA)|Open-Label Study to Assess the Safety of Etanercept Liquid Administered Once Weekly in Subjects With Active Rheumatoid Arthritis (RA)||Amgen||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 24, 2013|May 16, 2005||||||https://clinicaltrials.gov/show/NCT00110903||198618|
NCT00111839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 72000-031|Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer|Randomized, Phase II,Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine||EMD Serono|No|Completed|May 2005|March 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|May 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111839||198547|
NCT00107653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18179|Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.|An Open-label Study of PEGASYS Plus Ribavirin on Sustained Virological Response in Treatment-naïve Latino White Patients Compared With Non-Latino Caucasian Patients With Chronic Hepatitis C, Genotype 1||Hoffmann-La Roche||Completed|August 2004|February 2008|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|569|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|April 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107653||198857|
NCT00107965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-001|Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses|A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Actinic Keratoses||Peplin||Completed|March 2005|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8|||60|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|April 11, 2005||||No||https://clinicaltrials.gov/show/NCT00107965||198833|
NCT00108329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-005-00F|Weight Loss in Diabetic, Older Obese Adults|5449 Genetics, Weight Loss and Glucose Metabolism in Older Obese Men||VA Office of Research and Development||Completed|April 2003|March 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2007|January 20, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108329||198805|
NCT00097604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26241-D|Effects of Valerian on Sleep in Healthy Older Adults|Valerian for Sleep Disturbance in Healthy Older Adults||University of Washington|Yes|Completed|September 2004|April 2008|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||December 2009|July 28, 2010|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097604||199586|
NCT00097903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN22208|Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer|Phase 1 Trial of Oral Karenitecin® in Patients With Solid Tumors"||BioNumerik Pharmaceuticals, Inc.|No|Completed|May 2004|May 2013|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|December 1, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00097903||199564|
NCT00101972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415581|RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma|A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma||MacroGenics|No|Completed|December 2004|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|January 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101972||199270|
NCT00098969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000396464|UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants|Phase I Single-Dose Safety and Phamacokinetics Clinical Study of Resveratrol AKA IRB 2003-424|IRB 2004-535|National Cancer Institute (NCI)||Completed|September 2004|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Prevention|||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2010|December 13, 2012|December 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00098969||199491|
NCT00102661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-424|Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia|Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|October 2002|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|January 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102661||199217|
NCT00099632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5207|Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy|Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2006|November 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|484|||Female|13 Years|N/A|No|||December 2015|December 29, 2015|December 17, 2004|Yes|Yes||No|December 6, 2011|https://clinicaltrials.gov/show/NCT00099632||199443|
NCT00099294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-302|Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer|A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine||Threshold Pharmaceuticals||Completed|September 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|December 10, 2004||||||https://clinicaltrials.gov/show/NCT00099294||199468|
NCT00099307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050039|Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis|An Exploratory Study on Detection of Cortical Damage in Patients With Multiple Sclerosis Using Magnetic Resonance Imaging||National Institutes of Health Clinical Center (CC)||Completed|December 2004|September 2011||||N/A|Observational|N/A|||Actual|94|||Both|18 Years|85 Years|No|||September 2011|September 29, 2011|December 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00099307||199467|
NCT00098306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001027|Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.|MOTIVATE 1|ViiV Healthcare|Yes|Completed|November 2004|April 2011|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|601|||Both|16 Years|N/A|No|||April 2012|April 2, 2012|December 6, 2004|Yes|Yes||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00098306||199534|
NCT00098956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03092|7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer|A Phase II Study of UCN-01 in Combination With Topotecan in Patients With SCLC Who Relapsed or Progressed &gt;= 3 Months After Completing First-Line Platinum-Based Chemotherapy||National Cancer Institute (NCI)||Completed|January 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2013|August 10, 2015|December 8, 2004|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT00098956||199492|
NCT00099320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWAP|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin||AstraZeneca|No|Completed|May 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|21 Years|75 Years|No|||January 2015|February 20, 2015|December 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099320||199466|
NCT00099333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWAK|Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents|An Exploratory Study of the Safety of Substituting Exenatide for Insulin in Patients With Type 2 Diabetes Who Have Been Using Insulin in Combination With Oral Antidiabetic Therapy||AstraZeneca|No|Completed|February 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|35 Years|70 Years|No|||January 2015|February 20, 2015|December 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099333||199465|
NCT00100841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03006|Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer|Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer||National Cancer Institute (NCI)|Yes|Completed|November 2004|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||July 2013|June 26, 2015|January 6, 2005|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT00100841||199352|
NCT00110669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC0601|High-dose Prednisone in Duchenne Muscular Dystrophy|A Randomized Study of Daily vs. High-dose Weekly Prednisone Therapy in Duchenne Muscular Dystrophy||Cooperative International Neuromuscular Research Group|Yes|Completed|January 2004|February 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|64|||Male|4 Years|10 Years|No|||October 2011|October 26, 2011|May 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110669||198636|
NCT00110994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11715|Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma|Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Dacarbazine (DTIC) Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma||Bayer|Yes|Completed|April 2005|March 2008|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|May 16, 2005|Yes|Yes||No|January 26, 2011|https://clinicaltrials.gov/show/NCT00110994||198611|
NCT00110643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 494|Infrared Non-Cutting Laser Therapy for Acne|CoolTouch Non-ablative Laser Therapy for Acne Vulgaris||University of Michigan|No|Completed|February 2003|December 2005||||Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|13 Years|N/A|No|||April 2015|April 30, 2015|May 11, 2005||||No||https://clinicaltrials.gov/show/NCT00110643||198638|
NCT00075608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000347379|Second Autologous Stem Cell Transplant in Treating Patients With Persistent or Recurrent Primary Systemic (AL) Amyloidosis|Phase II Trial of Second Autologous Transplantation in AL Amyloidosis||Boston Medical Center|Yes|Completed|August 2001|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||December 2011|December 9, 2011|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075608||201131|
NCT00110630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15774-2|Smoking Treatment of Prisoners|Smoking Treatment of Prisoners: Project "STOP"|STOP|National Institute on Drug Abuse (NIDA)|Yes|Completed|June 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 29, 2008|May 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00110630||198639|
NCT00111527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1893A|APAF: Assessment of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation|An Assessment of the Echo-guided Optimal Cardiac Resynchronization Therapy in Patients Undergoing 'Ablate And Pace' Therapy for Permanent Atrial Fibrillation||Arcispedale Santa Maria Nuova-IRCCS|No|Completed|May 2005|March 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|458|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|May 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00111527||198571|
NCT00075673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICC3102|Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer|A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer||Case Comprehensive Cancer Center|Yes|Terminated|November 2003|February 2005|Actual|September 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||July 2011|July 21, 2011|January 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00075673||201126|
NCT00075686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000347414|S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer|A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer||Southwest Oncology Group|Yes|Completed|January 2004|April 2009|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|766|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075686||201125|
NCT00108667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050139|Talampanel to Treat Parkinson's Disease|AMPA Receptor Antagonist Treatment of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2005|February 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||February 2006|March 3, 2008|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108667||198781|
NCT00108680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050142|Effects of Two Different Kinds of Exercise on Stroke Rehabilitation|Effects of Unilateral and Bilateral Training on Motor Function in Chronic Stroke||National Institutes of Health Clinical Center (CC)||Completed|April 2005|January 2011||||N/A|Observational|N/A|||Actual|24|||Both|18 Years|N/A|No|||January 2011|September 26, 2015|April 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00108680||198780|
NCT00097942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-29|Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms||Forest Laboratories||Completed|August 2004|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|138|||Both|18 Years|65 Years|No|||March 2012|March 1, 2012|December 1, 2004||||||https://clinicaltrials.gov/show/NCT00097942||199561|
NCT00108290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-003-02F|Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer|Chemohormone Therapy Prior to Prostatectomy in High Risk Prostate Cancer||VA Office of Research and Development||Completed|April 2004|March 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|80 Years|No|||April 2007|April 2, 2008|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108290||198808|
NCT00097916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-23|An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimer's Disease||Forest Laboratories||Completed|September 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|34|||Both|50 Years|N/A|No|||March 2012|March 1, 2012|December 1, 2004||||||https://clinicaltrials.gov/show/NCT00097916||199563|
NCT00098631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02636|Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN)||National Cancer Institute (NCI)||Completed|October 2004|||December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|December 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00098631||199512|
NCT00099346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-001|MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)|A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors||Merck Sharp & Dohme Corp.||Terminated|January 2005|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2015|June 16, 2015|December 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00099346||199464|
NCT00098683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML0121|Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes|A Phase II Study Of Amifostine In Children With Myelodysplastic Syndrome||Children's Oncology Group|Yes|Completed|January 2005|October 2009|Actual|October 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|1 Year|21 Years|No|||February 2014|February 11, 2014|December 7, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00098683||199510|
NCT00098618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02638|Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer|A Phase 2 Study Of BAY 43-9006 In Combination With Interferon Alfa-2b In Metastatic Renal Cell Cancer||National Cancer Institute (NCI)||Terminated|October 2004|||January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098618||199513|
NCT00100269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCHDW002|Menevit Study: Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility|A Randomized Control Trial of the Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility||Repromed||Completed|December 2004|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2005|May 1, 2006|December 27, 2004||||No||https://clinicaltrials.gov/show/NCT00100269||199395|
NCT00100568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA-SN-001|Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal|A Pilot Study of Safety, Effectiveness, and Adherence of Lamivudine/Zidovudine and Efavirenz (3TC/ZDV + EFV) to Treat HIV-1 Infection in Senegal||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|January 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00100568||199372|
NCT00110422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV131-186|Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome|Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome||Bristol-Myers Squibb||Completed|November 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||400|||Both|18 Years|N/A|No|||June 2010|April 7, 2011|May 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110422||198655|
NCT00110435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-077|A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)|A Multicenter, Randomized, Double-blind, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|May 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1229|||Both|18 Years|79 Years|No|||October 2015|October 30, 2015|May 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110435||198654|
NCT00111007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11718|A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma|Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.||Bayer|Yes|Completed|May 2005|January 2009|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|May 16, 2005|Yes|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00111007||198610|Metastatic melanoma is notorious for its resistance to chemotherapy. Thus, it is unlikely that inhibition of a single factor or pathway would produce a sustained clinical effect in patients with previously treated, highly refractory disease.
NCT00110890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030187|A Research Study for Patients With End-Stage Renal Disease (ESRD)|An Open-Label, Randomised Study Using Cinacalcet to Improve Achievement of Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With ESRD||Amgen||Completed|May 2004|September 2007|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|552|||Both|18 Years|N/A|No|||February 2011|February 11, 2011|May 16, 2005||||No|October 15, 2010|https://clinicaltrials.gov/show/NCT00110890||198619|
NCT00110916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040100|Treatment for Patients With Osteoarthritis (OA) of the Knee|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Intra-Articular metHuIL-1ra (Anakinra) in Subjects With Osteoarthritis (OA) of the Knee||Amgen||Completed|June 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|N/A|No|||February 2008|February 20, 2008|May 16, 2005||||No||https://clinicaltrials.gov/show/NCT00110916||198617|
NCT00110929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020158|Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)|A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)||Amgen||Completed|November 2002|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||850|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|May 16, 2005||||||https://clinicaltrials.gov/show/NCT00110929||198616|
NCT00107367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378144|Radiation Therapy in Treating Patients Who Are Undergoing Surgery to Remove a Metastatic Brain Tumor|A Phase I/II Study Utilizing the Zeiss INTRABEAM System for the Treatment of a Resected Solitary Brain Metastasis||National Cancer Institute (NCI)||Recruiting|April 2004|||April 2010|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||July 2009|January 9, 2014|April 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107367||198878|
NCT00075699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS-MRC-MS01|Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma|A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Completed|September 2003|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|840|||Both|18 Years|N/A|No|||June 2008|August 6, 2013|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075699||201124|
NCT00081315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP079|Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer|Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) Versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer||MedImmune LLC||Completed|November 2003|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||130|||Both|18 Years|N/A|No|||August 2007|August 20, 2007|April 7, 2004||||||https://clinicaltrials.gov/show/NCT00081315||200736|
NCT00081328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND - DK61230-TODAY|Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)|Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial|TODAY|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|May 2004|February 2014|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|699|||Both|10 Years|17 Years|No|||December 2014|December 8, 2014|April 8, 2004|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00081328||200735|
NCT00077415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRG-LUN012|3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer|A Randomized Phase II Study Of Triapine® Alone Versus Triapine and Gemcitabine As Second-Line Treatment Of Advanced Non-Small-Cell-Lung Cancer In Patients Who Had Prior Gemcitabine With Evaluation Of The Effect Of Triapine® On Gemcitabine Pharmacokinetics and Cellular Uptake In Peripheral Mononuclear Cells||National Cancer Institute (NCI)||Completed|April 2004|February 2008|Actual|January 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|31|||Both|18 Years|N/A|No|||August 2006|May 14, 2013|February 10, 2004||||||https://clinicaltrials.gov/show/NCT00077415||201004|
NCT00078195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN019AD|Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies|Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2003|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4|||168|||Both|18 Years|50 Years|No|||June 2014|June 4, 2014|February 19, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078195||200949|
NCT00078208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040126|Exhaled Breath Condensate as a Measure of Airway Inflammation in Children With Asthma|Exhaled Breath Condensate as a Measurement of Airway Inflammation in Children With Asthma||National Institutes of Health Clinical Center (CC)||Completed|February 2004|August 2010||||N/A|Observational|N/A|||Actual|128|||Both|5 Years|17 Years|No|||August 2010|August 20, 2010|February 19, 2004||No||No||https://clinicaltrials.gov/show/NCT00078208||200948|
NCT00078234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL217|Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia|A Pilot Study of Genasense® (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia||Genta Incorporated||Completed|November 2003|September 2010|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2009|November 4, 2011|February 20, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078234||200946|
NCT00078546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14214|EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)|Administration of EBV-Specific Cytotoxic T Lymphocytes Following CD45 Antibody to Patients With EBV Positive Nasopharyngeal Carcinoma|CLANC|Baylor College of Medicine|Yes|Completed|September 2003|April 2007|Actual|January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||July 2012|July 27, 2012|March 1, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078546||200923|
NCT00079443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00043|FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma|A Phase II Study of Single Agent Depsipeptide (NSC 630176) Followed by a Phase I Study of Rituximab/Fludarabine Combination With an Escalating Dose of Depsipeptide in Relapsed or Refractory Low Grade B Cell Lymphomas||National Cancer Institute (NCI)||Terminated|January 2004|||September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079443||200863|
NCT00079755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG030-0003|Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma|A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma||Seattle Genetics, Inc.||Completed|February 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|March 12, 2004||||||https://clinicaltrials.gov/show/NCT00079755||200839|
NCT00079768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040133|Alemtuzumab to Treat Sporadic Inclusion Body Myositis|Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study||National Institutes of Health Clinical Center (CC)||Completed|March 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1|||20|||Both|25 Years|80 Years|No|||January 2009|June 16, 2010|March 12, 2004||No||No||https://clinicaltrials.gov/show/NCT00079768||200838|
NCT00080080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH-302|Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer|Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer||Point Therapeutics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|June 7, 2007|March 23, 2004||||||https://clinicaltrials.gov/show/NCT00080080||200814|
NCT00080093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI041323|Increasing Condom Use in People at Risk for HIV Infection|Increasing Condom Use With a Stage-Matched Intervention||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|January 2006|December 2008|Anticipated|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|534|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||September 2008|September 25, 2008|March 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00080093||200813|
NCT00079430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00620|Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma||National Cancer Institute (NCI)||Completed|June 2004|||May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079430||200864|
NCT00111241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/949|Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors|Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls||Monash University||Active, not recruiting|May 2005|December 2010|Anticipated|May 2010|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|170|||Female|40 Years|65 Years|No|Non-Probability Sample|Participants will be informed of study by their treating physician and invited to        participate and by community sample.|September 2009|September 17, 2009|May 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00111241||198593|
NCT00111254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 486|The Effects of Microdermabrasion on Skin Remodeling|The Effects of Microdermabrasion on Collagen and Elastin Biosynthesis||University of Michigan|No|Completed|June 2002|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|May 20, 2015|May 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00111254||198592|
NCT00111865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 Courneya|Healthy Exercise for Lymphoma Patients (HELP)|Randomized Controlled Trial of Exercise in Lymphoma Patients|HELP|Lance Armstrong Foundation|No|Active, not recruiting|April 2005|April 2009|Anticipated|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|122|||Both|18 Years|N/A|No|||August 2008|August 22, 2008|May 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00111865||198545|
NCT00111878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP119|Study to Evaluate MEDI-534 in Healthy Adults|Dose-Escalating Study to Evaluate MEDI-534 in Healthy Adults||MedImmune LLC||Completed|April 2005|December 2005||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||120|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2007|July 2, 2007|May 26, 2005||||||https://clinicaltrials.gov/show/NCT00111878||198544|
NCT00111891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-032|An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)|A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects||Merck Sharp & Dohme Corp.||Completed|June 2005|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|575|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|May 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00111891||198543|
NCT00108030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC 301974|PBWST (Partial Body-Weight Supported Treadmill Training) and Muscle Power Training After Sub-acute Stroke|A RCT of Power Training and Treadmill Training to Improve Walking Ability in Sub-acute Stroke Patients||University of Sydney||Completed|March 2004|December 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|102|||Both|45 Years|80 Years|No|||December 2015|December 2, 2015|April 12, 2005||||No||https://clinicaltrials.gov/show/NCT00108030||198828|
NCT00107692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC Project Grant 354101|Can a Physical Activity Skill Development and Parent-Centered Dietary Intervention Help Combat Child Obesity?|Effect of a Weight Management Program for Overweight and Obese Children: a Randomized Controlled Trial||University of Wollongong||Active, not recruiting|March 2005|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||216|||Both|66 Months|9 Years|Accepts Healthy Volunteers|||September 2006|September 11, 2006|April 6, 2005||||No||https://clinicaltrials.gov/show/NCT00107692||198854|
NCT00107705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TreeMATAMPL101|Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing|A Single-blind Phase I Study to Assess the Residual Allergenicity of Tree (Birch, Hazel and Alder) Pollen Allergoid Using Skin Prick Testing||Allergy Therapeutics||Completed|April 2005|May 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||12|||Both|18 Years|50 Years|No|||June 2010|June 16, 2010|April 7, 2005||||No||https://clinicaltrials.gov/show/NCT00107705||198853|
NCT00107991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802687|Etanercept for Treatment of Hidradenitis|A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa||University of Pennsylvania|No|Completed|April 2005|November 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|April 11, 2005||No||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00107991||198831|This study did not have a control group, and therefore, it is possible that observed benefits could be as a result of natural remission or a placebo effect.
NCT00108316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-003-02S|Determinants in Antidepressant Outcomes|SERT Affinity Determinants in Antidepressant Outcomes||VA Office of Research and Development||Withdrawn|January 2004|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|April 14, 2005||No|Study PI resigned|No||https://clinicaltrials.gov/show/NCT00108316||198806|
NCT00080756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02164|Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease|Biomarkers, Breast Density And Risk Reduction Perspectives In BRCA Carriers||City of Hope Medical Center|No|Active, not recruiting|February 2004|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|11|||Female|21 Years|48 Years|No|||June 2015|June 29, 2015|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080756||200770|
NCT00081731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161|Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions|Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)|CORAL|Harvard Clinical Research Institute|Yes|Completed|April 2004|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|947|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|April 19, 2004|Yes|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00081731||200707|Patients could be enrolled in the trial with renal artery stenosis > = 60%. Didn't include patients with fibromuscular dysplasia. Some screened and deemed to be eligible were not enrolled because of physician preference.
NCT00077194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02571|FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study Of Depsipeptide, A Histone Deacetylase Inhibitor, In Relapsed Or Refractory Mantle Cell Or Diffuse Large Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|January 2004|||December 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2005|February 8, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077194||201020|
NCT00077181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02570|3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies|A Phase I Study of Triapine in Combination With High Dose Ara-C (Hi-DAC) in Patients With Advanced Hematologic Malignancies||National Cancer Institute (NCI)||Completed|January 2004|||July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077181||201021|
NCT00077805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4563H_4001|PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)|An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke||Sanofi||Completed|August 2003|||July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||January 2011|January 10, 2011|February 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077805||200979|
NCT00077818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4563B_4001|Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)|A Prospective, Open-label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome||Sanofi||Completed|June 2002|||February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||October 2009|October 14, 2009|February 12, 2004|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00077818||200978|
NCT00077831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13813|Child and Infant Learning Project|Neurobehavioral Correlates of Craniosynostosis|CILP|Seattle Children's Hospital|No|Completed|September 2001|June 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|535|||Both|2 Months|7 Years|No|Non-Probability Sample|Children with single-suture craniosynostosis between the ages of 2 months and 3 years were        recruited and followed during phase 1. This same chort of children are now being followed        at the age of 7 (phase 2). See eligibility criteria section for more information.|July 2015|July 19, 2015|February 12, 2004||No||No||https://clinicaltrials.gov/show/NCT00077831||200977|
NCT00077844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4563_4001|Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)|An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Percutaneous Coronary Intervention||Sanofi||Completed|January 2004|September 2005|Actual|September 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|3532|||Both|18 Years|N/A|No|||January 2011|January 10, 2011|February 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077844||200976|
NCT00078949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY12|Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation||Canadian Cancer Trials Group|Yes|Active, not recruiting|August 2003|January 2016|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|619|||Both|16 Years|65 Years|No|||April 2015|September 18, 2015|March 8, 2004|Yes|Yes||No|September 17, 2014|https://clinicaltrials.gov/show/NCT00078949||200899|
NCT00079170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355083|Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Pilot Study to Evaluate the Influence of Garlic on the Pharmacokinetics of Docetaxel in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|January 2004|October 2007|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2006|June 18, 2013|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079170||200882|
NCT00079183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1706.00|Sirolimus as Secondary Therapy in Treating Patients With Chronic Graft-Versus-Host Disease That Did Not Respond To Prior Treatment|A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Sirolimus for Secondary Treatment of Chronic Graft-versus-Host Disease||Fred Hutchinson Cancer Research Center|No|Completed|April 2002|||July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|44|||Both|N/A|N/A|No|||March 2012|March 13, 2012|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079183||200881|
NCT00078923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000353197|Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate|Phase II Clinical Trial of Soy Isoflavones Prior to Radical Prostatectomy||Barbara Ann Karmanos Cancer Institute|Yes|Completed|November 2001|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|32|||Male|18 Years|N/A|No|||March 2014|March 4, 2014|March 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00078923||200900|
NCT00079781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP10003|RNS® System Feasibility Study|RNS® System Feasibility Clinical Investigation||NeuroPace|Yes|Completed|January 2004|December 2007|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|65 Years|No|||December 2013|December 23, 2013|March 12, 2004|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT00079781||200837|
NCT00080392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040143|EW-A-401 to Treat Intermittent Claudication|Modulation of Vascular Endothelial Growth Factor (VEGF) Using an Engineered Zinc-Finger Transcription Factor to Treat Lower Limb Intermittent Claudication||National Institutes of Health Clinical Center (CC)||Completed|March 2004|December 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|N/A|No|||December 2011|September 26, 2015|March 30, 2004||No||No||https://clinicaltrials.gov/show/NCT00080392||200792|
NCT00111917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJ202|Beryllium Infliximab Study: Clinical Interventional Trial|Clinical Efficacy of Remicade in Chronic Beryllium Disease: A Randomized, Double-Blind, Placebo-Controlled, Investigator Initiated Trial|BISCIT|Maier, Lisa, M.D.|Yes|Terminated|February 2005|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||September 2014|September 24, 2014|May 26, 2005|No|Yes|Not enough patients meeting criteria to enroll in the time period|No|October 29, 2013|https://clinicaltrials.gov/show/NCT00111917||198541|Although our goal was 20 CBD subjects, only 11 subjects were enrolled, 8:3 in the infliximab:placebo treatment arms as the study was stopped by the sponsor due to slow recruitment.
NCT00107432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02813|Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.|A Phase II Study of BAY 43-9006 (NSC #724772) in Patients With Malignant Mesothelioma||National Cancer Institute (NCI)||Completed|October 2004|||June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|April 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107432||198874|
NCT00111904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000433513|Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer|Phase II Clinical Trial of Genexol -PM in Patients With Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|May 2005|||August 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||June 2009|December 13, 2011|May 26, 2005||||No||https://clinicaltrials.gov/show/NCT00111904||198542|
NCT00108771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMF-202|Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain|Double-Blind, Parallel, Randomized, Placebo-Controlled 12-Week Efficacy and Safety Assessment of ZR-02-01 in the Treatment of Chronic, Moderate to Severe Osteoarthritis (OA) Pain||ZARS Pharma Inc.|No|Completed|April 2004|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|40 Years|75 Years|No|||June 2012|June 4, 2012|April 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00108771||198775|
NCT00109109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-004|A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)|Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma||Merck Sharp & Dohme Corp.||Terminated|December 2003|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|April 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109109||198751|
NCT00108342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-015-07S|Nicotine Delivery Systems: Research & Treatment|Nicotine Delivery Systems: Research and Treatment|NDS|VA Office of Research and Development|No|Terminated|October 2007|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|25|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|April 14, 2005||No|Common comorbidities of Veterans precluded sufficient recruitment and enrollment.|No|December 19, 2013|https://clinicaltrials.gov/show/NCT00108342||198804|Limitations of the study: early termination of the study occurred due to widespread comorbidities precluding recruitment and enrollment of Veterans in this NRT trial. Specifically, the sample size was too small for any data analyses.
NCT00080301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-046|Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer|A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant||R-Pharm|Yes|Completed|September 2003|March 2008|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|752|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|March 26, 2004|Yes|Yes||No|May 1, 2009|https://clinicaltrials.gov/show/NCT00080301||200798|
NCT00080314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-096|Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|January 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||400|||Both|18 Years|65 Years|No|||June 2008|November 7, 2013|March 26, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080314||200797|
NCT00080327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-113 ST|Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia|A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|November 2003|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4|||370|||Both|18 Years|N/A|No|||August 2008|November 7, 2013|March 26, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080327||200796|
NCT00081653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA17903|A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva|Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549||Hoffmann-La Roche||Completed|May 2004|May 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|719|||Female|N/A|N/A|No|||August 2015|August 7, 2015|April 19, 2004|Yes|Yes||No|December 22, 2008|https://clinicaltrials.gov/show/NCT00081653||200712|
NCT00081666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246|Logical Analysis of Data and Cardiac Surgery Risk|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2004|June 2007|Actual|June 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 24, 2008|April 19, 2004||||No||https://clinicaltrials.gov/show/NCT00081666||200711|
NCT00081679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1247|SES, Health Behaviors and CVD Among Vietnam-Era Twins|||The Miriam Hospital||Completed|June 2004|May 2007|Actual|May 2007|Actual|N/A|Observational|N/A|||||||Male|45 Years|65 Years|No|||January 2008|April 15, 2014|April 19, 2004||||No||https://clinicaltrials.gov/show/NCT00081679||200710|
NCT00077428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02574|Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck|Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|June 2004|||June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077428||201003|
NCT00077441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02806|Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)|Phase II Trial of PS-341 in Patients With Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|April 2005|||June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077441||201002|
NCT00077857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO16853|A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer|A Randomized, Open-label Study of the Effect of Different Dosing Regimens of Xeloda® in Combination With Taxotere® on Disease Progression in Patients With Locally Advanced and/or Metastatic Breast Cancer||Hoffmann-La Roche||Completed|July 2003|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|470|||Female|18 Years|N/A|No|||March 2013|March 27, 2013|February 12, 2004|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00077857||200975|
NCT00078559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN013ST|Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults|Campath-1H/Tacrolimus/Sirolimus Withdrawal in Renal Transplantation (ITN013ST)||University of Wisconsin, Madison|Yes|Completed|November 2003|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||July 2012|July 25, 2012|March 1, 2004|Yes|Yes||No|April 13, 2012|https://clinicaltrials.gov/show/NCT00078559||200922|The absence of a control group in this pilot trial precludes any comparison between alemtuzumab-induced patients with further minimization and patients with more conventional immunosuppressive approaches, and is a limitation of the current study
NCT00078572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100151|Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer|A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer||GlaxoSmithKline|Yes|Completed|March 2004|February 2010|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|408|||Female|18 Years|N/A|No|||December 2010|December 9, 2010|March 1, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00078572||200921|
NCT00078585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBC-PRO-002|PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy|A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate||Therion Biologics Corporation||Active, not recruiting|November 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Male|18 Years|N/A|No|||July 2005|July 7, 2005|March 1, 2004||||||https://clinicaltrials.gov/show/NCT00078585||200920|
NCT00078962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02577|GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Pharmacokinetics and Pharmacodynamic Study of GTI2040 in Combination With Gemcitabine in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|January 2004|||November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078962||200898|
NCT00079469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903308|Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke|Contingency Management to Enhance Smoking Cessation for Cancer Survivors: A Proof of Concept Trial||National Institutes of Health Clinical Center (CC)||Completed|February 2004|August 2004|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||March 2012|March 7, 2012|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079469||200861|
NCT00080119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1041|Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV|A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Terminated|February 2004|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|1354|||Both|91 Days|120 Days|Accepts Healthy Volunteers|||February 2011|February 10, 2011|March 23, 2004|Yes|Yes|Data Safety Monitoring Board (DSMB) recommended stopping study due to futility|No|July 1, 2010|https://clinicaltrials.gov/show/NCT00080119||200811|DSMB recommended stopping study due to futility: "no compelling reason to enroll additional infants" or "to continue to treat participants with the blinded study medication". Week 192 analyses not done as <4% (26%) of HIVpos (HIVneg) reached wk 192
NCT00080860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040114|Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer|Efficacy Of Sentinel Lymph Node Biopsy And Primary Tumor Gene Expression Profiling To Detect Axillary Lymph Node Metastases After Neoadjuvant Chemotherapy For Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2004|August 2007|Actual|||N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|60|||Female|18 Years|N/A|No|||March 2012|March 7, 2012|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00080860||200764|
NCT00079729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1036A|Directly Observed Therapy in HIV Infected Adolescent Focus Groups|Directly Observed Therapy (DOT) in HIV-Infected Adolescents: Part A-Focus Groups||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2004|July 2004|Actual|||N/A|Observational|Time Perspective: Prospective||||30|||Both|16 Years|21 Years|No|||October 2012|October 26, 2012|March 11, 2004||No||No||https://clinicaltrials.gov/show/NCT00079729||200841|
NCT00079742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L2762g|A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis|A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic Fibrosis||Genentech, Inc.||Completed|September 2003|May 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|68|||Both|5 Years|13 Years|No|||June 2008|June 5, 2008|March 11, 2004||||||https://clinicaltrials.gov/show/NCT00079742||200840|
NCT00107445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02649|EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer|Evaluation of Hypoxia by EF5 Binding in Gynecologic Cancer||National Cancer Institute (NCI)||Completed|February 2005|||September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Female|18 Years|N/A|No|||January 2013|January 15, 2013|April 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107445||198873|
NCT00107718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-485232/006|Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma|A Phase II, Multi-center, Open-label, Randomized Study Evaluating the Anti-tumor Activity of SB-485232, rhIL-18, Administered as Five Daily Intravenous Infusions Every 28 Days in Subjects With Previously Untreated Metastatic Melanoma||GlaxoSmithKline||Completed|November 2004|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||64|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|April 7, 2005||||||https://clinicaltrials.gov/show/NCT00107718||198852|
NCT00107731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1447C00126|Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder|A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated)||AstraZeneca||Completed|April 2004|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||710|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|April 7, 2005||||No||https://clinicaltrials.gov/show/NCT00107731||198851|
NCT00109460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-80460-1|Tobacco Cessation Field Study for Adults in Recovery - 1|Tobacco Cessation Clinical Field Study for Adults in Alcohol Abuse Recovery||Inflexxion, Inc.|Yes|Completed|March 2003|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind|||Actual|203|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|April 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00109460||198725|
NCT00108355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-016-03F|Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis|Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis||VA Office of Research and Development|Yes|Completed|December 2003|August 2012|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||February 2014|February 3, 2014|April 14, 2005||No||No|December 11, 2013|https://clinicaltrials.gov/show/NCT00108355||198803|Difficulty to enroll patient population lead to small sample size. Midodrine not titrated for a goal increase in mean arterial pressure. Blood tests for day 6 assessment of post paracentesis circulatory dysfunction not available for all patients.
NCT00108368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-057-00S|The Effects of Risperidone and Olanzapine on Thinking|The Cognitive Effects of Risperidone and Olanzapine||VA Office of Research and Development||Completed|October 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||September 2007|January 20, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108368||198802|
NCT00081341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51337DK (completed)|Cognition, Steroids, and Imaging in Cushings Disease|Cognition, Steroids, and Imaging in Cushings Disease||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||December 2002|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|9 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 12, 2010|April 8, 2004||||No||https://clinicaltrials.gov/show/NCT00081341||200734|
NCT00081354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040155|Early Detection of Barrett's Esophagus|Barrett's Esophagus Early Detection Study||National Institutes of Health Clinical Center (CC)||Completed|April 2004|||||N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|100 Years|No|||February 2016|February 27, 2016|April 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00081354||200733|
NCT00081367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067805|Community-Based Cognitive Therapy for Suicide Attempters|Community-Based Cognitive Therapy for Suicide Attempters||University of Pennsylvania|Yes|Completed|February 2004|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|16 Years|N/A|No|||June 2014|June 9, 2014|April 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00081367||200732|
NCT00081692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1248|Longitudinal Cardiac Outcomes and Body Composition|Longitudinal Cardiac Outcomes and Body Composition||Virginia Commonwealth University|No|Completed|January 2004|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|715|None Retained|Only receiving data|Both|20 Years|70 Years|No|Probability Sample|Echocardiographic measurements were made in 437 male and 492 female adults in the Fels        Longitudinal Study who had serial measurements of body composition made and recorded as        children. The selection criteria include participants who have at least 10 serial        anthropometric visits between 2 and 20 years of age. The anthropometric measurements        include weight and height for computation of BMI and blood pressure. Approximately        one-half of the sample is 50 years and older.|August 2013|August 5, 2013|April 19, 2004||No||No||https://clinicaltrials.gov/show/NCT00081692||200709|
NCT00081991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040166|Dynamic Light Scattering for Studying Lens Aging and Cataract Formation|A Cross Sectional Clinical Study of Human Lens Aging and Cataract Formation, in Vivo, Using Dynamic Light Scattering (DLS)||National Institutes of Health Clinical Center (CC)||Completed|April 2004|April 2005||||N/A|Observational|N/A||||267|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2005|March 3, 2008|April 28, 2004||||No||https://clinicaltrials.gov/show/NCT00081991||200687|
NCT00082017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040173|UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas|Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas||National Institutes of Health Clinical Center (CC)|No|Completed|April 2004|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|N/A|No|||June 2012|July 26, 2012|April 28, 2004||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00082017||200686|
NCT00082030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040160|Function of Catecholamines in the Brain During Depression|Neural Correlates of Depressive Symptoms and Reward Related Mechanisms Following AMPT Depletion in Remitted Depressed Patients Off Treatment and Healthy Controls||National Institutes of Health Clinical Center (CC)||Completed|April 2004|November 2011||||N/A|Observational|N/A|||Actual|71|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|December 1, 2011|April 28, 2004||No||No||https://clinicaltrials.gov/show/NCT00082030||200685|
NCT00077207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0223|Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma|A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas||Children's Oncology Group|Yes|Completed|July 2004|December 2013|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|N/A|10 Years|No|||June 2014|June 30, 2014|February 10, 2004|No|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00077207||201019|
NCT00078247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI051219-01A2|Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis|Delaying HIV Disease Progression With Punctuated Antiretroviral Therapy in HIV-Associated Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|13 Years|60 Years|No|||August 2010|August 10, 2010|February 20, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078247||200945|
NCT00077870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT2847g|A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis|A Randomized, Placebo-Controlled, Multicenter, Blinded Phase I/II Study of the Safety of Escalating Doses of Ocrelizumab (PRO70769) in Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate||Genentech, Inc.||Completed|February 2004|December 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||237|||Both|18 Years|80 Years|No|||September 2009|September 1, 2009|February 12, 2004||||No||https://clinicaltrials.gov/show/NCT00077870||200974|
NCT00078260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8433|A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer|A Randomized Phase 3 Study of Two Doses of Alimta in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy||Eli Lilly and Company|Yes|Completed|December 2003|April 2008|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|589|||Both|18 Years|N/A|No|||March 2009|March 23, 2009|February 20, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00078260||200944|
NCT00079794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001020-01|Iscar for Supplemental Care in Stage IV Lung Cancer|Iscar for Supplemental Care in Stage IV Lung Cancer||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2001|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|March 15, 2004||||||https://clinicaltrials.gov/show/NCT00079794||200836|
NCT00080106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5197|Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients|A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Antiretroviral Effect of Immunization With the MRK Ad5 HIV-1 Gag Vaccine in HIV-1 Infected Individuals Who Interrupt Antiretroviral Therapy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2004|May 2011|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|55 Years|No|||July 2013|July 1, 2013|March 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080106||200812|
NCT00079482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C701a/204/ON/US|Study of CEP-701 in Patients With Acute Myeloid Leukemia (AML)|A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations||Teva Pharmaceutical Industries||Completed|October 2003|January 2010|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00079482||200860|
NCT00080158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4623|Treatment of Adolescent Suicide Attempters (TASA)|||New York State Psychiatric Institute||Completed|March 2004|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|12 Years|18 Years|No|||July 2008|November 1, 2013|March 24, 2004||||No||https://clinicaltrials.gov/show/NCT00080158||200808|
NCT00080522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U19AI053217-02|Strategies for Delivering Anti-HIV Therapy in South Africa|Safeguard the Household: A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2005|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||813|||Both|3 Years|N/A|No|||August 2007|September 17, 2007|April 6, 2004||||No||https://clinicaltrials.gov/show/NCT00080522||200782|
NCT00080535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040142|Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas|A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas||National Institutes of Health Clinical Center (CC)|Yes|Completed|April 2004|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|April 7, 2004|Yes|Yes||No|September 24, 2012|https://clinicaltrials.gov/show/NCT00080535||200781|
NCT00080548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040151|Timing of Voluntary Movement in Patients With Schizophrenia|Timing of Voluntary Movement in Patients With Schizophrenia Using EEG and Surface EMG||National Institutes of Health Clinical Center (CC)||Completed|April 2004|January 2009||||N/A|Observational|N/A||||42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 7, 2009|April 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00080548||200780|
NCT00081159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0922|Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases|A Randomized Phase II Study Of Bone-Targeted Therapy In Advanced Androgen-Dependent Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|July 2004|||September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Male|N/A|N/A|No|||September 2014|September 10, 2014|April 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00081159||200746|
NCT00080418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEP-ETU-101-R03|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer|Phase I Study of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation in Patients With Advanced Cancer||INSYS Therapeutics Inc||Completed|July 2003|June 2010|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|March 30, 2004||||||https://clinicaltrials.gov/show/NCT00080418||200790|
NCT00080431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040149|Daclizumab to Treat HIV-Infected Patients|An Open Label Trial to Assess Safety and Tolerability of Daclizumab in HIV-Infected Individuals||National Institutes of Health Clinical Center (CC)||Completed|March 2004|December 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||December 2007|December 29, 2007|March 30, 2004||||No||https://clinicaltrials.gov/show/NCT00080431||200789|
NCT00108043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC 302013|Orthostatic Tolerance During FES (Functional Electrical Stimulation)-Walking in Paraplegia|Orthostatic Tolerance During FES-evoked Stepping in Paraplegia: A Safety and Viability Study||University of Sydney||Completed|March 2004|December 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Male|18 Years|55 Years|No|||December 2015|December 2, 2015|April 12, 2005||||No||https://clinicaltrials.gov/show/NCT00108043||198827|
NCT00108056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050136|Enzastaurin to Treat Recurrent Brain Tumor|A Phase I Trial of Enzastaurin (LY317615) in Patients With Recurrent Gliomas||National Institutes of Health Clinical Center (CC)||Terminated|April 2005|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||April 2014|December 16, 2015|April 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00108056||198826|
NCT00108069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050137|Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors|A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas||National Institutes of Health Clinical Center (CC)|No|Completed|April 2005|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|April 12, 2005|Yes|Yes||No|March 6, 2014|https://clinicaltrials.gov/show/NCT00108069||198825|
NCT00107744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No Id|Clinical Trial of Protein and Blood Pressure|Clinical Trial of Protein and Blood Pressure||Tulane University Health Sciences Center||Completed|January 2000|January 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2005|June 23, 2005|April 7, 2005||||No||https://clinicaltrials.gov/show/NCT00107744||198850|
NCT00109174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050144|MRS Measurement of Glutamate and GABA Metabolism in Brain|MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain||National Institutes of Health Clinical Center (CC)||Recruiting|April 2005|January 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|April 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00109174||198746|
NCT00109733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25253|Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency|A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS)||EMD Serono||Completed|January 2005|July 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|13 Years|25 Years|No|||August 2013|August 4, 2013|May 2, 2005|No|Yes||No|May 19, 2010|https://clinicaltrials.gov/show/NCT00109733||198705|
NCT00109122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-007|Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)|A Double-Blind, Placebo-Controled, Randomized Study to Evaluate Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine||Merck Sharp & Dohme Corp.||Completed|November 2001|July 2006|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|180|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|April 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109122||198750|
NCT00109434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 005|Study to Determine the Relationship Between Exercise and Hypoglycemia in Children With Type 1 Diabetes|The Effect of Exercise on the Development of Hypoglycemia in Children With Type 1 Diabetes; A Study Being Conducted by the Diabetes Research in Children Network||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|June 2004|November 2004||||N/A|Observational|Time Perspective: Prospective||||50|||Both|10 Years|17 Years|No|||September 2005|January 10, 2008|April 27, 2005||||No||https://clinicaltrials.gov/show/NCT00109434||198726|
NCT00081003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000358797|Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer|The Intraduct Environment: A Novel Approach to Risk Assessment of Women With a Family History of Breast Cancer||National Cancer Institute (NCI)||Completed|November 2003|||||N/A|Interventional|Primary Purpose: Screening|||Anticipated|1000|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||December 2005|July 22, 2014|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081003||200754|
NCT00081757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 98-023|An Open Protocol for the Compassionate Use of Thalidomide|An Open Protocol For The Compassionate Use of Thalidomide For Patients With Advanced Or Refractory Malignancies||University of Arkansas||Completed|September 1998|May 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|April 19, 2004||||||https://clinicaltrials.gov/show/NCT00081757||200705|
NCT00082043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040139|Dutasteride to Treat Women With Menstrually Related Mood Disorders|The Effects of Dutasteride on Mood, HPA Axis, and Serum Allopregnanolone Levels in Women With Menstrual-Related Mood Disorders and Controls||National Institutes of Health Clinical Center (CC)||Completed|March 2004|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|30 Years|50 Years|No|||February 2016|February 6, 2016|April 28, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082043||200684|
NCT00077454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01808|Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors||National Cancer Institute (NCI)||Completed|February 2004|||September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|N/A|21 Years|No|||June 2013|June 4, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077454||201001|
NCT00077883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2021|TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Cisplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Telik||Completed|February 2004|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2005|July 21, 2011|February 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077883||200973|
NCT00078975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-023|3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Recurrent/Unresectable/Metastatic Pancreatic Carcinoma||University Health Network, Toronto||Completed|April 2004|||January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00078975||200897|
NCT00079248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355122|Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer|UK Trial Of Hormone Replacement Therapy (HRT) In Women With A History Of Early Stage Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 2002|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Female|N/A|N/A|No|||June 2005|May 9, 2009|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079248||200878|
NCT00079222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355116|Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Randomized Trial Of Safety And Tolerability Of Intravenous/Oral Voriconazole Versus Intravenous/Oral Itraconazole For Long-Term Antifungal Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplant Recipients||Jonsson Comprehensive Cancer Center|Yes|Completed|November 2003|||April 2005|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||||||Both|12 Years|N/A|No|||January 2013|January 7, 2013|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00079222||200880|
NCT00079235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01810|CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|February 2004|||June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2013|July 15, 2013|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00079235||200879|
NCT00080470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-B-001|An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence|Battery Powered Bion Clinical Investigation: An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence||Boston Scientific Corporation|No|Completed|June 2003|December 2012|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|April 1, 2004|Yes|Yes||No|April 11, 2013|https://clinicaltrials.gov/show/NCT00080470||200786|This study was limited by poor adherence to the clinical protocol and by incomplete data recovery. Analysis of efficacy-related endpoints was not possible.
NCT00080483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR050618|Testosterone and Growth Hormone for Bone Loss in Men|Will Testosterone and Growth Hormone Improve Bone Structure?||University of Pennsylvania|Yes|Completed|March 2004|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Male|18 Years|N/A|No|||December 2013|June 12, 2014|April 5, 2004|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00080483||200785|
NCT00108108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHCD122A2101|Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy|An Open-label,Multi-center, Phase l/ll Study of Anti-CD40 Monoclonal Antibody (HCD122) Administered Intravenously to Subjects With Advanced Chronic Lymphocytic Leukemia That is Refractory or Relapsed After at Least One Previous Fludarabine-containing Chemotherapy Regimen||Novartis|No|Terminated|April 2005|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|April 14, 2005|Yes|Yes|Slow enrollment and minimal preliminary biological and clinical efficacy.|No||https://clinicaltrials.gov/show/NCT00108108||198822|
NCT00108784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACTORS (completed)|Factors Affecting Caloric Regulation in Human Feeding|The Effect of Decreases in Energy Density on Weight Loss and Weight Maintenance||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 2003|July 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|April 18, 2005||||No||https://clinicaltrials.gov/show/NCT00108784||198774|
NCT00108797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-2068|Trial of NovoSeven® in Haemophilia - Joint Bleeds|NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®||Novo Nordisk A/S|No|Completed|September 2001|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|42|||Male|N/A|20 Years|No|||April 2013|April 12, 2013|April 18, 2005||||No||https://clinicaltrials.gov/show/NCT00108797||198773|
NCT00108381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS042-03|Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain|Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain||VA Office of Research and Development|No|Completed|January 2004|September 2013|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|80 Years|No|||June 2014|July 1, 2014|April 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00108381||198801|
NCT00108394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-017-02S|Osteopenia and Renal Osteodystrophy: Evaluation and Management|Osteopenia and Renal Osteodystrophy: Evaluation and Management||VA Office of Research and Development||Completed|October 2002|September 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2008|January 20, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108394||198800|
NCT00110019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02978|Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma||National Cancer Institute (NCI)|Yes|Completed|June 2005|August 2012|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|823|||Both|18 Years|N/A|No|||July 2015|September 28, 2015|May 3, 2005|Yes|Yes||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00110019||198685|
NCT00109720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62323 (completed)|Evaluation of Diabetes Self-Management Consultant Care|Evaluation of Diabetes Self-Management Consultant Care||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|August 2002|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|310|||Both|21 Years|N/A|No|||January 2010|January 14, 2010|May 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00109720||198706|
NCT00081029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000358803|Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia|A Multicentre Randomised Study Of Parotid Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Head And Neck Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2004|||January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|84|||Both|N/A|N/A|No|||March 2008|March 22, 2011|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081029||200753|
NCT00077493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000352020|BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas||MedImmune LLC|No|Suspended|January 2004|October 2008|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|95|||Both|6 Months|24 Years|No|||December 2007|December 21, 2007|February 10, 2004|No|Yes|protocol development and Amended protocol revision|No||https://clinicaltrials.gov/show/NCT00077493||200999|
NCT00077467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01809|Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia|A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients With Refractory/Recurrent Leukemias||National Cancer Institute (NCI)||Completed|January 2004|||March 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|1 Year|21 Years|No|||June 2013|June 4, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077467||201000|
NCT00078988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0231|High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas|A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support||Children's Oncology Group|Yes|Completed|October 2004|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1|||Both|N/A|20 Years|No|||May 2015|May 6, 2015|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00078988||200896|
NCT00079521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20 AT000756-01P1|Therapeutic Touch for Wrist Fractures in Postmenopausal Women|The Effect of Therapeutic Touch on Bone Formation in Postmenopausal Women After Wrist Fracture||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2003|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Female|40 Years|85 Years|Accepts Healthy Volunteers|||August 2006|August 16, 2006|March 9, 2004||||No||https://clinicaltrials.gov/show/NCT00079521||200857|
NCT00079534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000485-01|Distant Healing for HIV/AIDS|Distant Healing Efforts for AIDS by Nurses and "Healers"||National Center for Complementary and Integrative Health (NCCIH)||Completed|December 2000|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years|No|||August 2006|August 16, 2006|March 9, 2004||||No||https://clinicaltrials.gov/show/NCT00079534||200856|
NCT00079820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-249-001|Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults|The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination||Sanofi|Yes|Completed|April 2004|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|110|||Both|18 Years|31 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|March 15, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079820||200834|
NCT00079833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612C00025|Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome|A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion With Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months||AstraZeneca||Completed|November 2003|July 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|March 16, 2004||||||https://clinicaltrials.gov/show/NCT00079833||200833|
NCT00080132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRL 2002-003|Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy|An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy||Medical Research Laboratories International||Terminated|October 2004|April 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|8 Years|70 Years|No|||April 2005|June 23, 2005|March 23, 2004||||||https://clinicaltrials.gov/show/NCT00080132||200810|
NCT00079274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00639|Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer|A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer||National Cancer Institute (NCI)|Yes|Completed|February 2004|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|3397|||Both|18 Years|N/A|No|||October 2014|January 23, 2015|March 8, 2004|Yes|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00079274||200876|Accrual to arms A and D terminated early based on the results of the planned 2nd interim analysis. Sample sizes limit statistical conclusions for data from the irinotecan treated patients as those treatment arms were discontinued early in the study.
NCT00079495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-5788-0201|Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis||Neurocrine Biosciences||Completed|July 2003|April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|55 Years|No|||September 2007|March 20, 2008|March 8, 2004||||||https://clinicaltrials.gov/show/NCT00079495||200859|
NCT00079508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-02-03|Angiomax in Patients With HIT/HITTS Type II Undergoing CPB|A Phase III Study of Angiomax (Bivalirudin) in Patients With HIT/HITTS Type II Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)|HIT/TS|The Medicines Company||Completed|April 2004|||October 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||November 2011|November 8, 2011|March 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079508||200858|
NCT00079807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001775|Painful HIV Neuropathy and Alpha-Lipoic Acid|Painful HIV Neuropathy: Treatment With Alpha-Lipoic Acid||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2003|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2008|April 21, 2008|March 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00079807||200835|
NCT00080886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMC-06302|Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma||University of Nebraska|Yes|Active, not recruiting|May 2002|January 2015|Anticipated|November 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|19 Years|N/A|No|||December 2013|December 13, 2013|April 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00080886||200762|
NCT00080899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02833|Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer|A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer||National Cancer Institute (NCI)||Completed|June 2004|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|N/A|N/A|No|||February 2013|February 19, 2015|April 7, 2004|No|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT00080899||200761|
NCT00109213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-SLIP-384|Greenwich Lumbar Stenosis SLIP Study|Greenwich Lumbar Stenosis SLIP Study: A Multi-center, Randomized, Prospective Clinical Trial Comparing Spinal Laminectomy to Laminectomy With Instrumented Pedicle Screw Fusion for Lumbar Stenosis With Grade I Spondylolisthesis|SLIP|Greenwich Hospital|Yes|Completed|May 2002|October 2014|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|50 Years|80 Years|No|||December 2015|December 2, 2015|April 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00109213||198743|
NCT00108420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-018-02F|Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance|Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance||VA Office of Research and Development||Completed|October 2003|March 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|January 20, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108420||198798|
NCT00109135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-007|A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)|A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation||Merck Sharp & Dohme Corp.||Completed|January 2005|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|April 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109135||198749|
NCT00109148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-006|An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)|A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients||Merck Sharp & Dohme Corp.||Completed|July 2004|February 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|500|||Both|18 Years|65 Years|No|||September 2015|September 8, 2015|April 22, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00109148||198748|
NCT00109161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC-1012|Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis|A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis||Facet Biotech||Completed|April 2005|October 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|18 Years|55 Years|No|||August 2008|August 2, 2008|April 22, 2005||||||https://clinicaltrials.gov/show/NCT00109161||198747|
NCT00110318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H/355/PHYSIO/01/NHMRC|Trial of Physiotherapy and Corticosteroid Injections in Lateral Epicondylalgia|A Pragmatic, Randomised Controlled Trial of Physiotherapy and Corticosteroid Injections in Lateral Epicondylalgia||The University of Queensland||Completed|March 2002|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||198|||Both|18 Years|65 Years|No|||December 2013|December 9, 2013|May 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00110318||198663|
NCT00110266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS03|Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients|An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring||Novartis|No|Completed|May 2005|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|176|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|May 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110266||198667|
NCT00110279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 211 (Study A)|Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)|Phase I Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study A)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 18, 2008|May 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110279||198666|
NCT00081744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-301|Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects|A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2002|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|850|||Both|8 Years|N/A|No|||February 2013|February 7, 2013|April 19, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00081744||200706|
NCT00081406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059087|Individual and Family Therapy for Children With Anxiety Disorders|Child and Family Therapy for Anxiety-Disordered Youth||Temple University||Completed|July 2000|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|9 Years|13 Years|No|||March 2005|March 5, 2014|April 9, 2004||||No||https://clinicaltrials.gov/show/NCT00081406||200730|
NCT00077220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000350015|Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer|Phase III Randomised Study Of Adjuvant Paclitaxel And Carboplatin (TAXOL-PARAPLATINE) With Concomittant Radiotherapy In Patients With Stage II or III Non-Metastatic Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2002|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|79 Years|No|||May 2007|February 6, 2009|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077220||201018|
NCT00077233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB 80203|FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum|A Phase II Trial Of Irinotecan /5-FU/ Leucovorin Or Oxaliplatin /5-FU / Leucovorin With And Without Cetuximab (C225) For Patients With Untreated Metastatic Adenocarcinoma Of The Colon or Rectum||Alliance for Clinical Trials in Oncology|No|Completed|December 2003|June 2010|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|238|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077233||201017|
NCT00078273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23848-C|Indicated Prevention With At-Risk Gamblers|Indicated Prevention With At-Risk Gamblers||University of Washington|Yes|Completed|July 2003|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|225|||Both|17 Years|24 Years|No|||December 2013|December 10, 2013|February 20, 2004||No||No||https://clinicaltrials.gov/show/NCT00078273||200943|
NCT00078598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBX001-049|A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma|A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma||Corixa Corporation||Recruiting|April 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||506|||Both|18 Years|N/A|No|||October 2004|November 8, 2005|March 1, 2004||||||https://clinicaltrials.gov/show/NCT00078598||200919|
NCT00079014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00011|3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors|A Phase I Study of Triapine® in Combination With Doxorubicin in Refractory Tumors||National Cancer Institute (NCI)||Completed|January 2004|||July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079014||200894|
NCT00079287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355138|Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|March 2001|November 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2005|September 16, 2013|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079287||200875|
NCT00080145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10MH066764|RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders|Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder||Yale University|Yes|Completed|February 2004|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|4 Years|13 Years|No|||August 2013|August 15, 2013|March 24, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00080145||200809|
NCT00080496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-311|Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||430|||Both|18 Years|70 Years|No|||July 2008|July 31, 2008|April 5, 2004||||||https://clinicaltrials.gov/show/NCT00080496||200784|
NCT00080509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOS-201/NO17352|Effectiveness of KOS-862 in the Treatment of Lung Cancer|A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease||Bristol-Myers Squibb||Terminated|December 2003|November 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||85|||Both|18 Years|N/A|No|||November 2009|February 2, 2010|April 5, 2004||||||https://clinicaltrials.gov/show/NCT00080509||200783|
NCT00086190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS046487|Study of Antidepressants in Parkinson's Disease|Study of Antidepressants in Parkinson's Disease|SAD-PD|University of Rochester|Yes|Completed|June 2005|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|115|||Both|30 Years|N/A|No|||January 2013|January 3, 2013|June 28, 2004|Yes|Yes||No|January 11, 2012|https://clinicaltrials.gov/show/NCT00086190||200402|
NCT00080873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL0331|Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation|A Randomized Double Blind Placebo Controlled Clinical Trial to Assess the Efficacy of Traumeel® S (IND#66649) for the Prevention and Treatment of Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation||Children's Oncology Group|Yes|Completed|April 2004|January 2011|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|195|||Both|3 Years|25 Years|No|||February 2014|January 5, 2016|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080873||200763|
NCT00081211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02723|Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck|A Phase I Study Of PV701 In Patients With Head And Neck Squamous Cell Carcinoma||National Cancer Institute (NCI)||Terminated|April 2004|||July 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|April 7, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00081211||200744|
NCT00108810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMK-202|Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee|Randomized, Double-Blind, Parallel, Placebo Controlled 4 Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of Transdermal Ketoprofen When Administered With Controlled Heat in Patients With Mild to Moderate OA Pain of the Knee||ZARS Pharma Inc.|No|Completed|April 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|40 Years|75 Years|No|||May 2012|May 30, 2012|April 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00108810||198772|
NCT00108823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-121|The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)|A 24-week, Double Blind, Randomized Study to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Parameters Indicative of Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease||Takeda||Completed|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||550|||Both|40 Years|N/A|No|||January 2012|May 4, 2012|April 19, 2005||||No||https://clinicaltrials.gov/show/NCT00108823||198771|
NCT00082069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC 2003.0006|Invaplex 50 Vaccine Dose-Ranging|Safety and Immunogenicity Study of an Intranasal Shigella Flexneri 2a Invaplex 50 Vaccine||U.S. Army Medical Research and Materiel Command||Completed|April 2004|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|April 28, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082069||200683|
NCT00082082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ta1-HCC-2K1001|A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma|A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial||SciClone Pharmaceuticals||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2008|January 8, 2008|April 28, 2004||||||https://clinicaltrials.gov/show/NCT00082082||200682|
NCT00077896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040122|Direct Current Brain Polarization in Frontotemporal Dementia|Direct Current Brain Polarization in Frontotemporal Dementia||National Institutes of Health Clinical Center (CC)||Completed|February 2004|August 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||6|||Both|N/A|N/A|No|||August 2005|March 3, 2008|February 12, 2004||||No||https://clinicaltrials.gov/show/NCT00077896||200972|
NCT00077909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040119|Study of Lung Proteins in Patients With Pneumonia|Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates||National Institutes of Health Clinical Center (CC)||Recruiting|February 2004|||||N/A|Observational|N/A|||Anticipated|750|||Both|N/A|N/A|No|||May 2015|May 19, 2015|February 12, 2004||No||No||https://clinicaltrials.gov/show/NCT00077909||200971|
NCT00077922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040121|Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia|A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2004|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|February 12, 2004|Yes|Yes||No|October 17, 2012|https://clinicaltrials.gov/show/NCT00077922||200970|
NCT00078286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010340|Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure|Safety and Efficacy of Sertraline for Depression CHF|SADHART-CHF|Duke University|Yes|Completed|November 2003|September 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|469|||Both|45 Years|N/A|No|||January 2013|January 23, 2013|February 20, 2004|Yes|Yes||No|May 11, 2009|https://clinicaltrials.gov/show/NCT00078286||200942|NFS may have limited our ability to detect effect of sertraline on depression scores. Dropout rate was higher than expected. A 12-week duration of therapy may have been insufficient to show potential effects of sertraline on clinical outcomes.
NCT00078611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN100226-CD307|A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease|A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn's Disease With Elevated C-Reactive Protein||Elan Pharmaceuticals||Completed|March 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||462|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|March 1, 2004||||||https://clinicaltrials.gov/show/NCT00078611||200918|
NCT00078624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-117|Knee Stability Training for Knee Osteoarthritis (OA)|Knee Stability Training in Individuals With Knee Osteoarthritis||University of Pittsburgh|No|Completed|April 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|231|||Both|40 Years|N/A|No|||January 2013|January 23, 2013|March 3, 2004||No||No||https://clinicaltrials.gov/show/NCT00078624||200917|
NCT00078637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7820-A001-102|Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma|Phase I and Pharmacokinetic Study of E7820 After Oral Administration to Patients With Malignancy||Eisai Inc.||Completed|January 2004|February 2007|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|37|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|March 3, 2004||||No||https://clinicaltrials.gov/show/NCT00078637||200916|
NCT00078663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040130|Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients|The Effect of a Systemic Oral Care Program on Reducing Exposure to Oropharyngeal Pathogens in Critically III Patients||National Institutes of Health Clinical Center (CC)||Completed|March 2004|August 2011|Actual|December 2007|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||August 2011|September 26, 2015|March 3, 2004||No||No||https://clinicaltrials.gov/show/NCT00078663||200915|
NCT00079872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2929|Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer|A Randomized Phase 2 Trial of ALIMTA Plus a Comparator Versus Leucovorin Modulated Fluorouracil Plus a Comparator in First Line Treatment of Locally Advanced or Metastatic Colorectal Cancer||Eli Lilly and Company||Completed|February 2004|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|March 17, 2004||||||https://clinicaltrials.gov/show/NCT00079872||200830|
NCT00080912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC20|Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases|A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases||Canadian Cancer Trials Group|Yes|Completed|January 2004|January 2014|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|850|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|April 7, 2004|Yes|Yes||No|February 11, 2015|https://clinicaltrials.gov/show/NCT00080912||200760|
NCT00080171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-109|Osteoarthritis Initiative (OAI): A Knee Health Study|Osteoarthritis Initiative (OAI): A Knee Health Study||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Active, not recruiting|February 2004|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Blood, urine|Both|45 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who have knee OA or are at high risk for developing knee OA|March 2009|March 31, 2009|March 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00080171||200807|
NCT00079547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001103-01|The Safety and Effectiveness of Low and High Carbohydrate Diets|The Safety and Efficacy of Low and High Carbohydrate Diets||Temple University|Yes|Completed|April 2003|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|June 28, 2013|March 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00079547||200855|
NCT00079846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRL 2002-001|Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy|Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy||Medical Research Laboratories International||Terminated|September 2003|April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|8 Years|70 Years|No|||April 2005|June 23, 2005|March 17, 2004||||||https://clinicaltrials.gov/show/NCT00079846||200832|
NCT00086203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH-203|Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)|||FDA Office of Orphan Products Development||Completed||September 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2006|March 24, 2015|June 28, 2004||||||https://clinicaltrials.gov/show/NCT00086203||200401|
NCT00081224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0346|Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum|A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum||Alliance for Clinical Trials in Oncology|Yes|Completed|December 2004|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081224||200743|
NCT00108862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5221|Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis|A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3|STRIDE|AIDS Clinical Trials Group|Yes|Completed|August 2006|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|809|||Both|13 Years|N/A|No|||January 2016|January 4, 2016|April 19, 2005|No|Yes||No|September 27, 2011|https://clinicaltrials.gov/show/NCT00108862||198768|
NCT00109226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2192g|A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer|A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-Fluorouracil and Leucovorin Chemotherapy in Subjects With Metastatic Colorectal Cancer Who Are Not Optimal Candidates for First Line CPT-11||Genentech, Inc.||Completed|August 2000|September 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2014|April 7, 2014|April 26, 2005||||||https://clinicaltrials.gov/show/NCT00109226||198742|
NCT00109239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2119g|A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer|A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer||Genentech, Inc.||Completed|November 2000|September 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2013|June 16, 2014|April 26, 2005||||||https://clinicaltrials.gov/show/NCT00109239||198741|
NCT00109473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB #: 04-12-06|Trial of Growth Hormone Therapy in Pediatric Crohn's Disease|A Phase II Randomized Trial of Growth Hormone Therapy in Pediatric Crohn's Disease||Children's Hospital Medical Center, Cincinnati|Yes|Completed|April 2005|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|5 Years|N/A|No|||October 2011|October 10, 2011|April 28, 2005|Yes|Yes||No|June 24, 2011|https://clinicaltrials.gov/show/NCT00109473||198724|
NCT00109746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 AT002499-01A1|Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults|A Novel Therapy for Glucose Intolerance in HIV Disease|NT|National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|November 2005|June 2010|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|39|||Both|18 Years|N/A|No|||May 2013|March 22, 2016|May 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00109746||198704|
NCT00110032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02651|Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors|Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors||National Cancer Institute (NCI)||Terminated|June 2005|||January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|46|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|May 3, 2005|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00110032||198684|
NCT00110045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-65041|Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant|A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2005|||March 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||Actual|171|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|May 3, 2005||||No||https://clinicaltrials.gov/show/NCT00110045||198683|
NCT00110058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1954.00|Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia|A Multi-Center Phase II Study of Nonmyeloablative Conditioning With TBI and Fludarabine for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Chronic Myeloid Leukemia in Chronic and Accelerated Phase||Fred Hutchinson Cancer Research Center||Completed|February 2005|July 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||November 2011|November 15, 2011|May 3, 2005||||No||https://clinicaltrials.gov/show/NCT00110058||198682|
NCT00109993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1Z04|Campath-1H + FK506 and Methylprednisolone for GVHD|Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease||Case Comprehensive Cancer Center|Yes|Completed|January 2005|May 2007|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|34|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|May 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109993||198687|
NCT00110006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2404|Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma|Prognostic Significance of Early Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F] FDG) in Intermediate and High Grade Non-Hodgkin's Lymphoma||Case Comprehensive Cancer Center|Yes|Withdrawn|December 2004|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|May 3, 2005|No|Yes|No accrual|No||https://clinicaltrials.gov/show/NCT00110006||198686|
NCT00077246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000350076|ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer|An Open-Label, Phase I/II Trial Of ABI-007 (A CREMOPHOR® El-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly In Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2003|||October 2008|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|No|||December 2009|November 5, 2013|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077246||201016|
NCT00077935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-05-04|Civamide in OA of the Knee(s)|An Open-Label Multicenter Study Evaluating the Safety of Civamide Cream 0.075% as a Treatment in Subjects With Osteoarthritis of the Knee(s)||Winston Laboratories|No|Completed|November 2003|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|351|||Both|40 Years|76 Years|Accepts Healthy Volunteers|||February 2004|June 6, 2011|February 13, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077935||200969|
NCT00077948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMPOWER (Protocol My-023)|Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure|A Phase III, Randomized, Double-Blind, Double Placebo-Controlled, Multicenter, Three Parallel Group Study of Enoximone Plus Extended-Release Metoprolol Succinate in Advanced CHF Subjects Previously Intolerant to Beta-Blocker Treatment||Gilead Sciences||Terminated|July 2003|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3|||175|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|February 13, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077948||200968|
NCT00079001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-90202|Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases|A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone||Alliance for Clinical Trials in Oncology|Yes|Completed|January 2004|October 2014|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|645|||Male|18 Years|N/A|No|||November 2015|November 23, 2015|March 8, 2004|Yes|Yes||No|October 27, 2014|https://clinicaltrials.gov/show/NCT00079001||200895|
NCT00079261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20021|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma|Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|January 2004|||March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|70 Years|No|||September 2012|September 20, 2012|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079261||200877|
NCT00079560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA012698-01A1|Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS|THC and Marijuana--Effects in Individuals With HIV/AIDS||National Institute on Drug Abuse (NIDA)|No|Completed|December 2001|August 2005|Actual|August 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|50 Years|No|||October 2008|October 23, 2008|March 9, 2004|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00079560||200854|
NCT00079859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRL 2002-002|Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy|Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy||Medical Research Laboratories International||Terminated|October 2003|April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|70 Years|No|||April 2005|June 23, 2005|March 17, 2004||||||https://clinicaltrials.gov/show/NCT00079859||200831|
NCT00080925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040116|T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies|T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies||National Institutes of Health Clinical Center (CC)||Completed|February 2004|December 2010|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|55 Years|No|||March 2012|March 7, 2012|April 7, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00080925||200759|
NCT00081250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N02C4|Creatine in Treating Patients With Cancer-Associated Weight Loss|Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|December 2004|||December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|April 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00081250||200741|
NCT00080574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040140|The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients|The Effects of Thyroid Hormone on Cytochrome P450 and P-Glycoprotein Activity in Thyroid Cancer Patients||National Institutes of Health Clinical Center (CC)||Completed|April 2004|November 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||November 2005|March 3, 2008|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00080574||200779|
NCT00080587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040154|Atherosclerosis in the Coronary and Carotid Arteries|Atherosclerosis in the Coronary and Carotid Arteries: Correlations Between Coronary IVUS, Carotid Ultrasound, and Carotid MRI||National Institutes of Health Clinical Center (CC)||Completed|April 2004|January 2005||||N/A|Observational|N/A||||125|||Both|N/A|N/A|No|||January 2005|March 3, 2008|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00080587||200778|
NCT00080600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040156|Brain Physiology in Polio Survivors|Central Motor Physiology in Polio Survivors||National Institutes of Health Clinical Center (CC)||Completed|April 2004|December 2007||||N/A|Observational|N/A||||90|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||December 2007|March 5, 2008|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00080600||200777|
NCT00081913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00165|Stem Cell Study for Patients With Heart Disease|Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia||Losordo, Douglas, M.D.||Completed|January 2004|June 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|21 Years|N/A|No|||January 2008|January 23, 2008|April 26, 2004||||||https://clinicaltrials.gov/show/NCT00081913||200693|
NCT00077376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02946|Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer|A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone(BMS-247550) and Carboplatin in Patients With HER2/Neu-Positive Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|March 2005|March 2011|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||December 2012|May 2, 2014|February 10, 2004|Yes|Yes||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00077376||201007|
NCT00081237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16033|OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer|A Phase I Study of OSI-7904L In Combination With Oxaliplatin In Patients With Advanced Colo-Rectal Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2004|||August 2005|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081237||200742|
NCT00109538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02978|Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)|A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia||Merck Sharp & Dohme Corp.|Yes|Terminated|May 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|April 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109538||198719|
NCT00109486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR101747|Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray|A Randomized, Double-Blind, Placebo-Controlled, 2-Week Crossover, Knemometric Assessment of the Effect of Once Daily GW685698X Aqueous Nasal Spray 100 Mcg on Short Term Growth in Children Ages 6 - 11 Years With Seasonal and/or Perennial Allergic Rhinitis||GlaxoSmithKline||Completed|April 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|6 Years|12 Years|No|||October 2008|October 15, 2008|April 28, 2005||||||https://clinicaltrials.gov/show/NCT00109486||198723|
NCT00109499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-003.001|Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)|An Open-label, Phase I, Single Administration, Dose- Escalation Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)||GenVec||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||May 2011|May 11, 2011|April 28, 2005||||||https://clinicaltrials.gov/show/NCT00109499||198722|
NCT00109759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RagweedMATAMPL102|Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)|A Double-Blind Phase I Study to Evaluate the Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL® in Healthy Volunteers.||Allergy Therapeutics||Withdrawn|May 2005|June 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 16, 2010|May 3, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00109759||198703|
NCT00110344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11547|Research Study for Patients With Metastatic Renal Cell Carcinoma|A Phase II Study of BAY 43-9006 Prior to and Following Nephrectomy in Patients With Metastatic Renal Cell Carcinoma.||Bayer|No|Terminated|November 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|May 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110344||198661|
NCT00110357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-085|Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors|Phase I Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors||Eli Lilly and Company|No|Completed|August 2005|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|48|||Both|1 Year|18 Years|No|||November 2015|November 24, 2015|May 6, 2005|No|Yes||No|April 21, 2009|https://clinicaltrials.gov/show/NCT00110357||198660|
NCT00110305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006760|A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines|A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects||Tibotec Pharmaceuticals, Ireland|Yes|Completed|June 2005|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|368|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|May 5, 2005|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT00110305||198664|
NCT00077532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040083|Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma|A Study of Intra-Patient Escalating Doses of MDX-010 Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 in the Treatment of Patients With Stage IV Melanoma||National Institutes of Health Clinical Center (CC)||Completed|March 2004|February 2008|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|179|||Both|16 Years|N/A|No|||June 2012|June 21, 2012|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077532||200997|
NCT00077545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02576|3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction|A Phase II Study Of Triapine In Combination With Cisplatin Esophageal Carcinoma||National Cancer Institute (NCI)||Completed|January 2004|||March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077545||200996|
NCT00078338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24735|Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis|Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis||EMD Serono||Completed|March 2004|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|764|||Both|18 Years|60 Years|No|||April 2011|August 5, 2014|February 23, 2004||||No||https://clinicaltrials.gov/show/NCT00078338||200938|
NCT00078689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040115|Daclizumab and Sirolimus to Treat Uveitis|Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis||National Institutes of Health Clinical Center (CC)||Completed|March 2004|July 2008||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||6|||Both|18 Years|N/A|No|||July 2008|September 26, 2015|March 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00078689||200914|
NCT00079300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355151|Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer|Double-Blind, Vehicle-Controlled Study to Evaluate Apoptosis in Basal Cell Carcinoma Treated With Aldara™ (Imiquimod) Cream, 5% Applied Once or Twice a Day||National Institutes of Health Clinical Center (CC)||Completed|January 2004|August 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 25, 2013|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079300||200874|
NCT00079313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040090|Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia|A Pilot Study of the Safety and Efficacy of Imatinib in Reducing Monocytosis or Leukocytosis in Patients With Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia, Respectively||National Institutes of Health Clinical Center (CC)||Completed|January 2004|October 2010|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2011|September 26, 2015|March 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00079313||200873|
NCT00080613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-02B4|Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer|Phase II Study of Neoadjuvant and Adjuvant Exemestane in Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||December 2006|July 9, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00080613||200776|
NCT00080626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0266 CDR0000346460|Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer|A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|July 2003|December 2015|Anticipated|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||March 2014|March 14, 2014|April 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00080626||200775|
NCT00084877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00013|Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Triapine® in Combination With Irinotecan in Refractory Tumors||National Cancer Institute (NCI)||Completed|March 2004|||July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084877||200485|
NCT00085202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJMB03|Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor|Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor||St. Jude Children's Research Hospital|No|Active, not recruiting|August 2003|September 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|416|||Both|3 Years|21 Years|No|||January 2016|January 29, 2016|June 10, 2004|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00085202||200469|The study is ongoing. Participant flow and adverse events will be updated as additional outcomes are reported.
NCT00081549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-726-02|Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies|A Phase I/II Study of Aroplatin and Gemcitabine In Subjects With Unresectable, Locally Advanced And/Or Metastatic Pancreatic Cancer||Aronex Pharmaceuticals||Active, not recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||111|||Both|18 Years|N/A|No|||April 2004|June 23, 2005|April 15, 2004||||||https://clinicaltrials.gov/show/NCT00081549||200720|
NCT00085865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040208|Serotonin Transporters in Alcoholism|PET Evaluation of Serotonin Transporters Using [C-11] DASB in Alcoholism||National Institutes of Health Clinical Center (CC)||Completed|June 2004|July 2006||||N/A|Observational|N/A||||60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2006|March 3, 2008|June 15, 2004||||No||https://clinicaltrials.gov/show/NCT00085865||200426|
NCT00085878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|485232/002|Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors|A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors||GlaxoSmithKline||Completed|January 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|June 16, 2004||||||https://clinicaltrials.gov/show/NCT00085878||200425|
NCT00078143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0013-1|Motivational Enhancement Therapy to Improve Treatment Utilization in Pregnant Substance Users - 1|Motivational Enhancement Therapy (MET) to Improve Treatment Utilization in Pregnant Substance Users||National Institute on Drug Abuse (NIDA)|Yes|Completed|October 2003|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||200|||Female|18 Years|N/A|No|||April 2010|April 13, 2010|February 19, 2004||||No||https://clinicaltrials.gov/show/NCT00078143||200953|
NCT00078156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0015-1|Women's Treatment for Trauma and Substance Use Disorders - 1|Women's Treatment for Trauma and Substance Use Disorders||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2004|October 2005||October 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||409|||Female|18 Years|N/A|No|||April 2010|April 13, 2010|February 19, 2004||||No||https://clinicaltrials.gov/show/NCT00078156||200952|
NCT00078468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4371004|Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment|A Phase 2 Open-Label Multicenter Study Of The Garft Inhibitor AG2037 In Patients With Metastatic Colorectal Cancer Who Failed Treatment With A 5-Fluorouracil/Leucovorin Regimen.||Pfizer||Completed|December 2003|September 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||August 2006|November 8, 2006|February 27, 2004||||No||https://clinicaltrials.gov/show/NCT00078468||200929|
NCT00109278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V205C-010|A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)|A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age||Merck Sharp & Dohme Corp.||Completed|October 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|1100|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||October 2015|October 22, 2015|April 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00109278||198738|
NCT00109291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-02|Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Patients With Chronic Kidney Disease Who Are Not on Dialysis and Who Have Not Had Prior Erythropoiesis Stimulating Agent (ESA) Treatment||Affymax|No|Terminated|March 2005|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|17|||Both|18 Years|75 Years|No|||December 2012|December 19, 2012|April 27, 2005|Yes|Yes|Due to slow enrollment|No||https://clinicaltrials.gov/show/NCT00109291||198737|
NCT00109512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-56418-0501|Endometriosis Trial: Study of NBI-56418 in Endometriosis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis||Abbott||Completed|April 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|76|||Female|18 Years|49 Years|No|||February 2012|February 21, 2012|April 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109512||198721|
NCT00109525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0030|Early Diagnosis of Candidiasis in Premature Infants|Early Diagnosis of Nosocomial Candidiasis Study|Candida|NICHD Neonatal Research Network|No|Completed|March 2004|December 2009|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|N/A|120 Days|Accepts Healthy Volunteers|Probability Sample|Infants with birth weights ≤1,000 grams|June 2015|June 16, 2015|April 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00109525||198720|
NCT00109772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CRPS-002|Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1|A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1|CRPS-002|Celgene|Yes|Terminated|February 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||August 2013|August 26, 2013|May 3, 2005|No|Yes|Interim analysis showed the primary outcome was not reached|No|May 7, 2013|https://clinicaltrials.gov/show/NCT00109772||198702|
NCT00109785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-97046|PET Scans in Patients With Locally Advanced Breast Cancer|Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis||Memorial Sloan Kettering Cancer Center||Completed|March 1997|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|120 Years|No|||December 2015|December 23, 2015|May 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109785||198701|
NCT00110578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01AI054334-02|Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults|Safety and Antiviral Efficacy of Cellular Adoptive Immunotherapy With Autologous CD8+ HIV-Specific Cytotoxic T Cells Combined With Interleukin-2 For HIV Seropositive Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 1998|April 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|No|||July 2007|August 7, 2008|May 10, 2005||||||https://clinicaltrials.gov/show/NCT00110578||198643|
NCT00077961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM.NHL233|Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL|Phase I/II Study of Rituximab Plus CAMPATH in Patients With Previously Treated Relapsed or Refractory Low-Grade Follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma||Sanofi||Terminated|December 2003|||February 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||49|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 13, 2004||||||https://clinicaltrials.gov/show/NCT00077961||200967|
NCT00077974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181006|A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.|A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma||Pfizer|Yes|Completed|February 2004|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||October 2010|October 8, 2010|February 13, 2004|No|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00077974||200966|
NCT00077987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181003|Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.|A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab||Pfizer||Completed|December 2003|April 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||84|||Both|18 Years|N/A|No|||October 2005|January 9, 2007|February 13, 2004||||No||https://clinicaltrials.gov/show/NCT00077987||200965|
NCT00079573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001098-01A1|Comparison of Popular Weight Loss Diets|Benefits & Risks of Popular Weight Loss Diets||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2002|June 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||August 2006|August 16, 2006|March 9, 2004||||No||https://clinicaltrials.gov/show/NCT00079573||200853|
NCT00078299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040128|Evaluation of the Age-Related Eye Disease Study (AREDS) Clinical Lens Grading System|Evaluation of the Age-Related Eye Disease Study (AREDS) Clinical Lens Grading System||National Institutes of Health Clinical Center (CC)||Completed|February 2004|April 2005||||N/A|Observational|N/A||||150|||Both|N/A|N/A|No|||April 2005|March 3, 2008|February 20, 2004||||No||https://clinicaltrials.gov/show/NCT00078299||200941|
NCT00078312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3023/ES/MN|Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder|A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)||Teva Pharmaceutical Industries|No|Completed|January 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|328|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|February 23, 2004|||||June 1, 2009|https://clinicaltrials.gov/show/NCT00078312||200940|
NCT00078715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040091|Rapid Antidepressant Effects of Yohimbine in Major Depression|An Investigation of a Pharmacologic Strategy to Bring About Rapid (Next Day) Antidepressant Effects||National Institutes of Health Clinical Center (CC)|Yes|Completed|March 2004|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|11|||Both|18 Years|65 Years|No|||August 2012|August 16, 2012|March 4, 2004|Yes|Yes||No|June 7, 2012|https://clinicaltrials.gov/show/NCT00078715||200913|
NCT00080184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000930-01A2|Effectiveness of Brainwave Biofeedback in the Treatment of Fibromyalgia|Effectiveness of EEG Biofeedback in the Treatment of Fibromyalgia||National Center for Complementary and Integrative Health (NCCIH)||Completed|December 2003|May 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2006|August 16, 2006|March 24, 2004||||No||https://clinicaltrials.gov/show/NCT00080184||200806|
NCT00080197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7070-A001-211|Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients|An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline, a Taxane, and Capecitabine||Eisai Inc.||Completed|February 2004|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Female|18 Years|N/A|No|||October 2006|October 10, 2006|March 24, 2004||||||https://clinicaltrials.gov/show/NCT00080197||200805|
NCT00084630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03184|Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans|A Phase II Study of Imatinib (NSC-716051) in Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans||National Cancer Institute (NCI)||Completed|May 2004|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084630||200502|
NCT00084890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000366942|Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix|Weekly Docetaxel and Carboplatin in Patients With Recurrent Squamous Carcinoma of the Cervix: A Phase I/II Study||Comprehensive Cancer Center of Wake Forest University|No|Terminated|November 2003|April 2010|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||July 2012|July 12, 2012|June 10, 2004||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00084890||200484|
NCT00085228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30021|Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate|Randomized Phase II Trial of Docetaxel (Taxotere) and Oblimersen (Antisense Oligonucleotide Directed to BCL-2) Versus Taxotere Alone in Patients With Hormone-Refractory Prostate Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 2004|||January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|116|||Male|18 Years|N/A|No|||September 2012|September 20, 2012|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00085228||200468|
NCT00085540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02596|FR901228 in Treating Patients With Recurrent High-Grade Gliomas|A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas||National Cancer Institute (NCI)||Completed|January 2005|||December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||January 2013|February 1, 2013|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00085540||200448|
NCT00085891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00133|Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia|A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia||AstraZeneca||Completed|June 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||535|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|June 16, 2004||||||https://clinicaltrials.gov/show/NCT00085891||200424|
NCT00085904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|485232/003|Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas|A Phase I, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Five Daily Intravenous Infusions Repeated Every 28 Days in Adult Patients With Solid Tumors and Lymphomas||GlaxoSmithKline||Completed|April 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|N/A|No|||October 2008|October 9, 2008|June 16, 2004||||||https://clinicaltrials.gov/show/NCT00085904||200423|
NCT00078858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1668.00|Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant|Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|September 2003|||January 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|N/A|No|||March 2016|March 1, 2016|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078858||200903|
NCT00082173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-002135-01|Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis|Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection||Johns Hopkins University|Yes|Completed|October 2004|September 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|April 30, 2004|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00082173||200675|
NCT00082186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-402|The Effect of Tracleer® on Male Fertility|TRACLEER® (Bosentan) Pulmonary Arterial Hypertension A Multicenter, Open-label, Single-arm Safety Study to Investigate the Effects of Chronic TRACLEER® Treatment on Testicular Function in Male Patients With Pulmonary Arterial Hypertension||Actelion||Completed|July 2003|November 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|65 Years|No|||February 2010|February 11, 2010|April 30, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082186||200674|
NCT00082199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-089|Study of Aripiprazole in Subjects With Alcoholism|A Randomized, Multicenter, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence From Alcohol in Subjects With Alcoholism||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|April 2004|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||400|||Both|21 Years|65 Years|No|||July 2008|November 7, 2013|April 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082199||200673|
NCT00100802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0423|Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas|A Phase II Study of Concurrent Radiation and Temozolomide Followed By Temozolomide and CCNU in the Treatment of Children With High-Grade Glioma||Children's Oncology Group|Yes|Active, not recruiting|July 2005|||September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Both|3 Years|21 Years|No|||March 2016|March 7, 2016|January 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100802||199355|
NCT00109798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM IRB#H-16155|Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma|Phase II Trial of Salvage Chemotherapy With Temozolomide in Combination With Topotecan for Primary CNS Lymphoma||The Methodist Hospital System|No|Withdrawn|March 2005|July 2006|Actual|July 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|May 3, 2005|Yes|Yes|Sub-Investigator reloacted to another institution|No||https://clinicaltrials.gov/show/NCT00109798||198700|
NCT00110071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1943.00|Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma|A Clinical Trial Evaluating I131-Tositumomab (Anti-CD20) With Escalating Doses of Fludarabine Followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma in Patients 60 Years of Age and Older||Fred Hutchinson Cancer Research Center|No|Completed|January 2005|||June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|60 Years|N/A|No|||August 2014|August 4, 2014|May 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00110071||198681|
NCT00101933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1604|SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy|SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy||MedtronicNeuro|Yes|Active, not recruiting|December 2003|October 2018|Anticipated|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|January 18, 2005|Yes|Yes||No|October 1, 2012|https://clinicaltrials.gov/show/NCT00101933||199273|No limitations leading to unreliable data were identified.
NCT00101946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|683699/004|Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease||GlaxoSmithKline||Completed|October 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|65 Years|No|||April 2015|April 10, 2015|January 18, 2005||||No||https://clinicaltrials.gov/show/NCT00101946||199272|
NCT00110331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050150|Central Nervous System Disease in HIV-infected Children on HAART|||National Institutes of Health Clinical Center (CC)||Completed|May 2005|September 2014||||N/A|Observational|N/A|||Actual|21|||Both|N/A|N/A|No|||September 2014|September 10, 2014|May 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00110331||198662|
NCT00078000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181002|A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.|A Phase 2 Study Of The Efficacy And Safety Of SU011248 In Patients With Metastatic Breast Cancer||Pfizer||Completed|March 2004|November 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|64|||Both|18 Years|N/A|No|||November 2008|November 24, 2008|February 13, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078000||200964|
NCT00078013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-135-A02|MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Examine the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Standard Therapy With Primary PCI in Patients Diagnosed as Having an ST Elevation Acute Myocardial Infarction||Mitsubishi Tanabe Pharma Corporation||Completed|April 2003|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||414|||Both|18 Years|N/A|No|||March 2005|June 23, 2005|February 13, 2004||||||https://clinicaltrials.gov/show/NCT00078013||200963|
NCT00078325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3021/AP/MN|Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)|A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome||Teva Pharmaceutical Industries|No|Completed|February 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|395|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|February 23, 2004||Yes|||June 1, 2009|https://clinicaltrials.gov/show/NCT00078325||200939|
NCT00083707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 99-006|Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia|UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia||University of Arkansas||Completed|January 1999|February 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|May 27, 2004||||||https://clinicaltrials.gov/show/NCT00083707||200567|
NCT00079027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000353298|Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)|A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 2004|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|280|||Both|18 Years|N/A|No|||May 2007|December 17, 2013|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079027||200893|
NCT00084383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J9988|Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas|A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Adjuvant Chemoradiotherapy for the Treatment of Adenocarcinoma of the Pancreas||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|January 2002|July 2006|Actual|December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|June 10, 2004|Yes|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00084383||200519|
NCT00084643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03077|GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors|A Phase I Study of GTI-2040 in Combination With Oxaliplatin and Capecitabine in Patients With Advanced Metastatic Solid Tumors||National Cancer Institute (NCI)||Completed|May 2004|||April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2013|March 26, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084643||200501|
NCT00081276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02585|3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338) In Combination With Cisplatin (Commercially Available: NSC # 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|July 2005|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||January 2013|January 23, 2013|April 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00081276||200739|
NCT00081289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0247|Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer|Randomized Phase II Trial Of Neoadjuvant Combined Modality Therapy For Locally Advanced Rectal Cancer||Radiation Therapy Oncology Group|Yes|Completed|March 2004|||May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|April 7, 2004|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00081289||200738|The study was temporarily closed to accrual due to excessive GI AEs in the first 35 pts. The protocol was amended to adjust the chemotherapy and the study reopened (treatment descriptions reflect the revision).
NCT00081588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006724|An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.|An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.||Tibotec Pharmaceuticals, Ireland|Yes|Completed|November 2003|December 2008|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|555|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|April 15, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00081588||200717|
NCT00085553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02597|Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors|Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|May 2004|||May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||October 2015|November 2, 2015|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085553||200447|
NCT00085566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-010|Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer|A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2004|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Male|18 Years|120 Years|No|||December 2015|December 15, 2015|June 10, 2004|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00085566||200446|
NCT00082277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5392C00050|Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer|A Multicentre Phase III/IV Study, of the Effects of Risedronate Sodium (ACTONEL™, 35mg/Week, Oral) on Bone, in Postmenopausal Women, With Hormone-receptor-positive Early Breast Cancer, Treated With Anastrozole (ARIMIDEX™, 1mg/Day Oral) With Risk of Fragility Fracture (High-risk Fragility Fracture-open-label, Non-comparative Stratum; Moderate-risk of Fragility Fracture-randomised, Double-blind Stratum; Low-risk of Fragility Fracture - Open-label, Non-comparative Stratum)Abbreviated|SABRE|AstraZeneca||Completed|April 2004|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|237|||Female|55 Years|N/A|No|||January 2011|January 25, 2011|May 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082277||200668|
NCT00086528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL647-001|Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors||Kadmon Corporation, LLC|Yes|Completed|June 2004|November 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|July 2, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00086528||200376|
NCT00086541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRHC-001|Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy|A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa Plus Ribavirin Therapy||Valeant Pharmaceuticals International, Inc.||Completed|June 2004|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|515|||Both|18 Years|N/A|No|||May 2007|May 3, 2007|July 2, 2004||||||https://clinicaltrials.gov/show/NCT00086541||200375|
NCT00100815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000409556|Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer|Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer||Roswell Park Cancer Institute|Yes|Completed|August 2004|||August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|120 Years|No|||November 2015|November 19, 2015|January 6, 2005|Yes|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT00100815||199354|
NCT00109551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD038753|Community Trial of Zinc Supplementation on Preschool Child Mortality and Morbidity in Southern Nepal|Zinc Supplementation Impact on Child Mortality--Nepal||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|October 2001|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||58000|||Both|1 Month|36 Months|Accepts Healthy Volunteers|||January 2006|April 30, 2013|April 28, 2005||||No||https://clinicaltrials.gov/show/NCT00109551||198718|
NCT00109811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02652|Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer|A Phase 2 Study of Prostate Specific Antigen Peptide 3A (PSA: 154-163(155L) ) (NSC # 722932, IND#9787) With Montanide ISA-51(NSC #675756, IND #9787) or Montanide® ISA 51 VG (NSC 737063) Vaccination in Prostate Cancer Recurrent||National Cancer Institute (NCI)||Completed|March 2005|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Male|18 Years|N/A|No|||January 2013|January 22, 2013|May 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109811||198699|
NCT00101660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-013|Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib|A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib||Bristol-Myers Squibb|No|Completed|February 2005|April 2008|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|387|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|January 12, 2005|Yes|Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00101660||199294|
NCT00110604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pou.0224L|The Effect of Folic Acid on Atherosclerosis, Cognitive Performance and Hearing|The Folic Acid and Carotid Intima-Media Thickness (FACIT) Study: A Randomized Controlled Trial||Wageningen University||Completed|September 2000|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||835|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||May 2005|December 29, 2008|May 10, 2005||||No||https://clinicaltrials.gov/show/NCT00110604||198641|
NCT00110617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2201|Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients|A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood Transfusions||Novartis||Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|2 Years|N/A|No|||May 2011|May 23, 2011|May 10, 2005|Yes|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00110617||198640|Due to severe good clinical practice violations, data from 9 participants recruited for Center 512 was excluded from the main analysis of the study.
NCT00079326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03123|Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer|A Phase 2 Study of Trastuzumab in Combination With BMS-247550 in Women With Metastatic Breast Cancer||National Cancer Institute (NCI)||Terminated|January 2004|October 2010|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||January 2013|May 29, 2014|March 8, 2004|Yes|Yes|Slow accrual.|No|November 4, 2013|https://clinicaltrials.gov/show/NCT00079326||200872|
NCT00083720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP02-0451|Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy|A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Refractory, EGFR-Negative Metastatic Colorectal Carcinoma||ImClone LLC|No|Completed|October 2004|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|May 28, 2004|Yes|Yes||No|April 16, 2009|https://clinicaltrials.gov/show/NCT00083720||200566|
NCT00079885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-308|Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2003|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|430|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|March 18, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079885||200829|
NCT00079898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000978-01A1|Effect of Acupuncture on Human Brain Activity|Modulatory Effect of Acupuncture on Human Brain Activity||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2002|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2008|January 23, 2008|March 18, 2004||No||No||https://clinicaltrials.gov/show/NCT00079898||200828|
NCT00084396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000361963|Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer|A Phase 2 Trial Of 4 Months Preoperative Letrozole 2.5 mg Daily For Postmenopausal Women With Estrogen Receptor Positive And/Or Progesterone Receptor Positive T2, T3, T4a-c, N0-2, M0 Breast Cancer- Novel Biomarkers for Aromatase Inhibitor Therapy||Washington University School of Medicine|Yes|Active, not recruiting|October 2003|March 2017|Anticipated|March 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Female|18 Years|N/A|No|||April 2015|April 24, 2015|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084396||200518|
NCT00084409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0279|Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease|A Randomized Phase II Chemoprevention Study of Iloprost Versus Placebo in Patients at High Risk for Lung Cancer||University of Colorado, Denver|Yes|Completed|November 2001|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|152|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|June 10, 2004|Yes|Yes||No|November 26, 2012|https://clinicaltrials.gov/show/NCT00084409||200517|
NCT00080951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0341|Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Trial Of Irinotecan + 5-Fluorouracil + Leucovorin + Oxaliplatin As First-Line Treatment For Metastatic Colorectal Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|March 2004|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2015|July 4, 2015|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080951||200757|
NCT00081601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0701a/203/ON/US|Study of CEP-701 in Treatment of Prostate Cancer|An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen||Teva Pharmaceutical Industries||Completed|March 2004|June 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|18 Years|N/A|No|||August 2012|August 22, 2012|April 15, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081601||200716|
NCT00081614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2938g|A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma|A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma||Genentech, Inc.||Completed|March 2004|July 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|April 15, 2004||||||https://clinicaltrials.gov/show/NCT00081614||200715|
NCT00081952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT001709-01|Amino Acid Therapy for Hot Flashes in Postmenopausal Women|Amino Acid Therapy for Hot Flashes/Postmenopausal Women||National Center for Complementary and Integrative Health (NCCIH)||Completed|October 2003|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||15|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2013|March 21, 2013|April 27, 2004||||||https://clinicaltrials.gov/show/NCT00081952||200690|
NCT00077155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02569|Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study Of Continuous Infusion EMD 121974 In Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|December 2003|||June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077155||201023|
NCT00081939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2003-33|UARK 2003-33, Total Therapy III|A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance||University of Arkansas|Yes|Completed|January 2004|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|303|||Both|18 Years|75 Years|No|||September 2015|September 18, 2015|April 27, 2004|Yes|Yes||No|September 18, 2015|https://clinicaltrials.gov/show/NCT00081939||200691|
NCT00082251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019-01-03-CR|Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST|Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST||Kos Pharmaceuticals||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||October 2006|October 31, 2006|May 3, 2004||||||https://clinicaltrials.gov/show/NCT00082251||200669|
NCT00077727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004366|A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.|A Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2003|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|107|||Both|18 Years|55 Years|No|||April 2010|May 20, 2011|February 11, 2004||||||https://clinicaltrials.gov/show/NCT00077727||200984|
NCT00078130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0010-1|Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1|Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents||National Institute on Drug Abuse (NIDA)|Yes|Completed|July 2003|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||223|||Both|14 Years|21 Years|No|||April 2010|April 13, 2010|February 19, 2004||||||https://clinicaltrials.gov/show/NCT00078130||200954|
NCT00079105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000354225|A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years|A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years; Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|January 2004|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|60 Years|120 Years|No|||October 2015|October 7, 2015|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00079105||200887|
NCT00079118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0332|Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer|Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|April 2004|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00079118||200886|
NCT00079131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01446|Oblimersen in Treating Patients With Merkel Cell Carcinoma|A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma||National Cancer Institute (NCI)||Completed|January 2004|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079131||200885|
NCT00086554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040231|Collection of Specimens for Study of Inflammatory Bowel Disease|Procurement of Clinical Specimens for Immunologic or Genetic Studies in Inflammatory Bowel Diseases||National Institutes of Health Clinical Center (CC)||Completed|July 2004|January 2010||||N/A|Observational|N/A|||||||Both|4 Years|N/A|No|||January 2010|September 26, 2015|July 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00086554||200374|
NCT00100828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0459, CDR0000409567|Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer|Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|November 2004|||November 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|January 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100828||199353|
NCT00101075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000406025|Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By Surgery|Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers||National Cancer Institute (NCI)||Active, not recruiting|October 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|N/A|No|||November 2006|July 23, 2008|January 7, 2005||||No||https://clinicaltrials.gov/show/NCT00101075||199336|
NCT00102037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7SPIN-2180|Use of Activated Recombinant FVII in Spinal Surgery|Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery||Novo Nordisk A/S|No|Completed|July 2004|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|50|||Both|15 Years|70 Years|No|||January 2012|June 26, 2012|January 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102037||199265|
NCT00102050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-IC-0201|Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication|A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication||Nissan Chemical Industries||Completed|April 2003|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||390|||Both|50 Years|N/A|No|||May 2006|May 17, 2006|January 19, 2005||||||https://clinicaltrials.gov/show/NCT00102050||199264|
NCT00101309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000404366|Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma|A Phase I Pilot Study of Tumor Cell - B Lymphoblastoid Cell Line Vaccination in Pediatric Subjects With Relapsed Ewing's Sarcoma and Neuroblastoma||National Cancer Institute (NCI)||Active, not recruiting|November 2004|||November 2007|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|10|||Both|1 Year|30 Years|No|||November 2007|December 17, 2013|January 7, 2005||||No||https://clinicaltrials.gov/show/NCT00101309||199319|
NCT00101335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-02028|Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia|A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia||Fox Chase Cancer Center|No|Completed|November 2003|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||July 2013|July 9, 2013|January 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101335||199318|
NCT00102375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 7|Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer|Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan||AGO Study Group||Completed|December 1999|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||900|||Female|18 Years|N/A|No|||February 2006|August 3, 2006|January 29, 2005||||No||https://clinicaltrials.gov/show/NCT00102375||199239|
NCT00078741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH065248|Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals With Severe Mental Illness|CBT for PTSD and SMI in Community Mental Health Centers||Medical University of South Carolina||Completed|January 2004|September 2007|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||December 2007|August 7, 2015|March 5, 2004||||No||https://clinicaltrials.gov/show/NCT00078741||200911|
NCT00078754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066984|A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder|Fluoxetine and Divalproex: Treatment Correlates in IED||University of Chicago|Yes|Completed|May 2003|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|21 Years|55 Years|No|||December 2014|December 29, 2014|March 5, 2004|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT00078754||200910|
NCT00084903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN97-244|Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears|Pathological Correlation of Colposcopically Directed Biopsies to Fluorescence EEM of the Normal Human Cervix||M.D. Anderson Cancer Center|No|Completed|April 1998|February 2009|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1070|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 1, 2012|June 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00084903||200483|
NCT00084071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTFP561A2308|Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia|Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia||Novartis||Completed|May 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|2136|||Both|N/A|N/A|No|||July 2012|July 12, 2012|June 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084071||200541|
NCT00084084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKT029|Replagal Enzyme Replacement Therapy for Children With Fabry Disease|An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy||Shire|No|Completed|June 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|7 Years|17 Years|No|||March 2014|March 25, 2014|June 5, 2004|Yes|Yes||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00084084||200540|
NCT00085579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-027|Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase II Study of Maintenance Biotherapy With Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor in Patients With Metastatic Melanoma With a Partial Response or Stable Disease After Systemic Therapy||Memorial Sloan Kettering Cancer Center||Withdrawn|March 2004|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|16 Years|N/A|No|||December 2012|December 11, 2012|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00085579||200445|
NCT00081302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0324|Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer|A Phase II Study Of Cetuximab (C225) In Combination With Chemoradiation In Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)||Radiation Therapy Oncology Group|Yes|Completed|March 2004|November 2013|Actual|December 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2015|November 14, 2015|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081302||200737|
NCT00077168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000349580|Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole|Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy||National Cancer Institute (NCI)||Active, not recruiting|April 2004|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Female|40 Years|70 Years|No|||October 2007|February 6, 2009|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077168||201022|
NCT00077402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRG-P18/02|Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer|A Phase 2 Study Of Fenretinide In Patients With Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|November 2003|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Male|18 Years|N/A|No|||December 2006|May 14, 2013|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077402||201005|
NCT00077389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000350221|Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma|Intensified Pre-Operative Chemotherapy And Radical Surgery For High Risk Hepatoblastoma||National Cancer Institute (NCI)||Active, not recruiting|January 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|57|||Both|N/A|17 Years|No|||December 2009|June 23, 2014|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077389||201006|
NCT00078169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0021-1|Motivational Enhancement for Spanish Speaking Individuals - 1|Motivational Enhancement for Spanish Speaking Individuals||National Institute on Drug Abuse (NIDA)|Yes|Completed|November 2003|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||463|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|February 19, 2004||||No||https://clinicaltrials.gov/show/NCT00078169||200951|
NCT00078494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040118|Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer|Phase I/II Trial of Latent Membrane Protein (LMP) - 2 Immunization for the Assessment of the Natural History and the Immunization-Induced Immunological Response in Patients at High Risk for Recurrence of Anaplastic Nasopharyngeal Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2004|May 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||99|||Both|N/A|N/A|No|||May 2006|March 3, 2008|February 27, 2004||||No||https://clinicaltrials.gov/show/NCT00078494||200927|
NCT00078507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13967|Sensory Re-Training Following Facial Surgery for Correction of Facial Skeletal Disharmony|Sensory Re-Training Following Orthognathic Surgery||University of North Carolina, Chapel Hill|Yes|Completed|December 2001|March 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|13 Years|50 Years|No|||February 2010|February 2, 2010|March 1, 2004||No||No||https://clinicaltrials.gov/show/NCT00078507||200926|
NCT00080028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0210|Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer|Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck||Pharmacyclics||Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||May 2007|May 4, 2007|March 22, 2004||||||https://clinicaltrials.gov/show/NCT00080028||200818|
NCT00080041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0214|Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors|Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors||Pharmacyclics||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||May 2007|May 11, 2007|March 22, 2004||||||https://clinicaltrials.gov/show/NCT00080041||200817|
NCT00077688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-8184-1073|TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium|A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium||OncoGenex Technologies||Completed|November 2003|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||44|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|February 10, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00077688||200986|
NCT00077714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004378|Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Paliperidone Extended Release Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2004|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|February 11, 2004||||||https://clinicaltrials.gov/show/NCT00077714||200985|
NCT00101361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|535|Oxandrolone to Heal Pressure Ulcers|CSP #535 - Anabolic Steroid Therapy on Pressure Ulcer Healing in Persons With Spinal Cord Injury||VA Office of Research and Development|Yes|Terminated|August 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|January 7, 2005|No|Yes|futility analysis showed low probability of detecting a significant difference|No|June 27, 2013|https://clinicaltrials.gov/show/NCT00101361||199316|Selection of severe wounds may have reduced treatment response. The study was terminated after a futility analysis showed a low probability of detecting a significant difference between groups.
NCT00101088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00073|Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase I Study of CCI-779 in Combination With Imatinib Mesylate in Chronic Myelogenous Leukemia||National Cancer Institute (NCI)|Yes|Terminated|April 2005|||June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101088||199335|
NCT00107380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415955|S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study||Southwest Oncology Group|No|Completed|November 2005|December 2015|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|120 Years|No|||February 2016|February 4, 2016|April 5, 2005|Yes|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT00107380||198877|
NCT00101985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223412/068|Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)|An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome||GlaxoSmithKline||Completed|October 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|741|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|January 18, 2005||||No||https://clinicaltrials.gov/show/NCT00101985||199269|
NCT00101998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|767905/008|Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects||Cubist Pharmaceuticals LLC||Completed|October 2003|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|233|||Both|18 Years|N/A|No|||September 2009|September 1, 2015|January 18, 2005||Yes||||https://clinicaltrials.gov/show/NCT00101998||199268|
NCT00102011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-046|Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer|Colonoscopy Screening Trial|00-046|Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2000|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|4952|||Both|40 Years|69 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|January 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102011||199267|
NCT00102024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159-01|Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma|A Phase I/II, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Single Dose 90Y-Labeled IDEC-159, Humanized, Domain Deleted, Anti TAG-72 Monoclonal Antibody, in Subjects With Metastatic Colorectal Adenocarcinoma||Biogen||Terminated|January 2005|January 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||August 2010|August 25, 2010|January 19, 2005||||||https://clinicaltrials.gov/show/NCT00102024||199266|
NCT00102401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49153|Internet-Based and Established Dyspnea Self-Management Programs in Chronic Obstructive Pulmonary Disease (COPD) Patients|Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD||Robert Wood Johnson Foundation||Completed|September 2003|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|50|||Both|40 Years|N/A|No|||August 2007|August 13, 2007|January 29, 2005||||No||https://clinicaltrials.gov/show/NCT00102401||199237|
NCT00083408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 99-016|Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide|UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve||University of Arkansas||Completed|March 1998|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|May 24, 2004||||||https://clinicaltrials.gov/show/NCT00083408||200589|
NCT00083421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2506POU010|Effects of ONO-2506PO in Patients With Alzheimer's Disease|Effects of ONO-2506PO in Patients With Alzheimer's Disease||Ono Pharmaceutical Co. Ltd||Completed|June 2004|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|647|||Both|50 Years|90 Years|No|||June 2012|June 12, 2012|May 24, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00083421||200588|
NCT00080275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019-02-03-CR|Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)|An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS)||Kos Pharmaceuticals||Completed|March 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|21 Years|N/A|No|||October 2006|October 31, 2006|March 25, 2004||||||https://clinicaltrials.gov/show/NCT00080275||200800|
NCT00080288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3022/CM/MN|Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD|A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder||Teva Pharmaceutical Industries||Completed|March 2004|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|March 25, 2004||Yes|||June 1, 2009|https://clinicaltrials.gov/show/NCT00080288||200799|
NCT00084097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040176|Omalizumab to Treat Eosinophilic Gastroenteritis|Pilot Study of Omalizumab in Eosinophilic Gastroenteritis||National Institutes of Health Clinical Center (CC)||Completed|June 2004|February 2007||||Phase 2|Interventional|Primary Purpose: Treatment|1|||30|||Both|12 Years|76 Years|No|||December 2008|October 31, 2009|June 5, 2004||No||No||https://clinicaltrials.gov/show/NCT00084097||200539|
NCT00085254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02932|Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme||National Cancer Institute (NCI)|Yes|Completed|April 2005|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|112|||Both|18 Years|N/A|No|||October 2015|January 28, 2016|June 10, 2004|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT00085254||200467|Study is safety run-in / phase 2 study. Pre-defined doses in safety run-in, 500, 1000 & 2000mg. Safety run-in is under an assumption of low probability of DLT with these dosages. NO actual MTD was defined in the safety run in, all doses were safe.
NCT00080977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000357581|High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2|Treatment of Patients With Metastatic Renal Cell Carcinoma Who Have Failed Low Dose Intensity Interleukin-2 With High-Dose Intravenous Recombinant Interleukin-2||National Cancer Institute (NCI)||Active, not recruiting|June 1998|||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2005|December 18, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00080977||200756|
NCT00081965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-108|Acupuncture in Treating Hot Flashes in Women With Breast Cancer|Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients: A Randomized Controlled Trial||Memorial Sloan Kettering Cancer Center||Completed||May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|80|||Female|N/A|N/A|No|||December 2012|December 11, 2012|April 27, 2004||||No||https://clinicaltrials.gov/show/NCT00081965||200689|
NCT00078182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01AI054241-01|Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia|Study of Daily Oral Tenofovir (Tenofovir Disoproxil Fumarate) to Prevent HIV-1 Infection Among Sex Workers in Cambodia||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||960|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2005|August 8, 2008|February 19, 2004||||||https://clinicaltrials.gov/show/NCT00078182||200950|
NCT00078520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11967|Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells|Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA)|CLIPA|Baylor College of Medicine|Yes|Completed|January 2003|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2010|April 21, 2010|March 1, 2004|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00078520||200925|
NCT00077753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4563C_3501|EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization|A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization||Sanofi||Completed|February 2002|February 2007|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||4726|||Both|40 Years|N/A|No|||January 2011|January 10, 2011|February 12, 2004||||||https://clinicaltrials.gov/show/NCT00077753||200983|
NCT00077766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA17283|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.|A Randomized Open-label Study of the Effect of Maintenance Intravenous Mircera on Hemoglobin Levels in Anemic Dialysis Patients With Chronic Kidney Disease||Hoffmann-La Roche||Completed|March 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|313|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|February 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077766||200982|
NCT00079677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3025/AP/MN|Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome||Teva Pharmaceutical Industries||Completed|March 2004|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|March 10, 2004||Yes|||June 1, 2009|https://clinicaltrials.gov/show/NCT00079677||200845|
NCT00079690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1244|Genetic Epidemiology of Blood Pressure Intervention|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2006|Actual|August 2006|Actual|N/A|Observational|N/A|||||||Both|18 Years|60 Years|No|||May 2009|May 1, 2009|March 10, 2004||||No||https://clinicaltrials.gov/show/NCT00079690||200844|
NCT00079703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245|Diet, Genetics, and CVD Risk Factor Response in Blacks|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2007|Actual|August 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2008|January 24, 2008|March 10, 2004||||No||https://clinicaltrials.gov/show/NCT00079703||200843|
NCT00079716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG040-0001|Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma|A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Refractory or Recurrent Multiple Myeloma||Seattle Genetics, Inc.|No|Completed|March 2004|November 2007|Actual|August 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|March 11, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079716||200842|
NCT00079456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01448|Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Trial of CCI-779 in Patients With Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|February 2004|||February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00079456||200862|
NCT00078481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040129|Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia|Phase 1B Clinical Trial to Establish the Safety and Tolerability of a Multiple-Dose Regimen of Idebenone Administered to Patients With Friedreich's Ataxia||National Institutes of Health Clinical Center (CC)||Completed|February 2004|April 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||16|||Both|N/A|N/A|No|||April 2006|March 3, 2008|February 27, 2004||||No||https://clinicaltrials.gov/show/NCT00078481||200928|
NCT00111553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LCVTC-101|Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis|Randomized, Double-Blind, Adjuvant- and Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine With Meglumine Antimoniate (Glucantime) in Cutaneous Leishmaniasis||IDRI||Completed|October 2004|August 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|60 Years|No|||February 2007|February 13, 2007|May 23, 2005||||||https://clinicaltrials.gov/show/NCT00111553||198569|
NCT00101348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02639|Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer|A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|January 2005|May 2008|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||December 2012|June 10, 2014|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101348||199317|
NCT00107393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUGSM-UHA-BC03-01|Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer|Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression||National Cancer Institute (NCI)||Completed|June 2003|November 2008|Actual|May 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Female|20 Years|75 Years|No|||October 2006|July 9, 2013|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107393||198876|
NCT00107419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415848|S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma|Phase II Trial of Pemetrexed for Advanced Chondrosarcomas||Southwest Oncology Group|No|Completed|September 2005|August 2009|Actual|May 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|April 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107419||198875|
NCT00102414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 2.5|Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer|A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy||AGO Study Group||Completed|September 1999|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||356|||Female|18 Years|N/A|No|||January 2005|November 13, 2006|January 29, 2005||||No||https://clinicaltrials.gov/show/NCT00102414||199236|
NCT00097617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-036, Substudy 11|A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)|National Cooperative Growth Study (NCGS) of Nutropin AQ, Nutropin, and Protropin in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)||Genentech, Inc.||Completed|March 2002|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|395|||Both|N/A|17 Years|No|Non-Probability Sample|primary care clinic|November 2012|November 13, 2012|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097617||199585|
NCT00097929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-013|An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)|A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)||Merck Sharp & Dohme Corp.||Completed|May 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 1, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097929||199562|
NCT00084656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365467|Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma|An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma||Bristol-Myers Squibb||Completed|May 2004|||October 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||April 2010|April 23, 2010|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084656||200500|
NCT00080990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00055|Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Oxaliplatin and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|February 2004|||April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|April 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00080990||200755|
NCT00085280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03147|Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Pilot Study to Determine if Downstream Markers of EGFR Linked Signaling Pathways Predict Response to OSI-774 (Erlotinib) in the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2004|||October 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||January 2013|March 28, 2014|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085280||200466|
NCT00081627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-CoFactor|Clinical Trial in Patients With Metastatic Colorectal Cancer|COFU: A Multi-Center Phase II Clinical Trial to Evaluate the Safety and Efficacy of Weekly Treatment With CoFactor and 5-Fluorouracil in Patients With Metastatic Colorectal Carcinoma||Mast Therapeutics, Inc.||Completed|April 2004|January 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||November 2007|November 26, 2007|April 15, 2004||||No||https://clinicaltrials.gov/show/NCT00081627||200714|
NCT00081640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 047|Safety and Acceptability of PRO 2000 Vaginal Gel in HIV Uninfected Women in India|Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|December 22, 2009|April 16, 2004||||||https://clinicaltrials.gov/show/NCT00081640||200713|
NCT00077779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-404|Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease|A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease|CHARM|Abbott||Completed|July 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|854|||Both|18 Years|75 Years|No|||September 2007|September 23, 2007|February 12, 2004||||||https://clinicaltrials.gov/show/NCT00077779||200981|
NCT00077792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6147|Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)|A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy||Sanofi||Completed|October 2002|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|20506|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|February 12, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077792||200980|
NCT00078533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12683-VICTA|Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant|Virus Specific Cytotoxic T-Lymphocytes for the Treatment of CMV After Allogeneic Stem Cell Transplant: A Dose-Finding Trial|VICTA|Baylor College of Medicine|Yes|Completed|April 2004|June 2011|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||June 2014|October 6, 2014|March 1, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00078533||200924|
NCT00078221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-02-99|Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)|||OccuLogix||Active, not recruiting|August 1999|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||December 2005|May 8, 2008|February 20, 2004||||||https://clinicaltrials.gov/show/NCT00078221||200947|
NCT00078910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000353196|Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer|A Prospective Phase II Study of Preoperative, Controlled Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis||National Cancer Institute (NCI)||Completed|August 2003|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|130|||Male|40 Years|N/A|No|||September 2006|June 21, 2013|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00078910||200901|
NCT00079144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000354491|Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment Of Patients With Metastatic Melanoma Using Nonmyeloablative But Lymphocyte Depleting Regimen Followed By The Administration Of In Vitro Sensitized Lymphocytes Reactive With ESO-1 Antigen||National Cancer Institute (NCI)||Completed|January 2004|August 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||May 2005|June 18, 2013|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079144||200884|
NCT00078897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000353185|Selenium for Prevention of Adenomatous Colorectal Polyps|Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence||University of Arizona|Yes|Active, not recruiting|January 2001|July 2016|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1800|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00078897||200902|
NCT00079157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000354502|Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer|Phase I Study Of Telomerase Peptide Vaccination For Patients With Advanced Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2004|||May 2008|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||July 2009|July 29, 2009|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079157||200883|
NCT00080067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040146|Rhythm Perception and Generation|fMRI Study on Mechanism of Rhythm Perception and Generation||National Institutes of Health Clinical Center (CC)||Completed|March 2004|February 2009||||N/A|Observational|N/A||||50|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 24, 2009|March 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00080067||200815|
NCT00079417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARET0331|Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma|Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma||Children's Oncology Group|Yes|Active, not recruiting|December 2005|||January 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|N/A|5 Years|No|||March 2016|March 14, 2016|March 8, 2004|No|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT00079417||200865|
NCT00101673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2329|Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%|Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%||Novartis||Completed|March 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|251|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|January 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101673||199293|
NCT00101686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTAIV-0020-411|Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.|A Randomized, Multi-Center Phase III Trial Of Irinotecan In Combination With Three Different Methods Of Administration Of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5-FU (Day 1 & 8), And Oral Capecitabine (Day 1-14); With Celecoxib Versus Placebo As First-Line Treatment For Patients With Metastatic Colorectal Cancer Study Amended April 23, 2004 To Include Bevacizumab||Pfizer|Yes|Completed|February 2003|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|547|||Both|18 Years|N/A|No|||January 2010|January 4, 2010|January 12, 2005|Yes|Yes||No|October 20, 2009|https://clinicaltrials.gov/show/NCT00101686||199292|
NCT00108004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-155|Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus|A Phase 3B, Multicenter, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Insulin Therapy||AstraZeneca||Completed|April 2003|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|April 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00108004||198830|
NCT00108017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507A-137|Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)|Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurnal Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Combo. Ophthalmic Sol. in Patients w/ Open Angle Glaucoma or Ocular Hypertension||Merck Sharp & Dohme Corp.||Completed|April 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|330|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00108017||198829|
NCT00107666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-01-C04-201|CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Proof of Concept Clinical Study of CTI-01 in Patients Undergoing Major Cardiac Surgery With Cardiopulmonary Bypass||Critical Therapeutics||Terminated|April 2005|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|18 Years|N/A|No|||March 2006|March 15, 2006|April 6, 2005||||||https://clinicaltrials.gov/show/NCT00107666||198856|
NCT00107679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 065G|A Study of Anal Cancer Development in HIV Infected People|Anal Dysplasia: A Substudy of a Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2005|March 2006|Actual|March 2006|Actual|N/A|Observational|Time Perspective: Prospective||||560|||Both|13 Years|N/A|No|||April 2014|April 15, 2014|April 6, 2005||||No||https://clinicaltrials.gov/show/NCT00107679||198855|
NCT00107978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0018|Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus|ATLAS2|Theravance Biopharma Antibiotics, Inc.|Yes|Completed|February 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1035|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|April 11, 2005|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00107978||198832|
NCT00079963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62378DK|Gender, Obesity, C-Reactive Protein, and Oxidative Stress|Gender, Obesity, C-Reactive Protein, and Oxidative Stress||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|April 2004|December 2017|Anticipated|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|396|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 18, 2004||No||No||https://clinicaltrials.gov/show/NCT00079963||200823|
NCT00081978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006736|TMC125-C223: TMC125 in HIV-1 Infected Subjects|A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125 in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations||Tibotec Pharmaceuticals, Ireland||Completed|March 2004|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|211|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|April 28, 2004||||||https://clinicaltrials.gov/show/NCT00081978||200688|
NCT00081705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1249|Estrogen Receptor Variants, HDL, and Atherosclerosis|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 2004|February 2007|Actual|February 2007|Actual|N/A|Observational|N/A|||||||Both|15 Years|34 Years|No|||January 2008|January 24, 2008|April 19, 2004||||No||https://clinicaltrials.gov/show/NCT00081705||200708|
NCT00080743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355145|Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer|ZD1839 (IRESSA) In Tamoxifen-Resistant Metastatic Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Completed|January 2004|November 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||August 2009|August 4, 2009|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080743||200771|
NCT00103376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000406013|Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer|VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer||Medical University of South Carolina|Yes|Completed|October 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Male|18 Years|N/A|No|||April 2012|April 26, 2012|February 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103376||199165|
NCT00103675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001121-01A1|Sensor Measurement of Acupuncture Needle Manipulation|Acupuncture Needling Torque Sensor||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2004|February 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|February 26, 2007|February 11, 2005||||No||https://clinicaltrials.gov/show/NCT00103675||199144|
NCT00104390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrassMATAMPL101|Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing|A Single-blind Phase 1 Study to Assess the Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing||Allergy Therapeutics||Completed|March 2005|April 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||14|||Both|18 Years|50 Years|No|||June 2010|June 9, 2010|February 28, 2005||||||https://clinicaltrials.gov/show/NCT00104390||199093|
NCT00104429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102881|GW873140 In Combination With Combivir In HIV Infected Subjects|See Detailed Description||GlaxoSmithKline||Terminated|January 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||125|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|February 28, 2005||||No||https://clinicaltrials.gov/show/NCT00104429||199090|
NCT00104702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000416123|Radiation Therapy in Treating Older Women Who Are Undergoing Surgery for Stage I or Stage II Breast Cancer|Radio-Surgical Treatment of Breast Cancer of Women Aged Over 70: Phase II Trial of Feasibility and Reproducibility of a Concentrated and Focalized Radiotherapy|GERICO03|UNICANCER||Completed|July 2004|March 2011|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|70 Years|N/A|No|||September 2013|September 2, 2013|March 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00104702||199069|
NCT00104923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000413887|Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer|Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies||California Cancer Consortium|Yes|Active, not recruiting|February 2005|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|March 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104923||199053|
NCT00105183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZ-2053-001|EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection|A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s)||Neovii Biotech|Yes|Completed|January 2005|January 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|223|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|March 8, 2005|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00105183||199034|Interim analysis: Dropped 5mg/kg arm. Study was insufficiently powered & focus shifted to safety endpoints. Eliminated some secondary endpoints eg. steroid resistant&antibody treated rejection,CNI&antiproliferative agent, bronchiolitis obliterans.
NCT00105196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-165|A Study of Aripiprazole in Patients With Major Depressive Disorder|A Study of Aripiprazole in Patients With Major Depressive Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|March 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|349|||Both|18 Years|65 Years|No|||April 2011|November 7, 2013|March 9, 2005|Yes|Yes||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00105196||199033|
NCT00106275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibromyalgia & Mindfulness|Mindfulness-Based Stress Reduction Program as an Intervention in Patients With Fibromyalgia|Mindfulness-Based Stress Reduction Program as an Intervention in Patients With Fibromyalgia: A Three-Armed Randomized Clinical Study||University Hospital Freiburg||Active, not recruiting|November 2003|November 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Female|18 Years|70 Years|No|||November 2005|January 30, 2006|March 21, 2005||||No||https://clinicaltrials.gov/show/NCT00106275||198953|
NCT00106587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT – Pac 1|Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR I)|Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons||University Hospital, Saarland||Completed|December 2003|March 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|N/A|No|||March 2005|November 9, 2005|March 25, 2005||||No||https://clinicaltrials.gov/show/NCT00106587||198930|
NCT00106600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIX109|Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)|A Phase I/II Study of Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)||CTI BioPharma||Completed|March 2005|March 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||119|||Both|18 Years|N/A|No|||August 2007|August 21, 2007|March 28, 2005||||||https://clinicaltrials.gov/show/NCT00106600||198929|
NCT00106899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0068|ADNI: Alzheimer's Disease Neuroimaging Initiative|Alzheimer's Disease Neuroimaging Initiative||Alzheimer's Disease Cooperative Study (ADCS)|Yes|Completed|July 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|818|Samples With DNA|blood, urine, cerebrospinal fluid|Both|55 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|community sample|September 2014|September 15, 2014|March 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00106899||198908|
NCT00106912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050129|Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity|A Study to Collect Normative Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity||National Institutes of Health Clinical Center (CC)||Completed|March 2005|March 2008||||N/A|Observational|N/A||||35|||Male|18 Years|N/A|No|||March 2008|September 26, 2015|March 31, 2005||||No||https://clinicaltrials.gov/show/NCT00106912||198907|
NCT00079664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH062327|Comparing Tai Chi Training to a Low-Stress Physical Activity to Enhance Sleep in Older Adults|Tai Chi Training and Sleep Enhancement in the Elderly||Oregon Research Institute|No|Completed|September 2001|July 2003|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 30, 2013|March 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00079664||200846|
NCT00081042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000358804|ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma|An Open-Label, Multicenter, Phase II Trial of ABI-007 (A Cremophor® -Free, Protein Stabilized, Nanoparticle Paclitaxel) in Previously Treated Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|February 2004|January 2010|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|December 18, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081042||200752|
NCT00081055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mesoblast|OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of OTI-010 in Subjects Who Receive HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies||Mesoblast, Ltd.||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Actual|0|||Both|18 Years|55 Years|No|||December 2014|December 3, 2014|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081055||200751|
NCT00081770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03471|Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)|Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1||Merck Sharp & Dohme Corp.|Yes|Completed|March 2004|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4469|||Both|18 Years|70 Years|No|||March 2015|March 31, 2015|April 20, 2004|Yes|Yes||No|November 3, 2008|https://clinicaltrials.gov/show/NCT00081770||200704|
NCT00103155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000410790|Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer|Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study||National Cancer Institute (NCI)||Active, not recruiting|September 2004|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||August 2005|September 19, 2013|February 7, 2005||||No||https://clinicaltrials.gov/show/NCT00103155||199182|
NCT00107120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT-MD-32|The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder|A Double-blind Flexible Dose Study of Escitalopram in Pediatric Patients With Major Depressive Disorder||Forest Laboratories||Completed|March 2005|||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|312|||Both|12 Years|17 Years|No|||April 2012|April 4, 2012|April 5, 2005|Yes|Yes||No|April 21, 2009|https://clinicaltrials.gov/show/NCT00107120||198892|
NCT00102778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100136|GW873140 In Combination With Kaletra In HIV Infected Subjects|See Detailed Description||GlaxoSmithKline||Terminated|December 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||175|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|February 1, 2005||||||https://clinicaltrials.gov/show/NCT00102778||199208|
NCT00104026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050103|Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth|Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth||National Institutes of Health Clinical Center (CC)||Completed|February 2005|April 2011||||N/A|Observational|N/A|||Actual|45|||Both|2 Years|80 Years|No|||April 2011|April 20, 2011|February 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00104026||199119|
NCT00104039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050105|Brain Changes in Children and Adolescents With Behavioral Problems|Investigating the Neuro-Cognitive Underpinnings of the Emotional Dysfunction Linked to Childhood Behavioral Disturbance||National Institutes of Health Clinical Center (CC)||Recruiting|February 2005|||||N/A|Observational|N/A|||Anticipated|640|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|February 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00104039||199118|
NCT00104052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02538: Part 1|Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)|Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C||Merck Sharp & Dohme Corp.|Yes|Completed|February 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|3 Years|17 Years|No|||March 2015|March 26, 2015|February 22, 2005|No|Yes||No|November 14, 2008|https://clinicaltrials.gov/show/NCT00104052||199117|
NCT00104403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV101983|Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy|A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea||GlaxoSmithKline|No|Completed|December 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|722|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|February 28, 2005||||||https://clinicaltrials.gov/show/NCT00104403||199092|
NCT00105209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL67771-01|A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension|A Double-Blind, Placebo-Controlled, Three Treatment Cross-Over Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension||Kawut, Steven, MD||Completed|April 2002|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||March 2005|June 23, 2005|March 9, 2005||||No||https://clinicaltrials.gov/show/NCT00105209||199032|
NCT00105222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050114|Effect of Nitrite on Exercise Physiology and Metabolism|Evaluation of Systemic Nitrite Infusion and Its Effect on Exercise Physiology and Metabolism||National Institutes of Health Clinical Center (CC)||Terminated|March 2005|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|15|||Both|21 Years|45 Years|No|||August 2013|September 7, 2013|March 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00105222||199031|
NCT00105521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62225-019|Sarizotan HCl in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia|A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia||EMD Serono||Completed|September 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|594|||Both|30 Years|N/A|No|||October 2013|October 23, 2013|March 15, 2005||||||https://clinicaltrials.gov/show/NCT00105521||199010|
NCT00106028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003100|Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children|Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children||Warner Chilcott|No|Completed|November 2004|March 2010|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|143|||Both|4 Years|15 Years|No|||April 2013|April 15, 2013|March 18, 2005|Yes|Yes||No|April 15, 2009|https://clinicaltrials.gov/show/NCT00106028||198972|The clinical meaningfulness of new fractures in the thoracic spine scored as Genant Grade I is unclear, thus the morphometric vertebral fracture data are evaluated further.
NCT00105755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 20-059|Dermal Thermometry and Self-Care of High Risk Diabetic Patients|Dermal Thermometry and Self-Care of High Risk Diabetic Patients||VA Office of Research and Development|No|Completed|January 2003|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105755||198992|
NCT00106002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9028|Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer|A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer||Eli Lilly and Company|Yes|Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||April 2009|May 29, 2009|March 18, 2005|Yes|Yes||No|December 23, 2008|https://clinicaltrials.gov/show/NCT00106002||198974|
NCT00106015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288|Diamond Blackfan Anemia Registry (DBAR)|Diamond Blackfan Anemia Registry (DBAR)|DBAR|Northwell Health||Recruiting|September 2004|||April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|850|||Both|N/A|N/A|No|Probability Sample|All subjects diagnosed with Diamond Blackfan anemia|November 2015|November 23, 2015|March 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00106015||198973|
NCT00106938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD-640-0052|Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)|Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)|ACT I|Abbott Vascular||Terminated|April 2005|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1663|||Both|18 Years|79 Years|No|||October 2014|October 13, 2014|April 1, 2005|Yes|Yes|Business decision and not a result of any patient or product safety issues.|No|April 2, 2014|https://clinicaltrials.gov/show/NCT00106938||198905|
NCT00107250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I171|AZD2171 and Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)|A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer or Other Tumor Types Suitable for Treatment With Capecitabine||Canadian Cancer Trials Group|Yes|Completed|January 2005|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|April 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00107250||198885|
NCT00107211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000416200|Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast|A HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|January 2005|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107211||198887|
NCT00102882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA100062|Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate|See Detailed Description||GlaxoSmithKline|No|Completed|October 2004|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|547|||Both|12 Years|N/A|No|||April 2015|April 15, 2015|February 3, 2005||||||https://clinicaltrials.gov/show/NCT00102882||199200|
NCT00102895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4031003|A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer|An Open-Label, Multi-Center, Phase 2 Study Of Cp 724,714 In Patients With Her2 Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy For Metastatic Disease And Is Previously Untreated With A Her2 Inhibitor||Pfizer||Terminated|April 2005|September 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Female|18 Years|N/A|No|||August 2010|August 26, 2010|February 3, 2005|||See Detailed Description|No||https://clinicaltrials.gov/show/NCT00102895||199199|
NCT00080054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0218|A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas|Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Temozolomide for Treatment of Malignant Gliomas||Pharmacyclics||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||January 2007|April 2, 2009|March 22, 2004||||||https://clinicaltrials.gov/show/NCT00080054||200816|
NCT00080795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355361|Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium|Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer||M.D. Anderson Cancer Center|No|Completed|July 2001|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|N/A|N/A|No|||October 2012|October 18, 2012|April 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00080795||200768|
NCT00080808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-304|Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer|A Randomized Phase II Trial Evaluating the Importance of Early Erectile Dysfunction Rehabilitation and Unilateral Autologous Sural Nerve Sparing Radical Prostatectomy Clinically Localized Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|August 2001|July 2009|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|111|||Male|N/A|65 Years|No|||July 2012|July 27, 2012|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080808||200767|
NCT00080834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000356034|DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma|A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum||Daiichi Sankyo Inc.||Completed|February 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 15, 2012|April 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080834||200766|
NCT00082095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004645|To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older|A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|April 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Female|60 Years|N/A|No|||October 2014|October 8, 2014|April 29, 2004|No|Yes|The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients    in 20 months|No||https://clinicaltrials.gov/show/NCT00082095||200681|
NCT00103753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02 065|Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major|A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance||Royal Brompton & Harefield NHS Foundation Trust||Active, not recruiting|May 2004|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||65|||Both|18 Years|N/A|No|||February 2005|June 23, 2005|February 14, 2005||||No||https://clinicaltrials.gov/show/NCT00103753||199139|
NCT00103701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-002|BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia|Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia||Bristol-Myers Squibb||Completed|November 2003|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|14 Years|N/A|No|||April 2011|April 13, 2011|February 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00103701||199143|
NCT00103402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cp/cpps (IND)|Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome|A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|270|||Male|18 Years|N/A|No|||April 2011|April 25, 2011|February 7, 2005||||||https://clinicaltrials.gov/show/NCT00103402||199163|
NCT00104078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3147K2-101|Study Evaluating MYO-029 in Adult Muscular Dystrophy|||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2005|January 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|February 22, 2005||||No||https://clinicaltrials.gov/show/NCT00104078||199115|
NCT00103714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-104|Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Cystic Fibrosis Lung Disease||Merck Sharp & Dohme Corp.||Completed|January 2005|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|72|||Both|8 Years|50 Years|No|||October 2015|October 19, 2015|February 14, 2005||||||https://clinicaltrials.gov/show/NCT00103714||199142|
NCT00103727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-223412/093|Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia|A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia||GlaxoSmithKline||Completed|December 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|282|||Both|18 Years|65 Years|No|||April 2015|April 27, 2015|February 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103727||199141|
NCT00104455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7DRC-2157|Dose Response to Recombinant Factor VIIa When Administered for Bleed|Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers||Novo Nordisk A/S|No|Completed|June 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|64|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|June 15, 2012|February 28, 2005||||No||https://clinicaltrials.gov/show/NCT00104455||199088|
NCT00104065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-421|Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant||Celldex Therapeutics||Completed|January 2005|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||February 2016|March 14, 2016|February 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104065||199116|
NCT00104416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM100036|Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures|A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic Seizures||GlaxoSmithKline|No|Completed|December 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|153|||Both|13 Years|N/A|No|||September 2012|September 20, 2012|February 28, 2005|Yes|Yes||No|April 16, 2010|https://clinicaltrials.gov/show/NCT00104416||199091|
NCT00105534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08635|Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)|A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis||Merck Sharp & Dohme Corp.|No|Completed|July 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|685|||Both|12 Months|N/A|No|||October 2013|October 29, 2013|March 15, 2005|Yes|Yes||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00105534||199009|
NCT00105768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHI 20-001|Effectiveness of Advisor-Teller Money Manager|Effectiveness of Advisor - Teller Money Manager (ATM)||VA Office of Research and Development|No|Completed|July 2002|October 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105768||198991|
NCT00106301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ-228-0007|Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228|A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Have Completed a Prior Clinical Study With FK228||Celgene|No|Completed|April 2004|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|March 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00106301||198951|
NCT00106314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-C002-00|An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease|A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease||Inflabloc Pharmaceuticals||Completed|January 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||October 2007|October 17, 2007|March 22, 2005||||||https://clinicaltrials.gov/show/NCT00106314||198950|
NCT00106288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-463-21-08|Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia|A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia||Astellas Pharma Inc|Yes|Completed|January 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|637|||Both|N/A|N/A|No|||September 2014|September 17, 2014|March 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00106288||198952|
NCT00106613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ-228-0001|A Research Study for Patients With Metastatic Renal Cell Carcinoma|An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy||Celgene|No|Completed|May 2003|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|March 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00106613||198928|
NCT00106925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050130|Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants|Long-Term Evaluation and Follow Up Care of Patients Treated With Allogeneic Stem Cell Transplants||National Institutes of Health Clinical Center (CC)||Recruiting|March 2005|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|2 Years|80 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|March 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00106925||198906|
NCT00102908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AI058756-01|Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density|Bisphosphonate Therapy for HIV-Associated Osteopenia||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|May 2005|December 2009|Anticipated|October 2007|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||September 2008|September 25, 2008|February 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102908||199198|
NCT00102921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL003_282|Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn’s Disease|Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn’s Disease||ChemoCentryx||Completed|August 2004|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|18 Years|65 Years|No|||March 2006|March 12, 2006|February 4, 2005||||||https://clinicaltrials.gov/show/NCT00102921||199197|
NCT00103207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000409755|Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer|Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features||Eastern Cooperative Oncology Group|No|Completed|August 2005|August 2012|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|February 7, 2005|Yes|Yes||No|December 3, 2012|https://clinicaltrials.gov/show/NCT00103207||199178|
NCT00103506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004117|Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma|A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma||Janssen Research & Development, LLC|Yes|Completed|December 2004|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|646|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|February 9, 2005|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT00103506||199157|Study stopped in terms of primary endpoint based on its results at planned interim analysis (28 Apr 2006). However, Long-term follow-up for survival continued until 16 May 2014.
NCT00103519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIT-803|Study of DITPA in Patients With Congestive Heart Failure|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients With NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels||Titan Pharmaceuticals||Terminated|December 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Both|18 Years|N/A|No|||November 2006|March 27, 2013|February 9, 2005|Yes|Yes|Study terminated for reasons unrelated to safety or efficacy.|No||https://clinicaltrials.gov/show/NCT00103519||199156|
NCT00080847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03031|S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) With Advanced Stage Diffuse Large B-Cell NHL of Low and Low-Intermediate IPI Risk||National Cancer Institute (NCI)||Terminated|March 2004|||June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|19 Years|59 Years|No|||January 2013|January 4, 2013|April 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00080847||200765|
NCT00080405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34103-058|Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma|Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma||Millennium Pharmaceuticals, Inc.||Completed|March 2004|||June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2009|March 26, 2009|March 30, 2004||||||https://clinicaltrials.gov/show/NCT00080405||200791|
NCT00081419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040153|Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder|Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder Using EEG and Surface EMG||National Institutes of Health Clinical Center (CC)||Completed|April 2004|January 2009||||N/A|Observational|N/A||||42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 13, 2009|April 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00081419||200729|
NCT00077519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000352182|Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer|A Phase I Trial of the Farnesyltransferase Inhibitor, R115777 (NSC# 702818) and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2004|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||April 2007|February 6, 2009|February 10, 2004||||||https://clinicaltrials.gov/show/NCT00077519||200998|
NCT00104481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R15CA077732-02A1|Group Counseling for Smoking Cessation|Cognitive Behavior Therapy for Smoking Cessation||American University||Completed|January 2005|August 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||March 2007|December 7, 2011|March 1, 2005||||No||https://clinicaltrials.gov/show/NCT00104481||199086|
NCT00103142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007616|Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer|A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma||Duke University|Yes|Completed|February 2005|March 2013|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||October 2015|October 11, 2015|February 7, 2005|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00103142||199183|
NCT00104091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-202-22-188|Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors|A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection||Teva Pharmaceutical Industries||Completed|December 2004|June 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|February 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104091||199114|
NCT00104442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BUS25|Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease|Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease||Novartis||Completed|October 2003|April 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|50 Years|85 Years|No|||December 2007|December 17, 2007|February 28, 2005||||||https://clinicaltrials.gov/show/NCT00104442||199089|
NCT00104715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000416096|Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer|Randomized Phase III Trial Comparing an Association of Hormonal Treatment and Docetaxel Versus the Hormonal Treatment Alone in Metastatic Prostate Cancers||National Cancer Institute (NCI)||Active, not recruiting|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|378|||Male|18 Years|N/A|No|||April 2008|November 6, 2010|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104715||199068|
NCT00104936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26021 -22021|Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery|Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|December 2004|||November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|9|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|March 3, 2005|||low accrual|No||https://clinicaltrials.gov/show/NCT00104936||199052|
NCT00106041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-294|Study to Improve Care for Veterans During Serious Illness|Randomized Trial of Care Management to Improve End of Life Care||VA Office of Research and Development|No|Completed|August 2004|September 2012|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|400|||Both|N/A|N/A|No|||September 2012|April 6, 2015|March 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00106041||198971|
NCT00102934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21AI055273-02|Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus|Treatment Intensification in HIV-1 Patients With Multi-Drug Resistant Virus||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|March 2003|March 2009|Anticipated|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2008|September 16, 2008|February 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102934||199196|
NCT00106626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_006|Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors|Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.||Completed|August 2005|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2009|March 16, 2009|March 28, 2005|No|Yes||No|November 25, 2008|https://clinicaltrials.gov/show/NCT00106626||198927|
NCT00106951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1292|Effects of Neighborhood SES on Coronary Heart Disease Burden in Communities - Ancillary to ARIC|Effects of Neighborhood SES on Coronary Heart Disease Burden in Communities - Ancillary to ARIC||University of North Carolina, Chapel Hill|No|Completed|April 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|12000|||Both|35 Years|74 Years|No|Probability Sample|Community surveillance of adults in four communities in the US|January 2012|January 29, 2012|April 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00106951||198904|
NCT00107237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEE788A2106|AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme|A Phase IB/II Multicenter, Two-Arm, Dose-Escalation Study of Oral AEE788 Administered in Combination With Oral RAD001 on a Continuous Once Daily Dosing Schedule in Adult Patients With First or Second Recurrent or Relapsing Glioblastoma Multiforme||Novartis||Completed|October 2003|June 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|April 5, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00107237||198886|
NCT00103805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-LD_01|Improved Language Acquisition With Levodopa|Improved Language Acquisition With Levodopa||University Hospital Muenster||Completed|March 2003|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|February 14, 2005||||No||https://clinicaltrials.gov/show/NCT00103805||199135|
NCT00103818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-014|An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy Study of MK0928 15 mg and 10 mg in the Treatment of Adult Outpatients With Primary Insomnia||H. Lundbeck A/S||Completed|February 2005|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|900|||Both|18 Years|64 Years|No|||January 2015|January 13, 2015|February 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103818||199134|
NCT00104169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0014|Idiopathic Anemia of Aging (IAA)|Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA)||National Institute on Aging (NIA)||Terminated|August 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Actual|0|||Both|70 Years|N/A|No|||August 2008|August 28, 2008|February 23, 2005|||No subject accrual|No||https://clinicaltrials.gov/show/NCT00104169||199108|
NCT00104507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-003|Safety and Efficacy of APD356 in the Treatment of Obesity|A 4-Week, Dose-ranging, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of APD356 in Obese Patients||Arena Pharmaceuticals||Completed|December 2004|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2006|February 1, 2010|March 1, 2005||||||https://clinicaltrials.gov/show/NCT00104507||199084|
NCT00103831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA165-021|Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer|Phase I Alimta Combination With BMS-275183 (Oral Taxane)||Bristol-Myers Squibb||Completed||||May 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|February 27, 2010|February 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103831||199133|
NCT00103844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-017|Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia|A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d||Bristol-Myers Squibb|No|Completed|February 2005|March 2008|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||June 2010|August 3, 2010|February 15, 2005|Yes|Yes||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00103844||199132|
NCT00081107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-134|Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy|A Phase II Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease||Memorial Sloan Kettering Cancer Center||Completed|December 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081107||200748|
NCT00081133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-126|Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous Leukemia in Accelerated or Blastic Phase Disease or Ph+ Acute Lymphoblastic Leukemia||Memorial Sloan Kettering Cancer Center||Completed|December 2003|February 2005|Actual|February 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081133||200747|
NCT00081094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000358907|Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer|Detection of Hepatocellular Carcinoma by Positron Emission Tomography With C-Acetate-11 and F-fluorodeoxyglucose-18||Washington University School of Medicine|No|Completed|September 2003|September 2005|Actual|June 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00081094||200749|
NCT00081432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040159|Language and Emotional Function in Patients With Temporal Lobe Epilepsy|Functional MRI (fMRI) and Diffusion Tensor Imaging (DTI) in Temporal Lobe Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|April 2004|April 2010||||N/A|Observational|N/A|||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|September 26, 2015|April 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00081432||200728|
NCT00081783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XT009|Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients|A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL)||Xcyte Therapies||Recruiting|March 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2005|June 23, 2005|April 20, 2004||||||https://clinicaltrials.gov/show/NCT00081783||200703|
NCT00077259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-113|Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer|A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic Colorectal Carcinoma (CRC)||Memorial Sloan Kettering Cancer Center||Completed|October 2003|||September 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 15, 2013|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077259||201015|
NCT00077298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01445|Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer|A Randomized Phase II Study of Bevacizumab in Combination With Cetuximab Plus Irinotecan, or in Combination With Cetuximab Alone, in Irinotecan-Refractory Colorectal Cancer||National Cancer Institute (NCI)||Completed|December 2003|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||December 2012|April 14, 2015|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077298||201013|
NCT00103415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01-213/04|Trial Investigating the Effect of Different Exercise Forms on Depression|Randomized Clinical Trial Investigating the Effect of Different Exercise Forms on Depression||Demostudiet||Active, not recruiting|February 2005|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|18 Years|55 Years|No|||February 2005|July 12, 2006|February 8, 2005||||No||https://clinicaltrials.gov/show/NCT00103415||199162|
NCT00103740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2305|Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period|Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period||Novartis||Completed|April 2002|April 2011|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|185|||Both|30 Years|N/A|No|||May 2012|May 29, 2012|February 14, 2005|Yes|Yes||No|April 5, 2012|https://clinicaltrials.gov/show/NCT00103740||199140|
NCT00104468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD758-110|Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)|An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia||SGX Pharmaceuticals, Inc.||Terminated|April 2003|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|February 28, 2005|||Trial stopped June 2007|||https://clinicaltrials.gov/show/NCT00104468||199087|
NCT00104728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13922|Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates|Pilot Neoadjuvant Study of ZD1839 (IRESSA®) as Single Agent Preoperative Therapy for Clinical Stage 1A and 1B (T1-2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) With Molecular Correlates||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|October 2004|March 2009|Actual|May 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2012|October 1, 2012|March 3, 2005|Yes|Yes|Early Stopping Rule: Would not meet interim analysis goal to proceed with enrollment|No|October 1, 2012|https://clinicaltrials.gov/show/NCT00104728||199067|Pilot study. At the time of interim analysis, the second early stopping rule was invoked for lack of activity (not enough responses to continue). Study closed to accrual 5/9/08.
NCT00104949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000413703|Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma|Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma||National Cancer Institute (NCI)||Completed|July 2005|August 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||December 2006|June 21, 2013|March 3, 2005||||||https://clinicaltrials.gov/show/NCT00104949||199051|
NCT00105235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN024ST|Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients|A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation (ITN024ST)|TILT|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2005|March 2011|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||November 2012|November 23, 2012|March 10, 2005|Yes|Yes||No|March 2, 2012|https://clinicaltrials.gov/show/NCT00105235||199030|This study was converted to a pilot study on May 23, 2006. Only 27 of the planned 211 participants were enrolled, thus reducing the number of subjects available for analysis.
NCT00107263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N03CC|Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer|A Randomized, Controlled, Open-Label Trial of Empiric Prophylactic vs. Delayed Use of Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women With Breast Cancer Initiating Therapy With Letrozole After Tamoxifen||Alliance for Clinical Trials in Oncology|No|Completed|January 2005|August 2012|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|558|||Female|18 Years|N/A|No|||July 2015|July 14, 2015|April 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107263||198884|
NCT00103220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01462|SJG-136 in Treating Patients With Advanced Solid Tumors|A Phase I Study With SJG-136 (NSC #694501) in Patients With an Advanced Solid Tumor||National Cancer Institute (NCI)||Completed|November 2004|||February 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|February 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00103220||199177|
NCT00103532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 004|Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth|Motivational Enhancement to Promote Health and Reduce Risk in HIV-Infected Youth||Westat|Yes|Completed|March 2005|April 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|16 Years|24 Years|No|||February 2016|February 29, 2016|February 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00103532||199155|
NCT00103233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000409573|Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer|A Randomized Study of Weekly Vinorelbine (Navelbine®) Alone or in Combination With Trastuzumab (Herceptin®) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III||National Cancer Institute (NCI)||Completed|December 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||August 2005|June 21, 2013|February 7, 2005||||||https://clinicaltrials.gov/show/NCT00103233||199176|
NCT00103545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 2.8|Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response|A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer||AGO Study Group||Completed|July 2003|August 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||36|||Female|N/A|N/A|No|||February 2006|September 29, 2006|February 10, 2005||||No||https://clinicaltrials.gov/show/NCT00103545||199154|
NCT00103558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152-30|Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)|A Phase I/II Study of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia||Biogen|Yes|Completed|March 2004|March 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|18 Years|N/A|No|||May 2010|September 17, 2015|February 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103558||199153|
NCT00080444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-097|Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Emetogenic Chemotherapy in Adolescent Patients||Merck Sharp & Dohme Corp.|No|Completed|April 2004|March 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|50|||Both|12 Years|17 Years|No|||August 2014|August 4, 2014|March 31, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00080444||200788|
NCT00080457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRIDE 2|Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hypertension (PAH)||Encysive Pharmaceuticals||Completed|May 2003|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|12 Years|75 Years|No|||November 2007|November 8, 2007|April 1, 2004||||||https://clinicaltrials.gov/show/NCT00080457||200787|
NCT00081796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6089|Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer|A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy||Sanofi||Completed|April 2004|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|438|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|April 20, 2004||||||https://clinicaltrials.gov/show/NCT00081796||200702|
NCT00081458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-004|Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome|A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome||Shire|Yes|Completed|April 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|N/A|No|||September 2014|November 10, 2015|April 13, 2004|Yes|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00081458||200727|
NCT00077285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-099|Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma|A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2003|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|N/A|50 Years|No|||October 2015|October 28, 2015|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077285||201014|
NCT00082121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP10-ACS-002|Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery|||Avant Immunotherapeutics||Completed|April 2004|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||300|||Female|18 Years|N/A|No|||July 2007|July 19, 2007|April 29, 2004||||||https://clinicaltrials.gov/show/NCT00082121||200679|
NCT00077558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000352322, J0357|3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome|A Phase I Trial Of Sequential Administration Of Triapine (3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone) Followed By Fludarabine In Adults With Relapsed And Refractory Leukemias And Myelodysplasias||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2004|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|March 9, 2010|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077558||200995|
NCT00104741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000416088|Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer|Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis||National Cancer Institute (NCI)||Recruiting|July 2004|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|450|||Male|N/A|74 Years|No|||April 2008|February 18, 2011|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104741||199066|
NCT00104754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0322|Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer|Phase II Trial of Liposome Encapsulated SN38 (LE-SN38) in the Treatment of Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology||Withdrawn||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2009|August 6, 2013|March 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104754||199065|
NCT00104975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000413698|Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer|Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells||National Cancer Institute (NCI)||Completed|February 2005|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|55 Years|No|||June 2007|May 14, 2011|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104975||199049|
NCT00104104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS97|A Multiple Myeloma Trial in Patients With Bone Metastases|A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases||Novartis||Completed|October 2004|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|February 22, 2005||No||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00104104||199113|
NCT00104117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-001|Study of XL999 in Adults With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors||Symphony Evolution, Inc.|Yes|Completed|November 2004|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|February 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104117||199112|
NCT00105248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B0-102137|Patient Centered Communication Training to Reduce Antibiotic Use in Acute Respiratory Tract Infections|Multidimensional Intervention Program to Reduce Antibiotic Prescriptions for Acute Respiratory Tract Infections in Adults: a Randomized Controlled Trial in Primary Care||University Hospital, Basel, Switzerland|No|Completed|January 2004|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||900|||Both|18 Years|N/A|No|||March 2005|June 9, 2015|March 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00105248||199029|
NCT00105547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-7869-04-005.02|Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's|Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type||Myrexis Inc.|Yes|Completed|February 2005|May 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1600|||Both|55 Years|N/A|No|||May 2009|May 3, 2009|March 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00105547||199008|
NCT00105781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 99-334|Nurse Physical Activity Counseling in Primary Care|Nurse Physical Activity Counseling in Primary Care||VA Office of Research and Development|No|Completed|November 2002|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|60 Years|85 Years|No|||May 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105781||198990|
NCT00106977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050131|Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)|Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)||National Institutes of Health Clinical Center (CC)||Recruiting|March 2005|||||N/A|Observational|N/A|||Anticipated|200|||Both|N/A|N/A|No|||June 2015|June 17, 2015|April 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00106977||198902|
NCT00107003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050134|GW572016 to Treat Recurrent Malignant Brain Tumors|A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma||National Institutes of Health Clinical Center (CC)||Completed|March 2005|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2012|October 23, 2014|April 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107003||198901|
NCT00106964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 024|Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth|A Randomized, Open-Label Trial of Three Hepatitis B Vaccination Schemas in HIV-Positive Youth||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|January 2004|June 2009|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|371|||Both|12 Years|24 Years|No|||December 2014|February 12, 2015|April 1, 2005|Yes|Yes||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00106964||198903|
NCT00107276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000423180|S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer|Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients With Metastatic Breast Cancer||Southwest Oncology Group|Yes|Completed|August 2005|August 2009|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Female|18 Years|N/A|No|||July 2013|July 3, 2013|April 5, 2005|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00107276||198883|
NCT00102947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-REN-03-06|Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections|An Open Label Phase 4 Trial to Further Evaluate the Pharmacokinetic Profile of Intravenous Daptomycin, and a Comparison of the Safety and Efficacy of Daptomycin Versus Comparator in the Treatment of Adult Patients With Renal Impairment and Complicated Skin and Skin Structure Infections Due, at Least in Part, to Gram-Positive Bacteria||Cubist Pharmaceuticals LLC||Terminated|January 2005|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||May 2007|May 21, 2007|February 4, 2005||||||https://clinicaltrials.gov/show/NCT00102947||199195|
NCT00102960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA ZA 002|Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth|A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2005|January 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|451|||Both|6 Weeks|12 Weeks|No|||July 2014|July 21, 2014|February 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102960||199194|
NCT00103571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8928|Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia|Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia||Eli Lilly and Company||Completed|July 2004|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|55 Years|No|||November 2007|November 5, 2007|February 10, 2005||||||https://clinicaltrials.gov/show/NCT00103571||199152|
NCT00103584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX012|Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers|A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers||VaxGen||Active, not recruiting|October 2004|July 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|18 Years|34 Years|Accepts Healthy Volunteers|||January 2007|January 11, 2007|February 10, 2005||||||https://clinicaltrials.gov/show/NCT00103584||199151|
NCT00103870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 12579|Mind Engagement With Music for Nondrug Pain Relief|Music Engagement for Non-Pharmacological Analgesia R21 AT001586-01||University of Utah||Completed|February 2005|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 8, 2009|February 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00103870||199130|
NCT00103883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 022|A Novel Method to Determine HIV Incidence Among Youth|A Novel Method to Determine HIV Incidence Among Youth||Westat|No|Completed|February 2003|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|440|Samples Without DNA|Phenotypic and genotypic testing for antiretroviral drug (ART) resistance will be done on      stored samples from all subjects who are identified as recently infected by the serum based      DV S/LS reference method. An assay for viral replication fitness will also be done on these      same samples. This testing will provide a recent assessment of prevalence of transmitted ART      resistant HIV-1 in this population.|Both|12 Years|24 Years|No|Non-Probability Sample|Two hundred fifty subjects will be recruited from the fifteen sites of the Adolescent        Trials Network for HIV/AIDS Interventions (ATN) and 190 from the BCHD STD Clinic, a        sexually transmitted disease clinic of the Baltimore City Health Department (BCHD). The        age range for subjects from the ATN clinical sites will be 12 through 24 years and those        from the BCHD STD Clinic will be 17 through 30 years.|February 2016|February 29, 2016|February 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00103883||199129|
NCT00081471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16738|A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis|A Randomized, Open-label Study of the Effect of Subcutaneous Mircera on Hemoglobin Level/Correction in Non-dialysis Patients With Chronic Kidney Disease||Hoffmann-La Roche||Completed|June 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 13, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081471||200726|
NCT00081484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA17284|A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients|A Randomized, Open-label Study of the Effect of Maintenance Mircera Administered With Pre-filled Syringes on Hemoglobin Levels in Anemic Dialysis Patients With Chronic Kidney Disease||Hoffmann-La Roche||Completed|June 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|336|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 13, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081484||200725|
NCT00081497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL02503|A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease|Multi-Center, Open-Label Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease That Previously Participated in the AGAL-008-00 Study||Sanofi||Completed|January 2004|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|16 Years|N/A|No|||March 2015|March 13, 2015|April 14, 2004|Yes|Yes||No|December 17, 2008|https://clinicaltrials.gov/show/NCT00081497||200724|No valid conclusions can be made from the predefined primary efficacy analysis. The sponsor believes that it is more statistically appropriate to compare placebo patients with Fabrazyme patients as they were randomized in the original Phase 4 trial.
NCT00081861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0520|Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma|A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Completed|March 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 2, 2012|April 23, 2004|Yes|Yes||No|March 5, 2009|https://clinicaltrials.gov/show/NCT00081861||200697|
NCT00082108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-104|Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry|National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members||University of Rochester|No|Recruiting|September 2000|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will volunteer to participate in this study. The study will be advertised        through neuromuscular disease clinics, the National Registry website, Patient Advocacy        Groups and MDA Clinics through out the United States.|January 2016|January 21, 2016|April 29, 2004||No||No||https://clinicaltrials.gov/show/NCT00082108||200680|
NCT00082134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILX651-241|Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel|A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel||Sanofi||Completed||December 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Male|19 Years|N/A|No|||March 2015|March 4, 2015|April 29, 2004||||||https://clinicaltrials.gov/show/NCT00082134||200678|
NCT00077584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPIDS-2 / AC-052-331|Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Scleroderma Patients|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis||Actelion||Completed|September 2003|December 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|February 10, 2004||Yes||||https://clinicaltrials.gov/show/NCT00077584||200994|
NCT00077597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16736|A Study of Mircera for the Treatment of Anemia in Dialysis Patients|A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease||Hoffmann-La Roche||Completed|February 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077597||200993|
NCT00104962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01820|Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes|Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome||National Cancer Institute (NCI)||Completed|March 2005|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|1 Year|21 Years|No|||December 2012|June 10, 2014|March 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00104962||199050|
NCT00105794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC 02-054|Psychiatric Advance Directives for Improved Mental Health Care|Psychiatric Advance Directives for Improved Healthcare||VA Office of Research and Development|No|Completed|March 2004|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|18 Years|N/A|No|||June 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105794||198989|
NCT00105807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 99-344|The Effect of Exercise on Muscle, Function and Cost in VA Nursing Home Residents|The Effect of Exercise on Muscle, Function and Cost in VA Nursing Home Residents||VA Office of Research and Development|No|Completed|July 2002|April 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|120|||Both|65 Years|N/A|No|||February 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105807||198988|
NCT00106054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5961065|Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases|An Open-Label, Multi-Center Phase II Trial of Neoadjuvant Irinotecan in Combination With Infusional 5-FU, Leucovorin (Folfiri) Plus Bevacizumab in Patients With Unresectable Hepatic-Only Metastases of Colorectal Carcinoma||Pfizer||Terminated|January 2006|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2|||Both|18 Years|N/A|No|||August 2010|August 26, 2010|March 18, 2005|||After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could    be performed.|No||https://clinicaltrials.gov/show/NCT00106054||198970|
NCT00106327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171|Improving Functioning in Peripheral Arterial Disease|Improving Functioning in Peripheral Arterial Disease||Northwestern University||Completed|September 2003|March 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|156|||Both|N/A|N/A|No|||July 2012|July 24, 2012|March 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00106327||198949|
NCT00106340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2308|Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes|Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes||Novartis||Completed|March 2005|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3118|||Both|18 Years|73 Years|No|||December 2012|December 28, 2012|March 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00106340||198948|
NCT00106639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921009|A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients|A 6-Month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study Of 2 Dose Levels Of CP-690,550 Administered Concomitantly With IL-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil And Corticosteroids Versus A Tacrolimus-Based Immunosuppressive Regimen For The Prevention Of Allograft Rejection In De Novo Renal Allograft Recipients||Pfizer|Yes|Completed|May 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|61|||Both|18 Years|70 Years|No|||February 2013|February 6, 2013|March 28, 2005|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00106639||198926|Results for first BPAR, BPCAN, treatment and efficacy failure, rejection, clinically significant infections, NODM and discontinuation reported as number and not percentage as planned. Stage 2 of study was not conducted due to administrative reasons.
NCT00096798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT001129|Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression|A Double-Blind, Placebo-Controlled Study of Ethyl Eicosapentanoic Acid (Ethyl-EPA) in Major Depressive Disorder||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2001|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|80 Years|No|||January 2008|January 15, 2008|November 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00096798||199645|
NCT00096811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-900|Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program|A Treatment Use Protocol of Entecavir in Subjects With Chronic Hepatitis B Infection Who Have Failed or Who Are Intolerant of Available Therapies||Bristol-Myers Squibb||No longer available|September 2003|August 2008|Actual|August 2008|Anticipated|N/A|Expanded Access|N/A|||||||Both|16 Years|N/A|No|||May 2010|May 7, 2010|November 15, 2004|Yes|Yes||||https://clinicaltrials.gov/show/NCT00096811||199644|
NCT00097188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2787g|A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis|A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis||Genentech, Inc.||Completed|December 2004|December 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|104|||Both|18 Years|55 Years|No|||February 2014|February 28, 2014|November 18, 2004||||||https://clinicaltrials.gov/show/NCT00097188||199617|
NCT00107289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-148|Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma|Pilot Phase II Study of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|May 2006|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|1 Year|N/A|No|||October 2015|October 18, 2015|April 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107289||198882|
NCT00102973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.3024|TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer|Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]||Telik||Completed|December 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Female|18 Years|N/A|No|||June 2006|May 30, 2012|February 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102973||199193|
NCT00097578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2941n|A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma|An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Adenocarcinoma||Genentech, Inc.||Completed|March 2004|July 2008|Actual|July 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1953|||Both|N/A|N/A|No|Non-Probability Sample|Sites were selected primarily from community-based oncology practices geographically        distributed across the United States.|March 2013|March 26, 2013|November 24, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00097578||199588|
NCT00103246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1Y04|Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides|Phase I Clinical Trial Using Topical Silicon Phthalocyanine (Pc 4) Photodynamic Therapy (PDT) for the Treatment of Pre-Malignant and Malignant Skin Conditions||Case Comprehensive Cancer Center|Yes|Completed|September 2004|August 2010|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2011|January 19, 2011|February 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00103246||199175|
NCT00093249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-03-01|Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)|Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)|ESCAPE-1|The Medicines Company|Yes|Completed|January 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|October 5, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093249||199903|
NCT00093522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000389145|Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer|A Phase II Pilot Study of Tumor-Loaded Dendritic Cells Alone or Following a Non-Myeloablative Conditioning Regimen in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|August 2004|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||May 2007|December 18, 2013|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093522||199885|
NCT00081172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC-03144|Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate|A Phase II Trial Of Lu Radiolabeled Monoclonal Antibody HuJ591-GS (Lu-J591) In Patients With Metastatic Androgen-Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|January 2004|May 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||April 2006|July 9, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081172||200745|
NCT00081874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0948|RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma|Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Completed|April 2004|September 2006|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|N/A|No|||March 2012|March 20, 2012|April 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081874||200696|
NCT00081809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-09|A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma|A Phase II Trial of Active Specific Immunotherapy in Patients With Indolent Lymphoma Using Autologous Lymphoma-Derived Heat Shock Protein-Peptide Complex (HSPPC-96)||Agenus, Inc.||Completed|March 2000|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||September 2012|September 6, 2012|April 20, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00081809||200701|
NCT00081822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040114019|Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia|A Phase I Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia||University of Alabama at Birmingham|Yes|Completed|January 2004|August 2011|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|60 Years|N/A|No|||April 2012|April 18, 2012|April 21, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00081822||200700|
NCT00081835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040157|Evaluation and Treatment of Eye Complications of Vaccinia Vaccination|Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31]||National Institutes of Health Clinical Center (CC)||Completed|April 2004|August 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||400|||Both|1 Year|N/A|No|||August 2007|September 26, 2015|April 22, 2004||||No||https://clinicaltrials.gov/show/NCT00081835||200699|
NCT00081848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040167|Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors|A Pilot Trial of a CEA-TRICOM Based Vaccine and Radiation to Liver Metastasis in Adults With CEA Positive Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|April 2004|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2012|September 26, 2015|April 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00081848||200698|
NCT00077311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000350089|Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|August 2004|April 2009|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|February 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00077311||201012|
NCT00078728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH063427|Family-Based Prevention Program for Childhood Anxiety|Family-Based Prevention for Childhood Anxiety||Johns Hopkins University|Yes|Completed|September 2003|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|7 Years|N/A|No|||March 2014|March 18, 2014|March 5, 2004||No||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00078728||200912|Of the 40 participants in the study, no adverse events occured or were reported.
NCT00079040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02944|Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer|A Phase II Study of Cisplatin Plus Etoposide (PE) Plus Bevacizumab (NSC #704865) for Previously Untreated Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|January 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||December 2012|April 28, 2014|March 8, 2004|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00079040||200892|
NCT00105560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415841|Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma|Phase II Study of Craniospinal and Posterior Fossa Irradiation Using Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma: Assessment of Acute and Long Term Sequelae||Massachusetts General Hospital|Yes|Active, not recruiting|May 2002|||December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|3 Years|21 Years|No|||March 2016|March 14, 2016|March 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00105560||199007|
NCT00105573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067792|Interventions for Depressed Low Income Mothers and Their Infants|Prevention for Infants of Low-Income Depressed Mothers||University of Rochester|Yes|Completed|January 2004|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|218|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||April 2013|April 29, 2013|March 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00105573||199006|
NCT00105274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050110|Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study|Intermediate Phenotype and Genetic Mechanisms for Psychosis and Cognitive Disturbance in 22q11.2-Hemideletion Syndrome||National Institutes of Health Clinical Center (CC)||Completed|March 2005|February 2010||||N/A|Observational|N/A|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2010|February 3, 2010|March 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00105274||199028|
NCT00106067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-255|Aging and Family Outcomes in Supportive Care of Advanced Cancer Patients|Aging and Family Outcomes in Supportive Care of Advanced Cancer Patients|A&SC|VA Office of Research and Development|No|Completed|June 2004|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|559|||Both|18 Years|N/A|No|||April 2009|April 6, 2015|March 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00106067||198969|
NCT00106353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-139|Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors|A Phase I/II Safety and Exploratory Pharmacogenomic/Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects With Relapsed/Refractory Solid Tumors||Pfizer|No|Completed|March 2005|January 2012|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|1 Year|21 Years|No|||January 2013|January 4, 2013|March 22, 2005|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00106353||198947|
NCT00106366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-2175|Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes|Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|389|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|March 22, 2005||||No||https://clinicaltrials.gov/show/NCT00106366||198946|
NCT00106652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11269-CP-001|Childhood Autism Risks From Genetics and the Environment (The CHARGE Study)|Environmental Factors in the Etiology of Autism||National Institute of Environmental Health Sciences (NIEHS)||Active, not recruiting|September 2001|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|N/A|||Anticipated|2000|||Both|24 Months|60 Months|Accepts Healthy Volunteers|||April 2015|April 13, 2015|March 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00106652||198925|
NCT00096824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5199|A Study of Dementia and Neurological Problems in HIV Infected Patients Who Are Participating in ACTG A5175|International Neurological Study: A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combination for Initial Treatment of HIV-1 Infected Individuals From Diverse Areas of the World)||AIDS Clinical Trials Group|Yes|Completed|February 2006|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|860|||Both|18 Years|N/A|No|Non-Probability Sample|All participants who enrolled in ACTG study 5175|March 2015|March 17, 2015|November 15, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096824||199643|
NCT00097214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-081|Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Phase II Trial of Carboplatin Plus Cetuximab for the Treatment of Stage IIIb/IV Non-Small Cell Lung Cancer||ImClone LLC|No|Completed|November 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||April 2010|April 8, 2010|November 18, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097214||199616|
NCT00092820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02243|Sitosterolemia Extension Study (0653-004)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia||Merck Sharp & Dohme Corp.||Completed|February 2001|November 2004|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|58|||Both|10 Years|N/A|No|||February 2015|February 16, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092820||199935|
NCT00097591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8695|A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention|A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention||Eli Lilly and Company|Yes|Completed|November 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13619|||Both|18 Years|N/A|No|||August 2010|August 25, 2010|November 24, 2004|No|Yes||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00097591||199587|
NCT00092833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-026|Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)|An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia||Merck Sharp & Dohme Corp.||Terminated|July 2002|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|8 Years|N/A|No|||March 2015|March 16, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092833||199934|
NCT00092846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803-084|A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)|A Consumer Use Study of OTC Lovastatin (CUSTOM): A 6-Month Consumer Behavior Study of the Lovastatin OTC Self-Management System||Merck Sharp & Dohme Corp.||Completed|December 2002|||September 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||1000|||Both|45 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 7, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092846||199933|
NCT00092872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0557-012|A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients||Merck Sharp & Dohme Corp.||Completed|November 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|359|||Both|18 Years|65 Years|No|||January 2015|January 29, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092872||199931|
NCT00093262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-03-02|Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)|Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)|ESCAPE-2|The Medicines Company|Yes|Completed|December 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|October 5, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00093262||199902|
NCT00093561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-2004-0040|Lycopene in Preventing Prostate Cancer in Healthy Participants|Phase I Single Dose Pharmacokinetic Study of the Dietary Supplement Lycopene Delivered in Capsule Form to Healthy Male Volunteers Between 18 and 45 Years of Age||National Cancer Institute (NCI)||Completed|August 2004|February 2006|Actual|||Phase 1|Interventional|Primary Purpose: Prevention|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2006|June 25, 2013|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093561||199883|
NCT00093587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000389241|Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|Pilot Trial of Two Dose Levels of Thymoglobulin® as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor (MRD) Stem Cell Transplant With Cyclosporine (CsA) as Posttransplant Graft vs Host Disease (GvHD) Prophylaxis||National Cancer Institute (NCI)||Active, not recruiting|August 2004|||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|18 Years|55 Years|No|||January 2006|November 5, 2013|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093587||199882|
NCT00081510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03480|Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)|A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer||Merck Sharp & Dohme Corp.|No|Completed|December 2003|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|N/A|N/A|No|||March 2015|March 26, 2015|April 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00081510||200723|
NCT00081887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0134|Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia|Phase I Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Terminated|May 2004|June 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||July 2012|July 31, 2012|April 23, 2004|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00081887||200695|
NCT00082147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040171|Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer|A Prospective Histopathologic Study of Dynamic Contrast Enhanced MRI for Prostate Cancer Delineation and Characterization With the APT-MRI System||National Institutes of Health Clinical Center (CC)||Completed|April 2004|February 2007|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Male|18 Years|90 Years|No|||July 2015|July 30, 2015|April 30, 2004||No||No||https://clinicaltrials.gov/show/NCT00082147||200677|
NCT00077324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z4031|Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions|Use Of Proteomic Analysis Of Serum Samples For Detection Of Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|February 2004|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Non-small cell lung cancer patients|July 2015|July 6, 2015|February 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00077324||201011|
NCT00078351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040111|Synvisc to Treat Osteoarthritis of the Temporomandibular Joint|The Effects of Viscosupplementation Using Synvisc in Symptomatic Osteoarthritis of the Temporomandibular Joint||National Institutes of Health Clinical Center (CC)||Completed|February 2004|October 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||October 2005|March 3, 2008|February 23, 2004||||No||https://clinicaltrials.gov/show/NCT00078351||200937|
NCT00105313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP107|Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia|A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia||MedImmune LLC||Terminated|February 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|March 11, 2005|||After review of safety events and have decided that further dose escalation of MEDI-507 as a    single agent is not feasible.|||https://clinicaltrials.gov/show/NCT00105313||199025|
NCT00105820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHI 99-375|Evaluation Study of TIDES Depression Care Quality Improvement Intervention|Well-being Among Veterans Enhancement Study (WAVES)||VA Office of Research and Development|No|Completed|June 2003|March 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|750|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105820||198987|
NCT00105833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHI 20-020|Improving Outcomes of Depression in Primary Care|Improving Outcomes of Depression in Primary Care|DEP-PC|VA Office of Research and Development|No|Completed|July 2002|December 2008|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|N/A|N/A|No|||March 2009|April 6, 2015|March 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00105833||198986|
NCT00106080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-292|Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Improving the Quality of End-of-Life Communication for Patients With COPD||VA Office of Research and Development|No|Completed|November 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|376|||Both|18 Years|N/A|No|||May 2014|April 6, 2015|March 18, 2005||No||No|August 6, 2014|https://clinicaltrials.gov/show/NCT00106080||198968|
NCT00106379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-104-0235|Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients|A Phase 4, Single-Arm Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Combination With Emtricitabine in HIV-1 Infected Patients Experiencing Various Degrees of Renal Impairment||Gilead Sciences||Completed|October 2004|January 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||52|||Both|18 Years|80 Years|No|||April 2008|February 1, 2010|March 23, 2005||||||https://clinicaltrials.gov/show/NCT00106379||198945|
NCT00106392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-03-001|A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy||Astellas Pharma Inc|Yes|Completed|February 2005|November 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|131|||Male|N/A|65 Years|No|||November 2010|November 15, 2010|March 23, 2005|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00106392||198944|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00106665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004H0255|New Onset Weakness in Critically Ill Patients and the Risk of Death and Recurrent ICU Admission|Intensive Care Unit(ICU)-Acquired Paresis and the Risk for Mortality and Recurrent ICU Admission (Weakness and ICU Readmission Evaluation-WIRE)||Ohio State University|No|Completed|June 2005|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|170|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients requireing mechanical ventilation|January 2016|January 15, 2016|March 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00106665||198924|
NCT00097253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002122-01|The Effects of Smell on Mood and Physical Responses|Psychoneuroimmunology and Mind-Body Medicine: Olfaction, Mood, and Physiological Responses||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|August 2005|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||February 2010|February 12, 2010|November 19, 2004||No||No|April 23, 2009|https://clinicaltrials.gov/show/NCT00097253||199613|
NCT00092339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-190|A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effects of Rofecoxib 50 mg and Valdecoxib 40 mg in Patients With Postoperative Dental Pain||Merck Sharp & Dohme Corp.||Completed|August 2002|September 2002|Actual|September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|125|||Both|16 Years|N/A|No|||September 2015|September 15, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092339||199971|
NCT00097227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-058|Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Trial of Two Dose Schedules of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-small Cell Lung Cancer||ImClone LLC|No|Completed|November 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||April 2010|April 8, 2010|November 18, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097227||199615|
NCT00092859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0557-011|A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients||Merck Sharp & Dohme Corp.||Completed|September 2003|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1500|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092859||199932|
NCT00095381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-T-04-201|Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia|A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use||BioCryst Pharmaceuticals||Completed|March 2004|December 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2012|January 18, 2012|November 3, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095381||199749|
NCT00095394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV131-176|Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension|The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension||Bristol-Myers Squibb||Completed|September 2004|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|645|||Both|18 Years|N/A|No|||August 2008|April 7, 2011|November 3, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095394||199748|
NCT00092885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-269|An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)|A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma||Merck Sharp & Dohme Corp.||Completed|March 2003|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|831|||Both|15 Years|85 Years|No|||November 2015|November 27, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092885||199930|
NCT00096603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD2601g|A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g|An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g||Genentech, Inc.||Completed|October 2002|July 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|N/A|N/A|No|||March 2014|March 19, 2014|November 12, 2004||||||https://clinicaltrials.gov/show/NCT00096603||199660|
NCT00097279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-2186|Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes|A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes|ACTION|Novo Nordisk A/S|No|Completed|August 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|230|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|November 19, 2004||||No||https://clinicaltrials.gov/show/NCT00097279||199611|
NCT00092378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-234|A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Parallel-Group Study of Rofecoxib and Diclofenac Sodium in the Treatment of Post-Bunionectomy Surgery Pain||Merck Sharp & Dohme Corp.||Completed|September 2003|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|251|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092378||199968|
NCT00092391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V205C-007|A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)|A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age||Merck Sharp & Dohme Corp.||Completed|February 1999|July 2001|Actual|July 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|1997|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||October 2015|October 22, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092391||199967|
NCT00094263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1273|Long-Term Predictors of Morbidity in Older Age|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2004|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||January 2008|February 17, 2016|October 15, 2004||||No||https://clinicaltrials.gov/show/NCT00094263||199833|
NCT00094523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100290|Fosamprenavir Versus Other Protease Inhibitors|A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks||GlaxoSmithKline|No|Completed|December 2004|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|312|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|October 20, 2004||||||https://clinicaltrials.gov/show/NCT00094523||199814|
NCT00081523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040161|Natural History of Sickle Cell Disease and Other Hemolytic Disorders|Studies of the Natural History of Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Recruiting|April 2004|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|5 Years|N/A|No|||September 2015|December 12, 2015|April 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00081523||200722|
NCT00077337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000350199|FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer|Phase II Trial of Depsipeptide (NSC-630176) in Colorectal Cancer Patients Who Have Received Either One or Two Prior Chemotherapy Regimens for Metastatic or Locally Advanced, Unresectable Disease||National Cancer Institute (NCI)||Completed|April 2004|April 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2005|June 21, 2013|February 10, 2004||||||https://clinicaltrials.gov/show/NCT00077337||201010|
NCT00077610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16739|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients|A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.||Hoffmann-La Roche||Completed|February 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|673|||Both|18 Years|N/A|No|||October 2015|January 29, 2016|February 10, 2004|Yes|Yes||No|January 29, 2016|https://clinicaltrials.gov/show/NCT00077610||200992|
NCT00082160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT000694-01|Brain Imaging Technology to Examine the Effects of Meditation|fMRI Investigation of Meditation||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2001|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2006|August 3, 2006|April 30, 2004||||No||https://clinicaltrials.gov/show/NCT00082160||200676|
NCT00077623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16740|A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.|A Randomized, Open-label Study of the Effect of Maintenance Subcutaneous Mircera on Hemoglobin Levels in Dialysis Patients With Chronic Kidney Disease||Hoffmann-La Roche||Completed|March 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|572|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077623||200991|
NCT00078026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APB-231|An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass|A Phase I/II Randomized Study of the Short-Term Effects of APOMINE vs Placebo in Postmenopausal Women With Osteoporosis or Low Bone Mass||Sanofi||Terminated|August 2003|December 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|45 Years|75 Years|No|||February 2014|February 4, 2014|February 16, 2004||||||https://clinicaltrials.gov/show/NCT00078026||200962|
NCT00078364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040125|Pain Pathways in the Brain|Imaging Neural Mechanisms Underlying Pain Modulation||National Institutes of Health Clinical Center (CC)||Completed|February 2004|August 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||August 2005|March 3, 2008|February 23, 2004||||No||https://clinicaltrials.gov/show/NCT00078364||200936|
NCT00078377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3020/NA/MN|Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy||Teva Pharmaceutical Industries||Completed|March 2004|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|196|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|February 24, 2004||Yes|||June 1, 2009|https://clinicaltrials.gov/show/NCT00078377||200935|
NCT00095329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AMS02|Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor|A Phase I/II, Open-Label Pilot Trial to Evaluate the Safety of Rapamune (Sirolimus) in Patients With Multiple Sclerosis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|May 2003|January 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|58 Years|No|||January 2013|January 16, 2013|November 2, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095329||199753|
NCT00105586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070547|Drug Therapy for Generalized Anxiety Disorder Among the Elderly|Pharmacotherapy of Late-Life Generalized Anxiety Disorder||National Institute of Mental Health (NIMH)||Completed|December 2004|April 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|60 Years|N/A|No|||September 2008|September 8, 2008|March 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00105586||199005|
NCT00095992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I168|SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer|A Phase II Study Of SB-715992 (NSC 727990) In Patients With Locally Advanced, Recurrent Or Metastatic Hepatocellular Carcinoma||Canadian Cancer Trials Group|No|Completed|November 2004|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|November 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00095992||199705|
NCT00096265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00720|Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer|A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases||National Cancer Institute (NCI)||Terminated|October 2004|April 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|N/A|No|||October 2011|May 5, 2014|November 9, 2004|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00096265||199685|
NCT00096278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03017|Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer|A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon||National Cancer Institute (NCI)||Completed|September 2004|December 2012|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2710|||Both|18 Years|N/A|No|||July 2013|May 16, 2014|November 9, 2004|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT00096278||199684|
NCT00096538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-055|Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma|Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma||Memorial Sloan Kettering Cancer Center||Completed|April 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|120 Years|No|||October 2015|October 21, 2015|November 9, 2004|No|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT00096538||199664|
NCT00096551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050017|A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy|A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer and Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy||National Institutes of Health Clinical Center (CC)||Completed|November 2004|July 2011|Actual|December 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||July 2011|September 23, 2015|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00096551||199663|
NCT00093301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/007|Levosimendan Versus Dobutamine in Shock Patients|Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study||Wentworth Area Health Services||Recruiting|October 2004|April 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||October 2004|June 23, 2005|October 5, 2004||||No||https://clinicaltrials.gov/show/NCT00093301||199899|
NCT00093548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000389221|Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer|A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma (AFP Prime-Boost Protocol)||Jonsson Comprehensive Cancer Center||Withdrawn||||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093548||199884|
NCT00093886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-03-03|Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)|Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Nitroglycerin as Active Comparator) (ECLIPSE-NTG)|ECLIPSE-NTG|The Medicines Company|Yes|Completed|April 2004|April 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|629|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|October 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093886||199861|
NCT00094198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1278|Pharmacogenetics and Cardiovascular Events|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||August 2008|August 20, 2008|October 15, 2004||||No||https://clinicaltrials.gov/show/NCT00094198||199837|
NCT00096031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000391201|S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer|Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II||Southwest Oncology Group|Yes|Completed|October 2004|January 2010|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||April 2012|April 4, 2012|November 9, 2004|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00096031||199702|
NCT00096616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.50|Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma|A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids||Boehringer Ingelheim||Completed|November 2004|||March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|113|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|November 12, 2004||||||https://clinicaltrials.gov/show/NCT00096616||199659|
NCT00097266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-162|Study of Aripiprazole in Patients With Acute Bipolar Mania|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|December 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3|||615|||Both|18 Years|N/A|No|||July 2010|November 7, 2013|November 19, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097266||199612|
NCT00092404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V205C-009|Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)|A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age||Merck Sharp & Dohme Corp.||Completed|December 2001|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|1210|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||April 2015|April 29, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092404||199966|
NCT00092937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040289|Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant|Secondary Transplantation Using Moderate Dose Busulfan as Conditioning for a Patient With Partial Reconstitution Post Initial Allogeneic Transplantation||National Institutes of Health Clinical Center (CC)||Completed|September 2004|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||April 2010|September 26, 2015|September 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00092937||199926|
NCT00092950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040276|Exercise in Women at Risk for Breast Cancer|A Pilot Study of a Three Month Intervention for Increasing Physical Activity in Sedentary Women at Risk for Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|September 2004|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|88|||Female|18 Years|75 Years|No|||September 2011|September 29, 2011|September 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00092950||199925|
NCT00093314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-CD20-402|HuMax-CD20 in Chronic Lymphocytic Leukemia|An Open-labeled, International, Multicenter, Dose Escalating, Phase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||GlaxoSmithKline||Withdrawn|October 2004|January 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2007|April 20, 2015|October 6, 2004|||Acquired asset|||https://clinicaltrials.gov/show/NCT00093314||199898|
NCT00081536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-726-03|Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies|A Phase I/II Study of Aroplatin and Capecitabine in Subjects With Unresectable Local Recurrence or Distant Metastases of Colorectal Cancer Refractory to 5-FU/Leucovorin and Irinotecan||Aronex Pharmaceuticals||Active, not recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||105|||Both|18 Years|N/A|No|||April 2004|June 23, 2005|April 15, 2004||||||https://clinicaltrials.gov/show/NCT00081536||200721|
NCT00081900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD3-165-101|A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care|A Phase 1/2 Study of DENSPM (N1, N11-diethylnorspermine) in Patients With Unresectable Hepatocellular Carcinoma||Sanofi|Yes|Terminated|March 2004|November 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|April 26, 2004|No|Yes|This study was terminated early by Genzyme because there were insufficient data to support    clinical benefit to HCC patients on the study.|No||https://clinicaltrials.gov/show/NCT00081900||200694|
NCT00077636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV17317|ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.|A Randomized, Open-label Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection||Hoffmann-La Roche||Completed|December 2003|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1469|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 10, 2004|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00077636||200990|
NCT00077649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV17318|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).|A Randomized, Double-blind Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Viral Kinetics and Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Infection||Hoffmann-La Roche||Completed|January 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|188|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077649||200989|
NCT00078039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003379|Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia|Randomized, Double-blind, Placebo- and Active-controlled Parallel Group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (6, 9, and 12 mg/Day) and Olanzapine (10 mg/Day) With Open-label Extension in Treatment of Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|630|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|February 17, 2004||||||https://clinicaltrials.gov/show/NCT00078039||200961|
NCT00078052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236|Genetic Markers of Coronary Heart Disease in Type 2 Diabetes|||Harvard School of Public Health||Completed|September 2003|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120000|Samples With DNA|Plasma and buffy coat|Both|N/A|N/A|No|Non-Probability Sample|Nurses' Health Study and Health Professionals' Follow-up Study|March 2013|March 18, 2013|February 17, 2004||No||No||https://clinicaltrials.gov/show/NCT00078052||200960|
NCT00082862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000360863|Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer|A Phase II Clinical Trial of a Timing/Schedule Optimized Combined-Modality Regimen: Cisplatin + Metronomic Low-Dose Interferon-α (IFN-α) Followed by Gemcitabine HCl (GEMZAR) in Combination With Mild, Fever-Range Whole-Body Hyperthermia (FR-WBH) in Patients With Advanced, Inoperable Pancreatic Cancer||National Cancer Institute (NCI)||Recruiting|July 2002|||November 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2008|February 10, 2012|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082862||200627|
NCT00083148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000363790|Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer|Phase I Study of Irinotecan Followed by Capecitabine in Patients With Advanced Breast Carcinoma||Roswell Park Cancer Institute|Yes|Completed|November 2002|September 2006|Actual|March 2005|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||March 2011|March 7, 2011|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083148||200608|
NCT00095342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3140A1-200|Study Evaluating TMI-005 in Active Rheumatoid Arthritis|A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|390|||Both|18 Years|75 Years|No|||September 2009|September 8, 2009|November 2, 2004||||||https://clinicaltrials.gov/show/NCT00095342||199752|
NCT00095355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050020|Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease|Stimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2004|March 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||March 2005|March 3, 2008|November 2, 2004||||No||https://clinicaltrials.gov/show/NCT00095355||199751|
NCT00095667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03178|Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer|A Phase 2 Study of GW572016 in Hormone Naive Recurrent or Metastatic Hormone Sensitive Prostate Cancer||National Cancer Institute (NCI)||Completed|November 2004|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Male|18 Years|N/A|No|||May 2013|May 7, 2013|November 5, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095667||199729|
NCT00096005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00043|Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial Of 17-Allylaminogeldanamycin (17-AAG) And PS341 In Advanced Malignancies||National Cancer Institute (NCI)||Terminated|November 2004|||March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2011|February 21, 2014|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096005||199704|
NCT00096291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000382123|Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer|Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response||Massachusetts General Hospital|Yes|Active, not recruiting|February 2000|||March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|62|||Female|18 Years|120 Years|No|||March 2016|March 14, 2016|November 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00096291||199683|
NCT00096304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378045|Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer|Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|June 2004|||March 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Male|18 Years|N/A|No|||November 2008|December 4, 2008|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096304||199682|
NCT00096564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050032|Brain Activities Associated With Different Facial Expressions Using Blood Oxygenation Level Dependent Functional MRI|Functional MRI Study of Brain Activation With Observation of Facial Expressions||National Institutes of Health Clinical Center (CC)||Completed|November 2004|August 2008||||N/A|Observational|N/A||||25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|September 26, 2015|November 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00096564||199662|
NCT00094211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1275|Understanding the Impact of Neighborhood Type on Physical Activity in Older Adults|Neighborhood Impact on Physical Activity in Older Adults||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|September 2004|June 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|985|||Both|65 Years|N/A|No|Non-Probability Sample|Residents of selected block groups in King County, WA and the Baltimore region.|February 2009|February 13, 2009|October 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00094211||199836|
NCT00094237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1274|Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke|Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke||University of North Carolina, Chapel Hill|No|Completed|September 2004|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3200|||Female|50 Years|79 Years|No|Probability Sample|Postmenopausal women aged 50-79 years, who enrolled in the Women's Health Initiative (WHI)        Observational Study (n=93,676). Participants include African American, Asian,        Hispanic/Latino and European-American individuals recruited from the communities        surrounding the WHI study centers..|December 2015|December 16, 2015|October 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00094237||199835|
NCT00094510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050006|Effect of Gabapentin on GABA Concentration and Emotional Processing|The Effect of Gabapentin on Prefrontal GABA Concentration and Emotional Processing in Healthy Humans||National Institutes of Health Clinical Center (CC)||Completed|October 2004|September 2010||||N/A|Observational|N/A|||Actual|30|||Both|18 Years|60 Years|No|||September 2010|September 4, 2010|October 19, 2004||No||No||https://clinicaltrials.gov/show/NCT00094510||199815|
NCT00092924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRM1-ST03|Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)|A Phase 2, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of TRM-1 (Fully Human Monoclonal Antibody To TRAIL-R1) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer||Human Genome Sciences Inc.||Completed||March 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 1, 2013|September 24, 2004||||||https://clinicaltrials.gov/show/NCT00092924||199927|
NCT00093899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-071|A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)|A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|November 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|611|||Both|18 Years|79 Years|No|||February 2015|February 16, 2015|October 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093899||199860|
NCT00094250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1272|HEARTS: Heart, Exercise, and Resistance Training Study|More Effective Exercise Modalities in Older Congestive Heart Failure Patients||National Heart, Lung, and Blood Institute (NHLBI)||Withdrawn|July 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment|||Anticipated|200|||Both|65 Years|90 Years|No|||February 2009|February 10, 2009|October 15, 2004|||Study was closed due to administrative reasons; study did not enroll any participants.|No||https://clinicaltrials.gov/show/NCT00094250||199834|
NCT00094783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050007|MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs|Real-Time MRI-Guided Percutaneous Intervention for Aorto-illac and Femoropopliteal, Artery Stenosis||National Institutes of Health Clinical Center (CC)||Completed|October 2004|June 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||June 2008|September 26, 2015|October 22, 2004||||No||https://clinicaltrials.gov/show/NCT00094783||199795|
NCT00094796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050009|Rosiglitazone to Reverse Metabolic Defects in Diabetes|Evaluation of Rosiglitazone in Reversing Metabolic Defects of Pre-Diabetes and Type 2 Diabetes Mellitus||National Institutes of Health Clinical Center (CC)||Completed|October 2004|September 2008||||Phase 2|Interventional|Primary Purpose: Treatment|1|||70|||Both|22 Years|N/A|No|||September 2008|September 26, 2015|October 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00094796||199794|
NCT00094809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020715|Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer|Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer||Amgen||Completed|February 2003|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|252|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|October 26, 2004||||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00094809||199793|
NCT00077350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02971|A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer|A Phase II Trial of Triapine® (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|July 2004|||April 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077350||201009|
NCT00087165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000372951|GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer|A Phase II Study of GTI-2040 in Combination With Docetaxel and Prednisone in Hormone-Refractory Prostate Cancer||National Cancer Institute (NCI)||Completed|January 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||November 2005|August 18, 2011|July 8, 2004||||||https://clinicaltrials.gov/show/NCT00087165||200333|
NCT00087178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-36|Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer|A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer||NSABP Foundation Inc|Yes|Active, not recruiting|May 2004|April 2016|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2722|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|July 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00087178||200332|
NCT00082563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661121|Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum|A Phase II, Randomized, Comparative Trial Of Azithromycin In Combination With Chloroquine Versus Chloroquine In The Eradication Of Asymptomatic Plasmodium Falciparum Infection In Semi-Immune Adults||Pfizer||Terminated|August 2004|November 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2011|April 25, 2011|May 12, 2004||||||https://clinicaltrials.gov/show/NCT00082563||200646|
NCT00082576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661134|Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa|A Phase II/III, Randomized, Double-Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa||Pfizer||Completed|June 2004|May 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|238|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|May 12, 2004||||||https://clinicaltrials.gov/show/NCT00082576||200645|
NCT00084110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08AT000722-03|Use of Complementary and Alternative Medicine Among Older Mexican Americans|Complementary Alternative Medicine||National Center for Complementary and Integrative Health (NCCIH)||Terminated|August 1993|September 2000||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||3000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2006|August 17, 2006|June 7, 2004||||No||https://clinicaltrials.gov/show/NCT00084110||200538|
NCT00084422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000363630|N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma|A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)||New Approaches to Neuroblastoma Therapy Consortium|Yes|Completed|August 2003|February 2011|Actual|September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|N/A|30 Years|No|||August 2014|August 28, 2014|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084422||200516|
NCT00079391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040112|Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Peri-transplant Cyclosporine on Chimerism||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2004|September 2011|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|2 Years|80 Years|No|||June 2014|October 5, 2015|March 8, 2004|No|Yes||No|April 20, 2011|https://clinicaltrials.gov/show/NCT00079391||200867|
NCT00095693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01457|Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer|Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma||National Cancer Institute (NCI)||Terminated|October 2004|December 2011|Actual|August 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|November 5, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095693||199727|
NCT00092963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-065|Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild||Merck Sharp & Dohme Corp.||Completed|August 2004|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|529|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 28, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092963||199924|
NCT00095680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005182|Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma|A 24-week, Open-label Extension Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed Refractory Patients With Multiple Myeloma||Scios, Inc.||Completed|November 2004|February 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2010|October 21, 2010|November 5, 2004||No||No||https://clinicaltrials.gov/show/NCT00095680||199728|
NCT00094536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMS043|Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System|A Study to Evaluate the Effectiveness of Extended Treatment Regimens With the Her Option® Cryoablation Therapy System for Treatment of Menorrhagia||American Medical Systems||Completed|April 2004|March 2008||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||76|||Female|30 Years|N/A|No|||July 2006|July 20, 2006|October 20, 2004||||||https://clinicaltrials.gov/show/NCT00094536||199813|
NCT00096070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01816|Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer|Phase II Study of Oxaliplatin, Continuous 5-Fluorouracil and External Beam Radiation Followed by Gemcitabine in Patients With Locally Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|December 2004|||April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2013|July 15, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096070||199699|
NCT00096876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENSOR|A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients|Screening Evaluations for Neurologic Syndromes: Olfactory Testing in Relatives of Parkinson's Disease Patients||Institute for Neurodegenerative Disorders||Completed|October 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 9, 2008|November 16, 2004||||No||https://clinicaltrials.gov/show/NCT00096876||199639|
NCT00096902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050024|Non-Pharmacologic Therapy for Neurocardiogenic Syncope|Non-Pharmacologic Therapy for Neurocardiogenic Syncope||National Institutes of Health Clinical Center (CC)||Completed|November 2004|September 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||September 2006|September 26, 2015|November 16, 2004||||No||https://clinicaltrials.gov/show/NCT00096902||199638|
NCT00104000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050099|Effect of Surface Electrical Stimulation on Movement of the Larynx|The Effect of Surface Electrical Stimulation on Hyo-Laryngeal Movement in Healthy Individuals at Rest and During Swallow||National Institutes of Health Clinical Center (CC)||Completed|February 2005|January 2006||||N/A|Observational|N/A||||47|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|February 17, 2005||||No||https://clinicaltrials.gov/show/NCT00104000||199121|
NCT00095706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORI B-03|Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)|Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor||Translational Oncology Research International|Yes|Completed|June 2003|January 2012|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|75 Years|No|||September 2015|September 23, 2015|November 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095706||199726|
NCT00096317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000393439|Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors|Effect Of Ketoconazole On The Pharmacokinetics Of BMS-247550 In Patients With Advanced Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 2003|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2006|November 12, 2008|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096317||199681|
NCT00096330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000393455|Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer|Phase I Clinical Study of Folate||Roswell Park Cancer Institute|Yes|Completed|September 2004|March 2008|Actual|February 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|40 Years|72 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096330||199680|
NCT00105118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050100|Effect of Transcranial Magnetic Stimulation on Memory|10 Hz rTMS to Subject Specific Regions of Cerebral Cortex Improves Memory in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Completed|March 2005|February 2006||||N/A|Observational|N/A||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2006|March 3, 2008|March 4, 2005||||No||https://clinicaltrials.gov/show/NCT00105118||199039|
NCT00105417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050112|Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment|A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment (A5214)||National Institutes of Health Clinical Center (CC)||Completed|March 2005|May 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||May 2006|March 3, 2008|March 11, 2005||||No||https://clinicaltrials.gov/show/NCT00105417||199018|
NCT00105430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050111|Deep Brain Stimulation for Cervical Dystonia|Deep Brain Stimulation of the Globus Pallidus Interna or the Subthalamic Nucleus for Treatment of Generalized Primary Dystonia||National Institutes of Health Clinical Center (CC)||Completed|March 2005|July 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||40|||Both|7 Years|70 Years|No|||July 2006|July 4, 2006|March 11, 2005||||No||https://clinicaltrials.gov/show/NCT00105430||199017|
NCT00105677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECV 03-201|Understanding the Differences in the Management of Patients With Arthritis of the Knee or Hip|Reasons for Disparities in Joint Replacement Utilization||VA Office of Research and Development|No|Completed|August 2004|September 2006|Actual|||N/A|Observational|N/A||1|Anticipated|980|||Both|50 Years|79 Years|No|||October 2006|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105677||198998|
NCT00105911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 00-097|A Cognitive-Behavioral Intervention for Depression and Anxiety in COPD|A Cognitive-Behavioral Intervention for Depression and Anxiety in COPD||VA Office of Research and Development|No|Completed|July 2002|June 2005|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|222|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 17, 2005||||No||https://clinicaltrials.gov/show/NCT00105911||198980|
NCT00086827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02785|Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of Single Agent Depsipeptide (FK228) (NSC 630176; IND 51,810) in Relapsed Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|May 2004|||November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||December 2012|April 9, 2014|July 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00086827||200356|
NCT00086840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02598|CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase II Study of CCI-779 in Patients With Relapsed, Refractory or Transformed Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Terminated|May 2004|||August 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|July 8, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00086840||200355|
NCT00082875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02884|Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma|A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Terminated|March 2004|||July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|May 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082875||200626|
NCT00083434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010549|Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy|||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|February 2004|October 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 25, 2011|May 24, 2004|||This study was stopped because of an inadequate rate of enrollment.|||https://clinicaltrials.gov/show/NCT00083434||200587|
NCT00083733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040199|Genetic and Protein Profiling in Normal and Cancerous Breast Tissue|Procurement of Normal Breast Tissue and Metastatic Breast Cancer Tissue for Molecular Profiling||National Institutes of Health Clinical Center (CC)||Completed|May 2004|November 2010||||N/A|Observational|N/A|||Anticipated|216|||Female|N/A|N/A|No|||November 2010|September 26, 2015|May 29, 2004||No||No||https://clinicaltrials.gov/show/NCT00083733||200565|
NCT00083759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN100226-RA201|Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate|A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)||Elan Pharmaceuticals||Terminated|May 2004|||February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|75 Years|No|||April 2009|June 1, 2009|June 1, 2004||Yes|The biological effect seen with natalizumab was not sufficient to warrant further development    in RA.||January 27, 2009|https://clinicaltrials.gov/show/NCT00083759||200564|The study was terminated prematurely on 28 February 2005. The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
NCT00079079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4|Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor|A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors||Canadian Cancer Trials Group||Completed|October 2003|February 2009|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|34|||Both|18 Years|N/A|No|||March 2010|November 7, 2010|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079079||200889|
NCT00079378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01447|Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies||National Cancer Institute (NCI)||Completed|February 2004|||May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079378||200868|
NCT00079612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100391|Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer|Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer.||Bayer||Completed|September 2002|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|501|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|March 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079612||200850|
NCT00079625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040131|Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer|Allogeneic Breast Protocol 2: Phase I Trial of T Cell Exchange With Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning for Metastatic Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|March 2004|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|75 Years|No|||August 2013|January 29, 2016|March 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079625||200849|
NCT00092976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082A2-401|Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery|A Phase IV Study of the Safety and Efficacy of ReFacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) in Subjects With Hemophilia A Undergoing Major Surgery Monitored Using the Chromogenic Substrate Assay at the Local Laboratory||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2003|July 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Male|6 Years|N/A|No|||May 2006|December 19, 2007|September 28, 2004||||No||https://clinicaltrials.gov/show/NCT00092976||199923|
NCT00092989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-288|Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)|A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma||Merck Sharp & Dohme Corp.||Completed|July 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|650|||Both|15 Years|N/A|No|||March 2015|March 9, 2015|September 28, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092989||199922|
NCT00093327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001414-01|Acupuncture for Irritable Bowel Syndrome (IBS)|Acupuncture for Irritable Bowel Syndrome (IBS) Trial||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2003|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||287|||Both|18 Years|80 Years|No|||August 2006|August 17, 2006|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093327||199897|
NCT00093600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVARTIS-CPKC412A2106|PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics of Twice Daily Oral Dosing of PKC412 Administered in Combinations Sequentially and Concomitantly With Daunorubicin and Cytarabine for Standard Induction Therapy, and High Dose Cytarabine for Consolidation in Patients With Acute Myeloid Leukemia (AML)||Novartis|No|Completed|February 2004|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|60 Years|No|||March 2015|March 9, 2015|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093600||199881|
NCT00097305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31AT001053|Body-Oriented Therapy for Sexual Abuse Recovery|Delving Intervention and Mindbody Integration||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Female|25 Years|N/A|No|||August 2006|September 7, 2007|November 19, 2004||||No||https://clinicaltrials.gov/show/NCT00097305||199609|
NCT00097318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050036|Safety Study of Interferon Beta 1a to for Acute Stroke|Recombinant Human Interferon Beta-1a in Acute Ischemic Stroke: A Dose Escalation and Safety Study||National Institutes of Health Clinical Center (CC)||Completed|November 2004|April 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||April 2011|June 3, 2011|November 20, 2004||No||No||https://clinicaltrials.gov/show/NCT00097318||199608|
NCT00097331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|683699/003|Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis||GlaxoSmithKline||Completed|September 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|261|||Both|18 Years|65 Years|No|||April 2015|April 10, 2015|November 22, 2004||||No||https://clinicaltrials.gov/show/NCT00097331||199607|
NCT00096642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT DEP|Cognitive Behavioral Therapy for Early-Onset Depression|Comprehensive Treatment for Depressed Youth: An Outcome Evaluation Study||Centre for Addiction and Mental Health|No|Completed|June 2002|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|30|||Both|10 Years|17 Years|No|||August 2011|August 4, 2011|November 12, 2004||No||No||https://clinicaltrials.gov/show/NCT00096642||199657|
NCT00096837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0215|A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma|An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma||Pharmacyclics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||June 2006|June 7, 2006|November 16, 2004||||||https://clinicaltrials.gov/show/NCT00096837||199642|
NCT00097240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD3100g|An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)|The Raptiva Pregnancy Registry: An Observational Study of the Use and Safety of Raptiva (Efalizumab) During Pregnancy|FOLLOW|Genentech, Inc.||Completed|January 2005|September 2009|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women solicited through advertising, physician and patient awareness, and other        programs.|August 2010|August 2, 2010|November 19, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00097240||199614|
NCT00092911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-320|Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|244|||Both|18 Years|N/A|No|||August 2009|August 18, 2009|September 24, 2004||||||https://clinicaltrials.gov/show/NCT00092911||199928|
NCT00104013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC2724|Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type||Sanofi||Completed|November 2003|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1455|||Both|50 Years|N/A|No|||August 2008|August 20, 2008|February 18, 2005||||No||https://clinicaltrials.gov/show/NCT00104013||199120|
NCT00104364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0731-002|A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)|An Open-label, Dose Escalation Phase I/II Trial of a KSP Inhibitor Given as a Constant 24-Hour Infusion in Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.||Completed|May 2005|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|February 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00104364||199095|
NCT00104650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040114|Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates|A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates||Amgen||Completed|January 2005|March 2010|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|111|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|March 3, 2005||||No|December 9, 2010|https://clinicaltrials.gov/show/NCT00104650||199073|
NCT00104858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1840.00|Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|December 2004|||December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|March 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00104858||199058|
NCT00104871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00045|Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy|A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma||National Cancer Institute (NCI)|No|Completed|December 2004|April 2014|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||June 2014|October 24, 2014|March 3, 2005|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT00104871||199057|
NCT00104884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415355|FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma|Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma||Eastern Cooperative Oncology Group|No|Terminated|January 2005|March 2009|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 3, 2005|Yes|Yes|The study was terminated on May 17, 2006 due to slow accrual.|No|December 15, 2015|https://clinicaltrials.gov/show/NCT00104884||199056|
NCT00105131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050115|Genetic Characterization of Parkinson's Disease|Genetic Characterization of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|March 2005|November 2005||||N/A|Observational|N/A||||2500|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|March 5, 2005||||No||https://clinicaltrials.gov/show/NCT00105131||199038|
NCT00105443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100554|A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|SHARP|Bayer|Yes|Completed|March 2005|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|602|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|March 14, 2005|Yes|Yes||No|December 11, 2009|https://clinicaltrials.gov/show/NCT00105443||199016|
NCT00086866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16032-18031|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery|Randomized, Open Phase II Study of Immunization With the Recombinant MAGE-3 Protein Combined With Adjuvant AS02B or AS15 in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|May 2004|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|165|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|July 8, 2004||||No||https://clinicaltrials.gov/show/NCT00086866||200354|
NCT00082589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141078|The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure|A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF Less Than or Equal to 35%) and Mild to Moderate Heart Failure|REMODEL|Pfizer||Completed|April 2004|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|21 Years|N/A|No|||April 2007|May 22, 2008|May 12, 2004||||||https://clinicaltrials.gov/show/NCT00082589||200644|
NCT00082602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004699|Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease|Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|April 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|60 Years|N/A|No|||April 2009|May 19, 2011|May 12, 2004||||||https://clinicaltrials.gov/show/NCT00082602||200643|
NCT00078442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5192|Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People|A Phase II Open-Label Pilot Trial of the Antiretroviral Activity, Safety, and Tolerability of Pegylated Interferon Alfa-2A (40KD) [PegasysTM] in HIV-1 Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2006|||January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2009|August 6, 2009|February 25, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00078442||200931|
NCT00078455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILX651-231|Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma|A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma||Sanofi||Completed|December 2003|August 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2015|March 4, 2015|February 25, 2004||||||https://clinicaltrials.gov/show/NCT00078455||200930|
NCT00078832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN31488319|Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer|International Breast Cancer Intervention Study|IBIS II|Queen Mary University of London|Yes|Active, not recruiting|September 2003|January 2022|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|3864|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|March 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00078832||200905|
NCT00079638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-09-03-CR|Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL|Comparative Efficacy Evaluation of Lipid Levels When Treated With Niaspan and Statin or Other Lipid-Modifying Therapies||Kos Pharmaceuticals||Completed|April 2004|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|21 Years|N/A|No|||October 2006|October 31, 2006|March 10, 2004||||||https://clinicaltrials.gov/show/NCT00079638||200848|
NCT00079976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-307|Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)|A Clinical Research Study to Evaluate the Safety and Efficacy of Tigecycline in the Treatment of Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2003|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|174|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|March 19, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079976||200822|
NCT00093912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-03-04|Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)|Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Sodium Nitroprusside as Active Comparator) (ECLISPE-SNP)|ECLISPE-SNP|The Medicines Company|Yes|Completed|June 2004|November 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|739|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|October 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093912||199859|
NCT00094276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168|Intervention for Improving Asthma Care for Minority Children in Head Start|Improving Asthma Care for Minority Children in Head Start||Johns Hopkins University|Yes|Completed|September 2004|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|336|||Both|2 Years|6 Years|No|||January 2013|January 18, 2013|October 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00094276||199832|
NCT00094289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-MDS-0003-1|Interactions Between Cocaine and Ethanol and Disulfiram - 1|Interactions Between IV Cocaine and Ethanol and Oral Disulfiram||National Institute on Drug Abuse (NIDA)||Active, not recruiting|August 2004|July 2005||||Phase 1|Interventional|Primary Purpose: Treatment||||16|||Both|18 Years|50 Years|No|||July 2005|October 25, 2007|October 15, 2004||||||https://clinicaltrials.gov/show/NCT00094289||199831|
NCT00094302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160|Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function|Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)|TOPCAT|New England Research Institutes|Yes|Completed|August 2006|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3445|||Both|50 Years|N/A|No|||January 2014|February 11, 2015|October 15, 2004|Yes|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT00094302||199830|
NCT00095745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-164|A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder|A Multicenter, Long-Term, Open-label, Study to Assess the Safety and Tolerability of Aripiprazole as an Adjunctive Therapy in the Treatment of Outpatients With Major Depressive Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|September 2004|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1002|||Both|18 Years|N/A|No|||April 2011|November 7, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095745||199723|
NCT00095758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-163|A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder|A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder||Bristol-Myers Squibb||Completed|September 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||1200|||Both|18 Years|65 Years|No|||November 2013|November 22, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095758||199722|
NCT00096590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000440092|Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery|Evaluation of a Novel Blood Test Hypercoagulability in Surgical Patients With Metastatic Carcinoma: A Pilot Study||National Cancer Institute (NCI)||Completed|November 2004|||||N/A|Observational|N/A|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|May 9, 2009|November 11, 2004||No||No||https://clinicaltrials.gov/show/NCT00096590||199661|
NCT00093275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6213|HP184 in Chronic Spinal Cord Injury Subjects|A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of HP184 Administered Orally Once Daily for Twenty-Four Weeks in Adult Subjects With Chronic Spinal Cord Injury (CSCI)||Sanofi||Completed|October 2004|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|262|||Both|18 Years|65 Years|No|||August 2008|August 20, 2008|October 5, 2004||||||https://clinicaltrials.gov/show/NCT00093275||199901|
NCT00093288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK130940|Major Depressive Disorder In The Elderly|A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg Once Daily) in Elderly Subjects With Major Depressive Disorder||GlaxoSmithKline||Completed|June 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||364|||Both|65 Years|N/A|No|||August 2013|August 29, 2013|October 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093288||199900|
NCT00104897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-PH2/049|17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma|A Phase II Trial to Assess the Activity of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) in Patients With Metastatic (M1, M1b & M1c) Malignant Melanoma||National Cancer Institute (NCI)||Completed|March 2005|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||March 2008|June 25, 2013|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104897||199055|
NCT00104377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrassMATAMPL201|Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen|A Multicenter, Single-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen||Allergy Therapeutics||Completed|March 2005|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Both|18 Years|50 Years|No|||September 2009|June 16, 2010|February 28, 2005||||||https://clinicaltrials.gov/show/NCT00104377||199094|
NCT00104663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.1|PRION-1: Quinacrine for Human Prion Disease|PRION-1: Quinacrine for Human Prion Disease. A Partially Randomized Patient Preference Trial to Evaluate the Activity and Safety of Quinacrine in Human Prion Disease||Medical Research Council||Completed|June 2004|March 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|12 Years|N/A|No|||April 2015|April 6, 2015|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104663||199072|
NCT00105703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHI 99-236|Evaluation of a Nurse Case Management Model for Chronic Heart Failure|Evaluation of a Nurse Case Management Model for Chronic Heart Failure|CHF ENCORE|VA Office of Research and Development|No|Completed|February 2002|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|969|||Both|18 Years|N/A|No|||September 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105703||198996|
NCT00105950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF103009|Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer|A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer||GlaxoSmithKline|No|Completed|March 2005|May 2010|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||May 2015|September 24, 2015|March 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00105950||198978|
NCT00106223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH070490|Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder|A Randomized Waitlist Controlled Treatment Trial Investigating CBT for Body Dysmorphic Disorder||Massachusetts General Hospital|Yes|Completed|April 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|March 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00106223||198957|
NCT00078091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040123|Genetics and Clinical Characteristics of Bardet-Biedl Syndrome|Bardet-Biedl Syndrome: Phenotype and Metabolic Characteristics||National Institutes of Health Clinical Center (CC)||Terminated|February 2004|February 2016||||N/A|Observational|N/A|||Actual|194|||Both|N/A|N/A|No|||February 2016|February 6, 2016|February 18, 2004||No||No||https://clinicaltrials.gov/show/NCT00078091||200957|
NCT00078104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040124|Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction|Proinflammatory Gene Expression and Prostanoid Levels in a Clinical Model of Tissue Injury||National Institutes of Health Clinical Center (CC)||Completed|February 2004|October 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||148|||Both|N/A|N/A|No|||October 2005|March 3, 2008|February 18, 2004||||No||https://clinicaltrials.gov/show/NCT00078104||200956|
NCT00078117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0003-1|Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1|Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules||National Institute on Drug Abuse (NIDA)|Yes|Completed|June 2003|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||516|||Both|15 Years|N/A|No|||April 2010|April 13, 2010|February 19, 2004||||||https://clinicaltrials.gov/show/NCT00078117||200955|
NCT00079092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000354204|Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma|A Phase II Trial Of Thalidomide And Procarbazine In Adults With Recurrent/Progressive Gliomas||Wake Forest Baptist Health||Completed|January 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|March 8, 2004||||No||https://clinicaltrials.gov/show/NCT00079092||200888|
NCT00079404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01811|17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia|A Phase I Study of 17-AAG in Relapsed/Refractory Pediatric Patients With Solid Tumors or Leukemia||National Cancer Institute (NCI)||Completed|March 2004|||May 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|1 Year|21 Years|No|||June 2013|June 3, 2013|March 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079404||200866|
NCT00080782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-035|Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases|A Randomized Phase II Trial of Bone-Targeted Therapy Consisting of Strontium-89 and Doxorubicin With or Without Celecoxib in Androgen-Independent Prostate Cancer||M.D. Anderson Cancer Center|No|Terminated|February 2002|January 2005|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|N/A|N/A|No|||August 2010|July 27, 2012|April 7, 2004|Yes|Yes|Low accrual due to competing trial.|No||https://clinicaltrials.gov/show/NCT00080782||200769|
NCT00106808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-062|Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes|A Phase 3, Randomized, Double-blind, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar (BMS-298585) Compared to Pioglitazone in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control||Bristol-Myers Squibb||Completed|August 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1440|||Both|18 Years|70 Years|No|||September 2007|September 10, 2010|March 31, 2005||||||https://clinicaltrials.gov/show/NCT00106808||198914|
NCT00106821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.294|Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease|An 8 Week Randomized, Placebo Controlled, Double-blind Study to Assess the Efficacy of Tiotropium Inhalation Capsules in Patients of African Descent With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|June 2004|||August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|166|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|March 31, 2005||||||https://clinicaltrials.gov/show/NCT00106821||198913|
NCT00094822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030123|Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)|Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer||Amgen||Completed|July 2003|February 2006|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Advanced or Metastatic NSCLC|February 2009|February 12, 2009|October 27, 2004||||No||https://clinicaltrials.gov/show/NCT00094822||199792|
NCT00095121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-103-0518|Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2 to Less Than 18) With Chronic Hepatitis B||Gilead Sciences||Completed|June 2004|April 2010|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|173|||Both|2 Years|17 Years|No|||May 2012|May 16, 2012|October 29, 2004|Yes|Yes||No|April 8, 2011|https://clinicaltrials.gov/show/NCT00095121||199769|
NCT00096018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000391769|Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia|A Phase I/II Study of Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients With Chronic Lymphocytic Leukemia||Roswell Park Cancer Institute|Yes|Completed|May 2002|May 2012|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|November 9, 2004|Yes|Yes||No|January 28, 2013|https://clinicaltrials.gov/show/NCT00096018||199703|The study was stopped early due to low accrual.
NCT00092352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-219|A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)|A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee||Merck Sharp & Dohme Corp.||Completed|April 2003|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|395|||Both|40 Years|N/A|No|||September 2015|September 15, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092352||199970|
NCT00092365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-220|A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)|A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee||Merck Sharp & Dohme Corp.||Completed|April 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|413|||Both|40 Years|N/A|No|||September 2015|September 1, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092365||199969|
NCT00092898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-062|An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous Sitosterolemia||Merck Sharp & Dohme Corp.||Completed|October 2004|October 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|30|||Both|18 Years|85 Years|No|||February 2015|February 16, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092898||199929|
NCT00103649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC2946|18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type||Sanofi||Completed|November 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1306|||Both|50 Years|N/A|No|||August 2008|August 20, 2008|February 11, 2005||||No||https://clinicaltrials.gov/show/NCT00103649||199146|
NCT00105144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0-192|Study of Micafungin in Patients With Invasive Candidiasis or Candidemia|A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients With Invasive Candidiasis or Candidemia||Astellas Pharma Inc|No|Completed|September 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|611|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|March 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00105144||199037|
NCT00105157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-005|Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)|Multicenter Study to Evaluate the Safety and Efficacy of MK0518 in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance||Merck Sharp & Dohme Corp.||Completed|March 2005|July 2009|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|179|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|March 8, 2005|Yes|Yes||No|September 14, 2009|https://clinicaltrials.gov/show/NCT00105157||199036|Due to a 3:1 randomization of MK-0518 to placebo and more discontinuations for placebo in the doubleblind phase, exposure for MK-0518 and placebo differs significantly with follow-up times of 336.3 and 39.7 patient-years, respectively.
NCT00105456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2757n|A Study of Patients With HER2-Positive Metastatic Breast Cancer|registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer||Genentech, Inc.||Completed|March 2003|May 2009|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||1000|||Both|N/A|N/A|No|Non-Probability Sample|Patients from managed care organizations, community physicians or practices, and academic        centers.|May 2010|May 4, 2010|March 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00105456||199015|
NCT00105469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08633|Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)|A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis||Merck Sharp & Dohme Corp.|No|Completed|July 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|743|||Both|1 Year|N/A|No|||November 2013|November 21, 2013|March 14, 2005||Yes||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00105469||199014|
NCT00105482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAOMA15632|Targeted Interventions for Weight-Concerned Smokers|Testing the Effectiveness of Low Dose Naltrexone for Smoking Cessation and Minimization of Post-cessation Weight Gain||Yale University|Yes|Completed|January 2005|October 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|March 14, 2005||No||No|January 28, 2013|https://clinicaltrials.gov/show/NCT00105482||199013|
NCT00105716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 20-034|Study to Lower Veterans BP: Patient/Physician Intervention|Study to Lower Veterans Blood Pressure: Patient/Physician Intervention||VA Office of Research and Development|No|Completed|March 2002|April 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|544|||Both|N/A|N/A|No|||April 2006|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105716||198995|
NCT00105729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 20-067|Substance Abuse Self-Help Group Referral: Outcomes and Services Use|Substance Abuse Self-Help Group Referral: Outcome and Services Use||VA Office of Research and Development|No|Completed|January 2003|April 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|345|||Both|18 Years|N/A|No|||September 2006|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105729||198994|
NCT00105963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPRCSBS-01|Prevention of Shaken Baby Syndrome|Parents Helping Infants Study: Preventing Shaken Baby Syndrome and Child Abuse||Harborview Injury Prevention and Research Center||Recruiting|January 2005|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||3000|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||March 2005|June 23, 2005|March 18, 2005||||No||https://clinicaltrials.gov/show/NCT00105963||198977|
NCT00078845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000330006|Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors|Phase II Trial Of Subcutaneous Amifostine For Reversal Of Persistent Paclitaxel-Induced Peripheral Neuropathy||M.D. Anderson Cancer Center|No|Completed|May 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|24|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|March 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00078845||200904|
NCT00079989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-309|Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms|A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2003|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|115|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|March 19, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00079989||200821|
NCT00080002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-9011|Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction|Effectiveness and Safety Study of Pegamotecan (PEG-Camptothecin) in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastroesophageal Junction Who Have Relapsed or Progressed Following a Previous Chemotherapy Treatment||Enzon Pharmaceuticals, Inc.||Terminated|December 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2005|September 5, 2012|March 19, 2004||||||https://clinicaltrials.gov/show/NCT00080002||200820|
NCT00080340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.3020|Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Telik||Completed||May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||520|||Both|18 Years|N/A|No|||March 2006|January 10, 2008|March 26, 2004||||||https://clinicaltrials.gov/show/NCT00080340||200795|
NCT00080353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040152|Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma|Phase II Study in Metastatic Melanoma Using Lymphocytes Reactive With the gp100 Antigen and Immunization Using a Recombinant rF-gp100P209 Virus Encoding a gp100 Peptide Following a Nonmyeloablative Lymphocyte Depleting Regimen||National Institutes of Health Clinical Center (CC)||Completed|March 2004|December 2008|Actual|December 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|58|||Both|7 Years|N/A|No|||June 2012|June 12, 2012|March 27, 2004||||No||https://clinicaltrials.gov/show/NCT00080353||200794|
NCT00081380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1447C00127|Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder|Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated)||AstraZeneca||Completed|March 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||710|||Both|18 Years|N/A|No|||December 2008|December 19, 2008|April 9, 2004||||||https://clinicaltrials.gov/show/NCT00081380||200731|
NCT00103389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000409568|Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2004|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2006|September 22, 2008|February 7, 2005||||No||https://clinicaltrials.gov/show/NCT00103389||199164|
NCT00102830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040169|Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors|A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of AMG 386 in Adult Patients With Advanced Solid Tumors||Amgen||Completed||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||August 2010|August 19, 2010|February 3, 2005||||||https://clinicaltrials.gov/show/NCT00102830||199204|
NCT00095420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54MH068172|Relationship Training for Children With Autism and Their Peers|Peer Related School Interventions in Autism||University of California, Los Angeles|Yes|Completed|September 2003|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|60|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|November 4, 2004||No||No||https://clinicaltrials.gov/show/NCT00095420||199746|
NCT00103090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000411938|Fenretinide and Lonafarnib in Treating Patients With Advanced or Recurrent Head and Neck Cancer|A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer||M.D. Anderson Cancer Center|No|Terminated|January 2005|November 2006|Actual|January 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|N/A|No|||November 2012|November 12, 2012|February 7, 2005|Yes|Yes|Slow Accrual.|No||https://clinicaltrials.gov/show/NCT00103090||199186|
NCT00103363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-0392|Sputum Cytology in Screening Heavy Smokers For Lung Cancer|Lung Cancer Screening and Tissue Procurement||University of Colorado, Denver|No|Completed|February 1993|February 1994|Actual|February 1994|Actual|Phase 2|Interventional|Primary Purpose: Screening|||Actual|3270|||Both|25 Years|N/A|No|||May 2014|May 5, 2014|February 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00103363||199166|
NCT00103662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-3102|Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation||Sanofi|No|Completed|January 2005|January 2008|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|78 Years|No|||February 2014|February 10, 2014|February 11, 2005|Yes|Yes||No|February 2, 2009|https://clinicaltrials.gov/show/NCT00103662||199145|
NCT00104676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000416124|Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors|A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors||National Cancer Institute (NCI)||Recruiting|November 2003|||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|16 Years|N/A|No|||November 2008|December 13, 2009|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104676||199071|
NCT00104689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000416120|Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer|Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70||National Cancer Institute (NCI)||Active, not recruiting|July 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|70 Years|N/A|No|||December 2006|July 23, 2008|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104689||199070|
NCT00104910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9918|Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer|A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer||Gynecologic Oncology Group||Completed|January 2005|||January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|March 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00104910||199054|
NCT00105170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202-01|Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors|A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors||Biogen||Terminated|January 2005|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|March 8, 2005||Yes||||https://clinicaltrials.gov/show/NCT00105170||199035|
NCT00105495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA16-0102|Efficacy Study in Removing Excess Iron From the Heart|Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients||ApoPharma||Completed|December 2002|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|36 Years|No|||October 2006|January 4, 2016|March 15, 2005||||No||https://clinicaltrials.gov/show/NCT00105495||199012|
NCT00105508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62225-018|Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia|A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia||EMD Serono||Completed|September 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|611|||Both|30 Years|N/A|No|||October 2013|October 23, 2013|March 15, 2005||||||https://clinicaltrials.gov/show/NCT00105508||199011|
NCT00105742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 99-377|Audiology Visits After Screening for Hearing Loss: An RCT|Audiology Visits After Screening for Hearing Loss: An RCT||VA Office of Research and Development|No|Completed||June 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1400|||Both|N/A|N/A|No|||July 2006|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105742||198993|
NCT00105976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-093-01-200|Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)|A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate||Merrimack Pharmaceuticals||Completed|February 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|18 Years|80 Years|No|||July 2008|July 10, 2008|March 18, 2005||||||https://clinicaltrials.gov/show/NCT00105976||198976|
NCT00105989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8606|Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder|Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder||Eli Lilly and Company||Completed|March 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|514|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|March 18, 2005|Yes|Yes||No|January 23, 2009|https://clinicaltrials.gov/show/NCT00105989||198975|
NCT00106249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5926R|Transcranial Magnetic Stimulation (TMS) and Obsessive Compulsive Disorder (OCD)|Treatment of Obsessive Compulsive Disorder (OCD) With Transcranial Magnetic Stimulation (TMS)||New York State Psychiatric Institute|Yes|Completed|November 2004|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|70 Years|No|||August 2014|August 8, 2014|March 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00106249||198955|
NCT00079651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063395|Montessori-Based Activities for Elderly Persons With Dementia|Programming for Dementia: Maximizing Abilities||Menorah Park|Yes|Completed|December 2002|July 2005|Actual|April 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||300|||Both|60 Years|N/A|No|||November 2013|November 21, 2013|March 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00079651||200847|
NCT00080015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-91-52990-708|Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)|A Phase II Open Label Study Investigating the Activity of Diflomotecan (BN80915) Administered at the Fixed Dose of 7mg as a 20 Minute Intravenous Infusion Once Every 3 Weeks in Patients With Sensitive Small Cell Lung Cancer (SCLC) Who Have Failed First-line Treatment With a Platinum Based Regimen.||Ipsen||Completed|March 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2009|July 23, 2009|March 19, 2004||||No||https://clinicaltrials.gov/show/NCT00080015||200819|
NCT00080366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040147|Octanol to Treat Essential Tremor|Treatment Efficacy of 1-Octanol Compared to Placebo in Adults With Essential Tremor||National Institutes of Health Clinical Center (CC)||Completed|March 2004|March 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||14|||Both|21 Years|N/A|No|||March 2007|April 3, 2007|March 27, 2004||||No||https://clinicaltrials.gov/show/NCT00080366||200793|
NCT00081068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000358811|Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)||Jonsson Comprehensive Cancer Center||Withdrawn|January 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|April 7, 2004||||No||https://clinicaltrials.gov/show/NCT00081068||200750|
NCT00102843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02.0505L|Effect of Betaine and Folic Acid on Vascular Function in Healthy Humans|Effect of Lowering of Fasting Plasma Homocysteine Concentrations Through Supplementation With Betaine or Folic Acid on Vascular Function in Healthy Volunteers||Wageningen Centre for Food Sciences||Completed|October 2002|June 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||August 2005|August 2, 2005|February 3, 2005||||No||https://clinicaltrials.gov/show/NCT00102843||199203|
NCT00107081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOG 2003 FN|Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting|A Prospective Multi-Center Study on Pediatric Patients With Fever in Severe Chemotherapy Induced Neutropenia, Including a Randomized Comparison of Outpatient Management and Oral Antimicrobial Therapy Versus Inpatient Management and Intravenous Antimicrobial Therapy in a Subgroup With Low Risk of Adverse Events (Low-Risk Subgroup Study)||Swiss Pediatric Oncology Group|No|Terminated|January 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|1 Year|18 Years|No|||December 2014|December 23, 2014|April 4, 2005||No|Accrual goal for interventional part not achievable|No||https://clinicaltrials.gov/show/NCT00107081||198895|
NCT00107094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA030|Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer|An Open Label, Pilot Study of Dose-Dense Adriamycin Plus Cyclophosphamide (AC) Followed by ABI-007 as Adjuvant Therapy for Patients With Breast Cancer||Celgene Corporation||Completed|March 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|70 Years|No|||July 2007|July 18, 2007|April 5, 2005||||||https://clinicaltrials.gov/show/NCT00107094||198894|
NCT00107107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-150E|Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus|A Multicenter, Open-Label, Extension Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus Completing Protocol 137-150||AstraZeneca||Completed|November 2002|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|18 Years|N/A|No|||August 2015|September 22, 2015|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107107||198893|
NCT00102765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA103153|Study Of Asthma In Patients Of African Descent|A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone||GlaxoSmithKline|No|Completed|November 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|479|||Both|12 Years|65 Years|No|||April 2015|April 15, 2015|February 1, 2005||||||https://clinicaltrials.gov/show/NCT00102765||199209|
NCT00103103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000410827|Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer|A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma||California Cancer Consortium||Terminated|March 2005|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2010|October 11, 2010|February 7, 2005||||No||https://clinicaltrials.gov/show/NCT00103103||199185|
NCT00077025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839US/0713|Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer|Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer||AstraZeneca|No|Completed|January 2004|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|174|||Female|18 Years|N/A|No|||July 2014|July 15, 2014|February 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077025||201033|
NCT00074009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000341565|Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma|A Multicenter, Open-Label, Two-Stage, Phase II Study Of PS-341 (LDP-341, NSC # 681239) In Patients With Unresectable Or Metastatic Gastric Adenocarcinoma||National Cancer Institute (NCI)||Completed|October 2003|||April 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|February 11, 2012|December 10, 2003||||No||https://clinicaltrials.gov/show/NCT00074009||201241|
NCT00074022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02563|GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors|A Phase I/2 Study of GTI-2040 Combined With Docetaxel In Metastatic Or Unresectable Locally Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|October 2003|||November 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|December 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00074022||201240|
NCT00074685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-101|National Registry for Ichthyosis and Related Disorders|Research Registry for Inherited Disorders of Keratinization||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|No|Active, not recruiting|September 1994|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|610|Samples With DNA|Histology, DNA from participating enrollees|Both|N/A|N/A|No|Non-Probability Sample|Patients with one of the following diseases: Erythrokeratoderma, Extensive Epidermal Nevi,        Darier disease, Hailey-Hailey disease, Ichthyosis, Palmar-Plantar Keratoderma, or        Pachyonychia Congenita|April 2009|April 28, 2009|December 18, 2003||No||No||https://clinicaltrials.gov/show/NCT00074685||201197|
NCT00073489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-461-005|A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)|A Pilot Trial of OSI-461 in Patients With Chronic Lymphocytic Leukemia||Astellas Pharma Inc||Completed|May 2001|December 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||23|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|November 21, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00073489||201279|
NCT00073502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-904-201|Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer|A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction||OSI Pharmaceuticals||Completed|October 2003|October 2003||||Phase 2|Interventional|Primary Purpose: Treatment||||43|||Both|18 Years|N/A|No|||October 2003|February 17, 2006|November 21, 2003||||||https://clinicaltrials.gov/show/NCT00073502||201278|
NCT00109330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|776423/001|A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine|A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Bios' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)||GlaxoSmithKline||Completed|November 2002|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|4116|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|April 27, 2005||||No||https://clinicaltrials.gov/show/NCT00109330||198734|
NCT00109343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-019|V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)|An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age||Merck Sharp & Dohme Corp.||Completed|March 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1027|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||February 2015|February 11, 2015|April 27, 2005|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00109343||198733|One subject (Group 3-ProQuad™ followed by PREVNAR™) was diagnosed (Day 8) with Stage IV neuroblastoma (considered not related to study vaccine by investigator) and discontinued from the study. Subject died (Day 218) due to neuroblastoma.
NCT00110409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173|Asthma Patient Education in the Emergency Room|Trial of Asthma Patient Education in the Emergency Room||Hospital for Special Surgery, New York|Yes|Completed|January 2005|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|296|||Both|18 Years|95 Years|No|||June 2013|June 7, 2013|May 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00110409||198656|
NCT00109850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000426442|S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer|Cetuximab Plus Cisplatin, Irinotecan and Thoracic Radiotherapy (TRT) for Locally Advanced (Non-Metastatic), Clinically Unresectable Esophageal Cancer: A Phase II Trial With Molecular Correlates||Southwest Oncology Group|Yes|Terminated|May 2005|May 2012|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|May 3, 2005|Yes|Yes|Closed due to poor accrual|No|June 14, 2012|https://clinicaltrials.gov/show/NCT00109850||198696|
NCT00110656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030219|Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation|A Retrospective Follow Up Study to Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation||Amgen||Completed|March 2004|October 2004|Actual|September 2004|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|38|None Retained|Retrospective data collected.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Secondary HPT and ESRD who previously qualified for Amgen AM 073 studies but        were withdrawn due to kidney transplant.|January 2011|January 20, 2011|May 12, 2005||||No||https://clinicaltrials.gov/show/NCT00110656||198637|
NCT00074165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-641|Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen|A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen||OHSU Knight Cancer Institute|Yes|Terminated|January 2003|December 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Months|75 Years|No|||November 2011|November 21, 2011|December 10, 2003|Yes|Yes|Lack of accrual|No|October 10, 2011|https://clinicaltrials.gov/show/NCT00074165||201232|
NCT00110396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25632|Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis|A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis|RNF|EMD Serono||Completed|January 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|260|||Both|18 Years|60 Years|No|||June 2015|June 18, 2015|May 6, 2005|Yes|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00110396||198657|
NCT00083005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040132|Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate|A Phase II Trial Combining Estramustine, Docetaxel And Thalidomide In Patients With Androgen-Independent Metastatic Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|March 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Male|18 Years|N/A|No|||March 2012|March 14, 2012|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00083005||200619|
NCT00083577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 98-003|Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma|UARK 98-003, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Multiple Myeloma||University of Arkansas||Completed|February 1998|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|May 25, 2004||||||https://clinicaltrials.gov/show/NCT00083577||200576|
NCT00083590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0052|Huperzine A in Alzheimer's Disease|A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function||National Institute on Aging (NIA)||Completed|April 2004|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|55 Years|N/A|No|||February 2008|February 19, 2008|May 26, 2004||||No||https://clinicaltrials.gov/show/NCT00083590||200575|
NCT00084539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365456|Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer|Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost in Early Stage Breast Cancer||Fox Chase Cancer Center|No|Completed|November 2003|||November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084539||200509|
NCT00083928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Å6-003|Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels|A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy||Ångstrom Pharmaceuticals||Completed|May 2004|December 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Female|18 Years|N/A|No|||January 2013|January 22, 2013|June 3, 2004||||||https://clinicaltrials.gov/show/NCT00083928||200551|
NCT00083941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV2 Renal|A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer|Clinical Trial Phase II (Single Centre Study) : A Preliminary Study of the Safety, Immunogenicity, and Clinical Efficacy of TroVax Given in Conjunction With Interleukin 2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer||Oxford BioMedica||Completed|August 2004|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|June 3, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083941||200550|
NCT00084773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-006|Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer|A Pilot Clinical Trial of Preoperative Cetuximab With Concurrent Continuous Infusion Fluorouracil and Pelvic Radiation in Patients With Local-Regionally Advanced Rectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2004|March 2010|Actual|January 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|120 Years|No|||December 2015|December 21, 2015|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084773||200492|
NCT00085111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01813|Bevacizumab in Treating Young Patients With Refractory Solid Tumors|A Phase I Study of Bevacizumab in Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|December 2003|||October 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|1 Year|21 Years|No|||June 2013|June 4, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085111||200475|
NCT00072631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-202|Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy||Astellas Pharma Inc|No|Completed|August 2003|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|November 5, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072631||201343|
NCT00072644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040040|Pharmacokinetic Interactions With Prednisolone in Healthy Volunteers and HIV-Infected Patients Receiving Single-Dose Prednisone|Pharmacokinetic Interactions With Prednisolone in Healthy Volunteers and HIV-Infected Patients Receiving Single-Dose Prednisone||National Institutes of Health Clinical Center (CC)||Completed|October 2003|June 2008||||N/A|Observational|N/A||||75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 18, 2008|November 6, 2003||||No||https://clinicaltrials.gov/show/NCT00072644||201342|
NCT00072657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR049840|Cognitive-Behavioral Therapy and Tai Chi Chih for Patients With Rheumatoid Arthritis|Behavioral Treatments for Rheumatoid Arthritis||University of California, Los Angeles||Completed|February 2004|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|November 7, 2003||No||No||https://clinicaltrials.gov/show/NCT00072657||201341|
NCT00073424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1042s|Factors Affecting Adherence to Anti-HIV Drug Regimens in Children and Adolescents|Cognitive, Behavioral, and Psychosocial Correlates of Medication Adherence in Children and Adolescents With HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2004|October 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||200|||Both|8 Years|19 Years|No|||May 2013|May 31, 2013|November 20, 2003||||No||https://clinicaltrials.gov/show/NCT00073424||201284|
NCT00074035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-100101|Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease|A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|December 2003|||August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|39|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|December 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074035||201239|
NCT00108940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1082-99|Siblings With Ischemic Stroke Study|Siblings With Ischemic Stroke Study|SWISS|Mayo Clinic|No|Completed|December 2000|June 2011|Actual|June 2009|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|900|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|in-patient or out-patient clinics, local community|September 2011|September 23, 2011|April 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00108940||198763|
NCT00110136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98301|St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer|A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer||Wake Forest NCORP Research Base|Yes|Terminated|March 2006|November 2008|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Female|18 Years|N/A|No|||December 2014|December 17, 2014|May 3, 2005|Yes|Yes|Stopped due to concerns about interaction between St. John's wort and Tamoxifen.|No|September 4, 2014|https://clinicaltrials.gov/show/NCT00110136||198677|This study was stopped early due to concerns about the interaction between St. John's wort and tamoxifen.
NCT00072865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7771|Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer|A Phase II Study of Alimta and Carboplatin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer||Eli Lilly and Company||Completed|June 2003|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|November 12, 2003||||||https://clinicaltrials.gov/show/NCT00072865||201326|
NCT00073268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14239 (completed)|Prevention of Type 2 Diabetes Mellitus in Children|Prevention of Type 2 Diabetes Mellitus in Children||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 2002|June 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|12 Years|15 Years|No|||January 2010|January 14, 2010|November 18, 2003||||No||https://clinicaltrials.gov/show/NCT00073268||201296|
NCT00110955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030232|Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy|A Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy||Amgen||Completed|February 2004|April 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|391|||Both|18 Years|N/A|No|||January 2010|January 14, 2010|May 16, 2005||||No||https://clinicaltrials.gov/show/NCT00110955||198614|
NCT00073281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9903 (completed)|Islet Transplantation for Patients With Type 1 Diabetes|Islet Transplantation for Patients With Type 1 Diabetes and Stable Renal Allografts Using Steroid Sparing Immunosuppression||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 2003|December 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||January 2010|January 14, 2010|November 18, 2003||||No||https://clinicaltrials.gov/show/NCT00073281||201295|
NCT00073580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-02-02|Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)|Angiomax in Patients With HIT/HITTS Type II Undergoing Off-PUMP CABG||The Medicines Company||Active, not recruiting|October 2003|||September 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||November 2011|November 8, 2011|November 26, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073580||201273|
NCT00073593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-02-07|Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB|A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Coronary Artery Bypass (OPCAB) Surgery|OPCAB|The Medicines Company||Completed|August 2003|||May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 8, 2011|November 26, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073593||201272|
NCT00074178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-5729-2|Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma|Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma|Protocol-B|OHSU Knight Cancer Institute|Yes|Completed|January 2000|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|16 Years|75 Years|No|||June 2010|May 24, 2012|December 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00074178||201231|
NCT00074191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-5729-1|Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma|Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma|Protocol-A|OHSU Knight Cancer Institute|Yes|Completed|January 2000|October 2000|Actual|October 2000|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Both|16 Years|75 Years|No|||February 2011|May 24, 2012|December 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00074191||201230|
NCT00074204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LILY1503|Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase III Study of Delayed vs. Immediate Second-Line Therapy With Docetaxel After Gemcitabine + Carboplatin in Advanced Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|October 2003|April 2008|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|December 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074204||201229|
NCT00074516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040057|Kidney Transplantation in Patients With Cystinosis|Renal Transplantation in Recipients With Nephropathic Cystinosis||National Institutes of Health Clinical Center (CC)||Completed|December 2003|June 2014||||N/A|Observational|N/A|||Actual|11|||Both|7 Years|N/A|No|||June 2014|June 12, 2014|December 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00074516||201208|
NCT00074529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0677-030|Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease||Merck Sharp & Dohme Corp.||Completed|October 2003|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|512|||Both|50 Years|N/A|No|||July 2015|July 23, 2015|December 15, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074529||201207|
NCT00083954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1447C00135|Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression|A Confirmatory Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression||AstraZeneca||Completed|June 2004|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||530|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|June 3, 2004||||||https://clinicaltrials.gov/show/NCT00083954||200549|
NCT00083967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-102|Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment|A Randomized, Double-Masked, Placebo Controlled, Parallel Group, Multi-Center, Dose-Ranging Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Rhegmatogenous Retinal Detachment||Merck Sharp & Dohme Corp.||Terminated|June 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|June 3, 2004||||||https://clinicaltrials.gov/show/NCT00083967||200548|
NCT00084240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661123|Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia|A Phase 2/3, Randomized, Comparative, Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia||Pfizer||Terminated|March 2004|April 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|85 Years|No|||October 2008|October 30, 2008|June 9, 2004|||See Detailed Description|||https://clinicaltrials.gov/show/NCT00084240||200528|
NCT00083980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000150-01A1|Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)|KAVA KAVA in Generalized Anxiety: A Double-Blind Trial||National Center for Complementary and Integrative Health (NCCIH)|No|Terminated|June 2002|August 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|N/A|N/A|No|||August 2006|October 18, 2012|June 4, 2004||No|European reports of liver toxicity from kava meant that the study had to stop|No||https://clinicaltrials.gov/show/NCT00083980||200547|
NCT00084266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951001|Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)|Linezolid In The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus|ZEPHYR|Pfizer|No|Completed|October 2004|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1225|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|June 9, 2004|Yes|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00084266||200526|EOS visit window of 15-21 days after last dose as specified in protocol was expanded during blinded evaluability assessments and prior to database lock and unblinding to 7-30 days after last dose in order to better fit the actual study visit days.
NCT00084279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGHC-002|CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)|Safety and Tolerability of Consensus Interferon-Alpha (CIFN) Plus Interferon Gamma-1b (IFN-γ 1b) With or Without Ribavirin (RBV) in the Treatment of Patients With Chronic Hepatitis C Who Are Non-Responders to PEG-IFN-a (2a or 2b) Plus RBV||InterMune||Completed|April 2004|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||July 2009|July 1, 2009|June 9, 2004||||No||https://clinicaltrials.gov/show/NCT00084279||200525|
NCT00084786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-003|Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation of ZD1839 (Iressa®) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor||Memorial Sloan Kettering Cancer Center||Completed|March 2004|||July 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 15, 2013|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00084786||200491|
NCT00073099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040048|Digital Photography to Evaluate Dry Eye|Digital Image Based Determination of Ocular Surface Vital Dye Staining||National Institutes of Health Clinical Center (CC)||Completed|November 2003|September 2007||||N/A|Observational|N/A||||60|||Both|2 Years|N/A|No|||September 2007|September 26, 2015|November 14, 2003||||No||https://clinicaltrials.gov/show/NCT00073099||201309|
NCT00073112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-416|A Study of ABT-751 in Patients With Renal Cell Cancer|A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma||Abbott|No|Completed|August 2003|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||60|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|November 17, 2003||||No||https://clinicaltrials.gov/show/NCT00073112||201308|
NCT00073437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005293|A Study of Infliximab in Patients With Sarcoidosis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade�) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement.||Centocor, Inc.||Completed|October 2003|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|139|||Both|18 Years|N/A|No|||April 2010|May 16, 2011|November 20, 2003||||||https://clinicaltrials.gov/show/NCT00073437||201283|
NCT00072709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCH346A2211|Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating Four Oral Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis||Novartis||Completed|September 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|551|||Both|21 Years|80 Years|No|||November 2011|November 22, 2011|November 7, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072709||201338|
NCT00072722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-PC-002|Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)|Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)||Celgene||Completed|September 2003|April 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Male|18 Years|N/A|No|||December 2006|December 18, 2006|November 7, 2003||||||https://clinicaltrials.gov/show/NCT00072722||201337|
NCT00073125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-428|Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma|A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma||Abbott|No|Completed|May 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||August 2007|August 13, 2007|November 17, 2003||||No||https://clinicaltrials.gov/show/NCT00073125||201307|
NCT00073723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA015|Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer|An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer||Celgene||Completed|December 2003|January 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|December 3, 2003||||No||https://clinicaltrials.gov/show/NCT00073723||201262|
NCT00073736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-101|Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma|A Phase 1/2 Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MB07133 in Subjects With Unresectable Hepatocellular Carcinoma and Child-Pugh Class A Liver Function||Ligand Pharmaceuticals|No|Completed|September 2003|||July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|28|||Both|18 Years|N/A|No|||August 2011|August 10, 2011|December 3, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073736||201261|
NCT00073749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K1-100|Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma|A Phase 1 Study Of CMC-544 Administered As A Single Agent In Subjects With B-Cell Non-Hodgkin's Lymphoma||Pfizer|No|Completed|August 2003|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|December 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073749||201260|
NCT00073450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02530|Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)|An Open-Label Phase 2 Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck||Merck Sharp & Dohme Corp.||Terminated|September 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|November 20, 2003||||||https://clinicaltrials.gov/show/NCT00073450||201282|
NCT00073164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-547|Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia|A Study of the Safety and Efficacy of Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia||Abbott||Completed|July 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|No|||August 2006|August 2, 2006|November 17, 2003||||||https://clinicaltrials.gov/show/NCT00073164||201304|
NCT00109863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000426431|Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma|Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma||University of Wisconsin, Madison||Completed|May 2005|February 2014|Actual|July 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|May 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109863||198695|
NCT00072449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-2201 CDR0000339737|Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma|A Phase II Study Of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy For Patients With Refractory Or Relapsed Primary CNS Lymphoma (PCNSL)||Sidney Kimmel Comprehensive Cancer Center||Terminated|May 2004|June 2010|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|November 4, 2003|No|Yes|slow accrual and lack of resources and priority due to combining 2 consortia|No|June 14, 2013|https://clinicaltrials.gov/show/NCT00072449||201357|Study terminated early due to slow accrual and lack of resources and priority due to NCI mandate of combining two consortia. Unable to fully analyze the data, or objectives, not enough patients. Not able to do statistics
NCT00072852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTAPO-0047-146|Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine|Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine||Pfizer||Completed|November 2003|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|134|||Female|18 Years|N/A|No|||October 2008|October 15, 2008|November 11, 2003||Yes||No||https://clinicaltrials.gov/show/NCT00072852||201327|
NCT00074230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERLANGEN-DERMA-ER-DC-06|Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma|Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding for Mage-3, MelanA, and Survivin Antigens||University Hospital Erlangen||Completed|July 2003|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|December 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00074230||201228|
NCT00074243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000343702|CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas|A Phase I Trial Of CC-8490 For The Treatment Of Patients With Recurrent/Refractory High-Grade Gliomas||National Cancer Institute (NCI)||Completed|December 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2006|April 29, 2015|December 10, 2003||||||https://clinicaltrials.gov/show/NCT00074243||201227|
NCT00074542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol TP0308 (EPIC-2)|An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease|A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease||Tillotts Pharma AG||Completed|September 2002|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||364|||Both|16 Years|N/A|No|||October 2005|February 20, 2007|December 15, 2003||||||https://clinicaltrials.gov/show/NCT00074542||201206|
NCT00084292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019920593|Database for Stroke in Infants and Children|International Pediatric Stroke Study||The Hospital for Sick Children|No|Recruiting|June 2004|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12000|||Both|N/A|18 Years|No|Probability Sample|neonates and children with arterial ischemic stroke and cerebral sinovenous thrombosis|May 2013|May 28, 2013|June 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00084292|12 Months|200524|
NCT00084578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-03018|Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder|A Randomized Trial of Celecoxib and Rosiglitazone, Alone and in Combination, in Patients With Early Stage Non-Invasive Bladder Carcinoma Undergoing Cystoscopic Surveillance and in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy||Fox Chase Cancer Center|No|Withdrawn|March 2004|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|June 10, 2004|Yes|Yes|Withdrawn due to drug toxicity|No||https://clinicaltrials.gov/show/NCT00084578||200506|
NCT00084799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365621|Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer|A Multiple-Dose Targeting Study of hu3S193 in Patients With Small Cell Lung Cancer||Ludwig Institute for Cancer Research|No|Completed|February 2004|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084799||200490|
NCT00085150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000367333|LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma|Pediatric Phase I Trial of LMB-2 for Refractory CD25-Positive Leukemias and Lymphomas||National Cancer Institute (NCI)||Completed|April 2004|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|21 Years|No|||February 2007|April 29, 2015|June 10, 2004||||||https://clinicaltrials.gov/show/NCT00085150||200473|
NCT00077064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0123|Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy|A Phase II Randomized Trial With Captopril In Patients Who Have Received Radiation Therapy +/- Chemotherapy For Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, Or Limited-Stage Small-Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|June 2003|||September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|81|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077064||201030|
NCT00072345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-084|Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma|A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma||Memorial Sloan Kettering Cancer Center||Completed|July 2003|||August 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 17, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072345||201362|
NCT00072683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-02-235|“SALT Trial” Study of Ascending Levels of Tolvaptan in Hyponatremia|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|April 2003|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|November 7, 2003||||||https://clinicaltrials.gov/show/NCT00072683||201339|
NCT00072358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-077|Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma|Phase II Study of Anti-GD2 3F8 Antibody and GM-CSF for High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2003|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|N/A|N/A|No|||October 2015|October 9, 2015|November 4, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072358||201361|
NCT00073138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-446|A Study of ABT-751 in Patients With Colorectal Cancer|A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma||Abbott|No|Completed|August 2003|February 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||40|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|November 17, 2003||||No||https://clinicaltrials.gov/show/NCT00073138||201306|
NCT00073151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-448|A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer|A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens||Abbott|No|Completed|September 2003|January 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|November 17, 2003||||No||https://clinicaltrials.gov/show/NCT00073151||201305|
NCT00072735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040042|Improvement of Use Dependent Plasticity in Chronic Stroke Patients|Improvement of Use Dependent Plasticity in Chronic Stroke Patients||National Institutes of Health Clinical Center (CC)||Completed|November 2003|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||August 2007|September 26, 2015|November 7, 2003||||No||https://clinicaltrials.gov/show/NCT00072735||201336|
NCT00073177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-012|Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)|A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Roflumilast (250 Mcg or 500 Mcg) Daily in Patients With Asthma||Takeda||Completed|November 2003|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||819|||Both|18 Years|70 Years|No|||January 2012|May 4, 2012|November 17, 2003||||No||https://clinicaltrials.gov/show/NCT00073177||201303|
NCT00073203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004339|A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder|A 6- Week, Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||488|||Both|18 Years|65 Years|No|||May 2004|August 27, 2009|November 17, 2003||||||https://clinicaltrials.gov/show/NCT00073203||201301|
NCT00072137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00020|Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy|Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy||National Cancer Institute (NCI)||Terminated|October 2003|November 2010|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|N/A|N/A|No|||August 2013|December 22, 2014|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072137||201374|
NCT00073294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9777 (completed)|Insulin Resistance and Insulin Secretion|Phenotypic Assessment of Insulin Resistance and Insulin Secretory Capacity||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|200|||Both|10 Years|20 Years|No|||January 2010|January 14, 2010|November 18, 2003||||No||https://clinicaltrials.gov/show/NCT00073294||201294|
NCT00073307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11213|Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer|A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.||Bayer|Yes|Completed|November 2003|April 2010|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|903|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|November 19, 2003|Yes|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00073307||201293|Per final PFS data (N=769) study unblinded; placebo-randomized subjects switched to sorafenib ~31May2005 (N=216) that diluted final OS, sorafenib treatment effect. Final ITT, N=903, reported safety data include additional data and cleaning.
NCT00073606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040054|Spinal Cord Plasticity|Intraspinal Plasticity Associated With Locomotor Learning||National Institutes of Health Clinical Center (CC)||Completed|December 2003|May 2008||||N/A|Observational|N/A||||70|||Both|21 Years|65 Years|No|||May 2008|May 21, 2008|December 1, 2003||||No||https://clinicaltrials.gov/show/NCT00073606||201271|
NCT00073619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063143|Preventing Anxiety Disorders in Youth|Community Violence and Youth: Preventing Anxiety Disorders||National Institute of Mental Health (NIMH)||Recruiting|December 2001|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||November 2005|November 17, 2005|December 2, 2003||||No||https://clinicaltrials.gov/show/NCT00073619||201270|
NCT00073879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000328247|Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation|Allogeneic Adoptive Immunochemotherapy For Treatment Of Renal Cell Carcinoma||Baylor College of Medicine||Completed|April 2003|April 2004|Actual|April 2004|Actual|N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 2015|January 27, 2015|December 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00073879||201250|
NCT00073892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000335412|PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma|A Phase I/II Study Of PI-88 In Advanced Malignancies (Phase I), And In Advanced Melanoma(Phase II)||National Cancer Institute (NCI)||Active, not recruiting|June 2001|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2004|September 17, 2008|December 10, 2003||||No||https://clinicaltrials.gov/show/NCT00073892||201249|
NCT00075153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR007975-01|Quality of Life in Children With HIV Infection|Quality of Life in Children With HIV Infection||Rutgers, The State University of New Jersey|No|Completed|September 2001|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1993|||Both|10 Months|25 Years|No|Non-Probability Sample|Children and youth, from birth to 25 years, with perinatally acquired HIV infection        enrolled in PACTG 219/219C|April 2014|April 21, 2014|January 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00075153||201162|
NCT00075166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040066|Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors|A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 2003|November 2005||||Phase 4|Interventional|Primary Purpose: Treatment||||130|||Both|N/A|N/A|No|||November 2005|March 3, 2008|January 2, 2004||||No||https://clinicaltrials.gov/show/NCT00075166||201161|
NCT00074555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR02247|Registry for African Americans With Early Rheumatoid Arthritis|Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (CLEAR)|CLEAR|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|No|Completed|January 2001|March 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|357|Samples With DNA|serum, DNA|Both|18 Years|N/A|No|Non-Probability Sample|African Americans|January 2016|January 5, 2016|December 16, 2003||No||No||https://clinicaltrials.gov/show/NCT00074555||201205|
NCT00083291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040190|Helicobacter Pylori and Dry Eye|Pilot Study of Helicobacter Pylori and Ocular Surface Disease||National Institutes of Health Clinical Center (CC)||Completed|May 2004|March 2005||||N/A|Observational|N/A||||10|||Both|N/A|N/A|No|||March 2005|March 3, 2008|May 18, 2004||||No||https://clinicaltrials.gov/show/NCT00083291||200598|
NCT00083603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 055|Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults|A Phase I Trial to Evaluate the Safety and Immunogenicity of rMVA-HIV (rMVA-HIV Env/Gag + rMVA-HIV Tat/Rev/Nef-RT) and rFPV-HIV (rFPV-HIV Env/Gag + rFPV-HIV Tat/Rev/Nef-RT) Vaccines, Alone or in Combination, in Healthy, Vaccinia Naive HIV-1 Negative Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2004|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|16||Actual|150|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|May 26, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00083603||200574|
NCT00084552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365458|Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer|Outcomes Following Intensity Modulated Radiation Therapy With And Without Erectile Tissue Dose Sparing For Favorable To Intermediate Risk Prostate Cancer||Fox Chase Cancer Center|No|Active, not recruiting|December 2003|||August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Male|18 Years|N/A|No|||March 2016|March 1, 2016|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084552||200508|
NCT00084565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-03035|Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer|Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma||Fox Chase Cancer Center|No|Withdrawn|November 2003|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Male|18 Years|N/A|No|||July 2013|July 9, 2013|June 10, 2004|Yes|Yes|Study was never activated at Fox Chase Cancer Center.|No||https://clinicaltrials.gov/show/NCT00084565||200507|
NCT00085163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40023|Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon|Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|March 2004|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||October 2015|October 19, 2015|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00085163||200472|
NCT00085449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-100102|Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer|A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells||Alliance for Clinical Trials in Oncology|No|Completed|May 2006|January 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|60 Years|No|||July 2015|July 14, 2015|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085449||200454|
NCT00085462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040181|Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma by Lymphodepleting Conditioning Followed by Infusion of TCR-Gene Engineered Lymphocytes and Subsequent Fowlpox gp100 Vaccination||National Institutes of Health Clinical Center (CC)||Completed|May 2004|September 2008|Actual|May 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|61|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|June 10, 2004||||||https://clinicaltrials.gov/show/NCT00085462||200453|
NCT00076726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003139|A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis|A Randomized, Double-Masked, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Infliximab in Subjects With Giant Cell Arteritis||Centocor, Inc.|Yes|Terminated|November 2003|July 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|44|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2010|May 16, 2011|February 2, 2004|||Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative    glucocorticosteroid dosage|||https://clinicaltrials.gov/show/NCT00076726||201051|
NCT00077077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346368|DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Study Of The Combination Of Oral DJ-927 And Capecitabine In Patients With Advanced Solid Tumors||Daiichi Sankyo Inc.||Completed|February 2004|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2012|May 15, 2012|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077077||201029|
NCT00072384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARET0231|Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma|A Single Arm Trial of Systemic And Subtenon Chemotherapy For Groups C And D Intraocular Retinoblastoma||Children's Oncology Group|Yes|Completed|April 2007|||February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|17 Years|No|||June 2013|June 18, 2013|November 4, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072384||201360|
NCT00072774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-306|Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Three Fixed Doses (100 Mg, 200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|480|||Both|18 Years|75 Years|No|||August 2009|August 18, 2009|November 10, 2003||||||https://clinicaltrials.gov/show/NCT00072774||201333|
NCT00072748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3095A1-200|Study Evaluating EKB-569 in Advanced Colorectal Cancer|||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|63|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|November 10, 2003||||||https://clinicaltrials.gov/show/NCT00072748||201335|
NCT00072761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS42804|Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial|Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial|SIT|Washington University School of Medicine|Yes|Completed|December 2004|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|5 Years|14 Years|No|||January 2016|January 7, 2016|November 10, 2003||No||No|May 4, 2015|https://clinicaltrials.gov/show/NCT00072761||201334|The SIT Trial results are not directly applicable to all children with SCA. Those who were on hydroxyurea therapy for severe disease, had abnormally elevated TCDs, were receiving blood transfusion for stroke prevention or had epilepsy were excluded.
NCT00073216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 049|Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine and a Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine in Healthy, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Primary Purpose: Prevention|||Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|November 18, 2003||||||https://clinicaltrials.gov/show/NCT00073216||201300|
NCT00108537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRD-013-01S|Non-Nicotine Agents for Smoking Cessation|Non-Nicotine Agents for Smoking Cessation||VA Office of Research and Development||Completed|October 2003|September 2005||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||October 2006|April 2, 2008|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108537||198790|
NCT00108550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNA-013-04S|Chronic Low Back Pain Research Project|Efficacy of Antidepressants in Chronic Back Pain||VA Office of Research and Development|Yes|Completed|October 2004|September 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|21 Years|70 Years|No|||December 2013|December 20, 2013|April 15, 2005|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT00108550||198789|Limitations include small sample size, high rate of early termination, and moderate baseline levels of pain intensity and disability in everyday function which may have limited ability to detect an effect.
NCT00072891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59048DK (completed)|Improving Medication Adherence in Comorbid Conditions|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||400|||Both|40 Years|N/A|No|||February 2010|February 12, 2010|November 12, 2003||||No||https://clinicaltrials.gov/show/NCT00072891||201325|
NCT00072904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58356DK (completed)|Diabetes Therapy to Improve BMI and Lung Function in CF|Diabetes Therapy to Improve BMI and Lung Function in CF||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 2001|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|108|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 27, 2012|November 12, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072904||201324|
NCT00074269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-020815|Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer|Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer||University of California, San Diego|Yes|Terminated|July 2003|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|60 Years|No|||November 2014|December 2, 2014|December 10, 2003||No|Terminated early due to poor enrollment|No|May 29, 2014|https://clinicaltrials.gov/show/NCT00074269||201226|Terminated early due to small numbers of subjects enrolled on study
NCT00074282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000343796|Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Lenalidomide for Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Recruiting|December 2004|||October 2014|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|December 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074282||201225|
NCT00074568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-108|Scleroderma Registry|Scleroderma Family Registry and DNA Repository|Registry|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|No|Recruiting|September 2000|||January 2022|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|5000|Samples With DNA|Serum, Plasma, DNA|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with Systemic Sclerosis or family member of patients with systemic        sclerosis        or        Healthy volunteer with no autoimmune disease and without a first degree relative with a        systemic autoimmune disease.|January 2016|January 4, 2016|December 16, 2003||No||No||https://clinicaltrials.gov/show/NCT00074568||201204|
NCT00073905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 44/02|Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer|Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|April 2003|January 2009|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|44|||Both|18 Years|80 Years|No|||June 2012|June 2, 2012|December 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00073905||201248|
NCT00074581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 052|Preventing Sexual Transmission of HIV With Anti-HIV Drugs|A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2005|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|3500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|December 16, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074581||201203|
NCT00074880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040062|The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy|The Role of Atrio-Ventricular Coupling in Exercise Tolerance in Non-Obstructive Hypertrophic Cardiomyopathy||National Institutes of Health Clinical Center (CC)||Completed|December 2003|March 2005||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||March 2005|March 3, 2008|December 22, 2003||||No||https://clinicaltrials.gov/show/NCT00074880||201182|
NCT00083993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066A1-303|Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer|A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|May 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1236|||Female|18 Years|N/A|No|||November 2011|November 7, 2011|June 4, 2004||||||https://clinicaltrials.gov/show/NCT00083993||200546|
NCT00084305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040211|Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis|Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis||National Institutes of Health Clinical Center (CC)||Recruiting|June 2004|||||N/A|Observational|N/A|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|June 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00084305||200523|
NCT00084318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0234|Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck|A Phase II Randomized Trial Of Surgery Followed By Chemoradiotherapy Plus Cetuximab For Advanced Squamous Cell Carcinoma Of The Head and Neck||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 2004|||March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084318||200522|
NCT00084812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-002|Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Safingol Administered With Cisplatin in Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|March 2004|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084812||200489|
NCT00084825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365625|Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008|Crossover From Docetaxel and Placebo to Docetaxel and Imatinib in Patients With Androgen-Independent Prostate Cancer With Bone Metastases: Extension Trial to ID03-0008||M.D. Anderson Cancer Center|No|Completed|May 2003|June 2008|Actual|July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|N/A|N/A|No|||October 2012|October 24, 2012|June 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00084825||200488|
NCT00085475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62027|Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma|Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|April 2004|||April 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00085475||200452|
NCT00076739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040113|Study of Brain Function During Cognitive Tasks|Examining Associative Relations in Structured Event Complexes Using Functional Neuroimaging||National Institutes of Health Clinical Center (CC)||Completed|February 2004|December 2011||||N/A|Observational|N/A|||Actual|452|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 13, 2011|February 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00076739||201050|
NCT00076752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040095|Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus|A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2004|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|15 Years|40 Years|No|||June 2014|June 13, 2014|February 2, 2004|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT00076752||201049|
NCT00077090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000349496|Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer|Randomized Phase II Trial Of Hyperbaric Oxygen Therapy In Patients With Chronic Arm Lymphoedema After Radiotherapy For Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2004|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|63|||Both|18 Years|N/A|No|||September 2007|December 17, 2013|February 10, 2004||||No||https://clinicaltrials.gov/show/NCT00077090||201028|
NCT00107939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2302|Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Licarbazepine 750 ¿ 2000 mg/d as Adjunctive Therapy to an Atypical Antipsychotic in the Treatment of Manic Episodes of Bipolar I Disorder Over 6 Weeks||Novartis||Completed|November 2004|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|453|||Both|18 Years|70 Years|No|||November 2011|November 22, 2011|April 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107939||198835|
NCT00072787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1101; ID02-694|Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer|A Phase I/II, Open-Label, Nonrandomized, Dose-Finding Safety, Tolerance, Pharmacokinetic, and Efficacy Study of Orally Administered S-1 in Combination With Cisplatin in Patients With Advanced Gastric Cancer||Taiho Oncology, Inc.||Completed|October 2003|May 2006|Actual|March 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||41|||Both|18 Years|N/A|No|||August 2009|August 6, 2009|November 10, 2003||||||https://clinicaltrials.gov/show/NCT00072787||201332|
NCT00073190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR048616|Patient- and Physician-Based Osteoporosis Education|Randomized Controlled Testing of Osteoporosis Education||Brigham and Women's Hospital||Completed|September 2003|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind||||30000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 13, 2013|November 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00073190||201302|
NCT00108563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-012-02S|VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients|VISN 20 Prophylactic Treatment of IFN-Induced Depression in Hepatitis C||VA Office of Research and Development||Completed|October 2003|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||May 2007|January 20, 2009|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108563||198788|
NCT00109590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1032|Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth|Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Didanosine/Lopinavir/Ritonavir||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2006|November 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|175|||Female|18 Years|N/A|No|||December 2014|December 30, 2014|April 29, 2005|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00109590||198715|
NCT00072930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP098|MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer|Phase II, Randomized, Open-Label, Two-Arm, Multicenter Study of MEDI-522, a HuMA Directed Against the Human Alpha V Beta 3 Integrin, in Combination With Docetaxel, Prednisone, and Zoledronic Acid in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer||MedImmune LLC||Completed|December 2003|June 2007|Actual|April 2007|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||150|||Male|18 Years|N/A|No|||January 2008|January 11, 2008|November 12, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072930||201322|
NCT00073320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004462|Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia|Pharmacokinetics, Tolerability, and Safety of Paliperidone After Repeated Intramuscular Injection of Paliperidone Palmitate in the Arm or the Buttock of Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2003|May 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|88|||Both|18 Years|65 Years|No|||April 2010|April 26, 2010|November 19, 2003||||||https://clinicaltrials.gov/show/NCT00073320||201292|
NCT00073346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH068539|Treatment of Compulsive Hoarding|Treatment of Compulsive Hoarding||Boston University||Completed|September 2003|August 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||52|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|November 19, 2003||||No||https://clinicaltrials.gov/show/NCT00073346||201290|
NCT00073931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1366.00|Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial Evaluating: Radioiodinated Anti-B1 (Anti-CD20) Antibody With Autologous Stem Cell Transplantation For Relapsed Or Refractory Non-Hodgkin's Lymphoma In Patients 60 Years Of Age And Older||Fred Hutchinson Cancer Research Center||Completed|October 1999|July 2014|Actual|May 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|60 Years|80 Years|No|||February 2015|February 3, 2015|December 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073931||201246|
NCT00074854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3521002|A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy|A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy (Paclitaxel And Carboplatin) Vs. Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer.||Pfizer||Completed|May 2002|March 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||87|||Both|18 Years|N/A|No|||July 2006|November 8, 2006|December 22, 2003||||No||https://clinicaltrials.gov/show/NCT00074854||201184|
NCT00074867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3521003|Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer|A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer||Pfizer||Completed|October 2003|September 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||29|||Female|18 Years|N/A|No|||July 2006|November 6, 2006|December 22, 2003||||No||https://clinicaltrials.gov/show/NCT00074867||201183|
NCT00074607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10564 IT Gemcitabine|Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine|Intrathecal Gemcitabine Therapy for Neoplastic Meningitis: A Phase I and Pharmacokinetic Study||Baylor College of Medicine|Yes|Terminated|December 2001|April 2007|Actual|July 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|3 Years|N/A|No|||November 2012|November 9, 2012|December 16, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00074607||201202|
NCT00074620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP200CRD01|A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis|A Randomised, Multicenter, Open-Label, Parallel Group Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Unfractionated Heparin as Anticoagulant Treatment in Patients Undergoing Haemodialysis Via an Arteriovenous Graft||Speedel Pharma Ltd.|No|Completed|November 2003|January 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||260|||Both|21 Years|75 Years|No|||October 2007|October 4, 2007|December 17, 2003||||||https://clinicaltrials.gov/show/NCT00074620||201201|
NCT00084019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5201|Atazanavir/Ritonavir Maintenance Therapy|A Prospective, Open-Label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2004|May 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|June 4, 2004||||||https://clinicaltrials.gov/show/NCT00084019||200545|
NCT00084032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEDRP AIN502|Anti-HIV Medications and Structured Treatment Interruptions for People Recently Infected With HIV|A Randomized, Multicenter Trial to Determine Whether Induction Therapy Followed by Treatment Interruption is Superior to Induction Therapy Alone in the Treatment of Primary HIV Infection (PHI): The Structured Treatment Interruption (STI) Study||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|June 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084032||200544|
NCT00084045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1031A|Voluntary HIV Counseling, Testing, and Medication for Pregnant Women to Prevent Mother-to-Child HIV Transmission|Mother Infant Rapid Intervention at Delivery (MIRIAD)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|283|||Female|14 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 26, 2012|June 4, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00084045||200543|
NCT00084344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 00B3|Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women|A Prospective, Randomized, Placebo-Controlled Trial of the Effects of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women||Northwestern University|Yes|Completed|April 2003|July 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Screening|||||||Female|30 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|June 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084344||200521|
NCT00084591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365462|Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer|Phase I Study of Preoperative Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer||Fox Chase Cancer Center||Completed|December 2003|February 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|February 11, 2010|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00084591||200505|
NCT00084838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-294 DFCI|Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT|A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor||Dana-Farber Cancer Institute|Yes|Completed|February 2003|March 2013|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|18 Years|No|||December 2015|December 18, 2015|June 10, 2004|Yes|Yes||No|December 14, 2012|https://clinicaltrials.gov/show/NCT00084838||200487|None. Trial was completed.
NCT00085527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12965A|FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer|A Phase II Study Of Depsipeptide In Patients With Relapsed Or Refractory Ovarian Carcinoma||University of Chicago|No|Withdrawn|May 2005|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||September 2013|September 4, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085527||200449|
NCT00077129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000349502|Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer|Phase II Trial Of Paclitaxel Plus Carboplatin In Patients With Metastatic Or Locally Advanced Collecting Duct Renal Cell Cancer||Eastern Cooperative Oncology Group|No|Completed|September 2004|||August 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|22|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|February 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00077129||201025|
NCT00112125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#IDPT 2003-07-C|Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5|Evaluation of the Safety and Efficacy of the OPTIMIZER System With Active Fixation Leads in Subjects With Heart Failure Resulting From Systolic Dysfunction: FIX-HF-5||Impulse Dynamics|Yes|Active, not recruiting|February 2005|July 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|428|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|May 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112125||198525|
NCT00107614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2002-10|DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients|UARK 2002-10, A Phase II Study of DT PACE Induction, Followed by Tandem Autologous Transplant and Maintenance Therapy for Patients With Advanced and/or Symptomatic Waldenstrom's Macroglobulinemia||University of Arkansas|Yes|Terminated|November 2002|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2011|August 24, 2011|April 5, 2005||No|Terminated due to poor accrual.|No|April 15, 2011|https://clinicaltrials.gov/show/NCT00107614||198860|Early termination due to small numbers of subjects enrolled. Only one participant completed the study. Other participants came off study due to death, toxicity, physician choice, or patient choice.
NCT00107627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIS001|Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery|Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery||Queensland Centre for Gynaecological Cancer|No|Completed|March 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|90|||Female|18 Years|N/A|No|||June 2009|June 24, 2009|April 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00107627||198859|
NCT00107926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2303|Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder||Novartis||Completed|October 2004|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|343|||Both|18 Years|70 Years|No|||November 2011|November 16, 2011|April 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107926||198836|
NCT00108576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-026-01|Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)|Divalproex Sodium in the Treatment of PTSD: A Placebo-Controlled Study||VA Office of Research and Development|No|Completed|October 2003|September 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|19 Years|65 Years|No|||October 2015|October 20, 2015|April 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00108576||198787|
NCT00108589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-014-03S|S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis|S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis||VA Office of Research and Development||Completed|January 2004|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||May 2007|January 20, 2009|April 15, 2005||||No||https://clinicaltrials.gov/show/NCT00108589||198786|
NCT00108238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-001-02F|Estrogen Alternatives Study|Estrogen Alternatives and Vascular Function in Post-Menopausal Women||VA Office of Research and Development||Completed|April 2003|December 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2007|January 20, 2009|April 14, 2005||||No||https://clinicaltrials.gov/show/NCT00108238||198812|
NCT00076830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040077|Evaluation and Treatment of Patients With Connective Tissue Disease|Screening and Diagnosis of Patients With Connective Tissue Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|February 2004|||||N/A|Observational|N/A|||Anticipated|400|||Both|N/A|70 Years|No|||December 2015|January 16, 2016|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00076830||201045|
NCT00076843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040071|Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis|Phase I/II Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2/IL-15R-Beta Subunit (CD122) That Blocks IL-15 Action||National Institutes of Health Clinical Center (CC)||Recruiting|January 2004|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|February 17, 2016|July 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00076843||201044|
NCT00073918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1368.00|Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma||Fred Hutchinson Cancer Research Center|No|Completed|February 1999|||July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|60 Years|No|||August 2014|August 4, 2014|December 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073918||201247|
NCT00073944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOCRYST-1777BC-101|BCX-1777 in Treating Patients With Refractory Cancer|Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies||National Cancer Institute (NCI)||Completed|April 2003|||January 2005|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2004|May 29, 2013|December 10, 2003||||No||https://clinicaltrials.gov/show/NCT00073944||201245|
NCT00074295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000343797|S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer|Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)||Southwest Oncology Group|Yes|Terminated|March 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|December 10, 2003|Yes|Yes|closed due to lack of availability of vaccine|No||https://clinicaltrials.gov/show/NCT00074295||201224|
NCT00074932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02603|Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease|Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease||Sanofi||Completed|November 2004|December 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|N/A|No|||February 2014|February 4, 2014|December 23, 2003|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00074932||201178|
NCT00074945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040061|Obesity and Fatty Acid Flux Comparison Trials|A Comparison of Free Fatty Acid Flux in African Americans and Caucasians||National Institutes of Health Clinical Center (CC)||Completed|December 2003|February 2013||||N/A|Observational|N/A|||Actual|30|||Both|18 Years|49 Years|No|||February 2013|October 23, 2014|December 23, 2003||No||No||https://clinicaltrials.gov/show/NCT00074945||201177|
NCT00083668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004375|Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (ER) Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|619|||Both|18 Years|65 Years|No|||March 2010|June 6, 2011|May 27, 2004||||||https://clinicaltrials.gov/show/NCT00083668||200570|
NCT00084058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1038|Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV|A Phase I/II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir With or Without Saquinavir in HIV-Infected Pediatric Subjects Previously Treated With Protease Inhibitors||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|2 Years|17 Years|No|||May 2012|May 17, 2012|June 4, 2004||||||https://clinicaltrials.gov/show/NCT00084058||200542|
NCT00084370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000352114|Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy|Molecular Alterations in Human Ovarian Epithelium Induced by Chemopreventive Agents in Patients at Elevated Inherited Risk of Ovarian Cancer: A Controlled Pilot Study in Ovarian Cancer Chemoprevention||University of Alabama at Birmingham|Yes|Withdrawn|June 2002|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|19 Years|N/A|No|||August 2013|August 21, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084370||200520|
NCT00084617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03010|Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma|Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma||National Cancer Institute (NCI)||Completed|March 2004|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||July 2013|April 15, 2015|June 10, 2004|Yes|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT00084617||200503|
NCT00084604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01450|Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|A Multicenter, Open-Label, Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma||National Cancer Institute (NCI)||Completed|April 2004|||October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00084604||200504|
NCT00085189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10M-03-3|Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma|A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA||University of Southern California||Completed|May 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|16 Years|N/A|No|||May 2014|May 20, 2014|June 10, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00085189||200470|
NCT00077142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-007|TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)|Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma||M.D. Anderson Cancer Center|No|Completed|April 2001|August 2005|Actual|July 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|80 Years|No|||July 2012|July 27, 2012|February 10, 2004||No||No||https://clinicaltrials.gov/show/NCT00077142||201024|
NCT00107640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAATAL13990|Project SHARE (Senior Health and Alcohol Risk Education)|Costs of Preventing Alcohol Problems in Older Adults||University of California, Los Angeles|No|Completed|May 2005|September 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|1186|||Both|60 Years|N/A|No|||September 2010|August 11, 2012|April 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00107640||198858|
NCT00107952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015|Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus|ATTAIN1|Theravance Biopharma Antibiotics, Inc.|Yes|Completed|February 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|761|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|April 11, 2005|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00107952||198834|
NCT00108251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-010-03S|Aldosterone Antagonism in Diastolic Heart Failure|Aldosterone Antagonism in Diastolic Heart Failure||VA Office of Research and Development|Yes|Completed|August 2004|October 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|April 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00108251||198811|
NCT00108264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-021-02S|Tumor RNA Transfected Dendritic Cell Vaccines|Tumor RNA Transfected Dendritic Cell Vaccines||VA Office of Research and Development||Completed||September 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Male|10 Years|N/A|No|||May 2007|January 20, 2009|April 14, 2005||||||https://clinicaltrials.gov/show/NCT00108264||198810|
NCT00108992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN-03-112|Efficacy and Safety of Topical Diclofenac Combined With Oral Diclofenac in the Treatment of Knee Osteoarthritis|||Nuvo Research Inc.||Completed|February 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|40 Years|85 Years|No|||January 2007|January 4, 2007|April 21, 2005||||No||https://clinicaltrials.gov/show/NCT00108992||198760|
NCT00109005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050095|Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma|A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma||National Institutes of Health Clinical Center (CC)|No|Completed|April 2005|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|April 21, 2005|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT00109005||198759|
NCT00108953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11546|A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma|A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.||Bayer|No|Completed|April 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|April 21, 2005|Yes|Yes||No|April 23, 2009|https://clinicaltrials.gov/show/NCT00108953||198762|The study had been prematurely terminated by the sponsor because positive results were obtained in another Nexavar trial (Phase 3 study 100554 NCT00105443). NCI-CTC was translated to MedDRA for SOCs only.
NCT00108979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT-MD-23|Study of Escitalopram in Adult Patients With Major Depressive Disorder|Double-Blind Study of Escitalopram in Adult Patients With Major Depressive Disorder||Forest Laboratories||Completed|March 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|80 Years|No|||March 2012|March 1, 2012|April 21, 2005||||||https://clinicaltrials.gov/show/NCT00108979||198761|
NCT00072462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN37546358|Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ|International Breast Cancer Intervention Study II (IBIS-II) (DCIS)|IBIS-II DCIS|Queen Mary University of London|Yes|Active, not recruiting|September 2003|January 2022|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2980|||Female|40 Years|70 Years|No|||August 2015|August 21, 2015|November 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00072462||201356|
NCT00072982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000309-01A2|Treatment of Rheumatoid Arthritis With Marine and Botanical Oils|Treatment of Rheumatoid Arthritis With Marine and Botanical Oils||National Center for Complementary and Integrative Health (NCCIH)|Yes|Active, not recruiting|November 2006|November 2008|Anticipated|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|156|||Both|18 Years|85 Years|No|||August 2008|August 22, 2008|November 13, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072982||201318|
NCT00073658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059666-02|Treating Behavioral Disturbances in Individuals With Dementia|Continuation Pharmacotherapy for Agitation of Dementia||University of Pittsburgh||Completed|January 2000|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||137|||Both|50 Years|N/A|No|||March 2014|March 7, 2014|December 2, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073658||201267|
NCT00073671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064735|Prevention of Depression in At-Risk Adolescents|Prevention of Depression in At-Risk Adolescents||Vanderbilt University|Yes|Completed|March 2003|January 2009|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|316|||Both|13 Years|17 Years|No|||March 2013|March 26, 2013|December 2, 2003||No||No||https://clinicaltrials.gov/show/NCT00073671||201266|
NCT00074321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01444|Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors|A Phase I And Pharmacogenetic Study Of CPT-11, Oxaliplatin, And Capecitabine In Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|November 2003|||July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|December 10, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00074321||201222|
NCT00074308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02564|Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers|A Phase I/II Study Of Imatinib Mesylate And Bevacizumab In Patients With Advanced Melanoma And Other Advanced Cancers||National Cancer Institute (NCI)||Completed|October 2003|||July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|21 Years|N/A|No|||December 2012|January 8, 2013|December 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074308||201223|
NCT00074334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000344416|TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma|A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38) In Pediatric Patients With Recurrent Or Progressive Supratentorial High Grade Gliomas||Pediatric Brain Tumor Consortium|Yes|Terminated|May 2004|June 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|3|||Both|3 Years|21 Years|No|||October 2009|October 20, 2009|December 10, 2003|Yes|Yes|Drug company withdrawal of support for investigational agent in this indication.|No||https://clinicaltrials.gov/show/NCT00074334||201221|
NCT00074360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040060|The Effect of Ethanol on Brain Activity|The Effect of Ethanol on Cerebral Blood Flow as Measured by Functional Magnetic Resonance Imaging and the Development of Conditioned Response to Ethanol Administration||National Institutes of Health Clinical Center (CC)||Completed|December 2003|December 2012||||N/A|Observational|N/A|||Actual|107|||Both|21 Years|45 Years|No|||December 2012|February 19, 2014|December 10, 2003||No||No||https://clinicaltrials.gov/show/NCT00074360||201220|
NCT00083681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 98-018|DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse|UARK 98-018, A Randomized Phase II Trial of DCEP or DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse in Patients With Multiple Myeloma||University of Arkansas||Completed|June 1998|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|May 27, 2004||||||https://clinicaltrials.gov/show/NCT00083681||200569|
NCT00073853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-P-01|Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries|A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries||Proneuron Biotechnologies||Suspended|September 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||61|||Both|16 Years|65 Years|No|||March 2006|August 27, 2009|December 10, 2003||||||https://clinicaltrials.gov/show/NCT00073853||201252|
NCT00074763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0088|Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets|Randomized Crossover Study Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets||M.D. Anderson Cancer Center|No|Terminated|July 2003|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2012|August 1, 2012|December 19, 2003|No|Yes|Terminated due to low recruitment.|No||https://clinicaltrials.gov/show/NCT00074763||201191|
NCT00075400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00653|Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus||National Cancer Institute (NCI)||Completed|January 2004|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|N/A|N/A|No|||March 2014|May 6, 2015|January 9, 2004|Yes|Yes||No|May 6, 2015|https://clinicaltrials.gov/show/NCT00075400||201146|
NCT00084864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365693|Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate|A Pilot Trial of Calcitriol in Localized Prostate Cancer: Investigation of Biologic Effects and Potential Intermediate Endpoints||Roswell Park Cancer Institute|Yes|Terminated|September 2002|May 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|25|||Male|18 Years|120 Years|No|||November 2015|November 19, 2015|June 10, 2004|Yes|Yes|sample size is too small to draw a conclusion|No||https://clinicaltrials.gov/show/NCT00084864||200486|
NCT00076804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI055359-01A1|Helping HIV Infected Patients in South Africa Adhere to Drug Regimens|DOT-HAART for HIV-Infected South African Adults||Johns Hopkins University|Yes|Terminated|February 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|February 3, 2004||No|DSMB stopped trial for futility|No|June 1, 2010|https://clinicaltrials.gov/show/NCT00076804||201047|Intervention was stopped at 12 months, transition phase did not ensure that participants developed a set of adherence strategies to replace DOT-ART. Low incidence of AIDS-defining illness and death limit our ability to make final conclusions
NCT00108277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-028-04S|Respiratory Dysregulation and Breathing Training in Anxious Outpatients|Respiratory Dysregulation and Breathing Training in Anxious Outpatients||VA Office of Research and Development|No|Completed|April 2005|September 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|92|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|April 14, 2005||No||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00108277||198809|
NCT00108602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP-017-03S|Sleep Apnea: Mechanism and Cerebrovascular Consequences|Sleep Apnea: Mechanism and Cerebrovascular Consequences||VA Office of Research and Development||Withdrawn|May 2007|May 2007|Actual|May 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|85 Years|No|||June 2015|June 25, 2015|April 15, 2005||No|This study of the overall grant was not pursued as the aims were changed|No||https://clinicaltrials.gov/show/NCT00108602||198785|
NCT00108615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-013-0S3|Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance|Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance||VA Office of Research and Development|Yes|Completed|January 2004|December 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|48|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 23, 2008|April 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00108615||198784|
NCT00076856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03247|Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)|A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.||Completed|March 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|95|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|February 4, 2004||||No||https://clinicaltrials.gov/show/NCT00076856||201043|
NCT00072150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02787|Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma|Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma||National Cancer Institute (NCI)||Completed|October 2003|||March 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072150||201373|
NCT00072488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000339811|Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma|Whole-Body MRI in the Evaluation of Pediatric Malignancies||National Cancer Institute (NCI)||Active, not recruiting|October 2004|||December 2005|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|226|||Both|N/A|21 Years|No|||October 2007|June 5, 2010|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072488||201354|
NCT00072501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000339812|Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer|Screening Breast Ultrasound in High-Risk Women||National Cancer Institute (NCI)||Completed|April 2004|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Screening|||||||Female|25 Years|N/A|No|||February 2006|October 27, 2012|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072501||201353|
NCT00072917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVOPOB DK62874 (complted)|The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women|The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2003|June 2008||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood and urine|Both|25 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects have been recruited through advertisements in local news media and on the        internet|January 2010|January 15, 2010|November 12, 2003||No||No||https://clinicaltrials.gov/show/NCT00072917||201323|
NCT00073372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004768|A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)|Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.||Centocor, Inc.|Yes|Terminated|October 2003|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|808|||Both|18 Years|N/A|No|||June 2010|May 16, 2011|November 19, 2003|||Based on the data and observed benefit-risk profile, the trial's independent oversight    committee recommended that enrollment not resume.|||https://clinicaltrials.gov/show/NCT00073372||201288|
NCT00073957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000341437|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Zevalin And Rituxan For The Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Recruiting|December 2003|||June 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|December 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073957||201244|
NCT00074633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBFRETTO (completed)|Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model|Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 2000|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||79|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|December 17, 2003||||No||https://clinicaltrials.gov/show/NCT00074633||201200|
NCT00074646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-8490-GLIO-001|Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas|Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas||Celgene||Completed|December 2003|June 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2007|January 2, 2007|December 17, 2003||||||https://clinicaltrials.gov/show/NCT00074646||201199|
NCT00072800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040034|Classification of Cerebral Palsy Subtypes|Classification of Cerebral Palsy Subtypes||National Institutes of Health Clinical Center (CC)||Completed|November 2003|August 2005||||N/A|Observational|N/A||||115|||Both|N/A|N/A|No|||August 2005|March 3, 2008|November 10, 2003||||No||https://clinicaltrials.gov/show/NCT00072800||201331|
NCT00074776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH067055|Acute Treatment of Bipolar II Depression|Acute Treatment of Bipolar II Depression||Stanford University|Yes|Completed|May 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|55 Years|No|||July 2012|July 19, 2012|December 19, 2003||No||No||https://clinicaltrials.gov/show/NCT00074776||201190|
NCT00075894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000349473|Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas|A Phase I/II, Open-Label, Non-Randomized, Multicenter, Single Agent Study Of Intravenous SDX-102 For The Treatment Of Patients With MTAP-Deficient High Grade Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|March 2004|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||August 2006|January 10, 2009|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075894||201110|
NCT00075634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01807|Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma|A Phase I Study of Decitabine (NSC# 127716, IND# 50733) in Combination With Doxorubicin and Cyclophosphamide in the Treatment of Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|December 2003|||September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|1 Year|21 Years|No|||September 2013|September 27, 2013|January 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00075634||201129|
NCT00073242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9631(completed)|Low-Dose Leptin and the Formerly-Obese|Effects of Low-Dose Leptin on the Metabolic/Behavioral Phenotypes of the Formerly-Obese||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|July 2000|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|25|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|November 18, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073242||201298|
NCT00073255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITNO17AI (completed)|Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)|Evaluation of Tolerability, Safety, and Pharmacokinetics of hOKT3g1 (Ala-Ala)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 2003|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|8 Years|30 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|November 18, 2003||||||https://clinicaltrials.gov/show/NCT00073255||201297|
NCT00075920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040082|Technical Development of Strain Rate Echocardiography|Technical Development of Strain Rate Echocardiography||National Institutes of Health Clinical Center (CC)||Completed|January 2004|October 2007||||N/A|Observational|N/A||||125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|September 26, 2015|January 11, 2004||||No||https://clinicaltrials.gov/show/NCT00075920||201108|
NCT00076479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040100|Role of the Right Brain in Recovery of Language Function in Chronic Stroke|||National Institutes of Health Clinical Center (CC)||Completed|January 2004|January 2006||||N/A|Observational|N/A||||40|||Both|N/A|N/A|No|||January 2006|March 3, 2008|January 22, 2004||||No||https://clinicaltrials.gov/show/NCT00076479||201069|
NCT00076869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-037|MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)|A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of MK0991 in Combination With Amphotericin B, Lipid Formulations of Amphotericin B, or Azoles in the Treatment of Invasive Aspergillus Infection in Adults Who Are Refractory to or Intolerant of Standard Therapy||Merck Sharp & Dohme Corp.||Completed|January 2003|August 2005|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|55|||Both|16 Years|N/A|No|||January 2015|January 12, 2015|February 5, 2004||||No||https://clinicaltrials.gov/show/NCT00076869||201042|
NCT00076921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209|Epidemiology & Intervention Research for Tobacco Control|Research on China Tobacco Control Epidemiology and Intervention||Johns Hopkins Bloomberg School of Public Health|No|Completed|September 2002|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|15705|None Retained|No bio-specimens collected. Sampled nicotine from buildings only.|Both|15 Years|80 Years|No|Probability Sample|Household representatives in 7 selected provinces will complete a survey.|April 2013|April 8, 2013|February 6, 2004||No||No||https://clinicaltrials.gov/show/NCT00076921||201041|
NCT00072163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02560|Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma|A Phase II Study Of Temozolomide And Thalidomide In Patients With Metastatic Melanoma In The Brain||National Cancer Institute (NCI)||Completed|October 2003|||September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072163||201372|
NCT00072475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-10105|Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes|A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)||Alliance for Clinical Trials in Oncology|No|Completed|December 2003|June 2014|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 4, 2003|Yes|Yes||No|May 22, 2014|https://clinicaltrials.gov/show/NCT00072475||201355|
NCT00073645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063997|Family and Peer Involvement in the Treatment of Anxiety Disorders in Children|Therapy Specificity and Mediation in Family and Group CBT||Florida International University|Yes|Completed|July 2002|July 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|241|||Both|8 Years|14 Years|No|||August 2013|August 19, 2013|December 2, 2003||No||No||https://clinicaltrials.gov/show/NCT00073645||201268|
NCT00073385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP-200-03-01|Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients With Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)||Titan Pharmaceuticals||Completed|September 2003|October 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||225|||Both|18 Years|N/A|No|||August 2005|August 26, 2005|November 19, 2003||||||https://clinicaltrials.gov/show/NCT00073385||201287|
NCT00073398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0101|Vaccine Treatment for Advanced Non-Small Cell Lung Cancer|A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer||NewLink Genetics Corporation|No|Completed|November 2003|March 2013|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|21 Years|65 Years|No|||June 2015|June 25, 2015|November 19, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073398||201286|
NCT00073983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC003|Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma|Phase II Study Of Sequential Gemcitabine Followed By Docetaxel For Recurrent Ewing's Sarcoma, Osteosarcoma, Or Unresectable Or Locally Recurrent Chondrosarcoma [SARC Study]||Sarcoma Alliance for Research through Collaboration|Yes|Completed|October 2006|December 2010|Actual|January 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|4 Years|N/A|No|||February 2012|February 8, 2012|December 10, 2003|Yes|Yes||No|March 15, 2011|https://clinicaltrials.gov/show/NCT00073983||201242|Since this design did not specify a rule for declaring the treatment as “active” a direct comparison to a standard 2 stage phase 2 design is not appropriate.
NCT00073684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064776|Optimal Treatment Strategies for Sexually Abused Children|Young Sexually Abused Children: Optimal CBT Strategies||Rowan University|Yes|Completed|August 2003|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|210|||Both|4 Years|11 Years|No|||May 2014|May 6, 2014|December 2, 2003||No||No||https://clinicaltrials.gov/show/NCT00073684||201265|
NCT00073970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0109|Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy|A Trial Of COX-2 Inhibitors In PSA Recurrence After Definitive Radiation Or Radical Prostatectomy For Prostate Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|April 2003|January 2006|Actual|June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Male|18 Years|N/A|No|||May 2012|May 21, 2012|December 10, 2003|Yes|Yes|Study stopped due to increased cardiovascular risks associated with Celebrex|No||https://clinicaltrials.gov/show/NCT00073970||201243|
NCT00074672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040059|Relationship Between Sensory and Motor Systems in Restless Leg Syndrome|Sensorimotor Gating Studies in Restless Legs Syndrome||National Institutes of Health Clinical Center (CC)||Completed|December 2003|April 2009||||N/A|Observational|N/A||||45|||Both|18 Years|80 Years|No|||April 2009|April 15, 2009|December 17, 2003||No||No||https://clinicaltrials.gov/show/NCT00074672||201198|
NCT00073528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF30008|Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer||GlaxoSmithKline||Active, not recruiting|December 2003|December 2016|Anticipated|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1286|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|November 24, 2003|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00073528||201276|
NCT00073840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-355|Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma|An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma||Sunovion|No|Completed|December 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|386|||Both|12 Years|N/A|No|||February 2012|February 21, 2012|December 9, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073840||201253|
NCT00076219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|530|Acute Renal Failure Trial Network (ATN) Study|CSP #530 - Intensive vs. Conventional Renal Support in Acute Renal Failure|ATN|VA Office of Research and Development|Yes|Completed|October 2003|July 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1124|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|January 15, 2004||No||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00076219||201088|
NCT00083772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0782|Use of Nesiritide in the Management of Acute Diastolic Heart Failure|The Use of Nesiritide in the Management of Acute Diastolic Heart Failure||M.D. Anderson Cancer Center|No|Terminated|May 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||July 2012|July 27, 2012|June 2, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083772||200563|
NCT00076934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN006AI|Safety of RG2077 in Patients With Multiple Sclerosis|A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2003|February 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|55 Years|No|||June 2014|June 4, 2014|February 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00076934||201040|
NCT00076232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 039|A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2005|November 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|3682|||Both|N/A|N/A|No|||August 2009|December 29, 2010|January 15, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00076232||201087|
NCT00076245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH065946|Cognitive Behavioral Therapy for the Treatment of Seasonal Affective Disorder (SAD)|Cognitive Behavioral Approaches to Seasonal Depression||Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Completed|November 2002|November 2005|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|61|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|January 16, 2004||No||No|February 24, 2014|https://clinicaltrials.gov/show/NCT00076245||201086|
NCT00076492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS43128-2|NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485|A Multi-center, Double-blind, Pilot Study of CoQ10 and GPI 1485 in Subjects With Early Untreated Parkinson's Disease||University of Rochester||Completed|January 2004|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||195|||Both|30 Years|N/A|No|||October 2012|October 31, 2012|January 23, 2004||||No||https://clinicaltrials.gov/show/NCT00076492||201068|
NCT00072943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|707|A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease|A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease||Facet Biotech||Completed|March 2002|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||175|||Both|18 Years|70 Years|No|||March 2012|March 9, 2012|November 12, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00072943||201321|
NCT00072956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040041|The Physiology of Tricks|The Physiology of Tricks||National Institutes of Health Clinical Center (CC)||Completed|November 2003|October 2005||||N/A|Observational|N/A||||49|||Both|N/A|N/A|No|||October 2005|March 3, 2008|November 12, 2003||||No||https://clinicaltrials.gov/show/NCT00072956||201320|
NCT00073333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062547|Assessment and Treatment of Social Skills Deficits in Individuals With Social Phobia|Social Phobia: Assessment and Treatment of Social Skills||Milton S. Hershey Medical Center|No|Completed|December 2002|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|379|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 1, 2013|November 19, 2003||No||No|May 14, 2013|https://clinicaltrials.gov/show/NCT00073333||201291|
NCT00073632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063208|Acceptance-Based Treatment for Generalized Anxiety Disorder|Developing a New Therapy for GAD: Acceptance-Based CBT||University of Massachusetts, Boston|No|Completed|May 2002|August 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A|No|||September 2008|November 5, 2013|December 2, 2003||No||No||https://clinicaltrials.gov/show/NCT00073632||201269|
NCT00072527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-30206|Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Induction Cisplatin/Irinotecan Followed By Combination Carboplatin, Etoposide And Chest Radiotherapy In Limited Stage Small Cell Lung Cancer: A Phase II Study||Alliance for Clinical Trials in Oncology|No|Completed|November 2003|January 2013|Actual|June 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072527||201351|
NCT00072969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040026|A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)|A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)||National Institutes of Health Clinical Center (CC)||Completed|November 2003|August 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||132|||Both|N/A|N/A|No|||August 2005|March 3, 2008|November 12, 2003||||No||https://clinicaltrials.gov/show/NCT00072969||201319|
NCT00073697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065376|Treatment of Depression in Adults|Depression: The Search for Treatment-Relevant Phenotypes||University of Pittsburgh||Completed|May 2003|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|290|||Both|18 Years|66 Years|No|||January 2012|January 10, 2012|December 2, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00073697||201264|
NCT00073710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-375|Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium|A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium||Abbott||Completed|September 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|20 Years|N/A|No|||July 2006|July 31, 2006|December 3, 2003||||||https://clinicaltrials.gov/show/NCT00073710||201263|
NCT00075556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346895|Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma|Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||May 2008|February 6, 2009|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075556||201135|
NCT00074373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-105|The Research Registry for Neonatal Lupus|The Research Registry for Neonatal Lupus||New York University School of Medicine|No|Recruiting|September 1994|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with a child affected by neonatal lupus, children affected by neonatal lupus,        siblings of children affected by neonatal lupus, siblings of women with a child affected        by neonatal lupus, fathers and maternal grandparents of children with neonatal lupus, and        unaffected people to serve as controls are invited to participate in this study.|April 2013|April 9, 2013|December 11, 2003||No||No||https://clinicaltrials.gov/show/NCT00074373||201219|
NCT00074997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010783|Trial of an Anti-HIV-1 Gene Transfer Product|A Randomized Phase II, Double-Blind, Controlled Trial to Evaluate the Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With Placebo or an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection||Janssen-Cilag Pty Ltd||Completed|July 2002|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|45 Years|No|||March 2013|March 15, 2013|December 28, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074997||201173|
NCT00074100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XANTHUS-0001A1-200-GL|Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy|Amonafide: Individual Phenotype-Adjusted Chemotherapy for Women With Metastatic Breast Cancer Who Have Progressed Despite Prior Chemotherapy||National Cancer Institute (NCI)||Completed|August 2003|September 2004|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||August 2004|May 29, 2013|December 10, 2003||||No||https://clinicaltrials.gov/show/NCT00074100||201235|
NCT00075036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040070|Patient-Provider Trust Among Individuals With End-Stage Kidney Disease|Exploring Patient-Provider Trust Among Individuals With End-Stage Renal Disease||National Institutes of Health Clinical Center (CC)||Completed|December 2003|||||N/A|Observational|Time Perspective: Prospective|||Actual|68|||Both|18 Years|N/A|No|||August 2015|August 8, 2015|December 30, 2003||No||No||https://clinicaltrials.gov/show/NCT00075036||201170|
NCT00075049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1032|Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria|Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactogenicity, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S||U.S. Army Medical Research and Materiel Command||Completed|December 2003|January 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||104|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|December 31, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00075049||201169|
NCT00083161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000363799|Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Pilot Study of a Combination of Standard Etoposide/Cisplatin and Metronomic Cyclophosphamide in Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer||Gundersen Lutheran Health System|No|Completed|June 2003|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||September 2012|September 1, 2012|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083161||200607|
NCT00083174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP3|Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer|A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer||Canadian Cancer Trials Group|Yes|Active, not recruiting|February 2004|December 2016|Anticipated|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|4560|||Female|35 Years|N/A|Accepts Healthy Volunteers|||April 2015|October 5, 2015|May 14, 2004|Yes|Yes||No|November 7, 2012|https://clinicaltrials.gov/show/NCT00083174||200606|
NCT00084448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG_0126P|Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation of Weekly Paclitaxel (NSC #673089) and Celecoxib (Celebrex®, NSC #719627) in the Treatment of Recurrent or Persistent Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Cancer||Gynecologic Oncology Group||Terminated|April 2004|||May 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2005|July 8, 2013|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00084448||200514|
NCT00076284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040087|GW873140 to Treat HIV-1 Infected Adults|A Phase II, Double-Blind RAndomized, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of GW873130 for 10 Days in HIV-1 Infected Adults||National Institutes of Health Clinical Center (CC)||Completed|January 2004|March 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||March 2005|March 3, 2008|January 16, 2004||||No||https://clinicaltrials.gov/show/NCT00076284||201083|
NCT00076310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-668|OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer|A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2004|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 20, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00076310||201082|
NCT00076258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067692|Adding Exercise to Antidepressant Medication Treatment for Depression|Treatment With Exercise Augmentation for Depression (TREAD)||National Institute of Mental Health (NIMH)||Active, not recruiting|April 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|122|||Both|18 Years|70 Years|No|||July 2007|July 5, 2007|January 16, 2004||||No||https://clinicaltrials.gov/show/NCT00076258||201085|
NCT00072514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 2003|Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies|A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies||Fred Hutchinson Cancer Research Center|No|Completed|August 2003|||July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072514||201352|
NCT00076947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AI045142-04|Safety of the EnvPro HIV Vaccine in Healthy Volunteers|Evaluation of Tolerability and Safety of a Recombinant Purified HIV Envelope Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2005|March 20, 2008|February 6, 2004||||||https://clinicaltrials.gov/show/NCT00076947||201039|
NCT00076960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99A|Compassionate Use of Stanate (TM) [Stannsoporfin]|Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions||InfaCare Pharmaceuticals Corporation||Available|October 2003|||July 2017|Anticipated|N/A|Expanded Access|N/A|||||||Both|N/A|1 Week|No|||January 2016|January 6, 2016|February 6, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00076960||201038|
NCT00072215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-90106|Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors|A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors||Alliance for Clinical Trials in Oncology|Yes|Terminated|April 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Male|18 Years|N/A|No|||June 2015|June 23, 2015|November 4, 2003|No|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00072215||201369|
NCT00073359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH065988|Effects of Therapist Behavior on the Treatment of Depressed Adolescents|Engagement and Alliance in CBT for Depressed Adolescents||University of Denver||Active, not recruiting|February 2003|June 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|13 Years|18 Years|No|||November 2005|May 19, 2014|November 19, 2003||||No||https://clinicaltrials.gov/show/NCT00073359||201289|
NCT00073034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912A2-212|Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 3 Fixed Doses of EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|January 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2013|February 20, 2013|November 14, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00073034||201314|
NCT00075270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF30001|Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer||GlaxoSmithKline|No|Completed|January 2004|March 2012|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|580|||Female|18 Years|N/A|No|||February 2014|April 16, 2015|January 7, 2004|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00075270||201153|
NCT00074399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI038576-05|Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV|Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2001|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|775|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2009|August 6, 2009|December 11, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00074399||201217|
NCT00075829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|417|Stem Cell Transplantation in Individuals With Multiple Myeloma|A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)|BMT CTN 0102|National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|December 2003|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|710|||Both|N/A|70 Years|No|||October 2013|October 31, 2013|January 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075829||201115|
NCT00075010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0314|Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes|Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes||M.D. Anderson Cancer Center|Yes|Completed|January 2004|November 2006|Actual|March 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|2 Years|N/A|No|||June 2012|June 8, 2012|December 29, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075010||201172|
NCT00074724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153|Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization|Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization|DECIPHER|Medstar Research Institute|Yes|Active, not recruiting|May 2003|April 2016|Anticipated|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|319|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|December 19, 2003||No||No||https://clinicaltrials.gov/show/NCT00074724||201194|
NCT00076050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR048932|Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms|Bone Sparing Effects of Soy Phytoestrogens in Menopause|SPARE|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Active, not recruiting|September 2003|June 2009|Anticipated|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 8, 2009|January 13, 2004||No||No||https://clinicaltrials.gov/show/NCT00076050||201098|
NCT00076063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 042|A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines|A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC Prime/LIPO-5 Boost in Healthy, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2004|March 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|174|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|January 13, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00076063||201097|
NCT00082888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02849|Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma|Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|March 2004|||May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|May 14, 2004|Yes|Yes||No|November 2, 2011|https://clinicaltrials.gov/show/NCT00082888||200625|
NCT00082641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|371-02|Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer|1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic||University of Nebraska|Yes|Active, not recruiting|January 2004|||December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Female|19 Years|N/A|No|||May 2013|May 14, 2013|May 14, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00082641||200640|
NCT00083187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-033|VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia|A Phase II Study of VNP40101M For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia||National Cancer Institute (NCI)||Completed|November 2005|August 2008|Actual|January 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|230|||Both|18 Years|N/A|No|||August 2008|July 17, 2013|May 14, 2004||||||https://clinicaltrials.gov/show/NCT00083187||200605|
NCT00083460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2001-37|Study of Combination PS-341 and Thalidomide in Multiple Myeloma|UARK 2001-37, A Phase I Exploratory Study of Combination PS-341 and Thalidomide in Refractory Multiple Myeloma||University of Arkansas|Yes|Completed|December 2001|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||July 2010|July 30, 2010|May 24, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083460||200585|
NCT00083473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIV-801|A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia|A Pilot Study of Pivanex, a Histone Deacetylase Inhibitor, in Patients With Chronic Lymphocytic Leukemia||Titan Pharmaceuticals||Terminated|May 2004|April 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||August 2005|August 26, 2005|May 24, 2004||||||https://clinicaltrials.gov/show/NCT00083473||200584|
NCT00083486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010939|Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy|||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Terminated|February 2004|October 2004|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 25, 2011|May 24, 2004||||||https://clinicaltrials.gov/show/NCT00083486||200583|
NCT00076453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS-116|A Study of Orthotic Shoe Inserts for Controlling Osteoarthritic Knee Pain|Clinical Effects of Altered Biomechanics in Knee Osteoarthritis||Rush University Medical Center|No|Completed|June 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|25 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 26, 2011|January 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00076453||201071|
NCT00076323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 992|A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency|A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency||Walter Reed Army Institute of Research (WRAIR)||Completed|December 2003|November 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2010|July 26, 2010|January 20, 2004||||No||https://clinicaltrials.gov/show/NCT00076323||201081|
NCT00076544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN92045-501|Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain|An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain||Elan Pharmaceuticals||Completed|February 2004|||March 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|January 26, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00076544||201064|
NCT00072176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00649|Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer|A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer||National Cancer Institute (NCI)||Completed|May 2004|August 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|18 Years|N/A|No|||March 2014|February 5, 2015|November 4, 2003|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00072176||201371|
NCT00072189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02829|A Phase II Study of UCN-01 in Metastatic Melanoma|A Phase II Study of UCN-01 in Metastatic Melanoma||National Cancer Institute (NCI)||Terminated|November 2003|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||October 2013|February 17, 2015|November 4, 2003|Yes|Yes|Early termination for discouraging results|No|February 17, 2015|https://clinicaltrials.gov/show/NCT00072189||201370|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results
NCT00072540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000340176|S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix|S0212: Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix||Southwest Oncology Group|Yes|Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|November 4, 2003|Yes|Yes|drug issues|No||https://clinicaltrials.gov/show/NCT00072540||201350|
NCT00072553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000340181|Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer|A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study||National Cancer Institute (NCI)||Active, not recruiting|September 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2007|February 6, 2009|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072553||201349|
NCT00072995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1238|Preventing Obesity Using Novel Dietary Strategies|Preventing Overweight Using Novel Dietary Strategies (Pounds Lost)||Brigham and Women's Hospital|Yes|Completed|September 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Primary Purpose: Prevention||||811|||Both|30 Years|70 Years|No|||January 2013|January 29, 2013|November 13, 2003||||No||https://clinicaltrials.gov/show/NCT00072995||201317|
NCT00073008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF20014|A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer|A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History||GlaxoSmithKline|Yes|Terminated|November 2003|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|November 13, 2003|||Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,    further enrollment was stopped due to lack of efficacy|No|June 15, 2009|https://clinicaltrials.gov/show/NCT00073008||201316|Based on interim analysis and predefined stopping rules for futility, the study was discontinued due to lack of efficacy. At that time, no additional participants were added; enrolled participants could continue on treatment, following the protocol.
NCT00073060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040046|Citrate Effects and Bone Density in Long-Term Apheresis Donors|Citrate Effects and Bone Density Studies in Long-Term Apheresis Donors||National Institutes of Health Clinical Center (CC)||Completed|November 2003|||||N/A|Observational|N/A|||Actual|273|||Both|18 Years|80 Years|No|||March 2015|April 9, 2015|November 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00073060||201312|
NCT00073086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040030|Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)|Clinical Evaluation and Management of Persons With Severe Acute Respiratory Syndrome (SARS)||National Institutes of Health Clinical Center (CC)||Withdrawn|November 2003|December 2010||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||December 2010|September 26, 2015|November 14, 2003||No||No||https://clinicaltrials.gov/show/NCT00073086||201310|
NCT00074412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 046|Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding|A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2007|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|2026|||Both|N/A|N/A|No|||July 2013|July 5, 2013|December 11, 2003|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT00074412||201216|The rate of maternal highly active antiretroviral therapy use was higher than expected in our study. Thus there were fewer infant infections which decreased the power to detect differences in HIV transmission risks between study groups.
NCT00074698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-MC3019-002|Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis|A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis||FibroGen||Completed||May 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|21 Years|80 Years|No|||December 2007|December 10, 2007|December 18, 2003||||No||https://clinicaltrials.gov/show/NCT00074698||201196|
NCT00074737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELP1001|Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML|Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)||Eleos, Inc.|No|Completed|April 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|December 19, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074737||201193|
NCT00075283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133E020724|Walking Therapy In Hemiparetic Stroke Patients Using Robotic-Assisted Treadmill Training|Gait Restoration In Hemiparetic Stroke Patients Using Goal-Directed, Robotic-Assisted, Treadmill Training||U.S. Department of Education||Recruiting|November 2002|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||January 2004|June 23, 2005|January 8, 2004||||No||https://clinicaltrials.gov/show/NCT00075283||201152|
NCT00075296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040075|FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression|FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression||National Institutes of Health Clinical Center (CC)||Completed|January 2004|April 2008||||N/A|Observational|N/A||||100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|January 8, 2004||||No||https://clinicaltrials.gov/show/NCT00075296||201151|
NCT00075335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040078|AMD3100 to Mobilize Stem Cells for Donation|Peripheral Blood Hematopoietic Progenitor Cell Mobilization With AMD 3100 in Healthy Volunteers Previously Mobilized With G-CSF||National Institutes of Health Clinical Center (CC)||Completed|January 2004|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2012|December 8, 2012|January 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00075335||201150|
NCT00082914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000361715|Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer|Phase II Evaluation of Denileukin Diftitox in Patients With Metastatic Melanoma or Metastatic Kidney Cancer||National Cancer Institute (NCI)||Completed|March 2004|July 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||December 2005|June 18, 2013|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00082914||200624|
NCT00083213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGENERON-VGFT-ST-0202|Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma|An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma||Regeneron Pharmaceuticals||Completed|January 2004|||May 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||December 2009|April 15, 2013|May 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00083213||200604|
NCT00083226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00654|Doxorubicin and Bortezomib in Treating Patients With Liver Cancer|A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma||National Cancer Institute (NCI)|No|Completed|March 2004|August 2012|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2014|October 24, 2014|May 14, 2004|Yes|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00083226||200603|
NCT00083499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040202|Mutations in Genes Associated With Pentalogy of Cantrell or Non-Muscle Myosin II Syndromes|Mutations in Genes Associated With Pentalogy of Cantrell or Non-Muscle Myosin II Syndromes||National Institutes of Health Clinical Center (CC)||Recruiting|May 2004|||||N/A|Observational|N/A|||Anticipated|100|||Both|N/A|N/A|No|||December 2015|January 9, 2016|May 25, 2004||No||No||https://clinicaltrials.gov/show/NCT00083499||200582|
NCT00083447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSB311R/CIII/001|Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme|A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme||Xenova Biomedix||Withdrawn|May 2004|June 2007|Anticipated|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||323|||Both|18 Years|N/A|No|||January 2008|January 6, 2009|May 24, 2004|Yes|Yes|This study has been withdrawn because the drug would not meet trial criteria for efficacy|No||https://clinicaltrials.gov/show/NCT00083447||200586|
NCT00083785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSC-OL003|Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases|Safety and Effectiveness of Treating Cancers With the Litx™ System and Chemotherapy. Section A: Phase II Safety and Effectiveness Study in Patients With Liver Metastases From Colorectal Cancer||Light Sciences LLC||Completed|May 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||April 2007|April 10, 2007|June 2, 2004||||||https://clinicaltrials.gov/show/NCT00083785||200562|
NCT00083798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1251|Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland|||University of Pennsylvania||Completed|September 2003|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2843|Samples With DNA|Samples with DNA|Both|N/A|N/A|No|Non-Probability Sample|Sleep apnea patient cohort|July 2013|July 2, 2013|June 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00083798||200561|
NCT00083811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1252|HYPGENE-Genetics Fitness Obesity & Risk of Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 2004|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||December 2008|December 3, 2008|June 2, 2004||||No||https://clinicaltrials.gov/show/NCT00083811||200560|
NCT00083824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1253|Estrogen, HDL, and Coronary Heart Disease in Women|Estrogen, HDL, and Coronary Heart Disease in Women||Tufts University|No|Completed|March 2004|February 2007|Actual|February 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|309|||Female|55 Years|80 Years|No|||January 2008|March 3, 2014|June 2, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083824||200559|
NCT00083837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1254|Gene-Specific Responses to Exercise in Discordant Twins|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 2004|April 2008|Actual|April 2008|Actual|N/A|Observational|N/A|||||||Both|18 Years|74 Years|No|||April 2008|April 22, 2008|June 2, 2004||||No||https://clinicaltrials.gov/show/NCT00083837||200558|
NCT00076336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2301|Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis|Randomized, Double-Blind Trial of Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis||Novartis||Completed|December 2003|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|16 Years|70 Years|No|||August 2011|August 4, 2011|January 20, 2004|Yes|Yes||No|January 3, 2011|https://clinicaltrials.gov/show/NCT00076336||201080|
NCT00076557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB IND 9398|Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B|A Phase I Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the Gene for Human Factor IX Into the Liver||Avigen||Terminated|January 2004|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Male|18 Years|N/A|No|||January 2004|April 2, 2007|January 26, 2004||||||https://clinicaltrials.gov/show/NCT00076557||201063|
NCT00076505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040092|Cell Studies of Parkinson's Disease|Bioenergetic Function in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2004|November 2006||||N/A|Observational|N/A||||150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|September 26, 2015|January 23, 2004||||No||https://clinicaltrials.gov/show/NCT00076505||201067|
NCT00076518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5186|The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)|A Phase II Trial of the Effect of Combination Therapy With Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) Who Are Not Responding to Either Fish Oil or Fenofibrate Alone||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|January 26, 2004||||No||https://clinicaltrials.gov/show/NCT00076518||201066|
NCT00076531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OL-007|Clinical Trial for Prostate Cancer|||Oakwood Laboratories, LLC||Completed|December 2003|||November 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Male|40 Years|N/A|No|||January 2008|January 24, 2008|January 26, 2004||||||https://clinicaltrials.gov/show/NCT00076531||201065|
NCT00072267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-019|UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase II Study of UCN-01 in Combination With Topotecan in Patients With Advanced Ovarian Cancer||University Health Network, Toronto||Completed|January 2004|||April 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2015|July 22, 2015|November 4, 2003||Yes||No||https://clinicaltrials.gov/show/NCT00072267||201367|
NCT00072566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02562|Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Clinical Trial of Bevacizumab (NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|December 2003|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|N/A|N/A|No|||December 2012|May 8, 2015|November 4, 2003|Yes|Yes||No|April 14, 2015|https://clinicaltrials.gov/show/NCT00072566||201348|
NCT00073021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000082|Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis|A Double-Blind, Randomized, 6-Week, Parallel-Group Design Clinical Trial to Assess Safety and Efficacy of Asacol 4.8 g/Day (800 mg Tablet) Versus Asacol 2.4 g/Day (400 mg Tablet) for the Treatment of Moderately Active Ulcerative Colitis||Warner Chilcott|No|Completed|September 2000|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|386|||Both|18 Years|75 Years|No|||June 2015|June 1, 2015|November 13, 2003|Yes|Yes||No|March 25, 2011|https://clinicaltrials.gov/show/NCT00073021||201315|
NCT00073411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7978|Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression|Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression||Eli Lilly and Company|No|Completed|November 2003|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||675|||Both|18 Years|N/A|No|||July 2007|July 30, 2007|November 20, 2003||||No||https://clinicaltrials.gov/show/NCT00073411||201285|
NCT00074984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL-008-00|A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease|Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Fabrazyme on Progression of Renal Disease and Significant Clinical Events in Patients With Fabry Disease||Sanofi|Yes|Completed|February 2001|January 2004|Actual|January 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|16 Years|N/A|No|||December 2013|December 2, 2013|December 24, 2003|Yes|Yes||No|July 21, 2010|https://clinicaltrials.gov/show/NCT00074984||201174|
NCT00074386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01AI052748|Kidney and Liver Transplantation in People With HIV|Solid Organ Transplantation in HIV: Multi-Site Study||University of California, San Francisco|Yes|Completed|October 2003|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|275|Samples Without DNA|Whole Blood, serum, PBMC, kidney and liver biopsy slides, saliva, spleen tissue|Both|1 Year|N/A|No|Probability Sample|HIV-positive patients who undergo kidney or liver transplantation.|January 2014|January 16, 2014|December 11, 2003||No||No||https://clinicaltrials.gov/show/NCT00074386||201218|
NCT00074048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000341680|BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia|Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia||MedImmune LLC|No|Completed|October 2003|July 2008|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|December 10, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074048||201238|
NCT00074074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06023|Infliximab in Treating Patients With Myelodysplastic Syndrome|Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia||European Organisation for Research and Treatment of Cancer - EORTC||Completed|October 2003|||December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|46|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|December 10, 2003||||No||https://clinicaltrials.gov/show/NCT00074074||201237|
NCT00074711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR048846|Adding Phosphorus to Osteoporosis Drug Treatment|Bone Sparing by Calcium Salts With and Without Extra Phosphorus||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|August 2004|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|240|||Female|60 Years|85 Years|No|||March 2009|March 31, 2009|December 19, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074711||201195|
NCT00109824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01465|Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|March 2006|||March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|May 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00109824||198698|
NCT00075348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030148|Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome|Genetic Mutation Analysis In A VHL Population||National Institutes of Health Clinical Center (CC)||Completed|December 2003|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A|||Anticipated|260|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|January 9, 2004||||No||https://clinicaltrials.gov/show/NCT00075348||201149|
NCT00082927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-NCRI-RT-02-01|Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain|A Multicentre Randomised Trial Of Single Dose Radiotherapy Compared To Ibandronate For Localised Metastatic Bone Pain||National Cancer Institute (NCI)||Completed|April 2003|July 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|580|||Both|18 Years|N/A|No|||June 2009|June 25, 2013|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00082927||200623|
NCT00083239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH-301|Study of Talabostat in Advanced Melanoma|||Point Therapeutics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|June 7, 2007|May 14, 2004||||||https://clinicaltrials.gov/show/NCT00083239||200602|
NCT00083512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040200|Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme|Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence||National Institutes of Health Clinical Center (CC)||Recruiting|May 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|99 Years|No|||September 2015|February 20, 2016|May 25, 2004||No||No||https://clinicaltrials.gov/show/NCT00083512||200581|
NCT00084136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5175|Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings|Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial|PEARLS|AIDS Clinical Trials Group|Yes|Completed|May 2005|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1571|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|June 7, 2004||No||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00084136||200536|
NCT00083850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1256|Genetics and Cardiovascular Reactivity in Young Twins|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 2004|May 2007|Actual|May 2007|Actual|N/A|Observational|N/A|||||||Both|14 Years|25 Years|No|||January 2008|January 24, 2008|June 2, 2004||||No||https://clinicaltrials.gov/show/NCT00083850||200557|
NCT00084175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0018-1|HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs - 1|HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||630|||Male|18 Years|N/A|No|||April 2010|April 13, 2010|June 8, 2004||||No||https://clinicaltrials.gov/show/NCT00084175||200533|
NCT00084188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0019-1|HIV/STD Safer Sex Skills Groups for Women in Drug Treatment Programs - 1|HIV/STD Safer Sex Skills Groups for Women in Drug Treatment Programs||National Institute on Drug Abuse (NIDA)|Yes|Completed|May 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Primary Purpose: Treatment||||541|||Female|18 Years|N/A|No|||April 2010|April 13, 2010|June 8, 2004||||No||https://clinicaltrials.gov/show/NCT00084188||200532|
NCT00076609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHY906-2002-1|Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma|A Phase I/II Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma||PhytoCeutica||Completed|October 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||31|||Both|18 Years|80 Years|No|||March 2007|March 27, 2007|January 27, 2004||||||https://clinicaltrials.gov/show/NCT00076609||201059|
NCT00076622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R37MH051247|Medication Treatment for Depression in Nursing Home Residents|Drug Treatment of Depression in the Nursing Home Aged||University of Pennsylvania|No|Completed|November 2003|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|65 Years|N/A|No|||April 2013|April 25, 2013|January 28, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00076622||201058|
NCT00076570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040099|Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation|Depletion Induction With Rabbit Anti-Thymocyte Globulin, Followed by Two Approaches Toward Monotherapy Immunosuppression in Kidney Transplant Recipients||National Institutes of Health Clinical Center (CC)||Completed|January 2004|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|N/A|N/A|No|||August 2013|August 12, 2013|January 26, 2004|Yes|Yes||No|August 7, 2013|https://clinicaltrials.gov/show/NCT00076570||201062|
NCT00076583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040107|Spinal Reflexes in Motor Skill Learning|Motor Skill Learning: Spinal Reflexes||National Institutes of Health Clinical Center (CC)||Completed|January 2004|November 2005||||N/A|Observational|N/A||||22|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|January 26, 2004||||No||https://clinicaltrials.gov/show/NCT00076583||201061|
NCT00076596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040098|Brain Control of Movements in Cerebral Palsy|Brain Reorganization in Cerebral Palsy||National Institutes of Health Clinical Center (CC)||Completed|January 2004|December 2007||||N/A|Observational|N/A||||130|||Both|6 Years|30 Years|Accepts Healthy Volunteers|||December 2007|March 5, 2008|January 26, 2004||||No||https://clinicaltrials.gov/show/NCT00076596||201060|
NCT00076973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-272|An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)|A Randomized, 2-Period, Multicenter, Dble-Blind, Parallel-Group Study Comparing Effects of 2 Doses of MK0476 and Placebo in the Tx of Respiratory Symptoms Associated w/ Respiratory Syncytial Virus-Induced Bronchiolitis in Children 3 to 24 Mths||Merck Sharp & Dohme Corp.||Completed|August 2003|October 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1125|||Both|3 Months|24 Months|No|||January 2016|January 21, 2016|February 6, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00076973||201037|
NCT00072228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIICHI-1027A-PRT008|Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Study of Soblidotin and Gemcitabine in Patients With Locally Advanced or Metastatic Solid Tumors||National Cancer Institute (NCI)||Withdrawn||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2006|July 9, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072228||201368|
NCT00072579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-23102|Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment|Phase II Study of GM-CSF in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Who Are Not in Complete Cytogenetic Remission After Initial Therapy||Comprehensive Cancer Center of Wake Forest University||Completed|May 2003|December 2007|Actual|April 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072579||201347|
NCT00072592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040022|An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies|An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies||National Institutes of Health Clinical Center (CC)||Completed|October 2003|August 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||August 2005|March 3, 2008|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072592||201346|
NCT00072605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040028|Experimental Ebola Vaccine Trial|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiple Strain Ebola DNA Plasmid Vaccine, VRC-EBODNA012-00-VP, in Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 2003|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||27|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||August 2007|August 23, 2007|November 4, 2003||||No||https://clinicaltrials.gov/show/NCT00072605||201345|
NCT00073047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008|Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis|A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis||Facet Biotech||Completed|April 2003|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|12 Years|N/A|No|||July 2009|July 17, 2009|November 14, 2003||||||https://clinicaltrials.gov/show/NCT00073047||201313|
NCT00073762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-308?|Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Fixed Doses (200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|375|||Both|18 Years|75 Years|No|||August 2009|August 18, 2009|December 4, 2003||Yes||||https://clinicaltrials.gov/show/NCT00073762||201259|
NCT00073775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1239|Epidemiology of Stress and the Metabolic Syndrome|Epidemiology of Stress and the Metabolic Syndrome||University of Florida|No|Completed|September 2003|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3075|Samples With DNA|DNA, blood|Both|70 Years|79 Years|No|Non-Probability Sample|Older persons|August 2013|August 8, 2013|December 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00073775||201258|
NCT00073788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-1028|Wounded Spirits, Ailing Hearts: Post-Traumatic Stress Disorder and Cardiovascular Disease in Indians|Wounded Spirits, Ailing Hearts: Post-Traumatic Stress Disorder and Cardiovascular Disease in Indians||University of Colorado, Denver|No|Completed|September 2003|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|267|||Both|18 Years|68 Years|No|Non-Probability Sample|American Indian people with, and without, PTSD|May 2014|May 30, 2014|December 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00073788||201257|
NCT00108927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R18 DK061709 (completed)|Improving Diabetes in Primary Care (IMPACT)|Improving Diabetes Through Primary Care Translation (IMPACT)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 2003|December 2005||||N/A|Observational|Time Perspective: Prospective||||6000|||Both|18 Years|90 Years|No|||March 2010|March 1, 2010|April 20, 2005||||No||https://clinicaltrials.gov/show/NCT00108927||198764|
NCT00109304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEE-01|Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine|Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE IA/B V3526 in VEE-Naive Healthy Volunteers After Single Dose Subcutaneous Administration||DynPort Vaccine Company LLC, A CSC Company|Yes|Withdrawn|July 2005|December 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|April 27, 2005|No|Yes|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT00109304||198736|
NCT00074425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 035|BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women|Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3101|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 5, 2013|December 11, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00074425||201215|
NCT00109317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD2600g|A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy|A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy||Genentech, Inc.||Completed|September 2002|February 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|686|||Both|18 Years|75 Years|No|||June 2013|June 19, 2013|April 27, 2005||||||https://clinicaltrials.gov/show/NCT00109317||198735|
NCT00110123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-18021|Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma|Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|January 2005|||June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|171|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|May 3, 2005|||low accrual|No||https://clinicaltrials.gov/show/NCT00110123||198678|
NCT00075023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040069|Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis|Evaluation of Efficacy and Mechanisms of Topical Thalidomide for Chronic Graft-Versus-Host-Disease Related Stomatitis||National Institutes of Health Clinical Center (CC)|Yes|Terminated|December 2003|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||October 2015|October 29, 2015|December 30, 2003|Yes|Yes|unable to enroll adequate subjects|No|October 29, 2015|https://clinicaltrials.gov/show/NCT00075023||201171|Small sample size due to difficult enrollment
NCT00082940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-27102|Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase II Study of ONTAK® (Denileukin Diftitox, DABIL-2) in Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia||Comprehensive Cancer Center of Wake Forest University||Completed|August 2002|June 2005|Actual|January 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00082940||200622|
NCT00082966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01812|Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|March 2004|||March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||June 2013|December 3, 2015|May 14, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00082966||200621|
NCT00083252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH-303|Study of Talabostat and Cisplatin in Advanced Melanoma|||Point Therapeutics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2007|June 7, 2007|May 14, 2004||||||https://clinicaltrials.gov/show/NCT00083252||200601|
NCT00083265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040183|Genetic Causes of Panic Disorder|Association Between Adenosine Receptor Gene Polymorphisms and Physiological Responses to Caffeine in Subjects With Panic Disorder and Healthy Controls||National Institutes of Health Clinical Center (CC)||Completed|May 2004|||||N/A|Observational|N/A|||Actual|117|||Both|18 Years|60 Years|No|||July 2015|July 17, 2015|May 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00083265||200600|
NCT00083525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX/50-005|Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies|||Wilex||Completed|May 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|N/A|No|||January 2008|January 21, 2008|May 25, 2004||||||https://clinicaltrials.gov/show/NCT00083525||200580|
NCT00083902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 98-025|Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy|UARK 98-025, A Randomized Phase II Trial of Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy for Low-Risk Post Transplantation Relapse in Patients With Multiple Myeloma||University of Arkansas||Completed|June 1998|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||190|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|June 3, 2004||||||https://clinicaltrials.gov/show/NCT00083902||200553|
NCT00083863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1257|Framingham: Inflammation, Genes & Cardiovascular Disease|||Boston University||Completed|June 2004|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|7374|||Both|N/A|N/A|No|Non-Probability Sample|Observational Cohort Study|August 2013|August 8, 2013|June 2, 2004||No||No||https://clinicaltrials.gov/show/NCT00083863||200556|
NCT00083876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 98-035|D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma|UARK 98-035, A Phase III Study of D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma||University of Arkansas||Completed|September 1998|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|June 2, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083876||200555|
NCT00083889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181034|SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma|A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma||Pfizer|Yes|Completed|August 2004|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|750|||Both|18 Years|N/A|No|||January 2010|January 19, 2010|June 3, 2004|Yes|Yes||No|September 16, 2009|https://clinicaltrials.gov/show/NCT00083889||200554|
NCT00084513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000365451|Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer|Phase I of Trastuzumab and Imatinib Mesylate (Gleevec®, Formerly Known as STI-571) in Patients With Recurrent or Metastatic Her-2/Neu Expressing Cancer||Fox Chase Cancer Center||Completed|August 2004|March 2007|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|June 10, 2004||||No||https://clinicaltrials.gov/show/NCT00084513||200511|
NCT00076362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995B2403|Pediatric Hypothalamic Obesity|||Novartis||Completed|March 2004|||July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|6 Years|18 Years|No|||September 2011|September 8, 2011|January 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00076362||201078|
NCT00076999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.14|Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children|Multiple-dose, Open-label, Randomized, Safety and Pharmacokinetic Study of Tipranavir in Combination With Low-dose Ritonavir in HIV-infected Pediatric Patients||Boehringer Ingelheim||Completed|November 2003|||June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|2 Years|18 Years|No|||April 2014|April 25, 2014|February 9, 2004||||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00076999||201035|
NCT00077012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPH 002|Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia|A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Transurethral Photodynamic Therapy With QLT0074 for Benign Prostatic Hyperplasia||QLT Inc.||Completed|March 2003|May 2005|Actual|May 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||May 2012|May 22, 2012|February 9, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00077012||201034|
NCT00076986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL13PEI-301-R03|The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme|PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence||INSYS Therapeutics Inc||Completed|February 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|February 6, 2004||Yes||||https://clinicaltrials.gov/show/NCT00076986||201036|
NCT00072293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000339581|Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases|A Randomized Trial Of Axillary Dissection Versus No Axillary Dissection For Patients With Clinically Node Negative Breast Cancer And Micrometastases In The Sentinel Node|23-01|International Breast Cancer Study Group|Yes|Active, not recruiting|December 2001|||September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1960|||Female|N/A|N/A|No|||August 2015|August 11, 2015|November 4, 2003||No||No||https://clinicaltrials.gov/show/NCT00072293||201365|
NCT00072618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026B|Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients|A Phase I/II Multi-Center Study of Weekly Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed a Prior Platinum-Containing Regimen||Astellas Pharma Inc||Completed|October 2001|August 2003|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||52|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|November 5, 2003|No|Yes||||https://clinicaltrials.gov/show/NCT00072618||201344|
NCT00073073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040044|Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer|A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer||Georgetown University|No|Completed|November 2003|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|46|||Female|N/A|N/A|No|||March 2014|May 7, 2014|November 14, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073073||201311|
NCT00073463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25E01|Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis|A Multicenter, Double-Blind, Placebo Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis||Targeted Genetics Corporation||Terminated|June 2003|October 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|12 Years|N/A|No|||January 2008|January 24, 2008|November 21, 2003|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00073463||201281|
NCT00073476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1611005|A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke|A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.||Pfizer||Terminated|September 2003|February 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|40 Years|90 Years|No|||June 2006|June 20, 2006|November 21, 2003||||||https://clinicaltrials.gov/show/NCT00073476||201280|
NCT00073801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040056|Pelvic Pain in Women With Endometriosis|The Neural Immune Mechanisms and Genetic Influences on Chronic Pelvic Pain in Women With Endometriosis||National Institutes of Health Clinical Center (CC)||Completed|December 2003|||||N/A|Observational|N/A|||Actual|78|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 13, 2016|December 8, 2003||No||No||https://clinicaltrials.gov/show/NCT00073801||201256|
NCT00109577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18229|Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder|Randomized Placebo-controlled Phase II Trial of MCN36 in Adults With Bipolar Disorder||University of Calgary|Yes|Terminated|April 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|April 28, 2005||No|Unable to recruit large enough sample; large expectancy effects but no adverse events|No|June 25, 2012|https://clinicaltrials.gov/show/NCT00109577||198716|
NCT00109564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-1734-112-CRD-004|A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)|A Safety and Efficacy Study of TC-1734-112 in Subjects With Age Associated Memory Impairment (AAMI)||Targacept Inc.||Completed|January 2005|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||174|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||July 2008|July 17, 2008|April 28, 2005||||||https://clinicaltrials.gov/show/NCT00109564||198717|
NCT00109837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0333|S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy||Southwest Oncology Group|Yes|Completed|April 2005|November 2014|Actual|November 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|64 Years|No|||March 2015|March 5, 2015|May 3, 2005|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00109837||198697|
NCT00110968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITOFD04-02|Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia|A Multicentre, Open-Label Extension Phase to Study the Long-Term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia||Axcan Pharma||Completed|September 2004|September 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||July 2008|July 24, 2008|May 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110968||198613|
NCT00110981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040171|Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis|A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis||Amgen||Completed|March 2005|March 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|May 16, 2005||||No||https://clinicaltrials.gov/show/NCT00110981||198612|
NCT00110084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000423195|ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer|Phase II Trial of Weekly Nab (Nanoparticle Albumin Bound)-Paclitaxel (Nab-paclitaxel) (Abraxane®) in Combination With Gemcitabine in Patients With Metastatic Breast Cancer||Mayo Clinic|Yes|Completed|August 2005|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||May 2011|May 31, 2011|May 3, 2005|Yes|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00110084||198680|
NCT00110110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000005587|Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma|Multicenter Phase II Study for International Intraocular Retinoblastoma Classification Groups B, C & D Tumors Treated With Carboplatin-Etoposide-Vincristine-Cyclosporine-Focal Therapy Multimodality Protocol (OCRN Multicenter RB 2003)||The Hospital for Sick Children|Yes|Active, not recruiting|June 2004|December 2019|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|N/A|N/A|No|||November 2014|November 20, 2014|May 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00110110||198679|
NCT00082979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000361751|Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer|Evaluation of the Role of Duct Endoscopy in the Assessment of Cellular Atypia Within Breast Duct Fluid in High-Risk Women Carrying BRCA1/2 or p53 Gene Mutations||National Cancer Institute (NCI)||Recruiting|October 2003|||||Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|60|||Female|18 Years|64 Years|No|||December 2005|August 23, 2013|May 14, 2004||||No||https://clinicaltrials.gov/show/NCT00082979||200620|
NCT00083278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX010-12|Study of MDX-010 in Stage IV Breast Cancer|A Phase II Study of MDX-010 in Patients With Stage IV Adenocarcinoma of the Breast||Bristol-Myers Squibb||Completed|May 2003|February 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|33|||Female|18 Years|N/A|No|||April 2012|April 26, 2012|May 17, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00083278||200599|
NCT00084253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-089 ST|Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients|Phase IV Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients||Bristol-Myers Squibb||Completed|June 2004|||August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2008|March 4, 2010|June 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084253||200527|
NCT00083538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2000-46|Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally|UARK 2000-46, A Phase II Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally in Multiple Myeloma Patients||University of Arkansas|No|Completed|February 2001|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2010|July 6, 2010|May 25, 2004||No||No||https://clinicaltrials.gov/show/NCT00083538||200579|
NCT00084201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002077-01|Interactions Between Cranberry Juice and Antibiotics Used to Treat Urinary Tract Infections|Cranberry: Interactions With Anti-Infectious Agents||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2006|June 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|6 Years|50 Years|Accepts Healthy Volunteers|||November 2006|November 28, 2006|June 8, 2004||||No||https://clinicaltrials.gov/show/NCT00084201||200531|
NCT00083915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2001-12|DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation|UARK 2001-12, A Phase III Study of DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation in Patients With Active Multiple Myeloma||University of Arkansas|No|Completed|June 2001|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||July 2011|July 7, 2011|June 3, 2004|Yes|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00083915||200552|
NCT00084214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4783-03|STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma|A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma||Synta Pharmaceuticals Corp.||Completed|May 2004|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||103|||Both|18 Years|N/A|No|||December 2008|March 5, 2014|June 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00084214||200530|
NCT00084227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661126|Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America|A Phase Ii/Iii, Randomized, Double Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America||Pfizer||Completed|July 2004|July 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|244|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|June 9, 2004||||||https://clinicaltrials.gov/show/NCT00084227||200529|
NCT00072319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-092|Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer|Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|August 2003|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2013|March 1, 2013|November 4, 2003|No|Yes||No||https://clinicaltrials.gov/show/NCT00072319||201364|
NCT00076635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPF-006|An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF|An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis||InterMune|No|Terminated|November 2003|April 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|N/A|N/A|No|||November 2007|November 2, 2007|January 28, 2004|||program discontinued based on GIPF-007 results|No||https://clinicaltrials.gov/show/NCT00076635||201057|
NCT00076648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTBSE-11-(N)|Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting|A Phase III, Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception From Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection [Polymerized Human Hemoglobin (Pyridoxylated), PolyHeme(R)] When Used to Treat Patients in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Prehospital Setting||Northfield Laboratories||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 31, 2006|January 28, 2004||||||https://clinicaltrials.gov/show/NCT00076648||201056|
NCT00076674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040101|Levetiracetam Treatment of L-Dopa Induced Dyskinesias|Levetiracetam Treatment of L-Dopa Induced Dyskinesias||National Institutes of Health Clinical Center (CC)||Completed|January 2004|October 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||October 2005|March 3, 2008|January 28, 2004||||No||https://clinicaltrials.gov/show/NCT00076674||201055|
NCT00072280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST03P1|Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma|A Pilot Phase II Study for Children With Infantile Fibrosarcoma||Children's Oncology Group|Yes|Terminated|November 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|N/A|2 Years|No|||September 2014|September 16, 2014|November 4, 2003|Yes|Yes|Due to poor accrual|No|September 23, 2013|https://clinicaltrials.gov/show/NCT00072280||201366|Study closed early due to slow accrual. Analysis plans were not carried out (lack of statistical precision compromised the ability to draw appropriate conclusions). Reported Primary Outcome Measure data reflects data collection through March 2008.
NCT00129662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLICX04Q0401103|Comprehension and Evaluation of a Pictorial Action Plan for Those With Asthma or COPD|Comprehension and Evaluation of a Pictorial Action Plan for Those With Asthma or Chronic Obstructive Pulmonary Disease||Imperial College London||Completed|January 2005|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2010|May 25, 2010|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129662||197214|
NCT00129675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Query-PD Study|Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty|Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms||Institute for Neurodegenerative Disorders|No|Completed|February 2003|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|169|||Both|21 Years|N/A|No|||July 2014|July 14, 2014|August 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00129675||197213|
NCT00125541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB2003.01C|C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema|Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema||Sanquin||Completed|November 2006|May 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|6|||Both|16 Years|N/A|No|||May 2009|May 1, 2009|July 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00125541||197522|
NCT00126087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Motor-Neuromod_01|Potentiation of Procedural Motor Learning in Health and Disease|Potentiation of Procedural Motor Learning by Pharmacological Neuromodulation and Transcranial Direct Current Stimulation in Health and Disease||University Hospital Muenster||Terminated|July 2005|January 2013|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|July 31, 2005||No|no further funding available for recruiting and testing participants|No||https://clinicaltrials.gov/show/NCT00126087||197480|
NCT00126100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. I01003|Bone Marrow Stem Cell Mobilisation Therapy for Acute Myocardial Infarction (AMI)(REVIVAL-2)|A Randomized Clinical Trial of Stem Cell Mobilization by Granulocyte-Colony-Stimulating Factor in Patients With Acute Myocardial Infarction. Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Trial||Deutsches Herzzentrum Muenchen|Yes|Completed|February 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|80 Years|No|||November 2007|November 23, 2007|August 1, 2005||||No||https://clinicaltrials.gov/show/NCT00126100||197479|
NCT00126789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMF-301|Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain|An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Cancer Pain||ZARS Pharma Inc.|No|Terminated|August 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||June 2012|June 4, 2012|August 2, 2005|No|Yes|Based on PK data, product did not meet requirement for further development.|No||https://clinicaltrials.gov/show/NCT00126789||197428|
NCT00127114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04033101|Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)|Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)||Johns Hopkins University||Terminated|September 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|52|||Both|40 Years|90 Years|No|||March 2009|March 16, 2009|August 3, 2005|Yes|Yes|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00127114||197403|
NCT00126308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1-0 4-05|Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy|A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH)||Kirby Institute|No|Terminated|November 2005|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2009|March 31, 2009|August 1, 2005||No|no change in primary endpoint at week 48|No||https://clinicaltrials.gov/show/NCT00126308||197463|
NCT00126542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02660|Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase II Trial of Bevacizumab (NSC# 704865) and OSI-774 (NSC# 718781) In Recurrent Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|April 2005|April 2010|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||December 2012|May 13, 2014|August 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00126542||197446|
NCT00126555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02893|Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer|A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin||National Cancer Institute (NCI)|No|Completed|March 2005|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2014|December 16, 2014|August 2, 2005|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00126555||197445|
NCT00126841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GY-03-0019|Computed Tomotherapy (CT) and Magnetic Resonance Imaging (MRI) Fusion on Radiation Treatment Planning for Patients With Cancer of the Cervix|To Assess the Feasibility and Impact of Computed Tomotherapy (CT) and Magnetic Resonance Imaging (MRI) Fusion on Radiation Treatment Planning for Ten Patients With Cancer of the Cervix||AHS Cancer Control Alberta||Completed|November 2004|November 2005||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||10|||Female|N/A|N/A|No|Non-Probability Sample|primary care clinic|December 2011|December 8, 2011|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00126841||197424|
NCT00126854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-15-0003 / 22011|High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation|High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation||AHS Cancer Control Alberta|No|Completed|October 2005|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Male|18 Years|N/A|No|||March 2012|February 24, 2016|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00126854||197423|
NCT00127491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000011/1; BIDMC|Mechanical Ventilation, Directed by Esophageal Pressure Measurements, in Patients With Acute Lung Injury|A RCT of Mechanical Ventilation, Directed by Esophageal Pressure Measurements, in Patients With Acute Lung Injury||Beth Israel Deaconess Medical Center|Yes|Completed|May 2004|May 2010|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|August 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00127491||197375|
NCT00096707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-101|Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors|Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination With Docetaxel in Subjects With Advanced Solid Malignancies||Threshold Pharmaceuticals||Completed|February 2004|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|November 12, 2004||||||https://clinicaltrials.gov/show/NCT00096707||199652|
NCT00097071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-2181|Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents|Safety and Efficacy of Insulin Aspart Versus Insulin Lispro in Insulin Pumps in Children and Adolescents With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|October 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|299|||Both|3 Years|18 Years|No|||October 2014|October 23, 2014|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097071||199625|
NCT00097084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1431|Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes||Novo Nordisk A/S|No|Completed|September 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|324|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 17, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00097084||199624|
NCT00092677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-043|An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Ezetimibe + Simvastatin on Clinical Outcomes in Patients With Aortic Stenosis||Merck Sharp & Dohme Corp.||Completed|January 2001|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1873|||Both|45 Years|85 Years|No|||February 2015|February 24, 2015|September 23, 2004|Yes|Yes||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00092677||199945|It is important to note that several of the ischemic outcomes making up the composite ischemic endpoint can occur as a causal consequence of aortic stenosis progression itself, or in association with its standard treatment (aortic valve replacement).
NCT00097513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-036, Substudy 12|National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients|National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Subjects||Genentech, Inc.||Completed|February 2003|June 2006|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|12 Years|17 Years|No|Probability Sample|Pubertal Growth Hormone Deficiency|November 2010|November 11, 2010|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097513||199593|
NCT00128583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439529|Vaccine Therapy in Treating Patients With Malignant Melanoma|Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™||National Cancer Institute (NCI)||Active, not recruiting|July 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||September 2005|December 18, 2013|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128583||197293|
NCT00128895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-ANCA-1|Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis|Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach||University Medical Center Groningen|No|Active, not recruiting|June 2003|December 2014|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00128895||197272|
NCT00129116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|792014/003|3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age|A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Three Different Formulations of GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups C and Y- Conjugate Vaccine and One Formulation of GSK Biologicals' Haemophilus Influenzae Type B-meningococcal Serogroup C Conjugate Vaccine Each Given Concomitantly With InfanrixTM Penta, Versus MeningitecTM, Given Concomitantly With InfanrixTM Hexa in Infants According to a 2-3-4 Month Schedule||GlaxoSmithKline||Completed|March 2003|October 2004|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|388|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2014|September 24, 2015|August 10, 2005|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00129116||197256|
NCT00129389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2003-02|FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients|Multicenter Randomized Phase III Clinical Trial to Compare 6 FAC Cycles(Fluorouracil, Doxorubicin, Cyclophosphamide) vs. 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients||Spanish Breast Cancer Research Group|No|Active, not recruiting|September 2003|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1929|||Female|18 Years|70 Years|No|||November 2012|November 21, 2012|August 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00129389||197235|
NCT00129688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE44290|Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children|Comparison of Efficacy, Safety and Economic Outcomes Between Once-Daily Versus Twice-Daily Amikacin in Combination With Cloxacillin in Febrile Neutropenic Children||Khon Kaen University||Completed|April 2002|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||166|||Both|1 Year|14 Years|No|||February 2005|September 22, 2005|August 10, 2005||||No||https://clinicaltrials.gov/show/NCT00129688||197212|
NCT00125554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH-PSY-ja-007|Metyrapone as Additive Treatment in Major Depression|Double-Blind, Placebo Controlled Trial of Metyrapone as Augmenting Agent in the Treatment of Major Depression||Universitätsklinikum Hamburg-Eppendorf||Completed|May 1998|July 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||63|||Both|18 Years|75 Years|No|||July 2005|August 11, 2005|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125554||197521|
NCT00125567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939111|Stalevo in Early Wearing-Off Patients|Multicentre, Randomised, Double-Blind Study to Compare Stalevo to Levodopa/Carbidopa in Patients With Parkinson's Disease Experiencing Symptoms of Early Wearing-Off|SEWOP|Orion Corporation, Orion Pharma|No|Completed|August 2005|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|223|||Both|30 Years|N/A|No|||June 2009|June 19, 2009|July 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125567||197520|
NCT00125814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 105 INTERVAC|Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression|Multi-Center Trial to Evaluate the Efficacy and Safety of Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression (ANRS 105 INTERVAC)||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|December 2001|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A||||August 2005|August 15, 2005|August 1, 2005||||No||https://clinicaltrials.gov/show/NCT00125814||197501|
NCT00126113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3951-R|The Performance-Perceptual Test as a Counseling Tool|The Performance-Perceptual Test as a Counseling Tool|PPT|VA Office of Research and Development|No|Completed|August 2005|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|74|||Both|45 Years|65 Years|No|||October 2014|October 6, 2014|August 1, 2005||No||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00126113||197478|
NCT00126321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAI|Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)|Phase II Study of Cladribine, High-dose Cytarabine and Idarubicin in Patients With Relapsed Acute Myeloid Leukemia||University Hospital, Bonn|No|Recruiting|November 2004|March 2011|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|August 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00126321||197462|
NCT00126334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-003|Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot||CRIT|Medstar Research Institute|Yes|Completed|April 2003|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|21 Years|N/A|No|||July 2011|July 20, 2011|August 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00126334||197461|
NCT00126867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-05-0049 / 21882|Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment|Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment||AHS Cancer Control Alberta|No|Recruiting|May 2005|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|104|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|October 2014|October 2, 2014|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00126867||197422|
NCT00127231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMCC014500|Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women|Brief Alcohol Intervention in HIV+ Women||Johns Hopkins University|Yes|Completed|September 2007|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|387|||Female|N/A|N/A|No|||February 2016|February 23, 2016|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00127231||197394|
NCT00127517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR118 04-002|Palliative Care Study in Patients With Advanced Cancer|A Phase II Double Blind, Placebo Controlled, Randomized, > Multicenter Study With AVR118 Solution in Patients With Advanced > Malignancies Who Are Not Candidates for Curative Chemotherapy.||Advanced Viral Research Corp||Terminated|March 2005|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||June 2011|June 6, 2011|August 5, 2005|||Company shifted focus|||https://clinicaltrials.gov/show/NCT00127517||197373|
NCT00096720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSPECT|Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease|Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's||Institute for Neurodegenerative Disorders|No|Completed|February 2004|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|1||Actual|112|||Both|30 Years|N/A|No|||May 2007|September 28, 2010|November 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096720||199651|
NCT00097461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050008|Revising Employee Benefits for the Sake of Health|Revising Employee Benefits for the Sake of Health||National Institutes of Health Clinical Center (CC)||Completed|September 2004|||||N/A|Observational|Time Perspective: Prospective|||Actual|408|||Both|18 Years|65 Years|No|||July 2015|August 8, 2015|November 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00097461||199597|
NCT00097474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050037|Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag|The Effects of Hydrocortisone, Melatonin, and Placebo on Symptoms of Jet Lag||National Institutes of Health Clinical Center (CC)||Completed|November 2004|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|57|||Both|18 Years|65 Years|No|||July 2015|January 22, 2016|November 23, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00097474||199596|
NCT00097487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2251n|A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane|Clinical Outcomes in Patients With HER2 Gene-Amplified Metastatic Breast Cancer Treated With First Line Herceptin in Combination With a Taxane: A Phase IV, Prospective, Community Based Study||Genentech, Inc.||Active, not recruiting|November 2000|September 2004||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1000|||Female|18 Years|N/A|No|||November 2004|June 23, 2005|November 24, 2004||||No||https://clinicaltrials.gov/show/NCT00097487||199595|
NCT00092690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-051|MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|June 2003|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1902|||Both|18 Years|79 Years|No|||February 2015|February 16, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092690||199944|
NCT00092703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-061|Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)|A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis||Merck Sharp & Dohme Corp.||Completed|June 2002|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||6000|||Both|50 Years|N/A|No|||May 2015|May 26, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092703||199943|
NCT00092729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-064|An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)|A Randomized, Placebo-and Active-Comparator-Controlled Study of Etoricoxib 120 mg in the Treatment of Primary Dysmenorrhea||Merck Sharp & Dohme Corp.||Completed|June 2002|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|129|||Female|18 Years|N/A|No|||June 2015|June 5, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092729||199941|
NCT00128596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000438662|Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery|A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer||National Cancer Institute (NCI)||Completed|June 2004|||December 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2006|August 18, 2009|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128596||197292|
NCT00128908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05IAT0061|Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients|Sequential HAART in Treatment Resistant HIV-1 Infected Patients||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Terminated|September 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2009|September 14, 2009|August 8, 2005|No|Yes|Did not recruit|No||https://clinicaltrials.gov/show/NCT00128908||197271|
NCT00128869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO5-368|Comparison of the Effectiveness of Mobilization and Manipulation of the Thoracic Spine in Patients With Mechanical Neck Pain|Comparison of the Effectiveness of Mobilization and Manipulation of the Thoracic Spine in Patients With Mechanical Neck Pain: A Randomized Clinical Trial||Newton-Wellesley Hospital||Completed|May 2005|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|96|||Both|18 Years|60 Years|No|||May 2008|May 8, 2008|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128869||197274|
NCT00128882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-2005-1|Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D|Treatment of Idiopathic Thrombocytopenic Purpura in Children With Subcutaneously Administered Anti-D||University of Aarhus|Yes|Completed|November 2004|December 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|1 Year|14 Years|No|||February 2009|February 2, 2009|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128882||197273|
NCT00129402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02579|Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)|Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|August 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|248|||Both|10 Years|17 Years|No|||September 2015|September 2, 2015|August 9, 2005|Yes|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00129402||197234|
NCT00129701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLICX3510|Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation|Proposal to Study Whether we Can Reduce Hospital Attendance by Those With Respiratory Conditions Without Compromising Care by the Use of Telephone Consultation||Imperial College London||Completed|November 2003|January 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2005|May 27, 2015|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129701||197211|
NCT00125827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO152|Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors|A Phase I Dose Escalation and Pharmacokinetic Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors||Sanofi||Completed|October 2003|February 2006|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|July 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00125827||197500|
NCT00125840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO151|Clofarabine in Adult Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetic Study of Clofarabine in Adult Patients With Advanced Solid Tumors||Sanofi||Completed|August 2002|August 2007|Actual|||Phase 1|Interventional|N/A|||||||Both|18 Years|N/A|No|||February 2014|February 4, 2014|July 29, 2005||||||https://clinicaltrials.gov/show/NCT00125840||197499|
NCT00125853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPSW02|The Effect of Nebivolol on Insulin Sensitivity|A Trial to Compare the Effects of Nebivolol Versus Atenolol on Various Cardiovascular Measurements Including Insulin Sensitivity||Imperial College London|No|Completed|July 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|N/A|N/A|No|||April 2014|April 7, 2014|July 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00125853||197498|
NCT00126126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3381-R|Evidence Based Amputee Rehabilitation (EBAR) Program|Evidence Based Amputee Rehabilitation (EBAR) Program|EBAR|VA Office of Research and Development|Yes|Completed|January 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|80 Years|No|||September 2015|September 21, 2015|August 1, 2005||No||No|November 24, 2014|https://clinicaltrials.gov/show/NCT00126126||197477|Recruitment was challenging. We screened over 350 veterans and non-veterans with lower limb loss and we were only able to enroll 20.
NCT00126139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-046/2001|Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis|Abciximab Versus Aspirin for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic >50% Carotid Stenosis: A Pilot Study (ASTERICS)||University of Zurich|Yes|Terminated|April 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2007|May 1, 2007|July 29, 2005|||Higher hemorrhage rates of Abciximab in ABESST II trial|No||https://clinicaltrials.gov/show/NCT00126139||197476|
NCT00126347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02.0470L|Effect of Betaine, Serine and Folic Acid on Vascular Function in Healthy Volunteers|Effect of Lowering of Plasma Homocysteine Concentrations After an Oral Methionine Load on Vascular Function in Healthy Volunteers||Wageningen Centre for Food Sciences||Completed|August 2002|July 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||August 2005|August 17, 2005|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126347||197460|
NCT00126568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00118|Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer|Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid||National Cancer Institute (NCI)||Terminated|June 2005|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2012|May 7, 2014|August 2, 2005|Yes|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00126568||197444|The study met the pre-specified criteria for enrollment of all planned 32 patients. However due to poor accrual the study was halted.
NCT00126581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00464|Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer|A Phase II Randomized Study of OSI-774 (ERLOTINIB) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers||National Cancer Institute (NCI)||Active, not recruiting|August 2005|||June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|N/A|No|||November 2015|February 2, 2016|August 2, 2005|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00126581||197443|
NCT00126880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-201|AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV|A Phase II, Randomised, Double-blind, Dose-ranging Study of AVX754 Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V Mutation in Reverse Transcriptase||Avexa|Yes|Completed|July 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|65 Years|No|||June 2011|June 22, 2011|August 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126880||197421|
NCT00126893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-401-AML-001|Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia|Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia||Celgene||Terminated|October 2005|September 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||December 2006|May 14, 2007|August 3, 2005||||||https://clinicaltrials.gov/show/NCT00126893||197420|
NCT00120016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051517|Design and Feasibility of a Mediterranean Diet|Design and Feasibility of a Mediterranean Diet||University of Michigan|Yes|Completed|January 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||November 2008|December 19, 2012|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00120016||197938|
NCT00120029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057103MP4F|Peer Counseling for Weight Loss|Peer Counseling for Weight Loss in African American Breast Cancer Survivors||Wayne State University||Recruiting|January 2004|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|100|||Female|18 Years|71 Years|Accepts Healthy Volunteers|||June 2008|September 4, 2008|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00120029||197937|
NCT00127218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0032|High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly|HDL Increased Plaque Stabilization in the Elderly|NIA-Plaque|Johns Hopkins University|Yes|Completed|September 2003|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|65 Years|N/A|No|||October 2015|October 12, 2015|August 3, 2005||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT00127218||197395|
NCT00097097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 03|Neonatal Resuscitation in Zambia|Neonatal Resuscitation in Zambia||NICHD Global Network for Women's and Children's Health|Yes|Completed|October 2004|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40000|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097097||199623|
NCT00097110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 05|RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil|RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil||NICHD Global Network for Women's and Children's Health|Yes|Completed|July 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||734|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 22, 2013|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097110||199622|
NCT00097500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-114|Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes|A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c||AstraZeneca|No|Completed|September 2004|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|30 Years|75 Years|No|||March 2015|March 19, 2015|November 24, 2004|Yes|Yes||No|December 24, 2010|https://clinicaltrials.gov/show/NCT00097500||199594|
NCT00092742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-072|Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)|A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis||Merck Sharp & Dohme Corp.||Completed|February 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|4086|||Both|50 Years|N/A|No|||June 2015|June 29, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092742||199940|
NCT00092755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-073|An Investigational Drug in Patients With Osteoarthritis (0663-073)|A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 2)||Merck Sharp & Dohme Corp.||Completed|April 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|548|||Both|40 Years|N/A|No|||June 2015|June 29, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092755||199939|
NCT00092768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-076|A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)|A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)||Merck Sharp & Dohme Corp.||Completed|March 2004|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|500|||Both|40 Years|N/A|No|||June 2015|June 15, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092768||199938|
NCT00128336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/173|The Heat Study: 2 Year Lifestyle Intervention in Overweight Women to Encourage Weight Management|The Heat Study: A 2-Year Lifestyle Intervention in Overweight Women to Determine Optimal Approaches for Successful Maintenance of Weight Loss||University of Otago||Active, not recruiting|May 2004|October 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Female|25 Years|70 Years|Accepts Healthy Volunteers|||August 2005|September 8, 2005|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128336||197311|
NCT00128622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000437795|Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer|A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA||Duke University||Completed|September 2005|May 2009|Actual|March 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|August 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00128622||197291|
NCT00129155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.332|MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies|Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies||Hospices Civils de Lyon||Recruiting|February 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|65 Years|No|||October 2007|October 3, 2007|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129155||197253|
NCT00129168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAN-979-01|Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)|An Open-Label, Phase I/II, Multicenter Dose Escalation Study of Zosuquidar, Daunorubicin, and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia||Kanisa Pharmaceuticals||Completed|August 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|55 Years|75 Years|No|||March 2008|March 28, 2008|August 9, 2005||||||https://clinicaltrials.gov/show/NCT00129168||197252|
NCT00129129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101858|Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine|Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 Years||GlaxoSmithKline||Completed|August 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|756|||Both|6 Weeks|15 Months|Accepts Healthy Volunteers|||June 2014|June 26, 2014|August 10, 2005|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00129129||197255|
NCT00129142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G300203|Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy|A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy||GTx||Completed|October 2003|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Male|50 Years|N/A|No|||November 2013|November 13, 2013|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129142||197254|
NCT00129415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 446|Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions|The Effectiveness of UVA1 and UVB Irradiation in the Treatment of Inflammatory Dermatoses: An Open Pilot Study||University of Michigan|No|Terminated|August 2000|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|10 Years|80 Years|No|||May 2015|May 21, 2015|August 9, 2005|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00129415||197233|
NCT00129714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|542|Westeinde Brachialgia Study|A Randomized Controlled Trial of Conservative Therapy in Cervical Radiculopathy|WEB|Medical Center Haaglanden||Completed|August 2003|July 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||240|||Both|18 Years|75 Years|No|||April 2012|April 23, 2012|August 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00129714||197210|
NCT00125606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML_CR2_allo_HSCT|Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide|Randomized Phase 3 Trial for Patients With AML in CR2 Comparing Total Body Irradiation (TBI) With 8Gy/Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide||University Hospital Muenster|Yes|Terminated|October 2004|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||December 2012|December 17, 2012|July 26, 2005||No|insufficient patient recruitement|No||https://clinicaltrials.gov/show/NCT00125606||197517|
NCT00125580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20970EP|Healthy Sleeping and Feeding During Infancy|Healthy Sleeping and Feeding During Infancy: Pilot Study for the Primary Prevention of Obesity in Primary Care||Penn State University||Completed|August 2005|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2007|November 30, 2007|July 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00125580||197519|
NCT00125593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSUSHARP1|Study of Heart and Renal Protection|Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial|SHARP|University of Oxford|Yes|Completed|June 2003|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|9438|||Both|40 Years|N/A|No|||January 2012|January 31, 2012|July 29, 2005|Yes|Yes||No|August 19, 2011|https://clinicaltrials.gov/show/NCT00125593||197518|
NCT00126152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U17/CCU022310|Senior Falls Prevention Study|Targeted Injury Prevention Program: Preventing Falls Among Older Adults||Washington State, Department of Health||Completed|September 2003|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||453|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2005|July 29, 2005|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00126152||197475|
NCT00126360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARS-Pilot (05/55 Graham)|STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)|Pilot for a Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Ant-Oestrogen Therapy Delayed Until After Radiotherapy||St George Hospital, Australia||Recruiting|August 2005|May 2016||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||August 2005|November 7, 2005|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126360||197459|
NCT00126594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02910|Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer|A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|June 2005|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||December 2013|December 22, 2014|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126594||197442|
NCT00119756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002350|A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia|A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|253|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|July 7, 2005||||||https://clinicaltrials.gov/show/NCT00119756||197956|
NCT00120055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVALIP04|Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity|||University of Oslo School of Pharmacy||Completed|February 2005|April 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||December 2014|December 2, 2014|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00120055||197935|
NCT00120068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-123|Improving Care for Nursing Home Pneumonia in NHCUs and Veterans' Homes|Improving Care for Nursing Home Pneumonia in NHCUs and Veterans' Homes||VA Office of Research and Development|No|Completed|November 2004|July 2005|Actual|March 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|July 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00120068||197934|
NCT00127790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160743209|Treatment of Insomnia Secondary to Chronic Pain|CBT for Co-Morbid Insomnia and Chronic Pain: Sleep, Pain and Immune Function Outcomes||University of Rochester|No|Completed|June 2005|November 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|35 Years|75 Years|No|||September 2012|September 14, 2012|August 3, 2005||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00127790||197352|The foremost limitation of this pilot study is its small sample size, particularly for a four-arm design. Accordingly, a cautious approach to the interpretation of the findings is warranted.
NCT00096746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-079|Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects|An Exploratory Study of the Effect of the Atazanavir (ATV) I50L Mutation on Subsequent Treatment Response||Bristol-Myers Squibb|No|Completed|November 2004|September 2006||September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2||200|||Both|18 Years|N/A|No|Non-Probability Sample|HIV infected individuals on first line ATV based HAART with presence of I50L mutation &        HIV infected PI naïve on failed NNRTI based regimen.|April 2011|April 12, 2011|November 15, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096746||199649|
NCT00097526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-036, Substudy 10|Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)|Bone Mineral Density in Adolescent Subjects With Growth Hormone Deficiency Who Are Completing Treatment With Nutropin AQ, Nutropin, or Protropin in the National Cooperative Growth Study (NCGS)||Genentech, Inc.||Completed|April 2000|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|N/A|17 Years|No|Non-Probability Sample|primary care clinic|November 2012|November 13, 2012|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097526||199592|
NCT00097539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-036|A Postmarketing Surveillance Program for Nutropin, Nutropin AQ, and Protropin|Genentech National Cooperative Growth Study (NCGS) Postmarketing Surveillance Program for Nutropin AQ [Somatropin (rDNA Origin) Injection], Nutropin [Somatropin (rDNA Origin) for Injection], and Protropin [Somatrem for Injection]||Genentech, Inc.||Completed|October 1985|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58998|||Both|N/A|17 Years|No|Non-Probability Sample|primary care clinic|November 2012|November 13, 2012|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097539||199591|
NCT00092781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-077|A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)|A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 2)||Merck Sharp & Dohme Corp.||Completed|March 2004|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|500|||Both|40 Years|N/A|No|||June 2015|June 15, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092781||199937|
NCT00092807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02257|Sitosterolemia Extension Study (0653-003)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension||Merck Sharp & Dohme Corp.||Completed|February 2001|November 2004|Actual|September 2001|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|37|||Both|10 Years|N/A|No|||February 2015|February 16, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092807||199936|
NCT00128947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050209|Pharmacokinetics of Mycophenolate Mofetil in Healthy Volunteers|Pharmacokinetics of Mycophenolic Acid and Mycophenolate 7-O-Phenolic Glucuronide in Healthy Subjects With or Without Two Common Genetic Polymorphisms in the Promoter Region of Uridine Diphosphate Glucuronosyltransferase 1A9||National Institutes of Health Clinical Center (CC)||Completed|July 2005|May 2006||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||130|||Both|N/A|N/A|No|||May 2006|March 3, 2008|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128947||197268|
NCT00129207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M34103-059|Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade|Effect of Ketoconazole Administration on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.||Completed||||September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2008|February 7, 2008|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129207||197249|
NCT00129220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9636|Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder|Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder||Eli Lilly and Company||Completed|July 2005|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|224|||Both|20 Years|65 Years|No|||December 2010|December 10, 2010|August 8, 2005|Yes|Yes||No|January 21, 2010|https://clinicaltrials.gov/show/NCT00129220||197248|Identified errors were corrected.
NCT00129181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAD001|Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease|A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease||Institute for Neurodegenerative Disorders|No|Completed|January 2005|January 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|30|||Both|40 Years|N/A|No|||August 2009|August 27, 2009|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00129181||197251|
NCT00129428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 447|Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix|The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study||University of Michigan|No|Completed|August 2002|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|33|||Both|10 Years|80 Years|No|||April 2015|April 30, 2015|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00129428||197232|
NCT00129727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-247|Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)|Phase II Evaluation of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy and Consolidation for Advanced Ovarian Cancer||Massachusetts General Hospital|Yes|Completed|June 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|18 Years|N/A|No|||August 2009|August 7, 2009|August 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00129727||197209|
NCT00129740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0048|Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib||M.D. Anderson Cancer Center|Yes|Active, not recruiting|June 2005|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|16 Years|N/A|No|||July 2015|July 22, 2015|August 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00129740||197208|
NCT00129753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0742|Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease|Phase II Study of Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease||M.D. Anderson Cancer Center|No|Terminated|June 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 8, 2010|August 11, 2005|Yes|Yes|Terminated due to slow accrual.|No|April 24, 2009|https://clinicaltrials.gov/show/NCT00129753||197207|
NCT00125866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPSW01|The Effect of Cocoa Flavonoids on Blood Pressure|The Effect of Cocoa Polyphenols on Various Cardiovascular Measurements Including Blood Pressure||Imperial College London||Completed|September 2005|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||April 2007|May 27, 2015|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125866||197497|
NCT00125879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02403|Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602|A Long-Term Continuation Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602||Sanofi||Completed|June 2005|December 2006|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||February 2014|February 4, 2014|August 1, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00125879||197496|
NCT00126165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17885|Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer|A Phase I/II Study of Escalated-dose Short-course Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer||AHS Cancer Control Alberta||Completed|September 2004|August 2011|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|72|||Male|18 Years|N/A|No|||January 2012|January 18, 2012|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126165||197474|
NCT00118937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Type-1-Metformin|Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet|Effect of Metformin On Glycaemic Control and Non-Glycaemic Cardiovascular Risk-Factors in Patients With Type-1 Diabetes, With Long-Standing Inadequate Glycaemic Control by Insulin and Diet||Steno Diabetes Center||Completed|December 2003|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|N/A|No|||December 2008|December 5, 2008|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118937||198014|
NCT00119171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSP10004|Ispinesib In Combination With Capecitabine In Patients With Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors||GlaxoSmithKline||Completed|November 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|July 5, 2005||||||https://clinicaltrials.gov/show/NCT00119171||197996|
NCT00119444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050606|Evaluation of Acetabular Perfusion After Ganz Osteotomy by Positron Emission Tomography|Evaluation of Acetabular Perfusion After Ganz Osteotomy by Positron Emission Tomography||University of Aarhus|No|Completed|January 2004|August 2009|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|No|||September 2009|November 19, 2015|July 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00119444||197980|
NCT00119457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP889-201|Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)|A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery||vTv Therapeutics||Completed|January 2005|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|July 5, 2005||||No||https://clinicaltrials.gov/show/NCT00119457||197979|
NCT00119769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFE001|The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients|The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)||Hvidovre University Hospital|No|Completed|February 2005|July 2008|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Male|21 Years|60 Years|No|||August 2008|August 26, 2008|July 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00119769||197955|
NCT00120042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC04-68.1|Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption|Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption||The University of Western Australia|No|Completed|February 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|251|||Female|16 Years|50 Years|No|||June 2009|June 29, 2009|July 5, 2005||No||No|April 1, 2009|https://clinicaltrials.gov/show/NCT00120042||197936|Planned interim analysis not performed as mifepristone became available in Australia. Study ceased at 251 women and enough power available to calculate the groups as a single stage analysis.
NCT00120081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-04-01|Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection|Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection||Albert B. Sabin Vaccine Institute|Yes|Completed|April 2005|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 20, 2012|July 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120081||197933|
NCT00129233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169|Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance|The Novel Antihypertensive Goal Of hYpertension With diAbetes ― Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study||Nagoya University|Yes|Completed|October 2004|April 2013|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1150|||Both|30 Years|75 Years|No|||April 2013|April 29, 2013|August 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00129233||197247|
NCT00129246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAOMA15632-B|Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain|Naltrexone & Bupropion to Stop Smoking With Less Weight Gain||Yale University||Completed|December 2004|December 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|August 9, 2005||No||No|January 2, 2013|https://clinicaltrials.gov/show/NCT00129246||197246|
NCT00097123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 08|RCT of Misoprostol for Postpartum Hemorrhage in India|RCT of Misoprostol for Postpartum Hemorrhage in India||NICHD Global Network for Women's and Children's Health|Yes|Completed|September 2002|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|1600|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097123||199621|
NCT00097552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-036, Substudy 9|A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone|Characterization of Subjects With Turner Syndrome Treated With Growth Hormone in the National Cooperative Growth Study (NCGS)||Genentech, Inc.||Completed|May 1997|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1696|||Female|N/A|17 Years|No|Non-Probability Sample|Primary care clinic|November 2012|November 13, 2012|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097552||199590|
NCT00097565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2963n|An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma|The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma||Genentech, Inc.||Completed|March 2004|March 2014|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2740|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with follicular NHL will be recruited from participating managed care        organizations, community physicians or practices, and academic centers throughout the        United States.|February 2015|February 27, 2015|November 24, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00097565||199589|
NCT00125905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI021471|ISTAPS: A Stepped Primary Care Smoking Cessation Intervention|Effectiveness of a Stepped Primary Care Smoking Cessation Intervention Based on an Evidence Based Clinical Practice Guideline (ISTAPS Project)||Jordi Gol i Gurina Foundation||Active, not recruiting|October 2003|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||3012|||Both|14 Years|75 Years|No|||November 2003|September 29, 2009|August 1, 2005||||No||https://clinicaltrials.gov/show/NCT00125905||197494|
NCT00121147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEF-042|Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan|A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Month Double-Masked, Multi-Center Trial in the United States||Hermann Eye Center||Completed|September 2003|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|35 Years|N/A|Accepts Healthy Volunteers|||July 2005|February 22, 2006|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121147||197852|
NCT00116961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.047|Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma|A Phase II Study of Combination of Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma||University of Michigan Cancer Center||Completed|June 2005|December 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2012|February 5, 2012|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00116961||198163|
NCT00116974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801404|Periodontal Infection and Prematurity Study|Periodontal Infection and Prematurity Study||University of Pennsylvania||Active, not recruiting|October 2004|May 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2100|||Female|N/A|N/A|No|||November 2007|November 30, 2007|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00116974||198162|
NCT00128921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2004-22|Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma|A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma||University of Arkansas|Yes|Terminated|April 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|18|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|August 8, 2005||No|study terminated due to low accrual|No|April 15, 2011|https://clinicaltrials.gov/show/NCT00128921||197270|Early termination due to difficulty in accruing participants.
NCT00129194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-1461-102|Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens|A Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults Who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART)||Koronis Pharmaceuticals.||Completed|August 2005|||June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|60 Years|No|||December 2007|December 30, 2007|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129194||197250|
NCT00129441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502027|Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study|Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist||University of Pittsburgh|No|Completed|August 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|No|||October 2011|October 14, 2011|August 10, 2005|Yes|Yes||No|May 25, 2011|https://clinicaltrials.gov/show/NCT00129441||197231|Small sample size; RBANS may lack appropriate sensitivity for short-term study; between-group differences in baseline clinical symptoms & neuropsychological function; excluding those with more modest cognitive impairments (RBANS standard score >90).
NCT00118417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH001831|Therapies for Treatment-Resistant Panic Disorder Symptoms|Treatment Refractory Panic Disorder||Massachusetts General Hospital||Completed|March 1999|October 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||June 2014|June 5, 2014|July 6, 2005||No||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00118417||198053|Power in Phase 2 limited detection to a large effect size. High drop-out for increased SSRI dose may indicate poor tolerability. Effectiveness of adding an SSRI to initial CBT was unexamined, limiting generalization to community treatment decisions.
NCT00125619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4032-I|Internally Versus Externally Guided Body Weight-Supported Treadmill Training (BWSTT) for Locomotor Recovery Post-stroke|Internally v. Externally Guided BWSTT for Locomotor Recovery Post-stroke||VA Office of Research and Development||Completed|September 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 27, 2014|July 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00125619||197516|
NCT00125632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3877R|Measuring Reading Rehabilitation Outcomes|Measuring Reading Rehabilitation Outcomes||VA Office of Research and Development||Completed|August 2005|May 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|90|||Both|18 Years|N/A|No|||December 2006|February 3, 2009|July 28, 2005||||No||https://clinicaltrials.gov/show/NCT00125632||197515|
NCT00125892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9075|A Study of Duloxetine in the Treatment of Fibromyalgia|A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome||Eli Lilly and Company||Completed|July 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|18 Years|N/A|No|||May 2007|May 16, 2007|July 29, 2005||||||https://clinicaltrials.gov/show/NCT00125892||197495|
NCT00119184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-25/01/02-HMO-CTIL|Spinal Analgesia Versus No Analgesia: Study for External Cephalic Version|A Prospective Randomized Study to Examine the Success Rate of External Cephalic Version for Breech Presentation at Term Presentation: Spinal Analgesia Versus No Analgesia||Hadassah Medical Organization|No|Terminated|October 2002|May 2008|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|45 Years|No|||May 2008|June 5, 2008|July 3, 2005||No|Multiparas study terminated due to poor recruitment. Randomization revealed only after    decision recorded on clinicaltrials.gov|No||https://clinicaltrials.gov/show/NCT00119184||197995|
NCT00119470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/276|EUS-FNA in the Pre-Operative Evaluation of Patients With Lung Cancer|EUS-FNA in the Pre-Operative Evaluation of Patients With Lung Cancer: A Randomized Trial||University Hospital, Ghent|No|Completed|February 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00119470||197978|
NCT00119782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193|Promoting Activity and Changes in Eating (PACE) to Reduce Obesity|Reducing Obesity at the Workplace: a Randomized Trial|PACE|Fred Hutchinson Cancer Research Center|Yes|Completed|September 2004|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3000|||Both|18 Years|70 Years|No|||August 2012|August 21, 2012|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00119782||197954|
NCT00120094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS2|International Study on Syncope of Uncertain Etiology|ISSUE 2. The Management of Patients With Suspected or Certain Neurally-Mediated Syncope After the Initial Evaluation||Arcispedale Santa Maria Nuova-IRCCS||Terminated|June 2002|June 2005||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||400|||Both|30 Years|N/A|No|||July 2005|April 10, 2006|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120094||197932|
NCT00097149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 04 Aim II|Systematic Pediatric Care for Oral Clefts - South America|Systematic Pediatric Care for Oral Clefts - South America||NICHD Global Network for Women's and Children's Health|Yes|Completed|May 2003|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||696|||Both|N/A|2 Years|No|||December 2013|December 16, 2013|November 17, 2004||No||No||https://clinicaltrials.gov/show/NCT00097149||199620|
NCT00097162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050005|Visual Cortex Stimulation in Patients With Amblyopia|Investigation of Visual Plasticity by a Direct Current Stimulation of Occipital Cortex in Adult Amblyopia||National Institutes of Health Clinical Center (CC)||Completed|November 2004|June 2006||||Phase 1|Interventional|Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||June 2006|June 23, 2006|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097162||199619|
NCT00097175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050035|Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders|The Effects of Mood and Tryptophan Depletion on the Neural Correlates of Affective Shifting in Mood Disorders||National Institutes of Health Clinical Center (CC)||Completed|November 2004|January 2014||||N/A|Observational|N/A|||Actual|95|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|February 19, 2014|November 17, 2004||No||No||https://clinicaltrials.gov/show/NCT00097175||199618|
NCT00125658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3964-R|Mechanisms of Upper-Extremity Motor Recovery in Post-stroke Hemiparesis|Mechanisms of Upper-Extremity Motor Recovery in Post-stroke Hemiparesis||VA Office of Research and Development||Completed|February 2008|September 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 27, 2014|July 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00125658||197513|
NCT00126633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000437858|Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer|A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer||University of California, San Francisco|Yes|Completed|April 2004|October 2008|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126633||197439|
NCT00116987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17096|Dual Chamber Versus Single Chamber Cardiac Pacing in People 80 Years of Age and Older|Pacing the Octogenarian Plus Population (POPP) A Comparison of Physiologic Versus Ventricular Pacing in Those Who Are 80 Years of Age and Older||University of Calgary|No|Terminated|August 2003|November 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|800|||Both|80 Years|N/A|No|||June 2015|June 11, 2015|June 30, 2005||No|Unable to recruit adequate number of participants in required time frame.|No||https://clinicaltrials.gov/show/NCT00116987||198161|
NCT00117364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIRB NO 940318-3|Effect of SACCHACHITIN on Healing of a Chronic Wound|Effect of SACCHACHITIN on Healing of Chronic Wound ---A Clinical Trial||Min-Sheng General Hospital||Recruiting|January 2005|June 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|16 Years|80 Years|No|||June 2005|July 5, 2005|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117364||198132|
NCT00129454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWI 04-355|Telemedicine Treatment for Veterans With Gulf War Illness|Telemedicine Treatment for Veterans With Gulf War Illness||VA Office of Research and Development|No|Completed|September 2005|March 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Actual|128|||Both|18 Years|70 Years|No|||October 2008|April 18, 2013|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129454||197230|
NCT00129467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-194|Methylphenidate for Depressed Cancer Patients Receiving Palliative Care|Methylphenidate for Depressed Cancer Patients in Hospice||VA Office of Research and Development|Yes|Completed|February 2005|December 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||August 2013|April 6, 2015|August 9, 2005|Yes|Yes||No|October 16, 2013|https://clinicaltrials.gov/show/NCT00129467||197229|Frequency threshold for reporting nonserious adverse events was not determined at the start of the study, but a % was required to be entered in order to complete the adverse event module
NCT00129766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP110|Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children|A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children||MedImmune LLC|Yes|Completed|November 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6635|||Both|N/A|24 Months|No|||June 2013|June 21, 2013|August 10, 2005|Yes|Yes||No|June 21, 2013|https://clinicaltrials.gov/show/NCT00129766||197206|
NCT00125645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF 20040053|Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)|Global Left Ventricular Function After Acute Myocardial Infarction. Treatment With the Angiotensin 2-Receptor Blocker Irbesartan||University of Southern Denmark||Suspended|March 2005|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||April 2007|August 15, 2011|July 29, 2005||No|Study terminated due to lack of patients|No||https://clinicaltrials.gov/show/NCT00125645||197514|
NCT00118196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000433313|Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia|A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes||Medical University of South Carolina|Yes|Completed|April 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|41|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|July 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118196||198070|
NCT00117910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020106|Treatment for Elderly Patients With High Risk Breast Cancer|An Open Label, Randomised, Multicentre Study of Pegfilgrastim in Primary Versus Secondary Prophylaxis of Neutropenia as an Adjunct to Chemotherapy in Elderly Subjects With High Risk Breast Cancer.||Amgen||Completed|October 2002|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|65 Years|N/A|No|||May 2008|May 15, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117910||198090|
NCT00118430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH071268|Stepped Care for Depression and Musculoskeletal Pain|Stepped Care for Affective Disorders and Musculoskeletal Pain||Indiana University|Yes|Completed|September 2004|August 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00118430||198052|
NCT00118677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 116 SALTO|Long-Term Supervised Treatment Interruption in HIV-Infected Patients|Long-Term Supervised Treatment Interruption in HIV-Infected Patients Who Started Antiretroviral Treatment With CD4 Over 350/mm3 and Plasma HIV RNA Below 50 000/mL ANRS 116 Trial SALTO||French National Agency for Research on AIDS and Viral Hepatitis||Completed|February 2003|May 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|18 Years|N/A|No|||August 2007|August 29, 2007|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118677||198034|
NCT00118664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004|Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children|Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children|TAMOF|Children's Healthcare of Atlanta|No|Recruiting|May 2005|||December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|6 Months|18 Years|No|Non-Probability Sample|Pediatric patients admitted to a participating PICU.|May 2009|March 14, 2012|July 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00118664||198035|
NCT00118924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 182|Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of Tick-Borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a Live Attenuated Vaccine for Tick-Borne Encephalitis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2005|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 18, 2008|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118924||198015|
NCT00119197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-8-ph2|Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata|Safety and Immunogenicity of a Killed, Oral Cholera Vaccine in Indian Subjects in Eastern Kolkata, West Bengal||International Vaccine Institute|Yes|Completed|August 2005|July 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|12 Months|40 Years|Accepts Healthy Volunteers|||June 2008|June 26, 2008|July 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00119197||197994|
NCT00119483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eldre menn og testosteron|Older Men and Testosterone|||University Hospital of North Norway||Completed|September 2005|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Male|60 Years|80 Years|No|||September 2011|September 2, 2011|July 5, 2005||||No||https://clinicaltrials.gov/show/NCT00119483||197977|
NCT00119795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197|Exercise and Weight Loss for Improving Mobility in Older Adults Who Are Obese|Cooperative Lifestyle Intervention Program (CLIP)|CLIP|Wake Forest School of Medicine|Yes|Completed|August 2005|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|288|||Both|60 Years|79 Years|No|||November 2011|November 2, 2011|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00119795||197953|
NCT00119821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225|Strategies to Reduce Weight Gain in Hypertensive Smokers|Weight Gain Prevention in Hypertensive Smokers||University of Tennessee|Yes|Completed|September 2004|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|459|||Both|18 Years|N/A|No|||July 2011|November 30, 2015|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00119821||197952|
NCT00120627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 04-041|Mantram Repetition to Manage PTSD in Veterans|Efficacy of Mantram Repetition on PTSD Symptoms in Veterans||VA Office of Research and Development|No|Completed|November 2005|September 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|July 12, 2005||No||No|September 23, 2014|https://clinicaltrials.gov/show/NCT00120627||197891|
NCT00129779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLICX3038|Assessment of the Effects of an Intermediate Care Package in Preventing Hospitalisation of Patients With COPD|A Randomised Control Trial Assessing the Effects of an Intermediate Care Package in Preventing Hospitalisation of Elderly Patients With Chronic Obstructive Pulmonary Disease (COPD)||Imperial College London||Completed|December 2003|August 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||122|||Both|50 Years|90 Years|No|||May 2008|June 4, 2015|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129779||197205|
NCT00125918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10303|PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension|PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension||Eli Lilly and Company|No|Completed|August 2005|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|406|||Both|12 Years|N/A|No|||February 2008|February 13, 2008|August 1, 2005||||No||https://clinicaltrials.gov/show/NCT00125918||197493|
NCT00129480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMI 03-195|Improving Chronic Pain Treatment in Primary Care|Improving the Treatment of Chronic Pain in Primary Care|SEACAP|VA Office of Research and Development|No|Completed|January 2006|July 2010|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||May 2014|April 6, 2015|August 9, 2005||No||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00129480||197228|
NCT00129493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRH 01-173|Group Visits to Improve Hypertension Management|Group Visits to Improve Hypertension Management||VA Office of Research and Development|No|Completed|February 2004|August 2007|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|N/A|No|||May 2009|April 6, 2015|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129493||197227|
NCT00126386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17280|Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community|Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study||AHS Cancer Control Alberta|Yes|Completed|January 2004|September 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2011|November 18, 2011|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126386||197457|
NCT00126646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000438672|BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma|Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas||MedImmune LLC|No|Completed|June 2005|June 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|August 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00126646||197438|
NCT00117000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030320|The Effects of Testosterone and Nutritional Supplementation in the Undernourished Elderly|The Effects of Testosterone and Nutritional Supplementation, Alone and Combined, on the Adverse Effects of Under-Nutrition in the Elderly||University of Adelaide||Active, not recruiting|July 2003|February 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|65 Years|N/A|No|||September 2006|September 7, 2006|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117000||198160|
NCT00117013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050186|A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a|A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha||National Institutes of Health Clinical Center (CC)||Completed|June 2005|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||August 2011|September 26, 2015|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00117013||198159|
NCT00117377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2436|Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis|Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis||Novartis||Completed|April 2004|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||70|||Male|20 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 13, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00117377||198131|
NCT00117390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/101|Evaluation of the Optimal Technique for Determination of Renal Function of Critically Ill Patients|Evaluation of the Optimal Technique for Determination of the Renal Function of Critically Ill Patients||University Hospital, Ghent|No|Completed|June 2004|October 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117390||198130|
NCT00117403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0067|Anti-Oxidant Treatment of Alzheimer's Disease|Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease||National Institute on Aging (NIA)|Yes|Completed|January 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|60 Years|85 Years|No|||April 2008|April 1, 2009|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117403||198129|
NCT00117416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/382|Mean Arterial Pressure (MAP) and Renal Perfusion: Evaluation of Critically Ill Patients With Normal Creatinine or Reduced Renal Function|MAP and Renal Perfusion: Evaluation of Critically Ill Patients With Normal Creatinine or Reduced Renal Function||University Hospital, Ghent|No|Suspended|February 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117416||198128|
NCT00117351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05002|VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features|A Multicenter, Open-Label, Phase 2 Study of VELCADE (Bortezomib) for Injection in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma With Bronchioloalveolar Features||Millennium Pharmaceuticals, Inc.||Terminated|April 2005|July 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2011|February 16, 2011|June 30, 2005|||insufficient efficacy|||https://clinicaltrials.gov/show/NCT00117351||198133|
NCT00117676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0102|A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B|A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B||Gilead Sciences|Yes|Completed|February 2005|January 2016|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|375|||Both|18 Years|69 Years|No|||February 2016|February 4, 2016|June 30, 2005|Yes|Yes||No|February 11, 2010|https://clinicaltrials.gov/show/NCT00117676||198108|
NCT00117663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-03-1-0447|Radiologic Evaluation and Breast Density (READ)|A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of Hormone Replacement Therapy (HRT) on Mammography Assessments and Breast Density||Group Health Cooperative||Recruiting|November 2004|November 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|1500|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 10, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117663||198109|
NCT00117897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010157|Treatment for Subjects With Non-Hodgkin's Lymphoma|An Open-Label, Randomized, Parallel, Phase II Study of CHOP Chemotherapy and Rituximab Administered Every 14 Days, With Pegfilgrastim or Filgrastim Support, for the Treatment of Subjects With Non-Hodgkin's Lymphoma||Amgen||Completed|July 2002|February 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|70 Years|No|||July 2009|July 16, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117897||198091|
NCT00117923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1514-RESI|Study With a Topical Gel to Treat Common Warts in Adults|A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults||Graceway Pharmaceuticals, LLC||Completed|August 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||88|||Both|18 Years|N/A|No|||November 2006|February 16, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00117923||198089|
NCT00118209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50303|Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma|Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|May 2005|||May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|July 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118209||198069|
NCT00118443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071189|Evaluation of a School-Based Training Program for Suicide Prevention|RCT of Gatekeeper Training for Suicide Prevention||University of Rochester||Completed|March 2004|December 2006|Actual|December 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|50000|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 27, 2013|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00118443||198051|
NCT00118690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA100316|A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise|A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With Activity-Induced Bronchospasm||GlaxoSmithKline|No|Completed|December 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|227|||Both|4 Years|17 Years|No|||April 2015|April 15, 2015|July 1, 2005||||||https://clinicaltrials.gov/show/NCT00118690||198033|
NCT00118703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR30007|Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 Years of Age and Older) With Vasomotor Rhinitis||GlaxoSmithKline||Completed|July 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|350|||Both|12 Years|N/A|No|||April 2015|April 14, 2015|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118703||198032|
NCT00118950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReMet|Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet|Effect of Metformin Versus Repaglinide Treatment on Glycemic Control and Non-Glycaemic Cardiovascular Risk Factors in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet||Steno Diabetes Center||Completed|March 2001|March 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4|||100|||Both|40 Years|N/A|No|||December 2008|December 5, 2008|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118950||198013|
NCT00119210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001769|Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women|Bupropion for Smoking Cessation in Postpartum Women||Massachusetts General Hospital||Terminated|March 2005|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||April 2011|April 28, 2011|July 5, 2005||No|We were unable to recruit sufficient numbers of patients and decided that the study protocol    was not feasible to implement|No||https://clinicaltrials.gov/show/NCT00119210||197993|
NCT00119496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES104033|Rosiglitazone Versus Theophylline in Asthmatic Smokers|A Clinical Study to Investigate the Effect of Rosiglitazone, Theophylline and Inhaled Corticosteroid, Inflammation and Pulmonary Function in Asthmatic Smokers||University of Glasgow|No|Completed|July 2005|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|79|||Both|18 Years|60 Years|No|||November 2007|January 26, 2010|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00119496||197976|
NCT00120393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-100|Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir|A Phase IIIB, Open-label, Randomized, Multi-center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r Based Regimen.||Bristol-Myers Squibb||Completed|January 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||July 2009|February 3, 2010|July 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120393||197909|
NCT00120406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-026|Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery|Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery|Zilver PTX|Cook|Yes|Completed|March 2005|February 2014|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|474|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|July 11, 2005|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00120406||197908|
NCT00120120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-RAD-001|Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy|A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy||Celgene|Yes|Completed|January 2005|November 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|July 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120120||197930|
NCT00125931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-001260|Effects of Pentazocine on Manic Symptoms|Inpatient Clinical Trial Examining the Effects of Pentazocine on Manic Symptoms||Mclean Hospital|No|Completed|September 2005|December 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||August 2014|August 25, 2014|August 1, 2005|Yes|Yes||No|October 22, 2012|https://clinicaltrials.gov/show/NCT00125931||197492|Small number of participants in open-label trial.
NCT00126191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-336|Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma|Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma||Dana-Farber Cancer Institute|Yes|Terminated|July 2005|June 2011|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|August 2, 2005|Yes|Yes|closed due to slow accrual|No|November 30, 2012|https://clinicaltrials.gov/show/NCT00126191||197472|Early termination leading to small numbers of subjects analyzed.
NCT00126399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-101-ROSE-301+302|A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea|||CollaGenex Pharmaceuticals||Completed|June 2004|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||528|||Both|18 Years|N/A|No|||August 2005|August 18, 2005|August 2, 2005||||||https://clinicaltrials.gov/show/NCT00126399||197456|
NCT00126412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBG308|Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma|||GE Healthcare||Completed|July 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||185|||Both|N/A|N/A|No|||May 2007|May 15, 2007|August 2, 2005||||||https://clinicaltrials.gov/show/NCT00126412||197455|
NCT00127582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUP02067|RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy|Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1)||Catholic University of the Sacred Heart||Recruiting|January 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||537|||Both|18 Years|70 Years|No|||May 2005|August 24, 2005|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127582||197368|
NCT00127595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMOX|Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract|A Phase II Monocentric Study of Oxaliplatin in Combination With Gemcitabine in Patients With Advanced/Metastatic Transitional Cell Carcinoma of the Urothelial Tract||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|January 2002|April 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||August 2005|August 23, 2005|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00127595||197367|
NCT00117026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AkerU|Effects of Vitamin B1 in Type 1 Diabetic Patients|Can Oral Benfotiamine Supplementation Influence Progression of Microvascular Complications in Patients With Type 1 Diabetes?||Oslo University Hospital||Completed|August 2005|February 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|60 Years|No|||May 2013|May 8, 2013|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00117026||198158|
NCT00117429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARC001|Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)|A Phase I, Randomized, Double-Blind Clinical Trial of the HIV gp120/NefTat/AS02A Vaccine Candidate in Subjects With Well-Controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)||Marcus Altfeld, M.D., Ph.D.||Completed|June 2005|January 2010|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|60 Years|No|||February 2010|February 12, 2010|June 30, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00117429||198127|
NCT00117442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010191|A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood|An Open-Label, Randomised Study of Multi-Cycle, Dose Intensive Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood||Amgen||Completed|August 2002|December 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|61|||Both|18 Years|65 Years|No|||May 2013|May 9, 2013|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117442||198126|
NCT00117689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thymo102700103|Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection|A Randomized, Controlled, Multi-Center Study of Thymoglobulin Induction Therapy With a Calcineurin Inhibitor Sparing Regimen in Liver Transplant Patients||Sanofi||Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|75|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|June 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00117689||198107|
NCT00117936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVBT-CHD07-01|Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease|Human Recombinant Fibroblast Growth Factor-1 (FGF-1) for Intramyocardial Injection for the Treatment of Coronary Heart Disease|ACORD|CardioVascular BioTherapeutics, Inc.|Yes|Active, not recruiting|September 2008|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|25 Years|75 Years|No|||August 2013|November 7, 2014|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117936||198088|
NCT00117949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS06|Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486|An Open-Label, Multi-Center, Ascending, Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486||Ferring Pharmaceuticals|Yes|Completed|April 2002|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Male|18 Years|N/A|No|||May 2011|May 18, 2011|June 30, 2005|Yes|Yes||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00117949||198087|
NCT00118222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU4303|High Light and Low Light Dose PDT in Glioma|A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin]||Case Comprehensive Cancer Center|Yes|Completed|March 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|July 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118222||198068|
NCT00118456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEE788A2101|Study of Oral AEE788 in Adults With Advanced Cancer|A Phase I/II, Multicenter, Randomized Dose-Escalation Study of Oral AEE788 on Intermittent Dosing Schedules in Adult Patients With Advanced Cancer (Effective Amendment 5) Previously Entitled A Phase IA, Multicenter, Dose-Escalating Study of Oral AEE788 on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Cancer||Novartis||Completed|July 2003|||January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|N/A|No|||January 2012|January 5, 2012|July 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118456||198050|
NCT00118469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067893|Parent Psychoeducation and Cognitive Behavior Therapy for Latino Adolescents With Depression|Parent Psychoeducation Intervention in CBT for Depressed Latino Youth||National Institute of Mental Health (NIMH)||Recruiting|July 2004|December 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|||Anticipated|144|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||February 2008|April 1, 2008|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00118469||198049|
NCT00118716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA100314|A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise|A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With Activity-Induced Bronchospasm||GlaxoSmithKline|No|Completed|December 2003|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|255|||Both|4 Years|17 Years|No|||April 2015|April 15, 2015|July 1, 2005||||||https://clinicaltrials.gov/show/NCT00118716||198031|
NCT00118963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reform|Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes|Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents||Steno Diabetes Center||Completed|January 2003|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|40 Years|N/A|No|||December 2008|December 5, 2008|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118963||198012|
NCT00119834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1296|Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)|Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|June 2005|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Observational|Observational Model: Case-Only||1|Anticipated|15000|Samples With DNA|DNA sample collection was an optional portion of the project during the first contract      period (2005-2010). Tissue and Blood specimens were collected at the time of implant,      explant or exchange of the mechanical circulatory assist device. Intermacs no longer      collects blood or tissue specimens.|Both|N/A|N/A|No|Non-Probability Sample|Patients with end-stage heart failure that receive a FDA approved mechanical circulatory        support device.|October 2015|October 12, 2015|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00119834||197951|
NCT00120107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT001899|Tea's Effect on Atherosclerosis Pilot Study (TEA Study)|Tea's Effect on Atherosclerosis Pilot Study (TEA Study)||Beth Israel Deaconess Medical Center||Completed|July 2003|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||30|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2005|November 7, 2005|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00120107||197931|
NCT00119847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221|Balloon Catheters and Stents to Prevent Heart Rhythm Irregularities in Individuals Post-Heart Attack|Electrophysiologic Effects of Late PCI (OAT-EP)||National Heart, Lung, and Blood Institute (NHLBI)||Active, not recruiting|September 2002|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||300|||Both|N/A|N/A|No|||February 2006|February 22, 2006|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119847||197950|
NCT00120133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#04 10-119|Atorvastatin (Lipitor) to Prevent Bone Pain|Use of Atorvastatin (Lipitor) to Prevent Bone Pain Following Infusion of Pamidronate or Zoledronic Acid||Children's Mercy Hospital Kansas City||Completed|December 2004|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|12|||Both|6 Years|25 Years|No|||July 2005|May 19, 2008|July 8, 2005||||No||https://clinicaltrials.gov/show/NCT00120133||197929|
NCT00126230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX-SAMAR|Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer|A Prospective Phase II Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer Who Achieve a Response or a Stabilization to Docetaxel-Estramustine||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|January 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||55|||Male|18 Years|80 Years|No|||September 2006|September 7, 2006|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126230||197469|
NCT00126425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBG311|Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease|An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event||GE Healthcare|Yes|Completed|July 2005|December 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|580|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 2, 2009|August 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00126425||197454|
NCT00126204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00012-0904-02|Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair|Adjunctive Treatment With Doxycycline in Endovascular Aneurysm Repair||Barnes-Jewish Hospital||Completed|March 2004|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|50 Years|N/A|No|||September 2006|March 3, 2010|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126204||197471|
NCT00126217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA4-CT-2002-10053-REVAC|Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine|BCG Vaccination and Childhood Morbidity and Mortality: Interventions With Possible Implications for the Immunisation Policy in Developing Countries. Revaccination of Young Children With BCG Vaccine.||Bandim Health Project||Terminated|July 2002|September 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2871|||Both|19 Months|24 Months||||October 2008|October 20, 2008|August 2, 2005||No|A cluster of deaths in the BCG-arm compared with controls|No||https://clinicaltrials.gov/show/NCT00126217||197470|
NCT00127010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103388|Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases|Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-Mumps-Rubella-Varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life||GlaxoSmithKline||Completed|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|11 Months|13 Months|Accepts Healthy Volunteers|||October 2008|October 9, 2008|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127010||197411|
NCT00127023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104389|Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases|Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life||GlaxoSmithKline||Completed|May 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||944|||Both|11 Months|21 Months|Accepts Healthy Volunteers|||October 2012|November 1, 2012|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127023||197410|
NCT00117065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030139|Study of Transplant Related Anemia Treated With Aranesp® (STRATA)|Study of Transplant Related Anemia Treated With Aranesp® (STRATA)||Amgen||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 24, 2013|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117065||198155|
NCT00117078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020380|Aranesp® Monthly Preference Study - 2|Aranesp® Monthly Preference Study - 2||Amgen||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2008|September 29, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117078||198154|
NCT00117702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30|Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus|Prophylaxis of the Graft-Versus-Host-Disease in Patients After Allogeneic Stem Cell Transplantation With a Combination of Tacrolimus and Everolimus||Technische Universität Dresden|Yes|Terminated|October 2005|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||June 2009|June 17, 2009|June 30, 2005||No|safety reasons|No||https://clinicaltrials.gov/show/NCT00117702||198106|
NCT00117962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB 30407|Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Randomized Phase II Study of Radiation Therapy, Pemetrexed and Carboplatin With or Without Cetuximab in Stage III Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|September 2005|September 2012|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|July 8, 2005|Yes|Yes||No|November 5, 2012|https://clinicaltrials.gov/show/NCT00117962||198086|
NCT00118235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02815|Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer|Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study||National Cancer Institute (NCI)||Completed|December 2004|July 2011|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||December 2012|June 16, 2014|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118235||198067|
NCT00118989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802193|Curcumin for the Chemoprevention of Colorectal Cancer|Phase II Double Blind Placebo-Controlled Trial of Curcuminoids' Effect on Cellular Proliferation, Apoptosis and COX-2 Expression in the Colorectal Mucosa of Subjects With Recently Resected Sporadic Adenomatous Polyps||University of Pennsylvania|No|Completed|July 2005|July 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|December 12, 2014|July 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00118989||198010|
NCT00119236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01467|17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Labeled Non-Randomized Phase I Study of 17-N-allylamino-17-demethoxy Geldanamycin (17AAG) Administered With Irinotecan (CPT-11) in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|May 2005|||October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|July 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00119236||197992|
NCT00118976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mace|Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease|Optimal Dose of ACE Inhibitor for Treatment of Diabetic Nephropathy in Type 1 Diabetic Patients With Hypertension and Diabetic Nephropathy||Steno Diabetes Center||Completed|March 2005|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|70 Years|No|||November 2006|November 22, 2006|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118976||198011|
NCT00119249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02659|Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase II Study of BAY 43-9006 (NSC 724772) in Unresectable Stage III and IV Melanoma (IND 69,869)||National Cancer Institute (NCI)||Completed|June 2005|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|July 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00119249||197991|
NCT00119262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02977|Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer|Phase II Feasibility Trial Incorporating Bevacizumab Into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients With Lymph Node Positive Breast Cancer||National Cancer Institute (NCI)||Completed|October 2005|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||December 2012|April 29, 2014|July 12, 2005|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00119262||197990|
NCT00119522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-003|Epidemiology and Cost of Falls in Veterans With a Spinal Cord Injury|Epidemiology and Cost of Falls in Veterans With Spinal Cord Injury||VA Office of Research and Development|No|Completed|April 2004|March 2008|Actual|March 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|702|||Both|18 Years|N/A|No|Non-Probability Sample|spinal cord injury population|July 2008|April 6, 2015|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00119522||197974|
NCT00119535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIT 02-064|Study to Evaluate the Effectiveness of a Program Developed to Improve Eye Care for Veterans With Diabetes|An Evaluation of a Coordinated Proactive Diabetes Eye Care Program||VA Office of Research and Development|No|Completed|August 2004|December 2005|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2000|||Both|N/A|N/A|No|||April 2006|April 6, 2015|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00119535||197973|
NCT00119873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 054|Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults|A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade, Multivalent Recombinant Adenoviral Vector HIV Vaccine, VRC-HIVADV014-00-VP, in Healthy, HIV-1 Uninfected Adult Participants Who Have Low Titers of Pre-Existing Ad5 Neutralizing Antibodies||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||October 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|48|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|July 12, 2005||||||https://clinicaltrials.gov/show/NCT00119873||197949|
NCT00126737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2920-R|Home-Based Exercise and Weight Control Program for Pain Control in Overweight Elderly With Osteoarthritis of the Knee|Home-Based Exercise and Weight Control Program for Pain Control in Overweight Elderly With Osteoarthritis of the Knee||VA Office of Research and Development|No|Completed|October 2002|December 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|110|||Both|50 Years|N/A|No|||December 2014|December 30, 2014|August 2, 2005||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00126737||197432|Due to the small number of females, the results may not be generalizable to females. Limitations include requirement of having good upper body strength, shoulder range, hand eye coordination, and an investment of purchasing poles of $30 per pair.
NCT00126672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000440080|Sirolimus in Treating Patients With Angiomyolipoma of the Kidney|A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas in TSC or LAM Patients||National Cancer Institute (NCI)||Active, not recruiting|June 2005|||April 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|65 Years|No|||October 2008|February 1, 2010|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126672||197436|
NCT00126685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000435933|Vaccine Therapy in Treating Patients With Stage IV Melanoma|Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With Unselected Autologous Amplified Tumor-RNA||National Cancer Institute (NCI)||Active, not recruiting|April 2005|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2007|September 16, 2013|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00126685||197435|
NCT00126659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02920|Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer|A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Terminated|January 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|No|||December 2012|April 21, 2014|August 2, 2005|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00126659||197437|
NCT00127361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC-1998|Study of Having a Female Friend as Labor Support|Evaluation of Continuous Support in Labor||Saint Peters University Hospital||Completed|January 1998|February 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||April 2005|August 22, 2005|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127361||197384|
NCT00127647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-327|An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)|MK0476 Phase III Double-Blind Comparative Study - Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|November 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1375|||Both|15 Years|64 Years|No|||June 2015|June 9, 2015|August 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00127647||197363|
NCT00127335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-05-001 (MER004241)|Is Myopathy Part of Statin Therapy (IMPOSTER-16)|Double Blind, Prospective Randomized, Crossover Study of Patients With Muscle Complaints on Statin Therapy||Scripps Health|No|Terminated|August 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|21 Years|N/A|No|||July 2011|July 26, 2011|August 4, 2005||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00127335||197386|
NCT00127348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 040165|Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness|Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness||Sociedad Española de Neumología y Cirugía Torácica||Completed|May 2004|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||700|||Both|18 Years|70 Years|No|||April 2006|April 2, 2007|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127348||197385|
NCT00127608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103815|Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients|An Open, Prospective, Non-prophylactic, Non Therapeutic Study for the Detection and Characterisation of Varicella Zoster Virus Collected From Dermal Lesions of Patients Who Are Diagnosed of Having Varicella||GlaxoSmithKline||Completed|June 2005|||July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|16 Years|No|||September 2011|September 29, 2011|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127608||197366|
NCT00117091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020364|Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)|An Open-Label Multicentre Study of Anakinra (Kineret®) in Combination With DMARDS in Subjects With Active Rheumatoid Arthritis (RA)||Amgen||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|December 20, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117091||198153|
NCT00117104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030133|Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis|A Multicenter Study Evaluating Once Weekly Intravenous Administration of Aranesp® in Subjects With End Stage Renal Disease on Chronic Hemodialysis||Amgen||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2009|October 15, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117104||198152|
NCT00117117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020132|A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®|A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®||Amgen||Completed|September 2002|December 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2423|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117117||198151|
NCT00117715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10390|Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body|Developmental Regulation of CYPs 1A2, 2D6, 3A4||Children's Mercy Hospital Kansas City|No|Completed|October 2000|||January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|121|Samples With DNA|Urine DNA (source: blood or saliva)|Both|12 Months|5 Years|Accepts Healthy Volunteers|Probability Sample|Healthy children 12 months of age at study entry. Followed longitudinally until 5 uears of        age.|April 2013|April 29, 2013|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00117715||198105|
NCT00117728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD047177|Pediatric Nevirapine Resistance Study|Clinical Relevance of Nevirapine Resistance||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|April 2005|September 2010|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|250|||Both|N/A|24 Months|No|||January 2006|June 28, 2007|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00117728||198104|
NCT00117975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50402|Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|A Phase II Trial of Extended Induction Galiximab (Anti-CD80 Monoclonal Antibody) (IND #12373) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)||Alliance for Clinical Trials in Oncology|No|Completed|June 2005|August 2013|Actual|June 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00117975||198085|
NCT00118248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00063|Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer|A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma||National Cancer Institute (NCI)||Completed|December 2004|April 2012|Actual|August 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||October 2011|September 18, 2014|July 8, 2005|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT00118248||198066|
NCT00118729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR101816|Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action|Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100 Mcg in Adolescent and Adult Subjects (=12 Years of Age) With Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber||GlaxoSmithKline||Completed|April 2005|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|12 Years|N/A|No|||June 2008|June 9, 2008|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118729||198030|
NCT00118274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430929|Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma|A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma||National Cancer Institute (NCI)||Active, not recruiting|March 2005|||February 2010|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|173|||Both|18 Years|N/A|No|||November 2008|February 6, 2009|July 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118274||198064|
NCT00118742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18423|Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant|A Randomized, Open-label Study of the Effect of a Long-term Calcineurin Inhibitor-free Maintenance Regimen With CellCept and Sirolimus on Preservation of Renal Function and Prevention of Acute Rejection in Recipients of an Orthotropic Liver Transplant||Hoffmann-La Roche||Completed|August 2005|December 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|293|||Both|18 Years|74 Years|No|||July 2010|July 30, 2010|June 30, 2005|Yes|Yes||No|May 13, 2009|https://clinicaltrials.gov/show/NCT00118742||198029|There were no overall limitations and caveats.
NCT00118755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18491|A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer|A Randomized, Open-label Study of the Effect of 2 Different Treatment Schedules of Xeloda With Eloxatin and Avastin on Progression-free Survival in Treatment-naïve Patients With Locally Advanced or Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|July 2005|||April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|435|||Both|18 Years|N/A|No|||February 2011|February 9, 2011|July 1, 2005|Yes|Yes||No|April 25, 2010|https://clinicaltrials.gov/show/NCT00118755||198028|
NCT00119509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211205_IMAP|The IMAP Study Improving Management of Mildly Abnormal Pap Smears|HPV DNA Testing Versus Conventional Management for Women With Minor Atypia on Pap Smear: Psychosocial and Quality of Life Outcomes and Development of a Decision Analytic Model||University of Sydney||Active, not recruiting|January 2004|April 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Female|18 Years|70 Years|No|||April 2007|April 24, 2007|July 11, 2005||||No||https://clinicaltrials.gov/show/NCT00119509||197975|
NCT00119301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-028|Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma|Phase I Study of High Dose Methotrexate With Simultaneous Trimetrexate and Leucovorin in Patients With Recurrent Osteosarcoma||Memorial Sloan Kettering Cancer Center||Completed|April 2005|||April 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|1 Year|35 Years|No|||January 2013|January 15, 2013|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00119301||197989|
NCT00119548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-023|Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling|Improving HIV Screening by Nurse Rapid Testing, Streamlined Counseling||VA Office of Research and Development|No|Completed|March 2005|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|251|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2009|April 6, 2015|July 5, 2005||||No||https://clinicaltrials.gov/show/NCT00119548||197972|
NCT00126464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430705|Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast|A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant (Faslodex) in Breast Ductal Carcinoma (DCIS)||National Cancer Institute (NCI)||Active, not recruiting|November 2004|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|100|||Female|N/A|N/A|No|||July 2006|November 5, 2013|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126464||197451|
NCT00127075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.363|POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis|POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis||Hospices Civils de Lyon|Yes|Active, not recruiting|June 2005|April 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|50 Years|No|||December 2011|December 28, 2011|August 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00127075||197406|
NCT00126698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-01|Prophylactic Antibiotics on Urethral Catheter Withdrawal|Use of Antibiotic Prophylaxis on Urethral Catheter Withdrawal: A Randomized Double-Blind Placebo-Controlled Trial||St. Antonius Hospital||Completed|January 2005|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|N/A|No|||April 2007|April 18, 2007|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126698||197434|
NCT00126724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13G01|Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects|A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists||Targeted Genetics Corporation|Yes|Completed|August 2005|May 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|75 Years|No|||July 2009|July 27, 2009|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126724||197433|
NCT00127036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13449|Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)|A Multicenter Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|October 2003|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||December 2011|November 21, 2013|August 3, 2005|Yes|Yes|drug now on market|No|January 5, 2012|https://clinicaltrials.gov/show/NCT00127036||197409|Study was Terminated early, not Completed. Study Drug now on the market. Due to slow accrual, too few patients who had both clinical and microarray data to perform the proposed analysis. 65 of 92 patients consented were assigned to treatment arms.
NCT00095771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000393829|Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas|A Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|November 2004|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|3 Years|21 Years|No|||April 2011|April 21, 2011|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00095771||199721|
NCT00127660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK67599 (completed)|Effect of Nutrition Labeling on Fast Food Choices|Effect of Nutrition Labeling on Fast Food Choices||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2005|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|4||Actual|605|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00127660||197362|
NCT00127673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066347|Comparison of Two Treatments for Post-Traumatic Stress Disorder|Effectiveness of PTSD Treatment: CBT Versus Sertraline||Case Western Reserve University|Yes|Completed|September 2004|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|65 Years|No|||January 2014|January 31, 2014|August 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00127673||197361|
NCT00128193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-002|Leprosy Skin Test Antigens Trial|Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2002|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|6||Actual|260|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2010|December 4, 2014|August 5, 2005|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00128193||197322|
NCT00117481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-DZL-201|Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain|A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate DR-2001 for the Management of Moderate to Severe Endometriosis-Related Nonmenstrual Pelvic Pain||Teva Pharmaceutical Industries||Completed|June 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|45 Years|No|||May 2014|May 8, 2014|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117481||198123|
NCT00117988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00101|17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma|A Phase II Study of 17-AAG in Patients With Relapsed/Refractory CD30+ Anaplastic Large Cell Lymphoma (ALCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL), and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL)||National Cancer Institute (NCI)||Completed|February 2005|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|16 Years|N/A|No|||February 2013|May 21, 2014|July 8, 2005|Yes|Yes||No|May 5, 2011|https://clinicaltrials.gov/show/NCT00117988||198084|
NCT00118261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2204|Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer|A Phase IB Study in Patients With Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab||Case Comprehensive Cancer Center|Yes|Completed|March 2005|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118261||198065|
NCT00118287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1926.00|Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes|Therapy of Myelodysplastic Syndrome (MDS) With Azacitidine Given in Combination With Etanercept: A Phase I/II Study.||Fred Hutchinson Cancer Research Center|Yes|Completed|April 2005|||October 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118287||198063|
NCT00118482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130312|Clinical Trial for the Prevention of Vasovagal Syncope|A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II)||University of Calgary|Yes|Completed|May 2005|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|14 Years|N/A|No|||December 2013|December 5, 2013|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118482||198048|
NCT00118495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-04|Zestra in Women With Mixed Sexual Dysfunction|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial of the Efficacy and Safety of Zestra(TM) in Women With Mixed Desire/Interest/Arousal/Orgasm Disorders||QualiLife Pharmaceuticals|Yes|Completed|March 2006|March 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|21 Years|65 Years|No|||July 2007|July 4, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00118495||198047|
NCT00118768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-08A-006|A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C|A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C||Merck Sharp & Dohme Corp.||Completed|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||175|||Both|18 Years|65 Years||||February 2009|February 27, 2009|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00118768||198027|
NCT00118781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002|Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia|Randomized, Double-Blind, Placebo-Controlled, Multinational Phase 3 Trial Of Iseganan In Prevention Of Ventilator-Associated Pneumonia||IntraBiotics Pharmaceuticals||Terminated|September 2003|June 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||900|||Both|18 Years|N/A|No|||July 2005|July 11, 2005|July 1, 2005||||||https://clinicaltrials.gov/show/NCT00118781||198026|
NCT00119002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC04298-01-00|The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis|The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis: A Multicenter Randomized Controlled Trial||University of Utah|Yes|Completed|January 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|598|||Both|2 Months|11 Months|No|||January 2008|March 13, 2008|July 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00119002||198009|
NCT00126022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S219.3.116|Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation||Solvay Pharmaceuticals||Completed|December 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2006|January 15, 2015|August 1, 2005||||||https://clinicaltrials.gov/show/NCT00126022||197485|
NCT00126035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-MIG-01|Study With Migraid Device in Acute, Early Treatment of Migraine With Typical Aura|Open, Randomised, Multi-Centre, Cross-Over Study to Investigate the Efficacy of the Migraid Device Compared With No Device Treatment in the Acute, Early Treatment of Migraine With Typical Aura||Profess Medical Consultancy||Completed|February 2004|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||134|||Both|18 Years|65 Years|No|||July 2005|August 16, 2005|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00126035||197484|
NCT00126269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEFCAPI O2|Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary|A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|May 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||192|||Both|18 Years|N/A|No|||September 2006|September 7, 2006|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126269||197466|
NCT00126477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1098.00|Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer|The Quality of Life of Adult Survivors Who Received a Marrow Transplant as a Child||Fred Hutchinson Cancer Research Center||Completed|March 1996|March 2010|Actual|April 2007|Actual|Phase 2|Observational|N/A|||Anticipated|750|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126477||197450|
NCT00095134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004726|Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy|A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2004|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|630|||Both|18 Years|65 Years|No|||December 2011|December 5, 2011|November 1, 2004||||||https://clinicaltrials.gov/show/NCT00095134||199768|
NCT00127049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIP-TG|Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors|A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|December 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||37|||Male|16 Years|N/A|No|||September 2006|September 7, 2006|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00127049||197408|
NCT00095433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF2508g|Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)|An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase I/II rhuFab V2 Study||Genentech, Inc.||Completed|September 2002|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||100|||Both|50 Years|N/A|No|||March 2014|March 25, 2014|November 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095433||199745|
NCT00096096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1893.00|Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation|A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease||Fred Hutchinson Cancer Research Center||Completed|August 2004|||May 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|N/A|65 Years|No|||May 2010|May 12, 2010|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096096||199697|
NCT00096109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03058|Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer|A Phase II Clinical Trial of 17-Allyamino-17-Demethoxygeldanamycin (17-AAG) in Chemotherapy Refractory Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|September 2005|||May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Female|18 Years|N/A|No|||January 2013|January 30, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096109||199696|
NCT00096083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000391827|Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer|A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver||Delcath Systems Inc.||Completed|September 2004|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|16 Years|N/A|No|||October 2013|October 22, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096083||199698|
NCT00128505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-13|An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression|An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features||Corcept Therapeutics|No|Completed|August 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|75 Years|No|||February 2012|February 14, 2012|August 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00128505||197299|
NCT00128531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-04-62|Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer|Efficacy and Safety of a New Leuprolide Acetate 3.75 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients||GP-Pharm||Completed|September 2005|November 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Male|18 Years|N/A|No|||November 2007|November 12, 2007|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128531||197297|
NCT00117494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001451-38|Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)|Randomised Comparative Study of the Efficacy and Safety of Rosuvastatin and Pravastatin in Dyslipidemic Patients Treated With Antiretroviral Agents. Anrs 126||French National Agency for Research on AIDS and Viral Hepatitis||Completed|October 2005|June 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||86|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00117494||198122|
NCT00117741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014997|Evaluation of DBT Compared to Drug Counseling for Opiate Addicts|Evaluation of Dialectical Behavior Therapy (DBT)||University of Washington|Yes|Completed|June 2004|April 2010|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|60 Years|No|||January 2012|January 31, 2012|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00117741||198103|
NCT00118001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO 1900/3-1, HO 1900/3-2|Psychotherapy of Generalized Anxiety Disorder|Worry Exposure Versus Applied Relaxation in the Treatment of Generalized Anxiety Disorder||German Research Foundation||Completed|October 2001|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|70 Years|No|||June 2005|March 31, 2015|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00118001||198083|
NCT00129324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11261-CP-001|HOME Study (Health Outcomes and Measures of the Environment Study)|Neurobehavioral Effects of Prevalent Neurotoxicants in Children: A Cohort Study of the Cincinnati Center for Children's Environmental Health||National Institute of Environmental Health Sciences (NIEHS)|No|Active, not recruiting|March 2003|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|468|||Female|18 Years|N/A|No|||February 2015|March 9, 2016|August 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00129324||197240|
NCT00129597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.349|Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy|Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy||Hospices Civils de Lyon||Active, not recruiting|December 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Female|18 Years|80 Years|No|||March 2007|March 9, 2007|August 10, 2005||||No||https://clinicaltrials.gov/show/NCT00129597||197219|
NCT00118508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0404173|The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)|The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)||University of Pittsburgh|Yes|Completed|May 2003|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|87|||Female|18 Years|N/A|No|||August 2015|August 10, 2015|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118508||198046|
NCT00125476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|235|Effects of Exercise Training on Diastolic Heart Function in Postmenopausal Women|Training and Diastolic Function in Postmenopausal Women||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||215|||Female|45 Years|75 Years|No|||October 2006|October 10, 2006|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125476||197527|
NCT00119015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13875B|The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis|The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis||University of Chicago|No|Terminated|July 2005|January 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|July 1, 2005|Yes|Yes|Difficulty in recruitment|No|December 20, 2012|https://clinicaltrials.gov/show/NCT00119015||198008|Early termination of study due to difficulty recruiting
NCT00126048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-001|Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma|Randomised Controlled Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma||University of Glasgow|Yes|Completed|July 2005|September 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|70 Years|No|||September 2008|March 17, 2010|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126048||197483|
NCT00126282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-0001325|A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder|A Randomized, Double-blind, Placebo-controlled Medication Trial With D-Cycloserine for Individuals With Obsessive-compulsive Disorder Currently Receiving Behavior Therapy||Massachusetts General Hospital|Yes|Completed|December 2003|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||May 2008|July 27, 2009|August 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00126282||197465|
NCT00126750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 03-090|Web-Enhanced Guideline Implementation for Post MI CBOC Patients|MI-Plus: Web-enhanced Guideline Implementation for Post MI CBOC Patients|VA MI Plus|VA Office of Research and Development|No|Completed|September 2003|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|847|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|August 2, 2005||No||No|January 27, 2015|https://clinicaltrials.gov/show/NCT00126750||197431|
NCT00126763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMF-303|Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain|An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Non-Malignant Chronic Pain||ZARS Pharma Inc.|No|Terminated|July 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|75 Years|No|||June 2012|June 4, 2012|August 2, 2005|No|Yes|PK results suggested product did not meet requirement for further development.|No||https://clinicaltrials.gov/show/NCT00126763||197430|
NCT00095147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-043|Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis|A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate||Bristol-Myers Squibb||Completed|February 2005|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|431|||Both|18 Years|75 Years|No|||March 2015|March 4, 2015|November 1, 2004|Yes|Yes||No|October 26, 2010|https://clinicaltrials.gov/show/NCT00095147||199767|
NCT00095160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003LS039|Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors|Phase I, Open Label Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation/De-escalation Study of 852A Administered Intravenously to Subjects With Refractory Solid Organ Tumors||Masonic Cancer Center, University of Minnesota||Completed|October 2003|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||October 2009|October 6, 2009|November 1, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095160||199766|
NCT00095446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-2190|NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes|An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart (NovoLog®) in Subjects With Type 1 and Insulin Requiring Type 2 Diabetes||Novo Nordisk A/S|No|Completed|July 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|513|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|November 4, 2004||||No||https://clinicaltrials.gov/show/NCT00095446||199744|
NCT00095459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050022|BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors|A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis||National Institutes of Health Clinical Center (CC)||Completed|November 2004|July 2012|Actual|November 2005|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||April 2014|October 4, 2014|November 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095459||199743|
NCT00095784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01444|Decitabine in Treating Patients With Myelofibrosis|A Phase II Study of Decitabine in Myelofibrosis||National Cancer Institute (NCI)||Active, not recruiting|September 2004|||July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 9, 2004|Yes|Yes||No|July 9, 2014|https://clinicaltrials.gov/show/NCT00095784||199720|
NCT00096993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC3258g|A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Pertuzumab (rhuMAb 2C4) in Combination With Gemcitabine and the Effect of Tumor-Based HER2 Activation in Subjects With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Genentech, Inc.|No|Completed|January 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|131|||Female|18 Years|N/A|No|||June 2015|June 8, 2015|November 17, 2004|No|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT00096993||199631|
NCT00097006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1243|Retrovirus Epidemiology Donor Study-II (REDS-II)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2004|September 2009|Actual|September 2009|Actual|N/A|Observational|N/A|||||||Both|N/A|100 Years|No|||September 2009|November 9, 2015|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097006||199630|
NCT00097019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2949g|A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed|A Multicenter, Single-Arm, Phase II Trial of Bevacizumab in Subjects With Platinum-Resistant Epithelial Carcinoma of the Ovary or Primary Peritoneal Carcinoma for Whom Subsequent Doxil or Topotecan Therapy Has Failed||Genentech, Inc.||Completed|February 2005|May 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||53|||Female|18 Years|N/A|No|||March 2014|March 12, 2014|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097019||199629|
NCT00096382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040288|Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma Using a Transplant of Autologous Lymphocytes Reactive With Tumor Following a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy, Total Body Irradiation and Reconstitution With CD34+ Cells||National Institutes of Health Clinical Center (CC)|No|Completed|September 2004|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|November 9, 2004|Yes|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00096382||199676|
NCT00096668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-8184-1074|Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer|A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(R) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) as Initial Treatment of Patients With Metastatic Breast Cancer||OncoGenex Technologies||Completed|October 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|N/A|No|||June 2009|June 2, 2009|November 12, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096668||199655|
NCT00128492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-AI-006|Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)|A Phase 3, Open-label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3)|AIR-CF3|Gilead Sciences|Yes|Completed|August 2005|January 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|274|||Both|6 Years|N/A|No|||May 2011|May 17, 2011|August 8, 2005|Yes|Yes||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00128492||197300|Descriptive statistics for all participants receiving 1 or more doses of AZLI were summarized for the safety, microbiology, and efficacy endpoints. No formal hypothesis tests were planned. Rates of AEs and SAEs are not adjusted for time on study.
NCT00117754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFO327C2302|Terbinafine Compared to Griseofulvin in Children With Tinea Capitis|Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis||Novartis||Completed|July 2004|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||720|||Both|4 Years|12 Years|No|||August 2006|February 20, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00117754||198102|
NCT00118014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-003152|Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania|Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania||Massachusetts General Hospital|No|Completed|January 2000|August 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|65 Years|No|||May 2008|May 19, 2008|July 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00118014||198082|
NCT00129337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0401|Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies|A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients With Refractory Advanced Solid Tumor Malignancies||Peregrine Pharmaceuticals|No|Completed|June 2005|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|28|||Both|18 Years|N/A|No|||February 2011|February 28, 2011|August 10, 2005|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00129337||197239|
NCT00129350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-069|Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation|An Assessment of Patient Outcomes Following a Rehabilitation Programme for Patients Who Have Received Lung or Heart-Lung Transplant - a Randomised Controlled Trial||Royal Brompton & Harefield NHS Foundation Trust||Recruiting|September 2004|February 2008||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||August 2005|September 6, 2005|August 10, 2005||||No||https://clinicaltrials.gov/show/NCT00129350||197238|
NCT00129610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.307|Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia|A Comparative Controlled Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia||Hospices Civils de Lyon||Active, not recruiting|January 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||90|||Both|18 Years|60 Years|No|||April 2007|April 26, 2007|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129610||197218|
NCT00129623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA18492|A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia|Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia||Hoffmann-La Roche||Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Female|45 Years|60 Years|No|||December 2015|December 5, 2015|August 11, 2005|Yes|Yes||No|December 5, 2015|https://clinicaltrials.gov/show/NCT00129623||197217|
NCT00125502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-038|Recombinant CMV gB Vaccine in Postpartum Women|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Recombinant CMV gB Vaccine in Postpartum Women||University of Alabama at Birmingham|Yes|Completed|August 1999|January 2010|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|464|||Female|14 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 16, 2011|July 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125502||197525|
NCT00125749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #005-065-02|Vaccination of Patients With Stage IV Melanoma With Dendritic Cells|Vaccination of Patients With Stage IV Melanoma With Dendritic Cells Generated Ex Vivo From Monocytes and Loaded With Heat Treated Killed Allogeneic Melanoma Cells||Baylor Research Institute|No|Completed|July 2005|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|75 Years|No|||September 2013|September 20, 2013|August 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125749||197506|
NCT00125723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030218|FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy|A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy||Amgen||Completed|May 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2252|||Both|18 Years|N/A|No|||December 2010|December 22, 2010|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125723||197508|
NCT00125736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0671-J081-291|A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium|A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium||Eisai Inc.||Completed|August 2005|||September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||520|||Both|20 Years|N/A|No|||January 2010|January 28, 2010|July 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00125736||197507|
NCT00126295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002000023|Evaluation of an Individualised Written Education Package for Stroke Patients|Evaluation of a Computer-Generated Individualised Written Education Package for Patients Following Stroke and Their Carers||Medical Benefits Fund of Australia||Completed|June 2003|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||130|||Both|N/A|N/A|No|||August 2005|August 18, 2005|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126295||197464|
NCT00127127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-029|A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Solid Tumors (0683-029)(COMPLETED)|A Phase I Clinical Study of MK0683 in Patients With Solid Tumors.||Merck Sharp & Dohme Corp.||Completed|June 2005|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|75 Years|No|||February 2015|February 2, 2015|August 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00127127||197402|
NCT00126490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02663|Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|Phase 2 Trial of Sequential Bevacizumab Then Subcutaneous Interleukin-2 in Metastatic Renal Cancer||National Cancer Institute (NCI)||Completed|March 2005|August 2013|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2013|June 3, 2015|August 2, 2005|Yes|Yes||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00126490||197449|Investigators planned to have 38 participants treated on this study. "0" had to be entered for Other (not including Serious) Adverse Events, because they were not tabulated for treatment 3/30/05 through 1/24/07.
NCT00127400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11487A|A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED|A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With Intermittent Explosive Disorder||University of Chicago||Completed|February 2002|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|21 Years|55 Years|No|||September 2013|September 4, 2013|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00127400||197381|
NCT00127413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3322-R|Integrated Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)|Integrated Treatment for Chronic Pain and PTSD||VA Office of Research and Development|No|Completed|September 2004|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|42|||Both|N/A|N/A|No|||March 2015|March 23, 2015|August 3, 2005||No||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00127413||197380|Failure to engage in treatment, failure to complete treatment in a timely manner due to missed treatment sessions, and difficulty with compliance with treatment session recommendations led to lower completion rates
NCT00127439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4024-I|Effects of Robotic Versus Manually-Assisted Locomotor Training for Individuals With Incomplete Spinal Cord Injury|Differential Effects of Robotic vs. Manually-Assisted Locomotor Training|DE|VA Office of Research and Development|No|Completed|June 2005|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00127439||197379|
NCT00127725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/023|Pulsed Electromagnetic Field (PEMF) Stimulation for Tibia Fractures|A Double Blind Randomised Controlled Trial of Pulsed Electromagnetic Field (PEMF) Stimulation in Acute Tibial Shaft Fractures||Sydney South West Area Health Service||Recruiting|August 2005|August 2009||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||340|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|November 14, 2005|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00127725||197357|
NCT00096395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03057|Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer|A Phase 2 Study of BAY 43-9006 in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Completed|September 2004|||February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||May 2013|June 11, 2013|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096395||199675|
NCT00096681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA-SA Project 3A|Prevalence of HIV and Tuberculosis in Masiphumelele Township, Cape Town, South Africa|Protocol for Cross-Sectional Survey of Acid-Fast Bacilli (AFB) Smear Positive and/or Culture Positive Tuberculosis in the Masiphumelele Township||CIPRA SA|No|Completed|February 2005|February 2006|Actual|August 2005|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|762|Samples With DNA|Sputum samples|Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Residents of the Masiphumelele township of Cape Town, South Africa|February 2011|February 17, 2011|November 12, 2004||No||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00096681||199654|
NCT00096694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5205|Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women|A Pilot Study Evaluating the Effect of the Levonorgestrel-Releasing Intrauterine Device on Genital HIV Shedding in HIV-1-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2005|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||41|||Female|18 Years|N/A|No|||May 2012|May 17, 2012|November 12, 2004||||||https://clinicaltrials.gov/show/NCT00096694||199653|
NCT00097435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinical Protocol ALFR-HC-05|A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C|A Multi-Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C||Human Genome Sciences Inc.||Completed|October 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|115|||Both|18 Years|65 Years|No|||August 2013|August 1, 2013|November 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097435||199599|
NCT00128206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-135|Treatment of Latent TB Infection for Jailed Persons|Clinical Trial of Short Course Rifampin Versus INH for LTBI in Jail||University of California, San Francisco|Yes|Completed|November 2004|September 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|August 5, 2005||No||No|September 21, 2010|https://clinicaltrials.gov/show/NCT00128206||197321|Initial enrollment estimates were not met, from lower TB rates, increased deportation rates and fewer Jail personnel for LTBI testing. The complexity of treatment in the jail led to technical problems in the analytic plan.
NCT00128830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002731|A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study|An Open-Label Trial With TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks||Tibotec Pharmaceuticals, Ireland|No|Completed|June 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|211|||Both|N/A|N/A|No|||June 2013|June 10, 2013|August 8, 2005|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00128830||197277|
NCT00128843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2001-03|Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients|Phase II Randomized, Multicenter, Crossover Clinical Trial for Administration of Exemestane vs. Anastrozole as First Line Treatment for Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer||Spanish Breast Cancer Research Group||Completed|August 2001|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|18 Years|90 Years|No|||September 2008|September 23, 2008|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128843||197276|
NCT00128856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2002-01|Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients|Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-Doxorubicin-Paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer||Spanish Breast Cancer Research Group||Completed|December 2002|August 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Female|18 Years|75 Years|No|||August 2005|August 29, 2005|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128856||197275|
NCT00128817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/196/2004|Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers|Phase III Randomized Clinical Trial to Compare Results of Concurrent Chemo-radiation With Surgery and Postoperative Radiotherapy/Chemoradiotherapy in Advanced Laryngeal and Hypopharyngeal Cancers||Tata Memorial Hospital|Yes|Terminated|May 2005|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2013|January 21, 2013|August 9, 2005||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00128817||197278|
NCT00128804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOVITA-2004-03-19-NZO|The STOVITA Study - Bioefficacy of Beta-Carotene in Oil and in a Mixed Diet in Ileostomy Patients|Bioefficacy and Bioavailability of Beta-Carotene in Oil and in a Mixed Diet in Ileostomy Patients Measuring Using Specifically 13C-Labelled Beta-Carotene and Retinol||Radboud University||Completed|July 2004|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2005|August 26, 2005|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128804||197279|
NCT00129064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000710|Improving the Outpatient Referral Process With Electronic Communications|Improving the Outpatient Referral Process With Electronic Communications||Brigham and Women's Hospital|Yes|Completed|November 2005|March 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||200|||Both|18 Years|N/A|No|||April 2007|April 23, 2007|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129064||197259|
NCT00129363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB 105517-396|Study to Evaluate the Safety of Twice Daily Oral Carvedilol|A Multicenter, Open Label Extension Study to Evaluate the Safety of Twice Daily Oral Carvedilol in Pediatric Patients With Chronic Heart Failure||Shaddy, Robert, M.D.||Completed|January 2002|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|N/A|17 Years||||December 2008|December 24, 2008|August 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00129363||197237|
NCT00129636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLICX3762|The Usefulness of Patients Receiving Their Own Letter After an Outpatient Attendance|A Study to Determine the Usefulness of Patients Receiving Their Own Letter After an Outpatient Attendance Compared to Receiving a Copy of the Letter Being Sent to Their General Practitioner||Imperial College London||Completed|March 2004|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||150|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2005|October 21, 2015|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129636||197216|
NCT00125489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0012|CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi|Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2005|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||210|||Both|6 Months|12 Years|No|||March 2007|August 26, 2010|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125489||197526|
NCT00125775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.134|Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?|Phase 4 Study of Recombinant Hepatitis B Vaccine in Peritoneal Dialysis Subjects||Chinese University of Hong Kong|No|Completed|May 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|N/A|No|||July 2009|January 6, 2010|August 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00125775||197504|
NCT00125788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10478|L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia|A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia||Emmaus Medical, Inc.|No|Completed|March 2004|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|5 Years|N/A|No|||November 2011|March 15, 2013|August 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125788||197503|
NCT00125762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004p-000251|FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy|Comparison of FibroScan With Histological Evaluations of Liver Fibrosis in Patients With Hepatitis B and C Presenting for Liver Biopsy||Beth Israel Deaconess Medical Center||Recruiting|March 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Both|18 Years|N/A|No|||July 2005|August 12, 2005|August 1, 2005||||||https://clinicaltrials.gov/show/NCT00125762||197505|
NCT00127140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-030|A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)|A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma||Merck Sharp & Dohme Corp.|No|Completed|June 2005|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|75 Years|No|||September 2015|September 25, 2015|August 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00127140||197401|
NCT00126516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-Ken-52|Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline|Effects of Angiotensin II Receptor Blockers (ARB) and Angiotensin Converting Enzyme Inhibitors (ACEI) on Progression of Silent Brain Infarction and Cognitive Decline in Japanese Patients With Essential Hypertension in the Elderly||Nara Medical University|Yes|Completed|May 2004|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|395|||Both|65 Years|N/A|No|||October 2013|October 28, 2013|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00126516||197447|
NCT00126802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-06-0052/ethics 21781|The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer|The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prostate Cancer||AHS Cancer Control Alberta|No|Active, not recruiting|April 2005|March 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|N/A|75 Years|No|||June 2014|June 4, 2014|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00126802||197427|
NCT00126815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-15-0002|Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy|Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy||AHS Cancer Control Alberta|Yes|Completed|February 2004|April 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1000|||Male|N/A|N/A|No|Non-Probability Sample|primary care clinic|December 2011|February 23, 2016|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00126815||197426|
NCT00127153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110-013|A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)|A Comparative Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of V110 Formulated With Either All New Process Polysaccharides or All Current Process Polysaccharides||Merck Sharp & Dohme Corp.||Completed|March 2005|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00127153||197400|
NCT00127166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-911|Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)|A Multicenter, Double-Blind, Randomized, Crossover Design Study to Evaluate the Effect of Montelukast Vs. Salmeterol on the Inhibition of Exercise-Induced Bronchoconstriction in Asthmatic Patients Aged 6-14 Years||Merck Sharp & Dohme Corp.|No|Completed|December 2005|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|154|||Both|6 Years|14 Years|No|||August 2015|August 24, 2015|June 30, 2005|Yes|Yes||No|June 16, 2009|https://clinicaltrials.gov/show/NCT00127166||197399|
NCT00127179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-140|A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)|MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia||Merck Sharp & Dohme Corp.||Completed|January 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|600|||Male|50 Years|79 Years|No|||October 2015|October 14, 2015|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00127179||197398|
NCT00096408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACE001|Laparoscopic Approach to Cancer of the Endometrium|LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial||Queensland Centre for Gynaecological Cancer|Yes|Active, not recruiting|October 2005|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|November 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00096408||199674|
NCT00092573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-036 Extension|Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)|Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|April 2003|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|576|||Both|18 Years|75 Years|No|||February 2015|February 17, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092573||199953|
NCT00097448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC006296|Sudden Deafness Treatment Trial|Sudden Hearing Loss Multicenter Treatment Trial|SSNHL|Massachusetts Eye and Ear Infirmary|Yes|Completed|December 2004|March 2011|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|November 23, 2004|Yes|Yes||No|November 8, 2012|https://clinicaltrials.gov/show/NCT00097448||199598|
NCT00128232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995B2401|Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients|Safety and Efficacy of Octreotide LAR in Treatment Naïve Acromegalic Patients||Novartis||Completed|December 2002|||August 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|80 Years||||April 2012|April 27, 2012|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128232||197319|
NCT00128518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.340|IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs|IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs||Hospices Civils de Lyon||Completed|October 2004|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|139|||Both|25 Years|60 Years|No|||December 2011|December 29, 2011|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00128518||197298|
NCT00128557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.03.01.09.A2|Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh|A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh||Johns Hopkins Bloomberg School of Public Health|Yes|Terminated|January 2004|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||25000|||Both|N/A|30 Days|Accepts Healthy Volunteers|||April 2007|April 9, 2007|August 9, 2005|||Study terminated based on DSMB recommendation in December 2006|No||https://clinicaltrials.gov/show/NCT00128557||197295|
NCT00129090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL 2002-1|Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma|A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL||German High-Grade Non-Hodgkin's Lymphoma Study Group|Yes|Active, not recruiting|March 2003|October 2017|Anticipated|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|450|||Both|18 Years|60 Years|No|||September 2015|September 8, 2015|August 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00129090||197257|
NCT00129077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-12005|Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?|Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|March 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|207|||Both|N/A|17 Years|No|||July 2007|July 9, 2007|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129077||197258|
NCT00129376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2002-03|Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients|Multicenter Phase II Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel (T) as Neoadjuvant Treatment for Operable Stage II and IIIA Breast Cancer Patients||Spanish Breast Cancer Research Group||Completed|December 2002|July 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||63|||Female|18 Years|70 Years|No|||August 2005|September 7, 2005|August 10, 2005||||No||https://clinicaltrials.gov/show/NCT00129376||197236|
NCT00129649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLICX3806|Service Development: Assessing Non-attendance Rates in Outpatient Clinics|Service Development: Assessing Non-attendance Rates in Outpatient Clinics||Imperial College London||Completed|May 2005|May 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2005|October 21, 2015|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129649||197215|
NCT00125528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1159|D-cycloserine in the Management of Chronic Low Back Pain|D-Cycloserine in the Management of Chronic Low Back Pain: A Double-Blind, Randomized, Placebo-Controlled Pilot Study||Northwestern University|No|Completed|July 2012|November 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||February 2015|February 14, 2016|July 29, 2005|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT00125528||197523|It is not clear whether observed effects are due to escalating dose or duration of D-cycloserine use. A larger population and longer duration of treatment would be needed to determine this.
NCT00125801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC 02-115|The Pain Pen for Breakthrough Cancer Pain|Breakthrough Cancer Pain: A Randomized Trial Comparing Oral Morphine Immediate Release and Self-Administration of Subcutaneous Hydromorphone Using an Injection Pen||Erasmus Medical Center|Yes|Terminated|August 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2008|October 13, 2008|August 1, 2005||No|Lack of patients|No||https://clinicaltrials.gov/show/NCT00125801||197502|
NCT00125515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4847/R01-15822|Memantine and Naltrexone Treatment for Opioid Dependence|Evaluation of NMDA Antagonist for Opiate Dependence|NAMHS-1|New York State Psychiatric Institute|Yes|Completed|June 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|60 Years|No|||January 2013|January 28, 2013|July 28, 2005|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00125515||197524|It is possible that concomitant naltrexone might have exacerbated protracted withdrawal, thus masking the potential ameliorative effects of memantine that have been previously observed in other trials.
NCT00126503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00066|Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer|A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer||National Cancer Institute (NCI)||Completed|May 2005|February 2012|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||September 2014|January 6, 2015|August 2, 2005|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00126503||197448|To depict results of this Phases I/II study accurately, each phase was entered as an ARM to enable separation of the data by phase. Events reported in the Adverse Event and Serious Adverse Event sections include AEs and SAEs from Phase I and Phase II
NCT00126776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISN 23 PC-SI 0401|Veterans Integrated Service Network (VISN) 23 Lung Disease Self Management/Case Management Program|VISN 23 Lung Disease Self Management/Case Management Program||VA Office of Research and Development|Yes|Completed|July 2004|July 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|743|||Both|N/A|N/A|No|||July 2009|July 14, 2009|August 3, 2005||No||No|July 14, 2009|https://clinicaltrials.gov/show/NCT00126776||197429|
NCT00126061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S219.3.117|Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter||Solvay Pharmaceuticals||Completed|October 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||March 2006|January 15, 2015|August 1, 2005||||||https://clinicaltrials.gov/show/NCT00126061||197482|
NCT00126074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S219.3.118|Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation or Flutter||Solvay Pharmaceuticals||Completed|October 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||March 2006|January 15, 2015|August 1, 2005||||||https://clinicaltrials.gov/show/NCT00126074||197481|
NCT00126828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-11-0031 / 17141|Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer|A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer||AHS Cancer Control Alberta||Completed|January 2003|October 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||October 2011|February 23, 2016|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00126828||197425|
NCT00127192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-044|A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)|Sitagliptin (MK0431) Late Phase II Double-Blind Dose-Response Study - Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|July 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|363|||Both|20 Years|75 Years|No|||May 2015|May 20, 2015|August 3, 2005|Yes|Yes||No|August 18, 2009|https://clinicaltrials.gov/show/NCT00127192||197397|
NCT00127205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000437061|S0307 Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer|Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|July 2005|May 2020|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|5400|||Female|18 Years|N/A|No|||May 2015|May 8, 2015|August 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00127205||197396|
NCT00127465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESRC-L328253025|Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants|Investigating the Impact of Tailored Reports on Anxiety||University of Plymouth||Completed|November 2001|July 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label||||400|||Both|18 Years|N/A|No|||August 2005|December 10, 2008|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127465||197377|
NCT00127478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-304|A Long Term Safety Study With Atrasentan|A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan||Abbott||Completed|July 2001|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Male|18 Years|N/A|No|||November 2007|November 28, 2007|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127478||197376|
NCT00096122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02862|Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia|PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS||National Cancer Institute (NCI)||Completed|September 2004|February 2010|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|15 Years|70 Years|No|||June 2013|May 9, 2014|November 9, 2004|No|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00096122||199695|
NCT00096135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL02P2|Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes|Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months)||Children's Oncology Group|Yes|Active, not recruiting|November 2004|||September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|18 Months|29 Years|No|||July 2015|February 9, 2016|November 9, 2004||No||No|July 10, 2015|https://clinicaltrials.gov/show/NCT00096135||199694|The COG SDC reviewed the NLM notification related to ct.gov AE/SAE reporting. The information in ‘Additional Description’ is accurate with respect to data supplied to ct.gov.COG plans to submit data AE/SAE data consistent with the text in this field.
NCT00096148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02627|Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia||National Cancer Institute (NCI)||Terminated|October 2004|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|N/A|59 Years|No|||January 2013|January 23, 2013|November 9, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00096148||199693|
NCT00097058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0063|Estrogen Use in Protection From Cognitive Decline|Estrogen Use in Protection From Cognitive Decline||Stanford University|Yes|Completed|August 2003|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|71|Samples With DNA|whole blood serum urine|Female|45 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women between the ages of 45 and 65 years of age, currently on estrogen therapy for 1 year        prior to enrollment in study, and at risk for cognitive decline.|November 2014|November 17, 2014|November 17, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097058||199626|
NCT00092612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-802|Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.||Merck Sharp & Dohme Corp.||Completed|May 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|372|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092612||199950|
NCT00092651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-038|A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|September 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1398|||Both|18 Years|80 Years|No|||October 2015|October 20, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092651||199947|
NCT00092664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-038 Extension|An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|January 2003|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1104|||Both|18 Years|80 Years|No|||February 2015|February 17, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092664||199946|
NCT00128284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102204|A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time|A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time||The SmartPill Corporation|No|Completed|February 2005|October 2005|Actual|October 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|148|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with gastroparesis referred to a tertiary motility center|May 2008|May 21, 2008|August 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00128284||197315|
NCT00128570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441158|An Individualized Internet-Based Health Behavior Program or a Standard Internet-Based Health Behavior Program in Preventing Cancer and Improving Physical Activity and Nutrition in Participants Who Are Physically Inactive With a Higher Body Mass Index|Cancer Prevention Mastery Model Internet Intervention||National Cancer Institute (NCI)||Completed|April 2006|March 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|300|||Both|18 Years|63 Years|No|||June 2009|September 16, 2013|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128570||197294|
NCT00100737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL2NHL006|Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin’s Lymphoma (NHL)|A Phase 2 Randomized, Open-Label, Controlled Trial of the Addition of 8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab in the Treatment of Rituximab Naïve Subjects With Follicular Non-Hodgkin’s Lymphoma, Refractory or Relapsed After Previous Chemotherapy||Chiron Corporation||Terminated||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||February 2006|February 2, 2006|January 6, 2005||||||https://clinicaltrials.gov/show/NCT00100737||199359|
NCT00101010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000407533|Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma|A Phase II Study Of Rituximab-CHOP With Pegylated Liposomal Doxorubicin In Patients Older Than 60 Years Of Age With Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Completed|September 2005|||September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|61 Years|N/A|No|||September 2014|September 10, 2014|January 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101010||199339|
NCT00101270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01819|Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas|A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas||National Cancer Institute (NCI)||Completed|March 2005|||September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|1 Year|21 Years|No|||June 2013|June 4, 2013|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101270||199322|
NCT00101582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020402|Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer|Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT)||Swedish Orphan Biovitrum|Yes|Active, not recruiting|August 2005|December 2015|Anticipated|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|January 12, 2005|Yes|Yes||No|January 3, 2014|https://clinicaltrials.gov/show/NCT00101582||199300|
NCT00101868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HS015084-01|Value of Technology to Transfer Discharge Information|Value of Technology to Transfer Discharge Information||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|December 2004|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|631|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|January 14, 2005||No||No|March 18, 2012|https://clinicaltrials.gov/show/NCT00101868||199278|Required medication reconciliation in both groups might have reduced the adverse event rates in both groups.
NCT00102284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-NEUROMOD_01, Stage Ia|Neuromodulation and Language Acquisition (Project Stage Ia)|Improved Language Acquisition Through Neuromodulation, Project Stage Ia||University Hospital Muenster||Terminated|March 2004|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||September 2006|January 26, 2010|January 26, 2005||||No||https://clinicaltrials.gov/show/NCT00102284||199246|
NCT00102297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-MC3019-003|Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus|A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus||FibroGen||Completed|January 2005|June 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|21 Years|80 Years|No|||December 2007|December 10, 2007|January 26, 2005||||No||https://clinicaltrials.gov/show/NCT00102297||199245|
NCT00102583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050002|Cyclosporine Implant for Ocular Graft-Versus-Host Disease|A Phase I Clinical Trial to Study the Safety of a Sustained-Release Subconjunctival Cyclosporine Implant for Ocular Graft-vs-Host Disease (GVHD1)||National Institutes of Health Clinical Center (CC)||Completed|October 2004|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|1||Actual|4|||Both|9 Years|N/A|No|||March 2011|September 26, 2015|January 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00102583||199223|
NCT00097773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169|Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis|Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis|EPIC|Seattle Children's Hospital|Yes|Completed|September 2004|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|304|||Both|1 Year|12 Years|No|||January 2014|January 28, 2014|November 30, 2004|Yes|Yes||No|June 11, 2013|https://clinicaltrials.gov/show/NCT00097773||199573|
NCT00097786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDJN608B2302|Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications|A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)|Navigator|Novartis|Yes|Completed|January 2002|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|9306|||Both|50 Years|N/A|No|||June 2011|June 27, 2011|November 30, 2004|Yes|Yes||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00097786||199572|
NCT00097799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.70|Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection|An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)||Boehringer Ingelheim||No longer available|December 2004|||August 2005|Actual|N/A|Expanded Access|N/A|||||||||||||October 2013|October 30, 2013|November 30, 2004||||No||https://clinicaltrials.gov/show/NCT00097799||199571|
NCT00098202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 06|Randomized Placebo-Controlled Trial (RPCT) of Maize/Zinc in Guatemala|Randomized Placebo-Controlled Trial (RPCT) of Maize/Zinc in Guatemala||NICHD Global Network for Women's and Children's Health|Yes|Completed|March 2003|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|420|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 3, 2004||||No||https://clinicaltrials.gov/show/NCT00098202||199542|
NCT00098215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD40683-1|Pediatric Residency Training On Tobacco|Pediatric Residency Training on Tobacco||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|March 2001|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||4000|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|November 9, 2005|December 3, 2004||||No||https://clinicaltrials.gov/show/NCT00098215||199541|
NCT00098241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AB351|Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients|Multicenter Trial of the Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients||Novartis||Completed|June 2000|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|N/A|16 Years|No|||June 2011|June 15, 2011|December 3, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00098241||199539|
NCT00127751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|373765|Heart Disease on the Mend|A Cardiovascular Disease Multifactor Risk Reduction Program for Medically Underserved High-Risk Patients||Stanford University||Completed|May 2000|May 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|35 Years|N/A|No|||August 2005|August 24, 2005|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00127751||197355|
NCT00127777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17002|Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)|Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection||University Hospital, Saarland||Active, not recruiting|July 2002|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||700|||Both|18 Years|70 Years|No|||August 2005|August 24, 2005|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127777||197353|
NCT00128661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441189|Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants|A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.||GlaxoSmithKline||Completed|June 2004|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|7466|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||May 2012|May 24, 2012|August 8, 2005|Yes|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT00128661||197289|The following analysis "occurence of histopathologically confirmed CIN2+ cases associated with HPV16 or HPV18 infection was not performed, in accordance with the Statistical Analysis Plan submitted to the FDA.
NCT00128687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240|Improving Coronary Prevention in a County Health System|Improving Coronary Prevention in a County Health System||Stanford University|Yes|Completed|April 2003|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|419|||Both|35 Years|85 Years|No|||February 2014|February 7, 2014|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128687||197288|
NCT00128934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A4-316|Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2005|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|744|||Female|18 Years|49 Years|No|||December 2007|December 18, 2007|August 8, 2005||||||https://clinicaltrials.gov/show/NCT00128934||197269|
NCT00098826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03127|SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes|Phase I and Pharmacodynamic Study of SB-715992 in Acute Leukemias||National Cancer Institute (NCI)||Completed|December 2004|||May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|December 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098826||199500|
NCT00099112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000357437|Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II|Transcriptional Profiling of the Epidermal Response to Solar-Simulated Ultraviolet Radiation||National Cancer Institute (NCI)||Completed|February 2004|||||N/A|Observational|N/A|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2005|April 29, 2015|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00099112||199482|
NCT00099125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0420|Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Study Of Radiation Therapy Plus Low Dose Temozolomide Followed By Temozolomide Plus Irinotecan For Glioblastoma Multiforme||Radiation Therapy Oncology Group|Yes|Completed|November 2004|November 2013|Actual|October 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|December 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099125||199481|
NCT00099489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-870|Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)||Biogen||Completed|February 2004|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||67|||Both|18 Years|75 Years|No|||March 2010|March 4, 2010|December 15, 2004||||||https://clinicaltrials.gov/show/NCT00099489||199454|
NCT00100139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEP-ETU-102A|Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer|A Randomized Two-Period Crossover, Clinical Bioequivalence Study Comparing the Pharmacokinetics of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation Versus Taxol® in Patients With Advanced Cancer||INSYS Therapeutics Inc||Completed|November 2004|June 2010|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|December 23, 2004||||||https://clinicaltrials.gov/show/NCT00100139||199405|
NCT00100152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0752-013|A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)|A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma||Merck Sharp & Dohme Corp.||Terminated|February 2005|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|12 Months|N/A|No|||May 2015|May 25, 2015|December 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100152||199404|
NCT00100750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00114|Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer|Gemcitabine and R115777 Combination Therapy for Metastatic Breast Cancer||National Cancer Institute (NCI)|Yes|Completed|September 2005|January 2010|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||October 2014|January 12, 2015|January 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00100750||199358|
NCT00100776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8333|Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder|Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder||Eli Lilly and Company||Completed|September 2003|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|60 Years|No|||January 2007|January 24, 2007|January 6, 2005||||||https://clinicaltrials.gov/show/NCT00100776||199357|
NCT00101036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03065|Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery|A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers||National Cancer Institute (NCI)||Completed|November 2004|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||October 2013|December 18, 2014|January 7, 2005|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT00101036||199338|
NCT00101283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000401795|Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma|Pemetrexed Plus Gemcitabine Or Carboplatin In Patients With Advanced Malignant Mesothelioma: A Randomized Phase II Trial||Eastern Cooperative Oncology Group|No|Completed|November 2005|May 2011|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|January 7, 2005|Yes|Yes||No|February 12, 2010|https://clinicaltrials.gov/show/NCT00101283||199321|
NCT00101595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-015|Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate||Bristol-Myers Squibb|No|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|January 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101595||199299|
NCT00101608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA183-001|Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium|A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium||Bristol-Myers Squibb|No|Completed|January 2005|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2008|February 27, 2010|January 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101608||199298|
NCT00101881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-3776-B05|Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER)|Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER)||University of Washington|No|Completed|November 2002|January 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||September 2008|September 30, 2008|January 18, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00101881||199277|
NCT00101894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040205|Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer|An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer||Amgen|No|Completed|December 2004|December 2011|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|14||Actual|119|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|January 18, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00101894||199276|
NCT00101907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040206|Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer|An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer||Amgen||Terminated|December 2004|April 2008|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|41|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|January 18, 2005|||Study terminated per recommendation of Data Review Team|No|August 13, 2010|https://clinicaltrials.gov/show/NCT00101907||199275|
NCT00102310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443-CL-008|YM443 in Subjects With Functional Dyspepsia|A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Dose Ranging Study of YM443 in Subjects With Functional Dyspepsia||Astellas Pharma Inc||Completed|March 2004|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|416|||Both|18 Years|75 Years|No|||June 2015|June 15, 2015|January 26, 2005||||||https://clinicaltrials.gov/show/NCT00102310||199244|
NCT00102323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030105|AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy|A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy||Amgen||Completed|March 2005|March 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|January 27, 2005||||No||https://clinicaltrials.gov/show/NCT00102323||199243|
NCT00102336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030212|AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy|A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy||Amgen||Completed|April 2005|April 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||May 2009|May 7, 2009|January 27, 2005||||No||https://clinicaltrials.gov/show/NCT00102336||199242|
NCT00102349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0017-1|HIV and HCV Intervention In Drug Treatment Settings - 1|HIV and HCV Intervention in Drug Treatment Settings||National Institute on Drug Abuse (NIDA)|Yes|Completed|November 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Primary Purpose: Prevention||||706|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|January 27, 2005||||No||https://clinicaltrials.gov/show/NCT00102349||199241|
NCT00102596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050092|Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor|Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor||National Institutes of Health Clinical Center (CC)|No|Completed|January 2005|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|21 Years|N/A|No|||January 2012|January 31, 2012|January 30, 2005|Yes|Yes||No|November 10, 2010|https://clinicaltrials.gov/show/NCT00102596||199222|Enrollment to study was ended early, as evidence became available, that a metabolite of the study substance promised significantly higher feasibility for treatment in ET.
NCT00097812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2313|Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid|A Study to Assess the Safety, Tolerability, and Efficacy of Switching Patients Currently on Oral Bisphosphonate to Zoledronic Acid||Novartis||Completed|May 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Female|45 Years|79 Years|No|||April 2012|April 26, 2012|November 30, 2004||Yes||||https://clinicaltrials.gov/show/NCT00097812||199570|
NCT00097825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446M2308|Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men|Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men||Novartis||Completed|April 2004|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||288|||Male|25 Years|85 Years|No|||April 2012|April 26, 2012|November 30, 2004||||||https://clinicaltrials.gov/show/NCT00097825||199569|
NCT00098228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2205|Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Dose-Ranging Study in Patients With COPD||Novartis||Completed|July 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|686|||Both|40 Years|75 Years|No|||October 2011|October 24, 2011|December 3, 2004||||||https://clinicaltrials.gov/show/NCT00098228||199540|
NCT00098254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050049|BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer|Phase II Study of Bay 43-9006 (Sorafenib) With Evaluation of RAS Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|December 2004|January 2011|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|December 3, 2004||No||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00098254||199538|
NCT00099216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BIA05|Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia|Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia||Novartis||Completed|August 2001|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|708|||Both|50 Years|85 Years|No|||November 2011|November 16, 2011|December 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099216||199474|
NCT00099229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2301|Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Tolerability of Licarbazepine 1000-2000mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Over 3 Weeks||Novartis||Completed|November 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|320|||Both|18 Years|70 Years|No|||November 2011|November 22, 2011|December 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099229||199473|
NCT00127764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|754309|European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus|European Randomised Placebo-Controlled Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus (Pempuls Trial)||University Medical Center Groningen||Completed|January 2001|April 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||August 2004|August 29, 2007|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127764||197354|
NCT00128362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/115/2003|Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer|Clinical Trial of Sentinel Node Biopsy Versus Axillary Sampling in Women With Clinically Node Negative Operable Breast Cancer||Tata Memorial Hospital||Terminated|September 2005|||December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|478|||Female|18 Years|70 Years|No|||June 2014|June 23, 2014|August 8, 2005||No|After initiation of study many studies reported an equivalence of SNB and ALND which led to    widespread adoption of the former as standard procedure.|No||https://clinicaltrials.gov/show/NCT00128362||197310|
NCT00128635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000438768|Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse||Abramson Cancer Center of the University of Pennsylvania||Completed|October 2005|October 2007|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|22|||Both|18 Years|120 Years|No|||May 2007|February 17, 2016|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128635||197290|
NCT00120848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/007|Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults|Study of the Efficacy of Candidate HPV 16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Adolescent & Young Adult Women in North America and Brazil Vaccinated in Primary Study 580299/001||GlaxoSmithKline||Completed|November 2003|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|776|||Female|20 Years|30 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|July 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00120848||197874|
NCT00121134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-055|Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer|Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|June 2005|May 2011|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|164|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|July 13, 2005|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00121134||197853|
NCT00099138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0012|CALERIE (Washington University): Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy|Caloric Restriction and Aging in Humans||National Institute on Aging (NIA)||Completed|March 2002|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||48|||Both|50 Years|60 Years|Accepts Healthy Volunteers|||February 2006|December 9, 2009|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00099138||199480|
NCT00099502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91162|BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients|International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.||Bayer|Yes|Completed|November 2003|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2244|||Both|18 Years|55 Years|No|||December 2008|December 18, 2008|December 15, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00099502||199453|
NCT00099515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9523|Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)|Standard Training Versus Intensive Training for HIIP Delivery System Usage in Insulin-Naïve Patients With Type 2 Diabetes Mellitus|IDAP|Eli Lilly and Company|No|Completed|November 2004|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||December 2007|December 18, 2007|December 15, 2004|Yes|Yes||||https://clinicaltrials.gov/show/NCT00099515||199452|
NCT00099775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050057|Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units|A Randomized Double-Masked Trial of Caspofungin Versus Placebo as Prophylaxis of Invasive Candidiasis in High-Risk Adults in the Critical Care Setting||National Institutes of Health Clinical Center (CC)||Completed|December 2004|September 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||1200|||Both|N/A|N/A|No|||September 2005|March 3, 2008|December 18, 2004||||No||https://clinicaltrials.gov/show/NCT00099775||199432|
NCT00100165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57710-2|Trial of DMXB-A in Schizophrenia|Phase 2 Trial of 3-2,4 Dimethoxybenzylidene Anabaseine in Schizophrenia||VA Office of Research and Development|Yes|Recruiting|January 2005|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|December 23, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00100165||199403|
NCT00100490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADE-RCD3|Immune and Endocrine Function in Post-Traumatic Stress Disorder|Immune and Endocrine Function in Post-Traumatic Stress Disorder||VA Office of Research and Development||Completed|October 1999|September 2002||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|December 30, 2004||||No||https://clinicaltrials.gov/show/NCT00100490||199378|
NCT00101062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040402-4671; CDR0000407502|Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|Phase II Study of Letrozole (Femara) and Celecoxib (Celebrex) in Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer||Rutgers, The State University of New Jersey|Yes|Terminated|January 2004|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||June 2011|June 3, 2011|January 7, 2005|Yes|Yes|study drug unavailable|No||https://clinicaltrials.gov/show/NCT00101062||199337|
NCT00101296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03078|Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia||National Cancer Institute (NCI)||Completed|October 2004|||May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|February 1, 2013|January 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101296||199320|
NCT00101621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10-04-02-007|Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain|A Randomized, Double-Blind, Placebo Controlled, Multi-Center, Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent in a Cancer Pain Model||MetaPhore Pharmaceuticals||Terminated|August 2004|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||February 2006|February 8, 2006|January 12, 2005||||||https://clinicaltrials.gov/show/NCT00101621||199297|
NCT00101920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20025408|ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)|A Clinical Trial of the Safety and Efficacy of ABX-EGF as Second Line Treatment for Advanced Non-Small Lung Cancer||Amgen||Completed|June 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|January 18, 2005||||No||https://clinicaltrials.gov/show/NCT00101920||199274|
NCT00102362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0020-1|Job-Seekers Training for Patients With Drug Dependence - 1|Job Seekers Training for Patients With Drug Dependence||National Institute on Drug Abuse (NIDA)|Yes|Completed|December 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized||||627|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|January 27, 2005||||No||https://clinicaltrials.gov/show/NCT00102362||199240|
NCT00102609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003250|A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma|A Phase I Study to Determine the Dose of the Combination of Yondelis and Doxorubicin for Which Neutropenia is Manageable With the Support of Granulocyte-Colony Stimulation Factor in Subjects With Recurrent or Persistent Soft Tissue Sarcoma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2005|October 2007|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|January 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102609||199221|
NCT00097838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 059|Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults|A Phase I, Dose Escalation, Safety, and Immunogenicity Trial of an Alphavirus Replicon HIV-1 Subtype C Gag Vaccine (AVX101) in Healthy HIV-1 Uninfected Adult Participants||AlphaVax, Inc.||Completed|October 2004|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|November 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097838||199568|
NCT00098267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050051|Collection of Dental Plaque and Saliva for Studies of Bacterial Colonization of Teeth|Collection of Dental Plaque and Saliva for Studies of Oral Microbial Colonization||National Institutes of Health Clinical Center (CC)||Completed|December 2004|August 2009|Actual|August 2009|Actual|N/A|Observational|N/A||||30|||Both|3 Months|N/A|Accepts Healthy Volunteers|||August 2009|September 26, 2015|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00098267||199537|
NCT00098579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00048|Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery|Phase I Trial of Doxorubicin and Alvocidib (Flavopiridol; NCI Supplied Agent, NSC 649890) in the Treatment of Metastatic Sarcoma||National Cancer Institute (NCI)||Completed|October 2004|||July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098579||199515|
NCT00098917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000396774|Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|A Phase I Clinical Trial of Mature Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells for the Treatment of Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Terminated|February 2005|||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||April 2007|January 24, 2008|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00098917||199494|
NCT00104273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012-A001-201|Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)|A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type||Teva Pharmaceutical Industries||Completed|August 2004|||March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|376|||Both|45 Years|90 Years|No|||April 2008|July 14, 2009|February 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104273||199102|
NCT00104286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD758-109|Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors|An Open-Label, Single-Arm, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With an Advanced Solid Malignancy||SGX Pharmaceuticals, Inc.||Terminated|January 2003|November 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||November 2006|November 1, 2006|February 24, 2005||||||https://clinicaltrials.gov/show/NCT00104286||199101|
NCT00104299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN021AI|Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis|Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)|RAVE|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2005|January 2010|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|197|||Both|15 Years|N/A|No|||October 2013|October 17, 2013|February 24, 2005|Yes|Yes||No|February 2, 2011|https://clinicaltrials.gov/show/NCT00104299||199100|
NCT00127504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3843|Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness|Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala||Centers for Disease Control and Prevention||Completed|July 2003|May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|5 Years|N/A|No|||August 2005|August 23, 2005|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127504||197374|
NCT00121160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-6003|Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response|Can Stress Management Improve Vaccine Immune Response||Fred Hutchinson Cancer Research Center|Yes|Completed|September 2005|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|July 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00121160||197851|
NCT00099528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REN-1654-2-02|Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia|REN-1654 in Post-Herpetic Neuralgia: a Multi-Center, Placebo Controlled, 3-week Dose-Finding Study, With a 3-Week Active-Treatment Extension||Renovis||Active, not recruiting|August 2003|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|55 Years|N/A|No|||March 2005|July 28, 2010|December 15, 2004||||||https://clinicaltrials.gov/show/NCT00099528||199451|
NCT00099788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 3036|Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes||Gilead Sciences|Yes|Completed|October 2004|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6560|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|December 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099788||199431|
NCT00100178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMFDZB|New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial|New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial (Preservation of Pancreatic Production of Insulin Through Immunosuppression-POPPII #1)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Active, not recruiting|May 2004|January 2009|Anticipated|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|108|||Both|8 Years|45 Years|No|||February 2009|February 4, 2009|December 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100178||199402|
NCT00100191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWO-DO 945-01-17|Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids|EMMY Trial: a Randomized Comparison of Uterine Artery Embolization and Hysterectomy for the Treatment of Symptomatic Uterine Fibroids||ZonMw: The Netherlands Organisation for Health Research and Development||Completed|February 2002|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Female|18 Years|N/A|No|||December 2004|June 23, 2005|December 23, 2004||||No||https://clinicaltrials.gov/show/NCT00100191||199401|
NCT00100503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050066|Brain Reorganization Following Constraint-Induced Therapy in Children With Cerebral Palsy|Cortical Reorganization Following Pediatric Constraint-Induced Therapy||National Institutes of Health Clinical Center (CC)||Completed|December 2004|August 2006||||N/A|Observational|N/A||||50|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||August 2006|March 5, 2008|December 31, 2004||||No||https://clinicaltrials.gov/show/NCT00100503||199377|
NCT00100516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050043|Donor Recipient Kidney Function Following Open Surgical vs. Laparoscopic Kidney Donation|Infrared Image Guided Minimally Invasive Live Donor Kidney Donation for Kidney Transplantation||National Institutes of Health Clinical Center (CC)||Completed|December 2004|June 2008||||N/A|Observational|N/A||||40|||Both|21 Years|65 Years|No|||June 2008|June 18, 2008|December 31, 2004||||No||https://clinicaltrials.gov/show/NCT00100516||199376|
NCT00106405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-27|An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder|A Pilot Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder||Forest Laboratories||Completed|February 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|65 Years|No|||March 2012|March 1, 2012|March 24, 2005||||||https://clinicaltrials.gov/show/NCT00106405||198943|
NCT00106418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ-228-0002|A Research Study for Patients With Prostate Cancer|An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA||Celgene||Completed|May 2003|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|N/A|No|||September 2014|September 12, 2014|March 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00106418||198942|
NCT00106431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPI-04-0001|A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)|A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma||Celgene|Yes|Completed|January 2005|December 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2011|March 14, 2011|March 24, 2005|Yes|Yes||No|March 2, 2010|https://clinicaltrials.gov/show/NCT00106431||198941|
NCT00106678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 023B|Typology of Adherence in Adolescents: Phase II|Typology of Adherence in Adolescents: Phase II||Westat|No|Completed|June 2004|April 2005|Actual|April 2005|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1200|||Both|12 Years|24 Years|No|Non-Probability Sample|The study population will consist of HIV-infected youth who are eligible for        antiretroviral therapy (ART) based on the US Public Health Service (PHS) guidelines and        have been offered and/or prescribed HAART by their healthcare provider. Subjects aged 12        through 24 years old will be recruited from youth engaged in care at the fifteen ATN        clinical sites located across the United States and in Puerto Rico. Youth engaged in care        at selected non- ATN clinic centers will also be offered the opportunity to participate in        this study.|February 2016|February 29, 2016|March 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00106678||198923|
NCT00107016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2222|Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women|A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women||Novartis||Completed|March 2005|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|267|||Female|18 Years|N/A|No|||February 2013|February 28, 2013|April 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107016||198900|
NCT00107315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 22204|Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer|A Phase II Study of Capecitabine and Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer||Roswell Park Cancer Institute||Terminated|July 2004|||June 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|70 Years|N/A|No|||June 2014|June 3, 2014|April 5, 2005|Yes|Yes|Terminated due to low accrual|No|January 8, 2014|https://clinicaltrials.gov/show/NCT00107315||198881|Due to the study's early termination, as a result of low accrual, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.
NCT00103272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01463|17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer|A Phase I Study of PS-341 (Velcade, Bortezomib) in Combination With 17-allylamino-17-demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Hematologic Malignancies||National Cancer Institute (NCI)||Terminated|April 2005|||April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|February 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00103272||199173|
NCT00102986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5223|Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women|Sex Differences in Lopinavir/Ritonavir Pharmacokinetics Among HIV-1-Infected Men and Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2005|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|116|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 4, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00102986||199192|
NCT00103259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02953|Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||National Cancer Institute (NCI)||Completed|July 2005|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||December 2012|May 7, 2014|February 7, 2005|Yes|Yes||No|November 24, 2012|https://clinicaltrials.gov/show/NCT00103259||199174|
NCT00103597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/135|Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy|Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy||Royal Brisbane and Women's Hospital||Completed|January 2005|September 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|40 Years|95 Years|No|||July 2005|October 19, 2005|February 11, 2005||||No||https://clinicaltrials.gov/show/NCT00103597||199150|
NCT00103896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 016b|Connect to Protect Partnerships for Youth Prevention Interventions: Phase II|Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 2003|September 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||1500|||Both|12 Years|24 Years|Accepts Healthy Volunteers|||July 2007|July 16, 2007|February 15, 2005||||No||https://clinicaltrials.gov/show/NCT00103896||199128|
NCT00105079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18413|GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection|A 48-week, Randomized, Open-label, 2-arm Study to Compare the Efficacy of Saquinavir/Ritonavir Twice Daily (BID) Plus Emtricitabine/Tenofovir Once Daily (QD) Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients (GEMINI Study)||Hoffmann-La Roche||Completed|April 2005|July 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|337|||Both|18 Years|N/A|No|||September 2011|September 23, 2011|March 4, 2005|Yes|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00105079||199042|
NCT00105092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8670|Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.|A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|March 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||April 2007|April 27, 2007|March 4, 2005||||||https://clinicaltrials.gov/show/NCT00105092||199041|
NCT00128037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG 9806|Trial of Pre-Operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806)|A Phase II Trial of Pre-Operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors: Initial Report of Japan Clinical Oncology Group Trial (JCOG 9806)||Japan Clinical Oncology Group||Completed|May 1999|February 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|15 Years|74 Years|No|||March 2007|March 5, 2007|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128037||197334|
NCT00120575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT CVVH|Hemofiltration for Respiratory Failure After Bone Marrow Transplantation|Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation||Stanford University||Recruiting|January 2005|September 2008||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||112|||Both|1 Month|21 Years|No|||December 2006|December 1, 2006|July 11, 2005||||No||https://clinicaltrials.gov/show/NCT00120575||197895|
NCT00120861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-08A-004|Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy|A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of NM283 and the Combination of Pegylated Interferon Plus NM283, in Patients With Chronic Hepatitis C Who Have Previously Failed to Respond to Standard Therapy||Merck Sharp & Dohme Corp.||Completed|January 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||June 2010|June 9, 2010|July 11, 2005||||||https://clinicaltrials.gov/show/NCT00120861||197873|
NCT00116662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1534-RESI|An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects|A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects||Graceway Pharmaceuticals, LLC||Completed|March 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||84|||Both|3 Years|11 Years|No|||November 2006|February 16, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116662||198186|
NCT00116675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1535-RESI|Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects|A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects||Graceway Pharmaceuticals, LLC||Completed|March 2005|April 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||84|||Both|3 Years|11 Years|No|||June 2006|February 16, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116675||198185|
NCT00099541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS99|Non-small Cell Lung Cancer Registry|A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis||Novartis||Completed|November 2004|November 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||November 2009|November 20, 2009|December 15, 2004||||No||https://clinicaltrials.gov/show/NCT00099541||199450|
NCT00099554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030236|Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)|A Phase 4, Open-Label, Single Arm, Observational Study Evaluating the Effectiveness and Safety of Enbrel® (Etanercept) 50 mg Once Weekly in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)||Amgen||Completed|May 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||November 2009|November 12, 2009|December 16, 2004||||||https://clinicaltrials.gov/show/NCT00099554||199449|
NCT00099801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A2307|Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant|Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant||Novartis||Completed|January 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 2014|January 14, 2014|December 21, 2004||||||https://clinicaltrials.gov/show/NCT00099801||199430|
NCT00099814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOP-UA-CT-01|Periodontal Ligament Stress Level and Tooth Movement|Clinical/Numerical Study of the Effects of Periodontal Ligament Stress Level on the Rate Bodily Tooth Movement||University of Alberta, Graduate Orthodontic Program|No|Completed|March 2004|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Female|12 Years|16 Years|Accepts Healthy Volunteers|||June 2010|June 28, 2010|December 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00099814||199429|
NCT00099827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDAP2|Teen Depression Awareness Project (TDAP)|Teen Depression Awareness Project- This Project Examines the Services Used by Teens Identified in Primary Care Settings With Depression||RAND|No|Completed|October 2003|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|368|||Both|13 Years|17 Years|No|||October 2011|October 14, 2011|December 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00099827||199428|
NCT00100204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050058|Salivary Proteins in Disease and Health|Salivary Proteomics in Disease and Health||National Institutes of Health Clinical Center (CC)||Completed|December 2004|April 2011||||N/A|Observational|N/A|||Actual|264|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2011|September 26, 2015|December 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00100204||199400|
NCT00100217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050062|Evaluation of Patients With Critical Illness|Evaluation of Patients With Critical Illness: Intensive Care Training Protocol||National Institutes of Health Clinical Center (CC)||Completed|December 2004|June 2010||||N/A|Observational|N/A|||Actual|1|||Both|18 Years|N/A|No|||June 2010|September 26, 2015|December 23, 2004||No||No||https://clinicaltrials.gov/show/NCT00100217||199399|
NCT00100789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000407644|S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer|A Phase II Study of Biweekly Gemcitabine and Paclitaxel (GEMTAX) Combination in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Southwest Oncology Group|No|Completed|January 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|January 6, 2005|Yes|Yes||No|July 12, 2012|https://clinicaltrials.gov/show/NCT00100789||199356|
NCT00107029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 026|Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth|Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles||Westat|No|Completed|December 2002|September 2005|Actual|September 2005|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|113|Samples Without DNA|Biomedical HIV-1 related data and samples are available for the time the subjects were      enrolled in REACH. HIV-1 genotyping will certainly be possible from these retrospective      samples and the stored PBMCs will be evaluated for usefulness in the HIV-1 specific assays.      Prospectively, samples will be collected every six months over a two-year period to evaluate      both HIV-1 specific CD8+ T cell responses and the dominant HIV-1 genotype longitudinally.|Both|N/A|N/A|No|Non-Probability Sample|Subjects who were identified as HLA Class I HLA-B*27, B*35, B*53, and/or B*57 positive        from the REACH study will be contacted for their interest in participating in this study.        Only former REACH sites in the ATN will be eligible to enroll subjects into this study.|February 2016|February 29, 2016|April 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00107029||198899|
NCT00107341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N044B|Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for Metastatic Adenocarcinoma of the Lower Esophagus, Gastroesophageal Junction, and Gastric Cardia||Alliance for Clinical Trials in Oncology|No|Completed|August 2005|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|April 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107341||198880|
NCT00107354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1334.00|Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant|Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant||Fred Hutchinson Cancer Research Center||Completed|December 1998|||August 2009|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|14 Years|N/A|No|||September 2010|September 16, 2010|April 5, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00107354||198879|
NCT00102999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050094|Brain Function in Focal Dystonia|Impaired Motor Learning and LTP/LTD-like Plasticity in Dystonia, Are Associated With Abnormal Modulation of Cortical Excitability by Somatosensory Volleys||National Institutes of Health Clinical Center (CC)||Completed|January 2005|January 2009||||N/A|Observational|N/A||||118|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|September 26, 2015|February 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00102999||199191|
NCT00103012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050082|Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers|The Influence of Concurrent Administration of Echinacea Purpurea, Ginkgo Biloba, or Panax Ginseng on the Steady State Pharmacokinetic Profile of Lopinavir/Ritonavir in Healthy Volunteers||National Institutes of Health Clinical Center (CC)|No|Completed|January 2005|June 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|47|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|February 5, 2005||No||No|December 12, 2011|https://clinicaltrials.gov/show/NCT00103012||199190|
NCT00103285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL0331|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|Yes|Active, not recruiting|April 2005|||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|5377|||Both|1 Year|9 Years|No|||April 2015|April 21, 2015|February 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103285||199172|
NCT00103610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-3101|Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 5 * 10^6 CD34+ Cells/kg in Non-Hodgkin's Lymphoma Patients for Autologous Transplantation||Sanofi||Completed|January 2005|December 2007|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|78 Years|No|||February 2014|February 10, 2014|February 11, 2005|Yes|Yes|||February 6, 2009|https://clinicaltrials.gov/show/NCT00103610||199149|
NCT00103922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIL103657|Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)|A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|November 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||600|||Both|40 Years|N/A|No|||October 2010|October 1, 2010|February 17, 2005||||||https://clinicaltrials.gov/show/NCT00103922||199127|
NCT00103935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993LAR-104|Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Pharmacokinetics of Exenatide Long-Acting Release Administered Weekly in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|February 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|75 Years|No|||January 2015|February 23, 2015|February 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103935||199126|
NCT00103948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-233|The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment|An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment||Eisai Inc.||Completed|February 2005|February 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|165|||Both|25 Years|70 Years|No|||November 2015|November 2, 2015|February 17, 2005||||No||https://clinicaltrials.gov/show/NCT00103948||199125|
NCT00104312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0016|Osteoarthritis: Weakness From Inflammation|Weakness From Inflammation: A Basis of Disability From Knee Osteoarthritis||National Institute on Aging (NIA)||Completed|April 2001|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|88|Samples Without DNA|Synovial fluid and tissue blood serum muscle biopsy|Both|50 Years|N/A|No|Non-Probability Sample|Community - Men and women|May 2009|May 28, 2009|February 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00104312||199099|
NCT00104585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5609|Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)|Genetic Epidemiology of Parkinson's Disease||Columbia University|No|Recruiting|July 2004|||September 2012|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|800|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Young onset PD patients|January 2012|January 18, 2012|March 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00104585||199078|
NCT00104598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13334-6|Framing Messages for Smoking Cessation With Bupropion - 6|Framing Messages for Smoking Cessation With Buproprion||Yale University|No|Completed|September 2000|December 2006|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|March 1, 2005||||No||https://clinicaltrials.gov/show/NCT00104598||199077|
NCT00120328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP301CRD15|To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy|ASCEND - A Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus and Diabetic Nephropathy||Speedel Pharma Ltd.|Yes|Terminated|July 2005|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2364|||Both|21 Years|80 Years|No|||October 2007|October 4, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00120328||197914|
NCT00120588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997/575/HP|Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth|Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate||University Hospital, Rouen|No|Completed|July 1997|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||700|||Both|N/A|N/A|No|||June 2013|June 17, 2013|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00120588||197894|
NCT00120874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12444-01 A|Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training|Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial||New York University School of Medicine|Yes|Active, not recruiting|August 2006|February 2015|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|20|||Both|50 Years|N/A|No|||September 2014|September 4, 2014|July 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120874||197872|
NCT00116688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030213|Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)||Amgen||Completed|August 2004|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|313|||Both|1 Year|N/A|No|||November 2013|November 25, 2013|June 30, 2005||||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00116688||198184|
NCT00117455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020113|A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma|A Randomised, Multi-Centre, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Non-Hodgkin's Lymphoma||Amgen||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2008|May 15, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117455||198125|
NCT00099567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0066|Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline|Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline||National Institute on Aging (NIA)||Completed|January 1997|December 2002||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||2632|||Both|70 Years|79 Years|Accepts Healthy Volunteers|||December 2004|October 31, 2005|December 16, 2004||||No||https://clinicaltrials.gov/show/NCT00099567||199448|
NCT00099840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARTIS|Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study|Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections in Primary Care - A Randomized Controlled Trial||University Hospital, Basel, Switzerland||Completed|December 2004|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||400|||Both|18 Years|N/A|No|||January 2006|April 24, 2007|December 21, 2004||||No||https://clinicaltrials.gov/show/NCT00099840||199427|
NCT00105846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEL 20-015|An Evaluation of Home-Based Telemedicine Services|An Evaluation of Home-Based Telemedicine Services||VA Office of Research and Development|No|Completed||June 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|April 6, 2015|March 17, 2005||||No||https://clinicaltrials.gov/show/NCT00105846||198985|
NCT00106132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050101|Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage|The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study||National Institutes of Health Clinical Center (CC)||Completed|March 2005|November 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||1260|||Both|N/A|N/A|No|||November 2005|March 3, 2008|March 19, 2005||||No||https://clinicaltrials.gov/show/NCT00106132||198964|
NCT00106093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050121|Alcoholism Assessment and Treatment|Assessment and Treatment of People With Alcohol Drinking Problems||National Institutes of Health Clinical Center (CC)||Completed|March 2005|September 2015||||N/A|Observational|N/A|||Actual|1192|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|March 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00106093||198967|
NCT00106106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050120|Acamprosate to Reduce Symptoms of Alcohol Withdrawal|Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal||National Institutes of Health Clinical Center (CC)|No|Completed|March 2005|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|56|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|March 19, 2005||No||No|November 30, 2011|https://clinicaltrials.gov/show/NCT00106106||198966|
NCT00107055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REN-1654-2-03|Study of REN-1654 in Patients With Sciatica Pain|REN-1654 in Sciatica: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study in Subjects With Pain Due to Lumbosacral Radiculopathy||Renovis||Active, not recruiting|December 2003|April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||72|||Both|18 Years|55 Years|No|||June 2005|June 23, 2005|April 4, 2005||||||https://clinicaltrials.gov/show/NCT00107055||198897|
NCT00102674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CAN-04-02|Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor|The Pharmacokinetics and Pharmacodynamics of a Cangrelor Bolus Plus Infusion in Healthy Volunteers||The Medicines Company||Completed|March 2005|May 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2005|August 15, 2011|January 31, 2005||||||https://clinicaltrials.gov/show/NCT00102674||199216|
NCT00102687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA PH US 2004 CL 003|Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes|A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes||Celgene|No|Completed|January 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|151|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|January 31, 2005|Yes|Yes||No|May 3, 2010|https://clinicaltrials.gov/show/NCT00102687||199215|
NCT00103025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050075|Nitrite Infusion in Healthy Volunteers|Evaluation of the Mechanism of NO Formation and Pharmacokinetics of Long-Term Intravenous Nitrite Infusion in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|February 2005|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|21 Years|60 Years|No|||May 2011|May 11, 2011|February 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00103025||199189|
NCT00103298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000409754|Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer|A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden||National Cancer Institute (NCI)||Completed|December 2004|July 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|June 18, 2013|February 7, 2005||||No||https://clinicaltrials.gov/show/NCT00103298||199171|
NCT00103623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149-IV-01|The Plenaxis® Experience Study|Incidence of Immediate Onset Systemic Allergic Reactions in Patients Treated With Plenaxis®||PRAECIS Pharmaceuticals Inc.||Suspended|June 2004|December 2008||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Male|18 Years|N/A|No|||September 2006|September 18, 2006|February 11, 2005||||||https://clinicaltrials.gov/show/NCT00103623||199148|
NCT00103961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01AI052403|An Observational Study of People Who Have Recently Been Infected With HIV|Primary HIV & Early Disease Research: American Cohort (PHAEDRA) AIEDRP||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|January 2004|December 2014|Anticipated|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples With DNA|Blood collection|Both|18 Years|64 Years|No|Probability Sample|Treatment-naive and treatment-experienced HIV-infected adults|September 2008|September 25, 2008|February 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00103961||199124|
NCT00104325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903316|Cytapheresis of Volunteer Donors|Cytapheresis of Volunteer Donors||National Institutes of Health Clinical Center (CC)||Recruiting|January 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|February 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00104325||199098|
NCT00104611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-01101-000|Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder|A Randomized, Parallel-Group, Sham-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of the Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic Stimulation (rTMS) System in Patients With Major Depression||Neuronetics|Yes|Completed|January 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|70 Years|No|||September 2013|September 19, 2013|March 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104611||199076|
NCT00104624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000417747|Docetaxel in Treating Older Women With Metastatic Breast Cancer|Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy With Biweekly Docetaxel in the Treatment of Metastatic Breast Cancer in Patients Over 70||UNICANCER|No|Terminated|May 2005|July 2008|Actual|July 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|53|||Female|70 Years|N/A|No|||September 2013|September 2, 2013|March 3, 2005||No|Toxicity issues|No||https://clinicaltrials.gov/show/NCT00104624||199075|
NCT00104819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAV-ID-09|Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma|Phase II Trial of FavId™ (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06||National Cancer Institute (NCI)||Terminated|September 2004|||June 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|238|||Both|18 Years|N/A|No|||August 2008|August 1, 2013|March 3, 2005|Yes|Yes|Withdrawn as company has shut down and filed for bankruptcy|No||https://clinicaltrials.gov/show/NCT00104819||199060|
NCT00120341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50100|Anodyne Therapy in Diabetic Sensory Neuropathy|A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy||Scott and White Hospital & Clinic||Completed|April 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|25 Years|N/A|No|||May 2007|May 30, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120341||197913|
NCT00120601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X99-0277|Trial for the Treatment of Alcohol Dependence|The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence||University of Sydney||Active, not recruiting|March 2003|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years|No|||June 2005|July 15, 2005|July 11, 2005||||No||https://clinicaltrials.gov/show/NCT00120601||197893|
NCT00120887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAPS|Lupus Atherosclerosis Prevention Study|Lupus Atherosclerosis Prevention Study||Johns Hopkins University||Completed|April 2002|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|18 Years|N/A|No|||September 2006|April 4, 2007|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120887||197871|
NCT00117468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-PGN-201|Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement|A Phase 2, Single-Center, Open-Label, Randomized, Controlled, Pharmacodynamic Study to Compare DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement||Teva Pharmaceutical Industries|No|Completed|June 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|50 Years|No|||May 2014|May 9, 2014|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117468||198124|
NCT00116714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021634|Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy|Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 1)||Amgen||Completed|October 2001|October 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4968|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with RA according to ACR criteria, and who are starting, adding or changing DMARD        therapy, including biologics.|May 2011|May 5, 2011|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00116714||198182|
NCT00105326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002281|Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients|A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2005|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|5|||Both|18 Years|45 Years|No|||May 2010|May 20, 2010|March 11, 2005||||||https://clinicaltrials.gov/show/NCT00105326||199024|
NCT00105599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHI 99-071|Effectiveness of the FairCare System for Patients With Advanced Illness|Effectiveness of the FairCare System for Patients With Advanced Illness||VA Office of Research and Development|No|Completed||September 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|140|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 15, 2005||||No||https://clinicaltrials.gov/show/NCT00105599||199004|
NCT00105612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0070|Memory Aid for Informed Consent in Alzheimer's Research|Improving Informed Consent in Alzheimer's Disease Research||National Institute on Aging (NIA)||Completed|September 2004|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study||||110|||Both|N/A|N/A|No|||December 2009|December 23, 2009|March 15, 2005||||No||https://clinicaltrials.gov/show/NCT00105612||199003|
NCT00106145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0752-014|A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)|A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors||Merck Sharp & Dohme Corp.||Completed|April 2005|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|103|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|March 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00106145||198963|
NCT00106457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1290|20 Year Changes in Fitness & Cardiovascular Disease Risk - Ancillary to CARDIA|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 2005|November 2008|Actual|November 2008|Actual|N/A|Observational|N/A|||||||Both|38 Years|50 Years|No|||November 2008|November 13, 2008|March 24, 2005||||No||https://clinicaltrials.gov/show/NCT00106457||198940|
NCT00106691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G300104|Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)||GTx|Yes|Completed|January 2005|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1590|||Male|30 Years|N/A|No|||January 2013|January 31, 2013|March 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00106691||198922|
NCT00106704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-035|Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)|A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination With Metformin||Merck Sharp & Dohme Corp.||Completed|March 2005|January 2007|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|441|||Both|18 Years|75 Years|No|||June 2015|June 4, 2015|March 29, 2005|Yes|Yes||No|November 19, 2010|https://clinicaltrials.gov/show/NCT00106704||198921|
NCT00106717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1736|Effectiveness of Narrative Medicine on Pain Intensity and Quality of Life|Effectiveness of Narrative Medicine on Pain Intensity and Quality of Life||Javeriana University||Completed|January 2004|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||210|||Both|18 Years|80 Years|No|||March 2005|March 19, 2008|March 29, 2005||||No||https://clinicaltrials.gov/show/NCT00106717||198920|
NCT00106743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050096|Natural History and Genetic Studies of Usher Syndrome|Natural History and Genetic Studies of Usher Syndrome||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2005|||||N/A|Observational|Time Perspective: Prospective|||Actual|237|||Both|2 Years|N/A|Accepts Healthy Volunteers|||May 2015|October 23, 2015|March 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00106743||198919|
NCT00102700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 501-212|ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer|A Phase II Study of ARQ 501 in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma||ArQule||Completed|January 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|February 1, 2005||||||https://clinicaltrials.gov/show/NCT00102700||199214|
NCT00102713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-714|A Study for Treatment of Partial Seizures in Children|An Open Label Study for Treatment of Partial Seizures in Children||Abbott||Completed|February 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|3 Years|10 Years|No|||May 2007|May 17, 2007|February 1, 2005||||||https://clinicaltrials.gov/show/NCT00102713||199213|
NCT00102726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|497115/003|SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy||GlaxoSmithKline||Completed|February 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|183|||Both|18 Years|N/A|No|||March 2012|April 16, 2015|February 1, 2005||||No||https://clinicaltrials.gov/show/NCT00102726||199212|
NCT00103038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-813|MRI Using Ferumoxytol in Patients With Primary Brain Cancer or Brain Metastases|NCI-Sponsored Multidisciplinary Study of Magnetic Resonance (MR) Imaging of Intravenous Superparamagnetic Crystalline Particle Ferumoxytol in Primary High-grade Brain Tumors and/or Cerebral Metastases||OHSU Knight Cancer Institute|Yes|Recruiting|May 2009|April 2020|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|120 Years|No|||October 2015|October 20, 2015|February 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103038||199188|
NCT00103311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02834|SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer|A Randomized Phase II Non-Comparative Study of SB-715992 Given Weekly or Every Three Weeks in Advanced or Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|January 2005|September 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||October 2013|February 13, 2015|February 7, 2005|Yes|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT00103311||199170|
NCT00103324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03180|S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer|Phase II Study of GW572016 (NSC-727989) as First Line Therapy in Patients With Advanced or Metastatic Gastric Cancer||National Cancer Institute (NCI)||Completed|December 2004|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|February 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00103324||199169|
NCT00103337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02904|Cilengitide in Treating Patients With Metastatic Prostate Cancer|Phase II Evaluation of EMD121974 (NSC 707544, Cilengitide) in Asymptomatic Patients With Metastatic Androgen Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|January 2005|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Male|18 Years|N/A|No|||February 2013|February 27, 2013|February 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00103337||199168|
NCT00103636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBWH 2003/131|Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change|Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change||Royal Brisbane and Women's Hospital||Active, not recruiting|March 2004|December 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||February 2005|June 23, 2005|February 11, 2005||||No||https://clinicaltrials.gov/show/NCT00103636||199147|
NCT00103974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHT-3009-01|Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis|A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis||Bayhill Therapeutics||Completed|July 2004|March 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||February 2008|April 4, 2008|February 17, 2005||||||https://clinicaltrials.gov/show/NCT00103974||199123|
NCT00103987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050102|Neurobiological Mechanisms in Panic Disorder|Neurobiological Mechanisms in Panic Disorder: Behavioral, Genetic, & Neural Correlates of Noradrenergic Function||National Institutes of Health Clinical Center (CC)||Completed|February 2005|November 2010||||N/A|Observational|N/A|||Actual|54|||Both|18 Years|60 Years|No|||November 2010|November 13, 2010|February 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00103987||199122|
NCT00104338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0-196|Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy|A Phase 2, Proof of Concept, Randomized, Open-label, Two-arm, Parallel Group, Multi-center Study to Assess the Efficacy and Safety of FK778 Compared With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy||Astellas Pharma Inc||Terminated|January 2005|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|February 24, 2005||||||https://clinicaltrials.gov/show/NCT00104338||199097|
NCT00104351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_005|A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)(TERMINATED)|A Phase I Dose Escalation Study of MK0457 Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.||Terminated|May 2005|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|February 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104351||199096|
NCT00104637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1022|Sildenafil for Chronic Obstructive Pulmonary Disease|A Double-blind, Placebo-controlled, Crossover Study of Sildenafil in Patients With Chronic Obstructive Pulmonary Disease||Kawut, Steven, MD|Yes|Completed|February 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|40 Years|N/A|No|||May 2012|May 18, 2012|March 3, 2005|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00104637||199074|The study had slow enrollment.
NCT00104845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-007|Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma|Injection of AJCC Stage IIB, IIC, III, and IV Melanoma Patients With Human and Mouse gp100 DNA: A Phase I Trial to Assess Safety and Immune Response||Memorial Sloan Kettering Cancer Center||Completed|September 2004|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|N/A|No|||March 2013|March 11, 2013|March 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00104845||199059|
NCT00120354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050195|Long-Term Lamivudine Therapy for Chronic Hepatitis B|Long-Term Lamivudine Therapy for Chronic Hepatitis B||National Institutes of Health Clinical Center (CC)||Completed|July 2005|March 2007||||Phase 4|Interventional|Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||March 2007|September 26, 2015|July 15, 2005||||No||https://clinicaltrials.gov/show/NCT00120354||197912|
NCT00120614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06990|Educational/Behavioral Intervention Program for Parents of Premature Infants|Improving Outcomes of LBW Premature Infants and Parents||University of Rochester||Completed|September 2001|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||260|||Both|18 Years|N/A||||April 2009|April 7, 2009|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00120614||197892|
NCT00117039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030206|A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia|SYNCHRONICITY: A Study to Evaluate the Effectiveness of Aranesp® at 300 Mcg Q3W on Clinical Outcomes in Cancer Patients With Anemia Due to Chemotherapy||Amgen||Completed|January 2004|April 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1500|||Both|18 Years|N/A|No|||August 2008|October 14, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117039||198157|
NCT00117052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040143|SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism|SENSOR: Study to InvestigatE Cinacalcet TreatmeNt in Haemodialysis Patients With SecOndary HyperparathyRoidism||Amgen||Completed|September 2004|February 2006|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|673|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117052||198156|
NCT00116727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021635|Rheumatoid Arthritis DMARD Intervention and UtilizationStudy|Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2)||Amgen||Completed|October 2002|October 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5103|||Both|18 Years|N/A|No|Non-Probability Sample|RA patients (by ACR criteria) starting on etanercept alone or in combination with other        DMARDs|May 2011|May 5, 2011|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00116727||198181|
NCT00116740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-004|Safety and Efficacy of APD356 in the Treatment of Obesity|A 12-Week, Dose-Ranging, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of APD356 in Obese Patients||Arena Pharmaceuticals||Completed|June 2005|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2006|March 24, 2010|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116740||198180|
NCT00105625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 99-340|VA Nutrition Study on Immune Function|Immunocompetency and Nutritive Status in Inpatient Gero-Rehabilitation||VA Office of Research and Development|No|Completed|March 2003|September 2007|Actual|September 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|55 Years|N/A|No|||June 2008|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105625||199002|
NCT00105859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 01-151|Preventing Pressure Ulcers in Veterans With Spinal Cord Injury (SCI)|Preventing Pressure Ulcers in Veterans With Spinal Cord Injury (SCI)||VA Office of Research and Development|No|Terminated||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|278|||Both|18 Years|N/A|No|||June 2005|May 6, 2010|March 17, 2005||||No||https://clinicaltrials.gov/show/NCT00105859||198984|
NCT00106119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050119|Thyroid and Glucose and Energy Metabolism|Peripheral Thyroid Hormone Conversion and Glucose and Energy Metabolism||National Institutes of Health Clinical Center (CC)|No|Completed|March 2005|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|18|||Both|18 Years|65 Years|No|||February 2015|February 20, 2015|March 19, 2005|Yes|Yes||No|November 12, 2014|https://clinicaltrials.gov/show/NCT00106119||198965|
NCT00106470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289|Genetic Factors That Influence Chronic Obstructive Pulmonary Disease in Hispanics|Genetic Epidemiology of COPD in Costa Rica||University of Pittsburgh|No|Completed|February 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|679|Samples With DNA|Serum|Both|21 Years|65 Years|No|Non-Probability Sample|Families of individuals with physician-diagnosed COPD and smoking-related airflow        obstruction who are younger than 71 years.|December 2012|December 12, 2012|March 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00106470||198939|
NCT00107042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 025|Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths|Hepatitis B Vaccination in Youth at Adolescent Trial Network Sites: Effectiveness of Two Strategies and Evaluation of Tools To be Used in Future HIV Prevention Trials.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2004|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|123|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||December 2014|February 12, 2015|April 4, 2005|Yes|Yes||No|September 5, 2011|https://clinicaltrials.gov/show/NCT00107042||198898|
NCT00098982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-16029|Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer|Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2004|||January 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00098982||199490|
NCT00099359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD/HPTN 040 (P1043)|Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission|Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2004|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1735|||Both|N/A|2 Days|Accepts Healthy Volunteers|||February 2011|October 26, 2012|December 10, 2004|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00099359||199463|
NCT00099645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5200|Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People|A Randomized, Placebo-Controlled, Phase I/II Trial of the Anti-HIV Activity and Safety of VGX-410 (Mifepristone) at Three Dose Levels in HIV-1 Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||August 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|December 17, 2004||||||https://clinicaltrials.gov/show/NCT00099645||199442|
NCT00099957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2217|A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes|A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes||Novartis||Completed|September 2003|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||38|||Both|30 Years|N/A|No|||May 2012|May 1, 2012|December 21, 2004||||||https://clinicaltrials.gov/show/NCT00099957||199418|
NCT00100282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1019-03-01|Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease|Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease||PRAECIS Pharmaceuticals Inc.||Completed|May 2003|June 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Both|50 Years|80 Years|No|||September 2006|September 18, 2006|December 27, 2004||||||https://clinicaltrials.gov/show/NCT00100282||199394|
NCT00100295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT000929|Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)|Controlled Trial of an Herbal Treatment for Juvenile Attention Deficit Hyperactivity Disorder||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|February 2005|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|6 Years|17 Years|No|||October 2007|October 24, 2007|December 28, 2004||||No||https://clinicaltrials.gov/show/NCT00100295||199393|
NCT00100581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5184|Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults|An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2|||Both|18 Years|65 Years|No|||May 2012|May 17, 2012|January 3, 2005||||No||https://clinicaltrials.gov/show/NCT00100581||199371|
NCT00100854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000407580|Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized, Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva®) and Fulvestrant (Faslodex®) Versus Erlotinib (Tarceva®) Alone in Advanced Non-Small Cell Lung Cancer Patients||Translational Oncology Research International|Yes|Active, not recruiting|October 2004|April 2017|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100854||199351|
NCT00101127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0087L|Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma|A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus||Gynecologic Oncology Group|Yes|Completed|December 2003|||July 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2014|February 12, 2014|January 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101127||199332|
NCT00101374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050065|Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Leflunomide on HIV-1 Associated Immune Proliferation In Vivo||National Institutes of Health Clinical Center (CC)||Completed|January 2005|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|65 Years|No|||February 2010|February 3, 2010|January 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00101374||199315|
NCT00120367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000424-16|Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)|Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial||French National Agency for Research on AIDS and Viral Hepatitis||Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00120367||197911|
NCT00120380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMBI|Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)|Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension||Hannover Medical School||Terminated|September 2004|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||January 2006|August 20, 2012|July 11, 2005|||Futility analysis|No||https://clinicaltrials.gov/show/NCT00120380||197910|
NCT00116701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040218|Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis|A Study to Evaluate the Efficacy of Converting From Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects With Chronic Kidney Disease Receiving Haemodialysis||Amgen||Completed|May 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||May 2008|May 1, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00116701||198183|
NCT00120913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 7198|Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?|||Oregon Health and Science University||Completed||August 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||160|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||July 2005|July 18, 2005|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120913||197869|
NCT00120926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX05-001|Dose Comparison of Amino Acids on Growth in Premature Neonates|Randomized Control Trial Evaluating the Effect of Two Different Doses of Amino Acids on Growth and Serum Amino Acids in Premature Neonates Admitted to the NICU||Mednax Center for Research, Education and Quality||Completed|August 2005|June 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|N/A|48 Hours|No|||September 2006|September 27, 2006|July 11, 2005||||No||https://clinicaltrials.gov/show/NCT00120926||197868|
NCT00116753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS15|A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer|An Open-label Multi-center, Randomized Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer||Ferring Pharmaceuticals|Yes|Completed|January 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|460|||Male|18 Years|N/A|No|||November 2010|November 12, 2010|June 30, 2005|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00116753||198179|
NCT00105872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 00-091|Behavioral Insomnia Therapy in Primary Care|Behavioral Insomnia Therapy in Primary Care||VA Office of Research and Development|No|Completed|March 2002|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2007|April 6, 2015|March 17, 2005||||No||https://clinicaltrials.gov/show/NCT00105872||198983|
NCT00106158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-005|Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1|Immunization of Patients With Tumors Expressing NY-ESO-1 or LAGE Antigen With Complex of NY-ESO-1 Protein and Cholesterol-bearing Hydrophobized Pullulan (CHP)||Ludwig Institute for Cancer Research||Completed|June 2004|December 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|9|||Both|18 Years|N/A|No|||August 2007|November 4, 2010|March 21, 2005||||No||https://clinicaltrials.gov/show/NCT00106158||198962|
NCT00106756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050104|Clinical and Genetic Studies of Familial Exudative Vitreoretinopathy|Familial Exudative Vitreoretinopathy Clinical and Molecular Studies||National Institutes of Health Clinical Center (CC)||Completed|March 2005|November 2006|Actual|November 2006|Actual|N/A|Observational|N/A||||105|||Both|1 Year|N/A|No|||June 2009|September 26, 2015|March 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00106756||198918|
NCT00107068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC 153970|Exercise Training and Walking Ability After Chronic Stroke|Does Aerobic or Resistance Exercise Training Improve Walking Ability in Chronic Stroke Patients?||University of Sydney||Completed|January 2001|May 2004|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|45 Years|90 Years|No|||December 2015|December 2, 2015|April 4, 2005||||No||https://clinicaltrials.gov/show/NCT00107068||198896|
NCT00099372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFD 001; U01HD41249|Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse|Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse: The Extended Colpopexy and Urinary Reduction Efforts (E-CARE) Study||NICHD Pelvic Floor Disorders Network|Yes|Terminated|May 2004|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|215|||Female|21 Years|N/A|No|Non-Probability Sample|Women who completed the CARE study|September 2013|September 27, 2013|December 10, 2004||No|resource and prioritization change as Network transition to a new funding cycle|No||https://clinicaltrials.gov/show/NCT00099372||199462|
NCT00099658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA-SA Project 4|Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children|Evaluation of Quantitative and Qualitative Antibody Responses to Streptococcus Pneumoniae and Haemophilus Influenzae Type b Conjugate Vaccines Amongst HIV-1-Exposed-Infected Children That Are Receiving Vs. Those Not Receiving Antiretroviral Therapy, as Well as Among HIV-1-Exposed-Uninfected Children and HIV-1-Unexposed-Uninfected Children||CIPRA SA|Yes|Active, not recruiting|April 2005|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|579|||Both|N/A|10 Weeks|Accepts Healthy Volunteers|||February 2011|February 14, 2011|December 17, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00099658||199441|
NCT00099970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M200-1203|Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy|Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo||Facet Biotech||Completed|December 2004|March 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2008|August 2, 2008|December 21, 2004||||||https://clinicaltrials.gov/show/NCT00099970||199417|
NCT00100308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLCIENCIAS -11150416347|Unfractioned Heparin for Treatment of Sepsis|Unfractioned Heparin for Treatment of Sepsis: A Randomized Clinical Trial (The HETRASE Study)||Universidad de Antioquia|Yes|Completed|July 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|December 28, 2004||No||No||https://clinicaltrials.gov/show/NCT00100308||199392|
NCT00100321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050044|Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study|Immunologic Studies of Tumors of the Pancreas||National Institutes of Health Clinical Center (CC)||Terminated|December 2004|November 2012||||N/A|Observational|N/A|||Actual|25|||Both|16 Years|N/A|No|||November 2012|January 14, 2014|December 28, 2004||No||No||https://clinicaltrials.gov/show/NCT00100321||199391|
NCT00100334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1019-04-01|Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease|Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease||PRAECIS Pharmaceuticals Inc.||Completed|December 2004|August 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|50 Years|80 Years|No|||September 2006|September 18, 2006|December 29, 2004||||||https://clinicaltrials.gov/show/NCT00100334||199390|
NCT00100594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA CH 004|Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China|A Feasibility Study of Lamivudine/Zidovudine (3TC/ZDV) Plus Efavirenz (EFV) as Initial Therapy of HIV-1 Infected Patients in a Rural Area of China||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||February 2011|February 22, 2011|January 3, 2005||||No||https://clinicaltrials.gov/show/NCT00100594||199370|
NCT00100607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE581A2203|Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis|Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis||Novartis||Completed|February 2004|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|676|||Female|50 Years|75 Years|No|||May 2012|May 7, 2012|January 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100607||199369|
NCT00100867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5190-P1054|Effects of Maternal Anti-HIV Treatment on Infants Born to HIV-Infected Women|Assessment of Safety and Toxicity Among Infants Born to HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World||AIDS Clinical Trials Group||Completed|June 2006|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|236|Samples With DNA|Blood and urine collection|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Infants born to HIV-infected women|March 2015|March 17, 2015|January 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00100867||199350|
NCT00101140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000405838|Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission|Phase II Study of Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia in First Remission||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|59 Years|No|||July 2006|July 6, 2006|January 7, 2005||||No||https://clinicaltrials.gov/show/NCT00101140||199331|
NCT00101387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000985-01A2|Effects of Lumbar PENS and Exercise in Older Adults With Chronic Low Back Pain|Functional Impact of PENS for 65+ Chronic Low Back Pain||University of Pittsburgh|Yes|Completed|September 2003|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|65 Years|N/A|No|||February 2011|February 17, 2011|January 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00101387||199314|
NCT00101400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100555|BAY43-9006 - Phase II in Advanced Breast Cancer|A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Subjects With Metastatic Breast Cancer.||Bayer|No|Completed|February 2004|January 2008|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||November 2013|November 19, 2013|January 10, 2005|No|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00101400||199313|Subjects had advanced disease and were heavily pretreated. Not all adverse events mentioned were assessed as drug-related. NCI-CTCAE was translated to Medical Dictionary for Regulatory Activities (MedDRA) for System Organ Classes (SOCs) only.
NCT00120900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA30007|Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee|See Detailed Description||GlaxoSmithKline||Completed|May 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1340|||Both|40 Years|N/A|No|||April 2015|April 14, 2015|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120900||197870|
NCT00120640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC#27253|Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate|||Yale University||Withdrawn|July 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|N/A|No|||September 2012|September 18, 2012|July 11, 2005|||funding|No||https://clinicaltrials.gov/show/NCT00120640||197890|
NCT00120939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0212|Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer|Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors||Pharmacyclics||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||May 2007|April 2, 2009|July 12, 2005||||||https://clinicaltrials.gov/show/NCT00120939||197867|
NCT00120952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2351-02|A Comparison Between Titanium Femoral Stem and Cobalt-Chromium Femoral Stem in Cemented Hip Arthroplasty|A Comparison Between Titanium Femoral Stem and Cobalt-Chromium Femoral Stem in Cemented Hip Arthroplasty. A Randomized Prospective Roentgen Stereogrammetric Analysis.||University of Aarhus||Active, not recruiting|January 2003|October 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|60 Years|75 Years|No|||August 2006|August 4, 2006|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120952||197866|
NCT00106171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI056990-01A1|Anti-HIV Medications for People Recently Infected With HIV|A Randomized Trial of HAART in Acute/Early HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2005|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2011|February 17, 2011|March 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00106171||198961|
NCT00106483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1291|Autoimmunity and Coronary Artery Disease - Ancillary to CARDIA|||Northwestern University||Completed|February 2005|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3020|||Both|N/A|N/A|No|Non-Probability Sample|All CARDIA participants with serum available in 1992 and coronary calcification measure in        years 2000 and 2005.|March 2015|March 18, 2015|March 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00106483||198938|
NCT00106496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-04-002|A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis|A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis||Astellas Pharma Inc|No|Completed|October 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|410|||Both|2 Years|N/A|No|||September 2014|September 17, 2014|March 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00106496||198937|
NCT00103051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08013|Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer|Phase II Study With Gefitinib (Sequentially) Following Gemcitabine/Cisplatin as Induction Regimen for Patients With Stage IIIA N2 NSCLC||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 2004|||November 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2012|July 13, 2012|February 7, 2005||||No||https://clinicaltrials.gov/show/NCT00103051||199187|
NCT00098735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A2302|Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation|Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation||Novartis||Completed|April 2004|||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Both|18 Years|65 Years|No|||November 2011|November 1, 2011|December 7, 2004||||||https://clinicaltrials.gov/show/NCT00098735||199507|
NCT00103350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG001-03|Safety of TG100-115 for Heart Attack Treated With Angioplasty|A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Prospective Study to Evaluate the Safety and Potential Efficacy of Single, Increasing Doses of TG100-115 in Subjects Undergoing Percutaneous Coronary Intervention for Acute Anterior ST Elevation Myocardial Infarction||TargeGen||Completed|January 2005|January 2008|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|80 Years|No|||May 2008|May 16, 2008|February 7, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00103350||199167|
NCT00098995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMCC-2004/354|Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer|A Phase I Study Of Tirapazamine In Combination With Radiation And Weekly Cisplatin In Patients With Locally Advanced Cervical Cancer||National Cancer Institute (NCI)||Completed|December 2004|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|22|||Female|N/A|N/A|No|||November 2006|June 25, 2013|December 8, 2004||||||https://clinicaltrials.gov/show/NCT00098995||199489|
NCT00099671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5214|Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs|A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2005|April 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|December 17, 2004||||||https://clinicaltrials.gov/show/NCT00099671||199440|
NCT00099983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|504|Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder|CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder|CSP #504|VA Office of Research and Development|Yes|Completed|October 2006|January 2011|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|296|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|December 21, 2004||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT00099983||199416|
NCT00100347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2458-04-01|Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors|A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors||PRAECIS Pharmaceuticals Inc.|No|Terminated|December 2004|July 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||July 2007|July 23, 2007|December 29, 2004|||terminated due to corporate transaction.|No||https://clinicaltrials.gov/show/NCT00100347||199389|
NCT00100360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050059|Hormonal Causes of Menstrual-Related Mood Disorders|5HT1A and SERT Imaging During Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Estrogen and Progesterone Replacement||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2004|||||N/A|Observational|N/A|||Actual|22|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|May 8, 2015|December 29, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00100360||199388|
NCT00100620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446O2306|Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis|Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis||Novartis||Completed|June 2004|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||802|||Both|18 Years|85 Years||||April 2012|April 26, 2012|January 3, 2005||||||https://clinicaltrials.gov/show/NCT00100620||199368|
NCT00100880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03176|Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors|A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors||National Cancer Institute (NCI)||Completed|November 2004|||November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|N/A|21 Years|No|||September 2013|September 27, 2013|January 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00100880||199349|
NCT00101153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-026|Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia|A Phase I Study Of Therapy With The Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined With Conventional Induction And Consolidation Chemotherapy For Previously Untreated Patients Over Age 55 With Acute Myeloid Leukemia (AML)||University Health Network, Toronto||Completed|April 2007|||March 2010|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|56 Years|N/A|No|||July 2015|July 22, 2015|January 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101153||199330|
NCT00101413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100557|BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)|A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma||Bayer|No|Completed|April 2004|April 2008|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||September 2013|September 29, 2013|January 10, 2005|Yes|Yes||No|April 17, 2009|https://clinicaltrials.gov/show/NCT00101413||199312|Due to rapid enrollment, no IA (interim analysis) was performed.
NCT00101725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRN 002 201|A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN 002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2004|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|245|||Both|18 Years|N/A|No|||November 2010|November 19, 2010|January 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101725||199289|
NCT00101738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2404|Freedom Study: Myfortic in Kidney Transplant Patients|Study to Investigate the Clinical Outcomes of Different Regimens of Myfortic® in De Novo Kidney Tx Pts Using Simulect® and Neoral® With or Without Steroids||Novartis||Completed|March 2003|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|342|||Both|18 Years|75 Years|No|||January 2011|January 28, 2011|January 12, 2005||Yes||||https://clinicaltrials.gov/show/NCT00101738||199288|
NCT00102128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC00202|Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.|Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure||Sanofi||Terminated|November 2002|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||May 2015|May 21, 2015|January 21, 2005|||DMC recommended stop|No||https://clinicaltrials.gov/show/NCT00102128||199258|
NCT00120419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAN2-study|Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)|||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|90|||Both|18 Years|N/A|No|||January 2006|July 21, 2009|July 11, 2005||||No||https://clinicaltrials.gov/show/NCT00120419||197907|
NCT00120653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050201|Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)|Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2005|June 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|72 Years|No|||June 2008|December 30, 2011|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00120653||197889|
NCT00120666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050188|Interhemispheric Plasticity in Humans|Interhemispheric Plasticity in Humans||National Institutes of Health Clinical Center (CC)||Completed|July 2005|June 2007||||N/A|Observational|N/A||||108|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2007|March 5, 2008|July 16, 2005||||No||https://clinicaltrials.gov/show/NCT00120666||197888|
NCT00127920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV53206s|Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients|A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer||Gynecologic Oncology Associates|No|Completed|August 2004|October 2012|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||March 2015|March 9, 2015|August 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00127920||197343|
NCT00128180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-010|Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Methylprednisolone as a Treatment for Presumed Hantavirus Cardiopulmonary Syndrome||University of New Mexico|Yes|Completed|January 2003|October 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|2 Years|N/A|No|||December 2014|December 5, 2014|August 5, 2005||No||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00128180||197323|While the study reached the target accrual of 60 confirmed cases, it was not powered to detect a difference in mortality. Higher disease severity in the placebo group at entry complicated both the efficacy and safety analyses.
NCT00106769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050126|Vaccine to Prevent West Nile Virus Disease|A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00 VP, in Healthy Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|March 2005|January 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 16, 2008|March 29, 2005||||No||https://clinicaltrials.gov/show/NCT00106769||198917|
NCT00097955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100C2201|Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria|Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria||Novartis||Completed|October 2004|April 2007||April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||496|||Both|18 Years|80 Years|No|||February 2011|February 24, 2011|December 1, 2004||||No||https://clinicaltrials.gov/show/NCT00097955||199560|
NCT00102739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA100773|SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)|See Detailed Description||GlaxoSmithKline|No|Completed|February 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|99|||Both|18 Years|N/A|No|||November 2012|April 11, 2013|February 1, 2005||||||https://clinicaltrials.gov/show/NCT00102739||199211|
NCT00102752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-301|Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer|A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma||Threshold Pharmaceuticals||Completed|December 2004|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||47|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|February 1, 2005||||||https://clinicaltrials.gov/show/NCT00102752||199210|
NCT00098748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001029|Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects|A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects||ViiV Healthcare|Yes|Completed|November 2004|April 2009|Actual|December 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|190|||Both|16 Years|N/A|No|||November 2010|November 19, 2010|December 7, 2004|Yes|Yes||No|March 25, 2010|https://clinicaltrials.gov/show/NCT00098748||199506|
NCT00099385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD045362|Comprehensive Elementary School Risk Prevention|Comprehensive Elementary School Risk Prevention||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|September 2004|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2620|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|December 13, 2004||No||No||https://clinicaltrials.gov/show/NCT00099385||199461|
NCT00099411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1279|Heart Muscle Viability and Remodeling in Individuals Post-Heart Attack|Myocardial Viability and Remodeling in the Occluded Artery Trial (OAT)-Ancillary to OAT||Tufts Medical Center|Yes|Active, not recruiting|January 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|People who have experienced a heart attack 3 to 28 days prior to study entry.|January 2013|January 31, 2013|December 13, 2004||No||No||https://clinicaltrials.gov/show/NCT00099411||199460|
NCT00099684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5209|Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults|A Pilot Study of the Safety, Efficacy, and Tolerability of Ezetimibe (Zetia) in Combination With Statin Therapy for the Treatment of Elevated LDL Cholesterol in HIV-Infected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2005|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|December 17, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00099684||199439|
NCT00099996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050060|Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia|A Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia||National Institutes of Health Clinical Center (CC)||Completed|December 2004|December 2005||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||3|||Both|N/A|N/A|No|||December 2005|March 3, 2008|December 21, 2004||||No||https://clinicaltrials.gov/show/NCT00099996||199415|
NCT00100009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050064|Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration|Multi-Center, Randomized, Phase II/III Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants With Neovascular Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Completed|December 2004|December 2006||||Phase 3|Interventional|Primary Purpose: Treatment||||30|||Both|50 Years|N/A|No|||December 2006|February 24, 2007|December 21, 2004||||No||https://clinicaltrials.gov/show/NCT00100009||199414|
NCT00100035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001627-01A1|Polarity Therapy for American Indian Caregivers of Dementia Patients|Polarity Therapy for Dementia Caregivers||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|August 2004|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 21, 2008|December 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00100035||199413|
NCT00100373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-035|RSV Challenge in Healthy Adults|Characterization of the Immune Response and Viral Shedding to Experimental Infection With Respiratory Syncytial Virus, Strain A-2, in Healthy Adults Ages 21 to 40 Years Old||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2004|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||13|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||February 2007|August 26, 2010|December 30, 2004||||||https://clinicaltrials.gov/show/NCT00100373||199387|
NCT00100633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO1AI55793|Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People|Immunologic Effects of CpG ODN Administration to HIV Uninfected and HIV Infected Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2004|October 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|September 29, 2008|January 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100633||199367|
NCT00100893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03178|IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer|A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer||City of Hope Medical Center|Yes|Completed|January 2005|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|37|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|January 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00100893||199348|
NCT00101166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13639|Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma|A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Malignant Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|October 2004|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||September 2012|November 16, 2012|January 7, 2005|Yes|Yes||No|October 18, 2012|https://clinicaltrials.gov/show/NCT00101166||199329|Due to the heterogeneity of the patient population, results were mainly descriptive in nature.
NCT00101426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-3201-253|Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy|||Sumitomo Dainippon Pharma Co., Ltd.||Completed|October 2004|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|70 Years|No|||January 2008|January 10, 2008|January 10, 2005||||||https://clinicaltrials.gov/show/NCT00101426||199311|
NCT00101439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-072|A Study to Evaluate the Effects of MK0653 on the Postprandial (Following a Meal) Lipoprotein Response in Patients With Primary Hypercholesterolemia (High Cholesterol) (0653-072)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Postprandial Lipoprotein Response in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|November 2005|November 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|60|||Both|18 Years|70 Years|No|||October 2015|October 21, 2015|January 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101439||199310|
NCT00101751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-2192|INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study|Efficacy and Safety of a Standard Titration Algorithm Coupled With a Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Algorithm, Alone, in Patients With Type 2 Diabetes Initiating NovoLog® Mix 70/30 Therapy|INITIATE plus|Novo Nordisk A/S|No|Completed|October 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4877|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|January 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101751||199287|
NCT00101764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050071|Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders|Phase I Study of Intravitreal Injections Versus Anterior Sub-Tenon Injections of Triamcinolone Acetonide Formulation for Macular Edema in Retinal Disorders||National Institutes of Health Clinical Center (CC)||Completed|January 2005|May 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||May 2008|September 26, 2015|January 12, 2005||||No||https://clinicaltrials.gov/show/NCT00101764||199286|
NCT00120432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE461104|Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation|Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation||Khon Kaen University|Yes|Completed|December 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|80|||Both|20 Years|80 Years|No|||March 2012|March 7, 2012|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00120432||197906|
NCT00127374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0541-F3R|Mood and Behavior Changes Among Overweight Adolescent Females|Mood and Behavior Changes Among Overweight Adolescent Females||University of Kentucky||Withdrawn|January 2005|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||100|||Female|10 Years|14 Years|Accepts Healthy Volunteers|||August 2007|January 8, 2008|August 4, 2005||No|withdrawn due to non-response. PI left university|No||https://clinicaltrials.gov/show/NCT00127374||197383|
NCT00127686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21163|Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep|Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Quality for Coughing Children and Their Parents||Penn State University||Completed|September 2005|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|105|||Both|2 Years|18 Years|No|||November 2007|November 30, 2007|August 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00127686||197360|
NCT00127699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21353EP|Triple Dye Plus Alcohol Versus Triple Dye Alone for Newborn Umbilical Cord Care|Triple Dye Plus Alcohol Versus Triple Dye Alone for Newborn Umbilical Cord Care||Penn State University||Completed|August 2005|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2007|November 30, 2007|August 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00127699||197359|
NCT00127933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18530|XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer|An Open-label Study of Xeloda Plus Taxotere on Treatment Response in Patients With HER2-neu-negative, and the Addition of Herceptin for HER2-neu-positive Breast Cancer||Hoffmann-La Roche||Completed|August 2005|July 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Female|18 Years|N/A|No|||July 2011|July 13, 2011|August 5, 2005|Yes|Yes||No|March 30, 2011|https://clinicaltrials.gov/show/NCT00127933||197342|
NCT00097968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2405|Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy|An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral® in Cardiac Transplant Recipients With Established Allograft Vasculopathy||Novartis||Completed|August 2004|||April 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|65 Years|No|||July 2010|July 9, 2010|December 1, 2004||||||https://clinicaltrials.gov/show/NCT00097968||199559|
NCT00098371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00111|Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia|A Phase II Study of Flavopiridol Administered as a 30 Minute Loading Dose Followed by a 4-Hour Continuous Infusion in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From CLL||National Cancer Institute (NCI)||Terminated|April 2005|||June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|December 7, 2004|Yes|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00098371||199529|
NCT00098345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00008|Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer|An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.||AstraZeneca||Active, not recruiting|November 2004|March 2016|Anticipated|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|130 Years|No|||December 2015|December 2, 2015|December 7, 2004|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00098345||199531|
NCT00098358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-02-C04-201|Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris||Critical Therapeutics||Active, not recruiting|November 2004|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|12 Years|N/A|No|||February 2007|February 5, 2007|December 7, 2004||||||https://clinicaltrials.gov/show/NCT00098358||199530|
NCT00098722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001028|Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects|MOTIVATE 2|ViiV Healthcare|Yes|Completed|December 2004|April 2011|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|474|||Both|16 Years|N/A|No|||April 2012|April 16, 2012|December 7, 2004|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00098722||199508|
NCT00099008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-GCRC-2107|Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women|Phase I Multiple Dose Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|March 2004|July 2006|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|December 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00099008||199488|
NCT00099424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2563|Exercise Training in Sarcoidosis (EXTRAS Study)|EXercise TRAining in Sarcoidosis (EXTRAS Study): A Prospective, Randomized, Controlled, Crossover Trial||University Hospital, Gasthuisberg||Completed|February 2004|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind||||30|||Both|N/A|N/A|No|||June 2008|June 4, 2008|December 13, 2004||||No||https://clinicaltrials.gov/show/NCT00099424||199459|
NCT00100048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-004|A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)|Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|January 2005|July 2010|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|206|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|December 22, 2004|Yes|Yes||No|January 21, 2010|https://clinicaltrials.gov/show/NCT00100048||199412|
NCT00100386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-081|Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial|Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2005|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||30000|||Both|N/A|N/A|No|||October 2007|June 9, 2011|December 30, 2004||||No||https://clinicaltrials.gov/show/NCT00100386||199386|
NCT00100646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI051986-01A2|Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa|A Randomized Clinical Trial Assessing Continuous HAART Versus Interrupted HAART in a Resource Poor Clinic||The Wistar Institute|Yes|Completed|March 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2013|August 26, 2014|January 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00100646||199366|
NCT00100906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13920|Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer|Randomized Phase II Trial Of Sequential ATRA Then IL-2 For Modulation Of Dendritic Cells And Treatment Of Metastatic Renal Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|August 2004|July 2013|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||July 2013|August 15, 2013|January 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100906||199347|
NCT00100919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050042|Sensing of Leg Position and Movement|Coupled Joint Proprioception and Multi-Joint Movement in the Lower Extremity: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|January 2005|July 2010||||N/A|Observational|N/A|||Actual|38|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||July 2010|July 7, 2010|January 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00100919||199346|
NCT00101179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00071|MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia|A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)||Active, not recruiting|November 2004|||April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||October 2015|March 11, 2016|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101179||199328|
NCT00101452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001638-01A1|Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression|A Double-Blind, Placebo-Controlled Study of the Alternative Therapy S-Adenosyl-L-Methionine (SAMe) vs Escitalopram in Major Depressive Disorder (MDD)||Massachusetts General Hospital|Yes|Completed|April 2005|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|199|||Both|18 Years|80 Years|No|||April 2015|April 7, 2015|January 10, 2005||No||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00101452||199309|
NCT00101777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020093|Ventilatory Physiology in Children at Risk for Anxiety|Ventilatory Physiology in Children at Risk for Anxiety||National Institutes of Health Clinical Center (CC)||Completed|December 2001|November 2005||||N/A|Observational|N/A||||479|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|January 12, 2005||||No||https://clinicaltrials.gov/show/NCT00101777||199285|
NCT00102193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512-04-205|Study for the Treatment of Ulcerative Colitis With Adacolumn|A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis||Otsuka America Pharmaceutical||Completed|July 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||168|||Both|18 Years|75 Years|No|||April 2008|September 5, 2008|January 24, 2005||||||https://clinicaltrials.gov/show/NCT00102193||199253|
NCT00102492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKF100092|Study Of GW679769 In Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.||GlaxoSmithKline||Completed|October 2004|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|356|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|January 29, 2005||||||https://clinicaltrials.gov/show/NCT00102492||199230|
NCT00102505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0220|A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)|Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)||Pharmacyclics||Completed|November 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||April 2009|April 2, 2009|January 29, 2005||||||https://clinicaltrials.gov/show/NCT00102505||199229|
NCT00127062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-194|Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street|Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street||Imperial College London|Yes|Completed|May 2003|August 2006|Actual|August 2006|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2||60|Samples Without DNA|Exhaled breath condensate|Both|18 Years|45 Years|No|||August 2005|March 25, 2015|August 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00127062||197407|
NCT00127712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0407-16|Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery|Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery||Indiana University|Yes|Completed|September 2004|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|40 Years|N/A|No|||September 2013|September 6, 2013|August 4, 2005|Yes|Yes||No|March 2, 2010|https://clinicaltrials.gov/show/NCT00127712||197358|
NCT00128245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981E2205|Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca|A 24-Week Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions Used Twice Daily in Patients With Moderate to Severe Keratoconjunctivitis Sicca||Novartis||Completed|September 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|August 5, 2005||||||https://clinicaltrials.gov/show/NCT00128245||197318|
NCT00127946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040416|Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses|Randomized Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses|AMNIOECHANGE|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2005|April 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||August 2005|August 8, 2011|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00127946||197341|
NCT00128219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-015|Prevention of GBS Colonization Via Immunity|A Phase II Randomized, Double-Blinded, Comparative Clinical Trial for a Group B Streptococcus Serotype III-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Acquisition of GBS Type III||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2003|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|667|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2009|January 15, 2015|August 5, 2005|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00128219||197320|
NCT00097981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004579|A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma|A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Subjects With Newly Diagnosed Multiple Myeloma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|January 2005|October 2009|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|December 1, 2004|Yes|Yes||No|October 2, 2008|https://clinicaltrials.gov/show/NCT00097981||199558|
NCT00098384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR 03|Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea|A Randomized, Double-Blind, Single Center, Comparative Dose Ranging Study of Rifaximin Vs. Placebo in the Prevention of Travelers' Diarrhea Due to Enteropathogenic Bacteria||DuPont, Hurbert L., MD||Completed|June 2003|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|May 8, 2006|December 7, 2004||||||https://clinicaltrials.gov/show/NCT00098384||199528|
NCT00098761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000396779|VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors|Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors||Pediatric Brain Tumor Consortium|Yes|Completed|February 2005|February 2008|Actual|October 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|N/A|21 Years|No|||June 2011|June 29, 2011|December 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098761||199505|
NCT00099021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00862|Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia|A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia||National Cancer Institute (NCI)||Completed|June 2003|January 2010|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Both|18 Years|N/A|No|||March 2013|June 3, 2015|December 8, 2004|Yes|Yes||No|October 13, 2009|https://clinicaltrials.gov/show/NCT00099021||199487|Study was closed prior to full accrual because results were very good and funding was discontinued (R-01 application was filed.)Immunohistochemistry (Outcomes #4 through #12) were not done due to laboratory limitations of time.
NCT00099047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00866|Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma|Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma||National Cancer Institute (NCI)|Yes|Completed|November 2004|November 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|23|||Both|18 Years|N/A|No|||October 2013|June 4, 2015|December 8, 2004|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00099047||199486|No overall limitations or caveats for this trial.
NCT00099437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997C00002|Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.|A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Fulvestrant (FASLODEX™) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy|CONFIRM|AstraZeneca||Active, not recruiting|February 2005|January 2017|Anticipated|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|834|||Female|45 Years|130 Years|No|||February 2016|February 3, 2016|December 13, 2004|Yes|Yes||No|February 23, 2010|https://clinicaltrials.gov/show/NCT00099437||199458|
NCT00099697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0013|Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans|Biologic Effects of DHEA in Humans||National Institute on Aging (NIA)||Completed|June 2001|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention||||56|||Both|65 Years|78 Years|Accepts Healthy Volunteers|||December 2004|December 9, 2009|December 17, 2004||||No||https://clinicaltrials.gov/show/NCT00099697||199438|
NCT00100399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-098|Fluarix Immunogenicity and Safety Trial|A Randomized, Double-blinded, Placebo Controlled Phase III Study to Evaluate the Immunogenicity and Safety of GSK Bio Influenza Vaccine (Fluarix) Administered Intramuscularly in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2004|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1050|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2007|August 26, 2010|December 30, 2004||||||https://clinicaltrials.gov/show/NCT00100399||199385|
NCT00100659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67767 (completed)|PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C|Pegylated Interferon +/- Ribavirin for Children With Hepatitis C||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 2004|February 2010|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|5 Years|18 Years|No|||July 2013|July 10, 2013|January 4, 2005|Yes|Yes||No|May 10, 2013|https://clinicaltrials.gov/show/NCT00100659||199365|
NCT00100672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LErafAON-ETU-104-R02|Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer|Phase I Study of an Easy-to-Use Intravenous Formulation of Liposome Entrapped C-raf Antisense Oligonucleotide (LErafAON-ETU) Administered on a Weekly Schedule in Patients With Advanced Cancer||INSYS Therapeutics Inc||Completed|December 2004|November 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|January 4, 2005||||||https://clinicaltrials.gov/show/NCT00100672||199364|
NCT00100932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-202|Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy|Phase II Study of E7389, a Halichondrin B Analog, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy||Eisai Inc.||Completed|December 2004|||June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|January 7, 2005|Yes|Yes||No|December 26, 2011|https://clinicaltrials.gov/show/NCT00100932||199345|
NCT00100945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0342|Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer|A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent||Alliance for Clinical Trials in Oncology|No|Completed|July 2005|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100945||199344|
NCT00101192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0076DD|Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix||Gynecologic Oncology Group|Yes|Completed|September 2004|||July 2011|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Female|18 Years|N/A|No|||February 2014|February 3, 2014|January 7, 2005|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00101192||199327|
NCT00101465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1281|Partnership Programs for Reducing Cardiovascular Disparities in Native Hawaiians|Partnership Programs to Reduce Cardiovascular Disparities - Heart Failure Disparities in Native Hawaiians||University of Hawaii||Completed|September 2004|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|276|||Both|21 Years|90 Years|No|Non-Probability Sample|Participants will be a Native Hawaiian or Pacific Islander (e.g., Samoan, Tongan,        Tahitian, Maori, Marshallese, etc.)|July 2009|July 2, 2013|January 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00101465||199308|
NCT00101478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1283|Improving Cardiovascular Treatment Approaches Among Minorities|Partnership Programs to Reduce Cardiovascular Disparities - Baltimore Partnership||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|September 2004|August 2009||||N/A|Observational|Observational Model: Case Control||1|Anticipated|800|||Both|N/A|N/A|No|Probability Sample|The study groups will be selected from primary and family health clinics, community, and        patients of physicians participating in the study.|April 2009|April 10, 2009|January 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00101478||199307|
NCT00101790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS044845|A Pilot Trial of Intravenous (IV) Pamidronate for Low Back Pain|A Pilot Trial of IV Pamidronate for Low Back Pain||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|September 2003|June 2010|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|44|||Both|21 Years|N/A|No|||January 2010|January 6, 2010|January 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101790||199284|
NCT00102206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1053|A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy|A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Two Antiretroviral Therapeutic Strategies: A Dual PI-Based HAART Regimen Versus a Multi-NRTI ART Regimen, in ART-Experienced Children and Youth Who Have Experienced Virologic Failure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Both|4 Years|21 Years|No|||May 2012|May 17, 2012|January 25, 2005||||||https://clinicaltrials.gov/show/NCT00102206||199252|
NCT00102518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-03-241|Aripiprazole Open-Label, Safety and Tolerability Study|A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) in the Treatment of Adolescent Patients With Schizophrenia and Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features|APEX 241|Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|September 2004|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|325|||Both|10 Years|17 Years|No|||July 2012|July 31, 2012|January 29, 2005|Yes|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT00102518||199228|
NCT00127387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-0015-211|Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia|A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia||The University of Texas Health Science Center at San Antonio||Terminated|May 2001|November 2005|Actual|September 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|54|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|August 3, 2005|||PI moved to Oregon|No||https://clinicaltrials.gov/show/NCT00127387||197382|
NCT00128258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#:0504126|Autologous Progenitor Stem Cell Therapy for Congestive Heart Failure|Phase 1 Study: Autologous Bone Marrow Progenitor Cell Treatment for Heart Failure||Amit, Patel N, M.D.|Yes|Terminated|May 2005|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 18, 2015|August 8, 2005|Yes|Yes|study no longer at pittsburgh|No||https://clinicaltrials.gov/show/NCT00128258||197317|
NCT00128544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-02C-004|Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B|A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B||Novartis||Completed|May 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|18 Years|70 Years||||May 2015|May 8, 2015|August 8, 2005||||||https://clinicaltrials.gov/show/NCT00128544||197296|
NCT00127985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAIF6MPMODS088UNK9071296|6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome|The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome|NAIF|Hospital Universitario Principe de Asturias|Yes|Recruiting|August 2005|July 2008|Anticipated|July 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||May 2008|May 12, 2008|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00127985||197338|
NCT00097994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0010|Does Menopause Matter?|Does Menopause Matter?||University of Pittsburgh||Completed|December 2004|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|732|||Female|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women from the University of Pittsburgh's Division of General Internal Medicine Outpatient        practice (GIMO)|May 2014|May 19, 2014|December 1, 2004||No||No||https://clinicaltrials.gov/show/NCT00097994||199557|
NCT00098007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2403|A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients|Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in Addition to Certican and Steroids in de Novo Heart Transplant Recipients||Novartis||Completed|August 2004|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|199|||Both|18 Years|65 Years|No|||November 2011|November 1, 2011|December 1, 2004||||||https://clinicaltrials.gov/show/NCT00098007||199556|
NCT00098020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050015|Retinoids for Minimal Change Disease and Focal Segmental Glomerulosclerosis|Retinoids for Podocyte Disease||National Institutes of Health Clinical Center (CC)||Recruiting|November 2004|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|N/A|No|||February 2016|February 24, 2016|December 1, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00098020||199555|
NCT00098397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02641|FR901228 in Treating Patients With Metastatic Breast Cancer|A Phase II Study Of Single Agent Depsipeptide (FK228) In Breast Cancer||National Cancer Institute (NCI)||Completed|February 2005|||September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098397||199527|
NCT00098423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00056|Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes|A Phase I And Pharmacological Trial Of 17-Allylamino -17-demethoxygeldanamycin (17-AAG) And Cytarabine In Refractory Leukemia And Myelodysplastic Syndrome||National Cancer Institute (NCI)||Completed|November 2004|||May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098423||199526|
NCT00098774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50202|Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma|Intensive Chemotherapy And Immunotherapy In Patients With Newly Diagnosed Primary CNS Lymphoma||Alliance for Clinical Trials in Oncology|No|Completed|October 2004|September 2014|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|N/A|N/A|No|||November 2015|November 23, 2015|December 8, 2004|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00098774||199504|
NCT00099060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I170|Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase I/II Study of GW572016 in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)|No|Completed|December 2004|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2012|January 24, 2014|December 8, 2004||No||No||https://clinicaltrials.gov/show/NCT00099060||199485|
NCT00100061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002090-01|Effects of Cranberry-Containing Products in Women With Recurrent Urinary Tract Infections (UTIs)|Dose Response to Cranberry of Women With Recurrent UTIs||National Center for Complementary and Integrative Health (NCCIH)|Yes|Active, not recruiting|May 2007|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|350|||Female|19 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|December 22, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00100061||199411|
NCT00100412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-001-99S1|Hyporeactivity and Gulf War Illness|Cardiovascular Hyporeactivity and Fatiguing Illness in Gulf War Veterans||VA Office of Research and Development||Completed|October 1999|September 2002||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|January 20, 2009|December 30, 2004||||No||https://clinicaltrials.gov/show/NCT00100412||199384|
NCT00100685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M200-1204|Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)|Phase 2 Open-Label Study of Volociximab (M200) in Patients With Metastatic Renal Cell Carcinoma||Abbott|Yes|Terminated|January 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|January 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100685||199363|
NCT00100958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000406002|Indole-3-Carbinol in Preventing Cancer in Healthy Participants|Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-Indolymethane (DIM) Nutritional Product||National Cancer Institute (NCI)||Completed|November 2004|||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2006|July 23, 2008|January 7, 2005||||No||https://clinicaltrials.gov/show/NCT00100958||199343|
NCT00101205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00075|Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma|A Phase I Trial of the Combination of Oxaliplatin (NSC 266046, IND 57004), Ifosfamide, and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas||National Cancer Institute (NCI)||Terminated|November 2004|||January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|21 Years|No|||April 2013|February 21, 2014|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101205||199326|
NCT00101231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01461|Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia|A Dose Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With Relapsed and Refractory Acute Leukemias||National Cancer Institute (NCI)||Terminated|October 2004|||November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|1 Year|N/A|No|||June 2013|June 3, 2013|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101231||199325|
NCT00101491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1282|STORIES-Stories to Communicate Risk About Tobacco|Partnership Programs to Reduce Cardiovascular Disparities - Deep South Partnerships for Prevention of CVD Disparities||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|September 2004|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|19 Years|78 Years|No|||February 2009|February 26, 2009|January 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00101491||199306|
NCT00101803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2355|Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|January 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|527|||Both|18 Years|80 Years|No|||May 2012|May 4, 2012|January 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101803||199283|
NCT00101816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-006|Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate|A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate||Bristol-Myers Squibb|No|Completed|December 2004|March 2008|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|N/A|No|||June 2010|August 3, 2010|January 13, 2005|Yes|Yes||No|December 15, 2009|https://clinicaltrials.gov/show/NCT00101816||199282|
NCT00102219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8426|A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer|A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer||Eli Lilly and Company||Completed|October 2004|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|77|||Female|18 Years|N/A|No|||November 2007|November 28, 2007|January 25, 2005||||||https://clinicaltrials.gov/show/NCT00102219||199251|
NCT00102232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNO4963|Effect of Phosphatidylcholine on Plasma Homocysteine in Healthy Volunteers|Effect of Choline Supplemented as Phosphatidylcholine on Post-Methionine Loading and Fasting Concentrations of Plasma Homocysteine in Healthy Volunteers||Wageningen Centre for Food Sciences||Completed|May 2003|July 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||26|||Male|50 Years|71 Years|Accepts Healthy Volunteers|||January 2005|June 23, 2005|January 25, 2005||||No||https://clinicaltrials.gov/show/NCT00102232||199250|
NCT00102531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-2421|Inhalation SLIT Cisplatin for the Treatment of Osteosarcoma Metastatic to the Lung|Phase Ib/IIa Study of SLIT Cisplatin by Inhalation in the Treatment of Patients Wtih Relapsed/Progressive Osteosarcoma Metastatic to the Lung||Insmed Incorporated||Completed|January 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|21|||Both|13 Years|50 Years|No|||July 2010|July 7, 2010|January 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102531||199227|
NCT00127088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peri-op|Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients|A Prospective Phase II of Peri-Operative Docetaxel + Laparoscopic Radical Prostatectomy in Patients With Localized Gleason 7 pT2a-pT2b Adenocarcinoma and a Risk of Relapse After Radical Prostatectomy||Gustave Roussy, Cancer Campus, Grand Paris||Suspended|October 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||37|||Male|18 Years|70 Years|No|||September 2006|September 7, 2006|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00127088||197405|
NCT00127101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-016|An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)|A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat; Zolinza) in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma||Merck Sharp & Dohme Corp.||Terminated|September 2005|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|23|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|August 2, 2005|No|Yes|The study was stopped due to low enrollment.|No|July 6, 2009|https://clinicaltrials.gov/show/NCT00127101||197404|Study was discontinued due to low enrollment
NCT00127738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216-2004|Renal Atherosclerotic Revascularization Evaluation: RAVE Study|||Sunnybrook Health Sciences Centre||Completed|January 2005|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|55 Years|N/A|No|||February 2006|January 8, 2007|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127738||197356|
NCT00127972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04IAT0035|2NN & CHARM Long-Term Follow-up Study|A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients||International Antiviral Therapy Evaluation Center|No|Completed|February 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|763|||Both|18 Years|N/A|No|||April 2007|April 27, 2007|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00127972||197339|
NCT00128271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0501|Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection|A Phase 1 Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients Chronically Infected With Hepatitis C Virus (HCV) Who Are Non-Responders or Relapsers After Treatment With Pegylated Interferon Plus Ribavirin||Peregrine Pharmaceuticals||Completed|August 2005|||August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||August 2006|April 28, 2008|August 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00128271||197316|
NCT00128297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2000-01|Pamidronate Administration in Breast Cancer Patients With Bone Metastases|Randomized, Multicentric Phase IV Clinical Trial for the Administration of Pamidronate in Breast Cancer Patients With Bone Metastases||Spanish Breast Cancer Research Group|No|Completed|January 2001|December 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||120|||Female|18 Years|N/A|No|||September 2009|September 25, 2009|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128297||197314|
NCT00098033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2127|Investigation of Clofarabine in Acute Leukemias|Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Acute Leukemias||FDA Office of Orphan Products Development||Completed|September 2002|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||64|||Both|12 Years|N/A|No|||December 2004|March 24, 2015|December 2, 2004||||||https://clinicaltrials.gov/show/NCT00098033||199554|
NCT00098436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-036|Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias|A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies||National Cancer Institute (NCI)||Completed|September 2004|August 2008|Actual|October 2006|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||August 2008|July 17, 2013|December 7, 2004||||No||https://clinicaltrials.gov/show/NCT00098436||199525|
NCT00098787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000398096|Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer|Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer||Eastern Cooperative Oncology Group|Yes|Active, not recruiting|July 2005|April 2016|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|247|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|December 8, 2004|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00098787||199503|
NCT00099710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0065|Curcumin in Patients With Mild to Moderate Alzheimer's Disease|A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Two Doses of Curcumin C3 Complex Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease||National Institute on Aging (NIA)||Completed|July 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|33|||Both|50 Years|N/A|No|||December 2009|December 2, 2009|December 17, 2004||||No||https://clinicaltrials.gov/show/NCT00099710||199437|
NCT00100074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0007-1|To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1|Safety and Tolerability Study of Sublingual Lobeline||National Institute on Drug Abuse (NIDA)||Active, not recruiting|September 2004|April 2005||||Phase 1|Interventional|Primary Purpose: Diagnostic||||8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2004|October 25, 2007|December 22, 2004||||||https://clinicaltrials.gov/show/NCT00100074||199410|
NCT00100087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPD-07-01|Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System|A Safety and Feasibility Study of the TheraSight(TM) Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration||Theragenics Corporation||Recruiting|October 2004|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|50 Years|N/A|No|||January 2005|June 23, 2005|December 22, 2004||||||https://clinicaltrials.gov/show/NCT00100087||199409|
NCT00100100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-MDS-0004-1|Modafinil for the Treatment of Cocaine Dependence - 1|Modafinil for the Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|October 2004|December 2006||||Phase 2|Interventional|Primary Purpose: Diagnostic||||210|||Both|18 Years|N/A|No|||July 2008|July 21, 2008|December 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100100||199408|
NCT00100451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-050-95S|Aging, Exercise, and Hormonal Influences of Fat Metabolism|Aging, Exercise, and Hormonal Influences of Fat Metabolism||VA Office of Research and Development||Completed|June 1994|June 2001||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|December 30, 2004||||No||https://clinicaltrials.gov/show/NCT00100451||199381|
NCT00100711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0222|Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease||Pharmacyclics||Terminated|October 2004|||February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|January 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00100711||199361|
NCT00100724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX006|Trial of rPA-102 Vaccine in Healthy Adult Volunteers|A Phase 2 Multi-Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers||VaxGen||Completed|April 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||480|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2006|January 10, 2006|January 5, 2005||||||https://clinicaltrials.gov/show/NCT00100724||199360|
NCT00100698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63639|Physiologic Growth Hormone Effects in HIV Lipodystrophy|Physiologic Growth Hormone Effects in HIV Lipodystrophy||Massachusetts General Hospital|Yes|Completed|January 2004|April 2009|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|60 Years|No|||July 2010|July 22, 2010|January 4, 2005|Yes|Yes||No|April 9, 2010|https://clinicaltrials.gov/show/NCT00100698||199362|
NCT00100971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000404382|Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia|Dendritic/Leukemic Fusion Cell Vaccine Therapy For AML Patients In First Remission; A Phase I Clinical Trial||Boston Medical Center||Terminated|April 2004|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment||||9|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|January 7, 2005|||Protocol is withdrawn due to inadequate accrual|No||https://clinicaltrials.gov/show/NCT00100971||199342|
NCT00101244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03193|SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma|A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Days 1-3 of a 21-Day Cycle in Patients With Solid Tumors||National Cancer Institute (NCI)||Terminated|November 2004|||February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|January 7, 2005|No|Yes|Administratively Complete.|No||https://clinicaltrials.gov/show/NCT00101244||199324|
NCT00101504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1286|Hypertension Education and Treatment Partnership for Reducing Ethnic Differences in the Risk of Cardiovascular Disease|Partnership Programs to Reduce Cardiovascular Disparities - Hypertension Education and Treatment (HEAT)||National Heart, Lung, and Blood Institute (NHLBI)||Not yet recruiting|September 2004|||||N/A|Observational|Observational Model: Defined Population|||||||Both|N/A|N/A|No|||April 2006|April 13, 2006|January 10, 2005||||No||https://clinicaltrials.gov/show/NCT00101504||199305|
NCT00101517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024856a|Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease|Partnership Programs to Reduce Cardiovascular Disparities - Morehouse-Emory Partnership|META-HEALTH|Emory University|Yes|Completed|September 2004|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|4024|||Both|30 Years|78 Years|Accepts Healthy Volunteers|Probability Sample|African-American and white residents in the metro Atlanta area (Cobb, DeKalb, Fulton,        Gwinnett counties) aged 30-78 years|September 2014|September 12, 2014|January 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00101517||199304|
NCT00101530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0621|Improving Prevention of Heart Disease in Latinos|Partnership Programs to Reduce Cardiovascular Disparities - Latinos Using Cardio Health Actions to Reduce Risk|LUCHAR|University of Colorado, Denver|No|Completed|September 2004|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|179|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|White and Latino patients in a safety net hospital|September 2015|September 29, 2015|January 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00101530||199303|
NCT00101829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ASJ01|Anti-CD20 Antibody Therapy for Sjogren's Syndrome|An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2004|August 2009|Actual|August 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|January 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101829||199281|
NCT00102245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050085|Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes|Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes||National Institutes of Health Clinical Center (CC)||Recruiting|January 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|1 Year|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00102245||199249|
NCT00102544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050091|Use of Tracking Devices to Locate Abnormalities During Invasive Procedures|Electromagnetic Tracking of Devices During Interventional Procedures||National Institutes of Health Clinical Center (CC)||Recruiting|January 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3215|||Both|18 Years|100 Years|No|||January 2016|January 22, 2016|January 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00102544||199226|
NCT00102557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050086|Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus|Hydroxychloroquine Versus Clobetasol 0.05% Rinse for the Treatment of Oral Lichen Planus||National Institutes of Health Clinical Center (CC)||Completed|January 2005|October 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||74|||Both|N/A|N/A|No|||October 2005|March 3, 2008|January 29, 2005||||No||https://clinicaltrials.gov/show/NCT00102557||199225|
NCT00097734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mc317|Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis|A Prospective, Multicenter, Open-Label, Randomized Clinical Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis||Klinikum Hanover-Siloah Hospital||Recruiting|July 2004|June 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||540|||Both|18 Years|75 Years|No|||February 2006|February 12, 2006|November 29, 2004||||No||https://clinicaltrials.gov/show/NCT00097734||199576|
NCT00127959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAT-0038-04|Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection|Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naïve Patients With HIV/HBV co-Infection||International Antiviral Therapy Evaluation Center|No|Completed|March 2004|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|70 Years|No|||April 2007|April 23, 2007|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00127959||197340|
NCT00127998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4314|Antimalarial Drug Resistance in Mali|Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali||Centers for Disease Control and Prevention||Completed|July 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1011|||Both|6 Months|59 Months|No|||August 2006|August 15, 2006|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00127998||197337|
NCT00128310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2000-04|Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients|Randomized Phase III Trial Comparing Vinorelbine vs. Gemcitabine Plus Vinorelbine in Patients With Advanced Breast Cancer, Previously Treated With Anthracyclines and Taxanes||Spanish Breast Cancer Research Group||Completed|January 2001|October 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||252|||Female|18 Years|N/A|No|||February 2007|February 6, 2007|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128310||197313|
NCT00128323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P.01/02/130|A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis|A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis||University of Malawi College of Medicine||Completed|November 2002|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||558|||Both|N/A|14 Years|No|||February 2008|February 7, 2008|August 7, 2005||||No||https://clinicaltrials.gov/show/NCT00128323||197312|
NCT00098800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000396796|Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries|A Multicenter Randomized Double-Blinded Trial for Chemoprevention of Ovarian Cancer: Modulation of Biomarkers and Spectral Properties Using Contrast Enhanced Ultrasound in High-Risk Women Using Fenretinide (4-HPR)||University of Arizona||Completed|October 2004|November 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|40|||Female|30 Years|N/A|No|||November 2006|March 23, 2010|December 8, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00098800||199502|
NCT00099086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000387959|Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer|Phase I Trial of Concurrent Taxotere With Radiation Therapy and Hormonal Therapy For Clinically Localized High Risk Prostate Cancer||Medical University of South Carolina|Yes|Active, not recruiting|July 2010|||January 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||December 2015|December 28, 2015|December 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099086||199484|
NCT00099450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025-101|Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers|Single-Center, Open-Labeled Dose Escalation Followed by Randomized, Double-Blind, Placebo-Controlled Cohort Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers||Merck Sharp & Dohme Corp.||Completed|December 2004|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|December 14, 2004||||||https://clinicaltrials.gov/show/NCT00099450||199457|
NCT00099723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS01305-01|The Effect of a Probiotic on Hepatic Steatosis|The Effect of a Probiotic on Hepatic Steatosis||VSL Pharmaceuticals||Terminated|October 2004|December 2005|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|45 Years|70 Years|No|||December 2004|February 10, 2010|December 17, 2004|||The hypothesis that probiotics would reduce hepatic steatosis in humans was not supported|||https://clinicaltrials.gov/show/NCT00099723||199436|
NCT00099736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A0125|Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant|Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant||Novartis||Completed|May 2003|||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||684|||Both|18 Years|65 Years|No|||November 2011|November 1, 2011|December 17, 2004||||||https://clinicaltrials.gov/show/NCT00099736||199435|
NCT00099749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A2218|Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant|Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant||Novartis||Completed|November 2003|||April 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||255|||Both|18 Years|65 Years||||November 2011|November 1, 2011|December 17, 2004||||||https://clinicaltrials.gov/show/NCT00099749||199434|
NCT00100126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231.301|APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat|A Phase III, Investigator Blind, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of APC-231 Sprinkle QD for 7 Days vs Penicillin VK 10 mg/kg QID for 10 Days in Pediatric Patients With Streptococcus Pyogenes||Advancis Pharmaceutical Corporation||Completed|December 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||500|||Both|6 Months|12 Years|No|||April 2005|October 23, 2006|December 23, 2004||||||https://clinicaltrials.gov/show/NCT00100126||199406|
NCT00100425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADE-ARCD2|Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome|Central Nervous System Modulation of Visceral Pain in Persian Gulf War Syndrome||VA Office of Research and Development||Completed|September 2000|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|72 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|December 30, 2004||||No||https://clinicaltrials.gov/show/NCT00100425||199383|
NCT00100438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epid-013-98S|Incidence of Parkinson's Disease Among Veterans|Incidence of Parkinson's Disease Among Veterans||VA Office of Research and Development||Completed|October 1998|September 2002||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||December 2004|January 20, 2009|December 30, 2004||||No||https://clinicaltrials.gov/show/NCT00100438||199382|
NCT00100984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18021|A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1|||Hoffmann-La Roche||Terminated||||||Phase 4|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|December 15, 2005|January 7, 2005||||||https://clinicaltrials.gov/show/NCT00100984||199341|
NCT00100997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-0408048-01|17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CNF1010 )17-(Allylamino)-17-Demethoxygeldanamycin [17-AAG]) in Patients With Gleevec-Resistent Chronic Myelogenous Leukemia||National Cancer Institute (NCI)||Completed|October 2004|October 2006|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2005|July 9, 2013|January 7, 2005||||No||https://clinicaltrials.gov/show/NCT00100997||199340|
NCT00101257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1942.00|Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD4+ Antigen-Specific T Cell Clones for Patients With Advanced Ovarian Cancer||Fred Hutchinson Cancer Research Center||Completed|October 2004|March 2010|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Female|18 Years|75 Years|No|||May 2010|May 5, 2010|January 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00101257||199323|
NCT00101543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3102R|Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training|Gait Training For Acute Stroke: FNS and Weight Supported Treadmill Training||VA Office of Research and Development||Completed|August 2003|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||January 2005|February 3, 2009|January 10, 2005||||||https://clinicaltrials.gov/show/NCT00101543||199302|
NCT00101569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-091|Aripiprazole Oral Acceptability Trial|Aripiprazole Oral Acceptability Trial||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|March 2004|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||59|||Both|18 Years|N/A|No|||July 2008|November 7, 2013|January 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101569||199301|
NCT00101842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9439|Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer|Phase I/II Study of Gemzar and Platinol Followed by Alimta and Gemzar in Patients With Advanced or Metastatic Bladder Cancer||Eli Lilly and Company||Completed|December 2004|July 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||61|||Both|18 Years|N/A|No|||August 2006|August 24, 2006|January 14, 2005||||||https://clinicaltrials.gov/show/NCT00101842||199280|
NCT00101855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS013302-03|Can Parental Activation Over the Internet Improve Pediatric Preventive Care?|Parent Initiated Prevention Program||Agency for Healthcare Research and Quality (AHRQ)||Active, not recruiting|October 2003|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||2000|||Both|N/A|11 Years|Accepts Healthy Volunteers|||January 2005|June 23, 2005|January 14, 2005||||No||https://clinicaltrials.gov/show/NCT00101855||199279|
NCT00102258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050077|Role of Nutrition and Hormones in Boys With Disordered Growth|Nutrients and Hormones: Effects in Boys With Disordered Growth - Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|January 2005|October 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Male|7 Years|10 Years|No|||October 2007|October 3, 2007|January 25, 2005||||No||https://clinicaltrials.gov/show/NCT00102258||199248|
NCT00102271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050088|Nitrite Infusion Studies|Evaluation of the Mechanism of NO Formation and Pharmacokinetics of Systemic Nitrite Infusion||National Institutes of Health Clinical Center (CC)||Completed|January 2005|April 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|36|||Both|21 Years|40 Years|No|||April 2011|June 2, 2011|January 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00102271||199247|
NCT00102570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050084|Clinical and Immunological Evaluation of Children With Allergies|Clinical and Immunological Evaluation of Children With Allergic Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2005|August 2010||||N/A|Observational|N/A|||Actual|270|||Both|3 Months|19 Years|No|||August 2010|August 11, 2010|January 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00102570||199224|
NCT00097747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-0401|Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers|A Phase 1, Double-blind, Placebo-controlled, Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers||Affymax|No|Completed|August 2004|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|28|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|November 30, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00097747||199575|
NCT00097760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1803|Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis|Safety Study of Natalizumab in Combination With Glatiramer Acetate (GA)||Biogen|Yes|Completed|June 2003|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|55 Years|No|||June 2009|June 17, 2009|November 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097760||199574|
NCT00098163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 027|Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers|A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||May 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 3, 2012|December 3, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098163||199544|
NCT00098189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ext. 1 to ASM981C201|Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis|A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis||Novartis||Completed|July 2004|||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|No|||August 2006|August 29, 2006|December 3, 2004||||||https://clinicaltrials.gov/show/NCT00098189||199543|
NCT00127452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-ZWH 0552|Alpha Omega Trial: Study of Omega-3 Fatty Acids and Coronary Mortality|Alpha Omega Trial: A Randomised, Placebo Controlled, Double Blind Intervention Study of the Effect of Low Doses of Omega-3 Fatty Acids on Cardiovascular Diseases in Patients With a History of Myocardial Infarction||Wageningen University|Yes|Completed|April 2002|June 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|4837|||Both|60 Years|80 Years|No|||July 2010|July 6, 2010|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00127452||197378|
NCT00128011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12|Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine|A Safety and Immunogenicity Study of a New Formulation of the Locally-Produced Bivalent Killed, Whole-Cell Oral Cholera Vaccine in Vietnamese Subjects||International Vaccine Institute||Completed|May 2005|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128011||197336|
NCT00128024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-RCT-2001-02|Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients|Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial||Kumamoto University||Completed|February 2002|February 2006|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|460|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128024||197335|
NCT00098813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01458|Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine|A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma||National Cancer Institute (NCI)||Completed|October 2004|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2013|May 13, 2014|December 8, 2004|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00098813||199501|
NCT00099099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0006|CALERIE (Tufts) - Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy|Dietary Energy Restriction and Metabolic Aging in Humans||National Institute on Aging (NIA)||Completed|March 2002|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||44|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||February 2006|December 9, 2009|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00099099||199483|
NCT00099463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050056|Phase I Study of a Vaccine for Severe Acute Respiratory Syndrome (SARS)|A Phase I Study of the Safety and Immunogenicity of a SARS Recombinant DNA Plasmid Vaccine, VRC-SRSDNA015-00-VP, in Healthy Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|December 2004|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2007|August 23, 2007|December 14, 2004||||No||https://clinicaltrials.gov/show/NCT00099463||199456|
NCT00099476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050047|Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure|Effects of Cocoa Consumption on Insulin Sensitivity and Capillary Recruitment in Subjects With Essential Hypertension||National Institutes of Health Clinical Center (CC)||Completed|December 2004|April 2009||||Phase 1|Interventional|Primary Purpose: Treatment|1|||65|||Both|21 Years|65 Years|No|||April 2009|April 17, 2009|December 14, 2004||No||No||https://clinicaltrials.gov/show/NCT00099476||199455|
NCT00099762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050050|Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia|Selective Venous Catheterization for the Localization of Phosphaturic Mesenchymal Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 2004|||September 2009|Actual|N/A|Observational|N/A||||45|||Both|8 Years|N/A|No|||September 2009|March 15, 2011|December 17, 2004||No||No||https://clinicaltrials.gov/show/NCT00099762||199433|
NCT00100113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0004-1|Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1|Study of Interactions Between GBR 12909 and Cocaine||National Institute on Drug Abuse (NIDA)||Active, not recruiting|June 2004|June 2005||||Phase 1|Interventional|Primary Purpose: Treatment||||24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2005|October 23, 2007|December 22, 2004||||||https://clinicaltrials.gov/show/NCT00100113||199407|
NCT00100464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP-013-98F|Serotonin and the Upper Airway in Obstructive Sleep Apnea|Serotonin and the Upper Airway in Obstructive Sleep Apnea||VA Office of Research and Development||Completed|November 2000|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|December 30, 2004||No||No||https://clinicaltrials.gov/show/NCT00100464||199380|
NCT00100477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADE-RCD1|Use of Topotecan in Patients With Refractory Acute Leukemia|Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia||VA Office of Research and Development||Completed|August 1998|June 2001|Actual|January 2001|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study|1||Actual|10|||Both|18 Years|60 Years|No|||September 2013|September 24, 2013|December 30, 2004||No||No||https://clinicaltrials.gov/show/NCT00100477||199379|
NCT00114985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-050|Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding|A Phase II Study of Late Rectal Toxicity Following 3-D Conformal External Beam Radiation Therapy Performed Using a Prostate Immobilization Device||Dana-Farber Cancer Institute|Yes|Completed|April 2001|October 2008|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Male|31 Years|N/A|No|||August 2012|August 22, 2012|June 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114985||198315|
NCT00114998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1294|CV Disease in Adolescents With Type 2 Diabetes|CV Disease in Adolescents With Type 2 Diabetes||Children's Hospital Medical Center, Cincinnati|No|Completed|June 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|750|||Both|10 Years|23 Years|Accepts Healthy Volunteers|Probability Sample|Three groups of adolescents:          1. Lean controls          2. Obese controls (without diabetes)          3. Obese with diabetes|July 2012|July 31, 2012|June 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00114998||198314|
NCT00115297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192|Montelukast for Early Life Wheezing|Effects of Montelukast on Early Life Wheezing||University of Massachusetts, Worcester|Yes|Active, not recruiting|September 2004|September 2020|Anticipated|September 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|150|||Both|1 Year|3 Years|No|||October 2015|October 31, 2015|June 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00115297||198291|
NCT00115310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C116|Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia||NeurogesX||Completed|June 2005|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|90 Years|No|||March 2008|March 4, 2008|June 21, 2005||||||https://clinicaltrials.gov/show/NCT00115310||198290|
NCT00116207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB:2002-0460|An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes|Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial||University of Michigan|Yes|Completed|January 2000|December 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|June 27, 2005|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00116207||198221|
NCT00112203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITOFD04-04|Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia|A Multicentre, Open-Label Extension Phase to Study the Long-Term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia||Axcan Pharma||Active, not recruiting|November 2004|August 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||January 2007|January 25, 2007|May 31, 2005||||No||https://clinicaltrials.gov/show/NCT00112203||198519|
NCT00113100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 530|Mechanisms of Skin Repair by Topical Estrogen|Mechanisms of Skin Repair by Topical Estrogen in Vivo||University of Michigan||Completed|August 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|152|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2008|May 20, 2015|June 3, 2005||||No||https://clinicaltrials.gov/show/NCT00113100||198459|
NCT00122772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33026|CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy|CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment||International Atomic Energy Agency|Yes|Completed|November 2005|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|601|||Female|18 Years|N/A|No|||October 2011|October 13, 2011|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00122772||197730|
NCT00122785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE44243|Single Injection of Dexamethasone for Acute Bronchiolitis in Young Children|Efficacy of Single Injection of Dexamethasone for Acute Bronchiolitis in Children Younger Than 2 Years Old: A Randomized, Double-Blind, Placebo Controlled Trial||Khon Kaen University||Completed|April 2002|September 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||170|||Both|N/A|24 Months|No|||February 2005|July 28, 2005|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00122785||197729|
NCT00123344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15099|Atrial Pacing for Termination and Prevention of Atrial Fibrillation|Atrial Pacing for Termination and Prevention of Atrial Fibrillation||University of Calgary||Completed|December 1999|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|120|||Both|18 Years|N/A|No|||December 2008|December 10, 2008|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123344||197687|
NCT00123071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236|Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network|Variability of Ventricular Mass, Volume, and Ejection Fraction in Pediatric Cardiomyopathy Patients (A Study Conducted by the Pediatric Heart Network)|VVV|New England Research Institutes|Yes|Completed|May 2005|June 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|N/A|22 Years|No|Non-Probability Sample|Patients up to 22 years of age with dilated cardiomyopathy followed at participating        clinical centers or newly diagnosed during the recruitment period|January 2013|January 24, 2013|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123071||197708|
NCT00112463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01037|Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma|A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas||National Cancer Institute (NCI)||Active, not recruiting|January 2004|||July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||June 2014|August 26, 2014|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112463||198500|
NCT00113360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0597|RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma|Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)||M.D. Anderson Cancer Center|No|Completed|January 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|June 7, 2005|Yes|Yes||No|August 12, 2009|https://clinicaltrials.gov/show/NCT00113360||198439|
NCT00123591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7CBI-1600|Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury|A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/NiaStase®) in Subjects With Brain Contusions||Novo Nordisk A/S|No|Completed|January 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|96|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00123591||197668|
NCT00105040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01103|A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures|A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures||UCB Pharma|No|Completed|September 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|4 Years|16 Years|No|||February 2015|February 27, 2015|March 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00105040||199045|
NCT00105053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0103|Vaccine Treatment for Hormone Refractory Prostate Cancer|A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Hormone Refractory Prostate Cancer||NewLink Genetics Corporation|No|Completed|March 2005|September 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|19 Years|N/A|No|||June 2009|June 30, 2009|March 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00105053||199044|
NCT00105339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 006|Simplified Consent for HIV Vaccine Trials|Simplified Consent for HIV Vaccine Trials||Westat|No|Completed|December 2003|February 2004|Actual|February 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|255|||Both|15 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|A sample of high-risk adolescents from 3 ATU sites will be recruited for both sets of        focus groups, the Illustration Style Preference Group (n = 30; 10 per site) and the Review        of Draft Groups (n = 45; 15 per site), and for the Comprehension/Recall Trial (n = 180; 60        per site), for total of 255 participants.|February 2016|February 29, 2016|March 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00105339||199023|
NCT00113555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URM01-01-01|Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence|Clinical Investigation of an Adjustable Continence Therapy (ACT) Periurethral Prosthetic System for Treatment of Female Stress Urinary Incontinence With or Without Hypermobility|ACT|Uromedica|No|Completed|December 2001|November 2010|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|June 10, 2011|June 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00113555||198424|
NCT00112827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|City of Hope 04064|Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma|Tandem High-Dose Therapy With Melphalan and Total Marrow Irradiation (TMI) With Peripheral Blood Progenitor Cell Support and Lenalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial||City of Hope Medical Center|Yes|Active, not recruiting|November 2004|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|N/A|70 Years|No|||December 2015|December 9, 2015|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112827||198478|
NCT00124761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021108|A Trial Comparing Radiosurgery With Surgery for Solitary Brain Metastases|A Randomised Trial of Surgery Plus Whole Brain Radiotherapy (WBRT) Versus Radiosurgery Plus WBRT for Solitary Brain Metastases||Royal Adelaide Hospital|No|Completed|December 2002|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||September 2010|September 2, 2010|July 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00124761||197582|
NCT00114426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-52684|Effects of NIMV on the Health Status of Chronic Obstructive Pulmonary Disease (COPD )Patients|Effects of Nocturnal Noninvasive Mechanical Ventilation on the Health Status of Patients With COPD||University of British Columbia||Terminated|January 2002|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|40 Years|90 Years|No|||February 2005|August 16, 2005|June 14, 2005||||No||https://clinicaltrials.gov/show/NCT00114426||198357|
NCT00114699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR5-HV01|Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy|A Phase 1, Randomized, Placebo-Controlled, Single-Injection, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ccr5mab004 (Human Monoclonal Igg4 Antibody To Ccr5) in Hiv-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy||Human Genome Sciences Inc.||Completed|April 2005|April 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|64 Years|No|||August 2013|August 1, 2013|June 16, 2005||||||https://clinicaltrials.gov/show/NCT00114699||198336|
NCT00113893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005179|SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.|A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic Syndromes||Scios, Inc.||Completed|May 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|N/A|No|||October 2013|October 15, 2013|June 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00113893||198398|
NCT00114244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02835|Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer|A Randomized Phase II Study of BAY 43-9006 in Combination With Gemcitabine in Metastatic Pancreatic Carcinoma||National Cancer Institute (NCI)||Completed|December 2004|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||October 2013|January 6, 2015|June 13, 2005|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT00114244||198371|
NCT00115011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-000888|Escitalopram for the Treatment of Self-Injurious Skin Picking|Escitalopram for the Treatment of Self-Injurious Skin Picking||Massachusetts General Hospital|No|Completed|September 2002|November 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||May 2008|May 19, 2008|June 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00115011||198313|
NCT00115869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IRB #324|Hutchinson Smoking Prevention Project|Hutchinson Smoking Prevention Project|HSPP|Fred Hutchinson Cancer Research Center|No|Completed|September 1984|August 1999|Actual|August 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8388|||Both|7 Years|9 Years|No|||October 2012|October 31, 2012|June 26, 2005||No||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00115869||198247|
NCT00112710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000429610|Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Recruiting|March 2005|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1350|||Both|18 Years|N/A|No|||May 2007|August 23, 2013|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112710||198483|
NCT00112723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01346|Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma|A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|December 2005|||February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||December 2013|December 6, 2013|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112723||198482|
NCT00112736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02921|Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma|Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)|Yes|Completed|April 2005|April 2014|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|June 2, 2005|Yes|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT00112736||198481|
NCT00113594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9483|Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder|Population Pharmacokinetic Study in Adolescent Patients With Schizophrenia or Bipolar I Disorder Treated With Olanzapine||Eli Lilly and Company||Completed|June 2005|March 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|13 Years|17 Years|No|||November 2007|November 5, 2007|June 9, 2005||||||https://clinicaltrials.gov/show/NCT00113594||198421|
NCT00123084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC001150|Efficacy of Voice Treatment for Parkinson's Disease|Efficacy of Voice Treatment for Parkinson's Disease||University of Colorado, Boulder||Recruiting|March 2002|December 2012|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|620|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||May 2011|May 6, 2011|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123084||197707|
NCT00123357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STI 20-029|Measuring Health Related Quality of Life in Veterans With Stroke|Measuring Health Related Quality of Life in Veterans With Stroke||VA Office of Research and Development|No|Completed||March 2003|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|||January 2005|April 6, 2015|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00123357||197686|
NCT00123604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK101598|Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes|Effects of Carvedilol and Metoprolol on Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus||St. Paul Heart Clinic|No|Completed|June 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|30 Years|80 Years|No|||November 2014|November 17, 2014|July 21, 2005|Yes|Yes||No|June 29, 2012|https://clinicaltrials.gov/show/NCT00123604||197667|The sample size was relatively small
NCT00123331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD_cardio_352/2003_dengler|Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation|Rapamycin Use in CNI-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation||Heidelberg University||Completed|October 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2005|August 1, 2005|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00123331||197688|
NCT00124150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMASH trial|Intravenous Magnesium Sulfate in Aneurysmal Subarachnoid Haemorrhage (IMASH)|Phase 3 Study (Multi-center, Randomized Controlled Clinical Trial) of Intravenous Magnesium Sulfate to Improve Outcome After Aneurysmal Subarachnoid Haemorrhage||Chinese University of Hong Kong|Yes|Completed|June 2002|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|327|||Both|18 Years|80 Years|No|||July 2009|December 21, 2009|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124150||197626|
NCT00104806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415574|Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes|Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome||Comprehensive Cancer Center of Wake Forest University|No|Terminated|November 2004|May 2010|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||July 2012|July 12, 2012|March 3, 2005||No|sponsor discontinues support|No||https://clinicaltrials.gov/show/NCT00104806||199061|
NCT00105066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0017|The Effects of Metformin on Blood Vessel Structure and Function|The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)||National Institutes of Health Clinical Center (CC)|No|Completed|January 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|21 Years|80 Years|No|||August 2012|August 2, 2012|March 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00105066||199043|
NCT00105352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMTTGST (IND) (completed)|Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials|Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|November 2004|November 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||120|||Both|8 Years|35 Years|No|||January 2011|January 31, 2011|March 11, 2005||||No||https://clinicaltrials.gov/show/NCT00105352||199022|
NCT00105638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-076|Telehealth Education Program for Caregivers of Veterans With Dementia|A Telehealth Education Program for Caregivers of Veterans With Dementia||VA Office of Research and Development|No|Completed|September 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|160|||Both|N/A|N/A|No|||November 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105638||199001|
NCT00114764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020163|Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)|A Multicentre, Double-Blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)||Amgen||Completed|March 2003|August 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||October 2008|October 30, 2008|June 17, 2005||||No||https://clinicaltrials.gov/show/NCT00114764||198332|
NCT00114777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-027|Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant|Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)|BENEFIT-EXT|Bristol-Myers Squibb|No|Completed|February 2005|September 2014|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|580|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|June 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114777||198331|
NCT00124774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-269|Nucleoplasty for Contained Herniated Lumbar Discs|Nucleoplasty for Contained Herniated Lumbar Discs: A Randomised, Double Blind, Prospective Comparison With Sham Treatment||Rijnstate Hospital||Completed|November 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|60 Years|No|||March 2008|March 28, 2008|July 27, 2005||||No||https://clinicaltrials.gov/show/NCT00124774||197581|
NCT00116493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.03.04.22.A2|Severe Anemia Treatment Trials, Pakistan|Evaluation of Anthelminthics and Multivitamins for Treatment of Severe Anemia in Pregnant Women and Children 6-24 Months of Age in Pakistan||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|April 2004|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1009|||Both|6 Months|45 Years|No|||April 2012|April 6, 2012|June 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00116493||198199|
NCT00113373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02654|Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer|A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|May 2005|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||December 2012|May 28, 2015|June 7, 2005|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00113373||198438|The clinical trial was a two-stage design, accruing approximately 25 patients in each stage. Early termination of the study would result if warranted from an interim futility analysis. This study stopped early for lack of treatment efficacy.
NCT00114439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSWAHS HREC 2005/047|Lithium Cannabis Withdrawal Study|An Open Label Trial of Lithium for the Management of Cannabis Withdrawal||Sydney South West Area Health Service||Completed|September 2005|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2007|September 26, 2007|June 14, 2005||||No||https://clinicaltrials.gov/show/NCT00114439||198356|
NCT00116194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0021|The LIFE Study: Lifestyle Interventions and Independence for Elders, Pilot|Physical Exercise to Prevent Disability Pilot Study||National Institute on Aging (NIA)||Completed|April 2004|January 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||424|||Both|70 Years|89 Years|Accepts Healthy Volunteers|||December 2008|March 24, 2010|June 27, 2005||||No||https://clinicaltrials.gov/show/NCT00116194||198222|
NCT00122564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS VAC14|Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers|Phase I Study Evaluating the Systemic and Mucosal Safety and Immunogenicity of a Recombinant HIV-1 Gp 160 (MN/LAI) Administered by Transmucosal (Nasal or Vaginal) Routes, Alone or Formulated With DC-Chol, in HIV Negative Volunteers (ANRS VAC14)||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|June 2003|April 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||36|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||November 2005|November 10, 2005|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122564||197746|
NCT00122798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 50|Improved Stroke Outcome at 6 Months|Improved Stroke Outcome at 6 Months Attained by a Chain of Structured Acute Treatment With Integrated Rehabilitation and Supported Discharge||Kantonsspital Baden||Completed|January 2002|January 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||200|||Both|18 Years|N/A|No|||December 2004|June 23, 2006|July 21, 2005||||No||https://clinicaltrials.gov/show/NCT00122798||197728|
NCT00122811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG/97010|The Hypertension in the Very Elderly Trial (HYVET)|The Hypertension in the Very Elderly Trial (HYVET)||Imperial College London|Yes|Active, not recruiting|November 2000|October 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4000|||Both|80 Years|N/A|No|||August 2007|August 20, 2007|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00122811||197727|
NCT00123617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-239|The Impact of Cardiac Rehabilitation Participation on Cardiac Syndrome X|The Impact of Cardiac Rehabilitation on Angina Frequency, Psychological Morbidity and Quality of Life in Women With Syndrome X||National Heart and Lung Institute|No|Completed|January 2003|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Female|30 Years|80 Years|No|||April 2015|April 21, 2015|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123617||197666|
NCT00123825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-065|Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer|A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer||Dana-Farber Cancer Institute||Completed|July 2002|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00123825||197651|
NCT00123838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostate Stage 3|Positioning and Tracking the Prostate During External Beam Radiation|Beacon® Transponder Implantation and Localization in the Prostate||Varian Medical|No|Completed|July 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|July 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00123838||197650|
NCT00123851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-269|Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer|A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer||Dana-Farber Cancer Institute||Completed|March 2003|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|July 25, 2005||||||https://clinicaltrials.gov/show/NCT00123851||197649|
NCT00124163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|633|Evaluation of Stool Tagging for Improved Patient Compliance|CT Colonography Ph. I CDI Trial: Evaluation of Stool Tagging for Improved Patient Compliance||Center for Diagnostic Imaging||Recruiting|July 2005|||||Phase 1|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal||||60|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||January 2006|January 31, 2006|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00124163||197625|
NCT00105365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3120-P|Shoe Modification and Knee Osteoarthritis|Shoe Modification and Knee Osteoarthritis||VA Office of Research and Development|No|Completed|March 2004|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|45 Years|85 Years|No|||October 2015|October 20, 2015|March 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00105365||199021|
NCT00105651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 98-500|A Smoking, Alcohol, and Depression Intervention for Head and Neck Cancer|A Smoking, Alcohol, and Depression Intervention for Head and Neck Cancer||VA Office of Research and Development|No|Completed||March 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|128|||Both|18 Years|N/A|No|||February 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105651||199000|
NCT00105885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEL 01-146|Telephone Care as a Substitute for Routine Psychiatric Medication|Telephone Care as a Substitute for Routine Psychiatric Medication Management|Telepsych|VA Office of Research and Development|No|Completed|November 2003|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||October 2008|February 6, 2014|March 17, 2005||||No||https://clinicaltrials.gov/show/NCT00105885||198982|
NCT00115622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR30003|Study In Adults And Adolescents With Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 Days in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis||GlaxoSmithKline||Completed|December 2004|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|304|||Both|12 Years|N/A|No|||April 2015|April 14, 2015|June 23, 2005||||No||https://clinicaltrials.gov/show/NCT00115622||198266|
NCT00115635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR0416|Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer|A Phase I/II Study With Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer||Herlev Hospital|Yes|Completed|March 2005|July 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|18 Years|95 Years|No|||October 2007|October 1, 2007|June 23, 2005||||No||https://clinicaltrials.gov/show/NCT00115635||198265|
NCT00114257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02657|Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders|A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease||National Cancer Institute (NCI)||Completed|May 2005|||September 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2006|February 8, 2013|June 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00114257||198370|
NCT00113620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-AVR-109|Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy|A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dextromethorphan and Quinidine at Two Dose Levels in the Treatment of the Pain of Diabetic Neuropathy||Avanir Pharmaceuticals||Completed|July 2005|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|450|||Both|18 Years|80 Years|No|||May 2014|May 5, 2014|June 9, 2005||||||https://clinicaltrials.gov/show/NCT00113620||198419|
NCT00113880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM025|A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults|Post-Marketing Evaluation of the Safety of Influenza Virus Vaccine Live, Intranasal (FluMist) in Healthy Children and Healthy Adults 5-49 Years of Age||MedImmune LLC|No|Completed|October 2003|June 2010|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|63061|||Both|5 Years|49 Years|Accepts Healthy Volunteers|Probability Sample|This is an observational study conducted over multiple years with multiple non-randomized        control groups.|December 2012|December 3, 2012|June 10, 2005|Yes|Yes||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00113880||198399|
NCT00115596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH 05-05-040|Reforming Pediatric Procedural Training|Reforming Pediatric Procedural Training: Developing an Evidence-Based Curriculum||Children's Hospital Boston||Active, not recruiting|June 2005|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||38|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|June 26, 2005|June 23, 2005||||No||https://clinicaltrials.gov/show/NCT00115596||198268|
NCT00115856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P-000114|Imaging of Plaque With Magnetic Resonance Imaging (MRI)|Imaging of Plaque in Atherosclerosis With Intravascular MRI||Brigham and Women's Hospital|No|Completed|January 2001|June 2005|Actual|June 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|25 Years|80 Years||||July 2015|July 31, 2015|June 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00115856||198248|
NCT00116454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-003883-31|Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis|A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis|Lipiocis|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|July 2005|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|75 Years|No|||September 2013|September 20, 2013|June 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00116454||198202|
NCT00122577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 107 Puzzle 2|Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients|Randomized Open Label Study Assessing the Antiviral Activity, Toxicity and Pharmacologic Interaction of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir as Part of a Salvage Regimen in HIV Infected Patients With Multiple Treatment Failures (ANRS 107 Trial PUZZLE 2)||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|March 2002|July 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||July 2005|July 27, 2005|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122577||197745|
NCT00122330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIUMPH|Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients|Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients||Alexion Pharmaceuticals||Completed|October 2004|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||75|||Both|18 Years|N/A|No|||November 2006|November 30, 2006|July 18, 2005||||||https://clinicaltrials.gov/show/NCT00122330||197764|
NCT00122343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-019|AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)|A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer||Merck Sharp & Dohme Corp.|No|Completed|August 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||February 2015|February 18, 2015|July 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00122343||197763|
NCT00123903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR103560|COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria|A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria||GlaxoSmithKline||Completed|July 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1220|||Both|18 Years|80 Years|No|||October 2010|October 1, 2010|July 22, 2005||||||https://clinicaltrials.gov/show/NCT00123903||197645|
NCT00124202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229-2003|Effect of a Fatty Meal on Endoscopic Retrograde Cholangiopancreatography (ERCP)|Effect of a Fatty Meal on Cannulation at Endoscopic Retrograde Cholangiopancreatography||Emory University|No|Completed|May 2003|May 2007|Actual|December 2004|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|July 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00124202||197622|
NCT00123097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14543|Clinical Trial of New Elastomer for Maxillofacial Prosthetics|Multicenter Trial of CPE for Maxillofacial Prosthetics||University of Louisville||Active, not recruiting|February 2005|August 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|N/A|No|||June 2011|June 10, 2011|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123097||197706|
NCT00123110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0031|Insulin Resistance and Testosterone in Women|Insulin Resistance and Testosterone in Non-Diabetic Postmenopausal Women||University of Pennsylvania|No|Completed|July 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Female|50 Years|79 Years|Accepts Healthy Volunteers|||March 2010|March 9, 2010|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00123110||197705|
NCT00123370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC05025|Trial of Modafinil for Methamphetamine Dependence|Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence||The University of New South Wales|No|Active, not recruiting|July 2006|September 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|87|||Both|18 Years|N/A|No|||July 2006|April 29, 2007|July 21, 2005||||No||https://clinicaltrials.gov/show/NCT00123370||197685|
NCT00123630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13623|A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab|A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab||University of Utah|No|Completed|November 2005|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|60 Years|No|||August 2013|August 9, 2013|July 21, 2005||No||No|September 5, 2012|https://clinicaltrials.gov/show/NCT00123630||197665|small numbers enrolled
NCT00123864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-4-0003|Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function|A Phase I/II Feasibility Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function||AHS Cancer Control Alberta||Completed|January 2000|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||July 2005|February 8, 2010|July 22, 2005||||No||https://clinicaltrials.gov/show/NCT00123864||197648|
NCT00123877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPX-100-003|Study of GPX-100 in the Treatment of Metastatic Breast Cancer|Phase II, Open Label, Non-Randomized, Efficacy and Safety Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer||Gem Pharmaceuticals||Terminated|March 2005|November 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|N/A|No|||January 2007|January 5, 2007|July 23, 2005||||No||https://clinicaltrials.gov/show/NCT00123877||197647|
NCT00124176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2004-12-4130|Continuous Levalbuterol for Treatment of Status Asthmaticus in Children|Continuous Levalbuterol for Treatment of Status Asthmaticus in Children||Children's Hospital of Philadelphia|Yes|Completed|April 2004|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|6 Years|18 Years|No|||December 2012|February 12, 2013|July 25, 2005|Yes|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00124176||197624|
NCT00124189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRN163L CP04-151|Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease||Geron Corporation|No|Completed|July 2005|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00124189||197623|
NCT00105378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEREASYEFF014-91-055|Dutch EASYcare Study|Effectiveness of EASYcare-Based Geriatric Intermediate Care||Radboud University||Completed|April 2003|July 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|155|||Both|70 Years|N/A|No|||August 2007|August 9, 2007|March 11, 2005||||No||https://clinicaltrials.gov/show/NCT00105378||199020|
NCT00105404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050107|Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation|A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|March 2005|October 2006||||Phase 3|Interventional|Primary Purpose: Treatment||||5|||Both|18 Years|N/A|No|||October 2006|September 26, 2015|March 11, 2005||||No||https://clinicaltrials.gov/show/NCT00105404||199019|
NCT00105664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHI 02-062|Collaborative Cardiac Care Project|Collaborative Cardiac Care Project (C3P)|C3P|VA Office of Research and Development|Yes|Completed|October 2004|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|287|||Both|18 Years|N/A|No|||October 2007|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105664||198999|
NCT00105898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEL 02-100|Internet-based Diabetes Education and Case Management|Internet-based Diabetes Education and Case Management||VA Office of Research and Development|No|Completed|February 2005|June 2010|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|152|||Both|25 Years|79 Years|No|||August 2010|April 6, 2015|March 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00105898||198981|
NCT00106184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01AR42273|Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)|Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)||University of Pittsburgh|Yes|Completed|March 2006|August 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|200|||Both|5 Years|N/A|No|||March 2015|March 3, 2015|March 21, 2005|Yes|Yes||No|October 10, 2013|https://clinicaltrials.gov/show/NCT00106184||198960|There was an overestimate of the rapidity of the rituximab response and an underestimate of DOI in those receiving placebo.
NCT00106509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD3-170-301|A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea|A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea||Sanofi||Completed|March 2005|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||520|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|March 25, 2005||||||https://clinicaltrials.gov/show/NCT00106509||198936|
NCT00112229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD 2000-018|Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients|Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients With CpG7909, Tumor Antigenic Peptides and Montanide||Centre Hospitalier Universitaire Vaudois||Completed|April 2003|June 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|May 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00112229||198517|
NCT00125268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|927-05 00|Near Infrared Light for the Treatment of Painful Peripheral Neuropathy|A Phase III, Double Blind, Randomized, Placebo-controlled Study to Assess the Efficacy of Adjunct Monochromatic Near-infrared Photoenergy (MIRE) in Patients With Painful Axonal Peripheral Neuropathy||Mayo Clinic|Yes|Terminated|July 2005|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|85 Years|No|||August 2012|August 2, 2012|July 27, 2005||No|Unable to enroll enough patients|No|August 2, 2012|https://clinicaltrials.gov/show/NCT00125268||197543|This study was terminated early because the study was unable to enroll enough patients.
NCT00125281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050207|SAMe to Treat Biliary Cirrhosis Symptoms|S-Adenosyl Methionine for Symptomatic Treatment of Primary Biliary Cirrhosis||National Institutes of Health Clinical Center (CC)||Terminated|July 2005|July 2008|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|21 Years|N/A|No|||July 2008|September 26, 2015|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125281||197542|
NCT00125294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17208|Sublingual Methadone for the Management of Cancer Breakthrough Pain|Evaluation of a Dose Titration Protocol for Sublingual Methadone Hydrochloride for the Management of Cancer-related Breakthrough Pain||AHS Cancer Control Alberta||Completed|September 2003|January 2007|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||August 2011|January 18, 2012|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125294||197541|
NCT00113126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCS # 356|Staccato: A Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection|A Randomized Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection||University Hospital, Geneva||Completed|January 2002|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||526|||Both|18 Years|N/A|No|||June 2005|November 28, 2006|June 3, 2005||||No||https://clinicaltrials.gov/show/NCT00113126||198457|
NCT00114192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11212|Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-Small Cell Lung Cancer||University of Virginia|Yes|Completed|June 2004|||June 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2010|January 29, 2010|June 13, 2005||||No||https://clinicaltrials.gov/show/NCT00114192||198375|
NCT00121992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 9805|Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (5 FAC) as Adjuvant Treatment of Breast Cancer Patients|A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes||Spanish Breast Cancer Research Group||Completed|June 1999|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1054|||Female|18 Years|70 Years|No|||August 2005|August 8, 2005|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00121992||197789|
NCT00122291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16080|A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer|A Phase 2 Study of Preoperative Radiation Therapy and Capecitabine (an Oral Fluoropyrimidine Carbamate) in Locally Advanced Rectal Cancer||AHS Cancer Control Alberta||Active, not recruiting|January 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|66|||Both|17 Years|N/A|No|||August 2011|January 18, 2012|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00122291||197767|
NCT00122304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEPHERD|Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab|Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study||Alexion Pharmaceuticals||Completed|December 2004|November 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||85|||Both|18 Years|N/A|No|||February 2007|February 20, 2007|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122304||197766|
NCT00122005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPMC-EACRI-IRB-02-119|GVAX in Advanced Prostate Cancer Patients Made Lymphopenic|Phase I/II Study of Human GM-CSF Gene-Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (GVAX®) in Advanced Prostate Cancer Patients Made Lymphopenic and Infused With Autologous Peripheral Blood Mononuclear Cells||Providence Health & Services||Active, not recruiting|July 2005|July 2005|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Male|18 Years|N/A|No|||February 2009|February 23, 2009|July 18, 2005||||||https://clinicaltrials.gov/show/NCT00122005||197788|
NCT00122018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPORT|An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery|N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery.||Pulmonary Critical Care Associates of Baltimore|No|Completed|May 2002|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4|||80|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|July 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00122018||197787|
NCT00122824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5075|Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder|Duloxetine Hydrochloride 60 mg or 120 mg Once Daily Compared With Placebo in Patients With Generalized Anxiety Disorder.||Eli Lilly and Company||Completed|June 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|July 20, 2005||||||https://clinicaltrials.gov/show/NCT00122824||197726|
NCT00122837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7106|A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder|A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder||Eli Lilly and Company||Completed|April 2005|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||560|||Both|18 Years|N/A|No|||October 2007|October 17, 2007|July 20, 2005||||||https://clinicaltrials.gov/show/NCT00122837||197725|
NCT00124527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IROF-019|Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer|Phase 2 Clinical Trial of Bi-Weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer||Eisai Inc.||Completed|March 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||November 2008|November 6, 2008|July 26, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00124527||197597|
NCT00124540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.5|Misoprostol for Preventing Postpartum Hemorrhage|Misoprostol for Preventing Postpartum Hemorrhage||Gynuity Health Projects||Completed|August 2005|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1200|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2008|May 26, 2008|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124540||197596|
NCT00124215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-5005-01|Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection|A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C Infection||GlobeImmune||Completed|June 2005|February 2010|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|July 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00124215||197621|
NCT00124228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS05/0273|Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis|Effects of Intravenous Albumin Administration on Renal Function and Survival in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. A Prospective, Stratified, Randomized and Controlled Study.|Infecir|Hospital Clinic of Barcelona|No|Completed|November 2004|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|80 Years|No|||August 2009|May 26, 2010|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124228||197620|
NCT00124501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003103|Effectiveness of Biofeedback-Assisted Relaxation Training in Children With Eosinophilic Duodenitis|The Impact of Biofeedback-Assisted Relaxation Training on Pain and Functional Disability in Children Diagnosed With Eosinophilic Duodenitis: Pilot Study||Children's Mercy Hospital Kansas City|No|Completed|October 2004|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|18 Years|No|||May 2008|May 29, 2008|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124501||197599|
NCT00124514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1045|Triptorelin for Ovary Protection in Childhood Onset Lupus|||Children's Hospital Medical Center, Cincinnati|Yes|Completed|June 2003|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|30|||Female|9 Years|21 Years|No|||July 2014|July 25, 2014|July 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00124514||197598|
NCT00123890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR104627|Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140|A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.||GlaxoSmithKline||Terminated|June 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|July 22, 2005|Yes|Yes|The study was terminated due to hepatoxicity of compound|||https://clinicaltrials.gov/show/NCT00123890||197646|
NCT00105105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0069|Mifepristone as Adjunctive Therapy in Alzheimer's Disease|A Double-blind, Placebo-controlled Trial of the Safety and Efficacy of C-1073 (Mifepristone) as Adjunctive Therapy in Alzheimer's Disease||National Institute on Aging (NIA)||Terminated|April 2003|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|N/A|N/A|No|||September 2005|December 10, 2009|March 4, 2005||||||https://clinicaltrials.gov/show/NCT00105105||199040|
NCT00101699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31AT001041-01|Effects of Soy Consumption on Symptoms of Menopause|Influence of Soy Consumption on Menopause||National Center for Complementary and Integrative Health (NCCIH)||Completed|November 2001|August 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||120|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||January 2005|August 17, 2006|January 12, 2005||||No||https://clinicaltrials.gov/show/NCT00101699||199291|
NCT00102076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020054|Implementing the Assent Requirement for Research With Children|Implementing the Assent Requirement for Research With Children||National Institutes of Health Clinical Center (CC)||Completed|November 2001|September 2006||||N/A|Observational|N/A||||800|||Both|7 Years|14 Years|No|||September 2006|March 5, 2008|January 19, 2005||||No||https://clinicaltrials.gov/show/NCT00102076||199262|
NCT00102089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050081|HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects Who Were Previously Immunized With VRC-HIVDNA009-00-VP in VRC 004||National Institutes of Health Clinical Center (CC)||Completed|January 2005|October 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2007|October 19, 2007|January 20, 2005||||No||https://clinicaltrials.gov/show/NCT00102089||199261|
NCT00102427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059395|Improving Quality of Primary Care for Patients With Anxiety and/or Panic Disorders|Improving Quality of Primary Care for Anxiety Disorders||University of Pittsburgh||Completed|July 2000|May 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|64 Years|No|||January 2014|January 21, 2014|January 29, 2005||||No||https://clinicaltrials.gov/show/NCT00102427||199235|
NCT00097630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0011|ABC Trial: Awakening and Breathing Controlled|Cognitive Impairment in the ICU: Evaluation and Outcomes||National Institute on Aging (NIA)||Completed|October 2003|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||334|||Both|18 Years|N/A|No|||August 2008|December 9, 2009|November 24, 2004||||No||https://clinicaltrials.gov/show/NCT00097630||199584|
NCT00124423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GY-03-0018/ethics 21373|Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer|Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer||AHS Cancer Control Alberta|No|Completed|June 2004|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Female|N/A|N/A|No|Non-Probability Sample|community sample|April 2012|February 24, 2016|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124423||197605|
NCT00124436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP00091|Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis|Follow up Efficacy and Safety Study of BAL4979 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Treatment||Basilea Pharmaceutica||Completed|March 2005|February 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||300|||Both|18 Years|75 Years|No|||July 2010|July 16, 2010|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00124436||197604|
NCT00121290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00085|SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Phase I Dose Escalation Study of Daily x 3 Intravenous SJG-136 in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|February 2005|||April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||April 2013|February 21, 2014|July 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00121290||197841|
NCT00121537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-1502-226|Study to Determine the Utility of Wound Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes|A Prospective Study to Determine the Utility of Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes With Regards to Lower Extremity Fasciotomy Wound Healing, Complications, Cost and Patient and Nursing Satisfaction||The University of Texas Health Science Center at San Antonio||Terminated|July 2005|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|99 Years|No|||October 2015|October 7, 2015|July 13, 2005|||terminated, due to lack enrollment,|No||https://clinicaltrials.gov/show/NCT00121537||197823|
NCT00115323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190|Comparison of Two Medication Adherence Strategies to Improve Asthma Treatment Adherence|Individualized Interventions to Improve Asthma Adherence||University of Pennsylvania|Yes|Completed|May 2005|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|90 Years|No|||December 2013|December 20, 2013|June 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00115323||198289|
NCT00121797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-5.9.03-HMO-CTIL|Peripartum Bacteruria and Urinary Tract Infections (UTI)|Risk Factors for Postpartum Bacteruria, Does Labor Cause UTI?||Hadassah Medical Organization||Recruiting|January 2004|June 2005|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2005|November 6, 2006|July 17, 2005||||No||https://clinicaltrials.gov/show/NCT00121797||197804|
NCT00122317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E05-001|Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)|Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH||Alexion Pharmaceuticals||Completed|May 2005|October 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|187|||Both|18 Years|N/A|No|||January 2009|January 14, 2009|July 20, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00122317||197765|
NCT00123643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK2002-2|Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients|Comparison of Rosiglitazone Versus Glyburide on Vascular Structure and Function in Type 2 Diabetic Patients||St. Paul Heart Clinic|No|Completed|May 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|25 Years|75 Years|No|||June 2013|June 26, 2013|July 21, 2005|Yes|Yes||No|July 2, 2012|https://clinicaltrials.gov/show/NCT00123643||197664|Small sample size; unbalanced sex distribution between groups
NCT00124839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Naltrexon-BPS|Naltrexone in Borderline Personality Disorder|Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder||Central Institute of Mental Health, Mannheim|No|Terminated|October 2005|March 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Female|18 Years|50 Years|No|||April 2008|April 14, 2008|July 27, 2005|||Difficulties in recruiting enough subjects|No||https://clinicaltrials.gov/show/NCT00124839||197576|
NCT00125112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK65757 (completed)|Internet Weight Control for Bingeing Adolescents|Internet Weight Control for Bingeing Adolescents||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2005|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||January 2010|January 15, 2010|July 28, 2005||||No||https://clinicaltrials.gov/show/NCT00125112||197555|
NCT00125125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320B2406|Fluvastatin in Adults With Dislipidemia With History of Muscle Problems|Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake||Novartis||Completed|May 2005|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|218|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|July 28, 2005||||||https://clinicaltrials.gov/show/NCT00125125||197554|
NCT00124826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/S0702/58|SELESTIAL: Trial of Insulin to Control Blood Sugar After Acute Stroke Using Magnetic Resonance Imaging (MRI) End-Points|Spectroscopic Evaluation of Lesion Evolution in Stroke: Trial of Insulin for Acute Lactic Acidosis (SELESTIAL)||University of Glasgow||Completed|May 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||July 2005|January 31, 2006|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00124826||197577|
NCT00102063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-03-239|Aripiprazole in Adolescents With Schizophrenia|Aripiprazole in Adolescents With Schizophrenia|APEX 239|Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|302|||Both|13 Years|17 Years|No|||August 2012|August 6, 2012|January 19, 2005|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00102063||199263|
NCT00101712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2307|Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia|Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia||Novartis||Completed|October 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|January 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00101712||199290|
NCT00102102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050080|Role of Substance P in Post-Traumatic Stress Disorder|PET Evaluation of NK1 Receptor Using [18F]SPA-RQ in Post-Traumatic Stress Disorder||National Institutes of Health Clinical Center (CC)||Completed|January 2005|January 2006||||N/A|Observational|N/A||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|January 20, 2005||||No||https://clinicaltrials.gov/show/NCT00102102||199260|
NCT00102115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSCOR-001|Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease|Phase 1 Dose Ranging Study to Evaluate Safety and Tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in Subjects With Advanced Age-Related Macular Disease||Light Sciences LLC||Terminated|December 2004|January 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|50 Years|N/A|No|||December 2005|March 11, 2010|January 21, 2005||||||https://clinicaltrials.gov/show/NCT00102115||199259|
NCT00102440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-010|Febuxostat Versus Allopurinol Control Trial in Subjects With Gout|A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout|FACT|Takeda|No|Completed|July 2002|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|760|||Both|18 Years|85 Years|No|||January 2012|January 31, 2012|January 29, 2005|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00102440||199234|
NCT00097643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0009|Problem Solving/Physical Interventions and Aging|Problem Solving/Physical Interventions and Aging||National Institute on Aging (NIA)||Completed|September 2000|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||273|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 12, 2008|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097643||199583|
NCT00125307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.229-T|Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis|Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis||Chinese University of Hong Kong||Completed|January 2004|February 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||May 2008|July 31, 2015|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125307||197540|
NCT00121303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000433422|Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t)||Stichting Hemato-Oncologie voor Volwassenen Nederland||Active, not recruiting|January 2005|June 2016|Anticipated|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|61 Years|N/A|No|||March 2015|March 23, 2015|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00121303||197840|
NCT00113828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-222|Non-Myeloablative HLA-Matched Ex-Vivo T-Cell Depleted Stem Cell Transplantation for Hematologic Malignancies|Non-Myeloablative HLA-Matched Ex-Vivo T-Cell Depleted Stem Cell Transplantation for Hematologic Malignancies||Massachusetts General Hospital|Yes|Terminated|December 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||December 2007|December 28, 2007|June 10, 2005||No|Insufficient accrual|No||https://clinicaltrials.gov/show/NCT00113828||198403|
NCT00113841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0436|Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma|Pilot Study of Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Completed|November 2004|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|N/A|N/A|No|||November 2011|November 15, 2011|June 10, 2005|No|Yes||No|September 13, 2011|https://clinicaltrials.gov/show/NCT00113841||198402|
NCT00121264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03194|17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors|A Phase I Dose-Escalation Study of Intravenous 17-Allylaminogeldanamycin (17-AAG) [NSC 330507and Oral BAY 43-9006 [NSC 724772] Administered in Patients With Pretreated Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|March 2005|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||January 2013|June 16, 2014|July 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00121264||197843|
NCT00121810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17140|Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients|An Open Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil (MMF) (CellCept®) and Sirolimus (Rapamune®)||Hoffmann-La Roche||Completed|August 2003|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|75 Years|No|||April 2011|April 13, 2011|July 15, 2005|Yes|Yes||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00121810||197803|
NCT00122590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS111 COPHAR 2|Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)|Prospective Trial to Evaluate How Therapeutic Drug Monitoring of Protease Inhibitors Increases Virologic Success and Tolerance of HAART (ANRS 111 COPHAR2)||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|July 2002|March 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||115|||Both|18 Years|N/A|No|||July 2005|July 29, 2005|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00122590||197744|
NCT00122603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-003470-20|Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)|Efficacy and Safety of Regimens Restricted to a Combination of Two Boosted Protease Inhibitors as Potent Antiretroviral Therapy in HIV-1 Infected Patients. ANRS 127 2IP||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|December 2005|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122603||197743|
NCT00124241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-02B-010|An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B|A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003||Novartis||Completed||November 2005|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||May 2015|May 8, 2015|July 25, 2005||||||https://clinicaltrials.gov/show/NCT00124241||197619|
NCT00124254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR047328|Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand|An Outcome Study of Rheumatoid Hand Arthroplasty||University of Michigan|Yes|Active, not recruiting|September 2003|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|July 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00124254||197618|
NCT00123656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12790|Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis|Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis||University of Utah|No|Completed|August 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||January 2008|January 10, 2008|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123656||197663|
NCT00123669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. SP/SO/B29/2000|Primary Progesterone Therapy for Operable Breast Cancer|The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial||Tata Memorial Hospital|No|Active, not recruiting|October 1997|December 2017|Anticipated|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1000|||Female|18 Years|75 Years|No|||June 2014|June 23, 2014|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123669||197662|
NCT00125359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0440|Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer|A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer||Dartmouth-Hitchcock Medical Center|Yes|Completed|August 2005|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||July 2013|November 11, 2014|July 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125359||197536|
NCT00121329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 6876|4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions|4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions||Oregon Health and Science University||Completed||December 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2005|July 19, 2005|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121329||197838|
NCT00102141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91202|Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women|A Multicenter, Double-blind, Randomized, Placebo-controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-estradiol 1 mg, Drospirenone 2 mg /17ß-estradiol 1 mg, Drospirenone 1 mg /17ß-estradiol 1 mg) Combinations and 17ß-estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension||Bayer|No|Completed|April 2004|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|750|||Female|45 Years|75 Years|No|||December 2014|December 11, 2014|January 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102141||199257|
NCT00102154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-007|An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia||H. Lundbeck A/S||Withdrawn|January 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|0|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2014|January 13, 2015|January 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102154||199256|
NCT00102167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-006|Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia||H. Lundbeck A/S||Completed|February 2005|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|663|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|January 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102167||199255|
NCT00102453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC0302|Pentoxifylline in Duchenne Muscular Dystrophy|An Open-Label Pilot Study of Pentoxifylline in Steroid-naive Duchenne Muscular Dystrophy||Cooperative International Neuromuscular Research Group|Yes|Completed|March 2002|May 2007|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|4 Years|7 Years|No|||October 2011|October 26, 2011|January 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00102453||199233|
NCT00097656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14577|MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk|MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk||University of North Carolina, Chapel Hill|Yes|Completed|February 2004|May 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|1800|||Female|16 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 3, 2011|November 24, 2004||No||No||https://clinicaltrials.gov/show/NCT00097656||199582|
NCT00125047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-7|Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood|Effectiveness of a Combined Vi Vaccination and Health Education Program on Reducing the Burden of Typhoid During Childhood: A Demonstration Project in Karachi||International Vaccine Institute|Yes|Completed|October 2001|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|27231|||Both|2 Years|16 Years|Accepts Healthy Volunteers|||August 2008|August 25, 2008|July 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00125047||197560|
NCT00125320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235-0104|Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery|A Phase III Study of the Conversion Efficacy and Safety of Repeated Intravenous Doses of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter Following Valvular and/or Coronary Artery Bypass Graft Surgery||Astellas Pharma Inc|Yes|Completed|June 2004|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|190|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|July 28, 2005||||No||https://clinicaltrials.gov/show/NCT00125320||197539|
NCT00125333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-01P|Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis|A Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety of Repeated Topical Application of Three Concentrations of NF-kappaB Decoy in Adults With Mild-to-Moderate Atopic Dermatitis||Anesiva, Inc.||Completed|March 2005|November 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|65 Years|No|||November 2008|November 18, 2008|July 28, 2005||||||https://clinicaltrials.gov/show/NCT00125333||197538|
NCT00125021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-070|Tarceva and Capecitabine for Pancreatic Cancer|A Phase II Study of OSI-774 (Tarceva) in Combination With Capecitabine in Previously Treated Patients With Metastatic Pancreatic Cancer||Dana-Farber Cancer Institute||Completed|October 2003|September 2008|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|July 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125021||197562|
NCT00125034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-047|Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)|Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer|OPUS|Merck KGaA|No|Completed|July 2005|November 2010|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|344|||Both|18 Years|N/A|No|||August 2011|August 5, 2014|July 28, 2005||No||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00125034||197561|A non-specific outcome measure 'Safety' was deleted from this entry in error. A replacement outcome has been created. The 'Safety' outcome refers to adverse events and these are shown in the 'Adverse Events' section.
NCT00122031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSG-04-006|Deep Brain Stimulation for Treatment-Refractory Major Depression|Deep Brain Stimulation for Treatment-Refractory Major Depression||University Hospital, Bonn|No|Completed|July 2005|January 2011|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|65 Years|No|||June 2012|June 13, 2012|July 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00122031||197786|
NCT00122356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCC 04.02|Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment|Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm|BATMAN|Barwon Health||Completed|September 2005|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|303|||Female|N/A|N/A|No|||March 2013|March 11, 2013|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00122356||197762|
NCT00121511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 549|The Effect of Efudex Treatment on Photoaged Skin|The Effect of Efudex (5-fluorouracil) Treatment on Photoaged Skin||University of Michigan|No|Completed|July 2005|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|21|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121511||197825|
NCT00121524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|525-02201|Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome|Effects of Epinephrine and I.V. Needle on CPR Outcome||University of Oslo|Yes|Completed|January 2003|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|904|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|July 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00121524||197824|
NCT00122850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7107|A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder|A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder.||Eli Lilly and Company||Completed|October 2004|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|July 20, 2005||||||https://clinicaltrials.gov/show/NCT00122850||197724|
NCT00123383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC05023|Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence|Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence||The University of New South Wales|No|Active, not recruiting|July 2005|September 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||July 2006|April 29, 2007|July 21, 2005||||No||https://clinicaltrials.gov/show/NCT00123383||197684|
NCT00123396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTI 02-092|VHA Clinicians and Bioterror Events: Interactive Web-based Learning|VHA Clinicians and Bioterror Events: Interactive Web-based Learning||VA Office of Research and Development|No|Completed|August 2004|September 2007|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123396||197683|
NCT00123162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20477|Viagra in the Treatment of Primary Dysmenorrhea|Sildenafil Citrate in the Treatment of Primary Dysmenorrhea||Milton S. Hershey Medical Center|No|Completed|May 2007|August 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|July 20, 2005|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00123162||197701|
NCT00123175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21012|Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD)|Levonorgestrel Containing Intrauterine Device in the Treatment of Endometrial Hyperplasia Without Atypia||Milton S. Hershey Medical Center|No|Withdrawn|September 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 7, 2013|July 20, 2005||No|Study has never received funding and has never been initiated|No||https://clinicaltrials.gov/show/NCT00123175||197700|
NCT00123448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050205|Mirroring a Movement|Mirroring a Movement||National Institutes of Health Clinical Center (CC)||Completed|July 2005|July 2008||||N/A|Observational|N/A||||36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 3, 2008|July 21, 2005||||No||https://clinicaltrials.gov/show/NCT00123448||197679|
NCT00114634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050168|Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome|Short-Term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome||National Institutes of Health Clinical Center (CC)|No|Completed|June 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|4 Years|17 Years|No|||December 2015|December 24, 2015|June 15, 2005||No||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00114634||198341|Poor power due to low enrollment
NCT00123916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEN01|BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease|Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial|BENEFIT|Population Health Research Institute|Yes|Recruiting|November 2004|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2005|August 1, 2011|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123916||197644|
NCT00123929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/117|Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer|Patterns of Genetic Expression Associated to Sensibility to Doxorubicin Versus Docetaxel as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer||Hospital San Carlos, Madrid|No|Completed|January 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|75 Years|No|||August 2009|August 3, 2009|July 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00123929||197643|
NCT00123942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP099|Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease|Phase I Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease||MedImmune LLC||Terminated|April 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|31|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|July 22, 2005|||After review of safety events and have decided that further dose escalation of MEDI-507 as a    single agent is not feasible.|||https://clinicaltrials.gov/show/NCT00123942||197642|
NCT00124267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/HD11/524/RQ|Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria|Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial||Makerere University||Active, not recruiting|September 2003|January 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|6 Months|5 Years|No|||July 2005|August 3, 2005|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00124267||197617|
NCT00102180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1287|Drug-Induced Sudden Death & Ventricular Arrhythmia|||University of Pennsylvania|No|Completed|January 2005|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|31000000|||Both|N/A|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Medicaid enrollees from CA, FL, NY, OH and PA combined with the UK General Practice        Research Database.|November 2015|November 30, 2015|January 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00102180||199254|
NCT00097682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050038|Views of Cancer Patients Regarding Financial Conflicts of Interest|Ethics Study to Understand the Views of Cancer Patients Regarding Financial Conflicts of Interest in Research||National Institutes of Health Clinical Center (CC)||Completed|November 2004|October 2007||||N/A|Observational|N/A||||300|||Both|18 Years|N/A|No|||October 2007|September 26, 2015|November 24, 2004||||No||https://clinicaltrials.gov/show/NCT00097682||199580|
NCT00102466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2338|Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes|Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes||Novartis||Completed|January 2005|||January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1007|||Both|18 Years|78 Years|No|||January 2013|January 3, 2013|January 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102466||199232|
NCT00102479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-03-238|Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents|A Phase II Study to Test PK Tolerability in Children and Adolescents||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|10 Years|17 Years|No|||April 2006|April 13, 2006|January 29, 2005||||||https://clinicaltrials.gov/show/NCT00102479||199231|
NCT00097669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ec550|VITATOPS: A Study of VITAmins TO Prevent Stroke|VITATOPS - A Study of VITAmins TO Prevent Stroke||VITATOPS|Yes|Completed|November 1998|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|8000|||Both|N/A|N/A|No|||February 2010|February 24, 2010|November 24, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097669||199581|
NCT00125060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-12-17-04|Transesophageal Magnetic Resonance Imaging (MRI) in Conjunction With Lipid Lowering Measures|Transesophageal MRI in Conjunction With Lipid Lowering Measures||Johns Hopkins University||Completed|August 2000|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||72|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2004|August 9, 2005|July 28, 2005||||No||https://clinicaltrials.gov/show/NCT00125060||197559|
NCT00122070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|702787|Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder|Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder||Rutgers, The State University of New Jersey|Yes|Completed|May 2005|May 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2008|June 9, 2008|July 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00122070||197783|
NCT00122044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOCOLATE|Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects|Childhood Hypertonia of Central Origin: An Open Label Trial of Anticholinergic Treatment Effects||University of Southern California||Completed|January 2003|December 2004||December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|5 Years|17 Years|No|||May 2014|May 21, 2014|July 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00122044||197785|
NCT00121277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-035|Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Capecitabine in Patients With Solid Tumors||University Health Network, Toronto||Completed|September 2005|||August 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|July 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00121277||197842|
NCT00121836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18527|A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer|An Open-label Study of Xeloda Plus Avastin at Time of Disease Progression in Treatment-naïve Women With HER2-negative Metastatic Breast Cancer||Hoffmann-La Roche||Completed|June 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Female|18 Years|N/A|No|||April 2011|April 25, 2011|July 18, 2005|Yes|Yes||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00121836||197801|The primary endpoint TTP was changed to overall survival (OS) due to issues regarding tumor assessment data based on RECIST and poor response from investigators to related queries that developed after the planned interim analysis.
NCT00122382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-023|Remission and Joint Damage Progression in Early Rheumatoid Arthritis|A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate||Bristol-Myers Squibb|No|Completed|July 2005|February 2009|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1052|||Both|18 Years|N/A|No|||November 2010|November 3, 2010|July 19, 2005|Yes|Yes||No|May 3, 2010|https://clinicaltrials.gov/show/NCT00122382||197760|
NCT00122369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD 17-01-1-0153|Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy|Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy||Beth Israel Deaconess Medical Center|Yes|Completed|March 2002|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|240|||Both|18 Years|N/A|No|||February 2013|February 23, 2013|July 20, 2005||No||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00122369||197761|For the assessment of the Secondary Outcome parameter we were able to recruit only 19 women whom we could contact early enough on the day of their breast cancer surgery to fill out the IES. This limits the power of the statistical analysis.
NCT00123409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-108|Telephone Disease Management At-Risk Drinking (TDM II)|Telephone Disease Management At-Risk Drinking (TDM 11)||VA Office of Research and Development|No|Completed|January 2004|February 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|N/A|No|||June 2014|April 6, 2015|July 20, 2005||No||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00123409||197682|
NCT00114114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001868|Dose-Response of Gonadal Steroids and Bone Turnover in Men|Dose-Response of Gonadal Steroids and Bone Turnover in Men||Massachusetts General Hospital|Yes|Recruiting|September 2004|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|900|||Male|60 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|June 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00114114||198381|
NCT00114374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001633|SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims|SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and Posttraumatic Stress Disorder in Physical Trauma Victims in the Medical Setting||Massachusetts General Hospital||Terminated|June 2005|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|60|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 14, 2005||||No||https://clinicaltrials.gov/show/NCT00114374||198361|
NCT00115518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEAR L-284/2004|Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Locoregional Radiotherapy in Combination With Cetuximab in Inoperable Non-Small Cell Lung Cancer Stage III||Heidelberg University|No|Completed|May 2005|August 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2011|August 3, 2011|June 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00115518||198274|
NCT00123955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0030|PIE II: Pharmacological Intervention in the Elderly II|Exercise Intolerance in Elderly Diastolic Heart Failure||Wake Forest School of Medicine|Yes|Completed|April 2005|December 2012|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|60 Years|N/A|No|||February 2015|February 23, 2015|July 22, 2005||No||No|February 6, 2015|https://clinicaltrials.gov/show/NCT00123955||197641|
NCT00123968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 172|Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults|A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Boosted by a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Adult Volunteers in East Africa||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2006|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|6||Actual|326|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|July 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00123968||197640|
NCT00124280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2235|Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Open Label, Non-randomized, Phase 2 Study Investigating the Effect of RAD001 Monotherapy in Patients With Advanced NSCLC Previously Treated With Either Chemotherapy Only or With Chemotherapy and EGFR Inhibitor(s)||Novartis||Completed|July 2005|||October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|July 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00124280||197616|
NCT00097695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE049 #2103|Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema|Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema||Shire|No|Completed|August 2004|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|November 26, 2004|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00097695||199579|
NCT00098046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810B2304|Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection|Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection||Novartis||Completed|July 2005|July 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|76|||Both|1 Year|12 Years|No|||September 2007|September 25, 2007|December 2, 2004||||||https://clinicaltrials.gov/show/NCT00098046||199553|
NCT00098059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810B2303|Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection|A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herpes Simplex Infection||Novartis||Completed|February 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|1 Year|12 Years|No|||April 2013|April 18, 2013|December 2, 2004|No|Yes||No|February 2, 2009|https://clinicaltrials.gov/show/NCT00098059||199552|
NCT00098462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000401501|Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase I/II Trial of ZD1839 (Iressa®) and Rapamycin (Rapamune) in Patients With Advanced Non Small Cell Lung Cancer||Jonsson Comprehensive Cancer Center||Withdrawn|October 2004|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|December 7, 2004|Yes|Yes|Withdrawn as study never opened|No||https://clinicaltrials.gov/show/NCT00098462||199524|
NCT00125073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK67885|Postoperative Dietary Counseling After Bariatric Surgery|Postoperative Dietary Counseling After Bariatric Surgery||University of Pennsylvania||Completed|July 2005|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|65 Years||||June 2010|June 25, 2010|July 28, 2005||||No||https://clinicaltrials.gov/show/NCT00125073||197558|
NCT00121368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP01 Tobacco Use|GN Tobacco Use Survey|Survey on Tobacco Use in the GN Sites||NICHD Global Network for Women's and Children's Health|Yes|Completed|February 2004|May 2005|Actual|May 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6000|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women 18-45|November 2013|November 22, 2013|July 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00121368||197836|
NCT00121381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2439|Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis|Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis||Novartis||Completed|May 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||400|||Both|2 Years|17 Years|No|||January 2008|January 10, 2008|July 14, 2005||||||https://clinicaltrials.gov/show/NCT00121381||197835|
NCT00122057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/0506|Impact of Antibiotic Treatment on Outcome in Patients With Ventilator-Associated Tracheobronchitis|||University Hospital, Lille||Completed|June 2005|June 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|58|||Both|18 Years|N/A|No|||September 2006|May 31, 2011|July 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00122057||197784|
NCT00121823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG37|Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-Erythrocytic Candidate Malaria Vaccines|Malaria Infection Diagnosed by PCR as a Means of Evaluating Pre-Erythrocytic Candidate Malaria Vaccines||Gates Malaria Partnership||Completed|June 2004|December 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||120|||Male|15 Years|45 Years|Accepts Healthy Volunteers|||July 2005|July 22, 2005|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00121823||197802|
NCT00122863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7108|Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder|Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder||Eli Lilly and Company||Completed|January 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|18 Years|N/A|No|||August 2007|August 29, 2007|July 20, 2005||||||https://clinicaltrials.gov/show/NCT00122863||197723|
NCT00122616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRSHC12 FIBROSTOP|Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C|Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and C Hepatitis Who Failed to Active Treatment for HCV. ANRSHC12 Fibrostop||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|November 2003|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00122616||197742|
NCT00123123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14685|Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients|Oral Health and Ventilator-associated Pneumonia||State University of New York at Buffalo||Completed|March 2004|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|175|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|July 21, 2005||No||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00123123||197704|
NCT00123136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-81440-DPN|Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy|Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial||Weintraub, Michael I., MD, FACP, FAAN||Recruiting|August 2005|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|18 Years|90 Years|No|||June 2006|June 28, 2006|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00123136||197703|
NCT00123422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F3845-R|Innovation in Pulmonary Rehabilitation|Innovation Methods to Augment Pulmonary Rehabilitation||VA Office of Research and Development|No|Completed|October 2005|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|103|||Both|40 Years|N/A|No|||October 2014|October 6, 2014|July 20, 2005||No||No|October 2, 2014|https://clinicaltrials.gov/show/NCT00123422||197681|
NCT00123435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3358-R|Veterans Walk for Health Study|Does Step Count Feedback Enhance Counseling for Weight Loss?|VWH|VA Office of Research and Development|No|Completed|July 2005|June 2009|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|254|||Male|18 Years|N/A|No|||August 2015|August 19, 2015|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123435||197680|
NCT00114933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPA-378-05-40|"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects|Phase III-IV, Comparative, Randomized, Open-Label, Study to Evaluate Safety and Efficacy of Suspending Nucleosides From a Triple-Drug Therapy Based on Lopinavir/Ritonavir Versus Continuing Triple-Drug Therapy in HIV-Infected Subjects With Undetectable Plasma HIV Viremia for Six Months||Arribas, Jose R., M.D.||Completed|January 2005|May 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||September 2005|March 20, 2008|June 20, 2005||||No||https://clinicaltrials.gov/show/NCT00114933||198319|
NCT00115232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-03-044|Inflammatory Profiles of Children at High Risk for Atherosclerosis|Inflammatory Profiles of Children at High Risk for Atherosclerosis||Children's Hospital Boston|No|Completed|July 2004|March 2007|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|300|Samples Without DNA|Fasting serum samples, frozen.|Both|8 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primarily children referred to preventive cardiology clinic.|January 2008|January 14, 2008|June 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00115232||198296|
NCT00114920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1508-RESI|Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults|A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults||Graceway Pharmaceuticals, LLC||Completed|March 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||88|||Both|18 Years|N/A|No|||November 2006|February 16, 2007|June 20, 2005||||||https://clinicaltrials.gov/show/NCT00114920||198320|
NCT00115206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020121|Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy|A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC||Amgen||Completed|July 2002|July 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2009|April 2, 2009|June 21, 2005||||||https://clinicaltrials.gov/show/NCT00115206||198298|
NCT00115219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040275|Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)|A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)||Amgen||Completed|May 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||200|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|June 21, 2005||||||https://clinicaltrials.gov/show/NCT00115219||198297|
NCT00115505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-70301|Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer|Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer With 0-3 Positive Axillary Lymph Nodes||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|October 2005|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|684|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with breast cancer with 0-3 positive axillary lymph nodes receiving adjuvant|July 2015|July 23, 2015|June 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00115505||198275|
NCT00115791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-7-010|Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter|A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter||Astellas Pharma Inc|Yes|Completed|June 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|No|||March 2008|March 29, 2008|June 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00115791||198253|
NCT00097708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JZP 04-001-01|Experimental Medication For the Treatment of Generalized Anxiety Disorder|A Double-Blind, Placebo Controlled Trial of an Experimental Medication For the Treatment of Generalized Anxiety Disorder||Jazz Pharmaceuticals||Completed|November 2004|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|511|||Both|18 Years|65 Years|No|||October 2014|October 1, 2014|November 29, 2004|||||September 14, 2011|https://clinicaltrials.gov/show/NCT00097708||199578|
NCT00097721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-201|A Study of E7389 in Advanced/Metastatic Breast Cancer Patients|A Phase II Open Label Study of E7389 (Halichondrin B Analog) in Patients With Advanced/Metastatic Breast Cancer Previously Treated With Chemotherapy Including An Anthracycline and A Taxane||Eisai Inc.||Completed|September 2004|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Female|18 Years|N/A|No|||April 2013|April 3, 2013|November 29, 2004|Yes|Yes||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00097721||199577|
NCT00098072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050041|Endothelial Cell Dysfunction in Pulmonary Hypertension|Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic Targets||National Institutes of Health Clinical Center (CC)||Completed|November 2004|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|December 2, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098072||199551|
NCT00098085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-26|Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer|A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer||Agenus, Inc.||Completed|September 2003|||November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||20|||Both|18 Years|N/A|No|||March 2009|March 6, 2009|December 3, 2004||||||https://clinicaltrials.gov/show/NCT00098085||199550|
NCT00098475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03150|Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma|A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-responders||National Cancer Institute (NCI)|Yes|Active, not recruiting|October 2004|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|452|||Both|18 Years|N/A|No|||November 2015|February 22, 2016|December 7, 2004|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00098475||199523|
NCT00098488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01460|17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia|A Phase 1 Study of 17-allylamino-17-demethoxygeldanamycin (17-AAG) (NSC 330507; IND 57,966) and Rituximab in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia (CLL)||National Cancer Institute (NCI)||Terminated|April 2005|||April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098488||199522|
NCT00121849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LCVPX-105|Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite|A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine in Montenegro Skin Test-Positive Healthy Adults||IDRI||Completed|August 2005|February 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2006|May 4, 2006|July 15, 2005||||||https://clinicaltrials.gov/show/NCT00121849||197800|
NCT00121394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 09 A|Chlorhexidine Vaginal and Infant Wash in Pakistan|Randomized Trial of Chlorhexidine Vaginal and Infant Wash to Reduce Neonatal Mortality||NICHD Global Network for Women's and Children's Health|Yes|Completed|June 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|5008|||Female|16 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|July 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00121394||197834|
NCT00122408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|promotion_070605-gibot_DRI|Probiotic Enteral Administration in Mechanically Ventilated Patients|Effect of Enterally Administered Probiotics in Mechanically Ventilated Patients: Double-Blind, Prospective Randomized Study Versus Placebo||Central Hospital, Nancy, France||Terminated|January 2006|December 2009|Anticipated|August 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|740|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00122408||197758|
NCT00121550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997-08-DP-42-RKF-13 CLARICOR;|The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease|The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial||Copenhagen Trial Unit, Center for Clinical Intervention Research||Completed|October 1999|September 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||4372|||Both|18 Years|84 Years|No|||September 1999|May 4, 2006|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121550||197822|
NCT00122876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSC-OL004|Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)|A Phase 1/2 Open-Label Study to Evaluate Safety and Preliminary Evidence of Effectiveness of Tumor Ablation With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LEDs) in the Treatment of Subjects With Inoperable Hepatocellular Carcinoma (HCC)||Light Sciences LLC||Completed|April 2005|October 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||December 2007|December 5, 2007|July 19, 2005||||||https://clinicaltrials.gov/show/NCT00122876||197722|
NCT00123149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002461|Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis|An Open-Label (OL) Extension Study to Assess Safety of PROCRIT (Epoetin Alfa) in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis (RA)||Ortho Biotech Products, L.P.||Withdrawn||October 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|July 19, 2005||||||https://clinicaltrials.gov/show/NCT00123149||197702|
NCT00122889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC-1984.00|Effects of Garlic Supplements on Drug Metabolism|Garlic Metabolism and Cytochrome P450 Modulation||Fred Hutchinson Cancer Research Center|No|Completed|July 2005|March 2009|Actual|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|Samples With DNA|Whole blood, urine|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|December 2009|December 30, 2009|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00122889||197721|
NCT00115531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-100|Eldery High Dose TIV 2005|Comparisons of the Reactogenicity and Immunogenicity in Ambulatory Elderly Subjects of a Standard-Dose Fluzone® (15 µg HA/Virus Strain) and a High-Dose (60 µg HA/Virus Strain) of a Trivalent Inactivated Influenza Virus Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2005|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|414|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2007|December 18, 2014|June 22, 2005||||No||https://clinicaltrials.gov/show/NCT00115531||198273|
NCT00115544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64,185-06-2W|Safety and Pharmacology of Stanate|An Open-Label Study of the Safety and Clinical Pharmacology of Stanate® in Infants At-Risk for Exchange Transfusion||InfaCare Pharmaceuticals Corporation|Yes|Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|55|||Both|N/A|7 Days|No|||February 2016|February 9, 2016|June 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00115544||198272|
NCT00115557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS014850|Delivery of Preventive Services in Primary Care|Delivery of Preventive Services in Primary Care||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|October 2004|July 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||September 2007|August 11, 2010|June 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00115557||198271|
NCT00115570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6096|Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents|Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial||Sanofi||Completed|March 2005|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||560|||Both|4 Years|17 Years|No|||March 2009|March 27, 2009|June 23, 2005||||||https://clinicaltrials.gov/show/NCT00115570||198270|
NCT00116168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP109|Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528|A Phase I, Open Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers||MedImmune LLC||Completed|June 2005|July 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|June 27, 2005||||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00116168||198224|
NCT00115817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000416|The Effects of Atorvastatin in Patients With Atherosclerosis|The Effects of Atorvastatin on the Rho/Rho Kinase Pathway in Patients With Atherosclerosis||Brigham and Women's Hospital|Yes|Completed|June 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|21 Years|80 Years|No|||April 2007|April 23, 2007|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00115817||198251|
NCT00116415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-071|DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy|Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Patients||Bristol-Myers Squibb||Completed|March 2002|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|June 29, 2005||||No||https://clinicaltrials.gov/show/NCT00116415||198205|
NCT00116428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWI03130|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation|Afib IDE|Biosense Webster, Inc.|Yes|Completed|October 2004|March 2011|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|June 29, 2005|Yes|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00116428||198204|
NCT00116129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0677/FM|Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in the Treatment of Primary Fibromyalgia||Bennett, Robert, M.D.|No|Completed|July 2005|April 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|64|||Female|30 Years|65 Years|No|||August 2012|August 2, 2012|June 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116129||198227|
NCT00116389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH-320|Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas|An Open-Label Phase 2 Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas||Point Therapeutics||Terminated||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2007|June 7, 2007|June 28, 2005|||FDA Hold May 2007|||https://clinicaltrials.gov/show/NCT00116389||198207|
NCT00116649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1520-IMIQ|Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis|Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis||Graceway Pharmaceuticals, LLC|No|Completed|June 2005|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|551|||Both|18 Years|N/A|No|||July 2010|July 14, 2010|June 30, 2005|Yes|Yes||No|October 21, 2008|https://clinicaltrials.gov/show/NCT00116649||198187|
NCT00098124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-02|Study of Milnacipran for the Treatment of Fibromyalgia|A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia||Forest Laboratories||Completed|November 2004|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1200|||Both|18 Years|70 Years|No|||December 2007|December 18, 2007|December 3, 2004||||||https://clinicaltrials.gov/show/NCT00098124||199547|
NCT00098137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET-B10|Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation|Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial (ANTIPAF Trial)||German Atrial Fibrillation Network|Yes|Completed|January 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|422|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|December 3, 2004||No||No||https://clinicaltrials.gov/show/NCT00098137||199546|
NCT00098150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ext 1 to ASM981C202|Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis|A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Atopic Dermatitis||Novartis||Completed|July 2004|||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||66|||Both|18 Years|N/A|No|||August 2006|August 29, 2006|December 3, 2004||||||https://clinicaltrials.gov/show/NCT00098150||199545|
NCT00098098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rBV A/B-01|Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults|A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults||DynPort Vaccine Company LLC, A CSC Company||Completed|August 2004|August 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|44|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|December 3, 2004||Yes||||https://clinicaltrials.gov/show/NCT00098098||199549|
NCT00098111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-02555-01|Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease|A Double-Blinded, Randomized, Parallel Arm, Dose Ranging Study of IMURAN in Subjects With Active Crohn's Disease Requiring Treatment With Prednisone: A Crohn's Disease Optimal Range Dose of IMURAN Study (ACORDIS)||Massachusetts General Hospital||Terminated|April 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|31|||Both|14 Years|N/A|No|||February 2014|February 19, 2014|December 3, 2004|Yes|Yes|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00098111||199548|
NCT00098501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01459|CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors|A Phase 1 Trial of CCI-779 in Combination With EKB-569, an EGFR Inhibitor, in Patients With Solid Tumors||National Cancer Institute (NCI)||Completed|October 2004|||October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098501||199521|
NCT00121862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LCVPX-201|Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite|A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine Compared to the Leish-111f Protein Alone in Montenegro Skin Test-Negative Healthy Adults||IDRI||Completed|August 2005|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2006|May 4, 2006|July 18, 2005||||||https://clinicaltrials.gov/show/NCT00121862||197799|
NCT00112346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-100|Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|A Randomized Multicenter Phase II Study of Gemcitabine/Platinum/Cetuximab Versus Gemcitabine/Platinum as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|January 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||120|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|June 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112346||198508|
NCT00121628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040273|A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer|A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer||Amgen||Completed|July 2005|October 2010|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|184|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|July 12, 2005||||||https://clinicaltrials.gov/show/NCT00121628||197817|
NCT00122395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-5-3793|Trial Regarding the Acceptability of Audiotape Intimate Partner Violence (IPV) Screening|A Randomized Clinical Trial Regarding the Acceptability of an Audiotape Questionnaire for Intimate Partner Violence Screening in a Pediatric ED||Children's Hospital of Philadelphia||Completed|January 2005|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2005|May 3, 2006|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00122395||197759|
NCT00122629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRSHC03 BITRI|Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders|Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|October 2000|May 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||405|||Both|18 Years|65 Years|No|||July 2005|July 28, 2005|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00122629||197741|
NCT00122642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-01|Alcohol Locks for the Prevention of Tunneled Catheter-related Infections|Short Daily Alcohol Locks for the Prevention of Tunneled Catheter Infection in Patients With Haematological Disease. Randomised Placebo Controlled Trial||Erasmus Medical Center||Completed|August 2005|September 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|July 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00122642||197740|
NCT00122434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.4|Dose Finding Study in COPD|A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|July 2005|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|389|||Both|40 Years|83 Years|No|||October 2013|October 28, 2013|July 18, 2005||||||https://clinicaltrials.gov/show/NCT00122434||197756|
NCT00122655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS108 NONUKE|Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy|A Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE Study||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|January 2001|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||November 2005|November 14, 2005|July 21, 2005||||No||https://clinicaltrials.gov/show/NCT00122655||197739|
NCT00113763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020408|Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer|An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer||Amgen||Completed|January 2004|June 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|June 10, 2005||||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00113763||198408|
NCT00115271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.98.09.02.C1|Antenatal Micronutrient Supplementation and Birth Weight|Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal||Johns Hopkins Bloomberg School of Public Health||Completed|January 1999|May 2001|Actual|May 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||5000|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 22, 2014|June 21, 2005||||No||https://clinicaltrials.gov/show/NCT00115271||198293|
NCT00115284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F10011|Changes in Physician Performance Through Continuous Professional Development|An Evaluation of Changes in Physician Performance Through Continuous Professional Development||Henry Ford Health System||Completed|January 2005|December 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 12, 2009|June 21, 2005||||No||https://clinicaltrials.gov/show/NCT00115284||198292|
NCT00116181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR 542|Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis|A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects With Psoriasis-EASE in Psoriasis||Rockefeller University|No|Completed|October 2004|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||March 2011|March 16, 2011|June 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116181||198223|
NCT00116441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-0007|Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma|Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line||Cell Genesys||Completed|October 2000|October 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|18 Years|70 Years|No|||December 2007|December 18, 2007|June 29, 2005||||||https://clinicaltrials.gov/show/NCT00116441||198203|
NCT00112190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITOFD04-01|Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal|A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia||Axcan Pharma|Yes|Completed|July 2004|March 2006|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|645|||Both|18 Years|65 Years|No|||July 2008|July 24, 2008|May 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112190||198520|
NCT00116142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-043|Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer|Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial||Dana-Farber Cancer Institute|Yes|Active, not recruiting|June 2005|June 2020|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Male|30 Years|N/A|No|||August 2015|August 3, 2015|June 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116142||198226|
NCT00116155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV787-9902|Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer|A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer||Cell Genesys||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||||||||June 2005|June 27, 2005|June 27, 2005||||||https://clinicaltrials.gov/show/NCT00116155||198225|
NCT00116402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13426B|A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations|A Pilot Study of the Mechanism of Synergism Between Fluticasone (FP) and Salmeterol in Preventing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations||University of Chicago|Yes|Completed|January 2005|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|50 Years|N/A|No|||August 2014|August 4, 2014|June 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00116402||198206|
NCT00098527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02637|FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer|A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers||National Cancer Institute (NCI)||Terminated|October 2004|||September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098527||199519|
NCT00098540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01818|Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study of the Raf Kinase Inhibitor BAY43-9006 in Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|December 2004|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||July 2013|August 1, 2013|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098540||199518|
NCT00098514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000400150|Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors|A Phase I Study Of PT523 In Patients With Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|October 2004|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||January 2007|July 23, 2008|December 7, 2004||||No||https://clinicaltrials.gov/show/NCT00098514||199520|
NCT00098839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL04P2|Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)|A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|Yes|Active, not recruiting|February 2005|||April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|2 Years|31 Years|No|||March 2015|March 24, 2015|December 8, 2004|Yes|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT00098839||199499|
NCT00098852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000398114|Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer|A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2004|||June 2010|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2009|January 3, 2014|December 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00098852||199498|
NCT00125372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0453|Study of Tarceva and Targretin in Stage I-II Lung Cancer|A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer||Dartmouth-Hitchcock Medical Center|Yes|Completed|December 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|July 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00125372||197535|
NCT00113282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-001329-29|Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)|Study of the Immunological Efficacy of Adding Subcutaneous Interleukin-2 (IL-2) to an Optimized Antiretroviral Regimen in HIV-1-infected Subjects Experiencing Therapeutic Failure on an Ongoing Antiretroviral Combination With a CD4 Cell Count ≤ 200/mm3 ANRS 123 Trial||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|June 2004|February 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|57|||Both|18 Years|N/A|No|||June 2009|December 21, 2011|June 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00113282||198445|
NCT00121641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-011|Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise||AstraZeneca||Completed|July 2005|February 2010|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1035|||Both|18 Years|77 Years|No|||March 2015|March 16, 2015|July 15, 2005|Yes|Yes||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00121641||197816|
NCT00121875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-002800|Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature|Growth Hormone and Insulin Resistance in Girls With Turner Syndrome or Idiopathic Short Stature||Massachusetts General Hospital|Yes|Terminated|June 2005|December 2008|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1|Samples Without DNA|Blood|Female|7 Years|14 Years|No|Non-Probability Sample|Girls, age 7-14 years, with short stature due to Turner syndrome or with idiopathic short        stature|September 2009|September 28, 2009|July 14, 2005||No|Enrollment was too low.|No||https://clinicaltrials.gov/show/NCT00121875||197798|
NCT00122083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOxford|An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression|A Cluster Randomised Controlled Trial to Assess the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression||University of Oxford||Completed|April 2004|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1680|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2004|July 25, 2005|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00122083||197782|
NCT00122096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDK001|Perioperative Inflammation and Cyclooxygenase 2 (COX-2)|Preoperative Valdecoxib: CNS Penetration and Effects on Biochemical Markers of Pain and Sensitization||University of Washington||Completed|November 2002|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||September 2008|September 25, 2008|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00122096||197781|
NCT00122421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000950/2; BWH|The Impact of Pharmacist Recommendations on Quality of Care in Diabetic Patients|The Impact of Pharmacist Recommendations on Quality of Care in Diabetic Patients||Brigham and Women's Hospital||Completed|June 2003|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00122421||197757|
NCT00122447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000749|Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance|CVD Risk and Prevention in Early Glucose Intolerance||Emory University|No|Completed|May 2005|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|84|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|July 21, 2005|Yes|Yes||No|May 18, 2012|https://clinicaltrials.gov/show/NCT00122447||197755|Not fully powered due to under-enrollment and high drop-out rate. Higher than anticipated precision error of FMD measures. Possible Hawthorne effect with lifestyle changes. Short treatment period relative to long-term CVD risk in prediabetes.
NCT00113789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030122|Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer|Randomized, Phase 2 Study of Pegfilgrastim Given on the Last Day of a Multi-Day Topotecan Regimen or the Day After in Subjects With Relapsed or Refractory Ovarian Cancer||Amgen||Completed|October 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|N/A|No|||February 2009|February 12, 2009|June 10, 2005||||No||https://clinicaltrials.gov/show/NCT00113789||198406|
NCT00113503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK60083 (terminated)|Imuran Dosing in Crohn's Disease Study|A Multi-site Trial of Azathioprine Dosing in Crohn's Disease||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Terminated|February 2005|November 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|226|||Both|10 Years|70 Years|No|||January 2010|January 12, 2010|June 8, 2005||||No||https://clinicaltrials.gov/show/NCT00113503||198428|
NCT00114647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810164|Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies|Apheresis Procedures to Obtain Plasma and/or Peripheral Blood Mononuclear Cells for In Vitro Studies||National Institutes of Health Clinical Center (CC)||Recruiting|October 1981|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2400|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|June 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00114647||198340|
NCT00114452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401|Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction|A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose Escalation, Multicenter Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel) Following Acute Myocardial Infarction||Mesoblast, Ltd.||Completed|February 2005|February 2009|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|53|||Both|21 Years|85 Years|No|||December 2014|December 2, 2014|June 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114452||198355|
NCT00115024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0026|EPAT: Estrogen in the Prevention of Atherosclerosis Trial|Estrogen in the Prevention of Atherosclerosis Trial||National Institute on Aging (NIA)||Completed|April 1994|November 1998|Actual|November 1998|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||222|||Female|46 Years|80 Years|Accepts Healthy Volunteers|||June 2005|December 9, 2009|June 20, 2005||||No||https://clinicaltrials.gov/show/NCT00115024||198312|
NCT00112177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITOFD04-03|Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal|A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia||Axcan Pharma||Active, not recruiting|July 2004|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|65 Years|No|||August 2006|January 25, 2007|May 31, 2005||||No||https://clinicaltrials.gov/show/NCT00112177||198521|
NCT00112411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-204-25-167|Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics|Dose-ranging Double-blind, Placebo-controlled Efficacy Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics||Teva Pharmaceutical Industries||Completed|June 2005|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|4 Years|11 Years|No|||December 2005|July 3, 2012|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112411||198503|
NCT00112385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS049639-01A2|A Pilot Study of Etanercept in Dermatomyositis|A Pilot Study of Etanercept in Dermatomyositis||Brigham and Women's Hospital|Yes|Completed|March 2006|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||May 2011|May 23, 2011|June 2, 2005|Yes|Yes||No|April 25, 2011|https://clinicaltrials.gov/show/NCT00112385||198505|
NCT00112398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIRT1|Head Injury Retrieval Trial|Randomised, Controlled Trial of Physician Prehospital Management of Severe Blunt Head Injury||CareFlight|Yes|Terminated|May 2005|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|338|||Both|16 Years|N/A|No|||March 2013|March 10, 2013|June 2, 2005||No|Inadequate recruitment rate combined with a high rate of patients dropping in to the treatment    group from standard care|No||https://clinicaltrials.gov/show/NCT00112398||198504|
NCT00098553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0377|Everolimus in Treating Patients With Stage IV Melanoma|Phase II Trial Of RAD-001 In Metastatic Malignant Melanoma||Alliance for Clinical Trials in Oncology|No|Completed|April 2005|February 2010|Actual|July 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|December 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098553||199517|
NCT00098865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-279 DFCI|Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma|A Phase II Pilot Study Of Thalidomide With Temozolomide In Patients With Relapsed Or Progressive Brain Tumors Or Neuroblastoma||Dana-Farber Cancer Institute|Yes|Completed|September 2002|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|21 Years|No|||September 2014|September 28, 2014|December 8, 2004|Yes|Yes||No|December 15, 2012|https://clinicaltrials.gov/show/NCT00098865||199497|
NCT00099151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0005|CALERIE (PBRC, Baton Rouge) - Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy|Metabolic Adaptations to Six Month Caloric Restriction||National Institute on Aging (NIA)||Completed|March 2002|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||48|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||December 2004|December 9, 2009|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00099151||199479|
NCT00125385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC100800103|Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary Fibrosis||Sanofi|Yes|Completed|July 2005|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|25|||Both|18 Years|79 Years|No|||April 2015|April 9, 2015|July 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00125385||197534|
NCT00114179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02661|Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab For Locally Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|January 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||December 2013|April 14, 2015|June 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00114179||198376|
NCT00113009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLTS-934-123|Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease||Valentis||Completed|March 2005|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||148|||Both|40 Years|78 Years|No|||March 2006|November 21, 2007|June 2, 2005||||||https://clinicaltrials.gov/show/NCT00113009||198466|
NCT00113022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050161|Org 24448 to Treat Major Depression|An Investigation of the Antidepressant Efficacy and Safety of an AMPAkine (Org 24448) in Major Depressive Disorder, A Double-Blind, Placebo-Controlled, Randomized Study||National Institutes of Health Clinical Center (CC)|Yes|Terminated|May 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|70 Years|No|||July 2012|July 9, 2012|June 2, 2005|Yes|Yes|Terminated due to concerns about adverse events in separate study.|No|April 13, 2011|https://clinicaltrials.gov/show/NCT00113022||198465|
NCT00121888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001879|Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy|Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy||Massachusetts General Hospital||Completed|December 2002|June 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|72 Years|No|||June 2014|June 5, 2014|July 14, 2005||||No||https://clinicaltrials.gov/show/NCT00121888||197797|
NCT00122109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEL 03-080|Telemedicine and Anger Management Groups With PTSD Veterans in the Hawaiian Islands|Telemedicine and Anger Management Groups for PTSD Veterans in the Hawaiian Islands||VA Office of Research and Development|No|Completed|August 2005|December 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Male|18 Years|N/A|No|||August 2014|April 6, 2015|July 18, 2005||No||No|August 22, 2014|https://clinicaltrials.gov/show/NCT00122109||197780|We conservatively excluced participants with acute safety concerns (homicidal or suicidal) and current substance dependence. However other literature suugests that both issues can be safely addressed via telemedicine.
NCT00122122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF 98-152|Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients|Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients||VA Office of Research and Development|No|Completed||March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|65 Years|N/A|No|||February 2007|April 6, 2015|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00122122||197779|
NCT00114127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001384|Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome|Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome||Massachusetts General Hospital||Completed|June 2004|July 2010|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 13, 2005||No||No|January 27, 2012|https://clinicaltrials.gov/show/NCT00114127||198380|Open-label in phase Phase 1; Limited power due to small sample size.
NCT00114387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0023|VEAPS: Vitamin E Atherosclerosis Prevention Study|VEAPS: Vitamin E Atherosclerosis Prevention Study||National Institute on Aging (NIA)||Completed|July 1996|September 2000|Actual|September 2000|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||353|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2005|December 9, 2009|June 14, 2005||||No||https://clinicaltrials.gov/show/NCT00114387||198360|
NCT00114946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3430n|A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer|A Randomized, Open-Label Trial Comparing Two Avastin (Bevacizumab)-Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer||Genentech, Inc.||Terminated|May 2005|December 2007||||Phase 4|Interventional|Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||May 2006|May 26, 2006|June 20, 2005||||No||https://clinicaltrials.gov/show/NCT00114946||198318|
NCT00115245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-02B-018|Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B|A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B||Novartis||Completed|November 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years||||May 2015|May 8, 2015|June 21, 2005||||No||https://clinicaltrials.gov/show/NCT00115245||198295|
NCT00115258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86483|Nutrition Support in Pediatric Stem Cell Transplantation|Nutrition Support in Pediatric Stem Cell Transplantation - A Randomized, Controlled Trial||Children's Hospital Boston|No|Completed|January 2004|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|6 Years|N/A|No|||February 2013|February 12, 2013|June 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00115258||198294|
NCT00115830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-002254|Rho Kinase in Patients With Atherosclerosis|Rho Kinase in Patients With Atherosclerosis: Effects of Statins - A Double Blind, Randomized Clinical Trial Comparing Rosuvastatin and Atorvastatin||Brigham and Women's Hospital|Yes|Completed|December 2004|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|40 Years|80 Years|No|||April 2007|April 23, 2007|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00115830||198250|
NCT00115843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000346|Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring|Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring||Beth Israel Deaconess Medical Center||Active, not recruiting|April 2005|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|N/A|N/A|No|||September 2006|September 6, 2006|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00115843||198249|
NCT00113334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1027|Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer|A Phase 1b/2 Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer||M.D. Anderson Cancer Center|No|Completed|April 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|June 7, 2005|Yes|Yes||No|April 24, 2009|https://clinicaltrials.gov/show/NCT00113334||198441|
NCT00115609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002470-30|Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)|Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|January 2006|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|June 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00115609||198267|
NCT00112424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH 02-12-155|Trial of Cardiac Magnetic Resonance Imaging (MRI) Versus Cardiac Catheterization Prior to Glenn Operation|Clinical Trial of Cardiac Magnetic Resonance Imaging in Routine Evaluation Prior to Superior Cavo-Pulmonary Anastomosis||Children's Hospital Boston|Yes|Completed|January 2004|January 2008|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|6 Weeks|5 Years|No|||January 2008|January 29, 2008|June 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00112424||198502|
NCT00115882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IRB #4727|Hutchinson Study of High School Smoking|Proactive Smoking Cessation for Adolescents||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|September 2000|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2151|||Both|16 Years|20 Years|No|||February 2016|February 29, 2016|June 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00115882||198246|
NCT00112697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430095|Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Randomized Phase II Trial Evaluating [Radiotherapy-Docetaxel-5 Fluorouracil] Association Versus [Radiotherapy-Docetaxel-Cisplatin] Association in Non Resecables First Line of Chemotherapy in Metastatics Pancreas Cancers Patients||National Cancer Institute (NCI)||Active, not recruiting|December 2002|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|75 Years|No|||December 2006|November 1, 2011|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112697||198484|
NCT00098566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1734.00|Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Long-Term Follow-Up Study Evaluating the Efficacy and Delayed Toxicities of Radioiodinated Tositumomab (Anti-CD20 Antibody) Followed by Autologous Transplantation for Relapsed or Refractory Non-Hodgkin's Lymphoma||Fred Hutchinson Cancer Research Center||Completed|December 2002|June 2011|Actual|June 2011|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|120 Years|No|Non-Probability Sample|Patients previously treated with myeloablative doses of iodine I^131 tositumomab and        autologous bone marrow or stem cell transplantation on 1 of the following phase I or II        protocols:          -  FHCRC-296          -  FHCRC-521          -  FHCRC-792          -  FHCRC-915|October 2015|October 13, 2015|December 7, 2004||No||No||https://clinicaltrials.gov/show/NCT00098566||199516|
NCT00098878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCOTTISH-SCOTROC-4|Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers||National Cancer Institute (NCI)||Completed|March 2004|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1300|||Female|18 Years|N/A|No|||July 2009|August 6, 2013|December 8, 2004||||No||https://clinicaltrials.gov/show/NCT00098878||199496|
NCT00099164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-STTARS|Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)|A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS)||The George Washington University Biostatistics Center|Yes|Completed|April 2004|September 2007|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|795|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|December 8, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099164||199478|
NCT00099177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO18039|A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain|A Randomized, Double-Blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain||Hoffmann-La Roche||Terminated|August 2005|January 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|December 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099177||199477|
NCT00116636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70-1002-064|Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients|A Phase II, Open Label, Single Arm Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) as a Single Agent in a Cohort of HIV Positive Adult Patients||Therapeutic Concepts||Recruiting|June 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A||||June 2005|July 18, 2005|June 29, 2005||||No||https://clinicaltrials.gov/show/NCT00116636||198188|
NCT00115037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAOSL014851|Managing Alcoholism in People Who Do Not Respond to Naltrexone|Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism|EXTEND|University of Pennsylvania|Yes|Completed|September 2003|July 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|302|||Both|18 Years|N/A|No|||August 2011|August 4, 2011|June 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00115037||198311|
NCT00113802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hLL2-18-US|Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia|A Phase II, Single-Arm Trial of Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients With Waldenstrom's Macroglobulinemia||Immunomedics, Inc.||Terminated|August 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||31|||Both|18 Years|N/A|No|||February 2008|February 4, 2008|June 10, 2005|||low accrual|||https://clinicaltrials.gov/show/NCT00113802||198405|
NCT00113269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-04-003|Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients|Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients|INTAC|Astellas Pharma Inc|Yes|Completed|May 2005|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|501|||Both|18 Years|N/A|No|||August 2011|August 9, 2011|June 7, 2005|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00113269||198446|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00113516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181057|A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer|Phase 2 Study Of SU011248 As Consolidation Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer||Pfizer|No|Completed|September 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|June 8, 2005|No|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00113516||198427|
NCT00113529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181038|Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma|A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma||Pfizer|No|Completed|October 2004|October 2008|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|June 8, 2005|No|Yes||No|March 1, 2010|https://clinicaltrials.gov/show/NCT00113529||198426|
NCT00113776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030194|Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer|A Multicenter, Open-label, Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects With Metastatic Colorectal Cancer||Amgen||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||January 2011|January 20, 2011|June 10, 2005||||||https://clinicaltrials.gov/show/NCT00113776||198407|
NCT00114660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM.HO.01|Cocoa Butter for Prevention of Stretch Marks|Topical Application of Cocoa Butter for Prevention of Striae Gravidarum||American University of Beirut Medical Center||Completed|November 2004|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2007|March 5, 2009|June 16, 2005||||No||https://clinicaltrials.gov/show/NCT00114660||198339|
NCT00114959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGX-635-CML-201|Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)|A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase||Teva Pharmaceutical Industries|No|Terminated|October 2005|March 2009|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|16 Years|N/A|No|||January 2015|January 8, 2015|June 20, 2005|Yes|Yes|Poor enrollment|No|January 8, 2015|https://clinicaltrials.gov/show/NCT00114959||198317|This study was intended to follow a Simon two stage design to test 18 patients in each stratum (chronic, accelerated and blast phase) for efficacy. Only 15 were enrolled, an insufficient number for a formal statistical analysis of efficacy.
NCT00114686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D144AL00002|Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder|A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder||AstraZeneca||Completed|January 2006|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Both|21 Years|60 Years|No|||January 2013|January 3, 2013|June 16, 2005||||No||https://clinicaltrials.gov/show/NCT00114686||198337|
NCT00114972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2024|SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries|SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery|SYNTAX|Boston Scientific Corporation|Yes|Active, not recruiting|March 2005|May 2012|Anticipated|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1800|||Both|21 Years|N/A|No|||May 2010|May 27, 2010|June 20, 2005|Yes|Yes||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00114972||198316|
NCT00113347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1049|Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase I Evaluation of Erlotinib and Docetaxel With Concomitant Boost Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck||M.D. Anderson Cancer Center|No|Completed|April 2005|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|June 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00113347||198440|
NCT00113854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD200211/246|Mannitol as Adjunct Therapy for Childhood Cerebral Malaria|Effect of Mannitol as Adjunct Therapy on the Clinical Outcome of Childhood Cerebral Malaria in Mulago Hospital: A Randomised Clinical Trial||Makerere University||Active, not recruiting|October 2004|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||156|||Both|6 Months|5 Years|No|||June 2005|June 23, 2005|June 10, 2005||||No||https://clinicaltrials.gov/show/NCT00113854||198401|
NCT00114712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPR-1|Ribavirin Pregnancy Registry|Ribavirin Pregnancy Registry||INC Research|Yes|Recruiting|January 2004|December 2027|Anticipated|November 2027|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|18 Years|65 Years|No|Non-Probability Sample|Primary Analysis - US|December 2013|March 30, 2015|June 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00114712|12 Months|198335|
NCT00114725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2004-1|Laser-Assisted Versus Conventional Intracytoplasmic Sperm Injection|Laser-Assisted Versus Conventional Intracytoplasmic Sperm Injection||Shady Grove Fertility Reproductive Science Center||Completed|March 2004|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|45 Years|No|||June 2005|June 23, 2005|June 16, 2005||||No||https://clinicaltrials.gov/show/NCT00114725||198334|
NCT00114738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050170|EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma|Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2005|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|100 Years|No|||January 2016|February 4, 2016|June 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114738||198333|
NCT00116233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMS0104RCV|Pediatric Multicenter Study of REPEL-CV|Peds. Multicenter Study||SyntheMed||Recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||June 2005|June 27, 2005|June 27, 2005||||||https://clinicaltrials.gov/show/NCT00116233||198219|
NCT00116467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-0009|Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia|Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line||Cell Genesys||Completed|March 2001|January 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||55|||Both|18 Years|60 Years|No|||December 2007|December 18, 2007|June 29, 2005||||||https://clinicaltrials.gov/show/NCT00116467||198201|
NCT00116220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-096|Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer|A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 1995|April 2016|Anticipated|April 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Male|41 Years|N/A|No|||June 2015|June 22, 2015|June 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116220||198220|
NCT00112216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD 1998-009|Immunotherapy of Melanoma Patients|Specific Immunotherapy of Skin Melanoma Patients With Antigenic Peptides and Immunological Analysis of the Vaccine Site Sentinel Lymph Node||Centre Hospitalier Universitaire Vaudois|No|Completed|May 1999|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2009|April 23, 2013|May 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00112216||198518|
NCT00104234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB-03-06|Study of rhASB in Patients With Mucopolysaccharidosis VI|A Multicenter, Multinational Open-Label Extension Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With Mucopolysaccharidosis VI||BioMarin Pharmaceutical||Completed|February 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|7 Years|N/A|No|||January 2010|January 26, 2010|February 24, 2005|||||February 4, 2009|https://clinicaltrials.gov/show/NCT00104234||199105|
NCT00104247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-003|Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels||BioMarin Pharmaceutical||Completed|March 2005|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|89|||Both|8 Years|N/A|No|||July 2014|July 15, 2014|February 24, 2005||Yes|||January 29, 2009|https://clinicaltrials.gov/show/NCT00104247||199104|
NCT00104260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-001|Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria|A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels||BioMarin Pharmaceutical||Completed|December 2004|November 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||700|||Both|8 Years|N/A|No|||April 2007|April 5, 2007|February 24, 2005||||||https://clinicaltrials.gov/show/NCT00104260||199103|
NCT00098891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02634|MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas|A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995, IND 61,198), in Combination With 13-Cis-Retinoic Acid in Metastatic Progressive Cancer.||National Cancer Institute (NCI)||Completed|October 2004|||March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|December 8, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00098891||199495|
NCT00104533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1753|Effectiveness of Magnetic Therapy on Pain Intensity|Effectiveness of Magnetic Therapy on Pain Intensity||Javeriana University||Completed|September 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||164|||Both|8 Years|N/A|No|||March 2005|March 19, 2008|March 1, 2005||||No||https://clinicaltrials.gov/show/NCT00104533||199082|
NCT00099190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 501-111|ARQ 501 in Combination With Docetaxel in Patients With Cancer|A Phase Ib Safety and Pharmacokinetic Study of ARQ 501 in Combination With Docetaxol in Adult Patients With Locally Advanced or Metastatic Carcinoma||ArQule||Completed|December 2004|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|December 10, 2004||||||https://clinicaltrials.gov/show/NCT00099190||199476|
NCT00099203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO18040|A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease|A Randomized, Placebo-Controlled, Double-Blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain||Hoffmann-La Roche||Terminated|July 2005|January 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|December 10, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00099203||199475|
NCT00113035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02905|Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease|Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)||Sanofi||Completed|May 2005|October 2005|Actual|||N/A|Observational|Time Perspective: Prospective||1||60|||Both|8 Years|N/A|No|||May 2015|May 4, 2015|June 3, 2005||||||https://clinicaltrials.gov/show/NCT00113035||198464|
NCT00113048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM111|Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies|A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies||Sanofi||Terminated|December 2003|September 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|June 3, 2005||||||https://clinicaltrials.gov/show/NCT00113048||198463|
NCT00116246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02151B|McRoberts Manoeuvre Or Pushing Study (McMOPS)|||University of Melbourne||Recruiting|August 2005|December 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||222|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2005|September 7, 2006|June 27, 2005||||No||https://clinicaltrials.gov/show/NCT00116246||198218|
NCT00114140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0424|Temozolomide and Radiation Therapy in Treating Patients With Gliomas|A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas||Radiation Therapy Oncology Group|Yes|Active, not recruiting|January 2005|||September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|June 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114140||198379|
NCT00114400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0024|BVAIT: B-Vitamin Atherosclerosis Intervention Trial|B-Vitamin Atherosclerosis Intervention Trial (BVAIT)||National Institute on Aging (NIA)||Completed|November 2000|February 2007|Actual|February 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||506|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2007|December 9, 2009|June 14, 2005||||No||https://clinicaltrials.gov/show/NCT00114400||198359|
NCT00114413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-01/DAIT ICAC-02|Evaluation of an Asthma Treatment Strategy Based on Exhaled Nitric Oxide Measurements in Adolescents|Asthma Control Evaluation (ACE): A Biomarker-Based Approach to Improving Asthma Control and Mechanistic Studies (DAIT ICAC-02)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2004|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|547|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|June 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00114413||198358|
NCT00114673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1521-R850|A Study to Validate Cosmetic Outcome Scales Used to Rate Uneven Skin Color and Wrinkling|A Multicenter Study to Validate Cosmetic Outcome Scales Used to Assess Irregular Skin Pigmentation and Wrinkling||Graceway Pharmaceuticals, LLC||Completed|June 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2006|February 16, 2007|June 16, 2005||||No||https://clinicaltrials.gov/show/NCT00114673||198338|
NCT00115583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-003104|The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries|The Contribution of Endothelin to Vasoreactivity in Atherosclerotic Coronary Arteries||Brigham and Women's Hospital||Active, not recruiting|November 1998|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label||||200|||Both|18 Years|75 Years|No|||May 2010|May 3, 2010|June 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00115583||198269|
NCT00112437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-004|A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK0822 in the Treatment of Postmenopausal Women With Osteoporosis||Merck Sharp & Dohme Corp.||Completed|June 2005|January 2016|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|399|||Female|45 Years|85 Years|No|||January 2016|February 3, 2016|June 2, 2005|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT00112437||198501|
NCT00115336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191|Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease|Ketorolac Versus Ibuprofen for the Painful Crisis of Sickle Cell Disease - Southwestern Comprehensive Sickle Cell Center||University of Texas Southwestern Medical Center|Yes|Terminated|January 2005|December 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|6 Years|18 Years|No|||January 2013|January 18, 2013|June 21, 2005||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00115336||198288|
NCT00116480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.2|Misoprostol in the Treatment of Postpartum Hemorrhage|Misoprostol in the Treatment of Post Partum Hemorrhage: A Placebo Randomised Controlled Trial in 4 Karachi Hospitals||Gynuity Health Projects|Yes|Completed|December 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|61|||Female|N/A|N/A|No|||March 2009|March 17, 2009|June 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00116480||198200|
NCT00112749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000428460|Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer|Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?||Jonsson Comprehensive Cancer Center|Yes|Terminated|February 2005|November 2012|Actual|January 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|7|||Female|45 Years|65 Years|No|||February 2016|February 12, 2016|June 2, 2005|Yes|Yes|Recruitment stopped due to slow accrual and lack of evidence of need for further continuation    of protocol in inpatient setting.|No||https://clinicaltrials.gov/show/NCT00112749||198480|
NCT00104559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43AI058870-01|Computer-Generated Vs. Standard Informed Consent for HIV Research Studies|Interactive Multimedia Informed Consent (iMIC) for HIV Research||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|January 2005|March 2009|Anticipated|July 2007|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 25, 2008|March 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00104559||199080|
NCT00104572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904338|Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.|The Effects of Aromatase Inhibition and Testosterone Replacement in Sex Steroids, Pituitary Hormones, Markers of Bone Turnover, Muscle Strength, and Cognition in Older Men||National Institutes of Health Clinical Center (CC)|No|Completed|March 2004|January 2015|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Male|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|March 1, 2005|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT00104572||199079|
NCT00104546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001957|Vitamin K Injections for the Treatment of Painful Menstruation|Vitamin K Injection Treatment for Primary Dysmenorrhea: A Controlled Pilot Study||National Center for Complementary and Integrative Health (NCCIH)||Completed|September 2004|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||36|||Female|14 Years|25 Years|No|||January 2008|January 23, 2008|March 1, 2005||||No||https://clinicaltrials.gov/show/NCT00104546||199081|
NCT00104793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMTO-LC02-02|Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer|Phase II Study of Weekly Irinotecan and Carboplatin in Extensive-Stage Small-Cell Lung Cancer||National Cancer Institute (NCI)||Completed|June 2003|November 2008|Actual|February 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|N/A|No|||October 2007|May 29, 2013|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104793||199062|
NCT00105027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-99|The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study|The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema|SCORE|The EMMES Corporation|Yes|Completed|October 2004|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|682|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|March 3, 2005|Yes|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00105027||199046|
NCT00113061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180|Effect of Exercise on Elevated C-Reactive Protein Concentrations in Formerly Inactive Adults|INFLAME: Inflammation and Exercise||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2004|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention||||162|||Both|18 Years|75 Years|No|||December 2007|December 11, 2007|June 3, 2005||||No||https://clinicaltrials.gov/show/NCT00113061||198462|
NCT00113074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179|Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers|Blood Pressure Control in Hypertensive Smokers||University of Iowa|Yes|Completed|September 2004|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|376|||Both|N/A|N/A|No|||January 2013|January 7, 2013|June 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00113074||198461|
NCT00112476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01382|Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors|A Phase I Study of Intravenous CCI-779 in Combination With Bryostatin-1 in Solid Tumors (10038414)||National Cancer Institute (NCI)||Completed|March 2005|||July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|June 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00112476||198499|
NCT00112775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000428457|BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate|A Randomized Multi-Center Open Label Study of BMS-354825 vs Imatinib Mesylate (Gleevec®) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Iamtinib at a Dose of 400-600 mg/d||National Cancer Institute (NCI)||Active, not recruiting|March 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2006|June 4, 2011|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112775||198479|
NCT00113542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 508|A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris|An Open Label Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris||University of Michigan||Completed|June 2004|June 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||August 2008|May 20, 2015|June 8, 2005||||||https://clinicaltrials.gov/show/NCT00113542||198425|
NCT00113815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002233|Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures|A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2005|November 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|118|||Both|1 Month|24 Months|No|||March 2014|March 25, 2014|June 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00113815||198404|
NCT00114153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000432949|Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Phase I Trial of Induction Paraplatin® and Xeloda® Followed by Concurrent Paraplatin and Xeloda With Intensity Modulated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|June 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||April 2007|November 25, 2009|June 13, 2005||||No||https://clinicaltrials.gov/show/NCT00114153||198378|
NCT00114166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0146Q|Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Gynecologic Oncology Group|Yes|Completed|January 2005|||January 2011|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Female|18 Years|N/A|No|||May 2014|May 27, 2014|June 13, 2005|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00114166||198377|
NCT00093379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0874|Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer|A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal||M.D. Anderson Cancer Center|No|Completed|April 2004|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|16 Years|N/A|No|||March 2014|March 12, 2014|October 6, 2004|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00093379||199894|
NCT00093704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000389476|Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma|EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir||Jonsson Comprehensive Cancer Center|Yes|Terminated|March 2005|||July 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2012|October 1, 2015|October 6, 2004|No|Yes|study could not recruit any more patients|No||https://clinicaltrials.gov/show/NCT00093704||199874|
NCT00094003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS9001|Study of NS-9 in Patients With Liver Metastases|A Phase I, Open-Label, Dose Escalation Study of Intravenously Administered NS-9 in Subjects With Liver Metastases From Various Primary Cancers||NS Pharma, Inc.||Completed|September 2002|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||November 2005|November 9, 2005|October 8, 2004||||||https://clinicaltrials.gov/show/NCT00094003||199852|
NCT00094380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN002AI|Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)|Treatment of Systemic Lupus Erythematosus With CTLA4-IgG4m Plus Cyclophosphamide: A Phase I/IIA Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2004|January 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|October 16, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094380||199824|
NCT00094393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050004|Clinical Studies of Progeria|Clinical Investigations Into Hutchison-Gilford Progeria Syndrome||National Institutes of Health Clinical Center (CC)||Completed|October 2004|||||N/A|Observational|Time Perspective: Retrospective|||Actual|15|||Both|6 Months|70 Years|No|||June 2015|June 5, 2015|October 16, 2004||No||No||https://clinicaltrials.gov/show/NCT00094393||199823|
NCT00094887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050019, INOT 36|Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises|A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis||INO Therapeutics|Yes|Completed|October 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|10 Years|N/A|No|||May 2015|May 5, 2015|October 28, 2004|Yes|Yes||No|December 4, 2009|https://clinicaltrials.gov/show/NCT00094887||199787|
NCT00094900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050014|Interleukin-1 Trap to Treat Autoinflammatory Diseases|Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis||National Institutes of Health Clinical Center (CC)||Completed|October 2004|December 2010|Actual|September 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|October 28, 2004|No|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00094900||199786|Secondary outcome analyses will be stratified based on primary outcome results - responders and non-responders.1 subject with Familial Mediterranean Fever (FMF) was recruited but outcomes were not collected due to insufficient accrual of FMF cases.
NCT00094874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801685|Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms|A Double-Blind, Randomized Study of Puncturing Versus Non-Puncturing Acupuncture for the Treatment of Interstitial Cystitis Symptoms||The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust||Recruiting|September 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||October 2004|June 23, 2005|October 27, 2004||||No||https://clinicaltrials.gov/show/NCT00094874||199788|
NCT00095550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV131-185|Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension|The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension||Bristol-Myers Squibb||Completed|October 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|496|||Both|18 Years|N/A|No|||August 2008|April 7, 2011|November 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095550||199736|
NCT00095563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03089|Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers|A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands||National Cancer Institute (NCI)||Completed|September 2004|||February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|November 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095563||199735|
NCT00095875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI 04-006|Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)|A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL]||Dana-Farber Cancer Institute|Yes|Completed|August 2004|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|November 9, 2004|Yes|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00095875||199714|
NCT00095888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02632|3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer|A Phase II Trial Of Gemcitabine And Triapine In Refractory Metastatic Breast Cancer||National Cancer Institute (NCI)||Terminated|October 2004|||June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|November 9, 2004|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00095888||199713|
NCT00096174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000390923|Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck|Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck||Eastern Cooperative Oncology Group|No|Active, not recruiting|December 2004|July 2016|Anticipated|July 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 9, 2004||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00096174||199691|
NCT00096733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2ALL (IND)|Adult-to-Adult Living Donor Liver Transplantation Study|Adult-to-Adult Living Donor Liver Transplantation Cohort Study|A2ALL-1|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|October 2004|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|2470|Samples With DNA|whole blood, serum, fixed tissue samples, frozen tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Potential recipients and donors for transplantation will be evaluated and invited to        participate in the study if they are eligible for LDLT using standard criteria for this        procedure according to the practice of the transplant center.|December 2012|December 7, 2012|November 12, 2004||No||No||https://clinicaltrials.gov/show/NCT00096733||199650|
NCT00103792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WG-MMF-1|Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)|Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis||University Medical Center Groningen|No|Recruiting|December 2004|January 2012|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|February 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00103792||199136|
NCT00104156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001352-01A2|Qigong Therapy for Individuals With Knee Osteoarthritis|Qigong Therapy for Osteoarthritis at Knees||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|80 Years|No|||January 2008|January 23, 2008|February 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00104156||199109|
NCT00103766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8736|Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion|Randomized Comparison of Two Dose and Frequency Regimens of Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion||O'Brien, Jeana D., MD, FACP, FCCP||Recruiting|October 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||July 2006|July 31, 2006|February 14, 2005||||||https://clinicaltrials.gov/show/NCT00103766||199138|
NCT00103779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG040-0002|A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma|A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Non-Hodgkin's Lymphoma||Seattle Genetics, Inc.|No|Completed|December 2004|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|February 14, 2005|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00103779||199137|
NCT00095017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-083|Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)|A 4 Week Randomized, Placebo-Controlled, Parallel Group, Double-Blind Pilot Study to Assess the Safety and Efficacy of Etoricoxib 90 mg Versus Placebo in the Treatment of Cancer Pain||Merck Sharp & Dohme Corp.||Withdrawn|November 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|October 29, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095017||199777|
NCT00095030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-048|Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone|A Phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Subjects Wtih Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone||Bristol-Myers Squibb||Completed|February 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1752|||Both|18 Years|70 Years|No|||September 2007|September 10, 2010|October 29, 2004||||||https://clinicaltrials.gov/show/NCT00095030||199776|
NCT00095043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-005|Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)|A 12-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Multicenter Long-Term Safety Study of MK0928 in the Treatment of Elderly Outpatients With Primary Insomnia||H. Lundbeck A/S||Completed|October 2004|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||320|||Both|65 Years|N/A|No|||January 2015|January 13, 2015|October 29, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095043||199775|
NCT00128154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 AT001147-01|Chromium Picolinate for the Treatment of Metabolic Syndrome|A Double-Blind Randomized Controlled Clinical Trial of Chromium Picolinate on Clinical and Biochemical Features of the Metabolic Syndrome||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2004|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|75 Years|No|||August 2006|August 17, 2006|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00128154||197325|
NCT00128167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP111|Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6–59 Months of Age|A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6–59 Months of Age||MedImmune LLC||Completed|October 2004|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||8500|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||July 2006|July 5, 2006|August 5, 2005||||||https://clinicaltrials.gov/show/NCT00128167||197324|
NCT00097370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100901|Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome|An Open-Label Extension Study to Study MHE100185, to Evaluate Long-term Safety, Efficacy and Optimal Dosing Frequency of 750 mg Intravenous Mepolizumab in Subjects With Hypereosinophilic Syndromes||GlaxoSmithKline|No|Completed|September 2004|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|75 Years|No|||January 2016|January 7, 2016|November 22, 2004|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT00097370||199604|
NCT00096356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-97202|Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer|A Randomized Double-Blind Placebo-Controlled Study Of Oral Coenzyme Q10 To Relieve Self-Reported Cancer Treatment Related Fatigue In Breast Cancer Patients|CoQ10|Wake Forest NCORP Research Base|Yes|Completed|August 2004|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|236|||Female|18 Years|N/A|No|||December 2014|December 17, 2014|November 9, 2004|No|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT00096356||199678|
NCT00096369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000393444|Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer|An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers That Are Modulated by Tamoxifen vs. Placebo in Women With an Increased Risk for Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2002|||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|130|||Female|35 Years|N/A|No|||May 2007|May 23, 2008|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096369||199677|
NCT00093041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zalutumumab|Zalutumumab in Head and Neck Cancer|An Open, Single Dose Escalation Study Followed by a Multiple Dose Extension of Anti-EGF Receptor Human Monoclonal Antibody (Zalutumumab) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Genmab||Completed|December 2003|January 2005|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|28|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|September 30, 2004||Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00093041||199918|The study comprised a single-dose escalation part for assessment of safety and a repeat dose extension including 4 weekly infusions. Please see the referred publication by Bastholt at al 2007 for detailed results.
NCT00093678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000389434|Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer|A Randomized, Double Blind, Placebo-Controlled Trial of Celecoxib in Patients With Advanced Cancer||Eastern Cooperative Oncology Group||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Actual|0|||Both|18 Years|120 Years|No|||October 2015|October 6, 2015|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093678||199875|
NCT00093977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040180|Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease|An Open-label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects With Chronic Kidney Disease||Amgen||Completed|October 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1100|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|October 7, 2004||||No||https://clinicaltrials.gov/show/NCT00093977||199854|
NCT00094913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0055|PET Changes in Alzheimer's Disease (AD)|Clinical Correlates of Longitudinal PET Changes in Alzheimer's Disease (AD)||National Institute on Aging (NIA)||Active, not recruiting|May 2004|April 2005||||N/A|Observational|Time Perspective: Prospective|||Anticipated|105|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||July 2007|May 26, 2009|October 28, 2004||||No||https://clinicaltrials.gov/show/NCT00094913||199785|
NCT00095225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI2950g|A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)|A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy (Docetaxel or Pemetrexed) or Tarceva (Erlotinib) Compared With Chemotherapy (Docetaxel or Pemetrexed) Alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer||Genentech, Inc.||Completed|July 2004|November 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|122|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|November 1, 2004||||||https://clinicaltrials.gov/show/NCT00095225||199761|
NCT00095212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK54167 (completed)|Androgen Effects in HIV-infected Women|Androgen Effects in HIV-infected Women||Massachusetts General Hospital|Yes|Completed|September 2004|February 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|55 Years|No|||April 2010|April 9, 2010|November 1, 2004|Yes|Yes||No|January 21, 2010|https://clinicaltrials.gov/show/NCT00095212||199762|
NCT00095576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V520-023|Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5 HIV-1 Gag/Pol/Nef) in Adults at High Risk of HIV-1 Infection||Merck Sharp & Dohme Corp.|Yes|Terminated|November 2004|September 2009|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3000|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|November 5, 2004|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00095576||199734|The DSMB (Data & Safety Monitoring Board) reviewed interim data which demonstrated that the investigational vaccine was not effective, and all vaccinations were halted. Long term follow up was available for participants in V520-030.
NCT00096187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000390347|Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy|A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor||Gynecologic Oncology Group||Terminated|July 2005|||July 2007||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Female|N/A|N/A|No|||May 2007|April 10, 2013|November 9, 2004||||||https://clinicaltrials.gov/show/NCT00096187||199690|
NCT00096473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-315|Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease|A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period||Eisai Inc.||Completed|January 2001|September 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|229|||Both|50 Years|N/A|No|||March 2011|March 31, 2011|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096473||199669|
NCT00096486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-033|Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer|A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|May 2004|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|120 Years|No|||December 2015|December 15, 2015|November 9, 2004|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00096486||199668|
NCT00104767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415733|Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase I Trial to Evaluate Cyclooxygenase 2 Inhibitor-Mediated Modulation of T Regulatory Cells in Advanced Non-Small Cell Lung Cancer (NSCLC)||Jonsson Comprehensive Cancer Center|No|Completed|January 2009|October 2015|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00104767||199064|
NCT00104988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000412048|S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma||Southwest Oncology Group|Yes|Completed|June 2005|August 2009|Actual|July 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|March 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00104988||199048|
NCT00105287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3039/BP/US|Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients|Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients||Teva Pharmaceutical Industries||Completed|January 2005|September 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|80 Years|No|||May 2014|May 8, 2014|March 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00105287||199027|
NCT00104494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRIFFI04A0|Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)|Zinc Homeostasis and Kinetics in Children With CF||Cystic Fibrosis Foundation Therapeutics|Yes|Completed|May 2004|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||March 2005|July 29, 2015|March 1, 2005||||No||https://clinicaltrials.gov/show/NCT00104494||199085|
NCT00095056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-028|An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)|Sitagliptin Study in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency||Merck Sharp & Dohme Corp.||Completed|October 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|October 29, 2004|Yes|Yes||No|June 22, 2010|https://clinicaltrials.gov/show/NCT00095056||199774|
NCT00095069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-003|Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Groups Efficacy and Safety Extension Study of MK0928 in the Treatment of Adult Outpatients With Primary Insomnia||H. Lundbeck A/S||Completed|October 2004|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||600|||Both|18 Years|64 Years|No|||January 2015|January 13, 2015|October 29, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095069||199773|
NCT00097383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4028|Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer|A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer||Eli Lilly and Company||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2006|July 18, 2006|November 22, 2004||||||https://clinicaltrials.gov/show/NCT00097383||199603|
NCT00092521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-013|Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)|A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women||Merck Sharp & Dohme Corp.||Completed|December 2001|January 2009|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|5759|||Female|16 Years|23 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 23, 2004|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00092521||199957|
NCT00093054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002086|Cranberry Juice for Treatment of Urinary Tract Infections|Cranberry Juice and Urinary Tract Infections||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|November 2004|December 2009|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Female|18 Years|40 Years|No|||April 2015|April 14, 2015|September 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093054||199917|
NCT00093405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000387952|17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG)In Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|August 2004|November 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2005|June 21, 2013|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093405||199893|
NCT00093418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03038|S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia|Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older||National Cancer Institute (NCI)||Completed|September 2004|||June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|296|||Both|70 Years|N/A|No|||January 2013|January 14, 2013|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093418||199892|
NCT00094406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050012|Carbon Monoxide to Prevent Lung Inflammation|Effects of Inhaled Carbon Monoxide on Pulmonary Inflammatory Responses Following Endotoxin Instillation||National Institutes of Health Clinical Center (CC)||Completed|October 2004|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|40 Years|No|||May 2015|May 20, 2015|October 16, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00094406||199822|
NCT00094692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-93|An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old|An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds||Jaeb Center for Health Research|Yes|Completed|October 2002|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||507|||Both|7 Years|17 Years|No|||May 2007|March 23, 2010|October 21, 2004||||No||https://clinicaltrials.gov/show/NCT00094692||199802|
NCT00094653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX010-20|MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma|A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma||Bristol-Myers Squibb|Yes|Completed|September 2004|October 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1783|||Both|18 Years|N/A|No|||June 2011|June 29, 2011|October 21, 2004|Yes|Yes||No|April 22, 2011|https://clinicaltrials.gov/show/NCT00094653||199805|
NCT00094666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-002|Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Elderly Patients With Primary Insomnia||H. Lundbeck A/S||Terminated|November 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||465|||Both|65 Years|N/A|No|||January 2015|January 13, 2015|October 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094666||199804|
NCT00094926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004693|A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.|A Prospective, Randomized, Double-blind, Placebo-controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-relapsing Bipolar Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|275|||Both|18 Years|70 Years|No|||April 2010|May 17, 2011|October 28, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094926||199784|
NCT00095251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#031089|MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status|A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status||Vanderbilt University|Yes|Active, not recruiting|August 2004|December 2016|Anticipated|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 1, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095251||199759|
NCT00095264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030207|A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome|A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome||Amgen||Completed|October 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||209|||Both|18 Years|N/A|No|||January 2010|January 14, 2010|November 2, 2004||||||https://clinicaltrials.gov/show/NCT00095264||199758|
NCT00095238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV131-148|Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)|Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)||Bristol-Myers Squibb||Completed|June 2002|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4128|||Both|60 Years|N/A|No|||March 2015|March 18, 2015|November 1, 2004|Yes|Yes||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00095238||199760|
NCT00095901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000393550|Capecitabine in Treating Patients With Locally Recurrent or Metastatic Nasopharygeal Cancer|A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|June 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|July 23, 2008|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00095901||199712|
NCT00095914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040280|Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|September 2004|March 2009|Actual|May 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2012|March 14, 2012|November 9, 2004||||||https://clinicaltrials.gov/show/NCT00095914||199711|
NCT00095927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000393493|Radiation Therapy, Carboplatin, and Paclitaxel With or Without Amifostine in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer|Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck||National Cancer Institute (NCI)||Active, not recruiting|May 2003|||June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||June 2009|January 8, 2010|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095927||199710|
NCT00096200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00067|Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer||National Cancer Institute (NCI)||Completed|August 2004|||August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|N/A|No|||February 2014|April 14, 2015|November 9, 2004|Yes|Yes||No|November 8, 2012|https://clinicaltrials.gov/show/NCT00096200||199689|Principal Investigator did not collect data on secondary outcomes because not relevant.
NCT00096759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002307-01|Comparing Tai Chi Chih and Relaxation Therapy in the Treatment of Rheumatoid Arthritis|Efficacy of CAM Interventions in Rheumatoid Arthritis||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|November 2004|August 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|85 Years|No|||March 2013|March 21, 2013|November 15, 2004||||No||https://clinicaltrials.gov/show/NCT00096759||199648|
NCT00104182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1632|Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening as Add-on to Oral Antidiabetic Drug(s) in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|February 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|503|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|February 23, 2005||||No||https://clinicaltrials.gov/show/NCT00104182||199107|
NCT00104520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-AI-005|Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary P. Aeruginosa Requiring Frequent Antibiotics (AIR-CF2)|AIR-CF2|Gilead Sciences|Yes|Completed|February 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|211|||Both|6 Years|N/A|No|||September 2010|February 16, 2011|March 1, 2005|Yes|Yes||No|September 10, 2010|https://clinicaltrials.gov/show/NCT00104520||199083|The study was designed such that participants were discontinued from study participation upon meeting the primary endpoint (time to need for inhaled or IV antipseudomonal antibiotics).
NCT00105300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-691|Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab||Abbott||Completed|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|75 Years|No|||August 2006|August 13, 2006|March 11, 2005||||||https://clinicaltrials.gov/show/NCT00105300||199026|
NCT00095368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111.301|APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat|A Phase III, Randomized, Double-Blind, Double-Dummy Multicenter Study to Evaluate the Efficacy and Safety of 775 mg APC-111 MP Tablet QD for 7 Days vs Penicillin VK 250 mg QID for 10 Days in Patients With Streptococcus Pyogenes||Advancis Pharmaceutical Corporation||Completed|October 2004|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|12 Years|N/A|No|||April 2005|December 6, 2006|November 3, 2004||||No||https://clinicaltrials.gov/show/NCT00095368||199750|
NCT00092417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-009|Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)|Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka/Merck)Among Adults 50 Years of Age or Older||Merck Sharp & Dohme Corp.|No|Completed|October 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|695|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 22, 2004|Yes|Yes||No|May 12, 2010|https://clinicaltrials.gov/show/NCT00092417||199965|
NCT00092534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-015|Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015)|A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety Immunogenicity and Efficacy on the Incidence of HPV 16/18-Related CIN2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18,) L1 Virus-Like Particle (VLP) Vaccine (V501, Gardasil) in 16- to 23-Year Old Women - The F.U.T.U.R.E. II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)||Merck Sharp & Dohme Corp.|No|Active, not recruiting|June 2002|January 2019|Anticipated|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|12167|||Female|16 Years|23 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 23, 2004|Yes|Yes||No|July 20, 2009|https://clinicaltrials.gov/show/NCT00092534||199956|
NCT00092547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-018|A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)|A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study).||Merck Sharp & Dohme Corp.|No|Completed|October 2003|June 2015|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|1781|||Both|9 Years|15 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|September 23, 2004|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00092547||199955|The difference between the prior and final data is a minor change in the definition of the per-protocol immunogenicity population, which was applied down to the base study. Also, protocol violators were identified and excluded from the analysis.
NCT00092560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-036|Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)|Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|December 2002|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|587|||Both|18 Years|75 Years|No|||October 2015|October 29, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092560||199954|
NCT00093067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-007|Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus|A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy In the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to Staph Aureus||Cubist Pharmaceuticals LLC||Completed|March 2002|February 2005|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 30, 2004||||No||https://clinicaltrials.gov/show/NCT00093067||199916|
NCT00093080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-018|Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)|A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma||Merck Sharp & Dohme Corp.||Completed|October 2004|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|15 Years|N/A|No|||February 2015|February 12, 2015|September 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093080||199915|
NCT00094029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181036|A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248|A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate||Pfizer|No|Approved for marketing|September 2004|October 2011|Actual|October 2011|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2012|March 8, 2012|October 8, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00094029||199850|
NCT00094705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 189|Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2005|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 18, 2008|October 21, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00094705||199801|
NCT00094679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS2B|Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia|A Randomized Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia|ATS2B|Jaeb Center for Health Research|Yes|Completed|May 2001|September 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|3 Years|7 Years|No|||September 2010|September 8, 2010|October 21, 2004||No||No||https://clinicaltrials.gov/show/NCT00094679||199803|
NCT00094939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0056|Predictors of Cognitive Decline in Normal Aging|Predictors of Cognitive Decline in Normal Aging||National Institute on Aging (NIA)||Recruiting|September 2003|August 2008||||N/A|Observational|Time Perspective: Prospective|||Anticipated|170|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||September 2009|December 10, 2009|October 28, 2004||||No||https://clinicaltrials.gov/show/NCT00094939||199783|
NCT00095589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000401496|Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer|Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-Institutional Study||National Cancer Institute (NCI)||Active, not recruiting|August 2004|||June 2009|Anticipated|N/A|Interventional|Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|500|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 26, 2009|November 5, 2004||||No||https://clinicaltrials.gov/show/NCT00095589||199733|
NCT00095277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030204|Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer||Amgen||Completed|October 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|November 2, 2004||||||https://clinicaltrials.gov/show/NCT00095277||199757|
NCT00095628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03091|SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|January 2005|||July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|November 5, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095628||199732|
NCT00096213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000390349|S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone|A Phase II Surgical Trial Of Intralesional Resection Of Low-Grade Intracompartmental Chondrosarcoma Of Bone||Southwest Oncology Group|No|Completed|December 2004|August 2009|Actual|April 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|November 9, 2004||No||No||https://clinicaltrials.gov/show/NCT00096213||199688|
NCT00096226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0229|Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer|A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For Locally Advanced Non-Small Cell Lung Carcinoma||Radiation Therapy Oncology Group|Yes|Completed|September 2004|||April 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|November 9, 2004|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00096226||199687|
NCT00096499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02630|SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel|A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer||National Cancer Institute (NCI)||Completed|April 2005|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||January 2013|January 24, 2013|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096499||199667|
NCT00096772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 066|Collection of Blood Samples From HIV Infected People|Collection and Use of Blood For Genetic and Other Related Analyses (The GENOMICS Protocol)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2005|September 2007|Actual|September 2007|Actual|N/A|Observational|N/A||1|Actual|2502|Samples With DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|Study participants will be selected from those who have given informed consent for        participation in a qualifying CPCRA clinical trial.|May 2014|May 16, 2014|November 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00096772||199647|
NCT00096785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-079|Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection|Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection||Bristol-Myers Squibb|No|Completed|December 2004|April 2008|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|16 Years|N/A|No|||June 2010|August 4, 2010|November 15, 2004|Yes|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00096785||199646|
NCT00094133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481365|Hypnosis in Treating Hot Flashes in Breast Cancer Survivors|Hypnosis for Hot Flashes in Breast Cancer Survivors||National Cancer Institute (NCI)||Recruiting|April 2006|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|60|||Female|18 Years|N/A|No|||September 2007|September 19, 2013|October 14, 2004||||No||https://clinicaltrials.gov/show/NCT00094133||199842|
NCT00094458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004804|Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC|Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy||Centocor Ortho Biotech Services, L.L.C.|No|Completed|March 2005|December 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|508|||Both|21 Years|N/A|No|||April 2014|April 2, 2014|October 19, 2004|Yes|Yes||No|April 30, 2009|https://clinicaltrials.gov/show/NCT00094458||199818|
NCT00104780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000415721|Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Active, not recruiting|December 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2006|November 5, 2013|March 3, 2005||||No||https://clinicaltrials.gov/show/NCT00104780||199063|
NCT00092430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-016|Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)|A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children||Merck Sharp & Dohme Corp.||Completed|September 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention||||1200|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||January 2015|January 23, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092430||199964|
NCT00092443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-007|Dose Confirmation Efficacy Study (V260-007)|Study of the Efficacy, Safety, and Immunogenicity of V260 at Expiry||Merck Sharp & Dohme Corp.||Completed|September 2002|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1312|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 22, 2004|Yes|Yes||No|May 19, 2009|https://clinicaltrials.gov/show/NCT00092443||199963|Safety has been reported in the literature.
NCT00096954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q2982g|A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)|A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)|EXACT|Genentech, Inc.||Completed|December 2005|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|333|||Both|12 Years|75 Years|No|||November 2011|November 3, 2011|November 17, 2004|Yes|Yes||No|August 8, 2011|https://clinicaltrials.gov/show/NCT00096954||199634|This is a stand-alone study to fulfill one of the post-marketing commitments.
NCT00097409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSP20008|Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer|A Phase II, Open-Label Study of Ispinesib in Subjects With Platinum/Taxane-Refractory or Resistant Relapsed Ovarian Cancer||GlaxoSmithKline||Completed|December 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Female|18 Years|N/A|No|||October 2010|October 1, 2010|November 23, 2004||||||https://clinicaltrials.gov/show/NCT00097409||199601|
NCT00097422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT-80 Phase 2A|OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)|An Open-Label, Dose Ranging, Randomized Clinical Evaluation of OPT-80 in Patients With Clostridium Difficile-Associated Diarrhea (CDAD)||Merck Sharp & Dohme Corp.||Completed|November 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2005|April 27, 2015|November 23, 2004||||||https://clinicaltrials.gov/show/NCT00097422||199600|
NCT00093444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040263|Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors|A Phase I Dose Escalation Study Of Heat Activated Liposome Delivery Of Doxorubicin And Radiofrequency Ablation Of Primary And Metastatic Tumors Of The Liver||National Institutes of Health Clinical Center (CC)||Completed|September 2004|January 2010|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|October 6, 2004|No|Yes||||https://clinicaltrials.gov/show/NCT00093444||199891|
NCT00093730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000389510|BMS-599626 in Treating Patients With Metastatic Solid Tumors|Phase I Study Of BMS-599626 In Patients With Advanced Solid Malignancies That Express Her2||Jonsson Comprehensive Cancer Center||Completed|August 2004|||April 2006|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093730||199873|
NCT00094042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0007|Work and Iron Status Evaluation|Work and Iron Status Evaluation (WISE)||National Institute on Aging (NIA)||Completed|January 2002|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16000|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2008|January 26, 2010|October 8, 2004||||No||https://clinicaltrials.gov/show/NCT00094042||199849|
NCT00094718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 206|Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|October 21, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00094718||199800|
NCT00094952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0054|Biomarkers and Early Alzheimer's Disease|Biomarkers and Early Alzheimer's Disease||National Institute on Aging (NIA)||Recruiting|April 2003|March 2008||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|October 28, 2004||||No||https://clinicaltrials.gov/show/NCT00094952||199782|
NCT00095303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090698|Brief Strategic Family Therapy for Adolescent Drug Abusers|Brief Strategic Family Therapy for Adolescent Drug Abusers|BSFT|University of Miami|Yes|Completed|August 2004|August 2011|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|480|||Both|12 Years|17 Years|No|||June 2015|June 10, 2015|November 2, 2004||No||No|May 17, 2014|https://clinicaltrials.gov/show/NCT00095303||199755|Main Study: Low rates self-reported drug use leading to only examination of prevention of relapse/escalation of drug use Follow Up Study: Variability between the time of participation in main and follow up, so no direct casuality could be concluded
NCT00095290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV131-169|Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria|Irbesartan Versus Placebo in Combination With Standard Cardiovascular Protection ACE-I Therapy With Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk||Bristol-Myers Squibb||Completed|September 2004|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||400|||Both|55 Years|N/A|No|||September 2008|April 7, 2011|November 2, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095290||199756|
NCT00095641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000394169|S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer|S0225: Phase II Study of Adjuvant Low-Dose Capecitabine After Salvage Surgery in Patients With Locally Recurrent or Persistent Squamous Cell Carcinoma of the Head and Neck||Southwest Oncology Group|Yes|Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|November 5, 2004|Yes|Yes|no longer studying this disease site|No||https://clinicaltrials.gov/show/NCT00095641||199731|
NCT00095940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03007|Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors|Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma||National Cancer Institute (NCI)||Completed|October 2004|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|21 Years|No|||January 2013|May 7, 2014|November 9, 2004|Yes|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00095940||199709|Accrual to the Molecular Biology phase (MBP) was contingent upon accrual being open for the Phase II since some participants in the MBP could be counted in the phase II. The phase II enrolled rapidly thus limiting enrollment to the MBP.
NCT00095953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I169|SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma|A Phase II Study of SB-715992 (NSC 727990) in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma||National Cancer Institute (NCI)|No|Completed|November 2004|September 2008|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||September 2011|May 16, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095953||199708|
NCT00096239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000390237|CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Phase II Open-Label, Multi-Center Study of CP-547, 632, an Oral Tyrosine Kinase Inhibitor of VEGFR-2, in Subjects With Recurrent or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Completed|December 2004|February 2005|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||February 2005|December 18, 2013|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096239||199686|
NCT00096512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03043|S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer||National Cancer Institute (NCI)||Completed|October 2004|||May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096512||199666|
NCT00096525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-014|Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer|Phase II Trial of CC-5013 in Patients With Advanced Renal Cell Carcinoma With Either No Prior Treatment or One Prior Treatment Regimen||Memorial Sloan Kettering Cancer Center||Completed|July 2004|||August 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2013|January 15, 2013|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096525||199665|
NCT00103857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-036|MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)|A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|March 2005|February 2008|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|1208|||Both|18 Years|78 Years|No|||February 2016|February 3, 2016|February 15, 2005|Yes|Yes||No|February 19, 2009|https://clinicaltrials.gov/show/NCT00103857||199131|Non-serious adverse experience results represent those events included in the primary safety analysis for this study (i.e., events that occurred prior to the initiation of glycemic rescue therapy).
NCT00094146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995GUS20|Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity|||Novartis||Completed|January 2002|December 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|70 Years|No|||October 2004|September 21, 2009|October 14, 2004||||||https://clinicaltrials.gov/show/NCT00094146||199841|
NCT00094159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0002|Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors|Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies||Sunesis Pharmaceuticals||Completed|October 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2007|May 9, 2007|October 14, 2004||||||https://clinicaltrials.gov/show/NCT00094159||199840|
NCT00094484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000178|Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis|A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis||Amgen||Completed|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||400|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|October 19, 2004||||||https://clinicaltrials.gov/show/NCT00094484||199817|
NCT00094731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0008|SeniorWISE: Improving Everyday Memory in At-Risk Elderly|Improving Everyday Memory in At-Risk Elderly||National Institute on Aging (NIA)||Completed|March 2001|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized||||260|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2006|December 9, 2009|October 21, 2004||||No||https://clinicaltrials.gov/show/NCT00094731||199799|
NCT00095004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-066|Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild||Merck Sharp & Dohme Corp.||Completed|October 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|167|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|October 29, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095004||199778|
NCT00096967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF2540g|A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study|An Open-Label, Multicenter Extension Study of rhuMAb VEGF (Bevacizumab) in Subjects Treated in a Previous Genentech-Sponsored Cancer Study||Genentech, Inc.||Completed|October 2002|July 2004|Actual|||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||March 2014|March 25, 2014|November 17, 2004||||||https://clinicaltrials.gov/show/NCT00096967||199633|
NCT00096980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD2243g|A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies|An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment||Genentech, Inc.||Completed|February 2001|May 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|70 Years|No|||June 2013|June 19, 2013|November 17, 2004||||||https://clinicaltrials.gov/show/NCT00096980||199632|
NCT00097396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rF1V-01|Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V|A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant Plague Vaccine rF1V in Healthy Volunteers||DynPort Vaccine Company LLC, A CSC Company|Yes|Completed|November 2004|September 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 29, 2011|November 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097396||199602|
NCT00093093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA003142-302|Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive|Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C|VISER2|Valeant Pharmaceuticals International, Inc.||Completed|June 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|September 30, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093093||199914|
NCT00093457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I167|Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer|A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer||Canadian Cancer Trials Group|No|Completed|July 2004|January 2011|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|N/A|No|||September 2011|September 27, 2011|October 6, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093457||199890|
NCT00093743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1444.00|Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia|Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|January 2000|||September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||March 2016|March 1, 2016|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093743||199872|
NCT00094419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32AT002012-01|Complementary and Alternative Medicine Use in Low-Income African American and Caucasian Adults With Asthma|The Role of Complementary and Alternative Medicine (CAM), Folk Care and Faith-Based Approaches in the Home Management of Persistent Asthma in Low-Income African American and Caucasian Adults||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|November 2004|June 2006|Actual|June 2006|Actual|N/A|Observational|N/A|||Anticipated|50|||Both|21 Years|50 Years|No|||August 2008|August 11, 2008|October 18, 2004||No||No||https://clinicaltrials.gov/show/NCT00094419||199821|
NCT00094432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-146|A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST.||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|June 2004|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||650|||Both|18 Years|65 Years|No|||June 2008|November 7, 2013|October 18, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094432||199820|
NCT00127244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-13850|Study Comparing Two Different Methods of Treating Periodontal Disease|Outcomes of Traditional and Medical Models of Periodontal Therapy||The Forsyth Institute||Completed|June 2000|October 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 30, 2010|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127244||197393|
NCT00094965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP5347|Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function|Phase II Trial of Oxaliplatin in Combination With Bolus/Infusional 5FU/LV (FOLFOX4) in Patients With Advanced Gastrointestinal (GI) Cancers With Varying Degrees of Renal Impairment|FOLFOX4|Sanofi||Completed|September 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2009|March 27, 2009|October 28, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00094965||199781|
NCT00094978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050010|Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum|Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum||National Institutes of Health Clinical Center (CC)||Terminated|October 2004|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||May 2013|January 27, 2015|October 28, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00094978||199780|
NCT00094991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-026|Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes|Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients||Bristol-Myers Squibb||Completed|May 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|70 Years|No|||September 2007|September 10, 2010|October 29, 2004||||||https://clinicaltrials.gov/show/NCT00094991||199779|
NCT00095316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-042|Caspofungin Study for Fungal Infections in Adults in Critical Care Settings|A Randomized, Double-Masked Trial of Caspofungin Versus Placebo as Prophylaxis of Invasive Candidiasis in High-Risk Adults in the Critical Care Setting||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|October 2004|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|1200|||Both|18 Years|N/A|No|||June 2006|December 4, 2014|November 2, 2004||||No||https://clinicaltrials.gov/show/NCT00095316||199754|
NCT00095654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DREAM30Nov2002|The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial|The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial||Gerstein, Hertzel, MD||Completed|July 2001|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||5000|||Both|30 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 9, 2009|November 5, 2004||||||https://clinicaltrials.gov/show/NCT00095654||199730|
NCT00095966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02629|Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Completed|September 2004|||September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095966||199707|
NCT00095979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02628|Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|May 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|N/A|N/A|No|||January 2013|May 5, 2015|November 9, 2004|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT00095979||199706|
NCT00128700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26041-22041|Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Study on Concomitant and Adjuvant Temozolomide and Radiotherapy With or Without PTK787/ZK222584 in Newly Diagnosed GBM||European Organisation for Research and Treatment of Cancer - EORTC||Completed|June 2005|||November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|69 Years|No|||September 2012|September 20, 2012|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128700||197287|
NCT00128713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238|Optimal Platelet Dose Strategy for Management of Thrombocytopenia|Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)|PLADO|New England Research Institutes|Yes|Completed|July 2004|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1351|||Both|N/A|100 Years|No|||August 2013|October 5, 2015|August 8, 2005||No||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00128713||197286|
NCT00128960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050216|Quality of Life in Patients Who Have Undergone Stem Cell Transplant|Prospective Assessment of Functional Status, Psychosocial Adjustment, Health Related Quality of Life and the Symptom Experience in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Completed|August 2005|||||N/A|Observational|N/A|||Actual|173|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00128960||197267|
NCT00128973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050213|Evaluation of Patients With Immune Function Abnormalities|Screening and Baseline Assessment of Patients With Abnormalities of Immune Function||National Institutes of Health Clinical Center (CC)||Recruiting|August 2005|||||N/A|Observational|N/A|||Anticipated|1400|||Both|N/A|90 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00128973||197266|
NCT00104195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11610|A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions|Decision-Making Processes and Brain Function in Anxiety-Disordered and Non-Anxious Youth||New York University School of Medicine|No|Completed|February 2004|April 2014|Actual|April 2014|Actual|Phase 1|Observational|Observational Model: Case Control||1|Actual|127|||Both|13 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Anxious and healthy adolescents|April 2014|April 15, 2014|February 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00104195||199106|
NCT00094172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN020AI|Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)|STAYCIS|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|82|||Both|18 Years|55 Years|No|||June 2014|June 4, 2014|October 14, 2004|Yes|Yes||No|September 29, 2011|https://clinicaltrials.gov/show/NCT00094172||199839|
NCT00094185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1277|Clotting Genetic Variants, Hormones, and Venous Thrombosis|||University of Washington||Completed|May 2004|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Female|18 Years|89 Years|No|Non-Probability Sample|General|December 2012|December 18, 2012|October 15, 2004||No||No||https://clinicaltrials.gov/show/NCT00094185||199838|
NCT00094497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-ACT-001|Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)|First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment||Collaborative Group for Adrenocortical Carcinoma Treatment|Yes|Completed|June 2004|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|October 19, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094497||199816|
NCT00094744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-88|Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia|A Randomized Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia||Jaeb Center for Health Research|Yes|Completed|May 2001|September 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|3 Years|7 Years|No|||September 2010|September 8, 2010|October 22, 2004||No||No||https://clinicaltrials.gov/show/NCT00094744||199798|
NCT00097032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004654|Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients|Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Actual|30|||Both|18 Years|45 Years|No|||March 2010|May 20, 2011|November 17, 2004||||||https://clinicaltrials.gov/show/NCT00097032||199628|
NCT00097045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomed 510-CLP-07|Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C|Phase 2 Study of Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C||Intarcia Therapeutics||Completed|November 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|64 Years|No|||August 2007|August 21, 2007|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00097045||199627|
NCT00093119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA014-0|Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma|A Phase II Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma||Celgene Corporation||Completed|January 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||33|||Both|18 Years|N/A|No|||January 2006|June 11, 2009|October 1, 2004||||||https://clinicaltrials.gov/show/NCT00093119||199913|
NCT00093756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00643|Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer|Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|September 2004|May 2013|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||November 2013|December 3, 2014|October 6, 2004|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00093756||199871|
NCT00094055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061014|Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer|Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment||Pfizer|No|Completed|September 2004|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|October 8, 2004|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00094055||199848|Population pharmacokinetics and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.
NCT00094068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050003|The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients|A Pilot Study to Detect the Effect of Sildenafil Citrate on Cerebral Blood Perfusion in Multiple Sclerosis Patients by Perfusion MRI||National Institutes of Health Clinical Center (CC)||Completed|October 2004|May 2006||||N/A|Observational|N/A||||76|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2006|March 3, 2008|October 9, 2004||||No||https://clinicaltrials.gov/show/NCT00094068||199847|
NCT00094445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0009|Trial of Curcumin in Advanced Pancreatic Cancer|Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Completed|November 2004|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|October 18, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094445||199819|
NCT00126919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-002|Reduction of Topical Anesthetic Time for Subcutaneous Port Access Using Ultrasound|Randomized Crossover Trial of Sonication Followed by 5 Minute LMX4 Application Compared With 30 Minute LMX4 Application for Topical Anesthesia Prior to Subcutaneous Port Access in Children||Connecticut Children's Medical Center||Completed|October 2004|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|3 Years|17 Years|No|||February 2012|February 8, 2012|August 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00126919||197418|
NCT00127543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 06-089E|Kid Cards: Teaching Kids About Medicines|Kid Cards: Teaching Kids About Medicines||Children's Mercy Hospital Kansas City||Active, not recruiting|August 2005|December 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||50|||Both|7 Years|11 Years|No|||December 2005|February 6, 2006|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00127543||197371|
NCT00127530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-F203|Study of Oral Fampridine-SR in Multiple Sclerosis|Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis||Acorda Therapeutics|Yes|Completed|May 2005|September 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|70 Years|No|||January 2016|January 4, 2016|August 4, 2005|Yes|Yes||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00127530||197372|
NCT00127803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-030-008|Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers|A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study of the Safety, Tolerability and Immunogenicity of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18-55 Years)||Sanofi|No|Completed|July 2005|March 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 7, 2012|August 5, 2005|Yes|Yes||No|March 13, 2012|https://clinicaltrials.gov/show/NCT00127803||197351|
NCT00128050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-SICH-2005|Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)|Efficacy and Safety of Factor VIIa (Eptacog Alfa) on Rebleeding After Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage. A Randomized, Controlled, Open-Label, Investigator-Blinded Pilot Study|PRE-SICH|IRCCS Policlinico S. Matteo|Yes|Completed|January 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||February 2009|February 3, 2009|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128050||197333|
NCT00128375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802295|Financial Incentives for Smoking Cessation|Financial Incentives for Smoking Cessation||University of Pennsylvania||Completed|March 2005|April 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||878|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128375||197309|
NCT00129506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|c04-0636|Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion|Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion||Wiebe, Ellen, M.D.||Completed|May 2005|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Female|16 Years|60 Years|No|||April 2007|April 18, 2007|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129506||197226|
NCT00096044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000391767|Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|CC-5013 Alone or in Combination With Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)||Roswell Park Cancer Institute|Yes|Active, not recruiting|March 2004|||June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|120 Years|No|||November 2015|November 18, 2015|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00096044||199701|
NCT00096057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCHE-NP17787|Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer|An Open Label Phase I Study of Humanized Human Milk Fat Globule-1 (huHMFG1) Antibody in Patients With Locally Advanced or Metastatic Breast Cancer (TOPCAT)||National Cancer Institute (NCI)||Completed|May 2004|December 2007|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Female|18 Years|N/A|No|||April 2007|June 25, 2013|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096057||199700|
NCT00094757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-023|An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)|A Multicenter, Randomized, Double-Blind Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Completed|October 2004|April 2006|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|521|||Both|18 Years|75 Years|No|||April 2015|April 27, 2015|October 22, 2004|Yes|Yes||No|June 22, 2010|https://clinicaltrials.gov/show/NCT00094757||199797|
NCT00094770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-024|An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)|A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.||Completed|September 2004|May 2007|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1172|||Both|18 Years|78 Years|No|||April 2015|April 27, 2015|October 22, 2004|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00094770||199796|
NCT00095082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1430|Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes||Novo Nordisk A/S|No|Completed|September 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|447|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|October 29, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095082||199772|
NCT00092586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-040|Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)|A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level||Merck Sharp & Dohme Corp.||Completed|September 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|2904|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092586||199952|
NCT00092599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-801|Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.||Merck Sharp & Dohme Corp.||Completed|February 2003|July 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|410|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092599||199951|
NCT00092625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-803|Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.||Merck Sharp & Dohme Corp.||Completed|March 2003|August 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|442|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092625||199949|
NCT00093470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00535|Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission|A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2004|||February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||July 2015|October 13, 2015|October 6, 2004|Yes|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT00093470||199889|
NCT00093184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-04-01|Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI|A Study Evaluating the Safety and Efficacy of Bivalirudin in the Management of Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary PCI (BIAMI)||The Medicines Company||Completed|April 2004|December 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||February 2006|February 8, 2006|October 4, 2004||||||https://clinicaltrials.gov/show/NCT00093184||199908|
NCT00093769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000390235|Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study of VELCADE With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma||Jonsson Comprehensive Cancer Center||Completed|August 2004|||August 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|October 6, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093769||199870|
NCT00093782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03053|Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma|A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas||National Cancer Institute (NCI)||Completed|December 2003|||April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093782||199869|
NCT00094081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4690|Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer|Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer||Sanofi||Completed|October 2002|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|861|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|October 11, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00094081||199846|
NCT00126932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003|Reduction of Topical Anesthetic Onset Time Using Ultrasound|Reduction of Topical Anesthetic Onset Time Using Ultrasound: A Randomized Controlled Trial Prior to Venipuncture in Young Children||Connecticut Children's Medical Center||Completed|October 2004|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|3 Years|7 Years|No|||December 2007|December 20, 2007|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00126932||197417|
NCT00127257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DK57048b (completed)|Biofeedback for Dyssynergic Constipation|Biofeedback for Fecal Incontinence and Constipation||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 1999|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||117|||Both|16 Years|N/A|No|||January 2010|January 12, 2010|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127257||197392|
NCT00128739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-23/02/01|Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation|A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD||Rafa Laboratories||Completed|January 2001|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|70 Years|No|||August 2005|August 26, 2005|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128739||197284|
NCT00127816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-14-0044 / 21694|Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy|Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy||AHS Cancer Control Alberta|Yes|Completed|April 2005|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|N/A|N/A|No|||March 2016|March 14, 2016|August 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00127816||197350|
NCT00128063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-IAT-0047|Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection|A Phase 1 & 2, Randomized Open-Label Study to Evaluate the Pharmacokinetics, Safety and Antiretroviral Activity of Succinylated Human Serum Albumin (Suc-HSA) in Treatment Naïve HIV-1 Infected Subjects||International Antiviral Therapy Evaluation Center|Yes|Completed|August 2005|June 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|N/A|No|||April 2007|April 23, 2007|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128063||197332|
NCT00128076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-82335|All-Arthroscopic Versus Mini-Open Repair of Small or Moderate Rotator Cuff Tears|All-Arthroscopic Versus Mini-Open Repair of Small or Moderate Rotator Cuff Tears||McMaster University|Yes|Active, not recruiting|August 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|75 Years|No|||September 2015|September 22, 2015|August 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00128076||197331|
NCT00128388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH001849|Psychodynamic Therapy for Treating Panic Disorder|Randomized Controlled Trial of Psychodynamic Psychotherapy vs. Applied Relaxation for Panic Disorder||Weill Medical College of Cornell University|No|Completed|February 2000|July 2005|Actual|January 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|55 Years|No|||June 2013|June 26, 2013|August 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00128388||197308|
NCT00128726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY01-190|The Effects of Continuous Administration of a Monophasic Oral Contraceptive on Bleeding Days and Endometrial and Ovarian Function|The Effects of Continuous Administration of a Monophasic Oral Contraceptive on Bleeding Days and Endometrial and Ovarian Function||Milton S. Hershey Medical Center|No|Completed|June 2001|August 2006|Actual|||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|Samples With DNA|whole blood, urines, tissue|Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy women between 18-35 years of age who wish to use a continuous combined oral        contraceptive and are non-smokers. Must have regular menstrual cycles for a 3 month        period.|December 2012|December 20, 2012|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128726||197285|
NCT00128986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-09-0029 / ethics 21879|Study of Tomotherapy in Patients With Benign Brain Tumour|A Phase I Study of Tomotherapy in Patients With Benign Brain Tumour||AHS Cancer Control Alberta|Yes|Active, not recruiting|May 2005|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|65 Years|No|||March 2014|March 4, 2014|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00128986||197265|
NCT00129259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN027AI|Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes|Phase II Multiple-Dose Treatment of New Onset Type 1 Diabetes Mellitus With Anti-CD3 mAb|AbATE|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2005|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|8 Years|30 Years|No|||June 2014|June 4, 2014|August 9, 2005|Yes|Yes||No|June 21, 2013|https://clinicaltrials.gov/show/NCT00129259||197245|
NCT00125684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10181|Bioavailability and Effectiveness of Transdermally Administered Morphine|Bioavailability and Effectiveness of Transdermally Administered Morphine||AHS Cancer Control Alberta||Completed|July 2003|July 2008|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|6|||Both|18 Years|65 Years|No|||August 2011|January 18, 2012|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125684||197511|
NCT00125944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP125|Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults||MedImmune LLC||Completed|July 2005|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2007|May 8, 2007|August 1, 2005||||||https://clinicaltrials.gov/show/NCT00125944||197491|
NCT00125671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-37413|Warfarin and Antiplatelet Vascular Evaluation|A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease||Warfarin and Antiplatelet Vascular Evaluation||Active, not recruiting|January 2000|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||2400|||Both|35 Years|85 Years|No|||September 2009|September 27, 2009|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125671||197512|
NCT00093509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008831|MRI Sarcoma Non Invasive Thermometry|Magnetic Resonance Based Non-Invasive Thermometry for Hyperthermic Treatment of Extremity Soft Tissue Sarcomas: A Multimodal Phase I/II Study||Duke University|No|Completed|November 1999|October 2009|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093509||199886|
NCT00093847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH069629|Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression|S-adenosyl Methionine (SAMe) Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) for Treatment-Resistant Depression (TRD)||Massachusetts General Hospital|Yes|Completed|May 2004|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|80 Years|No|||October 2014|October 10, 2014|October 6, 2004|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00093847||199864|
NCT00095095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL04-90|Lumbar Interbody Fusion Using the Telamon® Peek™ Versus the Telamon® Hydrosorb™ Fusion Device|Lumbar Interbody Fusion Using The Telamon® Peek™ Versus The Telamon® Hydrosorb™ Fusion Device - A Prospective, Randomized Controlled Trial To Assess Surgical And Clinical Outcomes||Medtronic||Terminated|October 2004|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||102|||Both|18 Years|70 Years|No|||March 2005|October 22, 2012|October 29, 2004||||No||https://clinicaltrials.gov/show/NCT00095095||199771|
NCT00095108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|494C10|Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer|A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Recombinant Human Interleukin-21 (rIL-21) in Subjects With Metastatic Melanoma or Metastatic Renal Cell Carcinoma||ZymoGenetics||Completed|May 2004|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|18 Years|N/A|No|||March 2009|March 6, 2009|October 29, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095108||199770|
NCT00095719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-131|Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia|A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|December 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||125|||Both|55 Years|95 Years|No|||August 2008|November 7, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095719||199725|
NCT00096629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-125|Vaccine Therapy in Treating Patients With Kidney Cancer|Injection of Renal Cell Carcinoma Patients With Human and Mouse Prostate Specific Membrane Antigen (PSMA) DNA: A Phase I Trial to Assess Safety and Immune Response||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2003|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 12, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096629||199658|
NCT00097292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHStudy (IND)|Pathway to Prevention Study|Natural History Study of the Development of Type 1 Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|February 2004|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75000|||Both|1 Year|45 Years|Accepts Healthy Volunteers|Probability Sample|First and second/third degree relatives of individuals with type 1 diabetes.|February 2016|February 18, 2016|November 19, 2004||No||No||https://clinicaltrials.gov/show/NCT00097292||199610|
NCT00092638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-804|An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.||Merck Sharp & Dohme Corp.||Completed|May 2003|August 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|450|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092638||199948|
NCT00093132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT1-04-02|Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy|A Phase 1/2 Study With Satraplatin and Simultaneous Radiation in Locally Advanced Non-Small Cell Lung Cancer||Agennix||Terminated|August 2004|February 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|October 1, 2004|Yes|Yes|Sponsor decided to discontinue study drug development.|No||https://clinicaltrials.gov/show/NCT00093132||199912|
NCT00093483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000387999|Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia|Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study||Roswell Park Cancer Institute|Yes|Completed|April 2002|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|59 Years|No|||January 2014|January 10, 2014|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093483||199888|
NCT00093808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0337|Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer|Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|August 2004|May 2013|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 4, 2015|October 6, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093808||199867|
NCT00094094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061011|Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer|Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later- Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer||Pfizer||Completed|February 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|October 11, 2004||||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00094094||199845|Population pharmacokinetics and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib Phase 2 studies would be pooled together in a separate report.
NCT00128401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050198|Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia|Effect of D-Cycloserine on Treatment of Social Phobia||National Institutes of Health Clinical Center (CC)||Completed|August 2005|August 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|8 Years|55 Years|No|||April 2014|April 17, 2014|August 8, 2005|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00128401||197307|The baseline mean and SD for CGI outcome measure was captured for 42 subjects only. The baseline mean and SD for LSAS outcome measure was captured for 40 subjects.
NCT00128752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARO-2002-12-12-NZO|The CARO Study - Bioefficacy of Beta-Carotene in Oil and in a Mixed Diet in Healthy Subjects|Bioefficacy and Bioavailability of Beta-Carotene in Oil and in a Mixed Diet in Healthy Subjects Measured Using Specifically 13C-Labelled Beta-Carotene and Retinol||Radboud University||Completed|March 2003|October 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2005|August 26, 2005|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128752||197283|
NCT00128999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-11-0035|Study Using Induction Chemotherapy and Intensity-Modulated Radiation Therapy Guided by Combined CT and PET Imaging for Patients With Non-Small Cell Lung Cancer|A Phase I/II Dose Escalation Study Using Induction Chemotherapy and Intensity-Modulated Radiation Therapy Guided by Combined CT and PET Imaging for Patients With Non-Small Cell Lung Cancer||AHS Cancer Control Alberta|Yes|Completed|September 2003|August 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|N/A|No|||October 2007|February 8, 2010|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128999||197264|
NCT00129272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15131-1|Effectiveness of Bupropion for Treating Nicotine Dependence in Young People|Stress Response and Smoking Cessation in Depressed Youth||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|May 2004|December 2010|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|12 Years|25 Years|No|||September 2009|September 2, 2009|August 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00129272||197244|
NCT00129519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491-IMIQ|A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence|Open-label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage||Graceway Pharmaceuticals, LLC|No|Completed|January 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||July 2010|July 14, 2010|August 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00129519||197225|
NCT00129532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9779|Trial of SAVVY and HIV in Ghana|Randomized Controlled Trial of SAVVY and HIV in Ghana||Biosyn||Active, not recruiting|January 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2142|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2005|September 7, 2005|August 11, 2005||||||https://clinicaltrials.gov/show/NCT00129532||197224|
NCT00125424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0520|Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy|A Randomized, Double-Blind, Dose-Response Study to Assess the Efficacy and Safety of AQUAVAN® Injection for Procedural Sedation in Patients Undergoing Colonoscopy||Eisai Inc.||Completed|July 2005|September 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Both|18 Years|N/A|No|||November 2008|November 6, 2008|July 27, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00125424||197531|
NCT00126243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 085 Rituximab|Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma|Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab + CHOP Regimen in Patients With HIV Related Non-Hodgkin’s Lymphomas. ANRS 085 Rituximab||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|January 1999|October 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|75 Years|No|||August 2005|August 16, 2005|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126243||197468|
NCT00125957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000502|The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression|The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression||Mclean Hospital|No|Completed|August 2005|December 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|70 Years|No|||August 2014|August 5, 2014|August 1, 2005|Yes|Yes||No|June 11, 2014|https://clinicaltrials.gov/show/NCT00125957||197490|
NCT00093860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050001|Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance|Propranolol for Syncope With Sympathoadrenal Imbalance in Children||National Institutes of Health Clinical Center (CC)||Completed|October 2004|March 2005||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||March 2005|March 3, 2008|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093860||199863|
NCT00093873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030116|Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors|A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects With Advanced Solid Tumors||Amgen||Completed|July 2003|December 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093873||199862|
NCT00095732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14269|Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency|A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency||Anthera Pharmaceuticals|Yes|Completed|June 2004|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|129|||Both|7 Years|N/A|No|||October 2014|October 15, 2014|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095732||199724|
NCT00093613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03102|Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma|A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma||National Cancer Institute (NCI)||Completed|December 2004|December 2011|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||December 2013|May 29, 2014|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093613||199880|
NCT00093145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA016|Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer|A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer||Celgene|No|Completed|June 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|October 4, 2004|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00093145||199911|
NCT00092716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-025|Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)|A Multicenter, Double-Blind, Randomized, Parallel Group, 28-Week Study to Evaluate the Efficacy and Safety of Ezetimibe and Simvastatin Co-administration Versus Atorvastatin in Patients With Hypercholesteremia||Merck Sharp & Dohme Corp.||Completed|May 2002|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|655|||Both|18 Years|79 Years|No|||October 2015|October 30, 2015|September 23, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092716||199942|
NCT00093158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-02-08|Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)|The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation||The Medicines Company||Completed|August 2003|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||13800|||Both|18 Years|N/A|No|||August 2007|August 20, 2007|October 4, 2004||||||https://clinicaltrials.gov/show/NCT00093158||199910|
NCT00093496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00052|Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer|A Phase II Trial Of Gemcitabine in Combination With 17-Allylaminogeldamycin (17-AAG) In Advanced Epithelial Ovarian And Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|October 2007|March 2012|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||October 2011|May 2, 2014|October 6, 2004|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00093496||199887|
NCT00093795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-38|Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer|A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC→P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC→PG)||NSABP Foundation Inc|Yes|Active, not recruiting|October 2004|March 2016|Anticipated|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4894|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|October 6, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093795||199868|
NCT00094107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061015|Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma|Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma||Pfizer|Yes|Completed|December 2004|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|October 11, 2004|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00094107||199844|Population pharmacokinetic and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.
NCT00094120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-1256F-208|MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)|Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)||Genaera Corporation||Terminated|October 2004|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|50 Years|N/A|No|||November 2007|January 8, 2008|October 11, 2004||||||https://clinicaltrials.gov/show/NCT00094120||199843|
NCT00126607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03172|Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer|Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma||National Cancer Institute (NCI)||Terminated|July 2005|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|August 2, 2005|No|Yes|Poor accrual.|No||https://clinicaltrials.gov/show/NCT00126607||197441|
NCT00126906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3429|Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi|Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly – Malawi||Centers for Disease Control and Prevention||Completed|October 2002|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||700|||Female|15 Years|N/A|No|||August 2005|August 22, 2005|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00126906||197419|
NCT00128414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCASL30501-2|Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP Trial: COlchicine for Recurrent Pericarditis|CORP|Azienda Sanitaria Locale 3, Torino|Yes|Completed|August 2005|October 2010|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128414||197306|
NCT00129025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-06-0047 / 21606|Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer|A Phase I/II Study of Escalated-Dose Short-Course Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer||AHS Cancer Control Alberta|Yes|Completed|October 2004|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|N/A|N/A|No|||October 2011|October 6, 2011|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129025||197262|
NCT00093002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238IL/0065|Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer|A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).||AstraZeneca||Completed|June 2004|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Female|N/A|N/A|No|||June 2008|June 11, 2008|September 28, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093002||199921|
NCT00129012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-11-0051 / 21808|Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer|Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer: A Feasibility Study||AHS Cancer Control Alberta|No|Completed|April 2005|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2012|February 24, 2016|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00129012||197263|
NCT00129285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15366-1|Modafinil Treatment for Cocaine-Dependent Individuals|A Double-Blind, Placebo-Controlled Study of Modafinil for Cocaine Dependence||University of Pennsylvania|No|Completed|July 2004|April 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|60 Years|No|||June 2012|October 7, 2015|August 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00129285||197243|
NCT00129545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST1021 and ST1055|WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation|WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)||Boston Scientific Corporation|Yes|Completed|February 2005|May 2014|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|800|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|August 10, 2005|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00129545||197223|
NCT00125437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05276101D-84|Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy|Safety and Efficacy of Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy||Hebei Medical University||Terminated|September 2005|September 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|80 Years|No|||December 2008|July 13, 2009|July 29, 2005|||Poor compliance with the therapy and lot of patients were lost to follow up.|No||https://clinicaltrials.gov/show/NCT00125437||197530|
NCT00126256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFCD 2000 - 05|Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer|Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05||Gustave Roussy, Cancer Campus, Grand Paris||Completed|February 2002|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|570|||Both|N/A|75 Years|No|||August 2015|August 11, 2015|August 2, 2005||||No||https://clinicaltrials.gov/show/NCT00126256||197467|
NCT00126438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBG312|Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease|An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event||GE Healthcare|Yes|Completed|July 2005|September 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|515|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 2, 2009|August 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00126438||197453|
NCT00095407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050018|The Functional Anatomy of Personality Trait Knowledge: An fMRI Study|The Functional Anatomy of Personality Trait Knowledge: an fMRI Study||National Institutes of Health Clinical Center (CC)||Completed|October 2004|December 2011||||N/A|Observational|N/A|||Actual|190|||Both|21 Years|65 Years|No|||December 2011|December 30, 2011|November 3, 2004||No||No||https://clinicaltrials.gov/show/NCT00095407||199747|
NCT00096343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000377728|Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer|A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer||University of Alabama at Birmingham|Yes|Completed|October 2002|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||November 2012|December 2, 2013|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096343||199679|
NCT00096850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5213|Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults|Safety, Tolerability, and Pharmacokinetic Interactions of Atazanavir and Rifampin in Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||December 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|November 16, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096850||199641|
NCT00096863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 040542|The MIND Study: Modifying the INcidence of Delirium|Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone||Vanderbilt University|Yes|Completed|December 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 16, 2004||No||No||https://clinicaltrials.gov/show/NCT00096863||199640|
NCT00106535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA17823|A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)|A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Completed|January 2005|July 2012|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1196|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|March 25, 2005|Yes|Yes||No|February 9, 2010|https://clinicaltrials.gov/show/NCT00106535||198934|
NCT00106795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050127|Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS|Assessing the Relationship Between Fatigue and Mitochondrial Toxicity in Patients With HIV/AIDS||National Institutes of Health Clinical Center (CC)||Completed|March 2005|April 2014||||N/A|Observational|N/A|||Actual|82|||Both|18 Years|55 Years|No|||April 2014|April 11, 2014|March 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00106795||198915|
NCT00093171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A1-302|Study Evaluating rFIX; BeneFIX® in Hemophilia B|An Open-label Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Previously Treated Patients (PTPs) With Hemophilia B (FIX:C ≤2%)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|12 Years|N/A|No|||August 2009|August 20, 2009|October 4, 2004||||||https://clinicaltrials.gov/show/NCT00093171||199909|
NCT00093197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-9803-001|Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack|Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction||KAI Pharmaceuticals|Yes|Completed|September 2004|October 2006|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|154|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|October 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093197||199907|
NCT00093821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01456|Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors|A Multicenter Phase I Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) in Patients With Recurrent/Refractory Pediatric Solid Tumors (Ewing's Sarcoma, Desmoplastic Small Round Cell Tumor, Osteosarcoma, Neuroblastoma, and Rhabdomyosarcoma) and Leukemia||National Cancer Institute (NCI)||Completed|September 2004|||August 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|N/A|21 Years|No|||June 2013|June 3, 2013|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093821||199866|
NCT00093834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0085 CDR0000391826|Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer|A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence With Immunomodulatory Doses of Cyclophosphamide and Doxorubicin||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2004|||August 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||April 2011|July 19, 2011|October 6, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093834||199865|
NCT00126620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-PHL-042|Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors||University Health Network, Toronto||Completed|September 2005|||May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126620||197440|
NCT00126945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104702|Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs|A Primary Vaccination Study to Assess the Immunogenicity, Safety & Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of MENCEVAX™ ACWY in Healthy Subjects Aged 15-19 Years||GlaxoSmithKline||Completed|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|125|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00126945||197416|
NCT00128765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MONC95582|Costs and Effects of Three Modes for Disease Management of Chronic Obstructive Pulmonary Disease in General Practice|Costs and Effects of Three Modes for Disease Management of Chronic Obstructive Pulmonary Disease (COPD) in General Practice. A Randomized Controlled Trial Comparing Regular Practice Nurse Review, Self-management Education and Usual Care||Radboud University|Yes|Completed|January 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|165|||Both|35 Years|N/A|No|||November 2011|November 21, 2011|August 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00128765||197282|
NCT00093015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010184|Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)|Trial to Reduce Cardiovascular Events With Aranesp® Therapy||Amgen||Completed|August 2004|August 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4038|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|September 28, 2004||||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00093015||199920|4047 subjects were enrolled, but before unblinding, all information from 9 subjects was excluded from two sites (3 and 6 subjects, respectively) that did not adhere to Good Clinical Practice guidelines. 4038 subjects were analyzed and reported.
NCT00092495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-016|Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)|A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine||Merck Sharp & Dohme Corp.||Completed|December 2002|February 2009|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|3055|||Both|10 Years|23 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|September 22, 2004|Yes|Yes||No|February 15, 2010|https://clinicaltrials.gov/show/NCT00092495||199959|Of note, the number of subjects who completed the Vaccination Period (N=1441) is slightly higher than that specified in the publication by Block, et al (2006; N=1430). The data provided here is based on final data.
NCT00129558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS103|A Study to Evaluate PT-523 in Patients With Refractory Leukemia|A Phase I/II Study of PT-523 in Patients With Refractory Leukemia||Spectrum Pharmaceuticals, Inc||Withdrawn|July 2005|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|August 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00129558||197222|
NCT00125450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030421|Evaluation of Chest Physiotherapy for Acute Bronchiolitis in Toddlers (BRONKINOU)|Efficacy and Safety of Chest Physiotherapy With Forced Expiratory Technique for Acute Bronchiolitis in Toddlers|BRONKINOU|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|N/A|24 Months|No|||October 2006|May 26, 2008|July 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00125450||197529|
NCT00125697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-09-0022 / ethics 21388|Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy|Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy||AHS Cancer Control Alberta|Yes|Active, not recruiting|May 2005|June 2015|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients with histologically-proven glioma of the brain, including both malignant gliomas        and high risk, low-grade gliomas as defined by Pignatti et al 2002|June 2014|June 10, 2014|July 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00125697||197510|
NCT00125970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 204|Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults|A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed By a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRC-HIVADV014-00-VP, in HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2005|January 2010|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|480|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125970||197489|
NCT00125983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5188|Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women|A Phase II Pharmacokinetic Study of the Transdermal Contraceptive System and Oral Contraceptive in HIV-1 Infected Women on Lopinavir/Ritonavir||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|32|||Female|13 Years|N/A|No|||May 2012|May 17, 2012|July 29, 2005||||||https://clinicaltrials.gov/show/NCT00125983||197488|
NCT00094549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7029|Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder|Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder||Eli Lilly and Company||Completed|October 2004|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|65 Years|No|||January 2007|January 24, 2007|October 20, 2004||||||https://clinicaltrials.gov/show/NCT00094549||199812|
NCT00094562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AT000437|A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss|AAFA™ Fish Oil Nutritional Supplementation to Maintain Body Weight in Patients With Disease-Related Weight Loss||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|June 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|90 Years|No|||April 2008|April 21, 2008|October 20, 2004||Yes||||https://clinicaltrials.gov/show/NCT00094562||199811|
NCT00126451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_014|A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)|A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer.||Merck Sharp & Dohme Corp.||Terminated|December 2004|||October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126451||197452|
NCT00106197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068391|Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression|Treatment Prediction in Adolescent and Adult Depression||Meharry Medical College|Yes|Active, not recruiting|June 2004|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|12 Years|50 Years|No|||August 2013|August 29, 2013|March 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00106197||198959|
NCT00106522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA18062|A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy|A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy||Hoffmann-La Roche||Completed|May 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|499|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00106522||198935|
NCT00105937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099-15|OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients|Multi-center, Open Label, Long-term Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients||Teva Pharmaceutical Industries||Completed|April 2004|November 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|80 Years|No|||May 2007|June 27, 2012|March 18, 2005||||||https://clinicaltrials.gov/show/NCT00105937||198979|
NCT00106782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050122|Transcranial Electrical Polarization to Treat Focal Hand Dystonia|Placebo Controlled Study of the Therapeutic Effect of the Transcranial Electrical Polarization in Patients With Focal Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|March 2005|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||May 2010|September 26, 2015|March 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00106782||198916|
NCT00103116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000410830|Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer|Autologous Dendritic Cell Vaccines in Non-small Cell Lung Cancer (NSCLC)||University of Kentucky||Active, not recruiting|October 2004|||April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||February 2013|February 21, 2013|February 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00103116||199184|
NCT00093210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A1-304|Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B|A Double-Blind, Randomized, Crossover Evaluation of the Pharmacokinetics of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R); and an Open-Label Safety and Efficacy Evaluation of rFIX-R in Previously Treated Patients With Moderate to Severe (FIX:C≤2%) Hemophilia B||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||December 2007|December 3, 2007|October 4, 2004||||||https://clinicaltrials.gov/show/NCT00093210||199906|
NCT00093223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVR001|A Safety Study of ABI-007 for In-Stent Restenosis|A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis||Celgene|Yes|Completed|September 2001|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||October 2011|March 27, 2013|October 4, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093223||199905|
NCT00093236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-15345|Impact of Gum Infection on Heart Disease|Systemic Endothelial Consequences of Periodontal Disease||Boston University|Yes|Active, not recruiting|September 2004|April 2011|Anticipated|November 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|160|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 29, 2011|October 5, 2004||No||No||https://clinicaltrials.gov/show/NCT00093236||199904|
NCT00126373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGO10410022|A Trial of Wellbutrin for Crohn's Disease|A Randomized Controlled Trial of Wellbutrin for Crohn's Disease||Altschuler, Eric, M.D.||Completed|May 2005|March 2006|Actual|March 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00126373||197458|
NCT00127270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328AUS01|Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder|Using Behavioral Therapy in Combination With Drug-Darifenacin for Symptoms of Overactive Bladder||Novartis||Completed|May 2005|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|395|||Both|18 Years|N/A||||January 2008|January 23, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00127270||197391|
NCT00127283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7ICH-1641|Recombinant Factor VIIa in Acute Intracerebral Haemorrhage|Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage|FAST|Novo Nordisk A/S|No|Completed|May 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|829|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00127283||197390|
NCT00127556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM-PROBE study|Transfusion Medicine - Prevention of Bedside Errors|Cluster-Randomised Controlled Trial of a Simple Intervention to Prevent Bedside Checking Errors in Blood Transfusion||Dartmouth-Hitchcock Medical Center||Completed|April 2005|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label||||300|||Both|N/A|N/A|No|||May 2008|May 6, 2008|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127556||197370|
NCT00127829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913C00022|Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic|A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA®) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic|AGUS|AstraZeneca||Completed|July 2005|January 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|August 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00127829||197349|
NCT00127842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040131|REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)|Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel®||Amgen||Completed|August 2005|September 2009|Actual|August 2005|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|August 5, 2005||Yes||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00127842||197348|
NCT00128089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1|Trial of New Dietary Treatment of Diabetes|Phase 1 Trial of A New Dietary Treatment of Obesity Related Type 2 Diabetes||Manassas Internal Medicine||Terminated|August 2005|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|70 Years|No|||December 2005|December 20, 2005|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00128089||197330|
NCT00128102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-014|Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy||Merck Sharp & Dohme Corp.|Yes|Completed|June 2005|November 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|662|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|August 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00128102||197329|
NCT00129038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.169|Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients|A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation.||Boehringer Ingelheim||Completed|April 2004|||January 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|August 10, 2005||||No||https://clinicaltrials.gov/show/NCT00129038||197261|
NCT00092508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-02-220|CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission|Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25 mg QD and 50 mg QD of OPC-6335 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Ulcerative Colitis Remission||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|May 2004|May 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1725|||Both|18 Years|80 Years|No|||June 2007|June 19, 2007|September 22, 2004||||||https://clinicaltrials.gov/show/NCT00092508||199958|
NCT00129571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL820-001|Study of XL820 in Adults With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors||Exelixis||Completed|August 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2008|June 2, 2008|August 10, 2005||||||https://clinicaltrials.gov/show/NCT00129571||197221|
NCT00129584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-0001|Endobronchial Valve for Emphysema Palliation Trial (VENT)|Endobronchial Valve for Emphysema Palliation Trial (VENT)||Emphasys Medical||Completed|January 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|40 Years|75 Years|No|||August 2009|August 14, 2009|August 10, 2005||||||https://clinicaltrials.gov/show/NCT00129584||197220|
NCT00125463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSH-00001|Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients|Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients||The Japanese Society of Hypertension||Active, not recruiting|September 2001|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||3200|||Both|25 Years|85 Years|No|||April 2005|August 8, 2005|July 29, 2005||||No||https://clinicaltrials.gov/show/NCT00125463||197528|
NCT00125710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-659|Comparative 2-D Tumor Analysis in Familial Gliomas|Comparative 2-D Tumor Analysis in Familial Gliomas||AHS Cancer Control Alberta|Yes|Completed|June 1998|||August 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|June 2014|June 10, 2014|July 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00125710||197509|
NCT00125996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FERRIC-HF|Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure|A Randomised Controlled Study to Assess the Acute and Chronic Effects of Intravenous Iron Supplementation in Anaemic and Non-Anaemic Iron Deficient Patients With Chronic Heart Failure||National Heart and Lung Institute||Recruiting|July 2004|February 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||42|||Both|30 Years|95 Years|No|||January 2005|August 16, 2005|August 1, 2005||||No||https://clinicaltrials.gov/show/NCT00125996||197487|
NCT00126009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C_8428|SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients|A 3-Month, Open, Randomised Trial Comparing the Efficacy and Safety of the Association Valproate-Amisulpride to the Association Valproate-Haloperidol in Bipolar I Patients Suffering From a Manic Episode||Sanofi||Completed|May 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|No|||April 2008|April 8, 2008|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00126009||197486|
NCT00094575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|498|Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)|CSP #498 - Open Versus Endovascular Repair (OVER) Trial for Abdominal Aortic Aneurysms|OVER|VA Office of Research and Development|Yes|Completed|October 2002|April 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|881|||Both|50 Years|N/A|No|||February 2016|February 8, 2016|October 20, 2004|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00094575||199810|
NCT00094835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040153|Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Dose-finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)||Amgen||Completed|January 2005|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 27, 2004||||No|August 13, 2010|https://clinicaltrials.gov/show/NCT00094835||199791|
NCT00105690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 00-078|TEAM Study to Improve Depression Care in Rural CBOCs|Telemedicine Intervention to Improve Depression Care in Rural CBOCs||VA Office of Research and Development|No|Completed|April 2003|October 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||September 2006|April 6, 2015|March 16, 2005||||No||https://clinicaltrials.gov/show/NCT00105690||198997|
NCT00107159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000422429|Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma|A Phase II Study Of Matured Dendritic Cells Pulsed Ex Vivo With 3 Melanoma Cell Line Lysates (IDD-3) in Patients With In-Transit or Metastatic Melanoma||National Cancer Institute (NCI)||Completed|January 2005|September 2010|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|37|||Both|18 Years|N/A|No|||April 2007|November 5, 2013|April 5, 2005||||No||https://clinicaltrials.gov/show/NCT00107159||198891|
NCT00106210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54MH066417|School- and Home-Based Early Intervention for Toddlers With Autism|Early Detection, Intervention, and Neurobiology in Autism: Early Intervention Portion||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|May 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Months|33 Months|No|||July 2013|July 3, 2013|March 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00106210||198958|
NCT00107172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z4032|Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer|A Randomized Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High Risk Patients With Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller||Alliance for Clinical Trials in Oncology||Active, not recruiting|July 2005|||April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|April 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00107172||198890|
NCT00102817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGH-2147|Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children|Somatropin (Norditropin) in Children With Growth Failure Associated With ICF Deficiency.||Novo Nordisk A/S|No|Completed|May 2003|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|149|||Both|3 Years|13 Years|No|||April 2013|April 15, 2013|February 1, 2005||||No||https://clinicaltrials.gov/show/NCT00102817||199205|
NCT00126178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-12 Part 2|Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer|A Multi-Center, Randomized, Phase 3 Study of Adjuvant Oncophage® Versus Observation in Patients With High Risk After Surgical Treatment for Renal Cell Carcinoma||Agenus, Inc.||Terminated|May 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|August 2, 2005||Yes||||https://clinicaltrials.gov/show/NCT00126178||197473|
NCT00127296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1654|Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe|Comparison of the Accuracy and Precision of NovoLog® Mix 70/30 FlexPen® to Vial and Syringe in Patients With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|July 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Actual|60|||Both|40 Years|N/A|No|||April 2013|April 12, 2013|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00127296||197389|
NCT00127309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sj_1|Effect of Glutathione on Blood Alcohol and Hangover Symptoms|||Piyavate Hospital||Completed|June 2005|August 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2005|August 23, 2005|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127309||197388|
NCT00127322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003EP005B|The Early High Risk Period for Patients With Heart Failure|The Early High Risk Period for Patients With Incident Heart Failure: A Population Based Study||Royal Brompton & Harefield NHS Foundation Trust||Active, not recruiting|January 2004|January 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||450|||Both|18 Years|N/A|No|||February 2006|February 9, 2006|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00127322||197387|
NCT00127569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 117 CastlemaB|Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy|Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|May 2003|January 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||January 2007|January 11, 2007|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00127569||197369|
NCT00127855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|792014/001|Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine|A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity (Including Immune Memory), Reactogenicity and Safety of Three Different Formulations of the GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups CY Conjugate Vaccine Given Concomitantly With Infanrix® Penta and Prevenar®, Versus ActHIB® and Meningitec® Given Concomitantly With Infanrix® Penta and Versus ActHIB® Given Concomitantly With Infanrix® Penta and Prevenar® in Infants According to a 2-4-6 Month Schedule.||GlaxoSmithKline||Completed|March 2003|August 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|409|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||October 2011|June 15, 2012|August 8, 2005|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00127855||197347|
NCT00128115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0677-032|Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)|Proprietary Information - Exploratory (Non-Confirmatory) Trial||Merck Sharp & Dohme Corp.||Terminated|September 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|83|||Both|60 Years|N/A|No|||January 2016|January 19, 2016|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00128115||197328|
NCT00092456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-009|Consistency Lots Vaccine Study (V260-009)|Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants||Merck Sharp & Dohme Corp.||Completed|May 2003|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|793|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 22, 2004|Yes|Yes||No|June 19, 2009|https://clinicaltrials.gov/show/NCT00092456||199962|
NCT00092469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V441-001|Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)|A Registration Study of the Safety, Tolerability, and Immunogenicity of V441 in Healthy Infants in Taiwan||Merck Sharp & Dohme Corp.||Completed|March 2002|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||151|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092469||199961|
NCT00092482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-012|Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)|Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)||Merck Sharp & Dohme Corp.||Completed|June 2002|August 2008|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|3882|||Female|16 Years|23 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|September 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00092482||199960|
NCT00093951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0061|SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease||National Institute on Aging (NIA)||Completed|April 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|55 Years|90 Years|No|||February 2009|December 10, 2009|October 7, 2004||||||https://clinicaltrials.gov/show/NCT00093951||199856|
NCT00093964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 121974-009|Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)|A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.||EMD Serono|No|Completed|October 2004|December 2007|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 7, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093964||199855|
NCT00129298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17782-1|Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1|Tiagabine for the Treatment of Cocaine Dependence in Methadone-Maintained Individuals||National Institute on Drug Abuse (NIDA)|No|Completed|December 2004|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||December 2007|December 14, 2007|August 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00129298||197242|
NCT00129311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15757-1|Usefulness of Selegiline as an Aid to Quit Smoking - 1|Usefulness of Selegiline for Smoking Cessation||Yale University|Yes|Completed|July 2004|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|March 11, 2015|August 9, 2005|Yes|Yes||No|June 16, 2014|https://clinicaltrials.gov/show/NCT00129311||197241|
NCT00093626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02624|Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer|A Phase II Evaluation of BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|October 2004|January 2011|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Female|18 Years|N/A|No|||January 2013|May 18, 2015|October 6, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093626||199879|
NCT00093639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVARTIS-CRAD001C2207|Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate|A Phase I-II, Study of RAD001 in Combination With Imatinib (Glivec®/Gleevec™) in Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase Who Are Not In Complete Cytogenetic Response to Imatinib-Alone at Study Entry||Novartis||Completed|August 2004|August 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 30, 2013|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093639||199878|
NCT00093925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-03-05|Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)|Evaluation of Clevidipine in the Postoperative Treatment of Hypertension Assessing Safety Events (With Nicardipine as Active Comparator) (ECLIPSE-NIC)|ECLIPSE-NIC|The Medicines Company|Yes|Completed|May 2004|September 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|739|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|October 7, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00093925||199858|
NCT00094315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTO-0014-1|Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1|Cocaine Relapse Prevention II||National Institute on Drug Abuse (NIDA)||Active, not recruiting|September 2004|July 2005||||Phase 1|Interventional|N/A||||16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2005|October 23, 2007|October 15, 2004||||||https://clinicaltrials.gov/show/NCT00094315||199829|
NCT00094328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6873C00047|Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]|An Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis|BATT|AstraZeneca||Active, not recruiting|November 2004|August 2017|Anticipated|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|2 Years|13 Years|No|||February 2016|February 3, 2016|October 16, 2004|Yes|Yes||No|May 19, 2009|https://clinicaltrials.gov/show/NCT00094328||199828|
NCT00094848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRM1-HM01|Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)|A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma||Human Genome Sciences Inc.||Completed|June 2004|May 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2013|August 1, 2013|October 27, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094848||199790|
NCT00094861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030185|Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)||Swedish Orphan Biovitrum|Yes|Completed|January 2005|January 2014|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|October 27, 2004|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT00094861||199789|
NCT00106548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA17822|A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Completed||October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|623|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|March 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00106548||198933|
NCT00106834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003130|A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients With Moderate to Severe Plaque Psoriasis||Centocor, Inc.||Completed||October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|378|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|May 18, 2011|March 31, 2005||||||https://clinicaltrials.gov/show/NCT00106834||198912|
NCT00106561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMH2001-142|Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney|A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker||Melbourne Health||Completed|January 2002|September 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|75 Years|No|||March 2005|June 23, 2005|March 25, 2005||||No||https://clinicaltrials.gov/show/NCT00106561||198932|
NCT00102791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-17043-10|A Stratified Sickle Event Randomized Trial (ASSERT)|A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months|ASSERT|Icagen|Yes|Terminated|February 2005|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|297|||Both|16 Years|65 Years|No|||September 2007|March 26, 2008|February 1, 2005|||Because of the low probability of achieving the primary endpoint.|No||https://clinicaltrials.gov/show/NCT00102791||199207|
NCT00102804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5122|Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)|A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer||Eli Lilly and Company|Yes|Completed|March 2005|December 2013|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|663|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|February 1, 2005|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT00102804||199206|Four participants (pts) assigned to placebo received pemetrexed; pts analyzed for efficacy as randomized. Three treated pts did not sign ICF, 1 treated pt signed ICF but did not complete entire randomization process; pts excluded from all analyses.
NCT00102856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-NEUROMOD_01, Stage Ib|Neuromodulation and Language Acquisition (Stage Ib)|Neuromodulation and Language Acquisition (KS-Neuromod_01, Stage Ib)||University Hospital Muenster||Suspended|January 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||September 2006|June 23, 2010|February 3, 2005||||No||https://clinicaltrials.gov/show/NCT00102856||199202|
NCT00126958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|*ZON-MW 945-02-046*|Cost-Effectiveness in Bladder Cancer|Cost-Effectiveness of Follow-up of Patients With Superficial Bladder Cancer||Erasmus Medical Center||Active, not recruiting|July 2002|July 2005||||Phase 4|Observational|Time Perspective: Prospective||||500|||Both|N/A|N/A|No|||August 2005|February 18, 2009|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00126958||197415|
NCT00126971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4341|Chlorproguanil-Dapsone in Pregnant Women|Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment||Centers for Disease Control and Prevention||Suspended|July 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||132|||Female|15 Years|49 Years|No|||August 2006|August 14, 2006|August 3, 2005||||No||https://clinicaltrials.gov/show/NCT00126971||197414|
NCT00128128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002105-01|Cranberry Juice for the Prevention of Recurrent Urinary Tract Infections|Cranberry and Prevention of UTI A Comprehensive Approach||National Center for Complementary and Integrative Health (NCCIH)|No|Completed|August 2005|June 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|176|||Female|18 Years|45 Years|No|||May 2015|May 14, 2015|August 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00128128||197327|
NCT00128427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCASL30501-3|Study of Colchicine to Prevent the Postpericardiotomy Syndrome|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The COPPS Trial: COlchicine for the Prevention of Postpericardiotomy Syndrome||Azienda Sanitaria Locale 3, Torino|Yes|Completed|June 2005|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|360|||Both|18 Years|N/A|No|||June 2010|June 13, 2010|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128427||197305|
NCT00128440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.6|High Dose Trial in COPD|A Randomized, Multiple-dose, Double-Blind, Crossover Study to Compare the Efficacy and Safety of 200 μg and 400 μg of BEA 2180 BR to Tiotropium 5 μg and Placebo When Each is Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|August 2005|||September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|78|||Both|40 Years|84 Years|No|||October 2013|October 28, 2013|August 9, 2005||||||https://clinicaltrials.gov/show/NCT00128440||197304|
NCT00097344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomed 777-CLP-30|The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer|Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer||Intarcia Therapeutics||Terminated|December 2004|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment||||842|||Female|18 Years|N/A|No|||August 2007|August 21, 2007|November 22, 2004|||Identical study Biomed 777-CLP-029 did not meet superiority endpoint|No||https://clinicaltrials.gov/show/NCT00097344||199606|
NCT00097357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-010|BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery|A Phase 2 Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery||Bristol-Myers Squibb||Completed|October 2004|December 2005|Actual|December 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|1238|||Both|18 Years|90 Years|No|||November 2008|February 27, 2010|November 22, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00097357||199605|
NCT00094614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-94|Trial Comparing Daily Atropine Versus Weekend Atropine|A Randomized Trial Comparing Daily Atropine Versus Weekend Atropine||Jaeb Center for Health Research||Completed|June 2002|April 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||168|||Both|3 Years|7 Years|No|||April 2006|March 24, 2010|October 21, 2004||||No||https://clinicaltrials.gov/show/NCT00094614||199808|
NCT00094627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-004|Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Adult Patients With Primary Insomnia||H. Lundbeck A/S||Completed|November 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|465|||Both|18 Years|64 Years|No|||January 2015|January 13, 2015|October 21, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00094627||199807|
NCT00093353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000373759|N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma|A Phase I Study Of Oral Irinotecan, Temozolomide, Cefixime In Children With Recurrent/Resistant High-Risk Neuroblastoma||Children's Hospital Los Angeles|Yes|Completed|May 2004|||July 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|1 Year|30 Years|No|||May 2009|October 14, 2010|October 6, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00093353||199896|
NCT00093366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1888.00|Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes|Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study||Fred Hutchinson Cancer Research Center||Completed|June 2004|July 2006|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|N/A|No|||November 2011|November 28, 2011|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093366||199895|
NCT00093652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 04603|Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer|ZD1839 (IRESSA®) With Oxaliplatin and Radiotherapy for Esophageal Carcinoma. A Phase I/II Study With Biologic Correlates||Roswell Park Cancer Institute||Terminated|May 2003|||May 2006|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|120 Years|No|||October 2015|October 5, 2015|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093652||199877|
NCT00093938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK068527-01 (completed)|Cranberry Juice for Preventing Bacteria in Urine During Pregnancy|Cranberry for Prevention of Bacteriuria in Pregnancy||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|December 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|360|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|October 7, 2004||||No||https://clinicaltrials.gov/show/NCT00093938||199857|
NCT00094341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040201|Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes|An Open-Label, Randomized, Crossover Study to Assess Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes||Amgen||Completed|October 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||215|||Both|18 Years|N/A|No|||December 2008|December 4, 2008|October 16, 2004||||||https://clinicaltrials.gov/show/NCT00094341||199827|
NCT00095511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-135|Aripiprazole in Patients With Acute Mania|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|June 2004|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||615|||Both|18 Years|N/A|No|||May 2008|November 7, 2013|November 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095511||199739|
NCT00095524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-122|Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder|A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|March 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||May 2008|November 7, 2013|November 5, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095524||199738|
NCT00095472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050016|Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease|Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2004|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 4, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095472||199742|
NCT00095485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050027|Impact of Move to Clinical Research Center on Physical Activity of Employees|Impact of Move to CRC on Physical Activity of Employees||National Institutes of Health Clinical Center (CC)||Completed|November 2004|November 2005||||N/A|Observational|N/A||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 3, 2008|November 5, 2004||||No||https://clinicaltrials.gov/show/NCT00095485||199741|
NCT00095498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040144|Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis||Amgen||Completed|August 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|227|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|November 5, 2004||||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00095498||199740|
NCT00095797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02633|XK469R in Treating Patients With Refractory Hematologic Cancer|A Phase I Study of XK469R (NSC 698215) in Patients With Refractory Hematologic Malignancies||National Cancer Institute (NCI)||Completed|October 2004|||March 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095797||199719|
NCT00095810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-060|Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease|An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2003|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||50|||Both|50 Years|N/A|No|||December 2010|November 7, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095810||199718|
NCT00106236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHPCR-2003-1|Efficacy of Exercise at a Fitness Club for Cardiovascular Risk Reduction|Sapporo Fitness Club Trial (SFCT): A Randomized Controlled Trial to Test the Efficacy of Exercise at a Fitness Club for the Reduction of Cardiovascular Risk Factors||Sapporo Health Promotion Foundation||Completed|April 2003|April 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||561|||Both|45 Years|89 Years|No|||March 2005|July 13, 2009|March 21, 2005||||No||https://clinicaltrials.gov/show/NCT00106236||198956|
NCT00106860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-003|A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder|A Long-Term, Open Label, Safety and Efficacy Study of an Experimental Medication in Adults With Generalized Anxiety Disorder (GAD)||Jazz Pharmaceuticals||Completed|March 2005|March 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||158|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 7, 2008|March 31, 2005||||||https://clinicaltrials.gov/show/NCT00106860||198910|
NCT00106886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE-2, CIHR FRN # MT-15428|HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)|HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)||McMaster University||Active, not recruiting|December 1999|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||5000|||Both|55 Years|N/A|No|||March 2005|September 16, 2005|March 31, 2005||||No||https://clinicaltrials.gov/show/NCT00106886||198909|
NCT00106847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005290|A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance InfliximabTherapy in Patients With Plaque-Type Psoriasis||Centocor, Inc.||Completed|January 2003|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|683|||Both|18 Years|N/A|No|||April 2010|May 16, 2011|March 31, 2005||||||https://clinicaltrials.gov/show/NCT00106847||198911|
NCT00103428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-0039|Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase 1/2a Dose-Escalation Trial of Intravenous CG7870 in Combination With Docetaxel in Chemotherapy-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer||Cell Genesys||Terminated|August 2004|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||69|||Male|18 Years|N/A|No|||January 2006|January 31, 2006|February 8, 2005||||||https://clinicaltrials.gov/show/NCT00103428||199161|
NCT00126984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104703 (Primary study)|Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine|A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC™ or MENCEVAX™ ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old||GlaxoSmithKline||Completed|July 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|508|||Both|12 Months|14 Months|Accepts Healthy Volunteers|||January 2012|October 2, 2014|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00126984||197413|
NCT00126997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104020|Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases|Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life||GlaxoSmithKline||Completed|May 2005|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1439|||Both|11 Months|21 Months|Accepts Healthy Volunteers|||September 2011|June 12, 2014|August 4, 2005||||No||https://clinicaltrials.gov/show/NCT00126997||197412|
NCT00127907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.329|Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest|Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests||Hospices Civils de Lyon||Completed|May 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2416|||Both|18 Years|85 Years|No|||October 2007|October 16, 2007|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00127907||197344|
NCT00128141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA03287|Effect of Tactile and Kinesthetic Stimulation on Very Low Birth Weight Preterm Infants|Effect of Maternal Tactile and Kinesthetic Stimulation on Length of Hospital Stay of Very Low Birth Weight Infants||National Bioethics Commission of Brazil|No|Completed|August 2003|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|N/A|3 Days|No|||February 2008|February 4, 2008|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128141||197326|
NCT00128453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCASL30501-1|Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The ICAP Trial: Investigation on Colchicine for Acute Pericarditis||Azienda Sanitaria Locale 3, Torino||Completed|August 2005|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|August 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00128453||197303|
NCT00128466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3700|Treatment and Diagnosis of Plague|Safety and Efficacy of Gentamicin Versus Streptomycin for the Treatment of Naturally Occurring Human Plague and Evaluation of Rapid Diagnostic Test Kits for Yersinia Pestis||Centers for Disease Control and Prevention|Yes|Completed|August 2004|February 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|114|||Both|2 Years|N/A|No|||February 2009|February 24, 2009|August 9, 2005||||||https://clinicaltrials.gov/show/NCT00128466||197302|
NCT00128778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2001-01|Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients|Phase IV.III Clinical Trial to Evaluate Maintenance Treatment With Caelyx vs. Observation After Administration of Induction Chemotherapy in Metastatic Breast Cancer Patients||Spanish Breast Cancer Research Group||Completed|October 2002|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|154|||Female|18 Years|90 Years|No|||September 2007|September 4, 2007|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128778||197281|
NCT00093665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AICHI-UHA-HN03-01|Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer|A Phase II Study Of Alternating Chemoradiotherapy For Nasopharyngeal Cancer Using Cisplatin And 5-Fluorouracil||National Cancer Institute (NCI)||Active, not recruiting|November 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|70 Years|No|||October 2006|May 14, 2013|October 6, 2004||||No||https://clinicaltrials.gov/show/NCT00093665||199876|
NCT00094016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-302-25-197|Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children|Safety and Efficacy Evaluation of Two Doses of HFA-Propelled Beclomethasone Dipropionate (QVAR) Versus Placebo by Breath Operated and Metered Dose Inhalers in Mild to Moderate Asthmatic Children||Teva Pharmaceutical Industries||Completed|October 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|5 Years|11 Years|No|||May 2014|May 9, 2014|October 8, 2004||Yes||No||https://clinicaltrials.gov/show/NCT00094016||199851|
NCT00094640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6106|Pharmacokinetic Characterization of Intramuscular Olanzapine Depot|||Eli Lilly and Company||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|76 Years|No|||July 2006|July 18, 2006|October 21, 2004||||||https://clinicaltrials.gov/show/NCT00094640||199806|
NCT00093028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2003-35|Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II|UARK 2003-35, A Phase III Study of Bortezomib Versus Bortezomib in Two Doses in Combination With Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (UARK 98-026)||University of Arkansas|No|Completed|January 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|315|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|September 29, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00093028||199919|
NCT00094601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050011|Relationship of Dopamine to Cognitive Function in Parkinson's Disease|Cognitive Function in Parkinson's Disease: Relationship to Cortical Dopamine Synthesis and Dopamine D1 Receptors||National Institutes of Health Clinical Center (CC)||Completed|October 2004|January 2008||||N/A|Observational|N/A||||75|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||January 2008|March 5, 2008|October 20, 2004||||No||https://clinicaltrials.gov/show/NCT00094601||199809|
NCT00095173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-033|BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis|A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)||Bristol-Myers Squibb||Completed|February 2004|November 2011|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|122|||Both|6 Years|17 Years|No|||September 2011|December 30, 2011|November 1, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095173||199765|
NCT00095537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA181-002|BMS-599626 in Patients With Advanced Solid Malignancies|Phase I Study of BMS-599626 in Patients With Advanced Solid Malignancies, Including Malignancies That Express HER2 at the Maximum Tolerated Dose and/or Recommended Phase II Dose||Bristol-Myers Squibb||Completed|March 2004|||May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||60|||Both|18 Years|N/A|No|||October 2008|February 27, 2010|November 5, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095537||199737|
NCT00095823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-139|A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.||Bristol-Myers Squibb||Completed|June 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3|||1200|||Both|18 Years|65 Years|No|||November 2013|November 22, 2013|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095823||199717|
NCT00095836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-220|Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy|A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|March 2003|March 2011|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|November 9, 2004|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00095836||199716|
NCT00096421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4374-04-13031|Tight Glycemic Control in Critical Care Patients|Tight Glycemic Control in Patients Hospitalized in a Medical-Surgery Intensive Care Unit: A Randomized Study||Hospital Pablo Tobón Uribe||Completed|July 2003|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||504|||Both|15 Years|N/A|No|||October 2006|October 24, 2006|November 9, 2004||||No||https://clinicaltrials.gov/show/NCT00096421||199673|
NCT00096434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01817|Sorafenib in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane||National Cancer Institute (NCI)||Completed|September 2004|||June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096434||199672|
NCT00106262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05122|Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer|A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer||Women and Infants Hospital of Rhode Island||Terminated|March 2005|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Female|18 Years|80 Years|No|||April 2007|April 17, 2007|March 21, 2005|||Lack of accrual|No||https://clinicaltrials.gov/show/NCT00106262||198954|
NCT00106574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA18063|A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy||Hoffmann-La Roche||Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1220|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00106574||198931|
NCT00102869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL_001, Project on aphasia|Dopaminergic Enhancement of Learning and Memory in Aphasia|Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia)||University Hospital Muenster|Yes|Completed|January 2005|December 2008|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2008|October 4, 2013|February 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00102869||199201|
NCT00107185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000420930|Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma|Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients||Jonsson Comprehensive Cancer Center|Yes|Completed|January 2005|March 2010|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|1 Year|18 Years|No|||August 2012|August 2, 2012|April 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107185||198889|
NCT00104130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOS-202/NO18401|Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer|A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease||Bristol-Myers Squibb||Terminated|December 2004|February 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||53|||Male|18 Years|N/A|No|||September 2008|September 16, 2008|February 23, 2005||||||https://clinicaltrials.gov/show/NCT00104130||199111|
NCT00104143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN18344|A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.|A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis.||Hoffmann-La Roche||Withdrawn|October 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|59 Years|No|||October 2007|October 10, 2007|February 23, 2005||||No||https://clinicaltrials.gov/show/NCT00104143||199110|
NCT00127868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Chen|Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm)|A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capitis in Children||Chen, Catherine, M.D.||Completed|March 2005|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|47|||Both|12 Months|12 Years|No|||May 2006|July 7, 2008|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00127868||197346|
NCT00128479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-06|A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of CORLUX™ (Mifepristone) Plus an Antidepressant vs. Placebo Plus an Antidepressant in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features (PMD)||Corcept Therapeutics|No|Completed|September 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|443|||Both|18 Years|75 Years|No|||February 2012|February 14, 2012|August 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00128479||197301|
NCT00128791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor323102ctil|Nitroprusside for Prevention of no-Reflow in Primary Angioplasty|Intracoronary Nitroprusside for the Prevention of the No-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. A Randomized, Double Blind, Placebo-Controlled Clinical Trial||Soroka University Medical Center||Terminated|January 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|N/A|N/A|No|||May 2007|May 24, 2007|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00128791||197280|
NCT00129051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-15-0005|Helical Tomotherapy as a Radiotherapy Technique for Treating Pelvic and Abdominal Metastases|Helical Tomotherapy as a Radiotherapy Technique for Treating Pelvic and Abdominal Metastases||AHS Cancer Control Alberta||Completed|August 2001|November 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2005|February 8, 2010|August 9, 2005||||No||https://clinicaltrials.gov/show/NCT00129051||197260|
NCT00096928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD3101g|A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)|Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)|RESPONSE|Genentech, Inc.||Completed|March 2005|October 2009|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1846|||Both|N/A|N/A|No|Probability Sample|managed care organizations, community or physician practices, and academic centers in the        United States|March 2011|July 1, 2015|November 17, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096928||199636|
NCT00093990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004372|Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)|A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or Older (Farnesyl Transferase Inhibition Global Human Trials AML 301 [F.I.G.H.T. AML 301])||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2004|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|457|||Both|70 Years|N/A|No|||April 2010|April 22, 2010|October 7, 2004||||||https://clinicaltrials.gov/show/NCT00093990||199853|
NCT00094367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101822|A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)|See Detailed Description||GlaxoSmithKline||Completed|July 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||900|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|October 16, 2004||||||https://clinicaltrials.gov/show/NCT00094367||199825|
NCT00094354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA CH 002A|HIV Assessment in Fuyang, Anhui Province, China|A Qualitative Study for the Development of an Intervention Among HIV-Positive Former Plasma Donors (FPDs) in Fuyang, Anhui Province, China||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|October 2004|April 2006|Actual|March 2005|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|111|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected former plasma donors (FPDs) , family members of HIV-infected FPDs, local        healthcare workers and villagers not related to an HIV-infected individual in Fuyang,        Anhui Province, China|January 2009|March 26, 2009|October 16, 2004||No||No||https://clinicaltrials.gov/show/NCT00094354||199826|
NCT00095186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-0209|Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma|A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant Human Lactoferrin (rhLF) Monotherapy in Patients With Advanced Renal Cell Carcinoma (RCC), Who Have Failed at Least One Regimen of Systemic Therapy for RCC||Agennix||Completed|September 2004|March 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2008|April 8, 2008|November 1, 2004||||||https://clinicaltrials.gov/show/NCT00095186||199764|
NCT00095199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13423|Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer|Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy||Eli Lilly and Company|Yes|Completed|January 2005|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|939|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|November 1, 2004|Yes|Yes||No|June 19, 2012|https://clinicaltrials.gov/show/NCT00095199||199763|
NCT00095862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000393552|Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers|A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor||National Cancer Institute (NCI)||Suspended|November 2004|||December 2014|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2011|December 17, 2013|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00095862||199715|
NCT00096161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1825.00|Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant|Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|May 2003|||February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|N/A|No|||January 2016|February 29, 2016|November 9, 2004|No|Yes||No||https://clinicaltrials.gov/show/NCT00096161||199692|
NCT00096447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02631|Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation Of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) In The Treatment Of Persistent Or Recurrent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|November 2004|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||January 2013|August 18, 2015|November 9, 2004|No|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT00096447||199671|The clinical trial was a two-stage design, accruing approximately 25 patients in each stage. Results from a planned interim futility analysis resulted in the early closure of the study. This study stopped early for lack of treatment efficacy.
NCT00096460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0202|Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)|Autologous Versus Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Chemosensitive Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response or First Partial Response (BMT CTN #0202)||Medical College of Wisconsin|Yes|Terminated|August 2004|March 2009|Actual|March 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|75 Years|No|||August 2015|August 5, 2015|November 9, 2004|Yes|Yes|lower than anticipated accrual|No|August 16, 2011|https://clinicaltrials.gov/show/NCT00096460||199670|
NCT00107198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD03P1|Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease|Treatment of Children With Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)||Children's Oncology Group|Yes|Active, not recruiting|January 2006|||November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|194|||Both|1 Month|21 Years|No|||March 2015|March 31, 2015|April 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00107198||198888|
NCT00103194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-01158|Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer|Phase II Trial of GW572016 in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA||National Cancer Institute (NCI)|Yes|Completed|September 2005|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Male|18 Years|N/A|No|||June 2014|September 19, 2014|February 7, 2005|Yes|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00103194||199179|
NCT00103454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR30002|A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).|See Detailed Description||GlaxoSmithKline||Completed|January 2005|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||288|||Both|12 Years|N/A|No|||January 2009|January 22, 2009|February 8, 2005||||||https://clinicaltrials.gov/show/NCT00103454||199160|
NCT00103467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX005|Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine|A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine||VaxGen||Completed|June 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2005|June 23, 2005|February 8, 2005||||||https://clinicaltrials.gov/show/NCT00103467||199159|
NCT00103493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-14261|Oral Health Education Program|Efficacy of a Tailored Oral Health Education Program||Temple University||Completed|October 2004|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Actual|1021|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||July 2009|November 19, 2010|February 9, 2005||||No||https://clinicaltrials.gov/show/NCT00103493||199158|
NCT00103168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62024|Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor|Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|December 2004|||October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|750|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|February 7, 2005||||No||https://clinicaltrials.gov/show/NCT00103168||199181|
NCT00103181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-39/RTOG 0413|Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer|A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer||NSABP Foundation Inc|Yes|Active, not recruiting|March 2005|April 2020|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4216|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|February 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00103181||199180|
NCT00105001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1938.00|Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer|A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|November 2004|||May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|210|||Both|N/A|N/A|No|||October 2015|October 14, 2015|March 3, 2005|No|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT00105001||199047|
NCT00127621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRACHEO|Early Tracheotomy Versus Prolonged Endotracheal Intubation in Intensive Care Unit (ICU) Patients|Early Tracheotomy Versus Prolonged Endotracheal Intubation in Intensive Care Unit Patients||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|April 2002|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||468|||Both|18 Years|N/A|No|||August 2005|August 24, 2005|August 5, 2005||||No||https://clinicaltrials.gov/show/NCT00127621||197365|
NCT00127634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6120|Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes|A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company||Completed|July 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|385|||Both|18 Years|N/A|No|||August 2008|August 6, 2008|August 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00127634||197364|
NCT00127881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-CD4-110|Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome|Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy||Emergent Product Development Seattle LLC|Yes|Terminated|July 2005|||February 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|August 8, 2005|Yes|Yes|New sponsor, other treatments available|No||https://clinicaltrials.gov/show/NCT00127881||197345|
NCT00096655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004783|A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis|A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis||Centocor, Inc.||Completed|May 2002|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|364|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|May 16, 2011|November 12, 2004||||||https://clinicaltrials.gov/show/NCT00096655||199656|
NCT00096915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040202|Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis|A Multicenter, Single-Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis||Amgen||Completed|October 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||May 2009|May 21, 2009|November 17, 2004||||No||https://clinicaltrials.gov/show/NCT00096915||199637|
NCT00096941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC2664g|A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study|An Open-Label, Multicenter Extension Study of Pertuzumab (rhuMAb 2C4) in Subjects Treated With Pertuzumab in a Previous Genentech-Sponsored Phase II Cancer Study||Genentech, Inc.||Completed|May 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||May 2015|May 29, 2015|November 17, 2004|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00096941||199635|
NCT00144612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA317JP|Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP||Chugai Pharmaceutical||Completed|July 2004|June 2009|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|2 Years|19 Years|No|||December 2009|December 21, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144612||196079|
NCT00144625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA319JP|Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP||Chugai Pharmaceutical||Completed|February 2005|June 2009|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|2 Years|19 Years|No|||December 2009|December 21, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144625||196078|
NCT00144989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0202-MF|A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC|A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF||Japan Clinical Oncology Group|Yes|Active, not recruiting|September 2002|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|281|||Both|20 Years|70 Years|No|||February 2009|February 2, 2009|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00144989||196051|
NCT00137111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTXV|Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia||St. Jude Children's Research Hospital|Yes|Active, not recruiting|June 2000|November 2020|Anticipated|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|501|||Both|12 Months|18 Years|No|||May 2015|May 27, 2015|August 25, 2005|Yes|Yes||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00137111||196647|
NCT00137397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121006|A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder|A Multi-Centre, Randomised, Placebo Controlled, Double Blind, Parallel Group Study in Female Patients to Evaluate Whether Tolterodine ER Can Reverse the Increased Bladder Wall Thickness in Patients With Overactive Bladder.||Pfizer||Completed|November 2004|August 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Female|18 Years|N/A|No|||October 2006|October 5, 2006|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00137397||196625|
NCT00137371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713S5-413|Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis|Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Female|45 Years|80 Years||||December 2007|December 7, 2007|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00137371||196627|
NCT00137384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050228|Movement-Related Brain Networks Involved in Hand Dystonia|The Role of Cortical Coherence in Focal Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|August 2005|||||N/A|Observational|Time Perspective: Prospective|||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137384||196626|
NCT00137657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3354|Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance|An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum, Streptococcus Pneumoniae, and Escherichia Coli||Centers for Disease Control and Prevention||Completed|February 2002|November 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1478|||Both|15 Years|N/A|No|||August 2005|December 12, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137657||196605|
NCT00138398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0056|T-cell Response-Flu Risk in Older Adults|T-cell Responses Predict Influenza Risk in Older Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|October 2005|October 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||850|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2007|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138398||196549|
NCT00134589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-R-01-PH-000018|CHOICE: Communicating Health Options Through Information and Cancer Education|Increasing CRC Screening in Health Plan Members||Centers for Disease Control and Prevention||Completed|April 2005|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind|||Actual|450|||Both|52 Years|75 Years|Accepts Healthy Volunteers|||July 2007|August 3, 2009|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00134589||196839|
NCT00134329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/096|Erectile Dysfunction and Diabetes Mellitus|Erectile Dysfunction and Diabetes Mellitus||University Hospital, Ghent|No|Completed|May 2005|March 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||300|||Male|18 Years|N/A|No|||December 2007|December 19, 2007|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00134329||196859|
NCT00136214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-000341|Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects|A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects||Beth Israel Deaconess Medical Center||Recruiting|March 2004|December 2006||||N/A|Observational|Time Perspective: Prospective|||Anticipated|26|||Both|18 Years|N/A|No|||August 2005|December 19, 2007|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136214||196716|
NCT00136461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-278|A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|A Randomized Phase II Trial of All-Trans Retinoic Acid and One of Two Schedules of Bryostatin 1 in Patients With Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)||Dana-Farber Cancer Institute||Completed|May 1997|August 2000|Actual|August 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136461||196697|
NCT00113256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-RUB-048|Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer|Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy||Astex Pharmaceuticals||Terminated|February 2005|||February 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||October 2009|January 22, 2013|June 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00113256||198447|
NCT00145041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSLI-12-HEPHARM|Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction|An Evaluation of the Pharmacokinetic Profile of VSLI (Vincristine Sulfate Liposome Injection, 0.16 mg/mL) in Patients With Malignant Melanoma and Hepatic Dysfunction Secondary to Metastases||Spectrum Pharmaceuticals, Inc|No|Completed|February 2005|November 2007|Actual|September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|September 1, 2005|Yes|Yes||No|November 29, 2011|https://clinicaltrials.gov/show/NCT00145041||196047|The dose administered to subjects with impaired liver function was ~1 mg/m2 which is lower than is administered to subjects with normal liver function (2 mg/m2). The impact of liver impairment on that higher dose remains unknown.
NCT00144690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-206|E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures||Eisai Inc.||Completed|March 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years||||November 2015|November 2, 2015|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00144690||196073|
NCT00135356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-131|Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome|A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study)||Bristol-Myers Squibb|No|Completed|July 2005|June 2008|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|N/A|No|||April 2010|April 20, 2010|August 25, 2005|Yes|Yes||No|December 15, 2009|https://clinicaltrials.gov/show/NCT00135356||196781|
NCT00135863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MesoHep II|MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis|Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis||Ribe County Hospital||Terminated|May 2004|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||36|||Both|18 Years|N/A|No|||January 2004|May 20, 2015|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135863||196742|
NCT00136175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9910|Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder|Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder||University of Michigan Cancer Center|Yes|Completed|November 1999|October 2007|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136175||196719|
NCT00136188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB 423 TP B5|Nitric Oxide (NO) Activity and Diabetic Nephropathy|Role of NO Activity for the Development of Diabetic Nephropathy||University of Erlangen-Nürnberg Medical School||Completed|August 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136188||196718|
NCT00135850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gene G-CSF|The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris|The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris||Rigshospitalet, Denmark||Completed|March 2003|February 2005|Actual|February 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|20 Years|80 Years|No|||October 2002|August 4, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135850||196743|
NCT00136084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML02|Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia|A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia||St. Jude Children's Research Hospital|Yes|Completed|August 2002|June 2012|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|238|||Both|N/A|21 Years|No|||November 2012|November 2, 2012|August 24, 2005|Yes|Yes||No|March 5, 2010|https://clinicaltrials.gov/show/NCT00136084||196725|
NCT00136097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/266|Study on the Infection Risk of Long Dwell Period Catheters in High Risk Intensive Care Unit (ICU) Patients|Study on the Infection Risk of Long Dwell Period Catheters in High Risk ICU Patients||University Hospital, Ghent|No|Terminated|August 2005|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||142|||Both|N/A|N/A|No|||December 2007|December 19, 2007|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136097||196724|
NCT00144638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSG1|Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality|Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality||Danish Procalcitonin Study Group||Completed|January 2002|January 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||450|||Both|N/A|N/A|No|||February 2005|September 1, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144638||196077|
NCT00144651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA010JP|Study of MRA in Patients With Rheumatoid Arthritis (RA)|An Open-label, Extension, Phase II Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Were Participated in Study MRA009JP||Chugai Pharmaceutical|No|Completed|August 2001|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|20 Years|N/A|No|||August 2013|August 6, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144651||196076|
NCT00145002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9801|A Study for Aggressive Adult T-Cell Leukemia-Lymphoma (ATLL)|Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-Cell Leukemia-Lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.||Japan Clinical Oncology Group||Completed|August 1998|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|15 Years|70 Years|No|||September 2005|January 17, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145002||196050|
NCT00145327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2301E1|Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)|A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D||Novartis||Completed|May 2005|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2456|||Female|68 Years|90 Years|No|||June 2011|June 24, 2011|September 1, 2005|Yes|Yes||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00145327||196025|
NCT00137410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|635-IFL-0508-015|Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee|Protocol For A Multicentre, Double Blind, Parallel Group Pilot Study To Compare Celecoxib Long Term Vs Celecoxib Short Term Therapy In Treatment And Prevention Of New Flare In Patients With Osteoarthritis Of The Knee||Pfizer||Completed|November 2002|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|50 Years|N/A|No|||July 2006|June 9, 2008|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137410||196624|
NCT00137423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181061|Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer|A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma||Pfizer|No|Completed|May 2005|May 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|August 26, 2005|No|Yes||No|May 14, 2009|https://clinicaltrials.gov/show/NCT00137423||196623|
NCT00137683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-9998|Colorectal Cancer Control in Appalachian Churches|Colorectal Cancer Control in Appalachian Churches||Centers for Disease Control and Prevention||Withdrawn|September 2001|March 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|August 27, 2005||||No||https://clinicaltrials.gov/show/NCT00137683||196603|
NCT00137670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3500|Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients|Effectiveness of a Video-based Educational Intervention to Prevent Human Immunodeficiency Virus (HIV) and Sexually Transmitted Diseases (STDs) Among Patients Attending STD Clinics||Centers for Disease Control and Prevention|No|Completed|April 2002|March 2009|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||45000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 26, 2012|August 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00137670||196604|
NCT00137943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2834|Parents Matter!: Interventions to Promote Effective Parent-Child Communication|Parents Matter!: Interventions to Promote Effective Parent-Child Communication About Sex and Sexual Risk Among African American Families||Centers for Disease Control and Prevention|No|Completed|September 1999|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||2210|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137943||196583|
NCT00134888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-2|Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence|The Acute and Protracted Blockade Efficacy of Buprenorphine/Naloxone||National Institute on Drug Abuse (NIDA)|No|Completed|December 2000|November 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|8|||Both|18 Years|55 Years|No|||July 2007|July 9, 2007|August 23, 2005||||||https://clinicaltrials.gov/show/NCT00134888||196817|
NCT00135915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDEC ALC 1|Influence of Binge Drinking on Glucose Metabolism in Patients With Type 1 Diabetes - A Pilot Study|Influence of Binge Drinking on Glucose Metabolism in Patients With Type 1 Diabetes - A Pilot Study||The Royal Bournemouth Hospital|Yes|Completed|August 2005|February 2007|Actual|||Phase 2/Phase 3|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Males or females of at least 18 years of age who were diagnosed with Type 1 diabetes more        than 5 years ago.|October 2009|October 30, 2009|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135915||196738|
NCT00144677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-290|Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation|Open Label Phase II Trial of Sirolimus in Combination With Tacrolimus for Graft-vs-Host Disease Prophylaxis After HLA-Matched, Unrelated, Allogeneic Hematopoietic Stem Cell Transplantation||Dana-Farber Cancer Institute||Completed|November 2003|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|18 Years|55 Years|No|||March 2009|January 24, 2012|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144677||196074|
NCT00144703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-090|Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation|Open Label Phase II Trial of Sirolimus in Combination With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation||Dana-Farber Cancer Institute||Completed|July 2002|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||55|||Both|18 Years|N/A|No|||January 2009|January 24, 2012|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144703||196072|
NCT00135876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|524E-CVD-0056-013|Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients|A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)||Ontario Clinical Oncology Group (OCOG)|No|Completed|October 2002|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||512|||Both|18 Years|N/A|No|||April 2007|April 25, 2007|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135876||196741|
NCT00136123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/218|Immediate Load of Dental Implants, Placed in Atrophic Upper and/or Lower Jaw of Partial or Complete Edentate Patients, According to Flapless Technique|Immediate Load of Dental Implants, Placed in Atrophic Upper and/or Lower Jaw of Partial or Complete Edentate Patients, According to Flapless Technique||University Hospital, Ghent|No|Recruiting|December 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136123||196722|
NCT00137761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-173|Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer|A Phase II Study of Docetaxel in Combination With ZD 1839 (IRESSA) in Previously Treated Patients With Metastatic Pancreatic Cancer||Dana-Farber Cancer Institute||Completed|October 2004|March 2009|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137761||196597|
NCT00136422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-249|Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia|A Phase I Study of Vaccination With Lethally Irradiated, Autologous Acute Myeloblastic Leukemia Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia||Dana-Farber Cancer Institute||Completed|January 2000|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|August 25, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00136422||196700|
NCT00136110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/182-0|Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis|A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS||UMC Utrecht||Completed|April 2005|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|165|||Both|18 Years|85 Years|No|||April 2007|April 30, 2007|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00136110||196723|
NCT00144326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.269|A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect, of Tiotropium Inhalation Capsules on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|July 2003|October 2005||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|250|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144326||196101|
NCT00144339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.235|Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients|A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|December 2002|||February 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|5993|||Both|40 Years|N/A|No|||April 2014|May 15, 2014|September 2, 2005||||No|February 21, 2009|https://clinicaltrials.gov/show/NCT00144339||196100|Tio patients had significantly longer drug exposure,thus had increased chance of AE.Simple frequencies are biased for AE comparisons;exposure-adjusted incidence rates (IR) should be used. IR for serious AE(>1% patients) are in Outcome Measures.
NCT00136630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM01-59 _ AOM03059|Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations|Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations||Institut National de la Santé Et de la Recherche Médicale, France||Active, not recruiting|May 2005|December 2012|Anticipated|||Phase 1|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|225|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|French population|January 2012|January 27, 2012|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136630||196684|
NCT00136812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18691-1|Treating Tobacco Dependence in Inpatient Psychiatry - 1|Treating Tobacco Dependence in Inpatient Psychiatry||Stanford University||Completed|July 2006|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 25, 2005||No||No|February 22, 2016|https://clinicaltrials.gov/show/NCT00136812||196670|
NCT00137696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NIP-3436|Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine|Immunogenicity of Inactivated Polio Vaccine in Puerto Rico; A Comparative Cohort Study of Two Vaccination Schedules||Centers for Disease Control and Prevention||Completed|September 2002|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||500|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||August 2005|December 12, 2005|August 27, 2005||||No||https://clinicaltrials.gov/show/NCT00137696||196602|
NCT00137969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2971g|A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus|EXPLORER|Genentech, Inc.|No|Completed|May 2005|||August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|262|||Both|16 Years|75 Years|No|||April 2015|April 30, 2015|August 26, 2005|Yes|Yes||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00137969||196581|
NCT00137956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-0005|Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study|Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study||Emphasys Medical||Terminated|December 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|40 Years|75 Years|No|||August 2009|August 14, 2009|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00137956||196582|
NCT00134342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0702-AE|Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations|A Comparison of Traditional Tuberculosis Screening Methods With the T-SPOT TB Test for the Diagnosis of Latent Tuberculosis Infection in Immunocompromised Populations||University Health Network, Toronto|No|Completed|January 2005|April 2005|Actual|April 2005|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|203|||Both|18 Years|N/A|No|Non-Probability Sample|patients with endstage renal disease|July 2005|December 22, 2010|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00134342||196858|
NCT00138177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00083|Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors||National Cancer Institute (NCI)||Completed|July 2005|||August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|August 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00138177||196565|
NCT00138203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03070|Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|June 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|19 Years|N/A|No|||December 2012|April 25, 2014|August 29, 2005|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00138203||196564|
NCT00135694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN030ST|Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant|A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients|A-WISH|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2005|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|275|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135694||196755|
NCT00135486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|711202/001|Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants|Evaluate Immunogenicity, Reactogenicity, Safety of GSK Biologicals' MenC-TT Vaccine (2 Formulations) Given With Infanrix Hexa® + GSK Biologicals' Hib MenC-TT Vaccine (2 Formulations) Given With Infanrix Penta® to Infants in Mths 3,4,5 of Life||GlaxoSmithKline||Completed|March 2002|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|500|||Both|8 Weeks|16 Weeks|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135486||196771|
NCT00135928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEMMI|Stem Cells in Myocardial Infarction|Bone Marrow Stimulation With G-CSF in Acute Myocardial Infarction,||Rigshospitalet, Denmark||Completed|May 2003|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||78|||Both|20 Years|70 Years|No|||February 2005|August 4, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135928||196737|
NCT00135941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3508|Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)|Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes||Sanofi||Completed|August 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|582|||Both|21 Years|70 Years|No|||June 2009|June 2, 2009|August 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135941||196736|
NCT00144365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4371|Comparison of Facility and Home-based ART Delivery Systems in Uganda|Comparison of Facility and Home-based ART Delivery Systems in Uganda||Centers for Disease Control and Prevention|No|Completed|February 2005|December 2010|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|1453|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144365||196098|
NCT00144716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG30|Evaluation of Combined Use of ITN's and Insect Repellents Against Malaria|Clinical Evaluation of Combined Use of ITN's and Plant-Based Insect Repellent Against Malaria in the Amazon||Gates Malaria Partnership||Completed|June 2003|October 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||4250|||Both|10 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144716||196071|
NCT00144729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC 0800.01|Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor|Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor||Fred Hutchinson Cancer Research Center||Completed|May 1993|July 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||85|||Both|N/A|55 Years|No|||April 2008|April 28, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144729||196070|
NCT00145067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-040|Osteoporosis Disease Management Demonstration Project (0000-040)|Three Methods of Delivering Health Care for Secondary Prevention of Osteoporosis||Merck Sharp & Dohme Corp.||Completed|November 2003|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|230|||Female|60 Years|N/A|No|||November 2015|November 2, 2015|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00145067||196045|
NCT00135889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|560-2003|Continuous Femoral Nerve Block Following Total Knee Replacement|Improving Postoperative Rehabilitation Following Total Knee Arthroplasty With Perineural Local Anesthetic Infusion||National Institute of General Medical Sciences (NIGMS)|Yes|Completed|January 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|80 Years|No|||October 2009|October 7, 2009|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135889||196740|
NCT00136435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-175|A Study in Adults With Untreated Acute Lymphoblastic Leukemia|A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol||Dana-Farber Cancer Institute||Active, not recruiting|June 2002|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|50 Years|No|||February 2016|February 11, 2016|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136435||196699|
NCT00136851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIB002FUS19|Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension|A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension||Novartis||Completed|December 2004|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|259|||Both|18 Years|80 Years||||June 2006|November 7, 2011|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00136851||196667|
NCT00136656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040422|Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old|Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence.||Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2005|February 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|700|||Both|1 Month|3 Years|No|||February 2009|February 11, 2009|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00136656||196682|
NCT00136383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007207|Comparing Paroxetine and Duloxetine on Cardiovascular Measures|A Study of the Effects of Paroxetine vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control||Duke University||Completed|March 2005|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|20 Years|60 Years|No|||September 2007|July 18, 2014|August 25, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00136383||196703|
NCT00136643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI-INV.06|Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance and Acceptability of a Vaginal Gel Containing Sodium Lauryl Sulfate (Invisible Condom®) in Healthy Female Subjects||Laval University||Completed|June 2005|July 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||452|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||October 2007|October 9, 2007|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00136643||196683|
NCT00136825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18501-1|Effectiveness of N-Acetylcysteine in Treating Cocaine Dependent Individuals - 1|N-Acetylcysteine as Treatment in Cocaine Addiction||National Institute on Drug Abuse (NIDA)|Yes|Completed|March 2003|September 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 17, 2007|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136825||196669|
NCT00137124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFO 106 TP8|L-Arginine Metabolism in Essential Hypertension|Transport and Metabolism of L-arginine: Role for Endothelial Dysfunction in Essential Hypertension||University of Erlangen-Nürnberg Medical School|No|Completed|May 2006|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137124||196646|
NCT00137137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/097|The Mini-Screw as Orthodontic Anchoring: Survival, Clinical Efficiency and Experience of the Patient|The Mini-Screw as Orthodontic Anchoring: A Clinical Trial to Study Survival, Clinical Efficiency and Experience of the Patient||University Hospital, Ghent|No|Completed|June 2005|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|10 Years|70 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137137||196645|
NCT00137150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/420|Comparison of Outcome and Complications Encountered in Flapless Surgery and Immediate Loading Versus the Classical Surgical Approach and Loading After 6-8 Weeks in the Posterior Maxilla|Comparison of Outcome and Complications Encountered in Flapless Surgery and Immediate Loading Versus the Classical Surgical Approach and Loading After 6-8 Weeks in the Posterior Maxilla||University Hospital, Ghent|No|Completed|January 2005|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 19, 2007|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137150||196644|
NCT00137982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030409/AOR03040|Evaluation of Therapeutic Strategies for Treatment of Ectopic Pregnancies (EP) and Evaluation of Subsequent Fertility|Prospective Study, Randomized Controlled Trial Between Medical Treatment by Methotrexate Versus Conservative Surgical Treatment (Group 1) and Conservative Versus Radical Surgical Treatment (Group 2) to Evaluate Subsequent Fertility||Hopital Antoine Beclere||Recruiting|August 2004|July 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Female|18 Years|44 Years|No|||August 2005|September 7, 2006|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137982||196580|
NCT00134355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005.014|Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer|Phase II Evaluation of PTK787, an Oral Vascular Endothelial Growth Factor Inhibitor, in Patients With Non-Metastatic Androgen Independent Prostate Cancer||University of Michigan Cancer Center|Yes|Completed|July 2005|March 2007|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||January 2015|January 15, 2015|August 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134355||196857|
NCT00138216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0414|Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors|A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors||Children's Oncology Group|Yes|Completed|October 2005|January 2011|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|1 Year|21 Years|No|||February 2014|February 18, 2014|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138216||196563|
NCT00135460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-2198|Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients|Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial.||Danish HIV Research Group||Active, not recruiting|June 2003|November 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||September 2005|March 13, 2006|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135460||196773|
NCT00134628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project HORTIS|Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries|Hyperbaric Oxygen Radiation Tissue Injury Study - Project HORTIS||Baromedical Research Foundation|Yes|Terminated|January 2001|December 2015|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|248|||Both|N/A|N/A|No|||February 2012|January 11, 2016|August 23, 2005||No|Discontinued cystitis study due to poor recruitment. To continue the trial under these    circumstances is considered non-viable.|No||https://clinicaltrials.gov/show/NCT00134628||196836|
NCT00135902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-Omega-3|Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies|A Randomized Trial of Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in Pregnancies at High Risk||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2005|March 2008|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|800|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2010|July 19, 2010|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135902||196739|
NCT00135200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005.035|Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma|A Phase II Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma||University of Michigan Cancer Center|Yes|Active, not recruiting|August 2005|January 2017|Anticipated|August 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|August 24, 2005|Yes|Yes||No|November 13, 2014|https://clinicaltrials.gov/show/NCT00135200||196793|
NCT00135954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUNMN01|Treatment of Patients With Idiopathic Membranous Nephropathy|Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy||Radboud University||Completed|July 1997|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||February 2007|January 27, 2014|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135954||196735|
NCT00144378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|irinotecan vs. bsc|Irinotecan Versus Only Best Supportive Care for Gastric Cancer|Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer||Charite University, Berlin, Germany||Completed|October 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||44|||Both|18 Years|75 Years|No|||April 2007|April 17, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144378||196097|
NCT00144391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-02-511-07|Testosterone Gel Applied to Women With Pituitary Gland Problems|Physiologic Testosterone Replacement in Women With Hypopituitarism||Charles Drew University of Medicine and Science|Yes|Recruiting|July 2003|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|160|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 23, 2009|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00144391||196096|
NCT00145106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T214|Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris|Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazorac .1% Gel or Vehicle Gel||KGL, Inc.||Completed|March 2002|August 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||189|||Both|12 Years|N/A|No|||September 2005|December 14, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145106||196042|
NCT00136448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-148|High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)|High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission||Dana-Farber Cancer Institute||Completed|February 1993|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136448||196698|
NCT00136682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-091|Patient-Controlled Epidural Analgesia (PCEA) for Patients Who Have Had Major Open Gynecologic Surgery|Postoperative Recovery in Patients Receiving Patient-Controlled Epidural Analgesia (PCEA) Compared to Patient-Controlled Intravenous Analgesia (PCA) After Major Open Gynecologic Surgery: A Randomized Controlled Trial||Memorial Sloan Kettering Cancer Center||Completed|August 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|N/A|No|||November 2008|November 6, 2008|August 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00136682||196680|
NCT00136695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0035|Anastrozole Administration in Elderly Hypogonadal Men|Anastrozole Administration in Elderly Hypogonadal Men||Massachusetts General Hospital|No|Completed|October 2004|October 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Male|60 Years|N/A|No|||October 2013|October 23, 2013|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136695||196679|
NCT00136864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-087276|Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)|The Impact of Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer: A Prospective Randomized Clinical Trial (PET START Trial)||Ontario Clinical Oncology Group (OCOG)|Yes|Completed|August 2004|September 2011|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|310|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136864||196666|
NCT00136396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-120|Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease|An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease||Dana-Farber Cancer Institute|Yes|Completed|January 2004|November 2010|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136396||196702|
NCT00137163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-04-026|Evaluation of Dermafill Dressing for Donor Sites|Evaluation of Dermafill Dressing for Autogenous Skin Donor Sites||United States Army Institute of Surgical Research|No|Completed|March 2005|March 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||17|||Both|18 Years|N/A|No|||July 2008|July 24, 2008|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00137163||196643|
NCT00137436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181043|Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer|A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC)||Pfizer|No|Completed|October 2005|March 2010|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Male|18 Years|N/A|No|||August 2011|August 25, 2011|August 26, 2005|No|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00137436||196622|Per FDAAA, only the Phase 2 study results are posted.
NCT00137449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181047|Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor|A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Advanced Gastrointestinal Stromal Tumor||Pfizer|No|Completed|September 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|August 26, 2005|No|Yes||No|April 10, 2009|https://clinicaltrials.gov/show/NCT00137449||196621|
NCT00134368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4489|Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo|Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo||Rutgers, The State University of New Jersey||Completed|November 2003|December 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2008|August 6, 2008|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134368||196856|
NCT00134641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-282|Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas|A Phase II Study Evaluating Efficacy of the Combination of Gemcitabine and Vinorelbine in Advanced Soft Tissue Sarcoma||Dana-Farber Cancer Institute||Completed|February 2003|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00134641||196835|
NCT00135473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPNET-200304|Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)|Prospective Randomized Multicenter Study on the Influence of Colloid vs Crystalloid Volume Resuscitation and of Intensive vs Conventional Insulin Therapy on Outcome in Patients With Severe Sepsis and Septic Shock||German Competence Network Sepsis||Completed|April 2003|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135473||196772|
NCT00135512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK1102364|Study Of 323U66 SR In Major Depressive Disorder|Clinical Evaluation of 323U66 SR in Patients With Depression - Open-Label Study -||GlaxoSmithKline|No|Completed|December 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|18 Years|64 Years|No|||July 2013|August 1, 2013|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135512||196769|
NCT00135967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUNMN02|Mycophenolate Mofetil in Membranous Nephropathy|Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study||Radboud University||Completed|May 2002|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||August 2005|December 5, 2005|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135967||196734|
NCT00135707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-CAPPS|Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)|A Randomized Clinical Trial of Antioxidants to Prevent Preeclampsia and An Observational Cohort Study to Predict Preeclampsia|CAPPS|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|June 2003|January 2009|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|10154|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2010|May 12, 2010|August 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135707||196754|
NCT00135980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACT-study M2100|Integrated Care for Cancer Patients; Developing, Implementing and Testing a Programme to Improve Integrated Care|Integrated Care for Cancer Patients||Radboud University||Recruiting|August 2004|July 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||300|||Both|18 Years|N/A|No|||February 2007|February 28, 2007|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135980||196733|
NCT00145691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2004-005266-20|The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD)|The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study||Sykehuset Innlandet HF|Yes|Completed|September 2005|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|55 Years|N/A|No|||March 2007|March 20, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145691||195997|
NCT00144768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID02003|A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients|A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients With Mucopolysaccharidosis I (MPS I) Being Treated With Aldurazyme® (Laronidase).||Sanofi|No|Completed|July 2004|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||April 2013|May 2, 2014|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00144768||196068|
NCT00137488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-09-0024/ethics 21656|Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG)|Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG)||AHS Cancer Control Alberta|No|Completed|November 2005|||December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|patients referred to Cross Cancer Institute between 2004 and 2005|April 2012|February 24, 2016|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137488||196618|
NCT00137748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2953|Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients|Does Replacement With CMVIG in Hypogammaglobulinemic Patients Decrease the Rate of Opportunistic Infections and Chronic Rejection?||The Cleveland Clinic||Completed|January 2001|January 2006|Actual|January 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|N/A|N/A|No|||June 2010|June 8, 2010|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00137748||196598|
NCT00136942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581089|A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol|A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin|ACTFAST SWISS|Pfizer||Completed|April 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||370|||Both|18 Years|80 Years|No|||April 2007|February 28, 2008|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136942||196660|
NCT00137228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-04-030|Measuring Hand Edema in Burn Patients|The Reliability and Concurrent Validity of the Figure-of-Eight Method of Measuring Hand Edema in Patients With Burn Injuries||United States Army Institute of Surgical Research|No|Completed|January 2005|November 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|89 Years|No|||December 2007|December 24, 2007|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00137228||196638|
NCT00136669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-106|Acupuncture For Pancreatic Cancer Pain|Acupuncture For Pancreatic Cancer Pain: A Randomized Phase III Study||Memorial Sloan Kettering Cancer Center||Completed|September 2003|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||September 2006|September 7, 2006|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136669||196681|
NCT00136877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diary nro 135/2001|Tonsillectomy in Recurrent Tonsillitis|Effect of Tonsillectomy on Preventing Recurrent Streptococcal Throat Infections: A Randomized Controlled Trial||Oulu University Hospital||Active, not recruiting|October 2001|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|14 Years|N/A|No|||December 2006|December 27, 2006|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00136877||196665|
NCT00137189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-MTPSY|Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation|Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation: A Randomised Controlled Trial||Uni Research||Completed|April 2005|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||June 2007|February 25, 2011|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137189||196641|
NCT00136838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17572-2|Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2|Effect of Smoking Exposure on Tobacco Self-Administration Following Brief Abstinence||National Institute on Drug Abuse (NIDA)||Completed|October 2001|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|12|||Both|21 Years|45 Years|No|||December 2009|December 8, 2009|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136838||196668|
NCT00137462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091019|Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.|A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias||Pfizer||Completed|November 2004|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|18 Years|N/A|No|||December 2006|November 15, 2007|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00137462||196620|
NCT00137722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 08-110X|Outcomes From an Asthma Disease Management Program|Identification of Outcomes From an Asthma Disease Management Program||Children's Mercy Hospital Kansas City||Completed|January 2000|August 2005||||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||December 2008|February 2, 2015|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137722||196600|
NCT00137709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.399|Hormone Profiles in Adults With Newly Diagnosed Epilepsy|Hormone Profiles in Adults Treated With Valproate vs. Lamotrigine Monotherapy for Newly Diagnosed Epilepsy: A Prospective Randomised Study||Chinese University of Hong Kong||Recruiting|November 2004|July 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|15 Years|55 Years|No|||October 2007|October 30, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137709||196601|
NCT00134901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4496-NIDA-12761-2|Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2|A Double-Blind, Placebo-Controlled Trial of the Effectiveness of Memantine in Treating Cocaine Dependence||New York State Psychiatric Institute|Yes|Completed|March 2003|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|August 23, 2005|Yes|Yes||No|August 25, 2014|https://clinicaltrials.gov/show/NCT00134901||196816|participants who had achieved abstinence during the lead-in remained abstinent throughout the trial and there was little relapse-like behavior for a medication to address.
NCT00134394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5085|Etanercept With Tacrolimus for Psoriasis|Double-Blind, Placebo-Controlled, Bilateral Comparison of Topical Tacrolimus 0.1% vs. Placebo Ointment as Adjunctive Therapy for Patients With Moderate to Severe Psoriasis Who Are Candidates for or Poor Responders to Etanercept Therapy||Rutgers, The State University of New Jersey|No|Completed|February 2005|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||August 2008|August 6, 2008|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134394||196854|
NCT00135187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.003|Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma|A Pilot Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma||University of Michigan Cancer Center|Yes|Completed|July 2004|December 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2012|February 5, 2012|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00135187||196794|
NCT00134667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1012|Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)|A Phase IIIb/IV Randomized, Double-Masked, Active Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 102 Weeks, to Pegaptanib Sodium Plus Photodynamic Therapy (PDT) With Visudyne, in Patients With Exudative Age-Related Macular Degeneration (AMD)||Eyetech Pharmaceuticals||Terminated|March 2005|October 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|50 Years|N/A|No|||January 2007|January 12, 2007|August 24, 2005||||||https://clinicaltrials.gov/show/NCT00134667||196833|
NCT00134914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-4|Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence|Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals||National Institute on Drug Abuse (NIDA)|No|Completed|August 1996|May 1998|Actual|April 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 11, 2008|August 23, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00134914||196815|
NCT00145509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05786|40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)|A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode||Merck Sharp & Dohme Corp.|Yes|Completed|August 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|September 1, 2005|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00145509||196011|
NCT00145522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S102.4.103|Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women|A Twelve 28-Day Cycles, Multicenter, Prospective, Randomized, Open, Blinded Endpoint, Parallel Group Study Comparing the Effect on Breast and Cardiovascular Metabolic Markers of Continuously Combined 17β-Estradiol/Dydrogesterone and Tibolone in Postmenopausal Women.||Solvay Pharmaceuticals|No|Completed|November 2005|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Female|45 Years|65 Years|No|||March 2009|March 31, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145522||196010|
NCT00145743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUZ-QL-RS-04|Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer|Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer: Protocol of a Randomized Clinical Trial at the Tumor Center Regensburg||Tumorzentrum Regensburg e.V.|Yes|Completed|November 2004|October 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|N/A|No|||November 2007|November 26, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145743||195993|
NCT00145704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB # 4689|Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density|Treatment of Childhood Cancer Therapy-induced Osteopenia in Growth Hormone Deficient Adult Survivors: Does Bisphosphonate Treatment Improve Bone Mineral Density?||State University of New York - Upstate Medical University|No|Terminated|June 2002|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|September 1, 2005||No|due to low enrollment, participants are no longer being examined or treated|No|October 26, 2010|https://clinicaltrials.gov/show/NCT00145704||195996|Early termination due to low enrollment, and lost to follow up of three subjects. Data was limited and therefore not reviewed/analyzed
NCT00145977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 11009B|Texture Analysis for Postmenopausal Osteoporosis|Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis||University of Chicago|No|Recruiting|July 2001|July 2010|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|59 Years|N/A|No|||March 2007|March 16, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145977||195977|
NCT00145951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13798A|Reducing the Risk of Developing Major Depression in Adolescents/Young Adults With Minor Depression/Depression Symptoms|Randomized Trial of a Motivational Interview Versus Brief Advice in Primary Care to Engage Mid-Late Adolescents With a Web-based Depression Prevention Intervention||University of Chicago||Terminated|May 2006|December 2011|Actual|September 2007|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|93|||Both|14 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Subjects are between the ages of 14-18 years and          -  have one risk factor for developing depression in the next two years:          -  sub-clinical depressed mood (not meeting criteria of major depression),          -  a family history of depression in a parent or sibling, or          -  past personal history of depression or personal perception of risk depression and             desire to participate|March 2014|March 27, 2014|September 1, 2005||No|Lost funding|No||https://clinicaltrials.gov/show/NCT00145951||195979|
NCT00145964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0461-AE|Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)|Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)||University Health Network, Toronto||Recruiting|August 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||500|||Both|18 Years|85 Years|No|||August 2005|November 28, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145964||195978|
NCT00136708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP02 FIRST BREATH|First Breath: Neonatal Resuscitation in Developing Countries|FIRST BREATH: Neonatal Resuscitation in Developing Countries||NICHD Global Network for Women's and Children's Health|Yes|Completed|March 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|120009|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136708||196678|
NCT00136929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 1999-225|Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly|A Prospective Randomized Trial of Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly "Senior PAMI"||PAMI Coordinating Center||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||530|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2005|December 12, 2005|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00136929||196661|
NCT00136955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4174/2502|Irinotecan Study For Cervical Cancer|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix||Pfizer|No|Completed|June 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|75 Years|No|||May 2015|May 22, 2015|August 25, 2005||Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00136955||196659|
NCT00136968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501060|Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy|Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy||Pfizer||Completed|April 2005|May 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 10, 2009|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136968||196658|
NCT00138008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0401|Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy|Randomized Controlled Trial to Evaluate Radiotherapy Followed by Endocrine Therapy vs. Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy (JCOG0401)||Japan Clinical Oncology Group|Yes|Recruiting|May 2004|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Male|20 Years|79 Years|No|||June 2010|June 13, 2010|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00138008||196578|
NCT00138242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMRC-8837|Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|Phase II Trial of Weekly Docetaxel (Taxotere®) and Carboplatin as Initial Chemotherapy for Women With Ovarian Cancer and Similar Malignancies||National Cancer Institute (NCI)||Completed|December 2004|October 2006|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||October 2006|June 25, 2013|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138242||196561|
NCT00137176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-NEUR-293|EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis|EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis||University of North Carolina, Chapel Hill|No|Completed|October 2004|October 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|30|||Both|18 Years|60 Years|No|||June 2009|June 22, 2009|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137176||196642|
NCT00137735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG-HK-GAB-01-02|Gabapentin for Carpal Tunnel Syndrome|Gabapentin for Carpal Tunnel Syndrome: A Randomised Controlled Trial||Chinese University of Hong Kong||Completed|October 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137735||196599|
NCT00137995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORAL|R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma|Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab||Lymphoma Study Association|Yes|Completed|June 2003|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|481|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00137995||196579|
NCT00138229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050194|Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma|Phase II Trial Using Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)||Terminated|July 2005|April 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|August 29, 2005||||||https://clinicaltrials.gov/show/NCT00138229||196562|
NCT00138255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-140|Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines|MMR and Varicella Vaccine Responses in Extremely Premature Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|June 2004|June 2005||||Phase 4|Observational|Time Perspective: Prospective||||32|||Both|N/A|16 Months|Accepts Healthy Volunteers|||May 2005|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138255||196560|
NCT00134927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15853-1|A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches|Usage Patterns of OTC Nicotine Patches: Consumer Survey||National Institute on Drug Abuse (NIDA)|Yes|Completed|September 2005|November 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|600 consumers who purchased over-the-counter nicotine patches from a random sample of 30        retail pharmacies in San Diego County|October 2008|October 2, 2008|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134927||196814|
NCT00134680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1144|Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC|Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 2 mg/kg Weekly in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer||Duke University|No|Completed|January 2000|July 2005|Actual|January 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||October 2012|September 12, 2014|August 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00134680||196832|
NCT00135499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH01-5B|R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-Cell Lymphoma|Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma||Lymphoma Study Association||Terminated|January 2002|January 2011||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||560|||Both|60 Years|65 Years|No|||September 2006|September 7, 2006|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135499||196770|
NCT00145535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLX41|SOLX Titanium Sapphire Laser for Trabeculoplasty|SOLX Titanium Sapphire Laser for Trabeculoplasty||SOLX, Inc.|No|Completed|May 2004|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2009|January 28, 2010|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00145535||196009|
NCT00145756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSS|China Salt Substitute Study|China Salt Substitute Study-A Randomised Trial to Determine the Long-Term Effects of a Low Sodium, High Potassium Salt Substitute on Blood Pressure Among High-Risk Individuals in Northern China||The George Institute||Completed|May 2004|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||600|||Both|18 Years|N/A|No|||September 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145756||195992|
NCT00145171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APO303|A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.|Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.||Mylan Bertek Pharmaceuticals||Completed|February 2001|August 2002||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||November 2002|September 2, 2005|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00145171||196037|
NCT00145470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05844|12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008)(COMPLETED)(P05844)|A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode||Merck Sharp & Dohme Corp.|No|Completed|June 2005|March 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00145470||196014|
NCT00145483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481107|Sildenafil For Meniere's Disease|A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Of The Efficacy and Safety Of Sildenafil Given For The Acute Treatment Of Meniere's Disease||Pfizer||Completed|June 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|75 Years|No|||January 2008|January 30, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145483||196013|
NCT00136721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9HD01H|Parkin Mutations and Their Functional Consequences|Parkin Mutations and Their Functional Consequences||Institut National de la Santé Et de la Recherche Médicale, France||Active, not recruiting|June 2002|May 2006||||Phase 1|Observational|Time Perspective: Prospective||||2500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00136721||196677|
NCT00137254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-05-004|Insulin on Post Burn Hypermetabolism|Effects of Insulin on Post Burn Hypermetabolism||United States Army Institute of Surgical Research|No|Completed|December 2005|August 2008|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|72 Years|No|||April 2012|April 10, 2012|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00137254||196636|
NCT00136903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260-261|Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute GVHD.|A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of aGVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation||Osiris Therapeutics|No|Completed|February 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|No|||September 2009|September 3, 2009|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136903||196663|
NCT00136916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171029|Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes|Efficacy and Safety of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 2 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial||Pfizer|No|Terminated|June 2002|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|635|||Both|35 Years|75 Years|No|||December 2009|February 12, 2010|August 25, 2005|Yes|Yes|See termination reason in detailed description.|No|December 10, 2009|https://clinicaltrials.gov/show/NCT00136916||196662|Due to early termination of study, none of the subjects completed the study as planned. Subjects active at the time of study termination completed an end-of-study assessment and a 3-month follow-up visit.
NCT00137215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-04-018|Evaluation of Silverlon Dressing for Autogenous Skin Donor Sites|Evaluation of Silverlon Dressing for Autogenous Skin Donor Sites||United States Army Institute of Surgical Research|No|Completed|January 2006|December 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2008|July 24, 2008|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00137215||196639|
NCT00137475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-15-0006 / 17086|Using Intensity-Modulated Radiation Therapy to Permit Sparing of Parotid Gland Function|A Phase I/II Feasibility/Efficacy Study Using Intensity-Modulated Radiation Therapy in Head and Neck (H&N) Cancer Patients to Permit Sparing of Parotid Gland Function||AHS Cancer Control Alberta|No|Completed|February 2002|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|18 Years|N/A|No|||February 2014|February 24, 2016|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137475||196619|
NCT00134654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-306|Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer|A Phase II Trial of Two Doses of Conjugated Estrogens (Premarin) in Patients With Androgen-Independent Prostate Cancer||Dana-Farber Cancer Institute||Completed|March 2003|June 2011|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||June 2011|June 14, 2011|August 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134654||196834|
NCT00138021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 -132|Cognitive Remediation in Supported Employment at Human Service Center (HSC)|Cognitive Remediation in Supported Employment at HSC|CT+SE|Human Service Center, Illinois|No|Active, not recruiting|July 2005|May 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2007|October 31, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138021||196577|
NCT00134693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA1104046|A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis|A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship||GlaxoSmithKline|Yes|Completed|June 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|77|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00134693||196831|
NCT00134706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-319|A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer|A Phase II Study of Docetaxel Plus Carboplatin in Hormone Refractory Prostate Cancer Patients Refractory to Prior Docetaxel-based Chemotherapy||Dana-Farber Cancer Institute||Completed|January 2004|September 2009|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||December 2009|December 7, 2009|August 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134706||196830|
NCT00134719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102370 (primary study)|Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines|A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months||GlaxoSmithKline||Completed|April 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1104|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2014|June 26, 2014|August 10, 2005||Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00134719||196829|
NCT00134940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2424|Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus|A Non-interventional Protocol to Collect Prospective and Retrospective Data in Patients Receiving Everolimus to Prevent Acute Rejection Following Cardiac Transplantation||Novartis||Completed|January 2005|November 2006|Actual|November 2006|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|100|||Both|18 Years|65 Years|No|Probability Sample|primary care clinic|June 2011|June 15, 2011|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00134940||196813|
NCT00135213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11585|PROS Brief Smoking Cessation Counseling in Pediatric Practice to Reduce Secondhand Smoke Exposure of Young Children|PROS Brief Smoking Cessation Counseling in Pediatric Practice to Reduce Secondhand Smoke Exposure of Young Children||University of Rochester||Completed|October 2005|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|December 20, 2007|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00135213||196792|
NCT00135226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSUASCEND1|ASCEND: A Study of Cardiovascular Events iN Diabetes|A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes||University of Oxford||Active, not recruiting|March 2005|||September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|15480|||Both|40 Years|N/A|No|||December 2015|December 2, 2015|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135226||196791|
NCT00145249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-154|Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis|A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|143|||Both|13 Years|N/A|No|||October 2009|May 10, 2012|September 2, 2005|Yes|Yes||No|March 18, 2010|https://clinicaltrials.gov/show/NCT00145249||196031|
NCT00145262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66|TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation|Therapeutic Angiogenesis Using Cell Transplantation (TACT) Study at Nagoya||Nagoya University||Recruiting|August 2003|||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|20 Years|80 Years|No|||August 2003|December 29, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145262||196030|
NCT00145548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-0003|Pilot Study of the Spiration IBV™ System|Pilot Study of the Spiration IBV™ System||Spiration, Inc.|Yes|Completed|December 2003|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|70 Years|No|||May 2007|June 14, 2011|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00145548||196008|
NCT00144807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH03-3B|ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma|Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)||Lymphoma Study Association|Yes|Completed|December 2003|April 2012|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|59 Years|No|||September 2015|September 1, 2015|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144807||196065|
NCT00144820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 99005gs|Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis|Intra-Articular Injections of Hyaluronan Versus 20 Ml NaCl Versus Placebo in Treatment of Knee Osteoarthritis: a Randomised, Double-Blind, Placebo Controlled Single Centre Trial.||Glostrup University Hospital, Copenhagen||Active, not recruiting|May 1999|November 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||251|||Both|60 Years|N/A|No|||August 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144820||196064|
NCT00145730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153712|Prevention of Ectopic Bone Related Pain and Disability After Hip Replacement Surgery With Peri-Operative Ibuprofen|A Multicentre Randomised Placebo-Controlled Trail of Ibuprofen for the Prevention of Ectopic Bone-Related Pain and Disability After Elective Hip Replacement Surgery (HIPAID)||The George Institute||Completed|February 2002|May 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1000|||Both|N/A|N/A|No|||September 2005|November 28, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145730||195994|
NCT00146003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5163|Efalizumab for Eczema|Investigator-Initiated Trial of Efalizumab for Atopic Dermatitis: A Proof of Concept Study in Adults||Rutgers, The State University of New Jersey|No|Completed|March 2005|December 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||August 2008|August 6, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00146003||195975|
NCT00136981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091003|Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.|Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.|RADIANCE 1|Pfizer||Completed|December 2003|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||800|||Both|18 Years|70 Years|No|||April 2015|April 21, 2015|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136981||196657|
NCT00136994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281045|IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)|An Open Trial to Evaluate the Efficacy and Tolerability of Ziprasidone IM and Oral in Patients With Psychosis and Acute Agitation.||Pfizer||Completed|March 2003|November 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|60 Years|No|||July 2011|July 28, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136994||196656|
NCT00146822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-022504-L|REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance|ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance Study||Boston Scientific Corporation||Completed|February 2004|March 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||1500|||Both|18 Years|N/A|No|||April 2006|November 13, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146822||195912|
NCT00137527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B03-07-008|Brain Oxygenation Monitoring in Patients Undergoing Coronary Artery Bypass Surgery|Prospective, Randomized Trial of Cerebral Oximetry Monitoring in Patients Undergoing Coronary Artery Bypass Surgery||Atlantic Health System||Terminated|February 2004|February 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||250|||Both|18 Years|90 Years|No|||January 2014|January 16, 2014|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137527||196615|
NCT00137787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-SHOT 0402|Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases|Randomized Controlled Trial Comparing Ciprofloxacin With Cefepime in Febrile Neutropenic Patients With Hematologic Diseases||Center for Supporting Hematology-Oncology Trials|Yes|Recruiting|April 2005|March 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|79 Years|No|||November 2008|November 11, 2008|August 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00137787||196595|
NCT00134381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3808|Green Tea and Ultraviolet Light-induced Skin Damage|The Effects of Topically Applied Constituents of Green Tea on UV Induced Increase in p53 and Apoptotic Markers in the Skin of Human Volunteers||Rutgers, The State University of New Jersey|No|Terminated|May 2003|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|August 22, 2005||No|Principal Investigator left institution before study could complete.|No||https://clinicaltrials.gov/show/NCT00134381||196855|
NCT00137501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGY.AN.01|Two Dose Regimens of Nifedipine for the Management of Preterm Labor|Study of Different Doses of Nifedipine to Treat Preterm Labor||American University of Beirut Medical Center|No|Terminated|May 2003|June 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Female|17 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|August 29, 2005|Yes|Yes|The trial was terminated because of difficulties in recruitement.|No||https://clinicaltrials.gov/show/NCT00137501||196617|
NCT00137774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-272|Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors|A Phase II Study of Bevacizumab in Combination With Temozolomide in Patients With Advanced Neuroendocrine Tumors||Dana-Farber Cancer Institute||Completed|November 2004|December 2012|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||April 2013|April 7, 2013|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137774||196596|
NCT00134407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFR 147339/320|Postoperative Oral Intake Trial|Postoperative Enteral Feeding or Early Oral Intake at Will. Effects on Clinical Outcome||University Hospital of North Norway||Completed|February 2001|June 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||450|||Both|18 Years|N/A|No|||September 2011|September 2, 2011|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134407||196853|
NCT00134420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-C07|Growth Hormone and Chromosome 18q- and Abnormal Growth|Growth Hormone Trial for Children With 18q- and Abnormal Growth||The University of Texas Health Science Center at San Antonio||Active, not recruiting|February 2001|June 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Both|N/A|18 Years|Accepts Healthy Volunteers|||July 2007|July 17, 2007|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134420||196852|
NCT00134433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA5163|Endothelial Modulation for Angiogenic Therapy|Endothelial Modulation With L-Arginine in Patients Undergoing Angiogenic Therapy (EMAT): A 2x2 Factorial Trial||Ottawa Heart Institute Research Corporation|Yes|Completed|November 2004|October 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00134433||196851|
NCT00144508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA012JP|Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)|An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA||Chugai Pharmaceutical|No|Completed|March 2003|February 2006|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|306|||Both|20 Years|N/A|No|||January 2009|January 30, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144508||196087|
NCT00134953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BDE05|Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment|Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment||Novartis||Terminated|January 2003|May 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|50 Years|85 Years||||December 2007|December 14, 2007|August 23, 2005|||The Principal Investigator left the clinic and there was no one who could take over this    study.|No||https://clinicaltrials.gov/show/NCT00134953||196812|
NCT00144859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC101614|Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 28-day, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Anti-inflammatory Effect and Steady-state Pharmacokinetics of SB-681323 7.5 mg Per Day in Patients With Chronic Obstructive Pulmonary Disease.||GlaxoSmithKline||Completed|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||82|||Both|40 Years|75 Years|No|||March 2011|May 31, 2012|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144859||196061|
NCT00145210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB310|Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans|A Double-Blind, Randomized, Placebo- and Active-Controlled, Forced Titration Study Evaluating the Effects of Nebivolol on Blood Pressure and Heart Rate in African American Patients With Hypertension||Mylan Bertek Pharmaceuticals||Completed|April 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|630|||Both|18 Years|N/A|No|||September 2005|March 6, 2008|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00145210||196034|
NCT00145275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2407|To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women|To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women||Novartis||Completed|December 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||455|||Female|45 Years|75 Years||||April 2012|April 26, 2012|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00145275||196029|
NCT00145561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 04.02|The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-Infected Pregnant Women.|The Pharmacokinetics of SAquinavir (Invirase New Tablet Formulation) 1,000mg + Ritonavir (Norvir) 100mg q12h in HIV-Infected Pregnant Women (SARA)||Radboud University|No|Completed|August 2005|February 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|40 Years|No|||October 2008|October 21, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145561||196007|
NCT00145574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-410|Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol|Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients With Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins or Treatment Naive to Lipid-lowering Therapy||Daiichi Sankyo Inc.||Completed|November 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|194|||Both|10 Years|17 Years|No|||April 2010|April 8, 2010|September 1, 2005|Yes|Yes||No|November 6, 2009|https://clinicaltrials.gov/show/NCT00145574||196006|
NCT00146094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2860|Bone Mineral Density (BMD) in HIV Infection|Osteopenia and Osteoporosis in HIV Infection. Prospective BMD Measurement in Antiretroviral (ARV) Treated and Untreated HIV-1 Infected Patients||University Hospital, Strasbourg, France||Completed|March 2003|||||N/A|Interventional|Primary Purpose: Basic Science|||||||Both|18 Years|N/A|No|||August 2011|August 29, 2011|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00146094||195968|
NCT00145496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05771|Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)|A Multicenter, Double-Blind, Flexible -Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia.||Merck Sharp & Dohme Corp.|Yes|Completed|December 2004|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|468|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 1, 2005|Yes|Yes||No|March 5, 2010|https://clinicaltrials.gov/show/NCT00145496||196012|
NCT00113139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009150|Investigational Study of Psychological Intervention in Recipients of Lung Transplant (INSPIRE)|An Investigation to Examine a Telephone Based Stress Management and Coping Skills Intervention for Patients Waiting for Lung Transplant|INSPIRE|Duke University|Yes|Completed|September 2000|August 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|389|||Both|18 Years|N/A|No|||March 2014|July 11, 2014|June 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00113139||198456|
NCT00113152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050154|Heart Disease in Sickle Cell Anemia|Are Left Ventricular Abnormalities Associated With Pulmonary Hypertension in Sickle Cell Anemia?||National Institutes of Health Clinical Center (CC)||Completed|June 2005|October 2007||||N/A|Observational|N/A||||120|||Both|18 Years|60 Years|No|||October 2007|March 5, 2008|June 3, 2005||||No||https://clinicaltrials.gov/show/NCT00113152||198455|
NCT00113165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM100034|Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures|A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures||GlaxoSmithKline|No|Completed|October 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|244|||Both|13 Years|N/A|No|||April 2015|April 14, 2015|June 6, 2005||||||https://clinicaltrials.gov/show/NCT00113165||198454|
NCT00113386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0412|Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer|Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Terminated|April 2005|||February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|June 7, 2005||No|This study terminated early due to low accrual.|No|November 27, 2012|https://clinicaltrials.gov/show/NCT00113386||198437|This study terminated early with 19 out of 574 subjects accrued. Therefore no analysis was performed.
NCT00113399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0421|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery|A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone||Radiation Therapy Oncology Group|Yes|Terminated|April 2005|||February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|June 7, 2005||No|Terminated early due to low accrual.|No|November 27, 2012|https://clinicaltrials.gov/show/NCT00113399||198436|This study terminated early with 15 subjects out of 240 subjects accrued, therefore no analysis was performed.
NCT00146588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-036|Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer|A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer||Dana-Farber Cancer Institute||Completed|April 2002|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|18 Years|N/A|No|||October 2014|March 23, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146588||195930|
NCT00137241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI 03-153|Veterans as Leaders in Understanding and Education (VALUE)|Determining the Prevalence of Health Literacy Among Veterans||VA Office of Research and Development|No|Completed|July 2004|November 2005|Actual|||N/A|Observational|N/A||1|Anticipated|1850|||Both|N/A|N/A|No|||October 2006|April 6, 2015|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00137241||196637|
NCT00137540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAT|FLAT Study: First Line Ablation Therapy for Treatment of Paroxysmal Atrial Fibrillation (RAAFT)|First Line Radiofrequency Ablation vs. Antiarrhythmic Drugs for Atrial Fibrillation Treatment||Biosense Webster, Inc.||Completed|September 2005|July 2008|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|70 Years|No|||November 2014|November 3, 2014|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00137540||196614|
NCT00137514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSB-2001-chl-amo|Chloroquine and Amodiaquine for Treatment of Malaria in Children|Chloroquine and Amodiaquine for Treatment of Symptomatic Children With Plasmodium Malaria in Guinea-Bissau||Bandim Health Project||Completed|March 2001|May 2004|Actual|May 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||720|||Both|N/A|15 Years|No|||April 2008|April 6, 2008|August 28, 2005||||No||https://clinicaltrials.gov/show/NCT00137514||196616|
NCT00138268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-236|Pilot Study Freeze and Transport Immune Cells|Pilot Study to Optimize and Standardize Umbilical Cord Blood Collection and the Isolation, Freezing and Transportation of Cells for Studies of Cellular Immune Responses to Immunization||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||February 2005||||N/A|Observational|Time Perspective: Prospective||||12|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|August 26, 2010|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00138268||196559|
NCT00138047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.02.03.25.B1|Safety and Efficacy of Zinc Supplementation in HIV-1-Infected Children in South Africa|Randomized, Double-Blind, Placebo-Controlled Trial of Zinc Supplementation in HIV-1-Infected Children||Johns Hopkins Bloomberg School of Public Health||Completed|March 2003|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|6 Months|60 Months|No|||August 2005|December 2, 2005|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138047||196575|
NCT00138281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-183|Influenza Immunity Against Pandemic Respiratory Virus|Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2006|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2010|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138281||196558|
NCT00143962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801787|Comparison of Two Approaches to Weight Loss Follow-Up Study|Comparison of Two Approaches to Weight Loss Follow-Up Study||University of Pennsylvania||Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2005|December 16, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143962||196129|
NCT00144495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO308JP|A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy|A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy||Chugai Pharmaceutical|No|Completed|February 2004|May 2005|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|20 Years|79 Years|No|||January 2009|January 29, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144495||196088|
NCT00144521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA213JP|Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)|A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA||Chugai Pharmaceutical|No|Completed|February 2004|April 2006|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|20 Years|75 Years|No|||January 2009|January 30, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144521||196086|
NCT00144261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1426|An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects|An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets||Boehringer Ingelheim||Completed|November 2003|||December 2006|Actual|Phase 4|Interventional|Primary Purpose: Prevention|||Actual|15|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144261||196106|
NCT00144872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM100118|LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures|An Open-label Evaluation of LAMICTAL (Lamotrigine) Monotherapy for the Treatment of Newly-diagnosed Typical Absence Seizures in Children and Adolescents||GlaxoSmithKline||Completed|November 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|N/A|12 Years|No|||March 2011|March 17, 2011|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144872||196060|
NCT00144885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040431|IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis|Resonance Magnetic Imaging at the Acute Phase of Endocarditis: Diagnostic and Therapeutic Impact|IMAGE|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|150|||Both|N/A|N/A|No|||September 2005|February 11, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144885||196059|
NCT00145223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-015|Research for Elim of Filariasis|Research for Elimination of Human Filariasis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2003|July 2005||||N/A|Observational|Time Perspective: Prospective|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2007|August 26, 2010|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145223||196033|
NCT00145236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB202|Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension|A Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension.||Mylan Bertek Pharmaceuticals||Completed|November 2001|August 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00145236||196032|
NCT00145808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13215A|Wireless Capsule Endoscopy in Ulcerative Colitis|Prospective Controlled Assessment of Wireless Capsule Endoscopy (WCE) in Ulcerative Colitis (UC)||University of Chicago||Completed|June 2005|November 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00145808||195988|
NCT00146081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704086|Weight Management Skills in African American Outpatients|Weight Management Skills in African American Outpatients|SHARE|University of Pennsylvania||Completed|August 2002|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4|||344|||Both|16 Years|70 Years|No|||March 2008|March 26, 2008|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00146081||195969|
NCT00146380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3677|A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding|A Phase II Open Label Clinical Trial of Maternal Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Maximal Reduction of Mother-to-child HIV Transmission in Resource-limited Settings Among Breastfeeding Populations|KiBS|Centers for Disease Control and Prevention|Yes|Active, not recruiting|July 2003|January 2013|Anticipated|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|520|||Female|15 Years|N/A|No|||September 2012|September 26, 2012|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00146380||195946|
NCT00147251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-285|Stop Atherosclerosis in Native Diabetics Study|Stop Atherosclerosis in Native Diabetics Study||Medstar Research Institute||Completed|May 2003|May 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||548|||Both|40 Years|N/A|Accepts Healthy Volunteers|||September 2005|October 31, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147251||195883|
NCT00112489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000432956|Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer|A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma||Gynecologic Oncology Group|Yes|Completed|May 2005|||July 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|18 Years|N/A|No|||April 2014|April 11, 2014|June 2, 2005|Yes|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT00112489||198498|
NCT00112840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00109|CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|May 2005|September 2015|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2015|October 22, 2015|June 2, 2005|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00112840||198477|
NCT00113178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-AFL-02|Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial Flutter|Clinical Study to Evaluate the Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Cavo-Tricuspid Valve Isthmus-Dependent Atrial Flutter||Boston Scientific Corporation||Completed|January 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|75 Years|No|||February 2011|February 23, 2011|June 6, 2005||||||https://clinicaltrials.gov/show/NCT00113178||198453|
NCT00113412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP01A-105-04|A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study Of Orally Administered SP01A As Monotherapy Treatment Of HIV-Infected Patients||Samaritan Pharmaceuticals, Inc||Active, not recruiting|May 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|18 Years|60 Years|No|||March 2006|March 21, 2006|June 7, 2005||||||https://clinicaltrials.gov/show/NCT00113412||198435|
NCT00113932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2003-41|UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma|UARK 2003-41: A Phase II Study of High-Dose Density Therapy With Tandem Autologous Transplants for Patients With Multiple Myeloma||University of Arkansas|Yes|Completed|December 2003|July 2010|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|June 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00113932||198395|
NCT00146614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-057|Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation|Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation||Dana-Farber Cancer Institute||Completed|July 2002|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||105|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146614||195928|
NCT00147186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100653|The Effectiveness of Hylan GF-20 on Joint Reaction Forces and Kinematic Patterns During Gait in Patients With Knee Osteoarthritis|||Kessler Foundation||Active, not recruiting|January 2000|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|41 Years|N/A|No|||June 2005|January 12, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00147186||195888|
NCT00147199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRX-TRIUMPH 001|Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)|TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension|TRIUMPH|United Therapeutics|No|Completed|June 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|235|||Both|18 Years|75 Years|No|||July 2013|July 11, 2013|September 2, 2005|Yes|Yes||No|December 3, 2012|https://clinicaltrials.gov/show/NCT00147199||195887|
NCT00137553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSB-2001-Fansidar|The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children|The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children With Recrudescent Malaria in Guinea-Bissau||Bandim Health Project|No|Completed|May 2001|March 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|15 Years|No|||March 2010|March 15, 2010|August 28, 2005||||No||https://clinicaltrials.gov/show/NCT00137553||196613|
NCT00137813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-179|Avastin and Taxotere for Esophagogastric Cancer|Phase II Study of Bevacizumab and Docetaxel (AvaTax) in Metastatic Esophagogastric Cancer||Dana-Farber Cancer Institute||Active, not recruiting|August 2004|December 2014|Anticipated|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137813||196593|
NCT00138034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRICOT-3|APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3|A Multicenter Randomized Trial in the Prevention of Reocclusion Following Successful Thrombolysis for Suspected Acute Myocardial Infarction: An Invasive Versus a Conservative Strategy||Heartcenter, University Medical Center St. Radboud|No|Completed|January 2005|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|N/A|N/A|No|||April 2012|April 25, 2012|August 29, 2005||No||No|February 20, 2012|https://clinicaltrials.gov/show/NCT00138034||196576|
NCT00143507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL3-16257-056|The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction|Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-year Randomised Double-blind Placebo-controlled International Multicentre Study.||Servier||Completed|December 2004|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10917|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|August 31, 2005||||No|May 13, 2015|https://clinicaltrials.gov/show/NCT00143507||196163|The section Other Adverse Events (Not including serious) has been completed by the sponsor to include only the Non Serious Adverse Events emergent on treatment during the study.
NCT00143520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0011-203|Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes|A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes||Daiichi Sankyo Inc.||Completed|December 2004|December 2005|Actual|December 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|441|||Both|18 Years|75 Years|No|||April 2011|April 8, 2011|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143520||196162|
NCT00143741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atorvastatin 13815B|Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers|Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers||University of Chicago||Completed|May 2005|July 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||January 2013|January 9, 2013|September 1, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00143741||196145|
NCT00143754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP00-02|Effect of Chronic Oral Hydration in Patients With Recurrent Unexplained Syncope|Benefit of Controlled Rehydration in Unexplained Syncope||University Hospital, Angers||Terminated||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|80 Years|No|||August 2005|August 31, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143754||196144|
NCT00144274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.487|Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis|Efficacy and Tolerability of Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis - A Randomised, Double-blind, Placebo-controlled Parallel Group Study. AMBROSIA: Ambroxol Lozenges In Sore Throat In Adolescents||Boehringer Ingelheim||Completed|April 2005|November 2005||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|12 Years|18 Years|No|||October 2013|October 28, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144274||196105|
NCT00144534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA215JP|Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP||Chugai Pharmaceutical||Completed|June 2004|June 2009|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|20 Years|75 Years|No|||December 2009|December 21, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144534||196085|
NCT00144547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA214JP|Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP||Chugai Pharmaceutical|No|Completed|April 2004|June 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|20 Years|N/A|No|||August 2013|August 6, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144547||196084|
NCT00144898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.312|GF-GS 01: Comparing Conventional Axillary Dissection Versus Sentinel Node Resection in Clinically Node-negative Operable Breast Cancer|A Randomized, Phase III Clinical Trial GF-GS 01 to Compare Conventional Axillary Dissection Versus Sentinel Node Resection (GS) in Clinically Node-negative Operable Breast Cancer Unifocal N0 Patients||Hospices Civils de Lyon|No|Completed|July 2003|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1627|||Female|18 Years|90 Years|No|||July 2013|July 26, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144898||196058|
NCT00144911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO40043|Advair® DISKUS® (Fluticasone Propionate/Salmeterol) Versus Serevent® DISKUS® (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations|See Detailed Description||GlaxoSmithKline|No|Completed|October 2004|||December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||740|||Both|40 Years|N/A|No|||March 2013|March 1, 2013|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00144911||196057|
NCT00146913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.317|AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year|A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate (IM) +-2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year||Hospices Civils de Lyon||Active, not recruiting|March 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|18 Years|90 Years|No|||April 2007|April 26, 2007|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146913||195905|
NCT00146926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.367|Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion|Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion||Hospices Civils de Lyon||Active, not recruiting|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||200|||Both|18 Years|75 Years|No|||April 2007|April 26, 2007|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146926||195904|
NCT00147485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7091001|A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer|A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of AG-024322, An Inhibitor Of Cyclin-Dependent Kinase 1, 2 And 4, Administered Intravenously Daily For 5 Days Every 3 Weeks To Patients With Advanced Cancer||Pfizer||Terminated|December 2004|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||August 2008|August 14, 2008|September 2, 2005|||See Detailed Description|No||https://clinicaltrials.gov/show/NCT00147485||195866|
NCT00146952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNMCA-PR1077|Use of a Vibrotactile Sensory Prosthesis in Patients With Postural Imbalance and Spatial Disorientation|Evaluation of a Vibrotactile Sensory Aid Developed by the US Navy to Combat Pilot Disorientation as a Prosthesis in Patients With Postural Imbalance and Spatial Disorientation||Imperial College London||Recruiting|January 2005|December 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||September 2005|March 17, 2016|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146952||195903|
NCT00112853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03160|Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Trial of Oral Etoposide in Combination With the Farnesyltransferase Inhibitor R115777 (ZARNESTRA, Tipifarnib, NSC #702818, IND #58,359) in Elderly Adults With Newly Diagnosed Acute Myelogenous Leukemia (AML)||National Cancer Institute (NCI)||Completed|March 2005|||May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|70 Years|N/A|No|||January 2013|January 8, 2013|June 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00112853||198476|
NCT00113425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 548|Non-cutting Laser Therapy in the Treatment of Acne|Photodynamic Therapy in the Treatment of Acne Vulgaris||University of Michigan||Completed|August 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|75|||Both|15 Years|N/A|No|||June 2011|June 2, 2011|June 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00113425||198434|
NCT00146835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/088|Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine|Phase IV, Prospective Study of the Safety of GSK Bios' Pediarix Administered to a Cohort of Infants in a US Health Maintenance Organization (HMO). (Post-Marketing PEDIARIX Safety Study)||GlaxoSmithKline||Completed|April 2003|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|120794|||Both|6 Weeks|9 Months|Accepts Healthy Volunteers|Probability Sample|The study will be conducted by the University of California, Los Angeles (UCLA) Center for        Vaccine Research (CVR) and the Southern California Kaiser Permanente Health Care Plan        (SCKP), the largest Health Maintenance Organization (HMO) in California.        All infants who receive at least one dose of PEDIARIX in the primary series will be        identified through the automated Kaiser Immunization Tracking System (KITS).|January 2014|January 9, 2014|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146835||195911|
NCT00146627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-HAT0105; Epicentre-NECT|Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis|Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase||Drugs for Neglected Diseases||Completed||June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|280|||Both|15 Years|70 Years|No|||September 2009|September 18, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146627||195927|
NCT00146848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-100604-H|PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy|Pacing Evaluation - Atrial Support Study in Cardiac Resynchronization Therapy|PEGASUS CRT|Boston Scientific Corporation|Yes|Completed|December 2004|February 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|1742|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|September 2, 2005||No||No|February 28, 2010|https://clinicaltrials.gov/show/NCT00146848||195910|Lack of longer-term follow-up. Single blind design where investigator could be aware of treatment assignment. Two conservative atrial support pacing modes; results should not be extended to substantially more atrial pacing and higher heart rates.
NCT00146861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-062703-B|LIFE Study - Limiting Chronotropic Incompetence for Pacemaker Recipients|Limiting Chronotropic Incompetence for Pacemaker Recipients||Boston Scientific Corporation||Completed|June 2003|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||1500|||Both|18 Years|N/A|No|||November 2006|November 20, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146861||195909|
NCT00147420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 10|RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet|RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet||NICHD Global Network for Women's and Children's Health|Yes|Completed|September 2005|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||848|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 16, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147420||195871|
NCT00147745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-201|Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes|Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|No|Completed|June 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|75 Years|No|||March 2014|March 5, 2014|September 2, 2005|Yes|Yes||No|July 15, 2009|https://clinicaltrials.gov/show/NCT00147745||195847|
NCT00147758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-303|WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents||Daiichi Sankyo Inc.||Completed|June 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|75 Years|No|||January 2012|January 16, 2012|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00147758||195846|
NCT00137800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-308|Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients|A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2003|December 2013|Anticipated|May 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|70 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 5, 2013|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137800||196594|
NCT00143975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG05-04|Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)|Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia||University of Ulm||Completed|June 2004|June 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|60 Years|No|||August 2010|August 11, 2010|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143975||196128|
NCT00143780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0182-C|Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination|Immunogenicity of Pneumococcal Conjugate Vaccine in Adult Allogeneic Bone Marrow Transplant Recipients - Randomized Controlled Trial of Pre-Transplant Donor Immunization||University Health Network, Toronto||Completed|May 2002|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||70|||Both|16 Years|N/A|No|||August 2005|April 15, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143780||196142|
NCT00144235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1232.1|Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue|A 28 Day, Randomised, Double-blind, Placebo-controlled, Single-centre Trial to Evaluate the Efficacy and Safety of Pharmaton® PHL 00749 Film Coated Tablets (G115 40 mg, Multivitamin, Multimineral + Guarana 75 mg) 1/Day p.o. in Improving Mental Performance and to Decrease Fatigue in Healthy Male and Female Subjects in Regular Employment.||Boehringer Ingelheim||Completed|March 2005|July 2005||July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||412|||Both|20 Years|50 Years|No|||October 2013|October 30, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144235||196108|
NCT00144248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1448|A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions|A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic Function||Boehringer Ingelheim||Completed|May 2004|||June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|51|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00144248||196107|
NCT00144287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.68|Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options|An Open Label Safety Study of Tipranavir Co-Administered With Low-Dose Ritonavir (TVP/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options||Boehringer Ingelheim||Completed|May 2004|April 2006||April 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|255|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144287||196104|
NCT00144560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA220JP|Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)|An Open-Label, Clinical Pharmacology Study to Investigate Drug-Drug Interaction in Patients With RA||Chugai Pharmaceutical||Completed|February 2005|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|20 Years|75 Years|No|||December 2008|December 11, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144560||196083|
NCT00144573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA221JP|Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment|An Open-Label, Clinical Pharmacology Study to Evaluate the Safety and PK of MRA in Patients With RA With Renal Impairment||Chugai Pharmaceutical||Completed|January 2005|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|75 Years|No|||December 2008|December 11, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144573||196082|
NCT00144924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03SG45|Open vs Laparoscopic Pyloromyotomy for Pyloric Stenosis|||Institute of Child Health||Recruiting|June 2004|August 2008|Anticipated|August 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|200|||Both|N/A|3 Months|No|||June 2008|June 12, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144924||196056|
NCT00144937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003020|Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease|A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP).||Hospital de Sabadell||Active, not recruiting|March 2003|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||120|||Both|45 Years|80 Years|No|||September 2005|September 1, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144937||196055|
NCT00144950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02AR04|Urokinase Versus Primary Video-Assisted Thorascopic Surgery for Empyema|||Institute of Child Health||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|16 Years|No|||September 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144950||196054|
NCT00146432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISASS-1|Immunoadsorption of LPS, C5a and IL-6 in Severe Sepsis and Septic Shock (ISASS-1)|Prospective, Controlled Pilot Trial: Treatment of Patients in Severe Sepsis and Septic Shock With Immunoadsorption of LPS, IL-6, C5a||Charite University, Berlin, Germany||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years||||August 2009|August 21, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146432||195942|
NCT00146679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0430-1999|Psychoeducational Intervention for ICD Patients (PEACE)|Psychoeducational Intervention for ICD Patients (PEACE)||Emory University|Yes|Completed|March 2001|February 2006|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|246|||Both|21 Years|75 Years|No|||September 2013|September 6, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00146679||195923|
NCT00146978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|903/11/0-HMO-CTIL|Intra-Arterial Catheter Directed Therapy for Severe Graft vs. Host Disease (GVHD)|A Phase 1/2 Study to Evaluate Intra-Arterial Catheter Directed Therapy for Severe Gastro-Intestinal and/or Hepatic Graft vs. Host Disease (GVHD)||Hadassah Medical Organization||Completed|December 2000|August 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||50|||Both|18 Years|70 Years|No|||March 2006|November 6, 2006|September 4, 2005||||No||https://clinicaltrials.gov/show/NCT00146978||195902|
NCT00147004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLK2-CT-2000-00589|Corticosteroid Therapy of Septic Shock - Corticus|Corticosteroid Therapy of Septic Shock - Corticus. A Multi-National, Prospective, Double-Blind, Randomized, Placebo-Controlled Study|Corticus|Hadassah Medical Organization|Yes|Completed|March 2002|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00147004||195901|
NCT00113191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgG-CL-006|Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants|A Phase III, Randomized, Double-blind, Multi-center Clinical Trial Comparing the Safety and Efficacy of Veronate® Versus Placebo for the Prevention of Nosocomial Staphylococcal Sepsis in Premature Infants (Birth Weight 500 - 1250 g)||Bristol-Myers Squibb|Yes|Completed|May 2004|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2000|||Both|N/A|5 Days|No|||July 2012|July 26, 2012|June 6, 2005||||No||https://clinicaltrials.gov/show/NCT00113191||198452|
NCT00113672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182|Make Better Choices Study|Multiple Behavior Change in Diet and Activity|MBC|Northwestern University|Yes|Completed|August 2004|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|204|||Both|21 Years|60 Years|No|||April 2013|April 2, 2013|June 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00113672||198415|
NCT00113685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178|Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury|Effect of Hypertonic Resuscitation for Blunt Trauma||University of Washington||Completed|April 2003|March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||209|||Both|18 Years|N/A|No|||April 2007|February 8, 2016|June 9, 2005||||No||https://clinicaltrials.gov/show/NCT00113685||198414|
NCT00146354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P000551|The Effects of a Results Management System on Physician Awareness of Post-Discharge Test Results|The Effects of a Results Management System on Physician Awareness of Post-Discharge Laboratory and Radiology Results||Brigham and Women's Hospital||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|March 1, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146354||195948|
NCT00147472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-088421|Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial)|A Prospective Cohort Study to Determine the Sensitivity of Positron Emission Tomography (PET) in Detecting Metastatic Cancer in Neck Lymph Nodes in Patients With Squamous Cell Head & Neck Cancer Managed With Primary Radiation Therapy||Ontario Clinical Oncology Group (OCOG)|Yes|Completed|May 2004|May 2011|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|400|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00147472||195867|
NCT00146874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-042704-H|CRT RENEWAL Registry|Cardiac Resynchronization Therapy Registry Evaluating Patient Response With RENEWAL Family Devices||Boston Scientific Corporation||Completed|May 2004|||March 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||1000|||Both|18 Years|N/A|No|Non-Probability Sample|Standard CRT population|November 2006|August 17, 2010|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146874||195908|
NCT00147433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD044111|The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children|Are IQs Low in Offspring of Euthyroid Women With Low T4?||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|February 2004|November 2008||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||5000|||Female|N/A|N/A|No|||September 2005|March 30, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147433||195870|
NCT00147771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007595|Imiquimod in Children With Plaque Morphea|Evaluation of the Efficacy and Safety of the Imiquimod 5% Topical Cream in Plaque Morphea: A Prospective, Multiple Baseline, Open Label Pilot Study||The Hospital for Sick Children|Yes|Completed|September 2005|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Years|18 Years|No|||August 2013|August 1, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00147771||195845|
NCT00147732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098|Randomized Trial of ARCON in Larynx Cancer|A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma.||Radboud University||Completed|April 2001|April 2013|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|345|||Both|19 Years|N/A|No|||May 2015|May 6, 2015|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147732||195848|
NCT00143793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80/05|NT-proBNP and New Biomarkers in Patients With Dyspnea and/or Peripheral Edema|Mannheim NT-proBNP Study (MANPRO) Evaluating NT-proBNP and New Biomarkers in Patients Suffering From Dyspnea and/or Peripheral Edema for the Differential Diagnosis of Congestive Heart Failure|MANPRO|Universitätsmedizin Mannheim|No|Active, not recruiting|June 2005|January 2016|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Peripheral blood samples|Both|18 Years|90 Years|No|Probability Sample|Patients suffering from dyspnea and peripheral edema|May 2015|May 9, 2015|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143793||196141|
NCT00143988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3255|Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers|Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers|SEXERRCISE|Rutgers, The State University of New Jersey|No|Completed|May 2004|March 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|36|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women over the age of 40 who are sexually active|August 2009|August 6, 2009|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00143988||196127|
NCT00144001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-274|Factors Associated With in Suboptimal Prescribing for Older Patients With Epilepsy|Appropriateness of Antiepileptic Drug Use for Older Veterans|TIGER|VA Office of Research and Development|No|Completed|October 2000|September 2008|Actual|September 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|9682|||Both|66 Years|N/A|No|Non-Probability Sample|Older veterans (66 years and older) with a new diagnosis of epilepsy between 2000-2004|September 2008|April 6, 2015|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00144001||196126|
NCT00144599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA316JP|Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)|A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA||Chugai Pharmaceutical|No|Completed|May 2004|October 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|2 Years|19 Years|No|||July 2008|July 29, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144599||196080|
NCT00144963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSLI-06-ALL|Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Phase I-II Study of Liposomal Vincristine (VSLI) and Dexamethasone in Relapsed or Refractory Acute Lymphoblastic Leukemia||Spectrum Pharmaceuticals, Inc|No|Completed|July 2002|August 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|N/A|No|||March 2014|March 27, 2014|September 1, 2005|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00144963||196053|
NCT00144976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 VADS 01|Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma|Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up.||Institut Claudius Regaud|Yes|Completed|October 2003|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|43|||Both|18 Years|N/A|No|||May 2008|March 26, 2015|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144976||196052|
NCT00145288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010|Prospective Study of Patients With Hirsutism|Prospective Study of Patients Med Hirsutism as Primary Work Diagnose||Odense University Hospital|No|Active, not recruiting|October 2003|March 2005||||Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||340|||Female|18 Years|45 Years|No|||March 2007|March 23, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145288||196028|
NCT00145587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPBMT2|Stem Cell Transplantation for Children Affected With Osteopetrosis|Allogeneic Hematopoietic Stem Cell Transplantation for Children Affected With Malignant Osteopetrosis: A Pilot Study||St. Jude Children's Research Hospital|No|Terminated|July 2004|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||January 2011|July 26, 2012|September 1, 2005|No|Yes|Due to the principal investigator having left the institution.|No|June 22, 2011|https://clinicaltrials.gov/show/NCT00145587||196005|This study closed prior to completion of enrollment due to the principal investigator having left the institution.
NCT00138385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-079|Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment|A Randomized Comparison of the Immune Response to Either Inactivated or Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2005|June 2007||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|5 Years|9 Years|Accepts Healthy Volunteers|||November 2007|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138385||196550|
NCT00134563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6049|Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses|TEMSO|Sanofi|Yes|Completed|September 2004|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1088|||Both|18 Years|55 Years|No|||January 2013|January 2, 2013|August 23, 2005|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00134563||196841|
NCT00113438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA4P-212|Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors|A Randomized Open-Labeled Phase II Study of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin to Evaluate the Safety and Efficacy in Subjects With Advanced Imageable Malignancies||OXiGENE|No|Completed|March 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|June 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00113438||198433|
NCT00114062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-103|Study to Treat Uveitis Associated Macular Edema|A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose Ranging Pilot Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Uveitis Associated Macular Edema||Merck Sharp & Dohme Corp.||Terminated|May 2005|||December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|June 13, 2005||||||https://clinicaltrials.gov/show/NCT00114062||198385|
NCT00146367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-0444|Evaluation of the Active Living Every Day Exercise Program for People With Arthritis|Evaluation of the Health Benefits of the Active Living Every Day Physical Activity Program Among Persons With Arthritis||Centers for Disease Control and Prevention||Completed|January 2004|October 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||355|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146367||195947|
NCT00143845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2-61|Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant|Phase II Trial of Adjuvant Cellular Immunotherapy for High-Risk Hematologic Malignancy After Reduced Intensity Allogeneic Stem Cell Transplantation||University of Michigan Cancer Center|Yes|Completed|April 2003|February 2013|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|N/A|N/A|No|||August 2014|August 13, 2014|August 31, 2005|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00143845||196137|
NCT00144053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJTOG0105|A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer|A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer||West Japan Thoracic Oncology Group||Completed|April 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|20 Years|74 Years|No|||August 2005|January 5, 2006|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00144053||196122|
NCT00147823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB # 5130|Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions|A Prospective Randomized Study Comparing Vitoss Alone Versus Vitoss With Bone Marrow Aspirate in Benign Bone Lesions||State University of New York - Upstate Medical University|Yes|Completed|December 2004|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|N/A|N/A|No|||December 2013|June 4, 2015|September 1, 2005||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00147823||195841|Limitation due to incomplete follow up by subjects or unavailability of radiographs. Also difficulties in assessing the outcomes of resorption if lesions were small or there was artifact from hardware in the area.
NCT00143585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-065|NOGA Angiogenesis Revascularization Therapy: Evaluation by RadioNuclide Imaging - The Northern Trial|Multicentre, Randomized,Double Blind,Placebo Controlled Trial of Myocardial Angiogenesis Using VEGF165, Intramyocardial Gene Delivery in Patients With Severe Angina||St. Michael's Hospital, Toronto||Active, not recruiting|June 2002|June 2007|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|75 Years|No|||July 2008|July 24, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143585||196157|
NCT00147212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-061|ET 743 (Yondelis) in Men With Advanced Prostate Cancer|A Phase II Study of Three Hour, Weekly Infusion of ET 743 (Yondelis) in Men With Advanced Prostate Cancer||Massachusetts General Hospital|No|Completed|June 2002|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|18 Years|N/A|No|||December 2012|December 11, 2012|September 2, 2005|Yes|Yes||No|March 16, 2012|https://clinicaltrials.gov/show/NCT00147212||195886|
NCT00147446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMS|Stress Management for Patients With Multiple Sclerosis|Phase II Study of the Effects of Stress Management on Neuroimaging, Clinical, Immune and Psychosocial Outcomes||Northwestern University|Yes|Completed|May 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|September 2, 2005||No||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00147446||195869|we caution that it is premature to make specific clinical recommendations regarding the use of SMT-MS to manage MS disease-related activity. Future work should identify, refine, and optimize the active ingredients in this behavioral intervention.
NCT00143767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 05/036|Magnetic Resonance Imaging of Brain Development in Attention Deficit Hyperactivity Disorder|Magnetic Resonance Imaging of Brain Development in Attention Deficit Hyperactivity Disorder||UMC Utrecht||Recruiting|August 2005|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||400|||Both|6 Years|20 Years|Accepts Healthy Volunteers|||March 2007|March 18, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143767||196143|
NCT00143533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTCEF|Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors|Phase I Study of Intravenous Irinotecan Using Selective Gastrointestinal Decontamination for Prevention of Diarrhea in Relapsed or Refractory Pediatric Solid Tumors||St. Jude Children's Research Hospital|No|Completed|September 2003|June 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|20 Years|No|||September 2011|September 29, 2011|September 1, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00143533||196161|
NCT00143546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETIDE|Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver|Compassionate Use of Defibrotide for Patients With Veno-Occlusive Disease||St. Jude Children's Research Hospital||No longer available|November 2003|||||Phase 2|Expanded Access|N/A|||||||Both|N/A|N/A|No|||June 2011|November 23, 2011|September 1, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00143546||196160|
NCT00144027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-257|Patient-Centered Medication Adherence Intervention for Schizophrenia|Patient-Centered Medication Adherence Intervention for Schizophrenia|AMAIS|VA Office of Research and Development|No|Completed|December 2004|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|75|||Both|18 Years|70 Years|No|||July 2014|April 6, 2015|September 1, 2005||No||No|October 28, 2014|https://clinicaltrials.gov/show/NCT00144027||196124|
NCT00144300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.538|Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients|A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients||Boehringer Ingelheim||Completed|January 2005|||September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|246|||Both|30 Years|N/A|No|||February 2014|February 17, 2014|September 2, 2005|Yes|Yes||No|September 16, 2011|https://clinicaltrials.gov/show/NCT00144300||196103|
NCT00144014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V10153-2S-01|Safety and Efficacy Study in Acute Ischaemic Stroke|A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.|VASST|Vernalis (R&D) Ltd|Yes|Completed|August 2005|March 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|49|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00144014||196125|
NCT00146107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG025501-01|Weight Loss and Exercise in Obese, Physically Limited, Older Women and Men|Weight Loss and Exercise in Frail Obese Elderly Subjects||Washington University School of Medicine|Yes|Completed|January 2005|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|107|||Both|65 Years|85 Years|No|||April 2013|April 22, 2013|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00146107||195967|
NCT00146406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4347|Multi-level Interventions for STD Prevention Among Adolescents|Integrated Multi-level Interventions to Improve Adolescent Health Through the Prevention of STD, Including HIV, and Teen Pregnancy||Centers for Disease Control and Prevention||Terminated|January 2005|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|36502|||Both|11 Years|20 Years|Accepts Healthy Volunteers|||September 2012|September 10, 2012|September 2, 2005||No|IRB terminated due to no continuation request.|No||https://clinicaltrials.gov/show/NCT00146406||195944|
NCT00146419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3979|Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)|Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)||Centers for Disease Control and Prevention|No|Completed|March 2004|June 2013|Actual|August 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|699|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected persons receiving care at HIV-specialty clinics|September 2012|July 28, 2015|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00146419||195943|
NCT00146653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286-2005|Heparin Management During Cardiopulmonary Bypass in Children|A Comparison of Heparin Management Strategies in Children Undergoing Cardiopulmonary Bypass.||Emory University|No|Completed|December 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|Samples With DNA|Blood is being collected to obtain Xa results.|Both|N/A|6 Months|No|Non-Probability Sample|Patients will be obtained from the patient's of Children's Healthcare of Atlanta at        Egleston. These patients will be obtained from the pre-operative clinc, the Cardiac        Intensive Care Unit or the Cardiac Stepdown unit.|November 2013|November 19, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00146653||195925|
NCT00146666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05US01|Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)|Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)||FlowMedic||Recruiting|September 2005|September 2006|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Both|40 Years|N/A|No|||August 2009|December 16, 2009|September 3, 2005||||No||https://clinicaltrials.gov/show/NCT00146666||195924|
NCT00134849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP #S-04-151|Hypertension in Management of Military Medicine|Hypertension in Management of Military Medicine||United States Naval Medical Center, San Diego|No|Terminated|September 2005|March 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|1000|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|August 24, 2005|||Inadequate number of records screened; primary investigator left institution.|No||https://clinicaltrials.gov/show/NCT00134849||196819|
NCT00135135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB2005|Therapy for Children With Neuroblastoma|Neuroblastoma Protocol 2005: Therapy for Children With Advanced Stage High-Risk Neuroblastoma||St. Jude Children's Research Hospital|Yes|Completed|August 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|18 Years|No|||June 2008|June 2, 2008|August 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135135||196798|
NCT00135148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/341|Decrease of Libido of Post-Operative Male-Female Transsexuals and a Healthy Female Control Group|Decrease of Libido of Post-Operative Male-Female Transsexuals and a Healthy Female Control Group||University Hospital, Ghent|No|Completed|April 2004|August 2005|Actual|||N/A|Observational|N/A||||150|||Female|18 Years|N/A|No|||December 2007|December 19, 2007|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135148||196797|
NCT00135369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI455-135|Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen|A Phase 3 Study Switching HIV-1 Infected Subjects With an Undetectable Viral Load From a HAART Regimen Dosed Twice Daily or More Frequently to a Once-Daily HAART Regimen||Bristol-Myers Squibb||Completed|September 2002|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00135369||196780|
NCT00113698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185|Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation|Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD|AceiMR|University of Utah|Yes|Terminated|December 2004|January 2006|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|N/A|18 Years|No|||March 2014|March 11, 2014|June 9, 2005|Yes|Yes|lower than expected enrollment|No||https://clinicaltrials.gov/show/NCT00113698||198413|
NCT00113711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184|Promoting Smoking Cessation and Reducing Weight Gain|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 1995|August 1999|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|N/A|100 Years|No|||June 2005|February 22, 2016|June 9, 2005||||No||https://clinicaltrials.gov/show/NCT00113711||198412|
NCT00113737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183|Fluoxetine as a Quit Smoking AID for Depression Prone|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 1998|January 2002|Actual|||N/A|Interventional|Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|100 Years|No|||June 2005|February 17, 2016|June 9, 2005||||No||https://clinicaltrials.gov/show/NCT00113737||198410|
NCT00147238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0003|A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast|A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast||M.D. Anderson Cancer Center|No|Terminated|July 2005|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|N/A|N/A|No|||July 2012|July 31, 2012|September 6, 2005|Yes|Yes|Terminated at request of sponsor.|No|April 24, 2009|https://clinicaltrials.gov/show/NCT00147238||195884|
NCT00135616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xd01|Treatment of Female Stress Urinary Incontinence: Study Comparing Two Suburethral Slings, Retropubic Approach (TVT) and Trans-Obturator (TVT-O) Approach|Randomized Controlled Study Comparing Two Types of Suburethral Slings for the Surgical Treatment of Female Stress Incontinence : TVT and TVT-O.||Hopital Antoine Beclere||Active, not recruiting|March 2005|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|180|||Female|18 Years|95 Years|No|||April 2007|April 27, 2007|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135616||196761|
NCT00135811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63490 (completed)|Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)|Focal Segmental Glomerulosclerosis Clinical Trial||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|November 2004|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|207|||Both|2 Years|40 Years|No|||May 2012|May 21, 2012|August 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00135811||196746|
NCT00144066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJTOG0203|A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer|A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer||West Japan Thoracic Oncology Group||Completed|January 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|20 Years|74 Years|No|||September 2005|September 1, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00144066||196121|
NCT00135824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCF355ADE01|Local Tolerability and Safety of Povidone K25 Eye Drops (Artificial Tears Containing Povidone) Versus Placebo in Healthy Volunteers|Local Tolerability and Safety of Povidone K25 (Artificial Tears Containing Povidone) vs. Placebo in Healthy Volunteers||Novartis||Completed|March 2004|May 2004|Actual|May 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 16, 2011|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00135824||196745|
NCT00147225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0099|AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin|Phase I/II Study of AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin||M.D. Anderson Cancer Center|No|Completed|August 2005|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|55|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|September 6, 2005|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00147225||195885|
NCT00147459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931205|Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation|Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation||National Taiwan University Hospital||Recruiting|September 2005|December 2012|Anticipated|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|31|||Both|N/A|N/A|No|||December 2012|December 4, 2012|September 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00147459||195868|
NCT00147797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-01|Influence of Pravastatin on Carotid Artery Structure and Function in HIV-Infected Patients Under Antiretroviral Therapy|Influence of Pravastatin on Carotid Artery Structure and Function in HIV-Infected Patients Under Antiretroviral Therapy||Saint Antoine University Hospital||Completed|May 2003|June 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||84|||Both|30 Years|N/A|No|||April 2007|April 18, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147797||195843|
NCT00147810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASHEW 200-95-0953-48|Adult Asthma Surveillance and Intervention in a Managed Care Setting|Adult Asthma Surveillance and Intervention in a Managed Care Setting||Kaiser Permanente||Completed|November 2001|July 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||6948|||Both|18 Years|N/A||||September 2005|March 23, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147810||195842|
NCT00147784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF-70332|HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.|HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a Methadone Maintenance Treated (MMT) Opioid Addicted Group.||Sorlandet Hospital HF||Completed|March 2006|January 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|25 Years|50 Years|No|||March 2008|March 26, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147784||195844|
NCT00143559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPREF|Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies|Haploidentical Hematopoietic Stem Cell Transplantation Utilizing Partial T-Cell Depletion as Immunotherapy for Hematologic Malignancies||St. Jude Children's Research Hospital|Yes|Completed|August 2005|January 2009|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|2 Years|21 Years|No|||January 2009|January 28, 2009|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143559||196159|
NCT00145301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2369|52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine|A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in Patients With Primary Osteoarthritis of Hip, Knee, Hand or Spine||Novartis||Completed|September 2004|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||3036|||Both|40 Years|N/A||||May 2012|May 18, 2012|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00145301||196027|
NCT00145314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nordic VII|FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer|5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.||The Nordic Colorectal Cancer Biomodulation Group||Completed|May 2005|August 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|571|||Both|18 Years|74 Years|No|||January 2011|January 13, 2011|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145314||196026|
NCT00144313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4127|VaxTeen Hepatitis B Vaccine Booster Study|Persistence of Antibody and Response to Booster of a Recombinant Hepatitis B Vaccine in Children Who Responded to a Primary Course of 2.5µg Recombinant Hepatitis B Vaccine as Infants||Centers for Disease Control and Prevention||Completed|August 2005|January 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|60|||Both|13 Years|16 Years|Accepts Healthy Volunteers|||September 2007|September 20, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144313||196102|
NCT00144586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA222JP|Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA220JP or MRA221JP||Chugai Pharmaceutical||Completed|March 2005|June 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|75 Years|No|||August 2013|August 6, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144586||196081|
NCT00145860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11589A|Do Patients With Colorectal Cancer Understand That Their Family is at Risk?|Do Patients With Colorectal Cancer Understand That Their Family is at Increased Risk?||University of Chicago||Terminated|April 2002|August 2005||||N/A|Observational|Time Perspective: Prospective||||650|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145860||195985|
NCT00146120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLHD98A|Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result|Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result||University of Ulm||Completed|May 1998|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|16 Years|60 Years|No|||December 2008|February 5, 2009|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00146120||195966|
NCT00146133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KO7AG2116401|Weight Loss and Exercise in Physically Limited Obese Elderly Subjects|Effect of Weight Loss and Physical Training on Musculoskeletal Status, Physical Function, and Quality-of-Life in Physically Limited, Obese, Elderly Subjects||Washington University School of Medicine||Completed|January 2003|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||28|||Both|65 Years|85 Years|No|||September 2005|May 2, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00146133||195965|
NCT00134602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3660|Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children|An Intervention to Promote Adherence to Antiretroviral Medications Among HIV-infected Children 5-12 Years of Age||Centers for Disease Control and Prevention|No|Completed|April 2003|October 2008|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|5 Years|12 Years|No|||September 2012|September 26, 2012|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00134602||196838|
NCT00134615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0080/07/04|Testing the Right Question Project (RQP) Health Education Strategy in a Mental Health Setting|Testing the Right Question Project Health Education Strategy in a Mental Health Setting|RQP|Cambridge Health Alliance|No|Completed|August 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|231|||Both|18 Years|65 Years|No|||October 2010|October 8, 2010|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00134615||196837|
NCT00134875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-3|Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers|Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers||National Institute on Drug Abuse (NIDA)||Terminated|December 2000|December 2009|Anticipated|December 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 27, 2008|August 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134875||196818|
NCT00113464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050162|Developing Newborn Screening for Infants With Primary Immunodeficiency|Developing Newborn Screening for Infants With Primary Immunodeficiency||National Institutes of Health Clinical Center (CC)||Completed|June 2005|April 2007||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||April 2007|September 26, 2015|June 7, 2005||||No||https://clinicaltrials.gov/show/NCT00113464||198431|
NCT00113724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI 287-01|Study of TPI 287 in Patients With Advanced Malignancies|A Phase I, Open-Label, Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies||Cortice Biosciences, Inc.|No|Completed|May 2005|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|June 9, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00113724||198411|
NCT00113750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TreeMATAMPL201|Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen|A Multicenter, Single-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Induction of Immunogenicity With Different Doses of Tree MATA in Subjects Allergic to Tree Pollen||Allergy Therapeutics||Completed|July 2005|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Both|18 Years|50 Years|No|||June 2010|June 16, 2010|June 10, 2005||||||https://clinicaltrials.gov/show/NCT00113750||198409|
NCT00143598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-63142|The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome|The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome After Symptomatic Proximal Deep Venous Thrombosis||Sir Mortimer B. Davis - Jewish General Hospital|Yes|Completed|June 2004|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|806|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|September 1, 2005||No||No|June 3, 2014|https://clinicaltrials.gov/show/NCT00143598||196156|While 14% withdrew or were lost to follow-up (F/U), the total rate of withdrawal, loss to F/U and death was less than what was projected. Adherence to study stockings tended to diminish over F/U; this occurred to a similar degree in both groups.
NCT00135629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHRG-UpDosing|Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever|Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever: A Pilot Study. (Up-dosing Study)||Imperial College London||Active, not recruiting|October 2002|February 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Both|18 Years|65 Years|No|||November 2010|November 22, 2010|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135629||196760|
NCT00135837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952B2401|Photodynamic Therapy in Occult-Only Lesions (POOL)|An Open-Label, Multicenter, Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration||Novartis||Completed|June 2003|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||202|||Both|50 Years|N/A|No|||June 2006|June 20, 2006|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135837||196744|
NCT00135642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHRG-CLUSTER|Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and Asthma|Randomized Double Blind Placebo Controlled Trial of Grass Pollen Immunotherapy Using a Cluster Regime||Imperial College London||Completed|February 1996|October 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||44|||Both|18 Years|60 Years|No|||August 2005|February 11, 2016|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135642||196759|
NCT00143832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03.0465C|Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning|Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning||UMC Utrecht||Recruiting|September 2004|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||90|||Male|8 Years|20 Years|Accepts Healthy Volunteers|||March 2007|March 18, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143832||196138|
NCT00144040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA 03-239|Improving Antibiotic Use in Acute Care Treatment|Improving Antibiotic Use in Acute Care Setting|IMPAACT|VA Office of Research and Development|No|Completed|February 2004|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|1000|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00144040||196123|
NCT00143572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUMG1|Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease|Phase I Study of Combination Treatment With Hydroxyurea and Magnesium Pidolate in Patients With Sickle Cell Disease||St. Jude Children's Research Hospital|Yes|Completed|November 2004|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|3 Years|15 Years|No|||February 2010|February 23, 2010|September 1, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00143572||196158|
NCT00143806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4513|Transitioning From Cyclosporine to Alefacept in Psoriasis|Investigator-Initiated, Use Study of Alefacept (Amevive) in Combination With Tapering Doses of Cyclosporine in Patients With Moderate to Severe Psoriasis||Rutgers, The State University of New Jersey|No|Completed|October 2003|May 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||13|||Both|18 Years|80 Years|No|||December 2008|December 31, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143806||196140|
NCT00143819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5494|Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis|Double-Blind, Bilateral, Vehicle-Controlled, Randomized Trial of Neuroskin Forte to Relieve Symptoms of Dry Skin||Rutgers, The State University of New Jersey|No|Completed|September 2005|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143819||196139|
NCT00145340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032|Pioglitazone Treatment in Polycystic Ovary Syndrome|The Effect of PPARgamma Stimulation on Glucose Metabolism, Insulin Resistance, Growth Hormone and Cortisol on Women Suffering From Polycystic Ovary Syndrome||Odense University Hospital|Yes|Completed|September 2002|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Female|18 Years|45 Years|No|||September 2008|September 25, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145340||196024|
NCT00137098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDEC Caffeine|Coronary Care Caffeine: Influence of Coffee on Heart Rate Post Myocardial Infarction|Influence of Coffee on Heart Rate Variability Post Myocardial Infarction||The Royal Bournemouth Hospital|Yes|Completed|September 2003|January 2006|Actual|||Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|80 Years|No|Probability Sample|Patients of either gender, over 18 and under 80 years of age, admitted to the Coronary        Care Unit following myocardial infarction.|October 2009|October 2, 2009|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137098||196648|
NCT00145834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-2002-653|Early Breastfeeding Cessation - is It Possible to Prevent?|A Randomised Community Based Experimental Trial in the Health Visitor's Practice Field||University of Aarhus||Completed|February 2004|April 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1456|||Both|N/A|N/A||||September 2005|September 1, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145834||195987|
NCT00145847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB # 4800|Naltrexone Treatment of Alcohol Abuse in Schizophrenia|Naltrexone Treatment of Alcohol Abuse in Schizophrenia||State University of New York - Upstate Medical University|Yes|Completed|April 2003|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|69 Years|No|||January 2013|January 7, 2013|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00145847||195986|
NCT00145600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOD99|Therapy for Pediatric Hodgkin Lymphoma|Risk-Adapted Therapy for Pediatric Hodgkin's Disease||St. Jude Children's Research Hospital|Yes|Active, not recruiting|March 2000|October 2021|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|296|||Both|N/A|21 Years|No|||July 2015|July 16, 2015|September 2, 2005|Yes|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT00145600||196004|
NCT00145613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REFSCT|Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies|Haploidentical Stem Cell Transplantation Utilizing T-Cell Depletion as Therapy for Patients With Refractory Hematological Malignancies||St. Jude Children's Research Hospital|No|Completed|June 2003|February 2009|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|2 Years|21 Years|No|||February 2009|February 12, 2009|September 1, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00145613||196003|
NCT00137930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104480|Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis|Compare the Immunogenicity, Reactogenicity & Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV||GlaxoSmithKline||Completed|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||250|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137930||196584|
NCT00138164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIGAND-PIND-123|Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Multicenter Study of Ontak® (Denileukin Diftitox) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|December 2004|November 2008|Actual|February 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2008|May 29, 2013|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138164||196566|
NCT00134576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DP000116|Automated Assessment of Mental Health in the Workplace|Automated Assessment of Mental Health in the Workplace||Boston Medical Center|No|Completed|May 2007|January 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||May 2010|June 1, 2010|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134576||196840|
NCT00135174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVZ/VAZ 01236|Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study|Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The FOLLOWPACE Study||UMC Utrecht|Yes|Active, not recruiting|September 2003|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1526|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring a PM for conventional reasons.|June 2008|June 12, 2008|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00135174||196795|
NCT00135421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN148-007|Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder||Bristol-Myers Squibb|No|Completed|November 2005|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|271|||Female|18 Years|65 Years|No|||September 2008|February 27, 2010|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135421||196776|
NCT00135434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-130|Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism|Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism||Bristol-Myers Squibb||Completed|September 2004|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2009|April 7, 2011|August 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00135434||196775|
NCT00135447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-128|A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen|A Phase IV, Multicenter, Cross-sectional Study to Evaluate the I50L Substitution Among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)||Bristol-Myers Squibb|No|Completed|September 2004|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|5000|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|HIV infected patients failing HAART regimen|April 2011|April 13, 2011|August 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00135447||196774|
NCT00113477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12004 - versjon 2|The Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy|A Single-Centre, Randomised Double-Blind Placebo-Controlled Study to Measure the Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy||Oslo University Hospital||Completed|May 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|75 Years|No|||September 2008|June 30, 2011|June 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00113477||198430|
NCT00113490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP118|A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children|A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), After Dosing for a Second Season in Children Who Previously Received MEDI-524 in Protocol MI-CP104||MedImmune LLC|No|Completed|May 2005|February 2006|Actual|February 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|136|||Both|N/A|24 Months|No|||April 2013|April 3, 2013|June 8, 2005|Yes|Yes||No|April 3, 2013|https://clinicaltrials.gov/show/NCT00113490||198429|
NCT00143611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-242-011|Efficacy & Safety of Resatorvid in Adults With Severe Sepsis|A Pivotal, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety of TAK-242 in Adults With Severe Sepsis||Takeda|Yes|Completed|September 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|277|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143611||196155|
NCT00136136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/139|Validation of Bispectral Index (BIS)-Monitor in 3 Groups of Newborn Children|Validation of BIS-monitor in 3 Groups of Newborn Children||University Hospital, Ghent|No|Recruiting|August 2003|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Newborn children|December 2014|December 4, 2014|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136136||196721|
NCT00136149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/439|Study on Immediate Placement to Evaluate Astra Tech Osseospeed Implants in an Immediate Loading Protocol in Extraction Sockets and Healed Ridges|An Open, Prospective, Controlled Study on Immediate Placement to Evaluate Clinical Outcome of Astra Tech Implants, Fixture Microthread Osseospeed in an Immediate Loading Protocol in Extraction Sockets and Healed Ridges||University Hospital, Ghent|No|Active, not recruiting|January 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136149||196720|
NCT00136409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-214|A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)|A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia||Dana-Farber Cancer Institute||Completed|May 2002|December 2008|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136409||196701|
NCT00121667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-014|Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone|"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone"||AstraZeneca||Completed|August 2005|February 2010|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1462|||Both|18 Years|77 Years|No|||March 2015|April 8, 2015|July 18, 2005|Yes|Yes||No|March 15, 2011|https://clinicaltrials.gov/show/NCT00121667||197814|
NCT00121680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-102|A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma|A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma||Eisai Inc.|No|Completed|July 2005|May 2015|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||November 2015|December 9, 2015|July 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00121680||197813|
NCT00121927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-02-27-08|Use of the Atkins Diet for Adults With Intractable Epilepsy|Use of the Atkins Diet for Adults With Intractable Epilepsy||Johns Hopkins University||Completed|June 2004|June 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||February 2007|January 26, 2010|July 15, 2005||||No||https://clinicaltrials.gov/show/NCT00121927||197794|
NCT00122213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000T205|A Physical Activity and Diet Program to Prevent Accumulation of Abdominal Fat Mass in Recently Retired Men and Women|An Individual-based Diet and Physical Activity Intervention Program to Prevent Accumulation of Abdominal Fat Mass in Recently Retired Men and Women||Wageningen University||Completed|September 2003|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|55 Years|65 Years|Accepts Healthy Volunteers|||April 2010|April 20, 2010|July 15, 2005||||No||https://clinicaltrials.gov/show/NCT00122213||197773|
NCT00122499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232.476/2003/180|A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer|A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer||Erasmus Medical Center||Completed|February 2003|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||July 2005|July 26, 2005|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122499||197751|
NCT00122512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9876|Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV|Phase 2a Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV – An Extended Safety Evaluation||FHI 360||Terminated||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2006|February 9, 2006|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122512||197750|
NCT00122954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT002155-01|Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis|Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis||Oregon Health and Science University|Yes|Completed|July 2005|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|85 Years|No|||February 2015|February 27, 2015|July 20, 2005|No|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00122954||197716|
NCT00123240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBR-0512|High Carbohydrate vs. High Fat Diets in the Treatment of Obesity (JBR 0512)|High Carbohydrate vs. High Fat Diets in the Treatment of Obesity (JBR 0512)||Rockefeller University|Yes|Completed|July 2004|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00123240||197695|
NCT00123539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237|Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery|Estradiol for Neurocognitive Dysfunction After CABG||National Heart, Lung, and Blood Institute (NHLBI)||Terminated|June 2001|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||334|||Female|55 Years|N/A|No|||December 2007|December 17, 2007|July 21, 2005|No|Yes|DSMB stopped the study based on conclusion of likely futility of treatment on the primary    outcome.|No||https://clinicaltrials.gov/show/NCT00123539||197672|
NCT00123552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-068|Longitudinal Antimalarial Combinations in Uganda|Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy||University of California, San Francisco||Completed|November 2004|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|690|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|July 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00123552||197671|
NCT00123760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-11-0035/DX-FDG-001/21221|Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer|A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer||AHS Cancer Control Alberta|No|Completed|February 2004|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10838|||Both|15 Years|N/A|No|||March 2012|February 24, 2016|July 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00123760||197656|
NCT00124046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70276|Treatment of Persistent Urinary Incontinence in Children|Treatment of Persistent Urinary Incontinence in Children||University of British Columbia|No|Active, not recruiting|September 2005|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|18 Years|No|||April 2015|April 1, 2015|July 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00124046||197634|
NCT00124059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706689|Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.|A Double-Blind Study of Quetiapine Fumarate (Seroquel) for the Treatment of Type A vs.Type B Alcoholics.||University of Pennsylvania|No|Completed|March 2003|October 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|61|||Both|18 Years|65 Years|No|||September 2013|October 2, 2015|July 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00124059||197633|
NCT00136240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063937|Automated Telephone System to Improve Treatment Adherence in People With Depression|Telecom System to Improve Adherence to Antidepressants||Boston Medical Center||Completed|April 2003|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label||||144|||Both|18 Years|N/A|No|||August 2008|July 24, 2013|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136240||196714|
NCT00136253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK51472|Overcoming Nutritional Barriers in Hemodialysis Patients|||Case Western Reserve University||Completed|February 2002|October 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||October 2004|December 12, 2005|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136253||196713|
NCT00136487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-193|Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer|A Randomized, Double Blind, Placebo-Controlled Trial of Celecoxib Versus Placebo in Men With Prostate Cancer With Rising PSA Following Prostatectomy or Radiation Therapy||Dana-Farber Cancer Institute||Completed|October 2002|September 2006|Actual|September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||85|||Male|18 Years|N/A|No|||December 2009|December 7, 2009|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00136487||196695|
NCT00124306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICCRN (IND)|Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)|A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients|IC01|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2005|December 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 28, 2013|July 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00124306||197614|
NCT00124319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR050461|Risk Factors for Anterior Cruciate Ligament (ACL) Injury|Epidemiology of Jump-Landing Movements and ACL Injury||University of North Carolina, Chapel Hill||Completed|June 2005|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4800|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Incoming cadets at the U.S. Naval, Air Force, or Military Academies|May 2009|October 3, 2011|July 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00124319||197613|
NCT00124904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DK57048a (completed)|Biofeedback for Fecal Incontinence|Biofeedback for Fecal Incontinence and Constipation||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 1999|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||165|||Both|16 Years|N/A|No|||January 2010|January 12, 2010|July 27, 2005||||No||https://clinicaltrials.gov/show/NCT00124904||197571|
NCT00124644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000437105|Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Study of R115777 (Zarnestra) in Combination With Induction Chemotherapy in Patients With Newly Diagnosed, High Risk Acute Myeloid Leukemia||National Cancer Institute (NCI)||Terminated|March 2006|January 2008|Actual|December 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment||||30|||Both|18 Years|59 Years|No|||January 2008|May 1, 2013|July 26, 2005|||Withdrawn due to "toxicity" problems|No||https://clinicaltrials.gov/show/NCT00124644||197590|
NCT00124917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050191|Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer|A Phase I Study of Image Guided Dose Escalation With Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|July 2005|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|90 Years|No|||June 2015|June 26, 2015|July 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00124917||197570|
NCT00124930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18731|Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer|A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer||AHS Cancer Control Alberta||Terminated|May 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|July 27, 2005|||Study suspended due to low enrollment|No||https://clinicaltrials.gov/show/NCT00124930||197569|
NCT00121953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-1012|Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis|Endometriosis: Immunomodulation||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|July 2005|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|0|||Female|18 Years|45 Years|No|||October 2012|October 16, 2012|July 18, 2005|Yes|Yes|Due to the recent meta-analysis about CV adverse effects.|No||https://clinicaltrials.gov/show/NCT00121953||197792|
NCT00121693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-01-03|The Use of Music Therapy in the Prevention of Falls|Posturographic Changes Associated With Music Therapy and Fall Prevention||Carrick Institute for Graduate Studies|No|Completed|December 2003|October 2006|Actual|September 2006|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|266|||Both|17 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00121693||197812|
NCT00121940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HS014580-01A1|Guided Care: Integrating High Tech and High Touch|Guided Care: Integrating High Tech and High Touch||Johns Hopkins Bloomberg School of Public Health|No|Completed|February 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|904|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 18, 2012|July 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00121940||197793|
NCT00122226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 02-72|MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)|MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)||VU University Medical Center||Active, not recruiting|January 2003|July 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||50|||Male|18 Years|70 Years|No|||July 2005|April 24, 2006|July 14, 2005||||No||https://clinicaltrials.gov/show/NCT00122226||197772|
NCT00123019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230|Work, Weight, and Wellness Program: The 3W Program|Overweight and Obesity Control in Worksites||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6100|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123019||197712|
NCT00123032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228|School- and Home-Based Program to Prevent Obesity in American Indian Children|Bright Start: Obesity Prevention in American Indian Children||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|January 2005|December 2011|Anticipated|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|5 Years|7 Years|No|||April 2011|April 18, 2011|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123032||197711|
NCT00123279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-001|Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy|A Dose-escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy||ThromboGenics|Yes|Completed|December 2004|November 2008|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|80 Years|No|||April 2014|April 4, 2014|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123279||197692|
NCT00122733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMR2|Loxapine and Weaning From Ventilator|Facilitation of Weaning From Ventilator by Loxapine||Assistance Publique - Hôpitaux de Paris|No|Completed|December 2005|December 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2007|July 20, 2007|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122733||197733|
NCT00122980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWiTCH|Stroke With Transfusions Changing to Hydroxyurea|Stroke With Transfusions Changing to Hydroxyurea||St. Jude Children's Research Hospital|Yes|Terminated|October 2006|December 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|134|||Both|5 Years|18 Years|No|||August 2012|January 14, 2013|July 20, 2005|Yes|Yes|The study has been stopped due to safety and futility concerns.|No|December 28, 2011|https://clinicaltrials.gov/show/NCT00122980||197715|The trial was stopped early due to a projected futility of the liver iron component of the primary endpoint in conjunction with the significantly higher number of strokes in the Hydroxyurea/Phlebotomy arm as compared to the Transfusion/Chelation arm.
NCT00122993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222|Worksite Program to Prevent Weight Gain Among Bus Drivers|Worksite Environmental Interventions for Weight Control||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2004|April 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|18 Years|70 Years|No|||January 2015|January 23, 2015|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00122993||197714|
NCT00123773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-14-0038/DX-FDG-003/21386|Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence|A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence||AHS Cancer Control Alberta|No|Completed|April 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1075|||Both|15 Years|N/A|No|||March 2012|February 24, 2016|July 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00123773||197655|
NCT00124085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-5001-057|Asthma in a Decentralized Patient Population: Is Traditional Disease Management Enough?|Asthma in a Decentralized Patient Population: Is Traditional Disease Management Enough? A Randomized, Controlled Trial Comparing Traditional Care to Two Systems of Disease Management for a Decentralized Population of Patients in South Texas||The University of Texas Health Science Center at San Antonio||Completed|October 2003|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||1053|||Both|5 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|July 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00124085||197631|
NCT00124098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030112|An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)|An Open-Label Study of Aranesp® (Darbepoetin Alfa) Administration Once Every Four Weeks in Anaemic Chronic Kidney Disease (CKD) Subjects||Amgen||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2008|June 13, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00124098||197630|
NCT00124072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSUSEARCH1|Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine|SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine|SEARCH|University of Oxford|Yes|Completed|July 1998|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|12064|||Both|18 Years|80 Years|No|||January 2012|January 31, 2012|July 22, 2005||||No|March 29, 2010|https://clinicaltrials.gov/show/NCT00124072||197632|
NCT00136266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-MM-0835-O5/05|Adherence With Iron Sprinkles Among High-Risk Infants|Adherence With Iron Sprinkles Among High-Risk Infants||Centers for Disease Control and Prevention|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|128|||Both|5 Months|7 Months|Accepts Healthy Volunteers|||September 2007|February 2, 2016|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136266||196712|
NCT00136279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-3486|Linking Lives: Building Quality Parent Components for School-Based Health Programs in Middle Schools|RCT of Tobacco Use Prevention and Sexual Risk Reduction Interventions for Parents of African American and Latino Youth in Middle School||Centers for Disease Control and Prevention|No|Completed|January 2004|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|9510|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2009|January 30, 2009|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136279||196711|
NCT00136500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FALS feasibility|Clinical Research in ALS Study|Clinical Research in ALS|CRiALS|University of Miami|No|Recruiting|February 2005|||September 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|DNA, blood, urine, CSF, skin biopsies|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The CRiALS research program aims to recruit three types of participants:          -  Individuals affected with ALS or a related neurodegenerative disease          -  Unaffected individuals from pedigrees in which the genetic cause of ALS is known          -  Healthy controls|October 2015|October 22, 2015|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136500||196694|
NCT00124943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVR003|Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis|A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis|SNAPIST-III|Celgene|No|Completed|July 2005|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|112|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|July 27, 2005|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00124943||197568|
NCT00124956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-04-050|Doxorubicin Pharmacokinetic (PK) Study|Impact of Body Composition on Pharmacokinetics of Doxorubicin in Pediatric Patients||Children's Hospital Boston||Terminated|June 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||9|||Both|1 Year|21 Years|No|||January 2006|January 17, 2006|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00124956||197567|
NCT00124657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHG04|Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma|A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma||St. Jude Children's Research Hospital|Yes|Completed|March 2005|September 2014|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|3 Years|21 Years|No|||October 2015|October 29, 2015|July 26, 2005|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00124657||197589|
NCT00121459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6070-22217-03|Effectiveness of the Diaphragm for HIV Prevention|The Latex Diaphragm to Prevent HIV Acquisition Among Women: A Female-Controlled, Physical Barrier of the Cervix||University of California, San Francisco||Withdrawn|September 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|July 12, 2005|||PI left and no data or information is available.|No||https://clinicaltrials.gov/show/NCT00121459||197829|
NCT00121732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7974-A001-101|An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies|A Phase 1, Two-Arm, Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies||Eisai Inc.||Completed|July 2005|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|July 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00121732||197809|
NCT00121173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0323 CDR0000439494|Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia|A Phase I/II Clinical Trial of pNGVL4a-Sig/E7 (Detox)/HSP70 for the Treatment of Patients With HPV 16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|November 2003|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|70|||Female|18 Years|N/A|No|||June 2013|June 10, 2013|July 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00121173||197850|
NCT00121186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000435930|S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma|Nonmyeloablative Allogeneic Stem Cell Transplantation For Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation ( A BMT Study)||Southwest Oncology Group|No|Terminated|July 2005|December 2011|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|July 19, 2005||No|poor accrual|No|March 5, 2012|https://clinicaltrials.gov/show/NCT00121186||197849|
NCT00121472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC010230-1|Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation|The HeartMate II LVAS Pivotal Study Protocol, Bridge to Cardiac Transplantation||Thoratec Corporation|Yes|Completed|March 2005|May 2010|Actual|November 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|194|||Both|N/A|N/A|No|||March 2013|March 18, 2013|July 12, 2005|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00121472||197828|
NCT00121706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30DK040561|Fast Food Feeding in Youth|Fast Food Feeding in Youth||Children's Hospital Boston||Completed|July 2005|September 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention||||18|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||January 2006|February 3, 2006|July 15, 2005||||No||https://clinicaltrials.gov/show/NCT00121706||197811|
NCT00121719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-E044-101|An Open Label Phase I Dose Escalation Study Of E7080|An Open Label Phase I Dose Escalation Study Of E7080||Eisai Inc.||Active, not recruiting|July 2005|||June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||December 2015|January 21, 2016|July 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00121719||197810|
NCT00122525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1265|Effect of Male Circumcision on HIV Incidence (ANRS 1265)|Effect of Safe Male Circumcision on Incidence of Infection by HIV, HSV-2 and of Genital Ulceration||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Terminated|July 2002|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3274|||Male|18 Years|24 Years|Accepts Healthy Volunteers|||April 2009|April 29, 2009|July 19, 2005|||following DSMB recommandation.|No||https://clinicaltrials.gov/show/NCT00122525||197749|
NCT00122746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33022|Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients|Doctoral CRP on Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients||International Atomic Energy Agency|Yes|Recruiting|December 2004|||June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|322|||Female|18 Years|N/A|No|||October 2011|October 12, 2011|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00122746||197732|
NCT00123006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229|Effectiveness of the DASH Diet at Reducing High Blood Pressure|Cardiovascular and Renal Hemodynamics and the DASH Diet||Brigham and Women's Hospital|Yes|Completed|January 2006|October 2014|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Both|20 Years|80 Years|No|||January 2016|January 12, 2016|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123006||197713|
NCT00123045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232|Patient-Physician Partnership to Improve High Blood Pressure Adherence|Patient-Physician Partnership to Improve High Blood Pressure Adherence||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2001|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|279|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123045||197710|
NCT00123058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005845|Comparison of Two Programs to Improve Blood Pressure Treatment Adherence|Take Control of Your Blood Pressure (TCYB)||Duke University|Yes|Completed|June 2003|June 2007|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|777|||Both|18 Years|90 Years|No|||September 2014|September 5, 2014|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00123058||197709|
NCT00123292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-M-002|Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion|An Open-label, Ascending-dose, Clinical Trial of Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion||ThromboGenics|Yes|Terminated|March 2005|November 2009|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|19|||Both|18 Years|80 Years|No|||April 2014|April 4, 2014|July 21, 2005||No|Sponsor's decision not to pursue development of uPLi for vascular conditions|No||https://clinicaltrials.gov/show/NCT00123292||197691|
NCT00123565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5228|Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction|A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE)|SHINE|Sanofi||Completed|December 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1257|||Both|21 Years|N/A|No|||August 2008|August 20, 2008|July 22, 2005||||No||https://clinicaltrials.gov/show/NCT00123565||197670|
NCT00123786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-12-0009/DX-FDG-005/21933|Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma|A Phase II Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma||AHS Cancer Control Alberta|No|Terminated|August 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|15 Years|N/A|No|||March 2012|February 24, 2016|July 22, 2005||No|Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT00123786||197654|
NCT00124111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030156|A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer|A Single-arm Study Evaluating the Relative Dose Intensity of IV CMF Given on Day 1 and Day 8 With Pegfilgrastim Support in Subjects With Stage I-III Breast Cancer||Amgen||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||||||Both|18 Years|N/A|No|||February 2010|February 25, 2010|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00124111||197629|
NCT00124124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 02-10|Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine|A Randomized, Controlled Trial of Melanoma Treatment: Comparison of Dendritic Cells Versus Montanide as Adjuvants to Stimulate Anti-tumor Immunity||Bhardwaj, Nina, M.D.|Yes|Completed|July 2005|April 2009|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|July 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00124124||197628|
NCT00124384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538a/6029/IN/US|The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia|Phase 4 Study of the Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia||University of Rochester|Yes|Completed|January 2005|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|July 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00124384||197608|
NCT00124397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000084|Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)|Effect of High Dose Statin Therapy on Endothelial Function in Patients With Type 2 Diabetes Mellitus Without CAD||University of Southern Denmark||Completed|July 2001|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||186|||Both|N/A|N/A|No|||July 2005|August 4, 2005|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00124397||197607|
NCT00136513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|743921/001|SB-743921 In Patients With Solid Tumors|A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB743921 on a Once Every 3 Week Schedule in Patients With Solid Tumors||GlaxoSmithKline||Completed|April 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136513||196693|
NCT00136734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3236-NIDA-011755-1|Methylphenidate Treatment for Cocaine Abuse and ADHD - 1|Methylphenidate Treatment for Cocaine Abuse and ADHD||New York State Psychiatric Institute|Yes|Completed|April 1998|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136734||196676|
NCT00125216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3719-R|Evaluation of the Effects of Response Elaboration Training for Aphasia|Evaluation of the Effects of Response Elaboration Training for Aphasia||VA Office of Research and Development|No|Completed|December 2004|December 2012|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 4, 2014|July 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00125216||197547|
NCT00125203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND 11090|Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis||The University of Texas Health Science Center at San Antonio|Yes|Completed|July 2003|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|21 Years|85 Years|No|||March 2012|March 13, 2012|July 27, 2005||||No||https://clinicaltrials.gov/show/NCT00125203||197548|
NCT00125229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-1503-266|Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients|Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients||The University of Texas Health Science Center at San Antonio||Terminated|August 2005|June 2006|Actual|June 2006|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with severe TBI (motor Glasgow Coma Scale [GCS] score < 5)          -  Age > 18 years          -  Health care provider indicated a treatment of intracranial hypertension using             hyperosmotic agent|June 2012|June 22, 2012|July 27, 2005||No|Dr. Hladky died Sept 2006 prior to study completion|No||https://clinicaltrials.gov/show/NCT00125229||197546|
NCT00121745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC044C|Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer|Phase I Evaluation of Safety of Intravenous Infusion of a Pathotropic Vector Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) as Intervention for Locally Advanced and Metastatic Pancreatic Cancer Refractory to Standard Chemotherapy||Epeius Biotechnologies|Yes|Terminated|July 2005|July 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||December 2007|December 15, 2007|July 15, 2005|Yes|Yes|poor enrollment|No||https://clinicaltrials.gov/show/NCT00121745||197808|
NCT00122239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-14-0043 / ethics 21725|A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers|A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers||AHS Cancer Control Alberta|Yes|Active, not recruiting|January 2005|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|13|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be selected consecutively if they have undergone a course of radical        radiotherapy.|March 2016|March 14, 2016|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00122239||197771|
NCT00122538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12103 BURKINAME|Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)|HAART Regimen Comprising 3TC + ddI + EFV in Once-daily Administration in HIV-1 Infected Children in Burkina Faso||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|February 2006|May 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|30 Months|15 Years|No|||December 2011|December 2, 2011|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00122538||197748|
NCT00122759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMR3|Ketamine Sedation in Mechanically Ventilated Patients|Prospective Study on the Cost-Effectiveness of Adding Ketamine to Midazolam-Sufentanil Sedation Regimen in Mechanically Ventilated Patients||Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2005|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2007|July 20, 2007|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122759||197731|
NCT00122551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 106 Window|Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)|A Prospective, Randomized, Multicenter Trial of Intermittent Therapy in HIV-Infected Patients With Successful Viral Suppression Under HAART (ANRS 106 Window Trial)||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|December 2001|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||July 2005|July 28, 2005|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122551||197747|
NCT00123305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-M-004|Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke|A Multicentre, Double-Blind, Placebo-Controlled, Ascending-dose, Clinical Trial of Intravenous Microplasmin Administration in Patients With Acute Ischemic Stroke||ThromboGenics|Yes|Completed|October 2005|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|85 Years|No|||November 2014|November 6, 2014|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123305||197690|
NCT00123578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14291-1|GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1|GHB: Effects, Withdrawal and Treatment||National Institute on Drug Abuse (NIDA)|Yes|Terminated|August 2004|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|55 Years|No|||November 2008|November 19, 2008|July 22, 2005||No|Unable to recruit adaquate number of GHB dependent subjects|No||https://clinicaltrials.gov/show/NCT00123578||197669|
NCT00120692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020152|Treatment for Patients Suffering From Anemia Due to Chemotherapy|An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy||Amgen||Completed|October 2002|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2007|December 20, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120692||197886|
NCT00120965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9613-B 01|AutoPulse Assisted Prehospital International Resuscitation Trial (ASPIRE)|AutoPulse Assisted Prehospital International Resuscitation Trial (ASPIRE)||University of Washington|Yes|Terminated|June 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1837|||Both|18 Years|N/A|No|||January 2011|January 26, 2011|June 30, 2005|||DSMB recommended termination due to lower survival to discharge in primary population and    worse discharge CPC scores in the treatment arm than control arm.|No||https://clinicaltrials.gov/show/NCT00120965||197865|
NCT00124410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-15-0001|Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation|A Pilot Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation||AHS Cancer Control Alberta||Completed|January 2000|||December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Male|N/A|N/A|No|Non-Probability Sample|primary care center|December 2011|February 24, 2016|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124410||197606|
NCT00124735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05797|A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)|An Open-label, Randomized, Phase IIIB, Multicenter Trial to Evaluate the Pharmacodynamic Parameters of Intubation Bolus, and Bolus and Infusion Maintenance Doses of Zemuron® in Pediatric and Adolescent Subjects||Merck Sharp & Dohme Corp.|No|Completed|October 2004|September 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|N/A|17 Years|No|||February 2015|February 13, 2015|July 26, 2005|Yes|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00124735||197584|
NCT00146341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.472|Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg|An Eight Week Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg to Telmisartan 80mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80mg.||Boehringer Ingelheim||Completed|April 2005|September 2006||September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|345|||Both|18 Years|80 Years|No|||November 2013|November 18, 2013|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146341||195949|
NCT00121199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03062|Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma|Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL||National Cancer Institute (NCI)||Completed|June 2005|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||December 2012|May 6, 2014|July 19, 2005|Yes|Yes||No|October 30, 2012|https://clinicaltrials.gov/show/NCT00121199||197848|
NCT00121485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC010230-2|Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy|The HeartMate II LVAS Pivotal Study Protocol, Destination Therapy||Thoratec Corporation|Yes|Completed|February 2005|January 2012|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|July 12, 2005|Yes|Yes||No|November 13, 2012|https://clinicaltrials.gov/show/NCT00121485||197827|
NCT00121212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000434994|Positron Emission Tomography in Prostate Cancer|Positron Emission Tomography in Prostate Cancer||Washington University School of Medicine|No|Completed|July 2003|October 2015|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|179|||Male|N/A|N/A|No|||October 2015|October 28, 2015|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00121212||197847|
NCT00121758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-000233-10|AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers|Randomised Double Blinded Phase II AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptide (LIPO-5) Versus Placebo in Non Infected HIV Volunteers (ANRS VAC 18)||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|September 2004|December 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|156|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||June 2008|June 5, 2008|July 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00121758||197807|
NCT00121771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG28|Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men|A Phase 1 Trial of the Malaria Candidate Vaccines FP9 CS and MVA CS in Adult Gambian Men Aged 18 - 45 Years||Gates Malaria Partnership||Completed|January 2004|July 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2005|August 3, 2005|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00121771||197806|
NCT00122252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-6-0045|Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) Contouring in Prostate Cancer to Improve the Possibilities for Intensity Modulated RadioTherapy (IMRT) Dose Escalation|Biological Imaging for Optimising CTV and GTV Contouring in Prostate Cancer to Improve the Possibilities for IMRT Dose Escalation||AHS Cancer Control Alberta||Terminated|May 2004|February 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||20|||Male|N/A|N/A|No|Non-Probability Sample|primary care clinic|December 2011|December 8, 2011|July 20, 2005|||Study abandoned.|No||https://clinicaltrials.gov/show/NCT00122252||197770|
NCT00122265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-6-0035/ethics 17075|Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer|Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal RT for Prostate Cancer||AHS Cancer Control Alberta|Yes|Terminated|April 2003|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|83|||Male|N/A|N/A|No|Non-Probability Sample|community sample|April 2012|February 24, 2016|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00122265||197769|
NCT00122278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC: 05-02-032S or CCI: 05-030|Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines|Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches||Montefiore Medical Center||Completed|July 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||February 2008|February 15, 2008|July 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00122278||197768|
NCT00119886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bosex|Botox on Vulvar Vestibulitis|||Rigshospitalet, Denmark||Recruiting|April 2005|June 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||April 2007|April 18, 2007|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119886||197948|
NCT00120146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-09-132R|Metformin Obesity Study|A Multi-Center, Randomized, Placebo Controlled, Double- Blind Trial of Metformin in Obese Adolescents||Children's Hospital Boston||Active, not recruiting|October 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||22|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||January 2006|January 17, 2006|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00120146||197928|
NCT00123318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 03.02|A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer|A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|February 2003|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00123318||197689|
NCT00120445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE470116|Comparison of Air and Expansile Gas in Pneumatic Retinopexy|Comparison of Air and Expansile Gas in Pneumatic Retinopexy||Khon Kaen University|Yes|Completed|July 2004|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|126|||Both|N/A|N/A|No|||March 2012|March 7, 2012|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00120445||197905|
NCT00120679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020165|Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy|An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patient With Non-Small Cell Lung Cancer Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy||Amgen||Completed|October 2002|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|December 20, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120679||197887|
NCT00120458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002289-01A1|Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety|Black Cohosh Therapy for Menopause-Related Anxiety||University of Pennsylvania|Yes|Completed|July 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||March 2010|March 1, 2010|July 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00120458||197904|
NCT00120705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020167|Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy|A Randomized, Open-Label, Pilot Study to Evaluate Every Three Week Maintenance Dosing of Darbepoetin Alfa Therapy in Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy||Amgen||Completed|November 2002|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||204|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120705||197885|
NCT00120718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-000890|The Effect of Fasudil on Vascular Function in Humans|The Effect of Fasudil on Vascular Function in Humans||Brigham and Women's Hospital|Yes|Completed|June 2002|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 26, 2008|July 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120718||197884|
NCT00136292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-PEDS-05-01|Study of Single Dose Daptomycin in Pediatric Patients With Gram-Positive Infection for Which They Are Receiving Standard Antibiotics|An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-Positive Infection||Cubist Pharmaceuticals LLC||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label||||24|||Both|2 Years|17 Years|No|||January 2007|January 16, 2007|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136292||196710|
NCT00146042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9901|UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer|Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer||University of Michigan Cancer Center|Yes|Completed|March 1999|March 2005|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||October 2012|October 3, 2012|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146042||195972|
NCT00146315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCAP-G03/170-200311075|ESCAP: Supervised Exercise for Patients With Coronary Heart Disease in the Primary Care Setting|Effectiveness of the Supervised Exercise for Patients With Coronary Heart Disease in the Primary Care Setting (ESCAP): a Randomized Clinical Trial||Basque Health Service|No|Completed|January 2005|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|20 Years|79 Years|No|||May 2011|May 31, 2011|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00146315||195951|
NCT00146328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.17|Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects|A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects||Boehringer Ingelheim||Completed|April 2001|||May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|997|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|September 5, 2005|Yes|Yes||No|May 26, 2009|https://clinicaltrials.gov/show/NCT00146328||195950|
NCT00124696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13586-1|Cocaethylene as a Treatment for Cocaine Dependence - 1|Cocaethylene Substitution Therapy and Tolerance Induction in Treating Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|December 2002|March 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||8|||Both|18 Years|55 Years|No|||August 2005|November 18, 2005|July 22, 2005||||||https://clinicaltrials.gov/show/NCT00124696||197587|
NCT00124982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-064|Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy|A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options||Bristol-Myers Squibb||Completed|April 2005|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1286|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|June 30, 2005|Yes|Yes||No|February 18, 2011|https://clinicaltrials.gov/show/NCT00124982||197565|
NCT00121225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00099|Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma|A Phase II Study of Vorinostat in Patients With Advanced Melanoma||National Cancer Institute (NCI)|Yes|Completed|September 2005|June 2013|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2013|October 1, 2014|July 19, 2005|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00121225||197846|
NCT00121498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1571CTIL|Preemptive Analgesia for Abdominal Hysterectomy|Preemptive Analgesia for Post Abdominal Hysterectomy Pain Management||Rambam Health Care Campus||Completed|November 2002|September 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||32|||Female|35 Years|58 Years|No|||December 2004|September 12, 2005|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121498||197826|
NCT00121784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT18328|Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients|A Randomized, Open-Label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients||Hoffmann-La Roche||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2007|April 19, 2007|July 15, 2005||||||https://clinicaltrials.gov/show/NCT00121784||197805|
NCT00118300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9804|Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer|Phase I Study of Capecitabine (Xeloda) and Radiation Therapy in Patients With Locally Advanced Cervical and Pelvic Malignancies||Case Comprehensive Cancer Center|Yes|Withdrawn|April 2005|||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||July 2011|July 7, 2011|July 8, 2005||No|Competing studies|No||https://clinicaltrials.gov/show/NCT00118300||198062|
NCT00118313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11490|Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma|Evaluation of Different Adjuvants for the Transdermal Administration of a Peptide-Based Vaccine in Participants With High-Risk Melanoma||University of Virginia|Yes|Completed|November 2004|||November 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||December 2014|December 18, 2014|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118313||198061|
NCT00118794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC975|Lapdap and Coartemether for Uncomplicated Malaria|Randomized Trial of the Safety and Effectiveness of Lapdap and Coartemether for Uncomplicated Malaria in Operational Settings||London School of Hygiene and Tropical Medicine||Completed|September 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1200|||Both|6 Months|10 Years|No|||January 2005|January 31, 2006|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118794||198025|
NCT00119028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNT 03-215|Expanding and Testing VA Collaborative Care Models for Depression|Expanding and Testing VA Collaborative Care Models for Depression|ReTIDES|VA Office of Research and Development|No|Withdrawn|April 2005|October 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|0|||Both|N/A|N/A|No|||April 2012|April 23, 2012|July 1, 2005||No|This study was withdrawn prior to enrollment.|No||https://clinicaltrials.gov/show/NCT00119028||198007|
NCT00121966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus|South Danish Diabetes Study: A Prospective Randomised Multi-Centre Study for the Evaluation of the Optimal Pharmacological Antidiabetic Treatment of Type 2 Diabetes Mellitus|SDDS|Odense University Hospital||Completed|January 2003|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|30 Years|70 Years|No|||June 2008|June 18, 2008|July 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00121966||197791|
NCT00121979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-PSI-RCV-04-201|Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects|Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir for 3TC in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART Regimen Containing Lamivudine||Pharmasset||Completed|September 2004|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||July 2005|July 2, 2007|July 18, 2005||||||https://clinicaltrials.gov/show/NCT00121979||197790|
NCT00119574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI 99-383|Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)|Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)||VA Office of Research and Development|No|Completed|January 2002|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|443|||Both|18 Years|N/A|No|||July 2005|April 6, 2015|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00119574||197970|
NCT00119587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010219|Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects|A Double-Blind, Randomized, Comparative Study of Darbepoetin Alfa Given Once Weekly or Once Every Other Week for Treatment of Anemia in Hemodialysis Subjects||Amgen||Completed|August 2002|September 2003||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|December 20, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00119587||197969|
NCT00119340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1939.00|Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia|Fludarabine and Low-Dose TBI Dose Escalation to Determine the Optimal Regimen for Achieving High Rates Engraftment of Unrelated Donor Peripheral Blood Stem Cell in Patients With Chronic Myeloid Leukemia - A Multi-Center Trial||Fred Hutchinson Cancer Research Center||Completed|April 2005|November 2007|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|75|||Both|N/A|N/A|No|||September 2010|September 20, 2010|July 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00119340||197987|
NCT00119613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010145|A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa|A Randomized, Double Blind, Placebo-Controlled Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa||Amgen||Completed|December 2002|April 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||August 2008|August 7, 2008|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00119613||197967|
NCT00120159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X03-12-080|Necrotizing Enterocolitis (NEC) Surgical Database|GPRN Neonatal Surgical Database: Necrotizing Enterocolitis (NEC) Protocol||Children's Hospital Boston||Active, not recruiting|December 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|300|||Both|N/A|2 Years|No|||January 2006|January 14, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120159||197927|
NCT00120172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOC-GI-010|Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer|A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Elderly Patients With Metastatic Colorectal Cancer||Geriatric Oncology Consortium||Terminated|May 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|65 Years|N/A|No|||November 2007|November 15, 2007|July 8, 2005|||positive results from a larger study with same regimen was released.|No||https://clinicaltrials.gov/show/NCT00120172||197926|
NCT00116831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD100521|Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes|A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)||GlaxoSmithKline|Yes|Completed|January 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|672|||Both|30 Years|80 Years|No|||July 2012|February 7, 2013|June 30, 2005|No|Yes||No|August 7, 2009|https://clinicaltrials.gov/show/NCT00116831||198173|
NCT00116844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLX103596|VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of VALTREX 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects With No Previous History of Symptomatic Genital Herpes Infection.||GlaxoSmithKline|No|Completed|March 2005|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 17, 2011|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116844||198172|
NCT00121030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020166|Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy|An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patients With Gynecological Malignancies Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy||Amgen||Completed|October 2002|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||December 2007|December 20, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00121030||197860|
NCT00117169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-EP4|Multi-Detector Spiral Computed Tomography Alone Versus Combined Strategy With Lower Limb Compression Ultrasonography in Outpatients Suspected of Pulmonary Embolism|Multi-Detector Spiral Computed Tomography Alone Versus Combined Strategy With Lower Limb Compression Ultrasonography in Outpatients Suspected of Pulmonary Embolism: A Randomised Non-Inferiority Trial [CTEP4]||University Hospital, Geneva||Completed|January 2005|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||1500|||Both|18 Years|N/A|No|||October 2012|October 12, 2012|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117169||198147|
NCT00117182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-COPD-201|Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD|A Phase II Study to Investigate Mannitol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD||Pharmaxis||Completed|July 2005|August 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||140|||Both|45 Years|80 Years|No|||August 2008|August 27, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117182||198146|
NCT00146016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRA-study|Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients|Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients||UMC Utrecht||Completed|February 2000|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||390|||Both|18 Years|N/A|No|||September 2005|September 1, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00146016||195974|
NCT00146055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9970|Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood|Low-Intensity Preparative Regimen and Allogeneic Peripheral Blood Stem Cell Transplantation From Unrelated Donor in Patients With Hematologic Malignancy||University of Michigan Cancer Center||Completed|March 2000|October 2007|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||August 2012|August 7, 2012|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146055||195971|
NCT00146068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-NEUR-387|EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis|Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period||University of North Carolina, Chapel Hill||Completed|September 2004|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|No|||February 2008|February 28, 2008|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146068||195970|
NCT00146601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-075|Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer|A Phase II Study of Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer||Dana-Farber Cancer Institute||Completed|June 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Female|18 Years|N/A|No|||December 2007|December 20, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146601||195929|
NCT00125242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3826-R|Word-Retrieval Treatment for Aphasia: Semantic Feature Analysis|Word-Retrieval for Aphasia: Facilitation of Generalization||VA Office of Research and Development|No|Completed|July 2005|April 2013|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|July 27, 2005||No||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00125242||197545|
NCT00121238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03066|Cilengitide in Treating Patients With Prostate Cancer|Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Patients With Non-Metastatic Androgen Independent Prostate Cancer||National Cancer Institute (NCI)||Completed|January 2005|||November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Male|18 Years|N/A|No|||January 2013|January 30, 2013|July 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00121238||197845|
NCT00121251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00108|Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer|A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 2005|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2015|December 4, 2015|July 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00121251||197844|
NCT00118326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1802.00|Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease|Feasibility of Granulocyte-Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow From Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant||Fred Hutchinson Cancer Research Center||Completed|August 2003|May 2007|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|N/A|18 Years|No|||May 2010|May 12, 2010|July 8, 2005||||No||https://clinicaltrials.gov/show/NCT00118326||198060|
NCT00119054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 03-312|Effectiveness of Home-Based Health Messaging for Patients With Hypertension and Diabetes|Effectiveness of Care Coordination in Managing Medically Complex Patients||VA Office of Research and Development|No|Completed|September 2005|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|302|||Both|N/A|N/A|No|||January 2008|April 6, 2015|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00119054||198005|
NCT00118807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC940|Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children|Randomized Trial of the Effectiveness of Amodiaquine-Artesunate, Amodiaquine-Sulfadoxine-Pyrimethamine, and Chloroquine-Sulfadoxine-Pyrimethamine, for Treatment of Uncomplicated Malaria in Gambian Children||London School of Hygiene and Tropical Medicine||Completed|August 2003|February 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1800|||Both|6 Months|10 Years|No|||June 2003|January 6, 2006|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118807||198024|
NCT00118820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P000048/11|Antibiotic Efficacy in Third Molar Surgery|Antibiotic Efficacy in Third Molar Surgery||Massachusetts General Hospital||Completed|March 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|132|||Both|13 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 14, 2010|July 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00118820||198023|
NCT00119314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000433512|Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin|Carcinoma Unknown Primary: Treatment With Gemcitabine, Docetaxel and Capecitabine (GTX) an Evaluation and Treatment Study of The Cancer Institute of New Jersey Oncology Group||Rutgers, The State University of New Jersey|Yes|Withdrawn|July 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2011|May 22, 2015|July 12, 2005|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00119314||197988|
NCT00119561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-287|Testing the Effectiveness of Telephone Support for Dementia Caregivers|Testing the Effectiveness of Telephone Support for Dementia Caregivers|CONNECT|VA Office of Research and Development|No|Completed|February 2005|January 2014|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|21 Years|N/A|No|||July 2014|April 6, 2015|July 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00119561||197971|
NCT00119600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030205|A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy|A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy||Amgen||Terminated||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||May 2009|May 7, 2009|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119600||197968|
NCT00120471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 057|Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies|A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and Their Infants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2006|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|122|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|July 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00120471||197903|
NCT00119899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLEM (ZonMW DO 945-11017)|Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases|Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases||Radboud University||Completed|March 2002|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||150|||Both|18 Years|75 Years|No|||August 2005|August 30, 2005|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119899||197947|
NCT00121004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13787A|A Study to Tailor Advance Directives|A Study to Tailor Advance Directives||University of Chicago|No|Completed|July 2005|September 2005|Actual|September 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hospitalized patients admitted to the general medical service at the University of Chicago|September 2013|September 4, 2013|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00121004||197862|
NCT00121017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-731|A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects|A Randomized, Open-Label Study Assessing Safety, Tolerability and Efficacy of an Induction-Maintenance Treatment Strategy Including Lopinavir/Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine Versus Efavirenz Plus Tenofovir Disoproxil Fumarate and Emtricitabine in Antiviral-naïve HIV-1/HCV Co-Infected Subjects||Abbott||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||July 2006|July 26, 2006|July 14, 2005||||||https://clinicaltrials.gov/show/NCT00121017||197861|
NCT00116857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186|Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors|Omega-3 for Depression and Other Cardiac Risk Factors||Washington University School of Medicine|Yes|Completed|February 2005|November 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|June 30, 2005|No|Yes||No|July 3, 2012|https://clinicaltrials.gov/show/NCT00116857||198171|
NCT00117559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F3332-P|Improving Quality of Life for Veterans Undergoing Interferon Treatment|Improving Quality of Life for Veterans Undergoing Interferon Treatment||VA Office of Research and Development|No|Completed|July 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|June 30, 2005||No||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00117559||198117|Small sample size, all male, no in-person comparison group, reporting bias in self-report measures.
NCT00146029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 3-27|Companion Pharmacogenetic Study to UMCC 9900/9901|||University of Michigan Cancer Center||Terminated||||||N/A|Observational|Time Perspective: Retrospective|||||||Female|18 Years|N/A|No|||March 2008|March 24, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00146029||195973|
NCT00145769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 01.04|A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum|A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum||Trans-Tasman Radiation Oncology Group (TROG)|Yes|Completed|July 2001|May 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|326|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145769||195991|
NCT00146887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-03.09.04-HMO-CTIL|Comparison of Coronary CT Angiography to Invasive Coronary Angiography|A Trial Comparing the Sensitivity and Specificity of Coronary Angiography With Coronary CT Angiography||Hadassah Medical Organization||Recruiting|January 2005|August 2005|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|40|||Both|18 Years|N/A|No|||August 2005|November 6, 2006|September 4, 2005||||No||https://clinicaltrials.gov/show/NCT00146887||195907|
NCT00146900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-27.06.03-HMO-CTIL|Prevention of Post Traumatic Stress Disorder by Early Treatment|Prevention of Post Traumatic Stress Disorder by Early Treatment||Hadassah Medical Organization|No|Completed|August 2004|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|298|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|September 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00146900||195906|
NCT00117520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-1987|The Effect of Caffeine in Elderly Citizens|The Effect of Caffeine as Endurance Enhancing Drug in the Elderly||Herning Hospital||Completed|July 2002|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|70 Years|N/A|Accepts Healthy Volunteers|||July 2002|July 3, 2006|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117520||198120|
NCT00117533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930904|Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta|A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta||National Taiwan University Hospital||Recruiting|September 2005|June 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2005|May 24, 2006|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117533||198119|
NCT00125255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-46-05|S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children|A Randomized, Double-blind, Placebo Controlled, Parallel Study Evaluating the Efficacy of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) for Induction of Local Dermal Anesthesia Before Vascular Access Procedures in Children||ZARS Pharma Inc.|No|Completed|June 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|5 Years|17 Years|No|||June 2012|June 4, 2012|July 27, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00125255||197544|
NCT00118040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00453|Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer|Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer||National Cancer Institute (NCI)||Completed|June 2005|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 23, 2016|July 8, 2005|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT00118040||198080|
NCT00118053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040412;CDR0000433511|Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer|A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or Inflammatory Breast Cancer||Rutgers, The State University of New Jersey|No|Terminated|April 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||September 2013|September 17, 2013|July 8, 2005|Yes|Yes|slow accrual|No|September 17, 2013|https://clinicaltrials.gov/show/NCT00118053||198079|
NCT00118560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3644P|Exercise Training for Patients With Poor Leg Circulation|Perfusion and Metabolism During Exercise in Peripheral Arterial Disease||VA Office of Research and Development||Completed|June 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 16, 2011|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00118560||198042|
NCT00118833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT000583-01|St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)|Placebo-Controlled Trial of Hypericum Perforatum in the Treatment of Generalized Social Anxiety Disorder (GSAD)||National Center for Complementary and Integrative Health (NCCIH)||Completed|August 2002|June 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|N/A|No|||September 2007|September 25, 2007|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00118833||198022|
NCT00118846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT001653|Women's Isoflavone Soy Health (WISH) Trial|Phytoestrogens and Progression of Atherosclerosis||National Center for Complementary and Integrative Health (NCCIH)|Yes|Active, not recruiting|March 2004|June 2009|Anticipated|January 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|350|||Female|30 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 14, 2008|July 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00118846||198021|
NCT00118521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003001023NHMRC|A Clinical Study in the Use of Orthotics in Treating Pain in the Front of the Knee|Foot Orthotics in the Treatment of Patellofemoral Pain Syndrome: A Randomised Clinical Trial in Primary Care||The University of Queensland||Completed|May 2004|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||176|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2006|December 18, 2013|July 1, 2005||||No||https://clinicaltrials.gov/show/NCT00118521||198045|
NCT00119626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-NXY-0006|Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke|SAINT I (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke.||AstraZeneca||Completed|June 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1700|||Both|18 Years|N/A|No|||November 2010|November 10, 2010|July 6, 2005||||||https://clinicaltrials.gov/show/NCT00119626||197966|
NCT00119639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11804|Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006|A Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of Sorafenib (BAY 43-9006, Nexavar).||Bayer||Completed|June 2005|December 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|40 Years|75 Years|No|||January 2009|January 15, 2009|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00119639||197965|
NCT00119041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-254|Diabetes Telemedicine Consultation: A Systems Improvement Intervention|Diabetes Telemedicine Consultation: A Systems Improvement Intervention||VA Office of Research and Development|No|Completed|September 2005|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|304|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|July 1, 2005||No||No|July 2, 2014|https://clinicaltrials.gov/show/NCT00119041||198006|A potential factor jeopardizing both internal and external validity relates to fact that the consultation process may be very dependent on the particular individuals involved.
NCT00120185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-003897-27|Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)|Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Naïve HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|December 2003|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|July 8, 2005||||No||https://clinicaltrials.gov/show/NCT00120185||197925|
NCT00120198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOC-LY-010|Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients|A Pilot Study of Cyclophosphamide/Pegylated Liposomal Doxorubicin/Vincristine/Prednisone (CDOP) Plus Rituximab for Treatment of Elderly Patients With Previously Untreated Non-Hodgkin's Lymphoma||Geriatric Oncology Consortium||Terminated|March 2005|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|65 Years|N/A|No|||November 2007|November 15, 2007|July 8, 2005|||slow accrual|No||https://clinicaltrials.gov/show/NCT00120198||197924|
NCT00120731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG#05036|Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones|Urinary Chemistry and Acid-Base Effects of Potassium Citrate in Children With Idiopathic Hypercalciuria and Urolithiasis||Children's Mercy Hospital Kansas City|No|Completed|July 2005|May 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|23|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||July 2005|June 14, 2007|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120731||197883|
NCT00120744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-12038|Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department|Randomized Trial of the Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Acute Gastroenteritis in a Pediatric Emergency Department||The Hospital for Sick Children||Completed|January 2004|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|6 Months|10 Years|No|||December 2013|December 10, 2013|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120744||197882|
NCT00117585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3616-R|Orthostatic Hypotension in Rehabilitation Patients|Orthostatic Hypotension in Rehabilitation Patients||VA Office of Research and Development|No|Completed|November 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|341|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 30, 2005||No||No|November 5, 2013|https://clinicaltrials.gov/show/NCT00117585||198115|
NCT00117598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-305|Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)|An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)|OPTIMAL|Pfizer|Yes|Completed|May 2005|January 2011|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|169|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|June 30, 2005|Yes|Yes||No|February 2, 2012|https://clinicaltrials.gov/show/NCT00117598||198114|After the primary analysis was completed, efficacy data was no longer collected nor analyzed; Participants were followed for safety up to 6 months after the last dose of temsirolimus.
NCT00145782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1990/1966|The Ebeltoft Health Promotion Project|The Ebeltoft Health Promotion Project - A Randomized Controlled Trial With Multiphasic Preventive Health Screenings and Discussions in General Practice.||University of Aarhus||Completed|September 1991|December 1999||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|30 Years|50 Years|Accepts Healthy Volunteers|||September 2005|September 1, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145782||195990|
NCT00147836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NECT-2004-WJP|Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients|Evaluation of the Effects of Oral Anti-Hyperglycemic Agents, Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion on Glycemic Control, B-Cell Function and the Remission Rate in Newly-Diagnosed Type 2 Diabetic Patients||Sun Yat-sen University|Yes|Completed|September 2004|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|436|||Both|25 Years|70 Years|No|||October 2007|March 31, 2008|September 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00147836||195840|
NCT00118092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01466|17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy|A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Hormone-Refractory Metastatic Prostate Cancer||National Cancer Institute (NCI)||Completed|January 2005|||May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Male|18 Years|N/A|No|||October 2013|October 7, 2013|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118092||198077|
NCT00117767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSFO327C2301|Terbinafine Compared to Griseofulvin in Children With Tinea Capitis|Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis||Novartis||Completed|June 2004|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2|||720|||Both|4 Years|12 Years|No|||November 2011|November 1, 2011|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00117767||198101|
NCT00118027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-713-624-02-0033|A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda|A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda||Gates Malaria Partnership|No|Completed|May 2003|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||2150|||Female|N/A|N/A|No|||January 2009|January 14, 2009|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00118027||198081|
NCT00118066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080404|Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia|A Randomized Phase II Trial Of Calcitriol In Patients With Prostatic Intraepithelial Neoplasia||Rutgers, The State University of New Jersey|No|Terminated|May 2004|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Male|18 Years|N/A|No|||May 2015|May 22, 2015|July 8, 2005|Yes|Yes|Slow accruaL, lack of scientific progress|No||https://clinicaltrials.gov/show/NCT00118066||198078|
NCT00118547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3319V|Health Behavior Change in Chronic Disease Management|Health Behavior Change in Chronic Disease Management||VA Office of Research and Development|No|Completed|September 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2011|August 11, 2011|July 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00118547||198043|
NCT00118573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|384/03|Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair|Randomized Clinical Trial Comparing Surveillance and Selective Surgical Treatment for Abdominal Aortic Aneurysms Less Than 5.5 cm in Diameter Versus Early Endovascular Treatment|CAESAR|University Of Perugia|Yes|Terminated|September 2004|September 2017|Anticipated|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|50 Years|80 Years|No|||December 2015|December 9, 2015|June 30, 2005||No|lower than anticipated events;slow recruitment;larger than predicted sample size|No||https://clinicaltrials.gov/show/NCT00118573||198041|
NCT00119392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1726.00|Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|June 2004|||July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00119392||197984|
NCT00118534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|519|Integrating Clinical Practice Guidelines for Smoking Cessation Into Mental Health Care for Veterans With Posttraumatic Stress Disorder|CSP #519 - Integrating Practice Guidelines for Smoking Cessation Into Mental Health Care for PTSD (SCP)||VA Office of Research and Development|Yes|Completed|July 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|943|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|July 1, 2005||No||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00118534||198044|
NCT00119379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI060484-01A2B|Effectiveness of Nucleoside Supplementation and Substituting Tenofovir Disoproxil Fumarate for Other Drugs in Anti-HIV Regimens in Reversing Fat Loss in HIV Infected Adults|Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2007|February 22, 2010|July 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00119379||197985|
NCT00119912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORCCAP-1|NORCCAP: Norwegian Colorectal Cancer Prevention Trial|Norwegian Colorectal Cancer Prevention Trial||Norwegian Department of Health and Social Affairs|Yes|Active, not recruiting|January 1999|March 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|100000|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00119912||197946|
NCT00119652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1447C00134|Seroquel in Bipolar Depression Versus SSRI|Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)|EMBOLDEN II|AstraZeneca||Completed|May 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|676|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119652||197964|
NCT00119925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRING 2005-01|'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"|Cost Effectiveness of Two Different Strategies to Implement the NVOG Guideline Programme on Subfertility||Radboud University||Recruiting|October 2005|May 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|5200|||Both|18 Years|80 Years|No|||October 2008|October 28, 2008|July 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00119925||197945|
NCT00120757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-002002-30|Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)|Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|October 2004|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00120757||197881|
NCT00120484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002571|Effects of Vitamin B12 on the Body's Internal Clock|Effect of Vitamin B12 on the Human Circadian Pacemaker||Brigham and Women's Hospital|No|Completed|April 2005|January 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|July 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120484||197902|
NCT00116870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0027|MARS - Monitored Atherosclerosis Regression Study|A Double-Blind, Placebo-Controlled Angiographic Study to Evaluate the Effect of Lovastatin on the Progression Rate of Atherosclerosis in the Coronary Arteries of Patients With Coronary Heart Disease||National Institute on Aging (NIA)||Completed|June 1985|February 1992|Actual|February 1992|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|21 Years|67 Years|No|||June 2005|December 9, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00116870||198170|
NCT00116896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-904-102|Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors|Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors||OSI Pharmaceuticals||Completed|June 2003|December 2004||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||November 2003|January 16, 2009|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116896||198168|
NCT00117195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurophysiologic|A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease|Open-Label Validation Study of Neurophysiologic Changes in Individuals With Parkinson's Disease, at Risk for Parkinson's Disease and Healthy Controls||Institute for Neurodegenerative Disorders|Yes|Completed|May 2003|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|620|Samples Without DNA|In addition, the study will evaluate serum samples for changes in proteins or metabolites      that may be indicators of early changes associated with Parkinson's disease or parkinsonian      syndrome.|Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|These neurophysiologic tests will be administered to individuals with Parkinson's disease        and parkinsonian syndrome and validated against a healthy control population.|February 2012|February 8, 2012|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00117195||198145|
NCT00117208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-CF-203|Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis|A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis||Pharmaxis||Completed|November 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|8 Years|18 Years|No|||January 2010|January 31, 2010|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117208||198144|
NCT00117221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050179|MRI Measurement of Brain Metabolism Across the Sleep-Wake Cycle|MRI Measurement of Brain Metabolism Across the Sleep-Wake Cycle||National Institutes of Health Clinical Center (CC)||Completed|June 2005|February 2014||||N/A|Observational|N/A|||Actual|56|||Both|18 Years|65 Years|No|||February 2014|August 6, 2015|July 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00117221||198143|
NCT00117234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020126|Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia|A Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia||Amgen||Completed|September 2002|July 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||||||Both|21 Years|N/A|No|||December 2010|December 2, 2010|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117234||198142|
NCT00145795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11711B|A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment|Randomized Trial of a Switch to a Kaletra + Current Dual Nucleoside Reverse Transcriptase Inhibitor (NRTI) Backbone Versus Continuation of the Current Regimen in Patients With Poor Immune Responses to Highly Active Antiretroviral Therapy (HAART) in Patients With Complete Viral Suppression: A Pilot Study||University of Chicago|Yes|Completed|April 2004|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||August 2013|August 23, 2013|September 1, 2005||No||No|October 24, 2012|https://clinicaltrials.gov/show/NCT00145795||195989|
NCT00147524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9061010|Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women|Multicenter, Open-Label (Non-Comparative) Study To Evaluate Changes In Flow Mediated Dilatation During And After A 6 Months Treatment Period With Step By Step Increased Doses With Quinapril Therapy In Post-Menopausal Women With Mild Or Moderate Hypertension||Pfizer||Completed|October 2003|May 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Female|18 Years|75 Years|No|||April 2007|April 26, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147524||195863|
NCT00147849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-63141|A Cluster Controlled Trial Comparing Three Methods of Disseminating Practice Guidelines for Children With Croup|A Cluster Controlled Trial Comparing Three Methods of Disseminating Practice||University of Calgary||Terminated|September 2000|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|N/A|No|||September 2005|November 28, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147849||195839|
NCT00118352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1959.00|Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer|Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|March 2005|||July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|74 Years|No|||June 2015|June 15, 2015|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118352||198058|
NCT00117780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1708|Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes|ADAPT|Novo Nordisk A/S|No|Completed|June 2005|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|520|||Both|18 Years|70 Years|No|||June 2012|June 26, 2012|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117780||198100|
NCT00119093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3666|Home-based AIDS Care Project|Home-based AIDS Care Project, Tororo, Uganda||Centers for Disease Control and Prevention|No|Terminated|May 2003|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1000|||Both|13 Years|N/A|No|||September 2012|September 10, 2012|July 8, 2005||No|Terminated by IRB for non-compliance with human subject regulations.|No||https://clinicaltrials.gov/show/NCT00119093||198002|
NCT00119106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4370|Bangkok Tenofovir Study|Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand||Centers for Disease Control and Prevention|Yes|Completed|June 2005|October 2014|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2413|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|July 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00119106||198001|
NCT00119119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRSHC10 PENTO|Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C|Efficacy and Safety of the Association With Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|February 2002|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|75 Years|No|||January 2007|January 11, 2007|July 4, 2005||||No||https://clinicaltrials.gov/show/NCT00119119||198000|
NCT00119366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1809.00|Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|May 2003|||August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|16 Years|50 Years|No|||November 2015|November 16, 2015|July 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00119366||197986|
NCT00119938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51758|An Online System to Improve Diabetes Self-Care|D-STAR (Diabetes-System To Access Records): An Online Patient Portal to Improve and Sustain Diabetes Self-Care||Robert Wood Johnson Foundation|No|Completed|September 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|2||Actual|331|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2007|August 19, 2008|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119938||197944|
NCT00119951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49152|Health eCommunities - The Impact of Listservs on Cancer Patients|Health eCommunities - The Impact of Listservs on Cancer Patients||Robert Wood Johnson Foundation||Completed|September 2003|August 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||3360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|August 2, 2007|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119951||197943|
NCT00119665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-101-002|Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes|A Phase II, Double-Blind, Placebo-Controlled, Randomized Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes and Menopausal Symptoms||Bionovo||Completed|February 2006|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||March 2007|May 16, 2007|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119665||197963|
NCT00120211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33018|Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer|Phase III Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer||International Atomic Energy Agency||Completed|September 1998|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|855|||Both|18 Years|N/A|No|||October 2011|October 12, 2011|July 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00120211||197923|
NCT00120497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000384|Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight|Growth Hormone and Insulin Resistance in Children With Intrauterine Growth Restriction||Massachusetts General Hospital|Yes|Recruiting|July 2005|December 2011|Anticipated|July 2011|Anticipated|Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|12|Samples Without DNA|Blood|Both|8 Years|12 Years|No|Non-Probability Sample|Children, age 6-12 years old, with short stature associated with low birth weight|July 2011|July 19, 2011|July 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00120497||197901|
NCT00120510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA HT 001|Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti|A Randomized Clinical Trial to Determine the Efficacy of Early Versus Standard Antiretroviral Therapy in HIV Infected Adults With CD4+ T Cell Counts Between 200 and 350 Cells/mm3||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|816|||Both|18 Years|N/A|No|||October 2014|October 13, 2014|July 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120510||197900|
NCT00120770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9757|Cellulose Sulfate (CS) Gel and HIV in Nigeria|Randomized Controlled Trial of Cellulose Sulfate Gel and HIV in Nigeria||FHI 360||Terminated|November 2004|March 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2160|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|July 11, 2005|||The study was halted in January 2007 due to safety concerns.|||https://clinicaltrials.gov/show/NCT00120770||197880|
NCT00121043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020125|Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire|An Open Label, Randomized, Crossover Study to Assess Acceptability and Functionality of SimpleJectTM Vs Pre-Filled Syringe(s) Using Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using A Self-Reported Questionnaire||Swedish Orphan Biovitrum||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|November 25, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00121043||197859|
NCT00117247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010198|A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects|A Study to Assess the Pharmacokinetics and Pharmacodynamics of Repeat-Sose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects||Amgen||Completed|June 2002|July 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 15, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117247||198141|
NCT00117260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA-305|Study to Evaluate the Safety and Efficacy of Seasonale for Treatment of Low Bone Mineral Density|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a 91-Day Extended-Cycle Combination Oral Contraceptive (Seasonale) for the Treatment of Low Bone Mineral Density in Adolescent Females With Secondary Amenorrhea and Osteopenia||Teva Pharmaceutical Industries||Withdrawn|July 2005|August 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Female|12 Years|17 Years|No|||August 2013|August 8, 2013|June 30, 2005|||Sponsor decision|||https://clinicaltrials.gov/show/NCT00117260||198140|
NCT00117845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050185|Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia|Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia||National Institutes of Health Clinical Center (CC)|No|Completed|July 2005|June 2013|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|July 7, 2005|Yes|Yes||No|September 25, 2012|https://clinicaltrials.gov/show/NCT00117845||198095|
NCT00117832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13716A|Nasal Ocular Reflexes Contribute to Eye Symptoms|Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis||University of Chicago|No|Completed|March 2005|October 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|June 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00117832||198096|
NCT00118144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00113|Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer|Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features||National Cancer Institute (NCI)||Completed|June 2005|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||April 2013|August 4, 2014|July 8, 2005|Yes|Yes||No|August 4, 2014|https://clinicaltrials.gov/show/NCT00118144||198074|
NCT00146393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-0275|Health Benefits of an Exercise Program for Adults With Arthritis|Evaluation of People With Arthritis Can Exercise||Centers for Disease Control and Prevention||Completed|July 2003|June 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||347|||Both|18 Years|N/A|No|||September 2005|December 8, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146393||195945|
NCT00146640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62215-003|Prednisone Timed-Release Tablet (TRT) Study: TRT Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis|A New Timed-release Tablet Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis- A Randomized, Multi-centre, Double-blind, Active Controlled Study With Open Extension on the New Drug Only||Merck KGaA||Completed|August 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|288|||Both|18 Years|80 Years|No|||February 2014|February 17, 2014|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146640||195926|
NCT00135109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0768|Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy||UCB Pharma||Completed|October 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|654|||Both|18 Years|N/A|No|||February 2010|September 19, 2014|August 23, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00135109||196800|
NCT00135122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70203|Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache|Medication Overuse Headache: A Randomised Double Blind Study of Prednisolone or Placebo in Withdrawal Therapy (Phase 3), and a Randomised 1 Year Follow up by Neurologist or General Physician After Successful Withdrawal Therapy||Sorlandet Hospital HF|No|Completed|September 2003|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|70 Years|No|||September 2008|September 11, 2008|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135122||196799|
NCT00118131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000433488|Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Weekly Docetaxel Together With Weekly Cisplatin in Chemotherapy-Naive Patients With Stage IV or Select Stage IIIB (Malignant Effusion) Non-Small Cell Lung Cancer||Rutgers, The State University of New Jersey|No|Terminated|December 2003|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|July 8, 2005|Yes|Yes|Slow accrual|No|September 19, 2013|https://clinicaltrials.gov/show/NCT00118131||198075|
NCT00118586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050189|Neuropathology of Spasmodic Dysphonia|Neuropathological Basis of Spasmodic Dysphonia and Related Voice Disorders||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2005|||||N/A|Observational|Time Perspective: Prospective|||Actual|97|||Both|21 Years|N/A|No|||November 2015|December 15, 2015|July 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00118586||198040|
NCT00118612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TreeMATAMPL203|Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen|A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Birch + Hazel + Alder Pollen Allergoid With MPL® in Patients Sensitized to Birch, Hazel, Alder Pollen||Allergy Therapeutics||Completed|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|18 Years|50 Years|No|||June 2010|June 16, 2010|July 1, 2005||||||https://clinicaltrials.gov/show/NCT00118612||198039|
NCT00118339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1845.00|Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma|A Prospective Randomized Pilot Study Using Ice Chips Versus Room Temperature Normal Saline Rinses Orally During Administration of Melphalan to Decrease the Severity and Duration of Oral Mucositis in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplant||Fred Hutchinson Cancer Research Center||Completed|July 2003|May 2006|Actual|May 2006|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||Actual|41|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|July 8, 2005||||No||https://clinicaltrials.gov/show/NCT00118339||198059|
NCT00118859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000905|Pilot Study to Test the Effectiveness of Combining Conventional and Complementary Medicine to Treat Low Back Pain|Model of Integrative Care in an Academic Health Center||National Center for Complementary and Integrative Health (NCCIH)||Completed|July 2004|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|70 Years|No|||December 2009|December 10, 2009|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00118859||198020|
NCT00118872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001486-01A2|Beneficial Bacteria to Prevent Malnutrition and Diarrhea in Pakistani Infants|Feasibility Study of Probiotics for Growth Faltering in Pakistan||Tufts University|Yes|Completed|March 2006|March 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|N/A|5 Weeks|Accepts Healthy Volunteers|||December 2007|December 22, 2014|July 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00118872||198019|
NCT00120250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000645|Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder|Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder||Massachusetts General Hospital|Yes|Completed|June 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|64 Years|No|||December 2013|December 26, 2013|July 7, 2005||No||No|July 19, 2013|https://clinicaltrials.gov/show/NCT00120250||197920|
NCT00119067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3344|CDC Anthrax Vaccine Clinical Trial|Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction||Centers for Disease Control and Prevention||Completed|May 2002|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|1560|||Both|18 Years|61 Years|Accepts Healthy Volunteers|||September 2012|February 25, 2014|July 6, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00119067||198004|
NCT00119080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4591|Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage|Evaluation of the Effect of Tetravalent (A, C, Y, W-135) Meningococcal Conjugate Vaccine on Serogroup-Specific Carriage of Neisseria Meningitidis||Centers for Disease Control and Prevention|No|Completed|August 2006|May 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||4000|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2007|March 16, 2007|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00119080||198003|
NCT00119691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P00235|Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction|Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction||Brigham and Women's Hospital|No|Completed|April 2003|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|July 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00119691||197961|
NCT00119964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51756|The Healthy Lifestyle Study|Weight Management for a Defined Employee Population Using an Interactive eHealth Portal||Robert Wood Johnson Foundation||Completed|September 2004|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|500|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119964||197942|
NCT00120224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1.2|De-Medicalizing Mifepristone Medical Abortion|De-Medicalizing Mifepristone Medical Abortion||Gynuity Health Projects||Completed|May 2005|April 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||4410|||Female|N/A|N/A|No|||April 2007|April 25, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00120224||197922|
NCT00120237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.4|Misoprostol for the Prevention of Postpartum Hemorrhage in Rural Pakistan|A Placebo-Controlled Randomized Trial of Misoprostol in the Management of the Third Stage of Labor in the Home Delivery Setting in Rural Pakistan||Gynuity Health Projects|Yes|Completed|July 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|1600|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2009|March 17, 2009|July 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00120237||197921|
NCT00120523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2306|Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis|Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis||MEDA Pharma GmbH & Co. KG||Completed|April 2004|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2418|||Both|3 Months|12 Months|No|||December 2012|December 10, 2012|July 11, 2005|Yes|Yes||No|November 9, 2012|https://clinicaltrials.gov/show/NCT00120523||197899|
NCT00120536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2384|Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|June 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|288|||Both|18 Years|80 Years|No|||May 2012|May 4, 2012|July 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120536||197898|
NCT00117273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR PSE 310|A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens|A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills||Teva Pharmaceutical Industries|No|Completed|June 2005|June 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117273||198139|
NCT00117286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS14A|Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer|An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer||Ferring Pharmaceuticals|No|Completed|March 2005|November 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Male|18 Years|N/A|No|||September 2010|September 29, 2010|June 30, 2005|Yes|Yes||No|September 29, 2010|https://clinicaltrials.gov/show/NCT00117286||198138|
NCT00121056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020145|REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations|Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations (REKinDLE)||Amgen||Completed|September 2002|||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|No|||December 2008|December 4, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00121056||197858|
NCT00116883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR100012|A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics|A Randomized, Double-blind, Parallel Group, Placebo Controlled, 6-week Study of the Effect of GW685698X Aqueous Nasal Spray 100mcg QD on the Hypothalamic Pituitary Adrenocortical (HPA) Axis in Children 2 to 11 Years of Age With Perennial Allergic Rhinitis (PAR).||GlaxoSmithKline||Completed|February 2005|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|2 Years|11 Years|No|||October 2010|October 1, 2010|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116883||198169|
NCT00118170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03083|Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function|Pharmacokinetic and Phase I Study of Sorafenib (BAY 43-9006, NSC 724772, IND 69896) for Solid Tumors and Hematologic Malignancies in Patients With Hepatic or Renal Dysfunction||National Cancer Institute (NCI)||Completed|October 2004|||May 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118170||198072|
NCT00118404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH058397|Cognitive Therapy for Recurrent Depression|Prophylactic Cognitive Therapy for Depression.||University of Texas Southwestern Medical Center|Yes|Completed|March 2000|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|523|||Both|18 Years|70 Years|No|||May 2014|May 13, 2014|July 6, 2005||No||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00118404||198054|To our knowledge in 2014 this is of the largest, cognitive therapy responders who presented with recurrent MDD and were followed longitudinallyProficient therapists;competency measured.Generalizability is limited by design characteristics.
NCT00118157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00080|Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen|A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen||National Cancer Institute (NCI)||Completed|May 2005|September 2014|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2014|July 28, 2015|July 8, 2005|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00118157||198073|The main limitation in this study was poor enrollment. The small number of cases makes the interpretation of results difficult.
NCT00147498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921019|Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis||Pfizer|No|Completed|January 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|264|||Both|18 Years|70 Years|No|||December 2012|December 20, 2012|September 2, 2005|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00147498||195865|
NCT00135655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-104|A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema|A Randomized, Double-Masked, Parallel, Group, Multi-Center, Dose Ranging Pilot Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema||Merck Sharp & Dohme Corp.||Withdrawn|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|August 24, 2005||||||https://clinicaltrials.gov/show/NCT00135655||196758|
NCT00119132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCR5098|Effectiveness of Intermittent Preventive Treatment for Malaria in Children|A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana||Gates Malaria Partnership|Yes|Completed|June 2005|December 2006|Actual|December 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2602|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||January 2009|January 14, 2009|July 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00119132||197999|
NCT00118365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00880|Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps|A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon||National Cancer Institute (NCI)||Completed|July 1998|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|375|||Both|40 Years|80 Years|No|||February 2014|January 12, 2015|July 8, 2005|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT00118365||198057|
NCT00118625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TreeMATAMPL202|Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine|A Double-Blind Phase IIa Study to Demonstrate the Contribution of MPL® to Tyrosine Adsorbed Birch + Hazel + Alder Pollen Allergoid (Tree MATA) With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Volunteers Allergic to Birch and Hazel and Alder Pollen||Allergy Therapeutics||Completed|July 2005|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|50 Years|No|||June 2010|June 16, 2010|July 1, 2005||||||https://clinicaltrials.gov/show/NCT00118625||198038|
NCT00119977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050605|Periacetabular Osteotomy.A Prospective Study With Reference to Cartilage, Migration and Bone Density|Periacetabular Osteotomy. A Prospective Study With Reference to Cartilage, Migration and Bone Density||University of Aarhus|No|Completed|October 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|60 Years|No|||January 2008|January 31, 2008|July 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00119977||197941|
NCT00119990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA20050009|Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis|Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis; the Effect of Different Dialysates||University of Aarhus|No|Terminated|January 2006|January 2010|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|85 Years|No|||December 2008|December 5, 2008|July 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00119990||197940|
NCT00119678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-042|Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone|A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects With Systemic Lupus Erythematosus and the Prevention of Subsequent Lupus Flares||Bristol-Myers Squibb|No|Completed|September 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|183|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|June 30, 2005|Yes|Yes||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00119678||197962|
NCT00120783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 109 VISTA|Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance|Efficacy and Tolerability of an Antiretroviral bi-Therapy in HIV-1 Infected Patients With Multidrug Resistant HIV ANRS 109 Vista Trial.||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|February 2002|August 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2007|January 17, 2007|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120783||197879|
NCT00121069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3990-02-9|Study of Escitalopram in the Treatment of Specific Phobia|Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia||Connor, Kathryn M., M.D.||Completed|September 2002|September 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2005|July 19, 2005|July 13, 2005||||||https://clinicaltrials.gov/show/NCT00121069||197857|
NCT00121095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|424Sm32|Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer|Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer||Cytogen Corporation|No|Recruiting|July 2005|June 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Male|N/A|N/A|No|||December 2007|December 17, 2007|July 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00121095||197856|
NCT00116909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-904-203|A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy|A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy||OSI Pharmaceuticals||Completed|August 2004|August 2005||||Phase 2|Interventional|Primary Purpose: Treatment||||85|||Both|18 Years|N/A|No|||March 2007|March 13, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116909||198167|
NCT00116922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANOE|A Lifestyle and Combination Medication Therapy Diabetes Prevention Study|CAnadian Normoglycemia Outcomes Evaluation Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|Yes|Completed|June 2004|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|207|||Both|18 Years|75 Years|No|||May 2012|May 22, 2012|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00116922||198166|
NCT00117299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787 A2401/300267|PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib|A Phase II, Open-Label Study of PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors (GISTs) Resistant to Imatinib Mesylate||Helsinki University|No|Completed|September 2004|January 2009|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00117299||198137|
NCT00117611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13916A|Xolair in Patients With Chronic Sinusitis|Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test||University of Chicago|No|Completed|July 2005|January 2009|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|75 Years|No|||September 2013|September 27, 2013|June 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00117611||198113|
NCT00122460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-002|Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)|Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck||Merck KGaA|Yes|Completed|December 2004|January 2011|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|442|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|July 19, 2005|Yes|Yes||No|August 25, 2011|https://clinicaltrials.gov/show/NCT00122460||197754|Non-specific outcome measures 'Safety' & 'QOL assessments' were deleted from this entry in error.Replacement outcomes have been created. The 'Safety' outcome refers to adverse events.
NCT00122915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONCEPT|CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain|A Prospective, Randomized, Double Blind, Crossover, Multi-center Study to Evaluate the Safety and the Efficacy of Motor Cortex Stimulation With the Cortical Stimulation Lead Model 2976 in Patients With Neuropathic Pain||Medtronic||Terminated|June 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|104|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 21, 2005|||Based on a consistently low enrolment rate and procedural challenges that were unknown at    study start. It was not based on safety or efficacy concerns.|No||https://clinicaltrials.gov/show/NCT00122915||197719|
NCT00122668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS121 HIPPOCAMPE|Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients|Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121)||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|November 2003|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||112|||Both|18 Years|N/A|No|||November 2005|November 14, 2005|July 21, 2005||||No||https://clinicaltrials.gov/show/NCT00122668||197738|
NCT00118911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069812|Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder|Efficacy of CBT for Residual ADHD in Adults||Massachusetts General Hospital|Yes|Completed|September 2004|July 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|65 Years|No|||March 2013|March 7, 2013|July 6, 2005||No||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00118911||198016|
NCT00147264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.433|Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial|A Randomized, Double Blind, 2X2 Factorial Design Study to Evaluate the Effects of Telmisartan Vs Placebo, and of a Low-Glycemic Diet Vs Control Diet, in Reducing Intra-Myocellular Lipids In Individuals With Abdominal Obesity||McMaster University||Active, not recruiting|April 2004|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|30 Years|70 Years|No|||August 2006|August 9, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147264||195882|
NCT00147511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXAA-0026-162|Time To Efficacy and Onset Of Action Of Linezolid|Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections||Pfizer||Completed|June 2003|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|118|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147511||195864|
NCT00135395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-103|A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen|A Phase IIIb, Open -Label, Randomized Multi-center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, in Combination With Two Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in HIV-1 Infected Subjects Experiencing Their First Virologic Failure While Receiving a NNRTI-containing HAART Regimen.||Bristol-Myers Squibb||Completed|May 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2008|February 3, 2010|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135395||196778|
NCT00135408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-007|A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide|Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients With Previously Treated Unresectable Stage III or IV Malignant Melanoma||Bristol-Myers Squibb||Completed|November 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||August 2008|February 27, 2010|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135408||196777|
NCT00119418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402M56292|TU 025 Keishi Bukuryo Gan for Post-menopausal Hot Flash Management|TU 025 Keishi Bukuryo Gan for Post-Menopausal Hot Flash Management||Plotnikoff, Gregory A., M.D.||Completed|November 2004|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|180|||Female|45 Years|58 Years|Accepts Healthy Volunteers|||July 2005|October 25, 2010|July 4, 2005||||||https://clinicaltrials.gov/show/NCT00119418||197982|
NCT00119704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2002.354-T|Treatment of Tennis Elbow With Botulinum Toxin|Treatment of Lateral Epicondylitis With Botulinum Toxin: A Randomized Controlled Trial||Chinese University of Hong Kong||Completed|September 2002|March 2005||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2005|May 8, 2006|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119704||197960|
NCT00119717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-0125|Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)|Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)|SENTIS|CoAxia|Yes|Completed|June 2005|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|515|||Both|18 Years|N/A|No|||May 2011|May 16, 2011|July 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00119717||197959|
NCT00119730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-251|Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma|Abbreviated Fludarabine / Mitoxantrone / Rituximab Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma||Dana-Farber Cancer Institute||Completed|February 2005|December 2013|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|July 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00119730||197958|
NCT00121121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS VAC16|Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers|A Phase Ib Vaccine Trial Evaluating the Safety and Immunogenicity of HIV Lipopeptides by Two Administration Routes (Intramuscular And Intradermal) in Healthy Adult Volunteers. ANRS VAC16 Trial||French National Agency for Research on AIDS and Viral Hepatitis||Completed|July 2004|December 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2005|March 14, 2007|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121121||197854|
NCT00119405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI060484-01A2A|Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Role of Mitochondria in the Development of HIV Atrophy||National Institute of Allergy and Infectious Diseases (NIAID)|No|Active, not recruiting|April 2005|December 2010|Anticipated|November 2010|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Fat and Blood for mitochindrial DNA and different nuclear genes that regulate fat and lipid      metabolism|Both|18 Years|N/A|No|Non-Probability Sample|HIV positive adults starting their first antiretroviral regimen with either AZT-containing        combination|December 2007|February 22, 2010|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00119405||197983|
NCT00120562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFN 0385|Studies of Biological Changes Related to Weight Loss After Gastric Bypass Surgery|A Gene Expression and Metabolic Profile of Weight Loss: Studies of Patients Following Gastric Bypass Surgery||Rockefeller University||Terminated|July 2007|||||Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|13|||Both|18 Years|65 Years|No|Probability Sample|Inclusion Criteria:          -  18 - 65 years old          -  Subjects approved for gastric bypass surgery|August 2009|August 27, 2009|July 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00120562||197896|
NCT00120796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12100 HEPADAK-2|Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)|Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Terminated|August 2005|July 2008|Anticipated|July 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|July 12, 2005||No|poor patient recrutment|No||https://clinicaltrials.gov/show/NCT00120796||197878|
NCT00120809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG27b|Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae|A Randomised, Placebo Controlled Trial of Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae.||Gates Malaria Partnership||Completed|July 2002|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3000|||Female|N/A|N/A|No|||July 2005|July 18, 2005|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120809||197877|
NCT00121108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP117|MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States|A Phase 3 Study of MEDI-524 (Motavizumab) for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States||MedImmune LLC|Yes|Completed|November 2004|March 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2127|||Both|1 Month|6 Months|Accepts Healthy Volunteers|||June 2012|June 27, 2012|July 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00121108||197855|
NCT00116935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSGXVIII/AIO|Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)|Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence||Scandinavian Sarcoma Group|No|Completed|February 2004|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||December 2011|December 28, 2011|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116935||198165|
NCT00117624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020118|A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy|A Randomized, Double-Blind, Study of Front-Loading Darbepoetin Alfa Compared With Standard Weekly Administration for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy and Receiving Multicycle Chemotherapy||Amgen||Completed|December 2002|December 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2007|December 20, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117624||198112|
NCT00117637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11848|BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma|A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.||Bayer|Yes|Completed|June 2005|March 2009|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|June 30, 2005|Yes|Yes||No|August 27, 2010|https://clinicaltrials.gov/show/NCT00117637||198111|
NCT00122928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009301|Comparison of Workplace Obesity Management Programs|Environmental Approaches for Obesity Management at Dow||Emory University|Yes|Completed|October 2004|September 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|5124|||Both|18 Years|70 Years|No|||November 2013|November 12, 2013|July 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00122928||197718|
NCT00123227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-210|Rosiglitazone Plaque Study|A Randomised, Double-Blind, Placebo-Controlled, Cardiovascular Magnetic Resonance (CMR) Study to Evaluate the Effect of Rosiglitazone on Carotid Atherosclerotic Plaques in Type 2 Diabetics With Vascular Disease or Hypertension||Royal Brompton & Harefield NHS Foundation Trust||Active, not recruiting|October 2002|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|30 Years|75 Years|No|||May 2005|July 29, 2005|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00123227||197696|
NCT00123214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 77-04|A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation|Pilot Study: A Dietary Intervention May Decrease the Negative Metabolic and Cognitive Consequences of Chronic Sleep Deprivation||St. Vincent's Medical Center||Completed|September 2004|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||18|||Both|25 Years|40 Years|Accepts Healthy Volunteers|||July 2005|June 26, 2006|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00123214||197697|
NCT00123487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-035|Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML|A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects With Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)||Bristol-Myers Squibb|No|Completed|June 2005|June 2013|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|638|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|July 21, 2005|Yes|Yes||No|October 16, 2014|https://clinicaltrials.gov/show/NCT00123487||197676|Amendment 3 (7 March 2007) allowed participants to switch from BID to QD dosing. Therefore, results for BID summarized by treatment group after Year 2 may not be a complete reflection of the BID experience and should be interpreted with this in mind.
NCT00122902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001147-01|Spirituality and Will to Live in Patients With HIV/AIDS|Spirituality and Will to Live in Patients With HIV/AIDS||National Center for Complementary and Integrative Health (NCCIH)||Completed|February 2002|February 2004||||N/A|Observational|Time Perspective: Longitudinal||||350|||Both|21 Years|N/A|No|||August 2006|August 17, 2006|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122902||197720|
NCT00123188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20175|Ultrasound and Endometrial Hyperplasia|Development of a Screening Test for Endometrial Hyperplasia in an At Risk Cohort||Milton S. Hershey Medical Center|No|Terminated|April 2005|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|36|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|July 20, 2005||No|enrollment of participants has halted prematurely; difficulty with recruitment|No||https://clinicaltrials.gov/show/NCT00123188||197699|
NCT00134836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHCTF G03-02795|Preventive Primary Care Outreach for High Risk Older Persons|Preventive Primary Care Outreach for High Risk Older Persons|PPCO|McMaster University|No|Completed|April 2004|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|719|||Both|75 Years|N/A|No|||December 2008|December 11, 2008|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134836||196820|
NCT00119431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB2003.01A|Kinetics, Efficacy and Safety of C1-Esteraseremmer-N|Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema||Sanquin||Completed|September 2005|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|12|||Both|18 Years|N/A|No|||May 2009|May 1, 2009|July 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00119431||197981|
NCT00119743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|347414/010|A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine|Assess, in Young Children, the Efficacy in Preventing Acute Otitis Media (AOM) of GSK Biologicals Undecavalent Pneumococcal-protein D Conjugate Vaccine, When Administered as a Three Dose Primary Vaccination Course During the First Year of Life With a Booster Dose in the Second Year of Life.||GlaxoSmithKline||Terminated|October 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||5000|||Both|6 Weeks|27 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|July 6, 2005||||No||https://clinicaltrials.gov/show/NCT00119743||197957|
NCT00119145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG44|Kintampo Trial of Combination Therapy for Malaria|A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Malaria Among Children In Ghana||Gates Malaria Partnership|Yes|Completed|June 2005|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|510|||Both|6 Months|10 Years|No|||February 2008|February 7, 2008|July 4, 2005||||No||https://clinicaltrials.gov/show/NCT00119145||197998|
NCT00120822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG27a|Folic Acid Supplementation in Gambian Primigravidae|A Study of the Effect of Folic Acid Supplementation on the Anti-Malarial Action of Sulfadoxine-Pyrimethamine When Used for Intermittent Preventive Treatment in Gambian Primigravidae.||Gates Malaria Partnership||Completed|July 2002|January 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1000|||Female|N/A|N/A|No|||July 2005|July 18, 2005|July 12, 2005||||No||https://clinicaltrials.gov/show/NCT00120822||197876|
NCT00120835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-08A-003|Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C|An Open-Label, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and the Antiviral Activity of NM283 When Administered Alone and in Combination With Pegylated Interferon Alfa 2b to Treatment-Naive Adults With Genotype-1 Chronic Hepatitis C||Merck Sharp & Dohme Corp.||Completed|July 2004|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||June 2010|June 9, 2010|July 11, 2005||||||https://clinicaltrials.gov/show/NCT00120835||197875|
NCT00125398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0413|GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting|A Phase II, Randomized, Open-Label Study to Examine the Safety and Efficacy of GPI 15715 for Sedation of Patients Requiring Intubation and Mechanical Ventilation in the Intensive Care Unit Setting||Eisai Inc.||Completed|July 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||November 2008|November 6, 2008|July 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00125398||197533|
NCT00120549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1588 WIRB|Study of Assisted Hatching of Cleavage Stage Embryos|Prospective Randomized Trial of Assisted Hatching of Cleavage Stage Embryos||Shady Grove Fertility Reproductive Science Center||Completed|August 2001|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|18 Years|39 Years|No|||July 2005|July 15, 2005|July 11, 2005||||No||https://clinicaltrials.gov/show/NCT00120549||197897|
NCT00117325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR30006|Study Of Adults And Adolescents With Vasomotor Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 Years of Age and Older) With Vasomotor Rhinitis||GlaxoSmithKline||Completed|July 2005|||February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Both|12 Years|N/A|No|||July 2012|August 2, 2012|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117325||198135|
NCT00117338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-301|A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)|A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Pediatric Patients (Ages 6 to 14 Years) With Acute Asthma||Merck Sharp & Dohme Corp.||Completed|July 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|276|||Both|6 Years|14 Years|No|||March 2015|March 27, 2015|June 30, 2005|Yes|Yes||No|March 16, 2009|https://clinicaltrials.gov/show/NCT00117338||198134|
NCT00117650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADHIF00704|Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication|WALK|Sanofi|Yes|Completed|February 2005|March 2010|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|289|||Both|40 Years|80 Years|No|||March 2015|March 17, 2015|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117650||198110|
NCT00122135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-224|A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making|A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making|Aim3|VA Office of Research and Development|No|Completed|December 2004|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|120|||Both|55 Years|N/A|No|||November 2015|November 16, 2015|July 18, 2005||No||No|July 10, 2015|https://clinicaltrials.gov/show/NCT00122135||197778|Difficulties in recruiting enough surrogates led to abandoning having a surrogate arm.
NCT00122148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 01-189|Can Vignettes Be Used to Improve Practice & Outcome|Can Vignettes be Used to Improve Practice and Outcomes?||VA Office of Research and Development|No|Terminated|September 2005|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||||||Both|N/A|N/A|No|||August 2006|February 4, 2010|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00122148||197777|
NCT00122161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI 99-275|Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation|Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation||VA Office of Research and Development|No|Completed||September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|190|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2007|April 6, 2015|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00122161||197776|
NCT00117858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050180|Double Blind Trial of DC Polarization in FTD|Double Blind Trial of DC Polarization in FTD||National Institutes of Health Clinical Center (CC)||Completed|June 2005|May 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||20|||Both|35 Years|75 Years|No|||May 2007|May 11, 2007|July 7, 2005||||No||https://clinicaltrials.gov/show/NCT00117858||198094|
NCT00117871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1515-RESI|Study With a Topical Gel to Treat Common Warts in Adults|A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults||Graceway Pharmaceuticals, LLC||Completed|October 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||November 2006|February 16, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00117871||198093|
NCT00117884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1537-851B|Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.|A Randomized, Double-blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities||Takeda|No|Terminated|April 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|240|||Female|18 Years|40 Years|No|||January 2012|January 31, 2012|July 1, 2005|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00117884||198092|
NCT00118183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02820|Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Trial of Docetaxel Plus Cetuximab and Docetaxel Plus Bortezomib (NSC #681239, IND #58443) in Advanced Non-Small Cell Lung Cancer Patients With Performance Status (PS) 2||National Cancer Institute (NCI)||Completed|July 2005|||April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|July 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00118183||198071|
NCT00123526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223|Workplace-Sponsored Diet and Exercise Program to Reduce Obesity|Active Living and Healthy Diet at the Workplace||University of Massachusetts, Worcester|Yes|Completed|September 2004|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|899|||Both|18 Years|65 Years|No|||September 2013|September 23, 2013|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123526||197673|
NCT00123513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196|Workplace-Sponsored Program to Reduce Obesity|Images of a Healthy Worksite-Preventing Weight Gain in the Workplace||University of Rochester|Yes|Completed|September 2004|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3938|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 12, 2012|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123513||197674|
NCT00123500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234|Wellness Program for Elementary School Personnel|ACTION! Wellness Program for Elementary School Personnel||Tulane University School of Public Health and Tropical Medicine|Yes|Completed|September 2004|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1202|||Both|18 Years|70 Years|No|||November 2013|November 25, 2013|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123500||197675|
NCT00135382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-406|Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen|A Phase 3 Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen||Bristol-Myers Squibb||Completed|June 2002|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||254|||Both|18 Years|N/A|No|||January 2010|January 27, 2010|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00135382||196779|
NCT00135161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/202|Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer|Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer||University Hospital, Ghent|No|Active, not recruiting|September 2003|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135161||196796|
NCT00135668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-2003-09-DR|Dose-Response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room|A Phase 2 Multicenter, Randomized, Double-Blind, Parallel Group, Dose-Ranging, Effect-Controlled Study to Determine the Pharmacokinetics and Pharmacodynamics of Sodium Nitroprusside in Pediatric Subjects||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|August 2005|February 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|203|||Both|N/A|17 Years|No|||May 2009|May 26, 2009|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135668||196757|
NCT00135681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244|Immune Dysregulation in Children and Adults With Asthma|||University of New Mexico||Completed|December 1996|November 2001||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|100 Years|No|||January 2016|January 14, 2016|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00135681||196756|
NCT00136201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-316|Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections|A Multicenter, Randomized, Open-Label Comparison of the Safety and Efficacy of Tigecycline> vs Imipenem/Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Chinese Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||200|||Both|18 Years|N/A|No|||July 2009|July 6, 2009|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136201||196717|
NCT00123981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTS-0001|The Danish On-pump, Off-pump Randomization Study (DOORS)|The Impact of Avoiding Cardiopulmonary By-pass During Coronary Artery Bypass Surgery for Ischemic Heart Disease in Elderly Patients: The Danish On-pump, Off-pump Randomization Study (DOORS)||Odense University Hospital|Yes|Completed|January 2005|January 2011|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|900|||Both|70 Years|N/A|No|||November 2013|November 5, 2013|July 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00123981||197639|
NCT00124293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7CBI-1587|Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury|A Multi Centre Observational Study to Evaluate the Incidence and Magnitude of Haemorrhagic Progression of Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury||Novo Nordisk A/S|No|Completed|October 2004|November 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|85 Years|No|Non-Probability Sample|Subjects were selected from a speciality practice group (Neurosurgery practices with a        focus on head trauma. Subjects will have had a mild-to-moderate head injury and require        hospitalization.|October 2013|October 23, 2013|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00124293||197615|
NCT00118885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0029|Shingles: Immune Effects of Tai Chi|Behavioral Intervention for Herpes Zoster Risk in Aging||National Institute on Aging (NIA)||Completed|July 2001|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||140|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||November 2006|December 9, 2009|July 8, 2005||||No||https://clinicaltrials.gov/show/NCT00118885||198018|
NCT00118898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5202|Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults|A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects||AIDS Clinical Trials Group|Yes|Completed|September 2005|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1864|||Both|16 Years|N/A|No|||January 2016|January 4, 2016|July 7, 2005|Yes|Yes||No|January 8, 2010|https://clinicaltrials.gov/show/NCT00118898||198017|HIV-1 drug resistance testing and HLA-B*5701 testing were not standard of care during enrollment. EFV and RTV-boosted ATV were open-label, and blinded FTC/TDF vs. ABC/3TC were unblinded in the >=100,000 cp/mL screening viral load stratum Feb 2008.
NCT00120302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CGB02|Quality of Life Study in Adults With Facial Eczema|Quality of Life Study in Adults With Facial Eczema||Novartis||Completed|March 2005|January 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||January 2008|January 15, 2008|July 8, 2005||||No||https://clinicaltrials.gov/show/NCT00120302||197916|
NCT00120315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-2176|Proton Pump Inhibitor Treatment Stop|Proton Pump Inhibitor Treatment Stop: Discontinuation of Acid-suppressive Medication Among Long-term Users in a Primary Health Care Setting||Odense University Hospital|No|Completed|December 2003|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|July 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00120315||197915|
NCT00125164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS301|Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency|Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial||Ipsen|Yes|Completed|March 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|137|||Both|3 Years|12 Years|No|||June 2012|June 14, 2012|July 27, 2005|Yes|Yes||No|July 8, 2009|https://clinicaltrials.gov/show/NCT00125164||197551|
NCT00121420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0224|Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases|Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases||Pharmacyclics||Terminated||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|July 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00121420||197832|
NCT00120263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR uop14875|Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma|A Randomized Controlled Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma||London Health Sciences Centre||Completed|September 1998|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||92|||Both|18 Years|81 Years|No|||July 2005|May 8, 2006|July 8, 2005||||No||https://clinicaltrials.gov/show/NCT00120263||197919|
NCT00120276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020202|RESTOR-MV: Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve|Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve (RESTOR-MV)||Myocor|Yes|Completed|June 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|250|||Both|18 Years|80 Years|No|||May 2008|May 5, 2009|July 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00120276||197918|
NCT00121654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITA-SCS1|Spinal Cord Stimulation (SCS) in Refractory Angina|Randomized Study on SCS for the Treatment of Refractory Angina Pectoris||Catholic University of the Sacred Heart|No|Recruiting|July 2005|December 2009|Anticipated|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|90 Years|No|||March 2009|March 9, 2009|July 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00121654||197815|
NCT00121901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPEPPS-06-2005|Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?|||Hvidovre University Hospital||Completed|October 2004|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|1600|||Both|18 Years|N/A|No|||October 2007|October 16, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00121901||197796|
NCT00122486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9780|Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV|Phase 2 Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV||FHI 360||Completed|July 2004|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2006|July 28, 2006|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00122486||197752|
NCT00122473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADO/VOD DFSP 001|Imatinib in Dermatofibrosarcoma Protuberans (DFSP)|Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans||Dermatologic Cooperative Oncology Group||Completed|January 2004|January 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00122473||197753|
NCT00122681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/008|Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18|A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.||GlaxoSmithKline||Completed|May 2004|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|18729|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||July 2013|April 23, 2015|July 20, 2005|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00122681||197737|
NCT00122694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2003.249|Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)|Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable COPD||Groningen Research Institute for Asthma and COPD||Completed|January 2005|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|40 Years|N/A|No|||July 2006|September 11, 2006|July 21, 2005||||No||https://clinicaltrials.gov/show/NCT00122694||197736|
NCT00123253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH9507/III/LIPO/010|TH9507 in Patients With HIV-Associated Lipodystrophy|A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation||Theratechnologies||Completed|June 2005|April 2007|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|412|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|July 20, 2005||||||https://clinicaltrials.gov/show/NCT00123253||197694|
NCT00123266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-M-003|Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion|An Open-label, Clinical Trial of Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion|MITI-IA|ThromboGenics|Yes|Terminated|December 2006|August 2008|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||April 2014|April 4, 2014|July 21, 2005||No|Sponsor's decision not to pursue development of uPLi for vascular conditions.|No||https://clinicaltrials.gov/show/NCT00123266||197693|
NCT00123734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN/US-001-II-DVT|Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis|Phase II Clinical Trial to Evaluate the Accuracy of Anti-Fibrin Humanized Monoclonal Antibody (DI-DD3B6/22-80B3) Fab' Protein Fragment (ThromboView) Conjugated With Technetium-99m in the Detection of Deep Vein Thrombosis||Agen Biomedical||Completed|March 2005|May 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|94|||Both|18 Years|N/A|No|||July 2009|July 9, 2009|July 24, 2005||Yes|||July 9, 2009|https://clinicaltrials.gov/show/NCT00123734||197658|
NCT00123708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050204|Hypertonia in Patients With Cerebral Palsy|Hypertonia in Patients With Cerebral Palsy||National Institutes of Health Clinical Center (CC)||Completed|July 2005|||November 2009|Actual|N/A|Observational|N/A||||100|||Both|6 Years|N/A|Accepts Healthy Volunteers|||November 2009|September 26, 2015|July 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00123708||197659|
NCT00136890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-088145|PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers|The Impact of Positron Emission Tomography (PET) Imaging in Staging Potentially Surgically Resectable Non-small Cell Lung Cancers: A Prospective Multicentre Randomized Clinical Trial|ELPET|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|July 2004|January 2013|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|337|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136890||196664|
NCT00137202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-04-006|Post Burn Pruritus Study in Patients Undergoing Wound Healing|A Pilot Study to Determine the Pruritic Benefits of Ondansetron Versus Diphenhydramine in Burn Patients Undergoing Wound Healing||United States Army Institute of Surgical Research|No|Completed|June 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2008|July 24, 2008|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137202||196640|
NCT00124618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0422|Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|Cetuximab (C225) and Radiation in Elderly and /or Poor Performance Status Patients With Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity||Alliance for Clinical Trials in Oncology|No|Completed|January 2006|March 2015|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|July 26, 2005|Yes|Yes||No|March 9, 2015|https://clinicaltrials.gov/show/NCT00124618||197591|
NCT00120003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050321|Scandinavian Candesartan Acute Stroke Trial (SCAST)|Scandinavian Candesartan Acute Stroke Trial||Oslo University Hospital|Yes|Completed|June 2005|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2500|||Both|18 Years|N/A|No|||September 2006|June 30, 2011|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00120003||197939|
NCT00120289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226|Niacin Plus Statin to Prevent Vascular Events|AIM HIGH: Niacin Plus Statin to Prevent Vascular Events||Axio Research. LLC|Yes|Terminated|September 2005|December 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3414|||Both|45 Years|N/A|No|||July 2015|July 27, 2015|July 6, 2005|Yes|Yes|AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin    in preventing primary outcome events.|No|June 1, 2015|https://clinicaltrials.gov/show/NCT00120289||197917|
NCT00124878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22006|Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community|Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community||Wawer, Maria J., M.D.|Yes|Active, not recruiting|August 2003|September 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5200|||Both|15 Years|49 Years|Accepts Healthy Volunteers|||July 2005|August 9, 2007|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00124878||197573|
NCT00124891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3163K1-200|Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia|Study Evaluating Subjects With Non-Sustained Ventricular Tachycardia||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|June 2005|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Both|18 Years|N/A|No|||December 2007|December 6, 2007|July 13, 2005||||||https://clinicaltrials.gov/show/NCT00124891||197572|
NCT00125411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 04904|Study of Satraplatin (JM-216) in Combination With Docetaxel|Phase I Study of the Oral Platinum Agent Satraplatin (JM-216) in Combination With Docetaxel in Treatment of Advanced Malignancies||Agennix||Terminated|March 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|July 28, 2005|No|Yes|Sponsor decided to discontinue study drug development.|No||https://clinicaltrials.gov/show/NCT00125411||197532|
NCT00121433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 1955|Leptin and Endothelial Function|The Role of Leptin in Modulating Vascular Tone and Endothelial Function in Obese and Normal Weight Adults: A Vascular-Protective Effect of Leptin?||University of Michigan||Completed|September 2004|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2005|June 23, 2006|July 13, 2005||||||https://clinicaltrials.gov/show/NCT00121433||197831|
NCT00116948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030289|A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter|A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter||University of Aarhus|No|Completed|January 2005|January 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|65 Years|No|||December 2014|December 3, 2014|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00116948||198164|
NCT00117312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS06A|Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients||Ferring Pharmaceuticals|Yes|Terminated|October 2002|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Male|18 Years|N/A|No|||May 2011|May 18, 2011|June 30, 2005|Yes|Yes|After 190 weeks [7 patients left] it was terminated for administrative reasons|No|January 22, 2009|https://clinicaltrials.gov/show/NCT00117312||198136|
NCT00121914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-327-2000|Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone|Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study With Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone||Medical University of Vienna||Active, not recruiting|October 2000|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|85 Years|No|||July 2005|October 17, 2005|July 15, 2005||||No||https://clinicaltrials.gov/show/NCT00121914||197795|
NCT00122174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 01-006|Stress-Busting Program for Caregivers of Patients With Neruological Diseases|Stress-Busting Program for Caregivers of Patients With Neurological Diseases||VA Office of Research and Development|No|Completed|July 2004|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2007|April 6, 2015|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00122174||197775|
NCT00122187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT 02-059|Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention|Translation of Colorectal Cancer Screening Guidelines: A System Intervention||VA Office of Research and Development|No|Completed|August 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|N/A|N/A|No|||September 2013|April 6, 2015|July 18, 2005||No||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00122187||197774|Half of the sites randomized did not complete the study. GI referral rates should have been nearly 100%, yet were not. Because of programming limitations, we were unable to evaluate the type of diagnostic interventions the patients received.
NCT00122720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-2277|The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery|The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer||Herning Hospital||Completed|June 2003|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||January 2006|July 3, 2006|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00122720||197734|
NCT00122707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMR1|Comparison of Central and Peripheral Venous Catheters|Randomized Controlled Trial of Mechanical and Infectious Complications of Central Versus Peripheral Venous Catheters in ICU Patients||Assistance Publique - Hôpitaux de Paris||Completed|April 2004|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|18 Years|N/A|No|||June 2005|March 21, 2006|July 19, 2005||||No||https://clinicaltrials.gov/show/NCT00122707||197735|
NCT00122941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/HD11/2078/MMS|Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda|Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda: a Randomised Double Blind Placebo-Controlled Trial|MMS|Makerere University|Yes|Completed|June 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|860|||Both|1 Year|5 Years|No|||June 2008|June 13, 2008|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00122941||197717|
NCT00123747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-11-0044/DX-FDG-007/21389|Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer|A Phase II Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer||AHS Cancer Control Alberta|No|Completed|August 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|N/A|No|||March 2012|February 24, 2016|July 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00123747||197657|
NCT00124033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/001|Management of Common Bile Duct (CBD) Stones at Laparoscopic Cholecystectomy|Management of CBD Stones at Laparoscopic Cholecystectomy: A NSW Collaborative Prospective Randomised Trial to Assess the Value of Transcystically Inserted CBD Stents to Facilitate Post-Operative ERCP||South West Sydney Local Health District||Terminated|March 2004|December 2015||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||340|||Both|18 Years|85 Years|No|||June 2005|September 7, 2006|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00124033||197635|
NCT00124332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5827|STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)|Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors||Sanofi||Completed|January 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|839|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|July 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00124332||197612|
NCT00136227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4527|Use and Decision-making About Colorectal Cancer Screening Among Hispanic Men and Women|Trial of Interventions to Increase Utilization of Colorectal Cancer Screening and Promote Informed Decision Making About Colorectal Cancer Screening Among Hispanic Men and Women||Centers for Disease Control and Prevention|No|Completed|October 2005|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|521|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 6, 2012|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136227||196715|
NCT00136474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-292|Amifostine for Head and Neck Irradiation in Lymphoma|A Randomized Phase II Trial of Amifostine for Head and Neck Irradiation in Lymphoma||Dana-Farber Cancer Institute|Yes|Completed|May 2003|March 2009|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|35 Years|N/A|No|||October 2009|October 30, 2009|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136474||196696|
NCT00124605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03082|Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma|Phase I Trial of Arsenic Trioxide in Combination With Pamidronate Disodium||National Cancer Institute (NCI)||Completed|April 2005|||June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|July 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00124605||197592|
NCT00125177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50HD044406|IRIS: Incontinence Research Intervention Study|Office for Research on Women's Health (ORWH): Specialized Centers of Research (SCOR) on Sex and Gender Factors Affecting Women's Health. Project 3: Selection Criteria For Muscle Therapy in SUI||University of Michigan||Completed|January 2003|April 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|320|||Female|18 Years|N/A|No|||July 2005|November 9, 2010|July 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00125177||197550|
NCT00125190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS308|Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency|Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study||Ipsen|Yes|Completed|July 2005|January 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|3 Years|N/A|No|||June 2012|June 14, 2012|July 27, 2005|Yes|Yes||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00125190||197549|
NCT00121446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVC1002|Which Therapy for Acute Heart Attacks? (The WEST Study)|Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study||University of Alberta||Completed|July 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||July 2005|January 19, 2006|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121446||197830|
NCT00121407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPD OCR 013 (VIO)|Visudyne® in Occult (VIO)|A Randomized, Placebo-Controlled, Double-Masked, Multicenter, Phase III Study of the Effect of Visudyne Therapy in Occult With No Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne in Occult (VIO)||QLT Inc.||Completed|March 2002|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||364|||Both|50 Years|N/A|No|||July 2005|July 19, 2005|July 12, 2005||||||https://clinicaltrials.gov/show/NCT00121407||197833|
NCT00130130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D 0403|Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes|Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes||Dartmouth-Hitchcock Medical Center||Completed|August 2005|December 2011|Actual|September 2010|Actual|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Cancer patients experiencing NP from a variety of causes|January 2012|January 30, 2012|August 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00130130||197179|
NCT00130429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P58/09ME/03/04|Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease|Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type||Phytopharm||Completed|January 2004|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|50 Years|N/A|No|||August 2009|August 20, 2009|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130429||197156|
NCT00129792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19AT002656|Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome|Expectancy, Self-Efficacy and Outcomes in Metabolic Syndrome||Oregon Health and Science University|Yes|Completed|January 2005|April 2014|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|79|||Both|21 Years|60 Years|No|||October 2014|October 27, 2014|August 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00129792||197204|
NCT00129805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI9042-15|Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)|Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial||Mitsubishi Tanabe Pharma Corporation|No|Completed|January 2001|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1510|||Both|20 Years|N/A|No|||August 2008|August 18, 2008|August 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00129805||197203|
NCT00130065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3683|The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya|The Effect of Folic Acid Supplementation on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya||Centers for Disease Control and Prevention||Completed|November 2003|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Female|15 Years|45 Years|No|||September 2012|September 26, 2012|August 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00130065||197184|
NCT00130364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2440|Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis|Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis||Novartis||Completed|August 2005|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||200|||Both|2 Years|11 Years||||January 2008|January 10, 2008|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130364||197161|
NCT00130377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506137|Evaluation of the Treatment of Thoracic & Cardiovascular Disease With Biological Therapy: ClinicalCellRegistry.Com|Biological Cell Therapy for the Treatment of Patients With Thoracic & Cardiovascular Disease||Amit, Patel N, M.D.|Yes|Recruiting|August 2002|December 2020|Anticipated|December 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|August 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130377||197160|
NCT00130663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219405|Recognition of Abnormal Pediatric Blood Pressures in Primary Care|Recognition of Abnormal Pediatric Blood Pressures in Primary Care||Nationwide Children's Hospital||Completed|January 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|3 Years|17 Years|Accepts Healthy Volunteers|||October 2007|October 19, 2007|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130663||197138|
NCT00130676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-07|A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression|A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features||Corcept Therapeutics|No|Completed|September 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|75 Years|No|||February 2012|February 14, 2012|August 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130676||197137|
NCT00130650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/31E|Pain Ease Spray in Reducing Needle Pain Associated With Intravenous Insertion in Children|Efficacy of Pain Ease Spray in Reducing Needle Pain Associated With Intravenous Insertion in Children||Children's Hospital of Eastern Ontario|Yes|Completed|May 2006|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|6 Years|12 Years|No|||January 2008|January 24, 2008|August 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00130650||197139|
NCT00131248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERD|Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants|Cross-over Trial of Medical Treatment for GERD in Preterm Infants||The University of Texas Health Science Center, Houston||Completed|April 2004|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|1 Month|6 Months|No|||December 2013|December 12, 2013|August 15, 2005||No||No|November 23, 2009|https://clinicaltrials.gov/show/NCT00131248||197093|
NCT00131235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-179787-1|Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth|Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin||University of Tampere|Yes|Completed|December 2003|March 2012|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1320|||Female|15 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 21, 2014|August 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00131235||197094|
NCT00131521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-1502-320|Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit|Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit: A Randomized, Double Blind, Controlled Trial||The University of Texas Health Science Center at San Antonio||Completed|January 2005|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|260|||Both|18 Years|N/A|No|||June 2009|June 20, 2009|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00131521||197072|
NCT00131794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG31|Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria|The Effect of BCG Vaccine on Morbidity From Malaria||Gates Malaria Partnership||Completed|January 2003|December 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||1200|||Both|18 Months|24 Months|No|||August 2005|October 13, 2005|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00131794||197051|
NCT00124371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001HS030B|Programme to Optimise Risk Factors in Patients Waiting for Coronary Artery Bypass Surgery|Fit For Surgery Study: A Randomised Controlled Trial of a Nurse-Led Programme to Optimise Mental and Physical Fitness for Surgery and Coronary Risk Factor Control in Patients Waiting for Coronary Artery Bypass Surgery||Royal Brompton & Harefield NHS Foundation Trust||Completed|January 2003|October 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||July 2005|August 4, 2005|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00124371||197609|
NCT00139945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/102|Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients|Effects of Acute Ghrelin Infusion to Growth Hormone Deficient Adults: Growth Hormone and Cortisol Interaction||University of Aarhus|No|Completed|October 2005|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|60 Years|No|||January 2010|January 19, 2010|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00139945||196433|
NCT00139958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACS|Prognosis of Acute Coronary Syndrome in HIV-infected Patients|Prognosis After Acute Coronary Syndrome in HIV-infected Patients||Saint Antoine University Hospital|Yes|Completed|November 2003|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|Samples Without DNA|Lipids, CRP, glycemia, insulinemia|Both|18 Years|N/A|No|Probability Sample|PAtients with de novo acute coronary syndromes age > 18years old.|May 2010|July 26, 2010|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139958||196432|
NCT00140543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUROSPK002|European Trial of Immunosuppression in SPK Tx|A European Multicenter Open-Label Randomised Trial to Evaluate the Efficacy and Safety of Sirolimus and Tacrolimus Compared to MMF and Tacrolimus With Short-Course Induction Therapy, Short-Term Steroids Application in De Novo SPK Transplanted Diabetic Patients||EUROSPK Study Group||Active, not recruiting|February 2002|April 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||228|||Both|18 Years|55 Years|No|||August 2005|November 17, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140543||196388|
NCT00131495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004031 and Yr 2 SB|Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido|A Randomized, Double-Blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy/Safety of Transdermal Patches Delivering Testosterone in Menopausal Women With Low Libido Not Receiving Estrogen Therapy||Warner Chilcott|No|Completed|July 2004|February 2007|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|814|||Female|20 Years|70 Years|No|||April 2013|April 15, 2013|August 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00131495||197074|
NCT00133146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrassMATAMPL202|Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine|A Double-Blind Phase IIa Study to Demonstrate the Contribution of MPL to Tyrosine Adsorbed Grass/Rye Pollen Allergoid (Grass MATA) With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Volunteers Allergic to Grass and Rye Pollen||Allergy Therapeutics||Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|50 Years|No|||September 2009|June 16, 2010|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00133146||196949|
NCT00133159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrassMATAMPL203|Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen|A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Grass/Rye Pollen Allergoid With MPL in Patients Sensitized to Grass and Rye Pollen||Allergy Therapeutics||Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|18 Years|50 Years|No|||June 2010|June 16, 2010|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00133159||196948|
NCT00133172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-011|Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection|Evaluation of the Long-term Safety and Efficacy of a Tacrolimus-based 5-day Steroid Rapid Withdrawal Immunoprophylactic Regimen in de Novo Renal Transplantation||Astellas Pharma Inc|Yes|Terminated|July 2005|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|August 22, 2005|No|Yes|Varience of supply chain from that required by protocol|No||https://clinicaltrials.gov/show/NCT00133172||196947|
NCT00131040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS/03/065/15951|Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass|Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass||Imperial College London||Completed|January 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||August 2005|May 27, 2015|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00131040||197109|
NCT00131326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNV-004-02|A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip|||Sanofi||Completed|November 2003|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|35 Years|N/A|No|||March 2015|March 17, 2015|August 17, 2005||||||https://clinicaltrials.gov/show/NCT00131326||197087|
NCT00129818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810A2404|A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding|A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding||Novartis||Completed|July 2004|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||April 2012|April 26, 2012|August 11, 2005||||||https://clinicaltrials.gov/show/NCT00129818||197202|
NCT00129831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2202|Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)|Dose Escalation Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|September 2004|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Both|40 Years|75 Years|No|||October 2011|October 24, 2011|August 11, 2005||||||https://clinicaltrials.gov/show/NCT00129831||197201|
NCT00129844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0227|Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer|Randomized Phase II Trial of Single Agent Motexafin Gadolinium for Second Line Treatment of Non-Small-Cell Lung Cancer||Pharmacyclics||Completed|September 2005|December 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|108|||Both|18 Years|N/A|No|||August 2008|August 19, 2008|August 10, 2005||||||https://clinicaltrials.gov/show/NCT00129844||197200|
NCT00130078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9784|Trial of SAVVY Vaginal Gel and HIV in Nigeria|Randomized Controlled Trial of SAVVY and HIV in Nigeria||Biosyn||Recruiting|September 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2142|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2005|September 22, 2005|August 11, 2005||||||https://clinicaltrials.gov/show/NCT00130078||197183|
NCT00130091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/17E|The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children|The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children||Children's Hospital of Eastern Ontario|Yes|Completed|September 2009|December 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|August 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00130091||197182|
NCT00130390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-2018|Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease|Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease in Adults||Romark Laboratories L.C.|No|Terminated|August 2005|July 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|August 12, 2005|Yes|Yes|terminated due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00130390||197159|
NCT00130689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-113|Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer|A Phase II Trial of Cetuximab in Unresectable or Metastatic Esophageal and Gastric Carcinoma||Dana-Farber Cancer Institute|Yes|Completed|July 2005|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|August 15, 2005|Yes|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT00130689||197136|
NCT00130975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRAF|Candesartan in the Prevention of Relapsing Atrial Fibrillation|||Asker & Baerum Hospital||Completed|April 2001|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||January 2007|January 3, 2007|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00130975||197114|
NCT00131261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-301-G|Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma|A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma||Onxeo||Completed|January 2005|June 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|August 17, 2005||||||https://clinicaltrials.gov/show/NCT00131261||197092|
NCT00131274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST1571E2401|Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study|A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis||Daniels, Craig E., M.D.||Completed|April 2003|August 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||120|||Both|20 Years|79 Years|No|||August 2005|October 4, 2005|August 17, 2005||||||https://clinicaltrials.gov/show/NCT00131274||197091|
NCT00131534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0031/01/04|The Trauma Recovery and Resiliency Research Project|The Trauma Recovery and Resiliency Research Project||Cambridge Health Alliance||Recruiting|August 1991|August 2010|Anticipated|||Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|65 Years|No|Non-Probability Sample|Trauma survivors receiving outpatient treatment.|June 2008|June 17, 2008|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131534||197071|
NCT00131807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPSW03|A Study to Explore the Association Between Blood Pressure, HIV and Antiretroviral Therapy|A Study to Explore the Association Between Blood Pressure, HIV and Antiretroviral Therapy||Imperial College London||Completed|September 2005|September 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||3000|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2007|May 27, 2015|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00131807||197050|
NCT00124709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CUS09|Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification|An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Open-label Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children||Novartis||Terminated|October 2003|November 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1091|||Both|3 Months|18 Months|No|||February 2011|February 25, 2011|July 26, 2005|Yes|Yes||No|December 8, 2010|https://clinicaltrials.gov/show/NCT00124709||197586|
NCT00124722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05798|A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia|A Randomized, Assessor-blind, Dose-ranging, Phase IIIB, Multicenter Trial Comparing the Intubating Conditions and Time Course of Block of Three Different Intubating Doses (0.45 mg/kg, 0.6 mg/kg, and 1.0 mg/kg) of Zemuron® in Pediatric and Adolescent Subjects Under General Anesthesia||Merck Sharp & Dohme Corp.|No|Completed|December 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|207|||Both|N/A|17 Years|No|||May 2015|May 29, 2015|July 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00124722||197585|
NCT00139984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB183/03|Ambulatory Blood Pressure Monitoring for Antihypertensive Treatment Guidance|Impact of Ambulatory Blood Pressure Monitoring for Antihypertensive Treatment Guidance in Medical Outpatients: The Hyper-ABC Study||University Hospital, Basel, Switzerland|No|Completed|October 2003|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|170|||Both|18 Years|N/A|No|||July 2007|August 29, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139984||196430|
NCT00140296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-TS-0768|Using the Healthcare Visit to Improve Contraceptive Use|Using the Healthcare Visit to Improve Contraceptive Use||Centers for Disease Control and Prevention||Completed|March 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||747|||Female|16 Years|44 Years|Accepts Healthy Volunteers|||August 2005|August 30, 2005|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140296||196407|
NCT00131170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVB1|Paravertebral Block for Breast Surgery|||University of Aarhus|No|Completed|September 2005|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|90|||Female|18 Years|85 Years|No|||July 2007|July 4, 2007|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00131170||197099|
NCT00132301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|553|Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma|CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment (CAP)|CAP|VA Office of Research and Development|Yes|Active, not recruiting|June 2006|April 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|298|||Male|N/A|N/A|No|||December 2015|December 16, 2015|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00132301||197013|
NCT00132821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16427-5|Impact of Smoking Cessation on Sleep - 5|Impact of Smoking Cessation on Sleep||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|August 2005|April 2009|Anticipated|August 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|136|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 5, 2008|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00132821||196973|
NCT00133185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.406|A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension|A Randomized, Double-Blind, Parallel-Group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5 mg in Comparison With Losartan 50 mg Plus Hydrochlorothiazide 12.5 mg in Taiwanese Patients With Mild to Moderate Hypertension||Boehringer Ingelheim||Completed|March 2004|March 2005||March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||31|||Both|20 Years|80 Years|No|||November 2013|November 18, 2013|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133185||196946|
NCT00133198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.543|Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks||Boehringer Ingelheim||Completed|April 2004|February 2005||February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|345|||Both|18 Years|80 Years|No|||November 2013|November 7, 2013|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133198||196945|
NCT00133432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-179|Zinc and Pneumonia Protocol|The Effect of Zinc Supplementation on Duration of Hospitalization in Tanzanian Children Presenting With Acute Pneumonia||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|September 2005|July 2007|Anticipated|July 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|6 Months|36 Months|No|||March 2010|August 26, 2010|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133432||196927|
NCT00132574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCRF-P11733|Pilot Study of a Dietary Intervention to Prevent Acne Recurrence|Milk Minimization and Acne Recurrence Trial (MMART)||Harvard School of Public Health||Terminated|August 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||30|||Both|16 Years|25 Years|No|||September 2006|September 20, 2006|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00132574||196992|
NCT00133393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-021|Pentoxifylline in Children With Malaria|Dose Finding Study of Pentoxifylline in Children With Cerebral Malaria||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|January 2002|July 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|9 Months|96 Months|No|||October 2005|August 26, 2010|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133393||196930|
NCT00133406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12475|Long-term Impact and Intervention for Diarrhea in Brazil|Long-term Impact and Intervention for Diarrhea in Brazil||University of Virginia|No|Recruiting|June 2006|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|321|||Both|2 Months|8 Years|No|||March 2011|March 4, 2011|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00133406||196929|
NCT00131586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-11-0033/ethics 17173|Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins|Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins||AHS Cancer Control Alberta|No|Terminated|April 2003|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|April 2012|February 24, 2016|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00131586||197067|
NCT00131599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-05-0021|Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer|Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer||AHS Cancer Control Alberta||Active, not recruiting|August 2002|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|104|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|October 2014|October 1, 2014|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00131599||197066|
NCT00129857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-2000-1|Dexanabinol in Severe Traumatic Brain Injury|Efficacy and Safety Evaluation of a Single Intravenous Dose of Dexanabinol in Patients Suffering From Severe Traumatic Brain Injury||Pharmos||Completed|January 2001|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||860|||Both|18 Years|65 Years|No|||November 2004|May 4, 2006|August 11, 2005||||||https://clinicaltrials.gov/show/NCT00129857||197199|
NCT00130104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-5-4319|Transthecal Metacarpal Block Versus Traditional Digital Block for Painful Finger Procedures in Children|Transthecal Metacarpal Block vs Traditional Digital Block for Painful Finger Procedures in Children||Children's Hospital of Philadelphia|No|Completed|July 2005|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|92|||Both|N/A|18 Years|No|||August 2005|October 3, 2007|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00130104||197181|
NCT00130403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_4034|OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women|Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide||Sanofi||Completed|March 2004|March 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|290|||Female|55 Years|85 Years|No|||January 2011|January 10, 2011|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130403||197158|
NCT00130416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51757|Improving Chronic Disease Care With PatientSite|Improving Chronic Disease Care With PatientSite||Robert Wood Johnson Foundation|No|Completed|September 2004|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||750|||Both|18 Years|N/A|No|||July 2008|July 3, 2008|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130416||197157|
NCT00130702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-086|Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia|A Phase II Study of Iressa (Gefitinib), in Patients With Relapsed or Refractory Acute Myelogenous Leukemia and in Older Patients With Newly Diagnosed Acute Myelogenous Leukemia||Dana-Farber Cancer Institute|No|Completed|August 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|August 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00130702||197135|
NCT00130988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00/00854|DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms|Efficacy of a Biopsychosocial Treatment for Somatizing Patients Carried Out by the General Practitioner||Basque Health Service|No|Completed|January 2001|March 2003|Actual|February 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||156|||Both|18 Years|65 Years|No|||July 2008|July 11, 2008|August 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00130988||197113|
NCT00131001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99.203|CARMEDAS: Cost-Effectiveness Analysis of Imaging Strategies in Symptomatic Carotid Stenosis|Cost-Effectiveness Analysis of Imaging Strategies in Symptomatic Carotid Stenosis||Hospices Civils de Lyon||Active, not recruiting|April 2001|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Both|18 Years|90 Years|No|||April 2007|October 17, 2008|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131001||197112|
NCT00131287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-EC-05-01|The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)|||ECbiotech Taiwan||Completed|July 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||April 2007|January 4, 2010|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131287||197090|
NCT00131300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNV-002-01|A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis|||Sanofi||Completed|April 2004|February 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00131300||197089|
NCT00131547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-264|Randomized Study of a Simple Weight Loss Program for Obese Patients With Obstructive Sleep Apnea|A Randomized Controlled Pilot Study of a Simple Weight Loss Program for Obese Patients With Mild to Moderate Obstructive Sleep Apnea||Lawson Health Research Institute|No|Completed|September 2004|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00131547||197070|
NCT00131820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-14|Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam|Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam. An Evaluation of Feasibility, Public Acceptability, Effectiveness and Cost-Effectiveness in Students||International Vaccine Institute||Completed|December 2001|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100742|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||March 2008|March 10, 2008|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00131820||197049|
NCT00124748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571K2301|Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)|A Randomized Open-label Study of 400 mg Versus 800 mg of Imatinib Mesylate in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints.|TOPS|Novartis||Terminated|June 2005|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|476|||Both|18 Years|75 Years|No|||January 2012|January 5, 2012|July 27, 2005|Yes|Yes|This study was prematurely discontinued because no improvement was observed in the 800mg dose    compared to 400mg dose|No|November 2, 2011|https://clinicaltrials.gov/show/NCT00124748||197583|
NCT00117130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020147|Study to Evaluate Effectiveness of Aranesp®|Aranesp® Monthly Preference Study||Amgen||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||January 2011|January 20, 2011|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117130||198150|
NCT00117143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010218|Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)|An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Efficacy of Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)||Amgen||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||May 2009|May 21, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00117143||198149|
NCT00140023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661149|Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia|A Multi-center, Open Label Study to Evaluate the Efficacy and Safety of Azithromycin Microspheres in Subjects Identified as Having Low Risk Community Acquired Pneumonia (CAP)||Pfizer||Completed|September 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00140023||196427|
NCT00140036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTAIV-0020-366|Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).|Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).||Pfizer||Completed|September 2002|August 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||137|||Both|18 Years|N/A|No|||February 2008|February 28, 2008|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00140036||196426|
NCT00131755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAZ 1|Efficacy of Diazoxide in Type 1 Diabetes|Efficacy of 6 Months Treatment With Diazoxide at Bedtime in Preventing Beta-cell Demise in Newly Diagnosed Type 1 Diabetes||Grill, Valdemar, M.D.|No|Completed|February 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|40 Years|No|||July 2011|July 15, 2011|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00131755||197054|
NCT00131183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH13979|Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina|The Effect of Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina||Sheffield Teaching Hospitals NHS Foundation Trust||Recruiting|September 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Male|20 Years|N/A|No|||September 2006|September 11, 2006|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00131183||197098|
NCT00132002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02836|Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer|Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer||National Cancer Institute (NCI)||Terminated|June 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2013|March 6, 2015|August 16, 2005|No|Yes|Early termination for discouraging results|No|March 6, 2015|https://clinicaltrials.gov/show/NCT00132002||197036|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results
NCT00132834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-05|Methods of Determining Asthma Severity in Children|Exhaled Breath Condensates ("EBC") Study: Research Plan NIH/NIAID: Inner City Asthma Consortium (ICAC)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2003|March 2004|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|80|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|August 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00132834||196972|
NCT00132847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-03|Comparing Allergenic Effects of 3 German Cockroach Extracts in Adults|German Cockroach Allergen Standardization Evaluation (CASE)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|April 2004|October 2004||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|65 Years|Accepts Healthy Volunteers||a group of adults who have a history of allergic disease or asthma and demonstrate        sensitivity to the German cockroach allergen being tested|January 2013|January 18, 2013|August 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00132847||196971|
NCT00133211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sks2005psh01|Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation|Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective Multicentre Study (MANTRA-PAF)|MANTRA-PAF|Danish Heart Foundation|Yes|Completed|September 2005|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|294|||Both|18 Years|71 Years|No|||March 2015|March 5, 2015|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133211||196944|
NCT00132587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.313|Total Knee Arthroplasty (TKA) Cemented Versus Cementless|Prospective Randomized Study of 130 Total Knee Arthroplasty With Cemented Femoral Implant Versus Cementless||Hospices Civils de Lyon||Completed|March 2004|March 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||130|||Both|50 Years|90 Years|No|||June 2008|June 30, 2008|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132587||196991|
NCT00132808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446N2312|Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older|A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia||Novartis||Completed|July 2004|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|581|||Female|45 Years|N/A||||July 2012|July 31, 2012|August 18, 2005|Yes|Yes||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00132808||196974|
NCT00134030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST0331|Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma|A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND# 12697)||Children's Oncology Group|Yes|Active, not recruiting|November 2005|||October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1164|||Both|5 Years|40 Years|No|||August 2015|August 20, 2015|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134030||196881|
NCT00134043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01468|Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer|Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma||National Cancer Institute (NCI)||Completed|December 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|August 22, 2005|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT00134043||196880|
NCT00132106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFALFA|The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure|The Effect of a-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure||Radboud University||Recruiting|August 2005|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|75 Years|No|||August 2007|August 30, 2007|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132106||197028|
NCT00132119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-N0406|Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling||Somaxon Pharmaceuticals|No|Completed|August 2005|August 2006|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|233|||Both|18 Years|70 Years|No|||May 2008|May 15, 2008|August 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00132119||197027|
NCT00130715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF97-0601|Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery|A Prospective, Randomized, Multicenter, Controlled Evaluation of the Efficacy and Safety of Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery||Sanofi||Completed|June 1998|August 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|85 Years|No|||March 2015|March 11, 2015|August 15, 2005||||||https://clinicaltrials.gov/show/NCT00130715||197134|
NCT00130728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI3364g|A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer|A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy||Genentech, Inc.||Completed|June 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|636|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|August 12, 2005|Yes|Yes||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00130728||197133|
NCT00130741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391-14.1.05-HMO-CTIL|Combination Herbal Therapy (CHT) Versus Placebo in Patients With Irritable Bowel Syndrome (IBS)|A Phase I, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of a Combination Herbal Therapy (CHT), Versus Placebo in Improving the Overall Quality of Life and Symptoms in Patients With Irritable Bowel Syndrome (IBS)||Hadassah Medical Organization||Completed|July 2005|January 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||April 2007|April 10, 2007|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130741||197132|
NCT00130117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000123|Study of Leptin for the Treatment of Hypothalamic Amenorrhea|Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea||Beth Israel Deaconess Medical Center|No|Active, not recruiting|April 2010|December 2015|Anticipated|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|57|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|August 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130117||197180|
NCT00131313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POI-02818|Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.|A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia.||East Valley Hematology and Oncology Medical Group||Recruiting|January 2003|April 2009||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||August 2005|August 17, 2005|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131313||197088|
NCT00131573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-B-002|An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome|Battery Powered Bion Clinical Investigation: Bion - An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urgency-Frequency Syndrome||Boston Scientific Corporation|No|Completed|May 2004|December 2012|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|August 17, 2005|Yes|Yes||No|April 11, 2013|https://clinicaltrials.gov/show/NCT00131573||197068|This study was limited by poor adherence to the clinical protocol and by incomplete data recovery. Analysis of efficacy-related endpoints was not possible.
NCT00131014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-165|Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies|Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies||Dana-Farber Cancer Institute||Recruiting|August 2004|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Anticipated|1500|Samples With DNA|Whole blood Cheek cells Paraffin blocks of tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|Group 1: Next of kin of a relative who has died from lymphoma Group 2: Subjects who have a        next of kin diagnosed with lymphoma and/or CLL Group 3: Subjects who have had or have        non-Hodgkin's lymphoma, CLL or Hodgkin's disease and had a relative who also had lymphoma        or CLL|August 2015|September 2, 2015|August 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00131014||197111|
NCT00132093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN04CA024|Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack|The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study||NHS Greater Glasgow and Clyde||Completed|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||November 2004|April 7, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132093||197029|
NCT00132379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05762003|ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer|An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||Active Biotech AB|No|Completed|November 2005|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00132379||197007|
NCT00131560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX496-USA-05-002|Safety and Efficacy of T Cell Genetic Immunotherapy for HIV|A Phase II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Single and Repeated Doses of Autologous T Cells Transduced With VRX496 in HIV-Positive Subjects||VIRxSYS Corporation|Yes|Active, not recruiting|July 2005|June 2023|Anticipated|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||June 2011|June 7, 2011|August 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00131560||197069|
NCT00131833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3|Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China|Typhoid Vi Vaccine Effectiveness in a Population Older Than 5 Years of Age Living in an Endemic Area in Hechi, Guangxi, P.R. China: A Group-Randomized Controlled Demonstration Project||International Vaccine Institute||Completed|October 2001|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||96468|||Both|5 Years|60 Years|Accepts Healthy Volunteers|||March 2008|March 10, 2008|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00131833||197048|
NCT00132080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241|Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network|Trial of Pulse Steroid Therapy in Kawasaki Disease (A Trial Conducted by the Pediatric Heart Network)||New England Research Institutes|Yes|Completed|December 2002|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|199|||Both|6 Months|18 Years|No|||April 2012|March 3, 2014|August 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00132080||197030|
NCT00116805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0103|A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B|A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B||Gilead Sciences|Yes|Completed|June 2005|January 2016|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|69 Years|No|||February 2016|February 22, 2016|June 30, 2005|Yes|Yes||No|February 11, 2010|https://clinicaltrials.gov/show/NCT00116805||198175|
NCT00116818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR20002|A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults|See Detailed Description||GlaxoSmithKline||Completed|January 2005|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|12 Years|65 Years|No|||October 2008|October 13, 2008|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116818||198174|
NCT00131768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNV-003-02|A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Ankle Osteoarthritis|||Sanofi||Completed|November 2003|February 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00131768||197053|
NCT00132288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-4349-E/A01|MY PALS: A Community-Based Physical Activity Support Program for Older Adults|A Randomized Controlled Trial Linking Clinical Quality Improvement Programs for Older Diabetics to a Community Based Activity Support Center||University of Washington|Yes|Completed|May 2005|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|305|||Both|50 Years|N/A|No|||December 2007|December 13, 2007|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00132288||197014|
NCT00132860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProToCOL|Prophylactic ﻿Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)|﻿Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin||Odense University Hospital||Active, not recruiting|May 2001|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||800|||Both|50 Years|N/A|No|||August 2005|October 18, 2005|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00132860||196970|
NCT00133497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-039|gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of the Cytomegalovirus gB/MF59 Vaccine in Preventing Systemic Cytomegalovirus Infection in Healthy Adolescent Females||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2006|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|409|||Female|12 Years|17 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133497||196922|
NCT00133770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259-2004|Intravenous (IV) Pantoprazole in Erosive Esophagitis|A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis||Emory University|No|Completed|July 2004|March 2007|Actual|July 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133770||196901|
NCT00133419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-095|Micronutrients and Enteric Infections in African Children|The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||January 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||516|||Both|4 Months|6 Months|Accepts Healthy Volunteers|||March 2007|August 26, 2010|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133419||196928|
NCT00133731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6199|The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention|A Multinational, Randomized, Double-Blind, Double-Dummy, Exploratory, Parallel Group, Dose-Ranging Phase II Study to Evaluate Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Several Intravenous Regimens of Factor Xa Inhibitor Otamixaban (XRP0673), in Comparison to Intravenous Unfractionated Heparin, in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention|SEPIA-PCI|Sanofi||Completed|September 2004|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|947|||Both|18 Years|N/A|No|||June 2008|July 1, 2008|August 23, 2005||||||https://clinicaltrials.gov/show/NCT00133731||196904|
NCT00133744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4084|Impact of Prenatal Vitamin/Mineral Supplements on Perinatal Mortality|Impact of Iron/Folic Acid Versus Multimicronutrient Versus Folic Acid Supplements During Pregnancy on Mortality, Morbidity, and Complications During Pregnancy, Labor, and Delivery: A Randomized Controlled Trial in China||Centers for Disease Control and Prevention|Yes|Completed|May 2006|December 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|18962|||Female|20 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 18, 2011|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133744||196903|
NCT00131859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-08-31-01|Diffusion-Tensor Magnetic Resonance Imaging (MRI) and the Evaluation of Perinatal Brain Injury|Diffusion-Tensor Magnetic Resonance Imaging and the Evaluation of Perinatal Brain Injury||Johns Hopkins University|No|Completed|October 2004|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|5|||Both|23 Weeks|18 Months|Accepts Healthy Volunteers|Non-Probability Sample|Neonates < 1500 grams, with suspected brain injury, and with severe metabolic acidosis|August 2009|August 12, 2009|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00131859||197046|
NCT00131027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JALSG ALL202-O|High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)|Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults||Japan Adult Leukemia Study Group|Yes|Recruiting|September 2002|September 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|25 Years|64 Years|No|||November 2008|November 13, 2008|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00131027||197110|
NCT00133523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-060|FLU-VACS Comparative Study in Adults|Comparative Study of Influenza Vaccines in Adults - FLU-VACS||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2004|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|2349|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2009|December 4, 2014|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133523||196920|
NCT00133536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-077|A/H5N1 Vaccine in Healthy Children Aged 2-9 Years|A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years Through 9 Years||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2006|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|157|||Both|2 Years|9 Years|Accepts Healthy Volunteers|||June 2008|August 26, 2010|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133536||196919|
NCT00129896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2003-03|Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients|Open-Label Phase I-II Clinical Trial to Evaluate Treatment With Myocet/Taxotere/Herceptin as Primary Chemotherapy Treatment for HER2neu Positive Breast Cancer Patients||Spanish Breast Cancer Research Group||Completed|January 2004|December 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|59|||Female|18 Years|70 Years|No|||April 2009|April 27, 2009|August 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00129896||197196|
NCT00131846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15-choju-003|Diuretics In the Management of Essential Hypertension (DIME) Study|Effect of Low Dose Thiazide Diuretics on New Onset Type 2 Diabetes in Patients With Essential Hypertension||Kyoto University|Yes|Active, not recruiting|January 2004|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1130|||Both|30 Years|79 Years|No|||August 2012|August 22, 2012|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00131846||197047|
NCT00131352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNV00704|A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee|A Multi-Centre, Parallel, Double-Blind, Blinded Evaluator, Randomised, Placebo-Controlled Evaluation of the Efficacy and Safety of a Single Dose of 6 mL of Synvisc in Patients With Symptomatic Osteoarthritis of the Knee||Sanofi|No|Completed|May 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|40 Years|N/A|No|||March 2015|March 17, 2015|August 17, 2005|No|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00131352||197085|
NCT00131612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-01-0031 / 17027|An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment|An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 Using Epirubicin Clearance and the Ratios of Epirubicin and Epirubicinol Glucuronide to Epirubicin||AHS Cancer Control Alberta|Yes|Terminated|January 2002|January 2013|Actual|December 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Cross Cancer Clinic patients|June 2012|February 24, 2016|August 17, 2005||No|did not apply for ethics renewal|No||https://clinicaltrials.gov/show/NCT00131612||197065|
NCT00132392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-2-010-1|ALGRX 4975 After Total Knee Replacement|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects After Total Knee Arthroplasty||AlgoRx Pharmaceuticals||Completed|July 2005|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|35 Years|80 Years|No|||August 2005|December 18, 2006|August 18, 2005||||||https://clinicaltrials.gov/show/NCT00132392||197006|
NCT00116766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIF28|Field Evaluation of Plant-Based Mosquito Control|Field Evaluation of Malaria Vector Control Using Traditional Plant-Based Anti-Mosquito Measures in Yunnan Province, P.R. China||Gates Malaria Partnership|No|Completed|July 2005|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|240|||Both|6 Years|N/A|Accepts Healthy Volunteers|||February 2007|July 3, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00116766||198178|
NCT00116779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS14|A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer|An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles||Ferring Pharmaceuticals|Yes|Completed|February 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Male|18 Years|N/A|No|||December 2011|December 15, 2011|June 30, 2005|Yes|Yes||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00116779||198177|
NCT00116792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-001717|PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions|PROVIDENCE: Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions||Gold, Herman K., MD||Active, not recruiting|March 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|120|||Both|18 Years|N/A|No|||May 2007|May 15, 2007|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00116792||198176|
NCT00117793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3666|Vacuum Suspension: Effects on Tissue Oxygenation, Activity and Fit|Vacuum Suspension: Effects on Tissue Oxygenation, Activity and Fit||VA Office of Research and Development|No|Completed|August 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|July 1, 2005||No||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00117793||198099|The small number of participants who completed the protocol precluded a statistical analysis on the secondary outcome measures.
NCT00132314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|555|Long-Acting Injectable Risperidone in the Treatment of Schizophrenia|CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia||VA Office of Research and Development|Yes|Completed|September 2006|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|382|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|August 17, 2005||No||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00132314||197012|
NCT00132600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mekos 05 P36/2|Clinical Evaluation of Bacitracin|Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study||Mekos Laboratories AS||Completed|April 2005|July 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||20|||Both|18 Years|N/A|No|||August 2005|October 18, 2005|August 19, 2005||||||https://clinicaltrials.gov/show/NCT00132600||196990|
NCT00132873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-SXB-27|Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy|Long-Term, Open-Label, Multi-Center Extension Trial of Xyrem® (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy||Jazz Pharmaceuticals||Completed|October 2004|December 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Both|12 Years|N/A|No|||September 2013|September 18, 2013|August 18, 2005|Yes|Yes||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00132873||196969|
NCT00132886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-04-247|Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure|Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Single Oral Tolvaptan Tablets on Hemodynamic Parameters in Subjects With Heart Failure||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|December 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|140|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|August 18, 2005||||||https://clinicaltrials.gov/show/NCT00132886||196968|
NCT00133445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-062|Pentavalent DTaP-Hep B-IPV|Randomized, Single Blinded Study of the Safety and Immunogenicity of Pentavalent DTaP-Hep B-IPV Combination Vaccine (Pediarix™; GlaxoSmithKline (GSK) Biologicals) Administered to Healthy Neonates and Infants at Birth, 2, and 6 Months of Age Compared to a Routine Infant Schedule at 2, 4, and 6 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|5|||Both|N/A|5 Days|Accepts Healthy Volunteers|||October 2009|November 3, 2011|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133445||196926|
NCT00133458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-003|RCT ALB for SA Cysticercosis|Randomized, Double Blind Comparison of Two Lenghts of Albendazole Therapy for Subarachnoid Cysticercosis||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||June 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|No|||October 2005|August 26, 2010|August 19, 2005||||||https://clinicaltrials.gov/show/NCT00133458||196925|
NCT00133757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/2005|Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers|Pharmacotherapy-assisted Extinction (Pharmacoextinction): A Novel Approach to the Treatment of Nicotine Dependence in Humans||Centre for Addiction and Mental Health||Completed|June 2005|May 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||50|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00133757||196902|
NCT00142051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-09-119|Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis|Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis||Children's Hospital Boston|Yes|Terminated|April 2005|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|9 Years|22 Years|No|||July 2014|July 21, 2014|August 31, 2005|Yes|Yes|18 or 20 enrolled, stopped due to paucity of available participants|No||https://clinicaltrials.gov/show/NCT00142051||196273|
NCT00142298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2303|Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies|An Open Label Trial of Telbivudine (LdT) in Adults With Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies||Novartis||Completed|March 2005|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1869|||Both|16 Years|70 Years|No|||March 2015|March 24, 2015|August 31, 2005|Yes|Yes||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00142298||196255|
NCT00142311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A02094|Functional Characterization of Parkin + Patients|Clinical, Molecular and Metabolic Comparison Between Early Onset Parkinsonian, With or Without Parkin Mutation: Physiopathological Perspectives||Institut National de la Santé Et de la Recherche Médicale, France||Terminated|November 2003|September 2006||||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||97|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2007|April 18, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142311||196254|
NCT00132405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3268-2-002-1|Study of ALGRX 3268 for Needlestick Pain in Children|Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effectiveness and Safety of ALGRX 3268 0.5 Mg/20 Bar at the Back of the Hand in Pediatric Subjects||AlgoRx Pharmaceuticals||Completed|May 2004|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|3 Years|18 Years|No|||August 2005|October 7, 2005|August 15, 2005||||||https://clinicaltrials.gov/show/NCT00132405||197005|
NCT00132678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002278|A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes|A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2005|December 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|559|||Both|18 Years|65 Years|No|||July 2013|July 23, 2013|June 30, 2005|Yes|Yes||No|October 24, 2008|https://clinicaltrials.gov/show/NCT00132678||196984|
NCT00134160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-April-2005|OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study|The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk||OSCAR Study|Yes|Completed|August 2005|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|65 Years|84 Years|No|||October 2010|October 3, 2010|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00134160||196872|
NCT00130455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIL-01|Treatment of Depression in the Elderly|A 12 Week Multi-Centre, Randomized, Double-Blind, Placebo Controlled Evaluation of the Most Efficacious and Tolerable Dose of Escitalopram in the Treatment of Elderly Patients||Psychiatric Hospital, Hillerod||Terminated|April 2006|January 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||189|||Both|65 Years|N/A|No|||February 2007|February 5, 2007|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130455||197154|
NCT00132132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00203 (number assigned by IRB)|Study of Impact of Behavioral Intervention- Exercise, Nutrition, Education- on Body Mass Index (BMI)|Type 2 Diabetes and Obesity Pediatric Prevention Project||Steward St. Elizabeth's Medical Center of Boston, Inc.|Yes|Completed|August 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|10 Years|20 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|August 17, 2005||No||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00132132||197026|A limitation of the study is the lost to follow up. However, our rate of lost to follow up is comparable to rates seen in similar studies in this field
NCT00132418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021629|Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders|Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders||Amgen||Completed|April 2000|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|564|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00132418||197004|
NCT00120978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC0100141|Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial|Advair - CRP Study||University of British Columbia||Recruiting|December 2004|August 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|45 Years|N/A|No|||April 2005|May 8, 2006|July 11, 2005||||No||https://clinicaltrials.gov/show/NCT00120978||197864|
NCT00120991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-11-DP-83-RKF-22|Best Bypass Surgery (BBS) Trial|Off-Pump Coronary Artery Bypass Grafting Versus Conventional Coronary Artery Bypass Grafting on Postoperative Mortality and Morbidity, A Randomized Clinical Trial||Rigshospitalet, Denmark||Active, not recruiting|April 2002|July 2008|Anticipated|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|341|||Both|55 Years|N/A|No|||February 2008|February 29, 2008|July 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00120991||197863|
NCT00118105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000433491|S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer|A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin, and Bevacizumab for Resectable Colorectal Metastases in the Liver||Southwest Oncology Group|Yes|Withdrawn|November 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|July 8, 2005|Yes|Yes|Budget Constraints|No||https://clinicaltrials.gov/show/NCT00118105||198076|
NCT00132327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050219|Analysis of Lyme Disease Lesions|Analysis of Erythema Migrans Lesions||National Institutes of Health Clinical Center (CC)||Recruiting|August 2005|||||N/A|Observational|N/A|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 24, 2015|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00132327||197011|
NCT00132613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9811|Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion|A Randomized Controlled Trial to Evaluate the Efficacy of Intra-Pericardial Instillation of a Sclerosing Agent After Pericardial Drainage in Patients With Malignant Pericardial Effusion Associated With Lung Cancer (JCOG9811)||Japan Clinical Oncology Group|Yes|Completed|August 1999|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|N/A|75 Years|No|||February 2008|February 29, 2008|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132613||196989|
NCT00133224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-0034|Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients|A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain||Cell Genesys||Terminated|July 2005|June 2009|Anticipated|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|408|||Male|18 Years|N/A|No|||September 2008|September 19, 2008|August 19, 2005|Yes|Yes|Accrual and treatment with CG1940/CG8711 stopped due to IDMC recommendation.|No||https://clinicaltrials.gov/show/NCT00133224||196943|
NCT00133484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-026|UMD rPA Regimen Trial in Adults|A Phase II Study to Assess the Safety, Tolerability, Immunogenicity, and Optimal Primary Schedule of 3 Recombinant Protective Antigen (rPA) Anthrax Vaccines Administered in Two Intramuscular Doses to Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated||May 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||270|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2005|August 26, 2010|August 19, 2005||||||https://clinicaltrials.gov/show/NCT00133484||196923|
NCT00133276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV05-01|Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment|Prophylactic Treatment of Peginterferon-associated Psychopathology. A Double-blind Placebo-controlled Trial on the Effects of Escitalopram (Lexapro®) in Patients Treated With Peginterferon and Ribavirin (POPS Study)||Foundation for Liver Research|No|Completed|August 2005|December 2009|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|70 Years|No|||February 2010|February 18, 2010|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133276||196939|
NCT00133289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-051205-B|ULTRA Study for Pacemaker Patients|Ventricular Automatic Capture Assessment Study||Boston Scientific Corporation||Completed|July 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||950|||Both|18 Years|N/A||||July 2007|July 9, 2007|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133289||196938|
NCT00133471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-019|Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults|Evaluation of the Reactogenicity and Immunogenicity of Four Dosage Levels of Intramuscular Monovalent Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|96|||Both|18 Years|34 Years|Accepts Healthy Volunteers|||January 2009|August 26, 2010|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133471||196924|
NCT00133783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG34|Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure|Intermedin is an Estrogen- Modulated Factor for Reducing Blood Pressure||Chang Gung Memorial Hospital||Recruiting|May 2005|May 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||500|||Female|20 Years|90 Years|Accepts Healthy Volunteers|||May 2005|October 25, 2005|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00133783||196900|
NCT00134095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439474|S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer|Phase II Clinical Study of Preoperative S-1/CPT-11 Combination Chemotherapy in Patients With Locally Advanced Gastric Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 2004|||August 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Both|20 Years|75 Years|No|||January 2010|September 16, 2013|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134095||196876|
NCT00132938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4020|PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis|An Open-label, Randomized, Multicenter, Clinical Study to Compare the Effects of Telithromycin, Azithromycin and Cefuroxime Axetil on the Penicillin or Macrolide Resistance of Streptococcus Pneumoniae in Patients With Acute Exacerbation of Chronic Bronchitis||Sanofi||Completed|January 2004|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||5660|||Both|35 Years|N/A|No|||June 2011|June 7, 2011|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00132938||196964|
NCT00132951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4019|KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections|A Randomized, Investigator Blinded, Multi-Center Clinical Study To Compare Patient Outcomes and Clinical Effectiveness of Telithromycin Versus Azithromycin in Outpatients With Lower Respiratory Tract Infections|KEYS|Sanofi||Terminated|October 2004|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|2051|||Both|18 Years|35 Years|No|||August 2009|August 26, 2009|August 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00132951||196963|
NCT00133263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI020827|Effectiveness of a Standardized Bereavement Intervention in Primary Care|Effectiveness of "Primary Bereavement Care" (PBC) in Widows: A Cluster Randomized Controlled Trial||Carlos III Health Institute|No|Completed|January 2001|December 2006|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Female|N/A|70 Years|No|||March 2008|July 9, 2014|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133263||196940|
NCT00133809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00041120|Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression|Islet Transplantation in Type 1 Diabetes Using the Edmonton Protocol of Steroid Free Immunosuppression||Emory University|Yes|Completed|July 2002|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||August 2015|August 4, 2015|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133809||196898|
NCT00143052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Bone Status and Insulin Resistance in Hirsutism|Body Composition, Insulin Concentration, Androgens and Bone Status in Women Referred With Hirsutism||Odense University Hospital||Completed|January 2002|January 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Female|20 Years|46 Years|Accepts Healthy Volunteers||hirsute patients vs. controls|June 2008|June 23, 2008|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00143052||196198|
NCT00143065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0404|Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Feasibility/Phase II Trial of Fludarabine, Rituximab, and Alemtuzumab for Previously Treated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||Ohio State University Comprehensive Cancer Center|Yes|Completed|August 2005|July 2009|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143065||196197|
NCT00130143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethyol Study #ETH156-03D|Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities|Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities||The Dale & Frances Hughes Cancer Center||Completed|June 2003|September 2004||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A||||August 2005|September 26, 2005|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130143||197178|
NCT00130156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTR-886-401|Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension|Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension||Eisai Inc.||Completed|October 2005|March 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|20 Years|80 Years|No|||February 2011|May 13, 2013|August 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00130156||197177|
NCT00130169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7974-A001-102|A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies|A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies||Eisai Inc.||Completed|January 2006|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|August 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130169||197176|
NCT00130182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-107|A Study in Pediatric Patients With Cystic Fibrosis Lung Disease|A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Pediatric Patients With Cystic Fibrosis Lung Disease||Merck Sharp & Dohme Corp.||Completed|August 2005|||September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|13|||Both|5 Years|7 Years|No|||May 2013|May 21, 2013|August 11, 2005||||||https://clinicaltrials.gov/show/NCT00130182||197175|
NCT00131053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JALSG ALL202-U|Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)|Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia||Japan Adult Leukemia Study Group|Yes|Recruiting|September 2002|September 2011|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|15 Years|24 Years|No|||November 2008|November 13, 2008|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00131053||197108|
NCT00132691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-106|Multicenter Uveitis Steroid Treatment (MUST) Trial|Multicenter Uveitis Steroid Treatment (MUST) Trial|MUST|JHSPH Center for Clinical Trials|Yes|Completed|September 2005|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Both|13 Years|N/A|No|||June 2012|June 22, 2012|August 19, 2005|Yes|Yes||No|May 14, 2012|https://clinicaltrials.gov/show/NCT00132691||196983|
NCT00132964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000000188|Brace Versus Casting in Pediatric Low Risk Ankle Fractures|Randomized Control Trial of Casting Versus Ankle Bracing in Children With Low-risk Ankle Fractures||The Hospital for Sick Children|No|Completed|July 2003|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|5 Years|18 Years|No|||January 2007|June 5, 2012|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132964||196962|
NCT00117546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-155|Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia|Cardiovascular Performance and Autonomic Reactivity in Formerly Preeclamptic Women With a Contracted Plasma Volume (CAPACITY Trial)||Radboud University|Yes|Recruiting|September 2005|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|35|||Female|N/A|N/A|No|||July 2007|June 7, 2010|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00117546||198118|
NCT00117819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|At-Risk|A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease|Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome||Institute for Neurodegenerative Disorders|No|Completed|March 2001|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|232|||Both|22 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117819||198097|
NCT00132340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050222|Deep Brain Stimulation to Treat Cervical Dystonia|Deep Brain Stimulation of the Globus Pallidus Interna or the Subthalamic Nucleus for Treatment of Primary Cervical Dystonia||National Institutes of Health Clinical Center (CC)||Completed|August 2005|July 2006||||Phase 1|Interventional|Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2006|July 4, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132340||197010|
NCT00132626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dopamine Transporter Imaging|Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome|Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism||Institute for Neurodegenerative Disorders||Completed|September 1992|August 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||500|||Both|35 Years|N/A|No|||February 2007|February 20, 2007|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132626||196988|
NCT00131885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13430|Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel|Effects of St. John's Wort on Levonorgestrel||University of Utah|Yes|Completed|August 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|36|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|August 17, 2005||No||No|March 21, 2010|https://clinicaltrials.gov/show/NCT00131885||197044|
NCT00133796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-10379|Neoadjuvant Herceptin in Patients With Breast Cancer|A Phase II Study of the Effects of Herceptin in Patients With Locally Advanced HER-2/NEU Overexpressing Breast Cancer||Baylor Breast Care Center|Yes|Terminated|October 2001|April 2007|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|90 Years|No|||March 2013|March 22, 2013|August 22, 2005|No|Yes|Study was closed to accrual as of 4/19/2006 / Study did not qualify for reporting.|No||https://clinicaltrials.gov/show/NCT00133796||196899|
NCT00133562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11375|HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition|Prospective Double Blind Randomized Clinical Trial of Alanyl-Glutamine or Glycine in Hospitalized Children With Persistent Diarrhea or Malnutrition.||University of Virginia|No|Withdrawn|August 2004|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|3 Months|3 Years|No|||October 2008|October 27, 2008|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00133562||196917|
NCT00134108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C8265/A3036|Clinical Benefit of Cognitive Behaviour Therapy (CBT) for Insomnia in Cancer Patients|Randomised Controlled Clinical Effectiveness Trial of Cognitive Behaviour Therapy (CBT) Versus Treatment as Usual (TAU) for Insomnia in Cancer Patients||NHS Greater Clyde and Glasgow||Active, not recruiting|January 2003|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||January 2003|October 25, 2005|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00134108||196875|
NCT00130754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39-14.01.05-HMO-CTIL|Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation|A Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Thymoglobuline in Non-myeloablative Allogeneic Hemapoietic Stem-cell Transplantation (NST)||Hadassah Medical Organization||Completed|February 2005|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|75 Years|No|||November 2007|February 22, 2011|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130754||197131|
NCT00130767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.316|Kinetics of the Finasteride Prostate Induced Apoptosis|Kinetics of the Finasteride Prostate Induced Apoptosis||Hospices Civils de Lyon||Active, not recruiting|December 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Male|40 Years|90 Years|No|||April 2007|April 26, 2007|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130767||197130|
NCT00142064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 06-080|A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures|A Randomized Control Trial Comparing Single to Multiple Application Lidocaine Analgesia Prior to Urethral Catheterization Procedures||Children's Mercy Hospital Kansas City|Yes|Completed|August 2005|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|2 Months|7 Years|Accepts Healthy Volunteers|||September 2006|April 16, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142064||196272|
NCT00142506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-007|Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer|This Protocol is a Randomized Prospective Study Comparing Prophylactic and on Demand Sildenafil Citrate Usage Administered During and After Radiotherapy With or Without Hormone Therapy Versus Radiotherapy With or Without Hormone Therapy Alone for the Preservation of Erectile Function After Therapy for Potent Patients With Clinically Localized Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|February 2005|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|290|||Male|N/A|N/A|No|||April 2014|April 23, 2014|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142506||196239|
NCT00133822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0184-2004|Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial|Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD||Emory University||Completed|April 2004|September 2006|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||65|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133822||196897|
NCT00142805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0076|Ketasyn in Mild to Moderate Alzheimer's Disease|Safety, Tolerability and Efficacy Study of Ketasyn™ (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity||National Institute on Aging (NIA)||Completed|October 2004|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|50 Years|N/A|No|||September 2006|December 30, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142805||196216|
NCT00142818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-12756-3|Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence|A Phase II, Double-blind, Placebo-Controlled, Pilot Trial of the Combination of Modafinil and Naltrexone for the Treatment of Cocaine and Alcohol Dependence|Mod-Nal|University of Pennsylvania|Yes|Completed|February 2006|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|164|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|September 1, 2005|Yes|Yes||No|August 12, 2014|https://clinicaltrials.gov/show/NCT00142818||196215|
NCT00130780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-052|Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC|Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) (BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC)||Memorial Sloan Kettering Cancer Center||Completed|August 2005|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|August 12, 2005|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT00130780||197129|
NCT00130793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-010|A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)|A Double-Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of a Refrigerator-Stable Formulation of Zoster Vaccine Live (Oka/Merck)||Merck Sharp & Dohme Corp.||Completed|August 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|368|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|August 11, 2005|Yes|Yes||No|May 11, 2009|https://clinicaltrials.gov/show/NCT00130793||197128|
NCT00131625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104.dan.8-839-exclbrea|Impact of Exclusive Breast-Feeding in Guinea Bissau|Aspects of Exclusive Breast-Feeding in Guinea Bissau. Intervention Study to Clarify Recommendations for Breast-Feeding Policy in Developing Countries||Bandim Health Project||Completed|March 2000|February 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1500|||Both|N/A|6 Months|No|||August 2005|October 7, 2005|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00131625||197064|
NCT00131872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00168|Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts|Clinical Study Comparing Expedial and ePTFE Vascular Access Grafts||LeMaitre Vascular||Terminated|March 2004|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||172|||Both|18 Years|N/A|No|||November 2006|January 24, 2008|August 17, 2005||||||https://clinicaltrials.gov/show/NCT00131872||197045|
NCT00139152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xolair ENO EBC Study|Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair|Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair||Creighton University|No|Completed|September 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|12 Years|N/A|No|||January 2014|January 6, 2014|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00139152||196491|
NCT00133848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC103469|Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment|A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo.||GlaxoSmithKline||Completed|April 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|9 Months|N/A|No|||March 2011|March 17, 2011|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133848||196895|
NCT00134173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091005|A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease|Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.|ILLUSTRATE|Pfizer||Completed|October 2003|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1100|||Both|18 Years|75 Years|No|||April 2007|December 6, 2007|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134173||196871|
NCT00117806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3773-R|Spinal Cord Injury Vocational Integration Program (SCI-VIP)|A Spinal Cord Injury Vocational Integration Program: Implementation and Outcomes|SCI-VIP|VA Office of Research and Development|Yes|Completed|April 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|249|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|July 1, 2005||No||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00117806||198098|Majority of sample is male; Potential selection bias (participants who decided to remain in study for second year may be different from those who did not though no statistical significance was detected between groups)
NCT00118638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030231|A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy|A Randomized, Double Blind, Active-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy||Amgen||Completed|March 2004|January 2005|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|705|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00118638||198037|
NCT00132353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050223|Training for Diagnosing Neurological Disorders|Clinical Neurophysiology: Training and Normative Values||National Institutes of Health Clinical Center (CC)||Recruiting|August 2005|||||N/A|Observational|N/A|||Anticipated|400|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 27, 2016|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00132353||197009|
NCT00132652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-02B-019|Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B|A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults With Chronic Hepatitis B||Novartis||Completed|February 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|70 Years|No|||May 2015|May 8, 2015|August 18, 2005||||||https://clinicaltrials.gov/show/NCT00132652||196986|
NCT00132639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG 0204-MF|Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for c-Stage IB-II Non-Small Cell Lung Cancer (NSCLC)|Randomized Phase II Study of the Induction Chemotherapy With Docetaxel Alone vs CDDP + Docetaxel for c-Stage IB-II Non-Small Cell Lung Cancer (JCOG 0204-MF)||Japan Clinical Oncology Group|Yes|Completed|October 2002|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|74 Years|No|||February 2009|February 2, 2009|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132639||196987|
NCT00133861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.351|Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles|Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles. Assessment of Efficiency of Botulinum Toxin on Spasticity in Agonist and Antagonist Muscles Using Clinical Assessment and Gait Analysis in Cerebral Palsy Children: Rectus Femoris and Semitendinosus||Hospices Civils de Lyon||Completed|April 2005|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|23|||Both|7 Years|17 Years|No|||June 2008|June 30, 2008|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00133861||196894|
NCT00133874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC100224|Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo|See Detailed Description||GlaxoSmithKline|No|Completed|April 2005|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|520|||Both|9 Months|N/A|No|||March 2011|May 31, 2012|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133874||196893|
NCT00134134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12452-01B|Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa|An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa||New York University School of Medicine||Completed|February 2005|August 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Female|18 Years|65 Years|No|||September 2006|September 7, 2006|August 23, 2005||||||https://clinicaltrials.gov/show/NCT00134134||196874|
NCT00134147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171018|A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control|A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents||Pfizer||Completed|April 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1100|||Both|35 Years|80 Years|No|||April 2008|April 16, 2008|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134147||196873|
NCT00131339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOLI001428HI|Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder|Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Panic Disorder||Hartford Hospital||Completed|November 2004|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2009|August 25, 2009|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131339||197086|
NCT00142324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN62185868|CALM-AD|A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention||Institute of Psychiatry, London||Active, not recruiting|November 2003|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||190|||Both|40 Years|N/A|Accepts Healthy Volunteers|||September 2005|December 13, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142324||196253|
NCT00142779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-10754-2|Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts|Serotonin Treatment of Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Completed|April 2001|March 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|60 Years|No|||May 2009|May 15, 2009|September 1, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00142779||196218|
NCT00142792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD049777|Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke|Electrical Stimulation for Upper Limb Recovery in Stroke||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|December 2005|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|122|||Both|21 Years|89 Years|No|||December 2011|December 22, 2011|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142792||196217|
NCT00142831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11512-1|Bupropion as an Adjunct to the Nicotine Patch Plus CBT|Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1||National Institute on Drug Abuse (NIDA)|No|Completed|April 1999|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|293|||Both|20 Years|65 Years|No|||August 2008|August 21, 2008|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00142831||196214|
NCT00138580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2305E1|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes||Novartis||Completed|November 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||345|||Both|18 Years|80 Years||||May 2012|May 4, 2012|August 27, 2005||||No||https://clinicaltrials.gov/show/NCT00138580||196535|
NCT00138593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2329E1|Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%|Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%||Novartis||Completed|July 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|August 27, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00138593||196534|
NCT00138853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030119|A Roentgen Stereophotogrammetric Analysis on Migration of Knee Prostheses.|A Roentgen Stereophotogrammetric Analysis on Migration of Knee Prostheses. A Randomised Prospective Study of Tantalum Versus Titanium Implants.|Ti-Tan|University of Aarhus|Yes|Completed|November 2003|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||October 2010|October 12, 2010|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00138853||196514|
NCT00138866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI REB #04-016|Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury|Risedronate for Treatment of Sublesional Osteoporosis After Spinal Cord Injury||Toronto Rehabilitation Institute|Yes|Completed|November 2004|March 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||July 2008|October 12, 2010|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00138866||196513|
NCT00138879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC3155|Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients|Plasma Citrulline Level: A Simple, Sensitive Method to Assess and Monitor Small Bowel Absorptive Function in Patients With Crohn's Disease?||St Mark's Hospital Foundation||Completed|May 2003|June 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||54|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2005|December 14, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138879||196512|
NCT00139477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-032|Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention|Understanding the Effects of Therapeutic Intervention on Cardiovascular Risk Markers, Insulin Resistance, and Intra-Hepatic Fat Contents in Obese Children at High Risk for the Metabolic Syndrome.||Nemours Children's Clinic|Yes|Completed|November 2003|September 2011|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||October 2012|October 21, 2012|August 29, 2005||No||No|June 25, 2012|https://clinicaltrials.gov/show/NCT00139477||196468|Protocol #2 attrition was high, such that, we could not derive conclusions beyond the 6 month time period. Therefore, conclusions were based on participants after completing the first intervention without crossover to the second intervention.
NCT00117572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13362B|Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)|A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer||University of Chicago|Yes|Active, not recruiting|November 2004|August 2013|Anticipated|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00117572||198116|
NCT00118651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG20040023H|Clinical Indicators of Radiographic Findings in Patients With Suspected Community-Acquired Pneumonia|Clinical Indicators of Radiographic Findings in Patients With Suspected Community-Acquired Pneumonia: Who Needs a Chest X-Ray?||David Grant U.S. Air Force Medical Center||Withdrawn|October 2004|May 2005||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2005|September 25, 2013|July 1, 2005|||PI location unknown|No||https://clinicaltrials.gov/show/NCT00118651||198036|
NCT00123474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-034|Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML|A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)||Bristol-Myers Squibb|No|Completed|July 2005|July 2014|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|724|||Both|18 Years|90 Years|No|||July 2015|July 29, 2015|July 21, 2005|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT00123474||197677|
NCT00133237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02005|Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)|Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)||Deutsches Herzzentrum Muenchen|Yes|Completed|July 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|607|||Both|18 Years|N/A|No|||October 2008|March 12, 2010|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133237||196942|
NCT00133250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. I00902|Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)|Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)||Deutsches Herzzentrum Muenchen|Yes|Completed|June 2003|March 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|800|||Both|18 Years|80 Years|No|||March 2010|March 15, 2010|August 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00133250||196941|
NCT00132899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP0401|COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)|A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Infliximab in Combination With Methotrexate for the Long-term Treatment of Crohn's Disease (CD)||University of Western Ontario, Canada|Yes|Completed|December 2005|July 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||December 2005|December 10, 2013|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132899||196967|
NCT00130468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9385|TREAD-20: Trial of Hyalgan Three Injection-Regimen for the Treatment of Knee Pain Due to Osteoarthritis|A Double Blind, Randomized Trial of Intra-Articular Injections of 20 mg of Hyalgan® for the Treatment of Knee Pain Due to Osteoarthritis (Three Injection-Regimen for Efficacy And Duration-20 mg/2mL Dose: Tread-20)||Sanofi||Completed|November 2004|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|40 Years|N/A|No|||April 2008|April 1, 2008|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130468||197153|
NCT00132977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050084|RethinQ Study - Evaluating Pacing in Heart Failure Patients|Resynchronization Therapy in Normal QRS (RethinQ) Clinical Investigation|RethinQ|St. Jude Medical|Yes|Completed|July 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|August 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00132977||196961|
NCT00129870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9444|CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer|CONCEPT - Phase IV, Randomized, Prospective, Multicenter Comparison of Intermittent Schedule of Oxaliplatin Combined With FOLFOX/Bevacizumab vs Conventional Mode of Administration of FOLFOX/Bevacizumab + Neuroprophylaxis With Calcium/Magnesium for Optimization of First-Line Therapy of Metastatic Colorectal Cancer||Sanofi|Yes|Terminated|February 2005|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|180|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|August 10, 2005|Yes|Yes|Unplanned interim analysis by DSMB indicated possible reduced response rate with the addition    of Ca/Mg in pooled population. Further analysis pending.|No||https://clinicaltrials.gov/show/NCT00129870||197198|
NCT00129883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAR-2001-1|Adherence to Guidelines for Antibiotic Use in Respiratory Infections at Hospitals|Prevention of Antimicrobial Resistance in Hospitals: Promoting Appropriate Use of Antibiotics in Hospital Departments of Internal and Pulmonary Medicine||Radboud University||Completed|September 2002|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||2000|||Both|18 Years|N/A|No|||August 2002|September 26, 2005|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129883||197197|
NCT00130442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR88205|Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma|A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma||Progen Pharmaceuticals|Yes|Active, not recruiting|June 2005|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||March 2009|March 2, 2009|August 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130442||197155|
NCT00141765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9626|Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers|Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers||University of Michigan Cancer Center|Yes|Completed|January 1997|February 2010|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|21 Years|No|||May 2014|May 19, 2014|August 31, 2005|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00141765||196295|
NCT00142090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04139-C|Use of Salt-Water Solution to Improve Symptoms in Concussion|Use of 3% Hypertonic Saline to Improve Clinical Symptoms in Concussed Patients||Rady Children's Hospital, San Diego|No|Completed|November 2004|July 2007|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|6 Years|17 Years|No|||January 2009|February 2, 2009|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142090||196270|
NCT00142103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1211001|CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects|CPG10101 Combination Therapy For The Treatment Of Hepatitis C: A Phase 1b Open Label Randomized Trial Of CPG10101 Alone, With Interferon, Ribavirin, Or Interferon And Ribavirin In The Treatment Of Relapsed Hepatitis C Virus (HCV) Subjects||Pfizer|Yes|Completed|September 2005|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|91|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142103||196269|
NCT00141778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040385|Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)|RAAS, Inflammation, and Post-operative AF||Vanderbilt University|Yes|Completed|April 2005|August 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|455|||Both|18 Years|80 Years|No|||February 2013|February 19, 2013|August 30, 2005|Yes|Yes||No|August 3, 2012|https://clinicaltrials.gov/show/NCT00141778||196294|We excluded patients with an ejection fraction less than 30% or a creatinine above 1.6 and therefore the results are not applicable to patients with left ventricular dysfunction or more severe chronic kidney disease.
NCT00141791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A8-205|Study Evaluating Etanercept in Moderate to Severe Asthma|A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25mg Twice Weekly in Subjects With Moderate to Severe Persistent Asthma||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|70 Years|No|||August 2009|August 6, 2009|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141791||196293|
NCT00142077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R01 CDC 000065-01|Electronic Health Records for Health Promotion|Health Promotion in the Workplace Using Personally Controlled Health Records||Children's Hospital Boston||Completed|October 2005|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||700|||Both|18 Years|N/A|No|||January 2006|April 4, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142077||196271|
NCT00142519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-025|Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain|Translational Studies in Analgesic Pharmacology: Analgesic Synergy in Clinical Pain. A Phase 2 Study Comparing a Single Dose of a 1:1 Combination of Methadone and Morphine With Morphine Alone in Patients With Post-operative Pain.||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2005|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|August 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00142519||196238|
NCT00142844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-12756-1|Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1|Two Medications, Disulfiram and Naltrexone, in the Treatment of Patients With Both Cocaine and Alcohol Dependence||National Institute on Drug Abuse (NIDA)|No|Completed|September 1999|January 2008|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|208|||Both|18 Years|65 Years|No|||December 2009|December 2, 2009|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142844||196213|
NCT00143130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081015|Pregabalin In Partial Seizures Extension Study|Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-month Follow-on Open-label, International, Multicenter Add-on Therapy Trial|PREPS EXT|Pfizer|No|Completed|April 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|227|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143130||196192|
NCT00143078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19366|Obesity and Weight Loss on Reproductive Function|The Effects of Morbid Obesity and Weight Loss on Reproductive Function: The Bariatric Surgery Model||Milton S. Hershey Medical Center|No|Terminated|June 2005|December 2009|Actual|June 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples With DNA|whole blood & urine|Both|18 Years|40 Years|No|Probability Sample|Participants eligible for bariatric surgery; BMI >40 or between 35 and 39.9 with a weight        related health problem; Failed medical weight loss; Ages 18-40; Not using hormonal        contraceptives; Females have not undergone and bilateral oophrectomy or hysterectomy;        Males have not had a vasectomy|November 2015|November 13, 2015|September 1, 2005||No|Close-out of the grant - study ceased on 1/1/2010|No||https://clinicaltrials.gov/show/NCT00143078||196196|
NCT00138606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2311E1|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes||Novartis||Completed|January 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|179|||Both|18 Years|80 Years||||May 2012|May 4, 2012|August 27, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00138606||196533|
NCT00138619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2327E1|Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|November 2004|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|478|||Both|18 Years|80 Years||||May 2012|May 4, 2012|August 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138619||196532|
NCT00138892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C01-0407|A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty|A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty||University of British Columbia|No|Active, not recruiting|August 2002|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|236|||Both|18 Years|N/A|No|||October 2011|October 12, 2011|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00138892||196511|
NCT00138905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2064-04-0009|Experimental Study of Mobile Base Station Related Radio-Frequency Electromagnetic Radiation|Experimental Study of Mobile Base Station Related Radio-Frequency Electromagnetic Radiation in Healthy Adults and Adolescents||University of Aarhus||Completed|February 2005|April 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||80|||Both|15 Years|40 Years|Accepts Healthy Volunteers|||September 2007|September 6, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138905||196510|
NCT00139165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|okbon123|Long-Term Treatment of Collagenous Colitis With Budesonide|Long-Term Treatment of Collagenous Colitis With Budesonide. Prospective, Doubleblind Placebo-Controlled Trial.||Bonderup, Ole K., M.D.|Yes|Active, not recruiting|September 2004|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||August 2005|March 3, 2008|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139165||196490|
NCT00139178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26122450|Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.|Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities||Danish HIV Research Group||Completed|March 2004|April 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A||||August 2005|September 2, 2005|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139178||196489|
NCT00118378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4839|Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS|Modafinil Treatment for Fatigue in HIV+ Patients||New York State Psychiatric Institute|Yes|Completed|December 2004|November 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|75 Years|No|||March 2013|June 6, 2014|July 6, 2005|Yes|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT00118378||198056|This study was conducted at a single site in an urban setting where most patients have good access to medical care. Women were under-represented despite outreach efforts.
NCT00123682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMV 04-088|TeleQuit Smoking Cessation Program|Telephone Care Coordination to Improve Smoking Cessation Counseling||VA Office of Research and Development|No|Completed|May 2005|September 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3120|||Both|N/A|N/A|No|||February 2015|February 26, 2015|July 21, 2005||No||No|January 8, 2015|https://clinicaltrials.gov/show/NCT00123682||197661|
NCT00130195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JALSG Ph+ALL202|Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)|Phase 2 Study of Imatinib-Combined Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia||Japan Adult Leukemia Study Group|Yes|Completed|September 2002|May 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|15 Years|64 Years|No|||November 2008|November 13, 2008|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130195||197174|
NCT00130208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-101-301|Effect of Sulodexide in Early Diabetic Nephropathy|The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria||Keryx Biopharmaceuticals||Completed|August 2005|February 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|August 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130208||197173|
NCT00130481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|576-2004|Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)|Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)||University of Florida||Completed|April 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|10 Years|18 Years|No|||March 2012|March 6, 2012|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130481||197152|
NCT00130806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0478-065|An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)|A Study to Assess the Efficacy and Tolerability of MK0478 (Muraglitazar, Also, BMS 298585) Coadministered With Insulin in Patients With Type 2 Diabetes||Merck Sharp & Dohme Corp.||Terminated|September 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||600|||Both|18 Years|70 Years|No|||December 2014|December 22, 2014|August 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130806||197127|
NCT00133510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-050|Influenza Vaccine in Pediatric Transplant Subjects|Prospective Comparative Study of the Humoral and Cell-Mediated Immune Responses to the Trivalent Subviron Influenza Vaccine in Pediatric Liver Transplant Recipients as an Indicator for Response of Immunocompromised Subjects to Vaccination Against Agents of Bioterrorism||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2004|September 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||March 2008|August 26, 2010|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133510||196921|
NCT00141505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.2.015|PK Effects of Bifeprunox & Valproate in Bipolar I|Placebo-controlled Study on the Pharmacokinetics,Pharmacodynamics, Safety and Tolerability of Concurrent Valproate and Bifeprunox Administration in Subjects With Bipolar I Disorder||Solvay Pharmaceuticals||Completed|February 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||September 2007|January 15, 2015|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141505||196315|
NCT00141518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S187.4.001|DAPHNE (Duodopa in Advanced Parkinson's: Health Outcomes & Net Economic Impact)|A Long-term Health Economics Study of Intraduodenal Levodopa (Duodopa®) in Routine Care for Patients With Advanced Idiopathic Parkinson's Disease With Severe Motor Fluctuations and Hyper-/Dyskinesia||Abbott||Completed|January 2006|April 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00141518||196314|
NCT00141531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI 05-003|Phase II Trial of EOquin in High-risk Superficial Bladder Cancer|Phase II Study of Intravesical Instillation of EOQUIN™ in High Risk Superficial Bladder Cancer||Spectrum Pharmaceuticals, Inc|No|Completed|July 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00141531||196313|
NCT00142116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-077|Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia|Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Completed|May 2003|February 2008|Actual|February 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|No|||May 2014|May 8, 2014|September 1, 2005|Yes|Yes||No|June 13, 2013|https://clinicaltrials.gov/show/NCT00142116||196268|
NCT00142363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4CH03G|Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and Epilepsies|The DNA and Cell Bank of IFR of Neurosciences: Clinical and Genetic Study of Parkinson's Disease and Epilepsies||Institut National de la Santé Et de la Recherche Médicale, France||Terminated|May 2004|December 2006||||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||1700|||Both|1 Year|90 Years|Accepts Healthy Volunteers|||February 2006|February 28, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142363||196250|
NCT00142532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-073|Acupuncture for Post-Thoracotomy Pain|Acupuncture for Post-Thoracotomy Pain: A Randomized Controlled Trial||Memorial Sloan Kettering Cancer Center||Completed|June 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|August 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00142532||196237|
NCT00143169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3481004|Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Of Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain Following Orthopedic Or Gynecological Surgery||Pfizer||Completed|September 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|65 Years|No|||November 2005|April 14, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143169||196189|
NCT00143182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07007|9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)|A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Asenapine vs. Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501006 (Secondary Title: ARES)||Merck Sharp & Dohme Corp.|Yes|Completed|January 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|504|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143182||196188|
NCT00143091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2211002|Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder|A Six-Week, Fixed Dose, Double-Blind, Double-Dummy, Placebo and Sertraline Controlled, Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Outpatients With Major Depressive Disorder||Pfizer|Yes|Terminated|April 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||March 2008|March 19, 2008|August 31, 2005|||See Detailed Description for termination reason.|||https://clinicaltrials.gov/show/NCT00143091||196195|
NCT00143104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171052|To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.|A Phase 2, Exploratory Study to Examine the Effects of Inhaled Insulin, Compared With Subcutaneously Administered Insulin, on Airway Lining Fluid Composition in Subjects With Type 1 Diabetes Mellitus.||Pfizer||Completed|December 2004|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|55 Years|No|||February 2007|March 9, 2008|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143104||196194|
NCT00143117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3871022|Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation|A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation||Pfizer||Completed|August 2004|June 2005|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||460|||Male|18 Years|N/A|No|||November 2012|November 5, 2012|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00143117||196193|
NCT00138632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787E2201|Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)|A Randomized, Double-Masked, Multicenter, Phase I/II Study of the Safety of PTK787 Administered to Patients With Predominantly Classic , Minimally Classic or Occult With no Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|ADVANCE|Novartis||Completed|September 2005|||November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|65 Years|N/A|No|||November 2008|November 12, 2008|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138632||196531|
NCT00138918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-0092|Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer|A Phase II Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer||University of British Columbia|No|Recruiting|June 2005|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Male|18 Years|N/A|No|||April 2012|April 24, 2012|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00138918||196509|
NCT00139191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-136|Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer|A Pilot Study Evaluating the Correlation Between Carbon 11 Acetate (C-11 Acetate) Uptake and Retention as Measured by Positron Emission Tomography (PET) and Fatty Acid Synthase (FAS) Expression in Prostate Cancer||Dana-Farber Cancer Institute||Completed|July 2005|May 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Male|18 Years|N/A|No|||October 2009|October 30, 2009|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139191||196488|
NCT00139529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248|Education and Counseling for Abstinence From Tobacco After Pregnancy|Postpartum Maintenance of Abstinence From Tobacco||Brown University|No|Completed|March 2006|August 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|757|||Female|16 Years|N/A|No|||December 2015|December 21, 2015|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139529||196465|
NCT00118391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060417-02|Cognitive-Behavioral Treatment of Gambling|Enhanced Cognitive Behavior Therapy for the Treatment of Pathological Gambling|CBT/CM|University of Connecticut Health Center|Yes|Completed|November 2002|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|July 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00118391||198055|
NCT00123994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAMCIG56|Tai Chi or Hydrotherapy for People With Osteoarthritis of the Hip(s) or Knee(s)|Tai Chi or Hydrotherapy for People With Osteoarthritis of the Hip(s) or Knee(s)||St George Hospital, Australia||Active, not recruiting|February 2004|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|59 Years|85 Years|No|||July 2005|November 2, 2005|July 22, 2005||||No||https://clinicaltrials.gov/show/NCT00123994||197638|
NCT00131365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF014 - 4.1/3T|Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids|Post Approval Study: MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids||InSightec||Completed|January 2006|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|N/A|N/A|No|||September 2012|September 13, 2012|August 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00131365||197084|
NCT00131638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040118|A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer|Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy(RT/CT)||Amgen|No|Active, not recruiting|January 2005|March 2016|Anticipated|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00131638||197063|
NCT00140751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA-030|Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients|A 48-Weeks National Multicenter Randomized Open Clinical Trial Evaluating Tolerance and Efficacy of a Treatment Simplification by Lopinavir/Ritonavir Versus Continuation of Current Treatment in HIV-Infected Patients With a Viral Load Inferior to 50 Copies/mL Since 6 Months At Least|KALESOLO|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba||Completed|October 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140751||196372|
NCT00141037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT SNS01|Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation|Randomized, Multi-Center Comparative Trial of Tacrolimus w/Steroids and Standard Daclizumab Induction vs a Novel Steroid-Free Tacrolimus Based Immunosuppression Protocol w/ Extended Daclizumab Induction in Pediatric Renal Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2004|November 2010|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|N/A|21 Years|No|||July 2013|July 11, 2013|August 1, 2005|No|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00141037||196351|The results cannot be generalized and daclizumab has since been withdrawn from the United States market (business-related, not due to any safety issues).The study was not powered to definitively evaluate small differences in rejection rate.
NCT00141050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124EUS12|Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD|Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD||Novartis||Completed|May 2005|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||90|||Both|6 Years|12 Years|No|||December 2007|December 17, 2007|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141050||196350|
NCT00141063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124EUS13|Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD|Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD||Novartis||Completed|June 2005|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|6 Years|12 Years|No|||December 2007|December 17, 2007|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141063||196349|
NCT00141492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S176.2.101|Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes|A Double Blind, Randomized, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Androgel, as an Adjunct to Hypoglycemic Therapy, in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes||Solvay Pharmaceuticals||Completed|October 2004|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|30 Years|80 Years|No|||January 2009|January 19, 2015|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141492||196316|
NCT00141544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S030.2.107|The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women|A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women||Solvay Pharmaceuticals|No|Terminated|July 2004|March 2008|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Female|35 Years|65 Years|No|||April 2008|April 10, 2008|August 30, 2005|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00141544||196312|
NCT00141557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S030.2.110|The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women|A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women||Solvay Pharmaceuticals|No|Terminated|July 2004|March 2008|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|133|||Female|35 Years|65 Years|No|||April 2008|April 10, 2008|August 30, 2005|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00141557||196311|
NCT00141856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-0023-313|Health E Heart Study (South Texas Veterans Health Care System Heart Failure Disease Management Program/Study)|Health E Heart Study (South Texas Veterans Health Care System Heart Failure Disease Management Program/Study)||VA Office of Research and Development||Completed|June 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|420|||Both|18 Years|N/A|No|||June 2008|June 19, 2008|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00141856||196288|
NCT00141869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050230|Brain Activity Associated With Tics in Patients With Tourette Syndrome|MEG Study of Altered Sensory Processing in Tourette Syndrome: An Exploration of Sensory Tics||National Institutes of Health Clinical Center (CC)||Completed|August 2005|September 2007||||N/A|Observational|N/A||||30|||Both|14 Years|65 Years|Accepts Healthy Volunteers|||September 2007|March 5, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141869||196287|
NCT00141882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192944-004|Memantine in Patients With Chronic Glaucoma|||Allergan|No|Completed|March 1999|August 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|1119|||Both|18 Years|80 Years|No|||November 2010|November 3, 2010|August 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00141882||196286|
NCT00142129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-248|Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia|Phase II Study of Velcade in Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute||Completed|December 2003|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|18 Years|90 Years|No|||June 2011|June 23, 2011|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00142129||196267|
NCT00142337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRD-UMI 174 PHPT-4|One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine|A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV||Institut de Recherche pour le Developpement||Completed|December 2004|February 2009|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|244|||Female|18 Years|N/A|No|||January 2012|January 4, 2012|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00142337||196252|
NCT00142350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9912|A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer|Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)||Japan Clinical Oncology Group|Yes|Completed|November 2000|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||690|||Both|20 Years|75 Years|No|||May 2007|May 31, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142350||196251|
NCT00142545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APO401|Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease|Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease||Mylan Bertek Pharmaceuticals||Completed|July 1999|July 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||July 2005|August 31, 2005|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00142545||196236|
NCT00142558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-081|A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)|A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout||Merck Sharp & Dohme Corp.||Completed|January 2005|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|180|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142558||196235|
NCT00142883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18197-3|The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3|The Effects of GABA Medications on Cocaine Responses in Humans||Yale University|Yes|Terminated|September 2004|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|45 Years|No|||July 2015|July 7, 2015|September 1, 2005||No|Study has been completed|No||https://clinicaltrials.gov/show/NCT00142883||196211|
NCT00143195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531076|Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina|Open Label Study Comparing Amlodipine vs Long-Acting Nitrates in Patients With Chronic Stable Angina.|ANISSA|Pfizer||Completed|April 2001|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||April 2007|April 17, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143195||196187|
NCT00143143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-000-164|Pregabalin Open-Label Extension Trial in Patients With Partial Seizures|Pregabalin BID Open-Label Add-On Trial: A Follow-Up Study To Determine Long-Term Safety and Efficacy in Patients With Partial Seizures||Pfizer||Completed|September 2001|February 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2006|July 21, 2006|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00143143||196191|
NCT00143156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081071|Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy||Pfizer||Completed|March 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|18 Years|N/A|No|||April 2008|April 9, 2008|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143156||196190|
NCT00138645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 25004|The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet|The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet|FORMULA|Pennington Biomedical Research Center|No|Completed|April 2005|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|August 29, 2005||No||No|April 21, 2009|https://clinicaltrials.gov/show/NCT00138645||196530|
NCT00139217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1386-2004|NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn|NO Need to Ventilate: A Trial of Non-invasive iNO in Persistent Pulmonary Hypertension of the Newborn||Emory University|Yes|Completed|August 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|N/A|N/A|No|||May 2014|May 27, 2014|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139217||196486|
NCT00139581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2314|Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects|Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects||Novartis||Completed|September 2004|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|2 Years|17 Years|No|||April 2008|April 22, 2008|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139581||196461|
NCT00139204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-419|Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients|An Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine (C11 MET) in Prostate Cancer, as Assessed by Positron Emission Tomography (PET)||Dana-Farber Cancer Institute||Completed|April 2005|July 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Male|18 Years|N/A|No|||October 2009|October 30, 2009|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139204||196487|
NCT00139555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIB002FUS16|Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension|Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension||Novartis||Completed|July 2004|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|125|||Both|55 Years|N/A|No|||November 2011|November 7, 2011|August 29, 2005||||||https://clinicaltrials.gov/show/NCT00139555||196463|
NCT00119158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-10-3975|Combination Therapy for Atopic Dermatitis|An Exploratory Double-blind, Randomized, Vehicle-controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Elidel Cream 1% and Cutivate Cream 0.05% in Patients With Severe Lesions of Atopic Dermatitis (AD)||Children's Hospital of Philadelphia|No|Completed|October 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|2 Years|65 Years|No|||July 2010|July 23, 2010|July 5, 2005||No||No|February 19, 2010|https://clinicaltrials.gov/show/NCT00119158||197997|
NCT00124683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13672-1|Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1|Optimizing Treatment for Schizophrenic Smokers||National Institute on Drug Abuse (NIDA)|Yes|Completed|September 2001|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2007|August 1, 2007|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00124683||197588|
NCT00132145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G03-02820|Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III)|A Randomized Trial of Electronic Integration of Care for Better Vascular Outcomes: The Compete III Study Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III)||St. Joseph's Healthcare Hamilton||Completed|April 2003|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1000|||Both|55 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 13, 2006|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00132145||197025|
NCT00132158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCPZD|ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors|A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and an Oral Formulation of Irinotecan (Camptosar™) in Children With Refractory Solid Tumors||St. Jude Children's Research Hospital|No|Completed|September 2005|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|21 Years|No|||April 2012|April 16, 2012|August 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00132158||197024|
NCT00132431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040123|START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism|Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism||Amgen||Completed|July 2004|July 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00132431||197003|
NCT00140764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METRO STUDY|Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi|||Johns Hopkins Bloomberg School of Public Health||Completed|January 2003|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|55 Years||||August 2011|August 9, 2011|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140764||196371|
NCT00141102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191084|Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis|Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events|CONDOR|Pfizer|Yes|Completed|October 2005|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4484|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|August 29, 2005|Yes|Yes||No|May 11, 2010|https://clinicaltrials.gov/show/NCT00141102||196346|
NCT00141076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59240-#2|Glycemic Index and CVD: a Crossover Feeding Study|Glycemic Index, Obesity, Insulin Resistance and CVD Risk, Part 2||Children's Hospital Boston||Completed|October 2003|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention||||24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2010|August 27, 2010|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141076||196348|
NCT00141089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919E2309|Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.|Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.||Novartis||Completed|March 2004|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1026|||Both|18 Years|N/A||||January 2008|January 31, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141089||196347|
NCT00141804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirTac 01|Efficacy and Safety of Sirolimus in Combination With Tacrolimus|A Randomized Multicenter Study to Compare Tacrolimus and MMF With Tacrolimus and Rapamycin in Patients After Renal Transplantation||University Hospital Muenster||Active, not recruiting|January 2002|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||190|||Both|18 Years|65 Years|No|||August 2005|November 30, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141804||196292|
NCT00141817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B3-334|Study Evaluating Pantoprazole in Children With GERD|A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|41|||Both|1 Year|11 Years|No|||November 2011|November 23, 2011|August 30, 2005||||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00141817||196291|
NCT00132795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAHEL014270|Using Telephone Technology to Prevent Relapse After Alcoholism Treatment|Therapeutic IVR to Augment CBT in Alcohol Dependence|ATIVR|University of Vermont|No|Completed|May 2005|July 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|158|||Both|19 Years|N/A|No|||June 2012|June 20, 2012|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132795||196975|
NCT00133081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITE|Study to Improve the Treatment of Epilepsy (SITE)|Study to Improve the Treatment of Epilepsy (SITE). A Randomized Study Comparing Adjustment of Treatment to Reduce Side Effects of Antiepileptic Drugs With Continuing Treatment Unchanged||UMC Utrecht||Active, not recruiting|October 2002|August 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||255|||Both|18 Years|N/A|No|||March 2004|October 20, 2005|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00133081||196953|
NCT00142571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-129|Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma|Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society||Memorial Sloan Kettering Cancer Center||Completed|January 2003|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|10 Years|N/A|No|||October 2007|October 1, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142571||196234|
NCT00142870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17275-1|Effectiveness of Bupropion in Treating Marijuana Dependent Individuals|Effects of Bupropion on Marijuana Withdrawal Symptoms||National Institute on Drug Abuse (NIDA)|No|Completed|March 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|50 Years|No|||September 2008|September 3, 2008|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00142870||196212|
NCT00133978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDOXS|Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients|REducing Deaths Due to OXidative Stress The REDOXS© Study|REDOXS|Clinical Evaluation Research Unit at Kingston General Hospital|Yes|Completed|April 2005|May 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1223|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|August 22, 2005||No||No|April 29, 2013|https://clinicaltrials.gov/show/NCT00133978||196885|
NCT00138658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGX-011-05|A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Phase 1-2 Study of Weekly OGX-011 Plus a Gemcitabine/Platinum-Based Regimen in Patients With Stage IIIB or IV Non Small Cell Lung Cancer||OncoGenex Technologies|No|Completed|November 2004|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|August 26, 2005|Yes|Yes||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00138658||196529|
NCT00138931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8249|Genetics of Cardiovascular and Neuromuscular Disease|Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.||University of Chicago|No|Recruiting|September 1996|||January 2025|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Patients of all ages with familial idiopathic cardiomyopathy, including dilated,        hypertrophic, and left ventricular non-compaction cardiomyopathy|October 2014|October 6, 2014|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00138931||196508|
NCT00138944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFO_TP5/2|Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension|Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension||University of Erlangen-Nürnberg Medical School|No|Completed|January 2007|July 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|75 Years|No|||April 2013|April 16, 2013|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00138944||196507|
NCT00138957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05102m|Study of a New Laparoscopic Technique for Parastomal Hernia Repair With Mesh|Laparoscopic Parastomal Hernia Repair Using an Innovative Composite Polypropylene Mesh - A Prospective Study||University Hospital, Gentofte, Copenhagen||Withdrawn|September 2005|December 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|80 Years|No|||July 2008|July 9, 2008|August 29, 2005|||too few patients included|No||https://clinicaltrials.gov/show/NCT00138957||196506|
NCT00130312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-101-401|Effect of Sulodexide in Overt Diabetic Nephropathy|The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy||Keryx Biopharmaceuticals|Yes|Terminated|August 2005|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1248|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|August 11, 2005|Yes|Yes|No difference in protein excretion at 6&12 months. No safety issues.|No||https://clinicaltrials.gov/show/NCT00130312||197165|
NCT00139594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2303E|Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder|A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder||Novartis||Completed|December 2004|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|181|||Both|18 Years|70 Years|No|||November 2011|November 16, 2011|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00139594||196460|
NCT00139607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARA-0505-079|Parecoxib In Post Surgery (Hemicolectomy) Pain|A Multicenter, Open Label, Pilot Study To Evaluate Analgesic Activity And Safety Of Parecoxib 40 Mg IV In Patients Undergoing Hemicolectomy, In The Optimal Management Of Acute Post-Operative Pain Of Surgical Patients||Pfizer||Terminated|September 2002|January 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||August 2009|August 13, 2009|August 29, 2005|||Please see detailed description for termination reason.|No||https://clinicaltrials.gov/show/NCT00139607||196459|
NCT00123201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S175.2.103|Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache||Solvay Pharmaceuticals||Completed|September 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||September 2006|January 15, 2015|July 21, 2005||||||https://clinicaltrials.gov/show/NCT00123201||197698|
NCT00123461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCI-CH-151|Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism|A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT).||Sanofi||Completed|July 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|July 21, 2005||||||https://clinicaltrials.gov/show/NCT00123461||197678|
NCT00124969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAM|Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure|Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])||Charite University, Berlin, Germany|Yes|Completed|January 2002|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|90 Years|No|||October 2006|May 7, 2008|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00124969||197566|
NCT00140257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 12-134/04|DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome|A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome||Bispebjerg Hospital|No|Active, not recruiting|November 2004|||December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|N/A|No|||December 2008|December 30, 2008|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140257||196410|
NCT00140491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0435-2005|Vision Restoration Therapy (VRT) to Treat Non-Arteritic Anterior Ischemic Optic Neuropathy|Visual Field Defects in Non-Arteritic Anterior Ischemic Optic Neuropathy: Effect of Vision Restoration Therapy (VRT)||Emory University||Completed|August 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|30 Years|N/A|No|||October 2013|October 22, 2013|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140491||196392|
NCT00132704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-109|An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation|An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation||Memorial Sloan Kettering Cancer Center||Completed|August 2004|July 2014|Actual|July 2014|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|149|Samples With DNA|tissue|Both|19 Years|N/A|No|Non-Probability Sample|undergoing surgery on the Neurosurgery, Hepatobiliary, Colorectal, Urology, Head and Neck,        Gynecology, GMT and Thoracic Services at Memorial Sloan- Kettering Cancer Center.|July 2014|July 23, 2014|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00132704||196982|
NCT00141115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4773|Levetiracetam for the Treatment of Alcohol Dependence and Anxiety|Pilot Trial of Levetiracetam in the Treatment of Alcohol Dependence With Comorbid Anxiety||New York State Psychiatric Institute||Completed|March 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||December 2011|December 14, 2011|August 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00141115||196345|
NCT00141128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061024|Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.|Measurement Of Urethral Function In Women With Stress Urinary Incontinence - Evaluation Of The Sensitivity Of Urethral Reflectometry Compared To Urethral Pressure Profilometry, Using [S,S]-Reboxetine To Detect Pharmacological Augmentation Of Urethral Pressure.||Pfizer||Completed|December 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|18|||Female|18 Years|65 Years|No|||May 2011|May 31, 2011|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00141128||196344|
NCT00141570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S030.2.106|Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women|A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women||Solvay Pharmaceuticals||Completed|June 2004|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Female|30 Years|65 Years|No|||January 2009|January 15, 2015|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141570||196310|
NCT00141583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 01.87.10|The Renin-Angiotensin System in Essential Hypertension|The Renin-Angiotensin System in Essential Hypertension||St George's, University of London||Terminated|April 2004|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|11|||Both|18 Years|70 Years|No|||May 2007|June 5, 2015|August 31, 2005|||Insufficient accrual rate|No||https://clinicaltrials.gov/show/NCT00141583||196309|
NCT00141843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-310|Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A|A Randomized Two-Way Blinded Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII,Refacto AF) With a Full Length Recombinant Factor VIII Preparation (FLrFVIII,Advate), Followed by an Open-Label Trial of the Safety and Efficacy of ReFacto AF in Previously Treated Patients With Hemophilia A.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Male|12 Years|N/A|No|||April 2008|April 21, 2008|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141843||196289|
NCT00133705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-HD042578-2|Trial of Mifepristone for Fibroids|Randomized Control Trial Of Mifepristone for Fibroids||University of Rochester|Yes|Completed|July 2003|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 13, 2014|August 22, 2005|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00133705||196906|There were no adverse events in this clinical trial.
NCT00133991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439521, J0409|Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia|Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma||Sidney Kimmel Comprehensive Cancer Center||Completed|March 2005|July 2012|Actual|July 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|30 Years|N/A|No|||April 2014|April 16, 2014|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133991||196884|
NCT00142376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0409HSE222|Short Term Outcomes of Children With Acute Respiratory Distress Syndrome|||Nationwide Children's Hospital||Completed|September 2004|August 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|18 Years|No|||September 2004|September 1, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142376||196249|
NCT00142584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB324|Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension|An Open-Label, Randomized Study Evaluating the Long-Term Effects of Metoprolol Versus Nebivolol as Monotherapy or in Combination With Amlodipine or Hydrochlorothiazide for the Treatment of Patients With Hypertension||Mylan Bertek Pharmaceuticals||Completed|August 2005|March 2008|Actual|March 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||August 2005|March 6, 2008|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142584||196233|
NCT00130949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-2-005-2|ALGRX 4975 in the Treatment of Tennis Elbow|A Randomized, Double-Blind, Placebo-Controlled, Phase II, Exploratory Evaluation of ALGRX 4975 in Subjects With Acute Lateral Epicondylitis||AlgoRx Pharmaceuticals||Completed|November 2004|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|75 Years|No|||August 2005|December 18, 2006|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130949||197116|
NCT00143208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XALACO-0076-033|Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.|Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy||Pfizer||Completed|May 2003|April 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||January 2008|January 18, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143208||196186|
NCT00143221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481217|Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)|A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States||Pfizer||Completed|March 2004|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Male|45 Years|N/A|No|||December 2006|December 7, 2006|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143221||196185|
NCT00138671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171030|A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD|Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial||Pfizer|No|Terminated|January 2003|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|30 Years|77 Years|No|||August 2009|January 25, 2010|August 26, 2005|Yes|Yes|See termination reason in detailed description.|No|September 2, 2009|https://clinicaltrials.gov/show/NCT00138671||196528|This study was terminated due to Pfizer's decision to stop marketing Exubera®. Due to inconsistency in concomitant medication data entry, interpretation of the event rates for non-severe exacerbations may be of limited clinical value.
NCT00130611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEL III - Private Practice|B-type Natriuretic Peptide for Acute Shortness of Breath EvaLuation (BASEL) Study - Private Practice|B-type Natriuretic Peptide for Acute Shortness of Breath EvaLuation (BASEL) Study - Private Practice||University Hospital, Basel, Switzerland||Completed|January 2004|January 2011|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|250|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|August 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00130611||197142|
NCT00139230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-184|Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma||Dana-Farber Cancer Institute||Completed|January 1997|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139230||196485|
NCT00123695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-193|Serial Echocardiography After Subarachnoid Hemorrhage|Serial Echocardiography After Subarachnoid Hemorrhage (S.E.A.S.)|SEAS|VU University Medical Center|Yes|Active, not recruiting|May 2005|June 2008|Anticipated|June 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|10 Years|N/A|No|||March 2008|March 26, 2008|July 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00123695||197660|
NCT00124995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-001|Trial of Terbutaline for the Treatment of Status Asthmaticus in Children|Double-blinded Randomized Trial of Terbutaline to Shorten ICU Length of Stay in the Treatment of Status Asthmaticus in Children||Connecticut Children's Medical Center||Completed|October 2003|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|N/A|18 Years||||February 2013|February 12, 2013|July 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00124995||197564|
NCT00140270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3185|RCT of PEP Program to Reduce ACL Injuries in Female Collegiate Soccer Players|Evaluating the Effectiveness of a Neuromuscular and Proprioceptive Training Program to Reduce Ligamentous Knee Injuries Among Female Collegiate Soccer Players.||Centers for Disease Control and Prevention||Completed|August 2002|December 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||4000|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2005|August 30, 2005|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140270||196409|
NCT00140738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100633|Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer|A Multicenter, Open-label Phase I/II Trial of the Safety and Efficacy of the dHER2 Recombinant Protein Combined With Immunological Adjuvant AS15 in Patients With Metastatic Breast Cancer Overexpressing HER2/Neu||GlaxoSmithKline||Completed|March 2005|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3|||Female|18 Years|N/A|No|||June 2011|June 16, 2011|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00140738||196373|
NCT00140504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-061|Preventing Adverse Drug Events With PatientSite|Preventing Adverse Drug Events With PatientSite||Dana-Farber Cancer Institute|No|Completed|April 2003|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 24, 2013|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140504||196391|
NCT00140803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISTA|Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration|A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD||Manhattan Eye, Ear & Throat Hospital|Yes|Completed|October 2003|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|106|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 11, 2007|August 30, 2005||||Yes||https://clinicaltrials.gov/show/NCT00140803||196369|
NCT00141596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 03.0001|Extracellular Fluid in Resistant Hypertension|A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension||St George's, University of London||Terminated|July 2003|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|80 Years|No|||May 2007|June 5, 2015|August 31, 2005|||Insufficient accrual rate|No||https://clinicaltrials.gov/show/NCT00141596||196308|
NCT00141830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142A1-202|Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis|A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|159|||Both|18 Years|80 Years|No|||September 2009|September 15, 2009|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141830||196290|
NCT00141609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 04.0013|Haemodialysis Salt Reduction Study|A Study Looking at the Effects of a Modest Reduction in Dietary Salt Intake on Blood Pressure Control in Haemodialysis Patients||St George's, University of London||Completed|April 2004|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|85 Years|No|||May 2007|May 10, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141609||196307|
NCT00133718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCD-study|A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control|Asker and Baerum Cardiovascular Diabetes Study||Asker & Baerum Hospital|Yes|Active, not recruiting|January 2002|June 2008|Anticipated|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|75 Years|No|||March 2008|March 4, 2008|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00133718||196905|
NCT00134004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0457 CDR0000440990|Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer|A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies||Sidney Kimmel Comprehensive Cancer Center||Completed|October 2004|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|6 Months|74 Years|No|||September 2015|September 2, 2015|August 22, 2005|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT00134004||196883|
NCT00134017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000440164, J0373|Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer|HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|May 2004|||January 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|N/A|65 Years|No|||March 2014|March 20, 2014|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00134017||196882|
NCT00133367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-154|Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus|Phase II Study of Sequential Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis||Massachusetts General Hospital|Yes|Completed|August 2005|November 2011||November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|65 Years|No|||May 2013|May 22, 2013|August 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00133367||196932|
NCT00133380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9591|A Study in People With High Cholesterol|PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia||Eli Lilly and Company||Completed|July 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|80 Years|No|||April 2007|April 4, 2007|August 19, 2005||||||https://clinicaltrials.gov/show/NCT00133380||196931|
NCT00133679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL079922-01|Chronic Sildenafil for Severe Diaphragmatic Hernia|Chronic Sildenafil for Severe Diaphragmatic Hernia||University of California, San Francisco|Yes|Terminated|February 2006|October 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|N/A|42 Days|No|||August 2014|August 11, 2014|August 22, 2005|Yes|Yes|Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with    possibility of placebo beyond 6 weeks of age on study protocol|No||https://clinicaltrials.gov/show/NCT00133679||196908|
NCT00134303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/045|Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity|Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity||University Hospital, Ghent|No|Recruiting|June 2005|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||December 2014|December 4, 2014|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134303||196861|
NCT00131209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-1200720-3|Trial to Test the Growth-Promoting Effect of Fortified Spreads When Used as Complementary Food for Infants|Lungwena Child Nutrition Intervention Study 3, LCNI-3. A Single-Centre Intervention Trial in Rural Malawi, Testing the Anthropometric and Health Benefits of Provision of Ready to - Use - Therapeutic Food RUTF as a Complementary Food||University of Tampere|Yes|Completed|October 2004|January 2008|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||180|||Both|6 Months|6 Months|Accepts Healthy Volunteers|||July 2008|July 3, 2008|August 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00131209||197096|
NCT00130026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000210|Caffeine in the Prevention of Post-Operative Nausea and Vomiting|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study of Caffeine in the Prevention of Post-Operative Nausea and Vomiting in Patients Undergoing Ambulatory Surgery Under General Anesthesia||Beth Israel Deaconess Medical Center|No|Completed|March 2005|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|135|||Both|18 Years|N/A|No|||September 2006|December 26, 2007|August 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00130026||197186|
NCT00130624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/AB|The Winchester Falls Project|The Winchester Falls Project: A Cluster Randomised Community Intervention Trial of Secondary Prevention of Falls in Community-Dwelling Older People||Winchester and Eastleigh Healthcare NHS Trust||Completed|June 2001|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||516|||Both|65 Years|N/A|No|||February 2005|October 4, 2005|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130624||197141|
NCT00130936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-05-0046|Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates|Combined Phase I/II Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates||AHS Cancer Control Alberta||Terminated|October 2005|November 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|70 Years|No|||September 2009|February 12, 2016|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130936||197117|
NCT00124007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI V001|Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults|A Phase I, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in Healthy Adult Volunteers Not Infected With HIV||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2005|April 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|114|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 22, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00124007||197637|
NCT00124020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019|Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus|ATTAIN2|Theravance Biopharma Antibiotics, Inc.|No|Completed|January 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|771|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|July 22, 2005|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00124020||197636|
NCT00124345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1457|Medical Gas Humidification During Noninvasive Mechanical Ventilation|The Humidification During Noninvasive Mechanical Ventilation Delivered by Helmet||Policlinico Hospital|No|Completed|June 2005|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2008|September 24, 2008|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124345||197611|
NCT00125008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-17|Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever|Randomized Controlled Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever in Eastern Kolkata, West Bengal, India||International Vaccine Institute|Yes|Completed|May 2003|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|37673|||Both|2 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 25, 2008|July 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00125008||197563|
NCT00140283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI031409|Effectiveness of a Educational Intervention to Improve the Resolution Capacity of Primary Health Care Teams.|Phase IV Cluster Randomised Controlled Trial With 2 Parallel Groups, to Evaluate the Effectiveness of a Educational Intervention to Improve the Resolution Capacity.||Catalan Institute of Health||Active, not recruiting|July 2004|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||48|||Both|N/A|N/A||||August 2005|August 31, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140283||196408|
NCT00140517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR/DD/677-01/DG-CM/624-02|Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance|Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance||Gates Malaria Partnership|Yes|Completed|October 2002|March 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||700|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||March 2009|March 30, 2009|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00140517||196390|
NCT00131729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2300.0020|Electronic Recording of Compliance With Occlusion Therapy for Amblyopia|Electronic Recording of Compliance With Occlusion Therapy for Amblyopia: 1 Effects of Patient Education on Compliance 2 Predictors for Non-Compliance||Erasmus Medical Center||Completed|July 2001|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||March 2006|March 17, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00131729||197056|
NCT00141141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581053|Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia|A Phase IV, Multicenter, Randomized, Open Label Study To Evaluate The Efficacy And Safety Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia||Pfizer||Completed|January 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|383|||Both|18 Years|75 Years|No|||October 2008|October 28, 2008|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141141||196343|
NCT00141154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191174|Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan|A Randomized, Multicenter, Active And Placebo Controlled Parallel Group Study To Evaluate The Efficacy And Safety Of Celecoxib (Ym177) 200 Bid Compared To Loxoprofen 60 Mg Tid In Patients With Low Back Pain||Pfizer||Completed|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1234|||Both|20 Years|N/A|No|||May 2011|May 27, 2011|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141154||196342|
NCT00141167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051045|A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation|A Twelve-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 MG BID for Smoking Cessation||Pfizer||Completed|February 2005|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|250|||Both|18 Years|75 Years|No|||September 2010|September 3, 2010|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141167||196341|
NCT00132262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA013824|Brief Intervention to Reduce Injury in Minorities|Brief Intervention to Reduce Injury in Minorities||The University of Texas Health Science Center, Houston|No|Completed|May 2003|December 2012|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1493|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|August 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00132262||197016|
NCT00132275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000928|Guidelines for Acute Sinusitis|Evaluation of National Guidelines for Acute Sinusitis||University of Pittsburgh||Completed|November 2003|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|240|||Both|1 Year|10 Years|No|||May 2008|May 19, 2008|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00132275||197015|
NCT00133094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XVA 72-029|Systematic Management of High Cholesterol Utilizing Computer Monitoring|Management of Hypercholesterolemia Utilizing a Case Management System, Incorporating Computer-Based Decision Support Technology||VA Office of Research and Development|No|Completed|June 2006|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|45 Years|70 Years|No|||December 2007|April 6, 2015|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00133094||196952|
NCT00134056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439434|S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy|Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer||Southwest Oncology Group|Yes|Active, not recruiting|August 2006|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1038|||Male|18 Years|N/A|No|||May 2015|May 6, 2015|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134056||196879|
NCT00134069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00110|Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer|Phase I/II Clinical, Pharmacological, and Biological Study of BAY 43-9006 in Combination With Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer||National Cancer Institute (NCI)|Yes|Completed|June 2005|December 2011|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|August 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00134069||196878|
NCT00134316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBC-SH-CECSH.P1&2-20R91396|Cervical or Endometrial Cancer and Sexual Health Study|Cervical or Endometrial Cancer and Sexual Health Study||University of British Columbia|No|Completed|August 2005|June 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|19 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 28, 2011|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00134316||196860|
NCT00130039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOSS-2|Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II|Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel|TOSS-2|Asan Medical Center|Yes|Completed|August 2005|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|457|||Both|35 Years|N/A|No|||November 2009|January 4, 2010|August 11, 2005||No||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00130039||197185|
NCT00130637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050208|Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis|Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab)||National Institutes of Health Clinical Center (CC)|Yes|Completed|August 2005|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|6 Years|18 Years|No|||November 2010|November 24, 2010|August 12, 2005|No|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00130637||197140|The results of this trial need to be interpreted cautiously because of the small number of patients, the heterogeneity of the patient population (such as one participant with systemic JIA), and the nonrandomized and unmasked nature of the trial.
NCT00130325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRS SCC965|A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts|A Double Blind Placebo-controlled Randomized Trial of Isoniazid for the Reversion of a Positive IFNg ELISPOT in TB Case Contacts|IRS|Medical Research Council Unit, The Gambia|No|Completed|October 2004|June 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|15 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00130325||197164|
NCT00130338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BIA05E1|Rivastigmine Capsules in Patients With Probable Vascular Dementia|An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia||Novartis||Completed|February 2002|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|521|||Both|50 Years|85 Years|No|||November 2011|November 16, 2011|August 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130338||197163|
NCT00130351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOR258F2309|A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma|A 3-week Multicenter Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma||Novartis||Completed|July 2005|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|155|||Both|5 Years|N/A|No|||October 2011|October 24, 2011|August 8, 2005||||||https://clinicaltrials.gov/show/NCT00130351||197162|
NCT00131222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-1200720-4|Trial to Alleviate Malnutrition With Fortified Spread Given as a Food Supplement to Underweight Infants|Lungwena Child Nutrition Intervention Study-4, LCNI-4. A Single-centre Intervention Trial in Rural Malawi, Testing the Potency of RUTF Supplementation to Alleviate Moderate Malnutrition Among 6-17 Month Old Infants||University of Tampere|Yes|Completed|February 2005|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||176|||Both|6 Months|15 Months|No|||April 2007|May 19, 2014|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131222||197095|
NCT00130962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-2-004-1|ALGRX 4975 in the Treatment of Patients With Morton's Neuroma|A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma||AlgoRx Pharmaceuticals||Completed|September 2004|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||August 2005|September 30, 2005|August 15, 2005||||||https://clinicaltrials.gov/show/NCT00130962||197115|
NCT00131508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCGLU2|Trial of Oral Glutamine in Patients With Sickle Cell Anemia|A Randomized Controlled Trial of Oral Glutamine Supplementation Versus a Placebo Supplement in Children With Sickle Cell Anemia||St. Jude Children's Research Hospital|Yes|Terminated|May 2004|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|27|||Both|5 Years|18 Years|No|||March 2010|May 18, 2010|August 17, 2005|Yes|Yes|Due to slow participant accrual|No|February 19, 2010|https://clinicaltrials.gov/show/NCT00131508||197073|The study was designed to enroll 46 participants (23 per arm). Due to slow accrual the study was terminated after enrolling 27 participants. Of the 27 participants enrolled, 2 dropped out of the study prior to randomization.
NCT00131781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000.230|Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder|Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder||Hospices Civils de Lyon||Active, not recruiting|March 2001|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||70|||Both|18 Years|65 Years||||April 2007|April 26, 2007|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00131781||197052|
NCT00124358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063005|Buprenorphine and Integrated HIV Care Evaluation|An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings||The New York Academy of Medicine||Recruiting|August 2005|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1350|||Both|18 Years|N/A|No|||March 2007|March 23, 2007|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00124358||197610|
NCT00117507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS02|Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients|An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients||Novartis|No|Completed|April 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|June 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00117507||198121|
NCT00117156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-294|Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma|A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma||Dana-Farber Cancer Institute|Yes|Completed|December 2003|January 2012|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|June 30, 2005|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00117156||198148|
NCT00140530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02103|Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)|A Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Prevention of Restenosis (ISAR-TEST-1)||Deutsches Herzzentrum Muenchen|Yes|Completed|March 2004|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|N/A|No|||January 2008|January 10, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140530||196389|
NCT00140790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-RCT-2005-02|Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study|Effects of Valsartan on Cardiovascular Events in Patients With Renal Dysfunction||Kumamoto University|Yes|Terminated|August 2006|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1000|||Both|30 Years|85 Years|No|||February 2016|February 25, 2016|August 31, 2005||No|The number of actual events was extremely low. We extended the study period, but it was still    not enough. Also, many patients were loss of follow up.|No||https://clinicaltrials.gov/show/NCT00140790||196370|
NCT00133133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-2-011-2|Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects After Open Cholecystectomy||AlgoRx Pharmaceuticals||Completed|July 2005|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|20 Years|65 Years|No|||February 2006|December 18, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00133133||196950|
NCT00131989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03154|Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia|Phase I Dose Escalation Trial of the Raf Kinase Inhibitor BAY 43-9006 (NSC #724772) as Single Agent for Adults With Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis||National Cancer Institute (NCI)||Completed|June 2005|||April 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|August 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00131989||197037|
NCT00133107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-efalizumab|Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus|A Single Center, Open-label, Pilot Study Evaluating the Safety and Effectiveness of Subcutaneous Efalizumab in the Treatment of Oral Lichen Planus||Washington University School of Medicine|No|Completed|January 2005|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 18, 2011|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133107||196951|
NCT00133692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVEST|INVEST: INternational VErapamil SR Trandolapril STudy|INternational VErapamil SR Trandolapril STudy||University of Florida||Completed|September 1997|February 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||22000|||Both|50 Years|N/A|No|||August 2010|September 16, 2011|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133692||196907|
NCT00134082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0528 , CDR0000441037|Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma|Pilot Study of Rituximab, High Dose Cyclophosphamide, and GM-CSF Based Immunotherapy for Relapsed Hodgkin's Lymphoma||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|July 2005|December 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|120 Years|No|||October 2015|October 30, 2015|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134082||196877|
NCT00115739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2003-044|Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma|Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer||University of Michigan Cancer Center|Yes|Terminated|February 2004|August 2010|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|June 23, 2005|Yes|Yes|Study was closed early due to slow accrual|No|July 24, 2012|https://clinicaltrials.gov/show/NCT00115739||198257|Study was closed early due to slow accrual. Planned accrual was 28
NCT00115752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050176|Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain|Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain||National Institutes of Health Clinical Center (CC)||Completed|June 2005|October 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||96|||Both|7 Years|35 Years|Accepts Healthy Volunteers|||October 2006|February 24, 2007|June 23, 2005||||No||https://clinicaltrials.gov/show/NCT00115752||198256|
NCT00116051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200330159|A Comparison of Two Surface Materials (Tantalum Versus Titanium Fiber Mesh) of Acetabular Components in Hip Arthroplasty|A Comparison of Two Surface Materials (Tantalum Versus Titanium Fiber Mesh) of Acetabular Components in Hip Arthroplasty||University of Aarhus|Yes|Completed|September 2004|April 2006||April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|50 Years|70 Years|No|||July 2009|July 6, 2009|June 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00116051||198233|
NCT00147537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021002|Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer|A Phase 1b Dose Escalation/Phase 2 Randomized, Non-Comparative, Multiple Center, Open Label Study Of CP 751,871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer||Pfizer|No|Completed|February 2005|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|N/A|No|||October 2013|October 1, 2013|September 2, 2005|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00147537||195862|
NCT00147550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4581001|MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.|A Multicenter, Open-Label, Noncomparative Phase 1-2 Clinical And Pharmacokinetic Study Of Oral PD 0325901 In Patients With Advanced Cancer||Pfizer|No|Terminated|February 2004|July 2013|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|September 2, 2005|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00147550||195861|
NCT00116623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704914|Magnesium Sulfate Versus Indomethacin for Preterm Labor|||University of Pennsylvania||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2007|May 7, 2007|June 29, 2005|||Funding completed|No||https://clinicaltrials.gov/show/NCT00116623||198189|
NCT00147875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVAG elderly|Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma|PVAG - Phase I/II Dose Finding Trial in Elderly Patients (> 60 Years) With Advanced Stages Hodgkin's Lymphoma||University of Cologne||Completed|March 2004|||July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|60 Years|75 Years|No|||September 2009|September 4, 2009|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147875||195837|
NCT00143299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051037|A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline|A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety of Varenicline Tartrate ( CP-526,555) for Smoking Cessation||Pfizer||Completed|October 2003|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||375|||Both|18 Years|75 Years|No|||June 2007|June 1, 2007|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143299||196179|
NCT00112320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|188|Comparison of Two Pulmonary Valve Replacement Methods to Treat Tetralogy of Fallot|Randomized Trial of Pulmonary Valve Replacement in Tetralogy of Fallot||Children's Hospital Boston|Yes|Completed|April 2004|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|10 Years|N/A|No|||December 2012|December 3, 2012|June 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00112320||198510|
NCT00112333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001304|Defining Central Circuits of Pain|Defining Central Circuits of Visceral Pain||Massachusetts General Hospital|No|Completed|October 2003|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|June 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00112333||198509|
NCT00112931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000427312|Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma|An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma||National Cancer Institute (NCI)||Recruiting|September 2004|||October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|N/A|No|||June 2007|August 23, 2013|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112931||198470|
NCT00112957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000424461|Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rF-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen||Ludwig Institute for Cancer Research|Yes|Completed|July 2004|May 2010|Actual|January 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||April 2013|April 9, 2013|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112957||198469|
NCT00144352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3537|In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults|The in-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Individuals-a 28 Day Efficacy Trial Involving HIV+ and HIV- Adults.||Centers for Disease Control and Prevention||Completed|September 2002|July 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||540|||Both|18 Years|N/A|No|||September 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144352||196099|
NCT00124488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-15-0004|Comparison of Tomotherapy Versus Intensity-modulated Step-and-shoot and Conventional Radiation Treatment Plans for Patients With Locally-advanced Squamous Cell Carcinoma of the Cervix|Comparison of Tomotherapy Versus Intensity-modulated Step-and-shoot and Conventional Radiation Treatment Plans for Patients With Locally-advanced Squamous Cell Carcinoma of the Cervix||AHS Cancer Control Alberta||Completed|June 2005|November 2005||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1||10|||Female|18 Years|N/A|No|Non-Probability Sample|primary care clinic|December 2011|December 8, 2011|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00124488||197600|
NCT00121316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2442|Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients|Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids||Novartis||Completed|October 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||200|||Both|12 Years|N/A|No|||January 2008|January 10, 2008|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121316||197839|
NCT00114075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HS014169|Effects of Walking Analysis on Surgical Outcomes|Impact of Gait Analysis on Surgical Outcomes||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|January 2005|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|3 Years|18 Years|No|||August 2011|July 17, 2012|June 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00114075||198384|
NCT00114088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01HS009506|Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB)|Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB)||Agency for Healthcare Research and Quality (AHRQ)||Completed|November 1997|January 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||242|||Female|18 Years|N/A|No|||June 2005|June 23, 2005|June 13, 2005||||No||https://clinicaltrials.gov/show/NCT00114088||198383|
NCT00114335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMWHplus_1|Epidemiologic Data of Patients in a Teaching Hospital|Prevalence of Impaired Renal Function in Medical Inpatients||Luzerner Kantonsspital||Completed|May 2005|July 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|352|||Both|N/A|N/A|No|Probability Sample|All patients hospitalized at the defined days (two days) at Kantonsspital Luzern,        Department of Medicine|October 2008|October 9, 2008|June 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00114335||198364|
NCT00114348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2002/6a|ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia|ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia||Charite University, Berlin, Germany||Completed|August 2003|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|338|||Both|N/A|18 Years|No|||February 2013|February 1, 2013|June 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00114348||198363|
NCT00113984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050167|Vaccine and Antibody Treatment of Prostate Cancer|Phase I Trial of a PSA Based Vaccine and an Anti-CTLA-4 Antibody in Adults With Metastatic Androgen Independent Prostrate Cancer||National Institutes of Health Clinical Center (CC)||Completed|June 2005|December 2011|Actual|February 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|85 Years|No|||November 2012|October 4, 2014|June 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00113984||198391|
NCT00113997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050164|Safety and Dosing Evaluation of REG1 Anticoagulation System|The Healthy Volunteer Evaluation of an Aptamer-RNA Target to Factor IXa||National Institutes of Health Clinical Center (CC)||Completed|June 2005|October 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment||||106|||Both|N/A|N/A|No|||October 2005|March 3, 2008|June 11, 2005||||No||https://clinicaltrials.gov/show/NCT00113997||198390|
NCT00114010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050133|Experimental Vaccine for Malaria|Phase 1 Study of the Safety of Immunization of Naive Individuals With AMA1-C1/Alhydrogel [R], an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria, and the Effect of Immunization on Antigen-specific Memory and Plasma B Cells and T Cells||National Institutes of Health Clinical Center (CC)||Completed|April 2005|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|50 Years|No|||August 2010|August 20, 2010|June 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00114010||198389|
NCT00114296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430701|Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer|A Pilot Study to Evaluate the Effects of Omega-3 Fatty Acids on Intermediate Markers of Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2005|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|80|||Female|18 Years|N/A|No|||July 2006|September 16, 2013|June 13, 2005||||No||https://clinicaltrials.gov/show/NCT00114296||198367|
NCT00114829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05028-MA|Preoperative Assessment of Colon Tumor|Preoperative Assessment of Colon Tumor: A Prospective, Blinded Study.||Herlev Hospital||Recruiting|July 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||60|||Both|18 Years|N/A|No|||May 2005|March 8, 2006|June 17, 2005||||No||https://clinicaltrials.gov/show/NCT00114829||198327|
NCT00115180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1HS13924|Racial and Ethnic Disparities in Acute Pain Control|Racial and Ethnic Disparities in Acute Pain Control||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|September 2003|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|285|||Both|18 Years|55 Years|No|Non-Probability Sample|Emergency Department patients with radiologically confirmed long bone fractures|November 2005|January 5, 2016|June 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00115180||198300|
NCT00115453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNCT-P01|Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma|Boron Neutron Capture Therapy in the Treatment of Glioblastoma Multiforme||Boneca Corporation|No|Terminated|May 1999|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||August 2008|August 14, 2008|June 22, 2005|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00115453||198279|
NCT00115466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX401/TCFIS|Autologous Stem Cells Derived From Lipoaspirates for the Non-Surgical Treatment of Complex Perianal Fistula|Phase II Clinical Trial, Multicentre, Randomised and Comparative, to Evaluate the Efficacy and Safety of a New Therapy With Autologous Stem Cells Derived From Lipoaspirates for the Non-Surgical Treatment of Complex Perianal Fistula||Cellerix||Active, not recruiting|October 2004|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||June 2005|June 23, 2005|June 22, 2005||||No||https://clinicaltrials.gov/show/NCT00115466||198278|
NCT00115778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB0431|Intravenous Immunoglobulin (IVIG) in Lung Transplantation|IVIG for Acquired Immunodeficiency in Lung Transplant Patients||Arcasoy, Selim, M.D.||Active, not recruiting|June 2005|December 2009|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|10|||Both|12 Years|75 Years|No|||June 2009|June 18, 2009|June 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00115778||198254|
NCT00147017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-093|Regulation of the Release of Inflammatory Mediators From Lung Macrophages.|Regulation of the Release of Inflammatory Mediators From Lung Macrophages.||Imperial College London||Completed|June 2001|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|protein samples have been retained|Both|21 Years|75 Years|No|Non-Probability Sample|All subjects undergoing lung resection surgery|September 2005|March 23, 2015|September 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00147017||195900|
NCT00116064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03/04/248|Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions|A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children||University of Malawi College of Medicine||Completed|July 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||156|||Both|2 Months|12 Years|No|||June 2005|July 20, 2006|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00116064||198232|
NCT00116077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050169|Dopamine Receptor Imaging in Mood Disorders|Dopamine Receptor Imaging in Mood Disorders||National Institutes of Health Clinical Center (CC)||Completed|June 2005|November 2010||||N/A|Observational|N/A|||Actual|145|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 13, 2010|June 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00116077||198231|
NCT00116090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050178|Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study|Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study||National Institutes of Health Clinical Center (CC)||Completed|June 2005|April 2008||||N/A|Observational|N/A||||6300|||Both|N/A|N/A|No|||April 2008|September 26, 2015|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00116090||198230|
NCT00147290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400ACRT|ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy|ADVANCE CRT - D: ATP Delivery for Painless ICD Therapy|ADVANCE-CRTD|Medtronic Bakken Research Center|No|Completed|February 2004|January 2008|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|526|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|September 6, 2005||No||No|November 20, 2008|https://clinicaltrials.gov/show/NCT00147290||195880|
NCT00147862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/185/IM-2004|Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?|Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?||Tata Memorial Hospital||Completed|May 2005|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|N/A|N/A|No|||February 2007|February 6, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147862||195838|
NCT00143312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501038|Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants|Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).|VOSIFI|Pfizer|Yes|Completed|February 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|45|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|August 31, 2005|No|Yes||No|April 2, 2009|https://clinicaltrials.gov/show/NCT00143312||196178|
NCT00143325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051044|An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation|An Open-Label, Multicenter Study With Follow-Up Evaluating the Safety and Efficacy of Varenicline Tartrate in Comparison to Transdermal Nicotine Patch for Smoking Cessation||Pfizer||Completed|January 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||730|||Both|18 Years|75 Years|No|||June 2007|June 1, 2007|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143325||196177|
NCT00143338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171053|To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.|A Phase 2, Exploratory Study to Examine the Effects of Inhaled Insulin, Compared With Subcutaneously Administered Insulin, on Airway Lining Fluid Composition in Subjects With Type 2 Diabetes Mellitus.||Pfizer||Completed|November 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|30 Years|55 Years|No|||February 2008|February 11, 2008|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143338||196176|
NCT00143858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4301|Assessment of the Clinical Utility of Non Invasive Peripheral Signal Averaged Pulse Volume|Assessment of the Clinical Utility of Non Invasive Peripheral Signal Averaged Pulse Volume||Rutgers, The State University of New Jersey|No|Completed|September 2004|October 2007|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|75 Years|No|Non-Probability Sample|Patient who are having a right heart catherization done for other diagnostic purposes or        patient in the critical care units who have Swan Ganz catheters in place for other medical        management|August 2009|August 6, 2009|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143858||196136|
NCT00112619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430504|Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors|A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis||Pediatric Brain Tumor Consortium|Yes|Terminated|August 2005|||August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|3 Years|21 Years|No|||June 2011|June 29, 2011|June 2, 2005|No|Yes|Slow accrual and company withdrawing support to supply the drug|No||https://clinicaltrials.gov/show/NCT00112619||198490|
NCT00112632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430499|Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor|Open-Label Trial of Neoadjuvant Imatinib Mesylate (Glivec) in Patients With Locally Advanced Malignant Gastrointestinal Stromal Tumors (GIST) Expressing c-Kit or Platelet-Derived Growth Factor Receptor-alpha||Technische Universität München||Completed|February 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112632||198489|
NCT00144105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.33|A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.|A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks||Boehringer Ingelheim||Terminated|February 2004|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|562|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00144105||196118|
NCT00144118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2000/01072|The Effect of Isoflurane or Sevoflurane on Kidney Function|Post-Operative Creatinine Changes In Patients With Pre-Existing Renal Impairment After Low-Flow Isoflurane Or Sevoflurane: A Randomised Clinical Trial||Austin Health||Terminated|January 2002|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||270|||Both|18 Years|N/A|No|||August 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144118||196117|
NCT00125346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2301|Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects|EVOLVE|Novartis||Terminated|September 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|98|||Both|6 Years|21 Years|No|||October 2011|October 10, 2011|July 28, 2005|||per Data Monitoring Committee recommendation|||https://clinicaltrials.gov/show/NCT00125346||197537|
NCT00114101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00439|Lenalidomide in Treating Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma|A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2004|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|70 Years|No|||November 2015|January 29, 2016|June 13, 2005|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00114101||198382|
NCT00114361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV05-01|48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection|Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study)||Foundation for Liver Research|Yes|Completed|March 2005|April 2010|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|138|||Both|18 Years|70 Years|No|||June 2010|June 18, 2010|June 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00114361||198362|
NCT00114569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN275200403393C|Lorazepam for the Treatment of Status Epilepticus in Children|Use of Lorazepam for the Treatment of Status Epilepticus||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|March 2005|February 2009|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|3 Months|17 Years|No|||May 2009|February 13, 2011|June 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114569||198346|
NCT00114842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05029-MA|Magnetic Resonance (MR) Colonography With Fecal Tagging|MR Colonography With Fecal Tagging: A Prospective, Randomized Study||Herlev Hospital||Completed|March 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|60|||Both|18 Years|N/A|No|||September 2007|September 19, 2007|June 17, 2005||||No||https://clinicaltrials.gov/show/NCT00114842||198326|
NCT00115167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020149|A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study|A Multicenter, Randomised, Double-Blind, Placebo-Controlled Roll Over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer||Amgen||Completed|August 2004|March 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|371|||Both|18 Years|N/A|No|||May 2009|May 7, 2009|June 21, 2005||||No||https://clinicaltrials.gov/show/NCT00115167||198301|
NCT00115193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020134|Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma|A Multicenter, Double-Blind, Randomized Study of Pegfilgrastim Administered on the Same Day or the Next Day of R-Chop Chemotherapy in Subjects With Non-Hodgkin's Lymphoma||Amgen|Yes|Completed|February 2003|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|June 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00115193||198299|
NCT00115479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S18630|KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients|KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients||Katholieke Universiteit Leuven||Completed|March 2002|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||1200|||Both|18 Years|N/A|No|||June 2005|May 3, 2006|June 22, 2005||||No||https://clinicaltrials.gov/show/NCT00115479||198277|
NCT00147030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN89547571(1)|TOBY: a Study of Treatment for Perinatal Asphyxia|Whole Body Hypothermia for the Treatment of Perinatal Asphyxial Encephalopathy||Imperial College London|Yes|Completed|December 2002|August 2008|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|325|||Both|N/A|6 Hours|No|||November 2013|November 25, 2013|September 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00147030||195899|
NCT00147277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900AD|ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy|ADVANCE-D: ATP Delivery for Painless ICD Therapy|ADVANCE_D|Medtronic Bakken Research Center|No|Completed|March 2004|January 2008|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|925|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|September 6, 2005||No||No|November 20, 2008|https://clinicaltrials.gov/show/NCT00147277||195881|
NCT00147303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI9042-17|Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study|Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Clinical-pharmacological Dose-response Study.||Mitsubishi Tanabe Pharma Corporation|No|Completed|April 2004|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|N/A|N/A|No|||April 2015|April 8, 2015|September 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00147303||195879|
NCT00147563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPLA-0501-077|Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT|A Double-Blind, Parallel Design Study to Compare the Effectiveness of Eplerenone Versus Atenolol in Reversing the Remodeling of Resistance Arteries in Subjects With Mild to Moderate Primary Hypertension||Pfizer||Completed|October 2003|||May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||34|||Both|30 Years|70 Years|No|||May 2007|April 14, 2008|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00147563||195860|
NCT00147576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5051005|Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.|Randomized, Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866,087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking Treatment||Pfizer||Completed|December 2003|December 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|88|||Both|21 Years|65 Years|No|||October 2012|October 1, 2012|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00147576||195859|
NCT00143351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281088|Mozart Relapse Study|Open Extension Study Evaluating the Long-Term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study||Pfizer||Completed|June 2003|September 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||December 2006|December 28, 2006|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143351||196175|
NCT00143364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051036|A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation||Pfizer||Completed|June 2003|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1005|||Both|18 Years|75 Years|No|||June 2007|June 1, 2007|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143364||196174|
NCT00144781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID-017-03|A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease|A Multicenter, Multinational, Randomized, Dose-Optimization Study of the Safety and Pharmacodynamic Response of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I||Sanofi||Completed|December 2004|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Both|N/A|N/A|No|||March 2015|March 17, 2015|September 2, 2005|Yes|Yes||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00144781||196067|This study is limited by its small sample size and ability to detect small differences in urinary GAG levels between groups.
NCT00143637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORMAS 24.2/2003-0464|Dose Response Relations for Health Effects Caused by Office Dust|Dose Response Relations for Health Effects Caused by Office Dust.||University of Aarhus|No|Completed|May 2005|November 2006|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00143637||196153|
NCT00144079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSDS|Multicenter Study Differentiated Thyroid Carcinoma|Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma||University Hospital Muenster||Completed|January 2000|January 2010||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|69 Years|No|||September 2005|May 8, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144079||196120|
NCT00144092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147|HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma|High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma||AHS Cancer Control Alberta||Completed|May 2001|June 2010|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|65 Years|No|||August 2011|November 18, 2011|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144092||196119|
NCT00144131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040262|Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy|Flexibility: A Study to Assess the Impact of Once Per Cycle Correction and Maintenance Dosing of Darbepoetin Alfa in Subjects With Non-Myeloid Malignancies With Anemia Due to Chemotherapy||Amgen||Completed|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||750|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00144131||196116|
NCT00144144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANCED-J01|A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes|A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists||Advanced-J||Active, not recruiting|September 2004|September 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|20 Years|N/A|No|||July 2006|July 13, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00144144||196115|
NCT00124852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_05/08|The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People|The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People: a Double-blind Placebo-controlled Trial||Wageningen University|No|Completed|October 2005|July 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|302|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 11, 2011|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124852||197575|
NCT00121563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050193|Evaluation of a TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect|Evaluation of TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect||National Institutes of Health Clinical Center (CC)||Completed|July 2005|February 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||90|||Male|N/A|N/A|No|||February 2006|March 3, 2008|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00121563||197821|
NCT00121589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050073|Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60|Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60||National Institutes of Health Clinical Center (CC)||Completed|July 2005|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||40|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2007|September 26, 2015|July 20, 2005||||No||https://clinicaltrials.gov/show/NCT00121589||197820|
NCT00121602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040104|Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease|Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis||Amgen||Completed|March 2005|October 2006|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|N/A|No|||February 2008|February 21, 2008|July 18, 2005||||No||https://clinicaltrials.gov/show/NCT00121602||197819|
NCT00121615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040216|Study of Etanercept in the Treatment of Psoriasis in Adult Subjects|An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects||Amgen||Completed|October 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||391|||Both|18 Years|N/A|No|||March 2009|March 5, 2009|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00121615||197818|
NCT00144664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA318JP|Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)|An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA||Chugai Pharmaceutical|No|Completed|November 2004|October 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|2 Years|19 Years|No|||July 2008|July 29, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144664||196075|
NCT00145015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR02/2004|FishGastro Study: Fish Consumption and Gastro-Intestinal Health|Fish Consumption and Gastro-Intestinal Health With Special Emphasis on Reduction of Risk of Colon Cancer and Inflammatory Bowel Disease||Institute of Food Research||Completed|December 2004|April 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|270|||Both|18 Years|80 Years|No|||July 2008|July 29, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145015||196049|
NCT00145028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 GENE 05|Determination of Carboplatin's Optimal Plasmatic Exposure|Determination of Carboplatin's Optimal Plasmatic Exposure||Institut Claudius Regaud|No|Completed|May 2005|February 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|400|||Both|18 Years|N/A|No|||March 2009|March 17, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145028||196048|
NCT00145353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose|Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose?||Odense University Hospital||Active, not recruiting|November 2004|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|60 Years|No|||October 2006|October 10, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145353||196023|
NCT00114855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPOCOL protocol 15.12.2004|The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose|A Single-Centre, Randomised Double-Blind Placebo-Controlled Study to Measure the Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose||Oslo University Hospital||Completed|March 2005|June 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2009|July 3, 2011|June 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00114855||198325|
NCT00114868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.02.03.06.C1|Vitamin A Supplementation in Newborns Study|Vitamin A Supplementation in Newborns Study||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|June 1998|April 2001|Actual|April 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|14035|||Both|N/A|2 Weeks|Accepts Healthy Volunteers|||January 2010|April 24, 2013|June 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00114868||198324|
NCT00114881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-07|Urban Environmental Factors and Childhood Asthma|Urban Environment and Childhood Asthma (URECA)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|January 2005|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|-  Sample of umbilical cord blood (mother)        -  Maternal blood sample        -  Blood and nasal mucus collection (infant through age 10 years)        -  DNA sample of mother and child        -  Urine sample        -  Saliva sample        -  Induced sputum sample        -  Nasal epithelial cells sample|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Inner city children|May 2015|May 12, 2015|June 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00114881||198323|
NCT00146445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2864|Behavioral Intervention Trial for HIV-infected Injection Drug Users|Intervention for Seropositive Injection Drug Users - Research and Evaluation (INSPIRE)||Centers for Disease Control and Prevention|No|Completed|August 2001|July 2006|Actual|July 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1000|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00146445||195941|
NCT00115492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO100250|Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations|See Detailed Description||GlaxoSmithKline|No|Completed|December 2004|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|797|||Both|40 Years|N/A|No|||April 2015|April 15, 2015|June 22, 2005||||||https://clinicaltrials.gov/show/NCT00115492||198276|
NCT00115765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040249|PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study|PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer||Amgen||Completed|June 2005|December 2009|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1053|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|June 26, 2005||||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00115765||198255|
NCT00146705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTFU HBV 99-01|Long Term Follow-up of Pegylated-Interferon Alpha-2b|Long Term Follow-up of Pegylated-Interferon Alpha-2b and Lamivudine Combination Therapy in Patients With Chronic HBV Infection||Foundation for Liver Research|No|Completed|May 2005|September 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|266|||Both|18 Years|N/A|No|||July 2007|July 31, 2007|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146705||195921|
NCT00147043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/6746|Adult Stem Cell Therapy in Liver Insufficiency|Adult Stem Therapy for Patients With Liver Insufficiency||Imperial College London||Completed|January 2005|June 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|20 Years|65 Years|No|||September 2005|February 11, 2016|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00147043||195898|
NCT00147316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527-0110|Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke|Japan Alteplase Clinical Trial (J-ACT): Phase 3 Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Acute Ischemic Stroke Within 3 Hours of Onset||Mitsubishi Tanabe Pharma Corporation||Completed|April 2002|September 2003||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|20 Years|N/A|No|||February 2012|February 29, 2012|September 5, 2005||||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00147316||195878|
NCT00147329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-093-02-200|Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis|A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Chronic Plaque Psoriasis||Merrimack Pharmaceuticals||Completed|September 2005|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||February 2007|February 21, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00147329||195877|
NCT00147589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141001|A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.|Peds I (Pediatric Eplerenone Development Study I): A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of Eplerenone In The Treatment Of Hypertension In Children||Pfizer||Completed|September 2004|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|6 Years|16 Years|No|||March 2007|January 23, 2008|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00147589||195858|
NCT00147602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0981-342|Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke|A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke|SPARCL|Pfizer||Completed|November 1998|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||4732|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00147602||195857|
NCT00147615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141077|The Long-Term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years|Peds II (Pediatric Eplerenone Development Study II)--An Open Label, Long-Term Study To Evaluate The Safety Of Eplerenone In The Treatment Of Hypertension In Children||Pfizer||Completed|October 2004|June 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Both|6 Years|16 Years|No|||June 2007|June 4, 2007|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00147615||195856|
NCT00144794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPS I Registry|Mucopolysaccharidosis I (MPS I) Registry|Mucopolysaccharidosis I (MPS I) Registry||Sanofi|No|Recruiting|November 2003|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1500|||Both|N/A|N/A|No|Probability Sample|All Patients with MPS I|March 2016|March 15, 2016|September 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00144794||196066|
NCT00143650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORMAS 24.2/2001-05|SENOC-I Det Sunda Huset II - Sensitization of Occupants of Water Damaged Buildings.|Does House Dust From Water Damaged Buildings Cause Stronger Responses Among Occupants Than Dust From Buildings Without Water Damage? Can Occupants’ Sensitivity be Predicted by Biomarkers?||University of Aarhus||Completed|January 2001|September 2002||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||27|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2005|January 16, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143650||196152|
NCT00143871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 0074|Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma|Rituximab Plus High-dose Chemotherapy With Autologous Stem Cell Support for Non-Hodgkin's Lymphoma||University of Michigan Cancer Center|Yes|Completed|April 2001|January 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||January 2012|January 30, 2012|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143871||196135|
NCT00144404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-04-376-07|Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism|Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism||Charles Drew University of Medicine and Science|Yes|Recruiting|August 2002|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 23, 2009|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00144404||196095|
NCT00144417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4448|TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment|TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment||Centers for Disease Control and Prevention|Yes|Completed|February 2006|December 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|433|||Both|18 Years|N/A|No|||June 2011|August 2, 2011|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00144417||196094|
NCT00144755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH03-6B|R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma|Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.||Lymphoma Study Association|Yes|Completed|December 2003|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|600|||Both|60 Years|80 Years|No|||September 2015|September 1, 2015|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144755||196069|
NCT00124865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC 2002.0003|Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study|Safety and Immunogenicity Evaluation of an Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) in Volunteers||U.S. Army Medical Research and Materiel Command||Completed|July 2005|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2010|June 2, 2015|July 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00124865||197574|
NCT00125138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13104A|Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease|Safety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's Disease||Lundbeck LLC|Yes|Completed|July 2005|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|90|||Both|N/A|N/A|No|||May 2011|May 17, 2011|July 27, 2005|Yes|Yes||No|April 11, 2011|https://clinicaltrials.gov/show/NCT00125138||197553|
NCT00145366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008|rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter|Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.||Odense University Hospital||Completed|April 2002|July 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|December 27, 2010|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145366||196022|
NCT00145379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006|The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus|The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus||Odense University Hospital||Completed|March 2003|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|60 Years|No|||May 2013|May 17, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145379||196021|
NCT00114595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/M044|Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia|A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia||University of Stellenbosch||Completed|April 2003|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|18 Years|60 Years|No|||June 2005|June 23, 2005|June 15, 2005||||No||https://clinicaltrials.gov/show/NCT00114595||198344|
NCT00114608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDY # 2|Venous Blood Flow Velocity: Electrical Foot Stimulation Compared to Intermittent Pneumatic Compression of the Foot|Venous Blood Flow Velocity: Electrical Foot Stimulation Compared to Intermittent Pneumatic Compression of the Foot||University at Buffalo|Yes|Completed|June 2005|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|40|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||March 2008|March 10, 2008|June 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00114608||198343|
NCT00114894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311M54041|Prevention of Jellyfish Stings|Field Study of the Prevention of Jellyfish Stings With a Topical Sting Inhibitor||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2004|February 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 12, 2009|June 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00114894||198322|
NCT00114907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEA|Effects of Black Tea on Cardiovascular Disease in the Mauritian Population|Effects of Black Tea on Cardiovascular Disease in the Mauritian Population||University of Mauritius||Completed|June 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||270|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||June 2005|April 5, 2007|June 17, 2005||||No||https://clinicaltrials.gov/show/NCT00114907||198321|
NCT00146185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3268-3-004-1|Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Effectiveness and Safety of ALGRX 3268 in Pediatric Subjects.||AlgoRx Pharmaceuticals||Completed|February 2005|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||504|||Both|3 Years|18 Years|No|||April 2005|November 15, 2005|September 4, 2005||||||https://clinicaltrials.gov/show/NCT00146185||195961|
NCT00146198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-2-007-2|Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects After Inguinal Hernia Repair||AlgoRx Pharmaceuticals||Completed|September 2005|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Male|18 Years|70 Years|No|||December 2006|December 18, 2006|September 4, 2005||||No||https://clinicaltrials.gov/show/NCT00146198||195960|
NCT00146692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCR5095|A Trial of Improved Financial Access to Healthcare in Ghana|Impact of Improved Financial Access to Health Care on Morbidity Due to Severe Malaria and Healthcare Utilization Among Children 6 Months to Five Years of Age in a Hyper Endemic Area in Ghana: a Randomized Controlled Trial||Gates Malaria Partnership|No|Completed|April 2004|February 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Both|6 Months|5 Years|No|||March 2009|March 5, 2009|September 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00146692||195922|
NCT00146718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG34|Anti-Malarial Drug Resistance in Cameroon|Anti-Malarial Drug Resistance in Cameroon: Therapeutic Efficacy and Biological Markers of Resistance||Gates Malaria Partnership||Completed|August 2003|May 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||755|||Both|6 Months|59 Months|No|||September 2005|February 22, 2006|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146718||195920|
NCT00147056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT002|MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors|A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors||InSightec|Yes|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||February 2016|February 1, 2016|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00147056||195897|
NCT00147069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-059|Leukocyte Function in Asthma and COPD|Investigation Into Inflammatory Mechanisms in Airway Cells in Smokers and Non-smokers With Inflammatory Lung Disease.||Imperial College London|No|Completed|April 2004|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|90|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2005|May 27, 2015|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00147069||195896|
NCT00143390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991048|Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer|A Randomized, Double-Blind, Controlled Study Of Exemestane (Aromasin) Vs Anastrozole (Arimidex) As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer||Pfizer|Yes|Completed|April 2005|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|298|||Female|20 Years|N/A|No|||December 2011|December 19, 2011|September 1, 2005|Yes|Yes||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00143390||196172|
NCT00143689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H02-50066|NRTI-Sparing Pilot Study|A Pilot Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor Sparing Regimen in Antiretroviral-Naïve, HIV-infected Patients||University of British Columbia||Completed|April 2002|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143689||196149|
NCT00147628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481236|Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire|A Multi-Center, Double-Blind Placebo Controlled, Flexible-Dose Study With An Open-Label Phase To Assess The Efficacy Of Sildenafil Citrate On Erectile Function And Intercourse Satisfaction As Well As To Validate The Sexual Experience Questionnaire And Its Treatment Responsiveness In Men With Erectile Dysfunction||Pfizer||Completed|November 2005|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|209|||Male|18 Years|N/A|No|||June 2011|June 7, 2011|September 4, 2005||||||https://clinicaltrials.gov/show/NCT00147628||195855|
NCT00147654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121120|Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction|A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction||Pfizer||Completed|November 2004|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||830|||Male|40 Years|N/A|No|||June 2011|June 7, 2011|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147654||195854|
NCT00143663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-475-008|Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol|A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg Versus Placebo in Subjects With Primary Hypercholesterolemia||Takeda|No|Completed|September 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|361|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143663||196151|
NCT00143676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-475-009|Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia|A Double-blind, Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of TAK-475 50 mg, 100 mg, or Placebo When Co-administered With Atorvastatin (10 mg to 40 mg) in Subjects With Primary Hypercholesterolemia||Takeda|No|Completed|August 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|448|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143676||196150|
NCT00143910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9109M04306|Natural History Study of Azathioprine Adherence|Measurement of Compliance in Renal Transplant Recipients||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 1993|October 1999|Actual|October 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||180|||Both|16 Years|N/A|No|Non-Probability Sample|Successful renal transplant recipients, discharged from hospital with a functioning renal        transplant.|December 2013|December 5, 2013|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00143910||196133|
NCT00143884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9979|Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood|Adjuvant Cellular Immunotherapy for High-Risk Hematologic Malignancy After Allogeneic Stem Cell Transplantation Using Low Intensity Conditioning||University of Michigan Cancer Center||Terminated|March 2000|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||30|||Both|N/A|N/A|No|||January 2007|April 20, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143884||196134|
NCT00125086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APG-01-0605|Platelets for Acute Wound Healing|Platelets in Acute Wounds: A Punch Biopsy Study (PAWS II)||Medtronic||Completed|July 2005|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|July 27, 2005||||No||https://clinicaltrials.gov/show/NCT00125086||197557|
NCT00125099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5187|Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection|Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (GAG-POL-NEF-MULTICLADE ENV) in HIV-1 Infected Subjects Treated During Acute HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|21|||Both|18 Years|50 Years|No|||May 2012|May 16, 2012|July 27, 2005||||||https://clinicaltrials.gov/show/NCT00125099||197556|
NCT00116116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI455-131|DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy|Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release (d4T XR) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Subjects||Bristol-Myers Squibb||Completed|March 2002|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||April 2011|April 14, 2011|June 27, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00116116||198228|
NCT00116363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 241-004|Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma|Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma||Introgen Therapeutics|Yes|Recruiting|March 2005|December 2006|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|June 28, 2005||||Yes||https://clinicaltrials.gov/show/NCT00116363||198209|
NCT00125151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB2003.01B|C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema|Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema||Sanquin||Completed|February 2006|April 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|16 Years|N/A|No|||May 2009|May 1, 2009|July 28, 2005||||No||https://clinicaltrials.gov/show/NCT00125151||197552|
NCT00145054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24MH061422|Study of a Self-Help Depression Skills Program for College-Aged Youth|Randomized, Controlled Pilot Study of a Self-Help Depression Skills Program for College-Aged Youth||Kaiser Permanente||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|14 Years|24 Years|Accepts Healthy Volunteers|||September 2005|March 23, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145054||196046|
NCT00145392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women|Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women||Odense University Hospital|No|Completed|September 2002|December 2007|Actual|January 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||||10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 23, 2008|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145392||196020|
NCT00114621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040283|Anthrax Vaccine Clinical Trials|Anthrax Vaccine Clinical Trials||National Institutes of Health Clinical Center (CC)||Completed|September 2004|May 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|45 Years|No|||March 2012|March 17, 2012|June 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00114621||198342|
NCT00146146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID/2004|Testosterone and Its Metabolites in GID|Role of Testosterone and Its Metabolites Regarding Different Physiological Functions in Subjects Affected by Gender Identity Disorder (FtM Transsexuals)||Unita Complessa di Ostetricia e Ginecologia|No|Completed|May 2005|January 2008|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00146146||195964|
NCT00146159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906E-100925|Study Evaluating Mitoxantrone in Multiple Sclerosis|A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|March 2005|||September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|336|||Both|18 Years|55 Years|No|||December 2007|December 21, 2007|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00146159||195963|
NCT00146172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-102|Study Evaluating HKI-272 in Tumors|An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors||Puma Biotechnology, Inc.||Completed|November 2003|January 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|72|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146172||195962|
NCT00146211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN01.01.0011|TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease|A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease||Amarin Neuroscience Ltd||Completed|September 2005|July 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|300|||Both|35 Years|N/A|No|||December 2007|December 24, 2007|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146211||195959|
NCT00146224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050113|Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis|A Randomized, Double-Blind, Equivalence Study of the Efficacy of Epoetin Alfa Manufactured by Deep Tank Bioreactor Technology and Epoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) Receiving Hemodialysis||Amgen||Completed|September 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||February 2010|February 25, 2010|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146224||195958|
NCT00146458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRP024|Usefulness of FDG-PET for Advanced Cervical Cancer|A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image||Chang Gung Memorial Hospital||Active, not recruiting|January 2002|December 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Female|N/A|N/A|No|||September 2006|September 19, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146458||195940|
NCT00146471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kep-F10.3.01|Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome|Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome [Sicherheit Und Wirksamkeit Von Levetiracetam (Keppra) für Die Behandlung Des stationären Alkoholentzugsyndroms]||Charite University, Berlin, Germany|Yes|Completed|January 2006|September 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||September 2008|December 29, 2009|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00146471||195939|
NCT00146731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG04|A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania|Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania||Gates Malaria Partnership|Yes|Completed|January 2004|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|310|||Female|15 Years|38 Years|No|||February 2010|February 17, 2010|September 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00146731||195919|
NCT00147342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 007|The Effect of Insulin During Exercise on the Development of Low Blood Sugar in Individuals With Type I Diabetes|The Effect of Basal Insulin During Exercise on the Development of Hypoglycemia in Children With Type 1 Diabetes||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|May 2005|December 2005||||N/A|Observational|Time Perspective: Prospective||||55|||Both|8 Years|17 Years|No|||December 2006|January 10, 2008|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147342||195876|
NCT00147082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-024|Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD)|Leukocyte Migration and Differentiation in COPD Patients Compared to Healthy Smokers and Healthy Non-smoking Subjects.||Imperial College London||Completed|February 2001|April 2007|Actual|December 2004|Actual|N/A|Observational|N/A||3|Anticipated|90|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2006|August 24, 2015|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147082||195895|
NCT00147095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-207|Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease|Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease||Imperial College London||Completed|February 2003|February 2005|Actual|February 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|80|Samples Without DNA|RNA was isolated and sent to GeneLogic|Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2005|May 27, 2015|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00147095||195894|
NCT00144170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.48|Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)|Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)||Boehringer Ingelheim||Completed|February 2003|||October 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|882|||Both|18 Years|N/A|No|||April 2014|June 23, 2014|September 2, 2005||Yes||No|September 11, 2009|https://clinicaltrials.gov/show/NCT00144170||196113|
NCT00144430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVH 0313|Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children|A Phase II Study of Pentostatin For the Treatment of High Risk or Refractory Chronic GVHD in Children||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|January 2004|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|1 Month|21 Years|No|||February 2009|February 2, 2009|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00144430||196093|
NCT00144183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1413|A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)|An Open-label Study Evaluating the Resistance Profile of Single Dose Nevirapine(NVP) When Combined With a 4 or 7 Day Course of Combivir® (ZDV/3TC) Compared to Single Dose Nevirapine for the Prevention of Mother to Child Transmission (pMTCT) of HIV - Treatment Options Preservation Study (T.O.P.S.)||Boehringer Ingelheim||Completed|January 2003|January 2007||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||407|||Female|18 Years|N/A|No|||November 2013|November 1, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144183||196112|
NCT00144196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.281|12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)|A 12-week Double-blind, Randomised, Parallel-group, Multi-centre Study Evaluating the Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD, According to Swedish Guidelines (SPIRIMILD)||Boehringer Ingelheim||Completed|March 2004|July 2005||July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||224|||Both|40 Years|N/A|No|||July 2014|July 22, 2014|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144196||196111|
NCT00145119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medtronic_BRC_CRM_001|CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction|Incidence and Prediction of Life-threatening Cardiac Arrhythmias in Patients With Depressed Left Ventricular Function After Acute Myocardial Infarction||Medtronic Bakken Research Center||Completed|August 2001|May 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|312|||Both|18 Years|N/A|No|||January 2014|November 4, 2015|September 2, 2005||||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00145119||196041|
NCT00145132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCIT-SPECT-Pogarell|Beta-CIT-SPECT and Neurophysiology in Depression|Serotonin and Dopamine Transporter (SERT, DAT) Availabilities as Assessed by b-CIT and SPECT, and Neurophysiological Measures of Central Serotonergic Activity in Patients With Depression Under Treatment With Escitalopram||Ludwig-Maximilians - University of Munich||Completed|June 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||May 2010|June 1, 2010|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00145132||196040|
NCT00144157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1414|Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV|An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1.||Boehringer Ingelheim||Completed|June 2003|July 2006||July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|53|||Female|19 Years|45 Years|No|||November 2013|November 13, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144157||196114|
NCT00121355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS241-1674|Novofine Autocover Safety Needle Versus BD Safety Glide|An Open-Label, Multi-Center, Prospective Cross-Over Study of Preference and Safety of NovoFine® Autocover(TM) Needles Compared to BD Safety Glide (TM) Syringes in the Hospital Setting||Novo Nordisk A/S|No|Completed|July 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|83|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 17, 2012|July 13, 2005||||No||https://clinicaltrials.gov/show/NCT00121355||197837|
NCT00124553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCDR_1|LOADD (Lifestyle Over and Above Drugs in Diabetes) Study|The Potential for Diet Modification to Improve Glycaemic Control and Cardiovascular Risk Factors Over and Above Drug Therapy in Type 2 Diabetes at High Risk of Cardiovascular Disease||Edgar National Centre for Diabetes Research||Recruiting|August 2006|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|N/A|70 Years|No|||March 2007|March 27, 2007|July 27, 2005||||No||https://clinicaltrials.gov/show/NCT00124553||197595|
NCT00112372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-016|Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)|A Phase I/IIa, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of AP23573 When Administered Orally in Patients With Refractory or Advanced Malignancies||Merck Sharp & Dohme Corp.|No|Completed|May 2005|March 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|June 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00112372||198506|
NCT00116376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEE788A2103|Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)|A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme||Novartis|No|Completed|January 2004|November 2005|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|June 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116376||198208|
NCT00145080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-039|Comparison of Osteoporosis Disease Management Strategies (0000-039)|Evaluation of Strategies for Increasing Osteoporosis Screening and Treatment in a Managed Care Organization||Merck Sharp & Dohme Corp.||Completed|July 2004|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|4685|||Female|50 Years|64 Years|No|||October 2015|October 30, 2015|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00145080||196044|
NCT00145093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04.0536P|Effects of Chromium Supplementation on Parameters of the Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus|The Effects of Organic Chromium Supplementation on Clinical Parameters of the Metabolic Syndrome, in Patients With Type 2 Diabetes Mellitus. A Randomised, Double-Blind, Placebo-Controlled Trial||Medical Research Foundation, The Netherlands||Completed|August 2004|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|November 21, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145093||196043|
NCT00145678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB 4968|Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder|Psychodynamic Therapy for Patients With Borderline Personality Disorder and Alcohol Abuse||State University of New York - Upstate Medical University|No|Completed|June 2004|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 5, 2015|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00145678||195998|
NCT00145873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12350A|Nesiritide in Chronic Heart Failure|Continuous Infusion Nesiritide in Chronic Heart Failure-University of Chicago (CINCH-UC)||University of Chicago||Terminated|August 2003|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2006|October 7, 2013|September 1, 2005|No|Yes|Unable to complete study|No||https://clinicaltrials.gov/show/NCT00145873||195984|
NCT00145886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12901A|rhPTH Therapy for Low Turnover Bone Fragility|Effect of 12 Months Treatment With rhPTH on Calcium Balance, Bone Turnover, Bone Mineral Density, and Bone Micro-architecture in Patients With Fractures Associated With Low Bone Turnover and Sclerosing Bone Disorders||University of Chicago|No|Terminated|February 2003|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|20 Years|N/A|No|||January 2016|January 8, 2016|September 1, 2005|No|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00145886||195983|
NCT00145912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A.T.C.H.-I.T. - 13240B|Primary Care Based Depression Prevention for Adolescents/Young Adults/Young Adults and Young Adults|Primary Care Based Depression Prevention for Adolescents/Young Adults/Young Adults and Young Adults|CATCH-IT|University of Chicago|No|Completed|February 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|49|||Both|15 Years|21 Years|No|||September 2013|September 4, 2013|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00145912||195982|
NCT00146237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3581|Phenytoin as an Augmentation for SSRI Failures|Phenytoin as an Augmentation for SSRI Failures: A Controlled Study||Beersheva Mental Health Center||Completed|November 2003|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||November 2009|November 23, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146237||195957|
NCT00146250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H99/00835|The Effect of N2O Administration on Arterial Oxygenation|Relationship of Oxygenation During Anaesthesia in the Presence of N2O or N2 to Mode of Ventilation||Austin Health||Completed|January 2005|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146250||195956|
NCT00146484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEO RI cc9993|A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes|A Randomized Controlled Trial of Two Versus Three Daily Insulin Injections in Children and Adolescents With New Onset Type 1 Diabetes Mellitus||Children's Hospital of Eastern Ontario||Completed|April 1996|January 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|17 Years|No|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146484||195938|
NCT00143702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00-0159|D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE)|Randomized, Open-Label Study of Continued Stavudine Versus Abacavir Substitution With or Without Riboflavin and Thiamine Supplementation in HIV-Infected Patients Who Have Elevated Venous Lactic Acid While on Stavudine-Based Therapy (DAVE)||University of British Columbia||Completed|August 2001|August 2006|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||September 2005|September 24, 2008|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143702||196148|
NCT00147667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03/03|Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD|Randomised Double Blind Placebo Controlled Trial of Effects of Long Term Low Dose Oral Erythromycin Therapy in Patients With Chronic Obstructive Pulmonary Disease||Royal Free and University College Medical School||Active, not recruiting|April 2004|March 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|40 Years|90 Years|No|||March 2004|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147667||195853|
NCT00143377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121122|Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB|A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).||Pfizer||Completed|September 2004|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||December 2006|November 17, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143377||196173|
NCT00143923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0301102|Novel Strategies for Reducing Heart Disease Risk Disparities|Heart Strategies Concentrating On Risk Evaluation (Heart SCORE) Study||University of Pittsburgh|No|Active, not recruiting|March 2003|December 2024|Anticipated|December 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2000|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00143923||196132|
NCT00144209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.518|Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome|Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome||Boehringer Ingelheim||Completed|February 2003|February 2005||February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|58|||Both|25 Years|85 Years|No|||October 2013|October 31, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144209||196110|
NCT00144469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JV15725|A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C|A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C||Chugai Pharmaceutical|No|Completed|May 2002|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|300|||Both|20 Years|N/A|No|||January 2009|January 29, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144469||196090|
NCT00144482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO307JP|A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy|A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy||Chugai Pharmaceutical|No|Completed|December 2003|August 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|20 Years|79 Years|No|||January 2009|January 29, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144482||196089|
NCT00145145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-001|Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma|Phase I/II Study of Immunization With the MAGE-3.A1 Peptide Mixed With the Immunological Adjuvant CpG 7909 in Patients With Metastatic Melanoma||Ludwig Institute for Cancer Research||Terminated|January 2005|April 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|14|||Both|18 Years|N/A|No|||August 2007|August 21, 2007|September 1, 2005|||Poor Accrual|No||https://clinicaltrials.gov/show/NCT00145145||196039|
NCT00145158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2003-007|Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma|Phase I/II Study of Immunization With Multiple Peptides Mixed With the Immunological Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma||Ludwig Institute for Cancer Research||Suspended|January 2005|December 2009|Anticipated|March 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||June 2009|June 19, 2009|September 1, 2005||No|Availability of Investigational agent|No||https://clinicaltrials.gov/show/NCT00145158||196038|
NCT00145418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-03-137 (0409)|Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer|Phase 2 Study Evaluating the Safety and Efficacy of Eloxatin (Oxaliplatin) and Docetaxel as First-line Therapy of Stage IV or IIIB Unresectable Non-Small Cell Lung Cancer||Oncology Specialists, S.C.|No|Terminated|February 2005|March 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|September 1, 2005||No|low enrollment|No|July 20, 2011|https://clinicaltrials.gov/show/NCT00145418||196018|Due to lack of recruitment, the study was closed early and conclusions should not necessarily be drawn from the data presented for duration of response
NCT00145431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091024|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.|Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia).||Pfizer||Terminated|March 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|41|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00145431||196017|
NCT00124566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IROF-018|Study of Irofulven in Patients With Hormone-refractory Prostate Cancer|Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients||Eisai Inc.||Completed|June 2004|December 2009|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|135|||Male|18 Years|N/A|No|||January 2016|January 15, 2016|July 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00124566||197594|
NCT00124579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0417|S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma||Southwest Oncology Group|Yes|Terminated|August 2005|June 2010|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 26, 2005|Yes|Yes|poor accrual|No|January 2, 2013|https://clinicaltrials.gov/show/NCT00124579||197593|
NCT00145405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009|Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction|Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction - A Twelve Month Randomized Cross-Over Study in Patients With Acromegaly||Odense University Hospital||Completed|September 2002|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|22 Years|72 Years|No|||September 2005|September 6, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145405||196019|
NCT00146770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID-006-01|Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients|A Multicenter, Multinational, Open-Label Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I||Sanofi||Completed|May 2001|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|N/A|N/A|No|||March 2015|March 17, 2015|September 2, 2005|Yes|Yes||No|January 7, 2009|https://clinicaltrials.gov/show/NCT00146770||195916|Rare disease with limited sample size, lack of control group.FVC calculations less reliable for patients whose height is below the 3rdpercent of general population.Height term used to calculate FVC may be influenced by joint contractures and posture.
NCT00145925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANCE|Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes|ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation||The George Institute|Yes|Completed|June 2001|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|11140|||Both|55 Years|N/A|No|||September 2008|September 16, 2008|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145925||195981|
NCT00146744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102374|Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults|Double-blind (Observer-blind), Randomised, Controlled, Phase I/II Study, to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months to Healthy PPD-positive Volunteers Aged 18 to 50 Years||GlaxoSmithKline||Completed|July 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146744||195918|
NCT00146497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR92-IRB-127|Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants|||China Medical University Hospital||Terminated|August 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|N/A|1 Day|No|||June 2006|June 26, 2006|September 4, 2005||||No||https://clinicaltrials.gov/show/NCT00146497||195937|
NCT00143455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4174D-3001|Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer|Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer||Pfizer|Yes|Completed|June 2002|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|485|||Both|18 Years|75 Years|No|||February 2010|February 10, 2010|September 1, 2005||No||No|December 11, 2009|https://clinicaltrials.gov/show/NCT00143455||196167|
NCT00143468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160|The Specific Elastance in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients|The Specific Elastance in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients: Barotrauma and Volutrauma||Policlinico Hospital|No|Completed|March 2005|May 2008|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|16 Years|90 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143468||196166|
NCT00143715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-66693|Oral Vitamin K for Warfarin Associated Coagulopathy|A Multicentre, Multinational Study of Oral Vitamin K for the Treatment of Warfarin Associated Coagulopathy||St. Joseph's Healthcare Hamilton|Yes|Completed|September 2004|January 2007|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|690|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143715||196147|
NCT00143494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200|The Estimation of Abdominal Pressure by the Bladder and Gastric Pressure|The Estimation of Abdominal Pressure by the Bladder and Gastric Pressure||Policlinico Hospital|No|Completed|July 2005|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Male|16 Years|90 Years|No|||September 2008|September 24, 2008|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00143494||196164|
NCT00143936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001103|The Safety and Efficacy of Low and High Carbohydrate Diets|The Safety and Efficacy of Low and High Carbohydrate Diets||Temple University|Yes|Completed|April 2003|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 14, 2010|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00143936||196131|
NCT00144222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.436|Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy|A Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg||Boehringer Ingelheim||Completed|January 2005|August 2005||August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|218|||Both|30 Years|70 Years|No|||November 2013|November 4, 2013|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144222||196109|
NCT00116259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG03-325a|Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)|Aripiprazole in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Double Blind Placebo Controlled Trial||Federal University of Rio Grande do Sul||Completed|March 2005|February 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|8 Years|17 Years|No|||August 2008|August 6, 2008|June 27, 2005||||No||https://clinicaltrials.gov/show/NCT00116259||198217|
NCT00145444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281006|Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study|A Multicenter, Double-Blind, Randomized Trial Of Ziprasidone (80 - 160 Mg) Versus Olanzapine (10 - 20 Mg) In Patients With Recent-Onset Schizophrenia, Schizoaffective And Schizophreniform Disorder.||Pfizer||Completed|March 2003|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|40 Years|No|||December 2006|December 28, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145444||196016|
NCT00145457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-MET-9002-040|IGF1 Generation Test|A Multicentre Study on the Capacity of the IGF-1 Stimulation Test to Predict the Growth Promoting Effect of Standard and High Doses of Genotonorm® in Prepubertal Children With Growth Hormone Deficiency.|CAREL|Pfizer||Completed|April 2001|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||82|||Both|4 Years|11 Years|No|||May 2007|June 5, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145457||196015|
NCT00115804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-3-22-1|Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia|An Open-Label Clinical Trial of Fluoxetine Treatment of Juvenile Primary Fibromyalgia Syndrome||University of Cincinnati|No|Completed|June 2005|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|13 Years|18 Years|No|||January 2013|January 15, 2013|June 26, 2005|Yes|Yes||No|November 7, 2012|https://clinicaltrials.gov/show/NCT00115804||198252|
NCT00116103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0-213|A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma||Astellas Pharma Inc||Completed|June 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||June 2012|June 6, 2012|June 27, 2005||||||https://clinicaltrials.gov/show/NCT00116103||198229|
NCT00113087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177|Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network|Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)|ISV|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|August 2003|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|N/A|45 Days|No|||September 2009|September 16, 2010|June 3, 2005|Yes|Yes||No|September 4, 2009|https://clinicaltrials.gov/show/NCT00113087||198460|
NCT00113321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0468|Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure|Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure||M.D. Anderson Cancer Center|No|Terminated|March 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||August 2012|August 1, 2012|June 7, 2005|Yes|Yes|Low Accrual|No|September 25, 2009|https://clinicaltrials.gov/show/NCT00113321||198442|
NCT00112645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSCI-20615|Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors|A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Pediatric Solid Tumors With Relapsed or Therapy Refractory Disease||National Cancer Institute (NCI)||Completed|April 2005|February 2011|Actual|April 2010|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|N/A|30 Years|No|||February 2011|July 17, 2013|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112645||198488|
NCT00112658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430100|Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer|Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients||National Cancer Institute (NCI)||Active, not recruiting|November 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|348|||Both|18 Years|75 Years|No|||December 2006|May 19, 2011|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112658||198487|
NCT00146536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-164|Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy|The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy||Dana-Farber Cancer Institute|No|Completed|November 2004|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|78|Samples With DNA|Option of keeping tissue sample for further research|Female|20 Years|N/A|No|Non-Probability Sample|Individuals who have ALH/LCIS detected on a needle biospy of the breast|November 2012|November 29, 2012|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00146536||195934|
NCT00146757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID-014-02|A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old|A Phase II Open-Label Clinical Trial of Recombinant Human Alpha-L-iduronidase (Aldurazyme®) to Evaluate the Safety and Pharmacokinetics in Mucopolysaccharidosis I (MPS I) Patients Less Than 5 Years Old||Sanofi||Completed|October 2002|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|N/A|5 Years|No|||March 2015|March 17, 2015|September 2, 2005|Yes|Yes||No|November 20, 2008|https://clinicaltrials.gov/show/NCT00146757||195917|Due to the rarity of the disease, this study is limited by its small sample size and lack of a control group.
NCT00146549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-087|Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer|A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing Metastatic Breast Cancer||Dana-Farber Cancer Institute||Completed|August 2001|December 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146549||195933|
NCT00145626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFT2|HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies|HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies||St. Jude Children's Research Hospital|No|Active, not recruiting|May 2004|June 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|24 Months|No|||January 2016|January 20, 2016|September 1, 2005|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00145626||196002|The study was limited due to the unavailability of the study drug OKT3 beginning in June 2011. The study was temporarily closed to accrual. Because OKT3 is still unavailable, the study was formally closed to accrual in March 2015.
NCT00145639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS99|Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma|Osteosarcoma 1999-A Study Of Intensive Chemotherapy Utilizing Ifosfamide, Carboplatin, and Doxorubicin for Adjuvant Chemotherapy for Treatment of Osteosarcoma||St. Jude Children's Research Hospital|Yes|Completed|May 1999|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|25 Years|No|||June 2011|June 8, 2011|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00145639||196001|
NCT00145938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12562A|Sildenafil and Pulmonary Artery Pressure|A Pilot Study of the Effect of Chronic Administration of Sildenafil on Pulmonary Artery Pressure in Patients With Portopulmonary Hypertension||University of Chicago||Terminated|September 2003|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||September 2006|October 7, 2013|September 1, 2005|No|Yes|Unable to complete study|No||https://clinicaltrials.gov/show/NCT00145938||195980|
NCT00147680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPSC - 001|Uterine Papillary Serous Cancer (UPSC) Trial|Prospective, Non-randomised Phase 2 Clinical Trial of Carboplatin Plus Paclitaxel With Sequential Radical Pelvic Radiotherapy for Uterine Serous Papillary Cancer||Queensland Centre for Gynaecological Cancer|No|Completed|September 2004|October 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||February 2012|February 1, 2012|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00147680||195852|
NCT00147108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BF002|MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas|Phase 3 Study of MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas||InSightec||Terminated|January 2003|October 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 13, 2012|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00147108||195893|
NCT00147719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-301|WelChol® With Metformin in Treating Patients With Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents||Daiichi Sankyo Inc.||Completed|June 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|75 Years|No|||January 2012|January 16, 2012|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00147719||195849|
NCT00143481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121002|Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women|A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women With Overactive Bladder||Pfizer||Completed|March 2005|||June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Female|18 Years|N/A|No|||April 2013|April 9, 2013|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00143481||196165|
NCT00143728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-0051|3TC or No 3TC for HIV With 3TC Resistance|A Randomized Study to Evaluate Virologic Response Following Discontinuation vs. no Discontinuation of 3TC in Patients Who Are Infected With HIV With Previously Documented Reduced Susceptibility to 3TC and Who Have Adequate Virologic Suppression on Combination Antiretroviral Therapy||University of British Columbia||Suspended|January 2004|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|152|||Both|18 Years|N/A|No|||September 2008|September 24, 2008|August 31, 2005||No|Enrollment.|No||https://clinicaltrials.gov/show/NCT00143728||196146|
NCT00143949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9601M10705|Renin Angiotensin System Study (RASS/B-RASS)|Renin Angiotensin System Blockage-DN (RASS)||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 1997|May 2008|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|285|||Both|16 Years|61 Years|Accepts Healthy Volunteers|||November 2008|November 5, 2008|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143949||196130|
NCT00116532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-000895|Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)|Escitalopram for the Treatment of Obsessive Compulsive Disorder||Massachusetts General Hospital|No|Completed|October 2002|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||April 2007|April 23, 2007|June 29, 2005||||No||https://clinicaltrials.gov/show/NCT00116532||198196|
NCT00144443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG00002078|Kansas City Community Environmental Remediation And Training (KC CERT)|Kansas City Community Environmental Remediation And Training (KC CERT)||Children's Mercy Hospital Kansas City||Active, not recruiting|March 2003|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||200|||Both|2 Years|17 Years|No|||May 2005|December 8, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00144443||196092|
NCT00144456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED-209JP|A New Active Vitamin D, ED-71 for Osteoporosis|A Prospective, Randomized, Double-blind Study to Compare the Effect of ED-71 With That of Alfacalcidol on Fracture Incidence in Osteoporotic Patients||Chugai Pharmaceutical||Completed|September 2004|October 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1056|||Both|N/A|N/A|No|||August 2013|August 6, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00144456||196091|
NCT00144833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV102002|Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects|A Phase III, Randomized, Controlled, Open-Label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-Boosted HIV-1 Protease Inhibitor Regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-Infected Adults Experiencing Virological Failure||GlaxoSmithKline|Yes|Terminated|March 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2007|November 9, 2007|September 1, 2005|||Incomplete data|No||https://clinicaltrials.gov/show/NCT00144833||196063|
NCT00145184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-117|Effect of Multivitamin Supplements on Clinical and Immunological Response in Childhood Tuberculosis|Effect of Multivitamin Supplements on Clinical and Immunological Response in Childhood Tuberculosis||Harvard School of Public Health|Yes|Terminated|May 2005|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|6 Weeks|5 Years|No|||March 2015|March 28, 2015|September 2, 2005||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00145184||196036|
NCT00145197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 00-0053|Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities|Improving the Delivery of Effective Care to Minorities||Icahn School of Medicine at Mount Sinai|No|Completed|January 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1164|||Female|18 Years|N/A|No|||December 2013|December 2, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00145197||196035|
NCT00112359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-AI-007|International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa|A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary Pseudomonas Aeruginosa (AIR-CF1)|AIR-CF1|Gilead Sciences|Yes|Completed|May 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|6 Years|N/A|No|||March 2011|March 21, 2011|June 1, 2005|Yes|Yes||No|September 10, 2010|https://clinicaltrials.gov/show/NCT00112359||198507|
NCT00113867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0022|Effects of Hormonal Infertility Treatment on Cognition in Pre-Menopausal Women|Effects of Hormonal Infertility Treatment on Cognition in Pre-Menopausal Women||National Institute on Aging (NIA)||Completed|September 2003|November 2006|Actual|November 2006|Actual|N/A|Observational|N/A||||80|||Female|25 Years|N/A|Accepts Healthy Volunteers|||November 2006|December 9, 2009|June 10, 2005||||No||https://clinicaltrials.gov/show/NCT00113867||198400|
NCT00112671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03095|Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract|A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)||National Cancer Institute (NCI)||Completed|April 2005|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2013|August 4, 2015|June 2, 2005|No|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT00112671||198486|
NCT00145990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257-2005|The Impact of Dosimeter on Measurement of Airway Responsiveness to Methacholine|||University of Florida||Completed|September 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||12|||Both|18 Years|60 Years|No|||March 2012|March 1, 2012|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145990||195976|
NCT00145652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Hedenus|Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.|Phase 3 Study of Recombinant Erythropoetin and Adjuvant I.V. Iron Therapy of Anemic Patients With Lymphoproliferative Disorders||Sundsvall Hospital||Completed|December 2003|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Both|18 Months|N/A|No|||September 2006|July 27, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00145652||196000|
NCT00146510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-0126|HealtheTech Lifestyle Program|HealtheLifestyle Behavioral Intervention Clinical Trial||The Cooper Institute||Completed|March 2004|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146510||195936|
NCT00146523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-09|An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression|An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD)||Corcept Therapeutics|No|Completed|May 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|75 Years|No|||February 2012|February 14, 2012|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146523||195935|
NCT00147368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arginine|Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria|Pharmacokinetic-Pharmacodynamic Study of Adjunctive Arginine in Falciparum Malaria||Menzies School of Health Research|Yes|Completed|February 2005|December 2007|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|60 Years|No|||May 2008|May 30, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147368||195874|
NCT00143403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT-GMA-301|Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer|Multi-Centre Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone, As Adjuvant Treatment After Resection Of Liver Metastases For Colorectal Cancer.||Pfizer|No|Completed|December 2001|September 2009|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|321|||Both|18 Years|75 Years|No|||September 2010|September 24, 2010|September 1, 2005||No||No|February 26, 2009|https://clinicaltrials.gov/show/NCT00143403||196171|
NCT00143416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6291011|Long Term Study With B2036-PEG|Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -||Pfizer||Completed|April 2004|July 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|20 Years|75 Years|No|||July 2008|July 24, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143416||196170|
NCT00143429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111127|Corneal Versus Conjunctival Delivery Using a Delivery Device|Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device||Pfizer||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143429||196169|
NCT00115375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY4422|Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)|Dose-Ranging Pharmacodynamic Assessment of Platelet Aggregation Inhibition With Clopidogrel in Children of Blalock-Taussig Shunt Age Categories (Neonates and Infants/Toddlers)||Sanofi||Completed|January 2004|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|92|||Both|N/A|24 Months|No|||March 2009|March 24, 2009|June 21, 2005||||||https://clinicaltrials.gov/show/NCT00115375||198285|
NCT00115648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPI-Malawi|Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission|Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|April 2004|October 2009|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3300|||Both|18 Years|54 Years|No|||March 2014|March 6, 2014|June 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00115648||198264|
NCT00115934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194|Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network|Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network)||New England Research Institutes|Yes|Completed|May 2005|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|555|||Both|N/A|N/A|No|||August 2013|August 2, 2013|June 26, 2005||No||No|September 14, 2010|https://clinicaltrials.gov/show/NCT00115934||198242|As in all surgical trials comparing two operations, it was not possible to blind the personnel caring for the subjects to the intervention. However, the components of the primary endpoint, death and transplantation, are discrete objective events.
NCT00115947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-000568-29|Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites|||Hvidovre University Hospital||Completed|December 2004|January 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|18 Years|75 Years||||June 2005|March 8, 2006|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00115947||198241|
NCT00115895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYTJ001T/2000|The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy|Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq||Helsinki University|No|Active, not recruiting|January 2000|September 2020|Anticipated|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|June 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00115895||198245|
NCT00115908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFR-HC-04|A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1|A Phase 2b, Randomized, Multi-Center, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 1||Human Genome Sciences Inc.|Yes|Completed|May 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|458|||Both|18 Years|65 Years|No|||November 2013|November 5, 2013|June 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00115908||198244|
NCT00115921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG40|Evaluation of Home-Based Management of Fever in Urban Ugandan Children|Evaluation of Home-Based Management of Fever in Urban Ugandan Children||Gates Malaria Partnership|Yes|Completed|July 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||540|||Both|1 Year|5 Years|No|||June 2007|June 13, 2007|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00115921||198243|
NCT00112268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS014854-01|Quitlink : A Leveraging Solution to Tobacco Counseling|Quitlink : A Leveraging Solution to Tobacco Counseling||Agency for Healthcare Research and Quality (AHRQ)||Completed|June 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||3200|||Both|18 Years|N/A|No|||October 2006|October 26, 2006|June 1, 2005||||No||https://clinicaltrials.gov/show/NCT00112268||198514|
NCT00144846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB030002|Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children|A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively With a Valved Holding Chamber and an Attached Facemask in Subjects Between Birth to 23 Months of Age With Acute Wheezing Due to Obstructive Airways Disease||GlaxoSmithKline|No|Completed|September 2004|||February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|N/A|23 Months|No|||March 2013|March 1, 2013|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00144846||196062|
NCT00116506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-365|Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer|A Phase II Study of Bevacizumab (Avastin™) and Erlotinib (Tarceva™) in Combination With FOLFOX for Patients With Untreated Metastatic Colorectal Cancer||Dana-Farber Cancer Institute||Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|June 29, 2005||||No||https://clinicaltrials.gov/show/NCT00116506||198198|
NCT00112242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD 2001-003|Immunotherapy of Stage III/IV Melanoma Patients|Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant||Centre Hospitalier Universitaire Vaudois|No|Completed|February 2004|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|38|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|May 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00112242||198516|
NCT00112151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1056|TEAM: Testosterone Supplementation and Exercise in Elderly Men|Testosterone Supplementation and Exercise in Elderly Men||University of Colorado, Denver|Yes|Completed|January 2005|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|167|||Male|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 14, 2015|May 27, 2005||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00112151||198523|
NCT00112164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175|Activated Protein C to Treat Acute Lung Injuries|Prospective, Randomized Phase II Clinical Trial of Activated Protein C (Xigris) Versus Placebo for the Treatment of Acute Lung Injury||University of California, San Francisco||Terminated|January 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|May 27, 2005|||Per recommendation of the NHLBI DSMB|No||https://clinicaltrials.gov/show/NCT00112164||198522|
NCT00146276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9E-MC-S062|Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer|Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study||Association of Urogenital Oncology (AUO)||Recruiting|July 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||178|||Both|18 Years|N/A|No|||September 2005|September 26, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00146276||195954|
NCT00146289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.469|The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects|A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group||Boehringer Ingelheim||Completed|February 2005|||October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||138|||Both|18 Years|65 Years|No|||October 2013|October 31, 2013|September 2, 2005||||||https://clinicaltrials.gov/show/NCT00146289||195953|
NCT00145665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT-PET CRC-LM|The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases|The Role of 3-Deoxy-3[18]Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases||Radboud University||Terminated|January 2005|December 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2007|September 2, 2011|September 1, 2005||No|no accrual achieved|No||https://clinicaltrials.gov/show/NCT00145665||195999|
NCT00147355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPRIT TOXIL-2 UNSW PSO 6361|Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy|An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity Substudy of ESPRIT: TOXIL-2 Substudy||Kirby Institute|Yes|Terminated|November 2005|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|September 5, 2005||No|28 of 168 patients only were enrolled, numbers too low to be conclusive|No||https://clinicaltrials.gov/show/NCT00147355||195875|
NCT00147147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9206-2|Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-Positive Gastric Cancer (JCOG9206-2)|Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-Positive Gastric Cancer (JCOG9206-2)||Japan Clinical Oncology Group||Completed|January 1993|March 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||280|||Both|N/A|75 Years|No|||August 2006|August 9, 2006|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00147147||195890|
NCT00147693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAD|Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?|Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?||Radboud University||Completed|June 2005|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|304|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2008|September 30, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147693||195851|
NCT00147706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051761|Does Access to an EHR Patient Portal Influence Chronic Disease Outcomes?|Does Access to an EHR Patient Portal Influence Chronic Disease Outcomes? A Randomised Trial Assessing Clinical and Behavioural Change Outcomes in Patients With CHF, Diabetes, or Secondary CVD||Robert Wood Johnson Foundation||Completed|September 2004|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|6000|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00147706||195850|
NCT00143442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061001|Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures|A 5-Week, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN), Who Are Gabapentin Treatment Failures.||Pfizer||Completed|December 2003|October 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||184|||Both|18 Years|N/A|No|||August 2006|August 4, 2006|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00143442||196168|
NCT00115388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COHSR4PG|Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease|Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease|POPI|St George's, University of London|No|Completed|September 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|2531|||Female|16 Years|27 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|June 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00115388||198284|
NCT00115661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-1013|Use of Rosiglitazone in the Treatment of Endometriosis|Treatment of Endometriosis Pain With Rosiglitazone: A Prospective Phase 2 Clinical Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Terminated|July 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|45 Years|No|||October 2012|October 16, 2012|June 23, 2005|Yes|Yes|Due to the meta-analysis about CV adverse effects of rosiglitazone.|No||https://clinicaltrials.gov/show/NCT00115661||198263|
NCT00116285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RagweedMATAMPL101|Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing|A Single-Blind Phase I Study to Assess the Residual Allergenicity of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL Using Skin Prick Testing||Allergy Therapeutics||Completed|June 2005|June 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||12|||Both|18 Years|50 Years|No|||September 2009|June 16, 2010|June 28, 2005||||No||https://clinicaltrials.gov/show/NCT00116285||198215|
NCT00115999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA004|Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries|Phase 3, Multicenter, Multi-National, Randomized, Partial Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion||ARCA Biopharma, Inc.|Yes|Completed|April 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|June 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00115999||198237|
NCT00116272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040246|Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project|OTIS Autoimmune Diseases in Pregnancy Project||Amgen|No|Completed|April 2005|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|830|None Retained|This is a prospective & observational, exposure cohort study|Both|N/A|N/A|No|Non-Probability Sample|Cohort 1: Exposure Cohort (300 subjects) Cohort 2: Matched diseased control Cohort (300        subjects) Cohort 3: Non-diseased Control Cohort (300 subjects)|August 2015|August 19, 2015|June 28, 2005|No|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00116272||198216|
NCT00112528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N034A|Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer|Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma||Alliance for Clinical Trials in Oncology|No|Completed|June 2005|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112528||198495|
NCT00112554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430677|Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse||National Cancer Institute (NCI)||Completed|March 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||February 2009|November 5, 2013|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112554||198494|
NCT00116519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5750|A Study in People With Abnormal Fat Levels in the Blood|PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly||Eli Lilly and Company||Completed|July 2005|October 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|80 Years|No|||January 2007|January 24, 2007|June 29, 2005||||||https://clinicaltrials.gov/show/NCT00116519||198197|
NCT00112502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0662|Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme|A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Completed|September 2005|||September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|178|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112502||198497|
NCT00112684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00135|Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Pilot Study of Flavopiridol in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)|Yes|Terminated|February 2006|||July 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2011|February 21, 2014|June 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00112684||198485|
NCT00114205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430930|Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion|Phase I Trial of Intrapleural Docetaxel Administered Via an Implantable Catheter in Subjects With a Malignant Pleural Effusion||National Cancer Institute (NCI)||Completed|July 2003|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||August 2006|March 17, 2010|June 13, 2005||||No||https://clinicaltrials.gov/show/NCT00114205||198374|
NCT00114218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0130E|Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus||Gynecologic Oncology Group||Completed|March 2005|||July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|N/A|N/A|No|||December 2014|December 23, 2014|June 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114218||198373|
NCT00114231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z6041|Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer|A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|May 2006|||October 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|June 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114231||198372|
NCT00113295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P001805|Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder|Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder||Massachusetts General Hospital|Yes|Completed|February 2004|November 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|72 Years|No|||March 2014|March 20, 2014|June 7, 2005||||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00113295||198444|Relatively small sample size of the randomized controlled phase (phase 2); conclusions from the study are limited to low power; improvement in Phase I open label paroxetine CR may include "placebo" response to ancillary aspects of a treatment study.
NCT00113308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA30009|COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis|A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis||GlaxoSmithKline|No|Completed|June 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|2208|||Both|18 Years|N/A|No|||May 2012|June 7, 2012|June 7, 2005||||||https://clinicaltrials.gov/show/NCT00113308||198443|
NCT00145717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPST|China Plant Sterol Trial|China Plant Sterol Trial – A Randomised Trial to Determine the Effects on Blood Cholesterol Levels of a Milk Tea Product Enriched With Plant Sterol Among 300 Chinese Living in Beijing||The George Institute||Completed|April 2005|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00145717||195995|
NCT00146562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-154|Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer|A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer||Dana-Farber Cancer Institute||Completed|July 2003|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00146562||195932|
NCT00146575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S01703|Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)|Randomized Trial of Paclitaxel-Eluting Stent and Sirolimus-Eluting Stent for Restenosis Reduction in Small Coronary Vessels (ISAR-SMART-3)||Deutsches Herzzentrum Muenchen|Yes|Completed|June 2003|February 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|No|||January 2008|January 10, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00146575||195931|
NCT00146263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-4018CTIL|Cognitive Training in the Elderly|The Effect of Computerized Cognitive Training on Neuropsychological Measures of Cognitive Function in the Elderly||Beersheva Mental Health Center||Recruiting|September 2005|June 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 5, 2010|September 4, 2005||||No||https://clinicaltrials.gov/show/NCT00146263||195955|
NCT00147134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0404|A Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer|Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer（JCOG 0404,CRC Surg-LAP/OPEN)||Japan Clinical Oncology Group|Yes|Active, not recruiting|November 2004|March 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1050|||Both|20 Years|75 Years|No|||August 2009|August 2, 2009|September 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00147134||195891|
NCT00114491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22352|Rosuvastatin Affecting Aortic Valve Endothelium|Rosuvastatin Affecting Aortic Valve Endothelium - RAAVE||Hospital Pedro Hispano||Completed|September 2003|May 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||200|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 30, 2006|June 15, 2005||||No||https://clinicaltrials.gov/show/NCT00114491||198352|
NCT00147381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaCam 07_MC|Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection|Effectiveness and Safety of Campath-1H as an Induction Agent in Combination With Tacrolimus Monotherapy for Prevention of Graft Rejection Compared to Tacrolimus in Combination With MMF and Steroids in Cadaveric Kidney Transplantation||Medical University Innsbruck|No|Completed|January 2004|July 2011|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|197|||Both|18 Years|65 Years|No|||June 2012|June 18, 2012|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147381||195873|
NCT00115687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15167-1|Nicotine Replacement Treatment for Pregnant Smokers - 1|Nicotine Replacement Treatment for Pregnant Smokers||National Institute on Drug Abuse (NIDA)|Yes|Terminated|June 2002|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|250|||Female|16 Years|50 Years|No|||April 2009|January 26, 2010|June 23, 2005|Yes|Yes|Efficacy rates did not show large enough differences between treatments|No||https://clinicaltrials.gov/show/NCT00115687||198261|
NCT00115960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 063|Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Gag DNA Vaccine Alone or With IL-15 DNA, Boosted With HIV-1 Gag DNA + IL-15 DNA or HIV-1 Gag DNA + IL-12 DNA, in Healthy, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|6||Actual|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|June 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00115960||198240|
NCT00115973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS253-1665|A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump|An Open-Label, Stepwise Basal Insulin Dose Titration Study Using Continuous Subcutaneous Insulin Infusion (CSII) in Oral Antidiabetic Drug-Treated Type 2 Diabetes Mellitus Subjects Followed by a 10-Week Out-Patient Maintenance Phase||Novo Nordisk A/S|No|Completed|June 2005|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|71|||Both|30 Years|70 Years|No|||April 2013|April 15, 2013|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00115973||198239|
NCT00115700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 99.03|Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma|A Randomised Multicentre Trial of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy in Combination With Rituximab (Mabthera®) for Stage I - II Low Grade Follicular Lymphoma||Trans-Tasman Radiation Oncology Group (TROG)|No|Active, not recruiting|February 2000|December 2022|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|June 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00115700||198260|
NCT00116298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI455-110|Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)|A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies AI455-096 and AI455-099||Bristol-Myers Squibb||Completed|January 2001|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||900|||Both|N/A|N/A|No|||April 2011|April 8, 2011|June 28, 2005||||||https://clinicaltrials.gov/show/NCT00116298||198214|
NCT00116545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0028|TART - Troglitazone Atherosclerosis Regression Trial|TART - Troglitazone Atherosclerosis Regression Trial||National Institute on Aging (NIA)||Completed|January 1997|April 2000|Actual|April 2000|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||288|||Both|30 Years|70 Years|No|||June 2005|December 9, 2009|June 29, 2005||||No||https://clinicaltrials.gov/show/NCT00116545||198195|
NCT00112905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02975|Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium|Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer||National Cancer Institute (NCI)||Terminated|October 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2012|May 20, 2014|June 2, 2005|Yes|Yes||No|December 30, 2010|https://clinicaltrials.gov/show/NCT00112905||198472|
NCT00112255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA_97/32/31|Partner Notification for Chlamydia in Primary Care|Partner Notification for Chlamydia in Primary Care: Randomised Controlled Trial and Economic Evaluation||University of Bristol||Completed|March 2001|December 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||214|||Both|16 Years|N/A|No|||May 2005|May 9, 2006|May 31, 2005||||No||https://clinicaltrials.gov/show/NCT00112255||198515|
NCT00112866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02653|Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme|Phase II Trial of EMD 121974 for Recurrent Glioblastoma: A Clinical Trial With Tissue Correlates of Response||National Cancer Institute (NCI)||Completed|January 2005|||December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112866||198475|
NCT00112879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF-IRB-7469|Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma|Phase II Study of Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Patients With Previously Untreated High-Risk or Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|July 9, 2013|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112879||198474|
NCT00113113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFS 2000-40|Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction|Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction||Astex Pharmaceuticals||Completed|August 2001|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|54|||Both|18 Years|N/A|No|||June 2005|January 22, 2013|June 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00113113||198458|
NCT00115349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181|Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases|Thalassemia Clinical Research Network - Cardiac L1/DFO Trial||New England Research Institutes|Yes|Terminated|June 2005|April 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|100 Years|No|||January 2014|October 5, 2015|June 21, 2005|Yes|Yes|due to low enrollment|No|May 16, 2013|https://clinicaltrials.gov/show/NCT00115349||198287|The study was stopped early by NHLBI when analysis of the interim data confirmed a required sample size of 86 that was not achievable within the required time frame within the participating or planned centres.
NCT00115362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEREIN|Serotonin Effect in Functional Dyspepsia|Serotonin Effect in Non-Ulcer Dyspepsia||Radboud University||Completed|July 2005|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|June 21, 2005||||No||https://clinicaltrials.gov/show/NCT00115362||198286|
NCT00113568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP12B-MR-302|Safety Study of XP12B in Women With Menorrhagia|Multicenter Study to Evaluate the Safety of XP12B in Women With Heavy Menstrual Bleeding Associated With Menorrhagia||Ferring Pharmaceuticals|Yes|Completed|June 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|784|||Female|18 Years|49 Years|No|||June 2010|June 9, 2010|June 8, 2005|Yes|Yes||No|December 11, 2009|https://clinicaltrials.gov/show/NCT00113568||198423|
NCT00113581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 72000-024|Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer|A Phase I Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Three Doses of Humanised EGFR Antibody EMD 72000 in Combination With ECX in Patients With Advanced Oesophagogastric Adenocarcinoma||Merck KGaA||Completed|October 2002|January 2007|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||26|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|June 9, 2005||||No||https://clinicaltrials.gov/show/NCT00113581||198422|
NCT00113633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-12-4130|Educational Video for Improving Follow-up After an Emergency Department Visit for Asthma|A Three-part Intervention to Improve Regular Care for Asthma After a Pediatric Emergency Department Visit: A Randomized Clinical Trial||Children's Hospital of Philadelphia|No|Completed|September 2003|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|439|||Both|1 Year|18 Years|No|||March 2014|March 3, 2014|June 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00113633||198418|
NCT00146809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEMSA-Study|Study About Efficacy and Safety to Treat Multi-System-Atrophy|Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment||German Parkinson Study Group (GPS)||Completed|December 2003|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|40 Years|75 Years|No|||March 2007|March 3, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00146809||195913|
NCT00147121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0203|Rituximab+Standard CHOP vs Rituximab+bi-Weekly CHOP for Untreated Stage III/IV Low-Grade B-Cell Lymphoma (JCOG0203)|Rituximab + Standard CHOP (R･S-CHOP) vs Rituximab+ bi-Weekly CHOP (R･Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-Grade B-Cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203)||Japan Clinical Oncology Group|Yes|Active, not recruiting|September 2002|February 2010|Anticipated|February 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|20 Years|69 Years|No|||February 2009|February 2, 2009|September 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00147121||195892|
NCT00146796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITIMVG38|A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Malaria in Tanzania|A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Non-Severe Malaria at Different Transmission Intensities of Plasmodium Falciparum in Tanzania||Gates Malaria Partnership|No|Completed|January 2005|November 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2400|||Both|N/A|N/A|No|||September 2005|July 3, 2007|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146796||195914|
NCT00115050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002755|TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options|Open-label Safety Study of TMC114 in Combination With Low Dose RTV and Other ARVs in Highly Experienced HIV-1 Infected Patients With Limited or no Treatment Options.||Tibotec Pharmaceuticals, Ireland||Completed|June 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|260|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|June 20, 2005||||||https://clinicaltrials.gov/show/NCT00115050||198310|
NCT00115063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 25002|LOSS- Louisiana Obese Subjects Study|Loss - Louisiana Obese Subjects Study|LOSS|Pennington Biomedical Research Center|Yes|Terminated|July 2005|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|390|||Both|20 Years|60 Years|No|||January 2016|January 22, 2016|June 20, 2005||No|ethical issues of continuing control group without treatment|No|March 1, 2010|https://clinicaltrials.gov/show/NCT00115063||198309|The study was stopped prematurely for efforts to be focused on assisting the Office of Group Benefits (OGB) in translating a policy that would allow for physician certification in order to offer participants the intensive treatment.
NCT00115440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN-BNCT-03/2000|BNCT to Treat Glioma That Has Progressed Following Radiotherapy|BPA-Mediated Boron Neutron Capture Therapy (BNCT) in the Treatment of Glioblastoma or Anaplastic Astrocytoma Progressing After Conventional External Beam Radiotherapy||Boneca Corporation|No|Completed|March 2001|January 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||September 2007|January 27, 2009|June 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00115440||198280|
NCT00115986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-063|A/H5N1in Adult - Aventis|A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2005|February 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|452|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2007|August 22, 2013|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00115986||198238|
NCT00116558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS045087|Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation (NIPPV)|Early Treatment of Amyotrophic Lateral Sclerosis With Nutrition and Non-Invasive Positive Pressure Ventilation||National Institute of Neurological Disorders and Stroke (NINDS)|Yes|Active, not recruiting|August 2004|October 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|80 Years|No|||January 2008|January 8, 2008|June 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00116558||198194|
NCT00112580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430666|MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery|Phase II Trial of Single Agent Ipilimumab (MDX-010 Anti CTLA-4) for Subjects With Locally Advanced or Metastatic Pancreatic Adenocarcinoma||Bristol-Myers Squibb||Completed|July 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|120 Years|No|||September 2015|September 23, 2015|June 2, 2005||||||https://clinicaltrials.gov/show/NCT00112580||198492|
NCT00112515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000432953|Modafinil in Treating Fatigue in Patients With Cancer|Pilot Study Evaluating the Safety and Efficacy of Modafinil in Improving Fatigue, Mood, Cognitive Ability, Functional Status, and Quality of Life of Cancer Patients||National Cancer Institute (NCI)||Active, not recruiting|February 2004|||||N/A|Interventional|Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||May 2006|August 19, 2009|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112515||198496|
NCT00113204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-01|Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma|A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma|IPi-504-01|Infinity Pharmaceuticals, Inc.|No|Completed|June 2005|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||May 2008|May 15, 2008|June 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00113204||198451|
NCT00113607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003448|An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer|An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS With DOXIL/CAELYX Alone in Subjects With Advanced Relapsed Ovarian Cancer||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|April 2005|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|672|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|June 9, 2005|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00113607||198420|
NCT00124137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-1|Ultrafiltration Versus Intravenous (IV) Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: (UNLOAD)|Ultrafiltration Versus IV Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Clinical Trial||CHF Solutions||Completed|April 2004|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||December 2005|March 14, 2007|July 25, 2005||||No||https://clinicaltrials.gov/show/NCT00124137||197627|
NCT00114465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL#3Freo|VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease|Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease||Orphan Australia|Yes|Completed|June 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|75 Years|No|||September 2009|September 17, 2009|June 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00114465||198354|
NCT00114478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMC03034|Trial of Epinephrine and Albuterol in Bronchiolitis|Randomized Controlled Trial of Epinephrine and Albuterol in Bronchiolitis||Kern Medical Center||Active, not recruiting|November 2003|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|N/A|18 Months|No|||January 2008|January 23, 2008|June 15, 2005||||No||https://clinicaltrials.gov/show/NCT00114478||198353|
NCT00113906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-003796-37|Melatonin Treatment After Laparoscopic Cholecystectomy|The Effect of Melatonin Treatment on Postoperative Fatigue and Sleep Disturbances: A Placebo Controlled Randomized Clinical Trial||University Hospital, Gentofte, Copenhagen|Yes|Completed|March 2005|August 2006|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|80 Years|No|||June 2005|February 10, 2014|June 10, 2005||||No||https://clinicaltrials.gov/show/NCT00113906||198397|
NCT00113919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-25|UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients|UARK 2003-25: A Phase I/II Open Label Study of IV Busulfan (Busulfex®) in Multiple Myeloma Patients Older Than 65 Years of Age or With Renal Insufficiency||University of Arkansas|Yes|Terminated|June 2004|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|June 10, 2005||No|Due to poor accrual|No|April 14, 2011|https://clinicaltrials.gov/show/NCT00113919||198396|Early termination, only 5 of the 14 completed, reasons as follows:Death Unrelated to Protocol Adverse Event Relapse Patient Choice
NCT00146783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCR5096|Navrongo Drug Options for IPT in Pregnancy Trial|Efficacy of Sulphadoxine-Pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial||Gates Malaria Partnership|Yes|Completed|June 2004|February 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|3642|||Female|15 Years|45 Years|No|||February 2008|February 7, 2008|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146783||195915|
NCT00147394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10544|Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)|Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder||Children's Hospital Medical Center, Cincinnati|No|Completed|December 2001|June 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|5 Years|16 Years|No|||October 2012|October 25, 2012|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00147394||195872|
NCT00114790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-BPA-01-2003|Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment Head and Neck Tumors|Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Inoperable and Irradiated Head and Neck Tumors: A Feasibility Study||Boneca Corporation|No|Completed|December 2003|January 2012|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|June 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00114790||198330|
NCT00115076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0511|Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis|A Phase IIIB Study to Evaluate the Mechanism of Action of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy||Rockefeller University|No|Completed|October 2003|||May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|70 Years|No|||May 2012|May 31, 2012|June 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00115076||198308|
NCT00115089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-926112-005A|7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis|A Phase II Multi-Center, Randomized, Double-Blind, Active and Placebo-Controlled 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis||Rigel Pharmaceuticals||Completed|July 2005|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||375|||Both|12 Years|N/A|No|||November 2005|November 9, 2005|June 20, 2005||||||https://clinicaltrials.gov/show/NCT00115089||198307|
NCT00115414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020778|Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)|A Randomized, Double-Blind, Phase 2 Study Evaluating the Safety of Same Day Versus Next Day Administration of Pegfilgrastim With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) in Women With Breast Cancer||Amgen||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2008|July 31, 2008|June 22, 2005||||||https://clinicaltrials.gov/show/NCT00115414||198282|
NCT00116571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPH 003|Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)|A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy With Lemuteporfin in Subjects With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia||QLT Inc.||Terminated|May 2005|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Male|21 Years|N/A|No|||May 2006|October 2, 2006|June 29, 2005||||||https://clinicaltrials.gov/show/NCT00116571||198193|
NCT00116584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRNT040954|Heliox-Driven Racemic Epinephrine Nebulization in Treatment of Moderate to Severe Bronchiolitis in Pediatric ED Patients|The Use of Heliox Driven Racemic Epinephrine Nebulization in the Treatment of Moderate to Severe Bronchiolitis in Pediatric Emergency Department Patients||University of Louisville|No|Completed|December 2004|October 2011|Actual|March 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|72|||Both|2 Months|12 Months|Accepts Healthy Volunteers|||June 2013|June 17, 2013|June 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00116584||198192|
NCT00116038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030192|A Comparison of Two Metal Surface Finishes on Femoral Components in Hip Arthroplasty|A Comparison of Two Metal Surface Finishes (Proximal-Coated Titanium Surface Versus Mid-Coated Titanium Surface) on Femoral Components in Hip Arthroplasty||University of Aarhus||Completed|January 2004|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|50 Years|70 Years|No|||July 2009|July 6, 2009|June 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00116038||198234|
NCT00112281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG-CS3-001|A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack|A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the TRIUMPH Trial||Arginox Pharmaceuticals||Terminated|May 2005|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||658|||Both|18 Years|N/A|No|||May 2005|August 2, 2006|June 1, 2005||||||https://clinicaltrials.gov/show/NCT00112281||198513|
NCT00112294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-099|Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|December 2004|August 2008|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|755|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 1, 2005|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00112294||198512|
NCT00112567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1629.00|Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants||Fred Hutchinson Cancer Research Center||Completed|April 2003|July 2007||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|20 Years|No|||September 2010|September 17, 2010|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112567||198493|
NCT00112892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000427616|Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetic Study of Selenomethionine With Fixed Dose Irinotecan in Advanced Solid Tumors||Roswell Park Cancer Institute|Yes|Completed|August 2004|December 2007|Actual|September 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|June 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00112892||198473|
NCT00113451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP-091-03|Radial Artery Bypass Graft Study of Tromsø|Radial Artery Bypass Graft Study of Tromsø||University Hospital of North Norway||Completed|January 2004|May 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||119|||Both|18 Years|N/A|No|||June 2005|June 23, 2005|June 7, 2005||||No||https://clinicaltrials.gov/show/NCT00113451||198432|
NCT00113230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0832|Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer|Phase II Trial Of Neoadjuvant Concurrent Capecitabine, RHUMAB VEGF (Avastin) And Radiotherapy In Patients Presenting With Locally Advanced Rectal Cancer||M.D. Anderson Cancer Center|No|Completed|February 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 31, 2012|June 6, 2005|Yes|Yes||No|April 17, 2009|https://clinicaltrials.gov/show/NCT00113230||198449|
NCT00123799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-01-0057/DX-FDG-002/17097|Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection|A Phase II Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection||AHS Cancer Control Alberta|No|Terminated|June 2004|April 2007|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|199|||Both|18 Years|N/A|No|||March 2012|June 10, 2014|July 22, 2005||No|sufficient enrollment reached|No||https://clinicaltrials.gov/show/NCT00123799||197653|
NCT00123812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-01-0056|Frequency of Portal Images Required to Enhance Quality Assurance for Breast Cancer Patients Treated With Radiotherapy|Frequency of Portal Images Required to Enhance Quality Assurance for Breast Cancer Patients Treated With Radiotherapy||AHS Cancer Control Alberta|No|Withdrawn|March 2004|July 2006||||N/A|Observational|N/A||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|December 2011|February 23, 2016|July 22, 2005||||No||https://clinicaltrials.gov/show/NCT00123812||197652|
NCT00124787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROJET 2078|A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis|A Randomized Double-blind Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Moderate Vomiting Due to Acute Gastroenteritis|GAG|St. Justine's Hospital|No|Completed|April 2005|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124787||197580|
NCT00113945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020390|Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)|TARGET: Treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on CinacalceT||Amgen||Completed|July 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|June 10, 2005||||||https://clinicaltrials.gov/show/NCT00113945||198394|
NCT00113958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020389|Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels|Cinacalcet Open Label Study to Reach K/DOQI Levels||Amgen||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2013|May 10, 2013|June 10, 2005||||||https://clinicaltrials.gov/show/NCT00113958||198393|
NCT00114023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1518-IMIQ|1-Year Follow up to the 1473-IMIQ Study|A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study||Graceway Pharmaceuticals, LLC||Completed|January 2005|||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||84|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|February 16, 2007|June 13, 2005||||||https://clinicaltrials.gov/show/NCT00114023||198388|
NCT00113646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-163|Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies|Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies||Massachusetts General Hospital||Terminated|November 2002|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|65 Years|No|||March 2016|March 4, 2016|June 9, 2005|Yes|Yes|Expiration of MEDI-507. MEDI-507 did not become available again to re-open the trial|No||https://clinicaltrials.gov/show/NCT00113646||198417|
NCT00113659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187|Use of a Probiotic Supplement to Prevent Asthma in Infants|Trial of Infant Probiotic Supplementation to Prevent Asthma||University of California, San Francisco|Yes|Active, not recruiting|June 2005|June 2015|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|203|||Both|N/A|4 Days|Accepts Healthy Volunteers|||February 2015|February 27, 2015|June 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00113659||198416|
NCT00146302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA4-CT-2002-10053LBW|Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth in Developing Countries?|BCG Vaccination and Childhood Morbidity and Mortality: Interventions With Possible Implications for the Immunisation Policy in Developing Countries. Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth?||Bandim Health Project||Completed|November 2002|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2320|||Both|N/A|30 Days||||March 2012|March 16, 2012|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00146302||195952|
NCT00147160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISTEM2|Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents|Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse||Gustave Roussy, Cancer Campus, Grand Paris||Completed|October 2003|December 2007|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|87|||Both|4 Years|21 Years|No|||September 2006|April 10, 2012|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147160||195889|
NCT00114803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calcitonin 1.0|Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease|Use of Intranasally Administered Calcitonin in the Treatment of Osteopenia and Osteoporosis in Children, Adolescents and Young Adults With IBD: A Pilot Study||Children's Hospital Boston||Completed|January 2004|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||66|||Both|8 Years|22 Years|No|||April 2007|December 4, 2007|June 17, 2005||||||https://clinicaltrials.gov/show/NCT00114803||198329|
NCT00115102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO1|Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls|||University of Aarhus||Completed|March 2004|October 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2006|June 15, 2006|June 20, 2005||||No||https://clinicaltrials.gov/show/NCT00115102||198306|
NCT00115115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074_KAC03.wpd|Donor Dopamine and Initial Graft Function|Prospective Randomized Trial to Evaluate the Efficacy of Donor Preconditioning With Dopamine on Initial Graft Function After Kidney Transplantation||Universitätsmedizin Mannheim|No|Completed|March 2004|March 2009|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|487|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|June 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00115115||198305|
NCT00115401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050175|Gait Adaptations to Passive Dynamic Ankle-Foot Orthosis Use|Gait Adaptations to Passive Dynamic Ankle-Foot Orthosis Use||National Institutes of Health Clinical Center (CC)||Completed|June 2005|October 2007||||N/A|Observational|N/A||||35|||Both|5 Years|N/A|Accepts Healthy Volunteers|||October 2007|September 26, 2015|June 21, 2005||||No||https://clinicaltrials.gov/show/NCT00115401||198283|
NCT00115427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020168|Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease||Amgen||Completed|March 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|35 Years|70 Years|No|||January 2008|January 10, 2008|June 22, 2005||||||https://clinicaltrials.gov/show/NCT00115427||198281|
NCT00115674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15774-1|To Examine Smoking Behavior of Prisoners - 1|Smoking Research With Incarcerated Females||University of Alabama at Birmingham|Yes|Completed|September 2002|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|360|||Female|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adult women incarcerated in a state prison in Virginia are eligible to participate.|August 2015|October 6, 2015|June 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00115674||198262|
NCT00115128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020143|Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors|Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors||Amgen||Completed|November 2003|September 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|309|None Retained|none collected|Both|18 Years|N/A|No|Non-Probability Sample|Normal donors|May 2013|May 10, 2013|June 21, 2005||||No||https://clinicaltrials.gov/show/NCT00115128||198304|
NCT00116337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB98-00091|Spinal Cord Stimulation to Restore Cough|Spinal Cord Stimulation to Restore Cough||Case Western Reserve University|Yes|Active, not recruiting|September 2004|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||April 2015|April 20, 2015|June 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00116337||198211|
NCT00116324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001696|Predicting the Response to Montelukast by Genetic Variation in Asthmatics|Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism||Brigham and Women's Hospital||Completed|April 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years|No|||April 2007|April 2, 2007|June 28, 2005||||No||https://clinicaltrials.gov/show/NCT00116324||198212|
NCT00116597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT1999017/05.050|Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma|Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma||University Hospital, Basel, Switzerland|Yes|Completed|November 2002|December 2008|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2009|December 1, 2009|June 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00116597||198191|
NCT00112307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-201|Magnetic Resonance Imaging Guided Gynecologic Brachytherapy|Pilot Study of Magnetic Resonance Imaging Guided Brachytherapy||Brigham and Women's Hospital||Completed|March 2003|October 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Female|18 Years|N/A|No|||September 2009|September 15, 2009|June 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00112307||198511|
NCT00112593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410.00|Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer|Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil||Fred Hutchinson Cancer Research Center|Yes|Completed|November 1999|||November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|75 Years|No|||August 2015|August 28, 2015|June 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00112593||198491|
NCT00113217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0982|Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma|A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMab VEGF (Bevacizumab) for Renal Cell Carcinoma||M.D. Anderson Cancer Center|No|Completed|February 2005|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|N/A|No|||December 2013|December 2, 2013|June 6, 2005||No||No|September 4, 2013|https://clinicaltrials.gov/show/NCT00113217||198450|
NCT00113243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUPUI 0503-14|Safety Study of Using Stem Cells to Stimulate Development of New Blood Vessels in Peripheral Vascular Disease|Phase I Study of Stem Cell Mediated Angiogenesis for Limb Threatening Ischemia||Murphy, Michael P., MD||Recruiting|December 2004|December 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|21 Years|80 Years|No|||June 2005|June 23, 2005|June 6, 2005||||||https://clinicaltrials.gov/show/NCT00113243||198448|
NCT00112983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALEXION-C04-001|Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria|TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients||National Cancer Institute (NCI)||Completed|November 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||June 2005|May 29, 2013|June 2, 2005||||No||https://clinicaltrials.gov/show/NCT00112983||198468|
NCT00124449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-046|Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients|A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA||Bristol-Myers Squibb|No|Completed|February 2005|April 2008|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|56|||Both|18 Years|75 Years|No|||March 2015|March 18, 2015|June 30, 2005|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00124449||197603|
NCT00124462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84.133G-1|Trial of Realignment Therapy for Treatment of Medial Knee Osteoarthritis|A Randomized Trial of Realignment Therapy for Treatment of Medial Knee Osteoarthritis||Boston University||Completed|March 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2009|January 28, 2009|July 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00124462||197602|
NCT00124800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-014|The Effect of Tinnitus Retraining Therapy on Subjective and Objective Measures of Chronic Tinnitus|The Effect of Tinnitus Retraining Therapy on Subjective and Objective Measures of Chronic Tinnitus||Tinnitus Research Consortium||Completed|November 2005|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2009|September 23, 2009|July 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00124800||197579|
NCT00114036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HS11331-01A1|Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)|Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)||Agency for Healthcare Research and Quality (AHRQ)||Active, not recruiting|August 2002|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|N/A||||June 2005|June 23, 2005|June 13, 2005||||No||https://clinicaltrials.gov/show/NCT00114036||198387|
NCT00114049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA30001|Dental Pain (Following Third Molar Tooth Extraction) Study|See Detailed Description||GlaxoSmithKline||Completed|December 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|June 13, 2005||||||https://clinicaltrials.gov/show/NCT00114049||198386|
NCT00114309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM-601-002|131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma|A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma||TransMolecular||Active, not recruiting|November 2004|August 2009|Anticipated|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||April 2009|April 1, 2009|June 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00114309||198366|
NCT00114270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000430927|Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density|Evaluating the Effect of Letrozole With or Without Concomitant Zoledronic Acid on Estrogen Responsive Targets in Postmenopausal Women||National Cancer Institute (NCI)||Completed|May 2004|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2006|March 25, 2013|June 13, 2005||||No||https://clinicaltrials.gov/show/NCT00114270||198369|
NCT00114504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KurumeU-2416|Detection of Plaque Inflammation by Positron Emission Tomography (PET)-Effects of Simvastatin on Plaque Inflammation|Detection of Atherosclerotic Plaque Inflammation and Visualization of Anti-inflammatory Effects of Statins on Plaque Inflammation by FDG-PET||Kurume University|No|Completed|September 2004|April 2009|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|30 Years|80 Years|No|||May 2015|May 13, 2015|June 15, 2005||No||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00114504||198351|
NCT00114543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0029|Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight|A Randomized Trial of Aggressive or Conservative Phototherapy for Extremely Low Birth Weight Infants|Phototherapy|NICHD Neonatal Research Network|Yes|Completed|September 2002|November 2007|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1974|||Both|N/A|36 Hours|No|||June 2015|June 3, 2015|June 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00114543||198348|
NCT00114556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446 AU02|The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients|The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients – A Prospective, Randomised, Controlled Clinical Trial||Royal Prince Alfred Hospital, Sydney, Australia||Completed|February 2000|August 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|17 Years|70 Years|No|||December 2004|May 8, 2006|June 15, 2005||||No||https://clinicaltrials.gov/show/NCT00114556||198347|
NCT00114816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBCG Protocol No. 01-2003|Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer|A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer||Finnish Breast Cancer Group||Completed|January 2004|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1500|||Female|18 Years|65 Years|No|||May 2007|May 18, 2007|June 17, 2005||||No||https://clinicaltrials.gov/show/NCT00114816||198328|
NCT00115141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1513-RESI|Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults|A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults||Graceway Pharmaceuticals, LLC||Completed|April 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||88|||Both|18 Years|N/A|No|||November 2006|February 16, 2007|June 21, 2005||||||https://clinicaltrials.gov/show/NCT00115141||198303|
NCT00116311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2004-253|Effects of Allergen Inhalation on Adenosine Receptor Expression in Sputum and Peripheral Blood|Effects of Allergen Inhalation on Adenosine Receptor Expression and Mast Cell Activation in Peripheral Blood and Sputum of Asthmatics and Healthy Subjects||Groningen Research Institute for Asthma and COPD|No|Active, not recruiting|July 2005|February 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2007|March 20, 2007|June 28, 2005||||No||https://clinicaltrials.gov/show/NCT00116311||198213|
NCT00115713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH-02-70-85|Effects of Aerobic Exercise Versus Weight Training in Breast Cancer Survivors During Chemotherapy|Comparison of Aerobic Versus Resistance Exercise Training in Enhancing Quality of Life in Early Stage Breast Cancer Survivors Receiving Chemotherapy: A Multi-Centre Randomized Trial||University of Alberta, Physical Education|Yes|Completed|April 2003|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Female|N/A|N/A|No|||March 2007|March 22, 2007|June 23, 2005||||No||https://clinicaltrials.gov/show/NCT00115713||198259|
NCT00115726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15326|Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure|Randomized Controlled Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure||University of Calgary|No|Completed|September 2000|April 2007|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|198|||Both|18 Years|N/A|No|||February 2008|February 20, 2008|June 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00115726||198258|
NCT00116350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.1|Misoprostol for the Treatment of Postpartum Hemorrhage|Misoprostol for the Treatment of Primary Postpartum Hemorrhage||Gynuity Health Projects|Yes|Completed|July 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1786|||Female|N/A|N/A|No|||March 2009|March 17, 2009|June 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00116350||198210|
NCT00116610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402|Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer|A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer||Poniard Pharmaceuticals||Completed|June 2005|March 2008|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||February 2007|January 19, 2009|June 29, 2005||||No||https://clinicaltrials.gov/show/NCT00116610||198190|
NCT00143624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02-0086|Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels|Effect of Rosiglitazone Maleate (Avandia®) on Carotid Intima Media Thickness, Brachial Artery Reactivity, Glucose Metabolism, Blood Lipid Concentrations, Body Fat Distribution, and Biochemical Markers of Cardiovascular Risk in Patients With the HIV Metabolic Syndrome||University of British Columbia|No|Completed|June 2003|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|70 Years|No|||December 2009|December 8, 2009|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143624||196154|
NCT00112918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000427299|Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer|A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma: The AVANT Study||Hoffmann-La Roche||Completed|December 2004|June 2012|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3451|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|June 2, 2005|Yes|Yes||No|June 1, 2012|https://clinicaltrials.gov/show/NCT00112918||198471|
NCT00112996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000403155|Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer|Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy With Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial||M.D. Anderson Cancer Center|No|Completed|January 2007|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|244|||Both|N/A|N/A|No|||April 2014|April 7, 2014|June 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00112996||198467|
NCT00124475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP00089|Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis|Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis||Basilea Pharmaceutica||Completed|December 2004|September 2007|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1035|||Both|18 Years|75 Years|No|||July 2010|July 16, 2010|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00124475||197601|
NCT00124813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-CID|Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma|Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma||University Hospital, Bonn||Recruiting|August 2002|November 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|July 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00124813||197578|
NCT00114322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000160|Light-Emitting Diode (LED) Light for Seasonal Affective Disorder (SAD) Treatment|Comparing Wavelengths Using LED Light for SAD Treatment||Brigham and Women's Hospital||Recruiting|May 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Both|18 Years|64 Years|No|||June 2005|January 12, 2007|June 14, 2005||||No||https://clinicaltrials.gov/show/NCT00114322||198365|
NCT00114582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2420.0021|Optimizing the Ambiance During Mealtimes in Dutch Nursing Homes|Optimizing the Ambiance During Mealtimes in Dutch Nursing Homes||Wageningen University||Completed|April 2002|December 2003||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|40 Years|N/A||||February 2009|February 12, 2009|June 15, 2005||||No||https://clinicaltrials.gov/show/NCT00114582||198345|
NCT00114283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03823|Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck||National Cancer Institute (NCI)||Completed|March 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2012|April 14, 2015|June 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00114283||198368|
NCT00113971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0002 (IMMU-103-SLE-02)|Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)|A Randomized Phase II Pharmacokinetics/Pharmacodynamics Study of Epratuzumab in Patients With Systemic Lupus Erythematosus||UCB Pharma||Terminated|April 2005|June 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|June 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00113971||198392|
NCT00114517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0025|ELITE: Early Versus Late Intervention Trial With Estradiol|Biologic Response of Menopausal Women to 17B-Estradiol||University of Southern California|Yes|Active, not recruiting|July 2004|July 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|643|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2010|June 17, 2010|June 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114517||198350|
NCT00114530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT SCSSc-01|Scleroderma: Cyclophosphamide or Transplantation (SCOT)|A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|June 2005|December 2017|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|69 Years|No|||April 2015|April 15, 2015|June 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00114530||198349|
NCT00115154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1516-IMIQ|Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands|Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities||Graceway Pharmaceuticals, LLC||Completed|May 2005|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|February 16, 2007|June 21, 2005||||||https://clinicaltrials.gov/show/NCT00115154||198302|
NCT00116012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVO-0201|Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32|A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32. Amendment #3 - A Single Arm, Open-Label Study of rNAPc2 With Reduced Doses of Unfractionated Heparin||ARCA Biopharma, Inc.||Completed|June 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|75 Years|No|||November 2006|November 27, 2006|June 26, 2005||||||https://clinicaltrials.gov/show/NCT00116012||198236|
NCT00116025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/100|Pharmacokinetics of Ghrelin|Pharmacokinetics of Ghrelin in Normal Subjects||University of Aarhus|No|Completed|March 2005|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||17|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|June 26, 2005||||No||https://clinicaltrials.gov/show/NCT00116025||198235|
NCT00165958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1023-2004|Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts|Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts||Emory University|No|Completed|January 2005|July 2011|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|September 12, 2005||No||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00165958||194472|The limitations of this study include the small, predominately male patient population, lack of complete follow-up of secondary endpoint measurements at every time point.
NCT00153426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4234|West Virginia WISEWOMAN Project|West Virginia WISEWOMAN Project||West Virginia University|No|Completed|July 2003|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|733|||Female|40 Years|64 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153426||195413|
NCT00153439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3928|Purdue University Parenting Program Attrition|Purdue University Parenting Program Attrition and Compliance Efficacy Trial||Centers for Disease Control and Prevention|No|Completed|July 2003|September 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||560|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 6, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153439||195412|
NCT00153712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNH Study|Natural History of Non-steroidal Anti-inflammatory Drug and Non-Helicobacter Pylori in Bleeding Peptic Ulcers|A Prospective Cohort Study to Study the Natural History and Ulcer Recurrence Without Acid Suppression of Non-NSAID, Non-HP Bleeding Peptic Ulcer Patients||Chinese University of Hong Kong|No|Completed|August 2002|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|391|||Both|18 Years|N/A|No|Non-Probability Sample|All peptic ulcer bleeding patients|February 2013|February 28, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153712||195391|
NCT00153686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE_Ang|Capsule Endoscopy or Mesenteric Angiogram in Patients With Overt Gastrointestinal Bleeding (GIB) of Obscure Origin|Capsule Endoscopy or Mesenteric Angiogram in Patients With Overt Gastrointestinal Bleeding of Obscure Origin: A Randomized Study||Chinese University of Hong Kong|No|Completed|June 2005|March 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|58|||Both|18 Years|65 Years|No|||May 2008|May 9, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153686||195393|
NCT00153907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-217|Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer|A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer||Dana-Farber Cancer Institute||Completed|March 2002|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||February 2013|February 5, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00153907||195376|
NCT00154167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA 03-001|Safety and Efficacy Study of NV-101 in Dental Patients|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of NV-101 in Dental Patients||Novalar Pharmaceuticals, Inc.||Completed|February 2003|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||122|||Both|10 Years|65 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00154167||195356|
NCT00154466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701248|Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement|An Association Study Between Cardiac Rehabilitation and Stem Cell Mobilization in Patients With Myocardial Infarction||National Taiwan University Hospital|Yes|Completed|July 2004|December 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|58|||Male|35 Years|65 Years|No|||May 2014|May 25, 2014|September 9, 2005||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00154466||195333|First, our trial is small size. Second, these results are applicable only for male patients less than 65 years old with ST-segment elevation MI after successful PCI. Third, the source of angiogenic cytokines cannot be elucidated.
NCT00154778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910703|Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer|An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer||National Taiwan University Hospital|Yes|Completed|March 2003|June 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||July 2005|July 30, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154778||195309|
NCT00155129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701099|The Role of CGRPand Nociceptin in Migraine|The Role of Calcitonin Gene-Related Peptide(CGRP)and Nociceptin in the Pathogenesis of Migraine||National Taiwan University Hospital||Recruiting|January 2005|June 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|3 Years|50 Years|Accepts Healthy Volunteers|||June 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155129||195283|
NCT00155480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700626|Establish Finite Element Mesh of the Numerical Models of the Thoracic Aorta|Establish Finite Element Mesh of the Numerical Models of the Thoracic Aorta||National Taiwan University Hospital||Completed|January 2000|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|80|||Both|N/A|80 Years|No|||November 2012|December 5, 2012|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155480||195257|
NCT00155493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700633|Age-Related Changes in Proliferation and Differentiation Capacity of Human Preadipocytes From Periorbital Fat.|||National Taiwan University Hospital||Not yet recruiting|January 2006|August 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155493||195256|
NCT00155844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200200606|Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"|||National Taiwan University Hospital||Recruiting|February 2003|July 2004||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2003|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155844||195229|
NCT00155857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100209868|The Genetic Study of Primary Angle-Closure Glaucoma|National Taiwan University Hospital||National Taiwan University Hospital||Recruiting|July 2003|July 2007||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|November 22, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155857||195228|
NCT00156130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2003-AROW|Accelerated Radiotherapy Outcomes in Women|Accelerated Radiotherapy Outcomes in Women (Long Term Outcomes of a Randomized Trial of Breast Irradiation Schedules After Lumpectomy in Women With Node-Negative Breast Cancer)(AROW)||Ontario Clinical Oncology Group (OCOG)|No|Active, not recruiting|October 2003|||June 2015|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Anticipated|1234|||Female|N/A|N/A|No|Non-Probability Sample|Extended long term follow-up of patients recruited into the "Randomized Trial of        Hypofractionated Radiotherapy Post-Lumpectomy in Women with Node Negative Breast Cancer"        study.|June 2015|October 14, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156130||195207|
NCT00156143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-MET-9002-016|Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents|GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.|TAUBER|Pfizer||Completed|April 2002|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|15 Years|20 Years|No|||July 2007|July 27, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156143||195206|
NCT00156741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 287|Efficacy of a Pacemaker Algorithm in Promotion of the Intrinsic Heart Activity.|IntAct, Study on Promotion of Intrinsic Activity.||Medtronic BRC||Active, not recruiting|April 2004|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2005|August 1, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156741||195160|
NCT00152347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70384|A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot|A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot||University of British Columbia|No|Active, not recruiting|September 2005|June 2016|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|36|||Both|N/A|2 Months|No|||July 2015|July 30, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152347||195496|
NCT00156702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTSF8520012|Researching the Youth Smoking Experience|Researching the Youth Smoking Experience||Virginia Commonwealth University|No|Completed|January 2001|October 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156702||195163|
NCT00157027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-05-012|RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)|The Use of Extracorporeal Photochemotherapy With UVADEX in Patients With HIV Who Are Refractory or Intolerant to HAART|HIV-HAART|Atlantic Health System|Yes|Withdrawn|December 2003|April 2010|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157027||195140|
NCT00152880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0337-T|Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative|Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative, Have Normal ALT, and HBV DNA ≥10,000 Copies/mL||University Health Network, Toronto||Recruiting|July 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||30|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2005|November 29, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152880||195455|
NCT00152841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0289-E|Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis|Effect of Iron and Antioxidant Vitamins on Disease Activity and Oxidative Stress in Inflammatory Bowel Disease (IBD)||University Health Network, Toronto|No|Terminated|June 2002|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|30|||Both|18 Years|N/A|No|||March 2009|March 16, 2009|September 7, 2005||No|Lack of patients|No||https://clinicaltrials.gov/show/NCT00152841||195458|
NCT00152854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACETAPLAC|Acetaminophen for Cancer Pain|A Randomised, Placebo-controlled, Crossover Trial of Acetaminophen in Cancer Patients on Strong Opioids||University Health Network, Toronto||Completed|July 2005|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152854||195457|
NCT00152867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDJV2|Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy|A Randomised Double-Blind Placebo Controlled Cross Over Trial of the Impact on Quality of Life of Continuing Dexamethasone Beyond 24 Hours Following Moderately Emetogenic Chemotherapy||University Health Network, Toronto|No|Completed|January 2005|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|N/A|No|||June 2012|June 26, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152867||195456|
NCT00153452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-4606|Workplace Productivity of Persons Who Use Controlling Behavior With Intimate Partners|Workplace Productivity of Persons Who Use Controlling Behavior With Intimate Partners||Centers for Disease Control and Prevention||Completed|November 2004|July 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||630|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153452||195411|
NCT00153725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPA Study|Intravenous Pantoloc In Aspirin-Induced Ulcer Bleeding|||Chinese University of Hong Kong||Completed|February 2003|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||156|||Both|18 Years|90 Years|No|||October 2006|October 26, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153725||195390|
NCT00153361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3985|Project MIX: Behavioral Intervention to Reduce Risk Among Substance-Using MSM|Project Mix: Behavioral Intervention to Reduce Sexual Risk Behavior of Substance-Using (Non-Injection) Men Who Have Sex With Men||Centers for Disease Control and Prevention||Completed|October 2002|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1750|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 6, 2010|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153361||195418|
NCT00153374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-3566|Iowa WISEWOMAN Project|Iowa WISEWOMAN Project||Centers for Disease Control and Prevention||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Female|40 Years|64 Years||||March 2012|March 13, 2012|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153374||195417|
NCT00153387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-3949|Illinois WISEWOMAN Project|Illinois WISEWOMAN Project||Centers for Disease Control and Prevention||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Female|40 Years|64 Years||||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153387||195416|
NCT00153400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-3898|California WISEWOMAN Project|California WISEWOMAN Project||Centers for Disease Control and Prevention||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Female|40 Years|64 Years||||September 2005|February 10, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153400||195415|
NCT00153413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4114|West Virginia WISEWOMAN Focus Groups|West Virginia WISEWOMAN Focus Groups||Centers for Disease Control and Prevention||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Female|40 Years|64 Years||||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153413||195414|
NCT00153699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.310|Relationship Between Topiramate Use and Ocular Angle Status|Relationship Between Topiramate Use and Ocular Angle Status: A Prospective Pilot Study||Chinese University of Hong Kong||Active, not recruiting|September 2004|July 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||October 2007|October 30, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153699||195392|
NCT00154193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400ANO01|Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels|A 12-month Study to Investigate the Correlations Between Cyclosporine Microemulsion C2 Levels (High, Medium and Low) and AUC0-4 With Regard to Outcome in de Novo Heart and Lung Transplantation - Identification of Target Cyclosporine Microemulsion C2 Levels.||Novartis||Completed|June 2004|||November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|190|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00154193||195354|
NCT00153920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-328|Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma|Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Completed|December 2003|September 2008|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 8, 2005|Yes|Yes||No|January 21, 2016|https://clinicaltrials.gov/show/NCT00153920||195375|
NCT00154180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLRI-04-1|Kronos Early Estrogen Prevention Study (KEEPS)|Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women||Kronos Longevity Research Institute|Yes|Active, not recruiting|September 2005|July 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|728|||Female|42 Years|58 Years|Accepts Healthy Volunteers|||September 2009|September 10, 2009|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00154180||195355|
NCT00154479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701235|The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus|||National Taiwan University Hospital||Recruiting|October 2003|December 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||700|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||October 2003|December 13, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154479||195332|
NCT00154492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7LIVER-1533|Use of NovoSeven® in Active Variceal Bleeding|Effectiveness and Safety of Use of NovoSeven® in the Treatment of Active Variceal Bleeding in Patients With Advanced Cirrhosis||Novo Nordisk A/S|No|Completed|April 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|265|||Both|18 Years|80 Years|No|||October 2013|October 28, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154492||195331|
NCT00154765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100207243|Effect of Sling Suspension Exercises in Proprioception of Patients With Knee Osteoarthritis|Graduate School of Physical Therapy, College of Medicine, NTU, Taiwan||National Taiwan University Hospital||Completed|March 2003|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||30|||Both|50 Years|70 Years|No|||December 2003|November 21, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154765||195310|
NCT00155519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10892|A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions|A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions||National Taiwan University Hospital||Completed|July 2002|July 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2000|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155519||195254|
NCT00155532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700704|Skin Denervation in Systemic Lupus Erythematosus|||National Taiwan University Hospital||Completed|April 2002|March 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|18 Years|80 Years||||June 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155532||195253|
NCT00155870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200201773|Health-Related QoL Among Women Receiving Hysterectomy in NTUH|Health-Related Quality of Life Among Women Receiving Hysterectomy in National Taiwan University Hospital||National Taiwan University Hospital||Recruiting|June 2005|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||80|||Female|21 Years|80 Years|No|||June 2005|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155870||195227|
NCT00156156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-FB04-078|Study of Asoprisnil in the Treatment of Uterine Fibroids.|A Phase 3, Continuation Study to Evaluate the Long-Term Safety of Asoprisnil in Subjects With Uterine Leiomyomata||Abbott|No|Completed|November 2004|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|149|||Female|18 Years|N/A|No|||May 2008|May 27, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156156||195205|
NCT00156429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507025|Genetic Predictors of Outcome in HCM Patients|Genetic Predictors of Outcome in HCM Patients||University of Pittsburgh|No|Recruiting|July 2005|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|540|Samples With DNA|Blood sample for DNA analysis|Both|18 Years|N/A|No|Non-Probability Sample|patients with HCM|December 2015|December 22, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156429||195184|
NCT00156767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050013|Adrenal Function in Critical Illness|Adrenal Function in Critical Illness||National Institutes of Health Clinical Center (CC)||Completed|October 2004|||||N/A|Observational|N/A|||Actual|218|||Both|15 Years|85 Years|No|||January 2016|February 3, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00156767||195159|
NCT00152360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-0151|The Effect of Xenical on Weight and Risk Factors|The Effect of Xenical on Weight, Risk Factors and Burden of Medication||University of British Columbia|No|Completed|June 2005|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 28, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152360||195495|
NCT00157040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060101|Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A|Recombinant Antihemophilic Factor (rAHF-PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Pharmacokinetics, Immunogenicity, Efficacy and Safety in Previously Treated Pediatric Patients With Hemophilia A||Baxalta US Inc.||Completed|June 2002|January 2005|Actual|January 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|N/A|6 Years|No|||September 2011|June 26, 2015|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00157040||195139|
NCT00152594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA 150 0009|Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia|Phase III Study of Safety, Tolerance, Efficacy, Pharmacokinetics, and Costs of Therapy With Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia||University of Cologne||Terminated|October 2004|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|18 Years|N/A|No|||November 2006|November 13, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152594||195477|
NCT00152893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0703-A|To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities|The Effects of Chromium Supplementation on Glucose and Lipid Metabolism in Patients With HIV Infection||University Health Network, Toronto||Completed|August 2002|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152893||195454|
NCT00153166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-001501|ARREST PAD (Peripheral Arterial Disease)|The Contribution of Inflammation and Insulin Resistance to Intermittent Claudication||Brigham and Women's Hospital|Yes|Completed|January 2004|December 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|76|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|September 8, 2005|Yes|Yes||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00153166||195433|
NCT00153465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3899|University of Oklahoma Parenting Program Attrition|University of Oklahoma Health Sciences Center Parenting Program Attrition and Compliance Efficacy Trial||Centers for Disease Control and Prevention|No|Completed|January 2004|September 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||450|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 6, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153465||195410|
NCT00153738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI0129|Phytosterol Supplementation and Cardiovascular Risk|Effectiveness of Phytosterol Supplementation on Select Indices of Cardiovascular Risk||The Cooper Institute||Completed|March 2004|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||72|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153738||195389|
NCT00153751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JC_IBS|The Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With Irritable Bowel Syndrome (IBS)|Clinical Study to Test the Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With IBS||Chinese University of Hong Kong|No|Completed|September 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|65 Years|No|||May 2008|May 9, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153751||195388|
NCT00153933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-130|Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma|An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma||Dana-Farber Cancer Institute||Completed|August 2004|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00153933||195374|
NCT00154206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AFR03|Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients|A Multicenter, Open, Single Arm, Pilot Study to Evaluate Efficacy, Tolerability and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients||Novartis||Completed|September 2004|||January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||15|||Both|5 Years|16 Years||||March 2014|March 6, 2014|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154206||195353|
NCT00154219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2367|Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis|A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control||Novartis||Completed|November 2004|||October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1200|||Both|40 Years|N/A|No|||May 2012|May 18, 2012|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00154219||195352|
NCT00154505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701245|Effects of Lateral Trunk Support on Spinal Alignment in Spinal Cord Injured Persons|Effects of Lateral Trunk Support on Spinal Alignment in Spinal Cord Injured Persons||National Taiwan University Hospital||Completed|September 2002|November 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||August 2002|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154505||195330|
NCT00154518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701411|The Role of Matrix Metalloproteinases (MMPs) in Orthodontic Tooth Movement|The Role of Matrix Metalloproteinases in Orthodontic Treatment||National Taiwan University Hospital||Completed|January 2004|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154518||195329|
NCT00154791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900905|Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma|Phase I/II Trial of Biweekly Gemcitabine, Oxaliplatin, and 48-Hour Infusion of High-Dose 5-FU/Leucovorin (GOFL) in Advanced Pancreatic Adenocarcinoma||National Taiwan University Hospital||Completed|March 2003|August 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|20 Years|75 Years|No|||August 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154791||195308|
NCT00155142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701104|Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.|Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.||National Taiwan University Hospital||Recruiting|September 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|15 Years|N/A|No|||September 2004|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155142||195282|
NCT00155506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14553|Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios|Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios||National Taiwan University Hospital||Completed|November 2002|December 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||600|||Both|18 Years|65 Years|No|||November 2002|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155506||195255|
NCT00155545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701286|Influence of Leg Length Discrepancy on the Spinal Shape and Biomechanics in Functional and Idiopathic Scoliosis Patients|Influence of Leg Length Discrepancy on the Spinal Shape and Biomechanics During Static and Dynamic Activities in Functional and Idiopathic Scoliosis Patients||National Taiwan University Hospital||Completed|September 2005|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2012|December 6, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00155545||195252|
NCT00155883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921101|Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer|Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer||National Taiwan University Hospital||Terminated|June 2004|July 2005|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|54|||Both|18 Years|75 Years|No|||July 2005|August 14, 2008|September 9, 2005|||slow a accrul due to many competitive trials.|No||https://clinicaltrials.gov/show/NCT00155883||195226|
NCT00155896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700719|Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer|||National Taiwan University Hospital||Recruiting|January 2003|December 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Female|18 Years|80 Years|No|||September 2002|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155896||195225|
NCT00155909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700803|Risk Factors of Radiation Pneumonitis|To Investigate Risk Factors of Radiation Pneumonitis, Fibrosis, and Impairment of Quality of Life by Radiotherapeutic Dosimetric and Biological Parameters for Lung Cancer Patients Receiving Thoracic Radiotherapy||National Taiwan University Hospital||Recruiting|July 2003|June 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||53|||Both|18 Years|N/A|No|||June 2005|November 22, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155909||195224|
NCT00156169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-01-2358-AH-CTIL|The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid on Lipid Profile in Fibrate Treated Patients.|The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid||Sheba Medical Center|No|Completed|May 2001|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|50|||Both|18 Years|70 Years|No|||August 2009|August 10, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156169||195204|
NCT00156182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-275|A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.|A Phase 2, Long-Term, Open-Label, Safety Extension Study of Asoprisnil (J867) in Patients With Uterine Leiomyomata||Abbott|No|Completed|April 2001|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Female|18 Years|48 Years|No|||May 2008|March 3, 2009|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156182||195203|
NCT00156442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11595|A Study to Examine the Relationship Between Sleep Apnea and Cleft Lip/Palate|OSAS in Children With Cleft Lip/Palate||University of Rochester|No|Completed|September 2005|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|1 Year|18 Years|No|Non-Probability Sample|children with celft palate and symptoms of OSA|September 2006|January 11, 2010|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156442||195183|
NCT00156455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10185|Sleep Disordered Breathing in Children With Single Ventricle Physiology|Sleep Disordered Breathing in Children With Single Ventricle Physiology||University of Rochester|No|Withdrawn|September 2004|||March 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|1 Month|2 Years|No|Non-Probability Sample|children with hypoplasic heart condition|April 2015|April 29, 2015|September 8, 2005|No|Yes|lack of study personel|No||https://clinicaltrials.gov/show/NCT00156455||195182|
NCT00156468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10035|Office-Based Asthma Screening Intervention|Office-Based Asthma Screening Intervention||University of Rochester||Completed|October 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||365|||Both|2 Years|12 Years|No|||May 2011|May 11, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156468||195181|
NCT00156481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10095|A Qualitative Study About Smoking Practices|Smoking Practices Among Parents of Urban Children With Asthma: A Qualitative Study||University of Rochester||Completed|December 2004|May 2006|Actual|May 2006|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|35|||Both|18 Years|60 Years|No|Non-Probability Sample|Parents of children with asthma in Rochester, NY|May 2011|May 11, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156481||195180|
NCT00156780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-700-05|Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF|A Phase 1, Double Blind, Crossover, Placebo-Controlled, Dual-Injection, Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF)||Acusphere||Completed|August 2004|July 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training|||||||||||||July 2006|October 19, 2006|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00156780||195158|
NCT00156793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-700-32|Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging|A Phase 3, International, Multicenter, Open Label, Dual-Injection, Echocardiographic Imaging and Safety Study of AI-700 in Patients With Suspected Ischemic Heart Disease Undergoing Single-Photon Emission Computed Tomography (Real-Time Assessment of Myocardial Perfusion With Echocardiography: RAMP 1)||Acusphere||Completed|December 2003|March 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||400|||Both|18 Years|80 Years|No|||July 2006|July 13, 2006|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00156793||195157|
NCT00152373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01102|Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS|A Double-blind, Placebo-controlled, Randomized Study: 16-week Evaluation of the Efficacy and Safety of Levetiracetam (LEV) as add-on Therapy in Adults and Adolescents Older Than 16 Years Suffering From Partial Seizures.||UCB Pharma||Completed|July 2004|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||192|||Both|16 Years|70 Years||||September 2009|December 2, 2013|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152373||195494|
NCT00152386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87027|A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis|A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate||UCB Pharma||Completed|February 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||950|||Both|18 Years|N/A|No|||July 2010|August 26, 2014|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152386||195493|
NCT00152607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10050|Orthotopic Liver Transplantation Using a Living Donor|Orthotopic Liver Transplantation Using a Living Donor Into An Adult Recipient||University of Chicago||Terminated|April 2000|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|No|||September 2013|September 26, 2013|September 8, 2005||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00152607||195476|
NCT00152919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0840-C|Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy|A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial||University Health Network, Toronto||Completed|February 2004|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Male|18 Years|N/A|No|||August 2010|August 12, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152919||195452|
NCT00153205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000322/1; BWH|Serious Medication Errors in Pediatrics: Evaluation of Prevention Strategies|Serious Medication Errors in Pediatrics: Evaluation of Prevention Strategies||Brigham and Women's Hospital||Recruiting|February 2000|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|1000|||Both|N/A|N/A|No|||May 2010|May 3, 2010|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153205||195430|
NCT00153179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000088|Free Fatty Acids and Vascular Function in Subjects With Diabetes|The Impact of Free Fatty Acid Reduction on Vascular Function and Skeletal Muscle Glucose Utilization in Type 2 Diabetes Mellitus||Brigham and Women's Hospital|No|Completed|September 2005|March 2013|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|September 8, 2005|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00153179||195432|
NCT00153764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI0039|Effectiveness of a Vitamin Mineral Supplement|Effectiveness of a One-a-Day Cooper Complete Vitamin / Mineral Supplement With or Without Omega-3 Fatty Acid Ingestion|Omega-3|The Cooper Institute|No|Completed|September 2004|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|75|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153764||195387|
NCT00153972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91052003|Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease|Dopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression Analysis of Early Parkinson's Disease||Technische Universität Dresden|Yes|Completed|February 2005|January 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|40 Years|85 Years|No|||December 2012|December 17, 2012|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153972||195371|
NCT00153946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAST|Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke|Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy|EAST|Combination Therapy for Acute Ischemic Stroke Study Group|Yes|Completed|August 2004|May 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|814|||Both|20 Years|N/A|No|||May 2008|May 12, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153946||195373|
NCT00154232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AAR01|Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)|A 3 Month, Multicenter, Open-label Study to Evaluate the Impact of the Immunosuppressive Combination of Enteric-Coated Mycophenolate Sodium (EC- MPS), Basiliximab and Cyclosporine for Microemulsion With C2 Monitoring, on Efficacy and Safety Outcomes in de Novo Kidney Transplant Recipients at Potential High Risk of DGF.||Novartis||Completed|June 2004|||March 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||46|||Both|18 Years|70 Years||||November 2011|November 1, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00154232||195351|
NCT00154245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ATW01|A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.|||Novartis||Completed|January 2004|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||20|||Both|18 Years|75 Years||||February 2011|February 1, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00154245||195350|
NCT00154531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701418|Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI|Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by Surface-Enhanced Laser Desorption/Ionization (SELDI)||National Taiwan University Hospital||Recruiting|August 2004|May 2005||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||230|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2003|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154531||195328|
NCT00154804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900603|CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer|A Phase II Study of Concurrent Chemoradiotherapy With Twice Weekly Paclitaxel and Cisplatin (Twice Weekly TP) Followed by Surgery for Locally Advanced Esophageal Cancer||National Taiwan University Hospital|No|Completed|August 2001|April 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2004|August 22, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154804||195307|
NCT00154817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910704|A Phase II Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma (HCC)|A Phase II Clinical and Mechanistic Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma||National Taiwan University Hospital||Completed|January 2002|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|20 Years|75 Years|No|||January 2002|November 21, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154817||195306|
NCT00155155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701122|Studies of Immune Responses in Patients With Chronic Hepatitis B|Analysis of HBV-Specific T Cell Responses and Regulatory T Cells in Patients With Chronic Hepatitis B Virus Infection||National Taiwan University Hospital|No|Completed|May 2005|||April 2008|Actual|Phase 1|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|N/A|N/A|No|||November 2008|December 1, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00155155||195281|
NCT00155558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159I13|A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers|A Phase I Trial of HDFL48(Weekly 48-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) in Recurrent or Metastatic Colorectal Cancers||National Taiwan University Hospital|No|Completed|March 2001|December 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||November 2000|July 23, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155558||195251|
NCT00155922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700953|The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients|The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients, Special Relevance to Atherosclerosis||National Taiwan University Hospital||Recruiting|November 2003|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||100|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||September 2005|December 13, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155922||195223|
NCT00155935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700718|The Development of Human Immunologic Assays Specific to Folate Receptor Antigen|The Development of Human Immunologic Assays Specific to Folate Receptor Antigen||National Taiwan University Hospital||Recruiting|January 2004|December 2008||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|50|||Female|10 Years|90 Years|Accepts Healthy Volunteers|||January 2004|August 10, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155935||195222|
NCT00156195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-391|Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids|A Phase 3, 12-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata||Abbott|Yes|Completed|September 2003|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|523|||Female|18 Years|N/A|No|||May 2008|May 27, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156195||195202|
NCT00156494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10182|Attitudes About Smoking: A Telephone Survey|"Attitudes About Smoking" A Telephone Survey of Parents of Young Urban Children||University of Rochester|No|Completed|June 2004|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|371|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parents of children in the Rochester City School District|May 2011|May 11, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156494||195179|
NCT00152646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 04-07|Platelets Induced Vasodilation, in Vitro and in Vivo Study|Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects.||University Hospital, Angers|Yes|Recruiting|March 2005|January 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|February 3, 2010|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152646||195473|
NCT00152659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9538|Developing Criteria for Cortical Resections|Developing Functional and Structural Criteria for Cortical Resections||University of Chicago|No|Recruiting|September 1998|||December 2030|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Surgical candidates with epilepsy or brain tumor(s)|January 2013|September 4, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152659||195472|
NCT00152672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 04-10|Treatment of Sleep Apnea Syndrome With nCPAP Versus Oral Appliance|Treatment of Sleep Apnea Syndrome With nCPAP Versus Oral Appliance: a Multicentre Prospective Randomized Crossover Trial||University Hospital, Angers||Recruiting|June 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Male|18 Years|70 Years|No|||February 2005|October 27, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152672||195471|
NCT00152620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13171B|Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease|Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease||University of Chicago||Terminated|June 2004|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|6 Years|19 Years|No|||September 2013|September 4, 2013|September 7, 2005||No|study completed|No||https://clinicaltrials.gov/show/NCT00152620||195475|
NCT00152906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0295-C|Stereotactic Radiotherapy (SRT) Liver (COLD 1)|Phase I/II Trial of Highly Conformal Radiotherapy for Unresectable Liver Metastases and Hepatobiliary Carcinoma||University Health Network, Toronto||Active, not recruiting|July 2003|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152906||195453|
NCT00153491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3602|Adherence to Lumefantrine-Artemether|Assessment of Adherence to a 6-Dose Regimen of Coartem for Treatment of Uncomplicated Malaria in Children Under 5 Years in Tanzania||Centers for Disease Control and Prevention||Completed|August 2002|August 2006||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|59 Months|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153491||195408|
NCT00153790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI0151|LEAN Project: Weight Loss and Appetite Suppression|The Effect of Soy Lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and Green Tea-derived Epigallocatechin Gallate (EGCG) on Indices of Weight Loss and Appetite Suppression||The Cooper Institute||Completed|April 2005|May 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153790||195385|
NCT00153192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000474|Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain|A Randomized Controlled Clinical Trial of Dronabinol (Marinol) vs Placebo as Add-on Therapy For Patients on Opioids for Chronic Pain||Brigham and Women's Hospital||Completed|April 2001|April 2006|Actual|April 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||April 2013|April 25, 2013|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00153192||195431|
NCT00153985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-338|Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies|Multi-Center Study Using Allogeneic Stem Cell Transplantation Following Reduced Intensity Chemotherapy in Patients With Hemoglobinopathies||Dana-Farber Cancer Institute|Yes|Completed|March 2004|July 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|September 8, 2005|Yes|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00153985||195370|Early termination leading to small numbers of subjects analyzed.
NCT00154284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2419|Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients|A 12 Month, Multicenter, Randomized, Parallel, Open-label Study, to Evaluate Renal Function and Efficacy of Everolimus With Basiliximab and Cyclosporine Microemulsion Discontinuation at 3 Month Post-transplant Versus Minimization, in de Novo Kidney Transplant Recipients|CERTES02|Novartis||Completed|July 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|65 Years|No|||March 2011|March 28, 2011|September 8, 2005||No||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00154284||195347|This is a combined analysis using 81 patients randomized and treated in CRAD001A2419 with 33 randomized and treated in CRAD001A2423. This approach is reflected in the protocol amendments for each study, and the one clinical study report for both.
NCT00154297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2420|Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients|A National Multicentre Randomized Study Comparing the Early Versus Delayed Administration of Everolimus in de Novo Kidney Transplant Recipients at Risk of Delayed Graft Function||Novartis||Completed|June 2005|||June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|139|||Both|18 Years|N/A|No|||March 2011|March 30, 2011|September 8, 2005||No||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00154297||195346|
NCT00153959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLG4-CT-2000-01700|Psychiatric Day Hospital Treatment|||Technische Universität Dresden||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Both|18 Years|65 Years|No|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00153959||195372|
NCT00154258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEX123J1202|A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia|An Open Extension Study to Phase IIb Study of Clozapine in Patients With Treatment-resistant Schizophrenia||Novartis||Completed|April 2001|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|64 Years|No|||May 2012|May 3, 2012|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00154258||195349|
NCT00154583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701445|Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions|||National Taiwan University Hospital||Recruiting|January 2003|December 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||500|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||January 2003|December 20, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154583||195324|
NCT00154544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701419|Searching for the Liver Cancer-Related Biomarkers|Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by PROTEOMEX||National Taiwan University Hospital||Recruiting|August 2004|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2003|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154544||195327|
NCT00154557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701413|Influence of the Psychophysiological Status of Elite Judo Athletes on Their Performance and Injury|||National Taiwan University Hospital||Recruiting|August 2004|July 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||60|||Both|16 Years|20 Years|No|||August 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154557||195326|
NCT00154869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921003|Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C|An Open Label, Comparative, Multi-Center Study, to Evaluate the Efficacy and Safety of Peginterferon Alfa-2a Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C||National Taiwan University Hospital||Recruiting|June 2004|August 2007||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|320|||Both|18 Years|N/A|No|||August 2005|August 10, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154869||195302|
NCT00154830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200201507|Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children|Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children||National Taiwan University Hospital||Completed|August 2004|July 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2005|November 22, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154830||195305|
NCT00155168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700452|Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System|Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System: Establishing a Novel Highly Efficient and Reliable SMA Carrier Screening Test||National Taiwan University Hospital||Recruiting|April 2004|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||500|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155168||195280|
NCT00155181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700387|Molecular Mechanism of Nasopharyngeal Carcinoma|the Garduate Institute of Microbiology in National Taiwan University||National Taiwan University Hospital||Recruiting|January 2005|August 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||25|||Both|30 Years|65 Years|No|||January 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155181||195279|
NCT00166049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045870|Education and Supportive Partners Improving Self-Care (ENSPIRE)|A Family Partnership Intervention in Heart Failure||Emory University|Yes|Completed|April 2005|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|170|||Both|21 Years|79 Years|No|||September 2013|November 9, 2015|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00166049||194465|
NCT00166062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0304-2003|Safety and Effectiveness of Computer Screening for Intimate Partner Violence|||Emory University||Completed|January 2004|December 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind|||||||Both|18 Years|55 Years||||September 2013|September 19, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00166062||194464|
NCT00156520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10504|Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis|Jeanne Grace; Head Research Subjects Review Board||University of Rochester||Completed|March 2005|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|||Anticipated|40|||Both|N/A|N/A|No|||April 2010|April 9, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156520||195177|
NCT00156806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-08-0006|Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.|Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.||AHS Cancer Control Alberta||Completed|March 2002|May 2006|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||231|||Female|18 Years|N/A|No|||December 2011|December 8, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156806||195156|
NCT00152399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9823|Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding|A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial To Study The Efficacy And The Safety Of The Early Administration Of Somatostatin (Ucb) 12 Mg/24 H IV Infusion And Two IV Boluses Of 250 Mcg During 72 Hours In The Treatment Of Subjects With Acute Severe Upper Gastrointestinal Bleeding (UGIB) With Suspicion Of Peptic Ulcer Bleeding [The PUB Study]||UCB Pharma||Completed|September 2000|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||370|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152399||195492|
NCT00152412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00385|Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis|A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis.||UCB Pharma||Completed|June 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|2 Years|6 Years||||September 2009|August 25, 2014|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152412||195491|
NCT00153244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-0902-LT-0503|Study of Efficacy of Lamotrigine in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Lamotrigine Efficacy in Asthma Therapy||Centre of Chinese Medicine, Georgia||Completed|August 2002|May 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||76|||Both|16 Years|65 Years|No|||February 2009|February 18, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153244||195427|
NCT00153257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040306|Comparative Study of Mesh Versus No Mesh in Prolapse Surgery|Comparison of the Prosthesis Ugytex by the Trans-Obturator Approach and Anterior Colporrhaphy for the Surgical Treatment of Anterior Vaginal Wall Prolapse.||Centre Hospitalier Universitaire de Nīmes||Recruiting|June 2005|June 2011||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||194|||Female|60 Years|N/A|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153257||195426|
NCT00152932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0645-A|Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide|Ocular Blood Flow Measured by HRF and CLBF in Newly Diagnosed and Early Glaucoma Patients Before and After Instillation of Dorzolamide 2%||University Health Network, Toronto||Recruiting|May 2005|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|17|||Both|20 Years|80 Years|No|||September 2005|July 23, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152932||195451|
NCT00152633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retina-Losartan|Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension|Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension||University of Erlangen-Nürnberg Medical School|No|Withdrawn|September 2005|January 2006|Actual|January 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||July 2012|July 4, 2012|September 8, 2005||No|No patient could be recruited.|No||https://clinicaltrials.gov/show/NCT00152633||195474|
NCT00153998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELIM|Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)|Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases||Technische Universität Dresden|No|Completed|November 2004|||March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||April 2007|February 26, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153998||195369|
NCT00154037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKPD 02-05|Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.|Characterization of Vascular Effects of Candesartan and Pioglitazone.||Technische Universität Dresden||Completed|October 2005|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2006|September 12, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154037||195366|
NCT00153478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-3271|Project CHOICES Efficacy Study|Project CHOICES Efficacy Study for Preventing Alcohol-Exposed Pregnancies||Centers for Disease Control and Prevention||Completed|July 2002|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1200|||Female|18 Years|44 Years|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153478||195409|
NCT00154310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2418|Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Everolimus in Comparison to Standard Therapy With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Cyclosporine Microemulsion in de Novo Renal Transplant Patients||Novartis||Completed|June 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|65 Years|No|||October 2013|October 21, 2013|September 8, 2005|No|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00154310||195345|
NCT00154323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476BES03|The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.|A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment||Novartis||Completed|January 2003|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|N/A|No|||November 2011|November 22, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00154323||195344|
NCT00154609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930701|Davallia Divaricata BL: The Use of Traditional Chinese Native Medicine for Osteoporosis|The Use Tradition Chinese Native Medicine Treats the Osteoporosis Research||National Taiwan University Hospital||Recruiting|January 2002|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|45 Years|70 Years|No|||January 2002|January 20, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154609||195322|
NCT00154622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701040|Management and Outcome of Work-Related Musculoskeletal Disorders|National Taiwan University Hospital||National Taiwan University Hospital||Completed|January 2004|December 2008|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|160|||Both|18 Years|65 Years|No|||December 2012|December 5, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00154622||195321|
NCT00154271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631DUS02|Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)|Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)||Novartis||Completed|January 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1677|||Both|18 Years|75 Years||||August 2006|November 7, 2011|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00154271||195348|
NCT00154570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701469|24 Hour Esophageal and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis|Integrating Simultaneous Recording of 24 Hour Esophageal pH and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis||National Taiwan University Hospital||Recruiting|February 2004|August 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2004|November 21, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154570||195325|
NCT00154843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920704|A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation|A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation||National Taiwan University Hospital|No|Completed|March 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|74|||Male|40 Years|N/A|No|||August 2006|January 8, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00154843||195304|
NCT00154856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92002015|Influence of Mechanical Stimulus on Distraction Osteogenesis|Influence of Mechanical Stimulus on Distraction Osteogenesis||National Taiwan University Hospital||Completed|August 2004|July 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2003|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154856||195303|
NCT00155194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701170|Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice|Impaired T-Lymphocyte Proliferative Function in Biliary Atresia Children With Prolonged Jaundice||National Taiwan University Hospital||Recruiting|April 2004|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||30|||Both|1 Year|N/A|No|||June 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155194||195278|
NCT00155207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701128|A Study on Risk Mutations of Vulnerability Genes of Schizophrenia|A Study on Risk Mutations of Vulnerability Genes of Schizophrenia||National Taiwan University Hospital||Recruiting|May 2005|April 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1065|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2005|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155207||195277|
NCT00155571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14881|The Occurrence of Periopathogens in Betel-Nut Chewers and the Effects of Areca-Nut on Periopathogens|The Occurrence of Periopathogens in Betel-Nut Chewers and the Effects of Areca-Nut on Periopathogens||National Taiwan University Hospital||Completed|August 2001|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||186|||Both|20 Years|N/A||||January 2001|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155571||195250|
NCT00155948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701132|Estimation of Muscle Area and Thickness of Deep Cervical Muscle Contraction During Cervical and Limb Movements|Estimation of Muscle Area and Thickness of Deep Cervical Muscle Contraction During Cervical and Limb Movements||National Taiwan University Hospital||Completed|September 2003|May 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||April 2004|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155948||195221|
NCT00155961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|016|Odense Androgen Study in the Elderly|Odense Androgen Study in the Elderly||Odense University Hospital||Completed|March 2002|||||Phase 1|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||600|||Male|60 Years|75 Years|Accepts Healthy Volunteers|||September 2005|February 2, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00155961||195220|
NCT00161928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216|Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants|A Randomized, Open-Label Trial of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants||Pfizer||Completed|April 2002|January 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||330|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161928||194776|
NCT00162370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMP 115-407|A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease|SMART: Stress Echocardiography in Menopausal Women at Risk for Coronary Artery Disease Trial||Lantheus Medical Imaging|No|Completed|April 2004|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|400|||Female|48 Years|60 Years|No|||May 2014|May 5, 2014|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162370||194743|
NCT00156533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI Initiated|Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing|Long Term Treatment With Zolpidem: The Relative Efficacy of Nightly (Quaque Hora Somni [QHS]) & Intermittent Dosing and the Potential for Long Term Clinical Gains After Treatment Discontinuation.||University of Rochester|Yes|Completed|March 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|20|||Both|25 Years|55 Years|No|||October 2015|October 21, 2015|September 7, 2005|Yes|Yes||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00156533||195176|About 25% of the target sample was obtained. As a result our capacity to detect trends and to calculate effect sizes was greatly diminished. Accordingly, our observations must be very limited in scope.
NCT00156819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAACRC-03|The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial|The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial||JHSPH Center for Clinical Trials||Completed|June 2003|August 2006|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|500|||Both|6 Years|N/A|No|||November 2015|November 4, 2015|September 8, 2005||Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00156819||195155|
NCT00152958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.546|A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)|A Double-blind, Placebo-controlled, Randomised Withdrawal Study of 3 Month Duration in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)||Boehringer Ingelheim||Completed|January 2004|||February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||224|||Both|18 Years|80 Years|No|||November 2013|November 18, 2013|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00152958||195449|
NCT00154349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571I1203|Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia|Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia||Novartis||Completed|October 2003|||February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|15 Years|N/A|No|||March 2011|March 9, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00154349||195342|
NCT00152945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0575-B|Determining the Responsiveness of Intestinal Lipoprotein Production to an Elevation of Plasma Free Fatty Acids|||University Health Network, Toronto|No|Completed|April 2005|October 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152945||195450|
NCT00153231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIC|Posterior IVS Versus Sacrospinous Suspension in Vaginal Vault Prolapse Repair|Clinical Evaluation of Morbidity and Efficacy of Posterior IVS (Infracoccygeal Sacropexy), in Comparison to the Standard Sacrospinous Suspension in the Surgical Treatment of Vaginal Vault Prolapse by the Vaginal Route.||Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2003|May 2007|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|49|||Female|18 Years|N/A|No|||March 2015|March 26, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153231||195428|
NCT00153218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2933s|An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu|An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu||Cancer Research Network||Completed|June 2004|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|94|||Female|N/A|N/A|No|Non-Probability Sample|Her-2-neu positive breast cancer patients|February 2012|February 13, 2012|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153218||195429|
NCT00154050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKPD KARDCHEM 02-04|High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty|||Technische Universität Dresden||Completed|May 2004|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||22|||Both|18 Years|80 Years|No|||September 2006|September 11, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154050||195365|
NCT00153777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-090|Cellulose Sulfate and HIV Transmission Among Women|Randomized Controlled Trial of 6% Cellulose Sulfate Gel and the Effect on Vaginal HIV Transmission||CONRAD|Yes|Terminated|July 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|1428|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 27, 2015|September 8, 2005|||IDMC recommendation|No||https://clinicaltrials.gov/show/NCT00153777||195386|
NCT00154934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700215|the Implications of Pathogenesis of Pre-Eclampsia|The Impact of Interleukin-10 in the Invasion Capacity and Immunoregulation During Pregnancy: the Implications of Pathogenesis of Pre-Eclampsia.||National Taiwan University Hospital|Yes|Terminated|January 2004|January 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|placenta biopsy|Female|20 Years|40 Years|No|Non-Probability Sample|pregnacnt women|January 2009|February 2, 2009|September 9, 2005||No|difficult to enroll subjects|No||https://clinicaltrials.gov/show/NCT00154934||195298|
NCT00154947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700330|Develop Biomarkers for Assessing RA Joint Erosion|Develop Biomarkers for Assessing RA Joint Erosion||National Taiwan University Hospital||Active, not recruiting|May 2004|May 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||60|||Both|18 Years|65 Years|No|||July 2006|July 18, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154947||195297|
NCT00154960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9300005565|Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.|Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.||National Taiwan University Hospital||Recruiting|June 2004|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2004|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154960||195296|
NCT00154973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701447|Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers|||National Taiwan University Hospital||Recruiting|August 2004|June 2005||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154973||195295|
NCT00155259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930607|Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer|Docetaxel by 1 Hour Infusion Followed by 24 Hour Infusion of Cisplatin Plus Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer||National Taiwan University Hospital|No|Completed|October 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|N/A|65 Years|No|||July 2005|July 23, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155259||195273|
NCT00155636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5287|A Study on Etiological Factors of Schizophrenia|A Study on Etiological Factors of Schizophrenia||National Taiwan University Hospital||Terminated|January 2002|December 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1056|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2002|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155636||195245|
NCT00154596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930004318|Etiology Study of Kawasaki Disease|Etiology Study of Kawasaki Disease--A Prospective Household and Case Control Study||National Taiwan University Hospital|No|Recruiting|February 2004|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|Blood, throat swab, nasopharyngeal aspiration, and rectal swab will be obtained during acute      illness and at convalescence (about 2 weeks after discharge). These specimens will be      processed for viral isolation, bacterial culture and toxin detection, PCR, subtractive      cloning, VIDISCA, gene chips, peptide library, cytokine/chemokine measurement, antibody      detection for specific pathogens, etc. Questionnaire for contact history and clinical      symptoms will be performed.|Both|1 Month|18 Years|Accepts Healthy Volunteers|Probability Sample|We will enroll Kawasaki disease cases who have at least five of the following        manifestations: 1) fever for over 5 days, 2) neck lymphadenopathy, 3) lip fissure and/or        strawberry tongue, 4) skin rah, 5) nonpurulent bulbar conjunctivitis, 6) palm/sole        erythema and induration followed by desquamation, or cases with coronary artery aneurysm        but less than 5 of the above manifestations (atypical Kawasaki disease).|March 2015|March 15, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00154596||195323|
NCT00154882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920705|Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer|Weekly Low-dose Paclitaxel (Phyxol) Plus 24-Hour Infusion of Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer||National Taiwan University Hospital|No|Recruiting|September 2003|July 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Female|18 Years|75 Years|No|||July 2005|January 20, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154882||195301|
NCT00154895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921204|Additional Minocycline Pleurodesis After Thoracoscopic Procedures for Primary Spontaneous Pneumothorax|Phase III Study of Additional Minocycline Pleurodesis After Video-Assisted Thoracoscopic Surgery for Primary Spontaneous Pneumothorax||National Taiwan University Hospital||Recruiting|June 2001|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|10 Years|50 Years|No|||June 2001|October 19, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154895||195300|
NCT00155220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701436|Treatment of Lymphedema: Application of the Kinesio Taping|Treatment of Lymphedema- Application of the Kinesio Taping||National Taiwan University Hospital||Recruiting|August 2004|March 2006||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Female|30 Years|90 Years|No|||August 2004|January 25, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155220||195276|
NCT00155233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931002|Interaction Between Nalbuphine and Morphine in PCA|Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients||National Taiwan University Hospital||Recruiting|January 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|18 Years|65 Years|No|||June 2005|November 22, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155233||195275|
NCT00155584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28MD01|Topical 5-ALA Photodynamic Therapy for the Treatment of Verruca Vulgaris|Topical 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of Verruca Vulgaris: Comparison of Red and Green Light-Emitting Diode Array||National Taiwan University Hospital||Recruiting|December 1994|December 1996||||Phase 3|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||80|||Both|10 Years|80 Years|No|||December 1994|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155584||195249|
NCT00155597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24368|The Outcome and Cost Analysis of Home-care Physical Therapy for Postoperative Hip Fracture Patients|||National Taiwan University Hospital||Completed|August 1999|July 2001|Actual|July 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||December 2009|January 11, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155597||195248|
NCT00155974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091603|Rapid Vaccination of Hard-To-Reach Populations|Rapid Vaccination of Hard-to-Reach Populations||The New York Academy of Medicine||Recruiting|February 2004|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 21, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155974||195219|
NCT00166361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|255-03|Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent|Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent||Mayo Clinic|Yes|Completed|February 2004|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|September 12, 2005|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00166361||194442|Low number of subjects in each cohort.
NCT00166374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1707-05|To Evaluate Success of Cement Treatment of Spinal Compression Fractures|Outcomes Following Balloon Kyphoplasty for Vertebral Compression Fracture||Mayo Clinic||Completed||June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|200|||Both|20 Years|N/A|No|||January 2010|January 19, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166374||194441|
NCT00156845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-700-33|Phase 3 Safety and Imaging Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing Coronary Angiography|A Phase 3, International, Multicenter, Open-Label, Dual-Injection, Echocardiographic Imaging and Safety Study in Patients With Suspected Ischemic Heart Disease Undergoing Diagnostic Coronary Angiography (Real-Time Assessment of Myocardial Perfusion With Echocardiography: RAMP 2)||Acusphere||Completed|December 2003|June 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||450|||Both|18 Years|80 Years|No|||July 2006|July 13, 2006|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00156845||195154|
NCT00156858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10156|Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study|Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell||AHS Cancer Control Alberta||Recruiting|January 1998|December 2010||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|N/A|70 Years|No|||September 2011|January 18, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156858||195153|
NCT00156871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181710-DRD 16|Individualized Exercise Program for Treatment of Fatigue in Patients After Hematologic Stem Cell Transplant (HSCT)|Individualized Exercise Program for Treatment of Fatigue in Patients After Hematologic Stem Cell Transplant||AHS Cancer Control Alberta||Completed|April 2003|December 2005|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|70 Years|No|||August 2011|January 18, 2012|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156871||195152|
NCT00152425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87032|Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).|A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870||UCB Pharma||Completed|February 2004|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||392|||Both|18 Years|N/A||||July 2010|September 6, 2013|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152425||195490|
NCT00152685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 02-04|High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury|||University Hospital, Angers||Recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind||||40|||Both|18 Years|55 Years|No|||September 2005|November 29, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152685||195470|
NCT00154076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-S082-403|A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies|||Eisai Inc.||Completed|September 2005|December 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|13 Years|N/A|No|||August 2009|September 1, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00154076||195363|
NCT00153829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-0528-029-22-CICM|Chronic Illness Care Management (CICM) Study In Primary Care|||Bruyere Research Institute||Completed|December 2004|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|50 Years|N/A|No|||February 2015|February 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153829||195382|
NCT00153517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-2752|Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy|Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy (Randomized Trial of BV Treatment in Pregnancy)||Centers for Disease Control and Prevention||Completed|October 1999|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||126|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153517||195406|
NCT00153504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4015|Housing and Health Study|Housing and Health Study|H&H|Centers for Disease Control and Prevention|No|Completed|July 2004|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|630|||Both|18 Years|N/A||||April 2012|April 4, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153504||195407|
NCT00155272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931003|Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma|A Pilot Clinical and Mechanistic Study of Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma||National Taiwan University Hospital||Recruiting|March 2005|August 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||19|||Both|20 Years|70 Years|No|||August 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155272||195272|
NCT00155285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700485|Evaluating the Infant Complex Congenital Heart Disease by Multidetector Computed Tomography|Integrated Evaluating the Infant Complex Congenital Heart Disease by Multidetector(16)Spiral Computed Tomography||National Taiwan University Hospital||Recruiting|January 2000|December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||200|||Both|N/A|20 Years|No|||April 2003|October 19, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155285||195271|
NCT00154011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKPD 01-05|Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.|Characterization of Vascular Effects of Rosiglitazone.||Technische Universität Dresden||Completed|September 2005|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2006|September 11, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154011||195368|
NCT00154024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKPD 03-02|Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.|Characterization of Local Vascular Effects of Angiotensin II and Histamine After Treatment With Irbesartan and Atorvastatin.||Technische Universität Dresden||Completed|March 2003|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2006|September 27, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154024||195367|
NCT00155740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100201610|Mesothelin as a New Tumor Marker for Ovarian Cancer|||National Taiwan University Hospital||Recruiting|January 2002|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||250|||Female|15 Years|90 Years|Accepts Healthy Volunteers|||October 2001|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155740||195237|
NCT00156026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2000-CIN1|Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1|Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1||Ontario Clinical Oncology Group (OCOG)|No|Completed|November 2000|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|415|||Female|16 Years|N/A|No|||January 2009|January 28, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156026||195215|
NCT00154921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700212|Clinical Usefulness of Optical Skin Biopsy|Clinical Usefulness of Optical Skin Biopsy||National Taiwan University Hospital||Recruiting|January 2004|December 2007||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2004|November 22, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154921||195299|
NCT00155246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930202|Efficacy of Pentoxifylline on Chronic Kidney Disease|Phase 4 Study of the Efficacy of Pentoxifylline in Patients With Chronic Kidney Disease Receiving Angiotensin Receptor Blockade||National Taiwan University Hospital|No|Completed|July 2004|January 2007|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|70 Years|No|||January 2010|January 27, 2010|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00155246||195274|
NCT00155610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31MD01|The Relationship Between Voiding Dysfunction and Intravesical Sensory Threshold in Diabetes Women|A Cross-Sectional Study of the Relationship Between Voiding Dysfunction and Intravesical Sensory Threshold in Diabetes Women||National Taiwan University Hospital||Terminated||December 2006||||Phase 1/Phase 2|Observational|Time Perspective: Prospective|||Anticipated|120|||Female|30 Years|85 Years|Accepts Healthy Volunteers|||September 2005|January 28, 2008|September 9, 2005|||No clinical significant|No||https://clinicaltrials.gov/show/NCT00155610||195247|
NCT00155623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24642|Establish Epidemiologic Data of H. Pylori Infection in Children and Adolescents-Using C13-UBT|Establish the Precise Epidemiologic Data of Helicobacter Pylori Infection in Children and Adolescents – Using the 13C-Urea Breath Test||National Taiwan University Hospital||Completed|February 2001|July 2003||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||3000|||Both|6 Years|60 Years|Accepts Healthy Volunteers|||January 2001|October 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155623||195246|
NCT00155987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68/02|The DECRA Trial: Early Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury|Multi-centre Prospective Randomised Trial of Early Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury||National Trauma Research Institute|Yes|Active, not recruiting|August 2003|December 2010|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|165|||Both|15 Years|60 Years|No|||September 2009|July 22, 2010|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00155987||195218|
NCT00156247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5487|Acitretin and Etanercept in Psoriasis|Pilot, Single-Arm Study of the Effect of Adding Acitretin to Etanercept Therapy in Patients With Moderate to Severe Psoriasis Who Fail to Respond to Etanercept Monotherapy||Rutgers, The State University of New Jersey|No|Completed|September 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||February 2015|February 13, 2015|September 7, 2005||No||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00156247||195198|small sample size; lack of control group
NCT00166400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960-04|A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.|Beta Blockade in Mitral Regurgitation||Mayo Clinic||Completed|July 2004|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|No|||July 2008|July 23, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166400||194439|
NCT00161967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700401|TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)|Open-label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-borne Encephalitis Vaccine in Children and Adolescents Aged 3 - 18 Years||Pfizer|Yes|Completed|May 2005|November 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|375|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161967||194773|
NCT00153530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-PCNSL-SG1|Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)|Phase IV Study on the Role of Whole Brain Irradiation in Primary CNS Lymphoma (PCNSL) After High-dose Methotrexate||Charite University, Berlin, Germany||Completed|May 2000|May 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|604|||Both|18 Years|N/A|No|||July 2009|December 23, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153530||195405|
NCT00153543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3316|Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders|Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders||Centers for Disease Control and Prevention||Completed|May 2002|June 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||90|||Both|55 Years|70 Years|Accepts Healthy Volunteers|||September 2005|March 19, 2007|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00153543||195404|
NCT00153816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA098286-03|Vitamin D/Calcium Polyp Prevention Study|Vitamin D/Calcium Polyp Prevention Study||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|July 2004|July 2016|Anticipated|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|2813|||Both|45 Years|75 Years|No|||September 2015|September 21, 2015|September 7, 2005|Yes|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT00153816||195383|
NCT00154063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-210|Efficacy and Safety Study of E2007 in Migraine Prophylaxis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis||Eisai Inc.||Completed|January 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|65 Years|No|||August 2009|May 21, 2015|September 6, 2005||||No|May 21, 2015|https://clinicaltrials.gov/show/NCT00154063||195364|
NCT00153556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-2961|Study to Eliminate Hib Carriage in Rural Alaska Native Villages|A Demonstration Project for the Elimination of Haemophilus Influenzae Type B in Three Rural Alaska Native Villages||Centers for Disease Control and Prevention||Completed|September 2001|November 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||3200|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|September 8, 2005|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00153556||195403|
NCT00154401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1571|Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.||Novo Nordisk A/S|No|Completed|January 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|177|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154401||195338|
NCT00154414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1334|Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes|Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes.||Novo Nordisk A/S|No|Completed|January 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|226|||Both|20 Years|75 Years|No|||November 2015|November 9, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154414||195337|
NCT00154648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941540200|CE-MRA Using Gadovist in Comparison to IA DSA Using Ultravist|An Open, Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) Study of Arteries Using Gadovist 1.0 in Comparison to Intra-Arterial Digital Subtraction Angiography (IA DSA) Using Ultravist||National Taiwan University Hospital||Recruiting|June 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|40|||Both|20 Years|75 Years|No|||June 2005|June 4, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154648||195319|
NCT00153803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0410|Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)|A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410).||Dartmouth-Hitchcock Medical Center|Yes|Completed|May 2005|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00153803||195384|
NCT00154999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700383|The Predictors of the Neonatal Hyperbilirubinemia|The Predictors of the Neonatal Hyperbilirubinemia||National Taiwan University Hospital||Completed|April 2005|June 2005||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|N/A|7 Days|Accepts Healthy Volunteers|||March 2004|November 28, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154999||195293|
NCT00154336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571E2201|A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.|3-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety & Tolerability of Imatinib 400 mg Daily in Combination With Methotrexate (MTX)Compared to MTX Alone in the Treatment of Rheumatoid Arthritis (RA).||Novartis||Completed|July 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|75 Years||||November 2009|November 19, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00154336||195343|
NCT00154635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931006|Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease|A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease||National Taiwan University Hospital||Not yet recruiting|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|50 Years|N/A|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154635||195320|
NCT00156312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2003.045|Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine|Evaluation of Thymidine Phosphorylase and Other Predictive/Prognostic Factors in Primary Breast Cancer Treated With Docetaxel and Capecitabine (DC)||University of Michigan Cancer Center|Yes|Completed|July 2003|February 2007|Actual|May 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Female|18 Years|N/A|No|||February 2012|February 5, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156312||195193|
NCT00156611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-1|Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease|ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease – A Randomized Prospective Trial (RIO-Trial)||University Hospital Tuebingen||Active, not recruiting|January 2002|December 2009||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||420|||Both|18 Years|90 Years|No|||September 2006|September 11, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156611||195170|
NCT00156000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0048.2|fFN & E3 in the Prediction of PTB in Women With Twin Pregnancies Receiving 17OHP or Placebo|Fetal Fibronectin (fFN) and Salivary Estriol (E3) in the Prediction of Preterm Birth in Women With Twin Pregnancies Receiving 17-Alpha-Hydroxyprogesterone Caproate or Placebo||Mednax Center for Research, Education and Quality|No|Withdrawn|August 2005|February 2006|Actual|February 2006|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|60 Years|No|Non-Probability Sample|Pregnant women (Twins or Triplets) already enrolled in the Obstetrix Clinical Trial "        Progesterone for prevention of PTB in twin and triplet pregnancies"|December 2014|December 17, 2014|September 8, 2005||No|This study was stopped because of insufficient enrollment.|No||https://clinicaltrials.gov/show/NCT00156000||195217|
NCT00156013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1066306 (0408)|Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)|A Phase I/II Open-label Study of Clofarabine in Patients With Relapsed or Refractory Diffuse Large Cell B-Cell NHL||Oncology Specialists, S.C.|No|Completed|September 2005|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 8, 2005||No||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00156013||195216|
NCT00155649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33979|A Positional Cloning Study on Schizophrenia|||National Taiwan University Hospital||Completed|April 2002|April 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||320|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2001|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155649||195244|
NCT00155662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100002906|The Effect of a Work-hardening Program for Return-to-work for Workers With Low Back Pain|||National Taiwan University Hospital||Completed|August 2002|September 2007|Actual|December 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|60|||Both|18 Years|65 Years|No|||December 2012|December 5, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00155662||195243|
NCT00155675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900505|Pseudodrynaria Coronana (Wall) Ching|Clinical Effect of Traditional Chinese Medicine - "Gusuibu"||National Taiwan University Hospital||Completed|January 2000|January 2001|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Female|45 Years|70 Years|No|||December 2009|January 11, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155675||195242|
NCT00156260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2-48|Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage|UMCC 2-48 Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage||University of Michigan Cancer Center||Terminated|January 2003|October 2008|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|88|||Female|18 Years|N/A|No|||October 2008|October 4, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156260||195197|
NCT00156559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 03-140|MMR and Varicella Vaccine in Premature Infants|MMR and Varicella Vaccine Responses in Extremely Premature Infants||University of Rochester||Completed|January 2004|May 2005|Actual|||Phase 4|Observational|Time Perspective: Prospective||||32|||Both|12 Months|16 Months|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156559||195174|
NCT00156884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUPPS2|A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer|A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer||AHS Cancer Control Alberta||Completed|August 2003|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Male|18 Years|N/A|No|||August 2008|January 18, 2012|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156884||195151|
NCT00152438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-0088|Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone|Vasomotor Symptoms and Endothelial Function—A Randomized Placebo-controlled Trial of Oral Micronized Progesterone (Prometrium®)||University of British Columbia|No|Active, not recruiting|September 2005|December 2012|Anticipated|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|125|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 20, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152438||195489|
NCT00162682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD042964|Monitoring Highly Active Antiretroviral Therapy in HIV-infected Parents in Thailand|A Phase III, Randomized, Non-inferiority Trial Comparing the Standard Viral Load Based Antiretroviral Monitoring Strategy With a CD4 Based Monitoring Strategy Among Antiretroviral Naive Immunocompromised Adults in Thailand||Institut de Recherche pour le Developpement|Yes|Completed|May 2005|December 2011|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|716|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00162682||194719|
NCT00152984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.301|Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma|A 12-week Randomised, Double Blind, Placebo Controlled, Parallel Group Trial Evaluating the Efficacy and Safety of Inhaled Tiotropium 18μg q.d. in Patients With COPD and a Concomitant Diagnosis of Asthma||Boehringer Ingelheim||Completed|December 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||472|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152984||195447|
NCT00152997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.557|Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome.||Boehringer Ingelheim||Completed|August 2004|||December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|41|||Both|20 Years|80 Years|No|||October 2013|October 30, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00152997||195446|
NCT00153283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTP-0904-GP-0404|Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Gabapentin Efficacy in Asthma Therapy||Centre of Chinese Medicine, Georgia||Completed|September 2003|April 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|16 Years|65 Years|No|||February 2009|February 18, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153283||195424|
NCT00154102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-013|Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)|Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer|CRYSTAL|Merck KGaA|Yes|Completed|May 2004|March 2011|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1221|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|September 8, 2005||No||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00154102||195361|A non-specific outcome measure 'Safety' was deleted from the entry in error. A replacement outcome was created. The outcome refers to adverse events.
NCT00155025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700594|Family History in Prostate Cancer Patients in Taiwan|||National Taiwan University Hospital||Recruiting|May 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||1500|||Male|N/A|N/A|No|||April 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155025||195291|
NCT00155038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700630|Imaging Characteristics of Breast Cancer in Women Under 40 Years of Age|||National Taiwan University Hospital||Recruiting|January 1998|December 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||75|||Female|20 Years|39 Years|No|||May 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155038||195290|
NCT00155350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701129|Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients|Treatment of Coronary Atherosclerosis and Calcification by Insulin Sensitizers in Insulin-Resistant Patients: Evaluated by EBCT, 16-Slice MDCT Coronary Angiography/Scanning, and Intravascular Ultrasound||National Taiwan University Hospital||Recruiting|November 2004|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||August 2005|February 24, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155350||195267|
NCT00154089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-1421 #201|A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia|A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus||Erimos Pharmaceuticals|No|Completed|November 2004|December 2006|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||August 2006|February 20, 2016|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00154089||195362|
NCT00154362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476BES04|The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.|A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents||Novartis||Completed|April 2003|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|50|||Both|6 Years|16 Years|No|||November 2011|November 22, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00154362||195341|
NCT00154375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BDE40|Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma|Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma||Novartis||Completed|October 2004|||August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|70 Years|No|||April 2011|April 19, 2011|September 9, 2005||No||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00154375||195340|
NCT00154986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700500|IGFBP-3 in Ovarian Cancer Invasion|Study of IGFBP-3 in the Ovarian Carcinoma Cell Invasion||National Taiwan University Hospital||Recruiting|August 2004|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||30|||Female|21 Years|80 Years|No|||April 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154986||195294|
NCT00154388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571B2225|Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases|Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases||Novartis||Completed|February 2001|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|15 Years|70 Years|No|||April 2012|April 18, 2012|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00154388||195339|
NCT00155324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701153|Change and Clinical Significance of Plantar Fascia Thickness After ESWT|Change and Clinical Significance of Plantar Fascia Thickness After Extracorporeal Shock Wave Therapy||National Taiwan University Hospital||Completed|October 2004|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|19 Years|N/A|No|||November 2012|November 30, 2012|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155324||195269|
NCT00155337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700753|Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia|Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia||National Taiwan University Hospital||Completed|August 2004|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|20 Years|80 Years|No|||December 2012|December 20, 2012|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155337||195268|
NCT00155688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53ml|A Genetic Linkage Study of Schizophrenia|A Genetic Linkage Study of Schizophrenia||National Taiwan University Hospital||Completed|December 1998|December 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||2400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 1998|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155688||195241|
NCT00155701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100003046|Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia|Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia||National Taiwan University Hospital||Completed|August 2002|July 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2002|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155701||195240|
NCT00155714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100017321|Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension|Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors (Sildenafil and Vadenafil) in Primary and Secondary Pulmonary Hypertension||National Taiwan University Hospital||Withdrawn|November 2002|May 2005|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|12 Years|N/A|No|||January 2010|March 15, 2010|September 9, 2005|||We can't obtained the test drug (Vadenafil) from Bayer. They decided not to carry out this    trail in Taiwan. Therefore this trail has never been started.|No||https://clinicaltrials.gov/show/NCT00155714||195239|
NCT00155727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100017028|Comparison of Laparoscopic Colectomy Versus Open Colectomy for Colorectal Cancer: … A Prospective Randomized Trial|Comparison of Treatment Outcome for Laparoscopic Colectomy Versus Traditional Open Colectomy for the Treatment of Colorectal Cancer: … A Prospective Randomized Clinical Trial||National Taiwan University Hospital||Recruiting|January 2000|July 2005||||Phase 3|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal||||600|||Both|18 Years|80 Years|No|||July 2005|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155727||195238|
NCT00165243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-101|Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer|Tangential Radiation Therapy Without Axillary Dissection in Early-Stage Breast Cancer||Dana-Farber Cancer Institute|No|Active, not recruiting|September 1998|December 2016|Anticipated|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|55 Years|N/A|No|||January 2016|January 26, 2016|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165243||194525|
NCT00156039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-1997-FUP|Randomized Trial of Follow-up Strategies in Breast Cancer|A Randomized Trial of Follow-up Strategies in Breast Cancer||Ontario Clinical Oncology Group (OCOG)|No|Completed|January 1997|June 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|968|||Female|N/A|N/A|No|||July 2009|July 24, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156039||195214|
NCT00156273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2003.075|Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer|A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|April 2005|May 2016|Anticipated|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|36|||Female|18 Years|N/A|No|Probability Sample|women with metastatic breast cancer|August 2015|August 31, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00156273||195196|
NCT00156286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2001-066|Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC|Phase II Trial of Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive, Extensive-Stage Small Cell Lung Cancer||University of Michigan Cancer Center|Yes|Completed|March 2002|April 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||November 2010|November 12, 2010|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156286||195195|
NCT00156572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyponatremia-Diuretics|Management of Hyponatremia in Preterm Infants on Diuretics|Management of Hyponatremia in Preterm Infants on Diuretics||The University of Texas Health Science Center, Houston||Terminated|April 2005|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Both|N/A|6 Months|No|||December 2007|December 26, 2007|September 7, 2005|||decreasing rate of enrollment|No||https://clinicaltrials.gov/show/NCT00156572||195173|
NCT00156897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL-962/175/CL|Efficacy and Safety of ATL-962 in Obese Diabetics|Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat||Alizyme||Completed|December 2004|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|65 Years|No|||August 2006|August 25, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156897||195150|
NCT00156910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-079|A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches|||Allergan||Completed|February 2006|July 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|679|||Both|18 Years|65 Years|No|||October 2013|October 24, 2013|September 7, 2005|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00156910||195149|
NCT00152451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01191|Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures|An Open-Label, Exploratory, Multicenter, Dose-Escalation Study Examining the Efficacy, Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg, 20 mg, 40 mg and 80 mg b.i.d. (Total Daily Dose of 20 to 160 mg) in Adult Subjects (18-65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures (Whether or Not Secondarily Generalized) and Treated With 1, 2 or 3 Approved Antiepileptic Drugs||UCB Pharma||Completed|May 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|18 Years|65 Years||||September 2008|September 30, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152451||195488|
NCT00152464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00309|Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)|The Early Prevention of Asthma in Atopic Children (EPAAC™) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for 18 Months in Preventing the Onset of Asthma in 12 to 24 Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens.||UCB Pharma||Completed|March 2002|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||2500|||Both|12 Months|24 Months||||September 2009|April 9, 2015|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152464||195487|
NCT00152737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 03-01|Objective Evaluation of Proximal Ischemia|Effet Des Gestes de Revascularisation à l'étage Proximal||University Hospital, Angers|Yes|Completed|March 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|165|||Both|18 Years|N/A|No|Non-Probability Sample|patients with claudication|July 2015|July 16, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152737||195466|
NCT00153010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1198.52|An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type|A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type||Boehringer Ingelheim||Completed|February 2003|||March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|430|||Both|40 Years|85 Years|No|||October 2013|October 28, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00153010||195445|
NCT00162968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|escit01|Escitalopram as a Treatment for Pain in Polyneuropathy|Escitalopram as a Treatment for Pain in Polyneuropathy. A Double-Blind, Randomized, Placebo Controlled Trial.||Odense University Hospital||Completed|December 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|20 Years|80 Years|No|||April 2007|April 23, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162968||194697|
NCT00153582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaemaCBFWT102|WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)|Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML||Charite University, Berlin, Germany||Recruiting|April 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||September 2005|February 21, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153582||195401|
NCT00153595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR93-IRB-90|EWO1 in Persistent Allergic Rhinitis Patients|A Double-Blind, Randomized Parallel Group, Placebo-Control Study of EW01 in Persistent Allergic Rhinitis (PAR) Patients||China Medical University Hospital||Recruiting|November 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|12 Years|N/A|No|||September 2005|July 23, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153595||195400|
NCT00153842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0109|A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer|Phase I and II Clinical Studies of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules for the Treatment of Patients With Advanced Non-Small Cell Lung Cancer||Dartmouth-Hitchcock Medical Center|Yes|Terminated|August 2001|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||October 2011|October 19, 2011|September 8, 2005||No|study closed to enrollment 04/07/2005 due to two large phase III trials showing no survival    benefit of combining bexarotene with platinum-based chemotherapy|No||https://clinicaltrials.gov/show/NCT00153842||195381|
NCT00154687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159I3|Weekly TP-HDFL in the Treatment of Advanced TCC|A Phase II Study of Weekly Paclitaxel, Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin(Weekly TP-HDFL) in the Treatment of Advanced Transitional Cell Carcinoma(TCC)||National Taiwan University Hospital|No|Completed|October 2000|December 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2005|July 30, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154687||195316|
NCT00164489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-CCR523273|Health Promotion of People With Disabilities|Intervention Research Grants to Promote the Health of People With Disabilities||Centers for Disease Control and Prevention||Completed|October 2003|June 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164489||194580|
NCT00164502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-CCR322981|Limb Loss Self-Management Program|Limb Loss Self-Management Program: "Promoting Amputee Life Skills"||Centers for Disease Control and Prevention||Completed|October 2003|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Both|18 Years|75 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164502||194579|
NCT00154674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25MD03|Safety and Feasibility of Endovascular Cooling Device in Patients With Hypothermic Cardiopulmonary Resuscitation|||National Taiwan University Hospital||Recruiting|April 2005|October 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|78 Years|No|||January 2004|November 21, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154674||195317|
NCT00154661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152S2|Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis|Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis||National Taiwan University Hospital||Completed|January 2000|June 2001||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|20 Years|60 Years|No|||June 2001|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154661||195318|
NCT00155311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700741|The Regulation of Osteoprotegerin by Mechanical Stimulation|||National Taiwan University Hospital||Completed|January 2005|||December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00155311||195270|
NCT00156624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pac-2|Thunder Trial - Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries|Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries (Thunder – Trial)||University Hospital Tuebingen||Active, not recruiting|July 2004|October 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||135|||Both|18 Years|95 Years|No|||September 2005|April 24, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156624||195169|
NCT00156299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540303|Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate|A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML)||Rutgers, The State University of New Jersey|No|Terminated|March 2003|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|September 8, 2005|No|Yes|Replaced by another study|No||https://clinicaltrials.gov/show/NCT00156299||195194|
NCT00156585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-063|Predictive Value of Dynamic Contrast Enhancement MRI on a Cerebral Tumor Response to Gamma Knife Treatment|Prospective Study of Predictive Value of Dynamic Contrast Enhancement Magnetic Resonance Imaging With Gadolinium on the Response of a Cerebral Tumor to a Treatment With Gamma Knife||Université de Sherbrooke|No|Completed|August 2005|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|oncology clinic|January 2015|January 13, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00156585||195172|
NCT00156598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-0031-006|Metal Ion Serum Concentrations in Patients With Total Hip Replacements|Cobalt, Chromium and Titanium Serum Concentrations in Patients With Metal-on-Metal vs. Metal on Polyethylene Total Hip Replacements||The University of Texas Health Science Center at San Antonio||Terminated|August 2004|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Local surgeon's patients who have had a hip implant.|June 2012|June 28, 2012|September 7, 2005||No|Resident graduated; faculty mentor retired|No||https://clinicaltrials.gov/show/NCT00156598||195171|
NCT00156923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-010|ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults|A Multi-Center Extension of Alkermes' Study ALK21-003-EXT (NCT01218971) to Evaluate the Long-Term Safety of Medisorb® Naltrexone||Alkermes, Inc.|No|Completed|October 2003|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||December 2010|December 7, 2010|September 7, 2005|Yes|Yes||No|October 8, 2010|https://clinicaltrials.gov/show/NCT00156923||195148|
NCT00152477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C79102|A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer|A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer||UCB Pharma||Completed|August 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|N/A|No|||July 2009|September 2, 2011|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00152477||195486|
NCT00153309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-0507|Program Evaluation of People With Arthritis Can Exercise|Evaluation of the Health Benefits of the People With Arthritis Can Exercise Program||Centers for Disease Control and Prevention||Completed|June 2003|June 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||320|||Both|18 Years|N/A|No|||September 2005|November 16, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00153309||195422|
NCT00153608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaemaCBFWT104|WT1 Peptid Vaccination in Carcinomas|Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas||Charite University, Berlin, Germany||Recruiting|April 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||September 2005|February 13, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153608||195399|
NCT00133302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9809|Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)|Randomized Phase III Study of Standard CHOP (S-CHOP) Versus Biweekly CHOP (Bi-CHOP) in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)||Japan Clinical Oncology Group||Terminated|February 1999|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|15 Years|69 Years|No|||August 2006|January 17, 2007|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133302||196937|
NCT00153855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-6-3818|Structural Brain Abnormalities in Children Born Prematurely: New Detection Methods and Clinical-Pathological Correlates|Structural Brain Abnormalities in Children Born Prematurely: New Detection Methods and Clinical-Pathological Correlates||Children's Hospital of Philadelphia||Terminated|January 2005|March 2006||||Phase 3|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||50|||Both|24 Months|27 Months|Accepts Healthy Volunteers|||September 2006|September 6, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153855||195380|
NCT00154115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070178|Levosimendan in High Risk Heart Valve Surgery|Efficacy of Levosimendan in Cardiac Failure After Heart Valve Surgery||Kuopio University Hospital|Yes|Completed|March 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00154115||195360|
NCT00154427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7CARD-1610|Use of Activated Recombinant Human Factor VII in Cardiac Surgery|A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass||Novo Nordisk A/S|No|Terminated|August 2004|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|172|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 9, 2005|Yes|Yes|Trial terminated after recruiting 172 patients but without proceeding to the highest dosing    cohort as this no longer reflects common clinical practice|No||https://clinicaltrials.gov/show/NCT00154427||195336|
NCT00164203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT_FC|The Feelings Club: Evaluating a School-based Intervention for Children at Risk for Depression and Anxiety Disorders|The Feelings Club: Evaluating a School-based Intervention for Children at Risk for Depression and Anxiety Disorders||Centre for Addiction and Mental Health|No|Completed|April 2005|August 2011|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|7 Years|13 Years|No|||August 2011|August 4, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164203||194602|
NCT00164775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA Study|The Efficacy of Imipramine in Treatment of Functional Dyspepsia|The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial||Chinese University of Hong Kong|Yes|Completed|June 2005|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||February 2011|February 18, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164775||194558|
NCT00164463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4222|TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment|TBTC Study 27/28 PK: Pharmacokinetic Issues in the Use of Moxifloxacin for Treatment of Tuberculosis||Centers for Disease Control and Prevention|Yes|Completed|July 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 7, 2011|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00164463||194582|
NCT00164476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-CCR323280|Promoting Clinical Preventive Services Among Adults With Disabilities|Promoting Prevention Among Adults With Disabilities||Centers for Disease Control and Prevention||Completed|October 2003|June 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|18 Years|70 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164476||194581|
NCT00155012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700491|Clinical Application of MDCT in Coronary Artery Disease|Clinical Application of 16-Detector Row Computed Tomography in Coronary Artery Disease||National Taiwan University Hospital||Recruiting|August 2004|August 2006||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||200|||Both|18 Years|N/A|No|||April 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155012||195292|
NCT00164736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-3946|Breastfeeding, Antiretroviral, and Nutrition Study|HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health||Centers for Disease Control and Prevention|Yes|Completed|March 2004|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|2369|||Both|14 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 22, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00164736||194561|
NCT00164749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2003.090-T|A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease|A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease||Chinese University of Hong Kong||Completed|October 2004|July 2006|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|36|||Both|50 Years|N/A|No|||April 2008|April 25, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164749||194560|
NCT00155753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100205245|Genomewide Screening of Pathological Myopia|Genomewide Screening of Pathological Myopia||National Taiwan University Hospital|No|Recruiting|August 2002|August 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|600|Samples With DNA|DNA extracted from blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Taiwanese|April 2010|June 8, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00155753||195236|
NCT00156052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-1993-hypo|Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer|A Randomized Trial of Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer||Ontario Clinical Oncology Group (OCOG)|No|Completed|April 1993|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1234|||Female|N/A|N/A|No|||June 2015|June 3, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156052||195213|
NCT00165490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-012|Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer|Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer||Dana-Farber Cancer Institute|Yes|Completed|August 2004|November 2014|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165490||194507|
NCT00165503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-063|Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate|A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin||Dana-Farber Cancer Institute|Yes|Terminated|April 2004|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|September 12, 2005|Yes|Yes|lack of acurral|No||https://clinicaltrials.gov/show/NCT00165503||194506|
NCT00165906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000300|Thrombin Generation in Neonates|A Pilot Study Examining Thrombin Generation in the Neonatal Population||Emory University|No|Completed|January 2005|January 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|Samples With DNA|A blood sample is obtained to measure the thrombin level.|Both|N/A|30 Days|No|Non-Probability Sample|The study patients will be obtained from Children's Healthcare of Atlanta at Egleston. The        study patients will be in the pre-operative clinic, Cardiac Intensive Care Unit or the        Cardiac Stepdown Unit.|November 2013|November 19, 2013|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00165906||194476|
NCT00156936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-006EXT|ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])|An Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of Medisorb® Naltrexone||Alkermes, Inc.|No|Terminated|August 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||November 2010|November 5, 2010|September 7, 2005|Yes|Yes|Business decision|No|October 8, 2010|https://clinicaltrials.gov/show/NCT00156936||195147|
NCT00156949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040268|EPO Deep Tank in Dialysis Subjects|An Open-Label, Single-Arm Study to Assess the Safety of Epoetin Alfa Manufactured by a Deep Tank Technology in Subjects With Chronic Kidney Disease Receiving Dialysis||Amgen||Completed|April 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|580|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156949||195146|
NCT00152490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87031|A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)|A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease||UCB Pharma||Completed|December 2003|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||604|||Both|18 Years|N/A||||February 2010|September 6, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152490||195485|
NCT00152750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StephensClonidine2005|Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD|Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)||University Health Network, Toronto||Recruiting|September 2006|October 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||October 2006|February 27, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152750||195465|
NCT00153023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.396|1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy|A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study||Boehringer Ingelheim||Completed|April 2003|December 2005||December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||885|||Both|30 Years|80 Years|No|||November 2013|November 12, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00153023||195444|
NCT00162981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13108A|Clobazam in Subjects With Lennox-Gastaut Syndrome|Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome||Lundbeck LLC|Yes|Completed|October 2005|October 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|2 Years|30 Years|No|||January 2012|January 6, 2012|September 9, 2005|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00162981||194696|
NCT00133913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMC-06|Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer|Longitudinal Enumeration of Circulating Tumor Cells in Patients With Metastatic Colorectal Carcinomas|IMMC-06|Immunicon|No|Active, not recruiting|March 2004|January 2009|Anticipated|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|486|||Both|18 Years|N/A|No|Probability Sample|Oncology patients from academic institutions and private practices|March 2008|March 17, 2008|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133913||196890|
NCT00163618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700501|Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children|Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children||Pfizer|No|Completed|June 2005|July 2006|Actual|||Phase 4|Observational|N/A|||||||Both|7 Years|11 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00163618||194647|
NCT00163631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4104|Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis|Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis||Bayside Health||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|70 Years|No|||September 2005|October 3, 2006|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00163631||194646|
NCT00163852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/04|Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis|Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis||Bayside Health||Recruiting|February 2004|February 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163852||194629|
NCT00164515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-R04CCR523275|Increasing Physical Activity Among Overweight Women With Mobility Disabilities.|Personalized Exercise Programme (PEP) I: Physician Referral Approach to Increasing Awareness and Sustainability of Physical Activity for Overweight Adults With Mobility Limitations.|PEP|Centers for Disease Control and Prevention|No|Completed|October 2004|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|75 Years|No|||July 2011|July 27, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00164515||194578|
NCT00165035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSTAR II|Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)|Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries||Cordis Corporation|Yes|Completed|May 2005|July 2011|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1701|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165035||194539|
NCT00164762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4535|Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers|Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi||Centers for Disease Control and Prevention|No|Completed|June 2005|November 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|126|||Female|18 Years|N/A|No|||September 2007|September 27, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164762||194559|
NCT00165009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET|Resolution Endoclips Vs Epinephrine Injection and Heater Probe|A Prospective Randomized Comparison of a Novel Hemostatic Clip (Resolution Clip™) to Combined Epinephrine Injection and Heater Probe Thermocoagulation in the Endoscopic Control of Ulcer Bleeding||Chinese University of Hong Kong|No|Terminated|June 2005|November 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|103|||Both|16 Years|N/A|No|||May 2013|May 10, 2013|September 12, 2005|Yes|Yes|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00165009||194541|
NCT00165256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-151|Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast|Wide Excision Alone for DCIS-Grades 1 and 2||Dana-Farber Cancer Institute|No|Active, not recruiting|May 1995|April 2016|Anticipated|July 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165256||194524|
NCT00165269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-035|Mantle Irradiation for Hodgkin's Disease|Mantle Irradiation for Selected Hodgkin's Disease Patients With Stage IA-IIA Disease||Dana-Farber Cancer Institute||Completed|May 1992|February 2008|Actual|June 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165269||194523|
NCT00164970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-B12|Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia?|Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia?||Chinese University of Hong Kong||Completed|October 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|166|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 2, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164970||194543|
NCT00164996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 2004.312|Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia|Comparison of Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patients With or Without Local Pharyngeal Anaesthesia: A Randomized Controlled Trial||Chinese University of Hong Kong||Completed|September 2004|||September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|70 Years|No|||September 2005|February 16, 2012|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00164996||194542|
NCT00165919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1358-2004|Immune Response to Hepatitis C Virus|Immunologic Determinants of Hepatitis C Virus Infection Resolution or Persistence||Emory University|No|Withdrawn|September 2005|September 2005|Actual|September 2005|Actual|Phase 1|Observational|N/A||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is not a clinical trial, but rather a basic science study using blinded human        specimens.        Individuals with HCV infection will be identified for enrollment into our study by our        clinical collaborators at the Crawford Long Infectious Diseases Clinic-Emory University.        Control individuals with no prior exposure to HCV will be identified and enrolled both        from the Crawford Long clinics and from the investigative donor pool at the Emory Vaccine        Center. Inclusion in the current study will be limited to individuals with HCV genotype 1        infection as well as uninfected normal controls as determined by antibody and viral load        measurements.|November 2013|November 12, 2013|September 9, 2005||No|Not a clinical trial; human specimens from treatment site for basic research.|No||https://clinicaltrials.gov/show/NCT00165919||194475|
NCT00166140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|549-2002|Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.|Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.||Emory University||Completed|December 2002|May 2006|Actual|May 2006|Actual|N/A|Observational|Time Perspective: Prospective||1||125|||Both|N/A|10 Years|No|Probability Sample|Children undergoing elective cardiac surgery requiring the use of cardiopulmonary bypass|November 2013|November 19, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166140||194458|
NCT00166452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|422-05|A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1|Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1||Mayo Clinic||Completed|July 2005|February 2009|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||March 2011|March 22, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00166452||194435|
NCT00162032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIOLITE® 301|A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease|A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of CARDIOLITE® Myocardial Perfusion Imaging in Pediatric Subjects With Kawasaki Disease||Lantheus Medical Imaging|No|Completed|August 2005|December 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|445|||Both|4 Years|16 Years|No|||April 2012|October 8, 2013|September 9, 2005|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00162032||194768|
NCT00162045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DuP 843-201|A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects|A Phase I-II, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of Technetium Tc99m Sestamibi in Pediatric Subjects||Lantheus Medical Imaging|No|Completed|January 2005|June 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|79|||Both|4 Years|16 Years|No|||June 2011|June 1, 2011|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162045||194767|
NCT00162487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19556-HMO-CTIL|Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation|Evaluation of β2 Genetic Polymorphisms and the Effect of Albuterol Inhalation on Potassium and Glucose Plasma Concentration||Hadassah Medical Organization||Recruiting|August 2002|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162487||194734|
NCT00162708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VADN3|Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC|A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma||Gustave Roussy, Cancer Campus, Grand Paris||Completed|July 1996|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|40 Years|75 Years|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162708||194717|
NCT00162994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K53715|Prevention Recurrent Otitis Media in the Young Children|Effect of Adenotomy and Tympanostomy on Preventing Recurrent Otitis Media in the Young Children||Oulu University Hospital||Active, not recruiting|February 2002|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|10 Months|24 Months|No|||February 2002|December 20, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00162994||194695|
NCT00163644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/02|RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT|Randomised Controlled Trial to Investigate the Effects of an Exercise Programme on Physical Performance and Quality of Life After a Bone Marrow Transplant||Bayside Health||Active, not recruiting|November 2003|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00163644||194645|
NCT00163865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA 46/05|A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents|A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents||Bayside Health|No|Completed|May 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|71|||Both|13 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents|September 2005|November 25, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00163865||194628|
NCT00164216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4476|Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru|Evaluation of the Efficacy and Effectiveness of Combined Therapy With Mefloquine and Artesunate for Uncomplicated Malaria Treatment in the Loreto Region (Amazon Basin), Peru||Centers for Disease Control and Prevention||Completed|March 2005|March 2008|Actual|March 2008|Actual|Phase 4|Observational|Time Perspective: Prospective|||Actual|208|||Both|1 Year|N/A|No|||September 2012|September 10, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164216||194601|
NCT00164788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ne_pH|A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole|A Randomized Comparison of High Dose Oral to Intravenous Esomeprazole in Patients After Endoscopic Control to Their Bleeding Peptic Ulcers: an Intra-gastric pH Study.||Chinese University of Hong Kong|No|Terminated|July 2004|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|80 Years|No|||August 2012|August 27, 2012|September 9, 2005||No|No suitable patients and many patients refused the study|No||https://clinicaltrials.gov/show/NCT00164788||194557|
NCT00165048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2001.462-T|Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial|Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial||Chinese University of Hong Kong||Active, not recruiting|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||206|||Both|18 Years|80 Years|No|||September 2005|December 8, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165048||194538|
NCT00165022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GQOL|Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population|Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population||Chinese University of Hong Kong||Completed|September 2003|October 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|330|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165022||194540|
NCT00165282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005285|Mindfulness Meditation in Bone Marrow Transplantation|Mindfulness Meditation in Bone Marrow Transplantation||Emory University|Yes|Completed|April 2005|June 2011|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|241|||Both|21 Years|N/A|No|||November 2013|November 26, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165282||194522|
NCT00165932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|417-2004|Ventricular Synchrony in Pediatric Patients|A Single Center Prospective, Pilot Study Examining the Non-invasive Evaluation of Ventricular Synchrony in Pediatric Patients||Emory University|No|Completed|June 2004|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|145|||Both|N/A|N/A|No|Non-Probability Sample|We are currently only enrolling those patients with the diagnosis of SVT who are scheduled        for an electrophysical study at Children's Healthcare of Atlanta Egleston Campus.|May 2012|May 30, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165932||194474|
NCT00165945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-2004|4-D Visualization Using Magnetic Resonance Imaging (MRI) in the Congenital Heart Disease Population|Using 4-D Visualization Software With Magnetic Resonance Images in the Congenital Heart Disease Population||Emory University|No|Completed|June 2004|March 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|500|||Both|N/A|N/A|No|Non-Probability Sample|Pediatrics patients in all age groups evaluated with MRI for complex congenital        cardiovascular lesions and associated hemodynamics. These are patients coming in for        standard of care cardiac MRI's|March 2012|March 30, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00165945||194473|
NCT00166192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024850|Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid|Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid: A Comparison of Clinical Efficacy||Emory University|Yes|Completed|January 2008|November 2013|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166192||194454|
NCT00166153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0685-2002|Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept|The Relationships Between Mycophenolic Acid Levels, T-Cell Subsets and Outcomes in Pediatric Heat Transplant Recipients Receiving Mycophenolate Mofetil (Cellcept)||Emory University||Terminated|January 2003|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|18 Years|No|||November 2013|November 19, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166153||194457|
NCT00166166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021886|Endothelial Hyperpolarization in Humans|Physiology and Pathologic Role of Endothelium-Derived Hyperpolarizing Factor in Humans||Emory University|No|Terminated|July 2002|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|174|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|September 13, 2005|Yes|Yes|Limited clinical staff|No|May 8, 2015|https://clinicaltrials.gov/show/NCT00166166||194456|Findings are limited to the forearm microcirculations, thus other vascular beds including conductance arteries warrant further investigation. Nevertheless, it is known that the contribution of EDHF is less in conductance vessels than in microvessels.
NCT00166179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000292|Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI|Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI||Emory University|No|Completed|November 2003|October 2006|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Both|18 Years|95 Years|No|Non-Probability Sample|Age > 25 yrs, mean + SD = 60.3 + 10.2, 83% male, are patients referred by cardiologist or        cardiac surgeon for assessment of myocardial viability by PET FDG.|September 2014|September 25, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00166179||194455|
NCT00166478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2297-01|Exisulind Prior to Radical Prostatectomy|A Prospective Controlled Phase II Study of Preoperative Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis||Mayo Clinic||Completed|April 2002|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|130|||Male|40 Years|N/A|No|||January 2010|January 26, 2010|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00166478||194433|
NCT00162097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-917|Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment|Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects With Hepatic Impairment.||Bristol-Myers Squibb|No|Completed|November 2004|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Both|18 Years|N/A|No|||September 2010|September 7, 2010|September 9, 2005|No|Yes||No|July 28, 2010|https://clinicaltrials.gov/show/NCT00162097||194763|The study was terminated early leading to a small number of participants treated and analyzed. Due to the small sample size, no conclusion could be made for participants with Child-Pugh scores B and C (moderate and severe hepatic impairment).
NCT00166465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0248|Stage IV Colorectal CA ALIMTA|A Phase I Dose-Finding Study and a Randomized Phase II Study of ALIMTA Plus Oxaliplatin Versus Oxaliplatin Plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) in the First-Line Treatment of Patients With Locally Advanced Unresectable or Stage IV Colorectal Cancer||Mayo Clinic|Yes|Completed|August 2003|June 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||March 2011|March 11, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166465||194434|
NCT00162058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMP 115-214|A Phase II Study of DMP 115 to Assess Focal Liver Lesions|An Open-Label, Non-Randomized, Phase II Trial To Assess Focal Liver Lesion Detection Using Definity-Enhanced Ultrasound Imaging||Lantheus Medical Imaging||Completed|March 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||80|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162058||194766|
NCT00162071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS068645-203|A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging|"A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration||Forest Laboratories||Terminated|July 2005|||March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Both|18 Years|N/A|No|||April 2008|January 18, 2011|September 9, 2005|No|Yes|Sponsor decided not to continue with the development program|No||https://clinicaltrials.gov/show/NCT00162071||194765|
NCT00162084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS068645-302|A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography|A Phase 3, Parallel, Double Blind, Multicenter Trial to Examine Inducible Myocardial Perfusion Abnormality Detection With BMS068645 and Adenosine Stress SPECT Compared to Coronary Angiography||Forest Laboratories||Terminated|April 2005|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||2000|||Both|18 Years|N/A|No|||April 2008|January 18, 2011|September 9, 2005|||Business decision to stop the program|No||https://clinicaltrials.gov/show/NCT00162084||194764|
NCT00162500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191203-HMO-CTIL|A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies|A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies||Hadassah Medical Organization||Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||September 2005|November 9, 2010|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162500||194733|
NCT00162721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC-GYN1|The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas|Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas||Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|September 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Female|18 Years|65 Years|No|||August 2007|August 9, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162721||194716|
NCT00163657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-01-L|Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection|An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among Three Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection||Baylor Research Institute||Active, not recruiting|July 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||312|||Both|18 Years|N/A|No|||October 2009|October 14, 2009|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00163657||194644|
NCT00163670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98/05|The Impact of Sleep Disorders on Motor Vehicle Accidents|The Impact of Sleep Disorders on Motor Vehicle Accidents||Bayside Health|No|Completed|September 2005|July 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A||||September 2005|December 4, 2013|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00163670||194643|
NCT00163878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4468|Is Sensory Stimulation Effective in Reducing Time Spent in a Coma or Vegetative State|A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment||Bayside Health||Recruiting|November 2004|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||August 2005|October 3, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163878||194627|
NCT00164229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-3721|Fetal Alcohol Syndrome: Socio-Cognitive Habilitation|Study to Investigate the Effectiveness of a Math Intervention for Children With Fetal Alcohol Syndrome or Related Condition||Centers for Disease Control and Prevention||Completed|October 2001|January 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||100|||Both|42 Months|81 Months|Accepts Healthy Volunteers|||September 2005|April 25, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164229||194600|
NCT00164242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00347|Treatment of Tardive Dyskinesia With Galantamine|Treatment of Tardive Dyskinesia With Galantamine||Caroff, Stanley N., M.D.||Completed|January 2002|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164242||194599|
NCT00164528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-3752|Intervening With Children/Adolescents With FAS/ARND|Intervening With Children/Adolescents With FAS/ARND||Centers for Disease Control and Prevention||Completed|October 2001|June 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||52|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164528||194577|
NCT00164814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPA study|The Role of Visceral Hyperalgesia, Gastroesophageal Reflux Disease (GERD) and Esophageal Motility Disorder (EMD) in NCCP Patients|Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pian in Chinese? Part I: The Role of Visceral Hyperalgesia, Gastroesophageal Reflux Disease (GERD) and Esophageal Motility Disorder (EMD) in NCCP Patients||Chinese University of Hong Kong||Terminated||||||N/A|Observational|Time Perspective: Prospective|||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2008|March 25, 2008|September 9, 2005|||Funding ended|No||https://clinicaltrials.gov/show/NCT00164814||194555|
NCT00156403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505070|A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis|Hereditary Pancreatitis Amlodipine Trial(H-PAT): A Pilot Study||University of Pittsburgh||Completed|August 2005|December 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|6 Years|N/A|No|||December 2007|December 13, 2007|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00156403||195186|
NCT00156689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050465|A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.|A Pilot Study in a Double Blind, Randomized, Placebo-Controlled, Parallel-Group, 16 Week, Trial Design Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (>18 Years of Ages) Suffering From Chronic Idiopathic Axonal Polyneuropathy||Vanderbilt University|No|Completed|August 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||January 2008|January 2, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156689||195164|
NCT00165295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-087|Sildenafil Citrate in Waldenstrom's Macroglobulinemia|Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute||Completed|September 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2011|June 23, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165295||194521|
NCT00165555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-124|Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma|Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin and Intravenous Sodium Thiosulfate in the Multimodality Treatment of Malignant Pleural Mesothelioma||Dana-Farber Cancer Institute|Yes|Completed|August 1999|November 2009|Actual|April 2002|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165555||194503|
NCT00166218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0793-2003|NIRS Monitoring in the Ambulatory Single Ventricle Patient|Evaluation of Near-infrared Spectroscopy for Non-invasive Monitoring of the Ambulatory Single Ventricle Patient||Emory University||Terminated|February 2004|February 2005||||N/A|Observational|Time Perspective: Prospective||||30|||Both|N/A|N/A|No|||November 2013|November 26, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00166218||194452|
NCT00166504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-092|Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)|A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|October 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|September 9, 2005|Yes|Yes||No|October 13, 2008|https://clinicaltrials.gov/show/NCT00166504||194431|
NCT00166205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-02-0006|Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity|A Single-Arm, Multi-Center Study of the Safety and Effectiveness of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity||Ethicon Endo-Surgery|No|Completed|June 2003|December 2006|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|276|||Both|18 Years|60 Years|No|||August 2015|August 3, 2015|September 9, 2005|Yes|Yes||No|October 21, 2008|https://clinicaltrials.gov/show/NCT00166205||194453|
NCT00166517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-013|V260 Registration Study (V260-013)(COMPLETED)|Immunogenicity and Safety of V260 in Healthy Infants in Korea||Merck Sharp & Dohme Corp.||Completed|August 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|178|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||March 2015|March 12, 2015|September 9, 2005|Yes|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00166517||194430|
NCT00166491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-05|Comparing Two Ways of Controlling Blood Sugar With Insulin in Patients Admitted to the Intensive Care Unit|Comparison of Two Approved Insulin Infusion Protocols for Glycemic Control in Critically Ill Patients||Mayo Clinic||Completed|July 2005|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|238|||Both|21 Years|N/A|No|||April 2011|April 15, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166491||194432|
NCT00162110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-063|A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces|A Phase II Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces||Eli Lilly and Company||Completed|November 2004|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162110||194762|
NCT00162513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191199-HMO-CTIL|Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia|Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia||Hadassah Medical Organization||Withdrawn|December 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|55 Years|N/A|No|||September 2006|April 27, 2011|September 11, 2005|||PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00162513||194732|
NCT00162734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRHC-002|Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy|A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa Plus Ribavirin Therapy and During at Least 24 Weeks of No Treatment in IRHC-001||Valeant Pharmaceuticals International, Inc.||Completed|February 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162734||194715|
NCT00163007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297|Nutritional Therapy for Stroke Patients|Nutritional Therapy for Patients With Acute Stroke and With Poor Nutritional Status or at Risk of Poor Nutritional Status||Ostfold Hospital Trust||Completed|May 2005|June 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|125|||Both|18 Years|N/A|No|||May 2009|May 8, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00163007||194694|
NCT00163332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-129|Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)|Comparison of Inhaled Ciclesonide (160 Mcg b.i.d. or 320 Mcg b.i.d.) and Fluticasone Propionate (250 Mcg b.i.d. or 500 Mcg b.i.d.) in Pretreated Patients With Mild to Moderate Asthma||Takeda||Completed|March 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163332||194669|
NCT00163683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A33420|Effects of a Mediterranean Style Diet on Vascular Health in Type 2 Diabetes|The Effect of a Mediterranean Style Diet Versus a Conventional High Carbohydrate, Low Fat Diet on Glycaemic and Lipid Control and on Vascular Inflammatory Markers in People With Newly Diagnosed Type 2 Diabetes||Bayside Health|No|Completed|January 2003|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|24|||Both|30 Years|75 Years|No|||September 2005|December 3, 2013|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00163683||194642|
NCT00163891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107/03|Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients|A Prospective Randomised Two Month Trial Comparing Twho Chest Physiotherapy Protocols in Lung Transplant Recipients||Bayside Health||Completed|September 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|16 Years|65 Years|No|||September 2005|October 3, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163891||194626|
NCT00164255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3807|Efficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy|Efficacy of Intermittent Sulfadoxine-Pyrimethamine and Sulfadoxine-Pyrimethamine + Artesunate Treatment in the Prevention of Malaria in Pregnancy in an Area With Chloroquine-Resistant Plasmodium Falciparum||Centers for Disease Control and Prevention|No|Completed|January 2003|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|1614|||Female|15 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164255||194598|
NCT00164268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-11249|Ke Ala Lokahi Demonstration Project for Sexual and Domestic Violence Prevention|Ke Ala Lokahi Demonstration Project for the Early Intervention and Prevention of Sexual and Domestic Violence Among Racial and Ethnic Populations||Centers for Disease Control and Prevention|No|Completed|October 2002|August 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 6, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164268||194597|
NCT00164541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3292|An Arts-Based Initiative for the Prevention of Violence Against Women and Girls|An Arts-Based Initiative for the Prevention of Violence Against Women and Girls||Centers for Disease Control and Prevention|No|Completed|September 2004|September 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|1440|||Both|11 Years|14 Years|No|||September 2007|September 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164541||194576|
NCT00164801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB study|Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?|Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients||Chinese University of Hong Kong||Terminated|November 2004|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|70 Years||||March 2008|March 25, 2008|September 9, 2005|||Funding ended|No||https://clinicaltrials.gov/show/NCT00164801||194556|
NCT00156117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05933|Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)|A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia||Merck Sharp & Dohme Corp.|Yes|Completed|May 2005|May 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|417|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156117||195208|
NCT00156390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0504006|Predictors of Response to Biventricular Pacing in Heart Failure|Predictors of Response to Biventricular Pacing in Heart Failure||University of Pittsburgh|No|Completed|June 2005|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|September 8, 2005||No||No|May 21, 2014|https://clinicaltrials.gov/show/NCT00156390||195187|
NCT00156715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16563|Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder|Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia||Dartmouth-Hitchcock Medical Center|Yes|Completed|March 2004|October 2008|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|65 Years|No|||February 2012|February 16, 2012|September 6, 2005||No||No|November 19, 2010|https://clinicaltrials.gov/show/NCT00156715||195162|Lack of a control group; Small study group size, and the consequent lack of power to detect a significant change; Differences between the populations at the two sites.
NCT00156728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 228|Study to Characterize Atrial Fibrillation in CHF Patients Indicated for CRT|Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)||Medtronic BRC||Completed|October 2003|December 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1|||172|||Both|18 Years|N/A|No|||November 2008|November 3, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156728||195161|
NCT00165308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-253|Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors|A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors||Dana-Farber Cancer Institute|Yes|Completed|April 2001|June 2009|Actual|March 2004|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Female|18 Years|35 Years|No|||July 2014|July 8, 2014|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00165308||194520|
NCT00152581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/0277|Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication|Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication||University College London Hospitals||Completed|April 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||September 2005|November 29, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152581||195478|
NCT00165516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-302|Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate|A Phase II Feasibility Study of Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate||Dana-Farber Cancer Institute|Yes|Completed|January 2004|December 2009|Actual|July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165516||194505|
NCT00165542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-137|A-Protein Levels in Adult and Pediatric Brain Tumor Patients|Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients||Dana-Farber Cancer Institute|No|Active, not recruiting|June 1998|February 2010|Anticipated|February 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|180|Samples With DNA|whole blood cerebrospinal fluid|Both|N/A|77 Years|No|Non-Probability Sample|Patients will be identified at the time of presentation to their neurologist, neurosurgeon        or oncologist|December 2007|December 21, 2007|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00165542||194504|
NCT00153127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851-17|Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications|Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications||Braintree Laboratories||Completed|November 2001|||September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||100|||Both|19 Years|N/A||||February 2013|February 6, 2013|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00153127||195436|
NCT00153140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851-ZCC|Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation|Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation||Braintree Laboratories||Completed|July 2004|||October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||239|||Both|18 Years|64 Years||||February 2013|February 6, 2013|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00153140||195435|
NCT00153153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851-CR1|Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients|Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients||Braintree Laboratories||Completed|August 2003|||December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A||||February 2013|February 6, 2013|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00153153||195434|
NCT00162149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-137|ATV/Ritonavir Nevirapine Interaction (USPAC)|Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Nevirapine on the Pharmacokinetics of Atazanavir in HIV-Infected Individuals||Bristol-Myers Squibb||Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4|||46|||Both|18 Years|55 Years|No|||June 2008|April 7, 2011|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00162149||194759|
NCT00162175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-021|PPAR-COMBO With Sulfonylurea|A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone||Bristol-Myers Squibb||Completed|July 2003|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||534|||Both|18 Years|70 Years|No|||September 2007|September 10, 2010|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00162175||194758|
NCT00162123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-025|A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies|A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.||Bristol-Myers Squibb|Yes|Completed|May 2006|April 2014|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|248|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|September 9, 2005|Yes|Yes||No|December 31, 2013|https://clinicaltrials.gov/show/NCT00162123||194761|Significant heterogeneity existed between patients, who rolled over from 6 studies assessing ipilimumab in different doses and combinations. Since not all eligible patients from parent studies were enrolled, some selection bias existed.
NCT00162136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-085|Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.|Phase I Study of Ixabepilone Administered as a 24-Hour Infusion in Patients With Advanced Solid Malignancies||R-Pharm|No|Completed|September 2005|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 9, 2005|No|Yes||No|July 3, 2009|https://clinicaltrials.gov/show/NCT00162136||194760|
NCT00162526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270505-HMO-CTIL|Tocopherol is a Novel Treatment for Cancer Related Mucositis|A Randomized Double Blind Placebo Controlled Clinical Trial Aim to Assess the Efficacy of Vitamin E Formulation (Tocopherol) in the Treatment of Chemotherapy Induced Stomatitis in Patients Undergoing Stem Cell Transplantation||Hadassah Medical Organization||Withdrawn|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||September 2005|April 7, 2011|September 11, 2005|||the PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00162526||194731|
NCT00162747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-04-21-03-2|Topical Therapy for Prevention of Infections in Preterm Infants|Topical Emollient Therapy for Prevention of Infections in Preterm Infants||Johns Hopkins Bloomberg School of Public Health||Completed|December 2001|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||600|||Both|7 Months|8 Months|Accepts Healthy Volunteers|||June 2005|September 11, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00162747||194714|
NCT00163020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0003|17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies|17-Alpha-Hydroxyprogesterone Caproate for Reduction of Neonatal Morbidity Due to Preterm Birth in Twin and Triplet Pregnancies - A Concurrent Randomized Double-blinded Clinical Trial|170HP|Mednax Center for Research, Education and Quality|Yes|Completed|November 2004|August 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|321|||Female|18 Years|65 Years|No|||October 2012|November 4, 2015|September 9, 2005|Yes|Yes||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00163020||194693|
NCT00163345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-131|Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)|Evaluation of Parameters of the Small Airways and Their Changes Under Treatment With Ciclesonide (320 Mcg Once Daily) Versus Placebo in Patients With Asthma||Takeda||Completed|September 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163345||194668|
NCT00154752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100013841|Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer|A Randomized Trial Comparing Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer||National Taiwan University Hospital||Recruiting|January 1999|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|75 Years|No|||January 1999|November 21, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154752||195311|
NCT00155116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701095|SERPIN D1 and Its Role in Lung Cancer Invasion and Metastasis|||National Taiwan University Hospital||Recruiting|October 2004|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|18 Years|N/A|No|||October 2004|November 22, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155116||195284|
NCT00155454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700621|Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy|Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy||National Taiwan University Hospital|Yes|Completed|September 2004|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|N/A|N/A|No|||December 2012|December 26, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00155454||195259|
NCT00155467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700815|Establish a CT Images Database of Patients With Congenital Heart Disease|Establish a CT Images Database of Patients With Congenital Heart Disease||National Taiwan University Hospital||Recruiting|January 1995|December 2010||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||5000|||Both|N/A|18 Years|No|||January 1995|October 19, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155467||195258|
NCT00155831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100208567|Neural Development and Its Influencing Factors in Premature Infants With Chronic Lung Disease|||National Taiwan University Hospital|Yes|Completed|August 2003|March 2007|Actual|March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|N/A|7 Days|No|Non-Probability Sample|premature infants with chronic lung disease(CLD) and 60 premature infants without CLD from        National Taiwan University Hospital and MacKay Memorial Hospital|March 2010|March 29, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00155831||195230|
NCT00156416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21CA106336-01A1|Menopause and Meditation for Breast Cancer Survivors|Menopause and Meditation for Breast Cancer Survivors||University of Pittsburgh|Yes|Completed|February 2005|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|51|||Female|30 Years|70 Years|No|||December 2014|December 2, 2014|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00156416||195185|
NCT00140062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|912-OPT-0091-156|Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.|A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension||Pfizer||Completed|February 2002|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||329|||Both|18 Years|N/A|No|||April 2008|April 4, 2008|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00140062||196424|
NCT00140309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3716|TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment|TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium||Centers for Disease Control and Prevention|Yes|Completed|July 2003|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||March 2007|March 16, 2007|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140309||196406|
NCT00140322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3954|Dane County Safety Assessment (SAFE) Research Study|Dane County Safety Assessment for Elders (SAFE) Research Study||Centers for Disease Control and Prevention|No|Completed|October 2002|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||455|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140322||196405|
NCT00140556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008840|Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer|Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer||Duke University|No|Completed|August 2005|April 2010|Actual|May 2009|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|August 29, 2005|No|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00140556||196387|
NCT00141635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUZ-QL-IP-03|Implementation of Quality of Life Diagnostics and Therapy|Enhancing the Status of Quality of Life Diagnostics in Caring for Breast Cancer Patients: Results From a Multilevel Implementation Study in a Regional Tumor Centre||Tumorzentrum Regensburg e.V.||Completed|December 2002|June 2004||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||190|||Female|18 Years|N/A|No|||August 2005|August 31, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141635||196305|
NCT00138723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP584|Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome|A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome||Pfizer||Completed|October 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||March 2008|April 9, 2008|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00138723||196524|
NCT00138411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-096|Monoclonal Antibody for Treatment of Inhalation Anthrax|Randomized, Placebo-Controlled, Double Blind, Dose-Escalation Phase I Study of the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 [Anthim(TM)] and Its Potential Interaction With Ciprofloxacin||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2005|March 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2006|August 26, 2010|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00138411||196548|
NCT00138424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-047|Cidofovir in Renal Transplant Recipients With BKVN|A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|May 2006|April 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||April 2011|February 28, 2013|August 26, 2005|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00138424||196547|The study closed early due to failure to enroll in a timely manner.
NCT00138710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-323-150405|Short-term Effects of Aromatase Inhibition in Obese Men|Short-term Effects of Aromatase Inhibition in Obese Men||Rijnstate Hospital||Completed|August 2005|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Male|20 Years|50 Years|No|||October 2010|October 21, 2010|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138710||196525|
NCT00139750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051046|12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation|A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking||Pfizer||Completed|December 2004|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|20 Years|75 Years|No|||June 2007|June 1, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139750||196448|
NCT00137852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-229|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer|Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer||Dana-Farber Cancer Institute||Active, not recruiting|January 2002|December 2014|Anticipated|November 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137852||196590|
NCT00137618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-2507|Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening|Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Univ of Texas - SIP 21-04||Centers for Disease Control and Prevention||Completed|November 2004|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|264|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||March 2010|March 16, 2010|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137618||196608|
NCT00137865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGEN-001-101|Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer|A Phase 1, Open Label, Dose Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intraperitoneal EGEN-001 in Patients With Recurrent Epithelial Ovarian Cancer||EGEN, Inc.||Terminated|August 2005|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|19 Years|N/A|No|||February 2013|February 27, 2013|August 26, 2005|No|Yes|Sponsor decided to terminate the study early so they could begin a second dose-escalation    study of EGEN-001 in combination with standard chemotherapy.|No||https://clinicaltrials.gov/show/NCT00137865||196589|
NCT00138125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439421|Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer|Phase II Randomized Trial of Faslodex and Herceptin, Alone and Combined, in the First - Line Treatment of Hormone Receptor-Positive, HER-2/Neu-Overexpressing Metastatic Breast Cancer||Translational Oncology Research International|Yes|Terminated|April 2005|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||January 2013|January 28, 2016|August 29, 2005|Yes|Yes|Due to low accrual|No|January 8, 2013|https://clinicaltrials.gov/show/NCT00138125||196569|Trial terminated due to slow patient accrual.Study closed with two subjects enrolled to treatment phase.Slow accrual was due to specific requirements of study population limiting enrollment and possibly due to availability of study drugs in clinic.
NCT00135057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3502|Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin|Insulin Glulisine Administered in a Fixed Bolus Regimen Versus Variable Bolus Regimen Based on Carbohydrate Counting in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin||Sanofi||Completed|April 2004|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||281|||Both|18 Years|70 Years|No|||January 2011|January 10, 2011|August 23, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00135057||196804|
NCT00135304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050102|ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism|ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone||Amgen||Completed|August 2005|December 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135304||196785|
NCT00134784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elldopa|Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression|[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease|ELLDOPA|Institute for Neurodegenerative Disorders|No|Completed|April 2000|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|142|||Both|22 Years|N/A|No|||July 2014|July 15, 2014|August 23, 2005|Yes|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00134784||196824|
NCT00135317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040156|AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies|A Randomized Open-Label Study of Darbepoetin Alfa Administered Every Three Weeks With or Without Parenteral Iron in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy||Amgen||Completed|November 2004|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2013|May 21, 2013|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135317||196784|
NCT00140335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4427|Evaluation of a Handwashing Promotion Program in Chinese Elementary Schools|Evaluation of a Handwashing Promotion Program in Chinese Elementary Schools||Centers for Disease Control and Prevention|Yes|Completed|December 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||5000|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||March 2010|March 8, 2010|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140335||196404|
NCT00140348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-0010|Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine|A Phase I/II Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer||Cell Genesys||Completed|December 2001|April 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Male|18 Years|N/A|No|||December 2007|December 18, 2007|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00140348||196403|
NCT00135603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020915|Antibiotic Therapy Versus Appendectomy for Acute Appendicitis|A Prospective Randomized Multicentric Trial Comparing Amoxicillin/Clavulanate Potassium Therapy to Appendectomy for Acute Non Complicated Appendicitis||Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2004|December 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|N/A|No|||January 2009|February 11, 2009|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135603||196762|
NCT00140049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641038|A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma|A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension.||Pfizer||Completed|July 2005|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||238|||Both|18 Years|N/A|No|||November 2007|November 29, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00140049||196425|
NCT00140842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002191|Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents|Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents||Massachusetts General Hospital|No|Completed|May 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|47|Samples Without DNA|Serum and urine collected|Female|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese and normal-weight girls between 12-18 years old|September 2011|October 3, 2011|August 30, 2005||No||No|March 3, 2011|https://clinicaltrials.gov/show/NCT00140842||196366|Limited number of participants-pilot study
NCT00141206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051028|A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation||Pfizer||Completed|May 2003|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1005|||Both|18 Years|75 Years|No|||June 2007|June 1, 2007|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141206||196338|
NCT00141219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081037|Pregabalin Peripheral Neuropathic Pain Study|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Peripheral Neuropathic Pain||Pfizer|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|August 30, 2005|Yes|Yes||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00141219||196337|
NCT00142181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-079|Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia|Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)||Dana-Farber Cancer Institute||Completed|March 2003|June 2008|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|80 Years|No|||December 2012|December 19, 2012|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142181||196264|
NCT00142428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-347|Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma|A Phase II Study of Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma||Massachusetts General Hospital|Yes|Completed|January 2005|October 2008|Actual|October 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2014|March 16, 2014|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142428||196245|
NCT00142441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63/2003|Effect of Pulse Width on Scar Treatment Using a 595-Nm Pulsed Dye Laser|Effect of Pulse Width of a 595-Nm Flashlamp-Pumped Pulsed-Dye Laser on the Treatment Response of Keloidal and Hypertrophic Sternotomy Scars||Mahidol University||Completed|June 2003|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||19|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2003|September 1, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142441||196244|
NCT00142610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AT002620-02|The Role of Vitamins E and C in Maintaining Lung Health in People With Asthma|Effect of Alpha Tocopherol and Ascorbate Supplementation on Airway Antioxidant Levels in Allergic Asthmatics|VITAS|University of North Carolina, Chapel Hill|Yes|Completed|August 2005|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|50 Years|No|||February 2013|March 1, 2013|September 1, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00142610||196231|
NCT00142623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|249|Tailored Videos to Reduce Tobacco Smoke Exposure Among Pregnant Women and Newborns|Reducing ETS Exposure of Pregnant Women and Newborns|ETS|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|February 2006|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|650|||Female|16 Years|N/A|No|||July 2008|July 29, 2008|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00142623||196230|
NCT00142948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18863|Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts|Heroin Addiction Treatment: Naltrexone and Adrenergic Agents||Baylor College of Medicine|Yes|Completed|February 2006|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|40 Years|No|||October 2012|October 22, 2012|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142948||196206|
NCT00142909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18219-1|Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1|Lofexidine: Enhancing Naltrexone Treatment for Opiate Addiction||Yale University|Yes|Completed|February 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|September 1, 2005|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00142909||196209|
NCT00142922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 60115 (completed)|Breaking Down Barriers to Diabetes Self-Care|Breaking Down Barriers to Diabetes Self-Care||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2002|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3|||222|||Both|18 Years|75 Years|No|||March 2010|March 1, 2010|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00142922||196208|
NCT00139282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-1256F-301|A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration|A Phase 3, Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration||Genaera Corporation||Terminated|June 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||November 2007|November 27, 2007|August 29, 2005||||||https://clinicaltrials.gov/show/NCT00139282||196481|
NCT00139295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVS00103|Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee|Comparison of the Efficacy and Safety of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee||Sanofi||Completed|October 2004|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|N/A|No|||February 2014|February 4, 2014|August 29, 2005||||||https://clinicaltrials.gov/show/NCT00139295||196480|
NCT00139763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171066|US Inhaled Insulin Therapeutic Choice Questionnaire Study|A US Randomized Questionnaire-Based Trial Assessing The Impact Of The Availability Of Inhaled Insulin On Therapeutic Choice In Patients With Suboptimally Controlled Type 2 Diabetes||Pfizer||Completed|July 2005|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||740|||Both|18 Years|80 Years|No|||March 2007|March 15, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139763||196447|
NCT00139022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB# 04-91|Home Diagnosis and Treatment of Obstructive Sleep Apnea|Can Obstructive Sleep Apnea be Diagnosed at Home? A Randomised Trial of Home vs.in-Lab Diagnosis and Treatment of OSA.||University of Saskatchewan||Completed|November 2004|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||February 2007|October 4, 2007|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00139022||196501|
NCT00138151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000433516|Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer|A Phase II Trial of Chemosensitization With Paclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma||Rutgers, The State University of New Jersey|No|Terminated|March 2001|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||September 2013|September 17, 2013|August 29, 2005|Yes|Yes|Slow accrual and lack of study drug|No|September 17, 2013|https://clinicaltrials.gov/show/NCT00138151||196567|
NCT00143234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841024|Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels|Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia|GEMINI-AALA|Pfizer||Completed|May 2004|July 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1825|||Both|18 Years|80 Years|No|||April 2015|April 21, 2015|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00143234||196184|
NCT00134810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-47-52120-722|Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome|A Phase II Multicentre Multinational Prospective Randomised Double-Blind Placebo-Controlled Study Assessing the Efficacy and Safety of a Single Application of Three Doses of Dysport® in Patients With Upper Back Myofascial Pain Syndrome||Ipsen||Completed|March 2005|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||340|||Both|18 Years|N/A|No|||January 2007|January 9, 2007|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00134810||196822|
NCT00135044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taurine05|A Trial of Taurine Supplementation in Parenteral Nutrition 1|A Randomised Double Blind Controlled Crossover Trial of Intravenous Taurine Supplementation in Parenteral Nutrition as an Effective Treatment for Reducing Hepatobiliary Complications in Chronic Intestinal Failure||London North West Healthcare NHS Trust||Recruiting|June 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2007|September 21, 2007|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135044||196805|
NCT00134823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002027|Improving Pediatric Safety and Quality With Health Care Information Technology|Improving Pediatric Safety and Quality With Health Care IT||Massachusetts General Hospital|No|Completed|March 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|5420|||Both|N/A|N/A|No|||July 2011|July 20, 2011|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134823||196821|
NCT00135070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.P.I.1|Hospital In-Patient Insulin Study|A Randomised Study Comparing Continuous Intravenous Insulin Infusion With Subcutaneous Insulin Analogues in Hospitalised Patients With Type II Diabetes and Hyperglycaemia||The Royal Bournemouth Hospital|Yes|Terminated|July 2005|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||April 2007|April 27, 2007|August 23, 2005|||No documentation with MHRA to support clinical trial of a medicinal product.|No||https://clinicaltrials.gov/show/NCT00135070||196803|
NCT00135590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO30418|Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients|Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients|PRO-PULSé|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2004|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|70 Years|N/A|No|||November 2004|November 20, 2007|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135590||196763|
NCT00135083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3511|Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus|One Versus Two Versus Three Daily Rapid-acting Insulin Injections of APIDRA (Insulin Glulisine) as add-on to Lantus® and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-label Clinical Study||Sanofi|No|Completed|August 2004|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|347|||Both|18 Years|79 Years|No|||January 2011|January 10, 2011|August 23, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00135083||196802|
NCT00135096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3503|Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin|APIDRA® (Insulin Glulisine) Administered Premeal vs Postmeal in Adult Subjects With Type 2 Diabetes Mellitus Receiving LANTUS® (Insulin Glargine) as Basal Insulin: a Multicenter, Randomized, Parallel, Open Label Clinical Study||Sanofi||Completed|August 2004|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|345|||Both|18 Years|70 Years|No|||January 2011|January 10, 2011|August 23, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00135096||196801|
NCT00140582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIMA|Primary Rituximab and Maintenance|Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy||Lymphoma Study Association|Yes|Active, not recruiting|December 2004|December 2016|Anticipated|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1217|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00140582||196385|
NCT00141258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081079|Pregabalin Epilepsy Add-On Trial|Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures||Pfizer||Completed|October 2005|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|178|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141258||196334|
NCT00140569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gelf-94|Randomized Study for Patients With Follicular Lymphoma Needing Treatment|Randomized Study for Patients With Follicular Lymphoma Needing Treatment||Lymphoma Study Association||Completed|January 1994|January 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||August 2005|August 31, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140569||196386|
NCT00141245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-012|To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.|Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.||Pfizer||Completed|October 1998|November 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||325|||Both|18 Years|N/A|No|||December 2006|December 28, 2006|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141245||196335|
NCT00141648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 99.04|Chemotherapy and Radiotherapy for Osteolymphoma|A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|September 2000|February 2008|Actual|February 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|17 Years|N/A|No|||September 2009|September 29, 2009|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00141648||196304|
NCT00141661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0341008|A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients|A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700||Pfizer|No|Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|50 Years|N/A|No|||August 2009|August 19, 2009|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00141661||196303|
NCT00141934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-AD452-022|A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.|Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.||Sosei||Completed|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||232|||Both|18 Years|75 Years|No|||April 2007|April 4, 2007|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00141934||196282|
NCT00142688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253|Examining Psychosocial Mediators of Exercise Behavior|Examining Psychosocial Mediators of Exercise Behavior||HealthPartners Institute||Completed|August 2004|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|448|||Both|N/A|100 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00142688||196225|
NCT00138437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-817H|Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses|Molecular Epidemiology of Leprosy in Colombia||Colorado State University|No|Completed|April 2006|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|1554|Samples With DNA|Blood, Nasal Swabs, Skin Biopsies and scrapings|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study participants for prospective sample collections will include volunteering and        consenting individuals older than 18 years of age, representing three study groups|November 2014|November 5, 2014|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00138437||196546|
NCT00142662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252|Cafeteria-Based Study of Weight Gain Prevention|||Drexel University||Completed|September 2002|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|21 Years|65 Years|No|||January 2008|March 26, 2014|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142662||196227|
NCT00142974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919G2203|Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy|Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy||Novartis||Terminated|May 2004|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||120|||Both|18 Years|65 Years||||April 2012|April 19, 2012|August 31, 2005|||This study was terminated early in April 2005 due to low patient enrollment|||https://clinicaltrials.gov/show/NCT00142974||196204|
NCT00138463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-114|West Nile Virus Natural History|Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2003|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples With DNA|Cerebrospinal fluid, urine, serum.|Both|18 Years|N/A|No|Non-Probability Sample|Adults, 18 and older, all study participants must have been diagnosed with West Nile Virus        (WNV) disease within the four months prior to enrollment.|February 2010|November 3, 2011|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00138463||196544|
NCT00139009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPER-CsA|Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation|||University of Oslo School of Pharmacy||Completed|June 2005|September 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|18 Years|N/A|No|||September 2006|June 14, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139009||196502|
NCT00138736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB2003.02|Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia|Phase II Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia||Sanquin|No|Completed|April 2004|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|N/A|12 Years|No|||August 2007|August 29, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138736||196523|
NCT00138749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061023|An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.|An 8-Week, Multi-Centre,Randomised Double-Blind, Placebo Controlled, Parallel Group Study To Evaluate The Efficacy,Toleration And Safety Of (+)- [S,S]- Reboxetine In The Treatment Of Stress Urinary Incontinence (SUI) In Women.||Pfizer||Completed|November 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||402|||Female|18 Years|65 Years|No|||April 2011|April 6, 2011|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00138749||196522|
NCT00139308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM0008|High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome|Pilot Study of Internal Globus Pallidus or Median Centre of the Thalamus High Frequency Stimulation for the Treatment of Patients With Severe Tourette's Syndrome||Groupe Hospitalier Pitie-Salpetriere||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||August 2005|August 30, 2005|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139308||196479|
NCT00139035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CsA-Dialysis 2004-004488-3|Effects of Cyclosporine A on Pancreatic Insulin Secretion|Effects of Cyclosporine A on Pancreatic Insulin Secretion||University of Oslo School of Pharmacy||Completed|April 2005|||January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|75 Years|No|||October 2012|October 31, 2012|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139035||196500|
NCT00143247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171036|Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus|An Open-Label, Phase 2, Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus Participating in Extension Protocols 217-102, 103, or 104||Pfizer|No|Terminated|March 2003|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|173|||Both|18 Years|65 Years|No|||July 2009|April 10, 2010|August 31, 2005||Yes|See termination reason in detailed description.|No|January 16, 2009|https://clinicaltrials.gov/show/NCT00143247||196183|Study terminated early due to business and operational issues. All subjects who were treated with inhaled insulin in parent protocols(217-102,-103,or-104) or in extension protocols (217-102E,-103E,-104E,or A2171036)are included in safety evaluation.
NCT00134524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMRI-DPN-01|The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy|A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy||Advanced Magnetic Research Institute International|No|Active, not recruiting|July 2005|January 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|79 Years|No|||July 2007|July 8, 2007|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134524||196844|
NCT00134537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN002-001-05|Wallis Mechanical Normalization System for Low Back Pain|||Zimmer Spine|Yes|Active, not recruiting|November 2004|April 2012|Anticipated|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|60 Years|No|||October 2011|October 3, 2011|August 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134537||196843|
NCT00134797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP #S-04-058|Glomerular Filtration Rate (GFR) Reporting on Nephrology Referral Patterns by Internists|The Effect of MDRD GFR Reporting on Nephrology Referral Patterns by Internists||United States Naval Medical Center, San Diego||Recruiting|February 2005|February 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|November 4, 2005|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00134797||196823|
NCT00134550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The IDUS trial|Improving Diabetic Foot Ulcers With Atorvastatin|Improving Diabetic Foot Ulcers With Atorvastatin||Asker & Baerum Hospital|No|Completed|February 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|30 Years|N/A|No|||September 2009|September 22, 2009|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134550||196842|
NCT00139646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124-IFL-0505-005|Parecoxib in Renal Colic|A Multicenter Single-Blind, Single Dose Efficacy and Safety Pilot Study Comparing Intramuscular Parecoxib and Diclofenac in Renal Colic||Pfizer||Terminated|April 2002|April 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||May 2008|May 2, 2008|August 29, 2005|||See Detailed Description|No||https://clinicaltrials.gov/show/NCT00139646||196456|
NCT00139659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171028|A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma|Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial||Pfizer|No|Completed|January 2003|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|288|||Both|18 Years|77 Years|No|||October 2009|May 26, 2010|August 29, 2005|Yes|Yes||No|October 21, 2009|https://clinicaltrials.gov/show/NCT00139659||196455|Data for some secondary endpoints were not tabulated or analyzed for this study and some concomitant medication data were not accurately recorded and tabulated due to lack of resources resulting from scaling down of Exubera® development.
NCT00139672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4451007|A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Investigate The Effect Of Pd-217,014 In Patients With Irritable Bowel Syndrome (IBS)||Pfizer||Completed|January 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|18 Years|75 Years|No|||June 2008|June 12, 2008|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139672||196454|
NCT00135330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-US-GWAY|An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus|An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin||AstraZeneca|No|Completed|October 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|137|||Both|18 Years|75 Years|No|||March 2015|March 19, 2015|August 24, 2005|Yes|Yes||No|July 21, 2009|https://clinicaltrials.gov/show/NCT00135330||196783|
NCT00140075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|378-ONC-0030-184|Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer|Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer||Pfizer|No|Completed|November 2000|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|606|||Female|18 Years|N/A|No|||May 2011|May 24, 2011|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00140075||196423|
NCT00140088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3268-3-003-1|Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Effectiveness and Safety of ALGRX 3268 in Pediatric Subjects.||AlgoRx Pharmaceuticals||Completed|December 2004|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||504|||Both|3 Years|18 Years|No|||August 2005|August 31, 2005|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00140088||196422|
NCT00141271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281136|A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression|A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients With Bipolar I Depression||Pfizer|Yes|Completed|July 2005|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|536|||Both|18 Years|N/A|No|||April 2009|April 3, 2009|August 30, 2005|Yes|Yes||No|February 24, 2009|https://clinicaltrials.gov/show/NCT00141271||196333|
NCT00140855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-010|A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma|A Phase II Study of Anti-CTLA4 Antibody in Advanced Synovial Sarcoma Patients||Ludwig Institute for Cancer Research|Yes|Terminated|July 2005|April 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||17|||Both|13 Years|N/A|No|||April 2007|April 4, 2007|August 30, 2005|||Study discontinued due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00140855||196365|
NCT00141232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581114|Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes|A Multicentre, Randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes|AFORRD|Pfizer||Completed|November 2004|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|810|||Both|18 Years|N/A|No|||November 2008|November 21, 2008|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141232||196336|
NCT00141947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3775|Bexarotene Treatment in Schizophrenia|Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial||Beersheva Mental Health Center|Yes|Recruiting|September 2005|September 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|60 Years|No|||October 2005|July 23, 2013|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00141947||196281|
NCT00141960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1170-CL-004|Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease|YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease||Astellas Pharma Inc||Completed|September 2005|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|20 Years|N/A|No|||June 2010|November 18, 2011|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00141960||196280|
NCT00141973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1408|Time Course of Procalcitonin and C Reactive Protein in Septic Patients Under Treatment With Corticosteroids|||Ospedale Regionale Bellinzona e Valli||Completed|November 2004|December 2005||||N/A|Observational|Time Perspective: Prospective|||||||Both|50 Years|80 Years|No|||May 2008|May 13, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00141973||196279|
NCT00142415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2003-006|Study of Lutetium-177 Labeled cG250 in Patients With Advanced Renal Cancer|Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 in Patients With Advanced Renal Cancer||Ludwig Institute for Cancer Research|No|Completed|February 2005|July 2013|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|27|||Both|18 Years|N/A|No|||December 2013|December 30, 2013|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00142415||196246|
NCT00142636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP #S-03-133|CRICKET Study, Coronary Calcium Scores in Patients With Chronic Kidney Disease|Coronary Artery Calcification in Chronic Kidney Disease Using Multidetector Row Spiral Computed Tomography||United States Naval Medical Center, San Diego||Active, not recruiting|February 2004|September 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2005|November 21, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142636||196229|
NCT00142233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUROPAC-2|EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis|Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis||University Medicine Greifswald||Recruiting|June 2004|December 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|240|||Both|5 Years|40 Years|No|||August 2005|September 11, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142233||196260|
NCT00142675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254|Using Peers to Promote Exercise in Older Adults|||Stanford University||Completed|February 2003|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|50 Years|N/A|No|||March 2014|March 4, 2014|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142675||196226|
NCT00142701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251|Enhancing Support for Women at Risk for Heart Disease|||Oregon Research Institute|No|Completed|April 1999|March 2005|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|N/A|100 Years|No|||February 2016|February 4, 2016|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00142701||196224|
NCT00142727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-6|Opioid Agonist and Antagonist Effects on Opioid Dependence|The Variability of Agonist and Antagonist Effects as a Function of Level of Physical Dependence||National Institute on Drug Abuse (NIDA)|No|Terminated|January 2004|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|55 Years|No|||July 2007|July 10, 2007|September 1, 2005|||Study terminated due to halt in funding; may resume recruiting in future|No||https://clinicaltrials.gov/show/NCT00142727||196222|
NCT00138450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-588|Urinary Schistosomiasis Infection|Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2004||||N/A|Observational|Time Perspective: Prospective||||4400|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2007|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138450||196545|
NCT00138775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-3093-MW-CTIL|Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia|D-Serine Adjuvant Pharmacotherapy for the Treatment of Schizophrenia||Sheba Medical Center||Recruiting|October 2004|October 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|64 Years|No|||October 2006|December 24, 2006|August 28, 2005||||No||https://clinicaltrials.gov/show/NCT00138775||196520|
NCT00139048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMDAT40|Australian Screening Mammography Decision Aid Trial: A Decision Aid for Women Aged 40 Thinking About Starting Mammography Screening|A Randomised Controlled Trial of an on-Line Decision Aid for Women Aged 40 Considering Whether to Have Screening Mammograms to Evaluate the Change in Knowledge Regarding Mammography Screening.||University of Sydney||Completed|September 2005|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||200|||Female|38 Years|45 Years||||August 2005|April 25, 2007|August 28, 2005||||No||https://clinicaltrials.gov/show/NCT00139048||196499|
NCT00138372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-110|Human Immunity to MSP-1 in Western Kenya|Human Immunity to MSP-1 in Western Kenya||Case Western Reserve University|No|Not yet recruiting||||||N/A|Observational|Time Perspective: Prospective||||445|||Both|1 Month|N/A|Accepts Healthy Volunteers|||September 2008|September 30, 2008|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00138372||196551|
NCT00139243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-130|Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Study of Taxotere, Cisplatin, 5-Fluorouracil and Leucovorin for Squamous Cell Carcinoma of the Head and Neck||Dana-Farber Cancer Institute||Completed|October 1997|January 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|August 29, 2005||||||https://clinicaltrials.gov/show/NCT00139243||196484|
NCT00140101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|640-0048|Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries|A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de Novo Coronary Artery Lesions|ZoMaxx™ II|Abbott Vascular|Yes|Completed|May 2005|January 2012|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1099|||Both|18 Years|N/A|No|||January 2012|January 6, 2012|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00140101||196421|
NCT00140361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-2577|Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria|Assessing and Monitoring the Efficacy of Sulfadoxine/ Pyrimethamine (SP) and the Combination of SP Plus Artesunate for Uncomplicated Malaria Infections Among Children||Centers for Disease Control and Prevention|No|Completed|January 2000|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|390|||Both|N/A|N/A|No|||September 2012|September 10, 2012|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140361||196402|
NCT00141674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0459|Age of Blood in Brain Injury|A Prospective Randomized Controlled Trial Comparing the Effects of Fresh vs. Old Blood on Cerebral Oxygen Extraction in Patients With Traumatic Brain Injuries||University of British Columbia||Completed|March 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|60|||Both|16 Years|N/A|No|||September 2008|September 2, 2008|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00141674||196302|
NCT00141284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4301003|An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C|A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction.||Pfizer||Completed|October 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|60 Years|No|||May 2011|May 9, 2011|August 30, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00141284||196332|
NCT00141687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0348|Early External Cephalic Version (ECV) 2 Trial|Early External Cephalic Version 2 Trial||McMaster University|No|Active, not recruiting|December 2004|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1460|||Female|14 Years|45 Years|No|||June 2008|October 28, 2008|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00141687||196301|
NCT00141986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1622|Feasibility Study of 2000 IU Per Day of Vitamin D for the Primary Prevention of Type 1 Diabetes|Pilot Trial of Vitamin D for the Prevention of Type 1 Diabetes||Canadian Diabetes Association|No|Completed|November 2003|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9|||Both|N/A|4 Weeks|No|||September 2005|April 25, 2011|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00141986||196278|
NCT00141999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-2998|Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents|An Evaluation of Long-Term Protection Against Hepatitis B Virus Infection: Response of Alaska Native Children and Adolescents Who Received the Primary Recombinant Hepatitis B Vaccine Series Beginning at Birth to an Additional Dose of Vaccine||Centers for Disease Control and Prevention|No|Completed|May 2001|March 2008|Actual|March 2005|Actual|Phase 4|Observational|Time Perspective: Prospective||||400|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00141999||196277|
NCT00142025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-0501-OC-0302|Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Oxcarbazepine Efficacy in Asthma Therapy||Centre of Chinese Medicine, Georgia||Completed|September 2001|March 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||55|||Both|17 Years|75 Years|No|||February 2009|February 18, 2009|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142025||196275|
NCT00142246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG41|Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education.|Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya||Gates Malaria Partnership|Yes|Completed|January 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6758|||Both|N/A|N/A|No|||February 2008|February 7, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142246||196259|
NCT00142259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15|Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia|Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie||German Parkinson Study Group (GPS)||Active, not recruiting|October 2002|August 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|14 Years|75 Years|No|||September 2005|December 5, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142259||196258|
NCT00142714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD030149-09|Effects of Spinal Cord Injury on Female Sexual Response|Effects of SCI on Female Sexual Response||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|August 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||70|||Female|18 Years|55 Years|No|||October 2006|October 13, 2006|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142714||196223|
NCT00142961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4988-NIDA-19233-1|Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder|Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment||New York State Psychiatric Institute|Yes|Completed|October 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|14 Years|21 Years|No|||March 2015|March 30, 2015|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142961||196205|
NCT00142740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 052|Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025|Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025||Westat|Yes|Completed|October 2005|June 2008|Actual|June 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|337|Samples With DNA|Approximately 5 ml whole blood or 5 x 106 peripheral blood mononuclear cells.|Both|12 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|All subjects who are currently enrolled or have completed ATN 024 or ATN 025 are eligible        for participation on this substudy with the exception of those who were discontinued from        ATN 024 or ATN 025 prior to completing the first post-vaccination serology (week 28)        visit.        Participants in ATN 024 are HIV-infected youths aged 12 to 24 years, while participants in        ATN 025 are HIV-uninfected youths aged 12 to17 years, thus participants in this substudy        will be HIV-infected and uninfected youth aged 12 to 24 years. All eligible youths must be        negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time        of enrollment in to the parent protocols.|February 2016|February 29, 2016|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142740||196221|
NCT00138476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-036|New Challenge Pool of Norwalk Virus Inoculum|Evaluation of a New Challenge Pool of Norwalk Virus Inoculum (Lot 42399) in Human Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2004|September 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|57|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|May 8, 2014|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138476||196543|
NCT00138762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091018|A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol|A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).||Pfizer||Completed|July 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||3800|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138762||196521|
NCT00138489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-004|Papua New Guinean Duffy Negativity And Vivax Malar|Protocol 3B Susceptibility to Plasmodium Vivax Infection and Malaria During Early Childhood||National Institute of Allergy and Infectious Diseases (NIAID)||Suspended|January 2004|||||N/A|Observational|Time Perspective: Prospective||||266|||Both|N/A|24 Months|Accepts Healthy Volunteers|||October 2007|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138489||196542|
NCT00156208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-062|Safety of Treatment of Uterine Fibroids With Asoprisnil|A Phase III, 18-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata||Abbott|No|Completed|April 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|166|||Female|18 Years|N/A|No|||May 2008|May 27, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156208||195201|
NCT00156507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09653|Improving Asthma Care for Very Low Birth Weight Infants|Improving Asthma Care for Very Low Birth Weight Infants||University of Rochester|No|Completed|January 2003|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|192|||Both|N/A|1 Year|No|||May 2011|May 11, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156507||195178|
NCT00138970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLARIFI|Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk|Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of Renal Function and Acute Rejection in 0 DR Mis-Matched Renal Allograft Recipients||University of Oslo School of Pharmacy||Completed|January 2002|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||70|||Both|18 Years|N/A|No|||August 2005|November 30, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138970||196505|
NCT00138983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG67-STOP-study|Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.|Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.||UMC Utrecht||Completed|May 2000|November 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|18 Years|90 Years|No|||March 2000|November 28, 2006|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138983||196504|
NCT00138684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2003/0052|Cytochrome P450 2E1 and Iron Overload|Cytochrome P450 2E1 and Iron Overload||Rennes University Hospital|Yes|Completed|September 2003|February 2006|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|70 Years|No|||May 2012|May 18, 2012|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00138684||196527|
NCT00139685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z54000261|Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception|Depo-Provera: Evaluation of Bone Mineral Density and Total Body Calcium in Adolescent DP 150 CI Users and Matched Controls||Pfizer||Completed|April 1998|July 2007|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||350|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||September 2008|September 23, 2008|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00139685||196453|
NCT00139698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0021002|Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension|A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension|OSCAR|Pfizer||Completed|September 2005|July 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||410|||Both|18 Years|65 Years|No|||April 2007|July 30, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139698||196452|
NCT00140114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGY.AN.02|Sublingual Versus Vaginal Misoprostol for Labor Induction at Term|||American University of Beirut Medical Center|Yes|Completed|January 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||August 2008|July 12, 2012|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140114||196420|
NCT00140140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA025|A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer|An Open-Label Phase I/II Study of Weekly ABI-007 and Vinorelbine With or Without G-CSF in Patients With Stage IV (Metastatic) Breast Cancer||Celgene|No|Terminated|August 2005|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|August 30, 2005|Yes|Yes|Unable to determine the optimum tolerated dose|No|August 20, 2013|https://clinicaltrials.gov/show/NCT00140140||196419|
NCT00140374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-9705A|Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)|Phase I/II Study of Vaccination Priming and Vaccine Boosting With Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines in Patients With Prostate Cancer||Cell Genesys||Completed|December 1998|February 2001||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Male|18 Years|N/A|No|||August 2005|August 30, 2005|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00140374||196401|
NCT00140387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-9802|Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)|Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) in Hormone-naïve Prostate Cancer Patients||Cell Genesys||Completed|May 1999|March 2001||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Male|18 Years|N/A|No|||August 2005|August 30, 2005|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00140387||196400|
NCT00140868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-125|Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or Surgery|Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery||Memorial Sloan Kettering Cancer Center||Completed|December 2002|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||180|||Both|18 Years|N/A|No|||December 2007|December 6, 2007|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140868||196364|
NCT00140881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-165|A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children||Merck Sharp & Dohme Corp.||Completed|June 2000|February 2003|Actual|February 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|220|||Both|2 Years|14 Years|No|||November 2015|November 27, 2015|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140881||196363|
NCT00141297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481001|A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer|A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer||Pfizer|No|Completed|September 2004|December 2014|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 30, 2005|No|Yes||No|March 4, 2015|https://clinicaltrials.gov/show/NCT00141297||196331|
NCT00141323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2181002|Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)|PEARL: Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene|PEARL|Ligand Pharmaceuticals|Yes|Completed|November 2001|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|8556|||Female|60 Years|80 Years|No|||August 2011|August 8, 2011|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00141323||196329|
NCT00141700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2-51|Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma|Rituximab Plus High-Dose Chemotherapy With Autologous Stem Cell Support for Poor-Prognosis Non-Hodgkin's Lymphoma||University of Michigan Cancer Center||Terminated|March 2003|December 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||December 2007|December 28, 2007|August 30, 2005|||enrollment completed|No||https://clinicaltrials.gov/show/NCT00141700||196300|
NCT00142012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-OPHR-321534|School-Based Obesity Prevention Program|School-Based Obesity Prevention Program||Centers for Disease Control and Prevention||Completed|October 2002|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||1500|||Both|8 Years|14 Years|No|||September 2005|November 16, 2005|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142012||196276|
NCT00142272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDR,B 2000-032|Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial|Randomised, Open, Parallel Group Clinical Trial to Compare the Efficacy and Safety of a Single Dose of Ciprofloxacin Oral Suspension 20 Mg/Kg With a 3-Day Course of Erythromycin Oral Suspension Administered in a Dose of 12.5 Mg/Kg Every 6 Hours (12 Doses) in the Treatment of Children,With Clinically Severe Cholera Due to V. Cholerae O1 or O139.||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|May 2001|July 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Male|2 Years|15 Years|No|||September 2005|November 18, 2005|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142272||196257|
NCT00142480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-144|Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer|Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer||Massachusetts General Hospital||Active, not recruiting|December 2004|||July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||December 2007|December 28, 2007|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142480||196241|
NCT00142753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 048|Immunologic Memory (Supp. of ATN 024)|Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025||Westat||Completed|August 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|95|||Both|12 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142753||196220|
NCT00142454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 04-53, LUD2004-006|NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)|NY-ESO-1 Protein Vaccination in Malignant Melanoma Administered With Imiquimod as Adjuvant||Ludwig Institute for Cancer Research||Completed|August 2005|June 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||9|||Both|18 Years|N/A|No|||September 2007|September 20, 2007|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00142454||196243|
NCT00138541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2301E1|Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes|Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes||Novartis||Completed|October 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|440|||Both|18 Years|80 Years||||May 2012|May 1, 2012|August 27, 2005||||No||https://clinicaltrials.gov/show/NCT00138541||196538|
NCT00142987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919A2417|Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS|Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS||Novartis||Completed|April 2004|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||664|||Female|18 Years|65 Years||||January 2008|January 24, 2008|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00142987||196203|
NCT00143000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swedish MPA nr. 151:2004/3458|Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3|A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection||NORDynamIC Study Group|Yes|Completed|April 2004|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|392|||Both|18 Years|N/A|No|||April 2008|April 4, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143000||196202|
NCT00138502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-050|Funguria in Hospitalized Patients|The Significance of Funguria In Hospitalized Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|September 2001|April 2005||||N/A|Observational|Time Perspective: Prospective||||926|||Both|N/A|N/A|No|||October 2007|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138502||196541|
NCT00138515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2303E1|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes||Novartis||Completed|November 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|418|||Both|18 Years|78 Years||||May 2012|May 1, 2012|August 27, 2005||||No||https://clinicaltrials.gov/show/NCT00138515||196540|
NCT00156221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC UMC Utrecht 99/184|MR Scanning of Very Young Children With Severe Developmental Disorders|MR Scanning of Very Young Children With Severe Developmental Disorders (Autistic Spectrum Disorders and/or Mental Retardation and/or Language Disorders)||UMC Utrecht||Completed|September 2000|September 2005||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||||||Both|18 Months|7 Years|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156221||195200|
NCT00156234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRUST-001|Skeletal Muscle Dysfunction in Heart Failure|Training and Congestive Heart Failure||Ullevaal University Hospital||Recruiting|March 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||45|||Both|40 Years|78 Years|Accepts Healthy Volunteers|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156234||195199|
NCT00138996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-01139|Quality of Cardiopulmonary Resuscitation Without and With Defibrillator Feedback|Can the Quality of Cardiopulmonary Resuscitation Improve With Direct Online Feedback From the Defibrillator to the Rescuers on Their Resuscitation Efforts||University of Oslo|No|Completed|March 2002|June 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||August 2007|August 24, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138996||196503|
NCT00139256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0894-2003|Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section|Randomized Controlled Trial of Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section||Emory University|No|Terminated|August 2005|September 2007|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|67|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 25, 2013|August 29, 2005||No|Slow enrollment and lack of funds.|No||https://clinicaltrials.gov/show/NCT00139256||196483|
NCT00139711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976C/2501|Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer|A Multicenter Randomized Phase II Study Evaluating The Activity And Tolerability Of Three Different Combinations Of Docetaxel (Taxotere) And Irinotecan (Campto) As Second Line Therapy For Recurrent Or Metastatic Non Small Cell Lung Cancer (NSCLS)||Pfizer||Completed|March 2003|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||138|||Both|18 Years|70 Years|No|||October 2006|March 27, 2008|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139711||196451|
NCT00139724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121112|Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet|A Phase III Randomized, Double-Blind, Double Dummy, Multi-Center Study To Compare The Efficacy, Safety And Tolerability Of Tolterodine Extended Release Capsule With Tolterodine Immediate Release Tablet In Subjects With Symptoms Of Overactive Bladder||Pfizer||Completed|May 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|260|||Both|18 Years|75 Years|No|||December 2009|December 18, 2009|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139724||196450|
NCT00139737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281061|Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia|Open Extension Study Evaluating the Safety and Tolerability of Oral Ziprasidone in the Treatment of Subjects Who Have Successfully Completed a Previous Ziprasidone Study||Pfizer|No|Completed|March 2002|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|344|||Both|18 Years|60 Years|No|||August 2010|August 2, 2010|August 29, 2005|No|Yes||No|June 15, 2010|https://clinicaltrials.gov/show/NCT00139737||196449|
NCT00140634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cartilage Repair Registry|The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients|Cartilage Repair Registry||Vericel Corporation|No|Completed|March 1995|January 2009|Actual|January 2009|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|2233|||Both|N/A|N/A|No|Non-Probability Sample|Registry of patients with diagnosis of chondral injury.|August 2015|August 17, 2015|August 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00140634||196381|
NCT00140920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-259|A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)|A Study to Compare Pre-Operative Administration of Rofecoxib Vs Post-Operative Administration of Diclofenac or Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement in Patients With Osteoarthritis of the Knee.||Merck Sharp & Dohme Corp.||Terminated|May 2004|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|August 30, 2005||Yes|Recruitment/study discontinued after withdrawal of marketing authorisation. No data entered.|No||https://clinicaltrials.gov/show/NCT00140920||196360|
NCT00140933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_056|A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome|A Randomized, Double-Blind, 7-Day Study of the Efficacy and Safety of Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome||Merck Sharp & Dohme Corp.||Terminated|April 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||274|||Both|18 Years|59 Years|No|||December 2006|December 1, 2006|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140933||196359|
NCT00140894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_052|A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)||Merck Sharp & Dohme Corp.||Terminated|March 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||62|||Both|18 Years|N/A|No|||November 2006|November 30, 2006|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140894||196362|
NCT00140907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-222|ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)|A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplant||Merck Sharp & Dohme Corp.||Completed|March 2000|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|367|||Both|18 Years|70 Years|No|||March 2015|March 17, 2015|August 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00140907||196361|
NCT00140946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-075|A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Two-Period, Parallel-group Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients.||Merck Sharp & Dohme Corp.||Completed|March 1998|October 2000|Actual|October 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|546|||Both|18 Years|70 Years|No|||January 2016|January 21, 2016|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140946||196358|
NCT00140959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-309|Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)|Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.||Merck Sharp & Dohme Corp.||Completed|February 2003|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 27, 2015|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00140959||196357|
NCT00141336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-035|To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.|Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.||Pfizer||Completed|November 1999|July 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||750|||Both|12 Years|N/A|No|||December 2006|December 28, 2006|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141336||196328|
NCT00141362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-000-166|Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.|An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Chronic Neuropathic Pain.||Pfizer||Completed|October 2001|August 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||325|||Both|18 Years|N/A|No|||December 2006|December 29, 2006|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141362||196326|
NCT00141375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-000-202|To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.|An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.||Pfizer||Completed|August 2002|January 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||132|||Both|18 Years|N/A|No|||January 2008|January 9, 2008|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141375||196325|
NCT00141713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 3-37|The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease|The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease||University of Michigan Cancer Center||Completed|October 2003|December 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||March 2013|March 12, 2013|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00141713||196299|
NCT00141401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-074|Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.|An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.||Pfizer||Completed|September 1999|July 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||August 2007|August 15, 2007|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00141401||196323|
NCT00141726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 3-31|Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant|Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study||University of Michigan Cancer Center|Yes|Completed|October 2003|February 2009|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|6 Years|N/A|No|||November 2015|November 4, 2015|August 30, 2005|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT00141726||196298|
NCT00142766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD045020|Sedation Management in Pediatric Patients Supported on Mechanical Ventilation|Sedation Management in Pediatric Patients Supported on Mechanical Ventilation||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2004|March 2007|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|N/A|18 Years|No|||October 2015|October 5, 2015|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00142766||196219|
NCT00143039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX 0005.3|Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR|Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by Nonimmune Hydrops and Severe Symmetrical Intrauterine Growth Restriction-A Multicenter Prospective Pilot Cohort Study|TandemMS|Mednax Center for Research, Education and Quality|Yes|Terminated|March 2006|August 2009|Actual|August 2009|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|||Female|18 Years|60 Years|No|Non-Probability Sample|Pregnancies complicated by NIH or SSIUGR fetuses as compared to a control group of        pregnancies with normally appearing fetuses requiring a diagnostic amniocentesis as part        of her care.|December 2014|December 17, 2014|August 31, 2005||No|No metabolic disordered ID'd by TMS in either control/test group at >50%enrolled|No||https://clinicaltrials.gov/show/NCT00143039||196199|
NCT00142467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-390|Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma|Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Patients With Hepatocellular Carcinoma||Massachusetts General Hospital|Yes|Completed|April 2004|June 2011|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||March 2014|March 15, 2014|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142467||196242|
NCT00138840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5326-07|Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease||Synta Pharmaceuticals Corp.||Completed|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||282|||Both|18 Years|75 Years|No|||December 2008|December 3, 2008|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00138840||196515|
NCT00139126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-4662|Research to Improve Smoke Alarm Functioning and Maintenance|Research to Improve Smoke Alarm Functioning and Maintenance||Centers for Disease Control and Prevention||Completed|August 2005|||May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|4500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139126||196493|
NCT00143013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Gene Expression Profiling and Bioinformatic Analysis Identifying Genes and Biochemical Pathways in Type 2 Diabetes|Gene Expression Profiling by DNA Chips and Subsequent Bioinformatic Analysis for Identification of Genes and Biochemical Pathways Associated With Type 2 Diabetes||Odense University Hospital||Recruiting|October 2004|April 2007||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00143013||196201|
NCT00139100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-2822|Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area|Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis||Centers for Disease Control and Prevention||Completed|February 2001|March 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|N/A|N/A|No|||August 2005|October 23, 2008|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139100||196495|
NCT00139113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-1358|Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children|Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children||Centers for Disease Control and Prevention|Yes|Completed|September 1996|June 2001|Actual|June 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|248|||Both|N/A|6 Months|Accepts Healthy Volunteers|||August 2012|August 29, 2012|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00139113||196494|
NCT00156546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS 2|Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection|Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a History of Upper Urinary Tract Infections:a Multicentre Randomised Study||University of Padova||Active, not recruiting|May 2000|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||660|||Both|2 Months|6 Years|No|||September 2005|November 30, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156546||195175|
NCT00152971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.24|Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement|A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery||Boehringer Ingelheim||Completed|November 2004|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|2615|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|September 8, 2005||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00152971||195448|
NCT00140153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3973|Testosterone in Female Hypoactive Sexual Desire Disorder|Transdermal Testosterone Gel Prn Application for Hypoactive Sexual Desire Disorder in Women: A Controlled Study||Beersheva Mental Health Center||Completed|April 2005|April 2006||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|21 Years|40 Years|No|||November 2009|November 23, 2009|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140153||196418|
NCT00139269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-199|Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Phase I/II Pilot Study of Induction Chemotherapy With Docetaxel in Combination With Cisplatin and 5-Fluorouracil (5-FU) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Dana-Farber Cancer Institute||Completed|February 1998|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 2, 2008|August 29, 2005||||||https://clinicaltrials.gov/show/NCT00139269||196482|
NCT00140166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3996|Treatment of Acute Schizophrenia With Vitamin Therapy|The Treatment of Acute Schizophrenia With High Dose Niacinmide Plus Ascorbate Plus Pyridoxine Plus Centrum Forte vs. Centrum Forte Only as an Add-On to Risperidone and Dietary Counseling||Beersheva Mental Health Center|Yes|Completed|July 2005|May 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|30 Years|No|||November 2009|November 23, 2009|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00140166||196417|
NCT00140179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3658|Valnoctamide in Mania|Valnoctamide as a Valproate Substitute With Low Teratogenic Potential: Double-Blind Controlled Clinical Trial||Beersheva Mental Health Center|Yes|Completed|September 2004|May 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|60 Years|No|||November 2009|November 23, 2009|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00140179||196416|
NCT00140595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH03-2B|ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1|Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.||Lymphoma Study Association||Completed|December 2003|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|380|||Both|18 Years|59 Years|No|||March 2011|March 3, 2011|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140595||196384|
NCT00140608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPACK00104ORP|Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery|||Sanofi||Terminated|June 2003|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00140608||196383|
NCT00140621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL03204|A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease|A Multicenter Open-label Study of the Safety and Efficacy of α-galactosidase A (R-h α-GAL) Replacement Therapy in Patients With Cardiac Fabry Disease||Sanofi|No|Completed|July 2005|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|64 Years|No|||April 2015|April 16, 2015|August 30, 2005|Yes|Yes||No|April 1, 2015|https://clinicaltrials.gov/show/NCT00140621||196382|
NCT00140647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARR|The Study of Atherosclerosis With Ramipril and Rosiglitazone|The Study of Atherosclerosis With Ramipril and Rosiglitazone||Gerstein, Hertzel, MD||Completed|July 2001|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Both|30 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 21, 2008|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00140647||196380|
NCT00141310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481206|Sildenafil Citrate for the Treatment of Established Pre-Eclampsia|A Randomised, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety and Toleration of Oral Sildenafil Citrate Administered in the Dose Range of 20 - 80 Mg TID for the Treatment of Pre-Eclampsia. (PET)||Pfizer||Terminated|September 2004|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||76|||Female|18 Years|N/A|No|||July 2007|July 23, 2007|August 30, 2005|||Study prematurely discont’d 20-Apr-2006 after interim analysis suggested sample size could be    reduced without losing power. No safety concerns led to decision.|No||https://clinicaltrials.gov/show/NCT00141310||196330|
NCT00140972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-080|A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)|A Multicenter, Randomized, Parallel-group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess Efficacy, Safety, and Tolerability of Etoricoxib 60 mg Once Daily Versus Diclofenac Sodium 75 mg Twice Daily in the Treatment of Chinese Patients With Osteoarthritis of the Knee or Hip||Merck Sharp & Dohme Corp.||Completed|December 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|160|||Both|40 Years|N/A|No|||April 2015|April 6, 2015|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00140972||196356|
NCT00140985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-213|Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)|A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors (TGFß and VEGF)||Merck Sharp & Dohme Corp.||Completed|February 2000|January 2002|Actual|January 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|97|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00140985||196355|
NCT00140998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-136|Estrogen Treatment (Oral vs. Patches) in Turner Syndrome|Estrogen Replacement in Hypogonadal Girls Treated With GH: Differential Effects of Mode of Estrogen Delivery||Nemours Children's Clinic||Completed|January 2001|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Female|10 Years|16 Years|No|||August 2010|August 12, 2010|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140998||196354|
NCT00141388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-010|To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures|Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.||Pfizer||Completed|July 1998|October 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|455|||Both|18 Years|N/A|No|||November 2009|November 5, 2009|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141388||196324|
NCT00141414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-008|To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.|Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.||Pfizer||Completed|November 1997|October 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||82|||Both|18 Years|N/A|No|||December 2006|December 28, 2006|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141414||196322|
NCT00142038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGST-Magen-CapDoc-04|Docetaxel and Capecitabine in Advanced Gastric Cancer|Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer||Charite University, Berlin, Germany||Completed|March 2004|December 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|75 Years|No|||April 2007|April 17, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142038||196274|
NCT00135239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0588|Study Care Versus Usual Care for Acute Mechanical Lower Back Pain|Study Care Versus Usual Care for Acute Mechanical Lower Back Pain||University of British Columbia||Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|88|||Both|19 Years|65 Years|No|||June 2008|June 16, 2008|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00135239||196790|
NCT00135525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRL29060A/856|Study Of Generalized Anxiety Disorder|Clinical Evaluation of BRL29060 A in Generalized Anxiety Disorder||GlaxoSmithKline|No|Completed|May 2003|May 2006|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||January 2011|January 27, 2011|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135525||196768|
NCT00143026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200A2406|Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States|Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.||Novartis||Completed|July 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|184|||Both|30 Years|N/A|No|||November 2011|November 22, 2011|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00143026||196200|
NCT00138528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BDE30|Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome|Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome||Novartis||Completed|October 2004|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|75 Years|No|||November 2011|November 7, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00138528||196539|
NCT00138827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/65 Graham|Mouth Care Regimes During Radiotherapy|A Pilot Randomised Comparison of Bicarbonate Based Mouth Care Versus Biotene Based Mouth Care During Radiotherapy||St George Hospital, Australia||Completed|November 1999|March 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 1998|December 14, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138827||196516|
NCT00139451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 04-016|Nutrients and Hormones: Effects in Boys With Disordered Growth|Nutrients and Hormones: Effects in Boys With Disordered Growth||Nemours Children's Clinic|No|Completed|May 2004|September 2010|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|7 Years|10 Years|No|||October 2011|October 11, 2011|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139451||196469|
NCT00139880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP867|A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease|A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease||UCB Pharma||Completed|June 2005|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|40 Years|N/A||||September 2009|September 3, 2013|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139880||196438|
NCT00153270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT-1000-SV-0201|Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Sodium Valproate Efficacy in Asthma Therapy||Centre of Chinese Medicine, Georgia||Completed|September 2000|April 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||46|||Both|16 Years|65 Years|No|||February 2009|February 18, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153270||195425|
NCT00139321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM0260|Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes|Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes||Groupe Hospitalier Pitie-Salpetriere||Terminated|June 2004|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139321||196478|
NCT00139776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191173|Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"|Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of "Continuous Use" Of Celecoxib Vs. The "Usual Use" Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-Inflammatory Medication for Control Of Their Pain||Pfizer|Yes|Completed|July 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|875|||Both|18 Years|80 Years|No|||June 2009|June 24, 2009|August 29, 2005|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00139776||196446|
NCT00140400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-9803|Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer|Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Hormone-Refractory Prostate Cancer||Cell Genesys||Completed|May 1999|January 2001||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Male|18 Years|N/A|No|||August 2005|August 30, 2005|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00140400||196399|
NCT00139789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP843|A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis|A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis||UCB Pharma||Completed|January 2005|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|65 Years||||September 2009|August 29, 2013|August 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00139789||196445|
NCT00139802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANSTENT|DANish Multicenter STENT Trial|Low Restenosis Rate of the NIR Coronary Stent: Results of the Danish Multicenter Stent Study (DANSTENT) – a Randomized Study Comparing a First-Generation With a Second-Generation Stent.||Rigshospitalet, Denmark||Completed|April 1997|June 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||January 1997|August 30, 2005|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139802||196444|
NCT00140192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3835|Creatine Treatment in Psychiatric Disorders|Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial||Beersheva Mental Health Center||Completed|September 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|||Actual|12|||Both|18 Years|60 Years|No|||October 2005|July 28, 2009|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140192||196415|
NCT00140413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.261|Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia|Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia||Children's Hospital Los Angeles|No|Completed|December 2004|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|N/A|5 Years|No|||March 2015|March 27, 2015|August 31, 2005||No||No|February 17, 2015|https://clinicaltrials.gov/show/NCT00140413||196398|
NCT00140439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ EDDP|Improving Asthma Outcomes in an Urban Pediatric Population|Improving Asthma Outcomes in a High Morbidity Urban Pediatric Population: an Emergency Department-based Randomized Clinical Trial||Children's Research Institute|No|Completed|April 2002|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|488|||Both|12 Months|17 Years|No|||August 2015|August 21, 2015|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00140439||196396|
NCT00141349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3711029|Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction|A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations of Immediate Release and Modified Release Formulations of UK369,003 in Adult Male Subject With Erectile Dysfunction||Pfizer||Completed|February 2005|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Male|18 Years|65 Years|No|||January 2006|July 23, 2006|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141349||196327|
NCT00140660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH03-1B|ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma|Randomized Study of ACVBP Versus ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 65 Years With Low-risk Localized Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 0)||Lymphoma Study Association||Terminated|December 2003|December 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|65 Years|No|||March 2011|March 3, 2011|August 31, 2005|||Low acrual|No||https://clinicaltrials.gov/show/NCT00140660||196379|
NCT00141440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1073|The Effect of Cycling Off Criteria During Pressure Support Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effect of Cycling Off Criteria During Pressure Support Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients||Policlinico Hospital|No|Completed|July 2005|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|16 Years|90 Years|No|||September 2008|December 29, 2009|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00141440||196320|
NCT00141739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.008|Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)|The Addition of Etanercept to Standard GVHD Prophylaxis in Patients Undergoing a Full Intensity Allogeneic Hematopoietic Stem Cell Transplant for the Prevention of Transplant Related Complications||University of Michigan Cancer Center|Yes|Completed|August 2004|September 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|1 Year|60 Years|No|||May 2014|May 20, 2014|August 30, 2005|Yes|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT00141739||196297|
NCT00142493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-087|Effect of Affective Content on Drug Induced Amnesia of Episodic Memory|Effect of Affective Content on Drug Induced Amnesia of Episodic Memory||Memorial Sloan Kettering Cancer Center||Completed|September 2004|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|79|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|August 31, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00142493||196240|
NCT00135746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11082-2|Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2|Effects of Transdermal Nicotine on Tobacco Withdrawal and the Effects of Smoking in Men and Women||National Institute on Drug Abuse (NIDA)||Completed|May 2004|June 2007|Actual|May 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|128|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 23, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00135746||196751|
NCT00136019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0754|SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization||UCB Pharma||Completed|March 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|400|||Both|16 Years|70 Years|No|||July 2010|September 19, 2014|August 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00136019||196730|
NCT00136552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL2000|Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden|FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden||Lymphoma Study Association||Completed|May 2000|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|18 Years|75 Years|No|||July 2007|July 2, 2007|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136552||196690|
NCT00138554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2304E1|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes||Novartis||Completed|November 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|318|||Both|18 Years|80 Years||||May 2012|May 3, 2012|August 27, 2005||||||https://clinicaltrials.gov/show/NCT00138554||196537|
NCT00138567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2309E1|Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|January 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||530|||Both|18 Years|78 Years||||May 2012|May 4, 2012|August 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138567||196536|
NCT00135720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002142|Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris|A Double-Blinded, Placebo-Controlled Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris||Massachusetts General Hospital|Yes|Completed|June 2004|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|65 Years|No|||May 2008|June 2, 2015|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135720||196753|
NCT00135733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P002141|A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Efficacy and Safety of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus||Massachusetts General Hospital|No|Terminated|April 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 10, 2009|August 24, 2005|No|Yes|Pharmaceutical sponsor withdrew financial support.|No||https://clinicaltrials.gov/show/NCT00135733||196752|
NCT00139139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-2643|A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A|A Blinded Randomized Comparative Study of Hepatitis A Vaccine and Immune Globulin for Postexposure Prophylaxis for Hepatitis A Disease||Centers for Disease Control and Prevention||Completed|September 2003|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1500|||Both|2 Years|40 Years|No|||August 2005|August 29, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139139||196492|
NCT00139438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-038|Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)|Improving Management of Patients at High Risk for Osteoporotic Fractures||Merck Sharp & Dohme Corp.||Completed|September 2004|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||4266|||Both|45 Years|N/A|No|||October 2015|October 9, 2015|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139438||196470|
NCT00136305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 08-102E|Comparing Asthma Action Plans for Pediatric Asthma|Relative Effectiveness of Pictorial and Written Asthma Action Plans for Pediatric Asthma||Children's Mercy Hospital Kansas City|No|Terminated|August 2005|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|6 Years|18 Years|No|||February 2015|February 3, 2015|August 26, 2005||No|PI moved to a different institution|No||https://clinicaltrials.gov/show/NCT00136305||196709|
NCT00139334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103992|A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh|Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh||GlaxoSmithKline||Completed|June 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|5 Weeks|7 Weeks|Accepts Healthy Volunteers|||September 2011|September 21, 2011|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139334||196477|
NCT00139347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/024|Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants|A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants||GlaxoSmithKline||Completed|December 2003|||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||6360|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2012|November 21, 2012|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139347||196476|
NCT00139815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103420|Michelangelo - Oasis 5|An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes||GlaxoSmithKline|Yes|Completed|March 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20078|||Both|21 Years|N/A|No|||October 2011|October 13, 2011|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00139815||196443|
NCT00139828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB2000.03|Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)|Post Marketing Study in Haemophilia B Patients Using Nonafact® 100 IU/ml Powder and Solvent for Solution for Injection(Human Coagulation Factor IX)(Human Plasma Derived Factor IX Product, Freeze Dried)||Sanquin|No|Completed|May 2003|February 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|6 Years|N/A|No|||August 2007|August 29, 2007|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139828||196442|
NCT00140426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0673|A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa|A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa||University of Colorado, Denver|Yes|Completed|August 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Female|12 Years|21 Years|No|||December 2015|December 29, 2015|August 31, 2005|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00140426||196397|
NCT00140673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/023|A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.|A Placebo-controlled, Multi-country & Multi-center Study to Assess the Efficacy, Safety & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants||GlaxoSmithKline||Completed|August 2003|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|63227|||Both|6 Weeks|13 Weeks|Accepts Healthy Volunteers|||September 2012|September 13, 2012|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140673||196378|
NCT00141011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI-ASP-0502|Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke|ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke||Neurobiological Technologies|Yes|Terminated|September 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|277|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|August 30, 2005|Yes|Yes|Futility|No||https://clinicaltrials.gov/show/NCT00141011||196353|
NCT00141427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081005|Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.|Pregabalin In Partial Seizures (Preps) : An Open-Label, International, Multicenter Add-On Therapy Trial||Pfizer||Completed|November 2004|May 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||540|||Both|18 Years|N/A|No|||June 2006|March 21, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141427||196321|
NCT00141752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSN II.10|Toronto Bedside Swallowing Screening Test (TOR-BSST) - A Bedside Swallowing Screening for Stroke Patients|Toronto Bedside Swallowing Screening Test (TOR-BSST) - A Bedside Swallowing Screening for Stroke Patients||University Health Network, Toronto||Completed|October 2002|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|311|||Both|N/A|N/A|No|Probability Sample|Newly admitted patients with a diagnosis of stroke (refer to eligibility criteria)|January 2012|January 9, 2012|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00141752||196296|
NCT00142285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDR,B 2004-010|Zinc Pneumonia Outpatient Trial in Children < 2 Years|Efficacy of Zinc in the Treatment of Outpatient Pneumonia in an Urban Slum Among Children Less Than 2 Years Old||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|November 2004|May 2008|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|2260|||Both|N/A|23 Months|No|||July 2006|January 6, 2013|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00142285||196256|
NCT00134966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200A2305|A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa|A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa||Novartis||Completed|August 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|493|||Both|30 Years|80 Years|No|||March 2008|March 28, 2008|August 23, 2005||||||https://clinicaltrials.gov/show/NCT00134966||196811|
NCT00136032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001p-001761|Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women|Gender-Specific Effects of Physiologic GH Administration on Cardiovascular Risk Factors in Women With Growth Hormone Deficiency||Massachusetts General Hospital|Yes|Completed|January 2002|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Female|18 Years|65 Years|No|||February 2008|February 12, 2008|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00136032||196729|
NCT00136331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-PAN-05-12|Study of a Pandemic Influenza Vaccine|Phase Ia Study of a Pandemic Influenza Vaccine||CSL Limited||Completed|October 2005|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||400|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 6, 2008|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00136331||196707|
NCT00136565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH05-1T|Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma|A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-Cell Lymphoma||Lymphoma Study Association||Active, not recruiting|November 2005|November 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||November 2007|November 6, 2007|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00136565||196689|
NCT00136318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18075|Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients|Efficacy and Tolerability of Escitalopram for the Prevention of Pegylated Interferon Alfa Associated Depression in Patients With Chronic Hepatitis C Infection: a Randomized Controlled Trial.|CIPPAD|Charite University, Berlin, Germany|Yes|Completed|January 2004|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|208|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|August 26, 2005||No||No|October 25, 2012|https://clinicaltrials.gov/show/NCT00136318||196708|Random assignment of patients before the preobservation period followed by patient withdrawal from the trial independent of antidepressant treatment weakens the strength of the randomization.
NCT00136539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-222|Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer|Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer||Dana-Farber Cancer Institute||Completed|March 1999|March 2012|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136539||196691|
NCT00135993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0792|Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome||UCB Pharma||Completed|May 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|811|||Both|18 Years|75 Years|No|||September 2009|September 24, 2014|August 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00135993||196732|
NCT00136006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05-0061|The Vancouver-BOLD Study: The Burden of Chronic Obstructive Lung Disease|The Burden of Chronic Obstructive Lung Disease (BOLD) Study||University of British Columbia||Active, not recruiting|August 2005|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|40 Years|90 Years|No|Probability Sample|Population of Vancouver, BC, Canada|January 2013|January 30, 2013|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00136006||196731|
NCT00152698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retina-Irbesartan|Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia|A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Study the Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia||University of Erlangen-Nürnberg Medical School|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||80|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152698||195469|
NCT00152711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 03-07|Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis|Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis: A Prospective Cross Over Trial||University Hospital, Angers||Recruiting|September 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||September 2005|February 12, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152711||195468|
NCT00152724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP96-04|Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers|Etude de la Reserve Vasomotrice Microcirculatoire cutanée||University Hospital, Angers|No|Recruiting|January 1996|January 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||85|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 16, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152724||195467|
NCT00139061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091034|Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia||Pfizer||Completed|March 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||128|||Both|18 Years|N/A|No|||December 2006|October 30, 2007|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00139061||196498|
NCT00139074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449L00010|Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients|Phase IV Study to Investigate if Valproate Add-on Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients||AstraZeneca|No|Terminated|July 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|August 29, 2005|Yes|Yes|terminated due to very low recruitment rate (27 June 2006)|No||https://clinicaltrials.gov/show/NCT00139074||196497|
NCT00139360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD-11933|Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma|Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma and Predictive Value of Angiogenic Markers||Haukeland University Hospital||Completed|May 2005|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00139360||196475|
NCT00139373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM0323|Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy|Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy||Groupe Hospitalier Pitie-Salpetriere||Recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Both|30 Years|80 Years|No|||July 2005|September 12, 2007|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139373||196474|
NCT00139841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDX-105-03|Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab|A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab||Teva Pharmaceutical Industries||Completed|October 2005|October 2009|Actual|July 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|August 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00139841||196441|
NCT00140205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000260|Pharmacokinetics of Leptin Administration During Fasting|Pharmacokinetics of Leptin Administration During Fasting||Beth Israel Deaconess Medical Center|No|Active, not recruiting|February 2001|December 2018|Anticipated|June 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|28|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|August 30, 2005||Yes||||https://clinicaltrials.gov/show/NCT00140205||196414|
NCT00141024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 064|Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Protein Vaccine EP-1043 and the DNA Vaccine EP HIV-1090 Given Alone or in Combination in Healthy, HIV-1-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00141024||196352|
NCT00141453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORIENT|ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial|CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.||Completed|April 2003|January 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|577|||Both|30 Years|70 Years|No|||May 2011|May 9, 2011|August 31, 2005|Yes|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00141453||196319|
NCT00134446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRJVAMC16744|Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder|A Prospective Double Blind Randomized Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder||White River Junction VAMC||Recruiting|March 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|No|||March 2005|October 28, 2005|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00134446||196850|
NCT00134459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3168A2-304|Study Evaluating Bifeprunox in Bipolar Depression|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients With Bipolar Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|434|||Both|18 Years|65 Years|No|||July 2009|February 12, 2013|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134459||196849|
NCT00134732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103478|Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis|Assess the Immunogenicity, Safety & Reactogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants (6-12 Weeks of Age at First Dose) Previously Uninfected With Human Rotavirus||GlaxoSmithKline||Completed|July 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00134732||196828|
NCT00135538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOVER1|The Additional Value of Noninvasive Ventilation Next to Rehabilitation in Hypercapnic COPD Patients|Does Chronic Ventilatory Support Improve the Outcomes of Rehabilitation in Hypercapnic COPD Patients?||Groningen Research Institute for Asthma and COPD|No|Active, not recruiting|November 2004|April 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|40 Years|75 Years|No|||April 2007|April 4, 2007|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135538||196767|
NCT00136045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0790|Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome|A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome||UCB Pharma||Completed|May 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|549|||Both|18 Years|75 Years|No|||February 2010|September 24, 2014|August 24, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00136045||196728|
NCT00136344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC Ref. no. 02/5/46|Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery|Antibiotic Prophylaxis for Cataract Surgery Version 7e January 22 2003||City University, London||Completed|September 2003|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||35000|||Both|18 Years|N/A|No|||June 2007|February 11, 2016|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00136344||196706|
NCT00136760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17566-1|Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia|Incentives Plus Bupropion for Smoking in Schizophrenics||Brown University|Yes|Completed|September 2003|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|57|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2013|October 5, 2015|August 25, 2005||No||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00136760||196674|
NCT00137046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171022|Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes|Efficacy and Safety of Exubera (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 1 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial||Pfizer|No|Terminated|May 2002|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|582|||Both|18 Years|65 Years|No|||December 2009|February 3, 2010|August 26, 2005|Yes|Yes|See termination reason in detailed description.|No|December 7, 2009|https://clinicaltrials.gov/show/NCT00137046||196652|Due to early termination of study, none of the subjects completed the study as planned. Subjects active at the time of study termination completed an end-of-study assessment and a 3-month follow-up visit.
NCT00137293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3163K1-201|Study Evaluating GAP-486 in Heart Rhythm|A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|November 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||30|||Both|18 Years|N/A|No|||December 2007|December 6, 2007|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00137293||196633|
NCT00137306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUT 02-211|Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs|Translating Depression Guidelines Into Substance Abuse Treatment||VA Office of Research and Development|No|Completed|January 2004|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|300|||Both|N/A|N/A|No|||February 2007|April 6, 2015|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00137306||196632|
NCT00137592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4547|Promoting Colorectal Cancer Screening in Rural Colorado|Promoting Colorectal Cancer Screening in Rural Colorado||Centers for Disease Control and Prevention|No|Completed|October 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|480|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 6, 2012|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137592||196610|
NCT00136747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4725(1)|The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1|Developing Medication For Tobacco Addiction: NMDA Agents||New York State Psychiatric Institute||Completed|January 2004|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136747||196675|
NCT00137033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191171|Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population|A Multicenter, Randomized, Active-Controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated With Celecoxib and Low Dose ASA Versus Naproxen and Low Dose ASA in Healthy Subjects (50-75 Years of Age)||Pfizer||Completed|September 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||605|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2007|July 14, 2008|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00137033||196653|
NCT00153296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTP-1004-CZ-0405|Study of Efficacy of Carbamazepine in Therapy of Patients With Moderate Persistent and Severe Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Carbamazepine Efficacy in Moderate Persistent and Severe Asthma Therapy||Centre of Chinese Medicine, Georgia||Completed|August 2004|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|16 Years|65 Years|No|||February 2009|February 18, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153296||195423|
NCT00153569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaemaCBFMM03|Multiepitope Peptide Vaccination in Melanoma|Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma||Charite University, Berlin, Germany||Active, not recruiting|March 2003|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||September 2005|May 25, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153569||195402|
NCT00139087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3010|Mother-Infant Rapid Intervention at Delivery Telephone Outreach for Neonatal Therapy (TOT) Trial.|Mother-Infant Rapid Intervention at Delivery Telephone Outreach for Neonatal Therapy (TOT) Trial.||Centers for Disease Control and Prevention||Completed|January 2002|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|N/A|2 Weeks|No|||August 2005|August 29, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139087||196496|
NCT00139386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-RCT-2005-01|Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial|Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation||Kumamoto University|Yes|Completed|October 2005|April 2012|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1119|||Both|N/A|N/A|No|||April 2013|April 17, 2013|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139386||196473|
NCT00140465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A00803|75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)|A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)||Deutsches Herzzentrum Muenchen|Yes|Completed|October 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||November 2007|November 13, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140465||196394|
NCT00140218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11736|R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis|Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis||Bennett, James P., Jr., M.D., Ph.D.|Yes|Completed|August 2005|December 2006|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|85 Years|No|||January 2008|January 5, 2008|August 30, 2005|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00140218||196413|
NCT00140452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-001|Phase II Study Using Thalidomide for the Treatment of ALS|Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis||Dartmouth-Hitchcock Medical Center|No|Completed|February 2005|November 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||November 2007|November 20, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140452||196395|
NCT00138060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLOGEN|Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants|Protocole Evaluant Chez Des Patients Porteurs de Cancers Colorectaux Metastatiques l'Interet Des Determinants Genotypiques Pour l'Optimisation de l'Efficacite et de la Tolerance de la Chimiotherapie Par Irinotecan et 5-fluorouracile||Institut de Recherche Clinique sur les Cancers et le Sang|No|Completed|June 2005|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|85 Years|No|||July 2010|July 19, 2010|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00138060||196574|
NCT00138294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM H-21853|Control of Epidemic Influenza Through a School-based Influenza Vaccination Program|Phase 4, School-based, Open-labeled Research Trial for Control of Epidemic Influenza Through a School-based Influenza Vaccination Program in Central Texas.|CEI|Baylor College of Medicine|Yes|Active, not recruiting|October 2003|December 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12000|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||March 2010|March 4, 2010|August 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00138294||196557|
NCT00134979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOR258F2402|Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease|Efficacy and Safety of Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease||Novartis||Completed|October 2004|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|847|||Both|40 Years|N/A|No|||October 2011|October 24, 2011|July 26, 2005||||No||https://clinicaltrials.gov/show/NCT00134979||196810|
NCT00135252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasal cannula|Method of Oxygen Delivery and the Effect on Transcutaneous PaCO2|Method of Oxygen Delivery (Comparison Nasal Cannula vs Oxygen Hood) and the Effect on Transcutaneous PaCO2||The University of Texas Health Science Center, Houston||Terminated|August 2005|June 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|44|||Both|N/A|6 Months|No|||December 2007|December 23, 2007|August 23, 2005|||Investigator left institution|No||https://clinicaltrials.gov/show/NCT00135252||196789|
NCT00135759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15469-1|Addition of Naltrexone to Methadone Taper|Place of Low-Dose Naltrexone in Opiate Detoxification||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2005|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|174|||Both|18 Years|65 Years|No|||August 2008|August 18, 2008|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00135759||196750|
NCT00136604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104727 (Booster - 15-24 mths)|Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m|Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax™ ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix™-HepB/Hib-MenAC||GlaxoSmithKline||Completed|January 2006|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|||Actual|617|||Both|427 Days|730 Days|Accepts Healthy Volunteers|||September 2011|September 29, 2011|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00136604||196686|
NCT00137072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481230|Mild To Moderate Erectile Dysfunction Study|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose||Pfizer||Completed|April 2005|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|355|||Male|18 Years|70 Years|No|||September 2011|September 3, 2011|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00137072||196650|
NCT00137345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-318|Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients|A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus Versus Cyclosporine When Combined in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticosteroids in Primary De Novo Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|June 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|13 Years|N/A|No|||September 2006|February 7, 2013|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00137345||196629|
NCT00136578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSP10014|Ispinesib In Combination With Carboplatin In Patients With Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Carboplatin on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors.||GlaxoSmithKline||Completed|October 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136578||196688|
NCT00136591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL05-1|A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma|A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma||Lymphoma Study Association|Yes|Terminated|September 2005|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||October 2010|October 22, 2010|August 26, 2005||No|An arm closed due to lack of efficacy|No||https://clinicaltrials.gov/show/NCT00136591||196687|
NCT00136773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIB002FUS12|Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus|Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus||Novartis||Completed|April 2003|November 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|332|||Both|21 Years|85 Years||||March 2008|March 8, 2011|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00136773||196673|
NCT00137878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-001.007|TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer|A Phase II Randomized Trial Comparing TNFerade™ Biologic With Capecitabine and Radiation Therapy Followed by Surgical Resection Versus Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer||GenVec||Completed||||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||May 2011|February 22, 2012|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00137878||196588|
NCT00137891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYR01205|Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone|Phase I Study Comparing Pharmacokinetics and Safety Profile of Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone||Sanofi||Completed|June 2005|August 2005||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||46|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|August 26, 2005||||||https://clinicaltrials.gov/show/NCT00137891||196587|
NCT00137059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI R02-52|Acetaminophen-Induced Hepatotoxicity in Chronic Alcohol Abusers|||Queen's University||Completed|November 2002|May 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||40|||Both|18 Years|N/A|No|||August 2005|December 12, 2005|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137059||196651|
NCT00137605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 147|Early Versus Delayed Pneumococcal Vaccination in HIV|A Pilot Study Assessing the Efficacy of Pneumococcal Vaccine in HIV Patients: Delayed Versus Immediate Immunization||CIHR Canadian HIV Trials Network||Completed|September 2004|October 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|79|||Both|18 Years|65 Years|No|||February 2014|February 11, 2014|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00137605||196609|
NCT00153621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3406|Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients|Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric Patients in the Special Immunology, Burgess, and Nephrology Clinics||Children's Research Institute||Completed|September 2004|September 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|320|||Both|1 Year|21 Years|No|||September 2005|May 2, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153621||195398|
NCT00139854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP829|A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety|A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety||UCB Pharma||Completed|August 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||September 2009|August 29, 2013|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139854||196440|
NCT00139867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0780|A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease|A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease||UCB Pharma||Completed|January 2004|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||September 2009|October 17, 2014|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139867||196439|
NCT00140231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002P-000049|Role of Leptin in the Neuroendocrine and Immune Response to Fasting|Role of Leptin in the Neuroendocrine and Immune Response to Fasting in Humans||Beth Israel Deaconess Medical Center|No|Active, not recruiting|October 2002|||October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00140231||196412|
NCT00140712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/253|Ropinirole Tablets In Young Patients With Restless Legs Syndrome|An Open Label, Single Dose, Dose Rising, Multi-centre Study to Assess the Tolerability and Pharmacokinetics of Ropinirole Immediate Release in Adolescent Patients With RLS.||GlaxoSmithKline|No|Completed|June 2005|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|17 Years|No|||May 2011|September 24, 2015|August 31, 2005||No||||https://clinicaltrials.gov/show/NCT00140712||196375|
NCT00140725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUC30938|Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)|A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV)||GlaxoSmithKline||Completed|April 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|65 Years|No|||October 2008|October 15, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140725||196374|
NCT00140686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102247/036|To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines|A Multi-country & Multi-center Study to Assess the Efficacy, Safety & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines||GlaxoSmithKline||Completed|September 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|3994|||Both|6 Weeks|14 Weeks|Accepts Healthy Volunteers|||August 2011|October 2, 2014|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00140686||196377|
NCT00140699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001.264|Balance Control and Maturation in Normal and Deaf Children Aged From 6 to 14 Years Old|Balance Control and Maturation in Normal and Deaf Children Aged From 6 to 14 Years Old||Hospices Civils de Lyon||Active, not recruiting||||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||240|||Both|6 Years|14 Years||||April 2007|April 26, 2007|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00140699||196376|
NCT00134472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H14-HEART-005|Therapeutic Hypothermia for Severe Traumatic Brain Injury in Japan|Therapeutic Strategy for Severe Head Trauma Patients With Mild Hypothermia and Estimation of Medical Expenses in Japan||Yamaguchi University Hospital||Completed|December 2002|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|15 Years|69 Years|No|||May 2012|May 10, 2012|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134472||196848|
NCT00134745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120895|Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome|The Growth of Genitalia Interna and the Bone Mineralization Under Hormonal Replacement Therapy and the Presence of Aortic Root Dilatation in Girls With Turner Syndrome||Hillerod Hospital, Denmark|Yes|Completed|June 2005|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Female|10 Years|25 Years|No|||June 2013|June 13, 2013|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00134745||196827|
NCT00134992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CULT 491 DE 02|A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers|Single-Center, Randomized, Double Masked, Two-Period Cross-Over, Three Days Per Period, Phase IV Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers||Novartis||Completed|August 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2006|June 7, 2006|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00134992||196809|
NCT00135551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|copeadministrator|Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients|The Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial|COPE|COPE Trial Group|Yes|Completed|May 2003|November 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|3501|||Both|40 Years|85 Years|No|||February 2012|February 19, 2012|August 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00135551||196766|
NCT00135772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14009-2|Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2|Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder||National Institute on Drug Abuse (NIDA)||Completed|October 2003|July 2004|Actual|July 2004|Actual|N/A|Observational|Time Perspective: Prospective||||100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2008|August 19, 2008|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00135772||196749|
NCT00141193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQ4-00-02-018|Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)|Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)|PRESAP|Pfizer|Yes|Completed|February 2001|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|1561|||Both|30 Years|N/A|No|||August 2008|August 5, 2008|August 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00141193||196339|
NCT00141908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGY.AN.04|Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate|Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate||American University of Beirut Medical Center|No|Completed|October 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|290|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00141908||196284|
NCT00141921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050111|Pediatric Open-Label Extension Study|An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis||Amgen|Yes|Active, not recruiting|August 2005|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|182|||Both|N/A|N/A|No|||March 2016|March 18, 2016|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00141921||196283|
NCT00137631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-CCU224517|Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM|Evaluation of Many Men, Many Voices, A Group Intervention for STD/HIV Prevention for Black Men Who Have Sex With Men (MSM) in the New York Metropolitan Area by People of Color in Crisis, Brooklyn, NY|3MV|Centers for Disease Control and Prevention|No|Completed|August 2005|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|341|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|June 23, 2010|August 26, 2005||No||No|March 10, 2010|https://clinicaltrials.gov/show/NCT00137631||196607|
NCT00137904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM0242|Sleep Disorders in Patients With Multiple Sclerosis|Study of Sleep Disorders and Fatigue in Patients With Multiple Sclerosis||Groupe Hospitalier Pitie-Salpetriere||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||51|||Both|18 Years|55 Years|No|||August 2005|February 8, 2006|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137904||196586|
NCT00138138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-100|Psychostimulants for Fatigue in Prostate Cancer|Psychostimulants for Fatigue in Advanced Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|October 2002|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Male|40 Years|90 Years|No|||December 2007|December 6, 2007|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138138||196568|
NCT00137319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-04-016|Impedance Threshold Device Tilt Study|An Evaluation of an Impedance Threshold Device (ITD) to Improve Hemodynamic Function During Orthostatic Challenge in Burn Patients||United States Army Institute of Surgical Research|No|Terminated|October 2004|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|August 25, 2005|||Aims of the study re-evaluated, did not justify allocation of resources.|No||https://clinicaltrials.gov/show/NCT00137319||196631|
NCT00137332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3163K1-202|Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease|A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|November 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||December 2007|December 6, 2007|August 25, 2005||||||https://clinicaltrials.gov/show/NCT00137332||196630|
NCT00163306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/M3-339|Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)|Complete Remission: Evaluation of the Complete Remission Rates in Patients With Symptomatic Non-erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (GERD) Treated With Pantoprazole 40 Milligram o.d. Over 4 or 8 or 12 Weeks||Takeda||Completed|May 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1200|||Both|18 Years|N/A|No|||May 2007|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163306||194671|
NCT00140244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000484|Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome|Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients||Beth Israel Deaconess Medical Center||Active, not recruiting|December 2001|July 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00140244||196411|
NCT00140478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-249|Mifepristone (RU-486) in Androgen Independent Prostate Cancer|A Phase II Study of Mifepristone (RU-486) in Androgen Independent Prostate Cancer With Correlative Assessment of Androgen Receptor Co-Repressor Proteins||Dana-Farber Cancer Institute||Completed|February 2005|January 2008|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Male|18 Years|N/A|No|||December 2009|December 7, 2009|August 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00140478||196393|
NCT00138073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001381/1; MGH|Effectiveness of a Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation|Effectiveness of a Web-Based Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation Among Nurses and Physicians||Massachusetts General Hospital|Yes|Terminated|December 2005|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|55|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|August 26, 2005||No|The study was terminated because of lack of resources to complete it.|No|March 24, 2014|https://clinicaltrials.gov/show/NCT00138073||196573|Study not completed.
NCT00138086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-BEAM|Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma|Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Transplantation (ASCT)||Lymphoma Study Association||Completed|March 2005|March 2009||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|65 Years|No|||September 2006|September 6, 2006|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138086||196572|
NCT00141466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPA-2005|Implementation of a New Strategy to Identify HNPCC Patients|Cost Effectiveness of Two Different Implementation Procedures to Change Clinicians Practice Roles in the Detection of Hereditary Colorectal Cancer||Radboud University||Recruiting|September 2005|July 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|360|||Both|N/A|N/A|No|||February 2007|April 22, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141466||196318|
NCT00141479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.2.013|To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox|A Single-center Safety and Tolerability Study to Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder||Solvay Pharmaceuticals||Completed|May 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||May 2006|January 15, 2015|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141479||196317|
NCT00134485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091026|Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia|Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia||Pfizer||Completed|March 2005|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||December 2006|October 28, 2007|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134485||196847|
NCT00134758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030419|Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients|Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF||Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|October 2004|October 2009|Anticipated|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|No|||July 2009|July 28, 2009|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134758||196826|
NCT00135564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|711202/008|Study to Evaluate GlaxoSmithKline (GSK) Biologicals’ MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers|Evaluate the Persistence and Immune Memory Induced by a Primary Vaccination Course With GSK Biologicals’ MenC-TT (1 Formulation) & GSK Biologicals’ Hib-MenC-TT (2 Formulations) or Meningitec™ in Healthy Toddlers Aged 12-15 Mths Primed in Study 711202/001||GlaxoSmithKline||Completed|January 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||November 2006|November 23, 2006|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00135564||196765|
NCT00136357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSG 2004-01|Treatment of Posttraumatic Stress Disorder in Kosovar High School Students Using Mind-Body Skills Groups|Treatment of Posttraumatic Stress Disorder in Kosovar High School Students Using Mind-Body Skills Groups: A Randomized Controlled Trial||The Center for Mind-Body Medicine|No|Completed|August 2004|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|82|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|August 26, 2005||No||No|January 27, 2014|https://clinicaltrials.gov/show/NCT00136357||196705|
NCT00142649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250|Adherence to Weight Loss for Hypertension in African American Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2007|Actual|August 2007|Actual|N/A|Interventional|Primary Purpose: Prevention|||||||Female|N/A|N/A|No|||January 2008|January 18, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142649||196228|
NCT00142935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18641-1|Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1|Opiate Replacement Therapy at Release From Incarceration||The Miriam Hospital|Yes|Completed|September 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|87|||Both|18 Years|N/A|No|||May 2009|May 8, 2014|September 1, 2005||No||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00142935||196207|
NCT00136786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4725(A)|Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3|Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals||New York State Psychiatric Institute||Completed|December 2006|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|25|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00136786||196672|
NCT00136799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320B2302|Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia|Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia||Novartis||Completed|June 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|325|||Both|18 Years|80 Years|No|||November 2011|November 7, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136799||196671|
NCT00137085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI R04-43|Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation|Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation||Queen's University||Completed|September 2004|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||124|||Both|14 Years|65 Years|No|||April 2006|June 13, 2007|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137085||196649|
NCT00137358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH175-04D|Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer|Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer||University of Alabama at Birmingham||Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|19 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|August 26, 2005||No|unable to obtain funding to conduct study|No||https://clinicaltrials.gov/show/NCT00137358||196628|
NCT00137644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-CCU324516|Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents|Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Innovative HIV Prevention Intervention for Minority Adolescents by the Philadelphia Health Management Corporation in Philadelphia, PA||Centers for Disease Control and Prevention|No|Completed|March 2005|January 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|264|||Male|12 Years|18 Years|Accepts Healthy Volunteers|||January 2010|January 6, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137644||196606|
NCT00138359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-043|Mass Treatment T Solium Community Study|The Effect of a Single Control Intervention in the T Solium Life Cycle||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|December 2004|January 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||4200|||Both|2 Years|N/A|Accepts Healthy Volunteers|||December 2006|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138359||196552|
NCT00163319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/IT-101|Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)|Comparison of Inhaled Ciclesonide (640 Mcg/Day) and Fluticasone Propionate (1000 Mcg/Day) in Patients With Moderate and Severe Persistent Asthma||Takeda||Completed|November 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|75 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163319||194670|
NCT00137020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281117|Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder|A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder||Pfizer||Completed|November 2004|April 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||294|||Both|18 Years|65 Years|No|||August 2006|August 11, 2006|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137020||196654|
NCT00137566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSB-2004-paracetamol|The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau|The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau||Bandim Health Project||Active, not recruiting|May 2004|January 2010|Anticipated|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|N/A|15 Years|No|||July 2010|July 6, 2010|August 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00137566||196612|
NCT00137826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-369|Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma|Phase II Study of Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Malignant Mesothelioma||Dana-Farber Cancer Institute||Completed|February 2004|July 2009|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2011|December 23, 2011|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137826||196592|
NCT00138099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092103|Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)|Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)||McMaster University|Yes|Completed|July 2004|June 2006|Actual|||Phase 2/Phase 3|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|140|||Both|18 Years|N/A|No|||November 2006|May 30, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138099||196571|
NCT00138307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-027|Correlates of Protection in Ghana|Immunological Correlates of Protection Against Clinical Malaria in a Cohort of Young Children in the Kassena Nankana District of Ghana||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2006||||N/A|Observational|Time Perspective: Prospective||||300|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||March 2007|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138307||196556|
NCT00135005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2103|Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)|A Phase I Multicenter, Dose Escalation Study of AMN107 in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant Gastrointestinal Stromal Tumors (GIST)||Novartis||Completed|August 2005|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|August 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135005||196808|
NCT00135018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEC-DOC-CXB-A3|Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer|Phase II Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer||Organisation for Oncology and Translational Research|Yes|Completed|February 2006|May 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Female|18 Years|N/A|No|||May 2012|May 22, 2012|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00135018||196807|
NCT00135291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2517-D02|Effect of Leukoreduced Blood Transfusions on Infection Following Trauma|Effect of Leukoreduction in Infection Risk in Trauma||University of Washington||Completed|February 2003|September 2004|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 2, 2008|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00135291||196786|
NCT00135265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15677|PROS Smokebusters: Adolescent Smoking Cessation in Pediatric Primary Care|Adolescent Smoking Cessation in Pediatric Primary Care||University of Rochester||Completed|October 2006|January 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|4100|||Both|14 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 24, 2010|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00135265||196788|
NCT00135278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0584|Cerebrospinal Fluid (CSF) Drainage and Cytokine Profiling in the Treatment of Acute Spinal Cord Injury (SCI)|Cerebrospinal Fluid (CSF) Drainage and Cytokine Profiling in the Treatment of Acute Spinal Cord Injury (SCI) - A Pilot Study||University of British Columbia|No|Recruiting|March 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Both|17 Years|65 Years|No|||April 2011|April 8, 2011|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00135278||196787|
NCT00136058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hipfracture1|Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients||University of Alberta||Completed|January 2002|April 2006||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||250|||Both|50 Years|N/A|No|||December 2011|December 15, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136058||196727|
NCT00136617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWS|Outpatient Treatment of Alcohol Withdrawal Syndrome|Comparison of a Fixed-Schedule Therapy Versus a Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome in Medical Out-Patients||Hvidovre University Hospital|Yes|Completed|August 2003|September 2008|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||February 2009|February 27, 2009|August 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00136617||196685|
NCT00140816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melk61015|Dairy Products and Metabolic Effects (Norwegian Part)|Dairy Products and Metabolic Effects - A Multicentre Nordic Study||Oslo University Hospital||Completed|September 2005|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|40|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2009|July 3, 2011|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00140816||196368|
NCT00141622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 04/Q0803/181|Sodium-Endothelial Function-CKD Study|Does Sodium Affect Endothelial Function in Individuals With Chronic Kidney Disease?||St George's, University of London||Completed|April 2005|October 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|50|||Both|18 Years|75 Years|No|||August 2005|May 14, 2007|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00141622||196306|
NCT00141895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGY.AN.03|A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death|A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Intrauterine Fetal Death||American University of Beirut Medical Center|No|Terminated|September 2004|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|September 1, 2005||No|Difficulty recruiting|No||https://clinicaltrials.gov/show/NCT00141895||196285|
NCT00142155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-075|Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia|Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute||Completed|January 2002|March 2007|Actual|March 2007|Actual|N/A|Interventional|N/A|||Anticipated|300|||Both|30 Years|90 Years|No|||June 2011|June 23, 2011|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142155||196266|
NCT00142389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26748|Mother's Gift Project|Comparison of Maternal and Infant Immunization Strategies to Prevent Pneumococcal Disease||Johns Hopkins Bloomberg School of Public Health||Completed|August 2004|December 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||680|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2005|June 21, 2011|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142389||196248|
NCT00142597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT001111-01|Effectiveness of Acupuncture in Relieving Pain Due to Fibromyalgia|Mechanisms of Acupuncture Analgesia||University of Michigan||Completed|May 2005|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Female|18 Years|75 Years|No|||December 2014|April 9, 2015|September 1, 2005|No|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00142597||196232|
NCT00137917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|710158/002|Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs|A Primary Vaccination Study to Evaluate Immunogenicity, Safety & Reactogenicity of 3 Doses of GSK Biologicals/Finlay's Meningococcal B Candidate Vaccine Given Intramuscularly Using Either 0-2-4 Mth or 0-1-6 Mth Schedule to Healthy Subjects Aged 12-18 Yrs||GlaxoSmithKline||Completed|July 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|478|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00137917||196585|
NCT00137579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINGRIP03|Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation Therapy|Phase IV, Simple Blind, 2-Parallel Groups Randomized Trial to Evaluate the Safety and Effectiveness of the Intramuscular Vs Subcutaneous Route for the Administration of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation||Catalan Institute of Health||Completed|September 2003|May 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||216|||Both|18 Years|95 Years|No|||January 2003|December 12, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00137579||196611|
NCT00137839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-253|Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung|A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2004|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|N/A|No|||August 2013|August 5, 2013|August 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00137839||196591|
NCT00134498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091025|A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides|Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia||Pfizer||Completed|February 2005|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||March 2007|November 15, 2007|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134498||196846|
NCT00134511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091027|Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder|Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia||Pfizer||Completed|March 2005|November 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2006|November 5, 2007|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134511||196845|
NCT00138320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-041|Herpevac Neonatal Substudy|Transfer of Herpes Simplex Virus Type 2 gD Subunit Vaccine-Induced Antibodies From Mothers to Neonates||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|August 2005|May 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|6|Samples Without DNA|Sera obtained from collected blood samples will be used. Ten mL of blood will be collected      at the maternal blood draw and from the umbilical vein. Three to 5 mL of blood will be      collected at each infant blood draw|Both|N/A|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who become pregnant while enrolled as participants in the Herpevac Trial for Women,        DMID Protocol 01-643|August 2013|September 12, 2013|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138320||196555|
NCT00135031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002089|Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Safety and Efficacy Evaluation of Bifidobacterium Infantis 35624 in Female Subjects With Irritable Bowel Syndrome||Procter and Gamble|No|Completed|January 2004|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||362|||Female|18 Years|65 Years|No|||June 2011|June 14, 2011|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00135031||196806|
NCT00135577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABD101684|Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects|A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects||Cubist Pharmaceuticals LLC||Completed|September 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|67|||Both|18 Years|N/A|No|||September 2009|September 1, 2015|August 24, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00135577||196764|
NCT00136370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3842|Prevention of Perinatal Sepsis (PoPS): Evaluation of Chlorhexidine Wipes of Birth Canal and Newborn|Preventing Serious Neonatal and Maternal Peripartum Infections in Developing Country Settings With a High Prevalence of HIV Infection: Assessment of the Disease Burden and Evaluation of an Affordable Intervention in Soweto, South Africa||Centers for Disease Control and Prevention|Yes|Recruiting|April 2004|November 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|8000|||Female|15 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 21, 2007|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136370||196704|
NCT00140829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM01-29|SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias|Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias|Spatax|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|July 2003|December 2012|Anticipated|||Phase 1|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|6000|||Both|2 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|French population|March 2012|March 26, 2012|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00140829||196367|
NCT00141180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3081018|CP-481,715 Nickel Allergy Study.|Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.||Pfizer||Completed|September 2003|October 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2005|July 23, 2006|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00141180||196340|
NCT00142194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|476-2005|Markers of Oxidative Stress Present in Blood in Patients With Atrial Fibrillation|Markers of Oxidative Stress Present in Blood in Patients With Atrial Fibrillation||Emory University|No|Completed|June 2005|November 2007|Actual|November 2007|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|47|||Both|18 Years|N/A|No|Probability Sample|Patients older than 18 years with or without permanent or persistent atrial fibrillation.|September 2013|September 26, 2013|August 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00142194||196263|
NCT00142207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVG32|Preventing Malaria During Pregnancy in Epidemic-Prone Areas.|The Efficacy and Cost-Effectiveness of Malaria Prevention in Pregnancy in an Area of Low and Unstable Transmission in Kabale, Uganda: Use of Intermittent Preventive Treatment and Insecticide-Treated Nets.||Gates Malaria Partnership|Yes|Completed|January 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|4775|||Female|N/A|N/A|No|||February 2008|February 7, 2008|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142207||196262|
NCT00142220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMEGAVEN|The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients|Comparison Between Two Different Proportions of Omega-3- and Omega-6-Fatty Acids in the Parenteral Nutrition of Critically Ill Patients||University Medicine Greifswald||Completed|January 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|N/A|N/A|No|||September 2006|September 8, 2006|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00142220||196261|
NCT00142168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-158|CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia|Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Terminated|September 2004|April 2008|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|80 Years|No|||November 2015|November 11, 2015|September 1, 2005|Yes|Yes|Toxicity|No|December 19, 2012|https://clinicaltrials.gov/show/NCT00142168||196265|Due to toxicity, study was terminated.
NCT00142402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ndcnmss2004|Modafinil in Multiple Sclerosis|Modafinil for Improving New Learning and Memory in Multiple Sclerosis||Kessler Foundation||Completed|June 2003|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||September 2013|September 25, 2013|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00142402||196247|
NCT00143260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481240|Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose|Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II||Pfizer||Completed|August 2005|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Male|18 Years|70 Years|No|||June 2012|June 7, 2012|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143260||196182|
NCT00143273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2181037|Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation|Dose Response Study Of Lasofoxifene In Postmenopausal Women With Osteoporosis (Placebo-Controlled, Multicenter, Double-Blind, Comparative Study) - Japanese Asian Dose Evaluation: JADE|JADE|Ligand Pharmaceuticals||Completed|June 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|497|||Female|40 Years|80 Years|No|||August 2011|August 8, 2011|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00143273||196181|
NCT00143286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051035|A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation|A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation||Pfizer||Completed|April 2003|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2000|||Both|18 Years|75 Years|No|||June 2007|June 1, 2007|August 31, 2005||||||https://clinicaltrials.gov/show/NCT00143286||196180|
NCT00138697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB97003 (A & B)|Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients|Kinetics, Efficacy and Safety of IVIG-L (Human Normal Intravenous Immunoglobulin for Intravenous Use) in Hypogammaglobulinemia Patients||Sanquin||Completed|May 2001|December 2004|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||April 2007|April 18, 2007|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138697||196526|
NCT00142896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18125-1|Tramadol to Reduce Opioid Withdrawal Symptoms|Withdrawal Suppression Efficacy of Tramadol||National Institute on Drug Abuse (NIDA)||Completed|February 2005|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|16|||Both|21 Years|55 Years|No|||August 2008|August 14, 2008|September 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00142896||196210|
NCT00137267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-145|A Brief Community Linkage Intervention for Dually Diagnosed Individuals|A Brief Community Linkage Intervention for Dually Diagnosed Individuals|TLC|VA Office of Research and Development|Yes|Completed|June 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|102|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|August 25, 2005||No||No|August 25, 2014|https://clinicaltrials.gov/show/NCT00137267||196635|
NCT00137280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNT 03-213|Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)|Implementing Effective, Collaborative Care for Schizophrenia|EQUIP-2|VA Office of Research and Development|No|Completed|June 2007|May 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1067|||Both|18 Years|N/A|No|||July 2014|April 6, 2015|August 25, 2005||No||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00137280||196634|
NCT00138112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-142|Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation|Randomized Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Early Viridans Streptococcal Sepsis After Hematopoietic Cell Transplantation||Memorial Sloan Kettering Cancer Center||Completed|November 2003|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||126|||Both|18 Years|N/A|No|||September 2006|September 7, 2006|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138112||196570|
NCT00138333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-046|Mercury Levels in Premature and LBW Infants Receiving Thimerosal-containing Vaccines|Assessment of Mercury Levels and Metabolism in Premature and Low Birth Weight (LBW) Infants Receiving Vaccines Containing Thimerosal||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2005|November 2006||||N/A|Observational|Time Perspective: Prospective|||Actual|71|||Both|32 Weeks|36 Weeks|Accepts Healthy Volunteers|||October 2007|November 10, 2011|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138333||196554|
NCT00138346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-045|Epi Cystic Hydatid Disease Peru|Epidemiology of Human Cystic Hydatid Disease||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2004|April 2007||||N/A|Observational|Time Perspective: Prospective||||840|||Both|5 Years|N/A|Accepts Healthy Volunteers|||December 2006|August 26, 2010|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00138346||196553|
NCT00134771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/2/109|Trial of Nutritional Supplementation in Infants Born Small for Gestational Age|||Institute of Child Health||Completed|February 2001|June 2003||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|10 Days||||August 2005|November 4, 2005|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00134771||196825|
NCT00135343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-121|A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen|A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen||Bristol-Myers Squibb||Completed|April 2004|October 2005||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2|||60|||Both|18 Years|N/A|No|||July 2008|April 7, 2011|August 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00135343||196782|
NCT00135785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18185-2|Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Bupropion vs Placebo for the Treatment of Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)|Yes|Completed|October 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 3, 2009|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00135785||196748|
NCT00135798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2ALL LADR Protocol 62498(IND)|Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation|The Adult-to-adult Living Donor Liver Transplantation Cohort Study (A2ALL) Low Accelerated Dosing Regimen (LADR) Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C Virus (HCV) After Liver Transplantation|LADR|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|September 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|79|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|August 24, 2005|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00135798||196747|Failure to reach target of 84 transplanted patients (47 achieved); Inability to complete planned 12 weeks of treatment for some; Incomplete HCV RNA follow up; Inconsistent limits of detection of HCV RNA; Noncompliance with assigned treatment.
NCT00136071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|msakr99|Transvaginal Tension Free Vaginal Tape-Obturator (TVT-O) Versus Transobturator Tape-Mentor (TOT) in the Management of Urodynamic Stress Urinary Incontinence|Randomised Prospective Blinded Trial Comparing Transvaginal Tension Free Vaginal Tape-Obturator (Outside-In) With Transobturator Tape-Mentor (Inside-Out) in Surgical Management of Urodynamic Stress Urinary Incontinence||South Glasgow University Hospitals NHS Trust||Recruiting|May 2005|May 2010||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||230|||Female|N/A|N/A|No|||May 2005|December 19, 2005|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136071||196726|
NCT00149578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1204|A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer|A Phase II Study of Induction Chemotherapy Followed by Concurrent Chemotherapy With Radiotherapy in Locally Advanced Pancreatic Cancer||National Health Research Institutes, Taiwan|Yes|Recruiting|October 2004|October 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||May 2007|May 16, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149578||195707|
NCT00151073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2001-051|Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate|An Evaluation of Estramustine, Docetaxel and Zoledronate in Patients With Hormone-Refractory Adenocarcinoma of the Prostate||University of Michigan Cancer Center|Yes|Completed|April 2002|September 2007|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|N/A|No|||January 2015|January 21, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151073||195594|
NCT00150839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COATS|Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy|Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-Blind, Placebo-Controlled Trial|COATS|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|March 2006|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||July 2008|November 20, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150839||195612|
NCT00151060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9815|Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate|Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Patients With Hormonally Responsive Adenocarcinoma of the Prostate||University of Michigan Cancer Center|Yes|Completed|December 1998|June 2006|Actual|November 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|N/A|No|||January 2015|January 19, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151060||195595|
NCT00151866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03.113|Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma|A Multicentre Randomised Study of the Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma||Sanquin Research & Blood Bank Divisions||Completed|October 2003|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||September 2005|February 26, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151866||195533|
NCT00152165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB# 4895|Use of Radiostereometric Analysis (RSA) Following Spinal Fusion Versus the DYNESYS Stabilization System|A Biomechanical Assessment of the DYNESYS Stabilization System Using Radiostereometric Analysis||State University of New York - Upstate Medical University||Completed|November 2003|||||N/A|Observational|Time Perspective: Prospective||||12|||Both|18 Years|60 Years|No|||December 2008|December 1, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152165||195510|
NCT00152178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91023033|The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)|The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)||Taiho Pharmaceutical Co., Ltd.||Completed|July 1996|August 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|680|||Female|20 Years|65 Years|No|||July 2011|July 6, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152178||195509|
NCT00148252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILS 02-08144|Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant|Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant - Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)||University of Oslo School of Pharmacy||Terminated|February 2003|February 2007|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||298|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|September 6, 2005|||To high rejection rate in CsA withdrawal arm|No||https://clinicaltrials.gov/show/NCT00148252||195808|
NCT00148564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Energy|Energy Homeostasis Under Treatment With Atypical Antipsychotics|Energy Homeostasis and Metabolism in Patients With Schizophrenic Disorders Under Treatment With Atypical Antipsychotics||Charite University, Berlin, Germany|Yes|Completed|March 2004|June 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||September 2008|September 26, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00148564||195784|
NCT00148538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-3-05-1903-RS|Type 1 Diabetes Aerobic and Resistance Exercise (T1-DARE)|Type 1 Diabetes Aerobic and Resistance Exercise (T1-DARE)||Ottawa Hospital Research Institute||Completed|July 2005|April 2012|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|66|||Both|16 Years|N/A|No|||February 2013|February 25, 2013|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00148538||195786|
NCT00148551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 (C03 - 0236)|Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.|Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.||Canadian Retinal Trials Group||Active, not recruiting|January 2004|March 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|50 Years|N/A|No|||July 2007|July 26, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148551||195785|
NCT00147927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49924|Using Tailored Emails to Motivate Healthy Behavior Among Employees|Using Tailored Emails to Motivate Healthy Behavior, Improve Health Status, & Reduce Health Care Costs in Employee Populations: A Randomized Trial||Robert Wood Johnson Foundation||Completed|December 2003|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 31, 2007|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147927||195833|
NCT00148213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETAT|Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma|Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma||University Hospital Muenster||Completed|September 2003|June 2005||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|N/A|N/A|No|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148213||195811|
NCT00148512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1198.101|A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations|A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)||Boehringer Ingelheim||Completed|March 2003|February 2005||February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|254|||Both|42 Years|80 Years|No|||October 2013|October 28, 2013|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148512||195788|
NCT00148993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100798-HMO-CTIL|Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors|Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors||Hadassah Medical Organization||Withdrawn|July 1998|July 2005|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|100|||Both|18 Years|N/A|No|||July 2005|April 7, 2011|September 7, 2005||No|PI (Prof. Slavin) not longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00148993||195752|
NCT00149006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271296-HMO-CTIL|Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors|Tumor-Selective and Systemic Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With rIL-2 and Non-Myeloablative Stem Cell Transplantation||Hadassah Medical Organization||Recruiting|December 1996|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|100|||Both|18 Years|70 Years|No|||September 2005|March 13, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149006||195751|
NCT00149591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000B026|The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial)|Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.||Netherlands Heart Foundation||Active, not recruiting|April 2001|January 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|18 Years|80 Years|No|||September 2006|September 4, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149591||195706|
NCT00149604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0036|AFTER: Altering Fat Through Estrogen and Raloxifene|Modulation of Visceral Fat by Estrogens After Menopause||National Institute on Aging (NIA)||Completed|March 2000|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||December 2009|December 1, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149604||195705|
NCT00149331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2429|The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy|A Randomized Controlled Trial Comparing the Effects of Two Education Strategies About Insulin on Preferences and Perceptions About Insulin Therapy||McMaster University||Completed|July 2005|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||86|||Both|18 Years|N/A|No|||September 2006|September 7, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149331||195726|
NCT00150527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCIT001|Specific Effects of Escitalopram on Neuroendocrine Response|Specific Effects of Escitalopram on Neuroendocrine Response||Queen's University|No|Completed|September 2005|December 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy people|February 2009|February 4, 2009|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150527||195636|
NCT00151086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2001-050|Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer|Phase I/II Evaluation of Oral Estramustine and Oral Vinorelbine on an Intermittent Schedule in Patients With Hormone-Refractory Adenocarcinoma of the Prostate||University of Michigan Cancer Center|Yes|Completed|December 2001|August 2006|Actual|March 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Male|18 Years|N/A|No|||January 2015|January 20, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151086||195593|
NCT00151320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309006313|Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL|Phase I/II Trial of VELCADE+ CHOP-Rituximab in Patients With Previously Untreated Diffuse Large B Cell or Mantle Cell Non-Hodgkin's Lymphoma||Weill Medical College of Cornell University||Active, not recruiting|January 2004|||June 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00151320||195575|
NCT00151606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 020551|Comparison of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus.|Evaluation of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus in Intensive Care Units.||Rennes University Hospital||Completed|December 2002|February 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Both|18 Years|N/A|No|||January 2006|January 9, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151606||195553|
NCT00151879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0757|Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures|A Multicenter, Open-label Trial to Investigate the Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization.||UCB Pharma||Completed|February 2005|May 2006|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|160|||Both|16 Years|N/A|No|||July 2010|September 19, 2014|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00151879||195532|
NCT00151892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-304|Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis|A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis||Shire||Completed|April 2005|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|829|||Both|18 Years|N/A|No|||June 2011|June 6, 2014|September 7, 2005|Yes|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00151892||195531|
NCT00151359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPP-53686|Clinical Trials Stage of 'SoleSensor': A Balance-Enhancing Shoe Insert.|Clinical Trials Stage of 'SoleSensor': A Balance-Enhancing Shoe Insert.||Wilfrid Laurier University||Completed|February 2002|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|65 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00151359||195572|
NCT00151372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201005319|Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients|Treatment Effectiveness in Depressed Patients With Chronic Obstructive Pulmonary Disease||Weill Medical College of Cornell University|Yes|Completed|March 2002|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|50 Years|95 Years|No|||December 2009|December 7, 2009|September 6, 2005||Yes||No|July 7, 2009|https://clinicaltrials.gov/show/NCT00151372||195571|
NCT00152139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUDSCT|Stem Cell Transplantation for Patients With Hematologic Malignancies|Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies||St. Jude Children's Research Hospital|Yes|Completed|May 2002|January 2009|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|2 Years|21 Years|No|||January 2009|January 28, 2009|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00152139||195512|
NCT00152152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB# 4715|Use of Radiostereometric Analysis Beads (RSA) to Measure Motion in the Spine, Following Lumbar Spinal Surgery|Use of Radiostereometric Analysis (RSA) for Measuring Spinal Motion Following Lumbar Spinal Surgery||State University of New York - Upstate Medical University||Completed|October 2002|||September 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|75|||Both|18 Years|N/A|No|||May 2008|May 22, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152152||195511|
NCT00148005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/267|Prevalence, Etiology and Therapy of Micturition Disorders of Children With a Mental and/or Motoric Disability|Prevalence, Etiology and Therapy of Micturition Disorders of Children With a Mental and/or Motoric Disability||University Hospital, Ghent|No|Completed|September 2004|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|4 Years|14 Years|No|||December 2007|December 19, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148005||195827|
NCT00148018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05132|Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma|A Phase II Study of Bortezomib in Combination With Dexamethasone in Patients With Relapsed Hodgkin's Lymphoma||University of Cologne||Terminated|March 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||37|||Both|18 Years|N/A|No|||September 2006|July 9, 2008|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00148018||195826|
NCT00148265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC project 352312|A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema|Phase II/III Multicentre Randomised Clinical Trial of Laser Treatment Plus 4 mg Intravitreal Triamcinolone Injection to Reduce Diabetic Macular Oedema||University of Sydney|Yes|Completed|April 2005|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||November 2005|June 21, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00148265||195807|
NCT00148824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 114 PNEUMOVAC|Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.|Immunological Efficacy of a Prime-Boost Strategy Combining a 7-Valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-Valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-Infected Adults. ANRS 114 PNEUMOVAC.||French National Agency for Research on AIDS and Viral Hepatitis||Completed|February 2003|January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||212|||Both|18 Years|N/A|No|||March 2008|March 20, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00148824||195765|
NCT00148525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA105832-02|The Study of Automated Telephone Programs for the Maintenance of Dietary Change|Trial of 2 TeleComputer Diet Change Maintenance Programs||Boston Medical Center|Yes|Completed|July 2006|July 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|1049|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|July 1, 2015|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00148525||195787|
NCT00148759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002448|Kaletra Sex/Gender Pharmacokinetics (PK) Study|A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir: A 24-hour Pharmacokinetic Profile to Evaluate Sex Differences|LPVGenderPK|Emory University|No|Completed|June 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|September 6, 2005||No||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00148759||195769|
NCT00148772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI3316s|Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy|Phase II Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising PSA on Hormone Therapy||NorthShore University HealthSystem Research Institute||Completed|August 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|29|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|June 24, 2011|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148772||195768|
NCT00149032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240801-HMO-CTIL|Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host|Treatment of Patients With Resistant Cancer/ Post Allogeneic Stem Cell Transplantation With Donor Lymphocytes Sensitized by Antigens Expressed by the Host||Hadassah Medical Organization||Withdrawn|August 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|N/A|No|||September 2005|April 7, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149032||195749|
NCT00149045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920010132-HMO-CTIL|Follow up and Observation of Charcot Marie Tooth Disease in Families|Clinical and Genetic Features of Familial Neuropathy||Hadassah Medical Organization||Completed|November 2001|August 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|8 Years|N/A|No|||August 2005|November 6, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149045||195748|
NCT00148733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003740|CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia|Community- and Health Facility-based Intervention With Zinc as Adjuvant Therapy for Pneumonia to Enhance Child Health and Nutrition||Centre For International Health||Completed|January 2004|January 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2628|||Both|2 Months|3 Years|No|||February 2015|February 2, 2015|September 6, 2005||No||No|February 2, 2015|https://clinicaltrials.gov/show/NCT00148733||195771|
NCT00148746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DERMA_AD_001|Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis|Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis||Technische Universität Dresden||Completed|May 2004|March 2008|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|2 Years|N/A|No|||June 2010|June 8, 2010|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148746||195770|
NCT00150150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017|Laser Therapy of Benign Thyroid Nodules|Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules||Odense University Hospital||Active, not recruiting|January 2001|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|20 Years|70 Years|No|||March 2007|March 26, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150150||195664|
NCT00150163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015|Odense Androgen Study: Study of Androgens, Body Composition, and Muscle Function in Danish Men|Odense Androgen Study – A Population-Based Study of Androgens, Body Composition, and Muscle Function in 20-29 Year-Old Danish Men||Odense University Hospital||Active, not recruiting|March 2002|December 2008||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal||||800|||Male|20 Years|29 Years|Accepts Healthy Volunteers|||September 2005|March 28, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150163||195663|
NCT00150111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014|Rituximab in the Treatment of Graves' Disease|B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease||Odense University Hospital||Completed|June 2003|October 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||October 2006|October 5, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150111||195667|
NCT00150137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013|Antithyroid Drugs During Radioiodine Therapy|The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism||Odense University Hospital||Completed|January 2003|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|85 Years|No|||September 2005|February 2, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150137||195665|
NCT00150540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-309|A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.|A Long Term, Open Label Extension Study of Protocols LAM-IV-301, LAM-IV 303, LAM-IV 307 AND LAM-IV 308.||Shire||Completed|October 2002|January 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||93|||Both|N/A|N/A|No|||September 2007|September 13, 2007|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150540||195635|
NCT00148057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0428-C|Diet and Breast Cancer Prevention Trial|An Explanatory Clinical Trial of Breast Cancer Prevention||University Health Network, Toronto||Completed|January 1988|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||4695|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||August 2005|September 2, 2005|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00148057||195823|
NCT00151333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098A1-200|Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)|A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending Fixed Doses of SRA-333 in Subjects With Mild to Moderate Alzheimer's Disease.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2005|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|50 Years|85 Years|No|||September 2009|September 3, 2009|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00151333||195574|
NCT00151619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 960723|Effects of Amlodipine in the Management of Chronic Heart Failure|Regional and Systemic Hemodynamic Effects of a Long-Term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin||Rennes University Hospital||Suspended|February 1999|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||December 2005|December 30, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151619||195552|
NCT00150644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-003|A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy|A Phase 2, 12-Week, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of J867 on Uterine Artery Blood Flow and the Morphology of the Endometrium, Myometrium, and Uterine Leiomyomata in Subjects With Uterine Leiomyomata Scheduled for Hysterectomy.||Abbott|No|Completed|July 2003|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Female|18 Years|N/A|No|||May 2008|May 27, 2008|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00150644||195627|
NCT00151918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-310|Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease|A Multi-Centre, Open Label, Randomized, Parallel Group Pilot Study to Assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease||Shire||Completed|January 2005|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||September 2007|June 6, 2014|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00151918||195529|
NCT00151931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-313|Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis|A Multi-Centre, Open-Label Study Assessing the Efficacy and Tolerability of Lanthanum Carbonate in the Reduction of Serum Phosphate Levels in End Stage Renal Disease Patients Receiving Dialysis||Shire||Completed|May 2004|January 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||456|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151931||195528|
NCT00148031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB # 4929|Improving Hepatitis C Treatment in Injection Drug Users|Improving Hepatitis C Treatment in Injection Drug Users||State University of New York - Upstate Medical University|Yes|Completed|September 2003|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|65 Years|No|||April 2013|April 23, 2013|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148031||195825|
NCT00148044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/298|Uremic Toxins of Patients With Acute Kidney Failure|Uremic Toxins of Patients With Acute Kidney Failure||University Hospital, Ghent|No|Completed|October 2003|February 2004|Actual|||N/A|Observational|Time Perspective: Prospective||||30|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148044||195824|
NCT00148278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 990931|Norepinephrine Plus Dobutamine Versus Epinephrine Alone for the Management of Septic Shock|Prospective, Multicenter, Randomized, Double-Blind Study Comparing Safety and Efficacy of Norepinephrine Plus Dobutamine Versus Epinephrine Alone in Septic Shock.|CATS|University of Versailles|Yes|Completed|October 1999|December 2005|Actual|December 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|N/A|No|||July 2010|July 21, 2010|September 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00148278||195806|
NCT00148590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIND 1|Memantine for the Prevention of Negative Symptomatology|Memantine for the Prevention of Negative Symptomatology and Cognitive Impairment in Schizophrenia||Charite University, Berlin, Germany|Yes|Terminated|November 2005|December 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|40 Years|No|||October 2013|October 17, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00148590||195782|
NCT00148577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG1159|Pain Relief by Applying TENS on Acupuncture Points During the First Stage of Labour|Pain Relief by Applying Transcutaneous Electrical Nerve Stimulation (TENS) on Acupuncture Points During the First Stage of Labour: a Randomised Controlled Trial||Chang Gung Memorial Hospital||Active, not recruiting|August 2002|December 2003||||Phase 3|Observational|Allocation: Random Sample, Time Perspective: Longitudinal||||100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148577||195783|
NCT00148785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006856|A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir|Pharmacokinetics of an Indinavir, Ritonavir and Amprenavir Regimen in HIV-Infected Individuals: A Pilot Study||Emory University||Completed|July 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148785||195767|
NCT00148798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-046|Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)|Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC.|FLEX|Merck KGaA|Yes|Completed|October 2004|May 2012|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1861|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|September 7, 2005|No|Yes||No|August 24, 2011|https://clinicaltrials.gov/show/NCT00148798||195766|
NCT00149058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/MREC00/7|Erythropoietin in Acute Myocardial Infarction|A Phase II Randomised Trial to Investigate the Safety and Efficacy of Recombinant Human Erythropoietin on Infarct Size in Patients Undergoing Primary Percutaneous Coronary Angioplasty for ST-Segment Elevation Myocardial Infarction||Hammersmith Hospitals NHS Trust||Not yet recruiting|October 2005|January 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||124|||Both|18 Years|80 Years|No|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149058||195747|
NCT00149370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-09-2005|Quality of Life Among Breast Reduction Patients|A Prospective Study of Patients Undergoing Breast Reduction Surgery: Health-Related Quality of Life and Clinical Outcomes||McMaster University||Completed|January 2001|August 2003||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||52|||Female|18 Years|N/A|No|||August 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149370||195723|
NCT00149344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2447|Vertical Scar Versus Inferior Pedicle Reduction Mammoplasty|Vertical Scar Versus Inferior Pedicle Reduction Mammoplasty: A Randomized Controlled Trial and Cost-Utility Analysis||McMaster University|No|Completed|September 2005|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|254|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 27, 2011|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149344||195725|
NCT00149357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2005-FLUTE|Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)|Determining the Risk of Fetal Loss in Women With Unprovoked Venous Thromboembolism (VTE) Who Do NOT Have Identifiable Inherited Thrombophilia Compared With Women Who Have the Diagnosis of VTE Excluded||McMaster University|Yes|Terminated|July 2005|April 2008|Anticipated|February 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|1880|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 18, 2008|September 6, 2005||No|Funding withdrawn due to low enrollment|No||https://clinicaltrials.gov/show/NCT00149357||195724|
NCT00150176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05770|To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)|A Randomized, Placebo-Controlled, Double-Blind Trial of Asenapine in the Prevention of Relapse After Long-Term Treatment of Schizophrenia||Merck Sharp & Dohme Corp.|Yes|Completed|April 2005|July 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|831|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|September 2, 2005|Yes|Yes||No|April 28, 2010|https://clinicaltrials.gov/show/NCT00150176||195662|
NCT00149812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH067861|A Clinic-Based Prevention Program for Families of Depressed Mothers|A Clinic-Based Program for Families of Depressed Mothers||National Institute of Mental Health (NIMH)||Recruiting|January 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|40|||Both|8 Years|N/A|No|||September 2005|October 29, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149812||195689|
NCT00150124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012|Block-replacement Therapy During Radioiodine Therapy|The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism||Odense University Hospital|No|Completed|January 2003|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|85 Years|No|||December 2013|December 3, 2013|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150124||195666|
NCT00150852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-012 (med 04-008)|Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus.|Vancomycin for Prophylaxis of PEG-Related Wound Infection in MRSA-Positive Patients: a Double-Blind, Randomized, Placebo-Controlled Study||University Hospital, Geneva||Recruiting|September 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||96|||Both|18 Years|N/A|No|||September 2005|December 28, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150852||195611|
NCT00148603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 01-009|Montelukast in the Treatment of Duodenal Eosinophilia|Montelukast in the Treatment of Duodenal Eosinophilia in Children With Dyspepsia: Effect on Eosinophil Density and Activation in Relation to Pharmacokinetics||Children's Mercy Hospital Kansas City||Completed|September 2005|December 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||December 2011|December 26, 2011|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148603||195781|
NCT00149149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0408/19|Effect of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers|Use of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers Taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)||Imperial College London||Recruiting|May 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2005|July 16, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149149||195740|
NCT00148863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-005033-19|Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C|Pilot Study on Interferon Gamma in Association With Peg-Interferon Alpha 2a and Ribavirin Among Patients With a Chronic Hepatitis C and Non Responders to the Association of Peg-Interferon Alpha 2b or 2a and Ribavirin ANRS HC16 Gammatri||French National Agency for Research on AIDS and Viral Hepatitis||Completed|June 2004|August 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|18 Years|N/A|No|||August 2007|August 29, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148863||195762|
NCT00149656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16551-1|The Effects of Nutritional Supplementation and Drug Abuse on HIV|HIV Disease, Drug Abuse, and Nutrient Therapy in Botswana||Florida International University|Yes|Completed|June 2003|April 2013|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|878|||Both|18 Years|90 Years|No|||April 2013|April 26, 2013|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149656||195701|
NCT00150215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6241001|A First In Human Study Of PF-00184562 In Healthy Volunteers|An Oral, Rising Single-Dose Tolerance, Pharmacokinetic, and Pharmacodynamic Study of Pf-00184562 Capsules In Healthy Volunteers||Pfizer||Completed|July 2005|October 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2006|July 24, 2006|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150215||195659|
NCT00151125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403006|Phase II Study of IL-11 (Neumega) in Von Willebrand Disease|Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease||University of Pittsburgh|Yes|Completed|July 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151125||195590|
NCT00148070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9900|Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer|Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer||University of Michigan Cancer Center|Yes|Completed|March 1999|February 2006|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||October 2012|October 3, 2012|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148070||195822|
NCT00152217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91023038|Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)|Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)||Taiho Pharmaceutical Co., Ltd.||Completed|September 2001|December 2010|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|20 Years|80 Years|No|||July 2011|July 6, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152217||195506|
NCT00152230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023002|A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)|A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone in Patients With Dukes C Colorectal Cancer (NSAS-CC)||Taiho Pharmaceutical Co., Ltd.||Completed|October 1996|February 2008|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|20 Years|75 Years|No|||July 2011|July 6, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152230||195505|
NCT00148876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 26|TBP Study With Capecitabine Plus Minus Trastuzumab|A Multicenter Randomized Phase III Study to Compare Capecitabine Alone or in Combination With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer and Progression After Previous Treatment With Trastuzumab||German Breast Group|Yes|Completed|September 2003|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|482|||Female|18 Years|N/A|No|||February 2011|February 22, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148876||195761|
NCT00149175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-156|Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment|Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment||Institut National de la Santé Et de la Recherche Médicale, France||Recruiting|December 2002|October 2007|Anticipated|||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|4000|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Patients presenting with a neurodegenerative disorder          -  At risk patients|March 2010|March 12, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149175||195738|
NCT00149903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2305|Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients|Multicenter, Double-blind, Randomized, Parallel Group Study on Efficacy and Safety of Enteric-coated Mycophenolate Sodium vs. Mycophenolate Mofetil in de Novo Chinese Renal Transplant Recipients||Novartis||Completed|January 2005|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|75 Years||||November 2011|November 1, 2011|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149903||195682|
NCT00149916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A107E|Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107|Multicenter, Open-label Follow-up Study on the Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Patients.||Novartis||Completed|April 2000|||April 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|18 Years|75 Years||||November 2011|November 1, 2011|September 6, 2005||Yes||||https://clinicaltrials.gov/show/NCT00149916||195681|
NCT00148850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 113 LIPIOT|Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients|A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|February 2003|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|18 Years|N/A|No|||September 2005|October 19, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148850||195763|
NCT00149071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1,2|Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression|Treatment of Therapy-Resistant Major Depression With Transcranial Stimulation rTMS in Combination With Escitalopram||Hillerod Hospital, Denmark|Yes|Completed|March 2004|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|75 Years|No|||November 2007|November 2, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149071||195746|
NCT00149084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hp.CYP.001|Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori|Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori||Hamamatsu University||Recruiting|April 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||296|||Both|15 Years|90 Years|No|||September 2005|September 8, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149084||195745|
NCT00149383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033-2004|Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria|A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection||Mahidol University||Completed|December 2004|January 2006|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149383||195722|
NCT00149617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15440-1|Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1|Career Training in Marijuana Dependence||Medical University of South Carolina||Completed|April 2004|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|81|||Both|18 Years|65 Years|No|||December 2007|October 8, 2015|September 6, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00149617||195704|
NCT00149396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT1030|Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to Treat Colorectal Cancer Metastatic to Liver|A Phase I/II, Open-Label Study (With a Sequential Dose Escalation Stage Followed by an Expansion of a Selected Dose Cohort), to Evaluate the Safety and Anti-Tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-Line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver||MediGene|Yes|Completed|July 2004|December 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||December 2008|December 12, 2008|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00149396||195721|
NCT00149825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH066131|Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome|||Stanford University||Completed|June 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||May 2014|May 12, 2014|September 6, 2005||No||No|July 30, 2009|https://clinicaltrials.gov/show/NCT00149825||195688|Limitations of the current pilot study include a small sample size, relative racial homogeneity, and exclusion of patients with comorbidity.
NCT00150566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-312|Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood|A Phase IIIb, Multi-center, Two-Cohort, Randomized Study, With an Open-Label Run-In and a Long-Term Extensions Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis||Shire||Completed|February 2004|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||460|||Both|18 Years|N/A|No|||April 2010|April 29, 2010|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150566||195633|
NCT00150579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD465-301|Efficacy and Safety of SPD465 in Adults With ADHD|A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).||Shire||Completed|January 2005|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|55 Years|No|||November 2007|November 2, 2007|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150579||195632|
NCT00150865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 02-01|Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery|Study of Posterior Lumbar Plexus Block for Pain Relief After Hip Surgery||University Hospital, Angers||Completed|September 2001|March 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00150865||195610|
NCT00149162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030441|Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2|Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2|Elam02|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2005|March 2012|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|580|||Both|N/A|18 Years|No|||February 2009|February 11, 2009|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149162||195739|
NCT00149448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304|Effectiveness of the TB Contact Priority Model|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|May 2004|March 2009|Actual|March 2009|Actual|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||April 2009|April 13, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149448||195717|
NCT00150228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051016|12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation|A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation||Pfizer||Completed|December 2001|September 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||May 2007|May 31, 2007|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150228||195658|
NCT00150241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051002|A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation|A Seven-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Three Doses of CP-526,555 ( 0.3 mg QD, 1 mg QD, and 1 mg BID ) in Comparison With Zyban in Smoking Cessation||Pfizer||Completed|February 2000|January 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||625|||Both|18 Years|65 Years|No|||October 2015|October 16, 2015|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150241||195657|
NCT00151645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 990434|Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.|Renal Cell Carcinoma Treatment With Activated Tumor- Infiltrated Lymphocytes. A Non-Randomized Phase II Trial.||Rennes University Hospital||Terminated|December 2003|July 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|70 Years|No|||December 2005|December 30, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151645||195550|
NCT00159952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133|Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock|Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock||Policlinico Hospital|No|Completed|November 2004|November 2007|Actual|March 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|90|||Both|16 Years|N/A|No|||February 2009|November 26, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00159952||194926|
NCT00160264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S105.4.107|Study to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal Women|A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmenopausal Women||Solvay Pharmaceuticals||Completed|January 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||40|||Female|55 Years|65 Years|No|||January 2009|January 29, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00160264||194902|
NCT00148317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0504007841|Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma|A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Pegylated Liposomal Doxorubicin (DOXIL) Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients||Weill Medical College of Cornell University||Completed|June 2005|November 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148317||195803|
NCT00148616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIND 2|Memantine for the Treatment of Negative Symptomatology|Memantine for the Treatment of Negative Symptomatology and Cognitive Impairment in Schizophrenia||Charite University, Berlin, Germany|Yes|Terminated|April 2004|December 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|40 Years|No|||October 2013|October 17, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00148616||195780|
NCT00149669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19386-1|Employment-Based Reinforcement to Motivate Naltrexone Ingestion and Drug Abstinence in the Treatment of Drug Addiction. - 1|Employment-Based Addiction Pharmacotherapy||National Institute on Drug Abuse (NIDA)||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||275|||Both|18 Years|65 Years|No|||November 2005|November 3, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149669||195700|
NCT00138788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95/29 Graham|Brain Metastases Study: Radiotherapy Fractionation Schemes in the Treatment of Brain Metastases|To Determine Which of Two Radiotherapy Brain Fractionation Schemes is Superior in the Treatment of Brain Metastases||St George Hospital, Australia||Completed|February 1996|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|112|||Both|18 Years|N/A|No|||November 2008|November 19, 2008|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138788||196519|
NCT00150254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051007|12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 ( 0.5 mg BID Titrated, 0.5 mg BID, 1 mg BID, and Titrated 1 mg BID ) in Smoking Cessation||Pfizer||Completed|September 2001|October 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||625|||Both|18 Years|65 Years|No|||June 2007|June 1, 2007|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150254||195656|
NCT00150267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|912-OPT-0076-019|A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension|A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension||Pfizer||Completed|February 2002|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|976|||Both|18 Years|N/A|No|||November 2008|November 4, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150267||195655|
NCT00148837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-001326-24|Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis|Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis||French National Agency for Research on AIDS and Viral Hepatitis|No|Active, not recruiting|September 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||February 2008|February 6, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00148837||195764|
NCT00149097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANS-M26|Role of the Autonomic Nervous System in HIV-Lipodystrophy|Autonomic Nervous System Activity in the Pathogenesis of the Lipodystrophy Syndrome in HIV-Infected Patients.||Hannover Medical School|No|Completed|March 2005|January 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|54|Samples Without DNA|Serum and Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with confirmed HIV infection and no active opportunistic infection during the        last 2 months.|May 2008|May 6, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149097||195744|
NCT00149110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001855-39 Eudra CT number|Chronos: the Use of Chronobiological Treatment in Depression|"The CHRONOS Study: Can the Sleep-deprivation Induced Antidepressive Effect in Patients With Major Depression be Sustained by Correction of Diurnal Rhythms, Long Term Light Treatment and Duloxetine Treatment?"||Hillerod Hospital, Denmark|Yes|Completed|September 2005|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|70 Years|No|||August 2009|August 4, 2009|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149110||195743|
NCT00149409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|n3-PUFA-HF|Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure|Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure:Effects On Endothelial Function, Left Ventricular Remodelling, Natriuretic Peptide Levels, And Exercise Capacity||Medical University of Vienna||Completed|September 2005|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||||||Both|18 Years|N/A|No|||September 2005|July 12, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149409||195720|
NCT00149838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069887|Magnetic Brain Stimulation for the Treatment of Adult Depression|Optimization of TMS for Depression||National Institute of Mental Health (NIMH)|Yes|Completed|February 2005|May 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|199|||Both|21 Years|70 Years|No|||April 2012|April 26, 2012|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00149838||195687|
NCT00149851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919B2203|A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)|A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)||Novartis||Completed|January 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||832|||Both|18 Years|70 Years||||January 2008|August 31, 2010|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00149851||195686|
NCT00149630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18197-2|Pharmacogenetics of Disulfiram for Cocaine|Effectiveness of Disulfiram for Treating Cocaine Dependence in Individuals With Different Dopamine Beta Hydroxylase (DBH) Genes|Disulfiram|Baylor College of Medicine|Yes|Completed|January 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|64 Years|No|||November 2012|November 27, 2012|September 6, 2005|Yes|Yes||No|October 22, 2012|https://clinicaltrials.gov/show/NCT00149630||195703|The sample size is small for this genetic association study, and larger replications of this preliminary study are needed. Most cocaine abusers are not also opioid dependent, which limits generalization of findings.
NCT00149643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19142-1|Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence|Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People|CADY|University of Pittsburgh|Yes|Completed|September 2004|December 2012|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|14 Years|25 Years|No|||June 2013|June 17, 2013|September 6, 2005||No||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00149643||195702|
NCT00150592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-206|Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17|A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire||Completed|May 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|6 Years|17 Years|No|||May 2011|May 6, 2011|September 6, 2005|||||September 10, 2009|https://clinicaltrials.gov/show/NCT00150592||195631|
NCT00150605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD417-308|Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder|A Phase IIIb, Open Label Observational Study of SPD417 Used in Combination With Other Psychotropic Medications for the Treatment of Bipolar I Disorder||Validus Pharmaceuticals||Completed|February 2005|October 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||June 2006|November 1, 2007|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150605||195630|
NCT00151632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 030200|Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation|Evaluation of the Benefit/Risk Ratio of a Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil on the Prevention of Complications in Adult Liver Transplantation|MMF-FK|Rennes University Hospital|Yes|Terminated|May 2003|May 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|195|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|September 8, 2005||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00151632||195551|
NCT00158691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2000-02|Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas|A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas||Groupe Oncologie Radiotherapie Tete et Cou||Completed|March 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||296|||Both|18 Years|75 Years||||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158691||195023|
NCT00149890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621ADE04|Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids|A Multicenter, Open-label, Randomized, Two Arm Study to Investigate the Efficacy and Safety of a Therapy Avoiding Intraoperative Steroids in Combination With Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients||Novartis||Completed|March 2004|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|77|||Both|N/A|16 Years|No|||August 2011|August 17, 2011|September 6, 2005||No||No|January 20, 2011|https://clinicaltrials.gov/show/NCT00149890||195683|
NCT00150891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTx-prosp-001|Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection|Role of Th1, Th2 and Monokine Responses as Risk Factors of Acute and Chronic Renal Transplant Rejection – Impact of Different Immunosuppressive Protocols||University of Giessen|No|Completed|January 1998|January 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|84|||Both|14 Years|N/A|No|||May 2007|May 8, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150891||195608|
NCT00159549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMF 05/414|Long Term Effect of an Education and Training Program for Patients With Chronic Obstructive Pulmonary Disease|Long Term Effect of an Education and Training Program for Patients With Chronic Obstructive Pulmonary Disease||Norwegian University of Science and Technology||Completed|January 2000|December 2005||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||November 2005|November 18, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159549||194957|
NCT00159939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392|Prone-Supine Study II: The Effect of Prone Positioning for Patients Affected by Acute Respiratory Distress Syndrome|Prone-Supine Study II: The Effect of Prone Positioning for Patients Affected by Acute Respiratory Distress Syndrome||Policlinico Hospital|Yes|Completed|February 2004|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|344|||Both|16 Years|N/A|No|||June 2008|June 9, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00159939||194927|
NCT00160303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1561|Efficacy Study of Prolotherapy vs Corticosteroid for Tennis Elbow|Prolotherapy vs. Corticosteroid Therapy for the Treatment of Lateral Epicondylitis of the Elbow, A Randomized Controlled Trial.||Spaulding Rehabilitation Hospital||Completed|January 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160303||194899|
NCT00149188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-97-52030-150|Somatuline Autogel: Acromegaly Self/Partner Injection Study|A Phase IV, Multicentre, Open Label, Controlled Study to Assess the Ability of Patients With Acromegaly, or Their Partners, to Administer Somatuline Autogel.||Ipsen||Completed|February 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00149188||195737|
NCT00160277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S220.3.124|Efficacy and Safety of Moxonidine in Indian Patients|Open Label, Multi-Center, Force-Titration Study to Evaluate the Efficacy and Safety of Moxonidine in Ambulatory Subjects With Essential Hypertension||Solvay Pharmaceuticals||Completed|July 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00160277||194901|
NCT00150904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-247E|Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)|Request for Blood Samples to Examine the Effect of Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Patients With Hepatitis C and in Patients Coinfected With Hepatitis C and HIV||UMC Utrecht||Completed|August 2005|January 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective|||Actual|28|||Both|18 Years|N/A|No|||February 2009|February 13, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150904||195607|
NCT00151138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HyperPetII|Cognitive/Cerebrovascular Consequences of HTN Treatment|Cognitive and Cerebrovascular Sequelae of Hypertension||University of Pittsburgh||Completed|September 2002|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|35 Years|65 Years|No|||December 2007|December 13, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00151138||195589|
NCT00138801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF813204|Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis|Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison||Sorlandet Hospital HF|No|Completed|March 2004|December 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||||||Both|18 Years|N/A|No|||March 2005|February 4, 2010|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138801||196518|
NCT00138814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96/84 Graham|Boost Use in Breast Conservation Radiotherapy|A Randomised Comparison of Breast Conservation With or Without Lumpectomy Radiotherapy Boost||St George Hospital, Australia||Recruiting|January 1997|December 2015||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||680|||Female|18 Years|N/A|No|||September 2005|December 14, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00138814||196517|
NCT00151151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405473|The S.A.F.E. Study : Computer-Aided Counseling to Prevent Teen Pregnancy/Sexually Transmitted Diseases (STDs)|The S.A.F.E. Study: Computer-Aided Counseling to Prevent Teen Pregnancy/STDs - Validity and Reliability Testing of Computer Measures, Pilot-testing of Timeline Followback Calendar Protocol, and Randomized Efficacy Study||University of Pittsburgh|No|Completed|February 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|660|||Female|13 Years|21 Years|Accepts Healthy Volunteers|||January 2008|September 12, 2011|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00151151||195588|
NCT00151385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082A-101342|Study Evaluating Inhibitor Specificity in Hemophilia A|A Multicenter Study to Describe the Immunogenic Epitope(s) of Factor VIII in Previously Treated Patients With Congenital Hemophilia A Who Develop De Novo Factor VIII Inhibitors While Receiving Factor VIII Infusion Therapy.||Wyeth is now a wholly owned subsidiary of Pfizer||Withdrawn|November 2005|October 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|0|||Both|N/A|N/A|No|||June 2012|June 26, 2012|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00151385||195570|
NCT00150657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3121s|Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer|Phase II Trial of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Non-Small Cell Lung Cancer||St. John Providence Health System||Recruiting|November 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||September 2005|November 28, 2005|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150657||195626|
NCT00151944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-303|Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.|A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.||Shire||Completed|November 2003|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||December 2008|June 6, 2014|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151944||195527|
NCT00151957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-303|Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials|A Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Noven Therapeutics|No|Completed|October 2004|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|450|||Both|6 Years|12 Years|No|||July 2015|July 8, 2015|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00151957||195526|
NCT00148889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-DBS-2005-JM|Double-Blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia|Prospective,Randomised, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Bilateral Globus Pallidus Internus - in Patients With Medically Refractory Primary Cervical Dystonia||German Parkinson Study Group (GPS)|No|Completed|July 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||February 2009|February 10, 2009|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00148889||195760|
NCT00150189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB NO. 2003-315|Utilization of Oral Sucrose to Decrease Pain in Infants During Immunizations|Efficacy of Oral Sucrose Analgesia During Routine Immunizations at 6 Weeks and 4 Months of Age||Penn State University||Completed|November 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|6 Weeks|4 Months|Accepts Healthy Volunteers|||December 2006|December 22, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150189||195661|
NCT00150202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751010|Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)|Clinical Study Of EYE001 In Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration||Pfizer||Completed|July 2004|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|50 Years|N/A|No|||November 2006|May 4, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150202||195660|
NCT00150618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-304|Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17|A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)||Shire||Completed|April 2004|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|324|||Both|6 Years|17 Years|No|||November 2009|November 25, 2009|September 6, 2005|||||September 10, 2009|https://clinicaltrials.gov/show/NCT00150618||195629|
NCT00150631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000114|Danish Hypertension Prevention Project - DHYPP|Danish Hypertension Prevention Project||Aarhus University Hospital Skejby|Yes|Active, not recruiting|November 2000|December 2014|Anticipated|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|100|||Both|18 Years|36 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150631||195628|
NCT00150878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9005-2003|Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission|Randomized Phase III Comparison of 12 Gy TBI and Cyclophosphamide 120 mg/kg With Fludarabine 120 mg/Sqm and 8 Gy TBI Before Allogeneic Transplantation in Patients With Acute Myeloid Leukemia in First Remission||University Hospital Carl Gustav Carus|Yes|Terminated|December 2003|December 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|60 Years|No|||June 2013|June 19, 2013|September 6, 2005||No|Insurance coverage reached|No||https://clinicaltrials.gov/show/NCT00150878||195609|
NCT00152191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023001|A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)|A Randomized Controlled Study of Postoperative Adjuvant Therapy of UFT Compared With CMF in High-risk Women With Axillary Node-negative Breast Cancer (NSAS-BC)||Taiho Pharmaceutical Co., Ltd.||Completed|October 1996|January 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1300|||Female|18 Years|75 Years|No|||July 2011|July 6, 2011|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152191||195508|
NCT00152204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMGF28580|The Community Effectiveness of IPTi in Southern Tanzania|Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants||Swiss Tropical & Public Health Institute|Yes|Active, not recruiting|March 2005|December 2008|Anticipated|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|13000|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2008|May 21, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152204||195507|
NCT00158704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-00-480|Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.|An Open-Label, Continued Access Study of Adefovir Dipivoxil for Patients With Chronic HBV Infection Who Have Completed a Gilead-Sponsored Study of Adefovir Dipivoxil.||Gilead Sciences||Terminated|January 2002|January 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|N/A|N/A|No|||April 2006|March 7, 2007|September 7, 2005|||The study stopped due to marketing approval by the FDA.|||https://clinicaltrials.gov/show/NCT00158704||195022|
NCT00158990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPL-0100-HMO-CTIL|Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.|Triiodothyronine (T3) Supplementation in Bipolar and Unipolar Depression: A Random Assignment, Double Blind, Placebo-Controlled Study.||Hadassah Medical Organization||Completed|October 2002|July 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|70 Years|No|||August 2005|January 2, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158990||195000|
NCT00159276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5899N00007A|GR Defect in Sputum Cells in COPD|GR Defect in Sputum Cells in COPD||Imperial College London||Completed|December 2005|December 2008||||N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|35 Years|85 Years||||August 2008|August 12, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159276||194978|
NCT00159536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PregMet|Metformin in Pregnant PCOS Women|Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)|PregMet|Norwegian University of Science and Technology|No|Completed|February 2005|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|257|||Female|18 Years|45 Years|No|||May 2014|May 23, 2014|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159536||194958|
NCT00159562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EW-2005|Effects of Psycho-education of Patients With Bipolar Disorder|Effects of Psycho-education of Patients With Bipolar Disorder||Norwegian University of Science and Technology|No|Completed|September 2005|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|70 Years|No|||September 2015|September 30, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159562||194956|
NCT00159965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23NS045902-05|Treatments for Psychogenic Nonepileptic Seizures (NES)|Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES|NES|Rhode Island Hospital|Yes|Completed|December 2003|June 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|95 Years|No|||November 2014|November 7, 2014|September 8, 2005|Yes|Yes||No|August 11, 2010|https://clinicaltrials.gov/show/NCT00159965||194925|pilot sample size; drop-outs because of some patient’s concern that they would receive the placebo, despite the equipoise that exists for NES treatment(s). Excluding patients who did not have vEEG may present a potential sampling bias.
NCT00160316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S102.3.117|Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination|Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study||Solvay Pharmaceuticals|No|Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|454|||Female|45 Years|N/A|No|||March 2008|March 11, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00160316||194898|
NCT00160329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|De-Escalate Trial|Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia|The De-Escalate Trial: Atazanavir or Atazanavir/Ritonavir Substitution for Ritonavir Boosted PI Therapy in HIV-Infected Individuals Experiencing Ongoing HIV Viremia and Hyperlipidemia: A Randomized Controlled Pilot Study||Stanford University|Yes|Completed|January 2004|March 2009|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160329||194897|
NCT00160290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S105.4.106|Trial to Evaluate Effect of Lactulose on Hard Stools in Patients With Hemorrhoids or Anal Fissures|An Open, Randomized, Parallel Group, Single Center Study to Investigate the Effect of Lactulose Versus Plantago Ovate on the Quality of Life of Patients With Hard Stools and Hemorrhoids or Anal Fissure||Solvay Pharmaceuticals|No|Terminated|March 2002|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||April 2008|April 29, 2008|September 9, 2005||No|This trial discontinued on 30 JUN 2006 due to a lack of enrolment|No||https://clinicaltrials.gov/show/NCT00160290||194900|
NCT00160550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01057|Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures|A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.||UCB Pharma||Completed|September 2001|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||154|||Both|4 Years|65 Years||||September 2009|November 25, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160550||194880|
NCT00160524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87033|A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]|A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032|PRECiSE 3|UCB Pharma|No|Completed|July 2004|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|596|||Both|18 Years|N/A|No|||August 2013|August 2, 2013|September 8, 2005|Yes|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00160524||194882|
NCT00160537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00391|POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)|A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen||UCB Pharma||Completed|May 2005|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||200|||Both|18 Years|N/A||||September 2009|December 13, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160537||194881|
NCT00139399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 98-010|Radial Artery Versus Saphenous Vein Patency (RSVP) Study|A Randomised Controlled Trial to Compare Angiographic Patency of Radial Artery Versus Saphenous Vein Used as Free Aorto-coronary Grafts in Coronary Revascularisation|RSVP|Imperial College London|No|Completed|May 1998|November 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|40 Years|70 Years|No|||October 2011|October 19, 2011|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00139399||196472|
NCT00139425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-037|Osteoporosis Disease Management Demonstration Project (0000-037)|Osteoporosis Prevention and Treatment Program: A Disease Management Demonstration Project||Merck Sharp & Dohme Corp.||Completed|May 2003|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||10000|||Female|65 Years|89 Years|No|||October 2015|October 9, 2015|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139425||196471|
NCT00152243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023003|A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)|A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone for Serosa-negative Advanced Gastric Cancer (NSAS-GC)||Taiho Pharmaceutical Co., Ltd.||Completed|June 1997|August 2007|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|75 Years|No|||July 2011|July 6, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152243||195504|
NCT00152256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-037|A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids|A Phase 3,6-Month, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Two Doses of Asoprisnil Versus Placebo in Subjects With Uterine Leiomyomata||Abbott|Yes|Completed|September 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|239|||Female|18 Years|53 Years|No|||May 2008|May 27, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00152256||195503|
NCT00151398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098B1-201, 3098B1-202|Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)|A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|September 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|229|||Both|50 Years|N/A|No|||July 2008|February 7, 2013|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151398||195569|
NCT00151658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCANDSTENT|Sirolimus Eluting Stents in Complex Coronary Lesions (SCANDSTENT)|Randomized Multicenter Comparison of Sirolimus Versus Bare Metal Stent Implantation in Complex Coronary Lesions. Acronym: Scand Stent||Rigshospitalet, Denmark||Completed|October 2002|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||322|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151658||195549|
NCT00149201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0106-MF|A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis|Randomized Phase III Study of 5-FU Continuous Infusion (5FUci) Versus MTX+5-FU Sequential Therapy (MF) in Gastric Cancer With Peritoneal Metastasis (JCOG0106-MF, MF/5FU)||Japan Clinical Oncology Group|Yes|Completed|November 2002|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||160|||Both|20 Years|75 Years|No|||February 2009|February 2, 2009|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00149201||195736|
NCT00157664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP - 64452|Long Study - Longitudinal Thrombosis in End Stage Renal Disease|Canadian Longitudinal Thrombosis in End Stage Renal Disease Pilot Study||McMaster University|Yes|Active, not recruiting|July 2004|December 2008|Anticipated|May 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|serum and plasma|Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects initiating dialysis|June 2008|June 16, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00157664||195101|
NCT00151099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-Anast-05|Safety of Preoperative Oral Administration of a High Caloric Drink With Protein|Safety of Preoperative Oral Administration of a High Caloric Drink With Protein in Patients With Dysgnathia||University Hospital Muenster||Withdrawn|September 2005|December 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Female|18 Years|40 Years|No|||August 2007|December 17, 2015|September 7, 2005|||There is no possibility to reach the target patient number within the set time frame|No||https://clinicaltrials.gov/show/NCT00151099||195592|
NCT00151112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-Anast-05|Comparison of Two Different Procedures for Plexus Anesthesia|Comparison of Two Different Procedures for Plexus Anesthesia: Standard Position Versus Combination of Lateral Position and 20° Trendelenburg Position||University Hospital Muenster|No|Completed|September 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||September 2008|September 10, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00151112||195591|
NCT00157898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-050|A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)|A Prospective, Multicenter, Open, Randomized, Comparative Study to Evaluate the Safety and Efficacy of Ertapenem Versus it's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults||Merck Sharp & Dohme Corp.||Completed|January 2004|September 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|134|||Both|18 Years|75 Years|No|||January 2015|January 28, 2015|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00157898||195083|
NCT00151346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306006204 (0603-889)|Combined Spinal-Epidural Versus Traditional Labor Epidural|Combined Spinal-Epidural Versus Traditional Labor Epidural: A Randomized, Controlled Trial Comparing Maternal and Fetal Effects||Weill Medical College of Cornell University|No|Completed|October 2003|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|127|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 17, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00151346||195573|
NCT00148291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJTOG9904|Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer|Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer||West Japan Thoracic Oncology Group||Completed|June 1999|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|70 Years|N/A|No|||September 2005|January 5, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148291||195805|
NCT00148304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-176|Insulin Treatment Variation in Southwestern Diabetics|Insulin Treatment Variation in Southwestern Diabetics - Therapeutic Decision-making||VA Office of Research and Development|No|Completed|September 2005|June 2008|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1248|||Both|18 Years|N/A|No|Non-Probability Sample|insulin-using diabetics in VISN 18|December 2008|April 6, 2015|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00148304||195804|
NCT00159016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291004-HMO-CTIL|Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.|The Possible Role of Glivec in Patients With Tumor Cells Positive for C-kit or Platelet Derived Growth Factor Receptor (PDGFR); a Multi Center Study.||Hadassah Medical Organization||Withdrawn|August 2002|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||September 2005|April 27, 2011|September 8, 2005|||the PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00159016||194998|
NCT00159003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132910-HMO-CTIL|Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel|Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel||Hadassah Medical Organization|No|Recruiting|January 1998|April 2012|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|DNA only|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Hadassah Hospital with AML or CLL.|June 2011|June 22, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159003||194999|
NCT00159289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002AT032B|Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Endotoxin on Inflammatory Markers in Exhaled Breath, Sputum, Saliva and Nasal Lavage in Healthy Non-Smokers and Current Smokers Including Patients With COPD||Imperial College London||Withdrawn|June 2003|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|0|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||August 2008|June 3, 2015|September 8, 2005|||No resources available|No||https://clinicaltrials.gov/show/NCT00159289||194977|
NCT00159302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES11115|Biomarkers of iNOS Activity in COPD, Asthma, Healthy Control|A Pilot Study to Evaluate and Develop Biomarkers of iNOS Activity in Patients With COPD or Asthma and Healthy Volunteers||Imperial College London||Completed|September 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159302||194976|
NCT00159978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100|Validation of 18F-MISO-PET and 18F-FLT-PET|Validation of 18F-MISO-PET and 18F-FLT-PET by Immunohistochemical Assessment of Head and Neck Cancer Resection Specimen||Radboud University|No|Terminated|July 2005|December 2013|Actual|December 2013|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|Samples With DNA|Tumor resection specimen|Both|18 Years|N/A|No|Non-Probability Sample|Squamous cell carcinoma of the head and neck|May 2015|May 6, 2015|September 9, 2005||No|Problems with FMISO supply|No||https://clinicaltrials.gov/show/NCT00159978||194924|
NCT00150956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C98-1750|Effects of Daily Home Hemodialysis on Circulation, Mental Functions, and Quality of Life|Study Into the Effects of Daily Home Hemodialysis on Hemodynamics, Neurocognitive Functions, and Quality of Life||UMC Utrecht||Completed|April 1999|January 2002||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||October 2000|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150956||195603|
NCT00160563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00384|Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)|The Prolongation of the EPAAC™ Trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). A Multi-country, Double Blind, Placebo (PLC) Controlled, Follow-up Trial With 3 Parallel Groups (LCTZ-LCTZ, LCTZ-PLC and PLC-PLC) : Evaluation of the Long Term Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for an Additional 18 Months Period in Preventing the Onset of Asthma in Children Coming From the EPAAC Trial.||UCB Pharma|No|Terminated|June 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|207|||Both|30 Months|42 Months|No|||May 2011|February 12, 2015|September 8, 2005||No|The predecessor study A00309 (NCT00152464) did not show statistical significance in time to    onset of asthma between the levocetirizine and placebo groups.|No|June 17, 2009|https://clinicaltrials.gov/show/NCT00160563||194879|
NCT00160888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K004|Vasoreactivity in Carriers of Genetic Polymorphisms|Endothelium-Dependent Vasoreactivity in Nitric Oxide Synthase Gene (Glu298Asp) Polymorphism: Studies in Healthy Volunteers||Heidelberg University||Recruiting|November 1999|December 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2005|September 9, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160888||194854|
NCT00139893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP850|A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis|A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis||UCB Pharma||Completed|June 2005|||October 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||May 2008|March 25, 2013|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139893||196437|
NCT00160862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K071|NK-1 Antagonism of SLV317 in Humans|A Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Effect of a Single Oral Dose of SLV 317 on Substance P-Induced Venodilation in the Hand Vein of Healthy Male Volunteers||Heidelberg University||Completed|May 2003|November 2003||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|September 9, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160862||194856|
NCT00160875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0484-C|Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer|A Phase II Study to Assess the Efficacy of Combined Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy (External Beam, Brachytherapy), Plus Surgery for Potentially Resectable Thoracic Esophageal Cancer||University Health Network, Toronto|Yes|Completed|April 2009|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160875||194855|
NCT00148083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-EMR-4033|Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia|Efficacy of Risperidone Consta for Improving Ability to Benefit From Skills Training in Schizophrenia||University of Illinois at Chicago||Recruiting|September 2005|August 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|18 Years|55 Years|No|||August 2005|February 27, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00148083||195821|
NCT00149461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA0864|Written Asthma Actions Plans Versus No Written Instructions In Specialty Care|The Efficacy of Written Treatment Plans in Asthma||Columbia University|Yes|Completed|September 2006|July 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|407|||Both|5 Years|80 Years|No|||January 2014|January 16, 2014|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149461||195716|
NCT00149474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260|Peak Flow Monitoring in Older Adults With Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 1994|July 1999|Actual|||N/A|Interventional|Allocation: Randomized|||||||Both|50 Years|90 Years|No|||September 2005|February 17, 2016|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149474||195715|
NCT00149422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003B131|Effect of NT-proBNP Guided Treatment of Chronic Heart Failure|Can Pro-brain-natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?||Netherlands Heart Foundation|Yes|Completed|June 2004|April 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|2||||||Both|N/A|N/A|No|||August 2008|February 8, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149422||195719|
NCT00149435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1295|Cardiovascular Health Study (CHS) Events Follow-up Study|||University of Washington||Completed|September 2005|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5888|||Both|65 Years|N/A|No|Non-Probability Sample|General population|December 2012|December 18, 2012|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149435||195718|
NCT00149864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A302E|Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302|Multicenter, Open-label Follow-up Study on the Safety of Enteric-coated Mycophenolate Sodium in Maintenance Renal Transplant Patients||Novartis||Completed|February 2000|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|264|||Both|18 Years|75 Years||||February 2011|February 1, 2011|September 6, 2005||Yes||||https://clinicaltrials.gov/show/NCT00149864||195685|
NCT00157300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05-026|PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation|PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation||Leiden University Medical Center|Yes|Completed|July 2005|July 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|92|||Both|18 Years|75 Years|No|||July 2010|July 30, 2010|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00157300||195119|
NCT00158015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1886-4|Prospective Minnesota Study of ECHO Tissue Doppler Imaging in Cardiac Resynchronization Therapy|Prospective Minnesota Study of ECHO Tissue Doppler Imaging in Cardiac Resynchronization Therapy||Minneapolis Medical Research Foundation|No|Completed|October 2004|September 2007|Actual|September 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|70|||Both|18 Years|N/A|No|Probability Sample|Stable Heart failure subjects receiving CRT|October 2012|October 3, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158015||195074|
NCT00157911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-042|A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)|A Double-Blind, Randomized, Multicenter, Active-Comparative, 12-Week Study to Assess the Efficacy and Safety of the Drug in Conjunction With Another Drug in Korean Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|December 2002|December 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|136|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00157911||195082|
NCT00157924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-093|Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)(COMPLETED)|A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Hypercholesterolemic Patients With Diabetes Mellitus or Metabolic Syndrome||Merck Sharp & Dohme Corp.||Completed|November 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00157924||195081|
NCT00151905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-09|The Use of an Inhaled Salt Solution to Treat Viral Lung Infections in Infants.|Nebulized Hypertonic Saline in the Treatment of Bronchiolitis in Infants||Sheikh Khalifa Medical City||Completed|November 2003|September 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|18 Months|No|||September 2005|May 4, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151905||195530|
NCT00158431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC-CIHR-1|Surgery Versus no Surgery for OA of the Knee|Arthroscopic Surgery Versus Non-surgical Treatment of Osteoarthritis of the Knee||Fowler Kennedy Sport Medicine Clinic|Yes|Completed|January 1999|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158431||195043|
NCT00159315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHTABPT0336|ATP/AMP Challenge in Healthy Non-smokers, Smokers, Patients With Asthma, and Patients With Chronic Obstructive Pulmonary Disease (COPD)|Adenosine 5`-Triphosphate (ATP) Challenge in Healthy Non-smokers, Current Smokers and Patients With Mild Asthma and Chronic Obstructive Pulmonary Disease (COPD)||Imperial College London||Withdrawn|October 2002|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Actual|0|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||August 2008|June 3, 2015|September 8, 2005|||no resources available|No||https://clinicaltrials.gov/show/NCT00159315||194975|
NCT00159575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET-AR study -PCOS 5|Metformin in Assisted Reproduction-MET-AR-study|Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome||Norwegian University of Science and Technology|No|Terminated|March 2005|April 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|150|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||January 2012|January 2, 2012|September 9, 2005||No|Slow patient recruitment and expiry of study medication(aug2009)|No||https://clinicaltrials.gov/show/NCT00159575||194955|
NCT00150735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01061|Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy|A Multicenter, Double-blind, Randomized, Parallel Group, Positive-controlled Trial Comparing the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) to Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy for up to a Maximum of 121 Weeks in Subjects (≥ 16 Years) Newly or Recently Diagnosed as Suffering From Epilepsy, and Experiencing Partial or Generalized Tonic-clonic Seizures||UCB Pharma||Completed|June 2002|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||580|||Both|16 Years|N/A||||July 2010|November 25, 2013|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00150735||195620|
NCT00150384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841025|Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population|Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE)|CAPABLE|Pfizer||Completed|July 2004|August 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|September 6, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00150384||195646|
NCT00150748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N167|Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy|An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less Than 50 kg), in Children (≥ 4 Years Old), Adolescents and Adults Suffering From Primary Generalized Seizures||UCB Pharma|No|Completed|November 2001|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|217|||Both|4 Years|64 Years|No|||March 2015|March 24, 2015|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00150748||195619|
NCT00160576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01105|Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias|A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease||UCB Pharma||Completed|July 2003|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|30 Years|N/A||||September 2009|December 5, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160576||194878|
NCT00160901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M16|Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer|Prospective Randomized Trial With Complementary Therapies During Chemotherapy at the Women's Hospital of the University of Heidelberg||Heidelberg University|No|Completed|August 2003|December 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Female|18 Years|75 Years|No|||March 2007|April 18, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160901||194853|
NCT00160914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11408B|Childhood Obesity: Variations in Management|Childhood Obesity: Variations in Management||University of Chicago|No|Completed|December 2001|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Practicing general pediatricians|August 2010|August 19, 2010|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160914||194852|
NCT00136526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-4599-V|Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer|Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer: A Phase II Study||University of Washington|Yes|Completed|December 2002|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|21 Years|83 Years|No|||May 2013|May 7, 2013|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00136526||196692|
NCT00137007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661082|Zithromax EV in Community-Acquired Pneumonia (CAP)|A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP)||Pfizer||Completed|November 2003|September 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|151|||Both|18 Years|N/A|No|||April 2011|April 20, 2011|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00137007||196655|
NCT00161408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GI9932-P2223|Psychological Intervention for Relapse Prevention in First Episode Schizophrenia|Psychological Intervention for Relapse Prevention in First Episode Schizophrenia||University Hospital Tuebingen||Active, not recruiting|December 2000|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||106|||Both|18 Years|55 Years|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161408||194814|
NCT00161681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A2-322|Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Levonorgestrel 90 Mcg and Ethinyl Estradiol 20 Mcg in a Continuous Daily Regimen on Menstrual Cycle-Related Symptoms||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Female|18 Years|49 Years|No|||May 2007|February 7, 2013|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00161681||194795|
NCT00148330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC project 402573|Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study|An Open Label Extension of the Phase II/III Clinical Trial of Intravitreal Triamcinolone on the Effects and Safety of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment||University of Sydney|Yes|Completed|May 2005|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||May 2005|June 29, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00148330||195802|
NCT00148343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD044816|Functional Electrical Stimulation for Footdrop in Hemiparesis|Functional Electrical Stimulation for Footdrop in Hemiparesis||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|July 2005|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|80 Years|No|||December 2011|December 22, 2011|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148343||195801|
NCT00148629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHS 02-10-030|Treatment and Prevention of Severe Anemia in Pregnant Zanzibari Women|Preventing Unnecessary Blood Transfusions in Pregnant Women in Africa Through Effective Primary Health Care||Cornell University||Active, not recruiting|April 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||2500|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2005|November 16, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148629||195779|
NCT00149123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.354|Low-dose Hydrocortisone in Acutely Burned Patients|Low-dose Hydrocortisone in the Treatment of the Shock of Burned Patients||Hospices Civils de Lyon||Completed|April 2005|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|40|||Both|18 Years|75 Years|No|||October 2007|February 11, 2015|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149123||195742|
NCT00149877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919EHK01|Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation|Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation||Novartis||Completed|April 2004|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|18 Years|N/A||||January 2008|January 31, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149877||195684|
NCT00161642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3152K1-100|Study Evaluating CMD-193 in Advanced Malignant Solid Tumors|A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2004|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00161642||194798|
NCT00158028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 94-561|Risperidone in the Treatment of Psychotic-Like and Deficit Symptoms of Schizotypal Personality Disorder|Risperidone in the Treatment of Psychotic-Like and Deficit Symptoms of Schizotypal Personality Disorder||Icahn School of Medicine at Mount Sinai||Active, not recruiting|November 1995|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||September 2005|November 21, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158028||195073|
NCT00148421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030125|Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.|A Study of Darbepoetin Alfa Administered Once Every 2 Weeks (Q2W) Compared With Epoetin Alfa Administered Once Every Week (QW) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.||Amgen||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2013|May 13, 2013|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00148421||195795|
NCT00157677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2005-SELECT|Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis (SELECT)|Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis: A Randomized Trial|SELECT|McMaster University|Yes|Completed|October 2004|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1727|||Both|18 Years|N/A|No|||October 2011|October 25, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00157677||195100|
NCT00157937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-329|A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)|A Randomized, Open Label, Cross-Over Study Comparing Effectiveness for the Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics||Merck Sharp & Dohme Corp.||Completed|February 2003|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|18 Years|60 Years|No|||October 2015|October 7, 2015|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157937||195080|
NCT00158210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18185-1|Rivastigmine For Methamphetamine Dependent Individuals|Double-Blind Randomized Placebo Controlled Trial of Rivastigmine (Excelon) as a Potential Medication for Methamphetamine Abuse||National Institute on Drug Abuse (NIDA)||Completed|May 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158210||195059|
NCT00157950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-023|Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)|An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea||Merck Sharp & Dohme Corp.||Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|176|||Female|9 Years|23 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 7, 2005|Yes|Yes||No|August 17, 2010|https://clinicaltrials.gov/show/NCT00157950||195079|
NCT00158444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC-Industry-1|Study of the HemiCAP™ Unicondylar Femoral Resurfacing Prosthesis."|"A Prospective, Non-Randomized, Non-Comparative, Open Label Multi-Center, Feasibility Study to Examine the Safety and Effectiveness of the HemiCAP™ Unicondylar Femoral Resurfacing Prosthesis."||Fowler Kennedy Sport Medicine Clinic|Yes|Active, not recruiting|August 2005|December 2009|Anticipated|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|40 Years|N/A|No|||August 2009|August 11, 2009|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158444||195042|
NCT00149500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259|Social Support and Education in Asthma Follow-up (SSEA)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|2 Years|10 Years|No|||July 2008|July 1, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149500||195713|
NCT00149721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B9R-US-X041 (terminated)|Anterior Pituitary Function in Patients With Hydrocephalus|Anterior Pituitary Function in Patients With Hydrocephalus||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Terminated|September 2005|December 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||30|||Both|18 Years|80 Years|No|||March 2010|March 1, 2010|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149721||195696|
NCT00149994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400ANL07|Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients|DELTA Study Dutch Evaluation in Liver Transplantation To Assess the Efficacy of Cyclosporine A Microemulsion With C-2h Monitoring Versus Tacrolimus With Trough Monitoring in de Novo Liver Transplant Recipients||Novartis||Completed|December 2002|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|171|||Both|18 Years|75 Years||||April 2011|April 7, 2011|September 6, 2005||||No|January 25, 2011|https://clinicaltrials.gov/show/NCT00149994||195676|
NCT00150358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481187|To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .|Open Label, Multicenter, Non Comparative Study, To Confirm The Efficacy And Tolerability Of Viagra In Subjects With Erectile Dysfunction And Arterial Hypertension Who Are Taking Antihypertensive Treatment.||Pfizer||Completed|March 2005|November 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||253|||Male|18 Years|N/A|No|||December 2006|December 7, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150358||195648|
NCT00150371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581091|Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration|A Multicenter, 12 Week Treatment Single Step Titration Open-Label Study Assessing The % Of Patients Achieving Ldl-C Target With Atorvastatin Starting Doses Of 10mg, 20mg, 40mg and 80mg.|CANACTFAST|Pfizer||Completed|June 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1100|||Both|30 Years|79 Years|No|||April 2007|July 1, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150371||195647|
NCT00150397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2641021|A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six-Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults With Persistent Asthma||Pfizer||Completed|March 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||112|||Both|18 Years|75 Years|No|||June 2012|June 7, 2012|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150397||195645|
NCT00150410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171017|Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose|A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera® (Insulin Dry Powder Pulmonary Inhaler) vs. Avandia® (Rosiglitazone Maleate) as Add-On Therapy vs. Exubera® Substitution of Sulfonylurea in Patients With Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment||Pfizer||Completed|January 2003|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|626|||Both|18 Years|80 Years|No|||October 2008|October 28, 2008|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150410||195644|
NCT00151255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG06-04|All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia||University of Ulm||Completed|June 2004|January 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|61 Years|N/A|No|||October 2011|October 12, 2011|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00151255||195580|
NCT00151229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-200310|Valsartan in Elderly Isolated Systolic Hypertension Study|Valsartan in Elderly Isolated Systolic Hypertension|VALISH|VALISH study|Yes|Completed|October 2003|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3079|||Both|70 Years|85 Years|No|||June 2015|June 3, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00151229||195582|
NCT00151476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NQ4-00-02-012|Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients|A Registry-Based Observational Study Assessing Clinical Outcomes In Familial Adenomatous Polyposis In Patients Receiving Celecoxib (Celebrex(Registered), Onsenal(Registered)) Compared With Control Patients||Pfizer|No|Terminated|November 2004|November 2008|Actual|November 2008|Actual|Phase 4|Observational|Observational Model: Cohort||2|Actual|68|||Both|12 Years|N/A|No|Non-Probability Sample|Patients with FAP|March 2010|March 4, 2010|September 7, 2005|No|Yes|See Detailed Description|No|November 19, 2009|https://clinicaltrials.gov/show/NCT00151476||195563|Study prematurely discontinued May 2008 prior to reaching enrollment target; due to limited number of matched pairs, results do not provide sufficient data to evaluate effectiveness of celecoxib. Last subject last visit was November 2008.
NCT00151489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081059|Safety and Efficacy Study of Pregabalin in Fibromyalgia|A Six-Month, Double-Blind, Placebo Controlled, Durability of Effect Study of Pregabalin for Pain Associated With Fibromyalgia||Pfizer||Completed|April 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1020|||Both|18 Years|N/A|No|||September 2006|March 14, 2008|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00151489||195562|
NCT00161161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOM 99/076|Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder|Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder||UMC Utrecht||Completed|October 1999|December 2002||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||90|||Male|7 Years|18 Years|Accepts Healthy Volunteers|||September 2005|December 29, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161161||194833|
NCT00161421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-4115-D|Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone|Oral Androgens in Man-3: Pharmacokinetics of Oral Testosterone With Concomitant Inhibition of 5α-Reductase by Dutasteride Short Title: ORAL T-3||University of Washington|No|Completed|March 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00161421||194813|
NCT00161135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOM 98/261|Magnetic Resonance Imaging in Children and Adolescents With Autism and Multiple Complex Developmental Disorders|Magnetic Resonance Imaging in Children and Adolescents With Autism and Multiple Complex Developmental Disorders||UMC Utrecht|No|Completed|January 1999|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||150|||Both|7 Years|24 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161135||194835|
NCT00161148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBPSC|Probiotics in Patients With Primary Sclerosing Cholangitis|Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial||UMC Utrecht||Recruiting|January 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||January 2007|January 8, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161148||194834|
NCT00149136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.280|Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.|Evaluation of Imatinib (GLIVEC) After Induction Therapy in Patients Aged More Than 55 Years With Philadelphia Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) : a Non Randomised, Controlled, Open, Multicentric, International Phase II Clinical Study (CSTI 571 AFR09 Trial)||Hospices Civils de Lyon||Active, not recruiting|August 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|55 Years|90 Years|No|||April 2007|April 26, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149136||195741|
NCT00161382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066640|Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students|HIV Prevention Programs for Middle School Students||The University of Texas Health Science Center, Houston|No|Completed|September 2002|July 2008|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3007|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|September 8, 2005||No||No|May 21, 2014|https://clinicaltrials.gov/show/NCT00161382||194816|
NCT00161655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101696|Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis|A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2005|December 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2009|September 25, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161655||194797|
NCT00161668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903X-100847|Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care|Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2001|||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||500|||Both|18 Years|65 Years|No|||March 2007|March 14, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161668||194796|
NCT00157989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0164-A|Pilot Study to Assess Safety and Feasibility of Resuscitation of Preterm Infants With Controlled Volume of Air/Oxygen|Safety and Feasibility of Controlled Tidal Volume Resuscitation of Preterm Infants ≤ 28 Weeks’ Gestation: A Randomized Controlled Pilot Study||Mount Sinai Hospital, Canada||Terminated|October 2004|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|N/A|1 Hour|No|||September 2006|September 8, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157989||195076|
NCT00148434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OOB/3/19/F25|Study on Impact of Patient-Held Guidelines on Blood Pressure|A Pilot Randomised Controlled Trial to Assess the Impact on Blood Pressure Control of Empowering Patients to Become Involved in Their Own Blood Pressure Management.||Ashgrove Research Practice||Completed|January 2002|March 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||300|||Both|N/A|N/A|No|||September 2005|September 26, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148434||195794|
NCT00157963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-314|Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)|A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients.||Merck Sharp & Dohme Corp.||Completed|February 2005|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|174|||Both|20 Years|75 Years|No|||April 2015|April 1, 2015|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157963||195078|
NCT00158717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-00-481|Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.|A Phase 3b, Long-Term, Observational Study of the Durability of Seroconversion in Patients With Chronic Hepatitis B Virus Infection Who Have Seroconverted While Participating in a Previous Gilead-Sponsored Study of Adefovir Dipivoxil.||Gilead Sciences||Completed|April 2003|April 2006|Actual|April 2006|Actual|N/A|Observational|N/A|||Actual|107|||Both|N/A|N/A|No|Probability Sample|Patients who demonstrate HBeAg seroconversion or durable HBeAg loss in one of the previous        Gilead-sponsored studies listed in Section 4.2 of this protocol and meet all inclusion and        none of the exclusion criteria for this study will be eligible for enrollment.|January 2014|January 6, 2014|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00158717||195021|
NCT00149266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9502|Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)|Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)||Japan Clinical Oncology Group|Yes|Terminated|July 1995|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|N/A|75 Years|No|||February 2009|February 2, 2009|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00149266||195731|
NCT00149513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263|Post-Hospital Case Management to Improve Clinical Outcomes in Individuals Requiring Mechanical Ventilation|King County Lung Injury Project: Survivor Outcome Study (KCLIP:SOS)||University of Washington|No|Completed|September 2003|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|90 Years|No|||December 2012|December 18, 2012|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149513||195712|
NCT00149734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0255|Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia|Atypical Antipsychotics and P50 Sensory Gating||University of Colorado, Denver|No|Completed|January 2005|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|55 Years|No|||August 2015|August 5, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00149734||195695|
NCT00150007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2407|Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)|Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)||Novartis||Completed|June 2004|||June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||335|||Both|18 Years|N/A||||November 2011|November 1, 2011|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00150007||195675|
NCT00150462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-002|Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies|A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies||Onyx Pharmaceuticals|No|Completed|September 2005|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Actual|48|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|September 6, 2005|No|Yes||No|October 29, 2015|https://clinicaltrials.gov/show/NCT00150462||195640|
NCT00150982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4588|Alefacept Mechanism of Action in Psoriasis|In Vivo Induction of T Cell Apoptosis by Alefacept (LFA-3/IgG1 Fusion Protein, Amevive) in Patients With Psoriasis: An Investigator-Initiated, Open-Label, Mechanism of Action Study||Rutgers, The State University of New Jersey|No|Completed|September 2003|February 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||9|||Both|18 Years|N/A|No|||August 2008|August 6, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150982||195601|
NCT00151242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG07-04|Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia|Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia||University of Ulm||Completed|July 2004|August 2013|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|920|||Both|18 Years|60 Years|No|||July 2014|July 22, 2014|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00151242||195581|
NCT00151502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581078|To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.|An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.||Pfizer||Completed|November 2002|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|50 Years|90 Years|No|||July 2008|July 9, 2008|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00151502||195561|
NCT00151736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDX-101-03|Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)|A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)||Teva Pharmaceutical Industries||Terminated|September 2004|February 2008|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00151736||195543|
NCT00161174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWF RUG 2004-3157|Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity|Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity. (KWF RUG 2004-3157)||University Medical Center Groningen||Completed|July 2005|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|173|Samples With DNA|For cured patients with complete data on cardiovascular risk factors and presence of      subclinical cardiovascular damage only DNA will be collected.|Male|N/A|N/A|No|Probability Sample|Patients with non-seminomatous testicular cancer who have been uniformly treated with        orchidectomy and cisplatin-bleomycin combination chemotherapy|April 2015|April 28, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161174||194832|
NCT00161187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010101|Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor|A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes for Patients With Selected Malignancies||Rutgers, The State University of New Jersey|No|Completed|May 2001|October 2011|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|N/A|No|||September 2013|November 5, 2015|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00161187||194831|
NCT00152035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD465-304|Safety of SPD465 in Treating Adults With ADHD.|A Phase III, Multi-Center, 12-Month, Open-Label Safety Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).||Shire||Completed|March 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1040|||Both|18 Years|55 Years|No|||November 2007|November 2, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152035||195520|
NCT00152048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD488-401|Evaluation of Eflornithine on Facial and Forearm Skin|A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women With Excessive Facial Hair||Shire||Completed|November 2004|October 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||78|||Female|18 Years|85 Years|No|||September 2007|June 6, 2014|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152048||195519|
NCT00161694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412007634|Use of Sucrose to Relieve Pain During Eye Exams in Infants|Effectiveness of an Oral Sucrose Solution in Reducing Pain and Anxiety Associated With Neonatal Ophthalmologic Examination||Weill Medical College of Cornell University||Terminated|July 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|300|||Both|5 Weeks|N/A|No|||June 2008|June 2, 2008|September 8, 2005|||results did not show intervention was beneficial|No||https://clinicaltrials.gov/show/NCT00161694||194794|
NCT00161707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410103|Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency|Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency||Baxalta US Inc.||Completed|January 2003|October 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2006|June 26, 2015|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00161707||194793|
NCT00161395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD001479|Study of Time to Pregnancy in Normal Fertility|Randomized Trial of Fertility Awareness and Time to Pregnancy in Couples of Normal Fertility||University of Utah|No|Completed|January 2003|March 2007|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|143|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2005|May 14, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161395||194815|
NCT00158002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS 299|A Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine|An Open-Label Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine||Monarch Medical Research||Completed|February 2004|August 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|6 Years|18 Years|No|||April 2007|April 4, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00158002||195075|
NCT00149279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9501|A Trial to Evaluate Para-Aortic Lymphadenectomy for Gastric Cancer|Randomized Controlled Trial to Evaluate Para-Aortic Lymphadenectomy for Gastric Cancer (JCOG9501)||Japan Clinical Oncology Group|Yes|Completed|July 1995|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||520|||Both|N/A|75 Years|No|||May 2007|May 31, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149279||195730|
NCT00149292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9777|Study of LY2140023 in Schizophrenia|A Randomized, Double-Blind Comparison of LY2140023, Olanzapine, and Placebo in the Treatment of Patients With Schizophrenia||Eli Lilly and Company||Completed|August 2005|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|18 Years|65 Years|No|||July 2006|July 31, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00149292||195729|
NCT00158223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 02-0517|Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia|Pimozide Augmentation of Clozapine in Schizophrenia||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2004|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|September 7, 2005|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT00158223||195058|Neither baseline nor follow-up clozapine plasma concentrations were reported. Possible that one or both groups did not have therapeutic baseline clozapine levels and/or had pharmacokinetic interactions with the study drug changing concentrations.
NCT00158457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1207|Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)|Pilot Trial to Evaluate the Efficacy and Tolerance of a Simple Once Daily Combined Regimen Including Tenofovir (TDF), Emtricitabine (FTC) and Efavirenz (EFV) in HIV-1 Infected Patients Naive to Prior Antiretroviral Treatment in Senegal||French National Agency for Research on AIDS and Viral Hepatitis||Completed|June 2004|December 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2007|July 2, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158457||195041|
NCT00150020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AUS02|Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance|Safety and Tolerability of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients With GI Intolerance||Novartis||Completed|October 2004|||February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|728|||Both|18 Years|75 Years||||January 2008|January 21, 2008|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150020||195674|
NCT00150423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-165|To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.|An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.||Pfizer||Completed|January 2001|July 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||384|||Both|18 Years|N/A|No|||December 2006|December 28, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150423||195643|
NCT00150436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-198|To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.|An Open-Label Extension Safety and Efficacy Study of Pregabalin in Patients With Postherpetic Neuralgia||Pfizer||Completed|February 2002|July 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||276|||Both|18 Years|N/A|No|||December 2006|December 20, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150436||195642|
NCT00150449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-100|Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.|A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders||Pfizer||Completed|January 2001|March 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||511|||Both|18 Years|N/A|No|||July 2006|July 13, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150449||195641|
NCT00150761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00380|Facial Thermography Study of Levocetirizine Versus Cetirizine|A Randomized, Double-blind, Double Dummy, Placebo Controlled, Cross-over Exploratory Trial in Healthy Male Adult Subjects: Comparison by Means of Infrared Thermography of the Anti-H1 Potency of Levocetirizine 5 mg and Cetirizine 10 mg Tablet Single Oral Dose After Nasal Histamine Provocation.||UCB Pharma||Completed|July 2004|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||60|||Male|18 Years|55 Years||||September 2009|August 25, 2014|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00150761||195618|
NCT00150475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI 04-58|Contamination During Removal of Two Different Personal Protective Systems|Contamination During Removal of Two Different Personal Protective Systems When Working Under Conditions Requiring Enhanced Respiratory and Contact Precautions||Queen's University||Completed|January 2005|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150475||195639|
NCT00150969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-50422|Vitamin K Supplementation in Post-Menopausal Osteopenia|Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia (ECKO Trial)||University Health Network, Toronto|Yes|Completed|January 2002|September 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|440|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2012|November 19, 2012|September 6, 2005||No||No|January 10, 2012|https://clinicaltrials.gov/show/NCT00150969||195602|Originally designed as a 2-year study with BMD as primary outcome. Thus, the number of women followed to 3 and 4 years was small, and the study was not powered to examine fracture outcomes.
NCT00151515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6221001|A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss|A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|352|||Male|15 Years|49 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00151515||195560|
NCT00151762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-304|Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes|A Multi-Center, 52-Week, Open-Label Extension Study (From Studies WEL-301, WEL-302, and WEL-303) to Evaluate the Long-Term Safety and Tolerability of WelChol® in Type 2 Diabetic Patients||Daiichi Sankyo Inc.|No|Completed|December 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment||||780|||Both|18 Years|75 Years|No|||December 2007|December 26, 2007|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151762||195541|
NCT00151775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0866-A-U301|Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure|Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension||Daiichi Sankyo Inc.||Completed|May 2005|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|362|||Both|1 Year|16 Years|No|||May 2010|May 20, 2010|September 7, 2005|Yes|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00151775||195540|
NCT00151710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6E-UT-O013|Effects of Pioglitazone in Congenital Adrenal Hyperplasia|Effects of Pioglitazone in Glucocorticoid-Induced Insulin Resistance. Studies in Congenital Adrenal Hyperplasia.||Radboud University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A|No|||February 2007|February 28, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151710||195545|
NCT00151723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUBstudie|Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?|Subclinical Hyperthyroidism ”To Treat or Not to Treat?” A Dutch Multicenter Trial||Radboud University||Recruiting|April 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|200|||Both|40 Years|N/A|No|||September 2005|July 17, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151723||195544|
NCT00148174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9611M11943|Predictors and Intervention for Noncompliance|Predictors and Intervention for Noncompliance||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|August 1998|December 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|273|||Both|14 Years|N/A|No|||May 2015|May 28, 2015|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00148174||195814|
NCT00161720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400501|Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND|A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND||Baxalta US Inc.||Completed|June 2005|December 2005||||Phase 4|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||October 2006|June 26, 2015|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00161720||194792|
NCT00161733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550003|Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery|Evaluation of the Topical Hemostatic Efficacy and Safety of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery||Baxter Healthcare Corporation||Completed|September 2002|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||October 2006|October 20, 2006|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00161733||194791|
NCT00157690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0217 Protocol 214|Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients|A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients||McMaster University|Yes|Completed|December 2003|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||October 2008|October 22, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157690||195099|
NCT00157976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRVT-920101-OPH005|Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration|A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD||Miravant Pharmaceuticals||Recruiting|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||660|||Both|50 Years|N/A|No|||November 2005|November 29, 2005|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00157976||195077|
NCT00148707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-299|Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer|Phase II Study of CT-2103 in Patients With Metastatic Breast Cancer||Dana-Farber Cancer Institute||Completed|October 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00148707||195773|
NCT00158236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-5|Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users|Effects of Buprenorphine/Naloxone in Non-Dependent Opioid Abusers||National Institute on Drug Abuse (NIDA)||Completed|January 1997|March 1998||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||7|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2006|January 20, 2006|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00158236||195057|
NCT00149253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acute pain service|Pre-Emptive Analgesia Efficacy of Etoricoxib for Postoperative Pain|A Randomized, Double-Blind, Controlled Trial of Etoricoxib as a Pre-Emptive Analgesic for Abdominal Hysterectomy||Khon Kaen University||Completed|December 2004|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Female|15 Years|65 Years|Accepts Healthy Volunteers|||October 2004|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149253||195732|
NCT00149539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-7|Abuse Potential of Buprenorphine/Naloxone|Abuse Potential of Buprenorphine/Naloxone as a Function of Maintenance Dose of Buprenorphine/Naloxone||National Institute on Drug Abuse (NIDA)|No|Terminated|June 2004|January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|No|||July 2007|July 9, 2007|September 6, 2005|||Funding ended for the study|No||https://clinicaltrials.gov/show/NCT00149539||195710|
NCT00150059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CPH01|Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis|||Novartis||Completed|December 2004|December 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Months|N/A||||February 2008|February 14, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00150059||195671|
NCT00149760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH066831|Effectiveness of Cognitive-Affective Behavior Therapy for the Treatment of Somatization Disorder|Cognitive Affective Behavior Therapy for Somatization||Rutgers, The State University of New Jersey|No|Completed|August 2003|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|65 Years|No|||February 2014|February 19, 2014|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149760||195693|
NCT00150033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011|Health-Related Quality of Life for Thyroid Patients|Development and Validation of a Thyroid-Specific Quality of Life Measure||Odense University Hospital||Completed|May 2005|October 2007|Actual|||Phase 2|Observational|Time Perspective: Prospective|||Anticipated|1200|||Both|15 Years|N/A|No|||May 2008|May 21, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150033||195673|
NCT00150046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2411|Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients|A 12-month, Multicenter, Randomized, Open-label Non-inferiority Study of Renal Function and Efficacy Comparing Concentration-controlled Certican (1.5 mg/Day Starting Dose) With Reduced Neoral Dose Versus MMF With Standard Neoral Dose in de Novo Heart Transplant Recipients||Novartis||Completed|December 2004|||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|176|||Both|18 Years|65 Years||||November 2011|November 1, 2011|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00150046||195672|
NCT00150995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9962|Tetrathiomolybdate in Hormone Refractory Prostate Cancer|A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer||University of Michigan Cancer Center|Yes|Completed|May 2001|April 2006|Actual|October 2003|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||January 2015|January 20, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00150995||195600|
NCT00150774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N166|Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults|A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (≥ 12 Years) and Adults (≤ 65 Years) Suffering From Idiopathic Generalized Epilepsy With Myoclonic Seizures.||UCB Pharma||Completed|November 2001|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||116|||Both|12 Years|65 Years||||February 2010|September 16, 2013|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00150774||195617|
NCT00151268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401007011|Genotype - Phenotype Correlations of LINCL|Genotype - Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis||Weill Medical College of Cornell University|Yes|Completed|March 2004|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|18|Samples With DNA|whole blood, serum|Both|2 Years|18 Years|No|Probability Sample|The study will be carried out in children diagnosed with LINCL in all stages.|October 2015|December 9, 2015|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00151268||195579|
NCT00151528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081057|An Open-Label Trial of Pregabalin in Patients With Fibromyalgia|A Long-Term, Open-Label, Safety Trial of Pregabalin in Patients With Fibromyalgia||Pfizer||Completed|January 2005|June 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||428|||Both|18 Years|N/A|No|||July 2006|March 7, 2008|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00151528||195559|
NCT00151541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP0407|A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%|A Phase 3, Randomized, Double-blind, Multi-dose Study to Evaluate the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG 5%) When Co-administered With Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% in the Treatment of Acne Vulgaris.||Allergan||Completed|February 2005|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|301|||Both|12 Years|N/A|No|||May 2011|May 27, 2011|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00151541||195558|
NCT00151788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505-205|Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.|A Randomized, Double-blind, Stratified, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Heterozygous Familial Hypercholesterolemia and Carotid Atherosclerosis Using Carotid Ultrasound (CUS)||Daiichi Sankyo Inc.||Terminated|February 2004|March 2006|Actual|March 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||796|||Both|40 Years|75 Years|No|||January 2012|January 16, 2012|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151788||195539|
NCT00151749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-302|WelChol® and Insulin in Treating Patients With Type 2 Diabetes|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetes With Inadequate Glycemic Control on Insulin Therapy Alone or Insulin Therapy Combination With Other Oral Anti-diabetic Agents||Daiichi Sankyo Inc.||Completed|June 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|18 Years|75 Years|No|||January 2012|January 16, 2012|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151749||195542|
NCT00152334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C01-0210|Efficacy of Botox in Patients With Idiopathic Clubfoot|Treatment of Idiopathic Clubfoot Utilizing Botulinum Toxin A: A New Treatment for Correction||University of British Columbia||Active, not recruiting|September 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|2 Years|No|||April 2015|April 14, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152334||195497|
NCT00152308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S01903|Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis|A Prospective, Placebo-Controlled, Double-Blind, Randomized Study Evaluating the Efficacy of Non-Polymer-Based Coating With Two Different Rapamycin-Dosages for the Prevention of Restenosis After Percutaneous Coronary Interventions||Translumina GmbH||Recruiting|December 2004|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||333|||Both|18 Years|85 Years|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152308||195499|
NCT00152321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Alberta|Strategies Targeting Osteoporosis to Prevent Recurrent Fractures|Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP# Study)||University of Alberta|No|Completed|September 2003|March 2010|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|242|||Both|50 Years|N/A|No|||July 2015|July 25, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152321||195498|
NCT00157313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPUS trial|Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis|Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis||Bispebjerg Hospital||Active, not recruiting|January 1998|December 2022|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|45 Years|No|||September 2005|January 27, 2016|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157313||195118|
NCT00157326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10077|Tadalafil in Subjects With Mild to Moderate Hypertension|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension||Eli Lilly and Company||Completed|September 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|180|||Both|18 Years|N/A|No|||October 2007|October 23, 2007|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00157326||195117|
NCT00157339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7091|Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD|A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma||Eli Lilly and Company||Completed|August 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|N/A|No|||July 2008|July 3, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00157339||195116|
NCT00157703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2001|G207 Followed by Radiation Therapy in Malignant Glioma|A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy||MediGene|Yes|Completed|May 2005|December 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|19 Years|N/A|No|||December 2008|December 12, 2008|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00157703||195098|
NCT00149318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FABRY DISEASE|Enzyme Replacement Therapy in Fabry Disease|Evaluation of the Long Term Efficacy of Enzyme Replacement Therapy in Fabry Disease||Mario Negri Institute for Pharmacological Research|No|Terminated|December 2002|November 2014|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|Samples With DNA|Whole blood on EDTA. Serum. Urine samples.|Both|16 Years|65 Years|No|Non-Probability Sample|Patients with Fabry disease.|November 2014|November 7, 2014|September 6, 2005||No|Difficulties in the patient's enrolment|No||https://clinicaltrials.gov/show/NCT00149318||195727|
NCT00148681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-273|Preoperative Herceptin and Navelbine for Breast Cancer|Preoperative Herceptin and Navelbine in Early Stage, HER-2 Positive Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2001|April 2010|Anticipated|May 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|49|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148681||195775|
NCT00148954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-032105-T|RIGHT: Rhythm ID Going Head-to-Head Trial|Rhythm ID Going Head-to-head Trial||Boston Scientific Corporation|Yes|Completed|July 2005|July 2010|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1962|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|September 6, 2005||No||No|October 7, 2011|https://clinicaltrials.gov/show/NCT00148954||195755|
NCT00150072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BIT15|Efficacy and Safety of Imatinib in Chordoma|Phase II Study of Imatinib Mesylate in Chordoma||Novartis||Completed|October 2004|||April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||August 2012|August 6, 2012|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00150072||195670|
NCT00149786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070621|Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa|Treatment of Adolescents With Anorexia Nervosa||Stanford University|Yes|Completed|October 2004|March 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|12 Years|18 Years|No|||April 2012|April 9, 2012|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149786||195691|
NCT00150488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uracyst-Stellar|URACYST® For the Treatment of GAG Deficient Interstitial Cystitis|URACYST® For the Treatment of GAG Deficient Interstitial Cystitis||Queen's University|No|Completed|September 2005|February 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|18 Years|N/A|No|||September 2008|September 17, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150488||195638|
NCT00150787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01093|Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.|A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Coming From the N01061 Trial.||UCB Pharma||Completed|July 2003|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||250|||Both|16 Years|N/A||||September 2009|November 25, 2013|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00150787||195616|
NCT00151008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4405|Bexarotene With Narrow-Band UVB for Psoriasis|Investigator-Initiated, Double Blind, Vehicle-Controlled, Bilateral Comparison Trial of Bexarotene (Targretin) Gel 1% vs. Vehicle Gel in Combination With Narrow Band UVB Phototherapy for Moderate to Severe Psoriasis Vulgaris||Rutgers, The State University of New Jersey|No|Completed|November 2003|August 2005||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||August 2008|August 6, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00151008||195599|
NCT00151021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDRTC 5P60DKK20572|Stepping Up to Health: Feedback to Promote Physical Activity in Diabetes|Automated Step-count Feedback to Promote Physical Activity in Diabetes||University of Michigan||Completed|June 2005|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|40|||Both|18 Years|N/A|No|||December 2009|December 8, 2009|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00151021||195598|
NCT00151281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|047080073974|Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma|Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma||Weill Medical College of Cornell University||Active, not recruiting|November 2004|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||June 2010|June 16, 2010|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151281||195578|
NCT00151567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 010751|Evaluation of Tamsulosin in the Treatment of Ureteral Stones|Interest of a Treatment With the alpha1-blocker Tamsulosin in the Elimination of Pelvis Ureteral Stones|TAMSULOSINE|Rennes University Hospital|Yes|Completed|February 2002|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||September 2008|December 3, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00151567||195556|
NCT00151554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PflegeverbundMarburg2|Reducing Intensive Care Unit (ICU) Related Anxiety Through a Structured Information Program|Reducing ICU Related Anxiety Through a Structured Information Program. A Randomized Controlled Clinical Trial||Philipps University Marburg Medical Center||Completed|February 2005|December 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|140|||Both|18 Years|N/A|No|||July 2010|July 28, 2010|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00151554||195557|
NCT00151801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU - PIL - 03|Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients|Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis||S. Andrea Hospital||Recruiting|May 2002|December 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Female|18 Years|40 Years|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151801||195538|
NCT00152087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCI015|A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.|Treatment of Unresectable Hepatocellular Carcinoma With Therasphere. A Human Device Evaluation Protocol.||St. Joseph's Hospital, Florida||Recruiting|October 2002|June 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||September 2005|September 7, 2005|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00152087||195516|
NCT00152061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74009|The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens|The Role of 3TC/FTC in Partially Suppressive Antiretroviral Regimens: The Switch Study||Stanford University|No|Completed|January 2005|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152061||195518|
NCT00148447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Escitalopram-118CTIL|The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia|Placebo-Controlled Trial of Cipralex in the Treatment of Negative Symptoms in Schizophrenia||BeerYaakov Mental Health Center|No|Completed|November 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|60 Years|No|||February 2007|May 2, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148447||195793|
NCT00148460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.8|Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction|A Randomised, Open-label, Multi-center, Angiographic Trial to Compare the Efficacy and Safety of Single Bolus of Tenecteplase (Metalyse®) With Accelerated Infusion of Alteplase in Asian Patients With Acute Myocardial Infarction||Boehringer Ingelheim||Completed|March 2001|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|75 Years|No|||October 2013|October 28, 2013|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148460||195792|
NCT00148694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-183|Preoperative Cisplatin in Early Stage Breast Cancer|A Phase II Trial of Cisplatin in Early Stage ER-, PR-, HER-2 Negative Breast Cancer||Dana-Farber Cancer Institute||Completed|July 2004|May 2010|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148694||195774|
NCT00148161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phonpaed001|Activity of the Auditory Cortex During Speech Perception and Speech Production in Stuttering|Evoked and Induced Auditory Cortical Activity During Speech Perception and Speech Production in Stuttering||University Hospital Muenster||Recruiting|November 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|April 26, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148161||195815|
NCT00149019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240502-HMO-CTIL|Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.|Innovative Approaches for Targeted Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.||Hadassah Medical Organization||Withdrawn|May 2002|September 2005|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|N/A|N/A|No|||September 2005|April 7, 2011|September 7, 2005|||the PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00149019||195750|
NCT00149526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261|Does Shared Decision-Making Improve Asthma Outcomes?|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|June 2001|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2008|February 17, 2016|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149526||195711|
NCT00149747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH058853|The Effectiveness of Regular Exercise on Improving Sleep in Older Adults|Promoting Exercise, Sleep and Well-Being in Older Adults|RTC|Stanford University|Yes|Completed|August 1999|September 2003|Actual|September 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 6, 2005||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00149747||195694|
NCT00150826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QWISE|QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia|A Double-Blind, Multicenter, Placebo Controlled Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease.||University of Florida|Yes|Completed|May 2000|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Female|21 Years|75 Years|No|||April 2012|April 12, 2012|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150826||195613|
NCT00150085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400AUS06|Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion|A Prospective, Randomized, Open-label, Twenty-six Week Study of the Efficacy and Safety of Converting Kidney and Liver Transplant Recipients With Tacrolimus-associated Abnormal Glucose Metabolism to Cyclosporine Micro-emulsion With C2 Monitoring||Novartis||Terminated|February 2004|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|75 Years||||February 2011|February 17, 2011|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150085||195669|
NCT00150514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0103|Effects of Sublingual Immunotherapy on Grasspollen Allergy|A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose.||Radboud University||Completed|January 2002|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2003|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00150514||195637|
NCT00150800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01199|This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment|An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy||UCB Pharma|No|Active, not recruiting|January 2006|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|668|||Both|16 Years|N/A|No|||February 2016|February 8, 2016|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00150800||195615|
NCT00150813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01127|Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.|A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials.||UCB Pharma||Completed|August 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|16 Years|N/A|No|||September 2009|December 5, 2013|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00150813||195614|
NCT00151580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 010588|Treatment of Recurrent Hepatitis C After Liver Transplantation|Comparison of Maintenance Treatment by Ribavirin to a Placebo, After an Initial One-year Treatment With Pegylated Interferon-α2a - Ribavirin Association in Hepatitis C Viral Recurrence After Liver Transplantation|TRANSPEG|Rennes University Hospital||Completed|February 2002|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|200|||Both|18 Years|N/A|No|||November 2007|May 18, 2012|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151580||195555|
NCT00151827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-866/43|Olmesartan Medoxomil in Hypertension and Renal Impairment|Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment||Daiichi Sankyo Inc.|No|Completed|August 2003|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|393|||Both|18 Years|75 Years|No|||October 2010|October 13, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151827||195536|
NCT00151840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB98001|Efficacy and Safety of IVIG-L in ITP Patients|Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients||Sanquin||Completed|October 2001|March 2002||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||January 2006|January 30, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151840||195535|
NCT00152126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST133|Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas|Busulfan and Melphalan With Autologous Hematopoietic Stem Cell Support With Positively-Selected CD133+ Hematopoietic Cells for Children With High Risk Solid Tumors and Lymphomas||St. Jude Children's Research Hospital|No|Completed|August 2003|February 2009|Actual|August 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|25 Years|No|||February 2009|February 12, 2009|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152126||195513|
NCT00151814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0866-A-U102|Olmesartan Pediatric Pharmacokinetic (PK) Study|An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension||Daiichi Sankyo Inc.||Completed|September 2005|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|12 Months|16 Years|No|||April 2010|April 12, 2010|September 8, 2005|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00151814||195537|
NCT00152113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCDHAP|Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound|Hematopoietic Stem Cell Transplantation for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Doppler Ultrasound Using Reduced-Intensity Conditioning and T-Cell Depleted HSC From Partially Matched Family Donors||St. Jude Children's Research Hospital|No|Completed|April 2005|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|16 Years|No|||February 2009|February 3, 2009|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152113||195514|
NCT00152100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSCID|Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome|Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome||St. Jude Children's Research Hospital|No|Completed|February 2004|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|2 Years|No|||May 2009|May 19, 2009|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152100||195515|
NCT00152074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/der/03.0214|Salt Reduction on Blood Pressure and Cardiovascular Organ Damage|Effects of Modest Salt Reduction on Blood Pressure and Markers of Target Organ Damage in Patients With Untreated Essential Hypertension or Prehypertension||St George's, University of London||Completed|April 2004|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|210|||Both|18 Years|75 Years|No|||September 2006|June 8, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152074||195517|
NCT00147888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13028A|Changes in Nasal Patency With Changes in Posture, Temperature, Humidity and Nasal Patency Seen by Acoustic Rhinometry|Physiological Changes in Nasal Patency in Response to Changes in Posture, Temperature, Humidity and Nasal Patency Measured by Acoustic Rhinometry||University of Chicago|Yes|Completed|March 2004|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|58 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00147888||195836|
NCT00147901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL-2L|Study to Evaluate the Combination of Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)|Multicenter Phase II Trial of Fludarabine and Cyclophosphamide in Combination With Alemtuzumab (FC-Cam) for Patients With Relapsed Chronic Lymphocytic Leukemia - CLL-2L Protocol of the German CLL-Study Group (GCLLSG)||University of Cologne||Completed|January 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147901||195835|
NCT00148187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0202M17442|Prediction of Medication Compliance Following Renal Transplantation|Prediction of Medication Compliance Following Renal Transplantation||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2003|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|14 Years|N/A|No|Non-Probability Sample|Pre-operative renal transplant recipients|May 2015|May 28, 2015|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00148187||195813|
NCT00148967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-051403-T|INTRINSIC RV - Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs|Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs||Boston Scientific Corporation||Completed|July 2003|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||1535|||Both|18 Years|N/A||||November 2006|November 20, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148967||195754|
NCT00149799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072854|Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder|Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder||Massachusetts General Hospital|Yes|Completed|May 2005|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|September 6, 2005|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT00149799||195690|Our findings may not be fully generalizable - for example, we excluded those with a co-occurring substance use disorder, higher levels of suicidality, and more severely ill patients who required concomitant therapy or a higher level of care.
NCT00150098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 406-04|Project UNITY - HIV Risk Reduction and Vaccine Education Interventions|Project UNITY - A Randomized Trial of Enhanced HIV Risk Reduction and Vaccine Education Interventions in Reducing Sexual Risk and Increasing Vaccine Trial Knowledge Among HIV-negative, High-risk Women Who Use Non-injection Drugs||New York Blood Center|No|Completed|February 2005|October 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 7, 2014|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150098||195668|
NCT00148980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220202-HMO-CTIL|Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation|Creation of Bone Marrow Microenvironment for Treatment of MDS in Conjunction With Allogeneic Stem Cell Transplantation||Hadassah Medical Organization||Withdrawn|April 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|24|||Both|18 Years|N/A|No|||February 2006|April 27, 2011|September 7, 2005|||the PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00148980||195753|
NCT00149305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOUTY DIATESIS|Genetic Study of Nephrolithiasis in Gouty Diathesis|Genetic Study of Nephrolithiasis in Gouty Diathesis||Mario Negri Institute for Pharmacological Research|No|Terminated|May 2005|May 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|37|Samples With DNA|Whole blood on EDTA|Both|10 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Unrelated patients with familial form of nephrolithiasis associated with gouty diathesis        (at least two affected subjects within a family).|October 2009|April 8, 2015|September 7, 2005||No|Non significative preliminary data|No||https://clinicaltrials.gov/show/NCT00149305||195728|
NCT00150553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD417-306|Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder|A Phase IIIb, Randomized, Double-Blind, Parallel Group Study in Bipolar I Patients to Assess the Efficacy and Safety of SPD417 Administered Once Daily vs Twice Daily in the Treatment of Manic Symptoms||Validus Pharmaceuticals||Completed|January 2005|October 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||102|||Both|18 Years|N/A|No|||May 2006|November 1, 2007|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00150553||195634|
NCT00151034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9955|Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer|Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer||University of Michigan Cancer Center|Yes|Completed|September 2000|October 2007|Actual|August 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151034||195597|
NCT00151047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2-42|Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer|Evaluation of Primary Chemotherapy With Docetaxel Plus Capecitabine in Selected Patients With Newly Diagnosed Localized or Locally Advanced Prostate Cancer||University of Michigan Cancer Center|Yes|Completed|March 2003|October 2007|Actual|January 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151047||195596|
NCT00151294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD 45|The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis|A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis||Weill Medical College of Cornell University||Terminated|November 2004|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2006|September 12, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00151294||195577|
NCT00151307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0599-691|Effects of Cerebral Oxygen Saturation on Neuropsychological Outcomes|The Effects of Monitoring and Maintaining Cerebral Oxygen Saturation on Neuropsychological Outcomes in Patients Undergoing Cardiac Surgery||Weill Medical College of Cornell University||Terminated|February 2001|April 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|200|||Both|18 Years|80 Years|No|||June 2008|June 5, 2008|September 6, 2005|||Could not recruit any more people.|No||https://clinicaltrials.gov/show/NCT00151307||195576|
NCT00151593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 020007|Evaluation of Celsior® in Liver Transplant Preservation.|Celsior®: Evaluation of an Organ Preservation Solution in Liver Transplantation.||Rennes University Hospital|No|Completed|February 2002|March 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|N/A|No|||November 2007|November 22, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151593||195554|
NCT00151853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAF2001.01|Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery|Phase IV Study on the Efficacy of PPSB-SD and VP-VI in Patients Using Oral Anticoagulant Therapy and Undergoing Acute Cardiac Surgery With a Cardiopulmonary Bypass||Sanquin||Completed|March 2002|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2006|January 30, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151853||195534|
NCT00147979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/042|Multicentric, Prospective, Randomized, Comparing Trial Between Bypass of the Femoropoplitea by PTFE and Heparin Bounded PTFE|Multicentric, Prospective, Randomized, Comparing Trial Between Bypass of the Femoropoplitea by PTFE and Heparin Bounded PTFE||University Hospital, Ghent|No|Completed|April 2004|August 2013|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|596|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147979||195829|
NCT00147992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/133|Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction|Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. A Retrospective Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction||University Hospital, Ghent|No|Recruiting|June 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00147992||195828|
NCT00147953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ritux plus TNI|Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma|A Phase II Study of Rituximab Plus Low-Dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma||University of Cologne||Completed|June 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00147953||195831|
NCT00147966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041569|Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)|Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies||University of California, San Diego|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|75 Years|No|||June 2008|March 22, 2010|September 2, 2005|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00147966||195830|
NCT00148239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR008272|Health Interventions for Survivors and Primary Support Persons of Spinal Cord Injury|Caregiver Intervention for Caregivers of SCI Patients|SCI|University of Pittsburgh|Yes|Completed|September 2002|July 2008|Actual|July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|380|||Both|30 Years|N/A|No|||November 2015|November 30, 2015|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00148239||195809|
NCT00147940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13093A|Correlation of Nasal Volume, Cross-Sectional Area With Nasalance Scores Measured by Acoustic Rhinometry and Nasometry|Correlation of Nasal Volume and Cross-Sectional Area With Nasalance Scores as Measured by Acoustic Rhinometry and Nasometry||University of Chicago||Terminated|April 2004|August 2005||August 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 11, 2013|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00147940||195832|
NCT00148226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211205|ICIBS Trial - Improving Patient Information About Bowel Cancer Screening - a Decision Aid Trial|Randomized Controlled Trial of Patient Decision Aids for Faecal Occult Blood Test Screening||University of Sydney||Completed|November 2003|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|50 Years|74 Years|Accepts Healthy Volunteers|||September 2005|January 3, 2006|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00148226||195810|
NCT00147914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11791A|Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life|A Comparison Study Between Cefdinir and Amoxicilline/Clavulanate in Patients With Acute Sinusitis and Assessment of Quality of Life (QOL)||University of Chicago|Yes|Active, not recruiting|February 2005|December 2015|Anticipated|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|September 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00147914||195834|
NCT00148200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSD/2005|Female Sexual Dysfunction: Prevalence Among Italian Healthy Women|Prevalence of Female Sexual Dysfunctions Among Healthy Women Coming to the University of Bologna Gynecology Clinic as Outpatients.||Unita Complessa di Ostetricia e Ginecologia||Completed|February 2005|February 2007|Actual|November 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|n° 500 Female outpatient coming to Gynecology Clinic|February 2009|February 17, 2009|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00148200||195812|
NCT00148486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1198.100|A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)|A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)||Boehringer Ingelheim||Completed|June 2003|||March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||261|||Both|40 Years|80 Years|No|||October 2013|October 28, 2013|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148486||195790|
NCT00148499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.489|Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis|Efficacy and Tolerability of Ambroxol Lozenge 20 mg in Relieving Pain of Sore Throat in Patients With Acute Viral Pharyngitis-A Randomised, Double-blind,Placebo- and Active-controlled Parallel Group Study||Boehringer Ingelheim||Completed|October 2005|June 2006||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||751|||Both|18 Years|80 Years|No|||October 2013|October 30, 2013|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148499||195789|
NCT00148720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-167|Capecitabine in Women With Operable Breast Cancer|A Phase II Study of Preoperative Capecitabine in Women With Operable Breast Cancer||Dana-Farber Cancer Institute||Terminated|September 2004|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|N/A|No|||November 2015|November 9, 2015|September 7, 2005|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00148720||195772|
NCT00148473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VJR-01|Oral Versus Vaginal Misoprostol for Induction of Labor|A Single Dose of Oral Versus Vaginal Misoprostol for Induction of Labor: A Randomized Controlled Trial||Bangkok Metropolitan Administration Medical College and Vajira Hospital||Completed|March 2000|October 2001||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148473||195791|
NCT00149552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14966-1|Zinc Therapy in HIV Infected Individuals Who Abuse Drugs|Zinc Therapy in Zinc Deficient HIV Positive Drug Users||Florida International University|Yes|Completed|June 2001|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149552||195709|
NCT00149565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1297|Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma|Hepatocellular Carcinoma Postoperative Adjuvant Therapy Disease Committee of Taiwan Cooperative Oncology Group||National Health Research Institutes, Taiwan||Completed|October 1997|July 2005||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||268|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2004|December 15, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149565||195708|
NCT00149773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH071905-01|Cognitive Therapy for Suicidal Older Men in Primary Care Settings|Cognitive Therapy for Suicidal Older Men in Primary Care Settings||University of Pennsylvania||Completed|May 2005|February 2011|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Male|60 Years|N/A|No|||June 2006|April 6, 2015|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149773||195692|
NCT00131079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI020015-G03/170|PEPAF: Evaluation of Family Physician's Effectiveness for Physical Activity Promotion|Multi-Center Evaluation of the Experimental Program for Physical Activity Promotion (PEPAF), Carried Out by Family Physicians||Basque Health Service|No|Completed|October 2003|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|4317|||Both|20 Years|80 Years|No|||October 2007|October 16, 2007|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131079||197106|
NCT00131092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0033|The CHAT (Community Health Advice by Telephone) Study|Exercise Advice by Human or Computer: Testing 2 Theories||National Institute on Aging (NIA)||Completed|June 1999|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||225|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 9, 2009|August 8, 2005||||No||https://clinicaltrials.gov/show/NCT00131092||197105|
NCT00130494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2001-05|Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-Symptomatic Bone Lesions|Multicenter, Open-Label, Randomized Phase III Trial for Administration of Zoledronate to Breast Cancer Metastatic Patients With Non-Symptomatic Bone Lesions||Spanish Breast Cancer Research Group||Terminated|August 2002|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||224|||Female|18 Years|70 Years|No|||February 2007|February 6, 2007|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130494||197151|
NCT00131911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00121|Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors|A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors||National Cancer Institute (NCI)||Completed|June 2005|April 2013|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||June 2014|November 14, 2014|August 16, 2005|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00131911||197042|
NCT00131924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 03B5|High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy|Phase II Study of High-Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies||Northwestern University||Terminated|March 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Female|18 Years|N/A|No|||June 2012|June 7, 2012|August 16, 2005|Yes|Yes|Data Monitoring Committee recommended closure due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00131924||197041|
NCT00132197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20052|Treatment of Patients With Longstanding Unexplained Health Complaints|Treatment of Patients With Chronic Functional Disorders. A Randomized Controlled Trial of Specialized Treatment Compared to Usual Care.||University of Aarhus|No|Completed|April 2005|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|20 Years|45 Years|No|||November 2011|November 11, 2011|July 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132197||197021|
NCT00132470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX200_P2A_1|Treatment With AX200 for Acute Ischemic Stroke|AXIS IIa - Treatment With AX200 for Acute Ischemic Stroke||Axaron Bioscience AG||Completed|December 2004|March 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|85 Years|No|||July 2007|July 23, 2007|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132470||197000|
NCT00132483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExStroke Pilot Trial|ExStroke Pilot Trial: Physical Exercise After Acute Ischaemic Stroke|||Bispebjerg Hospital|Yes|Completed|September 2003|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|314|||Both|40 Years|N/A|No|||October 2007|October 19, 2007|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00132483||196999|
NCT00132522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62206-015|EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide|A Study to Find the Highest Dose of Biological Study Drug (EMD 273066) That Can Be Given Safely to Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given a Low Dose of Cyclophosphamide||EMD Serono|No|Completed|May 2005|April 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|August 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00132522||196996|
NCT00132535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-714-624-03-0001|Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda|Influence of HIV Infection on the Effectiveness of Malaria Prevention During Pregnancy, With Emphasis on the Effect of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda||Gates Malaria Partnership||Completed|August 2003|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2548|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||January 2009|January 14, 2009|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132535||196995|
NCT00132756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO03-25-002|Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer|Liposomal Doxorubicin and Estramustine Phosphate: A Phase II Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer||Morton Plant Mease Health Care||Terminated|December 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|18 Years|N/A|No|||November 2006|November 6, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132756||196978|
NCT00133341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEKOS 05 P379/1|Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate|Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study.||Mekos Laboratories AS||Completed|April 2005|December 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||60|||Both|18 Years|N/A|No|||February 2006|February 24, 2006|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133341||196934|
NCT00133666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-11-11-05|Improving Asthma Communication in Minority Families|Improving Asthma Communication in Minority Families||National Institute of Nursing Research (NINR)||Completed|September 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|231|||Both|6 Years|12 Years|No|||July 2008|July 16, 2008|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00133666||196909|
NCT00166231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021881|Understanding Pediatric Chest Pain and Other Symptoms|Understanding Pediatric Symptoms and Other Symptoms||Emory University|No|Completed|March 2004|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|156|||Both|8 Years|18 Years|No|Non-Probability Sample|enrolling pediatric patients with either chest pain or innocent heart murmur referrals|February 2015|February 24, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00166231||194451|
NCT00132054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMTO-LC03-03|Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer|Phase I Study of Weekly Irinotecan Combined With Amrubicin in Previously Treated Small-Cell Lung Cancer||National Cancer Institute (NCI)||Completed|May 2004|November 2008|Actual|December 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||December 2006|May 29, 2013|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00132054||197032|
NCT00161954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225|Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years|Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years||Pfizer||Completed|March 2004|May 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|16 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161954||194774|
NCT00162422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19557-HMO-CTIL|Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo|The Effect of β2 Genetic Polymorphisms on the Brochodilatation Effect of Albuterol ex-Vivo||Hadassah Medical Organization||Recruiting|August 2003|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162422||194739|
NCT00162396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc195511-HMO-CTIL|Genetic Determinants of the Response to Salbutamol Among Asthma Patients|Evaluation of Genetic Factors That May Account for Variability in the Response to Salbutamol Among Patients Suffering From Asthma||Hadassah Medical Organization||Recruiting|August 1999|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|150|||Both|18 Years|N/A|No|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162396||194741|
NCT00162409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19552-HMO-CTIL|Relationship Between Folic Acid and Warfarin Metabolism and Effect|The Effect of Folic Acid Concentration and Folic Acid Supplementation on Warfarin Pharmacokinetic and Warfarin Dose Requirement at Steady State.||Hadassah Medical Organization||Recruiting|August 2001|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162409||194740|
NCT00163566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-DHT-01|Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80|A Phase II, Placebo-Controlled, Double-Blind, Dose-Ranging (35mg/Day or 70 mg/Day), Randomized, Study of Cutaneous Dihydrotestosterone (DHT)-Gel (0.7% Hydroalcoholic Gel) in Older Hypogonadal Males Ages 55-80 Years: Effect on Body Composition, Libido, and Physical and Sexual Functioning||ASCEND Therapeutics||Active, not recruiting|October 2004|December 2012|Anticipated|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|128|||Male|55 Years|80 Years|No|||July 2012|July 10, 2012|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00163566||194651|
NCT00163826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163/03|Spinal Clearance Study: Expediting the Spinal Clearance Process in the Major Trauma Patient|Optimisation of Patient Management Through Expediting the Spinal Clearance Process in the Major Trauma Patient||Bayside Health|No|Completed|March 2004|August 2006|Actual|August 2006|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|299|||Both|N/A|N/A|No|Non-Probability Sample|Hospital trauma patients|January 2016|January 6, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00163826||194631|
NCT00164125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851-CR3|An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients|An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients||Braintree Laboratories||Completed|July 2003|||November 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A||||February 2013|February 6, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00164125||194608|
NCT00163813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232/04|The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care (ENTERIC) Study|The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care Study|ENTERIC|Bayside Health||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||180|||Both|18 Years|N/A|No|||August 2005|February 23, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163813||194632|
NCT00130845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995 0804|Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy|A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)||Novartis||Completed|February 2000|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|70 Years|No|||November 2011|November 16, 2011|August 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130845||197124|
NCT00130858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWS-IV 2002|a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4|a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4||Cooperative Weichteilsarkom Study Group||Completed|January 2005|March 2009|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Both|N/A|21 Years|No|||April 2009|April 1, 2009|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130858||197123|
NCT00131430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-020|An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)|An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients||Merck Sharp & Dohme Corp.||Completed|September 2005|May 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|500|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|August 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00131430||197079|
NCT00131443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS 271|Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine|A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine||Monarch Medical Research||Completed|February 2004|August 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||40|||Both|6 Years|18 Years|No|||November 2006|November 9, 2012|August 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00131443||197078|
NCT00131456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4695|Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1|Marijuana Addiction and Depression: Venlafaxine Treatment|VEN|New York State Psychiatric Institute|Yes|Completed|March 2004|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|60 Years|No|||March 2015|March 30, 2015|August 16, 2005||No||No|April 18, 2013|https://clinicaltrials.gov/show/NCT00131456||197077|This was an outpatient study and excluded patients with very severe depression. Thus we cannot generalize the findings to individuals with more severe depressive symptoms. The study length was relatively brief.
NCT00131404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-015|A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)|A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension||Merck Sharp & Dohme Corp.||Terminated|September 2005|December 2008|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|2400|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|August 16, 2005|Yes|Yes|The overall profile does not support development for obesity|No||https://clinicaltrials.gov/show/NCT00131404||197081|
NCT00131417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/HD11/244U/RCT|Ready to Use Therapeutic Food in the Rehabilitation of Severely Malnourished Children|Comparison of the Efficacy of a Ready-to-Use Therapeutic Food With a Milk-Based Diet in the Rehabilitation of Severely Malnourished Ugandan Children||Makerere University||Active, not recruiting|October 2004|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||128|||Both|6 Months|59 Months|No|||August 2005|October 4, 2005|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00131417||197080|
NCT00131937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00658|Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)|No|Completed|October 2005|August 2012|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2015|August 5, 2015|August 16, 2005|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT00131937||197040|The study did not meet pre-specified criteria for continuing to second stage accrual (at least one response among the first 12 eligible patients), and was therefore closed per protocol without full accrual.
NCT00132210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN-102/02|Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients|Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients||University Hospital, Bonn|No|Completed|September 2002|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||November 2009|October 20, 2010|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00132210||197020|
NCT00132223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710/2004-IKR|Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients|Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging||University Hospital Muenster||Recruiting|April 2005|December 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||10|||Both|18 Years|60 Years|No|||April 2006|April 11, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132223||197019|
NCT00132782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242|Relationship Between Functional Health Status and Ventricular Performance After Fontan--Pediatric Heart Network|Relationship Between Functional Health Status and Ventricular Performance After Fontan (A Trial Conducted by the Pediatric Heart Network)||New England Research Institutes|Yes|Completed|March 2003|April 2004|Actual|April 2004|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|546|||Both|6 Years|18 Years|No|Non-Probability Sample|Subjects must have had Fontan surgery of any type at least 6 months prior to the time of        testing|February 2009|March 3, 2014|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00132782||196976|
NCT00132769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0873-012|A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)|A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK-0873 in Rheumatoid Arthritis||Merck Sharp & Dohme Corp.|No|Completed|January 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|August 2, 2005|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00132769||196977|
NCT00133055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67816; 280205-014|Parenting Matters: Helping Parents With Young Children|Parenting Matters: Helping Parents With Young Children||University of Western Ontario, Canada||Completed|July 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|548|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 15, 2011|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00133055||196955|
NCT00133354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSANAS0008|Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys|Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency||Nemours Children's Clinic|Yes|Completed|November 2001|August 2010|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|53|||Male|11 Years|18 Years|No|||October 2011|October 11, 2011|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133354||196933|
NCT00133653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-2001|The Double Exposure Study: The Impact of Job Strain and Marital Cohesion on Blood Pressure|The Impact of Job Strain and Marital Cohesion on Ambulatory Blood Pressure Over One Year: The Double Exposure Study||Sunnybrook Health Sciences Centre||Completed|August 2001|July 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||250|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||August 2004|October 28, 2005|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133653||196910|
NCT00166244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDCC|Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation|An Open, Prospective, Randomised, Controlled, Multi-Center Study Comparing Fixed Dose vs Concentration Controlled Mycophenolate Mofetil Regimens for de Novo Patients Following Transplantation||Erasmus Medical Center|Yes|Completed|May 2003|April 2006|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|901|||Both|2 Years|N/A|No|||February 2009|February 11, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166244||194450|
NCT00165984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599-2004|Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy|Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy||Emory University|No|Completed|January 2004|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|224|Samples With DNA|Whole blood and serum.|Both|N/A|N/A|No|Non-Probability Sample|All pediatric single ventricle patients or pediatric patients previously transplanted for        single ventricle, who undergo an invasive procedure (surgery or catheterization) will be a        candidate for enrollment in the study.|April 2012|April 4, 2012|September 9, 2005||No||No|November 11, 2011|https://clinicaltrials.gov/show/NCT00165984||194470|Relatively small number of patients given the low incidence of this mutation
NCT00132067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02667|Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer|A Phase II Evaluation of Vorinostat, (SAHA, NCI-Supplied Agent [NSC #701852]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|October 2005|July 2008|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||January 2013|June 11, 2014|August 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00132067||197031|
NCT00162669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGR 1123|Bevacizumab in Advanced Hepatocellular Carcinoma|Phase II Study Evaluating the Efficacy of Bevacizumab (Avastin@) in Hepatocellular Carcinoma Not Amenable to Curative Treatment||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|May 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||September 2006|September 7, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00162669||194720|
NCT00162942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512-04-206|Study for the Treatment of Crohn's Disease With Adacolumn|A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease||Otsuka America Pharmaceutical||Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|235|||Both|18 Years|75 Years|No|||March 2009|March 5, 2009|September 9, 2005||||No|January 15, 2009|https://clinicaltrials.gov/show/NCT00162942||194699|
NCT00163839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30/05|The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema|The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria or Angioedema: A Randomised Controlled Study||Bayside Health||Not yet recruiting|September 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|21 Years|75 Years|No|||September 2005|February 14, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163839||194630|
NCT00164164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F38-20|HalfLytely Bowel Prep System for Colonoscopy|HalfLytely Bowel Prep System for Colonoscopy||Braintree Laboratories||Completed|August 1999|||June 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||200|||Both|18 Years|N/A||||February 2013|February 6, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00164164||194605|
NCT00164177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F38-VC-002|Evaluation Of The Efficacy Of HalfLYTELY For Bowel Cleansing Before Virtual Colonoscopy and Conventional Colonoscopy.|A Preliminary Evaluation Of The Efficacy Of HalfLYTELY® For Bowel Cleansing Before Virtual Colonoscopy (VC) and Conventional Colonoscopy (CC).||Braintree Laboratories||Completed|October 2004|||December 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||20|||Both|18 Years|N/A||||February 2013|February 6, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00164177||194604|
NCT00164190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-69798|Routine Angioplasty and Stenting After Fibrinolysis for Acute Myocardial Infarction|Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction- The TRANSFER-AMI Trial||Canadian Heart Research Centre|Yes|Completed|July 2004|January 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164190||194603|
NCT00164138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108/01|Prevalence and Treatment of Urinary Incontinence in Women With Cystic Fibrosis and Chronic Obstructive Pulmonary Disease|Development of an Intervention and and Education Program for Adult Women With Urinary Incontinence and Chronic Lung Disease Including Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD)||Bayside Health|No|Completed|December 2001|June 2004|Actual|June 2004|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||September 2005|November 26, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00164138||194607|
NCT00164151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F38-23|A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy.|A Comparison of the Efficacy and Safety of Two Bowel Preparations: HalfLytely® (2L NuLYTELY and 20 mg Bisacodyl), and Visicol™ Prior To Colonoscopy.||Braintree Laboratories||Completed|June 2001|||May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind||||60|||Both|18 Years|N/A||||February 2013|February 6, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00164151||194606|
NCT00130897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181037|Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma|A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248||Pfizer|No|Approved for marketing|July 2005|November 2011|Actual|November 2011|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2012|March 8, 2012|August 14, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00130897||197120|
NCT00131144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995 0802|Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy|A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)||Novartis||Completed|November 1999|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|583|||Both|18 Years|70 Years|No|||November 2011|November 16, 2011|August 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00131144||197101|
NCT00131469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBMD-OI|Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta|A Study to Assess the Effectiveness of Teriparatide (FORTEO) for Increasing Bone Mass and Improving Bone Strength in Adults Affected With Osteogenesis Imperfecta (OI)|OI|Oregon Health and Science University|Yes|Completed|June 2005|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|85 Years|No|||October 2013|October 30, 2013|August 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00131469||197076|
NCT00131664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVM103436|Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)|Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients|AVALANCHE|Canadian Heart Research Centre|Yes|Completed|September 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|391|||Both|18 Years|75 Years|No|||April 2013|April 15, 2013|August 17, 2005||No||No|January 28, 2012|https://clinicaltrials.gov/show/NCT00131664||197061|The LOCF used in the ITT population for withdrawn subjects or missing values was analyzed as per protocol. The 3 treatment groups used throughout the results section were the numbers where the patients were originally randomized to.
NCT00131677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-4323|Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men|Phase II Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men||Centers for Disease Control and Prevention|Yes|Completed|February 2005|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|400|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|January 22, 2014|August 17, 2005|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00131677||197060|
NCT00131690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1994/2974|Effect of Caffeine on Fetal Growth|The Importance of Caffeine in Fetal Growth||The Danish Epdiemiology Science Centre||Completed|April 1996|August 2002||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Female|N/A|N/A|No|||August 2005|October 7, 2005|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00131690||197059|
NCT00131950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-0212-005|Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer Screening|Chicago Breast Health Project, Phase II||National Cancer Institute (NCI)||Completed|August 2003|November 2005|Actual|||N/A|Interventional|Primary Purpose: Screening|||||||Female|40 Years|N/A|Accepts Healthy Volunteers|||October 2005|July 9, 2013|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131950||197039|
NCT00132236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA01096gms|Nurse Smoking Cessation of Patients With Chronic Obstructive Pulmonary Disease (COPD) With Nicotine Replacement Therapy (NRT) and Behavioral Support|Smoking Cessation of Patients With COPD: A Multi-Center, Randomized, Placebo Controlled Nurse Conducted Smoking Cessation Trial||University Hospital, Gentofte, Copenhagen||Terminated|February 2002|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||July 2005|October 20, 2005|August 17, 2005||||No||https://clinicaltrials.gov/show/NCT00132236||197018|
NCT00132548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVF02|A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children|A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children||Gates Malaria Partnership||Completed|June 2004|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||2200|||Both|1 Year|5 Years|No|||August 2005|October 14, 2005|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132548||196994|
NCT00164827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2002-412-T|Surveillance of Bleeding Peptic Ulcer Using Wireless Capsule Endoscopy|Phase 3 Study on the Use of Capsule Endoscope for Surveillance and Detection of Peptic Ulcer Rebleeding After Therapeutic Endoscopy||Chinese University of Hong Kong||Recruiting|January 2003|||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||50|||Both|18 Years|N/A|No|||September 2005|September 11, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00164827||194554|
NCT00133068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|707850|Collaboration to Reduce Disparities in Hypertension|Collaboration to Reduce Disparities in Hypertension||University of Pennsylvania|Yes|Completed|March 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|802|||Both|21 Years|N/A|No|||December 2009|December 1, 2009|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00133068||196954|
NCT00165971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459-2003|Recovery From General Anesthesia|Recovery From General Anesthesia||Emory University||Completed|December 2003|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|N/A|No|||April 2007|April 16, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165971||194471|
NCT00165997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0147-2004|Quality of Life in Patients Post Radiofrequency Ablation|The Effects of Radiofrequency Ablation Procedures on Quality of Life in the Pediatric Cohort||Emory University||Terminated|February 2004|October 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|5 Years|18 Years|No|||December 2013|December 9, 2013|September 12, 2005|||sufficient data collected for significant conclusive results|No||https://clinicaltrials.gov/show/NCT00165997||194469|
NCT00161798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205|Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.|Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.||Pfizer||Completed|September 2001|March 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|6 Years|15 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161798||194786|
NCT00132366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050224|Brain Excitability in Patients With Succinic Semialdehyde Dehydrogenase Deficiency|Cortical Excitability in Succinic Semialdehyde Dehydrogenase Deficiency||National Institutes of Health Clinical Center (CC)||Completed|August 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A||||60|||Both|5 Years|55 Years|Accepts Healthy Volunteers|||June 2009|August 27, 2009|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00132366||197008|
NCT00162955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLSG-0401|Prevention of CHOP-induced Chronic Cardiotoxicity|The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP||Osaka City University|Yes|Completed|May 2004|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|15 Years|70 Years|No|||September 2010|May 7, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00162955||194698|
NCT00163267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mi-1|Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel|Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study||University Hospital Tuebingen||Completed|September 2005|April 2011|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|90 Years|No|||April 2007|August 5, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00163267||194674|
NCT00163280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL-104/034/CL|Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis|Randomised Double-Blind Placebo-Controlled Study of Orally Administered ATL-104 to Assess Safety, Tolerance and Effect on Oral Mucositis in Patients Following Treatment With Chemotherapy and Peripheral Blood Stem Cell Transplant (PBSCT)||Alizyme|Yes|Completed|July 2004|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|63|||Both|18 Years|65 Years|No|||February 2008|February 11, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00163280||194673|
NCT00129948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD758-216|Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage||SGX Pharmaceuticals, Inc.||Terminated|July 2005|October 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||211|||Both|18 Years|N/A|No|||November 2006|November 1, 2006|August 10, 2005||||||https://clinicaltrials.gov/show/NCT00129948||197192|
NCT00129961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-407|Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients|A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2005|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|86|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|August 1, 2005|Yes|Yes||No|January 29, 2010|https://clinicaltrials.gov/show/NCT00129961||197191|A blinded review of data in May 2007 determined there was minimal added power in follow-up through 2 years vs. 1 year. The study was then amended to require at least 1 year of follow-up instead of 2 years.
NCT00130507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2004-06|Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab|Randomized Clinical Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line Treatment for HER2 Positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Progressing to a Previous Therapy Line With Trastuzumab and Taxanes||Spanish Breast Cancer Research Group||Terminated|November 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|70 Years|No|||October 2011|October 25, 2011|August 12, 2005||No|A new alternative treatment caused the decrease in the rhythm of recruitment and finally    termination of the trial.|No||https://clinicaltrials.gov/show/NCT00130507||197150|
NCT00130520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC #05-47;AVF3117s|Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer|Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab in Women With Advanced Ovarian Cancer||University of Arizona|Yes|Completed|June 2005|May 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||December 2010|May 22, 2012|August 12, 2005|Yes|Yes||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00130520||197149|
NCT00134199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351013|A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects|A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects||Pfizer||Completed|March 2005|November 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|282|||Both|18 Years|65 Years|No|||April 2006|August 11, 2009|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134199||196869|
NCT00130533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIBOMA 2004-01|Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients|Multicenter, Open-label, Randomized Phase III Trial, to Evaluate Efficacy of Maintenance Treatment With Capecitabine (X) Following Standard Adjuvant Chemotherapy, in Operable Breast Cancer Patients With Negative Hormone Receptor, Negative HER2 Tumours||Spanish Breast Cancer Research Group||Active, not recruiting|January 2006|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|876|||Female|18 Years|70 Years|No|||July 2015|July 31, 2015|August 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00130533||197148|
NCT00131157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95500|Evaluation of Spirometry Expert Support in General Practice|A Randomized-Controlled Evaluation of Spirometry Expert Support in General Practice||Radboud University||Active, not recruiting|January 2003|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||39|||Both|18 Years|N/A|No|||February 2007|February 28, 2007|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131157||197100|
NCT00131105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0034|The TLC2 (Teaching Healthy Lifestyles to Caregivers 2)/CALM (Counseling Advice for Lifestyle Management) Study|Combining Exercise and Diet in Older Adults||National Institute on Aging (NIA)||Completed|July 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|200|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 22, 2008|August 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00131105||197104|
NCT00131118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2202E1|Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta|Efficacy and Safety of Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta||Novartis||Completed|July 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||127|||Both|1 Year|17 Years||||April 2012|April 26, 2012|August 15, 2005||||||https://clinicaltrials.gov/show/NCT00131118||197103|
NCT00131131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK46890 (completed 2006)|Epidemiology of Gallbladder Sludge and Stones in Pregnancy|Epidemiology of Gallbladder Sludge & Stones in Pregnancy||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|May 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||670|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00131131||197102|
NCT00131716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG33.|Prevention of Severe Anaemia in Gambian Children|Chemoprophylaxis With Sulfadoxine-Pyrimethamine to Prevent Recurrence of Severe Anaemia in Gambian Children Aged 3 Months to 9 Years||Gates Malaria Partnership|Yes|Completed|May 2003|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1200|||Both|3 Months|9 Years|No|||February 2008|February 7, 2008|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00131716||197057|
NCT00131703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCR5092|Efficacy and Safety of Sulphadoxine-Pyrimethamine and Amodiaquine in Ghanaian Pregnant Women|A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-Pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy||Gates Malaria Partnership||Completed|March 2003|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Female|N/A|N/A|No|||August 2005|December 1, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00131703||197058|
NCT00132249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-01-1-0675|Vietnam Head Injury Study - Phase III|A 40+ Year Post-Injury Follow-Up Study of Vietnam Veterans Who Sustained Traumatic Brain Injury While in Combat.||U.S. Army Medical Research and Materiel Command|No|Completed|April 2004|September 2010|Actual|September 2010|Actual|Phase 3|Observational|Observational Model: Case Control||2|Actual|254|||Male|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|199 head-injured subjects attended PH3. 55 control subjects attended PH3.|June 2015|June 8, 2015|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00132249||197017|
NCT00132561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCR 5094|A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children|A Double-Blind, Randomised, Placebo-Controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa||Gates Malaria Partnership||Completed|June 2002|December 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Both|6 Weeks|59 Months|Accepts Healthy Volunteers|||February 2006|May 3, 2006|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132561||196993|
NCT00165061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-9362|Multi-Center Prospective Randomized Trial Comparing Standard Esophagectomy Against Chemo-Radiotherapy for Treatment of Squamous Esophageal Cancer – Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)|Phase 3 Multicenter Randomized Study Comparing Esophagectomy Against Definitive Chemoradiation for Treatment of Squamous Esophageal Cancer||Chinese University of Hong Kong||Completed|July 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|75 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00165061||194537|
NCT00166023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0549-2005|Outcomes Following Medical or Surgical Management of Endocarditis|A Review of Outcomes Following Medical or Surgical Management of Endocarditis||Emory University||Completed|August 2005|December 2006||||N/A|Observational|N/A||||100|||Both|N/A|N/A|No|||November 2013|November 25, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166023||194467|
NCT00166036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1038-2004|Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells|Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells: Comparison of Atorvastatin With Pravastatin|STOPCAP|Emory University|No|Completed|September 2004|April 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|21 Years|80 Years|No|||August 2014|August 28, 2014|September 12, 2005|Yes|Yes||No|June 8, 2012|https://clinicaltrials.gov/show/NCT00166036||194466|Detection of changes in Oxidative stress with significance requires a much larger cohort study.
NCT00132912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03573|Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573AM1) (COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention||Merck Sharp & Dohme Corp.||Completed|August 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|1030|||Both|45 Years|N/A|No|||October 2015|October 19, 2015|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00132912||196966|
NCT00132925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRG5029C_3502|An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis|An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis||Sanofi||Completed|November 2003|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||460|||Both|2 Years|5 Years|No|||January 2011|January 10, 2011|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132925||196965|
NCT00163293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/CA-101|Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 y) (BY9010/CA-101)|Effect of Low Dose Continuous Treatment With Ciclesonide Over One Year on the Time to First Exacerbation in Children With Mild Asthma Versus Intermittent Treatment for Exacerbations|POPCICLE|Takeda|No|Completed|January 2005|April 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|240|||Both|4 Years|11 Years|No|||January 2011|May 4, 2012|September 12, 2005|Yes|Yes||No|December 1, 2010|https://clinicaltrials.gov/show/NCT00163293||194672|
NCT00163579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-2004-UFK-1|The Impact of Bryophyllum on Preterm Delivery|The Impact of the Prophylactic or Therapeutic Application of Bryophyllum on Preterm Delivery - a Prospective Study||Basel Women’s University Hospital|No|Recruiting|July 2004|March 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|180|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2005|April 14, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00163579||194650|
NCT00163592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|530301|Post-Marketing Surveillance of TISSUCOL for Hemostasis in Subjects Undergoing Vascular Reconstruction With Polytetrafluoroethylene (PTFE) Prosthesis|Non- Interventional Study of Tissucol® for Hemostasis in Subjects With Femoral Vascular Anastomosis Undergoing Vascular Reconstruction With PTFE Prosthesis||Baxter Healthcare Corporation||Completed|September 2003|February 2004||||Phase 4|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|N/A|N/A||||October 2006|October 20, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00163592||194649|
NCT00163605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|570201|Performance and Safety of Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures|A Prospective Clinical Study to Evaluate the Performance and Safety of the Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures||Baxter Healthcare Corporation||Completed|September 2004|November 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 14, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00163605||194648|
NCT00133887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.333|TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients|Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors||Hospices Civils de Lyon||Completed|April 2004|May 2014|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|80 Years|No|||May 2014|July 1, 2014|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00133887||196892|
NCT00130260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1372|Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease|Phase 3b Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating Immunogenicity and Safety of a 3rd and 4th Dose of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults With End-Stage Renal Disease|SHIELD-2|Nabi Biopharmaceuticals|No|Terminated|August 2005|April 2006|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|99|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|August 12, 2005|Yes|Yes|unsatisfactory efficacy data from preceding trial|No||https://clinicaltrials.gov/show/NCT00130260||197169|
NCT00130273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067498|Managed Problem Solving to Increase Treatment Adherence in Individuals With HIV|Managed Problem Solving: An HIV Adherence Trial|MAPS|University of Pennsylvania||Completed|July 2005|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|August 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00130273||197168|
NCT00130832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-014|Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)|Safety and Immunogenicity of Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants||Merck Sharp & Dohme Corp.||Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|735|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||March 2015|March 12, 2015|August 12, 2005|No|Yes||No|August 7, 2009|https://clinicaltrials.gov/show/NCT00130832||197125|
NCT00163709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116/05|BNP Testing in Patients With SOB on Presentation to ED|A Randomised Trial of BNP Testing in Patients With Shortness of Breath in the Emergency Department to Improve Patient Outcome||Bayside Health||Recruiting|August 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||600|||Both|40 Years|N/A|No|||May 2005|October 3, 2006|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00163709||194640|
NCT00131482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OL-ADRFX-03|A Study to Evaluate the Safety and Effectiveness of Different Doses of Chrysalin in Adults Who Have a Broken Wrist|A Double-blind, Randomized, Placebo-controlled Phase 2b Study to Establish the Effective Dose Range and to Evaluate the Safety of Chrysalin in Adult Subjects With a Fractured Distal Radius||Capstone Therapeutics|No|Terminated|November 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|274|||Both|18 Years|N/A|No|||August 2010|August 23, 2010|August 16, 2005|Yes|Yes|Treatment with Chrysalin did not demonstrate benefit compared to placebo.|No||https://clinicaltrials.gov/show/NCT00131482||197075|
NCT00163696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBNW alfred|Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease|Measurements of Inhomogeneity of the Small Airway With Patients With Cystic Fibrosis, Asthma and Bronchiolitis Obliterans Syndrome (Post Transplant) Using the Multi Breath Nitrogen Washout Technique||Bayside Health||Recruiting|September 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|90|||Both|18 Years|65 Years|No|||September 2005|July 25, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00163696||194641|
NCT00131963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014267|Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer|A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel||Duke University|No|Completed|October 2003|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Female|18 Years|N/A|No|||November 2015|December 8, 2015|August 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00131963||197038|
NCT00164281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3441|Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana|A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana||Centers for Disease Control and Prevention|Yes|Completed|November 2004|May 2011|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|2000|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164281||194596|
NCT00164294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-523255|ED Intervention to Reduce Risky Behaviors in Drivers|ED Intervention to Reduce Risky Behaviors in Drivers||Centers for Disease Control and Prevention||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|18 Years|44 Years||||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164294||194595|
NCT00164554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-3813|Fetal Alcohol Syndrome/ARND Research Consortion|Fetal Alcohol Syndrome/ARND Research Consortion-Oklahoma||Centers for Disease Control and Prevention||Completed|October 2001|June 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||100|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||September 2005|April 25, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164554||194575|
NCT00164567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3142|Intimate Partner Violence (IPV)Screening in Health Care Clinics in Rural South Carolina|IPV Screening in Health Care Clinics in Rural South Carolina||Centers for Disease Control and Prevention||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||1200|||Female|18 Years|65 Years|No|||October 2009|October 22, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164567||194574|
NCT00165334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-422|Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer|Phase II Trial of Cetuximab Plus Vinorelbine in Previously Untreated Patients > 70 With Advanced NSCLC||Dana-Farber Cancer Institute||Completed|June 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||53|||Both|70 Years|N/A|No|||July 2009|July 21, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165334||194519|
NCT00165347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-257|Protein Tyrosine Kinases (PTK) in Multiple Myeloma|Phase II Study of PTK787/ZK222584 in Multiple Myeloma||Dana-Farber Cancer Institute||Completed|December 2003|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165347||194518|
NCT00165087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-001|Treatment of Childhood Acute Lymphoblastic Leukemia|Treatment of Childhood Acute Lymphoblastic Leukemia||Dana-Farber Cancer Institute||Terminated|January 1996|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||491|||Both|N/A|18 Years|No|||December 2007|December 20, 2007|September 9, 2005|||Terminated by IRB for continuing review|||https://clinicaltrials.gov/show/NCT00165087||194535|
NCT00165360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-111|Prolonged Daily Temozolomide for Low-Grade Glioma|A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma||Dana-Farber Cancer Institute|Yes|Completed|September 2001|September 2009|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165360||194517|
NCT00165568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-415|Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer|Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer||Dana-Farber Cancer Institute||Completed|July 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165568||194502|
NCT00165581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-259|High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma|A Pilot Clinical Trial to Evaluate High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Favorable Stage I and II Breast Cancer||Dana-Farber Cancer Institute||Terminated|December 2002|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Female|45 Years|N/A|No|||December 2007|December 20, 2007|September 13, 2005|||Due to continuing review|No||https://clinicaltrials.gov/show/NCT00165581||194501|
NCT00132665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0301|Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)|Randomized Controlled Trial to Evaluate Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatine in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer (JCOG0301, NCSLC-Elderly-CBDCA-RT Phase III)||Japan Clinical Oncology Group|Yes|Completed|July 2003|February 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|71 Years|N/A|No|||December 2012|December 6, 2012|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00132665||196985|
NCT00133549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-023|9-valent CRM 197 Pneumococcal|Evaluation of a 9-valent CRM 197- Conjugated Pneumococcal Polysaccharide Vaccine in Elderly Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2000|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|180|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2011|October 16, 2014|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00133549||196918|
NCT00129909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPO402A; RPO402B|STITCH (Simplified Therapeutic Intervention To Control Hypertension)|Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Hypertension - Control and Intervention Arms||University of Western Ontario, Canada|No|Completed|May 2005|January 2007|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2081|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|August 10, 2005||||No||https://clinicaltrials.gov/show/NCT00129909||197195|
NCT00133575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0010|ACAM 3000 MVA at Harvard Medical School|ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2005|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|72|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||September 2009|December 11, 2014|August 19, 2005|Yes|Yes||No|March 26, 2009|https://clinicaltrials.gov/show/NCT00133575||196916|The Dryvax challenge was optional and administered to only a subset of participants before being discontinued prior to being offered to the subjects in the last cohort.
NCT00133588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0044|Proteomic Profiling for Influenza|Proteomic Profiling for Influenza Vaccination||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2006|January 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2007|August 26, 2010|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133588||196915|
NCT00133900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMC-38|Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy|Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy|IMMC-38|Immunicon|No|Active, not recruiting|December 2004|February 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|276|Samples With DNA|Serum Samples and RNA samples have been retained.|Male|18 Years|N/A|No|Probability Sample|Oncology patients from academic institutions and private practices|March 2008|July 27, 2009|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133900||196891|
NCT00129974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7338|Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer|A Phase II Trial of Pemetrexed in Combination With Gemcitabine as First Line Treatment in Extensive-Stage Small Cell Lung Carcinoma||Tufts Medical Center||Terminated|August 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||October 2007|July 24, 2009|August 10, 2005|||failure to accrue|No||https://clinicaltrials.gov/show/NCT00129974||197190|
NCT00130234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00000804|Effect of Anti-IgE in Chronic Urticaria|Effect of Anti-IgE in Chronic Urticaria||Johns Hopkins University||Completed|November 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||May 2008|May 6, 2008|August 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00130234||197171|
NCT00130247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-009|Tuberculosis Treatment Shortening Trial|A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2002|November 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|394|||Both|18 Years|60 Years|No|||April 2010|January 31, 2013|August 12, 2005|Yes|Yes||No|August 20, 2009|https://clinicaltrials.gov/show/NCT00130247||197170|Enrollment was stopped early and the number of patients enrolled was 1/2 of the original sample size. The study was completed.
NCT00130546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FreRace-Study 186/02|Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study)|A Prospective, Randomized Intra-Individual Study With the Sirolimus Coated Cypher Select(TM) and the Paclitaxel(TM) Coated Express Balloon Expandable Stents for the Treatment of Patients With Two de Novo Native Coronary Artery Lesions.||University Hospital Freiburg|Yes|Completed|November 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|85 Years|No|||May 2009|May 14, 2009|August 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00130546||197147|
NCT00130559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEL II - ICU|B-type Natriuretic Peptide (BNP)-Guided Diagnostic Strategy in Intensive Care Unit (ICU) Patients With Respiratory Failure|Does a Diagnostic Strategy Reduce Duration and Cost of Hospitalization in Patients With Acute Dyspnea? BASEL II Intensive Care Unit||University Hospital, Basel, Switzerland||Completed|December 2003|March 2008|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|286|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|August 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00130559||197146|
NCT00130884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001081|Peroral Levosimendan in Chronic Heart Failure|Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study||Orion Corporation, Orion Pharma||Completed|March 2005|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||February 2007|February 19, 2007|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130884||197121|
NCT00163397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-137|Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)|A Comparative Study of Inhaled Ciclesonide 160 Mcg/Day vs Budesonide 400 Mcg/Day in Patients With Asthma||Takeda||Completed|January 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|75 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163397||194664|
NCT00163358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-132|Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)|Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-term Asthma Control||Takeda||Completed|September 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||630|||Both|12 Years|75 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163358||194667|
NCT00163371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-208|Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)|Effect of Ciclesonide (320 Mcg/Day) vs Fluticasone Propionate (375 Mcg/Day) vs. Placebo on Short-term Linear Growth Rate and HPA-axis Function in Prepubertal Children With Mild Asthma||Takeda||Completed|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||28|||Both|6 Years|12 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163371||194666|
NCT00164307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-3642|Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships|Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships||Centers for Disease Control and Prevention||Completed|October 2001|January 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||100|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||September 2005|November 7, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164307||194594|
NCT00163904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/05|Can a Modified Fat Diet With Low Glycaemic Load Improve Insulin Sensitivity and Inflammatory Mediators in Overweight People With Chronic Heart Failure?|Can a Modified Fat Diet With Low Glycaemic Load Improve Insulin Sensitivity and Inflammatory Mediators in Overweight People With Chronic Heart Failure?||Bayside Health||Recruiting|January 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|50|||Both|18 Years|75 Years|No|||September 2005|July 31, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00163904||194625|
NCT00164580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-1733|Community Intervention Trial for Youth (CITY) Study|Prevention of HIV Infection in Youth at Risk: Developing Community-Level Intervention Strategies That Work (Community Intervention Trial for Youth (CITY) Study)||Centers for Disease Control and Prevention|No|Completed|October 1996|August 2004|Actual|August 2002|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||12000|||Male|15 Years|25 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164580||194573|
NCT00165074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-9-2968|Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory Decompensation|Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With||Children's Hospital of Philadelphia|No|Completed|June 2003|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|10 Days|No|||November 2007|November 19, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165074||194536|
NCT00164853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.067-T|Compare Combined Sphincterotomy and Balloon Dilation (ESBD) Versus Standard Sphincterotomy (ES) in Removing Biliary Stones|Combined Sphincterotomy and Balloon Dilation (ESBD) Versus Standard Sphincterotomy (ES) in Removing Biliary Stones—a Randomized Controlled Trial||Chinese University of Hong Kong|Yes|Completed|September 2005|||September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||September 2010|February 16, 2012|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00164853||194552|
NCT00165100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-331|Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer|Dynamic Area Telethermometry (DAT) as an Auxiliary Imaging Modality in Assessment of Patients With Cancer||Dana-Farber Cancer Institute||Completed|January 2000|October 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|16 Years|N/A|No|||December 2007|December 20, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165100||194534|
NCT00165633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0167-J081-551|A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma|A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma||Eisai Inc.||Terminated|March 2004|March 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|540|||Both|20 Years|N/A|No|||December 2008|December 5, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00165633||194497|
NCT00165646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-461|A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease|A Double-Blind, Placebo-Controlled, Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease||Eisai Inc.||Completed|September 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|288|||Both|20 Years|N/A|No|||August 2010|July 14, 2011|September 12, 2005||No||No|May 23, 2011|https://clinicaltrials.gov/show/NCT00165646||194496|
NCT00165659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-231|A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020|||Eisai Inc.||Completed|November 2002|||May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A||||January 2010|January 28, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165659||194495|
NCT00165672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-462|A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease|A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease||Eisai Inc.||Completed|May 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|N/A|No|||August 2010|September 6, 2011|September 12, 2005||No||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00165672||194494|
NCT00165594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7070-J081-217|A Study of E7070 in Patients With Gastric Cancer|Non-Randomized, Open, Uncontrolled, Dose Comparison Study of E7070 in Patients With Gastric Cancer||Eisai Inc.||Terminated|February 2005|August 2006|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|20 Years|74 Years|No|||January 2014|January 22, 2014|September 12, 2005||No|Study was completed.|No||https://clinicaltrials.gov/show/NCT00165594||194500|
NCT00165607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA001R00|Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)|||Eisai Inc.||Completed|April 1996|||June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|50 Years|N/A|No|||January 2010|January 28, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165607||194499|
NCT00165620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7337-J081-141|A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease|||Eisai Inc.||Completed|November 2004|||April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|20 Years|N/A||||January 2010|January 28, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165620||194498|
NCT00133835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97.187|Comparison of Extracorporeal Shock Wave Lithotripsy (ESWL) Alone and ESWL Plus Endoscopy for Painful Chronic Pancreatitis|Comparison of ESWL Alone and ESWL Combined With Endoscopic Drainage of the Main Pancreatic Duct for Painful Chronic Pancreatitis||Erasme University Hospital||Completed|March 1998|July 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||July 2005|October 24, 2005|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133835||196896|
NCT00134186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0219|Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer|Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma||Pharmacyclics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Both|18 Years|N/A|No|||March 2007|March 2, 2007|August 22, 2005||||||https://clinicaltrials.gov/show/NCT00134186||196870|
NCT00133627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZAD511ACN01|Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis|Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis||Novartis||Completed|April 2005|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|229|||Both|3 Years|N/A|No|||November 2011|November 16, 2011|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00133627||196912|
NCT00129987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLICX3224|Trial of Lay-led Individualised Self-management Education for Adults With Asthma|A Multi-centre Randomised Trial of Lay-led Individualised Self-management Education for Adults With Asthma||Imperial College London||Completed|November 2003|August 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||640|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2008|June 3, 2015|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129987||197189|
NCT00134238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091004|Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.|Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia|RADIANCE 2|Pfizer||Terminated|November 2003|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|755|||Both|18 Years|70 Years|No|||February 2012|February 15, 2012|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00134238||196866|
NCT00130000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050217|Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria|SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design||National Institutes of Health Clinical Center (CC)||Completed|August 2005|June 2007||||Phase 3|Interventional|Primary Purpose: Treatment||||87|||Both|18 Years|N/A|No|||June 2007|September 26, 2015|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00130000||197188|
NCT00130572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CDE12|Efficacy of Elidel Cream on Erosive Oral Lichen Planus|Randomized Placebo-Controlled Clinical Pilot Trial Regarding the Efficacy of Elidel Cream on Erosive Oral Lichen Planus||University Hospital Tuebingen||Completed|June 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|20|||Both|18 Years|N/A|No|||May 2008|May 21, 2008|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130572||197145|
NCT00130871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001079|Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass|Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG)||Orion Corporation, Orion Pharma||Completed|January 2004|January 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||February 2007|February 19, 2007|August 15, 2005||||No||https://clinicaltrials.gov/show/NCT00130871||197122|
NCT00130585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-007-RW|Bioavailability of Folate From a Mixed Diet Using a Stable Isotope Method|The Relative Bioavailability of Folate From a Mixed Diet Compared to Synthetic Folic Acid Using a Stable Isotope Method||Wageningen University||Completed|May 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2005|October 3, 2005|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130585||197144|
NCT00163735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124/02|Potential Allergens in Wine: Double-blind Placebo-controlled Trial|Potential Allergens in Wine: Double Blind Placebo-controlled Trial and Basophil Activation Analysis||Bayside Health||Completed|August 2002|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|December 3, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163735||194638|
NCT00163085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1611007|The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease||Pfizer||Completed|May 2005|January 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|30 Years|80 Years|No|||September 2006|September 21, 2006|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00163085||194688|
NCT00163917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107/ 04|A Study of the Effectiveness of Virtual Reality Relaxation Combined With Patient-Controlled Analgesia (PCA) Morphine for Those Undergoing Burn Dressing Changes|Predicting the Effectiveness of Virtual Reality Relaxation on Pain and Anxiety When Added to PCA Morphine in a Population of Burn Patients Having Dressing Changes||Bayside Health||Recruiting|September 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|80 Years|No|||September 2005|March 14, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163917||194624|
NCT00163930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlfRad2004-1|Post-Operative Pain Management in Patients Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata|Post-Operative Pain Management in Patients Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata||Bayside Health||Recruiting|January 2005|December 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Female|18 Years|80 Years|No|||September 2005|October 2, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163930||194623|
NCT00164320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3699|Project TEAM: Teaching HIV Prevention in the HIV Clinic|Project TEAM: Teaching HIV Prevention in the HIV Clinic||Centers for Disease Control and Prevention||Completed|May 2004|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||600|||Both|18 Years|N/A||||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164320||194593|
NCT00164840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG Study|Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy|Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy||Chinese University of Hong Kong||Completed|May 2003|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|244|||Both|18 Years|80 Years|No|||March 2010|March 29, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164840||194553|
NCT00164333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3797|The Treatment Advocacy Program|The Treatment Advocacy Program||Centers for Disease Control and Prevention|No|Completed|September 2004|April 2008|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Male|18 Years|N/A||||September 2012|September 26, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164333||194592|
NCT00164593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-4530|Youth Empowerment Solutions for Peaceful Communities|Youth Empowerment Solutions for Peaceful Communities||Centers for Disease Control and Prevention|No|Completed|April 2005|August 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1142|||Both|12 Years|15 Years|No|||April 2012|April 4, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00164593||194572|
NCT00165126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-315|Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma|Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma||Dana-Farber Cancer Institute|Yes|Completed|January 2004|July 2008|Actual|January 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Female|18 Years|90 Years|No|Non-Probability Sample|Patients with carcinoma of the uterus, post-hysterectomy stages I-IVA or vaginal cuff        recurrence or post-hysterectomy cervix cancer stages IA or IB or post hysterectomy vaginal        cancer stage I that will be undergoing radiation therapy.|October 2009|October 30, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165126||194533|
NCT00165373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-222|rhEndostatin Protein Involving Pediatric Patients With Cancer|A Phase I, Safety, Pharmacokinetic and Pharmacodynamic Study of rhEndostatin Protein Administered by Continuous Intravenous Infusion to Pediatric Patients With Cancer||Dana-Farber Cancer Institute|No|Terminated|January 2003|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|2 Years|18 Years|No|||December 2007|December 21, 2007|September 9, 2005|Yes|Yes|Lack of drug supply|No||https://clinicaltrials.gov/show/NCT00165373||194516|
NCT00165139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-131|Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas|Double Dose Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Stage Neuroblastoma and Sarcomas||Dana-Farber Cancer Institute|Yes|Completed|January 1996|February 2009|Actual|November 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|19 Years|No|||October 2009|October 30, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165139||194532|
NCT00165386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-108|MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients|MRI-guided Bone Marrow Biopsies of Advanced CaP Patients||Dana-Farber Cancer Institute||Completed|July 2001|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Male|30 Years|N/A|No|||December 2009|December 7, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165386||194515|
NCT00166010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003353|Effects of Nesiritide in Pediatric Patients With Heart Failure|A Single-center, Pharmacokinetic Evaluation of Nesiritide in the Pediatric Population With Heart Failure||Emory University|Yes|Withdrawn|October 2004|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|18 Years|No|||June 2014|June 3, 2014|September 12, 2005|Yes|Yes|Observational study that DSMB placed on hold (withdrew 4 subjects). Protocol revised and    received IND to become interventional PK study (no subjects enrolled).|No||https://clinicaltrials.gov/show/NCT00166010||194468|
NCT00131066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP085|Long-Term Follow-Up Study of Psoriasis Patients|Long-Term Safety Follow-Up Study of Psoriasis Patients Who Have Received MEDI-507||MedImmune LLC||Completed|August 2002|December 2007|Actual|October 2003|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|65 Years|No|Probability Sample|Patient has previously completed participation|September 2008|September 18, 2008|August 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00131066||197107|
NCT00133952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5882|Effect of Ruboxistaurin on Clinically Significant Macular Edema|The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema||Eli Lilly and Company||Completed|August 2005|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|309|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|August 22, 2005|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00133952||196887|
NCT00134212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 020193|Dopexamine and Norepinephrine Compared With Epinephrine Alone in Septic Shock|Prospective, Randomized Study on Two Parallel Groups Comparing Dopexamine and Norepinephrine in Combination to Epinephrine Alone on Systemic and Pulmonary Hemodynamics, Gastric Mucosal Perfusion, and Oxidative Stress in Septic Shock||Rennes University Hospital||Completed|March 2002|June 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||December 2005|December 30, 2005|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134212||196868|
NCT00134225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS MPR 480|Study to Demonstrate That Muscle Pattern Recognition (MPR) is an Effective Evaluation Tool for Musculoskeletal Neck or Back Pain|Multi-Center, Multi-National Study to Demonstrate That Muscle Pattern Recognition is a Reliable and Valid Evaluation Tool for Patients Who Present With Acute, Sub-Acute, or Chronic Symptoms of Neck or Back Pain of a Musculoskeletal Origin||iTech Medical, Inc.||Recruiting|April 2005|December 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||480|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||August 2005|October 25, 2005|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134225||196867|
NCT00134251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.3.005|Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease||Solvay Pharmaceuticals||Completed|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|N/A|No|||January 2009|January 29, 2009|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00134251||196865|
NCT00130013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDoseAmoxy|Efficacy of Single Versus Double Dose of Oral Amoxicillin for Non-Severe Pneumonia in Children|Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan||ARI Research Cell||Completed|September 2003|June 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|2 Months|59 Months|No|||July 2004|September 22, 2005|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130013||197187|
NCT00130299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59240-#1|An 18-month Trial of a Low Glycemic Load Diet|An 18-month Randomized Controlled Trial of a Low Glycemic Load Diet||Children's Hospital Boston||Completed|July 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2010|August 27, 2010|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130299||197166|
NCT00130286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65515|Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance|Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance||Weill Medical College of Cornell University|Yes|Completed|March 2005|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|77|||Both|18 Years|65 Years|No|||February 2014|February 10, 2014|August 12, 2005|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00130286||197167|
NCT00130910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1127-D03|Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation|Randomized, Double Blind, Placebo Controlled Trial of Albendazole in Soil-Transmitted Helminth and HIV-1 co-Infected Kenyan Individuals to Determine the Effect of Such Treatment on HIV-1 Disease Progression and Genital Shedding.||University of Washington|No|Completed|March 2006|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|N/A|No|||November 2007|November 13, 2007|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130910||197119|
NCT00130923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17359|Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder|Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2005|July 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|65 Years|No|||August 2015|August 3, 2015|August 15, 2005||No||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00130923||197118|
NCT00163098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3711028|A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD|A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease||Pfizer||Completed|December 2004|December 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||136|||Both|35 Years|75 Years|No|||October 2006|October 12, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00163098||194687|
NCT00163111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|608|A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.|A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non Neutropenic Subjects.||Pfizer||Completed|September 1998|May 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|412|||Both|18 Years|70 Years|No|||April 2011|April 25, 2011|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00163111||194686|
NCT00163436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-145|Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)|Comparison of the Efficacy and Safety of 160 Mcg Ciclesonide Administered Once Daily in the Evening With or Without Different Spacer Types in Patients With Asthma||Takeda||Completed|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|12 Years|75 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163436||194661|
NCT00163722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55/05|A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients|A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy||Bayside Health|Yes|Completed|September 2005|August 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|240|||Both|18 Years|80 Years|No|||September 2005|February 17, 2013|September 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00163722||194639|
NCT00164346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-3710|Neurocognitive Habilitation for Children With Fetal Alcohol Syndrome (FAS)/Alcohol-Related Neurodevelopmental Disorder (ARND)|Neurocognitive Habilitation for Children With FAS/ARND||Centers for Disease Control and Prevention||Completed|January 2002|December 2009|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|100|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2011|March 23, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164346||194591|
NCT00164606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3838|A Dissemination Trial of the Positive Parenting Program to Reduce Child Maltreatment in South Carolina|A Dissemination Trial of the Positive Parenting Program to Reduce Child Maltreatment in South Carolina||Centers for Disease Control and Prevention||Completed|May 2003|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Prevention|||Anticipated|14690|||Both|N/A|7 Years|No|||September 2007|September 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164606||194571|
NCT00164866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPE|Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy|Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study.||Chinese University of Hong Kong||Completed|February 2004|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||638|||Both|16 Years|N/A|No|||June 2007|June 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164866||194551|
NCT00164619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4048|Testing the Effectiveness of VOICES as Implemented by STD & HIV Prevention Agencies in the US and PR|Testing the Effectiveness of the VOICES/VOCES Intervention Package as Implemented by STD and HIV Prevention Agencies That Target Hispanics and African Americans in the U.S. and Puerto Rico||Centers for Disease Control and Prevention|No|Completed|July 2001|March 2008|Actual|November 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3660|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00164619||194570|
NCT00164879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2002.445-T|Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers|Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial||Chinese University of Hong Kong||Recruiting|January 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||September 2005|August 6, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164879||194550|
NCT00165399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-230|Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment|Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment||Dana-Farber Cancer Institute||Completed|March 2004|December 2012|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Male|18 Years|N/A|No|||July 2013|July 2, 2013|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165399||194514|
NCT00165685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KES524-J081-161|A Comparative Study of KES524 in Patients With Obesity Disease|A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease||Eisai Inc.||Completed|July 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|64 Years|No|||January 2010|January 28, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00165685||194493|
NCT00165698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-012 (GLA-CHN-05-01)|Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women|Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women||Eisai Inc.||Completed|May 2005|July 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Female|45 Years|75 Years||||July 2014|July 11, 2014|September 12, 2005||||No|December 2, 2010|https://clinicaltrials.gov/show/NCT00165698||194492|
NCT00165711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-006 (MBL-HKG-05-01)|The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.|||Eisai Inc.||Completed|March 2003|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|60 Years|N/A||||December 2005|December 8, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165711||194491|
NCT00139906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.2.016|Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia||Solvay Pharmaceuticals||Completed|August 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||March 2006|January 15, 2015|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00139906||196436|
NCT00139919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.2.017|Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder|A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study||Solvay Pharmaceuticals||Completed|January 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||November 2007|January 15, 2015|August 30, 2005||||||https://clinicaltrials.gov/show/NCT00139919||196435|
NCT00139932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04272|Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272) (COMPLETED)|A Double-Blind Randomized, Parallel-Group, Multicenter Clinical Study to Compare the Efficacy and Tolerability of Tiotropium Bromide Alone vs. the Co-Administration of Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD||Merck Sharp & Dohme Corp.||Completed|September 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|255|||Both|40 Years|N/A|No|||April 2015|April 15, 2015|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139932||196434|
NCT00133965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-042|Psychosocial Support for Cancer Patients|Psychosocial Support for Cancer Patients||Memorial Sloan Kettering Cancer Center||Completed|May 2005|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|281|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the Pain and Palliative Care Service and Gastrointestinal        Service of the Memorial Sloan Kettering Cancer Center.|April 2011|April 19, 2011|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00133965||196886|
NCT00133926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353577|Prevention of Pre-Term Birth by Treatment of Periodontal Disease|Prevention of Pre-Term Birth by Treatment of Periodontal Disease During Pregnancy - The Smile Study||King Edward Memorial Hospital|Yes|Recruiting|March 2005|June 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||1094|||Female|16 Years|N/A|No|||April 2007|April 4, 2007|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00133926||196889|
NCT00133939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.359|Proportional Ventilation and Ventilatory Synchronism|Proportional Ventilation and Ventilatory Synchronism||Hospices Civils de Lyon||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|80 Years|No|||April 2007|April 26, 2007|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00133939||196888|
NCT00162539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foetus iodine Status|Relation Between Maternal Iodine Status and Prenatal Foetal Thyroid Dimension|Relation Between Maternal Iodine Status and Prenatal Foetal Thyroid Dimension||Assistance Publique - Hôpitaux de Paris|No|Completed|October 2005|June 2006|Actual|June 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|130|||Female|18 Years|50 Years|No|||May 2005|July 25, 2012|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00162539||194730|
NCT00162760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG00519|Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide|Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide||Johns Hopkins University||Completed|October 2003|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||19|||Both|50 Years|80 Years|No|||October 2007|June 18, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00162760||194713|
NCT00162773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-10-25-03|Effect of Anti-IgE in Non-Allergic Asthma|Effect of Anti-IgE in Non-Allergic Asthma||Johns Hopkins University||Recruiting|April 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||September 2005|September 12, 2005|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00162773||194712|
NCT00130598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROVOCATION Trial|PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION|PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION||University Hospital, Basel, Switzerland|No|Completed|June 2005|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|258|||Both|18 Years|N/A|No|||March 2010|March 4, 2010|August 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130598||197143|
NCT00163384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-136|Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)|A Comparative Study of Inhaled Ciclesonide 160 Mcg/Day vs Budesonide 400 Mcg/Day in Patients With Asthma||Takeda||Completed|January 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|75 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163384||194665|
NCT00163046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451155|A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-Day, Polysomnographic Study of Gabapentin 250 mg in Transient Insomnia Induced by a Sleep Phase Advance||Pfizer|No|Completed|October 2005|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00163046||194691|
NCT00163449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-207|Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)|BALLOON: Efficacy and Safety - Study by ALTANA on Ciclesonide in Pre-school Asthma Patients||Takeda||Completed|November 2005|May 2007|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|1000|||Both|2 Years|6 Years|No|||December 2008|May 4, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00163449||194660|
NCT00163943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/05|Sympathetic Activity in Individuals With the Metabolic Syndrome: Benefits of Lifestyle Interventions|Neural Mechanisms Predisposing to Cardiovascular Risk in Individuals With the Metabolic Syndrome: Benefits of Dietary Weight Loss, Weight Loss Maintenance and Aerobic Exercise||Bayside Health||Recruiting|April 2005|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|66|||Both|45 Years|65 Years|No|||September 2005|July 31, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163943||194622|
NCT00163748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH152/00|Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma|A Pilot Study of Outpatient Vinorelbine and Gemcitabine With Filgrastim Support for Patients With Relapsed or Refractory Lymphoma.||Bayside Health||Completed|February 2001|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||January 2016|January 6, 2016|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163748||194637|
NCT00163956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlfRad2005-1|Failed Retrieval of Inferior Vena Cava (IVC) Filters: Long-Term Outcomes|Failed Retrieval of Inferior Vena Cava (IVC) Filters: Long-Term Outcomes||Bayside Health||Recruiting|August 2005|December 2010||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||20|||Both|18 Years|80 Years|No|||September 2005|October 3, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163956||194621|
NCT00163969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161/01|The Use of Ketamine as Rescue Analgesia in the Recovery Room Following Opioid Administration. A Double-blind Randomised Trial in Postoperative Patients|The Use of Ketamine as Rescue Analgesia in the Recovery Room Following Opioid Administration. A Double-blind Randomised Trial in Postoperative Patients.||Bayside Health||Completed|April 2002|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2005|January 13, 2016|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163969||194620|
NCT00163982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH4204|Vasoactive Peptides in Portal Pressure|||Bayside Health||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years||||September 2005|July 25, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00163982||194619|
NCT00163995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH4004|Urotensin II and Vascular Tone in Cirrhosis|||Bayside Health||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2005|July 25, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00163995||194618|
NCT00164359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4538|Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi|A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi||Centers for Disease Control and Prevention||Completed|April 2005|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||212|||Both|5 Years|N/A|No|||September 2012|September 26, 2012|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164359||194590|
NCT00164892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2001.463-T|Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial|Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial||Chinese University of Hong Kong||Active, not recruiting|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||214|||Both|18 Years|80 Years|No|||September 2005|November 16, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164892||194549|
NCT00165178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-001|Treatment of Acute Lymphoblastic Leukemia in Children|Treatment of Acute Lymphoblastic Leukemia in Children||Dana-Farber Cancer Institute|Yes|Completed|September 2000|May 2011|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|498|||Both|1 Year|18 Years|No|||April 2013|April 23, 2013|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165178||194530|
NCT00165152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-120|Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing|A Randomized Study of Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing||Dana-Farber Cancer Institute|Yes|Completed|July 1998|June 2005|Actual|September 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Female|18 Years|N/A|No|||August 2012|August 7, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165152||194531|
NCT00165763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-005 (ART-MNL-05-02)|Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia|An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia||Eisai Inc.|Yes|Completed|September 2005|||September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|40 Years|60 Years|No|||September 2009|May 2, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00165763||194487|
NCT00165724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKI-1002|Alzheimer's Disease Long-term Follow-up Study (ALF Study)|Alzheimer's Disease Long-term Follow-up Study (ALF Study)||Eisai Inc.||Completed|June 2004|December 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|114|||Both|40 Years|90 Years||||July 2010|May 2, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00165724||194490|
NCT00165737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-319|Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease|A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease||Eisai Inc.||Completed|March 2003|June 2006|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|974|||Both|41 Years|N/A|No|||March 2011|March 31, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165737||194489|
NCT00165750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-019 (EKI-5-003)|Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients|Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients||Eisai Inc.||Terminated|March 2005|November 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|60 Years|N/A|No|||November 2013|November 19, 2013|September 12, 2005||No|Lack of patients to enroll.|No||https://clinicaltrials.gov/show/NCT00165750||194488|
NCT00139490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246|Home-Based Program to Treat High Blood Pressure in African Americans|Home-Based Blood Pressure Interventions for African Americans||Visiting Nurse Service of New York|Yes|Completed|February 2006|September 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|846|||Both|21 Years|79 Years|No|||December 2012|December 19, 2012|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139490||196467|
NCT00139516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247|Chinese Community Smoking Cessation Project|||University of California, San Francisco||Completed|September 2001|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||March 2014|March 11, 2014|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139516||196466|
NCT00166530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-089|EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)(COMPLETED)|A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.||Merck Sharp & Dohme Corp.||Completed|November 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|367|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166530||194429|
NCT00134264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091043|A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease|Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents|ILLUMINATE|Pfizer||Terminated|July 2004|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|15067|||Both|45 Years|75 Years|No|||January 2012|January 30, 2012|August 22, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00134264||196864|
NCT00134277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/161|Trial Comparing Different Medical Devices for Infragenual Dilatation|Prospective Randomised Comparing Trial Between an Infragenual Dilatation (ID), an ID With Stenting, an ID With Cutting Balloon and Laser Therapy||University Hospital, Ghent|No|Completed|September 2004|April 2010|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|35|||Both|N/A|N/A|No|||September 2011|September 8, 2011|August 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00134277||196863|
NCT00162214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-021|Study of Dasatinib in Patients With Advanced Solid Tumors|Phase I Study to Evaluate the Effect of Ketoconazole on the Pharmacokinetics of Dasatinib and the Effect of Dasatinib on Pharmacodynamic Markers in Patients With Advanced Solid Tumors||Bristol-Myers Squibb||Terminated|August 2005|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||60|||Both|18 Years|N/A|No|||April 2011|April 13, 2011|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00162214||194755|
NCT00162227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-913|An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection|US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)||Bristol-Myers Squibb||No longer available|September 2000|December 2010|Anticipated|December 2010|Anticipated|N/A|Expanded Access|N/A|||||||Both|3 Years|16 Years|No|||January 2014|January 8, 2014|September 9, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00162227||194754|
NCT00162552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030439|Clinical Trial of Pentoxifylline in Patient With Cirrhosis|Clinical Trial of Pentoxifylline Administration Versus Placebo on Survival in Patients With Cirrhosis and Severe Liver Failure|PENTOCIR|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|342|||Both|18 Years|N/A|No|||August 2005|January 16, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00162552||194729|
NCT00163033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR3054|Study to Evaluate 3 Dosages of Estetrol After 28 Days Administration in Healthy Postmenopausal Women|Phase I Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics of 3 Dosages of Estetrol, the Lowest Dose of 2 mg Estetrol Compared With 2 mg of E2, After Daily Oral Administration for 28 Days in Healthy Postmenopausal Women||Pantarhei Bioscience|No|Completed|June 2005|September 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|49|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||May 2012|May 18, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00163033||194692|
NCT00162786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM02RUP/IV/04|Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance|Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance||J. Uriach and Company||Terminated|May 2005|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||20|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||December 2005|October 19, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162786||194711|
NCT00163059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1611006|The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD|A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder||Pfizer||Completed|May 2004|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||September 2006|September 21, 2006|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00163059||194690|
NCT00163410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-205|Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)|A Comparative Study of Inhaled Ciclesonide 200 Mcg/Day vs Fluticasone Propionate 200 Mcg/Day in Children With Asthma||Takeda||Completed|April 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|4 Years|15 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163410||194663|
NCT00163462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-206|Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)|Comparison of Ciclesonide (80 Mcg or 160 Mcg Once Daily in the Evening) and Fluticasone Propionate (100 Mcg Twice Daily in the Morning and Evening) in Pediatric Asthma Patients||Takeda||Completed|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|6 Years|11 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163462||194659|
NCT00163475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-015|Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)|The MOVE-study: Morning Versus Evening Administration of 500 Mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma||Takeda||Completed|May 2004|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||511|||Both|12 Years|70 Years|No|||December 2006|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163475||194658|
NCT00163423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-142|Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)|Comparison of Ciclesonide (80 Mcg Once Daily in the Evening) and Fluticasone Propionate (100 Mcg Twice Daily) in Patients With Mild to Moderate Asthma||Takeda||Completed|November 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|12 Years|75 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163423||194662|
NCT00164008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101/02|Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention|Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis||Bayside Health||Completed|October 2002|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|56|||Both|18 Years|N/A|No|||September 2005|December 3, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00164008||194617|
NCT00164021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/01|The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation|The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function||Bayside Health|No|Recruiting|February 2001|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|180|||Both|16 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients of the Cystic Fibrosis Unit|January 2016|January 13, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00164021||194616|
NCT00164372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2934|Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users|Collaborative Injection Drug Users Study III/Drug Users Intervention Trial (CIDUS III/DUIT)||Centers for Disease Control and Prevention|No|Completed|May 2002|December 2006|Actual|December 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1400|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164372||194589|
NCT00164632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-3339|No More Falls Injury Prevention Study|California No More Falls! Senior Injury Prevention Program||Centers for Disease Control and Prevention||Completed|October 2001|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||552|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164632||194569|
NCT00164645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-00019101|Problem Solving for Caregivers of Persons With Brain Injury|Problem Solving for Caregivers of Patients With Traumatic Brain Injury||Centers for Disease Control and Prevention||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|19 Years|N/A||||September 2005|April 26, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164645||194568|
NCT00164658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-OGDP-4444|Evaluating Tools for Health Promotion and Disease Prevention|Evaluating Tools for Health Promotion and Disease Prevention||Centers for Disease Control and Prevention|No|Completed|September 2005|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Anticipated|8400|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 6, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164658||194567|
NCT00165191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-048|Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus|A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus||Dana-Farber Cancer Institute||Completed|August 1998|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165191||194529|
NCT00165412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-241|Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease|Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease||Dana-Farber Cancer Institute|No|Completed|July 2005|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|168|||Female|20 Years|N/A|No|Non-Probability Sample|Survivors of Hodgkin's disease that have been previously received radiation therapy to the        chest area|August 2012|August 13, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165412||194513|
NCT00165776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2014-J081-131|Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis|Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis||Eisai Inc.||Completed|June 2004|November 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|133|||Both|20 Years|74 Years||||February 2014|February 6, 2014|September 12, 2005||||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00165776||194486|
NCT00165789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-214|A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations|A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations||Eisai Inc.||Completed|September 2005|September 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Actual|75|||Both|18 Years|N/A|No|||April 2015|May 28, 2015|September 12, 2005||||No|April 15, 2015|https://clinicaltrials.gov/show/NCT00165789||194485|
NCT00165802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7974-A001-103|A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors|A Phase I Open Label Study of E7974 Administered on Day 1 of a 21-Day Cycle In Patients With Advanced Solid Tumors||Eisai Inc.||Completed|May 2006|January 2009|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2009|May 20, 2013|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00165802||194484|
NCT00166075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0304-2003a|Mental Health Symptoms and Intimate Partner Violence|Mental Health Symptoms and Intimate Partner Violence||Emory University|No|Completed|January 2004|December 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|569|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|All eligible African American female patients were approached in the ED waiting room        during study periods. Patients participated in the screening process via a computer kiosk.        Questions regarding IPV and mental health symptoms were asked using validated tools.|December 2013|December 12, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00166075||194463|
NCT00166348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1069-03|Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?|Efficacy of Group Based Cognitive Rehabilitation Following Acquired Brain Injury||Mayo Clinic||Completed|March 2003|March 2008|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166348||194443|
NCT00139542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSPP01092005|AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute"|Automated External Defibrillator (AED) Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named "One Shock Per Minute"|DEFI2005|Fire Brigade Of Paris Emergency Medicine Dept|Yes|Completed|September 2005|June 2008|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5107|||Both|1 Year|N/A|No|||May 2009|May 8, 2009|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00139542||196464|
NCT00139568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919E2308|An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation|An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation||Novartis||Completed|February 2005|October 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||January 2008|January 31, 2008|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139568||196462|
NCT00166257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICN98008|PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism|Randomized Clinical Trial Comparing the Efficacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients With Cryptogenic Embolism||Foundation for Cardiovascular Research, Zurich|Yes|Active, not recruiting|February 2000|May 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|414|||Both|18 Years|60 Years|No|||May 2009|May 26, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166257||194449|
NCT00134290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/032|The Effects of Calorie Restriction With or Without Metformin on Weight and Insulin Resistance|The Effects of Calorie Restriction - Whether or Not Calculated Based on BMR (Basic Metabolic Rate) - With or Without Metformin on Weight and Insulin Resistance of Obese Insulin Resistant Patients||University Hospital, Ghent|No|Completed|January 2002|May 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|20 Years|55 Years|No|||December 2007|December 19, 2007|August 23, 2005||||No||https://clinicaltrials.gov/show/NCT00134290||196862|
NCT00162565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030414|Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening|Beta-Blocker Continuation Versus Interruption in Patients With Congestive Heart Failure Hospitalized for Heart Failure Worsening (B-CONVINCED)|BConvinced|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2004|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|18 Years|N/A|No|||August 2005|May 22, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00162565||194728|
NCT00162825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700717|Role of CD7 in Skin Inflammation and Psoriasis|||National Taiwan University Hospital||Completed|January 2004|December 2006|Actual|||N/A|Observational|N/A|||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2003|July 9, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00162825||194708|
NCT00162799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO5TRI/2/01|Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity|Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity||J. Uriach and Company||Completed|July 2002|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||September 2005|June 22, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162799||194710|
NCT00162812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP Trial|Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin|Prospective Evaluation of Topoisomerase II Alpha Gene Amplification and Protein Overexpression as Markers Predicting the Efficacy of Epirubicin in the Primary Treatment of Breast Cancer Patients|TOP|Jules Bordet Institute|No|Terminated|January 2003|April 2009|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|338|||Female|18 Years|70 Years|No|||July 2008|July 16, 2008|September 9, 2005||No|Low accrual rate|No||https://clinicaltrials.gov/show/NCT00162812||194709|
NCT00162838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700824|Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells|Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells.||National Taiwan University Hospital||Recruiting|October 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||20|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2003|November 22, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00162838||194707|
NCT00162851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM219|Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia|A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia||Karolinska University Hospital||Completed|April 2003|July 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|80 Years|No|||August 2005|July 23, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00162851||194706|
NCT00163761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH226/02|Efficacy Study of Outpatient Therapy for Lymphoma|A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma||Bayside Health|No|Completed|December 2002|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00163761||194636|
NCT00164385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3723|Adolescent Impact: A Behavioral Intervention for Adolescents Living With HIV/AIDS|Adolescent Impact: A Behavioral Intervention for Adolescents Living With HIV/AIDS||Centers for Disease Control and Prevention||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|13 Years|21 Years||||September 2005|October 20, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164385||194588|
NCT00164671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-3819|Testing the POWER Project: A Neighborhood Intervention Trial|Testing the POWER Project: A Neighborhood Intervention Trial||Centers for Disease Control and Prevention||Completed|November 2003|August 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||5000|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164671||194566|
NCT00164684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-US4CCU119008051|Men of Color Fatherhood Education and Violence Prevention Project|Men of Color Fatherhood Education and Violence Prevention Project||Centers for Disease Control and Prevention|No|Completed|September 2001|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00164684||194565|
NCT00164905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP-US study|Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage|Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage: Can it Guide the Use of and Predict Failure of Endoscopic Treatment? A Prospective, Multicenter, Randomized, Controlled Study||Chinese University of Hong Kong|No|Terminated|September 2004|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|September 12, 2005||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00164905||194548|
NCT00165204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-363|Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy|A Randomized Study of the Effects of Tibolone on Bone Density, Menopause Symptoms and Breast Density in High Risk Women After Prophylactic Oophorectomy||Dana-Farber Cancer Institute||Completed|April 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Female|18 Years|N/A|No|||December 2007|December 20, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165204||194528|
NCT00165425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-295|Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation|Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation||Dana-Farber Cancer Institute|No|Active, not recruiting|February 2004|April 2016|Anticipated|October 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|210|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165425||194512|
NCT00165828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZNS-D-04-001|Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization|Randomized Trial to Assess Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization||Eisai Inc.||Terminated|May 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|74 Years|No|||November 2013|June 26, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00165828||194482|
NCT00165841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-A001-203|Maintenance Intermittent Therapy for Symptomatic GERD Patients|A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease||Eisai Inc.|No|Completed|October 2004|June 2008|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||December 2009|May 13, 2013|September 13, 2005|Yes|Yes||No|August 18, 2009|https://clinicaltrials.gov/show/NCT00165841||194481|
NCT00161993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160001|Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)|Prospective Open-Label Study of Pharmacokinetics, Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Patients With Hypo- or Agammaglobulinemia||Baxalta US Inc.||Completed|June 2002|September 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||October 2006|June 26, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161993||194771|
NCT00166088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-2005|Effect of a Mediterranean Diet and Omega-3 Fatty Acids on Oxidative Stress and Endothelial Progenitor Cells (EPC's)|Effects of Mediterranean Diet and Omega-3 Fatty Acids on Oxidative Stress and EPC's||Emory University|No|Completed|December 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Both|40 Years|65 Years|No|||November 2013|November 15, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00166088||194462|
NCT00139971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJTOG0101|Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer|||West Japan Thoracic Oncology Group||Recruiting|December 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|20 Years|75 Years|No|||August 2005|January 5, 2006|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00139971||196431|
NCT00139997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22,777|Environmental Treatment for Seasonal Affective Disorder (SAD)|A Multicenter, Randomized Controlled Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy For Seasonal Affective Disorder||Yale University|No|Completed|January 2002|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||January 2013|January 29, 2013|August 29, 2005||No||No|September 7, 2012|https://clinicaltrials.gov/show/NCT00139997||196429|
NCT00161811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231|Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005|Single-blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety After a Single Vaccination With Three Different Lots of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell-derived) in Comparison to a Licensed Egg Derived Influenza Vaccine for Season 2004/2005.||Nanotherapeutics, Inc.||Completed|November 2004|July 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 7, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161811||194785|
NCT00161824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208|Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR|Single-blind, Randomized, Multicenter Comparison of FSME IMMUN NEW and ENCEPUR: Safety and Tolerability of Two Vaccinations in Healthy Volunteers Aged 16 to 65 Years.||Pfizer||Completed|October 2001|January 2002||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||3800|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161824||194784|
NCT00161837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|227|Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004|Single-blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) in Comparison to a Licensed Egg-derived Influenza Vaccine for Season 2003/2004||Nanotherapeutics, Inc.||Completed|December 2003|July 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 7, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161837||194783|
NCT00162188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-914|An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada|Canadian Sustiva Oral Liquid Expanded Access Program: An Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP266)||Bristol-Myers Squibb||No longer available|May 2001|December 2010|Anticipated|December 2010|Anticipated|N/A|Expanded Access|N/A|||||||Both|3 Years|16 Years|No|||January 2014|January 8, 2014|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162188||194757|
NCT00162201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-015|An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy|An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy||Bristol-Myers Squibb||Completed|December 2003|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||April 2011|April 11, 2011|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00162201||194756|
NCT00161850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206|FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years|Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 1 to 6 Years||Pfizer||Completed|February 2002|August 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||615|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161850||194782|
NCT00162266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-100|Abatacept With Methotrexate- Phase IIB|A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate||Bristol-Myers Squibb||Completed|October 2000|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|524|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|September 9, 2005|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00162266||194751|
NCT00162279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-101|The Study of Abatacept in Combination With Etanercept|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis||Bristol-Myers Squibb||Completed|October 2000|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||141|||Both|18 Years|N/A|No|||December 2010|December 2, 2010|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00162279||194750|
NCT00163072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM IRB# 18400|Pharmacokinetics and Safety of Transdermal Megestrol Acetate|Pharmacokinetics and Safety of Transdermal Megestrol Acetate||Milton S. Hershey Medical Center|No|Withdrawn|October 2005|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||April 2007|October 24, 2013|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00163072||194689|
NCT00163124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC2005-003|A Randomized Controlled Trial of Best Approach to Care Compared to Diversified Chiropractic Adjustive Technique|A Randomized Controlled Trial of Best Approach to Care Compared to Diversified Adjustive Technique||Parker College of Chiropractic||Completed|March 2005|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||155|||Both|18 Years|90 Years|No|||September 2005|September 12, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00163124||194685|
NCT00163137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2181030|Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss|Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women|CORAL|Ligand Pharmaceuticals||Completed|May 2003|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|540|||Female|48 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 10, 2011|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00163137||194684|
NCT00163774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145/02|Intensive Monitoring of Brain Injured Patients|Intensive Monitoring of Brain Injured Patients; Icp Monitoring, Transcranial Doppler, Jugular Bulb Oximetry, Brain Oxygenation, Brain Temperature and Microdialysis.||Bayside Health||Completed|November 2002|December 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|17 Years|70 Years|No|||September 2005|May 16, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163774||194635|
NCT00163787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79/03|Clinical Identification of Fall Risk Early After Unilateral Transtibial Amputation|Clinical Identification of Increased Fall Risk Early After Unilateral Transtibial Amputation||Bayside Health||Completed|June 2003|August 2005||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||50|||Both|18 Years|N/A|No|||September 2005|October 24, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163787||194634|
NCT00164034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166/03|Trauma Reception and Resuscitation Project|Trauma Reception and Resuscitation Project - 'Time for a New Approach'||Bayside Health||Completed|November 2005|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1171|||Both|16 Years|N/A|No|||September 2005|February 10, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00164034||194615|
NCT00164398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3986|HIP: HIV Intervention for Providers|HIP: HIV Intervention for Providers||Centers for Disease Control and Prevention|No|Completed|June 2004|September 2008|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164398||194587|
NCT00164697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-2524|Legacy for Children, an Early Intervention Study to Promote Optimal Child Development in Low-income Families|Legacy for Children, The CDC Parenting Research Projects|Legacy|Centers for Disease Control and Prevention|No|Completed|October 1999|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|547|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|February 2, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00164697||194564|
NCT00164918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.311|Role of Routine Nasogastric Decompression After Subtotal Gastrectomy|Role of Routine Nasogastric Decompression After Subtotal Gastrectomy||Chinese University of Hong Kong||Recruiting|September 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Weeks|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164918||194547|
NCT00166114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0473-2002|Depression, Epinephrine, and Platelet Function|Do Antidepressants Reverse the Effects of Early Life Stress on the Brain and Thrombovascular System and Improve Psychological, Neuroendocrine, and Platelet Function: A Study of Men and Women With Childhood Abuse.||Emory University|Yes|Completed|February 2002|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|September 13, 2005||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00166114||194460|
NCT00166413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105-04|Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis|A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis||Mayo Clinic|Yes|Completed|April 2005|||December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||May 2011|May 5, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166413||194438|
NCT00165438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-181|Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy|A Prospective Study of Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy With or Without Mediastinal Irradiation||Dana-Farber Cancer Institute|Yes|Completed|October 2001|January 2010|Actual|November 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed classic Hodgkin's disease with mediastinal involvement in        whom bleomycin-based chemotherapy alone or bleomycin-based chemotherapy and mediastinal        irradiation are recommended as initial treatment.|December 2012|December 19, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165438||194511|
NCT00165815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-E044-316|The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia|||Eisai Inc.||Completed|August 2002|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|N/A||||November 2005|May 8, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00165815||194483|
NCT00162435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19553-HMO-CTIL|Genetic Determinants of Warfarin Anticoagulation Effect|Warfarin Induction Regimen Based Upon CYP2C9, VKORC1 Factor VII Genotyping, PMR and INR Monitoring, as Compared to the Conventional Regimen: a Prospective Controlled Study||Hadassah Medical Organization||Recruiting|August 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|N/A|No|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162435||194738|
NCT00162461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19559-HMO-CTIL|Evaluation of CYP2C9 Activity|The Use of Phenytoin Metabolic Ratio as a Putative Marker of CYP2C9 Activity in-Vivo||Hadassah Medical Organization||Recruiting|August 1998|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|600|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162461||194736|
NCT00166101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459-2002|NIRS in Neonatal Cardiac Surgery|Near Infrared Spectroscopy Monitoring of Cerebral Oxygen Saturation in Neonatal Cardiac Surgery - Comparison With Common Methods of Estimating Adequate Systemic Perfusion||Emory University|No|Completed|August 2002|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|N/A|1 Year|No|Non-Probability Sample|Neonates with Hypoplastic Left Heart Syndrome undergoing stage 1 palliation with the        Norwood procedure.|November 2012|November 9, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00166101||194461|
NCT00166387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIGS|Hemophilia Inhibitor Genetics Study (HIGS)|Hemophilia Inhibitor Genetics Study (HIGS)||Skane University Hospital|Yes|Completed|April 2003|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Family-Based||1|Actual|1137|Samples With DNA|Plasma, cells, DNA|Both|N/A|N/A|No|Non-Probability Sample|People with hemophilia and their parents.|March 2014|March 24, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166387||194440|
NCT00140010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0108/87|Erythropoietin Therapy for Subarachnoid Hemorrhage|Effects of Systemic Erythropoietin Therapy on Cerebral Autoregulation and Incidence of Delayed Ischemic Deficits in Patients With Aneurysmal Subarachnoid Hemorrhage||University of Cambridge|Yes|Completed|April 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||May 2009|May 19, 2009|August 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00140010||196428|
NCT00139620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-104|A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function|An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function||Astellas Pharma Inc||Completed|May 2005|September 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|August 25, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00139620||196458|
NCT00166543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2216-03|Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer|A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy||SRI International||Completed|May 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|146|||Female|18 Years|N/A|No|||June 2015|July 28, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166543||194428|
NCT00162305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-003|A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects|A Double-blind, Placebo-controlled, Randomized, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Bms-512148 in Diabetic Subjects||AstraZeneca|No|Completed|April 2005|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|70 Years|No|||March 2015|March 20, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162305||194748|
NCT00162318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-064|A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|March 2005|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||30|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00162318||194747|
NCT00162331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIOLITE-413|CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI|AIR-MI: Assessment of Ischemia and Remodeling Following Acute Myocardial Infarction||Lantheus Medical Imaging|No|Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|74|||Both|18 Years|N/A|No|||April 2011|April 14, 2011|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162331||194746|
NCT00162591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040201 AT/AT/04-116|Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl|Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl||Assistance Publique - Hôpitaux de Paris||Recruiting|October 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|N/A|No|||October 2004|November 21, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00162591||194726|
NCT00162604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2602-415|Prophylactic Antibiotic Treatment During Vaginal Repair|Antibiotikaprofylakse Ved Vaginalplastik||Hvidovre University Hospital||Recruiting|May 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Female|18 Years|N/A|No|||February 2005|September 8, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162604||194725|
NCT00162578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMR4|Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis|Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis Treated With Dexamethasone||Assistance Publique - Hôpitaux de Paris|No|Completed|December 2002|November 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|14|||Both|18 Years|N/A|No|||July 2007|July 20, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162578||194727|
NCT00163150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581063|Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke|Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.|LA BICHAT|Pfizer||Completed|June 2003|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||128|||Both|18 Years|N/A|No|||April 2007|March 13, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00163150||194683|
NCT00163163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581051|Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women|Carotid Atorvastatin Study In Hyperlipidemic Post-Menopausal Women: A Randomized Evaluation of Atorvastatin, Versus Placebo (CASHMERE)||Pfizer||Completed|January 2003|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Female|18 Years|70 Years|No|||March 2008|March 17, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00163163||194682|
NCT00163800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|189/02|Outcome Predictors in Acute Brain Injury|Outcome Predictors in Acute Brain Injury, A Pilot Study||Bayside Health||Completed|July 2003|July 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||60|||Both|16 Years|N/A|No|||September 2005|December 7, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163800||194633|
NCT00164424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4294|Episodic Acyclovir Therapy for Genital Ulcers|Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa||Centers for Disease Control and Prevention||Completed|March 2005|July 2011|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|613|||Male|18 Years|N/A|No|||September 2012|September 10, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164424||194585|
NCT00164047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204/02|ENIGMA - Evaluation of Nitrous Oxide In the Gas Mixture for Anaesthesia: a Randomised Controlled Trial|Evaluation of Nitrous Oxide In the Gas Mixture for Anaesthesia: a Randomised Controlled Trial||Bayside Health||Completed|April 2003|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|2070|||Both|18 Years|N/A|No|||July 2009|July 29, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00164047||194614|
NCT00164411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NIP-3669|Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine|Pneumococcal Conjugate Vaccine (Prevnar; Wyeth) With Pneumococcal Polysaccharide Vaccine (23-valent) and Tetanus/Diphtheria Vaccine||Centers for Disease Control and Prevention||Completed|January 2004|March 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00164411||194586|
NCT00164710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4539|Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi|An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi||Centers for Disease Control and Prevention||Completed|April 2005|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||365|||Both|6 Months|59 Months|No|||September 2012|September 26, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00164710||194563|
NCT00164931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHCE03-43-SURG5|A Study Comparing High Dose Omeprazole Infusion Against Scheduled Second Endoscopy for Bleeding Peptic Ulcer|Phase 3 Study of Prospective Randomized Trial Comparing Adjunctive High Dose Omeprazole Infusion Against Scheduled Second Endoscopy in the Prevention of Peptic Ulcer Rebleeding After Therapeutic Endoscopy||Chinese University of Hong Kong||Completed|October 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|90 Years|No|||September 2005|June 9, 2011|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00164931||194546|
NCT00165854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7070-E044-209|Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer|||Eisai Inc.||Completed|March 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Both|18 Years|N/A|No|||October 2006|June 26, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00165854||194480|
NCT00166439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0485|Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma|A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma||Mayo Clinic|Yes|Completed|March 2005|||September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|100 Years|No|||October 2015|October 29, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166439||194436|
NCT00166426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526-02|Exisulind Versus Placebo After Surgical Removal of the Prostate|Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy||Mayo Clinic||Completed|February 2003|May 2008|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|240|||Male|18 Years|N/A|No|||November 2009|November 13, 2009|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00166426||194437|
NCT00161980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550002|Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites|A Randomized and Controlled Clinical Study to Evaluate the Efficacy and Safety of Fibrin Sealant VH S/D (FS VH S/D) in Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites||Baxter Healthcare Corporation||Completed|June 2001|December 2002||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Female|19 Years|N/A|No|||October 2006|October 20, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161980||194772|
NCT00162474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc195510-HMO-CTIL|Determinants of Warfarin Metabolism|Correlation Between Phenotypic Activity of CYP2C9 and Genetic Polymorphism in CYP2C9 and Warfarin Metabolism.||Hadassah Medical Organization||Recruiting|September 2003|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|200|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162474||194735|
NCT00132444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4413|Study of UC-781 Vaginal Microbicide|Phase I Study of the Safety and Acceptability of UC-781 Topical Vaginal Microbicide in Heterosexual Women and Their Male Partners||Centers for Disease Control and Prevention||Completed|October 2005|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 6, 2010|July 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00132444||197002|
NCT00162448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV175-003|A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators|Double-Blind, Randomized, Single-Dose Study to Evaluate the Atrial Selectivity and Safety of BMS-394136 in Patients With Implanted Dual-Chamber Pacemakers or Defibrillators||Bristol-Myers Squibb||Completed|January 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2|||36|||Both|18 Years|80 Years|No|||August 2008|August 18, 2008|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00162448||194737|
NCT00162695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMS95|Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood|||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|July 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|6 Months|21 Years|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00162695||194718|
NCT00139633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH097-02D|Selective Dose Escalation for Esophageal Cancer|Phase II Selective Dose Escalation of Chemoradiotherapy for Esophageal Cancer||The Oregon Clinic||Active, not recruiting|July 2000|June 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||August 2005|August 29, 2005|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00139633||196457|
NCT00166270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF014|MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids|Post Approval Study: MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids||InSightec||Completed|January 2005|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|N/A|No|||September 2012|September 13, 2012|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00166270||194448|
NCT00162240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-022|PPAR - Combination With Metformin|A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Metformin Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone||Bristol-Myers Squibb||Completed|June 2003|May 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||534|||Both|18 Years|70 Years|No|||April 2012|April 26, 2012|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00162240||194753|
NCT00162253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM117-005|Study of BMS-587101 in Patients With Moderate to Severe Psoriasis|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of BMS-587101 in Patients With Moderate to Severe Psoriasis||Bristol-Myers Squibb||Terminated|April 2005|||June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|75 Years|No|||September 2007|February 27, 2010|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00162253||194752|
NCT00162344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIOLITE-404|A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease.|AceP-D: Non-invasive Assessment of Atypical Chest Pain in Patients With Diabetes||Lantheus Medical Imaging||Completed|December 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|205|||Both|18 Years|76 Years|No|||April 2011|April 14, 2011|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162344||194745|
NCT00162357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIOLITE-406|Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty|Cardiolite-406; A Phase IV Open-Label, Randomized, Multi-Center Trial To Evaluate The Ability of Cardiolite Stress MPI to Detect Asymptomatic Restenosis in Diabetic Patients Who Have Undergone Percutaneous Coronary Intervention||Lantheus Medical Imaging|No|Completed|April 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|106|||Both|21 Years|N/A|No|||April 2011|April 14, 2011|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162357||194744|
NCT00162617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSG-RCT-03|The Effect of Liberal vs. Restrictive Transfusion Strategies on Rehabilitation After Hip Fracture Surgery|The Effect of Liberal vs. Restrictive Transfusion Strategies on Rehabilitation After Hip Fracture Surgery||Hvidovre University Hospital||Active, not recruiting|January 2004|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|65 Years|N/A|No|||September 2006|August 29, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00162617||194724|
NCT00162630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSG-rct-04|Fascia Iliaca Compartment Blockade as Analgesia for Hip Fractures in the Acute Phase|Fascia Iliaca Compartment Blockade as Analgesia for Hip Fractures in the Acute Phase||Hvidovre University Hospital||Completed|May 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||September 2006|September 13, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00162630||194723|
NCT00162864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MONTE|A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease|A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease||Kaiser Permanente||Completed|December 1999|April 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|50 Years|N/A|No|||September 2005|March 23, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00162864||194705|
NCT00163514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-403|Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age||Takeda||Completed|May 2004|February 2005||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||636|||Both|6 Years|11 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163514||194655|
NCT00163527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-013|Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)|A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Chronic Asthma||Takeda||Completed|April 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2054|||Both|12 Years|70 Years|No|||January 2012|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163527||194654|
NCT00164437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4020|CD-ROM Intervention for Prostate Cancer Screening|CD-ROM Intervention for Prostate Cancer Screening||Centers for Disease Control and Prevention||Completed|September 2002|September 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||554|||Male|45 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164437||194584|
NCT00164723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE_GIB|Endoscopic Evaluation of Lower Gastrointestinal Bleeding (GIB) in Patients Presenting With Melena|Endoscopic Evaluation of the Incidence and Etiology of Lower Gastrointestinal Bleeding in Patients Presenting With Melena||Chinese University of Hong Kong|No|Completed|February 2005|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|165|||Both|18 Years|N/A|No|||January 2011|August 10, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164723||194562|
NCT00164060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/04|Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection|Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection||Bayside Health||Terminated|February 2004|May 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Retrospective|||Actual|158|||Both|18 Years|80 Years|No|||September 2005|December 3, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00164060||194613|
NCT00164073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122/03|Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection|Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection||Bayside Health||Recruiting|February 2004|February 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|60|||Both|18 Years|70 Years|No|||September 2005|July 31, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00164073||194612|
NCT00164086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/04|Atorvastatin in Myeloma|||Bayside Health||Not yet recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||September 2005|October 10, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00164086||194611|
NCT00165217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-141|Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma|A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma||Dana-Farber Cancer Institute||Completed|November 2001|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||37|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165217||194527|
NCT00165451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-046|A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer|Anti-Angiogenic Chemotherapy: A Phase II Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer||Dana-Farber Cancer Institute|No|Completed|June 2001|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|N/A|21 Years|No|||July 2011|July 6, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00165451||194510|
NCT00165464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-140|Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer|A Phase II Trial of Taxotere, Cisplatin, and Irinotecan in Advanced Esophageal and Gastric Cancer||Dana-Farber Cancer Institute||Completed|August 2001|April 2009|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||April 2009|April 24, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165464||194509|
NCT00165867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7070-E044-214|An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin|||Eisai Inc.||Completed|April 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||October 2006|October 6, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00165867||194479|
NCT00165880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7070-E044-213|An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine|An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy||Eisai Inc.||Terminated|December 2004|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|62|||Female|18 Years|N/A|No|||March 2008|June 30, 2014|September 13, 2005|||This study was stopped prematurely due to lack of efficacy.|No||https://clinicaltrials.gov/show/NCT00165880||194478|
NCT00131898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-050|A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma|Phase III Prospective Randomized Trial of Pre-Operative Intensity Modulated Radiation Therapy (IMRT) Plus Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma||Memorial Sloan Kettering Cancer Center||Completed|May 2003|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||December 2008|December 22, 2008|August 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00131898||197043|
NCT00162006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160002|Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura|Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura||Baxalta US Inc.||Completed|January 2003|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|65 Years|No|||October 2006|June 26, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00162006||194770|
NCT00162019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040201|Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients|Phase 3, Prospective, Multicenter Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Efficacy of IMMUNATE Solvent Detergent (IMMUNATE SD) in Previously Treated Patients With Severe or Moderately Severe Hemophilia A||Baxalta US Inc.|Yes|Completed|March 2003|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|56|||Male|12 Years|65 Years|No|||April 2008|June 26, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00162019||194769|
NCT00132457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4274|Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection|Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection||Centers for Disease Control and Prevention||Completed|October 2003|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|1830|||Female|16 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 6, 2010|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132457||197001|
NCT00132717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-808|A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)|An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination Tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary Event||Merck Sharp & Dohme Corp.||Completed|January 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|450|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00132717||196981|
NCT00132990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16760|A Multicenter Pilot Study of Pallidal Deep Brain Stimulation for Cervical Dystonia|A Multicenter Pilot Study of Pallidal Deep Brain Stimulation of Cervical Dystonia||University of Calgary||Active, not recruiting|February 2003|September 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||10|||Both|18 Years|80 Years|No|||January 2007|January 11, 2007|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132990||196960|
NCT00131196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N8518|Functional Genomic Influences on Disease Progression and Outcome in Sepsis|Functional Genomic Influences on Disease Progression and Outcome in Sepsis Due to Pneumonia or Peritonitis|GAinS|University of Oxford|Yes|Recruiting|September 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|whole blood, plasma and extracted DNA|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Intensive Care Units or High Dependency Units in the UK with faecal        peritonitis or community acquired pneumonia|February 2015|February 5, 2015|August 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00131196||197097|
NCT00131742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-02B-015|Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B|A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B||Novartis||Completed|July 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|70 Years||||May 2015|May 8, 2015|August 18, 2005||||||https://clinicaltrials.gov/show/NCT00131742||197055|
NCT00166296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSQHEPGTP1|Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients|Study of the Efficacy and Safety of Escitalopram for the Prevention of Depressive Episodes Induced by Peg-Interferon Alpha2a and Ribavirin in Chronic Hepatitis C Patients. Randomized, Double-Blind, Placebo-Controlled Clinical Trial||Germans Trias i Pujol Hospital|No|Completed|March 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|133|||Both|18 Years|65 Years|No|||March 2011|March 4, 2011|September 9, 2005|Yes|Yes||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00166296||194446|The low depression rate found may have underpowered the study. Selection of a much less depressive sample than in other studies. Limitation to the first 12 weeks of antiviral treatment.
NCT00161863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209|Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years|Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years||Pfizer||Completed|September 2002|January 2003||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|1 Year|15 Years||||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161863||194781|
NCT00166283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ndcnih2004|Improving New Learning and Memory in Multiple Sclerosis|Improving New Learning in Multiple Sclerosis: A Randomized Clinical Trial||Kessler Foundation|Yes|Completed|February 2005|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|30 Years|70 Years|No|||June 2013|June 8, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166283||194447|
NCT00161876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213|FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years|Open-label, Multicenter, Follow-up Phase III Study to Investigate the Safety of the Third Vaccination of FSME-IMMUN NEW in Volunteers Aged 16 to 66 Years||Pfizer||Completed|May 2002|August 2002||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||3973|||Both|16 Years|66 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161876||194780|
NCT00161889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207|FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years|Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years||Pfizer||Completed|February 2002|August 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||615|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161889||194779|
NCT00162890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100002264|Evaluation and Physical Therapy for Patients With Degenerated Cervical Spine|Evaluation and Physical Therapy for Patients With Degenerated Cervical Spine||National Taiwan University Hospital||Completed|February 2002|July 2003|Actual|July 2002|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Subjects aged 20-75 year-old will be recruited. One hundred participants are anticipated        to be recruited in this study.|December 2009|March 15, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00162890||194703|
NCT00162903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26955|Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants|The Role of Nitric Oxide, Endothelin-1, and Inflammatory Mediators in the Patency of Ductus Arteriosus in Preterm Infants||National Taiwan University Hospital||Completed|January 2002|December 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||80|||Both|N/A|1 Year|No|||October 2001|November 22, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00162903||194702|
NCT00163176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|049|Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors|Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors||Radboud University|No|Completed|July 2005|December 2010|Actual|December 2008|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Stage II-IV squamous cell carcinoma of the head and neck|December 2011|December 15, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00163176||194681|
NCT00163189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281271|Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm|Evolution Of Growth Rate In Children With Growth Retardation Related To Long-term Corticotherapy And Treated By Genotonorm||Pfizer|No|Completed|January 2005|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|N/A|N/A|No|||June 2015|June 22, 2015|September 9, 2005|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT00163189||194680|
NCT00162877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920505|The Role of CYP2C19 on the Eradication of H. Pylori Infection:Implication of PK/PD Relationships|The Role of CYP2C19 Poor Metabolizers and Extensive Metabolizers of PPI in Short-Term Triple Therapy on the Eradication of H. Pylori Infection: Implication of PK/PD Relationships||National Taiwan University Hospital||Active, not recruiting|June 2004|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||January 2004|November 22, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00162877||194704|
NCT00164099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224-04|The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study|The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study||Beth Israel Medical Center|No|Terminated|November 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|40|||Both|N/A|N/A|No|||September 2006|October 30, 2007|September 9, 2005|||Patients would not take product|No||https://clinicaltrials.gov/show/NCT00164099||194610|
NCT00164112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-273|Comparative Effects of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes|Comparison of the Effect of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes Using the Validated Cooperstown 5+1 Cocktail||Bassett Healthcare||Completed|November 2004|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2005|September 13, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00164112||194609|
NCT00164957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-pumpfeeding|The Effect of Continuous Versus Enteral Pump Feeding in Aspiration in Tube Fed Patients|The Effect of Continuous vs Enteral Pump Feeding in Aspiration in Tube Fed Patients||Chinese University of Hong Kong||Completed|September 2002|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|222|||Both|N/A|N/A|No|||February 2009|February 2, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00164957||194544|
NCT00164944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDR|Screening for Colorectal Neoplasm in First Degree Relatives of the Affected|Colonoscopic Screening in First-degree Relatives of Hong Kong Chinese Patients With Sporadic Colorectal Cancer: a Cohort Study With Case Control Analysis||Chinese University of Hong Kong|No|Recruiting|April 2004|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|||Both|40 Years|70 Years|No|Probability Sample|First degree relatives of patients having CRC or patient having normal colonoscopy|March 2016|March 7, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00164944||194545|
NCT00165477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-222|Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study of Lenalidomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme.||Dana-Farber Cancer Institute|Yes|Completed|September 2005|July 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2010|March 8, 2010|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00165477||194508|
NCT00165893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0079-2004|Comparison of IDD Therapy and Non-surgical Treatment for Low Back Pain Caused by Degenerative Disc Disease|Comparison of Internal Disc Decompression (IDD) vs. a Standardized Non-surgical Treatment Program for Chronic Low Back Pain Secondary to Mild to Moderate Degenerative Disc Disease (DDD)||Emory University||Completed|September 2004|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165893||194477|
NCT00166127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0984-2003|Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery|Pharmacokinetics and Pharmacodynamics of Levosimendan During Cardiac Surgery||Emory University|No|Terminated|May 2005|January 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|21 Years|80 Years|No|||November 2013|November 13, 2013|September 12, 2005|||Unable to renegotiate an expired contract w/sponsor providing study med|No||https://clinicaltrials.gov/show/NCT00166127||194459|
NCT00132730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0873-005|An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK-0873 in Patients With COPD||Merck Sharp & Dohme Corp.|No|Terminated|June 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|604|||Both|40 Years|75 Years|No|||January 2016|January 7, 2016|August 3, 2005|Yes|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT00132730||196980|The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.
NCT00132743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224|Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)|Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)|CLEVER|Rhode Island Hospital|Yes|Active, not recruiting|February 2007|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|119|||Both|40 Years|N/A|No|||April 2013|April 24, 2013|August 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00132743||196979|
NCT00132171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66/2000/J|Helicobacter Pylori Eradication With a New Sequential Treatment|High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment||St. Orsola Hospital||Completed|January 2001|December 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|18 Years|70 Years|No|||March 2002|October 19, 2005|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132171||197023|
NCT00132184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001216-50|Vitamin D Treatment for Crohn´s Disease|Remission Keeping and Remission Inducing Effect by Vitamin-D in Crohns Disease, and in Vitro Vitamin-D Mediated T-Cell Immunomodulation||University of Aarhus||Active, not recruiting|September 2005|February 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||110|||Both|18 Years|90 Years|No|||April 2007|April 12, 2007|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00132184||197022|
NCT00133315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232-001|TNFalfa Blocking Treatment of Spondylarthropathies|TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies||Hvidovre University Hospital||Completed|September 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||April 2007|April 9, 2007|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133315||196936|
NCT00133601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9080|Cognitive Behavioral Therapy for Insomnia in Chronic Pain Patients|Cognitive Behavioral Therapy for Insomnia in Chronic Pain Patients||National Institute of Nursing Research (NINR)|Yes|Completed|October 2004|October 2008|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|25 Years|N/A|No|||January 2009|January 15, 2009|August 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00133601||196914|
NCT00133614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5336|Prone Positioning in Pediatric Acute Lung Injury|Prone Positioning in Pediatric Acute Lung Injury||National Institute of Nursing Research (NINR)||Completed|August 2001|April 2004||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||102|||Both|N/A|18 Years||||August 2005|October 28, 2005|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133614||196913|
NCT00133328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHS2002|A Morbidity-Mortality and Remodeling Study With Valsartan|A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease||Jikei University School of Medicine||Active, not recruiting|January 2002|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||3000|||Both|20 Years|79 Years|No|||January 2002|October 27, 2005|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133328||196935|
NCT00132015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060076|17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis|A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis||National Institutes of Health Clinical Center (CC)||Completed|May 2006|June 2008|Actual|December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|August 16, 2005||||||https://clinicaltrials.gov/show/NCT00132015||197035|
NCT00166309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENOC|The FEIBA NovoSeven Comparative Study|FENOC: The FEIBA NovoSeven Comparative Study||Skane University Hospital|Yes|Completed|July 2000|June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Male|2 Years|N/A|No|||April 2007|April 18, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00166309||194445|
NCT00166322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYN-SPECT-Pogarell|Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects|||Ludwig-Maximilians - University of Munich||Completed|January 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|35|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2008|May 6, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166322||194444|
NCT00162292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM119-010|Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background|Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background||Bristol-Myers Squibb||Completed|November 2005|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|70 Years|No|||August 2008|February 27, 2010|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00162292||194749|
NCT00161902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550001|Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Hemostasis in Subjects Undergoing Total Hip Replacement|A Randomized, Controlled, Multicenter Study to Evaluate Efficacy and Safety of Fibrin Sealant VH S/D for Hemostasis in Subjects Undergoing Total Hip Replacement||Baxter Healthcare Corporation||Completed|August 2001|March 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|19 Years|N/A||||October 2006|October 20, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161902||194778|
NCT00162656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAB LMB96|Treatment of Mature B-cell Lymphoma/Leukaemia|Treatment of Mature B-cell Lymphoma/Leukaemia A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study||Gustave Roussy, Cancer Campus, Grand Paris|Yes|Completed|May 1996|May 2011|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|848|||Both|6 Months|20 Years|No|||March 2012|March 27, 2012|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00162656||194721|
NCT00162916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rapoportm-ONF2004-abi-dep-03|Antidepressant Maintenance in Traumatic Brain Injury|A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury||Ontario Neurotrauma Foundation|No|Active, not recruiting|May 2005|October 2008|Anticipated|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|19 Years|N/A|No|||June 2008|June 3, 2008|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00162916||194701|
NCT00162929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-092517|Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)|A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Expressing Rat Her-2/Neu in Patients With Metastatic or Locally Recurrent Breast Cancer|AdHERe|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|January 2005|May 2012|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00162929||194700|
NCT00163488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-409|Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)|Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Fluticasone Propionate/Salmeterol (FP/SAL) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)||Takeda||Completed|January 2005|August 2005||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||106|||Both|18 Years|60 Years|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163488||194657|
NCT00163501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-404|Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older||Takeda||Completed|December 2003|April 2005||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|12 Years|N/A|No|||July 2008|May 4, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00163501||194656|
NCT00164450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4679|TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection|TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children Receiving Once Weekly Rifapentine and Isoniazid for the Treatment of Latent Tuberculosis Infection||Centers for Disease Control and Prevention|Yes|Completed|September 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|230|||Both|2 Years|N/A|No|||August 2008|August 22, 2008|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00164450||194583|
NCT00130221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-006|Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections|Skin Cleansing With Chlorhexidine to Improve Nosocomial Infection Risks. (SCCIN Project)||John H. Stroger Hospital|No|Completed|June 2005|July 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||208|||Both|16 Years|N/A|No|||April 2007|April 3, 2007|August 12, 2005||||No||https://clinicaltrials.gov/show/NCT00130221||197172|
NCT00165230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-011|Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors|A Phase II Study of Thalidomide in Combination With Temodar in Patients With Metastatic Neuroendocrine Tumors||Dana-Farber Cancer Institute||Completed|May 2002|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00165230||194526|
NCT00130819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H97HA03794|Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants|Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals||Johns Hopkins University||Completed|November 2005|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2009|April 14, 2015|August 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00130819||197126|
NCT00131378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|525|Growth Hormone, Cardiovascular Risk, and Visceral Adiposity|Growth Hormone, Cardiovascular Risk, and Visceral Adiposity||Massachusetts General Hospital|Yes|Completed|November 2004|June 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|142|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|August 16, 2005|No|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00131378||197083|
NCT00131391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-014|A Study of MK0364 in Obese Patients (0364-014)|A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension||Merck Sharp & Dohme Corp.||Terminated|July 2005|December 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|2400|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|August 16, 2005|Yes|Yes|The overall profile does not support development for obesity|No||https://clinicaltrials.gov/show/NCT00131391||197082|
NCT00131651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN-161-005|ATN-161 in Advanced Renal Cell Cancer|A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer||Attenuon||Terminated|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||December 2007|December 4, 2007|August 17, 2005||||||https://clinicaltrials.gov/show/NCT00131651||197062|
NCT00132496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-A001-202|Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole|Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients||Eisai Inc.|No|Completed|August 2005|July 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|111|||Both|12 Years|16 Years|No|||November 2009|November 2, 2009|August 19, 2005|Yes|Yes||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00132496||196998|
NCT00132509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000.208|FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke|Comparison of the Classical Rt-PA Procedure (0.9mg/kg Over 60 Minutes) With a Longer Procedure With Lower Dose (0.8mg/kg Over 90 Minutes) in Acute Ischemic Stroke||Hospices Civils de Lyon||Terminated|September 2001|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|81 Years|Accepts Healthy Volunteers|||February 2009|July 21, 2011|August 19, 2005||No|End of promotion by the sponsor|No||https://clinicaltrials.gov/show/NCT00132509||196997|
NCT00133003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A00500|Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)||Deutsches Herzzentrum Muenchen|Yes|Completed|March 2003|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2022|||Both|18 Years|N/A|No|||April 2008|April 12, 2008|August 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00133003||196959|
NCT00133016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701340|The Efficacy of Early Amniotomy for Induction of Labor|The Efficacy of Early Amniotomy for Induction of Labor||University of Pennsylvania||Withdrawn|August 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Female|N/A|N/A||||December 2015|December 1, 2015|August 19, 2005|||no funding|No||https://clinicaltrials.gov/show/NCT00133016||196958|
NCT00133029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|705719|The Timing of Prophylactic Antibiotics in Cesarean Section and the Risk of Post-Operative Febrile Morbidity|||University of Pennsylvania||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Female|N/A|N/A||||September 2006|September 7, 2006|August 19, 2005||||No||https://clinicaltrials.gov/show/NCT00133029||196957|
NCT00133042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025 US06|The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma|||University of Florida||Completed|December 2004|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|6 Years|26 Years|No|||February 2009|September 16, 2011|August 19, 2005||||||https://clinicaltrials.gov/show/NCT00133042||196956|
NCT00133640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405340-104845|Early Rehabilitation After Hip Fracture|Early Rehabilitation After Hip Fracture: A Randomized Controlled Trial Comparing Different Vitamin D and Rehabilitation Programs||Swiss National Science Foundation||Recruiting|January 2005|December 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||204|||Both|65 Years|N/A|No|||August 2006|September 7, 2006|August 22, 2005||||No||https://clinicaltrials.gov/show/NCT00133640||196911|
NCT00132028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03071|Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma|A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma||National Cancer Institute (NCI)||Completed|September 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||January 2013|May 7, 2014|August 16, 2005|Yes|Yes||No|February 28, 2012|https://clinicaltrials.gov/show/NCT00132028||197034|
NCT00132041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439446|Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis|Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients||National Cancer Institute (NCI)||Active, not recruiting|December 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||November 2007|February 6, 2009|August 16, 2005||||No||https://clinicaltrials.gov/show/NCT00132041||197033|
NCT00162383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19551-HMO-CTIL|Metabolic Capacity of Israeli Populations|Phenotypic and Genotypic Evaluation of Cytochrome P450 Isoforms in Populations of Different Ethnic Composition||Hadassah Medical Organization||Terminated|July 1995|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||1200|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00162383||194742|
NCT00161941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224|Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216|Open-label Multicenter Phase 3B Follow-up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens One Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in the NeisVac-C Non-interference Study 216||Pfizer||Completed|June 2003|December 2003||||N/A|Observational|N/A||||321|||Both|5 Months|22 Months|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161941||194775|
NCT00161915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|530001|Efficacy and Safety of Endoscopic Injection of Fibrin Sealant Versus Endoscopic Ligature for Bleeding Esophageal Varices|Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices||Baxter Healthcare Corporation||Completed|December 2000|January 2004||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||October 2006|October 20, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161915||194777|
NCT00162643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALUD-2003-C01-123|PI Vs. NNRTI Based Therapy for HIV Advanced Disease|Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||Recruiting|December 2004|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||September 2006|September 13, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00162643||194722|
NCT00163241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191068|Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression|A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE||Pfizer||Terminated|June 2004|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||666|||Both|18 Years|N/A|No|||July 2007|July 17, 2007|September 9, 2005|||Please see detailed description for termination reason.|No||https://clinicaltrials.gov/show/NCT00163241||194676|
NCT00163254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|btk-1|Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee|Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee||University Hospital Tuebingen||Active, not recruiting|September 2003|November 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|95 Years|No|||September 2006|September 11, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00163254||194675|
NCT00163540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|690501|Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)|Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225)||Pfizer||Completed|May 2005|June 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|17 Years|66 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00163540||194653|
NCT00163553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01833|Neuraxial Pethidine After Lumbar Surgery Trial|Neuraxial Pethidine After Lumbar Surgery Trial||Austin Health||Recruiting|December 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00163553||194652|
NCT00163202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581065|Comparative Atorvastatin Pleiotropic Effects|A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis|CAP|Pfizer||Completed|June 2002|August 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|18 Years|80 Years|No|||April 2007|March 14, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00163202||194679|
NCT00163215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281269|Growth Retardation In Children With Special Pathological Conditions Or Disease|Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.||Pfizer|Yes|Completed|January 2005|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|11 Years|13 Years|No|||November 2012|November 19, 2012|September 9, 2005||No||No|October 2, 2012|https://clinicaltrials.gov/show/NCT00163215||194678|
NCT00163228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWB Stratec 96856|Functional Evaluation of the Total Knee Prostheses:Rising From a Chair|Functional Evaluation of Total Knee Arthroplasties,Protocol for Rising From a Chair.||Radboud University||Withdrawn|January 2001|May 2007|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|October 15, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00163228||194677|
NCT00129922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 9906|Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) Versus FEC Plus Paclitaxel as Adjuvant Treatment for Node Positive Breast Cancer Patients|Multicenter Randomized Phase III Clinical Trial to Compare 6 Courses of FEC (Fluorouracil, Epirubicin and Cyclophosphamide) Vs. 4 Courses of FEC Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Positive Operable Breast Cancer Patients||Spanish Breast Cancer Research Group||Completed|November 1999|July 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1250|||Female|18 Years|70 Years|No|||August 2005|September 26, 2005|August 10, 2005||||No||https://clinicaltrials.gov/show/NCT00129922||197194|
NCT00129935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM 2003-10|EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients|Multicenter, Randomized Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment for Operable, Node Positive Breast Cancer Patients||Spanish Breast Cancer Research Group||Completed|February 2004|February 2012||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1382|||Female|18 Years|70 Years|No|||February 2007|February 6, 2007|August 11, 2005||||No||https://clinicaltrials.gov/show/NCT00129935||197193|
NCT00175227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRIF #96-20|Prevention of Contrast-Induced Nephropathy|Prevention of Contrast-Induced Nephropathy: a Randomized Controlled Trial of Saline + Furosemide + Mannitol in High Risk Patients Undergoing Cardiac Angiography||University of Alberta|No|Completed|May 1996|||October 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|21 Years|N/A|No|||May 2011|May 9, 2011|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00175227||193770|
NCT00175461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0070|Comparison of Two Minimally Invasive Surgical Techniques for Hip Replacement|Comparison of the Clinical Effectiveness and Cost-effectiveness of the MIS Anterolateral Approach (MIS Watson Jones, G3) Versus Anterolateral Mini or Posterolateral Mini Approaches in Primary Total Hip Arthroplasty||University of British Columbia|No|Active, not recruiting|September 2005|December 2012|Anticipated|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|156|||Both|19 Years|N/A|No|||September 2011|September 20, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175461||193753|
NCT00175487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70105|Comparison of Hip Resurfacing to Large Femoral Head Total Hip Arthroplasty|Femoral Head Resurfacing Versus a Large Femoral Head (Durom®) Total Hip System: A Prospective Randomized Trial||University of British Columbia|No|Active, not recruiting|September 2007|June 2014|Anticipated|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|19 Years|65 Years|No|||March 2014|March 17, 2014|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175487||193751|
NCT00175500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-0530|Comparison of Conventional and Large Diameter Femoral Heads for the Prevention of Hip Dislocation|A Randomized Multi-Centre Controlled Trial of Large Diameter (36/40 mm) Versus Conventional Diameter (32 mm) Femoral Heads for the Prevention of Post Revision Arthroplasty Dislocation||University of British Columbia|No|Active, not recruiting|September 2007|December 2012|Anticipated|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|19 Years|N/A|No|||September 2011|September 20, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175500||193750|
NCT00175760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0304|Can a Very High Result From a Screening Test for Celiac Disease be Used to Diagnose Celiac Disease?|Prospective Assessment of High Titre TTG to Diagnose Celiac Disease in Select Paediatric Patients.||University of British Columbia|No|Completed|December 2004|October 2006|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|2 Months|18 Years|No|Probability Sample|Aged 2 months to 18 years with a planned upper GI endoscopy.|April 2011|April 11, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175760||193730|
NCT00176020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-003234-18|Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression|Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects||Heidelberg University||Not yet recruiting||||||Phase 1|Interventional|N/A||||18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2005|March 14, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176020||193710|
NCT00171795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BDE01|Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment|Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment||Novartis||Completed|November 2002|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|67|||Both|18 Years|65 Years||||November 2011|November 22, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171795||194034|
NCT00171808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345ADE08|Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer|Phase II Study on Letrozole in Patients With Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer|deFEND|Novartis||Completed|April 2005|||May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||January 2014|January 22, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171808||194033|
NCT00172146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700329|Influences of Cane Use on Voluntary Forward Stepping Movement and Associated Attentional Demands in Hemiplegic Patients|Influences of Cane Use on Voluntary Forward Stepping Movement and Associated Attentional Demands in Hemiplegic Patients||National Taiwan University Hospital||Active, not recruiting|August 2002|July 2003||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||22|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172146||194007|
NCT00171756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AGB09|Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.|A Double-blind, Double-dummy, Multi-centre, Randomized, Active Controlled, Parallel Group Pilot Trial to Compare the Effects of Valsartan and Atenolol on the Pro-thrombotic State in Patients With Mild to Moderate Hypertension.||Novartis||Completed|June 2004|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|92|||Both|18 Years|75 Years||||November 2011|November 7, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00171756||194037|
NCT00171769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEX839BDE01|Atrial Fibrillation Feasibility Certoparin Trial - AFFECT|An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation||Novartis||Completed|April 2005|||August 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||March 2008|August 31, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00171769||194036|
NCT00171782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BCO02|Hypertension and Cardiovascular Risk Factors|Valsartan Plus Hydrochlorothiazide in Patients With Hypertension and Cardiovascular Risk Factors||Novartis||Completed|February 2004|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|76|||Both|18 Years|80 Years||||June 2006|November 7, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00171782||194035|
NCT00172081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX1-11-93001|TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis|An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis||Shire|Yes|Completed|April 2000|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2532|||Female|45 Years|N/A|No|||September 2005|November 10, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00172081||194012|
NCT00173108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700406|Early Intervention for Preterm Infants|Early Intervention for Preterm Infants||National Taiwan University Hospital|No|Completed|January 2006|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|4||Actual|240|||Both|N/A|7 Days|No|||March 2011|April 21, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00173108||193933|
NCT00160082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IvIG 1/00|Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)|Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS): A Randomized, Two-Arm, Parallel, Double-Blind, Multi-Centre, Placebo Controlled Study||Pharmalink AB||Completed|January 2001|May 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||124|||Both|18 Years|75 Years|No|||September 2005|April 2, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00160082||194916|
NCT00160394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S194-INT-04|Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris|Multi-Centre, Single-Blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Duac® Gel And Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris||GlaxoSmithKline||Completed|December 2004|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|130|||Both|12 Years|39 Years|No|||July 2011|July 12, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00160394||194892|
NCT00174772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976B_2505|Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)|A Two Arm Phase II Study Comparing Docetaxel/Cisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-Multiple cN2 or IIIB)||Sanofi||Completed|March 2004|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||February 2010|February 15, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00174772||193805|
NCT00174785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5555|A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation|A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)|ATHENA|Sanofi|Yes|Completed|June 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|4628|||Both|70 Years|N/A|No|||January 2010|January 5, 2010|September 13, 2005|Yes|Yes||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00174785||193804|
NCT00174746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI6153|Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma|A Placebo- and Active-Controlled (Ciclesonide Metered-Dose Inhaler), Randomized, Parallel-Group, Dose-Range Finding Study of Ciclesonide Administered by Dry Powder Inhaler (Ultrahaler) in Adult and Adolescent Patients With Persistent Asthma||Sanofi||Completed|March 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1145|||Both|12 Years|N/A|No|||April 2009|April 7, 2009|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174746||193807|
NCT00174759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C_9253|CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease|A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.||Sanofi||Completed|September 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1460|||Both|40 Years|80 Years|No|||January 2011|January 10, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174759||193806|
NCT00174369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4581002|MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer|Phase 2 Study Of The MEK Inhibitor PD-0325901 In Patients With Advanced Non-Small Cell Lung Cancer||Pfizer|No|Terminated|November 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||February 2009|March 16, 2009|September 9, 2005|Yes|Yes|Terminated [See Detailed Description for Termination Reason.]|No||https://clinicaltrials.gov/show/NCT00174369||193836|
NCT00175539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0400|Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties|Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties||University of British Columbia|No|Completed|November 2005|December 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|19 Years|65 Years|Accepts Healthy Volunteers|||June 2010|June 22, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00175539||193747|
NCT00175552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B05-0055|Ministry of Child and Family Development (MCFD) Interpersonal Psychotherapy for Adolescents (IPT-A) Training Project|Evaluating the Effectiveness of Different Interpersonal Psychotherapy for Adolescents (IPT-A) Therapist Training Models||University of British Columbia||Completed||July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|24|||Both|8 Years|18 Years|No|||July 2007|July 16, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00175552||193746|
NCT00174720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6164|Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.|A Multinational,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered Either in a Once-Daily in the Morning Regimen (160 μg qd AM) for 16 Weeks or in a 160 μg qd AM Regimen for 12 Weeks Preceded by a Twice-Daily Regimen (80 μg Bid) for 4 Weeks,or in an 80 μg Bid Regimen for 16 Weeks,in Adults and Adolescents With Mild to Moderate Persistent Asthma Not Treated With Steroids||Sanofi||Completed|September 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|708|||Both|12 Years|N/A|No|||April 2009|April 7, 2009|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174720||193809|
NCT00174993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD4833/EC444|Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes|PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy|PROactive|Takeda|No|Completed|May 2001|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4373|||Both|35 Years|75 Years|No|||February 2012|February 27, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174993||193788|
NCT00174694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4023|CHOOSE : Telithromycin, Acute Bacterial Sinusitis|A Prospective, Randomized, Open-label, Active-controlled Study in Adult Subjects With Acute Bacterial Sinusitis Comparing the Clinical Efficacy of Telithromycin (KETEK®) 800 mg Once a Day for 5 Days Versus Amoxicillin-clavulanic Acid (AUGMENTIN®) 875/125 mg Twice a Day for 10 Days||Sanofi||Completed|November 2004|||December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|298|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174694||193811|
NCT00174707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_IT1_302|Study of Docetaxel in Breast Cancer Patients|A Phase III Randomized Study of Sequential Epidoxorubicin Followed By CMF: Cyclophosphamide+Methotrexate+Fluorouracil (Arm A) Versus Sequential Epidoxorubicin Followed By Docetaxel Followed By CMF (Arm B) Versus Sequential Intensified Epidoxorubicin Followed By Docetaxel Followed By High-Dose Cyclophosphamide (Arm C) in Early Breast Cancer Patients With Positive Axillary Lymph Nodes||Sanofi||Completed|December 1997|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|998|||Female|18 Years|70 Years|No|||December 2009|December 4, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00174707||193810|
NCT00174967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-00-004|Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout|Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.||Takeda|No|Completed|January 2001|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|153|||Both|18 Years|85 Years|No|||July 2011|July 27, 2011|September 9, 2005|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00174967||193790|
NCT00175240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofA M2022|Enhancing the Secondary Prevention of Coronary Artery Disease|Enhancing the Use of Secondary Prevention Strategies in Patients With Coronary Artery Disease (The ESP-CAD Study)||University of Alberta||Completed|March 2005|July 2015|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|480|||Both|18 Years|N/A|No|||July 2015|July 25, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00175240||193769|
NCT00175747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPHS Grant N01-CN85188|A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)|A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People With Dysplasia of the Bronchial Epithelium||University of British Columbia||Completed|January 2000|December 2002||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||120|||Both|40 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00175747||193731|
NCT00176046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WD 40|Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study|Prospective Controlled Randomized Feasibility Study on a Treatment With Viscum Album in Patients With Breast Cancer to Identify Appropriate Surrogate Parameters for a Randomized Study of the Efficacy of Treatment With Mistletoe Extracts||Heidelberg University|No|Active, not recruiting|May 1999|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Female|18 Years|N/A|No|||June 2009|February 9, 2011|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00176046||193708|
NCT00171366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIB002H2304|A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.|A Multicenter, Group Study to Evaluate the Safety and Efficacy of Amlodipine and Benazepril Administered in Combination Compared to Amlodipine Monotherapy in Hypertensive Patients Not Adequately Controlled With Amlodipine Alone||Novartis||Completed|July 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1422|||Both|18 Years|N/A||||November 2011|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171366||194067|
NCT00171379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AIT01|Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant|Open-label Study to Evaluate the Tolerability, Safety and Efficacy of the Equimolar Conversion From Mycophenolate Mofetil (MMF) to Enteric-Coated Mycophenolate Sodium (EC-MPS) in Patients With Renal Transplant||Novartis||Completed|March 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|162|||Both|18 Years|N/A||||February 2011|February 1, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00171379||194066|
NCT00171834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2209|Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer|An Open Label, Phase I/II Dose Escalating Study Evaluating the Safety and Efficacy of EPO906, qw3, in Patients With Non-small Cell Lung Cancer.||Novartis||Completed|August 2003|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|September 13, 2005|Yes|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00171834||194031|
NCT00171847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345C2403|Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer|An Open Label, Randomized Comparison of Femara® 2.5mg Once Daily With or Without Weekly Herceptin® Until Disease Progression as First-line Treatment in Postmenopausal Women With Advanced Breast Cancer.|eLEcTRA|Novartis||Terminated|March 2003|||October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Female|18 Years|N/A|No|||March 2010|March 30, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171847||194030|
NCT00173147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700502|Morphology of the VMO in Patients With PFPS and Healthy Young Adults--A Sonographic Study|Morphology of the Vastus Medialis Obliquus in Patients With Patellofemoral Pain Syndrome and Healthy Young Adults --A Sonographic Study||National Taiwan University Hospital||Recruiting|May 2005|||||N/A|Observational|Time Perspective: Retrospective|||||||Both|15 Years|50 Years|Accepts Healthy Volunteers|||April 2005|October 24, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173147||193930|
NCT00173160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700426|Epidemiological Studies of Eating Disorders in Gifted Dance Students (2nd Year).|Epidemiological Studies of Eating Disorders in Gifted Dance Students: Prevalence Rate, Risk Factors and 1-Year Outcome (2nd Year).||National Taiwan University Hospital||Completed|August 2004|July 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||700|||Both|17 Years|19 Years|Accepts Healthy Volunteers|||August 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173160||193929|
NCT00173173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700424|Epidemiological Studies of Eating Disorders in Gifted Dance Students(1st Year)|Epidemiological Studies of Eating Disorders in Gifted Dance Students and Ordinary High School Students:Prevalence Rate, Risk Factors and 1-Year Outcome (1st Year).||National Taiwan University Hospital||Completed|August 2003|July 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||2200|||Both|16 Years|18 Years|Accepts Healthy Volunteers|||August 2003|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173173||193928|
NCT00172406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700202|The Relation Between Serum Level of Amioterminal Propeptide of Type I Procollagen and Diastolic Dysfunction in Hypertensive Patients Without Diabetes Mellitus|||National Taiwan University Hospital||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A||||August 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172406||193987|
NCT00172094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1776-005|Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches|A Phase 2 Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches||Shire|No|Completed|December 2003|July 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|189|||Both|18 Years|60 Years|No|||September 2005|November 11, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00172094||194011|
NCT00172107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1-11-821|A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis|A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis||Shire|No|Completed|May 1995|March 1997|Actual|March 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|217|||Female|50 Years|75 Years|No|||September 2005|November 11, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00172107||194010|
NCT00173420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700654|Mechanisms of Neuropathic Pain: Investigation by Contact Heat Evoked Potential|Mechanisms of Neuropathic Pain: Investigation by Contact Heat Evoked Potential||National Taiwan University Hospital||Recruiting|June 2005|||||N/A|Observational|N/A|||Anticipated|100|||Both|15 Years|N/A|Accepts Healthy Volunteers|||June 2005|October 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173420||193909|
NCT00173693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700347|What is the Best Policy to Prevent Osteoporotic Fracture?|||National Taiwan University Hospital||Withdrawn|January 2006|December 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Both|N/A|N/A|No|||November 2012|December 6, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00173693||193888|
NCT00161031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21702|Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia|Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia||University of Maryland||Completed|April 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|60 Years|No|||March 2015|March 4, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161031||194843|
NCT00174798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT5190|MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.|A Randomized, Double-blind, Placebo and Active-controlled Efficacy and Safety Study of SSR240600C in Patients With Overactive Bladder (OAB) or Urge Urinary Incontinence (UUI)||Sanofi||Completed|May 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|118|||Female|18 Years|75 Years|No|||February 2012|February 1, 2012|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174798||193803|
NCT00174811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6131|Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections|Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of Telithromycin 25 mg/kg Given Once Daily for 5 or 10 Days Depending on Age and Previous Treatment History Versus Cefuroxime Axetil 15 mg/kg, Given Twice Daily for 10 Days, in Children With Acute Otitis Media||Sanofi||Terminated|June 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|639|||Both|6 Months|59 Months|No|||April 2009|April 2, 2009|September 13, 2005|||Pediatric development program terminated by sponsor|No||https://clinicaltrials.gov/show/NCT00174811||193802|
NCT00175032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAN-0003-0041|A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin|A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin||Takeda|No|Completed|July 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1045|||Both|18 Years|N/A|No|||July 2010|July 20, 2010|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00175032||193785|
NCT00175019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-021|Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010|A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout|EXCEL|Takeda|No|Completed|July 2003|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1086|||Both|18 Years|85 Years|No|||July 2010|July 22, 2010|September 12, 2005|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00175019||193786|Subjects may receive >1 treatment. Adverse events are summarized by treatment at time of observation and subjects who receive >1 treatment are summarized for each treatment they receive, so subjects at risk will not match number of participants.
NCT00175006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-019|Validation Study of Physical Measurement of Tophi|A Study to Assess a Direct Physical Measurement Method for Evaluation of Tophus Nodules in Subjects With Gout.||Takeda|No|Completed|November 2002|January 2003|Actual|January 2003|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|13|None Retained|None taken or retained|Both|18 Years|85 Years|No|Non-Probability Sample|Subjects with palpable tophi >10mm in length and width and as round as possible will have        the tophus measured on two separate visits by two different raters to assess the inter-        and intra-rater reproducibility of direct physical measurement.|July 2010|July 22, 2010|September 12, 2005|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00175006||193787|
NCT00175253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5369|Alemtuzumab Induction in Islet Transplantation|Alemtuzumab Induction With Tacrolimus and MMF Maintenance Immunosuppression in Islet Transplantation||University of Alberta||Completed|November 2005|April 2012|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|65 Years|No|||July 2012|July 11, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00175253||193768|
NCT00174980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-CL-II-002|Study of Oxycyte in Severe Closed Head Injury|An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL-II-002||Tenax Therapeutics, Inc.||Completed|September 2005|July 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|No|||October 2008|June 9, 2011|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00174980||193789|
NCT00175773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0374|Mechanisms of Orthostatic Intolerance in Spinal Cord Injured Individuals and Following Bed Rest|Mechanisms of Orthostatic Intolerance in Spinal Cord Injured Individuals and Following Bed Rest||University of British Columbia|No|Completed|November 2004|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|19 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|SCI individuals (19 to 55 years of age) with a functionally complete or a functionally        incomplete spinal cord injury will constitute the study population.|July 2012|July 10, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175773||193729|
NCT00175786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0404|Magnetic Resonance Imaging of Patients With Normal Tension Glaucoma|Neuroradiologic Screening of Patients With Normal Tension Glaucoma||University of British Columbia||Completed|July 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 24, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175786||193728|
NCT00176059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTx-Ig-003|Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients|Immunoglobulin Induction Therapy in Renal Transplant Recipients on Tacrolimus/Azathioprine or Tacrolimus/MMF: Effects on Th1, Th2, B Cell-/Monokine Responses and Immunoregulatory Autoantibody Levels||University of Giessen|No|Completed|October 2001|May 2006|Actual|||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|14 Years|N/A|No|||May 2007|May 8, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00176059||193707|
NCT00171392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AIT02|Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus|Open-label Study to Evaluate the Tolerability, Safety and Efficacy of the Equimolar Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium in Patients With Stable Renal Transplant Receiving Tacrolimus||Novartis||Completed|March 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|132|||Both|18 Years|N/A||||February 2011|February 1, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00171392||194065|
NCT00171405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2302E1|A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg|A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension||Novartis||Completed|June 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|August 24, 2005||||||https://clinicaltrials.gov/show/NCT00171405||194064|
NCT00171821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2409|A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload|A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload||Novartis||Completed|April 2005|July 2010|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1784|||Both|2 Years|N/A|No|||June 2013|June 5, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171821||194032|
NCT00172692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701237|Observation and Evaluation of Chewing Velocity Changes on Soft Food Chewing Efficiency|||National Taiwan University Hospital||Completed|July 2004|August 2004||||Phase 2|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|20 Years|30 Years|Accepts Healthy Volunteers|||June 2005|December 14, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172692||193965|
NCT00172705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701262|Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique|Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique||National Taiwan University Hospital||Recruiting|September 2004|February 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||February 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172705||193964|
NCT00173186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700517|Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect|Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect||National Taiwan University Hospital||Recruiting|January 1987|February 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||411|||Both|N/A|N/A|No|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173186||193927|
NCT00172419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931204|The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.|Statin-Induced Vulnerable Plaque Regression After Atorvastatin Treatment: Serial Evaluation by 18F-Fluorodeoxyglucose Positron Emission Tomography Study||National Taiwan University Hospital|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|30 Years|80 Years|No|||December 2008|January 2, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172419||193986|
NCT00172432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700303|Aminoterminal Propeptide of Type III Procollagen and Severity of Coronary Artery Disease in Patients Without Myocardial Infarction|||National Taiwan University Hospital||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||||||Both|50 Years|75 Years||||August 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172432||193985|
NCT00172666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701218|Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)|Investigating Genetic Polymorphism of Decoy Receptor 3 (DcR3) Gene in Rheumatoid Arthritis and Systemic Lupus Erythematosus||National Taiwan University Hospital||Recruiting|August 2005|July 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|March 29, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172666||193967|
NCT00173719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100002423|Influence of Assistive Device Use While Performing Dual Task in Patients With Stroke|Influence of Assistive Device Use on Dynamic Balance and the Associated Attentional Demands During Standing and Walking in Patients With Stroke||National Taiwan University Hospital||Completed|September 2003|July 2004|Actual|January 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|40|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2013|August 26, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00173719||193886|
NCT00174824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS6036|Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients|Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin||Sanofi||Completed|June 2001|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1024|||Both|30 Years|70 Years|No|||March 2009|March 26, 2009|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174824||193801|
NCT00174837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5512|TRACE: Tirapazamine-Radiation And Cisplatin Evaluation|Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer|TRACE|Sanofi|Yes|Completed|April 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||January 2009|January 15, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00174837||193800|
NCT00175045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-039|Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis|A Phase 2, Open-Label Multicenter Study to Evaluate the Pharmacodynamics of Intravenous Lansoprazole to That of Oral Lansoprazole in Subjects With Erosive Esophagitis||Takeda|No|Completed|June 2003|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||July 2010|July 20, 2010|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00175045||193784|
NCT00175058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIHOT II|Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)|Acute Myocardial Infarction With HyperOxemic Therapy II|AMIHOT II|TherOx|Yes|Completed|August 2005|May 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00175058||193783|
NCT00175292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL-FED-01|A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.|A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.||University of Alberta||Completed|December 2003|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|120|||Both|16 Years|N/A|No|||May 2008|May 12, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00175292||193765|
NCT00175305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0007|Prader-Willi Syndrome and Appetite|Effect of Somatostatin on Ghrelin Concentrations, Food Seeking Behaviour and Weight in Patients With Prader-Willi Syndrome||University of British Columbia||Terminated|August 2004|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|10|||Both|10 Years|17 Years||||October 2007|October 29, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00175305||193764|
NCT00175279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN26365328|A Cluster Randomized Trial to Assess the Impact of Opinion Leader Endorsed Evidence Summaries on Improving Quality of Prescribing for Patients With Chronic Cardiovascular Disease|A Cluster Randomized Trial to Assess the Impact of Opinion Leader Endorsed Evidence Summaries on Improving Quality of Prescribing for Patients With Chronic Cardiovascular Disease||University of Alberta||Completed|January 2002|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||160|||Both|50 Years|N/A|No|||May 2011|May 9, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00175279||193766|
NCT00175565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4027|Inhaled Steroid Reduces Systemic Inflammation in COPD|Effects of Fluticasone On Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease||University of British Columbia||Completed|January 2002|July 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|40 Years|80 Years|No|||July 2010|July 26, 2010|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00175565||193745|
NCT00175812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-Vestnr21503|Differentiation Induction in Acute Myelogenous Leukemia|Differentiation Induction Therapy for Acute Myelogenous Leukemia||University of Bergen|No|Completed|November 2004|November 2009|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 23, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00175812||193726|
NCT00175266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3516|Islet Transplantation Using Campath-1H and Infliximab Induction|Islet Transplantation in Type 1 Diabetic Patients Using Campath-1H and Infliximab Induction||University of Alberta||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|65 Years|No|||October 2009|October 1, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00175266||193767|
NCT00175513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0503|V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis|V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis||University of British Columbia|No|Completed|September 2005|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||April 2011|April 12, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175513||193749|
NCT00175799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-70601|Validation of Severity of Illness Scoring Systems in Paediatric Intensive Care Units in Canada|Validation of Severity of Illness Scoring Systems in Paediatric Intensive Care Units in Canada Outcome: Validation and Comparison of 2 Severity of Illness Scores in Canadian PICU Population||University of British Columbia|No|Completed|September 2007|July 2013|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|10000|||Both|N/A|18 Years|No|Probability Sample|All children admitted to participating PICUs over a 1 year period.|May 2015|May 5, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175799||193727|
NCT00171860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571ABE01|A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome|A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome||Novartis||Terminated|September 2002|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2012|April 29, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171860||194029|
NCT00172159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170CL6|Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers|Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers||National Taiwan University Hospital||Recruiting|January 2000|June 2005|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|100|||Both|18 Years|75 Years|No|||January 2000|June 22, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172159||194006|
NCT00172445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700760|Clinical Studies of Kikuchi's Disease|||National Taiwan University Hospital||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|N/A|N/A|No|||June 2004|December 6, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172445||193984|
NCT00172458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700454|Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents|Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents||National Taiwan University Hospital||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||August 2005|September 14, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172458||193983|
NCT00172718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701264|Using 3.3mm Screw Tap and Cutting Resistance to Evaluate Bone Quality Around Dental Implant|Using 3.3mm Screw Tap to Modify the Standard Implantation Procedure and to Measure the Cutting Resistance for Establishing a More Objective Method to Evaluate the Peri-Implant Bone Quality||National Taiwan University Hospital||Recruiting|March 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||February 2005|June 5, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172718||193963|
NCT00174070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700726|Etiologies and Outcomes of Acute Respiratory Failure in Community|Etiologies and Outcomes Analysis of Acute Respiratory Failure in Community||National Taiwan University Hospital||Recruiting|August 2005|February 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||150|||Both|18 Years|N/A|No|||July 2005|November 2, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174070||193859|
NCT00174083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700717|Diagnosis of Active Tuberculosis by ELISPOT|Diagnosis of Active Tuberculosis in Endemic Area by Using Enzyme-Linked Immunospot Assay for Gamma-Interferon||National Taiwan University Hospital||Recruiting|August 2005|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|N/A|N/A|No|||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174083||193858|
NCT00172679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701225|Effects of Tai Chi Exercise on Innate and Adaptive Immune Function|||National Taiwan University Hospital||Recruiting|July 2005|June 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|30|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||December 2004|September 26, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172679||193966|
NCT00160407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12458|Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)|Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)||St. Louis University||Completed|October 2003|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||November 2007|November 19, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160407||194891|
NCT00160420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-408|A Long-Term Study to Evaluate the Safety of Asoprisnil in the Treatment of Women With Endometriosis From Study M01-398|A Phase 2, 12-Month, Open Label Extension Study to Evaluate the Safety of J867(5 mg QD) in Subjects With Endometriosis||Abbott|No|Completed|December 2002|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Female|18 Years|40 Years|No|||May 2008|May 27, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00160420||194890|
NCT00175071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL54727-1537|Effect of Vegetable Oils for Use by the Snack Food Industry on Plasma Lipid Levels and Inflammatory Markers|Effect of Conventional and Reformulated Vegetable Oils for Use by the Snack Food Industry on Plasma Lipid Levels and Inflammatory Markers||Tufts University|No|Active, not recruiting|March 2004|December 2015|Anticipated|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|30|||Female|50 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00175071||193782|
NCT00175318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B04-0295|Testing a Tooth Decay Prevention Program With Cree Mothers and Infants|A Clinical Trial of the Effectiveness of Motivational Interviewing as a Preventive Strategy for Dental Caries in Cree Infants||University of British Columbia||Completed|April 2005|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|309|||Female|14 Years|48 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00175318||193763|
NCT00175591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70077|The Effect of Femoral Nerve Block on Opioid Requirements After Surgery for a Femur Fracture in Children|The Effect of Femoral Nerve Block on Opioid Requirements Following Femoral Fracture Fixation With Flexible Nails in the Paediatric Population: A Double Blind, Prospective Randomized Clinical Trial||University of British Columbia|No|Terminated|August 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|25|||Both|5 Years|12 Years|No|||June 2011|June 8, 2011|September 13, 2005||No|It has become a standard of care to give Femoral nerve blocks and have discontinued this study|No||https://clinicaltrials.gov/show/NCT00175591||193743|
NCT00175877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87028|A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis|A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis||UCB Pharma|No|Completed|June 2005|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|857|||Both|18 Years|N/A|No|||March 2013|March 22, 2013|September 9, 2005|Yes|Yes||No|February 4, 2013|https://clinicaltrials.gov/show/NCT00175877||193721|
NCT00175578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0640|Detection of Early Lung Cancer by Serum Protein Expression Profiling|Differences in SELDI Produced Serum Protein Profiles of Non-small Cell Lung Cancer Patients Compared to Healthy Heavy Smoking Adults||University of British Columbia|No|Recruiting|May 2005|December 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients with non-small cell lung cancer and healthy heavy smoking adults.|November 2011|November 15, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175578||193744|
NCT00175825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01193|A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.|A Double-blind, Randomized, Placebo-controlled, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.||UCB Pharma|No|Completed|November 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|210|||Both|16 Years|65 Years|No|||August 2012|August 28, 2012|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00175825||193725|
NCT00175838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A05033|Primary Thrombocythaemia 1 Trial|A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia|PT-1|University of Cambridge|Yes|Active, not recruiting|July 1997|April 2024|Anticipated|April 2024|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Both|40 Years|59 Years|No|||December 2014|December 12, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00175838||193724|
NCT00176072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K102|BlueCQ Bioavailability|B l u e C Q - P r o j e c t: Bioavailability of Methylene Blue (MB) - Comparison of an Intravenous and Two Oral Formulations - and Influence of Sustained Release MB on Chloroquine (CQ) Concentrations||Heidelberg University||Completed|August 2004|November 2004||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176072||193706|
NCT00175526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-70137|Predicting Complications in Women With Toxaemia|PIERS (Pre-eclampsia Integrated Estimate of RiSk) Model: Predicting Adverse Maternal Outcomes in Pre-eclampsia||University of British Columbia|No|Active, not recruiting|September 2005|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Female|16 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Women with pre-eclampsia ('toxaemia of pregnancy') which is the most common cause for        women to die during or shortly after pregnancy.|April 2015|April 10, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00175526||193748|
NCT00171873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995ADE05|Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut|Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut||Philipps University Marburg Medical Center||Active, not recruiting|September 2001|December 2013|Anticipated|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|September 13, 2005||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00171873||194028|
NCT00172172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1-11-008|Calcium Supplementation in Postmenopausal Women|A Study to Evaluate the Effects of Calcium Supplementation on the Efficacy and Safety of Recombinant Human Parathyroid Hormone (ALX1-11) in Postmenopausal Women With Osteoporosis (CAP Study)|CAP|Shire|No|Completed|February 2004|April 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|374|||Female|45 Years|N/A|No|||August 2008|November 11, 2015|September 13, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00172172||194005|
NCT00172471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700775|The Relationship Between Sleep Disorders and Cytokine Levels Among Hemodialysis and Peritoneal Dialysis Patients|||National Taiwan University Hospital||Completed||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|18 Years|80 Years|No|||December 2004|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172471||193982|
NCT00172731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701289|Measurement of Activity Participation for Persons With Schizophrenia Living in the Community|||National Taiwan University Hospital||Completed|March 2005|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|No|||February 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172731||193962|
NCT00172744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701291|Effect of Cyclic Tensional Force on Osteogenic Differentiation of Human Periodontal Ligament Stem Cells|||National Taiwan University Hospital||Recruiting|April 2005|July 2006||||N/A|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|13 Years|N/A|Accepts Healthy Volunteers|||March 2005|October 10, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172744||193961|
NCT00173771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701233|Development of a Comprehensive ADL Scale for Stroke Patients|Development of a Comprehensive ADL Scale for Stroke Patients||National Taiwan University Hospital||Recruiting|August 2004|May 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|No|||August 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173771||193882|
NCT00173121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700414|Environmental Enterovirus Monitoring|Environmental Enterovirus Monitoring||National Taiwan University Hospital||Recruiting|May 2005|June 2005||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||50|||Both|N/A|18 Years|No|||April 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173121||193932|
NCT00173134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700404|The Prevalence of Erectile Dysfunction (ED) and ED Related Quality of Life of Diabetic Men|Investigating the Prevalence of Erectile Dysfunction and Erectile Dysfunction Related Quality of Life of Diabetic Men in Taiwan||National Taiwan University Hospital||Recruiting|May 2005|March 2006||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||300|||Male|20 Years|N/A|No|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173134||193931|
NCT00173459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700671|Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome|||National Taiwan University Hospital||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||||||Both|20 Years|N/A||||July 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173459||193906|
NCT00173433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700627|Exogenous Reinfection of Tuberculosis in Taiwan|The Importance of Exogenous Reinfection in the Tuberculosis Endemic of Taiwan||National Taiwan University Hospital||Completed|August 2005|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A||1|Anticipated|150|||Both|N/A|N/A|No|||December 2014|December 8, 2014|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173433||193908|
NCT00173446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700673|D2 Dopamine Receptor on Human Aldosterone-Producing Adenoma and Its Role in Aldosterone Secretion and Cell Proliferation|Expression of D2-Like Dopamine Receptor of Human Aldosterone-Producing Adenoma and Its Role in Regulation of Aldosterone Secretion and Cell Proliferation||National Taiwan University Hospital||Recruiting|January 2002|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|30|||Both|N/A|N/A|No|||August 2005|June 7, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173446||193907|
NCT00173992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701257|Balance Recovery and Training on Fall Prevention in Stroke|Balance Recovery and Training on Fall Prevention in Stroke||National Taiwan University Hospital||Not yet recruiting|September 2005|December 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||100|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||June 2005|September 13, 2005|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00173992||193865|
NCT00174005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701181|Validity and Reliability in Measuring Biceps and Triceps by Using Ultrasound|Validity and Reliability in Measuring Tendon and Muscular Morphologic Characteristics of Biceps and Triceps by Using Ultrasound||National Taiwan University Hospital||Recruiting|December 1994|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|20|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||December 1994|June 5, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174005||193864|
NCT00174018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700931|Validity and Reliability in Measuring the Subacromial Space by Using Ultrasound|Validity and Reliability in Measuring the Subacromial Space by Using Ultrasound||National Taiwan University Hospital||Completed|September 1993|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|19 Years|35 Years|Accepts Healthy Volunteers|||August 1993|December 6, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174018||193863|
NCT00174499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431088|A Pilot Drug Trial That Evaluates the Whitening Potential of Nicotine Gum|An Open-label Study on Nicorette Freshmint Gum, 2 MG AND 4 MG in Smokers With Visible Teeth Staining Motivated to Quit||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|July 2005|September 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 6, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174499||193826|
NCT00175344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-60011|Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer?|Does Scar Tissue Massage Improve Postoperative Pain and Function in Women With Breast Cancer? A Randomized Controlled Study.||University of British Columbia|No|Completed|February 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175344||193762|
NCT00175604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-0550|Comparative Trial of Botox in the Management of Children With Congenital Muscular Torticollis|Comparative Trial of Botox Versus Conventional Treatment Used in the Management of Children With Congenital Muscular Torticollis (CMT)||University of British Columbia|No|Withdrawn|August 2004|February 2008|Anticipated|February 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|4 Months|1 Year|No|||February 2011|May 5, 2015|September 13, 2005||No|Not able to recruit any subjects for the study and was closed in February 2008|No||https://clinicaltrials.gov/show/NCT00175604||193742|
NCT00175890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01009|A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.|A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009||UCB Pharma|No|Completed|October 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|116|||Both|1 Month|4 Years|No|||July 2015|July 6, 2015|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00175890||193720|
NCT00175864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01212|Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.|Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (Ucb 44212) at Individualized Doses up to a Maximum of 160mg/Day in Refractory Epileptic Patients.||UCB Pharma||Withdrawn|February 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|16 Years|65 Years||||March 2012|March 19, 2012|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00175864||193722|
NCT00175851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01197|Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy|An Open-label, Multicenter, Follow-up Trial to Evaluate the Long-term Safety and Efficacy of Seletracetam Used as Adjunctive Treatment Using a Flexible Dosing Scheme of 4 to 80 mg b.i.d. in Subjects Aged 16 Years or Older Suffering From Epilepsy||UCB Pharma||Withdrawn|May 2008|||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|16 Years|N/A||||May 2012|May 25, 2012|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00175851||193723|
NCT00176098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-KliMa-2005-1|Hypnosis for Eye Surgery|Correlation of Stress, Patient Comfort and Safety to Bispectral Index in Patients Under Hypnosis for Cataract Surgery||Heidelberg University||Recruiting|September 2005|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|10 Years|95 Years|No|||September 2005|February 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176098||193704|
NCT00176085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K107|Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH|Pharmacokinetics of 11-Nor-9-carboxy-D9-tetrahydrocannabinol (THCCOOH) and Its Acyl-glucuronide (THCCOOH-GLu) After Intravenous Administration of THCCOOH in Healthy Human Subjects||Heidelberg University||Completed|October 2004|March 2005|Actual|||Phase 1|Observational|Time Perspective: Prospective||1||10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176085||193705|
NCT00171418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919BUS26|Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).|Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).||Novartis||Completed|June 2003|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|18 Years|N/A||||January 2008|January 24, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171418||194063|
NCT00171431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919AUS33|The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)|The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)||Novartis||Terminated|November 2004|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|18 Years|N/A|No|||April 2012|April 19, 2012|September 12, 2005|||This study was terminated early in May 2006 due to low patient enrollment|No||https://clinicaltrials.gov/show/NCT00171431||194062|
NCT00171886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995BES02|Octreotide Efficacy and Safety in First-line Acromegalic Patients|Octreotide Efficacy and Safety in First-line Acromegalic Patients||Novartis||Suspended|July 2002|||May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||March 2011|March 23, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171886||194027|
NCT00172757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701298|Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan|Risk Factors of Colorectal Cancer in Taiwan-With Special Reference to the Association With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations||National Taiwan University Hospital||Recruiting|January 2002|June 2005||||Phase 2|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2003|November 25, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172757||193960|
NCT00172185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-005|Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)|A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)||Shire|Yes|Completed|January 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||September 2014|November 10, 2015|September 13, 2005|Yes|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00172185||194004|
NCT00172484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700808|North Taiwan Stroke Center for Prevention and Treatment|North Taiwan Stroke Center for Prevention and Treatment||National Taiwan University Hospital||Completed|January 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|250|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172484||193981|
NCT00173758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701276|The Expression of IL-15 and Its Receptor in Decidua|The Expression of IL-15 and Its Receptor in Uterine NK Cells and Clinical Applications||National Taiwan University Hospital||Recruiting|September 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||June 2005|December 20, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173758||193883|
NCT00173732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700629|Establishment of Comprehensive Genetic Analysis From a Single Cell|Establishment of Comprehensive Genetic Analysis From a Single Cell||National Taiwan University Hospital||Not yet recruiting|September 2005|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||50|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173732||193885|
NCT00173745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100012973|Treatment of Drooling With Type A Botulinum Toxin in Children With Cerebral Palsy|Treatment of Drooling With Type A Botulinum Toxin A in Children With Cerebral Palsy||National Taiwan University Hospital||Recruiting|June 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|6 Years|21 Years|No|||July 2002|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173745||193884|
NCT00174031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701434|Prevalence and Profiles of Sports Injury in Taiwanese Adolescent Baseball Players|Prevalence and Profiles of Sports Injury in Taiwanese Adolescent Baseball Players||National Taiwan University Hospital||Recruiting|December 1993|||||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||800|||Male|10 Years|19 Years|Accepts Healthy Volunteers|||September 1993|November 25, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174031||193862|
NCT00174044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700706|Control Strategies of the Locomotor System During Obstacle-Crossing in Stroke Patients|Control Strategies of the Locomotor System During Obstacle-Crossing in Stroke Patients||National Taiwan University Hospital||Recruiting|August 2005|July 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||120|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||August 2005|December 20, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174044||193861|
NCT00174057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700644|The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves’Ophthalmopathy|||National Taiwan University Hospital||Recruiting|August 2005|July 2006||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||50|||Both|20 Years|N/A|No|||June 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174057||193860|
NCT00175357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P99-0209|NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction|North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users||University of British Columbia|Yes|Completed|March 2005|April 2009|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|25 Years|N/A|No|||September 2014|September 25, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00175357||193761|
NCT00175617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0060|Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss|Efficacy of Therapy With the Anti-androgen Spironolactone Compared to Topical Minoxidil in Female Pattern Hair Loss||University of British Columbia|No|Recruiting|September 2005|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|75 Years|No|||November 2011|November 15, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175617||193741|
NCT00175630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70078|The Effect of Femoral Nerve Block on Postoperative Opioid Use After Anterior Cruciate Ligament (ACL) Reconstruction|Effect of Femoral Nerve Block on Opioid Requirements Following Anterior Cruciate Ligament Reconstruction: A Double Blind, Prospective Randomized Controlled Trial||University of British Columbia|No|Active, not recruiting|December 2010|September 2016|Anticipated|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|12 Years|17 Years|No|||April 2015|April 14, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175630||193740|
NCT00175903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01175|Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy|A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.||UCB Pharma|No|Completed|February 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1701|||Both|16 Years|N/A|No|||March 2015|March 12, 2015|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00175903||193719|
NCT00176150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K075|Drug Transport in Patients With Anorexia Nervosa|Influence of Cholesterol Plasma Levels on Drug Transport in Patients With Anorexia Nervosa||Heidelberg University||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Female|15 Years|30 Years||||April 2003|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176150||193700|
NCT00176137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLCCG01/95|Preoperative Twice Daily Chemoradiation in Addition to Chemotherapy Prior to Surgery in Stage III Non-Small Cell Lung Cancer (NSCLC)|Cisplatin/Etoposide Followed by Twice-Daily Chemoradiation (hfRT/CT) Versus Cisplatin/Etoposide Alone Before Surgery in Stage III Non-Small Cell Lung Cancer. A Phase III Trial of the German Lung Cancer Cooperative Group (GLCCG)||Heidelberg University||Completed|October 1995|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|69 Years|No|||April 2008|April 21, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176137||193701|
NCT00176124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniKlinMa-TF-2001-1|Leukocyte Depletion of Autologous Whole Blood|Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients|LDAWB-2001|Heidelberg University|Yes|Completed|April 2001|September 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1089|||Both|18 Years|85 Years|No|||June 2008|June 9, 2008|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00176124||193702|
NCT00171496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400A2419|Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients|A Six-month Open Label, Multicenter, Randomized Study to Evaluate the Incidence of New Onset Diabetes Mellitus and Glucose Metabolism in Patients Receiving Cyclosporine Microemulsion With C-2 Monitoring Versus Tacrolimus After de Novo Kidney Transplantation||Novartis||Completed|October 2003|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|693|||Both|18 Years|70 Years|No|||January 2011|January 28, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00171496||194057|
NCT00176111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nervstim001|Effects of Local Anesthetic or Saline Solution on Peripheral Nerve Stimulation – a Randomised Study|Effects of Local Anesthetic or Saline Solution on Peripheral Nerve Stimulation – a Randomised, Double-Blind, Multicenter Study About the Stimulability of Anesthetized Nerves||Heidelberg University||Terminated|January 2004|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2004|November 15, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176111||193703|
NCT00171470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919DUS46|The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.|The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.||Novartis||Completed|April 2005|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|18 Years|N/A||||January 2008|January 31, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171470||194059|
NCT00171444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631DFR06|Comparison of Two Treatment Strategies in Hypertensive Patients|A 8-week Comparison, in a General Practice Setting, Between Two Treatment Strategies With Valsartan and Valsartan/HCTZ Aiming at Normalizing de Novo Hypertensive Patients Who Are Not Adequately Controlled With Their Monotherapy or Biotherapy Treatment or Experiencing Unacceptable Side-effects, According to Their Baseline Blood Pressure||Novartis||Completed|June 2004|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|4445|||Both|18 Years|N/A||||September 2005|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171444||194061|
NCT00171457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919DUS45|The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.|The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.||Novartis||Completed|April 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A||||October 2007|October 9, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171457||194060|
NCT00172770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93621700617|The Establishment of the Early Intervention Program for Patients With Schizophrenia|||National Taiwan University Hospital||Recruiting|August 2004|July 2006||||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||20|||Both|N/A|N/A|No|||September 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172770||193959|
NCT00172783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940201|PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period|PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period||National Taiwan University Hospital||Recruiting|June 2005|December 2005||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||460|||Both|3 Months|15 Years|Accepts Healthy Volunteers|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172783||193958|
NCT00173199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700526|The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation|The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation||National Taiwan University Hospital||Recruiting|June 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||150|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|November 29, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173199||193926|
NCT00173212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700522|Proliferation of Endometrial Stromal Cells in Adenomyosis|||National Taiwan University Hospital||Active, not recruiting|September 2005|March 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||45|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||May 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173212||193925|
NCT00173485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700636|The Study of Infection and Cell Inflammation in Peritoneal Dialysate|||National Taiwan University Hospital||Recruiting|June 2005|June 2009||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|18 Years|80 Years|No|||June 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173485||193904|
NCT00173498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700672|Common Allergens in Skin Tests for Adult Atopic Dermatitis|Common Allergens in Skin Tests for Adult Atopic Dermatitis||National Taiwan University Hospital||Recruiting|July 2005|October 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|16 Years|60 Years|No|||July 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173498||193903|
NCT00173511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700701|Cardiovascular Events in Patients With CAD During Emergent Endoscopy for Upper Gastrointestinal Bleeding|||National Taiwan University Hospital||Recruiting|July 2005|February 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|20 Years|N/A|No|||July 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173511||193902|
NCT00182741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441172|Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer|Phase II Study of DN-101 (High Dose Pulse Calcitriol), Mitoxantrone, Prednisone in Androgen-Independent Prostate Cancer (AIPC)||OHSU Knight Cancer Institute|Yes|Completed|September 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||October 2009|May 24, 2012|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00182741||193216|
NCT00182754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N04C2|Octreotide in Treating Patients With Cancer-Related Malignant Ascites|An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LARDepot) for Symptomatic Ascites in Cancer Patients||Alliance for Clinical Trials in Oncology|Yes|Completed|October 2005|March 2013|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00182754||193215|
NCT00173472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700674|Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer|Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer||National Taiwan University Hospital||Active, not recruiting|July 2002|July 2005||||Phase 3|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||200|||Both|18 Years|75 Years|No|||July 2002|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173472||193905|
NCT00174850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4984|Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction|A 14 Week Open-Label Study to Evaluate the Tolerability of Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction in Generalized Anxiety Disorder Patients||State University of New York - Upstate Medical University||Completed|July 2004|May 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2008|September 17, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00174850||193799|
NCT00174863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5378|Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer|Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study|ODYSSEY|Sanofi||Completed|October 2003|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|232|||Male|18 Years|N/A|No|||December 2008|December 22, 2008|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174863||193798|
NCT00175084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL58008-1188|Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers|Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers||Tufts University|No|Completed|October 2004|December 2012|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|30|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00175084||193781|
NCT00183729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH064196-02|Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults|Memantine for Enhancement of Rehabilitation Efficacy and Prevention of Major Depressive Disorder in Older Adults||University of Pittsburgh||Completed|August 2005|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|60 Years|N/A|No|||March 2012|March 23, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183729||193142|
NCT00184002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13NHL-02-3|Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas|A Phase II Study Of Pegylated Liposomal Doxorubicin (Doxil) In Combination With Rituxan, Cyclophosphamide, Vincristine and Prednisone (DR-COP) In Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas||University of Southern California||Active, not recruiting|January 2003|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00184002||193121|
NCT00184366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCAC|Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis|Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab||Norwegian University of Science and Technology|No|Terminated|May 2005|July 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|96|||Both|18 Years|N/A|No|Non-Probability Sample|patients of both genders, over the age of 18 years who have been suffering from moderate        to severe plaque psoriasis for more than six months and who are eligible for efalizumab        treatment according to current Norwegian guidelines.|January 2012|January 18, 2012|September 13, 2005||No|efalizumab was withdrawn from market; full 2 years follow-up only 14 patients|No||https://clinicaltrials.gov/show/NCT00184366||193093|
NCT00184678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1369|Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency|Effect of Two Years of Treatment With Norditropin® SimpleXx® on Bone Mineral Density in Young Adults With Childhood-Onset Growth Hormone Deficiency||Novo Nordisk A/S|No|Completed|February 2002|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|161|||Both|18 Years|25 Years|No|||June 2012|June 28, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184678||193069|
NCT00184964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/032|Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis|The Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis With Histological Examination of the Resected Specimen||Radboud University||Recruiting|June 2004|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|15|||Both|18 Years|N/A|No|||June 2008|June 3, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184964||193048|
NCT00180882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMBA02|LMBA02 Protocol for Patients With a Burkitt Lymphoma|||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||260|||Both|18 Years|N/A|No|||September 2006|September 7, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180882||193344|
NCT00181233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU Reynolds P2|Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk|Functional Energetics and Imaging for Phenotypic Characterization of Patients at Risk for Sudden Cardiac Death||Johns Hopkins University|No|Recruiting|October 2003|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Patients with contractile dysfunction (EF<45%) on an ischemic or non-ischemic basis        undergoing clinically-indicated ICD implantation for primary prevention of sudden cardiac        death (SCD)|November 2015|November 11, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00181233||193318|
NCT00171522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919EUS49|Preference of Tegaserod vs. PEG 3350 in Patients With Constipation|A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation||Novartis||Completed|May 2005|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||52|||Female|18 Years|64 Years||||March 2016|March 2, 2016|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171522||194055|
NCT00171535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2308|Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension|A Study to Evaluate the Safety and Efficacy of Valsartan/Amlodipine Compared to Lisinopril/Hydrochlorothiazide Given Once Daily for 6 Weeks is Patients With Severe Hypertension||Novartis||Completed|October 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|130|||Both|18 Years|N/A||||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171535||194054|
NCT00171509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400A2421|Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients|A Multicenter, Randomized Open-label Pilot Study to Explore the Benefit of a Conversion From a Twice a Day Administration of Cyclosporine Microemulsion to a Once a Day Administration and to Identify the C2 Ranges to Target After Conversion in Stable Liver Transplant Recipients||Novartis||Completed|May 2004|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|61|||Both|18 Years|70 Years||||January 2011|January 31, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00171509||194056|
NCT00171899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571ACA09|Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)|Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML||Novartis||Completed|April 2005|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171899||194026|
NCT00171483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919BUS30|Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).|Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).||Novartis||Completed|January 2004|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|70 Years||||January 2008|January 24, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171483||194058|
NCT00172796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940202|Pancreatic Islet Function, Insulin Sensitivity, and Chronic Complications in Pre-Diabetes|||National Taiwan University Hospital||Recruiting|April 2005|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A||||April 2005|March 29, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172796||193957|
NCT00173225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700531|Sputum and Plasma Levels of Nociceptin and Substance P in Patients With Asthma, COPD and Chronic Cough|Association Between Sputum and Plasma Levels of Nociceptin and Substance P With Cough Severity and Airway Hyperreactivity in Patients With Asthma, COPD and Chronic Cough||National Taiwan University Hospital||Recruiting|June 2005|June 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173225||193924|
NCT00183001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0048|Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification|Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification||National Institute on Aging (NIA)||Completed|October 2001|October 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||452|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 13, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183001||193197|
NCT00183014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0049|Caminemos! Trial to Increase Walking Among Sedentary Older Latinos|Trial to Increase Walking Among Sedentary Older Latinos||National Institute on Aging (NIA)||Completed|September 2005|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 16, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183014||193196|
NCT00183274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065963|Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR|Short-term Versus Long-term Treatment in Generalized Anxiety Disorder||National Institute of Mental Health (NIMH)|Yes|Completed|January 2004|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|N/A|No|||September 2008|October 12, 2010|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183274||193176|
NCT00174512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001226|A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade|A Methodological Open-Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarisation and QT Interval At Fixed Heart Rate Under Autonomic Blockade||Pfizer||Completed|March 2005|June 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||36|||Both|18 Years|75 Years|No|||November 2006|November 7, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00174512||193825|
NCT00174525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI#585|Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease|A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD||Pharmacology Research Institute||Active, not recruiting|April 2005|April 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|85 Years||||May 2012|May 8, 2012|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00174525||193824|
NCT00174538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR007111|Codeine in Sickle Cell Disease|The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease||PriCara, Unit of Ortho-McNeil, Inc.||Completed|March 2005|December 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|75 Years|No|||July 2005|June 29, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174538||193823|
NCT00174551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20031050|Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD|The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD||Rainier Associates||Active, not recruiting|November 2003|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||September 2005|September 7, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174551||193822|
NCT00175097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 58008-1785|Soybean Based Diets and CVD Risk Factors|Impact of Different Forms of Soybean Based Foods on Cardiovascular Disease Risk Factors in Hypercholesterolemic Subjects.||Tufts University|No|Completed|June 2001|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|50 Years|N/A|No|||November 2014|November 26, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175097||193780|
NCT00184691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHRETARD-1106|Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years|Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone Which Will be Started Randomly at the Ages of 2 to 5, in Children Diagnosed of IUGR||Novo Nordisk A/S|No|Completed|April 1999|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|78|||Both|2 Years|5 Years|No|||July 2012|July 10, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184691||193068|
NCT00172874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700313|Cross-Cultural Validity of EDI-1 Among Clinical and Non-Clinical Taiwanese Population|Cross-Cultural Validity of EDI-1 Among Clinical and Non-Clinical Taiwanese Population||National Taiwan University Hospital|Yes|Completed|January 1998|December 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Clinical patients with eating disorders, other psychiatric disorders, and students|December 2008|December 29, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172874||193951|
NCT00172887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700311|Needs Assessment of Long-Term Care for Psychiatric Patients|||National Taiwan University Hospital||Recruiting|March 2005|July 2005||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2005|October 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172887||193950|
NCT00172900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700320|MRS and DTI of White Matter in Alzheimer's Disease|MR Spectroscopy and Diffusion Tensor Imaging of White Matter in Alzheimer's Disease||National Taiwan University Hospital||Recruiting|June 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||40|||Both|55 Years|95 Years|Accepts Healthy Volunteers|||June 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172900||193949|
NCT00181246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021288|Efficacy of Transdermal Fentanyl for Chronic Neuropathic Pain|||Johns Hopkins University||Completed|October 2003|September 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||53|||Both|18 Years|75 Years|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00181246||193317|
NCT00181207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_000202|Airway Clearance for Prevention of COPD Exacerbation|A Randomized, Sham-controlled, Double-blinded Pilot Study to Assess the Effects of High Frequency Chest Wall Oscillation (HFCWO) Therapy in Patients With Chronic Bronchitis||Johns Hopkins University||Active, not recruiting|May 2004|December 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|||Anticipated|50|||Both|45 Years|85 Years|No|||June 2011|March 29, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00181207||193320|
NCT00181220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valproic Acid NPC|Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma|Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma||Johns Hopkins University||Recruiting|April 2004|September 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|No|||September 2005|August 21, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181220||193319|
NCT00171912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BAU12|Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes|Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes||Novartis||Completed|September 2004|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|16 Years|80 Years|No|||November 2012|November 29, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171912||194025|
NCT00172497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700926|Aggressive Acts Among Patients With Schizophrenia|A Study of the Aggressive Acts Among Patients With Schizophrenia||National Taiwan University Hospital||Suspended|August 2001|October 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||450|||Both|N/A|N/A|No|||August 2001|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172497||193980|
NCT00172198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183CL1|Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.|A Prospective, Controlled, Randomized, Study Evaluating the Clinical Efficacy, Including Nutritional Status, Immune Function and Safety of Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.||National Taiwan University Hospital||Recruiting|March 2005|March 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|15 Years|75 Years|No|||January 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172198||194003|
NCT00172510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701060|Mutation Analysis of 17α-Hydroxylase|||National Taiwan University Hospital||Recruiting|August 2004|August 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||25|||Both|N/A|N/A|No|||August 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172510||193979|
NCT00182260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-MCT-38147|A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Treatment of Patients With Chronic GERD|ELVIS (Esophagitis-Laparoscopy Versus Inhibitors of Secretion) A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication (LNF) Versus Omeprazole for Treatment of Patients With Chronic Gastro-Esophageal Reflux Disease (GERD)||McMaster University||Completed|January 2000|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|70 Years|No|||November 2012|November 14, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00182260||193252|
NCT00182481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#97-1549|LOMA: Long-Term Management of Asthma|Long Term Management of Asthma (LOMA) Study- How Useful is the Sputum Count Compared With the Usual Clincal Variables?||McMaster University||Completed|September 1999|September 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||112|||Both|18 Years|70 Years|No|||October 2003|December 15, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00182481||193235|
NCT00174096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700624|The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma|||National Taiwan University Hospital||Recruiting|August 2005|July 2006||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|30 Years|75 Years|No|||June 2005|March 30, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174096||193857|
NCT00174109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700625|The Relation of Microtubule-Associated Protein 2 and Cell Migration|||National Taiwan University Hospital||Recruiting|August 2005|July 2006||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||30|||Both|30 Years|75 Years|No|||June 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174109||193856|
NCT00174122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701115|Procalcitonin in Diagnosing Bacteremia in the Emergency Department|||National Taiwan University Hospital||Recruiting|July 2005|June 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|15 Years|N/A|No|||September 2004|February 28, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174122||193855|
NCT00183261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIN504/A5218|Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection|A Randomized Phase II Study of Therapeutic Immunization and Treatment Interruption Among Subjects Who Began Potent Antiretroviral Therapy Within 30 Days of Diagnosis of Acute or Recent HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|October 2010|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|55 Years|No|||June 2013|June 7, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183261||193177|
NCT00183482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069940|Family Cognitive Behavioral Therapy for Preventing Depression in Children|Family Cognitive Behavioral Prevention of Depression in Children of Parents With a History of Major Depressive Disorder||Vanderbilt University|Yes|Recruiting|August 2014|February 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|750|||Both|10 Years|N/A|No|||November 2015|November 17, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183482||193160|
NCT00171990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810AAU01|Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes|Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes||Novartis||Completed|January 2003|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1461|||Both|18 Years|N/A||||August 2013|August 14, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00171990||194019|
NCT00172003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EDE15|Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis|Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis||Novartis|Yes|Completed|September 2004|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00172003||194018|
NCT00172250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701046|The Study of Relationship of Plasma Concentrations of Folic Acid, Vitamin B and Homocysteine With Carotid Atherosclerosis and Endothelium-Dependent Vasodilatation of Geriatric and Young Patients in the Ambulatory Care Department of NTUH|||National Taiwan University Hospital||Completed|September 2003|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A||||August 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172250||193999|
NCT00172224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32244|Dynamic Magnetic Resonance (MR) Study in Evaluating the Vertebral Bone Marrow Perfusion and Its Related Research|Dynamic MR Study in Evaluating the Vertebral Bone Marrow Perfusion and Its Related Research||National Taiwan University Hospital|Yes|Completed|August 2002|||||Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|subjects with osteoporosis|November 2012|November 13, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172224||194001|
NCT00172237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5460|Proprioception and Eye-head Coordination for the Cervical Spine|Proprioception and Eye-head Coordination for the Cervical Spine||National Taiwan University Hospital|No|Recruiting|December 2009|July 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|45 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|45-64 year-old healthy adults and adults with neck pain|January 2010|January 28, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172237||194000|
NCT00180895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rituximab childhood|Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL|A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|June 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|6 Months|20 Years|No|||September 2006|September 7, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180895||193343|
NCT00180908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS94|Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children|SFOP-OS94: Multicentric Randomised Phase III Trial Comparing Efficacy of Preoperative High-Dose Methotrexate Plus Doxorubicin to Efficacy of High-Dose Methotrexate Plus Etoposide and Ifosfamide, in Children and Adolescents Osteosarcoma||Gustave Roussy, Cancer Campus, Grand Paris||Completed|June 1994|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||226|||Both|N/A|20 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180908||193342|
NCT00172861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700304|Cyclooxygenase-2-Associated Factors and Gastric Carcinogenesis Mechanisms-Clinical Association and Genomic Investigation|||National Taiwan University Hospital||Recruiting|January 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||20|||Both|18 Years|N/A|No|||March 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172861||193952|
NCT00172913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700324|Aberration-Free Refraction Correction|National Taiwan University Hospital||National Taiwan University Hospital||Recruiting|June 2005|July 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172913||193948|
NCT00172926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700326|Study on the Relationship Between Physical Constitution and Diseases|Cross Sectional Study on Relationship Between Physical Constitution and Diseases in the Integrative Chinese Medicine and Western Medicine||National Taiwan University Hospital||Recruiting|May 2005|April 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||1000|||Both|18 Years|N/A|No|||June 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172926||193947|
NCT00173251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700605|The Difference in Presentation Level of Variant Receptors in Female Breast Tissue in Macromastia and Micromastia|||National Taiwan University Hospital||Not yet recruiting|January 2006|August 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173251||193922|
NCT00181584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-194|Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer|Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer||Massachusetts General Hospital||Completed|September 2003|||February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Male|18 Years|N/A|No|||July 2013|July 9, 2013|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181584||193304|
NCT00181571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-p-000037|A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder|A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder||Massachusetts General Hospital|Yes|Completed|June 2003|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|297|||Both|18 Years|55 Years|No|||June 2013|June 26, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181571||193305|
NCT00181779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000153|Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder|Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder||Massachusetts General Hospital||Completed|February 2003|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|6 Years|17 Years|No|||October 2013|October 21, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00181779||193289|
NCT00182000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001325|Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy|A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy||Massachusetts General Hospital||Completed|November 2003|||January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|September 13, 2005||No||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00182000||193272|
NCT00182494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2417|Diabetes Prevention Program in Schizophrenia [DPPS]|A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus.||McMaster University||Recruiting|February 2005|January 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|18 Years|65 Years|No|||July 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00182494||193234|
NCT00182767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00140|Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer|A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane||National Cancer Institute (NCI)|Yes|Completed|January 2006|May 2014|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||February 2014|February 11, 2016|September 15, 2005|Yes|Yes||No|June 17, 2015|https://clinicaltrials.gov/show/NCT00182767||193214|
NCT00175383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-1213|Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer|A Randomized Trial of Short Versus Long Acting LHRH Agonist Preparation Prior to Transperineal Implantation of the Prostate||University of British Columbia|No|Recruiting|June 2004|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|N/A|N/A|No|||April 2013|April 9, 2013|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175383||193759|
NCT00175396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-60050|Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy|A Randomized Phase III Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by High Dose 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by 125-Iodine Brachytherapy Implant Boost for Patients With Intermediate and High Risk Localized Prostate Cancer||University of British Columbia|No|Active, not recruiting|May 2004|June 2014|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|N/A|No|||March 2014|March 14, 2014|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175396||193758|
NCT00175370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-0106|Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus|Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus; Removal of Catheter Followed by 2 Days Compared With 7 Days Intravenous Vancomycin||University of British Columbia|No|Completed|September 2000|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|60|||Both|16 Years|N/A|No|||June 2008|June 18, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00175370||193760|
NCT00182975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0047|Effects of Dehydroepiandrosterone (DHEA) in Humans|Is DHEA Replacement Beneficial?||National Institute on Aging (NIA)||Completed|September 2002|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|142|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||August 2008|August 21, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182975||193199|
NCT00182988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0082|Alzheimer's Caregiver Communication Study|Alzheimer's Caregiver Ratings of Communication & Coping Behavior||National Institute on Aging (NIA)||Completed|October 2004|December 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|140|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 24, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00182988||193198|
NCT00183742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-00-6|Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)|Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)||University of Southern California||Completed|December 2000|May 2006|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00183742||193141|
NCT00184015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4K-05-1|Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)|||University of Southern California||Active, not recruiting|August 2005|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00184015||193120|
NCT00184028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7H-03-1|Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck|Phase II Trial of Taxotere and Oxaliplatin Combination Chemotherapy in Squamous Cell Carcinoma of the Head and Neck||University of Southern California||Terminated|September 2004|July 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 12, 2005|Yes|Yes|Insufficient Accrual|No|March 21, 2013|https://clinicaltrials.gov/show/NCT00184028||193119|
NCT00184041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9L-03-1|Intensified Post Remission Therapy Containing PEG-Asparaginase|Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase.||University of Southern California|Yes|Completed|July 2004|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|55 Years|No|||May 2014|May 20, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00184041||193118|
NCT00172016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EHU01|A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates|A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates||Novartis||Completed|January 2004|||April 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Male|18 Years|N/A|No|||April 2012|April 27, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00172016||194017|
NCT00172029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446ETR01|Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid|Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid||Novartis||Completed|April 2003|||September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Female|18 Years|N/A|No|||March 2010|March 26, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00172029||194016|
NCT00172263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701054|The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes|||National Taiwan University Hospital||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2012|December 6, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172263||193998|
NCT00172276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701241|Angiotensin Converting Enzyme Gene Polymorphism in Children With Idiopathic Nephrotic Syndrome|||National Taiwan University Hospital||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|1 Year|10 Years||||June 2005|September 14, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172276||193997|
NCT00172562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701183|Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image|||National Taiwan University Hospital||Recruiting||||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2005|February 28, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172562||193975|
NCT00172939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700332|Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model|Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model||National Taiwan University Hospital||Recruiting|June 2005|January 2008||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2005|September 14, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172939||193946|
NCT00173264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700601|Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis|||National Taiwan University Hospital||Recruiting|June 2005|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||30|||Both|N/A|N/A|No|||May 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173264||193921|
NCT00173537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700712|Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension|Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension||National Taiwan University Hospital||Recruiting|July 2005|December 2013|Anticipated|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2012|December 26, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00173537||193900|
NCT00181792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000278|Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta|Family Risk Analysis of Substance Use in ADHD Youth Treated With Concerta||Massachusetts General Hospital|Yes|Completed|May 2005|August 2009|Actual|August 2009|Actual|Phase 4|Observational|Observational Model: Family-Based||1|Actual|70|||Both|6 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|First-degree relative between the ages of 6-55 years of a family member (proband) between        the ages of 12-17 with the DSM-IV diagnosis of ADHD|May 2012|May 2, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181792||193288|
NCT00182013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P-000259|Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder|||Massachusetts General Hospital||Completed|June 2001|||February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|6 Years|18 Years|No|||June 2013|June 12, 2013|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00182013||193271|
NCT00182273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-24|Canalith Repositioning Procedure for BPPV in Primary Care|Treatment of Benign Paroxysmal Positional Vertigo With the Canalith Repositioning Procedure in Family Practice: A Randomized Controlled Trial||McMaster University||Completed|January 2002|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182273||193251|
NCT00174902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 32-68277|The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress|The Effect of Beta-Blockers, Aspirin, and Natural Habituation on Procoagulant Activity, Expression of Cellular Adhesion Molecules, and Endothelial Activation in Response to Acute Mental Stress: a Randomized Controlled Trial.||Swiss Federal Institute of Technology||Active, not recruiting|October 2003|August 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||80|||Both|40 Years|55 Years|Accepts Healthy Volunteers|||October 2003|October 24, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174902||193795|
NCT00175136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030239|A Comparison of the Design of Tibia Stems in Cemented Total Knee Arthroplasty - Wedge Stem Versus I-beam Stem.|A Comparison of the Design of Tibia Stems - Wedge Stem Versus I-beam Stem. A Prospective Randomized Migration- and Bone Density Study on Primary Cemented Knee Implants.||University of Aarhus|No|Completed|January 2005|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|70 Years|N/A|No|||October 2010|October 12, 2010|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00175136||193777|
NCT00175149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX 0203 DK|Active Vitamin D Effect on Left Ventricular Hypertrophy|The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction||University of Aarhus|No|Terminated|January 2002|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||December 2015|December 6, 2015|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175149||193776|
NCT00175409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0248|Breast Feeding Analgesia in Preterm Infants|Breast Feeding Analgesia in Preterm Infants||University of British Columbia|No|Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|37 Weeks|Accepts Healthy Volunteers|||April 2011|April 11, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175409||193757|
NCT00175656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-70522|Titanium Elastic Nails in the Treatment of Pediatric Femur Fractures|Titanium Elastic Nails in the Treatment of Paediatric Femoral Fractures: A Prospective Randomized Clinical Trial of Eliminating Nail Protrusion to Decrease Soft Tissue Complications||University of British Columbia|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|4 Years|15 Years|No|||April 2011|April 12, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175656||193738|
NCT00183495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH065599-01|Understanding Treatment Adherence Among Individuals With Bipolar Disorder|Determinants and Manifestation of Illness Behavior in Promoting Treatment Adherence Among Individuals With Bipolar Depression||Case Western Reserve University|No|Completed|March 2004|August 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|140|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with bipolar disorder receiving treatment at a Community Mental Health Clinic        in Northeast Ohio.|June 2013|July 1, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183495||193159|
NCT00176176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|235/04|Investigation of Cognitive Function Before and After Induced Ventricular Fibrillation in Electrophysiological (EP) Study|Change of EEG Activity and Cerebral Circulation During Induced Ventricular Fibrillation and Investigation of Cognitive Function Before and After Induced Ventricular Fibrillation in EP Study||Heidelberg University||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||30|||Both|18 Years|N/A||||November 2004|October 11, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176176||193698|
NCT00176189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cercon-giant|Clinical Performance of Extended All-Ceramic Fixed Partial Dentures Based on Zircon-Oxide Ceramics.|Clinical Performance of Extended All-Ceramic Fixed Partial Dentures Based on Zircon-Oxide Ceramics||Heidelberg University||Completed|February 2005|December 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||September 2006|September 25, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176189||193697|
NCT00155064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700632|Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism|||National Taiwan University Hospital||Completed|July 2002|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|100|||Both|18 Years|80 Years|No|||December 2014|December 15, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155064||195288|
NCT00155077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700771|The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients|The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients||National Taiwan University Hospital||Recruiting|June 2004|June 2009||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||200|||Female|18 Years|85 Years|No|||June 2004|October 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155077||195287|
NCT00172315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701422|Proton Magnetic Resonance Spectroscopy (1H MRS) in Evaluating the Bone Marrow, Muscle and Adipose Tissue on Normal and Human Immunodeficiency Virus Infected Subjects|Proton Magnetic Resonance Spectroscopy (1H MRS) in Evaluating the Bone Marrow, Muscle and Adipose Tissue on Normal and Human Immunodeficiency Virus Infected Subjects, With Serial Follow-Up||National Taiwan University Hospital||Recruiting|December 2003|||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2005|March 28, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172315||193994|
NCT00172289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701395|Measurement of Pulse Wave Velocity in Spinal Cord Injury and Stroke Patients|Measurement of Pulse Wave Velocity in Spinal Cord Injury and Stroke Patients||National Taiwan University Hospital||Recruiting|August 2004|December 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|January 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172289||193996|
NCT00172302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930105|Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?|Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?||National Taiwan University Hospital||Not yet recruiting|November 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|20 Years|80 Years|No|||May 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172302||193995|
NCT00172575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701184|Differentiation of Malig. & Ben. Solitary Pulm. Nodules & Prediction of Clin. Outcome Using Perfus. Analysis of DCEMRI|||National Taiwan University Hospital||Recruiting|December 2004|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|20 Years|N/A|No|||December 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172575||193974|
NCT00172952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700339|The Role of SNP of ECM and MMP on the Development of Pathological High Myopia|National Taiwan University Hospital||National Taiwan University Hospital||Recruiting|June 2005|January 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||600|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172952||193945|
NCT00172965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700341|Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography|Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography||National Taiwan University Hospital||Recruiting|August 2004|June 2005||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172965||193944|
NCT00173277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700610|Screening for CRC Using a Mixed Strategy of Sigmoidoscopy and Colonoscopy in Average-Risk Population According to Age|Screening for CRC Using a Mixed Strategy of Sigmoidoscopy and Colonoscopy in Average-Risk Population According to Age||National Taiwan University Hospital||Recruiting|June 2003|July 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||2500|||Both|50 Years|N/A|No|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173277||193920|
NCT00173550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700710|Perception and Attitude Toward Estrogen Therapy Among Surgically Menopausal Women|Perception and Attitude Toward Estrogen Therapy Among Operated Women With Premature or Immature Menopause||National Taiwan University Hospital||Recruiting|August 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||200|||Female|20 Years|50 Years|No|||July 2005|January 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173550||193899|
NCT00173797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701232|Comparison of Psychometric Properties of Three Depression Measures in Patients With Stroke|Comparison of Psychometric Properties of Three Depression Measures in Patients With Stroke||National Taiwan University Hospital||Recruiting|August 2005|April 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|No|||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173797||193880|
NCT00173810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701234|Development of a Refined Version of the Stroke Rehabilitation Assessment of Movement Scale for Stroke Patients|Development of a Refined Version of the Stroke Rehabilitation Assessment of Movement Scale for Stroke Patients||National Taiwan University Hospital||Recruiting|August 2005|April 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|No|||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173810||193879|
NCT00174161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700617|The Symptom Experience of Women With Perimenstrual Syndrome;Women's Health Related Quality of Life.|||National Taiwan University Hospital||Recruiting|August 2005|December 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1000|||Female|20 Years|N/A|Accepts Healthy Volunteers|||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174161||193852|
NCT00174590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-USA-248|Treatment of Major Depressive Disorder With Psychotic Features.|Treatment of Major Depressive Disorder With Psychotic Features With Risperidone Monotherapy; Risperidone and Sertraline; or Haloperidol and Sertraline||Rush University Medical Center||Terminated|September 2001|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|70 Years|No|||December 2007|December 28, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174590||193819|
NCT00175162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030249|A Comparison of Fixation Method in Total Knee Arthroplasty - Low Viscosity Versus High Viscosity Bone Cement|A Comparison of Fixation Method in Total Knee Arthroplasty - Low Viscosity Versus High Viscosity Bone Cement. A Prospective Randomized Migration- and Bone Density Study on Primary Cemented Knee Implants.||University of Aarhus|No|Withdrawn|June 2007|December 2010||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|70 Years|N/A|No|||October 2010|October 13, 2010|September 10, 2005||No|No financing possible|No||https://clinicaltrials.gov/show/NCT00175162||193775|
NCT00175175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHFMR #200100791|Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients||University of Alberta||Completed|March 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||220|||Both|50 Years|N/A|No|||September 2006|September 13, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00175175||193774|
NCT00175708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-70531|Pedobarographic Assessments of Clubfoot Treated Patients|Pedobarographic Assessments of Clubfoot Treated Patients||University of British Columbia|No|Recruiting|September 2005|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Months|5 Years|No|Probability Sample|Clubfoot patients seen at BC Children's Hospital in Vancouver.|July 2015|July 30, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175708||193734|
NCT00175669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-0160|Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking|Randomized Controlled Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking||University of British Columbia|No|Completed|August 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|32|||Both|5 Years|15 Years|No|||April 2011|April 11, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175669||193737|
NCT00175682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO4-0343|Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study|Prophylactic Value of Prazosin in Reducing the Objective and Subjective Measures of Autonomic Dysreflexia Provoked by Ejaculation in Men With Spinal Cord Injury||University of British Columbia|No|Recruiting|December 2004|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 15, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175682||193736|
NCT00175929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01114|A Study of Brivaracetam in Subjects With Partial Onset Seizures|A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized||UCB Pharma|Yes|Completed|May 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|157|||Both|16 Years|65 Years|No|||April 2015|April 10, 2015|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00175929||193717|
NCT00176202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-BIP-407|Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar|Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar||University of Illinois at Chicago|Yes|Completed|April 2003|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|10 Years|20 Years|No|||November 2015|November 4, 2015|September 9, 2005||No||No|June 2, 2015|https://clinicaltrials.gov/show/NCT00176202||193696|
NCT00176215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG-FL-1|Clinical Comparison of RPDs Retained by Conical and Galvanoformed Double Crowns.|||Heidelberg University||Active, not recruiting|May 2003|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176215||193695|
NCT00171249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A0109E2|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia||Novartis||Completed|August 2004|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00171249||194076|
NCT00155090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700788|Proton Magnetic Resonance Spectroscopy of Normal Breast Tissues in Women Volunteers|||National Taiwan University Hospital||Recruiting|January 2005|December 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||80|||Female|30 Years|N/A|Accepts Healthy Volunteers|||January 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155090||195286|
NCT00155103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700927|Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma|Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma||National Taiwan University Hospital||Recruiting|August 2004|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||1600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2005|March 20, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155103||195285|
NCT00173043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701208|The Role of Insulin Resistance in PCOS|The Role of Insulin Resistance and Adiponectin in the Pathogenesis of Polycystic Ovary Syndrome||National Taiwan University Hospital||Recruiting|October 2004|August 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||500|||Female|12 Years|50 Years|Accepts Healthy Volunteers|||October 2004|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173043||193938|
NCT00172601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701198|Mobilization Techniques in Patients With Frozen Shoulder: a Randomized Multiple-Treatment Trial|||National Taiwan University Hospital||Recruiting|August 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||December 2004|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172601||193972|
NCT00172978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700346|Indications and Related Factors for Caesarean Delivery, 1996 to 2002.|||National Taiwan University Hospital||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Female|10 Years|60 Years||||April 2005|October 26, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172978||193943|
NCT00172588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701197|Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis|||National Taiwan University Hospital||Recruiting|January 2005|October 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||40|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||December 2004|November 25, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172588||193973|
NCT00172991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100208420|Adiponectin Gene and Coronary Artery Disease|||National Taiwan University Hospital||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|20 Years|90 Years||||January 2003|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172991||193942|
NCT00173004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200200767|Angiotensinogen Gene and Hypertension|||National Taiwan University Hospital||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|20 Years|90 Years||||February 2003|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173004||193941|
NCT00173329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700615|The Quality of Life of Patients With Severe Illnesses|||National Taiwan University Hospital||Recruiting|August 2005|July 2006||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A|No|||September 2005|October 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173329||193916|
NCT00173615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700820|Extracorporeal Membrane Oxygenation Effect in Prolonged Cardiopulmonary Resuscitation|||National Taiwan University Hospital||Completed|April 1996|December 2006|Actual|||N/A|Observational|N/A||||100|||Both|18 Years|85 Years|No|||January 2009|January 16, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173615||193894|
NCT00173290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700613|Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function|||National Taiwan University Hospital||Recruiting|July 2004|December 2006|Anticipated|||N/A|Observational|N/A|||Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2005|June 2, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173290||193919|
NCT00173303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700528|The Diagnostic Efficacy of Computer-Aided Detection (CAD) in Full-Field Digital Mammography (FFDM)- A Prospective Study|||National Taiwan University Hospital||Not yet recruiting|January 2006|January 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||3000|||Female|20 Years|90 Years|Accepts Healthy Volunteers|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173303||193918|
NCT00173563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700731|Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children|Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children||National Taiwan University Hospital||Recruiting|January 2005|September 2005|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|10|||Both|2 Years|50 Years|Accepts Healthy Volunteers|||August 2005|November 30, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173563||193898|
NCT00173823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700840|Malnutrition and Inflammation in Dialysis Patients in Taiwan|Malnutrition and Inflammation in Taiwan: Prospective Outcome Evaluation Method (MIT-POEM) in Dialysis Patients||National Taiwan University Hospital||Recruiting|June 2004|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1500|||Both|18 Years|90 Years|No|||August 2005|March 10, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173823||193878|
NCT00174174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920203l|Provigil (Modafinil) Study by Taiwan Biotech Co.|A Placebo Control, Double Blind, Cross Over Study of Modafinil in Patients With Narcolepsy||National Taiwan University Hospital||Completed|September 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|12 Years|65 Years|No|||October 2004|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00174174||193851|
NCT00174187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-MET-9002-0009|Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy|Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety.||Pfizer|No|Terminated|September 2000|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|11 Years|17 Years|No|||November 2012|November 5, 2012|September 9, 2005||No|See termination reason in detailed description.|No|September 11, 2012|https://clinicaltrials.gov/show/NCT00174187||193850|Results for secondary and other pre-specified endpoints (except IGF-1) are reported for only up to 3 years because data beyond Year 3 was not summarized as the study was terminated due to Good Clinical Practice (GCP) non-compliance issues.
NCT00174603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET305|Treatment of Depression With Quetiapine|Treatment of Major Depressive Disorder With Psychotic Features With Quetiapine Monotherapy; Quetiapine and Citalopram; or Haloperidol and Citalopram||Rush University Medical Center|No|Terminated|August 2005|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|75 Years|No|||December 2007|December 28, 2007|September 9, 2005|||Unable to recruit subjects|No||https://clinicaltrials.gov/show/NCT00174603||193818|
NCT00174915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-009|Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.|A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.|APEX|Takeda|No|Completed|February 2003|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1072|||Both|18 Years|85 Years|No|||January 2012|January 31, 2012|September 9, 2005|No|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00174915||193794|
NCT00174928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-042|A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease|A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multi-center Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Neonates With Clinically-Evident Gastroesophageal Reflux Disease.||Takeda|No|Completed|May 2005|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|28 Days|No|||July 2010|July 20, 2010|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00174928||193793|
NCT00175422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B04-0785|Parents Helping Infants Study: Educational Intervention to Change the Knowledge, Attitudes and Behaviour of New Parents About Early Infant Crying|The Period of PURPLE Crying: An Educational Intervention to Change the Knowledge, Attitudes and Behaviour of New Parents About Early Infant Crying||University of British Columbia||Completed|May 2005|January 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|1833|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 15, 2010|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175422||193756|
NCT00171301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2402E1|Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)|1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration)|ESCALATOR|Novartis|Yes|Completed|June 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|233|||Both|2 Years|N/A|No|||August 2011|August 28, 2011|September 12, 2005||No||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00171301||194072|An internal review revealed major Good Clinical Practice violations at 2 sites in Saudi Arabia: 602 for core + extension, 601 for 2-yr extension. Therefore data was excluded (completely for 602 + partly for 601) from analyses.
NCT00175695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-0230|Disease Modification in Toxaemia of Pregnancy|A Safety and Efficacy Trial of Recombinant Human Activated Protein C in Both Early-onset Pre-eclampsia and Severe Postpartum Pre-eclampsia.||University of British Columbia|No|Completed|December 2004|October 2010|Actual|October 2010|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|40 Years|No|Probability Sample|Women with pre-eclampsia ('toxaemia of pregnancy').|February 2011|February 3, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175695||193735|
NCT00175942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0229.3|Risk Indicators in Patients With Ventricular Fibrillation During Acute Myocardial Infarction|Indicators of Coagulation Activation and Inflammation Contributing to Ventricular Fibrillation Complicating Acute Myocardial Infarction||Heidelberg University||Recruiting|February 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|No|||May 2005|September 10, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00175942||193716|
NCT00175955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01142|Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia|An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years.||UCB Pharma||Completed|May 2005|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||70|||Both|18 Years|80 Years||||September 2009|December 5, 2013|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00175955||193715|
NCT00171262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BES02|Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers|Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers||Novartis||Completed|August 2004|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|75 Years|No|||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171262||194075|
NCT00171691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-PN-309|Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Safety of Diclofenac Sodium Gel in Knee Osteoarthritis||Novartis||Completed|October 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|35 Years|N/A|No|||April 2012|April 20, 2012|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00171691||194042|
NCT00172042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446G2419|A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)|A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer||Novartis||Completed|March 2005|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|437|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|September 13, 2005||No||No|June 16, 2011|https://clinicaltrials.gov/show/NCT00172042||194015|
NCT00159588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/534|Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly?|Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly? A Randomized Multi-centre Follow-up.||Norwegian University of Science and Technology|No|Completed|January 2004|December 2007|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|70 Years|No|||February 2014|February 27, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159588||194954|
NCT00173082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700402|Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism|Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism||National Taiwan University Hospital||Recruiting|June 2005|July 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|80 Years|No|||November 2007|November 28, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173082||193935|
NCT00173355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700618|Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans|Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002||National Taiwan University Hospital||Recruiting|June 2005|August 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||12|||Both|N/A|18 Years|No|||August 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173355||193914|
NCT00173342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700620|Congenital or Idiopathic Complete Right Bundle Branch Block: Physiological Significance and Molecular Characterization|Congenital or Idiopathic Complete Right Bundle Branch Block: Physiological Significance and Molecular Characterization||National Taiwan University Hospital||Recruiting|June 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||50|||Both|8 Years|25 Years|No|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173342||193915|
NCT00173017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261700712|The Physiological Impact of N95 Masks on Medical Staff|The Physiological Impact of N95 Masks on Medical Staff||National Taiwan University Hospital||Completed|August 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173017||193940|
NCT00173316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700614|Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions|The Role of Vascular Endothelial Growth Factor-C (VEGF-C) and Its Receptors Induced Lymphangiogenesis on the Carcinogenesis of Oral Cancers and Premalignant Lesions||National Taiwan University Hospital||Recruiting|August 2004|June 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173316||193917|
NCT00173888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920303|Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer||National Taiwan University Hospital|No|Completed|July 2003|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||December 2012|December 4, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00173888||193873|
NCT00173875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940107|Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer|A Phase II Study to Evaluate the Efficacy and Safety of Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer (NSCLC)||National Taiwan University Hospital|No|Completed|March 2005|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|20 Years|N/A|No|||July 2005|July 27, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00173875||193874|
NCT00173576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700732|Clinical Study of SARS in Children|Clinical Study of SARS in Children||National Taiwan University Hospital||Completed|April 2003|March 2005||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||800|||Both|1 Month|18 Years|No|||August 2005|October 26, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173576||193897|
NCT00173589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700802|Inflammatory and Fibrotic Markers and Atrial Fibrillation|||National Taiwan University Hospital||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|20 Years|90 Years||||August 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173589||193896|
NCT00173602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700811|The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients|The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients||National Taiwan University Hospital||Recruiting|September 2005|August 2007|Anticipated|||N/A|Observational|N/A|||Anticipated|200|||Both|18 Years|90 Years|No|||August 2005|November 30, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173602||193895|
NCT00173836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yeun-Chung Chang|Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount|Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount||National Taiwan University Hospital|No|Completed|August 2003|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|122|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Nasopharyngeal cancer patients|August 2009|September 4, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00173836||193877|
NCT00173849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700656|The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma|||National Taiwan University Hospital||Not yet recruiting|January 2006|July 2006||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|30 Years|75 Years|No|||June 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173849||193876|
NCT00174200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001229|Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone|A Randomized, Double-Blind, Crossover Add-On Study To Assess The Differential Sensitivity Of 2 Spatial Working Memory Tests (The Groton Maze Learning Test [GMLT] And The Motor Delayed Response Test [MDR]) In Non-Agitated, Antipsychotic Drug-Naive First-Episode Schizophrenic Or Schizophreniform Patients Treated With Risperidone 2 Mg Daily Or Placebo||Pfizer||Completed|December 2004|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|50 Years|No|||July 2008|July 11, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174200||193849|
NCT00174213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701066|Validity and Reliability in Measuring Iliotibial Tract by Using Ultrasound|Validity and Reliability in Measuring Iliotibial Tract by Using Ultrasound||National Taiwan University Hospital||Recruiting|September 1994|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|40|||Both|18 Years|65 Years|No|||August 1994|August 29, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00174213||193848|
NCT00174226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001245|Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar|Eight-Week, Double-Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy And Safety Trial Of Atomoxetine, Atomoxetine Plus Buspirone, And Placebo In Adults With Attention Deficit Hyperactivity Disorder||Pfizer||Completed|November 2004|January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|241|||Both|18 Years|55 Years|No|||July 2008|July 10, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174226||193847|
NCT00174616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C_8601|CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision|Phase 2 Study of Weekly Oxaliplatin and Capecitabine (XELOX) in Combination With Preoperative Radiotherapy in Patients With MRI Defined Locally Advanced Rectal Cancer||Sanofi||Completed|July 2003|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174616||193817|
NCT00174629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_ES1_302|GILT Docetaxel - Non-Small Cell Lung Cancer|Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients||Sanofi||Completed|June 2001|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|449|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174629||193816|
NCT00175188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030240|An RSA and DEXA Study on Migration of Proximal Interphalangeal (PIP) Joint Prostheses of the Hand|A Roentgen Stereophotogrammetric Analysis and DEXA Study on Migration of Proximal Interphalangeal Joint Prostheses of the Hand. A Randomised Prospective Study of Cemented Versus Non-cemented Implants||University of Aarhus|No|Completed|June 2004|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2010|October 12, 2010|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00175188||193773|
NCT00175201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL-05-01|Cost Efficacy of a Clinical Pathway to Patients Undergoing Hip and Knee Replacement Surgery|From Efficacy to Effectiveness of a Proactive Perioperative Care and Rehabilitation in Patients Undergoing Primary Total Hip or Knee Replacement||University of Aarhus||Recruiting|May 2005|March 2008||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||May 2006|May 4, 2006|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00175201||193772|
NCT00175994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001649-41|Bioavailability and Metabolism of Voriconazole in Relation to Its Modulation by the CYP2C19 Genetic Polymorphism|Bioavailability and Metabolism of Voriconazole as a Function of the CYP2C19 Genotype||Heidelberg University||Completed|July 2005|July 2006|Actual|||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2007|April 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00175994||193712|
NCT00171314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345D2406|The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer|The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer||Novartis||Completed|March 2004|||November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|527|||Female|18 Years|N/A|No|||March 2012|March 19, 2012|September 12, 2005||No||No|December 15, 2011|https://clinicaltrials.gov/show/NCT00171314||194071|
NCT00171327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BRU01|Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction|Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction||Novartis||Completed|July 2004|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|213|||Both|30 Years|65 Years|No|||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171327||194070|
NCT00175981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K058|Interaction Between Fluvoxamine and Sildenafil|Pharmacokinetic and Pharmacodynamic Evaluation of the Interaction Between Fluvoxamine and Sildenafil in Healthy Males||Heidelberg University||Completed|February 2003|November 2004||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00175981||193713|
NCT00171275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BCZ01|Fluvastatin in the Therapy of Acute Coronary Syndrome|Fluvastatin in the Therapy of Acute Coronary Syndrome||Novartis||Completed|November 2003|||February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Both|18 Years|75 Years|No|||July 2010|July 15, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171275||194074|
NCT00175968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K008|Influence of Bedrest and Hypocaloric Nutrition on Endothelium-Dependent Vasoreactivity|Influence of Bed-Rest and Hypocaloric Nutrition on Endothelium-Dependent Vasoreactivity||Heidelberg University||Completed|March 2001|April 2003||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00175968||193714|
NCT00171236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320B2301|Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia|Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia||Novartis||Completed|October 2001|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|84|||Both|10 Years|16 Years|No|||September 2005|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171236||194077|
NCT00172341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930309|Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children|Efficacy and Safety of Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children: A Double-Blind, Randomized, and Placebo-Controlled Study||National Taiwan University Hospital||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|5 Years|15 Years|No|||July 2004|November 2, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172341||193992|
NCT00172354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930502|Hydrocortisone in Patients of Out-of-hospital Cardiac Arrest|Hydrocortisone in Patients of Out-of-hospital Cardiac Arrest||National Taiwan University Hospital||Completed|October 2004|May 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172354||193991|
NCT00172614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701201|The Roles of Cytokines in the Mechanism of Insulin Resistance and Energy Balance|||National Taiwan University Hospital||Recruiting|December 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2004|March 28, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172614||193971|
NCT00160615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01020|Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method|Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method||UCB Pharma||Completed|September 2001|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||97|||Both|16 Years|N/A||||September 2009|March 3, 2015|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160615||194875|
NCT00160628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01099|Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy|A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Levetiracetam as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy for Bridging Purpose With a Similar Study on Caucasian Epileptic Subjects||UCB Pharma||Completed|March 2004|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||100|||Both|18 Years|N/A||||February 2010|November 25, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160628||194874|
NCT00173095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700413|The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients|The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients||National Taiwan University Hospital||Recruiting|January 2005|January 2008||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||20|||Both|20 Years|65 Years|No|||January 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173095||193934|
NCT00173394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700630|The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients|||National Taiwan University Hospital||Recruiting|August 2005|December 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||250|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||July 2005|December 18, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173394||193911|
NCT00173368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700651|Study of Endoscopic Sphincterotomy With Needle Knife Papillotome in Patients of Ampullary Impacted Stone|||National Taiwan University Hospital||Completed|January 2003|March 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||20|||Both|18 Years|85 Years|No|||August 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173368||193913|
NCT00173381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700657|The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis|||National Taiwan University Hospital||Recruiting|August 2004|||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|30 Years|75 Years|No|||June 2005|March 29, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173381||193912|
NCT00173628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700824|Autoantibodies in Patients With Type 1 Diabetes Mellitus|||National Taiwan University Hospital||Recruiting|January 1990|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|N/A|20 Years|Accepts Healthy Volunteers|||August 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173628||193893|
NCT00173901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900104|Adverse Drug Reactions of Different Brands of Ceftazidime Injection|Adverse Drug Reactions of Different Brands of Ceftazidime Injection||National Taiwan University Hospital||Active, not recruiting|March 2001|April 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||536|||Both|1 Year|95 Years|No|||January 2001|September 13, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173901||193872|
NCT00173914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200000478|The Association of Endothelial Dysfunction and Cardiac Allograft Vasculopathy|||National Taiwan University Hospital||Recruiting|March 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|20 Years|80 Years|No|||September 2005|September 13, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00173914||193871|
NCT00174291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-MET-9002-052|Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy|Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years||Pfizer|No|Terminated|March 2002|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|4 Years|14 Years|No|||October 2012|October 26, 2012|September 9, 2005||No|See termination reason in detailed description.|No|October 26, 2012|https://clinicaltrials.gov/show/NCT00174291||193842|Data for bone mineral density (BMD), bone mineral content (BMC) and IGFBP3 were not analyzed because of change in planned analysis after the study was prematurely terminated due to Good Clinical Practice (GCP) non-compliance issues.
NCT00174304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841029|Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.|An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)|JEWEL II|Pfizer||Completed|October 2004|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1120|||Both|18 Years|80 Years|No|||April 2007|January 6, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174304||193841|
NCT00174265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05772|6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)|A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed Protocol A7501013||Merck Sharp & Dohme Corp.|Yes|Completed|July 2005|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|September 9, 2005|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00174265||193844|
NCT00174278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-8123-018|Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary|Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.||Pfizer||Completed|February 1997|October 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Both|6 Years|N/A|No|||August 2008|August 4, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174278||193843|
NCT00173862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155I1|Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC|A Phase II Study of Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced Transitional Cell Carcinoma||National Taiwan University Hospital|No|Completed|May 2000|June 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2005|July 23, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00173862||193875|
NCT00174239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7231001|Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.|A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.||Pfizer|No|Terminated|July 2004|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|80 Years|No|||May 2007|May 24, 2007|September 9, 2005|||See Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00174239||193846|
NCT00174252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281234|Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age|Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation.||Pfizer|No|Completed|February 2005|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|4 Years|9 Years|No|||June 2009|June 10, 2010|September 9, 2005||No||No|April 2, 2010|https://clinicaltrials.gov/show/NCT00174252||193845|
NCT00174642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3506|Opposing Step-by-step Insulin Reinforcement to Intensified Strategy|Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs|OSIRIS|Sanofi||Completed|December 2004|||December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|811|||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174642||193815|
NCT00174941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-01-005|Long-Term Safety of Febuxostat in Subjects With Gout.|Phase II, Open-Label Study, to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout|FOCUS|Takeda|No|Completed|March 2001|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|116|||Both|18 Years|85 Years|No|||January 2011|January 25, 2011|September 12, 2005|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00174941||193792|
NCT00175721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-50008|Trial Comparing Care in Multiple Clinics Versus Care in a Cardiac, Diabetes and Kidney Care Clinic|Randomized Controlled Trial Comparing Current Care in Multiple Clinics Vs Care in a Novel Cardiac, Diabetes & Kidney Care Clinic||University of British Columbia|No|Completed|December 2005|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|85 Years|No|||March 2014|March 14, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175721||193733|
NCT00176007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A001|Hypoxia Impairs Endothelial Function in HAPEs|Hypoxia Impairs Systemic Endothelial Function in Individuals Prone to High-Altitude Pulmonary Edema.||Heidelberg University||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2005|September 10, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00176007||193711|
NCT00171340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345D2405|Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.|An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy||Novartis|Yes|Completed|May 2003|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1065|||Female|N/A|N/A|No|||April 2012|April 10, 2012|September 12, 2005||No||No|March 22, 2011|https://clinicaltrials.gov/show/NCT00171340||194069|
NCT00171353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ARU01|A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure|A Study to Describe Vascular and Renal Effects and Safety of Valsartan 80 and 160 mg in Arterial Hypertension Patients||Novartis||Completed|July 2004|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|109|||Both|30 Years|65 Years||||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171353||194068|
NCT00171704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345D2407|A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer|A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer||Novartis||Completed|April 2005|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|263|||Female|50 Years|N/A|No|||May 2012|May 1, 2012|September 13, 2005||No||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00171704||194041|The study was designed to investigate the effects of letrozole compared with tamoxifen for 2 years on BMD spine (L2-L4). The study was too small to investigate the comparative efficacy of treatments on disease-free survival or on overall survival.
NCT00171717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400AFR04|Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant|Pilot Study of the Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients Presenting With New Onset Diabetes After the 3rd Month Post-transplant.||Novartis||Completed|February 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|70 Years||||January 2011|January 31, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171717||194040|
NCT00171288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BES03|Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone|Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone||Novartis||Completed|August 2003|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|83|||Both|18 Years|75 Years|No|||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171288||194073|
NCT00171652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-PE-314|Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis||Novartis||Completed|May 2005|October 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|40 Years|N/A|No|||October 2006|October 9, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00171652||194045|
NCT00171665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-PE-315|Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis||Novartis||Completed|May 2005|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|40 Years|N/A|No|||April 2015|April 13, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00171665||194044|
NCT00171678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-PN-310|Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis||Novartis||Completed|October 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|35 Years|N/A|No|||April 2012|April 20, 2012|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00171678||194043|
NCT00172367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930906|Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma|||National Taiwan University Hospital||Withdrawn|January 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|80|||Both|18 Years|N/A|No|||November 2004|September 25, 2008|September 12, 2005|||This study was for National Science Council project. The study was not funded, so the study    was withdrawn.|No||https://clinicaltrials.gov/show/NCT00172367||193990|
NCT00160368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/FR/04.0012|Effects of Potassium Salts on Blood Pressure and Target Organ Damage|Effect of Potassium Bicarbonate and Potassium Chloride on Blood Pressure and Markers of Target Organ Damage in Hypertensives||St George's, University of London||Recruiting|January 2005|March 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|75 Years|No|||April 2007|April 24, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160368||194894|
NCT00173667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182CL1|A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension|A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension||National Taiwan University Hospital||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|70 Years|No|||July 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173667||193890|
NCT00173680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700826|Methylation Status of CD44 Promoter Region in Primary Lung Cancer|||National Taiwan University Hospital||Recruiting|August 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||40|||Both|N/A|N/A|No|||August 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173680||193889|
NCT00173654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700825|Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency|||National Taiwan University Hospital||Recruiting|August 2005|August 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||20|||Both|N/A|N/A|No|||August 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173654||193891|
NCT00173641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700823|The Role of Regulatory T Cell in Patients With Type 1 Diabetes Mellitus|||National Taiwan University Hospital||Recruiting|September 2005|August 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|1 Month|20 Years|Accepts Healthy Volunteers|||September 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173641||193892|
NCT00174356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4161001|PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients|A Phase 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel And Carboplatin As First-Line Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer||Pfizer||Completed|December 2002|October 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||39|||Both|18 Years|N/A|No|||January 2006|November 6, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174356||193837|
NCT00174317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COXA-0508-261|Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip|Clinical Protocol For A Multicentre, Double-Blind, Randomised, Parallel Group Study To Compare The Efficacy and Tolerability Of Celecoxib Vs. Diclofenac In The Treatment Of Subjects With Osteoarthritis Of The Hip Requiring Joint Replacement Therapy||Pfizer||Completed|August 2003|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|45 Years|N/A|No|||December 2005|November 30, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174317||193840|
NCT00174330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841026|Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia|A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And Safety Of Dual Therapy With Atorvastatin Plus Amlodipine When Compared Amlodipine Therapy Alone In The Treatment Of Subjects With Concurrent Hyperlipidemia And Hypertension.||Pfizer||Completed|May 2005|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||330|||Both|18 Years|75 Years|No|||February 2007|February 20, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174330||193839|
NCT00174343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971-ONC-0028-095|Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients|Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.||Pfizer||Completed|November 2001|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Female|N/A|N/A|No|||April 2011|April 21, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174343||193838|
NCT00174668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3504|Insulin Glulisine in Diabetes Mellitus, Type 2|52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy|GINGER|Sanofi||Completed|November 2004|||November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|311|||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174668||193813|
NCT00174681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4042|Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes|Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes||Sanofi||Completed|April 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||390|||Both|40 Years|75 Years|No|||January 2011|January 10, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174681||193812|
NCT00174655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP56976_PR_315|BIG 02/98 Docetaxel - Breast Cancer|An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-positive Breast Cancer Patients.||Sanofi||Completed|June 1998|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2887|||Female|18 Years|70 Years|No|||November 2011|November 9, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174655||193814|
NCT00174954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-01-013|Magnetic Resonance Imaging in Subjects With Gouty Tophi|A Study to Validate Magnetic Resonance Imaging (MRI) in the Quantitative Assessment of Gouty Tophi.||Takeda|No|Completed|March 2002|January 2003|Actual|January 2003|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|32|None Retained|None taken or retained.|Both|18 Years|85 Years|No|Non-Probability Sample|Subjects with palpable gouty tophi.|July 2010|July 22, 2010|September 12, 2005|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00174954||193791|
NCT00175214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHFMR#2000000389|Controlled Trial to Increase Detection and Treatment of Osteoporosis in Older Patients With a Wrist Fracture|Controlled Trial to Increase Detection and Treatment of Osteoporosis in Older Patients With a Wrist Fracture||University of Alberta||Completed|January 2001|January 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||160|||Both|50 Years|N/A|No|||September 2005|September 10, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00175214||193771|
NCT00175435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0027|Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator|Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator||University of British Columbia|No|Completed|August 2005|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|39|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||October 2010|October 29, 2010|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175435||193755|
NCT00175448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-0249|Comparison of Physiotherapy Versus Home Exercise Following Hip Replacement Surgery|A Randomized Controlled Trial of Outpatient Physiotherapy Versus a Self-Administered Home Exercise Program Following Discharge Home From Total Hip Arthroplasty||University of British Columbia||Completed|September 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|144|||Both|N/A|N/A|No|||September 2005|September 24, 2008|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175448||193754|
NCT00175474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0036|Comparison of a Minimally Invasive Technique for Total Knee Replacement to a Standard Technique|Minimally Invasive Total Knee Arthroplasty Versus a Standard Surgical Technique: a Single-blinded Single-centre Randomized Controlled Trial||University of British Columbia|No|Completed|September 2005|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|19 Years|N/A|No|||October 2011|October 12, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00175474||193752|
NCT00175734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04-0007|Interactive Studies of Endstage Diabetic Dialysis Patients|Integrated Studies in Vascular Reactivity and Anemia Correction Therapy in Endstage Kidney Disease Patients||University of British Columbia|No|Active, not recruiting|August 2005|December 2013|Anticipated|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00175734||193732|
NCT00176033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K026|Influence of Drug Transporter Expression on the Pharmacokinetics of the HIV Protease Inhibitor Kaletra|Influence of Drug Transporter Expression on the Pharmacokinetics of the HIV Protease Inhibitor Kaletra (Lopinavir/Ritonavir) and on the Concentration Relations Between Plasma, Blood Cells, Saliva and Urine||Heidelberg University||Completed|January 2005|||||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176033||193709|
NCT00172120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1-11-016|Open Label Extension|An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)|TRES|Shire|No|Completed|January 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Female|45 Years|N/A|No|||September 2005|November 11, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00172120||194009|
NCT00172133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1-11-002|Open Label Extension Study of PREOS|An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)|OLES|Shire|Yes|Completed|October 2001|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1683|||Female|45 Years|N/A|No|||August 2008|November 11, 2015|September 12, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00172133||194008|
NCT00171730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2201E1|An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly|Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients||Novartis|No|Completed|August 2004|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||November 2014|November 7, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00171730||194039|
NCT00171743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400AIT03|Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients|Switch From Tacrolimus to Cyclosporine Microemulsion: Immunosuppressive Agents and Diabetes Management in Liver Transplant Recipients in Maintenance (DIALIVER)||Novartis||Completed|April 2004|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|47|||Both|18 Years|N/A||||January 2011|January 31, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171743||194038|
NCT00172068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GDE05|Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow|Efficacy and Tolerability of Intravenous Zometa® (Zoledronic Acid) 4 mg in Primary Breast Cancer Patients With Disseminated Tumor Cells in Bone Marrow. A Prospective, Randomized, Parallel Group, Open-label, Clinical Pilot Study.|MRD-1|Novartis||Terminated|January 2002|||November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Female|18 Years|N/A|No|||December 2009|December 21, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00172068||194013|
NCT00172328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930306|Antibody Response and Immune Memory 15-18 Years After HBV Vaccination|||National Taiwan University Hospital||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|15 Years|18 Years|Accepts Healthy Volunteers|||September 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172328||193993|
NCT00172380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930911|Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III|Phase II Study Evaluating Docetaxel and CDDP as Neoadjuvant Chemotherapy Prior to Surgery, Followed by Adjuvant Docetaxel Plus CDDP in Chemonaive Patients With NSCLC Stage III||National Taiwan University Hospital|No|Completed|February 2005|March 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|20 Years|N/A|No|||December 2012|December 19, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172380||193989|
NCT00172393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9311700446|Long Term Outcomes of EV71 CNS Infection|Long Term Outcomes of EV71 Central Nervous System Infection||National Taiwan University Hospital||Recruiting|January 2003|May 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||150|||Both|1 Month|18 Years|Accepts Healthy Volunteers|||June 2005|October 3, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172393||193988|
NCT00160056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB2-001|The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity|The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity in Subjects With Homozygous Arg16 and gly16 Polymorphism of the β2-adrenergic Receptor||Radboud University||Completed|April 2005|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00160056||194918|
NCT00174382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2501026|Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia|An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia||Pfizer|No|Terminated|June 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Both|50 Years|N/A|No|||March 2015|March 4, 2015|September 8, 2005||No|See Detailed Description|No|April 24, 2009|https://clinicaltrials.gov/show/NCT00174382||193835|
NCT00174395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1601107|A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine|A Multi-Center, Open-Label, Randomized, Parallel-Group Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine in Early Intervention.||Pfizer||Completed|March 2005|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|18 Years|65 Years|No|||October 2007|October 31, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174395||193834|
NCT00173953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90M010|Lymphocytic Subsets and Cytokine Production With H. Pylori Infection|Lymphocytic Subsets and Cytokine Production in the Gastric Samples of Patients With Helicobacter Pylori Infection||National Taiwan University Hospital||Completed|January 2001|October 2001||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|18 Years|75 Years|No|||December 2000|September 13, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173953||193868|
NCT00173966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701155|A Case Control Study to Investigate the Possible Association Between Atrial Fibrillation and Endothelium Dysfunction by Using Flow-Mediated Vasodilation Method|||National Taiwan University Hospital||Recruiting|January 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2004|September 13, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173966||193867|
NCT00173927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701156|Images in Extracranial Artery Stenosis|The Differences in Images of Vertebral Artery Stenosis and Carotid Artery Stenosis Pre- and Post-Percutaneous Transluminal Angioplasty and the Gene Expression Patterns in Peripheral White Blood Cells||National Taiwan University Hospital||Recruiting|March 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|30 Years|90 Years|No|||September 2005|October 29, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173927||193870|
NCT00173940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100203282|Collection of Blood and Urine Specimens From Volunteers Utilizing Health Examination Services|||National Taiwan University Hospital||Recruiting||||||N/A|Observational|N/A|||||||Both|18 Years|N/A||||July 2002|November 27, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173940||193869|
NCT00174733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6163|Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered for Twelve Weeks Either in a Once-Daily Regimen in the Morning (160 μg qd AM) or in a Twice Daily Regimen (80 μg Bid) in Adults and Adolescents With Mild to Moderate Persistent Asthma Treated Previously With Inhaled Corticosteroids||Sanofi||Completed|July 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|456|||Both|12 Years|N/A|No|||April 2009|April 7, 2009|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174733||193808|
NCT00158301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH072737|Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents|Continuation Phase CBT for Youth With MDD||University of Texas Southwestern Medical Center|Yes|Completed|September 2004|February 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|72|||Both|11 Years|18 Years|No|||November 2013|November 7, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158301||195052|
NCT00158106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA ref. 02/11/04|Assessing the Effectiveness of Communication Therapy in the North West (The ACT NoW Pilot Study)|Assessing the Effectiveness of Communication Therapy in the North West (The ACT NoW Pilot Study)||NHS Health Technology Assessment Programme||Completed|February 2005|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||60|||Both|18 Years|N/A|No|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00158106||195067|
NCT00158847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO30001|Modification Of Disease Outcome In COPD|Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.||Leiden University Medical Center||Terminated|April 2000|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|45 Years|75 Years|No|||January 2005|January 10, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158847||195011|
NCT00158860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS2100275|A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients|An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6- Month Study of the Efficacy and Safety of Valaciclovir 1g Once Daily vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Subjects||GlaxoSmithKline||Completed|June 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|315|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158860||195010|
NCT00159185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMOS|Epidemiology Study in Major Orthopaedic Surgery|Epidemiology Study in Major Orthopaedic Surgery||Hoersholm Hospital||Completed|January 2004|May 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||500|||Both|18 Years|N/A|No|||September 2005|July 20, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00159185||194985|
NCT00159432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-04-10|Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer|Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer||University of Southern California||Completed|February 2005|March 2013|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|September 7, 2005|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00159432||194966|
NCT00159445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-03-12|Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer|Phase II Study of Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer||University of Southern California||Completed|March 2004|November 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|53|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00159445||194965|
NCT00159757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281122|12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients|12 Week Open Label, Multicenter, Non-Comparative Switch Study Evaluating Efficacy, Tolerability And Safety Of Oral Ziprasidone In Treatment Of Patients Suffering From Schizophrenia Who Have Already Been Treated With An Other Antipsychotic.||Pfizer||Terminated|November 2003|February 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||August 2007|August 1, 2007|September 8, 2005|||See Detailed Description for Termination Reason|No||https://clinicaltrials.gov/show/NCT00159757||194941|
NCT00159770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281079|Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients|Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.||Pfizer||Completed|November 2001|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||290|||Both|18 Years|N/A|No|||December 2006|December 28, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159770||194940|
NCT00160108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR300-3|A Dietary Intervention- Randomized Controlled Trial (DIRECT) Study; BGU-Harvard–Robarts Collaboration|||The S. Daniel Abraham International Center for Health and Nutrition||Active, not recruiting|July 2005|July 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|40 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 11, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160108||194914|
NCT00160121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-401|Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease|A Phase IV, Open-Label, Multi-Center Trial Evaluating the Efficacy of Fosrenol Compared to Existing Therapy in Adults With End Stage Renal Disease Treated for Hyperphosphatemia||Shire||Completed|January 2005|November 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2500|||Both|18 Years|N/A|No|||December 2013|September 3, 2014|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160121||194913|
NCT00160784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-1997|Arthroscopy and Manipulation vs a Home Therapy Program in the Treatment of Adhesive Capsulitis|Arthroscopy and Manipulation vs a Home Therapy Program in the Treatment of Adhesive Capsulitis of the Shoulder - A Prospective Randomized Study||University of Florida|No|Completed|March 1997|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||November 2012|December 4, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160784||194862|
NCT00161083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLDS WS 00-08|UDCA for Symptomatic Gallstone Disease|Studie Naar De Effectiviteit Van Ursodeoxycholzuur Ter Preventie Van Galsteen-Gerelateerde Klachten Bij patiënten in Afwachting Van Een Cholecystectomie||UMC Utrecht||Completed|November 2001|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|75 Years|No|||September 2005|July 26, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00161083||194839|
NCT00170339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR-04-2404|Bone Density and Serum Testosterone in Male Methadone Maintained Patients|Bone Density and Serum Testosterone in Male Methadone Maintained Patients||Minneapolis Medical Research Foundation||Completed|April 2005|April 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||60|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 20, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170339||194142|
NCT00170690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3401000|Preference Study With Elderly Patients Recurrent Ovarian Cancer|Präferenz-Studie Bei älteren Patientinnen Mit Ovarialkarzinomrezidiv: Treosulfan Oral vs. intravenös||North Eastern Germany Society of Gynaecologic Oncology|No|Completed|August 2004|April 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Female|70 Years|N/A|No|||May 2013|May 31, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00170690||194117|
NCT00160667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01162|A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)|A Double Blind, Randomized, Placebo-controlled, Parallel Group Study, for the Assessment of Efficacy, Safety and Tolerability of Brivaracetam at the Doses of 200 mg/Day and 400 mg/Day, in Subjects (at Least 18 Years Old) Suffering From Post-herpetic Neuralgia (PHN)||UCB Pharma|No|Completed|October 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|N/A|No|||October 2010|October 15, 2010|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160667||194871|
NCT00160992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CePO-ITA-01|Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients|Phase I Study of in Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma||University of Lausanne Hospitals||Suspended|July 2004|August 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|N/A|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160992||194846|
NCT00161252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5276|Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly|Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly Men||Rutgers, The State University of New Jersey||Withdrawn|March 2005|December 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|0|||Male|75 Years|N/A|No|Probability Sample|To compare overall and prostate cancer specific survival among elderly patients receiving        primary androgen deprivation therapy and conservative management for non-metastatic        prostate cancer diagnosed in 1992-1999|May 2011|May 27, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161252||194826|
NCT00157183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/03|Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation|Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation||Bayside Health||Completed|March 2003|March 2006|Actual|March 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|59|||Both|18 Years|75 Years|No|||September 2005|December 4, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00157183||195128|
NCT00157131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550201|Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients|A Study To Evaluate the Safety and Efficacy of Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS 4IU VH S/D) to Adhere Tissues and Improve Wound Healing||Baxter Healthcare Corporation||Completed|June 2004|September 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|65 Years|No|||February 2008|February 6, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00157131||195132|
NCT00157144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186/04|Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005|||Bayside Health||Completed|October 2004|August 2006|Actual|August 2006|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|16 Years|N/A|No|||March 2014|March 6, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00157144||195131|
NCT00157157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060103|Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients|Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A||Baxalta US Inc.|Yes|Completed|April 2004|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|N/A|6 Years|No|||June 2014|June 26, 2015|September 9, 2005|No|Yes||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00157157||195130|
NCT00157794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_2|EnTRINSIC - EnPulse Trial on Search AV+ Influence|EnPulse Trial on Search AV+ Influence||Medtronic Bakken Research Center||Terminated|February 2004|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|September 9, 2005|||Protocol pre-specified interim analysis showed that difference between groups was too small to    reach significance.|No||https://clinicaltrials.gov/show/NCT00157794||195091|
NCT00157534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-04-001|A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection||BioWest Therapeutics Inc||Completed|October 2004|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Both|18 Years|65 Years|No|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157534||195111|
NCT00157547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001784|Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression|The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder||Massachusetts General Hospital|Yes|Completed|April 2003|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|65 Years|No|||May 2008|May 23, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00157547||195110|
NCT00158314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060417-01|Cognitive Behavioral Therapy for Treatment of Pathological Gambling|Cognitive Behavioral Treatment for Pathological Gambling||University of Connecticut Health Center|Yes|Completed|March 1998|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||231|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158314||195051|
NCT00158327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059395|Telephone-Based Care Management Program for Individuals With Anxiety Disorders|The RELAX Trial: Reducing Limitations From Anxiety in Primary Care||University of Pittsburgh||Completed|March 2004|February 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|64 Years|No|||January 2014|January 21, 2014|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158327||195050|
NCT00158587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIF23|Eight Week Primaquine Regimen for the Treatment of Vivax Malaria|A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.||Gates Malaria Partnership|Yes|Completed|April 2004|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|3 Years|70 Years|No|||June 2007|July 3, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00158587||195031|
NCT00158873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101653|Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects|A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation||GlaxoSmithKline||Completed|September 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||224|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158873||195009|
NCT00159172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parkostim|Safety and Efficacy of Motor Cortex Stimulation in the Treatment of Advanced Parkinson Disease|Phase 1 Study of Motor Cortex Stimulation in the Treatment of Advanced Parkinson Disease||Assistance Publique - Hôpitaux de Paris||Recruiting|September 2005|May 2008||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||10|||Both|18 Years|70 Years|No|||September 2005|March 5, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00159172||194986|
NCT00159198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC01107|Amyotrophic Lateral Sclerosis and Frontotemporal Dementia|Genetic Linkage in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia||Assistance Publique - Hôpitaux de Paris|Yes|Terminated|September 2002|June 2007|Actual|||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|400|Samples With DNA|Whole blood|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients and relatives coming in outcome clinics. They are all volunteers and agree to        give a blood sample and signing an informed consent explaining the study.|September 2008|September 5, 2008|September 7, 2005||No|Completed|No||https://clinicaltrials.gov/show/NCT00159198||194984|
NCT00159471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3P-03-2|Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.|A Pilot Trial of Germline Polymorphisms as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.||University of Southern California|Yes|Terminated|February 2005|July 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005|||Insufficient Accrual|No||https://clinicaltrials.gov/show/NCT00159471||194963|
NCT00159458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-03-1|Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer|Phase II Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer||University of Southern California||Terminated|July 2003|December 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|September 8, 2005|||Insufficient Accrual|||https://clinicaltrials.gov/show/NCT00159458||194964|
NCT00159783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05857|40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)|A Double-Blind, 40-Week Continuation Study Evaluating the Safety of Asenapine and Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501007 (Secondary Title: ARES)||Merck Sharp & Dohme Corp.|Yes|Completed|July 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|September 8, 2005|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00159783||194939|
NCT00159796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07009|3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)|A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501005 (Secondary Title: ARES)||Merck Sharp & Dohme Corp.|Yes|Completed|December 2004|April 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|489|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00159796||194938|
NCT00160134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S320.2.002|Study to Evaluate Cardiac Hemodynamics and Safety of SLV320 in Subjects With Congestive Heart Failure|A Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Parallel Group, Single Dose Study to Evaluate Cardiac Hemodynamics and Safety During Right Heart Catheterization of Three IV Doses of SLV320 in Subjects With Congestive Heart Failure Requiring Diuretic Treatment||Solvay Pharmaceuticals||Completed|January 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|85 Years|No|||January 2009|January 29, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160134||194912|
NCT00160147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.3.016|Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type|A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type||Solvay Pharmaceuticals||Terminated|December 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|65 Years|90 Years|No|||June 2009|January 29, 2015|September 8, 2005|Yes|Yes|The study was discontinued prematurely on 25 February 2008 due to slow enrollment|No||https://clinicaltrials.gov/show/NCT00160147||194911|
NCT00161330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS 1|Oral Vs Initial Intravenous Antibiotic Treatment of Urinary Tract Infections in Children: a RCT|A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid Vs Initial Iv Ceftriaxone.||University of Padova||Terminated|June 2000|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||440|||Both|2 Months|6 Years|No|||July 2004|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161330||194820|
NCT00160823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-147|Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients|Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital||University Hospital, Geneva||Recruiting|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||102|||Both|18 Years|90 Years|No|||September 2006|September 11, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160823||194859|
NCT00166712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU8789 0811-007|A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression|A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation|Cell220|Northwestern University|Yes|Terminated|April 2005|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|September 9, 2005|Yes|Yes|Study stopped due to lack of efficacy & funding.|No|November 29, 2012|https://clinicaltrials.gov/show/NCT00166712||194415|
NCT00166725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995A2402|Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients|A Randomized, Open Label, Multicenter Study Evaluating the Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients||Novartis||Completed|February 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|80 Years|No|||November 2009|November 18, 2009|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00166725||194414|
NCT00166738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700834|Analysis of Genomic DNA Alterations in Familial Schizophrenia|Analysis of Genomic DNA Alterations in Familial Schizophrenia||National Taiwan University Hospital||Recruiting|September 2005|December 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2005|August 23, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00166738||194413|
NCT00160381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-394|A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids|A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of J867 Versus Placebo in Subjects With Uterine Leiomyomata.||Abbott|Yes|Completed|September 2002|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|432|||Female|18 Years|N/A|No|||May 2008|May 27, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00160381||194893|
NCT00160680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00392|ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)|A Pilot, Open, Monocenter Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months||UCB Pharma||Completed|March 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||100|||Both|18 Years|N/A||||September 2009|December 13, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160680||194870|
NCT00160693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87015|Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis|A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis||UCB Pharma|No|Completed|March 2003|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|402|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|September 6, 2005|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT00160693||194869|
NCT00157170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92/02|The Effects of a Supervised Exercise Program on Self Efficacy of People Living With HIV/AIDS.|The Effects of a Supervised Exercise Program on Self Efficacy, Quality of Life Status, Cardiovascular Fitness and Hospital Readmission Rates of People Living With HIV/AIDS.||Bayside Health||Completed|September 2002|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2005|October 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00157170||195129|
NCT00157612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-1848|A Clinical Pathway for Nursing Home Acquired Pneumonia|A Randomized Control Trial of a Clinical Pathway for Nursing Home Pneumonia.||McMaster University||Completed|January 2001|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||680|||Both|64 Years|N/A|No|||September 2005|July 19, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157612||195105|
NCT00157807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CS_1|Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery|Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery. A Prospective Randomized Multi Center Trial||Medtronic Bakken Research Center||Terminated|September 2005|August 2013|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|75 Years|No|||May 2013|August 22, 2013|September 8, 2005||No|no eligible patients can be found|No||https://clinicaltrials.gov/show/NCT00157807||195090|
NCT00158119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0037|A Comparison of Weighted Vest Exercise and Strength Training|Ameliorating Disability Through Power Training||National Institute on Aging (NIA)||Completed|July 2001|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||160|||Both|65 Years|N/A|No|||July 2010|July 23, 2010|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158119||195066|
NCT00158340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066966|Guided Self-Help Treatment for Binge Eating Disorder|Binge Eating Self-Guided Treatment (BEST)|BEST|Kaiser Permanente|Yes|Completed|August 2004|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|284|||Both|18 Years|50 Years|No|||November 2011|November 4, 2011|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158340||195049|
NCT00158600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02704|A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease|Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.||Sanofi|Yes|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|8 Years|N/A|No|||April 2015|April 6, 2015|September 8, 2005|Yes|Yes||Yes|June 24, 2010|https://clinicaltrials.gov/show/NCT00158600||195030|
NCT00158613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARTCEL 012-99|Study of the Treatment of Articular Repair (STAR)|A Prospective, Longitudinal Within-Patient Evaluation of the Effectiveness (Durability) of Carticel® (Autologous Cultured Chondrocytes) Compared to Non-Carticel Surgical Treatment for Articular Cartilage Defects of the Knee.||Vericel Corporation|No|Completed|March 2000|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158613||195029|
NCT00158886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/517|Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer|A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer||GlaxoSmithKline||Terminated|November 2001|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||36|||Both|18 Years|N/A|No|||May 2009|May 21, 2009|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00158886||195008|
NCT00159484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3c-03-19|Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer|Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (CEPO906AUS10)||University of Southern California|Yes|Active, not recruiting|October 2004|January 2017|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00159484||194962|
NCT00159835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATV-N-98-001|Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD|Atorvastatin Compared With Simvastatin In The Prevention of CHD Morbidity And Mortality In Patients With CHD|IDEAL|Pfizer||Completed|February 1999|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||8600|||Both|N/A|80 Years|No|||April 2015|April 21, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159835||194935|
NCT00159848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA1481115|Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra|Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil||Pfizer||Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||8000|||Male|18 Years|N/A|No|||May 2013|May 2, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00159848||194934|
NCT00159861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481141|The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH|A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension.||Pfizer||Completed|July 2003|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|||Actual|267|||Both|16 Years|N/A|No|||December 2013|December 20, 2013|September 8, 2005|Yes|Yes||No|April 2, 2010|https://clinicaltrials.gov/show/NCT00159861||194933|
NCT00159809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481110|Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction|A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED)||Pfizer||Completed|March 2004|August 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Male|18 Years|N/A|No|||January 2008|January 18, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159809||194937|
NCT00159822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501061|Voriconazole For Chronic Bronchopulmonary Aspergillosis|Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts||Pfizer|No|Completed|July 2005|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|September 8, 2005|Yes|Yes||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00159822||194936|Study treatment duration is at least 6 months for subjects with best achievable response after 3 months of treatment, of 9 months for subjects with best achievable response after 6 months of treatment and of 12 months in other cases.
NCT00160160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S171.3.012|Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes|A Multi-Center, Double-Blind, Randomized Study Comparing the Efficacy of Combination Therapy of Eprosartan Respectively Ramipril With Low-Dose Hydrochlorothiazide and Moxonidine on Blood Pressure Levels in Patients With Hypertension and Associated Diabetes Mellitus Type 2||Solvay Pharmaceuticals||Completed|October 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|40 Years|80 Years|No|||January 2009|January 29, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160160||194910|
NCT00160173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S166.4.003|Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy|Efficacy Study Comparing 0.9 g and 1.25 g EstroGelÂ® 0.03% Doses With Placebo in the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated With Menopause||ASCEND Therapeutics||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|45 Years|65 Years|No|||July 2013|July 11, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160173||194909|
NCT00160186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.4.007|Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy|Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy||Solvay Pharmaceuticals|No|Completed|December 2003|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||40|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00160186||194908|
NCT00160446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M99-110|A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis|A Phase II Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of J867 Administered in Patients With Endometriosis||Abbott|No|Completed|May 2000|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|130|||Female|18 Years|40 Years|No|||May 2008|May 27, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00160446||194888|
NCT00161122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primakid 1|Prevention of Respiratory Infections and MAnagement Among Children (PRIMAKid)|Effectiveness and Costs of Combined Influenza and Pneumococcal Vaccination in Pre-School Children With Recurrent Respiratory Tract Infections (RTI): a General Practice-Based Randomized Controlled Trial||UMC Utrecht||Completed|September 2003|June 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||660|||Both|18 Months|72 Months||||July 2005|February 13, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161122||194836|
NCT00166751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701221|Sonographic Assessment of Laryngeal Elevation|Sonographic Assessment of Laryngeal Elevation in Cerebrovascular Accident Patients With Dysphagia||National Taiwan University Hospital||Recruiting|September 2005|November 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|October 26, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00166751||194412|
NCT00166764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700816|A Study on Evaluation of Mental Health Index of Patients With Psychiatric Disorders|A Study on Evaluation of Mental Health Index of Patients With Psychiatric Disorders||National Taiwan University Hospital||Recruiting|September 2005|July 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|18 Years|65 Years|No|||September 2005|October 26, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00166764||194411|
NCT00166777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700808|Effect of Hip Adduction Combination With Knee Extension Exercise on Morphology of Quadriceps Muscles, Pain and Functional Outcomes in Patients With PFPS|||National Taiwan University Hospital||Recruiting|September 2005|June 2006||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||90|||Both|20 Years|50 Years|No|||August 2005|September 7, 2006|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00166777||194410|
NCT00160706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87034|A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease|A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease.|PRECiSE 4|UCB Pharma|No|Completed|February 2004|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|310|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|September 8, 2005|Yes|Yes||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00160706||194868|
NCT00161018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20725|New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia|||University of Maryland||Completed|November 2003|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years|No|||March 2015|March 4, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161018||194844|
NCT00161564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2735S|A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone|A Randomized Trial Comparing Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine,and Prednisone) in Subjects With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment||Weill Medical College of Cornell University||Withdrawn|February 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|12 Years|N/A|No|||May 2008|May 15, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00161564||194804|
NCT00157625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-24|Automatic Stop Orders for Urinary Catheters|A Randomized Controlled Trial of Automatic Stop Orders for Urinary Catheterization in Hospitalized Patients||McMaster University||Completed|April 2003|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||630|||Both|18 Years|N/A|No|||September 2006|September 11, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157625||195104|
NCT00157560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-305|Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma|A Phase II Trial of ModifiedTriple Doublet Therapy in the Treatment of Women With Newly Diagnosed Carcinoma of Müllerian Origin||Massachusetts General Hospital|No|Completed|December 2000|July 2005|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||83|||Female|18 Years|N/A|No|||December 2007|December 28, 2007|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00157560||195109|
NCT00157573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-305|GM-CSF in Women With Recurrent Ovary Cancer|Phase II Trial of GM-CSF in Women With Asymptomatic Ovarian, Primary Peritoneal, or Tubal Carcinoma||Massachusetts General Hospital|No|Completed|December 2004|April 2010|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|18 Years|N/A|No|||April 2012|April 27, 2012|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00157573||195108|
NCT00157586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM/PR/7401/005/00|Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)|A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes||Mario Negri Institute for Pharmacological Research||Completed|February 2002|June 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||342|||Both|40 Years|75 Years|No|||March 2006|April 8, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157586||195107|
NCT00157820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-DATAS|DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study|DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study|DATAS|Medtronic Bakken Research Center|Yes|Completed|November 2000|October 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|354|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|September 8, 2005||No||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00157820||195089|The follow-up might have been too short to reveal differences in heart failure-related hospitalizations and related mortality.Premature crossovers are a limitation of RCT. However, our scoring system severely penalized this cross-overs.
NCT00158132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-12756-2|Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2|A Double-Blind, Placebo Controlled Trial of Propranolol and Amantadine for the Treatment of Cocaine Dependent Subjects With Severe Cocaine Withdrawal Symptoms||National Institute on Drug Abuse (NIDA)|No|Completed|September 1999|February 2006|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|199|||Both|18 Years|60 Years|No|||December 2009|December 2, 2009|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158132||195065|
NCT00158639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL075263|Electronic Communications and Home Blood Pressure Monitoring|Electronic Communications and Home Blood Pressure Monitoring||Group Health Cooperative|Yes|Completed|June 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Actual|778|||Both|25 Years|75 Years|No|||September 2009|September 10, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158639||195027|
NCT00158626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/95|Does Doing Pelvic Floor Exercise Ease Symptoms for Women Living With Prolapse?|A Feasibility Study for an RCT of a Pelvic Floor Muscle Training Intervention for Pelvic Organ Prolapse||Glasgow Caledonian University||Completed|September 2003|August 2005|Actual|August 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|N/A|No|||March 2015|March 18, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158626||195028|
NCT00158899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD20001|GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol|See Detailed Description||GlaxoSmithKline|No|Completed|August 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|424|||Both|18 Years|75 Years|No|||March 2011|March 17, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158899||195007|
NCT00159211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031006|Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin|Evolution of Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin, in Association With Metformin or Sulfonylurea.||Assistance Publique - Hôpitaux de Paris|No|Terminated|May 2005|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|35 Years|75 Years|No|||April 2007|November 6, 2007|September 7, 2005|||inclusion was finished|No||https://clinicaltrials.gov/show/NCT00159211||194983|
NCT00159510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4001.721.132|Studies of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome|A Controlled Prospective Randomized Open-Label Study of Methylene Blue and Inhaled Nitric Oxide in Patients With Septic Shock and Acute Lung Injury|MB-NO|Northern State Medical University|No|Terminated|April 2004|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 8, 2005||No|Inability to recruit the patients due to the short supply and changed local hospital protocol|No||https://clinicaltrials.gov/show/NCT00159510||194960|
NCT00159874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481156|A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children|A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil Citrate In The Treatment Of Subjects Who Have Completed Study A1481131||Pfizer|Yes|Completed|January 2004|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|234|||Both|1 Year|17 Years|No|||July 2014|July 17, 2014|September 8, 2005|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00159874||194932|
NCT00160199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S168.4.002|Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion|Evaluation of Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding in Subjects With Secondary Amenorrhea||Solvay Pharmaceuticals|No|Completed|November 2004|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Female|18 Years|45 Years|No|||June 2010|June 30, 2010|September 8, 2005|Yes|Yes||No|February 11, 2010|https://clinicaltrials.gov/show/NCT00160199||194907|
NCT00160212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S306.2.008|Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension|A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension||Solvay Pharmaceuticals||Completed|December 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2009|January 29, 2009|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00160212||194906|
NCT00160225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S306.2.009|Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension|A Randomized, Double-Blind, Placebo Controlled, Two-Treatment and Two-Period Cross-Over, Mono-Center Study to Evaluate the Efficacy and Safety of Daglutril 300 mg Once Daily Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension||Solvay Pharmaceuticals||Completed|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2007|November 9, 2007|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00160225||194905|
NCT00160459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M99-144|A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids|A Phase 2, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Asoprisnil (J867) in Patients With Uterine Leiomyomata.||Abbott|No|Completed|May 2000|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|129|||Female|18 Years|48 Years|No|||May 2008|May 27, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00160459||194887|
NCT00160472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMC 3H04|Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms|Evaluation of Vasopressin and Vasopressin Receptor Expression in the Arteries and Veins of Ovarian Neoplasms||Tripler Army Medical Center||Completed|March 2004|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|110|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2004|February 25, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160472||194886|
NCT00160797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580-2004|Total Knee Arthroplasty Outcome Study|MIS™ Minimally Invasive Solutions™ Total Knee Arthroplasty Outcome Study #02-800||University of Florida||Withdrawn|August 2005|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|September 8, 2005|||10/2005 PI assigned duties as trauma physician in addition other duties|No||https://clinicaltrials.gov/show/NCT00160797||194861|
NCT00154128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-B-01|The Influence of a Stabilization Splint on the Body Posture|The Influence of of a Stabilization Splint on the Body Posture in TMD Cases and Controls||University Medicine Greifswald||Completed|April 2005|August 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|November 17, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154128||195359|
NCT00168753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-US-064-04-AME|Community Based Trial for AMEVIVE®|An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of Alefacept, Following a Standard 12-Week Course of Amevive®, With Commonly Used Clinical Assessment Tools||Astellas Pharma Inc|No|Completed|July 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00168753||194260|
NCT00169091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH052376|Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia|Clozapine or Haloperidol in First Episode Schizophrenia||Harvard Medical School||Terminated|March 1996|October 2003||September 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|45 Years|No|||April 2015|April 6, 2015|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00169091||194234|
NCT00161265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.064|Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer|UMCC 2004.064: Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|May 2005|July 2016|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples Without DNA|tissue|Female|18 Years|N/A|No|Non-Probability Sample|women with breast cancer|November 2015|November 6, 2015|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161265||194825|
NCT00161551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODEST V.2.2.1|Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)|A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers||Medtronic BRC||Recruiting|November 2004|December 2010||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|402|||Both|18 Years|N/A|No|||October 2006|August 1, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00161551||194805|
NCT00161577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903-886|Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery|Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Ketorolac in the Management of Post-Operative Pain After Heart Surgery||Weill Medical College of Cornell University|No|Completed|January 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||May 2009|May 12, 2009|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00161577||194803|
NCT00157196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B25-LG-305 / EMR 63325-006|Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease|A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease||Merck KGaA||Completed|April 2005|April 2012|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|September 8, 2005|No|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT00157196||195127|
NCT00157859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Timika_FP_VP|To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia|To Evaluate the Efficacy of Chloroquine and SP for Acute Uncomplicated P. Falciparum and the Efficacy of Chloroquine for Acute Uncomplicated P. Vivax in the Timika Region of Papua, Indonesia.||Menzies School of Health Research||Completed|April 2004|September 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|12 Months|N/A|No|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157859||195086|
NCT00157872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-231|A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)|A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 mg Once Daily Versus Naproxen Table 500 mg Twice Daily in the Treatment of Chinese Patient With Rheumatoid Arthritis||Merck Sharp & Dohme Corp.||Completed|January 2004|September 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157872||195085|
NCT00157599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2002-MDA|MDA D-Dimer / Recurrent DVT Study|A Cohort Study Evaluating the Safety of a Diagnostic Strategy Involving D-Dimer and Compression Ultrasonography in Patients With Suspected Recurrent Deep Vein Thrombosis||McMaster University||Completed|January 2002|March 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||500|||Both|18 Years|N/A|No|||October 2007|July 25, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157599||195106|
NCT00158158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14538-2|Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2|Interventions for Tobacco Dependent Adolescents||National Institute on Drug Abuse (NIDA)|Yes|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||June 2008|June 27, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158158||195063|
NCT00158171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14538-1|Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1|Interventions for Tobacco Dependent Adolescents||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2002|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||June 2008|June 27, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158171||195062|
NCT00158145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13333-2|Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2|Longitudinal Study of Prostate, Lung, Colon, and Ovarian Cancer (PLCO) Screen Trial||National Institute on Drug Abuse (NIDA)||Completed|September 2005|April 2007|Actual|April 2007|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|72|Samples Without DNA|Urine and blood samples.|Both|55 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cigarette smokers|June 2008|June 27, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158145||195064|
NCT00158912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-060903-T|VAST - Ventricular Arrhythmia Suppression Trial|Ventricular Arrhythmia Suppression Trial||Boston Scientific Corporation||Completed|August 2003|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||550|||Both|18 Years|N/A||||November 2006|November 20, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00158912||195006|
NCT00159224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA-ARGE-04-001|Induction-maintenance of Lopinavir/r in HIV-infected Subjects|Study ACA-ARGE-04-001 "A Pilot, Open-Label Study Assessing Safety, Tolerability, Efficacy of a Simplified Lopinavir/Ritonavir Induction/Maintenance Therapy in HIV-Infected Subjects on Their First Protease Inhibitor-Based Regimen".||The Huesped Foundation|No|Completed|April 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00159224||194982|
NCT00159237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5899N00007|GR Defect in Peripheral Blood Mononuclear Cells in COPD|GR Defect in Peripheral Blood Mononuclear Cells in COPD||Imperial College London||Completed|February 2005|December 2008||||N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|35 Years|85 Years||||August 2008|August 12, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159237||194981|
NCT00159497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-001-MBL|Bone Remodeling Around HA-coated Acetabular Cups.|Bone Remodeling Around HA-coated Acetabular Cups.||Northern Orthopaedic Division, Denmark|No|Completed|October 1998|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||March 2014|March 28, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159497||194961|
NCT00159926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|959583153|Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response|Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ?||Rigshospitalet, Denmark|No|Terminated|January 2003|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2007|January 4, 2008|September 8, 2005|||For financial and logistical reasons|No||https://clinicaltrials.gov/show/NCT00159926||194928|
NCT00159887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481142|Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension|A Multi-Centre, Multinational, Long-Term Extension Study, to Assess the Safety and Toleration of Subject Optimised Treatment Regimens of Oral Sildenafil Citrate for Pulmonary Arterial Hypertension in Subjects Who Have Completed Study A1481140.||Pfizer||Completed|December 2002|February 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|260|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159887||194931|
NCT00159900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481222|Quality of Erection Study|A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate||Pfizer||Completed|May 2005|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Male|18 Years|55 Years|No|||April 2008|April 4, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159900||194930|
NCT00160238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S108.4.102|Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy|A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease||Solvay Pharmaceuticals||Completed|January 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||December 2006|December 21, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00160238||194904|
NCT00160485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMC 16H04|Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes|Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes||Tripler Army Medical Center|Yes|Withdrawn|June 2004|June 2010|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|February 10, 2014|September 8, 2005||No|Active Duty principle investigator currently deployed|No||https://clinicaltrials.gov/show/NCT00160485||194885|
NCT00160498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ler 25-03|Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Dose-Titration Study to Assess the Efficacy of Lercanidipine 10 mg and 20 mg Once Daily p. o. in Hypertensive Subjects (I or II WHO) With Elevated Body Weight.||UCB Pharma||Completed|May 2004|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||180|||Both|18 Years|75 Years||||March 2008|March 7, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160498||194884|
NCT00160810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-2001|Outcome Study of Complex Distal Radius Fractures|Outcome Study of Complex Distal Radius Fractures: Open Reduction Internal Fixation (ORIF) With A Volar Fixed Angled Plate Versus A Distal Radius Volar (DRV) Plate Versus External Fixation||University of Florida|No|Completed|April 2001|June 2012|Actual|October 2010|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|74|||Both|19 Years|75 Years|No|Non-Probability Sample|Orthopaedic clinic|June 2012|May 17, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160810||194860|
NCT00160758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214-1999|Physical Characteristics of Retrieved Massive Allografts|Physical Characteristics of Retrieved Massive Allografts||University of Florida|No|Completed|December 1999|September 2009|Actual|September 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18|||Both|N/A|N/A|No|Non-Probability Sample|Orthopaedic clinic|October 2012|October 26, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160758||194864|
NCT00160771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201501196|Biomechanics/Motion Analysis Laboratory Data Bank|University of Florida Biomechanics/Motion Analysis Laboratory Data Bank||University of Florida|No|Recruiting|January 2005|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|||Both|2 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Biomechanical/Motion Analysis Laboratory|February 2016|February 9, 2016|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160771||194863|
NCT00160745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rosuvastatin-study|Rosuvastatin and Renal Endothelial Function|A Randomised, Double-blind, Placebo-controlled, Mono-centre, Explorative Phase II Trial to Study the Effects of Rosuvastatin on Basal Production and Release of Nitric Oxide From the Renal Vasculature in Patients With Hypercholesterolemia.||University of Erlangen-Nürnberg Medical School||Completed||September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||46|||Both|18 Years|75 Years|No|||January 2013|January 18, 2013|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00160745||194865|
NCT00161044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23059|An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms|An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms||University of Maryland||Completed|September 2004|September 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||March 2015|March 4, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161044||194842|
NCT00161278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.058|Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling|Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer Through Gene Expression Profiling.||University of Michigan Cancer Center|Yes|Terminated|December 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|September 8, 2005||No|recruitment has ended|No||https://clinicaltrials.gov/show/NCT00161278||194824|
NCT00157209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B25-LG-304 / EMR 63325-005|Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)|A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer||Merck KGaA||Completed|August 2000|July 2012|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 8, 2005|No|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT00157209||195126|
NCT00157885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Timika_AMT|A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.|A Randomized Trial to Compare the Efficacy of Artekin and Amodiaquine Plus Artesunate for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua||Menzies School of Health Research||Completed|July 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|12 Months|N/A|No|||June 2006|June 23, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157885||195084|
NCT00157833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMIKA_FC|A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.|A Randomized Trial to Determine the Efficacy and Safety of Coartemether and Artekin for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua||Menzies School of Health Research||Completed|July 2004|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||750|||Both|12 Months|N/A|No|||June 2006|June 23, 2006|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157833||195088|
NCT00158366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066068|Reducing the Weight of Overweight Schizophrenia Patients|A Clinical Trial Of Weight Reduction in Schizophrenia||University of Pittsburgh|Yes|Active, not recruiting|May 2004|December 2016|Anticipated|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|14 Years|60 Years|No|||January 2016|January 5, 2016|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158366||195047|
NCT00158379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3002000|Taxol Carboplatin and Erythropoetin|Carboplatin With Following Taxol® Therapy Under Additional Application of Epoetin Alfa (ERYPO ®) With Female Patients With Advanced Ovarian Cancer FIGO IA/G3 - IV||North Eastern Germany Society of Gynaecologic Oncology||Completed|July 2003|June 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00158379||195046|
NCT00158353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH069564|Evaluation of a Youth Mentoring Program|Development and Evaluation of a Youth Mentoring Program||University of Illinois at Chicago|No|Active, not recruiting|May 2005|February 2014|Anticipated|February 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Female|10 Years|13 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158353||195048|
NCT00158665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC Protocol 4258|A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age|A Comparison of One Versus Two Doses of Influenza Vaccine in Children Aged 5-8 Years of Age Receiving Influenza Vaccine for the First Time||Group Health Cooperative|No|Completed|August 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|280|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||February 2014|February 25, 2014|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158665||195025|
NCT00158925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0001|The EASYTRAK EPI Clinical Investigation|The EASYTRAK EPI Clinical Investigation||Boston Scientific Corporation||Completed|September 2004|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||May 2008|May 19, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158925||195005|
NCT00158938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0007|Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense Lead|Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense Lead||Boston Scientific Corporation||Completed|May 2003|November 2004|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||115|||Both|18 Years|N/A|No|||June 2007|June 22, 2007|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00158938||195004|
NCT00159250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/MRE12/32|Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy|Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658||Imperial College London|Yes|Completed|October 2007|March 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|7|||Male|10 Years|17 Years|No|||February 2010|February 22, 2010|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159250||194980|
NCT00153049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.439|3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension|A Randomised, Double-Blind, Placebo-Controlled, 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension||Boehringer Ingelheim||Completed|June 2004|June 2005||June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|583|||Both|20 Years|80 Years|No|||November 2013|November 7, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00153049||195442|
NCT00160251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03659|Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)|PEG-Intron/REBETOL vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 (HCV-1) Peginterferon Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding Phase 2 Study||Merck Sharp & Dohme Corp.|Yes|Completed|September 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|9||Actual|357|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|September 8, 2005|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00160251||194903|The implementation of amendment 2 led to changes in boceprevir dose in all treatment arms and different overall lengths of therapy within the same treatment arm, making the SVR endpoint uninterpretable.
NCT00160511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01087|A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)|A Double-blind, Randomized, Placebo-controlled, Parallel-group, 16 Week, Multicenter Trial Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (≥ 18 Years of Age) Suffering From Postherpetic Neuralgia||UCB Pharma||Completed|April 2004|September 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||170|||Both|18 Years|N/A||||September 2009|November 25, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160511||194883|
NCT00160836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 04-117|Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter|Biliary Tissue Sampling Using a Cytology Brush or the G.I.U.M. Catheter: a Prospective Randomized Controlled Study.||University Hospital, Geneva||Recruiting|October 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||68|||Both|18 Years|N/A|No|||April 2007|April 18, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160836||194858|
NCT00160849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KalMo|Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression|Study on the Feasibility of Antiretroviral Therapy With a Single Agent - Lopinavir/r - in Patients Treated With HAART and With Viral Load Below 80 Copies/Ml||Universidade Federal do Rio de Janeiro||Completed|August 2004|March 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||July 2005|October 19, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160849||194857|
NCT00161109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03.0377C|Genetics and Psychopathology in the 22q11 Deletion Syndrome|Genetics and Psychopathology in the 22q11 Deletion Syndrome||UMC Utrecht||Recruiting|October 2002|October 2012||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||175|||Both|8 Years|20 Years|Accepts Healthy Volunteers|||October 2004|October 12, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161109||194837|
NCT00154440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELYX Study|Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation|Treatment of Low-Grade Gastric Non-Hodgkin‘s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study)||Technische Universität Dresden|Yes|Recruiting|November 2001|October 2013|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|75 Years|No|||March 2007|March 23, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154440||195335|
NCT00154726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36-3|Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers|A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers||National Taiwan University Hospital||Completed|April 1997|August 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||August 2005|November 21, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154726||195313|
NCT00161070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-217|ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial|ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial||UMC Utrecht||Completed|July 1997|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||4500|||Both|18 Years|75 Years|No|||March 2007|March 21, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161070||194840|
NCT00161057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 01/134|Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment|Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment||UMC Utrecht||Completed|December 2001|September 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|16 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|first episode schizophrenia patients, medication naive (or medication-free) and matched        healthy controls.|April 2009|April 22, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161057||194841|
NCT00161291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F041222006|Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer|A Phase II Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer||University of Alabama at Birmingham|Yes|Completed|June 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Female|60 Years|N/A|No|||December 2010|December 30, 2010|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00161291||194823|
NCT00161304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-001|Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency|Effects of Testosterone Administration on Tissues of Men With A.D.A.M. (Androgen Deficiency of Aging Men)||Urological Sciences Research Foundation||Completed|April 2003|November 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||44|||Male|50 Years|N/A|Accepts Healthy Volunteers|||November 2004|September 11, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161304||194822|
NCT00157638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G03-02671|Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics|Optimizing Drug Therapy in Primary Care: Integrating Pharmacists With Ontario Family Physician Group Practices.||McMaster University||Completed|February 2004|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1400|||Both|65 Years|N/A|No|||September 2006|September 8, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157638||195103|
NCT00155363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701293|Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis|The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis||National Taiwan University Hospital||Recruiting|September 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||June 2005|December 19, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155363||195266|
NCT00157846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_1|X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure|Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure to Investigate the Effect of Preventive Stimulation||Medtronic Bakken Research Center||Terminated|October 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind|||Anticipated|100|||Both|18 Years|N/A|No|||October 2008|October 8, 2008|September 9, 2005||No|Due to existing evidence eligible patients receive CRT treatment in first place|No||https://clinicaltrials.gov/show/NCT00157846||195087|
NCT00158652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 99-02|Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC|Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma||Groupe Oncologie Radiotherapie Tete et Cou||Completed|March 2000|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|840|||Both|20 Years|75 Years|No|||November 2011|November 7, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00158652||195026|
NCT00158951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0005|Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF|Device Evaluation of CONTAK(R) RENEWAL 2/4/4HE and EASYTRAK(R) 2: Assessment of Safety and Effectiveness in Heart Failure (DECREASE-HF)||Boston Scientific Corporation||Completed|March 2003|October 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|18 Years|N/A|No|||June 2007|June 22, 2007|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00158951||195003|
NCT00158964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0006|EASYTRAK 4 Steerable LV Lead|EASYTRAK® 4 STEERABLE LV Lead Clinical Investigation||Boston Scientific Corporation||Completed|March 2005|April 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||June 2007|June 22, 2007|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00158964||195002|
NCT00158977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0008|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT Study||Boston Scientific Corporation||Completed|November 2003|February 2008|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158977||195001|
NCT00159263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-039-0005|Effect of Symbicort on GR Localisation in Asthma|Effect of Symbicort on GR (Glucocorticoid Receptor) Translocation in Induced Sputum in Comparison With Budesonide, Formoterol and Placebo. A Single Dose Exploratory Study in Patients With Mild Asthma||Imperial College London||Completed|November 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||10|||Both|21 Years|60 Years|No|||September 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159263||194979|
NCT00159523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|097-03|Impact in Off-spring of Mothers After Perinatal Daily Intake of a Probiotic|The Impact of Perinatal Daily Supplement of a Probiotic (Lactobacillus Rhamnosus GG), Given to Mothers, on Immunological Development, Atopic Sensitisation and Allergic Disease in Their Off-spring||Norwegian University of Science and Technology|No|Completed|December 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|416|||Both|30 Weeks|36 Weeks|Accepts Healthy Volunteers|||August 2015|February 4, 2016|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159523||194959|
NCT00159913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481131|A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.|A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension.||Pfizer|Yes|Completed|August 2003|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|235|||Both|1 Year|17 Years|No|||January 2014|January 23, 2014|September 8, 2005|Yes|Yes||No|June 2, 2009|https://clinicaltrials.gov/show/NCT00159913||194929|
NCT00153647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAC Study|A Study to Assess Cap-Assisted Colonoscopy Versus Regular Colonoscopy for the First or Repeated Colonoscopy|A Study to Assess the Success Rate of Cap-Assisted Colonoscopy Versus Regular Colonoscopy for the First or Repeated Colonoscopy (CAC Study)|CAC|Chinese University of Hong Kong||Completed|May 2005|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|N/A|No|||August 2007|March 14, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153647||195396|
NCT00153322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-OPHR-121519|Shape Up Somerville: Eat Smart Play Hard|Shape Up Somerville: Eat Smart Play Hard||Centers for Disease Control and Prevention||Completed|November 2002|June 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||3000|||Both|5 Years|11 Years|Accepts Healthy Volunteers|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00153322||195421|
NCT00153634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BURNS03A0|Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)|Standard vs. Biofilm Susceptibility Testing in CF||Seattle Children's Hospital|Yes|Completed|March 2004|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|14 Years|N/A|No|||November 2007|March 12, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00153634||195397|
NCT00153868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0341|A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer|Pilot Web-based Study of Functional Status, Symptom Palliation and Quality of Life Benefits Associated With Darbepoetin Alfa (Aranesp®) Administration in Anemic Patients With Cancer.||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|October 2003|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153868||195379|
NCT00168155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTAIV-0020-357|Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma|Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma||AHS Cancer Control Alberta||Completed|January 2002|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||September 2011|January 18, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00168155||194305|
NCT00168168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-10-0053|ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159|ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159||AHS Cancer Control Alberta||Completed|July 2003|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2007|February 8, 2010|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00168168||194304|
NCT00161343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR008194|Maintaining HIV Prevention Gains in Female Adolescents|Randomized Controlled Trial of an Group Intervention to Maintain HIV Prevention Gains in Female Adolescents||University of Rochester|Yes|Completed|December 2004|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|640|||Female|15 Years|19 Years|Accepts Healthy Volunteers|||April 2009|September 4, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161343||194819|
NCT00161317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC 03-899|Evaluation of a Living With Hope Program|Development, Implementation and Evaluation of a Psychosocial Supportive Hope Focused Program for Patients With Advanced Cancer||University of Saskatchewan||Completed|December 2003|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|60 Years|N/A|No|||January 2016|January 5, 2016|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161317||194821|
NCT00161590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204-157|Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma|Phase I Study of CHOP Plus Campath (C-CHOP) for the Treatment of T-Cell, Null-Cell, and NK-Cell Lymphomas||Weill Medical College of Cornell University||Completed|July 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||October 2008|October 21, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00161590||194802|
NCT00157651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-15226|Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters|A Double-Blind, Placebo Controlled, Randomized Trial of Low-Intensity Adjusted-Dose Warfarin for the Prevention of Mechanical Malfunction of Double-Lumen Haemodialysis Catheters||McMaster University|Yes|Completed|February 1999|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|170|||Both|18 Years|N/A|No|||June 2008|June 16, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00157651||195102|
NCT00158197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17407-1|Long-term Behavior Change - 1|Behavior Change: Reinforcement Schedule Effects||Friends Research Institute, Inc.|Yes|Completed|December 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|119|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|September 8, 2005||No||No|May 30, 2013|https://clinicaltrials.gov/show/NCT00158197||195060|
NCT00158184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4691|Prescription Opioid Effects in Abusers Versus Non-Abusers|Prescription Opioid Effects in Drug and Non-drug Abusers - 1||New York State Psychiatric Institute|No|Completed|June 2004|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|96|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|January 24, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158184||195061|
NCT00158405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1269 TRIVACAN|Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)|Multicentric Randomised Controlled Trial Assessing the Efficacy of Two Strategies of Structured Treatment Interruption of Highly Active Antiretroviral Therapy (HAART) Compared With a Continuous HAART in HIV- Infected Adults in Abidjan||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|December 2002|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|840|||Both|18 Years|N/A|No|||December 2008|December 29, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00158405||195045|
NCT00152503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01192|Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam|An Open Label, Exploratory, Dose-Escalation, Multicenter Study Examining the Safety, Tolerability and Efficacy of Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures Who Are Currently Receiving Levetiracetam (LEV) But Still Experiencing Seizures||UCB Pharma||Completed|August 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||60|||Both|18 Years|65 Years||||September 2008|September 30, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152503||195484|
NCT00152516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01148|Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures|A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures.||UCB Pharma|No|Completed|October 2004|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|255|||Both|1 Month|16 Years|No|||April 2010|February 8, 2013|September 7, 2005|Yes|Yes||No|August 27, 2009|https://clinicaltrials.gov/show/NCT00152516||195483|
NCT00153062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.159|PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes|PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis||Boehringer Ingelheim||Completed|August 2003|||April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|20332|||Both|50 Years|N/A|No|||April 2014|April 22, 2014|September 9, 2005||||No|February 6, 2009|https://clinicaltrials.gov/show/NCT00153062||195441|All SAEs and AEs that led to temporary or permanent trial drug discontinuation were reported, except in Japan, where all AEs were collected. Protocol-defined outcome events were not reported as AEs, but were recorded on the appropriate form
NCT00152763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 5170|Psychological Support for Patients With an Implantable Cardioverter Defibrillator|Psychological Support for Patients With an Implantable Cardioverter Defibrillator||University Health Network, Toronto||Completed|October 2003|November 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|193|||Both|18 Years|N/A|No|||January 2011|January 5, 2011|September 7, 2005||No||No|October 27, 2010|https://clinicaltrials.gov/show/NCT00152763||195464|
NCT00153036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135.312|Rt-PA in the Treatment of Acute Ischemic Stroke|ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset||Boehringer Ingelheim||Completed|April 2003|||February 2008|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|821|||Both|18 Years|80 Years|No|||April 2014|April 30, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00153036||195443|
NCT00153894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-327|Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors|Pilot Study of the Effects of an Exercise Intervention on Insulin Levels in Breast Cancer Survivors||Dana-Farber Cancer Institute|No|Active, not recruiting|December 2003|June 2014|Anticipated|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|N/A|No|||October 2013|October 9, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153894||195377|
NCT00153881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-9939|Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer|Docetaxel and Carboplatin Followed by a Dose-Ranging Study of Oral Capecitabine, Weekly Docetaxel, and Concomitant External Beam Radiotherapy for the Treatment of Patients With Stage II-III Carcinoma of the Esophagus and Gastro-Esophageal Junction||Dartmouth-Hitchcock Medical Center|Yes|Completed|February 2000|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153881||195378|
NCT00154141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-05-001|Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures|A Prospective, Randomized Controlled Study to Compare the Effects of a Fibrin Sealant (FS2) Versus Manual Compression on Haemostatic Efficacy During Vascular Surgical Procedures Utilising Polytetrafluorethylene Graft Material on an End-to-Side Femoral or Upper Extremity Vascular Access Arterial Anastomosis||Ethicon, Inc.||Completed|June 2005|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||150|||Both|18 Years|N/A|No|||July 2006|July 11, 2006|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00154141||195358|
NCT00154739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46S1|Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)|A Phase II Randomized Trial of Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin in Stage IIIB/IV Non-Small Cell Lung Cancer||National Taiwan University Hospital||Completed|October 1998|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|86|||Both|18 Years|N/A|No|||July 2005|August 1, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154739||195312|
NCT00168181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-04-0010|Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients|A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients||AHS Cancer Control Alberta||Completed|April 2002|April 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|220|||Both|18 Years|N/A|No|||April 2011|April 15, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168181||194303|
NCT00168480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-513|A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis|||Allergan||Completed|November 2003|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|424|||Both|18 Years|N/A|No|||September 2008|September 26, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00168480||194280|
NCT00161096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/NL503|On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication|Comparison of the Percentage Chronic on-Demand Users Treated With 20 Mg Pantoprazole on-Demand and Placebo o.d Versus Placebo on-Demand and 20 Mg Pantoprazole o.d. After Symptom Relief With 20 Mg Pantoprazole o.d.||UMC Utrecht||Active, not recruiting|March 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||276|||Both|18 Years|75 Years|No|||November 2004|February 1, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161096||194838|
NCT00161603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (0698-267)|Cornell Translational Behavioral Science Research Consortium: Angioplasty Qualitative Study|Cornell Translational Behavioral Science Research Consortium: Angioplasty Qualitative Study||Weill Medical College of Cornell University|No|Completed|April 2003|September 2003||||N/A|Observational|Time Perspective: Prospective||||18|||Both|21 Years|N/A|No|||April 2008|April 1, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161603||194801|
NCT00157222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 2587558|Characterizing and Diagnosis’s of the Charcot Foot (Charcot Osteoarthropathy) in Diabetic Patients|Characterizing and Diagnosis’s of the Charcot Foot (Charcot Osteoarthropathy) in Diabetic Patients||Bispebjerg Hospital||Recruiting|May 2005|April 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||50|||Both|N/A|N/A|No|||September 2005|December 7, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157222||195125|
NCT00157235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.247|Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients|A Randomized, Double Blind , Placebo Controlled Trial to Compare the Effect of Tiotropium Inhalation Capsules on Exercise Tolerance in Patients With COPD Participating in 8 Weeks of Pulmonary Rehabilitation||Boehringer Ingelheim||Completed|September 2002|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||234|||Both|40 Years|80 Years|No|||October 2013|October 31, 2013|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157235||195124|
NCT00157248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.42|Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048|Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)||Boehringer Ingelheim||Terminated|December 2003|||January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Prevention|4||Actual|361|||Both|18 Years|N/A|No|||February 2014|May 8, 2014|September 8, 2005||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00157248||195123|
NCT00155766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100205963|Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)|A Pilot Study for the Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs) Pulsed With Human Papillomavirus Type 16 E7 Antigen||National Taiwan University Hospital||Recruiting|January 2003|March 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Female|18 Years|75 Years|No|||June 2002|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155766||195235|
NCT00156078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081030|A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)|A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).||Pfizer||Completed|January 2005|May 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156078||195211|
NCT00156065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05785|Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)|A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Haloperidol Positive Control in Subjects Who Complete Protocol 041023 [NCT00156104]||Merck Sharp & Dohme Corp.|Yes|Completed|September 2005|October 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|187|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|September 7, 2005|Yes|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00156065||195212|
NCT00158418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC-CIHR-2|Cemented vs. Non-Cemented TSA for OA of the Shoulder|Cemented Versus Uncemented Fixation of Humeral Components in Total Shoulder Arthroplasty for Osteoarthritis of the Shoulder||Fowler Kennedy Sport Medicine Clinic||Completed|August 2002|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||September 2005|January 28, 2009|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158418||195044|
NCT00158678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2004-01|IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC|Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma||Groupe Oncologie Radiotherapie Tete et Cou||Active, not recruiting|September 2005|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00158678||195024|
NCT00152776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD04|Treating Climacteric Symptoms With a Complex Homeopathic Remedy|Treatment of Climacteric Symptoms With Ovaria Comp - A Prospective Randomized Placebo Controlled Doubleblind Study||Heidelberg University|No|Completed|February 2005|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||102|||Female|45 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 18, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00152776||195463|
NCT00152789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0102-C|Normal Prostate: Oxygenation of the Prostate Gland in Men Undergoing Prostate Biopsy|Oxygenation of the Prostate Gland: a Polarographic Electrode Study in Men Undergoing Prostate Biopsy.||University Health Network, Toronto||Completed|April 2001|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Male|18 Years|N/A|No|||January 2008|August 7, 2009|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152789||195462|
NCT00153075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1364|Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|September 2005|December 2005||December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||19|||Both|40 Years|N/A|No|||October 2013|October 28, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00153075||195440|
NCT00153335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-OPHR-R01CD000122|Computerized Risk Assessment in an Employee Population|Computerized Risk Assessment in an Employee Population||Centers for Disease Control and Prevention||Completed|June 2005|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 24, 2010|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153335||195420|
NCT00154154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR: #200204MCT-101123|Hope for the Chronically Suicidal Patient|Hope for the Chronically Suicidal Patient: Evaluating the Clinical and Health Services Impact of Dialectical Behaviour Therapy in Individuals With Borderline Personality Disorder||Centre for Addiction and Mental Health|No|Completed|October 2002|April 2009|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00154154||195357|
NCT00154453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701166|Age-Related Changes in Myosin Heavy Chain Composition in Human Orbicularis Oculi Muscle|||National Taiwan University Hospital||Completed|January 2004|August 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2003|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00154453||195334|
NCT00159328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF008|Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids|Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids||Imperial College London||Completed|March 2003|December 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 12, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00159328||194974|
NCT00168818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.48|Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery|A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Replacement Surgery. RE-NOVATE (Extended Thromboembolism Prevention After Hip Surgery)||Boehringer Ingelheim||Completed|November 2004|||July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|3494|||Both|18 Years|N/A|No|||February 2014|May 8, 2014|September 12, 2005||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00168818||194255|
NCT00161369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2005001|Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients|Contribution of Homocysteine and Asymmetric Dimethylarginine to Atherosclerosis and Cardiovascular Events in Maintenance Hemodialysis Patients||University of Shizuoka||Completed|April 2000|March 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||200|||Both|N/A|70 Years|No|||October 2005|October 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00161369||194817|
NCT00161356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-0347|Ambisome in Liver Transplant Patients|Blood, Bile and Tissue Pharmacokinetics of Single Dose Liposomal Amphotericin B (AmBisome ®) in Liver Transplant Patients.||The University of Texas Health Science Center, Houston|No|Terminated|September 2005|December 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|70 Years|No|||June 2008|June 20, 2008|September 8, 2005||Yes|Budget issues|No||https://clinicaltrials.gov/show/NCT00161356||194818|
NCT00161616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100N8-400|Study Evaluating InductOs in Diaphyseal Tibia Fractures|A Prospective, Randomized, Controlled, Stratified Study of InductOs in Subjects With Open Diaphyseal Tibia Fractures Treated With Reamed Locked Intramedullary Nail Fixation||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2003|August 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|277|||Both|18 Years|N/A|No|||July 2009|July 31, 2009|September 7, 2005||No||No|July 31, 2009|https://clinicaltrials.gov/show/NCT00161616||194800|
NCT00155376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940104|Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography|||National Taiwan University Hospital||Recruiting|September 2005|September 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||100|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||April 2005|November 25, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155376||195265|
NCT00157261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.18|Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial|A Prospective, Randomised, Double-blind, Placebo-controlled, International, Multicentre, Parallel-group Comparison Trial Evaluating the Efficacy and Safety of Tenecteplase During Cardiopulmonary Resuscitation as Compared With Standard Treatment in Patients Suffering From Out-of-hospital Cardiac Arrest of Presumed Cardiac Origin Thrombolysis in Cardiac Arrest (TROICA) Trial||Boehringer Ingelheim||Terminated|January 2004|June 2006||June 2006||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1050|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157261||195122|
NCT00157274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF/SS|Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome|Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome||Latin American Cooperative Onco-Haematology Group - Peru||Recruiting|July 2005|July 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|No|||September 2005|April 2, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00157274||195121|
NCT00157287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-01-076|A Cluster Randomized Trial to Improve Weaning and Extubation From Mechanical Ventilation in Community Hospitals|||Lawson Health Research Institute||Completed|June 2003|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2006|April 24, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157287||195120|
NCT00156351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|707525|Walking For Wellness Program Evaluation|Evaluation of the National Black Women's Health Project Walking for Wellness Program||University of Pennsylvania||Completed|January 2003|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||186|||Female|18 Years|N/A|No|||March 2008|March 26, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156351||195190|
NCT00156650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0832-D-substudy|Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (HOP 5) Testicular Aspiration Addendum|Male Hormonal Contraception Development: Suppression of Spermatogenesis With the Addition of a Potent GnRH Antagonist (Acyline) to Testosterone and DMPA (ACY-5) -Sub-Study (HOP 5)|IHOP-5|University of Washington|No|Completed|December 2004|July 2005|Actual|July 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|23|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156650||195167|
NCT00156325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03283|Escitalopram as a Mood Stabilizer for Bipolar II Disorder|A Double-Blind, Placebo-Controlled Trial of Escitalopram as a Mood Stabilizer for Bipolar II Disorder||The University of New South Wales||Completed|February 2004|February 2005||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|December 30, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156325||195192|
NCT00156338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-Anast-05|Effect of Intraoperative Fluid Management on Morbidity|Effect of Intraoperative Fluid Management on Morbidity in Patients Undergoing Colorectal Surgery||University Hospital Muenster|No|Completed|July 2005|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|90 Years|No|||January 2012|January 16, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156338||195191|
NCT00156637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNT 02-210|A Study of Strategies to Improve Schizophrenia Treatment|A Study of Strategies to Improve Schizophrenia Treatment||VA Office of Research and Development|No|Completed|June 2005|March 2008|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|106|||Both|18 Years|65 Years|No|||April 2008|April 6, 2015|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00156637||195168|
NCT00156962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040259|Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)|A Randomized, Open-Label Study to Assess the Safety of Epoetin Alfa Manufactured by Deep Tank Technology and Epoetin Alfa Manufactured by Roller Bottle Technology in Subjects With Chronic Kidney Disease Not on Dialysis||Amgen||Terminated|April 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|850|||Both|18 Years|N/A|No|||July 2008|July 17, 2008|September 8, 2005|||Regulatory decision not to proceed|No||https://clinicaltrials.gov/show/NCT00156962||195145|
NCT00152802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0450-A|Pneumonia Vaccine in Liver Transplant Recipients: a Booster Strategy Using a Conjugate Vaccine|Immunogenicity of Pneumococcal Vaccine in Liver Transplant Recipients Using a Conjugate-Polysaccharide Priming-Booster Strategy||University Health Network, Toronto||Active, not recruiting|January 2005|January 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||130|||Both|16 Years|N/A|No|||September 2005|February 16, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00152802||195461|
NCT00152815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0297-B|Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions|Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions||University Health Network, Toronto|No|Terminated|October 2003|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|September 7, 2005||No|Not enough eligible patients available|No||https://clinicaltrials.gov/show/NCT00152815||195460|
NCT00153088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.413|INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy|A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study -||Boehringer Ingelheim||Completed|January 2003|November 2005||November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|527|||Both|30 Years|74 Years|No|||October 2013|October 31, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00153088||195439|
NCT00153348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-2916|South Central Foundation - WISEWOMAN Project|South Central Foundation - WISEWOMAN Project||Centers for Disease Control and Prevention||Completed|January 2001|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Female|40 Years|64 Years||||March 2012|March 13, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00153348||195419|
NCT00153660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8N Study|Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients|A Double-blind Randomized Comparison of Esomeprazole Plus Celecoxib Versus Esomeprazole Plus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients (NSAID#8 Study)||Chinese University of Hong Kong|Yes|Recruiting|June 2005|December 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00153660||195395|
NCT00158470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1210 VIETAR|Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)|Feasibility Study of a Once Daily Antiretroviral Regimen for HIV-Infected Patients With CD4 Below 200/mm3, in Hô Chi Minh City, Vietnam||French National Agency for Research on AIDS and Viral Hepatitis|No|Completed|September 2003|May 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||July 2007|July 2, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00158470||195040|
NCT00158483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1212|Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)|Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212)||French National Agency for Research on AIDS and Viral Hepatitis|No|Completed|May 2003|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|449|||Female|18 Years|N/A|No|||December 2008|December 29, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158483||195039|
NCT00158496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1211|Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)|Clinical Trial of the Efficacy of the Combination of Pegylated Interferon (PEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|August 2002|January 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||April 2007|April 23, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158496||195038|
NCT00158730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-131-101|Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment|Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients||Gilead Sciences||Completed|April 2003|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||800|||Both|1 Month|N/A|No|||September 2005|November 17, 2005|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00158730||195020|
NCT00159029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152910-HMO-CTIL|Genetics of Alpha Thalassemia in Israeli Ethnic Groups|Haplotype Analysis of Alpha Globin Genes in Israeli Ethnic Groups||Hadassah Medical Organization|No|Recruiting|April 2004|April 2012|Anticipated|||N/A|Observational|N/A||1|Anticipated|100|Samples With DNA|DNA isolated from peripheral blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who come to Hadassah Hospital for anemia with microcytosis who are found to have        alpha thalassemia.|June 2011|June 22, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159029||194997|
NCT00159042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302803-HMO-CTIL|Genetic Factors Affecting the Severity of Beta Thalassemia|Identification of Novel Genetic Modifiers in Beta-thalassemia||Hadassah Medical Organization|No|Recruiting|July 2004|April 2012|Anticipated|||N/A|Observational|N/A||1|Anticipated|200|Samples With DNA|DNA isolated from peripheral blood|Both|N/A|N/A|No|Non-Probability Sample|Patients analyzed for beta thalassemia in our laboratory in Hadassah.|June 2011|June 22, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159042||194996|
NCT00160004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSICEJ1|The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis|The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis||Radboud University||Terminated|March 2006|December 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||June 2009|June 5, 2009|September 9, 2005|||problems with including patients and a large multicenter Trial is now starting as follow-up|No||https://clinicaltrials.gov/show/NCT00160004||194922|
NCT00168532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProfAnt-BHP-1996|Prophylactic Antibiotics in Measles|Prophylactic Antibiotics in Measles Infection. A Community-Based Randomised Double-Blind Placebo-Controlled Trial in Guinea-Bissau||Bandim Health Project||Completed|January 1998|October 2001|Actual|October 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||218|||Both|3 Months|N/A|No|||February 2008|February 25, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168532||194276|
NCT00168831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.255|Tiotropium / Respimat One-Year Study|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|February 2003|||June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|1007|||Both|40 Years|N/A|No|||September 2013|May 15, 2014|September 12, 2005|||||January 30, 2009|https://clinicaltrials.gov/show/NCT00168831||194254|
NCT00168844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.254|Tiotropium / Respimat One-Year Study|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|January 2003|||June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|983|||Both|40 Years|N/A|No|||September 2013|May 15, 2014|September 12, 2005||||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00168844||194253|
NCT00154700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159I9|Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer|A Phase II Study of Twice Weekly Paclitaxel, Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Folinic Acid in the Treatment of Recurrent or Metastatic Esophageal Cancer||National Taiwan University Hospital||Completed|January 2001|July 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2005|December 19, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154700||195315|
NCT00154713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27MD02|Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment|A Phase I/II Clinical Study of Immunotherapy for Advanced Colorectal Cancers Using CEA-Pulsed Dendritic Cells Mixed With Tetanus Toxoid and Subsequent IL-2 Treatment||National Taiwan University Hospital||Recruiting|July 2005|July 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||37|||Both|20 Years|75 Years|No|||July 2005|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00154713||195314|
NCT00161629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100N7-114|Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures|A Phase 1 Dose-Escalating, Double-Blind, Placebo-Controlled, Multicenter, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy for Closed Distal Radius Fractures||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2005|January 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|50 Years|80 Years|No|||December 2007|December 3, 2007|September 1, 2005||||No||https://clinicaltrials.gov/show/NCT00161629||194799|
NCT00155389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940110|Community-based Helicobacter Pylori Eradication|Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer||National Taiwan University Hospital|Yes|Recruiting|January 2004|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5000|||Both|30 Years|N/A|Accepts Healthy Volunteers|||July 2012|November 12, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00155389||195264|
NCT00156377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4710F-186|Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections|Investigation of the Influence of Intranasal Mupirocin on the Prevalence of S. Aureus Nosocomial Infections by Eradication of Intranasal S. Aureus||University Hospital Muenster||Completed|November 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1200|||Both|18 Years|N/A|No|||September 2005|May 24, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156377||195188|
NCT00156364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8107M00116|Studies of Organ Transplantation in Animals and Man|"Ii-Pancreas Transplantation in Man", "Long Term Effects of Cyclosporine (CSA) and Tacrolimus (FK506) on Renal Structure and Function", "Studies of the Renal Interstitium Type I Diabetic Patients",||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 1981|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|655|Samples With DNA|Skin Fibroblasts, Plasma and Serum samples, Urine samples, kidney biopsy culture samples.|Both|18 Years|60 Years|No|Probability Sample|This is not a study that recruits from the general population. This study is selectively        offered to eligible patients who are scheduled for a Pre-pancreas Transplant evaluation        visit at the University of Minnesota Medical Center, Fairview Transplant Center. If        interested in learning more, contact the Transplant Center for more information.|December 2014|December 10, 2014|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00156364||195189|
NCT00156663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN 20-057|Toward Gender Aware VA Healthcare: Development and Evaluation of an Intervention|Toward Gender Aware VA Health Care: Development and Evaluation of an Intervention||VA Office of Research and Development|No|Completed|May 2004|September 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|April 6, 2015|August 25, 2005||||No||https://clinicaltrials.gov/show/NCT00156663||195166|
NCT00156975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHOC|Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases|Adjuvant Chemotherapy With Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases- Randomized Phase III Study||Arbeitsgruppe Lebermetastasen und Tumoren||Active, not recruiting|November 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||384|||Both|18 Years|N/A|No|||April 2007|December 24, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00156975||195144|
NCT00152529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12591A|C.A.T.C.H.-I.T.Competent Adulthood Transition With Cognitive, Humanistic and Interpersonal Teaching|"C.A.T.C.H.-I.T." Competent Adulthood Transition With Cognitive, Humanistic and Interpersonal Teaching||University of Chicago||Terminated|October 2003|June 2004|Actual|June 2004|Actual|N/A|Observational|N/A||||8|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 7, 2005||No|Study completed|No||https://clinicaltrials.gov/show/NCT00152529||195482|
NCT00153101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.373|Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.|ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.||Boehringer Ingelheim||Completed|November 2001|||June 2008|Actual|Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||Actual|31546|||Both|55 Years|N/A|No|||May 2014|May 13, 2014|September 9, 2005||||No|June 15, 2009|https://clinicaltrials.gov/show/NCT00153101||195438|Only non-serious Adverse Events (AE) which lead to discontinuation of study medication were assessed and collected; the frequency was under 5%. Non-serious AEs per se were not assessed or collected.
NCT00153114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851-15|PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children|PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children||Braintree Laboratories||Completed|January 2003|||September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|4 Years|16 Years||||February 2013|February 6, 2013|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00153114||195437|
NCT00153673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5NA study|Effect of Selective COX-2 Inhibition on Ulcer Healing|Phase III Study of a Double-Blind Randomized Comparison of Famotidine Plus Celecoxib Versus Dologesics for Gastric Ulcer Healing in Arthritis Patients (NSAID#5A Study)||Chinese University of Hong Kong||Suspended|February 2001|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|September 8, 2005||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00153673||195394|
NCT00158743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEEP|Efficacy Study of Digibind for Treatment of Severe Preeclampsia|A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia||BTG International Inc.|Yes|Completed|February 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Female|N/A|N/A|No|||July 2014|July 17, 2014|September 8, 2005|Yes|Yes||No|July 17, 2014|https://clinicaltrials.gov/show/NCT00158743||195019|
NCT00158756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104021|Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants|Assess Immunogenicity & Reactogenicity of 2 Formulations of GSK's DTPw-HBV Vaccines vs Concomitant Admn of CSL's DTPw & GSK's HBV Vaccine, Co-admnd With GSK's Rotavirus Vaccine, to Infants at 3, 4½ & 6 Mths, After Birth Dose of HBV Vaccine||GlaxoSmithKline||Completed|September 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|307|||Both|N/A|4 Months|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158756||195018|
NCT00159055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280303-HMO-CTIL|Adoptive Immunotherapy for CMV Disease|Prevention and Treatment of CMV Disease by Adoptive Immunotherapy With Immune Donor Lymphocytes in Conjunction With Non-myeloablative Stem Cell Transplantation (NST)||Hadassah Medical Organization||Withdrawn|February 2004|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|N/A|No|||September 2005|April 7, 2011|September 9, 2005|||the PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00159055||194995|
NCT00159341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0404/84|Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Cigarette Smoke Nasal and Whole Blood Challenge in Patients With COPD||Imperial College London|No|Completed|September 2005|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2008|August 12, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159341||194973|
NCT00159601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTNU-47019800|Quality of Life and Mental Health in Children and Adolescents|Quality of Life and Mental Health in Children and Adolescents in a Child and Adolescent Psychiatric Outpatient Clinic and in the Normal Population||Norwegian University of Science and Technology|No|Completed|June 2003|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective|||Actual|2342|||Both|8 Years|16 Years|No||All patients 8-10 years of age consecutively referred to to the childpsychiatric        outpatient clinic in the period from 1th of June 2003 until 31th of December 2005, having        a minimum of two direct contacts with the clinical staff. Follow up study finished in        2008.|February 2009|February 3, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159601||194953|
NCT00160017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breakthrough_LoesSchouten|Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative|Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative to Improve Diabetes Care, Its Health Outcomes and Economic Costs||Radboud University||Completed|January 2005|March 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1861|||Both|18 Years|N/A|No|Non-Probability Sample|6 intervention and 9 control sites representing multiporfessional provider teams from 13        outpatient clinics (47 internists) and 37 general practices (42 general practitioners)        NB To assess the effects of the collaborative, patient outcomes, professional performance,        and structural aspects of care management are measured. Patients visiting the clinics were        invited to participate by filling out questionnaires and providing written consent to have        their medical records examined. Below information on patient inclusion is provided.|November 2015|November 27, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00160017||194921|
NCT00168558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUF-91134-2601-Twodose2|Early Two-dose Measles Vaccination Trial|Measles Vaccination in Guinea-Bissau. Strategies to Reduce Disease Burden and Improve Child Survival||Bandim Health Project|Yes|Completed|July 2003|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|5879|||Both|4 Months|6 Months|Accepts Healthy Volunteers|||March 2012|March 4, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168558||194274|
NCT00168870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haema CBF AHM UK/AS 04|Study of Metastatic Ocular Melanoma|Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma||Charite University, Berlin, Germany||Recruiting|February 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||September 2006|August 30, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168870||194251|
NCT00155402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940208|The Application of Fibrin Glue in Ocular Surface Diseases|Phase 1 Study of Applying Fibrin Glue in Patients With Corneal Ulcer or Patients Requiring Wound Closure by Suture||National Taiwan University Hospital|No|Withdrawn|April 2005|March 2008||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|3 Years|N/A|No|||March 2005|May 28, 2008|September 8, 2005||No|Short of supply of fibrin glue|No||https://clinicaltrials.gov/show/NCT00155402||195263|
NCT00155415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700305|A Prospective Single-Blinded Randomized Trial Comparing Colonoscopic Preparation at Different Time|||National Taiwan University Hospital||Completed|April 2005|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||120|||Both|20 Years|85 Years|No|||September 2005|December 1, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155415||195262|
NCT00155428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700518|Biomodel in Tetralogy of Fallot|Application of Biocardiac Model in Total Correction of Tetralogy of Fallot||National Taiwan University Hospital||Recruiting|May 2005|December 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|1 Month|20 Years|No|||May 2005|December 19, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155428||195261|
NCT00155051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700762|Progestin Treatment for Endometrial Stromal Cells in Adenomyosis|||National Taiwan University Hospital||Recruiting|July 2004|April 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||45|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||June 2004|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155051||195289|
NCT00156091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05784|Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)|A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Olanzapine Positive Control in Subjects Who Complete Protocols 041021 or 041022.||Merck Sharp & Dohme Corp.|Yes|Completed|April 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|260|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156091||195210|
NCT00160940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0019-C|Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis|Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease||University Health Network, Toronto||Recruiting|February 2002|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||200|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2005|November 29, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160940||194850|
NCT00161772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199|Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.|Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.||Pfizer||Completed|March 2002|August 2002||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|1 Year|5 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161772||194788|
NCT00156676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4031-I|Restoration of Walking in Multiple Sclerosis Using Treadmill Training.|Pilot Study on Gait & Motor Function in MS Using BWS Treadmill Training||VA Office of Research and Development||Completed|September 2004|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 18, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00156676||195165|
NCT00157001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R98-09-013|Feasibility Study of Photopheresis Post Angioplasty|Feasibility Study of Photopheresis Post Angioplasty||Atlantic Health System|Yes|Terminated|August 2000|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||120|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157001||195142|
NCT00157014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-009|Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens|Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens With MPA TDM||Astellas Pharma Inc|Yes|Completed|July 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|111|||Both|N/A|N/A|No|||January 2011|January 24, 2011|September 8, 2005|Yes|Yes||No|October 28, 2010|https://clinicaltrials.gov/show/NCT00157014||195141|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00156988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO/P04.103|The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns|The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns||Association of Dutch Burn Centres||Completed|March 2004|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|N/A|No|||August 2009|August 7, 2009|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00156988||195143|
NCT00152542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9549 (temp19)|Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants|Follow up at School-age of Children Participating in the Nitric Oxide Ventilatory Approach (NOVA) Study||University of Chicago|Yes|Completed|May 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|4 Years|6 Years|No|||March 2009|June 11, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00152542||195481|
NCT00152555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13238B|Physical Therapy for Systemic Lupus Erythematosus (SLE)|Physical Therapy for Improvement of Quality of Life in Patients With Systemic Lupus Erythematosus (SLE)||University of Chicago||Terminated|March 2003|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|16 Years|N/A|No|||April 2007|June 11, 2013|September 8, 2005||No|study completed|No||https://clinicaltrials.gov/show/NCT00152555||195480|
NCT00157716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC6021-CR-03-02|MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Cardiovascular and Cerebrovascular Effects of MC-1 in Patients Undergoing High-Risk Coronary Artery Bypass Graft (CABG) Surgery||Medicure||Completed|April 2004|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||900|||Both|18 Years|N/A|No|||October 2006|October 30, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157716||195097|
NCT00158041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH056-01D|Subcutaneous Amifostine Safety Study|Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities||Mt. Sinai Medical Center, Miami||Completed|January 2002|January 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||452|||Both|18 Years|N/A|No|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00158041||195072|
NCT00158509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1285|Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding|Efficacy of an HSV2 Genital Herpes Suppressive Treatment on HIV and HSV2 Genital Shedding Among Co-Infected Patients Receiving or Not Antiretroviral Drugs||French National Agency for Research on AIDS and Viral Hepatitis||Completed|August 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||215|||Female|16 Years|N/A|No|||June 2006|June 6, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00158509||195037|
NCT00158769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD10007|A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers|An Open-Label, Non-Randomised, Pharmacokinetic, Metabolic Disposition and Safety Study of a 3 Day Continuous Infusion of GR270773 in Healthy Subjects and Subjects With Hepatic Impairment.||GlaxoSmithKline||Completed|March 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00158769||195017|
NCT00158782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG10006|Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients|An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients.||GlaxoSmithKline|No|Completed|September 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|21 Years|N/A|No|||March 2011|March 17, 2011|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00158782||195016|
NCT00159068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391200-HMO-CTIL|Analysis of Genetic Factors Which May Influence the Course of HIV Infection|Genetic Influences on the Course and Response to Treatment of HIV: Contribution of Polymorphisms in Drug Metabolism and Disposition Genes and Haptoglobin Polymorphisms||Hadassah Medical Organization|No|Completed|February 2004|April 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|DNA isolated from peripheral blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with HIV attending the HIV clinic at Hadassah colden globes.|June 2010|June 22, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159068||194994|
NCT00159081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GI 9932 - P 2.2.2.1 / 1|One Year Drug Treatment in First-Episode Schizophrenia|One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia||Heinrich-Heine University, Duesseldorf|Yes|Completed|November 2000|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|55 Years|No|||January 2008|February 6, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00159081||194993|
NCT00159354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDG-PETsmoking|Measurement of Smoking−Induced Neutrophil Activation|Evaluation of Smoking−Induced Neutrophil Activation as a Potential Biomarker of Response to Therapeutic Interventions in COPD: Proof of Concept Study||Imperial College London||Completed|June 2005|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Both|50 Years|80 Years|No|||November 2007|May 28, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159354||194972|
NCT00159367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR1|The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle|The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle in Patients With Chronic Obstructive Pulmonary Disease||Imperial College London||Completed|January 2005|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|40 Years|85 Years|No|||August 2008|February 16, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00159367||194971|
NCT00159614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKI-203|Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment|Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment||NovaCardia, Inc.||Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2008|January 28, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00159614||194952|
NCT00159627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKI-202|Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).|A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Effects of KW-3902 on Diuresis in Patients With Congestive Heart Failure (CHF) Refractory to High Dose Diuretic Therapy||NovaCardia, Inc.||Completed|August 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|N/A|No|||January 2008|January 28, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00159627||194951|
NCT00160043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91411|Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.|Phase II Open-label Study to Investigate the Efficacy and Safety of PTK787/ZK 222584 Orally Administered Once Daily or Twice Daily at 1250 mg as Second-line Monotherapy in Patients With Stage IIIB or Stage IV Non-small-cell Lung Cancer (NSCLC)||Bayer|No|Completed|March 2005|November 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||December 2014|December 14, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00160043||194919|
NCT00159666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081004|Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia|A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo||Pfizer||Completed|October 2004|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||255|||Both|18 Years|N/A|No|||November 2006|March 7, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00159666||194948|
NCT00169494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/012|Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18|Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process||GlaxoSmithKline||Completed|September 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|770|||Female|10 Years|25 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169494||194204|
NCT00155441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700509|Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients|Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients||National Taiwan University Hospital||Recruiting|June 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||May 2005|January 8, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00155441||195260|
NCT00155779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100207816|ACE Gene Polymorphism and ARDS Outcome|Polymorphism of the Angiotensin-Converting Enzyme Gene and the Outcome of Acute Respiratory Distress Syndrome||National Taiwan University Hospital||Completed|December 2003|December 2004||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2003|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155779||195234|
NCT00155792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100208476|The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being|||National Taiwan University Hospital||Recruiting|January 2002|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||300|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||December 2001|December 19, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155792||195233|
NCT00156104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05926|Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia||Merck Sharp & Dohme Corp.|No|Completed|July 2005|September 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|460|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00156104||195209|
NCT00160602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87050|A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis|A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.||UCB Pharma||Completed|June 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||590|||Both|18 Years|N/A|No|||February 2010|September 6, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160602||194876|
NCT00161785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223|Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years|||Pfizer||Completed|June 2004|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||340|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161785||194787|
NCT00161473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16508-A|Alzheimer's in Long-Term Care--Treatment for Agitation|Alzheimer's in Long-Term Care--Treatment for Agitation||University of Washington|Yes|Completed|January 2001|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|N/A|N/A|No|||June 2012|June 26, 2012|September 8, 2005||No||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00161473||194809|
NCT00161200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4310|Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor|Studies of Esophageal Metaplasia Using a Novel Antibody: Reversibility of Columnar Metaplasia by Proton Pump Inhibitor||Rutgers, The State University of New Jersey||Terminated|December 2002|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||December 2009|December 10, 2009|September 8, 2005||Yes|slow accrual|||https://clinicaltrials.gov/show/NCT00161200||194830|
NCT00161434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-6505-A|A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons|A Randomized, Double-Blind, Placebo Controlled Crossover Trial Using Valacyclovir to Suppress HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons||University of Washington|No|Completed|March 2003|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Male|18 Years|N/A|No|||December 2007|December 29, 2007|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161434||194812|
NCT00152568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11119A|The Effectiveness of Car Seat Checks at Routine Pediatric Visits|The Effectiveness of Car Seat Checks at Routine Pediatric Visits||University of Chicago|No|Completed|June 2001|December 2003|Actual|September 2003|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|364|||Both|N/A|8 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00152568||195479|
NCT00152828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 00-0431-C|Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix|A Phase I/II Trial of the Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix||University Health Network, Toronto|Yes|Completed|February 2001|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00152828||195459|
NCT00158522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1213|Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)|Clinical Trial of the Efficacy of Pegylated Interferon (PEG-IFNα-2a) Alone in Egyptian Patients With Acute Hepatitis C||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|February 2003|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||February 2008|February 6, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158522||195036|
NCT00158795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104124|Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine|Assess the Safety & Reactogenicity of GSK Biologicals Hib Vaccine Co-administered With Chinese Local DTPw Vaccine When Compared to Chinese Local DTPw Vaccine Administered Alone, in Healthy Infants at 3,4 & 5 Mths of Age||GlaxoSmithKline||Completed|January 2005|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|454|||Both|3 Months|4 Months|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158795||195015|
NCT00159094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO03-21-005|A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer|A Phase II Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer||Hematology Oncology Consultants||Recruiting|October 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||September 2005|May 30, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00159094||194992|
NCT00159107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EB0133|Integrative Therapy in Alcoholism|Acamprosate and Integrative Behavior Therapy in the Outpatient Treatment of Alcohol Dependents||Heinrich-Heine University, Duesseldorf|Yes|Completed|May 2003|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|371|||Both|25 Years|60 Years|No|||October 2007|January 29, 2008|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00159107||194991|
NCT00159380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002AT033B|Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects|A Double Blind, Crossover Placebo-controlled Study to Evaluate the Effect of L-arginine and Aminoguanidine on Bronchial, Alveolar and Nasal NO and NO Metabolites in Exhaled Air, Breath Condensate, Saliva, Nasal Lavage Fluid and Induced Sputum in 10 Normal and 15 Asthmatic Subjects||Imperial College London||Completed|September 2003|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|25|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||April 2008|June 3, 2015|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00159380||194970|
NCT00159640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4451006|Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia|A Multi-Center, Randomized, Double Blind, Dose-Response, Placebo And Gabapentin Controlled Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia||Pfizer||Terminated|February 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||315|||Both|18 Years|N/A|No|||March 2007|March 27, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00159640||194950|
NCT00159653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641027|A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma|A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension.||Pfizer||Completed|July 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|500|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00159653||194949|
NCT00160030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9326|Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer|Phase II Study Comparing Radiochemotherapy With the Folfox 4 Regimen Versus Radiochemotherapy With 5FU-Cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Esophageal Cancer||Sanofi|No|Completed|September 2004|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00160030||194920|
NCT00159679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081060|Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy|A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy||Pfizer||Completed|September 2004|October 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|167|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00159679||194947|
NCT00159692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531063|Amlodipine Diabetic Hypertension Efficacy Response Trial|A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating The Safety and Efficacy Of The Addition Of Amlodipine To Quinapril Or Losartan In The Treatment Of Diabetic Hypertensive Subjects|ADHERE|Pfizer||Completed|March 2003|August 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|739|||Both|30 Years|75 Years|No|||February 2009|February 6, 2009|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00159692||194946|
NCT00169507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104083|Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)|Phase III Multicentric Open Study to Evaluate Immunological Memory Induced by 3-dose Primary Vaccination Followed by Booster Dose of GSK Biologicals' 11-valent Conjugate Pneumococcal Vaccine Compared to Unprimed Subjects by Giving 1 Dose of Aventis Pasteur's Pneumo 23||GlaxoSmithKline||Completed|March 2005|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|31 Months|57 Months|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169507||194203|
NCT00169793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-076|Nephrolithiasis and Bariatric Surgery|Nephrolithiasis and Bariatric Surgery||Indiana Kidney Stone Institute|No|Completed|August 2005|December 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|89|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169793||194181|
NCT00159991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|961502837|Copenhagen Arterial Revascularization Randomized Patency and Outcome Trial|Arterial Revascularization for Coronary Bypass Surgery: A Randomized Trial Comparing the Outcome After Using LIMA + Vein Grafts Versus Total Arterial Revascularization With LIMA + RIMA + Radial Artery Grafts|CARRPO|Rigshospitalet, Denmark|No|Active, not recruiting|February 2002|February 2015|Anticipated|February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|70 Years|No|||January 2008|February 12, 2008|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159991||194923|
NCT00155805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200200605|Immunologic Factors in Reflux Esophagitis and Barrett’s Esophagus|Immunologic Factors Correlating With Cyclooxygenase and Nitric Oxide Synthase in Reflux Esophagitis and Barrett’s Esophagus||National Taiwan University Hospital||Recruiting|February 2004|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||90|||Both|18 Years|80 Years|No|||February 2004|November 25, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155805||195232|
NCT00155818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100209714|Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia|Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia||National Taiwan University Hospital||Completed|August 2003|July 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2003|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00155818||195231|
NCT00160927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 02-03|Microvascular Response in Diabetes Mellitus|Microcirculation cutanée et Vasodilatation Induite Par la Pression Non-Nociceptive Chez Les diabètiques||University Hospital, Angers|No|Recruiting|January 2003|January 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 16, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00160927||194851|
NCT00157482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESD|Ezetimibe and Simvastatin in Dyslipidemia of Diabetes|A Randomized, Prospective, Double-Blind Study to Evaluate the Effects on Lipid Profile of Combined Ezetimibe and Simvastatin Therapy as Compared to Simvastatin Alone in People With Type 2 Diabetes||Mario Negri Institute for Pharmacological Research||Completed|January 2005|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||108|||Both|18 Years|70 Years|No|||December 2006|February 12, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157482||195114|
NCT00157729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC6021-CL-04001|MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)|Evaluation of the Effects of MC-1 Alone and in Combination With an ACE Inhibitor on Ambulatory Blood Pressure and Metabolic Function in Hypertensive Patients With Type 2 Diabetes Mellitus||Medicure||Completed|August 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|85 Years|No|||October 2006|October 30, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157729||195096|
NCT00157742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRIT|Comparison of SCS and PMR in Patients With Refractory Angina Pectoris|An Open Single-Centre Parallel Randomised Trial of Spinal Cord Stimulation (SCS) and Percutaneous Myocardial Revascularisation (PMR) in Patients With Refractory Angina Pectoris||Medtronic||Terminated|September 2000|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Both|18 Years|N/A|No|||September 2005|December 15, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00157742||195095|
NCT00161746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146A|Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years|Multicentre Randomized Double-Blind Phase II/III Study on the Safety and Immunogenicity of Three Vaccinations With TICOVAC in Two Dosages in Healthy Children Aged Between Six Months and Three Years||Pfizer||Completed|April 1998|June 1999||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|6 Months|47 Months|Accepts Healthy Volunteers|||May 2015|May 20, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00161746||194790|
NCT00161759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|520001|Safety and Efficacy Study of Fibrin Sealant (FS 4IU) for Skin Graft Fixation and Wound Healing in Subjects With Burn Wounds|A Study to Assess the Safety and Efficacy of Fibrin Sealant (FS 4IU) for Wound Healing in Subjects With Burn Wounds Requiring Skin Grafting Procedures||Baxter Healthcare Corporation||Completed|March 2002|January 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|6 Years|65 Years||||October 2006|October 19, 2006|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00161759||194789|
NCT00157378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GI9933-P2.1.2.1|Optimization of Acute Treatment in First Episode Schizophrenia|Optimization of Acute Treatment in First Episode Schizophrenic Patients by New Pharmacological Treatments||Ludwig-Maximilians - University of Munich||Active, not recruiting|November 2000|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|55 Years|No|||January 2000|September 8, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157378||195115|
NCT00158249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19238-1|Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals|Cannabis Dependence: Imaging and Medication Development - 1||Mclean Hospital|No|Completed|September 2009|October 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|September 8, 2005|Yes|Yes||No|October 15, 2014|https://clinicaltrials.gov/show/NCT00158249||195056|
NCT00158535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC08 THEVIC|Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection|Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection ANRS HC08 Thevic||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|June 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|69 Years|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00158535||195035|
NCT00158548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVC98|ACT With Chloroquine, Amodiaquine & Sulphadoxine-Pyrimethamine in Pakistan|Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-Pyrimethamine in Pakistan||Gates Malaria Partnership|Yes|Completed|June 2001|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|9||Actual|650|||Both|5 Years|70 Years|No|||June 2007|July 3, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158548||195034|
NCT00158561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCKD45|Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria|An Open-Label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan||Gates Malaria Partnership|Yes|Completed|February 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||750|||Both|3 Years|N/A|No|||March 2009|March 5, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00158561||195033|
NCT00158808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101477|Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths|Assess the Immunogenicity &d Reactogenicity of a Booster Dose of a Formulation of GSK Biologicals' DTPw-HBV/Hib Vaccine at 15-18 Mths of Age in Infants Previously Primed With the Same Vaccine||GlaxoSmithKline||Completed|January 2005|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|175|||Both|15 Months|N/A|Accepts Healthy Volunteers|||February 2011|February 10, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158808||195014|
NCT00159120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GI 9932 - P 2.2.2.1 / 2|Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia|Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia||Heinrich-Heine University, Duesseldorf|Yes|Completed|November 2001|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|71|||Both|18 Years|55 Years|No|||January 2008|January 28, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00159120||194990|
NCT00159393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-096|Percutaneous Nephrolithotomy: A Registry and Database|Percutaneous Nephrolithotomy: A Registry and Database||Indiana Kidney Stone Institute|No|Recruiting|October 2003|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|urology clinic patients already scheduled for percutaneous removal of kidney stones|February 2016|February 22, 2016|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159393||194969|
NCT00159718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531031|Double Blind Atorvastatin Amlodipine Study|Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease.|DUAAL|Pfizer||Completed|July 2001|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|21 Years|80 Years|No|||January 2008|January 29, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159718||194944|
NCT00160069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91374|Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer|Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)||Bayer|No|Completed|August 2005|April 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160069||194917|
NCT00169520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSP10003|SB-715992 In Combination With Docetaxel In Patients With Solid Tumors|A Phase I, Open-Label Study of SB-715992 in Combination With Docetaxel in Patients With Advanced Solid Tumors.||GlaxoSmithKline||Completed|June 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00169520||194202|
NCT00160953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0041-C|Endorectal Coil Magnetic Resonance Images (ERC-MRI)|Development of a Prostate Deformation Model to Enable Accurate Registration of Endorectal Coil Magnetic Resonance Images (ERC-MRI) to Reference Treatment Planning CT Images||University Health Network, Toronto||Completed|February 2005|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||20|||Male|18 Years|N/A|No|||August 2010|August 10, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00160953||194849|
NCT00160342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S030.2.112|Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes|A Multi-Center, Double-Blind, Placebo-Controlled Comparison of Multiple Doses of Esterified Estrogens and Methyltestosterone, in Combination and Alone, in Relieving Vasomotor Symptoms in Postmenopausal Women||Solvay Pharmaceuticals|No|Completed|June 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Anticipated|1251|||Female|45 Years|65 Years|No|||August 2008|August 14, 2008|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00160342||194896|
NCT00160589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00401|LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)|A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)||UCB Pharma||Completed|April 2005|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||729|||Both|18 Years|N/A||||September 2009|December 13, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160589||194877|
NCT00161447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0832-D|Male Hormonal Contraceptive Development-ACY-5|Male Hormonal Contraceptive Development: Suppression of Spermatogenesis With the Addition of a Potent Antagonist (Acyline) to Testosterone and DMPA (ACY-5)|ACY-5|University of Washington|No|Completed|May 2004|April 2006|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00161447||194811|
NCT00161460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-3772-C01|Colorectal Cancer Screening Intervention in UWPN Clinics|Colorectal Cancer Screening Intervention in UWPN Clinics||University of Washington|No|Completed|June 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|50 Years|N/A|No|||December 2014|December 1, 2014|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161460||194810|
NCT00161226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4800|A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35|A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35||Rutgers, The State University of New Jersey||Terminated|February 2004|June 2006|Actual|June 2006|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|44|||Female|35 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Levonorgestrel IUD, Prevention of Endometrial Cancer, Patients Aged 35-50, BMI > 30|December 2009|December 10, 2009|September 8, 2005|||Principal investigator left institution|No||https://clinicaltrials.gov/show/NCT00161226||194828|
NCT00157053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060102|Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901|Evaluation of Pharmacokinetics, Safety, Efficacy and Immunogenicity of rAHF-PFM in Previously Treated Hemophilia A Patients - A Continuation Study||Baxalta US Inc.||Completed|November 2001|August 2004|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|10 Years|N/A|No|||February 2011|June 26, 2015|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00157053||195138|
NCT00157066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM1|Effects of Vitamin D Supplementation on Antimycobacterial Immunity|Effects of Vitamin D Supplementation on Antimycobacterial Immunity: A Randomised Trial||Barts & The London NHS Trust||Completed|December 2002|September 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||230|||Both|18 Years|N/A||||January 2007|January 5, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157066||195137|
NCT00157508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCX4016-X-204|Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy|A Pilot, Randomised, Double-blind, Cross-over Study to Assess the Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy||Mario Negri Institute for Pharmacological Research||Terminated|March 2003|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||13|||Both|18 Years|75 Years|No|||September 2005|April 8, 2015|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157508||195113|
NCT00158054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB5166|COPES Phase I Randomized Controlled Trial of Treatment For Distress in Heart Disease Patients|Consortium for Translation of Psychosocial Depression Theories to Interventions and Dissemination - Project 2: Phase I Randomized Controlled Trial of Patient Preference, Stepped-Care Treatment For Distress in Heart Disease Patients||Columbia University|Yes|Completed|January 2005|April 2015|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|157|||Both|21 Years|N/A|No|||February 2016|February 4, 2016|September 8, 2005||No||No|March 4, 2015|https://clinicaltrials.gov/show/NCT00158054||195071|
NCT00158067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006633|Study of an External Responsive Neurostimulator System on Epileptiform Activity|Automated Response to Spontaneous Epileptiform Activity Using the External Responsive Neurostimulator (eRNS) System Clinical Investigation||NeuroPace||Completed|March 2002|March 2008|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|12 Years|N/A|No|||August 2010|August 24, 2010|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00158067||195070|
NCT00158262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068603|Effect of Propranolol on Preventing Post-Traumatic Stress Disorder|Prophylaxis of Post-Traumatic Stress Disorder With Post-Trauma Propranolol||Massachusetts General Hospital|Yes|Completed|August 2004|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 26, 2013|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158262||195055|
NCT00158275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH070642|Combined Interventions for Treating Depression and Chronic Back Pain|Integrated Care for Depression and Chronic Back Pain||Group Health Cooperative||Completed|October 2004|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|25 Years|74 Years|No|||July 2014|July 14, 2014|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00158275||195054|
NCT00158574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVF01|Kilimanjaro IPTi Drug Options Trial|Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-Acting Antimalarial Drugs||Gates Malaria Partnership|Yes|Completed|January 2005|June 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|2419|||Both|2 Months|24 Months|Accepts Healthy Volunteers|||March 2009|March 5, 2009|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00158574||195032|
NCT00158821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-99-903|Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.|A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.(Extension)||Gilead Sciences||Completed|March 2000|June 2013|Actual|December 2001|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00158821||195013|
NCT00158834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS30018|Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications|Comparison of Stepwise Treatment of Asthmatic Children With Salmeterol/Fluticasone Propionate Combination Product (Seretide®) and/or Fluticasone Propionate (Flixotide®) Based on PD20 Methacholine and Symptoms or Based on Symptoms Only (Children Asthma Therapy Optimal)||GlaxoSmithKline||Completed|November 1999|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|6 Years|16 Years|No|||October 2008|October 9, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158834||195012|
NCT00159133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GI 9932 - P 2.2.2.2|Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia|Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepine in Patients With First-Episode Schizophrenia After One Year Maintenance Treatment Under Further Maintenance Treatment vs. Stepwise Discontinued Drugs||Heinrich-Heine University, Duesseldorf|Yes|Completed|November 2001|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|71|||Both|18 Years|55 Years|No|||January 2008|January 28, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00159133||194989|
NCT00159146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 5|Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression|A Short Term Double Blind Randomised Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression||Hillerod Hospital, Denmark|No|Terminated|August 2002|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|September 7, 2005||No|lack of participants fulfilling inclusion criteria|No||https://clinicaltrials.gov/show/NCT00159146||194988|
NCT00159406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-095|Laser Prostatectomy Database and Registry|Laser Prostatectomy for Benign Prostatic Hyperplasia: A Registry and Database||Indiana Kidney Stone Institute|No|Recruiting|October 2003|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Male|18 Years|N/A|No|Non-Probability Sample|Patients of IU Health Physicians Urology who are already scheduled to undergo a laser        prostatectomy|February 2016|February 22, 2016|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00159406||194968|
NCT00159705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081007|Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy|A Randomized Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy||Pfizer||Completed|April 2005|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|276|||Both|18 Years|N/A|No|||October 2008|October 9, 2008|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00159705||194945|
NCT00160719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173-2005|HLA Sensitization Following Major Cortical Allograft Bone Procedures|HLA Sensitization Following Major Cortical Allograft Bone Procedures||University of Florida|No|Completed|September 1999|March 2010|Actual|March 2010|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|12 Years|80 Years|No|Non-Probability Sample|Orthopaedic clinic|October 2012|October 26, 2012|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160719||194867|
NCT00160732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12176A|Allogenic Islet Cell Transplantation|Allogenic Islet Cells (Human, U. of Chicago) Administered Via Intraportal Infusion; and Immunosuppressive Therapy||University of Chicago|No|Active, not recruiting|October 2003|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|58 Years|No|||January 2016|January 13, 2016|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160732||194866|
NCT00169533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF19060|Rollover Study Of Lapatinib In Cancer Patients|An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.||GlaxoSmithKline||Completed|August 2004|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169533||194201|
NCT00169546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM40100|Study In Airway Physiology In Children|Comparator Study to Demonstrate Superiority of Salmeterol/Fluticasone Propionate 50/100mcg bd Over Fluticasone Propionate 200mcg bd With Respect to Airway Physiology in Children Treated for 6 Weeks.||GlaxoSmithKline||Completed|January 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|4 Years|11 Years|No|||October 2008|October 15, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169546||194200|
NCT00161213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539409|Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer|Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer||Rutgers, The State University of New Jersey|Yes|Completed|September 2005|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|September 8, 2005|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00161213||194829|
NCT00160966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTx-PV-002|Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy|Prospective Randomized Study to Characterize Risk Factors of Polyomavirus-related Transplant Nephropathy and the Impact of Three Immunosuppressive Regimens on Nephropathy Incidence||University of Giessen|Yes|Completed|September 2004|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|N/A|No|||July 2010|July 2, 2010|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160966||194848|
NCT00161239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5192|LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma|LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma||Rutgers, The State University of New Jersey||Terminated|February 2005|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 10, 2009|September 8, 2005|||toxicity|No||https://clinicaltrials.gov/show/NCT00161239||194827|
NCT00161486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9401-B|The Effects of Testosterone on Prostate Tissue (ACYP-1)|The Effects of Testosterone on Prostate Tissue in Normal Men (ACYP-1)|ACYP-1|University of Washington|No|Completed|July 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|13|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00161486||194808|
NCT00157079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160101|Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders|A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders||Baxalta US Inc.||Completed|June 2002|December 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|24 Months|N/A|No|||October 2006|June 26, 2015|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00157079||195136|
NCT00157092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410302|Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency|A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency||Baxalta US Inc.||Completed|March 2004|October 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||October 2006|June 26, 2015|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00157092||195135|
NCT00157105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|069902|Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery|Recombinant Antihemophilic Factor (rAHF PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Safety and Efficacy in Hemophilia A Patients Undergoing Surgical or Invasive Procedures||Baxalta US Inc.||Completed|February 2001|August 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|5 Years|N/A|No|||October 2006|June 26, 2015|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00157105||195134|
NCT00157755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDHF0025-70006|Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)|Gastric Stimulation for Vomiting, Nausea and Related Symptoms Associated With Gastroparesis Using Enterra® Gastric Stimulation System||MedtronicNeuro||Terminated|June 2002|March 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||December 2009|February 23, 2010|September 8, 2005|Yes|Yes||No|December 18, 2009|https://clinicaltrials.gov/show/NCT00157755||195094|Early termination of the study impacted the ability to analyze the primary endpoint and secondary endpoint 1 for the idiopathic arm of the study. The minimum sample size for analysis of these endpoints was 32 subjects.
NCT00157768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medtronic_BRC_CRM_002|IRIS : Use of Implantable Defibrillator in High-Risk Patients Early After Acute Myocardial Infarction|IRIS - Immediate Risk-Stratification Improves Survival - Joint Study of the German University Hospitals and German Society of Leading Cardiological Hospital Physicians (ALKK)||Medtronic Bakken Research Center||Active, not recruiting|June 1999|April 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|900|||Both|18 Years|80 Years|No|||August 2008|August 4, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157768||195093|
NCT00158080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K0001|Hemofiltration for Contrast-Induced Nephropathy|Prevention of Contrast-Induced Nephropathy by Real-Time Hemofiltration||Nara Medical University||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|20 Years|90 Years|No|||September 2005|September 7, 2005|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00158080||195069|
NCT00158093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB122|A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo|A Randomized, Parallel Group Safety Evaluation of Electrocardiographic Intervals and Blood Pressure in Normal Healthy Volunteers After Nebivolol, Atenolol, Moxifloxacin, or Placebo Administration After Single and Repeated Doses||Mylan Bertek Pharmaceuticals||Completed|June 2003|July 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 7, 2005|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00158093||195068|
NCT00158288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09876-1|The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1|LAAM With Behavioral Treatment for Opioid/Cocaine Abuse||National Institute on Drug Abuse (NIDA)||Completed|March 1997|August 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2005|November 3, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00158288||195053|
NCT00159159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.325|LOW CYCLO: Study Evaluating the Benefit of Two Doses of Ciclosporine in de Novo Cardiac Transplant|LOW CYCLO: A Multicenter, Prospective, Randomized Study Evaluating the Benefit, on Renal Function, of Two Doses of Ciclosporine: Low Dose Versus Usual Dose, in Association With Mycophenolate and Corticoïds, in de Novo Cardiac Transplant||Hospices Civils de Lyon||Active, not recruiting|March 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||106|||Both|18 Years|65 Years|No|||April 2007|April 26, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00159159||194987|
NCT00159419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9902-30|Bisphosphonate Therapy for Osteogenesis Imperfecta|Bisphosphonate Therapy for Osteogenesis Imperfecta||Indiana University|Yes|Completed|August 1999|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|3 Years|21 Years|No|||September 2011|September 26, 2011|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00159419||194967|
NCT00159731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081036|Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy|An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy||Pfizer||Completed|January 2005|May 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||July 2006|March 14, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00159731||194943|
NCT00159744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07008|3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)|A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES)||Merck Sharp & Dohme Corp.|Yes|Completed|November 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|488|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00159744||194942|
NCT00160095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088|Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas|Patient Selection for Hypoxia Modifying Treatments Based on Functional Microregional Imaging of Tumor Vasculature, Oxygenation and Proliferation in Squamous Cell Carcinoma of the Larynx||Radboud University||Completed|July 2001|March 2013|Actual|March 2010|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|79|Samples With DNA|Tumor biopsies|Both|18 Years|N/A|No|Non-Probability Sample|Squamous cell carcinoma of the larynx|May 2015|May 6, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00160095||194915|
NCT00160433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-398|A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.|A Phase II, 3-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Doses of J867 (0.5, 1.5 and 5 mg QD) Versus Placebo in Subjects With Endometriosis||Abbott|No|Completed|August 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|131|||Female|18 Years|40 Years|No|||May 2008|May 27, 2008|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00160433||194889|
NCT00160355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WASHAP|Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome|Haploidentical Hematopoietic Stem Cell Transplantation for Pediatric Patients With Wiskott-Aldrich Syndrome: A Pilot Study||St. Jude Children's Research Hospital|No|Completed|May 2005|February 2009|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|N/A|18 Years|No|||February 2009|February 12, 2009|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160355||194895|
NCT00160641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87051|A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis|A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050||UCB Pharma|No|Completed|November 2005|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|567|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|September 8, 2005|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00160641||194873|
NCT00160654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01036|Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy|A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra™ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.||UCB Pharma||Completed|November 2003|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||345|||Both|18 Years|N/A||||July 2010|November 14, 2013|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00160654||194872|
NCT00160979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 00-0443-C|Transrectal Tumour Oxygen - US Army|A Study of Transrectal Tumour Oxygen Measurements in Patients With Clinically Localized Prostate Cancer||University Health Network, Toronto||Active, not recruiting|January 2001|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|195|||Male|18 Years|80 Years|No|||February 2016|February 5, 2016|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00160979||194847|
NCT00161005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2935-0304 (UUS)|Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction|Benefits and Costs in Two Different Strategies for Treating Acute Myocardial Infarction With ST-Elevation.||Ullevaal University Hospital|Yes|Active, not recruiting|February 2005|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|266|||Both|18 Years|75 Years|No|||April 2009|April 16, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00161005||194845|
NCT00161538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASTA V.1.5|Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation|A Randomized, Prospective Multicenter Study to Examine the Optimal Position of the Atrial Leads for Therapy of the Sinus Node Syndrome||Medtronic BRC||Completed|July 2000|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||456|||Both|18 Years|N/A|No|||October 2006|October 19, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00161538||194806|
NCT00161525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095-053|Pneumatic Displacement of Subretinal Hemorrhage With Perfluorocarbon Gases|Perfluorocarbon Gases for the Repair of Retinal Detachments.||Weill Medical College of Cornell University|No|Recruiting|October 2003|June 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|95 Years|No|||January 2011|January 3, 2011|September 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00161525||194807|
NCT00157118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400101|Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency|A Phase II/III Clinical Study for the Determination of the Efficacy and Safety of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency||Baxalta US Inc.||Completed|August 2003|March 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|N/A|N/A|No|||July 2013|June 26, 2015|September 8, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00157118||195133|
NCT00157521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-ARG|L-Arginine in Pre-Eclampsia|A Double-Blind, Randomized, Pilot Study to Explore Whether Enhancing L-Arginine Bioavailability by Oral Supplementation Increases NO Production and Prevents Peroxynitrite Generation in the Pre-Eclamptic Placenta||Mario Negri Institute for Pharmacological Research||Completed|September 2002|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2006|December 21, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157521||195112|
NCT00157781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124|LEAF - Low Energy In Atrial Fibrillation|Low Energy in Atrial Fibrillation AF Phase IV Study in AT/AF Population Atrial Arrhythmias Prevention and Reduction With Low Energy Atrial Antitachycardia Pacemaker||Medtronic Bakken Research Center||Terminated|August 2000|November 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||237|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00157781||195092|
NCT00167531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/06/09|The Efficacy of Treadmill Training in Establishing Walking After Stroke|The Efficacy of Treadmill Training in Establishing Walking After Stroke||University of Sydney|No|Completed|August 2002|July 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|126|||Both|50 Years|85 Years|No|||September 2006|October 1, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00167531||194353|
NCT00167778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3611-R|Prosthetic Components and Stability in Amputee Gait|Turning Corners: Prosthetic Components and Stability in Amputee Gait||VA Office of Research and Development|No|Completed|January 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|July 1, 2005||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00167778||194334|Our sample population consisted of community ambulators whose results may not generalize to all lower limb amputees.
NCT00168727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-03-ZEV|Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma|Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma||Biogen||Completed|June 2003|October 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||October 2006|October 18, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00168727||194262|
NCT00167115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406M61001|Metabolic Effects of Alcohol|Metabolic Effects of Alcohol in the Form of Wine in Persons With Type 2 Diabetes Mellitus||University of Minnesota - Clinical and Translational Science Institute|No|Completed|December 2004|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|40 Years|N/A|No|||July 2012|July 9, 2012|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167115||194384|
NCT00177190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0307015|In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)|In Vitro Evaluation of Immune Responses in CTCL||University of Pittsburgh|Yes|Completed|June 2002|January 2006|Actual|January 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|8|Samples Without DNA|White cells|Both|18 Years|N/A|No|Non-Probability Sample|Cutaneous Lymphoma Clinic patients|June 2013|May 27, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177190||193623|
NCT00167804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3520P|Comparing Virtual Reality Therapy to Usual Treatment for PTSD|Comparing Virtual Reality Therapy to Usual Treatment for PTSD||VA Office of Research and Development||Completed|September 2004|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||December 2011|December 2, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167804||194332|
NCT00169650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-048|Laparoscopic Pyeloplasty Registry and Database|Laparoscopic Pyeloplasty: A Registry and Database||Indiana Kidney Stone Institute|No|Active, not recruiting|July 2003|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|64|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction|February 2016|February 22, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169650||194192|
NCT00169663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-049|Brushite Kidney Stones: A Registry and Database of Clinical and Laboratory Findings|Brushite Stones: A Registry and Database of Clinical and Laboratory Findings||Indiana Kidney Stone Institute|No|Completed|July 2003|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of Methodist Urology in Indianapolis, IN who have a stone analysis of 100%        brushite stone|April 2012|April 23, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169663||194191|
NCT00200616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/00/10-O|Usefulness of Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux.|Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux. A Randomised Prospective Study of Continuous Low Dose of Trimethoprim-Sulfamethoxazole Versus Surveillance.||Nantes University Hospital|No|Completed|April 2001|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||232|||Both|N/A|3 Years|No|||June 2008|June 30, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200616||191873|
NCT00200928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.2.93.96.2|Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood.|Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood.||The Netherlands Asthma Foundation||Completed|January 1999|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||120|||Both|N/A|N/A|No|||April 2006|April 3, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200928||191851|
NCT00167037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56m3|Fast Stepping in Stroke Patients for Fall Prediction and Prevention:Control Mechanisms and Clinical Implications|Fast Stepping in Stroke Patients for Fall Prediction and Prevention:Control Mechanisms and Clinical Implications||National Taiwan University Hospital||Active, not recruiting|August 1999|July 2002||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167037||194390|
NCT00170430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20486-A|Reducing Vaginal Infections in Women|Reducing Vaginal Infections in Women at Risk for HIV-1||University of Washington||Completed|May 2003|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Female|16 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 16, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00170430||194135|
NCT00167505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U48DP000057|All About Youth: Evaluation of Sexual Risk Avoidance and Risk Reduction Programs for Middle School Students|SIP 4-04 Evaluation of Abstinence-Only and Abstinence-Plus Program to Prevent HIV, STD, and Pregnancy Among Middle School Students||The University of Texas Health Science Center, Houston|No|Completed|September 2006|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1742|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||October 2010|October 25, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167505||194355|
NCT00167726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0482|Neuraxial and Neurolytic Analgesia for Intractable Pain|Neuraxial and Neurolytic Analgesia for Intractable Pain||University of Wisconsin, Madison|No|Completed|January 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|This is a prospective case series analysis. Subjects over the age of 18 who are offered        neuraxial (epidural or intrathecal) analgesia or neurolytic procedures (e.g. celiac,        hypogastric, or sacral nerve plexus block) to treat intractable pain through the UW        Interventional Pain Program.|December 2014|December 5, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167726||194338|
NCT00167739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2003/Q/SP|Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine|Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria||Albert Schweitzer Hospital||Completed|April 2003|February 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|2 Years|7 Years|No|||September 2005|September 19, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167739||194337|
NCT00168051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082A-101711/3082A1-900|Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A|A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2005|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|21|||Male|18 Years|64 Years|No|||February 2013|February 7, 2013|September 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00168051||194313|
NCT00169299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG017057|Herbal Alternatives for Menopause Symptoms (HALT Study)|Herbal Alternatives for Menopause Symptoms: A Randomized Trial||Group Health Cooperative||Active, not recruiting|June 2001|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||351|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169299||194218|
NCT00171106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489B2401|Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure|A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure||Novartis||Completed|December 2002|February 2008|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|21 Years|N/A||||June 2008|June 13, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00171106||194086|
NCT00180635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-104-170903|NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD|A Double Blind, Crossover Placebo-controlled Study to Evaluate the Effect of L-arginine and Aminoguanidine on Bronchial and Alveolar Nitric Oxide and Nitric Oxide Metabolites in Exhaled Air, Breath Condensate, Nasal Lavage, Mouth Wash Fluid, and Induced Sputum in 7 Healthy Non-smokers, 10 Smokers and 12 COPD Patients||Imperial College London||Completed|October 2003|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|2||Anticipated|29|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||April 2008|June 3, 2015|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00180635||193363|
NCT00168376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57/04|A Randomised Double-Blind Trial of Targeted Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder|A Randomised Double-Blind Trial of Targeted Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder||The Alfred||Completed|July 2004|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||60|||Both|18 Years|70 Years|No|||April 2007|April 13, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00168376||194288|
NCT00169312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000514226|Internet-Based Nutrition Education Program in Preventing Cancer in Participants of Health Maintenance Organizations|The HMO Cancer Research Network (CRN) - Making Effective Nutritional Choices for Cancer Prevention: The MENU Study||National Cancer Institute (NCI)||Active, not recruiting|August 2005|June 2007||||N/A|Interventional|Allocation: Randomized, Masking: Single Blind|||Anticipated|2619|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 19, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00169312||194217|
NCT00169325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031201|Clinical, Neurophysiological and Radiological Evaluation of Patients With Basal Ganglia Lesions|||Groupe Hospitalier Pitie-Salpetriere||Completed|September 2005|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with lesion of the basal ganglia structures|September 2015|September 11, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169325||194216|
NCT00167128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phonpaed002|The Phonak EduLink-System in Students With Specific Performance Deficits in Speech-in-Noise Intelligibility|The Phonak EduLink-System in Students With Specific Performance Deficits in Speech-in-Noise Intelligibility||University Hospital Muenster||Recruiting|March 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|6 Years|11 Years|No|||May 2006|August 14, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167128||194383|
NCT00167362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060902|Cognitive Enhancement Therapy for Early-Stage Schizophrenia|Rehabilitation, Brain Function and Early Schizophrenia||Beth Israel Deaconess Medical Center|No|Active, not recruiting|August 2001|September 2016|Anticipated|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|16 Years|51 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167362||194366|
NCT00177437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0404024|Home Screening for Chlamydia Surveillance|Home Screening for Chlamydia Surveillance||University of Pittsburgh||Completed|June 1999|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||403|||Female|15 Years|29 Years|Accepts Healthy Volunteers|||December 2007|December 12, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00177437||193604|
NCT00167830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760|Barriers to Treatment in Obese Adolescents|Understanding The Barriers in Treatment of Obesity in Adolescents 11-18 in Central Virginia||Virginia Commonwealth University|Yes|Completed|November 2003|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|292|||Both|11 Years|18 Years|No|||January 2014|January 16, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167830||194330|
NCT00167843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28574|Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses|A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health||Albert Schweitzer Hospital||Completed|December 2002|March 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1189|||Both|N/A|5 Months|Accepts Healthy Volunteers|||January 2013|January 23, 2013|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167843||194329|
NCT00201656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0002|Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)|Removal Versus Retention of Cervical Cerclage in Preterm Premature Rupture of Membranes-A Multicenter Randomized Clinical Trial|PROMCerclage|Mednax Center for Research, Education and Quality|Yes|Terminated|November 2004|April 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|60 Years|No|||December 2014|December 17, 2014|September 13, 2005|No|Yes|This trial was terminated following a futility analysis confirming futility of continuing the    study|No||https://clinicaltrials.gov/show/NCT00201656||191799|
NCT00201669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0442|A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2004|June 2006|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201669||191798|
NCT00200551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/00/6-G|A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant|A Prospective, Randomized, Open, Multicentric Study Intended to Evaluate the Efficacy and Tolerability of Sequential Treatment Based on Rabbit Anti-T-lymphocyte Serum, of Mycophenolate Mofetil and of Cyclosporin, Without Concomitant Corticosteroids, After a First Cadaveric Renal Transplant||Nantes University Hospital||Completed|January 2001|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years|No|||February 2013|February 4, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200551||191878|
NCT00200564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/03/12-H|Ketamine and Postoperative Analgesia in Children|Ketamine and Postoperative Analgesia in Children||Nantes University Hospital||Recruiting|February 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|74|||Both|6 Months|6 Years|No|||July 2005|October 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200564||191877|
NCT00169338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020918|Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia|||Groupe Hospitalier Pitie-Salpetriere||Completed|September 2005|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|15 Years|65 Years|No|||September 2015|September 14, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169338||194215|
NCT00169351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM0418|National Gilles De La Tourette Study Group|||Groupe Hospitalier Pitie-Salpetriere||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|15 Years|80 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169351||194214|
NCT00169364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P011104|Clinical, Molecular and Metabolic Characteristics of Parkinson's Disease (PD) Patients With Parkin Mutation|Comparison of Clinical, Molecular and Metabolic Characteristics of PD Patients With and Without Parkin Mutation||Groupe Hospitalier Pitie-Salpetriere||Recruiting|May 2002|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2005|August 28, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169364||194213|
NCT00167817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030762|Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study|Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study||Veterans Medical Research Foundation|No|Completed|July 2003|September 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||April 2007|April 18, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00167817||194331|
NCT00167089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47s1|Effects of Early Treadmill Training on Ambulatory Ability in Stroke Patients: Electromyographic and Kinematic Analyses|Effects of Early Treadmill Training on Ambulatory Ability in Stroke Patients: Electromyographic and Kinematic Analyses||National Taiwan University Hospital|Yes|Completed|August 1998|August 2000|Actual|August 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|40|||Both|40 Years|75 Years|No|||September 2009|October 5, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00167089||194386|
NCT00167102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506M70377|Alefacept in Patients With Severe Scalp Alopecia Areata|A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Evaluate The Safety and Therapeutic Efficacy of Intramuscular Administration of Alefacept in Patients With Chronic, Severe Scalp Alopecia Areata||University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 27, 2013|September 9, 2005|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00167102||194385|This study was limited by the number of patients randomized to receive treatment.
NCT00167557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-0346|Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment|Tacrolimus Monotherapy in OLT Recipients With HCV Under Preemptive Treatment With Interferon and Ribavirin||The University of Texas Health Science Center, Houston|No|Withdrawn|January 2005|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||November 2013|November 18, 2013|September 9, 2005|No|Yes|The PI left the institution.|No||https://clinicaltrials.gov/show/NCT00167557||194351|
NCT00167752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0420|Psychiatric Problems in Chronic Skin Diseases|Quality of Life, Emotional and Sleep Problems in Chronic Skin Diseases||University of Wisconsin, Madison||Completed||||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|No|||June 2008|June 11, 2008|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167752||194336|
NCT00167765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4S-SZ-O056|Abciximab in Wake-up Stroke|Does Abciximab Save Hypoperfused Ischemic Brain Tissue in Wake-Up Stroke: A Placebo-Controlled, Randomized, MR Imaging Study||University of Zurich|Yes|Terminated|March 2005|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2007|May 1, 2007|September 9, 2005|||Higher hemorrhage rates of Abciximab in ABESST II trial|No||https://clinicaltrials.gov/show/NCT00167765||194335|
NCT00179075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 030263|Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant|Repository for Study: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)||Vanderbilt University|No|Completed|April 2003|April 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant        for various hematologic conditions|December 2008|December 12, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179075||193481|
NCT00169676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-040|Registry and Database Lap Prostatectomy|Laparoscopic Radical Prostatectomy: A Registry and Database||Indiana Kidney Stone Institute|No|Suspended|June 2003|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|N/A|No|Non-Probability Sample|Patients of Methodist Urology that are scheduled to undergo a laser procedure for prostate        removal|September 2008|March 23, 2015|September 9, 2005||No|Study closed due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00169676||194190|
NCT00169858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV-257 ext. HBV-278|Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections|Open Randomised Clinical Study of the Long Term Immunogenicity of Engerix-B in 10 Year Old Children and of the Effect of Booster Injections Given 5, 10 or 15 Years After Primary Vaccination||Laval University|No|Completed|September 1995|May 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1129|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00169858||194176|
NCT00169871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-452-0011|Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia|Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia||Centre Hospitalier Universitaire de Québec, CHU de Québec||Completed|March 2005|December 2006|Actual|||Phase 4|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal||||1000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2006|April 20, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00169871||194175|
NCT00167063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55m1|Falls in Stroke Patients After Hospital Discharge: Prevalence and Risk Factors|Falls in Stroke Patients After Hospital Discharge: Prevalence and Risk Factors||National Taiwan University Hospital||Active, not recruiting|August 1999|December 2000||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||100|||Both|40 Years|75 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167063||194388|
NCT00170443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-119|Trivalent rHA Dose Escalation Study in Elderly Subjects|A Phase II Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Intramuscular Trivalent Baculovirus-expressed Influenza HA Vaccine in Healthy Elderly Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||June 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|399|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||April 2006|August 11, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170443||194134|
NCT00176423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01T-411|Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia|Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia||University of Maryland|Yes|Completed|May 2002|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|60 Years|No|||June 2007|June 26, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00176423||193679|
NCT00176631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539682|Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of Licorice Root and Docetaxel in Patients With Hormone Refractory Prostate Cancer||Rutgers, The State University of New Jersey|No|Terminated|September 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||November 2013|November 15, 2013|September 13, 2005|Yes|Yes|slow accrual|No|November 15, 2013|https://clinicaltrials.gov/show/NCT00176631||193663|
NCT00176644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445280|Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer|Phase II Trial of Transdermal Estradiol in Patients With Hormone Refractory Prostate Cancer||Rutgers, The State University of New Jersey|No|Terminated|May 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|N/A|No|||November 2013|November 5, 2013|September 13, 2005|Yes|Yes|Treatment ineffective|No|November 5, 2013|https://clinicaltrials.gov/show/NCT00176644||193662|
NCT00167596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05008|Near Infrared Spectroscopy (NIRS) in Severe Sepsis|Phase III Study of Usefulness of Near Infrared Spectroscopy to Optimize Tissues Perfusion and Oxygenation in Severe Sepsis|OTO-STS|University of Versailles|Yes|Terminated|July 2005|December 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||February 2009|March 19, 2010|September 9, 2005||No|recruitment was stopped as consequence of cessation of funding (economic crisis)|No||https://clinicaltrials.gov/show/NCT00167596||194348|
NCT00167375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSLP1|Testing the Nocturnal Sleep Latency Profile in Primary Insomnia|Testing the Nocturnal Sleep Latency Profile in Primary Insomnia||University of Pittsburgh||Completed|January 2005|June 2007|Actual|||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2008|February 13, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167375||194365|
NCT00167570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-A2755-r-UT-001-0011-267|Long Term Clinical Evaluation of SLS Transtibial Sockets|Long Term Clinical Evaluation of SLS Transtibial Sockets||The University of Texas Health Science Center at San Antonio|No|Completed|April 2003|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 17, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167570||194350|
NCT00167856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3070-R|Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury|Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury||VA Office of Research and Development|No|Completed|June 2005|August 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|70 Years|No|||February 2009|March 26, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167856||194328|
NCT00200967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262|Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)|Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)||Milton S. Hershey Medical Center|Yes|Completed|December 2004|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|90 Years|No|||February 2013|February 24, 2013|September 12, 2005|Yes|Yes||No|March 5, 2009|https://clinicaltrials.gov/show/NCT00200967||191848|The study used a moderately high dose of ICS. Genotype-specific effects may be evident at lower doses of ICS often used in combination therapy. Also, short-acting β2-agonists have been shown to have genotype-specific effects on asthma outcomes.
NCT00200577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/04/1-D|Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma|TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision|TIL|Nantes University Hospital|No|Completed|May 2005|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|N/A|75 Years|No|||January 2013|January 30, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200577||191876|
NCT00200590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/03/7-D|Analgesic Strategies in Newborns Receiving Prostaglandin Therapy|Analgesic Strategies in Newborns Receiving Prostaglandin Therapy||Nantes University Hospital||Terminated|December 2003|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|28 Days|No|||April 2008|April 18, 2008|September 12, 2005||No|More important number of SAE in one arms|No||https://clinicaltrials.gov/show/NCT00200590||191875|
NCT00170183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-03|Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure|BNP as Adjuvant Therapy to Preserve Renal Function and Facilitate Diuresis in Hospitalized Patients With Heart Failure||Mayo Clinic||Completed|March 2003|July 2008|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|104|||Both|18 Years|N/A|No|||November 2009|November 13, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00170183||194154|
NCT00167349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306088|Cardiopulmonary Bypass and Inflammatory Response|Cardiopulmonary Bypass and Inflammatory Response|CPB-I|University of Pittsburgh|No|Completed|December 2003|January 2005|Actual|January 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|Samples Without DNA|plasma and serum|Both|18 Years|90 Years|No|Non-Probability Sample|CABG patients|April 2011|April 14, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167349||194367|
NCT00168714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-871|Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)|Avonex Pregnancy Exposure Registry||Biogen|Yes|Completed|February 2004|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|329|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women with MS who were exposed to Avonex in the US|June 2014|June 6, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168714||194263|
NCT00169065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH049891|Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia|Clozapine vs. Olanzapine: An Effectiveness Study|COES|Harvard Medical School|Yes|Completed|August 1998|June 2002|Actual|June 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|20 Years|60 Years|No|||April 2015|April 6, 2015|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00169065||194236|
NCT00169689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS_S_01|Repetitive Transcranial Magnetic Stimulation|Therapeutic and Biological Effects of High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia||Heinrich-Heine University, Duesseldorf|No|Completed|June 2003|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|60 Years|No|||January 2008|January 28, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169689||194189|
NCT00170378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR #02-2113|The Use of Low Molecular Weight Heparin in Traumatic Brain Injury|The Use of Low Molecular Weight Heparin in Traumatic Brain Injury||Minneapolis Medical Research Foundation||Suspended|December 2002|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00170378||194139|
NCT00170391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02CP08|Do People With Insomnia Sleep Better After Psychological Treatment?|Does CBT for Insomnia Improve the PSG Sleep of Patients Treated in Primary Care?||NHS Greater Clyde and Glasgow||Active, not recruiting|October 2002|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2002|September 10, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00170391||194138|
NCT00170729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT 491 A DE 01|A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery|Multi-Center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular Inflammation After Cataract Surgery, Followed by an Open Label Observational Period of 12 Days||Novartis||Completed|August 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|40 Years|N/A|No|||June 2006|June 7, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170729||194114|
NCT00179751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-PANC-001|A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas|A Phase I/II Study Of Lenalidomide (Revlimid ) In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas||Celgene||Terminated|April 2005|August 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||November 2005|November 2, 2005|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00179751||193431|
NCT00180349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leader v. 1.0 10/04|Leader - Evaluation of Endotak Reliance|Short and Long Term Evaluation of Electrical Measurements and Defibrillation Energies, Results of ATP and Diagnostic Functions of Devices Connected to Endotak RELIANCE® Defibrillation Leads||Guidant Corporation|No|Completed|December 2004|July 2009|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with the indication for an implantable ICD are invited to        participate.|June 2011|June 3, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00180349||193385|
NCT00170859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE01|Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients|A One-year Multicenter, Randomized, Open-label Study of the Safety and Efficacy of Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients||Novartis||Completed|August 2004|December 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|75 Years||||June 2011|June 15, 2011|September 9, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00170859||194105|
NCT00170872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2365|6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis|A 6 Week, Multicenter, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Lumiracoxib 200mg o.d. in Patients With Primary Knee Osteoarthritis or Rheumatoid Arthritis||Novartis||Completed|November 2004|||July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||135|||Both|18 Years|N/A||||May 2012|May 18, 2012|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170872||194104|
NCT00170846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2413|ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients|Assessment of Everolimus in Addition to Calcineurin Inhibitors Reduction in Maintenance Renal Transplant Recipients||Novartis|Yes|Completed|February 2005|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|394|||Both|18 Years|N/A|No|||March 2011|January 15, 2015|September 9, 2005|No|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00170846||194106|
NCT00171184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328A2409|Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder|Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder||Novartis||Completed|April 2005|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|65 Years|N/A||||January 2008|January 14, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171184||194080|
NCT00166842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910506|Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets|Effects of Conversion From Sirolimus Oral Solution to Tablets in Renal Transplant Recipients.||National Taiwan University Hospital||Active, not recruiting|September 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|13 Years|65 Years|No|||July 2002|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166842||194405|
NCT00167882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/28|The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels|||VU University Medical Center||Completed|July 2005|August 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Both|18 Years|70 Years|No|||August 2006|September 8, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167882||194326|
NCT00167583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF 105-0-0|Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB)|Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)|INCYTOB|University Hospital Tuebingen|Yes|Recruiting|November 2004|December 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||March 2009|July 26, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167583||194349|
NCT00167869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-WU 04/04|LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.|LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.||Wageningen University||Completed|June 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||135|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||May 2008|May 23, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167869||194327|
NCT00201357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1802|An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer|An Open, Non-Comparative Trial to Assess the Efficacy and Safety of Oral Thalidomide (THADO) in Patientswith Hormone-Refractory Prostate Cancer-A PHASE II CLINICAL TRIAL||National Health Research Institutes, Taiwan|Yes|Completed|October 2002|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00201357||191821|
NCT00201370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1899|A Multi-center Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal Follow-up of LSIL Cases|A Multi-center Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal Follow-up of LSIL Cases||National Health Research Institutes, Taiwan|Yes|Completed|August 1999|March 2004|Actual|February 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1000|||Female|20 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Women were invited to participate in the cross-sectional study|September 2005|March 23, 2016|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00201370||191820|
NCT00200941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-178|Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS)||Neurocare||Completed|August 2001|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||44|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2005|December 15, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200941||191850|
NCT00201955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37E-03-201|Study of Rebamipide Eye Drops to Treat Dry Eye|Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multicenter, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 26 Week Study||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|May 2004|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||740|||Both|18 Years|N/A|No|||October 2006|October 31, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00201955||191776|
NCT00171158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A0102E2|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis||Novartis||Completed|August 2004|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00171158||194082|
NCT00171171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2402|A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis|A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis||Novartis||Completed|May 2004|||November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|252|||Both|2 Years|N/A|No|||May 2010|May 5, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00171171||194081|
NCT00166803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|931110|The Impact of Rosiglitazone on Regression of Atherosclerosis|The Impact of Rosiglitazone on Regression of Atherosclerosis: A Serial 18F-Fluorodeoxyglucose Positron Emission Tomography Study||National Taiwan University Hospital||Suspended|June 2005|||November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|50 Years|80 Years|No|||December 2008|January 2, 2009|September 11, 2005||No|no fund|No||https://clinicaltrials.gov/show/NCT00166803||194408|
NCT00166816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900604|The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients|The Pharmacokinetics and Dosage Regimen of Sirolimus in a Cyclosporine or Tacrolimus-Based Immunosuppression in Renal Transplant Patients||National Taiwan University Hospital||Active, not recruiting|March 2002|June 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|13 Years|65 Years|No|||July 2001|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166816||194407|
NCT00166829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920606|The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus|The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus||National Taiwan University Hospital||Recruiting|May 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|13 Years|65 Years|No|||August 2003|March 7, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166829||194406|
NCT00167518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF 1-2003-767|Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)|Phase II/III Intravitreal Triamcinolone for Treatment of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment||University of Sydney||Completed|March 2002|April 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||January 2005|September 11, 2005|September 5, 2005||||No||https://clinicaltrials.gov/show/NCT00167518||194354|
NCT00178737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SHIS-05-0240|Does the Message Matter? Enhancing Adherence in Healthcare Through Persuasive Messages|Does the Message Matter? Enhancing Adherence in Healthcare Through Persuasive Messages||The University of Texas Health Science Center, Houston||Completed||December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|||Anticipated|1200|||Both|18 Years|80 Years|No|||February 2010|February 18, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178737||193506|
NCT00178750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-248|"Loss of Resistance" Versus CompuFlo® for Epidural Placement|A Randomized Clinical Comparison of the "Loss of Resistance" Technique Versus the CompuFlo® Computerized Syringe Pump for Proper Epidural Placement||The University of Texas Health Science Center, Houston||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|100|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 27, 2007|September 13, 2005|||Study did not start due to investigator time constraints|No||https://clinicaltrials.gov/show/NCT00178750||193505|
NCT00169923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06.108|Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease|Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease|Hercules|Leiden University Medical Center|Yes|Withdrawn|April 2007|May 2009|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2008|September 30, 2008|September 13, 2005|||it was not possible to recruit any patient in the study|No||https://clinicaltrials.gov/show/NCT00169923||194171|
NCT00179361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003 -434 -000|Natural History of Oro-pharyngeal Cancer Precursors|Natural History of Oral Cancer Precursors||Albert Einstein College of Medicine of Yeshiva University|No|Withdrawn|November 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Oral brush samples.|Both|21 Years|N/A|No|Non-Probability Sample|Primary care Dental and Otolaryngology clinics.|November 2009|November 23, 2009|September 13, 2005||No|This study is not an applicable clinical trial.|No||https://clinicaltrials.gov/show/NCT00179361||193461|
NCT00179738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-PC-001|A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.|A Multicenter, Single-Arm, Open-Label, Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®) In Subjects With Androgen Independent Prostate Cancer||Celgene||Terminated|April 2005|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Male|18 Years|N/A|No|||September 2005|November 22, 2005|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00179738||193432|
NCT00170196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-018|Efficacy Studies of Corticosteroid Therapy in Community-Acquired Pneumonia|The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids||Medical Center Alkmaar||Completed|August 2005|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||September 2008|September 26, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00170196||194153|
NCT00166556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355-04|A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation|Thistlethwaite Protocol # ITN025ST - Immunosuppression With Campath-1H and Tacrolimus in Liver Transplantation||Mayo Clinic||Completed|January 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|70 Years|No|||May 2011|May 20, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00166556||194427|
NCT00166569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01HD044417-03|The Genetics of Polycystic Ovarian Syndrome|The Genetics of Polycystic Ovarian Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|January 2003|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2700|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with PCOS age 18 to 40 years, sampled from the population and controls without PCOS.|October 2015|October 5, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166569||194426|
NCT00171210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0107E1|An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload|An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload||Novartis|No|Completed|October 2004|||April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|506|||Both|2 Years|N/A|No|||May 2011|May 24, 2011|September 12, 2005|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00171210||194079|
NCT00171223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A0110E2|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia||Novartis||Completed|August 2004|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|356|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00171223||194078|
NCT00166855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701200|Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma|||National Taiwan University Hospital||Recruiting|July 2005|July 2009||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|N/A|N/A|No|||May 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166855||194404|
NCT00167388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0404184|The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants|The Effect of Packed Red Blood Cell Transfusion on Superior Mesenteric Artery Blood Flow Velocity in Premature Infants After Feeding||University of Pittsburgh||Completed|September 2005|November 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|80|||Both|25 Weeks|38 Weeks|No|||March 2008|March 25, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167388||194364|
NCT00167401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 1500|Trial of Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer|A Phase II Trial of One-Cycle Induction Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer||University of Rochester|Yes|Completed|February 2002|||June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2009|May 15, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167401||194363|
NCT00167609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P001108|Efficacy and Safety of DHEA for Myotonic Dystrophy|Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy||University of Versailles|Yes|Completed|November 2004|December 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|70 Years|No|||April 2010|April 5, 2010|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00167609||194347|
NCT00168194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|235/04|Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History|Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History||The Alfred|No|Completed|December 2004|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|Samples Without DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|HIV and hepatitis B co-infection|January 2012|January 19, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168194||194302|
NCT00168506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC P - 01|Panic Disorder and Cardiac Risk|Panic Disorder and Cardiac Risk: Evaluation of a Psychological Treatment Which Addresses Biology, Psychology and Behaviour||Baker Heart Research Institute||Recruiting|June 2002|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||April 2007|April 4, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00168506||194278|
NCT00201721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0143|Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia|Phase II Trial of Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|July 2002|November 2013|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201721||191794|
NCT00169897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN32824512|Pulmonary Rehabilitation at Home Versus at the Gymnasium|Effects of a Home-based Versus a Hospital-based Outpatient Pulmonary Rehabilitation Program in Patients With COPD: a Multicenter, Randomized Trial||Laval University|No|Completed|January 2004|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|252|||Both|40 Years|95 Years|No|||August 2005|November 11, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00169897||194173|
NCT00170794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2412|Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.|A One Year, Multicenter, Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.||Novartis||Completed|September 2004|||July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|70 Years||||March 2015|March 5, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00170794||194109|
NCT00168428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-080|A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches|||Allergan||Completed|March 2006|August 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|705|||Both|18 Years|65 Years|No|||October 2013|October 24, 2013|September 12, 2005|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00168428||194284|
NCT00168441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-066|A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia|||Allergan||Completed|June 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|117|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00168441||194283|
NCT00167050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700634|The Pathogenesis of Superior Limbic Keratoconjunctivitis|||National Taiwan University Hospital||Recruiting|July 2005|June 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||10|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2005|November 25, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167050||194389|
NCT00168766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-03-01|Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis||Biogen|No|Completed|January 2003|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|345|||Both|18 Years|55 Years|No|||April 2011|September 12, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00168766||194259|
NCT00168337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-011|A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema|||Allergan|No|Completed|May 2005|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|554|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|September 12, 2005|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00168337||194291|
NCT00168350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192944-005|Memantine in Patients With Chronic Glaucoma|||Allergan|No|Completed|March 2000|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|1179|||Both|18 Years|82 Years|No|||November 2010|November 3, 2010|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00168350||194290|
NCT00168363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-022|Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|January 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|207|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00168363||194289|
NCT00169377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030422|Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)|Study of the Effects of High Frequency Stimulation of the Subthalamic Stimulation in the Treatment of Severe Obsessive-Compulsive Disorders||Groupe Hospitalier Pitie-Salpetriere|Yes|Completed|October 2005|May 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|60 Years|No|||July 2008|July 22, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169377||194212|
NCT00169390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM0344|Monoamine Oxidases in Smoking Pregnant Women and Newborns|Comparison of Monoamines Oxidases A and B Activities and the Metabolism of Nicotine in Smoking and Nonsmoking Pregnant Women and in Their Newborns. Evaluation of Their Effects on the Newborns' Behavior||Groupe Hospitalier Pitie-Salpetriere|No|Completed|March 2004|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|59|Samples Without DNA|plasma DHPG, HVA, 5HIAA, 5HT, cotinine|Female|18 Years|N/A|No|Non-Probability Sample|pregnant smoking or not smoking women|August 2009|March 17, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169390||194211|
NCT00169936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-05|Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients|Evaluation of Magnetocardiography as a Tool for Non-invasive Detection of Tissue Rejection in Cardiac Transplant Recipients||Mayo Clinic||Completed|December 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|6|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00169936||194170|
NCT00169910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05.105|VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients|VIP: Vascular Imaging Project. Prospective Randomized Study on the Effect of AUC-monitored Treatment With Steroids Combined With Either a Calcineurin Inhibitor or Mycophenolate Mofetil on the Progression of Subclinical Cardiovascular Disease in Renal Transplant Recipients.||Leiden University Medical Center||Completed|December 2005|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|119|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169910||194172|
NCT00170456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0003|Phase II Study of Range and Schedule of rPA Doses|A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects||PharmAthene UK Limited|Yes|Completed|March 2005|February 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|415|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 12, 2008|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00170456||194133|
NCT00170469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0002|Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed|A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population||PharmAthene UK Limited|Yes|Completed|March 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|226|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 12, 2008|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00170469||194132|
NCT00166881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57M9|Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin|Phase II Trial of Consolidation or Salvage Chemotherapy by Using Weekly Docetaxel/Irinotecan After Cisplatin Plus Weekly 24-Hour Infusion of High-dose 5-Fluorouracil/Leucovorin for Non-resectable Gastric Cancers|P-HDFL-DI|National Taiwan University Hospital|Yes|Completed|June 2000|June 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|16 Years|75 Years|No|||November 2012|July 4, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00166881||194402|
NCT00166868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921201|Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy|Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia||National Taiwan University Hospital||Completed|December 2003|July 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Both|4 Months|3 Years|No|||August 2013|August 19, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00166868||194403|
NCT00167141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRM 2003/21|Contraception in Normal and Subnormal Men|Hormonal Male Contraception in Men With Normal and Subnormal Semen Parameters||University Hospital Muenster||Terminated|February 2005|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||March 2007|February 1, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00167141||194382|
NCT00167180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS006|Post Transplant Donor Lymphocyte Infusion|Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|January 2004|December 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Year|70 Years|No|||February 2016|February 23, 2016|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167180||194379|
NCT00167414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 8700|Study for Using Radiosurgery on Limited Metastases of Breast Cancer|A Phase II Study for Using Radiosurgery on Limited Metastases of Breast Cancer||University of Rochester|No|Active, not recruiting|December 2000|October 2021|Anticipated|October 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|N/A|N/A|No|||September 2013|September 30, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167414||194362|
NCT00167622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050103|Early Mechanical Ventilation for Guillain Barré Syndrome|Efficacy and Safety of Preventive Mechanical Ventilation in Adults With Guillain Barré Syndrome||University of Versailles|No|Completed|April 2005|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2009|February 17, 2009|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00167622||194346|
NCT00167908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH018-01D|Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer|Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT||Washington University School of Medicine||Completed|October 2001|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167908||194324|
NCT00167895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-035|The Use of Platelet Derived Growth Factors in Total Knee Arthroplasty, a Randomized Trial|The Use of Platelet Derived Growth Factors in Total Knee Arthroplasty, a Randomized Trial||Westfries Hospital|Yes|Completed|October 2004|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||100|||Both|18 Years|N/A|No|||April 2007|April 24, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00167895||194325|
NCT00168207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/05|IL-7 Receptor Polymorphisms and Immune Recovery With HAART|The Relationship of Single Nucleotide Polymorphisms in the Interleukin-7 Receptor-α Gene to CD4+ Immune Recovery in HIV Infected Patients Who Begin Antiretroviral Treatment With HAART||The Alfred|No|Completed|May 2005|May 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|106|Samples With DNA|Plasma, PBMC and DNA|Both|18 Years|N/A|No|Non-Probability Sample|HIV infected patients on HAART|January 2012|January 19, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168207||194301|
NCT00168519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51/02|Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes|Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes||Baker Heart Research Institute||Completed|October 2002|April 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 14, 2009|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00168519||194277|
NCT00201396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1303|A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma|A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC)||National Health Research Institutes, Taiwan||Completed|August 2003|December 2011|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Both|N/A|70 Years|No|||May 2006|February 23, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00201396||191818|
NCT00201409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258|A Randomized Trial of GM-CSF in Patients With ALI/ARDS|A Randomized Trial of GM-CSF in Patients With ALI/ARDS||University of Michigan|Yes|Completed|July 2004|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|90 Years|No|||November 2015|November 30, 2015|September 12, 2005|Yes|Yes||No|June 25, 2012|https://clinicaltrials.gov/show/NCT00201409||191817|
NCT00170820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AFR04|Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen|A Single Arm, Prospective, Open-label, Pilot Study to Assess Effects of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen||Novartis||Completed|February 2005|||March 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||20|||Both|18 Years|75 Years||||November 2011|November 1, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170820||194108|
NCT00170833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AUS09|Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients|A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Recipients||Novartis||Completed|November 2003|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||80|||Both|18 Years|65 Years||||November 2011|November 1, 2011|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00170833||194107|
NCT00168116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16620|Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure|To Evaluate the Effects of Transfer of Submandibular Salivary Gland to the Submental Region (Outside the Radiation Field) on Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure||AHS Cancer Control Alberta|Yes|Completed|July 2000|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Both|18 Years|N/A|No|||October 2011|February 23, 2016|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00168116||194308|
NCT00168792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.12|A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)|A Phase IIIb - IV, Randomised, Open Label Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early PCI as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction. ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.)||Boehringer Ingelheim||Terminated|November 2003|||July 2006||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1671|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00168792||194257|
NCT00168779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.476|Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension|A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.||Boehringer Ingelheim||Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||1185|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00168779||194258|
NCT00169104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0140|Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function|A Phase II Trial of Trastuzumab, Neupogen, and Vinorelbine Investigating the Effects on Immune Function and Clinical Outcomes in Patients With Metastatic Breast Cancer Overexpressing Her-2/Neu||Dartmouth-Hitchcock Medical Center|Yes|Terminated|July 2002|March 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Female|18 Years|N/A|No|||October 2011|October 19, 2011|September 10, 2005|Yes|Yes|Closed due to achievement of primary study endpoint|No||https://clinicaltrials.gov/show/NCT00169104||194233|
NCT00169702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1D-SB-018|The Effect of a Weight Management Program During Treatment With Olanzapine|The Effect of a Weight Management Program to Prevent Weight Gain and Metabolic Abnormalities During Treatment With the Atypical Neuroleptic Olanzapine: A Randomised Study||Heinrich-Heine University, Duesseldorf|No|Completed|June 2003|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|65 Years|No|||April 2007|January 28, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169702||194188|
NCT00169715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-019|Database and Registry for Renal Diverticulum|Percutaneous Surgical Outcomes and Metabolic Findings in Patients With Stone-Bearing Calicial Diverticula||Indiana Kidney Stone Institute|No|Completed|February 2003|April 2007|Actual|April 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|86|||Both|18 Years|N/A|No|||September 2008|September 16, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169715||194187|
NCT00170495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-049|Acute Viral Respiratory Infections in Elderly|Etiology and Impact of Acute Viral Respiratory Infections in Ambulatory Elderly Populations||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|September 2004|July 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3000|Samples Without DNA|blood, sputum, nasal and throat swabs|Both|65 Years|N/A|No|Non-Probability Sample|male and female adults age 65 and older with acute respiratory illness (common colds, flu,        bronchitis, pneumonia)|September 2008|August 26, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00170495||194130|
NCT00170508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0055|Young Adult Influenza Vaccine Immunogenicity Substudy|In Depth Immunologic Studies in Healthy Young Adults Who Receive The Standard Dose Fluzone® (15mcgHA/Virus Strain) Trivalent Inactivated Influenza Virus Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2005|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|August 22, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00170508||194129|
NCT00170209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-44154|Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)|A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial||McGill University|Yes|Active, not recruiting|August 2011|March 2016|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|822|||Both|N/A|18 Years|No|||January 2015|January 22, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00170209||194152|
NCT00170482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0028|Elderly Influenza Vaccine Immunogenicity Substudy|In Depth Immunologic Studies in Elderly Subjects Receiving Either Standard-Dose Fluzone (15mcg HA/Virus Strain) or High-Dose (60 Mcg HA/Virus Strain) Trivalent Inactivated Influenza Virus Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2005|May 2005|Actual|May 2005|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2011|August 11, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170482||194131|
NCT00170885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIT02|Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients|Multicenter, Randomized, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de Novo Renal Transplant Recipients||Novartis||Completed|May 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|75 Years||||January 2011|January 26, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170885||194103|
NCT00166595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10545s|Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)|Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)||Children's Hospital Medical Center, Cincinnati|No|Completed|February 2003|March 2005|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment||||100|||Both|4 Years|21 Years|No|||July 2012|January 27, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00166595||194424|
NCT00167154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F030929002|Risperidone and Suicidality in Major Depressive Disorder|Efficacy of Risperidone in the Management of Suicidality in Major Depressive Disorder||University of Alabama at Birmingham|No|Completed|June 2004|August 2008|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|19 Years|60 Years|No|||March 2012|March 15, 2012|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00167154||194381|
NCT00167635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12707-C|Nursing Management of Irritable Bowel Syndrome:Improving Outcomes|Nursing Management of Irritable Bowel Syndrome: Improving Outcomes||University of Washington|Yes|Completed|January 2003|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|188|||Both|18 Years|70 Years|No|||May 2009|May 21, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167635||194345|
NCT00167934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067795|Determining Metabolic Effects of Valproate and Antipsychotic Therapy|Metabolic Effects of Valproate and Antipsychotic Therapy||National Institute of Mental Health (NIMH)|No|Recruiting|December 2004|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|60 Years|No|||March 2009|March 10, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167934||194322|
NCT00168246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77/05|Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific|A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region||National Institute of Mental Health (NIMH)||Active, not recruiting|June 2005|||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||||600|||Both|18 Years|N/A||||February 2007|February 26, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00168246||194298|
NCT00168259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/04|Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals|Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals||The Alfred|No|Completed|December 2004|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Plasma, and DNA|Both|18 Years|N/A|No|Non-Probability Sample|HIV infected patients with past CMV infection initiating antiretroviral therapy|January 2012|January 19, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00168259||194297|
NCT00168571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTAB-2288/2292-Twodose1|Long-term Follow-up of Measles Antibodies|Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau||Bandim Health Project||Completed|March 2002|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1960|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||September 2006|September 21, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168571||194273|
NCT00167921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713S5-414|Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis|A Multiple-Dose, Comparative Bioavailability Study of Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Postmenopausal Women With Atrophic Vaginitis.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label||||24|||Female|45 Years|80 Years|No|||May 2007|May 25, 2007|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00167921||194323|
NCT00168220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113/05|Predictors of Drug Hypersensitivity in HIV Infected Subjects|Predictors of Drug Hypersensitivity in HIV Infected Subjects||The Alfred|No|Withdrawn|August 2005|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|0|Samples With DNA|plasma, DNA|Both|18 Years|N/A|No|Non-Probability Sample|HIV infection, exposed to antiretroviral treatment, either tolerant or hypersensitive to        treatment|January 2012|January 19, 2012|September 13, 2005||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00168220||194300|
NCT00168233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54/05|Impact of HIV and Its Treatment on Reverse Cholesterol Transport|Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport||The Alfred|No|Completed|June 2005|March 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|44|||Male|18 Years|N/A|No|Non-Probability Sample|HIV infected patients naive to ARV therapy|January 2012|January 19, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168233||194299|
NCT00168545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVO-2624-Twodose2_immunology|Immunology of Non-specific Effects of Vaccine|Non-specific Effects of Vaccines - In Search of the Immunological Background||Bandim Health Project||Completed|January 2006|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||400|||Both|4 Months|9 Months|Accepts Healthy Volunteers|||September 2006|September 21, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168545||194275|
NCT00201747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0151|Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer|Phase II Randomized Trial of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|September 2001|February 2010|Actual|October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201747||191792|
NCT00168129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-15-0007|Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases|Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases||AHS Cancer Control Alberta||Completed|June 2001|July 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168129||194307|
NCT00168142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21131|MVCT Imaging Pilot Study Using Helical Tomotherapy|MVCT Imaging Pilot Study Using Helical Tomotherapy||AHS Cancer Control Alberta|Yes|Completed|October 2003|August 2009|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|December 2011|February 23, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168142||194306|
NCT00168454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-077|A Research Study for Patients With Overactive Bladder|||Allergan|Yes|Completed|July 2005|June 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|313|||Both|18 Years|85 Years|No|||October 2013|October 11, 2013|September 12, 2005|Yes|Yes||No|September 2, 2009|https://clinicaltrials.gov/show/NCT00168454||194282|
NCT00168805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.25|RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery|RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days||Boehringer Ingelheim||Completed|November 2004|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|2101|||Both|18 Years|N/A|No|||February 2014|May 8, 2014|September 12, 2005||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00168805||194256|
NCT00169117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIF8|A Stitch in Time May Save Lives: Turning Poor Bednets Into Good Ones|A Stitch in Time May Save Lives: Turning Poor Bednets Into Good Ones||Gates Malaria Partnership|No|Completed|June 2002|December 2002|Actual|December 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|772|||Both|N/A|N/A|No|||February 2008|February 7, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00169117||194232|
NCT00169403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000201|Pallidal Stimulation in Patients With Idiopathic Generalised Dystonia|||Groupe Hospitalier Pitie-Salpetriere||Recruiting||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|65 Years|No|||September 2005|August 28, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169403||194210|
NCT00169416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS2101951|Evaluation Of Valaciclovir In Patients With Chickenpox|Clinical Evaluation of Valaciclovir Hydrochloride: 256U87 in Patients With Chickenpox - Open Uncontrolled Study.||GlaxoSmithKline|No|Completed|March 2005|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|1 Year|11 Years|No|||April 2015|April 14, 2015|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169416||194209|
NCT00169728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKAST-01|Vaccination of Children Following Allogeneic Stem Cell Transplantation|Immunogenicity of the DTaP-IPV-HBV/Hib Combination Vaccine Infanrix Hexa and the Heptavalent Pneumococcal Conjugate Vaccine Prevenar in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplantation||Heinrich-Heine University, Duesseldorf||Completed|September 2003|October 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|53|||Both|N/A|17 Years|No|||June 2012|June 6, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00169728||194186|
NCT00170261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_4|ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope|Early Loop-Recorder in Suspected Arrhythmogenic Syncope||Medtronic Bakken Research Center||Completed|April 2002|September 2006|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|100|||Both|18 Years|85 Years|No|||October 2008|October 8, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00170261||194148|
NCT00170274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_5|APART: Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias|Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias Who Need Cardiac Pacing||Medtronic Bakken Research Center|No|Completed|August 2000|October 2014|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00170274||194147|
NCT00170222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-007|Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|The Value of Antibiotic Treatment of Exacerbations of Hospitalised COPD Patients||Medical Center Alkmaar||Completed|July 2002|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|258|||Both|45 Years|N/A|No|||September 2008|September 26, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170222||194151|
NCT00170235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-05-017|Reducing Arm Morbidity in Pre- and Post-breast Cancer Surgery|Reducing Arm Morbidity Through Physical Therapy Provided Pre- and Post-breast Cancer Surgery||McGill University|No|Completed|August 2004|December 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|N/A|No|||May 2008|September 3, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00170235||194150|
NCT00166582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD039767|Parent-Youth Teamwork in Pediatric Asthma Management|Parent-Youth Teamwork in Pediatric Asthma Management||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|April 2002|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|9 Years|15 Years|No|||November 2005|June 28, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00166582||194425|
NCT00170924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AUS52|To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.|A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction||Novartis||Completed|August 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|317|||Both|45 Years|N/A||||November 2011|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00170924||194100|
NCT00167206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0312M54991|Stem Cell Transplantation for Fanconi Anemia|A Study of Thymic Shielding in Recipients of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia||Masonic Cancer Center, University of Minnesota|Yes|Terminated|March 2004|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|18 Years|No|||November 2009|November 30, 2009|September 9, 2005||No|Treatment with thymic shielding found safe, another study started.|No|July 7, 2009|https://clinicaltrials.gov/show/NCT00167206||194378|Study ended early as thymic shielding was found to be safe. Therefore, a new study was designed using thymic shielding.
NCT00166894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700516|Use of the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in the Diagnosis of Pleural Effusion|Evaluation of the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a Diagnostic Tool for Patients With Pleural Effusion||National Taiwan University Hospital||Recruiting|May 2005|||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||100|||Both|N/A|N/A|No|||May 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166894||194401|
NCT00167167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9510M10277|Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia|Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-Derived Lymphocytes||Masonic Cancer Center, University of Minnesota|No|Completed|December 1995|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|1 Year|60 Years|No|||July 2009|July 7, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167167||194380|
NCT00167648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-5564-V 01|Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer|Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer|NE2|University of Washington|Yes|Completed|March 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|N/A|No|||January 2009|January 15, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167648||194344|
NCT00167999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-101676|Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units|Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2005|||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||200|||Both|15 Years|N/A|No|||March 2007|March 14, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167999||194317|
NCT00167947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E-101629|Study Evaluating Sirolimus in Kidney Transplant Recipients.|A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Renal Transplant Patients.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2008|March 13, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167947||194321|
NCT00167960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-101525|Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit|Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2005|||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||1500|||Both|18 Years|N/A|No|||March 2007|March 14, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167960||194320|
NCT00168584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91096-2dos02|Different Doses of Vitamin A and Childhood Morbidity and Mortality|Randomised Study of the Impact of Different Doses of Vitamin A on Childhood Morbidity and Mortality||Bandim Health Project||Completed|November 2002|August 2003||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||5400|||Both|6 Months|5 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00168584||194272|
NCT00168597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-CT-2001-10095-VITA|Vitamin A With BCG Vaccine|Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries?||Bandim Health Project||Completed|August 2002|||November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||4800|||Both|N/A|1 Year|No|||November 2013|November 14, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168597||194271|
NCT00168909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ek.213-07 (IRB)|Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)|Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls||Charite University, Berlin, Germany|Yes|Completed|June 2003|May 2008|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|282|||Female|65 Years|N/A|No|||May 2008|May 8, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168909||194248|
NCT00168922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haema CBF SCLC UK/AS 02|Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)|Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy||Charite University, Berlin, Germany||Recruiting|February 2001|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|70 Years|No|||January 2001|April 27, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168922||194247|
NCT00169182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2000-01|Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma|Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma||Groupe Oncologie Radiotherapie Tete et Cou||Completed|December 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|18 Years|75 Years|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169182||194227|
NCT00202046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1728-03-B|Predictors of Lymphedema Following Breast Cancer Surgery|Predictors of Lymphedema Following Breast Cancer Surgery||HealthPartners Institute|Yes|Completed|January 2003|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|188|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with upper-extremety lymphedema(prevalent and incident cases) are identified at the        time they presented to the physical therapy department or cancer center at 5 participating        institutions (Park Nicollet health Services, fairview-University Medical Center, Fairview        Southdale medical Center, North Memorial medical Center, and healthEast Care System).        Controls were identified through the oncology Registry.|April 2007|December 2, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00202046||191769|
NCT00168467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/03|The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease|The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease||Baker Heart Research Institute||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|N/A|70 Years|No|||January 2009|January 28, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168467||194281|
NCT00169455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103477|Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants|See Detailed Description||GlaxoSmithKline||Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||450|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2015|November 20, 2015|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169455||194207|
NCT00169130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH98-B2|ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma|Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma||Lymphoma Study Association||Completed|October 1999|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|60 Years|No|||July 2007|July 12, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169130||194231|
NCT00169442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104065|Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants|Immune Memory of GSK's DTPw-HBV/Hib Vaccine by Giving Plain PRP Polysaccharide at 10 Mths. Immuno & Reacto of a Booster Dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 Mths in Infants Previously Primed With DTPw-HBV/Hib||GlaxoSmithKline||Completed|February 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|732|||Both|10 Months|18 Months|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169442||194208|
NCT00170248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN58726678|Computer-Based Decision Support in Managing Asthma in Primary Care|Evaluating the Impact of Computer-Based Decision Support for the Management of Asthma in Primary Care||McGill University||Completed|October 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|4447|||Both|5 Years|N/A|No|||April 2014|April 7, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00170248||194149|
NCT00170560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-337|Impact of Gender on Patients|Impact of Gender on Infected Hospitalized Patients||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|October 2001|February 2007||||N/A|Observational|Time Perspective: Prospective||||570|||Both|18 Years|N/A|No|||October 2007|August 26, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00170560||194125|
NCT00170898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189AGB02|Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain|A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Acute Musculoskeletal Pain Due to Uncomplicated Soft Tissue Injury||Novartis||Completed|November 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||419|||Both|18 Years|N/A||||June 2006|October 12, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170898||194102|
NCT00170911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE581A1201|Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.|Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.||Novartis||Completed|March 2005|||December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Female|50 Years|75 Years||||November 2011|November 1, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170911||194101|
NCT00166608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU-10369s|Cytokines Polymorphisms and Acetaminophen Toxicity|Measurement of Nitrotyrosine Adducts and Cytokines in Acetaminophen Overdose Patients||Arkansas Children's Hospital Research Institute|No|Completed|December 2002|September 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|111|||Both|N/A|N/A|No|Probability Sample|Publication Attached|April 2012|April 10, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166608||194423|
NCT00167219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999LS073|Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)|Hematopoietic Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|December 1999|December 2020|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|18 Years|No|||January 2016|January 22, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167219||194377|
NCT00167427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 3705|Genotoxicity Assessment for Patients Undergoing Radiation Treatment|Genotoxicity Assessment for Patients Receiving Large Field Irradiation||University of Rochester|No|Recruiting|April 2006|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that are scheduled to begin radiotherapy to the large-field chest region|August 2015|August 3, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167427||194361|
NCT00168012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB04_005CR|Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)|An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID)||CSL Behring||Completed|September 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|3 Years|70 Years|No|||February 2011|February 10, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00168012||194316|
NCT00168623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91096-2dos03|Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity|Randomised Trial of Vitamin A Supplementation Given With Routine Childhood Vaccines at National Immunisation Days||Bandim Health Project||Active, not recruiting|November 2003|December 2014|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||6200|||Both|6 Months|5 Years|No|||November 2013|November 14, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00168623||194269|
NCT00168935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN1|Malnutrition in Gastroenterology Patients|||Charite University, Berlin, Germany||Completed|March 2004|December 2008|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|85 Years|No|||September 2005|May 6, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00168935||194246|
NCT00168948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KA0202-T|Intermittent Antimalaria Treatment With SP in African Children|Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial||Charite University, Berlin, Germany||Active, not recruiting|March 2003|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Both|2 Months|4 Months|Accepts Healthy Volunteers|||February 2003|November 1, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00168948||194245|
NCT00169195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-GEMOX|Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma|Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation||Lymphoma Study Association||Completed|April 2003|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|75 Years|No|||September 2015|September 1, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169195||194226|
NCT00169208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFM Follicular lymphoma study|Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma|An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-Tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma.||Lymphoma Study Association||Completed|April 2001|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|No|||September 2005|December 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169208||194225|
NCT00202293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001.013|Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features|Comparison of Combination Olanzapine and Lithium and Combination Chlorpromazine and Lithium in the Treatment of a First Manic Episode With Psychotic Features.||Melbourne Health||Recruiting|October 2001|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|75|||Both|15 Years|29 Years|No|||November 2015|November 18, 2015|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00202293||191751|
NCT00202540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2-18986-009|Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients|Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period||Servier||Suspended|June 2005|May 2006||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|450|||Both|55 Years|N/A|No|||November 2010|November 15, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202540||191732|
NCT00202553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2-90652-001|S90652 in Paediatric Hypertension|Acceptability, Safety, Pharmacokinetics and Effects on Blood Pressure of a Daily Dose of 0.025 to 0.135 Milligram Per Kilogram of S90652, a Paediatric Formulation of Perindopril, in 2-16 Years Old Hypertensive Children - 3 Month Study||Servier||Completed|July 2003|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|2 Years|16 Years|No|||June 2011|June 15, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202553||191731|
NCT00168493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC D-01|The Neurobiology of Depressive Illness|The Neurobiology of Depressive Illness: Causes and Consequences of Altered Brain Monoaminergic Function||Baker Heart Research Institute|No|Recruiting|June 2000|December 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|75 Years|No|||May 2008|May 19, 2008|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00168493||194279|
NCT00169156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAIL|A Phase II Study of Rituximab Combined With CHOP in T-Cell Angio-Immunoblastic Lymphoma|Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-Cell Angioimmunoblastic Lymphoma (AIL).||Lymphoma Study Association||Active, not recruiting|September 2005|December 2009|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||May 2008|May 29, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169156||194229|
NCT00169741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-043|Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC|Alterations in Renal Blood Flow as a Consequence of Percutaneous Nephrolithotomy (PERC)||Indiana Kidney Stone Institute|No|Completed|May 2005|February 2016|Actual|February 2016|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169741||194185|
NCT00169949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-134|Aripiprazole Treatment of the Prodrome|Open-Label Study of Aripiprazole in Individuals at Risk for Chronic Mental Illness||Northwell Health|Yes|Terminated|January 2004|May 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|13 Years|22 Years|No|||April 2007|September 24, 2009|September 9, 2005|||The study was terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00169949||194169|
NCT00169962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.05.086|Study of Pulmozyme to Treat Severe Asthma Episodes|Use of Aerosolized rhDNase (Pulmozyme®) in Emergency Department Adults With Refractory Acute Asthma: A Pilot Study||Northwell Health||Completed|January 2004|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|51|||Both|18 Years|55 Years|No|||October 2015|October 9, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00169962||194168|
NCT00166621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10659s|Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy|Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy||Chugani, Diane C.|Yes|Completed|March 2004|August 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|2 Years|6 Years|No|||July 2011|July 19, 2011|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00166621||194422|
NCT00170521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0018|Mol Epi GrAS in Nicaragua|The Molecular Epidemiology of Streptococcus Pyogenes Among Children in Leon, Nicaragua||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|August 2006|August 2008||||N/A|Observational|Time Perspective: Prospective||||13000|||Both|3 Years|15 Years|No|||December 2006|August 26, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00170521||194128|
NCT00170534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-106|Intervention for Male STDs in India|An Intervention for Male STD Patients in India||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|October 2004|April 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||1892|||Male|16 Years|N/A|Accepts Healthy Volunteers|||April 2009|August 26, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00170534||194127|
NCT00167661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0661 (2003-0493)|Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation|Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation||University of Wisconsin, Madison|Yes|Terminated|June 2004|May 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Months|19 Years|No|||October 2015|October 9, 2015|September 11, 2005|Yes|Yes|Enrollment suspended pending protocol revision to change study to observational|No||https://clinicaltrials.gov/show/NCT00167661||194343|
NCT00167674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-5529-A03|ARVs to Prevent Breastmilk HIV:Viral and Immune Responses|ARVs to Prevent Breastmilk HIV:Viral and Immune Responses||University of Washington|No|Completed|May 2003|April 2006|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|N/A|No|||June 2012|June 14, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167674||194342|
NCT00167440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10398|Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Pediatric Patients|Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Patients||University of Rochester|No|Withdrawn|August 2004|July 2008|Actual|July 2008|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|16 Years|No|Non-Probability Sample|Children, newborn through age 16 admitted to a pediatric intensive care unit (PICU)|November 2015|November 25, 2015|September 9, 2005|No|Yes|Personelle changes mandated suspension.|No||https://clinicaltrials.gov/show/NCT00167440||194360|
NCT00169000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0139|Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers|Phase I Study of a Novel Schedule of Capecitabine and Docetaxel in Patients With Advanced Solid Tumors||Dartmouth-Hitchcock Medical Center|Yes|Completed|January 2003|March 2006|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2009|August 4, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00169000||194241|
NCT00168272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/04|Priming rTMS In Major Depression|A Randomised Double-Blind Trial of Low and High Frequency Stimulation rTMS (Repetitive Transcranial Magnetic Stimulation) In Major Depression||The Alfred||Completed|June 2004|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||April 2007|April 13, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00168272||194296|
NCT00168610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-FY04-51-VITA2|Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine|Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau||Bandim Health Project||Active, not recruiting|November 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|7600|||Both|N/A|5 Months|No|||November 2013|November 14, 2013|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168610||194270|
NCT00168636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91096-2dos04|Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality|The Impact of Different Doses of Vitamin A Supplementation on Male and Female Childhood Morbidity and Mortality||Bandim Health Project||Completed|November 2004|||November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||11000|||Both|6 Months|5 Years|No|||November 2013|November 14, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00168636||194268|
NCT00168961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE1|Enteral Nutrition in Liver Cirrhosis|||Charite University, Berlin, Germany||Completed|December 2003|June 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|85 Years|No|||September 2005|May 6, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00168961||194244|
NCT00168974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fabry2003|Neuropathic Pain and Fabry Disease|Somatosensoric and Autonomic Disturbances in Female Patients With Fabry Disease||Danish Pain Research Center||Completed|January 2004|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 15, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00168974||194243|
NCT00169221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2004-02|Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas|CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) in Upper Aerodigestive Tract Carcinomas||Groupe Oncologie Radiotherapie Tete et Cou||Terminated|September 2005|July 2011|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|September 12, 2005||No|Toxicity in an independent study IMEX. The trial was subsequently terminated (54 pts instead    of 140) despite safety analyses showing no excess of toxicity|No||https://clinicaltrials.gov/show/NCT00169221||194224|
NCT00169234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC Protocol 3848|Pneumococcal Adult-dose Ranging Immunization Study|Immunogenicity and Safety of Varying Doses of a 7-valent Conjugate Pneumococcal Vaccine in Adults 70-79 Years of Age Who Were Previously Vaccinated With the 23-valent Pneumococcal Polysaccharide Vaccine||Group Health Cooperative|Yes|Completed|May 2003|February 2005|Actual|February 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|5||Actual|220|||Both|70 Years|79 Years|No|||February 2014|February 25, 2014|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00169234||194223|
NCT00202592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2-90652-002|S90652 in Paediatric Hypertension|Safety and Effects on Blood Pressure of Daily Dose 0.025 to 0.135 Milligram Per Kilogram of S90625 a Paediatric Formulation of Perindopril, in Hypertensive Children - 24 Months||Servier||Completed|November 2003|April 2010|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|50|||Both|30 Months|17 Years|No|||June 2011|June 15, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202592||191728|
NCT00202605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD465-203|Safety and Efficacy of SPD465 in Adults With ADHD|A Phase II, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)||Shire||Completed|September 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|18 Years|55 Years|No|||November 2007|November 2, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00202605||191727|
NCT00169143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH 03-39B|Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma|Study of R-ACVBP Regimen Supported by Pegfilgrastim in Previously Untreated Patients Aged From 18 to 60 Years With High-Risk Diffuse Large B-Cell Lymphoma (Age-Adjusted Ipi >or= 2)||Lymphoma Study Association||Completed|May 2004|January 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|61 Years|No|||September 2006|September 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169143||194230|
NCT00169169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH-98.3|Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma|Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT).||Lymphoma Study Association||Terminated|October 1999|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||430|||Both|18 Years|59 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00169169||194228|
NCT00169468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-CHOP VELCADE|Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma|Phase II Study of the Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma||Lymphoma Study Association||Active, not recruiting|January 2005|August 2011|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|80 Years|No|||May 2009|May 26, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00169468||194206|
NCT00169754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-031|Attached Stone Project: Do Calcium Oxalate Renal Calculi Originate From Randall's Plaque?|Do Calcium Oxalate Renal Calculi Originate From Randall's Plaque?||Indiana Kidney Stone Institute|No|Completed|April 2005|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||September 2008|September 16, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169754||194184|
NCT00170287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_3|SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD)|Substrate Modification Study in Patients Getting an ICD|SMS|Medtronic Bakken Research Center|No|Completed|May 2002|August 2011|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|80 Years|No|||January 2013|January 14, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00170287||194146|
NCT00170547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0075|Comparison of Delivery Routes of Flu Vaccine in Adults|Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone(R) in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2005|February 2006||January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|1597|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2006|December 4, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170547||194126|
NCT00166933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700530|Minimal Erythema Dose of UV-B in Normal Population of Taiwan|Minimal Erythema Dose of UV-B in Normal Population of Taiwan||National Taiwan University Hospital||Completed|June 2005|August 2005||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|10 Years|65 Years|Accepts Healthy Volunteers|||August 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166933||194398|
NCT00166946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701179|Effects of Arsenic on Keratinocytes in a Skin Equivalent Model|Effects of Arsenic on Keratinocytes in a Skin Equivalent Model||National Taiwan University Hospital||Recruiting|June 2005|January 2008||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2004|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166946||194397|
NCT00170937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2426|A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome|A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome||Novartis||Completed|November 2004|||March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||507|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2008|September 19, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00170937||194099|
NCT00170950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIB002I2301|Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension|A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension|ACCOMPLISH|Novartis||Terminated|October 2003|May 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11506|||Both|55 Years|N/A|No|||April 2011|April 19, 2011|September 10, 2005|Yes|Yes|The study was terminated early because of significant efficacy results for the primary    endpoint in favor of benazepril/amlodipine treatment.|No|January 13, 2011|https://clinicaltrials.gov/show/NCT00170950||194098|Study was stopped early, as recommended by the Data Monitoring Committee, due to positive efficacy results.
NCT00166907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100005692|Balance Recovery and Training on Fall Prevention in Stroke|Balance Recovery and Training on Fall Prevention in Stroke||National Taiwan University Hospital||Recruiting|January 2002|December 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||100|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||June 2005|September 13, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166907||194400|
NCT00166920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701261|Measurement of Cerebral Oxygen Extraction Fraction Using MRI Technique|||National Taiwan University Hospital||Recruiting|July 2004|July 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|1 Year|N/A|Accepts Healthy Volunteers|||February 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166920||194399|
NCT00167466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-REB 05-20|Placebo Controlled Trial of a Titanium Dioxide Semiconductor Toothbrush on Mild-to-moderate Gum Disease|Randomized, Double-blind, Placebo-controlled Crossover Trial of the Soladey-3 Toothbrush on Periodontal Disease Indices in Patients With Mild-to-moderate Periodontal Disease||University of Saskatchewan|Yes|Completed|October 2005|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|30 Years|70 Years|No|||October 2010|October 26, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167466||194358|
NCT00167973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A-101039|Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use|A Prospective Registry of European Hemophilia B Patients Receiving BeneFIX®(Nonacog Alfa, Recombinant Human Factor IX) for Usual Use||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2002|June 2009|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|N/A|N/A|No|Non-Probability Sample|All EU patients beginning treatment with BeneFIX|May 2010|May 25, 2010|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00167973||194319|
NCT00167986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101498|Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care|Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2005|||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||480|||Both|18 Years|N/A|No|||March 2007|March 14, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167986||194318|
NCT00169572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV20001|Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy|See Detailed Description||GlaxoSmithKline||Completed|February 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||492|||Both|18 Years|N/A|No|||May 2010|May 6, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169572||194198|
NCT00169585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEV102341|Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)|A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA.||GlaxoSmithKline||Completed|March 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|240|||Male|45 Years|N/A|No|||April 2011|April 28, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169585||194197|
NCT00168285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIDe|Pulmonary Rehabilitation in Interstitial Lung Disease|Pulmonary Rehabilitation in Interstitial Lung Disease - a Multi-Centre, Single-Blinded Randomised Controlled Trial||The Alfred|No|Active, not recruiting|March 2005|May 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||56|||Both|40 Years|90 Years|No|||April 2007|April 4, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00168285||194295|
NCT00169832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/416|Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial|A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression After Coronary Bypass Surgery in Diabetic Patients|VICTORY|Laval University|Yes|Completed|June 2003|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|193|||Both|40 Years|75 Years|No|||October 2008|October 9, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169832||194178|
NCT00168987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/174/05|Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors|Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors||Charite University, Berlin, Germany||Completed|January 2005|June 2007|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2008|May 5, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00168987||194242|
NCT00169247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC-TREMPLIN|Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation|Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study||Groupe Oncologie Radiotherapie Tete et Cou||Completed|October 2005|||April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|156|||Both|18 Years|75 Years|No|||June 2011|June 23, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169247||194222|
NCT00168857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.397|A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)|A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)||Boehringer Ingelheim||Completed|July 2003|||June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|860|||Both|21 Years|80 Years|No|||November 2013|November 4, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00168857||194252|
NCT00168883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haema CBF NSCLC UK/AS 03|Study for Patients With Non Small Cell Lung Cancer (NSCLC)|Randomized Phase II Study to Determine the Efficacy of a Three Weekly vs. Weekly Therapy With Paclitaxel Plus Carboplatin vs. Paclitaxel Plus Vinorelbine for Patients With Non Small Cell Lung Cancer According to UICC Stage IIIB and IV||Charite University, Berlin, Germany||Recruiting|October 2002|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||September 2006|October 31, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168883||194250|
NCT00169988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-04-103|Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms|Sertraline Alone vs. in Combination With Risperidone in the Treatment of Attenuated Positive and Negative Symptoms||Northwell Health|Yes|Completed|March 2004|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|8|||Both|12 Years|22 Years|No|||October 2007|December 16, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169988||194166|
NCT00170001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|452-05|Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy|Which Supraesophageal Reflux Symptoms Reliably Respond to PPI Therapy: A Large Simple Trial||Mayo Clinic|Yes|Completed|April 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 13, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00170001||194165|
NCT00169481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103488|A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine|Study to Evaluate Safety & Immunogenicity of Different Formulations of GSK Biologicals' 11-valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly as a 3-dose Primary Immunization (2-3-4 Month Schedule) Before 6 Mths of Age||GlaxoSmithKline||Completed|October 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||689|||Both|8 Weeks|16 Weeks|Accepts Healthy Volunteers|||November 2012|November 21, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169481||194205|
NCT00169767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-042|Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate|Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate: A Randomized Comparison Study||Indiana Kidney Stone Institute|No|Terminated|May 2005|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Male|18 Years|N/A|No|Probability Sample|urology clinic|April 2008|April 23, 2008|September 9, 2005||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00169767||194183|
NCT00169975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|738-04|Efficacy of the CMI Magnetocardiograph in Diagnosing Acute Coronary Syndromes in Patients Presenting With High Risk Unstable Angina.|Efficacy of the CMI Magnetocardiograph in Diagnosing Acute Coronary Syndromes in Patients Presenting With High Risk Unstable Angina as Defined by ACC/AHA Guidelines||Mayo Clinic|No|Completed|August 2004|February 2008|Actual|February 2008|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|137|||Both|18 Years|N/A|No|Non-Probability Sample|*ACC/AHA Guidelines for Unstable Angina: High Risk (≥1 of the following)        History          -  Accelerating tempo of ischemic symptoms in the last 48 hrs Pain          -  Prolonged, ongoing (>20 min) rest pain (resistant to treatment) Clinical findings          -  Pulmonary edema          -  New / ↑ MR murmur          -  S3 or new/ ↑ rales          -  Hypotension, brady -/tachycardia - Age>75y ECG          -  Angina at rest with transient ST changes >0.05 mV          -  New (L)BBB          -  Sustained VT Cardiac Markers          -  Markedly elevated troponin        Patients classified as having high-risk unstable angina at presentation in the ED will be        approached for enrollment in the study.|July 2011|July 15, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169975||194167|
NCT00170963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2305|Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone|Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy||Novartis||Completed|October 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1018|||Both|18 Years|N/A||||September 2005|November 7, 2011|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00170963||194097|
NCT00170976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2307E1|A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension|A 54 Week, Extension to the Double-blind, Multicenter, Multifactorial, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients||Novartis||Completed|April 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|403|||Both|18 Years|N/A||||November 2011|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00170976||194096|
NCT00170989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631C2302|Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone|Comparison of the Combination of Valsartan 320 mg Plus Hydrochlorothiazide 12.5 mg and Valsartan 320 mg Plus Hydrochlorothiazide 25 mg to Valsartan 320 mg in Mild to Moderate Hypertensive Patients Not Adequately Controlled With Valsartan 320 mg||Novartis||Completed|September 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|2714|||Both|18 Years|80 Years||||June 2006|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00170989||194095|
NCT00166647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU-10728|Thiopurine Methyltransferase Polymorphisms Evaluation|Evaluation of Thiopurine Methyltransferase Polymorphisms in the Hispanic Population||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|February 2004|||||Phase 4|Observational|N/A|||Actual|0|||Both|N/A|18 Years|No|||January 2013|January 10, 2013|September 9, 2005|||Observational Study should not be in CT.gov|No||https://clinicaltrials.gov/show/NCT00166647||194420|
NCT00167232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57300|Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence|Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence||University of Pennsylvania||Completed|January 1998|July 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|65 Years|No|||September 2013|October 5, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167232||194376|
NCT00167245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801385|Topiramate for Alcohol and Cocaine Dependence|A Phase II, Randomized, Double-blind, Placebo-Controlled, Pilot Trial of Topiramate for Alcohol and Comorbid Cocaine Dependence|TOP2|University of Pennsylvania|Yes|Completed|September 2004|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||June 2014|August 21, 2014|September 9, 2005|Yes|Yes||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00167245||194375|The total number of subjects was relatively small and thus the results should be considered preliminary. The study drop-out rate was formidable, though it was comparable with most trials involving cocaine-dependent patients.
NCT00167453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-REB 05-71|Benefits of Exercise and Education for Individuals With Parkinson's Disease (BEEP)|Evaluation of the Benefits of a Group Exercise Program and a Group Exercise and Education Program for Individuals With Parkinson's Disease (BEEP)||University of Saskatchewan||Completed|September 2005|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|45|||Both|40 Years|80 Years|No|||September 2006|October 4, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167453||194359|
NCT00167258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|702110|Effectiveness and Costs of Enhanced Cocaine Treatments|||University of Pennsylvania||Completed||February 2007||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||December 2009|December 14, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167258||194374|
NCT00168025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB03_002CR|Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)|A Multicenter Study on the Efficacy, Safety and Pharmacokinetics of IgPro10 in Patients With Primary Immunodeficiency (PID)||CSL Behring||Completed|September 2004|March 2006|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|3 Years|70 Years|No|||June 2012|June 5, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00168025||194315|
NCT00168298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-009|A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion|||Allergan|No|Completed|November 2004|September 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|668|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|September 12, 2005|Yes|Yes||No|July 15, 2009|https://clinicaltrials.gov/show/NCT00168298||194294|
NCT00167687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-5895-V 02|Prazosin Alcohol Dependence IVR Study|A Double-Blind Placebo-Controlled Trial of Prazosin for the Treatment of Alcohol Dependence||University of Washington|Yes|Completed|September 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2008|February 13, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167687||194341|
NCT00170118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49-05|Effects of Motivational Interviewing on Self-Efficacy and Standardized Low Back Pain Outcomes in Patients With Chronic Back Pain"|Effects of Motivational Interviewing on Self-Efficacy and Standardized Low Back Pain Outcomes in Patients With Chronic Back Pain||Mayo Clinic||Completed|June 2005|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind|||Actual|6|||Both|21 Years|N/A|No|||January 2010|January 27, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00170118||194159|
NCT00170131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1801-02|MMF Influence on HCV Viral Evolution After Liver Transplantation|The Influence MMF on 5UTR HCV Quasispecies Variation: A Potential Factor in the Natural History of Post-OLT x HCV Infection||Mayo Clinic||Completed|September 2002|July 2007|Actual|July 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A||Non-Probability Sample|All patients enrolled into - An Open Randomized, Prospective Multicenter Study to Compare        the Efficacy and Safety Among Three Immunosuppressant Treatment Regimens in Patients        Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C        Infection|May 2011|May 20, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00170131||194158|
NCT00169260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA100341-02|Proactive Health Intervention for Tobacco Users (Get PHIT)|Proactive Cessation Intervention With Biomarker Feedback||Group Health Cooperative|No|Completed|February 2005|February 2010|Actual|February 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|536|||Both|18 Years|N/A|No|||December 2010|December 27, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169260||194221|
NCT00169559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAA20001|Dyslipidemia Study Investigating The Increase In "Good Cholesterol"|A Multi-center, Three-staged, Randomized, Parallel Group, Sequential, Double-blind, fenofibrate-and Placebo-controlled Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma HDLc and TG of Eight Weeks Treatment With 1µg to 20µg Daily Doses of GW590735 in Otherwise Healthy Subjects With Low HDLc, Mildly to Moderately Elevated TG, and Normal LDLc||GlaxoSmithKline||Completed|November 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00169559||194199|
NCT00170105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1487-05|Posturing Effects on Perception of Time and Perceptions of the Provider-Patient Interaction in the Emergency Department|Posturing Effects on Perception of Time and Perceptions of the Provider-Patient Interaction in the Emergency Department||Mayo Clinic|Yes|Completed|August 2005|August 2006|Actual|August 2006|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|244|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|•- The subject population represents a convenience sample of patients 18 years and older        who give consent.          -  All English speaking individuals with adequate health status and cognitive function             to communicate answers to the investigator.          -  There are no foreseen reasons to exclude pregnant women as they are not likely to be             vulnerable in this study.|February 2010|February 1, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00170105||194160|
NCT00170079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1730-04|Prolonged Smoking Cessation Using Prescription Step Care|Prolonged Smoking Cessation Using Prescription Step Care||University of Tennessee|Yes|Completed|April 2005|June 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00170079||194161|
NCT00171067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ADE20|VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria|A Study to Evaluate the Effectiveness of Valsartan 320 mg in Combination With Lisinopril 20 mg Versus Monotherapy With Lisinopril 40 mg or Valsartan 320 mg in Hypertensive Patients With Microalbuminuria on the Reduction of Urinary Albumin Creatinine Ratio||Novartis||Completed|July 2004|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|134|||Both|18 Years|75 Years||||November 2011|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00171067||194089|
NCT00193921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 03.07|Chemoradiotherapy in Patients With Localised Lung Cancer|A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|February 2003|December 2012|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193921||192377|
NCT00168896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haema CBF SCLC UK/AS 01|A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage|A Randomised Phase II/III Study to Compare the Combination of Carboplatin Plus Irinotecan Vs. the Combination of Carboplatin Plus Etoposide for SCLC in Extensive Disease Stage||Charite University, Berlin, Germany||Recruiting|October 2001|December 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||286|||Both|18 Years|75 Years|No|||September 2001|February 13, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168896||194249|
NCT00169780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-035|Kidney Stone Structural Analysis By Helical Computed Tomography (CT)|Kidney Stone Structural Analysis by Helical Computed Tomography (A Pilot Study)||Indiana Kidney Stone Institute|No|Completed|July 2002|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of Methodist Urology, Indianapolis, Indiana who require a CT scan prior to        percutaneous removal of renal calculi.|December 2011|December 5, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169780||194182|
NCT00170313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_6|CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation|Conducted AF-Response Study (Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation Treated With InSync III Marquis)||Medtronic Bakken Research Center||Terminated|December 2003|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||October 2008|October 8, 2008|September 13, 2005|||Ventricular rate during AF in CRT-patients much lower than expected|No||https://clinicaltrials.gov/show/NCT00170313||194144|
NCT00170300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Care-HF 2.02.02|Care-HF CArdiac Resynchronization in Heart Failure|Outcome Trial (Long Term)to Evaluate the Effects of Cardiac Resynchronization Therapy on the Mortality and Morbidity of Patients With Heart Failure||Medtronic Bakken Research Center||Completed|January 2001|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||813|||Both|18 Years|N/A|No|||September 2005|December 29, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170300||194145|
NCT00170573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32005000|Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer|||North Eastern Germany Society of Gynaecologic Oncology|No|Completed|October 2001|August 2010|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00170573||194124|
NCT00170586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-241|Novel Protective Underglove|Novel Protective Underglove||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2003|August 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||325|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||March 2007|August 26, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00170586||194123|
NCT00166634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10668s|Ambulatory Blood Pressure Monitoring in Hypertension|The Role of Ambulatory Blood Pressure Monitoring (ABPM) in Interventional Trials Conducted in Children With Hypertension||Arkansas Children's Hospital Research Institute|No|Completed|July 2003|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|126|||Both|5 Years|16 Years|No|||January 2011|January 10, 2011|September 9, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00166634||194421|
NCT00166972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701255|Molecular Mechanism of Trophinin in Cancer Invasion and Metastasis|Molecular Mechanism of Trophinin in Cancer Invasion and Metastasis||National Taiwan University Hospital||Completed|January 2005|April 2005||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||||150|||Both|N/A|N/A|No|||July 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166972||194395|
NCT00166985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701182|The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients|The Role of Functional MRI and Doppler Sonography in Assessing Intratumoral Angiogenesis of Endometrial Cancer Patients||National Taiwan University Hospital||Recruiting|September 2004|December 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Female|18 Years|80 Years|No|||August 2004|December 26, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166985||194394|
NCT00166959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700931|Reliability and Validity of Modified Postural Assessment Scale for Stroke Patients and the Application of This Scale on Early Detection of Patients With Stroke at High Risk of Falls|Reliability and Validity of Modified Postural Assessment Scale for Stroke Patients and the Application of This Scale on Early Detection of Patients With Stroke at High Risk of Falls||National Taiwan University Hospital||Recruiting|January 2005|December 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||90|||Both|30 Years|80 Years|No|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166959||194396|
NCT00167271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020771|Promoting Health in People With Fibromyalgia|Efficacy of Computer and SenseWear Technologies for Promoting Health in People With Fibromyalgia: A Randomized Clinical Trial||University of Pittsburgh|No|Completed|October 2002|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||February 2011|February 18, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00167271||194373|
NCT00167479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101541d|A Study of Risperidone Monotherapy in Bipolar Anxiety|A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder||University of South Florida||Completed|September 2003|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2006|September 8, 2006|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00167479||194357|
NCT00169026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA11904|Alcoholism and Schizophrenia: Effects of Clozapine|Alcoholism and Schizophrenia: Effects of Clozapine||Dartmouth-Hitchcock Medical Center||Terminated|May 1999|January 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||64|||Both|19 Years|65 Years|No|||September 2005|September 10, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00169026||194239|
NCT00168649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9583-2625-VITA-LPS|Vitamin A and Response to Endotoxin|The Effect of Vitamin A on the Response to Endotoxin||Bandim Health Project||Active, not recruiting|June 2005|June 2014||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00168649||194267|
NCT00169078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCR5093|Impact of Insecticide-Treated Curtains on Antimalarial Drug Resistance|A Study of the Impact of Insecticide-Treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso||Gates Malaria Partnership||Completed|July 2002|December 2002||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1035|||Both|6 Months|59 Months|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169078||194235|
NCT00169845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27370|Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients|Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients||Laval University|Yes|Active, not recruiting|October 1994|||June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|540|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169845||194177|
NCT00170703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0325|Assessment of Cortical Stimulation Combined With Rehabilitation to Enhance Recovery in Broca's Aphasia.|Assessment of the Safety and Effectiveness of Targeted Sub-Threshold Epidural Cortical Stimulation Delivered Concurrent With Speech-Language Rehabilitation to Enhance Recovery in Patients Suffering From Broca's Aphasia, Following a Stroke.||Northstar Neuroscience|No|Completed|December 2004|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||8|||Both|21 Years|N/A|No|||September 2007|September 19, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00170703||194116|
NCT00171080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ADE19|VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis|A 2 x 5-week Multicenter, Cross-over Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan 80 mg Compared to Irbesartan 150 mg in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis||Novartis||Completed|April 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|86|||Both|18 Years|80 Years||||November 2011|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00171080||194088|
NCT00171093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAS489A2316|A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia|A 10-12 Week Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of the Combination of Valsartan (320 mg) and Simvastatin (80 mg) Compared to Valsartan (320 mg) and Simvastatin (80 mg) Monotherapies in Essential Hypertension and Hypercholesterolemia||Novartis||Completed|September 2004|||January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||369|||Both|18 Years|75 Years||||September 2008|September 19, 2008|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00171093||194087|
NCT00199745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muskelbiopsistudie Lipid05-06|Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity|Investigations on Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity||Oslo University Hospital||Completed|October 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 9, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00199745||191940|
NCT00199953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-USA-57|Post-nasal Drainage as an Extraesophageal Manifestation of Reflux|Post-nasal Drainage as an Extraesophageal Manifestation of Reflux||Medical College of Wisconsin||Completed|June 2002|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||50|||Both|18 Years|70 Years|No|||November 2013|November 25, 2013|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00199953||191924|
NCT00170014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850-04|Precision of the Magnetocardiographer for Data Aquision and Analysis.|Reproducibility of Magnetocardiography Measurements Using the Cardiomag Magnetocardiograph System Model 2409 and Its Software for Data Acquisition and Analysis||Mayo Clinic||Completed|October 2004|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|12|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 14, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00170014||194164|
NCT00170027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999-03|Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease|Safety and Efficacy of the CMI Magnetocardiograph Model 2409 for Diagnosing Coronary Heart Disease||Mayo Clinic||Completed|July 2003|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|250|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00170027||194163|
NCT00170612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-042|Pneumococcal Vaccination of Fiji Infants|A Single-Blind Open-Label Randomized Phase II Study of the Safety, Immunogenicity and Impact on Pneumococcus (Pnc) Carriage of the Pnc Vaccination Regimens Combining 1, 2, or 3 Doses of 7-Valent Pneumococcal Conjugate Vaccine (PCV) in the First 4 Months of Life Followed by a Single Dose of 23-Valent Pneumococcal Polysaccharide Vaccine (PPS) at 12 Months of Age||University of Melbourne|Yes|Completed|November 2005|August 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|552|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||October 2008|October 20, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00170612||194122|
NCT00171002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2306|Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone|A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy||Novartis||Completed|November 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|936|||Both|18 Years|N/A||||June 2006|November 7, 2011|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00171002||194094|
NCT00170625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310300|Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer|Multicenter, Prospective Phase-I/II-study: Topotecan and Carboplatin in the Therapy of Patients With Relapsed Ovarian Cancer||North Eastern Germany Society of Gynaecologic Oncology|No|Completed|June 2004|September 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00170625||194121|
NCT00171015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BDE10|VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil|An Open,Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Valsartan/Hydrochlorothiazide 160/25 (Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg) in Patients Not Adequately Responding to a 4 Week Monotherapy With Olmesartan Medoxomil 40 mg or Combination Therapy With Olmesartan Medoxomil 20 mg Plus HCTZ 12.5 mg||Novartis||Completed|December 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|212|||Both|18 Years|N/A||||November 2011|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00171015||194093|
NCT00167713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2003/IBU|Treatment of Fever Due to Malaria With Ibuprofen|Randomised, Double-Blind, Placebo Controlled Study of the Antipyretic Effect of Ibuprofen in Children With Uncomplicated Malaria||Albert Schweitzer Hospital||Completed|April 2003|January 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|2 Years|7 Years|No|||September 2005|September 19, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167713||194339|
NCT00167284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010157|Patient Provider Partnership: Improving Diabetes Care in the Community|Patient Provider Partnership: Improving Diabetes Care in the Community||University of Pittsburgh||Completed|October 2001|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||270|||Both|18 Years|N/A|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167284||194372|
NCT00167700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15214|Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight|Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight|NAMI|University of Turku|No|Recruiting|February 1997|December 2015|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|6||Anticipated|800|||Female|18 Years|N/A|No|||September 2012|October 3, 2012|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00167700||194340|
NCT00169286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH065530|Organized Self-management Support for Chronic Depression|Organized Self-management Support for Chronic Depression||Group Health Cooperative||Completed|July 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind||||104|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00169286||194219|
NCT00169273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R202009|Epidemiology and Care of Comorbid Obesity and Depression|Epidemiology and Care of Comorbid Obesity and Depression||Group Health Cooperative|Yes|Completed|April 2004|April 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Female|40 Years|65 Years|No|||September 2009|September 10, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169273||194220|
NCT00169637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.301|Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome|Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome||Hospices Civils de Lyon||Completed|June 2006|June 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|3 Years|18 Years|No|||June 2008|October 30, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169637||194193|
NCT00169884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2100.0068|The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients|The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients: A Randomized Controlled Trial Among Adolescents and Young Adults||Leiden University Medical Center||Recruiting|March 2002|March 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|15 Years|35 Years|No|||January 2005|January 31, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00169884||194174|
NCT00170170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2275-04|Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation|Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis||Mayo Clinic||Completed|November 2004|June 2007|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Recipients of liver, kidney, pancreas, heart or lung transplantation|February 2010|February 1, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00170170||194155|
NCT00170352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR2000-858|Comparison Between Different Types of Oxygen Treatment Following Traumatic Brain Injury|Hyperbaric and Normobaric Oxygen in Severe Brain Injury||Minneapolis Medical Research Foundation|Yes|Completed|November 2002|November 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|80|||Both|16 Years|65 Years|No|||August 2015|August 27, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00170352||194141|
NCT00170365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR-04-2412|Restorative Yoga for Stress Management|Restorative Yoga for Stress Management||Minneapolis Medical Research Foundation||Completed|July 2004|March 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2005|March 19, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170365||194140|
NCT00170716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0267|Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis|Safety and Effectiveness of Targeted Sub-Threshold Epidural Cortical Stimulation Delivered Concurrent With Rehabilitation Activities to Enhance Motor Recovery in Patients Suffering From Upper Extremity Hemiparesis Following a Stroke|EVEREST|Northstar Neuroscience|Yes|Active, not recruiting|September 2004|March 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|174|||Both|21 Years|N/A|No|||December 2007|December 18, 2007|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00170716||194115|
NCT00168402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-046|A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis|||Allergan||Completed|February 2002|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|193|||Both|18 Years|75 Years|No|||May 2011|May 27, 2011|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00168402||194286|
NCT00168415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-075|A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis|||Allergan||Completed|August 2005|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|12 Years|17 Years|No|||September 2008|September 26, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00168415||194285|
NCT00168740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEC-102-05|Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)|Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma||Biogen||Completed|April 1995|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00168740||194261|
NCT00200837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08AT000987-01|Ethnopharmacological Studies in Oral Medicine|Ethnopharmacological Studies in Oral Medicine||National Center for Complementary and Integrative Health (NCCIH)||Completed|March 2002|February 2007|Actual|||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||1000|||Both|N/A|N/A|No|||March 2007|March 27, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00200837||191857|
NCT00200850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002326-01A1|Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy|Sublingual Immunotherapy in Dust Mite Allergy||University of Wisconsin, Madison|Yes|Completed|January 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|50 Years|No|||September 2015|September 30, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00200850||191856|
NCT00169806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-073|Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis|Randall's Plaques: Pathogenesis and Relationship to Nephrolithiasis||Indiana Kidney Stone Institute|Yes|Recruiting|November 1998|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00169806||194180|
NCT00170053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37-05|Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids|Randomized Trial of Thymoglobulin Induction, Initial Tacrolimus, and Mycophenolate Mofetil Therapy With Steroid Avoidance in Primary Kidney Transplant Recipients Followed by Continued Tacrolimus/Mycophenolate Mofetil Therapy vs. Sirolimus/ Mycophenolate Mofetil Therapy||Mayo Clinic||Completed|June 2005|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|177|||Both|18 Years|80 Years|No|||July 2012|July 27, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00170053||194162|
NCT00170326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreVent-HF|Progressive Ventricular Dysfunction Prevention in Pacemaker Patients|Progressive Ventricular Dysfunction Prevention in Pacemaker Patients|Prevent-HF|Medtronic Bakken Research Center|Yes|Completed|January 2002|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|108|||Both|18 Years|N/A|No|||April 2009|May 8, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00170326||194143|
NCT00170638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-202|Tuberculosis Immunity in Children|Tuberculosis Immunity in Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2005|April 2010||||N/A|Observational|Time Perspective: Prospective||||260|||Both|N/A|N/A|No|||January 2008|April 24, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00170638||194120|
NCT00171028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2307|A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension|A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertension Patients 1 - 5 Years Of Age||Novartis||Completed|December 2003|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|90|||Both|1 Year|5 Years||||June 2006|November 7, 2011|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00171028||194092|
NCT00166660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD046855|Preterm Fetal Growth Restriction and Developmental Care|Preterm Fetal Growth Restriction and Developmental Care||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|July 2004|June 2009|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|30|||Both|28 Weeks|33 Weeks|No|||March 2009|April 1, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166660||194419|
NCT00166673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 006|Pilot Study of the Navigator Continuous Glucose Monitor|A Pilot Study to Evaluate the Navigator Continuous Glucose Sensor in the Management of Type 1 Diabetes in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 2005|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||60|||Both|3 Years|17 Years|No|||December 2006|January 10, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00166673||194418|
NCT00168038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB03_003CR|Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10|An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)||CSL Behring||Completed|December 2004|February 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|12 Years|65 Years|No|||October 2011|October 18, 2011|September 12, 2005|No|Yes||No|August 22, 2011|https://clinicaltrials.gov/show/NCT00168038||194314|
NCT00168662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC18-CT95-0011-Twodose1|Non-Specific Effects of Standard Titre Measles Vaccination|Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age||Bandim Health Project||Completed|March 1995|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||7800|||Both|6 Months|8 Months|Accepts Healthy Volunteers|||February 2008|February 25, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00168662||194266|
NCT00169013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gabapentin2002|Gabapentin in Phantom and Stump Pain|Gabapentin in the Prevention of Phantom Limb Pain||Danish Pain Research Center|Yes|Completed|May 2002|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2007|April 11, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169013||194240|
NCT00169598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000.232|Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study|Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study|TEPELY|Hospices Civils de Lyon||Active, not recruiting|February 2002|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||80|||Both|18 Years|80 Years|No|||April 2007|April 26, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00169598||194196|
NCT00168077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE1116_3001|Prothrombin Complex Concentrate for Anticoagulant Reversal|Efficacy and Tolerance of BERIPLEX® P/N in Subjects With Acquired Deficiency of Coagulation Factors II, VII, IX and X Due to Oral Anticoagulation||CSL Behring||Completed|September 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||February 2011|February 10, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00168077||194311|
NCT00170404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-032|TB Nutrition, Immunology and Epidemiology|Nutrition, Immunology, and Epidemiology of Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2000|October 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||887|||Both|18 Years|65 Years|No|||February 2007|August 26, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170404||194137|
NCT00170417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/Z|Clinical Benefit of CBT for Insomnia in Primary Care|Clinical and Health Economic Benefit of Non-Pharmacological Treatment of Chronic Insomnia in Primary Care||NHS Greater Clyde and Glasgow||Completed|December 2000|May 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||December 2000|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170417||194136|
NCT00170768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328A2403|Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over|Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over||Novartis||Completed|February 2005|May 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|60 Years|N/A||||January 2008|January 18, 2008|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00170768||194111|
NCT00170781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2426|Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout|A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day)||Novartis||Completed|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||234|||Both|18 Years|N/A|No|||June 2006|November 29, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00170781||194110|
NCT00171132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ADE21|VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women|A 26-week Double-blind, Randomized, Multicenter Parallel-group Trial to Compare the Effects of Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women With Impaired Exercise Tolerance||Novartis||Completed|August 2004|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|64|||Female|18 Years|N/A||||November 2011|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00171132||194084|
NCT00171145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328A2401|A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.|A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.||Novartis||Completed|April 2004|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|445|||Both|18 Years|N/A||||January 2008|January 18, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00171145||194083|
NCT00167544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23NS048152|Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants|A Randomized Trial of Hydrocortisone in Very Preterm Infants at High Risk for Neurologic and Pulmonary Impairments||Nationwide Children's Hospital|Yes|Completed|November 2005|November 2012|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Both|N/A|3 Weeks|No|||July 2013|July 29, 2013|September 9, 2005||No||No|March 25, 2013|https://clinicaltrials.gov/show/NCT00167544||194352|
NCT00167791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0265|Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant|Multicenter Trial Using Multi-dose Rituximab as Induction and Desensitization Therapy for Patients on the Waiting List for Kidney Transplant With a Positive Donor Specific Crossmatch to a Living Donor||University of Wisconsin, Madison|Yes|Withdrawn|July 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2014|October 13, 2015|September 9, 2005||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00167791||194333|
NCT00200512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APO301|Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months|A Prospective, Randomized, Placebo-Controlled, Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of "Off" Episodes in Patients With "On/Off" or "Wearing Off" Effects Associated With Late Stage Parkinson's Disease||Mylan Bertek Pharmaceuticals||Completed|September 1999|November 1999||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||March 2000|December 15, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00200512||191881|
NCT00200525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APO302|Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease|A Randomized, Placebo-Controlled Study of the Continued Efficacy and Safety of SC Apomorphine in the Treatment of Off Episodes in Patients With "On/Off" or "Wearing-Off" Effects Associated With Late-Stage PD After Apomorphine Use||Mylan Bertek Pharmaceuticals||Completed|July 2001|June 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|December 15, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00200525||191880|
NCT00200538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 05/1-E|Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients|Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients||Nantes University Hospital||Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|52|||Both|45 Years|75 Years|No|||January 2005|May 2, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200538||191879|
NCT00200239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2047-05|Provision of Breakfast Food in Behavioral Weight Loss|Provision of Breakfast Food in Behavioral Weight Loss||The Miriam Hospital||Completed|September 2005|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2007|April 19, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200239||191902|
NCT00169819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4S-CA-0050|EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study|A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting||Laval University|Yes|Completed|October 2003|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|18 Years|N/A|No|||February 2007|February 23, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169819||194179|
NCT00166686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10706|Clonidine for Neurocognitive Sequelae|Clonidine for the Treatment of Neurocognitive Sequelae Following Cancer Treatment in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|5 Years|16 Years|No|||January 2013|January 10, 2013|September 9, 2005|||Study was never initiated|No||https://clinicaltrials.gov/show/NCT00166686||194417|
NCT00166699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04AN003(1)|A Trial of the Use of Ultrasound to Aid the Insertion of Combined Spinal Epidural Anaesthesia|The Clinical Evaluation of a Novel Ultrasound Probe to Guide the Insertion of Central Regional Anaesthesia Using a Regional Anaesthetic Needle Modified to Aid Insertion Under Ultrasound Guidance in Morbidly Obese Women Undergoing Elective Caesarean Section||NHS Greater Glasgow and Clyde|No|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|N/A|N/A|No|||June 2008|June 10, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00166699||194416|
NCT00170664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020114|Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer|||North Eastern Germany Society of Gynaecologic Oncology||Completed|January 1999|September 2004|Actual|March 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Female|18 Years|75 Years|No|||March 2016|March 24, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00170664||194119|
NCT00170677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4401000|Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer|Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer||North Eastern Germany Society of Gynaecologic Oncology|No|Completed|September 2005|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Female|18 Years|N/A|No|||July 2010|May 13, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00170677||194118|
NCT00171041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2302|A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age|A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertensive Patients||Novartis||Completed|December 2002|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|265|||Both|6 Years|16 Years||||November 2011|November 7, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00171041||194091|
NCT00167492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-05-0197|Enteric Coated Myfortic for Liver Transplant Recipients|Enteric Coated Mycophenolic Acid (Myfortic) in Liver Transplant Recipients- Effect on Compliance and Calcineurin Inhibitor and Corticosteroid Sparing||The University of Texas Health Science Center, Houston||Withdrawn|September 2005|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||December 2013|December 5, 2013|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00167492||194356|
NCT00168311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81/02|A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia|A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magentic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia and Related Disorders|rTMS|The Alfred|No|Completed|August 2002|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||April 2012|April 15, 2012|September 14, 2005||No||No|June 15, 2010|https://clinicaltrials.gov/show/NCT00168311||194293|Insufficient time period used to be able to establish a substantive therapeutic effect of rTMS; standard dosing method may be inadequate due to volumetric changes in brain regions in schizophrenia; concurrent antipsychotic medication.
NCT00168324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-008|A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion|||Allergan|No|Completed|October 2004|October 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|599|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|September 12, 2005|Yes|Yes||No|July 15, 2009|https://clinicaltrials.gov/show/NCT00168324||194292|
NCT00168688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUF-2001-91057-PREGNUT|Prenatal Multi-micronutrient Supplementation and Pregnancy Outcome|The Effects of Prenatal Multi-micronutrient Supplements on Pregnancy Outcome, Peri- and Neonatal Mortality on Maternal and Infant Nutritional Status: A Randomised, Controlled Trial Among Women in Guinea-Bissau||Bandim Health Project||Completed|January 2001|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2100|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 15, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00168688||194265|
NCT00168701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1900|Efficacy and Safety of BG00012 in MS|Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis||Biogen||Completed|October 2004|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|18 Years|55 Years|No|||November 2007|November 14, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00168701||194264|
NCT00170144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004000|Effect of Branched Chain Amino Acids on Muscle|Branched Chain Amino Acids as Stimulant of Muscle Mitochondrial Function in Elderly People||Mayo Clinic||Completed|September 2005|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 14, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00170144||194157|
NCT00169039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH049891|Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia|Clozapine Response and Biogenic Amines in Schizophrenia||Harvard Medical School||Terminated|December 1994|February 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|19 Years|60 Years|No|||April 2015|April 6, 2015|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00169039||194238|
NCT00169052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062324|Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People|Rehabilitation and Health Care for Elderly With SMI||Dartmouth-Hitchcock Medical Center||Completed|September 2001|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||180|||Female|50 Years|N/A||||September 2001|September 6, 2013|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00169052||194237|
NCT00167323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0307095|Early Recovery Adherence Therapy for Bipolar Alcoholics|Early Recovery Adherence Therapy for Bipolar Alcoholics||University of Pittsburgh||Completed|July 2003|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|65 Years|No|||May 2008|May 16, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167323||194369|
NCT00168090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP7000/1-4002|Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)|Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von Willebrand's Disease.||CSL Behring||Completed|October 2001|May 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||February 2011|February 10, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00168090||194310|
NCT00176904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT1995-01|Stem Cell Transplant for Inborn Errors of Metabolism|Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation||Masonic Cancer Center, University of Minnesota|No|Completed|January 1995|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|N/A|N/A|No|||November 2012|November 6, 2012|September 12, 2005||No||No|May 17, 2011|https://clinicaltrials.gov/show/NCT00176904||193643|Change in Neuropsychometric function data is not available. Data would have been noted as descriptive and patient specific, as well as disease specific; not table format. No formal analysis was intended.
NCT00176917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN-MT1999-07|Stem Cell Transplantation for Hurler|Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)||Masonic Cancer Center, University of Minnesota|No|Completed|May 1999|May 2010|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|N/A|N/A|No|||November 2012|November 6, 2012|September 12, 2005|Yes|Yes||No|July 28, 2009|https://clinicaltrials.gov/show/NCT00176917||193642|Based on variability in age, diagnosis and condition of these patients, the data on enzyme levels and neuropsych testing is extremely difficult to report.See Secondary Outcome Measures #3 and #4; no other adverse events were collected.
NCT00167076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56m2|Clinical Applications and Evaluations of A Portable In-Shoe Plantar Pressure Monitoring and Biofeedback Gait System for Ambulation Training in Stroke Rehabilitation|Clinical Applications and Evaluations of A Portable In-Shoe Plantar Pressure Monitoring and Biofeedback Gait System for Ambulation Training in Stroke Rehabilitation||National Taiwan University Hospital||Active, not recruiting|August 1999|July 2002||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||30|||Both|40 Years|75 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167076||194387|
NCT00167336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403027|Developing an Instrument to Measure Personal Keyboarding Style|Developing an Instrument to Measure Personal Keyboarding Style||University of Pittsburgh||Completed|May 2004|March 2005||||N/A|Observational|Time Perspective: Prospective||||40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2006|December 15, 2015|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00167336||194368|
NCT00168103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1145_3001|Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks|Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency and Acute Abdominal or Facial HAE Attacks||CSL Behring|Yes|Completed|June 2005|December 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|126|||Both|6 Years|N/A|No|||February 2011|March 11, 2015|September 12, 2005|No|Yes||No|April 21, 2010|https://clinicaltrials.gov/show/NCT00168103||194309|A test for futility of the C1-INH 10 U/kg bw group conducted during a planned interim analysis led to ceasing recruitment for the C1-INH 10 U/kg bw group.
NCT00168389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-010|A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema|||Allergan|No|Completed|February 2005|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|494|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|September 12, 2005|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00168389||194287|
NCT00200278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL064342|Exercise Instruction Via Phone or Print|Exercise Instruction Via Phone or Print||The Miriam Hospital||Completed|August 2000|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||228|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200278||191899|
NCT00200252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC05.79|Oxytocin Administration in the Third Stage of Labour - A Study of Appropriate Route and Dose|Intramuscular Versus Intravascular Oxytocin for the Third Stage of Labour||Memorial University of Newfoundland||Completed|September 2005|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Female|19 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 8, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200252||191901|
NCT00200863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002129-01|Effects of Different Colors of Light on Human Physiology|Mechanism Underlying the Effects of Blue Light in Humans||Brigham and Women's Hospital|No|Completed|April 2005|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|47|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200863||191855|
NCT00171054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2418|Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension|A Randomized, Double-blind, Parallel Group, Active-controlled, 38-week Study to Evaluate the Efficacy of Valsartan Versus Amlodipine on the Arterial Properties of Postmenopausal Women With Mild to Moderate Hypertension||Novartis||Completed|September 2003|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Female|50 Years|75 Years||||June 2011|June 2, 2011|September 10, 2005||||No|December 21, 2010|https://clinicaltrials.gov/show/NCT00171054||194090|
NCT00167310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA 0455676U|Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation|CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation|CAD|University of Pittsburgh|No|Completed|September 2005|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167310||194370|
NCT00166998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701271|The Study of Infrared Imaging on Breast Cancer|||National Taiwan University Hospital||Recruiting|March 2005|July 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||600|||Female|18 Years|N/A|No|||February 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00166998||194393|
NCT00167011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700813|Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography|Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography||National Taiwan University Hospital||Completed|July 1995|January 2002|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|200|||Both|N/A|18 Years|No|||November 2012|December 5, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167011||194392|
NCT00167024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700307|Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome|||National Taiwan University Hospital||Recruiting|March 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||100|||Male|N/A|N/A|No|||March 2005|November 25, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00167024||194391|
NCT00167297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801701|Atomoxetine for the Treatment of Cannabis Dependence|A Pilot Trial of Atomoxetine to Enhance Motivational Interviewing Therapy for the Treatment of Cannabis Dependence||National Institute on Drug Abuse (NIDA)|No|Completed|November 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||December 2009|December 2, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00167297||194371|
NCT00168064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005NMMF-201-US|Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides|A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)||Yaupon Therapeutics|No|Completed|May 2006|August 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|N/A|N/A|No|||October 2012|October 2, 2012|September 7, 2005|Yes|Yes||No|July 12, 2011|https://clinicaltrials.gov/show/NCT00168064||194312|
NCT00169611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.310|NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate|Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo||Hospices Civils de Lyon||Completed|January 2004|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|80|||Both|7 Years|12 Years|No|||January 2011|January 26, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00169611||194195|
NCT00169624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.346|Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin|The DIAMET Study: Peripheral and Coronary Endothelial Dysfunction in Type 2diabetic Patients- Evaluation of Reversibility Following 3 Months of Metformin Treatment||Hospices Civils de Lyon||Terminated|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||30|||Both|18 Years|70 Years|No|||October 2007|October 4, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00169624||194194|
NCT00170157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0253|MDX-010 for Advanced Prostate Cancer|A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer||Mayo Clinic|Yes|Completed|June 2005|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Male|18 Years|N/A|No|||December 2013|December 20, 2013|September 13, 2005|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00170157||194156|
NCT00170742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS 995 H DE 07|Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.|A Randomized, Open Label, Controlled Study on the Efficacy and Safety of Octreotide i.m. in Patients With Proliferative Diabetic Retinopathy (PDR) After Start of Laser Coagulation||Novartis||Terminated|December 2003|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||17|||Both|18 Years|70 Years|No|||August 2008|August 8, 2008|September 9, 2005|||trial stopped on Sept 24, 2007|No||https://clinicaltrials.gov/show/NCT00170742||194113|
NCT00170755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328A2301|A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder|A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder||Novartis||Completed|April 2002|January 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|718|||Both|18 Years|N/A||||January 2008|January 15, 2008|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00170755||194112|
NCT00171119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ATR05|A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril|A 24-Week Study to Assess Blood Pressure Independent Effects of Valsartan Treatment, Benazepril Treatment and Combination of Both Valsartan and Benazepril Treatment on Urinary Albumin Excretion Rate With Type II Diabetes Mellitus and Microalbuminuria||Novartis||Terminated|January 2004|||March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|81|||Both|35 Years|75 Years||||December 2008|December 16, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00171119||194085|
NCT00166790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700666|Detection of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease|Detection of Minimal Amount of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease||National Taiwan University Hospital||Recruiting|September 2005|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|30|||Female|20 Years|50 Years|No|Probability Sample|GTD|December 2014|December 5, 2014|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00166790||194409|
NCT00184743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1519|Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)|Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency||Novo Nordisk A/S|No|Completed|December 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|112|||Both|18 Years|66 Years|No|||June 2012|June 28, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184743||193065|
NCT00185016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1,SLFW|Women Abuse and the Role of the Family Doctor.|Women Abuse and the Role of the Family Doctor. Testing an Intervention in a Randomised Controlled Trial.||Radboud University||Terminated|March 2003|November 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training|||||||Female|18 Years|N/A||||September 2005|September 15, 2005|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00185016||193044|
NCT00184717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1517|Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)|GHLIQUID-1516: A 104-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Subjects With Short Stature Born Small for Gestational Age / GHLIQUID-1517: A Long-term, Multi-centre, Randomised, Controlled, Double-blind, Parallel-group Trial, Investigating the Efficacy and Safety of Two Doses of NN-220 in Subjects With Short Stature Born Small for Gestational Age||Novo Nordisk A/S|No|Completed|July 2003|December 2009|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|98|||Both|N/A|N/A|No|||March 2015|March 23, 2015|September 13, 2005|Yes|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00184717||193067|
NCT00180921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI BFR 17|Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck|Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|July 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||September 2006|September 24, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180921||193341|
NCT00180934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JANORL|Reirradiation With Concomitant Chemotherapy After Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area|Interest of a Reirradiation With Concomitant Chemotherapy After Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area: a Multicentric Phase III Randomized Trial||Gustave Roussy, Cancer Campus, Grand Paris||Active, not recruiting|July 1999|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||280|||Both|18 Years|N/A|No|||September 2005|December 22, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180934||193340|
NCT00180947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVE-CYCLO|Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse|Phase II Study of Vinorelbine + Cyclofosfamide Association Among Patients Reached of Refractory Tumours or in Relapse||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|June 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||210|||Both|12 Months|25 Years|No|||September 2006|September 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180947||193339|
NCT00184977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-46140|COPD on Primary Care Treatment (COOPT)|A Double-blind Placebo-controlled Trial Comparing the Efficacy and Cost-effectiveness of Inhaled Fluticason Propionate Versus Oral N-acetylcysteine in the Treatment of Patients With COPD in General Practice||Radboud University||Completed|December 1998|January 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|30 Years|75 Years|No|||August 2006|March 11, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184977||193047|
NCT00184990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP01|Effect of Selective iNOS Inhibition During Human Endotoxemia|Effect of Selective iNOS Inhibition During Human Endotoxemia||Radboud University|No|Completed|January 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184990||193046|
NCT00185003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP02|Blockade of Vascular Potassium Channels During Human Endotoxemia|Blockade of Vascular Potassium Channels During Human Endotoxemia||Radboud University|No|Completed|January 2003|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2008|October 16, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00185003||193045|
NCT00181662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000650|Pharmacokinetics of Curcumin in Healthy Volunteers|Evaluation of Naturally Occurring Inhibitors of UDP-Glucuronyltransferase on the Oral Bioavailability of Curcumin in Normal Healthy Volunteers||Massachusetts General Hospital||Completed|August 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 2, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00181662||193298|
NCT00181831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-000661|Spectroscopy in Children and Adolescents With Bipolar Disorder|Proton Magnetic Resonance Spectroscopy in Children and Adolescents With Bipolar Disorder||Massachusetts General Hospital||Completed|December 2002|November 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||80|||Both|6 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 children with bipolar disorder between the ages of 6-17 years old free of risperidone        treatment and 20 children with bipolar disorder after an eight-week or longer treatment        with risperidone.|June 2013|June 12, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181831||193285|
NCT00181844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001419|Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder|A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders||Massachusetts General Hospital|Yes|Completed|January 2005|April 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|6 Years|17 Years|No|||March 2012|March 9, 2012|September 13, 2005|Yes|Yes||No|July 27, 2011|https://clinicaltrials.gov/show/NCT00181844||193284|
NCT00182559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004209-98|The Vienna Prograf and Endothelial Progenitor Cell Study|The Vienna Prograf and Endothelial Progenitor Cell Study||Medical University of Vienna|No|Completed|April 2004|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|148|||Both|18 Years|80 Years|No|||February 2014|February 4, 2014|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00182559||193229|
NCT00182572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018297|Science-Based Treatment for Opioid-Dependent Adolescents|Science-Based Treatment for Opioid-Dependent Adolescents||National Development and Research Institutes, Inc.||Recruiting|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|13 Years|18 Years|No|||August 2008|August 11, 2008|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00182572||193228|
NCT00173407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700640|PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion|Correlation of PTEN and IGFBP-3 in the Invasion of Ovarian Endometrioid Carcinoma||National Taiwan University Hospital|No|Withdrawn|January 2006|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|21 Years|80 Years|No|||December 2012|December 26, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00173407||193910|
NCT00183690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071660|Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents|Treating Terror-Related PTSD in Adolescents||National Institute of Mental Health (NIMH)|Yes|Completed|September 2004|June 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|12 Years|18 Years|No|||December 2008|December 11, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183690||193145|
NCT00183937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-04-3|Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer|A Phase II Study of Bortezomib (Velcade®, PS-341) and Docetaxel for Patients With Hormone Refractory Prostate Cancer||University of Southern California|Yes|Completed|April 2005|December 2011|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183937||193126|
NCT00183950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-99-16|Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy|Phase I/II Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy||University of Southern California|Yes|Terminated|March 2000|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005|||No funding|||https://clinicaltrials.gov/show/NCT00183950||193125|
NCT00184275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12621|Characterization of Brain Metastases|Brain Metastases Tissue Characterized by High-resolution Magic Angle Spinning MR and Micro Array||Norwegian University of Science and Technology|No|Completed|May 2005|December 2010|Actual|May 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|Samples With DNA|frozen tumor tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|patients with brain metastases|March 2014|March 6, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184275||193100|
NCT00184314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148-02|Follow-up of Eating Disorder Patients From a 15-year Period.|Follow-up Eating Disorder Patients and Their Parents Leaving Treatment From 1988 to 2002 at Child and Adolescent Department at Levanger Hospital.||Norwegian University of Science and Technology|No|Completed|March 2004|August 2004|Actual|||Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|40|||Both|8 Years|18 Years|No|Non-Probability Sample|former eating disorder patients|December 2011|December 16, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184314||193097|
NCT00184327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Forskpro p03000213|Changes Following Inpatient Child-oriented Family Treatment|Change Across Intensive Inpatient Family Treatment in Child and Adolescent Psychiatry. A Multi-site Study of Parents and Children in Inpatient Family Treatment||Norwegian University of Science and Technology|No|Completed|January 2002|June 2008|Actual|December 2006|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|6 Years|N/A|No|Non-Probability Sample|Family offered inpatient family treatment in child and adolescent psychiatry|January 2009|May 6, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184327||193096|
NCT00184613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS253-1666|Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes|An Open-label, Randomised, In-patient, Cross Over PK/PD Trial Investigating the Pharmackinectic and Pharmacodynamic Profiles Following Continuous Subcutaneous Infusion of Insulin Aspart or Injection of Insulin Glargine in Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|May 2005|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|75 Years|No|||June 2012|June 20, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184613||193074|
NCT00184626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1594|Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.|Safety and Efficacy of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.||Novo Nordisk A/S|No|Completed|September 2004|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|97|||Both|35 Years|N/A|No|||June 2012|June 15, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184626||193073|
NCT00184925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO 2003/144|Ventilator Associated Pneumonia and Late Complications of Percutaneous Tracheostomy|The Development of Ventilator Associated Pneumonia and Late Complications of Two Different Percutaneous Tracheostomy Techniques||Radboud University|Yes|Terminated|October 2003|August 2005|Actual|April 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|September 12, 2005||No|Analysis was frustrated by inadequate PhD's....|No||https://clinicaltrials.gov/show/NCT00184925||193051|
NCT00184938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPIRI|Opioid Receptors Influence Ischemia-Reperfusion Injury|Opioid Induced Acute Preconditioning||Radboud University||Suspended|January 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 27, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00184938||193050|
NCT00180869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSFUGE|Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients|A Randomized Study of Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion During Surgery in Cancer Patients||Gustave Roussy, Cancer Campus, Grand Paris||Completed|September 1997|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|70 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180869||193345|
NCT00181181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV03-03-03-02|The Effect of Statin Use on Vascular Function in Hypertensive Subjects|The Effect of Statin Use on Vascular Function in Hypertensive Subjects||Johns Hopkins University||Terminated|May 2003|April 2007|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|20 Years|75 Years|No|||September 2006|May 27, 2010|September 13, 2005||No|Coronary flow by echo Doppler was obtainable in about 50% of subjects. The study was stopped    early because of insufficient sample size to achieve adequate power|No||https://clinicaltrials.gov/show/NCT00181181||193322|
NCT00181194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021855|Reducing Asthma Disparities by Improving Provider-Patient Communication|Reducing Asthma Disparities by Improving Provider-Patient Communication About Asthma Severity and Adherence With Therapy||Johns Hopkins University||Recruiting|May 2005|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||350|||Both|12 Years|85 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181194||193321|
NCT00150280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191086|Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery|A Prospective, Randomized, Double-Blind, Double-Dummy, Multi-Center Study Comparing Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery||Pfizer||Completed|October 2004|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||132|||Both|18 Years|65 Years|No|||November 2005|July 23, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150280||195654|
NCT00184756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1424|Efficacy on Height in SGA Children Treated With Growth Hormone|Effect of Two Years Treatment With Growth Hormone on Height in SGA Children.||Novo Nordisk A/S|No|Completed|November 2002|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|151|||Both|5 Years|8 Years|No|||June 2012|June 28, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184756||193064|
NCT00184769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHCRF/E/2|Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.|Open Randomized Trial Examining the Growth and Safety Effects of Treatment With Recombinant Growth Hormone on Infants Aged 1 to 2 Years With Growth Retardation Secondary to Chronic Renal Insufficiency||Novo Nordisk A/S|No|Completed|January 1998|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|9 Months|15 Months|No|||June 2012|June 28, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184769||193063|
NCT00180674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aclf01|Anticoagulation in Liver Fibrosis|Anticoagulation for Liver Fibrosis in Patients With Hepatitis C Virus Infection: Pilot Study||Imperial College London||Recruiting|August 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|70 Years|No|||September 2005|September 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180674||193360|
NCT00180687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.CD/218E|Clinical Trial of the Use of Intraperitoneal Local Anaesthetic|Prospective Double Blind Randomized Controlled Trial of the Use of Intraperitoneal Nebulised Local Anaesthetic||Imperial College London|Yes|Completed|October 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 12, 2015|September 12, 2005|No|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT00180687||193359|
NCT00180960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIP4 Phase II|Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia|Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|June 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||September 2006|September 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180960||193338|
NCT00181272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-02-17-01|Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease|Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease||Johns Hopkins University||Terminated|September 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|September 15, 2005||No|Principal Investigator moved institutions|No||https://clinicaltrials.gov/show/NCT00181272||193315|
NCT00182078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC Grant No. 8840|A Study of Sertraline to Prevent PTSD|A Study of Sertraline to Prevent PTSD||Massachusetts General Hospital|Yes|Completed|November 2002|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26|||Both|6 Years|20 Years|No|||July 2014|July 8, 2014|September 14, 2005||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00182078||193266|One limitation of this study was the small sample size, due to the challenge of recruiting traumatized children and their parents for participation in a randomized controlled trial of a medication.
NCT00183118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASAM014821|Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)|HIV Prevention Partnership in Russian Alcohol Treatment||Boston Medical Center||Completed|October 2004|December 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||180|||Both|18 Years|70 Years|No|||November 2007|June 1, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00183118||193188|
NCT00183131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASAI013759|The iHealth Study in College Students|Internet Screening and Brief Intervention for Hazardous Drinking in College Students: A Pilot Study||Boston Medical Center||Completed|October 2004|November 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||4300|||Both|18 Years|N/A|No|||December 2007|May 5, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00183131||193187|
NCT00183144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASIL12154|A Therapeutic Workplace for Alcohol Dependence|A Therapeutic Workplace for Alcohol Dependence||Johns Hopkins University||Completed|November 2001|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||156|||Both|18 Years|65 Years|No|||October 2007|May 18, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183144||193186|
NCT00182585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA015964|Computer-Assisted HIV Prevention for Young Drug Users|Computer-Assisted HIV Prevention for Young Drug Users||National Development and Research Institutes, Inc.||Active, not recruiting|August 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|56|||Both|13 Years|18 Years|No|||August 2008|August 11, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00182585||193227|
NCT00182598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R42DA014727|Applying Web Technology to Buprenorphine Treatment|Applying Web Technology to Buprenorphine Treatment||National Development and Research Institutes, Inc.||Recruiting|December 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|N/A|No|||August 2008|August 11, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00182598||193226|
NCT00173706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930404|Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis|Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis||National Taiwan University Hospital||Recruiting|October 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2005|February 28, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173706||193887|
NCT00173979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700520|Tendon Mechanical Properties and Morphological Characteristics of Human Bicep and Tricep Muscles: An In Vivo Ultrasonographical Study|Tendon Mechanical Properties and Morphological Characteristics of Human Muscle||National Taiwan University Hospital||Recruiting|June 2005|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|15|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||June 2005|June 5, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173979||193866|
NCT00174408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-041|Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age|Growth Hormone Treatment in Short Children Born Small for Date (Genotonorm)||Pfizer||Completed|March 1990|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|3 Years|7 Years|No|||May 2007|May 1, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00174408||193833|
NCT00183703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH065599-02|Understanding Treatment Adherence Among Individuals With Rapid Cycling Bipolar Disorder|Rapid Cycling Bipolar Disorder (RCBPD), Subjective Illness Experience and Gender||Case Western Reserve University|No|Completed|July 2004|August 2007|Actual|November 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|The population includes 20 individuals receiving treatment at an academic medical center        and 20 individuals seeking treatment at a community mental health clinic.|June 2013|July 1, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00183703||193144|
NCT00183963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-03-7|A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)|A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)||University of Southern California||Terminated|August 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|4|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|September 12, 2005|Yes|Yes|Insufficient accrual|No|November 9, 2012|https://clinicaltrials.gov/show/NCT00183963||193124|Due to insufficient accrual, analysis was not conducted.
NCT00184639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1630|Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and Insulin Semilente®MC in Children, Adolescents and Young Adults With Type 1 Diabetes on Basal-Bolus Regimen.||Novo Nordisk A/S|No|Completed|August 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|71|||Both|6 Years|21 Years|No|||July 2012|July 24, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184639||193072|
NCT00184652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1606-1442|Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease|The Effect of Norditropin® on Nutritional Status in Adult Patients in Chronic Haemodialysis||Novo Nordisk A/S|No|Completed|April 2003|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|140|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184652||193071|
NCT00184665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1595|Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes|2 Year Efficiency and Safety Comparison of Insulin Detemir and NPH Insulin in Type 1 Diabetes.||Novo Nordisk A/S|No|Completed|June 2004|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|501|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184665||193070|
NCT00184951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 03.01|Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients|Pharmacodynamics and Pharmacokinetics of Combined Use of Rosuvastatin (Crestor) and Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients With Hyperlipidemia (ROSALKA)||Radboud University||Completed|April 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||October 2008|October 21, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184951||193049|
NCT00149682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAEI (completed)|Obesity Assessment and Education Through the Internet|Obesity Assessment and Education Through the Internet||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 2005|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149682||195699|
NCT00149929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A301E|Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301|Multicenter, Open-label Follow-up Study on the Safety of Enteric-coated Mycophenolate Sodium in de Novo Renal Transplant Patients||Novartis||Completed|December 1999|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|246|||Both|18 Years|75 Years|No|||February 2011|February 1, 2011|September 6, 2005||Yes||||https://clinicaltrials.gov/show/NCT00149929||195680|
NCT00149942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ABE01|Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy|Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-Coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From GI Adverse Events While on Mycophenolate Mofetil Therapy||Novartis||Completed|October 2004|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|N/A||||February 2011|February 1, 2011|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149942||195679|
NCT00150293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-114|Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.|Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.||Pfizer||Completed|March 2002|November 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||337|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150293||195653|
NCT00150683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONBO-99135|Effectiveness of Vibration and Standing Versus Standing Alone for the Treatment of Osteoporosis for People With Spinal Cord Injury.|Evaluation of Conventional and Innovative Standing Frame for the Treatment of Osteoporosis After Spinal Cord Injury||Toronto Rehabilitation Institute||Completed|March 1999|July 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|16 Years|80 Years|No|||September 2005|September 6, 2005|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150683||195624|
NCT00150696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI REB #02-040|Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.|Risedronate for Prevention of Osteoporosis After Spinal Cord Injury||Toronto Rehabilitation Institute||Completed|February 2000|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||38|||Both|16 Years|60 Years|No|||November 2007|November 20, 2007|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150696||195623|
NCT00184782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 2005|Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning|Exploratory Study on FDG-PET Scanning in Evaluating the Metabolic Activity of Liver Metastases Before and After Resection of the Primary Tumor in Patients With a Colorectal Malignancy||Radboud University||Recruiting|September 2003|December 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|No|||September 2005|September 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184782||193062|
NCT00184795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD-1537|Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations|A Six Month Double-blind, Randomised, Parallel-group, Placebo-controlled, Multi-centre Trial to Investigate the Efficacy and Safety of Two Ultra-low Dose Combinations With 0.5 mg Estradiol and 0.1 mg or 0.25 mg Norethisterone Acetate (Activelle Low Dose 0.1/Activelle Low Dose 0.25) for Treatment of Menopausal Symptoms|CHOICE|Novo Nordisk A/S|No|Completed|May 2004|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|576|||Female|45 Years|65 Years|No|||March 2012|March 19, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184795||193061|
NCT00180700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Johrei_HIV1|The Influence of Psychological Interventions Upon Disease Progression in HIV-infected Patients Receiving no Medication|The Effects of Two Psychological Intervention Techniques, Self-hypnosis and Johrei Healing Method, on Quality of Life, Psychological Well-being, EEG Measures and Various Immunological Measures Including CD4+ Counts in Early HIV: a Randomly Controlled Pilot Study||Imperial College London||Completed|June 2003|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||100|||Both|20 Years|N/A|No|||September 2005|February 11, 2016|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180700||193358|
NCT00180986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minnie|Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child|Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child||Gustave Roussy, Cancer Campus, Grand Paris||Active, not recruiting|October 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|N/A|15 Years|No|||September 2005|December 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180986||193336|
NCT00180973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMCA2|PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.|MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.||Gustave Roussy, Cancer Campus, Grand Paris||Active, not recruiting|February 1995|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||520|||Both|15 Years|70 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180973||193337|
NCT00181285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14831A|Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT)|Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT)||Johns Hopkins University|Yes|Completed|October 2003|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181285||193314|
NCT00181857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002687|Risk of Attention Deficit Hyperactivity Disorder (ADHD) in the Children of Adults With ADHD Not Otherwise Specified (NOS)|Risk of Attention Deficit Hyperactivity Disorder in the Children of Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified: A Pilot Study||Massachusetts General Hospital|Yes|Completed|February 2005|February 2008|Actual|February 2006|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children of Adults with ADHD NOS|October 2013|October 30, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181857||193283|
NCT00181870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000763|Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder|Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder||Massachusetts General Hospital|Yes|Completed|July 2005|||August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|6 Years|12 Years|No|||June 2010|June 18, 2010|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181870||193282|
NCT00182091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004p-001078|Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency|Effects of Physiologic Growth Hormone Administration on Cardiovascular Risk in Subjects With Growth Hormone Deficiency Following Cure of Acromegaly||Massachusetts General Hospital|Yes|Completed|August 2004|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|85 Years|No|||April 2012|April 26, 2012|September 14, 2005||No||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00182091||193265|
NCT00182104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-1998-Fontan|International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures|An International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures||McMaster University||Completed|August 1998|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||111|||Both|N/A|N/A|No|||April 2007|April 19, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00182104||193264|
NCT00183170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAHOW013759|Residual Effects of Intoxication on Student Performance|Residual Effects of Intoxication on Student Performance||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Recruiting|February 2004|January 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|200|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||June 2007|June 14, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183170||193184|
NCT00174421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-8122-011|Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height|Genotropin in Short Children Born Small for Gestational Ag - A Long-Term Study in Belgium||Pfizer||Completed|April 2001|August 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|N/A|N/A|No|||May 2007|May 1, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00174421||193832|
NCT00174434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181073|Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer|A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting||Pfizer|No|Completed|September 2005|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2008|January 26, 2009|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174434||193831|
NCT00174447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281060|Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031|Open Extension Study Evaluating The Long Term Efficacy , Safety And Tolerability Of Oral Ziprasidone In The Treatment Of Patients Who Have Successfully Completed The Previous Ziprasidone Study A1281031||Pfizer|No|Completed|October 2001|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|70 Years|No|||November 2009|November 20, 2009|September 12, 2005|No|Yes||No|October 15, 2009|https://clinicaltrials.gov/show/NCT00174447||193830|
NCT00183976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17NHL-03-2|Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas|A Pilot Phase II Study of Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas||University of Southern California|Yes|Terminated|April 2005|January 2006|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||May 2006|May 20, 2014|September 12, 2005|||Insufficient Accrual|No||https://clinicaltrials.gov/show/NCT00183976||193123|
NCT00183989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13NHL-99-2|Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma|A Pilot Phase II Trial of Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma||University of Southern California||Terminated|August 2000|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 12, 2005|||Insufficient accrual|No||https://clinicaltrials.gov/show/NCT00183989||193122|
NCT00184340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORSKPRO-ID p03000217|Secured Internet-Mediated Psychotherapy With Psychiatry Patients|Secured Internet-Mediated Psychotherapy With Psychiatry Patients. Software Improvement, Clinical Trials and Development of Clinical Precautions||Norwegian University of Science and Technology|No|Completed|January 2004|January 2006|Actual|January 2006|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|6|||Both|10 Years|30 Years|No|Non-Probability Sample|Clients in CAMH services|January 2009|January 5, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184340||193095|
NCT00184353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173-03|Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.|In Vivo Proton MR Spectroscopy of Brain Metastases Obtained at 1,5T and 3T.||Norwegian University of Science and Technology|No|Completed|November 2003|June 2005|Actual|December 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with brain metastases|October 2011|October 20, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184353||193094|
NCT00149487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257|Enhancing Treatment Adherence in Pediatric Asthma With a Problem Solving Intervention|Randomized Controlled Trial of Problem Solving Intervention to Enhance Treatment Adherence in Pediatric Asthma||National Heart, Lung, and Blood Institute (NHLBI)||Active, not recruiting|January 2001|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment||||120|||Both|6 Years|17 Years|No|||November 2006|November 6, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00149487||195714|
NCT00149695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW006818-Fogarty (completed)|Soft Drink, Milk and Obesity in Chilean Children|Soft Drink, Milk and Obesity in Chilean Children||Children's Hospital Boston||Completed|July 2004|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||96|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||August 2010|August 20, 2010|August 31, 2005||||No||https://clinicaltrials.gov/show/NCT00149695||195698|
NCT00149968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ADE05|Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)|Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)||Novartis|No|Completed|April 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|196|||Both|18 Years|N/A|No|||October 2009|October 14, 2009|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149968||195678|
NCT00150709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N157|A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy|A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam (Ucb L059) In Children With Epilepsy||UCB Pharma||Completed|February 1998|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||238|||Both|N/A|16 Years||||September 2009|September 16, 2013|September 6, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00150709||195622|
NCT00150306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501061|A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD|A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD)||Pfizer|No|Terminated|November 2002|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|6 Years|17 Years|No|||August 2007|August 16, 2007|September 6, 2005|||Please see Detailed Description below for termination reason.|||https://clinicaltrials.gov/show/NCT00150306||195652|
NCT00150319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501070|An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend|An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Iv Containing Sbecd As An Excipient Following Multiple Dosing With Vfend®; I.V. In Subjects With Moderately Impaired Renal Function||Pfizer||Terminated|June 2005|October 2005|Actual|October 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|1|||Both|18 Years|70 Years|No|||September 2008|September 25, 2008|September 6, 2005|No|Yes|See Detailed Description|No||https://clinicaltrials.gov/show/NCT00150319||195651|
NCT00151216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401007010|Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis|Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children With Late Infantile Neuronal Ceroid Lipofuscinosis||Weill Medical College of Cornell University|Yes|Active, not recruiting|June 2004|June 2019|Anticipated|June 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|3 Years|18 Years|No|||December 2015|December 16, 2015|September 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00151216||195583|
NCT00151450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081012|Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder|An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients||Pfizer||Completed|March 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||390|||Both|18 Years|65 Years|No|||March 2008|March 19, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151450||195565|
NCT00180713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WILK10554|Simvastatin as a Treatment for Pulmonary Hypertension|Simvastatin as a Treatment for Pulmonary Hypertension||Imperial College London|No|Completed|October 2005|May 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||July 2009|June 3, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00180713||193357|
NCT00180999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUMFATIGUE|Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course|Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|February 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||420|||Both|18 Years|70 Years|No|||September 2006|September 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180999||193335|
NCT00182117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Division of Nephrology Funds|Pilot Bleeding Study: Risk and Protective Factors Associated With Bleeding in the Hemodialysis Population|Pilot Bleeding Study||McMaster University||Recruiting|October 2003|April 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||490|||Both|N/A|N/A|No|||September 2005|January 23, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00182117||193263|
NCT00182130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-50013|Quality Initiative in Rectal Cancer (QIRC) Trial|Quality Initiative in Rectal Cancer (QIRC) Trial||McMaster University||Active, not recruiting|May 2002|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||691|||Both|N/A|N/A|No|||July 2005|September 10, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00182130||193262|
NCT00181311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-P-26|Investigation of the Incidence of Complications After Vaginal and Abdominal Hysterectomy|Prospective Investigation of the Incidence of Complications After Vaginal and Abdominal Hysterectomy||Maasland Hospital||Recruiting|August 2005|October 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||200|||Female|N/A|N/A|No|||August 2005|October 25, 2006|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00181311||193312|
NCT00181298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-20|Memantine in Systemic Lupus Erythematosus|Memantine in Systemic Lupus Erythematosus||Johns Hopkins University|No|Completed|March 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||March 2008|March 5, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00181298||193313|
NCT00181649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P001209-2|Recombinant Human Prolactin for Lactation Induction|Recombinant Human Prolactin for Lactation Induction in Adoptive Mothers||Massachusetts General Hospital||Withdrawn|September 2006|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|45 Years|No|||May 2013|May 8, 2013|September 9, 2005|Yes|Yes|Not able to recruit any subjects.|No||https://clinicaltrials.gov/show/NCT00181649||193299|
NCT00182403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2005-FIDO|Fixed Dose Heparin Study|Fixed Dose Unfractionated Heparin for Initial Treatment of Venous Thromboembolism||McMaster University||Completed|September 1998|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||866|||Both|18 Years|N/A|No|||September 2005|November 29, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182403||193241|
NCT00182611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYUH-UHA-GC04-03|S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer|Phase III Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Potentially Resectable Stage III Advanced Gastric Cancer||National Cancer Institute (NCI)||Completed|April 2004|November 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|100|||Both|20 Years|N/A|No|||November 2008|June 25, 2013|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00182611||193225|
NCT00182624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040109|Magnetic Resonance Imaging to Evaluate Prostate Cancer|Comprehensive Prostate MRI for the Evaluation of Prostate Cancer at 3.0T: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|February 2004|September 2007||||N/A|Observational|N/A||||80|||Male|18 Years|N/A|No|||September 2007|September 26, 2015|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00182624||193224|
NCT00183183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAASE15123|Impact of a Brief Motivational Interview on Drinking Behaviors of At Risk Drinkers Screened in the Emergency Room|Alcohol Screening and Brief Intervention in the Emergency Department||University of Connecticut Health Center||Completed|April 2004|December 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1137|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 21, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00183183||193183|
NCT00174460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281273|Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age|Somatropin Therapy For Short Children Born Of Premature Gestation, A Controlled, Prospective Randomized, Multicenter Study With An Untreated Control Group.|AGA|Pfizer|No|Completed|August 2005|March 2010|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|4 Years|10 Years|No|||March 2011|March 23, 2011|September 12, 2005|Yes|Yes||No|March 16, 2009|https://clinicaltrials.gov/show/NCT00174460||193829|Result values for the primary outcome measures were revised at the final analysis due to programmatic corrections: age rounded up if >6 months past last birthday. Height and height SDS not rounded for final analysis; rounded only for the reports.
NCT00174473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501037|A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children|An Open-label, Intravenous to Oral Switch, Multiple Dose Multi-Centre Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Hospitalized Children Aged 2 to 12 Years Who Require Treatment for the Prevention of Systemic Fungal Infections.||Pfizer||Completed|June 2003|August 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|49|||Both|2 Years|12 Years|No|||May 2011|May 9, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00174473||193828|
NCT00174486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3711030|Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction|A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Duration Of Action, Safety And Toleration Of Differing Doses and Combinations Of Immediate and Modified Release Formulations Of UK-369,003 and Cialis Compared To Placebo In Adult Male Subjects With Erectile Dysfunction||Pfizer||Completed|February 2005|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Male|18 Years|65 Years|No|||November 2005|July 23, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00174486||193827|
NCT00148642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5003A|Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)|Multi-center Clinical Trial of the Bard Silver-coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)|NASCENT|C. R. Bard|Yes|Completed|November 2002|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2003|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148642||195778|
NCT00148902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF10021|Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)|A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (TAXOTERE)||GlaxoSmithKline||Completed|April 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||October 2008|October 6, 2008|September 6, 2005||||||https://clinicaltrials.gov/show/NCT00148902||195759|
NCT00148915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BON103593|A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo|A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150 mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis||Hoffmann-La Roche|Yes|Completed|August 2005|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Female|55 Years|80 Years|No|||July 2015|July 20, 2015|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148915||195758|
NCT00149214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7113|Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens|A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer||Eli Lilly and Company|No|Completed|September 2005|March 2011|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|257|||Female|18 Years|70 Years|No|||March 2012|March 15, 2012|September 2, 2005|Yes|Yes||No|February 11, 2009|https://clinicaltrials.gov/show/NCT00149214||195735|
NCT00149981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2401|A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation|A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation|Umbrella|Novartis|No|Completed|August 2003|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1025|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00149981||195677|
NCT00150332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12600067|Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan|Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial||Pfizer||Completed|January 2003|January 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|16 Years|N/A|No|||May 2011|May 9, 2011|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150332||195650|
NCT00150345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501029|Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients|Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In High-Risk Neutropenic Patients With Fever And A Positive Panfungal Polymerase Chain Reaction Assay (IDEA Study)|IDEA|Pfizer|No|Completed|January 2005|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|September 6, 2005|Yes|Yes||No|April 5, 2010|https://clinicaltrials.gov/show/NCT00150345||195649|One participant in the Immediate Voriconazole treatment group was incorrectly included in the original Primary efficacy analysis and has now been excluded; IFI was identified on the day study treatment started (not prior to study treatment).
NCT00183027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0044|Dietary Energy Restriction and Metabolic Aging in Humans|Dietary Energy Restriction and Metabolic Aging in Humans||National Institute on Aging (NIA)||Completed|November 2002|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||44|||Both|20 Years|42 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183027||193195|
NCT00150722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethics 18228, TPD 096237|High-Density Lipoprotein (HDL) Modulation and Endothelial Function|HDL Modulation and Endothelial Function||University of Calgary||Completed|September 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|80 Years|No|||November 2008|November 7, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150722||195621|
NCT00150943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C99.1810-STAR|Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis|The Benefit of STent Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR)||UMC Utrecht||Completed|June 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||April 2006|April 26, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150943||195604|
NCT00183755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068376|Understanding Brain Reward Responses in Individuals With Major Depressive Disorder|Neuroimaging Studies of Reward Processing in Depression||Mclean Hospital|Yes|Completed|April 2005|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|87|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Control participants, Participants with MDD|April 2014|April 16, 2014|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00183755||193140|
NCT00184054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9L-02-1|Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia|Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia||University of Southern California||Terminated|April 2002|August 2011|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|September 12, 2005|Yes|Yes|Competing studies|No|June 13, 2014|https://clinicaltrials.gov/show/NCT00184054||193117|
NCT00181688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-250|Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer|A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer||Massachusetts General Hospital|Yes|Completed|October 2003|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Female|18 Years|N/A|No|||December 2012|December 4, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181688||193296|
NCT00182377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-183|Pentastarch Use in Cardiac Surgery|A Randomized, Prospective, Blinded Clinical Trial to Evaluate the Efficacy and Safety of Pentastarch Use in Patients Undergoing Coronary Artery Bypass Surgery or Valve Replacement Surgery Using Cardiopulmonary Bypass Circuits||McMaster University||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||September 2004|September 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182377||193243|
NCT00182143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN54618366|PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)|PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)||McMaster University|Yes|Completed|May 2006|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3659|||Both|18 Years|N/A|No|||October 2007|January 7, 2011|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00182143||193261|
NCT00182845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0078|Donepezil in the Prevention of Post-Operative Cognitive Decline|Preventing Post-Operative Cognitive Decline||National Institute on Aging (NIA)||Completed|February 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|65 Years|N/A|No|||February 2008|February 28, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00182845||193208|
NCT00182390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2001-PINT|Premature Infants in Need of Transfusion (PINT)|A Randomized Controlled Trial of Two Hemoglobin Thresholds for Transfusion in Newborns <1000g Birth Weight||McMaster University||Completed|February 2001|November 2005|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||424|||Both|N/A|48 Hours|No|||September 2015|September 22, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182390||193242|
NCT00182689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03074|Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer|A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|July 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||December 2012|May 6, 2014|September 15, 2005|Yes|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00182689||193220|
NCT00182637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439458|Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma|A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)||Jonsson Comprehensive Cancer Center|Yes|Completed|July 2004|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 15, 2005|Yes|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT00182637||193223|
NCT00183196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAANT09568-2005a|Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone|Gabapentin as an Adjunct to Naltrexone for Alcoholism||Medical University of South Carolina|No|Completed|January 2003|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|70 Years|No|||January 2013|April 23, 2013|September 13, 2005|Yes|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00183196||193182|
NCT00183443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069801|Treatment of Mania Symptoms With Drug Therapy|Divalproex Extended Release and Placebo, Lithium, or Quetiapine for Mania||Palo Alto Veterans Institute for Research|Yes|Completed|February 2005|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|65 Years|No|||October 2013|October 8, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183443||193163|
NCT00148928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102238|Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA|A Multicenter, Open-label Phase I/II Trial to Evaluate the Safety and Activity of CPC-P501 Protein Formulated With the Adjuvant AS15 as First-line Treatment in Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA||GlaxoSmithKline||Completed|March 2005|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|25|||Male|18 Years|75 Years|No|||March 2011|March 24, 2011|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148928||195757|
NCT00149240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52120-089|Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome|A Phase II, Multicentre, Randomised, Double-blind, Parallel and Controlled With Placebo Pilot Study to Evaluate the Efficacy and Safety of a Single Dose of Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment, in Patients With Primary Myofascial Syndrome of Cervical and Dorsal Localisation||Ipsen||Completed|January 2005|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||July 2007|September 29, 2015|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00149240||195733|
NCT00149227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHS2004|Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)|Add-on Effects of Valsartan on Morbi- Mortality in High Risk Hypertension||Kyoto Prefectural University of Medicine|Yes|Completed|January 2004|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|3031|||Both|20 Years|79 Years|No|||December 2012|December 9, 2012|September 6, 2005||No||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00149227||195734|The study was performed using PROBE design, which does not exclude possible bias for softer endpoints such as angina and TIA. However, all softer endpoints were diagnosed by CAG and CT/MRI. We believe that under reporting would be unlikely.
NCT00149708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 65718 (completed)|Consequence of Lifetime Isolated Growth Hormone Deficiency|Consequence of Lifetime Isolated Growth Hormone Deficiency||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|80 Years|No|||June 2010|June 13, 2010|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00149708||195697|
NCT00182507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-167|Olanzapine in the Treatment of Hair Pulling (Trichotillomania)|A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania||McMaster University||Completed|June 2000|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2006|September 8, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00182507||193233|
NCT00182780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N03CA|American Ginseng in Treating Patients With Cancer-Related Fatigue|The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Dose-Finding, Placebo-Controlled Study||Alliance for Clinical Trials in Oncology|No|Completed|October 2005|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|290|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00182780||193213|
NCT00183040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0045|HORMA: Hormonal Regulators of Muscle and Metabolism in Aging|Hormonal Regulators of Muscle and Metabolism in Aging||National Institute on Aging (NIA)||Completed|September 2002|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|108|||Male|65 Years|90 Years|No|||May 2009|May 28, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183040||193194|
NCT00183287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 020|Long Term Follow-Up of HIV Infected Patients Who Have Previously Participated in HIV Clinical Trials|Clinical, Virologic, and Immunologic Evaluation and Monitoring of Patients With Known or Suspected HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||March 2003|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||150|Samples With DNA|Blood collection|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected individuals who have previously participated in NIAID-funded HIV clinical        trials|April 2012|April 25, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183287||193175|
NCT00183508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH064584|Behavioral Treatments for Acute Stress Disorder In Firefighters|Developing Group Treatments for Acute Stress Disorder||Boston University||Completed||May 2009|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183508||193158|
NCT00184405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2005.393|Child Results Following Preventive Children of Parents With Psychiatric and Addictive Problems (COPP) Groups|Preventive Peer Groups for Children of Parents With Psychiatric and Addictive Problems (COPP). Child Experiences and Observed Child Changes Following the Intervention||Norwegian University of Science and Technology|Yes|Terminated|March 2005|December 2008|Actual|December 2008|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|8 Years|N/A|No|Non-Probability Sample|Families with at least one parent with psychiatric or addictive problem|January 2009|January 5, 2009|September 15, 2005||No|Terminated to financial cut|No||https://clinicaltrials.gov/show/NCT00184405||193090|
NCT00184730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1650|Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)|Investigation of the Efficacy and Safety of hGH in Long Term (More Than 48 Weeks) in GHDA.||Novo Nordisk A/S|No|Completed|November 2004|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|86|||Both|19 Years|67 Years|No|||June 2012|June 28, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184730||193066|
NCT00181675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001937|A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder|A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder||Massachusetts General Hospital||Completed|December 2002|September 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|58 Years|No|||July 2010|July 22, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00181675||193297|
NCT00181883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001509|Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder|Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder||Massachusetts General Hospital|Yes|Completed|February 2005|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|4 Years|6 Years|No|||March 2012|March 9, 2012|September 13, 2005|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00181883||193281|
NCT00181064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-08-10-04|Atkins Diet for Difficult-to-Control Headaches in Teenagers|Use of the Atkins Diet for Adolescents With Chronic Daily Headache.||Johns Hopkins University|Yes|Completed|September 2005|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|19 Years|No|||June 2009|July 1, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00181064||193330|
NCT00181077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03--03-13-06|Hypertonic Saline Use in Preeclampsia|Hypertonic Saline Use for Volume Expansion in Postpartum Preeclampsia||Johns Hopkins University|No|Completed|June 2003|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|18 Years|N/A|No|||September 2012|September 21, 2012|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00181077||193329|
NCT00181090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-01-26-05|Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits|||Johns Hopkins University||Completed|February 2005|September 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|3 Years|18 Years|No|||March 2009|March 26, 2009|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00181090||193328|
NCT00181896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001727|Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder|Open-Label Study of Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar and Bipolar Spectrum Disorder||Massachusetts General Hospital|Yes|Terminated|January 2005|||February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|6 Years|17 Years|No|||July 2011|July 14, 2011|September 13, 2005|Yes|Yes|Study was terminated due to lack of recruitment|No||https://clinicaltrials.gov/show/NCT00181896||193280|
NCT00181909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-P-002438|Efficacy of Proactive Telephone Counseling for Pregnant Smokers Enrolled in a Managed Care Organization|||Massachusetts General Hospital||Completed|September 2001|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||434|||Female|18 Years|N/A|No|||September 2005|November 27, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181909||193279|
NCT00182156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nephrology Divisional Funds|Cohort Study Comparing Short Daily Hemodialysis (HD) With Conventional HD|Cohort Study Examining the Effects of Short Daily Hemodialysis As Compared to Conventional Hemodialysis in Outpatients Treated at St Joseph's Healthcare, Hamilton||McMaster University|No|Active, not recruiting|October 2004|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Short daily HD v PD v conventional HD|June 2008|June 16, 2008|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00182156||193260|
NCT00182169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004h00512|Evaluation of the Effect of Human Recombinant Growth Hormone in Patients With Advanced Heart Failure|Randomized, Placebo Control, Clinical Trial Evaluating the Effect of Human Recombinant Growth Hormone in Patients With Severe Congestive Heart Failure. The Growth Hormone In Heart Failure Trial (GIFT)||McMaster University||Completed|July 1997|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2003|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00182169||193259|
NCT00182923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0038|Forearm Vascular Relaxation|Determinants of Forearm Vascular Relaxation: Role of Genetic Polymorphisms||National Institute on Aging (NIA)||Completed|May 2003|December 2006|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Prospective||||400|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 28, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00182923||193203|
NCT00183677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067111|Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram|Biochemical Brain Changes Correlated With the Antidepressant Effect of Escitalopram: A Magnetic Resonance Spectroscopic Imaging Study||National Institute of Mental Health (NIMH)||Active, not recruiting|July 2003|June 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 9, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183677||193146|
NCT00183456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066810|A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs|Network HIV Prevention Intervention for Drug Users||Johns Hopkins Bloomberg School of Public Health||Completed|September 2005|December 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|746|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|September 13, 2005||No||No|September 14, 2012|https://clinicaltrials.gov/show/NCT00183456||193162|
NCT00182520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-133|Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)|A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder||McMaster University|No|Recruiting|January 2002|February 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||March 2013|March 4, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00182520||193232|
NCT00182026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-68786|Diabetes IN-CHARGE: Trial of Diabetes Intervention in the Community to Help Achieve Reduced Glucose Elevation|A Randomized Trial of Diabetes Intervention in the Community to Help Achieve Reduced Glucose Elevation: Diabetes IN-CHARGE||McMaster University|No|Active, not recruiting|June 2005|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2009|October 7, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00182026||193270|
NCT00182286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 1030106|Evaluation of Continuity of Care at a Health Service Organization|The Evaluation of the Continuity of Care at the Group Health Centre, A Unique Multi-Specialty, Multi-Disciplinary Health Service Organization||McMaster University||Completed|September 1999|July 2001||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||342|||Both|18 Years|N/A|No|||August 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182286||193250|
NCT00183053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0050|Proximity Alarms to Reduce Patient Falls|Trial of Proximity Alarms to Reduce Patient Falls||National Institute on Aging (NIA)||Completed|May 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10000|||Both|N/A|N/A|No|||October 2009|October 29, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183053||193193|
NCT00183300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062003|Relationship Between the Biological and Psychological Correlates of PTSD|Effectiveness of Prolonged Exposure Therapy on Reducing Neuroendocrine-Related Symptoms of Post-Traumatic Stress Disorder in Women||University of Pennsylvania||Completed|September 2001|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Female|18 Years|N/A|No|||December 2007|October 2, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00183300||193174|
NCT00183521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066953|Breathing Regulation Training for Individuals With Panic Disorder|Respiratory Therapeutic Procedures in Panic Disorder||Stanford University|No|Completed|March 2005|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183521||193157|
NCT00183768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061141|Cognitive Behavioral Therapy Combined With Antidepressants to Reduce HIV Risk and Drug Relapse Among Depressed Intravenous Drug Users|Antidepressant Treatment to Reduce HIV Risk Among IDUs||Butler Hospital||Completed|September 1999|February 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||175|||Both|18 Years|75 Years|No|||August 2013|August 20, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00183768||193139|
NCT00184067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10M-03-8|Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma|A Randomized Phase II Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Resected Stages IIB/C, III, and IV Melanoma||University of Southern California||Terminated|May 2004|September 2009|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2014|May 20, 2014|September 12, 2005|Yes|Yes|Primary PI left institution|No||https://clinicaltrials.gov/show/NCT00184067||193116|
NCT00184080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13NHL-04-1|Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multicenter Open-Label Non-Randomized Phase II Study of Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma||University of Southern California||Completed|May 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00184080||193115|
NCT00184418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94463|The Immune System and Psychiatric Disorders|The Immune System and Psychiatric Disorders||Norwegian University of Science and Technology|No|Completed|January 2005|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1400|Samples Without DNA|Serum, frozen|Both|N/A|N/A|No|Probability Sample|Adults aged 18 years and above. ADmitted to psychiatric acute ward.|April 2015|April 7, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184418||193089|
NCT00181363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03.1446L|Prone Breast Irradiation for Pendulous Breasts|Mamma Board Project: Prone Breast Irradiation for Pendulous Breasts||Maastricht Radiation Oncology|Yes|Active, not recruiting|December 2003|January 2010|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Female|18 Years|N/A|No|||April 2007|April 25, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00181363||193310|
NCT00181922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-p-000183|Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder|Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder||Massachusetts General Hospital||Completed|March 2002|December 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|6 Years|17 Years|No|||October 2013|October 21, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181922||193278|
NCT00181506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01.1314L|HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy|HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Accelerated Conformal Radiotherapy in Patients With Inoperable Non-Small Cell Lung Cancer.||Maastricht Radiation Oncology||Completed|December 2001|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181506||193309|
NCT00182416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2005-CTOPPII|Second Canadian Trial of Physiologic Pacing (CTOPP II): Pilot Trial|Second Canadian Trial of Physiologic Pacing (CTOPP II): Pilot Trial||McMaster University||Completed|May 2004|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|66 Years|N/A|No|||October 2007|October 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182416||193240|
NCT00182650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000438797|Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma|Pilot/Feasibility Study To Evaluate The Safety Of Cellular Immunotherapy For CD19+ Follicular Lymphoma Using Autologous Cytolytic T Cells Genetically-Modified To Be CD19-Specific And Co-Express HyTK||City of Hope Medical Center||Completed|June 2004|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|5|||Both|16 Years|70 Years|No|||December 2009|December 23, 2009|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00182650||193222|
NCT00182663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1767.00|Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant|Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|June 2003|||April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|14 Years|N/A|No|||October 2015|October 30, 2015|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00182663||193221|
NCT00182936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0040|A Trial to Reduce Delirium in Aged Post Acute Patients|A Trial to Reduce Delirium in Aged Post Acute Patients||National Institute on Aging (NIA)||Completed|May 2000|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||500|||Both|65 Years|N/A|No|||November 2006|November 16, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182936||193202|
NCT00182871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0043|Testosterone Effects on Bone and Frailty|Testosterone Effects on Bone and Frailty in Men With Osteoporosis||National Institute on Aging (NIA)||Completed|November 2001|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Male|60 Years|N/A|No|||October 2009|October 29, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00182871||193206|
NCT00182884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0079|Donepezil in Preventing Delirium in Hospitalized Elderly|Preventing Delirium in Hospitalized Elderly||National Institute on Aging (NIA)||Completed|July 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 28, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00182884||193205|
NCT00183716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068252|The Trauma Recovery and Empowerment Model for Treating Post-Traumatic Stress Disorder in Women|An Randomized Controlled Trial (RCT) of the Trauma Recovery and Empowerment Model|TREM|Dartmouth-Hitchcock Medical Center|Yes|Completed|April 2004|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|20 Years|60 Years|No|||July 2012|July 20, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00183716||193143|
NCT00182793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05042|Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer|Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) ± Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer||City of Hope Medical Center|Yes|Completed|July 2005|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|N/A|65 Years|No|||October 2014|October 9, 2014|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00182793||193212|
NCT00183066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0046|Collection of Bone Marrow Aspirate From Volunteer Donors|Collection of Bone Marrow Aspirate From Volunteer Donors for In Vitro Hematopoietic Research||National Institutes of Health Clinical Center (CC)||Completed|July 2002|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|63|Samples With DNA|Bone marrow aspirates Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy males and females 18 years and older|August 2012|August 3, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183066||193192|
NCT00183313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002164|Improving Primary Care in Patients With Mental Disorders|Improving Primary Care in Patients With Mental Disorders||Emory University|Yes|Completed|July 2004|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|407|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00183313||193173|
NCT00183547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071300|Depression Prevention Program for American Indian Adolescents During and After Pregnancy|Depression Prevention in Pregnant American Indian Teens Using CBT||Johns Hopkins University||Completed|January 2005|September 2007||March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2|||45|||Female|15 Years|19 Years|Accepts Healthy Volunteers|||December 2008|May 28, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183547||193156|
NCT00183781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063051|Effectiveness of a Telephone Intervention Program in Improving Depression, Coping, and Family Functioning in HIV-Infected Individuals and Caregivers|Adapting to HIV Disease - A Family Intervention||Butler Hospital||Completed|September 2000|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|75 Years|No|||August 2013|August 20, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00183781||193138|
NCT00184093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5C-99-1|Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma|Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study||University of Southern California||Completed|June 1999|May 2009|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00184093||193114|
NCT00184431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU01-ISM-NTNU|Does Intensive Task Specific Training Improve Balance After Acute Stroke?|A Randomized Controlled Trial Comparing Intensive Task Specific Training With Traditional Follow up Care After Discharge From a Stroke Unit.||Norwegian University of Science and Technology|No|Completed|April 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|62|||Both|N/A|N/A|No|||October 2011|October 17, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184431||193088|
NCT00184444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-2004|Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients|Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients||Norwegian University of Science and Technology|No|Completed|September 2004|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||November 2011|November 16, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184444||193087|
NCT00180765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-215|Regulation of the Release of Inflammatory Mediators From Blood Leukocytes|Regulation of the Release of Inflammatory Mediators From Blood Leukocytes: A Comparison of Healthy Subjects, Healthy Smokers and Patients With COPD.||Imperial College London||Completed|October 2001|February 2008|Actual|February 2007|Actual|N/A|Observational|N/A||||30|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||September 2005|August 24, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180765||193353|
NCT00182182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSF2004h00511|Evaluation of a Primary Care Based Heart Failure Management Program|Congestive Heart Failure Assessment and Management in Primary Care: CHAMP||McMaster University||Active, not recruiting|July 2003|October 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||170|||Both|18 Years|N/A|No|||September 2006|September 8, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00182182||193258|
NCT00182195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38141-1|Lung Open Ventilation to Decrease Mortality in the Acute Respiratory Distress Syndrome|A Randomized Trial of a Lung-Open Ventilation Strategy in Acute Lung Injury|LOVS|McMaster University|Yes|Completed|August 2000|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||980|||Both|18 Years|N/A|No|||April 2007|April 19, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00182195||193257|
NCT00182429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2261|Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment|Prospective, Randomized Study of Oral Metronidazole Vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)||McMaster University||Completed|February 2004|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|14 Years|N/A|No|||April 2005|February 15, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182429||193239|
NCT00183235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAANT010761-2005b|Aripiprazole Effects on Alcohol Reactivity and Consumption|Effectiveness of Aripiprazole to Reduce Craving for Alcohol and Drinking Under Natural Observation, During Cue Induced Brain Imaging, and During a Motivated Free Choice Drinking Procedure Compared to Placebo||Medical University of South Carolina||Completed|June 2005|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||May 2010|May 4, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183235||193179|
NCT00183248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN022ST|Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients|Pilot Study Using Donor Stem Cells and Campath-1H to Induce Renal Transplant Tolerance (ITN022ST)||University of Miami|Yes|Completed|September 2004|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||September 2012|September 17, 2012|September 11, 2005|Yes|Yes||No|April 5, 2012|https://clinicaltrials.gov/show/NCT00183248||193178|In July 2007 after the trial had been enrolling for approximately 42 months, enrollment was stopped at the current number of nine subjects due to time and resource constraints.
NCT00182897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0081|PACT: Providers and Alzheimer's Caregivers Together|Providers and Alzheimer's Caregivers Together||National Institute on Aging (NIA)||Completed|October 2000|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 9, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00182897||193204|
NCT00148356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|640-0047|Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries|A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions|ZoMaxx™ I|Abbott Vascular|Yes|Completed|September 2004|October 2010|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||March 2011|March 31, 2011|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00148356||195800|
NCT00182299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63140-1|An RCT to Compare the Outcomes of Patients With Large Rotator Cuff Repair That Undergo Repair With or Without SIS|A Randomized Clinical Trial Comparing the Effectiveness of Rotator Cuff Repair With or Without Augmentation With Porcine Small Intestine Submucosa (SIS) for Large Rotator Cuff Tears: Pilot Study Phase||McMaster University|Yes|Active, not recruiting|September 2003|April 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2007|April 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182299||193249|
NCT00182312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-1999-CAP|Caffeine for Apnea of Prematurity (CAP)|Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants||McMaster University|Yes|Active, not recruiting|October 1999|July 2016|Anticipated|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|2000|||Both|N/A|10 Days|No|||December 2014|December 4, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00182312||193248|
NCT00182533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-195|Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders|Sertraline in the Treatment of Generalized Social Phobia With Comorbidity||McMaster University|No|Recruiting|July 2002|March 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|70 Years|No|||March 2013|March 4, 2013|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00182533||193231|
NCT00182806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441226|Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Irinotecan Followed by Gemcitabine in NSCLC Following Failure of Platinum Based Therapy||Roswell Park Cancer Institute|Yes|Completed|September 2004|July 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00182806||193211|
NCT00183079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAARAM13895|Reducing Alcohol Use in Depressed Patients|Brief Alcohol Intervention With Depressed Patients||Rhode Island Hospital||Completed|March 2004|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||October 2008|November 5, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00183079||193191|
NCT00183326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072590|Treating Post Traumatic Stress Disorder in Children Exposed to Domestic Violence|Treating PTSD in Children Exposed to Domestic Violence||Allegheny Singer Research Institute|Yes|Completed|May 2004|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|7 Years|14 Years|No|||July 2015|July 20, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00183326||193172|
NCT00183560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066992|Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy|Prevention of Relapse in Recurrent Depression With MBCT||Centre for Addiction and Mental Health|No|Completed|July 2004|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|184|||Both|18 Years|65 Years|No|||June 2015|June 30, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183560||193155|
NCT00184106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP/NTNU-2005|RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo|A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia||Norwegian University of Science and Technology|No|Completed|October 2004|December 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|65 Years|No|||August 2011|August 23, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00184106||193113|
NCT00184808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dialypd|Ambulatory Assessment of Motor State in Patients With Parkinson's Disease in Real Daily Life|||Radboud University||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||15|||Both|N/A|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184808||193060|
NCT00181051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEA|Clinical Utility of the Alaris MidLatencyAuditoryEvoked Potentials Monitor to Titrate the Anesthetic-Hypnotic Component of Anesthesia|Clinical Utility of the Alaris MidLatencyAuditoryEvoked Potentials Monitor to Titrate the Anesthetic-Hypnotic Component of Anesthesia||Gustave Roussy, Cancer Campus, Grand Paris||Suspended|February 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||128|||Both|18 Years|65 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181051||193331|
NCT00181532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02.1376L|Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC|A Multicentre Randomised Double Blind Placebo-Controlled Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC. An Evaluation of Both Tumor Radiosensitization and Normal Tissue Protection||Maastricht Radiation Oncology|Yes|Completed|May 2003|January 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||102|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181532||193308|
NCT00181727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001557|Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder|Open-Label Study of Divalproex Sodium Extended Release for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder||Massachusetts General Hospital||Completed|January 2004|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Both|6 Years|12 Years|No|||October 2013|October 21, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00181727||193293|
NCT00181935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000422|Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder|Open-Label Comparative Study of Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Spectrum Disorder||Massachusetts General Hospital|No|Completed|March 2001|July 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|4 Years|6 Years|No|||May 2013|May 3, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181935||193277|
NCT00182442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2179|Cognition, Functioning and Quality of Life|A One-Year Multi-Centre Randomized, Double Blind, Controlled Effectiveness Study of Quetiapine and Olanzapine, Comparing Their Relative Potential in Improving Neuro-Cognitive Deficits, Functional Outcomes and Quality of Life in Schizophrenia||McMaster University||Completed|October 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|65 Years|No|||March 2005|October 10, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00182442||193238|
NCT00182702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02669|Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer|A Phase II Trial of BMS 247550 (Ixabepilone) in Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|July 2005|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2013|March 22, 2013|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00182702||193219|
NCT00182715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000440085|Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Metastatic Colorectal Cancer (COIN)||National Cancer Institute (NCI)||Active, not recruiting|March 2005|||May 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|2421|||Both|18 Years|N/A|No|||December 2007|September 16, 2013|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00182715||193218|
NCT00152269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-390|Treatment of Uterine Fibroids With Asoprisnil(J867)|A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety (Including Bone Density Assessment) of Two Doses of J867 Versus Placebo in Subjects With Uterine Leiomyomata||Abbott|Yes|Completed|July 2002|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|475|||Female|18 Years|N/A|No|||May 2008|May 27, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00152269||195502|
NCT00183209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAGWA12113|Interventions for HIV+ Mothers With Problem Drinking|Interventions for HIV+ Mothers With Problem Drinking||New York University|No|Completed|December 2001|January 2008|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|11 Years|N/A|No|||October 2006|April 29, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183209||193181|
NCT00148655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-331|Educational Interventions for Patients With DCIS|A Randomized Trial for Educational Interventions for Patients With DCIS Actually Making Treatment Decisions||Dana-Farber Cancer Institute||Completed|May 2003|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Female|25 Years|N/A|No|||December 2007|December 22, 2007|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00148655||195777|
NCT00182546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-1999-CANPEDS|Canadian Pulmonary Embolism Diagnosis Study (CANPEDS)|Canadian Pulmonary Embolism Diagnosis Study||McMaster University||Terminated|August 1998|January 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1126|||Both|N/A|N/A|No|||August 2005|April 27, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182546||193230|
NCT00182832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0077|e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems|Enhancing Care for Hospitalized Older Adults With Cognitive Impairment||Indiana University|No|Completed|June 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|424|||Both|65 Years|N/A|No|||August 2015|August 27, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00182832||193209|
NCT00182819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22033-26033|Radiation Therapy or Temozolomide in Treating Patients With Gliomas|Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 2005|December 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|709|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00182819||193210|
NCT00183573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068171|HIV Prevention Program for Patients Receiving Care at a Sexually Transmitted Diseases Clinic|HIV Prevention for STD Clinic Patients||The Miriam Hospital|No|Completed|March 2004|July 2007|Actual|July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|1554|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 6, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183573||193154|
NCT00183586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070620|Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents|Treatment for Adolescent Anorexia Nervosa||University of Chicago|Yes|Active, not recruiting|April 2004|||March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|121|||Both|12 Years|18 Years|No|||December 2014|December 4, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183586||193153|
NCT00183092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0083|CJD (Creutzfeldt-Jakob Disease) Quinacrine Study|Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease||University of California, San Francisco|Yes|Completed|April 2005|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|September 14, 2005|Yes|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT00183092||193190|
NCT00184119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEV-01|Effects of a Psychiatric Intensive Care Unit|Effects of a Psychiatric Intensive Care Unit in an Acute Psychiatric Department.||Norwegian University of Science and Technology||Completed|October 2001|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2010|June 7, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00184119||193112|
NCT00184132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEV-00|The Effects of Different Interior Decorations in a Psychiatric Intensive Care Unit.|The Effects of Different Interior Decorations in a Psychiatric Intensive Care Unit.||Norwegian University of Science and Technology|No|Completed|November 2000|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||June 2010|June 7, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00184132||193111|
NCT00184457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25060100|Maximal Leg Press Strength Training Study for Coronary Artery Disease Patients|Maximal Leg Press Strength Training for Coronary Artery Disease Patients. Training Effect on Serum Testosterone and Work Economy||Norwegian University of Science and Technology|No|Completed|September 2005|September 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||November 2011|November 16, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184457||193086|
NCT00184470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTNU-Traume-1|Trauma Registration at St. Olavs Hospital 2000-2003|Mapping of Traumatized Patients Referred to St. Olavs Hospital in the Period 2000-2003-Norwegian University of Science and Technology||Norwegian University of Science and Technology||Terminated|December 2004|January 2007||June 2006|Actual|Phase 3|Observational|Time Perspective: Retrospective||||1000|||Both|N/A|N/A|No|||April 2008|April 18, 2008|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184470||193085|
NCT00184847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACAD|Adenosine Receptors Influence Ischemia-Reperfusion Injury|Adenosine Receptor Involvement in Acute Ischemic Preconditioning of the Vascular Endothelium||Radboud University||Suspended|March 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 27, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00184847||193057|
NCT00181701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-100|Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin|A Phase II Trial of Intraperitoneal Paclitaxel and Carboplatin Therapy in the Treatment of Women With Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin||Massachusetts General Hospital|Yes|Completed|October 2004|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Female|18 Years|N/A|No|||December 2012|December 4, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181701||193295|
NCT00181714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001313|Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta|Prevention of Cigarette Smoking in ADHD Youth With Concerta||Massachusetts General Hospital|Yes|Completed|November 2003|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|203|||Both|12 Years|17 Years|No|||May 2013|May 2, 2013|September 13, 2005|Yes|Yes||No|January 5, 2012|https://clinicaltrials.gov/show/NCT00181714||193294|The main limitation of this report stems from its uncontrolled, open-label design. Thus, we cannot assert a causal relationship between lower smoking rates and OROS MPH prescription.
NCT00181948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000883|Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy|A Pilot Study of Strattera Treatment in Children With Attention-Deficit/Hyperactivity Disorder Who Have Poor Response to Stimulant Therapy||Massachusetts General Hospital|No|Completed|September 2004|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|6 Years|17 Years|No|||June 2010|June 18, 2010|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181948||193276|
NCT00181961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001269|Safety and Effectiveness Study of Maca Root to Treat Antidepressant-Induced Sexual Dysfunction|A Dose-Finding Study of the Tolerability and Efficacy of Maca Root in Patients With Antidepressant-Induced Sexual Dysfunction||Massachusetts General Hospital||Active, not recruiting|April 2005|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||February 2006|February 9, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181961||193275|
NCT00182208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2005-VENOPTS|Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial|Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial||McMaster University|Yes|Completed|May 2004|December 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||July 2008|July 21, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00182208||193256|
NCT00182221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2005-SIMPLE|Safety of a Diagnostic Strategy With D-Dimer Testing for PE|A Cohort Study Evaluating the Safety of a Diagnostic Strategy Involving D-Dimer Testing in Patients With Suspected Pulmonary Embolism||McMaster University|Yes|Completed|August 2003|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|1000|||Both|18 Years|N/A|No|||April 2008|April 18, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00182221||193255|
NCT00182455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-080|Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)|Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial.||McMaster University|No|Recruiting|March 2004|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||March 2013|March 4, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00182455||193237|
NCT00182728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0218|Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer|Partial Breast Treatment Using Single Dose Intraoperative Radiotherapy for Patients With Early Stage Breast Cancer - A Feasibility Study With Molecular Analysis of Tumors and Normal Breast Epithelial Tissue|NRR|UNC Lineberger Comprehensive Cancer Center|No|Active, not recruiting|February 2003|December 2016|Anticipated|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Female|48 Years|120 Years|No|||January 2016|January 20, 2016|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00182728||193217|
NCT00148109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004-078|Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas|Phase II Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas||University of Michigan Cancer Center|Yes|Completed|June 2005|December 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|16 Years|N/A|No|||January 2013|January 15, 2013|September 2, 2005|Yes|Yes||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00148109||195819|accrual to EGFR + cohort suspended after first step for lack of efficacy of cetuximab.
NCT00148122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2-33|A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer|A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients With Metastatic or Advanced, Locally, Recurrent Head and Neck Cancer||University of Michigan Cancer Center|Yes|Completed|November 2002|July 2010|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|September 2, 2005|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT00148122||195818|
NCT00148369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040256|A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin|A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin||Amgen||Completed|June 2005|September 2007|Actual|November 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|31|None Retained|none collected.|Both|35 Years|70 Years|No|Non-Probability Sample|Subjects with idiopathic Parkinson's Disease|February 2010|February 18, 2010|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148369||195799|
NCT00183222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAANT010761-2005a|Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking|Alcohol Research Center Grant. Component #1. COMBINING MEDICATIONS: ALCOHOL REACTIVITY AND CONSUMPTION||Medical University of South Carolina||Completed|May 2005|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2010|May 4, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183222||193180|
NCT00184379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2005.389|Effects of Psychoeducation of Relatives to Patients With Serious Mental Illness|Effects of Psychoeducation of Relatives to Patients With Serious Mental Illness||Norwegian University of Science and Technology|No|Completed|April 2005|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|70 Years|No|||June 2010|June 11, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184379||193092|
NCT00171587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787 0134/306220|Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer|A Phase IB, Open-label, Dose-escalating Study of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer||Novartis||Completed|May 2002|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|22|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00171587||194050|
NCT00171964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EDE06|Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions|Evaluation of the Efficacy and Tolerability of Zoledronic Acid in Combination With Radiotherapy in Patients With Advanced Osteolytic Bone Lesions||Novartis|Yes|Completed|May 2002|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171964||194021|
NCT00183105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASaitz12617-ASAP|ASAP Study - Hospital-Based Brief Intervention for Alcohol Problems|Hospital-based Brief Intervention for Alcohol Problems||Boston Medical Center||Completed|February 2001|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||December 2007|May 5, 2010|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00183105||193189|
NCT00183339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54MH066418|Early Intervention With Fluoxetine in Autism|A Randomized, Placebo-controlled Trial of Fluoxetine in Preschool Children||University of North Carolina, Chapel Hill|Yes|Completed|July 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|30 Months|58 Months|No|||February 2014|February 7, 2014|September 6, 2005|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00183339||193171|It took twice as long to recruit subjects for a study in children 30-58 months than it generally takes to recruit older children. It is possible to maintain subjects in double-blind trails for extended periods.
NCT00184158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056-02|Treatment for Cubital Tunnel Syndrome|Cubital Tunnel Treatment, Evaluation of Conservative and Operative Alternatives||Norwegian University of Science and Technology|No|Completed|January 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|N/A|N/A|No|||August 2011|August 25, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00184158||193109|
NCT00184483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Norwegian Hernia Study|A Multi-site Trial Comparing Lichtensteins Operation and Prolene Hernia System in Inguinal HErnia Repair|Randomized Multi Site Trial Comparing Lichtensteins Operation and Prolene Hernia System in Inguinal HErnia Repair.||Norwegian University of Science and Technology|No|Completed|October 2001|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|405|||Both|20 Years|80 Years|No|||February 2016|February 4, 2016|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184483||193084|
NCT00184821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QKF03-diab|Ischemic Injury and Ischemic Preconditioning in Diabetes|Acute Local Ischemic Preconditioning in Patients With Type 1 Diabetes in Vivo||Radboud University|No|Completed|June 2004|May 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||20|||Both|18 Years|50 Years|No|||April 2007|April 4, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00184821||193059|
NCT00183794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5GYN-02-2|Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma|Phase II Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma||University of Southern California||Completed|November 2002|May 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||December 2012|May 20, 2014|September 9, 2005|Yes|Yes||No|October 6, 2012|https://clinicaltrials.gov/show/NCT00183794||193137|
NCT00183807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3E-02-1|A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer|A Phase II Study of Irinotecan (Camptosar), Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer||University of Southern California|Yes|Terminated|October 2003|March 2008|Actual|February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005|||Insufficient Accrual|No||https://clinicaltrials.gov/show/NCT00183807||193136|
NCT00183820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4T-03-1|Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma|A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma||University of Southern California||Active, not recruiting|November 2004|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|16 Years|N/A|No|||March 2015|March 25, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183820||193135|
NCT00181012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIDODOULABDO|Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics|Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics: Efficacy Study in Adults and Children. Randomized Prospective Study With Direct Individual Benefit||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|May 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|6 Years|70 Years|No|||September 2006|September 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181012||193334|
NCT00181025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIP|Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs’ Girdle|Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs’ Girdle||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|May 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|33|||Both|16 Years|N/A|No|||September 2006|June 11, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181025||193333|
NCT00181350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03.1426L|Serial CT Scans in Fractionated Stereotactic Radiotherapy|Serial CT Scans for the Evaluation of Two Different Relocatable Fixation Systems in Fractionated Stereotactic Radiotherapy||Maastricht Radiation Oncology|Yes|Completed|November 2003|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00181350||193311|
NCT00181142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIND 8543|The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation|A Phase 3 Study Comparing the Use of Daclizumab Vs Thymoglobulin as Induction Therapy in Lung Transplantation||Johns Hopkins University||Completed|October 1999|December 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|66 Years|No|||August 2004|September 10, 2005|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00181142||193325|
NCT00181740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001355|Concerta Treatment in Adults With ADHD NOS|A Pilot Study of Concerta Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified||Massachusetts General Hospital||Completed|December 2003|July 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||July 2010|July 22, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181740||193292|
NCT00181753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P50GM021700-27A1|Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition|Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition||National Institute of General Medical Sciences (NIGMS)|Yes|Not yet recruiting|November 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||August 2009|August 12, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00181753||193291|
NCT00181974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Not sponsored|Efficacy of a Fibrin Sealant in Burn Surgery|Efficacy of a Fibrin Sealant in Burn Surgery||Massachusetts General Hospital||Completed|March 2000|November 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|N/A|N/A|No|||October 2012|October 22, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00181974||193274|
NCT00182468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MacMillan_VAW_RCT|Does Routine Screening for Intimate Partner Violence Against Women in Health Care Settings do More Good Than Harm?|If, When and How to Ask the Question(s): Assessing Screening Approaches to Identifying Woman Abuse in Health Care Settings||McMaster University|Yes|Completed|April 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|5681|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||September 2009|September 8, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182468||193236|
NCT00182949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904317|Genetics and Epidemiology of Aging Associated Conditions in the Sardinian Population|Genetics and Epidemiology of Aging Associated Conditions in the Sardinian Population (SARDINIA)||National Institutes of Health Clinical Center (CC)||Completed|November 2003|January 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|15000|||Both|14 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 3, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00182949||193201|
NCT00182962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0042|GRACE: Geriatric Resources for Assessment and Care of Elders|Geriatric Resources for Assessment and Care of Elders||National Institute on Aging (NIA)||Completed|March 2002|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||1270|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 16, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182962||193200|
NCT00148668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-311|Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer|A Randomized Phase II Study of Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Early Stage, HER-2 Positive Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|December 2003|August 2011|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|September 7, 2005|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00148668||195776|
NCT00183469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH068662|Maintenance Treatment of Bipolar Depression|Eight-Month Maintenance Treatment of Bipolar Depression With Lamotrigine or Lamotrigine Plus Divalproex Combination||The University of Texas Health Science Center at San Antonio|Yes|Completed|December 2004|April 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|September 13, 2005|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00183469||193161|
NCT00171977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BJP07|Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)|Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)||Novartis||Completed|July 2004|||April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|20 Years|74 Years|No|||August 2012|August 6, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171977||194020|
NCT00183599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-205|Gambling and Brief Interventions|Effect of Type and Duration of Therapy on Treatment for Gambling||University of Connecticut Health Center|Yes|Completed|April 1999|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||500|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183599||193152|
NCT00183833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-02-1|Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors|Phase I/II Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors||University of Southern California||Completed|December 2002|August 2010|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00183833||193134|
NCT00184145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPLK-2004|EMDR in the Treatment of Specific Phobia.|EMDR (Eye Movement Desensitization and Reprocessing) in the Treatment of Specific Phobia. A Randomised Controlled Trial.||Norwegian University of Science and Technology|Yes|Completed|June 2004|September 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|15 Years|65 Years|No|||January 2008|January 22, 2008|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00184145||193110|
NCT00183846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-00-8|Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers|Phase I Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers||University of Southern California||Completed|December 2000|July 2009|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00183846||193133|
NCT00184171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLV 01-07035|Treatment of Microscopic Colitis|Treatment of Microscopic Colitis (Collagenous Colitis and Lymphocytic Colitis) With Budesonide, Bismuth or Fiber||Norwegian University of Science and Technology|No|Terminated|November 2001|October 2014|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|September 10, 2005||No|insufficient data quality|No||https://clinicaltrials.gov/show/NCT00184171||193108|
NCT00184184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB- TKR 2004|Registration of Tobacco, Coffee and Substance Use Among Acutely Admitted Psychiatric Patients|Registration of Tobacco, Coffee and Substance Use Among Acutely Admitted Psychiatric Patients||Norwegian University of Science and Technology||Completed|October 2004|June 2010||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||500|||Both|18 Years|80 Years|No|||July 2006|July 24, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184184||193107|
NCT00180726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLI-MB-1|Molecular Mechanism of Asthma|Regulation of Inflammatory Mediators in Asthma||Imperial College London|Yes|Withdrawn|December 2003|July 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2008|August 12, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180726||193356|
NCT00184834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qol1|Quality of Life and Liver Metastases|Quality of Life After Surgical Treatment of Colorectal Liver Metastases||Radboud University||Completed|June 1999|November 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|N/A|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184834||193058|
NCT00180739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF004|Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future|Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies||Imperial College London||Completed|April 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 12, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180739||193355|
NCT00180752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MusHDAC -1|HDAC Activity in Peripheral Skeletal Muscle in COPD|The Investigation of HDAC and NF Kappa B Activity in Peripheral Skeletal Muscle in COPD||Imperial College London|No|Completed|September 2005|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|31|Samples With DNA|Plasma and serum samples, quadriceps muscle specimens|Both|40 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|COPD patients and healthy age-and sex-matched controls|August 2008|February 17, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180752||193354|
NCT00181038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERONE|Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery|Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery: Comparing Continuous Infusion of Local Anesthetic With Systemic Multimodal Analgesia||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|June 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||September 2006|August 27, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181038||193332|
NCT00181155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB: 04-10-12-06|Intravenous Allopurinol in Heart Failure|Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure||Johns Hopkins University|No|Completed|November 2004|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 12, 2005||No||No|November 11, 2015|https://clinicaltrials.gov/show/NCT00181155||193324|The limitations of the current study include the small placebo group sample size and the etiologic heterogeneity of the nonischemic cardiomyopathy group.
NCT00181987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001148|Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder|Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder||Massachusetts General Hospital||Completed|August 2002|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|6 Years|55 Years|No|||October 2013|October 21, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00181987||193273|
NCT00182234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74867|SONICS - Effectiveness of Specialist Oncology Nursing|A Study of the Effectiveness of Specialist Oncology Nursing Case Management in Improving Continuity of Supportive Cancer Care in the Community (SONICS)||McMaster University|No|Completed|December 2005|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|183|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00182234||193254|
NCT00182247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-1998-DIRECT|D-Dimer and IPG for Recurrent Thrombosis (DIRECT)|D-Dimer and IPG for Recurrent Thrombosis (DIRECT) Study||McMaster University||Terminated|December 1998|January 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||600|||Both|N/A|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182247||193253|
NCT00151671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 21541|Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer|Prospective, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Oral Immune-Enhancing Nutritional Supplement on Hepatic Function After Liver Resection for Primary or Secondary Cancer on Cirrhosis or Liver Fibrosis|IMPACT|Rennes University Hospital|No|Terminated|April 2003|September 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|N/A|No|||September 2008|February 24, 2012|September 8, 2005||No|insufficient enrollment rate|No||https://clinicaltrials.gov/show/NCT00151671||195548|
NCT00151970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-304|Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD|A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transdermal System (MTS) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Noven Therapeutics|No|Completed|June 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|128|||Both|6 Years|12 Years|No|||July 2015|July 8, 2015|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00151970||195525|
NCT00181805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-PediGERD|Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents|The Natural History of Children With Persistent Gastroesophageal Reflux Disease (Ages 12 to 17 Years)||Massachusetts General Hospital|No|Active, not recruiting|September 2004|December 2014|Anticipated|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|25|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|The subjects will be selected from a database of patients seen at Children's Hospital,        Boston or Massachusetts General Hospital between 1977 and 1990 who had biopsies or pH        probe for symptoms of GERD.|October 2013|October 23, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00181805||193287|
NCT00148096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZB/4/47|Mechanical Heat Recovery Ventilation on House Dust Mite Sensitive Asthma|Randomised Controlled Trial of Mechanical Heat Recovery Ventilation on Asthma Control of Patients Allergic to the House Dust Mite||University of Glasgow|No|Completed|February 2003|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||November 2007|December 23, 2009|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00148096||195820|
NCT00171600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AES15|Antialbuminuric Effects of Valsartan and Lisinopril|Comparative, Open Multicenter Trial Assessing the Effect on Albumin Excretion Rate of 320mg Valsartan (With or Without HCTZ) vs 40mg Lisinopril (With or Without HCTZ) on Hypertensive Patients With Diabetic and Non-diabetic Nephropathy and Albuminuria||Novartis||Terminated|July 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Both|40 Years|75 Years||||November 2011|November 7, 2011|September 12, 2005|||unknown|No||https://clinicaltrials.gov/show/NCT00171600||194049|
NCT00183612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08MH001765|Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents|Developmental Pharmacokinetics of Psychotropic Drugs: Olanzapine||Massachusetts General Hospital||Terminated|May 2000|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||68|||Both|6 Years|18 Years|No|||January 2014|January 7, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00183612||193151|
NCT00183365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-8-3934|Effect of Family-Based Prevention on Children of Depressed Parents|Children of Depressed Parents: Family-Based Prevention||Children's Hospital of Philadelphia||Completed|October 2005|November 2009|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|9 Years|N/A|No|||February 2014|February 6, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00183365||193169|
NCT00183625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH041573|Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients|The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training||University of California, Los Angeles|Yes|Completed|June 2000|September 2006|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|107|||Both|18 Years|60 Years|No|||November 2005|May 20, 2015|September 13, 2005||No||No|May 21, 2010|https://clinicaltrials.gov/show/NCT00183625||193150|
NCT00184496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI 03/008|Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study|Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study||Norwegian University of Science and Technology|No|Completed|August 2004|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184496||193083|
NCT00184197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-000724-32|Botulinum Toxin Injection in Neck Muscles in Cervicogenic Headache|Botulinum Toxin Injection in Neck Muscles in Cervicogenic Headache: A Prospective, Randomized, Double-blind, Cross-over Study||Norwegian University of Science and Technology|No|Completed|May 2005|December 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|70 Years|No|||September 2010|September 1, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00184197||193106|
NCT00184210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154080/I30|Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue|HR MAS MR Spectroscopy of Breast Cancer Tissue||Norwegian University of Science and Technology|No|Recruiting|January 2000|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|tissue|Female|18 Years|N/A|No|Non-Probability Sample|women in surgery for breast cancer|February 2016|February 4, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00184210||193105|
NCT00184509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDIR-1992-1995; NFR-1997-1999|Continued Early Intervention for Recent-Onset Schizophrenia|Continued Early Intervention for Recent-Onset Schizophrenia. A Randomized Controlled Study.||Norwegian University of Science and Technology||Terminated|February 1993|May 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|35 Years|No|||September 2005|September 15, 2005|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00184509||193082|
NCT00184522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLV 02-01973|On Demand Treatment of Reflux Disease|Aflurax Versus Nexium Given on Demand to Patients With Gastro-esophageal Reflux Disease.||Norwegian University of Science and Technology|No|Completed|August 2002|December 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||September 2005|August 8, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184522||193081|
NCT00181558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-200|Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone|Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study||Massachusetts General Hospital||Completed|December 2001|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||44|||Male|18 Years|N/A|No|||May 2010|May 7, 2010|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181558||193306|
NCT00181545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04.1338L|Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.|Individualised Radiation Dose Determination on Basis of Normal Tissue Dose Constraints in Patients With Non-Small-Cell Lung Cancer: A Phase I Study||Maastricht Radiation Oncology|Yes|Completed|December 2004|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00181545||193307|
NCT00181766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-002052|Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)|A Pilot Study of Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified||Massachusetts General Hospital|Yes|Completed|December 2003|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|55 Years|No|||December 2013|December 2, 2013|September 13, 2005|Yes|Yes||No|February 26, 2010|https://clinicaltrials.gov/show/NCT00181766||193290|small, open label studyshort exposure to medication
NCT00151164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|551|Thymic Tolerance in Pediatric Heart Transplantation|Thymic Tolerance in Pediatric Heart Transplantation||National Heart, Lung, and Blood Institute (NHLBI)||Terminated|April 2004|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|48|||Both|N/A|20 Years|No|||January 2008|January 31, 2008|September 6, 2005|||Due to failure to control sufficient patients in the active arm, this study has now been    closed.|No||https://clinicaltrials.gov/show/NCT00151164||195587|
NCT00151177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMF-DZ-110413|Continuous Positive Airway Pressure Ventilation After Acute Ischemic Stroke|Feasibility and Efficacy Study of Early Continuous Positive Airway Pressure Ventilation in Patients With Acute Ischemic Stroke||University Hospital Muenster|No|Completed|April 2005|April 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||April 2008|November 23, 2010|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151177||195586|
NCT00151411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-172|Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)|The Effect of Combination Therapy With Lifestyle Intervention and Metformin in Females With Polycystic Ovary Syndrome||Milton S. Hershey Medical Center|No|Completed|October 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|114|||Female|12 Years|39 Years|Accepts Healthy Volunteers|||December 2012|December 20, 2012|September 8, 2005|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00151411||195568|
NCT00151983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-305|Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy|A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.||Noven Therapeutics|No|Completed|June 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|6 Years|12 Years|No|||July 2015|July 8, 2015|September 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00151983||195524|
NCT00151996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-205|Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire||Completed|August 2004|May 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|6 Years|17 Years|No|||November 2009|November 25, 2009|September 7, 2005|||||September 10, 2009|https://clinicaltrials.gov/show/NCT00151996||195523|
NCT00152282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M00-198|A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women|A Phase II Pilot Study to Evaluate the Safety and Efficacy of J867 Administered With Estrogen to Postmenopausal Women||Abbott|No|Completed|September 2000|August 2001|Actual|August 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|105|||Female|48 Years|65 Years|No|||May 2008|May 27, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00152282||195501|
NCT00182052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-100|Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer|Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer: A Randomized Double-Blind, Placebo Controlled Phase III Study||Massachusetts General Hospital|Yes|Completed|September 2000|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Male|18 Years|N/A|No|||May 2013|May 22, 2013|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00182052||193268|
NCT00148382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL-962/191/CL|Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects|Randomized, Double Blind, Parallel Group, Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 (40mg, 80mg, 120mg 240mg) in Otherwise-Healthy Obese Volunteers||Alizyme||Completed|April 2005|July 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2007|April 10, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148382||195798|
NCT00148395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCLC 06/2001|Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.|Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.||Aktion Bronchialkarzinom e.V.||Completed|June 2002|April 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||280|||Both|18 Years|75 Years|No|||April 2008|April 21, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148395||195797|
NCT00171613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995B2403E1|A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients|A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients||Novartis||Completed|February 2005|||October 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|6 Years|17 Years|No|||April 2012|April 27, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00171613||194048|
NCT00171626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-PN-304|Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis||Novartis||Completed|August 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|35 Years|N/A|No|||April 2012|April 20, 2012|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00171626||194047|
NCT00171639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS72|The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis|The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis||Novartis|No|Completed|June 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|28|||Male|18 Years|N/A|No|||February 2011|February 24, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00171639||194046|
NCT00183352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066033|Reproductive Function and Mood in Women With Bipolar Disorder|Reproductive Endocrine Function and Mood Over the Menstrual Cycle of Women Treated for Bipolar Disorder||Stanford University|No|Completed|January 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|90|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women diagnosed with Bipolar Disorder, between 18-40 years of age, who are currently        treated with a mood stabilizing agent for a period of at least 3 months and are not taking        birth control pills currently. Participants must be willing to travel to Stanford        University (near San Francisco, CA) at their own expense for study visits.|April 2009|May 14, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00183352||193170|
NCT00183157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAABER13759|Project RAP: Reaching Adolescents for Prevention|RAP: Reaching Adolescents for Prevention - A Randomized Trial of a Brief Negotiated Interview and Active Referral to Reduce Alcohol Related Morbidity Among Youth and Young Adults in the Pediatric Emergency Department||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Recruiting|October 2004|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1400|||Both|14 Years|21 Years|No|||February 2009|February 12, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00183157||193185|
NCT00183872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3G-03-5|Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma|Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma||University of Southern California||Active, not recruiting|April 2005|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00183872||193131|
NCT00183885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3L-03-1|A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma|A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C||University of Southern California||Active, not recruiting|October 2004|October 2015|Anticipated|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00183885||193130|
NCT00184223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB-MI-2004|Motivational Interviewing to Acutely Admitted Psychiatric Patients With Comorbid Substance Use|Motivational Interviewing to Acutely Admitted Psychiatric Patients With Comorbid Substance Use||Norwegian University of Science and Technology||Completed|October 2004|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||135|||Both|18 Years|80 Years|No|||July 2006|July 24, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00184223||193104|
NCT00184535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 4.2005.885|Recording Methods of Muscle Activity "Onset".|Muscle Activity "Onset" in the Transversus Abdominis - Simultaneous Recordings by Intramuscular Electromyography and High Frame Rate Ultrasound Imaging.||Norwegian University of Science and Technology|No|Completed|July 2005|October 2005|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|||Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men and women between 30-65 yrs with no recent low back pain|October 2012|October 17, 2012|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184535||193080|
NCT00183859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-99-7|Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan|Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan||University of Southern California||Completed|September 1999|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00183859||193132|
NCT00180778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0403/155|Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss|Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS||Imperial College London||Not yet recruiting|October 2005|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Female|N/A|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180778||193352|
NCT00180791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNET HR|High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood|Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|71|||Both|N/A|10 Years|No|||September 2006|September 17, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00180791||193351|
NCT00181116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-02-18-06|Levetiracetam for Benign Rolandic Epilepsy|Efficacy of Levetiracetam for Language Dysfunction Associated With Benign Epilepsy With Centrotemporal Spikes||Johns Hopkins University||Completed|March 2005|September 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|6 Years|12 Years|No|||March 2009|March 26, 2009|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00181116||193327|
NCT00181129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NINR:RO1NRO4991|Fatigue and Cancer Treatment(FACT)- an Exercise Intervention|Mitigating Cancer Treatment-Related Fatigue by Exercise||Johns Hopkins University||Completed|September 2002|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|140|||Both|21 Years|N/A|No|||September 2008|September 29, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00181129||193326|
NCT00150670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91023039|Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer|Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer||Taiho Pharmaceutical Co., Ltd.||Completed|March 2002|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||300|||Both|20 Years|74 Years|No|||July 2011|July 6, 2011|September 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00150670||195625|
NCT00150917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN02-0603-E|RCT of a Group Intervention for Women With a Family History of Breast Cancer|A Randomized Controlled Trial of a Group Intervention for Women With a Family History of Breast Cancer||University Health Network, Toronto|No|Completed|July 2001|January 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2006|June 12, 2008|September 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00150917||195606|
NCT00151190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-05-0092|Community Diabetes Education Program Evaluation "Code Evaluation"|Community Diabetes Education Program Evaluation||The University of Texas Health Science Center, Houston||Completed|April 2005|August 2006||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||180|||Both|18 Years|N/A||||January 2010|January 7, 2010|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00151190||195585|
NCT00151424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05947|Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)|A Multicenter, Randomized, Double-Blind, Flexible-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia||Merck Sharp & Dohme Corp.|Yes|Completed|February 2005|February 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|277|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151424||195567|
NCT00151437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6291017|Canadian Pegvisomant Compassionate Study In Acromegalic Patients|A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program.||Pfizer||Completed|November 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||April 2008|April 22, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151437||195566|
NCT00151684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-268-060504|Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men|Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men: a Dose Response Study, Part II||Rijnstate Hospital||Completed|November 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||February 2008|February 27, 2008|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151684||195547|
NCT00148135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2001-021|Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site|A Phase II Trial Evaluating the Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site||University of Michigan Cancer Center||Terminated|May 2001|October 2007|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||December 2007|December 28, 2007|September 2, 2005|||recruitment goals met|No||https://clinicaltrials.gov/show/NCT00148135||195817|
NCT00148148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-MS-005-KMT-10/03|A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation|Phase II Randomised Study of the Safety, Efficacy and Pharmacokinetics of Caspofungin (CAS), Liposomal Amphotericin B (LAMB) or the Combination of Caspofungin With Liposomal Amphotericin B for Patients After Stem-Cell Transplantation||University Hospital Muenster||Completed|May 2004|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||January 2007|January 9, 2008|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148148||195816|
NCT00148408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAACRC-04|Trial of Asthma Patient Education (TAPE)|Trial of Asthma Patient Education (TAPE)||American Lung Association Asthma Clinical Research Centers||Completed|December 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind||||600|||Both|15 Years|N/A|No|||September 2006|April 28, 2010|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00148408||195796|
NCT00182065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117947-BCA-CEBA-126289|Heart Failure, Functional and Cognitive Decline, and Psychiatric Symptoms in Nursing Home Patients|The Effect of Congestive Heart Failure on Functional and Cognitive Decline and Neuropsychiatric Symptoms in Residents of Long-Term Care Facilities||McMaster University||Active, not recruiting|March 2004|October 2006||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||586|||Both|65 Years|N/A|No|||August 2005|September 7, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00182065||193267|
NCT00148941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213503/048|Immune Response & Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccine.|Safety, Immunogenicity&Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine vs Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Admd as Booster Doses to Healthy Children 4-6 Yrs, Each Co-admd With Merck's MMR Vaccine||GlaxoSmithKline||Completed|January 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|4087|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00148941||195756|
NCT00172055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GBE03|Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy|Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy||Novartis||Completed|December 2004|||July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|218|||Both|18 Years|N/A|No|||June 2011|June 15, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00172055||194014|
NCT00172627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701204|Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer|Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer||National Taiwan University Hospital||Recruiting|January 2005|||||N/A|Observational|Time Perspective: Cross-Sectional||||60|||Both|18 Years|N/A|No|||December 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172627||193970|
NCT00173030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700499|Genetic Study of Atrial Fibrillation: Focusing on Renin-Angiotensin System and C-Reactive Protein Genes|||National Taiwan University Hospital||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|20 Years|90 Years||||April 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173030||193939|
NCT00182858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903322|Gerontology Research Center Tissue Procurement for Biomedical Research|Tissue Procurement for Biomedical Research||National Institutes of Health Clinical Center (CC)||Recruiting|February 2003|December 2018||December 2018|Anticipated|N/A|Observational|N/A|||Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00182858||193207|
NCT00183378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072736|Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease|Behavioral Treatment of Nocturnal Disturbances in Alzheimer's Disease||University of Washington|Yes|Completed|September 2005|March 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|132|||Both|55 Years|N/A|No|||January 2012|January 12, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183378||193168|
NCT00183638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0764a|A Tailored Interactive Website for Promoting Condom Use Among Young Adults|Randomized Controlled Trial to Establish Efficacy of a Website to Promote Condom Use for Adults Aged 18-25|Youthnet|University of Colorado, Denver|No|Completed|June 2003|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1870|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183638||193149|
NCT00183898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3G-03-4|Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer|Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer||University of Southern California||Active, not recruiting|December 2004|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Female|18 Years|N/A|No|||October 2015|October 24, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00183898||193129|
NCT00184236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ts-aet01|Cardiovascular Risk Factors in Overweight Adolescents|Aerobic Interval Training Reduces Cardiovascular Risk Factors More Than a Multitreatment Approach in Overweight Adolescents||Norwegian University of Science and Technology|No|Completed|February 2005|May 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|13 Years|16 Years|Accepts Healthy Volunteers|||October 2011|October 31, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184236||193103|
NCT00184561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1707|Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes|Change in HbA1c With Biphasic Insulin Aspart 70/30 in Two Different Treatment Regiments in Subjects With Type 2 Diabetes Inadequately Controlled With Oral Anti-diabetic Drug Therapy.||Novo Nordisk A/S|No|Completed|July 2005|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|321|||Both|18 Years|75 Years|No|||October 2014|October 24, 2014|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00184561||193078|
NCT00184548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7TRAUMA-1711|Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/NiaStase®) in Severely Injured Trauma Patients With Bleeding Refractory to Standard Treatment|CONTROL|Novo Nordisk A/S|No|Terminated|October 2005|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|554|||Both|18 Years|70 Years|No|||June 2014|June 13, 2014|September 9, 2005|Yes|Yes|See termination reason in detailed description|No|September 4, 2009|https://clinicaltrials.gov/show/NCT00184548||193079|Trial was terminated after planned interim analysis for futility showed a lower than expected conditional power for showing superiority (11.2% [actual] vs. 50% [required]). 554 of 1502 planned patients were included in the intent-to-treat population.
NCT00184860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/153|The Role of CT-PET-MRI Image Fusion in Determining Radiation Treatment Volumes of Head-and-Neck Cancer Patients|The Value of CT-PET-MRI Image Fusion in Determining Radiation Treatment Volumes in Patients With a Squamous Cell Carcinoma of the Head-and-Neck Region, Who Are to be Treated With Definitive Radiotherapy||Radboud University||Completed|June 2003|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||April 2007|April 26, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184860||193056|
NCT00184873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13091966|Legtest Multi Centre Testing of the Lively Legs Program for Promoting Compliance in Leg Ulcer Patients|Legtest Multi Centre Testing of the Lively Legs Program for Promoting Compliance With Compression Therapy and Prescribed Exercise in Leg Ulcer Patients||Radboud University|No|Completed|January 2005|December 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|180|||Both|N/A|N/A|No|||August 2007|February 8, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00184873||193055|
NCT00180804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/MRE02/20|Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages|Combination of Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages||Imperial College London||Recruiting|April 2005|August 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||400|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|December 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180804||193350|
NCT00180817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC3103|Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.|Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies in Women Presenting as Recurrent Miscarriages.||Imperial College London||Recruiting|September 1998|August 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||250|||Female|N/A|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180817||193349|
NCT00150930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-02-017|Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness|Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness||UMC Utrecht||Active, not recruiting|October 2002|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||August 2005|November 27, 2006|September 6, 2005||||No||https://clinicaltrials.gov/show/NCT00150930||195605|
NCT00151203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0409007427|Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma|A Phase II Study of Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) for Newly Diagnosed Subjects With Multiple Myeloma||Weill Medical College of Cornell University||Active, not recruiting|September 2006|||May 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2009|December 18, 2009|September 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00151203||195584|
NCT00152009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-301|Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17|A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire||Completed|January 2003|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|345|||Both|6 Years|17 Years|No|||November 2009|November 25, 2009|September 7, 2005|||||September 10, 2009|https://clinicaltrials.gov/show/NCT00152009||195522|
NCT00152022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD465-303|Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.|A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).||Shire||Completed|April 2005|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||412|||Both|18 Years|55 Years|No|||November 2007|November 2, 2007|September 7, 2005||||||https://clinicaltrials.gov/show/NCT00152022||195521|
NCT00152295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-280|A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women|A Phase II Long-Term Extension Safety Study of J867 Administered With Estrogen to Postmenopausal Women||Abbott|No|Completed|April 2001|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|48 Years|65 Years|No|||May 2008|May 27, 2008|September 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00152295||195500|
NCT00181259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00044690|Magnetic Resonance Spectroscopy Studies of Cardiac Muscle Metabolism|In Vivo Cardiac Metabolism in Normal, Ischemic, and Cardiomyopathic Patients During Rest and Stress||Johns Hopkins University|No|Recruiting|January 1988|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with coronary artery disease, dilated cardiomyopathy, or left ventricular        hypertrophy|November 2015|November 11, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00181259||193316|
NCT00181610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P001475|Recombinant Human Prolactin for Lactation Induction|Recombinant Human Prolactin for Lactation Induction in Mothers of Premature Infants||Massachusetts General Hospital|Yes|Completed|September 2004|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|11|||Female|18 Years|45 Years|No|||May 2013|May 8, 2013|September 9, 2005|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT00181610||193302|
NCT00181597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-037|Trilostane for Androgen-Independent Prostate Cancer|A Phase II Study of Trilostane for Androgen-Independent Prostate Cancer||Sanofi||Completed|March 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|N/A|No|||December 2013|December 2, 2013|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00181597||193303|
NCT00182338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD 04-2305|Evaluation of Volume Status in Peritoneal Dialysis Patients|Evaluation of Volume Status in Peritoneal Dialysis Patients||McMaster University|No|Completed|January 2005|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Peritoneal dialysis clinic|July 2011|July 19, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00182338||193246|
NCT00182039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-50851-CT|POISE Trial: Perioperative Ischemic Evaluation Study|Perioperative Ischemic Evaluation Study (POISE) Trial|POISE|McMaster University|Yes|Terminated|October 2002|August 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8351|||Both|45 Years|N/A|No|||January 2008|April 10, 2008|September 9, 2005|Yes|Yes|Please see detailed description for reason why study was terminated.|No||https://clinicaltrials.gov/show/NCT00182039||193269|
NCT00172640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701211|Genetic Studies in Liver Cancer Patients|Identification of Differentially Expressed Genes in Hepatocellular Carcinoma With DNA Microarrays||National Taiwan University Hospital||Recruiting|January 2005|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172640||193969|
NCT00173056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700731|The Factors Predicting Change of Peritoneal Transport Characters in Peritoneal Dialysate|||National Taiwan University Hospital||Recruiting||||||N/A|Observational|N/A|||||||Both|18 Years|80 Years|No|||December 2004|November 23, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173056||193937|
NCT00173069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700403|A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)|A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)||National Taiwan University Hospital||Not yet recruiting|January 2006|December 2010||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||324|||Both|18 Years|65 Years|No|||July 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173069||193936|
NCT00183391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070935|Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children|Measuring and Predicting Response to Atomoxetine and Methylphenidate||National Institute of Mental Health (NIMH)||Recruiting|July 2005|November 2010|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|6 Years|17 Years|No|||April 2009|April 6, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183391||193167|
NCT00183404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073524|Long-Term Olanzapine Treatment in Children With Autism|Long-Term Olanzapine Treatment in Children With Autism||Drexel University|Yes|Completed|September 2004|October 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|3 Years|12 Years|No|||August 2014|August 14, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00183404||193166|
NCT00183651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH034486|Treatment of Suicidal Women With Borderline Personality Disorder|Assessment and Treatment of Parasuicidal Patients||University of Washington|Yes|Completed|April 2004|June 2010|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Female|18 Years|60 Years|No|||January 2012|January 31, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183651||193148|
NCT00183911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3G-03-1|Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma|Phase II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-Fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma||University of Southern California|Yes|Completed|November 2003|April 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00183911||193128|
NCT00183924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-01-1|Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.|A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.||University of Southern California|Yes|Completed|March 2001|December 2008|Actual|July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00183924||193127|
NCT00184249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120905|A Prospective Multi Centre Trial on Bipolar Radiofrequency Ablation of Atrial Fibrillation|A Prospective Multi Centre Trial on Bipolar Radiofrequency Ablation of Atrial Fibrillation||Norwegian University of Science and Technology|No|Withdrawn|June 2005|June 2012|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||March 2015|March 18, 2015|September 13, 2005||No|Collaborators did not enter patients into the study|No||https://clinicaltrials.gov/show/NCT00184249||193102|
NCT00184262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4941.1|Exposure and Response Prevention With Behavioral- Versus Cognitive Therapy Rationale in Obsessive Compulsive Disorder|Exposure and Response Prevention (ERP) With Behavioral- Versus Cognitive Therapy Rationale in the Treatment of OCD||Norwegian University of Science and Technology|No|Completed|January 2003|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 20, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184262||193101|
NCT00184574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1440|Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes|Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 70/30, Biphasic Insulin Aspart 50/50, and Biphasic Insulin Aspart 30/70 All in Combination With Metformin in Subjects With Type 2 Diabetes (the INTENSIMIX Trial).||Novo Nordisk A/S|No|Completed|April 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|603|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184574||193077|
NCT00184886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-Ado|The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans|The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans||Radboud University||Completed|November 2003|January 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|75 Years|No|||February 2006|February 13, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184886||193054|
NCT00184899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intralipid-Ado|The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids|The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids||Radboud University||Completed|August 2005|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2007|February 28, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184899||193053|
NCT00180830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGPS-01|Glivec Phase II Pediatric Study|Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|December 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|6 Months|21 Years|No|||September 2006|September 7, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00180830||193348|
NCT00180843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/6741|Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease|Assessment of Ventilation-perfusion Abnormalities in Patients With Smoking-related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy||Imperial College London|No|Terminated|September 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|2|||Both|35 Years|75 Years|No|||September 2013|September 21, 2013|September 13, 2005||No|lack of resources research fellow left|No||https://clinicaltrials.gov/show/NCT00180843||193347|
NCT00151463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481195|QEQ Treatment Responsiveness Evaluation Study|An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)||Pfizer||Completed|January 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Male|18 Years|N/A|No|||August 2007|August 15, 2007|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00151463||195564|
NCT00151697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC 297-161104|LANN-study: Lantus, Amaryl, Novorapid, Novomix Study|New Approach to Treat Type II Diabetes Failing on Maximal Oral Treatment||Rijnstate Hospital||Completed|May 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|30 Years|75 Years|No|||August 2011|August 8, 2011|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00151697||195546|
NCT00181623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P001209-1|Recombinant Human Prolactin for Lactation Induction|Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers||Massachusetts General Hospital||Completed|January 2005|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|45 Years|No|||May 2013|May 7, 2013|September 9, 2005|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT00181623||193301|Small numbers as this was an orphan disease trial.
NCT00181636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-000030/24|Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder|||Massachusetts General Hospital|No|Completed||October 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|No|||April 2007|April 23, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00181636||193300|
NCT00181818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-002639|Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease|Safety and Efficacy of Sustained-Release (SR) Bupropion for Smokers Hospitalized Smokers With Acute Coronary Heart Disease||Massachusetts General Hospital||Completed|October 1999|December 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||248|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00181818||193286|
NCT00182351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-1995-DDCUS|D-Dimer Vs Serial Compression Ultrasound Study|Evaluation of the Safety, Efficacy and Cost-Effectiveness of Two Strategies for the Diagnosis of Deep Vein Thrombosis||McMaster University||Completed|April 1996|July 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||810|||Both|N/A|N/A|No|||September 2006|September 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182351||193245|
NCT00182364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54618366 PROTECT pilot|PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)|PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)||McMaster University||Completed|February 2003|February 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|No|||November 2006|November 16, 2006|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00182364||193244|
NCT00182325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDF-160|Effects of a Personalized Web-Based Antenatal Care Planner|Women's Web Access to Their Own Antenatal Health Record and Personalized Health Information: Effect on Pregnancy Health Outcomes and Patient Satisfaction||McMaster University|No|Completed|February 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||210|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2007|April 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00182325||193247|
NCT00172653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701216|Function-Related Tests for Subjects With Stiff Shoulders: Reliability and Validity|Assessment of Function-Related Tests for Subjects With Stiff Shoulders: Reliability, Validity, Clinical Usefulness, and Biomechanical Analysis||National Taiwan University Hospital||Recruiting|August 2005|July 2006||||N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|18 Years|80 Years|No|||August 2005|October 15, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172653||193968|
NCT00183417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067183|Depression Prevention Program for Adolescents|Depression Prevention Program for High-Risk Adolescents||University of Texas at Austin||Completed|September 2004|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|350|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00183417||193165|
NCT00183430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069867|Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder|Prazosin for Noncombat Trauma PTSD||Seattle Institute for Biomedical and Clinical Research|Yes|Terminated|October 2003|December 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|September 13, 2005|Yes|Yes|Insufficient Enrollment|No|October 22, 2012|https://clinicaltrials.gov/show/NCT00183430||193164|
NCT00183664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH058356|Cognitive Therapy for Treating Depression and Preventing Relapse|Prophylactic Cognitive Therapy for Depression||National Institute of Mental Health (NIMH)|Yes|Terminated|December 1999|June 2011|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|523|||Both|18 Years|70 Years|No|||March 2009|March 16, 2009|September 13, 2005|Yes|Yes|Enrollment into acute phase therapy ended August 1st, 2008. Randomized continuation phase    trial is slated to end in June 2009 and follow-up to end in June 2011.|No||https://clinicaltrials.gov/show/NCT00183664||193147|
NCT00184288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11184|Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.|Single Volume 1H MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.||Norwegian University of Science and Technology|No|Withdrawn|November 2004|December 2010|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|patients with brain metastases|October 2011|November 1, 2011|September 13, 2005||No|no patients recruited|No||https://clinicaltrials.gov/show/NCT00184288||193099|
NCT00184301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064.03|A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.|Treatment of Patients With Concurrent Eating Disorder and Personality Disorder: A Controlled Randomized Comparison Study, of Treatments Given to In-patients and Out-patients.||Norwegian University of Science and Technology|No|Completed|September 2005|October 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|43|||Female|18 Years|45 Years|No|||October 2013|October 9, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184301||193098|
NCT00184600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1613|Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes|A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes Inadequately Controlled on Therapy With Oral Agents, and Assessing the Requirement for More Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, Their Efficacy and Durability|4T|Novo Nordisk A/S|No|Completed|November 2004|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|708|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|September 13, 2005|Yes|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00184600||193075|
NCT00184912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFIRI|The Effect of Caffeine on Ischemic Preconditioning|Caffeine Reduces Acute Ischemic Preconditioning||Radboud University||Completed|September 2003|January 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2006|November 28, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00184912||193052|
NCT00184587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L0004|Prophylactic Treatment of Episodic Cluster Headache|Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study||Norwegian University of Science and Technology||Completed|March 2005|December 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2010|April 22, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00184587||193076|
NCT00180856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFPULM|Radiofrequency Ablation of Lung Tumors|A Phase II Study of Radiofrequency Ablation of Lung Tumors||Gustave Roussy, Cancer Campus, Grand Paris||Completed|January 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 11, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00180856||193346|
NCT00181168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYR01105ORP|Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer|Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-Differentiated Epithelial Thyroid Cancer||Johns Hopkins University||Recruiting|March 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|70|||Both|18 Years|N/A|No|||September 2007|September 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00181168||193323|
NCT00184392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229-04|Cleaning of the Nose After Sinus Surgery: Necessary or Only Bothersome?|Debridement After Functional Endoscopic Sinus Surgery||Norwegian University of Science and Technology|No|Completed|January 2005|September 2007|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|No|||February 2014|February 27, 2014|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00184392||193091|
NCT00194077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Children with Mania|Study of Aripiprazole (Abilify) in Children With Symptoms of Mania|Aripiprazole in Children With Symptoms of Mania||University Hospital Case Medical Center|Yes|Completed|August 2004|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|4 Years|9 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|September 11, 2005|No|Yes||No|June 26, 2013|https://clinicaltrials.gov/show/NCT00194077||192365|No deaths occured during this study.
NCT00194090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-04-41|Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk|A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy of Celecoxib 200 Mg Qd in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee||University Hospital Case Medical Center||Recruiting|June 2004|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|45 Years|85 Years|No|||July 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00194090||192364|
NCT00194350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704111|Factor V Leiden Mutation and Implantation Failure|Evaluation of the Role of Factor V Leiden Mutation in Implantation Failure||University of Pennsylvania|No|Completed|September 2001|August 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1||399|||Female|18 Years|N/A|No|Non-Probability Sample|Women undergoing in-vitro fertilization with successful ovarian hyperstimulation, oocyte        retrieval, and fertilization; and the transfer of at least 2 fresh embryos of Grade 2        (preembryo with blastomeres of equal size and <=10% cytoplasmic fragmentation) or better|August 2011|August 8, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194350||192344|
NCT00190034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-93010|Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.|N-Acetylcysteine Protects Against Acute Renal Insult in Patients With Abnormal Renal Function Undergoing Cardiopulmonary Bypass.||Far Eastern Memorial Hospital||Suspended|January 2005|June 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|60|||Both|16 Years|N/A|No|||June 2006|February 6, 2009|September 11, 2005|||opposite result|No||https://clinicaltrials.gov/show/NCT00190034||192671|
NCT00190268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020304|Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis|Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis||Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|60 Years|No|||March 2007|February 18, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190268||192653|
NCT00190814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6192|Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.|Efficacy and Safety of Duloxetine Compared With Placebo in Women With Symptoms of Mixed Urinary Incontinence.||Eli Lilly and Company||Completed|September 2003|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190814||192611|
NCT00190827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6195|Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)|The Effectiveness of Duloxetine Compared With Placebo in the Treatment of Predominant Stress Urinary Incontinence||Eli Lilly and Company||Completed|September 2003|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190827||192610|
NCT00191152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4703|A Phase III Trial For Patients With Metastatic Breast Cancer|Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd||Eli Lilly and Company|Yes|Completed|February 2002|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|475|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|September 12, 2005|Yes|Yes||No|November 4, 2009|https://clinicaltrials.gov/show/NCT00191152||192585|
NCT00191503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9508|Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma|Phase II Study of Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma||Eli Lilly and Company||Completed|January 2005|November 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191503||192559|
NCT00191802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8370|Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients|Compliance With and Acceptance of Teriparatide Pen Injection in Severely Osteoporotic Patients [CATS]||Eli Lilly and Company||Completed|September 2003|October 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|30 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191802||192537|
NCT00177047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS001|Autologous Transplant for Multiple Myeloma|Autologous Transplantation for Multiple Myeloma||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|April 2004|January 2018|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177047||193632|
NCT00177060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308M50994|Topical Hydromorphone for Wound Healing|Topical Hydromorphone for Wound Healing||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|October 2003|May 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 26, 2010|September 13, 2005|Yes|Yes|No funding available.|No||https://clinicaltrials.gov/show/NCT00177060||193631|
NCT00177619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK061536|Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)|Prevention of Osteoporosis in Men With Prostate Cancer||University of Pittsburgh||Completed|May 2002|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Male|18 Years|N/A|No|||February 2014|February 10, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177619||193591|
NCT00177632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402119|Evaluation of Alternative Exercise Treatments on Weight Loss in Overweight Women.|Evaluation of Alternative Exercise Treatments on Weight Loss in Overweight Women.||University of Pittsburgh||Completed|July 2003|July 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177632||193590|
NCT00177645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405245|Inhaled Bicarbonate Therapy in Cystic Fibrosis|Inhaled Bicarbonate Therapy in Cystic Fibrosis||University of Pittsburgh|No|Completed|March 2002|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|12 Years|N/A|No|||January 2016|February 12, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177645||193589|
NCT00193206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 73|Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer|Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer||SCRI Development Innovations, LLC|No|Completed|September 2005|May 2009|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Female|18 Years|N/A|No|||October 2012|October 31, 2012|September 12, 2005||No||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00193206||192432|
NCT00193427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 76|Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer|Phase II Trial of Preoperative (Neo-adjuvant) Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|April 2004|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|September 12, 2005|No|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT00193427||192415|
NCT00193648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK70341|Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)|Novel Therapies for Resistant FSGS||Northwell Health|Yes|Completed|July 2005|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|2 Years|40 Years|No|||October 2007|October 19, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00193648||192398|
NCT00193661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMD-01-090|Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism|A Multi-Center, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Hypogonadism||Solvay Pharmaceuticals||Completed|August 2002|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|13 Years|17 Years|No|||September 2006|January 15, 2015|September 11, 2005||||||https://clinicaltrials.gov/show/NCT00193661||192397|
NCT00193908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 04.01|Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream|A Paired Double Blind Randomised Comparison of Cavilon(TM) Durable Barrier Cream(TM)[CDBC] to 10% Glycerine ("Sorbolene") Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|March 2004|October 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|333|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00193908||192378|
NCT00193895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 05.01|Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck|Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck||Trans-Tasman Radiation Oncology Group (TROG)|No|Active, not recruiting|April 2005|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|321|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193895||192379|
NCT00194129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH050165|Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder|A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence||University Hospital Case Medical Center|Yes|Completed|November 1997|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|16 Years|65 Years|No|||November 2013|November 4, 2013|September 13, 2005|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00194129||192361|
NCT00194116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHHS 08-03-07|Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression|Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression||University Hospital Case Medical Center|Yes|Completed|September 2004|February 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194116||192362|
NCT00194402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-6262-A|SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia|SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers||University of Washington|No|Completed|August 2003|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|21 Years|75 Years|No|||August 2008|August 20, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194402||192341|
NCT00190047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ptcl-01213|Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Study To Evaluate The Effects Of DP-b99 On Neurologic Function And Disability In Subjects With Acute Ischemic Hemispheric Stroke||D-Pharm Ltd.||Completed|February 2005|October 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|85 Years|No|||November 2007|November 22, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190047||192670|
NCT00190281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 025|Contrast-Enhanced US of Spleen, Liver and Kidney|Contrast-Enhanced US of Spleen, Liver and Kidney in Patients With Acute Infection (Malaria and Other Infectious Diseases: a Functional Study||Assistance Publique - Hôpitaux de Paris||Recruiting|August 2005|||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||53|||Both|18 Years|N/A|No|||March 2005|December 12, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00190281||192652|
NCT00190502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD CD IKEM 1|Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes|The Use of Polyclonal Anti-T-Lymphocyte Globulin to Prevent Progression of Autoimmune Beta-Cell Destruction in Recent Type 1 Diabetes||Institute for Clinical and Experimental Medicine||Recruiting|November 2000|December 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||28|||Both|15 Years|35 Years|No|||February 2004|January 8, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190502||192635|
NCT00190840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6685|A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer|Open-Label Single-Arm Phase 2 Study of ALIMTA in Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy||Eli Lilly and Company||Completed|September 2003|October 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||186|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190840||192609|
NCT00191516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9496|An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder|An Open-Label Study on Effectiveness and Tolerability of Atomoxetine as Perceived by Patients, Parents, and Physicians in Children With Attention-Deficit/Hyperactivity Disorder in Germany||Eli Lilly and Company||Completed|October 2004|February 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||257|||Both|6 Years|11 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191516||192558|
NCT00191529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6581|Growth Hormone Treatment in Short Children Born Small for Gestational Age|Optimization of Growth Hormone Treatment in Short Children Born Small for Gestational Age Based on a Growth Prediction Model-The OPTIMA Trial||Eli Lilly and Company||Completed|December 2002|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|3 Years|N/A|No|||June 2007|June 13, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191529||192557|
NCT00191828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7399|A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme|A Prospective/Parallel Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme||Eli Lilly and Company||Completed|March 2003|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191828||192535|
NCT00191815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7311|Combination Chemotherapy for Metastatic Breast Cancer|Phase II Study of Gemcitabine Plus Cisplatin as First-line Treatment of Metastatic Breast Cancer||Eli Lilly and Company||Completed|October 2002|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|75 Years|No|||November 2009|November 9, 2009|September 12, 2005||||No|October 13, 2008|https://clinicaltrials.gov/show/NCT00191815||192536|
NCT00192244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P501|Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in Healthy Children||MedImmune LLC||Completed|September 2000|October 2002||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3000|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||October 2006|October 2, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00192244||192505|
NCT00192257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P515|Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma|A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children With Asthma Aged 6 Years to 17 Years||MedImmune LLC||Completed|October 2002|May 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2229|||Both|6 Years|17 Years|No|||October 2006|October 2, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00192257||192504|
NCT00177086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412M65851|Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi|Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177086||193630|
NCT00177099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306M49486|Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice|Neurotrophic Effects of Immunophilin Ligands on Human Hair Follicles Grafted Onto Service Combined Immunodeficient (SCID) Mice||University of Minnesota - Clinical and Translational Science Institute||Completed|July 2003|September 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177099||193629|
NCT00177931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0403014|Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit|Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit||University of Pittsburgh||Completed|March 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|All biologic samples will be under the control of the principal investigator of this      research project. To protect confidentiality, all personal identifiers will be removed and      replaced with a specific code number. The information linking these code numbers to the      corresponding subjects' identities will be kept in a separate, secure location. The      investigators on this study will keep the samples indefinitely. All samples will be provided      to investigators not associated with the study without any identifiers and only contain a      code number. If a subject withdraws samples collected and not already processed will be      destroyed.|Both|18 Years|N/A|No|Non-Probability Sample|Liver transplant patients in the ICU|December 2015|December 16, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177931||193568|
NCT00193219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 64|Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer|A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer||SCRI Development Innovations, LLC|No|Completed|July 2005|July 2010|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|September 12, 2005|No|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00193219||192431|
NCT00193440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 22|Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma|Phase II Trial of Rituximab and Short Duration Chemotherapy Followed by Zevalin as First-Line Treatment for Patients With Low Grade Follicular Non-Hodgkin's Lymphoma||SCRI Development Innovations, LLC||Completed|April 2002|January 2009|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2010|December 29, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193440||192414|
NCT00193674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S102.3.116|Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage|Oral Dydrogesterone Treatment During the First Trimester of Pregnancy in Women With Recurrent Miscarriage: A Double-Blind, Prospectively Randomized, Placebo-Controlled, Parallel Group Trial||Abbott|No|Completed|September 2003|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Female|18 Years|38 Years|No|||August 2011|August 25, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00193674||192396|
NCT00193687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.3.002|Bifeprunox in the Treatment of Schizophrenia|An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizpohrenia (Extension of S154.3.001)||Solvay Pharmaceuticals||Completed|September 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|986|||Both|18 Years|75 Years|No|||March 2008|March 20, 2008|September 11, 2005||||||https://clinicaltrials.gov/show/NCT00193687||192395|
NCT00193700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMD-01-080|Pharmacokinetic Evaluation of Testosterone Gel (1%)|Pharmacokinetic Evaluation of Testosterone Gel (1%) in Prepubertal Boys of Adolescent Age||Solvay Pharmaceuticals||Completed|August 2002|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|13 Years|17 Years|No|||November 2006|December 23, 2006|September 11, 2005||||||https://clinicaltrials.gov/show/NCT00193700||192394|
NCT00194155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 17625-03-13|Cytomegalovirus (CMV) Infection in Pregnancy|Cytomegalovirus Infection and Pregnancy Outcomes||University of Pennsylvania||Active, not recruiting|May 2003|May 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Anticipated|220|||Female|15 Weeks|N/A|Accepts Healthy Volunteers|||August 2007|August 27, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194155||192359|
NCT00194142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803583|Cytomegalovirus (CMV) Infection in Amniotic Fluid|||University of Pennsylvania||Not yet recruiting|July 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Anticipated|300|||Female|15 Years|45 Years|No|||May 2007|June 6, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194142||192360|
NCT00194415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9950-E/A|A Study of HSV Testing Among Pregnant Women|A Randomized Clinical Trial of Antenatal vs Delayed (Post Partum) Testing for HSV Type-Specific Antibodies Among Pregnant Women.||University of Washington|No|Terminated|January 2004|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|173|||Female|14 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 29, 2007|September 12, 2005||No|An interim data analysis found no significant difference between testing groups.|No||https://clinicaltrials.gov/show/NCT00194415||192340|
NCT00190073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-94003|Cutaneous Denervation in Alcoholic Neuropathy|Cutaneous Denervation in Alcoholic Neuropathy||Far Eastern Memorial Hospital||Recruiting|January 2005|December 2005||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2005|September 11, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190073||192668|
NCT00190086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-94001|Syndrome X and Endothelial Dysfunction|||Far Eastern Memorial Hospital||Terminated|January 2001|December 2001||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||28|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2001|September 11, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190086||192667|
NCT00190060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMCHUT PIN 9197|Study of The Effects of Testosterone in Frail Elderly Men|Study of The Effects of Testosterone on Muscle Function, Physical Performance, Body Composition and Quality of Life in Frail Elderly Men||Central Manchester University Hospitals NHS Foundation Trust|Yes|Completed|October 2004|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|262|||Male|65 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 29, 2007|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00190060||192669|
NCT00190294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P011017|Expectant Versus Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW|Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2003|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Female|18 Years|48 Years|No|||March 2007|April 29, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190294||192651|
NCT00190515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG-0205-MF|A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)|Randomized Phase III Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)||Japan Clinical Oncology Group|Yes|Active, not recruiting|February 2003|November 2011|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1101|||Both|20 Years|75 Years|No|||February 2009|February 2, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00190515||192634|
NCT00190853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9587|Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence|Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women With Stress Urinary Incontinence||Eli Lilly and Company||Completed|January 2005|September 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||93|||Female|18 Years|75 Years|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190853||192608|
NCT00191165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5202|Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency|Efficacy and Safety of a High Dosage Compared to the Label Dosage of Humatrope in Early Pubertal Stage Children With Growth Hormone Deficiency||Eli Lilly and Company|No|Completed|March 2004|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|N/A|14 Years|No|||June 2009|June 8, 2009|September 12, 2005|Yes|Yes||No|April 7, 2009|https://clinicaltrials.gov/show/NCT00191165||192584|
NCT00191542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6671|Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents|A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and Adolescents||Eli Lilly and Company||Completed|March 2005|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|7 Years|15 Years|No|||October 2006|October 10, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191542||192556|
NCT00191841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7410|Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy|Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer||Eli Lilly and Company||Completed|December 2002|February 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||July 2006|July 21, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191841||192534|
NCT00191854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7451|Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line|Randomized Phase II Study of Biweekly Gemcitabine-Paclitaxel, Biweekly Gemcitabine-Carboplatin and Biweekly Gemcitabine-Cisplatin as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure||Eli Lilly and Company|Yes|Completed|March 2005|November 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|147|||Female|18 Years|N/A|No|||February 2010|February 24, 2010|September 12, 2005|Yes|Yes||No|July 21, 2009|https://clinicaltrials.gov/show/NCT00191854||192533|
NCT00192283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153 P502|Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in Healthy Children Attending Day Care Centers||MedImmune LLC|No|Completed|September 2000|May 2002|Actual|April 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|2903|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||April 2009|April 8, 2009|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00192283||192502|
NCT00192296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP105|Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers|A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers||MedImmune LLC||Completed|August 2004|March 2005|Actual|February 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 4, 2014|September 12, 2005||Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00192296||192501|
NCT00192309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153 P004|Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.|A Randomized, Open-Label, Placebo-Controlled Trial to Investigate the Kinetics of the Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Adults Aged 18 to <65 Years.||MedImmune LLC|No|Completed|September 2001|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|31|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192309||192500|
NCT00177671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH043832-03|Antidepressant Medication Plus Donepezil for Treating Late-life Depression|Maintenance Therapies in Late-Life Depression: MTLD III||University of Pittsburgh|Yes|Completed|December 2003|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 31, 2013|September 13, 2005|No|Yes||No|February 18, 2011|https://clinicaltrials.gov/show/NCT00177671||193587|Observations about dementia conversion rates were obtained from post hoc subgroup analyses of participants with mild cognitive impairment (N=57) and participants with normal cognition at time of randomization (N=63).
NCT00177684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0407015|Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)|Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)||University of Pittsburgh||Completed|September 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||48|||Both|18 Years|70 Years|No|||December 2008|December 16, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177684||193586|
NCT00177957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0504090|Gram Negative Bacteremia, Risk Factors for Failure of Therapy|Gram Negative Bacteremia, Risk Factors for Failure of Therapy||University of Pittsburgh|Yes|Recruiting|April 2005|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|patients with gram negative bacteremia|December 2015|December 16, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177957||193566|
NCT00178230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 4595|Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity|Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity in Thoracic Malignancies||University of Rochester||Suspended||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|No|||September 2006|September 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178230||193545|
NCT00198315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNBE-03-01|Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma|A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Anterior Oral Cavity, Soft Palate, or Tonsil That Have Failed Primary Curative Therapy||Inovio Pharmaceuticals|Yes|Suspended|June 2004|June 2007||June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|September 12, 2005|Yes|Yes|Enrollment was stopped based on the Data Monitoring Committee's recommendation.|No||https://clinicaltrials.gov/show/NCT00198315||192049|
NCT00198692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04/CCU322981-02|Self-Management Program for Persons With Limb Loss|Randomized Clinical Trial of Self-Management Educational Program for Persons With Limb Loss.||Johns Hopkins Bloomberg School of Public Health||Completed|August 2003|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||500|||Both|18 Years|85 Years|No|||September 2005|October 27, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198692||192020|
NCT00198978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL02|German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2)||Johann Wolfgang Goethe University Hospitals||Recruiting|January 2003|||June 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|55 Years|N/A|No|||June 2008|June 4, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198978||191998|
NCT00199277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM01VEN/4/03|Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.|Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia.||J. Uriach and Company||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00199277||191976|
NCT00194441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14622-C|Cerebral Perfusion Pressure (CPP) Management Information Feedback and Nursing|CPP Management Information Feedback and Nursing||University of Washington|No|Completed|April 1999|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|N/A|N/A|No|||May 2014|May 29, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194441||192338|
NCT00194428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802132|Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons|Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons||Temple University|No|Completed|February 2005|October 2009|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2008|March 26, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00194428||192339|
NCT00190099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-93005|Dexamethasone-Eluting Stent in Acute Coronary Syndrome to Prevent Restenosis|||Far Eastern Memorial Hospital||Completed|January 2003|December 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|N/A|N/A|No|||December 2004|November 17, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190099||192666|
NCT00190112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-E-940002|Change of Heart Rate Variability and Baroreflex Sensitivity After Ventral Cardiac Denervation|||Far Eastern Memorial Hospital||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|N/A|No|||December 2004|October 5, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00190112||192665|
NCT00190307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030440|STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery|Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery|STRATAGEM|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Actual|293|||Both|18 Years|N/A|No|||September 2005|September 20, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00190307||192650|
NCT00190528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0102|A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer|Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Bulky Stage I/II Cervical Cancer: Japan Clinical Oncology Group Trial (JCOG0102)||Japan Clinical Oncology Group||Terminated|February 2002|February 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Female|20 Years|70 Years|No|||September 2005|January 17, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00190528||192633|
NCT00190866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6222|Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome|Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome||Eli Lilly and Company||Completed|June 2005|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190866||192607|
NCT00190879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9855|Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder|Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder||Eli Lilly and Company||Completed|June 2005|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|18 Years|65 Years|No|||June 2007|June 6, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190879||192606|
NCT00191178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4957|Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes|Pilot Study Investigating the Effects of Insulin Lispro Low Mixture Therapy Compared With Insulin Glargine on Perceived Mood Symptoms in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company||Completed|August 2003|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|21 Years|79 Years|No|||October 2010|October 12, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191178||192583|
NCT00196664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004102-24|Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin|Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin. Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg||French National Agency for Research on AIDS and Viral Hepatitis||Completed|October 2005|February 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|144|||Both|18 Years|N/A|No|||May 2009|May 12, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196664||192169|
NCT00196950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134612/003|Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years|Assess the Safety, Reactogenicity, Immunogenicity & Long-term Persistence of One Intramuscular Dose of GSK Biologicals' MenACWY Conjugate Vaccine vs One Subcutaneous Dose of Mencevax™ ACWY in Healthy Adults Aged 18-25 Yrs||GlaxoSmithKline||Completed|September 2003|September 2006|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|50|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2011|November 17, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196950||192147|
NCT00192322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P002|Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children|A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live Cold Adapted (CAIV-T) in Healthy Children Aged 6 to Less Than 36 Months|CAIVT|MedImmune LLC|No|Completed|September 2001|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|173|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||February 2012|February 15, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192322||192499|
NCT00177944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0503062|Invasive Fungal Infections Surveillance Initiative|Invasive Fungal Infections Surveillance Initiative||University of Pittsburgh|Yes|Completed|August 2005|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|172|||Both|18 Years|N/A|No|Non-Probability Sample|patients with funal infections|January 2013|January 15, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177944||193567|
NCT00175643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK-IMIQUIMOD CYCLING|Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses|Open-Label Study to Assess Safety and Efficacy of Imiquimod 5% Cream Applied 3 Days Per Week in 1 or 2 Cycles for Treatment of Actinic Keratoses on the Head||University of British Columbia||Completed|February 2005|November 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2006|May 8, 2006|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00175643||193739|
NCT00198328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNBE-03-02|Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma|A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Base of the Tongue, Posterior Lateral Pharyngeal Wall, Hypopharynx, or Larynx That Have Failed Primary Curative Therapy||Inovio Pharmaceuticals|Yes|Suspended|November 2004|June 2007||June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|September 12, 2005|Yes|Yes|Enrollment was stopped based on the Data Monitoring Committee's recommendation.|No||https://clinicaltrials.gov/show/NCT00198328||192048|
NCT00198341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0302|Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up|Multicentric Randomized Phase III Study of Post-Surgical NSCLC Follow-up||Intergroupe Francophone de Cancerologie Thoracique||Active, not recruiting|January 2005|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1744|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198341||192047|
NCT00198705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.00.12.06.BX|Community Based Interventions to Reduce Neonatal Mortality in Bangladesh|Community Based Interventions to Reduce Neonatal Mortality in Bangladesh||Johns Hopkins Bloomberg School of Public Health||Completed|June 2003|August 2012|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|10670|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 12, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198705||192019|
NCT00198718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(CIDA) (R/C Project 690/M3688)|Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates|Vitamin A Supplementation of Breast Feeding Mothers and Their Neonates at Delivery: Impact on Mother to Child Transmission of HIV During Lactation, HIV Infection Among Women During the Postpartum Year, and Infant Mortality.|ZVITAMBO|Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|November 1997|May 2016|Anticipated|May 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|28220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198718||192018|
NCT00190346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2001|Comparison of Humidification Devices During Non Invasive Ventilation, in Acute Respiratory Failure|Randomized RCT Comparing HH and HME During NIV in Acute Respiratory Failure||Assistance Publique - Hôpitaux de Paris||Terminated|December 2001|April 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||250|||Both|18 Years|85 Years|No|||August 2005|October 25, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00190346||192647|
NCT00190580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|620|Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease|Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT)||KVT-Study Group|Yes|Completed|February 2003|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|20 Years|N/A|No|||March 2009|March 30, 2015|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00190580||192629|
NCT00190593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1865|Raloxifene Use for The Heart|Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events||Eli Lilly and Company||Completed|June 1998|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||10000|||Female|55 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190593||192628|
NCT00194740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-5372-A|Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer|Taxotere Plus Weekly Navelbine and G-CSF: A Phase II Study in Stage IV Breast Cancer||University of Washington|No|Completed|November 1997|June 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||December 2007|December 3, 2007|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194740||192316|
NCT00190125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-94008|The Influences of Malnutrition and Inflammation Complex Syndrome in Hemodialysis Patients|The Influences of Malnutrition and Inflammation Complex Syndrome in Hemodialysis Patients||Far Eastern Memorial Hospital||Not yet recruiting||August 2007|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|N/A|No|||August 2005|February 6, 2009|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190125||192664|
NCT00190333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020305|Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension|Evaluation of the Therapeutic Effects of Escitalopram in Pulmonary Hypertension, Either Primary or Associated||Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2007|February 17, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190333||192648|
NCT00190554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9907|A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma|A Randomized Controlled Trial of Chemotherapy With 5FU and Cisplatin Before and After Surgery for Stage II,III Squamous Cell Carcinoma of the Thoracic Esophagus:JCOG9907||Japan Clinical Oncology Group|Yes|Terminated|May 2000|May 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||330|||Both|N/A|75 Years|No|||May 2007|May 31, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00190554||192631|
NCT00195286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101315|Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.|Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2004|July 2007|Actual|July 2007|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|180|||Both|16 Years|N/A|No|Non-Probability Sample|Patients treated at internal medicine units|September 2009|September 24, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195286||192274|
NCT00190320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030417|DAME: Induction of Labor or Waiting for Suspicion Fetal Macrosomia|Induction of Labor or Waiting for Suspicion Fetal Macrosomia (DAME)||Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2005|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1000|||Female|18 Years|48 Years|No|||March 2007|February 16, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190320||192649|
NCT00190541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0212|Mesorectal Excision (ME) Versus ME With Lateral Node Dissection for Stage II, III Lower Rectal Cancer (JCOG0212)|Mesorectal Excision With Lateral Lymph Node Dissection Versus Without Lateral Lymph Node Dissection for Clinical Stage II, III Lower Rectal Cancer (JCOG0212)||Japan Clinical Oncology Group|Yes|Recruiting|June 2003|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|21 Years|74 Years|No|||June 2010|June 13, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190541||192632|
NCT00191204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5309|Open Label Phase III Duloxetine Study for Stress Urinary Incontinence|Long Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence||Eli Lilly and Company||Completed|September 2001|May 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||363|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191204||192581|
NCT00191230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5489|Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer|A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC||Eli Lilly and Company||Completed|September 2001|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191230||192580|
NCT00196027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001 version 1|Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism|Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism||Cierra||Active, not recruiting|April 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2006|November 27, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196027||192218|
NCT00196040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002|The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness|Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness||Cierra||Completed|October 2005|November 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||December 2007|December 18, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196040||192217|
NCT00196378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-ENJ-301|A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy|A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Synthetic Conjugated Estrogens, B (Enjuvia) 0.3 mg Tablets for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women||Teva Pharmaceutical Industries|No|Completed|November 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Female|30 Years|80 Years|No|||January 2010|August 30, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196378||192191|
NCT00196963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103532|Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs|Assess the Immunogenicity, Safety, Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of Mencevax™ ACWY in Healthy Subjects Aged 15-19 Yrs||GlaxoSmithKline||Completed|March 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||125|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196963||192146|
NCT00197236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208109/232|Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months|Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 Months of Age||GlaxoSmithKline||Completed|November 2003|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|468|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||March 2011|April 11, 2013|September 15, 2005|Yes|Yes||No|December 2, 2008|https://clinicaltrials.gov/show/NCT00197236||192125|
NCT00197249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270362/006|Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity|A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Bios' Combined Vi Polysaccharide Typhoid Vac and Inactivated Hepatitis A Vac, to That Elicited by GSK Bios' Hepatitis A Vac, Admin Singly or Concomitantly With GSK Bios' Vi Polysaccharide Vac||GlaxoSmithKline||Completed|May 2002|November 2005|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|1034|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 17, 2011|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00197249||192124|
NCT00197223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104438|Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine|A Randomized, Double-blind, Placebo-controlled, Post-marketing Phase III Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults.||GlaxoSmithKline||Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|6213|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2012|January 31, 2012|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00197223||192126|
NCT00177970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311034|IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff|Intravenous Immunoglobulin G Versus Placebo for the Treatment of Patients With Severe Clostridium Difficile-Associated Diarrhea and Colitis||University of Pittsburgh|Yes|Terminated|October 2003|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 13, 2005||No|We were unable to receive IVIG free from phamaceutical company.|No||https://clinicaltrials.gov/show/NCT00177970||193565|
NCT00190151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031007|Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora|Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora||Assistance Publique - Hôpitaux de Paris|No|Terminated|September 2004|July 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 17, 2012|September 12, 2005||No|terminated|No||https://clinicaltrials.gov/show/NCT00190151||192662|
NCT00190359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC00007|Growth Hormone and Heart Failure|Modifications of the Growth Hormone/IGF1 Axis in Heart Failure Patients||Assistance Publique - Hôpitaux de Paris||Terminated|September 2000|February 2003||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||180|||Both|18 Years|N/A|No|||April 2002|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00190359||192646|
NCT00190606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2615|Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence|Efficacy and Safety of Duloxetine Compared With Placebo,Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects With Moderate to Sever Stress Urinary Incontinence||Eli Lilly and Company||Completed|January 2002|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|18 Years|75 Years|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190606||192627|
NCT00190619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2624|Efficacy and Safety of Duloxetine|Efficacy and Safety of Duloxetine Compared With Placebo in Subjects Electing Surgery for Severe Pure Genuine Stress Incontinence||Eli Lilly and Company||Completed|May 2001|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|18 Years|75 Years|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190619||192626|
NCT00190632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2690|To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence||Eli Lilly and Company||Completed|March 2001|April 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190632||192625|
NCT00190918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8366|A Trial for Patients With Gestational Trophoblastic Disease|A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor||Eli Lilly and Company||Completed|July 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Female|N/A|N/A|No|||August 2007|August 7, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190918||192603|
NCT00191282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5509|Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes|Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D)|IONM|Eli Lilly and Company|Yes|Completed|October 2002|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1116|||Both|30 Years|N/A|No|||January 2011|January 18, 2011|September 12, 2005|Yes|Yes||No|October 17, 2008|https://clinicaltrials.gov/show/NCT00191282||192576|
NCT00191295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5285|Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|February 2005|September 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|6 Years|18 Years|No|||November 2007|November 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191295||192575|
NCT00191594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9548|Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials|Open-Label Duloxetine Extension Phase in Patients Who Have Completed the HMDG Clinical Trial||Eli Lilly and Company||Completed|March 2005|August 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||105|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191594||192552|
NCT00191919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8605|A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain|A Ten-Week, Randomized, Double-Blind Study Evaluating the Efficacy of Duloxetine 60mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain||Eli Lilly and Company||Completed|May 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||310|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191919||192528|
NCT00190905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8363|Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.|Study of Duloxetine HCl in Women of Different Demographic Characteristics and Co-Morbidities With Stress Urinary Incontinence: Evaluation of Efficacy and Safety||Eli Lilly and Company||Completed|February 2004|July 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||4000|||Female|18 Years|N/A|No|||July 2006|July 21, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190905||192604|
NCT00191269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9065|Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen|A Multicenter Study of LY188011 in Anthracyclines and Taxanes Pre-treated Metastatic/Recurrent Breast Cancer||Eli Lilly and Company|Yes|Completed|June 2005|March 2010|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Female|20 Years|74 Years|No|||March 2010|March 10, 2010|September 12, 2005|Yes|Yes||No|March 23, 2009|https://clinicaltrials.gov/show/NCT00191269||192577|
NCT00195000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403-762|Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS|Phase II Evaluation of Gemtuzumab Ozogamicin in Combination With Cytarabine in Untreated Patients Above the Age of 60 Years With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome||Weill Medical College of Cornell University||Completed|May 2003|February 2008|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|60 Years|N/A|No|||June 2013|June 17, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00195000||192296|
NCT00195013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309006308|Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy|A Randomized Placebo-controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients With a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy||Weill Medical College of Cornell University|No|Active, not recruiting|December 2003|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00195013||192295|
NCT00195299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-147|Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck|An Exploratory Biomarker Trail of Temsirolimus in Subjects With Newly Diagnosed Advanced Stage Squamous Cell Carcinoma of the Head & Neck||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2005|February 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||20|||Both|18 Years|N/A|No|||December 2007|December 18, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195299||192273|
NCT00191893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7918|Bone Effects of Teriparatide Following Alendronate|Bone Effects of Subcutaneous Teriparatide Following Discontinuation of Alendronate Treatment in Postmenopausal Women With Osteoporosis||Eli Lilly and Company||Completed|September 2003|November 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Female|55 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191893||192530|
NCT00190567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2595|Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence|Biomechanical Effects of Duloxetine on Bladder Function and Sphincter Resistance During the Emptying Phase and on Urethral Function During the Filling Phase of the Micturition Cycle in Women With Pure Genuine Stress Incontinence||Eli Lilly and Company||Completed|October 2001|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Female|18 Years|75 Years|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190567||192630|
NCT00190892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7031|Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania|Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder||Eli Lilly and Company||Completed|September 2004|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190892||192605|
NCT00191191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5250|To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)|LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial||Eli Lilly and Company|No|Completed|October 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|20 Years|75 Years|No|||December 2009|December 4, 2009|September 12, 2005|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00191191||192582|
NCT00196391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-MPG-201|A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea|A Multicenter Study to Evaluate Induction of Withdrawal Bleeding After Administration of DR-2021 in Women With Secondary Amenorrhea||Teva Pharmaceutical Industries|No|Completed|September 2005|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|180|||Female|18 Years|50 Years|No|||May 2014|July 29, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196391||192190|
NCT00196404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-OXY-202|Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder|A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder||Teva Pharmaceutical Industries|No|Completed|October 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|800|||Female|18 Years|N/A|No|||August 2012|August 17, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196404||192189|
NCT00196677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|g88|Study of Glaucoma Treatment With Food Additives|Treatment of Glaucomatous Neuropathy With Food Additives||Future Products Management||Terminated|September 2005|October 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|25|||Both|40 Years|75 Years|No|||March 2009|March 10, 2009|September 12, 2005|||The trial was terminated due to investigator's decision|No||https://clinicaltrials.gov/show/NCT00196677||192168|
NCT00193466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 21|Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Rituximab/Fludarabine Followed by CAMPATH-1H in the First-Line Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||SCRI Development Innovations, LLC||Completed|January 2002|April 2008|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2010|December 29, 2010|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193466||192412|
NCT00193739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119 of 2003|Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix|A Prospective Randomized Trial of Neoadjuvant Chemotherapy and Surgery Versus Concurrent Chemoradiation Therapy in Patients With Stage IB2-IIB Squamous Carcinoma of the Uterine Cervix|NACTcervix|Tata Memorial Hospital|Yes|Recruiting|September 2003|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|730|||Female|18 Years|65 Years|No|||November 2015|November 6, 2015|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00193739||192391|
NCT00194181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|705565|Rt-PA Infusion Versus Catheter Exchange for Dialysis Catheter Malfunction Due to Fibrin Sheath|Randomized Prospective Trial of Rt-PA Infusion Versus Catheter Exchange for Treatment of Dialysis Catheter Malfunction Due to Fibrin Sheath Formation||University of Pennsylvania||Terminated|March 2003|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2006|July 14, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194181||192357|
NCT00175110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV3727|The Effect of Hibiscus Sabdariffa L. Tea on Blood Pressure|The Effect of Hibiscus Sabdariffa L. Tisane on Blood Pressure in Prehypertensive and Mildly Hypertensive Men and Women||Tufts University|No|Completed||December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||December 2009|December 2, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00175110||193779|
NCT00175123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Botox|Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele|Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele||University of Aarhus|No|Active, not recruiting|May 2005|June 2008|Anticipated|March 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|2 Years|16 Years|No|||February 2009|February 19, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00175123||193778|
NCT00190645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2688|To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence||Eli Lilly and Company||Completed|February 2001|May 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190645||192624|
NCT00190658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2704|Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome|Safety and Efficacy of Humatrope in Pediatric Patients With Genetic Short Stature (SHOX Gene Defect)||Eli Lilly and Company||Completed|February 2000|September 2010|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|3 Years|N/A|No|||December 2010|December 17, 2010|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190658||192623|
NCT00190931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7066|A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder|A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|November 2003|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|49 Years|No|||July 2006|July 21, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190931||192602|
NCT00190944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8175|Effects of Teriparatide on Distal Radius Fracture Healing|Effects of Teriparatide on Distal Radius Fracture Healing||Eli Lilly and Company||Completed|December 2004|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||105|||Female|45 Years|85 Years|No|||October 2007|October 10, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190944||192601|
NCT00191308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9356|Molecular Profiling in Lung Cancer Patients|Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy||Eli Lilly and Company|No|Completed|May 2005|December 2010|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2011|October 13, 2011|September 12, 2005|Yes|Yes||No|March 16, 2010|https://clinicaltrials.gov/show/NCT00191308||192574|Trial enrollment was terminated early due to lack of eligible participants.
NCT00191607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6890|A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.|A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy||Eli Lilly and Company||Completed|July 2002|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||162|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191607||192551|
NCT00191945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8836|Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 Weeks in Newly Diagnosed Children and Adolescents Outpatients With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company|No|Completed|May 2005|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|6 Years|15 Years|No|||January 2010|January 26, 2010|September 12, 2005|Yes|Yes||No|February 6, 2009|https://clinicaltrials.gov/show/NCT00191945||192526|
NCT00191971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7994|2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen|A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium||Eli Lilly and Company||Completed|January 2004|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|20 Years|74 Years|No|||November 2007|November 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191971||192525|
NCT00192478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP104|Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524|A Phase 1/2, Open-Label, Repeat-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children at Risk for Serious RSV Disease||MedImmune LLC||Completed|February 2004|August 2006|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|217|||Both|6 Months|24 Months|No|||July 2008|July 24, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192478||192487|
NCT00191932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8604|Switching to Duloxetine From Other Antidepressants|Switching to Duloxetine From Other Antidepressants: A Regional Multicentre Trial Comparing Two Switching Techniques||Eli Lilly and Company||Completed|August 2004|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|18 Years|N/A|No|||July 2006|July 21, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191932||192527|
NCT00192413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P516|Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza|A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older|FluMist|MedImmune LLC|No|Completed|March 2002|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3009|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192413||192492|
NCT00192426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P511|Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.|A Prospective, Randomized, Partially-Blinded, Placebo-Controlled, Phase III, Multicenter Trial to Assess Safety, Tolerability and Immunogenicity of Liquid CAIV-T Administered Concomitantly With OPV in Healthy Children||MedImmune LLC||Completed|September 2001|December 2001||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2400|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||October 2006|October 2, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192426||192491|
NCT00191581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9537|Local Registration Trial in China Humalog Mix 50|Comparison of 2-Hour Postprandial Blood Glucose Excursion in Response to a Standard Test Meal in Insulin-Requiring Diabetic Patients Treated Twice Daily With Either Insulin Lispro Mix 50/50 or Human Insulin Mix 50/50||Eli Lilly and Company||Completed|March 2005|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|70 Years|No|||July 2006|July 28, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191581||192553|
NCT00191906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7955|Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)|A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder.||Eli Lilly and Company|No|Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|121|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||May 2010|May 17, 2010|September 12, 2005|Yes|Yes||No|December 11, 2008|https://clinicaltrials.gov/show/NCT00191906||192529|
NCT00195663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE013|Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis|A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis (PREMIER).|PREMIER|AbbVie|No|Completed|December 2000|April 2012|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|799|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|September 13, 2005|Yes|Yes||No|December 8, 2009|https://clinicaltrials.gov/show/NCT00195663||192245|
NCT00196053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDS-EU04-001|The Effectiveness of Pain Management Using the ARCHIMEDES® Constant-Flow Infusion Pump System for Intrathecal Delivery|Observational Registry: The Effectiveness of Pain Management Using the ARCHIMEDES® Implantable Constant-Flow Infusion Pump System for Intrathecal Delivery||Codman & Shurtleff|No|Completed|March 2005|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00196053||192216|
NCT00193037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 43|Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer|A Phase II Randomized Crossover Study Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|February 2001|November 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|September 12, 2005||No||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00193037||192445|
NCT00193245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 47|Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer|A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|November 2000|January 2009|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||January 2009|June 24, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193245||192429|
NCT00193258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 22|Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma|A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma||SCRI Development Innovations, LLC|No|Completed|June 2004|August 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|September 12, 2005|No|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00193258||192428|
NCT00193934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 04.02|Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer|Prospective Study to Determine the Relationships Between Survival and FIGO Stage, Tumour Volume and Corpus Invasion in Cervical Cancer||Trans-Tasman Radiation Oncology Group (TROG)|No|Suspended|January 2006|March 2016|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|||Female|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed cervical cancer patients, Female|August 2015|August 27, 2015|September 12, 2005||No|Trial Management related issues|No||https://clinicaltrials.gov/show/NCT00193934||192376|
NCT00194194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801363|Healthetech, Inc. SMART Study|The Effect of Measuring Resting Metabolic Rate (RMR) in the Context of Moderate or Intensive Behavior Modification Treatment on Weight Loss||Temple University|No|Completed|August 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2008|March 13, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194194||192356|
NCT00194207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103700|Risk Factors of Ectopic Pregnancy|Risk Factors as Predictors of Ectopic PRegnancy||University of Pennsylvania|No|Active, not recruiting|October 1999|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples Without DNA|Serum|Female|N/A|N/A|No|Non-Probability Sample|Women with early pregnancy with symptoms of pain and bleeding, presenting to the ER at the        Hospital of University of Pennsylvania|August 2011|August 8, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194207||192355|
NCT00189826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506E-11-03|A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.|A Multicentre, Randomised, Double Blind, Two Arm Parallel Group Study to Evaluate and Compare the Efficacy and Safety of Modified Release Tacrolimus FK506E (MR4) Versus Tacrolimus FK506 in Combination With Steroids in Patients Undergoing Primary Liver Transplantation||Astellas Pharma Inc|Yes|Completed|August 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|475|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00189826||192685|
NCT00180388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version vom 30.01.2004|VENEK: Healing in Different Vein Harvesting Methods During Aortocoronary Coronary Artery Bypass Graft Surgery (CABG)|Comparison of Clinical and Economical Parameters of Healing in Different Vein Harvesting Methods During Aortocoronary CABG||Guidant Corporation||Terminated|May 2004|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|60 Years|N/A|No|||March 2007|March 9, 2007|September 12, 2005|||terminated for logistical reasons|No||https://clinicaltrials.gov/show/NCT00180388||193382|
NCT00190970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7550|The Effect of Ruboxistaurin on Small Fiber Function|The Effect of Ruboxistaurin Mesylate (LY333531) on Small Fiber Function as Measured by Microvascular Skin Blood Flow, C-Fiber Quantitations in Skin and Quantitative Sensory Testing of Cold and Heat.||Eli Lilly and Company||Completed|October 2004|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190970||192599|
NCT00191334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9340|Gemcitabine in Ovarian Cancer|Phase II Study of Gemcitabine Plus Cisplatin as First-Line Therapy in Patients With Epithelial Ovarian Cancer||Eli Lilly and Company|No|Completed|December 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||February 2009|February 24, 2009|September 12, 2005|Yes|Yes||No|December 17, 2008|https://clinicaltrials.gov/show/NCT00191334||192572|
NCT00191321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9151|Teriparatide Use in Hip Replaced Subjects|TUHRS Study - Teriparatide Use in Hip Replaced Subjects A Pilot Study on the Use of Teriparatide in Severe Osteoporotic Women With Hip Fracture and Submitted to Hip Replacement||Eli Lilly and Company||Completed|July 2004|December 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|55 Years|85 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191321||192573|
NCT00191620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6952|Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.|Randomized Phase II Study of Cisplatin + Gemcitabine Administered Either as Short Infusion or at a Fixed Dose Rate in Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|March 2004|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||64|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191620||192550|
NCT00191633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9684|Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes|A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes.||Eli Lilly and Company||Completed|April 2005|June 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|6 Years|11 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191633||192549|
NCT00191984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8673|A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer|Open Multicenter Phase II Study in Second-Line Metastatic Colorectal Cancer Patients: Combination of ALIMTA and Irinotecan Administered Every Two-Weeks||Eli Lilly and Company|No|Completed|June 2004|May 2008|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2011|January 3, 2011|September 12, 2005|Yes|Yes||No|April 27, 2009|https://clinicaltrials.gov/show/NCT00191984||192524|
NCT00191997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8834|Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode|Optimal Treatment Duration With Olanzapine Following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies.||Eli Lilly and Company||Completed|October 2004|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||July 2006|July 21, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191997||192523|
NCT00192465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP101|Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults|A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 (NUMAX TM), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Healthy Adults||MedImmune LLC||Completed|November 2003|November 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|30|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00192465||192488|
NCT00192491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV018|Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children|A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRIIÒ) and Varicella (VARIVAXÒ) Vaccines Administered Concurrently to Healthy Children (AV018)||MedImmune LLC|No|Completed|December 2000|December 2003|Actual|September 2003|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|1200|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||February 2008|February 7, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192491||192486|
NCT00192439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP096|Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk|A Study to Describe the Incidence Rate and Clinical Features of Human Meta Pneumovirus (hMPV) Infection of the Lower Respiratory Tract in Hospitalized Children at High Risk for Severe Disease||MedImmune LLC||Completed|December 2003|December 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|1500|||Both|N/A|24 Months|No|||May 2007|May 4, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192439||192490|
NCT00192452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP074|Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis|A Phase II Randomized, Double-Blind, Placebo-Controlled Study of MEDI-507, a Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults With Plaque Psoriasis||MedImmune LLC||Completed|March 2001|December 2001||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|64 Years|No|||October 2006|October 23, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00192452||192489|
NCT00192751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|compliance_CTIL|From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management|Impact of Psycho-Educational Intervention on Patients With Severe Mental Illness Recently Discharged From Psychiatric Inpatient Services||Rambam Health Care Campus||Recruiting|February 2004|December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||150|||Both|18 Years|70 Years|No|||September 2005|October 26, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192751||192467|
NCT00193050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 51|Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer|Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients||SCRI Development Innovations, LLC|No|Completed|November 2001|March 2009|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Female|18 Years|N/A|No|||August 2012|August 22, 2012|September 12, 2005||No||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00193050||192444|
NCT00192387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P005|Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)|A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate Viral Shedding in Healthy Children (6 Mos and Less Than or Equal to 18 Months of Age) Vaccinated With Two Doses of Liquid Formulation of Influenza Virus Vaccine, Live Cold Adapted (CAIV-T)||MedImmune LLC||Completed|September 2001|December 2001||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||December 2006|December 27, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00192387||192494|
NCT00192400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P504|Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of One Dose and Two Doses of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) Compared With Placebo in Healthy Children||MedImmune LLC||Completed|March 2002|November 2002||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||2160|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||October 2006|October 2, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00192400||192493|
NCT00192725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tryp.dep.maniaCTIL|Tryptophan Depletion in Acute Mania|Tryptophan Depletion in Acute Mania - A Randomized Controlled Trial||Rambam Health Care Campus||Completed|March 2003|June 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||September 2005|August 24, 2010|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00192725||192469|
NCT00192738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSA1677CTIL|Does Telephone Follow-up Improve Patients Satisfaction|Does Telephone Follow-up After Discharge Improve Patients Satisfaction and Decrease Hospitalization||Rambam Health Care Campus||Completed|April 2003|January 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||400|||Both|18 Years|N/A|No|||April 2007|April 10, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192738||192468|
NCT00193752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/205/2004/Cx_PET STUDY|Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cancer Cervix|Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cancer Cervix||Tata Memorial Hospital|Yes|Recruiting|September 2005|September 2010|Anticipated|||Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|65 Years|No|Probability Sample|Patients with hisotologically proven cervical cancers with FIGO II-IIIB eligible for the        study will be invited for the study|July 2008|July 14, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193752||192390|
NCT00194220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706658|Infertility Markers in Serum, Urine, and Follicular Fluid|Markers in Women Undergoing Infertility Treatment||University of Pennsylvania|No|Completed|September 2002|February 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1235|Samples With DNA|Blood, Urine, Follicular Fluid|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing In vitro fertilization at the University of Pennsylvania|September 2015|September 28, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194220||192354|
NCT00194233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708870|Serum and Peritoneal Fluid Bank for Endometriosis Markers|Serum and Peritoneal Fluid Bank for Assessment of Markers of Endometriosis||University of Pennsylvania||Completed|November 2003|June 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Serum, Plasma, Peritoneal fluid|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing Laparoscopy at HUP|August 2011|August 8, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194233||192353|
NCT00193947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0162-B|An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy|An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy||University Health Network, Toronto|No|Terminated|November 2003|May 2008|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|56|||Female|18 Years|N/A|No|Non-Probability Sample|Women attending the UHN immunodeficiency clinic|April 2007|August 2, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00193947||192375|
NCT00190177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020925|ECLAXIR:Search for an Association Between CX3CR1 V249I Polymorphism, Preeclampsia and Endothelial Injury|||Assistance Publique - Hôpitaux de Paris|No|Completed|March 2003|October 2007|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|370|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2005|October 17, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00190177||192660|
NCT00179764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 0300 Mini|Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])|Immunoablative Protocol for Allogeneic Related and Unrelated Hematopoietic Peripheral Blood Stem Cell Transplant (HPBSC)||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|March 2000|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|21 Years|No|||January 2014|January 30, 2014|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179764||193430|
NCT00180102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK1-95|AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years|AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.||Technische Universität Dresden||Completed|December 2003|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|16 Years|60 Years|No|||December 2009|December 23, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00180102||193404|
NCT00191347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9305|A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer|A Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer||Eli Lilly and Company||Completed|October 2004|November 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191347||192571|
NCT00191646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6891|An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy|Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma||Eli Lilly and Company|Yes|Completed|October 2002|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|919|||Female|18 Years|N/A|No|||February 2011|February 28, 2011|September 12, 2005|Yes|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00191646||192548|Trial was designed with overall survival as primary endpoint. Enrollment was slower than expected. After 4 years, 919 patients were randomized and in August 2006, protocol was amended: primary endpoint was changed to progression free survival (PFS).
NCT00192023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8856|An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).|An Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder||Eli Lilly and Company|No|Completed|October 2004|May 2008|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|6 Years|15 Years|No|||December 2009|December 9, 2009|September 12, 2005|Yes|Yes||No|May 15, 2009|https://clinicaltrials.gov/show/NCT00192023||192522|Due to the open-ended timing of the open-label period (up to 1.5 years or until commercial availability) the efficacy data from the open-label extension phase is not included except for adverse event data.
NCT00192036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8984|Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer|Multicenter Phase II Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|August 2004|November 2009|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||November 2010|November 22, 2010|September 12, 2005|Yes|Yes||No|February 23, 2009|https://clinicaltrials.gov/show/NCT00192036||192521|Enrollment was stopped early due to difficulties with patient recruitment. Given the number of missing/unknown tumor assessments, care should be taken when interpreting the primary outcome measure. An identified error was corrected in the results.
NCT00192504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP106|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection|A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection||MedImmune LLC||Completed|March 2004|January 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||31|||Both|1 Month|24 Months|Accepts Healthy Volunteers|||October 2006|October 23, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00192504||192485|
NCT00192517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP102|Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis||MedImmune LLC||Completed|December 2003|September 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||April 2009|April 2, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192517||192484|
NCT00192803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE2.CTIL|Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs|ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs||Rambam Health Care Campus||Not yet recruiting||||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||20|||Both|18 Years|90 Years|No|||September 2005|February 22, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00192803||192463|
NCT00192816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2038CTIL|Pain Perception in Alzheimer's Disease|Pain Perception in Alzheimer's Disease||Rambam Health Care Campus||Recruiting|June 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|55 Years|95 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192816||192462|
NCT00193089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 46|Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer|Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2||SCRI Development Innovations, LLC|Yes|Completed|April 2001|September 2009|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00193089||192441|
NCT00192829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrombosis and cancer.CTIL|Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma|Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma||Rambam Health Care Campus||Recruiting|June 2005|||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||100|||Both|N/A|N/A|No|||March 2007|April 10, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192829||192461|
NCT00192790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSA1871CTIL|Pain Perception is Attenuated in Patients With Painless Myocardial Infarction|Clinical and Experimental Pain Perception is Attenuated in Patients With Painless Myocardial Infarction||Rambam Health Care Campus|Yes|Completed|January 2004|March 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|18 Years|85 Years|No|||April 2007|April 10, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192790||192464|
NCT00192764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RonHDCHOP.CTIL|High Dose CHOP in Lymphoma|Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma||Rambam Health Care Campus||Completed|December 1996|September 2010|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|65 Years|No|||September 2010|September 21, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192764||192466|
NCT00192777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-RT-Xeloda.CTIL|Concurrent Xeloda and Radiotherapy for Bone Metastases|Concurrent Xeloda and Radiotherapy for Bone Metastases||Rambam Health Care Campus||Recruiting|November 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||September 2005|October 5, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192777||192465|
NCT00193063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 44|Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer|Phase II Trial of Weekly Gemcitabine and Herceptin in the Treatment of Patients With HER-2 Overexpressing Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|July 2001|August 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|September 12, 2005||No||No|August 16, 2013|https://clinicaltrials.gov/show/NCT00193063||192443|
NCT00193271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 19|Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer|Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer||SCRI Development Innovations, LLC|No|Completed|August 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193271||192427|
NCT00193479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 28|Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma|A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma||SCRI Development Innovations, LLC|No|Completed|April 2003|February 2010|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|September 12, 2005|No|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00193479||192411|
NCT00193960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|In process|The Results of Ahmed Valve Operations|A Comparison Between Superior and Inferior Ahmed Glaucoma Valve Implantation: Surgical Success and Complications||University Health Network, Toronto||Recruiting|January 1997|June 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||80|||Both|20 Years|85 Years|No|||September 2005|November 29, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00193960||192374|
NCT00194246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 AT01103-01|Cognitive Function and Cue-Reactivity Study|Cognitive Performance and Food Reactivity During High and Low Carbohydrate Obesity Treatment||Temple University|No|Completed|August 2003|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29|Samples Without DNA|salivary cortisol|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|all participants who took part in the Safety and Efficacy of Low and High Carbohydrate        Diets study|August 2007|June 28, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194246||192352|
NCT00189839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506E-12-03|A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation|A Multicentre, Randomised, Double Blind, Two Arm Parallel Group Study to Evaluate and Compare the Efficacy and Safety of Modified Release Tacrolimus FK506E (MR4) Versus Tacrolimus FK506 in Combination With MMF (Cellcept®) and Steroids in Patients Undergoing Kidney Transplantation||Astellas Pharma Inc|Yes|Completed|August 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|699|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00189839||192684|
NCT00190190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040604|Internal Limiting Membrane Peeling for Large Macular Holes|Comparison of the Success Rate of a Procedure With Peeling of Limiting the Intern of the Retina Versus a Traditional Procedure Without Peeling of Limiting, at Patients Presenting a Macular Hole.||Assistance Publique - Hôpitaux de Paris|No|Completed|January 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||July 2007|July 16, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190190||192659|
NCT00180089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGAST|Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation|Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation||Technische Universität Dresden||Completed|January 2004|January 2010||March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|242|||Both|12 Years|65 Years|No|||March 2010|March 29, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00180089||193405|
NCT00180375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPERA Registry|OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator|OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator||Guidant Corporation|No|Completed|May 2002|August 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||700|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a conventional indication of ICD or CRT-D|June 2011|June 3, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00180375||193383|
NCT00176722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120040320|Intraocular Pressure During Prone Spinal Surgery|The Effect of Table Position on Intraocular Pressure (IOP) and Ocular Perfusion Pressure (OPP) During Prone Spine Surgery||Rutgers, The State University of New Jersey|No|Terminated|June 2006|January 2012|Actual|October 2011|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|7|||Both|18 Years|65 Years|No|Probability Sample|Subjects undergoing spine surgery in the prone position.|April 2015|April 23, 2015|September 13, 2005||No|Principal Investigator is leaving the UMDNJ|No||https://clinicaltrials.gov/show/NCT00176722||193657|
NCT00191373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6133|A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease|Phase II Study of Gemcitabine and Trastuzumab Therapy in Patients With HER2 Overexpressing Metastatic Breast Cancer||Eli Lilly and Company||Completed|March 2002|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Female|18 Years|N/A|No|||September 2007|September 11, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191373||192569|
NCT00191659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6962|Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents|A Randomised, Controlled, Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents||Eli Lilly and Company||Completed|June 2004|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|7 Years|15 Years|No|||February 2007|February 28, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191659||192547|
NCT00191672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6966|A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer|A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer||Eli Lilly and Company||Completed|December 2003|November 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191672||192546|
NCT00192049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8048|A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer|A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer||Eli Lilly and Company||Completed|December 2003|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||May 2007|May 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192049||192520|
NCT00192543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283304|The Fish and Fruit Study: Trial of Fish and Fruit to Improve Survival of Aboriginal People With End Stage Renal Disease|A Clinical Trial of Fish and Fruit to Improve Survival of Aboriginal People With End Stage Renal Disease||Menzies School of Health Research|No|Completed|May 2004|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|152|||Both|18 Years|N/A|No|||March 2009|August 3, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00192543||192483|
NCT00192842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RonCurcuminPancreas.CTIL|Gemcitabine With Curcumin for Pancreatic Cancer|Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer||Rambam Health Care Campus|No|Completed|July 2004|September 2010|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192842||192460|
NCT00192855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|entacapon.schiz.CTIL|Entacapone Augmentation for Schizophrenia|Entacapone Augmentation for Schizophrenia- A Randomized Controlled Trial||Rambam Health Care Campus||Completed|June 2003|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|75 Years|No|||September 2005|August 24, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00192855||192459|
NCT00193310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 53|Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer|Preoperative (Neoadjuvant) or Postoperative (Adjuvant) Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|November 2000|January 2009|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193310||192424|
NCT00193076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 63|Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer|A Phase II Trial of Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer||SCRI Development Innovations, LLC||Completed|November 2003|October 2008|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Female|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00193076||192442|
NCT00193297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GYN 08|Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma|A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma||SCRI Development Innovations, LLC||Completed|February 2002|June 2006|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193297||192425|
NCT00193284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI HN 04|Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer|A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck||SCRI Development Innovations, LLC||Completed|October 2003|January 2009|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||January 2009|June 18, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193284||192426|
NCT00193492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 37|A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma|Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial||SCRI Development Innovations, LLC|Yes|Completed|September 2005|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|August 22, 2005|No|Yes||No|December 5, 2014|https://clinicaltrials.gov/show/NCT00193492||192410|
NCT00193765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/131/2003|Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity|Elective Versus Therapeutic Neck Dissection in the Treatment of Early Node Negative Squamous Cell Carcinoma of the Oral Cavity||Tata Memorial Hospital|Yes|Active, not recruiting|January 2004|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|710|||Both|18 Years|75 Years|No|||April 2015|April 6, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193765||192389|
NCT00193973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 01.02|Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma|A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|July 2001|August 2013|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||August 2013|August 8, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193973||192373|
NCT00190203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P001004|Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts|Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts : A Sequential Design, Multicenter, Randomized, Controlled Trial|DECIMAL|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|December 2001|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|55 Years|No|||September 2007|January 16, 2008|September 13, 2005||No|the study is publiched|No||https://clinicaltrials.gov/show/NCT00190203||192658|
NCT00189852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPSRC Grant No. GR/S29058/01|Supporting Care and Independence at Home|Supporting Care and Independence at Home||Barnsley Hospital|No|Completed|November 2005|February 2009|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|62|||Both|60 Years|N/A|No|||February 2016|February 18, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00189852||192683|
NCT00179790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP RIT|Reduced Intensity Transplant Using Extracorporeal Photopheresis|Reduced Intensity Stem Cell Transplant in Children and Young Adults Utilizing Photopheresis, Fludarabine, and Busulfan||Ann & Robert H Lurie Children's Hospital of Chicago||Recruiting|July 2005|January 2010|Anticipated|January 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||February 2009|March 10, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00179790||193428|
NCT00176501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540187|Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer|Immunotherapy for Patients With Renal Cell Carcinoma||Rutgers, The State University of New Jersey|No|Terminated|August 2004|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||November 2013|November 18, 2013|September 12, 2005|Yes|Yes|Slow accrual|No|November 18, 2013|https://clinicaltrials.gov/show/NCT00176501||193673|
NCT00191399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9370|Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response|Bipolar Depression Assessment Study on Tx Response||Eli Lilly and Company||Completed|May 2004|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191399||192567|
NCT00191425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6537|2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis|Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis||Eli Lilly and Company||Completed|August 2002|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||810|||Female|55 Years|N/A|No|||July 2007|July 12, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191425||192565|
NCT00191685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8163|Duloxetine in the Treatment of Melancholic Depression|Duloxetine in the Treatment of Melancholic Depression: An 8-Week Open-Label Dose Study||Eli Lilly and Company||Completed|May 2004|September 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years|No|||July 2006|July 21, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191685||192545|
NCT00192062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7775|A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer|A Phase II Trial of Gemcitabine (Gemzar) Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer||Eli Lilly and Company||Completed|July 2004|June 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Female|18 Years|N/A|No|||August 2007|August 29, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192062||192519|
NCT00192075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8142|A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer|A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer||Eli Lilly and Company||Completed|June 2003|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||November 2009|February 4, 2011|September 12, 2005||Yes||No|October 30, 2008|https://clinicaltrials.gov/show/NCT00192075||192518|
NCT00192556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FITTCET_1|Food Incentives for TB Treatment Compliance in East Timor (FITTCET)|Food Incentives for TB Treatment Compliance in East Timor||Menzies School of Health Research||Completed|March 2005|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|15 Years|N/A|No|||February 2007|February 8, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00192556||192482|
NCT00192868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEDICATION|Drug Elution and Distal Protection During Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction|Drug Elution and DIstal Protection During Percutaneous CoronAry Intervention in sT Elevation Myocardial InfarctiON. Acronym: Dedication||Rigshospitalet, Denmark||Active, not recruiting|May 2005|November 2011|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192868||192458|
NCT00193102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 60|Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer|Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer||SCRI Development Innovations, LLC||Terminated|April 2001|June 2010|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193102||192440|
NCT00193518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 33|Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||SCRI Development Innovations, LLC||Completed|April 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||41|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193518||192408|
NCT00193791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/114/2003/CRACX TRIAL|Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix|Concomitant Chemo-radiation in Advanced Stage Carcinoma Cervix: A Phase III Randomized Trial|CRACx|Tata Memorial Hospital|Yes|Active, not recruiting|July 2003|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|850|||Female|18 Years|65 Years|No|||April 2015|April 22, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193791||192387|
NCT00193505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 27|Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma|Phase II Trial of Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in the Treatment of Patients With Relapsed/Refractory Intermediate Grade B-Cell Lymphoma||SCRI Development Innovations, LLC|No|Completed|October 2003|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193505||192409|
NCT00193778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/153/2004|Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation|A Randomized Trial To Assess The Impact Of Loco-Regional Treatment On Survival Of Patients With Metastatic Breast Cancer At First Presentation||Tata Memorial Hospital|Yes|Active, not recruiting|February 2005|December 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Female|21 Years|65 Years|No|||March 2015|March 7, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00193778||192388|
NCT00189878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC/03/4/003|A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria|Multi-centre Prospective Randomised Double-blind Placebo-controlled Study of Methotrexate in the Treatment of Chronic Idiopathic Urticaria||Barnsley Hospital|Yes|Terminated|August 2003|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 11, 2005||No|unable to recruit|No||https://clinicaltrials.gov/show/NCT00189878||192682|
NCT00189904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-010|Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients|A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination||Bavarian Nordic||Completed|July 2005|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|151|||Both|18 Years|55 Years||||December 2007|September 27, 2012|September 11, 2005||Yes||||https://clinicaltrials.gov/show/NCT00189904||192681|
NCT00189930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NEF-004|An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients|A Single-blind, Randomized, Controlled, Phase II Study to Evaluate Immunogenicity and Safety of Two Doses of the MVA-nef HIV Vaccine in HIV-1 Infected Patients With CD4 > 250/µl||Bavarian Nordic|No|Completed|April 2005|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|60 Years|No|||September 2012|September 28, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189930||192679|
NCT00189943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVA-POX-001|Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects|Phase I Study on Safety, Tolerability and Immunogenicity of the MVA-BN Vaccine Administered to Healthy Subjects||Bavarian Nordic||Completed|April 2001|July 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||90|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189943||192678|
NCT00189956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-004|Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.|Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects||Bavarian Nordic||Completed|April 2003|November 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|165|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00189956||192677|
NCT00190216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM98099|Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)|Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression||Assistance Publique - Hôpitaux de Paris|No|Terminated|December 2001|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|55 Years|No|||July 2005|November 6, 2007|September 13, 2005|||terminated|No||https://clinicaltrials.gov/show/NCT00190216||192657|
NCT00190398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P990402|EVA3S: Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis|Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis||Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2000|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|900|||Both|18 Years|N/A|No|||February 2007|April 29, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00190398||192643|
NCT00190411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P010309|Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type|Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2003|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|15 Years|65 Years|No|||March 2007|January 15, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190411||192642|
NCT00190424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050305|Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma|Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma||Assistance Publique - Hôpitaux de Paris||Completed|September 2005|October 2010|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|40 Years|N/A|No|||September 2005|December 12, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00190424||192641|
NCT00176241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-H&N-16-EL|Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer|A Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent Head & Neck Cancer||University of Kentucky|No|Terminated|December 2005|November 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|September 12, 2005||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00176241||193693|
NCT00176254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-H&N-11-BMS|Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer|Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer||University of Kentucky|No|Completed|May 2000|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|September 9, 2005||No||No|December 8, 2013|https://clinicaltrials.gov/show/NCT00176254||193692|Heterogeneity of post-induction treatment given. While definitive therapy did differ, it was stratified by response to induction therapy, an accepted practice. Conclusions remain exploratory, because of the small sample size and heterogeneity.
NCT00176748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005-036|Treatment for Patients With Metastatic Thyroid Cancer|Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment||University of Michigan Cancer Center||Completed|July 2005|June 2009|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2010|January 14, 2010|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176748||193655|
NCT00191698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7068|Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD|A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder||Eli Lilly and Company|No|Completed|December 2003|November 2007|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||October 2008|October 29, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00191698||192544|
NCT00192114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9098|Enzastaurin for Patients With Metastatic Colorectal Cancer|A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer||Eli Lilly and Company|No|Completed|August 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|19 Years|N/A|No|||October 2009|October 5, 2009|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192114||192515|
NCT00192088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8059|A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma|Open-Label Single-Arm Phase II Study of ALIMTA in Combination With Oxaliplatin as First-Line Therapy in Advanced Gastric Carcinoma||Eli Lilly and Company||Completed|May 2004|May 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192088||192517|
NCT00192101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9590|Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes|Randomized Phase II Study of the Combination of Gemcitabine (Gemzar) Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines an/or Taxanes||Eli Lilly and Company||Completed|October 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|18 Years|N/A|No|||November 2007|November 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192101||192516|
NCT00192569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA015999-01|Australian Trial in Acute Hepatitis C|Australian Trial in Acute Hepatitis C||Kirby Institute|Yes|Completed|July 2004|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|16 Years|N/A|No|||October 2009|April 13, 2011|September 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00192569||192481|
NCT00192881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCANDSTENT A|Stenting With or Without Coating Compared With Angioplasty in Non-benestent Disease|Stenting With or Without Coating Compared With Angioplasty in Non-benestent Disease. A Randomised Comparison of Optimal Balloon Angioplasty and Primary Implantation of Stents With and Without Drug Elution in Complex Coronary Lesions||Rigshospitalet, Denmark||Not yet recruiting|October 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2010|August 17, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192881||192457|
NCT00193128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 57|Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer|A Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction||SCRI Development Innovations, LLC|No|Completed|April 2004|January 2009|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|September 12, 2005||No||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00193128||192438|
NCT00193115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 69|Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer|Phase II Pilot Trial of Dose-Dense Docetaxel Followed by Doxorubicin Plus Cyclophosphamide (T-AC) Given as Adjuvant or Neoadjuvant Treatment for Women With Node Positive or High-Risk Primary Breast Cancer||SCRI Development Innovations, LLC||Completed|March 2004|January 2009|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Female|18 Years|N/A|No|||January 2009|August 3, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00193115||192439|
NCT00193323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 52|Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients|A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|August 2001|January 2009|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||346|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|June 24, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193323||192423|
NCT00193531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MISC 16|Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma|Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma||SCRI Development Innovations, LLC||Completed|December 1998|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||October 2008|June 28, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193531||192407|
NCT00193986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0252-B|Assessment of Prepulse Inhibition for Shock Pain Reduction|Assessment of Prepulse Inhibition for Shock Pain Reduction- Ventricular||University Health Network, Toronto||Completed|May 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention||||10|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||September 2006|November 13, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00193986||192372|
NCT00194259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL70301|Sleep Apnea in Look AHEAD (Action for Health in Diabetes)|Sleep Apnea in Look AHEAD (Action for Health in Diabetes)||Temple University|Yes|Active, not recruiting|August 2001|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|Samples Without DNA|Saliva Samples|Both|45 Years|75 Years|No|Non-Probability Sample|Patients with Type II diabetes previously enrolled into the "Look-AHEAD" Study. Comid        diagnosis of sleep apnea|January 2008|March 5, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194259||192351|
NCT00194272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701460|Two-Dose Methotrexate for Ectopic Pregnancy|Two-Dose Methotrexate for Ectopic Pregnancy||University of Pennsylvania|No|Completed|March 2001|June 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|N/A|N/A|No|||August 2011|August 8, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194272||192350|
NCT00189917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-007|Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders|An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders||Bavarian Nordic||Completed|April 2004|April 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|September 11, 2005||||||https://clinicaltrials.gov/show/NCT00189917||192680|
NCT00189969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-ELS-001|Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects|Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic’s Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years||Bavarian Nordic||Completed|September 2003|February 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|18 Years|32 Years|Accepts Healthy Volunteers|||April 2006|April 20, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189969||192676|
NCT00189982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060401|Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101|Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (ADVATE rAHF-PFM): Safety Monitoring in Pediatric Patients Diagnosed With Severe to Moderately Severe Hemophilia A - A Continuation of Baxter Clinical Study 060101||Baxalta US Inc.||Completed|December 2004|November 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Male|N/A|6 Years|No|||July 2013|June 26, 2015|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00189982||192675|
NCT00190229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P011014|Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura|CESAR (Randomized Therapeutic Study of Steroid vs. Steroid Plus Cyclosphosphamide for Severe Viscera Henoch-Schoenlein Purpura)||Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2002|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||March 2007|May 3, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190229||192656|
NCT00190437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P010310|ANTEAB: a Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD|ANTEAB: a Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD||Assistance Publique - Hôpitaux de Paris|Yes|Completed|August 2003|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|520|||Both|18 Years|70 Years|No|||March 2007|April 29, 2011|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00190437||192640|
NCT00190736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9040|Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)|Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months); With a Brief Evaluation of Executive Cognition||Eli Lilly and Company||Completed|September 2004|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|18 Years|54 Years|No|||November 2007|November 5, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190736||192617|
NCT00176488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539565|Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer|A Phase II Trial of Sequential Epirubicin/Vinorelbine in Patients With Advanced Breast Cancer||Rutgers, The State University of New Jersey|No|Terminated|June 2003|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|21 Years|N/A|No|||September 2013|September 18, 2013|September 12, 2005|Yes|Yes|Competing studies|No|September 18, 2013|https://clinicaltrials.gov/show/NCT00176488||193674|
NCT00177333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pittirb0504092|Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens|Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens||University of Pittsburgh|No|Completed|September 2005|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177333||193612|
NCT00192127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP113|Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults||MedImmune LLC||Completed|August 2004|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2|||300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2007|December 12, 2007|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192127||192514|
NCT00192140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM026|Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age|An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age||MedImmune LLC|Yes|Completed|June 2004|January 2005|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||345|||Both|5 Years|49 Years|Accepts Healthy Volunteers|||December 2007|December 27, 2007|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192140||192513|
NCT00192582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIMHINTRPT|AIMHI NT Relapse Prevention Trial|Relapse Prevention Trial in Top End Aboriginal People With Chronic Mental Illness||Menzies School of Health Research||Active, not recruiting|July 2005|August 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||90|||Both|18 Years|N/A|No|||May 2007|May 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192582||192480|
NCT00192894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-04-0019|New Methods to Detect a Decrease in Heart Function|Cardiac Output Changes During Onset of Spinal Anesthesia in Elderly Patients||Rigshospitalet, Denmark||Completed|May 2004|March 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||32|||Both|60 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192894||192456|
NCT00193141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 23|Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer|Paclitaxel, Carboplatin, Infusional 5-Fluorouracil, and Radiation Therapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer||SCRI Development Innovations, LLC||Completed|October 1999|July 2007|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193141||192437|
NCT00193362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 54|Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer|Phase III Randomized Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine as First-Line Chemotherapy for Stage IIIB and IV Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|June 2004|September 2007|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193362||192420|
NCT00193349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 59|Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer|Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC||SCRI Development Innovations, LLC||Completed|September 2002|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||January 2008|June 24, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193349||192421|
NCT00193336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 71|Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer|Phase II Trial of Single Agent ZD1839 (Iressa) in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|March 2003|September 2005|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193336||192422|
NCT00193544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MM 03|Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma|Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients With Refractory Multiple Myeloma||SCRI Development Innovations, LLC||Completed|March 2002|January 2009|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2009|January 21, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193544||192406|
NCT00193804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/158/2004/Cx_IMRT TRIAL|A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix|A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix||Tata Memorial Hospital|Yes|Active, not recruiting|February 2005|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|65 Years|No|Probability Sample|Patients with histologically proven cervical cancers, FIGO Stage IIb eligible for the        study will be invited for the study|April 2015|April 24, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193804||192386|
NCT00193999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 02-0601-B|Do Nasogastric Tubes After Cardiac Surgery Reduce Nausea and Vomiting|Do Nasogastric Tubes After Cardiac Surgery Reduce Nausea and Vomiting. A Prospective Randomized Clinical Trial.||University Health Network, Toronto||Completed|February 2003|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|80 Years|No|||September 2008|October 26, 2009|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00193999||192371|
NCT00194012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|At Risk|Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder|Aripiprazole in At-Risk Children With Symptoms of Bipolar Disorder||University Hospital Case Medical Center|Yes|Completed|August 2004|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|September 11, 2005|Yes|Yes||No|June 26, 2013|https://clinicaltrials.gov/show/NCT00194012||192370|
NCT00194285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-AR048241-03|FDG-PET Imaging in Painful Joint Prosthesis|FDG-PET Imaging in Painful Joint Prosthesis (Protocol Amendment, Version 11, Dated 9/2005)||University of Pennsylvania||Active, not recruiting|March 2001|||January 2016|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|530|||Both|18 Years|N/A|No|Non-Probability Sample|Five hundred patients selected for entry into this study will be men or women of any        ethnic background who are scheduled to undergo clinical and diagnostic evaluation for        joint prosthesis revision by members of the Department of Orthopedic Surgery at the        University of Pennsylvania Health System (Hospital of University of Pennsylvania and        Pennsylvania Hospital) or by the collaborating physicians at the Rothman Institute at        Thomas Jefferson University Hospital or the VA Hospital.|August 2006|December 8, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194285||192349|
NCT00194298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-DK063579-04|FDG-PET Imaging in Complicated Diabetic Foot|FDG-PET Imaging in Complicated Diabetic Foot (Protocol Version Dated 3/01/2004)||University of Pennsylvania||Active, not recruiting|October 2002|||January 2016|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|240 patients selected for entry into this study will be men or women of any ethnic        background diagnosed with diabetic foot disease and/or patients with diabetes and        suspected infection(s) below the hip by members of the Diabetes Center of the Department        of Medicine, the Division of Vascular Surgery of the Department of Surgery at the        University of Pennsylvania Health System (Hospital of the University of Pennsylvania), the        Ankle and Foot Medical Centers of Delaware Valley (PENN Presbyterian Hospital, and the        Pennsylvania Orthopedic Foot and Ankle Surgeons (Pennsylvania Hospital).|August 2006|December 8, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194298||192348|
NCT00190463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020905|Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia|The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT"||Assistance Publique - Hôpitaux de Paris||Terminated|April 2003|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||September 2006|September 20, 2006|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00190463||192638|
NCT00190775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9043|A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder: With a Secondary Examination of Impact of Treatment on Family Functioning||Eli Lilly and Company|No|Completed|September 2004|October 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|502|||Both|18 Years|N/A|No|||October 2010|August 18, 2011|September 12, 2005|Yes|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00190775||192614|
NCT00190450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 001106|MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease|Multicentric Intracerebral Grafting in Huntington's Disease|MIG-HD|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2002|May 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||March 2007|July 27, 2012|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00190450||192639|
NCT00176293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-GU-52-B|Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer|A Randomized Phase II Trial of Doxil With or Without Dexamethasone in Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer||University of Kentucky||Terminated|October 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Male|18 Years|N/A|No|||April 2015|April 20, 2015|September 13, 2005|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00176293||193689|
NCT00177034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0310M52823|Examination Of Vitiligo Skin Samples Before and After UVB Treatment|Characterization of Keratinocyte Populations From Normal, Perilesional and Lesional Skin in Vitiligo Patients by Laser Capture Microdissection and Gene Array Analysis Before and After Narrow Band UVB Treatment||University of Minnesota - Clinical and Translational Science Institute||Terminated|November 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177034||193633|
NCT00192166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P522|Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months|Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months||MedImmune LLC||Completed|October 2002|May 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Both|11 Months|24 Months|Accepts Healthy Volunteers|||December 2008|December 5, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00192166||192511|
NCT00192595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHWG001|Tenofovir in HIV/HBV Coinfection|Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection|TICO|Kirby Institute|Yes|Completed|January 2004|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|70 Years|No|||March 2015|March 30, 2015|September 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192595||192479|
NCT00192907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-160/02 Main|Inflammation and Infection in Trauma, Role in Posttraumatic Complications|||Rigshospitalet, Denmark||Active, not recruiting|March 2003|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||380|||Both|18 Years|N/A|No|||September 2005|September 16, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192907||192455|
NCT00192920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-PJJS-12092005|Evaluation of the Quality of the Transfusion Practice at Rigshospitalet, Copenhagen University Hospital|||Rigshospitalet, Denmark||Recruiting|January 2000|December 2010||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||September 2005|October 18, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192920||192454|
NCT00192933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-41-3996|Evaluation of the Quality of the NovoSeven (rFVIIa) Tratment Practice at Rigshospitalet, Copenhagen University Hospital|||Rigshospitalet, Denmark||Recruiting|January 2000|December 2010||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||September 2005|October 18, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192933||192453|
NCT00193154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 17|OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma|A Phase II Trial of Tarceva (OSI-774) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Renal Cell Carcinoma||SCRI Development Innovations, LLC|No|Completed|February 2003|March 2014|Actual|January 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193154||192436|
NCT00193375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 72|Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer|Phase II Trial of Concurrent Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab (Avastin) in the Treatment of Patients With Limited Stage Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|August 2003|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|September 12, 2005|No|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT00193375||192419|
NCT00193570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 34|Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors|A Phase I Study of Topotecan in Combination With Docetaxel in Patients With Refractory and/or Advanced Solid Tumors||SCRI Development Innovations, LLC||Completed|February 2002|January 2009|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||January 2009|January 22, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193570||192404|
NCT00193557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MM 06|Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma|Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma||SCRI Development Innovations, LLC||Completed|May 2004|January 2009|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2009|June 28, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193557||192405|
NCT00194038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10864-01-L0363|Aripiprazole in Late Life Bipolar Disorder|Aripiprazole in Late Life Bipolar Disorder||University Hospital Case Medical Center|No|Completed|April 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|N/A|No|||January 2010|December 16, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194038||192368|
NCT00193817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH 111/IM-2004|Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial|||Tata Memorial Hospital||Recruiting|January 2005|December 2015||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||700|||Both|18 Years|70 Years|No|||July 2005|February 6, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00193817||192385|
NCT00194025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10850-01-L0348|Valproate in Late Life Schizophrenia|Add-on Valproate in Late Life Schizophrenia||University Hospital Case Medical Center|No|Completed|November 2004|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|N/A|No|||February 2011|December 16, 2014|September 13, 2005|Yes|Yes||No|January 26, 2009|https://clinicaltrials.gov/show/NCT00194025||192369|The findings of this study must be interpreted cautiously given the limitations of small sample size, open-label, add-on design and lack of a control or comparator group. The mean age of 61 years is not representative of the “old-old” populations.
NCT00190242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050706|Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients|Study of Immunogenicity of Anti-HAV Immunisation in HIV-1 Infected Patients, Co-infected or Not With HBV and/or HCV. HEP.A.VAC Study.|HEPAVAC|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2003|October 2009|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|55 Years|No|||June 2005|December 15, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190242||192655|
NCT00190255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030412|Pharmacogenetics of Gastrointestinal Bleeding|Pharmacogenetics of Gastrointestinal Bleeding Under Nonsteroidal Anti-inflammatory Drugs : the Role of Cytochrome P450 2C9||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2004|July 2007|Actual|July 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the      use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for      the elimination of several NSAIDs. This protein is inactive in 12% of the subjects because      of genetic mutations. We hypothesized that individuals carrying such mutations should be at      higher risk of gastrointestinal bleeding since they display decreased NSAIDs elimination.|Both|18 Years|N/A|No|Non-Probability Sample|Inclusion Criteria:          -  Upper gastrointestinal bleeding revealed by hematemesis, melena or lowering of at             least 2g/dl of haemoglobin          -  Endoscopic report of gastrointestinal ulcer or haemorrhagic lesion          -  Immediate antecedents of NSAID therapy        Exclusion Criteria:          -  Cirrhosis (Child B or C)          -  Coma          -  Concomitant therapy with substrates or inhibitors of CYP2C9 : ketoconazole,             itraconazole, ritonavir, phenobarbital, rifampicin, depakine, phenytoin, St John's             worts          -  Patients treated by a NSAID metabolized by CYP2C9 and a NSAID not metabolized by             CYP2C9|March 2007|May 9, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00190255||192654|
NCT00190476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0207|Elderly NSCLC/D vs DP (JCOG0207)|Randomized Controlled Trial Comparing Docetaxel-Cisplatin Combination With Docetaxel Alone in Elderly Patients With Advanced Non-Small-Cell Lung Cancer(JCOG0207)||Japan Clinical Oncology Group|Yes|Terminated|April 2003|April 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||230|||Both|70 Years|N/A|No|||May 2007|May 31, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190476||192637|
NCT00191074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|843|Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature|Phase III Study of Humatrope in Non-Growth Hormone Deficient Children With Short Stature||Eli Lilly and Company||Completed|February 2001|January 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||11|||Both|9 Years|16 Years|No|||March 2007|March 7, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00191074||192591|
NCT00191087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2686|Duloxetine in the Treatment of Stress Urinary Incontinence.|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence.||Eli Lilly and Company||Completed|April 2001|May 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||458|||Female|18 Years|75 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191087||192590|
NCT00176514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074|A Pilot Trial to Assess the Effects of Green Tea in the Prevention of Therapy-Induced Mucositis|A Pilot Trial to Assess the Effects of Green Tea in the Prevention of Therapy-Induced Mucositis||Rutgers, The State University of New Jersey|No|Terminated|July 2000|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||37|||Both|18 Years|N/A|No|||December 2009|December 10, 2009|September 12, 2005||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00176514||193672|
NCT00177359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508137|Restoring Skill in Walking|Restoring Skill in Walking||University of Pittsburgh|Yes|Completed|November 2005|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|65 Years|N/A|No|||December 2007|December 12, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00177359||193610|
NCT00177606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0409061|Donors After Cardiac Death: Validating Identification Criteria|Donors After Cardiac Death: Validating Identification Criteria||University of Pittsburgh||Completed|July 2003|December 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||600|||Both|N/A|90 Years|No|||March 2008|March 31, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177606||193592|
NCT00192608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASK-500 14047|A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study|A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation.|ASK-500|Kirby Institute|No|Completed|November 2004|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2009|June 25, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00192608||192478|
NCT00192946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-230/04|The CRT-KIR Study (Cardiac Resynchronization Therapy [CRT] in the Early Phase After Heart Surgery)|Cardiac Resynchronization Therapy (CRT) in the Early Phase After Heart Surgery||Rigshospitalet, Denmark||Withdrawn||September 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||February 2006|July 9, 2007|September 11, 2005|||The study population is smaller than expected. No subjects were included.|No||https://clinicaltrials.gov/show/NCT00192946||192452|
NCT00193167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 56|Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer|Phase II Study of Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer||SCRI Development Innovations, LLC||Completed|January 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193167||192435|
NCT00193388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 66|Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer|Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|September 2002|February 2007||December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193388||192418|
NCT00193596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI UNKPRI 12|Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site|A Randomized, Phase III Comparison of Gemcitabine/Irinotecan Followed by IRESSA Versus Paclitaxel/Carboplatin/Etoposide Followed by IRESSA in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site||SCRI Development Innovations, LLC|No|Completed|September 2003|June 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||March 2013|March 22, 2013|September 12, 2005|No|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00193596||192402|
NCT00193583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 40|Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors|A Phase I Study of Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Patients With Refractory and/or Advanced Solid Tumors||SCRI Development Innovations, LLC||Completed|May 2003|May 2005|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||May 2011|May 3, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193583||192403|
NCT00193843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/177/2004|Oral Cancer Adjuvant Therapy (OCAT) Trial|Phase III Trial of Surgery Followed by Conventional RT(5fr/Week)Vs.Concurrent Chemo-Radiotherapy Vs.Accelerated RT(6fr/Week)in High Risk, Loco-Regionally Advanced, Stage III&IVA, Resectable, Squamous Cell Carcinomas of Oralcavity||Tata Memorial Hospital||Recruiting|June 2005|June 2017||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||900|||Both|18 Years|65 Years|No|||September 2005|December 23, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00193843||192383|
NCT00193856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 03.04|RADAR Trial - Randomised Androgen Deprivation and Radiotherapy|A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate.||Trans-Tasman Radiation Oncology Group (TROG)|Yes|Active, not recruiting|October 2004|August 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1000|||Male|18 Years|N/A|No|||January 2016|January 19, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00193856||192382|
NCT00194311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801452|Human Papillomavirus (HPV) Infection in Pregnancy|||University of Pennsylvania||Recruiting|April 2005|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Anticipated|620|||Female|13 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 20, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00194311||192347|
NCT00194324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708889|Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina|Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE||University of Pennsylvania|No|Completed|July 2004|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label||||12|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 8, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194324||192346|
NCT00189995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-4000|Clozapine IM and Aggression in Schizophrenic Patients|Intramuscular Clozapine in the Management of Aggression in Schizophrenic Patients||Beersheva Mental Health Center||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||October 2005|July 23, 2013|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00189995||192674|
NCT00190008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3529|Piracetam for Treatment Tardive Dyskinesia|Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study||Beersheva Mental Health Center||Completed|August 2003|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|No|||November 2009|November 23, 2009|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190008||192673|
NCT00190021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-3495CTIL|Donepezil Treatment of Psychotic Symptoms in Dementia Patients|Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type||Beersheva Mental Health Center||Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|65 Years|90 Years|No|||October 2005|September 5, 2010|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00190021||192672|
NCT00190801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6154|Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma|Open-Label Single-Arm Phase 2 Study of ALIMTA Plus Cisplatin in Korean Patients With Advanced Gastric Carcinoma||Eli Lilly and Company||Completed|September 2003|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|70 Years|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190801||192612|
NCT00191113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|817/4419|Somatropin Treatment to Final Height in Turner Syndrome|Humatrope Treatment to Final Height in Turner's Syndrome|GDCT|Eli Lilly and Company|Yes|Completed|February 1989|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Female|7 Years|13 Years|No|||December 2009|December 13, 2009|September 12, 2005|Yes|Yes||No|December 1, 2008|https://clinicaltrials.gov/show/NCT00191113||192588|
NCT00190788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6001|Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion|A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96 Hour Infusion With Commercial Drotrecogin Alfa (Activated)||Eli Lilly and Company||Completed|June 2004|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||October 2007|October 10, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190788||192613|
NCT00191100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4015|Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix|Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA||Eli Lilly and Company||Completed|May 2002|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|515|||Female|18 Years|70 Years|No|||August 2009|August 8, 2009|September 12, 2005|Yes|Yes||No|March 30, 2009|https://clinicaltrials.gov/show/NCT00191100||192589|
NCT00177021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9908M15841|Aldara for the Treatment of Extensive Alopecia Areata|Aldara for the Treatment of Extensive Alopecia Areata||University of Minnesota - Clinical and Translational Science Institute||Completed|October 2000|August 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 8, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00177021||193634|
NCT00177372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pittirb0409119|Mifepristone and Misoprostol for Fetal Demise|Mifepristone and Misoprostol for the Treatment of Early Pregnancy Failure: a Pilot Clinical Trial|MIMID|University of Pittsburgh|No|Completed|January 2005|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177372||193609|
NCT00192959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 02-065/03|Xenon Inhalation During Orthopaedic Surgery in Elderly Subjects.|Xenon Inhalation as Cover Sedation During Orthopaedic Surgery in Elderly Subjects Comparing the Effects of Inhaled Xenon and Intravenous Propofol||Rigshospitalet, Denmark||Completed|March 2004|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||44|||Both|60 Years|N/A|No|||June 2005|September 16, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192959||192451|
NCT00193180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 74|Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer|Phase II Trial of Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|May 2005|January 2009|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|September 12, 2005||No||No|March 25, 2013|https://clinicaltrials.gov/show/NCT00193180||192434|
NCT00193401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 65|Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer|Phase II Trial of Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|August 2002|November 2004||June 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193401||192417|
NCT00193609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI UNKPRI 14|Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site|A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site||SCRI Development Innovations, LLC|No|Completed|September 2004|January 2009|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|September 12, 2005|No|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00193609||192401|
NCT00193882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 03.01|Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.|A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients Treated With Radiotherapy vs ChemoRadiotherapy.||Trans-Tasman Radiation Oncology Group (TROG)|Yes|Completed|July 2003|March 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||July 2013|July 11, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00193882||192380|
NCT00193869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 01.05|SuperDEX Trial (Comparison of Two Doses of Dexamethasone for Malignant Spinal Cord Compression Treated by Radiotherapy).|A Pilot Randomised Comparison of Dexamethasone 96 mg Versus 16 mg Per Day for Malignant Spinal Cord Compression Treated by Radiotherapy||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|September 2001|December 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|17 Years|N/A|No|||May 2007|May 8, 2007|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00193869||192381|
NCT00194103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708753|Effectiveness of Extended Telephone Monitoring||ETM|University of Pennsylvania||Completed|May 2004|April 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|252|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2010|June 25, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194103||192363|
NCT00194376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802805|Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea|Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea||University of Pennsylvania||Completed|June 2005|June 2007|Actual|September 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2010|September 22, 2010|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00194376||192342|
NCT00193830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH/11062/1996/Cx_HDR STUDY|High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix|High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix||Tata Memorial Hospital||Completed|May 1996|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||750|||Female|18 Years|65 Years|No|||January 2007|May 5, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00193830||192384|
NCT00194051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-03-10|Symptomatic, Biomechanical and Radiographic Outcomes in Knee Osteoarthritis Following Gastric Bypass Surgery|Symptomatic, Biomechanical and Radiographic Outcomes in Knee Osteoarthritis Following Gastric Bypass Surgery||University Hospital Case Medical Center||Active, not recruiting|February 2003|May 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||35|||Both|35 Years|60 Years|No|||September 2005|October 5, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00194051||192367|
NCT00194064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1DMC-X136|Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine|Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Disorder Mania||University Hospital Case Medical Center|Yes|Terminated|July 2002|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|70 Years|No|||December 2014|December 1, 2014|September 13, 2005|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00194064||192366|
NCT00194363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA106851-01|Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status|The PAL Trial (Physical Activity and Lymphedema)||University of Pennsylvania|Yes|Active, not recruiting|October 2005|June 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|295|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 15, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194363||192343|
NCT00194337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515329|Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer|Evaluation of Multimodality Breast Imaging: Project 3-Lesion Staging||National Cancer Institute (NCI)||Completed|October 1999|||June 2007|Actual|Phase 2/Phase 3|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|400|||Female|18 Years|N/A|No|||January 2007|May 9, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00194337||192345|
NCT00190489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG9802|A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer|Phase III Trial of Doxorubicin /Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D (AC-D) as Front-Line Chemotherapy for Metastatic Breast Cancer: Japan Clinical Oncology Group Trial (JCOG9802)||Japan Clinical Oncology Group|Yes|Completed|January 1999|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||450|||Female|20 Years|75 Years|No|||February 2009|February 2, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00190489||192636|
NCT00191126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3532|Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC|Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages(T2N0, T1 - 2N1, T3N0 AND T3N1) Non-Small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|Yes|Completed|September 2000|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||June 2008|June 20, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00191126||192587|
NCT00191139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4697|Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)|A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC||Eli Lilly and Company|No|Completed|March 2003|February 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|September 12, 2005|Yes|Yes||No|November 20, 2009|https://clinicaltrials.gov/show/NCT00191139||192586|
NCT00191490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6549|A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer|A Multicenter Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel (RP56976, TAXOTERE *) and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non Small Cell Lung Cancer||Eli Lilly and Company||Completed|July 2002|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||162|||Both|18 Years|70 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191490||192560|
NCT00191477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6138|Instillation of Gemcitabine in Patients With Superficial Bladder Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder||Eli Lilly and Company|Yes|Terminated|January 2004|June 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|September 12, 2005|Yes|Yes|The study was stopped early for futility reasons.|No|March 17, 2009|https://clinicaltrials.gov/show/NCT00191477||192561|The study was stopped early for futility reasons. In addition, due to limitations in this databank, some original outcome measures are not disclosed. Time to Recurrence and Recurrence-Free Survival in Subgroups had data that were un-estimated.
NCT00176800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2001-007|Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma|Pre-Operative Chemoradiation Followed by Post-Operative Tetrathiomolybdate (TM) in Patients With Loco-Regional Esophageal Carcinoma (UMCC 2001-007)||University of Michigan Cancer Center|Yes|Active, not recruiting|November 2001|November 2015|Anticipated|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176800||193651|
NCT00192972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASCAR|A Randomized Trial of the Ostial Versus the Extra-Ostial Ablation Strategy for Atrial Fibrillation|A Randomized Trial of the Ostial Versus the Extra-Ostial Ablation Strategy for Atrial Fibrillation (LASso Vs CARto)||Rigshospitalet, Denmark||Completed|November 2002|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||100|||Both|18 Years|N/A|No|||November 2003|December 21, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192972||192450|
NCT00193193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 10|Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma|A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma||SCRI Development Innovations, LLC||Completed|August 2000|February 2007|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||July 2010|August 3, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193193||192433|
NCT00193414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 91|Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study of First-Line Therapy With Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|May 2005|August 2009|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|September 12, 2005|No|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT00193414||192416|
NCT00193622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI UNKPRI 15|Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site|A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site||SCRI Development Innovations, LLC||Completed|April 2004|January 2009|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||September 2010|September 15, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193622||192400|
NCT00193635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL214|Pilot Study of Mycophenolate Mofetil in Congenital Uropathies|Pilot Study of Mycophenolate Mofetil in Congenital Uropathies||Northwell Health|Yes|Completed|March 2002|August 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|3 Years|16 Years|No|||October 2007|October 17, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00193635||192399|
NCT00177710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0408180|Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study|Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study||University of Pittsburgh||Completed|January 2006|December 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|48|||Both|18 Years|65 Years|No|||December 2008|December 16, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177710||193584|
NCT00173524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700718|PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)|PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) : A Cost-Effectiveness Analysis and Cost-Utility Analysis||National Taiwan University Hospital||Active, not recruiting|September 2005|September 2005|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|N/A|No|Non-Probability Sample|Patients accrued to a gefitinib first line prospective study.|April 2009|May 18, 2009|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00173524||193901|
NCT00178243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 2298|Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation|A Phase I/II Trial Of the Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation Delivered by 3D Conformal Radiation Therapy and Radiosurgery||University of Rochester||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2006|September 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178243||193544|
NCT00179101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040251|Effect of Deep Brain Stimulation on Depression and Quality of Life in Parkinson’s Patients|Effect of Deep Brain Stimulation on Depression and Quality of Life in Parkinson’s Patients||Vanderbilt University||Completed|April 2004|November 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||42|||Both|50 Years|85 Years|No|||August 2006|August 11, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179101||193479|
NCT00179400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-200|Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone|The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans||Albert Einstein College of Medicine of Yeshiva University||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|||||||Both|18 Years|65 Years|No|||March 2012|March 7, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179400||193458|
NCT00179413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000002|Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders.|Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial||Beth Israel Deaconess Medical Center||Active, not recruiting|January 2001|December 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||800|||Both|18 Years|75 Years|No|||September 2005|June 23, 2006|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00179413||193457|
NCT00180427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version vom 01.03.2001|VERRARI - "Are Ventricular Arrhythmic Episodes Reduced by Rate Response in ICDs?"|VERRARI - "Are Ventricular Arrhythmic Episodes Reduced by Rate Response in ICDs?"||Guidant Corporation||Completed|June 2001|November 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||75|||Both|18 Years|80 Years|No|||April 2008|April 22, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180427||193379|
NCT00186277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLDR0001|Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer|Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer||Stanford University|Yes|Completed|December 2003|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|18 Years|70 Years|No|||March 2011|March 28, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186277||192955|
NCT00186667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT81|Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease|An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant||Stanford University||Completed|January 1999|September 2005|Actual|January 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||July 2010|July 23, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00186667||192926|
NCT00186953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTUS|Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors|Determination of Optimal Dose and Safety Profile of Optison Ultrasound Contrast Agent in Pediatric Solid Tumor Patients||St. Jude Children's Research Hospital|No|Completed|June 2002|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|2 Years|20 Years|No|||September 2011|September 19, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00186953||192904|
NCT00186966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAL|Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia|A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia||Dutch Childhood Oncology Group|Yes|Completed|March 2002|September 2010|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|394|||Both|N/A|18 Years|No|||April 2011|April 5, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00186966||192903|
NCT00187213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR03019HF|B-Left HF: Biventricular Versus Left Univentricular Pacing With Implantable Cardiac Defibrillator (ICD) Back-Up in Heart Failure Patients|Biventricular Versus Left Univentricular Pacing With ICD Back-up in Heart Failure Patients||St. Jude Medical|Yes|Completed|December 2004|January 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2008|February 21, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187213||192884|
NCT00177879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0411096|Usability of a Website for People With Schizophrenia|Schizophrenia Website Usability||National Institute of Mental Health (NIMH)||Withdrawn|August 2005|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||August 2008|May 6, 2015|September 13, 2005|||Funding was never granted for this study. No participants were ever enrolled.|No||https://clinicaltrials.gov/show/NCT00177879||193571|
NCT00177892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0089|Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress|OSA and Metabolic Syndrome: Role of Oxidative Stress||National Institute on Aging (NIA)|Yes|Recruiting|September 2003|August 2008|Anticipated|August 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Anticipated|76|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2008|February 28, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177892||193570|
NCT00178451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 10187|Stroke Prevention With Abciximab in Carotid Endarterectomy|Stroke Prevention With Abciximab in Carotid Endarterectomy||University of Rochester||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00178451||193528|
NCT00178711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01 NS043353-06|Effects of Hypothermia Upon Outcomes After Acute Traumatic Brain Injury|National Acute Brain Injury Study: Hypothermia IIR|NABIS:HIIR|The University of Texas Health Science Center, Houston|Yes|Terminated|November 2005|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|16 Years|45 Years|No|||September 2014|September 13, 2014|September 13, 2005|Yes|Yes|Futility|No|July 31, 2014|https://clinicaltrials.gov/show/NCT00178711||193508|Early termination for futility.
NCT00179348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI# 00-7|Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer|Evaluation of a Yoga-Based Cancer Rehabilitation Program||Albert Einstein College of Medicine of Yeshiva University|No|Active, not recruiting|February 2001|||January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|December 9, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179348||193462|
NCT00179686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NSCL-001|A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer|A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer||Celgene||Completed|March 2005|July 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2006|December 19, 2006|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00179686||193436|
NCT00179023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020548|The Autonomic Nervous System and Obesity|The Autonomic Nervous System and Obesity||Vanderbilt University|No|Recruiting|April 2003|October 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|288|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179023||193485|
NCT00179036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060426|Biomagnetic Signals of Intestinal Ischemia II|Biomagnetic Signals of Intestinal Ischemia II|SQUID|Vanderbilt University|No|Recruiting|January 2000|June 2012|Anticipated|||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|June 2011|June 24, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179036||193484|
NCT00180011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20041332|Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma|Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma||DiMango, Emily, M.D.|No|Completed|September 2005|February 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|50 Years|No|||February 2012|February 27, 2012|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00180011||193411|
NCT00180024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKPD 01-02|Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.|||Technische Universität Dresden||Completed|January 2002|September 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00180024||193410|
NCT00180336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0004|Safety and Efficacy Study of RENEWAL 4 AVT|CONTAK RENEWAL 4 AVT Field Following||Boston Scientific Corporation||Completed|July 2004|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||170|||Both|18 Years|N/A|No|||June 2007|June 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180336||193386|
NCT00178256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 1597|Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer|A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers||University of Rochester||Completed|June 1998|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|September 12, 2005||No||No|December 11, 2013|https://clinicaltrials.gov/show/NCT00178256||193543|
NCT00177983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063484|Web-based Support for People With Schizophrenia and Their Families|Support to Patients and Families||University of Pittsburgh||Completed|January 2003|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind||||80|||Both|14 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177983||193564|
NCT00178516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 10160|Vitamin E and Male Infertility|Vitamin E and Male Infertility||University of Rochester|No|Completed|June 2004|December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|Samples With DNA|whole blood, serum, semen|Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infertility clinic, community sample|July 2009|July 29, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178516||193523|
NCT00178776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA015453-02|A Transtheoretical Model Group Therapy for Cocaine|A Transtheoretical Model Group Therapy for Cocaine||National Institute on Drug Abuse (NIDA)|No|Completed|October 2003|June 2007|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|65 Years|No|||September 2014|September 29, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178776||193503|
NCT00178789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-05-0011|Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis|Prospective Observational Trial of Point-of-Care, Limited Ultrasonography (PLUS) for Lower Extremity Deep Venous Thrombosis in the Emergency Department: The Sonography Outcomes Assessment Program (SOAP-4 Trial)||The University of Texas Health Science Center, Houston||Completed|September 2005|May 2007|Actual|||Phase 1/Phase 2|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|51|||Both|18 Years|N/A|No|||May 2007|May 22, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178789||193502|
NCT00179114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMPEP-9.1|Vanderbilt University Spasticity Management Program Evaluation Plan|Vanderbilt University Spasticity Management Program Evaluation Plan||Vanderbilt University|No|Completed|August 2002|February 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||August 2007|August 17, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179114||193478|
NCT00176280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-GU-51-B|Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma|A Randomized Phase II Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemcitabine and 5-Fluorouracil (5-FU) in Patients With Metastatic Renal Cell Carcinoma (RCC)||University of Kentucky||Withdrawn|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|September 9, 2005|||Slow accrual|No||https://clinicaltrials.gov/show/NCT00176280||193690|
NCT00180453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-350|SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System|SPIRIT First: A Clinical Evaluation of an Investigational Device. The Abbott XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions||Abbott Vascular|Yes|Completed|December 2003|June 2009|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2009|January 5, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180453||193377|
NCT00186693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2453|How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction in Asthma|How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction in Asthma||St. Joseph's Healthcare Hamilton||Withdrawn|September 2006|June 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|65 Years|No|Probability Sample|adults with asthma|July 2006|July 25, 2011|September 10, 2005|||never received funding|No||https://clinicaltrials.gov/show/NCT00186693||192924|
NCT00186706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.P. #04-2326|Selenium Supplementation in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effect of Selenium Supplementation on Anti-Oxidant Levels in COPD Patients: A 12-Week, Randomized, Placebo-Controlled Trial||St. Joseph's Healthcare Hamilton||Completed|September 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|60|||Both|40 Years|N/A|No|||May 2008|May 21, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00186706||192923|
NCT00186732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2484|Comparison of Subcuticular Suture Versus Surgical Staples for Closure of Pfannenstiel Skin Incisions|Pfannenstiel Incision Closure: Subcuticular Suture Versus Surgical Staples||St. Joseph's Healthcare Hamilton||Completed|July 2005|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|288|||Female|N/A|N/A|No|||August 2011|August 10, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00186732||192921|
NCT00186745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 5723|Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure|Tinzaparin for Treatment of Venous Thromboembolism in Renal Insufficiency: A Pilot Study||St. Joseph's Healthcare Hamilton|No|Recruiting|March 2005|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186745||192920|
NCT00187226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT1|A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects|A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects||St. Jude Children's Research Hospital|No|Completed|June 1997|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Both|8 Months|25 Years|No|||August 2012|August 17, 2012|September 13, 2005|Yes|Yes||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00187226||192883|
NCT00177918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0212095|Prospective Evaluations of Infectious Complication in Lung Transplant Recipients|Prospective Evaluations of Infectious Complications in Lung Transplant Recipients||University of Pittsburgh|Yes|Recruiting|August 2006|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|All biologic samples will be under the control of the principal investigator of this      research project. To protect confidentiality, all personal identifiers will be removed and      replaced with a specific code number. The information linking these code numbers to the      corresponding subjects' identities will be kept in a separate, secure location. The      investigators on this study will keep the samples indefinitely. All samples that are      provided to outside facilities will be sent with a code number. Samples may be sent to other      investigators not associated with this study to perform diagnostic testing (e.g., viral,      fungal, bacterial and immunological). All samples will be provided to investigators not      associated with the study without any identifiers and only contain a code number. If a      subject withdraws and provides the request in writing, samples collected and not already      processed will be destroyed.|Both|18 Years|N/A|No|Non-Probability Sample|all lung transplant patients transplanted at UPMC|December 2015|December 16, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177918||193569|
NCT00178724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002187|North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury - Registry|North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury|NACTN|The Methodist Hospital System|No|Recruiting|July 2005|July 2023|Anticipated|July 2020|Anticipated|Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Admitted to a NACTN hospital through the Emergency Department at the time of injury.|March 2016|March 15, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178724||193507|
NCT00179049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 030261|Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant|Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)||Vanderbilt University|No|Completed|April 2003|April 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant        for various hematologic conditions|December 2008|December 12, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179049||193483|
NCT00179062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990472|Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder|Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients||Vanderbilt University|No|Completed|February 2000|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|60 Years|No|||August 2008|August 25, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179062||193482|
NCT00171925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446 DE01|Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I|Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I||Novartis||Terminated|August 2000|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||April 2012|April 5, 2012|September 13, 2005||No|Recruitment in study could not be reached after 8 yrs of recruiting|No|January 20, 2011|https://clinicaltrials.gov/show/NCT00171925||194024|Only exploratory analyses were performed as the trial was terminated early due to lack of obtaining the required sample size. Secondary Outcomes for Quality of Life and Bone Markers not posted due to sparse data.
NCT00179699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NSCL-002|Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer|Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer||Celgene||Terminated|September 2005|November 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||October 2005|November 2, 2005|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00179699||193435|
NCT00179712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-OVRY-002|Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma|Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma||Celgene||Completed|April 2005|November 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label||||60|||Female|18 Years|N/A|No|||December 2006|December 19, 2006|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00179712||193434|
NCT00179725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-OVRY-001|Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma|Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma||Celgene||Terminated|November 2005|June 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|18 Years|N/A|No|||April 2006|April 10, 2006|September 10, 2005||||||https://clinicaltrials.gov/show/NCT00179725||193433|
NCT00172523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701094|Metabolic Disorders in Polycystic Ovarian Syndrome|||National Taiwan University Hospital||Recruiting|October 2004|August 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Female|17 Years|40 Years|No|||October 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172523||193978|
NCT00172835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700208|Use of Procalcitonin in the Diagnosis of Pleural Effusion|Evaluation of Procalcitonin as a Diagnostic Tool for Patients With Pleural Effusion||National Taiwan University Hospital||Recruiting|March 2005|||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||100|||Both|18 Years|N/A|No|||March 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172835||193954|
NCT00172809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940209|Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease|A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C||National Taiwan University Hospital|Yes|Completed|July 2005|January 2007|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||June 2007|March 5, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172809||193956|
NCT00172822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940701|Appendicitis With Medical Treatment|||National Taiwan University Hospital||Recruiting|January 2003|June 2005||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||80|||Both|16 Years|N/A|No|||June 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172822||193955|
NCT00178009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403075|Developing and Assessing Competencies for Caregivers and Patients With Ventricular Assist Devices|Developing and Assessing Competencies for Patients, Caregivers and Health Professionals for the Care of Patients Implanted With Ventricular Assist Devices||University of Pittsburgh|No|Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|95 Years|No|Non-Probability Sample|Four males; 4 females. Mean age of 39.6 (age range = 26-67) Caucasian = 100%|February 2011|February 18, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178009||193562|
NCT00178269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 1328|Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix|A Phase Ii Clinical Study Using Weekly Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix||University of Rochester||Completed|January 2005|||June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||May 2009|May 15, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178269||193542|
NCT00178282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11098|Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence|Pilot Study: Low Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence||University of Rochester|No|Terminated|June 2005|October 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|23|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 2, 2011|September 12, 2005|||The study was terminated early due to poor subject enrollment.|No||https://clinicaltrials.gov/show/NCT00178282||193541|
NCT00178529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR035316|Intervention for Stroke Survivors and Their Spousal Caregivers|Intervention for Stroke Survivors and Their Spousal Caregivers||The University of Texas Health Science Center, Houston||Completed|July 2001|September 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||160|||Both|50 Years|N/A|No|||March 2007|March 2, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178529||193522|
NCT00179452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-000337|Yoga for Patients With Epilepsy|Is Yoga Safe for Patients With Epilepsy?||Beth Israel Deaconess Medical Center||Recruiting|October 2003|October 2004|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|64 Years|No|||December 2007|December 27, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179452||193454|
NCT00179816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 0499 Solid|Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors|High-Dose Chemotherapy With Tandem Peripheral Blood Stem Cell (PBSC) Rescue for the Treatment of High-Risk Pediatric Solid Tumors.||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|April 1999|September 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|21 Years|No|||October 2010|October 7, 2010|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179816||193426|
NCT00180115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK1-191|AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients|AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group.||Technische Universität Dresden||Completed|February 1996|November 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|16 Years|N/A|No|||July 2007|July 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180115||193403|
NCT00180466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-800|PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions|Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) An Imaging Study in Patients With Unstable Atherosclerotic Lesions||Abbott Vascular|Yes|Completed|October 2004|July 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|697|Samples With DNA|Aproximately 1 ML blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with an Acute Coronary Syndrome that require catheterization and        interventional treatment of a culprit lesion(s).|May 2010|May 24, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180466||193376|
NCT00176306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-391|Levofloxacin Pharmacokinetics (PK) in the Severely Obese|Levofloxacin Pharmacokinetics in the Severely Obese||University of Kentucky|No|Completed|January 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 12, 2012|September 12, 2005||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00176306||193688|The number of ambulatory volunteers was low The acutely ill cohort was a heterogeneous population We remain unable to predict the precise effect of all of these different physiologic processes on drug pharmacokinetics
NCT00186719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2182|How Smoking Causes COPD: Examination of Immune System Changes|How Smoking Causes COPD: Examination of Immune System Changes||St. Joseph's Healthcare Hamilton||Recruiting|May 2005|April 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|smokers and non-smokers|July 2011|July 25, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186719||192922|
NCT00187239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD292|Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study|Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search (REDUCE Study)||St. Jude Medical||Completed|July 2005|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187239||192882|
NCT00187252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR03001HF|Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity Therapy|Management of Atrial Fibrillation Suppression in AF-HF COmorbidity Therapy|MASCOT|St. Jude Medical|No|Completed|September 2003|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187252||192881|
NCT00178191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10466|Randomized Trial for Botox Urinary Incontinence|A Randomized Trial of Botox for Severe Urge Incontinence||University of Rochester|Yes|Completed|June 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|28|||Female|21 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 27, 2011|September 12, 2005||No||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00178191||193548|Please see published manuscripts for additional details
NCT00171548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AIT05|Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients|Project to Promote the Evaluation of Cardiovascular Risk in Clinical Practice, and Assess Its Evolution After the Implementation of Multifactorial Preventive Strategy Aimed at Reducing the Level of Global Risk (SCORE Algorithm) in Subjects With Metabolic Syndrome and a Risk Level of 5%||Novartis||Completed|October 2004|||July 2007|Actual|Phase 4|Observational|Time Perspective: Prospective|||Actual|600|||Both|40 Years|65 Years||||September 2008|September 19, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171548||194053|
NCT00171561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631B2404|Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.|A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria||Novartis||Completed|March 2003|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|144|||Both|40 Years|80 Years||||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171561||194052|
NCT00171938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BBR03|Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)|Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)||Novartis||Suspended|April 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||November 2009|November 20, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00171938||194023|
NCT00171951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2208E1|Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease|Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease||Novartis||Completed|August 2004|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00171951||194022|
NCT00172211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185-CL4|Comparison of Oxidative Stress and Insulin Resistance Before and After Using Physioneal in Peritoneal Dialysis Patients|Comparison of Oxidative Stress and Insulin Resistance Before and After Using Physioneal in Peritoneal Dialysis Patients||National Taiwan University Hospital||Completed|September 2005|December 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|70 Years|No|||January 2007|May 4, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172211||194002|
NCT00172848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700303|Mastery, Social Support and Depression of Patients With Major Depression|||National Taiwan University Hospital||Completed|October 2004|April 2005||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A||||July 2005|November 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172848||193953|
NCT00177723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0501019|Towards Reducing Resistance and Hematological Toxicity of Linezolid|Towards Reducing Resistance and Hematological Toxicity of Linezolid||University of Pittsburgh||Completed|August 2005|February 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective||||50|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177723||193583|
NCT00177463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chengappa L-carnosine|L-Carnosine for Bipolar I Disorder|A Pilot Add-on Randomized, Placebo Controlled Intervention Trial of Cognitive Enhancement in Persons With Bipolar Disorder Using an Antioxidant and Advanced Glycation End (AGE) Product Inhibitor: L-Carnosine||University of Pittsburgh|Yes|Completed|September 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00177463||193603|
NCT00178802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-01-111|Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers|Phase II Study of Mild Whole Body Hyperthermia Combined With 5-Fluorouracil/Interferon-a/Liposomal Doxorubicin in Patients With Advanced Malignancy||The University of Texas Health Science Center, Houston|Yes|Active, not recruiting|June 1996|December 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2010|April 22, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178802||193501|
NCT00178828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000373|Dynamic Measures of Neurochemistry in Mood Disorders|Dynamic Measures of Neurochemistry in Mood Disorders||Vanderbilt University||Active, not recruiting|October 2002|June 2015|Anticipated|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 23, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178828||193500|
NCT00179127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040643|Use of Insulin Glargine to Treat Diabetic Ketoacidosis|Early Use of Insulin Glargine in Diabetic Ketoacidosis||Vanderbilt University|No|Active, not recruiting|August 2004|September 2012|Anticipated|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|6 Years|18 Years|No|||June 2012|June 20, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179127||193477|
NCT00179140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20064|The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients|The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients||Vanderbilt University|No|Completed|November 2002|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|26|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179140||193476|
NCT00179803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 0398|Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors|Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors||Ann & Robert H Lurie Children's Hospital of Chicago|No|Active, not recruiting|March 1998|||January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Months|25 Years|No|||March 2011|March 10, 2011|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179803||193427|
NCT00179829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 0399|WT1 for the Detection of Minimal Residual Disease|Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR||Ann & Robert H Lurie Children's Hospital of Chicago||Completed|February 1999|April 2006|Actual|April 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|21 Years|No|||January 2008|January 14, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00179829||193425|
NCT00180128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK1-192|AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia|AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL)||Technische Universität Dresden||Recruiting|January 2000|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Both|16 Years|N/A|No|||July 2011|July 8, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00180128||193402|
NCT00180141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CDE16|Elidel-Study: Elidel in Patients With Atopic Dermatitis|Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods||Technische Universität Dresden|No|Completed|April 2005|June 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00180141||193401|
NCT00180440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSURE 1.3|INSURE: INcidence Free SUrvival Before and After Implantable Cardioverter Defibrillator (ICD) Replacement|INcidence Free SUrvival Before and After ICD Replacement||Guidant Corporation||Completed|July 2002|November 2008|Actual|November 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|528|||Both|18 Years|N/A|No|Non-Probability Sample|all patients who are considered for ICD replacement due to normal battery depletion|March 2009|March 25, 2009|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00180440||193378|
NCT00176267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-H&N-15-BMS|Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer|Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer||University of Kentucky|No|Active, not recruiting|September 2002|||January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00176267||193691|
NCT00176761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9947|Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine|A Phase II Trial Assessing Autologous, Tumor-Pulsed Dendritic Cells as a Tumor Vaccine Administered With IL-2 in Patients With Metastatic Colorectal Cancer||University of Michigan Cancer Center||Terminated|March 2000|May 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||September 2006|September 6, 2006|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00176761||193654|
NCT00176774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 0075|Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma|A Pilot Trial of Irinotecan, 5-Fluorouracil, and Leucovorin Combined With the Anti-Angiogenesis Agent Tetrathiomolybdate in Metastatic Colorectal Carcinoma (UMCC 0075)||University of Michigan Cancer Center||Completed|February 2001|April 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2012|February 5, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176774||193653|
NCT00186368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0009|Microarray Analysis of Gene Expression in Prostate Tissues|Microarray Analysis of Gene Expression in Prostate Tissues (Translating Prostate Cancer Gene Expression Sub-types)||Stanford University|Yes|Active, not recruiting|April 1999|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Male|18 Years|N/A|No|Non-Probability Sample|Per the original application in 1999: After obtaining informed consent (via the Tissue        Bank consent), Protocol # 13873 (Continuing Review) PROTOCOL Print Date: September 22,        2010 PD: James Duane Brooks APPLICATION FORM Page 11 of 22 Review Type: Expedited Human        Subjects Research Medical Stanford University Title: Microarray Analysis of Gene        Expression in Prostatic Tissues (SQL 76528) Approval Period: 07/31/2010 - 06/30/2011        specimens will be collected from the Stanford University Department of Pathology (Tissue        Bank) for patients treated at Stanford. Patients will be followed up via chart or tumor        registries. Data will be used strictly for research purposes. Gene expression arrays are        done in Dr. Brook's laboratory.|February 2013|February 21, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186368||192948|
NCT00186381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT8N|Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission|Autologous Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission||Stanford University||Completed|November 1995|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|16 Years|69 Years|No|||July 2010|July 23, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186381||192947|
NCT00187278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR03006HF|Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization|Biventricular Pacing for Atrioventricular Block in Left Ventricular Dysfunction to Prevent Cardiac Desynchronization||St. Jude Medical|Yes|Completed|May 2003|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1833|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187278||192879|
NCT00186979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZD1839|Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors|A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors||St. Jude Children's Research Hospital|No|Completed|May 2003|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|21 Years|No|||October 2011|October 3, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00186979||192902|
NCT00186992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTSARC|Radiation Therapy to Treat Musculoskeletal Tumors|Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects||St. Jude Children's Research Hospital|No|Active, not recruiting|January 2003|January 2024|Anticipated|January 2024|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|280|||Both|N/A|25 Years|No|||July 2015|July 24, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00186992||192901|
NCT00187005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTXIV|Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia||St. Jude Children's Research Hospital|Yes|Terminated|July 1998|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|N/A|18 Years|No|||June 2008|March 29, 2011|September 12, 2005|||Toxicity|No||https://clinicaltrials.gov/show/NCT00187005||192900|
NCT00187265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR03005HF|Trip HF Study: Triple Resynchronization in Paced Heeart Failure Patients|Triple Resynchronization in Paced Heart Failure Patients||St. Jude Medical||Completed|April 2003|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2006|October 5, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187265||192880|
NCT00178204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSG-04-233-01-CPPB|Sleep Architecture and Chemotherapy-Related Fatigue|Sleep Architecture and Chemotherapy-Related Fatigue||University of Rochester|No|Completed|November 2004|December 2011|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|patients beginning chemotherapy|December 2014|December 3, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178204||193547|
NCT00178217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9507|Music Therapy During Botulinum Injections|Music Therapy as Procedural Support During Botulinum Injections for Pediatric Patients||University of Rochester|No|Completed|July 2002|November 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|101|||Both|1 Year|17 Years|No|||December 2015|December 22, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178217||193546|
NCT00178464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09661|Aspirin Prophylaxis in Sickle Cell Disease|Aspirin Prophylaxis in Sickle Cell Disease|START|University of Rochester|Yes|Completed|March 2005|November 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|2 Years|7 Years|No|||September 2011|November 29, 2011|September 13, 2005|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00178464||193527|
NCT00178477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 3701|Study of Breath-holding as a Means to Reduce Tumor Motion From Breathing|Feasibility Study for Gated External-Beam Radiotherapy for Patients With Internal, Extra-cranial Tumors||University of Rochester|No|Terminated|January 2002|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|September 13, 2005||No|Drs Okunieff and ODell have left the University of Rochester|No|August 12, 2011|https://clinicaltrials.gov/show/NCT00178477||193526|
NCT00171574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AES13|Antiproteinuric Effect of Valsartan and Lisinopril|Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up||Novartis||Completed|November 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|124|||Both|18 Years|70 Years||||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00171574||194051|
NCT00177203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021115|Agewise Project 3: Brief Behavioral Treatment of Insomnia in Primary Care|Agewise Project 3: Brief Behavioral Treatment of Insomnia in Primary Care|AW3|University of Pittsburgh|Yes|Completed|June 2003|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177203||193622|
NCT00172536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701147|Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft|Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft||National Taiwan University Hospital|Yes|Completed|October 2004|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|65|||Both|40 Years|70 Years|No|||March 2011|April 21, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00172536||193977|
NCT00172549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701176|Quality of Life and Its Related Factors of Patients With Major Depressive Disorder|||National Taiwan University Hospital||Completed|March 2004|October 2004||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Female|18 Years|N/A||||July 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00172549||193976|
NCT00177489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG13305|Coordinating Center for Caregiver Intervention Trial|Coordinating Center for Multisite Intervention Trial for Diverse Caregivers|REACH|University of Pittsburgh|Yes|Completed|June 2002|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|613|||Both|21 Years|N/A|No|||January 2016|January 4, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177489||193601|
NCT00177996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010403|Pharmacotherapy in Depression With Panic Spectrum|Pharmacotherapy in Depression With Panic Spectrum||University of Pittsburgh|No|Completed|October 2001|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||January 2016|January 14, 2016|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00177996||193563|
NCT00179153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040345|Improving The Nutritional Status Of The Malnourished Chronic Hemodialysis Patients In The State Of Tennessee|Improving The Nutritional Status Of The Malnourished Chronic Hemodialysis Patients In The State Of Tennessee||Vanderbilt University|No|Completed|February 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|352|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179153||193475|
NCT00179465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000078|Treating Schizophrenia by Correcting Abnormal Brain Development|Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex||Beth Israel Deaconess Medical Center||Recruiting|November 2003|||July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|25 Years|No|||July 2011|July 28, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179465||193453|
NCT00179478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000086|Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis|Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS)|CHAMPIONS10|Beth Israel Deaconess Medical Center|Yes|Completed|February 2001|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00179478||193452|
NCT00179842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 1202|Immune Ablation and Stem Cell Support for Crohn's Disease|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease||Ann & Robert H Lurie Children's Hospital of Chicago|No|Withdrawn||December 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||January 2009|September 21, 2015|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179842||193424|
NCT00179855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 0703|Extracorporeal Photopheresis for Acute Graft Versus Host Disease|Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study.||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|July 2003|July 2012|Anticipated|July 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|30 Years|No|||October 2010|October 7, 2010|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179855||193423|
NCT00180154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA-FDG-FU|Tumor Metabolism of Lung Cancer in Patients Who Underwent Percutaneous Radiation Measured With F-18-FDG-PET|Tumor Metabolism of Lung Cancer Underwent Percutaneous Radiation Measured With F-18-FDG-PET||Technische Universität Dresden||Completed|July 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The study includes consecutive patients from Department of Radiooncology with inoperable        non-small cell lung cancer (NSCLC) intended for a curative radiotherapy.|August 2011|August 23, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180154||193400|
NCT00180167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML_GT60_DD|Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC|Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC||Technische Universität Dresden|No|Completed|January 2005|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|492|||Both|60 Years|N/A|No|||August 2010|August 19, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180167||193399|
NCT00187291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010050|Study to Compare TWA Test and EPS Test for Predicting Patients at Risk for Life-threatening Heart Rhythms (ABCD Study)|Alternans Before Cardioverter Defibrillator (ABCD) Trial||St. Jude Medical|Yes|Completed|April 2001|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||618|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187291||192878|
NCT00187824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0505/2|Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis|Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis||University College London Hospitals||Recruiting|July 2004|August 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||30|||Both|16 Years|N/A|No|||March 2004|September 11, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00187824||192839|
NCT00187512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01330|SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era|SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era|SCOPE|University of California, San Francisco|No|Recruiting|March 2000|December 2020|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|Samples With DNA|Plasma, serum, PMBCs, saliva|Both|18 Years|N/A|No|Non-Probability Sample|The study is open to eligible subjects who are able to perform study visits at San        Francisco General Hospital or the San Francisco VA Medical Center.|May 2015|May 5, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187512||192861|
NCT00175916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01125|Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy|An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy||UCB Pharma|No|Active, not recruiting|September 2005|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|853|||Both|16 Years|N/A|No|||March 2016|March 18, 2016|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00175916||193718|
NCT00176163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kfg107|Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain|Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain||Heidelberg University||Completed|August 2005|May 2009||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|70 Years|No|||September 2005|February 1, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176163||193699|
NCT00176436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21874|Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients|Double-Blind Study of Atomoxetine for Weight Management in Patients Taking Olanzapine or Clozapine||University of Maryland|Yes|Completed|February 2004|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||May 2013|May 7, 2013|September 12, 2005|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00176436||193678|
NCT00176930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001LS049|Stem Cell Transplant for Hematological Malignancy|Allogeneic Transplant for Hematological Malignancy||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|October 2001|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|N/A|55 Years|No|||January 2016|January 21, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176930||193641|
NCT00176943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0009M64941|Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%|Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry||University of Minnesota - Clinical and Translational Science Institute|No|Completed|October 2000|August 2002|Actual|August 2002|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 13, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176943||193640|
NCT00177476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL067826-01A2|Enhancing Exercise Participation in Overweight Adults|Enhancing Exercise Participation in Overweight Adults||University of Pittsburgh||Completed|September 2003|May 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||225|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00177476||193602|
NCT00178022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0410002|A Trial of Two On-Line Interventions for Child Brain Injury|A Trial of Two On-Line Interventions for Child Brain Injury||University of Pittsburgh||Completed|February 2005|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind||||120|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||May 2008|May 27, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178022||193561|
NCT00178295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 11095|Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury|Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury||University of Rochester|No|Completed|November 1999|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|Samples Without DNA|Blood plasma|Both|N/A|N/A|No|Non-Probability Sample|Patient who are going to receive radiation therapy as part of the treatment for their        brain cancer|August 2015|August 3, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178295||193540|
NCT00177736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0505059|Pharmacodynamic Parameters of Two Different Doses of Cefepime|Pharmacodynamic Parameters of Two Different Doses of Cefepime||University of Pittsburgh||Completed|September 2005|December 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective|||Anticipated|180|||Both|18 Years|N/A|No|||December 2007|December 11, 2007|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177736||193582|
NCT00177749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0307071|Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095|Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095||University of Pittsburgh||Terminated|August 2004|November 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||10|||Both|18 Years|80 Years|No|||December 2008|December 16, 2008|September 13, 2005|||Study is complete Analysis is complete|||https://clinicaltrials.gov/show/NCT00177749||193581|
NCT00179166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30941|Assessment of Metabolic Response in Critically Ill Patients With Acute Renal Failure|Assessment of Metabolic Response in Critically Ill Patients With Acute Renal Failure||Vanderbilt University|No|Terminated|June 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|September 13, 2005||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00179166||193474|
NCT00179179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50189|The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis|The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis||Vanderbilt University|No|Completed|April 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|75 Years|No|||July 2009|July 8, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179179||193473|
NCT00179491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-002125|Study of the Therapeutic Effects of Intercessory Prayer (STEP)|Study of the Therapeutic Effects of Intercessory Prayer (STEP)||Beth Israel Deaconess Medical Center||Completed|April 1998|November 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1802|||Both|18 Years|N/A|No|||November 2007|November 2, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179491||193451|
NCT00179504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000110|The Effect of Relaxation Response Training on Declarative Memory and Learning in High School Students|The Effect of Relaxation Response Training on Declarative Memory and Learning in High School Students||Beth Israel Deaconess Medical Center||Completed|July 2000|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|90|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2007|November 2, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179504||193450|
NCT00179868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0403 CRP|C-Reactive Protein as a Predictor of Stem Cell Transplant Complications|C-Reactive Protein As a Predictor of Major Transplant Complications in Pediatric Stem Cell Transplant Patients||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|January 2003|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|44|||Both|6 Months|20 Years|No|Non-Probability Sample|Children undergoing a stem cell transplant|August 2008|August 26, 2008|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00179868||193422|
NCT00180180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNO-FMISO-FU|Tumor Hypoxia of Head-and-neck Cancer Underwent Radiation Therapy Measured With F-18-FMISO|Tumor Hypoxia of Head-and-neck Cancer Underwent Radiation Therapy Measured With F-18-FMISO||Technische Universität Dresden|No|Active, not recruiting|July 2006|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|70 Years|No|Non-Probability Sample|The study includes consecutive patients from the Department of Radiooncology with head and        neck cancer (HNC) intended for a curative chemoradiotherapy.|March 2016|March 15, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180180||193398|
NCT00180193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-OMFD-FU|F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response|F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response||Technische Universität Dresden|No|Terminated|December 2003|||||Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|OMFD-PET of all patients after subtotal resection or biopsy of malignant glioma was        evaluated.|August 2009|August 25, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180193||193397|
NCT00180479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-360|SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions||Abbott Vascular|Yes|Completed|June 2005|November 2011|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1002|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|September 13, 2005|Yes|Yes||No|October 15, 2008|https://clinicaltrials.gov/show/NCT00180479||193375|
NCT00176527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540176|Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer||Rutgers, The State University of New Jersey|Yes|Terminated|November 2002|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|N/A|No|||December 2009|December 10, 2009|September 12, 2005|Yes|Yes|accrual goal met|No||https://clinicaltrials.gov/show/NCT00176527||193671|
NCT00176787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 0046|Radiation Therapy With Capecitabine in Rectal Cancer|Phase II Trial of Preoperative Radiation Therapy With Capecitabine in Rectal Cancer (UMCC 0046)||University of Michigan Cancer Center||Terminated|October 2000|June 2007|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2007|December 28, 2007|September 12, 2005|||recruitment goals met|No||https://clinicaltrials.gov/show/NCT00176787||193652|
NCT00187317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET-54025-01|Evaluation of a Balance-recovery Specific Falls Prevention Exercise Program|Development and Evaluation of a Perturbation-based Balance-training Program for Older Adults||Sunnybrook Health Sciences Centre|No|Completed|November 2005|March 2008|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|64 Years|80 Years|Accepts Healthy Volunteers|||April 2010|April 1, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00187317||192876|
NCT00188071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 02-02|Postoperative Pain After Medical Abortion Under Local Anesthesia : Comparison of Several Analgesic Regimen|Postoperative Pain After Medical Abortion Under Local Anesthesia : a Prospective and Randomized Trial Comparing Several Analgesic Regimen||University Hospital, Angers||Completed|September 2002|August 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||240|||Female|18 Years|N/A|No|||September 2005|December 28, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188071||192820|
NCT00188084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC03-02|Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia|Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial||University Hospital, Angers||Recruiting|November 2003|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||400|||Both|15 Years|59 Years|No|||September 2005|October 27, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188084||192819|
NCT00180037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78052003|Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease|Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease||Technische Universität Dresden|Yes|Completed|September 2003|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||132|||Both|40 Years|75 Years|No|||January 2009|January 16, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00180037||193409|
NCT00180050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLYCK|Budesonide Treatment for Lymphocytic Colitis|Efficacy and Safety of Budesonide for Treatment of Lymphocytic Colitis||Technische Universität Dresden||Completed|January 2002|August 2007|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|80 Years|No|||March 2010|March 29, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00180050||193408|
NCT00180063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKPD 01-02 Amend LNMMA|Characterization of Local Vascular Effects of LNMMA|||Technische Universität Dresden||Completed|October 2003|September 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|November 1, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00180063||193407|
NCT00180076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIMIC|Budesonide for Maintenance Treatment of Collagenous Colitis|Efficacy and Safety of Budesonide in Maintenance Treatment of Collagenous Colitis||Technische Universität Dresden||Completed|July 2004|March 2008||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|80 Years|No|||March 2010|March 29, 2010|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00180076||193406|
NCT00180362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version vom 31.3.1999|Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ?|Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary in Patients After Survived Cardiac Arrest? A Prospective Randomised Multi-centre Trial.|Quick ICD|Guidant Corporation||Completed|May 2004|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||February 2010|February 3, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00180362||193384|
NCT00180648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0405/83|Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure|Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure||Imperial College London|Yes|Completed|February 2005|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Intestinal failure patients at St Mark's hospital|May 2008|February 19, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00180648||193362|
NCT00177502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL070257-01A1|Effect of Exercise on Prevention of Weight Gain|Effect of Exercise on Prevention of Weight Gain||University of Pittsburgh||Completed|January 2003|December 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||294|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00177502||193600|
NCT00177216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH024652|Characteristics of Sleep Patterns in Young Adults With and Without Insomnia|Psychobiology and Treatment Response in Primary Insomnia||National Institute of Mental Health (NIMH)||Active, not recruiting|February 2002|||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 30, 2009|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177216||193621|
NCT00177229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405048|KidQuest Family-Based Weight Control|Family-Based Treatment of Severe Pediatric Obesity||University of Pittsburgh|No|Completed|July 2001|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|8 Years|12 Years|No|||February 2008|February 15, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177229||193620|
NCT00178321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10055|Improving Sleep in the Pediatric Intensive Care Unit|Improving Sleep and Outcomes in Critically Ill Children||University of Rochester||Withdrawn|September 2005|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Both|1 Year|15 Years|No|||April 2015|April 29, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178321||193538|
NCT00178308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 1702|Measuring Alterations of DNA in Human Blood|||University of Rochester||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||24|||Both|21 Years|70 Years||||September 2006|September 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178308||193539|
NCT00178542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG and TEG|Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle|Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle||The University of Texas Health Science Center, Houston|No|Terminated|September 2005|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|50 Years|No|Probability Sample|Females with a diagnosis of von Willebrand Disease|May 2013|May 3, 2013|September 12, 2005||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00178542||193521|
NCT00178841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050416|Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL|Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma||Vanderbilt University|No|Completed|June 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 12, 2005|No|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00178841||193499|
NCT00178854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030101|Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment|Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment||Vanderbilt University||Withdrawn|May 2004|December 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|50 Years|No|||February 2010|February 5, 2010|September 12, 2005||Yes|failed recruitment efforts|No||https://clinicaltrials.gov/show/NCT00178854||193498|
NCT00178867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020116|A National Registry of Patients With Hepatocellular Carcinoma|A National Registry of Patients With Hepatocellular Carcinoma||Vanderbilt University|No|Completed|January 2002|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|N/A|N/A|No|Non-Probability Sample|All patients seen in Hepatobiliary Surgery Clinic at Vanderbilt University Medical Center        who are diagnosed with hepatocellular carcinoma.|October 2008|October 9, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178867||193497|
NCT00179192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9318|Prevention and Treatment of Hemodialysis Vascular Access Malfunction|Prevention and Treatment of Hemodialysis Vascular Access Malfunction||Vanderbilt University|No|Withdrawn|May 1998|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|85 Years|No|||May 2015|May 21, 2015|September 13, 2005||No|non-enrollment|No||https://clinicaltrials.gov/show/NCT00179192||193472|
NCT00180206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DresdenU|Birmingham Hip Resurfacing (BHR) Study: Implantation of a Hip Resurfacing Endoprosthesis|Prospective, Non-Randomised, Non-Comparative Multicentric Investigation of the Functional and Radiological Result and Subjective Patient Outcome After Implantation of a Hip Resurfacing Endoprosthesis (Birmingham Hip Resurfacing)||Technische Universität Dresden||Recruiting|January 2005|December 2008||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||September 2005|January 13, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180206||193396|
NCT00180219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKPD-S-01-04|Clinical Trial to Assess the Influence of Gestational Stage and Maternal Age on Arterial Stiffness of the Mother|An Open Clinical Trial to Assess the Influence of Gestational Stage and Maternal Age on Arterial Stiffness of the Mother (Hormonal and Age Related Changes of the Aortal Elasticity)||Technische Universität Dresden|No|Terminated|January 2006|June 2006|Actual|||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Female|20 Years|42 Years|Accepts Healthy Volunteers|Probability Sample|three age groups|September 2005|February 12, 2009|September 14, 2005||No|recruitment failure|No||https://clinicaltrials.gov/show/NCT00180219||193395|
NCT00180492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-715|Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE|Carotid RX ACCULINK(TM)/ACCUNET(TM) Post-Approval Trial to Uncover Unanticipated or Rare Events - CAPTURE||Abbott Vascular||Completed|October 2004|August 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label||||1500|||Both|N/A|N/A|No|||October 2008|October 27, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00180492||193374|
NCT00176319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI 535/1-1|Leipzig Exercise Intervention in Chronic Heart Failure and Aging|Age-related Functional and Molecular Effects of Short-term Aerobic Endurance Training in Patients With Stable Chronic Heart Failure and Age-matched Healthy Controls.|LEICA|University of Leipzig||Completed|May 2005|||December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|8||Actual|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2009|July 14, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00176319||193687|
NCT00176813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2001-071|Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer|Phase II Study of Gemcitabine, Cisplatin, and Celecoxib in the Treatment of Metastatic Pancreatic Cancer||University of Michigan Cancer Center||Completed|March 2003|November 2006|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2008|April 29, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00176813||193650|
NCT00176826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN-MT2000-21|T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders|In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|September 2000|July 2015|Anticipated|August 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|55 Years|No|||April 2015|April 22, 2015|September 12, 2005||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00176826||193649|
NCT00187330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|724180589|A Study of The Effectiveness of N-Acetylcysteine in Kidney Protection Following Cardiopulmonary Bypass|A Randomized Placebo Controlled Trial of Intravenous N-Acetylcysteine (NAC) As A Renal Protective Agent for Prevention of Renal Dysfunction Following Cardiopulmonary Bypass (CPB)||Sunnybrook Health Sciences Centre||Completed|March 2004|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||104|||Both|20 Years|N/A|No|||August 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00187330||192875|
NCT00187538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9291-19207-05|Effect of Dietary Protein Source on Calcium Metabolism|Effect of Dietary Protein Source on Calcium Metabolism||University of California, San Francisco|No|Completed|February 2002|July 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|183|||Female|55 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 20, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187538||192859|
NCT00180661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-69155|Inflammation and Corticosteroid Responsiveness in Severe Asthma|Inflammation and Corticosteroid Responsiveness in Severe Asthma|SARP|Imperial College London|Yes|Completed|August 2003|May 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|95|Samples With DNA|endobronchial biopsies and blood specimens.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Asthma population living in the UK - ranging in severity (from mild, to severe).|October 2015|October 27, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00180661||193361|
NCT00176449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2407ko|A Comparison of Bupropion SR and Placebo for Smoking Cessation|A Comparison of Bupropion SR and Placebo for Smoking Cessation||University of Maryland|Yes|Completed|April 2001|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00176449||193677|
NCT00176228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-04|Lamotrigine Monotherapy in Pediatric Bipolar Disorder|Open Trial of Lamotrigine Monotherapy in Pediatric Bipolar Disorder||University of Illinois at Chicago|Yes|Completed|February 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|10 Years|20 Years|No|||June 2015|July 28, 2015|September 13, 2005||No||No|June 20, 2013|https://clinicaltrials.gov/show/NCT00176228||193694|
NCT00176956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0110M09983|Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients|Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|November 2002|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|N/A|||Anticipated|30|||Both|N/A|16 Years|No|||February 2013|February 1, 2013|September 12, 2005||No|IRB approval has lapsed.|No||https://clinicaltrials.gov/show/NCT00176956||193639|
NCT00177242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-027|Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma|Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma||University of Pittsburgh|Yes|Completed|September 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177242||193619|
NCT00176657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120040166|The Use of HEMOBAG to Salvage Blood After Cardiac Surgery|Comparison of Whole Blood Return and Normal Practice Red Blood Cell Salvage Return Following Cardiopulmonary Bypass||Rutgers, The State University of New Jersey||Terminated|September 2004|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|18 Years|80 Years|No|||April 2007|April 27, 2007|September 13, 2005|||Inability to attain sufficient numbers of subjects|No||https://clinicaltrials.gov/show/NCT00176657||193661|
NCT00176670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120030315|A GameBoy as a Distraction Before Surgery in Children|Is Preoperative Distraction With a Hand Held Game Boy as Effective as Midazolam in Reducing Preoperative Anxiety Levels in Children?||Rutgers, The State University of New Jersey||Completed|January 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||158|||Both|4 Years|16 Years|No|||June 2008|June 23, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176670||193660|
NCT00177255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-026|A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers|A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas.||University of Pittsburgh|Yes|Terminated|April 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 10, 2016|September 12, 2005||No|Roche has withdrawn support|No|January 10, 2016|https://clinicaltrials.gov/show/NCT00177255||193618|
NCT00177515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2582-25916-01A|Computer-assisted Preventive Health Education for Women of Reproductive Age in Urgent Care Settings|Preventive Health Education for Women of Reproductive Age||University of Pittsburgh|No|Completed|March 2005|January 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|2||Actual|446|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 4, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177515||193599|
NCT00177788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0508150|Voriconazole as Prophylaxis for Liver Transplant Recipients|Voriconazole as Prophylaxis for Liver Transplant Recipients||University of Pittsburgh|Yes|Completed|September 2005|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|liver transplant patients receiving voriconazole|August 2012|August 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177788||193578|
NCT00177762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL064991|Dose-Response of Exercise on Long-Term Weight Loss|Dose-Response of Exercise on Long-Term Weight Loss||University of Pittsburgh||Completed|September 1999|December 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177762||193580|
NCT00177775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0412033|Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea|Whey Protein Concentrate 40% (WPC-40) Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea: A Prospective, Randomized, Controlled Phase II Study - Version 5.1.B||University of Pittsburgh||Terminated|April 2005|August 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|September 13, 2005|||Study is completed and analysis completed|No||https://clinicaltrials.gov/show/NCT00177775||193579|
NCT00178568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021117|Reducing Caregiver Stress and Sleep Disturbances in Patients With Progressive Dementia|AgeWise Project 2: Reducing Stress and Sleep Disturbances in Caregivers of Patients With Progressive Dementia||University of Pittsburgh|Yes|Completed|February 2003|November 2009|Actual|November 2008|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|60|Samples Without DNA|Saliva collected on cotton rolls and frozen by participant. Kept frozen until shipped for      assay.|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males and females over the age of 60 who are primary caregiver for spouse/partner        diagnosed with progressive dementia.|May 2015|May 26, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178568||193519|
NCT00178555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-03-082|Comparison of the Video and Macintosh Laryngoscope in Patients Who May be Difficult to Intubate|A Comparison of Laryngoscopy Techniques Using the Video Laryngoscope and the Traditional Macintosh Laryngoscope in Patients Who May be Difficult to Intubate||The University of Texas Health Science Center, Houston||Completed|August 2003|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||200|||Both|18 Years|80 Years||||March 2016|March 22, 2016|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00178555||193520|
NCT00178594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rotem|Evaluation of Hemostasis in Bleeding and Thrombotic Disorders|Evaluation of Hemostasis in Bleeding and Thrombotic Disorders Using the Roteg Analyzer and the Thrombin Generation Assay||The University of Texas Health Science Center, Houston|No|Recruiting|October 2002|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Subjects with an Acquired or Congenital Bleeding Disorder or Acquired Thrombotic Disorder|June 2015|June 11, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178594||193517|
NCT00178880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010242|MRI Imaging of Chronobiologic Abnormalities in Depression|MRI Imaging of Chronobiologic Abnormalities in Depression||Vanderbilt University||Completed||November 2009|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and depressed patients.|December 2009|December 30, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178880||193496|
NCT00179881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS 1099|Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma|Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma||Ann & Robert H Lurie Children's Hospital of Chicago||Completed|December 1999|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|47|||Both|3 Years|21 Years|No|||June 2011|June 22, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00179881||193421|
NCT00180505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-100|ASSESS Study: Evaluation of ABSOLUTE™ Stent System for Occluded Arteries|Non-Randomized, Prospective, Multi-center Evaluation of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System for Occluded or Stenotic Superficial Femoral or Proximal Popliteal Arteries||Abbott Vascular|No|Completed|March 2005|October 2009|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180505||193373|
NCT00176332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121/2003|Impact of Rosuvastatin on Endothelial Function and Inflammation in Patients With Chronic Heart Failure|Impact of Three Months of Rosuvastatin Treatment on Peripheral Endothelial Function, Inflammatory Markers in the Blood and the Skeletal Muscle and on Postnatal Vasculogenesis in Patients With Severe Chronic Heart Failure||University of Leipzig||Completed|March 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|No|||July 2007|July 31, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00176332||193686|
NCT00176540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539650|Dextromethorphan in Treating Patients With Fatigue Caused by Cancer|A Pilot Trial to Evaluate the Effects of Dextromethorphan in Patients Suffering From Cancer-Related Fatigue||Rutgers, The State University of New Jersey|Yes|Terminated|October 2003|August 2007|Actual|August 2007|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|30|||Both|12 Years|75 Years|No|||May 2011|May 16, 2011|September 12, 2005|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00176540||193670|
NCT00176839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000LS040|Stem Cell Transplantation for Hematological Malignancies|Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies||Masonic Cancer Center, University of Minnesota|Yes|Terminated|June 2000|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|35 Years|No|||March 2013|March 12, 2013|September 12, 2005|Yes|Yes|Replaced by a different study|No|January 11, 2013|https://clinicaltrials.gov/show/NCT00176839||193648|
NCT00188136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDEATX|Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)|Phase II Study of Early Allogeneic Blood Stem Cell Transplantation During Induction-chemotherapy Induced Aplasia in High-risk Acute Myeloid Leukemia||University Hospital Carl Gustav Carus||Completed|August 2002|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|16 Years|75 Years|No|||December 2015|December 7, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188136||192815|
NCT00187551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8211-18804-05|Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance|Partial Treatment Interruptions in HIV-1 Patients With Multi-Drug Resistant Virus||University of California, San Francisco|No|Completed|May 2000|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||June 2006|February 8, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187551||192858|
NCT00180401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version vom 05.08.2002|MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms|MODULA-Study: Modul 10: Benefit of CRT-therapy in CRT-Patients With QRS-complex of 120 - 150 ms||Guidant Corporation||Terminated|June 2002|October 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|||April 2009|March 9, 2015|September 12, 2005|||no longer interest from medical community|No||https://clinicaltrials.gov/show/NCT00180401||193381|
NCT00180414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version vom 10.07.2003 BIS|MODULA Modul 7 VRR: Correlation Between Ventricular Rate Regulation (VRR) and the Percentage of Biventricular Pacing in Cardiac Resynchronization Therapy (CRT) Patients With Atrial Fibrillation|MODULA-Study: Modul 7 VRR: Correlation Between Ventricular Rate Regulation (VRR) and the Percentage of Biventricular Pacing as Well as Subjective Quality of Life and Level of Physical Ability in CRT Patients With Atrial Fibrillation||Guidant Corporation||Terminated|August 2003|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|September 12, 2005|||low enrolment rate|No||https://clinicaltrials.gov/show/NCT00180414||193380|
NCT00176683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120010351|The Use of Capnography as a Guide for Oral Intubation|Assessing the Use of Capnography as a Guide for Endotracheal Intubation||Rutgers, The State University of New Jersey|No|Terminated|July 2005|January 2009|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|99|||Both|18 Years|70 Years|No|||April 2015|April 23, 2015|September 13, 2005||No|study was suspended because of difficluty maintaining equipment|No||https://clinicaltrials.gov/show/NCT00176683||193659|
NCT00176969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9707M00122|Response of Topical Capsaicin in Alopecia Areata|Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|August 1997|June 2000||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176969||193638|
NCT00177268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0411029|Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research|Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research||University of Pittsburgh|No|Recruiting|October 2004|January 2023|Anticipated|January 2022|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|White blood cells and/or skin biopsy tissue are retained.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with cutaneous t-cell lymphoma and/or Sezary syndrome and atopic dermatitis or        eczema patients|December 2015|December 14, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177268||193617|
NCT00177281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-052|Safety Study of S-CKD602 in Patients With Advanced Malignancies|A Phase I Study to Evaluate the Safety and Pharmacokinetics of S-CKD602 in Patients With Advanced Malignancies||University of Pittsburgh||Completed|September 2003|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00177281||193616|
NCT00178048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970357|Paroxetine in the Treatment of Chronic Primary Insomnia|Paroxetine in the Treatment of Chronic Primary Insomnia: A Double-Blind, Randomized, Placebo-Controlled Study of Efficacy Over Six Weeks||University of Pittsburgh||Completed|September 1998|December 2003||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|55 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178048||193559|
NCT00178035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH037869-02|Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals|Geriatric Depression: Neurobiology of Treatment||University of Pittsburgh||Completed|December 1999|August 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||158|||Both|60 Years|N/A|No|||July 2013|July 31, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178035||193560|
NCT00178360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10336|Effects of Music Therapy on Huntington's Disease|The Effects of Music Therapy on Depression, Chorea and Other Symptoms of Huntington's Disease||University of Rochester|No|Completed|July 2004|June 2010|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|11|||Both|18 Years|N/A|No|||August 2011|August 19, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178360||193535|
NCT00178581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-05-0144|Enteral Glutamine Supplementation for the Patient With Major Torso Trauma|Early Enteral Glutamine Supplement to Enteral Nutrition Support of the Major Torso Trauma Patient: Proposal for a Prospective Randomized Clinical Trial||The University of Texas Health Science Center, Houston||Terminated|June 2005|September 2006||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||December 2007|April 22, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178581||193518|
NCT00179205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50006|Complementary Intradialytic Nutritional Supplementation in Dialysis Patients|Complementary Intradialytic Nutritional Supplementation in Dialysis Patients||Vanderbilt University|No|Terminated|May 2005|December 2007|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||August 2008|August 5, 2008|September 13, 2005||No|funding exhausted|No||https://clinicaltrials.gov/show/NCT00179205||193471|
NCT00179218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50149|The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients|The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients||Vanderbilt University|No|Completed|April 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2009|July 8, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179218||193470|
NCT00179517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P-000149|Treatment of Sexual Dysfunction in Men With Epilepsy With Testosterone and Either Arimidex or Placebo|Comparison of Arimidex and Testosterone Versus Placebo and Testosterone Treatment of Reproductive and Sexual Dysfunction in Men With Epilepsy and Hypogonadism||Beth Israel Deaconess Medical Center||Completed|June 2001|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|50 Years|No|||October 2007|May 5, 2008|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00179517||193449|
NCT00179530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-002249|The Effect of Relaxation Response Training on Declarative Memory and Salivary Cortisol in Older Adults|The Effect of Relaxation Response Training on Declarative Memory and Salivary Cortisol in Older Adults||Beth Israel Deaconess Medical Center||Completed|May 1999|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||November 2007|November 2, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179530||193448|
NCT00180232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK160082004|An Open Clinical Trial to Assess the Influence of Newly Prescribed Aminobiphosphonates on Arterial Stiffness|An Open Clinical Trial to Assess the Influence of Newly Prescribed Aminobiphosphonates on Arterial Stiffness (Changes of the Aortal Elasticity Due to a Newly Established Aminobiphosphinate Therapy for the Treatment of Osteoporosis)||Technische Universität Dresden|No|Withdrawn|April 2006|June 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index:        between -20 and +25%|February 2012|February 2, 2012|September 14, 2005||No|Clinical partner left University,|No||https://clinicaltrials.gov/show/NCT00180232||193394|
NCT00180245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNO-FDG-FU|Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET|||Technische Universität Dresden|No|Completed|July 2005|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|18 Years|70 Years|No|Non-Probability Sample|The study includes consecutive patients from the Department of Radiooncology with head and        neck cancer (HNC) intended for a curative chemoradiotherapy.|March 2016|March 15, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00180245||193393|
NCT00180518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-706|ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial"|Prospective, Non-Randomized, Multi-Center, Single-Arm Trial to Assess Safety & Efficacy of the Acculink Carotid Stent System With the Accunet Embolic Protection System in High-Risk Patients With Carotid Artery Lesions.||Abbott Vascular|Yes|Completed|May 2000|November 2003|Actual|October 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||581|||Both|18 Years|N/A|No|||September 2008|September 10, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00180518||193372|
NCT00176345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|639/97|Impact of Exercise Training on Endothelial Function in CAD|Impact of Exercise Training on Bradykinin-Mediated Endothelial Function in Patients With Coronary Artery Disease||University of Leipzig||Recruiting|January 2001|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||20|||Male|18 Years|75 Years|No|||September 2005|September 11, 2005|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00176345||193685|
NCT00176553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3708|A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity|A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity||Rutgers, The State University of New Jersey|Yes|Terminated|March 2003|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|21 Years|No|||December 2009|December 10, 2009|September 12, 2005||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00176553||193669|
NCT00176852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2002-07|Stem Cell Transplant for Hemoglobinopathy|Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|June 2002|June 2016|Anticipated|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|N/A|50 Years|No|||February 2016|February 23, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00176852||193647|
NCT00177125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406M61241|Evaluating the Effect of the VCD on Erectile Function and Penile Length Post RRP|Evaluating the Effect of the Vacuum Constriction Device on Erectile Function and Penile Length Post Radical Retropubic Prostatectomy||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2004|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||220|||Male|18 Years|N/A|No|||February 2012|February 3, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177125||193627|
NCT00177385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #021116|Aging Well, Sleeping Efficiently: Protecting Health In Later Life|AGEWISE Project 4: PROTECTING HEALTH IN LATER LIFE|AgeWise|University of Pittsburgh|Yes|Completed|June 2003|September 2011|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||66|||Both|75 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177385||193608|
NCT00188903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0873-A|Diastolic Dysfunction and Atrial Fibrillation in CABG Surgery|Diastolic Dysfunction and Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery||University Health Network, Toronto||Completed|March 2004|March 2010|Actual|November 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Elective coronary artery bypass graft patients either on or off pump in acute care centre|April 2008|August 3, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00188903||192756|
NCT00188916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 04-0407-AE|A Clinical Comparison of Three Bronchial Blockers for One-Lung Ventilation in Thoracic Surgery|||University Health Network, Toronto||Recruiting||||||Phase 4|Observational|Allocation: Random Sample, Time Perspective: Longitudinal|||Anticipated|120|||Both|16 Years|N/A||||September 2006|June 11, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00188916||192755|
NCT00188383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94759-200109MCT|Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy|Effects of NMDA-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy in Young and Elderly Patients||University Health Network, Toronto||Recruiting|January 2004|December 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||132|||Male|18 Years|80 Years|No|||September 2005|March 13, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188383||192796|
NCT00176696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120050013|Biobehavioral Recovery From Surgery and Anesthesia|Detection of Nociception ("Pain") During General Anesthesia||Rutgers, The State University of New Jersey|No|Terminated|August 2005|April 2007|Actual|April 2007|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Non-Probability Sample|subjects undergoing surgery|June 2008|June 24, 2008|September 13, 2005||No|Principal Investigator has left the UMDNJ|No||https://clinicaltrials.gov/show/NCT00176696||193658|
NCT00177528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000918|Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression|Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression||University of Pittsburgh||Completed|October 2000|||November 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|60 Years|N/A|No|||October 2008|October 8, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177528||193598|
NCT00177801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0408132|Organ Transplant Infection Prevention and Detection Project|Organ Transplant Infection Prevention and Detection Project 1.0; Cohort Study of Transplant Recipients at "Ultra-High" Risk for Invasive Fungal Infections||University of Pittsburgh|Yes|Completed|May 2006|August 2012|Actual|August 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|200|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. The biologic samples may be given to the Centers for Disease Control and      Prevention. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|lung transplant recepients|August 2012|August 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177801||193577|
NCT00177814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0508074|Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit|Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit||University of Pittsburgh|Yes|Active, not recruiting|September 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|patients treated with piperacillin/tazobactam and or piperacillin|December 2015|December 16, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177814||193576|
NCT00178061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970843-0109|Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder|Treatment of Primary Mood Disorders in the Comorbidly Ill||University of Pittsburgh||Completed|August 1997|August 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||13|||Both|18 Years|60 Years|No|||June 2013|June 21, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178061||193558|
NCT00178334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11355|Screening for Urinary Incontinence by Primary Care Providers|Screening for Urinary Incontinence by Primary Care Providers||University of Rochester|No|Completed|March 2006|July 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|554|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care providers|January 2013|January 28, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178334||193537|
NCT00178893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040220|Hepatocellular Research Registry|CellzDirect: Hepatocellular Research Registry||Vanderbilt University|No|Recruiting|April 2004|December 2012|Anticipated|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Hepatocytes|Both|18 Years|N/A|No|Non-Probability Sample|Any patient having liver resection operation.|August 2010|August 20, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178893||193495|
NCT00178906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9956|Acoustical Properties of Speech as Indicators of Suicidal Risk|Acoustical Properties of Speech as Indicators of Suicidal Risk||Vanderbilt University|No|Suspended|December 1999|December 2010|Anticipated|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|225|||Both|25 Years|65 Years|No|Probability Sample|Acutely suicidal depressed patients; non-suicidal depressed patients;|December 2009|December 30, 2009|September 12, 2005||No|Administrative suspension|No||https://clinicaltrials.gov/show/NCT00178906||193494|
NCT00179231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990172|Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia|||Vanderbilt University||Completed|May 2000|February 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|60 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179231||193469|
NCT00179543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001727|Mechanisms and Therapeutic Effects of the Relaxation Response in Elderly Hypertensive Patients|Mechanisms and Therapeutic Effects of the Relaxation Response in Elderly Hypertensive Patients||Beth Israel Deaconess Medical Center||Completed|August 2001|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||122|||Both|55 Years|N/A|No|||September 2006|September 18, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179543||193447|
NCT00179894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066866|Improving Attention Deficit Hyperactivity Disorder Treatment Adherence and Outcome in Primary Care Settings|Improving Medication Use for ADHD in Primary Care||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|June 2003|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|270|||Both|6 Years|11 Years|No|||August 2015|August 14, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00179894||193420|
NCT00180258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0002|Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure|Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure||Boston Scientific Corporation||Completed|January 2000|December 2002||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2200|||Both|18 Years|N/A|No|||January 2007|January 23, 2007|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00180258||193392|
NCT00180271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0003|MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy|Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy|MADIT-CRT|Boston Scientific Corporation|Yes|Completed|December 2004|September 2010|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1820|||Both|21 Years|N/A|No|||January 2012|January 24, 2012|September 9, 2005|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00180271||193391|The FDA Circulatory Devices advisory panel recommended approval for the patient subpopulation with left bundle branch block (LBBB) only. Consequently, FDA has restricted indications for use to LBBB.
NCT00180531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mona Lisa v. 1.1 3/12/03|Monitoring of Arrhythmias and HRV in Patients With Heart Failure Treated With the CRT Pacemaker Renewal TR2|Monitoring of Arrhythmias and Heart Rate Variability in Patients With Congestive Heart Failure Treated With the Cardiac Resynchronisation Pacemaker Renewal TR2||Guidant Corporation||Completed|February 2004|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||500|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00180531||193371|
NCT00180544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-707|Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease|A Prospective, Non-Randomized, Multicenter, Single-Arm, Clinical Trial to Assess the Safety and Efficacy of the RX HERCULINK 14 Peripheral Stent System for Treatment in de Novo or Restenotic Renal Artery Stenosis|HERCULINK 14|Abbott Vascular|Yes|Terminated|July 2000|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Both|18 Years|N/A|No|||July 2008|July 24, 2008|September 13, 2005|Yes|Yes|Device superceded by next generation device. Enrollment stopped, long term follow up was    completed in August of 2004.|No||https://clinicaltrials.gov/show/NCT00180544||193370|
NCT00176358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139/2001|Percutaneous Coronary Angioplasty Compared With Exercise Training in Symptomatic Coronary Artery Disease|||University of Leipzig||Recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|75 Years|No|||September 2005|September 7, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00176358||193684|
NCT00177112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412M65852|Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy|Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy||University of Minnesota - Clinical and Translational Science Institute||Completed|June 2005|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|275|||Both|18 Years|N/A|No|||January 2008|January 31, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177112||193628|
NCT00177398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0408186|Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings|The Effect of Insulin Glargine on Glycemic Control, Morbidity, and Length of Stay in Hospitalized Subjects With Diabetes Receiving Enteral Nutrition||University of Pittsburgh||Completed|February 2005|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||December 2007|December 13, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00177398||193607|
NCT00177658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0602124 (Old #0303110)|NCCLS Interpretive Criteria for Salmonella|NCCLS Interpretive Criteria for Salmonella||University of Pittsburgh|Yes|Enrolling by invitation|March 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|isolates with salmonella|December 2015|December 16, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177658||193588|
NCT00176462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020101|CINJALL: Treatment for Children With Acute Lymphocytic Leukemia|CINJALL: Treatment for Children With Acute Lymphocytic Leukemia||Rutgers, The State University of New Jersey|No|Completed|February 2001|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|1 Year|30 Years|No|||May 2014|May 12, 2014|September 12, 2005|Yes|Yes||No|November 15, 2013|https://clinicaltrials.gov/show/NCT00176462||193676|Antifolate therapy was non-randomly assigned, therefore, we do not have a statistical basis to compare the toxicity observed among patients on the standard risk and high risk treatment arms.
NCT00176475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540171|Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease|A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes in Conjunction With Rituximab for Selected Patients With CD20 + Malignancies||Rutgers, The State University of New Jersey|Yes|Terminated|January 2005|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|September 12, 2005|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00176475||193675|
NCT00177294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH037869-01|Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression|Geriatric Depression: Getting Better, Getting Well||University of Pittsburgh|Yes|Completed|April 2004|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Both|60 Years|N/A|No|||November 2010|January 10, 2012|September 12, 2005|No|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00177294||193615|The study design does not allow an inference about which specific intervention led to further improvement. Was it simply a dose increase of escitalopram from 10mg to 20mg? Is this intensive contact necessary for improvement?
NCT00177307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-118|Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer|Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated Advanced Colorectal Cancer||University of Pittsburgh|Yes|Completed|January 2005|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177307||193614|
NCT00177554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI #03-005|Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma|Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma||University of Pittsburgh|Yes|Completed|November 2003|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||May 2008|May 27, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177554||193596|
NCT00177541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AG020629-02|Further Enhancing Non-pharmacologic Therapy for Incontinence|Further Enhancing Non-pharmacologic Therapy for Incontinence||University of Pittsburgh|Yes|Active, not recruiting|February 2004|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Female|60 Years|N/A|No|||January 2016|January 7, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177541||193597|
NCT00178373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2702|Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer|Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer||University of Rochester|Yes|Completed|May 2004|March 2006|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178373||193534|
NCT00178074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH037869-03|The Effects of Sleep Deprivation on Antidepressant Response|The Effects of Sleep Deprivation on Antidepressant Response in Geriatric Depression: Neurometabolic Substrates Studied With PET||University of Pittsburgh||Completed|February 1999|April 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||80|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 31, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178074||193557|
NCT00178347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 11070|Radiation Dosimetry in Teeth|Radiation Dosimetry in Teeth||University of Rochester|No|Terminated|December 2004|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|discarded pathological specimen(teeth)|May 2009|May 15, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178347||193536|
NCT00178919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010876|Nitric Oxide and the Autonomic Nervous System|Cardiovascular Regulation: Autonomic/Metabolic Mechanisms PO1 HL56693, Project 4: Cardiovascular Regulation: Autonomic/Metabolic Mechanisms||Vanderbilt University|No|Completed|August 2002|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|112|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|September 12, 2005|No|Yes||No|April 10, 2009|https://clinicaltrials.gov/show/NCT00178919||193493|
NCT00178932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9132|Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors|Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors||Vanderbilt University|No|Recruiting|November 1998|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 1, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178932||193492|
NCT00179556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002P-000037|Effects of Soy Isoflavones on Menopausal Hot Flashes|Daidzein-rich Isoflavone-aglycones for Menopausal Symptoms||Beth Israel Deaconess Medical Center||Completed|June 2003|September 2005|Actual|July 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Female|38 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179556||193446|
NCT00179907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS 0201|A Phase I/II Study of the Photon Radiosurgery System|A Phase I/II Study of Reirradiation for Recurrent Pediatric Brain and Spinal Cord Tumors and Primary Glioblastoma Multiforme Using the Photon Radiosurgery System||Ann & Robert H Lurie Children's Hospital of Chicago||Completed|May 2001|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|2 Years|32 Years|No|||February 2015|February 27, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00179907||193419|
NCT00179920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS 0294|Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma|Chemotherapy Plus Local Surgical Treatment in Children With Intraocular Germ-Line Retinoblastoma||Ann & Robert H Lurie Children's Hospital of Chicago||Active, not recruiting|April 1996|September 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||June 2011|September 25, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00179920||193418|
NCT00180284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0009|SITELINE 2 Polyurethane|SITELINE 2 Polyurethane Clinical Investigation||Boston Scientific Corporation||Completed|November 2004|February 2008|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00180284||193390|
NCT00176371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|school project|Improvement of Physical Activity and Correction of Body Mass Index in School Children|||University of Leipzig||Recruiting|July 2005|December 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|500|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||September 2006|September 7, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176371||193683|
NCT00176566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4383|A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia|A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia||Rutgers, The State University of New Jersey||Terminated|September 2003|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|N/A|No|||December 2009|December 10, 2009|September 12, 2005||No|Transitioned into a national study through ECOG|No||https://clinicaltrials.gov/show/NCT00176566||193668|
NCT00177138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308M51264|Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation|Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|July 2004|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|60 Years|No|||February 2013|February 5, 2013|September 13, 2005|||The clinical use of Campath for transplant patients was temporarily suspended.|No||https://clinicaltrials.gov/show/NCT00177138||193626|
NCT00177411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0507001|"PTHrP(1-36) IV Dose Escalation Study"|"Determining the Maximum Tolerable Dose and Pharmacokinetic Parameters of Intravenous PTHrP(1-36)"||University of Pittsburgh|Yes|Withdrawn|July 2005|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|0|||Both|24 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|September 12, 2005|Yes|Yes|Protocol design was changed so it no longer fit the description of this study.|No||https://clinicaltrials.gov/show/NCT00177411||193606|
NCT00218309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15462-1|Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals|Biobehavioral Studies of Opioid Drug Seeking Behavior: Study 1||National Institute on Drug Abuse (NIDA)||Completed|September 2003|July 2005||||Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||16|||Both|18 Years|55 Years|No|||May 2006|May 5, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218309||190545|
NCT00218322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16264-1|Effectiveness of ATMX in Treating Adolescents With ADHD and SUD|Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD)||Massachusetts General Hospital|Yes|Completed|September 2004|April 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|15 Years|30 Years|No|||November 2012|November 6, 2012|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218322||190544|
NCT00218114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4767R|Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults|Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents||New York State Psychiatric Institute|No|Active, not recruiting|February 2000|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|12 Years|55 Years|No|||December 2012|March 6, 2014|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218114||190560|
NCT00218127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13664-1|Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens|Opioid Maintenance: Optimum Stabilization and Withdrawal||National Institute on Drug Abuse (NIDA)|Yes|Completed|November 2001|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|142|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||August 2008|August 18, 2008|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218127||190559|
NCT00176982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0202M18141|Plaquenil for Alopecia Areata, Alopecia Totalis|Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis||University of Minnesota - Clinical and Translational Science Institute||Completed|April 2002|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 12, 2009|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176982||193637|
NCT00176995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9902M00119|Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae|Phase II, Open-Label Study of the Effect of 15% Eflornithine Hydrochloride Cream on Facial Hair of Men of African-American Descent With Pseudofolliculitis Barbae: A Laser Scanning Confocal Microscopy and Video Imaging Study||University of Minnesota - Clinical and Translational Science Institute||Completed|March 1999|October 2000||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||15|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 8, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00176995||193636|
NCT00178087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072947|Determining Changes in Brain Structure Associated With Symptoms of Late-life Depression|Pathways Linking Late-Life Depression to MCI & Dementia||University of Pittsburgh|Yes|Completed|August 2005|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|331|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|150 elderly, non-demented, non-depressed subjects, 60 non-depressed mild cognitive        impairment subjects and 270 late-life depression subjects|April 2015|April 6, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178087||193556|
NCT00178386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10309|Comparison of Educational Services and Outcomes for Patients Treated for Childhood Cancer|Comparison of Educational Services and Outcomes for Patients Treated for Childhood Cancer and Brain Tumor in Facilities With and Without Educational Liaison Services.||University of Rochester|No|Completed|September 2004|April 2008|Actual|September 2005|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|220|||Both|6 Years|N/A|No|Non-Probability Sample||June 2015|June 11, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178386||193533|
NCT00178607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inhibitors|Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia|Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia||The University of Texas Health Science Center, Houston|No|Recruiting|August 2002|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Serum and Plasma|Male|N/A|N/A|No|Probability Sample|Subjects with Severe Hemophilia A and a positive inhibitor|June 2015|June 11, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178607||193516|
NCT00178620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATCAR Pilot Trial HSC 03-021|Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization|PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization|PATCAR|The University of Texas Health Science Center, Houston|Yes|Completed|November 2003|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|N/A|No|||December 2014|December 6, 2014|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00178620||193515|
NCT00178958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030459|Evaluation of QTc Interval by Continuous Holter ECG Recording in Antipsychotic Drug-Treated Patients With Schizophrenia|||Vanderbilt University|No|Completed|August 2003|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 3, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178958||193490|
NCT00179569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000418|Molecular Processes of the Relaxation Response in Older Adults|Molecular Processes of the Relaxation Response in Older Adults||Beth Israel Deaconess Medical Center||Completed|August 2005|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||November 2007|November 2, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179569||193445|
NCT00179582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000001|Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS|A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients||Beth Israel Deaconess Medical Center||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|180|||Both|18 Years|N/A|No|||May 2010|May 26, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179582||193444|
NCT00179933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-12574|The Impact of Implementing NIDCAP on Preterm Infants in the NICU|The Impact of Implementing the Newborn Individualized Developmental Care and Assessment Program on Neurobehavioral Organization of Preterm Infants in the NICU||Ann & Robert H Lurie Children's Hospital of Chicago|No|Terminated|September 2005|February 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||October 2010|October 7, 2010|September 14, 2005|||Unable to fulfill intention of study, lost investigators.|No||https://clinicaltrials.gov/show/NCT00179933||193417|
NCT00179946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT 0603 HLA|HLA Matching - Unrelated Umbilical Cord Blood Transplantation|Impact of HLA Matching on Outcome in Pediatric Patients Undergoing Unrelated Umbilical Cord Blood Transplantation.||Ann & Robert H Lurie Children's Hospital of Chicago||Completed|June 2003|April 2006|Actual|April 2006|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|N/A|N/A|No|||January 2008|January 14, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00179946||193416|
NCT00180570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALT-2|SALT - Success of Active Versus Passive Lead Fixation of Atrial Pacing/Sensing Electrodes|Scandinavian Atrial Lead Trial|SALT|Guidant Corporation||Suspended|January 1997|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||385|||Both|18 Years|N/A|No|||September 2005|March 10, 2015|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00180570||193368|
NCT00176579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539677|Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer|Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer||Rutgers, The State University of New Jersey|Yes|Completed|June 2003|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|27|||Male|50 Years|75 Years|No|Probability Sample|Subjects will be recruited from urologists' offices and the oncological practices of CINJ.        This will be done by verbal communication through the office staff and with the        distribution of a brochure briefly describing the study. If a person is interested, he        will be given information that briefly describes the study and his name will be taken        down. A research assistant will call him and set up a meeting, preferably at the same time        he is scheduled to see his physician. At that meeting, a research assistant will go over        the consent form with him and cover all questions concerning the study. Eligibility (based        on history) will also be verified at this meeting. If he wishes to participate, he will be        instructed to sign the consent and an appointment for the blood tests and DXA scan will be        arranged.|August 2011|August 11, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176579||193667|
NCT00176865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2002-12|Stem Cell Transplant for Immunologic or Histiocytic Disorders|Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|August 2002|August 2017|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|N/A|35 Years|No|||October 2012|October 26, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00176865||193646|
NCT00177164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-PSY-405|Risperdal Consta for Bipolar Disorder|A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study||University of Pittsburgh|Yes|Completed|November 2003|December 2009|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||January 2016|January 7, 2016|September 12, 2005|No|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT00177164||193625|
NCT00177697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK058002|A Mentor-Based Approach to Long-Term Weight Loss|A Mentor-Based Approach to Long-Term Weight Loss||University of Pittsburgh||Completed|September 1999|July 2002||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||174|||Female|21 Years|55 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177697||193585|
NCT00219245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BUS11E1|An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits|A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/Day in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits||Novartis||Completed|November 2002|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|157|||Both|18 Years|50 Years|No|||November 2011|November 16, 2011|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00219245||190477|
NCT00219258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446E2301|Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma|A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma||Novartis||Completed|July 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||November 2009|November 20, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00219258||190476|
NCT00218569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15801-1|Combined Treatment for Cocaine-Alcohol Dependence - 1|Combined Treatment for Cocaine-Alcohol Dependence||The University of Texas Health Science Center, Houston|Yes|Completed|April 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218569||190526|
NCT00218582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15912-1|Effectiveness of Self-Help for Dually-Diagnosed Persons - 1|Effectiveness of Self-Help for Dually-Diagnosed Persons||National Institute on Drug Abuse (NIDA)|No|Completed|March 2003|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|64 Years|No|||October 2008|October 27, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218582||190525|
NCT00218829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-002|DMSO-PDT of BCC - A 6 Year Follow Up|Dimethylsulphoxide-Supported Photodynamic Therapy of Basal Cell Carcinoma Combined With Curretage - A 6 Year Clinical and Histological Evaluation.||Norwegian University of Science and Technology||Completed|September 1997|||||N/A|Observational|Time Perspective: Longitudinal||||48|||Both|18 Years|N/A|No|||September 2005|May 16, 2006|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00218829||190508|
NCT00176735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2001-046|Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer|Pilot Trial of Capecitabine and Radiation Therapy With Pre and Post Combination Chemotherapy in Advanced Pancreatic Cancer||University of Michigan Cancer Center||Terminated|December 2001|August 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||May 2015|May 18, 2015|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00176735||193656|
NCT00177320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502148|Rheumatic Diseases and Computer Use|Rheumatic Diseases and Computer Use: A Needs Assessment||University of Pittsburgh|No|Completed|March 2005|May 2005|Actual|May 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|359|||Both|18 Years|65 Years|No|Non-Probability Sample|Respondents were recruited from the University of Pittsburgh Medical Center Arthritis        Network Disease Registry,|January 2016|January 21, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00177320||193613|
NCT00177827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0304017|Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients|Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients: Pharmacokinetics and Correlation Between Plasma and Lung Concentrations With Toxicity/Efficacy||University of Pittsburgh|Yes|Completed|March 2004|March 2006|Actual|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||104|||Both|18 Years|N/A|No|Probability Sample|Chart review|December 2009|December 2, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177827||193575|
NCT00177840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506139|Acupuncture to Treat Cancer-Related Fatigue in Breast Cancer Patients|Acupuncture for Cancer-Related Fatigue in Breast Cancer Patients||University of Pittsburgh|No|Completed|September 2005|September 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|54|||Female|21 Years|N/A|No|||March 2008|March 27, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00177840||193574|
NCT00178100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH043832-02|Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression|Maintenance Therapies in Late-Life Depression 2 (MTLD-2)||University of Pittsburgh||Completed|March 1999|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||225|||Both|69 Years|N/A|No|||July 2013|July 31, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178100||193555|
NCT00178399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 9700|A Study For Using Radiosurgery On Limited Metastases|A Pilot Study For Using Radiosurgery On Limited Metastases||University of Rochester|Yes|Suspended|April 2001|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|September 12, 2005||No|to analyze data of subjects already enrolled.|No||https://clinicaltrials.gov/show/NCT00178399||193532|
NCT00178633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-02-137|Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery|Dramatic Reversal of Derangements in Muscle Metabolism and Left Ventricular Function After Bariatric Surgery||The University of Texas Health Science Center, Houston|No|Completed|May 2004|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples Without DNA|Skeletal muscle biopsies, plasma|Both|18 Years|70 Years|No|Probability Sample|Male and female, adult patients with clinically severe obesity who have undergone elective        bariatric surgery.|September 2014|September 3, 2014|September 12, 2005||No||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00178633||193514|
NCT00179959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12624|The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis|The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis||Northwestern University|No|Completed|September 2005|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|6 Months|17 Years|No|||November 2014|November 20, 2014|September 13, 2005||No||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00179959||193415|
NCT00179972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-196N|Evaluation of Pulse Oximetry Sensors in Neonates|Evaluation of Pulse Oximetry Sensors in Neonates||Ann & Robert H Lurie Children's Hospital of Chicago||Terminated|September 2005|May 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|32|||Both|N/A|2 Weeks|No|Probability Sample|NICU of Ann & RObert H. Lurie Children's Hospital of CHicago|July 2015|July 29, 2015|September 14, 2005||No|Lack of resources and loss of personnel precluded study progress. No adverse events or    unanticipated problems involving risks to subjects.|No||https://clinicaltrials.gov/show/NCT00179972||193414|
NCT00180297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Septal 1.1 / 14.04.2005|Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead|Evaluation of the Success Rate and the Clinical Evolution of a Ventricular Lead Implanted in the Septum Versus the Right Ventricular Apex.||Guidant Corporation||Completed|April 2005|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|208|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00180297||193389|
NCT00180557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Austria Study v. 1.2|Austria Study - Analysis of Difference Between Active and Passive Fixation Leads|Analyse Der Unterschiede Zwischen Aktiv-fixierenden Und Passiv-fixierenden Stimulations-Elektroden Hinsichtlich Implantationsdauer Und Elektrischer Parameter||Guidant Corporation|No|Completed|September 2003|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||December 2007|March 10, 2015|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00180557||193369|
NCT00176384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F21/02|Impact of Exercise Training on Exercise Capacity in Patients With Severe Chronic Heart Failure|Impact of Three Months of Aerobic Exercise Training on Exercise Capacity and Peripheral Maladaptations in Patients With Severe Chronic Heart Failure (NYHA III b)||University of Leipzig||Completed|March 2003|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||36|||Male|18 Years|75 Years|No|||July 2007|July 31, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00176384||193682|
NCT00176397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/2003|Percutaneous Coronary Intervention (PCI) With Drug-Eluting Stents (DES) Versus Coronary Artery Bypass Graft (CABG) for Patients With Significant Left Main Stenosis|PCI With DES Versus CABG for Patients With Significant Left Main Stenosis||University of Leipzig||Recruiting|August 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|80 Years|No|||September 2005|September 6, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00176397||193681|
NCT00176592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120020167|Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI|Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium|BECOME|Rutgers, The State University of New Jersey|Yes|Active, not recruiting|January 2003|January 2016|Anticipated|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|55 Years|No|||November 2014|November 7, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00176592||193666|
NCT00176605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080408|Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer|A Phase II Trial of Metronomic Dosing of Etoposide and Cyclophosphamide in Patients With Stage D0 Prostate Cancer.||Rutgers, The State University of New Jersey|No|Completed|May 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|No|||April 2014|April 18, 2014|September 13, 2005|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00176605||193665|
NCT00176878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2000-18|Stem Cell Transplant for Bone Marrow Failure Syndromes|Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders||Masonic Cancer Center, University of Minnesota|Yes|Completed|June 2000|March 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|35 Years|No|||November 2012|November 6, 2012|September 12, 2005||No||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00176878||193645|Pharmacokinetic parameters in patients receiving 2 mg/kg/dose of busulfan twice daily was not performed. No data is available.
NCT00177424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067710-02|Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes|Intervention to Prevent Post-Stroke Major Depression.||University of Pittsburgh||Terminated|July 2004|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|154|||Both|40 Years|N/A|No|||February 2009|June 26, 2014|September 12, 2005||No|Recruitment goals could not be met.|No||https://clinicaltrials.gov/show/NCT00177424||193605|
NCT00185783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95230|Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis|Pilot Study of White Blood Cell Gene Expression in Critically Ill Patients With Severe Sepsis and Relative Adrenal Insufficiency After Hydrocortisone Administration||Stanford University|Yes|Completed|March 2005|November 2006|Actual|November 2006|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Stanford Hospital ICU with Sepsis.|April 2011|April 7, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185783||192990|
NCT00219531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-073|Effect of Menstrual Cycle on CNS Processing of Gut Stimuli in IBS and Control|Effect of Menstrual Cycle and Irritable Bowel Syndrome on the Central Nervous System Processing of Gut Stimuli||Penn State University|No|Terminated|March 1999|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|women with menstrual cycle|September 2009|June 1, 2011|September 14, 2005||No|inadequate number of patients, study completed with normal subjects|No||https://clinicaltrials.gov/show/NCT00219531||190455|
NCT00177008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4680|Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety|Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety||Rutgers, The State University of New Jersey||Completed|March 2004|January 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|65 Years|No|||January 2007|January 25, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00177008||193635|
NCT00177580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308022|Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin|A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Adjunctive Treatment With Pravastatin in Partially Remitted Patients With Schizophrenia or Schizoaffective Disorder||University of Pittsburgh||Completed|July 2003|July 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|65 Years|No|||January 2008|January 8, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177580||193594|
NCT00177593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0503021|The Effect of HealthWear on Short-Term Weight Loss|The Effect of HealthWear on Short-Term Weight Loss||University of Pittsburgh||Completed|June 2005|September 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177593||193593|
NCT00177853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-128|Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer|A Phase I Study of Celecoxib, Irinotecan and Concurrent Radiotherapy in the Preoperative Treatment of Pancreatic Cancer||University of Pittsburgh|Yes|Terminated|December 2006|July 2010|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|September 13, 2005|Yes|Yes|terminated|No||https://clinicaltrials.gov/show/NCT00177853||193573|
NCT00178113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA084950-05S1|A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia|Phase I Clinical Trial: Randomized Lycopene Supplementation in Tobago Men With High-Grade Prostatic-Intraepithelial Neoplasia||University of Pittsburgh||Completed|July 2003|July 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||80|||Male|40 Years|79 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00178113||193554|
NCT00178971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020724|Serotonin 1A Agonists and Cognition in Schizophrenia|Serotonin 1A Agonists and Cognition in Schizophrenia||Vanderbilt University|No|Completed|January 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2010|January 6, 2010|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00178971||193489|
NCT00178984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051175|Biomagnetic Characterization of Gastric Dysrhythmias:Study 2|Biomagnetic Characterization of Gastric Dysrhythmias:Study 2|SQUID|Vanderbilt University|No|Recruiting|June 2000|September 2013|Anticipated|||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|14 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care clinic|June 2011|June 24, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178984||193488|
NCT00178646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-01-103|Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity|Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity||The University of Texas Health Science Center, Houston|No|Completed|January 2002|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Both|12 Years|N/A|No|||December 2013|December 9, 2013|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00178646||193513|
NCT00178945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030797|Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain|Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Botulinum Toxin Type A (Botox) for the Treatment of Pain Associated With Cervical Dystonia and Refractory Cervicothoracic Myofascial Pain Syndrome||Vanderbilt University||Completed|March 2004|March 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|August 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178945||193491|
NCT00179244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS vs. BUP Augmentation Depr.|Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression|Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression||Vanderbilt University||Completed|July 2004|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||30|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179244||193468|
NCT00179257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lexapro Failure Study|The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram|The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to||Vanderbilt University||Completed|June 2004|March 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179257||193467|
NCT00180310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-364|SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System|A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions|SPIRIT II|Abbott Vascular|Yes|Completed|July 2005|February 2011|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00180310||193388|
NCT00180583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vision II v. 1.1 07/02/2002|Vision II: Evaluation of GALILEO Intravascular Radiotherapy System|Vision II: Non Randomized French Evaluation of GALILEO Intravascular Radiotherapy System in Patients With de Novo Coronary Arteries Lesions by Restenosis on Angioplasty or Restenosis on Endoprosthesis||Abbott Vascular||Completed|February 2002|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|268|||Both|18 Years|N/A|No|||July 2008|July 31, 2008|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00180583||193367|
NCT00180596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACMAN-1099|PACMAN - PAcing for CardioMyopathies, a EuropeAN Study|Pacing for Cardiomyopathies, a European Study- A Therapy Acceptance Study||Boston Scientific Corporation||Completed|January 2000|September 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||262|||Both|18 Years|80 Years|No|||June 2005|January 5, 2016|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00180596||193366|
NCT00180609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCANCAP-1003|SCANCAP Scandinavian Automatic Capture Study|Scandinavian Automatic Capture Study||Guidant Corporation||Completed|December 2003|July 2006||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||203|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00180609||193365|
NCT00176891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2004-09|Stem Cell Transplant w/Laronidase for Hurler|Phase II Study of Combined Laronidase (AldurazymeTM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)||Masonic Cancer Center, University of Minnesota|No|Completed|March 2004|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|7 Years|No|||April 2014|July 8, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00176891||193644|
NCT00177177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03T-413|L-carnosine for Schizophrenia|L-Carnosine, an Antioxidant and AGE Inhibitor (Advanced Glycation End Products) for Cognitive Enhancement Among Persons With Schizophrenia: A Randomized, Add-on Double-Blind, Placebo Controlled, Clinical Trial||University of Pittsburgh|Yes|Completed|March 2004|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|65 Years|No|||January 2013|January 15, 2013|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00177177||193624|
NCT00174564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C_8552|EXIBIT: Oxaliplatin in Biliary Tract Cancer|A Multicentre Phase II Trial of Gemcitabine and Oxaliplatin (GEMOX) in Patients With Biliary Tract Cancer||Sanofi||Completed|April 2003|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|67|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00174564||193821|
NCT00179088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC IRB#030167|Safety of Non-delayed Weight Bearing After Total Hip Replacement With Non-Cemented Fiber Metal Taper Stem|Fiber Metal Taper Prospective Randomized Weight Bearing Investigation||Vanderbilt University||Completed|May 2003|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||33|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2010|November 1, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179088||193480|
NCT00174876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4894|Aripiprazole as Augmentation for TRD|An Open-Label Study of Aripiprazole (Abilify) as an Augmentation Agent in Patients With Treatment-Resistant Depression||State University of New York - Upstate Medical University||Completed|July 2004|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 17, 2008|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174876||193797|
NCT00174889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREG 6/2004|Pregnenolone in the Management of Schizophrenia Patients|Efficacy and Safety of Pregnenolone Augmentation in the Management of Schizophrenia Patients: a Randomised Double-Blind Placebo-Controlled Trial||Sha’ar Menashe Mental Health Center||Completed|January 2005|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|20 Years|55 Years|No|||May 2008|May 20, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00174889||193796|
NCT00186251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT24|High Dose Chemotherapy Followed By PBSC Rescue for HD|Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease||Stanford University||Completed|March 1998|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|N/A|70 Years|No|||July 2012|November 9, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186251||192957|
NCT00186264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wyeth 0600B-100625|Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?|Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?||Stanford University||Active, not recruiting|August 2002|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||December 2007|December 14, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186264||192956|
NCT00219843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-MM-01|Intralesional PV-10 Chemoablation of Metastatic Melanoma|A Phase 1 Safety and Tolerability Study of Intralesional PV-10 Chemoablation in Subjects With Metastatic Melanoma||Provectus Pharmaceuticals|No|Completed|August 2005|August 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|85 Years|No|||August 2007|August 22, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00219843||190431|
NCT00220142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2348|Molecular Markers of Prognosis in Colorectal Cancer Patients|Molecular Markers of Prognosis in Colorectal Cancer Patients||Royal Marsden NHS Foundation Trust|No|Completed|November 2003|||||N/A|Observational|Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|The GI unit Royal Marsden Hospital NHS trust (RMHNHST) has co-ordinated and published        results from a large multicentre randomised clinical trial of patients with locally        advanced CRC (Saini et al. 2003). A total of 716 patients Dukes' B and C CRC operated with        curative intent were randomised to receive either bolus or infusional 5FU regimes.        Patients treated at the RMHNHST made up the majority of the total sample cohort (n=550).        Analysis of results after a median of 19.8 months follow-up showed that infused 5-FU given        over 12 weeks resulted in similar survival to bolus 5-FU and FA over a six-month period        (log rank p=0.764). There was, however, significantly less toxicity associated with the        infusional regime.|May 2013|May 30, 2013|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00220142||190408|
NCT00186212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5BB-1801|Alternative Support for Rural and Isolated Women in an HMO|Alternative Support for Rural and Isolated Women in an HMO||Stanford University|No|Completed|September 2000|May 2002|Actual|May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|150|||Female|18 Years|N/A|No|||June 2011|June 29, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186212||192960|
NCT00177567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010614|Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study|Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study||University of Pittsburgh||Completed|July 2001|January 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|60 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00177567||193595|
NCT00178126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403061|An RCT on Preventing Pressure Ulcers With Wheelchair Seat Cushions|An RCT on Preventing Pressure Ulcers With Seat Cushions||University of Pittsburgh|No|Completed|March 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|232|||Both|65 Years|N/A|No|||June 2013|June 26, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00178126||193553|
NCT00178139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10243|Music Therapy for Patients Being Weaned From Mechanical Ventilation|Music Therapy as an Adjunctive Treatment in the Management of Stress for Patients Being Weaned From Mechanical Ventilation||University of Rochester|No|Completed|April 2004|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178139||193552|
NCT00178412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR008455-01|Improving Outcomes of Hospitalized Elders and Caregivers|Improving Outcomes of Hospitalized Elders and Caregivers||University of Rochester|Yes|Completed|April 2003|March 2009|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|421|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178412||193531|
NCT00178659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-040|Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)|Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)|Proteomics|The University of Texas Health Science Center, Houston|No|Active, not recruiting|July 2004|December 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|260|Samples Without DNA|Plasma and serum samples for use in identifying proteins related to head trauma|Both|14 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Consenting healthy volunteers, head trauma, mild head trauma or acute orthopedic injury        patients meeting enrollment criteria listed below.|December 2015|December 10, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178659||193512|
NCT00178997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040014|Realistic Models of Gastrointestinal Bioelectromagnetism|Realistic Models of Gastrointestinal Bioelectromagnetism|SQUID|Vanderbilt University|No|Recruiting|February 2004|July 2011|Anticipated|||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic|June 2011|June 24, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178997||193487|
NCT00179010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030371|AMP as a Better Delivery System of Adenosine|Use of AMP to Improve Tissue Delivery of Adenosine||Vanderbilt University|No|Suspended|October 2003|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|64|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|September 13, 2005|Yes|Yes|In process of renewing IND for AMP|No||https://clinicaltrials.gov/show/NCT00179010||193486|
NCT00179283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sert-Ven|Sertraline vs. Venlafaxine XR|A Multi-center, Randomized, Double-blind, Parallel-group Study of Sertraline vs. Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder||Vanderbilt University||Completed|April 2002|April 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179283||193466|
NCT00179309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050229|Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer|A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer||National Institutes of Health Clinical Center (CC)|Yes|Completed|September 2005|October 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|85 Years|No|||June 2014|June 30, 2014|September 15, 2005|Yes|Yes||No|April 29, 2013|https://clinicaltrials.gov/show/NCT00179309||193465|The goal of this study was to get preliminary evidence of improved progression free survival with the combination compared with docetaxel alone and obtain data on which to plan a larger more definitive study in a more uniform patient population.
NCT00179595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001747|Does the Relaxation Response Inhibit Acute Stress?|Does the Relaxation Response Inhibit Acute Stress?||Beth Israel Deaconess Medical Center||Recruiting|May 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|140|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2007|October 30, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00179595||193443|
NCT00179608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MEL-003|Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy|Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy||Celgene||Completed|September 2005|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||January 2010|January 8, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00179608||193442|
NCT00179998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z2910s|Effectiveness of Pulmozyme in Infants With Cystic Fibrosis|Efficacy of Pulmozyme in Infants and Young Children With Cystic Fibrosis||Nationwide Children's Hospital|No|Active, not recruiting|January 2005|July 2015|Anticipated|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|1 Month|30 Months|No|||August 2013|August 19, 2013|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00179998||193412|
NCT00180323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC Version 1.1 11/09/2003|ACC - Atrial Contribution to CRT|ACC - Atrial Contribution to CRT||Boston Scientific Corporation|No|Completed|November 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||October 2012|January 5, 2016|September 12, 2005|Yes|Yes||No|March 9, 2012|https://clinicaltrials.gov/show/NCT00180323||193387|
NCT00176618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4611|The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon|The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon||Rutgers, The State University of New Jersey||Terminated|April 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 10, 2009|September 13, 2005|Yes|Yes|principal Investigator left institution|No||https://clinicaltrials.gov/show/NCT00176618||193664|
NCT00174135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701210|Sarcopenia Studies for the Elderly Population in Taiwan|Sarcopenia Studies for the Elderly Population in Taiwan||National Taiwan University Hospital||Recruiting|August 2005|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2004|August 29, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174135||193854|
NCT00174148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701250|Sensorimotor Dysfunction of Individuals With Neck Pain|Sensorimotor Dysfunction of Individuals With Neck Pain||National Taiwan University Hospital||Recruiting|July 2005|July 2006||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2004|December 20, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00174148||193853|
NCT00174577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-Dep-402|Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant|Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to an Adequate Trial of Antidepressant||Rhode Island Hospital||Active, not recruiting|February 2003|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|18 Years|65 Years|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00174577||193820|
NCT00179777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-49395|TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk|TRIGR - Trial to Reduce IDDM in the Genetically at Risk||Children's Hospital of Eastern Ontario|Yes|Active, not recruiting|March 2002|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|2032|||Both|N/A|7 Days|No|||February 2014|February 14, 2014|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00179777||193429|
NCT00179374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2003-068|Improving Diabetes Outcomes With Activity, Nutrition and Medication|Improving Diabetes Medication Adherence and Outcomes||Albert Einstein College of Medicine of Yeshiva University|No|Completed|July 2003|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|556|||Both|40 Years|N/A|No|||April 2009|April 27, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179374||193460|
NCT00179387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #2003-412|Mind-Body Program for Cancer Patients|Evaluation of Mind-Body Groups on the Quality of Life of Cancer Patients||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|December 2004|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00179387||193459|
NCT00186680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT86|CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant|Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment||Stanford University||Completed|September 1996|June 2005|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99|||Both|19 Years|70 Years|No|||February 2010|February 26, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00186680||192925|
NCT00186225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT22|Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors|Stem Cell Transplantation From Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY)||Stanford University||Completed|November 1989|May 2010|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|N/A|50 Years|No|||July 2010|July 23, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186225||192959|
NCT00186238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT27|High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma|High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma||Stanford University||Completed|September 1994|April 2010|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|75 Years|No|||September 2010|September 10, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186238||192958|
NCT00186641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT42|High Dose Chemotherapy and Autologous Transplant for Breast Cancer|High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer||Stanford University||Active, not recruiting||March 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 2007|July 10, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00186641||192928|
NCT00177346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MakarounIDE|A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection|A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection||University of Pittsburgh||Completed|October 2003|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A||||January 2016|January 5, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00177346||193611|
NCT00178152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11627|Erythema Toxicum Neonatorum in Newborns and the Development of Asthma|The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma||University of Rochester||Completed|May 2005|November 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|334|||Both|3 Years|9 Years|No|Probability Sample|Case studies will include subjects between the ages of 3-9 years who have had at least 2        asthma diagnoses within the last 2 years. Patients will be selected based upon their ICD9        codes for asthma. Control subjects will be age matched and without an asthma diagnosis.|May 2011|May 11, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00178152||193551|
NCT00178165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG13305-01|Coordinating Center for Enhancing ADRD Caregiving|Coordinating Center for Enhancing Alzheimer Disease and Related Disorder Caregiving||University of Pittsburgh||Completed|September 1996|November 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1200|||Both|21 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00178165||193550|
NCT00178425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 10410|PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients|Pharmacokinetics of Intravenous / Oral MMF and Oral Tacrolimus in Live Donor and Deceased Donor Liver Transplant Patients||University of Rochester|No|Completed|January 2005|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||April 2007|April 18, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00178425||193530|
NCT00178672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS 01-269 Single Center|A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease|A Single Center IDE Study on Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease||The University of Texas Health Science Center, Houston|Yes|Completed|November 2002|August 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|69|||Both|18 Years|N/A|No|||December 2007|December 11, 2007|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00178672||193511|
NCT00178685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10085|Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence|Self-determination and Maintaining Tobacco Abstinence|SHP|University of Rochester||Completed|August 2004|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|837|||Both|18 Years|N/A|No|||July 2009|January 15, 2013|September 13, 2005||No||No|January 15, 2013|https://clinicaltrials.gov/show/NCT00178685||193510|A limitation of this study is the low completion rate of smokers enrolling in the study. This increases the chance of accepting the null hypothesis when there may be differences between groups if all smokers had provided their outcomes.
NCT00179322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050238|Effects of Sleep Deprivation and Recovery on Cognitive Functions|Effects of Sleep Deprivation and Recovery Sleep on Speech, Language and Other Higher Cognitive Functions: A Combined EEG-fMRI Study||National Institutes of Health Clinical Center (CC)||Completed|September 2005|||||N/A|Observational|N/A|||Actual|29|||Both|20 Years|40 Years|No|||March 2015|April 10, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00179322||193464|
NCT00179621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-004|Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of the Efficacy and Safety of 2 Doses of Lenalidomide Versus Placebo in Red Blood Cell (RBC) Transfusion-Dependent Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With a Deletion (Del) 5q[31] Cytogenetic Abnormality||Celgene|Yes|Completed|July 2005|June 2010|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|205|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|September 10, 2005|Yes|Yes||No|February 9, 2011|https://clinicaltrials.gov/show/NCT00179621||193441|
NCT00179634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000115; BIDMC|Study of Fine Art Photographs and Visualization Tapes to Improve Surgical Recovery in Breast Cancer|Using Visual Milieu Enrichment and Guided Visualization to Augment Patient Well-being and Post-surgical Recovery||Beth Israel Deaconess Medical Center|No|Terminated|March 2005|January 2009|Anticipated|January 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|18 Years|N/A|No|||February 2010|February 3, 2010|September 13, 2005||No|Expired for lack of continuing review|No||https://clinicaltrials.gov/show/NCT00179634||193440|
NCT00179985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2005-12423|The Impact of Implementing NIDCAP on the Developmental Sensitivity of Nurses Caring for Preterm Infants|The Impact of Implementing The Newborn Individualized Developmental Care & Assessment Program on the Developmental Sensitivity of Nurses Caring for Preterm Infants||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|December 2004|July 2011|Actual|May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|NICU Nurse|July 2011|July 28, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00179985||193413|
NCT00180622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-000-068|Markers for COPD|Non-Invasive Markers for COPD||Imperial College London||Completed|July 2001|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||52|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00180622||193364|
NCT00176410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leipzig aortic valve study|Statin Therapy in Asymptomatic Aortic Stenosis|||University of Leipzig||Recruiting|January 2003|December 2009|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|80 Years|No|||September 2006|January 13, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00176410||193680|
NCT00173784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701231|Development of an Instrumental Activities of Daily Living Scale|Development of an Instrumental Activities of Daily Living Scale for Patients||National Taiwan University Hospital||Recruiting|August 2005|April 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||200|||Both|N/A|N/A|No|||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00173784||193881|
NCT00178490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550|Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children|Neurocognitive Function in Children With Hypertension||University of Rochester|No|Completed|January 2005|January 2010|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00178490||193525|
NCT00178503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072263|Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children|ADHD Symptoms in Autism: Cognition, Behavior, Treatment||The University of Texas Health Science Center, Houston|Yes|Completed|September 2005|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|September 12, 2005|Yes|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00178503||193524|We did not have teacher behavioral data for all of the children because some of them were seen during the summer, when teacher input was not available.
NCT00178763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-02-117|Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer|Phase II Clinical Trial of Cisplatin + Gemcitabine in Combination With Mild, Fever-Range Whole-Body Hyperthermia to Treat Patients With Advanced, Inoperable Pancreatic Cancer|FR-WB-TT|The University of Texas Health Science Center, Houston|Yes|Recruiting|September 2003|June 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2011|March 2, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178763||193504|
NCT00179426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000596|Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy|Antiseizure Medication-Induced Elevation of Serum Estradiol and Reproductive Dysfunction in Men With Epilepsy||Beth Israel Deaconess Medical Center||Completed|October 1999|June 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||175|||Male|18 Years|50 Years|No|||September 2005|September 7, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00179426||193456|
NCT00179439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000316|NPDT Evaluation in Children With CFTR and (PSC)|Nasal Potential Difference Testing: Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Children With Primary Sclerosing Cholangitis (PSC)|NPD|Beth Israel Deaconess Medical Center||Terminated|January 2004|||January 2006||N/A|Observational|N/A|||Anticipated|50|||Both|12 Years|N/A|No|||March 2015|March 10, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00179439||193455|
NCT00185796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT168|TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD|Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)||Stanford University||Completed|July 2004|February 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|49 Years|75 Years|No|||March 2015|March 16, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185796||192989|
NCT00185809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSMTS0002|Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study|Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study||Stanford University||Completed|November 2000|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Archival tissue blocks and blood|Female|18 Years|70 Years|No|Non-Probability Sample|Eligibility criteria include histological proof of invasive breast cancer and current        radiological evidence of metastatic disease.|July 2010|July 16, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185809||192988|
NCT00186940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASALL|Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients|A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies||St. Jude Children's Research Hospital|No|Completed|March 2005|February 2010|Actual|February 2010|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|72|||Both|N/A|N/A|No|Non-Probability Sample|Patients at high risk of tumor lysis syndrome who have a history of asthma, eczema, or        significant allergies (to substances other than rasburicase).|October 2011|October 5, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00186940||192905|
NCT00186654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS09988|Acupuncture and Massage for Depression During Pregnancy|Acupuncture and Massage for Depression During Pregnancy||Stanford University||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||180|||Female|18 Years|45 Years|No|||August 2008|September 22, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00186654||192927|
NCT00177866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0312013|Safety of Celecoxib in Patients With Crohn's Disease|The Safety of Celecoxib (Celebrex) in Patients With Crohn's Disease||University of Pittsburgh|Yes|Terminated|December 2003|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|September 13, 2005||No|We were unable to get additional funding to complete study.|No||https://clinicaltrials.gov/show/NCT00177866||193572|
NCT00178178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain Catheter Study|Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions|A Placebo Controlled, Prospective, Randomized Clinical Investigation of the Efficacy of Continuous Infusion Regional Anesthetic on Postoperative Pain Following Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions||University of Rochester|No|Completed|March 2005|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|96|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|September 12, 2005||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT00178178||193549|
NCT00178438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB # 10455|Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease|A Prospective Trial of Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease||University of Rochester||Withdrawn|June 2005|June 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 13, 2005|||Unknown|No||https://clinicaltrials.gov/show/NCT00178438||193529|
NCT00178698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-259|Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors|A Phase II Clinical Trial of Cisplatin + Gemcitabine HCl (GEM) + Low-Dose Metronomic Interferon-a (IFN-a) Combined With Fever-Range Whole-Body Thermal Therapy (FR-WB-TT) in Patients With Metastatic/or Locally Advanced Malignancies (Small-Cell Lung Cancer, Neuroendocrine Cancer, Gastric Cancer)|FR-WB-TT/che|The University of Texas Health Science Center, Houston|Yes|Recruiting|July 2002|June 2014|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2011|March 2, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00178698||193509|
NCT00179335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI 03 143|Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults|Cross Sectional Case-Sectional Control Pharmacokinetic Study of Efavirenz or Lopinavir/Ritonavir as Part of an Antiretroviral Regimen With Two Nucleosides in HIV-Infected Adults 55 Years of Age or Older Compared With Adults Aged 18-35 Years||Albert Einstein College of Medicine of Yeshiva University||Completed|August 2003|September 2006|Actual|January 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|45|Samples Without DNA|Residual plasma left from measurement of drug levels.|Both|18 Years|N/A|No|Non-Probability Sample|Pts enrolled in our clinic who are on either lopinavir/ritonavir or efavirenz, who are        tolerating their HIV meds and who are judged to be compliant.|August 2009|August 5, 2009|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00179335||193463|
NCT00179647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-016|Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma|A Multicenter, Single-Arm, Open-Label, Expanded Access Program for Lenalidomide With or Without Dexamethasone in Previously Treated Subjects With Multiple Myeloma||Celgene|No|Completed|September 2005|April 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1913|||Both|18 Years|N/A|No|||March 2010|March 10, 2010|September 13, 2005|Yes|Yes||Yes|December 21, 2009|https://clinicaltrials.gov/show/NCT00179647||193439|
NCT00179660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NHL-002|Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)|A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma||Celgene||Completed|August 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|September 13, 2005|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT00179660||193438|
NCT00179673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NHL-001|Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma||Celgene|No|Completed|August 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|September 10, 2005|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00179673||193437|
NCT00173238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700533|The Study of Human Atherosclerosis by Polarization-Sensitive Optical Coherence Tomography|||National Taiwan University Hospital||Recruiting|June 2005|June 2008||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||5|||Both|N/A|N/A|No|||June 2005|December 20, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00173238||193923|
NCT00189605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-704LB|Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression|Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression Efficacy|SPINE|ArthroCare Corporation|No|Completed|September 2004|April 2009|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00189605||192702|
NCT00189618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN0104|The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD)|The Effects of Physical Training, Aspirin, and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease||Arteriogenesis Competence Network|Yes|Completed|May 2005|June 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|45 Years|95 Years|No|||October 2008|October 3, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189618||192701|
NCT00185172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-OLM-01-00|Olmesartan in Essential Hypertension|Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension||Daiichi Sankyo Inc.|No|Completed|January 2002|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2333|||Both|18 Years|75 Years|No|||April 2008|April 28, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00185172||193032|
NCT00185562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-033|A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis|A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis||Stanford University||Completed|June 2005|January 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|45 Years|N/A|No|||March 2006|March 23, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00185562||193006|
NCT00186459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR16071-01|Obesity, Weight Loss, and Cardiovascular Disease Risk|GCRC-CAP-Tracey McLaughlin, MD||Stanford University||Enrolling by invitation|October 2000|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|550|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 12, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186459||192941|
NCT00187304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS04012TV|ACTION - Anticoagulation Treatment Influence on Post-operative Patients|Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial||St. Jude Medical||Withdrawn|September 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|September 15, 2005||No|Study replaced by an observational study|No||https://clinicaltrials.gov/show/NCT00187304||192877|
NCT00187044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DID955|Evaluation of the Safety of a Polyvalent Virus in Healthy Adults|Evaluation of the Safety of a Polyvalent Vaccinia Virus-HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults||St. Jude Children's Research Hospital|No|Completed|October 1997|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|September 28, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187044||192897|
NCT00212485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS|Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease|Evaluation of the Role of Power Doppler Sonography in the Diagnosis of Hemophilic Joint Disease||New York Presbyterian Hospital|No|Completed|September 2005|May 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|43|||Both|1 Year|60 Years|No|||June 2010|June 30, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212485||190981|
NCT00212498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11354 (previously 4424)|Tuberculosis Research Blood Bank|||New York University School of Medicine||Withdrawn|November 2006|||January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|21 Years|75 Years|No|Non-Probability Sample|TB patients|December 2015|December 7, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212498||190980|
NCT00212511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10386-02 A|Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry|Prospective Evaluation of Patients With Idiopathic Pulmonary Fibrosis Through an IPF Registry||New York University School of Medicine|Yes|Recruiting|November 2004|January 2018|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients with interstitial lung disease.|September 2014|September 3, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212511||190979|
NCT00212849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF_ACIPF091305|Autologous Chondrocyte Implantation in the Patellofemoral Joint|Autologous Chondrocyte Implantation in the Patellofemoral Joint||Orthopaedic Research Foundation||Completed|January 1995|August 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||35|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212849||190955|
NCT00212537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9698|Disease Modifying Genes in Severe Asthma|Disease Modifying Genes in Severe Asthma||New York University School of Medicine||Active, not recruiting|April 2002|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|2000|Samples With DNA|The total amount of blood drawn is approximately 5 tablespoons (75 ml). The blood sample      will be processed to isolate "genetic material" (mainly DNA, RNA and protein). This genetic      material will be used to try to identify the "genetic factors" or genes that a person      inherits that make him or her more likely to develop asthma. The blood is used to test for      allergies to weeds, trees, insects and molds (RAST) and a complete blood count.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All individuals approached for participation in the Research Registry shall be able to        read or comprehend English. Since participation in the Research Registry does not involve        a risk of physical harm, women of childbearing potential will not be queried as to        pregnancy status or tested for pregnancy unless they are requested to undergo a        methacholine challenge test. There are no additional inclusion/exclusion criteria.|March 2016|March 3, 2016|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00212537||190978|
NCT00208481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03071|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2004|||||N/A|N/A|N/A||||||||||||||September 30, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208481||191284|
NCT00208494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03062|Metal on Metal Versus Ceramic on Metal Hip Replacement|Comparative Study to Evaluate the Safety and Efficacy of the DePuy Ceramic-on-metal Total Hip Prosthesis Versus the DePuy Metal-on-metal Total Hip Prosthesis Through Clinical and Radiographical Data||DePuy Orthopaedics|No|Completed|August 2005|June 2011|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|392|||Both|20 Years|75 Years|No|||August 2013|August 6, 2013|September 13, 2005|Yes|Yes||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00208494||191283|
NCT00187486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC 04101|Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors|Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma||University of California, San Francisco|Yes|Completed|August 2004|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|September 13, 2005|Yes|Yes||No|April 25, 2011|https://clinicaltrials.gov/show/NCT00187486||192863|
NCT00187759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS placebo|Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection|A Placebo Controlled, Randomized, and Blinded Study of Antibiotic Treatment of Patients With Uncomplicated Soft Tissue Infection||University of California, San Francisco||Completed|November 2004|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00187759||192844|
NCT00188019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 04-01|Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers|Evaluation Des méthodes de dépistage du Paragangliome héréditaire Chez Les Sujets prédisposés génétiquement||University Hospital, Angers||Completed|November 2005|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|248|||Both|6 Years|N/A|No|||July 2015|July 22, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188019||192824|
NCT00188552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0244-C|The Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries|A Phase II Study of the Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries||University Health Network, Toronto||Terminated|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|75 Years|No|||August 2010|August 12, 2010|September 12, 2005|||May 2007: No annual renewal|No||https://clinicaltrials.gov/show/NCT00188552||192783|
NCT00188825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621AES05|Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant|A Randomized, Double Blind, Placebo Controlled Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans Syndrome in Bilateral Lung and Single Lung Transplant Patients||University Health Network, Toronto||Completed|May 2004|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||September 2014|September 3, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188825||192762|
NCT00188565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 02-0130-C|Celebrex With Preoperative Chemoradiation - Rectal Cancer|A Phase I/II Trial of Celecoxib With Preoperative Chemoradiation for Resectable Rectal Cancer With In Vivo Analysis of Celecoxib Effector Pathways||University Health Network, Toronto||Completed|March 2004|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188565||192782|
NCT00189345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 2.10|Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients|Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients||AGO Study Group||Completed|May 2004|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||44|||Female|18 Years|N/A||||December 2003|November 7, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189345||192722|
NCT00189631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERO-MB02|UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy|||Association Européenne de Recherche en Oncologie||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2005|December 7, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189631||192700|
NCT00186446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK 103341|Treatment of Nicotine Dependence and Acute Depression|Treatment of Nicotine Dependence and Acute Depression||Stanford University||Active, not recruiting|June 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||February 2007|February 8, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186446||192942|
NCT00186030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R03MH063643-02|Reducing Risk and Trauma-Related Stress in Persons Living With HIV|Reducing Risk and Trauma-Related Stress in Persons Living With HIV||Stanford University||Terminated|April 2003|March 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||102|||Both|18 Years|70 Years||||September 2005|October 5, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186030||192973|
NCT00186043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79739|Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II|A Double-Blind, Placebo-Controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients||Stanford University|No|Completed|August 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||December 2012|December 11, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00186043||192972|
NCT00186472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 5 T 32 MH19908-7|Intervention to Decrease Anxiety in Parents of Infants in the Neonatal Intensive Care Unit (NICU)|||Stanford University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||December 2006|May 31, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186472||192940|
NCT00186810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCALLO|Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease|Allogeneic Stem Cell Transplantation From HLA/MLC Genotype Identical Donors for Patients With High Risk Sickle Cell Disease||St. Jude Children's Research Hospital|No|Completed|December 1992|October 2007|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|21 Years|No|||May 2009|May 28, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00186810||192915|
NCT00187057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-1|Study for Treatment of Cancer in Children With Ataxia-telangiectasia|Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia||St. Jude Children's Research Hospital|No|Completed|September 2002|June 2013|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|6|||Both|N/A|10 Years|No|||August 2013|August 26, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187057||192896|
NCT00187070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCLIII|Large Cell Lymphoma Pilot Study III|Large Cell Lymphoma, Pilot Study III||St. Jude Children's Research Hospital|No|Completed|December 1997|July 2001|Actual|July 2001|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|18 Years|No|||May 2008|May 6, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187070||192895|
NCT00212199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK58299 (completed 2205)|Effectiveness of Brief Counseling for Weight Management|Effectiveness of Brief Counseling for Weight Management||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 2002|August 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||246|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212199||191003|
NCT00212550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9250-04B|Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb|||New York University School of Medicine||Completed|November 2006|||||N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|TB patients|June 2012|June 20, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212550||190977|
NCT00212576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The BELLE Project|Promoting Early School Readiness in Primary Health Care|Promoting Early School Readiness in Primary Health Care||New York University School of Medicine|Yes|Active, not recruiting|November 2005|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|675|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00212576||190976|
NCT00209053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-1999|SMART Trial Longitudinal Follow-Up:Off-Pump Versus On-Pump Coronary Artery Bypass Surgery|A Prospective, Randomized Comparison of Graft Patency and Clinical Outcomes After Coronary Bypass Surgery Performed With and Without the Use of Cardiopulmonary Bypass:Longitudinal Follow-Up||Emory University||Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|87|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00209053||191240|
NCT00187499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6788-20160-04|Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma|Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma||University of California, San Francisco||Completed|October 2002|February 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||September 2005|April 2, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187499||192862|
NCT00187772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH059661|Child-Parent Psychotherapy for Preschooler Witnesses of Domestic Violence Program|Preschooler Witnesses of Domestic Violence: A Preventive Intervention Program||University of California, San Francisco||Completed|December 1996|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00187772||192843|
NCT00187733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005|Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides|Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides||University of California, San Francisco|No|Completed|January 2005|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples With DNA|Blood Draw (10cc) to determine eligibility (CBC, blood chemistries). Blood draw (20cc) at      t=0 in fasting state for baseline measurement of biochemical markers (including carnitine,      acylcarnitines, creatinine, and total lipid panel) Urine collection at t=0 Blood draw (20cc)      at t=2 hours for measurement of biochemical markers (including carnitine, acylcarnitines,      creatinine, and total lipid panel) Urine collection at t=2 hours Transformation of blood to      establish lymphoblastoid cell lines (from blood samples collected at t=0 and t=2 hours)|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals per screening laboratory results and health questionnaire|September 2012|September 11, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00187733||192846|
NCT00187746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|992|Effect of Age on the Renal Clearance of Adefovir|Effect of Age on the Renal Clearance of Adefovir||University of California, San Francisco|Yes|Withdrawn|August 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|September 14, 2005||No|Budget exceeded for project.|No||https://clinicaltrials.gov/show/NCT00187746||192845|
NCT00188006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL 97-01|Complement Activation and Central Nervous System Injury After Coronary Artery Surgery|Biocompatible Cardiopulmonary Bypass and Neuropsychological Outcome After Coronary Artery Bypass Surgery||University Hospital, Angers||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188006||192825|
NCT00189371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 2.7|Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum|Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum||AGO Study Group||Terminated|February 2004|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Female|18 Years|N/A||||September 2005|September 16, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189371||192720|
NCT00189384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC/SNL 11150-0902-50001-269|Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants|Randomized Controlled Trial of Intramuscular Ceftriaxone Versus Procaine Penicillin Versus Cotrimoxazole and Gentamicin for Management of Serious Bacterial Infections in Young Infants in Community Settings||Aga Khan University||Active, not recruiting|November 2003|December 2005||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||426|||Both|N/A|59 Days|No|||September 2006|September 7, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189384||192719|
NCT00189059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/341-E|Effects of Amitriptyline for the Treatment of Pain on Driving Performance and Cognition.|Effects of Pain and the Treatment of Pain With Amitriptyline on Driving Performance, Attentional Capacity and Psychomotor Performance in Chronic Neuropathic Pain Patients||UMC Utrecht||Terminated|October 2002|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|30 Years|60 Years|No|||April 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189059||192744|
NCT00189358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 2.6|A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy|A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy||AGO Study Group||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||July 2010|July 19, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189358||192721|
NCT00185601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R18DK065729-02|Internet Diabetes Self-Management Workshop|Internet Diabetes Self-Management Evaluation||Stanford University|No|Completed|February 2006|June 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|761|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00185601||193003|
NCT00185653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT126|Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma|Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors for the Treatment of Multiple Myeloma||Stanford University||Completed|October 2000|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|60 Years|No|||February 2011|February 10, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185653||193000|
NCT00185666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN0001|Cyberknife Precision Radiation Delivery System for Tumors of the Spine|Cyberknife Precision Radiation Delivery System for Tumors of the Spine||Stanford University||Completed|May 2002|May 2006|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|5 Years|N/A|No|||July 2010|July 12, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185666||192999|
NCT00186056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78804|Mifepristone in Refractory Depression|Mifepristone in Refractory Depression||Stanford University||Active, not recruiting|January 2003|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||September 2005|December 23, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00186056||192971|
NCT00186069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79811|Magnesium Sulfate vs Placebo for Placental Abruption|Randomized, Double Blind Trial of Magnesium Sulfate Tocolysis Versus Intravenous Saline for Suspected Placental Abruption||Stanford University|No|Active, not recruiting|March 2004|June 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|N/A|No|||March 2015|March 30, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186069||192970|
NCT00187083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLR16|A Study of Children With Refractory or Relapsed ALL|A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16)||St. Jude Children's Research Hospital|No|Completed|February 1997|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|18 Years|No|||June 2008|June 3, 2008|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00187083||192894|
NCT00187343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BreastIMRT|A Clinical Trial to Reduce Skin Burn Induced by Breast Radiotherapy Using Intensity Modulated Radiation Therapy (IMRT)|A Phase III Study of Adjuvant Radiation Therapy in Early Breast Cancer Comparing the Use of Breast Intensity Modulated Radiation Therapy (IMRT) to Conventional Wedge Technique||Sunnybrook Health Sciences Centre||Completed|September 2003|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||340|||Female|N/A|N/A|No|||September 2005|September 5, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00187343||192874|
NCT00186823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPSCT|Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies|Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies||St. Jude Children's Research Hospital|Yes|Completed|March 2002|January 2009|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|2 Years|21 Years|No|||January 2009|January 28, 2009|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00186823||192914|
NCT00187876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|566-2003|Evaluation of Biocleanse Allografts For ACL Reconstruction|Evaluation of Biocleanse Patellar Tendon Allografts For The Reconstruction of Anterior Cruciate Ligaments: A Prospective, Randomized Investigation||University of Florida|Yes|Completed|February 2004|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|55 Years|No|||January 2014|January 30, 2014|September 12, 2005|Yes|Yes||No|December 4, 2013|https://clinicaltrials.gov/show/NCT00187876||192835|
NCT00208520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO 2002/183|Second-Line Treatment Choice for Epilepsy|Second-Line Treatment Choice for Epilepsy||Dutch Epilepsy Clinics Foundation||Active, not recruiting|July 2003|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2006|September 11, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208520||191281|
NCT00208767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024913|Effect of Valsartan on Carotid Artery Disease|Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)||Emory University|Yes|Completed|February 2005|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|21 Years|80 Years|No|||November 2015|November 9, 2015|September 13, 2005|Yes|Yes||No|September 12, 2014|https://clinicaltrials.gov/show/NCT00208767||191262|
NCT00208780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-2004|Effects of Tetrahydrobiopterin on Blood Pressure|Effects of Tetrahydrobiopterin on Blood Pressure||Emory University|No|Completed|December 2004|December 2005|Actual|December 2005|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||November 2013|November 15, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208780||191261|
NCT00217646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00081|Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia|Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase||National Cancer Institute (NCI)||Completed|October 2005|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||February 2013|April 27, 2015|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00217646||190593|
NCT00188058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 01 - 02|Comparison of 2 Strategies of Adjustment of Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome|Comparison of Two Strategies for Setting Positive End-Expiratory Pressure in Acute Lung Injury/ Acute Respiratory Distress Syndrome (ExPress Study).||University Hospital, Angers||Recruiting|September 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188058||192821|
NCT00188604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0741-C|The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer|A Randomized Phase II Placebo-controlled Double Blind Study of Using Selenium in the Treatment of Secondary Lymphedema in Breast Cancer Patients||University Health Network, Toronto||Completed|January 2004|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|34|||Female|18 Years|N/A|No|||August 2010|August 12, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188604||192779|
NCT00188032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-04-01|Strategies for Suspected Pulmonary Embolism in Emergency Departments|Strategies for Suspected Pulmonary Embolism in Emergency Departments - SPEED Study||University Hospital, Angers||Completed|June 2005|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|1331|||Both|N/A|N/A|No|||February 2009|February 4, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188032||192823|
NCT00188305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN04-0729-CE|A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients|A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients||University Health Network, Toronto|No|Completed|January 2005|August 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|252|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188305||192802|
NCT00188578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0298-C|Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)|A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2)||University Health Network, Toronto||Completed|June 2003|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188578||192781|
NCT00189397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD 358|Azathioprine Versus Corticosteroids in Parthenium Dermatitis|Azathioprine Versus Corticosteroids for the Treatment of Parthenium Dermatitis||All India Institute of Medical Sciences, New Delhi|Yes|Completed|February 2003|January 2006|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||May 2008|May 6, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189397||192718|
NCT00189072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/327|Effects of Gabapentin in the Treatment of Neuropathic Pain on Driving Performance and Cognition|Effects of Pain and the Treatment of Pain With Gabapentin (900-3600 Mg) on Driving Ability, Attentional Capacity and Psychomotor Performance in Chronic Neuropathic Pain Patients||UMC Utrecht||Terminated|April 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|30 Years|60 Years|No|||May 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189072||192743|
NCT00185185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-866/27|Olmesartan Medoxomil in Atherosclerosis|Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)||Daiichi Sankyo Inc.||Completed|November 2001|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|165|||Both|35 Years|75 Years|No|||December 2007|December 12, 2007|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00185185||193031|
NCT00185588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-06999|Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer|A Phase 1-2 Study of the VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 <Vatalanib> and Gemcitabine in Patients With Advanced Pancreatic Cancer||Stanford University|Yes|Completed|October 2004|December 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 12, 2005|No|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT00185588||193004|
NCT00185614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT109|Mixed Chimera Allo Transplantation in Multiple Myeloma|Mixed Chimera Allogeneic Transplantation With or Without Allogeneic Idiotyped Pulsed Dendritic Cells for the Treatment of Multiple Myeloma||Stanford University|Yes|Completed|August 2000|April 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|70 Years|No|||April 2011|April 18, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185614||193002|
NCT00185640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT153|Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies|Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies||Stanford University|Yes|Completed|March 2003|January 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|299|||Both|N/A|70 Years|No|||February 2015|February 18, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185640||193001|
NCT00186485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanford 79133|Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression|Safety and Efficacy of Open Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression||Stanford University||Active, not recruiting|May 2003|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2007|December 14, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00186485||192939|
NCT00187096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKAML|Natural Killer (NK) Cell Transplantation for AML|Pilot Study Of Haplo-Identical Natural Killer Cell Transplantation For Acute Myeloid Leukemia||St. Jude Children's Research Hospital|Yes|Completed|September 2005|March 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|N/A|21 Years|No|||October 2013|June 18, 2014|September 12, 2005|Yes|Yes||No|October 10, 2012|https://clinicaltrials.gov/show/NCT00187096||192893|
NCT00186836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2400|Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients|Efficacy of Combined Hepatitis A and Hepatitis B (Twinrix) Vaccine Compared With Hepatitis B Vaccine Alone in Providing Seroprotection Against Hepatitis B in Hemodialysis Patients||St. Joseph's Healthcare Hamilton||Completed|November 2004|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186836||192913|
NCT00187889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWISE|EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia|A Double-Blind, Multicenter, Placebo Controlled Study of Aldosterone Blockade (Eplerenone) in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease||University of Florida|Yes|Completed|August 2004|December 2011|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Female|21 Years|75 Years|No|||October 2011|August 7, 2013|September 10, 2005|Yes|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT00187889||192834|
NCT00188149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGC05MK1002|Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET|Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy||University Hospital Carl Gustav Carus||Recruiting|May 2000|December 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|16 Years|75 Years|No|||September 2005|December 28, 2005|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00188149||192814|
NCT00187564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7023-25421|Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus|Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus||University of California, San Francisco||Completed|August 2004|October 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|8 Years|21 Years|No|||September 2005|May 2, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187564||192857|
NCT00187863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61-2005|Biopsychosocial Factors' Influence on Shoulder Pain|Biopsychosocial Factors' Influence on Shoulder Pain||University of Florida||Completed|May 2005|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|340|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with chronic shoulder pain and disability|March 2015|March 20, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00187863||192836|
NCT00188682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNREB#00-0081-C|Breast Study to Determine the Ability of Non-Invasive Optical Transillumination Spectroscopy to Predict Breast Density.|Optical Transillumination Spectroscopy of Breast Tissue in Pre- and Post-Menopausal Women.||University Health Network, Toronto|No|Completed|March 2000|September 2003|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|300|||Female|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cohort recruited from the Marvelle Koffler Centre at Mount Sinai Hospital (Toronto,        Ontario, Canada)|November 2007|November 13, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188682||192773|
NCT00217906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|299|A+ Asthma Early Intervention in Asthma Management|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|October 1999|March 2004|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|3 Years|4 Years|No|||December 2005|February 17, 2016|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00217906||190575|
NCT00221663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7945-00|Conventional Versus Mini-Sternotomy for Aortic Valve Surgery|Clinical Trial Comparing a Conventional Median Sternotomy Versus a Minimally Invasive Technique for Aortic Valvular Replacement in Adults||University Hospital, Bordeaux|Yes|Terminated|January 2002|December 2006|Actual|January 2002|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|78|||Both|18 Years|N/A|No|||August 2008|August 14, 2008|September 13, 2005||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00221663||190291|
NCT00217425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441194|Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms|Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms||Eastern Cooperative Oncology Group|No|Completed|July 2006|March 2014|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|September 20, 2005|Yes|Yes||No|February 20, 2014|https://clinicaltrials.gov/show/NCT00217425||190610|
NCT00217659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000442919|S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer|A Phase II Study of Goserelin Plus Anastrozole for the Treatment of Male Patients With Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer||Southwest Oncology Group|Yes|Withdrawn|September 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Male|18 Years|N/A|No|||January 2013|January 2, 2013|September 20, 2005|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00217659||190592|
NCT00188617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB04-0420-C|Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC|Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery||University Health Network, Toronto|Yes|Completed|January 2005|November 2009|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00188617||192778|
NCT00188045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 01-13|Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients|Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients||University Hospital, Angers||Terminated|April 1995|December 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||54|||Both|18 Years|75 Years|No|||December 2001|December 28, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188045||192822|
NCT00188318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0557-C|Hardwins - Squamous Cell Carcinoma Head & Neck (Surgery/RT)|A Phase II Study of Hyperfractionated Accelerated Radiotherapy Delivered With Integrated Neck Surgery for Node-positive Cases in Squamous Cell Carcinoma of the Head and Neck||University Health Network, Toronto||Completed|June 1998|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188318||192801|
NCT00188591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNREB#05-0154-CE|Light Based Analysis of Developing Breast Tissue in Adolescent Girls: a Feasibility Study|Pilot Study to Investigate the Feasibility of Optical Spectroscopy to Quantify Bulk Breast Tissue Properties in Girls Age 10 - 14 Years||University Health Network, Toronto|No|Completed|April 2005|November 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Female|10 Years|14 Years|Accepts Healthy Volunteers|Probability Sample|Residents of Toronto, Ontario, Canada.|November 2008|November 21, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188591||192780|
NCT00189111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC.2004.100-GROUND|Non-Invasive Cardiac Screening in High Risk Patients -The GROUND Study|Non-Invasive Cardiac Screening in High Risk Patients -The GROUND Study||UMC Utrecht||Recruiting|January 2005|April 2012|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|1200|||Both|50 Years|N/A|No|||November 2008|November 13, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189111||192740|
NCT00189124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-0822|Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention|Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?||University of Michigan||Recruiting|June 2001|October 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|18 Years|N/A|No|||September 2005|February 22, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00189124||192739|
NCT00189644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERO-B2000|6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer|||Association Européenne de Recherche en Oncologie||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189644||192699|
NCT00185211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91031|BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study|Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.||Bayer|Yes|Completed|August 2002|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|468|||Both|18 Years|48 Years|No|||December 2013|December 4, 2013|September 9, 2005|Yes|Yes||No|July 23, 2009|https://clinicaltrials.gov/show/NCT00185211||193029|Participant Flow: Subject with "Other" as reason for not completing a study period are presented according to the NIH pre-specified categories as far as possible.
NCT00185224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90927|Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive|A Single-center, Open-label, Controlled, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive (SH T00658ID) as Compared to a Sequential Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D00264A) on Plasma Lipids, Hemostatic Variables, and Carbohydrate Metabolism in Healthy Female Volunteers Aged 18-50 Years Over 7 Treatment Cycles, Including the Pharmacokinetics||Bayer||Completed|March 2005|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|58|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 14, 2011|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185224||193028|
NCT00185237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91441|Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch|A Multicenter, Double-blind, Randomized, Placebo Controlled Study on the Effect of Ultra-low Dose Transdermal Estradiol (Menostar®) on the Incidence and Severity of Hot Flushes, Other Menopausal Symptoms and on Well-being in Postmenopausal Asian Women Over 12 Weeks.||Bayer|No|Completed|July 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|165|||Female|45 Years|65 Years|No|||December 2014|December 22, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00185237||193027|
NCT00218803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV 99-01-11-01|Teaching Children With Asthma and Who Live in a Rural Setting How to Self-Manage Their Asthma|A+ Asthma Rural Partnership||National Institute of Nursing Research (NINR)|Yes|Completed|August 2000|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|220|||Both|5 Years|12 Years|No|||September 2008|September 3, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218803||190510|
NCT00218816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-01-06-02|Nebulizer Intervention for Minority Children With Asthma|Nebulizer Intervention for Minority Children With Asthma||National Institute of Nursing Research (NINR)|Yes|Completed|August 2000|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|221|||Both|2 Years|8 Years|No|||September 2008|September 3, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218816||190509|
NCT00187577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7285-26596-01|Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata|Efficacy and Safety of Latanoprost (Xalatan) and Bimatoprost (Lumigan) Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata||University of California, San Francisco|No|Completed|June 2005|March 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187577||192856|
NCT00221013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-RE-ARF001-40-R|Augmented Vs. Normal Renal Replacement Therapy in Severe Acute Renal Failure (ARF).|Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).||The George Institute|Yes|Completed|November 2005|January 2009|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1508|||Both|18 Years|N/A|No|||February 2009|February 25, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221013||190341|
NCT00188162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0898|Minimum Dose CT Post Lung Biopsy|Can Minimum Dose CT Post Lung Biopsy Predict Patient Outcome?||University Health Network, Toronto||Completed|January 2004|September 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|16 Years|N/A|No|||September 2005|April 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188162||192813|
NCT00188396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0225-AE|Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response|The Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response: A Comparison of Premenopausal, Perimenopausal and Postmenopausal Women||University Health Network, Toronto|No|Completed|April 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|65 Years|No|||January 2007|March 12, 2009|September 9, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00188396||192795|
NCT00188409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0122|Pneumothorax Post CT Lung Biopsy|Pneumothorax Following CT-Guided Lung Biopsy: Is There a Role for the Post Biopsy CT in Patient Management||University Health Network, Toronto||Completed|February 2002|February 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Both|16 Years|N/A|No|||September 2005|April 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188409||192794|
NCT00221377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STV1/05|"Cuffed Versus Uncuffed Tracheal Tubes in Small Children"|"Cuffed Versus Uncuffed Tracheal Tubes in Small Children"||University Children's Hospital, Zurich||Completed|April 2005|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|4000|||Both|N/A|5 Years|No|||December 2011|May 16, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221377||190313|
NCT00221676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-UA-20011207|Effectiveness of Influenza Vaccination Among General Practitioners|Effectiveness of Influenza Vaccination (Alfarix)in Preventing Clinical Influenza Cases Among General Practitioners: Non-Randomized Clinical Trial.||University Hospital, Antwerp||Completed|July 2002|June 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|25 Years|76 Years|Accepts Healthy Volunteers|||September 2005|November 27, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221676||190290|
NCT00217438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.00|Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma|A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine||Fred Hutchinson Cancer Research Center|Yes|Completed|July 2005|||October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|70 Years|No|||August 2015|August 4, 2015|September 20, 2005|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00217438||190609|
NCT00187785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC200552|Doctor-Patient Communication in Spanish|Doctor-Patient Communication in Spanish||University of California, San Francisco||Terminated|September 2005|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||100|||Both|18 Years|N/A|No|||August 2005|January 13, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00187785||192842|
NCT00187798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|928|Impact of Genetics on Metformin Pharmacokinetics|Impact of Genetics on Metformin Pharmacokinetics||University of California, San Francisco|Yes|Completed|August 2001|July 2007|Actual|July 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187798||192841|
NCT00188331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COIT1|Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy|Cognitive Function and Fatigue in Cancer Patients After Chemotherapy: A Longitudinal Controlled Study in Patients With Colorectal Cancer||University Health Network, Toronto|No|Completed|November 2003|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|441|Samples With DNA|cytokines, genotyping apoE, EUC, LFTs, sex hormones, coagulation factors|Both|18 Years|75 Years|No|Probability Sample|colorectal cancer patients aged 18-75|March 2016|March 21, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188331||192800|
NCT00188344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-76449|A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia|A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia||University Health Network, Toronto|Yes|Active, not recruiting|September 2005|March 2015|Anticipated|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188344||192799|
NCT00188838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0378-E|Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder|Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder||University Health Network, Toronto||Active, not recruiting|July 2002|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||210|||Both|18 Years|60 Years|No|||July 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188838||192761|
NCT00189085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZET|Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function|The Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Dysfunction in Patients With the Metabolic Syndrome.||UMC Utrecht||Completed|December 2004|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Male|18 Years|70 Years|No|||August 2004|June 9, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189085||192742|
NCT00189423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265|ResQ Trial: Impact of an ITD and Active Compression Decompression CPR on Survival From Out-of-Hospital Cardiac Arrest|ResQ Trial: Comparison of Standard CPR Alone Versus Active Compression Decompression CPR Plus an ITD on Survival From Out-of-Hospital Cardiac Arrest|ResQ|Advanced Circulatory Systems|Yes|Terminated|October 2005|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1653|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|September 12, 2005|Yes|Yes|Terminated due to lack of funding. Follow-up completed for all enrolled subjects.|No|March 1, 2012|https://clinicaltrials.gov/show/NCT00189423||192716|
NCT00189657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERO-R98|5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer|||Association Européenne de Recherche en Oncologie||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189657||192698|
NCT00185198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91297|Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)|Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone 50-100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up||Bayer|No|Completed|September 2004|October 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|363|||Male|50 Years|80 Years|No|||April 2014|April 1, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00185198||193030|
NCT00189670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERO-B03|Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer|A Phase II Randomized Trial of 6 TEC Every 3 Weeks, Versus 4 EC Followed by 4 Taxotere Every 2 Weeks, Versus 4 Taxotere Followed by 4 EC Every 2 Weeks in Node Positive Breast Cancer||Association Européenne de Recherche en Oncologie||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A||||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189670||192697|
NCT00185692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT124|Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies|Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies||Stanford University|Yes|Completed|August 2000|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|12 Months|80 Years|No|||January 2015|January 30, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185692||192997|
NCT00186082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95339|Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs|A Randomized Controlled Trial of the Effect of Prophylactic Antibiotics on the Infection Rate in Postpartum Third and Fourth Degree Perineal Tear Repairs||Stanford University|No|Completed|September 2003|June 2008|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|147|||Female|18 Years|N/A|No|||June 2011|June 13, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186082||192969|
NCT00186095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT129|Mixed Chimeric Transplantation for Primary Amyloidosis|Mixed Chimeric Transplantation for Primary Amyloidosis||Stanford University|Yes|Withdrawn|December 2000|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|N/A|60 Years|No|||October 2007|October 5, 2007|September 13, 2005|||Closed, never started.|No||https://clinicaltrials.gov/show/NCT00186095||192968|
NCT00219518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY03-368|Mechano-physiological Approach to Anorectal Function|Mechano-physiological Approach to Normal Anorectal Function and the Classification of Defecatory Disorders||Penn State University||Terminated|February 2006|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|women with no defecatory dysfunctionl|September 2009|June 1, 2011|September 14, 2005||No|inadequate no of constip patients|No||https://clinicaltrials.gov/show/NCT00219518||190456|
NCT00219817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-1291-203|Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss|||Helsinn Therapeutics (U.S.), Inc||Completed|June 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|September 12, 2005||Yes||||https://clinicaltrials.gov/show/NCT00219817||190433|
NCT00219830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM2376-02-02|A Trial of a Home Based Walking Program as an Alternate Program for Non Attenders at Cardiac Rehabilitation|Health and Social Inequalities in the Uptake of Cardiac Rehabilitation in Northern Ireland: an Alternative Program for Non-Attenders: (2) a Randomised Controlled Trial.|CRU-SHAL|Queen's University, Belfast|No|Completed|January 2005|May 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|432|||Both|N/A|N/A|No|Non-Probability Sample|Patients registered in selected general practices who had a record of having had a        myocardial infarction 12 weeks previous to identification point|February 2009|February 18, 2009|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00219830||190432|
NCT00221637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9236-01|Efficacy of Valproate in Peripheral Neuropathic Pain|Efficacy of a Therapeutic Strategy in Peripheral Neuropathic Pain: Intravenous Sodium Valproate Followed by Oral Route Treatment Versus Placebo (Clinical and Neurophysiologic Evaluation)||University Hospital, Bordeaux|Yes|Terminated|March 2002|July 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|September 13, 2005|||slow recruitment and treatments beyond expiry date|No||https://clinicaltrials.gov/show/NCT00221637||190293|
NCT00221390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2003-3096|Trial of Ropinirole in Motor Recovery After Stroke|Randomized, Placebo-Controlled, Double-Blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery After Stroke||University of California, Irvine|No|Completed|October 2003|May 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||June 2008|June 19, 2008|September 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00221390||190312|
NCT00221689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9244-01|Intrathecal Baclofen Therapy and Paroxysmal Dysautonomia in Severe Brain-Injured Patients|Early Treatment of Paroxysmal Dysautonomia and Hypertonia for Severe Brain Injured Patients by Intrathecal Baclofen Therapy||University Hospital, Bordeaux|Yes|Terminated|March 2003|February 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|September 13, 2005|||very slow recruitment and treatments beyond expiry date|No||https://clinicaltrials.gov/show/NCT00221689||190289|
NCT00217451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2002/FOS-CLIN/JP006|Treatment of Malaria in Gabon With Fosmidomycin-Clindamycin|Evaluation of Fosmidomycin in Combination With Clindamycin in Children With Acute Uncomplicated Plasmodium Falciparum Malaria||Albert Schweitzer Hospital||Completed|June 2002|March 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||51|||Both|12 Months|14 Years|No|||September 2005|September 19, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00217451||190608|
NCT00187837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10001|The CAP-1 Trial: Stepwise Excavation Versus One Completed Excavation in Deep Caries|The CAP-1 Trial: Effect of Stepwise Versus One Completed Excavation in Deep Caries in Permanent Teeth: A Randomised, Patient - and Observer-blinded Multicenter Trial||University of Copenhagen|Yes|Active, not recruiting|February 2005|December 2009|Anticipated|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|314|||Both|18 Years|N/A|No|||October 2009|October 2, 2009|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00187837||192838|
NCT00188097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 03-04|Diagnosis of Variceal Bleeding and Its Control in Cirrhosis|Diagnosis of Variceal Bleeding and Its Control in Cirrhosis||University Hospital, Angers||Terminated|November 1999|June 2002||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|18 Years|75 Years|No|||August 2005|January 18, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188097||192818|
NCT00188110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-02-01|Performance of the Water-Enema Computed Tomography (WE-CT)|Evaluation of the Water-Enema Computed Tomography for the Diagnosis of Colon Tumor||University Hospital, Angers||Recruiting|March 2003|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Both|18 Years|N/A|No|||September 2005|January 8, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188110||192817|
NCT00188123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151:2004/8333 MPA Sweden|Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With Magnetic Resonance Imaging (MRI)|Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With MRI||University Hospital, Linkoeping|No|Completed|April 2004|April 2009|Actual|September 2005|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|20 Years|80 Years|No|Non-Probability Sample|Patient with an in-hospital diagnosis of myocardial infarction having permanent atrial        fibrillation.|September 2005|July 14, 2009|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00188123||192816|
NCT00188370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0508-C|Ultrasound Biomicroscopy - Apoptosis|Ultrasound Biomicroscopy for Monitoring Apoptosis in Lymphoma, Melanoma and Basal Cell Carcinoma Patients During Chemotherapy or Radiation Therapy||University Health Network, Toronto||Completed|April 1999|December 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|18 Years|N/A|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188370||192797|
NCT00188656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0467|Computed Tomography (CT) in Head and Neck Patients|Minimum Dose CT in the Detection of Lung Nodules in Patients With Head and Neck Cancer||University Health Network, Toronto||Terminated|August 2003|September 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|16 Years|N/A|No|||December 2010|December 14, 2010|September 12, 2005|||insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00188656||192775|
NCT00188851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR82716|Structured Treatment Interruption for HIV Patients With Virologic Failure|A Prospective Randomized Trial of Structured Treatment Interruption(STI) Followed by Initiation of a New Antiretroviral Regimen(ARV) Versus Immediate Switching to a New ARV in HIV-Infected Patients Experiencing Virologic Failure on HAART||University Health Network, Toronto||Completed|January 2001|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||196|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188851||192760|
NCT00189098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAZ 01-235|Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media|Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media||UMC Utrecht||Completed|February 2003|November 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|1 Year|12 Years|No|||April 2012|June 8, 2012|September 12, 2005||||No|April 12, 2012|https://clinicaltrials.gov/show/NCT00189098||192741|
NCT00185705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telmisartan adolescents|Treatment of Insulin Resistance in Hypertensive, Obese Adolescents|Randomized, Placebo Controlled, Double Blind Trial of Telmisartan in Hypertensive, Obese Adolescents||Stanford University||Recruiting|October 2006|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||February 2007|February 12, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00185705||192996|
NCT00189410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-GYN 3|Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours|Phase II Trial With Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin (PLD) and Carboplatin in Malignant Gynecologic Tumour's||AGO Study Group||Completed|June 2003|September 2006|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Female|18 Years|N/A|No|||July 2010|July 19, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189410||192717|
NCT00189683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERO-MC04|Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy|||Association Européenne de Recherche en Oncologie||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189683||192696|
NCT00185250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91115|Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy|Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study to Evaluate Efficacy and Safety of 4 and 8 Million Units Betaferon®/Betaseron® (Interferon Beta-1b) Given Subcutaneously Every Other Day Over 24 Weeks in Patients With Chronic Viral Cardiomyopathy||Bayer|Yes|Completed|December 2002|November 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|138|||Both|18 Years|75 Years|No|||December 2008|December 18, 2008|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185250||193026|
NCT00185679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-12600|Haploid Allogeneic Transplant Using the CliniMACS System|A Feasibility Study Evaluating Haploidentical Allogeneic Transplantation Using the CliniMACS System in Patients With Advanced Hematologic Malignancies||Stanford University|Yes|Terminated|November 2001|February 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|50 Years|No|||February 2015|February 26, 2015|September 12, 2005|Yes|Yes|This study was superseded by the subsequent study IRB-15919 (NCT01050764)|No|February 26, 2015|https://clinicaltrials.gov/show/NCT00185679||192998|
NCT00186849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-97|Therapy for Children With Advanced Stage High Risk Neuroblastoma|Therapy for Children With Advanced Stage High Risk Neuroblastoma||St. Jude Children's Research Hospital|Yes|Completed|October 1997|April 2001|Actual|April 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|18 Years|No|||May 2009|May 19, 2009|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00186849||192912|
NCT00217607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441642|Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery|Multicentric Phase II Study Evaluating the Efficacy and Toxicity of Weekly Paclitaxel in Locally Advanced or Metastatic Soft Tissue Angiosarcomas That Cannot be Treated by Surgery||National Cancer Institute (NCI)||Recruiting|February 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|70 Years|No|||December 2006|December 13, 2009|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00217607||190596|
NCT00220116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2147|Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer|A Phase II Trial Assessing the Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer.||Royal Marsden NHS Foundation Trust|No|Completed|August 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|N/A|No|||January 2010|January 5, 2010|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220116||190410|
NCT00220129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2186|Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus|Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus||Royal Marsden NHS Foundation Trust|No|Completed|November 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2009|December 15, 2009|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220129||190409|
NCT00220714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-SCH-420|PREvent First Episode Relapse (PREFER)|Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia||State University of New York - Downstate Medical Center||Active, not recruiting|November 2004|December 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|16 Years|50 Years|No|||March 2008|March 28, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220714||190364|
NCT00189501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040159|A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)|A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)||Amgen||Completed|December 2004|||||N/A|Observational|Time Perspective: Prospective||||1000|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189501||192710|
NCT00221325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC05254|A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma|Phase I Study of Intraventricular Administration of Rituximab in Combination With Methotrexate in the Treatment of Recurrent CNS and Intraocular Lymphoma||University of California, San Francisco|Yes|Completed|April 2007|March 2013|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00221325||190317|
NCT00221338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5636-26795-01|Clinical Trial of Gabapentin to Improve Postoperative Pain in Surgical Patients|Clinical Trial of Gabapentin to Improve Postoperative Pain in Surgical Patients||University of California, San Francisco|Yes|Completed|January 2006|July 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|750|||Both|65 Years|N/A|No|||July 2015|July 14, 2015|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00221338||190316|
NCT00217620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03063|S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas|Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas||National Cancer Institute (NCI)|No|Completed|March 2006|September 2012|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||January 2013|May 5, 2014|September 20, 2005|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00217620||190595|
NCT00217893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293|Environmental Tobacco Smoke Exposure Reduction in High-Risk Preteens|ETS Reduction in High-Risk Preteens: A Controlled Trial||San Diego State University|Yes|Completed|February 2003|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|203|||Both|8 Years|13 Years|No|||October 2013|October 22, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217893||190576|
NCT00217464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441210|Fulvestrant in Treating Patients With Recurrent Prostate Cancer|Multicenter Study of Fulvestrant (Faslodex®) in Early, Recurrent Prostate Cancer Following Local Therapy: A Phase II Trial||Roswell Park Cancer Institute|Yes|Terminated|June 2004|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|N/A|N/A|No|||March 2015|March 31, 2015|September 20, 2005|Yes|Yes|Closed for futility|No|March 17, 2015|https://clinicaltrials.gov/show/NCT00217464||190607|
NCT00217698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 19/03|Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)||Swiss Group for Clinical Cancer Research|Yes|Completed|November 2003|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||June 2012|June 2, 2012|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00217698||190590|
NCT00217997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-6|Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals|Impulsivity, Brain Function and Substance Abuse Treatment||The University of Texas Health Science Center, Houston|No|Completed|September 2005|January 2013|Actual|January 2013|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|192|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Cocaine Dependent Subjects|May 2013|May 3, 2013|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00217997||190568|
NCT00187850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10002|The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy|The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy on CAP-1 Patients: A Randomised, Patient - and Observer-Blinded Multicenter Trial||University of Copenhagen|Yes|Active, not recruiting|February 2005|December 2009|Anticipated|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2009|October 2, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187850||192837|
NCT00188357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0605-A|HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus|HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus||University Health Network, Toronto||Recruiting|August 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||360|||Female|18 Years|N/A|No|||September 2005|February 13, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188357||192798|
NCT00188890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asbestos Screening Study|Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers|Early Diagnosis of Mesothelioma and Lung Cancer Following Asbestos Exposure Using Low-dose Computed Tomography||University Health Network, Toronto|No|Recruiting|March 2005|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|2000|||Both|30 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|prior exposure to asbestos and or documented pleural plaques|March 2016|March 17, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188890||192757|
NCT00189436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUD ER 3425|Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children|A Pilot Study to Evaluate the Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Pediatric Patients Following Discharge From the Emergency Department/Outpatient Care Facility|BudER|West Penn Allegheny Health System||Completed|March 2003|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|1 Year|8 Years|No|||July 2014|July 8, 2014|September 12, 2005|Yes|Yes||No|July 8, 2014|https://clinicaltrials.gov/show/NCT00189436||192715|
NCT00221039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECTCL1|Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A|UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A||Therakos|No|Completed|September 2004|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221039||190339|
NCT00188630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0376-B|N-Acetylcysteine for Preventing Renal Injury After Cardiac Surgery|The PRIME (Perioperative Renal Insufficiency Management) Study: A Randomized, Double-blinded, Placebo-controlled Trial of N-acetylcysteine for Preventing Renal Injury After Cardiac Surgery.||University Health Network, Toronto||Completed|July 2003|July 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|176|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188630||192777|
NCT00188643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Venlafaxine Versus Lamotrigine in the Treatment of Bipolar I/II Depression|Double-Blind, Acute Depression Study Comparing Venlafaxine XR and Lamotrigine When Added to Mood Stabilizer in the Treatment of Bipolar Depression||University Health Network, Toronto||Completed|January 2002|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||February 2005|February 8, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188643||192776|
NCT00188864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0662-C|Dexamethasone for Palliation - Brain Metastases|Dexamethasone as Palliative Treatment in Addition to Radiation Therapy for Patients With Brain Metastases: A Prospective Study||University Health Network, Toronto||Active, not recruiting|November 2003|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188864||192759|
NCT00189696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-202|Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)|||Astellas Pharma Inc||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|64 Years|No|||October 2015|October 9, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189696||192695|
NCT00186108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0006|A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer|A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer||Stanford University|Yes|Completed|October 2002|September 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|N/A|No|||July 2007|July 24, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186108||192967|
NCT00186121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSMTS0001|Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women|A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women||Stanford University||Completed|October 2000|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|70 Years|No|||July 2013|July 24, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186121||192966|
NCT00186498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-10|Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode|Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode||Stanford University||Active, not recruiting|February 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||20|||Both|18 Years|75 Years|No|||October 2008|November 6, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00186498||192938|
NCT00218556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16797-1|Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1|Preventing Depression in MMT Patients on Interferon||National Institute on Drug Abuse (NIDA)||Completed|January 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218556||190527|
NCT00219193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2331|A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients|An Eight Week, Multicenter Study to Evaluate Efficacy and Safety of the Triple Combo of Aliskiren /Valsartan/HCTZ (300/320/25 mg), Compared to the Double Combos of Aliskiren/HCTZ (300/25 mg) or Valsartan/HCTZ (320/25 mg) in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg||Novartis||Completed|October 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|641|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00219193||190480|
NCT00189215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOM protocol 98/009-O|Long-Term Cognitive Decline After Coronary Artery Bypass Grafting: is Off-Pump Surgery Beneficial?|Long-Term Cognitive Decline After Coronary Artery Bypass Grafting: is Off-Pump Surgery Beneficial?||UMC Utrecht||Completed|March 1998|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||280|||Both|18 Years|N/A||||March 2005|December 3, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189215||192732|
NCT00189514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137OB-201E|A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects|Extension Study of Protocol 137OB-201 to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects||AstraZeneca|No|Completed|September 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|210|||Both|18 Years|70 Years|No|||May 2015|June 10, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00189514||192709|
NCT00189527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-2|Assist Control Versus Pressure Support Modes for Domiciliary Noninvasive Ventilation in Chronic Respiratory Failure|Assist Control Versus Pressure Support Modes for Domiciliary Noninvasive Ventilation||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|No|Completed|January 2006|October 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2011|February 16, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189527||192708|
NCT00221845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLRT-2001-00908|Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients|Molecular Mechanisms of Disease Progression and Renoprotective Pharmacotherapy in Children With Chronic Renal Failure|ESCAPE|Heidelberg University|Yes|Completed|January 1998|January 2010|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|3 Years|18 Years|No|||January 2010|January 11, 2010|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00221845||190277|
NCT00221858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN02-0508-E|Regional Anesthesia Database|Regional Anesthesia Database||University Health Network, Toronto||Completed|August 2002|April 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|80 Years|No|||August 2005|September 20, 2005|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00221858||190276|
NCT00185380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91412|Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)|Multi-center, Open, Randomized, Dose Finding Phase II Study to Investigate Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) Releasing Different Amounts of Levonorgestrel Compared to MIRENA in Nulliparous and Parous Women in Need of Contraception.||Bayer|No|Completed|April 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|742|||Female|21 Years|40 Years|No|||May 2015|May 15, 2015|September 13, 2005||No||No|December 10, 2009|https://clinicaltrials.gov/show/NCT00185380||193016|
NCT00217477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441212|Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer|An Open Label, Dose Escalation Study of Paricalcitol (Zemplar™) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies||Roswell Park Cancer Institute|Yes|Completed|August 2004|September 2014|Actual|May 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00217477||190606|
NCT00217711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/03|Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer||Swiss Group for Clinical Cancer Research|Yes|Completed|May 2005|October 2011|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|70 Years|No|||June 2012|June 2, 2012|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00217711||190589|
NCT00218673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA016142|RCT of Russian IDU Peer Network HIV Prevention Intervention - 1|Randomized Controlled Trial of Russian IDU Peer Network HIV Prevention Intervention||Johns Hopkins Bloomberg School of Public Health||Completed|October 2003|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|400|||Both|16 Years|N/A|No|||August 2015|August 31, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218673||190519|
NCT00188669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNH REB 02-0137-C|The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain|A Phase II Study of the Use of Pentoxifylline and a-Tocopherol in the Treatment of Chronic Breast Pain Associated With Breast Radiotherapy||University Health Network, Toronto||Terminated|July 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Female|18 Years|75 Years|No|||August 2010|August 10, 2010|September 12, 2005|||date: August 2006. No annual renewal|No||https://clinicaltrials.gov/show/NCT00188669||192774|
NCT00221052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNO-P6374|Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men|Relation Between Reduction of the Inflammatory Status and Glucose Metabolism in Healthy Overweight Men||TNO||Completed|June 2005|July 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||20|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2006|October 10, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221052||190338|
NCT00188877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0158-C|Intensity Modulated Radiation Therapy for Head and Neck Cancer|A Phase II Study of Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer||University Health Network, Toronto||Active, not recruiting|June 2003|June 2018|Anticipated|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|70 Years|No|||February 2016|February 8, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188877||192758|
NCT00189137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.010|Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma|Phase II Evaluation of Ifosfamide Plus Doxorubicin & Filgrastim Versus Gemcitabine Plus Docetaxel & Filgrastim in the Treatment of Localized Poor Prognosis Soft Tissue Sarcoma||University of Michigan Cancer Center|Yes|Completed|August 2004|October 2015|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|10 Years|N/A|No|||November 2015|November 6, 2015|September 13, 2005|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00189137||192738|
NCT00185263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305602|Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina|A Multinational Multicenter, Randomized , Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients With Stable Angina|AGENT-4|Cardium Therapeutics|Yes|Active, not recruiting|March 2002|November 2008|Anticipated|January 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|116|||Both|30 Years|75 Years|No|||November 2008|November 4, 2008|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185263||193025|
NCT00218777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070802|Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children|Behavior Therapy for Children With Chronic Tic Disorders|CBIT|Tourette Association of America||Completed|December 2004|May 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|9 Years|17 Years|No|||December 2015|December 10, 2015|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00218777||190512|
NCT00218790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602-2002a|The Effects of Cool Dialysate on the Sleep/Wake Cycle in Patients on Chronic Hemodialysis - "The Sleep Cool Study"|The Effects of Hemodialysis on the Sleep/Wake Cycle||Emory University|Yes|Completed|April 2003|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|21 Years|75 Years|No|||September 2005|February 10, 2014|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218790||190511|
NCT00219791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR001-CLN-rpt002|Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance|Study of Recombinant Carboxypeptidase G2 (CPG2) for the Management of Patients With Delayed Methotrexate (MTX) Clearance or Intrathecal MTX Overdosage||BTG International Inc.||Completed|January 2000|June 2003||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00219791||190435|
NCT00219804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103,004|Efficacy and Safety of Tetrabenazine in Chorea|A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea||Prestwick Pharmaceuticals||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A|No|||September 2005|September 14, 2005|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00219804||190434|
NCT00220987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-IAT-NIC-G|Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)|A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients.||The George Institute|Yes|Completed|April 2005|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6104|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00220987||190343|
NCT00221000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-1|Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis|A Phase II, Multicenter, Randomized, Double-blind, "Sham" Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological Agents|RA-1|Therakos|No|Completed|August 2003|November 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Both|18 Years|N/A|No|||April 2010|April 7, 2010|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00221000||190342|
NCT00219219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EIT04|Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases|Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases||Novartis||Completed|September 2003|October 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||April 2015|April 13, 2015|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00219219||190479|
NCT00219232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713D2320E1|An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease|An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease||Novartis||Completed|February 2003|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|868|||Both|50 Years|85 Years|No|||November 2011|November 22, 2011|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00219232||190478|
NCT00189241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412-IMIQ|A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma|An Open-Label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 5 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma||MEDA Pharma GmbH & Co. KG||Completed|February 2001|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||August 2010|August 25, 2010|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00189241||192730|
NCT00189254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1524-IMIQ|A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ|A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study||MEDA Pharma GmbH & Co. KG||Completed|April 2005|||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||73|||Both|18 Years|N/A|No|||August 2006|February 20, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00189254||192729|
NCT00185055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-448|The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects|The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects||Daiichi Sankyo Inc.||Completed|November 2004|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|September 15, 2005|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00185055||193041|
NCT00185081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRISCO|Imaging Colo-Rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging|Radioimmunodetection of CEA-Producing Tumors Using a Bispecific Antibody Pre-Targeting Method and an In-Labeled Peptide||Radboud University||Recruiting|July 2005|December 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|February 28, 2007|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00185081||193039|
NCT00185029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sinerem1|MR-Lymphography and Lymph Node Staging in Prostate Cancer|MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer?||Radboud University||Active, not recruiting|April 2002|August 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||396|||Male|18 Years|N/A|No|||September 2005|September 14, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00185029||193043|
NCT00185042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505-202|Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Coronary Artery Disease Using Intravascular Ultrasound (IVUS)||Daiichi Sankyo Inc.||Completed|November 2002|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|534|||Both|18 Years|N/A|No|||September 2007|September 10, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00185042||193042|
NCT00185393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90966|Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy|Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial||Bayer|No|Completed|August 2001|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|414|||Both|18 Years|N/A|No|||November 2008|November 26, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185393||193015|
NCT00185419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91330|A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception|An Open-Label, Randomised, Parallel-Group Comparison to Investigate the Efficacy of Yasmin® (30 µg Ethinylestradiol, 3mg Drospirenone) and Marvelon® (30 µg Ethinylestradiol, 150 µg Desogestrel) on Cycle Control in Healthy Chinese Women Over 13 Cycles||Bayer|No|Completed|November 2003|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|842|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||January 2009|January 13, 2009|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185419||193014|
NCT00218218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14002-1|Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia|Transdermal Nicotine and Bupropion for Smoking in Schizophrenics (Study 1)||National Institute on Drug Abuse (NIDA)|No|Completed|June 2002|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2008|August 19, 2008|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218218||190552|
NCT00218439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17307-1|Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1|Smoking, Antidepressants, and Response to Mental Stress||University of Minnesota - Clinical and Translational Science Institute||Completed|October 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|September 16, 2005|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00218439||190536|
NCT00219401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071613/Z/03/Z|Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea|Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea||Papua New Guinea Institute of Medical Research|Yes|Completed|May 2005|May 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|318|||Both|N/A|3 Days|Accepts Healthy Volunteers|||July 2011|July 10, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00219401||190465|
NCT00218842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203-04|The Effect on Function of Increasing Activity for Nursing Home Residents|Physical and Daily Activity for Residents in a Nursing Home Setting. -A Nordic Multi-Centre Study||Norwegian University of Science and Technology|No|Completed|October 2005|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|65 Years|N/A|No|||March 2014|March 6, 2014|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218842||190507|
NCT00220441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDIS 0009|Cognitive Effects of Aerobic Exercise for IGT Adults|Cognitive Effects of Aerobic Exercise for Adults With Impaired Glucose Tolerance: A Controlled Trial||Seattle Institute for Biomedical and Clinical Research|No|Completed|July 2004|April 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||July 2008|July 29, 2008|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00220441||190385|
NCT00220454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDIS 0007|Effect of Estrogen & Stress for Postmenopausal Women|Effect of Estrogen on the Stress Response for Postmenopausal Women||Seattle Institute for Biomedical and Clinical Research|No|Completed|December 2002|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Female|55 Years|90 Years|Accepts Healthy Volunteers|||February 2007|February 26, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220454||190384|
NCT00189449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST Nasacort AQ NAS.US1.631|Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis|Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis||West Penn Allegheny Health System||Completed||June 2007||||Phase 4|Observational|N/A|||||||Both|6 Years|13 Years|No|||April 2008|April 30, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189449||192714|
NCT00189709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCFGCAN-0301F-TW|Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia|A Single Center, Open, Parallel, Comparative, Randomized Study of Micafungin (FK463) vs Fluconazole (Diflucan) in the Treatment of Invasive Candidiasis and Candidaemia (Protocol No: MCFGCAN-0301F-TW)||Astellas Pharma Inc||Completed|August 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|16 Years|N/A|No|||December 2007|December 26, 2007|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00189709||192694|
NCT00189722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-17-05|Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma|||Astellas Pharma Inc||Completed||July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|160|||Both|18 Years|70 Years|No|||April 2008|April 15, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00189722||192693|
NCT00185276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91208|Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries|Randomized, Multi-center Open Label Study of the Safety (Open-label) and Efficacy (Open-label & Blinded Reader) of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) at Two Dose Levels and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients Undergoing MRA of the Infrarenal Aorta and Peripheral Arteries With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as Standard of Reference||Bayer|No|Completed|March 2003|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|365|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185276||193024|
NCT00186524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4 BB-2901|Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?|||Stanford University||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Female|18 Years|N/A||||March 2011|March 11, 2011|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00186524||192936|
NCT00219505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-343|Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS|Effect of Acupuncture on Symptoms of Diarrhea and Pain in Diarrhea Predominant Irritable Bowel Syndrome (IBS) and Effect on Plasma Beta-endorphin and Serotonin Levels.||Penn State University||Terminated|August 2001|January 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||36|||Both|18 Years|90 Years|No|||September 2006|June 1, 2011|September 14, 2005|||no eligible subjects identified during recruitment|No||https://clinicaltrials.gov/show/NCT00219505||190457|
NCT00220090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-MD-05|DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)|A 24-wk, Prospective, d/b, Placebo Controlled, Parallel Group, Multicenter, Randomized/Withdrawal Efficacy and Safety Study of Dexloxiglumide for the Relief of Symptoms in Patients With Constipation-Predominant Irritable Bowel Syndrome||Rottapharm||Completed|July 2003|||September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||May 2008|May 13, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220090||190412|
NCT00220103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2185|Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma|Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma||Royal Marsden NHS Foundation Trust|No|Completed|November 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||December 2009|December 15, 2009|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220103||190411|
NCT00220688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC1|Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients?|Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients?||Gloucestershire Hospitals NHS Foundation Trust||Completed|September 2005|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||March 2007|October 13, 2009|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00220688||190366|
NCT00220701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD-34|Escitalopram in the Treatment of Dysthymic Disorder, Double Blind|Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder||St. Luke's-Roosevelt Hospital Center|No|Completed|June 2002|January 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||November 2007|October 13, 2015|September 21, 2005||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT00220701||190365|Small double blinded study with limited power.
NCT00221832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0261.5|Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases|Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases||Heidelberg University|No|Recruiting|October 2003|December 2011|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|no biospecimens are to be retained.|Both|N/A|N/A|No|Non-Probability Sample|Consecutive patient sampling with history of syncope, aborted SCD, familial sudden cardiac        death, high suspicion of familial cardiac arrhythmias.|October 2003|January 12, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221832||190278|
NCT00188968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2004:172|Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants.|A Randomized, Controlled Trial of Synchronized Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure Using the Infant Flow Advance to Facilitate Successful Extubation in Premature Infants.||University of Manitoba|Yes|Completed|November 2004|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|No|||April 2007|April 30, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00188968||192751|
NCT00189540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-CLI-0205|Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers|A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers||AnGes|No|Completed|August 2005|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|N/A|No|||July 2011|July 25, 2011|September 12, 2005|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00189540||192707|
NCT00185445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308580|Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL|A Phase II Study to Evaluate the Efficacy and Safety of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL||Sanofi|No|Completed|June 2004|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00185445||193013|
NCT00185484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91353|Efficacy and Safety Oral Contraceptive Study|Multi-center, Open, Uncontrolled Study to Investigate the Efficacy and Safety of the Oral Contraceptive SH T 186 D Containing 0.02 mg Ethinylestradiol-b-cyclodextrin Clathrate and 3 mg Drospirenone in a 24-day Regimen for 13 Cycles in 1010 Healthy Female Volunteers||Bayer|No|Completed|March 2004|January 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1113|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00185484||193011|
NCT00185068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-443|An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension|A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension||Daiichi Sankyo Inc.||Completed|March 2004|October 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||September 2005|September 9, 2005|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00185068||193040|
NCT00185848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRNCNS0003|Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis|Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.||Stanford University|Yes|Completed|April 2005|June 2013|Actual|June 2013|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|None Retained|Patients with intact or surgically removed gliomas.Patients with Rheumatoid Arthritis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Rheumatoid Arthritis.Patients with intact or surgically removed gliomas.|November 2015|November 16, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185848||192986|
NCT00185861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRNCNS0001|Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma|Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma||Stanford University||Completed|December 2003|April 2009|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2009|April 8, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185861||192985|
NCT00218465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19378-2|Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking|A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking||Massachusetts General Hospital|Yes|Completed|August 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|264|||Female|18 Years|65 Years|No|||January 2014|January 14, 2014|September 16, 2005|Yes|Yes||No|August 2, 2010|https://clinicaltrials.gov/show/NCT00218465||190534|
NCT00218686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA013142|A Network Intervention for Prevention of HIV Infection in Chennai, India - 1|Supplement to the Long-term Impact of a Network Outreach Intervention||Johns Hopkins Bloomberg School of Public Health|No|Withdrawn|January 2003|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|September 16, 2005||No|In ability to obtain Indian governmental approval from the study from NACO|No||https://clinicaltrials.gov/show/NCT00218686||190518|
NCT00218985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIM 158-04|Exercise-training Before Coronary Artery Bypass Graft (CABG)|Exercise-training Before Coronary Artery Bypass Graft (CABG)||Norwegian University of Science and Technology|No|Recruiting|January 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218985||190496|
NCT00218998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Training in metabolic syndrome|Effective Endurance Training in Metabolic Syndrome|Effective Endurance Training in Metabolic Syndrome||Norwegian University of Science and Technology|No|Completed|January 2004|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||30|||Both|20 Years|N/A||||September 2005|August 25, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218998||190495|
NCT00219414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512-04-205-CS|Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205)|||Otsuka Frankfurt Research Institute GmbH||Completed|June 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|N/A|N/A|No|||September 2007|September 26, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00219414||190464|
NCT00219427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCUM2004681|Retina Projection System Trials for Low Vision People|Multicenter Clinical Trials of Retina Projection System||Osaka City University|Yes|Completed|January 2005|December 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|58|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|May 2008|May 20, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00219427||190463|
NCT00221351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-1|C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough|A Randomized, Controlled Trial of a C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough Illness in the Emergency Department||University of California, San Francisco||Completed|October 2005|July 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|139|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00221351||190315|
NCT00186589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT134|90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL|90Y-Ibritumomab Tiuxetan and Autologous Hematopoietic Cell Infusion Followed by High Dose Chemotherapy and Autologous Transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma||Stanford University||Completed|May 2004|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||October 2010|June 5, 2012|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00186589||192931|
NCT00220727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100422|Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP|Randomized, Controlled, Open Study Investigating IGIV-C, 10% Given at Different Infusion Rates on Intravascular Hemolysis in Patients With Idiopathic (Immune) Thrombocytopenic Purpura (ITP)||Grifols Therapeutics Inc.|No|Completed|July 2003|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|12 Years|75 Years|No|||August 2014|August 19, 2014|September 13, 2005|No|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00220727||190363|
NCT00221026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2|Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease|A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents||Therakos|No|Completed|December 2004|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00221026||190340|
NCT00185731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0020|Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma|A Phase II Study of Atorvastatin in Patients With Low Grade or Refractory Non-Hodgkin's Lymphoma||Stanford University|Yes|Active, not recruiting|April 2005|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185731||192994|
NCT00186134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95378|Walk to School and Physical Activity|Walk to School and Physical Activity||Stanford University||Completed|October 2004|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||30|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186134||192965|
NCT00189735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-778-02-60|A Study to Evaluate FK778 in Kidney Transplant Patients|A Multicentre, Randomised, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Different Concentrations of FK778 With Tacrolimus (FK506) and Steroids Versus a Standard Regimen of Tacrolimus, MMF and Steroids in Renal Transplant Patients||Astellas Pharma Inc||Completed|September 2003|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|364|||Both|18 Years|N/A|No|||April 2008|April 15, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189735||192692|
NCT00189748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ-506E-BT02|A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-|An Extension Study of the Patients Enrolled in Acute Graft Versus Host Disease (GVHD) Prophylaxis Study (Protocol No. FJ-506E-BT01) to Assess Safety and Efficacy of GVHD Prophylaxis of a Tacrolimus New Oral Formulation (MR4).||Astellas Pharma Inc||Completed|August 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|54 Years|No|||September 2006|September 19, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189748||192691|
NCT00185289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91191|Study to Investigate Efficacy and Safety of a New Oral Contraceptive|Multi-center , Open, Uncontrolled Study to Investigate the Efficacy and Safety of a 4 Phasic Oral Contraceptive SH T00658 in a 28-day Regimen for 20 Cycles in Healthy Female Volunteers||Bayer||Completed|April 2004|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1392|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 14, 2011|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185289||193023|
NCT00186862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYCHAL|Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma|Phase I Study of Chemokine and Cytokine Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma Using a Retroviral Vector||St. Jude Children's Research Hospital|No|Completed|August 1998|October 2007|Actual|April 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|21 Years|No|||June 2008|June 2, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00186862||192911|
NCT00220428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-98-1754-AA-CTIL|T-Cell Vaccination in Multiple Sclerosis (MS)|The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial||Sheba Medical Center||Recruiting|July 1998|December 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||20|||Both|16 Years|60 Years|No|||January 2007|January 23, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00220428||190386|
NCT00221624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7929-01|Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients|Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Interferon and Ribavirin|PEGARI|University Hospital, Bordeaux|Yes|Completed|November 2001|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|70 Years|No|||June 2007|June 12, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221624||190294|
NCT00217867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297|Educational and Supportive Interventions to Prevent Cardiopulmonary Rehospitalization|A RCT to Reduce Cardiopulmonary Rehospitalization||Boston Medical Center|Yes|Completed|October 2008|June 2012|Actual|April 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|832|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217867||190578|
NCT00217880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292|Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease|Prognostic Significance of Biological Markers in Patients With ALI/ARDS||University of Michigan|Yes|Completed|July 2004|June 2009|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|95 Years|No|||July 2009|August 16, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217880||190577|
NCT00188981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMOP02.0441C|Dutch Prediction of Psychosis Study|Dutch Prediction of Psychosis Study||UMC Utrecht|No|Active, not recruiting|June 2003|June 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||120|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188981||192750|
NCT00189228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMSCOR|Immune Dysfunction in Allergic Asthma|Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma||University of New Mexico|Yes|Completed|September 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|45 Years|No|||January 2013|January 18, 2013|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00189228||192731|
NCT00185094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-440|A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin|The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension||Daiichi Sankyo Inc.||Completed|February 2004|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|75 Years|No|||September 2005|December 22, 2005|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00185094||193038|
NCT00185510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91424|Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis|Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis With Advantan Cream||Bayer|No|Completed|March 2005|June 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|12 Years|N/A|No|||February 2014|February 23, 2014|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00185510||193010|
NCT00185458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90660|Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).|A 60-month Non-comparative Study on Bleeding Profiles With Levonorgestrel Intrauterine System in Transition From Reproductive Age Contraception to Menopause Age Endometrial Protection During Estrogen Replacement Therapy.||Bayer|No|Completed|May 2000|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|394|||Female|46 Years|51 Years|No|||November 2013|November 5, 2013|September 13, 2005||No||No|July 23, 2009|https://clinicaltrials.gov/show/NCT00185458||193012|
NCT00185835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0012|Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck|Phase I Study of Cisplatin And ZD1839 (IRESSA®) in Combination With Concomitant Re-Irradiation in Patients With Loco-Regional Recurrent Squamous Cell Cancer of the Head and Neck||Stanford University||Completed|June 2002|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2010|March 25, 2010|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185835||192987|
NCT00185874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0002|Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases|A Phase I Trial of Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases||Stanford University||Terminated|January 2004|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|September 12, 2005|No|Yes|Study closed due to lack of funding|No||https://clinicaltrials.gov/show/NCT00185874||192984|
NCT00186290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT34|Allo BMT in Advanced Leukemia or High Grade Lymphoma|Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma||Stanford University||Completed|December 1989|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|N/A|50 Years|No|||October 2010|October 7, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186290||192954|
NCT00186303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT88|Transplantation for Patients With Chronic Lymphocytic Leukemia|Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia||Stanford University||Completed|November 1996|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|60 Years|No|||December 2012|December 13, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186303||192953|
NCT00186316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT155|Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells|A Phase I/II Study of Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells||Stanford University||Completed|April 2003|December 2008|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|17 Years|70 Years|No|||August 2009|August 21, 2009|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00186316||192952|
NCT00218699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065138|Pre-HIV Test Counseling Intervention to Reduce HIV Infection Risk Behavior in Men Who Are Not HIV Infected|Changing Sexual Behavior in Gay Male Repeat HIV Testers: A Randomized Trial of a Single Session Counseling Intervention||University of California, San Francisco|No|Completed|August 2002|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|300|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 2, 2013|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218699||190517|
NCT00219011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2313|"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure|A Twelve-week, Randomized, Double-blind, Multi-center, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Aliskiren 150 mg When Added to Standard Therapy in Hypertensive Patients With Stable Heart Failure||Novartis||Completed|May 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||280|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00219011||190494|
NCT00219024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2204|Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.|An 8 Week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension||Novartis||Completed|August 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|2775|||Both|18 Years|N/A|No|||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219024||190493|
NCT00219739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030482|STI571 ProspectIve RandomIzed Trial: SPIRIT|A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase|SPIRIT|Poitiers University Hospital||Active, not recruiting|September 2003|December 2015|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|789|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00219739||190439|
NCT00186602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7BB-2400|Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?|Does a Peer Navigator Improve Quality of Life at Diagnosis?||Stanford University||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Female|20 Years|85 Years||||September 2005|October 4, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00186602||192930|
NCT00186628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT172|Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD|An Open Label, Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation||Stanford University|Yes|Completed|June 2005|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|17 Years|76 Years|No|||March 2011|March 11, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00186628||192929|
NCT00187395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT- 59755|CHIPS (Control of Hypertension in Pregnancy Study): A Pilot Trial|Control of Hypertension in Pregnancy Study: A Pilot Trial||Sunnybrook Health Sciences Centre||Completed|April 2003|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||132|||Female|18 Years|48 Years|No|||September 2005|March 9, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187395||192870|
NCT00187161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJBCII|Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL|Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II||St. Jude Children's Research Hospital|No|Completed|November 1994|January 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|68|||Both|N/A|18 Years|No|||June 2008|June 3, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187161||192888|
NCT00186147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT19|Bone Marrow Grafting for Leukemia and Lymphoma|Bone Marrow Grafting for Leukemia and Lymphoma||Stanford University||Recruiting|March 1988|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9999|Samples With DNA|Tissue samples will be obtained from subjects undergoing transplantation or donors providing      the graft.|Both|N/A|70 Years|No|Non-Probability Sample|All hematopoietic cell transplant recipients and donors who agree to participate|February 2015|February 3, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186147||192964|
NCT00186511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10AB-2801|Expanding Rural Access: Distance Delivery of Support|Expanding Rural Access: Distance Delivery of Support||Stanford University||Completed|November 2004|June 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|21 Years|N/A|No|||December 2006|December 4, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186511||192937|
NCT00219154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2323|A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine|A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension||Novartis||Completed|March 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1125|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219154||190483|
NCT00219167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2324|A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure|An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference||Novartis||Completed|April 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|355|||Both|65 Years|N/A|No|||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219167||190482|
NCT00219180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2327|Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure|An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension||Novartis||Completed|June 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1797|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219180||190481|
NCT00188227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGC05MK1001|Comparison of Three Different Pain and Anxiety Reducing Methods in Adult Patients Undergoing Bone Marrow Puncture|Comparison of Three Different Pain and Anxiety Reducing Methods in Adult Patients Undergoing Bone Marrow Puncture||Technische Universität Dresden||Completed|September 2001|November 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||748|||Both|18 Years|85 Years|No|||September 2005|April 19, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00188227||192808|
NCT00188474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0233-CE|A Quality of Life Study re Management of Malignant Pleural Effusions|A Prospective Study of Patient Centered Outcomes in the Management of Malignant Pleural Effusions||University Health Network, Toronto|No|Completed|August 2004|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|149|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with malignant pleural effusions|September 2014|October 7, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188474||192789|
NCT00188734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-ELCAP|Early Lung Cancer Detection Using Computed Tomography|Lung Cancer Screening in High-risk Smokers Using Low-dose Computed Tomography||University Health Network, Toronto||Recruiting|September 2003|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|55 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|high risk current and former smokers|June 2015|June 22, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188734||192769|
NCT00189267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1443-IMIQ|A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients|Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days Per Week for the Treatment of Actinic Keratoses in Immunosuppressed Organ Transplant Recipients.||MEDA Pharma GmbH & Co. KG||Completed|November 2002|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||August 2006|November 19, 2010|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00189267||192728|
NCT00189280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1475-IMIQ|Aldara for the Treatment of Large and/or Multiple sBCC|Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma.||MEDA Pharma GmbH & Co. KG||Completed|May 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||September 2008|September 24, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189280||192727|
NCT00185107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-408|Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Combination With Zetia® Compared to Zetia® Alone in Patients With Primary Hypercholesterolemia||Daiichi Sankyo Inc.|No|Completed|March 2005|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|80 Years|No|||September 2007|September 10, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00185107||193037|
NCT00185120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-447|Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker|A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension||Daiichi Sankyo Inc.||Completed|September 2005|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||152|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00185120||193036|
NCT00185523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT142|Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)|Allogeneic Peripheral Blood Stem Cell Transplantation for Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia in First or Second Remission or Chronic Myelogenous Leukemia in First and Second Chronic Phase or Accelerated Phase||Stanford University||Completed|May 2002|April 2009|Actual|April 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|88|||Both|N/A|55 Years|No|Probability Sample|Primary care clinic|January 2013|January 22, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185523||193009|
NCT00185887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79504|Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation|Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation||Stanford University||Completed|October 2003|October 2007|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|N/A|No|||March 2011|March 4, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185887||192983|
NCT00185900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76145|Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial|Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial||Stanford University||Completed|April 1999|July 2007|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Female|18 Years|N/A|No|||April 2015|April 3, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185900||192982|
NCT00185913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0006|Identification of Serum Markers For Tumor Hypoxia in Non-Small Cell Lung Cancers|Identification of Serum Markers For Tumor Hypoxia in Non-Small Cell Lung Cancers||Stanford University||Completed|September 2000|May 2008|Actual|October 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed patients with lung cancer who are undergoing surgical resection of their        tumors|April 2010|April 20, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185913||192981|
NCT00186329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC79741|BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)|B-type Natriuretic Peptide for Cardio-Renal Decompensation Syndrome||Stanford University||Completed|March 2004|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00186329||192951|
NCT00186342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT45|Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies|Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide||Stanford University||Completed|September 1992|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|51 Years|60 Years|No|||December 2012|December 13, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186342||192950|
NCT00219037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2302|Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension|A 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long Term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.||Novartis||Completed|June 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|1955|||Both|18 Years|N/A|No|||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219037||190492|
NCT00219050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2303|A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension|An Eight-week, Randomized, Double-blind, Multi-center, Active-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of an Aliskiren-based Regimen Compared to a Lisinopril-based Regimen in Patients With Uncomplicated Severe Hypertension||Novartis||Completed|February 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00219050||190491|
NCT00219063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2306|A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.|A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patients With Essential Hypertension||Novartis||Completed|February 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|844|||Both|18 Years|N/A|No|||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219063||190490|
NCT00219440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 24005|A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS|A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS|TAKE II|Pennington Biomedical Research Center|Yes|Completed|February 2003|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|35 Years|75 Years|No|||January 2016|January 22, 2016|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00219440||190462|
NCT00219453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS243|Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination|A Pilot Safety Study to Determine the Presence of Hepatitis B Virus in Downstream Injection Samples Using the HSI-500 Jet Injector With Protector Cap||PATH||Completed|October 2004|January 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2007|April 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219453||190461|
NCT00220363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP583|A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome|A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome||Pfizer||Completed|January 2004|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||April 2008|April 29, 2008|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00220363||190391|
NCT00220376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP739|Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome|Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome||Pfizer||Completed|April 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||November 2008|November 21, 2008|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00220376||190390|
NCT00187187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G990333/SO28|DAVID II (Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial II)|DAVID II (Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial II)|DAVIDII|St. Jude Medical|Yes|Completed|June 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|600|||Both|N/A|N/A|No|||October 2010|October 20, 2010|September 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187187||192886|
NCT00189150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Val060|Pharmacokinetics of Mmf and Valganciclovir|Pharmacokinetics of Mycophenolate Mofetil Alone and in Combination With Valganciclovir in Renal and Heart Transplant Recipients||University of Michigan||Recruiting|April 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|75 Years|No|||August 2005|September 19, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189150||192737|
NCT00189163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pio-hcv-108|Pioglitazone in Hepatitis C|Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-Controlled Study||University of Michigan||Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||September 2005|February 15, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189163||192736|
NCT00189176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0806|Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis|Phase I/II Trial of Tetrathiomolybdate (TM) in Patients With Usual Interstitial Pneumonia Refractory to Previous Therapy||University of Michigan||Completed|March 2003|May 2006|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|35 Years|80 Years|No|||February 2013|February 5, 2013|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00189176||192735|
NCT00187174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD001|Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors|Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors||St. Jude Children's Research Hospital|No|Completed|October 2004|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|3 Years|21 Years|No|||December 2009|March 3, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187174||192887|
NCT00218543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4611|Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial|Atom|New York State Psychiatric Institute|Yes|Completed|June 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|September 20, 2005||No||No|January 12, 2012|https://clinicaltrials.gov/show/NCT00218543||190528|Clearly, there are limitations of this study including the high drop-out rate, small sample size, and lack of a control group.
NCT00187928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-217|Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder||University of Florida|Yes|Completed|January 2003|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|18 Years|65 Years|No|||October 2011|October 4, 2011|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187928||192831|
NCT00188240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0510-AE 04-0292-A|Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy|Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Anti-Viral Therapy||University Health Network, Toronto||Recruiting|August 2003|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|85 Years|No|||September 2005|November 28, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188240||192807|
NCT00188487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0174|Magnetic Resonance (MR) in Asthmatic Patients|MR Perfusion Imaging in Asthmatic Patients||University Health Network, Toronto||Suspended|September 2005|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||80|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 20, 2007|September 12, 2005|||no funding|No||https://clinicaltrials.gov/show/NCT00188487||192788|
NCT00188500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0027-AE|Efficacy of Modified Ketogenic Diet (Atkins) in Management of Epilepsy|Efficacy, Tolerability and Long-Term Adherence of a Modified Ketogenic Diet (Atkins) in the Management of Pharmacoresistant Epilepsy||University Health Network, Toronto||Recruiting|August 2005|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||March 2004|December 28, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188500||192787|
NCT00188747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0054-B|Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding|Comparison of Three Management Strategies for Post Cardiac Surgery Coagulopathy.||University Health Network, Toronto||Completed|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||April 2006|October 10, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188747||192768|
NCT00189553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALYPSO|Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse|A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months)|CALYPSO|ARCAGY/ GINECO GROUP|Yes|Completed|April 2005|June 2012|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|976|||Female|18 Years|N/A|No|||January 2014|January 9, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189553||192706|
NCT00189579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHERCEPTIN1|Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer|A Phase II Study Designed to Evaluate the Safety and Efficacy of the Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Early Relapse Patients (< 6 Months) With Ovarian Cancer, Overexpressing HER2, Previously Treated With Carboplatin-Paclitaxel||ARCAGY/ GINECO GROUP||Terminated||January 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Female|18 Years|N/A|No|||August 2007|August 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189579||192704|
NCT00189592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0105WW|Plantar Fasciosis Treatment Using Coblation|Plantar Fasciosis Treatment Using Coblation® Prospective, Double-Blind, Randomized Controlled Study||ArthroCare Corporation|No|Completed|August 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|72 Years|No|||August 2015|August 25, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189592||192703|
NCT00185133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8663-A-U301|Study of co-Administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension|A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of co-Administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension||Daiichi Sankyo Inc.|No|Completed|May 2005|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1900|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00185133||193035|
NCT00185146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-505/14|Efficacy and Safety of Pactimibe in Patients With Atherosclerosis|Effect of Pactimibe on the Progression of Atherosclerosis as Measured by 2-D and 3-D Carotid Ultrasound||Daiichi Sankyo Inc.||Completed|September 2002|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|30 Years|75 Years|No|||March 2007|March 27, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00185146||193034|
NCT00185991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80104|Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis|Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis||Stanford University||Completed|June 2004|February 2010|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Female|18 Years|N/A|No|||June 2011|June 13, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185991||192976|
NCT00185939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR002137|The Use of Prophylactic Antibiotics In the Management of Dog Bites|||Stanford University||Completed|August 2003|November 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||125|||Both|N/A|N/A|No|||December 2006|December 1, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00185939||192980|
NCT00185978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL054102|Obesity Prevention for Pre-Adolescents|School- and Family-Based Obesity Prevention for Children||Stanford University||Completed|April 1998|March 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||900|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00185978||192977|
NCT00186355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT4IJ|Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma|Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma||Stanford University||Completed|October 2003|February 2010|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|N/A|75 Years|No|||May 2012|May 10, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186355||192949|
NCT00219752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020948|Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years|Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase With Age More Than 70, Diagnosis of CML is Being Performed Within 1 Year||Poitiers University Hospital||Completed|May 2002|May 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|70 Years|N/A|No|||September 2005|December 21, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219752||190438|
NCT00220012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHO-0514|Effect of Folate on Colon and Blood Cells|Effect of Folate on Colonic and Blood Cells||Rockefeller University||Completed|June 2003|September 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||20|||Both|40 Years|72 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00220012||190418|
NCT00220350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lupron trial|Lupron Sex Offender Therapy|Leuprolide Acetate Suppresses Pedophilic Urges and Arousability||Schober, Justine, M.D.||Active, not recruiting|October 2001|August 2005||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00220350||190392|
NCT00220389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP669|Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase|Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder(OAB): a Double-Blind Phase Followed by an Open-Label Extension Phase||Pfizer||Completed|June 2003|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||October 2008|October 15, 2008|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00220389||190389|
NCT00185302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91410|Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma|Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma||Bayer|No|Completed|December 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185302||193022|
NCT00185315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90570|Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension|Open-label, Uncontrolled, Long-term Surveillance Study of Iloprost Aerosol Inhalation Therapy in the Treatment of Patients With Primary or Secondary Pulmonary Hypertension. Follow-up Program for Patients Who Completed 12 Weeks in Study ME97218/300180.||Bayer||Completed|February 2000|August 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|71 Years|No|||April 2010|April 19, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00185315||193021|
NCT00185718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT160|Impact of Treatment Induced Premature Menopause on Quality of Life|Impact of Treatment Induced Premature Menopause on Quality of Life Following Blood and Marrow Transplantation||Stanford University||Completed|November 2003|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|97|||Female|18 Years|N/A|No|Non-Probability Sample|Women become menopausal as a result of BMT|December 2012|December 12, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185718||192995|
NCT00187421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSF NA 5530|Using Intraoperative Coronary Bypass Graft Imaging to Improve Graft Patency|Graft Imaging to Improve Patency (GRIIP)|GRIIP|Sunnybrook Health Sciences Centre||Completed|July 2005|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|156|||Both|N/A|N/A|No|||December 2012|December 11, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187421||192868|
NCT00187668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701|Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)|Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)|SOPHIE|University of California, San Francisco|Yes|Recruiting|February 2004|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|500|Samples With DNA|40 mL of blood for DNA extraction|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants that are willing to be called back for subsequent genotype to        phenotype studies.|October 2014|October 20, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187668||192850|
NCT00187681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|865|Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects|Effect of Genetic Variants in the Xenobiotic Transporter, OCT1, on Response to Metformin in Healthy Subjects||University of California, San Francisco|Yes|Completed|July 2003|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|September 13, 2005||No||No|May 20, 2011|https://clinicaltrials.gov/show/NCT00187681||192849|
NCT00187941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL470|MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression|Pilot Trial for Implementation of a Medroxyprogesterone(MPA)Pharmacokinetic(PK) Monitoring Strategy in Patients on Mycophenolate Mofetil(MMF)/FK Based Immunosuppression.||University of Florida|No|Completed|August 2005|November 2006|Actual|November 2006|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|80 Years|No|||June 2012|June 19, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187941||192830|
NCT00188513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0181-C|Intensity Modulated Radiation Therapy - Prostate Cancer|A Phase I-II Prospective Trial of Conformal Hypofractionated Intensity Modulated Radiotherapy (IMRT) for Localized Adenocarcinoma of the Prostate||University Health Network, Toronto||Active, not recruiting|May 2001|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|267|||Male|18 Years|80 Years|No|||June 2015|June 16, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188513||192786|
NCT00188526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0516|Computed Tomography (CT) Guided Lung Biopsy: Core or Fine Needle Aspiration|CT Guided Lung Biopsy: Core or Fine Needle Aspiration||University Health Network, Toronto|No|Recruiting|September 2005|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|200|||Both|16 Years|N/A|No|||March 2016|March 7, 2016|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188526||192785|
NCT00188760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNREB#02-0712-C|Breast Study Investigating a New Light Technique to Monitor Changes in Breast Tissue Density|Optical Quantification of Breast Density Changes Due to Hormone Treatment, Pregnancy and Breast-feeding.||University Health Network, Toronto|No|Completed|May 2004|September 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|300|||Female|25 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Cases recruited from the Reproductive Biology Unit at Mount Sinai Hospital and the        University Health Network community. Controls recruited from University Health Network        community and the University of Toronto community. (Toronto, Ontario, Canada)|October 2011|October 6, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188760||192767|
NCT00188539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0376-C|Cervix:Hypoxia, Interstitial Fluid Pressure and GSH Levels|Predictive Assays in Cervix Cancer: Assessment of Hypoxia, Interstitial Fluid Pressure, and GSH Levels||University Health Network, Toronto|No|Active, not recruiting|December 1995|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Female|18 Years|N/A|No|||June 2015|June 16, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188539||192784|
NCT00188994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-E089|Insulin Cardioplegia for Poor Left Ventricular Function|Insulin Cardioplegia Trial for Poor Left Ventricular Function||University Health Network, Toronto||Recruiting|August 1999|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||800|||Both|N/A|N/A|No|||July 2005|December 28, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00188994||192749|
NCT00189007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw 170991001|Antenatal Allopurinol During Fetal Hypoxia|Does Antenatal Allopurinol Administration Reduce Post-hypoxic-ischemic Reperfusion Damage During Fetal Hypoxia in the Newborn?||UMC Utrecht|Yes|Active, not recruiting|October 2009|December 2016|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|222|||Both|N/A|N/A|No|||March 2012|March 28, 2012|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00189007||192748|
NCT00189566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR\TAXHY|Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse|National, Randomized, Phase II Study Comparing Efficacy of Weekly Administration of Paclitaxel in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse||ARCAGY/ GINECO GROUP||Completed|April 2004|April 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|165|||Female|18 Years|N/A|No|||February 2011|February 24, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189566||192705|
NCT00185549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78910|An Interactive Program to Improve Care for Children With CF|An Interactive Program to Improve Care for Children With Cystic Fibrosis||Stanford University||Completed|March 2004|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||60|||Both|1 Month|21 Years|No|||September 2005|October 4, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00185549||193007|
NCT00186004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78694|Correlation Between Continuous Glucose Monitoring and Intermittent Glucose Monitoring Values and Pregnancy Outcomes|Correlation Between Continuous Glucose Monitoring and Intermittent Glucose Monitoring Values and Pregnancy Outcomes||Stanford University|No|Completed|December 2002|May 2008|Actual|September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients 18 years or older, less than 28 weeks gestation without pregestational        diabetes.|June 2011|June 13, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186004||192975|
NCT00186394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT4L|High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma|High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma||Stanford University||Completed|April 2000|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|61 Years|No|||July 2010|July 23, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186394||192946|
NCT00185536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80618|Effects of Advertising on Young Children's Perception of Taste|Effects of Advertising on Young Children's Perception of Taste||Stanford University||Completed|April 2002|||||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00185536||193008|
NCT00185952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76251|Nifedipine vs Placebo for Maintenance Tocolysis of Preterm Labor.|Nifedipine for the Maintenance Tocolysis of Preterm Labor: Comparison to Placebo in a Prospective, Randomized Double Blind Trial||Stanford University|No|Completed|November 2001|August 2008|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|55 Years|No|||June 2011|June 10, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185952||192979|
NCT00185965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-13063|CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas|Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas||Stanford University|Yes|Completed|July 2004|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|September 12, 2005|No|Yes||No|July 7, 2014|https://clinicaltrials.gov/show/NCT00185965||192978|
NCT00186771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-2363|Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia|Transcranial Magnetic Stimulation Used to Treat Auditory Hallucinations in Schizophrenia||St. Joseph's Healthcare Hamilton|No|Recruiting|November 2004|January 2015|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||July 2011|July 27, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186771||192918|
NCT00219765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010495|Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients|Phase I/II Trial to Study the Dose, Tolerability and the Effectiveness of Imatinib in Combination With Daunorubicine and Cytarabine for Patients With Chronic Myelogenous Leukemia in Myeloid Acute Phase||Poitiers University Hospital||Terminated|May 2001|January 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||September 2005|November 25, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219765||190437|
NCT00220064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1810|A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours|A Phase II Trial Evaluating Irinotecan With 5_fluorouracil Plus Leucovorin in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours||Royal Marsden NHS Foundation Trust|No|Completed|July 2000|November 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|65|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220064||190414|
NCT00220025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0338|Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.|A Study To Determine the Efficacy of Whole Body Narrowband UVB Phototherapy in People With Darker Skin Types||Rockefeller University|Yes|Completed|June 1999|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|14 Years|N/A|No|||October 2012|October 24, 2012|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00220025||190417|
NCT00220038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVO-0539|Experiments to Test How and Why the Sense of Smell Differs Between People|Genetic Basis of Specific Anosmias||Rockefeller University|No|Completed|May 2004|May 2010|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples With DNA|whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|700 healthy normal volunteers will be recruited from the New York City area|January 2012|January 10, 2012|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00220038||190416|
NCT00220662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM99-0177|The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa|The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa||St. Paul's Hospital, Canada||Active, not recruiting|June 2000|June 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|45 Years|No|||July 2004|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00220662||190368|
NCT00220675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9427-T0926-28C|Erythropoietin Spinal Cord Compression Randomized Trial|Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study||Sunnybrook Health Sciences Centre|Yes|Terminated|August 2005|July 2007|Actual|July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|19 Years|N/A|No|||May 2008|May 21, 2008|September 20, 2005||No|Insufficient accrual|No||https://clinicaltrials.gov/show/NCT00220675||190367|
NCT00186927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENDAI|A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers|A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity||St. Jude Children's Research Hospital|Yes|Recruiting|March 2005|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|54|||Both|12 Months|6 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00186927||192906|
NCT00186914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOD|Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation|Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation: A Phase I Study||St. Jude Children's Research Hospital|No|Completed|July 1999|January 2008|Actual|November 2001|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||February 2008|March 3, 2015|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00186914||192907|
NCT00187707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003|Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin|Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin||University of California, San Francisco|Yes|Completed|September 2005|August 2008|Actual|January 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00187707||192848|
NCT00187408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|524E-CVD-0042-042|The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial|Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention||Sunnybrook Health Sciences Centre||Completed|August 2002|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||700|||Both|16 Years|N/A|No|||February 2006|February 26, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187408||192869|
NCT00188253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0264-C|Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma.|Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma.||University Health Network, Toronto||Active, not recruiting|March 2005|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Patients with histologically diagnosed nasopharyngeal carcinoma presenting to the        University Health Network for which a course of curative radiation therapy +/-        chemotherapy is planned.|March 2016|March 3, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188253||192806|
NCT00188266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 02-0134-C|Study of Adjuvant Radiochemotherapy for Gastric Cancer|Prospective Phase I/II Study of Adjuvant Radiochemotherapy for Gastric Cancer||University Health Network, Toronto|Yes|Active, not recruiting|August 2002|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|70 Years|No|||June 2015|June 12, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188266||192805|
NCT00189020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINOES 01, STEG R05 008|Effect of Two Versus Three Pneumococcal Conjugate Vaccinations|Effect of 2 Versus 3 Pneumococcal Conjugate Vaccinations Prevnar on Nasopharyngeal Carriage, Transmission and Herd-immunity;a Randomized, Controlled Study|MNOES|UMC Utrecht|Yes|Completed|June 2005|||February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1005|||Both|2 Months|3 Months|Accepts Healthy Volunteers|||August 2011|August 19, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00189020||192747|
NCT00189293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1526-IMIQ|Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts|Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts||MEDA Pharma GmbH & Co. KG||Completed|June 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||September 2008|January 5, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00189293||192726|
NCT00189332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1527-852A|Use of 852A in Metastatic Cutaneous Melanoma.|Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma.||Pfizer||Completed|February 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||October 2008|October 24, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189332||192723|
NCT00185575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUSPO30478|Duloxetine for the Treatment of Dysthymia|Duloxetine for the Treatment of Dysthymia||Stanford University||Completed|September 2004|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2009|April 7, 2009|September 9, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00185575||193005|
NCT00186017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79897|Short Term Rescue Study of Olanzapine|Double-Blind Placebo-Controlled Olanzapine Add-on Therapy in the Treatment of Acute Syndromal and Subsyndromal Exacerbations in Bipolar Disorders||Stanford University|No|Completed|July 2005|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||December 2012|December 11, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00186017||192974|
NCT00186420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0004|Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation|Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation||Stanford University|Yes|Completed|July 2003|September 2009|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Male|18 Years|N/A|No|||June 2012|June 12, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00186420||192944|
NCT00186407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT92|Autologous Stem Cell Rescue for Primary Amyloidosis|High Dose Chemotherapy and Autologous Stem Cell Rescue for Primary Amyloidosis||Stanford University||Completed|April 1998|February 2010|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||September 2010|September 10, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186407||192945|
NCT00186758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS2092|Transcranial Magnetic Stimulation in Bipolar Depression|A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression|TMS|St. Joseph's Healthcare Hamilton|No|Completed|July 2002|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||August 2011|August 2, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186758||192919|
NCT00187018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOD2|Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study|Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study||St. Jude Children's Research Hospital|No|Completed|March 2004|August 2007|Actual|August 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|9|||Both|N/A|N/A|No|||May 2007|March 3, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187018||192899|
NCT00220077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2110|Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer|Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer||Royal Marsden NHS Foundation Trust||Recruiting|June 2002|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220077||190413|
NCT00220402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP738|Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome|Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome||Pfizer||Completed|July 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||November 2008|November 21, 2008|August 30, 2005||||No||https://clinicaltrials.gov/show/NCT00220402||190388|
NCT00220415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0755|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization||UCB Pharma||Completed|May 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|70 Years|No|||February 2010|September 19, 2014|August 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00220415||190387|
NCT00208728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0227-2003|Cardiopulmonary Circuits in the Pediatric Population|Prospective Evaluation of Modified Cardiopulmonary Bypass Circuits in the Pediatric Population||Emory University||Completed|May 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|N/A|N/A|No|||November 2013|November 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208728||191265|
NCT00208988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511-2005|A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening|A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening||Emory University||Completed|May 2003|August 2003||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||250|||Male|45 Years|70 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208988||191245|
NCT00187447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1|Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus|Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus||University of California, San Francisco||Completed|August 2003|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|100|||Both|N/A|48 Hours|No|||September 2005|June 2, 2008|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00187447||192866|
NCT00187200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD299|Response of Cardiac Resynchronization Therapy Optimization With Ventricle to Ventricle Timing in Heart Failure Patients|RESPONSE HF - Response of Cardiac Resynchronization Therapy Optimization With Interventricular (VV) Timing in Heart Failure Patients||St. Jude Medical|No|Completed|January 2005|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|816|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|September 10, 2005||No||No|August 27, 2014|https://clinicaltrials.gov/show/NCT00187200||192885|Due to the lower than expected non-responder rate at 3 months, the study did not reach the target randomized sample size.
NCT00187434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240-2003|Comparison of Two Methods of Continuous Positive Airway Pressure (CPAP) to Support Successful Extubation of Infants of Birth Weights ≤ 1500 Grams (C2CPAP)|A Randomized Control Trial Comparing Two Methods of Delivering Continuous Positive Airway Pressure (CPAP), Infant Flow System CPAP and Bubble CPAP, in Supporting Successful Extubation of Infants of Birth Weights Less Than or Equal to 1500 Grams at Birth (C2CPAP)||Sunnybrook Health Sciences Centre||Recruiting|September 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||76|||Both|N/A|N/A|No|||September 2005|January 22, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00187434||192867|
NCT00187954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISE ARIC|WISE ARIC: Retinal Photography in Women With Chest Pain|Retinal Photography in Women With Chest Pain: A WISE/ARIC Collaboration||University of Florida|Yes|Completed|June 2003|September 2014|Actual|September 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Female|18 Years|75 Years|No|Non-Probability Sample|Women who participated in or are being screened for the WISE or EWISE or any ancillary        studies|October 2015|October 2, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00187954||192829|
NCT00187980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 05-02|Sleep Disturbance in Lung Cancer Patients.|||University Hospital, Angers||Recruiting|June 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||50|||Female|18 Months|N/A|No|||September 2005|September 9, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00187980||192827|
NCT00188292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB #02-0325-B|Screening for HIV-Associated Anal Cancer|Screening for HIV-Associated Anal Cancer|TRACE|University Health Network, Toronto|Yes|Completed|August 2002|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|401|||Male|18 Years|N/A|No|Probability Sample|HIV + MSM who had High Resolution Anoscopy|March 2016|March 4, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188292||192803|
NCT00189033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJ6Z|Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?|Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre? A Randomized Controlled Trial in Primary Care.||UMC Utrecht||Completed|April 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||285|||Both|18 Years|65 Years|No|||April 2007|April 19, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00189033||192746|
NCT00189306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1413-IMIQ|Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream|An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma||Graceway Pharmaceuticals, LLC|No|Completed|March 2001|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|September 13, 2005|Yes|Yes||No|October 30, 2008|https://clinicaltrials.gov/show/NCT00189306||192725|
NCT00189319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1478-FLEC|To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation|Impact of Oral Controlled Release Flecainide Acetate Capsules on Health-Related QoL in Patients With Paroxysmal Atrial Fibrillation||MEDA Pharma GmbH & Co. KG||Completed|September 2003|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|80 Years|No|||September 2006|February 20, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189319||192724|
NCT00185159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-866/44|Olmesartan Medoxomil in Diabetes Mellitus|Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)||Daiichi Sankyo Inc.||Completed|October 2004|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|4449|||Both|18 Years|75 Years|No|||January 2010|January 19, 2010|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185159||193033|
NCT00186797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AACD34|Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia||AACD34|St. Jude Children's Research Hospital||Completed|December 2002|May 2007|Actual|September 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|N/A|21 Years|No|||April 2010|April 7, 2010|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00186797||192916|
NCT00187031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WILTOP|A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor|A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor||St. Jude Children's Research Hospital|Yes|Completed|November 2002|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|21 Years|No|||June 2008|June 3, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00187031||192898|
NCT00186433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0006|A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations|A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations||Stanford University|Yes|Completed|November 2001|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|49|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Having a new diagnosis of Nasopharyngeal carcinoma|May 2015|May 22, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186433||192943|
NCT00186784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS1871|Transcranial Magnetic Treatment (TMS) in Unipolar Depression|Repetitive Transcranial Magnetic Stimulation (rTMS) in Unipolar Depression||St. Joseph's Healthcare Hamilton|No|Completed|December 2000|July 2011|Actual|July 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|65 Years|No|||August 2011|August 2, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186784||192917|
NCT00187525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-02A|A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration|||University of California, San Francisco||Completed|May 2004|October 2006|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|40 Years|80 Years|No|||November 2012|November 8, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187525||192860|
NCT00187811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00/0139|The Safety and Efficacy of Photodynamic Therapy for Femoral Artery Stenosis|Randomised Controlled Trial of Adjuvant Photodynamic Therapy to Reduce Restenosis After Percutaneous Transluminal Angioplasty to the Superficial Femoral Angioplasty||University College London Hospitals||Active, not recruiting|February 2001|June 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||September 2005|December 28, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00187811||192840|
NCT00212472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI|International Immune Tolerance Study|An International Randomised Controlled Trial Of Immune Tolerance Induction||New York Presbyterian Hospital|Yes|Terminated|July 2002|December 2012|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|N/A|7 Years|No|||October 2009|December 4, 2009|September 13, 2005||No|The DSMB recommended stopping the study due to safety concerns.|No||https://clinicaltrials.gov/show/NCT00212472||190982|
NCT00212836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05817|Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)|A Multicenter, Double-Blind, Flexible -Dose, 6-Month Trial Comparing the Efficacy Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia||Merck Sharp & Dohme Corp.|Yes|Completed|May 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|444|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00212836||190956|
NCT00208741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0337-2002|Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder|A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD)||Emory University||Completed|June 2002|November 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||November 2013|November 8, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208741||191264|
NCT00208468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT99/02|A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement|A Multi-centre, Randomised, Parallel Group, Controlled Study to Compare the Performance of the Future Hip Against Three Currently Used Implants in Total Hip Replacement||DePuy International|No|Terminated|February 2000|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|312|||Both|18 Years|75 Years|No|||September 2011|September 1, 2011|September 13, 2005|Yes|Yes|Slow recruitment, investigators not wishing to continue with randomisation and a decision to    rationalise this product from the Sponsors portfolio.|No||https://clinicaltrials.gov/show/NCT00208468||191285|
NCT00187460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT43823|Study of the Effectiveness of Report Cards on the Quality of Care for Heart Attack and Heart Failure Patients|Enhanced Feedback for Effective Cardiac Treatment (EFFECT)|EFFECT|Sunnybrook Health Sciences Centre|No|Completed|November 2001|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|46000|||Both|20 Years|N/A|No|||May 2005|November 30, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187460||192865|
NCT00187473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10102-17633|Natural History of Hepatitis C in Patients With Normal Liver Tests|Determinants of Disease Severity in Patients With Chronic Hepatitis C and Normal Serum Aminotransferases (Normal Liver Tests)||University of California, San Francisco|No|Active, not recruiting|June 2000|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|92|||Both|18 Years|N/A|No|Non-Probability Sample|HCV patients with normal ALT|July 2014|July 18, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187473||192864|
NCT00187993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-04-03|Growth Hormone Treatment of Young Growth Hormone-Deficient Adults|Growth Hormone Treatment of Young Adults Deficient in Growth Hormone Since Childhood : Study of Body Composition Modifications.||University Hospital, Angers||Recruiting|May 2005|August 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||30|||Both|18 Years|35 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00187993||192826|
NCT00188279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0051-C|Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma|Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma||University Health Network, Toronto|No|Active, not recruiting|July 2005|April 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188279||192804|
NCT00187720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|787|Genetic Basis for Variation in the Renal Elimination of Metformin|Genetic Basis for Variation in the Renal Elimination of Metformin||University of California, San Francisco|Yes|Completed|May 2002|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|September 13, 2005||No||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00187720||192847|Recruitment of subjects with interested genotypes was our limitation.
NCT00187967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 03-03|Cardiopulmonary Bypass (CPB) Pumps and Blood Activation|Blood Activation During Cardiopulmonary Bypass Using Roller or Centrifugal Pumps||University Hospital, Angers||Recruiting|January 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A||||September 2005|September 24, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00187967||192828|
NCT00188799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0483-CE|Xray Volume Imaging (Cone Beam CT) - Prostate Cancer|A Clinical Study of X-ray Volume Imaging to Evaluate the Daily Set-up Accuracy of Conformal Prostate Radiotherapy||University Health Network, Toronto||Completed|November 2003|November 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|18 Years|N/A|No|||July 2015|July 15, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188799||192764|
NCT00188812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0725-AE|Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease|Open-Label, Multicentre, One Year Extension of the Evaluation of the Safety of Donepezil Hcl in Patients With Dementia Associated With Cerebrovascular Disease||University Health Network, Toronto||Completed|May 2004|August 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|45 Years|N/A||||September 2005|January 9, 2009|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00188812||192763|
NCT00188773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0871-A|Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion|||University Health Network, Toronto|No|Completed|January 2004|January 2008|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||June 2007|June 4, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188773||192766|
NCT00188786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0037-C|Cone Beam CT for Daily Image Guidance - Prostate Cancer|A Phase II Feasibility Study of Cone Beam Computed Tomography for Daily Image Guidance in Patients Receiving Dose Escalated Conformal Radiation Therapy for Prostate Cancer||University Health Network, Toronto||Completed|April 2005|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Male|18 Years|N/A|No|||February 2011|February 11, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188786||192765|
NCT00189046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/237-E|Effects of Pain on Driving Performance and Cognition.|Effects of Pain on Driving Performance, Attentional Capacity and Psychomotor Performances: a Comparative Study Between Healthy Controls and Chronic Pain Patients.||UMC Utrecht||Terminated|January 2004|April 2005||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||30|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00189046||192745|
NCT00199927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPLANADE|Statins in Proteinuric Nephropathies|A Prospective, Randomized, Multicenter Trial Testing the Antiproteinuric Effect of Statins Added to Combined ACE-inhibitor and Angiotensin Receptor Antagonist Therapy in Proteinuric, Chronic Nephropathies|ESPLANADE|Mario Negri Institute for Pharmacological Research|No|Completed|March 2003|March 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|16 Years|80 Years|No|||April 2010|April 27, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00199927||191926|
NCT00199888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-003|Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.|Pilot Study of Iodine-124 Labeled Chimeric G250 (124 I-cG250) in Presurgical Patients With Renal Masses||Ludwig Institute for Cancer Research||Completed|February 2005|June 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||54|||Both|18 Years|N/A|No|||August 2006|August 29, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00199888||191929|
NCT00200148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-004|Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy|A Prospective Randomized Trial of Acute Normovolemic Hemodilution Compared to Standard Intraoperative Management in Patients Undergoing Major Hepatic Resection and Pancreaticoduodenectomy||Memorial Sloan Kettering Cancer Center||Completed|March 2004|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|372|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200148||191909|
NCT00200408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-01-008S|Assessment of Early Genetic Changes in Smokers|Assessment of Early Genetic Changes in Smokers||Montefiore Medical Center||Terminated|March 2004|||January 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy smokers and non-smokers|April 2015|April 7, 2015|September 13, 2005||No|unable to obtain funding|No||https://clinicaltrials.gov/show/NCT00200408||191889|
NCT00200421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB203|A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension|A Double-Blind, Randomized, Multi-Center, Active Comparator, Five Treatment Study of the Effects of Nebivolol Compared to Atenolol on Cardiovascular Hemodynamics and Exercise Capacity in Patients With Mild to Moderate Hypertension||Mylan Bertek Pharmaceuticals||Completed|May 2002|August 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||August 2003|December 15, 2005|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00200421||191888|
NCT00200733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31AT000789-01|The Use of Narrative in Public Health Research and Practice: Patient Experience of Wellness Acupuncture|The Use of Narrative in Public Health Research and Practice: Patient Experience of Wellness Acupuncture||National Center for Complementary and Integrative Health (NCCIH)||Terminated|June 2003|March 2004||||N/A|Observational|Time Perspective: Longitudinal||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|August 17, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200733||191864|
NCT00201474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEV-98|Acute, Affective, Organic Disorders.|Signs of Organic Brain Dysfunction in Psychiatric Patients With Fluctuating Psychiatric Symptoms Including Brief Depressions Compared to Patients With a Major Depressive Episode.||Norwegian University of Science and Technology|No|Completed|October 1998|June 2010|Actual|October 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|Samples Without DNA|Ordinary laboratory tests, medication, substances.|Both|18 Years|N/A|No|Probability Sample|Study and control groups both from a psychiatric acute ward. The patients are acutely        admitted suffering from different types of depressive symptoms.|April 2015|April 7, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201474||191812|
NCT00201786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0301|Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease|Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease||Ohio State University Comprehensive Cancer Center|Yes|Completed|July 2003|July 2013|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201786||191789|
NCT00202059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1769-03-A|Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer|The Effects of Zoledronic Acid (Zometa) and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer||HealthPartners Institute||Completed|June 2003|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||72|||Female|40 Years|55 Years|No|||April 2007|December 15, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202059||191768|
NCT00192673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000658-56|Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses|PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia||Nordic Society for Pediatric Hematology and Oncology||Recruiting|June 2005|December 2013|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|85|||Both|1 Year|14 Years|No|||September 2009|September 29, 2009|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00192673||192473|
NCT00192686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-011-CP|Cultures a.m.Kamme-Lindbergh in Suspicion of Infected TKA|Cultures From Total Knee Arthroplasties, Obtained a.m. Kamme-Lindberg in Revision Cases.||Northern Orthopaedic Division, Denmark||Completed|January 2004|November 2006|Actual|November 2006|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|N/A|No|||March 2014|March 28, 2014|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00192686||192472|
NCT00192985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-160/02 Catheter|Does a Nitrofurazone Coated Bladder Catheter Reduce the Number of Urinary Tract Infections in Trauma|||Rigshospitalet, Denmark||Active, not recruiting|May 2003|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||216|||Both|18 Years|N/A|No|||September 2005|September 16, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192985||192449|
NCT00192998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERT-AD|The Serotonergic Transmitter System in Dementia and Affective Disorders|||Rigshospitalet, Denmark||Recruiting|October 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 26, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00192998||192448|
NCT00201318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1401|A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen|A Randomized Study of Lamivudine Prophylaxis or Treatment Against Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen||National Health Research Institutes, Taiwan||Completed|September 2001|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201318||191824|
NCT00202215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS002|Chrysalis Day Program Body Mass Index Study|A Study on the Effects of a Personality Disorder Day Hospital Program on Clients Body Mass Index||Queen's University|No|Completed|October 2001|June 2007|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|16 Years|N/A|No|||September 2005|October 15, 2007|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00202215||191757|
NCT00202436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO-C- 03-006|Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy|Therapeutic Erythrocytapheresis as Treatment for Hemochromatosis Patients.||Sanquin Research & Blood Bank Divisions|No|Completed|October 2004|September 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2009|October 19, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00202436||191740|
NCT00202748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF70201|Change of Lifestyle by Persons in Risk of Type 2 Diabetes|Phase 3 Study of Changing of Lifestyle by Persons in Risk of Type 2 Diabetes||Sorlandet Hospital HF||Active, not recruiting|March 2004|March 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||220|||Both|20 Years|64 Years|No|||December 2003|December 22, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202748||191716|
NCT00202761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF70339|Project:Intensive Habilitation (PIH)|Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities||Sorlandet Hospital HF|Yes|Active, not recruiting|March 2004|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|20|||Both|N/A|5 Years|No|||May 2014|May 27, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202761||191715|
NCT00202774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-TTD-01|Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer|Phase III, Multicenter, Ramdomised, Open-label, Study to Evaluate the Safety and Efficacy of Combination Therapy With XELOX vs. Oxaliplatin and 5-FU CI as First Line Treatment in Advanced or Metastatic Colorectal Cancer||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|April 2002|December 2005|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||348|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202774||191714|
NCT00203047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNC GA MS 2004_01|Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate|A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-on Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated With Glatiramer Acetate (GA)|ASSERT|Teva Pharmaceutical Industries|Yes|Terminated|January 2005|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|414|||Both|18 Years|55 Years|No|||November 2013|November 15, 2013|September 13, 2005|Yes|Yes|Slow enrollment decreased sample size; No unexpected safety issues.|No|August 29, 2013|https://clinicaltrials.gov/show/NCT00203047||191693|
NCT00203684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23RR018538-03|Mentored Patient-Oriented Research Career Development Award|The Effects of Different Sized Inhaled Corticosteroids on Peripheral Lung Inflammation in Asthma Assessed Through Lung Tissue Samples (SMART Protocol)||University of California, Los Angeles||Recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2005|October 18, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00203684||191646|
NCT00203697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002Kleerup|Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study|Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study||University of California, Los Angeles||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|79 Years|No|||September 2006|September 7, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00203697||191645|
NCT00199667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I02013|Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients|APOMYGRE : Multicenter, Randomized, Open-Label Study of MMF Therapeutic Follow-up's Interest in the the 12 First Months in Kidney Transplantation||University Hospital, Limoges||Active, not recruiting|October 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||137|||Both|18 Years|N/A|No|||December 2008|December 14, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199667||191946|
NCT00200447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI 0011|An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)|Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)||Molecular NeuroImaging||Completed|March 2004|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|30 Years|N/A|No|||January 2008|January 17, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200447||191886|
NCT00199901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2003-009|Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma|Randomized, Double-blind Phase II Trial of NY-ESO-1 ISCOMATRIX® Vaccine and ISCOMATRIX® Adjuvant Alone in Patients With Resected Stage IIc, III or IV Malignant Melanoma||Ludwig Institute for Cancer Research||Completed|September 2005|December 2011|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00199901||191928|
NCT00200161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-079|Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma|A Randomized Phase II Trial of Concurrent Temozolomide and Radiotherapy Followed by Dose Dense Versus Metronomic Temozolomide and Maintenance Cis-Retinoic Acid for Patients With Newly Diagnosed Glioblastoma and Other Malignant Gliomas||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2005|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00200161||191908|
NCT00200759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002073-01|Drug Interactions and Bioavailability of Cranberry|Drug Interactions and Bioavailability of Cranberry||Medical University of South Carolina|Yes|Completed|October 2004|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200759||191862|
NCT00200746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002394-01A1|Treatment of Alcohol-Related Hepatitis With Arginine|Arginine Treatment for Alcoholic Hepatitis||National Center for Complementary and Integrative Health (NCCIH)|Yes|Withdrawn|April 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|70 Years|No|||March 2013|March 11, 2013|September 12, 2005||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00200746||191863|
NCT00201110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274|Problem Solving and Cardiovascular Disease Risk Management in Diabetic Blacks|Problem Solving & CVD Risk Management in Diabetic Blacks||Johns Hopkins University|Yes|Completed|July 2004|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|N/A|N/A|No|||March 2013|March 19, 2013|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201110||191839|
NCT00202072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208/03|Mucin in Sputum of CF During Pulmonary Exacerbation|||Philipps University Marburg Medical Center||Recruiting|January 2004|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||25|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202072||191767|
NCT00202306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI 01-038|Indicated Prevention of Psychotic Disorders With Low-dose Lithium|An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder||Melbourne Health|Yes|Completed|November 2001|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|15 Years|30 Years|No|||September 2005|May 28, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00202306||191750|
NCT00197860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR0414|Dendritic Cell Based Therapy of Renal Cell Carcinoma|Vaccination With Autologous Dendritic Cells Pulsed With Tumor Antigens for Treatment of Patients With Renal Cell Carcinoma.A Phase I/II Study.||Herlev Hospital||Completed|September 2004|October 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||November 2011|November 22, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197860||192083|
NCT00193011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 41|Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer|A Randomized Multicenter Trial Comparing Weekly Docetaxel and CMF in the Adjuvant Treatment of Women With High-Risk Breast Cancer Who Are > 65 Years Old or Are Not Candidates for Anthracycline-Based Adjuvant Therapy||SCRI Development Innovations, LLC||Completed|March 2002|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00193011||192447|
NCT00201682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0113|Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Phase I/II Study of Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2002|August 2009|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||April 2012|April 13, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201682||191797|
NCT00201695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0354|Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma|Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in Combination With Arsenic Trioxide (Trisenox) in Untreated Patients With Symptomatic Multiple Myeloma||Ohio State University Comprehensive Cancer Center|Yes|Completed|July 2004|August 2008|Actual|September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201695||191796|
NCT00202449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Raskind 0046|Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance|A Placebo-Controlled Trial of Prazosin vs. Paroxetine in Combat Stress-Related PTSD Nightmares and Sleep Disturbance||Seattle Institute for Biomedical and Clinical Research|Yes|Terminated|July 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|50 Years|No|||June 2012|June 11, 2012|September 12, 2005||No|recruitment difficulties|No|February 24, 2012|https://clinicaltrials.gov/show/NCT00202449||191739|High rate of early termination leading to small number of patients analyzed.
NCT00202462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDIS 0004|The Effect of Testosterone on Mood and Quality of Life|The Effect of Testosterone Treatment on Depressive Symptoms and Quality of Life in Older Men With Age-Related Hypogonadism and Subsyndromal Depression.||Seattle Institute for Biomedical and Clinical Research|No|Completed|November 2002|November 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Male|50 Years|N/A|No|||September 2008|September 30, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202462||191738|
NCT00203411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORI GI-04|Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer|A Phase II Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Capecitabine (Xeloda) in Frail Patients With Untreated Metastatic Colorectal Cancer||Translational Oncology Research International|Yes|Active, not recruiting|March 2006|||February 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2011|February 16, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203411||191666|
NCT00203424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORI GU-01|Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib|A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer||Translational Oncology Research International|Yes|Completed|January 2006|June 2010|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|N/A|No|||February 2016|February 26, 2016|September 13, 2005|Yes|Yes||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00203424||191665|This was a small study with only 22 participants who received study treatment. With such a small sample size the study doesnt have the statistcical power to make categorical assessments or statements.
NCT00203671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-05-018-01|Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation|Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation||University of California, Los Angeles||Completed|April 2006|May 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|651|||Both|18 Years|N/A|No|Non-Probability Sample|Data from existing medical records of 651 UCLA patients who received a kidney transplant,        between the dates of January 1, 1995 - December 31st, 2003 All data was reviewed and        analyzed as part of this study.|May 2007|July 12, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203671||191647|
NCT00199446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-201|Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome|A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) in Subjects With Restless Legs Syndrome||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|July 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||February 2007|June 22, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199446||191963|
NCT00199459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-481|Proteomic Study of Urinary Stone Disease|Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers||Lawson Health Research Institute|No|Completed|January 2005|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|This observational study will compare stone formers meeting the inclusion criteria with a        cohort of age and sex matched non-stone formers as controls.|September 2009|September 2, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00199459||191962|
NCT00192348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P518|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Infants||MedImmune LLC||Completed|May 2002|December 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|6 Weeks|24 Weeks|Accepts Healthy Volunteers|||October 2006|October 2, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192348||192497|
NCT00192361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153 P500|Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)|A Randomized, Double-Blind Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)||MedImmune LLC||Completed|November 1999|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|8 Months|36 Months|Accepts Healthy Volunteers|||October 2006|October 23, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192361||192496|
NCT00192374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P513|Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase III, Multicenter Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B,Live, Cold-Adapted (CAIV-T) in Healthy Children||MedImmune LLC||Completed|February 2002|November 2002||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1920|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||October 2006|October 2, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192374||192495|
NCT00199914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34/2003|Efficacy Study of Shortwave Diathermy for the Treatment of Patients With Knee Osteoarthritis|The Effectiveness of Shortwave Diathermy in Knee Osteoarthritis: A Randomized Controlled Trial||Mahidol University|No|Completed|January 2004|June 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Female|50 Years|80 Years|No|||September 2013|September 6, 2013|September 12, 2005||No||No|May 19, 2013|https://clinicaltrials.gov/show/NCT00199914||191927|
NCT00200434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB321|A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension|A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Mild to Moderate Hypertension||Mylan Bertek Pharmaceuticals||Completed|October 2002|October 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00200434||191887|
NCT00201149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|255|Clinician Counseling and Cultural Competency to Improve Hypertension Control and Therapy Adherence|Hypertension Control and Therapy Adherence||Boston Medical Center|Yes|Active, not recruiting|February 2004|December 2016|Anticipated|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|870|||Both|21 Years|100 Years|No|||December 2015|December 15, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201149||191836|
NCT00201487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11870|Choline Quantification in Breast Cancer by MRS|Choline Quantification in Breast Cancer by MRS||Norwegian University of Science and Technology|No|Withdrawn|November 2007|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|20 Years|N/A|No|Probability Sample|breast cancer|October 2013|October 30, 2013|September 16, 2005||No|We chose to use an exsisting NMR pulse sequence already established and available at the    hospital.|No||https://clinicaltrials.gov/show/NCT00201487||191811|
NCT00201500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEETLV|Left Ventricular and Endothelial Function in Preeclampsia|Left Ventricular and Endothelial Function in Preeclampsia, a Case Control Study||Norwegian University of Science and Technology|No|Completed|October 2004|March 2006|Actual|December 2005|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control||2|Actual|50|Samples With DNA|Blood samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Women with preeclampsia and women with normotensive pregnancies.|April 2015|April 7, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201500||191810|
NCT00201123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264|Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs|Host Response to Tuberculosis and Acquired Immune Deficiency Syndrome||New York University School of Medicine|Yes|Completed|April 2005|August 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|September 16, 2005|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT00201123||191838|
NCT00201136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013310|Interventions to Improve Hypertension Control and Reduce Cardiovascular Disease Risk|Hypertension Improvement Project (HIP)|HIP|Duke University|Yes|Completed|February 2004|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|574|||Both|25 Years|N/A|No|||February 2012|October 11, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00201136||191837|
NCT00193726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122 of 2003|Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer|Estrogen Priming to Increase the Efficacy of Standard Adjuvant Chemotherapy in Operable Breast Cancer.||Tata Memorial Hospital||Recruiting|July 2005|December 2011||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1400|||Female|18 Years|70 Years|No|||August 2005|February 6, 2006|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00193726||192392|
NCT00199524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-002|Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate|A Prospective Randomized Controlled Clinical Trial of the Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate||Lawson Health Research Institute|No|Terminated|May 2005|May 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||October 2009|October 13, 2009|September 13, 2005||No|Enrollment was slower than anticipated.|No||https://clinicaltrials.gov/show/NCT00199524||191957|
NCT00198107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072961|Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism|Novel Pharmacological Strategies in Autism||Indiana University|Yes|Completed|September 2005|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|88|||Both|5 Years|17 Years|No|||October 2015|October 30, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00198107||192064|
NCT00202241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-99|The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS|The Effects of Anabolic Steroids and Protease Inhibitors on Serum Blood Lipids,Muscle Mass, and Total Body Fat in People Living With HIV/AIDS||Queen's University||Completed|September 1999|June 2001||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202241||191755|
NCT00201968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REL-2004-3|Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury|Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury||Ontario Neurotrauma Foundation|Yes|Active, not recruiting|April 2005|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00201968||191775|
NCT00201981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37E-03-202|Study of Rebamipide Eye Drops to Treat Dry Eye|Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multicenter, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 52 Week Study||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|May 2004|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|740|||Both|18 Years|N/A|No|||January 2008|January 4, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00201981||191774|
NCT00201994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-03-238|"SALT-2 Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia|Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia, Study 2||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|November 2003|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|243|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|September 13, 2005||Yes||||https://clinicaltrials.gov/show/NCT00201994||191773|
NCT00202228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-629-02|Lactate Metabolism Study in HIV Infected Persons|Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation.||Queen's University|No|Completed|July 2002|September 2011|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202228||191756|
NCT00202787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-04-02|Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer|Open-label, Phase II, Randomised, Pilot Study to Evaluate the Safety and Efficacy of Combination Therapy With Cetuximab and FOLFOX4 or FOLFOX4 Alone in Patients Colorectal Cancer and Initially Non-resectable||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|February 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|75 Years|No|||February 2013|February 19, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202787||191713|
NCT00203060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/232|Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa||Teva Pharmaceutical Industries|Yes|Completed|July 1997|July 2000|Actual|July 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|404|||Both|35 Years|N/A|No|||April 2011|April 8, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203060||191692|
NCT00203073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-100|A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.|A Multi-Center, Randomized, Open Label Study To Evaluate Safety, Tolerability And Efficacy Of Treatment With Mitoxantrone; Pre-Treatment With Glatiramer Acetate (GA) Versus Treatment With GA Alone In Relapsing Forms Of Multiple Sclerosis.||Teva Pharmaceutical Industries|No|Completed|June 2003|April 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|55 Years|No|||April 2011|April 13, 2011|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00203073||191691|
NCT00203086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM025|A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis|A Multi-Centered, Two Arm, Open Label Extension Study (to Protocol NC-100) to Evaluate the Long-Term Safety and Efficacy of Short-Term Induction Treatment With Mitoxantrone (Novantrone®) Preceding Treatment With Glatiramer Acetate (Copaxone®) vs. Chronic Treatment With Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis||Teva Pharmaceutical Industries|Yes|Completed|October 2005|December 2009|Actual|October 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|20 Years|57 Years|No|Non-Probability Sample|Neurology Clinics|April 2010|April 27, 2010|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203086||191690|
NCT00203450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC Zonegran for Weight Loss|Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial|Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial|Zonegran|Tuscaloosa Research & Education Advancement Corporation|No|Completed|May 2003|March 2006|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|65 Years|No|||August 2012|August 30, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203450||191664|
NCT00203151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-4710/201|A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus|A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Edratide for Subcutaneous Injection in Systemic Lupus Erythematosus (SLE)|PRELUDE|Teva Pharmaceutical Industries||Terminated|July 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|65 Years|No|||April 2011|April 8, 2011|September 13, 2005|Yes|Yes|TV-4710/201 did not meet its primary endpoints in patients with SLE|Yes||https://clinicaltrials.gov/show/NCT00203151||191685|
NCT00203710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-TR-001|Concentric Retriever Device (CRD) in Acute Ischemic Stroke|A Single-Center Controlled Registry to Evaluate the Concentric Retriever System for the Treatment of Stroke||University of California, Los Angeles||Completed|October 2003|September 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00203710||191644|
NCT00203723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB #03-10-049-01|Use of Risperidone in ECT for Treatment Resistant Depression|A Comparison Study of Combined ECT and Risperidone Versus ECT Alone for Treatment Resistant Depression.||University of California, Los Angeles||Terminated|March 2005|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|89 Years|No|||May 2006|May 17, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00203723||191643|
NCT00199472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07378|Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO|Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of Ureteropelvic Junction Obstruction||Lawson Health Research Institute||Terminated|April 2001|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||10|||Both|18 Years|N/A|No|||June 2006|June 19, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199472||191961|
NCT00202319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001.102|Effectiveness of Sedation Management in an Australian Intensive Care Unit|Evaluating the Effectiveness of Protocol Directed Sedation Management With Non-Protocol Directed Sedation Management on Mechanically Ventilated Patients in an Australian Intensive Care Unit.||Melbourne Health||Completed|November 2001|September 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||316|||Both|17 Years|N/A|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00202319||191749|
NCT00202332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999.115|CABG Without the Use of CPB|A Prospective Randomised Study od Coronary Artery Bypass Surgery Without the Use of Cardiopulmonary Bypass||Melbourne Health||Completed|February 2001|February 2004|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|18 Years|85 Years||||July 2015|July 15, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00202332||191748|
NCT00200174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-017|Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease|Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease: A Pilot Chemoprevention Trial||Memorial Sloan Kettering Cancer Center||Completed|July 1999|August 2008|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00200174||191907|
NCT00201162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280|Soy and Lipoproteins in Postmenopausal Women|||Johns Hopkins University||Completed|September 2001|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||||||Female|N/A|N/A|No|||January 2008|March 19, 2014|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00201162||191835|
NCT00201188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279|Enhancing Collaboration Between Doctors and Patients to Improve Asthma|Cueing Patient-Clinician Collaboration to Improve Asthma||University of California, San Francisco|Yes|Completed|December 2003|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|72 Years|No|||March 2013|March 7, 2013|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201188||191834|
NCT00193232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 18|Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer|A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer||SCRI Development Innovations, LLC||Completed|May 2004|February 2007|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Male|18 Years|N/A|No|||July 2010|July 27, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00193232||192430|
NCT00201799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0323|Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation|Phase II Trial of Infliximab for the Prevention of Acute Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation||Ohio State University Comprehensive Cancer Center|Yes|Completed|February 2004|March 2008|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|19|||Both|20 Years|N/A|No|||June 2015|June 9, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201799||191788|
NCT00203788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH037705|Improving Work Outcome in People With Recent-onset Schizophrenia|Developmental Processes in Schizophrenic Disorders: Improving and Predicting Work Outcome in Recent-Onset Schizophrenia||University of California, Los Angeles|No|Completed|May 1999|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|45 Years|No|||May 2008|July 28, 2013|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203788||191638|
NCT00199537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-055|Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer|Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer||Lawson Health Research Institute|No|Completed|February 2005|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Male|40 Years|N/A|No|Non-Probability Sample|Men with Prostate Cancer undergoing continued treatment with leuteinizing        hormone-releasing hormone [LHRH] therapy|July 2008|July 25, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199537||191956|
NCT00199758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I03022|Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer|A Randomized Phase II Trial of Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer.||University Hospital, Limoges||Completed|September 2003|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||227|||Both|18 Years|70 Years|No|||November 2007|November 9, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199758||191939|
NCT00197496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-05055|Body Weight Supported Treadmill Training Following Hip Fracture|Body Weight Supported Treadmill Training Following Hip Fracture||McMaster University|Yes|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||September 2009|September 19, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197496||192105|
NCT00197873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18581|Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea|Randomized, Double Blind, Placebo Controlled, Cross-over Phase II Study on the Effects of Lactobacillus Rhamnosus GG Supplementation in Patients on 1st Line XELOXA Treatment for Metastatic Colorectal Cancer||Helsinki University|No|Active, not recruiting|September 2005|October 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197873||192082|
NCT00202020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBRI0001|Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke|Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial||Otsuka Beijing Research Institute||Completed|May 2004|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||720|||Both|18 Years|75 Years|No|||March 2006|March 15, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202020||191771|
NCT00202475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO-C-02-15|Collection of Autologous Blood Products by Double Erythrocytapheresis|Collection of Autologous Blood Products by Double Erythrocytapheresis - Cost Effectiveness Study||Sanquin Research & Blood Bank Divisions|No|Completed|September 2003|December 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2009|October 19, 2009|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00202475||191737|
NCT00202488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1807-B 03|The Effect of H. Pylori Infection on Iron Metabolism|The Effect of H. Pylori Infection on Iron Metabolism||Seattle Institute for Biomedical and Clinical Research||Completed|November 2002|September 2007||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 29, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202488||191736|
NCT00202800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARI-002-1|Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer|Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer||Spectrum Health Hospitals||Completed|March 2002|January 2011|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202800||191712|
NCT00203112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA 9014|Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline|A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA).||Teva Pharmaceutical Industries|Yes|Completed|June 2004|July 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|50 Years|No|||April 2011|April 11, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00203112||191688|
NCT00203125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP - 1012/133a|A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.|Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)||Teva Pharmaceutical Industries|Yes|Completed|October 2000|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||April 2011|April 8, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203125||191687|
NCT00203736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEACAT 01 Am 4 (RCT)|A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria|Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections||University of Cape Town||Completed|January 2003|October 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|12 Months|N/A|No|||August 2005|November 15, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00203736||191642|
NCT00203463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC Topiramate in PTSD|Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)|Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)||Tuscaloosa Research & Education Advancement Corporation||Completed|July 2001|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2009|July 28, 2009|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00203463||191663|
NCT00199719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I02022|Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM|Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C Non 2 -3 Genotype naïve Patients Treated With a 12 Weeks Bitherapy of Peginterferon Alpha 2a-Ribavirin, and Followed by a Tritherapy of Peginterferon Alpha 2a-Ribavirin-Amantadine for 36 Weeks|CINAM|University Hospital, Limoges||Completed|June 2003|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||June 2007|October 30, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199719||191942|
NCT00200772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001944-01|A Safety Study of Sutherlandia Frutescens, a South African Medicinal Plant, in Healthy Adult Volunteers|A Randomized, Double Blind Placebo Controlled Study to Investigate the Safety of Sutherlandia Frutescens (Subspecies Microphylla) in Health Adult Volunteers.||University of Missouri-Columbia|Yes|Completed|July 2004|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 6, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200772||191861|
NCT00192699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-008b-JPE|Bimetric-10: Investigation of Patients Who Have Underwent Total Hip Arthroplasty With a Cemented Bi-Metric Stem|10 Year Follow-up Investigation of Patients Who Have Underwent Total Hip Arthroplasty With a Cemented Bi-metric Stem||Northern Orthopaedic Division, Denmark|Yes|Completed|January 2004|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with osteoarthrosis in hip who have underwent surgery for 10 years ago using        Cemented Bi-Metric femoral stem.|March 2014|March 28, 2014|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00192699||192471|
NCT00193024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 39|Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer|A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer||SCRI Development Innovations, LLC||Terminated|September 2001|October 2004|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Female|18 Years|N/A|No|||May 2011|May 2, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00193024||192446|
NCT00193453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 92|Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer|A Phase II Trial of First-Line Therapy With Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|July 2005|December 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|September 12, 2005|No|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT00193453||192413|
NCT00193713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.3.004|Bifeprunox in the Treatment of Schizophrenia|A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)||Solvay Pharmaceuticals||Completed|May 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2007|January 15, 2015|September 11, 2005||||||https://clinicaltrials.gov/show/NCT00193713||192393|
NCT00190164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031004|Alleviated Positioning for Small Macular Holes|Evaluation of the Success Rate of a Procedure Without Strict Positioning Post Surgical Versus With Positioning Face Towards the Strict Ground, at Patients Presenting a Macular Hole. Study of Non-Inferiority.||Assistance Publique - Hôpitaux de Paris|Yes|Completed|August 2005|June 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||July 2007|July 17, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00190164||192661|
NCT00194467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1500-B|Suppression of Oral HHV8 Shedding With Valganciclovir|Suppression of Oral Shedding of Human Herpesvirus 8 (HHV-8) With Valganciclovir||University of Washington|Yes|Completed|December 2002|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|32|||Male|18 Years|N/A|No|||December 2007|December 29, 2007|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194467||192336|
NCT00201344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1394|A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients|A Phase III Study of Radiotherapy With or Without Adjuvant Chemotherapy in Advanced Stage Nasopharyngeal Carcinoma Patients||National Health Research Institutes, Taiwan||Terminated|November 1994|January 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||320|||Both|N/A|70 Years|No|||June 2009|March 25, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201344||191822|
NCT00202267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT 63175|Community RCT of the Effectiveness of Two Compression Bandaging Technologies|Community Randomised Control Trial of the Effectiveness of Two Compression Bandaging Technologies||Queen's University|Yes|Completed|January 2004|December 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|426|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00202267||191753|
NCT00202254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 2004.101|Multiple Sclerosis Rehabilitation Study|'Functioning and Disability' and 'Quality of Life' in an Australian Community Cohort With Multiple Sclerosis.||Melbourne Health||Completed|December 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|19 Years|64 Years|No|||June 2015|June 1, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202254||191754|
NCT00202501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI030184|Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome|Usefulness of Nasal CPAP Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome||Sociedad Española de Neumología y Cirugía Torácica||Completed|September 2005|March 2009|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||May 2009|May 20, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202501||191735|
NCT00203099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA 9015|Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine|A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)||Teva Pharmaceutical Industries||Completed|December 2004|June 2008|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|50 Years|No|||May 2012|May 11, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203099||191689|
NCT00199732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I04002|Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a|Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a|DNA-EVAL|University Hospital, Limoges|No|Completed|December 2004|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|19|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with chronic hepatitis B infection and treated with adefovir dipivoxil and peg        interferon alpha 2a.|September 2005|April 16, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00199732||191941|
NCT00199485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-01-007|Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer|Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer||Lawson Health Research Institute|No|Completed|October 2002|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Male|N/A|N/A|No|||July 2008|July 25, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199485||191960|
NCT00200187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003|A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery|A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Radical Retropubic Prostatectomy||Memorial Sloan Kettering Cancer Center||Completed|February 2005|January 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||246|||Male|18 Years|N/A|No|||January 2007|January 25, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200187||191906|
NCT00200200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-086|Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer|Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo With/Without Bevacizumab (mAB to Vascular Endothelial Growth Factor-A) in Patients With Resected Hepatic Metastases From Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2004|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|19 Years|N/A|No|||November 2015|November 25, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00200200||191905|
NCT00202618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART001|Rationale and Design for Shiga Microalbuminuria Reduction Trial|The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART)||Shiga University||Recruiting|December 2003|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|35 Years|75 Years|No|||July 2005|April 27, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202618||191726|
NCT00192712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RonIrinoGem.CTIL|Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer|Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer||Rambam Health Care Campus||Completed|November 2002|September 2010|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2010|November 9, 2010|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00192712||192470|
NCT00203229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAS/LAM101|Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia|A Double-Blind Placebo Controlled Add-on Study to Determine the Efficacy and Safety of Lamictal (Lamotrigine) in Patients With Trigeminal Neuralgia (Tic Doloureux)||Thomas Jefferson University|No|Completed|June 2003|July 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|15 Years|75 Years|No|||May 2014|May 2, 2014|September 13, 2005||No||No|February 7, 2014|https://clinicaltrials.gov/show/NCT00203229||191679|Limited enrollment due to fear of placebo and high drop out rate.
NCT00203242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/DEP/01|An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.|An Open-label Pilot Study to Collect/Evaluate Data on the Use of Consecutive Daily Intravenous Doses of Depacon in Combination With Daily Dose of Depakote ER During a Cluster Headache Cycle.||Thomas Jefferson University||Completed|July 2003|December 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||July 2011|July 13, 2011|September 13, 2005|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00203242||191678|
NCT00203203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-141|Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)|Randomized Controlled Single Blind Trial of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Therapeutic Angiogenesis||Texas Heart Institute|Yes|Completed|April 2004|November 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||June 2015|June 5, 2015|September 12, 2005|No|Yes||No|July 6, 2011|https://clinicaltrials.gov/show/NCT00203203||191681|The study is a preliminary study based on a small sample size which limits the statistical rigor of the analysis.
NCT00203216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBY/LEV01|A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches|A Single-Center, Open-Label Trial Examining the Efficacy and Safety of Levetiracetam for the Prophylactic Treatment of Migraine, With or Without Aura||Thomas Jefferson University||Completed|September 2002|September 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||July 2011|July 15, 2011|September 13, 2005||No||No|May 23, 2011|https://clinicaltrials.gov/show/NCT00203216||191680|
NCT00203528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC Dual Diagnosis Study|Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder|Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder||Tuscaloosa Research & Education Advancement Corporation|No|Completed|January 2004|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|19 Years|65 Years|No|||March 2007|March 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203528||191658|
NCT00203775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-USA-269|Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates|Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates||University of Connecticut Health Center||Terminated|July 2002|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||May 2005|October 12, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203775||191639|
NCT00199966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 03/163, HRRC 539-03|Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder|A Pilot Study Of Safety And Effectiveness For Depakote ER In Pediatric Bipolar Disorder||Medical College of Wisconsin|No|Completed|December 2003|November 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|6 Years|17 Years|No|||March 2008|March 6, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199966||191923|
NCT00199979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUFIN|Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients|Multicenter, Randomized, Open-Label Trial, Assessing the Efficacy of Zidovudine, Lamivudine and Nevirapine Combination Administered Twice Daily, Versus the Association of Tenofovir, Lamivudine and Nevirapine, Once Daily, in Antiretroviral Naive HIV-1 Infected Patients||MEDEX||Recruiting|April 2005|June 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||September 2005|December 15, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199979||191922|
NCT00190385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM03009|Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis|Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis. A Randomized Trial Comparing Two Periodicities of Ultrasonographic Surveillance: 3-month vs 6-month||Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2000|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Actual|1200|||Both|30 Years|75 Years|No|||March 2007|February 24, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00190385||192644|
NCT00190671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4029|A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients|A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer||Eli Lilly and Company|No|Completed|June 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|N/A|No|||November 2009|November 17, 2009|September 12, 2005|Yes|Yes||No|March 17, 2009|https://clinicaltrials.gov/show/NCT00190671||192622|600 mg/m2 arm discontinued at end of Phase 1 because of lack of efficacy. Enrollment in 1800 mg/m2 arm continued to Phase 2. (Phase 1 outcomes were tumor response and pharmacokinetics). Secondary efficacy endpoints analyzed for 1800 mg/m2 arm only.
NCT00190372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030437|AIDMA: A Psycho-educational Program Designed to Support and Train Carers of Alzheimer's Disease (AD) Patients|Contribution of a Psycho-Educational Program of Help to Help in the Pharmacological Assumption of Responsibility of the Disease of Alzheimer||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|1||Actual|240|||Both|60 Years|N/A|No|||March 2007|February 16, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00190372||192645|
NCT00201708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0450|Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer|Phase II Randomized Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide (AC) in Axillary Node-Positive Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2004|February 2014|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|N/A|No|||August 2015|August 18, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201708||191795|
NCT00202527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI041110|Spanish Cohort for the Study of the Effect of CPAP in Hypertension (CEPECTA)|Efficacy of the Treatment With Nasal Positive Continuous Airway Pressure to Reduce the Arterial Blood Pressure in Patients With Apneas-Hypopneas During the Sleep and Systemic Hypertension||Sociedad Española de Neumología y Cirugía Torácica||Recruiting|January 2005|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||340|||Both|18 Years|75 Years|No|||September 2005|December 22, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202527||191733|
NCT00202514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D protocol #: RDIS 0009|Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms|Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms||Seattle Institute for Biomedical and Clinical Research|Yes|Completed|September 2004|July 2006|Actual|July 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||October 2009|October 7, 2009|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202514||191734|
NCT00203164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP - 1012/135 Open Label|Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients|A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy||Teva Pharmaceutical Industries|No|Completed|May 2002|September 2006|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|254|||Both|30 Years|N/A|No|||March 2010|March 8, 2010|September 13, 2005||Yes||||https://clinicaltrials.gov/show/NCT00203164||191684|
NCT00202813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-104|Study of the Use of Coated Venous Catheters in the Critically Ill Child|The Use of Antibiotic-coated Venous Catheters in the Critically Ill Child: Reducing the Rate of Bloodstream Related Infections||Spectrum Health Hospitals||Completed|July 2003|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||500|||Both|N/A|18 Years|No|||December 2009|December 29, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202813||191711|
NCT00203138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP - 1012/233|Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease|A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease||Teva Pharmaceutical Industries||Completed|June 2004|December 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|306|||Both|35 Years|N/A|No|||April 2011|April 8, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203138||191686|
NCT00191243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5758|Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer|A Randomized Phase II Study Comparing Single-Agent Docetaxel to Alternating Docetaxel-Gemcitabine as Primary Chemotherapy in Patients With Metastatic Breast Cancer||Eli Lilly and Company|No|Completed|March 2002|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|70 Years|No|||March 2008|March 26, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00191243||192579|
NCT00191256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5488|Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer|Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC||Eli Lilly and Company||Completed|June 2001|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||77|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191256||192578|
NCT00199940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 03/162, HRRC 538-03|Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness|A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness||Medical College of Wisconsin|No|Completed|December 2003|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|7 Years|17 Years|No|||March 2008|March 6, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199940||191925|
NCT00191867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8464|Clinical Trial of Teriparatide in Japan|Assessment of Dose Response of LY333334 in Japanese Postmenopausal Women With Osteoporosis||Eli Lilly and Company||Completed|February 2005|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Female|55 Years|N/A|No|||November 2007|November 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191867||192532|
NCT00191880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7649|Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder|A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|May 2004|June 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|8 Years|11 Years|No|||August 2006|August 24, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191880||192531|
NCT00192335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP112|Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants|A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years||MedImmune LLC||Completed|July 2004|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|890|||Both|5 Years|49 Years|Accepts Healthy Volunteers|||November 2007|November 26, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192335||192498|
NCT00202631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbdomGlasgow|Abdominal Functional Electrical Stimulation in Tetraplegia|Abdominal Functional Electrical Stimulation to Augment Breathing in Tetraplegia||South Glasgow University Hospitals NHS Trust||Active, not recruiting|June 2002|November 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||4|||Both|N/A|N/A|No|||November 2006|November 24, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202631||191725|
NCT00203255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/SOY/02|Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache|An Open-Label, Pilot Study Examining the Use of Soy Isoflavones in the Prevention of Menstrually-Associated Migraine||Thomas Jefferson University||Completed|May 2003|March 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||25|||Female|N/A|N/A|No|||January 2009|January 22, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00203255||191677|
NCT00202878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04103|IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)|A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)||Merck Sharp & Dohme Corp.|Yes|Completed|October 2005|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18144|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|September 13, 2005|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT00202878||191706|
NCT00199316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I48015|Postoperative Pain Control After Kidney Surgery : a Comparison of Intrathecal Morphine Plus PCA and PCA Only|||Khon Kaen University||Recruiting|January 2005|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|15 Years|60 Years|No|||October 2007|October 31, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199316||191973|
NCT00199550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-533|Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)|A Prospective Randomized Clinical Trial of Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)||Lawson Health Research Institute|No|Completed|May 2004|June 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Male|50 Years|85 Years|No|||July 2008|July 25, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199550||191955|
NCT00203541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301.18|Effects of a New Antimicrobial Dressing on Wound Healing and Incidence of Sternal Wound Infections|Effects of a New Antimicrobial Dressing on Wound Healing and Incidence of Sternal Wound Infections in Subjects Who Have Undergone Cardiac Surgical Procedures Requiring Median Sternotomy||Tyco Healthcare Group||Terminated|February 2004|June 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||1100|||Both|18 Years|N/A||||November 2007|November 16, 2007|September 12, 2005|||Reallocation of funding.|No||https://clinicaltrials.gov/show/NCT00203541||191657|
NCT00203554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020306|Percutaneous Vertebroplasty Versus Conservative Treatment of Pain|Percutaneous Vertebroplasty Versus Conservative Treatment of Pain: A Prospective, Randomized Controlled Study of Osteoporotic Fractures in the Spine||University of Aarhus|Yes|Completed|March 2004|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|N/A|N/A|No|||March 2008|March 26, 2008|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00203554||191656|
NCT00203801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEACAT 01 Mono (Am 1,2,3,5,6)|Combination Antimalarials in Uncomplicated Malaria|An Open Label In Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT),in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carriage and Prevalence of Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections.||University of Cape Town||Completed|January 2002|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||700|||Both|12 Months|N/A|No|||August 2005|September 7, 2006|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00203801||191637|
NCT00200265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-05-HFC-27|Changing Eating Behaviors in Young Children: Should Healthy Foods be Increased or Unhealthy Foods Decreased?|Changing Eating Behaviors in Young Children: Should Healthy Foods be Increased or Unhealthy Foods Decreased?||The Miriam Hospital||Completed|July 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|4 Years|9 Years|Accepts Healthy Volunteers|||December 2007|April 19, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200265||191900|
NCT00200018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1163-85585|Study of Weight Loss Using Gastric Stimulation in Obese Patients With Type 2 Diabetes|ASSIST: Appetite Suppression Induced by Stimulation Trial|ASSIST|MedtronicNeuro|Yes|Completed|June 2005|December 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|70 Years|No|||February 2009|February 3, 2009|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00200018||191919|
NCT00190697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5234|A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment|Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer||Eli Lilly and Company||Completed|January 2001|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Female|N/A|N/A|No|||May 2007|May 23, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190697||192620|
NCT00190684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4331|Long-Term, Open Label Atomoxetine Study|Long-Term, Open Label Safety Study of Atomoxetine Hydrochloride in Patients, 6 Years and Older With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|August 2000|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1553|||Both|6 Years|18 Years|No|||December 2010|December 15, 2010|September 12, 2005|Yes|Yes||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00190684||192621|
NCT00190957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7069|Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse|Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial||Eli Lilly and Company||Completed|August 2004|January 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190957||192600|
NCT00202007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBRI0002|Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia|A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia||Otsuka Beijing Research Institute||Completed|February 2005|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|65 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202007||191772|
NCT00201734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0317|Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary|A Phase I Dose Escalation Study of Capecitabine, Carboplatin and Weekly Paclitaxel and a Phase II Trial of the Same Combination in Patients With Adenocarcinoma of Unknown Primary||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|June 2005|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201734||191793|
NCT00202839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04144|Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)|Comparison of the Sustained Response of Peg-Intron/Ribavirin Combination Therapy in Genotype 1-Infected Hepatitis C Patients for Non-extended Versus 24-week Extended Treatment After 24 Weeks Pilot Treatment in Taiwan||Merck Sharp & Dohme Corp.|No|Completed|March 2005|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|September 12, 2005||No||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00202839||191709|
NCT00202826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-181|Study of Fluid Collection of the Chest in Children With Pneumonia|Parapneumonic Effusion in Children Study||Spectrum Health Hospitals||Completed|November 2003|March 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|18 Years|No|||January 2009|January 16, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202826||191710|
NCT00203749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH066701|Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand|NIMH Project Accept: A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand||University of California, Los Angeles|Yes|Completed|December 2004|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|192814|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00203749||191641|
NCT00203476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC Cholesterol Study|A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction|A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction||Tuscaloosa Research & Education Advancement Corporation|No|Completed|May 2005|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|50 Years|N/A|No|||August 2014|August 8, 2014|September 12, 2005||No||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00203476||191662|Open label.
NCT00201201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H02-602|Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension|Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension||University of Connecticut|Yes|Completed|September 2007|July 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|160|||Both|60 Years|N/A|No|||December 2013|December 17, 2013|September 16, 2005||No||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00201201||191833|
NCT00201513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 4.2005.1720|Anticipatory Muscle Control and Effect of Stabilizing Exercises in Patients With Subacute and Chronic Low Back Pain|Randomized Controlled Trial of Stabilizing Exercises and Effect on Anticipatory Muscle Control in Patients With Subacute and Chronic Low Back Pain||Norwegian University of Science and Technology|No|Completed|January 2006|October 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|20 Years|60 Years|No|||October 2012|October 8, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201513||191809|
NCT00191555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6589|Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment|Double-Blind Long-term Study Comparing the Efficacy and Safety of Olanzapine Versus Haloperidol in Patients With Schizophrenia Previously Stabilized With Conventional Antipsychotic Treatment||Eli Lilly and Company||Completed|August 2003|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|18 Years|65 Years|No|||July 2006|June 8, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191555||192555|
NCT00191568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6866|Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer|A Phase II Trial of Adjuvant Treatment With Gemcitabine and Oxaliplatin Followed by Concomitant Gemcitabine and Radiation Therapy in Patients With Resected Pancreatic Adenocarcinoma||Eli Lilly and Company||Completed|October 2002|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||October 2007|October 18, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191568||192554|
NCT00202098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11|Effects of Variable Ventilation on Respiratory System of Acute Respiratory Distress Syndrome (ARDS) Patients|Effects of Variable Ventilation on Respiratory System of ARDS Patients||Policlinico Hospital|No|Completed|March 2005|March 2015|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202098||191766|
NCT00202111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83449871|Comparative Study of Laparoscopic Versus Open Operations for Colon Cancer|Australasian Multicentered Prospective Randomised Clinical Study Comparing Laparoscopic and Conventional Open Surgical Treatments of Colon Cancer in Adults||The Queen Elizabeth Hospital||Active, not recruiting|January 1998|March 2010||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||February 2006|October 16, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202111||191765|
NCT00203268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/DHE/01|A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity|An Open Label Pilot Trial to Collect and Evaluate Data on the Use of Dihydroergotamine Mesylate in the Treatment of Two Migraine Attacks Associated With Cutaneous Allodynia||Thomas Jefferson University|No|Completed|December 2003|March 2005|Actual|March 2005|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||May 2014|May 8, 2014|September 13, 2005|No|Yes||No|October 25, 2010|https://clinicaltrials.gov/show/NCT00203268||191676|
NCT00202891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04460|Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)|Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas||Merck Sharp & Dohme Corp.||Withdrawn|May 2007|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|6 Years|N/A|No|||June 2015|June 2, 2015|September 16, 2005|||No further local interest in pursuing the study.|No||https://clinicaltrials.gov/show/NCT00202891||191705|
NCT00202904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03740|Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)|A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of the Daily Co-Administration of Ezetimibe 10 mg or Ezetimibe Placebo to Ongoing Treatment With Atorvastatin 10 mg in Subjects With Primary Hypercholesterolemia and Coronary Heart Disease||Merck Sharp & Dohme Corp.|No|Completed|May 2005|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|75 Years|No|||April 2015|April 28, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202904||191704|
NCT00199563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-402|Use of Sildenafil (Viagra) in Diabetic Men With Erectile Dysfunction: the Impact on Blood Vessels|The Use and Efficacy of Sildenafil in Diabetic Men With Erectile Dysfunction: the Impact on Endothelial Function, a Pilot Feasibility Study||Lawson Health Research Institute|No|Completed|August 2004|December 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|January 24, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199563||191954|
NCT00199771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-HSD|Hypertonic Saline Dextran in Pediatric Cardiac Surgery|The Use of Hypertonic Saline Dextran in Cardiac Surgery Utilizing Cardio Pulmonary Bypass in Children Less Than 17 Weeks Old.||Oslo University Hospital||Completed|June 2003|February 2005|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||14|||Both|N/A|16 Weeks|No|||January 2008|June 30, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199771||191938|
NCT00199784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elangesectio2005-1|Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia|Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia||Oslo University Hospital||Completed|June 2005|April 2007||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2009|July 3, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199784||191937|
NCT00199992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APG-01-02-05|Platelets in Acute Wounds: A Pilot Study (PAWS)|Platelets in Acute Wounds: A Pilot Study (PAWS)||Medtronic||Completed|January 2005|August 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199992||191921|
NCT00200005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mdt-301 November 03,1998|Sacral Nerve Stimulation for Anal Incontinence and Bowel Control|Sacral Nerve Stimulation for Anal Incontinence and Bowel Control|MDT-301|MedtronicNeuro|No|Completed|November 1998|September 2012|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|75 Years|No|||January 2014|January 9, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200005||191920|
NCT00200031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4348|A Cost Analysis of Interstim Therapy|Interstim Therapy Retrospective Cost Analysis and Quality of Life||MedtronicNeuro||Completed|July 2005|April 2006|Actual|||N/A|Observational|N/A||||150|||Both|18 Years|N/A||||July 2008|July 24, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200031||191918|
NCT00200291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3U01DK067861-02S1|Changes in Food Reinforcement During Obesity Treatment|Changes in Food Reinforcement During Obesity Treatment||The Miriam Hospital||Completed|July 2004|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|147|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||December 2007|April 19, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200291||191898|
NCT00200304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2083-00|Evaluation of a SlimFast Internet Behavioral Weight Loss Program|Development and Evaluation of a SlimFast Internet Behavioral Weight Loss Program||The Miriam Hospital||Completed|January 2001|January 2003|Actual|January 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||225|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2005|April 23, 2013|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00200304||191897|
NCT00190710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9297|A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer|A Randomized Phase III Trial of Paraplatin (Carboplatin) + Gemzar Versus Gemzar Alone in Patients With Advanced Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|March 2004|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||242|||Both|18 Years|N/A|No|||November 2007|November 10, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190710||192619|
NCT00190723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5799|A Study of LY317615 in Patients With Brain Tumors|A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas||Eli Lilly and Company||Completed|October 2002|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190723||192618|
NCT00190983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8367|A Trial for Patients With Advanced/Recurrent Cervical Cancer|A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix||Eli Lilly and Company||Completed|February 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|N/A|N/A|No|||November 2009|November 13, 2009|September 12, 2005||Yes|||October 21, 2008|https://clinicaltrials.gov/show/NCT00190983||192598|
NCT00190996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8049|Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence|The Safety and Effectiveness of Duloxetine Compared With Placebo and Its Long-Term Safety and Efficacy in the Treatment of Predominant Stress Urinary Incontinence||Eli Lilly and Company||Completed|January 2003|June 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2765|||Female|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190996||192597|
NCT00202033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01856-04-C|Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes|Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes||HealthPartners Institute|Yes|Completed|September 2004|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|79 Years|No|||April 2013|December 2, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202033||191770|
NCT00194454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-3203-V 06|Psychosocial/Behavioral Intervention in Post-Stroke Depression|Psychosocial/Behavioral Intervention in PSD||University of Washington|No|Completed|March 2002|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|21 Years|N/A|No|||September 2008|September 21, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194454||192337|
NCT00203177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP - 1012/135 Double Blind|Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.|A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.||Teva Pharmaceutical Industries|Yes|Completed|October 2001|||December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|254|||Both|30 Years|N/A|No|||March 2010|March 8, 2010|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203177||191683|
NCT00203190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/TOP-CL/01/CAPSS-322|A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache|A Single-Center, Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache.||Thomas Jefferson University||Terminated|September 2004|June 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||January 2009|January 22, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203190||191682|
NCT00203762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRC 102770-001|Effect of Public Sector Antiretroviral Treatment Programme on Tuberculosis and Immunization Care|Effect of the South African Public Sector Antiretroviral Treatment Programme on the Performance of Tuberculosis and Immunization Programmes - A Cluster Controlled (Non-Randomized) Trial||University of Cape Town||Recruiting|May 2003|December 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|39|||Both|N/A|N/A|No|||March 2004|October 23, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203762||191640|
NCT00199498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-399|Right Apical Versus Septal Pacing Trial|Right Apical Versus Septal Pacing Trial|RASP|Lawson Health Research Institute|No|Active, not recruiting|April 2005|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||April 2012|May 1, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199498||191959|
NCT00201838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0041|Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma|A Phase I/II Study of Etanercept and Gemcitabine in Patients With Advanced Stage and Chemotherapy Naive Pancreatic Adenocarcinoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|July 2001|May 2007|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|September 12, 2005|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00201838||191785|The interpretation of the results for this study is limited by the relatively small patient sample and correlative samples.
NCT00201851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0483|Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer|Phase III Randomized Study of Immediate Versus Luteal Phase Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-positive Breast Cancer||International Breast Cancer Research Foundation|Yes|Completed|January 2004|May 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|740|||Female|18 Years|50 Years|No|||April 2015|April 13, 2015|September 12, 2005|Yes|Yes||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00201851||191784|
NCT00201812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0023|Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors|Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors||Ohio State University Comprehensive Cancer Center|Yes|Completed|November 2000|May 2005|Actual|January 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201812||191787|
NCT00201825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0356|A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients|A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients||Ohio State University Comprehensive Cancer Center|Yes|Completed|December 2004|April 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|September 12, 2005|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT00201825||191786|
NCT00202917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E203/2004|Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies|Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies||University Hospital Tuebingen||Completed|February 2004|December 2010|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|61|||Both|18 Years|60 Years|No|||May 2014|May 28, 2014|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202917||191703|
NCT00203580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2736-1|Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)|A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)||University of Calgary||Completed|December 1994|March 2002||||Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment||||910|||Both|18 Years|N/A|No|||September 2005|February 8, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00203580||191654|
NCT00203567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC Equetro in Bipolar|Carbamazepine Extended-Release for the Treatment of Bipolar Depression|Carbamazepine Extended-Release for the Treatment of Bipolar Depression||Tuscaloosa Research & Education Advancement Corporation|No|Completed|August 2005|May 2008|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|19 Years|65 Years|No|||June 2008|June 23, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00203567||191655|
NCT00199303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|efficacy of dextromethorphan|Efficacy of Pre- and Post-Operative Oral Dextromethorphan|Efficacy of Pre- and Post-Operative Oral Dextromethorphan for Reduction of Intra- and 24-Hr Post-Operative Morphine Consumption for Transabdominal Hysterectomy||Khon Kaen University||Completed|December 2002|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||July 2002|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199303||191974|
NCT00199355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-0406|A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|Placebo-Controlled , Double-Blind , Exploratory Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Adjunctive Therapy to Levodopa]||Kyowa Hakko Kirin Company, Limited|No|Completed|April 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|30 Years|N/A|No|||August 2012|May 21, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00199355||191970|
NCT00199797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2003-005|Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer|Phase I Trial of huA33 Plus 5-Fluorouracil (5FU), Leucovorin and Oxaliplatin in Patients With Metastatic Colorectal Cancer||Ludwig Institute for Cancer Research|No|Completed|October 2004|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2009|March 2, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00199797||191936|
NCT00199810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elangepreeklampsi2005-|Hemodynamic Measurements in Women With Serious Preeclampsia|Hemodynamic Measurements in Women With Serious Preeclampsia||Oslo University Hospital|No|Recruiting|July 2005|December 2006|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant women with moderate-to-severe pre-eclampsia|September 2009|September 15, 2009|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00199810||191935|
NCT00199823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03115|Autologous Stem Cell Transplantation in Acute Myocardial Infarction|Autologous Stem Cell Transplantation in Acute Myocardial Infarction||Oslo University Hospital||Completed|September 2003|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|40 Years|75 Years|No|||September 2010|July 3, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199823||191934|
NCT00200603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/99/3-G|Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy|Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy||Nantes University Hospital||Active, not recruiting|May 1999|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|No|||May 2004|December 15, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00200603||191874|
NCT00201331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1202|Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer|Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer||National Health Research Institutes, Taiwan||Recruiting|April 2002|October 2012||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||162|||Both|18 Years|70 Years|No|||December 2005|December 15, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201331||191823|
NCT00190749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5296|Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder|Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone||Eli Lilly and Company|No|Completed|October 2003|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|65 Years|No|||April 2010|April 26, 2010|September 12, 2005|Yes|Yes||No|June 3, 2009|https://clinicaltrials.gov/show/NCT00190749||192616|
NCT00191022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7958|Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder|A Randomized, Double-Blind Comparison of LY686017, Paroxetine, and Placebo in the Treatment of Social Anxiety Disorder||Eli Lilly and Company||Completed|December 2004|January 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||185|||Both|18 Years|65 Years|No|||February 2007|February 12, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00191022||192595|
NCT00191009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7951|Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease|Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer's Disease||Eli Lilly and Company||Completed|October 2003|January 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||124|||Both|55 Years|N/A|No|||November 2007|November 5, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00191009||192596|
NCT00191360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6018|Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency|Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency||Eli Lilly and Company||Completed|January 2003|May 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||68|||Both|18 Years|65 Years|No|||November 2007|November 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191360||192570|
NCT00202280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPREC 26/2004|Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication|VIP (Vitamins In Psychosis) Study. A Randomized Double Blind Placebo Controlled Trial of the Effects of Vitamin B12, B6 and Folic Acid Augmentation on Cognition and Symptoms in Early Psychosis.||Melbourne Health|Yes|Completed|September 2004|June 2009|Actual|September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|15 Years|25 Years|No|||November 2015|November 18, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00202280||191752|
NCT00202566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL3-16257-057|Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris|Evaluation of the Anti-anginal Efficacy and Safety of Oral Administration of Ivabradine Compared to Placebo on Top of Background Therapy With Atenolol in Patients With Stable Angina Pectoris. A Four-month Randomised Double-blind, Parallel Group International Multicentre Study.|ASSOCIATE|Servier||Completed|June 2005|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|750|||Both|18 Years|75 Years|No|||June 2011|June 15, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202566||191730|
NCT00200486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-05-127E|Molecular and Genomic Profiling of Head and Neck Tumors|Molecular and Genomic Profiling of Head and Neck Tumors to Explore Biomarkers Associated With Prognosis and Response to Therapy||Montefiore Medical Center|Yes|Recruiting|May 2002|||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|1. Tumor specimens along with normal mucosa obtained at the time of surgery for biopsy or           resection of primary or recurrent tumors of the head and neck        2. blood, urine and sputum from patients participating in the tumor collection described           above|Both|N/A|N/A|No|Non-Probability Sample|Patients with tumors of the head and neck who ar ehaving diagnostic biopsy or surgical        resection of primary lesions or recurrences|March 2016|March 15, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200486||191883|
NCT00200499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB306|A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients|A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients With Mild to Moderate Hypertension||Mylan Bertek Pharmaceuticals||Completed|March 2002|September 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||845|||Both|18 Years|N/A|No|||September 2005|December 15, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00200499||191882|
NCT00200460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB302|A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients|A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Dosing Study Evaluating the Effects of Nebivolol on Blood Pressure in Patients With Mild to Moderate Hypertension||Mylan Bertek Pharmaceuticals||Completed|September 2001|March 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||825|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00200460||191885|
NCT00200473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB305|A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients|A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Effects of Nebivolol on Safety and Efficacy in Patients With Mild to Moderate Hypertension||Mylan Bertek Pharmaceuticals||Completed|September 2001|March 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00200473||191884|
NCT00199511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-154|Hypertonic Saline 75% vs Mannitol 20%|Comparison of Equiosmolar Doses of Mannitol 20% Versus Hypertonic Saline 7.5% Infusion in the Reduction of Brain Bulk During Elective Craniotomies for Supratentorial Brain Tumor Resection||Lawson Health Research Institute||Completed|January 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||162|||Both|18 Years|75 Years|No|||June 2007|June 21, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199511||191958|
NCT00202124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFW-TRP01|Double Blind Study of Trp01 in Patients With Alzheimer's Disease|Double Blind Medium Term Efficacy Study of Trp01 in Patients With Mild to Moderate Alzheimer's Disease||Queen's University||Completed|April 2001|March 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|N/A|N/A|No|||November 2002|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202124||191764|
NCT00202644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-403|A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients|A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.||Shire||Completed|January 2006|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202644||191724|
NCT00203281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03U.86|Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis|Pharmacokinetic Evaluation of Plasmapheresis in Cross Match Positive or ABO Incompatible Kidney Allograft Recipients||Thomas Jefferson University|No|Withdrawn|February 2003|September 2009|Anticipated|September 2009|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|75 Years|No|Non-Probability Sample|Hospital setting|March 2014|March 5, 2014|September 13, 2005||No|funding withdrawn|No||https://clinicaltrials.gov/show/NCT00203281||191675|
NCT00202943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911007|Randomized Controlled Trial of TCRFVR and LAUP in Snorers|Comparison of Clinical Effect Between Temperature-Controlled Radio-Frequency Uvuloplasty and Laser Assisted Uvulo-Pharyngoplasty in Patients Who Snore||Taichung Veterans General Hospital||Completed|March 2003|March 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202943||191701|
NCT00203294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GONB/ STE/ 01|A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache|Comparison Of Greater Occipital Nerve Block With Lidocaine And Bupivicaine Alone Or With Steroids In a Chronic Headache Population||Thomas Jefferson University|No|Completed|June 2005|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||April 2014|April 7, 2014|September 13, 2005||No||No|May 19, 2011|https://clinicaltrials.gov/show/NCT00203294||191674|
NCT00199329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I48027|Antiemetic Effect of the Addition of Ondansetron to the Morphine Solution in Patient-Controlled Analgesia (PCA)|||Khon Kaen University||Completed|January 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|160|||Both|15 Years|60 Years|No|||October 2007|October 31, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199329||191972|
NCT00199342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2871-US-002|A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma|An Open-Label Study of KW-2871 Administered With a Premedication Regimen in Patients With Advanced Stage IV Melanoma||Kyowa Hakko Kirin Pharma, Inc.|No|Terminated|November 2004|||October 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2007|February 24, 2015|September 12, 2005|No|Yes|Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I.|No||https://clinicaltrials.gov/show/NCT00199342||191971|
NCT00199589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I01014|Treatment of Spastic Equinovarus Foot After Stroke|Treatment of Spastic Equinovarus Foot After Stroke. Efficacy: Association Between Ankle Foot Orthosis and Botulinum Toxin A (BTA) Injection||University Hospital, Limoges|No|Completed|October 2002|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2008|December 29, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199589||191952|
NCT00199576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 001533|Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids|Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids: a Prospective, Double-Blind, Placebo-Controlled Trial.||University Hospital, Limoges||Completed|December 2000|January 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||670|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199576||191953|
NCT00200044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGU - 002|An Evaluation of the Medtronic Gatekeeper System in the Treatment of SUBJECTS With Gastroesophageal Reflux Disease (GERD)|Gatekeeper® System Sham-Controlled Study for the Treatment of GERD||MedtronicNeuro|Yes|Terminated|December 2002|June 2008|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||July 2009|July 10, 2009|September 12, 2005|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00200044||191917|
NCT00200057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010206|Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence|Medtronic InterStim® Sacral Nerve Stimulation Therapy for Bowel Control: Fecal Incontinence Study||MedtronicNeuro|No|Completed|January 2002|September 2011|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|285|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 17, 2013|September 12, 2005|Yes|Yes||No|April 13, 2011|https://clinicaltrials.gov/show/NCT00200057||191916|
NCT00190762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5362|A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma|A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma||Eli Lilly and Company||Completed|October 2001|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00190762||192615|
NCT00191048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7975|Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD|Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia||Eli Lilly and Company||Completed|October 2003|March 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||105|||Both|10 Years|16 Years|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00191048||192593|
NCT00191035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7974|Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD|Maintenance of Benefit After 8-Week and 52-Week Treatment With Atomoxetine Hydrochloride in Adolescents With ADHD||Eli Lilly and Company||Completed|March 2004|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||520|||Both|13 Years|16 Years|No|||December 2006|December 12, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00191035||192594|
NCT00191386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9315|Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)|Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company|No|Completed|May 2005|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|6 Years|17 Years|No|||December 2010|December 14, 2010|September 12, 2005|Yes|Yes||No|August 24, 2010|https://clinicaltrials.gov/show/NCT00191386||192568|
NCT00191061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8950|A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder|A Comparison of Duloxetine Dosing Strategies in The Treatment of Patients With Major Depression||Eli Lilly and Company||Completed|October 2004|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||640|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00191061||192592|
NCT00202579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2-16257-053|Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure|Evaluation of the Effects on Peripheral and Central Haemodynamics Parameters, Safety, and Tolerance of Three-hour Intravenous Perfusion (0.1 mg/kg) of Ivabradine Given to Severe Congestive Heart Failure Patients||Servier||Completed|September 2004|February 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|12|||Both|18 Years|75 Years|No|||June 2011|June 15, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202579||191729|
NCT00202852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04280|A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)|A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate||Merck Sharp & Dohme Corp.|No|Completed|June 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202852||191708|
NCT00202865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04352|Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)|CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis|CANDLE|Merck Sharp & Dohme Corp.|No|Completed|May 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00202865||191707|
NCT00201539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI 02/001|Double Bedtime Dosing During Immediate-release Morphine Administration to Cancer Patients|Double Bedtime Dosing During Immediate-release Morphine Administration to Cancer Patients: A Randomized, Double-blind Cross-over Comparison of a Double Bedtime Dose Ver-sus Two Standard Doses at Bedtime and at Night||Norwegian University of Science and Technology|No|Completed|April 2002|February 2008|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201539||191807|
NCT00201552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|930106|Statin and PAF in Patients With Pacemaker|Atorvastatin Decreases Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation||National Taiwan University Hospital||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|20 Years|90 Years||||September 2005|September 19, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201552||191806|
NCT00203489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study Protocol 331.18|A Clinical Study of An Antimicrobial Gauze Dressing|A Prospective Randomized Double-Blind Trial of a Polyhexamethylene Biguanide (PHMB) Impregnated Gauze Dressing for the Prevention of Chronic Wound Colonization With Resistant and Prevalent Microorganisms||Tyco Healthcare Group||Terminated|June 2005|August 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|200|||Both|18 Years|N/A|No|||November 2007|November 16, 2007|September 12, 2005|||Reallocation of funding.|No||https://clinicaltrials.gov/show/NCT00203489||191661|
NCT00203502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2004-59|Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer|Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer||University of Arkansas|No|Completed|September 2005|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 12, 2005||No||No|October 21, 2015|https://clinicaltrials.gov/show/NCT00203502||191660|
NCT00203515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302.18|Study Comparing the DOVER Silver Foley Catheter to a Standard of Care Catheter and a Marketed Silver Coated Foley Catheter|A Prospective, Randomized, Controlled Study Comparing the DOVER Silver Foley Catheter to a Standard of Care Catheter and a Marketed Silver Coated Foley Catheter||Tyco Healthcare Group||Completed|January 2005|||March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||1000|||Both|18 Years|N/A|No|||January 2008|January 4, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00203515||191659|
NCT00201214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281|Citrulline for Children Undergoing Cardiopulmonary Bypass Surgery|Phase I/II Clinical Trial to Determine the Pharmacokinetics and Safety Profile of Citrulline in Children Undergoing Cardiopulmonary Bypass||Vanderbilt University|Yes|Completed|December 2003|December 2009|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|18 Years|No|||September 2013|September 10, 2013|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201214||191832|
NCT00200785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001512-01|Identifying the Anti-Blood-Clotting Compounds in Garlic|Identification of the Antiplatelet Compounds of Garlic Ex Vivo||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|March 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|September 12, 2005||No||No|April 23, 2009|https://clinicaltrials.gov/show/NCT00200785||191860|
NCT00202345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iron Sucrose 61864|Iron Sucrose in Stage 3/4 Kidney Disease|Assessment of the Use of Intravenous Iron Sucrose to Maintain Haemoglobin Levels and Delay the Onset of Use of Erythropoietic Agents and/or Dialysis in Stage 3/4 Chronic Kidney Disease||Melbourne Health||Completed|August 2004|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|80 Years|No|||May 2015|May 4, 2015|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00202345||191747|
NCT00202358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEACK|Perioperative Effect of Atenolol on Cytokine Profiles|The Effect of Perioperative Atenolol on Post-Operative Cytokines||Saini Foundation||Active, not recruiting|November 2002|September 2008|Anticipated|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202358||191746|
NCT00202930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0405652|Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma|Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma||Tersak, Jean M., M.D.||Recruiting|July 2005|July 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|2 Months|18 Years|No|||September 2006|September 19, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00202930||191702|
NCT00203307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/ZYP/02|A Research Study Examining the Use of Olanzapine for the Prevention of Migraine|A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.||Thomas Jefferson University||Terminated|May 2004|June 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|65 Years|No|||August 2011|August 23, 2011|September 13, 2005|Yes|Yes|Study terminated by sponsor|No|May 24, 2011|https://clinicaltrials.gov/show/NCT00203307||191673|
NCT00203320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10007|TNF-Alpha Inhibition for Treatment of Alzheimer's Disease|Etanercept for Alzheimer's-Type Memory Loss Pilot Study II||Tobinick, Edward Lewis, M.D.||Completed|April 2005|January 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||April 2006|April 20, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203320||191672|
NCT00203606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21995|Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C|Effectiveness of Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C||University of Calgary|No|Completed|January 2004|August 2011|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00203606||191652|
NCT00203593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18413|Exercise and Prevention of Syncope: EXPOSE|EXercise for the Prevention of Syncope Evaluation||University of Calgary||Suspended|March 2006|June 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||March 2007|March 12, 2007|September 13, 2005|||No Resources - No Personnel|No||https://clinicaltrials.gov/show/NCT00203593||191653|
NCT00199849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0013|NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine|Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-Mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen.||Ludwig Institute for Cancer Research||Completed|May 2004|May 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||August 2007|August 21, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00199849||191932|
NCT00199836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-007|A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.|A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1.||Ludwig Institute for Cancer Research||Completed|September 2003|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||9|||Both|18 Years|N/A|No|||August 2006|August 21, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00199836||191933|
NCT00200317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL069866|Interactive Technologies to Increase Exercise Behavior|Interactive Technologies to Increase Exercise Behavior||The Miriam Hospital||Completed|February 2003|May 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|240|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|April 27, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00200317||191896|
NCT00200954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANDA|Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics|Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics.||The Netherlands Asthma Foundation||Completed|January 2004|August 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|157|||Both|20 Years|45 Years|No|||May 2007|August 13, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200954||191849|
NCT00200629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPEC-BB|Both Exercise and Adenosine Stress Testing|A Pilot Study Examining the Value of Combined Exercise and Adenosine Stress Myocardial Perfusion Imaging as Compared With Adenosine Testing Alone for the Evaluation of Women at Intermediate or High Likelihood for Coronary Artery Disease||Midwest Heart Foundation||Terminated|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|200|||Female|60 Years|N/A|No|||August 2011|August 8, 2011|September 12, 2005||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00200629||191872|
NCT00200642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/03/6-F|Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease|Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease||Nantes University Hospital||Completed|December 2003|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200642||191871|
NCT00200655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/03/10-I|Safety and Efficacy of Pravastatin in Relapsing-Remitting Multiple Sclerosis|Safety and Efficacy of Pravastatin in Relapsing-Remitting MS: a Double Blind Placebo Controlled Study||Nantes University Hospital|No|Completed|December 2004|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|No|||June 2008|June 6, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200655||191870|
NCT00191438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6136|Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents|Phase III Study of Docetaxel in Combination With Gemcitabine Versus Docetaxel in Combination With Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer||Eli Lilly and Company||Completed|October 2002|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Female|18 Years|N/A|No|||May 2007|May 25, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191438||192564|
NCT00191451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9397|A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer|Phase II Trial of Gemzar Plus Paraplatin (Plus Herceptin in HER2+ Patients) in Metastatic Breast Cancer||Eli Lilly and Company||Completed|April 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||November 2009|November 17, 2009|September 12, 2005||No||No|October 12, 2009|https://clinicaltrials.gov/show/NCT00191451||192563|
NCT00191412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9417|A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver|Phase II Study of Single-Agent Alimta in the Treatment of Patients With Advanced and Metastatic Hepatoma||Eli Lilly and Company||Completed|January 2005|March 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||41|||Both|18 Years|N/A|No|||November 2007|November 19, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191412||192566|
NCT00194168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|705016|Ectopic Pregnancy Biomarkers|Serum Bank for Assessment of Markers of Ectopic Pregnancy||University of Pennsylvania|No|Completed|June 2000|June 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood (Plasma, Serum)|Female|N/A|N/A|No|Non-Probability Sample|Women undergoing treatment for infertility at the University of Pennsylvania Penn        Fertility Practice|February 2013|March 14, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194168||192358|
NCT00200213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2107-02|Liking of Snack Foods - Sub-Study 1|The Effect of Portion Size and Quantity of Food Provided on Intake||The Miriam Hospital||Completed|February 2004|March 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200213||191904|
NCT00201565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700336|Association Between Peripheral Artery Stiffness and Cardiovascular Disease|||National Taiwan University Hospital||Recruiting|May 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2005|September 19, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201565||191805|
NCT00201578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701120|Case Control Study of Non Viral Hepatitis Relating to Herbal Drug Use in the Emergency Department|||National Taiwan University Hospital||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A||||January 2005|April 27, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201578||191804|
NCT00201591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trehab I NTNU|Training at Different Intensities in Coronary Artery Disease -Effects on Myocardial Function|Which Training Intensity is Most Effective in Improving Myocardial Function in Patients With Coronary Artery Disease?||Norwegian University of Science and Technology|No|Completed|August 2002|January 2004|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|17|||Both|20 Years|80 Years|No|||August 2011|August 25, 2011|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201591||191803|
NCT00190138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-93014|Effect of Bi-ventricular Pacing on Autonomous Nervous System|Effect of Bi-ventricular Pacing on Autonomous Nervous System||Far Eastern Memorial Hospital||Not yet recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||December 2004|October 5, 2010|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00190138||192663|
NCT00200798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002817-01|An Assessment of Milk Thistle Pharmacokinetics and Drug Interactions|Pharmacokinetics and Drug Interactions With Milk Thistle||Medical University of South Carolina|Yes|Recruiting|May 2006|August 2007||||Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|32|Samples Without DNA|plasma & urine|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy volunteers|December 2009|December 9, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00200798||191859|
NCT00202137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBPM|Home Blood Pressure Monitoring and Blood Pressure Control|A Randomized Controlled Trial of the Effects of Home Blood Pressure Monitoring on Blood Pressure Control||Queen's University|No|Completed|July 2002|June 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|597|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00202137||191763|
NCT00201526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAIN-04|Bipolar Research And Innovation Network - BRAIN|Bipolar Research And Innovation Network - BRAIN||Norwegian University of Science and Technology|No|Recruiting|January 2003|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|3000|Samples With DNA|Blood samples|Both|N/A|N/A|No|Non-Probability Sample|Secondary care clinics|November 2015|November 25, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201526||191808|
NCT00202384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU - FCG - 02|Gene Expression in MS Patients Before and During Treatment With Interferon-beta|Gene Expression in MS Patients Before and During Treatment With High-dose Interferon Beta: Prospective Study for the Identification of Predicting Factors of Therapeutic Response.||S. Andrea Hospital|Yes|Completed|November 2004|||||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Outpatient MS centres|July 2010|July 26, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00202384||191744|
NCT00202657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-03|Observational Study of Heart Valve Disease in Patients With Parkinson's Disease Treated With Pergolide|Etude Observationnelle Des Valvulopathies Chez Les Patients Parkinsoniens Traites Par Pergolide Par Rapport a Une Population Temoin||Société Française de Cardiologie||Completed|April 2005|February 2007||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|149|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with Pergolide for Parkinson disease or Patients with parkinson disease        not treated with Pergolide|December 2011|December 5, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202657||191723|
NCT00202670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-04|Diagnosis of Coronary Artery Disease in High Risk Diabetic Patients|Diagnosis of Coronary Artery Disease in High Risk Diabetic Patients :Comparison Between Stress Echocardiography and Stress Scintigraphy in the Detection of Silent Myocardial Ischemia||Société Française de Cardiologie|Yes|Terminated|January 2004|June 2010|Actual|May 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|220|||Both|18 Years|N/A|No|Probability Sample|high risk diabetic patients|January 2004|October 19, 2010|September 13, 2005||No|Positive Predictive value not related to follow up duration.|No||https://clinicaltrials.gov/show/NCT00202670||191722|
NCT00202683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-04|Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness|Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Associated With Chemoreflex Failure||Société Française de Cardiologie|No|Completed|March 2005|December 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|83|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|May 16, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00202683||191721|
NCT00202696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-N0408|Nalmefene Smoking Cessation Study|A Single Center Evaluation of Nalmefene HCl Versus Placebo on Smoking Cessation||Somaxon Pharmaceuticals|No|Completed|September 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|76|||Both|25 Years|65 Years|No|||May 2008|May 15, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202696||191720|
NCT00203619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Capsule Endoscopy in Obscure GI Bleeding|An Economic Evaluation of Capsule Endoscopy for Obscure Gastrointestinal Bleeding||University of Calgary|No|Active, not recruiting|May 2005|June 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||June 2008|June 9, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00203619||191651|
NCT00199394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-EU-007|A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease|A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|November 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||405|||Both|30 Years|N/A|No|||February 2007|March 30, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199394||191967|
NCT00199368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-INT-001|An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018|A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|October 2004|March 2007||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1100|||Both|30 Years|N/A|No|||October 2007|June 22, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199368||191969|
NCT00199381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-025|An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001|An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.||Kyowa Hakko Kirin Pharma, Inc.|No|Terminated|October 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|504|||Both|30 Years|N/A|No|||October 2013|October 29, 2013|September 12, 2005|Yes|Yes|Additional long-term safety data no longer needed|No|April 4, 2013|https://clinicaltrials.gov/show/NCT00199381||191968|The Sponsor decided to terminate the study early (not for safety reasons); as a result 323 subjects discontinued early. Mean duration of therapy was 18.7 months (0.4 to 31.4 months); median duration was 21.0 months. Total exposure 767 subject years.
NCT00200096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-081|Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial|Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial||Memorial Sloan Kettering Cancer Center||Completed|July 2004|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|101|||Both|18 Years|64 Years|No|||February 2011|February 11, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00200096||191913|
NCT00200109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1602|Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.|ONSTIM: Occipital Nerve Stimulation for the Treatment of Intractable Migraine.|ONSTIM|MedtronicNeuro|No|Completed|May 2004|May 2011|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|110|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200109||191912|
NCT00200070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1659|Neurostimulation to Treat Refractory Angina Pectoris Pain|STARTSTIM - Stimulation Therapy for Angina Refractory To Standard Treatments, Interventions and Medications|STARTSTIM|MedtronicNeuro||Terminated|December 2002|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||228|||Both|18 Years|N/A|No|||August 2010|August 26, 2010|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00200070||191915|
NCT00200083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-2002-015|Study of Weight Loss Using Gastric Stimulation in Obese Patients|SHAPE: Screened Health Assessment & Pacer Evaluation|SHAPE|MedtronicNeuro|Yes|Completed|May 2004|January 2008|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00200083||191914|
NCT00200668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/04/6-H|Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.|||Nantes University Hospital||Terminated|March 2005|December 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|0|||Both|18 Years|65 Years|No|||June 2008|June 5, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200668||191869|
NCT00200681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 04/11-J|IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma|Etude Multicentrique Ouverte Randomisée de Phase III Comparant l'Association de VELCADE®-Dexaméthasone à la Chimiothérapie de Type VAD Pour le Traitement Des Patients Porteurs de Myélome Multiple de Novo Jusqu'à l'âge de 65 Ans||Nantes University Hospital|Yes|Completed|June 2005|June 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|493|||Both|18 Years|65 Years|No|||February 2009|February 4, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200681||191868|
NCT00200980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0504609|Importance of Non-Acid Reflux in Asthma in Children|Importance of Non-Acid Reflux in Moderate and Severe Asthma||Nemours Children's Clinic||Completed|August 2005|||||N/A|Observational|N/A|||Anticipated|120|||Both|1 Year|18 Years|No|||March 2009|March 6, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200980||191847|
NCT00200993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268|Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1998|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|40 Years|69 Years|No|||April 2009|April 13, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200993||191846|
NCT00201006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273|Treatment of Obesity in Underserved Rural Settings (TOURS)|Treatment of Obesity in Underserved Rural Settings (TOURS)|TOURS|University of Florida|Yes|Completed|June 2003|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|234|||Female|50 Years|75 Years|No|||January 2014|January 21, 2014|September 12, 2005||No||No|November 2, 2013|https://clinicaltrials.gov/show/NCT00201006||191845|
NCT00191464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6146|Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes|Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes: A Comparison of Premeal Insulin Lispro Mixtures to Once-Daily Insulin Glargine||Eli Lilly and Company||Completed|December 2003|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||320|||Both|35 Years|75 Years|No|||October 2010|October 12, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191464||192562|
NCT00191737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7233|An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder|An Open-Label Study on Effectiveness and Tolerability of Atomoxetine, as Perceived by Patients, Parents, and Physicians in Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany||Eli Lilly and Company||Completed|October 2004|February 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||147|||Both|12 Years|17 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191737||192541|
NCT00191711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8332|Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.|Phase II Study of 6 Weeks Intravesical Gemcitabine Instillation Followed By Transurethral Resection in Patients Affected By Superficial Bladder Cancer at Low Risk||Eli Lilly and Company||Completed|February 2004|October 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Both|18 Years|80 Years|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191711||192543|
NCT00191724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8354|Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study|Drotrecogin Alfa (Activated) (LY203638)] Exploratory, Safety Study, Multi-Center, Randomized, Placebo-Controlled, Dose Escalating Study Design, Comparing a Standard Therapy (Enoxaparin Sodium) for Submassive Pulmonary Embolism to a Combined Therapy of Drotrecogin Alfa (Activated) Plus Enoxaparin Sodium.||Eli Lilly and Company|Yes|Completed|September 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|47|||Both|18 Years|80 Years|No|||June 2009|June 16, 2009|September 12, 2005|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00191724||192542|This study was stopped early after 47 patients had been enrolled (planned enrollment was 48 patients). Study was stopped early due to slow enrollment.
NCT00200226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC02.159|Oral Misoprostol Before Endometrial Biopsy|Oral Misoprostol Before Endometrial Biopsy||Memorial University of Newfoundland|No|Completed|February 2003|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|72|||Female|19 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00200226||191903|
NCT00201227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278|Trial to Enhance Adherence to Multiple Guidelines|Using Learning Teams for Reflective Adaptation|ULTRA|Rutgers, The State University of New Jersey|Yes|Completed|September 2002|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|N/A|N/A|No|||October 2015|October 27, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201227||191831|
NCT00201266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283|Histoblood Group Antigens as a Risk Factor of Asthma|Histoblood Group Antigens, Viruses and Asthma||University of California, San Francisco|No|Completed|July 2005|||August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|126|Samples With DNA|DNA, plasma, saliva, induced sputum.|Both|18 Years|75 Years|No|Non-Probability Sample|Asthmatics of two types: 1. Exacerbation resistant asthma (no requirement for prednisone        for asthma since age 12). 2. Exacerbation prone asthma (requirement for prednisone for        asthma in the past 2 years).|March 2013|March 11, 2013|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201266||191828|
NCT00201279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1399|Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma|Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients||National Health Research Institutes, Taiwan||Completed|April 1999|September 2012||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||342|||Both|20 Years|65 Years|No|||January 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201279||191827|
NCT00200824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000486|Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health|Effects of Soy Isoflavones on the Prostate, Breast and Bone||National Center for Complementary and Integrative Health (NCCIH)||Completed|May 2000|January 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2006|March 10, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00200824||191858|
NCT00201864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0494|Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer|Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|September 2005|||December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||October 2012|October 9, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201864||191783|
NCT00201877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0430|Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma|A Phase II Study of Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|December 2004|March 2012|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|September 12, 2005|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00201877||191782|
NCT00202150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G03-02765|Primary Care Management/Action Plans for Advanced Chronic Diseases|Primary Care Management/Action Plans for Advanced Chronic Diseases (The RoadMAP Project)||Queen's University||Completed|September 2004|September 2006|Actual|September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|55 Years|N/A|No|||March 2015|March 10, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00202150||191762|
NCT00202371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-021|Transfusion Effects in Myelodysplastic Patients: Limiting Exposure|Transfusion Effects in Myelodysplastic Patients: Limiting Exposure (Temple)||Sanquin Research & Blood Bank Divisions|No|Withdrawn|July 2002|July 2005|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|September 12, 2005|||Too few inclusions|No||https://clinicaltrials.gov/show/NCT00202371||191745|
NCT00202163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHEA-RCT|ANDRO 2002: Dehydroepiandrosterone (DHEA) or Testosterone Versus Placebo in Men With Sexual Dysfunction|A Randomized Double-Blind Placebo-Controlled Study Comparing the Safety and Efficacy of Dehydroepiandrosterone (DHEA) or Testosterone Versus Placebo in Men With Sexual Dysfunction||Queen's University||Completed|December 2006|September 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202163||191761|
NCT00202397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU - RLZ - 05|Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia|Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia||S. Andrea Hospital|Yes|Completed|June 2005|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||December 2013|February 10, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202397||191743|
NCT00202956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JL-HM-01-01|Safety and Efficacy Study of Bugusan (BGS)to Treat Osteoporosis.|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects on Biomarkers and Safety of Bugusan (BGS) in Postmenopausal Patients With Osteoporosis.||Taichung Veterans General Hospital||Recruiting|June 2004|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|45 Years|75 Years||||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202956||191700|
NCT00199407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-013|A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|June 2004|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||230|||Both|30 Years|N/A|No|||February 2007|June 22, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199407||191966|
NCT00199615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I00021|Follow-up of Patients With Curative-Intent Surgical Resection for NSCLC|Follow-up of Patients With Curative-Intent Surgical Resection for NSCLC : CT Scanning Versus 18 FDG Imaging.||University Hospital, Limoges|No|Completed|April 2001|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|73|||Both|18 Years|N/A|No|||September 2005|October 30, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199615||191950|
NCT00199602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I99006|Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients|Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study||University Hospital, Limoges|No|Recruiting|August 1999|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|420|||Both|18 Years|75 Years|No|||December 2008|December 30, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199602||191951|
NCT00200122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1617|Restore Claims Characterization Study|Restore Claims Characterization Study||MedtronicNeuro||Completed|January 2005|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||100|||Both|18 Years|N/A|No|||October 2007|January 20, 2009|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00200122||191911|
NCT00200356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI186-13|Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke|Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke||Mitsubishi Tanabe Pharma Corporation|No|Completed|August 2004|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|401|||Both|20 Years|N/A|No|||December 2012|December 9, 2012|September 12, 2005||No||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00200356||191893|
NCT00200330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL077082|Modifying Obesogenic Homes: Impact on Weight Maintenance|||The Miriam Hospital||Active, not recruiting|November 2004|April 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2005|April 17, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00200330||191895|
NCT00201019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272|Improving Adherence to Blood Pressure Guidelines|Improving Adherence to Blood Pressure Guidelines||University of Iowa|Yes|Completed|August 2003|July 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|623|||Both|21 Years|N/A|No|||November 2015|November 30, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00201019||191844|
NCT00201045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271|Team Management of High Blood Pressure|Collaborative Management of Hypertension||University of Iowa|Yes|Completed|July 2003|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|21 Years|85 Years|No|||December 2007|March 26, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00201045||191843|
NCT00201383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2399|Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients|Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients||National Health Research Institutes, Taiwan||Completed|October 1999|August 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||161|||Both|N/A|N/A|No|||January 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201383||191819|
NCT00191763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7138|Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer|Phase II Trial of Gemcitabine and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|November 2002|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||52|||Both|18 Years|70 Years|No|||November 2007|November 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191763||192539|
NCT00191789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7117|Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer|Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study||Eli Lilly and Company|No|Completed|February 2003|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|N/A|No|||July 2010|July 21, 2010|September 12, 2005|Yes|Yes||No|April 29, 2010|https://clinicaltrials.gov/show/NCT00191789||192538|
NCT00191750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7209|A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned|Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer||Eli Lilly and Company||Completed|July 2004|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||January 2007|January 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00191750||192540|
NCT00192153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153 P003|Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older|A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Adults 18 to 59 Years and Healthy Adults,60 Years/Older||MedImmune LLC||Completed|July 2001|October 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||240|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2006|October 23, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00192153||192512|
NCT00201240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0303|Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)|A Single Arm, Multicenter Phase II Trial of Transplants of HLA-Matched, CD34+ Enriched, T Cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With AML in First or Second Morphologic Complete Remission (BMT CTN #0303)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|June 2005|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|September 16, 2005|Yes|Yes||No|May 14, 2012|https://clinicaltrials.gov/show/NCT00201240||191830|
NCT00201292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC0931203|Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)|Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)||National Health Research Institutes, Taiwan|Yes|Recruiting|March 2005|October 2008|Anticipated|||N/A|Observational|N/A|||Anticipated|1350|||Both|18 Years|65 Years|No|||May 2007|November 14, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201292||191826|
NCT00201305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3202|Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract|Prospective Phase II Randomized Trial-Weekly Gemcitabine Plus High-Dose 5-Fluorouracil/ Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract||National Health Research Institutes, Taiwan||Completed|July 2002|August 2012||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|80 Years|No|||September 2005|March 30, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201305||191825|
NCT00201630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-005|Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy|Randomized, Open-Labeled Study of Prophylactic Vs. Therapeutic Use of Uroxatrol to Determine Improvements in Urinary Morbidity Following Men Undergoing Prostate Brachytherapy||New York Prostate Institute||Not yet recruiting|September 2005|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Male|N/A|N/A|Accepts Healthy Volunteers|||August 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201630||191801|
NCT00201890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCRA- 013260|Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer "DELTA STUDY"|DELTA - A Randomized Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer||Ontario Clinical Oncology Group (OCOG)|Yes|Completed|March 2003|February 2010|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|N/A|No|||October 2012|October 9, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00201890||191781|
NCT00201903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2003-TFsubstudy|The Roles of Tissue Factor in Malignant Gliomas|The Roles of Tissue Factor in Malignant Gliomas||Ontario Clinical Oncology Group (OCOG)|Yes|Completed|January 2004|October 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|30|||Both|18 Years|N/A|No|||May 2007|May 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201903||191780|
NCT00201916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-1995-PR.5|Shorter Radiation Schedule for the Treatment of Prostate Cancer|A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer||Ontario Clinical Oncology Group (OCOG)|No|Completed|March 1995|December 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|936|||Male|N/A|N/A|No|||August 2010|August 16, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00201916||191779|
NCT00202410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU - BCG - 01|Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis|Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, Randomized, Single Blind Study.||S. Andrea Hospital|Yes|Completed|November 2001|April 2008|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2011|May 18, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202410||191742|
NCT00202709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF-AUIR-1|Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?|Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.||Sorlandet Hospital HF|No|Completed|May 2002|August 2003|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|N/A|N/A|No|||September 2005|July 27, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202709||191719|
NCT00203333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05901|Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death|Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death||Thomas Jefferson University|Yes|Recruiting|April 2002|June 2006||||Phase 2/Phase 3|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|16 Years|49 Years|No|||May 2015|May 15, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00203333||191671|
NCT00199420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-018|A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa|A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|July 2004|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||580|||Both|30 Years|N/A|No|||February 2007|March 30, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199420||191965|
NCT00199628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I05001|Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization|Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization||University Hospital, Limoges||Recruiting|September 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Female|N/A|N/A|No|||September 2005|March 10, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199628||191949|
NCT00199641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2002/0361|Evaluation of Two Enteral Nutrition Strategies in Mechanically Ventilated Patients|Evaluation of Two Enteral Nutrition Strategies in Mechanically Ventilated Patients||University Hospital, Limoges||Completed|July 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||December 2008|December 2, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199641||191948|
NCT00199862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-124|Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer|A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2004|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00199862||191931|
NCT00200694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 03-5-D|Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.|||Nantes University Hospital||Terminated|March 2005|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||18|||Both|18 Years|80 Years|No|||February 2009|February 3, 2009|September 13, 2005|||difficulty in patients's inclusion|No||https://clinicaltrials.gov/show/NCT00200694||191867|
NCT00200343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT711-01|Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C|A 24-week Multicenter Double-blind Control Trial With Ursodeoxycholic Acid in Patients With Chronic Hepatitis C||Mitsubishi Tanabe Pharma Corporation||Completed|July 2002|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|596|||Both|20 Years|N/A|No|||March 2012|March 7, 2012|September 12, 2005||No||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00200343||191894|
NCT00200720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT000525-01|Effectiveness of a Low Carbohydrate Diet Versus a High Carbohydrate Diet in Promoting Weight Loss and Improved Health|Metabolic Consequences of High and Low Carbohydrate Diets||Kaiser Permanente|Yes|Completed|April 2005|June 2010|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|21 Years|N/A|No|||February 2008|December 4, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200720||191865|
NCT00201058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1299|Tailored Asthma Management for Urban Teens|Tailored Asthma Management for Urban Teens|Puff City|Henry Ford Health System|Yes|Completed|July 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|450|||Both|14 Years|18 Years|No|||December 2012|December 18, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201058||191842|
NCT00192218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA004|Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program|A Phase IV Study to Evaluate the Effectiveness of Flumist (Influenza Vaccine, Live Intranasal) Vaccination in a School-Based Intervention Program||MedImmune LLC||Completed|October 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3022|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||September 2008|September 19, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00192218||192507|
NCT00192231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153 P510|Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)|A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults Aged 18 and Older||MedImmune LLC||Completed|April 2001|June 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 23, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00192231||192506|
NCT00192179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P526|A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.|A Phase II, Prospective, Randomized, Double-Blind, Placebo, Controlled Trial, to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation (CAIV-T) in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.|FluMist|MedImmune LLC|No|Completed|June 2003|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192179||192510|
NCT00192192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153 P001|Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults|A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults Aged 18 to 64 Years||MedImmune LLC||Completed|November 2000|December 2000||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2006|October 23, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00192192||192509|
NCT00192205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P514|Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children|A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children With a History of Recurrent Respiratory Tract Infections Aged 6 Months to Less Than 72 Months||MedImmune LLC||Completed|October 2002|June 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2200|||Both|6 Months|71 Months|No|||October 2006|October 2, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00192205||192508|
NCT00201253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286|Expression of Tuberculosis in the Lung|Expression of Tuberculosis in the Lung||Rutgers, The State University of New Jersey||Completed|September 2000|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|40|Samples With DNA|Cell culture supernatants and cell lysates from bronchoalveolar cells, as well as peripheral      blood mononuclear cells.      Bronchoalveolar lavage fluid|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with tuberculosis and household contacts of patients with tuberculosis.|January 2015|January 22, 2015|September 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00201253||191829|
NCT00201643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0001|A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome|A Randomized Double-Blinded Study Comparing the Impact of One Versus Two Courses of Antenatal Steroids on Neonatal Outcome|ACS|Mednax Center for Research, Education and Quality|Yes|Completed|November 2003|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|437|||Female|18 Years|60 Years|No|||December 2014|December 17, 2014|September 12, 2005|Yes|Yes||No|September 7, 2010|https://clinicaltrials.gov/show/NCT00201643||191800|
NCT00201617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.33|Efficacy of the Bone-anchored Hearing Aid for Unilateral Deafness|Short-term and Long-term Efficacy of the BAHA for Single Sided Deafness||The New York Eye & Ear Infirmary||Completed|July 2004|August 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|28|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201617||191802|
NCT00202176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-833-04|Effects of Bronchodilators in Mild Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Bronchodilators on Exertional Dyspnea and Exercise Performance in Mild Chronic Obstructive Pulmonary Disease (COPD) Patients and Healthy Elderly Subjects.||Queen's University|Yes|Completed|July 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00202176||191760|
NCT00202722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF812310|Remifentanil as Intravenous Patient-controlled Analgesia (IVPCA) During Labour|Remifentanil as Analgesia for Labour Pain||Sorlandet Hospital HF|Yes|Completed|January 2004|August 2007|Actual|July 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 22, 2014|September 12, 2005|Yes|Yes||No|March 16, 2010|https://clinicaltrials.gov/show/NCT00202722||191718|
NCT00202995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9013|Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS|A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone® to That of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients||Teva Pharmaceutical Industries|Yes|Terminated|July 2004|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|50 Years|No|||October 2010|October 14, 2010|September 13, 2005|Yes|Yes|Slow enrollment decreased sample size No unexpected safety issues.|No||https://clinicaltrials.gov/show/NCT00202995||191697|
NCT00202969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC101|Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer|An Open-label, Multicenter, Randomized, 3 Arm Study of S-1 Compared With S-1/CDDP, or S-1/CDDP Compared With 5-FU/CDDP in Patients With Advanced Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease||Taiho Pharmaceutical Co., Ltd.||Completed|July 2005|June 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||July 2011|July 6, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00202969||191699|
NCT00202982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9006|A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose|A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients||Teva Pharmaceutical Industries||Completed|August 2003|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|50 Years|No|||January 2010|January 12, 2010|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00202982||191698|
NCT00203632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPD 084385|Glitazones and Endothelial Function (GATE)|A Trial of the Effect of Rosiglitazone as Add on to Metformin Therapy on Endothelial Function in Subjects With Type II DM||University of Calgary|Yes|Terminated|September 2003|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2008|October 30, 2008|September 13, 2005|||Terminated at 50% enrollment due to recent concerns about rosiglitazone|No||https://clinicaltrials.gov/show/NCT00203632||191650|
NCT00203658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2736-2|Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin|LITE Study, Appendix A (HOME-LITE), Amendment 6||University of Calgary||Completed|April 1997|October 2000||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||September 2005|February 8, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00203658||191648|
NCT00199433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-051|A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients|A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|May 2005|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|30 Years|N/A|No|||February 2007|June 22, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199433||191964|
NCT00199875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-022|Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250|Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer||Ludwig Institute for Cancer Research||Recruiting|July 2005|September 2012|Anticipated|September 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|N/A|N/A|No|||May 2011|May 9, 2011|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00199875||191930|
NCT00200707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/03/2-B|BONAMI (BOne Marrow in Acute Myocardial Infarction)|Intracoronary Injection of Autologous Bone Marrow Mononuclear Cells for Severe Myocardial Infarction||Nantes University Hospital|No|Completed|December 2004|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|75 Years|No|||April 2014|April 29, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00200707||191866|
NCT00201071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1298|Asthma Surveillance and Education in Preschool Settings|Asthma Surveillance and Education in Preschool Settings||National Heart, Lung, and Blood Institute (NHLBI)||Recruiting|September 2004|||||N/A|Observational|Observational Model: Natural History, Time Perspective: Prospective|||Anticipated|240|||Both|2 Years|4 Years|No|||April 2007|April 27, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00201071||191841|
NCT00201084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|276|Physician Uncertainty Reduction for Hypertension|Physician Uncertainty Reduction for Hypertension||Baylor College of Medicine|Yes|Completed|September 2004|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|670|||Both|N/A|N/A|No|||July 2014|July 17, 2014|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00201084||191840|
NCT00201422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1296|Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-Grade B Cell Lymphoma of MALToma|Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-Grade B Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type of The Stomach||National Health Research Institutes, Taiwan||Completed|June 1996|January 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|N/A|N/A|No|||September 2005|April 2, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201422||191816|
NCT00201435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBCG10|Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC|Weekly Taxol® Plus Xeloda® Versus Taxotere® Every Three Weeks Plus Xeloda® in the Treatment of Metastatic Breast Cancer A Phase II/III Study||Norwegian Breast Cancer Group|No|Completed|March 2005|May 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|224|||Female|18 Years|N/A|No|||May 2008|May 19, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00201435||191815|
NCT00192270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P503|Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children|A Prospective, Open-label, Phase II, Multi-center Study of the Safety, Tolerability and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children, Aged 6 to 17 Years|FluMist|MedImmune LLC|No|Completed|October 2000|January 2001|Actual|January 2001|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|498|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00192270||192503|
NCT00192647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17908|A Study of Induction Dosing With Peginterferon Alfa-2a (40KD) and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1|A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1||Hoffmann-La Roche||Completed|September 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|896|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00192647||192475|
NCT00192621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMA 002 Version 5|Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects|A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism||Kirby Institute|No|Completed|November 2004|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 11, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00192621||192477|
NCT00200876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001415-01A1|Effects of Anticipation of Pain Relief on Brain Mechanisms|Neurochemical Mediation of Placebo Responses in Humans||University of Michigan|Yes|Completed|September 2003|June 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|60|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00200876||191854|
NCT00201929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCR-Unit-Decision Board|A Decision Aid for Women With Early Stage Breast Cancer|Development and Evaluation of Different Versions of the Decision Board for Early Breast Cancer||Ontario Clinical Oncology Group (OCOG)||Completed|April 2002|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||300|||Female|N/A|N/A|No|||June 2007|June 27, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201929||191778|
NCT00202423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-CAN-04|Use of Cannabinoids in Patients With Multiple Sclerosis|fMRI and Neurophysiological Study Protocol on Cannabinoids in Multiple Sclerosis||S. Andrea Hospital||Recruiting|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||September 2005|November 28, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00202423||191741|
NCT00203008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP002|A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma|A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients||Teva Pharmaceutical Industries|No|Completed|January 2003|September 2003|Actual|||N/A|Observational|N/A||1|Actual|2106|||Both|N/A|N/A|No|Non-Probability Sample|Patients known to have Parkinson's Disease will be invited to join the study by their        treating physicians as long as they are not taking investigational product.|October 2010|October 14, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00203008||191696|
NCT00203021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-9004|Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.|Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®||Teva Pharmaceutical Industries|No|Active, not recruiting|July 1994|September 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|208|||Both|18 Years|50 Years|No|||March 2016|March 1, 2016|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00203021||191695|
NCT00203346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBY/GON|Research Study Examining Nerve Block for Migraine|Greater Occipital Nerve (GON) Block for Migraine||Thomas Jefferson University||Completed|June 2005|||||N/A|Observational|Time Perspective: Prospective||||30|||Both|18 Years|80 Years|No|||January 2009|January 22, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00203346||191670|
NCT00203645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110328 - CIHR|Minimal and Brief Treatments for Pathological Gamblers|Minimal and Brief Treatments for Pathological Gamblers: Developing Effective Treatment Systems||University of Calgary|No|Completed|July 2003|February 2009|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|312|||Both|18 Years|N/A|No|||February 2009|February 13, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00203645||191649|
NCT00199680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I03017|Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer|Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer||University Hospital, Limoges||Recruiting|October 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||42|||Female|18 Years|N/A|No|||September 2005|January 31, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199680||191945|
NCT00199693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elangestork2005-1|Hemodynamic and Respiratory Function in Healthy Pregnant Women|Hemodynamic and Respiratory Function in Healthy Pregnant Women - A Longitudinal Study||Oslo University Hospital||Completed|April 2007|June 2009|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy pregnant women|June 2009|July 3, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199693||191944|
NCT00199654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I03001|Positron Emission Tomography (PET) Interest in the Follow Up of Colorectal Cancer Stage II and III|PET Interest in the Follow Up of Colorectal Cancer Stage II and III: Phase III Randomised Study||University Hospital, Limoges||Completed|February 2004|April 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|376|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00199654||191947|
NCT00200135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 04-18|Financial and Clinical Impact of Repeal of the Pennsylvania Motorcycle Helmet Law|Financial and Clinical Impact of Repeal of the Pennsylvania Helmet Law: A Multi-Center Prospective Study Comparing Helmeted and Non-Helmeted Motorcycle Accident Victims||Memorial Medical Center|No|Completed|June 2005|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|480|||Both|18 Years|N/A|No|Non-Probability Sample|60 helmeted and 60 unhelmeted motorcycle riders in each cohort|July 2013|July 2, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00200135||191910|
NCT00200382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Velcade|Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer|Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer||Montefiore Medical Center||Terminated|May 2004|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|27|||Both|18 Years|N/A|No|||December 2007|December 7, 2007|September 13, 2005|||The study did not achieve the statistical success to continue.|||https://clinicaltrials.gov/show/NCT00200382||191891|
NCT00200395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tarceva|Phs. II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients W/Advanced Stage or Inoperable Non-Small Cell Lung Cancer (NSCLC)|Phase II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients With Advanced Stage or Inoperable Non Small Cell Lung Cancer (NSCLC)||Montefiore Medical Center||Suspended|June 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|65 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00200395||191890|
NCT00200369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-10-268|Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen|Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen||Montefiore Medical Center||Completed|May 2004|March 2006|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|19 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the Montefiore Medical Center Infectious Diseases Clinic        with eligibility criteria as listed below.|November 2009|November 4, 2009|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00200369||191892|
NCT00201448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-078|Evaluation of the Immunogenicity and Efficacy of the Towne Strain of CMV in Seronegative Women|Epidemiology of Cytomegalovirus -- Evaluation of the Immunogenicity and Efficacy of the Towne Strain of CMV in Seronegative Women: A Phase II-III Study||Virginia Commonwealth University||Terminated|June 2007|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|83|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|September 13, 2005|Yes|Yes|Suspended in 2005 for audit by NIH. Restarted June 2007. Closed out with IRB in April 2010 due    to lack of funding|No||https://clinicaltrials.gov/show/NCT00201448||191814|
NCT00201461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G980031|Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)|A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale||NMT Medical|Yes|Active, not recruiting|June 2003|April 2010|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|60 Years|No|||November 2008|December 29, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201461||191813|
NCT00201760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0342|Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer|A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|February 2005|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00201760||191791|
NCT00201773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0245|Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer|A Phase II Trial of Exemestane (Aromasin) in Combination With Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|July 2003|June 2011|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||June 2015|June 25, 2015|September 12, 2005|Yes|Yes||No|February 17, 2015|https://clinicaltrials.gov/show/NCT00201773||191790|
NCT00192660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAMA 001 Version 6|HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)|Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time||Kirby Institute|No|Completed|February 2003|December 2007|Actual|October 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 11, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00192660||192474|
NCT00192634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEAL|A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study|A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study.||Kirby Institute|Yes|Completed|December 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00192634||192476|
NCT00200889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT002166-01|Effect of Acupuncture on Human Brain Activity|Exploring Neurocircuitry of Acupuncture Action With fMRI||Massachusetts General Hospital|No|Completed|May 2005|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00200889||191853|
NCT00200902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002479-02|Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression|Factors of Treatment Response in Major Depressive Disorder||University of California, Los Angeles|Yes|Suspended|August 2005|June 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|140|||Both|18 Years|65 Years|No|||November 2009|November 19, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00200902||191852|
NCT00202189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-892-05|Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)|Acute Effects of Inhaled Corticosteroids on Dynamic Airway Function During Rest and Exercise in Chronic Obstructive Pulmonary Disease (COPD)||Queen's University|Yes|Completed|September 2005|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2008|August 12, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00202189||191759|
NCT00202202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS001|User Satisfaction Survey - Personality Disorder Service|Survey of the Consultation Service of the Providence Continuing Care Centre Personality Disorder Service Users Satisfaction With the Change in Service Delivery||Queen's University|No|Completed|November 2002|April 2004|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|16 Years|N/A|No|||March 2015|March 10, 2015|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00202202||191758|
NCT00201942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-092493|PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)|A Prospective Study to Determine the Role of 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)Positron Emission Tomography (PET)in the Assessment of Regional Nodal Spread of Disease in Breast Cancer Patients||Ontario Clinical Oncology Group (OCOG)|Yes|Completed|February 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|336|||Female|18 Years|N/A|No|||October 2007|October 17, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00201942||191777|
NCT00202735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811327|Does Immobilization of the Shoulder in External Rotation Reduce the Recurrence Rate of Shoulder Dislocation?|Does Immobilization of the Shoulder in External Rotation Reduce the Recurrence Rate of Shoulder Dislocation?||Sorlandet Hospital HF|Yes|Completed|January 2005|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|188|||Both|16 Years|40 Years|No|||January 2005|May 7, 2009|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00202735||191717|
NCT00203034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-1012/133|Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations|A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations||Teva Pharmaceutical Industries|Yes|Completed|May 2000|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|472|||Both|30 Years|N/A|No|||March 2010|March 8, 2010|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203034||191694|
NCT00203359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10005|TNF-Alpha Inhibition for Treatment of Alzheimer's Disease|Etanercept for Alzheimer's-Type Memory Loss Pilot Study||Tobinick, Edward Lewis, M.D.||Completed|September 2004|April 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|N/A|N/A|No|||April 2006|April 20, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203359||191669|
NCT00203372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORI B-02|Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)|A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer||Translational Oncology Research International|Yes|Completed|May 2005|||June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|6|||Female|18 Years|N/A|No|||February 2011|October 9, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00203372||191668|
NCT00203385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC Maintenance DVX PTSD|Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder|Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder||Tuscaloosa Research & Education Advancement Corporation|No|Completed|May 2003|March 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|19 Years|N/A|No|||March 2007|March 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00203385||191667|
NCT00199706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-SAHA|HyperHAES Versus Placebo - Effect on Intracranial Pressure in SAH Patients|7.2% NaCl in 6% Hydroxyethyl Starch Versus Placebo - Effect on Intracranial Pressure and Haemodynamics in Subarachnoidal Haemorrhage (SAH) Patients.||Oslo University Hospital||Completed|April 2002|October 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||November 2005|June 30, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199706||191943|
NCT00210756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004603|Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.|Comparative Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2004|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210756||191113|
NCT00210769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004426|A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia|Open-label Extension of A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Extended Release OROS� Paliperidone (6 and 12 mg/Day) and Olanzapine (10 mg/Day), in Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2004|December 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|203|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210769||191112|
NCT00210964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005032|Ceftobiprole in Hospital Acquired Pneumonia|A Phase III Randomized Double-Blind Study Of Ceftobiprole Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia||Basilea Pharmaceutica|Yes|Completed|April 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|781|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00210964||191097|
NCT00208585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-7102|Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury|A Randomized Placebo-Controlled Trial of Sertraline for the Neurobehavioral Sequelae of Traumatic Brain Injury||Walter Reed Army Medical Center||Recruiting|February 2000|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 9, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208585||191276|
NCT00208819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0673-2003|A Comparison of Two Standard Therapies in the Management of Dementia With Agitation|Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies||Emory University||Completed|September 2003|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|65 Years|N/A|No|||November 2013|November 12, 2013|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00208819||191258|
NCT00209105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021800|Characterizing Psychological Consequences of Childhood Trauma|Emory Conte Center for the Neuroscience of Mental Disorders: Psychobiology of Childhood Trauma||Emory University|Yes|Completed|January 2005|March 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|This study will include participants who have experienced early-life trauma.|November 2013|November 11, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209105||191236|
NCT00209404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXV407|Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)|||GE Healthcare||Completed|July 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|August 18, 2005||||No||https://clinicaltrials.gov/show/NCT00209404||191216|
NCT00212615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XELOX III|XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer|XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study||Odense University Hospital||Active, not recruiting|February 2004|October 2008||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||116|||Both|18 Years|N/A|No|||October 2009|October 16, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212615||190973|
NCT00212628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5920-04|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan||Ono Pharmaceutical Co. Ltd||Completed|June 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|444|||Female|55 Years|80 Years|No|||June 2012|June 12, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212628||190972|
NCT00197522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|file#9427-HO778-34C|Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2|A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Vector Expressing Inactivated HER-2/Neu in Patients With Metastatic Breast Cancer||McMaster University||Completed|October 2004|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|16 Years|80 Years|No|||October 2012|October 31, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197522||192103|
NCT00197912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM0413|Dendritic Cell Based Therapy of Malignant Melanoma|Vaccination With Autologous Dendritic Cells Pulsed With Tumor Antigens for Treatment of Patients With Malignant Melanoma. Phase I/II Study||Herlev Hospital||Completed|September 2004|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2009|April 23, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197912||192079|
NCT00198770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC2004-01|Dietary Compensation With Substitution of Meat Products With White Button Mushrooms.|Does Substitution of Meat Products With White Button Mushrooms Have Potential for Weight Reduction? Studies of the Level of Short and Intermediate-term Caloric Compensation, Satiety, and Dietary Satisfaction Among Lean and Obese Men and Women.|Mush 1|Johns Hopkins Bloomberg School of Public Health|No|Completed|March 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|October 19, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00198770||192014|
NCT00199082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL05|Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults|Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)||Johann Wolfgang Goethe University Hospitals||Recruiting|July 2002|||June 2010||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|650|||Both|15 Years|N/A|No|||May 2008|May 29, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199082||191990|
NCT00199095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL11|Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia|Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia||Johann Wolfgang Goethe University Hospitals||Completed|February 1997|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|65 Years|N/A|No|||May 2008|May 16, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199095||191989|
NCT00209924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10403|A Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia||H. Lundbeck A/S|No|Completed|April 2004|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||505|||Both|66 Years|N/A|No|||March 2007|March 29, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209924||191176|
NCT00209937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99775|A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Active-Reference Study of Gaboxadol in Primary Insomnia||H. Lundbeck A/S|No|Completed|January 2003|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||675|||Both|18 Years|65 Years|No|||March 2007|March 29, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209937||191175|
NCT00209950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10440|A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia|A Prospective Open-Label Extension Study (to Study 99784) of Gaboxadol in Primary Insomnia||H. Lundbeck A/S|No|Completed|July 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years|No|||March 2007|March 29, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209950||191174|
NCT00209989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02 TETE 02|Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme|Phase I/II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme||Institut Claudius Regaud||Completed|October 2005|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||November 2011|November 23, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209989||191172|
NCT00210340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG24|A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis|A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis||International Extranodal Lymphoma Study Group (IELSG)||Withdrawn||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|September 13, 2005||No|lack of accrual|No||https://clinicaltrials.gov/show/NCT00210340||191145|
NCT00210587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003223|An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation|A Pilot Study to Evaluate the Response Rate of Epoetin Alfa (PROCRIT) at 80,000 Units Every Three Weeks in Anemic Patients With Cancer Not Receiving Chemotherapy or Radiation Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2005|December 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|51|||Both|18 Years|N/A|No|||May 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210587||191126|
NCT00211250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCCR-001|Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER|An Exploratory Study Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar I and II Patients From Valproic Acid to Depakote ER||Joliet Center for Clinical Research|Yes|Completed|July 2005|September 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 27, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211250||191075|
NCT00210782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004663|A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment|A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2004|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|262|||Both|12 Years|65 Years|No|||March 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210782||191111|
NCT00210977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003277|A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies|An Observational Study of Subjects Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Withdrawn|December 2005|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood samples will be collected for pharmacogenomic analysis.|Both|N/A|N/A|No|Non-Probability Sample|Participants with positive or borderline serum anti erythropoietin antibody titer and who        are responding to any erythropoietin receptor agonist (ERA) therapy for any cause of        anemia|August 2013|August 29, 2013|September 13, 2005||No|The study never started due to zero enrolment|No||https://clinicaltrials.gov/show/NCT00210977||191096|
NCT00215306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990303|CHARITÉ™ Artificial Disc Compared to Anterior Interbody Fusion for Treatment of Degenerative Disc Disease|Clinical Investigation of the SB Charite III Intervertebral Disc Spacer.||DePuy Spine||Completed|March 2000|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|60 Years|No|||May 2014|May 22, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215306||190770|
NCT00211445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT for CSC|Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)|||Manhattan Eye, Ear & Throat Hospital|No|Completed|July 2002|January 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||September 2007|September 27, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211445||191060|
NCT00211744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0379|Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder|Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder||Icahn School of Medicine at Mount Sinai||Recruiting|August 2004|August 2006|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|65 Years|No|||December 2005|September 5, 2008|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211744||191037|
NCT00211757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 01-0294|Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism|Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism||Montefiore Medical Center||Completed|September 2002|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|5 Years|17 Years|No|||April 2011|April 15, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211757||191036|
NCT00208598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCDR_3|Measures of Obesity and Co-Morbid Conditions in Maori|||Edgar National Centre for Diabetes Research||Completed|January 2003|December 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||220|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208598||191275|
NCT00208858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-2004|A Pilot Study of the Neural Correlates of Treatment Effect on Nicotine Craving|Nicotine Craving: Neural Correlates of Treatment Effect - A Pilot Study||Emory University||Completed|December 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Male|18 Years|55 Years||||June 2014|June 13, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208858||191255|
NCT00209664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0303|Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer|Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0303||Hokkaido Gastrointestinal Cancer Study Group||Suspended|January 2004|December 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|No|||January 2004|January 31, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209664||191196|
NCT00209092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1114-2003|Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer|Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer||Emory University|Yes|Completed|August 2006|October 2012|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Female|18 Years|N/A|No|||March 2015|March 6, 2015|September 14, 2005|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00209092||191237|
NCT00197925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA0415|Dendritic Cell Based Therapy of Metastatic Breast Cancer|Vaccination With Autologous Dendritic Cells Pulsed With Onco-Peptides for Treatment of Patients With Metastatic Breast Cancer.A Phase I/II Study||Herlev Hospital||Terminated|September 2004|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||January 2008|January 2, 2008|September 12, 2005|||all patients recruited|No||https://clinicaltrials.gov/show/NCT00197925||192078|
NCT00198146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9910-34|Prevention of Diabetes Progression Trial (PDPT)|PD Initiated/Prevention of Diabetes Progression Trial (PDPT) ZEN119||Indiana University||Completed|July 2000|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|2 Years|40 Years|No|||September 2005|October 25, 2005|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00198146||192061|
NCT00198419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-VIT-CS04|Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)|Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Open Label, Normal Volunteer Study||Bausch & Lomb Incorporated|No|Completed|March 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 13, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198419||192041|
NCT00199108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL06|Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt|A Phase-2 Clinical Study to Determine the Efficacy and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of CNS Relapse in Adult Patients With Acute Lymphoblastic Leukemia or Very Aggressive Lymphoma||Johann Wolfgang Goethe University Hospitals||Active, not recruiting|April 2004|June 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||May 2008|May 29, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199108||191988|
NCT00194558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-3892-G-01|Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care|Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care||University of Washington||Completed|February 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|82|||Both|18 Years|39 Years|No|||September 2008|September 30, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194558||192329|
NCT00194571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-2050-C06|Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child|Helping the Mother With Breast Cancer Support Her Child|EC R01|University of Washington|No|Active, not recruiting|June 1999|May 2009|Anticipated|May 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|181|||Both|18 Years|65 Years|No|||January 2008|January 2, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194571||192328|
NCT00209599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0415|A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy|A Phase II, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Colonoscopy Procedures||Eisai Inc.||Terminated|February 2005|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|65 Years|N/A|No|||November 2008|November 6, 2008|September 13, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00209599||191201|
NCT00209612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0402|Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.|Phase I/II Study of Biweekly Administration Regimen of Paclitaxel Combined With CPT-11 in Patients With Second Line Chemotherapy of Inoperable or Recurrent Gastric Cancer(GC).||Hokkaido Gastrointestinal Cancer Study Group|Yes|Withdrawn|April 2004|March 2009|Anticipated|November 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|75 Years|No|||February 2009|February 16, 2009|September 13, 2005||No|due to strong side effect|No||https://clinicaltrials.gov/show/NCT00209612||191200|
NCT00209963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99784|A Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia||H. Lundbeck A/S|No|Completed|June 2003|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|65 Years|No|||March 2007|March 29, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209963||191173|
NCT00210353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG19|Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma|Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)||International Extranodal Lymphoma Study Group (IELSG)|Yes|Active, not recruiting|January 2003|June 2020|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00210353||191144|
NCT00210808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004657|A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity|A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2003|March 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|407|||Both|18 Years|65 Years|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210808||191109|
NCT00211003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005401|Doripenem in the Treatment of Hospital-Acquired Pneumonia|A Multicenter, Randomized, Open-Label, Phase 3 Study to Compare the Safety and Effectiveness of Doripenem Versus a Comparator Antibiotic in Hospital-Acquired Pneumonia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|240|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211003||191094|
NCT00211016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005386|Doripenem in the Treatment of Ventilator-Associated Pneumonia|A Multicenter, Randomized, Open-Label, Phase 3 Study of Doripenem Versus a Comparator Antibiotic in the Treatment of Ventilator-Associated Pneumonia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2004|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|318|||Both|18 Years|N/A|No|||March 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211016||191093|
NCT00212030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSCJ-2|Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP|Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP||National Cerebral and Cardiovascular Center||Completed|October 2001|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|20 Years|79 Years|No|||October 2007|October 31, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212030||191016|
NCT00212043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRG L08/99|Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma|Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma||National University Hospital, Singapore||Completed|July 2000|February 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||74|||Both|18 Years|N/A|No|||May 2008|October 7, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212043||191015|
NCT00210990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005398|Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis|A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|403|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210990||191095|
NCT00211224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLG1-2000-01262|Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)|Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)||King's College London||Terminated|April 2000|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||800|||Both|30 Years|80 Years|No|||September 2005|December 14, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211224||191077|
NCT00211237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0401 - CAFE Study|CAFE Study - Cancer Patient Fracture Evaluation|A Multicenter, Prospective, Randomized, Controlled Study to Compare Balloon Kyphoplasty to Non-surgical Fracture Management in the Treatment of Painful, Acute Vertebral Body Compression Fractures in Cancer Patients|CAFE|Medtronic Spine LLC|Yes|Completed|May 2005|December 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|21 Years|N/A|No|||May 2010|February 16, 2012|September 13, 2005|Yes|Yes||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00211237||191076|
NCT00211458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Failed PDT treated with AA|Treatment of Age-Related Macular Degeneration With Anecortave Acetate|Treatment of Age-Related Macular Degeneration With Open-label Anecortave Acetate Sterile Suspension (15mg) Following Failed Treatment With Photodynamic Therapy With Visudyne||Manhattan Eye, Ear & Throat Hospital|No|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|50 Years|N/A||||October 2012|October 24, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211458||191059|
NCT00211185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#35|A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma|A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma.||Eisai Inc.|Yes|Active, not recruiting|March 2004|||August 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2008|August 27, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211185||191080|
NCT00211198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#33|Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)|Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status||Eisai Inc.|Yes|Completed|May 2001|January 2006|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||February 2008|February 29, 2008|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00211198||191079|
NCT00211211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0201 - FREE Study|FREE Study - Fracture Reduction Evaluation|An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures||Medtronic Spine LLC||Completed|February 2003|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||300|||Both|21 Years|N/A|No|||January 2012|April 18, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211211||191078|
NCT00211770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 04-0629|Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.|Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.||Icahn School of Medicine at Mount Sinai|No|Completed|February 2005|December 2012|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who are enrolled in the approved double-blind placebo controlled trial of        citalopram in young children with autism.|June 2013|June 11, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211770||191035|
NCT00212264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK60044 (completed)|Conservative Treatment of Postprostatectomy Incontinence|Conservative Treatment of Postprostatectomy Incontinence||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|August 2003|August 2011|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|208|||Male|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 29, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212264||190998|
NCT00212641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5129POU006|A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus|Randomized Double-Blind Placebo-Controlled Pharmacodynamic Evaluation of ONO-5129 in Patients With Treatment Naive Type 2 Diabetes Mellitus||Ono Pharmaceutical Co. Ltd||Completed|June 2005|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||105|||Both|18 Years|75 Years|No|||October 2012|October 10, 2012|September 12, 2005||No||||https://clinicaltrials.gov/show/NCT00212641||190971|
NCT00212654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-1101-21|Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan|Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan||Ono Pharmaceutical Co. Ltd||Completed|June 2001|||April 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||165|||Both|21 Years|84 Years|No|||October 2012|October 10, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212654||190970|
NCT00209430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXV405|Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.||GE Healthcare||Completed|August 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||408|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209430||191214|
NCT00209677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0405|Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer||Hokkaido Gastrointestinal Cancer Study Group|Yes|Suspended|December 2004|December 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|75 Years|No|||October 2007|October 31, 2007|September 13, 2005|||Unfortunately, other Phase III clinical Study (GEM+S-1 vs GEM vs S-1) have been started in    Japan.    h|No||https://clinicaltrials.gov/show/NCT00209677||191195|
NCT00209417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXV406|Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.||GE Healthcare||Terminated|June 2005|July 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|656|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|August 24, 2005|No|Yes|Supported by preliminary interim analysis. Not based on any safety signals in study or any    quality issues that could affect efficacy of the product.|No|October 2, 2014|https://clinicaltrials.gov/show/NCT00209417||191215|
NCT00209638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0002|Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer|Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0101||Hokkaido Gastrointestinal Cancer Study Group||Completed|May 2000|April 2003||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|75 Years|No|||April 2006|April 19, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209638||191198|
NCT00198159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0211-07|A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR|A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR)|IUCRO-0021|Indiana University||Terminated|September 2002|March 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||21|||Both|15 Years|N/A|No|||September 2014|September 18, 2014|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00198159||192060|
NCT00198432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0201|Chemoradiotherapy of NSCLC Stage IIIB|Randomized Phase II Study Evaluating an Induction Chemotherapy Followed by a Concomitant Chemoradiotherapy and a Concomitant Chemoradiotherapy Followed by a Consolidation Chemotherapy Among Patients With NSCLC Stage III Not Resectable||Intergroupe Francophone de Cancerologie Thoracique||Completed|March 2002|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198432||192040|
NCT00198445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-BR-CS001|Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery|Efficacy and Safety of Topical Bromfenac Ophthalmic Solution, 0.1% vs. Placebo for Treatment of Ocular Inflammation Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|May 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|527|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00198445||192039|
NCT00194584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0564-01|Childhood Chronic Illness: An Educational Program for Parents of Children With On-Going Health Care Needs|Building on Family Strengths: An Educational Program for Parents of Children With On-Going Health Care Needs||University of Washington|No|Completed|October 2004|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 25, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194584||192327|
NCT00194922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-03-02003|Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Tolerance and Efficacy of the Probiotic E. Coli Strain M17 on Symptoms and Quality of Life in Individuals With Irritable Bowel Syndrome (IBS)||Weill Medical College of Cornell University|Yes|Completed|August 2004|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|80 Years|No|||April 2008|April 3, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194922||192302|
NCT00194896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16707-D|Preferred Treatment of Type 1.5 Diabetes|Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes||University of Washington|Yes|Completed|February 2000|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|35 Years|69 Years|No|||August 2011|August 16, 2011|September 14, 2005||No||No|February 22, 2011|https://clinicaltrials.gov/show/NCT00194896||192304|Small numbers based on high drop out of participants.
NCT00195520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0753T-101537|Study Evaluating Totelle® in Menopausal Symptoms and Sexual Function|An Open Assessment of the Effect of Low-Dose Totelle® 1 mg on Menopausal Symptoms, Sexual Function and Quality of Life||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2004|December 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Female|45 Years|60 Years|No|||August 2008|August 1, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195520||192256|
NCT00210600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003196|Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy|Assessment of Early and Standard Intervention With PROCRIT (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2005|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|186|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210600||191125|
NCT00211276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#123|A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma|A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non-Hodgkins Lymphoma.||Eisai Inc.||Completed|March 2005|February 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||March 2011|March 13, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211276||191073|
NCT00211497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A99005|Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne|A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris||BioWest Therapeutics Inc||Completed|January 2003|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||255|||Both|12 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211497||191056|
NCT00211809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 00-0211PS*|CBT as an Adjunct to SRIs in the Treatment of BDD|A Controlled Trial of Cognitive-Behavioral Therapy as an Adjunct to Serotonin Reuptake Inhibitors in Body Dysmorphic Disorder||Icahn School of Medicine at Mount Sinai||Active, not recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|16 Years|65 Years|No|||May 2008|May 23, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211809||191032|
NCT00211822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO#04-1034|Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)|fMRI Studies in Pathological Gambling and Obsessive-Compulsive Disorder||Icahn School of Medicine at Mount Sinai|No|Terminated|November 2004|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|57|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|July 2011|July 13, 2011|September 13, 2005||No|Enrollments closed after former PI Eric Hollander left institution. There are no results.|No||https://clinicaltrials.gov/show/NCT00211822||191031|
NCT00211783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 04-0749|Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism|fMRI for the Study of Response Inhibition, and Face and Linguistic Processing in Autism||Icahn School of Medicine at Mount Sinai|No|Completed|November 2004|June 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|71|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thirty adults with ASD and 30|June 2012|June 26, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211783||191034|
NCT00212017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSCJ-3|Assessment of an Alpha-Glucosidase Inhibitor to Block Cardiac Events in Patients With Myocardial Infarction and IGT (ABC Study)|The Japan Working Group for the Assessment That the Alpha-Glucosidase Inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT||National Cerebral and Cardiovascular Center||Recruiting|April 2005|April 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|3000|||Both|20 Years|N/A|No|||November 2007|November 7, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212017||191017|
NCT00212004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSCJ-4|Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study)|The Japan Working Group for the Assessment That the Pioglitazone Protects DM Patients Against Re-Infarction||National Cerebral and Cardiovascular Center||Recruiting|April 2005|April 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||3000|||Both|20 Years|N/A|No|||November 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212004||191018|
NCT00212277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKH-01-5|Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.|Phase3,Open-label,Long-term,NSAID-Add-on,Clinical Trial of Mono-phase Low-dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis.||Nobelpharma||Completed|February 2005|February 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2010|September 9, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212277||190997|
NCT00212290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61606 (completed)|Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|November 2002|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|140|||Both|55 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 12, 2010|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00212290||190996|
NCT00212667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5920-02|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan||Ono Pharmaceutical Co. Ltd||Completed|August 2002|||September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||650|||Female|55 Years|80 Years|No|||October 2012|October 10, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212667||190969|
NCT00212680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-1101-1906|Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan|Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan||Ono Pharmaceutical Co. Ltd||Completed|December 1996|||April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|21 Years|79 Years|No|||October 2012|October 10, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212680||190968|
NCT00209443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOV302|A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-Iliac Arteries While Using Gadodiamide|||GE Healthcare||Completed|September 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||295|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00209443||191213|
NCT00210093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-106|A Pharmacokinetic Evaluation Study in Healthy Volunteers|A Single-Center, Randomized, Crossover Pharmacokinetic Evaluation of the Effect of Single Doses of Intravenous INS37217, Nasally Inhaled INS37217 and Orally Inhaled INS37217 Solution in Healthy Volunteers||Merck Sharp & Dohme Corp.||Completed|April 2003|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|N/A|N/A||||October 2015|October 15, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210093||191164|
NCT00210041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 GENH 06|Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma|Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin||Institut Claudius Regaud||Completed|February 2004|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||March 2015|March 26, 2015|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00210041||191168|
NCT00198172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0008-02|Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors|Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors||Indiana University||Terminated|October 2000|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||37|||Both|15 Years|N/A|No|||May 2014|May 30, 2014|September 8, 2005|||Accrual Goal Met|No||https://clinicaltrials.gov/show/NCT00198172||192059|
NCT00198458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-VIT-CS05|Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)|Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase, 150 USP Units/mL) Open Label, Normal Volunteer Study||Bausch & Lomb Incorporated|No|Completed|July 2004|September 2004|Actual|July 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1|||65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 14, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198458||192038|
NCT00198783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA2005-01|Real-Time Assessment of Food Craving, Use, and Triggers During Outpatient Treatment of Obesity: A Development and Feasibility Study|Real-Time Assessment of Food Craving, Use, and Triggers During Outpatient Treatment of Obesity: A Development and Feasibility Study||Johns Hopkins Bloomberg School of Public Health|No|Completed|August 2005|January 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2007|April 3, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198783||192013|
NCT00195130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0397-727|Prognostic Measures in Ambulatory Care Settings|Prognostic Measures in Ambulatory Care Settings||Weill Medical College of Cornell University||Completed|January 1998|January 1999||||N/A|Observational|N/A||||2000|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00195130||192286|
NCT00195533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100943|Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients|Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2001|March 2005|Actual|March 2005|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|801|Samples Without DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Hematology units|November 2009|November 13, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195533||192255|
NCT00195546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-321|Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2005|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|465|||Female|40 Years|65 Years|No|||May 2007|May 31, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00195546||192254|
NCT00211263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME# 02-385|Bipolar Disorder Research Study for Ages 12 and Older|Bipolar Disorder Center for Pennsylvanians (BDCP) Research Study||Kupfer, David J., M.D.||Completed|November 2003|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||750|||Both|12 Years|N/A|No|||June 2005|April 7, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211263||191074|
NCT00211510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 178/Z25/A2|Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes|Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes: A Multi-center, Randomized Controlled Trial|STAR1|Medtronic Diabetes|No|Completed|June 2005|February 2007|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|12 Years|80 Years|No|||April 2011|April 28, 2011|September 12, 2005|Yes|Yes||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00211510||191055|
NCT00211471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rubeosis iridis|Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).|Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension (15mg.).||Manhattan Eye, Ear & Throat Hospital|No|Terminated|March 2002|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2007|May 4, 2007|September 13, 2005|||poor enrollment|Yes||https://clinicaltrials.gov/show/NCT00211471||191058|
NCT00211796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO#04-1106|Divalproex Sodium ER in Adult Autism|Divalproex Sodium ER in Adult Autism||Icahn School of Medicine at Mount Sinai||Recruiting|April 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||April 2007|April 17, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211796||191033|
NCT00212329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tcell (IND) (completed)|T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus|A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2005|September 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|8 Years|35 Years|Accepts Healthy Volunteers|||January 2011|January 31, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212329||190993|
NCT00212303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK62368 (completed)|Exercise Training in Type 2 Diabetes and Hypertension|Exercise Training in Type 2 Diabetes and Hypertension|SHAPE2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|May 2004|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|40 Years|65 Years|No|||January 2013|January 18, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212303||190995|
NCT00212693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2506PO-03|Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan|Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan||Ono Pharmaceutical Co. Ltd||Completed|January 2004|||September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||165|||Both|20 Years|79 Years|No|||October 2012|October 10, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212693||190967|
NCT00212706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-8025-06|Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan|Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan||Ono Pharmaceutical Co. Ltd||Completed|October 2001|||November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|20 Years|N/A|No|||October 2012|October 11, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212706||190966|
NCT00208611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045854|Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease|Assessment of Cobalamin Status and Responses to Supplementation in Patients With Parkinson's Disease : a Pilot Study||Emory University|No|Terminated|September 2006|February 2010|Actual|February 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|57|||Both|21 Years|N/A|No|||December 2014|December 16, 2014|September 13, 2005||No|Funding ended and enrollment not completed within a certain time period|No||https://clinicaltrials.gov/show/NCT00208611||191274|
NCT00208871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045816|An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall|An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall||Emory University|No|Completed|December 2004|March 2011|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1467|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 19, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208871||191254|
NCT00209118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0112-1998|Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C|Paroxetine for the Prevention of IFN-Alpha Associated Depression in Patients With Chronic Hepatitis C||Emory University||Completed||July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00209118||191235|
NCT00209131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0128-2005|Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy|Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy||Emory University|No|Terminated|April 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|September 14, 2005|Yes|Yes|Due to frequent turnover of research coordinators and thus poor study accrual.|No|June 5, 2012|https://clinicaltrials.gov/show/NCT00209131||191234|Study was terminated due to turnovers of personnel to assist with recruitment and execution of the study.Recruitment was strained and patients recruited could not be followed up in a timely fashion to adhere to protocol. Thus, no data was generated.
NCT00209690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0305-1|Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.|Phase I/II Study of Docetaxel, Cisplatin and 5-fluorouracil(TPF) as 1st-line Chemotherapy in Patients With Metastatic Esophageal Cancer.||Hokkaido Gastrointestinal Cancer Study Group|Yes|Completed|October 2003|April 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|75 Years|No|||May 2010|May 24, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209690||191194|
NCT00210080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-312|A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)|A Double-Blind, Placebo-Controlled, Parallel Group Study of Uridine 5'-Triphosphate (UTP) Solution for Inhalation as an Adjunct in the Diagnosis of Lung Cancer by Sputum Cytology||Merck Sharp & Dohme Corp.||Completed|April 2001|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||700|||Both|N/A|N/A||||September 2015|September 3, 2015|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00210080||191165|
NCT00210665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003583|A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment|A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment||Janssen Research & Development, LLC||No longer available||||||Phase 3|Expanded Access|N/A|||||||Both|15 Years|N/A|No|||January 2016|January 19, 2016|September 13, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00210665||191120|
NCT00210054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-105|A Pharmacokinetic Evaluation Study in Healthy Volunteers|Pilot Single-Dose Intravenous Pharmacokinetic Evaluation of INS37217 Solution in Healthy Volunteers||Merck Sharp & Dohme Corp.||Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Both|N/A|N/A||||October 2015|October 9, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210054||191167|
NCT00210067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-101|A Study in Subjects With Retinal Detachment|A Double-Masked, Randomized, Dose-Ranging Study of a Single Intravitreal (IVT) Injection of INS37217 Intravitreal Injection in Subjects With Retinal Detachment||Merck Sharp & Dohme Corp.||Completed|May 2001|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|14|||Both|N/A|N/A||||October 2015|October 8, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210067||191166|
NCT00198471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-VIT-CS07|Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment|An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy||Bausch & Lomb Incorporated|No|Completed|July 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||10|||Both|50 Years|N/A|No|||March 2013|March 13, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198471||192037|
NCT00198484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-VIT-SA-CS06|Evaluation of Vitrase as a Spreading Agent|Evaluation of Vitrase (Hyaluronidase for Injection) Ovine, 200 USP Units/mL, as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Drugs Prior to Ocular Surgery||Bausch & Lomb Incorporated|No|Completed|October 2004|February 2005|Actual|December 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198484||192036|
NCT00199121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAZE001|A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients|An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine||Johann Wolfgang Goethe University Hospitals||Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2005|December 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199121||191987|
NCT00195143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902-478|Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease|Phase I Study of Subthalamic GAD Gene Transfer in Medically Refractory Parkinson's Disease Patients||Neurologix, Inc.||Completed|August 2003|August 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|25 Years|75 Years|No|||September 2005|March 26, 2008|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00195143||192285|
NCT00210821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004666|Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches|A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2004|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|347|||Both|18 Years|N/A|No|||May 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210821||191108|
NCT00212082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO B17/02|Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer|Gene Expression Profiles of Breast Cancer Treated With Sequential Adriamycin and Docetaxel in Relation to Tumor Responses||National University Hospital, Singapore||Completed|April 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|18 Years|N/A|No|||June 2008|June 11, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212082||191012|
NCT00212342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKH-01-4|Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea|Phase 3,Placebo Controlled,Randomized,Double-Blinded,NSAID-Add-on,Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis.||Nobelpharma||Completed|December 2004|March 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||September 2010|September 6, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212342||190992|
NCT00211484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA outside standard care|Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.|||Manhattan Eye, Ear & Throat Hospital|No|Completed|May 2003|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Both|18 Years|N/A||||May 2007|May 4, 2007|September 13, 2005||||Yes||https://clinicaltrials.gov/show/NCT00211484||191057|
NCT00212758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genentech # 303-MO1|A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood|IGF-1 Generation Test in Children With Chronic Kidney Disease||Oregon Health and Science University|No|Completed|January 2005|May 2010|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|17|||Both|2 Years|18 Years|No|||October 2011|October 22, 2011|September 14, 2005|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00212758||190962|Slow enrollment and the small number of participants in the study is the main limitation.
NCT00212056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSCJ-1|Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP|Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP||National Cerebral and Cardiovascular Center||Completed|October 2001|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|20 Years|79 Years|No|||October 2007|October 31, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212056||191014|
NCT00212316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS45242|Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)|Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's Disease||University of Rochester||Completed|August 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2007|August 14, 2012|September 19, 2005||||||https://clinicaltrials.gov/show/NCT00212316||190994|
NCT00212719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5920-03|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan||Ono Pharmaceutical Co. Ltd||Completed|May 2003|||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Female|45 Years|N/A|No|||October 2012|October 10, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212719||190965|
NCT00212732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-8025-08|Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan|Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan||Ono Pharmaceutical Co. Ltd||Completed|October 2003|||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|20 Years|N/A|No|||October 2012|October 10, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212732||190964|
NCT00208624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-118|Rhythm Disturbances After Ventricular Septal Defects|Rhythm Disturbances After Ventricular Septal Defects||Emory University||Terminated|December 2004|May 2005||||N/A|Observational|Time Perspective: Retrospective||||30|||Both|N/A|N/A|No|||May 2014|May 1, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208624||191273|
NCT00208884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001-2003|Terminal Graft Failure|Terminal Graft Failure: A Combined Pathologic and Clinical Study||Emory University|No|Terminated|October 2003|November 2005||||N/A|Observational|Time Perspective: Retrospective||||19|||Both|N/A|N/A|No|||November 2013|November 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208884||191253|
NCT00209144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|867-2004|Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.|Effects of Intense Glycemic Control on Markers of Inflammation and Thrombosis in Patients Treated With Percutaneous Coronary Intervention for Acute Myocardial Infarction.||Emory University||Completed|October 2004|December 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|89 Years|No|||June 2014|June 13, 2014|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00209144||191233|
NCT00209456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT301|Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title||GE Healthcare||Completed|November 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||326|||Both|55 Years|90 Years|No|||May 2007|May 15, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209456||191212|
NCT00210119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2005-25|Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response|Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy|AFR22|Institut Bergonié||Terminated|September 2005|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|N/A|No|||October 2007|July 25, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00210119||191162|
NCT00210132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2003-23|Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery|Randomized Trial to Evaluate the Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery|ROPAL 1|Institut Bergonié||Completed|October 2003|February 2008|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00210132||191161|
NCT00210678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004225|A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation|An Observational Study to Evaluate Intravaginal Ejaculatory Latency Time and Patient-Reported Outcomes in Men With and Without Premature Ejaculation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|March 2005|September 2005|Actual|September 2005|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1115|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|One thousand patients (at least 200 men with premature ejaculation (PE) and at least 800        men without PE) will be enrolled in the study.|October 2012|October 9, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00210678||191119|
NCT00210457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-54-52030-081 (311)|Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients|Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues.||Ipsen||Completed|September 2000|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2008|June 26, 2008|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00210457||191136|
NCT00210652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004147|An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy|A Double-Blind, Placebo-Controlled, Dose-Titration Study to Determine Safety, Tolerability and Preliminary Efficacy of RWJ-333369 as Adjunctive Therapy in Subjects With Treatment-Resistant Partial Seizures (With or Without Secondary Generalization) or Primarily Generalized Tonic-Clonic Seizures||SK Life Science||Completed|July 2004|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|17 Years|N/A|No|||January 2013|January 15, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00210652||191121|
NCT00198796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR #193|Enterotoxigenic E. Coli (ETEC)|Dose-Finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic E. Coli (ETEC) Challenge Strains That Express Colonization Factors CS17 and CFA/I||Johns Hopkins Bloomberg School of Public Health||Completed|September 2005|October 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||5|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00198796||192012|
NCT00194597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9558-D 02|Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III|Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III||University of Washington||Terminated|July 2004|July 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Male|18 Years|65 Years|No|||October 2008|October 21, 2008|September 13, 2005|||Illness of PI forced termination.|||https://clinicaltrials.gov/show/NCT00194597||192326|
NCT00194909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103-032|An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)|An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)||Weill Medical College of Cornell University|No|Completed|August 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2008|March 24, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194909||192303|
NCT00195949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-01-004|Laparoscopic Versus Open Pyloromyotomy for Infants With Idiopathic Hypertrophic Pyloric Stenosis|Laparoscopic Versus Open Pyloromyotomy for Infants With Idiopathic Hypertrophic Pyloric Stenosis||Children's Mercy Hospital Kansas City|No|Completed|April 2003|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|N/A|12 Weeks|No|||September 2005|April 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195949||192224|
NCT00196261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00195|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Long-Term Prediction|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Long-Term Prediction||Deutsches Herzzentrum Muenchen||Completed|January 1995|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||3500|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196261||192200|
NCT00211055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004396|A Study to Observe the Causes and Treatment of Anemia in Critically Ill Children|A Multicenter, Epidemiological, Observational Study of the Management of Anemia in Critically Ill Pediatric Patients||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2004|March 2005|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|1201|||Both|N/A|17 Years|No|||April 2013|April 15, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211055||191090|
NCT00211536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-025A6|Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration|A Randomized, Active Control, Multi-Center Study Comparing the Effect of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration on Glycemic Control and the Frequency of Severe Hypoglycemia|MIP310|Medtronic Diabetes|No|Completed|June 2002|September 2008|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|65 Years|No|||August 2011|September 19, 2011|September 13, 2005|Yes|Yes||No|April 25, 2011|https://clinicaltrials.gov/show/NCT00211536||191053|
NCT00211029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004405|A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins|An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa Therapy or Other Recombinant Erythropoietins||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2003|July 2005|Actual|July 2005|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4670|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with chronic renal disease receiving treatment with epoetin alfa or other        recombinant erythropoietins.|July 2015|July 30, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211029||191092|
NCT00211042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004393|A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment|Observational, Multicenter Study of Subjects With Pure Red Cell Aplasia Associated With r-HuEPO Treatment||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|February 2004|December 2006|Actual|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|N/A|N/A|No|Non-Probability Sample|Participants diagnosed with Pure Red Cell Aplasia (PRCA)|April 2013|April 29, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211042||191091|
NCT00212784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05935|Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)|A Phase III, Double-Blind, Randomized, Active-Controlled, Two-Armed, Multicenter, Efficacy and Safety Assessment (ACTAMESA) of Org 5222 and Olanzapine in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder||Merck Sharp & Dohme Corp.|Yes|Completed|September 2003|March 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1225|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212784||190960|
NCT00212069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR01/12/03|Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer|Serum Protein Profiling as a Predictor of Gemcitabine Sensitivity in Breast Cancer With Prior Exposure to Anthracyclines and Taxanes||National University Hospital, Singapore||Completed|March 2004|April 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||December 2013|December 10, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212069||191013|
NCT00212355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-02-2|Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.|Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.||Nobelpharma|No|Completed|March 2005|January 2009|Actual|April 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|1 Year|N/A|No|||April 2014|April 10, 2014|September 13, 2005||No||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00212355||190991|
NCT00208923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709-1997|Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies|Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies Using a Preparative Regimen of Busulfan, Cyclophosphamide, and Fludarabine||Emory University|Yes|Completed|July 1998|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||April 2012|April 5, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208923||191250|
NCT00208936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0691-1995|Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus|Phase II Study of Pre-Operative Chemotherapy With Taxol, Cisplatin, and 5-Fluorouracil Followed by G-CSF in Patients With Resectable Local-Regional Carcinoma of Esophagus||Emory University||Terminated|January 1996|||March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00208936||191249|
NCT00212745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRF #0425|Pilot Trial of a Behavioral Treatment for Epilepsy|Nonrandomized Pilot Trial of the Andrews/Reiter Behavioral Treatment for Epilepsy||Oregon Health and Science University|Yes|Active, not recruiting|February 2004|March 2010|Anticipated|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|16 Years|50 Years|No|||September 2009|September 22, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212745||190963|
NCT00208637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kai Study|He Purongo Mo Nga Kai Hei Arai i Te Matehuka – Dietary Diabetes Prevention Study for Maori|||Edgar National Centre for Diabetes Research||Completed|August 2002|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|17 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208637||191272|
NCT00208897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001850|Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?|Does Fluoxetine Reverse the Effects of Early Life Stress on the CNS Corticotropin-Releasing Factor System and Improve Psychological and Neuroendocrine Function?: A Therapy Outcome Study in Women With Childhood Abuse Experiences||Emory University|No|Completed|December 1997|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208897||191252|
NCT00209170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001092|Depression-Diabetes Mechanisms: Urban African Americans|Depression-Diabetes Mechanisms: Urban African Americans||Emory University|Yes|Completed|May 2004|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|81 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|September 14, 2005|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT00209170||191232|
NCT00209469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPRN1.OSTEO.PL.6.0|Network Osteoporosis Study|Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis||Glaser Pediatric Research Network||Active, not recruiting|July 2002|February 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|8 Years|22 Years||||September 2005|September 13, 2005|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00209469||191211|
NCT00210873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004672|An Open Label Extension of a Study of Topiramate in Chronic Migraine.|An Open-label Study of the Safety and Efficacy of Topiramate for the Prophylaxis of Chronic Migraine: Extension Study to CAPSS-276||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2004|August 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|200|||Both|18 Years|N/A|No|||May 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210873||191104|
NCT00211081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-2004|Spironolactone in Patients With Single Ventricle Heart|Impact of Spironolactone on Endothelial Function in Patients With Single Ventricle Heart||Emory University|No|Completed|November 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|September 13, 2005||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT00211081||191088|
NCT00199134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAGRANCE|FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole|FRAGRANCE Trial(Femara Reanalysed Through Genomics for Response Assessment, Calibration and Empowerment)||Jules Bordet Institute|Yes|Completed|November 2004|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Female|N/A|N/A|No|||December 2014|January 5, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00199134||191986|
NCT00194935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-636|Weekly Topotecan Therapy in Patients With Ovarian Cancer|A Phase II Trial of Weekly Topotecan As Consolidation Therapy in Ovarian Cancer Patients After Initial Chemotherapy||Weill Medical College of Cornell University||Terminated|February 2003|August 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Female|18 Years|N/A|No|||September 2006|September 12, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00194935||192301|
NCT00195169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042677|Quality of Life After Myocardial Infarction|Quality of Life After Myocardial Infarction: The Impact of Social Support||Weill Medical College of Cornell University|No|Completed|July 2001|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|213|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Convenience sample|August 2010|August 10, 2010|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00195169||192283|
NCT00195962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040107|Risk Factors of Breastfeeding Study|Identification of Risk Factors Among Breast-Fed Infants||Children's Mercy Hospital Kansas City||Completed|June 2004|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|-  Mothers of healthy infants that are breastfeeding          -  At least 24 hours post delivery          -  Mother and baby will be dismissed from the hospital together.|May 2008|December 17, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00195962||192223|
NCT00195975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00005085|Heart Rate Variability in Children With a Functional Gastrointestinal Disorder|Heart Rate Variability in Children With Abdominal Pain Related to a Functional Gastrointestinal Disorder: Relationship to Anxiety/Stress, Electrogastrography, and Rapid Water Loading||Children's Mercy Hospital Kansas City|No|Completed|June 2005|March 2009|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with IBS, FD, or IBS and FD, as well as healthy controls without these        conditions.|June 2011|June 27, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00195975||192222|
NCT00212095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR01/07/05|Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer|Phase II Study of Docetaxel Combined With Ketoconazole in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor||National University Hospital, Singapore|Yes|Completed|June 2005|June 2012|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||October 2012|October 31, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212095||191011|
NCT00212381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9218|Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia|Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN)||New York Downtown Hospital||Recruiting|September 2000|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||62|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212381||190989|
NCT00211289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09091E|Trial of Education and Compliance in Heart Dysfunction (TEACH)|Trial of Education and Compliance in Heart Dysfunction. A Study Measuring the Impact of Multi-Disciplinary Education as an Intervention to Increase Patient Concordance and the Cost Effectiveness of Treatment in Patients With Heart Dysfunction||London Health Sciences Centre||Recruiting|July 2002|December 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|383|||Both|18 Years|N/A|No|||June 2005|November 14, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211289||191072|
NCT00208689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1058-2003|Critical Congenital Heart Defect (CHD) Outcomes in Children|A Review of the Diagnosis, Treatment and Outcomes of Children With Critical Congenital Heart Defects||Emory University||Terminated|January 2004|||May 2006|Actual|N/A|Observational|N/A||||150|||Both|N/A|21 Years|No|||February 2014|February 11, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208689||191268|
NCT00212368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-02-1|Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.|Phase3,Open-label,Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.||Nobelpharma||Completed|October 2004|December 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|1 Year|N/A|No|||September 2010|September 9, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212368||190990|
NCT00209261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS022|A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)|A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate (120 μg and 240 μg) and 2 Different Daily Doses of Minirin® Tablet (0.2 mg and 2 x 0.2 mg) in Children and Adolescents With Primary Nocturnal Enuresis (PNE)|PALAT|Ferring Pharmaceuticals|No|Completed|December 2004|September 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|221|||Both|5 Years|15 Years|Accepts Healthy Volunteers|||May 2011|May 18, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209261||191227|
NCT00209521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0104|Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery|Phase 2, Randomized Study of AQUAVAN® Injection In Elective Coronary Artery Surgery With Comparison to DISOPRIVAN® Injectable Emulsion||Eisai Inc.|No|Completed|June 2002|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|21 Years|70 Years|No|||June 2010|June 10, 2010|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00209521||191207|
NCT00208650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0620-2004|Tissue Doppler Echo Imaging of Heart Function After Transplant|Non-Invasive Quantitation of Myocardial Dysfunction by Tissue Doppler/Synchronization Imaging After Orthotopic Heart Transplantation in Children||Emory University||Completed|September 2005|September 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||75|||Both|N/A|N/A|No|||November 2013|November 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208650||191271|
NCT00208663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814-2005|Validation of an Instrument to Qualitatively and Quantitatively Profile Hospitalist Workflow|Validation of an Instrument to Qualitatively and Quantitatively Profile Hospitalist Workflow||Emory University|No|Withdrawn|September 2005|December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians|April 2015|April 10, 2015|September 13, 2005||No|Resources|No||https://clinicaltrials.gov/show/NCT00208663||191270|
NCT00208910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0860-2003|Muscle Relaxation Therapy With Odorant Cue|A Study of Enhancement of Progressive Muscle Relaxation Therapy for Generalized Anxiety Disorder Through Use Of An Odorant Cue.||Emory University||Completed|November 2003|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||November 2013|November 8, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208910||191251|
NCT00209196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045836|Quality of Life in Pediatric Transplant Recipients|Health Behaviors and Quality of Life in Pediatric Solid Organ Transplant Recipients||Emory University|No|Completed|May 2005|January 2015|Actual|July 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|65|||Both|11 Years|18 Years|No|Non-Probability Sample|Male or female Patients at Children's Healthcare of Atlanta Patients at least 11 years old        and living at home for 6 months Solid organ transplant patients between 1.1.1988 and        12.31.2004|February 2015|February 10, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00209196||191231|
NCT00209209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL2004-1|Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL|Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation|MCLelderly|European Mantle Cell Lymphoma Network|Yes|Recruiting|January 2004|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|570|||Both|60 Years|N/A|No|||September 2012|September 6, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209209||191230|
NCT00209222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL2004-2|Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL|Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation||European Mantle Cell Lymphoma Network|Yes|Recruiting|July 2004|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|65 Years|No|||July 2009|September 7, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209222||191229|
NCT00209482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPRN410.PL2.02|Glaser Obesity Study|A Multi-Center, Randomized, Placebo Controlled, Double Blind Trial of Metformin in Obese Adolescents.||Glaser Pediatric Research Network||Active, not recruiting|October 2003|November 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||76|||Both|13 Years|18 Years||||November 2005|October 4, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209482||191210|
NCT00209495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-04|Effect of Paracetamol,Pregabalin and Dexamethasone on Pain and Opioid Requirements in Postoperative Patients|Effect of Paracetamol Versus Paracetamol Combined With Pregabalin Versus Paracetamol Combined With Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for Abdominal Hysterectomy.||Glostrup University Hospital, Copenhagen|Yes|Completed|June 2005|February 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|130|||Female|18 Years|75 Years|No|||February 2008|February 28, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209495||191209|
NCT00210145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2003-22|Socio-aesthetic Intervention on Body Image and Quality of Life in Women With Breast Cancer.|Impact of a Socio-aesthetic Intervention on Body Image and Quality of Life in Patients With Mastectomy or Tumorectomy for Breast Cancer.|ASE K SEIN|Institut Bergonié||Completed|October 2003|June 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Female|30 Years|75 Years|No|Non-Probability Sample|Breast cancer|October 2007|December 29, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210145||191160|
NCT00209703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0501|Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer|Feasibility Study of mFOLFOX6 (Oxaliplatin Combined With l-Leucovorin (l-LV) and 5-Fluorouracil) in Patients With Advanced Colorectal Cancer||Hokkaido Gastrointestinal Cancer Study Group||Terminated|January 2005|June 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|15 Years|75 Years|No|||April 2006|April 19, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209703||191193|
NCT00210106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2003-11|Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.|Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy. A Phase 2 Study.|ARF2003|Institut Bergonié|No|Completed|June 2003|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|53|||Both|18 Years|75 Years|No|||March 2015|March 3, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00210106||191163|
NCT00210470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRX-2 2005-A|A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer|A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck||IRX Therapeutics|No|Completed|July 2005|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|80 Years|No|||May 2012|May 22, 2012|September 13, 2005|Yes|Yes||No|January 6, 2012|https://clinicaltrials.gov/show/NCT00210470||191135|
NCT00211614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-04-00029|Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea|Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea||MetroHealth Medical Center||Terminated|July 2006|July 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||February 2007|June 20, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211614||191047|
NCT00210886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004705|A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.|A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1109|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210886||191103|
NCT00210899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005029|Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections|A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections||Basilea Pharmaceutica|No|Completed|September 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|828|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00210899||191102|
NCT00211328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA in IPT|Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).|||Manhattan Eye, Ear & Throat Hospital|No|Completed|March 2002|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|September 13, 2005||||Yes||https://clinicaltrials.gov/show/NCT00211328||191069|
NCT00194610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25398-D|Botox as a Treatment for Interstitial Cystitis in Women|Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial||University of Washington|No|Completed|May 2004|September 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||September 2012|September 12, 2012|September 13, 2005|Yes|Yes||No|December 29, 2010|https://clinicaltrials.gov/show/NCT00194610||192325|
NCT00194623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-5458-A 04|Botox as a Treatment for Chronic Male Pelvic Pain Syndrome|Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial||University of Washington||Terminated|August 2003|August 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Male|18 Years|N/A|No|||October 2007|October 17, 2007|September 13, 2005|||Reorganization of personnel forced termination.|No||https://clinicaltrials.gov/show/NCT00194623||192324|
NCT00195572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO/5FU-10|Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer|Post-Approved Phase III Study of 1-LV/5FU Therapy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2002|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|20 Years|77 Years|No|||August 2009|August 12, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195572||192252|
NCT00195585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO/5FU-11|Study Evaluating Isovorin in Colon Cancer|Post-Approved Phase III Study of 1-LV/5FU Therapy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2002|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||650|||Both|20 Years|75 Years|No|||August 2009|August 12, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195585||192251|
NCT00196638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 112 INTERPRIM|Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection|Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection.ANRS 112 INTERPRIM||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|May 2002|March 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||August 2006|August 28, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196638||192171|
NCT00212407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234|New York Blood Center National Cord Blood Program|New York Blood Center National Cord Blood Program||New York Blood Center|No|Recruiting|February 1993|December 2020|Anticipated|December 2020|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5000|||Both|N/A|N/A|No|||March 2016|March 24, 2016|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00212407||190987|
NCT00208702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-1996|Thyroid Medication and Antidepressants for Treating Major Depression|Thyroid Axis in Major Depression||Emory University|No|Completed|September 1996|July 2003|Actual|July 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|60 Years|No|||November 2015|November 16, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208702||191267|
NCT00208676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807-2004|Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease|Non-Invasive Quantitation of Myocardial Dysfunction by Tissue Doppler / Synchronization Imaging in Children With Congenital Heart Defects (CHD)||Emory University||Terminated|September 2005|January 2006||||N/A|Observational|Time Perspective: Prospective||||200|||Both|N/A|21 Years|No|||November 2013|November 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208676||191269|
NCT00209274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #0401|Pivotal Study of a Percutaneous Mitral Valve Repair System|Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVERESTIIRCT)|EVERESTIIRCT|Evalve|Yes|Active, not recruiting|May 2005|December 2014|Anticipated|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1317|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00209274||191226|
NCT00209235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00044877|Albright Hereditary Osteodystrophy: Growth Hormone Trial and Cognitive/Behavioral Assessments|Study of Growth Hormone Use in Patients With Pseudohypoparathyroidism Type 1a and Assessment of Cognitive/Behavioral Status in Albright Hereditary Osteodystrophy||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Recruiting|January 2003|December 2025|Anticipated|October 2019|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|2 Months|89 Years|No|||February 2016|February 4, 2016|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00209235||191228|
NCT00209508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-0201|2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.||Eisai Inc.||Completed|November 2002|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|40 Years|80 Years|No|||November 2008|November 6, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209508||191208|
NCT00209716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0305-2|Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.|Phase I/II Study of Docetaxel, Cisplatin and 5-fluorouracil(TPF) as Chemotherapy in Pre-treated Patients With Metastatic Esophageal Cancer.||Hokkaido Gastrointestinal Cancer Study Group|Yes|Completed|December 2003|November 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|75 Years|No|||May 2010|May 24, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209716||191192|
NCT00209729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0502|Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.|Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer||Hokkaido Gastrointestinal Cancer Study Group|Yes|Suspended|April 2005|March 2010|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|76 Years|80 Years|No|||May 2010|May 24, 2010|September 13, 2005||No|Registration is less|No||https://clinicaltrials.gov/show/NCT00209729||191191|
NCT00210158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2005-05|Intraoperative Nitrous Oxide and Postoperative Pain for Patients With Current Opioid Treatment|Effects of Intraoperative Nitrous Oxide on Postoperative Pain for Patients With Current Opioid Treatment After Vertebroplasty.|PROTOX|Institut Bergonié||Completed|January 2005|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|N/A|No|||October 2007|July 25, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00210158||191159|
NCT00210691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004291|A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder|Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 1999|February 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|273|||Both|18 Years|55 Years|No|||November 2010|November 18, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210691||191118|
NCT00216398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-9B-52030-159|Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR|A Phase IV, Multicentre, Open-Label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR||Ipsen||Completed|June 2004|December 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|18 Years|N/A|No|||October 2007|October 11, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216398||190689|
NCT00216411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-9B-52120-097|Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm|A Prospective Phase IV, Multicentre, Placebo-Controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients||Ipsen||Completed|November 2004|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||102|||Both|18 Years|N/A|No|||October 2007|October 11, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216411||190688|
NCT00211900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1367|Evaluation of Manufacturing Lot of StaphVAX|A Phase 3, Multicenter, Open-Label, Historical Comparative Study to Evaluate Immunogenicity and Safety of a Commercial Lot of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis||Nabi Biopharmaceuticals|No|Completed|March 2005|November 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|65|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211900||191026|
NCT00212160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #040572|The Role of the Omentum in the Treatment of Morbid Obesity|The Role of the Omentum in the Treatment of Morbid Obesity||Vanderbilt University|Yes|Active, not recruiting|January 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212160||191006|
NCT00194948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH069784|Treatment Choices for Improving Adherence and Outcome|Patient Preference in Primary Care Depression Treatment||Weill Medical College of Cornell University||Completed|September 2003|May 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 1, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194948||192300|
NCT00195156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-536|Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies|Phase I Trial of ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies||Weill Medical College of Cornell University||Terminated|July 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||September 2006|September 12, 2006|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00195156||192284|
NCT00195598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B-101359|Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder|Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|65 Years|No|||March 2010|April 1, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195598||192250|
NCT00195611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-100918|Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media|Observational Study of the Rhinopharyngeal Carriage of Streptococcus Pneumoniae (Sp) in Infants With Acute Otitis Media (AOM)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2005|June 2006|Actual|June 2006|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|3293|||Both|6 Months|24 Months|No|Probability Sample|Screening, Cross-Sectional, Defined Population, Prospective Study|June 2010|June 27, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195611||192249|
NCT00196651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 095 PRIMOVAC|HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection|Randomized Study on HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides (LIPO-6T) in Patients Treated Early With HAART During Primary Infection. ANRS 095 PRIMOVAC||French National Agency for Research on AIDS and Viral Hepatitis||Terminated|August 2000|February 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196651||192170|
NCT00212147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK32640 (completed)|Interaction of Cobalamin Status With Nitrous Oxide in Relation to Postoperative Cognitive Changes in the Elderly|Subtle Disturbances of Cobalamin Status||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|September 2003|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|444|||Both|60 Years|N/A|No|||November 2012|November 6, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212147||191007|
NCT00212420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0405/CEF106|Nutritional Management of Acute and Chronic Enterocutaneous Fistulae|Nutritional Management of Acute and Chronic Enterocutaneous Fistulae||London North West Healthcare NHS Trust||Recruiting|December 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212420||190986|
NCT00212433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0405/CT2|Optimisation and Performance of Reduced Preparation CT Colography|Multidetector-Row CT Colonography: Optimisation of Reduced Bowel Preparation Regimes and Diagnostic Performance in Comparison to Colonoscopy||London North West Healthcare NHS Trust||Completed|July 2004|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||120|||Both|50 Years|N/A|No|||December 2005|July 20, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00212433||190985|
NCT00211835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 04-0782|Treatment of Post-TBI Depression|Treatment of Post-TBI Depression - A Randomized Clinical Trial||Icahn School of Medicine at Mount Sinai|Yes|Completed|November 2005|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211835||191030|
NCT00212394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOD1|Tourniquet Complications in Orthopaedic Surgery|A Prospective, Epidemiological Study of the Incidence and Nature of Tourniquet Complications in Norway||Norwegian University of Science and Technology||Completed|January 2005|September 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||10|||Both|N/A|N/A|No|||June 2006|June 22, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00212394||190988|
NCT00209560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0412|A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures|A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Minor Surgical Procedures||Eisai Inc.||Terminated|October 2004|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|168|||Both|18 Years|N/A|No|||July 2014|December 22, 2014|September 13, 2005|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00209560||191204|Analysis of results from a previous fospropofol study (3000-0410) completed during the enrollment of this study indicated that the dosing regimen needed to be re-evaluated. The study was prematurely terminated after 168 subjects were randomized.
NCT00208949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0693-2002|A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF|A Randomized Comparison of Dendritic Cell Content and T-Cell Phenotype Between G-CSF(Granulocyte Colony-Stimulating Factor)or G-CSF+GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor) for the Mobilization of Normal Allogeneic Peripheral Blood Stem Cell Donors||Emory University|Yes|Terminated|September 2002|May 2012|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 17, 2012|September 13, 2005|Yes|Yes|slow accrual|No|March 22, 2012|https://clinicaltrials.gov/show/NCT00208949||191248|
NCT00209807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFD-ESC|Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder|Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial||Hospital Universitari Vall d'Hebron Research Institute||Recruiting|September 2005|April 2011|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209807||191185|
NCT00209534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0207|A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy|A Phase 2, Two Part Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy||Eisai Inc.||Completed|January 2003|February 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|85 Years|No|||December 2009|December 3, 2009|September 13, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00209534||191206|
NCT00209742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG-CAD|Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer|Randomized Phase III Clinical Study Comparing Postoperative UFT+LV, UFT+LV/UFT and UFT+LV+PSK/UFT+PSK Therapies for Stage III Colorectal Cancer||Hokkaido Gastrointestinal Cancer Study Group|Yes|Active, not recruiting|April 2005|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|340|||Both|20 Years|80 Years|No|||May 2010|May 24, 2010|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00209742||191190|
NCT00209755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ribatop - afssaps #031161|Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C|Diagnostic Value of Plasma Ribavirin Assay During the Combination Therapy « Pegylated Interferon + Ribavirin » in Chronic Hepatitis C.||Hopital A Michallon||Terminated|October 2003|July 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|18 Years|65 Years|No|||September 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209755||191189|
NCT00210171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2004-20|Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer|Multicentric Phase II Study of Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer, With :- Induction Chemotherapy by Cisplatin - Docetaxel- Concomitant Chemo-radiotherapy by Weekly Cisplatin - Docetaxel- Consolidation Chemotherapy by Docetaxel|BIB 01|Institut Bergonié||Terminated|May 2004|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|3|||Both|18 Years|70 Years|No|||October 2007|July 25, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00210171||191158|
NCT00210184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2004-18|Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer|Multicentric Phase II Trial: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years Old and More Presenting Gastric Cancer Locally Advanced or Metastatic|CEPAFIRI|Institut Bergonié||Completed|July 2004|July 2009||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|43|||Both|70 Years|N/A|No|||October 2007|December 29, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210184||191157|
NCT00210483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004567|A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents|A Randomized, Double-blind, Placebo-controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents||Janssen-Ortho LLC||Completed|July 2003|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|866|||Both|12 Years|17 Years|No|||April 2010|May 16, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210483||191134|
NCT00211354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA in RVO|Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)|||Manhattan Eye, Ear & Throat Hospital|No|Withdrawn|March 2002|April 2007|Anticipated|March 2007|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|September 13, 2005|Yes|Yes|No subjects enrolled|Yes||https://clinicaltrials.gov/show/NCT00211354||191067|
NCT00216424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEL372|Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma|An Open Label, Phase II Study of Capecitabine (Xeloda) Plus Conformal Radiotherapy for Patients With Locally Advanced, Non-Metastatic Rectosigmoid Carcinoma||James A. Haley Veterans Administration Hospital||Terminated|February 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||November 2007|November 9, 2007|September 21, 2005|||lack of accrual|No||https://clinicaltrials.gov/show/NCT00216424||190687|
NCT00216632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003211|A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)|Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)||Janssen Pharmaceutica N.V., Belgium||Completed|March 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|99|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00216632||190671|
NCT00216827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0405 INT|Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle, and the Gel Vehicle Alone in Scalp Psoriasis||LEO Pharma||Completed|November 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1485|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00216827||190656|
NCT00195182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0302006001|Psychosocial Determinants of Medication Adherence in Hypertensive African Americans|Psychosocial Determinants of Medication Adherence in Hypertensive African Americans||Weill Medical College of Cornell University|Yes|Active, not recruiting|September 2003|June 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|262|||Both|18 Years|N/A|No|Non-Probability Sample|Hypertensive African Americans|May 2008|May 15, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00195182||192282|
NCT00195195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468-101157|Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries|A Rapamune Follow-up Registry in Transplant Recipients in the Nordic Countries, "Wrap-up"||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|N/A|N/A|No|Non-Probability Sample|Transplantation patients treated with sirolimus.|January 2012|January 26, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00195195||192281|
NCT00196339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-PCA-201|A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients|A Dose-ranging Clinical Trial to Study the Efficacy and Safety of DR-2031 for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients||Teva Pharmaceutical Industries|Yes|Completed|June 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|315|||Male|18 Years|N/A|No|||August 2012|August 27, 2013|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196339||192194|
NCT00187109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO|Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy|A Phase I/II Trial of Recombinant Human Thrombopoietin in Children With Malignant Solid Tumors and Lymphoma Receiving Ifosfamide, Carboplatin and Etoposide||St. Jude Children's Research Hospital||Completed|June 2000|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|21 Years|No|||May 2007|April 8, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187109||192892|
NCT00187122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL13|Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma|Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study)||St. Jude Children's Research Hospital|No|Completed|March 1993|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|N/A|N/A|No|||April 2008|April 21, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187122||192891|
NCT00208715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1021-2002|Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.|A DOUBLE-BLIND PILOT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PROVIGIL® (MODAFINIL) AT FIXED/FLEXIBLE DOSES, IN CONJUNCTION WITH IDENTIFIED SSRIs FOR THE TREATMENT OF EXCESSIVE SLEEPINESS IN PATIENTS WITH MILD TO MODERATE DEPRESSION WITH ATTENDANT SYMPTOMS OF SLEEPINESS AND FATIGUE||Emory University||Completed|February 2003|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||November 2013|November 8, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208715||191266|
NCT00212771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05846|Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)|Long-Term Efficacy and Safety Evaluation of Asenapine (10-20 mg/Day) in With Schizophrenia or Schizoaffective Disorder, in a Multicenter Trial Using (10-20 mg/Day) as a Control|ACTAMESA|Merck Sharp & Dohme Corp.|Yes|Completed|September 2004|October 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212771||190961|
NCT00212797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05845|A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)|Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).|Hermes|Merck Sharp & Dohme Corp.|Yes|Completed|July 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|273|||Both|18 Years|70 Years|No|||November 2015|November 25, 2015|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00212797||190959|
NCT00214175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO04323|Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy|Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy||University of Wisconsin, Madison|No|Completed|June 2004|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|18 Years|N/A|No|Non-Probability Sample|Study patients will come from the population that is referred to radiotherapy for        treatment of their low grade glioma or benign brain lesion and will undergo fractionated        radiotherapy. The volunteers will be a spouse or sibling of a patient|February 2012|February 22, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00214175||190853|
NCT00214201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-125|Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation|Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation||University of Wisconsin, Madison|Yes|Completed|May 2003|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||September 2012|September 21, 2012|September 13, 2005|Yes|Yes||No|August 13, 2012|https://clinicaltrials.gov/show/NCT00214201||190852|
NCT00208962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000722|Allogeneic Cell Therapy for Adults With Hematologic Malignancies|Allogeneic Cell Therapy for Adults With Hematologic Malignancies||Emory University|Yes|Completed|September 1998|August 2013|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208962||191247|
NCT00209547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0411|Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization|A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Percutaneous Coronary (PC) Procedures||Eisai Inc.||Completed|February 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||November 2008|November 6, 2008|September 13, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00209547||191205|
NCT00209768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3702|Use of In-Line Filtration in Critically Ill Children|Randomised, Prospective Study of the Use of In-Line Filtration on the Reduction of Complication Rate in Critically Ill Children||Hannover Medical School||Completed|February 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|821|||Both|N/A|18 Years|No|||September 2008|November 28, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209768||191188|
NCT00209781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TimNet|IPTp Plus ITNs for Malaria Control in Pregnant Women|Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women||Hospital Clinic of Barcelona||Active, not recruiting|August 2003|December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||1028|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2008|February 29, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209781||191187|
NCT00215579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5631|Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence|||Duke University|No|Completed|April 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|64|||Both|18 Years|65 Years|No|||March 2012|September 19, 2014|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215579||190751|
NCT00215592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-401|Open Label, Zonegran (Zonisamide) In Partial Onset Seizures|An Open Label Study Of Zonegran (Zonisamide) In Patients With Partial Onset Seizures||Eisai Inc.||Completed|October 2005|||July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1000|||Both|18 Years|75 Years|No|||November 2015|January 6, 2016|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00215592||190750|
NCT00210496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002875|Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine|Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)||Janssen-Ortho LLC||Completed|June 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|406|||Both|18 Years|65 Years|No|||April 2010|May 16, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210496||191133|
NCT00210912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004684|A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2003|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|328|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210912||191101|
NCT00216151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG MM02-35|Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma|A Randomized Phase II Study of Bisphosphonate: Zoledronic Acid (Zometa) in the Management of Asymptomatic/Early Stage Multiple Myeloma: Hoosier Oncology Group MM02-35||Hoosier Cancer Research Network|Yes|Terminated|June 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|September 12, 2005||No|Study terminated due to low patient enrollment.|No||https://clinicaltrials.gov/show/NCT00216151||190707|
NCT00216645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004867|Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy|Open-label Study to Verify Effectiveness, Safety of Pegylated Liposomal Doxorubicin 50 mg/m2 Administered Every 4 Weeks to Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Who Have Undergone Prior Platinum-based Chemotherapy.||Janssen Pharmaceutical K.K.||Completed|January 2005|November 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|74|||Female|20 Years|79 Years|No|||March 2010|May 16, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216645||190670|
NCT00216840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0406 INT|Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis||LEO Pharma||Completed|December 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1350|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00216840||190655|
NCT00195988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDS-CZD-piokal|Comparison of Immunosuppression Protocols After LTx in Children|Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy||Children's Memorial Health Institute, Poland||Completed|September 2002|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|18 Years|No|||June 2005|November 16, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195988||192221|
NCT00196365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-PSE-305|A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain|A Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval Compared to Conventional Oral Contraceptive Therapy for Cyclic Pelvic Pain||Teva Pharmaceutical Industries|No|Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|97|||Female|18 Years|40 Years|No|||May 2014|May 9, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196365||192192|
NCT00186875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLR17|Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia|A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia||St. Jude Children's Research Hospital|No|Active, not recruiting|November 2003|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|N/A|21 Years|No|||April 2015|May 8, 2015|September 1, 2005|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00186875||192910|
NCT00187135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFE|Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration|Fentanyl-Propofol-EMLA or L.M.X4™ Technique for Bone Marrow Aspiration in Pediatric Patients - A Phase III Study||St. Jude Children's Research Hospital|No|Terminated|March 2002|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|168|||Both|2 Years|17 Years|No|||March 2010|March 3, 2015|September 12, 2005|Yes|Yes|The study was terminated due to slow accrual.|No|October 13, 2009|https://clinicaltrials.gov/show/NCT00187135||192890|All 162 participants were expected to receive three treatments. Not all participants received all three treatments. Therefore, analysis required the identification of subsets of treated participants. The trial terminated early due to slow accrual.
NCT00213408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999/026/HP|Catheter Ablation as the First Line Therapy for Typical Atrial Flutter|Catheter Ablation as the First Line Therapy for Symptomatic Typical Atrial Flutter: A Multicenter Randomized Study of Cost/Effectiveness||University Hospital, Rouen||Terminated|June 2001|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|September 13, 2005|||end of the follow-up period|No||https://clinicaltrials.gov/show/NCT00213408||190912|
NCT00213421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/014/HP|Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus|||University Hospital, Rouen||Completed|August 2001|November 2008|Actual|October 2004|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|330|||Both|18 Years|N/A|No|Non-Probability Sample|patients with compatible bullous pemphigoid clinical exam|June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213421||190911|
NCT00212810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002854|Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.|TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study||Ortho-McNeil Neurologics, Inc.||Completed|September 2005|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|385|||Both|18 Years|65 Years|No|||March 2010|May 17, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212810||190958|
NCT00212446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I123|Pilot Study to Evaluate a Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions|Pilot Study to Evaluate a Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions||St. Luke's-Roosevelt Hospital Center|No|Completed|September 2014|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 19, 2015|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00212446||190984|
NCT00214214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2003-0405|A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus|A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus||University of Wisconsin, Madison||Withdrawn|October 2005|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Both|18 Years|35 Years||||October 2015|October 6, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00214214||190851|
NCT00209794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIM|IPTi in Mozambican Infants for Malaria Prevention|The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children||Hospital Clinic of Barcelona||Active, not recruiting|September 2002|December 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1498|||Both|N/A|3 Months||||November 2006|November 15, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209794||191186|
NCT00214500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA1565520 (FAB-CL-201)|A Study of AT1001 in Patients With Fabry Disease|A Phase 2, Open-Label, Multicenter, Ascending-Dose, 12-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AT1001 in Patients With Fabry Disease||Amicus Therapeutics||Completed|September 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|14|||Male|18 Years|55 Years|No|||May 2015|May 5, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214500||190831|
NCT00214721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-RENAL-REG-062|A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis|A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis||Baxter Healthcare Corporation||Completed|February 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00214721||190814|
NCT00214708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-02-04-CG|Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?|Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? A Cluster Randomised Controlled Trial in an East London Primary Care Trust||Barts & The London NHS Trust||Active, not recruiting|January 2002|September 2004||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||200|||Both|N/A|N/A|No|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00214708||190815|
NCT00215241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5816|Risperidone Augmentation for PTSD|Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD||Duke University||Completed|April 2004|July 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|65 Years|No|||June 2006|September 18, 2014|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00215241||190775|
NCT00215254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5639-04-3R0|Quetiapine in Social Anxiety Disorder|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder||Duke University||Completed|March 2004|February 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||March 2006|December 18, 2006|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00215254||190774|
NCT00215267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS02310105|The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda|The Effect of One Versus Two Praziquantel Treatments on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria in Uganda||DBL -Institute for Health Research and Development||Completed|September 2005|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|540|||Both|8 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 19, 2008|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00215267||190773|
NCT00215930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13208|The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer|Phase II Study on the Use of Molecular Analyses-Based Customized Chemotherapy in Patients With Stage IV/IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer (NSCLC)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|February 2004|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||March 2011|December 13, 2013|September 15, 2005|Yes|Yes||No|October 8, 2010|https://clinicaltrials.gov/show/NCT00215930||190724|
NCT00215943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13043|Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)|Phase III Randomized Trial of Thalidomide/Dexamethasone vs VAD as Induction Chemotherapy for Newly Diagnosed Myeloma Patients and Evaluation of the Effects of Zoledronate on Chemotherapy Induced Apoptosis and Antigen Presentation.||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|June 2003|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||August 2013|April 1, 2014|September 15, 2005||No|Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more    effective regimens.|No|August 21, 2013|https://clinicaltrials.gov/show/NCT00215943||190723|Target accrual for planned analysis (176) was not met. Principal Investigator (PI) determined study must close due to changes in the management of newly diagnosed myeloma (emergence of new drugs, more effective regimens).
NCT00215956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12349|A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma|A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma||H. Lee Moffitt Cancer Center and Research Institute||Completed|November 2001|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||January 2009|December 20, 2013|September 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215956||190722|
NCT00216164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LYM03-64|Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64||Hoosier Cancer Research Network|Yes|Terminated|April 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|September 12, 2005||No|Study terminated due to lack of response at the first efficacy analysis|No||https://clinicaltrials.gov/show/NCT00216164||190706|
NCT00216177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232-003|Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis|Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks||Hvidovre University Hospital|Yes|Recruiting|September 2005|June 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|112|||Both|18 Years|80 Years|No|||August 2009|August 17, 2009|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00216177||190705|
NCT00216437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEL346|Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma|A Phase I Dose Escalation Study to Assess the Maximum Tolerated Dose and Feasibility of Combining Oral Capecitabine (Xeloda) and Conformal Radiotherapy (CRT) for Patients With Unresectable Hepatocellular Carcinoma, Multiple Hepatic Metastases or Cholangiocarcinoma||James A. Haley Veterans Administration Hospital||Terminated|December 2004|March 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||November 2007|November 9, 2007|September 20, 2005|||lack of accrual|No||https://clinicaltrials.gov/show/NCT00216437||190686|
NCT00216853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-03-202|A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection|A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection||Lawson Health Research Institute|No|Completed|September 2003|March 2007|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|44|||Female|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample||April 2009|April 15, 2009|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00216853||190654|
NCT00216879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0407 INT|Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis|Long-term Treatment of Scalp Psoriasis With Calcipotriol Plus Betamethasone Dipropionate Gel||LEO Pharma||Completed|February 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00216879||190652|
NCT00195637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050236|Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy|Pilot Study of the Use of Intravenous Immune Globulin in Hereditary Inclusion Body Myopathy||National Institutes of Health Clinical Center (CC)||Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|70 Years|No|||June 2015|June 6, 2015|September 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00195637||192247|
NCT00196352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSE-304|A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.|A Prospective, Multiple Site Study to Evaluate the Safety of an Extended Cycle Combination Oral Contraceptive, Seasonique, Which Utilizes Ethinyl Estradiol During the Pill-free Interval.||Teva Pharmaceutical Industries|No|Completed|May 2003|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|320|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196352||192193|
NCT00186888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET5|Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma|Protocol for the Study and Treatment of Patients With Intraocular Retinoblastoma||St. Jude Children's Research Hospital|Yes|Active, not recruiting|February 2005|November 2016|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|107|||Both|N/A|N/A|No|||May 2015|May 18, 2015|September 12, 2005|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00186888||192909|
NCT00186537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79301|Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.|Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.||Stanford University||Recruiting|September 2003|September 2010||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2006|December 1, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00186537||192935|
NCT00213434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/055/HP|Evaluation of a Mandibular Advancement Device in the Treatment of Obstructive Sleep Apnea Syndrome|Prospective Evaluation of Mandibular Advancement by Herbst Device in the Treatment of Moderate Obstructive Sleep Apnea Syndrome||University Hospital, Rouen||Completed|November 2001|June 2006|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||June 2013|June 25, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213434||190910|
NCT00213447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/056/HP|T Cell Response in Hypersensitivity Syndrome|Characterization of T Cell Response in Hypersensitivity Syndrome||University Hospital, Rouen|No|Completed|November 2002|December 2005||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|patients with Drug rash with eosinophilia and systemic symptoms|June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213447||190909|
NCT00213772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2030|Risk Factors of Porphyria Cutanea Tarda (PCT)|“Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus”||University Hospital, Strasbourg, France||Completed|May 1999|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||280|||Both|N/A|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213772||190884|
NCT00208975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1048-2001|Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab|Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability||Emory University|Yes|Terminated|July 2002|September 2011|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2012|May 25, 2012|September 13, 2005|Yes|Yes|slow accrual|No|March 16, 2012|https://clinicaltrials.gov/show/NCT00208975||191246|The protocol was closed early due to slow and poor accrual.
NCT00214240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-492|The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease|The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease||University of Wisconsin, Madison|Yes|Completed|January 2000|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214240||190849|
NCT00214526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #0602-20|Asthma Intervention Research (AIR) Trial|Multicenter Randomized Clinical Trial of the Alair System for the Bronchial Thermoplasty Treatment of Asthma||Asthmatx, Inc.|Yes|Completed|November 2002|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|September 15, 2005|Yes|Yes||No|September 8, 2010|https://clinicaltrials.gov/show/NCT00214526||190829|
NCT00214513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maintain|A Randomized Trial of Effect of Low-Cost Maintenance Training on Exercise Capacity, Quality of Life and Morbidity|Maintain. A Randomized Trial of Effect of Low-Cost Maintenance Training on Exercise Capacity, Quality of Life and Morbidity||Amager Hospital||Completed|June 2004|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|160|||Both|N/A|N/A|No|||May 2007|May 16, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00214513||190830|
NCT00214734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVATE PASS|ADVATE Post Authorization Safety Surveillance|Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study||Baxalta US Inc.||Completed|August 2004|January 2007||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|450|||Male|N/A|N/A|No|||April 2009|June 26, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00214734||190813|
NCT00214747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRU-003|An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina|An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina: Candidate Formulations||Biosyn||Active, not recruiting|March 2005|November 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||6|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|October 24, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00214747||190812|
NCT00215046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH 02-04-054 R|Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis|Vinblastine and Methotrexate in Children With Multivessel Pulmonary Vein Stenosis-A Phase II Study||Children's Hospital Boston|Yes|Completed|March 2000|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|N/A|21 Years|No|||June 2011|June 22, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00215046||190790|
NCT00215631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-165|Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?|Can Tadalafil (Cialis)® Maintain Erectile Function In Patients Treated With External-beam Radiotherapy For Prostate Cancer? A Randomized, Double-blind, Placebo-controlled Study||Erasmus Medical Center||Terminated|October 2005|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Male|18 Years|N/A|No|||April 2007|September 14, 2015|September 18, 2005|||slow recruitment|No||https://clinicaltrials.gov/show/NCT00215631||190747|
NCT00215605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-001|Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies||Exelixis||Completed|September 2005|July 2012|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215605||190749|
NCT00215618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-010|Uterine Balloon Treatment for Heavy Period Bleeding.|Clinical Evaluation of Uterine Balloon Therapy System for Menorrhagia||Ethicon, Inc.|No|Completed|March 2003|September 2008|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|30 Years|N/A|No|||January 2009|January 13, 2009|September 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215618||190748|
NCT00216450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003478|Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.|An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection||Janssen Cilag Pharmaceutica S.A.C.I., Greece||Completed|October 2004|February 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Both|18 Years|60 Years|No|||April 2010|April 22, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216450||190685|
NCT00216671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002257|Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode|Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode||Janssen Pharmaceutica N.V., Belgium|No|Completed|November 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|September 13, 2005|Yes|Yes||No|January 7, 2011|https://clinicaltrials.gov/show/NCT00216671||190668|Due to the substantial number of protocol deviations (mainly due to prohibited medication), the study did not have the required power to demonstrate non-inferiority in the per protocol population
NCT00217152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112-05|A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors|An Open Label, Prospective, Randomized, Controlled, Multicenter Study Assessing Fixed Dose vs. Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Combination With Full Dose and Reduced Dose Calcineurin Inhibitors||Mayo Clinic||Terminated|March 2005|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|70 Years|No|||December 2011|December 16, 2011|September 20, 2005|||Roche decided to prematurely terminate study.|No||https://clinicaltrials.gov/show/NCT00217152||190631|
NCT00186550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH054930-04|Group Psychotherapy for People With HIV|An Evaluation of Group Psychotherapy for People With HIV||Stanford University|No|Completed||November 2000|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|186|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186550||192934|
NCT00186901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BONEII|A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors|Diminished Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial||St. Jude Children's Research Hospital|No|Completed|July 2000|September 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|429|||Both|N/A|N/A|No|||December 2011|December 6, 2012|September 12, 2005||No||No|December 20, 2011|https://clinicaltrials.gov/show/NCT00186901||192908|
NCT00213473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/001/HP|Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study|Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study||University Hospital, Rouen|No|Completed|June 2001|May 2006||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|N/A|No|Non-Probability Sample|patient with Acquired haemophilia|June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213473||190907|
NCT00213811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2899|Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults|Bardet-Biedl Syndrome: Clinical and Genetic Epidemiology Study in the Adults||University Hospital, Strasbourg, France||Completed|June 2003|||||N/A|Observational|N/A||||40|||Both|16 Years|N/A||||August 2008|August 7, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213811||190881|
NCT00213824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142|A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis|A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis||University Hospital, Strasbourg, France||Terminated|February 2004|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|79|None Retained|tissue (skeletal muscle)|Both|18 Years|N/A|No|Non-Probability Sample|University Hospital, Strasbourg, France|March 2015|March 26, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213824||190880|
NCT00213746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/011/HP|Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)|Prediction of Left Ventricular Function Changes Using Low Dose Dobutamine Gated SPECT in Patients Referred for Viability Assessment: The DOGS (DObutamine Gated Spect)Study.||University Hospital, Rouen|No|Completed|October 2003|December 2005||||N/A|Observational|Time Perspective: Prospective||||75|||Both|18 Years|80 Years|No|Non-Probability Sample|The study population consists with patients with documented coronary artery disease and        left ventricular dysfunction (LVEF < 50%)referred to aNuclear Medicine department for        myocardial viability assessment|June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213746||190886|
NCT00213759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2712|Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF|Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF||University Hospital, Strasbourg, France||Completed|March 2002|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|N/A|35 Weeks|No|||November 2007|November 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213759||190885|
NCT00214266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0209|A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation|A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation||University of Wisconsin, Madison|Yes|Completed|January 2005|September 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214266||190847|
NCT00214760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBL_2005_01|Polymethyl Methacrylate and (PEGT/PBT) Centralizer by the Uncemented BIHAPRO THP|Phase 3 Randomised, Prospective Study Comparing the PMMA and the Resorbable PEGT/PBT Centralizer by the Uncemented BIHAPRO Total Hip Prosthesis||Biomet Nederland BV|No|Terminated|May 2005|September 2011|Anticipated|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||November 2009|January 29, 2010|September 16, 2005||No|On of the liners has been taken from the market|No||https://clinicaltrials.gov/show/NCT00214760||190811|
NCT00215059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH X00-09-050|Measurement of Angiogenic Related Growth Factors in Urine and Blood From Patients With Pulmonary Vein Stenosis|Measurement of Angiogenic Related Growth Factors in Urine and Blood From Patients With Multivessel Pulmonary Vein Stenosis||Children's Hospital Boston|No|Terminated|August 2000|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|patients with pulmonary vein stenosis|August 2012|August 1, 2012|September 15, 2005||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00215059||190789|
NCT00215293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G000019|Cervical I/F Cage for Anterior Cervical Fusion|A Randomized Multi-Center Study to Evaluate the Safety and Efficacy of the Cervical I/F Cage for Anterior Cervical Fusion||DePuy Spine|No|Completed|August 2000|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|70 Years|No|||May 2014|May 22, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215293||190771|
NCT00215020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-04-060|Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease|Phase I Evaluation of Urinary Isoprostane Levels in Pediatric Patients With Inflammatory and Non-Inflammatory Gastrointestinal Disease||Children's Hospital Boston|No|Completed|September 2003|June 2006|Actual|June 2006|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|Samples Without DNA|Specimens stored at -80 in the Center for IBD at Boston Children's Hospital.|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with known or suspected IBD.|January 2016|January 26, 2016|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00215020||190792|
NCT00215033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-089|Relationship Between EBV and PTLD|Relationship Between Quantitative Epstein-Bar Viral(EBV) Titres and Post-Transplant Lymphoproliferative Disease||Children's Healthcare of Atlanta|No|Terminated|April 2005|May 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|160|||Both|N/A|N/A|No|Non-Probability Sample|patients undergone pediatric heart transplant|May 2007|March 14, 2012|September 20, 2005|||sufficient data gathered to support conclusion|No||https://clinicaltrials.gov/show/NCT00215033||190791|
NCT00215995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13426|Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas|A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|July 2003|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||May 2007|January 12, 2012|September 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215995||190719|
NCT00216008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13946|Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.|Phase II Pharmacogenomic Study of Neoadjuvant Pre-irradiation Docetaxel and Cisplatin, Followed by Neoadjuvant Concomitant Docetaxel, Cisplatin and Irradiation, Followed by Surgery (CD-CDR-S) in Adult Patients With Operable Adenocarcinomas of the Esophagus or Gastroesophageal Junction||H. Lee Moffitt Cancer Center and Research Institute||Terminated|July 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|N/A|No|||July 2009|November 21, 2013|September 19, 2005|||IRB Closure|No||https://clinicaltrials.gov/show/NCT00216008||190718|
NCT00215969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0104|Prospective Study in Pregnant Women With Hypercoagulopathy|Prospective Study of Hypercoagulation in Pregnant Women||Hillerod Hospital, Denmark||Recruiting|January 2004|October 2007||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|February 1, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00215969||190721|
NCT00215982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13424|Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer|A Phase II Study of Capecitabine in Combination With Irinotecan and Oxaliplatin (Eloxatin) in Adult Patients With Advanced Colorectal Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|December 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||September 2010|November 21, 2013|September 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215982||190720|
NCT00216463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012CS3|Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels|A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 301012 Administered to Hypercholesterolemic Subjects||Sanofi||Completed|August 2005|August 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|65 Years|No|||December 2013|December 2, 2013|September 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00216463||190684|
NCT00211432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pseudovitellium Detachment|Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)|||Manhattan Eye, Ear & Throat Hospital|No|Completed|April 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211432||191061|
NCT00216658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004876|Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -|Open Label Study to Confirm Effectiveness, Safety and Pharmacokinetics of Fentanyl Transdermal Matrix Patch, in Japanese Patients With Cancer Pain Who Have Had a Minimum Amount of Morphine Therapy, Such as Equal to Less Than 45 mg/Day of Oral Morphine or Oxycodone Equal to Less Than 30 mg/Day.||Janssen Pharmaceutical K.K.||Completed|December 2004|September 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|87|||Both|20 Years|N/A|No|||January 2011|January 20, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216658||190669|
NCT00216866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-02-191|The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis|A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity||Lawson Health Research Institute||Completed|September 2002|March 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||September 2006|September 6, 2006|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00216866||190653|
NCT00217178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HART, CIHR Grant # MCT 44159|Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)|Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)||McMaster University||Active, not recruiting|January 2000|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||900|||Both|55 Years|N/A|No|||October 2004|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00217178||190629|
NCT00196001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.4204|ACTH Stimulation and G Protein|G Protein Expression in Response to ACTH Stimulation Testing||Children's Mercy Hospital Kansas City||Recruiting|July 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|6 Years|60 Years|Accepts Healthy Volunteers|||February 2006|February 16, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196001||192220|
NCT00196014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1989|Individual Workload Perception Scale - Revised (IWPS-R)|Evaluation of a Tool to Measure a Nurse's Individual Perception of Workload|IWPS-R|Children's Mercy Hospital Kansas City|Yes|Enrolling by invitation|October 2001|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12000|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|LPNS and Registered Nurses|September 2005|July 31, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196014||192219|
NCT00198133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412-18; IUCRO-0088|Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma|Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma||Indiana University||Completed|January 2005|May 2012|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 12, 2005||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00198133||192062|
NCT00213486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/141/HP|Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial|Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial||University Hospital, Rouen||Completed|June 2002|December 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Both|18 Years|N/A|No|||September 2005|October 27, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213486||190906|
NCT00213850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2667|Reference Values for Respiratory Resistance Measured by the Interrupter Technique in Adults|Reference Values for Respiratory Resistance Measured by the Interrupter Technique in Adults||University Hospital, Strasbourg, France||Completed|January 2002|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|122|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213850||190878|
NCT00213785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2558|A Study of Plasmatic Concentrations of Endothelin-1 (ET1), Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP) in Acute Ischemic Stroke.|A Study of Plasmatic Concentrations of Endothelin-1 (ET1), Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP) in Acute Ischemic Stroke.||University Hospital, Strasbourg, France||Completed|November 2001|March 2004||||N/A|Observational|Time Perspective: Prospective|||Actual|14|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213785||190883|
NCT00213798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2731|Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients|Detection of Plasma DNA by Allelotyping in Non Small Cell and Small Cell Lung Cancer Patients. Evolution During Treatment and Follow-up.||University Hospital, Strasbourg, France||Completed|December 2003|August 2011|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213798||190882|
NCT00213837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3096|Reconstruction Implant Bone After Removal Using Porous Titanium Prosthesis|Reconstruction Implant Bone (Anterior Mandibular Arch) After Removing Using Porous Titanium Prosthesis in ENT Surgery||University Hospital, Strasbourg, France|No|Completed|October 2003|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|18 Years|N/A|No|||February 2009|February 24, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213837||190879|
NCT00209586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0409|A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy|A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Flexible Bronchoscopy Procedures||Eisai Inc.||Terminated|September 2004|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|September 13, 2005|||Patient enrollment was stopped prior to completion of the study in order to re-evaluate the    dosing regimen.|||https://clinicaltrials.gov/show/NCT00209586||191202|
NCT00214539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #0903-27|Research in Severe Asthma (RISA) Trial|Multicenter Randomized Clinical Trial of Bronchial Thermoplasty With the Alair System for the Treatment of Severe Asthma||Asthmatx, Inc.|Yes|Completed|April 2004|August 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|No|||September 2011|September 30, 2011|September 15, 2005|Yes|Yes||No|September 8, 2010|https://clinicaltrials.gov/show/NCT00214539||190828|
NCT00214552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-USA-38|Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.|A Double-blind Placebo Controlled Clinical Trial to Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.||Associated Scientists to Help Minimize Allergies|No|Completed|September 2002|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|80|||Both|18 Years|85 Years|No|||June 2011|June 22, 2011|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00214552||190827|
NCT00214773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPSVI CSP|Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)|MPS VI Clinical Surveillance Program (CSP)||BioMarin Pharmaceutical|No|Recruiting|July 2005|December 2020|Anticipated|July 2020|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Urine and serum|Both|N/A|N/A|No|Non-Probability Sample|All patients with a confirmed diagnosis of MPS VI disease may participate in the CSP. It        is not a requirement that the patients enrolled in the CSP receive Galsulfase 1mg/kg to        participate as this is an observational program.|March 2016|March 14, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00214773||190810|
NCT00214786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #003-040|Pancreatic Islet Cell Transplantation|Pancreatic Islet Cell Transplantation - A Novel Approach to Immunosuppression and Validation of Remote Site Islet Cell Processing, Islet Cell Culture and Two-Layer Preservation||Baylor Research Institute|Yes|Completed|April 2005|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||May 2014|May 15, 2014|September 14, 2005|Yes|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00214786||190809|Three of the four patients voluntarily withdrew from the study.
NCT00215072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-090|Death Following Congenital Heart Surgery|Death Following Congenital Heart Surgery||Children's Healthcare of Atlanta|No|Terminated|July 2005|February 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients in the congenital surgery database|May 2007|March 14, 2012|September 20, 2005|||insufficient number of patient charts to support hypothesis|No||https://clinicaltrials.gov/show/NCT00215072||190788|
NCT00215085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-091|Cardiac Tumors in Children|Cardiac Tumors in Children||Children's Healthcare of Atlanta|No|Terminated|May 2005|November 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|Patients in the congenital surgery database          -  Children who have been treated for a primary cardiac tumor|May 2007|March 14, 2012|September 20, 2005|||insufficient data|No||https://clinicaltrials.gov/show/NCT00215085||190787|
NCT00215280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV917090205|Epidemiology and Control of Mansonella Perstans Infection in Uganda|Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda||DBL -Institute for Health Research and Development||Completed|November 2005|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Both|5 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 19, 2007|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00215280||190772|
NCT00215644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 72000-032|MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)|Randomized Phase II Open-label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-gastric Adenocarcinoma||Merck KGaA|No|Completed|August 2005|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00215644||190746|
NCT00215670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1006|Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)|A Randomized, Double-Masked, Multi-Center Trial of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Intravitreal Injections of Pegaptanib Sodium (Anti-Vegf Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)||Eyetech Pharmaceuticals||Completed|November 2002|May 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Both|50 Years|N/A|No|||May 2006|May 2, 2006|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00215670||190744|
NCT00215683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS12A|An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer|An Open-Label, Multi-Centre, Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer.||Ferring Pharmaceuticals|Yes|Completed|February 2005|November 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|137|||Male|18 Years|N/A|No|||March 2015|March 12, 2015|September 20, 2005|Yes|Yes||No|November 12, 2010|https://clinicaltrials.gov/show/NCT00215683||190743|
NCT00216190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-001|A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation|A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation||Hospira, Inc.|No|Completed|March 2005|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00216190||190704|
NCT00211172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 U18 HS01391-04|HMO Research Network CERT: Acute Myocardial Infarction|The HMO Research Network CERT: Acute Myocardial Infarction||Kaiser Permanente|No|Completed|October 2003|May 2009|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|836|||Both|18 Years|N/A|No|||July 2011|October 7, 2014|September 13, 2005||No||No|August 5, 2009|https://clinicaltrials.gov/show/NCT00211172||191081|
NCT00212251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012546|Promoting Postpartum Weight Loss in Overweight Women|Promoting Postpartum Weight Loss in Overweight Women||Duke University||Completed|August 2004|April 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||450|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|July 14, 2014|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00212251||190999|
NCT00216892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCB 0402 INT|Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris|Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris||LEO Pharma||Completed|April 2005|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1032|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00216892||190651|
NCT00216905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mulert_LMU_EEG/fMRI|Simultaneous Measurement of Electroencephalography (EEG) and Functional Magnetic Resonance Imaging (fMRI) in Patients With Alcoholism|Neurobiological Correlates of Disturbed Cognitive Function in Patients With Alcoholism - Simultaneous Measurement With EEG and fMRI||Ludwig-Maximilians - University of Munich||Completed|October 2004|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|60 Years|No|Non-Probability Sample|patients with alcohol use disorder|May 2010|June 1, 2010|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00216905||190650|
NCT00211978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi 6402|EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)|EPIC (Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of PhosLo on Phosphorus Levels in Subjects With Chronic Kidney Disease||Nabi Biopharmaceuticals|No|Completed|May 2005|October 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211978||191020|
NCT00186173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-0851-05/05|Sports to Prevent Obesity: Feasibility and Pilot RCT|Sports to Prevent Obesity: Feasibility and Pilot RCT||Stanford University|No|Completed|November 2004|||February 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 11, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186173||192963|
NCT00186576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT128|Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders|Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)||Stanford University||Completed|December 2001|July 2010|Actual|March 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||October 2010|October 13, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00186576||192932|
NCT00198393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0301|Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV|Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV||Intergroupe Francophone de Cancerologie Thoracique|No|Completed|November 2004|December 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|80 Years|No|||April 2010|April 28, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00198393||192043|
NCT00198406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0202|A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.|A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.||Intergroupe Francophone de Cancerologie Thoracique||Completed|September 2002|December 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1653|||Both|70 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198406||192042|
NCT00198120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH068627|Safety and Effectiveness of D-Cycloserine in Children With Autism|A Randomized Controlled Trial of D-Cycloserine in Autism||National Institute of Mental Health (NIMH)||Active, not recruiting|February 2004|September 2010|Anticipated|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Years|12 Years|No|||October 2008|October 7, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198120||192063|
NCT00198354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0002|Stage I/II NSCLC Perioperative Chemotherapy|Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC||Intergroupe Francophone de Cancerologie Thoracique|Yes|Completed|May 2001|December 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|530|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00198354||192046|
NCT00214279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-040|MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal|MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal||University of Wisconsin, Madison||Completed|May 2002|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|55 Years|N/A|No|||June 2012|June 22, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00214279||190846|
NCT00214292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2002-0211|Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy|A Pilot Study of Intraoperative Margin Assessment Comparing Optical Spectroscopy and Frozen Section Analysis for Ductal Carcinoma In Situ of the Breast||University of Wisconsin, Madison||Completed|May 2005|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00214292||190845|
NCT00214227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO05305|ATM Variants in Radiotherapy Patients|ATM Variants in Radiotherapy||University of Wisconsin, Madison||Completed|December 2007|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples With DNA|direct sequence analysis of all exons and intron-exon junctions of the ATM gene. DNA will be      isolated from lympocytes using the PAX blood DNA system.|Male|18 Years|N/A|No|Non-Probability Sample|Patients who have been enrolled on RO02803.|June 2013|June 18, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214227||190850|
NCT00213863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3097|Implantation of Porous Titanium Prosthesis in Laryngeal Surgery|Implantation of Porous Titanium Prosthesis in Laryngeal Surgery||University Hospital, Strasbourg, France|No|Recruiting|December 2010|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213863||190877|
NCT00209885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMA-LC01|Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy|||Hvidovre University Hospital||Not yet recruiting|October 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00209885||191179|
NCT00209898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12952|Hepatitis C Treatment of Inmates|Hepatitis C Treatment of Inmates. A Randomized, Open-label Study Evaluating the Feasibility, Safety and Efficacy of Treatment With Peginterferon Alfa-2a in Combination With Ribavirin in Inmate Patients With Chronic Hepatitis C|PEGPRI|Haukeland University Hospital|No|Terminated|August 2003|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||June 2003|March 19, 2015|September 13, 2005||No|Low inclusion rate|No||https://clinicaltrials.gov/show/NCT00209898||191178|
NCT00210574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002872|A Pilot Study of Topiramate in Childhood Absence Epilepsy|A Pilot Study of Topiramate in Childhood Absence Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|4 Years|9 Years|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210574||191127|
NCT00210301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS|Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS||Institute for Clinical Research||Recruiting|January 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|20 Years|65 Years|No|||August 2005|September 6, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210301||191148|
NCT00210561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002863|A Study of the Effectiveness and Safety of Tramadol HCl/Acetaminophen Compared to Placebo in Treating Acute Low Back Pain|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) for the Treatment of Acute Low Back Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|March 2005|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|65 Years|No|||April 2010|June 8, 2011|September 13, 2005|||Study was stopped shortly after initiation due to change in strategic direction of the    company; no safety concerns were observed that impacted this decision.|||https://clinicaltrials.gov/show/NCT00210561||191128|
NCT00215657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS07A|Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients||Ferring Pharmaceuticals|No|Terminated|March 2003|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|131|||Male|18 Years|N/A|No|||May 2011|May 18, 2011|September 20, 2005|Yes|Yes|The doses were not effective in maintaining testosterone suppression|No|January 22, 2009|https://clinicaltrials.gov/show/NCT00215657||190745|
NCT00216021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG BRE03-60|Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer|A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60||Hoosier Cancer Research Network|Yes|Completed|March 2004|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00216021||190717|
NCT00211991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1369|Evaluation of Consistency of StaphVAX Manufacturing Lots|A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Compare Immunogenicity and Safety Between Three Commercial Lots of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Normal, Healthy, Adult Volunteers||Nabi Biopharmaceuticals||Completed|April 2005|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||354|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 10, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211991||191019|
NCT00208832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0784-2003|A Randomized Controlled Trial to Improve Medication Compliance Among Patients With Coronary Heart Disease|A Randomized Controlled Trial to Improve Medication Compliance Among Patients With Coronary Heart Disease||Emory University||Completed|March 2004|March 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind||||440|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208832||191257|
NCT00208845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0996-2001|Hypernet- Hypertension Screening|Hypernet- Hypertension ED Surveillance||Emory University|No|Terminated|September 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|adult ED patients|November 2013|November 19, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208845||191256|
NCT00211731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0053|Preventing Recurrent Stroke in Minority Populations|Improving the Delivery of Effective Care to Minorities||Icahn School of Medicine at Mount Sinai||Completed|September 2002|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|87|||Both|40 Years|N/A|No|||December 2007|November 10, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211731||191038|
NCT00208559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00936|Ziprasidone in Children With Autism: A Pilot Study|Ziprasidone in Children With Autism: A Pilot Study||Drexel University|Yes|Completed|February 2002|August 2006|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|12 Years|18 Years|No|||June 2010|June 15, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208559||191278|
NCT00208572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-71013|Treatment of Citalopram for Anxiety Disorders Following a Traumatic Brain Injury|A Randomized Placebo-Controlled Trial of Citalopram for Anxiety Disorders Following Traumatic Brain Injury||Walter Reed Army Medical Center||Recruiting|November 2003|February 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|104|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 4, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208572||191277|
NCT00197886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-7041-20|Dose of Norepinephrine and the Concentration of L-Lactate in the Rectum and Stomach in Patients With Septic Shock.|||Herlev Hospital||Completed|October 2004|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||September 2006|September 19, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00197886||192081|
NCT00197899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 04015|Low-Dose Endotoxemia and the Acute Phase Response|||Herlev Hospital||Active, not recruiting|March 2004|January 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Male|18 Years|40 Years|No|||September 2005|December 12, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197899||192080|
NCT00198757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDI2002-01|Efficacy of 2 Diet Plans Designed for People With Type II Diabetes on Weight and Health Measures|Efficacy of 2 Diet Plans Designed for People With Type II Diabetes on Weight and Health Measures||Johns Hopkins Bloomberg School of Public Health||Completed|July 2002|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198757||192015|
NCT00198380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0401|Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature|Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)||Intergroupe Francophone de Cancerologie Thoracique|No|Completed|April 2005|December 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||April 2010|April 28, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00198380||192044|
NCT00199069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL09|German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)|Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)||Johann Wolfgang Goethe University Hospitals||Completed|April 1993|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||720|||Both|15 Years|65 Years|No|||May 2008|May 16, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199069||191991|
NCT00209352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IR 420|Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant|Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant||Fred Hutchinson Cancer Research Center||Completed|June 1985|July 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||120|||Both|10 Years|N/A|No|||December 2007|December 17, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209352||191220|
NCT00209365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/07 Starch granules ITEM|The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit|||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|September 2005|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||24|||Both|18 Years|55 Years|No|||May 2007|May 15, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209365||191219|
NCT00214253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-529|Islet Transplantation in Type 1 Diabetic Patients|Islet Transplantation in Type 1 Diabetic Patients Using a Steroid-free Immunosuppression Protocol and Thiazolidinedione Insulin Sensitizers||University of Wisconsin, Madison||Completed|February 2002|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214253||190848|
NCT00209911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|susette_phd|Study of the Effect of Cardioversion on Cardiac Volume in Patients With Persistent Atrial Fibrillation|Atrial and Ventricular Volume and Function In Atrial Fibrillation - A Magnetic Resonance Imaging Study||Hvidovre University Hospital||Terminated|January 2001|January 2003||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||60|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2001|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209911||191177|
NCT00210314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG20|Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma|Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma||International Extranodal Lymphoma Study Group (IELSG)||Completed|July 2003|December 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|75 Years|No|||March 2015|March 27, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00210314||191147|
NCT00210327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG25A|VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy|Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142)||International Extranodal Lymphoma Study Group (IELSG)|Yes|Completed|July 2005|April 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00210327||191146|
NCT00210795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004627|A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia|A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Anemia of Chronic Disease (ACD) Receiving Epoetin Alfa (PROCRIT�)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|June 2004|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Both|65 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005|||This study was stopped due to slow enrollment after enrolling only 12 of 80 patients over 14    months time.|||https://clinicaltrials.gov/show/NCT00210795||191110|
NCT00198042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22129|Bone Tunnel Widening Following ACL Reconstruction|Bone Tunnel Widening Following ACL Reconstruction||Hospital for Special Surgery, New York||Recruiting|June 2004|December 2008||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2006|June 20, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198042||192069|
NCT00198614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16C-9|Carvedilol Versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery|A Comparison of the Effectiveness of Carvedilol Versus Metoprolol for Atrial Fibrillation Appearing After Off-Pump Coronary Bypass Surgery in the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT)||Ministry of Health, Labour and Welfare, Japan||Completed|January 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||650|||Both|20 Years|89 Years|No|||February 2007|February 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198614||192026|
NCT00199225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC012RUP/1/04|Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers|Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers: A Randomised, Parallel, Placebo and Positive Controlled Study||J. Uriach and Company||Completed|February 2005|July 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||160|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|December 14, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199225||191980|
NCT00194675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01166|TRADE-Testosterone Replacement and Dutasteride Effectiveness|Testosterone Replacement and Dutasteride Effectiveness (TRADE)|TRADE|University of Washington|Yes|Completed|March 2005|December 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Male|50 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|September 13, 2005|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT00194675||192321|
NCT00195208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B1-332|Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis|A Randomized, 2-Period, Crossover, Pharmacodynamic Comparability Study Comparing A Pantoprazole Spheroid Formulation to the Currently Marketed Tablet Formulation in Subjects With GERD and a History of Erosive Esophagitis.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|97|||Both|18 Years|65 Years|No|||February 2013|February 7, 2013|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00195208||192280|
NCT00195221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A-101657|Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B|A Retrospective Study to Describe the Incidence of Moderate to Severe Allergic Reactions to Factor IX in Patients With Hemophilia B||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2005|November 2007|Actual|||Phase 4|Observational|Time Perspective: Retrospective||||166|||Both|N/A|N/A|No|||December 2007|December 3, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195221||192279|
NCT00195624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050242|Alemtuzumab to Treat Severe Aplastic Anemia|A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2005|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|2 Years|N/A|No|||December 2015|December 30, 2015|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00195624||192248|
NCT00237250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2357|Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance|Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance||Novartis||Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|171|||Both|18 Years|80 Years||||May 2012|May 4, 2012|October 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00237250||189134|
NCT00237497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375-EC301|Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia|A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ramelteon Compared to Placebo With Zopiclone as a Reference Arm in Adults With Chronic Insomnia||Takeda|No|Completed|July 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|275|||Both|18 Years|64 Years|No|||January 2012|January 31, 2012|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00237497||189115|
NCT00237744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3709-I|Brain and Coordination Changes Induced By Robotics and FES Treatment Following Stroke|CNS Plasticity Induced By Motor Learning Technologies Following Stroke||VA Office of Research and Development||Completed|April 2005|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 3, 2014|October 7, 2005||No||No|November 8, 2013|https://clinicaltrials.gov/show/NCT00237744||189096|
NCT00237757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3225-R|Rehabilitation Team Functioning and Patient Outcomes|Rehabilitation Team Functioning and Patient Outcomes||VA Office of Research and Development|No|Completed|January 2002|September 2009|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|31|||Both|N/A|N/A|No|||July 2013|July 2, 2013|October 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00237757||189095|
NCT00238069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-1866|Effect of CPAP (Continuous Positive Airway Pressure) on Lung Function in Asthmatics With Sleep Apnea|Effect of CPAP (Continuous Positive Airway Pressure) on Airway Inflammation in Asthmatics With Sleep-Disordered Breathing: A Pilot Study||National Jewish Health||Completed|December 2004|August 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00238069||189072|
NCT00238316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP1|Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density|A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density||Canadian Cancer Trials Group||Completed|December 2000|February 2009|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|68|||Female|N/A|N/A|No|||September 2011|May 30, 2013|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238316||189056|
NCT00238329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445593|PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma|Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 2001|June 2007||December 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238329||189055|
NCT00194883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0596-363|Effect of Cytokines on Growth of Children With Chronic Kidney Failure|Cytokines and Growth in Children With CRI and ESRD||Weill Medical College of Cornell University||Suspended|April 1997|May 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|6 Months|21 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194883||192305|
NCT00195104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603-887|Arsenic Trioxide in Combination With Cytarabine in Patients With High-Risk MDS and Poor-Prognosis AML|Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-Risk Myelodysplastic Syndrome and Poor-Prognosis Acute Myelogenous Leukemia||Weill Medical College of Cornell University||Completed|July 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|No|||October 2007|October 2, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00195104||192288|
NCT00195442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082A-100690|Study Evaluating Refacto For Pharmacovigilance|Pharmacovigilance Evaluation Of Refacto In Usual Care Settings||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|July 1999|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|288|||Male|N/A|N/A|No|Non-Probability Sample|Patients with hemophilia A|February 2011|February 7, 2011|September 13, 2005|No|Yes||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00195442||192262|
NCT00195455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0753T-101538|Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.|A Prospective Open Label Study to Evaluate Vasomotor Symptoms Control and Bleeding Patterns With a Continuous Regimen of a New Progestin Trimegestone 0.125 mg and 17 b Estradiol 1 mg (Totelle),as HT on Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2005|March 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|133|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 17, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195455||192261|
NCT00195468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-101116|Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus|A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2004|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|280|||Both|18 Years|N/A|No|||December 2007|March 7, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00195468||192260|
NCT00195884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-44155|Diabetes Aerobic and Resistance Exercise (DARE) Study|Resistance Exercise as an Intervention in Type 2 Diabetes Mellitus||Ottawa Hospital Research Institute|No|Completed|September 1999|April 2011|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|251|||Both|40 Years|70 Years|No|||January 2013|January 22, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00195884||192229|
NCT00195897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001-CHB|Early Assessment of Anthracycline-Induced Cardiotoxicity (CARDIOTOX)|Early Assessment of Anthracycline-Induced Cardiotoxicity: Usefulness of Biochemical Markers and Ventricular Function Assessment.||Centre Henri Becquerel||Not yet recruiting|October 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||40|||Both|18 Years|70 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195897||192228|
NCT00196196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPV-US03-001|A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.|A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.||Codman & Shurtleff|No|Completed|September 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|274|||Both|N/A|N/A|No|||February 2011|May 22, 2012|September 12, 2005|Yes|Yes||No|November 4, 2008|https://clinicaltrials.gov/show/NCT00196196||192205|
NCT00196573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC-AOSSM-1|Subacromial Decompression Versus Subacromial Bursectomy for Patients With Rotator Cuff Tendinosis|A Randomized Clinical Trial Comparing the Effectiveness of Subacromial Decompression (Acromioplasty) Versus Subacromial Bursectomy (no Acromioplasty) in the Arthroscopic Treatment of Patients With Rotator Cuff Tendinosis||University of Western Ontario, Canada||Active, not recruiting|November 2003|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|114|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196573||192176|
NCT00197405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-FRT-001|Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma|Comparative Study of Fecal RNA Test With Immunochemical Fecal Occult Blood Test for Detecting Colorectal Cancer and Adenoma||Hamamatsu University|Yes|Recruiting|August 1999|December 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|400|Samples Without DNA|freces, biopsy tissue samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|outpatients and inpatients of hospitals, subjects of parimary care clinics|August 2009|August 3, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197405||192112|
NCT00197730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD43688|Trial of Vitamins Among Children of HIV-infected Women|Trial of Vitamins Among Children of HIV-infected Women||Harvard School of Public Health|Yes|Completed|June 2004|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2387|||Both|6 Weeks|24 Months|No|||August 2009|August 20, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197730||192093|
NCT00197743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD32257|Trial of Vitamins in HIV Progression and Transmission|Trial of Vitamins in HIV Progression and Transmission||Harvard School of Public Health|Yes|Completed|April 1995|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1085|||Female|18 Years|N/A|No|||November 2010|November 9, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00197743||192092|
NCT00198029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23034|An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study|An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study||Hospital for Special Surgery, New York|Yes|Completed|October 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|32|||Both|45 Years|95 Years|No|||May 2013|May 3, 2013|September 13, 2005|No|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00198029||192070|
NCT00198887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.02.08.30.A2|Operations Research to Improve Newborn Health|Operations Research to Improve Newborn Health and Survival in the (INHP-II) Area of CARE/India||Johns Hopkins Bloomberg School of Public Health||Completed|January 2003|October 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|59651|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2007|July 3, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198887||192005|
NCT00198900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA2000-01|Diabetes Knowledge Assessment|Use of Modified Foods in the Dietary Treatment of Type II Diabetes Mellitus: Knowledge Assessment||Johns Hopkins Bloomberg School of Public Health||Completed|January 2000|March 2000||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2000|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198900||192004|
NCT00194688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-8470-V 04|Breath Ammonia Method for H. Pylori Detection: Phase II|Breath Ammonia Method for H. Pylori Detection: Phase II||University of Washington||Completed|March 2003|June 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||278|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 2, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194688||192320|
NCT00194701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-4765-D09|Exercise to Improve Sleep in Heart Failure|Exercise to Improve Sleep in Heart Failure||University of Washington||Completed|April 1998|March 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||152|||Both|18 Years|N/A|No|||January 2008|January 2, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194701||192319|
NCT00195260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A1-100|Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors|Phase I Dose-Escalation Study Of Oral SKI-606 In Subjects With Advanced Malignant Solid Tumors||Pfizer|No|Completed|October 2004|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|151|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|September 12, 2005|Yes|Yes||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00195260||192276|
NCT00195273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H-101466|Study Evaluating Sirolimus in Kidney Transplant Recipients|A Randomized Open-Label Study Comparing the Efficacy and Safety of Sirolimus Combined With Daclizumab, Mycophenolate and Corticosteroids vs Cyclosporine, Mycophenolate and Corticosteroids in Renal Allograft Recipients Receiving Kidneys From Older Donors||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|September 12, 2005|Yes|Yes||No|July 31, 2009|https://clinicaltrials.gov/show/NCT00195273||192275|
NCT00195234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6112K2-100|Study Evaluating Vaccine in Adults With HIV|A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV CTL Multi-Epitope Peptide Vaccine Formulated With RC529-SE and GM-CSF Given to HIV-1 Positive Adults on Stable HAART.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2004|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2007|December 3, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00195234||192278|
NCT00195247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3162K1-101|Study Evaluating TTI-237 in Advanced Malignant Solid Tumors|A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|May 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||March 2007|March 22, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00195247||192277|
NCT00238342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445437|Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass|Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis||National Cancer Institute (NCI)||Active, not recruiting|October 2005|||October 2007|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|2000|||Female|18 Years|N/A|No|||April 2007|February 6, 2010|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238342||189054|
NCT00240110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070289|Valproate Efficacy in Cocaine-Bipolar Comorbidity|Valproate Efficacy in Cocaine-Bipolar Comorbidity||University of Miami|Yes|Completed|March 2006|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00240110||188921|
NCT00236535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002815|A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament|A Comparison of the Efficacy and Safety of Tramadol HCl/Acetaminophen Versus Hydrocodone Bitartrate/Acetaminophen Versus Placebo in Subjects With Acute Musculoskeletal Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2003|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|603|||Both|18 Years|75 Years|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236535||189188|
NCT00238745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3068A1-207|Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.|Bone Mineral Density Increase and Safety of TSE-424 Compared to Placebo in Osteoporotic Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2003|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||375|||Female|N/A|85 Years|No|||December 2007|December 17, 2007|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238745||189024|
NCT00237822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA015144|Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders|Increasing Treatment Adherence in Co-Occurring Disorders||National Institute on Drug Abuse (NIDA)||Recruiting|September 2003|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||75|||Both|18 Years|85 Years|No|||October 2005|March 2, 2006|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237822||189090|
NCT00195117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (030200599)|A Randomized Trial of Changing Exercise and Physical Activity Behavior in Asthma Patients|A Randomized Trial of Changing Exercise and Physical Activity Behavior in Asthma Patients||Weill Medical College of Cornell University|No|Completed|October 2004|July 2007|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|258|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00195117||192287|
NCT00195481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H-101543|Study Evaluating Sirolimus in Kidney Transplant Recipients in India|A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|13 Years|N/A|No|||December 2007|December 21, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195481||192259|
NCT00195494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101548|Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis|A 24-Month,Randomized,Double-Blind,Two-Period Study to Evaluate the Efficacy and Safety of the Combination of Etanercept and Methotrexate and Methotrexate Alone in Subjects With Early Rheumatoid Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2004|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|542|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|September 13, 2005||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00195494||192258|
NCT00195507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-101764|Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis|A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2004|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|720|||Both|18 Years|N/A|No|||April 2010|February 20, 2013|September 13, 2005||||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00195507||192257|
NCT00196586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC09 SECOIIA|Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients|Pilot Study of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin for the Treatment of Chronic Hepatitis C in HIV-HCV Coinfected Patients Non Responders to Three Months of Therapy With Pegylated Interferon Alpha 2a and Ribavirin. ANRS HC09 SECOIIA||French National Agency for Research on AIDS and Viral Hepatitis||Completed|April 2003|November 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|65 Years|No|||November 2007|November 15, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196586||192175|
NCT00196248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No.N00300|Out-of Hospital Resuscitation Study|||Deutsches Herzzentrum Muenchen||Recruiting||||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196248||192201|
NCT00196833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 29|Breast Cancer in Pregnancy Register Study|Prospective and Retrospective Register Study of the German Breast Group (GBG) for Diagnosis and Treatment of Breast Cancer in Pregnancy|BCP|German Breast Group|No|Recruiting|April 2003|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|N/A||1|Anticipated|500|Samples With DNA|Tumour and placenta specimens are collected|Female|N/A|N/A|No|Non-Probability Sample|Women with histologically confirmed breast cancer during pregnancy.|February 2016|February 9, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196833||192156|
NCT00197106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM101667|Treatment Of Symptomatic Asthma In Children|See Detailed Description||GlaxoSmithKline||Completed|June 2005|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|176|||Both|6 Years|12 Years|No|||April 2012|May 31, 2012|September 9, 2005||No||No|September 11, 2009|https://clinicaltrials.gov/show/NCT00197106||192135|
NCT00197119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100566|Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years|Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 Years at Time of First Vaccine Dose||GlaxoSmithKline||Completed|May 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|244|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||November 2011|November 3, 2011|September 14, 2005|Yes|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00197119||192134|
NCT00197392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAC-IN02-002|Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System|Establishment of Baseline and Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System||Codman & Shurtleff|No|Completed|November 2004|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|434|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|September 13, 2005||No||No|March 2, 2012|https://clinicaltrials.gov/show/NCT00197392||192113|
NCT00197418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HighdosePPI|Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection|Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection||Hamamatsu University||Recruiting|August 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|90 Years|No|||March 2003|March 20, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197418||192111|
NCT00197431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12005|Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer|Pharmacokinetic and Pharmacodynamic Study of S-1 and Its Effects in Patients With the Digestive Organ Cancer With Reference to Genetic Polymorphism and Activity of CYP2A6 and DPD||Hamamatsu University||Recruiting|January 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|85 Years||||December 2003|March 21, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197431||192110|
NCT00197756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD45134|Vitamins, Breastmilk HIV Shedding, and Child Health|Vitamins, Breastmilk HIV Shedding, and Child Health||Harvard School of Public Health|No|Completed|September 2004|August 2007|Actual|August 2007|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|771|Samples Without DNA|Breast milk samples collected from breast at delivery and at 3 month intervals thereafter.|Female|18 Years|N/A|No|Non-Probability Sample|The data and samples used in this study are from HIV-infected pregnant women who        participated in the "Trial of Vitamins in HIV Transmission and Progression". Between 1995        and 1997, 1,078 African, HIV positive women who were between gestatopm weeks 12 and 27        were recruited. They were followed until August 2003. This study was conducte among 771 of        these women, for whom breast milk samples were available at delivery. There were no        differences in baseline characteristics between this subset and the originally randomized        group of 1,069.|August 2009|August 20, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197756||192091|
NCT00198263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-HNBE-2003|Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer|An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer||Inovio Pharmaceuticals|No|Completed|January 2004|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00198263||192053|
NCT00199238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/47|Efficacy of Rupatadine 5, 10 and 20 Mg in Chronic Idiopathic Urticaria|A 4-Week Dose-Finding, Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Different Doses of Rupatadine Compared to Placebo in the Treatment of Chronic Idiopathic Urticaria||J. Uriach and Company||Terminated|October 2002|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||248|||Both|12 Years|65 Years|No|||December 2003|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199238||191979|
NCT00199251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC010RUP304|Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria|A 6-Week Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Rupatadine 10 and 20 Mg in the Treatment of Chronic Idiopathic Urticaria (CIU): a Phase III Clinical Trial||J. Uriach and Company||Terminated|April 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|12 Years|65 Years|No|||September 2005|December 22, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199251||191978|
NCT00194987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102004801|A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia|A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia||Weill Medical College of Cornell University|No|Recruiting|April 2001|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Female|18 Years|50 Years|No|||June 2013|June 13, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194987||192297|
NCT00189761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ-506E-BT01|A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients|A Phase 2, Open-Label, Multi-Center Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in De Novo Bone Marrow Transplant Recipients||Astellas Pharma Inc||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|54 Years|No|||September 2006|September 19, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189761||192690|
NCT00189774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026-CL-004|Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients|||Astellas Pharma Inc||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|N/A|No|||March 2008|March 11, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189774||192689|
NCT00189787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-17-07|Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma|||Astellas Pharma Inc||Completed||August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|370|||Both|18 Years|70 Years|No|||April 2008|April 15, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00189787||192688|
NCT00194974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0304-191|Treatment Targets for Chronic Hypertension in Pregnancy|Treatment Targets for Chronic Hypertension in Pregnancy||Weill Medical College of Cornell University||Recruiting|July 2004|June 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2005|April 26, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00194974||192298|
NCT00185744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0003|Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer|Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer||Stanford University||Active, not recruiting|September 2002|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|40 Years|N/A|No|||May 2013|May 28, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185744||192993|
NCT00239733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AI065319-01|Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection|The Safety and Efficacy of Intravenous Anti-D for the Treatment of Thrombocytopenia in Patients With HCV Infection Prior to or During Treatment With Pegylated-Interferon and Ribavirin||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|March 2005|March 2010|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|October 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00239733||188949|
NCT00236340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMNIO-2000|Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.|Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|January 2002|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Female|18 Years|40 Years|No|||October 2005|April 18, 2007|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00236340||189203|
NCT00239109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281064|Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.|Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study.||Pfizer||Completed|April 2003|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||112|||Both|18 Years|70 Years|No|||March 2008|March 17, 2008|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00239109||188997|
NCT00239122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E00013|Recovery Therapy Trial|Applicability of CBT to Unselected Mental Health Service Clients With Psychotic Disorders||Melbourne Health||Completed|June 2000|February 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||94|||Both|16 Years|65 Years|No|||October 2005|October 12, 2005|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00239122||188996|
NCT00238147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6227|Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer|Phase I Trial With Weekly Docetaxel, Capecitabine and Carboplatin as Induction Chemotherapy Followed by Concomitant Capecitabine and Radiotherapy in Patients With Locally Advanced Esophageal Cancer||University of Washington||Completed|September 2004|August 2008|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|October 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00238147||189068|
NCT00195910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-04-08-225|Safety and Efficacy Study of Hydromorphone and Morphine|Safety and Efficacy of Hydromorphone as an Analgesic Alternative to Morphine in Acute, Severe Pain: A Randomized Clinical Trial||Chang, Andrew, M.D.||Active, not recruiting|October 2004|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||198|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195910||192227|
NCT00196209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. C00705|Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation|Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation||Deutsches Herzzentrum Muenchen|Yes|Recruiting|August 2005|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|20 Years|75 Years|No|||March 2008|March 18, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196209||192204|
NCT00196599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 091 MONTANA|Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults|Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA||French National Agency for Research on AIDS and Viral Hepatitis||Completed|February 1999|September 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||39|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196599||192174|
NCT00197158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104387|Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response|Demonstrate the Non-inferiority of Immunogenicity Elicited by GSK Biologicals' Hepatitis B Vaccine, Multidose Engerix™-B to That of Monodose Engerix™-B When Administered According to 0,1,6 Mths Schedule in Healthy Adults Aged ≥ 18 Yrs||GlaxoSmithKline||Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||280|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00197158||192131|
NCT00196846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG37|Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)|Prospective Randomized Multicenter Study to Prevent Chemotherapy Induced Ovarian Failure With the GnRH-Agonist Goserelin in Young Hormone Insensitive Breast Cancer Patients Receiving Anthracycline Containing (Neo-)Adjuvant Chemotherapy||German Breast Group|Yes|Completed|March 2005|March 2010|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|62|||Female|18 Years|45 Years|No|||June 2010|June 11, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196846||192155|
NCT00196859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 32|Study in Elderly Patients With Early Breast Cancer (ICE)|Ibandronate With or Without Capecitabine in Elderly Patients With Early Breast Cancer||German Breast Group|Yes|Completed|June 2004|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Female|65 Years|N/A|No|||August 2011|July 16, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196859||192154|
NCT00197132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/375|Study In Patients With Insulin Resistance|A Single-centre, Randomised, Double-blind, Placebo Controlled, Two 12 Week Period, Cross-over Phase III Study to Investigate the Effect of Rosiglitazone 4mg bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects.||GlaxoSmithKline||Completed|October 2002|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|18|||Both|30 Years|65 Years|No|||April 2015|April 10, 2015|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00197132||192133|
NCT00197145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR102709|Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.||GlaxoSmithKline||Terminated|July 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|September 13, 2005|Yes|Yes|The study was terminated due to hepatoxicity of compound|||https://clinicaltrials.gov/show/NCT00197145||192132|
NCT00198055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0302-24|A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.|An Open-Label Study of Aripiprazole in Children and Adolescents With Autistic Disorder||Indiana University|Yes|Completed|January 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|4 Years|17 Years|No|||June 2014|June 3, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198055||192068|
NCT00198601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.02.08.30.B1|Determination of Gentamicin Dosing in Neonatal Patients|Determination of Gentamicin Dosing in Neonatal Patients for Use in the Uniject Pre-Filled Syringe [A Three-Site Study at: 1) Dhaka Shishu Hospital, Dhaka Bangladesh; 2) Christain Medical Center, Vellore, India; and 3) Aga Khan University Medical Center, Karachi, Pakistan]||Johns Hopkins Bloomberg School of Public Health||Active, not recruiting|August 2003|July 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|28 Days|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198601||192027|
NCT00194714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6304|Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells|Phase I-II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo||University of Washington|No|Completed|June 2004|||December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00194714||192318|
NCT00194727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20912-A|Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer|Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer: A Phase II Trial With Molecular Correlates||University of Washington|No|Completed|May 2002|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|85 Years|No|||September 2012|September 12, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194727||192317|
NCT00189462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC - 3643|A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children|A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children||West Penn Allegheny Health System|No|Completed|March 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|99|||Both|18 Months|5 Years|No|||October 2014|October 13, 2014|September 13, 2005|No|Yes||No|September 23, 2014|https://clinicaltrials.gov/show/NCT00189462||192713|
NCT00185354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91402|FC Patch Comparator Study|Multi-center, Open, Randomized, Parallel Group Comparison of Cycle Control for Seven Cycles and Endometrial Safety in a Subgroup for Thirteen Cycles of Contraceptive Patch SH P00331F (0.9 mg Ethinylestradiol/1.9 mg Gestodene) vs. a Contraceptive Comparator Patch (0.6 mg Ethinylestradiol/6 mg Norelgestromin) in 400 Healthy Female Volunteers||Bayer|No|Completed|November 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|422|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00185354||193018|
NCT00185367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90883|Comparative Cycle Control Europe|A Multi-center, Double-blind, Double-dummy, Controlled, Randomized Study to Evaluate Cycle Control and Safety of a Four Phasic Oral Contraceptive (SH T00658ID) in Comparison to an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D 593 B) in Healthy Female Volunteers Aged Between 18 and 50 Years.||Bayer||Completed|March 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|798|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 14, 2011|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185367||193017|
NCT00185757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT162|Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation|Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation||Stanford University||Active, not recruiting|June 2004|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||December 2012|December 13, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185757||192992|
NCT00195650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE020|Long Term Open Label Continuation Study|A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis||Abbott|No|Completed|July 2000|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|846|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|September 13, 2005|Yes|Yes||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00195650||192246|
NCT00185328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91436|Efficacy and Tolerability of Angeliq in Thai Women|A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of Angeliq® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles||Bayer|No|Completed|September 2005|December 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|45 Years|N/A|No|||December 2008|December 11, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00185328||193020|
NCT00186199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1790|Determination of Voiding Patterns of Children With Vesicoureteral Reflux|Determination of Voiding Patterns of Children With Vesicoureteral Reflux||Stanford University|No|Enrolling by invitation|June 2005|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|250|||Both|3 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with history of vesicoureteral reflux, toilet trained, ambulatory, and able to        void on command. Children scheduled to have procedural correction of vesicoureteral reflux|June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186199|12 Months|192961|
NCT00186563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79723|A Human In-vivo Model for the Detection of Inflammatory and Nociceptive Biomarkers|Proof-of-concept Study for Bio-marker Assay Validation in Humans||Stanford University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||13|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00186563||192933|
NCT00236067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6671/3031/AX/US|A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril(up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder||Teva Pharmaceutical Industries||Completed|October 2004|March 2006||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|18 Years|64 Years|No|||May 2014|May 8, 2014|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236067||189223|
NCT00236080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3045/CM/US|Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil (150, 200, and 250 mg) and PROVIGIL® (200 mg) in Patients With Chronic Shift Work Sleep Disorder||Teva Pharmaceutical Industries||Completed|August 2005|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|136|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|October 7, 2005|No|Yes|||June 1, 2009|https://clinicaltrials.gov/show/NCT00236080||189222|In analyzing the PVT data, it was discovered that data transfer errors had occurred at certain study centers. The ability to interpret the efficacy results from this study is limited, and the findings should be considered inconclusive.
NCT00236990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004687|An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland|A Double-Blind, Randomized, Placebo-Controlled Trial of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Prostatitis||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed||September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|283|||Male|18 Years|65 Years|No|||June 2011|June 30, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236990||189153|
NCT00237562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA076501|Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit|Single Visit Cervical Cancer Prevention Program||University of California, Irvine||Completed|July 1999|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2005|May 4, 2006|October 10, 2005||||No||https://clinicaltrials.gov/show/NCT00237562||189110|
NCT00237809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23594|D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia|D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia||Yale University||Recruiting|September 2002|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|72|||Both|18 Years|65 Years|No|||August 2010|August 30, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00237809||189091|
NCT00239005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AGB03|Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation|A Study of the Effect of Conversion to Enteric-Coated Mycophenolate Sodium (EC-MPS) on Quality of Life in Patients With Gastrointestinal (GI) Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation (MYQOL)||Novartis||Completed|September 2005|||March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|October 12, 2005||No||No|December 8, 2010|https://clinicaltrials.gov/show/NCT00239005||189005|
NCT00195923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-149|Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis|Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis||Children's Mercy Hospital Kansas City|No|Completed|April 2005|January 2007|Actual|||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|1 Month|18 Years|No|||September 2005|April 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00195923||192226|
NCT00195936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 02-027|Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets|Effect of Calcimimetic (Cinacalcet) on Phosphate-Induced Hyperparathyroidism in Children With Hypophosphatemic Rickets||Children's Mercy Hospital Kansas City||Recruiting|June 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|5 Years|N/A|No|||August 2005|October 22, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195936||192225|
NCT00196222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. C00403|European Multicenter Study Radiofrequency (RF) Versus Cryo in Atrioventricular Nodal Reentry Tachycardia (AVNRT)|European Multicenter Study RF Versus Cryo in AVNRT: A Randomized Study Comparing Cryo-Energy vs. Radiofrequency-Energy Ablation Technique for AV Nodal Reentry Tachycardia (AVNRT)||Deutsches Herzzentrum Muenchen|Yes|Completed|March 2003|May 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|509|||Both|18 Years|80 Years|No|||July 2013|July 3, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00196222||192203|
NCT00196235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00295|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Diabetes Mellitus|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Diabetes Mellitus||Deutsches Herzzentrum Muenchen||Completed|January 1995|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||650|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196235||192202|
NCT00197171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100386 (EXT Y5)|Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine|Evaluate the Persistence of Immune Response of GSK Biologicals' TWINRIX™ ADULT, Administered According to 0,6 m Schedule and 0,12 m Schedule, in Volunteers Aged 12-15 y Inclusive at the Time of First Vaccine Dose||GlaxoSmithKline||Completed|September 2003|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|143|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00197171||192130|
NCT00197184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208127/132 (EXT Y2)|Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared|Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 Month Schedule and a 0,1,6 Month Schedule, in Healthy Children Aged Between 1-11 Years at the Time of First Vaccine Dose||GlaxoSmithKline||Completed|November 2003|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|276|||Both|3 Years|13 Years|Accepts Healthy Volunteers|||November 2011|October 2, 2014|September 15, 2005|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00197184||192129|
NCT00197444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAMA-M1-C001|Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer|A Phase II Study of Daily Low-Dose of Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum) and Continuous Infusion of 5-FU Combined With Radiation for the Treatment of Esophageal Cancer||Hamamatsu University|Yes|Completed|January 2003|December 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|20 Years|85 Years|No|||February 2009|February 19, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00197444||192109|
NCT00197769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNC1/2|Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants|||Public Health England||Completed|September 2000|January 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|7 Weeks|18 Months|Accepts Healthy Volunteers|||February 2008|April 30, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197769||192090|
NCT00198276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-CCBE-2003|Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer|An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer||Inovio Pharmaceuticals|No|Completed|February 2004|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||September 2012|April 24, 2013|September 12, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00198276||192052|
NCT00198627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.01.09.05.A1|Etiology, Prevention and Treatment of Neonatal Infections in the Community|Etiology, Prevention, and Treatment of Neonatal Infections in the Community||Johns Hopkins Bloomberg School of Public Health|Yes|Active, not recruiting|December 2003|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16359|||Both|1 Month|N/A|Accepts Healthy Volunteers|||April 2007|April 23, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198627||192025|
NCT00198640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.02.06.06.A1|AMR of Streptococcus Pneumoniae Carriage Strains|Antimicrobial Resistance of Streptococcus Pneumoniae Carriage Strains Among Bangladeshi Neonates: Epidemiology, Determinants and Risk Factors||Johns Hopkins Bloomberg School of Public Health||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|N/A||||August 2005|November 1, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198640||192024|
NCT00189189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-119|Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children|Parent Management Training to Prevent Oppositional Defiant and Conduct Disorders in Preschool Children||UMC Utrecht||Recruiting|July 2003|November 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|160|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||July 2005|October 1, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189189||192734|
NCT00189800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90502/KOoTD01|A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder|||Astellas Pharma Inc||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2006|November 15, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189800||192687|
NCT00189813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-305|A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Potential Efficacy, Safety and Tolerability of Different Oral Doses of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome||Astellas Pharma Inc||Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|691|||Both|18 Years|70 Years|No|||August 2014|August 27, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00189813||192686|
NCT00196976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103533|Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old|Evaluate the Immunogenicity, Reactogenicity, Safety of 4 Different Formulations of GSK Biologicals' Conjugate Vaccine (MenACWY) vs 1 Dose of MenC-CRM197 or Mencevax™ ACWY in Children Aged 12-14 Months & 3-5 Years||GlaxoSmithKline||Completed|March 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|5||Actual|461|||Both|12 Months|60 Months|Accepts Healthy Volunteers|||June 2014|June 26, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196976||192145|
NCT00196989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADG20001|Study In People With Type 2 Diabetes|See Detailed Description||GlaxoSmithKline|No|Completed|September 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|448|||Both|18 Years|70 Years|No|||March 2012|June 17, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00196989||192144|
NCT00185341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91399|Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability and Efficacy of the CCR1 Antagonist ZK 811752, Given Orally in a Dose of 600 mg Three Times Daily, for the Treatment of Endometriosis Over 12 Weeks||Bayer||Completed|February 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|45 Years|No|||July 2009|July 14, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00185341||193019|
NCT00185770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL062224|Reducing Television Viewing to Prevent Childhood Obesity|Reducing Television Viewing to Prevent Childhood Obesity||Stanford University||Completed|April 1999|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||900|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00185770||192991|
NCT00197509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-359|Sit-to-Stand Training for Survivors of Stroke in a Long-Term Care Setting|Task Specific Training for Stroke Patients||Hamilton Health Sciences Corporation||Active, not recruiting|January 2005|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197509||192104|
NCT00236743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005467|A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy|Topiramate (RWJ 17021-000) Clinical Trial In Children With Partial Onset Seizures||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 1994|October 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|90|||Both|1 Year|16 Years|No|||January 2011|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236743||189172|
NCT00237315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5101|Longitudinal Study of Urea Cycle Disorders|Longitudinal Study of Urea Cycle Disorders||Children's Research Institute|Yes|Recruiting|February 2006|December 2019|Anticipated|July 2019|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|N/A|N/A|No|Non-Probability Sample|>550 individuals with urea cycle disorders, up to a total of 1,100 enrolled|November 2015|November 2, 2015|October 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00237315||189129|
NCT00238654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM08|A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy|A Multicenter, Open-Label, Two-Arm Prospective Study to Evaluate the Impact of Patient Readiness to Self-Inject on Outcomes When Using the Copaxone® Prefilled Syringes [The "READY" Trial]||Teva Pharmaceutical Industries|No|Completed|May 2003|July 2008|Actual|July 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|257|||Both|18 Years|N/A|No|Probability Sample|RRMS patient with treatment-naïve or treatment-experienced|April 2011|April 8, 2011|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238654||189031|
NCT00238667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMER5UA|To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection|Cervical Artery Dissection in Stroke Study|CADISS|St George's, University of London||Completed|November 2005|May 2014|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|N/A|N/A|No|||September 2005|May 19, 2015|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00238667||189030|
NCT00195559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A4-318|Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2005|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|526|||Female|18 Years|49 Years|No|||December 2007|December 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195559||192253|
NCT00196274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00500|Autonomic Regulation Trial (ART)|Autonomic Regulation Trial (ART)||Deutsches Herzzentrum Muenchen||Completed|May 2000|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1000|||Both|18 Years|80 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196274||192199|
NCT00196287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00395|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Female Patients|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Female Patients||Deutsches Herzzentrum Muenchen||Completed|January 1995|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||750|||Female|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196287||192198|
NCT00196300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00495|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Eldery|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Eldery||Deutsches Herzzentrum Muenchen||Completed|January 1995|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||500|||Both|76 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196300||192197|
NCT00196612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 099 ALIZE|Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART|Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE||French National Agency for Research on AIDS and Viral Hepatitis||Completed|April 2001|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196612||192173|
NCT00196872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 33|A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)|A Phase III Trial to Compare ETC vs, EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)||German Breast Group||Completed|July 2004|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|3000|||Female|18 Years|65 Years|No|||August 2012|July 16, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196872||192153|
NCT00196885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|whilde157/2003|Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training|Effect of N-Acetylcysteine on Skeletal Muscle in Cachectic Cancer Patients Undergoing a Resistance Training Program (Phase 2 Study)||German Cancer Research Center||Completed|December 2003|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2008|June 18, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196885||192152|
NCT00197457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pepsinogen2005|Pepsinogens as the Early Marker of H. Pylori Eradication|Serum Pepsinogens as an Early Diagnostic Marker of H. Pylori Eradication||Hamamatsu University||Completed|June 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|20 Years|90 Years|No|||May 2001|January 31, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197457||192108|
NCT00197808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sched1|Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines|Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines|sched1|Public Health England||Completed|April 2005|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|392|||Both|7 Weeks|11 Weeks|Accepts Healthy Volunteers|||March 2012|March 27, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197808||192087|
NCT00197782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hibboost|The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine|||Public Health England||Completed|April 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|9 Months|4 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197782||192089|
NCT00197795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNB1|Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults|||Public Health England||Completed|January 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197795||192088|
NCT00198068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22122|Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)|Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)|PROMISSE|Hospital for Special Surgery, New York|Yes|Recruiting|September 2003|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|700|Samples With DNA|Serum, plasma, whole blood, RNA, urine|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients identified by investigators at each study site|December 2015|December 8, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198068||192067|
NCT00198653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.02.07.15.A1|Newborn Thermal Care Practices: A Community Based Program to Prevent Hypothermia|Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia||Johns Hopkins Bloomberg School of Public Health||Terminated|March 2003|October 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2007|May 3, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198653||192023|
NCT00198666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.03.01.06.A2|Efficacy of Zinc in the Treatment of Pneumonia|Efficacy of Zinc in the Treatment of Pneumonia in Hospitalized Children Less Than 2 Years of Age||Johns Hopkins Bloomberg School of Public Health|No|Completed|September 2003|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|299|||Both|N/A|23 Months|No|||January 2015|January 9, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198666||192022|
NCT00198913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA2000-03|Long Term Free Living Study With Modified Foods and Type 2 Diabetics|Use of Modified Foods in the Dietary Treatment of Type II Diabetes Mellitus: Long Term Free Living Study||Johns Hopkins Bloomberg School of Public Health||Completed|June 2002|February 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2003|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198913||192003|
NCT00198926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA2000-02|Type 2 Diabetes Controlled Eating Experiment|Use of Modified Foods in the Dietary Treatment of Type II Diabetes Mellitus: Short Term Feeding Study||Johns Hopkins Bloomberg School of Public Health||Completed|May 2000|August 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2001|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198926||192002|
NCT00198939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA015075-03|Neurological Influences on Drug Prevention Intervention|Neurological Influences on Drug Prevention Intervention||University of Florida|No|Completed|January 2005|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|330|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00198939||192001|
NCT00198952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP2000-01|Effects of Herbal Products on Metabolism and Hunger|Effects of Herbal Products on Metabolism and Hunger||Johns Hopkins Bloomberg School of Public Health||Completed|February 2000|March 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2002|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198952||192000|
NCT00189475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC - 3559|Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds|A Pilot Study to Evaluate the Potential of Montelukast to Prevent the Development of Nasal Symptomatology During Natural Viral Upper Respiratory Infections||West Penn Allegheny Health System|No|Completed|October 2003|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|84|||Both|18 Years|50 Years|No|||October 2014|October 13, 2014|September 13, 2005||No||No|September 23, 2014|https://clinicaltrials.gov/show/NCT00189475||192712|
NCT00189488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040213|Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation|A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation||Swedish Orphan Biovitrum||Completed|December 2005|August 2013|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|September 15, 2005|Yes|Yes||No|November 25, 2009|https://clinicaltrials.gov/show/NCT00189488||192711|
NCT00196690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0509|Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial|Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial.||Gabinete Berthier y Martínez||Completed|February 2003|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|69 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196690||192167|
NCT00196430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III PV 08/03|Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute Neurodermatitis|Prospective, Controlled Three-Armed Study About Effectiveness and Compatibility of Silver-Containing Textiles for Treatment of Acute Neurodermatitis||University Medicine Greifswald||Completed|January 2004|August 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||32|||Both|2 Years|70 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196430||192187|
NCT00196703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10830|Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial|A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.||Gabinete Berthier y Martínez||Recruiting|March 2005|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|69 Years|No|||March 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196703||192166|
NCT00186186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79130|Depakote ER in Bipolar Depression|Depakote ER in Bipolar Depression||Stanford University|No|Completed|January 2004|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00186186||192962|
NCT00197275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104733|Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants|Demonstrate Lot-to-lot Consistency of Final Production Method of GSK Biologicals' Hib-MenAC Vaccine Mixed Extemporaneously With Tritanrix™-HepB & Demonstrate Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Healthy Infants at 2,4&6 Months||GlaxoSmithKline||Completed|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||800|||Both|56 Days|83 Days|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00197275||192122|
NCT00207233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22398|Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients|Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients 2002-292G||Boston Medical Center|No|Completed|July 2004|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|65 Years|No|||February 2009|January 24, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00207233||191378|
NCT00207506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4337|Lay Health Advisors for Sexually Transmitted Disease Prevention|HoMBReS: A Lay Health Advisor Approach to Sexually Transmitted Disease Prevention||Centers for Disease Control and Prevention|No|Completed|October 2004|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|354|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207506||191358|
NCT00207779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E02|Prevention of Catheter-Related Bloodstream Infection in Patients With Haemato-Oncological Disease|||Centre National de Greffe de Moelle Osseuse||Completed|May 2005|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|4 Years|60 Years|No|||September 2007|September 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207779||191338|
NCT00196313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-PSE-306|A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain|A Multicenter Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval to Placebo for the Treatment of Cyclic Pelvic Pain in Adolescents||Teva Pharmaceutical Industries|No|Completed|May 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|95|||Female|N/A|17 Years|No|||September 2015|September 21, 2015|September 12, 2005|Yes|Yes||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00196313||192196|
NCT00196326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-PSE-309|Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive|A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose, Combination Oral Contraceptive, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle||Duramed Research||Completed|June 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2235|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|September 12, 2005|Yes|Yes||No|November 21, 2008|https://clinicaltrials.gov/show/NCT00196326||192195|
NCT00196625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 104 PUZZLE1|Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.|Study on Safety and Efficacy of Salvage Therapy With Amprenavir, Lopinavir and Ritonavir 200 Mg/d or 400 Mg/d in HIV-Infected Patients in Virological Failure.ANRS 104 PUZZLE 1||French National Agency for Research on AIDS and Viral Hepatitis||Completed|November 2000|February 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196625||192172|
NCT00196898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0 / 03.02.05|Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists|A National, Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson´s Disease Treated With Dopamine Agonists||German Parkinson Study Group (GPS)||Recruiting|March 2005|December 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|PD Patients|April 2011|March 16, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196898||192151|
NCT00196911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 125/00|STN-Stimulation Versus Best Medical Treatment in Advanced PD|Randomized, Multicenter, Prospective, Parallel-Group Study of the Effect of Deep Brain Stimulation (Subthalamic Nucleus) on Quality of Life and Motor Complications in Patients With Advanced Parkinson's Disease Compared With Best Medical Treatment||German Parkinson Study Group (GPS)||Completed|January 2001|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||156|||Both|20 Years|75 Years|No|||September 2005|November 29, 2006|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00196911||192150|
NCT00197821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNCA|Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults|||Public Health England||Completed|January 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|611|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197821||192086|
NCT00198081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0305-20|Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)|A Phase II Trial of Celecoxib in Patients With IPMN||Indiana University|Yes|Terminated|September 2005|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 12, 2005|Yes|Yes|Lack of funding and personnel to conduct study.|No|October 21, 2015|https://clinicaltrials.gov/show/NCT00198081||192066|
NCT00198289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INH-AUR-004|Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs|A Phase IIa Dose Escalation Study to Assess Safety and Pharmacokinetics of Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs||Bristol-Myers Squibb||Completed|April 2005|June 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|7 Years|N/A|No|||March 2013|March 28, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00198289||192051|
NCT00198679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.03.10.07.A2|Effect of Chlorhexidine Skin Cleansing on Skin Flora|Effect of Chlorhexidine Skin Cleansing on Skin Flora of Newborn Infants in Bangladesh||Johns Hopkins Bloomberg School of Public Health||Active, not recruiting|March 2004|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||210|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||May 2006|May 1, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198679||192021|
NCT00198965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG1999-01|Olestra Containing Foods and Weight Loss and Weight Maintenance|Benefits of Sensory-Enhanced Products in Weight Loss and Maintenance||Johns Hopkins Bloomberg School of Public Health||Completed|March 1999|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||257|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198965||191999|
NCT00199264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO8ATM/2/03|Efficacy Vulvovaginitis Candida|A Single-Blind, Randomized, Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis||J. Uriach and Company||Terminated|June 2004|October 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||October 2003|October 2, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199264||191977|
NCT00196417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The HIT-TRAP Trial|Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial||University Medicine Greifswald||Active, not recruiting|January 2003|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196417||192188|
NCT00196443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bau-Phleb-17032005|The Influence of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Disease|Prospective, Randomized and Explorative Controlled Study About Influences of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Insufficiency||University Medicine Greifswald||Completed|June 2005|July 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||42|||Both|18 Years|80 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196443||192186|
NCT00197288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104437|Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines|A Phase III, Observer-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix™ (GlaxoSmithKline Biologicals) Compared With Fluzone® (Aventis Pasteur) Administered Intramuscularly in Adults 18 Years and Older in the U.S.||GlaxoSmithKline||Completed|October 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Actual|1847|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 31, 2012|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00197288||192121|
NCT00197301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-05.08.05-HMO-CTIL|Liposomal Based Intranasal Influenza Vaccine:Safety and Efficacy|Phase 1 Study to Examine the Safety and Efficacy of a Novel Liposomal Based Intranasal Influenza Vaccine||Hadassah Medical Organization||Completed|October 2005|April 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||200|||Both|20 Years|95 Years|Accepts Healthy Volunteers|||September 2005|November 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197301||192120|
NCT00197262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR104861|Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 2 Weeks in Adult and Adolescent Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis (SAR)||GlaxoSmithKline||Completed|August 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||288|||Both|12 Years|N/A|No|||October 2010|October 1, 2010|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00197262||192123|
NCT00197002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208109/220|Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age|A Phase IIIb, Open, Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine Administered on a 0-6 Mth Schedule Concomitantly With Wyeth Lederle's Pneumococcal Conjugate Vaccine in Healthy Children 15 Months of Age||GlaxoSmithKline||Completed|September 2003|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|521|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||August 2013|August 8, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00197002||192143|
NCT00206934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363037-1|The Effects of Increased Central Serotonergic Activity on Information Processing|The Effects of Increased Central Serotonergic Activity on Psychophysiological Parameters of Human Information Processing||University of Copenhagen|No|Completed|March 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2008|September 16, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00206934||191401|
NCT00207259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-005|Study of Complementary Therapies in Men Receiving Radiation Therapy for Prostate Cancer: A Feasibility Trial|Study of Complementary Therapies in Men Receiving Radiation Therapy for Prostate Cancer: A Feasibility Trial||Brigham and Women's Hospital|Yes|Active, not recruiting|March 2005|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Male|30 Years|N/A|No|||February 2013|February 14, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207259||191377|
NCT00207272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24641|Use of MCT Oil for Enhancement of Weight Loss in Obese Patients|Use of MCT Oil for Enhancement of Weight Loss in Obese Patients-Preliminary Phase 2002-291G||Boston Medical Center||Completed|July 2003|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|65 Years|No|||March 2008|May 22, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207272||191376|
NCT00207519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24640|Liquid Meal Replacements in Conjunction With Lifestyle Intervention in Overweight Adolescents|The Use of Liquid Meal Replacements in Conjunction With Lifestyle Intervention in Overweight Adolescents: A 12 Week Safety and Efficacy Study||Boston Medical Center|No|Completed|April 2003|January 2009|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||February 2009|February 10, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207519||191357|
NCT00207792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSF|Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation|Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation||Centre National de Greffe de Moelle Osseuse||Recruiting|July 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|160|||Both|16 Years|45 Years|No|||September 2007|November 5, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207792||191337|
NCT00208052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-11-1-1EE|Behavioral Indicators of Pain:Tool Development With Concurrent and Construct Validity|||Cincinnati VA Medical Center||Completed|January 2004|July 2005||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||10|||Both|18 Years|75 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208052||191317|
NCT00196924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/013|Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.|Evaluate the Safety & Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects (10 - 14 Years)||GlaxoSmithKline||Completed|June 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|2067|||Female|10 Years|14 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196924||192149|
NCT00197197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR104458|Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.||GlaxoSmithKline||Terminated|July 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|September 12, 2005|Yes|Yes|The study was terminated due to hepatoxicity of compound|||https://clinicaltrials.gov/show/NCT00197197||192128|
NCT00197470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mitsu-001|Cytokine Gene Polymorphisms in Gastric Diseases|Effects of Pro-Inflammatory and Anti-Inflammatory Cytokine Gene Polymorphism on the Development of Gastric Cancer and Peptic Ulcer in Japanese||Hamamatsu University||Recruiting|January 2000|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197470||192107|
NCT00197834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEIRB05032|Study of Depakote for Behavioral and Psychological Symptoms in Dementia|An Open-Label Prospective Study of Depakote for Behavioral and Psychological Symptoms in Dementia (BPSD): Use Alone and in Co-Prescription With Atypical Antipsychotic Medications||Hearthstone Alzheimer Care||Recruiting|March 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|60 Years|N/A|No|||September 2005|August 10, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197834||192085|
NCT00197847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 02071|Infection Surveillance in Intensive Care Patients|||Herlev Hospital||Active, not recruiting|December 2002|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||549|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197847||192084|
NCT00198094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311-34|A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients|A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients||Indiana University|Yes|Completed|December 2003|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||October 2007|October 19, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198094||192065|
NCT00198302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INH-AUR-002|Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)|A Phase II, Randomized, Double-blind, Multi-center Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)||Bristol-Myers Squibb||Completed||February 2005||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||60|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00198302||192050|
NCT00188695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0838-C|Combidex USPIO - Ultra-Small Superparamagnetic Iron Oxide|A Pilot Study of MR Imaging With Ultra-Small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition||University Health Network, Toronto|Yes|Completed|April 2004|June 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|18 Years|N/A|No|||April 2008|May 5, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188695||192772|
NCT00188708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 00-0430-C|Effect of Casodex on Tumour Hypoxia - Prostate Cancer|A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer||University Health Network, Toronto||Active, not recruiting|April 2001|April 2016|Anticipated|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|N/A|No|||February 2016|February 2, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188708||192771|
NCT00188929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0339-C|Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma|Spatio-temporal Response of Non-Hodgkin's Lymphoma to External Beam Radiation Therapy Measuring 18F-Fluorodeoxyglucose (FDG) Uptake Using a Combined PET/CT Scanner: A Pilot Study||University Health Network, Toronto||Completed|August 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|10|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188929||192754|
NCT00196079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506|The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial|The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial||Cook||Completed|February 2000|August 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||177|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00196079||192214|
NCT00196092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-514|Zenith® AAA Endovascular Graft Clinical Study|Zenith® AAA Endovascular Graft Clinical Study||Cook||Completed|January 2000|July 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|819|||Both|18 Years|N/A|No|||December 2007|March 11, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00196092||192213|
NCT00197028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103967|Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region|A Phase I/IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine in Infants Living in a Malaria-endemic Region||GlaxoSmithKline||Completed|August 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|214|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||July 2014|July 3, 2014|September 13, 2005|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00197028||192141|
NCT00197587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 10411/9912BOTS|Prevention of Milk-Borne Transmission of HIV-1C in Botswana|Prevention of Milk-Borne Transmission of HIV-1C in Botswana ("Mashi")|Mashi|Harvard School of Public Health|Yes|Completed|August 2002|||May 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1200|||Female|15 Years|45 Years|No|||May 2013|May 17, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197587||192100|
NCT00197938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 05091m|Lactic Acid in the Rectum and Life-Threatening Infection|Does the Concentration of L-Lactate in the Rectum Correlate With Mortality and Morbidity in Patients With Septic Shock?||Herlev Hospital||Completed|November 2005|April 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with early septic shock (< 24 h).|June 2009|June 5, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00197938||192077|
NCT00197015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208109/231|Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children|Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age||GlaxoSmithKline||Completed|October 2003|June 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1474|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||January 2015|January 22, 2015|September 13, 2005|Yes|Yes||No|March 11, 2010|https://clinicaltrials.gov/show/NCT00197015||192142|
NCT00197548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD37701|A Trial of Micronutrients and Adverse Pregnancy Outcomes|A Trial of Micronutrients and Adverse Pregnancy Outcomes||Harvard School of Public Health|Yes|Completed|August 2001|July 2006|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8468|||Female|18 Years|N/A|No|||November 2010|November 9, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197548||192102|
NCT00207805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM01|The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma|||Centre National de Greffe de Moelle Osseuse||Completed|May 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||202|||Both|N/A|61 Years|No|||January 2009|January 26, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207805||191336|
NCT00207818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOEX 005|Treatment of Cutaneous Ulcers With a Novel Biological Dressing|Treatment of Cutaneous Ulcers With a Novel Biological Dressing||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|September 1999|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|85 Years|No|||February 2014|February 10, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207818||191335|
NCT00208065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evaluation-Histamine,CGRP,VIP|Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers|Evaluation of Histamine, CGRP and VIP as Biological Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers in Response to "Sinus" Symptoms||Clinvest||Completed|May 2004|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 5, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208065||191316|
NCT00208299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 5131|ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)|A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging||Gilead Sciences|No|Completed|October 2003|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1231|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208299||191298|
NCT00203944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11685A|International Adoption and Stress Response Study|International Adoption and Stress Response Study||University of Chicago|No|Completed|July 2002|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|39|||Both|N/A|1 Year|Accepts Healthy Volunteers|Non-Probability Sample|infants from international adoption clinic for adoptees and U of C pediatric follow-up        clinic for controls|October 2013|October 8, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00203944||191626|
NCT00203957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13711A|Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa|A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy||University of Chicago|Yes|Completed|March 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00203957||191625|
NCT00196937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103514|Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18|Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up||GlaxoSmithKline||Completed|October 2004|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|667|||Female|15 Years|55 Years|Accepts Healthy Volunteers|||January 2012|June 12, 2014|September 13, 2005|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00196937||192148|
NCT00197210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/028/029/030|A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants|A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants||GlaxoSmithKline||Completed|December 2003|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|||Actual|10708|||Both|6 Weeks|17 Weeks|Accepts Healthy Volunteers|||March 2012|October 2, 2014|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00197210||192127|
NCT00197483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01T-080|Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia|Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia||Hamamatsu University||Suspended|March 2003|||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||20|||Both|18 Years|50 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197483||192106|
NCT00187603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12AT-1700|Protecting the 'Hood Against Tobacco|Protecting the 'Hood Against Tobacco: Cessation Project||University of California, San Francisco||Completed|July 2003|June 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|270|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2005|May 5, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187603||192854|
NCT00187902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1079-26791-01|Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM|Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM||University of California, San Francisco|No|Completed|October 2005|December 2008|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|907|Samples With DNA|self-collected glans swab; clinician-collected rectal and pharyngeal swabs|Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men who have sex with men (MSM) voluntarily presenting at the City STD clinic.|April 2011|April 13, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00187902||192833|
NCT00188175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0107-C|IMRT Lower Limb Soft Tissue Sarcoma|A Phase II Study of Preoperative Intensity-Modulated Radiation Therapy For Lower Limb Soft Tissue Sarcoma||University Health Network, Toronto|Yes|Completed|May 2003|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|59|||Both|16 Years|N/A|No|||June 2014|June 2, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188175||192812|
NCT00188188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLED|Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease|Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion.||University Health Network, Toronto||Recruiting|March 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|20 Years|N/A|No|||March 2005|December 28, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188188||192811|
NCT00188448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0223|MRI Superficial Temporal Artery|MRI of the Superficial Temporal Artery||University Health Network, Toronto||Completed|April 2003|April 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||5|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2005|April 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188448||192791|
NCT00188422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0468-CE|Study of Low Dose CT in Sarcoma Patients|Surveillance Low Dose Computed Tomography of the Thorax in Patients With High Grade Extremity Soft Tissue Sarcoma||University Health Network, Toronto||Completed|August 2003|January 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||70|||Both|16 Years|N/A|No|||April 2007|April 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188422||192793|
NCT00188435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0731|Comparison of CXR and MnDCT|A Comparison of Chest Radiography and Minimum Dose Chest CT||University Health Network, Toronto||Completed|November 2003|December 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|16 Years|N/A|No|||September 2005|April 23, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188435||192792|
NCT00188942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 04-0204-B|A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder|Neural Correlates of Emotional Processing in Depressed and Remitted Bipolar and Unipolar Depressed Subjects: An fMRI Investigation||University Health Network, Toronto||Completed|February 2005|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 6, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00188942||192753|
NCT00188955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WINNIPEG-CAN-1|Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant|Phase 4 Randomized, Controlled Study Comparing Sirolimus and Mycophenolate Mofetil to Prevent or Reverse Progression in Pediatric Renal Transplants With Chronic Allograft Nephropathy||University of Manitoba||Completed|March 2004|October 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|6 Years|18 Years|No|||February 2010|February 19, 2010|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00188955||192752|
NCT00189202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Steroid Avoidance in A.A.|Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans|Efficacy of Sirolimus-Based, Steroid Avoidance Maintenance Immunosuppression in Black de Novo Kidney Transplant Recipients||University of Michigan||Active, not recruiting|August 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||October 2008|October 9, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00189202||192733|
NCT00196716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL-017-01|A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease|A Multicenter, Open-label Study of Low Dose Maintenance Treatment of Fabrazyme (Recombinant Human Alpha-Galactosidase A (R-h Alpha-GAL)) Replacement Therapy in Patients With Fabry Disease||Sanofi||Completed|June 2003|March 2007|Actual|April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|16 Years|N/A|No|||March 2015|March 17, 2015|September 12, 2005||No||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00196716||192165|
NCT00197314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204-20-22-HMO-CTIL|Effectiveness of Circular Muscle Exercise (Paula Method) Versus Kegel Exercise for Urinary Stress Incontinence|A Randomized Controlled Trial of Circular Muscle Exercises (Paula Method) vs. Pelvic Floor Training (Kegel Exercises) for Urinary Stress Incontinence in Women||Hadassah Medical Organization||Completed|June 2004|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Female|20 Years|65 Years|No|||September 2005|November 6, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197314||192119|
NCT00197613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC #0110THEA|The Adult Antiretroviral Treatment and Resistance Study (Tshepo)|The Adult Antiretroviral Treatment and Resistance Study (Tshepo)||Harvard School of Public Health|Yes|Completed|December 2002|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||650|||Both|18 Years|N/A|No|||September 2012|September 14, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197613||192099|
NCT00197561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD43555|Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection|Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection||Harvard School of Public Health|Yes|Completed|September 2003|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|915|||Female|18 Years|N/A|No|||November 2010|November 9, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197561||192101|
NCT00197951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-001056-36|Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism|Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology, Not Being a Severe Mental Disorder, Associated to Alcohol Dependence Disorder.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|October 2004|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||April 2007|April 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197951||192076|
NCT00208312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 5132|ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)|A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging||Gilead Sciences|No|Completed|April 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|787|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208312||191297|
NCT00208325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 9923|PFC Sigma Fixed and Mobile Knee Study|Clinical Evaluation of the P.F.C. Sigma (Fixed Bearing) and P.F.C. Sigma RP (Mobile Bearing) Total Knee Systems||DePuy International|No|Terminated|May 1999|July 2022|Anticipated|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|683|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|September 13, 2005|Yes|Yes|The study was terminated at the point the primary endpoint and early milestones were reached    and because long term outcomes were available from other sources|No||https://clinicaltrials.gov/show/NCT00208325||191296|
NCT00203970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10895A|Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services|Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services||University of Chicago|No|Active, not recruiting|February 2001|January 2014|Anticipated|March 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|645|||Both|18 Years|N/A|No|Probability Sample|Patients admitted into the general medicine services with a primary or secondary diagnosis        related to Venous Thromboembolism.|August 2010|September 4, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00203970||191624|
NCT00204256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ven-PD-03|Intravenous Iron in Patients With Anemia of Chronic Kidney Disease|Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease||University Hospital Muenster||Active, not recruiting|March 2004|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204256||191603|
NCT00204503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-048|Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence|An Open Label Pilot Study Evaluating Safety and Efficacy of Divalproex Sodium (Depakote ER) in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence.||The University of Texas Medical Branch, Galveston||Withdrawn|June 2003|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00204503||191584|
NCT00187382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRN: 38142|Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS)|Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS)||Sunnybrook Health Sciences Centre|Yes|Completed|April 2001|December 2011||June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|1858|||Female|14 Years|45 Years|No|||June 2010|June 14, 2010|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187382||192871|
NCT00187616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEPAE-001|Questioning Patients About Adverse Medical Events: A Randomized Controlled Trial|Questioning Patients About Adverse Medical Events: A Randomized Controlled Trial||University of California, San Francisco||Completed|April 2002|April 2003||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||214|||Male|50 Years|N/A|No|||April 2003|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00187616||192853|
NCT00188201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0827-E|Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication|An Investigation of Cognitive Functioning and Brain Metabolites in Patients With Non-Cirrhotic Hepatitis-C Both Pre- and Post-Treatment With Antiviral Medication||University Health Network, Toronto||Recruiting|January 2002|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|November 28, 2005|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00188201||192810|
NCT00188214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0420-CE|CT Perfusion Scans for Assessment of Lung Cancer Before and After Chemo +/- Radiotherapy|Dynamic CT Perfusion for Assessment of Lung Cancer Before and After Neoadjuvant Chemo-/ Radiotherapy||University Health Network, Toronto|No|Completed|October 2003|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|38|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188214||192809|
NCT00188461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0875|Dose Reduction in Thoracic CT|Dose Reduction in Thoracic CT: A Comparison of on Line Automatic Dose Reduction and a 50% Reduction in Dose||University Health Network, Toronto||Completed|January 2004|August 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|16 Years|N/A|No|||September 2005|April 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00188461||192790|
NCT00195026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309006370|Infrared Imaging (Breast Scan IR) for Early Breast Cancer Detection|Infrared Imaging (Breast Scan IR) for Early Breast Cancer Detection||Weill Medical College of Cornell University||Completed|March 2005|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Patients already recommended for breast biopsy|March 2008|March 13, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00195026||192294|
NCT00188721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNREB#03-0462-CE|Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.|Transillumination for Breast Cancer Risk Assessment||University Health Network, Toronto|No|Completed|July 2006|September 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|500|||Female|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Cases and controls recruited from the Breast Imaging Clinic at Princess Margaret Hospital        or the Marvelle Koffler Centre at Mount Sinai Hospital (Toronto, Ontario, Canada)|August 2011|August 11, 2011|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00188721||192770|
NCT00195325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3162K1-100|Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.|A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|August 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||45|||Both|18 Years|N/A|No|||March 2007|March 22, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00195325||192271|
NCT00195676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-658|Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab||Abbott||Completed|May 2004|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1469|||Both|18 Years|N/A|No|||April 2011|April 11, 2011|September 13, 2005|Yes|Yes||No|October 20, 2010|https://clinicaltrials.gov/show/NCT00195676||192244|
NCT00196066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-513|Evaluation of the Zilver Vascular Stent in the Iliac Arteries (ZIPS)|||Cook||Completed|October 2002|April 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||150|||Both|50 Years|N/A|No|||January 2012|January 30, 2012|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00196066||192215|
NCT00195689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-537|Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis|A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis||Abbott|No|Completed|August 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||August 2007|August 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195689||192243|
NCT00196729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYR00800|Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration|A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State||Sanofi||Completed|December 2001|September 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||63|||Both|20 Years|68 Years|No|||March 2015|March 17, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00196729||192164|
NCT00197977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98101|Addressing Patients' Expectations of Total Knee Arthroplasty in a Randomized Trial|Addressing Patients' Expectations of Total Knee Arthroplasty: Developing and Testing an Educational Intervention in a Randomized Trial||Hospital for Special Surgery, New York|No|Completed|November 2001|September 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|||Actual|146|||Both|40 Years|N/A|No|||November 2011|November 22, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197977||192074|
NCT00197990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22078|Expectations, Satisfaction and Quality of Life in Total Hip Arthroplasty|Expectations, Satisfaction and Quality of Life in Total Hip Arthroplasty||Hospital for Special Surgery, New York|No|Completed|July 2003|June 2004|Actual|June 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|405|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who had total hip arthroplasty|November 2011|November 22, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197990||192073|
NCT00197964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI K23 HL 04067|A Randomized Trial to Improve Quality of Life Outcomes in Asthma Patients|A Randomized Trial to Improve Quality of Life Outcomes in Asthma Patients||Hospital for Special Surgery, New York|No|Completed|August 2001|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|||Actual|180|||Both|18 Years|N/A|No|||November 2011|November 22, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197964||192075|
NCT00208351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT01/95|A Randomised Single Centre Study to Compare the Long-term Performance of 4 Designs of the DePuy Ultima LX Stem in Primary Total Hip Replacement|Clinical and Radiographic Evaluation to Compare a Polished and Non-polished Collared Stem and a Polished and Non Polished Collarless Stem in Primary Total Hip Replacement||DePuy International|No|Terminated|October 1997|June 2012|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|165|||Both|60 Years|80 Years|No|||May 2013|May 29, 2013|September 13, 2005|Yes|Yes|The final assessments were conducted late and in a reduced format due to resource limitations    at the site.|No||https://clinicaltrials.gov/show/NCT00208351||191294|
NCT00208364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT01/11|A Two Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle Acetabular Cup Prosthesis With a Metal on Metal Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement||DePuy International|No|Active, not recruiting|April 2004|October 2024|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|18 Years|70 Years|No|||April 2014|April 29, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00208364||191293|
NCT00203996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12861B|Polycystic Ovary Syndrome (PCOS) and Sleep Apnea|Sleep, Metabolic, and Cardiovascular Dysfunction in Polycystic Ovary Syndrome||University of Chicago|No|Terminated|September 2003|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|10||Actual|37|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|September 13, 2005|Yes|Yes|Did not meet target patient accrual goals|No|March 5, 2013|https://clinicaltrials.gov/show/NCT00203996||191623|No participants were randomized to any of the 3 study arms in Aim 1. Also, the recruitment of control subjects for Aim 2 was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria.
NCT00204269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRM 2002/37|Three-Year Trial on a New Testosterone Gel|Three-Year Trial on a New Testosterone Gel: Clinical Efficacy, Tolerability and Compliance||University Hospital Muenster||Active, not recruiting|January 2003|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Male|18 Years|N/A|No|||May 2006|May 12, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204269||191602|
NCT00204516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA-Mel-03|Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens|Pilot Study of Intradermal Vaccination of Melanoma Patients With a Fixed Combination of mRNAs Compared to an Individualized Selection After Analysis of Antigen Expression in Tumor Tissue||University Hospital Tuebingen||Completed|April 2007|December 2012|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|80 Years|No|||January 2013|January 15, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204516||191583|
NCT00204529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17840|Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB|Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002)||University Hospital Tuebingen||Active, not recruiting|October 2004|December 2015|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|880|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204529||191582|
NCT00204841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998-129|Childhood Origins of Asthma (COAST)|Rhinovirus Infection and Asthma in Childhood and Adolescents|COAST|University of Wisconsin, Madison|No|Active, not recruiting|October 1998|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|nasal mucus samples, cord blood, peripheral blood samples, nasal cell brushing samples, cell      lines|Both|N/A|2 Minutes|No|Non-Probability Sample|High risk birth cohort of children (one or both parents have allergies and/or asthma).|November 2015|November 24, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204841||191559|
NCT00204854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-514|Telephone and Mail Intervention for Alcohol Use Disorders|Telephone and Mail Intervention for Alcohol Use Disorders|TAMI|University of Wisconsin, Madison|No|Completed|December 2001|November 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||900|||Both|21 Years|59 Years|No|||January 2011|October 1, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204854||191558|
NCT00187148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EnvDNA|Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults|Evaluation of the Tolerability and Safety of a Recombinant HIV-1 Multi-Envelope DNA Plasmid Vaccine (EnvDNA) in Healthy Adults||St. Jude Children's Research Hospital|No|Completed|February 2005|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00187148||192889|
NCT00187356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MCT# 52681|Multicentre Radial Artery Patency Study: Results of Patency Beyond 5 Years After Coronary Artery Bypass Surgery|Multicentre Radial Artery Patency Study: Results of Patency Beyond 5 Years After Coronary Artery Bypass Surgery|RAPS - 5 years|Sunnybrook Health Sciences Centre||Completed|July 2002|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|269|||Both|30 Years|80 Years|No|||June 2013|June 4, 2013|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00187356||192873|
NCT00187369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-63164|The Twin Birth Study: A Trial Comparing Planned Vaginal Birth to Elective Caesarean Section of Twins|The Twin Birth Study: A Multicentre Randomised Controlled Trial Comparing Planned Vaginal Birth to Elective Caesarean Section of Twins More Than or Equal to 32 Weeks Gestation||Sunnybrook Health Sciences Centre|Yes|Completed|December 2003|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2804|||Female|15 Years|45 Years|No|||October 2013|October 8, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00187369||192872|
NCT00187590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC200517|A Case Management Intervention to Prevent ER Visits in HIV-infected Persons|||University of California, San Francisco||Terminated|April 2004|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|612|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|September 13, 2005||No|Intervention was taken up as a standard of care.|No||https://clinicaltrials.gov/show/NCT00187590||192855|
NCT00187915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL330|Pilot Trial for Implementation of a MPA PK Monitoring Strategy|Pilot Trial for Implementation of a MPA PK Monitoring Strategy|MPA|University of Florida|No|Completed|July 2003|December 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||October 2011|October 19, 2011|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00187915||192832|
NCT00194753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18229-A|Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12|Adjuvant Therapy for High-Risk Localized Breast Cancer With Weekly Adriamycin +/- Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Taxol for 12 Weeks, Phase II||University of Washington|No|Completed|December 2001|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194753||192315|
NCT00194766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-1283-A|Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer|Continuous Temozolomide (SCH 52365) in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer, Phase II||University of Washington|No|Completed|July 2000|December 2006|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||November 2007|November 13, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00194766||192314|
NCT00195312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6120K1-100|Study Evaluating Vaccine in Adults With HIV|A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine Administered Alone or With Escalating Doses of IL-12 DNA or IL-15 DNA Molecular Adjuvants to HIV-1 Positive Adults Receiving Stable HAART.||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|August 2005|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|91|||Both|18 Years|50 Years|No|||December 2007|December 3, 2007|August 5, 2005||||||https://clinicaltrials.gov/show/NCT00195312||192272|
NCT00195039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403-791|Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer|A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Androgen-Independent Prostate Cancer||Weill Medical College of Cornell University||Completed|August 2004|October 2013|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Male|18 Years|N/A|No|||October 2013|October 25, 2013|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00195039||192293|
NCT00195338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881-101343|Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg|A Post-Marketing Surveillance Looking At Safety And Adherence To Treatment Of Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg||Pfizer|Yes|Completed|May 2004|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|17 Years|N/A|No|Probability Sample|Patients will be included after the physician decided to prescribe Enbrel.|December 2011|December 16, 2011|September 12, 2005||No||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00195338||192270|
NCT00195351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-400|Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection|A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|467|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|September 12, 2005||No||No|February 27, 2009|https://clinicaltrials.gov/show/NCT00195351||192269|
NCT00195702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE019|Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate||Abbott|Yes|Completed|February 2000|August 2010|Actual|September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|619|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|September 13, 2005|Yes|Yes||No|December 8, 2009|https://clinicaltrials.gov/show/NCT00195702||192242|
NCT00196456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III UV 06/04|Photodynamic Lasertherapy (PDT) in Periodontal Treatment (in Vivo)|Photodynamic Lasertherapy (PDT) in Periodontal Treatment (in Vivo)||University Medicine Greifswald||Completed|April 2004|January 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|35 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196456||192185|
NCT00197340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACET1-ginosar-HMO-CTIL|Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction|Antepartum Chronic Epidural Therapy (ACET) Using Ropivacaine to Improve Uteroplacental Blood Flow in Pre-Eclampsia and Intrauterine Growth Restriction||Hadassah Medical Organization||Completed|August 2003|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|45 Years|No|||February 2006|July 14, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197340||192117|
NCT00197041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257049/026|A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.|A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule in Toddlers and Children Aged 1 to 4 Years in a Malaria-endemic Region of Mozambique.||GlaxoSmithKline||Completed|July 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|2022|||Both|1 Year|4 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197041||192140|
NCT00197327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primip-ginosar-HMO-CTIL|Dilute Versus Concentrated Epidural Bupivacaine in Labor|Analgesia Requirement and Maternal Satisfaction Following Epidural PCA in Nulliparous Labor: the Effect of a Four-Fold Change in Local Anesthetic Concentration.||Hadassah Medical Organization||Completed|February 1998|March 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||60|||Female|18 Years|40 Years|No|||March 2003|March 2, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197327||192118|
NCT00198198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69883|Aripiprazole Treatment of Bipolar Depression|Open Label Pilot Study of Aripiprazole Treatment of Difficult to Treat Bipolar Depression||Indiana University||Completed|August 2005|November 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||April 2007|April 3, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00198198||192057|
NCT00198185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24087|Cascade PRFM Study: The Evaluation of Cascade Platelet-Rich Fibrin Matrix (PRFM) on Rotator Cuff Healing|The Evaluation of Cascade PRFM on Rotator Cuff Healing||Hospital for Special Surgery, New York||Recruiting|January 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||136|||Both|45 Years|N/A|Accepts Healthy Volunteers|||September 2005|January 11, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198185||192058|
NCT00198497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT-03-08961X|Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage|Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage||Bausch & Lomb Incorporated|No|Completed|June 1999|June 2003|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||510|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198497||192035|
NCT00204542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADO-Solaraze-AK-3-6|Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head|Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head||University Hospital Tuebingen||Completed|June 2005|December 2010|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|418|||Both|18 Years|80 Years|No|||March 2009|August 18, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204542||191581|
NCT00204867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0104|Virtual Colonoscopy (VC) for Primary Colorectal Screening|CT Virtual Colonoscopy for Primary Colorectal Screening||University of Wisconsin, Madison|Yes|Active, not recruiting|July 2004|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1000|||Both|50 Years|N/A|No|Non-Probability Sample|Screening population for colorectal cancer|December 2014|December 5, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204867||191557|
NCT00204880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0341|Aging and Cancer Effects (ACE) Study|Aging and Cancer: The Effects of Comorbidities on Cancer and it's Treatment||University of Wisconsin, Madison|Yes|Completed|February 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|34|||Both|55 Years|N/A|No|Non-Probability Sample|Men and women over the age of 55 newly diagnosed with lung, breast, colon or rectal        cancer, and with an anticipated life expectancy of at least 2 years for breast cancer        patients,1 year for patients with lung cancer, and 2 years for patients with colon or        rectal cancer. There is no upper age limit for participation in this study.|September 2010|October 1, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204880||191556|
NCT00205192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0335|Optimizing Cardiac Resynchronization|Optimizing Cardiac Resynchronization||University of Wisconsin, Madison|No|Completed|June 2004|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have previously had a resynchronization pacemaker system placed at the        University of Wisconsin Hospital or at the Middleton Veterans Hospital are potentially        eligible for this study.|August 2012|August 28, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205192||191532|
NCT00205569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A02051603|Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation|Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)||Virginia Commonwealth University|No|Completed|October 2002|October 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Probability Sample|Individuals with traumatic brain injury requiring inpatient rehabilitation and admitted to        Virginia Commonwealth University's Medical College of Virginia Hospitals acutely after        injury.|February 2009|February 21, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205569||191503|
NCT00198367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0101|Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)|Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) NSCLC. Randomized Phase II Study||Hospices Civils de Lyon||Active, not recruiting|January 2003|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|70 Years|No|||October 2007|October 4, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198367||192045|
NCT00187629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H40550-24730|Phosphate Intake's Effect on the Skeletal System - Pilot|Phosphate Intake's Effect on the Skeletal System Calcitropic Hormones and FGF23 - Pilot Study||University of California, San Francisco|No|Completed|March 2004|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00187629||192852|
NCT00187655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|867|Effect of, OAT3, on the Renal Secretion of Cefotaxime|Effect of Genetic Variation in the Transporter, OAT3, on the Renal Secretion of Cefotaxime||University of California, San Francisco|Yes|Completed|January 2004|December 2013|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|September 13, 2005||No||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00187655||192851|
NCT00199290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCB-1D-02|A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan|A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan||Kaken Pharmaceutical|No|Completed|August 2005|December 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|267|||Both|20 Years|N/A|No|||February 2008|February 1, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199290||191975|
NCT00199017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL04|German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults|Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1)||Johann Wolfgang Goethe University Hospitals||Completed|April 2004|||March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Both|15 Years|65 Years|No|||May 2008|August 20, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199017||191995|
NCT00194480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16066-1|Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users|Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2003|June 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|15 Years|N/A|No|||October 2008|October 24, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194480||192335|
NCT00194779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6278|Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery|A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study||University of Washington|No|Completed|October 2003|||June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||May 2013|May 7, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00194779||192313|
NCT00194792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6277|Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer|Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study||University of Washington|No|Terminated|August 2005|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||May 2013|May 7, 2013|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00194792||192312|
NCT00195715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-690|Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease|A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease||Abbott||Completed|September 2004|December 2008|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|777|||Both|18 Years|75 Years|No|||July 2011|July 8, 2011|September 13, 2005|Yes|Yes||No|December 1, 2009|https://clinicaltrials.gov/show/NCT00195715||192241|This study was stopped by the sponsor in December 2008 when the pre-specified termination criteria were met. Subjects who continued in the study through the termination date were considered as having completed the study.
NCT00195728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-666|Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain|An Open-Label Study Evaluating the Safety and Tolerability of Long Term Administration of Hydrocodone/Acetaminophen Extended ReleaseTablets (Vicodin® CR) in Subjects With Moderate to Severe Chronic, Non-Malignant Pain||Abbott|No|Completed|June 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|431|||Both|21 Years|75 Years|No|||January 2011|January 17, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00195728||192240|
NCT00195741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-488|The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents|Phase III, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Center Study Designed to Evaluate the Safety and Efficacy of Prophylactic Depakote ER in the Treatment of Adolescent Migraine||Abbott||Completed|May 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|12 Years|17 Years|No|||February 2007|February 7, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00195741||192239|
NCT00196105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-MOZ|Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)|Multicenter Prospective Randomized Controlled Trial of the Nitinol ZILVER Expandable Endoprosthesis in the Palliation of Extrahepatic Malignant Biliary Obstruction||Cook||Completed|September 2003|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|241|||Both|21 Years|N/A|No|||September 2011|September 28, 2011|September 12, 2005||Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00196105||192212|
NCT00196118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-507-01|Study of IVC Filter Retrieval With the Günther Tulip Vena Cava Filter|A Non-Randomized Prospective Study of IVC Filter Retrieval||Cook||Completed|April 2005|July 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||800|||Both|18 Years|N/A|No|||December 2007|December 7, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196118||192211|
NCT00196469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMAU16253.00.00|Impact of Heparin on the Need for Mechanical Ventilation in Neonates|Randomized Double Blind Trial Comparing Heparin and Placebo as Additives to Continuous Infusion in Intensive Care Neonates for Prevention of Ventilation||University Medicine Greifswald||Recruiting|December 2003|March 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|270|||Both|N/A|28 Days|No|||September 2006|October 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196469||192184|
NCT00196495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-016|Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse|Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse||Ethicon, Inc.||Completed|June 2004|November 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||90|||Female|21 Years|N/A|No|||December 2006|December 15, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196495||192182|
NCT00197652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD001330-05|Botswana Diarrheal Diseases Study|Botswana Diarrheal Diseases Study||Harvard School of Public Health|No|Completed|March 2001|March 2008|Actual|October 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1350|||Female|18 Years|55 Years|No|Probability Sample|Primary care clinic|October 2011|October 6, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197652||192097|
NCT00197678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD32257-2|Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women|Comparison of Two Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women From Tanzania||Harvard School of Public Health|No|Completed|November 2002|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1141|||Female|18 Years|N/A|No|||November 2010|November 9, 2010|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00197678||192096|
NCT00197639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 10913|Pharmacokinetic Study of Indinavir Drug Levels When Boosted With Ritonavir in Thailand|A Pharmacokinetic Study to Assess the Inter-patient Variability of Indinavir Drug Levels When Boosted With Ritonavir in Thai Patients on Highly Active Antiretroviral Therapy||Harvard School of Public Health|No|Completed|September 2006|August 2010|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|60 Years|No|Non-Probability Sample|HIV-infected Thai adults|November 2010|November 10, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00197639||192098|
NCT00198224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0212-78|Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients|Pilot Study of In Vitro Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients||Indiana University||Completed|January 2003|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|18 Years|N/A|No|||November 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198224||192056|
NCT00198510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT-02-08961X|Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage|Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage||Bausch & Lomb Incorporated|No|Completed|November 1998|March 2003|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||750|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198510||192034|
NCT00198523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-TP-CPK01|A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte|A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension||Bausch & Lomb Incorporated|No|Completed|July 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||132|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198523||192033|
NCT00204295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FET-HT-MS|Study on Amino Acid Uptake in Brain Tumors|Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET)||University Hospital Muenster||Active, not recruiting|January 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||60|||Both|N/A|N/A|No|||September 2006|September 13, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204295||191600|
NCT00204555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-IMI-001|Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma|A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma||University Hospital Tuebingen||Completed|January 2002|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||April 2007|August 31, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204555||191580|
NCT00204893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-297|Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects|Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects||University of Wisconsin, Madison||Active, not recruiting|July 2003|||March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||12|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204893||191555|
NCT00204906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0057|Correction of Vitamin D Inadequacy in Nursing Home Residents|Effect of Vitamin D Supplementation on Skeletal and Overall Health of Nursing Home Residents||University of Wisconsin, Madison||Completed|January 2005|||January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||June 2015|October 1, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204906||191554|
NCT00205205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2003-0505|Peer Mentoring for Persons With Spinal Cord Injury (SCI)|Peer Mentoring for Persons With Spinal Cord Injury: Program Satisfaction and Outcome for Mentor/Mentee||University of Wisconsin, Madison||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2008|October 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205205||191531|
NCT00205218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-1998-0373|Validation of Methods to Estimate Body Fat|Validation of Methods to Estimate Body Fat||University of Wisconsin, Madison||Completed|November 1998|August 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||150|||Both|12 Years|N/A|Accepts Healthy Volunteers|||April 2007|October 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205218||191530|
NCT00205231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-557|A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease|A Pilot Study to Examine the Feasibility and Effect on Tumor Necrosis Factor (TNF) Inhibition on HIV Disease||University of Wisconsin, Madison||Recruiting|May 2002|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|25|||Both|18 Years|N/A||||September 2005|October 1, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00205231||191529|
NCT00205582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/028|Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study|The Role of Excitatory Amino Acids on Neuronal Damage and Outcome After Traumatic Brain Injury: Assessment in Patients Using Microdialysis and (R)-[11C]PK11195 Positron Emission Tomography||VU University Medical Center||Active, not recruiting|May 2001|December 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Both|18 Years|70 Years|No|||May 2001|November 3, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205582||191502|
NCT00199030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL07|Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath|German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure||Johann Wolfgang Goethe University Hospitals||Completed|February 2004|December 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||May 2008|May 29, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199030||191994|
NCT00194493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APP00000089|Computerized Assessment for Patients With Cancer|Computerized Assessment for Patients With Cancer|ESRA-C|Dana-Farber Cancer Institute|Yes|Completed|April 2005|June 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1058|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194493||192334|
NCT00198991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL01|German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)|German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003)||Johann Wolfgang Goethe University Hospitals||Recruiting|April 2003|||December 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1250|||Both|15 Years|65 Years|No|||May 2008|May 29, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198991||191997|
NCT00199004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL03|Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab|German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2)||Johann Wolfgang Goethe University Hospitals||Completed|April 2004|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|15 Years|65 Years|No|||May 2008|August 20, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199004||191996|
NCT00194805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-5886-V03|Telehealth for Diabetes Self-Management|Telehealth for Diabetes Self-Management||University of Washington|Yes|Completed|September 2003|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 13, 2007|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00194805||192311|
NCT00195052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102004808|Intrinsic Optical Imaging Study to Map Neocortical Seizure in Human Epilepsy Patients|Intraoperative Optical Mapping of Human Epileptiform and Functional Cortex||Weill Medical College of Cornell University|No|Recruiting|May 2002|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|6 Years|65 Years|No|Non-Probability Sample|The patient, who is going to undergo a neurosurigcal procedure which will require        intraoperative brain mapping to determine the brain organization, is the potential study        subject.|January 2016|January 28, 2016|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00195052||192292|
NCT00195364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-301, 101492|Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain|Long-Term Safety Study of Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2003|October 2008|Actual|October 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1||93|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis who completed trial 0881A1-301-EU in Spain who fulfill        inclusion/exclusion criteria, treated in rheumatology units|June 2009|June 3, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195364||192268|
NCT00195377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101393|Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain|Evaluating Safety and QoL in Patients Treated With Etanercept: an Open Multicenter Study||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2003|April 2006|Actual|April 2006|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||1000|||Both|4 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis, psoriatic arthritis or AIJ, treated with etanercept in        rheumatology units|June 2009|June 17, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195377||192267|
NCT00195767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-555|Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents|An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents||Abbott||Completed|July 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|10 Years|17 Years|No|||March 2007|March 17, 2007|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00195767||192237|
NCT00195780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-647|A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents|An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents||Abbott||Completed|February 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|227|||Both|10 Years|17 Years|No|||June 2007|June 29, 2007|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00195780||192236|
NCT00196131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dal05-01|Problems With Morphine Use in Patients With a Severe Brain Injury|Changes in Morphine Handling and Response in Patients With Brain Trauma||Dalhousie University|No|Active, not recruiting|January 2005|April 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|N/A|N/A|No|||September 2006|April 8, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196131||192210|
NCT00196144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. P00202|FFS - Far Field Sensing Test Study in Cardiac Dual Chamber Pacemakers|Far Field Sensing Test Study in Patients With Implanted Cardiac Dual Chamber Pacemakers||Deutsches Herzzentrum Muenchen|Yes|Completed|July 2002|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|207|||Both|18 Years|N/A|No|||November 2007|November 23, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196144||192209|
NCT00196482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fortifier 01|Human Milk Fortifiers and Acid-Base Status|Impact of Human Milk Fortifiers on Acid-Base Status in Preterm Infants||University Medicine Greifswald||Recruiting|June 2004|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|N/A|3 Months|No|||September 2005|September 11, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196482||192183|
NCT00196742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FABRY REGISTRY|Fabry Disease Registry|Fabry Disease Registry||Sanofi|No|Recruiting|July 2001|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|9000|||Both|N/A|N/A|No|Non-Probability Sample|All patients with a confirmed diagnosis of Fabry disease are eligible for inclusion in the        Registry.|March 2016|March 4, 2016|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00196742||192163|
NCT00196755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REN00304|Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis|An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride (Renagel®) Compared With Calcium Acetate in Peritoneal Dialysis Patients||Sanofi||Completed|December 2004|April 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00196755||192162|
NCT00197704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI45441|Nutrition, Immunology and Epidemiology of Tuberculosis|Nutrition, Immunology and Epidemiology of Tuberculosis||Harvard School of Public Health|Yes|Completed|March 2000|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|876|||Both|18 Years|N/A|No|||November 2010|November 9, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00197704||192094|
NCT00198003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99104|Addressing Patients' Expectations of Total Hip Arthroplasty in a Randomized Trial|Addressing Patients Expectations of Total Hip Arthroplasty: Developing and Testing an Educational Intervention in a Randomized Trial||Hospital for Special Surgery, New York|No|Completed|November 2001|September 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|||Actual|178|||Both|55 Years|N/A|No|||November 2011|November 22, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198003||192072|
NCT00198536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-ECBT-CS01|Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome|Efficacy and Safety of Ecabet Ophthalmic Solution (2.83% and 3.70%) for Treatment of Dry Eye Syndrome||Bausch & Lomb Incorporated|No|Completed|April 2005|December 2005|Actual|December 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198536||192032|
NCT00204919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-099|Vitamin D Administration in the Nursing Home|Intermittent Vitamin D Administration in the Nursing Home: Impact on Vitamin D Status, Falls, Bone Turnover and Bone Density||University of Wisconsin, Madison|No|Completed|June 2001|November 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|55 Years|N/A|No|||September 2015|September 30, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204919||191553|
NCT00205244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2003-0495|Preoperative Preparation for Children|Preoperative Preparation for Children: Use of Relaxation and Distraction||University of Wisconsin, Madison||Recruiting||||October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|4 Years|12 Years|Accepts Healthy Volunteers|||August 2013|October 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205244||191528|
NCT00205257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-252|Prediction of Acute Rejection in Renal Transplant|Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant||University of Wisconsin, Madison||Completed|September 2001|February 2007|Actual|February 2007|Actual|Phase 1|Observational|N/A|||||||Both|18 Years|N/A|No|||December 2013|October 1, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205257||191527|
NCT00205595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/001|Normal Binding of R-[11C]PK11195 in Human Subjects|The Distribution and Quantification of Specific Binding of the Positron Emission Tomography Tracer R)-[11C]PK11195 in Normal Human Subjects||VU University Medical Center||Active, not recruiting|February 2001|January 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2008|July 3, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205595||191501|
NCT00205855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-S-003|An Implantable Spinal Cord Stimulation Pain Management System|Stimulus Confirmatory Study - An Implantable Spinal Cord Stimulation Pain Management System||Boston Scientific Corporation|No|Completed|February 2003|March 2005|Actual|October 2003|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|September 13, 2005|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT00205855||191482|
NCT00198731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.04.09.03.D1|Evaluation of the Effects of Community-based Interventions|Evaluation of the Effects of Community-based Interventions on Maternal Morbidity in the Early Postpartum Period in Rural Bangladesh||Johns Hopkins Bloomberg School of Public Health|No|Completed|April 2005|May 2007|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1506|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Community sample|July 2007|July 13, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198731||192017|
NCT00194506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-3882-E/A 05|Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home|Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home||University of Washington||Completed|August 2002|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||82|||Both|18 Years|75 Years|No|||April 2006|April 12, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194506||192333|
NCT00194519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25802-A|Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission|Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples||University of Washington|Yes|Completed|November 2004|March 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3408|||Both|18 Years|N/A|No|||March 2011|March 16, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194519||192332|
NCT00194818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1694-A 01|Asacol Dosing Study for Active Ulcerative Colitis|Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis||University of Washington|No|Completed|June 2003|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|7|||Both|18 Years|80 Years|No|||February 2008|February 13, 2008|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194818||192310|
NCT00194831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000501007693|Correlation of Volumetric Brain Analysis With Development at 18 Months|Volumetric Brain Analysis in the Premature Brain: Correlation With Future Development||Weill Medical College of Cornell University||Withdrawn|June 2005|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|0|||Both|18 Months|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|Premature infants < 1000 gram birthweight who are followed post discharge as part of        standard clinical care|June 2015|June 11, 2015|September 12, 2005||No|No data. Study never completed.|No||https://clinicaltrials.gov/show/NCT00194831||192309|
NCT00195065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (9811003566)|Cornell Translational Behavioral Science Research Consortium: Asthma Qualitative Study|Cornell Translational Behavioral Science Research Consortium: Asthma Qualitative Study||Weill Medical College of Cornell University|No|Completed|April 2003|September 2003||||N/A|Observational|Time Perspective: Prospective||||60|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00195065||192291|
NCT00195390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101583|Study Investigating Administration of Prevenar for Post-Marketing Surveillance|Investigation of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine) Administration for Post-Marketing Surveillance||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2004|July 2008|Actual|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|6 Weeks|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic, secondary and tertiary medical centers|September 2008|September 24, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00195390||192266|
NCT00195754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-554|A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.|The Safety of Divalproex Sodium Extended Release Tablets in Migraine Prophylaxis: An Open-Label Extension Study in Adolescents||Abbott||Completed|July 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|12 Years|17 Years|No|||July 2007|July 30, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00195754||192238|
NCT00196157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. C00604|Line Versus Spot Ablation in Persistent Atrial Fibrillation|Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation||Deutsches Herzzentrum Muenchen|Yes|Recruiting|August 2004|November 2008|Anticipated|May 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|80 Years|No|||May 2009|May 28, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196157||192208|
NCT00196508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-04-001|A Study Comparing Topical Skin Adhesive or Sutures for Closure Due to Episiotomy or Perineal Tears Following Childbirth|A Randomized, Multi Center Study to Evaluate the Clinical Performance of Topical Skin Adhesive in Comparison to Sutures for Perineal Skin Closure Following Childbirth||Ethicon, Inc.||Completed|April 2005|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||118|||Female|18 Years|N/A|No|||June 2006|October 13, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00196508||192181|
NCT00196521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-04-004|A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)|A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence||Ethicon, Inc.|No|Completed|January 2005|March 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||300|||Female|18 Years|N/A|No|||March 2007|December 11, 2007|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00196521||192180|
NCT00196534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-04-005|A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery|A Comparative Evaluation of Human Thrombin Versus Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Cardiovascular, Neurologic (Spine) and General Surgery Procedures.||Ethicon, Inc.||Completed|November 2004|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||304|||Both|18 Years|N/A|No|||August 2007|August 24, 2007|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00196534||192179|
NCT00197054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13399|A Study to Evaluate Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.|A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.||U.S. Army Medical Research and Materiel Command||Completed|July 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|255|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 1, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00197054||192139|
NCT00198562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H16-CV-001|Hypertension Control Based on Home Blood Pressure|Hypertension Control Based on Home Systolic Pressure Study (HOSP Study)||Ministry of Health, Labour and Welfare, Japan|Yes|Active, not recruiting|April 2000|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2600|||Both|40 Years|79 Years|No|||April 2008|April 18, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198562||192030|
NCT00198016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOSPITEN|Coil Embolization of Coronary Artery Fistulas|Coil Embolization of Coronary Artery Fistulas: A Single Centre Experience||HOSPITEN||Completed|January 2004|August 2005||||Phase 4|Observational|N/A|||||||Both|18 Years|85 Years|No|||August 2005|October 16, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198016||192071|
NCT00198809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WELL2001-01|Use of Herbal Supplements in Weight Loss and Weight Maintenance|Use of Herbal Supplements in Weight Loss and Weight Maintenance||Johns Hopkins Bloomberg School of Public Health||Terminated|November 2002|February 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198809||192011|
NCT00198822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-A-00-03-00019-00|Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh|Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|August 2001|March 2008|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|59666|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|September 12, 2005||No||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00198822||192010|
NCT00198835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.03.06.02.A2|Evaluation Research of the Nutrition Interventions in the INHP II Areas of CARE India|Evaluation Research of the Nutrition Interventions in the INHP II Areas of CARE India||Johns Hopkins Bloomberg School of Public Health||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||17000|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198835||192009|
NCT00199147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-elderly 01/99 Trial|Efficacy of G-CSF-Priming in Elderly AML Patients|Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation||Johann Wolfgang Goethe University Hospitals||Recruiting|January 2000|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|61 Years|N/A|No|||September 2005|October 25, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00199147||191985|
NCT00199160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAY 43-9006 Head and Neck|Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer|||Jules Bordet Institute||Completed|April 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2005|May 19, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199160||191984|
NCT00204932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0060|Effects of CLA Supplements on Body Weight and Fat Oxidation|Effects of CLA Supplements on Body Weight and Fat Oxidation||University of Wisconsin, Madison|Yes|Completed|July 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|44 Years|No|||December 2014|October 1, 2015|September 12, 2005||No||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00204932||191552|
NCT00205270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0240|Influenza Vaccine in Lung Transplant Patients|Influenza Vaccine in Lung Transplant Patients||University of Wisconsin, Madison|No|Completed|December 2004|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|152|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205270||191526|
NCT00237172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571B1202|Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)|Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)||Novartis||Completed|September 2002|||July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|20 Years|74 Years|No|||April 2012|April 29, 2012|October 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00237172||189140|
NCT00205868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM -SCS -120904|Spinal Cord Stimulation for Low Back Pain|Effectiveness of the Precision Spinal Cord Stimulation System in Patients With Failed Back Surgery Syndrome and Axial Low Back Pain||Boston Scientific Corporation|No|Completed|December 2004|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|304|||Both|18 Years|N/A|No|||October 2008|October 10, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205868||191481|
NCT00205881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUD-BL-070705|Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System|Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System||Advanced Bionics|No|Completed|October 2004|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2012|February 28, 2012|September 13, 2005||No||No|September 29, 2011|https://clinicaltrials.gov/show/NCT00205881||191480|
NCT00206206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-04-002|Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart|Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart.||Atlantic Health System||Terminated|July 2005|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||235|||Both|18 Years|N/A|No|||September 2005|February 2, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206206||191455|
NCT00198744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDI2004-01|Efficacy of Parent-Child Dieting Plans Incorporating Medifast Meal Replacements for Weight Loss|||Johns Hopkins Bloomberg School of Public Health||Completed|June 2004|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||January 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198744||192016|
NCT00199043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL08|Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma|Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs)||Johann Wolfgang Goethe University Hospitals||Completed|May 2003|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|15 Years|N/A|No|||May 2008|August 20, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199043||191993|
NCT00199056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMALL10|German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)|Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99)||Johann Wolfgang Goethe University Hospitals||Completed|October 1999|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||225|||Both|15 Years|65 Years|No|||May 2008|May 16, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00199056||191992|
NCT00195078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0404-218|Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer|Phase I-II Study of ZD1839 (IRESSA®), Cisplatin, and External-Beam Radiation Therapy in Patients With Locally Advanced, Non-Metastatic, Squamous Cell Carcinoma of the Head and Neck||Weill Medical College of Cornell University||Terminated|April 2004|September 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|29|||Both|18 Years|N/A|No|||July 2007|July 19, 2007|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00195078||192290|
NCT00195403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101575|A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA|A Drug Use Investigation of Enbrel for Post-Marketing Surveillance||Pfizer|No|Completed|May 2004|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1014|||Both|4 Years|N/A|No|Non-Probability Sample|Primary care clinic, secondary and tertiary medical centers|June 2013|June 11, 2013|September 12, 2005||No||No|June 11, 2013|https://clinicaltrials.gov/show/NCT00195403||192265|
NCT00195793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-661|A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin|A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of Fenofibrate or Ezetimibe as Add-On Therapy to Atorvastatin in Subjects With Combined Hyperlipidemia, Typical of the Metabolic Syndrome||Abbott|No|Completed|August 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|N/A|No|||October 2007|October 2, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00195793||192235|
NCT00195806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-648|Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine|Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents: An Open-Label, Long-Term Safety Study||Abbott||Completed|February 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||315|||Both|12 Years|17 Years|No|||August 2007|August 30, 2007|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00195806||192234|
NCT00195819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-606|Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis|A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis||Abbott|No|Completed|December 2003|June 2009|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|September 16, 2005|Yes|Yes||No|December 17, 2009|https://clinicaltrials.gov/show/NCT00195819||192233|The modified SASSS was pooled with a study (NCT00085644) similar in structure and sharing the same endpoints as this study.
NCT00195858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-71979|Healthy Eating Aerobic and Resistance Training in Youth (HEARTY) Trial|Healthy Eating, Aerobic and Resistance Training in Youth (HEARTY) Trial||Ottawa Hospital Research Institute|No|Completed|April 2005|June 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|304|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00195858||192231|
NCT00196547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.P. #05-2440|Montelukast in Modulating Exacerbations of Asthma in Children|Randomized Placebo-controlled Trial of Montelukast in Modulating Exacerbations of Asthma in Children, September 2005||Firestone Institute for Respiratory Health||Completed|September 2005|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|2 Years|14 Years|No|||March 2012|March 15, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196547||192178|
NCT00196768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30052004|Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic|Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study)||German AML Cooperative Group||Recruiting|January 2005|December 2010||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||October 2007|October 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196768||192161|
NCT00196781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-02-1-0062|Treatment Decision Making in Early-Stage Prostate Cancer|Treatment Decision Making in Early-Stage Prostate Cancer: Evaluation of Computer Based Patient Education and an Interactive Decision Aid||Georgetown University|Yes|Completed|September 2002|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Male|N/A|N/A|No|||January 2010|January 11, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196781||192160|
NCT00197353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPG1-ginosar-HMO-CTIL|Study of Different Concentrations of Epidural Bupivacaine for the Effects on Vasodilatation and Sensory Block|Sympathectomy-Mediated Vasodilatation and Differential Sensory Block After Epidural Bupivacaine: a Randomized Concentration Ranging Study||Hadassah Medical Organization||Completed|March 1999|September 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|70 Years|No|||May 2005|March 5, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197353||192116|
NCT00198250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308-07|Venlafaxine for Hot Flashes After Breast Cancer|Venlafaxine for Hot Flashes After Breast Cancer||Indiana University|No|Completed|May 2000|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|75|||Female|21 Years|N/A|No|||November 2008|November 13, 2008|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00198250||192054|
NCT00198575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15C-1-3|A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients|A Multicenter, Prospective Cohort Study to Determine the Prevalence and Profile of Heparin-Induced Thrombocytopenia in Patients Undergoing Cardiovascular Surgery or Percutaneous Coronary Intervention||Ministry of Health, Labour and Welfare, Japan||Active, not recruiting|November 2004|March 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1500|||Both|20 Years|N/A|No|||February 2006|February 15, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00198575||192029|
NCT00198588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG-HIT-CVD|Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia|Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia||Ministry of Health, Labour and Welfare, Japan|Yes|Completed|June 2005|September 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|20 Years|80 Years|No|||November 2008|November 11, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00198588||192028|
NCT00198848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.32.04.11.22.A2|Iron Supplementation Among Adolescent Girls in India|Iron Supplementation Among Adolescent Girls in India||Johns Hopkins Bloomberg School of Public Health||Recruiting|September 2005|July 2007||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||2800|||Female|12 Years|19 Years|Accepts Healthy Volunteers|||January 2006|September 6, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00198848||192008|
NCT00199173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sir-Spheres1|Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only|Comparison Hepatic Intra-arterial Injection of Yttrium-90 Versus 5FU in Colorectal Cancer Metastatic to the Liver Only||Jules Bordet Institute||Completed||January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2011|February 23, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00199173||191983|
NCT00194636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9426-A 02|Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)|Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)||University of Washington||Suspended|November 2003|November 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Male|18 Years|65 Years|No|||October 2007|October 17, 2007|September 13, 2005|||PI health issues|No||https://clinicaltrials.gov/show/NCT00194636||192323|
NCT00236886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003703|Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients|Prospective Pilot Study on Metabolism and Weight Changes in Subjects With Diagnosed Partial Onset Epilepsy, With or Without Secondarily Generalized Seizures and Treated With Topiramate.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 1998|June 2000|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|49|||Both|16 Years|N/A|No|||April 2010|April 26, 2010|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236886||189161|
NCT00237185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571B2222|A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene|Open, Randomized, Phase II Study of Glivec in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Plus 10 Year Extension Study||Novartis|No|Completed|June 2000|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|October 9, 2005|Yes|Yes||No|June 13, 2014|https://clinicaltrials.gov/show/NCT00237185||189139|No safety data was collected in the extension.
NCT00237198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345F1203|Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment|Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment||Novartis||Completed|March 2004|||July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|20 Years|79 Years|No|||August 2012|August 15, 2012|October 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00237198||189138|
NCT00237445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4027|Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days|A Multinational, Multicenter, Randomized, Double-blind, Study in Areas of High Pneumococcal Resistance Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Ketek® Telithromycin Once Daily for 7 Days, or Zithromax® Azithromycin Once Daily for 5 Days|COBRA II|Sanofi||Terminated|November 2005|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|110|||Both|18 Years|N/A|No|||January 2011|January 10, 2011|October 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00237445||189119|
NCT00237458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0647|An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain|An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain||UCB Pharma|No|Completed|May 2001|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2012|September 19, 2014|October 11, 2005|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00237458||189118|
NCT00237718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050377|Provision of Antioxidant Therapy in Hemodialysis (PATH) Study|Provision of Antioxidant Therapy in Hemodialysis (PATH) Study||Vanderbilt University|Yes|Completed|April 2006|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|385|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|October 10, 2005|Yes|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00237718||189098|
NCT00194532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27085-D|Cefpodoxime vs Ciprofloxacin for Acute Cystitis|Cefpodoxime vs Ciprofloxacin for Acute Cystitis||University of Washington|Yes|Completed|June 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|September 13, 2005||No||No|March 30, 2011|https://clinicaltrials.gov/show/NCT00194532||192331|
NCT00194844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-1206-G 02|Couples Miscarriage Healing Project:Randomized Trial|Caring Interventions for Couples Who Have Miscarried||University of Washington|Yes|Completed|September 2001|June 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|682|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 15, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00194844||192308|
NCT00195091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903-882|Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer|A Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer at Moderate to High Risk of Recurrence||Weill Medical College of Cornell University|Yes|Active, not recruiting|December 2003|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||December 2015|December 11, 2015|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00195091||192289|
NCT00195416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-102018|Study Investigating Enbrel Treatment for Ankylosing Spondylitis|A Drug Use Investigation of Enbrel for Post-marketing Surveillance (PMS) for Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2005|August 2008|Actual|August 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|526|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic, secondary and tertiary medical centers|September 2009|September 15, 2009|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00195416||192264|
NCT00195429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E-101535|A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients|A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2005|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|13 Years|N/A|No|||April 2010|April 22, 2010|September 12, 2005||||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00195429||192263|
NCT00195845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-USA-T102|A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder|A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder||Cambridge Health Alliance||Active, not recruiting|April 2003|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2005|March 28, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00195845||192232|
NCT00196170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. C00303|Randomized Study of Radiofrequency- vs. Cryo-Ablation for Typical Isthmus-Dependent Atrial Flutter|Multicenter Prospective Randomized Clinical Study Comparing Radiofrequency- vs. Cryo-Ablation in Typical Isthmus-Dependent Atrial Flutter||Deutsches Herzzentrum Muenchen|Yes|Active, not recruiting|May 2003|July 2008|Anticipated|April 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|500|||Both|18 Years|80 Years|No|||March 2008|March 18, 2008|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196170||192207|
NCT00196794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD3-170-302|A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea|A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea||Sanofi||Completed|April 2005|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|520|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00196794||192159|
NCT00196807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA098967|Prostate Cancer Screening: Fostering Informed Decisions|Prostate Cancer Screening: Fostering Informed Decisions||Georgetown University|Yes|Completed|August 2004|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|543|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196807||192158|
NCT00197067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257049/034|A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.|A Bridging Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.||GlaxoSmithKline||Completed|March 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||200|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||September 2011|December 26, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00197067||192138|
NCT00197379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-61|The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia|The Study for New Effect of Roxithromycin on Androgenetic Alopecia.||Hamamatsu University||Active, not recruiting|May 2005|January 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2005|July 28, 2010|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00197379||192114|
NCT00197691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 10027/000BOTS|Botswana Pediatric Respiratory Disease and Bloodstream Infection Study|Botswana Pediatric Respiratory Disease and Bloodstream Infection||Harvard School of Public Health|No|Completed|March 2001|October 2005|Actual|October 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|45 Years|No|Non-Probability Sample|LIVEBORN INFANT IN THE MASHI PMTCT TRIAL|March 2012|March 30, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00197691||192095|
NCT00198861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA014498-05|Neurobehavioral Model of HIV in Injection Drug Users|Neurobehavioral Model of HIV in Injection Drug Users||The City College of New York|No|Active, not recruiting|February 2002|March 2016|Anticipated|March 2015|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|836|||Both|15 Years|50 Years|No|Probability Sample|In total, we seek to recruit 150 HIV positive and 800 HIV negative drug users who are        between the ages of 15 and 50 years and who have used illicit drugs within the previous        five years of enrollment.|May 2015|May 28, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00198861||192007|
NCT00198874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA010777-08|Youth Drug Abuse Family and Cognitive-Behavioral Therapy|Youth Drug Abuse Family and Cognitive-Behavioral Therapy||University of Florida||Completed|January 2005|December 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|296|||Both|13 Years|21 Years|No|||September 2012|September 27, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00198874||192006|
NCT00199186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571ADE10|Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)|A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (> 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia (ALL)||Johann Wolfgang Goethe University Hospitals||Recruiting|March 2002|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|56 Years|N/A|No|||September 2005|October 18, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00199186||191982|
NCT00199212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herceptin-proteasome inhibitor|PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2|A Phase I, Open Label, Dose-escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2||Jules Bordet Institute|No|Completed|October 2003|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||February 2011|February 23, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00199212||191981|
NCT00194649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-3806-D|Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)|Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study|MIG-2|University of Washington|No|Completed|June 2005|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00194649||192322|
NCT00194961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2758s|Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease|A Multicenter Study of the Effect of Recombinant Human Growth Hormone on Leptin and Cytokines in Relation to Body Composition in Pediatric Patients With Growth Failure Due to Chronic Kidney Disease (CKD)||Weill Medical College of Cornell University||Terminated||December 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|6 Months|18 Years|No|||March 2008|March 24, 2008|September 12, 2005|||Funding was not approved|No||https://clinicaltrials.gov/show/NCT00194961||192299|
NCT00237211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345F1201|Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer|Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer||Novartis||Completed|June 2001|||October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|20 Years|74 Years|No|||May 2012|May 9, 2012|October 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00237211||189137|
NCT00237224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345EMX01|Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole|Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole||Novartis||Completed|February 2003|||February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|45 Years|80 Years|No|||November 2009|November 18, 2009|October 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00237224||189136|
NCT00237471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.116|Impact of Tight Glycaemic Control in Acute Myocardial Infarction|Impact of Tight Glycaemic Control With Insulin on Novel Vascular Disease Risk Factors and Myocardial Function and Perfusion in Acute Myocardial Infarction Patients With Hyperglycaemia||Melbourne Health||Terminated|October 2005|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|October 10, 2005||No|difficulty recruiting patients|No||https://clinicaltrials.gov/show/NCT00237471||189117|
NCT00237484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04257|Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)|Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy|Pegade|Merck Sharp & Dohme Corp.|No|Completed|July 2005|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|65 Years|No|||October 2015|October 1, 2015|October 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00237484||189116|
NCT00237731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505103|Pre-hospital Morphine Titration : Comparison of 0,05 Versus 0,1 mg/kg|Pre-hospital Morphine Titration : Comparison of 0,05 Versus 0,1 mg/kg||University Hospital, Toulouse|No|Completed|September 2005|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||February 2010|February 25, 2010|October 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00237731||189097|
NCT00238056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 05/9-C|Effect of Domperidone on QT Interval in Premature Infants|Effect of Domperidone on QT Interval in Premature Infants||Nantes University Hospital||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2005|January 26, 2015|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00238056||189073|
NCT00238043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 05-17|Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia|||Ministry of Health, Malaysia|No|Active, not recruiting|August 2005|April 2011|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|2000|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2005|June 12, 2008|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238043||189074|
NCT00194545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1519-D 02|Effect of Medication Diaries on Adherence to Highly Active Antiretroviral Drugs Among HIV-1 Infected Kenyan Children|Effect of Medication Diaries on Adherence to Highly Active Antiretroviral Drugs Among HIV-1 Infected Kenyan Children||University of Washington|No|Completed|July 2004|December 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Months|12 Years|No|||July 2012|July 5, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194545||192330|
NCT00194857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03850-001|Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin|A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV.||Weill Medical College of Cornell University||Terminated|February 2002|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||December 2012|December 14, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00194857||192307|
NCT00194870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309006367|Electroencephalography (EEG) and Deep Brain Stimulation (DBS) in Epilepsy|||Weill Medical College of Cornell University|No|Recruiting|October 2003|||December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|65 Years|No|||January 2011|January 3, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00194870||192306|
NCT00195871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL03|Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma|A Multicenter, Phase 2 Study, to Evaluate Safety and Efficacy of an Acute Lymphoblastic Leukemia (ALL) Intensive Chemotherapy for Adult Lymphoblastic Lymphoma (LL).||Centre Henri Becquerel|No|Active, not recruiting|February 2004|December 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|59 Years|No|||November 2013|November 6, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00195871||192230|
NCT00196183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. C00504|Trigger- vs. Substrate-Ablation for Paroxysmal Atrial Fibrillation|Randomized Study Comparing Pulmonary Vein Isolation Alone vs. Pulmonary Vein Isolation Plus Electrogram-Guided Substrate Ablation||Deutsches Herzzentrum Muenchen|Yes|Completed|August 2004|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|80 Years|No|||March 2008|March 14, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00196183||192206|
NCT00196560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC PSI ERAADS|Immobilization in External Rotation of Acute Shoulder Dislocations|A Randomized Evaluation of Immobilization in External Rotation in the Management of Acute Anterior Dislocations of the Shoulder||Fowler Kennedy Sport Medicine Clinic|No|Completed|September 2003|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|15 Years|30 Years|No|||November 2015|November 26, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196560||192177|
NCT00196820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 39|Mono Efficacy of Capecitabine (MoniCa)|A Multicenter Phase II Study to Determine the Efficacy of Capecitabine as First Line Monochemotherapy in Patients With HER2 Negative, Medium-risk, Metastatic Breast Cancer||German Breast Group|Yes|Completed|July 2005|December 2008|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||May 2008|October 5, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00196820||192157|
NCT00197080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/205|Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome|A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome||GlaxoSmithKline|No|Completed|June 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|18 Years|79 Years|No|||February 2013|February 13, 2013|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00197080||192137|
NCT00197093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|773812/003|In-Patient Study In Schizophrenic Patients|A Placebo Controlled, Double-Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Ascending Multiple Oral Doses of SB-773812 in Male and Female Schizophrenic Patients for up to 28 Days||GlaxoSmithKline||Completed|September 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||60|||Both|18 Years|55 Years|No|||May 2009|May 15, 2009|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00197093||192136|
NCT00197366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-25.02.05-HMO-CTIL|Development of Resistance Mutations in Pregnant HIV-Positive (+) Women Following Perinatal Antiretroviral Therapy in Israel|Development of Resistance Mutations in the Human Immunodeficiency Virus (HIV) in Pregnant HIV+ Women Receiving Perinatal Antiretroviral Therapy in Israel||Hadassah Medical Organization||Recruiting|March 2005|December 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|50|||Female|18 Years|N/A|No|||September 2005|June 11, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00197366||192115|
NCT00198237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0211-27|Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer|Genomic and Proteomic Analysis of Docetaxel and Capecitabine as Primary Chemotherapy for Stage II-III Breast Cancer||Indiana University||Completed|March 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00198237||192055|
NCT00198549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-VIT-SA-MA02|Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics|Phase IV Post-Approval Evaluation of Vitrase as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Anesthetics for Ophthalmic Surgical Procedures||Bausch & Lomb Incorporated|No|Completed|September 2004|March 2005|Actual|January 2005|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00198549||192031|
NCT00236054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6671/3032/AX/US|A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril (up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder||Teva Pharmaceutical Industries||Completed|October 2004|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|18 Years|64 Years|No|||May 2014|May 8, 2014|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236054||189224|
NCT00236730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005458|A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Difficult to Control Epilepsy|Double-Blind Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 1988|December 1990|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|178|||Both|18 Years|65 Years|No|||January 2011|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236730||189173|
NCT00237536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-203|Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia||Threshold Pharmaceuticals||Terminated|June 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Male|65 Years|80 Years|No|||April 2009|April 28, 2009|October 10, 2005||||||https://clinicaltrials.gov/show/NCT00237536||189112|
NCT00237549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The ADDITION-study|The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care.|The ADDITION Study. Anglo-Danish-Dutch Study of Intensive Treatment In PeOple With screeN Detected Diabetes in Primary Care|ADDTION|University of Aarhus|Yes|Completed|January 2001|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3057|||Both|40 Years|69 Years|No|||August 2012|December 19, 2013|October 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00237549||189111|
NCT00239083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ATR01|Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients|Phase IV Study of Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Kidney Transplant Patients||Novartis||Completed|January 2005|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|6 Years|N/A||||October 2009|October 30, 2009|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00239083||188999|
NCT00239096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF20040245|Prevention of Decompensation in Liver Cirrhosis|Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study||Odense University Hospital||Recruiting|September 2005|September 2011||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|70 Years|No|||October 2005|October 13, 2005|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00239096||188998|
NCT00239408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.282|Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).|Spiriva Assessment of FEV1 - (SAFE-Portugal). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Treatment in Patients With COPD. A Three-month Parallel Group, Double-blind, Randomised, Placebo-controlled Study.||Boehringer Ingelheim||Completed|December 2002|April 2004||April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||311|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239408||188974|
NCT00239421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.287|A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)|A Six-Week, Randomized, Double-Blind, Quadruple-Dummy Parallel Group Multiple Dose Study Comparing the Efficacy and Safety of Tiotropium Inhalation Capsules Plus Formoterol Inhalation Capsules to Salmeterol Inhalation Aerosol Plus Fluticasone Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|November 2003|September 2004||September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||605|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239421||188973|
NCT00238823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-108|Cryoablation Versus Radiofrequency Ablation|A Review and Comparison of Cryoablation and Radiofrequency Ablation in Children||Children's Healthcare of Atlanta||Terminated|January 2004|December 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||50|||Both|N/A|N/A|No|||May 2007|May 22, 2007|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238823||189019|
NCT00239538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.399|SMOOTH - Blood Pressure Control in Diabetic/Obese Patients|Prospective, Randomized, Open-label, Blinded Endpoint, Forced Titration Study to Compare Telmisartan Combined With HCTZ (80mg/12.5mg), to Valsartan Combined With HCTZ (160mg/12.5mg), for the Control of Mild-to-moderate Hypertension in Obese Patients With Type 2 Diabetes Mellitus Using ABPM.||Boehringer Ingelheim||Completed|January 2003|December 2004||December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|840|||Both|30 Years|N/A|No|||November 2013|November 7, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239538||188964|
NCT00238160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYUH-UHA-HCC02-01|Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer|Phase III Randomized Study of Surgical Resection With Versus Without Postoperative Hepatic Arterial Chemotherapy in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus||National Cancer Institute (NCI)||Withdrawn||||||Phase 3|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||July 2006|May 29, 2013|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238160||189067|
NCT00239850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2005.33|Morbid Obesity: Effects of Conservative Treatments and Gastric Bypass Surgery|Morbid Obesity: Effects of Conservative Treatments and Gastric Bypass Surgery||Norwegian University of Science and Technology||Completed|August 2005|August 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|65 Years|No|||February 2015|February 5, 2015|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00239850||188940|
NCT00239863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A0125E1|Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients|A Two-year Extension to a One-year, Multicenter, Partially Blinded, Double-dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients.||Novartis||Completed|May 2004|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||684|||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239863||188939|
NCT00239499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.273|Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)|A Six-Week, Randomised, Double-Blind, Triple-Dummy, Parallel Group, Multiple Dose, Pilot Study Comparing Tiotropium Inhalation Capsules to Salmeterol Inhalation Aerosol Combined With Fluticasone Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|September 2003|August 2004||August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||107|||Both|40 Years|N/A|No|||November 2013|November 8, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239499||188967|
NCT00238641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myobloc2002|“DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?”|“DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?”||Stanford University||Completed|January 2002|May 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|2 Years|18 Years|No|||October 2005|October 11, 2005|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00238641||189032|
NCT00238992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405ES01|Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.|A Prospective, Randomized, Open Label, Multicenter Trial of EC-MPS With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen for the Prevention of Acute Rejection Episodes in de Novo Renal Transplant Recipients.||Novartis||Completed|December 2002|||July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||144|||Both|18 Years|70 Years||||November 2011|November 1, 2011|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238992||189006|
NCT00239330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00011|Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy|An Open-label, Randomised, Multi-centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia||AstraZeneca||Completed|June 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||824|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239330||188980|
NCT00236028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003118|A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis|A Randomized, Double-blind, Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared With Methotrexate Alone for the Treatment of Patients With Early Rheumatoid Arthritis||Centocor, Inc.||Completed||April 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|607|||Both|18 Years|75 Years|No|||March 2010|May 18, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236028||189226|
NCT00236041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C8278b/202/BP/US-CA|Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)|A Double-Blind, Placebo-Comparison Study to Evaluate the Efficacy and Safety of ACTIQ® (Oral Transmucosal Fentanyl Citrate [OTFC®]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain||Teva Pharmaceutical Industries||Completed|April 2004|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||38|||Both|3 Years|15 Years|No|||May 2014|May 8, 2014|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236041||189225|
NCT00236704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005455|A Study of the Efficacy and Safety of Topiramate as "Add on" Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures|Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 1994|December 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|80|||Both|4 Years|N/A|No|||January 2011|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236704||189175|
NCT00237523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM1210|Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease||Symbollon Pharmaceuticals|No|Active, not recruiting|July 2005|March 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|175|||Female|18 Years|50 Years|No|||June 2007|June 15, 2007|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237523||189113|
NCT00238355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445848|Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems|Phase II Trial of Voriconazole Plus Caspofungin for the Initial Treatment of Invasive Fungal Infections||OHSU Knight Cancer Institute|Yes|Terminated|August 2003|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|18 Years|N/A|No|||December 2011|December 12, 2011|October 12, 2005|Yes|Yes|competing study at site|No|November 7, 2011|https://clinicaltrials.gov/show/NCT00238355||189053|
NCT00238368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0348 CDR0000445618|Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant|Autologous Blood or Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning||Sidney Kimmel Comprehensive Cancer Center||Completed|February 2004|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Primary Purpose: Diagnostic|1||Actual|59|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238368||189052|
NCT00240097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F041222002|Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)|Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin-Etoposide/Carboplatin in Extensive SCLC||University of Alabama at Birmingham|Yes|Completed|June 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|19 Years|80 Years|No|||November 2014|November 26, 2014|October 13, 2005|Yes|Yes||No|June 8, 2012|https://clinicaltrials.gov/show/NCT00240097||188922|
NCT00235768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMW 310-00-036|The NeXT Study; The Netherlands XTC Toxicity Study|Neurotoxicity of Ecstasy: Causality, Course and Clinical Relevance||UMC Utrecht||Completed|April 2002|July 2005||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||225|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2004|October 6, 2005|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235768||189246|
NCT00236522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002809|A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.|A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Levofloxacin 750 mg Once Daily for 5 Days Versus Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2002|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|784|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236522||189189|
NCT00237302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002662|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Preventing Migraine Headaches in Children|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects||Ortho-McNeil Neurologics, Inc.||Completed|July 2001|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|162|||Both|6 Years|15 Years|No|||April 2010|May 17, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237302||189130|
NCT00238121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00068|Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer|A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma||National Cancer Institute (NCI)||Completed|February 2005|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|18 Years|N/A|No|||January 2014|November 17, 2015|October 12, 2005|Yes|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT00238121||189069|
NCT00235781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0783|Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients|Non-Phased Study of the Use of a Single Dose of Thymoglobulin for Immunosuppressive Induction in Renal Transplant Recipients as Compared to a Standard Four Dose Regimen||Washington University School of Medicine||Terminated|January 2006|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||October 2006|October 13, 2006|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235781||189245|
NCT00238420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00730|Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer|A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer||National Cancer Institute (NCI)||Completed|July 2005|||October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||March 2014|March 16, 2015|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238420||189048|
NCT00238836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTCare|Anticipatory & Preventive Team Care (APTCare): At Risk Patients of Family Health Networks|||C. T. Lamont Primary Care Research Centre||Active, not recruiting||March 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||240|||Both|50 Years|N/A|No|||June 2005|October 12, 2006|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238836||189018|
NCT00238810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.068|Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome|Retrospective Evaluation of Serum B-type Natriuretic Peptide Hormone Levels in Post-operative Patients and the Relationship of BNP Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome||Children's Healthcare of Atlanta||Completed|April 2005|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients with congenital heart defects|November 2014|November 26, 2014|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238810||189020|
NCT00239512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR94-IRB-13|New Management Strategy of PDA for VLBW Preterm Infants|New Management Strategy of PDA for VLBW Preterm--Comparison of Indomethacin and Ibuprofen||China Medical University Hospital||Terminated|March 2005|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|N/A|7 Days|No|||June 2006|June 23, 2006|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239512||188966|
NCT00239525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008393|3-D Transcranial Ultrasound Analysis Study|3-D Transcranial Ultrasound Analysis Using Definity Injectable Suspension|Definity|Duke University|Yes|Completed|May 2006|December 2013|Actual|April 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|October 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00239525||188965|
NCT00238394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01822|Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer|A Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|December 2005|||March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238394||189050|
NCT00238732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-306|Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause|A Double-Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogens Combinations for Treatment of Moderate to Severe Vulvar/Vaginal Atrophy in Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||650|||Female|40 Years|65 Years|No|||December 2007|December 19, 2007|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238732||189025|
NCT00239382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.266|A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis|A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.||Boehringer Ingelheim||Completed|July 2004|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||May 2012|May 11, 2012|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239382||188976|
NCT00239694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0055|PPV: Pneumococcal Polysaccharide Vaccine in Older Adults|Immunogenicity of Pneumococcal Vaccination and Revaccination in Older Adults||National Institutes of Health Clinical Center (CC)|No|Completed|April 2001|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 14, 2015|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00239694||188952|
NCT00236509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002254|A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2001|September 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|763|||Both|12 Years|65 Years|No|||November 2010|November 15, 2010|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236509||189190|
NCT00237289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002653|Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting|Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting||Ortho-McNeil Neurologics, Inc.||Completed|October 2001|October 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|287|||Both|18 Years|70 Years|No|||April 2010|May 17, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237289||189131|
NCT00238108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002713|Melatonin Supplements for Improving Sleep in Individuals With Hypertension|Melatonin Supplementation in Hypertensive Patients||Brigham and Women's Hospital|Yes|Completed|October 2005|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|35 Years|65 Years|No|||July 2012|August 24, 2012|October 11, 2005|Yes|Yes||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00238108||189070|
NCT00239044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405NL01|An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients|An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients||Novartis||Completed|December 2002|||July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|18 Years|80 Years||||November 2011|November 1, 2011|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00239044||189002|
NCT00239057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405IT03|Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,|Enteric-Coated Mycophenolate Sodium (EC-MPS) Administration in Maintenance Renal Transplant Patients Receiving Cyclosporine Microemulsion (CsA-ME) and Steroids, for the Withdrawal of Concomitant Steroid Therapy: a Prospective, Open-label, Exploratory Study||Novartis||Completed|May 2002|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|23|||Both|18 Years|N/A||||January 2011|January 28, 2011|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00239057||189001|
NCT00236327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002920|Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain|Evaluation of the Efficacy and Safety of Transdermal Fentanyl in Patients Suffering From Chronic Cancer Pain in an Ambulatory Setting||Janssen Cilag S.A.S.|No|Terminated|June 2003|May 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|34|||Both|18 Years|N/A|No|||April 2010|May 16, 2011|October 7, 2005|||Sponsor discontinued the study following the discovery of a number of incompletely sealed    batches that were unusable.|No||https://clinicaltrials.gov/show/NCT00236327||189204|
NCT00236964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN99012|Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis|Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis||Luitpold Pharmaceuticals||Completed|February 2001|May 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||78|||Both|18 Years|N/A|No|||October 2005|October 13, 2005|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236964||189155|
NCT00236977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN03027|Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia|Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia||Luitpold Pharmaceuticals|No|Completed|August 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 7, 2005|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00236977||189154|
NCT00237796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3341-R|Functional Rehabilitation of Older Patients With Schizophrenia|Functional Rehabilitation of Older Patients With Schizophrenia||VA Office of Research and Development|Yes|Completed|February 2005|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|45 Years|N/A|No|||March 2015|March 23, 2015|October 7, 2005||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT00237796||189092|Randomization of treatment groups were not matched on the primary outcome (ILSS) at baseline but this was controlled using baseline ILSS as a covariate.Participant dropout varied across assessments
NCT00238706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHF PG/2001096|Use of Radiofrequency Ablation to Eliminate Continuous Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery|Left Atrial Radiofrequency Ablation During Mitral Valve Surgery for Continuous Atrial Fibrillation: A Prospective Randomized Clinical Trial||University Hospitals, Leicester||Completed|December 2001|November 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2005|May 4, 2006|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238706||189027|
NCT00238719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B4-389|Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 1999|June 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||293|||Both|8 Years|17 Years|No|||May 2006|May 17, 2006|October 12, 2005||||||https://clinicaltrials.gov/show/NCT00238719||189026|
NCT00238199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445077|Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer|Phase II Study of Calcitriol-Enhanced Docetaxel in Patients With Previously Untreated Metastatic or Locally Advanced Pancreatic Cancer||OHSU Knight Cancer Institute|Yes|Completed|June 2002|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238199||189065|
NCT00238238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50401|Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab|A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|March 2006|||June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238238||189062|
NCT00239551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|623-2005|Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer|Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer||Emory University|Yes|Completed|October 2005|December 2007|Actual|October 2006|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00239551||188963|
NCT00239837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH054257|Prevention Program for Problem Behaviors in Girls in Foster Care|Preventing Problems for Girls in Foster Care||Oregon Social Learning Center|No|Completed|December 2003|April 2013|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Female|10 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|October 13, 2005||No||No|May 6, 2013|https://clinicaltrials.gov/show/NCT00239837||188941|Sample is relatively small in size, and limited to girls in foster care in two Oregon Counties
NCT00239187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-202|A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Response of Repeated Subcutaneous Doses of E1 in Combination With G1 in Patients With Type 2 Diabetes||Transition Therapeutics||Completed|September 2005|January 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|30 Years|60 Years|No|||July 2006|July 17, 2008|October 12, 2005||||||https://clinicaltrials.gov/show/NCT00239187||188991|
NCT00239564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX054-B04-06|Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease|An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease||IMPAX Laboratories, Inc.|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|30 Years|N/A|No|||March 2009|March 13, 2009|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00239564||188962|
NCT00239577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103996|A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults|Observer-Blind, Single Center, Controlled Study of 2 Doses of Various Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6-Mth Schedule, to Healthy Adults||GlaxoSmithKline||Completed|April 2006|||June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||132|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239577||188961|
NCT00239876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A2302E1|Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A Two-year Extension to a One-year, Multicenter, Open-label, Randomised Study to Evaluate the Safety and Efficacy of FTY720 Combined With Tacrolimus and Steroids Versus Mycophenolate Mofetyl Combined With Tacrolimus and Steroids, in de Novo Adult Renal Transplant Recipients||Novartis||Completed|May 2005|||December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239876||188938|
NCT00239018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405FR01E1|Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients|A Prospective, Open-label, Multicenter, Follow-up Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients||Novartis||Completed|April 2003|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|144|||Both|18 Years|75 Years||||January 2011|January 28, 2011|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00239018||189004|
NCT00239356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-112|Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials|Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|March 2003|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|70 Years|No|||December 2014|December 4, 2014|October 13, 2005|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT00239356||188978|
NCT00239369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.480|Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5|A Prospective Randomised Study to Compare a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 25 mg With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Uncontrolled Hypertension Who Fail to Respond Adequately to Treatment With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg||Boehringer Ingelheim||Completed|October 2005|August 2006||August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||713|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239369||188977|
NCT00235755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX-RET-E22-302|Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy|Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures|RESTORE2|GlaxoSmithKline|No|Completed|December 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|539|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|October 6, 2005|Yes|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00235755||189247|
NCT00236951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN02023|Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy|A Phase III Randomized Controlled Study Comparing Iron Sucrose Intravenously to No Iron Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy||Luitpold Pharmaceuticals||Completed|February 2003|December 2005||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|224|||Both|18 Years|N/A|No|||May 2010|May 6, 2010|October 10, 2005|Yes|Yes||No|June 24, 2009|https://clinicaltrials.gov/show/NCT00236951||189156|
NCT00237783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP0008|Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension|Hemodynamic Changes During Dialysate Sodium Individualization in Hemodialysis Patients||Yale University|No|Terminated|October 2005|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|90 Years|No|||September 2015|September 23, 2015|October 7, 2005||No|Unable to recruit enough subjects|No||https://clinicaltrials.gov/show/NCT00237783||189093|
NCT00238680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHTIMER2005|Programmable Timer in the Bladder Rehabilitation Treatment of OAB|The Effect of Programmable Timer in Bladder Rehabilitation Treatment of Idiopathic Overactive Bladder in Children||University of Aarhus||Completed|March 2005|April 2007|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|5 Years|15 Years|No|||June 2008|June 13, 2008|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238680||189029|
NCT00238693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU3127|Transplant Patient Registry of Liver, Kidney and/or Pancreas|Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas||Virginia Commonwealth University|No|Recruiting|April 2003|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|N/A|N/A|No|Probability Sample|Patients followed in the transplant clinic at Virginia Commonwealth University Health        System|December 2015|December 4, 2015|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00238693||189028|
NCT00239031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405IT01|Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids|Multicentre, Controlled, Prospective, Randomized, Open-label Clinical Trial to Compare Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced Dose Cyclosporine Microemulsion (CsA-ME) Vs EC-MPS Plus Standard Dose CsA-ME in Elderly de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids||Novartis||Completed|March 2002|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|117|||Both|55 Years|75 Years|No|||January 2011|January 28, 2011|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00239031||189003|
NCT00239720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN011AI|hOKT3gamma1 (Ala-Ala) for the Treatment of Psoriatic Arthritis|Treatment of Psoriatic Arthritis With hOKT3gamma1 (Ala-Ala)|PART|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|March 2006|June 2008|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|October 13, 2005|Yes|Yes|FDA Clinical Hold|No|February 15, 2012|https://clinicaltrials.gov/show/NCT00239720||188950|This study was put on voluntary clinical hold after a serious adverse event occurred. After a review of the data, the team decided to close the study to further enrollment. Due to limited participants, no formal statistical analyses were performed
NCT00205725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer IVGTT/941273|Pfizer/IVGTT/Ziprasidone/Olanzapine|Glucose Regulation During Ziprasidone Treatment||Washington University School of Medicine|No|Completed|November 2000|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205725||191492|
NCT00205985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-scaph-04|Operative Versus Conservative Treatment of Scaphoid Fractures|Comparison of Time to Return to Previous Activity Between Operative Treatment and Cast Immobilization of Complete Fracture of the Middle Part of the Scaphoid Without Dislocation||AO Clinical Investigation and Documentation|No|Completed|December 2003|April 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||November 2007|November 16, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00205985||191472|
NCT00205998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-LCP2,4/3,5-03|Surgical Plate Osteosynthesis of Distal Radius Fractures|Surgical Plate Osteosynthesis of Distal Radius Fractures. Prospective Study of the Locking Compression Plate (LCP)||AO Clinical Investigation and Documentation|No|Terminated|December 2001|December 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|450|||Both|18 Years|80 Years|No|||April 2007|April 26, 2007|September 13, 2005|||Study completed|No||https://clinicaltrials.gov/show/NCT00205998||191471|
NCT00206336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-286|An Open-Label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.|An Open-Label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome||Baylor College of Medicine|No|Completed|October 2004|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|7 Years|65 Years|No|||April 2009|April 30, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00206336||191445|
NCT00206349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15806|Ability to Cope With Type 1 Diabetes|Evaluation of Coping Skills in Type 1 Diabetes||Baylor College of Medicine||Completed|June 2004|May 2005||||Phase 4|Observational|Time Perspective: Cross-Sectional||||220|||Both|8 Years|21 Years|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00206349||191444|
NCT00206635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308272|Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis|A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron® (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis||Bayer|No|Completed|January 2005|December 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|432|Samples With DNA|Whole blood, serum|Both|33 Years|N/A|No|Non-Probability Sample|Original pivotal trial population of Betaseron pivotal study (1989-1993)|November 2012|November 21, 2012|September 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00206635||191423|
NCT00206609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149/00|The Role of Oxygen in the Management of Dyspnoea in Advanced Cancer|A Randomised, Double-Blind Cross-Over Trial of the Effect of Oxygen on Dyspnoea in Patients With Advanced Cancer||Bayside Health||Completed|November 2000|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||September 2005|September 18, 2005|September 18, 2005||||No||https://clinicaltrials.gov/show/NCT00206609||191425|
NCT00206622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91429|Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing a 2.2mg 17 Beta-Estradiol/0.69mg Levonorgestrel Combination Transdermal Patch, and a 1mg 17 Beta-Estradiol Transdermal Patch With a Placebo Patch in Postmenopausal Women to Determine the Lowest Effective Dose of Estradiol for the Relief of Moderate to Severe Hot Flushes||Bayer||Completed|December 2004|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|425|||Female|40 Years|N/A|No|||May 2009|May 28, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00206622||191424|
NCT00206921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-236/04|Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness|Pulsed Dye Laser and Intense Pulsed Light for the Treatment of Telangiectasia and Skin Redness||Bispebjerg Hospital||Recruiting|February 2005|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||December 2004|July 23, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206921||191402|
NCT00238459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P01AI57127-2|Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised|Immunopathogenesis of Acute and Early HIV Infection and the Role of HIV-Specific CD4 T Cell Responses and the Effect of Their Enhancement by Potent Antiretroviral Drugs and an HIV Vaccine Adequate Vaccine Was Not Provided.||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2005|October 2013|Actual|March 2011|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|Samples Without DNA|Sequential samples from patients with acute and recent HIV infection|Both|18 Years|65 Years|No|Non-Probability Sample|Acutely HIV infected patients: virus positive antibody negative Recently HIV infected        patients: virus positive, low titers of antibody|November 2013|November 19, 2013|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00238459||189045|
NCT00238472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDJN608AIT05|A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion|A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion||Novartis||Completed|May 2003|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|75 Years||||April 2012|April 25, 2012|October 12, 2005||||||https://clinicaltrials.gov/show/NCT00238472||189044|
NCT00238498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1202|A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes|A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes||Novartis||Completed|July 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|291|||Both|20 Years|75 Years||||April 2012|April 30, 2012|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238498||189042|
NCT00238511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0690|An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)|An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)||UCB Pharma||Completed|November 2002|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|September 19, 2014|October 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00238511||189041|
NCT00238849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-03-087|Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.|Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer||Integrated Community Oncology Network||Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||October 2005|October 13, 2005|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238849||189017|
NCT00238862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP0511-P|Treatment of PED With AMT and Autologous Serum|Efficacy of Amniotic Membrane Transplantation and Autologous Serum in Treatment of Persistent Epithelial Defects||King Khaled Eye Specialist Hospital|Yes|Completed|October 2005|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||March 2007|March 5, 2007|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238862||189016|
NCT00239915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI#600|Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)|An 8-week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Pilot Study of Pagoclone in Patients With Persistent Developmental Stuttering Followed by a 52-week Open-Label Extension.||Pharmacology Research Institute||Completed|April 2005|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||May 2012|May 8, 2012|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239915||188935|
NCT00239928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751015|Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration|Long-Term Study For Pegaptanib Sodium In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration (Extension Study From A5751010)||Pfizer|No|Completed|September 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|51 Years|N/A|No|||May 2011|May 11, 2011|October 13, 2005||No||No|November 4, 2009|https://clinicaltrials.gov/show/NCT00239928||188934|
NCT00240084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NES V02|Nesiritide and Vo2 Max in Heart Failure Patients|Nesiritide and Vo2 Max in Heart Failure Patients||University of Rochester|No|Completed|July 2003|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||June 2013|June 17, 2013|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00240084||188923|
NCT00236301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P021204|Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers|Pro-Inflammatory Effects of Two Different Doses of 17 Beta Estradiol in Menopausal Women|THS|Assistance Publique - Hôpitaux de Paris|No|Terminated|March 2004|January 2007|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|99|||Female|18 Years|65 Years|No|||October 2005|January 16, 2008|October 11, 2005||No|terminated|No||https://clinicaltrials.gov/show/NCT00236301||189205|
NCT00204451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio 05-67|Human Ovarian Follicular Dynamics and Emergency Contraception|Human Ovarian Follicular Dynamics and Emergency Contraception||University of Saskatchewan||Completed|July 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204451||191588|
NCT00204711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0014|Use of the SNAP II Electroencephalography (EEG) Monitor in Outpatients Undergoing Surgery/Procedures With Sedation|Use of the SNAP II EEG Monitor in Outpatients Undergoing Surgery/Procedures With Sedation||University of Wisconsin, Madison|No|Completed|January 2005|November 2006|Actual|June 2008|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204711||191568|
NCT00204737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2004-0039|Short Course Glucocorticoid Treatment for PTSD|A Placebo-controlled, Randomized, Double-blind Comparison of Placebo vs Short Course Low Dose Corticosteroids on Posttraumatic Stress Disorder (PTSD)||University of Wisconsin, Madison|Yes|Completed|December 2004|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204737||191567|
NCT00205101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 2004-0235|Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion|Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion||University of Wisconsin, Madison||Completed|September 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 14, 2007|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205101||191539|
NCT00205439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-431|Surveillance For New Lung Primaries|Fluorescence Bronchoscopic Surveillance For New Lung Primaries After Curative Therapy for Squamous Cell Carcinoma of the Aerodigestive Tract"||University of Wisconsin, Madison||Terminated|December 2001|December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|N/A|N/A|No||Patients with new lung primaries after curative therapy for squamous cell carcinoma of the        aerodigestive tract|July 2015|July 9, 2015|September 13, 2005||No|low accrual|No||https://clinicaltrials.gov/show/NCT00205439||191513|
NCT00205452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-164|Quality of Life (QOL) Following Parathyroid Surgery|Does Quality of Life Improve Following Minimally Invasive Parathyroid Surgery?||University of Wisconsin, Madison||Completed|June 2003|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing parathyroid surgery|October 2012|October 16, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205452||191512|
NCT00205465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX04-765-301|Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765|A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy||Vertex Pharmaceuticals Incorporated||Completed|December 2004|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|18 Years|70 Years||||December 2007|December 3, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00205465||191511|
NCT00205478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX04-702-301|Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702|A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis||Vertex Pharmaceuticals Incorporated||Completed|June 2005|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|75 Years|No|||December 2007|December 5, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205478||191510|
NCT00205491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A02051602|Pharmacological Intervention in Depression After Traumatic Brain Injury|Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System)||Virginia Commonwealth University||Completed|October 2004|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205491||191509|
NCT00205738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Janssen IVGTT/940780|Janssen - Glucose Regulation/Risp/Olanz|Glucose Regulation During Risperidone and Olanzapine Treatment||Washington University School of Medicine|No|Completed|July 2000|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205738||191491|
NCT00206011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-CMF-01|Open Versus Endoscopic Surgery of Craniomaxillofacial (CMF) Condylar Neck Fractures|Open Versus Endoscopic Surgery of Condylar Neck Fractures||AO Clinical Investigation and Documentation|No|Completed|April 2003|January 2009|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00206011||191470|
NCT00206024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00064|Acid-Associated Heartburn Symptoms and Dose of Esomeprazole|A 4-week Study to Investigate the Relationship Between Resolution of Acid-Associated Heartburn Symptoms and Dose of Esomeprazole Magnesium||AstraZeneca||Completed|November 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|18 Years|75 Years|No|||November 2010|November 18, 2010|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00206024||191469|
NCT00206674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308380|Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease|Phase 3 Randomized, Double-Blind, Placebo Controlled Induction Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease||Sanofi||Completed|September 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00206674||191420|
NCT00206947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363051|The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia|PHARMACOLOGICAL TREATMENT OF COGNITIVE DEFICITS IN SCHIZOPHRENIC PATIENTS: The Effects of Central Cholinergic Augmentation on Cognitive Deficits and Psychopathology||University of Copenhagen|No|Terminated|December 2002|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|September 19, 2011|September 11, 2005||No|No more funding|No||https://clinicaltrials.gov/show/NCT00206947||191400|
NCT00207285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1 OH008496|Sleep Disorders Management, Health and Safety in Police|Sleep Disorders Management, Health and Safety in Police||Brigham and Women's Hospital||Completed|May 2005|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|731|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207285||191375|
NCT00206648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91293|An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS|A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex|ABOVE|Bayer|Yes|Completed|March 2003|October 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|60 Years|No|||December 2014|December 30, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00206648||191422|
NCT00207532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-4501|Dosage Effects of Folic Acid on Blood Folates of Honduran Women|Dosage Effects of Folic Acid on Blood Folates of Honduran Women||Centers for Disease Control and Prevention||Completed|March 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207532||191356|
NCT00238485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2302E1|An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder|A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder.||Novartis||Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|251|||Both|18 Years|70 Years|No|||November 2011|November 22, 2011|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238485||189043|
NCT00237965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001402|The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy|The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy||Brown University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2004|October 11, 2005|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00237965||189080|
NCT00239200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005-037|Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus|Lapatinib (GW572016) a Dual Inhibitor of EGFR and ErbB2, for Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus||University of Michigan Cancer Center||Terminated|October 2005|September 2007|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|29|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|October 12, 2005|Yes|Yes|notification from sponsor|No||https://clinicaltrials.gov/show/NCT00239200||188990|
NCT00239213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2005002|Catechin Gargling for Influenza Infection|A Randomized Clinical Study of Catechin Gargling Effects on the Prevention of Influenza Infection||University of Shizuoka||Completed|November 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2006|October 28, 2006|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239213||188989|
NCT00238901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621AIT06|Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation|Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF)||Novartis||Completed|December 2002|||July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|194|||Both|18 Years|75 Years||||August 2010|August 31, 2010|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238901||189013|
NCT00239226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPASS|Electrophysiologically Guided PAcing Site Selection Study|Investigational New Drug Application/ Investigational Device Exemption Information|EPASS|Medtronic BRC|Yes|Completed|November 2005|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|102|||Both|18 Years|N/A|No|||April 2012|September 20, 2013|October 13, 2005||No||No|November 6, 2009|https://clinicaltrials.gov/show/NCT00239226||188988|
NCT00239707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0056|GIP: Glucose-dependent Insulinotropic Peptide|Effect of GIP / GIP Analog in Type 2 Diabetes After a Meal||National Institutes of Health Clinical Center (CC)|No|Completed|February 2003|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|October 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00239707||188951|
NCT00203879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11447A|Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma|Randomized Phase II Study of Immunization With MAGE-3/Melan-A/gp 100/NA17 Peptide-Pulsed Autologous PBMC and rhIL-12 With or Without Low Dose IL-2 Inpatients With Metastatic Melanoma||University of Chicago|Yes|Completed|February 2002|May 2007|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00203879||191631|
NCT00208260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METHEP/2004/22|Intensified Chemotherapy in CRC After Resection of Liver Metastases|Randomized Phase II Trial Followed by Phase III Trial With Molecular Biology Study, Comparing a Standard Bi-therapy vs 3 Arms of Intensified Chemotherapy in Patients With Unresectable or Not Optimally Resectable Colorectal Cancer Liver Metastases.||Institut du Cancer de Montpellier - Val d'Aurelle||Completed|April 2004|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|124|||Both|18 Years|75 Years|No|||June 2010|June 15, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208260||191301|
NCT00204204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216-05-04273|Importance of Forces and Safety Features in Car Crash Multitrauma|The Multitraumatized Patient. What is the Importance of Forces Involved and the Use of Safety Equipment for the Amount of Trauma to the Patient Inside the Vehicle.||University of Oslo|No|Completed|January 2005|January 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||200|||Both|N/A|N/A|No|||August 2007|August 24, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204204||191607|
NCT00204217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|313-04124|Monitoring of Intubation and Ventilation During Resuscitation|Monitoring of Intubation and Ventilation During Resuscitation||University of Oslo|No|Completed|September 2004|April 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||15|||Both|18 Years|N/A|No|||August 2007|August 24, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204217||191606|
NCT00204464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS_EX|Study of the Effects Strengthening Exercises in Individuals With ALS|Preliminary Study: The Effects of a Strengthening Program on Maximum Voluntary Isometric Contraction, Functional Abilities, Fatigue and Quality of Life in Individuals With Amyotrophic Lateral Sclerosis||University of Saskatchewan||Completed||December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|80 Years|No|||December 2004|November 3, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00204464||191587|
NCT00204750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8953|Trial of Electrosurgical Incision Versus Bougie Dilation of Symptomatic Lower Esophageal (Schatzki's) Rings|A Randomized, Prospective Trial of Electrosurgical Incision Followed by Rabeprazole Versus Bougie Dilation Followed by Rabeprazole of Symptomatic Lower Esophageal (Schatzki's) Rings||University of Utah|No|Completed|August 2001|December 2006|Actual|December 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||December 2007|December 23, 2007|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204750||191566|
NCT00205114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-042|Dane County Safety Assessment for Elders (SAFE) Research Study|Dane County Safety Assessment for Elders (SAFE) Research Study||University of Wisconsin, Madison|No|Completed|December 2003|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|500|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2007|October 1, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205114||191538|
NCT00205764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/99|Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy|Randomised, Non-blind, Parallel Group Study to Compare Tandem High Dose Melphalan (200mg/m²) Versus Triple Intermediate Dose Melphalan (100mg/m²) and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma||Austrian Forum Against Cancer||Completed|March 1999|October 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|212|||Both|19 Years|70 Years|No|||November 2013|November 21, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205764||191489|
NCT00206037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-hto-colloss-05|Open Wedge High Tibia Osteotomy|Comparison of Open Wedge High Tibia Osteotomy Surgeries Using Colloss E and Tomofix and Tomofix Only, Regarding the Bone Healing||AO Clinical Investigation and Documentation|Yes|Terminated|May 2005|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||November 2007|November 19, 2007|September 14, 2005|||Interim analysis showed significant results, thus study was stopped|No||https://clinicaltrials.gov/show/NCT00206037||191468|
NCT00206362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16040|Ability to Cope With Type 1 Diabetes|Evaluation of Ongoing Management of Type 1 Diabetes||Baylor College of Medicine|No|Completed|July 2004|April 2010|Actual|February 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|8 Years|21 Years|No|Non-Probability Sample|Patients of diabetes clinic, Texas Children's Hospital.|September 2015|September 11, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00206362||191443|
NCT00206661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308001|Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease|Phase 1/2 Safety, Pharmacokinetic, and Pharmacodynamic Study of Sargramostim (Leukine®) in Pediatric Patients With Active Crohn's Disease, With One-year Surveillance and Retreatment Extension||Sanofi||Terminated|December 2004|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|6 Years|16 Years|No|||December 2013|December 2, 2013|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00206661||191421|
NCT00207831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP276|Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma|Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma|UFT RT Phase 3|ICO Paul Papin|Yes|Terminated|July 2004|February 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|219|||Both|18 Years|80 Years|No|||July 2010|July 20, 2010|September 13, 2005||No|Terminated after interim analysis|No||https://clinicaltrials.gov/show/NCT00207831||191334|
NCT00207558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-3970|Blood Folate and Homocysteine Levels Following Administration of Folic Acid According to Different Daily Dosing Schedules:a Simulation of Food Fortification|Blood Folate and Homocysteine Levels Following Administration of Folic Acid According to Different Daily Dosing Schedules:a Simulation of Food Fortification||Centers for Disease Control and Prevention||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1100|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||September 2005|July 12, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207558||191355|
NCT00237978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-Akne02-003|Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)|Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)||Technische Universität Dresden|No|Recruiting|September 2006|September 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|14 Years|N/A|No|||May 2008|May 13, 2009|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00237978||189079|
NCT00238914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4260R|Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1|Opiate Dependence: Combined Naltrexone/Behavior Therapy||New York State Psychiatric Institute|Yes|Completed|August 1999|July 2002|Actual|July 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|60 Years|No|||January 2012|January 12, 2012|October 13, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00238914||189012|
NCT00238927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAP30006|Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma|Multicenter Randomised Controlled Trial of Episodic Fluticasone Versus Placebo in Viral-induced Asthma in Children||McGill University Health Center|No|Completed|November 1999|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|1 Year|6 Years|No|||March 2014|March 25, 2014|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238927||189011|
NCT00239239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040232|Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies|An Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Darbepoetin Alfa Administered Three Times Per Week for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy||Amgen||Completed|August 2005|March 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||March 2010|March 4, 2010|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239239||188987|
NCT00239252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6431/HCT1|Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C|||Astellas Pharma Inc||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|N/A|No|||August 2014|August 25, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239252||188986|
NCT00239265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6171/LCT2|Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome|||Astellas Pharma Inc||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|20 Years|90 Years|No|||October 2007|October 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239265||188985|
NCT00239590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000AE13B|Testosterone and Myocardial Perfusion in CHD|Effects of Chronic Testosterone on Myocardial Ischaemia and Endothelial Function in Men With Documented Coronary Heart Disease||Imperial College London|No|Completed|June 2001|April 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|35 Years|75 Years|No|||October 2005|March 25, 2015|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00239590||188960|
NCT00239980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA6300011-FOCUS-II|Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)|A Phase II Randomized Study of Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)||Ontario Clinical Oncology Group (OCOG)|Yes|Completed|October 2005|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|77|||Female|18 Years|75 Years|No|||February 2010|February 2, 2010|October 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00239980||188931|
NCT00208039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-9-3983|Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates|Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates Less Than or Equal to 1250 gm Birthweight Ver 4.0||Children's Hospital of Philadelphia|No|Completed|September 2004|November 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|N/A|10 Days|No|||November 2007|November 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208039||191318|
NCT00208273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-HO-RT/2004/31|Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer|A Phase II Randomized Study to Compare Skin Late Toxicities of Concomitant Letrozole-Radiotherapy and Radiotherapy Followed by Letrozole as Adjuvant Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors||Institut du Cancer de Montpellier - Val d'Aurelle||Completed|January 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|N/A|No|||December 2007|December 13, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208273||191300|
NCT00203918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12843B|Prostate Cancer Utilities and Cost-Effectiveness Analysis|Prostate Cancer Utilities and Cost-Effectiveness Analysis||University of Chicago|No|Active, not recruiting|January 2004|January 2015|Anticipated|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Male|18 Years|N/A|No|Probability Sample|Patients visiting the urology clinic at the University of Chicago.|August 2010|September 4, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00203918||191628|
NCT00203892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12095B|Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma|A Randomized Pilot Phase II Study of Immunization With Modified CEA (CAP1-6D) Peptide In Patients With Locally Advanced Or Surgically Resected Adenocarcinoma of the Pancreas||University of Chicago|Yes|Completed|April 2003|May 2012|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|September 12, 2005|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00203892||191630|
NCT00204477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-422|Soy Protein and Breast Cancer Risk Reduction|Soybean Diet and Breast Density||The University of Texas Medical Branch, Galveston|No|Active, not recruiting|April 2002|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|313|||Female|30 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00204477||191586|
NCT00204763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12127|Comparison of Esophageal and Anorectal Manometry Catheters|Comparison of Solid-State Esophageal Manometry and Water Perfused Anorectal Manometry Catheters With Air Filled Multi-Balloon Esophageal and Anorectal Manometry Catheters||University of Utah|No|Terminated|January 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|5|||Both|18 Years|80 Years|No|||January 2008|January 11, 2008|September 13, 2005||No|We determined that the results would not be worth reporting.|No||https://clinicaltrials.gov/show/NCT00204763||191565|
NCT00204776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 04104|XELOX for Metastatic Breast Cancer|A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer||University of Wisconsin, Madison|Yes|Completed|March 2005|November 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|37|||Both|18 Years|N/A|No|||September 2005|September 30, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00204776||191564|
NCT00205127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-241|Cardiac Water and Fluoromethane Cardiac PET|Comparison of Cardiac Perfusion by O15-water and F17-fluoromethane PET||University of Wisconsin, Madison|No|Completed|January 2004|March 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205127||191537|
NCT00205140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2005-1166|Effect of Pharmacist Initiated Recommendations On Prescribing For Participants In the Senior MEDS Personalized Medication Review|Participant Characteristics, Medication Utilization, and the Effects of Pharmacist Initiated Recommendations On the Prescribing For Participants In the Senior MEDS Personalized Medication Review for Adults Age 55 and Older||University of Wisconsin, Madison||Terminated|July 2005|May 2007|Actual|||N/A|Observational|N/A|||Anticipated|100|||Both|55 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 13, 2005|||The program responsible for recruitment was dismantled in 2006.|No||https://clinicaltrials.gov/show/NCT00205140||191536|
NCT00205504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD Williams|Oral Contraceptives in the Metabolic Syndrome|Oral Contraceptives in the Metabolic Syndrome||Virginia Commonwealth University||Active, not recruiting|June 2005|December 2016|Anticipated|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|36|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|September 13, 2005|Yes|Yes||No|January 25, 2012|https://clinicaltrials.gov/show/NCT00205504||191508|
NCT00205517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23GM068842|Sedation and Psychopharmacology in Critical Care|Pharmacokinetics and Dynamics in Patients Randomized to Once Daily Awakening and Sedated According to Standardized Algorithm||Virginia Commonwealth University||Terminated|September 2002|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|75|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|September 12, 2005|||End point reached at interim analysis|No||https://clinicaltrials.gov/show/NCT00205517||191507|
NCT00205751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-002-0601|Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy|International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma||Austrian Forum Against Cancer||Completed|August 2001|October 2009|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|350|||Both|19 Years|N/A|No|||November 2013|November 21, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205751||191490|
NCT00206687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91039|STEPS Trial - Spheramine Safety and Efficacy Study|Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's Disease||Bayer|Yes|Terminated|January 2003|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|30 Years|70 Years|No|||November 2014|September 23, 2015|September 13, 2005|Yes|Yes|Study was completed, only life long extended follow-up phase was discontinued after 12 years.|No||https://clinicaltrials.gov/show/NCT00206687||191419|
NCT00206700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307340|Open-label Trial of Leukine in Active Crohn's Disease|Open-label Trial of Leukine® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease||Sanofi||Terminated|February 2003|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|378|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00206700||191418|
NCT00207298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0076|18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology|Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology||British Columbia Cancer Agency||Recruiting|June 2005|November 2008||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|5000|||Both|19 Years|90 Years|No|||November 2010|November 3, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207298||191374|
NCT00207571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3590|Partner Notification Intervention for STD Clinics.|Computer-assisted STD Partner Notification||Centers for Disease Control and Prevention|No|Completed|April 2001|October 2005|Actual|October 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||150|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207571||191354|
NCT00207584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-9997|Randomized Controlled Trial of Doxycycline to Prevent Acquisition of Mycoplasma Pneumoniae in an Outbreak Setting|A Double-Blind, Randomized Placebo-Controlled Trial of Doxycycline for Chemoprophylaxis in the Setting of an Outbreak of Mycoplasma Pneumoniae||Centers for Disease Control and Prevention||Completed|January 1994|April 1994||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207584||191353|
NCT00207844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 10602|Selenium, as Sodium Selenite, in the Treatment of Septic Shock|Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of a Therapeutic Administration of Selenium, as Selenite, in Septic Shock Patients.||Centre Hospitalier de Meaux||Completed|January 2002|January 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207844||191333|
NCT00208078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206/08-11-04|Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.|Evaluation of the Effects of Long Term Non-Invasive Ventilation in Patient With Cystic Fibrosis and Chronic Hypercapnic Respiratory Failure.||Cochin Hospital|Yes|Terminated|May 2005|May 2011|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|September 13, 2005||No|Not enough patient recruited|No||https://clinicaltrials.gov/show/NCT00208078||191315|
NCT00238537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145671|Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET)|Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET) in Acute Stroke||Melbourne Health||Completed|August 2001|April 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2009|May 28, 2013|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00238537||189039|
NCT00238940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405DE01E1|Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants|A One-year, Randomized, Open Label, Parallel Group Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Either Full Dose or Reduced Dose Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients||Novartis||Completed|February 2003|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|55|||Both|18 Years|75 Years||||January 2011|January 28, 2011|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238940||189010|
NCT00230620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS1|Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families|Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families With Pulmonary Arteriovenous Malformations||Imperial College London||Recruiting|December 1998|November 2020|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Patients with hereditary haemorrhagic telangiectasia and their families|August 2008|May 28, 2015|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230620||189631|
NCT00230893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC - PTSD Retrospective|Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years|Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years||Tuscaloosa Research & Education Advancement Corporation||Completed|July 2005|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||99|||Both|19 Years|N/A|No|||September 2006|September 20, 2006|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230893||189610|
NCT00239993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM016|A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®|An Open-Label, Randomized, Single Cross-Over Study of Warm Compress Versus Usual Injection Site Preparation on Local Injection Site Reactions Among Persons With MS Who Perform Daily Injections of Copaxone®.||Teva Pharmaceutical Industries|No|Completed|August 2005|February 2006|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|55 Years|No|||April 2009|April 16, 2009|September 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00239993||188930|
NCT00208286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT0101|P.F.C. Sigma Fixed Versus P.F.C. RP Mobile Bearing Total Knee Systems|Clinical Evaluation of the P.F.C. Sigma (Fixed Bearing) and P.F.C. Sigma Rotating Platform (Mobile Bearing) Total Knee Systems.||DePuy International|No|Terminated|November 2001|October 2009|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|September 13, 2005|No|Yes|Primary outcome of the study achieved; investigator decided to conduct the study without    sponsor support after 2009.|No||https://clinicaltrials.gov/show/NCT00208286||191299|
NCT00203905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12652A|A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck|A Randomized Phase II Study of Concomitant Chemoradiotherapy With 5-Fluorouracil/Hydroxyurea Compared to FHX Plus Bevacizumab for Intermediate Stage and Selected Stage IV Cancers of the Head and Neck||University of Chicago|Yes|Completed|January 2004|November 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00203905||191629|
NCT00203931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13722A|Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer|A Randomized Phase II Trial Comparing Cetuximab With Concurrent Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer Refractory to Primary Treatment||University of Chicago|Yes|Terminated|March 2005|November 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|September 12, 2005|Yes|Yes|Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed    after first-line therapy|No|December 10, 2013|https://clinicaltrials.gov/show/NCT00203931||191627|
NCT00204230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|MMF and Calcineurin Inhibitor Withdrawal in CAN|Randomized Controlled Study: Effect of Mycophenolatmofetil in Patients With Histologically Proven Chronic Allograft Nephropathy||University Hospital Muenster||Terminated|October 1999|September 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||86|||Both|18 Years|70 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204230||191605|
NCT00205153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2000-0284|A Team Model of Hypertension Care in African Americans|A Team Model of Hypertension Care in African Americans||University of Wisconsin, Madison|Yes|Completed|December 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|576|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205153||191535|
NCT00205530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A02051604|Evaluation of an Intervention Model for Family Crisis and Support|Evaluation of an Intervention Model for Family Crisis and Support (a Research Project Within the Traumatic Brain Injury Model System Grant)||Virginia Commonwealth University|No|Completed|January 2003|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|18 Years|N/A|No|Probability Sample|Family members/caregiver friends and persons with ABI who are at least three months        postinjury will be eligible to participate in the present investigation. ABI is defined as        damage to brain tissue caused by stroke, aneurysm, anoxia, non-progressive brain tumor,        infection, or an external mechanical force as evidenced by: loss of consciousness, post        traumatic amnesia (PTA), objective neurological findings, or skull fracture. Penetrating        wounds fitting the definition listed above will be included. Lacerations and/or bruises of        the scalp or forehead without other criteria listed above will be excluded. All        participants must be at least 18 years of age or older and able to understand and provide        consent.|July 2013|July 29, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205530||191506|
NCT00205777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3068A1-301|Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women|Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women||Pfizer|No|Completed|December 2001|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7609|||Female|55 Years|80 Years|No|||February 2013|February 28, 2013|September 16, 2005|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00205777||191488|
NCT00206050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00066|Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po|A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-Hour Intragastric pH Profile After 5 Days of Once Daily Oral Administration of Either Esomeprazole 40 mg or Pantoprazole 40 mg Following Once Daily Infusion of Intravenous Pantoprazole 40 mg for 5 Days in Healthy Volunteer Subjects||AstraZeneca||Completed|September 2004|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2011|January 20, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00206050||191467|
NCT00206063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-TPA-0004|Long Term Open Follow-up With H376/95 vs. Warfarin|Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients With Atrial Fibrillation. A Long Term Follow-Up Study||AstraZeneca||Terminated|August 1999|April 2006|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||220|||Both|18 Years|N/A|No|||November 2010|November 10, 2010|September 13, 2005|||Melagatran/ximelagatran was withdrawn from the market and clinical development in February    2006 in the interest of patient safety.|No||https://clinicaltrials.gov/show/NCT00206063||191466|
NCT00206375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13213|Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism|Concomitant Use of Growth Hormone and GnRH Agonist in Adolescent Patients With Acquired Hypothyroidism||Baylor College of Medicine|Yes|Completed|May 2003|November 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00206375||191442|
NCT00207311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2004.140|Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus|A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus|HCVNASH|Brooke Army Medical Center|No|Completed|August 2005|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00207311||191373|
NCT00207597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCBDDD-1455|Joint Outcome Study|A Clinical Trial of Primary Prophylaxis Against Joint Disease in Children With Severe Hemophilia||Centers for Disease Control and Prevention||Completed|September 1995|August 2005||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||64|||Male|1 Year|30 Months|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207597||191352|
NCT00207610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-TS-0780|Iron Supplementation Among Low-Income Postpartum Women|Phase 3 Study of the Prevention of Postpartum Anemia by Three Different Strategies||Centers for Disease Control and Prevention|No|Completed|June 2003|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|959|||Female|13 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 30, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00207610||191351|
NCT00204009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK044752|Chicago Childhood Diabetes Registry|Population-based Epidemiologic Study of Childhood Diabetes in Chicago: a) Disease Surveillance; b) Family Studies; c) Questionnaire Followup.||University of Chicago||Completed|July 1992|September 2005|Actual|September 2005|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|2400|||Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|target all diagnosed with diabetes before age 18 AND resident of the City of Chicago at        diagnosis|September 2013|September 4, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204009||191622|
NCT00204022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWPSLE-LN-02|Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.|A Randomized Multicenter Trial Comparing Mycophenolate Mofetil and Azathioprine as Remission-maintaining Treatment for Proliferative Lupus Glomerulonephritis. The MAINTAIN Nephritis Trial.|MAINTAIN|Université Catholique de Louvain|No|Completed|February 2001|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|14 Years|N/A|No|||October 2011|October 13, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204022||191621|
NCT00208091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2808|Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia|An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®).||Columbia University|No|Completed|April 2003|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|25 Years|69 Years|No|||April 2014|April 11, 2014|September 13, 2005||No||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00208091||191314|
NCT00208338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 04/17|Pilot Study to Evaluate the Restore Orthobiologic Implant in Rotator Cuff Tear Repair|A Prospective, Randomised Pilot Study to Determine the Variability of Early Clinical Outcome in Subjects Undergoing Full Thickness Rotator Cuff Tear Repair, When Augmented With or Without Porcine Small Intestine Submucosa (RESTORE)||DePuy International|No|Completed|June 2005|July 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|40 Years|N/A|No|||April 2015|August 26, 2015|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00208338||191295|
NCT00238563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/8/05-21|Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery|Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery||Stanford University||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||August 2007|February 22, 2008|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00238563||189037|
NCT00230074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCH346A2211E1|A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)|A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)||Novartis||Completed|November 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|350|||Both|21 Years|80 Years|No|||November 2011|November 22, 2011|September 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230074||189673|
NCT00230633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS3|Studies of White Blood Cells Derived From HHT Patients|Studies of White Blood Cells Derived From HHT Patients||Imperial College London||Recruiting|April 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|N/A|N/A|No|||August 2008|August 12, 2008|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230633||189630|
NCT00230906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/182|Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane|Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane||University Hospital, Ghent|No|Completed|January 2001|April 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230906||189609|
NCT00226512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230704-HMO-CTIL|To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning|Phase III Trial of a Non-myeloablative Preparative Regimen With Fludarabine and Busulfan With or Without Anti-lymphocyte Antibodies (Campath-1H or ATG) for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation From an HLA Compatible Donor||Hadassah Medical Organization||Withdrawn|July 2004|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|203|||Both|18 Years|N/A|No|||September 2005|April 7, 2011|September 9, 2005|||the PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00226512||189928|
NCT00226525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-03.09.04-HMO-CTIL|Effect of Metal Skin Sensitivity on Restenosis After Stent Implantation|Rate of Metal Skin Allergy in Cohorts of Patients With and Without Coronary Stent Restenosis||Hadassah Medical Organization||Active, not recruiting|February 2005|August 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label||||150|||Both|18 Years|N/A|No|||September 2006|November 6, 2006|July 10, 2005||||No||https://clinicaltrials.gov/show/NCT00226525||189927|
NCT00226499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100388|Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox|Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine||GlaxoSmithKline||Completed|September 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|5735|||Both|11 Months|22 Months|Accepts Healthy Volunteers|||January 2015|January 12, 2015|September 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226499||189929|
NCT00204243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project B: 160115|Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services|Naltrexone Implants Compared to Methadone Maintenance Treatment (MMT) Among Inmates About to be Released From Prison - a Randomized Controlled Trial||University of Oslo|Yes|Completed|May 2005|December 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|65 Years|No|||May 2011|May 18, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204243||191604|
NCT00204815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0015|Bone Mineral Density in Pediatric Epilepsy|Bone Mineral Density in Pediatric Epilepsy: AED-Specific and Duration of Treatment-Specific Effects||University of Wisconsin, Madison|No|Completed|January 2005|October 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|98|||Both|8 Years|18 Years|No|Non-Probability Sample|Pediatric subjects with generalized or partial seizures|June 2008|October 1, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204815||191561|
NCT00204490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-260|Soy Isoflavones and Breast Cancer Risk Reduction|Mammographic Density and Soy Isoflavones||The University of Texas Medical Branch, Galveston|No|Active, not recruiting|April 2004|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|187|||Female|30 Years|42 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204490||191585|
NCT00204789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-414|Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients|Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR)||University of Wisconsin, Madison||Completed|July 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|52|||Both|21 Years|N/A|No|||December 2007|September 30, 2015|September 12, 2005||Yes||||https://clinicaltrials.gov/show/NCT00204789||191563|
NCT00204802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-165|Patient-Centered Advance Care Planning|A Patient-Centered Approach to Advance Care Planning of Patients With End Stage Heart Failure and Renal Disease||University of Wisconsin, Madison||Completed|January 2004|July 2008|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||Actual|313|||Both|18 Years|N/A|No|||March 2009|October 1, 2015|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204802||191562|
NCT00206076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL350|Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation|CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver Disease - A Prospective, Randomized, Multicenter Trial.||Albert Einstein Healthcare Network|No|Completed|August 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|September 13, 2005|No|Yes||No|February 23, 2012|https://clinicaltrials.gov/show/NCT00206076||191465|
NCT00206089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4003C00030|Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events|The "EXTEND" Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery.|EXTEND|AstraZeneca||Terminated|September 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3300|||Both|18 Years|N/A|No|||November 2010|November 11, 2010|September 13, 2005|||Melagatran/ximelagatran was withdrawn from the market and clinical development in February    2006 in the interest of patient safety.|No||https://clinicaltrials.gov/show/NCT00206089||191464|
NCT00206388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16758|Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement|A Phase I Study of Zoledronic Acid (Zometa) With Cyclophosphamide in Children With Recurrent or Refractory Neuroblastoma and Cortical Bone Involvement (NANT 2004-01)||Baylor College of Medicine|Yes|Completed|April 2005|May 2013|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|30 Years|No|||August 2013|August 1, 2013|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00206388||191441|
NCT00206713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308180|Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim|Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostim||Sanofi||Terminated|July 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00206713||191417|
NCT00207623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-SIP 3-01|Evaluation of the Arthritis Basics for Change (ABCs) Self Management Program|Evaluation of the Arthritis Basics for Change (ABCs) Self Management Program||Centers for Disease Control and Prevention||Completed|July 2002|July 2003||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207623||191350|
NCT00207337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0304-28|Exhale (R) Stent for Emphysema|A Prospective Feasibility Study to Evaluate the Safety and Performance of the Exhale(R) Drug-Eluting Stent System in Patients With Emphysema||Broncus Technologies||Completed|July 2004|May 2006|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||January 2008|January 21, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00207337||191371|
NCT00206960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363002|Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia|Effects of Classical and Atypical Antipsychotics on Dopamine Receptor Binding of 123I-epidepride, Cognition, Startle Response and Extrapyramidal Side-effects in Drug-naive First-episode Schizophrenic Patients||University of Copenhagen|No|Completed|January 1998|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 16, 2011|September 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00206960||191399|
NCT00206973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7654 - man 05|Bronchial Response to Mannitol and Inflammation in Steroid Naive Asthmatics.|Bronchial Response to Mannitol and Inflammation in Steroid Naive Asthmatics||Bispebjerg Hospital||Recruiting|August 2005|September 2005||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|18 Years|70 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206973||191398|
NCT00206986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363037-2|Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?|Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?||University of Copenhagen|No|Completed|May 2005|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00206986||191397|
NCT00208104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA0311|Motivational Interviewing|Motivational Interviewing in Hypertensive African Americans||Columbia University|No|Terminated|July 2002|September 2008|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|167|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|September 14, 2005||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00208104||191313|
NCT00208377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT01/21|A Multi-centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery|Prospective Multi-Centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-Term Performance of the DePuy ASR Hip System in Subjects With Suitable Indications for a Primary Resurfacing Hip Arthroplasty||DePuy International|No|Terminated|July 2003|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|18 Years|65 Years|No|||February 2015|February 9, 2015|September 13, 2005|No|Yes|DePuy discontinued this product in 4Q2009. At the time of this decision DePuy reviewed all    clinical studies for this product and decided to close this Study.|No||https://clinicaltrials.gov/show/NCT00208377||191292|
NCT00208390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT01/25|A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement|Prospective, Uncontrolled, Multi-Centre, Post-Marketing Surveillance Study to Evaluate the Long-Term Performance of Summit Tapered Hip in Cementless Total Hip Arthroplasty||DePuy International|No|Terminated|February 2003|November 2011|Actual|December 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|275|||Both|18 Years|70 Years|No|||September 2015|December 14, 2015|September 13, 2005|No|Yes|Study closed after the 5 year end-point was reached after a review of the status further to a    request from the investigators to discontinue participation.|No||https://clinicaltrials.gov/show/NCT00208390||191291|
NCT00204282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12567A|The Effectiveness of Improving Compliance With Diabetic Preventative Services and Modifying Vascular Risk|The Effectiveness of Nurse Practitioner Led Group Visits in Improving Compliance With Diabetic Preventative Services and Modifying Vascular Risk||University of Chicago||Completed|August 2003|December 2005||||N/A|Interventional|N/A||||150|||Both|18 Years|79 Years|No|||September 2013|September 20, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204282||191601|
NCT00230347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0003|Evaluation of Stereotactic Radiosurgery For Liver Malignancies|Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies||Stanford University||Completed|October 2003|February 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2010|March 30, 2010|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230347||189652|
NCT00230360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-20050020|Diagnosis of Functional Defecation Disorders in Childhood|Diagnosis of Functional Defecation Disorders in Childhood||University of Aarhus||Completed|June 2005|April 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||90|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||February 2007|February 1, 2007|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230360||189651|
NCT00230919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161327/V50|Weight Loss and Changes in Cardiovascular Risk Markers With a Low Glycemic Diet Compared With a Standard Diet|Weight Loss and Changes in Cardiovascular Risk Markers With a Low Glycemic Load Diet Compared With a Standard National Nutrition Council-recommended Diet: a Randomized Trial||Oslo University Hospital|No|Completed|April 2004|November 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|30 Years|65 Years|No|||February 2004|June 30, 2011|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00230919||189608|
NCT00226538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19555-HMO-CTIL|Prediction of Drug Interactions With CYP2C9 Substrates|Prediction of Potential Drug Interaction With CYP2C9 Substrate by Using Phenytoin Metabolic Ratio as a Marker of Its Activity in-Vivo.||Hadassah Medical Organization||Completed|August 1999|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||16|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00226538||189926|
NCT00226772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03512|Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction|Double-Blind, Multicenter Phase 3 Study Comparing the Efficacy and Safety of OMS103HP With Vehicle in Patients Undergoing Autograft ACL Reconstruction||Omeros Corporation|No|Completed|June 2005|March 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|326|||Both|15 Years|65 Years|No|||October 2012|October 10, 2012|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226772||189908|
NCT00204828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0224|T Regulatory and Childhood Asthma|T Regulatory and Childhood Asthma||University of Wisconsin, Madison|No|Active, not recruiting|October 2005|December 2015|Anticipated|June 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|Samples Without DNA|blood, PBMC culture supes and nasal lavage|Both|6 Years|7 Years|No|Non-Probability Sample|6-7 yo children of either gender|October 2015|October 13, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204828||191560|
NCT00205166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-109|Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?|Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?||University of Wisconsin, Madison|No|Completed|June 1999|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|80 Years|No|||October 2012|October 25, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205166||191534|
NCT00205543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03802|Study of Effects of Sutures on Results of Palate Surgery for Obstructive Sleep Apnea|Role of Suture Closure in Post-Operative Uvulopalatopharyngoplasty Outcomes||Virginia Commonwealth University|No|Completed|July 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|21 Years|N/A|No|||June 2012|June 19, 2012|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00205543||191505|
NCT00205790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT-01-04|GORE-TEX PROPATEN Vascular Graft Study|Comparison of Primary Patency Between GORE-TEX PROPATEN Vascular Grafts and Thin Walled GORE-TEX Stretch Vascular Grafts||W.L.Gore & Associates||Completed|February 2003|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|21 Years|N/A|No|||August 2008|August 6, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205790||191487|
NCT00205803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-003|Study Evaluating Pneumococcal Vaccine in Healthy Infants|A Phase I/II, 2-stage, Randomized, Double-Blind Trial of the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in Healthy Infants||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2004|May 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|249|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||July 2012|July 6, 2012|September 19, 2005|||||March 26, 2010|https://clinicaltrials.gov/show/NCT00205803||191486|
NCT00206726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13603|Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)|Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)|ECO-1|Sanofi||Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|September 19, 2005|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00206726||191416|
NCT00206999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363052-2|The Effect of Imipramine on Early Information Processing|Early Information Processing in Healthy Controls: Studies on the Relation Between Two Different Paradigms (PPI and P50ERP) and Effects of Pharmacological Interventions||University of Copenhagen|No|Completed|September 2004|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2011|September 19, 2011|September 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00206999||191396|
NCT00207324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-0030|The Use of Silver Leaf Dressing in the Prevention of Radiotherapy Induced Skin Reactions|A Phase III Study of the Efficacy of Silver Leaf Nylon Dressing in the Prevention of Severe Skin Reactions in the Inframammary Skin Fold of Patients Receiving Adjuvant Whole Breast Radiotherapy||British Columbia Cancer Agency|No|Completed|January 2004|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||100|||Female|N/A|N/A|No|||June 2007|June 26, 2007|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00207324||191372|
NCT00207350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001794|Neurosurgical Use of Interstitial Laser Therapy (ILT)|Neurosurgical Use of Interstitial Laser Therapy (ILT)|ILT|Brigham and Women's Hospital|Yes|Recruiting|January 2002|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00207350||191370|
NCT00207649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-R-01-PH-000019|Shared Decision Making: Prostate Cancer Screening|Shared Decision Making: Prostate Cancer Screening||Centers for Disease Control and Prevention|No|Active, not recruiting|November 2005|February 2011|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|1||Actual|641|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|March 23, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00207649||191348|
NCT00207857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duchenne's Muscular Dystrophy|Test-Retest Reliability of Pulmonary Function Tests in Patients With Duchenne's Muscular Dystrophy|Test-Retest Reliability of Pulmonary Function Tests in Patients With Duchenne's Muscular Dystrophy||Children's Healthcare of Atlanta||Withdrawn|March 2004|August 2005|Anticipated|August 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Male|6 Years|21 Years|No|||February 2015|February 2, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207857||191332|
NCT00207870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Type II Supracondylar FX|Type II Supracondylar Fractures in Children|Comparison of Crossed Pin Versus Lateral-Entry Pin Fixation for Type II Supracondylar Fractures in Children: A Prospective, Randomized Trial||Children's Healthcare of Atlanta|No|Withdrawn|October 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|3 Years|10 Years|No|Non-Probability Sample|all patients less than 10 with a supracondylar fx|July 2011|July 21, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207870||191331|
NCT00208117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4976 (Davidson)|A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease|A Randomized Controlled Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease|CHIME|New York State Psychiatric Institute|No|Terminated|April 2005|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|7|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|September 15, 2005||No|Unable to enroll subjects|No||https://clinicaltrials.gov/show/NCT00208117||191312|
NCT00204308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGSA 19-02|Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP|Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission|TD-2|University of North Carolina, Chapel Hill|Yes|Completed|March 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Female|16 Years|N/A|No|||May 2012|May 30, 2012|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00204308||191599|
NCT00204035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13199A|Evaluation of TEACH (Training Early Achievers for Careers in Health) Research|Evaluation of TEACH (Training Early Achievers for Careers in Health) Research||University of Chicago|No|Recruiting|June 2004|September 2020|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|7 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|High School students|May 2014|May 22, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204035||191620|
NCT00230646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA101770|Promoting Physical Activity After Colorectal Cancer|Promoting Physical Activity After Colorectal Cancer||The Miriam Hospital||Completed|July 2005|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|||Actual|46|||Both|18 Years|N/A|No|||September 2005|October 4, 2010|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230646||189629|
NCT00227630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08031|Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma|A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Postoperative Radiotherapy in Patients With Malignant Pleural Mesothelioma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 2005|||August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Actual|59|||Both|N/A|69 Years|No|||July 2012|July 17, 2012|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227630||189846|
NCT00226785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005011|Dexmedetomidine for Continuous Sedation|A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of Intravenous Dexmedetomidine With Propofol/Midazolam for Continuous Sedation (24 Hours to 14 Days) of Ventilated Patients in Intensive Care Unit||Orion Corporation, Orion Pharma||Terminated|October 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|18 Years|N/A|No|||November 2006|November 10, 2006|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226785||189907|
NCT00205179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0048|Alzheimer's Disease: Potential Benefit of Isoflavones|Alzheimer's Disease: Potential Benefit of Isoflavones||University of Wisconsin, Madison|Yes|Completed|January 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|55 Years|N/A|No|||September 2010|October 1, 2015|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00205179||191533|
NCT00205556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC VUmc 03/097|Effect of Increased Convective Clearance by On-Line Hemodiafiltration on All Cause Mortality in Chronic Hemodialysis Patients|Effect of Increased Convective Clearance by On-line Hemodiafiltration on All Cause and Cardiovascular Mortality in Chronic Hemodialysis Patients: The Dutch Convective Transport Study (CONTRAST)|CONTRAST|VU University Medical Center|Yes|Completed|June 2004|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|715|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205556||191504|
NCT00205816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-310|Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.|An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|8 Years|N/A|No|||February 2013|February 7, 2013|September 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00205816||191485|
NCT00206102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077IL/0089|A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder|A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder||AstraZeneca||Completed|September 2003|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1098|||Both|18 Years|65 Years|No|||January 2013|January 8, 2013|September 14, 2005|Yes|Yes||No|October 22, 2009|https://clinicaltrials.gov/show/NCT00206102||191463|
NCT00206115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00132|SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia|A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy & Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia||AstraZeneca||Completed|November 2004|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||535|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00206115||191462|
NCT00206739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KA0202-K7.3|Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants|Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial||Bernhard Nocht Institute for Tropical Medicine|Yes|Completed|January 2003|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1070|||Both|2 Months|4 Months|Accepts Healthy Volunteers|||September 2005|March 29, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00206739||191415|
NCT00207012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA181-003|MAD Refractory: Solid Tumor QD w/o Break|Continuous Dosing Phase I Study of BMS-599626 in Patients With HER2-Expressing Advanced Solid Malignancies||Bristol-Myers Squibb||Completed|May 2004|||February 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||January 2009|February 27, 2010|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00207012||191395|
NCT00207025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA165-012|A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies|A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies||Bristol-Myers Squibb||Terminated|October 2004|||February 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||July 2008|February 27, 2010|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00207025||191394|
NCT00207662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004771|A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease|ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease||Centocor, Inc.||Completed|July 2000|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|580|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00207662||191347|
NCT00207636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-2504|Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening|Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Harvard - SIP 21-04||Centers for Disease Control and Prevention||Recruiting|December 2004|September 2007||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1120|||Male|45 Years|65 Years|No|||September 2005|September 15, 2005|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00207636||191349|
NCT00208403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT02/08|A Randomised Single Centre Study to Compare the Long-term Performance of SmartSet® HV and Palacos® R Bone Cements in Primary Total Hip Replacement|Randomised, Prospective, RSA, PMS Study Comparing SmartSet HV & Palacos R in Primary Total Hip Arthroplasty||DePuy International|No|Active, not recruiting|October 2002|||January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|60 Years|75 Years|No|||September 2011|September 1, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208403||191290|
NCT00204048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9967|A Multicenter Trial of Academic Hospitalists|A Multicenter Trial of Academic Hospitalists||University of Chicago|No|Recruiting|July 2001|December 2025|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|45000|||Both|16 Years|N/A|No|Probability Sample|Inpatients admitted in General Medicine at the University of Chicago|May 2014|May 22, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204048||191619|
NCT00204061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 GI 9935 - P 1.1.3|Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis|Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis||University of Cologne|No|Completed|January 2001|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|14 Years|36 Years|No|||December 2014|December 23, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204061||191618|
NCT00204321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hausberg_Lang-Sir/MMF|Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients|Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression||University Hospital Muenster||Completed|June 2005|January 2010|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|75 Years|No|||January 2010|January 12, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204321||191598|
NCT00204334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haus_Lang-Endothel-Mono-Hb|Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients|Effects of Anemia Correction on Vascular Function, Endothelial Cell Markers and Monocyte Apoptosis in Renal Transplant Recipients||University Hospital Muenster||Completed|June 2005|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|75 Years|No|||May 2008|January 12, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204334||191597|
NCT00204568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jth_001|Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)|Randomized Phase II Trial of Trofosfamide vs. Adriamycin in Elderly Patients With Previously Untreated Metastatic Soft Tissue Sarcoma||University of Schleswig-Holstein||Active, not recruiting|August 2004|October 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Both|60 Years|N/A|No|||January 2013|January 7, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204568||191579|
NCT00226213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406143|Peripherally Inserted Central Catheter Placement by Interventional Radiologists Using the Sonic Flashlight|Peripherally Inserted Central Catheter Placement by Interventional Radiologists Using the Sonic Flashlight||University of Pittsburgh||Completed|February 2005|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||December 2007|December 11, 2007|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00226213||189951|
NCT00226551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19558-HMO-CTIL|Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms|ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol||Hadassah Medical Organization||Completed|August 1999|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label||||100|||Both|20 Years|N/A|No|||October 2008|October 28, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00226551||189925|
NCT00226564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yc19554-HMO-CTIL|Genetic Determinants of Opioids Analgesia|The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy||Hadassah Medical Organization||Completed|August 1997|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|20 Years|N/A|No|||October 2008|October 28, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00226564||189924|
NCT00226174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1113-19156-03|A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus|A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus||University of California, San Francisco||Terminated|February 2003|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||September 2005|September 22, 2005|September 22, 2005||||||https://clinicaltrials.gov/show/NCT00226174||189954|
NCT00226187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|A Randomized Clinical Trial on Supplementation of DHA and AA to Preterm Infants|||University of Oslo||Completed|December 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|N/A|1 Month|No|||September 2005|February 14, 2007|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00226187||189953|
NCT00227331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRN-A-00-96-90010-00-1|Equivalency Of Oral Amoxicillin Vs Injectable Penicillin In Children With Severe Pneumonia|A Randomized Multicentre Equivalency Study Of Oral Amoxicillin Versus Injectable Penicillin In Children Aged 3 To 59 Months With Severe Pneumonia||Boston Medical Center||Completed|January 1998|January 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Months|59 Months||||September 2005|May 2, 2006|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227331||189865|
NCT00226811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181054|An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy|An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy||Pfizer|No|Completed|January 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|September 23, 2005|No|Yes||No|May 14, 2009|https://clinicaltrials.gov/show/NCT00226811||189905|
NCT00227877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-R01DA0118848|Screening and Brief Advice to Reduce Teen Substance Use|Screening and Brief Advice to Reduce Teen Substance Use||Children's Hospital Boston|Yes|Completed|September 2004|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2145|||Both|12 Years|18 Years|No|||June 2011|June 16, 2011|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00227877||189830|
NCT00205829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-B-(E)-003|Bion for Occipital Nerve Stimulation|Bion for Occipital Nerve Stimulation||Boston Scientific Corporation|No|Completed|June 2004|January 2009|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205829||191484|
NCT00206128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00146|Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia|6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated)||AstraZeneca||Completed|November 2004|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|454|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206128||191461|
NCT00206453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11058|Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer|An Extension Phase II Study of the Clinical and Biologic Effects of Docetaxel (Taxotere) in Patients With Locally Advanced Breast Cancer||Baylor Breast Care Center||Terminated|January 2002|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||February 2013|February 4, 2013|September 14, 2005|No|Yes|accrual too difficult to meet|No||https://clinicaltrials.gov/show/NCT00206453||191436|
NCT00206466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11624|Biologic Correlative Taxotere/AC|A Randomized Multicenter Trial of Neoadjuvant Taxotere and Adriamycin/Cytoxan(AC): A Biologic Correlative Study|TAX/AC|Baylor Breast Care Center||Completed|April 2002|January 2012|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|N/A|No|||January 2012|January 24, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00206466||191435|
NCT00206401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16559|Lantus in the Treatment of Type 1 Diabetes Children|Conventional Insulin Therapy Vs Intensive Insulin Management In Children With Type 1 Diabetes Mellitus||Baylor College of Medicine||Completed|November 2004|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|6 Years|25 Years|No|||December 2007|December 4, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206401||191440|
NCT00206414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-14732|Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer|Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer||Baylor Breast Care Center|Yes|Terminated|January 2003|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|N/A|No|||February 2013|February 4, 2013|September 12, 2005|No|Yes|Difficulty accruing subjects the study accrual was closed|No||https://clinicaltrials.gov/show/NCT00206414||191439|
NCT00206427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 15430|Neoadjuvant GW572016 to Treat Breast Cancer|A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study|GW|Baylor Breast Care Center|Yes|Completed|August 2004|February 2012|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Female|18 Years|N/A|No|||July 2013|July 26, 2013|September 14, 2005|Yes|Yes||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00206427||191438|
NCT00206440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16348|Nexium Study To Suppress Nausea During Chemotherapy|Evaluation of the Efficacy of Esomeprazole in Suppressing Nausea and Vomiting in Patients Undergoing Chemotherapy for Breast Cancer|NEXIUM|Baylor Breast Care Center|Yes|Terminated|August 2005|February 2012|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Female|18 Years|N/A|No|||April 2012|April 27, 2012|September 13, 2005|Yes|Yes|Accrual was not optimized|No|February 1, 2012|https://clinicaltrials.gov/show/NCT00206440||191437|
NCT00207038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 261528|Airway Inflammation in Swimmers|Airway Inflammation in Swimmers: Development and Risk Factors||Bispebjerg Hospital||Completed|September 2005|February 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|90|Samples Without DNA|Blood samples EBC Sputum|Both|10 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Elite swimmers|February 2009|February 10, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00207038||191393|
NCT00207051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-003|BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies|Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy||Bristol-Myers Squibb|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||March 2009|January 24, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00207051||191392|
NCT00207363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2002.076|Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC|Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With Chronic Hepatitis C||Brooke Army Medical Center|No|Completed|February 2002|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|610|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00207363||191369|
NCT00207376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04k001|Safety and Effectiveness Study of the Solysafe Septal Occluder in Patients With Atrial Septum Defect and Patent Foramen Ovale|Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device in Patients With Atrial Septum Defect (ASD) and Patent Foramen Ovale (PFO)||Carag AG||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Years|N/A||||February 2007|June 23, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207376||191368|
NCT00207896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-068|Neuroendocrine Dysfunction in Critically Ill Pediatric Patients|Defining the Prevalence of Acute Neuroendocrine Dysfunction and Correlating the Dysfunction With Outcomes in Critically Ill Pediatric Patients: A Pilot Study||Children's Healthcare of Atlanta||Completed|August 2004|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|||Both|5 Months|N/A|No|Probability Sample|All patients admitted to PICU|November 2014|November 25, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207896||191329|
NCT00207883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-130|Ultrasound Guided Vascular Access in Pediatric Intensive Care Patients|Ultrasound Guided Vascular Access: A Prospective Comparison Study||Children's Healthcare of Atlanta||Active, not recruiting|January 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|1 Month|18 Years|No|Non-Probability Sample|All patients admitted to the PICU at Children's Healthcare of Atlanta at Egleston|May 2008|May 5, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207883||191330|
NCT00208130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-201|Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians||Creighton University|No|Completed|October 2001|March 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||April 2009|April 28, 2009|September 13, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00208130||191311|
NCT00208416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT02/29|A Randomised Multi-centre Study to Compare the Short-term Outcomes of Minimally Invasive and Conventional Surgery in Primary Total Hip Replacement|Randomised, Prospective, Post-Market Surveillance Study Comparing the Outcomes of Minimally Invasive and Conventional Surgical Procedures in Subjects Requiring Primary Total Hip Arthroplasty for Osteoarthritis.||DePuy International|No|Terminated|October 2005|April 2009|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|75 Years|No|||July 2014|September 8, 2014|September 13, 2005|No|Yes|Combination of departure of Investigator from one site and slow recruitment rate|No||https://clinicaltrials.gov/show/NCT00208416||191289|
NCT00204074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mensmig1|Treatment of Menstrual Migraine With Sequential, Transdermal, 17-Beta-Estradiol. A Double-Blind, Randomised, Cross-Over Trial.|||University Hospital, Linkoeping||Active, not recruiting|October 2001|July 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|45 Years||||September 2005|December 28, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204074||191617|
NCT00204945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-496|Catheterization Laboratory Study: Acute Responses in Diastolic Heart Failure|Acute Responses in Diastolic Heart Failure||University of Wisconsin, Madison||Completed|February 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|65|||Both|18 Years|90 Years|No|||January 2009|January 15, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00204945||191551|
NCT00204581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL-2-LOK-MM|Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases|Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases. A Phase II, Prospective, Open, Multicenter Trial||University Hospital Tuebingen||Completed|August 2003|December 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||February 2009|August 18, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204581||191578|
NCT00204594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rM28-001|Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28|Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28||University Hospital Tuebingen|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||January 2013|January 15, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204594||191577|
NCT00226265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203-069|The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients|The Short Form-36: Pre-vs. Post-Surgical Administration in Cardiac Surgery Patients||Weill Medical College of Cornell University|No|Active, not recruiting|January 2000|September 2007|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac Surgery Patients at New York Presbyterian Hospital-Weill Cornell Medical College|March 2008|March 31, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00226265||189947|
NCT00226278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28130|Safety Study of ORG 34517 for Major Depression With Psychotic Features|Prospective, Double Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunct"||Weill Medical College of Cornell University||Completed|September 2004|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2008|March 28, 2008|September 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226278||189946|
NCT00227344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACAF2|CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation|Catheter Ablation for Cure of Atrial Fibrillation|CACAF-2|Biosense Webster, Inc.|No|Terminated|December 2004|May 2009|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|70 Years|No|||January 2015|January 5, 2015|September 15, 2005||No|Study prematurely terminated due to randomization imbalance.|No|May 27, 2014|https://clinicaltrials.gov/show/NCT00227344||189864|The study was terminated early due to randomization imbalance. The relatively small number of subjects enrolled limited the amount of data available for analysis. Because the study did not reach its targeted enrollment, the study is underpowered.
NCT00227383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR94-IRB-69|Effect of Electroacupuncture in Diabetic Patients With Gastroparesis|||China Medical University Hospital||Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|20 Years|N/A|No|||September 2005|January 19, 2007|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00227383||189861|
NCT00205842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3753-001|Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus|A Phase IIIb, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus||Cubist Pharmaceuticals LLC|No|Completed|June 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||660|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00205842||191483|
NCT00206141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1447C00001|Seroquel in Bipolar Depression Versus Lithium|Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)||AstraZeneca||Completed|August 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||672|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206141||191460|
NCT00206154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5899C00002|A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients|A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients||AstraZeneca||Completed|April 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1500|||Both|40 Years|N/A|No|||March 2009|March 26, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00206154||191459|
NCT00206778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-03|Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania|A Randomized Open-Label 6 Month Acute and Maintenance Trial of Lamotrigine vs. Standard of Care Sodium Valproate Monotherapy for Treatment of Mixed Mania.||Beth Israel Medical Center||Completed|July 2003|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|65 Years|No|||November 2010|November 24, 2010|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00206778||191412|
NCT00207077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-101|Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors|A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies||Eli Lilly and Company||Completed|August 2005|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00207077||191390|
NCT00207090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-102|Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer|Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer||R-Pharm|No|Completed|September 2005|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 12, 2005|No|Yes||No|September 3, 2010|https://clinicaltrials.gov/show/NCT00207090||191389|
NCT00206752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186-03|Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck|A Randomized Prospective Evaluation of Unilateral/Ipsilateral Neck Irradiation in Selected Patients With Squamous Cell Carcinoma of the Head and Neck Who Are Managed by Radiation Therapy|Unilateral|Beth Israel Medical Center||Completed|August 2004|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00206752||191414|
NCT00207389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22610|A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients|A Pilot Study to Examine the Relationship Between Changes in Plasma GIP Levels and Other Gastrointestinal Peptides Following Gastric Bypass Surgery in Obese Patients||Boston Medical Center||Suspended|March 2004|March 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||30|||Both|21 Years|64 Years|No|||August 2005|November 15, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207389||191367|
NCT00207675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004786|A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease|A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease.||Centocor, Inc.||Completed|February 2003|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|112|||Both|6 Years|17 Years|No|||March 2010|May 16, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00207675||191346|
NCT00208429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT03/40|A Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle Acetabular Cup System With a Metal on Enduron Polyethylene Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement||DePuy International|No|Withdrawn||||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||February 2013|February 12, 2013|September 13, 2005|||Site Principal Investigator became seriously ill, so study abandoned before the start of    recruitment|No||https://clinicaltrials.gov/show/NCT00208429||191288|
NCT00208143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET00292|Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia|Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone||Creighton University|No|Completed|November 2003|December 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||October 2006|December 11, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208143||191310|
NCT00204347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-DED-WTJ|Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder|Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS)||University of Alabama at Birmingham||Completed|July 2003|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|19 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204347||191596|
NCT00204360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pediatric epilepsy database|Pediatric Epilepsy Database|Pediatric Epilepsy Database||University of Alabama at Birmingham||Completed||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal|||||||Both|N/A|17 Years|Accepts Healthy Volunteers|||August 2005|April 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204360||191595|
NCT00204607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA-Mel-02|Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients|Induction of Specific Immune Responses Against Melanoma-Associated Antigens in Vivo by Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial||University Hospital Tuebingen||Completed|July 2004|January 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|No|||April 2007|April 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204607||191576|
NCT00204620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jth_002|Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)|Multicenter Phase II Study With Bendamustin for Patients With Refractory Soft Tissue Sarcoma||University Hospital Tuebingen||Completed|March 2002|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||April 2007|April 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204620||191575|
NCT00236665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003727|A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2001|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|531|||Both|18 Years|75 Years|No|||April 2010|April 26, 2010|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236665||189178|
NCT00236899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9846|Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC|A Randomized Phase III Trial of Gemcitabine and Docetaxel Versus Gemcitabine and Paclitaxel in Patients With Metastatic Breast Cancer: A Comparison of Different Schedules||Eli Lilly and Company|No|Completed|September 2005|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|241|||Female|18 Years|N/A|No|||August 2011|August 22, 2011|October 7, 2005|Yes|Yes||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00236899||189160|
NCT00205283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-212|Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection|Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection||University of Wisconsin, Madison||Recruiting|August 2003|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A||||September 2005|October 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205283||191525|
NCT00205296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-090|Fitness Training in Children|Effect of Fitness Training on Insulin Sensitivity and Body Composition in Children||University of Wisconsin, Madison|No|Completed|March 2002|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|7 Years|16 Years|No|||October 2008|October 1, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205296||191524|
NCT00226824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-EMR-4017|Safety Study of Galantamine in Tic Disorders|Pilot Examination of Galantamine in the Management of Tic Disorders||Parkinson's Disease and Movement Disorders Center||Terminated|September 2005|May 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|50 Years|No|||August 2009|August 21, 2009|September 23, 2005|||Unable to recruit subjects into the trial.|No||https://clinicaltrials.gov/show/NCT00226824||189904|
NCT00238407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 76/02|Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery|Docetaxel and Cisplatin Chemotherapy Followed by Radiochemotherapy in Patients With Inoperable, Locally Advanced Esophageal Cancer, A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|March 2004|August 2010|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|70 Years|No|||June 2012|June 4, 2012|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238407||189049|
NCT00227045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL305|CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients|The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction: A Two Phase Pharmacokinetic Study in Renal Allograft Recipients at the University of Michigan Transplant Program||University of Michigan||Completed|October 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||20|||Both|18 Years|N/A|No|||April 2007|April 19, 2007|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00227045||189887|
NCT00206167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5899C00001|A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD|A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD||AstraZeneca||Completed|April 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1600|||Both|40 Years|N/A|No|||March 2009|March 26, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206167||191458|
NCT00206180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00062|NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis|A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily||AstraZeneca||Completed|June 2004|August 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||120|||Both|18 Years|75 Years|No|||March 2009|March 25, 2009|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00206180||191457|
NCT00206193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP-protocol|Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone|||Atrium Medical Center||Recruiting||||||Phase 2|Observational|Time Perspective: Prospective|||||||Female|18 Years|N/A||||September 2005|October 29, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00206193||191456|
NCT00206492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 13546|Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients|A Neoadjuvant Phase II Trial of ZD1839 (Iressa) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study (AZ #1839US/0303)||Baylor Breast Care Center|No|Terminated|July 2003|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|September 14, 2005|Yes|Yes|halted by the PI only 3 of 45 subjects were accrued.|No||https://clinicaltrials.gov/show/NCT00206492||191434|
NCT00206765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082-02|Risperidone vs. Paroxetine for Panic Attacks|A Single-blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks||Beth Israel Medical Center||Terminated|January 2003|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|21 Years|55 Years|No|||October 2012|October 19, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00206765||191413|
NCT00207103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-002|MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors|Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|September 2004|September 2008|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|68|||Both|18 Years|N/A|No|||November 2008|November 3, 2008|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00207103||191388|
NCT00238576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79890|Lamotrigine in the Treatment of Bipolar Disorder in Women of Reproductive Age|Lamotrigine in the Treatment of Bipolar Disorder in Women of Reproductive Age||Stanford University||Active, not recruiting|May 2008|||December 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|30|||Female|18 Years|45 Years|No|Non-Probability Sample|Females age 18 through 45 with a diagnosis of bipolar, considering treatment with        Lamotragine.|December 2012|May 14, 2014|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00238576||189036|
NCT00207064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363055|Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia|5-HT2A-receptor Binding: Implications for the Pathophysiology of Schizophrenia and Effects of Treatment With Antipsychotic Drugs||University of Copenhagen|No|Completed|April 2004|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 16, 2011|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00207064||191391|
NCT00207688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004801|A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients|A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis||Janssen Research & Development, LLC|No|Completed|August 2004|September 2015|Actual|September 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|505|||Both|N/A|N/A|No|Non-Probability Sample|Patients with ulcerative colitis who have participated in infliximab clinical studies and        must have received at least 1 dose of study medication to be eligible for participation in        C0168T62.|March 2016|March 14, 2016|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00207688||191345|
NCT00208156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-10|A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression|An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features||Corcept Therapeutics|No|Completed|May 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|75 Years|No|||February 2012|February 14, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208156||191309|
NCT00240032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM014|A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.|A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.||Teva Pharmaceutical Industries|No|Completed|October 2004|July 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00240032||188927|
NCT00240344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL401142|Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal|REALISTIC: Protocol for an Observational Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New EAS LDL-C Target Goal||AstraZeneca||Completed|September 2004|February 2008|Actual|February 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2650|||Both|18 Years|70 Years|No|Non-Probability Sample|primary care|August 2011|August 29, 2011|October 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00240344||188905|
NCT00204087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 GI 9935 – P 1.1.2|Psychological Intervention for Persons in the Early Initial Prodromal State|Psychological Intervention for Persons at Risk of Psychosis in the Early Initial Prodromal State||University of Cologne||Active, not recruiting|January 2001|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||126|||Both|17 Years|36 Years|No|||June 1999|January 10, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204087||191616|
NCT00236262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040202|Effect of Positive Expiratory Pressure on Right Ventricular Function in Patients With Respiratory Distress Syndrome|Effect of the Positive Expiratory Pressure on the Right Ventricular Function in Patient With Adult Respiratory Distress Syndrome Ventilated With Limited Plateau Pressure||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2005|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||March 2007|March 23, 2007|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236262||189208|
NCT00236470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002149|A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders|Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders - an Open Label Follow-up Trial of CR002020||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2002|July 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|232|||Both|5 Years|17 Years|No|||January 2011|June 6, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236470||189193|
NCT00236678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004624|Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT|A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT� (Epoetin Alfa)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|July 2004|January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|N/A|No|||March 2010|June 8, 2011|October 7, 2005|||This study was terminated due to slow enrollment, despite protocol amendments to change the    entrance criteria.|||https://clinicaltrials.gov/show/NCT00236678||189177|
NCT00236912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002656|A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated Appendicitis|A Multi-center, Open-label, Randomized Study to Compare the Safety and Efficacy of Once Daily Levofloxacin Along With Once Daily Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Appendicitis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|July 2003|September 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|October 7, 2005|||This study was terminated due to low enrollment.|||https://clinicaltrials.gov/show/NCT00236912||189159|
NCT00237848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPA/020/03|D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia|D-Serine Augmentation of Cognitive Retraining in Schizophrenia||Yale University||Completed|February 2005|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|65 Years|No|||April 2008|June 15, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00237848||189089|
NCT00226798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1747CTIL|Immunochemotherapy for Metastatic Renal Cell Carcinoma|Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study||Rambam Health Care Campus||Recruiting|December 2003|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|80 Years|No|||September 2005|December 31, 2005|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00226798||189906|
NCT00227058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHK040213|Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis|Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic||University of Mississippi Medical Center||Completed|January 2005|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||100|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2007|January 24, 2007|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00227058||189886|
NCT00206505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 8448|Neoadjuvant Taxotere|A PHASE II STUDY OF THE CLINICAL AND BIOLOGIC EFFECTS OF DOCETAXEL (TAXOTERE) IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER||Baylor Breast Care Center|No|Completed|January 1999|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|N/A|No|||November 2011|November 16, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00206505||191433|
NCT00206518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 16039|Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients|A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation|TACAC|Baylor Breast Care Center|Yes|Recruiting|September 2004|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|153|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00206518||191432|
NCT00206791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/01/001|Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects|Study of Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects From Various Origins||Biomatlante||Recruiting|May 2006|May 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|70 Years|No|||October 2006|October 25, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00206791||191411|
NCT00238602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0008|Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer|Evaluation of the Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Tumors - A Phase I/II Study||Stanford University||Completed|March 2000|June 2012|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00238602||189035|
NCT00207402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2005.143|Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin|A Pilot Trial of Combination Therapy With Interferon Alfacon1, Ribavirin, & Rosiglitazone in a Group of Insulin Resistant, Chronic Hepatitis C, GT 1 Patients Who Are Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin||Brooke Army Medical Center|No|Completed|October 2005|July 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00207402||191366|
NCT00207415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-MM0512-03/03|A Comparison of the ASHC and CDSMP|A Comparison of the ASHC and CDSMP||Centers for Disease Control and Prevention||Completed|January 2003|December 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207415||191365|
NCT00239278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0698|Budesonide / Formoterol in Treatment of Exacerbations of COPD|Effects of High Dose Inhaled Budesonide+ Formoterol Versus Placebo and Oral Prednisolone on Biomarkers of Airway Inflammation in the Treatment of Exacerbations in Non-hospitalised Patients With Mild to Moderate COPD.||AstraZeneca||Completed|January 2001|January 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|40 Years|N/A|No|||January 2011|January 21, 2011|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239278||188984|
NCT00239291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0118|Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer|A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer||AstraZeneca||Completed|January 2003|May 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|42|||Male|18 Years|N/A|No|||April 2009|April 22, 2009|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239291||188983|
NCT00239642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN03017|Safety and Efficacy of Iron Sucrose in Children|Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients||Luitpold Pharmaceuticals||Completed|July 2005|April 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|141|||Both|2 Years|21 Years|No|||October 2012|October 22, 2012|October 13, 2005|Yes|Yes||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00239642||188956|
NCT00239655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_087|A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)|A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI||Merck Sharp & Dohme Corp.||Completed|August 2004|||January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|120|||Both|18 Years|55 Years|No|||May 2008|May 14, 2008|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00239655||188955|
NCT00240370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-025|A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics|A Phase 3, Randomized, Double-Blind, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Metformin Compared to Pioglitazone in Combination With Metformin in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone||Bristol-Myers Squibb||Completed|October 2003|||March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1159|||Both|18 Years|70 Years|No|||June 2008|September 10, 2010|October 17, 2005||||||https://clinicaltrials.gov/show/NCT00240370||188903|
NCT00240383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-006|Dose Ranging Study With LT, Monotherapy, PPAR|A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes||Bristol-Myers Squibb||Completed|May 2002|June 2006|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1260|||Both|18 Years|70 Years|No|||June 2008|September 10, 2010|October 17, 2005||||||https://clinicaltrials.gov/show/NCT00240383||188902|
NCT00240357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00002|Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia|Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement of LDL Goals. - Denmark||AstraZeneca||Withdrawn|February 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1175|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|October 16, 2005|||Study cancelled prior to FSI|No||https://clinicaltrials.gov/show/NCT00240357||188904|
NCT00235989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91272|Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis|An Open-label Extension Study of the Double-blind, Randomized, Parallel Group, Multicenter Phase 2 Study 307000A to Further Evaluate the Safety and Tolerability of Betaseron® 500 mcg Subcutaneously Every Other Day and Betaseron® 250 mcg Subcutaneously Every Other Day in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)||Bayer|No|Completed|June 2003|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|63|||Both|18 Years|55 Years|No|||April 2014|April 25, 2014|October 10, 2005|Yes|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00235989||189229|The 40 patients in the NAb frequency summaries are the total number of patients with NAb titers at week 234. Official HARTS-to-MedDRA Mapping was used.
NCT00236275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020907|PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer|PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer||Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Female|18 Years|N/A|No|||March 2007|April 29, 2011|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00236275||189207|
NCT00236483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002806|A Comparison of the Effectiveness and Safety of ULTRACET® (Tramadol Hydrochloride/Acetaminophen) Versus ULTRAM® (Tramadol Hydrochloride) Versus Placebo in Patients With Pain After Oral Surgery|A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus ULTRAM® (Tramadol HCl) Versus Placebo in Subjects With Pain Following Oral Surgery||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2002|February 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|456|||Both|18 Years|75 Years|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236483||189192|
NCT00237770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3600-R|Prevention of Low Blood Pressure in Persons With Tetraplegia|Prevention of Low Blood Pressure in Persons With Tetraplegia||VA Office of Research and Development|No|Completed|June 2003|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|October 7, 2005|No|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00237770||189094|The small sample of subjects tested and the heterogeneity of spinal lesions.
NCT00236925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|348/02|Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia|A Double-Blind Crossover Within Subject Study on Low-Dose Hydrocortisone for Fibromyalgia||Ludwig-Maximilians - University of Munich|Yes|Completed|May 2003|June 2007|Actual|May 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||March 2015|March 30, 2015|October 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00236925||189158|
NCT00237237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2354|Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes|Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes||Novartis||Completed|October 2005|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||588|||Both|18 Years|77 Years||||August 2008|August 21, 2008|October 9, 2005||||||https://clinicaltrials.gov/show/NCT00237237||189135|
NCT00238784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00004|SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults|A Comparison of Symbicort® Single Inhaler Therapy (Symbicort® 200 Turbuhaler® 1 Inhalation b.i.d. Plus as Needed) & Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents & Adults-a 26-Week, Randomised, Open-Label, Parallel Group, Multicentre Study||AstraZeneca||Completed|May 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1300|||Both|12 Years|N/A|No|||January 2008|January 11, 2008|October 12, 2005||||||https://clinicaltrials.gov/show/NCT00238784||189022|
NCT00238797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0088|A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme|A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme||AstraZeneca||Completed|February 2003|March 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238797||189021|
NCT00226590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13240|Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC|Phase II Trial of Induction Gemcitabine and Carboplatin Followed by Paclitaxel and Carboplatin With Concurrent Thoracic Radiation for Patients With Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|April 2003|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||May 2011|December 13, 2013|September 23, 2005|Yes|Yes||No|March 11, 2011|https://clinicaltrials.gov/show/NCT00226590||189922|
NCT00239148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-201|A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1|A Randomized, Double-Blind, Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Effects of Repeated Subcutaneous Doses of E1 in Combination With G1 in Type 1 Diabetes||Transition Therapeutics||Completed|June 2005|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|40 Years|No|||July 2006|May 25, 2009|October 12, 2005||Yes||||https://clinicaltrials.gov/show/NCT00239148||188994|
NCT00227682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000443708|Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid||OHSU Knight Cancer Institute||Terminated|June 2004|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||June 2010|May 24, 2012|September 26, 2005|No|Yes|Terminated early due to funding suspension by grant sponsor.|No||https://clinicaltrials.gov/show/NCT00227682||189843|
NCT00238030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-298|Thyroxine Replacement in Organ Donors|Efficacy and Pharmacokinetics of Oral Thyroid Replacement Therapy in Organ Donors||Lawson Health Research Institute|No|Completed|December 2004|October 2010|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 4, 2011|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238030||189075|
NCT00238290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 23/03|Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer|Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|May 2005|April 2011|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||June 2012|June 4, 2012|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238290||189058|
NCT00238979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ADE03|A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)|A 6-month, 1-arm, Open-label Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)||Novartis||Completed|January 2003|||February 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|18 Years|75 Years||||November 2011|November 1, 2011|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238979||189007|
NCT00239304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0151|Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer|A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer||AstraZeneca||Completed|June 2003|March 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2007|December 14, 2007|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239304||188982|
NCT00238953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080APL01|Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients|A Prospective, Open Label Protocol to Assess the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients||Novartis||Completed|February 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|75 Years||||October 2009|October 30, 2009|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238953||189009|
NCT00238966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405DE02E1|Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil|A One Arm, Open-label Study to Investigate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Recipients Who Received Mycophenolate Mofetil (MMF)||Novartis||Completed|November 2002|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|187|||Both|18 Years|75 Years||||January 2011|January 28, 2011|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238966||189008|
NCT00239668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000452/19|Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors|Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors||Massachusetts General Hospital|No|Recruiting|March 2000|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients admitted to Shriners Hospitals-Boston,MA Cincinnati,OH, Galveston,TX and        Sacramento, CA burn hospitals with a diagnosis of burn injury.|May 2012|May 2, 2012|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00239668||188954|
NCT00240045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-PG-007|The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction|The Use of Midodrine, Octreotide and Albumin in Refractory Ascites||University of Alberta|No|Completed|October 2005|July 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|19 Years|N/A|No|||October 2005|December 3, 2007|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00240045||188926|
NCT00240058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRDA05-0222|Pilot Study On The Role Of Nitric Oxide In Alpha 1-Adrenergic Vasoreactivity|Pilot Study On The Role Of Nitric Oxide In Alpha 1-Adrenergic Vasoreactivity||University of Michigan||Completed|July 2005|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2006|November 2, 2006|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00240058||188925|
NCT00236496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002659|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2001|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|223|||Both|18 Years|80 Years|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236496||189191|
NCT00236691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005452|A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.|Double-Blind, Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 1988|December 1990|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|188|||Both|18 Years|65 Years|No|||January 2011|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236691||189176|
NCT00236002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA-CANA-04-012|Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )|A Phase III, Double-blind, Randomized, Parallel Group, Placebo-controlled Study of Oral Fosamax, 70 mg Once a Week, for the Prevention of Androgen Deprivation Bone Loss in Non-metastatic Prostate Cancer||Canadian Urology Research Consortium|No|Terminated|July 2005|August 2009|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|182|||Male|18 Years|N/A|No|||August 2009|August 11, 2009|October 11, 2005||No|Slow accrual than anticipated.|No||https://clinicaltrials.gov/show/NCT00236002||189228|
NCT00237276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/CL05/70|Experience and Enhancement: Improving Colonoscopic Polyp Detection|Evaluation of Effect of Colonoscopist Experience and Addition of of Mucosal Enhancement Techniques on Detection of Colonic Polyps When Viewing Videotaped Colonoscopic Withdrawals||London North West Healthcare NHS Trust||Recruiting|October 2005|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 21, 2007|October 10, 2005||||No||https://clinicaltrials.gov/show/NCT00237276||189132|
NCT00236717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005461|A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy|TOPAMAX (Topiramate) Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy (RWJ-17021-000); Phase IIIB||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 1997|November 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|865|||Both|6 Years|N/A|No|||January 2011|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236717||189174|
NCT00237510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05U.84|Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating|A Pilot Study of the Efficacy and Tolerability of Terazosin for the Treatment of Antidepressant-Induced Excessive Sweating||Thomas Jefferson University|Yes|Completed|May 2005|May 2007|Actual|May 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|75 Years|No|||March 2014|March 4, 2014|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00237510||189114|
NCT00238381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 40/04|Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer|Clinical Function After Total Mesorectal Excision and Rectal Replacement. A Prospective Randomized Trial Comparing Side-to-End Anastomosis, Colon-J-Pouch and Straight Coloanal Anastomosis||Swiss Group for Clinical Cancer Research|Yes|Active, not recruiting|July 2005|June 2016|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|336|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238381||189051|
NCT00239070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405IN01E1|Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients|A Prospective, Open-label, Multicenter, International Follow-up Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients||Novartis||Completed|April 2003|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|69|||Both|18 Years|75 Years||||January 2011|January 28, 2011|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00239070||189000|
NCT00238082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-1277|The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease|The Effect of HFA-beclomethasone Dipropionate on Static Lung Volumes in COPD||National Jewish Health||Terminated|November 1999|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|45 Years|N/A|No|||September 2014|September 24, 2014|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00238082||189071|
NCT00238433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446086|Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma|A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma||OHSU Knight Cancer Institute||Active, not recruiting|March 2005|||January 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|70 Years|No|||May 2013|May 10, 2013|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238433||189047|
NCT00227071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC 1999-65|Aquatic Verses Land Exercise to Decrease Fall Risk|The Effect of Water Verses Land Exercise to Decrease Fall Risk in Older Women With Osteoporosis||University of Saskatchewan||Completed|September 1999|June 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||73|||Female|60 Years|N/A|Accepts Healthy Volunteers|||September 2005|January 3, 2006|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00227071||189885|
NCT00227084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2005.419|Effect of Arista Powder on Bleeding in Reductive Mammary Surgery|Effect of Arista AH-Haemostatic Powder in Plastic Surgery. A Prospective, Consecutive Randomized Study in 30 Women Undergoing Reduction of Both Mamma||University of Oslo|Yes|Completed|September 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|N/A|N/A|No|||August 2007|August 24, 2007|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00227084||189884|
NCT00239161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-353|Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin|TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot Study||University of Manitoba||Terminated|September 2004|July 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2005|October 12, 2005|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00239161||188993|
NCT00239174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5029|A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study Evaluating the Efficacy and Safety of Four Doses of SR147778 in Obese Patients||Sanofi||Completed|November 2004|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|394|||Both|18 Years|65 Years|No|||December 2008|December 9, 2008|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00239174||188992|
NCT00238758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05157|A Study of Omega-3 as a Treatment for Major Depression|A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acids as a Monotherapy for Major Depression||The University of New South Wales||Recruiting|October 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||128|||Both|21 Years|65 Years|No|||September 2006|September 11, 2006|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00238758||189023|
NCT00238303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00646|Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma||National Cancer Institute (NCI)||Completed|September 2005|March 2010|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||October 2011|May 7, 2014|October 12, 2005|Yes|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00238303||189057|
NCT00238615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0002|Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC|A Phase II Trial of Concurrent Docetaxel (Taxotere) / Carboplatin / Radiotherapy Followed by Surgical Resection Followed by Consolidation Taxotere / Carboplatin in Stage III Non-Small Cell Lung Cancer (NSCLC)||Stanford University|Yes|Terminated|March 2003|November 2014|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|October 11, 2005|Yes|Yes|low accrual|No|September 24, 2012|https://clinicaltrials.gov/show/NCT00238615||189034|Accrual was very slow. The study was halted with accrual of only 13 patients. These results were published.
NCT00238628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0005|A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer|A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC)||Stanford University||Completed|April 2004|December 2005|Actual|April 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2010|July 16, 2010|October 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238628||189033|
NCT00239343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0712|Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer|Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer||AstraZeneca||Completed|October 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Female|18 Years|N/A|No|||January 2011|January 25, 2011|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239343||188979|
NCT00239681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00030|JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events|A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein||AstraZeneca|Yes|Terminated|February 2003|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|17802|||Both|50 Years|N/A|No|||February 2014|February 6, 2014|October 13, 2005|Yes|Yes|See detailed description for reason.|No|August 20, 2009|https://clinicaltrials.gov/show/NCT00239681||188953|
NCT00239317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B617/LCT3|Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome|||Astellas Pharma Inc||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|20 Years|90 Years|No|||October 2007|October 18, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00239317||188981|
NCT00240071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F050103001|Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.|The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial||University of Alabama at Birmingham|Yes|Completed|October 2005|April 2011|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|19 Years|80 Years|No|||August 2011|August 21, 2011|October 13, 2005|Yes|Yes||No|April 20, 2011|https://clinicaltrials.gov/show/NCT00240071||188924|A Phase II trial.
NCT00235729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024|Lofexidine for Inpatient Opiate Detox|CSP #1024 - A Phase III, Randomized, Multi-Center, Double Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification.||VA Office of Research and Development|Yes|Completed|June 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|October 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235729||189248|
NCT00236015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6671/3030/AX/US|A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Gabitril at 4, 8, and 12 mg/Day in the Treatment of Adults With Generalized Anxiety Disorder.||Teva Pharmaceutical Industries||Completed|November 2004|March 2006||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||880|||Both|18 Years|64 Years|No|||May 2014|May 8, 2014|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236015||189227|
NCT00236288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508-12|A Feasibility Study of Smoking Cessation Program in Radiation Oncology|A Feasibility Study of Smoking Cessation Program in Radiation Oncology||Indiana University||Completed|October 2005|April 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2007|October 29, 2007|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236288||189206|
NCT00239395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.265|A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis|A Randomised, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 7.5 mg IM Ampoules Once Daily and Meloxicam 7.5 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With Osteoarthritis (OA)||Boehringer Ingelheim||Completed|July 2004|December 2004||December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||168|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239395||188975|
NCT00236938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN02021 / 1VEN02022|Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis|Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis||Luitpold Pharmaceuticals|No|Completed|July 2002|October 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 10, 2005|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00236938||189157|
NCT00237263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOM998A1204|An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States|An Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off||Novartis||Completed|February 2003|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|285|||Both|20 Years|N/A|No|||November 2011|November 22, 2011|October 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00237263||189133|
NCT00219271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GGR01|Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer|Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer||Novartis||Completed|September 2003|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|18 Years|80 Years|No|||May 2013|May 21, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00219271||190475|
NCT00219284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200AUS11|Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease|A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off||Novartis||Completed|January 2005|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|359|||Both|30 Years|85 Years|No|||February 2011|February 16, 2011|June 30, 2005||Yes||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00219284||190474|
NCT00220818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-043|A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.|A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Infants With Clinically-Evident Gastroesophageal Reflux Disease.||Takeda|No|Completed|January 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|364 Days|No|||July 2010|July 20, 2010|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00220818||190356|
NCT00220467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDIS 0008|Cognitive Effects of Aerobic Exercise for MCI Adults|Cognitive Effects of Aerobic Exercise for Adults With Mild Cognitive Impairment: A Controlled Trial||Seattle Institute for Biomedical and Clinical Research|No|Completed|January 2005|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||July 2008|July 29, 2008|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00220467||190383|
NCT00220480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3434-JZ-CTIL|A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression|||Sheba Medical Center|No|Recruiting|February 2005|||June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||February 2010|February 7, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00220480||190382|
NCT00220155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2398|Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer|A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced or Metastatic Colorectal Cancer.||Royal Marsden NHS Foundation Trust|No|Completed|May 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2009|December 15, 2009|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00220155||190407|
NCT00220740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100538|Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy|ICE|Grifols Therapeutics Inc.|No|Completed|April 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 13, 2005|No|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00220740||190362|
NCT00220753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR CLEANER TRIAL 2 SIHF|Air Cleaners for Children and Adolescents With Asthma and Dog Allergy|Air Cleaners for Children and Adolescents With Asthma and Dog Allergy||Sykehuset Innlandet HF|Yes|Completed|September 2005|April 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|8 Years|17 Years|No|||July 2009|July 21, 2009|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00220753||190361|
NCT00217165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-002669|Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study|Taurine as an Anti-manic Agent: a Double-blind Placebo-controlled Study.||Mclean Hospital|No|Completed|April 2005|December 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|68 Years|No|||June 2014|June 2, 2014|August 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217165||190630|
NCT00212875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003397|A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.|An Open-Label, Randomized, Multicenter Study of the Initiation of Four Dosing Regimens of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease (CKD). Protocol Addendum: Due to Space Constraints, See Detailed Description for Full Title of Addendum.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|267|||Both|18 Years|N/A|No|||March 2010|May 19, 2011|September 16, 2005||||||https://clinicaltrials.gov/show/NCT00212875||190953|
NCT00213499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/012/HP|Non Invasive Ventilation and Weaning : VENISE Trial|Randomized Prospective Multicenter Study of Non Invasive Ventilation Assessment for Weaning From Mechanical Ventilation in Patients With Chronic Respiratory Failure. NIV and Weaning (VENISE)Trial.|VENISE|University Hospital, Rouen|Yes|Completed|January 2002|September 2008|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||205|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213499||190905|
NCT00213161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000001031|Using Iron Supplementation to Decrease Iron Deficiency Anemia in Infants and Young Children in India|Establishing an Iron Supplementation Strategy to Reduce the Prevalence of Iron Deficiency Anemia Among Infants and Young Children in India.||The Hospital for Sick Children||Completed|August 2004|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||425|||Both|6 Months|18 Months|No|||September 2005|October 10, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213161||190931|
NCT00209014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0544-2003|Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease|Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease||Emory University||Terminated|July 2003|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2009|May 6, 2009|September 13, 2005|||Celgene unable to continue funds.|No||https://clinicaltrials.gov/show/NCT00209014||191243|
NCT00218153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13334-1|Naltrexone Augmentation of Nicotine Patch Therapy - 1|Naltrexone Augmentation of Nicotine Patch Therapy||National Institute on Drug Abuse (NIDA)||Completed|November 2000|April 2004||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||September 2005|November 3, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218153||190557|
NCT00209326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200440 CS004|A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor|A Randomised, Double-blind, Parallel Group, Dose-ranging, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 (0.3, 1, 3, 10 mg) and Placebo on Stopping Preterm Labour and Uterine Contractions in Pregnant Women With Advanced Gestational Age||Ferring Pharmaceuticals||Completed|November 2003|August 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|163|||Female|18 Years|N/A||||December 2011|December 15, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00209326||191222|
NCT00217932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00451-1|Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings|Double-Blind, Placebo-Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings||National Institute on Drug Abuse (NIDA)||Completed|September 2000|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|7 Years|11 Years|No|||April 2006|April 27, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00217932||190573|
NCT00218140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11082-1|Effectiveness of the Nicotine Patch in Suppressing Nicotine Withdrawal Symptoms in Women Versus Men - 1|Effects of Nicotine Patch in Men and Women||National Institute on Drug Abuse (NIDA)||Completed||April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2005|November 21, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218140||190558|
NCT00218881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-090|An Effective Alternative to the Standard Referral System for HIV Testing in the Emergency Department During Off Hour Tours: A Randomized Trial|An Effective Alternative to the Standard Referral System for HIV Testing in the ED||North Bronx Healthcare Network||Completed|October 2003|July 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||408|||Both|18 Years|N/A|No|||September 2005|October 21, 2005|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00218881||190504|
NCT00219297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2227|Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer|An Open-label, Multi-center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-small Cell Lung Cancer.||Novartis||Completed|November 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|September 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00219297||190473|
NCT00219310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810AUS07|RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir|A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction||Novartis||Completed|June 2003|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||April 2012|April 26, 2012|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00219310||190472|
NCT00219323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A1307|Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.|Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma||Novartis||Completed|November 2003|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|133|||Both|20 Years|75 Years||||October 2011|October 24, 2011|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00219323||190471|
NCT00219622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2641022|A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults Diagnosed With Chronic Obstructive Pulmonary Disease||Pfizer||Completed|May 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|40 Years|75 Years|No|||November 2012|November 5, 2012|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00219622||190448|
NCT00219635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3871029|Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation|A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation||Pfizer||Completed|January 2005|July 2005|Actual|July 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||138|||Male|18 Years|N/A|No|||November 2012|November 5, 2012|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00219635||190447|
NCT00220194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBU001|A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer|A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer||San Bernardino Urological Associates Medical Group Inc||Completed|April 2003|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Male|18 Years|N/A|No|||September 2005|October 19, 2005|September 17, 2005||||No||https://clinicaltrials.gov/show/NCT00220194||190404|
NCT00219869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-EMR-4006|Galantamine in the Treatment of Post-Traumatic Headache|Galantamine in the Preventive Treatment of Chronic Post-Traumatic Headache||Rapoport, Alan, M.D.||Recruiting|July 2005|August 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219869||190429|
NCT00220168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2166|Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours|A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours||Royal Marsden NHS Foundation Trust|No|Completed|January 2003|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2009|December 15, 2009|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220168||190406|
NCT00221455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51760|The Potential of Technology to Improve Chronic Disease Management and Quality of Care|The Potential of Technology to Improve Chronic Disease Management and Quality of Care||Robert Wood Johnson Foundation||Completed|September 2004|September 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1000|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00221455||190307|
NCT00221468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET0296|A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents|A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents||University of Cincinnati||Completed|June 2003|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|18 Years|No|||March 2007|July 17, 2012|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00221468||190306|
NCT00220493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-2966-AA-CTIL|Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients|Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients||Sheba Medical Center||Recruiting|June 2003|June 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||80|||Both|25 Years|65 Years|No|||January 2007|January 4, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00220493||190381|
NCT00220766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100348|Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients|IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients||Grifols Therapeutics Inc.|No|Completed|August 2002|March 2004|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||September 2009|September 24, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00220766||190360|
NCT00220779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100434|Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis|Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis|PRIVIG|Grifols Therapeutics Inc.|No|Completed|December 2002|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|55 Years|No|||March 2014|March 6, 2014|September 13, 2005|No|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00220779||190359|
NCT00221091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI NPH 03-01|Study to Evaluate Efficacy of Shunt Operation for Idiopathic Normal Pressure Hydrocephalus|Clinical Study of Idiopathic Normal Pressure Hydrocephalus for Neurological Improvement||Translational Research Informatics Center, Kobe, Hyogo, Japan||Completed|September 2004|October 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|60 Years|85 Years|No|||February 2009|February 6, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221091||190335|
NCT00221065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI REB 04-043|Effect of Continuous Positive Airway Pressure (CPAP) on Cognitive and Functional Performance in Stroke Patients With Obstructive Sleep Apnea|Influence of CPAP on Cognitive Function and Outcome of Stroke Patients With Obstructive Apnea||Toronto Rehabilitation Institute|No|Completed|June 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2009|February 4, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221065||190337|
NCT00221078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88098-0461-RR001|Benefits of Applying Neuroprosthesis for Improving Reaching and Grasping Functions in Stroke Patients|Restoration of Reaching and Grasping Functions in Stroke Patients Using Functional Electrical Stimulation.||Toronto Rehabilitation Institute|Yes|Completed|April 2003|December 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||February 2009|February 4, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221078||190336|
NCT00212901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004482-01|High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy|Addition of Angiotensin Receptor Blockade to ACE Inhibition Versus High Dose ACE Inhibition for Reduction of Proteinuria in Patients With Diabetic Nephropathy||Ottawa Hospital Research Institute||Completed|August 2004|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|30|||Both|18 Years|75 Years|No|||July 2007|July 25, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212901||190951|
NCT00213174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000003531|Study of Sand Versus Wood Chip Surfaces on School Playgrounds to Minimize Injury in School Children|School Playground Surfacing - A Randomized Prospective Comparison of Injury Rates on Sand Versus Wood Chip Surfaces||The Hospital for Sick Children||Recruiting|January 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|34|||Both|5 Years|11 Years|No|||August 2013|August 14, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213174||190930|
NCT00208533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02841|Aripiprazole in Children With Autism: A Pilot Study|Aripiprazole in Children With Autism: A Pilot Study||Drexel University|Yes|Completed|February 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|12 Years|18 Years|No|||August 2014|August 13, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00208533||191280|
NCT00208546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIRO2|Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer|Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study||Dutch Colorectal Cancer Group|Yes|Completed|June 2005|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|750|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208546||191279|
NCT00213876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3154|Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours|Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.||University Hospital, Strasbourg, France||Completed|February 2004|August 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|189|||Both|1 Year|N/A|No|Non-Probability Sample|Patient with oligodendroglioma or medulloblastoma or glioma|August 2011|August 29, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213876||190876|
NCT00213889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2602|TWIST Human Gene and Cleft Lips and Palates|TWIST Human Gene and Cleft Lips and Palates||University Hospital, Strasbourg, France||Terminated|February 2003|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|1 Month|N/A|No|||March 2015|March 26, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213889||190875|
NCT00208754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0489-2004|Heart Failure in Adult Patients With a History of Congenital Heart Disease|Heart Failure in Adult Patients With a History of Congenital Heart Disease.||Emory University||Terminated|May 2004|December 2005||||N/A|Observational|Time Perspective: Retrospective||||350|||Both|N/A|N/A|No|||November 2013|November 8, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208754||191263|
NCT00218166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA013567|Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine|GABA Agonists as Pharmacotherapies for Cocaine Abuse||National Institute on Drug Abuse (NIDA)|No|Completed|August 2001|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|50 Years|No|||December 2007|December 31, 2007|September 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00218166||190556|
NCT00217633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0222|Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer|Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer||Gynecologic Oncology Group||Completed|January 2006|||January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00217633||190594|
NCT00217919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|296|Reducing Risk Factors in Peripheral Arterial Disease|Reducing Risk Factors in Peripheral Arterial Disease||Northwestern University|Yes|Completed|February 2006|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|355|||Both|21 Years|N/A|No|||April 2014|April 7, 2014|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217919||190574|
NCT00218608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13441-1|Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone|Disulfiram for Cocaine Abuse in Methadone- Patients||University of Arkansas|Yes|Completed|April 2001|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|158|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218608||190523|
NCT00218894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196-03|The Influence of Vision on Balance, Gait and Falls|The Effect of Cataract Surgery on Gait, Balance and Falls in Older Persons||Norwegian University of Science and Technology|No|Completed|January 2004|December 2009|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|70 Years|N/A|No|||May 2010|May 20, 2010|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218894||190503|
NCT00219336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U50/CCU300860|A Media Based Motivational Intervention to Prevent Alcohol Exposed Pregnancies (AEPs)|A Media Based Motivational Intervention to Reduce Alcohol Exposed Pregnancies (AEPs)||Nova Southeastern University|No|Completed|November 2005|March 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|355|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||September 2009|September 21, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00219336||190470|
NCT00219349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4941|Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)|Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation||New York State Psychiatric Institute|No|Completed|January 2005|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|No|||April 2012|April 11, 2012|September 14, 2005|No|Yes||No|February 29, 2012|https://clinicaltrials.gov/show/NCT00219349||190469|
NCT00219609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3871028|Assessment Of Safety Of UK-390,957|A Phase 2 Multi-Center, Open Label Long-Term Extension Trial To Assess The Safety Of Oral Uk-390,957 Administered As Required In Adult Men With Premature Ejaculation||Pfizer||Completed|January 2005|March 2006|Actual|March 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1058|||Male|18 Years|N/A|No|||November 2012|November 5, 2012|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00219609||190449|
NCT00220207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49154|Determining the Effect on Patients of Internet-Based Diabetes Disease Management|A Randomized Controlled Trial of Diabetes Disease Management Over the Internet||Robert Wood Johnson Foundation|No|Completed|September 2003|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||63|||Both|18 Years|75 Years|No|||July 2007|July 31, 2007|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00220207||190403|
NCT00220220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8663-A-E302|Amlodipine as Add-on to Olmesartan in Hypertension|Efficacy and Safety of Amlodipine Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy||Daiichi Sankyo Inc.||Completed|April 2005|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|429|||Both|18 Years|N/A|No|||October 2007|October 10, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00220220||190402|
NCT00219882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEER-106|Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis|A Phase I Safety and Dose Finding Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis Who Are Homozygous for Delta F508 Cystic Fibrosis Transmembrane Conductance Regulator (ΔF508 CFTR) Mutation|SEER|Ramsey, Bonnie, MD|Yes|Completed|April 2005|January 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|40 Years|No|||December 2007|December 18, 2007|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00219882||190428|
NCT00221104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-STARS|Japan Statin Treatment Against Recurrent Stroke (J-STARS)|Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke||Translational Research Informatics Center, Kobe, Hyogo, Japan||Active, not recruiting|March 2004|||July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1578|||Both|45 Years|80 Years|No|||March 2015|March 19, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221104||190334|
NCT00221117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI REB #02-032|Benefits of Applying Neuroprosthesis to Improve Grasping and Reaching in Spinal Cord Injury Patients|Neuroprosthesis for Improving Grasping Function in Spinal Cord Injured Patients||Toronto Rehabilitation Institute|Yes|Completed|August 2005|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2010|September 28, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221117||190333|
NCT00220792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA61309|Group Therapy for Primary Breast Cancer|A Multicenter Trial of Group Therapy for Breast Cancer||Stanford University||Completed|June 1993|June 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||480|||Female|N/A|N/A|No|||September 2005|September 15, 2005|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00220792||190358|
NCT00221702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9267-01|PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)|Randomized, Multicenter Phase III Trial Comparing Adjuvant Treatment With PegIntron Over 36 Months Versus Reference Treatment With IntronA Over 18 Months in Cutaneous Melanoma Patients AJCC Stage II (>=1.5 mm Clinically Node Negative)|EADO|University Hospital, Bordeaux|Yes|Completed|June 2003|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|898|||Both|18 Years|75 Years|No|||October 2010|October 12, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221702||190288|
NCT00208806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0418-2004|Resynchronization Therapy in Young Patients With and Without CHD|Clinical Evaluation of Dilated Cardiomyopathy and Cardiac Resynchronization Therapy for Ventricular Dysfunction in Young Patients With and Without Congenital Heart Disease||Emory University||Completed|June 2004|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||50|||Both|N/A|18 Years|No|||December 2013|December 9, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208806||191259|
NCT00212238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK60058 (completed 2007)|Enhanced Internet Behavior Therapy for Treating Obesity|Enhanced Internet Behavior Therapy for Treating Obesity||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2003|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00212238||191000|
NCT00212602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-7436-01|ONO-7436 Phase II Study in Japan|ONO-7436 Phase II Study - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7436 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Japan||Ono Pharmaceutical Co. Ltd||Completed|August 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||420|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212602||190974|
NCT00209378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.187|Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration|Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial|CASH-CVVH|Free University Medical Center|No|Completed|May 2005|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|80 Years|No|||April 2013|April 1, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209378||191218|
NCT00208793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0126-2004|Calcium and Vitamin D vs Markers of Adenomatous Polyps|Calcium, Vitamin D, and Colon Cancer Risk Biomarkers|CaDvMAP|Emory University|No|Completed|May 2005|February 2013|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|92|||Both|30 Years|74 Years|No|||November 2013|November 22, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208793||191260|
NCT00209066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0422-1998|Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy|A Means to Enhanced Cardiovascular Outcomes: Reduction of Exaggerated Platelet Activity Through Treatment of Depression.||Emory University||Completed|November 1998|April 2005||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with major depressive disorder presenting for a course of electroconvulsive        therapy.|November 2013|November 17, 2013|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00209066||191239|
NCT00209339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #0301|Feasibility Study of a Percutaneous Mitral Valve Repair System.|A Study of the Evalve Cardiovascular Valve Repair System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST I).|EVEREST(I)|Evalve|Yes|Completed|July 2003|October 2011|Actual|February 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00209339||191221|
NCT00218374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15463-1|Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia|Hyperalgesia in Methadone Patients: Can it be Treated?||National Institute on Drug Abuse (NIDA)||Active, not recruiting|October 2006|||June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|55 Years|No|||August 2008|August 11, 2008|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218374||190540|
NCT00218348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16305-1|Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo|Pharmacotherapy for Cocaine Dependence - 1||National Institute on Drug Abuse (NIDA)||Completed|September 2003|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|140|||Both|25 Years|50 Years|No|||January 2009|January 7, 2009|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218348||190542|
NCT00218621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04032202|The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1|Maternal Buprenorphine Administration and Fetal/Infant Neurobehavior||Johns Hopkins University|Yes|Completed|September 2005|February 2009|Actual|February 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|40 Years|No|Non-Probability Sample|Opioid dependent pregnant women enrolled in parent study (Maternal Opioid treatment: Human        Experimental Research)|February 2013|February 20, 2013|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218621||190522|
NCT00219648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP0301|Two-Stage Study to Assess the Efficacy and Safety of 12 Weeks of Treatment With PEP03 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose- Finding, Two-Stage Study to Assess the Efficacy and Safety of 12 Weeks of Treatment With PEP03 in Patients With Chronic Obstructive Pulmonary Disease (COPD)||PharmaEngine||Recruiting|September 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|N/A|No|||September 2005|September 20, 2005|September 20, 2005||||||https://clinicaltrials.gov/show/NCT00219648||190446|
NCT00219375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-601/602/603-0001|Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan|Efficacy and Safety of Sivelestat Sodium Hydrate in Acute Lung Injury Associated With Systemic Inflammatory Response Syndrome, Compared With the Conventional Treatment in Japan||Ono Pharmaceutical Co. Ltd||Completed|June 2004|||July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|649|||Both|18 Years|N/A|No|||June 2012|April 21, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00219375||190467|
NCT00219895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOM0003|Assessment of Inflammatory Mediators (AIM)|Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients With Cystic Fibrosis||Ramsey, Bonnie, MD||Completed|August 2004|March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|10 Years|N/A|No|||August 2006|December 18, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00219895||190427|
NCT00219908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|981166|Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis|Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b||Rennes University Hospital||Terminated|July 1999|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||124|||Both|18 Years|45 Years|No|||September 2005|December 21, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00219908||190426|
NCT00220233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8663-A-E303|Olmesartan as an Add-on to Amlodipine in Hypertension|Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone||Daiichi Sankyo Inc.||Completed|April 2005|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||632|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00220233||190401|
NCT00220506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3769-MD-CTIL|Fatigue Treatment Using Provigil|Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis||Sheba Medical Center||Recruiting|September 2005|December 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|55 Years|No|||February 2006|February 16, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00220506||190380|
NCT00220519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001990/1|Lactobacillus GG Supplementation During Pediatric Burn Injuries|Lactobacillus GG Supplementation During Pediatric Burn Injuries||Shriners Hospitals for Children|Yes|Terminated|October 2004|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|3|||Both|N/A|18 Years|No|||September 2005|December 21, 2007|September 14, 2005||No|Study stopped due to low enrollment|No||https://clinicaltrials.gov/show/NCT00220519||190379|
NCT00221728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9359-03|Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors|Treatment of Renal Tumors With Radiofrequency: Efficacy Evaluation in Comparison With Conservative Surgery (Multicentric Randomized Trial)||University Hospital, Bordeaux|Yes|Terminated|April 2005|January 2008|Anticipated|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|September 13, 2005|||lack of patients|No||https://clinicaltrials.gov/show/NCT00221728||190286|
NCT00217503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441214|Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma|Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir||National Cancer Institute (NCI)||Completed|July 2005|June 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||April 2007|June 18, 2013|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00217503||190604|
NCT00221130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI PDT03-01|Clinical Trials of Regeneration for Periodontal Tissue|Clinical Trial of Regenerative Periodontal Tissue by Transplanting Mesenchymal Stem Cells and Osteoblast Cells - I, II Phase-||Translational Research Informatics Center, Kobe, Hyogo, Japan||Completed|July 2004|December 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 6, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221130||190332|
NCT00221403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-12-26|Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders|Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders||Children's Hospital Medical Center, Cincinnati|Yes|Completed|September 2004|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|46|||Both|3 Years|7 Years|No|||June 2011|June 24, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221403||190311|
NCT00221416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-7-11|An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder|An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder||University of Cincinnati|No|Completed|June 2005|December 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|7 Years|18 Years|No|||June 2013|June 26, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221416||190310|
NCT00221715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9248-01|Comparison of Two Lower Limb Bypass Types : Prosthesis Versus Autologous Vein|Randomised Study Comparing Prosthesis and Autologous Vein for Revascularisation With Above Knee Femoropopliteal Bypass.|REVA|University Hospital, Bordeaux|Yes|Completed|July 2002|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221715||190287|
NCT00209391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOV301|A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title||GE Healthcare||Completed|September 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||270|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00209391||191217|
NCT00209079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804-2004|Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma|Phase II Trial of Gleevec (Imatinib Mesylate) and Taxotere (Docetaxel) as a Combined Regimen for Advanced Gastric Adenocarcinoma||Emory University|Yes|Terminated|September 2004|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2007|December 27, 2007|September 14, 2005|Yes|Yes|Terminated 4/17/07. Drug sponsor withdrew.|No||https://clinicaltrials.gov/show/NCT00209079||191238|
NCT00210002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 DIVE 01|Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced|Evaluation of Systematic Intravenous Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced.||Institut Claudius Regaud||Terminated|November 2003|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||55|||Both|18 Years|N/A|No|||November 2006|November 13, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00210002||191171|
NCT00210392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG25B|VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy|Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142)||International Extranodal Lymphoma Study Group (IELSG)|Yes|Terminated|July 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|September 13, 2005||No|After IELSG25A study amendment, patients subject of the present study were eligible for    inclusion in the IELSG25A study|No||https://clinicaltrials.gov/show/NCT00210392||191141|
NCT00210366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG21|Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma|Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas||International Extranodal Lymphoma Study Group (IELSG)||Terminated|November 2004|||July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|75 Years|No|||July 2010|July 29, 2010|September 13, 2005||No|due to slow accrual|No||https://clinicaltrials.gov/show/NCT00210366||191143|
NCT00217945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|294|Does Shared Decision-Making Improve Adherence in Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2008|January 18, 2008|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00217945||190572|
NCT00217958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295|Better Asthma Outcomes: Lowering Tobacco Smoke Exposure|||Palo Alto Medical Foundation||Completed|May 2002|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|3 Years|12 Years|No|||October 2014|October 27, 2014|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00217958||190571|
NCT00218387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16368-1|Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1|CBT and Modafinil for Cocaine Addiction||Medical University of South Carolina|Yes|Completed|April 2004|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|326|||Both|18 Years|65 Years|No|||September 2010|November 7, 2011|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218387||190539|
NCT00218361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15462-2|Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals|Biobehavioral Study of Opioid Drug Seeking Behavior: Study 2||Wayne State University||Completed|August 2005|||||Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|Samples With DNA|Whole Blood|Both|18 Years|55 Years|No|Non-Probability Sample|Heroin dependent research volunteers|June 2012|June 1, 2012|September 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00218361||190541|
NCT00219362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORVACS 002|Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients|A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients|MANON 02|Objectif Recherche Vaccins SIDA|No|Completed|April 2004|September 2006|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|65|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00219362||190468|
NCT00219921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-349-030905|Postoperative Analgesia After Total Hip Replacement|Postoperative Analgesia After Total Hip Replacement||Rijnstate Hospital||Completed|September 2005|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|30 Years|85 Years|No|||March 2007|March 29, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219921||190425|
NCT00219661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|323|Effect of Drainage of Subglottic Secretions on Pneumonia Acquired Under Mechanical Ventilation|Impact of Drainage of Subglottic Secretions on Ventilator-Associated Pneumonia:a Randomised Multicentre Trial||Poissy-Saint Germain Hospital|No|Completed|June 2003|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||440|||Both|18 Years|N/A|No|||April 2007|April 20, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00219661||190445|
NCT00220831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL-2004|Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment|Prevention of Diabetic Cardiovascular Complications With Vitamin E 400 IU Treatment to High Risk Patients by Haptoglobin Phenotype (I CARE – Israel Cardiovascular Atherosclerosis Risk and Vitamin E)||Technion, Israel Institute of Technology||Terminated|April 2005|December 2009||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2000|||Both|55 Years|N/A|No|||February 2007|February 28, 2007|September 13, 2005|||interim analysis showed significant differences between two treatment groups|No||https://clinicaltrials.gov/show/NCT00220831||190355|
NCT00220844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU4255|Tricyclic Antidepressants (TCAs) on Gastric Emptying|Effect of Tricyclic Antidepressant Agents on Gastric Accommodation and Emptying||Temple University||Recruiting|September 2005|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||September 2005|February 8, 2006|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220844||190354|
NCT00220246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOMSD2004|Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer|||Radboud University||Active, not recruiting|March 2004|September 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||130|||Both|N/A|51 Years|No|||February 2007|February 28, 2007|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00220246||190400|
NCT00220532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH 13608|Folate and Protection Against Cervical Cancer|A Randomised Placebo-Controlled Trial to Evaluate Interactions Between Riboflavin and Folate Intake and Genotype in Reducing Risk of Cervical Cancer||Sheffield Teaching Hospitals NHS Foundation Trust||Terminated|July 2005|May 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||180|||Female|N/A|N/A|No|||September 2006|September 11, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220532||190378|
NCT00217516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441225|Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer|Supplementation of L-Selenomethionine in Patients With Prostate Cancer Prior to Brachytherapy. Selenium Brachytherapy Trial: Phase I/Pilot Study||Roswell Park Cancer Institute|Yes|Completed|March 2005|October 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Male|N/A|N/A|No|||September 2010|February 8, 2012|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217516||190603|
NCT00217490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441203|Individual Counseling and/or Computer-Based Counseling in Helping Healthy Women Adopt a Cancer Prevention Diet|Helping Women Adopt a Cancer Prevention Diet||National Cancer Institute (NCI)||Active, not recruiting|March 2005|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Female|30 Years|70 Years|Accepts Healthy Volunteers|||April 2006|March 7, 2009|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00217490||190605|
NCT00221429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063632|Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder|Pediatric Bipolar Collaborative Mood Stabilizer Trial||National Institute of Mental Health (NIMH)||Active, not recruiting|March 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||154|||Both|7 Years|18 Years|No|||November 2002|February 22, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00221429||190309|
NCT00221442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51-345-740|Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity|Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients||Lindner Center of HOPE||Completed|August 2005|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||June 2011|June 21, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221442||190308|
NCT00218010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00495-2|Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2|Breastfeeding Among Methadone Maintained Women||National Institute on Drug Abuse (NIDA)|No|Completed|November 2000|September 2005|Actual|August 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Female|18 Years|40 Years|No|Non-Probability Sample|lactating women|April 2015|April 15, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218010||190567|
NCT00209651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0302|Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer|Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302||Hokkaido Gastrointestinal Cancer Study Group|Yes|Active, not recruiting|January 2004|December 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||October 2007|October 31, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209651||191197|
NCT00210015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-105|A Study in Subjects With Perennial Allergic Rhinitis|A Multi-Center, Randomized, Parallel-Group, Double-Blind, Efficacy and Safety Study of INS37217 Nasal Spray Versus Placebo in Subjects With Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|December 2002|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||630|||Both|N/A|N/A||||January 2016|January 22, 2016|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210015||191170|
NCT00209625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0001|Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer|Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer：Hokkaido Gastrointestinal Cancer Study Group:HGCSG0001||Hokkaido Gastrointestinal Cancer Study Group||Completed|April 2000|November 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||23|||Both|18 Years|75 Years|No|||April 2000|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209625||191199|
NCT00210028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 SEIN 04|Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer|Open, Single-Arm Phase II Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer Expressing the Estrogen and/or Progesterone Receptor||Institut Claudius Regaud||Terminated|August 2003|August 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|N/A|No|||November 2006|November 10, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210028||191169|
NCT00210613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003451|A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation|A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As-Needed Dosing With Dapoxetine in the Treatment of Premature Ejaculation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2004|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|199|||Male|18 Years|N/A|No|||December 2010|June 6, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210613||191124|
NCT00217672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000442877|Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer|A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for HER2-Negative Metastatic Breast Cancer||Translational Oncology Research International|Yes|Active, not recruiting|May 2005|||September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Female|18 Years|N/A|No|||September 2010|September 1, 2010|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217672||190591|
NCT00217971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4886-NIDA-09236-11|Dronabinol Treatment for Marijuana Addiction|A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction|MARINOL|New York State Psychiatric Institute|Yes|Completed|March 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|September 16, 2005|Yes|Yes||No|September 13, 2011|https://clinicaltrials.gov/show/NCT00217971||190570|Consequences of use are often long-term and more subtle. Thus, trying to initiate change over a relatively short period (i.e. patients in the present trial were maintained on the maximum dronabinol dose for only 6 weeks), may have been inadequate.
NCT00218660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-5186-1|Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1|Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence||University of Pennsylvania|No|Completed|April 1998|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|164|||Both|18 Years|65 Years|No|||June 2010|October 21, 2015|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218660||190520|
NCT00218907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-073|An Educational HIV Pre-Test Counseling Video Program for Off Hours Testing in the ED: A Randomized Control Trial|An Educational HIV Pre-Test Counseling Video Program for Off Hours Testing in the ED: A Randomized Control Trial||North Bronx Healthcare Network||Terminated|June 2003|August 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||130|||Both|18 Years|N/A|No|||September 2005|October 21, 2005|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00218907||190502|
NCT00218920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2005.542|Effective Training in Overweight and Obese People|Effective Training in Overweight and Obesity||Norwegian University of Science and Technology||Completed|September 2005|January 2008||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|N/A||||August 2008|August 25, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218920||190501|
NCT00220857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU4504|Rabeprazole Protection of Aspirin Induced Gastric Damage.|Rapid Protection of the Gastroduodenal Mucosa Against Aspirin-Induced Damage by Rabeprazole||Temple University||Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2008|January 2, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00220857||190353|
NCT00220870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-43794-5/9|Shared Decision Making for Schizophrenia|Shared Decision Making in the Therapy of Schizophrenia||Technische Universität München||Completed|January 2003|August 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|65 Years|No|||April 2010|April 7, 2010|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00220870||190352|
NCT00220545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/173|Comparison Between Laparoscopic Ovarian Diathermy and Clomiphene Citrate in Women With Anovulatory PCOS|A Prospective Randomized Controlled Trial to Compare Laparoscopic Ovarian Diathermy With Clomiphene Citrate as a First Line Treatment of Anovulatory Infertility in Patients With Polycystic Ovarian Syndrome||Sheffield Teaching Hospitals NHS Foundation Trust||Completed|March 2002|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|72|||Female|19 Years|39 Years|No|||October 2007|October 22, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00220545||190377|
NCT00221481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00-12-071-11A|An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder|An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder||Mayo Clinic||Withdrawn||March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Male|18 Years|65 Years|No|||February 2009|May 29, 2015|September 13, 2005|Yes|Yes|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00221481||190305|
NCT00221143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI ASO 03-01|Stem Cell Study for Patients With Leg Ulcer/Gangrene|Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Critical Limb Ischemia||Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Completed|November 2003|January 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|20 Years|80 Years|No|||February 2009|February 6, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221143||190331|
NCT00217776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288|School-based Approaches to Help Pre-teens Manage Asthma||DMSP|University of Michigan||Completed|February 2003|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1292|||Both|11 Years|12 Years|No|||January 2013|January 16, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217776||190585|
NCT00217737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00562|Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer|A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2005|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3610|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217737||190587|
NCT00217724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446073|Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer|A Double-blinded Pilot Study of Glutamine for the Prevention of Paclitaxel-Induced Myalgias and Arthralgias||OHSU Knight Cancer Institute|Yes|Terminated|July 1999|March 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|120 Years|No|||December 2015|December 10, 2015|September 20, 2005|Yes|Yes|Only able to accrue just 18 of the 40 target & funds were limited.|No|June 10, 2010|https://clinicaltrials.gov/show/NCT00217724||190588|We were able to only accrue 18 of the 40 patient target. This, plus confounded results and limited funds, the remaining research funds were returned to the sponsor and no evaluation of serum or dietary glutamine levels was done.
NCT00218231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14002-2|Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia|Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)||National Institute on Drug Abuse (NIDA)|No|Completed|January 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2008|August 19, 2008|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218231||190551|
NCT00218452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1996-04|Smoking Cessation for Young Adults Who Binge Drink - 1|Smoking Cessation for Young Adults Who Binge Drink||Mayo Clinic|No|Completed|September 2005|April 2008|Actual|December 2007|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218452||190535|
NCT00210405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0460-INTFOO-01-3-IFPRI|Feasibility and Effectiveness of Distributing Micronutrient Sprinkles to Reduce Prevalence of Anemia|Assessing the Feasibility and Effectiveness of Distributing Micronutrient Sprinkles Within a Title II Food Aid and Maternal and Child Health Program in Rural Haiti||International Food Policy Research Institute||Completed|March 2005|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|450|||Both|6 Months|20 Months|Accepts Healthy Volunteers|||August 2012|August 29, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210405||191140|
NCT00210418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212620-0S-IFPRI|Effectiveness of Targeting Food Aid to Malnourished Children Compared to Targeting All Children Under Two Years|Prevention or Cure: A Comparison of the Effectiveness of Targeting Food Supplements to Malnourished Children Compared to Universal Targeting of Children Under Two in Haiti||International Food Policy Research Institute||Completed|May 2002|September 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2|||1500|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2012|August 29, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210418||191139|
NCT00210431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-47-52120-093|Post Marketing Surveillance Study of Dysport|A Post Marketing Surveillance Study of Dysport Formulated With a Batch of Bulk Active Substance From a New Primary Manufacturing Facility at the Centre for Applied Microbiology & Research.||Ipsen||Completed|October 2004|June 2006|Actual|||Phase 4|Observational|Time Perspective: Prospective||1||800|||Both|2 Years|N/A|No|||September 2007|September 29, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210431||191138|
NCT00210379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG10|Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma|A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma||International Extranodal Lymphoma Study Group (IELSG)||Completed|November 2000|March 2007|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Male|18 Years|N/A|No|||July 2009|July 21, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00210379||191142|
NCT00210834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004633|An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.|A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Initiated At 40,000 Units Every Week Versus 80,000 Units Every Two Weeks In Anemic Patients With Cancer Receiving Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|310|||Both|18 Years|N/A|No|||May 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210834||191107|
NCT00218179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13333-1|Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1|Prostate, Lung, Colon, and Ovarian Cancer (PLCO) Screen Trial||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|200|||Both|55 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Case-control study nested within the Prostate Lung Colorectal and Ovarian Cancer Screening        Trial. Subjects consisted of screening arm subjects who were smokers at baseline and who        contributed biorepository samples at the first screening visit.|August 2014|August 25, 2014|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218179||190555|
NCT00218959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2005.1100|Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees|Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees and Asylum Seekers in Mid-Norway||Norwegian University of Science and Technology|No|Completed|September 2005|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218959||190498|
NCT00218634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18603-1|Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1|CBT for Depression & Adherence in HIV Methadone Patients||Massachusetts General Hospital|No|Completed|February 2005|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|65 Years|No|||June 2012|June 22, 2012|September 20, 2005||No||No|January 3, 2012|https://clinicaltrials.gov/show/NCT00218634||190521|
NCT00218933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFEX-1|High-intensity Exercise Training in Patients With Post-infarction Heart Failure|Anti-remodeling Effect of High-intensity Interval Training in Patients With Post-infarction Heart Failure on Optimal Treatment||Norwegian University of Science and Technology|No|Completed|October 2001|September 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||27|||Both|30 Years|N/A||||August 2008|September 30, 2015|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218933||190500|
NCT00218946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISE-2005-1|Nasogastric Tube in Premature Babies - Pain and Treatment|Nasogastric Tube in Premature Babies - Pain and Treatment. A Randomised, Partly Blinded, Placebo-controlled Factorial Clinical Trial of Sucrose and Pacifier||Norwegian University of Science and Technology|No|Completed|January 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver)|6||Actual|24|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||April 2015|April 7, 2015|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218946||190499|
NCT00221156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI_CAD_04-02|Acarbose and Secondary Prevention After Coronary Stenting|Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study)||Translational Research Informatics Center, Kobe, Hyogo, Japan||Completed|May 2005|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|300|||Both|20 Years|75 Years|No|||June 2009|June 23, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221156||190330|
NCT00221494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-09-045-11|Can Additional Drug Therapy Accelerate Response Time to Antidepressants|Can Additional Drug Therapy Accelerate Response Time to Antidepressants: A Double-blind, Placebo-controlled Randomization Research Study for Major Depression||Mayo Clinic|Yes|Withdrawn|January 2004|||June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||June 2006|May 29, 2015|September 13, 2005|Yes|Yes|PI move|No||https://clinicaltrials.gov/show/NCT00221494||190304|
NCT00221741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9293-02|Fresh Frozen Plasma in Cardiac Surgery: Descriptive and Prognostic Study|PLASMACARD - Fresh Frozen Plasma in Cardiac Surgery: Descriptive and Prognostic Study|PLASMACARD|University Hospital, Bordeaux|No|Completed|February 2004|March 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|1497|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221741||190285|
NCT00218270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14404-2|Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users||National Institute on Drug Abuse (NIDA)|Yes|Completed|December 2002|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2008|June 27, 2008|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218270||190548|
NCT00217763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-758010|European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients|A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease||Bellus Health Inc||Active, not recruiting|September 2005|December 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|930|||Both|50 Years|N/A|No|||December 2007|December 7, 2007|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00217763||190586|
NCT00218036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-8|Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8|Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|July 2006|July 2011|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|200|||Both|22 Years|50 Years|Accepts Healthy Volunteers|||December 2009|December 11, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218036||190565|
NCT00218023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-7|Medications for Stopping Cocaine Dependence and Preventing Relapse|Screening Medications for Cocaine Cessation and Relapse Prevention||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|March 2006|March 2011|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 11, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218023||190566|
NCT00218478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19236-1|Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1|Cue Reactivity Model for Assessing Pharmacologic Intervention in Treatment of Cannabis Use Disorders (Study 1)||Wayne State University||Completed|September 2004|July 2008|Actual|||Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Marijuana dependent volunteers|June 2012|June 1, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218478||190533|
NCT00210444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-714|Efficacy Study of Dysport® in the Treatment of Anal Fissure.|A Phase II, Multicentre, Open, Randomised, Parallel Group, Dose Ranging Study to Define the Efficacy of Dysport® in the Treatment of Anal Fissure.||Ipsen||Completed|June 2003|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||152|||Both|18 Years|75 Years|No|||September 2007|September 12, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00210444||191137|
NCT00210626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003235|Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT®)) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|August 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|55 Years|No|||April 2014|April 2, 2014|September 13, 2005|Yes|Yes||No|June 26, 2009|https://clinicaltrials.gov/show/NCT00210626||191123|The study was stopped early due to slow enrollment. Four subjects were randomized but withdrew prior to hospital entry and no data were collected
NCT00210847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004660|A Study Comparing the Effectiveness and Safety of Tramadol HCl/Acetaminophen Versus Placebo for the Treatment of Painful Neuropathy in Diabetic Patients|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Tramadol HCl/Acetaminophen for the Treatment of Painful Diabetic Neuropathy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2003|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|313|||Both|18 Years|75 Years|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210847||191106|
NCT00217984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09253-6|Intensive Intervention for Smokers - 6|Intensive Intervention for Smokers in Alcohol Treatment||University of California, San Francisco|Yes|Completed|July 2006|June 2010|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|75 Years|No|||June 2012|June 25, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00217984||190569|
NCT00218205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-EPIRU-0030-280-US|A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer|A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC)||Department of Veterans Affairs, New Jersey||Recruiting|July 2002|June 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Male|18 Years|N/A|No|||September 2005|September 20, 2005|September 20, 2005||||||https://clinicaltrials.gov/show/NCT00218205||190553|
NCT00218192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13759-1|A Trial to Reduce Hepatitis C Among Injection Drug Users - 1|A Trial to Reduce Hepatitis C Among Injection Drug Users||Butler Hospital|No|Completed|September 2000|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|277|||Both|18 Years|75 Years|No|||April 2013|May 21, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218192||190554|
NCT00219388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001075|Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.|Efficacy and Safety of Short-Term Intravenous Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients Treated With Beta-Receptor Blocking Agents.||Orion Corporation, Orion Pharma||Completed|November 2002|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 21, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00219388||190466|
NCT00219700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-IB-002|Ibuprofen-PC Compared With Ibuprofen in a GI Safety Trial|Phase II, Randomized, Blinded Study of Ibuprofen-PC and Ibuprofen in Patients With Osteoarthritis to Investigate Efficacy and Gastrointestinal Toxicity||PLx Pharma|No|Completed|January 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||125|||Both|18 Years|N/A|No|||November 2008|November 25, 2008|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00219700||190442|
NCT00220285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91102|Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma|A Phase II Open-label Study of SH L 749 in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphomas||Bayer|Yes|Completed|August 2004|October 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|74 Years|No|||December 2014|December 29, 2014|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00220285||190397|
NCT00220298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91186|Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism|Open One-arm Study to Investigate Safety and Efficacy of Intramuscular Injections of 1000 mg Testosterone Undecanoate (TU) in Hypogonadal Men at Variable Intervals During a 136-week to 192-week Treatment Including Pharmacokinetics||Bayer|No|Completed|February 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Male|18 Years|75 Years|No|||December 2014|December 29, 2014|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00220298||190396|
NCT00219674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL074098-01A1|At-Home Automated External Defibrillator (AED) Training Study|Home Automatic External Defibrillator Training for High-Risk Patients||Public Health - Seattle and King County|Yes|Completed|July 2004|March 2011|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|305|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00219674||190444|
NCT00219687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RARC-0001-01|Dispatcher-Assisted Resuscitation Trial (DART)|Randomized Trial of Dispatcher-Assisted CPR:Chest Compression Alone Versus Chest Compression Plus Ventilation||Public Health - Seattle and King County|Yes|Completed|June 2004|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5494|||Both|9 Years|N/A|No|||October 2014|October 28, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00219687||190443|
NCT00220558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRDIT 00-01/04|GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions|A Randomized Comparison of Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions: The Gruppo Italiano di Studio Sullo Stent Nelle Occlusioni Coronariche. The GISSOC II Study.||Società Italiana di Cardiologia Invasiva|No|Active, not recruiting|May 2005|February 2010|Anticipated|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||May 2009|December 3, 2009|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00220558||190376|
NCT00220571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT(IT) H4S-IT-O038|CARESS in Acute Myocardial Infarction|Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction||Società Italiana di Cardiologia Invasiva|Yes|Completed|May 2003|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|N/A|75 Years|No|||September 2005|July 2, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220571||190375|
NCT00220584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96239|An Open-Label Trial of Donepezil in Fragile X Syndrome|An Open-Label Trial of Donepezil in Fragile X Syndrome||Stanford University|No|Completed|July 2005|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|14 Years|N/A|No|||December 2012|December 11, 2012|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00220584||190374|
NCT00221169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-may-00142 OCRN|Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer|Can PET CT Coregistration Imaging Adequately Determine the Gross Tumor Volume and Microscopic Extension in Non-Small Cell Lung Cancer Patients for Radical Radiation Therapy?||Toronto Sunnybrook Regional Cancer Centre|No|Completed|October 2005|January 2009|Actual|June 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|N/A|No|||February 2009|February 4, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221169||190329|
NCT00221182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI CAD 04-01|Stem Cell Study for Patients With Heart Disease|Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Myocardial Ischemia||Foundation for Biomedical Research and Innovation||Terminated|September 2005|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|20 Years|80 Years|No|||June 2011|June 21, 2011|September 13, 2005||No|slow recruitment of the study subjects|No||https://clinicaltrials.gov/show/NCT00221182||190328|
NCT00221754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9268-02|Pravastatin and Protease Inhibitors in HIV-Infected Patients|Pravastatin in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy||University Hospital, Bordeaux|Yes|Completed|March 2003|March 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221754||190284|
NCT00217529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 2001|Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer|A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer||Fred Hutchinson Cancer Research Center||Completed|June 2004|||November 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2010|September 20, 2010|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00217529||190602|
NCT00218517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19246-1|Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1|Selegiline for Treatment of Cannabis Dependence||National Institute on Drug Abuse (NIDA)|Yes|Completed|March 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2008|July 31, 2008|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218517||190530|
NCT00218049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-10|Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals|Phase 1, Double-Blind, Placebo-Controlled Assessment of Interactions Between 2 Doses of Cocaine and Three Doses of Escalating Vanoxerine (GBR 12909) in Cocaine Using Volunteers||National Institute on Drug Abuse (NIDA)|Yes|Terminated|December 2004|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 18, 2008|September 16, 2005||No|Issue of priority of resources|No||https://clinicaltrials.gov/show/NCT00218049||190564|
NCT00218257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14573-1|Progesterone for the Treatment of Cocaine Dependence - 1|Interactions Between Progesterone and Cocaine in Women||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2002|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|46 Years|No|||November 2015|November 16, 2015|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218257||190549|
NCT00218244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14404-1|Using Smokeless Tobacco Products With Lower Nicotine Levels to Reduce Negative Effects of Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users: Use of Nicotine Replacement Products to Reduce Smokeless Tobacco Use|Brandswitch|National Institute on Drug Abuse (NIDA)|Yes|Completed|August 2001|November 2004|Actual|November 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|70 Years|No|||June 2008|June 27, 2008|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218244||190550|
NCT00218712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073425|Specialized Cognitive-Behavioral Counseling Intervention to Reduce HIV Transmission Risk Behavior in HIV-Infected Men|Reducing HIV Transmission Risk Behavior: a Trial of a Two Session Risk-Reduction Intervention With HIV-Positive Men Who Have Sex With Men||University of California, San Francisco|Yes|Completed|September 2005|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|488|||Male|18 Years|N/A|No|||April 2012|April 30, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218712||190516|
NCT00218725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH071905-02|Effectiveness of Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder|Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder||University of Pennsylvania|No|Completed|May 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00218725||190515|
NCT00210860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004669|An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.|An Open-label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study to CAPSS-277||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|142|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210860||191105|
NCT00210639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004171|A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection|A Multicenter, Long-Term, Active-Surveillance Study of Musculoskeletal Disorders That Occur After Initiating a Course of Levofloxacin (RWJ-25213-097) or Non-Fluoroquinolone Therapy for Acute Infectious Diseases in Children Who Were Enrolled in Phase 3 Clinical Trials Involving Levofloxacin Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2002|May 2010|Actual|April 2010|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2233|||Both|6 Months|16 Years|No|Probability Sample|Children who have received levofloxacin or a standard non-fluoroquinone therapy for acute        bacterial infection in one of the Phase 3 interventional studies will be enrolled in this        study.|April 2014|April 2, 2014|September 13, 2005|Yes|Yes||No|April 26, 2011|https://clinicaltrials.gov/show/NCT00210639||191122|This was an observational safety study with no efficacy endpoints. Adverse event data is entered into the appropriate section within this submission.
NCT00211302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSUHSC #H04-022|Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)|Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia. (BMS)||Louisiana State University Health Sciences Center Shreveport|No|Terminated|August 2003|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 2, 2011|September 13, 2005||No|Enrollment too difficult|No||https://clinicaltrials.gov/show/NCT00211302||191071|
NCT00211523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A99004|Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne|Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris||BioWest Therapeutics Inc||Completed|October 2000|September 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|13 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211523||191054|
NCT00218413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17894-2|Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals|A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers||National Institute on Drug Abuse (NIDA)|No|Completed|October 2004|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|51|||Both|18 Years|N/A|No|||November 2008|November 3, 2008|September 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00218413||190538|
NCT00218426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17317-1|Addiction Treatment in Russia: Oral vs. Naltrexone Implant|Addiction Treatment in Russia: Oral and Depot Naltrexone||University of Pennsylvania|Yes|Completed|July 2006|October 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|306|||Both|18 Years|50 Years|No|||January 2012|July 3, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218426||190537|
NCT00219960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFMC-0001-77|The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension|The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension||Risk Factor Modification Centre||Completed|April 2001|October 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|85 Years|No|||June 2004|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00219960||190422|
NCT00220597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060556|Group Therapies for Reducing HIV-risk Behavior in Women Who Have Survived Childhood Sexual Abuse|Group Interventions to Prevent HIV in High Risk Women||Stanford University|No|Completed|September 1999|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|171|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 2, 2013|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00220597||190373|
NCT00220883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU4687|Electrogastrogram (EGG) Reproducibility Study: EEG Readings in Normal Subjects and Dyspeptic Patients|Reproducibility and Inter-Reader Reliability of Electrogastrographic Readings in Normal Subjects and Dyspeptic Patients||Temple University||Recruiting|August 2005|September 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||September 2005|February 6, 2006|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00220883||190351|
NCT00221208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHP - 69441|Home Based Resistance Training For Type 2 Diabetes|A Home Based Resistance Training Program for Obese Adults With Type 2 Diabetes||University of Alberta, Physical Education||Completed|April 2005|December 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||March 2009|March 16, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221208||190326|
NCT00221507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ 048472|Increasing Infant Preventive Health Service Delivery in an Inner City Population|Increasing Infant Preventive Health Service Delivery in an Inner City Population||University of Colorado, Denver||Recruiting|February 2004|June 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|800|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2007|July 17, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00221507||190303|
NCT00217789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120040230; M-230-2004; 287|Pathogen Specific Immunity in Patients With Sarcoidosis|Pathogen Specific Immunity in Sarcoidosis||Rutgers, The State University of New Jersey||Completed|July 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Sarcoidosis patients and healthy subjects|December 2013|December 23, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217789||190584|
NCT00218062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-12|Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals|Pharmacotherapy Dosing Regimen (Cocaine Dependence Population)||The University of Texas Health Science Center, Houston|Yes|Completed|March 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|73|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 2, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218062||190563|
NCT00218530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18197-1|Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1|Naltrexone and Lofexidine in Detoxified Heroin Addicts||National Institute on Drug Abuse (NIDA)||Completed|March 2003|September 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||September 2005|November 21, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218530||190529|
NCT00219128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2308|A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.|An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension||Novartis||Completed|November 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|671|||Both|18 Years|N/A|No|||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219128||190485|
NCT00218504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19236-2|Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2|Cue Reactivity Model for Assessing Pharmacologic Intervention in Treatment of Cannabis Use Disorders (Study 2)||Wayne State University||Completed|December 2005|October 2009|Actual|||Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Marijuana dependent volunteers.|June 2012|June 1, 2012|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00218504||190531|
NCT00218491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19903-1|Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1|A Controlled Trial of N-Acetylcysteine (NAC) for Cocaine Dependence|NAC|Medical University of South Carolina|Yes|Completed|November 2005|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|235|||Both|18 Years|65 Years|No|||September 2010|November 7, 2011|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218491||190532|
NCT00219466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2301007|Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash|A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|June 2005|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|2 Months|36 Months|Accepts Healthy Volunteers|||August 2011|August 19, 2011|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00219466||190460|
NCT00211315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA in Coat's Disease|Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)|||Manhattan Eye, Ear & Throat Hospital|No|Completed|March 2002|March 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211315||191070|
NCT00211068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004408|A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa|Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|March 2004|March 2006|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|124|Samples With DNA|Blood sample collected for pharmacogenomic analysis|Both|N/A|N/A|No|Non-Probability Sample|Participants having chronic kidney disease and an immune-mediated cause of pure red cell        aplasia indicated by the presence of anti-erythropoietin antibodies in their serum at the        time of loss of efficacy|April 2013|April 29, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211068||191089|
NCT00211848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA12867|Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers|Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers||Icahn School of Medicine at Mount Sinai||Active, not recruiting|June 2000|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||207|||Both|21 Years|67 Years|No|||April 2007|April 27, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211848||191029|
NCT00218972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Traininghypertension|Physical Exercise in Hypertension, Randomised Clinical Trial|Physical Exercise in Hypertension, Randomised Clinical Trial||Norwegian University of Science and Technology|No|Completed|February 2005|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|88|||Both|18 Years|65 Years|No|||December 2013|December 5, 2013|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218972||190497|
NCT00219973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-BEM-2003-02|CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)|Multicentric, Rand., D-b, Pbo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of the Thromboprophylaxis With Bemiparin 3,500 IU/d for 28 Days Compared to 8 Days, in Patients Undergoing Oncological Abdominal/ Pelvic Surgery||Rovi Pharmaceuticals Laboratories|Yes|Completed|May 2005|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|526|||Both|40 Years|N/A|No|||April 2010|April 27, 2010|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00219973||190421|
NCT00220337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0830|A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy|A Multicenter, Open-label Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy||UCB Pharma||Completed|December 2004|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|371|||Both|N/A|N/A||||September 2009|September 19, 2014|September 1, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00220337||190393|
NCT00219934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA 0465|Observational Study of Treated and Untreated Acute and Early HIV-1 Infection|Observational Study of Treated and Untreated Acute and Early HIV-1 Infection||Rockefeller University|Yes|Completed|February 2002|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|399|Samples With DNA|PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS|Both|16 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the community or from existing ADARC clinical trials.        Participants will give written informed consent.|February 2012|February 15, 2012|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00219934||190424|
NCT00219947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA-448|Viral and Host Factors in the Transmission and Pathogenesis of HIV|Viral and Host Factors in the Transmission and Pathogenesis of HIV||Rockefeller University|No|Active, not recruiting|July 2000|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|whole blood|Both|16 Years|N/A|No|Non-Probability Sample|Subjects are either referred by primary health care providers, self-referred, or may be        seeking enrollment in other ADARC clinical trials in the NYC area.|June 2015|June 30, 2015|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00219947||190423|
NCT00221221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTION|Physical Activity Promotion in Breast Cancer Survivors|Physical Activity Promotion in Breast Cancer Survivors: A Population Based Randomized Controlled Trial||University of Alberta, Physical Education||Completed|July 2005|March 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label||||300|||Female|N/A|N/A|No|||May 2007|May 2, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221221||190325|
NCT00220259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01PRT/31|Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)|Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)||Royal Brompton & Harefield NHS Foundation Trust||Completed|May 2001|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||240|||Both|6 Years|N/A|No|||September 2005|November 7, 2005|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00220259||190399|
NCT00220272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT5288|Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease|A Phase II, Randomized, Multicenter, Multinational, Double-Blind, Placebo-Controlled, Study of the Effect of SR57667B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients With Early Parkinson's Disease||Sanofi||Completed|January 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|183|||Both|35 Years|N/A|No|||December 2008|December 22, 2008|September 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00220272||190398|
NCT00220896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSYTUM1|Prevention of Postoperative Delirium With Donepezil|||Technische Universität München||Completed|January 2006|March 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|37|||Both|70 Years|N/A|No|||September 2011|September 13, 2011|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00220896||190350|
NCT00221195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-FEIBA Study|A Prospective, Randomized, Cross-Over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors|||Tulane University School of Medicine||Recruiting|June 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||42|||Both|24 Months|N/A|No|||September 2005|September 19, 2005|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00221195||190327|
NCT00217542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00152|Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery|A Phase 1 Study of 5-azacitidine in Combination With Interferon-Alfa 2B in Unresectable or Metastatic Melanoma and Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|July 2005|||July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00217542||190601|
NCT00218075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-9|Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence|Behavioral Strategies to Maximize the Efficacy of Pharmacotherapy for Cocaine Dependence: Relapse Prevention With Contingency Management Procedures||The University of Texas Health Science Center, Houston||Completed|March 2000|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|55 Years|No|||January 2016|January 4, 2016|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218075||190562|
NCT00218283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14404-3|Nicotine Lozenge to Reduce Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2008|June 27, 2008|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00218283||190547|
NCT00218764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069618|Cognitive Therapy Versus Medication Treatment for Preventing Depression Relapse|Are CT's Effects Durable?||National Institute of Mental Health (NIMH)|Yes|Active, not recruiting|December 2003|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|70 Years|No|||October 2008|October 21, 2008|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00218764||190513|
NCT00218751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060733|Early Home Visitation Program to Promote Good Health and Development in Children at Risk for Abuse|Promoting Child Mental Health: RCT of Home Visiting||Johns Hopkins University||Completed|March 2000|August 2005|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||1122|||Both|14 Years|N/A|Accepts Healthy Volunteers|||February 2008|September 23, 2013|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218751||190514|
NCT00219076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2305|A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients|A Six-Week, Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren 150 mg and Amlodipine 5 mg Compared to Amlodipine 5 mg and 10 mg in Hypertensive Patients Not Adequately Responsive to Amlodipine 5 mg||Novartis||Completed|February 2005|||October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||504|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00219076||190489|
NCT00219089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2307|A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.|An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus||Novartis||Completed|November 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|839|||Both|18 Years|N/A|No|||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219089||190488|
NCT00219479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #96-264|Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study|Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study||Penn State University|No|Terminated|August 1997|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|September 15, 2005||No|Difficulty recruiting subjects|No||https://clinicaltrials.gov/show/NCT00219479||190459|
NCT00211562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omega-3 Fatty Acids|Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids|Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids||Georgia Regents University||Terminated|October 2005|||January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00211562||191051|
NCT00211575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-042|Instrument Utility for Suspected Asthma (0000-042)(COMPLETED)|Clinical Utility of an Instrument in the Evaluation of Young Children With Suspected Asthma||Merck Sharp & Dohme Corp.||Completed|May 2003|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|400|||Both|N/A|6 Years|No|||January 2015|January 2, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211575||191050|
NCT00211549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-III-04|An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Doses of IDEA-033 in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of Osteoarthritis of the Knee||IDEA AG||Completed|June 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||875|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211549||191052|
NCT00212108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP01/07/03|A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839|A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839||National University Hospital, Singapore||Completed|November 2003|January 2009|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212108||191010|
NCT00212121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03RBC-young boost|Radiation Dose Intensity Study in Breast Cancer in Young Women|Radiation Dose Intensity Study in Breast Cancer in Young Women: a Randomized Phase III Trial of Additional Dose to the Tumor Bed||The Netherlands Cancer Institute|No|Active, not recruiting|July 2004|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2400|||Female|18 Years|50 Years|No|||April 2012|April 24, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212121||191009|
NCT00219713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|991300|Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture.|A Randomized Placebo-Controlled Double Blind Trial Comparing Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture in Combination With Local Local 1% Xylocaine Anesthetic Versus Placebo in Order to Evaluate Pain Intensity During Bone Marrow Biopsy.||Poitiers University Hospital||Terminated|March 2000|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||280|||Both|16 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219713||190441|
NCT00220610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMO03.3741/SH/P03.1231L|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN the Treatment of DEPRESSION|Right Parietal Inhibition With rTMS in the Treatment of Depression||St. Lucas Andreas Ziekenhuis Hospital||Recruiting|May 2004|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|16 Years|65 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220610||190372|
NCT00220922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM013|A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.|An Open-Label, Randomized, Single Cross-Over Study of Isopropyl Alcohol Wipes Versus No Injection Site Preparation on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone®||Teva Pharmaceutical Industries|No|Completed|August 2004|February 2006|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00220922||190348|
NCT00220311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303530|A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia|A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia||Sanofi|No|Completed|November 2000|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|15 Years|80 Years|No|||December 2013|December 2, 2013|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00220311||190395|
NCT00221533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/196|Relation Between Renin-Angiotensin Gene Polymorphisms, Plasma Adiponectin and Arterial Stiffness in Renal Transplant Recipients|Relation Between Renin-Angiotensin Gene Polymorphisms, Plasma Adiponectin and Arterial Stiffness in Renal Transplant Recipients||University Hospital, Ghent|No|Completed|March 2004|August 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||250|||Both|18 Years|80 Years|No|||December 2007|December 19, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00221533||190301|
NCT00221546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/220|Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis|Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis||University Hospital, Ghent|No|Completed|September 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|6 Years|N/A|No|||September 2011|September 27, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00221546||190300|
NCT00221559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZGhent 001|Serum Zn Status of Patients With Cystic Fibrosis at Diagnosis and One Year Later, Compared to a Healthy Control Group|Serum Zn Status of Patients With Cystic Fibrosis at Diagnosis and One Year Later, Compared to a Healthy Control Group||University Hospital, Ghent||Completed|September 2004|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||0|||Both|N/A|N/A|No|||May 2006|May 7, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00221559||190299|
NCT00221520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200-068312|Sedation in the Intensive Care Unit|Trial on The Efficacy of Sedation in Mechanically Ventilated Critically Ill Patients||University Hospital, Geneva||Active, not recruiting|February 2003|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||126|||Both|16 Years|N/A|No|||January 2007|January 9, 2007|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00221520||190302|
NCT00221767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9415-04|Medico-economical Impact of the Brindley Neurosurgical Technique in France|Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord|BRINDLEY|University Hospital, Bordeaux|Yes|Completed|June 2005|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221767||190283|
NCT00217802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|289|The Effect of Self-Regulatory Education on Women With Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 2000|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|95 Years|No|||January 2008|January 18, 2008|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00217802||190583|
NCT00217815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTP/ONC/001|Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer|A Phase Ib, Pharmacokinetic, Multiple Center, Open Label Study Evaluating the Safety and Efficacy of Mycograb Administered IV in Combination With Docetaxel in Metastatic or Recurrent Breast Cancer Patients||NeuTec Pharma||Completed|September 2005|October 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|18 Years|70 Years|No|||July 2008|July 14, 2008|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00217815||190582|
NCT00218101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-11|Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids|Dose Reduction Strategies in Oral Opioid Dependence Subsequent to Pain Management: An Exploratory Study||National Institute on Drug Abuse (NIDA)||Completed|May 2004|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||August 2008|August 11, 2008|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00218101||190561|
NCT00218296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14404-4|Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|September 16, 2005|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00218296||190546|Sample size was limited.
NCT00211367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA in Rad.Ret.|Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)|||Manhattan Eye, Ear & Throat Hospital|No|Terminated|April 2004|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2|||Both|18 Years|N/A||||June 2007|June 20, 2007|September 13, 2005|||poor enrollment|Yes||https://clinicaltrials.gov/show/NCT00211367||191066|
NCT00211380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSUHSC #H04-021|Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)|Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia, (SFBRI).||Louisiana State University Health Sciences Center Shreveport|No|Terminated|August 2003|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 2, 2011|September 13, 2005||No|Recruitment was too difficult|No||https://clinicaltrials.gov/show/NCT00211380||191065|
NCT00219141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2316|Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension|A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension|ALLAY|Novartis||Completed|October 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|460|||Both|18 Years|80 Years|No|||May 2011|May 20, 2011|September 12, 2005|Yes|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00219141||190484|
NCT00219102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2310|A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients|A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 mg||Novartis||Completed|June 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||336|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00219102||190487|
NCT00219115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2309|A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg|A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Responsive to HCTZ 25 mg||Novartis||Completed|January 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|493|||Both|18 Years|N/A|No|||June 2006|November 7, 2011|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00219115||190486|
NCT00219778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUFIB|A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas|A Placebo Controlled Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas||Poitiers University Hospital||Terminated|December 2004|February 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Female|25 Years|49 Years|No|||March 2010|March 2, 2010|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00219778||190436|
NCT00220051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1973|A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer|A Phase II Study of Oxaliplatin (Eloxatin) Capecitabine (Xeloda) and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer.||Royal Marsden NHS Foundation Trust|No|Completed|November 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00220051||190415|
NCT00211874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 99-0347|Improving Heart Failure Care in Minority Communities|Improving Heart Failure Care in Minority Communities||Icahn School of Medicine at Mount Sinai|No|Completed|September 2000|September 2002|Actual|September 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|406|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00211874||191028|
NCT00211887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 02-0526|Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx|A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2005|March 2013|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1008|||Both|18 Years|60 Years|No|||March 2014|March 6, 2014|September 13, 2005|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT00211887||191027|absence of a comparative randomized placebo only group
NCT00212134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024837|Infant Aphakia Treatment Study (IATS)|Infant Aphakia Treatment Study (IATS)|IATS|Emory University|Yes|Completed|December 2004|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|N/A|210 Days|No|||February 2015|February 6, 2015|September 13, 2005|No|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT00212134||191008|
NCT00219726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020947|Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation|Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase in Relapse After Allogeneic Stem Cell Transplantation||Poitiers University Hospital||Completed|May 2002|July 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||September 2005|August 28, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219726||190440|
NCT00219986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA 520|Phase I/II, Open-Label Trial of Three Monoclonal Antibodies|A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection||Rockefeller University||Completed|October 2003|September 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|July 16, 2007|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00219986||190420|
NCT00220935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P608|A Randomized, Controlled Trial of Treatment for Disc Herniation With Radiating Leg Pain|Orthotrac Pneumatic Vest: A Randomized, Controlled Trial of Treatment for Disc Herniation With Radiating Leg Pain||Texas Back Institute||Completed|January 2003|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|21 Years|55 Years|No|||July 2005|October 4, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220935||190347|
NCT00220948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P699|Large Array EMG Discriminability in Discogenic Low Back Pain|Large Array EMG Discriminability in Discogenic Low Back Pain||Texas Back Institute||Recruiting|August 2004|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||60|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220948||190346|
NCT00220909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU4572|Lansoprazole Preventing Gastroduodenal Stress Ulcerations|A Prospective, Randomized, Double-Blind Protocol to Compare the Efficacy of Lansoprazole to Ranitidine in Healing Pre-Existing and/or Preventing the Development of Gastroduodenal Stress Ulceration and Postoperative Bleeding in Patients Undergoing Elective Coronary Artery Bypass Graft or Cardiac Valve Replacement Surgery||Temple University||Terminated|September 2005|January 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|40|||Both|18 Years|65 Years|No|||January 2008|January 2, 2008|September 20, 2005|||Recruitment slow|||https://clinicaltrials.gov/show/NCT00220909||190349|
NCT00221572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/149|Can Quantitative Ultrasound be Used for the Evaluation of Bone Health in Adolescents and Adults With Cystic Fibrosis|Can Quantitative Ultrasound be Used for the Evaluation of Bone Health in Adolescents and Adults With Cystic Fibrosis||University Hospital, Ghent|No|Recruiting|July 2005|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|12 Years|N/A|No|Non-Probability Sample|Patients with Cystic Fibrosis|December 2014|December 4, 2014|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00221572||190298|
NCT00221585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5490-184|The National Danish Schizophrenia Project|||University of Copenhagen||Active, not recruiting|October 1997|July 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|16 Years|35 Years|No|||July 1997|November 6, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00221585||190297|
NCT00221780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9426-01|Role of Left Ventricular Pacing Site|Importance of Left Ventricular Pacing Site in Biventricular Resynchronization Therapy for Severe Heart Failure||University Hospital, Bordeaux|No|Recruiting|November 2003|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|N/A|No|||June 2007|June 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221780||190282|
NCT00217555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 1901|Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer|Phase II Trial for the Treatment of Recurrent or Persistent Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With Gemcitabine and Topotecan||Fred Hutchinson Cancer Research Center||Completed|July 2002|||February 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2010|September 20, 2010|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00217555||190600|
NCT00217841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTP/Aurograb/003|Aurograb and Vancomycin in MRSA Infection|A Multi Centre, Double-Blind, Randomised, Placebo Controlled Prospective Study on the Safety and Efficacy of Aurograb in Patients With Severe, Deep-Seated Staphylococcal Infections Receiving Vancomycin||NeuTec Pharma||Completed|January 2004|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||180|||Both|18 Years|80 Years|No|||September 2006|September 18, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00217841||190580|
NCT00217854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291|Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity|Mechanisms of Airway Inflammation: Natural Exacerbation of Asthma Induced by Glucocorticoid Withdrawal||Washington University School of Medicine||Completed|September 2001|February 2011|Actual|February 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|27|||Both|18 Years|60 Years|No|||June 2015|June 30, 2015|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217854||190579|
NCT00210925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004681|An Efficacy and Safety Study of Topiramate in the Treatment of Alcohol Dependence|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|371|||Both|18 Years|65 Years|No|||April 2010|June 6, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210925||191100|
NCT00219492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21370|Role of Esophageal Mast Cell Activation in Noncardiac Chest Pain (NCCP)|Role of Esophageal Mast Cell Activation in Noncardiac Chest Pain (NCCP)||Penn State University||Recruiting|September 2005|September 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00219492||190458|
NCT00212173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK54713 (completed 2007)|Adolescent Weight Management Study|Behavioral & Pharmacologic Therapy of Adolescent Obesity||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00212173||191005|
NCT00211094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006091|A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation|A Placebo-Controlled, Double-blind, Randomized, Parallel Study of the Efficacy and Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation||Alza Corporation, DE, USA||Completed||June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1320|||Male|18 Years|N/A|No|||February 2011|February 10, 2011|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00211094||191087|
NCT00211341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ObaapaVitA|Trial of the Impact of Vitamin A on Maternal Mortality|Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana|ObaapaVitA|London School of Hygiene and Tropical Medicine|Yes|Completed|December 2000|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100000|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 17, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211341||191068|
NCT00211588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-EMR-4022|Galantamine Executive Function in Parkinson's Disease|Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease||Memorial Hospital of Rhode Island|Yes|Active, not recruiting|June 2004|May 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Anticipated|90|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||May 2007|May 4, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211588||191049|
NCT00211601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-041|Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)|Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis|C-PHONE|Merck Sharp & Dohme Corp.||Completed|August 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||1500|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211601||191048|
NCT00219999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDU-0437|Hepatitis C Virus and the Humoral Immune System|Hepatitis C Virus and the Humoral Immune System||Rockefeller University|Yes|Completed|September 2001|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|161|Samples With DNA|whole blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinics of doctors at NYPH and the NYC metropolitan area|August 2013|August 6, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00219999||190419|
NCT00220324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91313|Pearl Index Study With Low Dose Combined Oral Contraceptive|Prospective, Multicenter, Open-label, Uncontrolled Study to Investigate the Contraceptive Efficacy, Bleeding Patterns, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 0.125 mg Levonorgestrel (SH D00342A) Applied for 13 Cycles to Healthy Female Volunteers||Bayer|No|Completed|February 2004|November 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|840|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00220324||190394|
NCT00220961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-062A|Actos Now for Prevention of Diabetes (ACT NOW)|Actos Now for Prevention of Diabetes (ACT NOW)||The University of Texas Health Science Center at San Antonio||Completed|January 2004|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||600|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00220961||190345|
NCT00221299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513216|Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use|Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis?||University of California, Davis|No|Completed|September 2005|May 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|September 14, 2005|Yes|Yes||No|January 23, 2014|https://clinicaltrials.gov/show/NCT00221299||190319|
NCT00221234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-69070|Alberta Diabetes and Physical Activity Trial|The Development and Evaluation of Physical Activity Behavioural Strategies for Adults With Type 2 Diabetes: A Population Based Approach||University of Alberta, Physical Education||Completed|September 2005|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 13, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221234||190324|
NCT00221247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC #04-126|Acupuncture as Complementary Therapy for Cerebral Palsy|Acupuncture as Complementary Therapy for Cerebral Palsy||University of Arizona||Recruiting|October 2004|July 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|12 Months|72 Months|No|||October 2007|October 4, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221247||190323|
NCT00221819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9300-02|Gases Humidification During Noninvasive Ventilation : Heat and Moisture Exchanger or Heated Humidifier ?|Prospective Study of the Influence of the Humidification Mode on Ventilation Parameters and Arterial Blood Gases in Non Invasive Ventilation||University Hospital, Bordeaux||Terminated|June 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2013|May 7, 2013|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00221819||190279|
NCT00221793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9212-02|Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation|Study of Ponderal Load in Parkinsonian Patients After Deep Brain Stimulation of the Subthalamic Nucleus||University Hospital, Bordeaux|No|Completed|December 2002|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|35 Years|70 Years|No|||September 2008|September 17, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221793||190281|
NCT00221806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9256-01|Comparison of Two Under Knee Lower Limb Bypass Types:Endothelialised Prosthesis Versus Autologous Vein Graft|Randomised Study Comparing Endothelialised Prosthesis and Autologous Vein for Under Knee Revascularisation With Femoro Popliteal Bypass. ePTFE||University Hospital, Bordeaux||Recruiting|June 2004|June 2012||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221806||190280|
NCT00217568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 1702|Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer|A Phase II Trial of Docetaxel and Carboplatin for First Relapsed Platinum-Sensitive Stage III and IV Advanced Ovarian Cancer or Peritoneal Carcinoma||Fred Hutchinson Cancer Research Center||Completed|May 2005|||March 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2010|September 20, 2010|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00217568||190599|
NCT00217828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290|Effects of Citalopram on Hostility and CHD Risk|||University of Pittsburgh||Completed|March 2002|February 2003|Actual|February 2003|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2014|June 10, 2014|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00217828||190581|
NCT00209820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF 20050055|Nordic Walking and Chronic Low Back Pain|||Human Locomotion Science||Recruiting|September 2005|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|8 Weeks|8 Weeks|No|||September 2005|April 10, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209820||191184|
NCT00210704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004228|A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation|A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1067|||Male|18 Years|N/A|No|||March 2010|June 6, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210704||191117|
NCT00210717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004195|A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia|A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2005|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|748|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210717||191116|
NCT00211159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OmegAD#1|OmegAD (Omega-3 and Alzheimer's Disease)|Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-Blind Trial||Karolinska University Hospital||Completed|December 2000|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||204|||Both|N/A|N/A|No|||April 2005|February 7, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211159||191082|
NCT00211406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetic Retinopathy|Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)|||Manhattan Eye, Ear & Throat Hospital|No|Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||May 2007|May 6, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211406||191063|
NCT00211120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004588|Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)|Correction of Hemoglobin and Outcomes In Renal Insufficiency||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|March 2002|August 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1432|||Both|18 Years|N/A|No|||March 2010|May 17, 2011|September 13, 2005|||Stopped by the DSMB due to a trend toward more adverse events in the higher hemoglobin (Hb)    arm and <5% chance that the study would show benefit for higher Hb.|No||https://clinicaltrials.gov/show/NCT00211120||191085|
NCT00211133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004414|A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2000|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|939|||Female|18 Years|N/A|No|||November 2010|November 29, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211133||191084|
NCT00211107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006088|A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.|A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation||Alza Corporation, DE, USA||Completed|June 2003|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1294|||Male|18 Years|N/A|No|||March 2010|May 18, 2011|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00211107||191086|
NCT00211627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILC - KEEPASLEEP - 0704|Clinical Study to Determine Safety and Effectiveness of KEEPASLEEP Device in Simple Snorers.|Clinical Study to Determine Safety and Effectiveness of KEEPASLEEP Device in Simple Snorers.||Miller, Chipp St. Kevin, M.D.||Recruiting|June 2004|June 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211627||191046|
NCT00211640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMHC001|Identification and Treatment of Men With BPH in the Primary Care Setting|A Proactive Approach to the Identification and Treatment of Men With BPH Inthe Primary Care Setting||Mid Michigan Health Centers||Completed||||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||1100|||Male|18 Years|N/A|No|||August 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211640||191045|
NCT00211913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1366|StaphVAX in Cardiovascular Surgery Patients|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Undergoing Cardiovascular Surgery||Nabi Biopharmaceuticals|No|Completed|June 2004|January 2006|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 26, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211913||191025|
NCT00212186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK54819|Selenium Supplementation of Patients With Cirrhosis|||Vanderbilt University||Completed|October 1998|November 2003|Actual|November 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 6, 2012|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00212186||191004|
NCT00212459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bleeding Logs|The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs|A Prospective Randomized Pilot Study on the Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs||New York Presbyterian Hospital|No|Completed|May 2005|April 2008|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Male|12 Years|20 Years|No|||May 2008|March 26, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212459||190983|
NCT00217373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01347|Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)|A Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-Tricom (B7.1/ICAM/LFA3) and Vaccinia-CEA (6D)-Tricom, in Combination With GM-CSF and Interferon-Alfa-2B in Patients With CEA-Expressing Carcinomas||National Cancer Institute (NCI)||Completed|June 2005|March 2015|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2014|April 17, 2015|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00217373||190614|
NCT00217386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1872.00|Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes|Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept||Fred Hutchinson Cancer Research Center||Completed|March 2004|||December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2010|September 13, 2010|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217386||190613|
NCT00212823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004708|The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain|AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain||Ortho-McNeil Neurologics, Inc.||Completed|June 2004|February 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1450|||Both|18 Years|65 Years|No|||April 2010|May 17, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212823||190957|
NCT00220623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#04-013|Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression|Efficacy and Cost-Effectiveness of 18-Months of Antidepressive Medication Plus Either Cognitive-Behavior Therapy or Dynamic Psychotherapy Compared to Supportive Clinical Management for Recurrent Major Depression: a Pilot Study||Sir Mortimer B. Davis - Jewish General Hospital||Recruiting|August 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00220623||190371|
NCT00221312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H675-20192|Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss|Alendronate to Prevent Perimenopausal Transition Bone Loss||University of California, San Francisco|No|Completed|May 2002|July 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|48|||Female|40 Years|54 Years|Accepts Healthy Volunteers|Non-Probability Sample|Perimenopausal women|May 2005|May 5, 2008|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00221312||190318|
NCT00221260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0078|Perioperative Epidural Trial (POET) Pilot Study|Perioperative Epidural Trial (POET) Pilot Study||University of British Columbia||Completed|September 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|250|||Both|45 Years|N/A|No|||September 2008|September 24, 2008|September 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00221260||190322|
NCT00221273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0302|Use of Graft Tensioner Device in ACL (Knee) Repair|Randomized Clinical Trial to Assess the Clinical Effectiveness of a Measured Objective Tensioning in Hamstring ACL Reconstruction||University of British Columbia|No|Active, not recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|130|||Both|19 Years|N/A|No|||April 2011|April 26, 2011|September 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00221273||190321|
NCT00221286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-18150|Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients|Pegylated Interferon Alfa-2a Versus Emtricitabine / Tenofovir +/- Pegylated Interferon Alfa-2a for the Treatment of Chronic HBe-Ag Positive Hepatitis B Infection in HIV-Coinfected Patients - the PEGPLUS Trial||University Hospital, Bonn|No|Terminated|September 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|65 Years|No|||February 2009|February 17, 2009|September 14, 2005||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00221286||190320|
NCT00209833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML 01/99 trial|Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T|Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial)||Hannover Medical School||Active, not recruiting|January 1999|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|16 Years|60 Years|No|||September 2005|November 17, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209833||191183|
NCT00217581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441641|Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer|Phase II Trial of Bevacizumab, Docetaxel, and Oxaliplatin in Gastric and Gastroesophageal Junction Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 2004|January 2013|Actual|November 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|September 20, 2005|Yes|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00217581||190598|The trial completed its planned accrual. There were no significant limitations.
NCT00217594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050206|A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome|A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2005|December 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|72 Years|No|||October 2015|January 14, 2016|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217594||190597|
NCT00210197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2005-06|Hypercoagulability After Breast Cancer Surgery|Plasma Coagulation Parameters and Hypercoagulability After Breast Cancer Surgery|EHC|Institut Bergonié||Completed|January 2005|January 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|48|||Female|18 Years|N/A|No|Probability Sample|Breast Cancer|October 2007|July 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210197||191156|
NCT00210210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2004-04|Administration of Ketamine to Prevent the Post-operative Pain|Effect of Ketamine, at the Induction and Its Maintenance to Prevent the Post-operative Pain: Clinical Trial in Cancerology|KETAMINE|Institut Bergonié||Completed|February 2004|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|230|||Female|18 Years|N/A|No|||October 2007|July 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210210||191155|
NCT00210249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2002-26|Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment|Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country.|ONCOGERIATRIE|Institut Bergonié||Completed|September 2002|June 2006|Actual|||N/A|Observational|N/A||1|Actual|360|||Both|70 Years|N/A|No|Probability Sample|-  cancer du colon en indication de chimiothérapie (adjuvante ou palliative) ;          -  cancer de l'estomac en indication de chimiothérapie (d'induction ou palliative) ;          -  Cancer du pancréas en indication de chimiothérapie          -  cancer de l'ovaire en indication de chimiothérapie (adjuvante ou palliative) ;          -  tous lymphomes diffus à grandes cellules B, tous lymphomes T périphériques (la             majorité de ces patients seront a priori inclus dans les essais 20991 et 20992 de             l'EORTC) ;          -  tous lymphomes de faible malignité : lymphocytiques, lympho-plasmocytaires,             folliculaires, manteau, zone marginale (MALT et autres).          -  Cancer de la prostate en indication de chimiothérapie          -  Cancer de la vessie en indication de chimiothérapie          -  Cancer bronchique en indication de chimiothérapie          -  Adénocarcinome de primitif inconnu compatible avec une origine citée ci-dessus en             indication de chimiothérapie|September 2005|July 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210249||191152|
NCT00210509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004714|A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache|AXERT® Early miGraine Intervention Study (AEGIS): Efficacy and Safety of Almotriptan Malate (AXERT®) Versus Placebo for the Acute Treatment of Migraine Headache||Janssen-Ortho LLC||Completed|November 2004|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|378|||Both|18 Years|65 Years|No|||April 2010|May 16, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210509||191132|
NCT00210522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002191|An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy|A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Protocol 333369-EPY-2003 [Double-blind] and Protocol 333369-EPY-2006 [Open-label Extension])||SK Life Science||Completed|May 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|421|||Both|18 Years|70 Years|No|||January 2013|January 15, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00210522||191131|
NCT00210730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004591|The Duration Study|An Open Label Randomized Study To Evaluate The Response Rate Of Epoetin Alfa (PROCRIT�) Versus No/Delayed PROCRIT Treatment In Patients With Cancer And Persistent Chemotherapy-Induced Myelosuppression (Anemia)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|June 2004|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2|||Both|18 Years|N/A|No|||March 2010|June 8, 2011|September 13, 2005|||This study was stopped early due to slow enrollment.|||https://clinicaltrials.gov/show/NCT00210730||191115|
NCT00210938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005383|Doripenem in the Treatment of Complicated Intra-Abdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Versus Comparator Antibiotic in the Treatment of Complicated Intra-Abdominal Infections||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|478|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210938||191099|
NCT00219544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081084|Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.|A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain||Pfizer|No|Completed|November 2005|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|158|||Both|18 Years|N/A|No|||April 2011|April 22, 2011|September 13, 2005||No||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00219544||190454|
NCT00219557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061016|AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer|A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combination With Gemcitabine In Patients With Chemotherapy Naive Advanced Pancreatic Cancer Preceded By A Phase 1 Portion||Pfizer|No|Completed|July 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|September 13, 2005|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00219557||190453|
NCT00211419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Double Injection|Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)|Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)||Manhattan Eye, Ear & Throat Hospital||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||September 2005|October 23, 2012|September 13, 2005||Yes||||https://clinicaltrials.gov/show/NCT00211419||191062|
NCT00211705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEGA|Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)|Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)||Mitsukoshi Health and Welfare Foundation||Completed|February 1994|March 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||8000|||Both|40 Years|70 Years|No|||June 2005|November 30, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211705||191040|
NCT00211653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3212-B|Acetylcysteine in the Prevention of Renal Failure After Bypass Surgery|Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure||Minneapolis Veterans Affairs Medical Center|No|Completed|April 2003|November 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||September 2007|September 18, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211653||191044|
NCT00211666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01HS010859-05|Improving Hypertension Control in East and Central Harlem|Improving the Delivery of Effective Care to Minorities||Icahn School of Medicine at Mount Sinai||Completed|September 2002|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||480|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211666||191043|
NCT00211926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1365|StaphVAX Immunogenicity in Orthopedic Implant Patients|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Receiving an Orthopaedic Prosthetic Implant||Nabi Biopharmaceuticals|No|Completed|December 2004|October 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 21, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211926||191024|
NCT00211679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Number 03393B|Intra-articularInjection of Botulinum Toxin Type|Intra-articularInjection of Botulinum Toxin Type a for the Treatment of Chronic Knee Pain: A Randomized, Placebo Controlled, Double Blind Study||Minneapolis Veterans Affairs Medical Center||Recruiting|June 2004|June 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2005|September 13, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211679||191042|
NCT00211939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi 6404|CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients|CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2)||Nabi Biopharmaceuticals|No|Completed|January 2005|March 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211939||191023|
NCT00211952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102 PLCSG|Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients|A Randomized, Double Blind, Placebo Controlled Phase III Trial Evaluating the Role of Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) Non-Small Cell Lung Cancer (NSCLC) Patients||Medical University of Gdansk||Suspended|March 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||542|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00211952||191022|
NCT00217087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1399-05|Endoscopic Therapy of Early Cancer in Barretts Esophagus|Endoscopic Therapy of Early Cancer in Barretts Esophagus||Mayo Clinic|Yes|Completed|September 2005|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 20, 2005||No||No|March 2, 2015|https://clinicaltrials.gov/show/NCT00217087||190636|
NCT00217399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00069|Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|June 2005|January 2013|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||December 2012|May 12, 2014|September 20, 2005|Yes|Yes||No|March 23, 2011|https://clinicaltrials.gov/show/NCT00217399||190612|
NCT00213096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #323|Effects of Hormonal Contraceptives on Liver Proteins and Coagulation Factors: A Comparison of a Contraceptive Vaginal Ring and an Oral Contraceptive|A Randomized, Open-Label Study Comparing the Effect of a Contraceptive Vaginal Ring Delivering Daily Doses of 150 Micrograms Nestorone and 15 Micrograms Ethinyl Estradiol to an Oral Contraceptive Containing 150 Micrograms of Levonorgestrel and 30 Micrograms of Ethinyl Estradiol Per Tablet on Hepatic Factors Including Coagulation Factors||Population Council||Completed|March 2003|February 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||50|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||May 2006|May 30, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00213096||190936|
NCT00213109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1006|Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|N/A|No|||September 2006|September 20, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213109||190935|
NCT00213122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1007|Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|20 Years|74 Years|No|||September 2006|September 25, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213122||190934|
NCT00220636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR-04-028|Abilify as an Adjunctive Treatment for Refractory Depression|Abilify (Aripiprazole) as an Adjunctive Treatment for Refractory Unipolar Depression||St. Luke's-Roosevelt Hospital Center|No|Completed|March 2005|January 2008|Actual|March 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|70 Years|No|||October 2014|February 18, 2015|September 21, 2005||No||No|April 15, 2009|https://clinicaltrials.gov/show/NCT00220636||190370|Open label study without comparison group.
NCT00220649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175-03|Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas|Phase I Study to Determine the Safety, Maximum Tolerated Dose, and Efficacy of Biweekly Oxaliplatin (Eloxatin) in Combination With Gemcitabine, Irinotecan, and 5-FU/Leucovorin (G-Flie) in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Exocrine Pancreas||St. Luke's-Roosevelt Hospital Center|Yes|Completed|March 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2009|August 14, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00220649||190369|
NCT00209313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR File 5687|Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon|A Randomized, Double-blind, Placebo-controlled Crossover Trial of Acyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons in Cameroon||Fred Hutchinson Cancer Research Center|No|Completed|March 2005|April 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|N/A|No|||December 2011|December 14, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00209313||191223|
NCT00221598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/148|Effect of Dialysate Temperature on Haemodynamic Stability and Haemodialysis Efficiency|Effect of Dialysate Temperature on Haemodynamic Stability and Haemodialysis Efficiency||University Hospital, Ghent|No|Recruiting|June 2005|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|90 Years|No|||December 2014|December 4, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00221598||190296|
NCT00221611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999/152|Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity|Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity||University Hospital, Ghent|No|Completed|January 2000|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|5 Years|25 Years|No|||December 2007|December 19, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00221611||190295|
NCT00210223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB2004-16|Radiofrequency of Breast Cancers in Non Surgical Patients|Radiofrequency of Breast Cancers : Pilot Study in Non Surgical Patients|RF SEIN|Institut Bergonié||Completed|April 2004|July 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Female|70 Years|N/A|No|||October 2007|July 25, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210223||191154|
NCT00210236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB1995-28|Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer|Surgical Resection With or Without Axillary Lymph Node Excision in Treating Menopausal Women With Infiltrative Breast Cancer Smaller Than 10 mm|AXIL95|Institut Bergonié||Terminated|September 1995|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|592|||Female|50 Years|N/A|No|||October 2007|July 25, 2013|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00210236||191153|
NCT00210262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251.070|Promoting Blood Pressure Control and Cholesterol Reduction to Prevent Major Complications in Persons With Diabetes|Promoting Blood Pressure Control and Cholesterol Reduction to Prevent Major Complications in Persons With Diabetes||Institute for Clinical Evaluative Sciences||Completed|October 2002|January 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|65 Years|N/A|No|||November 2003|September 15, 2005|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00210262||191151|
NCT00210535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002245|A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|110|||Both|12 Years|17 Years|No|||January 2010|June 6, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210535||191130|
NCT00210743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004600|Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.|An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week Epoetin Alfa (PROCRIT)in the Treatment of Subjects With the Anemia of Chronic Kidney Disease (CKD)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|October 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|67|||Both|18 Years|N/A|No|||April 2010|May 19, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210743||191114|
NCT00220181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2240|Prospective Study in Pelvic Radiotherapy Patients|A Prospective Study to Identify Changes in Nutritional Status and Bowel Symptoms in Patients Receiving a Course of Radical Radiotherapy to the Pelvis for Treatment of Gynaecological, Urological or Rectal Cancer.||Royal Marsden NHS Foundation Trust||Completed|April 2003|September 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||100|||Both|N/A|N/A|No|||September 2005|September 21, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00220181||190405|
NCT00219856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 040366|Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy|Prospective, Randomized, Simple Blind Study Comparing the Effects of an Anaesthesia With Propofol to an Anaesthesia With Desflurane on Oxydative Stress and Liver Function Recovery After Hepatectomy||Rennes University Hospital|No|Completed|August 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||June 2012|June 25, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00219856||190430|
NCT00211393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M00.013|A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole|A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole.|CSC/Keto|Manhattan Eye, Ear & Throat Hospital|No|Completed|May 2005|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|60 Years|No|||October 2012|October 24, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00211393||191064|
NCT00211692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVRI001|Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial|Prospective Randomized Pilot Study of Daily Consensus Interferon (CIFN) and Ribavirin for 52 Wks vs Extended Duration 72 Wks Based on Virologic Response for the Initial Treatment of Difficult-to-treat Patients With Chronic HCV Genotype 1||Minneapolis Veterans Affairs Medical Center|Yes|Completed|July 2005|September 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||November 2014|November 20, 2014|September 13, 2005|No|Yes||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00211692||191041|
NCT00212589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.02|Patients Preference for Oral or i.v. Therapy|A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer||Odense University Hospital||Completed|December 2002|April 2004||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||May 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212589||190975|
NCT00208507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COC 28 mm|28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study|Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis Study (28mm)||DePuy Orthopaedics|No|Completed|April 2003|December 2010|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|264|||Both|20 Years|75 Years|No|||December 2013|December 18, 2013|September 13, 2005|Yes|Yes||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00208507||191282|
NCT00217100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1965-04|A Multivitamin Comparison Study in Kidney Transplant Recipients.|Folic Acid for Vascular Outcome Reduction in Transplantation.||Mayo Clinic||Completed|October 2004|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|75 Years|No|||April 2012|April 23, 2012|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00217100||190635|
NCT00217113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1752-05|An Intervention to Preserve Functional Status and Independence Among Community Dwelling Elderly|An Intervention to Preserve Functional Status and Independence Among Community Dwelling Elderly||Mayo Clinic||Completed|September 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|100|||Both|65 Years|N/A||||January 2010|January 20, 2010|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00217113||190634|
NCT00212862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004561|Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia|Dosing and Outcomes Study of Erythropoietic Stimulating Therapies|DOSE|Ortho Biotech Products, L.P.|No|Completed|December 2003|July 2009|Actual|July 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2130|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are being treated with an erythropoiesis-stimulating therapy for chemotherapy        induced anemia.|June 2014|June 27, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212862||190954|
NCT00213135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25643|A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)|A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)|CLARITY|EMD Serono||Completed|April 2005|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1326|||Both|18 Years|65 Years|No|||January 2014|January 10, 2014|September 13, 2005|Yes|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT00213135||190933|
NCT00220974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-CAT|Study to Assess if Internet-Based Tailored Advice Could Modify Behaviour to Improve Health|Internet-Based Cholesterol Assessment Trial||The George Institute||Completed|October 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|3708|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00220974||190344|
NCT00209027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024777|The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia|Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia||Emory University|Yes|Terminated|April 2005|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|20|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|September 13, 2005||No|difficulty with technical aspect of fMRI, resources to complete the study ran out|No|April 13, 2012|https://clinicaltrials.gov/show/NCT00209027||191242|Although the study was planned as a repeated measures study with fMRI testing at baseline and after 3 months, difficulty with recruitment and technical difficulties with obtaining fMRI data relegated the study to a single baseline timepoint.
NCT00209040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000983|Fear Potentiation and Fear Inhibition in Posttraumatic Stress Disorder|Fear Potentiation and Fear Inhibition in Posttraumatic Stress Disorder||Emory University|No|Active, not recruiting|January 2001|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|see protocol description|November 2015|November 4, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00209040||191241|
NCT00209573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0410|A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy|A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN Injection Versus Midazolam HCl for Sedation in Patients Undergoing Colonoscopy Procedures||Eisai Inc.||Completed|September 2004|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|65 Years|No|||November 2008|November 6, 2008|September 13, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00209573||191203|
NCT00209846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10402|A Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia||H. Lundbeck A/S|No|Completed|June 2004|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|66 Years|N/A|No|||March 2007|March 29, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209846||191182|
NCT00209859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232-002|Methotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis|Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis.||Hvidovre University Hospital||Completed|October 1998|November 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|75 Years|No|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00209859||191181|
NCT00210288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM 2004.20|Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine|A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers||Institut Pasteur||Completed|May 2005|April 2007|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|111|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00210288||191149|
NCT00210548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002353|A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|366|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00210548||191129|
NCT00218855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG #12|Thalidomide to Patients With Previously Untreated Multiple Myeloma|A Phase 3 Study With Randomization to Melphalan/Prednisone/Thalidomide Versus Melphalan/Prednisone/Placebo to Patients With Previously Untreated Multiple Myeloma||Norwegian University of Science and Technology|No|Completed|January 2002|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|363|||Both|N/A|N/A|No|||March 2014|March 6, 2014|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218855||190506|
NCT00218868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-001|Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear|Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunvald-giemsa Stained Cutaneous Tissue Smear in Relation to Photodynamic Therapy||Norwegian University of Science and Technology|No|Completed|January 2000|November 2007|Actual|February 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|N/A|N/A|No|Non-Probability Sample|50 BCC and 28 AK histologically verified lesions, from 41 and 25 patients, respectively|February 2012|February 9, 2012|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218868||190505|
NCT00220805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100586|Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration|Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-C, 10% Treatment in Subjects With Pure Occult Choroidal Neovascularization Due to Age Related Macular Degeneration||Grifols Therapeutics Inc.|No|Completed|January 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|51 Years|N/A|No|||February 2016|February 22, 2016|September 14, 2005|No|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00220805||190357|
NCT00211718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol Number 03404B|Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain|Intra-Articular Injection of Botulinum Toxin Type A for the Treatment of Shoulder Pain: A Randomized, Double Blinded, Placebo Controlled Trial||Minneapolis Veterans Affairs Medical Center||Recruiting|July 2004|June 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2005|November 2, 2005|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00211718||191039|
NCT00211965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-1363|StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adult Patients Receiving an Orthopedic Prosthetic Implant||Nabi Biopharmaceuticals|No|Completed|April 2005|August 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 26, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00211965||191021|
NCT00212212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK58763|Selenium Supplementation of Patients With Cirrhosis|Human Selenium Nutritional Requirement and Biomarkers in Health and Disease||Vanderbilt University|Yes|Terminated|March 2006|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|4||Actual|99|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|September 19, 2005||No|Insufficient funds to complete study.|No||https://clinicaltrials.gov/show/NCT00212212||191002|
NCT00212225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK53708 (completed)|Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)|Risk Factors for Gastric Disease in Pediatric H. Pylori||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|October 1997|December 2007|Actual|||N/A|Observational|N/A|||Anticipated|755|||Both|6 Months|18 Years|No|||January 2010|January 12, 2010|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00212225||191001|
NCT00221364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02630|Trachoma Elimination Follow-up|Trachoma Elimination With Repeated Mass Azithromycin Treatments|TEF|University of California, San Francisco|Yes|Completed|March 2003|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20000|||Both|1 Year|N/A|No|||July 2015|July 13, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221364||190314|
NCT00217126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143-05|The Study of Long-term Deterioration of Kidney Transplants.|Long-term Kidney Function (2 Arms-Prospective and Retrospective)||Mayo Clinic|Yes|Completed|October 2005|August 2012|Actual|August 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|870|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Kidney Transplant Recipients|January 2013|January 2, 2013|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00217126||190633|
NCT00217139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-05-002|A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy||BioWest Therapeutics Inc||Completed|September 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||September 2006|September 27, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00217139||190632|
NCT00212888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000456-01H|Combination Vaccination Before HIV Treatment Interruption|A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression||Ottawa Hospital Research Institute|Yes|Completed|April 2004|November 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00212888||190952|
NCT00213148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25550|Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction|A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction||EMD Serono||Completed|March 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|271|||Female|18 Years|40 Years|No|||August 2014|August 5, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00213148||190932|
NCT00213460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/103/HP|Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up|Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up||University Hospital, Rouen||Completed|August 2001|July 2003|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|80 Years|No|||April 2013|April 15, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213460||190908|
NCT00209001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0533-2003|Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer|Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer||Emory University|Yes|Terminated|July 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|September 13, 2005|Yes|Yes|Principal investigator Peter Johnstone, MD relocated to another institution|No||https://clinicaltrials.gov/show/NCT00209001||191244|
NCT00221650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9232-01|Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients|Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment|ROCO2|University Hospital, Bordeaux|Yes|Completed|April 2002|June 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||June 2007|June 12, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00221650||190292|
NCT00217412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01821|Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia|A Phase 1 Study of SAHA (NSC# 701852) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|August 2005|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|1 Year|21 Years|No|||April 2013|June 16, 2014|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00217412||190611|
NCT00209287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mesalazine 2004-01|Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis|Study of Histological Modifications, of Pro-apoptotic Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis (Clinical and Endoscopic Remission) Taking 5-ASA||Ferring Pharmaceuticals|No|Terminated|June 2005|September 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|September 13, 2005||No|Recruitment problematic|No||https://clinicaltrials.gov/show/NCT00209287||191225|
NCT00209300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999907 CS003|Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission|Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission. A European Multi-centre Investigator Blinded Randomized Controlled Study of Pentasa Sachet Comparing One Gram Twice With Two Grams Once Daily||Ferring Pharmaceuticals|Yes|Completed|May 2005|June 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|362|||Both|18 Years|N/A|No|||May 2011|May 18, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00209300||191224|
NCT00209872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMA-AH01|Optimal Multimodal Analgesia in Abdominal Hysterectomy|||Hvidovre University Hospital||Not yet recruiting|October 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Female|18 Years|N/A|No|||September 2005|November 6, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00209872||191180|
NCT00210275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-67916|Ontario Printed Educational Materials (PEMs) for Physician Behaviour Change|The Ontario Printed Educational Message (OPEM) Trial to Narrow the Evidence-practice Gap With Respect to Prescribing Practices of General and Family Physicians: a Cluster Randomized Controlled Trial|OPEMS|Institute for Clinical Evaluative Sciences|No|Active, not recruiting|July 2005|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|5000|||Both|N/A|N/A|No|||March 2015|March 25, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00210275||191150|
NCT00218335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA016555-1|A Network & Dyad HIV Prevention Intervention for IDU's - 1|A Network & Dyad HIV Prevention Intervention for IDU's||Johns Hopkins Bloomberg School of Public Health|No|Completed|June 2003|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1024|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2013|March 7, 2013|September 16, 2005||No||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00218335||190543|
NCT00218595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010957|DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients. - 1|Evaluation of Dialectical Behavior Therapy in Treatment of Opioid Addiction and Emotional Problems||Duke University|Yes|Completed|August 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|70 Years|No|||January 2013|July 31, 2014|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00218595||190524|
NCT00219570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6881003|Dalacin-T Gel Post Approval Study|Phase IV Clinical Study Of Clindamycin Phosphate Topical Gel In The Treatment Of Acne Vulgaris||Pfizer||Completed|January 2005|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|134|||Both|13 Years|35 Years|No|||May 2011|May 9, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00219570||190452|
NCT00219583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3871027|Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation|A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation||Pfizer||Completed|August 2004|June 2005|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||460|||Male|18 Years|N/A|No|||November 2012|November 5, 2012|September 9, 2005||||||https://clinicaltrials.gov/show/NCT00219583||190451|
NCT00219596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641028|Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension|An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension||Pfizer||Completed|June 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||November 2006|September 13, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00219596||190450|
NCT00210951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003925|Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin|An Active Safety Surveillance Plan to Conduct Serologic Testing for Anti-erythropoietin Antibodies and Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa or Another Erythropoietin||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2003|July 2005|Actual|July 2005|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4761|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with chronic renal disease receiving treatment with epoetin alfa or other        recombinant erythropoietins.|March 2015|March 23, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00210951||191098|
NCT00211146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004621|A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)|An Open-Label, Randomized, Parallel-Group Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Subjects Undergoing Major Elective Spinal Surgery||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 1998|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|680|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00211146||191083|
NCT00231530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003712|A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients on a Controlled Diet||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2001|May 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|541|||Both|18 Years|75 Years|No|||April 2010|June 6, 2011|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231530||189564|
NCT00232388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L06-006|Association of PICP Serum Marker in Patients With LVSD|Phase 1 Study of PICP Serum Marker of Myocardial Fibrosis and Diastolic Function in Patients With Systolic Dysfunction||Texas Tech University Health Sciences Center|No|Terminated|September 2005|September 2007|Actual|||Phase 1|Observational|N/A||1|Actual|45|None Retained|PLEASE NOTE THAT THE INVESTIGATOR LEFT THE INSTITUION WITHOUT PROVIDING ANY INFORMATION      REGARDING THIS PROJECT. NO FORWARDING INFORMATION IS AVAILABLE FROM THE INVESTIGATOR.|Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|Persons with left ventricular systolic dysfunction from the Texas Tech University Health        Sciences Center outpatient clinic and University Medical Center, Lubbock, Texas|October 2015|October 6, 2015|October 3, 2005|||PI left institution; Data collected from 45 participants, but no results are available.|No||https://clinicaltrials.gov/show/NCT00232388||189498|
NCT00232401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neo.02.2005|The Circadian Rhythm of Urine Output in Healthy Infants|The Circadian Rhythm of Urine Output in Healthy Infants||University of Aarhus||Completed|October 2005|August 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|N/A|3 Years|Accepts Healthy Volunteers|||February 2009|February 13, 2009|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00232401||189497|
NCT00232375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-81|Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes|||Tokyo Study Group||Completed|January 1996|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||42|||Both|N/A|N/A|No|||January 2005|September 30, 2005|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00232375||189499|
NCT00205894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-B-003|Occipital Nerve Stimulation to Treat Chronic Headaches|Multicenter Feasibility Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches||Boston Scientific Corporation|No|Completed|January 2004|September 2007|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2008|September 4, 2008|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00205894||191479|
NCT00215917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lichtenberg1CTIL|D-Serine Monotherapy for Schizophrenia|||Herzog Hospital||Recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||May 2006|May 1, 2006|September 18, 2005||||No||https://clinicaltrials.gov/show/NCT00215917||190725|
NCT00206219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0704|Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)|A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck||AstraZeneca||Completed|November 2003|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||477|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|September 16, 2005||||||https://clinicaltrials.gov/show/NCT00206219||191454|
NCT00206531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/05|The Role of Naive T-Cells in HIV Pathogenesis|Role of Naive T-Cells in the Pathogenesis of T-Cell Decline and Long Term Persistence of HIV||Bayside Health||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||75|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|October 3, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206531||191431|
NCT00206830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011|SHORTness of Breath In the Emergency Department (SHORTIE)|SHORTness of Breath In the Emergency Department (SHORTIE)||Biosite||Completed|April 2005|August 2007|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2|||306|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206830||191409|
NCT00207155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-045|An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer|An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer||Eli Lilly and Company||Completed|December 2003|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||110|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00207155||191384|
NCT00207168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI454-194|To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine|A Randomized, Multi-center, Open Label Study in Well Controlled Treatment-experienced HIV- Infected Patients to Assess Compliance With a Once-daily Regimen||Bristol-Myers Squibb||Completed|April 2004|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00207168||191383|
NCT00207441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-S2233-22/33|Comparing ASHC and CDSMP Outcomes In Arthritis|Comparing ASHC and CDSMP Outcomes In Arthritis||Centers for Disease Control and Prevention||Completed|April 2003|August 2006|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|416|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 23, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207441||191363|
NCT00234156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUH IRB #LHU 0471|The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers|Sensitivity to Fructose-Induced Palmitate Synthesis in End-Stage Renal Disease||Rockefeller University|No|Completed|September 2004|October 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00234156||189364|
NCT00235495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH NINDS 5U01 NS040406-08|Albumin in Acute Ischemic Stroke Trial|A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke|ALIAS|University of Miami|Yes|Terminated|June 2006|June 2014|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|843|||Both|18 Years|83 Years|No|||November 2012|November 14, 2012|September 14, 2005|Yes|Yes|Recruitment halted by DSMB following interim analysis.|No||https://clinicaltrials.gov/show/NCT00235495||189264|
NCT00235508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-902|Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder|The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.||Sunovion|No|Completed|June 2005|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|64 Years|No|||February 2012|February 21, 2012|October 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235508||189263|
NCT00235183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFS plasma trial|Plasma Transfusion in Liver Transplantation|Plasma Transfusion in Liver Transplantation : a Randomized, Double Blind, Multicenter Trial of Methylene Blue, Solvent/Detergent and Quarantined Plasma.||Etablissement Français du Sang||Completed|June 2005|December 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235183||189287|
NCT00235469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0742|A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety OF 200, 400, AND 600 mg/Day SPM 927 in Subjects With Painful Distal Diabetic Neuropathy||UCB Pharma||Completed|April 2004|June 2005|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|496|||Both|18 Years|N/A||||February 2010|September 19, 2014|October 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00235469||189266|
NCT00230958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA003142-301|Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive|Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C||Valeant Pharmaceuticals International, Inc.||Completed|December 2003|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|September 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230958||189605|
NCT00231322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30/CNSB/03/624-03-0021|Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique|The Influence of Transmission Season on Outcome of Schistosoma Haematobium Infection Treatment Among School Children in Urban and Peri-Urban Areas of Maputo and Matola, Mozambique||DBL -Institute for Health Research and Development||Completed|March 2004|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||520|||Both|8 Years|12 Years|No|||April 2007|April 19, 2007|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231322||189579|
NCT00230971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-315|Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)|A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|473|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|September 30, 2005||No||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00230971||189604|
NCT00231296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-AF-02|Safety and Efficacy of CryoCor™ Cryoablation for PAF|A Clinical Study to Evaluate the Safety and Efficacy of the CryoCor(TM)Cardiac Cryoablation System for the Treatment of Paroxysmal Atrial Fibrillation||Boston Scientific Corporation|No|Completed|November 2004|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|75 Years|No|||July 2011|July 14, 2011|September 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00231296||189581|
NCT00235716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|546|A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease|CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)|TEAM-AD|VA Office of Research and Development|Yes|Completed|August 2007|October 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|613|||Both|40 Years|N/A|No|||July 2014|July 14, 2014|October 6, 2005|No|Yes||No|December 6, 2013|https://clinicaltrials.gov/show/NCT00235716||189249|
NCT00231764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYMPHONY|MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients|Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx||Ekberg, Henrik, M.D.||Completed|November 2002|February 2008|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||1760|||Both|18 Years|75 Years|No|||April 2008|April 22, 2008|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231764||189546|
NCT00231244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-6310|Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)|Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry||Cordis Corporation|No|Completed|March 2002|November 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|252|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|October 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00231244||189585|
NCT00231803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC#04.154|The Canadian Prevention of Renal and Cardiovascular Endpoints Trial|Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial||Memorial University of Newfoundland||Recruiting|April 2005|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Both|40 Years|75 Years|No|||October 2005|October 6, 2005|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231803||189543|
NCT00231985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069877|Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder|Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder||Massachusetts General Hospital||Completed|October 2005|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|16 Years|N/A|No|||February 2012|February 8, 2012|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00231985||189529|
NCT00231998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C1302|Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis|A Clinical Study Continued From the Confirmatory Study to Validate the Efficacy and Safety of Pimecrolimus Cream in Pediatric Atopic Dermatitis Patients||Novartis||Completed|May 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||240|||Both|2 Years|16 Years||||December 2007|December 13, 2007|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231998||189528|
NCT00232011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C1304|Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis|A Clinical Study Continued From the Confirmatory Study to Assess the Efficacy and Safety of ASM981 Cream in Adult Atopic Dermatitis Patients||Novartis||Completed|May 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||160|||Both|16 Years|65 Years||||December 2007|December 13, 2007|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232011||189527|
NCT00232882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00003|Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.|Neurohumoral and Oxidative Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Essential Hypertensive Patients.||Institut de Recherches Cliniques de Montreal|No|Completed|December 2003|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|86|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00232882||189460|
NCT00232895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02AR36|Pain of Injection of Lipuro Propofol in Children Aged 1-7 Years|||Institute of Child Health||Completed||August 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Year|7 Years|No|||March 2007|March 27, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232895||189459|
NCT00232648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004-0768|Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma|Investigation of Safety and Efficacy of Budesonide Inhalation Suspension in the Long-Term Use in Japanese Children With Bronchial Asthma (Open Long-Term Extension Study Following Study SD-004-0765||AstraZeneca||Completed|January 2004|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|13 Months|65 Months|No|||March 2009|March 24, 2009|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00232648||189478|
NCT00205907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-003|Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation|Phase 1/Phase 2 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema||Aeris Therapeutics|No|Terminated|January 2005|April 2007|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2008|February 27, 2008|September 13, 2005||No|Change in Formulation|No||https://clinicaltrials.gov/show/NCT00205907||191478|
NCT00206232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H - 13988|Novel Treatment for Diastolic Heart Failure in Women|Novel Treatment for Diastolic Heart Failure in Women||Baylor College of Medicine|No|Completed|July 2004|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|48|||Female|18 Years|N/A|No|||February 2013|February 15, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00206232||191453|
NCT00206544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRC 77/02|Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?|Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?||The Alfred||Completed|January 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|51|||Female|18 Years|50 Years|No|||October 2008|October 23, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00206544||191430|
NCT00207454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3197|Optimizing Strategies to Improve STD Partner Services|Optimizing Strategies to Improve STD Partner Services||Centers for Disease Control and Prevention||Completed|June 2001|August 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||800|||Both|18 Years|N/A|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207454||191362|
NCT00207727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005284|A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis|A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis||Centocor, Inc.||Completed|July 2004|August 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|249|||Both|18 Years|65 Years|No|||April 2012|April 20, 2012|September 13, 2005|||||October 25, 2009|https://clinicaltrials.gov/show/NCT00207727||191342|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00234546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-713|Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity|A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke.||Ipsen||Completed|February 2003|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|80 Years|No|||June 2012|June 18, 2012|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00234546||189336|
NCT00234559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACP2005-001|Trial of Vacuum Assisted Closure® Therapy Versus Control Therapy in Angiogenesis|A Randomized Controlled Study Comparing Vacuum Assisted Closure® Therapy to Moist Wound Therapy in Angiogenesis||KCI USA, Inc.||Withdrawn|September 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|October 5, 2005|||Study terminated due to no subject enrollment.|No||https://clinicaltrials.gov/show/NCT00234559||189335|
NCT00235196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-04-001|Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers|A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers||Ethicon, Inc.||Completed|July 2004|December 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A||||October 2006|October 12, 2006|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235196||189286|
NCT00231049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-400-01|Trial Evaluating Safety, Tolerability and Immune Response of AG-707|A Phase 1 Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Compared to Placebo in HSV-2 Seropositive Patients||Agenus, Inc.||Completed|March 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|50 Years|No|||October 2008|October 24, 2008|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231049||189599|
NCT00231062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00313|Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)|Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)||Acclarent|Yes|Completed|April 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||June 2011|June 10, 2011|September 30, 2005||No||No|April 29, 2011|https://clinicaltrials.gov/show/NCT00231062||189598|
NCT00231309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0561-2003|Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)|Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies||Emory University|Yes|Completed|July 2003|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|55 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|October 3, 2005||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00231309||189580|Our study is also limited by its small patient population and short follow-up time.
NCT00231335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|408-2005|Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia|The Efficacy and Safety of Escitalopram Augmentation of Risperidone and Olanzapine in Treatment Resistant Schizophrenia: a Double Blind Placebo Controlled Pilot Study||Emory University||Completed|March 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2006|December 6, 2010|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231335||189578|
NCT00230932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-150|Help Veterans Experience Less Pain Study (HELP-Vets)|Validation of Pain as a Vital Sign Among Veterans With Advanced Illness|HELP-Vets|VA Office of Research and Development|No|Completed|October 2005|September 2008|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|654|||Both|18 Years|N/A|No|Probability Sample|654 veterans, 50% with fair to poor, and 50% with good to excellent self-reported health|November 2008|April 6, 2015|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230932||189607|
NCT00230945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 HL65111-65112--2|Couples-Oriented Psychosocial Intervention for Osteoarthritis|Psychobiological Pathways: Osteoarthritis Interventions||University of Pittsburgh|No|Completed|January 2000|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|543|||Both|50 Years|N/A|No|||March 2008|March 27, 2008|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230945||189606|
NCT00231257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02-6313|Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)|A Multicenter, Randomized Study of the Sirolimus-Eluting Bx VELOCITY® BALLOON Expandable Stent vs. Intravascular Brachytherapy in the Treatment of Patients With In-Stent Restenotic Coronary Artery Lesions||Cordis Corporation|Yes|Completed|February 2003|September 2009|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|384|||Both|18 Years|N/A|No|||November 2009|November 17, 2009|September 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00231257||189584|
NCT00231270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P98-5201|Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)|Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy||Cordis Corporation|Yes|Completed|August 2000|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1300|||Both|18 Years|80 Years|No|||July 2007|April 17, 2008|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231270||189583|
NCT00232414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET0384|A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder|A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder||University of Cincinnati|Yes|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|12 Years|18 Years|No|||December 2013|December 9, 2013|September 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232414||189496|
NCT00232427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PiCCO|PiCCO Guided Therapy in Liver Cirrhosis|Optimized Therapy of Decompensated Liver Cirrhosis by Hemodynamic Monitoring Using the PiCCO System||Heidelberg University||Completed|August 2005|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|20|||Both|18 Years|80 Years|No|||September 2007|October 2, 2007|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00232427||189495|
NCT00231777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-015|A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)|A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety and Tolerability of IV MK0517 for the Prevention of Postoperative Nausea and Vomiting (PONV)||Merck Sharp & Dohme Corp.|No|Completed|July 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|216|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|September 30, 2005|Yes|Yes||No|May 10, 2010|https://clinicaltrials.gov/show/NCT00231777||189545|The formulation of MK0517 used in this study was a non polysorbate (PS80) formulation which was not further developed and is not available for use.
NCT00231790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0634-007|A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of MK0634 in Postmenopausal Women With Overactive Bladder||Merck Sharp & Dohme Corp.|No|Completed|August 2005|October 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|848|||Female|40 Years|74 Years|No|||December 2015|December 16, 2015|September 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00231790||189544|
NCT00233207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328|IC14 Antibodies to Treat Individuals With Acute Lung Injury|Acute Lung Injury Clinical Trials Incubator Unit||National Heart, Lung, and Blood Institute (NHLBI)||Terminated|September 2005|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|13|||Both|18 Years|70 Years|No|||December 2007|December 13, 2007|October 3, 2005|||Unable to meet enrollment number to complete study, study stopped June 30, 2007|No||https://clinicaltrials.gov/show/NCT00233207||189436|
NCT00233181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298|Adherence Intervention for Minority Children With Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 2000|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|2 Years|12 Years|No|||December 2005|February 17, 2016|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00233181||189438|
NCT00233194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|324|Identification of Sleep-Disordered Breathing in Children|Identification of Sleep-Disordered Breathing in Children||University of Michigan|No|Completed|January 2005|July 2011|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|3 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children who are scheduled to undergo adenotonsillectomy for clinical indications, as well        as a group of control subjects will be enrolled.|May 2015|May 28, 2015|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233194||189437|
NCT00206557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRC 146/02|The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study|The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study||The Alfred||Completed|October 2002|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|45 Years|70 Years|No|||April 2007|April 20, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206557||191429|
NCT00206843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT II)|Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT II)||Biosite|No|Completed|November 2004|August 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|630|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00206843||191408|
NCT00207181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 CA106745-021|The Development and Testing of an Electronic Tool to Measure Physical Activity in Domestic Settings|Context Sensitive Measurement of Physical Activity||Boston Medical Center|No|Completed|May 2005|January 2007|Actual|||Phase 1|Observational|Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults 18 years or older.|June 2011|June 30, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00207181||191382|
NCT00207467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3196|Study to Improve Partner Services for STD Prevention|Prospective Study for Cost-Effectiveness Strategies to Improve Partner Notification: Female Trichomonas and Male Urethritis Studies||Centers for Disease Control and Prevention||Completed|December 2001|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1500|||Both|16 Years|44 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207467||191361|
NCT00207740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005281|A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma||Centocor, Inc.|Yes|Completed|August 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|309|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|September 13, 2005|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00207740||191341|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00207987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-93-41|Changes in Cerebral Oxygenation During Deliberate Hypotensive Anesthesia|||China Medical University Hospital||Recruiting|October 2003|December 2006||||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|16 Years|75 Years|No|||September 2005|November 20, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207987||191322|
NCT00235209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-04-002|A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Venous Leg Ulcers|A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Venous Leg Ulcers||Ethicon, Inc.||Completed|November 2004|December 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||48|||Both|18 Years|N/A||||October 2006|June 8, 2011|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235209||189285|
NCT00235222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREPATS 05-01-PHOENIX|Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY|Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY||Groupe Hospitalier Pitie-Salpetriere||Active, not recruiting|June 2004|March 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||57|||Both|18 Years|65 Years|No|||October 2005|October 24, 2005|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235222||189284|
NCT00228397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066A2-210|Study Evaluating CCI-779 in Relapsing Multiple Sclerosis|A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2003|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|221|||Both|N/A|N/A|No|||February 2013|February 11, 2013|September 16, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00228397||189790|
NCT00228852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|296-2003|IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency|Phase I/II Trial of De-Escalation of Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency||Emory University||Completed||November 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|June 29, 2009|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228852||189765|
NCT00231608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003724|A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity|The Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity: A 6-Month Double-Blind, Randomized, Placebo-Controlled Study With a 6-Month Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 1998|January 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|68|||Male|25 Years|55 Years|No|||April 2010|June 6, 2011|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231608||189558|
NCT00231556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003259|A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy|A Randomized, Double-Blind, Parallel-Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topiramate in the Treatment of Newly Diagnosed or Recurrent Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 1999|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|750|||Both|N/A|N/A|No|||January 2010|June 6, 2011|September 30, 2005||||||https://clinicaltrials.gov/show/NCT00231556||189562|
NCT00231569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012CS4|Dose-escalating Safety Study in Subjects on Stable Statin Therapy|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose‑Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy||Sanofi|Yes|Completed|September 2005|December 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|74|||Both|18 Years|65 Years|No|||December 2013|December 2, 2013|October 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00231569||189561|
NCT00231582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031101|High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II|Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation||Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2004|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|18 Years|65 Years|No|||March 2007|February 24, 2011|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00231582||189560|
NCT00231816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-011|A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)|A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V211 Administered Concomitantly Versus Nonconcomitantly With Influenza Virus Vaccine (Inactivated)||Merck Sharp & Dohme Corp.||Completed|September 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|763|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|September 30, 2005|Yes|Yes||No|May 12, 2010|https://clinicaltrials.gov/show/NCT00231816||189542|
NCT00231829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-03-04-084|A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers|A Pilot Phase II Trial of Celecoxib in Patients With Grade 2 or 3 Endometrioid-type, Clear Cell, and Papillary Serous Uterine Cancers||Montefiore Medical Center|Yes|Terminated|April 2003|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||23|||Female|18 Years|N/A|No|||April 2012|April 22, 2012|September 30, 2005||No|Due to reported toxicity of Celecoxib at high doses|No||https://clinicaltrials.gov/show/NCT00231829||189541|
NCT00231283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04-6324|NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions|A Multicenter, Non-Randomized Study of the CYPHER NxT Sirolimus-Eluting Coronary Stent on BX SONIC OVER-THE-WIRE (OTW) Stent Delivery System(SDS)for the Treatment of de Novo Native Coronary Artery Lesions||Cordis Corporation|No|Completed|April 2004|July 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|September 30, 2005||||No|November 18, 2008|https://clinicaltrials.gov/show/NCT00231283||189582|
NCT00231543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99SG92|Laparoscopy in Children: Does it Decrease the Metabolic, Endocrine and Inflammatory Stress Response to Surgery|||Institute of Child Health||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Month|16 Years|No|||October 2005|October 11, 2006|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231543||189563|
NCT00232687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-169|A Switch Study of BMS-337039 in Schizophrenic Out-patients|A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|June 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|65 Years|No|||February 2012|November 7, 2013|October 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232687||189475|
NCT00232908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18018|QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection|An Open-label Study of a HAART (Highly Active Antiretroviral Therapy) Regimen Containing Subcutaneous Injection of Fuzeon on Quality of Life in Clinically Stable, Treatment-experienced Patients With HIV-1 Infection||Hoffmann-La Roche||Completed|June 2004|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|361|||Both|16 Years|N/A|No|||March 2016|March 1, 2016|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232908||189458|
NCT00232063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400D1304|Long-term Study of Ciclosporin for Atopic Dermatitis|Long-term Study of Ciclosporin for Atopic Dermatitis||Novartis||Completed|May 2004|||November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|64 Years||||November 2011|November 1, 2011|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232063||189523|
NCT00233220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322|Blood Pressure Control in African Americans|Multi-site Randomized Controlled Trial for Blood Pressure Control in Hypertensive African Americans||New York University School of Medicine|Yes|Completed|September 2004|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1039|||Both|N/A|N/A|No|||February 2014|February 12, 2014|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233220||189435|
NCT00233233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|325|Influence of Data Collection Mode on Self-Report Validity of Asthma Therapy Adherence|Assessment Mode and Validity of Self-Reports in Adults||Johns Hopkins University||Completed|August 2002|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized|||Actual|139|||Both|19 Years|95 Years|No|||September 2015|September 15, 2015|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00233233||189434|
NCT00233584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5254C00004|Pulmicort Asthma Prevention (Post-PAC)|A Study to Evaluate the Feasibility of a Treatment Algorithm in Newly Diagnosed Asthmatic Children. An Open Follow-up to Asthma Prevention in Infants/Young Children (PAC)||AstraZeneca||Completed|July 2001|June 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|N/A|6 Years|No|||January 2008|January 11, 2008|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233584||189407|
NCT00233597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62745-5|Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients|A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy||AMAG Pharmaceuticals, Inc.||Completed|August 2004|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||230|||Both|18 Years|N/A|No|||October 2007|February 26, 2009|October 4, 2005||||||https://clinicaltrials.gov/show/NCT00233597||189406|
NCT00206583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90959|Efficacy and Safety Study of an Oral Contraceptive in Healthy Females|A Multicenter, Open-label Uncontrolled Study to Investigate the Efficacy and Safety of a 4-phasic Oral Contraceptive SH T0065 in a 28-day Regimen for 13 Cycles in Healthy Female Subjects||Bayer|No|Completed|March 2005|July 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|499|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00206583||191427|
NCT00206895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-177/04|Photodynamic Therapy of Acne Vulgaris - a Randomized Blinded Controlled Study|||Bispebjerg Hospital||Completed|November 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A||||October 2004|October 10, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00206895||191404|
NCT00206856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)|Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)||Biosite|No|Terminated|July 2003|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic||||720|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|September 13, 2005|No|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00206856||191407|
NCT00207194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 69395|Interactive Multirisk-Factor Intervention for Hypertension (HTN) Blacks|Interactive Multirisk-Factor Intervention for HTN Blacks||Boston Medical Center|Yes|Completed|October 2001|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|337|||Both|35 Years|N/A|No|||June 2011|February 21, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00207194||191381|
NCT00208234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xolair Asthma|Effect of Xolair on Airway Hyperresponsiveness|The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness||Creighton University|No|Active, not recruiting|January 2004|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|19 Years|50 Years|No|||September 2011|September 22, 2011|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208234||191303|
NCT00203853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13640A|Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults|Evaluation of an Intervention (Consisting of an Electronic Reminder Device, Pillboxes, and Monthly Telephone Calls) on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults||University of Chicago||Terminated|January 2005|March 2007|Actual|March 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||200|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00203853||191633|
NCT00204191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/25/03|Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation|Open, Prospective, Randomized Study to Compare the Efficacy and Safety of Immunosuppression Regimens Based on Cyclosporine (Neoral®) and Tacrolimus (Prograf®) in Renal Transplant Patients||Uniwersytet Mikolaja Kopernika w Toruniu||Recruiting|May 2003|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|70 Years|No|||September 2005|October 18, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204191||191608|
NCT00235521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iloprost-Study|Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery|Comparison of Inhaled Nitric Oxide With Aerosolized Iloprost (Ventavis®) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery||Heidelberg University|Yes|Completed|May 2005|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|N/A|2 Years|No|||December 2012|December 11, 2012|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235521||189262|
NCT00228176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5828|Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant (Auditor)|Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors||Sanofi||Terminated|August 2005|April 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|661|||Both|55 Years|N/A|No|||July 2009|July 17, 2009|September 26, 2005|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00228176||189807|
NCT00230984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 01 05|IRAD2 : Patients With Respiratory Failure at Home|Effects of Home Pulmonary Rehabilitation in Patients With Chronic Respiratory Failure and Nutritional Depletion.||University Hospital, Grenoble||Completed|April 2003|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||200|||Both|18 Years|N/A|No|||July 2006|July 7, 2009|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00230984||189603|
NCT00230997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-ALZ-421|Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies|An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies||Neurological Research Center||Completed|December 2002|August 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|51 Years|N/A|No|||September 2005|December 15, 2005|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230997||189602|
NCT00231010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050143|Molecular Genetics of Retinal Degenerations|Molecular Genetics of Retinal Degenerations||National Institutes of Health Clinical Center (CC)||Recruiting|September 2005|||||N/A|Observational|N/A|||Anticipated|5000|||Both|4 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 2, 2015|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00231010||189601|
NCT00231023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050251|Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema|Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)||Completed|September 2005|May 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment||||10|||Both|N/A|N/A|No|||May 2006|March 3, 2008|October 2, 2005||||No||https://clinicaltrials.gov/show/NCT00231023||189600|
NCT00229177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2506-08|Study of ONO-2506 in Patients With Acute Ischemic Stroke|Controlled Study of ONO-2506 in Patients With Acute Ischemic Stroke||Ono Pharmaceutical Co. Ltd||Completed|September 2005|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|757|||Both|20 Years|79 Years|No|||June 2012|June 12, 2012|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229177||189740|
NCT00229190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-227|Nasal Lavage Study: Comparing Single Versus Multi Sample Lavages|Reproducibility of Cell Counts in Nasal Lavage: A Comparison of Pooled Versus Non-Pooled Nasal Lavage Samples||McMaster University|No|Completed|September 2004|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 23, 2007|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00229190||189739|
NCT00231595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003208|A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2001|November 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|768|||Both|12 Years|65 Years|No|||November 2010|November 18, 2010|September 30, 2005||||||https://clinicaltrials.gov/show/NCT00231595||189559|
NCT00231842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-03-02-040|A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus|A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors||Montefiore Medical Center|Yes|Completed|February 2003|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||April 2012|April 22, 2012|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00231842||189540|
NCT00232102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919D2302E1|Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia|Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia||Novartis||Completed|September 2004|August 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||423|||Female|18 Years|N/A||||January 2008|January 31, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00232102||189520|
NCT00232076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400D1303|Verification Study of Ciclosporin for Atopic Dermatitis|Verification Study of Ciclosporin for Atopic Dermatitis||Novartis||Completed|May 2004|||March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|64 Years||||November 2011|November 1, 2011|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232076||189522|
NCT00232089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919D2302|Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia|Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia||Novartis||Completed|May 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1296|||Female|18 Years|N/A||||January 2008|August 31, 2010|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00232089||189521|
NCT00232700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050041|Investigation of a Combination Treatment of Escitalopram and rTMS|Investigation of Efficacy and Response Speed of a Combination Treatment of Escitalopram and Repetitive Transcranial Magnetic Stimulation||Charite University, Berlin, Germany||Completed|September 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|42|||Both|18 Years|85 Years|No|||September 2007|June 22, 2011|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232700||189474|
NCT00232661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033IL/0039|PROACT - Pre-Operative Arimidex Compared To Tamoxifen|A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer.||AstraZeneca||Completed|August 2000|December 2007|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|452|||Female|60 Years|N/A|No|||February 2010|February 2, 2010|September 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232661||189477|
NCT00232674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-004-0001|Efficacy Study of the Effect of Budesonide on Emphysema|The Effect of Inhaled Corticosteroids on the Development of Emphysema in Smokers Assessed by Computed Tomography (CT).||AstraZeneca||Completed|July 1999|February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|50 Years|N/A|No|||January 2011|January 21, 2011|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232674||189476|
NCT00232921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02AR07|The Effect of Caudal Volumes on the Anatomical Spread of Caudals in Children|||Institute of Child Health||Completed||February 2003||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Year|7 Years|No|||December 2006|December 22, 2006|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232921||189457|
NCT00233259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|327|Lifestyle Modification Program to Reduce Risk of Coronary Heart Disease in Latina Women With Diabetes|CHD Lifestyle Modification for Latinas With Diabetes||Oregon Research Institute|Yes|Completed|March 2006|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|273|||Female|30 Years|75 Years|No|||October 2011|October 24, 2011|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233259||189432|
NCT00233636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0070|Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck|A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck||AstraZeneca||Withdrawn|July 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233636||189403|
NCT00233649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL401017|DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines|DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines||AstraZeneca||Completed|May 2004|||||Phase 4|Observational|Time Perspective: Prospective||1||2500|||Both|18 Years|70 Years|No|Probability Sample|Diabetes Mellitus Type 2|November 2010|November 18, 2010|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00233649||189402|
NCT00233610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7054IT/0003|Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer|A Comparative Trial of the Efficacy of Two Different Nolvadex (NDX) Dosing and Scheduling Regimens in Preventing Gynecomastia Induced by Casodex (CDX) 150 Monotherapy in Prostate Cancer Patients. An Open, Multicenter, Phase III Trial.||AstraZeneca||Completed|December 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||180|||Male|18 Years|75 Years|No|||January 2011|January 25, 2011|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233610||189405|
NCT00233623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0138|Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer|A Randomised, Non-Comparative, Multicentre, Phase II, Parallel-Group Trial Of ZD1839 (Iressa™) In Combination With 5 Fluorouracil, Leucovorin And Cpt-11 (Irinotecan) In Patients With Metastatic Colorectal Cancer||AstraZeneca||Withdrawn|July 2004|January 2006|Anticipated|January 2006|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||190|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233623||189404|
NCT00207207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol # 03-004C|Self Monitoring of Blood Glucose With Finger Tip vs. Alternate Site Sampling: Effect on Long Term Glycemic Control|Randomized Trial to Assess the Effect of Using Alternate Site Blood Glucose Testing Versus Finger-Tip Testing on Long-Term Glycemic Control.||Boston Medical Center|No|Completed|July 2003|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||174|||Both|18 Years|70 Years|No|||February 2009|February 10, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207207||191380|
NCT00207480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4415|Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women|Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women||Centers for Disease Control and Prevention||Suspended|October 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||270|||Female|16 Years|24 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207480||191360|
NCT00208221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 0507/17259|Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes|Comparison of a Higher Dose of Ramipril to the Addition of Telmisartan 80 mg+Ramipril 10 mg in Patients With Hypertension and Diabetes||Institut de Recherches Cliniques de Montreal|No|Terminated|August 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||November 2007|November 7, 2007|September 13, 2005|||Not enough recruitment|No||https://clinicaltrials.gov/show/NCT00208221||191304|
NCT00203840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13270A|Pediatric Sleep Questionnaire: Normalization and Validation Study|Pediatric Sleep Questionnaire: Normalization and Validation Study||University of Chicago|No|Active, not recruiting|August 2004|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|325|||Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with sleep disorders|September 2013|September 4, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00203840||191634|
NCT00208247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-11-DP-82-RKF-21|KATHY:Cognitive-Behavioural Therapy for Hypochondriasis|Cognitive-Behavioural Therapy Versus Short-Term Psychodynamic Psychotherapy: a Randomised Clinical Trial||Copenhagen Trial Unit, Center for Clinical Intervention Research||Completed|August 2001|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|65 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208247||191302|
NCT00203866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12403B|Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma|A Randomized Pilot Phase II Trial of Adjuvant Immunization With G250 Peptide andThree Different Dose Levels of IL-2 Following Surgical Resection of Locally Advanced or Metastatic Renal Cell Carcinoma||University of Chicago|Yes|Terminated|October 2003|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|September 12, 2005|No|Yes|Study completed|No||https://clinicaltrials.gov/show/NCT00203866||191632|
NCT00235248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P991205|Aortic Arch Related Cerebral Hazard Trial (ARCH)|Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery|ARCH|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2002|July 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|350|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235248||189282|
NCT00235534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11779-26464-01|Trial of Immediate Versus Delayed Initiation of Oral Contraceptive Pills After Abortion|Immediate Versus Delayed Initiation of Oral Contraceptive Pills After Therapeutic Abortion - A Randomized Trial||University of California, San Francisco||Completed|October 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Female|13 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235534||189261|
NCT00231348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707-1997|Nefazodone in the Treatment of Social Phobia|Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates||Emory University||Completed||April 2000|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231348||189577|
NCT00228865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-66-COG|Clinical Effects of Pulsatile Insulin Delivery on Cognitive Function- Phase 1|Effects of Pulsatile IV Insulin on Cognitive Deficits in Diabetic Patients||Florida Atlantic University|Yes|Terminated|June 2003|December 2010|Anticipated|June 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|21 Years|85 Years|No|||August 2009|August 25, 2009|September 27, 2005||No|Administrative|No||https://clinicaltrials.gov/show/NCT00228865||189764|
NCT00228878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-66-QOL|Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes|Quality of Life With and Without Pulsatile IV Insulin Therapy in Diabetes.||Florida Atlantic University|Yes|Terminated|March 2003|June 2010|Anticipated|January 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||August 2009|August 25, 2009|September 27, 2005||No|Administrative|No||https://clinicaltrials.gov/show/NCT00228878||189763|
NCT00231868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-01-09-227|A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma|A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma||Montefiore Medical Center|Yes|Completed|December 2001|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Female|18 Years|N/A|No|||April 2012|April 22, 2012|October 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00231868||189538|
NCT00231855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-04-05-131|Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers|Phase II Trial- Weekly Taxotere and Topotecan for Recurrent Ovarian, Primary Peritoneal, Endometrial and Uterine Cancers||Montefiore Medical Center|Yes|Completed|November 2004|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||31|||Female|18 Years|N/A|No|||April 2012|April 22, 2012|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00231855||189539|
NCT00232128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI LUN 02|Protocol for Radiofrequency Ablation of Pulmonary Neoplasms|Protocol for Radiofrequency Ablation of Pulmonary Neoplasms||Oncology Specialties, Alabama||Terminated|June 2003|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2006|January 11, 2007|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232128||189518|
NCT00232115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CDE15|Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis|Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis||Novartis||Completed|September 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A||||January 2008|January 15, 2008|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232115||189519|
NCT00232440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 02-0526-C|Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma|A Study to Examine the Reproducibility of an Immobilization Device (BodyFIX ) to Deliver High Precision Radiation Therapy for Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma||University Health Network, Toronto||Completed|January 2003|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||August 2010|August 10, 2010|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232440||189494|
NCT00232713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFB04-101|Uterine Fibroid Pregnancy Registry|||INC Research||Terminated|December 2005|December 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||2360|||Female|20 Years|55 Years|Accepts Healthy Volunteers|||February 2006|August 29, 2006|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232713||189473|
NCT00232960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marges-ORL|Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC|Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Early Stages Oral and Oropharyngeal Squamous Cell Carcinomas: A Prospective Study||Gustave Roussy, Cancer Campus, Grand Paris||Active, not recruiting|October 2005|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|310|||Both|18 Years|N/A|No|||March 2012|March 27, 2012|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00232960||189454|
NCT00232934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISMM2001-A|Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients|Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.||Gruppo Italiano per lo Studio del Mieloma Multiplo||Completed|January 2002|May 2010||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|N/A|N/A|No|||October 2005|October 4, 2005|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232934||189456|
NCT00232947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDB707-108|Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over|A Non-Inferiority Comparison of Fluviral™ Influenza Vaccine to a U.S. Licensed Inactivated Split-Virion Vaccine (Fluzone®) in Adults ≥ 50 Years Old Living in the Community||ID Biomedical Corporation, Quebec||Completed|October 2005|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||900|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2005|January 19, 2007|October 3, 2005||||||https://clinicaltrials.gov/show/NCT00232947||189455|
NCT00233935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00855|Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus|Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients With Barrett's Esophagus||National Cancer Institute (NCI)|No|Completed|November 2005|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|55|||Both|18 Years|N/A|No|||April 2013|September 10, 2014|October 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00233935||189380|
NCT00233948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04090|Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma|A Phase I/II Study of Nelfinavir in Liposarcoma||City of Hope Medical Center|Yes|Terminated|March 2006|||July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|October 5, 2005|Yes|Yes|Drug availability issues|No|February 2, 2015|https://clinicaltrials.gov/show/NCT00233948||189379|After 12 patients were accrued to the Phase II portion, the study was terminated…protocol objectives for the Phase II portion not met. Closed prematurely due to drug availability issues.
NCT00214305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-373|Effects of Swallowing Therapy in Head and Neck Cancer|Effects of Swallowing Therapy in Head and Neck Cancer||University of Wisconsin, Madison|Yes|Withdrawn|August 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|80 Years|No|||September 2015|September 30, 2015|September 13, 2005||No|low accrual|No||https://clinicaltrials.gov/show/NCT00214305||190844|
NCT00214578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C00125|Seroquel on Glucose Metabolism|Seroquel on Glucose Metabolism||AstraZeneca||Completed|April 2004|October 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||572|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00214578||190825|
NCT00215111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02819-8|Role of Carbohydrate Modification in Weight Management Among Obese Children|Role of Carbohydrate Modification in Weight Management Among Obese Children||Children's Hospital Medical Center, Cincinnati||Completed|March 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00215111||190785|
NCT00227916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13375-1|Motivational Interviews for Incarcerated Teens - 1|Motivational Interviews for Incarcerated Teens||Brown University||Completed|November 2000|July 2004|Actual|May 2004|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|200|||Both|14 Years|19 Years|No|||September 2014|September 24, 2014|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00227916||189827|
NCT00228163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS6048|Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses|Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses||Sanofi|No|Completed|January 2002|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|65 Years|No|||March 2015|March 24, 2015|September 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00228163||189808|
NCT00229593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26852-D|NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel|A Randomized, Open Label Clinical Trial to Evaluate if Nestorone Gel Has Gonadotropin Suppressive Activity and if Nestorone in Combination With Testosterone Will Have an Additive Effect on Gonadotropin Suppression When Applied Transdermally in Healthy Men|NES-1|University of Washington|Yes|Completed|September 2005|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|7||Actual|140|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229593||189709|
NCT00229619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050244|Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia|A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia||National Institutes of Health Clinical Center (CC)|Yes|Completed|September 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|2 Years|N/A|No|||July 2014|July 1, 2014|September 29, 2005||No||No|January 28, 2013|https://clinicaltrials.gov/show/NCT00229619||189708|
NCT00229164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701148|The Effect of Transcutaneous Electric Nerve Stimulation on Primary Dysmenorrhea-a Randomized Control Study|The Effect of Transcutaneous Electric Nerve Stimulation on Primary Dysmenorrhea-a Randomized Control Study||National Taiwan University Hospital|No|Completed|October 2005|January 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|40 Years|No|||November 2012|December 26, 2012|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229164||189741|
NCT00228410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-305|Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections|A Multicenter, Randomized, Double-Blind Comparison of the Safety and Efficacy of Tigecycline With Those of Vancomycin With Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2002|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|503|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|September 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00228410||189789|
NCT00230191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RK:0202-02|Safety and Efficacy of RK0202 in Oral Mucositis|Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region||RxKinetix||Completed|January 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||110|||Both|18 Years|N/A|No|||October 2005|January 12, 2007|September 28, 2005||||||https://clinicaltrials.gov/show/NCT00230191||189664|
NCT00230490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA200103-202|Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201|Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201||Valeant Pharmaceuticals International, Inc.||Terminated|June 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|60 Years|No|||June 2012|June 21, 2012|September 28, 2005|Yes|Yes|Adverse findings from nonclinical carcinogenicity studies.|No||https://clinicaltrials.gov/show/NCT00230490||189641|
NCT00229580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-8752-V 03|Health Behavior Feedback Study for Veterans With Hepatitis C|Health Behavior Feedback Study for Veterans With Hepatitis C||University of Washington|No|Completed|December 2003|January 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|80 Years|No|||November 2007|November 28, 2007|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229580||189710|
NCT00232154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661151|A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To|An Open-Label Study Of Azithromycin Pharmacokinetics In Sinus Mucosal Tissue And Plasma In Subjects With Chronic Rhinosinusitis Following A Single 2g Dose Of Azithromycin Extended Release For Oral Suspension Or Azithromycin 500mg Tablet Formulation Once Daily For A Maximum Of Three Days||Pfizer||Completed|November 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|72|||Both|18 Years|N/A|No|||April 2011|April 20, 2011|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00232154||189516|
NCT00232167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5761022|Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Tolerability Of Indiplon Therapy Initiated With Sertraline Versus Sertraline Monotherapy In Subjects With Insomnia And Co-Existing Major Depressive Disorder||Neurocrine Biosciences|No|Terminated|November 2005|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|18 Years|65 Years|No|||October 2007|October 1, 2007|September 30, 2005|||Please see Detailed Description below for termination reason.|||https://clinicaltrials.gov/show/NCT00232167||189515|
NCT00232141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081066|Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With HIV Neuropathy.||Pfizer|No|Completed|October 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||June 2009|June 22, 2009|September 30, 2005|Yes|Yes||No|November 25, 2008|https://clinicaltrials.gov/show/NCT00232141||189517|
NCT00232453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0024-C|Preoperative Combined Radiation and Chemotherapy - Rectal Cancer|A Phase II Protocol of Preoperative Combined Radiation and Chemotherapy for Resectable Primary Rectal Cancer||University Health Network, Toronto||Completed|March 2001|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||34|||Both|18 Years|N/A|No|||February 2011|February 11, 2011|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232453||189493|
NCT00232973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-VLU-003|Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers|A Prospective, Multi-Centre, Double Blind, Randomized, Placebo Controlled Trial to Evaluate the Safety and Efficacy of ICXP007 in a Phase III Trial With Four-Layer Therapeutic Compression, for the Treatment of Non-Infected Skin Leg Ulcers, Due to Venous-Insufficiency||Intercytex|Yes|Recruiting|July 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|396|||Both|18 Years|N/A|No|||February 2008|February 4, 2008|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232973||189453|
NCT00233246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|326|Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures|Study of Hemostasis and Invasive Procedures (SHIP: A TMH CTN Study)||Massachusetts General Hospital||Withdrawn|March 2006|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Both|4 Years|N/A|No|||June 2014|June 5, 2014|October 3, 2005|||Study never activated|No||https://clinicaltrials.gov/show/NCT00233246||189433|
NCT00230724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL76734|Maintaining Exercise After Cardiac Rehabilitation|Maintaining Exercise After Cardiac Rehabilitation||The Miriam Hospital||Recruiting|April 2005|April 2007||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||180|||Both|40 Years|N/A|No|||September 2005|September 29, 2005|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230724||189623|
NCT00230737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001521-01A1|Effects of Melatonin on Insomnia Symptoms in Older Adults|Melatonin Randomized Trial for Insomnia in the Elderly||University of Pennsylvania|Yes|Completed|October 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|190|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00230737||189622|
NCT00226330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00048|GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Multi-Centre, Active-Controlled (15, 30, and 45 mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar (0.5 and 1 mg) in Patients With Type 2 Diabetes Mellitus (GALLEX 6)||AstraZeneca||Terminated|March 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1100|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|September 23, 2005|||The development program has been terminated|||https://clinicaltrials.gov/show/NCT00226330||189942|
NCT00207753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4283|Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections|Efficacy and Nutritional Assessment Following Albendazole and Combined Albendazole/Ivermectin Treatment for Intestinal Helminth Infections in Rural Guatemalan Schoolchildren||Centers for Disease Control and Prevention||Completed|February 2005|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||550|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||September 2005|November 16, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207753||191340|
NCT00207766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005413|A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease|ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease||Centocor, Inc.||Completed|June 2000|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|306|||Both|18 Years|N/A|No|||January 2009|April 26, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00207766||191339|
NCT00214591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00029|GALLANT 5 Tesaglitazar Versus Metformin|A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes||AstraZeneca||Terminated|August 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||580|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|September 20, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00214591||190824|
NCT00208013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-2314-B-039-025|The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients|The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients||China Medical University Hospital|Yes|Completed|July 2005|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|advanced cancer patients|July 2005|November 26, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00208013||191320|
NCT00208026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-11-4063|Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome|Exploratory Safety and Systemic Absorption of Elidel (Pimecrolimus) 1% Cream for the Treatment of Netherton Syndrome||Children's Hospital of Philadelphia|Yes|Completed|September 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|2 Years|18 Years|No|||December 2014|December 6, 2014|September 13, 2005|Yes|Yes||No|March 9, 2011|https://clinicaltrials.gov/show/NCT00208026||191319|There were no early termination for any of the subjects.
NCT00215371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-050|Study in Patients With Asthma|||Dey||Completed|July 2002|November 2005|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|5 Years|11 Years|No|||February 2008|November 10, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215371||190765|
NCT00215384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-052|Study in Patients With COPD|||Dey||Completed||October 2005|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||35|||Both|50 Years|N/A|No|||February 2008|November 10, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215384||190764|
NCT00227695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 35/03|Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma|Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|June 2004|September 2017|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00227695||189842|
NCT00227929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067085|Culturally Sensitive Collaborative Treatment for Depressed Chinese Americans|Effectiveness of Culturally Sensitive Collaborative Treatment (CSCT) of Depressed Chinese Americans in Primary Care||Massachusetts General Hospital||Completed|July 2003|June 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00227929||189826|
NCT00229931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2746|Triamcinolone vs. Laser for Diabetic Macular Edema|The Role of Triamcinolone Injection During Cataract Extraction for Diabetic Patients With Pre-Operative Macular Edema|IVTA|University of Oklahoma|Yes|Completed|November 2005|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229931||189684|
NCT00229944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-022|Single Dose Azithromycin in the Treatment of Adult Cholera|Randomized, Double-Blind, Controlled Clinical Trial to Compare Efficacy of a Single Dose of Azithromycin Versus a Single Dose of Ciprofloxacin in the Treatment of Adults With Clinically Severe Cholera Due to V. Cholerae O1 or O139||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|December 2002|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|60 Years|No|||September 2005|July 20, 2006|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00229944||189683|
NCT00229957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-052|Rehabilitation in Primary Care: A Project to Maximize the Health Status of Adults With Chronic Illness|Rehabilitation in Primary Care: A Project to Maximize the Health Status of Adults With Chronic Illness||McMaster University|No|Completed|June 2004|October 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|303|||Both|44 Years|N/A|No|||September 2009|July 13, 2010|September 28, 2005||No||No|May 18, 2009|https://clinicaltrials.gov/show/NCT00229957||189682|
NCT00229203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-B-014-03|A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma|"Phase II Multicenter, Open-Label, Clinical and Pharmacokinetic Study of Aplidin® As A 3-Hour Infusion Every 2 Weeks Alone or in Combination With Dexamethasone, in Pre-Treated Patients With Relapsing or Refractory Multiple Myeloma."||PharmaMar|No|Completed|February 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||December 2009|December 14, 2009|September 27, 2005|Yes|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00229203||189738|32 patients were treated with plitidepsin as single agent;afterwards 19 of them were treated with plitidepsin+dexamethasone combination.Therefore 32+19=51 is the no. patients at risk for plitidepsin and 19 is no. of patients at risk for dexamethasone
NCT00229216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-500|Treatment of Bacterial Vaginosis With Oral Tinidazole|A Phase III Randomized, Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets.||Mission Pharmacal||Completed|January 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|18 Years|N/A|No|||June 2007|June 18, 2007|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00229216||189737|
NCT00229892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-120|Incisions for Cardiac Surgery|Small Incisions for Cardiac Surgery||Children's Healthcare of Atlanta|No|Terminated|February 2005|September 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|90|||Both|N/A|N/A|No|Probability Sample|children who have undergone cardiac surgery at Children's, Egleston, before 11.1.2004|May 2007|November 16, 2011|September 13, 2005|||after 90 charts reviewed, insufficient data to support conclusion|No||https://clinicaltrials.gov/show/NCT00229892||189687|
NCT00232466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-06-351|VERTOS-II. Percutaneous Vertebroplasty Versus Conservative Therapy|VERTOS II. Percutaneous Vertebroplasty Versus Conservative Therapy in Patients With Osteoporotic Vertebral Fractures||UMC Utrecht||Active, not recruiting|October 2005|May 2010|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|50 Years|N/A|No|||June 2008|June 24, 2008|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00232466||189492|
NCT00230165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCO-0417/0726|The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.|Studies of Interactions Among Normal and Abnormal Blood Cells, and the Vessel Wall, and Studies of Genetic and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell and Coagulation Disorders||Rockefeller University|No|Recruiting|September 2005|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|whole blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|For normal volunteers, we recruit from laboratory personnel and other volunteers from the        NYC area. Patients with sickle cell disease and cardiovascular disease associated with        increased intravascular shear forces are recruited from physicians in the New York area        who care for such patients. Patients with platelet disorders, coagulation disorders, or        white blood cell disorders, are recruited from among patients referred by other physicians        to the P.I. for assessment or via the internet.|February 2016|February 16, 2016|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230165||189666|
NCT00230464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2346|Acute Metabolic Effects of LAF 237 in Type 2 Diabetics|A Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Explore the Acute Effects of LAF 237 on the Rate of Appearance and Disappearance of Glucose During the Overnight Post-Absorptive Period in Type 2 Diabetics||The University of Texas Health Science Center at San Antonio||Completed|November 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|75 Years|No|||September 2005|January 3, 2006|September 28, 2005||||||https://clinicaltrials.gov/show/NCT00230464||189643|
NCT00230750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-076|Inactivated Influenza A/H5N1 Vaccine in the Elderly|A Randomized, Double-Blinded, Placebo-Controlled Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Elderly Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2005|January 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|261|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2008|August 22, 2013|September 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230750||189621|
NCT00226343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Depakote-ER for Depressive and Bipolar Depression|Phase 4 Study: Double-Blind Placebo-Controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non-Refractory Bipolar Depression||Cambridge Health Alliance||Active, not recruiting|August 2003|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2006|April 13, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00226343||189941|
NCT00226356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0048/04/04|Natural Supplements for Unipolar Depression|Phase 4 Study: An Open Study of the Efficacy and Tolerability in Unipolar Depression of Augmentation of the One-Carbon Cycle With L-Methionine, Betaine and Folate||Cambridge Health Alliance||Recruiting|December 2004|September 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2006|October 19, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00226356||189940|
NCT00226655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI 0501|An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies|An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies||Celtic Pharma Development Services|Yes|Completed|July 2005|April 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|September 23, 2005|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00226655||189917|
NCT00213902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153|Clonidine and Left Ventricular Dysfunction|Evaluation of Effects of Central Sympathetic Inhibition in Elderly With Left Ventricular Diastolic Dysfunction and Preserved Ejection Fraction: A Proof-of-Concept Trial With Clonidine||University Hospital, Strasbourg, France||Withdrawn|April 2004|||||Phase 2|Observational|Time Perspective: Prospective|||Anticipated|70|||Both|60 Years|N/A|No|||November 2007|November 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213902||190874|
NCT00213915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3031|L-Arginine Supplementation and Exercise; L-Arginine Supplementation and Renal Function|Effects of Oral Chronic L-Arginine Supplementation on Exercise and Renal Function of Heart Transplant Recipients||University Hospital, Strasbourg, France||Completed|February 2004|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213915||190873|
NCT00214838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-102|An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer|An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer||Callisto Pharmaceuticals||Active, not recruiting|March 2005|March 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||61|||Both|13 Years|N/A|No|||December 2006|December 1, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00214838||190806|
NCT00215761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET-B05|Recurrence of Atrial Fibrillation in Patients With Dual-chamber Pacemakers and Drug Therapy|A Multicenter Study to Investigate Preventive Pacing in Combination With Antiarrhythmic Beta-Blocker Oder AT-I-/ACE-inhibitor Therapy on the Recurrence of Atrial Fibrillation in Patients With Dual-chamber Pacemakers||German Atrial Fibrillation Network||Completed|January 2005|December 2008|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|263|||Both|18 Years|N/A|No|Probability Sample|Paroxysmal symptomatic atrial fibrillation with implemented dual-chamber pacemakers|September 2012|September 7, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00215761||190737|
NCT00215774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET-B11|Flecainide-Short Long Study (Flec-SL)|Targeted Pharmacological Reversal of Electrical Remodeling After Cardioversion.||German Atrial Fibrillation Network|Yes|Completed|March 2005|March 2011|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|760|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00215774||190736|
NCT00228891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-66 NEU1|Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus|Effects of Pulsatile Insulin Delivery on Peripheral Diabetic Neuropathy||Florida Atlantic University|Yes|Terminated|February 2004|October 2011|Anticipated|May 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|90 Years|No|||August 2009|August 25, 2009|September 27, 2005||No|Administrative|No||https://clinicaltrials.gov/show/NCT00228891||189762|
NCT00229255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-0557|Relation of Obesity With Frequency of Meals (MST 0557)|Relation of Obesity With Frequency of Meals (MST 0557)||Rockefeller University|No|Completed|March 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229255||189734|
NCT00229229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-793-04|Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease|Comparison of a Low Glycemic Load Diet With a Canada Food Guide Diet in the Management of Overweight Patients With Cardiovascular Disease||Queen's University|Yes|Terminated|September 2004|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|80 Years|No|||January 2009|January 27, 2009|September 9, 2005||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00229229||189736|
NCT00229242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-676-03|Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures|Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures||Queen's University|Yes|Completed|November 2003|March 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|15 Years|65 Years|No|||December 2009|December 11, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229242||189735|
NCT00229632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050245|Idebenone to Treat Friedreich's Ataxia|A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia||National Institutes of Health Clinical Center (CC)||Completed|September 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|51|||Both|9 Years|17 Years|No|||May 2015|May 20, 2015|September 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00229632||189707|
NCT00229970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-322|MK0476 Study in Adult Patients With Acute Asthma (0476-322)|MK0476 Phase II/III Placebo Controlled Double Blind Study||Merck Sharp & Dohme Corp.|No|Completed|September 2005|June 2007|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|225|||Both|15 Years|65 Years|No|||May 2015|May 5, 2015|September 28, 2005|Yes|Yes||No|May 22, 2009|https://clinicaltrials.gov/show/NCT00229970||189681|
NCT00230230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03069|Comparison of SCH 486757 to Codeine and Placebo in Subjects With Persistent Postviral Cough (Study P03069AM2)(COMPLETED)|SCH 486757 vs Codeine and Placebo in Subjects With Persistent Postviral Cough||Merck Sharp & Dohme Corp.||Completed|October 2005|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|91|||Both|18 Years|64 Years|No|||September 2015|September 15, 2015|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00230230||189661|
NCT00230542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-220|Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer|Phase II Study of Carboplatin and Pemetrexed in Patients With Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Dana-Farber Cancer Institute|Yes|Completed|September 2005|April 2011|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||January 2015|January 9, 2015|September 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230542||189637|
NCT00230503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA200103-201|Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B|Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B||Valeant Pharmaceuticals International, Inc.||Completed|June 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|18 Years|60 Years|No|||June 2012|June 21, 2012|September 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230503||189640|
NCT00229905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-042|Child With Anomalous Drainage of IVC to Left Atrium|A Case Report of a Child With Anomalous Drainage of the Inferior Vena Cava to the Left Atrium||Children's Healthcare of Atlanta|No|Terminated|March 2005|November 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Male|N/A|N/A|No|Non-Probability Sample|child with anomalous drainage of the inferior vena cava to the left atrium|May 2007|March 14, 2012|September 13, 2005|||sufficient data|No||https://clinicaltrials.gov/show/NCT00229905||189686|
NCT00229918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PST/CSME|PST/Laser v. Laser Alone for CSME|Combined Posterior Sub-Tenon Injection of Triamcinolone Acetonide and Laser Photocoagulation for the Treatment of Clinically Significant Macular Edema||Edward Hines Jr. VA Hospital||Recruiting|September 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Male|25 Years|80 Years|Accepts Healthy Volunteers|||September 2005|September 28, 2005|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229918||189685|
NCT00230178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4978|Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome|Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment With Rasburicase From Day 1 Through 3 Followed by Oral Allopurinol From Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients With Leukemia, Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor Lysis Syndrome||Sanofi||Completed|April 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|280|||Both|18 Years|N/A|No|||January 2010|January 8, 2010|September 28, 2005|Yes|Yes||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00230178||189665|
NCT00230477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-5944-A03|Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT|Efficacy of Adefovir Dipivoxil Versus Adefovir Dipivoxil Plus Lamivudine for the Treatment of Chronic Hepatitis B in Patients With Normal Baseline ALT||University of Washington|No|Completed|April 2003|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|70 Years|No|||November 2007|November 14, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00230477||189642|
NCT00226876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/016|Dreaming During Anaesthesia and Anaesthetic Depth|Dreaming During Anaesthesia and Anaesthetic Depth||Melbourne Health|No|Completed|February 2005|March 2006|Actual|March 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|50 Years|No|Probability Sample|Patients presenting for elective non-cardiac surgery|September 2005|May 28, 2013|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00226876||189900|
NCT00227136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-HTPSVU|Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion|Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion||University of Western Ontario, Canada||Terminated|May 2005|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 11, 2006|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00227136||189880|
NCT00227435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-08A-001|Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C|A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C||Merck Sharp & Dohme Corp.||Completed|February 2003|July 2004|Actual|July 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||August 2015|August 19, 2015|September 26, 2005||||||https://clinicaltrials.gov/show/NCT00227435||189858|
NCT00213928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-050|Horse Chestnut Seed Extract for Lymphedema|A Single-blind, Randomized Trial of Horse Chestnut Seed Extract for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors||University of Wisconsin, Madison|No|Completed|May 2002|September 2008|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|56|||Female|17 Years|N/A|No|||July 2011|May 29, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00213928||190872|
NCT00214318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2005-0006|Beta-2 Polymorphisms and Beta Receptor Selectivity|The Effects of ß2 Polymorphisms on Beta Selectivity After ß-adrenergic Blockade in Patients With Heart Failure||University of Wisconsin, Madison|No|Completed|January 2005|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00214318||190843|
NCT00214851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA002|The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria|The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria||Nova Scotia Health Authority|No|Completed|September 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||May 2008|May 30, 2008|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00214851||190805|
NCT00215137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013150|Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder|Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder||Duke University|No|Completed|October 2004|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||August 2013|July 14, 2014|September 20, 2005|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT00215137||190783|
NCT00215124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5225|A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction|Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction||The Cleveland Clinic|Yes|Completed||February 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2008|September 17, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00215124||190784|
NCT00215358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-048|Study in Patients With Asthma|||Dey||Completed|July 2002|December 2005|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|12 Years|70 Years|No|||February 2008|November 10, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215358||190766|
NCT00215397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-053|Study in Patients With Asthma|||Dey||Completed||December 2005|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|5 Years|70 Years|No|||February 2008|November 10, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215397||190763|
NCT00216554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005068|The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania|A Multicenter, Open-Label Study to Evaluate Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania||Janssen Korea, Ltd., Korea||Completed|September 2004|March 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|118|||Both|18 Years|65 Years|No|||January 2011|January 20, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216554||190677|
NCT00228904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-66 NEU2|Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes|Effects of Pulsatile IV Insulin Delivery on Peripheral Diabetic Neuropathy||Florida Atlantic University|Yes|Terminated|February 2005|October 2011|Anticipated|May 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|90 Years|No|||August 2009|August 25, 2009|September 27, 2005||No|Administrative|No||https://clinicaltrials.gov/show/NCT00228904||189761|
NCT00229996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD044870|Medical Treatment of Endometriosis-Associated Pelvic Pain|Oral Contraceptives Versus Depot-Leuprolide Taken After Surgery for Endometriosis-Associated Pelvic Pain||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 2004|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|194|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229996||189679|
NCT00229645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C00017|A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI’s, and SNRI’s Treatment in Major Depression With Anxiety|A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms||Dr Alexander McIntyre Inc.||Completed|November 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2006|February 1, 2006|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229645||189706|
NCT00229983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-R01DA014553|Medical Office Intervention for Adolescent Drug Use|Medical Office Intervention for Adolescent Drug Use||Children's Hospital Boston|Yes|Completed|June 2004|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|12 Years|21 Years|No|||February 2011|February 18, 2011|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00229983||189680|
NCT00230217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5339|Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy|Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease||Sanofi||Completed|March 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|94|||Both|N/A|N/A|No|||March 2009|March 27, 2009|September 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230217||189662|
NCT00230828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.3.005|Patient-reported Outcomes in the Treatment of Schizophrenia|Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials||Solvay Pharmaceuticals||Completed|May 2005|||January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||September 2007|September 11, 2013|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00230828||189615|
NCT00230841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020010158|Comparing Different Ways of Delivering Humidity to Children With Croup|Efficacy of Optimal Versus 'Traditional' Delivery of Humidity in Children With Croup||The Hospital for Sick Children||Completed|September 2001|April 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||129|||Both|3 Months|10 Years|No|||July 2013|July 31, 2013|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230841||189614|
NCT00230204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3868-AA-CTIL|Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis|Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.||Sheba Medical Center||Recruiting|September 2005|April 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2006|February 15, 2006|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230204||189663|
NCT00230516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00080|Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects|A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects on Days 1 and 5 of Intravenous Treatment||AstraZeneca||Completed|September 2005|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label||||100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|September 28, 2005||||||https://clinicaltrials.gov/show/NCT00230516||189639|
NCT00230763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641040|Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure|Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension|PREDICOM|Pfizer|No|Completed|September 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|396|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230763||189620|
NCT00230776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081077|A Controlled Pregabalin Trial In Fibromyalgia|A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia||Pfizer||Completed|October 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||740|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|September 29, 2005||||||https://clinicaltrials.gov/show/NCT00230776||189619|
NCT00226369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X04-01-007R|Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery|Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy/Safety of CY-1503 (Cylexin) in Prevention of Reperfusion Injury in Neonates/Infants Undergoing Hypothermic Cardiopulmonary Bypass||Children's Hospital Boston||Completed|December 1997|June 2001||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||242|||Both|N/A|45 Days|No|||September 2005|February 11, 2010|September 21, 2005||||||https://clinicaltrials.gov/show/NCT00226369||189939|
NCT00226382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pegasys Study|Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment|Treatment With Peginterferon Alfa-2a (40 KD) (PEGASYS®) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment. A Pilot Study.||Chinese University of Hong Kong|No|Completed|January 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|70 Years|No|||October 2008|June 10, 2010|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226382||189938|
NCT00226668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI 0302|XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema|A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma||Celtic Pharma Development Services|Yes|Withdrawn|January 2006|January 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2007|December 27, 2007|September 23, 2005|Yes|Yes|Alternate study projected to assess imaging endpoints versus clinical endpoints.|No||https://clinicaltrials.gov/show/NCT00226668||189916|
NCT00226889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACTNR.2004-000650-23|Treatment of Early Systemic Sclerosis by Bosentan||TRANOS|Rikshospitalet University Hospital||Terminated|January 2005|June 2009||January 2009||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2006|June 11, 2009|September 23, 2005|||failure of recruiting a sufficient number of patients|No||https://clinicaltrials.gov/show/NCT00226889||189899|
NCT00227149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO 4406|Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C|Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C Infection and a Former (Peg)Interferon Alfa-2b-Based Therapy||University of Wuerzburg|No|Completed|July 2005|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|||Both|18 Years|65 Years|No|Probability Sample|HCV outpatients (University Hospital)|February 2009|February 3, 2009|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00227149||189879|
NCT00214331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-524|Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy|Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy||University of Wisconsin, Madison|Yes|Recruiting|April 2003|April 2011|Anticipated|April 2011|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who are prescribed antibiotics as part of their clinical care|July 2010|July 15, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00214331||190842|
NCT00214604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560C00071|Type III Dysbetalipoproteinemia|An 18-week, Randomized, Multicenter, Phase 3b, Double-blind, Crossover Study, Followed by an 18-week Open-Label Period to Evaluate the Efficacy & Safety of the Lipid-Regulating Agents, Rosuvastatin & Pravastatin in the Treatment of Subjects With Dysbetalipoproteinemia (Frederickson Type III Hyperlipoproteinemia)||AstraZeneca||Completed|February 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|September 21, 2005||||||https://clinicaltrials.gov/show/NCT00214604||190823|
NCT00215150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012882|Geodon for the Treatment of Refractory Social Anxiety Disorder|Ziprasidone for the Treatment of Refractory Social Anxiety Disorder|SAD|Duke University|No|Completed|November 2004|July 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|65 Years|No|||April 2013|October 23, 2014|September 20, 2005|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00215150||190782|
NCT00215449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-059|Study in Patients With COPD|||Dey||Completed||April 2006|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||690|||Both|40 Years|N/A|No|||January 2009|November 10, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215449||190759|
NCT00215462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-012|Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma|A Phase II Study of Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma||Dana-Farber Cancer Institute|Yes|Completed|June 2000|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215462||190758|
NCT00215410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-055|Study in Patients With Asthma|||Dey||Completed||October 2005|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|5 Years|12 Years|No|||February 2008|November 10, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215410||190762|
NCT00215423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-057|Study in Patients With COPD|||Dey||Completed||September 2005|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||49|||Both|5 Years|70 Years|No|||August 2008|November 10, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215423||190761|
NCT00215436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-065|A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD|A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease||Dey||Completed|March 2005|September 2006|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||345|||Both|40 Years|N/A|No|||April 2008|November 9, 2010|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00215436||190760|
NCT00217009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2435-04|Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.|A Randomized Controlled Trial of Narrowband Ultraviolet B vs Topical Psoralen Plus Ultraviolet A Photochemotherapy for Hand and Foot Dermatoses||Mayo Clinic||Terminated|March 2005|November 2008|Actual|November 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 14, 2005||No|Unfortunately we had unforeseen difficulty recruiting to this study. Therefore we have decided    to halt the study and not publish the results.|No||https://clinicaltrials.gov/show/NCT00217009||190642|
NCT00228917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103812|Safety Study of Tritanrix™-HepB/Hib-MenAC, Tritanrix™-HepB/Hiberix™, and Mencevax™ ACWY Vaccines in Children|Assess Reactogenicity & Safety of a Booster of Either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) & a Dose of Mencevax™ ACWY at 24-30 Mths (Open Label)||GlaxoSmithKline||Completed|June 2005|September 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Actual|798|||Both|427 Days|577 Days|Accepts Healthy Volunteers|||October 2011|October 27, 2011|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228917||189760|
NCT00230022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14621-1|Pilot Clinical Trial of Computer-based Motivational Intervention - 1|Pilot Clinical Trial of Computer-based Motivational Intervention||Wayne State University|No|Completed|October 2004|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|September 29, 2005||No||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00230022||189677|Small sample size in the pilot clinical trial. Because of this lack of power, a statistically significant difference between groups was not demonstrated, and the 95% Confidence Interval (CI) for the effect size estimate included zero.
NCT00230035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT SCSLE-01|Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)|A Randomized, Open Label, Phase II Multicenter Study of Non-Myeloablative Autologous Transplantation With Auto-CD34+HPC Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Systemic Lupus Erythematosus||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||January 2013|January 31, 2013|September 28, 2005|No|Yes|Recommended by DSMB due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00230035||189676|
NCT00230256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0003|Treatment Outcomes and Quality of Life After IMRT Treatments of Head and Neck Cancers|Treatment Outcomes and Quality of Life After IMRT Treatments of Head and Neck Cancers||Stanford University|Yes|Completed|April 2003|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who complete radiation therapy for H&N cancers at Stanford University|July 2012|July 11, 2012|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230256||189659|
NCT00230243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02387|Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)|A Retrospective Study to Establish an Historical Database on the Efficacy of Standard Antifungal Therapy in Patients With Invasive Fungal Infections||Merck Sharp & Dohme Corp.||Completed|March 1997|September 2002|Actual|September 2002|Actual|N/A|Observational|Time Perspective: Retrospective||||330|||Both|13 Years|N/A|No|||September 2015|September 9, 2015|September 28, 2005||||||https://clinicaltrials.gov/show/NCT00230243||189660|
NCT00230555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-4-2388|The MOM Program at the Children's Hospital of Philadelphia|The MOM Program at the Children's Hospital of Philadelphia||Children's Hospital of Philadelphia||Completed|July 2001|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|N/A|3 Days|Accepts Healthy Volunteers|||April 2005|September 29, 2005|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230555||189636|
NCT00230568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-413|EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)|A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease||Eisai Inc.||Completed|December 2005|December 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|50 Years|N/A|No|||March 2011|March 31, 2011|September 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230568||189635|
NCT00230854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IET-202|Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin|An Open Label, Dose Escalation Study of EMZ702 in Combination With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Non-responsive to Prior Therapy With Pegylated Interferon and Ribavirin||Transition Therapeutics||Completed|August 2005|July 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|65 Years|No|||June 2013|June 4, 2013|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230854||189613|
NCT00230802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK44128 (completed)|Thyroid Hormone Dose Adjustment in Pregnancy|Thyroid Hormone Dose Adjustments During Pregnancy in Women With Primary Hypothyroidism.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Recruiting|July 2005|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Female|N/A|N/A|No|||February 2011|February 9, 2011|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230802||189617|
NCT00230815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24785|A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction|A Phase IIIb, Prospective, Multicenter Trial to Evaluate Subject Satisfaction With Follitropin Alfa Injection Applied by Pen Device Compared With Other Injectable Gonadotropins in Oligoanovulatory Infertile Women Undergoing Ovulation Induction||EMD Serono||Completed|July 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|18 Years|40 Years|No|||November 2013|November 27, 2013|September 29, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00230815||189616|
NCT00230529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003124|A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis|A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE�) Induction Therapy in Patients With Plaque-type Psoriasis||Centocor, Inc.||Completed||January 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|249|||Both|18 Years|N/A|No|||August 2010|June 8, 2011|September 29, 2005||||||https://clinicaltrials.gov/show/NCT00230529||189638|
NCT00230789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121146|Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.|A Multicenter, Multiphase, Single Arm, Open Label Study To Evaluate The Effects Of Tolterodine ER In Conjunction With Behavioral Intervention On Subject Satisfaction And Over- Active Bladder Symptoms (Urgency Urinary Incontinence (UUI), Urgency, Frequency) In Overactive Bladder Subjects Who Were Dissatisfied With Their Most Recent Antimuscarinic OAB Medication Therapy.||Pfizer||Completed|October 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||417|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|September 29, 2005||||||https://clinicaltrials.gov/show/NCT00230789||189618|
NCT00226395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3203-009|Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain|Randomized, Double-Blind, Placebo- and Active-Control, Single- and Multiple-Dose Evaluation of the Analgesic Efficacy and Safety of Oxymorphone Immediate Release (IR) Tablets in Patients With Moderate/Severe Pain Following Abdominal Surgery||Endo Pharmaceuticals||Completed|September 2004|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|September 23, 2005||Yes||||https://clinicaltrials.gov/show/NCT00226395||189937|
NCT00226681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4766|Nurses Helping Sudden Cardiac Arrest Survivors Recover After Getting An Implantable Cardioverter Defibrillator (ICD)|Nursing Interventions Following Sudden Cardiac Arrest||National Institute of Nursing Research (NINR)|Yes|Completed|September 1999|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|150|||Both|12 Years|90 Years|No|||September 2008|September 9, 2008|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226681||189915|
NCT00227162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (0103-661)|Pilot Study of Changing Exercise and Physical Activity Behavior in Asthma Patients|Pilot Study of Changing Exercise and Physical Activity Behavior in Asthma Patients||Weill Medical College of Cornell University|Yes|Completed|February 2004|May 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|40|||Both|18 Years|N/A|No|||April 2008|April 9, 2008|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00227162||189878|
NCT00227474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441167|S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission|S0348: A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer||Southwest Oncology Group|Yes|Withdrawn||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|September 26, 2005|Yes|Yes|SWOG has decided to not pursue this trial|No||https://clinicaltrials.gov/show/NCT00227474||189855|
NCT00214864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRN-003|A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer|A Pilot Study of Taxotere (Docetaxel) Combined With Xeloda (Capecitabine) in the Treatment of Metastatic Breast Cancer||Cancer Research Network|Yes|Completed|December 2002|||January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|75 Years|No|||February 2012|February 13, 2012|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00214864||190804|
NCT00215800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP 516|The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome|A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME)||Hemispherx Biopharma|No|Completed|December 1998|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||234|||Both|18 Years|60 Years|No|||April 2013|April 16, 2013|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215800||190734|
NCT00215813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP 511|Ampligen in Chronic Fatigue Syndrome|An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN®) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)||Hemispherx Biopharma|No|Recruiting|March 1997|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215813||190733|
NCT00216073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG BRE03-61|Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer|A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients With HER-2 Positive Metastatic Breast Cancer: Hoosier Oncology Group BRE03-61||Hoosier Cancer Research Network|Yes|Terminated|March 2004|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||April 2011|April 29, 2011|September 9, 2005||No|Lack of patient accrual|No||https://clinicaltrials.gov/show/NCT00216073||190713|
NCT00215787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0165|Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease|Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease||Head and Neck Surgery Associates|Yes|Completed|September 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 21, 2010|September 15, 2005||No||No|August 10, 2010|https://clinicaltrials.gov/show/NCT00215787||190735|
NCT00216281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-47|Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia|Correlation of Phenotype, Genotype and Clinical Efficacy/Toxicity of Clozapine Augmented by Atomoxetine for Treatment Refractory Schizophrenia (CAPG Study)||Indiana University|No|Terminated|September 2005|September 2008|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|65 Years|No|||March 2013|March 25, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00216281||190697|
NCT00217022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1132-03|Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis|A Randomized, Double-Blind, Placebo Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis||Mayo Clinic|No|Terminated|June 2003|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|September 14, 2005|Yes|Yes|Study closed early, because of low enrollment.|No|July 15, 2011|https://clinicaltrials.gov/show/NCT00217022||190641|Study closed early, because of low enrollment. Primary physician for patients with lymphocytic colitis would prescribe Budesonide off label for them. Subjects not interested in placebo trial.
NCT00229658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-161|An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes|A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace||AstraZeneca|No|Completed|September 2005|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1297|||Both|18 Years|N/A|No|Non-Probability Sample|cross-section of clinical practice settings|February 2015|March 5, 2015|September 28, 2005|No|Yes||No|May 5, 2009|https://clinicaltrials.gov/show/NCT00229658||189705|
NCT00229684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00040|ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)|A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus||AstraZeneca||Terminated|September 2004|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||100|||Both|45 Years|N/A|No|||August 2011|August 29, 2011|September 28, 2005|||The development program has been terminated|||https://clinicaltrials.gov/show/NCT00229684||189703|
NCT00230269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0005|The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers|The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers||Stanford University||Completed|May 2003|November 2007|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are scheduled to receive radiation therapy for head and neck cancer at        Stanford.|July 2012|July 10, 2012|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230269||189658|
NCT00230581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP225-04-006|8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS|A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea||Dynogen Pharmaceuticals||Completed|September 2005|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|88|||Female|18 Years|65 Years|No|||October 2007|October 12, 2007|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230581||189634|
NCT00230282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-13053|Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia|A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia||Stanford University|Yes|Completed|July 2004|October 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|September 28, 2005|Yes|Yes||No|August 27, 2014|https://clinicaltrials.gov/show/NCT00230282||189657|
NCT00230594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026, CLN 10.3.26|Desmopressin Response in the Young|Desmopressin Response in the Young: A Double-blind, Randomised, Placebo-controlled, Dose-titration Study With Three Different Doses (120 Mcg, 240 Mcg and 360 Mcg) of Desmopressin Administered as a New Melt Tablet in Children and Adolescents With Primary Nocturnal Enuresis (PNE).|DRY|Ferring Pharmaceuticals|No|Completed|July 2004|February 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|5 Years|16 Years|No|||May 2011|May 18, 2011|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230594||189633|
NCT00226421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202-032|Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain|An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Experienced Patients With Chronic Low Back Pain||Endo Pharmaceuticals||Completed|October 2004|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|September 23, 2005||||||https://clinicaltrials.gov/show/NCT00226421||189935|
NCT00226408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-ADJ-5|Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon|Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy||Dermatologic Cooperative Oncology Group||Recruiting|November 2003|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|70 Years|No|||September 2005|June 20, 2006|September 25, 2005||||No||https://clinicaltrials.gov/show/NCT00226408||189936|
NCT00226694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAANH013307|Alcohol and Gender Effects on Stress Circuit Function|Alcohol and Gender Effects on Stress Circuit Function||University of Cincinnati||Completed|September 2003|August 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|96|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226694||189914|
NCT00226902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interactedd|Vascular Reactivity in Kidney Disease Patients|Integrated Studies in Vascular Reactivity and Anaemia Correction Therapy in Endstage Kidney Disease Patients||Melbourne Health|No|Completed|September 2006|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|80 Years|No|||May 2015|May 4, 2015|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00226902||189898|
NCT00227487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPP1|Intestinal Inflammation and Carbohydrate Digestion in Autistic Children|The Evaluation of Intestinal Inflammation and Carbohydrate Digestion in Children With Autistic Spectrum Disorders||Massachusetts General Hospital|No|Active, not recruiting|October 2005|December 2012|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|100|Samples Without DNA|stool, urine|Both|18 Months|17 Years|No|Non-Probability Sample|Subjects with and without autism who have documented gastrointestinal symptoms requiring        endoscopy and colonoscopy with biopsy for the standard medical treatment of their        gastrointestinal symptoms|April 2012|April 25, 2012|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00227487||189854|
NCT00227760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-01072|Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery|A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC)||National Cancer Institute (NCI)||Completed|December 2005|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|19 Years|N/A|No|||December 2013|January 29, 2016|September 26, 2005|Yes|Yes||No|January 29, 2016|https://clinicaltrials.gov/show/NCT00227760||189837|
NCT00215501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-042|Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies|A Phase I Trial of Capecitabine or Continuous Infusion 5-Fluorouracil in Combination With Weekly Irinotecan and Cisplatin in Patients With Advanced Solid Tumor Malignancies||Dana-Farber Cancer Institute||Active, not recruiting|November 2001|December 2014|Anticipated|September 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|September 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215501||190757|
NCT00216320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WalkAide Trials|Efficacy of the WalkAide and AFOs for CVA|A Three-Arm, Randomized Crossover Study Comparing the Innovative Neurotronics WalkAide™ System to Ankle-Foot Orthosis [AFO]||Innovative Neurotronics|No|Completed|September 2005|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|September 19, 2005||No||No|April 18, 2013|https://clinicaltrials.gov/show/NCT00216320||190695|
NCT00216567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005077|Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy|A Randomized, Open Label, Comparative, Multi-center Clinical Trial to Determine the Efficacy and Safety of Topiramate Comparing With Carbamazepine in Benign Rolandic Epilepsy.||Janssen Korea, Ltd., Korea||Completed|December 2002|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|114|||Both|5 Years|15 Years|No|||January 2011|January 31, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216567||190676|
NCT00216294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0407-32|Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder|An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD)||Indiana University||Completed|February 2005|April 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||16|||Both|18 Years|40 Years|No|||April 2006|July 14, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00216294||190696|
NCT00229671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P01HS011534-03|Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics|Ambulatory Medication Errors and Adverse Drug Events (ADEs) in Pediatrics||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|September 2001|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||30000|||Both|N/A|21 Years|Accepts Healthy Volunteers|||September 2005|September 28, 2005|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229671||189704|
NCT00230009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00516-3|Brief Intervention in At-Risk First-time Mothers|Brief Intervention in At-Risk First-time Mothers||Wayne State University|No|Completed|April 2004|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|September 29, 2005||No||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00230009||189678|This study is limited by the relatively small sample size and the restriction to low-income, urban women, thus limiting generalizability to other populations.
NCT00229697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0225|Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study|A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours||AstraZeneca||Completed|October 2003|June 2015|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|317|||Female|18 Years|130 Years|No|||October 2015|October 2, 2015|September 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229697||189702|
NCT00230048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14621-3|Interactive Motivational Media for Perinatal Drug Abuse - 3|Interactive Motivational Media for Perinatal Drug Abuse||Wayne State University|No|Completed|September 2001|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|September 29, 2005||No||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00230048||189675|Generalizability limited by relatively small sample, attrition of 29%, and restriction to low-income mothers. Second, power limitations prevented verification of effects on the dichotomous outcomes, despite effects in the small-moderate range.
NCT00230295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0010|Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast|Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast||Stanford University||Completed|February 2003|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2010|July 23, 2010|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230295||189656|
NCT00230308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0008|Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer|Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer||Stanford University|Yes|Recruiting|April 2002|December 2024|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|At the time of biospy or surgery, a small amount of tumor tissue (approximately 1 cc) will      be taken from the main tumor specimen and stored until analysis.|Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing surgery at Stanford University for head and neck cancer.|March 2015|March 30, 2015|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230308||189655|
NCT00230607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL02603|A Study of the Effects of Fabrazyme (Agalsidase Beta) on Mother's Lactation and on the Growth, Development and Immunologic Response of Their Infants|A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants||Sanofi|No|Recruiting|August 2006|January 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|10|||Both|N/A|N/A|No|||October 2015|October 27, 2015|September 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230607||189632|
NCT00226434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 1295 CAMELIA|Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA)|Early vs Late Introduction of Antiretroviral Therapy in Naive HIV-infected Patients With Tuberculosis in Cambodia||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|January 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|661|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|September 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226434||189934|
NCT00226707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981M2301|Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis|A 6-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Pimecrolimus Cream 1% in Patients With Mild-to-Moderate Chronic Hand Dermatitis Followed by a 6-Week Open-Label Phase to Assess the Safety of Pimecrolimus Cream 1%||Novartis||Completed|July 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||652|||Both|18 Years|N/A||||February 2008|February 13, 2008|September 26, 2005||||||https://clinicaltrials.gov/show/NCT00226707||189913|
NCT00226915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGOG3016|Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma|Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma||Japanese Gynecologic Oncology Group|Yes|Active, not recruiting|April 2003|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|637|||Female|20 Years|N/A|No|||April 2012|April 2, 2012|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226915||189897|
NCT00227175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (0103-659)|Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study|Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study||Weill Medical College of Cornell University|No|Completed|April 2003|September 2003||||N/A|Observational|Time Perspective: Prospective||||60|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00227175||189877|
NCT00227188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887-101317|Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.|Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain||Pfizer|No|Completed|May 2003|December 2005|Actual|December 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|408|Samples Without DNA|Samples without DNA|Both|N/A|5 Years|No|Non-Probability Sample|All public and private hospitals with a pediatric department belonging to one of the two        autonomous communities.|November 2012|November 28, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00227188||189876|
NCT00227500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAVA|Pravastatin for Hyperlipidaemia in HIV.|A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV||Kirby Institute||Completed|July 2001|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||June 2006|June 8, 2006|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00227500||189853|
NCT00227773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446076|Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors|Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors||Eastern Cooperative Oncology Group||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|120 Years|No|||October 2015|October 6, 2015|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227773||189836|
NCT00215826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDO-102|Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers|A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS||Hemispherx Biopharma|No|Completed|November 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215826||190732|
NCT00215839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRN 004|HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy|A Multi-Center, Randomized, Open-Label, Phase IIIb Study Investigating the Safety and Efficacy of Peginterferon a-2a Plus Ribavirin for the Treatment of Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy||Hepatitis Resource Network||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2005|October 24, 2005|September 20, 2005||||||https://clinicaltrials.gov/show/NCT00215839||190731|
NCT00216333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUATLD CT Study C|Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis|International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis||International Union Against Tuberculosis and Lung Diseases||Recruiting|December 2003|June 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1500|||Both|18 Years|65 Years|No|||September 2006|September 12, 2006|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00216333||190694|
NCT00216762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00000857|Safety Study of Rituximab (Rituxan®) in Chronic Urticaria|Phase I/II Open Label Evaluation of the Safety and Efficacy of Rituximab in Patients With Chronic Urticaria (The Rituximab Urticaria Study - "RUSTY")||Johns Hopkins University|Yes|Terminated|January 2006|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||August 2015|August 31, 2015|September 16, 2005|Yes|Yes|Full Clinical Hold|No||https://clinicaltrials.gov/show/NCT00216762||190661|
NCT00216775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H16-697|Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C|||Kyoto University||Completed|December 2004|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|20 Years|70 Years|No|Probability Sample|patients with chronic hepatitis C|September 2015|September 1, 2015|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00216775||190660|
NCT00216788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSESOM0388|The Effect of Nexium on Transmucosal Esophageal Leak|The Effect of Proton Pump Inhibitors on Transmucosal Esophageal Leak||Main Line Health||Not yet recruiting|January 2006|January 2006|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||November 2005|March 15, 2010|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00216788||190659|
NCT00229359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-99-1813-JZ-CTIL|Characteristics of Post-Traumatic Stress Disorder (PTSD) and Non-PTSD Subjects|Risk Factors for PTSD||Sheba Medical Center||Completed|January 2000|December 2002||||N/A|Observational|N/A|||||||Both|N/A|N/A||||December 2007|December 18, 2007|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229359||189726|
NCT00229372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-02-2732-JZ-CTIL|Prolonged Exposure Versus Treatment as Usual in Chronic Posttraumatic Stress Disorder Combat and Terror Related Patients|||Sheba Medical Center||Completed|November 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Male|18 Years|65 Years|No|||January 2008|January 28, 2008|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00229372||189725|
NCT00229385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-3061-JS-CTIL|Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)|Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)||Sheba Medical Center|No|Completed|January 2006|April 2010|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|45|||Both|18 Years|65 Years|No|||December 2013|December 30, 2013|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00229385||189724|
NCT00229398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-99-1744-JZ-CTIL|Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder|||Sheba Medical Center||Completed|November 1998|December 2004|Actual|December 2004|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|N/A|No|||January 2008|January 28, 2008|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00229398||189723|
NCT00234468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0126|Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC|A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy||AstraZeneca||Terminated|January 2004|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|490|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|October 5, 2005||No|Closed due to insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00234468||189342|
NCT00234481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL844-001|Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia||Exelixis||Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2008|June 2, 2008|October 5, 2005|||Study closed due to slow enrollment|||https://clinicaltrials.gov/show/NCT00234481||189341|
NCT00230061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNO-T-07-102|Hepatitis B Vaccination in HIV-infected Persons|Randomised Open Label Clinical Trial of the Immune Response to Hepatitis B Vaccination in HIV-infected Persons.||Erasmus Medical Center||Completed|April 2004|February 2010|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|No|||June 2010|June 1, 2010|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230061||189674|
NCT00230321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMDS0001|A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)|A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)||Stanford University||Completed|February 2002|January 2008|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|September 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00230321||189654|
NCT00230334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMPD0001|Phase II Gleevec Idiopathic Hypereosinophilic Syndrome|Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)||Stanford University||Withdrawn|June 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||April 2011|April 11, 2011|September 28, 2005|||Withdrawn by PI due to insufficient accrual|||https://clinicaltrials.gov/show/NCT00230334||189653|
NCT00235417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stem cell|Stem Cell Therapy in Chronic Ischemic Heart Failure|||Odense University Hospital||Completed|October 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|N/A|N/A|No|||June 2007|June 7, 2007|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235417||189269|
NCT00235703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS1/CCR820631-01|Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)|Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)||University of Utah||Completed|October 2001|September 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||13000|||Both|N/A|N/A|No|||October 2005|May 4, 2006|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235703||189250|
NCT00230867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-203|Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis|A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical Iontophoretic Application of Acyclovir 5% Cream With an Open Label Conventional Therapy Treatment Arm, and a Blinded Evaluator, for the Treatment of Recurrent Herpes Labialis||Transport Pharmaceuticals||Completed|April 2005|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1800|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2006|June 30, 2006|September 29, 2005||||||https://clinicaltrials.gov/show/NCT00230867||189612|
NCT00226720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000807|Outpatient Versus Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence: The IN/OUT Study|Comparison of Efficacy of an Outpatient vs Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence. A Prospective Randomized Clinical Trial.||Assistance Publique - Hôpitaux de Paris|No|Completed|September 2002|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|500|||Both|18 Years|N/A|No|||April 2007|May 5, 2008|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226720||189912|
NCT00226928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH047226|Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer|Psychosocial Treatment Effects on Cancer Survival||Stanford University|No|Completed||July 2005|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Female|18 Years|N/A|No|||December 2013|December 2, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00226928||189896|
NCT00226941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR0001|Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer|A Phase I/II Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgical Resection for Locally-Advanced Rectal Cancer||Stanford University||Completed|June 2004|February 2009|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|N/A|No|||July 2010|November 6, 2012|September 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226941||189895|
NCT00227201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0301005948|The Association Between the Use of Complementary and Alternative Medicine and Medication Adherence in Hypertensive African-Americans|The Association Between the Use of Complementary and Alternative Medicine and Medication Adherence in Hypertensive African-Americans||Weill Medical College of Cornell University||Completed|June 2003|May 2005||||N/A|Observational|N/A||||60|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00227201||189875|
NCT00227214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101539|Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.|Prevalence of Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2004|December 2006|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|160|||Both|N/A|14 Years|No|Non-Probability Sample|Children from 0 up to 14 years of age with a diagnosis of confirmed or probable        pneumococcal meningitis or with a diagnosis of suspected bacterial meningitis without        bacterial or viral isolation.|June 2010|June 24, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00227214||189874|
NCT00227227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101540|Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis|Observational Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2004|June 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|750|||Both|18 Years|N/A|No|||December 2007|December 7, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00227227||189873|
NCT00227240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101789|Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis|Observational Study With Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis||Pfizer||Completed|April 2005|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|753|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinical and community sample|March 2012|March 20, 2012|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00227240||189872|
NCT00227253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chromosome 18|Chromosome 18 Clinical Research Center|The Chromosome 18 Clinical Research Center|Chromosome18|The University of Texas Health Science Center at San Antonio|No|Recruiting|September 1993|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|N/A||1|Anticipated|1000|Samples With DNA|blood specimens are collected from study participant and both biological parents if      available and are processed for DNA and to establish cell lines|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Must have a confirmed diagnosis of Chromosome 18 or be the parent/guardian of a child with        Chromosome 18          -  Subject must be at least one year of age to participate in the clinical examination             aspect of the study (due to issues of venous access and blood volume required to             complete studies)          -  General health status: good|October 2015|October 27, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00227253||189871|
NCT00227513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00097|Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Bortezomib in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|July 2005|||June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||April 2013|February 21, 2014|September 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00227513||189852|
NCT00216112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GYN 03-62|Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer|Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62||Hoosier Cancer Research Network|Yes|Completed|December 2003|July 2007|Actual|October 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00216112||190710|
NCT00216086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GI03-53|Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer|A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53||Hoosier Cancer Research Network|Yes|Terminated|January 2005|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|September 9, 2005||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00216086||190712|
NCT00216099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GU03-67|Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer|A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67||Hoosier Cancer Research Network|Yes|Completed|February 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|43|||Male|18 Years|N/A|No|||April 2011|April 27, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00216099||190711|
NCT00216593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003940|Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study|Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.||Janssen Pharmaceutica N.V., Belgium||Completed|December 2003|March 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|415|||Both|40 Years|N/A|No|||April 2010|June 7, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216593||190674|
NCT00216580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003358|A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis|An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis||Janssen Pharmaceutica N.V., Belgium|No|Completed|February 2004|December 2006|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|16 Years|45 Years|No|||March 2013|March 22, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00216580||190675|
NCT00216372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-54-52030-156 (408)|Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis|Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients.||Ipsen||Completed|September 2003|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00216372||190691|
NCT00216606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003928|The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine|A Randomized Double-Blind Placebo Controlled Trial to Investigate the Efficacy and Tolerability of Topiramate in the Prophylaxis of Chronic Migraine||Janssen Pharmaceutica N.V., Belgium||Completed|December 2003|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|59|||Both|18 Years|65 Years|No|||January 2011|January 31, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216606||190673|
NCT00229411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3710-AN-CTIL|Simulation Training as a Tool for Teamwork Improvement in Multidisciplinary Intensive Care Team|Experimental Like Observational Study of Teamwork Improvement in Multidisciplinary Intensive Care Team Before and After Simulation Training.||Sheba Medical Center||Withdrawn|January 2006|May 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2007|January 23, 2007|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00229411||189722|
NCT00234494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GU04-75|Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer|A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75||Hoosier Cancer Research Network|Yes|Completed|November 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 5, 2005||No||No|January 19, 2016|https://clinicaltrials.gov/show/NCT00234494||189340|
NCT00234507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-47-52120-706|Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm|Phase II, Multi-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection, of Three Doses of Dysport (40 Units/Eye, 80 Units/Eye, and 120 Units/Eye) for the Treatment of Benign Essential Blepharospasm||Ipsen||Completed|January 2003|May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2006|April 12, 2006|October 5, 2005||||||https://clinicaltrials.gov/show/NCT00234507||189339|
NCT00234806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8858|Health-e-Access Telemedicine in Primary Pediatric Care|Health-e-Access: A Study of Telemedicine in Primary Pediatric Care in Rochester, NY||University of Rochester||Completed|December 2000|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2000|||Both|6 Weeks|18 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234806||189316|
NCT00235131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE04-02|The Study to Compare the Cordis SMART™ Stent System With the Bard® Luminexx™ Stent|A Clinical Investigation of the Cordis S.M.A.R.T. ™ CONTROL ™ Nitinol Stent System Versus the Bard® Luminexx™ 6F Vascular Stent for the Treatment of TASC C & D Superficial Femoral Artery Long Lesions|SUPER SL|Cordis Corporation|Yes|Completed|May 2005|May 2009|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|80 Years|No|||February 2010|February 3, 2010|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235131||189291|
NCT00235443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0745|A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy|A Multi-Center, Open-Label, Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy||UCB Pharma|No|Completed|September 2004|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|451|||Both|32 Years|81 Years|No|||September 2011|September 19, 2014|October 6, 2005|Yes|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00235443||189268|
NCT00230880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR# 04038166|The Young Woman's Reach Project: Trial of an Intervention to Impact Contraceptive Behavior, Unintended Pregnancy, and Sexually Transmitted Infections (STIs) Among Adolescent Females|Randomized Trial of an Intervention to Impact Contraceptive Behavior, Unintended Pregnancy, and STIs Among Adolescent Females Receiving Family Planning Clinic Services|REACH|University of California, San Francisco|No|Completed|July 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|800|||Female|14 Years|18 Years|No|||December 2012|December 3, 2012|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230880||189611|
NCT00226473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADO-MM-PAL8|Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma|Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma||Dermatologic Cooperative Oncology Group||Recruiting|September 2001|September 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|75 Years|No|||September 2005|June 20, 2006|September 25, 2005||||No||https://clinicaltrials.gov/show/NCT00226473||189931|
NCT00226447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03227|Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients|A Study on the Viral Kinetics of Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in HBeAg Positive Chronic Hepatitis B||Chinese University of Hong Kong||Completed|December 2002|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||30|||Both|18 Years|65 Years|No|||October 2008|October 23, 2008|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226447||189933|
NCT00226460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD96-1101|Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.|||Sanofi||Completed|August 1997|January 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|70 Years|No|||March 2015|March 17, 2015|September 23, 2005||||||https://clinicaltrials.gov/show/NCT00226460||189932|
NCT00226733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BypassRoros1|Training Intensity After Coronary Bypass Grafting|Training Intensity After Coronary Bypass Grafting||Norwegian University of Science and Technology|No|Terminated|March 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||60|||Both|N/A|N/A|No|||April 2008|May 17, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00226733||189911|
NCT00226954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0001|Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer|Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer||Stanford University||Completed|March 2003|February 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||July 2009|July 27, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00226954||189894|
NCT00226967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0006|Stress, Diurnal Cortisol, and Breast Cancer Survival|Stress, Diurnal Cortisol, and Breast Cancer Survival||Stanford University|Yes|Active, not recruiting|September 2002|December 2012|Anticipated|November 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|115|Samples Without DNA|Saliva|Female|35 Years|N/A|No|Non-Probability Sample|patients with recurrent or metastatic breast cancer|November 2012|November 9, 2012|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00226967||189893|
NCT00232362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L05-115|Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus|Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus||Texas Tech University Health Sciences Center||Withdrawn|June 2007|June 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|September 30, 2005|||This study was not conducted as the Principal Investigator left the institution|No||https://clinicaltrials.gov/show/NCT00232362||189500|
NCT00232609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02254, 0410155|Development of the GameCycle Exercise System: Phase II|Development of the GameCycle Exercise System: Phase II||VA Pittsburgh Healthcare System|No|Completed|August 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00232609||189481|
NCT00227526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC02-053|Enhancing Outcomes After Colon Surgery|Enhancing Outcomes After Colon Surgery: Role of Prehabilitation Facilitating the Recovery Process.||McGill University|No|Completed|February 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2010|September 2, 2010|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00227526||189851|
NCT00215553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL4-ARDS-04|KL₄Surfactant Treatment in Patients With ARDS|A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of SURFAXIN® (Lucinactant) Delivered Via Bronchopulmonary Segmental Lavage to Standard of Care in Patients With Acute Respiratory Distress Syndrome (ARDS).||Discovery Laboratories, Inc.|Yes|Terminated|May 2001|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|124|||Both|16 Years|75 Years|No|||April 2012|April 2, 2012|September 14, 2005|Yes|Yes|Slow enrollment and administrative reasons|No|April 2, 2012|https://clinicaltrials.gov/show/NCT00215553||190753|
NCT00216346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLPM01|Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis|A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis||PATH||Completed|June 2003|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||667|||Both|5 Years|55 Years|No|||October 2014|October 2, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216346||190693|
NCT00216359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radata Fuzeon Cohort|Cohort Study for Patients Using Fuzeon (Enfuvirtide)|The Radata-Fuzeon Cohort - An Observational Cohort-Study in HIV-Infected Patients Using Fuzeon (Enfuvirtide) as Part of Their Antiretroviral Combination Therapy||Institute for Interdisciplinary Infectiology||Active, not recruiting|May 2003|December 2006||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||200|||Both|N/A|N/A|No|||September 2005|October 21, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00216359||190692|
NCT00216125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LUN01-24|Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer|A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24||Hoosier Cancer Research Network|Yes|Completed|February 2002|March 2008|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|243|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|September 12, 2005||No||No|November 23, 2015|https://clinicaltrials.gov/show/NCT00216125||190709|
NCT00216385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA4-CT 2002-10057|A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis|A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis||Institut de Recherche pour le Developpement||Recruiting|January 2005|December 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2070|||Both|18 Years|65 Years|No|||September 2005|September 20, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00216385||190690|
NCT00216619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003931|The Prolonged Use of Topiramate for Preventing Migraine Headaches|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention|PROMPT|Janssen Pharmaceutica N.V., Belgium|No|Completed|November 2003|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|834|||Both|18 Years|80 Years|No|||July 2014|July 1, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00216619||190672|
NCT00234130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUH IRB # LHU 0486|The Effect of Nighttime Dialysis on the Inflammation of Kidney Failure|A Comparison of the Effects of Conventional and Nocturnal Hemodialysis on the Inflammatory Response of Chronic Renal Failure||Rockefeller University|No|Terminated|July 2002|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|October 5, 2005||No|The patient population was not enough to complete enrollment|No||https://clinicaltrials.gov/show/NCT00234130||189366|
NCT00234520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-47-52030-721|A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide|A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide||Ipsen||Completed|May 2003|||||Phase 4|Observational|Time Perspective: Prospective||||200|||Both|18 Years|N/A|No|||June 2008|June 26, 2008|October 5, 2005||||||https://clinicaltrials.gov/show/NCT00234520||189338|
NCT00234533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-79-58035-700|Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq|Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method|OPTIMA|Ipsen|No|Completed|June 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|N/A|18 Years|No|||May 2009|May 14, 2009|October 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00234533||189337|
NCT00234819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-305|Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause|A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogen Combinations for Treatment of Vasomotor Symptoms Associated With Menopause||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2005|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||325|||Female|40 Years|64 Years|No|||December 2007|December 19, 2007|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234819||189315|
NCT00234832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-392|A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients|Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event|SCOUT|Abbott|Yes|Completed|January 2003|November 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|10777|||Both|55 Years|N/A|No|||May 2010|May 6, 2010|September 13, 2005||No||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00234832||189314|Most subjects not indicated for sibutramine (sbt) due to CV disease. Long-term sbt use (6 yrs) regardless of weight loss, is inconsistent with label (limits use to 1-2 yrs & 5% weight loss). Trial lacked true placebo; all received Lead-in Period sbt.
NCT00235144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC00-07|The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.|E-Sirius Study: a European, Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions|E-SIRIUS|Cordis Corporation|Yes|Completed|March 2001|September 2008|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|353|||Both|18 Years|N/A|No|||May 2009|May 8, 2009|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235144||189290|
NCT00235456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETIQ|Supplemental Oxygen Reduces Surgical Infection|Supplemental Perioperative Oxygen Reduces the Risk of Surgical Wound Infection: A Randomized, Double-Blind Trial||Outcomes Research Consortium|Yes|Completed|March 2003|January 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|18 Years|80 Years|No|||August 2007|November 9, 2007|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235456||189267|
NCT00231218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8348|Echinacea, Propolis and Vitamin C for URI Prevention in Preschoolers|the Effectiveness of Echinacea, Propolis and Vitamin C in the Prevention of Respiratory Tract Infections and Gastroenteritis in Preschool Age Children: a Prospective Study||The Cleveland Clinic||Completed|January 2006|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||104|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||December 2006|December 13, 2006|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231218||189587|
NCT00231231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04-5204|Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)|Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)||Cordis Corporation|Yes|Completed|September 2004|November 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1500|||Both|18 Years|80 Years|No|||July 2007|July 19, 2007|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231231||189586|
NCT00231517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01MH17|Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa|||Institute of Child Health||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|4 Years|18 Years|No|||October 2005|October 11, 2006|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231517||189565|
NCT00226486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05059|Examination and Treatment of Elderly After a Fall|Examination and Treatment of Elderly After a Fall- an Analysis in a Medical Technology Evaluation Perspective||Glostrup University Hospital, Copenhagen||Completed|September 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|392|||Both|65 Years|N/A|No|||August 2008|August 20, 2008|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226486||189930|
NCT00231751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIBS|The Malmö International Brother Study (MIBS)|The Malmö International Brother Study (MIBS)||Skane University Hospital||Completed|November 2002|June 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Male|N/A|N/A|No|||September 2005|September 30, 2005|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231751||189547|
NCT00226746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYM # 179; AM-05|Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer|A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer||New York Methodist Hospital||Recruiting|March 2003|December 2010||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||September 2006|March 20, 2007|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226746||189910|
NCT00226980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENAL0001|A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma|A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma||Stanford University||Completed|October 2002|July 2006|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2009|April 10, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00226980||189892|
NCT00226993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0021|Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.|Phase I/II Study of Intratumoral Injection of CPG 7909, A TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides||Stanford University||Withdrawn|March 2005|||December 2006|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 13, 2005|Yes|Yes|unknown|No||https://clinicaltrials.gov/show/NCT00226993||189891|
NCT00232024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919D2301|Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia|Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia||Novartis||Completed|January 2004|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1296|||Female|18 Years|N/A||||January 2008|January 31, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00232024||189526|
NCT00232037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919D2301E1|Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia|Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia||Novartis||Completed|September 2004|August 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||359|||Female|18 Years|N/A||||January 2008|January 31, 2008|September 8, 2005||||||https://clinicaltrials.gov/show/NCT00232037||189525|
NCT00232050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A1304|Study of Omalizumab in Moderate to Severe Bronchial Asthma|Study of Omalizumab in Moderate to Severe Bronchial Asthma||Novartis||Completed|October 2002|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|327|||Both|20 Years|75 Years||||October 2011|October 24, 2011|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232050||189524|
NCT00232622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-29/3.3.2004|A Study Comparing a New Dosing Regimen of Clot-dissolving Drug for Mechanical Heart Valves Which Show Clots|A Prospective Randomized Trial of a Rapid Fibrinolytic Protocol for Left-sided Prosthetic Valve Thrombosis|RAFT-PVT|All India Institute of Medical Sciences, New Delhi|No|Completed|November 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|12 Years|70 Years|No|||October 2013|October 23, 2013|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00232622||189480|
NCT00215566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP733-04-007|A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation||Dynogen Pharmaceuticals||Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|65 Years|No|||March 2006|May 25, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00215566||190752|
NCT00215904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heresco1CTIL|D-serine Adjuvant Treatment for Parkinson's Disease|D-serine Adjuvant Treatment for Parkinson's Disease||Herzog Hospital|Yes|Completed|August 2003|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|13|||Both|30 Years|75 Years|No|||July 2012|July 5, 2012|September 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00215904||190726|
NCT00216138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG HN02-40|Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck|A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40||Hoosier Cancer Research Network|Yes|Terminated|March 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|September 12, 2005||No|Interim analysis results did not meet criteria for second stage of trial|No||https://clinicaltrials.gov/show/NCT00216138||190708|
NCT00206817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020|Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)|Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)||Biosite||Withdrawn|October 2003|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|0|||Both|21 Years|N/A|No|||July 2015|July 20, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206817||191410|
NCT00207116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-065|An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma|An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma||Eli Lilly and Company||Completed|September 2005|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||120|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00207116||191387|
NCT00207129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-038|Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies|Effect of Capecitabine on the Pharmacokinetics of BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies||Bristol-Myers Squibb||Completed|October 2004|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||25|||Both|18 Years|N/A|No|||April 2011|April 11, 2011|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00207129||191386|
NCT00207142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-136|Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)|A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase With Unboosted vs. Boosted Reyataz After an Induction Phase With Reyataz and Ritonavir in Treatment Naive HIV Patients (the INDUMA Study)|INDUMA|Bristol-Myers Squibb|No|Completed|November 2005|January 2008|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|252|||Both|18 Years|N/A|No|||January 2010|January 7, 2010|September 16, 2005|Yes|Yes||No|June 2, 2009|https://clinicaltrials.gov/show/NCT00207142||191385|
NCT00234143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q1907/94|Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)|A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha With or Without Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Versus Best Supportive Care in Patients With Low-Risk Myelodysplastic Syndromes||St. Bartholomew's Hospital|Yes|Active, not recruiting|October 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|N/A|No|||March 2009|March 11, 2009|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234143||189365|
NCT00234871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-599|Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)|A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy|TANDEM|Abbott|No|Completed|January 2004|||March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|N/A|No|||July 2008|July 11, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00234871||189311|
NCT00235170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC01-03|The Arterial Revascularization Therapies Study Part II.|ARTS II: Arterial Revascularization Therapies Study Part II of the Sirolimus-Eluting Bx VELOCITY™ Balloon Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions.|ARTS II|Cordis Corporation|Yes|Completed|February 2003|April 2009|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|607|||Both|18 Years|80 Years|No|||May 2009|May 4, 2009|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235170||189288|
NCT00234845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-527|Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis|A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis||Abbott|No|Completed|March 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|148|||Both|18 Years|N/A|No|||August 2007|August 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00234845||189313|
NCT00234858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-598|Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)|A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome|STAR|Abbott|No|Completed|March 2004|||April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|21 Years|N/A|No|||June 2008|July 11, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00234858||189312|
NCT00235157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE01-01|A Comparison of Coated and Uncoated Stents in Renal Artery Treatment.|Palmaz Genesis Peripheral Stainless Steel Balloon Expandable Stent, Comparing a Sirolimus Coated Versus an Uncoated Stent in REnal Artery Treatment.|GREAT|Cordis Corporation|Yes|Completed|November 2001|July 2005|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|30 Years|N/A|No|||August 2008|August 5, 2008|October 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235157||189289|
NCT00235482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSX-X-02|Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma|Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma||Viralytics||Completed|August 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||3|||Both|21 Years|70 Years|No|||September 2007|September 12, 2007|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235482||189265|
NCT00205374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-196|Use of Cidofovir for Recurrent Respiratory Papillomatosis|Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis."||University of Wisconsin, Madison|Yes|Completed|November 1999|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|5 Years|N/A|No|||March 2012|March 30, 2012|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00205374||191518|
NCT00205946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002234-1|The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity|The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity||Affective Neuroscience Laboratory|Yes|Completed|April 2005|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|64 Years|No|||November 2007|December 4, 2007|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00205946||191475|
NCT00207493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3305|The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services.|The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services.||Centers for Disease Control and Prevention|No|Completed|October 2000|September 2007|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||494|||Both|15 Years|N/A|No|||September 2012|September 26, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00207493||191359|
NCT00213512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/020/HP|Effect of Anti CD20 in Pemphigus Desease|Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera).||University Hospital, Rouen|No|Completed|June 2003|October 2008|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||22|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213512||190904|
NCT00213525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/039/HP|Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls|Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Healthy Controls||University Hospital, Rouen|No|Completed|October 2004|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|||Both|18 Years|76 Years|Accepts Healthy Volunteers|Probability Sample|100 Patients With Scleroderma and 300 Healthy Controls|February 2015|February 4, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213525||190903|
NCT00256984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-05-0004|Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)|A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)||Ethicon Endo-Surgery|No|Completed|October 2005|June 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Female|21 Years|80 Years|No|||March 2011|March 7, 2011|November 18, 2005||No||No|October 27, 2009|https://clinicaltrials.gov/show/NCT00256984||187652|
NCT00257231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 U54 GM062119_trauma|Inflammation and the Host Response to Injury (Trauma)|Inflammation and the Host Response to Injury||National Institute of General Medical Sciences (NIGMS)|Yes|Active, not recruiting|November 2003|September 2015|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|610|Samples Without DNA|Plasma, blood leukocyte nucleic acids (only RNA, no DNA)|Both|16 Years|N/A|No|Non-Probability Sample|Acute hospitalized blunt trauma patients|February 2015|February 24, 2015|November 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00257231||187633|
NCT00254436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-264|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery||M.D. Anderson Cancer Center|Yes|Terminated|December 2002|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 27, 2012|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254436||187842|
NCT00257244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 U54 GM062119_burn|Inflammation and the Host Response to Injury (Burns)|Inflammation and the Host Response to Injury||National Institute of General Medical Sciences (NIGMS)|Yes|Active, not recruiting|April 2004|September 2015|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|Samples Without DNA|Plasma, blood leukocyte nucleic acids (RNA), solid tissue nucleic acids (only RNA, no DNA)|Both|N/A|N/A|No|Non-Probability Sample|Acute hospitalized burn patients|February 2015|February 24, 2015|November 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00257244||187632|
NCT00257309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2004-001943-31|Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients|TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction|TRIANA|Spanish Society of Cardiology|Yes|Terminated|April 2005|December 2008|Anticipated|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|75 Years|N/A|No|||May 2008|May 19, 2008|November 18, 2005|Yes|Yes|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00257309||187627|
NCT00257634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS-3260|Randomized Trial of Iontophoresis Versus Injection of Corticosteroids for Lateral Epicondylitis|Dexamethasone Delivery for Treatment of Lateral Epicondylitis (IRB #3260)||Henry Ford Health System||Completed|December 2004|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|80 Years|No|||April 2007|April 26, 2007|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257634||187602|
NCT00257647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|497169-HMO-CTIL|Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)|Use of SV40 siRNA Vectors to Treat CML||Hadassah Medical Organization|No|Completed|September 2005|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|CML patients which were seen at Hadassah hospital.|April 2007|February 17, 2009|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00257647||187601|
NCT00207428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-CZ-0999-0400|Antiepileptic Drug Carbamazepine in Treatment of Bronchial Asthma|Randomized, Placebo Controlled, Double Blind Study of Carbamazepine in Treatment of Bronchial Asthma||Centre of Chinese Medicine, Georgia||Completed|August 1999|April 2000||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||65|||Both|16 Years|N/A|No|||July 1999|May 15, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207428||191364|
NCT00204698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 11690|Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment|Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment||University of Utah|No|Completed|August 2003|May 2006|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00204698||191569|
NCT00203827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13272A|Pediatric Sleep Questionnaire: Use for Collection of Clinical Data|Pediatric Sleep Questionnaire: Use for Collection of Clinical Data||University of Chicago|No|Completed|September 2004|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|N/A|17 Years|No|Non-Probability Sample|Problems or habits children experience with sleep|September 2013|September 4, 2013|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00203827||191635|
NCT00204152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13166B|Treatment for Chronic Depression|Treatment for Chronic Depression With Behavioral Interventions||University of Chicago|No|Terminated|June 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|58 Years|No|||September 2013|September 4, 2013|September 13, 2005||No|PI left U of C|No||https://clinicaltrials.gov/show/NCT00204152||191611|
NCT00204139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BvanDyk USS|Routine Versus Selective Midtrimester Ultrasound in a Poorly Resourced Setting: a Cluster Randomised Controlled Trial|||University of Johannesburg||Completed|June 2002|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||900|||Female|18 Years|N/A|No|||July 2004|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204139||191612|
NCT00204412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|686868|Exercise and Flax-Based Nutritional Supplementation for Lowering Cholesterol|Effectiveness of Flax Lignan and Exercise Training for Improving Lipid Profiles||University of Saskatchewan|No|Completed|March 2005|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 1, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204412||191591|
NCT00205049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2004-0388|Pentoxifylline for Acute Alcoholic Hepatitis (AAH)|A Pilot Study of Pentoxifylline-Therapy for Acute Alcoholic Hepatitis||University of Wisconsin, Madison|No|Terminated|March 2005|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|4|||Both|21 Years|N/A|No|||April 2014|April 10, 2014|September 13, 2005||No|lack of funding|No|August 4, 2011|https://clinicaltrials.gov/show/NCT00205049||191543|Study was terminated before any data was gathered/analyzed.
NCT00205062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2004-0251|Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)|Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease||University of Wisconsin, Madison||Terminated|October 2004|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||September 2008|October 1, 2015|September 13, 2005|||No Accrual|No||https://clinicaltrials.gov/show/NCT00205062||191542|
NCT00205972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-NRH-04|Non Randomized Humerusshaft Fracture|Comparison (Conservative Versus Operative) of Standardized Treatment for Defined Humerusshaft Fractures||AO Clinical Investigation and Documentation|No|Completed|December 2000|October 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|16 Years|N/A|No|||November 2007|November 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205972||191473|
NCT00205387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2004-1260|Cardiac Elastography to Determine Strain and Strain Rates in the Heart|Cardiac Elastography||University of Wisconsin, Madison|No|Completed|November 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers and patients with known heart disease caused by myocardial inarction or        cardiomyopathy|August 2012|August 28, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205387||191517|
NCT00205400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-1999-0280|Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care|Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care||University of Wisconsin, Madison||Active, not recruiting|August 1999|||March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||192|||Both|18 Years|N/A|No|||August 2013|October 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205400||191516|
NCT00207220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-001769|Ventricular-Vascular Coupling in Heart Failure|Ventricular-Vascular Coupling in Patients With Heart Failure and Preserved Ejection Fraction||Brigham and Women's Hospital|No|Completed|January 2004|January 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|adults with heart failure and preserved left ventricular function|November 2007|November 7, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207220||191379|
NCT00212914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR- KTE 110023|Increasing Screening for Type 2 Diabetes in Women With Previous Gestational Diabetes.|Mailing Recommendations to the Individual or Physician to Increase Screening for Type 2 Diabetes in Women With Previous Gestational Diabetes: Clinical Trial.||Ottawa Hospital Research Institute||Completed|May 2002|January 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label||||268|||Female|N/A|N/A|No|||September 2008|September 8, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212914||190950|
NCT00213187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020020201|PEAK Study (Physical Exercise and Activity in Kids)|The Effect of Vigorous Exercise on Motor Function and Functional Fitness in Juvenile Arthritis||The Hospital for Sick Children||Completed|August 2002|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|8 Years|16 Years|No|||December 2013|December 17, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213187||190929|
NCT00213538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/020/HP|Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis|Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis||University Hospital, Rouen|No|Active, not recruiting|June 2003|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|341|||Both|18 Years|N/A|No|Probability Sample|Patients who Satisfied the 1987 American College of Rheumatology revised criteria for        Rheumatoid arthritis|January 2016|January 22, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213538||190902|
NCT00223067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes|A Multi-Center Open-Labeled Study of the Administration of Allogenic and Autologous Regulatory Cells for the Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor)||University of Schleswig-Holstein||Recruiting|March 2005|May 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||April 2004|October 27, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223067||190187|
NCT00254085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-2368|Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.|Multiple Substitution of First Phase Insulin Response With a Rapid Action Insuli Analogue in Patient With Newly Diagnosed Type 2 Diabtes.||University Hospital, Gentofte, Copenhagen||Recruiting|March 2005|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|35 Years|75 Years|No|||September 2005|November 14, 2005|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00254085||187868|
NCT00254410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0106|FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years|Phase 2 Study of the Activity and Safety of Fludarabine, Cyclophosphamide, and Mitoxantrone Plus Rituximab (FCM-R) With Pegfilgrastim (Neulasta) as Frontline Therapy for Patients < 70 Years With Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2005|||March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|70 Years|No|||February 2016|February 18, 2016|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254410||187844|
NCT00254423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0422|Study of Dasatinib in Patients With Chronic Myelogenous Leukemia|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2005|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|N/A|No|||May 2015|May 28, 2015|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254423||187843|
NCT00254696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-101462|Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)|Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|710|||Both|18 Years|N/A|No|||April 2011|April 13, 2011|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00254696||187822|
NCT00255645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00056|G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)|A Long-Term, Post-Treatment, Safety Follow-Up, Multi-Center Study in Patients With Type 2 Diabetes Mellitus From the GALLANT, GALLEX or ARMOR Studies.||AstraZeneca||Terminated|September 2005|December 2006|Actual|||Phase 3|Observational|Time Perspective: Prospective||||4500|||Both|18 Years|N/A|No|||March 2008|March 14, 2008|November 18, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00255645||187752|
NCT00223314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD038457-01|Safer Choices 2 - HIV, STD, & Pregnancy Prevention Program|HIV Prevention Among Alternative School Youth||The University of Texas Health Science Center, Houston|No|Completed|November 2000|February 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1000|||Both|N/A|N/A|No|||December 2007|December 20, 2007|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223314||190168|
NCT00223327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023-1904-101|Measurement of Bite Force in Humans|Measurement of Bite Force in Humans||The University of Texas Health Science Center at San Antonio|No|Completed|March 2005|June 2008|Actual|June 2008|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|89|||Both|16 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Normal subjects and patients with orofacial pain presenting in the dental clinic.|March 2012|March 7, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223327||190167|
NCT00257582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104915|Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics|Long-term Study of Cetirizine Dry Syrup in Children Suffering From Various Type of Cutaneous Disease Accompanied With Pruritus.||GlaxoSmithKline|No|Completed|August 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|2 Years|14 Years|No|||May 2013|May 3, 2013|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257582||187606|
NCT00257907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060030|Immune Response to Mycobacterium Tuberculosis Infection|Correlation of the Precursor Frequency of CD4 + Effector Memory T Cells With Induration Measured in the Tuberculin Skin Test (TST)||National Institutes of Health Clinical Center (CC)||Completed|November 2005|February 2016||||N/A|Observational|N/A|||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00257907||187581|
NCT00257920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-726|A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease|A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis||Abbott||Completed|June 2006|||January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|N/A|No|||December 2009|December 22, 2009|November 22, 2005|Yes|Yes||No|January 26, 2009|https://clinicaltrials.gov/show/NCT00257920||187580|The null hypothesis was not tested appropriately as a result of measurable differences in parathyroid hormone (PTH) suppression indicating dose exposure was different. Therefore, differences in calcium absorption could not be determined.
NCT00253812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05ADR-88|Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy|Adenoma Detection Rate in Rectal Remnants of Familial Polyposis (FAP) Patients Using Standard (White Light), Auto-Fluorescence (AFI), Narrow Band Imaging (NBI) and Chromoscopic Endoscopy||London North West Healthcare NHS Trust||Recruiting|November 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|60|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253812||187889|
NCT00253825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701254|mCIMT and Eye Patching for Neglect Rehabilitation Post Stroke: A Longitudinal Study of Separate and Combined Effects|Modified Constraint-Induced Movement Therapy and Eye Patching for Neglect Rehabilitation Post Stroke: A Longitudinal Study of Separate and Combined Effects||National Taiwan University Hospital||Recruiting|November 2005|July 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|45 Years|75 Years|No|||August 2005|December 20, 2005|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00253825||187888|
NCT00207714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005263|An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis|A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate||Centocor, Inc.|No|Completed|November 2003|February 2006|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|172|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|September 13, 2005||Yes|||May 21, 2009|https://clinicaltrials.gov/show/NCT00207714||191343|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00215098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-093|Chylothorax Following Heart Surgery|Chylothorax in Children Following Congenital Heart Surgery||Children's Healthcare of Atlanta|No|Terminated|May 2005|November 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|Patients in the congenital surgery database|June 2007|March 14, 2012|September 20, 2005|||insufficient data|No||https://clinicaltrials.gov/show/NCT00215098||190786|
NCT00205075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0161|Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression|The Use of Validated Measures of Alcohol Intake to Measure the Impact of Moderate Alcohol Consumption on Hepatic Fibrogenesis in Individuals Infected With Hepatitis C||University of Wisconsin, Madison||Completed|August 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|47|||Both|18 Years|N/A|No|Non-Probability Sample|outpatient with HCV not receiving or planning treatment but is receiving standard of care        monitoring every 3 months, abstinent or drinking|December 2015|December 7, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205075||191541|
NCT00205088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-253|The Use of Shunt Tap in Assessing Ventriculoperitoneal (VP) Shunt Malfunction|The Use of Shunt Tap in Assessing Ventriculoperitoneal (VP) Shunt Malfunction||University of Wisconsin, Madison||Completed|August 2002|May 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|N/A|18 Years|No|||June 2008|October 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205088||191540|
NCT00205413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-376|Surveillance For New Lung Primaries|Low Dose Helical Computed Tomographic (CT) Screening Followed by Anatomic Co-Registered Computed Tomography With Positron Emission Tomography (CT/PET) for Patients With Indeterminate (5-9 mm) Nodules||University of Wisconsin, Madison||Terminated|September 2002|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A|||Anticipated|250|||Both|50 Years|N/A|No|||September 2015|September 30, 2015|September 13, 2005|||low accrual|No||https://clinicaltrials.gov/show/NCT00205413||191515|
NCT00204165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|431-04150|Comparison of MR Enteroclysis and MRI With Per Oral Contrast Using a 6 % Mannitol Solution.|MRI of the Small Bowel. Comparison of Different Techniques and Contrast.||University of Oslo||Active, not recruiting|November 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|18 Years|N/A|No|||September 2006|September 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204165||191610|
NCT00204178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/38/2003|The Role of Reactive Oxygen Species in Ischaemia-Reperfusion Injury of the Transplanted Kidney|The Role of Reactive Oxygen Species in Ischaemia-Reperfusion Injury of the Transplanted Kidney||Uniwersytet Mikolaja Kopernika w Toruniu||Active, not recruiting|April 2003|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||60|||Both|18 Years|N/A|No|||August 2005|November 30, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204178||191609|
NCT00204425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio 03-1077|Effect of Exercise Training and Soy-based Nutritional Supplementation on Prevention of Osteoporosis|Effect of Combined Exercise Therapy and Isoflavone Supplementation on Prevention of Osteoporosis||University of Saskatchewan|Yes|Completed|December 2004|April 2010|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|351|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 9, 2011|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00204425||191590|
NCT00205712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD - Kids|Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids|Prevention of NMDA Antagonist-induced Psychosis and Memory Impairment in Children||Washington University School of Medicine|No|Completed|February 2003|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|7 Years|17 Years|No|||January 2016|January 12, 2016|September 13, 2005|Yes|Yes||No|October 27, 2009|https://clinicaltrials.gov/show/NCT00205712||191493|
NCT00205959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-LPP-04|LPHP-Philos-PHN Conservative Treatment|Comparison of Standard Treatment Methods for Proximal Humerus Fractures||AO Clinical Investigation and Documentation||Completed|August 2002|August 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||640|||Both|18 Years|N/A|No|||September 2005|September 6, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205959||191474|
NCT00206310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0098|Crestor Versus Placebo in Subjects With Heart Failure|Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure||AstraZeneca||Completed|September 2003|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||5013|||Both|60 Years|N/A|No|||November 2010|November 17, 2010|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00206310||191447|
NCT00206323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-176|A Randomized, Placebo-Controlled, Tourette Syndrome Study.|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Topiramate in the Treatment of Tourette Syndrome.||Baylor College of Medicine|No|Completed|September 2004|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Both|7 Years|65 Years|No|||April 2009|April 30, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00206323||191446|
NCT00206908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)|BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)||Biosite||Completed|July 2002|||||Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1||900|||Both|18 Years|N/A|No|Probability Sample|Cerebral ischemia or intracranial hemorrhage suspected.|July 2015|July 20, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206908||191403|
NCT00212927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|carl001|Continuity of Care and Outcomes After Discharge From Hospital|The Association of Provider Continuity and Information Continuity With Patient Outcomes After Discharge From Hospital||Ottawa Hospital Research Institute|No|Completed|October 2002|December 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|5900|||Both|N/A|N/A|No|||July 2007|August 31, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212927||190949|
NCT00212940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999565-01H|Supportive Therapy for Adherence to ART(STAART)|Increasing Patient Adherence to HIV Medications: A Prospective Intervention Study||Ottawa Hospital Research Institute||Completed|October 2000|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|112|||Both|18 Years|N/A|No|||July 2007|July 25, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212940||190948|
NCT00213200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019990251|Intravenous and Topical Analgesics for Procedural Pain in Neonates|Systemic Analgesia and Local Anaesthesia for Percutaneous Venous Catheter Placement in Preterm Neonates||The Hospital for Sick Children||Completed|July 2003|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|N/A|30 Days|No|||September 2005|October 10, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213200||190928|
NCT00213213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000002771|Using Sugar Water to Relieve Pain in Infants|Effectiveness of Sucrose Analgesia in Reducing Pain Responses in Infants Born to Diabetic and Non-diabetic Mothers: A Randomized Controlled Trial||The Hospital for Sick Children||Active, not recruiting|July 2003|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|N/A|3 Days|No|||September 2005|March 11, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213213||190927|
NCT00223080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV144|HIV Vaccine Trial in Thai Adults|A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults||U.S. Army Medical Research and Materiel Command|Yes|Completed|October 2003|June 2009|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|16402|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223080||190186|
NCT00255047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5A10|Safety and Immune Response of Different Pediatric Combination Vaccines.|Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers||Sanofi|No|Completed|November 2005|February 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|2167|||Both|42 Days|89 Days|Accepts Healthy Volunteers|||January 2014|January 21, 2014|November 15, 2005|Yes|Yes||No|September 14, 2010|https://clinicaltrials.gov/show/NCT00255047||187796|
NCT00255320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP-KASGlo2004|Experimental Headache Induced by Vasoactive Intestinal Polypeptide|Experimental Headache Induced by Vasoactive Intestinal Polypeptide||Danish Headache Center||Completed|December 2003|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2003|December 7, 2005|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255320||187776|
NCT00256178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-475/EC302|Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.|A Placebo-controlled, Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 50 mg and 100 mg Versus Placebo, When Co-administered With Simvastatin 20 mg or 40 mg in Subjects With Primary Dyslipidemia.||Takeda|No|Completed|October 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|411|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|November 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256178||187713|
NCT00224159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00710|Does Statin Initiation Undermine Dietary Behavior?|Does Statin Initiation Undermine Dietary Behavior?||Weill Medical College of Cornell University||Completed|February 2005|June 2006||||N/A|Observational|N/A||1||100|||Both|18 Years|N/A|No|Probability Sample|All English-speaking adults who have recently (within 1 week)received their first        prescription for a statin will be eligible.|February 2011|February 18, 2011|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00224159||190105|
NCT00223808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2695-I|Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial|Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial||VA Office of Research and Development|No|Completed|January 2002|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|71|||Both|21 Years|N/A|No|||January 2014|January 3, 2014|September 14, 2005||No||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00223808||190131|Limitations include the relatively small number of subjects in each group and the variation in severity level across subjects. Subjects at the Houston site were enrolled earlier after stroke than in the LA site and the Palo Alto site.
NCT00207974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR94-IRB-68|Pharmacokinetic Study of Marine Active in Health Men|||China Medical University Hospital||Active, not recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|20 Years|35 Years|Accepts Healthy Volunteers|||September 2005|November 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00207974||191323|
NCT00215319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G990313|Titanium Surgical Mesh and MOSS-Miami Screws for Lumbar Fusion.|A Multi-center Study to Evaluate the Safety and Efficacy of DePuy AcroMed Titanium Surgical Mesh and MOSS-Miami Spinal Fixation System Pedicle Screws for Intradiscal Fusion in the Lumbar Spine||DePuy Spine|No|Completed|December 2000|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|18 Years|79 Years|No|||May 2014|May 22, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215319||190769|
NCT00205426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2005-0185|Natrecor for Pulmonary Hypertension in Lung Transplants|Natrecor® (Nesiritide) as a Nitric Oxide Sparing Agent in Patients Undergoing Lung Transplantation||University of Wisconsin, Madison|Yes|Completed|August 2005|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00205426||191514|
NCT00216489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003502|A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)|A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD)||Janssen Cilag Pharmaceutica S.A.C.I., Greece||Completed|March 2003|November 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|191|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216489||190682|
NCT00216918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9721|Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.|An Open-Label Pilot Study of Atomoxetine Hydrochloride to Evaluate Neuropsychological Function in Children Ages 6 to 10 Years With Attention-Deficit/Hyperactivity Disorder.||Eli Lilly and Company||Completed|September 2005|June 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|6 Years|10 Years|No|||January 2007|January 24, 2007|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00216918||190649|
NCT00216931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-001551-11|Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost|Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost||Lund University Hospital||Withdrawn|May 2006|October 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|48 Hours|No|||February 2009|February 3, 2009|September 15, 2005|||No patients enrolled after three years|No||https://clinicaltrials.gov/show/NCT00216931||190648|
NCT00217191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRAP040833|Ibuprofen and Renal Function in Premature Infants|Ibuprofen and Renal Function in Premature Infants||Maternite Regionale Universitaire||Completed|September 2004|September 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|N/A|28 Days|No|||September 2006|September 18, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00217191||190628|
NCT00213551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/037/HP|Glutamine and Intestinal Protein Metabolism|Comparative Effects of Glutamine and Glucose on Intestinal Protein Metabolism in Healthy Humans||University Hospital, Rouen||Completed|April 2004|June 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213551||190901|
NCT00213941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3214|Study Protocol Evaluating Transient Tachypnoea of the Newborn in Term and Near Term Neonates|Study Protocol Evaluating Transient Tachypnoea of the Newborn in Term and Near Term Neonates||University Hospital, Strasbourg, France||Recruiting|November 2004|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|N/A|6 Hours|No|||October 2006|October 2, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213941||190871|
NCT00223106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHC03001|Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault Prolapse|A Prospective Multicenter Clinical Study on a New Approach in Treating Stress and Mixed Incontinence and Vaginal Vault Prolapse||Medtronic - MITG||Completed|March 2004|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|467|||Female|18 Years|N/A|No|||July 2015|July 23, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00223106||190184|
NCT00255892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 055|Intervention Development for Newly Diagnosed Youth With HIV|Intervention Development for Newly Diagnosed Youth With HIV||Westat|No|Completed|February 2006|March 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|48|||Both|16 Years|24 Years|No|Non-Probability Sample|The provider interviews will be comprised of participants who are clinical providers,        mental health providers, and case managers with at least 1 year of experience working with        HIV+ youth; a target number of one from each category will be interviewed from all 15 ATN        sites.        The focus groups will be comprised of participants who are between the ages of 16 and 24,        diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive        services at one of the three selected ATN sites or their community partner.        Focus group participants will be balanced to reflect the diversity (i.e., age, pregnant        and parenting women, men who have sex with men (MSM), mono-lingual Spanish-speaking, etc.)        of the clinic populations.|February 2016|February 29, 2016|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00255892||187735|
NCT00256451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803866|Endophenotype for Alcohol Misuse in Healthy Minority Populations|Defining an Endophenotype for Alcohol Misuse: A Focus On Minority Populations|DEFINE|University of Pennsylvania|No|Completed|November 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|38|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 3, 2011|November 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00256451||187692|
NCT00223834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3436R|Pathways to Vocational Rehabilitation: Enhancing Entry and Retention|Pathways to Vocational Rehabilitation: Enhancing Entry and Retention||VA Office of Research and Development|No|Completed|March 2005|September 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|55 Years|No|||March 2008|March 11, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223834||190129|
NCT00253552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445188|G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders|A Pilot Study of Using Filgrastim-Primed Bone Marrow in Human Leukocyte Antigen (HLA) Matched Related Donor Allogenetic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies||OHSU Knight Cancer Institute||Terminated|May 2004|May 2006|Actual|May 2006|Actual|N/A|Interventional|Primary Purpose: Treatment|||Actual|4|||Both|N/A|24 Years|No|||June 2010|May 24, 2012|November 11, 2005|No|Yes|Terminated at request of PI as study was outdated.|No||https://clinicaltrials.gov/show/NCT00253552||187907|
NCT00253565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009521|Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies||Duke University||Completed|August 2003|July 2010|Actual|July 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|November 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00253565||187906|
NCT00224640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P041201|Iron-Chelating Therapy and Friedreich Ataxia|Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II||Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|13 Years|N/A|No|||March 2007|March 3, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00224640||190068|
NCT00225186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91234|Safety and Efficacy of SH T00660AA in Treatment of Endometriosis|A Multi-center, Open, One-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of T00660AA for the Treatment of Endometriosis Over 52 Weeks (Follow-up to Study 307041)||Bayer|No|Completed|July 2004|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Female|18 Years|45 Years|No|||January 2014|January 8, 2014|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225186||190027|
NCT00208000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR93-IRB-22|A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.|||China Medical University Hospital||Recruiting|July 2004|April 2006|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||September 2005|November 26, 2010|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00208000||191321|
NCT00216047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG BRE04-80|PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer|A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80||Hoosier Cancer Research Network|Yes|Terminated|January 2005|August 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|September 12, 2005|Yes|Yes|Low patient enrollment; toxicities|No||https://clinicaltrials.gov/show/NCT00216047||190715|
NCT00216229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEWE-301|Twinrix Alternative Schedule Study|A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20)||IDEWE Occupational Health Services||Active, not recruiting|September 2004|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|December 13, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00216229||190701|
NCT00215696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-002.001|A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard Therapies|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA™-GUIDED/MYOSTAR™ Catheter in "No Option" Patients With Class II-IV Stable Angina||GenVec||Completed|April 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||129|||Both|18 Years|80 Years|No|||May 2011|May 12, 2011|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00215696||190742|
NCT00215709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOC GU-010|Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer|A Pilot Study of Docetaxel on a Bi-Weekly Schedule in the Treatment of Elderly Men With Hormone-Refractory Prostate Cancer (HRPC)||Geriatric Oncology Consortium||Completed|July 2004|July 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|65 Years|N/A|No|||November 2007|November 15, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00215709||190741|
NCT00216957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QE-RS/1998-220|Randomized Clinical Trial Comparing Coronary Bypass Grafting With or Without Cardiopulmonary Bypass|Randomized Clinical Trial Comparing Coronary Bypass Grafting With or Without Cardiopulmonary Bypass||Maritime Heart Centre||Completed|October 1998|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|N/A|N/A|No|||September 2005|September 19, 2005|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00216957||190646|
NCT00216203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LUN04-79|Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer|A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79||Hoosier Cancer Research Network|Yes|Completed|May 2005|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00216203||190703|
NCT00216476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002269|A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder|CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness||Janssen-Cilag International NV|No|Completed|October 2004|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|753|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|September 13, 2005|Yes|Yes||No|July 8, 2010|https://clinicaltrials.gov/show/NCT00216476||190683|
NCT00217204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002665|An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption|A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Effectiveness of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and Toddlers With Cystic Fibrosis-Related Pancreatic Insufficiency and Fat Malabsorption||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed|July 2005|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|18|||Both|6 Months|30 Months|No|||April 2010|May 17, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00217204||190627|
NCT00214344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2003-0040|Family Preparation Study For Withdrawal of Mechanical Ventilation From Their Family Member|Evaluating the Usefulness of Preparing Families For Withdrawal of Mechanical Ventilation From Their Family Member: A Pilot Study||University of Wisconsin, Madison||Completed|October 2003|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|October 1, 2015|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00214344||190841|
NCT00214357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2004-1277|The Effects of Mindfulness Training on School Staff|The Effects of Mindfulness Training on School Staff Emotions, Attention, and Stress||University of Wisconsin, Madison||Completed|October 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|October 1, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00214357||190840|
NCT00214617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREF_Le_IRUSROSU 0021|Effect of Crestor on Lipoprotein Metabolism in Humans|Effect of Crestor on the Kinetics of Plasma Apolipoproteins: Dose-Response Study||Atlanta Research and Education Foundation||Completed|January 2005|February 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2006|September 22, 2006|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00214617||190822|
NCT00223119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN03001|Comparison of Absorbable Sutures in Perineal Laceration Repair|||Medtronic - MITG||Terminated|January 2004|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||October 2012|October 24, 2012|September 13, 2005|||Study recruitment very slow.|No||https://clinicaltrials.gov/show/NCT00223119||190183|
NCT00223132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN04002|Suture Granuloma in Body Contouring Surgery|||Medtronic - MITG||Completed|February 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||October 2012|October 24, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00223132||190182|
NCT00256152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD291|Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial|Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial||St. Jude Medical||Completed|September 2004|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2580|||Both|65 Years|N/A|No|||July 2012|July 27, 2012|September 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00256152||187715|
NCT00256165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS04009TV|REST Study: Left Ventricular Regression European Study|Left Ventricular Regression European Study||St. Jude Medical|No|Completed|January 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00256165||187714|
NCT00223041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Cranoc Lipid Study in Renal Transplantation|Cardiovascular Events in Renal Transplant Recipients With Low LDL-cholesterol Receiving Tacrolimus in Combination With the Statin Fluvastatin||University of Schleswig-Holstein|Yes|Terminated|April 2003|December 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|65 Years|No|||May 2006|August 4, 2011|September 14, 2005||No|No possibilty to receive all plened patients for this study|No||https://clinicaltrials.gov/show/NCT00223041||190189|
NCT00223054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Polymorphism of the Cytochrome P450-system in Renal Transplants|Polymorphism of the Cytochrome P450-system and the MDR-system in Renal Transplants Receiving the Immunosuppressive Drugs Tacrolimus, Sirolimus, Everolimus or Cyclosporine A||University of Schleswig-Holstein|Yes|Completed|March 2005|October 2006|Actual|June 2006|Actual|Phase 4|Observational|Time Perspective: Retrospective||1|Actual|200|Samples With DNA|DNA samples to analyze polymorphisms|Both|18 Years|70 Years|No|Probability Sample|Patinets after kidney transplantation|June 2008|August 3, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223054||190188|
NCT00223847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3091R|An Investigation of Constraint Induced Language Therapy for Aphasia|An Investigation of Constraint Induced Language Therapy for Aphasia||VA Office of Research and Development||Completed|August 2002|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||December 2008|December 31, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223847||190128|
NCT00224393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC018A|Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis|||The Cleveland Clinic||Suspended|February 2001|August 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||August 2005|September 21, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224393||190087|
NCT00223574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44205|Canadian Trial of Dietary Carbohydrates in Diabetes|Long-Term Effect of Altering the Source or Amount of Dietary Carbohydrate in Type 2 Diabetes||University of Toronto||Completed|January 2002|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||168|||Both|35 Years|75 Years|No|||September 2005|September 21, 2005|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00223574||190149|
NCT00214565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00030|GALLANT 6 Tesaglitazar vs. Pioglitazone|A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes||AstraZeneca||Terminated|August 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1450|||Both|18 Years|N/A|No|||November 2010|November 17, 2010|September 20, 2005|||The development program has been terminated|||https://clinicaltrials.gov/show/NCT00214565||190826|
NCT00204438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC 2001-249|Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle|Follicular Profiles After Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle||University of Saskatchewan||Completed|February 2002|December 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204438||191589|
NCT00216710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0155|Evaluation of the Healthy Families Alaska Program|Evaluation of the Healthy Families Alaska Program||Johns Hopkins University||Completed|July 1999|February 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||380|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00216710||190665|
NCT00216034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKIT-GC|Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK|Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy||Hokuriku-Kinki Immunochemotherapy Study Group|Yes|Active, not recruiting|March 2005|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|20 Years|80 Years|No|||March 2012|March 20, 2012|September 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00216034||190716|
NCT00216502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004996|A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease|Long Term Treatment With Galantamine In Dementia||Janssen-Cilag S.p.A.||Completed|August 2001|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|254|||Both|50 Years|N/A|No|||January 2011|January 20, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216502||190681|
NCT00216515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005047|The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type|A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type||Janssen Korea, Ltd., Korea||Completed|March 2004|November 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|102|||Both|50 Years|N/A|No|||January 2011|January 20, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216515||190680|
NCT00216216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LUN04-78|Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer|Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78)||Hoosier Cancer Research Network|Yes|Terminated|January 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|September 12, 2005||No|The results from the interim analysis were not favorable to continue this trial.|No||https://clinicaltrials.gov/show/NCT00216216||190702|
NCT00212979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI Grant R03-59|Measuring Kidney Function in Kidney Transplantation|The Accurate Prediction of Renal Function in Kidney Transplant Recipients||Ottawa Hospital Research Institute||Completed|April 2004|October 2006|Actual|October 2006|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|19 Years|N/A|No|||February 2009|February 19, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212979||190945|
NCT00217217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-002631|Low Field Magnetic Stimulation Treatment for Bipolar Depression|Low Field Magnetic Stimulation in Bipolar Depression||Mclean Hospital|Yes|Terminated|September 2004|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|70 Years|No|||March 2012|March 13, 2012|September 15, 2005||No|Study was terminated for lack of recruitment.|No||https://clinicaltrials.gov/show/NCT00217217||190626|
NCT00217230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153-P507|Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older CAIV-T, Liquid Formulation||MedImmune LLC||Completed|April 2001|November 2001||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||3000|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 2, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00217230||190625|
NCT00216684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004879|Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics|An Open Label Study to Confirm the Effectiveness, and Safety of Fentanyl Transdermal Matrix Patch in Japanese Patients With Chronic Intractable Pain Who Has Prior Therapy of Codeine, Morphine Hydrochloride, or Fentanyl Injectable Preparations.||Janssen Pharmaceutical K.K.||Completed|May 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|139|||Both|20 Years|N/A|No|||January 2011|January 31, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216684||190667|
NCT00216944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT EU 2004-001583-52|Balanced Anesthesia for Intubation of Premature Infants|Balanced Anesthesia for Intubation of Newborn Premature Infants - a Randomized Intervention Study||Lund University Hospital||Completed|August 2005|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||December 2010|February 12, 2010|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00216944||190647|
NCT00213226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020010349|Single Dose Versus Multiple Doses of Dexamethasone in Children With Acute Bronchiolitis|Efficacy of Single Dose Versus Multiple Doses of Dexamethasone in Outpatients With Acute Bronchiolitis||The Hospital for Sick Children||Completed|December 2001|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|2 Months|24 Months|No|||May 2014|May 12, 2014|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213226||190926|
NCT00213954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3446|Ultrasound Guidance in Nerve Block Anaesthesia|Ultrasound Guidance in Nerve Block Anaesthesia: Classic Nerve Stimulation Technique Versus Ultrasound-Neurostimulation Combination in Four Blocks: Interscalene, Humeral, Parasacral and Lumbar Blocks||University Hospital, Strasbourg, France|No|Active, not recruiting|May 2005|September 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1002|||Both|18 Years|N/A|No|||February 2009|February 24, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213954||190870|
NCT00214877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QE-RS/2002-173|Methylene Blue for Cognitive Dysfunction in Bipolar Disorder|Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder||Nova Scotia Health Authority|No|Completed|November 2003|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||March 2008|March 28, 2008|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00214877||190803|
NCT00215163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4304|Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy|Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post-Traumatic Stress Disorder (PTSD) Remaining Symptomatic After Initial Exposure Therapy||Duke University||Completed|December 2002|June 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|65 Years|No|||September 2005|May 29, 2013|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215163||190781|
NCT00224185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0005004439|Evaluation of Lungs of Normal Individuals by Lung Lavage, Brushing and Bronchial Wall Biopsy|Evaluation of the Lungs of Normal Individuals With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing and Bronchial Wall Biopsy||Weill Medical College of Cornell University|Yes|Completed|January 2004|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|196|Samples With DNA|Specimens will be retained from both a blood draw and a bronchial wall biopsy which obtains      tissue to a depth of 2-3 mm and includes epithelial and subepithelial tissue.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The source of potential subjects will be the population of 'normal', as defined by the        eligibility criteria below, individuals in the New York metropolitan area and elsewhere.        Up to one hundred volunteers will take part in the study each year. Accrual will be random        with no bias as to gender or racial/ethnic group. All study individuals will be males or        females that are 18 years or older and are able to provide informed consent.        Advertisements will be posted at various educational institutions and hospitals and placed        in newspapers in the New York metropolitan area. Paid volunteer referrals will also be        used for patient recruitment.|April 2015|April 20, 2015|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00224185||190103|
NCT00222807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306110|Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus|Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus||University of Pittsburgh|Yes|Recruiting|August 2003|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood samples are collected, stored at minus 70 degree C and analyzed in batches.|Both|14 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Patients with psychosis|February 2011|February 16, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222807||190207|
NCT00223340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R34 DK 067300-1A1 [NIDDK]|The ABC Planning Study: Diabetes and Cardiovascular Risks in Primary Care|Diabetes and Cardiovascular Risks in Primary Care||The University of Texas Health Science Center at San Antonio|No|Completed|March 2005|June 2007||June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind||||400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 28, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223340||190166|
NCT00223587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/089-E|Seasonal Allergic Rhinitis and Driving Ability|Study to Investigate the Effects of Seasonal Allergic Rhinitis on Over-the-Road Driving Performance and Memory Functioning||Utrecht Institute for Pharmaceutical Sciences|No|Terminated|September 2004|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|21 Years|50 Years|No|||April 2008|April 11, 2008|September 13, 2005||No|slow recruitment rate|No||https://clinicaltrials.gov/show/NCT00223587||190148|
NCT00223821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2899-R|Enhancing Conservative Treatment for Urge Incontinence|Enhancing Conservative Treatment for Urge Incontinence|COMBO|VA Office of Research and Development|No|Completed|September 2003|December 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Female|19 Years|N/A|No|||October 2013|October 29, 2013|September 14, 2005||No||No|October 11, 2013|https://clinicaltrials.gov/show/NCT00223821||190130|Secondary objectives could not be achieved because, based on a conditional power calculation, the trial was stopped early for futility.
NCT00225251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gsk 102149|Wellbutrin XL for Dysthymic Disorder|Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL||St. Luke's-Roosevelt Hospital Center|No|Completed|November 2004|June 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||October 2014|October 29, 2015|September 21, 2005||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT00225251||190022|Early termination led to small numbers of subjects analyzed
NCT00225264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-OPI-518|Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.|A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickness|CHICAGO|Takeda|No|Completed|October 2003|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|458|||Both|45 Years|85 Years|No|||February 2012|February 27, 2012|September 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00225264||190021|
NCT00225277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-01-TL-OPI-516|Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus|A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultrasound|PERISCOPE|Takeda|No|Completed|July 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|547|||Both|35 Years|85 Years|No|||February 2012|February 27, 2012|September 21, 2005|Yes|Yes||No|October 17, 2008|https://clinicaltrials.gov/show/NCT00225277||190020|Composite Endpoints A,B,C include cardiovascular mortality, nonfatal MI and nonfatal stroke. In addition, B: coronary revascularization, carotid endarterectomy/stenting, unstable angina hosp. or CHF; C: hospitalization for unstable angina or CHF.
NCT00224367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T10414|Does Early Ambulation After Hip Fracture Surgery Accelerate Recovery?|Does Early Ambulation After Hip Fracture Surgery Accelerate Recovery?: A Randomised Controlled Trial||Bayside Health||Completed|February 2004|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||February 2005|September 21, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224367||190089|
NCT00215332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040006|CHARITE™ vs. ALIF 5-Year Follow-up|Five-year Follow-up of the CHARITÉ™ Artificial Disc Compared to Anterior Lumbar Interbody Fusion With the BAK Cage.||DePuy Spine|No|Completed|March 2005|July 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective||3|Anticipated|367|||Both|N/A|N/A|No|||April 2015|April 10, 2015|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00215332||190768|
NCT00215345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COXAON-0509-047|A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer|A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer||Department of Veterans Affairs, New Jersey||Recruiting|August 2002|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||66|||Male|18 Years|N/A|No|||September 2005|September 20, 2005|September 20, 2005||||||https://clinicaltrials.gov/show/NCT00215345||190767|
NCT00214812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRU-005|An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots|An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots||Biosyn||Recruiting|June 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||6|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|October 24, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00214812||190808|
NCT00214825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001273 BWH|Aldosterone and Vascular Disease in Diabetes Mellitus|Aldosterone and Vascular Disease in Diabetes Mellitus||Brigham and Women's Hospital||Completed|August 2003|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|46|||Both|21 Years|64 Years|No|||December 2007|December 28, 2007|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214825||190807|
NCT00216541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003541|A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy|Randomised Study to Evaluate the Effect of Early Intervention to Treat Anemia With Epoetin Alfa Versus Standard Use on Hemoglobin Levels and the Incidence of Blood Transfusions in Cancer Patients Receiving Chemotherapy||Janssen-Cilag B.V.||Completed|August 2003|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|110|||Both|18 Years|N/A|No|||June 2010|May 18, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216541||190678|
NCT00216970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-008460|Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients|Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients||National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|August 1997|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||August 2009|August 12, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00216970||190645|
NCT00216697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004843|An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy|An Extension or Re-Treatment Study of Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma||Janssen Pharmaceutical K.K.||Completed|March 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|20 Years|74 Years|No|||April 2010|May 16, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216697||190666|
NCT00217269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP060|The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions|A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|ENDEAVOR IV|Medtronic Vascular|Yes|Completed|April 2005|July 2011|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1548|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217269||190622|
NCT00212992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001266-01H|Biphasic Defibrillation Study: Trial to Compare Fixed Versus Escalating Energy|A Pilot Randomized Controlled Trial to Compare Fixed Versus Escalating Energy Regimens for Biphasic Waveform Defibrillation||Ottawa Hospital Research Institute||Completed|March 2001|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|8 Years|N/A|No|||September 2006|September 23, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00212992||190944|
NCT00213239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007479|A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children|The Minimum Effective Dose of Remifentanil When Co-administered With Propofol for Lumbar Puncture in Children: A Dose-finding Study||The Hospital for Sick Children|No|Completed|September 2005|January 2008|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|4 Years|11 Years|No|||August 2013|August 19, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213239||190925|
NCT00212953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997576-01H|OPALS Critical Care Sub-Studies|Ontario Prehospital Advanced Life Support (OPALS) Study Phase III Cardiac Arrest and Critical Care Sub-Studies - Chest Pain Sub-Study, Respiratory Sub-Study, and Major Trauma Sub-Study||Ottawa Hospital Research Institute|No|Completed|March 1997|May 1999|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||21000|||Both|16 Years|N/A|No|||October 2010|October 13, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212953||190947|
NCT00212966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200334201H|Shared Mental Health Care Linking Mental Health Services With Family Medicine Groups|Shared Mental Health Care Linking General Hospital Acute Care Mental Health Services With Two Comprehensive Family Medicine Groups||Ottawa Hospital Research Institute|No|Completed|July 2004|September 2007|Actual|September 2007|Actual|N/A|Observational|N/A||1|Anticipated|350|||Both|16 Years|N/A|No|Non-Probability Sample|family practice patients|August 2010|August 19, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00212966||190946|
NCT00213967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0247|The Effect of Needle Temperature on Pain Ratings Following Intramuscular Injection|The Effect of Needle Temperature on Pain Ratings Following Intramuscular Injection||University of Wisconsin, Madison||Completed|October 2005|January 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind|||Anticipated|80|||Both|18 Years|N/A|No|||January 2008|October 1, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213967||190869|
NCT00214370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0470|Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma|Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma||University of Wisconsin, Madison||Completed|July 2004|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|2 Years|18 Years|No|||July 2007|October 1, 2015|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00214370||190839|
NCT00215176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4428|Modafinil for Atypical Depression|A Study of Modafinil for Atypical Depression||Duke University||Completed|February 2003|April 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||65|||Both|18 Years|65 Years|No|||September 2005|June 17, 2013|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00215176||190780|
NCT00215514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-165|Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma|A Pilot Study of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Junction Adenocarcinoma||Dana-Farber Cancer Institute|Yes|Completed|September 2000|July 2014|Actual|November 2003|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215514||190756|
NCT00224198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0005004440|Evaluation of the Lungs of Individuals With Lung Disease|Evaluation of the Lungs of Individuals With Lung Disease With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing and Bronchial Wall Biopsy||Weill Medical College of Cornell University|Yes|Completed|January 2004|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|196|Samples With DNA|Specimens will be retained from both a blood draw and a bronchoscopy procedure.|Both|18 Years|N/A|No|Non-Probability Sample|The source of potential subjects will be the population of individuals defined by the        eligibility criteria below, individuals in the New York metropolitan area and elsewhere.        Up to one hundred volunteers will take part in the study each year. Accrual will be random        with no bias as to gender or racial/ethnic group. All study individuals will be males or        females that are 18 years or older and are able to provide informed consent.        Advertisements will be posted at various educational institutions and hospitals and placed        in newspapers in the New York metropolitan area. Paid volunteer referrals will also be        used for patient recruitment.|April 2015|April 20, 2015|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00224198||190102|
NCT00223353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|978-0011-149|Quantitative Gait Analysis for Clinical Decision Making|Quantitative Gait Analysis for Clinical Decision Making||The University of Texas Health Science Center at San Antonio||Completed|November 1998|August 2011|Actual|August 2011|Actual|N/A|Observational|N/A||2|Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults aged 18-75|February 2012|February 15, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223353||190165|
NCT00223600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRIP19902010|Special Turku Atherosclerosis Risk Factor Intervention Project for Children (STRIP)|Special Turku Atherosclerosis Risk Factor Intervention Project for Children (STRIP)||University of Turku||Active, not recruiting|May 1990|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1062|||Both|7 Months|7 Months|Accepts Healthy Volunteers|||August 2005|September 18, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00223600||190147|
NCT00224172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306006224 (Formerly 0603-908)|Ambulatory Care Characteristics as Predictors of Mortality and Re-Admission|Ambulatory Care Characteristics as Predictors of Mortality and Re-Admission||Weill Medical College of Cornell University|No|Completed|January 2001|December 2001||||N/A|Observational|N/A||||302|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00224172||190104|
NCT00224406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0104|Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Repertaxin in the Prevention of Primary Graft Dysfunction After Lung Transplantation||Dompé Farmaceutici S.p.A||Completed|May 2005|May 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|65 Years|No|||November 2008|November 26, 2008|September 21, 2005||||||https://clinicaltrials.gov/show/NCT00224406||190086|
NCT00215748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOC S-010|Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel|Feasibility of A Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Treated With Weekly Docetaxel||Geriatric Oncology Consortium||Terminated|August 2004|April 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|65 Years|N/A|No|||November 2007|November 15, 2007|September 19, 2005|||slow accrual|No||https://clinicaltrials.gov/show/NCT00215748||190738|
NCT00215722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GICR-P003|XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer|||Grupo de Investigacao do Cancro Digestivo||Active, not recruiting|July 2005|July 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||April 2007|April 5, 2007|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00215722||190740|
NCT00215735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1|Effect of Platelet Concentrate in Treatment of Diabetic Ulcers|Clinical Evaluation of the Safety and Effectiveness of Harvest Autologous Platelet Concentrate and Autologous Thrombin for Treatment of Lower Extremity Chronic Diabetic Ulcers||Harvest Technologies||Terminated|June 2004|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind|1||||||Both|18 Years|N/A|No|||March 2012|March 16, 2012|September 14, 2005|Yes|Yes|inconclusive results, market feasiblity|No||https://clinicaltrials.gov/show/NCT00215735||190739|
NCT00217282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN08|Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer|Phase II Trial OF Oxaliplatin and Gemcitabine With Bevacizumab in Advanced Non-Small Cell Lung Cancer||Mt. Sinai Medical Center, Miami|No|Completed|June 2004|March 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|80 Years|No|||May 2008|May 20, 2008|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217282||190621|
NCT00217295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-101|A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis|A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis.||Multiple Sclerosis Institute||Recruiting|April 2004|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||June 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00217295||190620|
NCT00216723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korea Abilify PMS|Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder|Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder||Korea Otsuka Pharmaceutical Co.,Ltd.||Completed|April 2004|December 2009|Actual|||Phase 4|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|80 Years|No|Probability Sample|-  Patient with a schizophrenia or schizoaffective disorder or bipolar disorder             according to DSM-IV criteria          -  Age: more than 18 years of age|October 2013|October 22, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00216723||190664|
NCT00216736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.221|Oral Dexamethasone for Treatment of Migraine|Does a Single Oral Dose of Dexamethasone After Successful Emergency Treatment of Migraine Reduce the Incidence or Severity of Rebound Headache Within 48 Hours?||The Joseph Epstein Centre for Emergency Medicine Research|No|Completed|April 2005|July 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|63|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|September 14, 2005||No||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00216736||190663|
NCT00217243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH04-196|Evoked Fields After Median and Ulnar Stimulation|Evoked (Magnetic) Cortical Fields for the Comparative Study of Mechanisms Underlying Chronic Non-malignant Pain in Peripheral Nerve Injury (CRPS II) and CRPS I (Chronic Regional Pain Syndrome I)||Medical Center Alkmaar|No|Completed|June 2005|June 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|17 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjetcs were sampled from the hospital staff of two hospitals all patients were recruited        from one hospital|September 2009|September 17, 2009|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217243||190624|
NCT00214006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0053|Carotid Atherosclerotic Plaque Study|Carotid Atherosclerotic Plaque Study||University of Wisconsin, Madison|No|Completed|November 2001|February 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|162|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing carotid endarectomy|March 2013|March 6, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00214006||190866|
NCT00214019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2003-0469|The Effect of Salmeterol on Eosinophil Function|The Effect of Salmeterol on Eosinophil Function||University of Wisconsin, Madison||Completed|November 2003|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||16|||Both|18 Years|55 Years|No|||October 2008|October 31, 2008|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00214019||190865|
NCT00213252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007674|Use of Montelukast to Treat Children With Mild to Moderate Acute Asthma|Can Montelukast Shorten Corticosteroid Therapy In Children With Mild To Moderate Acute Asthma?||The Hospital for Sick Children|Yes|Completed|September 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|2 Years|17 Years|No|||May 2014|May 12, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213252||190924|
NCT00213577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/112/HP|NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder|Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment||University Hospital, Rouen|Yes|Terminated|December 2003|October 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|September 13, 2005|||the study has concluded normally;|No||https://clinicaltrials.gov/show/NCT00213577||190899|
NCT00213590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998/081/HP|Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients|A Multicentric, Randomized, Opened Study to Evaluate Efficacy on Renal Function of an Immunosuppressant Regimen Based on Cyclosporine A Dose Reduction in Combination With Mycophenolate Mofetil, From the Second Year of Renal Transplantation|DICAM|University Hospital, Rouen|Yes|Completed|April 2000|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|75 Years|No|||February 2012|February 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213590||190898|
NCT00213564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/061/HP|Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis|Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis||University Hospital, Rouen|No|Completed|April 2003|December 2005|Actual|May 2004|Actual|Phase 4|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213564||190900|
NCT00214630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522US/0001|LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes|A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes||AstraZeneca||Completed|December 2003|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|825|||Both|18 Years|70 Years|No|||November 2010|November 18, 2010|September 21, 2005||||||https://clinicaltrials.gov/show/NCT00214630||190821|
NCT00214890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG584|Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir|CCTG584: Viral Dynamics and Pharmacokinetics of Tenofovir and Abacavir Monotherapy Versus the Combination Therapy of TDF-ABC in HIV-Infected Treatment Naive Patients||California Collaborative Treatment Group||Completed|April 2005|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00214890||190802|
NCT00215527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRC-001|Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I|A Study of Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis I||Dickson, Patricia I., M.D.|Yes|Terminated|November 2005|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|8 Years|N/A|No|||February 2013|February 20, 2013|September 19, 2005|No|Yes|Due to slow enrolment.|No||https://clinicaltrials.gov/show/NCT00215527||190755|
NCT00215852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDO-101|A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects|A Randomized, Dose-Ranging Study of Alferon® LDO [Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)] in Asymptomatic HIV+ Subjects||Hemispherx Biopharma|No|Terminated|July 2005|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00215852||190730|
NCT00215865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRN 003|PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy|HRN 003PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy||Hepatitis Resource Network||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||September 2005|September 20, 2005|September 20, 2005||||||https://clinicaltrials.gov/show/NCT00215865||190729|
NCT00223366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20020071H|In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors|Studies on Normal and Inflamed Dental Pulp, NPY Regulation of Peripheral Human Nociceptors, Peripheral Mechanisms of Opioid Analgesia, Cannabinoid-induced Desensitization of TRPV1 Receptors Adrenergic Modulation of Trigeminal Nociceptors||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|October 2001|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|2000|Samples With DNA|Whole blood, serum, sputum, oral mucosa tissue, teeth|Both|16 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers between ages 16-90 y.o. presenting to the dental clinics within the        University Health Science Center San Antonio for extraction of teeth.|February 2016|February 4, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223366||190164|
NCT00223613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPP19942014|Intranasal Insulin for Prevention of Type 1 Diabetes|Intranasal Insulin for Prevention of Type 1 Diabetes in Children Carrying Increased HLA-Conferred Genetic Risk||University of Turku||Recruiting|August 1997|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||240|||Both|1 Year|15 Years|Accepts Healthy Volunteers|||August 2005|September 18, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00223613||190146|
NCT00223626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12350|Topiramate to Reduce Cocaine Dependence|Lab Trials to Develop Medication for Cocaine Dependence||University of Virginia|Yes|Completed|January 2007|December 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|45 Years|No|||April 2012|April 17, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223626||190145|
NCT00224419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007724|Testing Pharmacological Therapies for Pregnant Smokers|Testing Pharmacological Therapies for Pregnant Smokers||Duke University|Yes|Terminated|June 2003|||August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|181|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|July 18, 2014|September 21, 2005|No|Yes|was terminated due to meeting a priori stopping rule set by DSMB|No||https://clinicaltrials.gov/show/NCT00224419||190085|
NCT00224432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc/99/07/116|Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis|Double-Blind, Parallel, Randomised Study to Investigate the Clinical and Immunological Effects of Oral Administration of Probiotic Bacteria in Infants With Atopic Dermatitis With and Without Cow’s Milk Allergy.||Groningen Research Institute for Asthma and COPD||Completed|March 2001|September 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|N/A|5 Months|No|||September 2006|September 26, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00224432||190084|
NCT00224666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000901|Efficacy of Cortex Stimulation in Neuropathic Pain|Evaluation of the Effectiveness of Stimulation Cortex Sensorimotor for the Treatment of Rebel Neuropathic Pains||Assistance Publique - Hôpitaux de Paris||Terminated|March 2001|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||16|||Both|18 Years|N/A|No|||January 2007|January 9, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00224666||190066|
NCT00216242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDB707-106|Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.|A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age||ID Biomedical Corporation, Quebec||Active, not recruiting|September 2005|May 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||7400|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2006|December 8, 2006|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00216242||190700|
NCT00216528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004966|A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres|A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)||Janssen Korea, Ltd., Korea||Completed|July 2005|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|527|||Both|18 Years|75 Years|No|||April 2010|April 26, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00216528||190679|
NCT00213005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #297|Safety and Acceptability of Carraguard® in HIV Positive Women and Men|A Phase 1 Safety and Acceptability Study of Carraguard® Among HIV Positive Women and Men in Durban, South Africa||Population Council||Completed|June 2002|August 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||60|||Both|18 Years|45 Years|No|||February 2005|December 21, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00213005||190943|
NCT00216983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-008463|Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding|Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding.||National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|September 1997|January 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Anticipated|24|||Both|18 Years|N/A|No|Probability Sample|Critically ill burn patients|August 2009|August 12, 2009|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00216983||190644|
NCT00217256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP056|The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial|A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|ENDEAVOR III|Medtronic Vascular|Yes|Completed|February 2004|December 2010|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|436|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00217256||190623|
NCT00214435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEddI|Once Daily 3TC, Efavirenz and ddI for HIV Infection|A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily||407 Doctors||Recruiting|May 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||September 2005|October 21, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00214435||190836|
NCT00214383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-163|Internet Telehealth for Pediatric Asthma Case Management|Internet Telehealth for Pediatric Asthma Case Management|CHESS|University of Wisconsin, Madison|Yes|Completed|May 2004|May 2009|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|301|||Both|4 Years|12 Years|No|||January 2013|January 16, 2013|September 13, 2005||No||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00214383||190838|
NCT00214422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050241|Intensity Modulated Radiation Therapy for Prostate Cancer|A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|September 2005|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Male|18 Years|90 Years|No|||June 2015|June 25, 2015|June 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00214422||190837|
NCT00213980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 99103|Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer|Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer||University of Wisconsin, Madison|Yes|Completed|January 2000|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Female|18 Years|N/A|No|||January 2013|January 16, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00213980||190868|
NCT00213993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0487|Topical Antiperspirant for Hand-Foot Syndrome|Topical Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Associated With Capecitabine||University of Wisconsin, Madison||Completed|May 2005|January 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|N/A|No|||December 2007|October 1, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213993||190867|
NCT00214903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG 2000_3|European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)|European Active Surveillance Study of Women Taking HRT||Center for Epidemiology and Health Research, Germany|Yes|Completed|November 2004|November 2011|Actual|May 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30597|||Female|40 Years|N/A|No|Non-Probability Sample|Women aged 40 or more years using HRT|November 2014|November 13, 2014|September 19, 2005||No||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00214903||190801|In non-experimental studies like EURAS-HRT the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.
NCT00215540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL4-BPD-01|SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.|A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of SURFAXIN® (Lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dysplasia||Discovery Laboratories, Inc.|Yes|Terminated|February 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|136|||Both|N/A|10 Days|No|||May 2012|May 11, 2012|September 14, 2005|Yes|Yes|Concerns related to availability of drug product|No|April 2, 2012|https://clinicaltrials.gov/show/NCT00215540||190754|
NCT00215878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heresco2CTIL|D-serine for Posttraumatic Stress Disorder Treatment|D-serine for Posttraumatic Stress Disorder Treatment||Herzog Hospital|Yes|Completed|August 2003|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|25 Years|75 Years|No|||July 2012|July 5, 2012|September 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00215878||190728|
NCT00215891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRN 005|PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon|PEG-Interferon a-2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon||Hepatitis Resource Network||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||September 2005|October 24, 2005|September 20, 2005||||||https://clinicaltrials.gov/show/NCT00215891||190727|
NCT00215215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-20|Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures|Post Marketing Study; Randomized, Parallel-Group Comparison of Treatment With Pharmacotherapy or Adjunctive Vagus Nerve Stimulation Therapy for Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial||Cyberonics, Inc.||Terminated|February 2005|November 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|12 Years|N/A|No|||February 2006|February 20, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00215215||190777|
NCT00223860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2648|Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.|Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury||VA Office of Research and Development|No|Completed|July 2001|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2008|March 5, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223860||190127|
NCT00223873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7927-09|The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury|The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury||VA Office of Research and Development||Completed|November 2002|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|18 Years|70 Years|No|||May 2006|January 20, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00223873||190126|
NCT00223379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-1904-342|Longitudinal Endodontic Study of Apical Preparation Size|Longitudinal Endodontic Study of Apical Preparation Size||The University of Texas Health Science Center at San Antonio|No|Completed|December 2002|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223379||190163|
NCT00224952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10606|Pathogenesis of Adverse Drug Reactions|The Role of Drug Metabolizing Enzymes in the Pathogenesis Adverse Drug Reactions in Children||Children's Mercy Hospital Kansas City|No|Completed|July 2002|||March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|98|Samples With DNA|Urine DNA (source: blood or saliva)|Both|1 Year|16 Years|No|Probability Sample|Pediatric patients of both genders between 1 and 16 years of age receiving carbamazepine        (CBZ) or valproic acid (VPA) as monotherapy or polytherapy|April 2013|April 29, 2013|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224952||190044|
NCT00224458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-164-0107|Combination of Efavirenz and Truvada - COMET Study|Combination of Efavirenz & Truvada (COMET Study): Phase 4 Evaluation of Switching Twice Daily Combivir to Once-Daily Regimen Co-Formulated Truvada in Virologically Suppressed HIV Infected Patients Taking Efavirenz.||Gilead Sciences||Completed|September 2004|February 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||400|||Both|18 Years|N/A|No|||February 2008|April 7, 2008|September 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00224458||190082|
NCT00225550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adherex Protocol AHX-01-003|A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors|Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Daily for 5 Consecutive Days by Intravenous Infusion in Subjects With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX 01 003)||Adherex Technologies, Inc.||Terminated||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2007|August 3, 2007|September 22, 2005||||||https://clinicaltrials.gov/show/NCT00225550||189999|
NCT00216268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/8/7/1/13/2001-ECD1|Treatment of Japanese Encephalitis|Treatment of Japanese Encephalitis - a Double Blind Placebo Controlled Trial||Indian Council of Medical Research||Recruiting|July 2005|May 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|6 Months|12 Years|No|||September 2005|February 8, 2006|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00216268||190698|
NCT00213265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020020011|Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants|Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Among Solid Organ Transplant Recipients: Protocol 1A and 1B||The Hospital for Sick Children|No|Active, not recruiting|July 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|2 Months|18 Years|No|||August 2013|August 15, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213265||190923|
NCT00213278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020010429|Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma|A Phase 2 Study of Vinblastine Sulphate Injection in Children With Recurrent or Refractory Low Grade Glioma||The Hospital for Sick Children|Yes|Completed|January 2002|September 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|21 Years|No|||November 2014|November 19, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213278||190922|
NCT00213616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999/141/HP|Bilateral Laryngeal Paralysis Reinnervation|Bilateral Laryngeal Paralysis Reinnervation. Speech and Ventilatory Results Analysis||University Hospital, Rouen|Yes|Completed|March 2004|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213616||190896|
NCT00213629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/094/HP|myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies|Transcriptome Analysis Through a Dedicated Macro-array and TcLandscape Repertoire Analysis for Diagnosis of Myositis.|MYOARRAY|University Hospital, Rouen|Yes|Completed|November 2004|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|76 Years|No|||February 2012|February 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213629||190895|
NCT00213642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/003/HP|Tc-99m Renography and Cisplatin-induced Nephrotoxicity|Value of Tc-99m Renography for Early Diagnosis of Cisplatin-induced Renal Toxicity||University Hospital, Rouen|No|Terminated|July 2001|August 2004||||N/A|Observational|Time Perspective: Prospective||||20|||Both|18 Years|80 Years|No|||June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213642||190894|
NCT00214032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0047|Pycnogenol for the Treatment of Lymphedema|Treatment of Arm Lymphedema in Breast Cancer Survivors: A Double-Blind, Randomized Study of Pycnogenol vs. Placebo||University of Wisconsin, Madison||Completed|May 2002|January 2007|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Female|18 Years|N/A|No|||January 2008|October 1, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214032||190864|
NCT00213603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/032/HP|Follow-up Modalities of Low Grade Precancerous Bronchial Lesions|Endoscopic Follow-up of Low Grade Precancerous Bronchial Lesions in High Risk Patients (SELEPREBB1)||University Hospital, Rouen|Yes|Completed|April 2002|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|365|Samples Without DNA|bronchial biopsies (fixed samples)|Both|18 Years|80 Years|No|Non-Probability Sample|subjects at high risks for developping a lung cancer|January 2013|January 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213603||190897|
NCT00214071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-284|Immunological Consequences of Obstructive Sleep Apnea|Influence of Obstructive Sleep Apnea on Humoral and Cell-Mediated Vaccine Responses||University of Wisconsin, Madison||Completed|October 2004|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|October 1, 2015|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00214071||190861|
NCT00214656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2005/02047|"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery|"Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial||Austin Health||Recruiting|June 2005|June 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00214656||190819|
NCT00214643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2005/FOS-CLIN/SP|Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children|A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria||Albert Schweitzer Hospital||Completed|June 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|3 Years|14 Years|No|||February 2009|February 3, 2009|September 11, 2005||||No||https://clinicaltrials.gov/show/NCT00214643||190820|
NCT00215189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS200406|Evaluation of a Health Promotion Intervention for Persons With Mental Illness|Evaluation of a Health Promotion Intervention for Persons With Mental Illness||Dartmouth-Hitchcock Medical Center|Yes|Completed|August 2004|December 2007|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|145|||Both|18 Years|N/A|No|Non-Probability Sample|Community Mental Health Center|September 2009|September 22, 2009|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00215189||190779|
NCT00215228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007159|Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression|Effects of Escitalopram vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control||Duke University||Completed|July 2005|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|26|||Both|20 Years|60 Years|No|||September 2007|July 18, 2014|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00215228||190776|
NCT00224679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 95176|APACC Study:Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence|Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence||Assistance Publique - Hôpitaux de Paris||Terminated|March 1997|March 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|75 Years|No|||September 2006|June 4, 2012|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00224679||190065|
NCT00224224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9510000400 (Formerly 1095-071)|A Comparison of Primary Care and Traditional Internal Medicine Residents|A Comparison of Primary Care and Traditional Internal Medicine Residents||Weill Medical College of Cornell University|No|Completed|January 1995|January 2005||||N/A|Observational|Time Perspective: Retrospective|||||||Both|21 Years|64 Years|No|||March 2008|April 2, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00224224||190100|
NCT00224445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-164-0115|Boosted Atazanavir and Truvada Given Once-Daily - BATON Study|Boosted Atazanavir and Truvada Given Once-Daily (BATON Study): A Phase 4 Study of Safety, Efficacy & Adherence in HIV Infected, Antiretroviral Naïve Subjects Treated With a Simple Once-Daily Regimen||Gilead Sciences||Completed|September 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00224445||190083|
NCT00256906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB1205-HMO-CTIL|Isolated Mild Fetal Ventriculomegaly and Neurodevelopmental Outcome|Isolated Mild Fetal Ventriculomegaly and Neurodevelopmental Outcome||Hadassah Medical Organization|No|Active, not recruiting|January 2006|January 2012|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|1 Year|10 Years|No|Non-Probability Sample|Children up to the age of 10 years who were diagnosed with isolated mild ventriculomegaly        as fetuses|June 2007|May 12, 2008|November 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00256906||187658|
NCT00224692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P010918|Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine|MK III Trial: Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine||Assistance Publique - Hôpitaux de Paris||Terminated|February 2003|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|5 Years|18 Years|No|||October 2006|October 25, 2006|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00224692||190064|
NCT00216060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GU02-41|Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41||Hoosier Cancer Research Network|Yes|Active, not recruiting|October 2003|March 2008|Anticipated|February 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Male|18 Years|N/A|No|||December 2007|December 28, 2007|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00216060||190714|
NCT00216255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP456-039|EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study|An 8-week, Double-blind, Randomized, Multicenter, Flexible-dose, Placebo Controlled Pilot Study of Pagoclone in Patients With PDS Followed by a 52-week Open-label Extension||Endo Pharmaceuticals|Yes|Completed|April 2005|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||August 2012|August 27, 2012|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00216255||190699|
NCT00216996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-008464|Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Burns|Study on the Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Severely Burned Patients||National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|August 1997|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||August 2009|August 12, 2009|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00216996||190643|
NCT00213291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000004731|Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure|Extended Dosing of Darbepoetin Alfa (Aranesp) for the Management of Anemia in Children With Chronic Renal Failure||The Hospital for Sick Children|No|Completed|April 2005|October 2005||September 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|17 Years|No|||August 2013|August 23, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213291||190921|
NCT00214045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0254|Rigid Versus Flexible Cystoscopy in Women|Rigid Versus Flexible Cystoscopy in Women in Outpatient Clinic||University of Wisconsin, Madison|No|Completed|July 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|36|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|November 19, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00214045||190863|
NCT00214058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 02701|Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer|Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma||University of Wisconsin, Madison||Completed|August 2002|February 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Female|18 Years|N/A||||June 2008|September 30, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214058||190862|
NCT00213655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/081/HP|URO-BCG-4 : Bladder Tumors Immunotherapy|Clinical Evaluation of Maintenance BCG Immunotherapy in Superficial Bladder Tumors||University Hospital, Rouen|No|Completed|June 2004|December 2013|Actual|May 2013|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|146|||Both|N/A|N/A|No|Probability Sample|Bladder Cancer|July 2014|July 30, 2014|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00213655||190893|
NCT00214097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO02803|Phase I/II Hypofractionated Radiotherapy for Prostate Cancer|Phase I/II Trial Examining Dose-per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer||University of Wisconsin, Madison|Yes|Active, not recruiting|August 2002|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|309|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214097||190859|
NCT00214448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-801|Reproducibility of the Array-Based Comparative Genomic Hybridization (aCGH) System Using Whole Blood Samples|Reproducibility of the GeneTrait™ CGH Microarray System DX Using Whole Blood Samples||Abbott Molecular||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||4|||Both|N/A|N/A|No|||September 2005|July 13, 2006|September 20, 2005||||||https://clinicaltrials.gov/show/NCT00214448||190835|
NCT00214916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICU-insulin study|Tight Glycemic Control With Intensive Insulin Therapy in PICU|KULeuven Intensive Insulin Study in Pediatric Intensive Care Patients||Katholieke Universiteit Leuven|Yes|Active, not recruiting|October 2004|February 2012|Anticipated|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|700|||Both|N/A|16 Years|No|||August 2011|August 24, 2011|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00214916||190800|
NCT00215202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0327|Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)|A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)||Dartmouth-Hitchcock Medical Center|Yes|Completed|August 2004|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|33|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00215202||190778|
NCT00214929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIO30192|Home Treatment of Pulmonary Embolism|Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism||Carlos III Health Institute||Active, not recruiting|December 2004|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2005|December 8, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00214929||190799|
NCT00214942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3042/BP/US|Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Low Back Pain||Teva Pharmaceutical Industries||Completed|September 2005|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||May 2014|May 8, 2014|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214942||190798|
NCT00214955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3041/BP/US|Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain||Teva Pharmaceutical Industries||Completed|September 2005|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|80 Years|No|||May 2014|May 8, 2014|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214955||190797|
NCT00214968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/3034/ES/MN|Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness|A 6-Month Open Label, Flexible-Dosage Study to Assess the Safety and Effectiveness of PROVIGIL (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome||Teva Pharmaceutical Industries||Completed|January 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|6 Years|16 Years|No|||May 2012|May 23, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214968||190796|
NCT00214981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538D/312/AD/US|Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD|A 1-Year, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Continued Efficacy of Modafinil (Film-coated Tablet Formulation) in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (Followed by an Open-Ended Extension Period)||Teva Pharmaceutical Industries||Completed|September 2003|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|6 Years|17 Years|No|||July 2012|July 25, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214981||190795|
NCT00223418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023-0013-300|Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills|Do Patients Taking Aripiprazole Learn More in Vocational Skills Training Than Patients Taking Olanzapine?||The University of Texas Health Science Center at San Antonio|No|Completed|January 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|43|||Both|18 Years|52 Years|Accepts Healthy Volunteers|||April 2013|April 5, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223418||190161|
NCT00223665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30296-A|Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy|A Prospective Study of Intermittent Androgen Suppression in Men With Localized Prostate Cancer Who Have Biochemical Relapse After Radiation Therapy or Radical Prostatectomy||University of Washington|No|Recruiting|January 1997|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|21 Years|N/A|No|||January 2011|January 19, 2011|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00223665||190142|
NCT00223678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000294|Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure|Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure||Vanderbilt University|No|Active, not recruiting|June 2000|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|N/A|No|||February 2008|February 21, 2008|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00223678||190141|
NCT00224211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506007948|Music's Effects on Premature Babies.|Effects of Homophonic Sounds on Preterm Infants||Weill Medical College of Cornell University|Yes|Completed|June 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|Premature infants|September 2005|March 12, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00224211||190101|
NCT00256321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 03-34|Celecoxib/Oxaliplatin/Capecitabine for Gastric/GE Junction Carcinoma|A Phase II Study of Celecoxib/Oxaliplatin/Capecitabine Combination Chemotherapy for Unresectable,Recurrent, or Metastatic Gastric/Gastroesophageal Junction Carcinoma||University of California, Irvine||Completed|October 2004|August 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||February 2008|February 27, 2008|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00256321||187702|
NCT00256581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0273|Imaging Studies With GE C-Hawk Gamma Camera Compared to Routine Clinical Exam|Imaging Studies With GE C-Hawk Gamma Camera Compared to Routine Clinical Exam||University of Wisconsin, Madison|No|Completed|November 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Adults undergoing SPECT Myocardial perfusion imaging|August 2012|August 28, 2012|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00256581||187682|
NCT00224705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030423|The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure|Efficacy and Safety of the Albumin Dialysis MARS® Therapy in Patients With Fulminant and Subfulminant Hepatic Failure||Assistance Publique - Hôpitaux de Paris|Yes|Completed|August 2004|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|70 Years|No|||July 2007|February 16, 2011|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00224705||190063|
NCT00216749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korea Pletaal CSPS PMS|Efficacy and Safety of Cilostazol for the Indication of CSPS|Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|December 2003|October 2007|Actual|October 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|650|||Both|18 Years|80 Years|No|Probability Sample|Patients in restabilization status after cerebral infarction (excluding cardiogenic        cerebral embolism)|December 2009|December 15, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00216749||190662|
NCT00217334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-149-02|Community Hypertension Assessment Trial (CHAT)|A Pragmatic Trial of Community Pharmacy Blood Pressure Clinics Linked With Family Medicine Practices to Improve the Monitoring and Management of High Blood Pressure Among Older Adults||McMaster University||Completed|November 2002|January 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||28|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 19, 2005|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00217334||190617|
NCT00217048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|275-05|Effect of Yohimbine on Colon Transit|Effect of Oral Yohimbine on Colonic Transit: Randomized, Placebo-Controlled Trial||Mayo Clinic||Completed|June 2005|October 2005|Actual|October 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|65 Years|No|||April 2009|April 27, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00217048||190639|
NCT00213018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #210|Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission|A Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing STI/HIV Transmission||Population Council||Completed|October 1999|January 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2004|October 21, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00213018||190942|
NCT00213031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #271|Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide|A Randomized, Placebo-Controlled, Double-Blind Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of PC-515 (Lambda Carrageenan) for Vaginal Use as a Possible Microbicide||Population Council||Completed|February 2000|December 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||165|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2002|May 10, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00213031||190941|
NCT00213317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/041/HP|Effect of Lumbo-sacral Magnetic Stimulation on Colonic Motility|Could Lumbo-sacral Magnetic Stimulation Modify Recto-colonic Motility?||University Hospital, Rouen|No|Completed|April 2005|August 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers without anorectal or neurological disease|February 2012|February 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213317||190919|
NCT00213330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/105/HP|Cerebral Resonance Magnetic Imaging During Rectal Distention|Cerebral Activity During Rectal Pain in Patients With Irritable Bowel Syndrome or Inflammatory Bowel Disease:Resonance Magnetic Imaging Study.||University Hospital, Rouen||Withdrawn|April 2003|February 2006||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects and patients with irritable bowel syndrome|April 2012|April 20, 2012|September 13, 2005|||patients with inflammatory colitis not included|No||https://clinicaltrials.gov/show/NCT00213330||190918|
NCT00213681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/059/HP|CPAP Versus Bilevel Pressure Support Ventilation in Cardiogenic Pulmonary Edema|CPAP Boussignac Versus Bilevel Pressure Support Ventilation in Severe Acute Cardiogenic Pulmonary Edema||University Hospital, Rouen||Completed|November 2002|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2013|June 17, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00213681||190891|
NCT00213668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/111/HP|Effect of Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates|Effect of Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates||University Hospital, Rouen||Completed|April 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|10 Days||||June 2013|June 17, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213668||190892|
NCT00213694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/052/HP|PROSTACOX : Metastatic Prostate Chemotherapy|Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer||University Hospital, Rouen||Completed|November 2003|June 2006||||Phase 2|Observational|Time Perspective: Prospective||||52|||Male|N/A|N/A|No|||March 2013|March 4, 2013|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213694||190890|
NCT00213707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2864|Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution.|Liver Transplanted Patients for HCV Related End Stage Liver Disease.Functional Role of Blood Circulating Dendritic Cells in the Pathogenesis of Hepatitis C Virus Infection During Liver Transplantation.||University Hospital, Strasbourg, France|No|Active, not recruiting|May 2003|May 2011|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Serum peripheral blood mononuclear cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients for liver transplantation indicated after chronic hepatitis C.|February 2009|February 24, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213707||190889|
NCT00214461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-030-009|Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers|A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Elderly Volunteers (> or =65 Years)||Sanofi|No|Completed|November 2005|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|48|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 9, 2012|September 16, 2005|Yes|Yes||No|March 13, 2012|https://clinicaltrials.gov/show/NCT00214461||190834|
NCT00214669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG-09-05-IHS|Can Education for South Asians With Asthma and Their Clinicians Reduce Unscheduled Care? A Randomised Trial|Can Education for South Asians With Asthma and Their Clinicians Reduce Unscheduled Care? A Cluster Randomised Trial|OEDIPUS|Barts & The London NHS Trust||Completed|November 2005|April 2009|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|375|||Both|3 Years|65 Years|No|||May 2009|June 3, 2009|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00214669||190818|
NCT00214695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-RENAL-REG-064|A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis|A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis||Baxter Healthcare Corporation||Completed|May 2005|July 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||November 2006|November 20, 2006|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00214695||190816|
NCT00214994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6671/3033/AX/US|Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.|A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment (up to 16 mg/Day) in Adults With Generalized Anxiety Disorder.||Teva Pharmaceutical Industries||Completed|January 2005|December 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|64 Years|No|||May 2014|May 8, 2014|September 14, 2005||||||https://clinicaltrials.gov/show/NCT00214994||190794|
NCT00215007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levosta-CBF-02/04|Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)|Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem Cells||Charite University, Berlin, Germany||Recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|N/A|No|||February 2004|November 29, 2007|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00215007||190793|
NCT00205335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2004-1069|Free Test Strips and Blood Glucose Control|The Impact of Increased Availability of Test Strips on Blood Glucose Control in Patients With Diabetes||University of Wisconsin, Madison|No|Completed|January 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205335||191521|
NCT00205608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/194|Microglia Activation in Schizophrenia|Microglia Activation in Schizophrenia: a Pilot Study||VU University Medical Center|No|Completed|January 2004|December 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2008|June 25, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205608||191500|
NCT00205621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/90|Positron Emission Tomography of Amyloid in Alzheimer's Disease|Positron Emission Tomography of Cerebral Amyloid Load as a Potential Diagnostic Marker for Pre-Symptomatic Alzheimer’s Disease.||VU University Medical Center||Suspended|October 2005|December 2009||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Male|60 Years|80 Years|Accepts Healthy Volunteers|||August 2005|September 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205621||191499|
NCT00255775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0427, CDR0000450158|Broccoli Sprout Extract in Preventing Lung Cancer in Smokers|Evaluation of the Biological Effects of Broccoli Sprout Extract in Smokers||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2005|||May 2009|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Prevention|||Anticipated|70|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00255775||187743|
NCT00223899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM01-101|A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma|A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma||Vical|No|Completed|July 2005|October 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00223899||190125|
NCT00257179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700609|The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor|||National Taiwan University Hospital||Recruiting|June 2005|||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||200|||Both|16 Years|N/A|No|||June 2005|March 13, 2006|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257179||187637|
NCT00257140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005494|A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria|A Multicenter, Active-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Oral Levofloxacin Versus Cefaclor in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis in Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 1931|July 1994|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|367|||Both|18 Years|N/A|No|||January 2011|June 8, 2011|November 18, 2005||||||https://clinicaltrials.gov/show/NCT00257140||187640|
NCT00257153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEAR-MI|Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction.|||Niguarda Hospital||Completed|March 2004|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|N/A|80 Years|No|||June 2005|December 1, 2006|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00257153||187639|
NCT00257166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281132|Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)|Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)||Pfizer||Completed|January 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|238|||Both|10 Years|17 Years|No|||July 2013|July 24, 2013|November 21, 2005|No|Yes||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00257166||187638|
NCT00257465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/100/0401|Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma|M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma||AVAX Technologies|Yes|Completed|June 2005|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257465||187615|
NCT00257478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-007|A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy|||Astellas Pharma Inc||Completed||March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||June 2012|June 6, 2012|November 22, 2005||||||https://clinicaltrials.gov/show/NCT00257478||187614|
NCT00217308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0169-A|Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery|Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery||Mount Sinai Hospital, Canada|No|Suspended|February 2005|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|160|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2007|August 23, 2007|September 14, 2005|||Tightly defined inclusion criteria were making recruitment very slow.|No||https://clinicaltrials.gov/show/NCT00217308||190619|
NCT00217061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-05|Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus|The Statin Choice Decision Aid and Its Effects on Statin Decisions in Patients With Type 2 Diabetes Mellitus. A Clustered Randomized Trial||Mayo Clinic||Completed|April 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||98|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00217061||190638|
NCT00217074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2294-03|Acupuncture and Hot Flashes|Acupuncture for Hot Flashes: A Randomized Sham Controlled Clinical Study||Mayo Clinic||Terminated|January 2004|October 2005|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|103|||Female|45 Years|59 Years|Accepts Healthy Volunteers|||February 2010|February 1, 2010|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00217074||190637|
NCT00213044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #316|A Randomized, Controlled, Cross-Over Trial of Safety of Vaginal Use of Carraguard by HIV-Infected Women|A Randomized, Controlled, Double-Blind, Cross-Over Trial of Safety, Effect on Genital Tract HIV Shedding, and Acceptability of Vaginal Use of Carraguard by HIV-Infected Women||Population Council||Completed|March 2003|June 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Female|18 Years|50 Years|No|||October 2004|October 21, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00213044||190940|
NCT00213304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019990029|The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation|Safety and Immunogenicity of Live Attenuated Oka/Merck Varicella Vaccine in Children Listed to Undergo Solid Organ Transplantation||The Hospital for Sick Children||Active, not recruiting|June 1999|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|9 Months|18 Years|No|||August 2013|August 15, 2013|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00213304||190920|
NCT00213057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #270|Safety and Acceptability of Carraguard™ Among HIV-Negative Couples in Thailand|A Randomized, Placebo-Controlled, Double-Blind Trial to Assess Expanded Safety and Acceptability of Carraguard™ (PC-515) Vaginal Gel Among Heterosexual Couples in Chiang Rai||Population Council||Completed|June 2001|June 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2002|December 21, 2005|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00213057||190939|
NCT00213070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1005|Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|N/A|No|||September 2006|September 20, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213070||190938|
NCT00214084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-085|Vascular Pathophysiology in Obstructive Sleep Apnea|Influence of Xanthine Oxidase Inhibition on Vascular Function in Obstructive Sleep Apnea||University of Wisconsin, Madison||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00214084||190860|
NCT00213343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002 /149/HP|Effects of Phrenic Nerve Stimulation During Swallowing : Experimental Model of Aspiration|Effects of Phrenic Nerve Stimulation During Swallowing : Experimental Model of Aspiration||University Hospital, Rouen|No|Terminated|May 2005|July 2005|Actual|June 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Stroke patients|June 2013|June 17, 2013|September 13, 2005||No|dyspnea|No||https://clinicaltrials.gov/show/NCT00213343||190917|
NCT00213733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3207|Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer|Research of Molecular Markers for Diagnosis and/or Prognosis in Lymph Node Metastasis of Resected Non-small Cell Lung Cancer||University Hospital, Strasbourg, France||Completed|June 2004|August 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Patients with resectable non-small cell lung cancer (stage I to IIIA), with a complete        resection of the tumor and paired lymph nodes|August 2011|August 29, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213733||190887|
NCT00214136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO04807|Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes|A Phase II Prostate Cancer Trial Treating Pelvic Lymph Nodes to High Dose Using Intensity Modulated Radiation Therapy||University of Wisconsin, Madison|Yes|Completed|March 2005|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||March 2016|March 18, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00214136||190856|
NCT00214110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-486|Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]|Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]||University of Wisconsin, Madison|Yes|Completed|January 2001|January 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||100|||Both|18 Years|90 Years|No|||August 2008|October 1, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00214110||190858|
NCT00214123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO04502|Hypofractionated Radiotherapy for Lung Cancer|The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer||University of Wisconsin, Madison|Yes|Completed|June 2004|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|79|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00214123||190857|
NCT00214682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/188 HREC|Beyond Ageing Project: A Study for the Prevention of Depression|Beyond Ageing Project: A RCT to Assess the Benefit of Improving Mental Health Literacy as Well as the Effect of Folate and B12, and Physical Activity, in Preventing Major Depression and Cognitive Decline Among Older Australians||Australian National University|Yes|Completed|October 2005|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|909|||Both|65 Years|74 Years|No|||September 2011|September 12, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00214682||190817|
NCT00205309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-562|Airway IgA: Respiratory Tract IgA Levels in Critically Ill Intubated Patients|Respiratory Tract IgA Levels in Critically Ill Intubated Patients||University of Wisconsin, Madison||Completed|January 2003|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Intubated intensive care patients|October 2012|October 16, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205309||191523|
NCT00205322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2003-0544 (CO03216)|Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer|A Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Metastatic Colorectal Cancer||University of Wisconsin, Madison|Yes|Completed|April 2004|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00205322||191522|
NCT00205348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-093|Swallowing Function Before and After Surgery for Thyroid Goiter|Swallowing Function Before and After Surgery for Thyroid Goiter||University of Wisconsin, Madison||Completed|April 2002|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Subjects undergoing thyroid surgery|February 2009|February 19, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205348||191520|
NCT00205634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG99-486|Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis|Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis||Wake Forest School of Medicine||Active, not recruiting|December 2000|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|6 Years|50 Years|No|||December 2007|December 13, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00205634||191498|
NCT00205647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAM-13343|Study of Expectorant Activity of Oral N-Acetylcystein (NAC) in Patients With Stable Chronic Bronchitis|A Phase II Multicenter Efficacy, Safety and Dose-Effect Study of the Expectorant Activity of Oral N-Acetylcystein (NAC) in Patients With Stable, Chronic Bronchitis||Wake Forest School of Medicine||Completed|January 1997|March 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|75 Years|No|||March 2000|January 4, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205647||191497|
NCT00256594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R04RH05814-01-00|Evaluation of an Outpatient Modified Prescription Form|Evaluation of an Outpatient Modified Paper Prescription Form in 4 Rural States to Address the Public Health Problem of Prescribing Error||University of Vermont|No|Completed|August 2005|January 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|84|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 14, 2011|November 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00256594||187681|
NCT00256022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000.177|The Effect of Prophylactic Pre Operative Probiotic Therapy on Endotoxin Levels in Cardiac Surgery Patients|The Effect of Prophylactic Pre Operative Probiotic Therapy on Peri Operative Endotoxin Levels in Cardiac Surgery Patients.||Melbourne Health|No|Withdrawn|July 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|0|||Both|18 Years|N/A|No|||April 2015|November 18, 2015|November 17, 2005|||Due to delays with logistics and protocol revision not viable to continue.|No||https://clinicaltrials.gov/show/NCT00256022||187725|
NCT00257192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281134|Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia|Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia||Pfizer|Yes|Terminated|April 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|284|||Both|13 Years|17 Years|No|||December 2011|December 2, 2011|November 21, 2005|Yes|Yes|Please see Detailed Description for termination reason.|No|March 23, 2010|https://clinicaltrials.gov/show/NCT00257192||187636|The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators.
NCT00257205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671009|CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy|A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma||AstraZeneca|Yes|Completed|March 2006|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|655|||Both|18 Years|N/A|No|||June 2012|June 25, 2012|November 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257205||187635|
NCT00257517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021873|Multisite Feeding Study: Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle|Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle||Emory University|No|Completed|October 2005|June 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|30 Days|No|Non-Probability Sample|hypoplastic left heart syndrome|February 2014|February 11, 2014|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00257517||187611|
NCT00257491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.488|Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension|An Open-label Study to Evaluate the Trough and Peak Effect of Once Daily Micardis Plus (Telmisartan 80mg / Hydrochlorothiazide 12.5 mg) by 24 ABPM in Patients With Mild to Moderate Essential Hypertension||Boehringer Ingelheim||Completed|November 2005|August 2006||August 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|80 Years|No|||November 2013|November 8, 2013|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257491||187613|
NCT00257504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBV estimation|Central Blood Volume in Hypotensive Dialysis Patients|Registration of Central Blood Volume in Hypotensive Dialysis Patients - a Comparison of Thoracic Impedance and Central Venous Saturation Monitoring||Danish State Hospital||Completed|November 2005|May 2006||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||20|||Both|18 Years|N/A||||September 2006|September 11, 2006|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257504||187612|
NCT00217321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03BN117|Parkinson's Disease Registry of the Muhammad Ali Parkinson Center|Parkinson's Disease Registry||Muhammad Ali Parkinson Research Center||Active, not recruiting|November 2003|December 2015|Anticipated|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|Participants must be over 18 years old, have idiopathic Parkinson's disease diagnosed by a        physician.|September 2006|July 20, 2010|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00217321||190618|
NCT00207701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004792|A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.|A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy||Centocor, Inc.||Completed|September 2002|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|279|||Both|18 Years|N/A|No|||August 2010|May 16, 2011|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00207701||191344|
NCT00217347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/05/3-J|Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy|||Nantes University Hospital||Completed|September 2005|July 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|150|||Both|18 Years|70 Years|No|||June 2008|June 4, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00217347||190616|
NCT00213083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #322|Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission|Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard® in Preventing HIV Seroconversion in Women||Population Council||Completed|April 2004|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||6203|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00213083||190937|
NCT00213382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/031/HP|Cortical Pharyngeal Area: Excitability, Facilitation and Plasticity in Healthy Subjects|Cortical Pharyngeal Area: Excitability, Facilitation and Plasticity in Healthy Subjects||University Hospital, Rouen||Completed|February 2005|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|February 2011|February 23, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213382||190914|
NCT00213356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/099/HP|Study of the Nervous Control of the Anal Sphincter|Evoked Responses of External Anal Sphincter After Cortical and Lombo-sacral Magnetic Stimulations||University Hospital, Rouen|No|Withdrawn|April 2003|March 2004||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|healthy volunteers patients with spinal lesion patients with cauda equina syndrome|June 2013|June 17, 2013|September 13, 2005||No|patients with neurological disease not included|No||https://clinicaltrials.gov/show/NCT00213356||190916|
NCT00213369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/08/HP|Neuromodulation of Aspiration Secondary to Stroke|Neuromodulation of Aspiration Secondary to Stroke||University Hospital, Rouen|No|Completed|January 2007|May 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|No|Non-Probability Sample|stroke patients|February 2012|February 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213369||190915|
NCT00208442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT99/31|A Randomised Single Centre Study to Compare the Long-Term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement|A Prospective, Randomised, Controlled, Single Centre, Blinded Study of the Wear Characteristics of Two Polyethylene Bearing Surfaces, Enduron vs. Marathon||DePuy International|No|Active, not recruiting|June 2001|||September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|45 Years|75 Years|No|||April 2009|April 7, 2009|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00208442||191287|
NCT00214149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO04102|Multi-catheter High Dose Rate (HDR) Breast Brachytherapy|A UW Phase II Trial of Multi-catheter HDR Brachytherapy Following Lumpectomy for Early Stage Breast Breast Cancer||University of Wisconsin, Madison|Yes|Terminated|October 2004|October 2010|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Female|18 Years|N/A|No|||June 2013|June 17, 2013|September 13, 2005|Yes|Yes|lost funding|No||https://clinicaltrials.gov/show/NCT00214149||190855|
NCT00214162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-436|CHESS Caregivers Study: Web-based Support for Informal Caregivers in Cancer|Web-based Support for Informal Caregivers in Cancer||University of Wisconsin, Madison|No|Completed|August 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|235|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00214162||190854|
NCT00204100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEScyclingGlasgow|Paraplegic Cycling: Improving Health After Spinal Cord Injury|The Development of Systems for Paraplegic Cycling: Improving Health After Spinal Cord Injury||University of Glasgow||Active, not recruiting|January 2003|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|N/A||||May 2005|October 11, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204100||191615|
NCT00214474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS014864-01|Improving Diabetes Efforts Across Language and Literacy (IDEALL)|Improving Diabetes Efforts Across Language and Literacy (IDEALL)||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|November 2002|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|339|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00214474||190833|
NCT00204958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-222|Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients|Evaluation of Glutamine Popsicles in Adult/Pediatric Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients||University of Wisconsin, Madison||Completed|February 2004|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|50|||Both|4 Years|75 Years|No|||September 2015|September 29, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204958||191550|
NCT00204971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0409|Enteral Glutamine in Neurologically-injured Patients|Randomized, Placebo-controlled Clinical Trial of Enteral Glutamine Supplementation in Neurologically-injured Patients||University of Wisconsin, Madison||Completed|January 2003|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|102|||Both|18 Years|75 Years|No|||September 2015|September 29, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00204971||191549|
NCT00205920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-012|Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation|Dose Escalation Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema||Aeris Therapeutics|No|Terminated|May 2005|May 2007|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2010|January 14, 2010|September 13, 2005||No|Change in formulation|No||https://clinicaltrials.gov/show/NCT00205920||191477|
NCT00206245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9770C00012|A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.|A Randomised, Double-blind, Multicentre Dose-finding Phase IIb Study for up to 8 Weeks' Treatment With AZD0865 25, 50, 75 mg and Esomeprazole 40 mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects With GERD With Erosive Esophagitis According to the LA Classification in Adult Subjects.||AstraZeneca||Completed|May 2004|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1400|||Both|18 Years|70 Years|No|||January 2013|January 3, 2013|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00206245||191452|
NCT00206258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11741|The Role of Amylin and Glucagon in T1DM|The Role of Amylin and Glucagon in the Management of Normalizing Glucose Excursions in Children With Type 1 Diabetes||Baylor College of Medicine||Completed|July 2002|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||March 2005|June 19, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00206258||191451|
NCT00256607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465A|Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes|CSP #465A - Non-Traditional Cardiovascular Risk Factors And Atherosclerosis In Type 2 Diabetes||VA Office of Research and Development|Yes|Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|40 Years|N/A|No|Non-Probability Sample|This observational study of patients who are enrolled in the ongoing randomized clinical        trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@|June 2014|June 26, 2014|November 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00256607||187680|
NCT00256620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9407000398 Formerly 0794-502CR|Improving Outcomes and Quality of Life After CABG|Improving Outcomes and Quality of Life After CABG||Weill Medical College of Cornell University|No|Completed|December 1996|December 1999||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||412|||Both|35 Years|89 Years|No|||March 2008|March 31, 2008|November 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00256620||187679|
NCT00256919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA3103730|Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)|A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship||GlaxoSmithKline|No|Completed|November 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|51|||Both|18 Years|N/A|No|||October 2012|November 1, 2012|November 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256919||187657|
NCT00256932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-767905/012|Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain||Cubist Pharmaceuticals LLC||Completed|August 2005|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|518|||Both|18 Years|N/A|No|||December 2011|September 1, 2015|November 21, 2005||Yes||||https://clinicaltrials.gov/show/NCT00256932||187656|
NCT00257556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999906 CS004 (PROSPECT)|A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa|A Prospective, Open Label, Randomised, Parallel Group, Comparative Pilot Study to Study the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant FSH (Follitropin Alfa) Administered Subcutaneously to Subfertile Female Patients Undergoing IVF Using Antagonist Downregulation||Ferring Pharmaceuticals|No|Completed|October 2005|April 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||February 2010|February 12, 2010|November 22, 2005||No||No|January 8, 2010|https://clinicaltrials.gov/show/NCT00257556||187608|
NCT00257569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104913|Study Of Atopic Dermatitis In Pediatrics|Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Atopic Dermatitis-||GlaxoSmithKline|No|Completed|August 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||278|||Both|3 Years|14 Years|No|||May 2013|May 3, 2013|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257569||187607|
NCT00257530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-IMQ-05|Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis|Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients||Drugs for Neglected Diseases||Completed|December 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|5 Years|65 Years|No|||June 2008|June 11, 2008|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257530||187610|
NCT00257543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|876-2003|SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease|SALT - Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease||Emory University|Yes|Terminated|January 2006|August 2012|Actual|August 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|16 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|November 22, 2005||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00257543||187609|
NCT00257842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DK 57100-05|Randomized Controlled Trial of Biofeedback Therapy for Dyssynergic Defecation|||Georgia Regents University||Terminated||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|75 Years|No|||September 2014|September 16, 2014|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257842||187586|
NCT00217035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-008462|Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients|Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients.||National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|August 1997|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||August 2009|August 12, 2009|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00217035||190640|
NCT00207948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K12RR017613-03|Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents|Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents||Children's Research Institute|Yes|Terminated|November 2004|July 2009|Actual|May 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|4 Years|21 Years|No|Non-Probability Sample|The total number of recruited subjects in a previous the study was 78 with 50 subjects on        LPV/RTV based ART. Based on PK analysis 4 patients fit inclusion criteria for a dose        adjustment feasibility pilot (this study)|August 2015|August 3, 2015|September 13, 2005||No|no measurable response was detected at the 50% increase threshold.|No||https://clinicaltrials.gov/show/NCT00207948||191325|
NCT00207961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-93-43|The Threshold Value of Regional Cerebral Oxygenation in Detecting Cerebral Ischemia|||China Medical University Hospital||Completed|October 2003|October 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Female|20 Years|45 Years||||September 2005|December 8, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207961||191324|
NCT00217360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 2001.034|RCT to Reduce Further Falls and Injuries for Older Fallers Presenting to an Emergency Department|RCT to Evaluate the Effectiveness of a Targeted and Personalised Multifactorial Program to Reduce Further Falls and Injuries for Community-Dwelling Older Fallers Presenting to and Being Discharged Directly From an Emergency Department.||National Ageing Research Institute, Australia||Recruiting|December 2002|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||700|||Both|60 Years|N/A||||September 2005|October 3, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00217360||190615|
NCT00213395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/015/HP|Clinical Efficacy of a Cephalic Mask for Noninvasive Ventilation During Acute Hypercapnic Respiratory Failure|||University Hospital, Rouen||Terminated|October 2004|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2012|February 14, 2012|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00213395||190913|
NCT00213720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3463|Treatment of Subclinical Hyperthyroidism|Place de l'Iode RadioActif Dans l'HyperThyroïdiE Sub-clinique (PIRHATES)/ Evaluation of the Interest of Subclinical Hyperthyroidism Treatment||University Hospital, Strasbourg, France||Recruiting|August 2005|||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|serum|Both|50 Years|N/A|No|Probability Sample|patients referred to tertiary hospitals for advice on thyroïd disease|November 2007|April 19, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00213720||190888|
NCT00204386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-205|Safety & Efficacy Study Using Topiramate in Posttraumatic Stress Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder||University of Oklahoma|Yes|Completed|September 2002|May 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2007|May 29, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204386||191593|
NCT00204399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSF2001|Examining Physician Counseling to Promote Adoption of Physical Activity: A Controlled Trial|Examining Physician Counseling to Promote Adoption of Physical Activity: A Controlled Trial||University of Saskatchewan||Completed|July 2001|December 2004||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2000|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204399||191592|
NCT00204113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUStandingSCI|Control of Unsupported Paraplegic Standing|Integrated Voluntary Control of Unsupported Paraplegic Standing||University of Glasgow||Active, not recruiting|June 2002|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|16 Years|N/A||||June 2008|June 10, 2008|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204113||191614|
NCT00214487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0107|Bifocal Soft Contact Lenses and Their Effect on Myopia Progression in Children and Adolescents.|Bifocal Soft Contact Lenses - Do They Slow Progression of Myopia Relative to Single Vision Soft Contact Lenses in Children and Adolescents?||Aller, Thomas A., OD|No|Completed|October 2003|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|78|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|September 14, 2005||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT00214487||190832|
NCT00205361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-027|Airway IgA: Respiratory Tract IgA Levels in Anesthetized Patients Undergoing Elective Surgical Procedures|Respiratory Tract IgA Levels in Anesthetized Patients Undergoing Elective Surgical Procedures||University of Wisconsin, Madison||Completed|January 2002|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing surgery with general anesthesia|October 2012|October 16, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205361||191519|
NCT00205660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS #942370|Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole|Changes in Adiposity and Metabolic Measures During Medication Switches to Aripiprazole From Other Atypical Antipsychotics||Washington University School of Medicine|No|Completed|February 2005|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|78|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00205660||191496|
NCT00205933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000994|Behavioral Processes Underlying Reward Processing in Depression|Behavioral Processes Underlying Reward Processing in Depression||Affective Neuroscience Laboratory|Yes|Completed|April 2004|June 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|78|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Control participants, Participants with MDD, Participants with Bipolar Disorder|November 2007|December 4, 2007|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205933||191476|
NCT00206271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000268|Comparison of the Effect of Neck Collar, Act-as-Usual, and Active Mobilisation Early After a Whiplash Injury|A Randomized Early Intervention Study Comparing the Effect of Stiff Neck Collar, “Act-as-Usual” and Active Mobilisation on the One Year Outcome Following Whiplash Injury.||The Back Research Center, Denmark||Completed|May 2001|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||450|||Both|18 Years|70 Years|No|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206271||191450|
NCT00206284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9770C00011|A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.|A 4-week, Randomised, Double-blind, Multicentre, Dose-finding Phase IIb Study With AZD0865 25, 50, 75 mg and Esomeprazole 20 mg, Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification in Adult Subjects.||AstraZeneca||Completed|May 2004|April 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1400|||Both|18 Years|70 Years|No|||January 2013|January 3, 2013|September 15, 2005||||||https://clinicaltrials.gov/show/NCT00206284||191449|
NCT00206570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRC 75/02|Clinical Estradiol Trial in Women With Schizophrenia|Double Blind Study of Estradiol Plus Neuroleptic Versus Placebo Plus Neuroleptic in the Treatment of Psychotic Symptoms in Women With Schizophrenia||Bayside Health||Completed|January 2001|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|45 Years|No|||February 2015|February 2, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00206570||191428|
NCT00256633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465C|Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal|CSP #465C - Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal||VA Office of Research and Development|Yes|Completed|April 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|874|Samples With DNA|Blood draws of DNA samples.|Both|40 Years|N/A|No|Non-Probability Sample|This is an observational study of patients who are enrolled in the ongoing randomized        clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.|May 2014|May 21, 2014|November 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00256633||187678|
NCT00256646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465D|Markers and Mechanisms of Vascular Disease in Type II Diabetes|CSP #465D - Markers And Mechanisms of Vascular Disease in Type II Diabetes||VA Office of Research and Development|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|298|Samples Without DNA|samples without DNA|Both|40 Years|N/A|No|Non-Probability Sample|Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and        Complications in Diabetes Mellitus Type 2".|May 2014|May 21, 2014|November 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00256646||187677|
NCT00256945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191057HMO-CTIL|Surface Roughness of a Dental Restorative Material and Biofilm Formation|In Vivo Study of the Relationship Between Surface Roughness of a Dental Restorative Material and Biofilm Formation||Hadassah Medical Organization||Completed|January 2005|August 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|January 5, 2010|November 20, 2005||||No||https://clinicaltrials.gov/show/NCT00256945||187655|
NCT00257972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-134|Study of Aripiprazole in Patients With Bipolar I Disorder|Efficacy of Aripiprazole in Combination With Valproate or Lithium in the Treatment of Mania in Patients With Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|October 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||May 2008|November 7, 2013|November 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257972||187576|
NCT00257985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHM-GTN 2005|Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2|Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2||Danish Headache Center||Completed|April 2005|March 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|July 31, 2006|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257985||187575|
NCT00257881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3152K1-101|Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors|Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|November 2005|December 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Both|20 Years|74 Years|No|||December 2007|December 6, 2007|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257881||187583|
NCT00257894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-029-04F|Baclofen Effects on Smoking Urge and Withdrawal|Baclofen Effects on Smoking Urge and Withdrawal||VA Office of Research and Development|No|Terminated|December 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|November 21, 2005|No|Yes|Enrollment was completed with insufficient sample size for publishable results|No|January 28, 2014|https://clinicaltrials.gov/show/NCT00257894||187582|
NCT00257855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001949-42|A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis|A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial||University College London Hospitals|Yes|Completed|November 2005|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|60 Years|No|||February 2009|February 5, 2010|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257855||187585|
NCT00257868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 204/05|Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery|Rivastigmine for the Prevention of Postoperative Delirium After Cardiac Surgery||University Hospital, Basel, Switzerland||Completed|January 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|120|||Both|65 Years|N/A|No|||July 2007|July 30, 2007|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257868||187584|
NCT00216801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-082|Relationship of Ochratoxin A to Upper Urologic Cancers|The Relationship of Ochratoxin A to Upper Tract TCC Malignancies, Testicular Cancer, and Renal Cell Cancer||Lawson Health Research Institute|No|Completed|September 2005|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Must have resectable non-metastatic upper tract transitional cell carcinoma, renal cell        carcinoma, or testicular carcinoma.|January 2009|January 20, 2009|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00216801||190658|
NCT00208195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-13258|Depakote ER Therapy for Mania Comorbid With Substance Abuse|Depakote ER Therapy for Mania Comorbid With Substance Abuse||Creighton University|No|Completed|March 2004|November 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 12, 2007|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00208195||191306|
NCT00208182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-USA-245B|Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma|Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial||Creighton University||Completed|July 2001|August 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||20|||Female|19 Years|64 Years|Accepts Healthy Volunteers|||March 2006|March 8, 2006|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00208182||191307|
NCT00207909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-114|Study of Patients With Acute Renal Failure on CVVH|The Role of Hemodynamics, Cytokine Response, and Modulators of Apoptosis on Urine Output in Patients With Acute Renal Failure on CVVH||Children's Healthcare of Atlanta|Yes|Active, not recruiting|February 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|5 Months|N/A|No|Probability Sample|Patients Pediatric Intensive Care Unit @ Egleston meeting inclusion criteria / avoiding        exclusion criteria.|December 2014|December 10, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00207909||191328|
NCT00207922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR92-IRB-135|The Polarization and Expression of Chemokine Receptors of T Help Cell in the Pathogenesis of Acute and Chronic GVHD|||China Medical University Hospital||Active, not recruiting|December 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||December 2003|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00207922||191327|
NCT00207935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC IRB 3579|Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population|Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population||Children's Research Institute||Completed|August 2005|March 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|4 Years|18 Years|No|||September 2005|May 1, 2008|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00207935||191326|
NCT00208169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-13685|Abilify Therapy for Reducing Comorbid Substance Abuse|Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse||Creighton University|No|Completed|March 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||August 2007|August 22, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00208169||191308|
NCT00204672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-USA-46|The Role of GER in Exercise Triggered Asthma|The Role of GER in Exercise Triggered Asthma||University of Utah||Completed|October 2000|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||36|||Both|18 Years|65 Years|No|||September 2005|September 12, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204672||191571|
NCT00205010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 03701|Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer|Laparoscopic Sentinel Lymph Node Localization in Patients With Operable Cervical Cancer - A Pilot Study||University of Wisconsin, Madison|Yes|Completed|October 2003|June 2006|Actual|February 2006|Actual|Phase 1|Observational|Time Perspective: Prospective|||Actual|20|||Female|18 Years|N/A|No|||June 2008|September 30, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205010||191546|
NCT00204646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jth_005|Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)|Phase II Study of Neoadjuvant Dose-Intensive Chemotherapy With Adriamycin and Ifosfamide Followed by High-Dose ICE in Locally Advanced Soft Tissue Sarcomas||University Hospital Tuebingen||Completed|February 1999|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||April 2007|April 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204646||191573|
NCT00204659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64-03|Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma|Phase II Study With Rituximab and CHOP in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma||University Hospital Tuebingen|No|Completed|March 2003|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2008|October 17, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00204659||191572|
NCT00204373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F030107005|Treatment of Zollinger-Ellison Syndrome With Prevacid|Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors||University of Alabama at Birmingham|No|Completed|March 2003|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|19 Years|N/A|No|||October 2012|October 23, 2012|September 13, 2005|No|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT00204373||191594|
NCT00204633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jth_004|Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)|Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP Regimen)||University Hospital Tuebingen||Completed|July 2003|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|108|||Male|18 Years|65 Years|No|||February 2009|February 13, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00204633||191574|
NCT00205686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23RR016191|Effects of DHEA and Exercise in the Elderly|DHEA+Exercise-Effect on Sarcopenia and Osteopenia of Aging||Washington University School of Medicine||Completed|April 2001|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|65 Years|78 Years|Accepts Healthy Volunteers|||September 2005|January 4, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205686||191495|
NCT00205699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMH|Metabolic Effects of Antipsychotics in Children|Metabolic Effects of Antipsychotics in Children|MEAC|Washington University School of Medicine|Yes|Completed|October 2004|July 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|240|||Both|6 Years|18 Years|No|||March 2014|March 12, 2014|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205699||191494|
NCT00206297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-14358|The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes|The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes||Baylor College of Medicine||Completed|October 2003|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||July 2005|June 19, 2006|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00206297||191448|
NCT00206596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307501|Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease|Randomized, Stratified, Double-Blind, Placebo-Controlled Phase 2 Study of Steroid-Sparing Properties of Sargramostim (Leukine) Therapy in Patients With Cortico-Dependent Crohn's Disease||Sanofi||Completed|July 2003|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|80 Years|No|||December 2013|December 2, 2013|September 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00206596||191426|
NCT00206869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-169/02|Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria|||Bispebjerg Hospital||Recruiting|January 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|14 Years|70 Years||||December 2002|October 10, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00206869||191406|
NCT00206882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-272662|The Sun Protection Effect and Efficacy in Treatment of Sunburn Using Topical Corticosteroids.|||Bispebjerg Hospital||Recruiting|September 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|October 10, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00206882||191405|
NCT00256971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEN-BM-HMO-CTIL|Balance in Patients After Surgery for Torn Meniscus|Functioning Balance in Patients After Surgery for Torn Meniscus: Meniscectomy vs Meniscal Repair; A Prospective Study||Hadassah Medical Organization||Recruiting|November 2005|January 2008|Anticipated|||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|18 Years|40 Years||||November 2005|May 12, 2008|November 20, 2005||||No||https://clinicaltrials.gov/show/NCT00256971||187653|
NCT00257218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701008|A Study on Effect of Health Promotion for Prevention NIDDM in People With Prediabetes|||National Taiwan University Hospital||Not yet recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||1000|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||November 2005|November 21, 2005|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257218||187634|
NCT00256958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKR-BM-HMO-CTIL|Static and Dynamic Balance in Correlation With Quality of Life, in Primary Total Knee Replacement|Static and Dynamic Balance During Standing and Walking in Correlation With Quality of Life, in Primary Total Knee Replacement||Hadassah Medical Organization||Recruiting|November 2005|June 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|150|||Both|50 Years|90 Years|No|||November 2005|May 12, 2008|November 20, 2005||||No||https://clinicaltrials.gov/show/NCT00256958||187654|
NCT00256724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43-0278-00|Efficacy Study of a Facemask Device to Treat Hypotension|Evaluation of an Inspiratory Impedance Threshold Device (ITD) in the Emergency Department for the Treatment of Hypotension||Advanced Circulatory Systems|No|Completed|June 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|85 Years|No|||July 2013|July 24, 2013|November 18, 2005||No||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00256724||187671|
NCT00256737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9584C00004|Sopran - Omeprazole Treatment Versus Surgery|Omeprazole Versus Anti-reflux Surgery in the Long-term Management of Peptic Esophagitis - a 10 Year Follow up Study of Patients Previously Studied for 5 Years - A Nordic Multicentre Study||AstraZeneca||Completed|January 1998|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||219|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|November 20, 2005||||No||https://clinicaltrials.gov/show/NCT00256737||187670|
NCT00257010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002827|A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches|Long-Term, Open-Label Safety Study of Oral Almotriptan Malate 12.5 mg in the Treatment of Migraine in Adolescents||Janssen-Ortho LLC|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|447|||Both|12 Years|17 Years|No|||January 2014|January 23, 2014|November 18, 2005|No|Yes||No|October 11, 2013|https://clinicaltrials.gov/show/NCT00257010||187650|
NCT00253786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNETT-Japan|Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy|Study for the Effectiveness of Intensive Therapy for Diabetic Nephropathy in Unblinded, Randomized Intergroup Comparison Study.||Okayama University||Recruiting|July 2005|June 2011||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|20 Years|75 Years|No|||January 2007|January 15, 2007|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00253786||187891|
NCT00253799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0133-003|A Safety Study of Hylan GF-20 to Treat Shoulder Osteoarthritis|Prospective, Single Arm, Pilot Study Evaluating the Safety and Efficacy of Hyaluronan (Hylan GF-20) in Patients With Painful Shoulder Osteoarthritis||Northwestern Ophthalmic Institute S.C.|Yes|Active, not recruiting|December 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|35 Years|N/A|Accepts Healthy Volunteers|||June 2007|June 21, 2007|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00253799||187890|
NCT00216814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-03-275|Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors|Intravesically Administered BCG May Have Antiangiogenic Effects on Urinary Concentrations of Basic Fibroblast Growth Factor ( bFGF), Vascular Endothelial Growth Factor (VEGF) and Interleukin (IL-8)||Lawson Health Research Institute||Terminated|October 2003|September 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with bladder cancer that are receiving treatment with BCG.|January 2008|April 18, 2008|September 19, 2005|||No funding and data was not appropriate to consider continuing.|No||https://clinicaltrials.gov/show/NCT00216814||190657|
NCT00208208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-0261|Geodon (Ziprasidone) for Posttraumatic Stress Disorder|Geodon (Ziprasidone) for Posttraumatic Stress Disorder||Creighton University||Completed|December 2002|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||80|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||April 2005|September 14, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00208208||191305|
NCT00203814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEACAT 01a ASSP|A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria|Open-Label, Randomised, Parallel Group in Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT), Artesunate and Sulfadoxine-Pyrimethamine Versus Sulfadoxine-Pyrimethamine Alone, in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carriage and Prevalence of Molecular Markers Associated With SP Resistance In Uncomplicated Plasmodium Falciparum Infections.||University of Cape Town||Completed|January 2004|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||280|||Both|12 Months|N/A|No|||August 2005|November 15, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00203814||191636|
NCT00208455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT03/09|A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement|An Uncontrolled, Multi-Centre, Prospective, Post Marketing Surveillance Study to Monitor the Long Term Survivorship of the DePuy PROXIMA™ Hip in Subjects Requiring a Total Hip Replacement||DePuy International|No|Terminated|February 2005|February 2013|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|184|||Both|18 Years|70 Years|No|||September 2015|December 17, 2015|September 13, 2005||No|DePuy discontinued this product in 2013, the clinical program was reviewed and this Study was    closed.|No||https://clinicaltrials.gov/show/NCT00208455||191286|
NCT00204126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUTreadmillSCI|Exercise Testing During Treadmill Gait in Incomplete Spinal Cord Injury|Determination of Novel Methods of Exercise Testing During Treadmill Gait in Incomplete Spinal Cord Injury||University of Glasgow||Active, not recruiting|February 2005|February 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||4|||Both|16 Years|N/A||||September 2006|September 8, 2006|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00204126||191613|
NCT00204685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUFIT|Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa|Beatmungsdauer Und Lungenfunktion Bei Beatmeten Patienten Unter Therapie Mit Dornase Alfa - Randomisierte, Doppel-Blinde, Placebo-Kontrollierte, Multizentrische, Prospektive Klinische Studie||University Hospital Tuebingen||Active, not recruiting|August 2003|July 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||540|||Both|18 Years|N/A|No|||September 2006|September 13, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00204685||191570|
NCT00205023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 03702|Disseminated Endometrial Cancer Cells During Sonohysterography|The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study||University of Wisconsin, Madison||Completed|January 2004|August 2006|Actual|February 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Female|18 Years|N/A|No|||June 2008|September 30, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00205023||191545|
NCT00205036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2004-1308|Calcium DXA: Impact of Calcium Supplements on Lumbar Spine Bone Mineral Density|Impact of Calcium Supplements on Lumbar Spine Bone Mineral Density||University of Wisconsin, Madison||Completed|January 2005|||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 26, 2007|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00205036||191544|
NCT00204984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-382|Heart and Blood Pressure Study: The Effect of Aortic Impedance on Myocardial Relaxation|The Effect of Aortic Impedance on Myocardial Relaxation||University of Wisconsin, Madison||Completed|May 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2009|October 1, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00204984||191548|
NCT00204997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 02702|Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix|Preservation of Ovarian Function Via Laparoscopic Transposition in Patients With Locally Advanced Squamous Cell Carcinoma of the Cervix||University of Wisconsin, Madison|Yes|Terminated|September 2002|February 2008|Actual|September 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|40 Years|No|||June 2008|September 30, 2015|September 13, 2005||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00204997||191547|
NCT00223158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 03-52-R1|Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer|L-T3 Preparation for I131 Whole Body Scintigraphy: A Randomized Controlled Trial||Université de Sherbrooke||Completed|September 2003|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||July 2005|April 8, 2014|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00223158||190180|
NCT00256035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.156|Interleukin-4 (IL-4) as a Marker of Atherosclerosis|IL-4 as a Marker of Atherosclerosis||Melbourne Health|No|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|0|||Both|N/A|N/A|No|||April 2015|April 23, 2015|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00256035||187724|
NCT00256373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 01011|Treatment of Chronic Low Back Pain: A Trial Comparing Traditional Back School and Individual Therapist-Assisted Exercise|||University Hospital, Gentofte, Copenhagen||Active, not recruiting|January 2001|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||September 2005|April 18, 2006|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00256373||187698|
NCT00246246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005818|A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder|A Randomized, Open-label Trial of RISPERDAL® CONSTA™ Versus Oral Antipsychotic Care in Subjects With Bipolar Disorder||Janssen-Ortho Inc., Canada||Completed|January 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|65 Years|No|||February 2011|February 10, 2011|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246246||188456|
NCT00247546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02032002|Prevention of Falls and Injurious Falls Among Elderly People|||The Hospital District of Satakunta||Completed|March 2003|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||592|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||September 2006|October 17, 2006|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247546||188358|
NCT00247819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-IRP-148|The Genetic Basis for Vulnerability to Substance Abuse|Allelic Linkage in Substance Abuse||National Institute on Drug Abuse (NIDA)||Recruiting|August 1992|February 2006||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||8000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2005|October 31, 2005|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247819||188339|
NCT00257023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004939|An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia|Exploratory Study of Paliperidone in Patients With Schizophrenia to Investigate the Safety and Efficacy||Janssen Pharmaceutical K.K.||Completed|February 2005|September 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|52|||Both|20 Years|64 Years|No|||January 2011|May 16, 2011|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00257023||187649|
NCT00257322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 02-60|Cellular Immune Augmentation in Colon and Rectal Cancer|A Pilot Study of Cellular Immune Augmentation in Colon and Rectal Cancer Therapy||University of California, Irvine|Yes|Active, not recruiting|April 2003|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2008|March 21, 2008|November 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257322||187626|
NCT00257660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-47-52120-051|Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia|A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia||Ipsen|No|Completed|October 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|November 22, 2005|Yes|Yes||No|January 6, 2010|https://clinicaltrials.gov/show/NCT00257660||187600|
NCT00253903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTE6262|Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year|Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study Followed by an Open Treatment Phase Extension With Eplivanserin for a 40-week Period|EPLILONG|Sanofi||Completed|November 2005|September 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1155|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00253903||187882|
NCT00254150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O2ER GDT|A Therapy to Reduce Morbidity and Hospital Length of Stay of High-Risk Surgical Patients|Goal-Directed Intraoperative Therapy Reduces Morbidity and Length of Hospital Stay in High Risk Surgical Patients||Università Politecnica delle Marche||Completed|May 1995|December 1996||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|16 Years|N/A|No|||April 1995|November 14, 2005|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00254150||187864|
NCT00254163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03017|Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients|A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia||US Oncology Research|No|Completed|December 2003|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|November 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254163||187863|
NCT00255125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-006-05S|Role of Soy Supplementation in Prostate Cancer Development|Role of Soy Isoflavones in Prostate Cancer Prevention||VA Office of Research and Development|Yes|Completed|September 2005|October 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|86|||Male|18 Years|N/A|No|||June 2015|June 12, 2015|November 15, 2005||No||No|December 24, 2013|https://clinicaltrials.gov/show/NCT00255125||187790|
NCT00255398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060020|Kidney Disease Biomarkers|Kidney Disease Biomarkers||National Institutes of Health Clinical Center (CC)||Completed|November 2005|December 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|25|||Both|2 Years|N/A|No|||December 2014|December 5, 2014|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00255398||187770|
NCT00224614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040420|Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia|Randomised Prospective Comparison of the nonmyélo-Ablative Allograft and the Traditional Allograft in Acute Myeloid Leukaemia in Complete Remission of the Adult||Assistance Publique - Hôpitaux de Paris||Recruiting|July 2005|July 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|35 Years|55 Years|Accepts Healthy Volunteers|||June 2005|December 13, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00224614||190070|
NCT00224133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI04011|The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months|A Multi-Center, Open-Label Evaluation of the Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia||Watson Pharmaceuticals|No|Completed|September 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|661|||Male|50 Years|N/A|No|||April 2010|April 6, 2010|September 14, 2005|No|Yes||No|December 23, 2009|https://clinicaltrials.gov/show/NCT00224133||190107|
NCT00255606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVENTIS-FIN-1-2003|Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer|A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial||National Cancer Institute (NCI)||Completed|August 2005|August 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|360|||Male|18 Years|N/A|No|||September 2010|June 25, 2013|November 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255606||187754|
NCT00224874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0302|Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)|Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2005|June 2012|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|180|||Both|2 Years|N/A|No|||January 2015|January 26, 2015|September 21, 2005|Yes|Yes||No|January 29, 2010|https://clinicaltrials.gov/show/NCT00224874||190050|
NCT00224627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040101|Capsule Endoscopy vs. Push Enteroscopy in Occult Gastrointestinal Bleeding OGIB|Efficiency of Capsule Endoscopy and Push Enteroscopy in Obscure Gastrointestinal Bleeding. A Prospective Randomized Study.||Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2002|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||45|||Both|18 Years|N/A|No|||March 2007|March 23, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00224627||190069|
NCT00224887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320|Family-Based Nutrition Intervention for Latino Children|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||||||Both|6 Years|9 Years|No|||July 2008|July 23, 2008|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224887||190049|
NCT00222014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402308|TIPS With Coated Stents for Refractory Ascites in Patients With Cirrhosis|TIPS (With Coated Stents) OR PARACENTESIS + ALBUMIN ADMINISTRATION FOR THE TREATMENT OF REFRACTORY ASCITES IN PATIENTS WITH CIRRHOSIS : A RANDOMIZED TRIAL COMPARING SURVIVAL, QUALITY OF LIFE AND NUTRITIONAL STATUS||University Hospital, Toulouse|Yes|Completed|May 2005|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|70 Years|No|||January 2013|January 22, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222014||190264|
NCT00226083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUH IRB # AST-0565-0805|Study of Blood Platelets in Sickle Cell Disease|Studies of Large Platelets in Patients With Sickle Cell Disease||Rockefeller University|No|Withdrawn|August 2005|September 2007|Anticipated|September 2007|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults and children with sickle cell disease (Hb SS)|June 2015|June 5, 2015|September 22, 2005||No|PI returned to India|No||https://clinicaltrials.gov/show/NCT00226083||189961|
NCT00221988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB MRS001|Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers|A Randomized, Double-Blind, Cross-Over Study of the Cognitive and Mood Effects of KEPPRA (Levetiracetam) Tablets in Healthy Older Adults.||University Hospital Case Medical Center||Recruiting|March 2004|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00221988||190266|
NCT00222846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-R01-NR008792|Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study|Enhancing Adherence in Type 2 Diabetics|ENHANCE|University of Pittsburgh|Yes|Completed|May 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|288|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00222846||190204|
NCT00222859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0503113|Reasons for Non-treatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting|Reasons for Nontreatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting||University of Pittsburgh|Yes|Completed|March 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|patients with HCV diagnosis|July 2013|July 29, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222859||190203|
NCT00222872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0503166|3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women|A Three Week Dose Escalation Study of PTHrP(1-36) in Postmenopausal Women||University of Pittsburgh|Yes|Completed|July 2005|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|61|||Female|50 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00222872||190202|
NCT00256048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.228|Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.|Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.||Melbourne Health|No|Completed|May 2003|July 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00256048||187723|
NCT00256659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9808003482|Hospital Outcomes: Intervention in Moderately III Patients|Hospital Outcomes: Intervention in Moderately III Patients||Weill Medical College of Cornell University|No|Completed|September 1998|April 1999||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||444|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|November 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00256659||187676|
NCT00247039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|384 gar 1- HMO-CTIL|Garlic in Patients With Febrile Neutropenia|A Controlled Study to Determine The Clinical Efficacy Of Garlic Compounds In Patients With Chemotherapy Related Febrile Neutropenia||Hadassah Medical Organization|Yes|Recruiting|June 2006|August 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|16 Years|N/A|No|||July 2013|July 4, 2013|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247039||188396|
NCT00247052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-06|Non Steroidal Anti Inflammatory Treatment for Post Operative Pericardial Effusion|the Post Operative Pericardial Effusion (POPE) Treatment Study||French Cardiology Society||Completed|March 2006|February 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2009|July 31, 2009|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00247052||188395|
NCT00256750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-008|Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)|Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)|BENEFIT|Bristol-Myers Squibb|Yes|Completed|March 2005|April 2015|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|685|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|November 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256750||187669|
NCT00253630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02843|Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma|A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|September 2005|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||November 2015|December 14, 2015|November 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00253630||187902|
NCT00253890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DA 020479|Insomnia and Drug Relapse Risk|Insomnia and Drug Relapse Risk||Butler Hospital|Yes|Completed|October 2005|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|75 Years|No|||October 2013|October 22, 2013|November 10, 2005||No||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00253890||187883|
NCT00254189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A2-208|Study Evaluating Effects of Levonorgestrel and Ethinyl Estradiol on Ovulation|A Single Center, Open-Label Study to Evaluate the Effects on Ovulation of Levonorgestrel 90mg and Ethinyl Estradiol 20mg in a Daily, Continuous, Oral Regimen.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2002|October 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|N/A|36 Years|Accepts Healthy Volunteers|||May 2006|May 17, 2006|November 11, 2005||||||https://clinicaltrials.gov/show/NCT00254189||187861|
NCT00254202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VYV-683-3101|Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.||Vanda Pharmaceuticals||Completed|November 2005|March 2007||September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|65 Years|No|||July 2012|July 18, 2012|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00254202||187860|
NCT00254514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1606-1365|Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures|A Multi-centre, Randomised, Double-blind, Placebocontrolled, Parallel-group Trial Investigating the Efficacy and Safety of Norditropin® SimpleXx® in Tibia Fractures||Novo Nordisk A/S|No|Completed|August 2001|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|407|||Both|18 Years|65 Years|No|||November 2013|November 18, 2013|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254514||187836|
NCT00254527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 04 11-135E|Colonization, Infection, and Molecular Typing of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Children.|Colonization, Infection, and Molecular Typing of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Children.||Children's Mercy Hospital Kansas City||Completed|January 2005|April 2007|Actual|||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|477|||Both|3 Months|12 Years|Accepts Healthy Volunteers|||November 2005|April 30, 2007|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00254527||187835|
NCT00224146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXY0402|Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder|Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)|MATRIX|Watson Pharmaceuticals||Completed|May 2004|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2878|||Both|18 Years|N/A|No|||November 2011|November 29, 2011|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00224146||190106|
NCT00225199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91233|Efficacy and Safety of SH T00660AA in Treatment of Endometriosis|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Oral Administration of SH T00660AA for the Treatment of Endometriosis Over 12 Weeks||Bayer|No|Completed|March 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|198|||Female|18 Years|45 Years|No|||April 2010|April 22, 2010|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225199||190026|
NCT00224354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17656|Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells|Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells After Depletion of Regulatory T Cells|CLONTAK|Baylor College of Medicine|Yes|Withdrawn|September 2005|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00224354||190090|
NCT00225784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS 0432|Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer|A Phase II Trial of Cetuximab, Radiotherapy and Twice Weekly Gemcitabine in Patients With Adenocarcinoma of the Pancreas||Dartmouth-Hitchcock Medical Center|Yes|Completed|February 2005|September 2012|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||October 2011|July 10, 2014|September 22, 2005|Yes|Yes||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00225784||189982|Our study suffers limitations common to single institution trials, namely small patient numbers and selection bias. Our cohort of subjects is too small to adequately assess the effect of tumor EGFR and KRAS status on outcome.
NCT00226057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|578|Efalizumab for Moderate to Severe Atopic Dermatitis|Efalizumab for Moderate to Severe Atopic Dermatitis - A Phase I Pilot Study in Adults||Oregon Health and Science University||Completed|June 2005|November 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|September 22, 2005|September 22, 2005||||||https://clinicaltrials.gov/show/NCT00226057||189963|
NCT00226070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301500110|Rehabilitation to Patients Over 65 Years Undergoing THA|Cross-Section Study Among Patients Waiting for or Already Undergoing THA Followed by a RCT||University of Aarhus||Recruiting|September 2004|September 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||160|||Both|65 Years|95 Years|Accepts Healthy Volunteers|||December 2006|December 18, 2006|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226070||189962|
NCT00222287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC No. 040730|The Effect of Feldenkrais Lessons on Walking and Balance|The Effect of Feldenkrais Lessons on Walking and Balance||University of Melbourne||Active, not recruiting|September 2004|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|65 Years|90 Years|No|||September 2006|September 21, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222287||190244|
NCT00222612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKALL2003|Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003|Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003||University of Oxford|Yes|Recruiting|October 2003|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|2100|||Both|1 Year|18 Years|No|||February 2010|February 2, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222612||190222|
NCT00254878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124DDE01|Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14|A 7 Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Cross-Over Evaluation of the Efficacy and Safety of Two Different Brands of Modified-Release Oral Dosage Forms of Methylphenidate-HCl (20 mg, q.d.) in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14||Novartis||Completed|October 2005|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|6 Years|14 Years||||December 2007|December 17, 2007|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254878||187808|
NCT00256061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.229|Assessment of Electrolyte Values in the Intensive Care Unit:Comparison Between Arterial and Venous Blood Gas Analysis and Formal Laboratory Testing|Assessment of Electrolyte Values in the Intensive Care Unit:Comparison Between Arterial and Venous Blood Gas Analysis and Formal Laboratory Testing||Melbourne Health|No|Withdrawn|February 2003|February 2004||||N/A|Observational|Time Perspective: Retrospective|||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|November 17, 2005||No|Due to the publication of significant literature in this area since commencement of the    project which has now rendered the project unnecessary.|No||https://clinicaltrials.gov/show/NCT00256061||187722|
NCT00256386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-9520 Garfield Mem Trust|LabAlert: Enhancing Medication Safety Through Electronic Interventions to Improve Laboratory Monitoring|LabAlert: Enhancing Medication Safety Through Electronic Interventions to Improve Medication Safety||Kaiser Permanente||Completed|January 2004|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||800|||Both|18 Years|N/A|No|||November 2005|November 29, 2006|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00256386||187697|
NCT00256672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9155-200513332|Effectiveness of Bracing in Preventing Scoliosis in Children With Spinal Cord Injury|Effectiveness of Full-Time Prophylactic Bracing at Preventing or Delaying Curve Progression in Paralytic Scoliosis Secondary to Spinal Cord Injury in the Growing Child: Randomized Trial||Shriners Hospitals for Children||Active, not recruiting|June 2005|December 2012|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|88|||Both|5 Years|16 Years|No|||June 2008|June 11, 2008|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00256672||187675|
NCT00256464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCYI-PTSD|Evaluation of a MCYI as Adjunct to Psychiatric Treatment for Vietnam Veterans With PTSD - RCT|Evaluation of a Multi-Component Yoga Intervention as Adjunct to Psychiatric Treatment for Vietnam Veterans With Posttraumatic Stress Disorder (PTSD): A Randomized Controlled Trial (RCT).||The University of Queensland||Not yet recruiting|June 2007|January 2008||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||30|||Male|50 Years|70 Years|Accepts Healthy Volunteers|||August 2005|September 7, 2006|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00256464||187691|
NCT00258011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID02205|Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease|A Safety Confirmatory Study of JC0498 (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients||Sanofi||Completed|December 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||February 2014|February 4, 2014|November 22, 2005||No||No|January 13, 2009|https://clinicaltrials.gov/show/NCT00258011||187573|Due to the rarity of the disease, this study is limited by its small sample size, lack of a control group and patients had variable treatment durations.
NCT00253643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000443617|Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer|Catechins and Omega-3 Fatty Acids Impact on Fatty Acid Synthase Activity in the Prostate: A Randomized Controlled Trial||OHSU Knight Cancer Institute|Yes|Completed|July 2005|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|89|||Male|21 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|November 11, 2005|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00253643||187901|
NCT00253916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCIC 013232|Exercise in Men Receiving Radiation Therapy for Prostate Cancer.|Exercise in Men Receiving Radiation Therapy for Prostate Cancer: Effects on Fatigue, Toxicity, Body Composition, Muscular Fitness, Cardiorespiratory Fitness and Quality of Life.||Ottawa Hospital Research Institute||Completed|June 2002|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|121|||Male|N/A|N/A|No|||November 2015|November 23, 2015|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00253916||187881|
NCT00254826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045982|Yellow Fever Virus Vaccine and Immune Globulin Study|Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX)Given Alone or in Combination With Human Immune Globulin (Gama STAN S/D)||Emory University|No|Completed|June 2006|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|November 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254826||187812|
NCT00254839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-HMO-CTIL|Association Between Dental Implants Properties and Malodor Production|Bacterial Accumulation and Malodor Production in Various Types of Dental Implants||Hadassah Medical Organization||Completed|December 2005|||||N/A|Observational|Time Perspective: Cross-Sectional||||60|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||November 2005|September 14, 2006|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00254839||187811|
NCT00254540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181072|Study of SU011248 in Patients With Advanced Kidney Cancer|Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma||Pfizer|No|Completed|December 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|N/A|No|||February 2010|February 17, 2010|November 14, 2005|No|Yes||No|January 15, 2010|https://clinicaltrials.gov/show/NCT00254540||187834|
NCT00254553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05815|A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two Period Cross Over Trial to Validate Patient-Reported Outcome Measures for Use in Men With Late Onset Hypogonadism||Merck Sharp & Dohme Corp.|No|Terminated|July 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 14, 2005|Yes|Yes|Recruitment issues|No||https://clinicaltrials.gov/show/NCT00254553||187833|
NCT00254865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003007|A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers|A Comparative Pharmacokinetic Study of EVRA and CILEST in Healthy Female Volunteers||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2002|March 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|34|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||January 2011|June 6, 2011|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254865||187809|
NCT00225498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-200|Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade|Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade||Northwell Health|No|Completed|June 2002|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|50 Years|No|||September 2015|September 2, 2015|September 21, 2005|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00225498||190003|This is a small sample.
NCT00225511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B1-816|Study Evaluating Effexor XR for Major Depression.|Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|590|||Both|20 Years|64 Years|No|||May 2007|May 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225511||190002|
NCT00225212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol97|Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma|Clinical Trial Of C2B8 Monoclonal Antibody Following High Dose Therapy And Autografting In B-Cell Non-Hodgkin's Lymphoma||Stanford University|No|Completed|November 1997|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|16 Years|65 Years|No|||September 2014|September 4, 2014|September 21, 2005|No|Yes||No|August 26, 2014|https://clinicaltrials.gov/show/NCT00225212||190025|
NCT00222560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G03-05441|The PAC Project: Integrating a Physical Activity Counsellor in the Primary Health Care Team|The PAC Project: Integrating a Physical Activity Counsellor in the Primary Health Care Team: A Randomized Controlled Trial|PAC|University of Ottawa|No|Completed|May 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|69 Years|No|||April 2007|April 27, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00222560||190224|
NCT00222573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMMIT-CCS2|Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction|Clopidogrel Or Metoprolol in Myocardial Infarction Trial||University of Oxford||Completed|July 1999|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||46000|||Both|N/A|N/A|No|||March 2005|May 4, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222573||190223|
NCT00222326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-15-10-01|The Effect of Physiotherapy Treatment Following Gynaecological Surgery|The Effect of a Physiotherapy Treatment Program on Pelvic Function Following Gynaecological Surgery||University of Melbourne|No|Completed|July 2002|April 2007|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 17, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222326||190242|
NCT00223184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2472|Genetic Characterisation of High-grade Paediatric Osteosarcomas|Study of Prognostic Value by Molecular Analysis in Paediatric Osteosarcomas of the Chromosomal Regions Containing Rb, p16, p53, Cycline D1, APC, erbB2 and C-met Genes||University Hospital, Strasbourg, France||Completed|March 2003|August 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|20 Years|No|Non-Probability Sample|Patients under 20 years of age with primary osteosarcomas|August 2011|August 29, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223184||190178|
NCT00255489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0524|A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer|A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer||AstraZeneca||Completed|May 2004|June 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255489||187763|
NCT00255788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I163|Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer|A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients With Recurrent/Metastatic Breast Cancer||Canadian Cancer Trials Group||Completed|January 2005|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||January 2011|January 18, 2011|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00255788||187742|
NCT00256399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-9835|Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)|A Prospective, Open Label, Study to Assess the Efficacy of Alfuzosin 10 mg Tablet Once a Day in Male Subjects Suffering From Benign Prostate Hypertrophy Associated Lower Urinary Tract Symptoms and Erectile Dysfunction||University Hospital Case Medical Center||Recruiting|November 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Male|45 Years|75 Years|Accepts Healthy Volunteers|||November 2005|November 26, 2007|November 18, 2005||||||https://clinicaltrials.gov/show/NCT00256399||187696|
NCT00256412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-01 200408033|Essential Fatty Acids for Major Depression|Essential Fatty Acids in Management of MDD - A Pilot Study||University of Iowa|No|Completed|October 2005|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|No|||June 2008|June 3, 2008|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00256412||187695|
NCT00253851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2002597-01H|Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery|Multi-centre, Double-blind, Randomized, Controlled Trial Comparing Intra-operative Regional Heparinization to Placebo for the Prevention of Deep Vein Thrombosis Following Total Knee Arthroplasty||Ottawa Hospital Research Institute||Completed|July 2003|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|90 Years|No|||April 2012|April 13, 2012|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00253851||187886|
NCT00257673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM 1003-004|Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease||Memory Pharmaceuticals|No|Completed|November 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|183|||Both|50 Years|90 Years|No|||May 2008|May 5, 2008|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257673||187599|
NCT00258037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-KA98117|Effect of Pelvic Floor Muscle Training in Stroke|Six Months Follow-Up of Pelvic Floor Muscle Training in Women With Urinary Incontinence After Stroke||Glostrup University Hospital, Copenhagen||Terminated|January 1999|September 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Female|40 Years|85 Years|Accepts Healthy Volunteers|||March 2000|May 25, 2010|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258037||187571|
NCT00258050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF10015|To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients|A Four-Way Cross-Over Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally and Intravenously Administered Midazolam in Cancer Patients||GlaxoSmithKline||Completed|November 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|70 Years|No|||October 2008|October 9, 2008|November 22, 2005||||||https://clinicaltrials.gov/show/NCT00258050||187570|
NCT00254215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHF G02S 0768 - Brand-Miller|Glycemic Load, Weight Loss and Cardiovascular Disease Risk|The Effect of 4 Diets Varying in Glycemic Index, Glycemic Load, Carbohydrate and Protein, on Weight, Body Composition and Cardio-Vascular Risk Factors||University of Sydney||Completed|March 2002|October 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2005|November 27, 2006|November 13, 2005||||No||https://clinicaltrials.gov/show/NCT00254215||187859|
NCT00254501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU_COP_PP_0105|Empowering Patients to Better Manage Diabetes Through Self-Care|Empowering Patients to Better Manage Diabetes Through Self-Care||Oregon State University|No|Withdrawn|November 2005|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00254501||187837|
NCT00254228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCB1-001|Safety and Efficacy of the BrainPort™ Balance Device to Improve Balance in Bilateral Vestibular Hypofunction|A Clinical Study to Evaluate the Safety and Efficacy of the BrainPort™ Balance Device When Used to Improve Postural Control in Subjects With Bilateral Vestibular Disorders||Wicab||Terminated|November 2005|December 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|85 Years|No|||October 2008|October 8, 2008|November 10, 2005|||Terminated due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00254228||187858|
NCT00224653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040405|Comparison Between Volume Controlled Ventilation and Pressure Controlled Ventilation|||Assistance Publique - Hôpitaux de Paris||Completed|January 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||September 2005|April 12, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00224653||190067|
NCT00225225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96242|Rosiglitazone-Induced Weight Gain|Rosiglitazone-Induced Weight Gain||Stanford University||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||45|||Both|20 Years|75 Years|No|||February 2008|February 21, 2008|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225225||190024|
NCT00225537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSCSA 045-900-246|4-Methylumbelliferone as a Treatment for Chronic HBV/HCV|Evaluation of 4-Methylumbelliferone for Treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV)||MTmedical Institute of Health||Active, not recruiting|September 2005|August 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|65 Years|No|||April 2006|September 7, 2006|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00225537||190000|
NCT00224900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 045a|Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers|Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers Part A: Focus Group And Measurement Evaluation||Westat|No|Terminated|September 2005|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10|||Both|11 Years|16 Years|No|Non-Probability Sample|Young adolescents perinatally infected with HIV, 11 to 14 years of age and their        caregivers.|February 2016|February 29, 2016|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224900||190048|
NCT00224913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD041055|Electrical Stimulation After Total Knee Arthroplasty|NMES for Older Individuals After Total Knee Arthroplasty||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|March 2002|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|45 Years|85 Years|No|||October 2005|October 11, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224913||190047|
NCT00226096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDA1INTERACT|Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage|A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage||The George Institute|Yes|Completed|November 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|404|||Both|18 Years|N/A|No|||June 2008|June 25, 2008|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226096||189960|
NCT00222040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0302208|Microbubbles and Ultrasound in Stroke Trial: MUST Study|||University Hospital, Toulouse|No|Terminated|June 2004|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||June 2008|April 29, 2010|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00222040||190262|
NCT00222885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011178|Multi-Tracer PET Quantitation of Insulin Action in Muscle (Phase 1, Phase 2, Phase 3, Phase 4)|Three-Tracer PET Quantitation of Insulin Action in Muscle||University of Pittsburgh||Completed|December 2002|December 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||50|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 14, 2007|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00222885||190201|
NCT00222898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANDA|Cancer Detection in Pancreatic Cysts|Pancreatic Cyst DNA Analysis||University of Pittsburgh||Completed|June 2004|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||300|||Both|18 Years|N/A|No|||February 2007|February 16, 2007|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00222898||190200|
NCT00255502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4020C00001|307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects|A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Open-Label Extension of Protocol 307A||AstraZeneca||Completed|July 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|6 Years|16 Years|No|||November 2006|November 20, 2006|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255502||187762|
NCT00255528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4020C00033|Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects|Dose Ranging, Safety and Tolerability of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study|307A|AstraZeneca||Completed|July 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||144|||Both|6 Years|16 Years|No|||March 2007|March 19, 2007|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255528||187760|
NCT00255801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-098|Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma|Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2005|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255801||187741|
NCT00257335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 03-58|Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer|A Phase II Protocol of Intensity-Modulated Radiotherapy for Treatment of Previously Irradiated Recurrent Head and Neck Cancer||University of California, Irvine||Withdrawn|October 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||February 2008|February 27, 2008|November 21, 2005|||Due to no patient enrollment this study was withdrawn/closed|No||https://clinicaltrials.gov/show/NCT00257335||187625|
NCT00257348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 03-04|Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer|A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer||University of California, Irvine|Yes|Completed|March 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||February 2013|February 6, 2013|November 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257348||187624|
NCT00257686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-306|Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients|Study Of Pitavastatin 1 Mg Vs. Pravastatin 10 Mg, Pitavastatin 2 Mg Vs. Pravastatin 20 Mg And Pitavastatin 4 Mg Vs. Pravastatin 40 Mg (Following Up-Titration) In Elderly Patients With Primary Hypercholesterolemia Or Combined Dyslipidemia||Kowa Research Europe|No|Completed|September 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|962|||Both|65 Years|N/A|No|||March 2010|March 9, 2010|November 21, 2005||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00257686||187598|
NCT00257699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH REB 04-0257-A|Study of Antibiotics in the Treatment of Colonic Crohn's Disease|Metronidazole and Ciprofloxacin in the Treatment of Colonic Crohn's Disease: The MACINTOCC Trial.||Mount Sinai Hospital, Canada||Terminated|May 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|16 Years|N/A|No|||August 2008|August 11, 2008|November 22, 2005|||Inadequate recruitment to meet completion date|No||https://clinicaltrials.gov/show/NCT00257699||187597|
NCT00257712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28287-K|SMART: Somatotrophics, Memory, and Aging Research Trial|GHRH: Cognition in Aging and MCI||University of Washington|Yes|Completed|February 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|151|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|November 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257712||187596|
NCT00258024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ghana5.2.malaria|Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment|Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment Through Community Involvement in Rural Ghana||DBL -Institute for Health Research and Development||Completed|November 2005|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|420|||Female|14 Years|45 Years|No|||February 2008|February 19, 2008|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258024||187572|
NCT00253929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNPAdenosine|Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia|The Influence of the 1976T>C Polymorphism in the Adenosine A2A Receptor Gene on Adenosine-Induced Vasodilation and the Influence of the 34C>T Polymorphism in the AMP Deaminase Gene on Post-Occlusive Reactive Hyperemia.||Radboud University||Completed|November 2005|February 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2006|April 4, 2007|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253929||187880|
NCT00253942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OABVTKNEE-001|Safety and Efficacy Study of Bee Venom to Treat Knee Osteoarthritis|A Randomized, Double-Blind, Histamine-Controlled, Phase 3 Study to Determine the Safety and Efficacy of Bee Venom in the Treatment of Knee Osteoarthritis||Rheumatology Therapeutics Medical Center||Recruiting|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|35 Years|N/A|Accepts Healthy Volunteers|||October 2005|November 14, 2005|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00253942||187879|
NCT00254241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-5077-0011|Safety and Efficacy of Seroquel in First Episode Schizophrenia|Safety and Efficacy of Seroquel in First Episode Schizophrenia||AstraZeneca||Completed|May 2002|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|35 Years|No|||June 2009|June 9, 2009|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00254241||187857|
NCT00254254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993-124|A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus|A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|February 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|13|||Both|10 Years|16 Years|No|||January 2015|February 19, 2015|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254254||187856|
NCT00224380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA200316456|Medication Adherence in Older Adults With Serious Mental Illness|Medication Adherence in Older Adults||Dartmouth-Hitchcock Medical Center||Completed|July 2003|February 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||72|||Both|50 Years|N/A|No|||September 2009|September 22, 2009|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00224380||190088|
NCT00225238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03C.433|The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep|The Effect of Esomeprazole (Nexium) on the Incidence and Severity of Gastrointestinal Adverse Events Associated With a Colonoscopy Purgative||Thomas Jefferson University|No|Completed|December 2003|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|500|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00225238||190023|
NCT00222027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0200701|Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial|GRAALL 2003 Trial (ALL 15-59 Years). Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial|GRAALL2003|University Hospital, Toulouse|No|Completed|November 2003|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|15 Years|59 Years|No|||January 2009|January 6, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222027||190263|
NCT00225810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PENT-IBD-CH CZ|A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease|Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tbl. 500 mg in Children With Crohn´s Disease||Ferring Pharmaceuticals|No|Completed|October 2005|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|50|||Both|8 Years|18 Years|No|||May 2011|May 18, 2011|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225810||189980|
NCT00226122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDO181202|The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal|The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal||University of Aarhus|No|Completed|January 2003|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|56|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||June 2010|June 24, 2010|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226122||189958|
NCT00222066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OV-UTERO 2000|Effect of Fetal Ovarian Cyst Aspiration to Prevent Torsion|Comparison Between Abstention and Intrauterine Aspiration in the Treatment of Anechoic Fetal Ovarian Cysts to Prevent Ovarian Torsion||University Hospital, Tours|Yes|Completed|June 2001|September 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|40 Years|No|||September 2006|February 2, 2010|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00222066||190260|
NCT00222625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002155-40|rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets|Randomized, Open, Prospective, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII in Acute Intracerebral Haemorrhage in Patients Treated With Oral Anticoagulants or Antiplatelets Agents.||University Of Perugia||Recruiting|September 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||September 2006|September 19, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222625||190221|
NCT00254891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8501001|Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer|International, Randomized, Open-Label, Phase 3 Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer||Pfizer|Yes|Terminated|November 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|828|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 15, 2005|Yes|Yes|See Termination Reason in Detailed Description|No||https://clinicaltrials.gov/show/NCT00254891||187807|
NCT00255177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT003|Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients|A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients||VGX Pharmaceuticals, LLC|No|Completed|November 2005|January 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 30, 2009|November 15, 2005|No|Yes||No|April 22, 2009|https://clinicaltrials.gov/show/NCT00255177||187786|
NCT00255541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00028|GALLANT 4 Tesaglitazar vs. Glibenclamide|A 52-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes||AstraZeneca||Terminated|September 2004|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||580|||Both|18 Years|N/A|No|||March 2008|March 14, 2008|November 17, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00255541||187759|
NCT00255814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0438|Radiation Therapy in Treating Patients With Liver Metastases|A Phase I Trial of Highly Conformal Radiation Therapy for Patients With Liver Metastases||Radiation Therapy Oncology Group|Yes|Completed|November 2005|November 2013|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|November 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00255814||187740|
NCT00256997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006016|A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication|Pragmatic Randomized Trial of Risperdal Consta Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting||Janssen-Ortho Inc., Canada|No|Terminated|January 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|65 Years|No|||November 2013|November 12, 2013|November 18, 2005|Yes|Yes|Inability to recruit number of planned patients|No|February 27, 2013|https://clinicaltrials.gov/show/NCT00256997||187651|The study was terminated due to futility.
NCT00257283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN K85 02024|Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis|A Double Blind Comparison of Omacor and Placebo as Secondary Prevention Against Cardiovascular Events in Patients Undergoing Chronic Hemodialysis||Pronova BioPharma||Completed|November 2002|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||March 2008|March 10, 2008|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257283||187629|
NCT00257361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol #639-2004|D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder|D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder||University of Florida|No|Withdrawn|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|18 Years|65 Years||||August 2011|September 27, 2013|November 18, 2005|No|Yes|PI left the university|No||https://clinicaltrials.gov/show/NCT00257361||187623|
NCT00258076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002215|A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)|Open-Label, Randomized, Partially Balanced, Incomplete Block Design Sudy to Evaluate the Hormone Exposure From Commercial ORTHO EVRA�||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2004|September 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|18 Years|45 Years|No|||December 2012|December 11, 2012|November 22, 2005||||||https://clinicaltrials.gov/show/NCT00258076||187568|
NCT00258089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005482|A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections|A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 1993|January 1995|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|578|||Both|18 Years|N/A|No|||November 2010|May 19, 2011|November 22, 2005||||||https://clinicaltrials.gov/show/NCT00258089||187567|
NCT00258102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005488|A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections|A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 1993|January 1995|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|603|||Both|18 Years|N/A|No|||January 2011|June 8, 2011|November 22, 2005||||||https://clinicaltrials.gov/show/NCT00258102||187566|
NCT00253669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0307 CDR0000441111|Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas|Pilot Study of Thrombophilic States in Newly Diagnosed Patients With High-Grade Gliomas||Sidney Kimmel Comprehensive Cancer Center||Completed|April 2005|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|outpatient clinic|May 2012|May 24, 2012|November 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00253669||187900|
NCT00253682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|342|Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers|Cardiac Status of HAART Exposed Infants of HIV-Infected Mothers (CHAART I)|CHAART-1|University of Miami|Yes|Completed|September 2002|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|167|Samples Without DNA|Blood samples were collected for analysis of cardiac biomarkers high sensitivity C REactive      PRotein (hsCRP) and N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP).|Both|N/A|2 Years|No|Non-Probability Sample|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active        Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission        Study (WITS).        The comparison group will be a historical cohort of HIV-uninfected infants born to        HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV        Study (P2C2 HIV) who were not exposed to HAART.|March 2014|March 17, 2014|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00253682||187899|
NCT00253955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR355_3035|Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia|An Open-Label, Multicenter, Multinational, Centrally Randomized, Two-Arm Parallel-Group Study to Demonstrate the Non-Inferiority in Clinical Efficacy of Levofloxacin 750mg od in Comparison With Piperacillin/Tazobactam 4g/500mg Every 8 Hours in the Treatment of Mild to Moderate Hospital-Acquired Pneumonia Adult Patients in Both General Wards and ICU (Intensive Care Unit)||Sanofi||Completed|June 2003|November 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|N/A|No|||November 2008|November 7, 2008|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00253955||187878|
NCT00253968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTE6217|Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia|Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study|GEMS|Sanofi|No|Completed|November 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|967|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00253968||187877|
NCT00246675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.167|Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.|Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery||Melbourne Health|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|October 27, 2005|||The study has ceased recruiting as Ethics approval has lapsed and the investigator    availability reduced.|No||https://clinicaltrials.gov/show/NCT00246675||188424|
NCT00247182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAABOR015518|Stepped Care for Mandated College Students|Stepped Care for Mandated College Students||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Completed|October 2006|June 2011|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|598|||Both|18 Years|N/A|No|||November 2009|April 25, 2012|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00247182||188386|
NCT00224926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10704|The Natural Course of Trichophyton Tonsurans Carriage and Infection: A Molecular and Biochemical Evaluation|The Natural Course of Trichophyton Tonsurans Carriage and Infection: A Molecular and Biochemical Evaluation||Children's Mercy Hospital Kansas City|No|Completed|September 2003|September 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|446|Samples With DNA|fungal scalp cultures|Both|2 Years|5 Years|Accepts Healthy Volunteers|Probability Sample|preschool aged children|September 2011|September 16, 2011|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224926||190046|
NCT00224939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 62714 (terminated)|Pre-ESRD Syndrome in High Risk African Americans|Pre-ESRD Syndrome in High Risk African American Young Adults||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Terminated|July 2002|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|144|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|September 21, 2005|||Only apx 1/3 of enrolled subjects (signed consent) participated. Futility analysis to show    primary endpoint|No||https://clinicaltrials.gov/show/NCT00224939||190045|
NCT00226109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFDV01|Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic Alcoholics|Effect of Spironolactone Treatment on Heart- and Skeletal Muscle in Chronic Alcoholics|SPICA|University of Aarhus|Yes|Suspended|April 2004|December 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|65 Years|No|||October 2010|October 19, 2010|September 23, 2005||No|Problems recruting patients|No||https://clinicaltrials.gov/show/NCT00226109||189959|
NCT00225563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7UC1HS015316-02|Taconic Health Information Network and Community (THINC)|Transforming Healthcare Quality Through I.T.||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|October 2004|September 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|9000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|June 12, 2007|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00225563||189998|
NCT00222300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2002/01532|A Targeted Strengthening Program Following Total Hip Replacement.|A Targeted Strengthening Program Following Total Hip Replacement.||University of Melbourne||Completed|May 2003|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||October 2003|August 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222300||190243|
NCT00254267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050129|Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors|An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate||Amgen|Yes|Completed|November 2005|December 2012|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|20 Years|N/A|No|||February 2014|February 26, 2014|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00254267||187855|
NCT00254280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-255566|Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial|Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light and Paring Versus Paring Alone - a Randomized Controlled Trial With Blinded Response Evaluation||Bispebjerg Hospital||Active, not recruiting|November 2005|September 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A|No|||May 2008|May 30, 2008|November 15, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00254280||187854|
NCT00254566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661147|A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)|A Phase 3B Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial To Evaluate The Efficacy and Safety Of Azithromycin SR (Microspheres Formulation) Versus Moxifloxacin For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB).||Pfizer|No|Completed|February 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|398|||Both|50 Years|N/A|No|||November 2009|November 3, 2009|November 14, 2005|Yes|Yes||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00254566||187832|
NCT00254579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671008|Study of CP-675,206 in Refractory Melanoma|A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma||AstraZeneca|No|Completed|December 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|251|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254579||187831|
NCT00255190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-GI04-088|Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn|A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD)||Takeda|No|Completed|January 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|591|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|November 15, 2005|Yes|Yes||No|June 24, 2009|https://clinicaltrials.gov/show/NCT00255190||187785|The incidence of adverse events was considered one of the primary outcome measures of this study. These results are presented in the Adverse Events Section and are not reposted as a separate primary endpoint.
NCT00255515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449L00004|Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia|An Open, Randomised, Parallel, Three Treatment Groups, Multicentre, Phase IV Study - in Real Life - to Compare the Change in Social Outcome of Quetiapine Fumarate (Seroquel®) Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia.|SCORE|AstraZeneca||Completed|September 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|64 Years|No|||March 2009|March 24, 2009|November 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255515||187761|
NCT00255827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0105|Vaccine Treatment for Surgically Resected Pancreatic Cancer|A Phase I/II Study of Algenpantucel-L (HyperAcute Pancreas) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Pancreatic Cancer||NewLink Genetics Corporation|Yes|Completed|November 2005|September 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|November 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255827||187739|
NCT00255840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA-SA Project 1|Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities|"Safeguard the Household" - A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country||CIPRA SA|No|Completed|July 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|812|||Both|16 Years|N/A|No|||June 2011|June 17, 2011|November 16, 2005|Yes|Yes||No|March 2, 2011|https://clinicaltrials.gov/show/NCT00255840||187738|The study design did not address nurse-initiated ART because the prescription of ART in South Africa is restricted to doctors. We noted a high rate of loss to follow-up, but this rate was similar to other resource-constrained settings.
NCT00256074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.263|The Effects of Nutritional Support of Critically Ill Patients Requiring Mechanical Ventilation|The Effects of Nutritional Support of Critically Ill Patients Requiring Mechanical Ventilation||Melbourne Health|No|Terminated|June 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|November 17, 2005||No|Decision was made to terminate the project due to slower than anticipated recruitment and many    of the investigators no longer being available.|No||https://clinicaltrials.gov/show/NCT00256074||187721|
NCT00257946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510128|Type of Material in Repair of Congenital Diaphragmatic Hernia|Prospective Randomized Trial Comparing Type of Material in Repair of Congenital Diaphragmatic Hernia||Children's Mercy Hospital Kansas City|No|Terminated|December 2005|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|N/A|2 Months|No|||December 2011|December 14, 2011|November 22, 2005||No|poor accrual|No||https://clinicaltrials.gov/show/NCT00257946||187578|
NCT00257959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)|||Connolly, Stuart, M.D.||Completed|January 2001|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|18 Years|N/A|No|||November 2005|July 26, 2006|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257959||187577|
NCT00257725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4939|Long Duration Stimulant Treatment Study of Preschoolers With ADHD-Feasibility Study|||New York State Psychiatric Institute|No|Completed|March 2005|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||February 2009|February 4, 2009|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257725||187595|
NCT00258063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002212|A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)|Open-Label, Randomized, Partially Balanced, Incomplete Block Design Study to Evaluate the Hormone Exposure From Commercial EVRA (Manufactured by LOHMANN Therapie-Systeme) and an Oral Contraceptive||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|September 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|June 6, 2011|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258063||187569|
NCT00257777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR03|Intermittent Cold Blood vs Crystalloid Cardioplegia in Aortic Valve Surgery|Intermittent Cold Blood vs Crystalloid Cardioplegia in Aortic Valve Surgery||Oslo University Hospital||Completed|November 2003|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|350|||Both|N/A|N/A|No|||November 2005|July 3, 2011|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00257777||187591|
NCT00258128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 00-01|Effect of Salicylate on Glucose Metabolism in Insulin Resistance States|Effect of Salicylate on Glucose Metabolism in Insulin Resistance States||Joslin Diabetes Center||Completed|January 2000|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||20|||Both|18 Years|65 Years||||November 2008|November 26, 2008|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258128||187564|
NCT00258141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM03RUP/IV/05|Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects|A Placebo-Controlled, Double-Blind, Cross-Over Study With Rupatadine 10 Mg in 30 Mosquito-Bite Allergic Adult Subjects||J. Uriach and Company||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|65 Years|No|||November 2005|November 23, 2005|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258141||187563|
NCT00253708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445117|Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer|Body-Based Complementary Therapies for Patients With Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 2003|||||N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Supportive Care|||||||Both|18 Years|N/A|No|||December 2005|August 19, 2009|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253708||187897|
NCT00253695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1317|Sleep, HIV Disease Progression, and Function in HIV Infected Children and Adolescents|Sleep Studies in HIV+ Older Children/Adolescents||Baylor College of Medicine|No|Completed|July 2004|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|90|Samples Without DNA|Blood|Both|8 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|HIV-infected children with and without asthma.|March 2013|March 26, 2013|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00253695||187898|
NCT00246649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0563|Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia|Pilot Study of Ex Vivo Expansion of Mafosfamide-Purged CD34-Positive Cells for Autologous Peripheral Blood Stem Cell or Bone Marrow Transplantation in Patients With Acute Leukemia||Sidney Kimmel Comprehensive Cancer Center||Completed|September 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|1 Year|70 Years|No|||December 2008|December 16, 2008|October 27, 2005||||||https://clinicaltrials.gov/show/NCT00246649||188426|
NCT00246662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0004|Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies|Phase 1b Open-Label, Multicenter Clinical Study of the Safety and Activity of Intravenous Administration of SNS-595 in Patients With Advanced Hematologic Malignancies||Sunesis Pharmaceuticals|No|Completed|September 2005|April 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 10, 2011|June 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00246662||188425|
NCT00247195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4985|Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder|Culturally Congruent Care for Hispanic Outpatients With Major Depressive Disorder (MDD)||New York State Psychiatric Institute|No|Completed|November 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|80 Years|No|||October 2012|October 24, 2012|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00247195||188385|
NCT00247208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISN 17, 10N17|The SOS (Stenting Of Saphenous Vein Grafts) Trial|The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions||North Texas Veterans Healthcare System|Yes|Completed|May 2005|June 2011|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247208||188384|
NCT00225823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR103184|Study In Adults And Adolescents With Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 Mcg in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis in Europe||GlaxoSmithKline||Completed|May 2005|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||288|||Both|12 Years|N/A|No|||October 2010|October 1, 2010|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00225823||189979|
NCT00225290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2202|Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve|Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve||TTY Biopharm||Terminated|February 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|230|||Both|20 Years|N/A|No|||September 2005|October 7, 2011|September 21, 2005|||slowly recruitment rate|No||https://clinicaltrials.gov/show/NCT00225290||190019|
NCT00225576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS015397|Statewide Implementation of Electronic Health Records|Statewide Implementation of Electronic Health Records||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|September 2005|December 2012|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2030|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225576||189997|
NCT00225589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0088|A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)|A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)||AstraZeneca||Completed|August 2002|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||840|||Both|45 Years|70 Years|No|||November 2010|November 18, 2010|September 22, 2005||||||https://clinicaltrials.gov/show/NCT00225589||189996|
NCT00225836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVA study|Treatment of Dysmenorrhoea With the OVA TENS Apparatus|Treatment of Dysmenorrhoea With the OVA TENS Apparatus||The Hospital of Vestfold||Completed|September 2005|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2007|January 12, 2007|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00225836||189978|
NCT00254592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 05-38|Neoadjuvant Treatment of Breast Cancer|Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study||University of California, Irvine|Yes|Active, not recruiting|October 2005|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||September 2013|September 6, 2013|November 15, 2005|Yes|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00254592||187830|
NCT00254618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005018|A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.|Study to Determine the Pharmacokinetics of Mesalamine Following Administration of 30, 60, and 90 mg/kg/Day as 400 mg Delayed-release Tablets Given Every 12 Hours for 28 Days to Children/Adolescents With Active Ulcerative Colitis.||Warner Chilcott|No|Terminated|October 2005|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|34|||Both|5 Years|17 Years|No|||April 2013|April 15, 2013|November 14, 2005|Yes|Yes|Slow enrollment.|No||https://clinicaltrials.gov/show/NCT00254618||187828|
NCT00254904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8501002|Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC|International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer||Pfizer|Yes|Terminated|November 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|839|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 15, 2005|Yes|Yes|See Termination Reason in Detailed Description|No||https://clinicaltrials.gov/show/NCT00254904||187806|
NCT00255216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Poli-01|Policosanol for the Treatment of Hypercholesterolemia|Policosanol for the Treatment of Hypercholesterolemia||Carolinas Healthcare System||Completed|January 2005|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2005|November 17, 2005|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255216||187784|
NCT00255229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-05-0024|Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea|Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea||AHS Cancer Control Alberta|Yes|Completed|December 2002|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||January 2012|February 24, 2016|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00255229||187783|
NCT00255866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26082-ED|Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers|Improving Affect and Behavior in Assisted Living Residents||University of Washington||Completed|January 2004|December 2006|Actual|December 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||90|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2013|November 30, 2015|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255866||187737|
NCT00256087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.067|The Effect of Prophylactic Probiotic Lactobacilli in Enteral Feeding on Nosocomial Pneumonia Rates in Critically Ill Patients|The Effect of Prophylactic Probiotic Lactobacilli in Enteral Feeding on Nosocomial Pneumonia Rates in Critically Ill Patients||Melbourne Health||Completed|January 2005|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|57|||Both|18 Years|N/A|No|||April 2015|November 18, 2015|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00256087||187720|
NCT00254709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468-100970|Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients|Open, Pilot, Comparative Study to Evaluate the Efficacy and Safety of Two Immunosuppressor Regimens, Anti Il-2, Sirolimus Mycophenolate, Mophetyl and Steroids Versus Sirolimus, Cyclosporine, and Withdrawal of Cyclosporine Since the Third Month and Steroids in Elderly Population||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2002|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|66|||Both|60 Years|N/A|No|||January 2012|January 26, 2012|November 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00254709||187821|
NCT00254722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-05-0004|Safety of Autologous Stem Cell Treatment for Traumatic Brain Injury in Children|Safety of Autologous Stem Cell Treatment for Traumatic Brain Injury in Children||The University of Texas Health Science Center, Houston|Yes|Completed|April 2006|October 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|5 Years|14 Years|No|||January 2010|January 4, 2010|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254722||187820|
NCT00255034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04143|Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)|Phase IV Study of Tailored Therapy With Peg Interferon Alfa 2b and Ribavirin for Patients With Genotype 3 and High Viral Load. Genotype 3 Extended Treatment for HCV (GET-C Study)||Merck Sharp & Dohme Corp.|No|Terminated|February 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|November 15, 2005||No|Recruitment targets were unachievable in the currently available population.|No|June 4, 2009|https://clinicaltrials.gov/show/NCT00255034||187797|No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfill the recruitment target.
NCT00257738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041372|MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck|A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously in Combination With Montanide and GM-CSF on Immunological Response, Safety, Tolerability, and Preliminary Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck||University of Maryland|Yes|Recruiting|November 2005|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||December 2009|December 10, 2009|November 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00257738||187594|
NCT00257751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APROT04|Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)|Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving||Oslo University Hospital|No|Completed|March 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|N/A|N/A|No|||March 2009|July 3, 2011|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00257751||187593|
NCT00245583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-314|Topiramate in the Treatment of Pathological Gambling|Topiramate in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study||Icahn School of Medicine at Mount Sinai||Active, not recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|70 Years|No|||May 2008|May 19, 2010|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245583||188506|
NCT00245856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10206|Treatment of Upper Extremity Deep-Vein Thrombosis|Treatment of Upper Extremity Deep-Vein Thrombosis||University of Oklahoma||Completed|September 2002|December 2011|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|October 26, 2005|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT00245856||188485|
NCT00246389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002884|An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm|Flexeril� (Cyclobenzaprine Hydrochloride) Community Based Study - An Evaluation of Cyclobenzaprine HCl Monotherapy and in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed||July 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1000|||Both|18 Years|65 Years|No|||February 2011|February 17, 2011|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246389||188446|
NCT00246402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|337|Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV|Anti-Lipolytic Strategy for HIV Lipodystrophy||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|65 Years|No|||December 2007|May 14, 2014|October 27, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00246402||188445|
NCT00246415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-EVA12599|A Placebo-Controlled Trial of Memantine for Alcohol Dependence|Medications Development for Alcohol Abuse: NMDA Agents -- A Placebo-Controlled Trial of Memantine for Alcohol Dependence||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|November 2002|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|65 Years|No|||October 2008|October 7, 2008|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00246415||188444|
NCT00247221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASPI013385|Brief Intervention for Families of Teens Treated in the Emergency Department for an Alcohol-Related Event|Family Motivational Interviews for ETOH+ Teens in the ER||Brown University|Yes|Completed|October 2002|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||July 2012|July 28, 2012|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00247221||188383|
NCT00247481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913C00148|ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer|A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer||AstraZeneca||Completed|September 2002|June 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||77|||Female|18 Years|70 Years|No|||April 2009|April 22, 2009|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247481||188363|
NCT00224965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13334-5|Early Tobacco Abstinence - 5|Early Tobacco Abstinence in High Risk Smokers||National Institute on Drug Abuse (NIDA)||Active, not recruiting||October 2004||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||140|||Both|18 Years|60 Years|No|||September 2005|November 3, 2005|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00224965||190043|
NCT00225303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006730|TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use|A Phase II, Randomized, Active Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-na�ve and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use.||Tibotec Pharmaceuticals, Ireland||Completed|March 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|116|||Both|18 Years|N/A|No|||October 2010|May 18, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225303||190018|
NCT00253721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-1299|Melphalan With BBBD in Treating Patients With Brain Malignancies|Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study||OHSU Knight Cancer Institute|Yes|Terminated|May 1998|December 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|120 Years|No|||February 2016|February 12, 2016|November 11, 2005|No|Yes|Other competing clinical trials affecting enrollment|No||https://clinicaltrials.gov/show/NCT00253721||187896|
NCT00226135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-1400|Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder|Lamotrigine Versus Lithium in Subjects With Bipolar Affective Disorders - a Randomised Study of Prophylactic Effect||University of Aarhus|No|Completed|March 2001|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||April 2007|April 4, 2007|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226135||189957|
NCT00222053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 98-45-N|IFM 99-02 Thalidomide in Myeloma|||University Hospital, Toulouse|No|Completed|April 2000|December 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|800|||Both|18 Years|65 Years|No|||April 2010|April 1, 2010|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00222053||190261|
NCT00254930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005797|A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children|Prospective Trial of Risperdal (Risperidone) Following Psychological Therapy for Challenging Behaviour in Learning Disabled Children||Janssen-Cilag Ltd.||Completed|September 2003|June 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|5 Years|16 Years|No|||March 2010|May 18, 2011|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254930||187804|
NCT00254917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I29|Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines|||Sanofi||Completed|October 2003|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|387|||Both|6 Weeks|19 Months|Accepts Healthy Volunteers|||April 2012|April 13, 2012|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00254917||187805|
NCT00255554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3277-03-0027|DBT and Escitalopram in Borderline Personality Disorder|Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder||Bronx VA Medical Center||Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||November 2005|November 17, 2005|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255554||187758|
NCT00255567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-LEAP0104|Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis|A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan||Drugs for Neglected Diseases|Yes|Completed|November 2004|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1142|||Both|4 Years|60 Years|No|||March 2016|March 21, 2016|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00255567||187757|
NCT00255307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-E002-2005-4|Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection.|A Pilot Evaluation of Two Dosing Schedules of American Ginseng Extract in Pediatric Upper Respiratory Tract Infection.||Afexa Life Sciences Inc||Completed|November 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|75|||Both|3 Years|12 Years|Accepts Healthy Volunteers|||June 2007|June 14, 2007|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255307||187777|
NCT00256438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05125|Depression and Transcranial Direct Current Stimulation (tDCS)|The Treatment of Depression Using Transcranial Direct Current Stimulation (tDCS): a Pilot Study.||The University of New South Wales||Recruiting|February 2006|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||July 2006|July 6, 2006|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00256438||187693|
NCT00222469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0652|Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer|A Phase II Trial of Bevacizumab Plus Gemcitabine™ and Oxaliplatin™ as First Line Therapy in Metastatic or Locally Advanced (Unresectable) Pancreatic Cancer||University of Oklahoma||Completed|August 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|No|||July 2008|July 8, 2008|September 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00222469||190231|
NCT00222482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306M49703|Depakote ER in Borderline Personality Disorder|A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder||University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 2003|September 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|21 Years|55 Years|No|||August 2007|August 8, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00222482||190230|
NCT00257439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN 2005/44|Vitamin Metabolism in Kidney Disease|Vitamin Metabolism in Kidney Disease||Aalborg Universitetshospital|No|Recruiting|December 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. CKD, proteinuria          2. Healthy controls|September 2012|September 24, 2012|November 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00257439||187617|
NCT00257764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPH00096|Behavioural Intervention for Dysphagia in Acute Stroke|A Randomised Controlled Trial of Dysphagia Therapies for Swallowing Disorders Following Stroke.||Royal Perth Hospital||Completed|May 1996|May 1999||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||June 1999|May 4, 2006|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257764||187592|
NCT00245869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT03-FD/COR|Ultrasound and Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response|Contrast-Enhanced Ultrasound and Neoadjuvant Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response||University Hospital, Tours||Completed|March 2004|February 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||30|||Female|18 Years|75 Years|No|||July 2006|February 19, 2007|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245869||188484|
NCT00246168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005929|ULTRACET (Tramadol Hydrochloride and Acetaminophen) for the Treatment of Rheumatoid Arthritis Pain.|ULTRACET (Tramadol Hydrochloride and Acetaminophen) add-on Therapy for the Treatment of the Pain of Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Study||Janssen Korea, Ltd., Korea||Completed||June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|277|||Both|18 Years|79 Years|No|||November 2010|November 29, 2010|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246168||188462|
NCT00246155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-103|Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain|A Prospective Study to Evaluate the Potential Effects on Function and Size in Back Muscle After Injection of Botulinum Toxin Type A (Dysport®) in the Treatment of Chronic Low Back Pain||Ipsen||Completed|January 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|60 Years|No|||October 2006|October 10, 2006|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00246155||188463|
NCT00246428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMON09892-10|Motivational Interviewing for Alcohol-Positive Teens in the Emergency Room|Motivational Interviewing (MI) for ETOH+ Teens in the ER||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Active, not recruiting|January 2000|July 2003|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|198|||Both|18 Years|24 Years|No|||December 2007|December 6, 2007|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00246428||188443|
NCT00246688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91447|Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer|Randomized, Multicenter, Prospective Two-arm, Open-label Phase II Study to Investigate the Efficacy and Safety of Two ZK219477 i.v. Infusions (3-hour Infusion of 16mg/m2 Versus 0.5-hour Infusion of 16 mg/m2) in Patients With Recurrent Ovarian Cancer Progressing During, or Within 6 Months of the End of Platinum-based Chemotherapy||Bayer|No|Completed|November 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Female|18 Years|N/A|No|||December 2015|December 30, 2015|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00246688||188423|
NCT00246896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HS10884|Care Management for Patients With Alzheimer Disease and Their Family Caregivers|A Program of Collaborative Care for Alzheimer Disease||Agency for Healthcare Research and Quality (AHRQ)||Completed|August 2001|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||220|||Both|65 Years|N/A|No|||October 2005|July 26, 2006|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246896||188407|
NCT00247494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myocardh|Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients|Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|90|||Both|18 Years|N/A|No|||November 2005|July 21, 2009|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247494||188362|
NCT00224978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/99|Chloroquine for Treatment of Glioblastoma Multiforme|Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial||National Institute of Neurology and Neurosurgery, Mexico||Completed|January 2005|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years||||November 2009|November 17, 2009|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224978||190042|
NCT00257816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 03-33|Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma|Feasibility Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma||University of California, Irvine|Yes|Recruiting|April 2004|January 2009|Anticipated|January 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|N/A|No|||March 2008|March 26, 2008|November 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257816||187588|
NCT00258167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH12/2005.CTIL|Family Involvement in The Treatment Of a Mentally Ill Relative|Family Involvement in The Treatment Of a Mentally Ill Relative||Lev-Hasharon Mental Healtlh Center||Recruiting|November 2005|November 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 10, 2008|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258167||187561|
NCT00254007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205-2003|Depression and Traumatic Brain Injury|The Serotonin Transporter Gene Polymorphism and Major Depression Following Traumatic Brain Injury||Sunnybrook Health Sciences Centre||Completed|July 2003|May 2010|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2006|February 28, 2011|November 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254007||187874|
NCT00254293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-063|Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)|A Study to Assess the Steady-State Trough Serum Concentration, Safety, and Immunogenicity of Abatacept (BMS-188667) Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Who Are Receiving Disease Modifying Ant-Rheumatic Drugs (DMARDs)||Bristol-Myers Squibb||Completed|January 2006|July 2012|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|87|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|November 15, 2005|Yes|Yes||No|August 20, 2013|https://clinicaltrials.gov/show/NCT00254293||187853|Error resulted in 4 participants being treated with study drug they were not randomized to receive. ST data were summarized by study drug participants actually received while LT data were summarized by what participants were randomized to receive.
NCT00253981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBAMC #05/13|Light Therapy in the Treatment of Leg Pain|Monochromatic Near-Infrared Light Energy (MIRE) in the Treatment of Tibial Stress Reaction|MilCAM|Samueli Institute for Information Biology|Yes|Terminated|November 2005|November 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|No|||May 2014|May 20, 2014|November 10, 2005||No|Enrollment not achieved succesfully|No|August 28, 2013|https://clinicaltrials.gov/show/NCT00253981||187876|
NCT00253994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL-03-01|Auricular Acupuncture for Acute Pain|Auricular Acupuncture in the Treatment of Acute Pain Syndromes (AATAPS) Pilot||Samueli Institute for Information Biology||Completed|August 2003|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|18 Years|50 Years|No|||September 2007|September 4, 2007|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00253994||187875|
NCT00254956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY6160|Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma|A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide Hfa-Mdi 640 μg/Day and Beclomethasone Hfa-Mdi 640 μg/Day on Lens Opacification in Adult Subjects With Moderate to Severe Persistent Asthma||Sanofi||Completed|January 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1568|||Both|18 Years|N/A|No|||April 2009|April 7, 2009|November 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00254956||187803|
NCT00254969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I43|Immunogenicity and Safety of Pentaxim in South African Infants|||Sanofi|No|Completed|October 2005|January 2010|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|212|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2012|April 16, 2012|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00254969||187802|
NCT00255242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRAYNA04A0|Effect of Simvastatin on CF Airway Inflammation|Effect of Simvastatin on CF Airway Inflammation||Akron Children's Hospital|No|Completed|July 2004|May 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|10 Years|N/A|No|||January 2008|July 31, 2009|November 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255242||187782|
NCT00255580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-SD-104|Medicinal Cannabis for Painful HIV Neuropathy|Placebo-Controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy||Center for Medicinal Cannabis Research|Yes|Completed|September 2001|November 2006|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|21 Years|65 Years|No|||February 2008|February 20, 2008|November 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255580||187756|
NCT00254384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0221|Neoadjuvant, Tarceva, Surgery for Non-Small Cell Lung Cancer (NSCLC)|Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2005|||October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00254384||187846|
NCT00256126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24531|Predictive Markers in GHD and TS Children Treated With SAIZEN®|A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated With SAIZEN®||Merck KGaA||Completed|May 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|318|||Both|2 Years|16 Years|No|||March 2014|March 26, 2014|November 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256126||187717|
NCT00256139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24011|CLEAR Study: Clinical Experience Acquired With Raptiva Study|||Merck KGaA||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years||||February 2014|February 17, 2014|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00256139||187716|
NCT00256711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791AC00001|Phase II Iressa Versus Vinorelbine (INVITE)|A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC||AstraZeneca||Completed|July 2004|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||192|||Both|70 Years|N/A|No|||April 2009|April 22, 2009|November 20, 2005||||No||https://clinicaltrials.gov/show/NCT00256711||187672|
NCT00257296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1751|Evaluation of an Intimate Partner Violence Screening-Intervention|Evaluation of an Intimate Partner Violence Screening-Intervention||University at Albany||Suspended||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||2000|||Female|18 Years|45 Years||||November 2005|November 21, 2005|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257296||187628|
NCT00257621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPR10006|GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults|A Pilot, Phase II, Open-label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GW640385 When Administered With Ritonavir in Combination With NRTIs for 48 Weeks in HIV-1 Infected Adults||ViiV Healthcare|No|Completed|October 2004|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|November 21, 2005||||||https://clinicaltrials.gov/show/NCT00257621||187603|
NCT00222248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251632|Pelvic Floor Muscle Training for Incontinence in Older Women.|The Effect of Pelvic Floor Muscle Training for the Management of Incontinence in Older Women: a Single Blind Randomised Controlled Trial.||University of Melbourne||Active, not recruiting|March 2003|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||90|||Female|65 Years|N/A|Accepts Healthy Volunteers|||June 2003|August 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222248||190247|
NCT00257803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70504|Does the Rapid Intravenous Administration of Oxytocin After Delivery of the Baby Decrease the Bleeding During Cesarean Section in Women at Risk of Bleeding During Cesarean Section?|A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage||University of British Columbia|No|Completed|November 2005|December 2012|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|150|||Female|19 Years|N/A|Accepts Healthy Volunteers|||February 2014|March 14, 2014|November 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00257803||187589|
NCT00258115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 03-48|The Study of Inflammation on Blood Glucose Levels in Obese People|The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity||Joslin Diabetes Center|No|Completed|December 2003|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2012|September 21, 2012|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00258115||187565|
NCT00246181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9910-35|Phase I and II Study Of Stereotactic Body Radiotherapy in Medically Unresectable Patients With Stage 1 NSCLC|Phase I and II Study Of Stereotactic Body Radiotherapy in Medically Unresectable Patients With Stage 1 NSCLC|SBF-NSCLC|Indiana University|Yes|Completed|December 1999|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00246181||188461|
NCT00246454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341|Circadian Rhythms and Sleep in Familial DSPS and ASPS|Circadian Rhythms and Sleep in Familial Delayed Sleep Phase Syndrome (DSPS) and Advanced Sleep Phase Syndrome (ASPS)||Northwestern University|No|Recruiting|September 2003|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|N/A||3|Anticipated|156|Samples Without DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with circadian rhythm sleep disorders and healthy age and gender matched controls|October 2015|October 5, 2015|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00246454||188441|
NCT00246441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAARAN013379|Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism|Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism||Medical University of South Carolina||Completed|March 2002|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||November 2009|November 17, 2009|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00246441||188442|
NCT00246701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM6 program (Reliant)|Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Omacor and Simvastatin Therapy in Hypertriglyceridemic Subjects|COMBOS|GlaxoSmithKline||Completed|November 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|79 Years|No|||December 2009|December 10, 2009|October 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246701||188422|
NCT00246909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/M3-340|Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)|Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week.||Takeda||Completed|November 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||June 2011|May 4, 2012|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00246909||188406|
NCT00247507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94029|The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients|||Far Eastern Memorial Hospital||Active, not recruiting|September 2005|December 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2005|October 17, 2006|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247507||188361|
NCT00258154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-010|V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)|Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants||Merck Sharp & Dohme Corp.||Completed|February 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|403|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||October 2015|October 5, 2015|November 15, 2005|Yes|Yes||No|August 10, 2009|https://clinicaltrials.gov/show/NCT00258154||187562|
NCT00258180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0326, CDR0000441133|Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy|High-Dose Cyclophosphamide for the Treatment of Severe Autoimmune Enteropathy||Sidney Kimmel Comprehensive Cancer Center||Completed|June 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|3|||Both|1 Year|21 Years|No|||June 2012|June 13, 2012|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258180||187560|
NCT00253734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0109|Immunogenicity and Safety of Different Doses of Fluzone® Influenza|Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone® in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2005|November 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|217|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2008|May 30, 2013|November 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00253734||187895|
NCT00254020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380-2004|The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression|The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression||Sunnybrook Health Sciences Centre|No|Completed|June 2005|December 2013|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00254020||187873|
NCT00254306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050893-HMO-CTIL|Functional Brain Imaging in Recreational Users of Ecstasy|Functional Brain Imaging in Recreational Users of Ecstasy||Hadassah Medical Organization|Yes|Completed|January 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients from treatment centers for drug abuse. Control subjects will be recruited from        the general population.|July 2011|July 6, 2011|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00254306||187852|
NCT00254319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3158'S|Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)|Phase II Trial of Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)||The Cooper Health System||Recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||November 2005|November 14, 2005|November 14, 2005||||||https://clinicaltrials.gov/show/NCT00254319||187851|
NCT00257257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5825|Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20 mg) Multicenter Study of Long-Term Glycemic Control With Rimonabant in Treatment-naïve Patients With Type 2 Diabetes|SERENADE|Sanofi||Completed|March 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|281|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|November 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00257257||187631|
NCT00257270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-073|The Effect of Gabapentin on the Sensation and Impact of Tinnitus|The Effect of Gabapentin on the Sensation and Impact of Tinnitus||Tinnitus Research Consortium||Completed|August 2003|January 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2005|November 18, 2005|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00257270||187630|
NCT00255255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890C00009|Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma|An Open, Phase III, Multicentre, 52-week Study, Evaluating the Safety and Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma||AstraZeneca||Completed|November 2005|June 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|16 Years|N/A|No|||January 2011|January 21, 2011|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255255||187781|
NCT00255268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6876L00010|CMAB vs IMAB in Metastatic Prostate Cancer|Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer||AstraZeneca||Withdrawn|August 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Male|18 Years|N/A|No|||August 2007|August 24, 2007|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00255268||187780|
NCT00254397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0502|Melanoma Vaccine With Peptides and Leuprolide|Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients||M.D. Anderson Cancer Center|Yes|Completed|November 2005|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|98|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254397||187845|
NCT00222235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059807|Adjunctive Treatment for Decreasing Symptoms of Schizophrenia|Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST)||University of Maryland||Completed|January 2000|June 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|54 Years|No|||June 2013|November 21, 2013|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00222235||190248|
NCT00245258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481239|Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction|A Multicenter, Double-Blind Placebo Controlled, Fixed Dose Study With An Open-Label, Flexible Dose Phase To Assess The Efficacy Of Sildenafil Citrate In Providing A Better Sexual Experience Including Quality Of Erections And Satisfaction In Men With Erectile Dysfunction||Pfizer||Completed|November 2005|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||312|||Male|18 Years|65 Years|No|||October 2006|October 5, 2006|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245258||188531|
NCT00245570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-316|Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)|A Double-Blind, Randomized Multicenter, 3-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast Compared With Placebo and Salmeterol on Exercise-Induced Bronchoconstriction||Merck Sharp & Dohme Corp.|No|Completed|December 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|47|||Both|15 Years|45 Years|No|||June 2015|June 22, 2015|October 26, 2005|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00245570||188507|
NCT00246194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005035|Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)|The SOURCE Study: Schizophrenia Outcomes-utilization, Relapse, and Clinical Evaluation: a Prospective 2-year Observational Study of Patients With Schizophrenia Who Initiate Treatment With Injectable Risperidone Long-acting Microspheres (RISPERDAL CONSTA)|SOURCE|Janssen, LP|No|Completed|September 2004|November 2007|Actual|November 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|532|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with schizophrenia|April 2014|April 2, 2014|October 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00246194||188460|
NCT00246467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0005|One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)|A Phase 1b, Multi-Centre, Parallel Group, Single Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Plague Vaccine (rF1 and rV Antigens) in Healthy Subjects||PharmAthene UK Limited|Yes|Completed|October 2005|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Actual|123|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 12, 2008|October 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246467||188440|
NCT00246714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP03|Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans|Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans||Radboud University|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|October 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246714||188421|
NCT00246922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTA-2217-07|Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)|A Long-term Study of APTA-2217 in Adult Patients With Bronchial Asthma||Takeda||Completed|December 2004|October 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|20 Years|71 Years|No|||December 2008|May 4, 2012|October 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246922||188405|
NCT00246935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTA-2217-08|Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)|A Long-term Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease||Takeda||Completed|May 2005|October 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|40 Years|N/A|No|||December 2008|May 4, 2012|October 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246935||188404|
NCT00247520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV-71-004|Safety and Efficacy Study of rEV131 in Allergic Rhinitis|Two Center Evaluation of the Safety and Efficacy of Topical Nasal rEV131 Versus rEV131 Vehicle (Placebo)in the Prevention of the Signs and Symptoms of Allergic Rhinitis Induced by Nasal Allergen Challenge||Evolutec Group||Active, not recruiting|May 2005|August 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||112|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2005|November 1, 2005|November 1, 2005||||||https://clinicaltrials.gov/show/NCT00247520||188360|
NCT00247533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-E-940004|Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia|The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography||Far Eastern Memorial Hospital||Recruiting|October 2005|August 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|30|||Both|N/A|N/A|No|||August 2005|February 6, 2009|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247533||188359|
NCT00257829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 03-41|Improving Tumor Oxygenation in Cervical Cancer|Improving Tumor Oxygenation in Cervical Cancer With Methazolamide||University of California, Irvine|Yes|Withdrawn|July 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Female|18 Years|N/A|No|||February 2008|February 27, 2008|November 21, 2005|||This study was closed due to lack of funding.|No||https://clinicaltrials.gov/show/NCT00257829||187587|
NCT00253747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0029|Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD||University of Cincinnati|Yes|Completed|November 2005|March 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|55 Years|No|||August 2012|August 17, 2012|November 13, 2005||No||No|July 16, 2012|https://clinicaltrials.gov/show/NCT00253747||187894|
NCT00254332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 0509084|Effect of Denileukin Diftitox on Immune System in CTCL Patients|Effect of Denileukin Diftitox in T-Regulatory Cells in CTCL Patients||FDA Office of Orphan Products Development||Completed|November 2005|September 2007||||N/A|Observational|Time Perspective: Prospective|||Anticipated|10|||Both|18 Years|N/A|No|||December 2007|March 24, 2015|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254332||187850|
NCT00254605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12225-27221-0+1|Retinal Imaging in Patients With Inherited Retinal Degenerations|High Resolution Retinal Imaging in Patients With Inherited Retinal Degenerations||University of California, San Francisco|Yes|Recruiting|November 2005|November 2016|Anticipated|October 2016|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|||Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with inherited retinal degenerations, including retinitis pigmentosa,        choroideremia, x-linked retinoschisis and Usher syndrome. We are also studying a small        number of patients with age-related macular degeneration.|May 2015|May 26, 2015|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00254605||187829|
NCT00254631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pre-oxy.CTIL|Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures|Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures||Rambam Health Care Campus||Completed|April 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|60 Years|No|||February 2015|February 4, 2015|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00254631||187827|
NCT00257933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-9-4377|Oral Prednisolone Dosing in Children Hospitalized With Asthma|Oral Prednisolone Dosing in Children Hospitalized With Asthma||Children's Hospital of Philadelphia|No|Completed|February 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|2 Years|18 Years|No|||December 2010|December 23, 2010|November 22, 2005|Yes|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00257933||187579|Limited ability to measure pulmonary function in hospitalized children with asthma did not allow measurement of this outcome.Some protocol violations occurredSingle center study
NCT00253578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03064|Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients With Relapsing or Resistant Multiple Myeloma||National Cancer Institute (NCI)||Completed|March 2006|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|November 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00253578||187905|
NCT00255021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I34|Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand|||Sanofi||Completed|December 2005|January 2009|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|186|||Both|2 Months|2 Months|Accepts Healthy Volunteers|||April 2012|April 13, 2012|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00255021||187798|
NCT00221923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI U10 EY 14267|African Descent and Glaucoma Evaluation Study|African Descent and Glaucoma Evaluation Study (Formerly African Americans With Glaucoma Study)|ADAGES|University of California, San Diego|No|Active, not recruiting|September 2002|February 2015|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1540|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults of African or European descent based on self-report.|August 2011|August 29, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221923||190271|
NCT00226044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-001|Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.|Rectal and Oral Omeprazole Treatment of Gastroesophageal Reflux in Infants With Esophageal Atresia or Congenital Diaphragmatic Hernia; A Pharmacodynamic and Pharmacokinetic Study.||Rijnstate Hospital||Recruiting|September 2005|December 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|6 Weeks|3 Months|No|||April 2013|April 25, 2013|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00226044||189964|
NCT00221936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN04-0394-AE|Patient Controlled Oral Analgesia for Postoperative Pain Management After Total Knee Replacement|Patient Controlled Oral Analgesia (PCOA) for Postoperative Pain Management After Total Knee Replacement-A Pilot Study||University Health Network, Toronto||Completed|July 2004|July 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|80 Years|No|||July 2005|December 4, 2008|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00221936||190270|
NCT00221949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN05-0491-AE|Visualizing Peripheral Nerves Using Ultrasound-Guided Approach|Development of a Comprehensive Study of the Peripheral Nerves in the Lower Arm and Lower Leg Using an Ultrasound Guided Approach||University Health Network, Toronto||Completed||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2005|December 4, 2008|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00221949||190269|
NCT00222820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011015|Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study|Depression: The Search for Treatment-Relevant Phenotypes||University of Pittsburgh||Completed|April 2002|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|65 Years|No|||September 2005|September 19, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222820||190206|
NCT00223093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006|TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)|A Single-Center Open-Labelled Study of the Administration of Transplant-Acceptance Inducing Cells (TAIZ) for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)||University of Schleswig-Holstein||Active, not recruiting|February 2004|August 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||April 2003|October 27, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223093||190185|
NCT00245596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481210|Evaluation of the Index of Sexual Life Questionnaire|An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)||Pfizer||Completed|October 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Male|18 Years|N/A|No|||February 2008|February 22, 2008|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00245596||188505|
NCT00245609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081072|Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Of The Anxiolytic Efficacy Of Pregabalin And Alprazolam IR In Subjects With Anxiety Prior To Dental Procedure||Pfizer||Completed|January 2006|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||March 2008|March 19, 2008|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245609||188504|
NCT00246480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0083|RSV Disease in the Elderly|Pathogenesis of RSV Disease in the Elderly||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|October 2005|October 2009||||N/A|Observational|Time Perspective: Prospective||||2000|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2008|August 26, 2010|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00246480||188439|
NCT00246727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV-001 and SV-002|Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer|Study 1: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Chemotherapy: A Randomized Double Blind Placebo Controlled Study; Study 2: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Best Supportive Care: A Randomized Double Blind Placebo Controlled Study||Sun Farm Corporation|Yes|Recruiting|December 2005|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|October 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246727||188420|
NCT00246948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF 20010134|The Efficacy of Active Conservative Treatment for Patients With Severe Sciatica. A Randomized Clinical Controlled Trial|The Efficacy of Active Conservative Treatment for Patients With Severe Sciatica. A Randomized Clinical Controlled Trial||The Back Research Center, Denmark||Completed|November 2001|August 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||181|||Both|18 Years|65 Years|No|||October 2005|October 16, 2008|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00246948||188403|
NCT00246961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5392NL0002|Arimidex Observational: Reason for and Effect of Change From Tamoxifen|Arimidex: Reason for and Effect of Change From Tamoxifen|ARREST|AstraZeneca|No|Completed|July 2004|||||Phase 4|Observational|Time Perspective: Prospective||||200|||Female|18 Years|N/A|No|||June 2007|October 11, 2007|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00246961||188402|
NCT00246974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0063|Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT|An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium||AstraZeneca||Completed|May 2003|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||October 2008|October 14, 2008|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00246974||188401|
NCT00247234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ursula.falkmer+AEA-stolav.no|Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders|Effectiveness of Group Based Schema Therapy in the Treatment of Borderline Personality Disorder and Avoidant Personality Disorder||Norwegian University of Science and Technology|No|Completed|September 2004|January 2015|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|20 Years|50 Years|No|||May 2015|May 12, 2015|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247234||188382|
NCT00247247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939089|Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.|Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon||Orion Corporation, Orion Pharma||Completed|December 2002|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||300|||Both|60 Years|N/A||||June 2007|June 22, 2007|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247247||188381|
NCT00253526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448825|Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer|Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas||National Cancer Institute (NCI)||Withdrawn||||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|April 27, 2015|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253526||187909|
NCT00253760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK66008 (completed 2007)|Metabolic Analysis in Human Sulfur Amino Acid Deficiency|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2004|February 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00253760||187893|
NCT00253773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES12929 (completed)|Metabolic Effects of Chemical Interactions in Toxicity|Metabolic Effects of Chemical Interactions in Toxicity||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 2005|November 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00253773||187892|
NCT00254345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191056HMO-CTIL|Effect of Provisional-Crown Surface Coating on Biofilm Formation|Effect of Provisional-Crown Surface Coating on Biofilm Formation||Hadassah Medical Organization|No|Completed|September 2006|April 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||1|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 10, 2007|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254345||187849|
NCT00254644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRR04-CH/DYS|Morphofunctional Imaging and Developmental Dyslexia||PHRR04-CH/DYS|University Hospital, Tours|No|Completed|February 2007|May 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|This is a prospective study including 15 right-handed male subjects, aged 18 to 35 years,        carrying a developmental dyslexia and 15 control subjects handed the same sex. We chose to        include only male subjects to obtain a homogeneous population and to avoid the problem of        a functional organization differs according to gender.|May 2011|May 2, 2011|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00254644||187826|
NCT00254657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5612-23162|Levetiracetam for Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Treatment of Pain Associated With Fibromyalgia||University of California, San Francisco||Completed|March 2004|April 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254657||187825|
NCT00253838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2001215-01H|A Comparison of Two Type of Stems in Revision Hip Arthroplasty|A Randomized Controlled Trial Comparing a Titanium to a Cobalt Chrome Femoral Stem in Revision Hip Arthroplasty: A Pilot Study||Ottawa Hospital Research Institute|No|Active, not recruiting|October 2001|February 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||October 2011|October 21, 2015|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00253838||187887|
NCT00254072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 2005 4474|Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)|Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)a Prospective Randomized Comparison of the 3.5 mm vs 4.8 mm Circular Stapler for Creation of the Gastrojejunostomy in Prevention of Staple Line Hemorrhage During Laparoscopic Gastric Bypass|EEA-LGB|University of California, Irvine|No|Completed|January 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|355|||Both|18 Years|60 Years|No|||February 2010|February 11, 2010|October 31, 2005||No||No|November 5, 2009|https://clinicaltrials.gov/show/NCT00254072||187869|Difficulty discerning GI bleeding attributed to the gastrojejunostomy vs gastric pouch staple-lineTechnological differences between 3.5mm vs 4.8 mm staplerOperative techniques varying between study sitesStudy size may be underpowered
NCT00255619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2372|Open Label Trial to Establish the Equivalence Between ANDY-Disc® and Ultrabag® in Patients on CAPD.|A Randomized, Multi-Center, Open Label Trial to Establish the Equivalence Between ANDY-Disc® (Fresenius Medical Care) and Ultrabag® (Baxter) in Patients on CAPD. [CAPD-2 Trial]||Ministry of Health, Malaysia||Completed|May 2002|May 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||264|||Both|N/A|N/A|No|||November 2005|October 25, 2006|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255619||187753|
NCT00222534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREMA|Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis|Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis||University of Oslo School of Pharmacy||Completed|January 2002|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00222534||190226|
NCT00222547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEVTA|Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6|Deworming and Enhanced Vitamin A Supplementation DEVTA Project||University of Oxford||Completed|January 1999|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||720000|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||February 2005|October 27, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222547||190225|
NCT00223639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AA014628-02|New Medications to Treat Alcohol Dependence|New Medications to Treat Alcohol Dependence||University of Virginia|Yes|Completed|September 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|29|||Both|21 Years|45 Years|No|||February 2012|February 3, 2012|September 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223639||190144|
NCT00222833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0312010|The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia|The Effect of Switching to Aripiprazole on Indices of Cardiovascular Health in Overweight and Obese Patients With Schizophrenia||University of Pittsburgh||Completed|October 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||January 2008|January 8, 2008|September 7, 2005||||No||https://clinicaltrials.gov/show/NCT00222833||190205|
NCT00245882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02324; 02489|The Diabetes Telemonitoring (DiaTel) Study|The Diabetes Telemonitoring (DiaTel) Study|DiaTel|VA Pittsburgh Healthcare System|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|79 Years|No|||September 2012|September 17, 2012|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00245882||188483|
NCT00246220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002479|A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.|A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder||Janssen Pharmaceutica N.V., Belgium||Completed|March 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|402|||Both|18 Years|65 Years|No|||April 2010|May 16, 2011|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246220||188458|
NCT00246740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protect Study Protocol|Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting|Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting: A Pilot Study||University of Alberta|No|Completed|October 2005|May 2009|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||January 2010|January 11, 2010|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00246740||188419|
NCT00246987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-018|A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control||Bristol-Myers Squibb||Completed|June 2003|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||341|||Both|18 Years|70 Years|No|||April 2012|April 26, 2012|October 28, 2005||||||https://clinicaltrials.gov/show/NCT00246987||188400|
NCT00247260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOSP 202|Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma|A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered With the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma||pSiVida Limited||Active, not recruiting|October 2005|February 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||October 2005|March 13, 2007|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247260||188380|
NCT00253591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449972|Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Randomised Phase II/III Trial of Induction Chemotherapy Followed by Continuous Hyperfractionated Accelerated Radiotherapy (CHART) Versus CHART Alone in Patients With Inoperable Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|June 2005|December 2009|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|N/A|No|||July 2007|December 18, 2013|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253591||187904|
NCT00253539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-4713|Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer|A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer||The Cleveland Clinic|Yes|Completed|January 2002|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|3|||Female|18 Years|N/A|No|||April 2011|April 11, 2011|November 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00253539||187908|
NCT00255294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-085|Contraceptive Effectiveness Trial of Cellulose Sulfate Gel|Non-Comparative Contraceptive Effectiveness Trial of Cellulose Sulfate (CS) Gel||CONRAD||Completed|January 2005|October 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2005|November 17, 2005|November 17, 2005||||||https://clinicaltrials.gov/show/NCT00255294||187778|
NCT00255593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT: 2005-001231-29|Safety and Efficacy Study of Rituximab in Renal Transplantation|A Prospective, Randomised, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Rituximab as Induction Therapy Together With Tacrolimus, Mycophenolate Mofetil and Steroids for Patients Undergoing Renal Transplantation||Karolinska University Hospital||Completed|November 2005|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|140|||Both|18 Years|70 Years|No|||October 2007|November 29, 2007|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00255593||187755|
NCT00256100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.066|Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.|Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.||Melbourne Health|No|Terminated|June 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|November 17, 2005||No|Teh Priincipal investigator responsible for the trial no longer employed at the study site.|No||https://clinicaltrials.gov/show/NCT00256100||187719|
NCT00256113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5575|An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder||Sanofi||Completed|December 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|467|||Both|18 Years|64 Years|No|||December 2008|December 22, 2008|November 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00256113||187718|
NCT00225745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS 0405|Ghrelin Levels in Pancreatic Cancer Patients|Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer||Dartmouth-Hitchcock Medical Center|Yes|Completed|April 2004|September 2015|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|72|Samples Without DNA|Whole Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pancreatic cancer patients who have not received treatment. Healthy age-matched controls.|August 2015|October 12, 2015|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225745||189984|
NCT00254683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|717/05|Use of Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Tumor Response to Neoadjuvant Treatment for Distal Rectal Cancer|Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy||University of Sao Paulo|No|Recruiting|September 2005|September 2015|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2009|April 13, 2009|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00254683||187823|
NCT00225758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0520|Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy|Lapatinib in Endocrine-Resistant Metastatic Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Terminated|January 2006|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||August 2013|January 12, 2015|September 22, 2005|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00225758||189983|
NCT00222495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0205M26041|A Comparative Study of New Medications for Psychosis in Adolescents|A Comparative Study of New Medications for Psychosis in Adolescents||University of Minnesota - Clinical and Translational Science Institute||Completed|August 2002|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|12 Years|18 Years|No|||September 2006|September 7, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00222495||190229|
NCT00222508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012M75862|The Microvascular Complications Study|Microvascular Complications of Cystic Fibrosis Related Diabetes||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|April 2001|July 2005||||Phase 3|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|CFRD Patients|July 2012|July 31, 2012|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00222508||190228|
NCT00223652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-069|Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas|Tele-Mental Health Intervention to Improve Depression Outcomes in Community Based Outpatient Clinics (CBOCs)||VA Office of Research and Development|No|Completed|March 2006|April 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|September 20, 2005||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT00223652||190143|
NCT00255463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0223|Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study|Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicentre Trial Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination as Neoadjuvant Treatment in Postmenopausal Women With Stage I-IIIB Breast Cancer and Oestrogen Receptor (ER) and/or Progesterone (PgR) Positive Tumours||AstraZeneca||Completed|January 2004|November 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||185|||Female|N/A|N/A|No|||April 2009|April 22, 2009|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255463||187765|
NCT00255476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0544|The IRESSA Novel Head and Neck Chemotherapy Evaluation Study|A Randomised Phase II Study to Investigate the Feasibility and Benefits of Combining ZD1839 and Cisplatin/5FU, as Induction Therapy, in Patients With Locally and Advanced Squamous Cell Carcinoma of the Head and Neck||AstraZeneca||Completed|February 2004|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||64|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255476||187764|
NCT00245895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-6503-A|Study of Aranesp to Treat Anemia in Prostate Cancer Patients.|Phase II Study of Aranesp (Darbepoetin Alfa) to Treat Anemia in Prostate Cancer Patients.||University of Washington|No|Completed|April 2003|February 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Male|N/A|N/A|No|||November 2007|November 27, 2007|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245895||188482|
NCT00246753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0505|Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Study of Oral Once Daily GW572016 (Lapatinib) In Patients With Hormone Refractory Prostate Cancer|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|October 2005|May 2013|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|N/A|No|||January 2016|January 20, 2016|October 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00246753||188418|
NCT00247000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA005|A Strategy of Home Telehealth for Management of Congestive Heart Failure(STARTEL)|A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL||Nova Scotia Health Authority||Not yet recruiting|September 2007|November 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|N/A|N/A|No|||February 2006|June 27, 2007|October 30, 2005||||No||https://clinicaltrials.gov/show/NCT00247000||188399|
NCT00247273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005032|A Study of Monthly Risedronate for Osteoporosis|A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)||Warner Chilcott|No|Completed|October 2005|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1294|||Female|50 Years|N/A|No|||April 2013|April 15, 2013|October 28, 2005|Yes|Yes||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00247273||188379|
NCT00253617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXCAN-PHOCCC04-01|Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery|Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma||National Cancer Institute (NCI)||Withdrawn||||||Phase 3|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||December 2006|April 2, 2013|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253617||187903|
NCT00254059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-0079|A Randomized Study to Compare Polysomnography With Overnight Home Oximetry and Auto – CPAP for Sleep Apnea|A Randomized Study to Compare Polysomnography With Overnight Home Oximetry and Auto – CPAP for Diagnosis and Nasal CPAP Titration in Patients With a High Probability of Obstructive Sleep Apnea.||University of British Columbia||Completed||December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||November 2005|November 10, 2005|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00254059||187870|
NCT00254033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065-2003|Apathy Associated With Alzheimer's Disease|The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease||Sunnybrook Health Sciences Centre||Completed|October 2003|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|55 Years|N/A|No|||April 2007|May 21, 2008|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00254033||187872|
NCT00254046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002752|TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.|A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treatment to no Treatment Options.||Tibotec Pharmaceuticals, Ireland|Yes|Completed|November 2005|July 2008|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|616|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|November 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254046||187871|
NCT00255879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059101|Movement Disorders Caused by Antipsychotic Drugs in Older Patients|Neuroleptic Induced Movement Disorders in Older Patients||University of California, San Diego||Completed|January 1999|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|40 Years|N/A|No|||November 2005|June 5, 2013|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00255879||187736|
NCT00256685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-319|Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause|A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2004|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||568|||Female|N/A|N/A|No|||May 2006|May 17, 2006|November 17, 2005||||||https://clinicaltrials.gov/show/NCT00256685||187674|
NCT00256698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997L00002|Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy|FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy; an Open Randomized, Comparative, Phase III Multicentre Study in Postmenopausal Women With Hormone Receptor Positive Breast Cancer in First Relapse After Primary Treatment of Localized Tumor.|FACT|AstraZeneca||Completed|January 2004|February 2012|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|514|||Female|N/A|N/A|No|||July 2012|July 27, 2012|November 20, 2005|Yes|Yes||No|April 29, 2010|https://clinicaltrials.gov/show/NCT00256698||187673|
NCT00225173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G6HD|Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease|A Phase II Trial of Stanford VI ± Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease With 3+ Risk Factors: the G6 Study||Stanford University||Terminated|October 2001|September 2006|Actual|September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|70 Years|No|||September 2005|August 26, 2014|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00225173||190028|
NCT00226031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTS-62358|Optimal Management of Women With Wrist Fractures|Optimal Management of Older Women With Distal Forearm Fractures||Queen's University|No|Completed|September 2003|August 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|270|||Female|50 Years|N/A|No|||March 2015|March 10, 2015|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00226031||189965|
NCT00222001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-001-2002|Telephone Triage Study|Outcome Evaluation of Triage for Health Maintenance Organization (HMO) Patients Performed by Doctors in a Medical Telemedicine Center||University Hospital, Basel, Switzerland|No|Completed|December 2002|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Regular HMO patients|January 2015|January 27, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00222001||190265|
NCT00222521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0205M25461|Insulin Glargine Vs Standard Insulin Therapy|Comparison of Insulin Glargine Vs Standard Insulin Therapy in CFRD Without Fasting Hyperglycemia||University of Minnesota - Clinical and Translational Science Institute||Completed|April 2003|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|12 Years|N/A|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00222521||190227|
NCT00223171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-990-0056,1|Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers|Randomized, Multicentre, Phase III Study: Assessment of the Duration of Androgen Blockade Combined With Pelvic Irradiation in High-risk Prostate Cancers|PCS IV|Université de Sherbrooke|No|Active, not recruiting|October 2000|December 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Male|18 Years|80 Years|No|||January 2015|January 22, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223171||190179|
NCT00256334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 05-20|Resveratrol for Patients With Colon Cancer|Resveratrol for Patients With Colon Cancer||University of California, Irvine|Yes|Completed|July 2005|April 2009|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|November 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256334||187701|
NCT00246207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003097|CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults|An Open-label Study Evaluating the Safety and Effectiveness of OROS Methylphenidate Hydrochloride (CONCERTA) in Adults With Attention Deficit Hyperactivity Disorder||Janssen-Ortho Inc., Canada||Completed|March 2005|December 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|No|||February 2012|February 9, 2012|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246207||188459|
NCT00246493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904294|Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)|Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|510|||Both|30 Years|N/A|No|||May 2015|October 27, 2015|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00246493||188438|
NCT00246506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD044547|Infertility Therapy for Women Age Thirty-eight and Older|Optimal Infertility Therapy RCT: Women 40 and Older|FORT-T|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|July 2003|April 2013|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|38 Years|43 Years|Accepts Healthy Volunteers|||December 2012|January 14, 2013|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00246506||188437|
NCT00246766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT04/ACTIFOETUS|Study of Fetal Movements Using Multichannel Ultrasound Pulsed Doppler in Normal and Pathologic Pregnancy|Qualitative and Quantitative Study of Fetal Movements Using Multichannel Ultrasound Pulsed Doppler in Normal and Pathologic Pregnancy||University Hospital, Tours|No|Recruiting|March 2005|June 2010|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|90|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women|November 2007|November 21, 2007|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246766||188417|
NCT00246779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant NA 5565|A Study of the Effect of Blinding in a Trial of Blood Filtration During Heart Surgery|Transfusion Reduction and Modified Ultrafiltration After Cardiopulmonary Bypass (TRAM Trial) - A Pilot Feasibility Trial||Ottawa Heart Institute Research Corporation||Completed|November 2005|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|78|||Both|18 Years|N/A|No|||October 2007|October 26, 2007|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00246779||188416|
NCT00247013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA084447-01|Automated Tele Counseling for Screening Mammography|Automated Tele Counseling for Screening Mammography||Boston Medical Center||Completed|January 1996|January 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||2120|||Female|50 Years|74 Years|Accepts Healthy Volunteers|||September 2010|February 19, 2016|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00247013||188398|
NCT00247026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385-mds 1-HMO-CTIL|The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes|A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes||Hadassah Medical Organization||Withdrawn|April 2007|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|16 Years|N/A|No|||April 2007|April 10, 2007|October 31, 2005|||No funding|No||https://clinicaltrials.gov/show/NCT00247026||188397|
NCT00247286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBGY-076-00|Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial.|A Randomised, Single-Blind Comparison of Pelvic Floor Muscle Exercises With Biofeedback Versus Weighted Vaginal Cones in the Management of Genuine Stress Incontinence : A Pilot Study||Queen's University|No|Terminated|September 2001|October 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 31, 2005||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00247286||188378|
NCT00254176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-035-05|Cysteine Supplementation in Critically Ill Neonates|Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates||University of California, Los Angeles|Yes|Active, not recruiting|September 2006|July 2011|Anticipated|March 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|N/A|30 Days|No|||February 2010|February 25, 2010|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00254176||187862|
NCT00254475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAS489A2403|A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia|A Study to Evaluate the Efficacy of the Valsartan/Simvastatin Combinations 160/20mg up Titrated to 320/20mg Versus 160/40mg up Titrated to 320/40mg in Patients With Both Essential Hypertension and Hypercholesterolemia||Novartis||Completed|November 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|871|||Both|18 Years|N/A||||August 2014|August 18, 2014|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00254475||187839|
NCT00254670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5612-26059|Naltrexone Effects on Alcohol Intake|Naltrexone Effects on Alcohol Intake Using a Laboratory Bar in Asp40 Positive and Negative Alcohol Users Characterized by fMRI and Genetic Screening||University of California, San Francisco||Completed|February 2005|December 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2011|April 12, 2011|November 15, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00254670||187824|
NCT00254982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04320|Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)|An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I ("High Need") and GROUP II ("Low Need") Patients Suffering From Chronic Plaque Psoriasis (Psoriasis Vulgaris)||Merck Sharp & Dohme Corp.|No|Completed|August 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|593|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|November 15, 2005|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00254982||187801|
NCT00254358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|842902-HMO-CTIL|A Brain Imaging Study of Nicotine Release in Cigarette Smokers|A Brain Imaging Study of Nicotine Release in Cigarette Smokers||Hadassah Medical Organization|Yes|Terminated|April 2007|April 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|smokers in treatment with bupropion|June 2008|July 3, 2008|November 15, 2005||No|It was decided to use a different protocol with a different radioligand|No||https://clinicaltrials.gov/show/NCT00254358||187848|
NCT00254371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547-96|DHEA and Testosterone Replacement in Elderly|Pathogenesis of Sarcopenia and Metabolic Changes in Aging||Mayo Clinic||Completed|July 1998|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 20, 2011|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00254371||187847|
NCT00256425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU 2003-2783|Cognitive Rehabilitation of Glioma Patients|Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study||UMC Utrecht|No|Active, not recruiting|October 2003|September 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|70 Years|No|||July 2007|March 20, 2008|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00256425||187694|
NCT00257595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104914|Perennial Allergic Rhinitis In Pediatric Subjects|Long-term Study of Cetirizine Dry Syrup in Children. Suffering From Perennial Allergic Rhinitis.||GlaxoSmithKline|No|Completed|August 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|2 Years|14 Years|No|||May 2013|May 3, 2013|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257595||187605|
NCT00257608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3671g|A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)|A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer||Genentech, Inc.||Completed|January 2006|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1145|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 21, 2005|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT00257608||187604|
NCT00221962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cognition|Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)|The Cognitive Effects of Aripiprazole in Children||University Hospital Case Medical Center|Yes|Completed|April 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||June 2013|December 12, 2014|September 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00221962||190268|
NCT00221975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02T 183|Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling|Combination Therapy in Dual Diagnosis Rapid Cycling Bipolar Disorder||University Hospital Case Medical Center|Yes|Completed|July 2002|December 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|98|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00221975||190267|
NCT00225524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B1-818|Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.|Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|20 Years|65 Years|No|||May 2007|May 22, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225524||190001|
NCT00225472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-566|Organ Preservation Media Investigation|Organ Preservation Media Investigation||University of Wisconsin, Madison||Completed|June 2004|||July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|20|||Both|18 Years|N/A|No|||June 2008|October 1, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00225472||190005|
NCT00225485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B1-817|Study Evaluating Effexor XR in Elderly Patients With Major Depression.|Phase III Study of Effexor XR for the Treatment of Elderly Patients With Depression||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|65 Years|N/A|No|||May 2007|May 25, 2007|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225485||190004|
NCT00223145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-990-0049,1|Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone|Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy|PCS III|Université de Sherbrooke|No|Active, not recruiting|December 2000|December 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|600|||Male|18 Years|80 Years|No|||January 2015|January 22, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223145||190181|
NCT00222274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4145|HRV Biofeedback in Fibromyalgia|A Pilot Study of the Efficacy of Biofeedback in Patients With Fibromyalgia Syndrome.||Rutgers, The State University of New Jersey|No|Completed|July 2004|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|65 Years|No|||February 2015|February 6, 2015|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00222274||190245|
NCT00255164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-EE04-086|Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis|A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis||Takeda|No|Completed|January 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|451|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|November 15, 2005|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00255164||187787|
NCT00256347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5612-25135|Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine|Development of Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine Using the Brief Thermal Sensitization Model in Healthy Volunteers||University of California, San Francisco||Completed|March 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||30|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2011|April 12, 2011|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00256347||187700|
NCT00256360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001876-11|Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer|A Randomized Phase II Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer||Universitaire Ziekenhuizen Leuven||Completed|September 2005|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||117|||Female|18 Years|70 Years|No|||December 2014|December 8, 2014|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00256360||187699|
NCT00245921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A2-313, 314, 320|Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception|A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2003|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||2000|||Female|18 Years|49 Years|No|||May 2006|February 7, 2013|October 26, 2005||||||https://clinicaltrials.gov/show/NCT00245921||188480|
NCT00245934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101354|Study Evaluating Enbrel in Patients With Rheumatoid Arthritis|Observational Study With Enbrel in Patients With Rheumatoid Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2003|July 2005|Actual|||N/A|Observational|Time Perspective: Prospective||||1500|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245934||188479|
NCT00246519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01GM074492|Pharmacogenomic Evaluation of Antihypertensive Responses|Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)||University of Florida|Yes|Completed|October 2005|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1701|||Both|17 Years|65 Years|No|||May 2015|May 20, 2015|October 27, 2005||No||No|May 20, 2013|https://clinicaltrials.gov/show/NCT00246519||188436|The trial has limited number of hypertensive patients of African ancestry, therefore power is limited to those patients.
NCT00247832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05 - 0500|Readiness for Discharge Following Lobectomy|Readiness for Discharge Following Lobectomy: Effects of the Thoracic Risk Intervention and Management (T.R.I.M.) Protocol||University of British Columbia|No|Recruiting|October 2005|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247832||188338|
NCT00248131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS9950802E1|Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)||Novartis||Terminated|November 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||260|||Both|18 Years|70 Years|No|||April 2012|April 8, 2012|November 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00248131||188316|
NCT00248144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810A2403|A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis|A Randomized, Multicenter, Double-Blinded Controlled Study to Compare the Effectiveness of a Single Dose (1500 mg) of Famciclovir, One Day (750 mg q12) of Famciclovir and Placebo in Patient-Initiated Episodic Treatment of Recurrent Herpes Labialis||Novartis||Completed|October 2003|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||August 2006|December 7, 2007|November 2, 2005||||||https://clinicaltrials.gov/show/NCT00248144||188315|
NCT00248456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX 0501 CN|Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris|A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris||LEO Pharma||Completed|October 2005|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|18 Years|65 Years|No|||February 2008|February 20, 2008|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00248456||188292|
NCT00257998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 05-17|Effectiveness of Three Manual Physical Therapy Techniques in a Subgroup of Patients With Low Back Pain|Comparison of the Effectiveness of Three Manual Physical Therapy Techniques in a Subgroup of Patients With Low Back Pain Who Satisfy a Clinical Prediction Rule: A Randomized Clinical Trial.||Franklin Pierce University||Completed|November 2005|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|60 Years|No|||October 2007|October 31, 2007|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00257998||187574|
NCT00254488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH068847|Treatment of Bipolar Mania in Older Adults|Acute Pharmacotherapy of Late-Life Mania (GERI-BD)|GERI-BD|Weill Medical College of Cornell University|Yes|Completed|November 2005|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|224|||Both|60 Years|N/A|No|||July 2013|July 24, 2013|November 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254488||187838|
NCT00254995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA30|Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine|Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra ™)||Sanofi|No|Completed|July 2005|May 2013|Actual|May 2013|Actual|Phase 4|Observational|Observational Model: Cohort||2|Actual|62626|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Past receipt of Menactra vaccine|November 2014|November 3, 2014|November 15, 2005|Yes|Yes||No|September 4, 2014|https://clinicaltrials.gov/show/NCT00254995||187800|
NCT00255008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04212|Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)|SEASON South East Asian Study Of Novel Genotypes in Hepatitis C Infection: Pegylated-Interferon and Ribavirin Therapy (PEGATRON REDIPEN Combination Therapy (PEG-Intron® REDIPEN Plus REBETOL®)) in Treatment Naive Patients With Genotypes 1, 6, 7, 8, 9: A Comparison of Race and Genotype on Treatment Outcome.||Merck Sharp & Dohme Corp.|No|Terminated|March 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|121|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|November 15, 2005||No|Slow enrollment|No|December 5, 2008|https://clinicaltrials.gov/show/NCT00255008||187799|
NCT00255281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1461C00006|Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation|A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase II Study to Assess the Efficacy of AZD7009 (AR H065522XX) Given Intravenously (Infusion for 15 or 30 Minutes) to Patients for Conversion of Atrial Fibrillation||AstraZeneca||Completed|September 2005|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|80 Years|No|||December 2007|December 4, 2007|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255281||187779|
NCT00225160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCAR|ALCAR Prophylaxis Study|A Randomised Double Blinded Placebo Controlled Pilot Study to Evaluate the Safety and Efficacy of Acetyl L Carnitine in Combination With Antiretroviral Therapy for the Prevention of Distal Symmetric Polyneuropathy and Lipid Abnormalities in Treatment naïve HIV Infected Subjects||Royal Free Hampstead NHS Trust||Active, not recruiting|November 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||50|||Both|18 Years|N/A|No|||September 2008|September 17, 2008|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225160||190029|
NCT00225459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beh-REB 05-18|Does Spiritual/Religious Commitment Mediate the Relationship Between Mood Variability and Suicidal Ideation.|Does Spiritual/Religious Commitment Mediate the Relationship Between Mood Variability and Suicidal Ideation.||University of Saskatchewan||Completed|June 2005|December 2008|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|70 Years|No|Non-Probability Sample|The study population is psychiatric inpatients and outpatients with depressive symptoms        between the ages or 18 and 70. Co-morbid anxiety, bipolar spectrum, and eating disorders        will be allowed. Involuntary patients and those with psychosis, organic brain impairment,        and current substance dependence will be excluded. We will recruit patients prospectively,        as they attend psychiatrists' clinics and are admitted to hospital.|October 2011|October 4, 2011|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00225459||190006|
NCT00225797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202-031|Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain|An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naïve Patients With Chronic Low Back Pain||Endo Pharmaceuticals||Completed|November 2004|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|September 22, 2005||||||https://clinicaltrials.gov/show/NCT00225797||189981|
NCT00222261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCET|Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.|Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.|ASCET|Oslo University Hospital|Yes|Completed|April 2003|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1001|||Both|18 Years|80 Years|No|||March 2011|March 22, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222261||190246|
NCT00223405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-1901-369|Analysis of Enamel Wear Against Ceramic Restorations|Analysis of Clinical Wear Patterns of Tooth Enamel and Ceramic Restorations as a Function of Particle Size, Inter-Particle Spacing and Fracture Toughness of Ceramic Crystals||The University of Texas Health Science Center at San Antonio||Completed|April 2003|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223405||190162|
NCT00237991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104147|Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population|A Multicentric, Post-Marketing Surveillance to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals Hepatitis A Vaccine Administered in Korean Population.||GlaxoSmithKline||Completed|June 2005|||||N/A|Observational|Time Perspective: Prospective||||600|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|October 15, 2008|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00237991||189078|
NCT00237419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASIC 30505|Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis|An Open Label Extension, Investigator Initiated Trial to Examine Radiographic Progression , Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis. EASIC (European Ankylosing Spondylitis Infliximab Cohort)||Rheumazentrum Ruhrgebiet||Recruiting|December 2005|April 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|149|||Both|18 Years|N/A|No|||May 2008|May 30, 2008|October 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00237419||189121|
NCT00237692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-426|Hypertension Intervention Nurse Telemedicine Study (HINTS)|Behavioral/Pharmacological Telemedicine Interventions for BP Control||VA Office of Research and Development|No|Completed|May 2006|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|591|||Both|N/A|N/A|No|||August 2014|April 6, 2015|October 7, 2005|Yes|Yes||No|August 29, 2014|https://clinicaltrials.gov/show/NCT00237692||189100|
NCT00238004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-001690-26|The Low HDL On Six Weeks Statin Therapy (LOW) Study|The Low HDL On Six Weeks Statin Therapy (LOW) Study||Craigavon Area Hospital||Active, not recruiting|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2006|September 11, 2006|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238004||189077|
NCT00238264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0221|Radiation Therapy in Treating Young Patients With Gliomas|A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas||Children's Oncology Group|Yes|Active, not recruiting|November 2006|||December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|3 Years|20 Years|No|||March 2015|March 4, 2015|October 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00238264||189060|
NCT00232635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP204|A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT|A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of A-60444 in Adults With RSV Infection Following Stem Cell Transplantation||Arrow Therapeutics|Yes|Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||February 2010|February 11, 2010|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232635||189479|
NCT00232856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC01-06|A Study of the Cypher SES to Treat Restenotic Native Coronary Artery Lesions.|A Multi-Center, Non-Randomised Study of the CYPHER™ Sirolimus-Eluting Stent in the Treatment of Patient With an in-Stent Restenotic Native Coronary Artery Lesion|TROPICAL|Cordis Corporation|Yes|Completed|December 2002|August 2006|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|N/A|No|||April 2008|April 29, 2008|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232856||189462|
NCT00233129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 04-0782|Improving Executive Functions After Traumatic Brain Injury (TBI): A Clinical Trial of the "Executive Plus" Program|Improving Executive Functions After TBI: A Randomized Clinical Trial of the "Executive Plus" Program||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2005|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233129||189442|
NCT00233142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002477|Expressive Writing for Reducing Stress and Diabetic Symptoms in Diabetes Patients|Expressive Writing: Complementary Treatment for Diabetes||Syracuse University|Yes|Completed|September 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|225|||Both|25 Years|75 Years|No|||November 2009|November 24, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00233142||189441|
NCT00233480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB #04-12-007-01|Statin Therapy in Heart Failure: Potential Mechanisms of Benefit|A Double-blind Randomized, Placebo-Controlled, Single-Center Study to Assess the Impact of Statins on the Autonomic Nervous System and Cardiac Structure/Function in Non-Ischemic Heart Failure||University of California, Los Angeles|Yes|Completed|August 2005|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00233480||189415|
NCT00233857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III UV 23/03|Auricular Acupuncture for Pain Relief After Ambulatory Knee Arthroscopy|Auricular Acupuncture Versus Placebo (Sham Acupuncture) for Postoperative Pain Relief After Ambulatory Knee Arthroscopy - a Randomized Controlled Trial||University Medicine Greifswald||Completed|August 2003|August 2004|Actual|July 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|16 Years|65 Years|No|||February 2011|February 25, 2011|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00233857||189386|
NCT00239785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A0124|Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A One-year, Multicenter, Partially Blinded, Double-dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients||Novartis||Completed|April 2003|||April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||684|||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239785||188945|
NCT00239798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A2218E1|Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A 24-month Extension of a One-year, Multicenter, Double Blinded Double Dummy, Randomized Study to Evaluate the Safety and Efficacy of Two Doses of FTY720 Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids, in Adult de Novo Renal Transplant Recipients||Novartis||Completed|November 2004|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||255|||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239798||188944|
NCT00235833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-564|Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|Long-term Continuously Repeated Dose Study of Adalimumab (D2E7) in Patients With Rheumatoid Arthritis||Abbott|No|Completed|June 2003|||October 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|N/A|No|||April 2011|April 7, 2011|October 7, 2005||No||No|October 12, 2009|https://clinicaltrials.gov/show/NCT00235833||189241|Due to the small population, statistical tests were not performed.
NCT00236171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAPSO|Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test|Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test||Technische Universität Dresden|No|Completed|September 2004|June 2010|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2010|June 7, 2010|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00236171||189215|
NCT00236197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-A001-312|E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers|E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers||Eisai Inc.||Completed|October 2005|June 2008|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|619|||Both|19 Years|N/A|No|||November 2009|November 4, 2009|October 10, 2005|Yes|Yes||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00236197||189213|
NCT00236600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003706|A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Patients Following Participation in an Intensive, Non-Pharmacologic Weight Loss Program||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2000|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|561|||Both|18 Years|75 Years|No|||April 2010|April 26, 2010|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236600||189183|
NCT00228280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|journal n. 20050041|Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling|Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling||University of Aarhus|No|Active, not recruiting|January 2005|September 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|70 Years|No|||December 2008|December 3, 2008|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00228280||189799|
NCT00237705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO4-0025|Intravenous Metoclopramide for the Treatment of Post Concussive Headache: a Randomized Placebo Controlled Trial|||Vancouver General Hospital||Recruiting|May 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|19 Years|N/A|No|||December 2006|December 4, 2006|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237705||189099|
NCT00238017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP05-M4|Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate|A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria||Charite University, Berlin, Germany||Active, not recruiting|October 2005|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|6 Months|59 Months|No|||July 2005|February 1, 2006|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00238017||189076|
NCT00238277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445270|Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme|Phase II Study of Temozolomide and Radiation in Newly Diagnosed GBM Patients After Resection and Insertion of Gliadel® Wafers||National Cancer Institute (NCI)||Terminated|March 2005|||December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||December 2007|January 30, 2008|October 12, 2005|||Withdrawn - due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00238277||189059|
NCT00238550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/343|Study of CBME in the Relief of Painful Diabetic Neuropathy|Randomised Control Trial Studying the Addition of CBME to Conventional Treatment for the Relief of Painful Diabetic Neuropathy||Sheffield Teaching Hospitals NHS Foundation Trust||Completed|October 2003|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||October 2005|July 19, 2011|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238550||189038|
NCT00232869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE00-02|A Study of the SMART Stent in the Treatment SFA Disease.|A Clinical Investigation of the SIROlimus Coated Cordis SMART™ Nitinol Selfexpandable Stent for the Treatment of Obstructive Superficial Femoral Artery Disease.|SIROCCO|Cordis Corporation|Yes|Completed|February 2001|May 2009|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|30 Years|N/A|No|||February 2010|February 3, 2010|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232869||189461|
NCT00233168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|323|Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents|Promoting Adherence to TB Regimens in High Risk Youth||San Diego State University|Yes|Completed|September 2003|August 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|13 Years|18 Years|No|||June 2014|June 24, 2014|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233168||189439|
NCT00233155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C118|Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)|A Multicenter, Open-Label, Phase 2 Study of NGX-4010 for the Treatment of Neuropathic Pain in Patients With Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)||NeurogesX||Completed|August 2005|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||March 2008|March 4, 2008|October 3, 2005||||||https://clinicaltrials.gov/show/NCT00233155||189440|
NCT00233532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANA-03-003|Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)|A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)|TRAIL|Abbott|No|Completed|March 2004|||June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2000|||Both|18 Years|N/A|No|||July 2008|July 18, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00233532||189411|
NCT00233493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSFO327KUS16|Spread of Dermatophytes Among Families|Demonstration of the Spread of Dermatophytes Through Casual Contact Among Family Household Members||University Hospital Case Medical Center||Recruiting|March 2005|February 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|14 Years|N/A|Accepts Healthy Volunteers|||November 2004|October 3, 2005|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00233493||189414|
NCT00233506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200402002|A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated|A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia||University of Iowa||Active, not recruiting|July 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||June 2010|June 14, 2010|October 3, 2005||||||https://clinicaltrials.gov/show/NCT00233506||189413|
NCT00233519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 U54 NS048843-03 A|Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)|Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)||University of Rochester|Yes|Completed|November 2005|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|October 3, 2005|Yes|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00233519||189412|
NCT00234169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/09|A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone|A Phase I/II Study of Peripheral Blood Progenitor Cells Mobilisation With VTP195183 Plus G-CSF Compared to Mobilisation With G-CSF Alone in Patients With Multiple Myeloma and Lymphoma.||Peter MacCallum Cancer Centre, Australia|Yes|Completed|October 2005|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||May 2012|May 9, 2012|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00234169||189363|
NCT00239811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A0124E1|Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A Two-year Extension to a One-year, Multicenter, Partially Blinded, Double Dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients||Novartis||Completed|April 2004|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||684|||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239811||188943|
NCT00239824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK4.2005.211|Pelvic Floor Muscle Training to Treat Urinary Incontinence After Radical Prostatectomy|Urinary Incontinence After Radical Prostatectomy. - Effect of Pelvic Floor Muscle Training. A Randomised Controlled Trial||Norwegian University of Science and Technology|No|Completed|October 2005|January 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|80 Years|No|||March 2008|March 31, 2008|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00239824||188942|
NCT00235846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN 2004/14|Endoscopic Vessel Harvesting During Coronary Bypass Surgery|Endoscopic Vessel Harvesting During Coronary Bypass Surgery||Aalborg Universitetshospital|No|Completed|December 2004|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|October 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235846||189240|
NCT00235859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-556|Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate||Abbott|No|Completed|July 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|128|||Both|18 Years|N/A|No|||August 2007|August 28, 2007|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235859||189239|
NCT00236184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-A001-313|E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers|E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers||Eisai Inc.|Yes|Completed|October 2005|June 2008|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|629|||Both|19 Years|N/A|No|||March 2010|March 30, 2010|October 10, 2005|Yes|Yes||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00236184||189214|
NCT00236626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003715|A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes|A 9 Month, Double-Blind, Placebo-Controlled Study With a Blinded Crossover Transition to Open-Label Extension, Evaluating the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Type 2 Diabetes Patients||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2000|May 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|38|||Both|35 Years|75 Years|No|||April 2010|June 6, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236626||189181|
NCT00236392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003121|A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)|Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of "On-Demand" Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week Open Acute Phase||Janssen Pharmaceutica N.V., Belgium||Completed|October 2001|October 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|422|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236392||189199|
NCT00236405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003193|PROCRIT and Short-Term Outcomes in Orthopedic Surgery|A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of of PROCRIT� (Epoetin Alfa) on Short-Term Outcomes in Orthopedic Subjects Undergoing Primary Unilateral Knee Arthroplasty||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|March 2005|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|6|||Both|18 Years|N/A|No|||March 2010|June 8, 2011|October 7, 2005|||The study was terminated due to poor enrollment.|||https://clinicaltrials.gov/show/NCT00236405||189198|
NCT00236613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003709|A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2000|July 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|385|||Both|18 Years|75 Years|No|||December 2010|December 2, 2010|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236613||189182|
NCT00228605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3040/BP/US|Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain|An Open-Label 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Noncancer Pain||Teva Pharmaceutical Industries||Completed|March 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|80 Years|No|||May 2014|May 8, 2014|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00228605||189775|
NCT00228618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1098-2003|Dietary Effects of Sulfur Amino Acids|Dietary Effects of Sulfur Amino Acid Depletion and Repletion on Glutathione and Cysteine Pools.||Emory University||Completed|January 2005|January 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|January 2009|January 29, 2009|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00228618||189774|
NCT00237432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI-0505|Study of the Immune Response to Hepatitis C Virus|HCV Pathogenesis and Dendritic Cell Immunobiology||Rockefeller University|No|Completed|April 2003|February 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|Samples With DNA|White blood cells|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with confirmed HCV infection recruited from the NYC metropolitan area|December 2010|December 9, 2010|October 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00237432||189120|
NCT00229008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005140|Ceftobiprole in Hospital Acquired Pneumonia|A Phase 3 Randomized Double-Blind Study Of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia||Basilea Pharmaceutica|Yes|Completed|November 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229008||189753|
NCT00229424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10019350|Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -|Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -||Taiho Pharmaceutical Co., Ltd.||Completed|April 2005|January 2007|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3|||325|||Both|20 Years|N/A|No|||July 2011|July 6, 2011|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00229424||189721|
NCT00229437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-128-003|Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy||Takeda|No|Completed|March 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|343|||Both|18 Years|70 Years|No|||February 2012|February 27, 2012|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229437||189720|
NCT00229450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD06806-001|Estrogen and Perimenopausal Depression|Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression||University of California, Los Angeles||Recruiting|October 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Female|40 Years|60 Years|No|||June 2008|June 2, 2008|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229450||189719|
NCT00229710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00049|GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes|An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 0.5mg When Added to Insulin Therapy in Patients With Type 2 Diabetes Mellitus (GALLEX 9)||AstraZeneca||Terminated|February 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|September 28, 2005|||The development program has been terminated|||https://clinicaltrials.gov/show/NCT00229710||189701|
NCT00233558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAN-04-002|Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis|Multicentre, Randomised, Open Label Study Comparing a “Scheduled Steroid Reduction Strategy” Versus a Free Steroid Reduction Strategy (Physician’s Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months||Abbott||Terminated|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||April 2007|April 23, 2007|September 13, 2005|||Study terminated due to low subject enrollment. Safety results consistent with product label.|No||https://clinicaltrials.gov/show/NCT00233558||189409|
NCT00233571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE018|A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis|A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab)||Abbott|No|Completed|June 2000|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|796|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00233571||189408|
NCT00233883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18596|WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.|An Open-label Study of the Tolerability of a Subcutaneous Needle-free Injection Device Used to Administer Fuzeon, Compared With the Standard Needle/Syringe Supplied With Commercial Fuzeon in HIV-1 Infected, ARV Treatment-experienced Adults||Hoffmann-La Roche||Completed|August 2005|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00233883||189384|
NCT00234195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot105042|Wellbutrin XL, Major Depressive Disorder and Breast Cancer|A Pilot Study of the Efficacy and Tolerability of Bupropion Extended Release (Wellbutrin XL) for the Treatment of Major Depressive Disorder in Women With Breast Cancer||Thomas Jefferson University|No|Completed|September 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Female|18 Years|N/A|No|||April 2007|April 16, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00234195||189361|
NCT00233545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2005|Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia|Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia||AB Foundation||Completed|September 2005|September 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|3 Years|N/A|No|||May 2010|May 29, 2010|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00233545||189410|
NCT00233870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL03004|A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.|Special Survey in Long-Term Use of Fabrazyme||Sanofi||Completed|June 2004|March 2011|Actual|March 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|405|||Both|N/A|N/A|No|Non-Probability Sample|Japanese patients with Fabry Disease|May 2015|May 7, 2015|October 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00233870||189385|
NCT00234884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-634|Post-marketing Observational Study in Subjects With Rheumatoid Arthritis|A Five-year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis Formerly Treated in Study M02-497 (ReAct) and Subsequently Prescribed Humira|ReAlise|Abbott|No|Completed|September 2003|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3435|||Both|18 Years|N/A|No|Non-Probability Sample|Participants were patients with rheumatoid arthritis (RA) who had received adalimumab for        at least 3 months in NCT00448383 (Study M02-497) and had been prescribed commercial        adalimumab following termination of that study. At the time of enrollment in NCT00448383        (Study M02-497), participants had failed one or more disease-modifying antirheumatic drugs        (DMARDs) and had active, moderate to severe RA despite concurrent RA treatment.|August 2011|August 25, 2011|September 16, 2005||No||No|July 15, 2011|https://clinicaltrials.gov/show/NCT00234884||189310|
NCT00240227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REAP 05-0020|Prazosin for ETOH or Cocaine Craving|The Role of the Alpha 1-adrenergic Antagonist, Prazosin, in the Reduction of Craving and Relapse in Alcohol and Cocaine-dependent Individuals: a Double-blind, Randomized, Controlled Clinical Trial||VA Office of Research and Development|No|Terminated|April 2004|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|No|||March 2016|March 11, 2016|October 13, 2005|Yes|Yes|Experimental procedure did not induce sufficient craving to determine any possible effect of    medication.|No|November 25, 2013|https://clinicaltrials.gov/show/NCT00240227||188913|The study procedure intended to induce substance craving failed to induce craving. Thus, any difference between placebo and active medication conditions could not be measured and so the study was terminated.
NCT00235872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-651|Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis||Abbott|No|Completed|August 2004|||July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|309|||Both|20 Years|N/A|No|||April 2011|April 7, 2011|October 7, 2005||No||No|December 9, 2009|https://clinicaltrials.gov/show/NCT00235872||189238|
NCT00235885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-724|Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)|Safety and Efficacy of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) - An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy, Including Patients Who Failed Prior Treatment With Other TNF-Inhibitors (STEREO)|STEREO|Abbott||Completed|July 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||445|||Both|18 Years|N/A|No|||August 2007|August 28, 2007|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235885||189237|
NCT00235898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-CoFactor|Clinical Trial in Patients With Metastatic Colorectal Cancer|A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU Versus Leucovorin and 5-FU in Subjects With Metastatic Colorectal Carcinoma||Mast Therapeutics, Inc.|Yes|Completed|May 2005|||March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||August 2008|August 22, 2008|October 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235898||189236|
NCT00236444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002020|A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders|Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2001|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|375|||Both|5 Years|17 Years|No|||November 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236444||189195|
NCT00236418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005830|A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures|Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 1994|December 1996|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|80|||Both|4 Years|N/A|No|||April 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236418||189197|
NCT00236834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005557|A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization|A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 1997|June 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|438|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236834||189165|
NCT00237094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65787 (completed)|Use of Midlevel Providers in Diabetes Management|Use of Midlevel Providers in Diabetes Management||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|600|||Both|21 Years|N/A|No|||January 2010|January 14, 2010|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00237094||189146|
NCT00237107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-003|Debulking Effect of Curretage on BCC's - a Histological Assessment.|Relation of BCC Tumour Thickness, Histologically Estimated, in Punch Biopsies Performed Before and After Curretage.||Norwegian University of Science and Technology||Completed|April 2002|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2005|May 16, 2006|October 10, 2005||||No||https://clinicaltrials.gov/show/NCT00237107||189145|
NCT00229749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4065-20|Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients|Exploratory Study of AVI-4065 Injection to Design Therapeutic Dosing for Chronic Active HCV Patients||Sarepta Therapeutics||Terminated|September 2005|January 2007|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|64 Years|No|||April 2008|April 9, 2008|September 28, 2005|Yes|Yes|Limited viral load reduction in HCV subjects|No||https://clinicaltrials.gov/show/NCT00229749||189698|
NCT00229762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NIP-4252|Racial Disparities in Pneumococcal Vaccination in Managed Care|Racial Disparities in Pneumococcal Vaccination in Managed Care: the Effects of Randomized Telephone Outreach||Centers for Disease Control and Prevention||Completed|March 2004|June 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||7000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2005|September 28, 2005|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229762||189697|
NCT00229775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3913|Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines|Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines||Centers for Disease Control and Prevention||Completed|July 2003|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|560|||Both|N/A|N/A|No|||September 2012|September 10, 2012|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00229775||189696|
NCT00228592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepeX-B 2003-12|HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection|A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-Bä, a Mixture of Two Monoclonal Antibodies, as Compared to Hepatitis B Immune Globulin in Patients Who Have Received Hepatic Allografts for Treatment of End-Stage Liver Disease Due to Hepatitis B Virus Infection||Cubist Pharmaceuticals LLC||Terminated||August 2005||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||February 2007|February 12, 2007|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00228592||189776|
NCT00229463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-10-049|Study of Genetic Differences in People With Depression|Study of Genetic Differences in People With Depression|Genetics|University of California, Los Angeles|No|Active, not recruiting|January 2002|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from previous studies conducted at the Laboratory of Brain,        Behavior, and Pharmacology, where subjects' response to treatment has already been        determined. This strategy offers the advantage that no new subjects need to be enrolled in        placebo-controlled treatment studies.|July 2014|July 1, 2014|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00229463||189718|
NCT00229476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-08-033|Study of Medication and Placebo Response in Major Depression|||University of California, Los Angeles||Completed|December 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||April 2007|April 20, 2007|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229476||189717|
NCT00229723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0706|IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma|A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multicentre Comparative Study of Gefitinib 250 mg or 500 mg (IRESSA™) Given Either Continuously or Concomitantly With Cisplatin Plus Radiotherapy for the Treatment of Patients With Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma||AstraZeneca||Completed|November 2004|June 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|224|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|September 28, 2005|Yes|Yes||No|June 17, 2009|https://clinicaltrials.gov/show/NCT00229723||189700|
NCT00229736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAVhAADC2003|A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease|A Phase1 Open Label Safety Study of Intrastriatal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV-hAADC-2) in Subjects With Parkinson's Disease [AAV-hAADC-2-003]||Sanofi|Yes|Completed|November 2004|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|40 Years|75 Years|No|||December 2013|December 2, 2013|September 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00229736||189699|
NCT00230373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04CA05-IMIQ|Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study|Evaluation of the Efficacy and Safety of Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study||University of Alberta|Yes|Withdrawn|November 2005|June 2007|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|September 28, 2005|||Study never started.|No||https://clinicaltrials.gov/show/NCT00230373||189650|
NCT00233896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT 00-02|Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD|A Randomized, Placebo-Controlled, Multi-Center Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal Graft Vs. Host Disease||Enteron Pharmaceuticals||Completed|July 2001|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|N/A|N/A|No|||December 2004|October 4, 2005|October 4, 2005||||||https://clinicaltrials.gov/show/NCT00233896||189383|
NCT00234208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 186/05|Early Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Parapneumonic Effusion and Pleural Empyema|A Randomized Controlled Study of Early Mini-Invasive Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Parapneumonic Effusions or Pleural Empyema – ESMITE (European Study on Mini-Invasive Thoracoscopy in Empyema)||University Hospital, Basel, Switzerland||Recruiting|October 2005|October 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||October 2005|April 24, 2007|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234208||189360|
NCT00234182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 1018-98|Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC|Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of Hepatocellular Carcinoma: a Randomized Controlled Trial||The University of Hong Kong||Completed|January 2000|December 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||84|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2005|November 29, 2005|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234182||189362|
NCT00234572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-28-52030-717|Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly|Phase II, Multicentre, Randomized, Double-blind Study in Acromegalic Patients Evaluating the Efficacy and Safety of a Single Deep Subcutaneous Administration of Lanreotide Autogel (60, 90 or 120mg) Versus Placebo Followed by a Single Blind Fixed Dose Phase Evaluating the Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Profile of Multiple Deep Subcutaneous Administrations of Lanreotide Autogel (60, 90 & 120mg) Ending in Open Label Dose Titration Phase.||Ipsen||Completed|May 2000|January 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|18 Years|N/A|No|||November 2009|November 16, 2009|October 6, 2005||||||https://clinicaltrials.gov/show/NCT00234572||189334|
NCT00234897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-684|Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis|Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)|HERO|Abbott|No|Completed|August 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1938|||Both|18 Years|N/A|No|||August 2007|August 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00234897||189309|
NCT00235235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG COE-01|A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01||Hoosier Cancer Research Network|Yes|Terminated|September 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|80|Samples With DNA|core biopsy, serum, urine|Female|18 Years|N/A|No|Probability Sample|Study limited to patients with breast cancer.|December 2015|December 8, 2015|October 6, 2005||No|Funding terminated|No||https://clinicaltrials.gov/show/NCT00235235||189283|
NCT00240175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056-0011-010|Evaluating the Effects of Foot Orthotics on Plantar Pressures in the Diabetic Population|Evaluating the Effects of Foot Orthotics on Plantar Pressures in the Diabetic Population||The University of Texas Health Science Center at San Antonio||Completed|August 2005|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|65|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00240175||188916|
NCT00240188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-011-03S|A Study to Compare Ventral Incisional Hernia by Laparoscopic vs Open Repair With Mesh|Ventral Incisional Hernia Repair: Comparison Of Laparoscopic and Open Repair With Mesh||VA Office of Research and Development|Yes|Completed|February 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||September 2010|September 15, 2010|August 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00240188||188915|
NCT00235911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN-00S-0011|Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting|Effects of Symbicort Single Inhaler Therapy on Bronchial Hyper Responsiveness, Asthma Control and Safety in Mild to Moderate Asthmatics in General Practice, Compared to Usual Care Therapy||AstraZeneca||Completed|September 2003|December 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235911||189235|
NCT00236210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Go3-03031|A Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program|The Vascular Intervention Project (VIP): a Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program in the Algoma District of Northern Ontario||Group Health Centre|No|Completed|August 2004|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|422|||Both|30 Years|N/A|No|||July 2009|July 31, 2009|October 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00236210||189212|
NCT00236431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002014|A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment|A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2001|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1063|||Both|50 Years|N/A|No|||November 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236431||189196|
NCT00236652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004678|A Study Evaluating the Safety and Efficacy of Treating Sinus Infection With Levofloxacin 750 mg for 5 Days.|An Open-label, Multi-center, Non-comparative Sinus Puncture Study of 750 mg, Short-course Levofloxacin in the Treatment of Acute Maxillary Sinusitis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2003|June 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236652||189179|
NCT00236847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005566|A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy.|Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 1989|July 1993|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|65 Years|No|||April 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236847||189164|
NCT00236860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005569|A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures|Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 1989|February 1992|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|56|||Both|18 Years|65 Years|No|||April 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236860||189163|
NCT00237120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571AJP02|Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)|Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)||Novartis||Completed|November 2002|June 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|15 Years|74 Years|No|||November 2009|November 20, 2009|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237120||189144|
NCT00229515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSES-02-III|Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI|Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial||Università degli Studi di Ferrara|Yes|Active, not recruiting|November 2004|March 2012|Anticipated|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|744|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229515||189715|
NCT00229021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005404|Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis|A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2003|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|741|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00229021||189752|
NCT00229034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-382|Effect of APC and Epo on the Inflammatory Response During Sepsis|Effect of Activated Protein C and Erythropoietin on the Microvascular Inflammatory Response During Severe Sepsis.||Lawson Health Research Institute|Yes|Recruiting|September 2005|September 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the ICU in severe septic shock receiving either APC and/or Epo|December 2008|December 19, 2008|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229034||189751|
NCT00230386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0272-CE|Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma|The Role of MRI Perfusion to Detect Locally Recurrent or Persistent Disease in Prostate Carcinoma Treated With Radiation Therapy - A Pilot Study||University Health Network, Toronto||Completed|May 2003|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Male|18 Years|N/A|No|||September 2005|July 10, 2009|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00230386||189649|
NCT00230399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 3-24|Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer|C-2424: Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer||University of Michigan Cancer Center||Completed|June 2003|March 2008||January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00230399||189648|
NCT00230659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS6|Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia|Investigation of Coagulation Parameters in Hereditary Haemorrhagic||Imperial College London||Completed|August 2004|July 2008|Actual|July 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||2||100|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|May 28, 2015|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230659||189628|
NCT00230672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS7|Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs|Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients||Imperial College London||Recruiting|March 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|70|||Both|N/A|N/A|No|||August 2008|August 12, 2008|September 29, 2005||||No||https://clinicaltrials.gov/show/NCT00230672||189627|
NCT00233909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAN-979-02|A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia|An Open-Label, Phase I/II Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia||Kanisa Pharmaceuticals||Completed|October 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|October 4, 2005||||||https://clinicaltrials.gov/show/NCT00233909||189382|
NCT00233922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG/RPR/04024|Reconstruction of the Orbit With a Bioresorbable Polycaprolactone Implant|Reconstruction of the Orbit With a Bioresorbable Polycaprolactone Implant||National University Hospital, Singapore||Completed|July 2004|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2008|May 12, 2008|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00233922||189381|
NCT00234221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA014665-01A1|Services Interventions for Injured ED Problem Drinkers|||University of Michigan||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||October 2005|December 29, 2005|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00234221||189359|
NCT00234234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/145/HP|Predictors of the Response to Adalimumab in Rheumatoid Arthritis|Predictors of the Response to Adalimumab in Rheumatoid Arthritis||University Hospital, Rouen||Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00234234||189358|
NCT00234585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xMUO-01|Prospective Randomized Study Comparing Renal Artery Stenting (RESIST)With/Without Distal Protection|A Prospective Randomized Multicenter Study Comparing the Safety and Efficacy of Renal Artery Stenting With/Without Distal Protection Device (AngioGuard) and With/Without the Use of a Platelet Aggregator Inhibitor (Abciximab-Reopro) (RESIST)||University of Toledo Health Science Campus||Completed|August 2002|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|October 5, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00234585||189333|
NCT00234910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITAL-04-002|Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients|A Phase III, Open Label, Randomized, Comparative Study of the Antiviral Efficacy of ARV Therapy With Lopinavir/Ritonavir (LPV/r-Kaletra) in Combination With Tenofovir (TDF) Versus Standard of Care (Kaletra in Combination With 2 Nucleoside RTIs) in naïve-HIV-1 Positive Patients|KALEAD|Abbott|No|Completed|January 2005|June 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||July 2008|July 9, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00234910||189308|
NCT00234923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAN-03-001|Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients|A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen Versus Lopinavir/Ritonavir in Combination With Lamivudine/Zidovudine in Antiretroviral Naïve Patients|MONARK|Abbott|No|Completed|August 2003|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|138|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00234923||189307|
NCT00239954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI#591 & #592|Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder|Fixed Dose Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder||Pharmacology Research Institute||Active, not recruiting|March 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years||||May 2012|May 8, 2012|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239954||188933|
NCT00239967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5823|An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients|A Randomized, Double-Blind, Two-Arm Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients|ADAGIO-lipids|Sanofi||Completed|May 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|803|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|October 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00239967||188932|
NCT00239889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC051A2402|Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women|Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women||Novartis||Completed|March 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Female|60 Years|N/A|No|||March 2006|November 29, 2006|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239889||188937|
NCT00239902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720A0121E1|Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|Two-year Extension of a One-year, Multicenter, Randomized, Partially-blinded Study of the Safety and Efficacy of FTY720 Combined With Corticosteroids and Full or Reduced-dose Cyclosporine, USP [Modified] (Novartis Brand) in de Novo Adult Renal Transplant Recipients||Novartis||Completed|May 2002|||November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||396|||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239902||188936|
NCT00240214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E-100875|Study Evaluating Rapamune in Patients After Kidney Transplantation|An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|April 2001|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|March 2008|March 13, 2008|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00240214||188914|
NCT00235924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHY04GE01|Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women|Study Assessing the Effects on Endometrium and Breast of a Standardized Isoflavone Extract(Phytosoya) in Post Menopausal Women.||Laboratoires Arkopharma||Active, not recruiting|June 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Female|45 Years|65 Years|No|||October 2005|December 7, 2005|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235924||189234|
NCT00236223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-05|The Effect of Gabapentin, Ketamine and Dexamethasone on Pain and Opioid Requirements After Hip Surgery|The Effect of Gabapentin, Low Dose Ketamine, Paracetamol, NSAID and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for Primary Total Hip Replacement||Glostrup University Hospital, Copenhagen|Yes|Terminated|October 2005|May 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|55 Years|85 Years|No|||May 2008|May 14, 2008|October 7, 2005||No|Structural changes that stopped the type of operations used in the study|No||https://clinicaltrials.gov/show/NCT00236223||189211|
NCT00236236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-022103-H|The HF-HRV Registry|CONTAK RENEWAL® Heart Failure Heart Rate Variability Registry||Boston Scientific Corporation||Completed|February 2003|May 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1400|||Both|18 Years|N/A|No|||October 2005|November 13, 2006|September 2, 2005||||No||https://clinicaltrials.gov/show/NCT00236236||189210|
NCT00227539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6228|Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer||University of Washington||Completed|July 2005|||March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|September 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00227539||189850|
NCT00236639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003721|A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2000|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1293|||Both|18 Years|75 Years|No|||April 2010|April 26, 2010|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236639||189180|
NCT00237146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EVE01|Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy|Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy.||Novartis||Completed|November 2003|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||February 2013|February 11, 2013|October 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00237146||189142|
NCT00237159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EDE07|Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis|Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis||Novartis||Completed|October 2002|||December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|284|||Male|18 Years|N/A|No|||March 2011|March 21, 2011|October 9, 2005||||No||https://clinicaltrials.gov/show/NCT00237159||189141|
NCT00230139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endocrineCTIL|SPECT/CT in Endocrine and Neuroendocrine Tumors|The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors||Rambam Health Care Campus||Completed|January 2002|January 2006|Actual|January 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|200|||Both|18 Years|N/A|No|||September 2005|October 11, 2008|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230139||189668|
NCT00229788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.018|Impact of Race and Re-Transplantation|Impact of Race and Re-Transplantation in Childhood: Analysis of Data From the United Network of Organ Sharing||Children's Healthcare of Atlanta||Terminated|March 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|18 Years|No|||June 2007|June 12, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00229788||189695|
NCT00229801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renal Function/Brain Tumors|Evaluation of Kidney Function in Children With Brain Tumors|Evaluation of Renal Function in Children With Brain Tumors||Children's Healthcare of Atlanta||Withdrawn|June 2004|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|18 Years|No|||September 2012|September 20, 2012|September 13, 2005||No|No funds available, hard to enroll patients-Terminated in 2008|No||https://clinicaltrials.gov/show/NCT00229801||189694|
NCT00230087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 61728-S1 (completed)|Iron Depletion Therapy for Type 2 DM and NAFLD|Iron Depletion Therapy for Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|September 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||November 2012|November 6, 2012|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230087||189672|
NCT00230100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15434-1|Group Therapy for Women Recovering From Alcohol and Drug Abuse - 1|Recovery Group for Women With Substance Use Disorders||Mclean Hospital|No|Completed|March 2003|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||June 2011|June 14, 2011|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230100||189671|
NCT00230412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSP-233-05|Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)|Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)|HSP|University of Munich Children's Clinic|No|Recruiting|October 2005|December 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Whole blood, serum and urine.|Both|N/A|18 Years|No|Non-Probability Sample|Patients on paediatric intensive care units.|January 2010|February 1, 2010|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230412||189647|
NCT00230685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS2|Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia|Hammersmith Hospital Patients With Pulmonary Arteriovenous Malformations (PAVMs) and Hereditary Haemorrhagic Telangiectasia||Imperial College London||Recruiting|January 2000|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Patients referred to the hereditary haemorrhagic telangiectasia clinical service at        Hammersmith Hospital, imperial College Healthcare NHS Trust|August 2008|May 28, 2015|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230685||189626|
NCT00226200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AUS10|Soluble CD23 Expression in Asthma Patients Treated With OMA|Soluble CD23 Expression as a Marker of Immunomodulation and CLinical Response in Asthma Patients Treated With Omalizumab||University of Mississippi Medical Center|Yes|Terminated|November 2004|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|64 Years|No|||November 2008|November 26, 2008|September 22, 2005|||Completed|||https://clinicaltrials.gov/show/NCT00226200||189952|
NCT00234247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL069991|Prolonged Outcomes After Nitric Oxide (PrONOx)|Study of the Long-Term Outcomes of Nitric Oxide for Ventilated Premature Babies||University of Pittsburgh||Active, not recruiting|December 2002|||November 2008|Anticipated|Phase 3|Observational|Time Perspective: Prospective||||652|||Both|N/A|48 Hours|No|||November 2008|November 5, 2008|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00234247||189357|
NCT00234260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL075572|Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)|Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)||The University of Texas Health Science Center, Houston||Terminated|April 1995|||||N/A|Observational|Time Perspective: Prospective|||||||Both|N/A|64 Years||||October 2005|July 15, 2008|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00234260||189356|
NCT00234611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-MDT-01|Localization of CRT According to Echocardiography: LOCATE-Pilot Study|Localization of CRT According to Echocardiography: LOCATE-Pilot Study||Michigan Heart, PC||Active, not recruiting|September 2005|April 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||November 2006|November 2, 2006|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234611||189331|
NCT00234624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700821|Hepatic Hemodynamic Changes and Simulation in Living-Related Liver Transplantation|Hepatic Hemodynamic Changes and Simulation Before /After Living-Related Liver Transplantation in Donors/Recipients||National Taiwan University Hospital||Recruiting|September 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||10|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2005|October 5, 2005|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234624||189330|
NCT00234598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU1006|Strategies to Prevent Pneumonia (SToP Pneumonia)|Oral Care Intervention in Mechanically Ventilated Adults||Virginia Commonwealth University|No|Completed|March 2002|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|547|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00234598||189332|
NCT00234949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-699|A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections|A Comparative Study of the Safety, Tolerability, and Efficacy of Cefdinir and Cephalexin for the Treatment of Subjects With Mild to Moderate Uncomplicated Skin and Skin Structure Infections||Abbott||Completed|March 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||380|||Both|13 Years|N/A|No|||October 2007|October 23, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00234949||189305|
NCT00234936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEXI -P01-03|Quality of Life Study With Adalimumab in Rheumatoid Arthritis|Quality of Life Study With Adalimumab in Rheumatoid Arthritis||Abbott||Completed|December 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|200|||Both|18 Years|N/A|No|||October 2007|October 2, 2007|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00234936||189306|
NCT00235261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM3-05|Effect of Paracetamol, Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients After Hip Operations|Effect of Paracetamol Versus Paracetamol Combined With Pregabalin Versus Paracetamol Combined With Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for a Primary Total Hip Replacement||Glostrup University Hospital, Copenhagen|Yes|Completed|October 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|55 Years|75 Years|No|||August 2007|August 16, 2007|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235261||189281|
NCT00240305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522AS/0004|A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome|A Randomised, Double-Blind, Placebo Controlled, Crossover Dose-Ranging Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome||AstraZeneca||Completed|April 2004|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 13, 2009|October 16, 2005||||No||https://clinicaltrials.gov/show/NCT00240305||188908|
NCT00235937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5390L00061 Roche Study|Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex|An Open, Phase II Trial Assessing the Objective Response Rate After Combination of Arimidex® 1mg Per os/Day and Zoladex® 3.6 mg Sub Cut/Monthly as 1st Treatment for Premenopausal Receptor Positive Advanced or Metastatic Breast Cancer||AstraZeneca||Completed|December 2001|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Female|18 Years|N/A|No|||January 2011|January 20, 2011|October 10, 2005||||No||https://clinicaltrials.gov/show/NCT00235937||189233|
NCT00240253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-156|A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Who Are Not Achieving Glycemic Targets||AstraZeneca||Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|75 Years|No|||March 2015|March 26, 2015|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240253||188912|
NCT00240266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522AS/0003|Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)|A Randomised, Double-blind, Placebo-controlled, Crossover Pilot Study to Define the High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)||AstraZeneca||Completed|August 2003|December 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Male|45 Years|65 Years|No|||November 2010|November 18, 2010|October 16, 2005||||No||https://clinicaltrials.gov/show/NCT00240266||188911|
NCT00236249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P041008|Safety and Efficacy Study of Intravenous Lidocaine After Colorectal Surgery: LIDOREHAB|Evaluation of Lidocaine Continuous Intravenous Administration for Postoperative Recovery After Colorectal Surgery||Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|75 Years|No|||March 2007|February 17, 2011|October 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00236249||189209|
NCT00236457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002026|A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder|Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2000|December 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|629|||Both|18 Years|N/A|No|||November 2010|June 6, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236457||189194|
NCT00235963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-000215|A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm|A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm||Brigham and Women's Hospital||Completed|December 2002|February 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||104|||Both|18 Years|N/A|No|||October 2008|October 14, 2008|October 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235963||189231|
NCT00227825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14710-1|The Aim of This Study is to Determine the Effectiveness of a Motivational Enhancement Intervention in Reducing Risk Behaviors (Drug and Alcohol Use, Sexual Risk Behavior, Poor Adherence to Medications) Among HIV+ Youth. - 1|Motivational Enhancement Therapy to Reduce Risk Behaviors in HIV Infected Youth||National Institute on Drug Abuse (NIDA)||Completed|January 2002|June 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|16 Years|24 Years|No|||September 2005|November 3, 2005|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00227825||189833|
NCT00228059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2301E1|An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.|A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750- 2000 mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder||Novartis||Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|132|||Both|18 Years|70 Years|No|||November 2011|November 22, 2011|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00228059||189816|
NCT00236873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005563|A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.|Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 1989|May 1993|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|65 Years|No|||April 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236873||189162|
NCT00228046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH064975|Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder|Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder||Stony Brook University||Completed|January 2004|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|6 Years|14 Years|No|||October 2013|October 29, 2013|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00228046||189817|
NCT00229541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKZ 01GL0306|Medical In-Patient Rehabilitation in Rheumatoid Arthritis|Medical In-Patient Rehabilitation in Rheumatoid Arthritis: Acceptance and Outcomes in Insurants of Compulsory Health Insurances and Statutory Pension Insurances (VERA)||University of Luebeck|Yes|Completed|October 2003|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|20 Years|62 Years|No|||October 2007|October 26, 2007|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00229541||189713|
NCT00229554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-042|Survey of ColoRectal Cancer Education and Environment Needs|Assessing and Addressing Patient Colorectal Cancer Screening Barriers|SCREEN|VA Office of Research and Development|No|Completed|March 2006|March 2008|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|4644|||Both|50 Years|75 Years|No|Probability Sample|Primary care patients|January 2009|April 6, 2015|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229554||189712|
NCT00230425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC 02-760|The Measurement of Mood Variability and Sustained Attention in Women With Alcohol Dependence.|The Measurement of Mood Variability and Sustained Attention in Women With Alcohol Dependence.||University of Saskatchewan||Completed|February 2003|June 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||30|||Female|18 Years|50 Years|No|||September 2005|October 10, 2006|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00230425||189646|
NCT00229840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Functional MRI|Evaluation of Functional MRI and DTI (Imaging Techniques) in Children With Epilepsy and Focal Brain Lesions|Advanced MR Imaging Evaluation Of Neurosurgical Candidates With Focal Abnormalities||Children's Healthcare of Atlanta|No|Completed|February 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|4 Years|21 Years|No|||June 2011|June 24, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00229840||189691|
NCT00230113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61728-S2|Effect of Omega-3 PUFA Supplementation in NAFLD Patients|A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Diet Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|September 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230113||189670|
NCT00230126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0443|OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer|A Phase II Randomized Study of OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC)||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2005|July 2013|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|September 28, 2005|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT00230126||189669|
NCT00226239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003|Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer|A Phase II Trial of Docetaxel, Cetuximab (C225), and Cisplatin Followed by Radiation, Cetuximab, and Cisplatin in Locally Advanced Head and Neck Cancer||University of Pittsburgh|Yes|Completed|October 2005|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|September 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226239||189949|
NCT00226252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02159|Manual Wheelchair Propulsion Training|Manual Wheelchair Propulsion Training||VA Pittsburgh Healthcare System|No|Completed|December 2003|November 2012|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00226252||189948|
NCT00226577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13726|Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.|Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Pemetrexed in Resectable Non-Small-Cell Lung Cancer (NSCLC) With Pharmacogenomic Correlates.||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|February 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||January 2011|December 13, 2013|September 23, 2005|Yes|Yes||No|October 26, 2010|https://clinicaltrials.gov/show/NCT00226577||189923|
NCT00226629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-03-155|Evaluation of the Endovascular Repair for Aortic Aneurysm (EVAR) Program at LHSC|Evaluation of the Endovascular Repair for Aortic Aneurysm (EVAR) Program at LHSC||Lawson Health Research Institute||Completed|August 2003|August 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|40 Years|N/A|No|||April 2006|April 24, 2006|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226629||189919|
NCT00226642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNDS-2.1|Treatment of Mild and Subthreshold Depressive Disorders|Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT")||Ludwig-Maximilians - University of Munich||Active, not recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||369|||Both|18 Years|N/A|No|||February 2002|September 23, 2005|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226642||189918|
NCT00226837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.109|Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling|Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling||Melbourne Health|No|Completed|August 2004|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|60|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00226837||189903|
NCT00226850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1HUK610|Using Hypnosis to Help Children Undergoing a Difficult Medical Procedure|||Stanford University||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|5 Years|18 Years||||September 2005|September 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00226850||189902|
NCT00234962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUER-01-001|Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy|Factors Associated With Adherence in a Cohort of HIV Positive Subjects on a First Time PI Containing HAART Regimen: Observational Study of the Impact of Adherence on Viral Load for a HAART Regimen Containing Kaletra vs Other Selected PI Containing HAART.||Abbott||Terminated|August 2002|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||November 2008|November 19, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00234962||189304|
NCT00227409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG3029|Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency|Long-Term Repeated Lead Chelation Therapy in Non-Diabetic Patients With Chronic Renal Insufficiency and High-Normal Body Lead Burden||Chang Gung Memorial Hospital||Completed|November 2001|October 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||September 2005|October 17, 2006|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227409||189860|
NCT00240279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0096 Dutch SubStudy|The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study|The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study||AstraZeneca||Completed|January 2003|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|50 Years|80 Years|No|||November 2010|November 18, 2010|October 16, 2005||||No||https://clinicaltrials.gov/show/NCT00240279||188910|
NCT00240292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522AS/0002|Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines|A Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre, Phase III Study to Assess the Impact of Rosuvastatin Treatment for 26 Weeks (Titrated to a Maximum Dose of 40mg Once Daily) on Left Ventricular Function, Cytokines and Lipid Parameters in Patients With Established Systolic Chronic Heart Failure.||AstraZeneca||Completed|February 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|October 16, 2005||||No||https://clinicaltrials.gov/show/NCT00240292||188909|
NCT00240318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3562C00076|A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)|A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease||AstraZeneca||Completed|November 2002|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|October 16, 2005||||||https://clinicaltrials.gov/show/NCT00240318||188907|
NCT00240331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0096|AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)|A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events (AURORA). A Double Blind, Randomised, Phase 3b, Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival & Cardiovascular Events When Given to Subjects With End-stage Renal Failure on Chronic Haemodialysis Treatment||AstraZeneca||Completed|January 2003|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|2776|||Both|50 Years|80 Years|No|||May 2011|May 17, 2011|October 16, 2005|Yes|Yes||No|September 29, 2009|https://clinicaltrials.gov/show/NCT00240331||188906|The endpoints were originally intended to be time to event endpoints, however we are unable to report the data as intended due to the nature of time to event endpoints. Therefore we have reported the number of participants who reached the event.
NCT00235976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/EUM202|The Efficacy and Safety of Gantacurium Chloride for Injection in Tracheal Intubation in Healthy Adult Patients Undergoing Surgery Under General Anesthesia|A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate the Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patients Undergoing Surgery With General Anesthesia||Avera Pharmaceuticals||Completed|May 2005|March 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years||||July 2006|July 20, 2006|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235976||189230|
NCT00228306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9903|The Effect of Aerobic Exercise on Learning After Stroke|Effect of Cardiovascular Fitness on Motor Learning and Executive Function in Individuals After Stroke||University of Kansas Medical Center|Yes|Completed|September 2005|December 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|85 Years|No|||April 2012|April 27, 2012|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00228306||189797|
NCT00228631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021821|Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD|Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease (ImmuneReconstSCD)||Emory University|Yes|Completed|September 2005|July 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|7|||Both|6 Months|21 Years|No|Probability Sample|At in-patient or out-patient transplant clinic (All sickle cell disease bone marrow        transplant patients will be offered participation)|May 2014|May 23, 2014|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00228631||189773|
NCT00227812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08654-1|Integrated Treatment for Cocaine and Mood Disorders - 1|ERP-8654 - Integrated Treatment for Cocaine and Mood Disorders||National Institute on Drug Abuse (NIDA)||Completed|April 2001|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|January 7, 2009|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00227812||189834|
NCT00228293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11754B|Assessing CPR Quality During In-Hospital Cardiac Arrest|Assessment of Cardiopulmonary Resuscitation Quality During In-Hospital Cardiac Arrest||University of Chicago||Terminated|December 2002|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|September 23, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00228293||189798|
NCT00229567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-REB 03-1316|Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function|A Randomised Controlled Trial of Lidocaine Infusion Plus Ketamine Injection Versus Placebo to Decrease Postoperative Ileus||University of Saskatchewan||Terminated|September 2005|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|79 Years|No|||April 2007|April 18, 2007|September 27, 2005|||insufficient numbers of eligible patients as laparscopic surgery increased and open surgery    decreased.|No||https://clinicaltrials.gov/show/NCT00229567||189711|
NCT00229853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-069|Thoracoscopic Vascular Rings Chart Review|Thoracoscopic Vascular Rings Chart Review||Children's Healthcare of Atlanta|No|Terminated|August 2004|July 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|47|||Both|N/A|N/A|No|Non-Probability Sample|retro chart review|July 2011|July 5, 2011|September 13, 2005|||sufficient data gathered to support hypothesis|No||https://clinicaltrials.gov/show/NCT00229853||189690|
NCT00229866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-072|Feeding After Neonate Surgery Review|Feeding After Neonatal Surgery Chart Review||Children's Healthcare of Atlanta|No|Terminated|August 2005|June 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|90|||Both|N/A|N/A|No|Probability Sample|Neonates who undergo cardiac surgery|July 2011|July 5, 2011|September 13, 2005|||sufficient data gathered for study conclusion|No||https://clinicaltrials.gov/show/NCT00229866||189689|
NCT00230698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002503|A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure|Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 1995|August 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|451|||Both|3 Years|N/A|No|||November 2010|November 12, 2010|September 29, 2005||||||https://clinicaltrials.gov/show/NCT00230698||189625|
NCT00226226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506042|Peripherally Inserted Central Catheter Placement by IV Team Nurses Using the Sonic Flashlight|Peripherally Inserted Central Catheter Placement by IV Team Nurses Using the Sonic Flashlight||University of Pittsburgh||Completed|June 2006|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|230|||Both|18 Years|N/A|No|||February 2008|February 10, 2008|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00226226||189950|
NCT00230438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 04-0759-CE|External Beam Radiation Therapy - Target Volume|A Pilot Study to Develop a Technique for External Beam Radiotherapy After Radical Prostatectomy Based on MRI-Delineation of the Clinical Target Volume||University Health Network, Toronto||Completed|January 2005|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|N/A|No|||January 2014|January 3, 2014|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230438||189645|
NCT00226304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050246|Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma|The Evaluation of Focal Contrast-Enhancing Brain Lesions in HIV-Infected Patients||National Institutes of Health Clinical Center (CC)||Completed|September 2005|April 2009||||N/A|Observational|N/A||||120|||Both|18 Years|N/A|No|||April 2009|September 26, 2015|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00226304||189944|
NCT00230711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|American Cancer Society|Physical Activity Promotion in Cancer Follow-Up Care|Physical Activity Promotion In Cancer Follow-up Care||The Miriam Hospital||Completed|April 2004|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|2||Anticipated|300|||Female|18 Years|N/A|No|||September 2005|November 29, 2012|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230711||189624|
NCT00226616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-022|Zinc Supplementation in Cholera Patients|Clinical Trial of Zinc Supplementation in Cholera Patients||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|November 2000|July 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|3 Years|14 Years|No|||September 2005|October 19, 2005|September 25, 2005||||No||https://clinicaltrials.gov/show/NCT00226616||189920|
NCT00227123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602342|A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence|A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder Outpatients With Current Stimulant Dependence||University of Texas Southwestern Medical Center|No|Completed|October 2002|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|96|||Both|20 Years|50 Years|No|||October 2007|January 3, 2008|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00227123||189881|
NCT00227422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102394|Assess the Non-Inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs|A Phase IV, Partially Double-Blind Study to Demonstrate Non-Inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs||GlaxoSmithKline||Completed|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||324|||Both|2 Years|30 Years|Accepts Healthy Volunteers|||May 2009|May 21, 2009|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227422||189859|
NCT00227708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000443593|Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70||National Cancer Institute (NCI)||Active, not recruiting|June 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Both|70 Years|N/A|No|||December 2006|August 19, 2009|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227708||189841|
NCT00227097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 02 03|Educ'Avk: Recommendations for the Antivitamin K's Gestion|Implication of Patient in the Making Ready of Recommendations for the Antivitamin K's Gestion in Case of Thrombosis Embolic Venous's Illness. Randomised Study for Clinical Validation.||University Hospital, Grenoble||Terminated|December 2002|December 2004||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|18 Years|N/A|No|||July 2006|July 6, 2006|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00227097||189883|
NCT00228423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI 2006-111|Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)|Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?||Ottawa Heart Institute Research Corporation||Completed|May 2006|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|92|||Both|18 Years|N/A|No|||June 2010|June 25, 2010|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00228423||189788|
NCT00239603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|867-2005|Efficacy Study of the OV-Watch™ Personal Fertility Monitor for Women Using Clomiphene Citrate.|Clinical Investigation of the OV-Watch™ Personal Fertility Monitor for Women Undergoing Ovulation Induction With Clomiphene Citrate.||Emory University||Completed|October 2005|June 2007||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||40|||Female|21 Years|42 Years|Accepts Healthy Volunteers|||April 2007|April 16, 2007|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239603||188959|
NCT00239616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN01016|Pharmacokinetic Study of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin|Open-label Multicenter, Pharmacokinetic Study of a Single Dose of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin||Luitpold Pharmaceuticals||Completed|June 2002|November 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|12 Years|18 Years|No|||March 2011|March 16, 2011|October 13, 2005||||||https://clinicaltrials.gov/show/NCT00239616||188958|
NCT00239629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10080|Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial|Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis||Eli Lilly and Company||Completed|September 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||73|||Female|45 Years|90 Years|No|||June 2007|June 11, 2007|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239629||188957|
NCT00235950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00039|Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease|A Multicentre Study Comparing the Efficacy of Rosuvastatin With Atorvastatin When Given for a Period of 16 Wks to Subjects With Coronary Heart Disease & a Previously Performed Percutaneous Coronary Intervention||AstraZeneca||Completed|January 2004|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||255|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235950||189232|
NCT00240006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM024|A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone|An Open Label, Prospective Parallel Cohort Study Comparing A 90-day Copaxone® Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions® Alone or in Partnership With Their MS Center||Teva Pharmaceutical Industries|No|Completed|January 2006|September 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|307|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00240006||188929|
NCT00227266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13698|Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy|Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)||University of Utah|Yes|Completed|September 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|94|||Both|2 Years|17 Years|No|||September 2011|September 22, 2011|September 23, 2005|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00227266||189870|
NCT00227279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-08|A Trial of the ALK Grass Tablet in Subjects With Hayfever|A Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis||ALK-Abelló A/S||Completed|October 2004|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|634|||Both|18 Years|65 Years|No|||January 2013|January 28, 2013|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00227279||189869|
NCT00227565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0423|Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|February 2006|October 2009|Actual|December 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00227565||189849|
NCT00228098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF 20040136|Smoking Cessation Intervention After Stroke or Transient Ischaemic Attack.|Smoking Cessation Intervention After Stroke or Transient Ischaemic Attack. A Randomised Controlled Trial||Odense University Hospital||Recruiting|February 2005|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|18 Years|75 Years|No|||September 2005|September 27, 2005|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00228098||189813|
NCT00228072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF20030189|Liposuction as Treatment for Excessive Axillary Sweat|Suction-Curettage vs. Standard Excision in Axillary Hyperhidrosis||Odense University Hospital||Completed||||February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||May 2008|May 28, 2008|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00228072||189815|
NCT00229060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005389|Doripenem in the Treatment of Complicated Intra-Abdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Versus Comparator Antibiotic in the Treatment of Complicated Intra-Abdominal Infections||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|483|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00229060||189749|
NCT00229502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10066|Cognitive Effects of Immunomodulatory Drugs in MS|Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study||University of Kansas Medical Center|No|Completed|September 2005|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|96|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Multiple sclerosis clinic|March 2012|March 21, 2012|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229502||189716|
NCT00236548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002896|Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection|An Open-label Evaluation of the Utility of the RISPERDAL CONSTA Treatment Guidebook During Transition of Adult Patients With Schizophrenia or Schizoaffective Disorder to RISPERDAL CONSTA (Risperidone) Treatment Over Three Months in the Community Mental Health Center (CMHC) Setting||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||January 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|65 Years|No|||March 2011|May 17, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236548||189187|
NCT00229879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-119|Rare Tumor Case Review|Rare Tumor Case Review||Children's Healthcare of Atlanta|No|Terminated|December 2004|September 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|Children with intrapericardial teratoma tumors|May 2007|March 14, 2012|September 13, 2005|||sufficient data gathered to support conclusion|No||https://clinicaltrials.gov/show/NCT00229879||189688|
NCT00236756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005464|A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome|A Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 1993|February 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|100|||Both|12 Months|30 Years|No|||January 2011|June 2, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236756||189171|
NCT00230152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|infectionCTIL|Hybrid Imaging Modalities for the Evaluation of Infection|Nuclear Medicine for the Evaluation of Infection-the Added Value of Hybrid Imaging Modalities||Rambam Health Care Campus|No|Completed|February 2006|March 2009|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|300|||Both|18 Years|N/A|No|||September 2005|October 21, 2010|September 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00230152||189667|
NCT00226317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0030/01/04|Aripiprazole in the Treatment of Bipolar Depression|Phase 4 Study: An Open Prospective Study of the Safety and Effectiveness of Aripiprazole in the Treatment of Bipolar Depression||Cambridge Health Alliance||Active, not recruiting|April 2004|March 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2008|June 17, 2008|September 12, 2005||||||https://clinicaltrials.gov/show/NCT00226317||189943|
NCT00226603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-171/97|Lyske Trial (Danish) Groin Trial|Prevention of Groin Injuries in Football Players||Hölmich, Per, M.D.||Active, not recruiting|September 1997|June 1998||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||1600|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 1998|September 26, 2005|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00226603||189921|
NCT00237575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-GU-53B|Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer|A Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin and Gemcitabine for Regionally Advanced or Metastatic Urothelial Cancer||University of Kentucky||Terminated|November 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|October 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00237575||189109|
NCT00238173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-2050|Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors|Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors||OHSU Knight Cancer Institute|Yes|Suspended|December 2004|||February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|1 Year|18 Years|No|||March 2011|September 22, 2011|October 12, 2005|No|Yes|OHSU IRB closed study to further enrollment 2/17/2006|No||https://clinicaltrials.gov/show/NCT00238173||189066|
NCT00227734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/04|Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Capecitabine and Oxaliplatin Alone or in Combination With Cetuximab as First-Line Treatment for Metastatic EGFR-Positive Colorectal Cancer, A Randomized Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|June 2004|February 2006|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00227734||189839|
NCT00227942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH066978|Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia|Understanding the Role That Hot Flashes and Sleep Disruption Play in the Effect of Estrogen Replacement Therapy on Mood in Perimenopausal and Postmenopausal Women||Massachusetts General Hospital|No|Completed|August 2003|November 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00227942||189825|
NCT00228189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920-03-250|Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients|Induction of Specific T Cell Responses in Colorectal Cancer Patients With Liver Metastases Upon Vaccination With Autologous Dendritic Cells Pulsed With CEA-peptide or Electroporated With CEA-RNA: Evaluation of in Vivo Immune Response.||Radboud University||Completed|December 2003|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|No|||November 2010|November 26, 2010|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00228189||189806|
NCT00228436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-04|Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients|A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of Subcutaneously Administered Peginesatide in Chronic Kidney Disease Patients Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment||Affymax|No|Completed|September 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|139|||Both|18 Years|80 Years|No|||December 2012|December 19, 2012|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00228436||189787|
NCT00228449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-03|Peginesatide for Anemia in Chronic Hemodialysis Patients|A Phase 2, Open-label, Multi-center, Sequential, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Peginesatide Administered Intravenously for the Maintenance Treatment of Anemia in Chronic Hemodialysis Patients||Affymax|No|Completed|July 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|165|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00228449||189786|
NCT00226759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03511|Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction|Double-Blind, Multicenter Phase 3 Study Comparing the Efficacy and Safety of OMS103HP With Vehicle in Patients Undergoing Allograft ACL Reconstruction||Omeros Corporation|No|Completed|November 2004|March 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|321|||Both|15 Years|65 Years|No|||October 2012|October 10, 2012|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226759||189909|
NCT00240019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-063011|Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.|Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy||Stanford University||Completed|December 2003|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||June 2006|October 16, 2006|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00240019||188928|
NCT00227006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29HL060154|Promoting Long-term Behavior Change to Reduce CVD Risk|Promoting Long-term Dietary Change to Reduce CVD Risk||Stanford University||Completed|January 1999|April 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|163|||Both|25 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00227006||189890|
NCT00227591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02976|Lenalidomide and Prednisone in Treating Patients With Myelofibrosis|A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia||National Cancer Institute (NCI)||Completed|December 2005|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||December 2012|May 2, 2014|September 26, 2005|Yes|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT00227591||189848|
NCT00227838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15968-1|Modifying Group Therapy for Bipolar Substance Abusers - 1|Modifying Group Therapy for Bipolar Abusers||National Institute on Drug Abuse (NIDA)||Recruiting|July 2003|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|70 Years|No|||September 2005|November 3, 2005|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00227838||189832|
NCT00228085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700907|Changes of Parameters of Transcranial Magnetic Stimulation in Patients With Spinal Cord Injury|Reorganization of Cortical Motor Activation in Patients With Spinal Cord Injury: a Study of Motor Evoked Potential||National Taiwan University Hospital||Not yet recruiting|September 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2005|September 26, 2005|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00228085||189814|
NCT00228644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501-2004|Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione|Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione and Cysteine.||Emory University||Completed|July 2005|January 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Months|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|January 2009|January 29, 2009|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00228644||189772|
NCT00229047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-133|Ischemia and Reperfusion Injury in the Human: An Observational Study|Ischemia and Reperfusion Injury in the Human: An Observational Study||Lawson Health Research Institute|Yes|Recruiting|April 2005|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing routine and elective varicose vein stripping.|December 2008|December 18, 2008|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229047||189750|
NCT00228657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137/99|Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride|The Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride Administration (Substudy of SAFE Protocol 153711)||Bayside Health|No|Completed|July 2002|August 2003|Actual|August 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||1100|||Both|18 Years|N/A|No|||September 2005|November 25, 2013|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00228657||189771|
NCT00237016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF1|Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever|Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever||Medical Corps, Israel Defense Force||Completed|April 2002|April 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||140|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2003|October 23, 2008|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237016||189151|
NCT00237341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002446|Duragesic® (Fentanyl Transdermal System) Functionality Trial in Chronic Low Back Pain|Assessing Functionality Changes Associated With Patients Who Were Taking Short Acting Opioids Chronically and Who Initiated Treatment With Duragesic® (Fentanyl Transdermal System) for the Management of Chronic Low Back Pain.||PriCara, Unit of Ortho-McNeil, Inc.||Completed|June 2002|January 2004|Actual|||Phase 4|Interventional|N/A|||Actual|358|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|October 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00237341||189127|
NCT00237354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-BC-04|PV-10 Chemoablation of Recurrent Breast Carcinoma|A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma||Provectus Pharmaceuticals|No|Completed|October 2005|July 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|85 Years|No|||October 2008|October 22, 2008|October 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00237354||189126|
NCT00230451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 9740|Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma|A Phase II Trial of Preoperative Chemotherapy and Radiation Therapy Followed by Adjuvant Combination Chemotherapy for Patients With Loco-Regional Esophageal Carcinoma||University of Michigan Cancer Center|Yes|Completed|November 1997|July 2008|Actual|December 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2010|January 14, 2010|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00230451||189644|
NCT00226291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040624|The Clinical Informationist: Does the Model Work|The Clinical Informationist: Does the Model Work||Vanderbilt University|No|Completed|August 2004|May 2007|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|299|||Both|N/A|N/A|No|||May 2014|May 27, 2014|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00226291||189945|
NCT00237328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010736|Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery|The Incidence of Thromboembolic Events in Patients With Antibodies to Heparin-PF4 After Cardiac Bypass|HIT|Duke University|No|Completed|June 2006|July 2012|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1015|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals undergoing cardiac bypass surgery with heparin as the intra-operative        anticoagulant at Duke University Hospital.|February 2013|February 22, 2013|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00237328||189128|
NCT00226863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1HSA698|Meditation and Hypnosis for Chronic Depressed Mood|||Stanford University||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||September 2005|September 23, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00226863||189901|
NCT00227110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSCSA IRB# 001-5014-331|Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)|Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)||The University of Texas Health Science Center at San Antonio|No|Completed|October 2002|January 2006|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||October 2009|October 12, 2009|September 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00227110||189882|
NCT00227981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH049115|Maintenance Interpersonal Psychotherapy for Sustaining Remission of Depression|Maintenance Psychotherapies in Recurrent Depression: Study II||University of Pittsburgh||Completed|March 1995|March 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||93|||Female|20 Years|60 Years|No|||June 2013|June 21, 2013|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227981||189822|
NCT00227955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|871250|Comparing Various Treatments for Achieving and Maintaining Remission of Depression|Maintenance Therapies in Recurrent Depression-Study I||University of Pittsburgh||Completed|December 1987|December 1993||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|21 Years|65 Years|No|||June 2013|June 21, 2013|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227955||189824|
NCT00228202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3867-NK-CTIL|Genotyping of Cytomegalovirus From Patients in Israel|Cytomegalovirus Glycoprotein B Genotypes in Israeli Patients: Relationship Between CMV Genotype, Clinical and Demographic Factors||Sheba Medical Center||Recruiting|September 2005|||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||||100|||Both|N/A|N/A|No|||January 2006|August 17, 2006|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00228202||189805|
NCT00228462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00004|Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo|A 1-year, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo (Abbreviated)||AstraZeneca||Completed|March 2005|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|197|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00228462||189785|
NCT00228475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5254C00763|A Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women|An Open Single Centre Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women on Maintenance Treatment w/Pulmicort ® Turbuhaler ® at the Dose Levels 200/400 µg Bid||AstraZeneca||Completed|September 2004|October 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Female|N/A|N/A|No|||January 2011|January 21, 2011|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228475||189784|
NCT00227019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0014|Phase II Trial of Bevacizumab in Combination With Pemetrexed as 2nd Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer|Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC)(Excluding Squamous Cell Carcinoma)||Stanford University|Yes|Active, not recruiting|March 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00227019||189889|
NCT00227292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Nr.2005-001673-10|Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain|Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain||Martin-Luther-Universität Halle-Wittenberg|No|Withdrawn|November 2007|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||June 2014|June 15, 2014|September 26, 2005||No|Mutual agreement between Sponsor and Investigator.|No||https://clinicaltrials.gov/show/NCT00227292||189868|
NCT00227617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04458|Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors|A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors||University of California, San Francisco|Yes|Active, not recruiting|June 2005|June 2016|Anticipated|January 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00227617||189847|
NCT00227864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18954-1|A Brief Marijuana Intervention for Adolescent Women - 1|A Brief Marijuana Intervention for Adolescent Women||Butler Hospital||Completed|September 2004|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|326|||Female|15 Years|24 Years|No|||November 2015|November 10, 2015|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00227864||189831|
NCT00229073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004231|A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation|A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study Of The Efficacy And Safety Of Dapoxetine In The Treatment Of Subjects With Premature Ejaculation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2004|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1116|||Male|18 Years|N/A|No|||March 2010|June 6, 2011|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00229073||189748|
NCT00229086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGU-004|Gatekeeper European 005|Long Term Follow-up European Gatekeeper Study 005||MedtronicNeuro||Terminated||||||N/A|Observational|N/A||||55|||Both|N/A|N/A||||July 2008|July 24, 2008|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00229086||189747|
NCT00229099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT05-02|Efficacy and Safety Study of GerEPO|A Randomized, Multi-Center, Open Label Trial to Establish the Therapeutic Equivalence Between GerEpo and Eprex® and to Determine the Long Term Safety Profile of GerEpo in Patients on Hemodialysis.||Ministry of Health, Malaysia||Completed|April 2005|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|70 Years|No|||December 2005|October 25, 2006|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229099||189746|
NCT00228319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7823|Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants|Antioxidant Effects on the Outcome of Ovarian Cancer||University of Kansas Medical Center|Yes|Completed|October 2002|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|September 23, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00228319||189796|
NCT00228332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/005|A Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares|A Double-Blind, Placebo-Controlled Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares||University Hospital, Ghent|No|Completed|April 2004|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00228332||189795|
NCT00229827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-092|Optimal Timing for Repair of Left to Right Shunt Lesions|Optimal Timing for Repair of Left-to-Right Shunt Lesions||Children's Healthcare of Atlanta||Terminated|May 2005|August 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1||200|||Both|N/A|N/A|No|Non-Probability Sample|Patients in the congenital surgery database          -  Patients who have undergone repair of ventricular septal defects          -  Patients who have undergone repair of atrioventricular canal defects|May 2007|March 14, 2012|September 13, 2005|||sufficient data was collected|No||https://clinicaltrials.gov/show/NCT00229827||189692|
NCT00229112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-034|Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)|A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.||Merck Sharp & Dohme Corp.||Completed|April 2001|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229112||189745|
NCT00237042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27729-D|Managing Temporomandibular Disorder (TMD) Symptoms|Hormonal Cycles in Women: Effects on TMD Pain & Symptoms||University of Washington|Yes|Completed|October 2005|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|252|||Female|18 Years|45 Years|No|||June 2011|June 10, 2011|October 7, 2005|Yes|Yes||No|May 2, 2011|https://clinicaltrials.gov/show/NCT00237042||189150|
NCT00237003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASTE14495|A Brief Alcohol Intervention for Incarcerated Women|A Brief Alcohol Intervention for Incarcerated Women||Butler Hospital||Completed|September 2003|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|326|||Female|18 Years|75 Years|No|||May 2010|May 10, 2010|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00237003||189152|
NCT00237861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH57292|Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia|Effectiveness of Atypical Vs Conventional Antipsychotics||Yale University||Completed||||December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2014|June 5, 2014|October 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00237861||189088|
NCT00237874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YaleHIC26037|Aripiprazole Treatment of Prodromal Patients|Aripiprazole Treatment of Prodromal Patients||Yale University||Completed|February 2004|February 2007|Actual|February 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|13 Years|40 Years|No|||June 2014|June 5, 2014|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237874||189087|
NCT00227721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445432|Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer|Phase II Trial of Weekly Gemcitabine and Docetaxel Combination Therapy for Relapsed Ovarian or Peritoneal Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|February 2004|December 2016|Anticipated|June 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|120 Years|No|||February 2016|February 16, 2016|September 26, 2005|Yes|Yes||No|November 18, 2014|https://clinicaltrials.gov/show/NCT00227721||189840|Small sample size
NCT00227968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R37 MH29618-95|Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder|Maintenance Therapies in Bipolar Disorder||University of Pittsburgh||Completed|March 1995|April 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||181|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227968||189823|
NCT00228488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0547|Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma|Phase II Study of Iressa With/Without Concurrent Chemoradiotherapy in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma and to Study the Effect of Iressa™ (ZD1839) on Tumour Gene Expression Profiles ®||AstraZeneca||Completed|June 2004|December 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2007|December 16, 2007|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228488||189783|
NCT00228215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007776|Tips for Infant and Parent Sleep (TIPS)|Tips for Infant and Parent Sleep (TIPS) Pilot Study||The Hospital for Sick Children|No|Completed|September 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|7 Days|Accepts Healthy Volunteers|||November 2014|November 18, 2014|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00228215||189804|
NCT00229268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-0513|Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes|FOXA2 Expression in Adipose Tissue of Human Subjects With Obesity/Insulin-Resistance||Rockefeller University|Yes|Completed|September 2005|April 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|14|||Both|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers of different BMI classifications|May 2012|May 31, 2012|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00229268||189733|
NCT00227032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0424|Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme|Phase I Study of Erlotinib Administered Every 72 Hours in Patients With Glioblastoma Multiforme With Pharmacokinetic/Pharmacodynamic Correlates||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|September 2005|March 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|September 23, 2005|No|Yes|Loss of funding|No||https://clinicaltrials.gov/show/NCT00227032||189888|
NCT00227305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C00150|Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder|A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)|ANCHOR 150|AstraZeneca||Completed|August 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|381|||Both|10 Years|17 Years|No|||January 2013|January 3, 2013|September 27, 2005|Yes|Yes||No|December 22, 2008|https://clinicaltrials.gov/show/NCT00227305||189867|No comparator group, open label treatment, duration only 26 weeks - not long enough to assess full impact on growth and development
NCT00227318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-AHM-0030|TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial|A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)||AstraZeneca||Completed|July 1998|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention||||1000|||Both|30 Years|65 Years|No|||August 2011|August 29, 2011|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00227318||189866|
NCT00228670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00041094|Herpesvirus in Idiopathic Pulmonary Fibrosis|Herpesvirus in Idiopathic Pulmonary Fibrosis||Emory University|No|Completed|July 2005|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|41|Samples Without DNA|Lung tissue at the time of lung transplantation. Saliva, induced sputum, and blood at clinic      visitis|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with idiopathic pulmonary fibrosis (IPF) or controls with no underlying pulmonary        disease|December 2013|December 24, 2013|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00228670||189770|
NCT00228124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-OCT-0203|PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition|Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition in a Phase III Randomized Trial||Ontario Cancer Research Network||Recruiting|April 2004|April 2008||||Phase 3|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|No|||September 2005|January 25, 2006|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228124||189811|
NCT00228150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5287|Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease|A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease||Sanofi||Completed|July 2003|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|564|||Both|35 Years|N/A|No|||December 2008|December 22, 2008|September 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00228150||189809|
NCT00228358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6223|Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine|A Phase I Study of Infusion of HER-2/Neu Specific T Cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine||University of Washington|No|Completed|June 2003|||May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00228358||189793|
NCT00229528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000774|Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease|Dose Ranging Study of the Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease||University of Oklahoma||Completed|March 2004|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 19, 2008|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00229528||189714|
NCT00229814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tectal Tumors MRS|Study of Brain Tumors (Tectal Tumors) Using Magnetic Resonance Imaging|Magnetic Resonance Spectroscopic Analysis of Pediatric Tectal Tumors: Insight Into Pathology and Behavior||Children's Healthcare of Atlanta||Withdrawn|August 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteer children.|September 2012|September 20, 2012|September 12, 2005|||There were technical difficulties and the study was terminated in 2008|No||https://clinicaltrials.gov/show/NCT00229814||189693|
NCT00229125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMAL10761-b|Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam|Gabapentin Vs. Lorazepam in Alcohol Withdrawal||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|July 2001|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2005|September 27, 2005|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00229125||189744|
NCT00229151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2005.1.depr|Sleep Deprivation and Advancement of Sleep Period as Treatment for Bipolar Depression.|Sleep Deprivation and Three Days Sleep Phase Advancement as Treatment for Bipolar Depression.||Norwegian University of Science and Technology|No|Terminated|October 2005|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 6, 2012|September 27, 2005||No|recruiting problems|No||https://clinicaltrials.gov/show/NCT00229151||189742|
NCT00236769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005500|A Study of Efficacy and Safety With the Transdermal Contraceptive System.|An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17deacetyl-norgestimate and Ethinyl Estradiol.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 1997|October 1999|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1751|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 15, 2010|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236769||189170|
NCT00236782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005503|A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.|An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17dNorgestimate and Ethinyl Estradiol With the Oral Contraceptive Mercilon.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 1997|March 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1517|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236782||189169|
NCT00237627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 2020|Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer|A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|May 2001|January 2010|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|October 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00237627||189105|
NCT00237588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308-1|Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)|Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)||Oslo University Hospital||Completed|December 2004|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||25|||Both|18 Years|N/A|No|||October 2005|July 3, 2011|October 10, 2005||||No||https://clinicaltrials.gov/show/NCT00237588||189108|
NCT00237887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-656|Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Abbott|No|Completed|December 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1212|||Both|18 Years|N/A|No|||August 2007|August 28, 2007|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237887||189086|
NCT00237900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0539|Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer|An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer||AstraZeneca||Terminated|July 2003|February 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||34|||Both|45 Years|70 Years|No|||April 2009|April 22, 2009|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00237900||189085|
NCT00227448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-NS-042607-1|Induced Hypertension for Acute Ischemic Stroke|Induced Hypertension for Acute Ischemic Stroke||Johns Hopkins University||Completed|June 2003|April 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227448||189857|
NCT00227461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBarrett1|Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.|Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.||Kessler Foundation|Yes|Active, not recruiting|September 2005|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|September 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00227461||189856|
NCT00228228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-01-2490-AA-CTIL|TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis|T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis||Sheba Medical Center||Recruiting|May 2002|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|15 Years|50 Years|No|||August 2006|August 27, 2006|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00228228||189803|
NCT00228241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130472|Left Ventricular Function and Remodelling During Permanent Pacing|Left Ventricular Function and Remodelling During Permanent Pacing||Aarhus University Hospital Skejby||Active, not recruiting|September 2003|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|20 Years|N/A|No|||September 2005|October 25, 2006|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00228241||189802|
NCT00228514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0098 Dutch SubStudy|Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study|Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) PET Sub Study||AstraZeneca||Completed|February 2004|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|60 Years|N/A|No|||November 2010|November 11, 2010|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228514||189782|
NCT00228527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9614C00097|Esomeprazole for Treatment of GERD in Pediatric Patients|A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive.||AstraZeneca||Completed|October 2004|October 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|1 Year|11 Years|No|||November 2009|November 18, 2010|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228527||189781|
NCT00228930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0208-14|Tamoxifen Pharmacogenetics and Clinical Effects|A Pilot Trial Correlating Metabolic Profile of Tamoxifen With Pharmacogenetic Predictors and Clinical Effects||National Institute of General Medical Sciences (NIGMS)||Completed|September 2002|August 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|297|Samples With DNA|Whole Blood Serum Plasma|Female|18 Years|70 Years|No|Non-Probability Sample|Eligible patients included women 18 years or older, non-pregnant or lactating, who were        recommended tamoxifen for adjuvant treatment or for the prevention of breast cancer from        the oncology clinics.|November 2007|September 24, 2008|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228930||189759|
NCT00229281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3680-JZ-CTIL|Short Term Group Therapy for Anxiety Disorder|||Sheba Medical Center||Completed|February 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||December 2007|December 18, 2007|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229281||189732|
NCT00229294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA- 03-2925-JZ-CTIL|Fibromyalgia in Men Suffering From PTSD|||Sheba Medical Center||Completed|March 2004|March 2005||||N/A|Observational|Time Perspective: Retrospective|||||||Male|20 Years|60 Years|Accepts Healthy Volunteers|||December 2007|December 18, 2007|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229294||189731|
NCT00229307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3709-JZ-CTIL|Prolonged Exposure (PE) Treatment for Post Traumatic Stress Disorder (PTSD) 20 Minutes Versus 40 Minutes|||Sheba Medical Center|No|Completed|December 2005|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|65 Years|No|||January 2013|January 26, 2013|September 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00229307||189730|
NCT00229320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3679-JZ-CTIL|Short Term Group Therapy for OCD|||Sheba Medical Center|No|Completed|February 2005|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|65 Years|No|||January 2008|January 28, 2008|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229320||189729|
NCT00228111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/093|TRACT Study: Evaluation of the Value of Routine Thoraco-abdominal CT in Blunt Trauma Patients|Prospective Evaluation of the Additional Value of Routine Thoraco-abdominal CT in Patients That Suffered Severe Blunt Trauma of the Abdomen/Thorax||Radboud University|No|Completed|June 2005|December 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|16 Years|N/A|No|Probability Sample|Adult blunt trauma patients|September 2009|September 23, 2009|August 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00228111||189812|
NCT00228345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12896A|The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy|The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy||University of Chicago||Terminated|January 2004|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 26, 2005||No|Study Completed|No||https://clinicaltrials.gov/show/NCT00228345||189794|
NCT00227890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18851-1|Skills and Motivation at the Rhode Island Training School (Project SMART) - 1|Motivation and Skills for THC/ETOH+ Teens in Jail||University of Rhode Island||Completed|March 2005|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|205|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00227890||189829|
NCT00228371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 23|STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy|Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.||University Hospital, Grenoble|Yes|Terminated|September 2005|March 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|50 Years|No|||May 2015|May 27, 2015|September 26, 2005||No|insufficent enrolement|No||https://clinicaltrials.gov/show/NCT00228371||189792|
NCT00228384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA 05-03|GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study|GORE VIABAHN Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Lesion (>8cm) Superficial Femoral Artery Occlusive Disease||W.L.Gore & Associates|No|Completed|September 2005|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|21 Years|N/A|No|||May 2012|May 25, 2012|September 26, 2005|Yes|Yes||No|January 27, 2012|https://clinicaltrials.gov/show/NCT00228384||189791|
NCT00228813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0159-2004|G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome|Feasibility Study of Using G-CSF Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome With Partially Mismatched Related Donors|G-CSF PMRD|Emory University|Yes|Terminated|April 2004|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|22 Years|No|||January 2015|January 7, 2015|September 27, 2005||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00228813||189767|
NCT00228683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024899|Hepatoblastoma Biology Study and Tissue Bank|Hepatoblastoma Biology Study and Tissue Bank||Emory University|Yes|Withdrawn|September 2005|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|6 Months|21 Years|No|||November 2013|November 23, 2013|September 27, 2005||No|national study, local site not responsible for any analysis/results/etc|No||https://clinicaltrials.gov/show/NCT00228683||189769|
NCT00228696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024842|National Wilm's Tumor Study Late Effects|National Wilm's Tumor Study Late Effects||Emory University|Yes|Withdrawn|September 2005|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|0|||Both|18 Years|85 Years|No|||November 2013|November 23, 2013|September 27, 2005||No|national study, local site not responsible for results/analysis|No||https://clinicaltrials.gov/show/NCT00228696||189768|
NCT00228839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|540-2003|GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease|A Pediatric Phase I Pharmacokinetic Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease||Emory University|No|Completed||October 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|18 Years|Accepts Healthy Volunteers|||December 2007|June 29, 2009|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00228839||189766|
NCT00236353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002830|Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder|An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder||Janssen, LP||Completed|May 2002|December 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|86|||Both|18 Years|65 Years|No|||March 2011|May 16, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236353||189202|
NCT00237640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11798|Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus|Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus||University of Oklahoma|No|Completed|March 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||September 2008|September 19, 2008|October 10, 2005||||No||https://clinicaltrials.gov/show/NCT00237640||189104|
NCT00237653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 21|MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus|Relevance of Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus||University Hospital, Grenoble||Terminated|February 2004|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|75 Years|No|||April 2009|April 2, 2009|October 11, 2005||No|difficulty to include patients|No||https://clinicaltrials.gov/show/NCT00237653||189103|
NCT00237601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF 198|Home or Home-like Hospital Birth|Home or Home-like Hospital Birth for Low-risk Nulliparae: Does it Matter?||Maastricht University Medical Center|No|Completed|January 2006|December 2008|Actual|March 2008|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with a low-risk pregnancy under the care of an independent midwife. Women are free        to choose where to give birth, at home or in a short-stay hospital setting. The women are        fluent in de Dutch language.|April 2010|April 1, 2010|October 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00237601||189107|
NCT00237614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS16 RC/2003|Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction|||University of Milan||Completed|February 2003|May 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||300|||Both|18 Years|90 Years|No|||July 2005|July 17, 2006|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237614||189106|
NCT00237913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-152|Schizophrenia Trial of Aripiprazole|A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||700|||Both|18 Years|65 Years|No|||July 2008|November 7, 2013|October 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00237913||189084|
NCT00238212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03181|S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma|Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma||National Cancer Institute (NCI)||Completed|October 2005|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||January 2013|January 11, 2013|October 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00238212||189064|
NCT00238446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2401E1|Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients|A Prospective, Open-label, Multicenter Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Heart Transplant Recipients||Novartis||Completed|April 2003|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 11, 2005||||||https://clinicaltrials.gov/show/NCT00238446||189046|
NCT00227747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445034|Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer|Randomized Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine vs 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Carcinomas T3-4 No-2 Mo||National Cancer Institute (NCI)||Active, not recruiting|July 2005|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|590|||Both|18 Years|80 Years|No|||December 2006|April 14, 2010|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227747||189838|
NCT00228540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/3044/AD/US|Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD|An 8 Week, Open-Label Study to Characterize the Response to Modafinil (85 mg Film Coated Tablet) Treatment at Dosages Up to 425 mg/Day in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD) (With an Open Ended Extension Period)||Teva Pharmaceutical Industries||Completed|September 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|6 Years|17 Years|No|||May 2014|May 8, 2014|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00228540||189780|
NCT00228254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD038327-01|Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study|Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study||Tufts University||Completed|January 2000|June 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2582|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||September 2005|September 23, 2005|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00228254||189801|
NCT00228943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-03|The Role of Serotonin in Hot Flashes After Breast Cancer|The Role of Serotonin in Hot Flashes After Breast Cancer||Indiana University|Yes|Completed|July 2005|November 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|28|||Female|18 Years|N/A|No|||March 2015|March 24, 2015|September 14, 2005||No||No|November 13, 2008|https://clinicaltrials.gov/show/NCT00228943||189758|
NCT00228956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412-14|Aromatase Inhibitor Clinical Trial|A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism||National Institute of General Medical Sciences (NIGMS)||Recruiting|January 2005|February 2009|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood Serum and Plasma Urine|Female|40 Years|70 Years|No|Non-Probability Sample|Oncology clinics.|September 2005|September 24, 2008|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00228956||189757|
NCT00228982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005038|Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections|A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections||Basilea Pharmaceutica|No|Completed|October 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|784|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|September 27, 2005||Yes||||https://clinicaltrials.gov/show/NCT00228982||189755|
NCT00229333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-3124-AS-CTIL|Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia|Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia||Sheba Medical Center||Recruiting|December 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|60 Years|N/A|No|||August 2006|August 28, 2006|September 27, 2005||||No||https://clinicaltrials.gov/show/NCT00229333||189728|
NCT00229346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3457-JZ-CTIL|Fibromyalgia and Psychiatric Symptoms Among PMS and PMDD Patients|||Sheba Medical Center||Completed|October 2004|January 2006||||N/A|Observational|Time Perspective: Retrospective|||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 18, 2007|September 28, 2005||||No||https://clinicaltrials.gov/show/NCT00229346||189727|
NCT00227357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-H97HA03796-01-00|The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration|SPNS - An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care|BUP|Ruth M. Rothstein CORE Center|No|Completed|July 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|101|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving buprenorphine treatment Patients not receiving buprenorphine treatment        (methadone or none)|September 2005|June 4, 2010|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00227357||189863|
NCT00227656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0727|Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer|Phase II Trial of Capecitabine (Xeloda®) and Pegylated Interferon Alfa-2A(Pegasys®) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma||M.D. Anderson Cancer Center|No|Terminated|September 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|September 26, 2005||No|Study slow to accrue.|No||https://clinicaltrials.gov/show/NCT00227656||189845|
NCT00227903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19135-1|Therapeutic Substance Abuse Treatment in Pregnancy - 1|Psychosocial Research to Improve Drug Treatment in Pregnancy (PRIDE-P)|PRIDE-P|Yale University|Yes|Completed|September 2004|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Female|16 Years|45 Years|No|||June 2013|June 14, 2013|September 27, 2005||No||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00227903||189828|Did not acheive desired sample size; results were averaged across substances; women were not seeking substance abuse treatment (i.e. they were attending for prenatal care); treatment was brief
NCT00228137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM25577|Randomised Controlled Trial PFC Versus CKS Total Knee Prostheses|A Prospective Randomized Double-Blind Study to Assess the Functional Differences Between the PFC and CKS Knee Prostheses||Radboud University||Active, not recruiting|November 2002|November 2012|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||90|||Both|N/A|N/A|No|||August 2007|August 8, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00228137||189810|
NCT00240123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10454|Effect of Benadryl Sedation During ERCP or EUS|Effect of Diphenhydramine Sedation During Endoscopic Retrograde Cholangio-pancreatography (ERCP) or Endoscopic Ultrasound (EUS)||University of Rochester||Withdrawn|July 2005|July 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00240123||188920|
NCT00240136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-10-435-32|Long-term Observation of Patients With Early Rheumatoid Arthritis|Long-term Observation of Patients With Early Rheumatoid Arthritis||University of California, Los Angeles|Yes|Active, not recruiting|January 1993|July 2023|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|372|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with rheumatoid arthritis|February 2016|February 17, 2016|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00240136||188919|
NCT00235794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066A1-132|An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients|An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2004|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|50|||Male|18 Years|N/A|No|||December 2007|December 18, 2007|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235794||189244|
NCT00236093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C8278/2022/BP/US-CA|Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain|A 4-week, Open-Label Extension Study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain||Teva Pharmaceutical Industries||Completed|October 2006|||December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Years|15 Years|No|||May 2014|May 8, 2014|October 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00236093||189221|
NCT00229138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2409|Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients|A Six-month, Prospective, Multicenter, Open Label, Parallel, Randomized Study of the Safety, Tolerability and Efficacy of EC-MPS With Basiliximab, Corticosteroids and Two Different Levels of Tacrolimus in de Novo Renal Transplant Recipients||Novartis||Completed|September 2005|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|291|||Both|18 Years|70 Years||||January 2011|January 28, 2011|September 27, 2005||Yes||||https://clinicaltrials.gov/show/NCT00229138||189743|
NCT00236106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKR-AD-04|Short Term Growth in Children With Atopic Dermatitis|||Children´s Clinic, Randers||Completed|February 2005|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind||||20|||Both|5 Years|14 Years|No|||March 2005|December 8, 2005|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236106||189220|
NCT00236561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003205|A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine|A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2001|December 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|786|||Both|12 Years|65 Years|No|||November 2010|November 18, 2010|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236561||189186|
NCT00237367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004618|A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn|A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn||PriCara, Unit of Ortho-McNeil, Inc.||Completed||April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|52|||Both|18 Years|65 Years|No|||April 2010|April 26, 2010|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237367||189125|
NCT00237380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-005-CF|Safety and Efficacy of PTC124 for Cystic Fibrosis|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis||PTC Therapeutics||Completed|November 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00237380||189124|
NCT00237081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66136-MaGIC (completed)|Genetics of Interstitial Cystitis|Maryland Genetics of Interstitial Cystitis (MaGIC)|magic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 2004|November 2008|Actual|||N/A|Observational|N/A|||||||Both|13 Years|N/A||||March 2010|March 2, 2010|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00237081||189147|
NCT00237926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N05-006|Comparing Aerobic to Resistance Training in Recovery From Cancer|Comparing Aerobic to Resistance Training in Recovery From Cancer||Brooke Army Medical Center|No|Completed|November 2005|||March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|58|||Both|18 Years|N/A|No|||July 2008|July 29, 2008|October 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00237926||189083|
NCT00237939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-100|A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices|A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA)||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|September 2002|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1200|||Both|18 Years|65 Years|No|||October 2007|November 7, 2013|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00237939||189082|
NCT00238225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 33204|Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Oral Calcitriol in Combination With Ketoconazole in Refractory Advanced Malignancies||Roswell Park Cancer Institute||Completed|November 2004|||June 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238225||189063|
NCT00227786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448865|Primary Care Physicians' Use of Stop-Smoking Plans to Help Patients Who Are Smokers|Using Electronic Medical Records to Measure and Improve Adherence to Tobacco Treatment Guidelines in Primary Care||Kaiser Permanente|No|Completed|January 2003|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|344|||Both|18 Years|N/A|No|||November 2005|August 15, 2013|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00227786||189835|
NCT00232336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA 1 26|Quetiapine for Cocaine Use and Cravings|Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence||Seattle Institute for Biomedical and Clinical Research|No|Completed|October 2003|January 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|65 Years|No|||July 2008|July 29, 2008|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00232336||189502|
NCT00227994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH064196-01|Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke|Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly||University of Pittsburgh||Completed|April 2003|March 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|60 Years|N/A|No|||March 2014|March 7, 2014|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227994||189821|
NCT00228007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062719|Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users|Maintaining HIV Risk Reduction Among Needle Exchangers||Butler Hospital||Completed|September 2000|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||265|||Both|18 Years|75 Years|No|||August 2013|August 20, 2013|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00228007||189820|
NCT00228553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3024/ES/MN|Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness|A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)||Teva Pharmaceutical Industries||Completed|May 2004|July 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|743|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|September 27, 2005||Yes|||June 1, 2009|https://clinicaltrials.gov/show/NCT00228553||189779|
NCT00228267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 001|Propofol Injection for Daily Headache|The Effect of Single-Dose Propofol Injection on Pain and Quality of Life in Chronic Daily Headache: a Randomized Double-Blind Controlled Trial||University of Alberta||Completed|September 2004|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|65 Years|No|||November 2007|November 5, 2007|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00228267||189800|
NCT00228566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3046/ES/US|Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome|A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome||Teva Pharmaceutical Industries||Completed|October 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|247|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|September 27, 2005|No|Yes|||June 1, 2009|https://clinicaltrials.gov/show/NCT00228566||189778|
NCT00228969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333369-EPY-2003|Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy|||SK Life Science||Completed|February 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|79 Years|No|||August 2012|August 1, 2012|June 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00228969||189756|
NCT00228995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004630|A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia|A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Idiopathic Anemia of Aging (IAA) Receiving Epoetin Alfa (PROCRIT�)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|June 2004|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|9|||Both|65 Years|N/A|No|||April 2010|June 8, 2011|September 27, 2005|||This study was stopped due to slow enrollment after enrolling only 9 of 80 patients over 14    months time.|||https://clinicaltrials.gov/show/NCT00228995||189754|
NCT00227370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013245|Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation|A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation|Valgan|Duke University||Completed|July 2003|December 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|136|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|September 26, 2005|Yes|Yes||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00227370||189862|
NCT00227669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000443572|Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma|Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas||National Cancer Institute (NCI)||Recruiting|October 2005|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|80|||Female|18 Years|N/A|No|||December 2006|December 13, 2009|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00227669||189844|
NCT00239746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0086|BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories|Biomarkers of Nonsteroidal Anti-Inflammatories||National Institute on Aging (NIA)|Yes|Active, not recruiting|October 2005|August 2009|Anticipated|August 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|59 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 28, 2009|October 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00239746||188948|
NCT00235807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3214R|Multi-Site Randomized Clinical Study of Tinnitus Treatment Methods|Multi-Site Randomized Clinical Study of Tinnitus Treatment Methods||VA Office of Research and Development||Completed|June 2004|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|21 Years|80 Years|No|||March 2011|March 23, 2011|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235807||189243|
NCT00236132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #01-02-FB-0032|"A Multicenter Study Comparing the Clinical Outcomes of the Nuss and Ravitch Procedures for Repair Of Pediatric Pectus Excavatum|" A Multicenter Study Comparing the Clinical Outcomes of the Nuss and Ravitch Procedures for Repair of Pediatric Pectus Excavatum"||Children's Health System, Inc.||Active, not recruiting|August 2001|December 2008|Anticipated|||N/A|Observational|N/A|||Anticipated|360|||Both|3 Years|21 Years|Accepts Healthy Volunteers|||October 2007|October 11, 2007|October 10, 2005||||No||https://clinicaltrials.gov/show/NCT00236132||189218|
NCT00236145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C8278A/302/ON/MN|Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain|A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain||Teva Pharmaceutical Industries||Completed|June 2004|||August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2005|January 28, 2013|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236145||189217|
NCT00236119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0701/2024/DR/US|Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis|A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe, Recalcitrant, Plaque Type Psoriasis||Teva Pharmaceutical Industries||Completed|June 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|46|||Both|18 Years|75 Years|No|||August 2012|August 22, 2012|October 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00236119||189219|
NCT00236366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003004|A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With Osteoarthritis|Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Trial To Investigate Durogesic™ In Comparison To Placebo In Subjects With Moderate To Severe Pain Induced By Osteoarthritis Of The Hip Or The Knee, Who Are In Need Of And Waiting For Hip Or Knee Replacement.||Janssen Pharmaceutica N.V., Belgium||Completed|June 2002|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|418|||Both|41 Years|N/A|No|||December 2010|May 16, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236366||189201|
NCT00237068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERD AsthmaStudy|A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.|A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy ( Lansoprazole; Solutab) in the Management of Childhood Asthma||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|March 2006|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Both|4 Years|11 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|October 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00237068||189148|
NCT00237393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0058|Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)|A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD|PTSD|Ralph H. Johnson VA Medical Center|No|Completed|August 2003|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||October 2005|February 20, 2008|October 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00237393||189123|
NCT00238251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 70/03|Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases|Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|May 2005|November 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|October 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00238251||189061|
NCT00237952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPG340711|Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy|Environmental Lead Exposure and Progressive Renal Insufficiency in Patients With Type II Diabetes and Diabetic Nephropathy||Chang Gung Memorial Hospital||Completed|August 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|20 Years|80 Years|No|||June 2009|June 21, 2009|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00237952||189081|
NCT00237666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-3945-A 01|Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression|An Open-Label, Flexible-Dose Trial of the Safety and Efficacy of Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression||The Medical Research Network|Yes|Completed|February 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|October 7, 2005||No||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00237666||189102|
NCT00232349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA1 28|Efficacy of Galantamine to Treat Schizophrenia|An Open-Label Trial of Adjunctive Galantamine Maintenance Therapy to Treat Functional Impairments in Chronic Outpatients With Schizophrenia||Seattle Institute for Biomedical and Clinical Research|Yes|Terminated|February 2005|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|No|||July 2008|July 30, 2008|September 30, 2005|Yes|Yes|Study terminated due to no apparent benefit.|No||https://clinicaltrials.gov/show/NCT00232349||189501|
NCT00228020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621ADE01|Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients|A Randomized, Placebo-controlled, Double-blind, Multicenter Study Investigating Basiliximab in Combination With MMF, Cyclosporine Microemulsion and Prednisone in the Prevention of Acute Rejection in Pediatric Renal Allograft Recipients||Novartis||Completed|May 2001|||January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|212|||Both|1 Year|18 Years||||August 2010|August 24, 2010|September 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00228020||189819|
NCT00228033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH063242|Effectiveness of Supplemental Calcium in Preventing Postpartum Depression|Calcium for the Prevention of Postpartum Depression||Oregon Health and Science University||Completed|April 2002|August 2007|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||238|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|March 19, 2014|September 26, 2005||||No||https://clinicaltrials.gov/show/NCT00228033||189818|
NCT00232830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC03-03|The Study to Assess AMI Treated With Balloon Angioplasty.|Trial to Assess the Use of the Cypher TM Stent in Acute Myocardial Infarction Treated With Balloon Angioplasty|TYPHOON|Cordis Corporation|Yes|Completed|October 2003|April 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|715|||Both|18 Years|N/A|No|||April 2009|September 15, 2009|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232830||189464|
NCT00228579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333-2002|Assessment of Changes in Abdominal Fat|Assessment of Changes in Abdominal Fat and Metabolic and Tissue Biomarkers During a Bariatric Surgery Weight Loss Intervention Program||Purdue University|No|Active, not recruiting|June 2003|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|65 Years|No|Non-Probability Sample|Severely obese volunteers who are undergoing bariatric surgery. Subjects will be recruited        from patients who are undergoing bariatric surgery procedures at Emory Bariatrics. The        costs of surgical procedures are not provided by the research study.|March 2015|March 17, 2015|September 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00228579||189777|
NCT00233818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC99-07|FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent|An Evaluation of Sirolimus-Coated Modified BX VELOCITY Balloon-Expandable Stents for the Treatment of Patients With de Novo Native Coronary Artery Lesions||Cordis Corporation|Yes|Completed|February 2000|June 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2007|October 11, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233818||189389|
NCT00239135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-004|Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel|An Open-label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks||Peplin||Completed|September 2005|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||34|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|October 12, 2005||||||https://clinicaltrials.gov/show/NCT00239135||188995|
NCT00239434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.245|A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)|Comparison of 18 mg of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20 mg, Four Times Daily) in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|June 2003|March 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|40 Years|N/A|No|||May 2012|May 11, 2012|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239434||188972|
NCT00239447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.249|Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD|Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|November 2002|April 2004||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||131|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239447||188971|
NCT00239460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.284|Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD|Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With Chronic Obstructive Pulmonary Disease (a 12-week, Parallel Group, Randomized, Placebo-cotrolled, Double-blind Study).||Boehringer Ingelheim||Completed|July 2003|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||196|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00239460||188970|
NCT00239759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0085|MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology|Genetic Epidemiological Studies of Apolipoprotein E and Alzheimer's Disease||National Institute on Aging (NIA)||Completed|September 2002|June 2008|Actual|||N/A|Observational|N/A|||Anticipated|2000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 24, 2009|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239759||188947|
NCT00240149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95771|Pilot Study to Evaluate a Method of Controlling High Blood Sugar in the Pediatric Intensive Care Unit|Pilot Study Evaluating Use of Insulin-Glucose Algorithm and Glucose Monitoring Techniques to Control Hyperglycemia in the Pediatric Intensive Care Unit||Stanford University||Completed|October 2005|March 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||0|||Both|1 Year|18 Years|No|||November 2007|December 19, 2007|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00240149||188918|
NCT00236158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25100|The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome|The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome||The DANPACE Investigator Group|Yes|Terminated|March 1999|July 2010|Anticipated|July 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1415|||Both|18 Years|N/A|No|||February 2009|February 20, 2009|October 10, 2005||No|Not able to recruit the estimated number of patients|No||https://clinicaltrials.gov/show/NCT00236158||189216|
NCT00236379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002758|A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder|A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder||Janssen, LP||Completed||August 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|65 Years|No|||March 2011|May 16, 2011|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00236379||189200|
NCT00236574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003145|A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment|A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2001|November 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|974|||Both|50 Years|N/A|No|||November 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236574||189185|
NCT00237679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-487|Quantifying Effects of Treatment of Pediatric Dysphonia|Quantifying Effects of Treatment of Pediatric Dysphonia||University of Wisconsin, Madison|Yes|Terminated|January 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|6 Years|11 Years|No|||October 2015|October 13, 2015|October 7, 2005||No|Terminated due to funding loss.|No||https://clinicaltrials.gov/show/NCT00237679||189101|
NCT00237406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4065-05|Interactive Voice Response (IVR) for Methadone Patients|Interactive Voice Response for Methadone Patients||Butler Hospital||Completed|January 2006|October 2006|Actual|||Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2||50|||Both|18 Years|75 Years|No|Probability Sample|Individuals who recently enrolled in methadone maintenance for opioid addiction.|March 2010|March 24, 2010|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00237406||189122|
NCT00238524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0743|A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy|A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy||UCB Pharma||Completed|December 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|357|||Both|18 Years|N/A|No|||April 2010|September 19, 2014|October 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00238524||189040|
NCT00238875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0403|A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-Small Cell Lung Cancer (JCOG0403)|A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-Small Cell Lung Cancer (JCOG0403)||Japan Clinical Oncology Group|Yes|Active, not recruiting|July 2004|November 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|167|||Both|20 Years|N/A|No|||February 2009|February 2, 2009|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00238875||189015|
NCT00238888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015117|Randomised Controlled Trial of a Multi-faceted Community-based Intervention to Improve Asthma in Children|Randomised Controlled Trial of a Multi-faceted Community-based Intervention to Improve Pediatric Morbidity: a PRIISME Project (Program to Integrate Information Service and Manage Education)||McGill University Health Center||Completed|August 2002|||April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Actual|298|||Both|5 Years|17 Years|No|||November 2010|November 26, 2010|October 12, 2005||||No||https://clinicaltrials.gov/show/NCT00238888||189014|
NCT00232843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE04-01UK|The Study to Treat Superficial Femoral Artery Occlusions.|A Clinical Investigation of the SMART™ Nitinol Self-Expandable Stent Versus Balloon Angioplasty Only for the Treatment of SUPERficial Femoral Artery Occlusions|SUPER UK|Cordis Corporation|Yes|Completed|March 2005|May 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|30 Years|N/A|No|||June 2009|June 2, 2009|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232843||189463|
NCT00232596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX-RET-E22-301|Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures|RESTORE1|GlaxoSmithKline|No|Completed|September 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|75 Years|No|||September 2011|March 15, 2012|September 30, 2005|Yes|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00232596||189482|
NCT00233467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC Retro PTSD|Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade|Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade||Tuscaloosa Research & Education Advancement Corporation||Completed|September 2005|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||30|||Both|19 Years|N/A|No|||September 2006|September 20, 2006|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00233467||189416|
NCT00233831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III UV 11/03|Millimeter Wave Therapy (MWT) for Analgesia After Total Knee Replacement|Millimeter Wave Therapy (MWT) Versus Placebo for Analgesia and Wound Healing After Elective Total Knee Arthroplasty - a Randomized Controlled Trial||University Medicine Greifswald||Completed|March 2004|October 2007|Actual|October 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|35 Years|80 Years|No|||February 2011|February 25, 2011|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233831||189388|
NCT00233844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III UV 82/03|Studying the Analgesic Mechanism of the "Cough-Trick"|Studying the Analgesic Mechanism of the "Cough-Trick" - Randomized Crossover Volunteer Study||University Medicine Greifswald||Completed|February 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||21|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2005|October 5, 2005|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00233844||189387|
NCT00239473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.251|12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD|A Randomised, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Comparison of 12-Week Treatment of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|November 2002|||December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||429|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239473||188969|
NCT00239486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.515|Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)|Evaluation of the Effect of Different Doses of Pramipexole on Subjective and Objective Symptoms of Idiopathic Restless Legs Syndrome (RLS).||Boehringer Ingelheim||Completed|October 2002|April 2004||April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||109|||Both|18 Years|80 Years|No|||October 2013|October 31, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00239486||188968|
NCT00239772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH051509-05|Cognitive Processing Therapy Versus Prolonged Exposure for Treating Women With Post-Traumatic Stress Disorder Brought on by Sexual Assault|Cognitive Processes in PTSD: Treatment||University of Missouri, St. Louis||Completed|May 1994|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Female|18 Years|N/A|No|||June 2014|June 4, 2014|October 13, 2005||||No||https://clinicaltrials.gov/show/NCT00239772||188946|
NCT00240162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0639|PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma|A Phase II Study of PTK787/ZK 222584, a Novel, Oral Angiogenesis Inhibitor as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma Following High Dose Chemotherapy and Autologous Stem Cell Transplant||Washington University School of Medicine||Terminated|September 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|October 13, 2005|Yes|Yes|investigator letter from drug manufacturer stating animal studies showed increased risk of    cancer which was an unknown adverse event|No|August 22, 2014|https://clinicaltrials.gov/show/NCT00240162||188917|In November 2008, it was reported that the drug might have carcinogenic potential in animal models. At that time, the remaining three patients were taken off study.
NCT00235820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-716|Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis|CHAMPION|Abbott|No|Completed|July 2005|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|271|||Both|18 Years|N/A|No|||June 2008|July 15, 2008|October 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235820||189242|
NCT00236587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003274|A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia|An Open Label, Long Term Trial of Risperidone Long Acting Microspheres in the Treatment of Patients Diagnosed With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2001|February 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|18 Years|N/A|No|||January 2011|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236587||189184|
NCT00236795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005506|A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.|An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 1997|March 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1494|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|June 6, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236795||189168|
NCT00237055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK64544 (completed)|Infectious Agents in Pediatric Crohn's|Infectious Agents in Pediatric Crohn's Disease||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 2004|September 2006||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|6 Months|18 Years|No|||March 2010|March 17, 2010|October 11, 2005||||No||https://clinicaltrials.gov/show/NCT00237055||189149|
NCT00237133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345EBR01|Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women|PREDICT TRIAL- Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR)|PREDICT|Novartis||Completed|March 2003|||January 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|October 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00237133||189143|
NCT00236808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005551|A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis|A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2000|November 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|383|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236808||189167|
NCT00236821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005554|A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia|Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2001|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|530|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|October 7, 2005||||||https://clinicaltrials.gov/show/NCT00236821||189166|
NCT00251719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-EE04-085|Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis|A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis||Takeda|No|Completed|December 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2054|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|November 8, 2005|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00251719||188047|
NCT00251472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-04-012|A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer|A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer||Veeda Oncology|No|Completed|March 2005|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251472||188065|
NCT00251732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merit Review Study|Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)|Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI.||Southern Arizona VA Health Care System|No|Completed|March 2005|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|75 Years|No|||August 2010|August 18, 2010|November 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00251732||188046|
NCT00222092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIG-2005|Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers|Effect of Octreotide, Somatostatin, Pentoxyfilline or Placebo in the Prevention and the Course of Post-ERCP Pancreatitis and Study of Molecular Markers in Post-ERCP Pancreatitis||University of Ioannina||Completed|September 2005|September 2006||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing endoscopic retrograde cholangiopancreatography|September 2005|August 23, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222092||190258|
NCT00222105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doxil|A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life|Doxil® (Pegylated Liposomal Doxorubicin), Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life||University of Kansas Medical Center|Yes|Withdrawn|November 2002|July 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||February 2011|February 16, 2011|September 13, 2005|Yes|Yes|PI left institution, study closed September 2009|No||https://clinicaltrials.gov/show/NCT00222105||190257|
NCT00223275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-03-107|Naltrexone for Bipolar Disorder and Alcohol Dependence|Naltrexone for Bipolar Disorder and Alcohol Dependence||University of Texas Southwestern Medical Center||Completed|May 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|70 Years|No|||May 2011|May 23, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00223275||190171|
NCT00222664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Qidong-HBV-Study|Qidong Hepatitis B Intervention Study|||University of Oxford||Completed|September 1983|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||80000|||Both|N/A|N/A||||August 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222664||190218|
NCT00222677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRU-UniPg-01-03|Aspirin for the Prevention of Recurrent Venous Thromboembolism|Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.||University Of Perugia||Active, not recruiting|May 2004|||January 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||August 2011|August 21, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222677||190217|
NCT00222911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506173|Treatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports|Conservative Treatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports: a Prospective Randomized Study||University of Pittsburgh||Completed|August 2005|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||May 2008|May 19, 2008|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00222911||190199|
NCT00223717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010189|Treatment of Supine Hypertension in Autonomic Failure|The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure||Vanderbilt University|No|Recruiting|June 2001|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|80 Years|No|||March 2016|March 7, 2016|September 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223717||190138|
NCT00223483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20040268H|Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers|Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|March 2005|December 2019|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Whole blood, serum, white cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic and community samples|December 2015|December 17, 2015|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223483||190156|
NCT00223951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003-10|Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers|A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of R89674 0.25% Ophthalmic Solution in Healthy, Normal Volunteers||Vistakon Pharmaceuticals||Completed|September 2005|||December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|3 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 19, 2015|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223951||190121|
NCT00223964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR01006|Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients|Randomized Double-Blind Parallel Group MultiCenter Study of the Efficacy of Two Doses of Ferrlecit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin.||Watson Pharmaceuticals||Completed|June 2003|||October 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|2 Years|16 Years|No|||August 2012|August 10, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223964||190120|
NCT00224263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA702B02|Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI||Xuanwu Hospital, Beijing|Yes|Completed|September 2005|February 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|30 Years|80 Years|No|||August 2011|August 15, 2011|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00224263||190097|
NCT00249847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKCCC J0360|Study of PET Scans and Serotonin in Hot Flashes Treatment|A Feasibility Study of Positron Emission Tomography (PET) of the Serotonin Transporter (SERT) Before and After Treatment With Conjugated Equine Estrogen or Paroxetine for Hot Flashes||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|October 2005|April 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|N/A|No|||October 2014|October 1, 2014|November 4, 2005|Yes|Yes|Unable to complete accrual; elected to close the study in April 2008.|No||https://clinicaltrials.gov/show/NCT00249847||188189|
NCT00250978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-089|Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC|Phase I of Bevacizumab Plus Chemotherapy in Patients With Malignant Pleural Effusion Due to Advanced Non-Small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|November 2005|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2008|April 29, 2008|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250978||188103|
NCT00251251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRN 63208|Resynchronization/Defibrillation for Ambulatory Heart Failure Trial|Resynchronization/Defibrillation for Ambulatory Heart Failure Trial|RAFT|Ottawa Heart Institute Research Corporation|Yes|Completed|April 2003|May 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1798|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251251||188082|
NCT00250744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 3204C|Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting|Comparison of Aprepitant vs. Gabapentin in the Prevention of Delayed Nausea and Vomiting||New Mexico Cancer Care Alliance|Yes|Completed|December 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||December 2009|September 23, 2011|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250744||188121|
NCT00251771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2005.650|Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis|Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial|CaVenT|Oslo University Hospital|Yes|Completed|January 2006|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|209|||Both|18 Years|75 Years|No|||November 2014|April 29, 2015|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00251771||188043|
NCT00251784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 98/297|Healthy Volunteer Study of Sildenafil Effects Upon Vision|A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil||University of Cambridge||Completed|February 2002|June 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training|||||||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2003|November 9, 2005|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251784||188042|
NCT00251485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-03-002|A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer|A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer||Veeda Oncology|No|Completed|March 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251485||188064|
NCT00251745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-GD04-082|Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn|A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)||Takeda|No|Completed|December 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|908|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|November 8, 2005|Yes|Yes||No|February 26, 2009|https://clinicaltrials.gov/show/NCT00251745||188045|
NCT00252057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU18HS015905-01|Testing the Re-Engineered Hospital Discharge|Testing the Re-Engineered Hospital Discharge||Boston University|No|Completed|December 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|749|||Both|18 Years|N/A|No|||April 2009|January 14, 2016|November 10, 2005||No||No|February 10, 2009|https://clinicaltrials.gov/show/NCT00252057||188021|
NCT00252850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERE-120-01|Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease|A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease||Ceregene|Yes|Completed|June 2005|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|35 Years|75 Years|No|||March 2009|March 25, 2009|November 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00252850||187961|
NCT00252330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5116|Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder|An Eight-Week, Double-Blind, Placebo Controlled, Multicenter Study With Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With MDD|PHOENIX|Sanofi||Completed|September 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|476|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|November 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00252330||188001|
NCT00222690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505178|Living With Fibromyalgia: Triggers,Subgroups, and a Cognitive-Behavioral and Interactive Technology-Based Intervention|Living With Fibromyalgia (FM): Triggers,Clinical Subgroups, and the Effects Of A Self-Monitored Cognitive-Behavioral and Interactive Technology-Based Intervention on Clinical Subgroups||University of Pittsburgh||Completed|June 2005|June 2006||||N/A|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional||||30|||Female|18 Years|N/A|No|||September 2005|May 26, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00222690||190216|
NCT00223223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112004-003|Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study|Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study||University of Texas Southwestern Medical Center||Completed|February 2005|November 2005||November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|65 Years|No|||September 2005|August 2, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223223||190175|
NCT00224003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRO2001|Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients|Open-Label, Multi-Center Study of the Safety and Efficacy of Ferrlecit® in the Maintenance of Iron Stores in Pediatric Hemodialysis Patients Receiving Epoetin||Watson Pharmaceuticals|No|Completed|April 2003|February 2005|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|2 Years|16 Years|No|||August 2009|August 18, 2009|September 13, 2005|Yes|Yes||No|August 18, 2009|https://clinicaltrials.gov/show/NCT00224003||190117|
NCT00224016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O03010|Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition|A Multi-Center, Open-Label (OL), Active-Controlled, Dose-Titration Study Evaluating the Safety, Efficacy and PK of Oxybutynin Transdermal Systems in the Treatment of Detrusor Overactivity in Pediatric Patients||Watson Pharmaceuticals|No|Completed|December 2004|September 2008|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|6 Years|15 Years|No|||February 2012|February 7, 2012|September 13, 2005|No|Yes||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00224016||190116|The transdermal groups included more males and younger subjects. The study was not designed to compare the transdermal and oral groups. Advserse event data reported for the titration and maintenance periods.
NCT00223730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990675|Chemotherapy Toxicity Reduction Via Urea Cycle Support|Chemotherapy Toxicity Reduction Via Urea Cycle Support||Vanderbilt University|Yes|Completed|October 2001|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|13 Years|65 Years|No|||December 2015|December 8, 2015|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00223730||190137|
NCT00223977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR03001|2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.|A Multi-center, Randomized, Open Label Study of the Efficacy and Safety of Two Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peroneal Dialysis Patients Receiving Erythropoietin.||Watson Pharmaceuticals|No|Completed|December 2003|February 2008|Actual|November 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|146|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|September 13, 2005|No|Yes||No|August 19, 2009|https://clinicaltrials.gov/show/NCT00223977||190119|Primary endpoint for the 250 mg dose was 4 weeks earlier than the endpoint for the 125 mg dose, which may have contributed to lower Hbg increase with the 250 mg dose at endpoint.
NCT00223990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1123|Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine|A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine||U.S. Army Medical Research and Materiel Command||Completed|March 2005|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Both|12 Months|47 Months|Accepts Healthy Volunteers|||February 2013|February 1, 2013|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223990||190118|
NCT00249587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13169-1|Medication Adherence Therapy for Opioid Abusing Pain Patients|Medication Adherence Therapy for Opioid Abusing Pain Patients||National Institute on Drug Abuse (NIDA)|No|Completed|September 2000|September 2005|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||September 2008|September 19, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249587||188209|
NCT00251264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15740|Arthroscopic Versus Open Stabilization for Traumatic Shoulder Instability|Arthroscopic Versus Open Stabilization of Traumatic Unidirectional Anterior Shoulder Instability: A Randomized Clinical Trial||University of Calgary|No|Completed|November 2001|December 2013|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|14 Years|N/A|No|||July 2015|July 9, 2015|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251264||188081|
NCT00251498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-04-002|Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer||Veeda Oncology||Completed||October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A||||August 2008|August 20, 2008|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251498||188063|
NCT00251511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-04-001|A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome|A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome||Veeda Oncology|No|Terminated|August 2004|May 2007|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|90 Years|No|||May 2012|May 9, 2012|November 8, 2005||No|Sponsor terminated trial|No||https://clinicaltrials.gov/show/NCT00251511||188062|
NCT00252395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S&W e-RX|Evaluation of Electronic Prescribing in Hospital Ambulatory Care Clinics|Effects of Electronic Prescribing on Safety and Quality in Hospital-Based Ambulatory Are: a Randomised Controlled Trial||Sunnybrook Health Sciences Centre||Completed|August 2005|August 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|November 9, 2005|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252395||187996|
NCT00252083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-U65/CCU623833|ADAPT-POL: Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques|Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques With Popular Opinion Leader (ADAPT-POL)||Centers for Disease Control and Prevention|Yes|Completed|July 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|41|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 4, 2012|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00252083||188019|
NCT00252096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3881|Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections|Nucleic Acid Amplification Tests for the Diagnosis of Pharyngeal and Rectal Chlamydia Trachomatis and Neisseria Gonorrhoeae Infections||Centers for Disease Control and Prevention|No|Completed|June 2003|June 2010|Actual|January 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|3900|||Both|16 Years|N/A|No|||September 2012|September 26, 2012|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00252096||188018|
NCT00252343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5892|Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder|An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Escitalopram (10mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder|LIBRA|Sanofi||Completed|September 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|360|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|November 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00252343||188000|
NCT00252590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-003-05S|Health Focused Motivational Treatment for Alcohol Dependent Veterans|Health Focused Motivational Treatment for Alcohol Dependent Veterans||VA Office of Research and Development|Yes|Completed|November 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|99|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|November 9, 2005||No||No|June 25, 2015|https://clinicaltrials.gov/show/NCT00252590||187981|
NCT00252603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4682|Galantamine Versus Placebo in Childhood Autism|Galantamine Versus Placebo in Childhood Autism||Rutgers, The State University of New Jersey||Completed|April 2004|April 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|5 Years|17 Years|No|||January 2007|January 25, 2007|November 9, 2005||||||https://clinicaltrials.gov/show/NCT00252603||187980|
NCT00252863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00011|DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults|A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study||AstraZeneca||Completed|December 2004|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1600|||Both|18 Years|N/A|No|||March 2009|March 16, 2009|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00252863||187960|
NCT00253123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006022|A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia|A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia||Janssen, LP||Completed||March 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|626|||Both|55 Years|N/A|No|||December 2010|December 2, 2010|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253123||187940|
NCT00222950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plant Sterols 159/04|Concentration of Plant Sterols in Serum and Aortic Valve Cusps|Concentrations of Plant Sterols in Serum and Aortic Valve Cusps: a Prospectiv Observational Study||University Hospital, Saarland||Recruiting|September 2003|September 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|N/A|N/A|No|||September 2005|September 14, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00222950||190196|
NCT00222976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-REB 05-96|Oral vs Rectal Admin of Naproxen for Post-Vag Perineal Pain Control|Oral vs Rectal Administration of Naproxen for Post-Vaginal Perineal Pain Control: A Randomized Clinical Trial||University of Saskatchewan|No|Completed|September 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2007|November 13, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00222976||190194|
NCT00222989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#026020|PPI Versus Placebo in Severe Functional Heartburn|PPI Versus Placebo in Severe Functional Heartburn||University of Southern California||Recruiting|October 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2006|September 13, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00222989||190193|
NCT00223002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC# 03-1315|Chlorhexidine Versus Povidone-Iodine for Prevention of Epidural Needle Contamination in the Parturient|Chlorhexidine Versus Povidone-Iodine for Prevention of Epidural Needle Contamination in the Parturient||University of Saskatchewan|No|Completed|November 2004|January 2008|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 12, 2009|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00223002||190192|
NCT00222924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021165|Mitochondrial Impairment in Muscle Insulin Resistance|Mitochondrial Impairment in Muscle Insulin Resistance||University of Pittsburgh||Completed|December 2003|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||49|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 14, 2007|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00222924||190198|
NCT00222937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0304044|Voice Therapy for Teachers With Voice Problems|Efficacy of Voice Therapy for Phonotrauma in Teachers||University of Pittsburgh|Yes|Completed|October 2005|August 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|105|||Both|21 Years|N/A|No|||January 2016|January 21, 2016|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00222937||190197|
NCT00223236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03T-439|Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence|A Double-blind, Placebo-controlled Trial of Citicoline add-on Therapy in Patients With a History of Mania or Hypomania and Cocaine Abuse/Dependence||University of Texas Southwestern Medical Center|No|Completed|July 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||August 2014|August 7, 2014|September 15, 2005||No||No|July 8, 2013|https://clinicaltrials.gov/show/NCT00223236||190174|Low retention rate in the end of study (12 weeks) leading to a potential underestimation of treatment effectiveness.
NCT00223756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3457-R|VA Low Vision Intervention Trial|VA Low Vision Intervention Trial|LOVIT|VA Office of Research and Development|Yes|Completed|November 2004|August 2007|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|61|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223756||190135|
NCT00224289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27390|Effect of Age on Latanoprost 0.005% in Patients With Glaucoma|Effect of Age on Efficacy and Response Time of Latanoprost 0.005% in Patients With Glaucoma||Yale University|No|Completed|March 2005|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 9, 2012|September 16, 2005|Yes|Yes||No|November 9, 2012|https://clinicaltrials.gov/show/NCT00224289||190095|
NCT00224302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duloxetine-Zink|Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine|Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine||Central Institute of Mental Health, Mannheim||Completed|August 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|65 Years|No|||September 2005|June 3, 2008|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00224302||190094|
NCT00250159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060011|Natural History Study of Patients With Excess Androgen|Natural History Study of Patients With Excess Androgen||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|October 2005|||||N/A|Observational|Time Perspective: Prospective|||Actual|676|||Both|N/A|80 Years|No|||November 2015|November 19, 2015|November 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00250159||188166|
NCT00251550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5249|Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma|Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma||Eli Lilly and Company||Completed|October 2005|August 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|20 Years|75 Years|No|||November 2007|November 5, 2007|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251550||188059|
NCT00251797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2799C|A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors|A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors.||University of New Mexico|Yes|Completed|March 2000|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2008|January 6, 2010|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251797||188041|
NCT00251524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-04-015|A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC|A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC||Veeda Oncology|No|Completed|November 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|November 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251524||188061|
NCT00251810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMtrial|Can CSM Monitor Depth of Anaesthesia Just as Good as BIS?|Can CSM Monitor Depth of Anaesthesia Just as Good as BIS?||Oslo University Hospital|No|Active, not recruiting|November 2004|||||N/A|Observational|Time Perspective: Prospective||1|Actual|60|||Both|18 Years|70 Years|No|Probability Sample|60 patients undergoing general anaesthesia|August 2011|August 15, 2011|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00251810||188040|
NCT00252122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-6-3708|Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease|A Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease||Children's Hospital of Philadelphia|No|Terminated|June 2004|January 2007|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|7 Years|18 Years|No|||March 2009|March 12, 2009|November 9, 2005||No|Recruitment was very slow.|No||https://clinicaltrials.gov/show/NCT00252122||188016|
NCT00252655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122102M1F|Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients|Use of Sirolimus Vs. Tacrolimus As The Primary Agent In Immunosuppressive Regimen For African-American Renal Allograft Recipients With Immediate Graft Function: A Pilot Study||Wayne State University||Active, not recruiting|January 2004|June 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2007|April 18, 2007|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252655||187976|
NCT00252616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020744|Timing of Target Enteral Feeding in the Mechanically Ventilated Patient|Phase III Study of Early vs. Delayed Goal Enteral Nutrition in Mechanically Ventilated Patients||Vanderbilt University|Yes|Completed|September 2003|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|13 Years|N/A|No|||December 2013|December 16, 2013|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00252616||187979|
NCT00252629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCD-001-05S|Sleep Disordered Breathing in Gulf War Illness and the Effect of Nasal CPAP Treatment|Inspiratory Flow Dynamics During Sleep in Gulf War Syndrome (GWS) and the Effect of Continuous Positive Airway Pressure (CPAP)||VA Office of Research and Development|Yes|Completed|November 2005|November 2010|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Male|32 Years|52 Years|No|||December 2014|December 10, 2014|November 9, 2005||No||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00252629||187978|
NCT00252876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00038|GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes|An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus.||AstraZeneca||Terminated|March 2005|January 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Both|18 Years|N/A|No|||March 2008|March 14, 2008|November 10, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00252876||187959|
NCT00252889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24062|Doxil Topotecan Doublet Cancer Study|GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in Patients With Advanced Solid Tumors||Christiana Care Health Services|Yes|Completed|May 2004|June 2008|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2009|January 26, 2009|November 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00252889||187958|
NCT00253136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006055|A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia|Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia||Janssen, LP||Completed|November 1999|December 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|458|||Both|18 Years|55 Years|No|||December 2010|December 2, 2010|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253136||187939|
NCT00253357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226|PROSPECT: Predictors of Response to Cardiac Re-Synchronization Therapy|Predictors of Response to Cardiac Re-Synchronization Therapy||Medtronic Cardiac Rhythm Disease Management||Completed|March 2004|June 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||450|||Both|18 Years|N/A|No|||December 2007|December 17, 2007|November 13, 2005||||No||https://clinicaltrials.gov/show/NCT00253357||187922|
NCT00222716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01NR004749|Managing Medications|Improving Adherence to Antiretroviral Therapy||University of Pittsburgh|Yes|Active, not recruiting|January 2004|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00222716||190214|
NCT00222729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-002|Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer|Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer||University of Pittsburgh|Yes|Completed|November 2005|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 16, 2005|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT00222729||190213|
NCT00223496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0340013419|12- Week Open Label Treatment of Refractory Bipolar Depression|12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP)||The University of Texas Health Science Center at San Antonio|Yes|Completed|September 2004|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|No|||April 2013|April 9, 2013|September 14, 2005|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00223496||190155|
NCT00223743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0030|A Safety/Efficacy Trial of Zonisamide for Essential Tremor|Novel Therapies for Essential Tremor - Zonisamide Pilot Study||VA Greater Los Angeles Healthcare System||Completed|November 2004|||September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|September 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223743||190136|
NCT00224042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER0201|Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents|A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy||Watson Pharmaceuticals||Completed|April 2003|||May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|September 13, 2005|Yes|Yes||No|December 23, 2009|https://clinicaltrials.gov/show/NCT00224042||190114|
NCT00224055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER0202|Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients|A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease||Watson Pharmaceuticals|No|Completed|April 2003|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|September 13, 2005|Yes|Yes||No|February 29, 2012|https://clinicaltrials.gov/show/NCT00224055||190113|
NCT00224029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXY0401|A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition|A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury||Watson Pharmaceuticals|No|Completed|December 2004|May 2008|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2010|April 7, 2010|September 13, 2005|Yes|Yes||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00224029||190115|
NCT00224601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040423|CHROENDOHNPCC: Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer Syndrome|Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndrome: Assessment of Coloscopy With Chromoscopy Benefit||Assistance Publique - Hôpitaux de Paris|No|Completed|July 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|25 Years|75 Years|No|||July 2007|February 17, 2011|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00224601||190071|
NCT00224861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318|Hypertension Telemanagement in African Americans|Hypertension Telemanagement in African Americans||Johns Hopkins University||Completed|September 2004|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2013|March 21, 2013|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224861||190051|
NCT00250471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-046|PROTECT-TIMI 30 Trial|A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents||Millennium Pharmaceuticals, Inc.||Completed|May 2003|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||900|||Both|18 Years|80 Years|No|||November 2005|November 7, 2005|November 7, 2005||||||https://clinicaltrials.gov/show/NCT00250471||188142|
NCT00250484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000259 DK71851|TMS Treatment for Pain in Chronic Pancreatitis|The Effect of 10-Day Treatment of Repetitive Transcranial Magnetic Stimulation on Abdominal Pain in Patients With Chronic Pancreatitis||Beth Israel Deaconess Medical Center|Yes|Completed|November 2004|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||March 2015|March 13, 2015|November 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250484||188141|
NCT00250757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2904C|Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions|Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions||New Mexico Cancer Care Alliance|Yes|Terminated|October 2005|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|101|Samples Without DNA|Semen samples or Prostatic secretions (via prostate massage).|Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males with and without Prostate cancer.|January 2016|January 6, 2016|November 4, 2005||No|Study was not renewed timely with IRB of record.|No||https://clinicaltrials.gov/show/NCT00250757||188120|
NCT00251823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO4319|Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)|The Safety and Efficacy of Eptifibatide-Facilitated Percutaneous Coronary Angioplasty Versus Primary Percutaneous Coronary Angioplasty Alone||Ottawa Heart Institute Research Corporation||Completed|July 2005|September 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|N/A|N/A|No|||September 2008|September 3, 2008|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251823||188039|
NCT00252109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-U65/CCU623818|ADAPT-POL New Orleans: Adaptation of Prevention Techniques With Popular Opinion Leader|New Orleans AIDS Task Force Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT) With Popular Opinion Leader (POL)||Centers for Disease Control and Prevention|Yes|Completed|July 2004|January 2009|Actual|September 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|27|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men who have sex with men (MSM) of color who access Websites and chat rooms primarily        frequented by MSM in the New Orleans, LA area.|August 2012|August 15, 2012|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00252109||188017|
NCT00252421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-169|The Nitrate and Bone Study: Effects of Nitrates on Osteoporosis|The Effects of Organic Nitrates on Osteoporosis: Part 2||University of Toronto|Yes|Completed|October 2005|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|243|||Female|50 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 20, 2014|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00252421||187994|
NCT00252408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1990/1821|Danish Osteoporosis Prevention Study|Danish Osteoporosis Prevention Study||University of Aarhus||Completed|October 1990|December 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||2000|||Female|45 Years|58 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00252408||187995|
NCT00252369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3762-OZ-CTIL|Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.|Instillation of Fibrin Glue After Induction of Local Conditions Using Infliximab, in the Treatment of Perianal Crohn's Disease.||Sheba Medical Center|No|Terminated||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|90 Years|No|||April 2009|April 23, 2009|November 10, 2005||No|Low accrual rate|No||https://clinicaltrials.gov/show/NCT00252369||187998|
NCT00252382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0005|Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC|Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of the Intravenous Administration of SNS-595 as Second-Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Sunesis Pharmaceuticals||Completed|November 2005|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||January 2007|May 9, 2007|November 9, 2005||||||https://clinicaltrials.gov/show/NCT00252382||187997|
NCT00252928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4730|Health Impact Study of Aquatabs in Tamale, Ghana|Health Impact Study of a Water Treatment Tablet, Aquatabs, in Tamale, Ghana||Centers for Disease Control and Prevention||Completed|July 2006|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|240|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2007|October 29, 2007|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00252928||187955|
NCT00252642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-VCU-05|Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C|The Impact of Peginterferon Alpha-2a Maintenance Therapy on Portal Hypertension in Patients With Chronic Hepatitis C Virus Infection and Advanced Fibrosis and Cirrhosis Enrolled in the HALT-C Trial||Virginia Commonwealth University|Yes|Completed|November 2005|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||August 2006|December 14, 2007|November 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00252642||187977|
NCT00252902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-16698-01|Emergency Department Initiated Tobacco Treatment (EDITT)|Emergency Department Initiated Tobacco Treatment (EDITT)||National Institute on Drug Abuse (NIDA)||Completed|December 2005|December 2007|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|75|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00252902||187957|
NCT00252915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-CSF-1|Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock|Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock: a Prospective, Randomised, Double-blind, Placebo-controlled Study||Charite University, Berlin, Germany|No|Completed|November 2005|April 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||July 2009|May 24, 2011|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00252915||187956|
NCT00253149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006040|A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder|The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||April 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|158|||Both|18 Years|65 Years|No|||January 2011|January 20, 2011|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253149||187938|
NCT00222742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01-NS052478-01|Hypothermia in Children After Trauma|Pediatric Traumatic Brain Injury Consortium: Hypothermia||Phoenix Children's Hospital|Yes|Terminated|November 2007|March 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|90|||Both|N/A|17 Years|No|||July 2012|July 10, 2012|September 16, 2005||No|Futility|No||https://clinicaltrials.gov/show/NCT00222742||190212|
NCT00222755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02394|Improving Care for Patients With Bipolar Disorder|Improving Care for Veterans With Bipolar Disorder|CIVIC-2|University of Michigan|No|Completed|January 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 3, 2008|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00222755||190211|
NCT00223782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3117R|Motor Learning in Gait in Subjects With Diabetic Peripheral Neuropathy|Motor Learning in Gait in Subjects With Diabetic Peripheral Neuropathy||VA Office of Research and Development||Completed|May 2004|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|50 Years|80 Years|No|||March 2008|March 21, 2008|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223782||190133|
NCT00223795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F3873-R|Walking Aids in the Management of Knee Osteoarthritis|Walking Aids in the Management of Obesity-Related Knee Osteoarthritis||VA Office of Research and Development|No|Completed|July 2006|October 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|45 Years|85 Years|No|||May 2014|May 5, 2014|September 13, 2005|No|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00223795||190132|Had high drop out rate leading to small numbers of subjects analyzed.
NCT00223262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMC-R62|Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients|||University of Texas Southwestern Medical Center||Completed|August 2002|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|65 Years||||January 2010|August 2, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00223262||190172|
NCT00223509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0340013418|Lamictal As Add on Treatment in Mixed States of Bipolar Disorder|Lamictal As Add on Treatment in Mixed States of Bipolar Disorder||The University of Texas Health Science Center at San Antonio|Yes|Completed|August 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|13 Years|75 Years|No|||June 2012|June 19, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00223509||190154|
NCT00224068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR01008|Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy|A Multicenter, Randomized, Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit® in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment||Watson Pharmaceuticals|No|Completed|May 2002|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00224068||190112|
NCT00224081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER0401|DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)|Dialysis Patients' Response to IV Iron With Elevated Ferritin|DRIVE|Watson Pharmaceuticals||Completed|September 2004|||May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00224081||190111|
NCT00224094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO0102|A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women|A Comparison of Transdermal vs. Oral Estrogen Replacement Therapy on Androgen Levels and Thyroid Function in Naturally Menopausal Women||Watson Pharmaceuticals||Completed|January 2002|||May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|42 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00224094||190110|
NCT00224315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZR-zink|Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial|Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial||Central Institute of Mental Health, Mannheim||Completed|November 2003|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|70 Years|No|||June 2008|June 2, 2008|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00224315||190093|
NCT00224588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P990911|KETOR: Effects of Peri Operative Administration of Ketamine on Long Term Post Thoracotomy Pain|Effects of Peri Operative Administration of Ketamine on Long Term Post Thoracotomy Pain||Assistance Publique - Hôpitaux de Paris||Completed|January 2003|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|80 Years|N/A|No|||September 2005|April 12, 2006|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00224588||190072|
NCT00249899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-475-021|Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat or Placebo When Co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia||Takeda|No|Terminated|November 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|649|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|November 4, 2005|Yes|Yes|Overall profile of the compound does not offer significant clinical advantage to patients over    currently available lipid lowering agents|No||https://clinicaltrials.gov/show/NCT00249899||188185|
NCT00250991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS044283|Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial|Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial||University of Cincinnati|Yes|Completed|July 2003|July 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|94|||Both|18 Years|80 Years|No|||May 2009|May 7, 2009|November 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250991||188102|
NCT00251576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0733-180|Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)|A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction With Aspirin||Merck Sharp & Dohme Corp.||Completed|November 1999|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|4497|||Both|18 Years|80 Years|No|||February 2015|February 2, 2015|November 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251576||188057|
NCT00251836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 34-2005|Adrenal Function After Living Kidney Donation|Prospective Evaluation of Adrenal Function After Living Donor Nephrectomy With or Without Ligation of the Adrenal Vein||University of Zurich||Recruiting|December 2005|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||30|||Both|18 Years|80 Years|No|||April 2007|April 17, 2007|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251836||188038|
NCT00251849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-1648-022|PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients|Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients||ActivBiotics||Active, not recruiting|November 2005|December 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||274|||Both|40 Years|80 Years|No|||October 2006|August 20, 2008|November 9, 2005||||||https://clinicaltrials.gov/show/NCT00251849||188037|
NCT00245414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18501|Trial of Pegasys® in Patients With Chronic Hepatitis C|Post-marketing Clinical Trial of Pegasys® 180μg for Subcutaneous Injection in Patients With Chronic Hepatitis C. General Clinical Study in Interferon (IFN)-Treated and IFN-untreated Chronic Hepatitis C Patients, Except for Those Infected With High Viral Load of Genotype 1b||Chugai Pharmaceutical|No|Completed|October 2005|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|108|||Both|20 Years|N/A|No|||November 2010|November 16, 2010|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00245414||188519|
NCT00252681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HD38462|Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants|Surgery for Necrotizing Enterocolitis in Human Infants: A Randomized Trial||Yale University||Completed|July 1999|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|N/A|3 Months|No|||November 2005|July 20, 2006|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252681||187974|
NCT00252941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8488|Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma|The Role Of Prophylactic Urethral Stenting With Memokath® 028SW in Patients Undergoing Prostate 125I Seed Implants For Prostate Carcinoma: A Phase I/II Study||The Cleveland Clinic||Completed|November 2005|November 2006|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Male|50 Years|N/A|No|||December 2010|December 20, 2010|November 14, 2005||||||https://clinicaltrials.gov/show/NCT00252941||187954|
NCT00252668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-101631|Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects|An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2004|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||May 2011|May 17, 2011|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252668||187975|
NCT00253162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006049|A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol|The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2001|September 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|439|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00253162||187937|
NCT00253383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000452966|Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients|Improving Palliative Care for Patients With Cancer||Dartmouth-Hitchcock Medical Center|Yes|Completed|January 2003|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|329|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|November 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00253383||187920|
NCT00249457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13107-2|Employment-Based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2|A Therapeutic Workplace for Drug Abusers||National Institute on Drug Abuse (NIDA)||Active, not recruiting|October 1996|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|50 Years|No|||November 2005|November 3, 2005|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249457||188219|
NCT00234273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 09|APAD2: Effects of Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics|Effects Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics Persons||University Hospital, Grenoble|No|Terminated|November 2004|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|10|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 18, 2013|October 5, 2005||No|recrutment|No||https://clinicaltrials.gov/show/NCT00234273||189355|
NCT00234637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BFR05|Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment|An Open-label Study to Evaluate the Efficacy and Safety of add-on Memantine [5-10 mg b.i.d (10-20 mg/Day)] to Rivastigmine [1.5-6 mg b.i.d. (3-12 mg/Day)] Treatment in Patients With Alzheimer's Disease Who Continued With Rivastigmine Treatment After a Previous Decline While on Donepezil or Galantamine Treatment||Novartis||Completed|November 2003|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|204|||Both|50 Years|N/A|No|||November 2011|November 16, 2011|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00234637||189329|
NCT00223522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-0013-002|Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?|Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?||The University of Texas Health Science Center at San Antonio||Completed|April 2004|March 2005||||N/A|Observational|Allocation: Random Sample, Time Perspective: Longitudinal||||50|||Both|18 Years|55 Years|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223522||190153|
NCT00223769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2656C|The Use of Anabolic Steroids to Improve Function After Spinal Cord Injury|The Use of Oxandrolone to Improve Function in Persons With Chronic Spinal Cord Injury||VA Office of Research and Development||Completed|January 2004|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|20 Years|70 Years|No|||May 2006|February 12, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00223769||190134|
NCT00235547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11779-2703-01|Trial of Immediate Versus Delayed Initiation of Transdermal Hormonal Contraception After Therapeutic Abortion|Immediate Versus Delayed Initiation of Transdermal Hormonal Contraception After Therapeutic Abortion: A Randomized Trial||University of California, San Francisco|No|Completed|August 2005|December 2012|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Female|13 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235547||189260|
NCT00224328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIO-UHN-001|Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia|Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia: A Phase Iia, Non-Randomized Study Using the ODISsey Tissue Oximeter to Evaluate the Correlation Between Tissue Oxygen Saturation and Symptom Resolution in Patients With Chronic Critical Limb Ischemia Undergoing Treatment Interventions||ViOptix Canada||Terminated|August 2005|January 2007|Actual|||Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|100|||Both|18 Years|N/A|No|||September 2007|September 11, 2007|September 13, 2005|||The results were not able to be consistantly reproduced. Thus the trial was terminated|No||https://clinicaltrials.gov/show/NCT00224328||190092|
NCT00250497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63107 (completed)|New Moves - Obesity Prevention Among Adolescent Girls|New Moves: Obesity Prevention Among Adolescent Girls||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|356|||Female|14 Years|19 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|November 7, 2005||No||No|July 12, 2012|https://clinicaltrials.gov/show/NCT00250497||188140|Control group also had all-girls PE. Some girls missing body composition data.
NCT00251277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0409007463|Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura|Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura||Weill Medical College of Cornell University|No|Withdrawn|November 2005|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|17 Years|N/A|No|||November 2012|November 14, 2012|November 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251277||188080|
NCT00251537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTB4 200501|A Pilot Study of LTB4 in HIV-1 Infected Adults|A Pilot Study Assessing Safety and Antiretroviral Activity of Intravenously Administered LTB4 in HIV-1 Infected Adults With a CD4 Count Greater Than 250 Cells/mm3 and a Viral Load Greater Than 5,000 Copies/mL, and Who Have Not Received Antiretroviral Therapy Within Two Months||LTB4 Sweden AB||Completed|November 2005|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||July 2006|July 7, 2006|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251537||188060|
NCT00251862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HS013912-05|Shared Decision-Making for Colorectal Cancer Screening|Shared Decision-Making for Colorectal Cancer Screening||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|January 2005|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Actual|825|||Both|50 Years|75 Years|No|||September 2013|December 2, 2013|November 9, 2005||No||No|July 23, 2013|https://clinicaltrials.gov/show/NCT00251862||188036|
NCT00252135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q2948g|A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma|An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)||Genentech, Inc.||Completed|June 2004|||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8023|||Both|12 Years|N/A|No|Non-Probability Sample|Patients will be recruited from a variety of practice settings, including managed care        organizations, community physicians, and academic centers.|November 2011|November 23, 2011|November 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00252135||188015|
NCT00245427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A-6012|Outcomes of Patients Not Responding to Antibiotics in the Community|Outcomes of Patients Not Responding to Outpatient Macrolide or b-Lactam Therapy for the Treatment of Community Acquired Pneumonia: Expansion to Include Acute Exacerbations of Chronic Bronchitis and Acute Sinusitis||CPL Associates||Completed|December 2005|March 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|200|||Both|N/A|95 Years|No|||October 2007|October 29, 2007|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245427||188518|
NCT00245440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A-6045|Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis|Influence of Oral Telithromycin vs. Azithromycin on the Endogenous Microflora in Adults With Acute Sinusitis||CPL Associates||Terminated|December 2005|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|192|||Both|18 Years|75 Years|No|||October 2007|October 29, 2007|October 26, 2005|||Sponsor Terminated|No||https://clinicaltrials.gov/show/NCT00245440||188517|
NCT00245752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040001|Can Acupuncture be Used as Preparation for Induction of Labour|Randomised Study of the Effect of Acupuncture as Induction of Labour||Aarhus University Hospital Skejby|No|Completed|November 2005|December 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 4, 2009|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00245752||188493|
NCT00252954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEV-2005|Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury|Effects of Levetiracetam on Chronic Neuropathic Pain Following Spinal Cord Injury: a Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study||Danish Pain Research Center|Yes|Completed|November 2005|December 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||August 2009|August 19, 2009|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00252954||187953|
NCT00253175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005572|A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine|A Comparison Of The Efficacy And Safety Of Topamax® (Topiramate) Tablets Versus Placebo For The Prophylaxis Of Migraine||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2000|December 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|211|||Both|18 Years|65 Years|No|||April 2010|April 26, 2010|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253175||187936|
NCT00253396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2482|Patients Preference With Self-Injection: The PRISM Study|THE PRISM Study-Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Perioperative Bridging Anticoagulation: the Patient Preference for Self-Injection Study and Related Measurements||McMaster University|No|Completed|October 2005|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|March 9, 2009|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00253396||187919|
NCT00249717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18883-1|Group-Based Contingency Management for Substance Abuse Treatment - 1|Group-Based Contingency Management for Substance Abuse Treatment||University of Connecticut Health Center|No|Completed|May 2005|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|312|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249717||188199|
NCT00234988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THAI-03-002|A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.|Safety and Weight Reduction of Sibutramine in the Treatment of Thai Obese and Overweight Subjects||Abbott|No|Completed|June 2004|||January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|65 Years|No|||July 2008|July 11, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00234988||189302|
NCT00235001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUSS-04-01|Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension|A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension||Abbott|No|Completed|June 2004|||November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|75 Years|No|||July 2008|July 9, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00235001||189301|
NCT00235014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VeraTran 083|A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)|A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)|BENEDICT|Abbott|No|Completed|March 1997|||January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1204|||Both|40 Years|N/A|No|||June 2008|July 11, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00235014||189300|
NCT00235287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAS-block study|Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease|Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study||Herlev Hospital|Yes|Recruiting|September 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|75 Years|No|||January 2009|January 16, 2009|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235287||189279|
NCT00235300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-101-1010|An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.|An Open-Label Prospective, Randomized, Multicenter Phase II Comparative Trial of Thymoglobulin® Versus Simulect® for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients||Sanofi||Completed|May 2000|June 2005|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|October 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00235300||189278|
NCT00223288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHGP MM12|Impact of Caregiver Depression on Asthma in the Child|Caregiver Psychiatric Symptomatology and it's Relationship to Service Utilization by Children With Asthma||University of Texas Southwestern Medical Center||Completed|March 2003|February 2006|Actual|February 2006|Actual|Phase 4|Observational|N/A||1||175|||Both|18 Years|70 Years||Non-Probability Sample|Primary caregiver of a child currently hospitalized at Children's Medical Center of Dallas        for an asthma exacerbation and between the ages of 5 and 16 years old|August 2011|August 2, 2011|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00223288||190170|
NCT00223535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-0013-164|Cognitive Remediation and Social Skills Training in Schizophrenia|Cognitive Remediation and Social Skills Training in Schizophrenia||The University of Texas Health Science Center at San Antonio||Completed|February 2003|March 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|60 Years|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223535||190152|
NCT00231114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-02|Asthma Intervention Research 2 (AIR2) Trial|Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)||Asthmatx, Inc.|Yes|Completed|September 2005|April 2013|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|297|||Both|18 Years|65 Years|No|||March 2014|March 28, 2014|September 30, 2005|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00231114||189595|
NCT00231075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAG-2|Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV|National, Phase II Study Designed to Evaluate the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III and IV. FAG-2||ARCAGY/ GINECO GROUP||Completed|January 2001|May 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Female|70 Years|N/A|No|||September 2005|November 2, 2005|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231075||189597|
NCT00231101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH Protocol 03-08|Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia|Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia||Arthur P. Noyes Research Foundation||Recruiting|January 2004|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||40|||Both|18 Years|65 Years|No|||September 2005|October 16, 2006|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231101||189596|
NCT00251004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2309|Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients|Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients||Novartis||Completed|October 2005|October 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|833|||Both|18 Years|70 Years|No|||April 2011|April 7, 2011|November 7, 2005|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00251004||188101|
NCT00251017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701301|Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs|Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs||National Taiwan University Hospital|No|Completed|July 2005|June 2006|Actual|June 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|34|||Both|16 Years|N/A|No|||December 2012|December 25, 2012|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251017||188100|
NCT00251563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP036|Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Cancer.|||Nanjing Medical University||Recruiting|August 2005|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|18 Years|89 Years|Accepts Healthy Volunteers|||November 2005|October 12, 2006|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251563||188058|
NCT00251069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCTnr 2005-000541-11|Glucosamine Sulphate and Increased Level of Blood Cholesterol|Glucosamine Sulphate and Hypercholesterolaemia||Slidgigtinstituttet||Completed|April 2005|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|40 Years|N/A|Accepts Healthy Volunteers|||July 2005|November 7, 2005|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00251069||188096|
NCT00245167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1316|Possible Relation of Toll-Like Receptors and Nitric Oxide to Chronic Lung Disease|TLR's, Nitric Oxide and Chronic Lung Disease: Any Connections?||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 2002|May 2006|Actual|May 2006|Actual|N/A|Observational|N/A||||120|||Both|N/A|1 Year|No|||March 2008|March 3, 2008|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245167||188538|
NCT00246077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH 05 07-098E|Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport|Quality of Life of Children With Sickle Cell Disease Who Are Receiving Chronic Transfusion Therapy With a Lifeport Device||Children's Mercy Hospital Kansas City||Completed|October 2005|December 2005|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||||5|||Both|8 Years|18 Years|No|||November 2005|April 10, 2007|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00246077||188469|
NCT00246090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-211|A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine|A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease||Eisai Inc.||Completed|October 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|298|||Female|18 Years|N/A|No|||April 2012|June 30, 2014|October 27, 2005|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00246090||188468|
NCT00245765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87040|Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy|Multicenter, Dose Response, Randomized, Double Blind, Parallel, Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy||UCB Pharma||Completed|October 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|176|||Both|18 Years|N/A|No|||September 2009|September 6, 2013|October 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00245765||188492|
NCT00245778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-R-2003-INCA|fMRI Study of Grasping in Autistic Patients|fMRI Study of Grasping in Autistic Patients||University Hospital, Tours||Terminated|March 2004|February 2007|Actual|||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2007|May 25, 2007|October 26, 2005|||All the patients were included|No||https://clinicaltrials.gov/show/NCT00245778||188491|
NCT00252967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024771|Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)|Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)||Emory University|Yes|Terminated|October 2005|October 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|November 14, 2005|Yes|Yes|Insufficient power to show therapy difference at interim analysis.|No|April 21, 2014|https://clinicaltrials.gov/show/NCT00252967||187952|Limited enrollment; recurrence rate of AF was slightly higher than other trials indicated that the study sample may be a high-risk population.
NCT00253188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006031|A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease|Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 1997|December 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|653|||Both|18 Years|N/A|No|||November 2010|May 17, 2011|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00253188||187935|
NCT00249470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-12564-1|Employment-Based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction - 1|The Therapeutic Workplace Initiation Study||National Institute on Drug Abuse (NIDA)||Active, not recruiting|April 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||117|||Both|18 Years|N/A|No|||January 2008|January 22, 2008|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249470||188218|
NCT00246805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RARE-PEARL|Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study|Post Marketing Study on Heart Rate Regularization in Patients With Permanent Atrial Fibrillation|RARE-PEARL|Medtronic BRC|Yes|Completed|January 2006|March 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||March 2010|August 23, 2011|October 28, 2005||No||No|November 6, 2009|https://clinicaltrials.gov/show/NCT00246805||188414|
NCT00235326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-026; 05-346|Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario|Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario||McMaster University|No|Completed|January 2002|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4561|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|residents of walkerton|March 2009|March 16, 2009|October 6, 2005||No||No|February 5, 2009|https://clinicaltrials.gov/show/NCT00235326||189276|
NCT00231166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHCD122A2102|Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma|A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)||Novartis||Completed|September 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|100 Years|No|||November 2015|November 7, 2015|September 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00231166||189591|
NCT00224107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI04009|A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo|A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia||Watson Pharmaceuticals|No|Completed|May 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|461|||Male|50 Years|N/A|No|||July 2011|July 5, 2011|September 14, 2005|Yes|Yes||No|September 8, 2009|https://clinicaltrials.gov/show/NCT00224107||190109|
NCT00224120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI04010|A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo|A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia||Watson Pharmaceuticals|No|Completed|May 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|462|||Male|50 Years|N/A|No|||December 2009|December 11, 2009|September 14, 2005|Yes|Yes||No|September 8, 2009|https://clinicaltrials.gov/show/NCT00224120||190108|
NCT00224341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARREST-AF|Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation|||Vitatron France||Recruiting|November 2003|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||360|||Both|18 Years|N/A|No|||September 2005|October 17, 2006|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00224341||190091|
NCT00231647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002674|A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Topiramate OROS Controlled-Release in the Treatment of Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2004|October 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|113|||Both|18 Years|75 Years|No|||January 2011|June 6, 2011|September 30, 2005||||||https://clinicaltrials.gov/show/NCT00231647||189555|
NCT00231387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRL-049563/351|Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus|Rosiglitazone and Plaque Study: A 12 Month Randomised, Double-Blind, Placebo-Controlled, Magnetic Resonance Imaging Study to Evaluate the Effect of Rosiglitazone on the Structure and Composition of Carotid Atherosclerotic Plaques in Subjects With Type 2 Diabetes Mellitus and Coexisting Vascular Disease or Hypertension||GlaxoSmithKline||Completed|September 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|30 Years|75 Years|No|||June 2007|June 14, 2007|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231387||189575|
NCT00251290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ-GPFS-051081|Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack|Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack||Yale University||Completed|November 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|45 Years|N/A|No|||March 2009|March 2, 2009|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00251290||188079|
NCT00251303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050225|Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders|An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent||National Institutes of Health Clinical Center (CC)|No|Completed|August 2005|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|7 Years|17 Years|No|||July 2014|July 14, 2014|November 9, 2005|Yes|Yes||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00251303||188078|Only treatment-refractory subjects were eligible for study participation. This may have decreased treatment response. Further, 98% were taking psychotropic drugs at baseline, which may have reduced between-group differences.
NCT00251589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-025|A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)|A Phase I/II Clinical Trial of Oral Vorinostat (MK0683) in Combination With Erlotinib in Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer||Merck Sharp & Dohme Corp.|No|Terminated|January 2006|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|November 7, 2005|Yes|Yes|This trial is being closed based on lack of substantive efficacy, slow accrual and overall    tolerance in patients treated to date.|No|October 27, 2008|https://clinicaltrials.gov/show/NCT00251589||188056|Due to the slow pace of patient accrual, failure to observe meaningful efficacy in treated patients, and overall intolerance of the combination regimen, the study was terminated prematurely on 12-Oct-2007.
NCT00249210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005485|A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses|A Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With Amoxicillin/Clavulanate Potassium in the Treatment of Acute Sinusitis in Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 1993|July 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|614|||Both|18 Years|N/A|No|||February 2011|June 8, 2011|November 4, 2005||||||https://clinicaltrials.gov/show/NCT00249210||188238|
NCT00249223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006061|A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia|Risperidone Depot (Microspheres) vs. Risperidone Tablets - a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia||Janssen Pharmaceutica N.V., Belgium||Completed|January 2000|December 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|641|||Both|18 Years|65 Years|No|||January 2011|January 13, 2011|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249223||188237|
NCT00245180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239|Preventing American Indian Children From Becoming Overweight|Primordial Prevention of Overweight in American Indian Children||Kaiser Permanente|No|Completed|May 2006|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|577|||Both|15 Years|40 Years|Accepts Healthy Volunteers|||April 2006|March 10, 2014|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00245180||188537|
NCT00246103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13693|Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies|Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies||H. Lee Moffitt Cancer Center and Research Institute||Completed|March 2004|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|65|||Both|18 Years|N/A|No|||January 2009|November 21, 2013|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246103||188467|
NCT00246324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-090|Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis|An Open Label Trial of Safety and Efficacy of Combination Therapy With Interferon-B-1a and Oral Doxycycline in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)||Louisiana State University Health Sciences Center Shreveport|No|Completed|December 2003|October 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|October 27, 2005|Yes|Yes||No|May 5, 2011|https://clinicaltrials.gov/show/NCT00246324||188451|
NCT00246038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810-0001|The Boston Scientific ENOVUS Trial|A Phase II Evaluation of the Safety and Efficacy of the Boston Scientific ENOVUS AAA Endograft in the Treatment of Abdominal Aortic Aneurysms||Boston Scientific Corporation|No|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|October 27, 2005|||Sponsor cancelled the development program, and never conducted the study.|No||https://clinicaltrials.gov/show/NCT00246038||188472|
NCT00246051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL00067|Comprehensive Police Fatigue Management Program|Testing the Effectiveness of a Comprehensive Fatigue Management for the Police||Brigham and Women's Hospital||Completed|November 2005|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|683|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 13, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00246051||188471|
NCT00246272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005956|An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone|An Open-label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL® Tablets (Risperidone) to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone||Janssen-Ortho Inc., Canada||Completed|October 2004|May 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246272||188454|
NCT00246545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fase I|Effect Evaluation of Early Exercise Training After Myocardial Infarction|Effect Evaluation of Early Exercise Training After Myocardial Infarction||Norwegian University of Science and Technology|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|39|||Both|18 Years|90 Years|No|||August 2011|August 25, 2011|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00246545||188434|
NCT00246558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-02-011-OSi|Tight Achilles Tendon, Hyperpronation and Anterior Knee Pains|Is There a Connection Between a Tight Achilles Tendon, Hyperpronation of the Foot and Pain in the Anterior Part of the Knee||Northern Orthopaedic Division, Denmark||Withdrawn|November 2005|November 2005||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective|||Actual|0|||Both|16 Years|18 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|October 28, 2005||No|The study stopped due to unforeseen circumstances.|No||https://clinicaltrials.gov/show/NCT00246558||188433|
NCT00246571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181077|Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer|A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer||Pfizer|Yes|Completed|January 2006|June 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|No|||July 2012|July 2, 2012|October 27, 2005|Yes|Yes||No|May 31, 2011|https://clinicaltrials.gov/show/NCT00246571||188432|
NCT00231439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS1|Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)|Post-Polio Syndrome Treated With Intravenous Immunoglobulin (IvIg)||Haukeland University Hospital||Completed|August 2003|July 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|N/A|75 Months|Accepts Healthy Volunteers|||July 2003|December 12, 2005|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231439||189571|
NCT00235573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|433-2005|Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption|Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption||University of Florida|No|Completed|October 2005|November 2005|Actual|November 2005|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2011|December 15, 2011|October 6, 2005||No||No|September 30, 2011|https://clinicaltrials.gov/show/NCT00235573||189258|
NCT00235586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9248|Vitamin D Deficiency: Bone Loss and Vascular Dysfunction|Vitamin D Deficiency: Bone Loss and Vascular Dysfunction||University of Kansas Medical Center|No|Completed|April 2004|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|50 Years|90 Years|Accepts Healthy Volunteers|||September 2007|September 18, 2007|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235586||189257|
NCT00234975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUER-02-003|Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score|Evaluation of Clinical Response and Safety in HIV Positive Subjects Co-infected With Hepatitis C Treated With a Kaletra Containing HAART Regimen||AbbVie|No|Completed|October 2002|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00234975||189303|
NCT00235274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507-30|Effects of RG1068 (Secretin) on Information Processing in Schizophrenia|Effects of RG1068 (Secretin) on Information Processing in Schizophrenia||Indiana University||Completed|November 2005|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||July 2006|July 18, 2006|October 6, 2005||||||https://clinicaltrials.gov/show/NCT00235274||189280|
NCT00235560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402008|Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients|Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)|LAM-RAPA|University Hospital, Toulouse|No|Completed|June 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|60 Years|N/A|No|||June 2008|June 19, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00235560||189259|
NCT00231660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003718|A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Treated With Metformin||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2000|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|211|||Both|18 Years|75 Years|No|||January 2011|June 6, 2011|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231660||189554|
NCT00231907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-101|A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist|Influenza Vaccines: Mix and Match of Trivalent Inactivated Influenza (TIV) and Live Attenuated Influenza Vaccine (LAIV), a Phase I Safety, Immunogenicity, and Viral Shedding Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2005|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|56|||Both|12 Months|35 Months|Accepts Healthy Volunteers|||February 2010|August 26, 2010|September 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00231907||189535|
NCT00250809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVC|Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study|CVC Pros and Cons of Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study||University of New Mexico|Yes|Completed|March 1994|March 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||March 2009|January 6, 2010|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250809||188116|
NCT00250822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0521C|Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter|Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.||New Mexico Cancer Care Alliance|Yes|Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2011|September 23, 2011|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250822||188115|
NCT00251056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-CF-202|Mannitol Dose Response Study in Cystic Fibrosis|A Phase IIa Randomised, Open Label, Dose Response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement In Patients With Cystic Fibrosis||Pharmaxis|Yes|Completed|October 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|7 Years|N/A|No|||August 2008|August 27, 2008|June 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00251056||188097|
NCT00248950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (0103-660)|A Pilot Study: Changing Multiple Behaviors in Post-Angioplasty Patients|A Pilot Study: Changing Multiple Behaviors in Post-Angioplasty Patients||Weill Medical College of Cornell University|No|Completed|February 2004|June 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind||||40|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248950||188256|
NCT00249236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006064|A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder|The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2001|December 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|291|||Both|18 Years|N/A|No|||January 2011|January 13, 2011|November 4, 2005||||||https://clinicaltrials.gov/show/NCT00249236||188236|
NCT00249249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-301|Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels|Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia||Kowa Research Europe||Completed|October 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|830|||Both|18 Years|75 Years|No|||January 2010|January 7, 2010|November 4, 2005||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00249249||188235|
NCT00245791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-383|Urinary Tract Infection Study With the Antibiotic Levofloxacin Given at a Higher Dose Over a Shorter Period of Time|TREATMENT OF COMPLICATED URINARY INFECTION WITH FIVE DAY HIGH DOSE LEVOFLOXACIN||University of Manitoba||Terminated|October 2004|July 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2005|June 2, 2015|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00245791||188490|
NCT00245804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRR02/CH/DYS-AUT|Developmental Dyslexia and Functional Maturation of Auditory Cortex||DYS-AUT|University Hospital, Tours|Yes|Completed|March 2003|February 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4||60|||Both|8 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Patients with developmental reading disorders from 8 to 25 jears. Control groupes with        healthy people in de same age|January 2005|June 29, 2010|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00245804||188489|
NCT00246116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201-06|Functional Imaging of Treatment Effects: A Companion Protocol to a Study of Extracranial Stereotactic Radioablation in Early Stage Non-Small Cell Lung Cancer|Functional Imaging of Treatment Effects: A Companion Protocol to a Phase II Study of Extracranial Stereotactic Radioablation (a.k.a. Stereotactic Body Radiotherapy) in Early Stage Non-Small Cell Lung Cancer.|SBF Companion|Indiana University|Yes|Completed|February 2002|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00246116||188466|
NCT00246337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-004|A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)|A Multicenter, Double-Blind, Placebo and Active-Controlled, Dose-Finding Study of MK0974 in the Treatment of Acute Migraine||Merck Sharp & Dohme Corp.||Completed|November 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|420|||Both|20 Years|65 Years|No|||October 2015|October 30, 2015|October 27, 2005|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00246337||188450|
NCT00246064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003127|The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol|The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol. Tapering Methotrexate in Patients With Rheumatoid Arthritis Beginning Therapy With Infliximab||Centocor Ortho Biotech Services, L.L.C.||Completed|December 2001|November 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|210|||Both|18 Years|80 Years|No|||January 2011|May 18, 2011|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246064||188470|
NCT00246584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A1202|A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)|Long-Term Treatment, Multicenter, Open-Label Study With SPP100 in Patients With Essential Hypertension||Novartis||Completed|October 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|20 Years|80 Years|No|||July 2006|July 27, 2006|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00246584||188431|
NCT00246285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003364|A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia|The Efficacy And Safety Of Risperidone In The Treatment Of Adolescents With Schizophrenia: A Six-Month Open-Label Study.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2001|December 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|381|||Both|13 Years|17 Years|No|||March 2010|June 6, 2011|October 28, 2005||||||https://clinicaltrials.gov/show/NCT00246285||188453|
NCT00246298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003220|A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients|A Randomized, Open-Label Study Assessing the Efficacy of Initiating PROCRIT (Epoetin Alfa) Dosing at Q2W vs. PROCRIT Dosing at QW in Anemic HIV-infected Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|October 2005|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|18 Years|75 Years|No|||March 2010|June 8, 2011|October 28, 2005|||OBI business decision not to complete any additional research in HIV.|||https://clinicaltrials.gov/show/NCT00246298||188452|
NCT00234650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/CO05/15|Adenoma Detection Rate With Position Change at Colonoscopy|Evaluation of the Effect of Position Change During the Withdrawal Phase of Colonoscopy on Adenoma Detection Rate||London North West Healthcare NHS Trust||Completed|October 2005|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|130|||Both|50 Years|80 Years|No|||December 2008|April 1, 2009|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234650||189328|
NCT00231452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AgeMal|Age of Exposure and Immunity to Malaria in Infants|Age of Exposure and Immunity to Malaria in Infants||Hospital Clinic of Barcelona|Yes|Completed|September 2005|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|349|||Both|N/A|1 Week|Accepts Healthy Volunteers|||October 2011|October 27, 2011|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00231452||189570|
NCT00235599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305-SG01|The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.|The Insulin-Like Growth Factor Binding Protein-3 Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.||University of Massachusetts, Worcester|No|Completed|September 2005|October 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|10|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||May 2007|May 15, 2007|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235599||189256|
NCT00231127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-1522|Osteoporosis and Chronic Obstructive Pulmonary Disease (COPD)|Osteoporosis and COPD (Making of a Database)||Catharina Ziekenhuis Eindhoven|No|Completed|April 2005|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Chronic Obstructive Pulmonary Disease Patients visiting the pulmonary outpatient clinic of        the Catharina Hospital Eindhoven.|November 2009|November 9, 2009|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00231127||189594|
NCT00231400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pompe Registry|Pompe Disease Registry|Pompe Disease Registry||Sanofi|No|Recruiting|September 2004|September 2021|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with Pompe disease|February 2016|February 18, 2016|September 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00231400||189574|
NCT00231673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003202|A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy|A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Topiramate on Electrophysiological Parameters in Subjects With Diabetic Peripheral Polyneuropathy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2001|January 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|75 Years|No|||April 2011|June 6, 2011|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231673||189553|
NCT00231920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-057|Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age|Prospective Pilot Safety Study Administering Two Doses of Inactivated Influenza Vaccine to Infants 10-22 Weeks of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2004|October 2006||August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|23|||Both|10 Weeks|22 Weeks|Accepts Healthy Volunteers|||November 2006|August 11, 2011|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231920||189534|
NCT00251316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060025|Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer|The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment||National Institutes of Health Clinical Center (CC)|Yes|Completed|November 2005|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|16 Years|N/A|No|||January 2013|January 29, 2013|November 9, 2005|Yes|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00251316||188077|
NCT00245193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH064518|Motivationally-Enhanced Brief Interpersonal Psychotherapy for Depressed Mothers of Ill Children|Motivationally-Enhanced Brief Interpersonal Psychotherapy for Depressed Mothers of Ill Children (MI-IPT-B-II)||University of Pittsburgh||Completed|April 2003|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|65 Years|No|||June 2013|June 21, 2013|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245193||188536|
NCT00245453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A6004|Outpatient Registry Trial of Respiratory Tract Infections in Adults|Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT)||CPL Associates||Withdrawn|October 2005|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|October 26, 2005|||Terminated by sponsor|No||https://clinicaltrials.gov/show/NCT00245453||188516|
NCT00245466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS02A|Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients|An Open-Label, Multi-Centre, Extension Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients.||Ferring Pharmaceuticals|No|Terminated|October 2001|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|88|||Male|18 Years|N/A|No|||May 2011|May 18, 2011|October 26, 2005|Yes|Yes|The maintenance doses were too low to maintain testosterone suppression|No|January 22, 2009|https://clinicaltrials.gov/show/NCT00245466||188515|
NCT00245817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HINCAB|HINCAB-study. Home Based Intervention in Nursing for Coronary Artery Bypass Patients|Coronary Artery Bypass Grafting (CABG) Patients in the Rehabilitation Phase. A Randomised Controlled Trial.||Oslo University Hospital|Yes|Completed|August 2003|July 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|203|||Both|18 Years|80 Years|No|||December 2010|March 10, 2011|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00245817||188488|
NCT00247143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWL-001|High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease|Prospective Open Label Non-Comparative Study of the Safety, Efficacy and Tolerability of High Dose Ritonavir/Lopinavir Liquid in Salvage Therapy for PI Resistant HIV & a PK Equivalence Sub-Study of High Dose Ritonavir/Lopinavir Capsules||Lampiris, Harry W., M.D.||Recruiting|October 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||September 2006|September 18, 2006|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00247143||188389|
NCT00246350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002324|Spinal Manipulation for Treatment of Chronic Headaches|Dose-Response of Manipulation for Chronic Headache||University of Western States|No|Completed|September 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|80 Years|No|||November 2010|November 19, 2010|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00246350||188449|
NCT00246610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4301017|Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy|A Phase IV, Non-Randomized, Open-Label Trial Evaluating The Safety Of 625 mg Formulation Of VIRACEPT When Administered To HIV-Infected Women During Pregnancy||Pfizer|Yes|Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|N/A|No|||April 2011|April 26, 2011|October 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00246610||188429|
NCT00246597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002305|A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer|A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer||Ortho Biotech Products, L.P.|No|Terminated|December 2002|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|37|||Female|18 Years|N/A|No|||March 2010|May 17, 2011|October 28, 2005|||Study stopped to avoid treating enrolled subjects to hemoglobin levels higher than those    specified in current labeling.|No||https://clinicaltrials.gov/show/NCT00246597||188430|
NCT00247104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRANBERRIES-HMO-CTIL|The Use of Cranberries in Women With Preterm Premature Rupture of Membranes|The Use of Cranberries in Women With Preterm Premature Rupture of Membranes||Hadassah Medical Organization||Not yet recruiting|May 2007|February 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|April 10, 2007|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247104||188392|
NCT00235313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040406|Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS)|Does Dose Adjustment of Nicotine Replacement Therapies According to Saliva Cotinine Increase Efficacy of These Treatments of Assistance To the Nicotinic Weaning Of the High-Risk Patients?|ADONIS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||March 2007|March 28, 2008|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235313||189277|
NCT00231738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYokoyama - 001|Protective Effect of EPA on Cardiovascular Events|Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)||Kobe University||Completed|November 1996|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||18000|||Both|40 Years|75 Years|No|||October 2005|November 19, 2015|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231738||189548|
NCT00231686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUKOTRAIN|Effects of a 6-Months Physical Conditioning Program in Patients With Cystic Fibrosis|Effects of a 6-Months Physical Conditioning Program on Health Status and Physical Activity in Youths and Young Adults With Cystic Fibrosis - MUKOTRAIN||Julius-Maximilians University||Completed|November 2000|May 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|12 Years|N/A|No|||September 2005|September 30, 2005|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231686||189552|
NCT00231140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL-ALS01|Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)|Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)||Charite University, Berlin, Germany||Terminated|December 2005|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|25 Years|80 Years|No|||January 2007|January 18, 2007|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231140||189593|
NCT00231413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102115|Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.|A Dose-range Study to Assess the Safety & Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-mth) in Healthy Adult Females (18-25 Yrs of Age)||GlaxoSmithKline||Completed|March 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||383|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231413||189573|
NCT00232791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC03-04|The Study to Compare Cypher Versus Cypher Select in Treating Cornary Artery Lesions.|A Randomized Study With the CYPHER SELECT™ Sirolimus-Eluting Balloon-Expandable Coronary Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions.|DOMINO|Cordis Corporation|Yes|Completed|January 2004|March 2005|Actual|August 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|85 Years|No|||August 2008|August 5, 2008|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232791||189467|
NCT00231933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067687|Culturally Responsive Person-Centered Care for Psychosis|Culturally-responsive, Person-centered Care for Psychosis||Yale University|No|Completed|October 2005|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|290|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00231933||189533|
NCT00232245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.216|Use of Fish Oils to Reduce the Frequency and Duration of Episodes of Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation.|||Melbourne Health|Yes|Completed|December 2003|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||February 2013|May 28, 2013|October 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00232245||189509|
NCT00248937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (0203-703)|A Pilot Study of Changing Medication Adherence In Hypertensive African-American Patients|A Pilot Study of Changing Medication Adherence In Hypertensive African-American Patients||Weill Medical College of Cornell University|No|Completed|February 2004|June 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||40|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248937||188257|
NCT00245206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH071536|Side Effects of Newer Antipsychotics in Older Adults|Metabolic Effects of Newer Antipsychotics in Older Patients||Veterans Medical Research Foundation|Yes|Completed|August 2005|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|406|||Both|40 Years|N/A|Accepts Healthy Volunteers|||April 2009|June 11, 2013|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00245206||188535|
NCT00245479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS002|A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis|An Open Label, Multi-national Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis|DRIP|Ferring Pharmaceuticals|No|Completed|April 2002|November 2006|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|802|||Both|5 Years|15 Years|Accepts Healthy Volunteers|||May 2011|May 18, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00245479||188514|
NCT00245505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999907 CS004|The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"|The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s Disease, Evaluated by Video Capsule Endoscopy After 6 and 12 Weeks Treatment. A Pilot Study||Ferring Pharmaceuticals|No|Terminated|February 2009|July 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||March 2012|March 9, 2012|October 26, 2005||No|Study terminated due to lack of eligible patients|No||https://clinicaltrials.gov/show/NCT00245505||188512|
NCT00246636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM5 program (Reliant)|Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Omacor Therapy in Hypertriglyceridemic Subjects Treated With Antara, Followed by an 8-week Extension||GlaxoSmithKline||Completed|October 2005|March 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|167|||Both|18 Years|79 Years|No|||December 2009|December 10, 2009|October 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246636||188427|
NCT00250939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02804|A Study of rhGAA in Patients With Late-Onset Pompe Disease|Single-center, Open-label Study of Safety, Pharmacokinetics and Efficacy of rhGAA in Patients With Late-Onset Pompe Disease||Sanofi||Completed|February 2005|November 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|5 Years|18 Years|No|||February 2014|February 4, 2014|November 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250939||188106|
NCT00247390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375-EC302|Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.|A Randomised, Double-blind, Placebo-controlled Study to Determine the Long-term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.||Takeda|No|Completed|July 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|451|||Both|18 Years|N/A|No|||June 2010|June 2, 2010|October 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00247390||188370|
NCT00246623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171067|US Inhaled Insulin Dose Titration Study|A Randomized, Open-Label, Multicenter Study Assessing the Effects of Forced Exubera Dose Titration on Glycemic Control in Patients With Suboptimally Controlled Type 2 Diabetes on Two or More Oral Antidiabetic Agents||Pfizer||Completed|November 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|80 Years|No|||May 2007|February 6, 2008|October 28, 2005||||||https://clinicaltrials.gov/show/NCT00246623||188428|
NCT00246818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060016|Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors|A Randomized Study of the Effect of Tai Chi Chuan Compared to a Structured Exercise Program on Parameters of Physical Fitness and Stress in Adult Cancer Survivors||National Institutes of Health Clinical Center (CC)||Completed|October 2005|February 2011|Actual|July 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|65 Years|No|||February 2011|March 1, 2011|October 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00246818||188413|
NCT00247117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-2003|Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)|Study of the Effect of Metformin in Patients With Non-Alcoholic Fatty Liver Disease||Kaplan Medical Center||Recruiting|January 2004|August 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|60 Years|No|||October 2003|October 6, 2006|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247117||188391|
NCT00235040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS015169-1|Evaluating the Effectiveness of the Acute Respiratory Infection Smart Form|Evaluating Smart Forms and Quality Dashboards in an EHR: Effectiveness of the Acute Respiratory Infection Smart Form||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|November 2005|August 2007|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18257|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235040||189298|
NCT00235053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NONE0-L00081|Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID|A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma||Allergy & Asthma Medical Group & Research Center||Active, not recruiting|August 2005|November 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||13|||Both|18 Years|55 Years|No|||September 2005|January 30, 2006|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235053||189297|
NCT00231699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prevention of Hypothermia|A Comparison of Prevention of Hypothermia in Pediatric Patient Between Wrapping With Cotton and Plastic.|A Comparison of Prevention of Hypothermia in Pediatric Patient Between Wrapping With Cotton (Webril) and Plastic (Mwrap).||Khon Kaen University||Completed|January 2004|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||42|||Both|1 Month|3 Years|Accepts Healthy Volunteers|||October 2005|October 3, 2005|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231699||189551|
NCT00231153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-226-03|Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters|A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Omiganan 1% Gel in Preventing Local Catheter Site Infections/Colonization in Patients Undergoing Central Venous Catheterization||Mallinckrodt|No|Completed|August 2005|July 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1859|||Both|13 Years|N/A|No|||June 2009|June 30, 2009|October 3, 2005|Yes|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00231153||189592|
NCT00231426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-031203-M|ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations|Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICDs Study||Boston Scientific Corporation||Completed|June 2003|November 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||November 2006|November 20, 2006|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231426||189572|
NCT00232804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01290402|The BRIDGE Registry: Safety and Efficacy Registry of Bx Cypher Stent|Safety and Efficacy Registry of Bx Cypher Stent in the Revascularisation of Patients With Significant Risk of Restenosis||Cordis Corporation|Yes|Completed|June 2002|February 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|639|||Both|18 Years|N/A|No|||October 2007|October 8, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232804||189466|
NCT00233077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 03-0593|Patient Centered Randomized Controlled Trial|Patient Assistance to Reduce Breast Cancer Disparities||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2006|January 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|374|||Female|18 Years|N/A|No|||December 2013|December 2, 2013|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233077||189445|
NCT00233389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03700-003|Post-Marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer|A Post-Marketing Clinical Study of Rebamipide to Investigate the Gastric Ulcer Healing Effect of Continued Dosing Following Helicobacter Pylori Eradication Therapy||Otsuka Pharmaceutical Co., Ltd.||Completed|January 2004|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|20 Years|N/A|No|||May 2007|May 25, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233389||189422|
NCT00248729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 001|Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.|Etomidate Versus Midazolam for Pre-Hospital Intubation: A Prospective, Randomized Trial||St. Luke's Hospital, Pennsylvania||Completed|October 2002|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2005|August 28, 2006|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248729||188273|
NCT00249262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-04-21|Taxoprexin Treatment for Advanced Skin Melanoma|Phase II Open-Label Study of Weekly Taxoprexin (DHA-Paclitaxel) Injection as First Line Treatment of Patients With Metastatic Non-Choroidal Melanoma||Luitpold Pharmaceuticals||Completed|October 2005|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||January 2009|January 14, 2009|November 3, 2005||||||https://clinicaltrials.gov/show/NCT00249262||188234|
NCT00245219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|338|Understanding Shared Psychobiological Pathways|Understanding Shared Psychobiological Pathways--Project 4. Psychobiological Pathways: Breast Cancer Interventions||Carnegie Mellon University|Yes|Completed|September 1999|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|245|||Female|25 Years|N/A|No|||December 2015|February 3, 2016|October 26, 2005||No||No|August 25, 2015|https://clinicaltrials.gov/show/NCT00245219||188534|The study was originally planned as a 2(early stage, late stage) X 3(education intervention, peer support intervention, control condition) design; however, the education condition for the late stage cancer group was dropped, due to slow recruitment.
NCT00245492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508-64|Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.|Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.||Indiana University||Completed|May 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|792|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 27, 2009|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00245492||188513|
NCT00246129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMHREN0501|Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation|A Randomised Controlled Comparison of Campath−Tacrolimus vs IL2R MoAb−Tacrolimus/MMMF in Kidney Transplantation||Hammersmith Hospitals NHS Trust|Yes|Active, not recruiting|October 2005|April 2011|Anticipated|April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|75 Years|No|||May 2008|May 9, 2008|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00246129||188465|
NCT00250705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200306035|Trial of Aripiprazole in the Treatment of CD in Adolescents|Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents||University of Iowa|No|Completed|May 2004|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|13 Years|17 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00250705||188124|
NCT00250731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DK06799501A2|Improving Diabetes Outcomes: a Couples Intervention|Improving Diabetes Outcomes: a Couples Intervention||State University of New York - Upstate Medical University|Yes|Completed|January 2006|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|21 Years|95 Years|No|||June 2009|June 15, 2009|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250731||188122|
NCT00247637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065571|The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia|The Genetics of Endophenotypes and Schizophrenia||University of California, San Diego||Completed|May 2003|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|2025|Samples With DNA|Whole blood was sent to the Cell Repository at Rutgers toestablish cell lines.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The subject population will include schizophrenia probands (12 per site per year), first        degree relatives (36 per site per year) and normal comparison subjects (15 per site per        year). The proband must meet the diagnosis of schizophrenia by DSM-IV criteria. There must        be at least one parent and one unaffected sibling in the pedigree. Therefore a total of        315 subjects will be enrolled at each site each year with a total of 2205 enrolled across        all 7 sites. Schizophrenia probands and normal subjects will be between 18 and 65 years of        age. Exclusion criteria include visual or hearing impairments, history of head trauma,        organic brain dysfunction, neurological disease, and significant drug or alcohol use and        for controls, significant psychiatric history and/or current use of psychotropic        medications. We will include equal numbers of men and women and all appropriate subjects        willing to participate regardless of ethnic background.|July 2013|July 1, 2013|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247637||188352|
NCT00246831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060023|Brain Networks Responsible for Self-Agency|Brain Networks Responsible for Self-Agency: An fMRI Study||National Institutes of Health Clinical Center (CC)||Completed|October 2005|October 2008||||N/A|Observational|N/A||||80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2008|October 29, 2008|October 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00246831||188412|
NCT00247130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEIO-UGI-001|Comparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer|A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer||Keio University|No|Withdrawn|October 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|0|||Both|20 Years|80 Years|No|||March 2015|March 31, 2015|October 28, 2005||No|Superiority of iv omeprazole to ranitidine has already been proven by others.|No||https://clinicaltrials.gov/show/NCT00247130||188390|
NCT00247377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2002-2394|Laparoscopic Gastric Bypass vs LAP-BAND for Treatment of Morbid Obesity|A Prospective Randomized Trial of Laparoscopic Gastric Bypass vs Laparoscopic Adjustable Gastric Banding (LAP-BAND) for Treatment of Morbid Obesity||University of California, Irvine|No|Completed|October 2002|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|60 Years|No|||May 2010|May 11, 2010|October 31, 2005||No||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00247377||188371|
NCT00235339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-05-01|Effect of Standard Care Rehabilitation Versus Interval Treadmill Training After Myocardial Infarction|Comparative Study of Training Modality After Myocardial Infarction; Standard Care Rehabilitation Training or Interval Treadmill Training||Norwegian University of Science and Technology|No|Completed|October 2005|December 2009|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|90 Years|No|||May 2012|May 11, 2012|October 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00235339||189275|
NCT00235625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803489|Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris|A Phase II Open Label Study of the Safety and Efficacy of Curcuminoids C3 Complex® in Patients With Chronic Psoriasis Vulgaris.||University of Pennsylvania|Yes|Completed|October 2005|November 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||December 2007|December 12, 2007|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235625||189255|
NCT00222339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2001/01313|Task-Related Training of Arm Use After Stroke|Task-Related Training of Arm Use After Stroke: a Randomised Controlled Trial||University of Melbourne||Completed|February 2002|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2001|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222339||190241|
NCT00222352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJH 0428|Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes|Diagnosis and Treatment of Acute Coronary Syndromes in the Emergency Department: The Impact of Rapid Bedside cTnI Testing on Outcomes||University Emergency Physicians|No|Active, not recruiting|December 2004|December 2006||||Phase 4|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||2000|||Both|21 Years|N/A|No|||February 2007|February 27, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00222352||190240|
NCT00231946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0084|ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)|A Double-Blind Placebo-Controlled Study of VP4896 For the Treatment of Mild-to-Moderate Alzheimer's Disease||National Institute on Aging (NIA)||Completed|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||555|||Both|60 Years|N/A|No|||September 2007|September 18, 2007|September 30, 2005||||||https://clinicaltrials.gov/show/NCT00231946||189532|
NCT00232258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI4553|Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study|Nolpitantium Besylate in Patients With Mild to Moderate Ulcerative Colitis, a Double-Blind, Placebo Controlled Efficacy and Safety, 8 Week Study|NICE|Sanofi||Completed|April 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|307|||Both|18 Years|N/A|No|||December 2008|December 9, 2008|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00232258||189508|
NCT00232544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-230|Telecommunications System in Sleep Apnea|RCT of a Telecommunications System in Sleep Apnea||VA Office of Research and Development|No|Completed|October 2004|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|250|||Both|18 Years|N/A|No|||October 2013|April 6, 2015|September 30, 2005||No||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00232544||189486|
NCT00232817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6698|Anesthesia and Postoperative Pain|Intranasal Nicotine for Postoperative Pain Treatment: A Comparison of Its Effects in the Context of Isoflurane-induced Anesthesia Versus Propofol Anesthesia||Columbia University|No|Completed|July 2003|March 2006|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 12, 2011|October 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232817||189465|
NCT00233090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0677|Post-Traumatic Brain Injury (Post-TBI) Fatigue and Its Treatment|Post-TBI Fatigue and Its Treatment||Icahn School of Medicine at Mount Sinai||Completed|July 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233090||189444|
NCT00249275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRBY79|Effectiveness of Alternative Approaches to Providing Spectacles in Tanzanian Secondary School Students|Evaluation of the Effectiveness of Alternative Approaches to Providing Spectacles in Secondary School Students in Dar Es Salaam, Tanzania||London School of Hygiene and Tropical Medicine||Completed|January 2004|August 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||250|||Both|N/A|N/A|No|||January 2004|November 3, 2005|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249275||188233|
NCT00249288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000495|Folate Supplementation in Schizophrenia|Folate Supplementation in Schizophrenia||Massachusetts General Hospital|No|Completed|December 2003|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|68 Years|No|||July 2014|July 14, 2014|November 3, 2005|Yes|Yes||No|June 11, 2014|https://clinicaltrials.gov/show/NCT00249288||188232|
NCT00245830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120010348|Ischemic Preconditioning of Liver in Cadaver Donors|Ischemic Preconditioning of Liver in Cadaver Donors||Rutgers, The State University of New Jersey|No|Completed|October 2003|March 2007|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||January 2015|January 16, 2015|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00245830||188487|
NCT00250718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1003C|Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach|Phase II Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-angiogenic Approach||New Mexico Cancer Care Alliance|Yes|Terminated|October 2004|May 2014|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 4, 2005|Yes|Yes|Low rate of accrual|No|June 13, 2015|https://clinicaltrials.gov/show/NCT00250718||188123|
NCT00251238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|523052.01.002|Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon|Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon||VSM Geneesmiddelen b.v.||Active, not recruiting|November 2005|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||45|||Both|18 Years|75 Years|No|||September 2005|February 17, 2006|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251238||188083|
NCT00250926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-180|Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia|A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Completed|October 2005|February 2009|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2009|June 22, 2011|November 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250926||188107|
NCT00251199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX05-950-103|VX-950 and Peginterferon for Hepatitis C|A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C||Vertex Pharmaceuticals Incorporated||Completed|October 2005|March 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||20|||Both|18 Years|60 Years||||December 2007|December 17, 2007|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00251199||188086|
NCT00251173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA016591-01A1|Services Interventions for Injured ED Substance Abusers|||University of Michigan||Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|19 Years|55 Years||||November 2005|November 7, 2005|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00251173||188088|
NCT00251186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5536|First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients|Phase II Study of First-Line Capecitabine and Cetuximab for Treatment of Metastatic Colorectal Cancer in Elderly Patients and/or Those With Multiple Comorbidities Unable to Receive Chemotherapy Doublets||Rutgers, The State University of New Jersey||Terminated|April 2006|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||January 2010|January 25, 2010|November 7, 2005|||Funding unavailable|No||https://clinicaltrials.gov/show/NCT00251186||188087|
NCT00246844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060019|Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants|Assessing Arginine-Stimulated Native Pancreas Insulin Production Via Selective Venous Sampling in Patients With Long-Functioning Pancreas Allografts||National Institutes of Health Clinical Center (CC)||Completed|October 2005|August 2007||||N/A|Observational|N/A||||10|||Both|18 Years|N/A|No|||August 2007|September 26, 2015|October 29, 2005||||No||https://clinicaltrials.gov/show/NCT00246844||188411|
NCT00248274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406094|Atrial Tissue Banking: Atrial Tissue Obtained From Patients Undergoing Heart Surgery|Assessment of Atrial Tissue Obtained From Patients Undergoing Heart Surgery||University of Pittsburgh|Yes|Terminated|January 2005|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|300|Samples With DNA|1. myocardial tissue        2. DNA|Both|18 Years|N/A|No|Non-Probability Sample|Subjects are patients of UPMC Cardiothoracic Surgery who are having standard of care CT        surgery.|November 2011|November 21, 2011|November 2, 2005||No|Staffing and departmental changes at our site made it difficult to enroll subjects.|No||https://clinicaltrials.gov/show/NCT00248274||188305|
NCT00248287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04070|PhII ICb With/Without Erbitux in MBC Pts|Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer|CA225200|US Oncology Research||Active, not recruiting|July 2005|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|November 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248287||188304|
NCT00231179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-10-3495|The MOM Program: 5 Year Follow-up Study of a Home Visiting Program at The Children's Hospital of Philadelphia|The MOM Program Continuation - 5 Year Follow-up|MOM Program|Children's Hospital of Philadelphia|No|Completed|February 2004|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|302|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|September 30, 2005||No||No|March 1, 2010|https://clinicaltrials.gov/show/NCT00231179||189590|The initial high rate of refusal to participate in the study may affect the generalizability of our results. Those who refused study participation were older and did not elaborate on their lack of interest.
NCT00222365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 10|Homeopathy Assessment in Terms of the Consumption of Analgesics After Knee Ligamentoplasty|Homeopathy Assessment in Terms of the Consumption of Analgesics After Knee Ligamentoplasty||University Hospital, Grenoble||Terminated|December 2003|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||165|||Both|18 Years|60 Years|No|||July 2006|November 9, 2006|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00222365||190239|
NCT00231959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067060|Effectiveness of Pramipexole for Treatment-Resistant Depression|A Double-Blind Placebo-Controlled Trial of Adjunctive Pramipexole, a Dopamine Receptor Agonist, for Treatment Resistant Major Depressive Episodes||Massachusetts General Hospital|Yes|Completed|September 2003|April 2008|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|75 Years|No|||April 2012|April 25, 2012|September 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00231959||189531|
NCT00231972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068746|Enhancing HIV Prevention by Using Behavioral Intervention Among HIV-Infected Men|Enhancing HIV Prevention Among HIV Infected Men|Enhance|Fenway Community Health|No|Completed|December 2003|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|201|||Male|18 Years|N/A|No|||February 2011|April 7, 2011|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00231972||189530|
NCT00232271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-157|The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.|The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.||Melbourne Health||Terminated|August 2005|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2005|May 28, 2013|October 2, 2005||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00232271||189507|
NCT00232557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 01-054|Telecommunications System in Asthma|Effectiveness of a Telecommunications System in Asthma Management||VA Office of Research and Development|No|Completed|August 2004|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|136|||Both|18 Years|N/A|No|||October 2013|April 6, 2015|September 30, 2005||No||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00232557||189485|
NCT00232570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-234|Quetiapine for the Treatment of Insomnia in Alzheimer's Disease|Quetiapine for the Treatment of Insomnia Associated With Alzheimer's Disease||University of Vermont||Recruiting|November 2005|January 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|18|||Both|55 Years|90 Years|No|||May 2009|May 4, 2009|September 30, 2005||Yes||||https://clinicaltrials.gov/show/NCT00232570||189484|
NCT00223912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3168P|Effect of Exercise on Blood Coagulation in Persons With Chronic Spinal Cord Injury|Effect of FES- Exercise on Hemostasis in Persons With Chronic Spinal Cord Injury|FES|VA Office of Research and Development|No|Completed|November 2003|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|65 Years|No|||September 2010|September 15, 2010|September 14, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00223912||190124|
NCT00233103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 02-0677|Treatment of Post-Traumatic Brain Injury (TBI) Depression|Treatment of Post-TBI Depression||Icahn School of Medicine at Mount Sinai|Yes|Completed|June 2003|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 3, 2005||No||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00233103||189443|Sample size was small - those who dropped out could have reduced the differential effect.Sample was heterogeneous for severity and time since injury.
NCT00249301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10001|A Study of MLN8054 in Patients With Advanced Solid Tumors|An Open-Label, Dose Escalation Phase 1 Study of MLN8054, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.|No|Terminated|October 2005|||January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00249301||188231|
NCT00249314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mol-SHARE|(Mol-SHARE) Molecular Study of Health Assessment and Risk in Ethnic Groups|A Prospective, Cross-Sectional, Case-Control, Molecular Study of Health Assessment and Risk in Ethnic Groups||McMaster University||Recruiting|November 2005|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2007|April 18, 2007|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249314||188230|
NCT00250133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0503005|Microbiologic Effect of Selective Decontamination of the Digestive Tract With Colistin, Gentamicin and Nystatin|Microbiologic Effect of Selective Decontamination of the Digestive Tract With Colistin, Gentamicin and Nystatin||University of Pittsburgh||Terminated||||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||40|||Both|18 Years|N/A|No|||August 2007|August 31, 2007|November 4, 2005|||Unable to obtain funding to complete study never started study|No||https://clinicaltrials.gov/show/NCT00250133||188168|
NCT00246363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 02-1185|A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C|A Pilot Randomized Placebo-Controlled Trial Designed to Determine the Tolerability and Efficacy of Silymarin (Milk Thistle) vs. Placebo for the Treatment of Chronic Hepatitis C in HIV Infected Patients||Icahn School of Medicine at Mount Sinai|No|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|N/A|No|||September 2011|September 14, 2011|October 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00246363||188448|
NCT00246376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-14105|Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia|Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy|HeartPositive|Baylor College of Medicine|Yes|Completed|January 2004|February 2012|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|221|||Both|18 Years|65 Years|No|||February 2016|February 25, 2016|October 27, 2005|Yes|Yes||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00246376||188447|High dropout rate, especially by loss to follow-up (with no explanation). Flushing was common among patients taking niacin, and this (with transportation and socio-economc problems) could have contributed to the high drop-out rate.
NCT00250419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V930-002|V930 First in Man (FIM) Study (V930-002)(COMPLETED)|A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA||Merck Sharp & Dohme Corp.||Completed|September 2005|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|November 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250419||188146|
NCT00250432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-801|A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults||Merck Sharp & Dohme Corp.||Completed|January 2006|March 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|November 4, 2005|Yes|Yes||No|January 13, 2009|https://clinicaltrials.gov/show/NCT00250432||188145|
NCT00252070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-ASPH3497|Fitness and Exercise for People With Arthritis|Fitness and Functional Exercise for People With Arthritis||Centers for Disease Control and Prevention||Completed|November 2005|January 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||September 2007|September 6, 2007|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00252070||188020|
NCT00251212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-014889-01A1|Tailored Teen Alcohol and Violence Prevention in the Emergency Room (ER)|Tailored Teen Alcohol and Violence Prevention in the ER||University of Michigan|No|Completed|September 2006|October 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3694|||Both|14 Years|18 Years|No|||April 2014|April 9, 2014|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00251212||188085|
NCT00251420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G22-1|Writing About Disease: Effect on Rehabilitation?|Writing About Disease: Effect on Rehabilitation?||LHL Helse|No|Completed|December 2005|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|180|||Both|20 Years|70 Years|No|||May 2009|May 6, 2009|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251420||188069|
NCT00251433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF100161|GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer|An Open-label, Multicenter, Phase I/II Dose Escalation Study of Oral GW572016 in Combination With Docetaxel (Taxotere) Plus Trastuzumab (Herceptin) in Subjects Previously Untreated for ErbB2-overexpressing Metastatic Breast Cancer||Novartis||Active, not recruiting|September 2005|June 2016|Anticipated|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00251433||188068|
NCT00247936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 2003-3422|Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.|Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.||University of California, Irvine|No|Withdrawn|May 2004|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2009|November 4, 2009|October 31, 2005||No|Prior to recruitment, study terminated lack of recruitment interest.|No||https://clinicaltrials.gov/show/NCT00247936||188330|
NCT00251706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAPABEAR|Amiodarone to Prevent Post-Operative Arrhythmias|Prophylactic Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valve Replacement, or Repair - PAPABEAR||University of Calgary||Completed|February 1999|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||600|||Both|N/A|N/A|No|||November 2005|May 4, 2006|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251706||188048|
NCT00231712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/04|Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant|Prospective Analysis of the Patterns of Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Autologous/Allogeneic Stem Cell Transplant||Julius-Maximilians University||Recruiting|March 2005|February 2009||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||50|||Both|N/A|N/A|No|||September 2005|August 22, 2006|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231712||189550|
NCT00231725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9673|Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin|Complaints Associated With Use of Pre-Filled Pen B When Used by Patients With Type 2 Diabetes on Twice-Daily Insulin Therapy||Eli Lilly and Company||Completed|September 2005|April 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label||||370|||Both|25 Years|75 Years|No|||June 2007|June 26, 2007|September 30, 2005||||||https://clinicaltrials.gov/show/NCT00231725||189549|
NCT00223249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET0233|Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence|A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence.||University of Texas Southwestern Medical Center|No|Completed|November 2002|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|70 Years|No|||January 2010|July 31, 2012|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00223249||190173|
NCT00232310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5760|Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr|Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 300 or 600 mg for the Conversion of Atrial Fibrillation / Flutter|CORYFEE|Sanofi||Completed|October 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|150|||Both|21 Years|N/A|No|||May 2012|May 7, 2012|October 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00232310||189504|
NCT00232323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3711-AN-CTIL|Simulation Training as a Tool to Decrease Occupational Stress in ICU Personnel|Experimental Like Study of Stress Reduction in Intensive Care Teams by Use of Simulation Training||Sheba Medical Center||Suspended|January 2006|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2007|January 23, 2007|October 2, 2005||||No||https://clinicaltrials.gov/show/NCT00232323||189503|
NCT00232284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHREC 2004.030|Treatment of Comorbid Depression and Substance Abuse in Young People|An Integrated Pharmacological and Psychological Approach to Young People With Comorbid Depression and Substance Abuse||Melbourne Health|No|Completed|September 2004|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|26 Years|No|||June 2015|June 24, 2015|October 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00232284||189506|
NCT00232297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5349|Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS|Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 100 OR 300 mg for the Prevention of Ventricular Arrhythmia-Triggered ICD Interventions|ICARIOS|Sanofi||Completed|June 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|153|||Both|21 Years|N/A|No|||May 2012|May 7, 2012|October 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00232297||189505|
NCT00232583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003-623|Preservation of Beta-cell Function in Type 2 Diabetes Mellitus|Preservation of Beta-cell Function in Type 2 Diabetes Mellitus||University of Texas Southwestern Medical Center|No|Completed|November 2003|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|25 Years|65 Years|No|||October 2013|May 26, 2015|September 30, 2005||No||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00232583||189483|Relatively small trial, but longest (6-year) follow-up.
NCT00224237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505007876|Exploring Folk Health Practices in Latinos With Chronic Medical Conditions|Exploring Folk Health Practices in Latinos With Chronic Medical Conditions||Weill Medical College of Cornell University|No|Active, not recruiting|December 2005|October 2007|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be self-identified, adult Latino men and women from the community        setting. The sample will comprise of a convenience sample from community-based        organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central        American, South American, or other Spanish-speaking culture.|November 2010|November 4, 2010|September 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00224237||190099|
NCT00245518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-08-09-04|Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy|Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy||Johns Hopkins University|Yes|Completed|June 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Male|21 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 27, 2009|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00245518||188511|
NCT00245531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-01-12-04|Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs|Effects of Endocrine Health on the Cognitive Function of Men and Women Using Drugs: A Cross-sectional Investigation||Johns Hopkins University|Yes|Completed|August 2004|December 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|males and females 18-50 years old who have completed the 8th grade and are using drugs|March 2015|March 30, 2015|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00245531||188510|
NCT00249860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23744|A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects|A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects||EMD Serono||Completed|September 2002|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|65 Years|No|||August 2013|August 4, 2013|November 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00249860||188188|
NCT00250406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-646|Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation|Assessment of Bacterial Adherence and Biofilm Formation on a Triclosan Loaded Ureteral Stent: A Phase II Study||Lawson Health Research Institute|No|Completed|November 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00250406||188147|
NCT00250965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20R20015|MPAACS: Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery|Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery||University of British Columbia|No|Terminated|July 2004|February 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|927|||Both|20 Years|N/A|No|||March 2009|November 3, 2010|November 7, 2005||No|Terminated by DSMB; futility analysis showing Mg treatment not efficacious|No||https://clinicaltrials.gov/show/NCT00250965||188104|
NCT00252356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5041|Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder|An Eight-Week, Double-Blind, Placebo Controlled, Multicenter Study With Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With MDD|ORION|Sanofi||Completed|September 2005|May 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|468|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|November 10, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00252356||187999|
NCT00250952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR-001|Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection Affects Its Overall Effect and Duration.|A Randomized, Evaluator-Blinded, Two Centre Study of the Safety and Effect of Volume on the Diffusion and Efficacy of BOTOX Cosmetic™ (Botulinum Toxin Type A) in the Treatment of Lateral Orbital Rhytides.||Carruthers Dermatology Centre||Completed|February 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2005|November 8, 2005|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00250952||188105|
NCT00251225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-019|A Study of Imatinib and Docetaxel in Prostate Cancer|A Phase II Study of Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer||University of Pittsburgh|Yes|Completed|August 2005|March 2014|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Male|18 Years|N/A|No|||May 2015|May 28, 2015|November 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251225||188084|
NCT00251446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-05-009|A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer|A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer||Veeda Oncology|No|Completed|October 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|November 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251446||188067|
NCT00251459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3689g|A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)||Genentech, Inc.||Completed|November 2005|September 2007|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||5000|||Both|50 Years|N/A|No|||March 2014|March 6, 2014|November 8, 2005||||||https://clinicaltrials.gov/show/NCT00251459||188066|
NCT00251407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-149|Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies|Phase I Study of Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies||Dana-Farber Cancer Institute||Completed|September 1999|April 2009|Actual|January 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|November 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251407||188070|
NCT00252018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-257/04|The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease|The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease.||Bispebjerg Hospital||Completed|January 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|160|||Both|18 Years|80 Years|No|||May 2008|May 13, 2008|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00252018||188024|
NCT00252031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3277-02-0002|DBT in Borderline Personality Disorder|Dialectical Behavioral Therapy for Patients With Borderline Personality Disorder||Bronx VA Medical Center||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||November 2005|November 17, 2005|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252031||188023|
NCT00231491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030438|Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.|Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder (OAB). A Multicenter Phase II, Randomized, Double-blind, Placebo Controlled 6 Month Study . VESITOX||Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2005|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|N/A|No|||March 2007|February 16, 2011|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00231491||189567|
NCT00231504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P041013|Study of Follicle Stimulating Hormone (FSH) Receptor in Women With Low Antral Follicle Count|Study of Follicle Stimulating Hormone (FSH) Receptor in Women With Low Antral Follicle Count||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2005|May 2009|Actual|March 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|Samples With DNA|DNA|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|YOUNG WOMAN|March 2007|January 5, 2010|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00231504||189566|
NCT00222963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10297|Pilot Study to Assess the Effectiveness of Tonsil and Adenoidectomy (T+A) in Overweight Children and Adolescents|Pilot Study to Assess the Effectiveness of Tonsil and Adenoidectomy (T+A) in Overweight Children and Adolescents||University of Rochester|No|Completed|September 2004|||||N/A|Observational|Time Perspective: Prospective||1|Actual|250|||Both|8 Years|18 Years|No|||September 2006|February 12, 2009|September 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00222963||190195|
NCT00222638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 MICV AI 01|Influenza Vaccination and Oral Anticoagulant Therapy|Randomized Blinded Cross-Over Clinical Trial Investigate the Interactions Between Influenza Vaccination and Oral Anticoagulant Therapy||University Of Perugia||Completed|October 2004|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||June 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222638||190220|
NCT00222651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRU-UniPg-01-02|Tenecteplase Pulmonary Embolism Italian Study|A Phase II Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Single Bolus i.v. Tenecteplase Versus Placebo in Normotensive Patients With Pulmonary Embolism and Right Ventricular Dysfunction||University Of Perugia||Terminated|July 2004|July 2006|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|85 Years|No|||April 2008|April 29, 2008|September 16, 2005|||competitor study about to start|No||https://clinicaltrials.gov/show/NCT00222651||190219|
NCT00223431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-1998|Clinical Performance of 3-Unit FPDs|Clinical Performance of Three-Unit Fixed Partial Dentures (FPDs) Made From a Hot-Pressed Ceramic (Five-Year Study)||The University of Texas Health Science Center at San Antonio||Completed|February 1998|May 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00223431||190160|
NCT00223691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000814|Treatment of Orthostatic Hypotension in Autonomic Failure|Evaluation and Treatment of Autonomic Failure.||Vanderbilt University|No|Recruiting|March 2002|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|85 Years|No|||May 2015|May 21, 2015|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223691||190140|
NCT00223470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-1904-455|Cytokine Regulation of Periradicular Pain in Humans|Cytokine Regulation of Periradicular Pain in Humans||The University of Texas Health Science Center at San Antonio|No|Completed|October 2002|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|Sterile paper points are placed in the canal for 30 seconds|Both|16 Years|60 Years|No|Non-Probability Sample|Patients presenting to the Endodontics department with an indication for root canal        treatment|March 2012|March 7, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223470||190157|
NCT00223197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103-714|Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse|A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse||University of Texas Southwestern Medical Center||Completed|February 2004|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|70 Years|No|||August 2006|April 2, 2012|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223197||190177|
NCT00223210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET 0397|An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence|A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence||University of Texas Southwestern Medical Center|Yes|Completed|November 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||August 2012|August 16, 2012|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00223210||190176|
NCT00223444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21-AA13435-03-A1|Clinical-Genetic Variation in GABA/Alcohol Sensitivity|Clinical-Genetic Variation in GABA/Alcohol Sensitivity|GABA-Alcohol|The University of Texas Health Science Center at San Antonio|No|Completed|August 2002|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|23|Samples With DNA|Specifically, we will determine whether the subject's gene for a brain protein called      GABA-alpha-6 is of the "Pro" type or "Ser" type.|Both|21 Years|25 Years|No|Non-Probability Sample|Subjects who are English-speaking, children of Hispanic ancestry, 21-25 years of age, who        drink alcohol but are not alcohol dependent will be recruited.|April 2009|April 30, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00223444||190159|
NCT00223457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS DMA Compliance|Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis|Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis||University of Texas Southwestern Medical Center||Completed|April 2004|September 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||1040|||Both|18 Years|N/A|No|||April 2005|January 23, 2007|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00223457||190158|
NCT00245843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vermont|Vermont Intervention: Effect on Joint Attention Skills Between Parents and Moderate/Late Preterm Infants in the First Year of Life|Vermont Intervention: Effect on Joint Attention Skills Between Parents and Moderate/Late Preterm Infants Int the First Year of Life||Ullevaal University Hospital|Yes|Active, not recruiting|January 2005|February 2010|Anticipated|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|1||Actual|170|||Both|30 Weeks|N/A|Accepts Healthy Volunteers|||March 2009|March 31, 2009|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00245843||188486|
NCT00246142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-104|A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.|A 16-Week Prospective Randomised Double-Blind Study on Facilitation of DYSPORT® Effect on Myofascial Pain Syndrome (MPS) by Electrical Stimulation.||Ipsen||Completed|April 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|21 Years|N/A|No|||October 2007|October 11, 2007|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00246142||188464|
NCT00250445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-066|A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)|A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis||Merck Sharp & Dohme Corp.||Completed|January 2003|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|23498|||Both|50 Years|N/A|No|||July 2015|July 29, 2015|November 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250445||188144|
NCT00250458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-074|Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT)||Merck Sharp & Dohme Corp.||Completed|March 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|346|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|November 7, 2005|Yes|Yes||No|September 21, 2009|https://clinicaltrials.gov/show/NCT00250458||188143|
NCT00250146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-2000-611|Multicenter Study on the Toxicity of Gluten Traces in the Treatment of Celiac Disease|||Università Politecnica delle Marche||Terminated|February 2001|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||39|||Both|18 Years|N/A|No|||April 2005|November 3, 2005|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00250146||188167|
NCT00251758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-GD04-083|Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn|A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)||Takeda|No|Completed|December 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|908|||Both|18 Years|N/A|No|||May 2010|May 12, 2010|November 8, 2005|Yes|Yes||Yes|February 26, 2009|https://clinicaltrials.gov/show/NCT00251758||188044|
NCT00223301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103-716|Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis|A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis||University of Texas Southwestern Medical Center|No|Completed|July 2004|March 2007|Actual|March 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|21 Years|45 Years|No|||April 2013|April 18, 2013|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00223301||190169|
NCT00223548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A119/2002|MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application|MESNA Zur Prophylaxe Der Kontrastmittel-Induzierten Nephropathie||University of Ulm||Completed|October 2002|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||106|||Both|18 Years|N/A|No|||September 2002|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223548||190151|
NCT00223561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/021|Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder|A Double Blind, Placebo-Controlled Crossover Study to Determine the Effects of Methylphenidate on Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder||Utrecht Institute for Pharmaceutical Sciences||Completed|February 2003|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||18|||Both|21 Years|55 Years|No|||February 2006|February 28, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00223561||190150|
NCT00273325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0031|Immunogenicity of PCV-7 Vaccine in VLBW Infants|Observational Study of the Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Very-low-birth-weight Infants|PCV-7|NICHD Neonatal Research Network|Yes|Completed|July 2004|March 2009|Actual|July 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|368|Samples With DNA|Serum was separated from blood samples. After all study assays were completed on all      subjects, if a subject's parents asked that his/her serum not be stored, the serum was      destroyed. For subjects whose parents permit it, leftover serum was re-labeled with a new,      randomly-generated unique de-identifier, linked only to the subject's gestational age, birth      weight, and chronologic age at the time of sampling. The link to any other subject      identifiers will then be destroyed. The serum will be stored indefinitely at the University      of Rochester for other, non-genetic-testing-related research.|Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants <1,500g birth weight who receive the 3-dose primary series of PCV-7 immunization        by 3 months and complete it by 8 months postnatal age|June 2015|June 16, 2015|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00273325||186427|
NCT00273832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC – 2005 – 010|Study of Coronary Artery Computed Tomography to Diagnose Emergency Chest Pain|Randomized Controlled Trial of Multi-Slice Coronary Computed Tomography for Evaluation of Acute Chest Pain||William Beaumont Hospitals||Completed|March 2005|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Both|25 Years|N/A|No|||December 2005|January 4, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00273832||186388|
NCT00274105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.350|SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients|A Double Blind, 2:1 Randomised Monocentre Study to Investigate the Efficacy and Safety of Telmisartan (80 mg qd) Concerning the Amelioration of Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients)||Boehringer Ingelheim||Terminated|March 2001|October 2004||October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||22|||Both|36 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274105||186368|
NCT00274118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.236|DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril|DETAIL = Diabetics Exposed to Telmisartan And enalapIL: A Randomised, Double-blind, Parallel-group Comparison of the Renal and Antihypertensive Effects of Telmisartan and Enalapril in Subjects With Mild to Moderate Hypertension and Concurrent Type II Diabetes Mellitus and Diabetic Nephropathy||Boehringer Ingelheim||Completed|July 1997|January 2004||January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||250|||Both|35 Years|80 Years|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274118||186367|
NCT00240786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002485|An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (1950 mg/Day or 3900 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee||Johnson & Johnson Consumer and Personal Products Worldwide||Completed|April 2002|March 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|483|||Both|40 Years|N/A|No|||June 2011|June 28, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240786||188871|
NCT00241124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2420|Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes|A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension And Non-Insulin Dependent Diabetes||Novartis||Completed|April 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1099|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 22, 2011|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00241124||188847|
NCT00241462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997-NL-001|Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients|Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients|FORUM|AstraZeneca||Terminated|June 2005|December 2009|Anticipated|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|N/A|No|||April 2009|April 21, 2009|October 18, 2005|||Due to poor patient enrollment|No||https://clinicaltrials.gov/show/NCT00241462||188821|
NCT00241475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0155|Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy|An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy||AstraZeneca||Completed|December 2003|October 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|18 Years|N/A|No|||April 2009|April 22, 2009|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00241475||188820|
NCT00241488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00009|DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia|: An Open-Label, Randomised, Multi-Centre, Phase IIIb/IV, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia (DISCOVERY)||AstraZeneca||Completed|June 2003|February 2007|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1362|||Both|18 Years|N/A|No|||February 2008|February 5, 2008|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00241488||188819|
NCT00242788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0505|IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure|A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of First-Line Chemotherapy||AstraZeneca||Completed|February 2004|November 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00242788||188720|
NCT00242801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0709|Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study|A Double Blind,Placebo Controlled,Parallel Group,Multicentre,Randomised,Phase Iii Survival Study Comparing ZD1839 (IRESSA™)(250mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced NSCLC Who Have Received One Or Two Prior Chemotherapy Regimens And Are Refractory Or Intolerant To Their Most Recent Regimen||AstraZeneca||Completed|July 2003|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1692|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|October 19, 2005||||||https://clinicaltrials.gov/show/NCT00242801||188719|
NCT00242775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890C00002|Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg|Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).||AstraZeneca||Completed|May 2005|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2100|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00242775||188721|
NCT00224809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266|Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation|Functional Mitral Regurgitation in STICH||Baylor Research Institute||Completed|September 2002|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Prevention|||Anticipated|250|||Both|18 Years|N/A|No|||December 2007|February 18, 2014|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224809||190055|
NCT00225394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL031|Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients|Long-Term Valcyte Therapy in Transplant Patients and the Development of Ganciclovir Resistant CMV||University of Massachusetts, Worcester||Completed|October 2003|July 2006||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|18 Years|N/A|No|||August 2005|September 21, 2005|September 21, 2005||||||https://clinicaltrials.gov/show/NCT00225394||190011|
NCT00225407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V/267002|Processing and Effects of Cannabis|A Double-Blind, Randomised, Placebo-Controlled, Cross-Over Study on the Pharmacokinetics and Effects of Cannabis||UMC Utrecht||Recruiting|July 2005|December 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2005|September 21, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225407||190010|
NCT00225680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|524|In Stent ELUTES Study|ELUTES II - In Stent ELUTES Study|ELUTES II|Cook||Completed|April 2002|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||124|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225680||189989|
NCT00226005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRT04-001|PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma|Phase II Trial of PTK787/ZK222584 in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Who Failed First-Line Gemcitabine Therapy.||Pancreatic Cancer Research Team|Yes|Completed|December 2005|February 2010|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|September 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226005||189967|
NCT00233298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905254|A Study of the Function of Hormones Present In Taste Buds|A Study of the Function of Hormones Present In Taste Buds||National Institutes of Health Clinical Center (CC)||Completed|May 2005|January 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|12 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 3, 2015|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233298||189429|
NCT00222209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG HO 904/11-3,4|Clinical Study on Implicit Learning, Comorbidity and Stress Vulnerability in Chronic Functional Pain|Implicit Learning, Comorbidity and Stress Vulnerability in Chronic Functional Pain Syndromes||Universitätsmedizin Mannheim||Recruiting|September 2005|November 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||64|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2005|August 2, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222209||190250|
NCT00223015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Investigation of the Steady State Pharmacokinetics of Tacrolimus, Mycophenolate Mofetil and Fluvastatin After Renal Transplantation|||University of Schleswig-Holstein||Completed|May 2004|April 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||15|||Both|18 Years|65 Years|No|||May 2004|October 19, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223015||190191|
NCT00233662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-733|Safety and Tolerability of Repeat Courses of IM Alefacept|An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients With Chronic Plaque Psoriasis||Biogen||Completed|December 2002|June 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|16 Years|N/A|No|||October 2005|October 4, 2005|October 4, 2005||||||https://clinicaltrials.gov/show/NCT00233662||189401|
NCT00233675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6671A/301/AX/US|Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder|A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder||Teva Pharmaceutical Industries||Completed|August 2003|||February 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||||||||May 2014|May 8, 2014|September 27, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00233675||189400|
NCT00233688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-4601|Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)|A Prospective, Multicenter Study of the Cordis Endovascular QUANTUM LP™ Stent Graft System for the Treatment of Abdominal Aortic Aneurysms (AAA)-FORTRON||Cordis Corporation|Yes|Completed|November 2001|April 2009|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|21 Years|N/A|No|||April 2009|April 30, 2009|October 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00233688||189399|
NCT00233961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441128|G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission|Peripheral Blood Stem Cell Mobilization With Filgrastim in Patients With Chronic Myeloid Leukemia in Cytogenetic Response||National Cancer Institute (NCI)||Completed|January 2005|January 2008|Actual|November 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||January 2008|February 1, 2013|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00233961||189378|
NCT00244959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0365 CDR0000446285|Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer|Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy||Sidney Kimmel Comprehensive Cancer Center|No|Completed|January 2004|November 2011|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||March 2013|March 18, 2013|October 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244959||188554|
NCT00240565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/032|Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma|A Single Arm, Open-label, Multicentre, Phase II Study of Tositumomab and Iodine 131-Tositumomab in Subjects With Indolent Non-Hodgkin's Lymphoma Who Have Previously Received Rituximab.||GlaxoSmithKline|No|Completed|April 2004|September 2011|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00240565||188888|
NCT00273780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29936-G|Highly Active Antiretroviral Therapy (HAART) Adherence Interventions|HAART Adherence Interventions in Africa: An RCT||University of Washington|Yes|Completed|May 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|400|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273780||186392|
NCT00241826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|329|Prospective Investigation of Pulmonary Embolism Diagnosis III|Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III)||George Washington University||Completed|April 2006|April 2009||September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1256|||Both|18 Years|N/A|No|Non-Probability Sample|People with suspected acute pulmonary embolism will be recruited for this study.|July 2009|August 19, 2013|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241826||188793|
NCT00241839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332|Uric Acid and Hypertension in African Americans|Uric Acid and Hypertension in African Americans||University of Florida|Yes|Completed|August 2005|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|No|||July 2013|July 18, 2013|October 17, 2005|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00241839||188792|For all 4 outcomes analyzed, patients required to have data at both baseline and 8-10 weeks on that field to be included. Thus, the numbers of subjects varies slightly from analysis to analysis.
NCT00242151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0223-AE|Prevalence of Delirium in Patients Undergoing Cardiac Surgery|Prevalence of Delirium in Patients Undergoing Cardiac Surgery||University Health Network, Toronto||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|18 Years|N/A|No|||September 2006|October 11, 2006|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242151||188769|
NCT00242437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-05-002|Hemostatic Matrix in Endoscopic Sinus Surgery|A Prospective, Multicenter Study to Evaluate Hemostatic Matrix With Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Endoscopic Sinus Surgery||Ethicon, Inc.||Completed|October 2005|February 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||30|||Both|18 Years|N/A||||July 2006|July 11, 2006|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242437||188747|
NCT00242814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.486|Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities|A Phase IV Study, Prospective, Randomised, Open Label, Blinded Endpoint, Parallel Group, 9 Weeks of Comparison Between Oral Administration of Telmisartan Tablet (80mg Once Daily) and Amlodipine Tablet (10 mg Once Daily) on Biological PPAR Gamma Activities in Non Controlled Hypertensive Male Patients With Metabolic Syndrome||Boehringer Ingelheim||Completed|October 2005|||March 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Actual|100|||Male|18 Years|N/A|No|||May 2012|May 18, 2012|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242814||188718|
NCT00242827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0701/2025/ON/US|Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma|An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma||Teva Pharmaceutical Industries||Terminated|April 2006|May 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2006|August 22, 2012|September 27, 2005||||||https://clinicaltrials.gov/show/NCT00242827||188717|
NCT00242840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV30007|Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)|A 24 Week Phase IIIb/IV Single Arm Open Label Observational Study to Explore the Efficacy of Protease Inhibitors Given in Combination With Reverse Transcriptase Inhibitors to HIV-1 Infected Subjects With Protease Mutations Selected During Therapy With GW433908 Containing Antiretroviral Therapy||ViiV Healthcare||Completed|June 2003|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|N/A|||Actual|20|||Both|13 Years|N/A|No|||April 2013|April 1, 2013|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242840||188716|
NCT00243074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02902|S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery|A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Completed|November 2005|December 2011|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||February 2014|September 21, 2015|October 20, 2005|No|Yes||No|October 30, 2012|https://clinicaltrials.gov/show/NCT00243074||188698|
NCT00224536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOOST-1|Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration|Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration-1||Hannover Medical School||Completed|January 2002|October 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 21, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224536||190076|
NCT00224549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040407|PHARES Study: Management of Resistant Hypertension|Management of Resistant Hypertension -Pharmacokinetic Assessment of Different Antihypertensive Regimen -Comparison of Two Treatment Strategies: Increase Sodium Depletion or Combined Blockage of Renin-angiotensin System (RAS)||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2005|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|18 Years|75 Years|No|||March 2007|February 25, 2011|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00224549||190075|
NCT00225095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osiris 550|A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy|A Phase I/II, Randomized, Controlled, Double Blind, Study of Chondrogen - Adult Universal Cell Delivered by Intra-Articular Injection Following Meniscectomy in Patients 18-60 Years||Mesoblast, Ltd.||Completed|September 2005|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|60 Years|No|||December 2014|December 2, 2014|September 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00225095||190033|
NCT00225108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002191-01H|The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section|The Cesarean Section Thromboprophylaxis Pilot Study:A Randomized Open-Label Controlled Pilot Study of Prophylactic Low Molecular Weight Heparin in High Risk Postpartum Women Following Cesarean Section||Ottawa Hospital Research Institute||Completed|July 2002|September 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Female|18 Years|N/A|No|||September 2006|September 23, 2006|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225108||190032|
NCT00225082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNAP|SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function|SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial||Northwestern University|No|Completed|November 2004|October 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|adipose tissue, blood|Both|N/A|N/A|No|Non-Probability Sample|HIV infected subjects receiving antiretroviral treatment (lopinavir/ritonavir, stavudine,        and lamivudine) for greater than 6 years through the Abbott M97-720 protocol with be        evaluated for clinical lipoatrophy and mitochondrial function prior to switching        nucleoside analogues from stavudine (d4T) to tenofovir and after 48 weeks or tenofovir        treatment. Subjects with or without lipoatrophy are eligible for the study.|October 2010|October 4, 2010|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00225082||190034|
NCT00225693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|578|V-Flex Plus PTX Drug Eluting Coronary Stent|ELUTES III - V-Flex Plus PTX Drug Eluting Coronary Stent|ELUTES III|Cook||Completed|October 2003|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225693||189988|
NCT00226018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG01|Performance of Acceleromyography With and Without Preload|Performance of Acceleromyography With and Without Preload During Neuromuscular Blockade||Rigshospitalet, Denmark|No|Completed|March 2005|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4|||60|||Both|18 Years|65 Years|No|||April 2008|April 16, 2008|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00226018||189966|
NCT00222456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP 46-04|Project Early Intervention 2000|Can Early Intervention Prevent Developmental Disturbances/Delays and Improve the Health of Children Born Prematurely||University Hospital of North Norway||Completed|March 1999|September 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||210|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2005|September 15, 2005|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00222456||190232|
NCT00234312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2801-A 02|Medications for the Treatment of Dysthymic Disorder and Double Depression|Escitalopram Vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression||Oregon Health and Science University||Active, not recruiting|September 2005|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||September 2006|September 7, 2006|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00234312||189352|
NCT00234338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101850|Study Evaluating Prevenar in High-Risk Children|Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2005|April 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||December 2007|December 7, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00234338||189351|
NCT00223028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation|Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation||University of Schleswig-Holstein||Completed|April 2005|July 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||July 2004|October 27, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00223028||190190|
NCT00233974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9924|Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery|Axillary Lymph Nodes and PET (Positron Emission Tomography) Probe-Guided Surgical Resection in Locally Advanced Breast Cancer Patients: Molecular Marker Profile and Response to Neoadjuvant Chemotherapy||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|May 2002|March 2006|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|N/A|N/A|No|||March 2012|March 5, 2012|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00233974||189377|
NCT00233987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000442392|S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma|Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II||Southwest Oncology Group|Yes|Active, not recruiting|October 2005|February 2016|Anticipated|February 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|15 Years|70 Years|No|||May 2015|May 8, 2015|October 5, 2005|Yes|Yes||No|January 2, 2013|https://clinicaltrials.gov/show/NCT00233987||189376|
NCT00234286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-126|Intervention to Improve Care at Life's End|Intervention to Improve Care at Life's End in VA Medical Centers|BEACON|VA Office of Research and Development|No|Completed|August 2005|September 2013|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|78|||Both|N/A|N/A|No|||April 2015|April 23, 2015|October 4, 2005||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT00234286||189354|
NCT00234299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01426-V|Effects of ASA on Prostate Tissue|In Vivo Molecular Effects of Aspirin on Prostate Tissue||University of Washington|Yes|Active, not recruiting|December 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Male|45 Years|74 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00234299||189353|
NCT00240578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEX104528|Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab|A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036||GlaxoSmithKline|No|Completed|November 2003|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|88|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of subjects which have been previously treated with Iodine I        131 Tositumomab in Studies 104505, 93229/023, 393229/007, 104514 and 393229/028.|January 2016|January 28, 2016|October 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00240578||188887|
NCT00241137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489H2301|A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg|A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg||Novartis||Completed|September 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|3790|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2006|November 22, 2011|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00241137||188846|
NCT00241501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9614C00098|Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients|A Phase III, Multicentre, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GERD) in Pediatric and Adolescent Patients 12 to 17 Years of Age, Inclusive.||AstraZeneca||Completed|February 2004|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|12 Years|17 Years|No|||November 2010|November 18, 2010|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00241501||188818|
NCT00241813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|330|Effects of Behavioral Stress Reduction Programs on Blood Pressure in African American Youth|Stress Reduction: Impact on Blood Pressure in African American Youth||Medical University of South Carolina|No|Completed|January 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|283|||Both|14 Years|17 Years|No|||December 2012|December 13, 2012|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241813||188794|
NCT00241852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333|Family Approach to Managing Asthma in Early Teens|Family Approach to Managing Asthma in Early Teens||New York University School of Medicine|No|Completed|May 2005|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|392|||Both|11 Years|14 Years|No|||January 2014|January 9, 2014|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241852||188791|
NCT00242463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-390|Anabolic Steroids for Nutritional Rehabilitation of Critically Ill Patients|The Efficacy of Anabolic Steroids for the Nutritional Rehabilitation of Critically Ill Patients||Lawson Health Research Institute|No|Terminated|October 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 4, 2011|October 19, 2005||No|drug no longer available in canada|No||https://clinicaltrials.gov/show/NCT00242463||188745|
NCT00273949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZ00001|Lactulose for the Prevention of Nosocomial Infections in Children|Lactulose for the Prevention of Nosocomial Infections in Children||Bnai Zion Medical Center|No|Active, not recruiting|January 2006|January 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|2 Months|36 Months|No|||September 2005|February 5, 2008|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00273949||186380|
NCT00274209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509-71|Chromoendoscopy for Ulcerative Colitis Surveillance|Impact of Chromoendoscopy on the Detection of Neoplasia in Ulcerative Colitis||Indiana University|Yes|Completed|December 2005|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|endoscopic biopsies|Both|18 Years|N/A|No|Non-Probability Sample|Patients with ulcerative colitis satisfying criteria for surveillance colonoscopy|November 2011|November 21, 2011|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00274209||186360|
NCT00243087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446176|Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)|An Open Phase I Single Dose Escalation Study of BI 2536 Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma||Boehringer Ingelheim||Completed|July 2005|||August 2008|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|41|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00243087||188697|
NCT00224562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists|The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists||Assistance Publique - Hôpitaux de Paris||Recruiting|February 2004|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||February 2004|October 25, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00224562||190074|
NCT00224575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM03099|Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly|Therapeutical Impact of a Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly|IRIDIA|Assistance Publique - Hôpitaux de Paris|No|Terminated|November 2004|November 2006|Actual|November 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|260|||Both|75 Years|N/A|No|||March 2016|March 7, 2016|September 13, 2005||No|End of recruitment period|No||https://clinicaltrials.gov/show/NCT00224575||190073|
NCT00225446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 04 14|Micron Tracker: Computer-Assisted Orthognathic Surgery With a Third Generation Optic Repositioning System|Computer-Assisted Orthognathic Surgery With a Third Generation Optic Repositioning System.||University Hospital, Grenoble||Suspended|February 2006|January 2009|Anticipated|January 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2008|June 3, 2008|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225446||190007|
NCT00225706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-005|A Study of Caldolor in Hospitalized Febrile Pediatric Patients|Efficacy and Safety Study of Caldolor in Hospitalized Febrile Pediatric Patients||Cumberland Pharmaceuticals||Completed|October 2005|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|6 Months|17 Years|No|||October 2007|April 8, 2010|September 22, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00225706||189987|
NCT00225420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0420|Docetaxel, Androgen Ablation Therapy, and External-Beam Radiation Therapy in Treating Patients With High-Risk Localized Prostate Cancer|A Phase I/II Study of Concurrent Weekly Docetaxel (Taxotere®), Androgen Ablation, and Adaptive External Beam Radiotherapy for Localized High-Risk Adenocarcinoma of the Prostate|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|August 2005|August 2012|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|120 Years|No|||January 2016|January 20, 2016|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00225420||190009|
NCT00222222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nr.0244.4_1|Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis|Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis||Universitätsmedizin Mannheim|No|Completed|March 2003|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 14, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222222||190249|
NCT00232479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCC 2004-064|Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer|Phase II Study of Dose Dense Carboplatin and Taxotere With Herceptin As Primary Systemic Therapy in Breast Cancer||University of Miami|Yes|Completed|September 2005|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||July 2012|July 16, 2012|September 30, 2005||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00232479||189491|
NCT00232726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-201|Clinical Study of Previously Untreated Patients With Malignant Melanoma|A Non-Randomised, Multicentre, Phase II Clinical Study of CP-4055 in Chemotherapy-Naïve Patients With Metastatic Malignant Melanoma||Clavis Pharma|Yes|Completed|September 2005|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|42|||Both|18 Years|N/A|No|||July 2007|July 9, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00232726||189472|
NCT00234039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446074|S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin|Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG||Southwest Oncology Group|No|Completed|November 2006|April 2013|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|120 Years|No|||December 2015|December 8, 2015|October 5, 2005|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00234039||189373|
NCT00233272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030325|Baltimore Longitudinal Study of Aging|Longitudinal Studies of Human Physiology, Biochemistry, and Psychology (The Baltimore Longitudinal Syudy of Aging - BLSA)||National Institutes of Health Clinical Center (CC)||Recruiting|January 2003|||||N/A|Observational|N/A|||Anticipated|10000|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233272||189431|
NCT00235027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HS 11169|Improving Safety By Computerizing Outpatient Prescribing|Improving Safety By Computerizing Outpatient Prescribing||Agency for Healthcare Research and Quality (AHRQ)||Completed|August 2000|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|701|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235027||189299|
NCT00244972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00132|Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer|Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers||National Cancer Institute (NCI)||Active, not recruiting|October 2005|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|October 28, 2015|October 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244972||188553|
NCT00241150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2416|Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome|A Multicenter, Double Blind, Randomized Study With Two Parallel Groups Comparing The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome||Novartis||Completed|November 2002|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|80|||Female|45 Years|N/A|Accepts Healthy Volunteers|||June 2006|November 7, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00241150||188845|
NCT00241514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9617C00002|Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs||AstraZeneca||Completed|February 2001|February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||334|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00241514||188817|
NCT00242476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822A-009|A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Study to Assess the Effect of Vitamin D3 8400IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Aged 70 Years or Older||Merck Sharp & Dohme Corp.||Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|216|||Both|70 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|October 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00242476||188744|
NCT00242489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-007|Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)|A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.||Merck Sharp & Dohme Corp.||Completed|June 1998|July 2002|Actual|February 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1167|||Both|40 Years|N/A|No|||February 2015|February 24, 2015|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00242489||188743|
NCT00242502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0874|Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery|A Phase II Study of the Combination of Bevacizumab and Erlotinib in Patients With Unresectable Hepatocellular Carcinoma||M.D. Anderson Cancer Center|No|Completed|October 2005|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|October 18, 2005||No||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00242502||188742|
NCT00274521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.230|Tiotropium (Spiriva) Rehabilitation Study|A Randomized, Double-blind, Placebo Controlled 25-week Trial to Compare the Effect of Tiotropium Inhalation Capsuled (18 Mcg) Once Daily on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 8 Weeks of Pulmonary Rehabilitation.||Boehringer Ingelheim||Completed|May 2001|||February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274521||186337|
NCT00274534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.234|A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.|A Comparison of the Effects of Tiotropium (18 Mcg) Inhalation Capsule q.d. and Salmeterol (50 Mcg) Inhalation Aerosol b.i.d. on Arterial Blood Gases in a Double-blind, Double-dummy, 4-week Crossover Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|December 2000|July 2003||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|50 Years|N/A|No|||November 2013|November 4, 2013|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274534||186336|
NCT00274495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098-04|Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver|Randomized Placebo-Control Pilot Study Evaluating the Efficacy and Safety of Rosiglitazone Combined With Pegylated Interferon Plus Ribavirin Versus Pegylated Interferon Plus Ribavirin Alone in Genotype 1 Hepatitis C With Steatosis||Beth Israel Medical Center||Terminated|January 2006|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|21 Years|65 Years|No|||January 2006|October 31, 2007|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274495||186339|
NCT00274508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.223|Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients|Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study)||Boehringer Ingelheim||Completed|October 2000|||January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|261|||Both|40 Years|75 Years|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274508||186338|
NCT00224822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-0001|The Effects of Aripiprazole on Patients With Metabolic Syndrome|The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial||New Mexico VA Healthcare System|Yes|Completed|March 2004|March 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27|||Both|18 Years|65 Years|No|||September 2007|March 23, 2010|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224822||190054|
NCT00224835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|319|Mindfulness-Based Stress Reduction and Myocardial Ischemia|Mindfulness-Based Stress Reduction and Myocardial Ischemia||University of Florida|Yes|Completed|May 2003|August 2008|Actual|August 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||December 2013|December 13, 2013|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224835||190053|
NCT00224848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314|Guideline Adherence for Heart Health||GLAD Heart|National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|July 2002|August 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|21 Years|84 Years|Accepts Healthy Volunteers|||August 2008|November 9, 2015|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224848||190052|
NCT00231881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 05-3-H|Functional and Molecular Characterisation of Oesophageal Distal Epithelium: Correlations With Acid and Non Acid Reflux|Functional and Molecular Characterisation of Oesophageal Distal Epithelium: Correlations With Acid and Non Acid Reflux||Nantes University Hospital||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|60|||Both|18 Years|70 Years|No|||April 2007|April 27, 2007|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00231881||189537|
NCT00225719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-HDL-04-06|Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL|Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound.||CSL Limited||Completed|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|180|||Both|30 Years|75 Years|No|||November 2008|November 6, 2008|September 23, 2005||||No||https://clinicaltrials.gov/show/NCT00225719||189986|
NCT00225732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-008|Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Ibuprofen Injection (IVIb) for Treatment of Pain in the Post-Operative Adult Patients||Cumberland Pharmaceuticals|Yes|Completed|January 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Female|18 Years|70 Years|No|||August 2011|August 10, 2011|September 22, 2005|Yes|Yes||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00225732||189985|
NCT00232492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOK-015|Ketamine on Acute Pain in Females and Males|Effect of Racemic Ketamine on Pain in Females and Males After Surgical Removal of Third Molars||Oslo University Hospital|No|Completed|January 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|128|||Both|20 Years|30 Years|No|||April 2008|July 3, 2011|September 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232492||189490|
NCT00233012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002236|A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures|A Randomized, Open-label (OL), Multicenter Study With OL Extension of the Pharmacokinetics and Safety of Topiramate Administered as Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1-24 Months, Inclusive) With Refractory Partial-onset Seizures||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2005|October 2007|Actual|||Phase 1|Interventional|N/A|||Actual|16|||Both|1 Month|24 Months|No|||May 2010|May 24, 2010|October 3, 2005||||||https://clinicaltrials.gov/show/NCT00233012||189450|
NCT00233285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306|Factors in Childhood Lung Susceptibility to Pollution|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 1999|March 2009|Actual|March 2009|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2009|April 13, 2009|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00233285||189430|
NCT00234052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04L2|Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer||Northwestern University||Active, not recruiting|June 2005|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|October 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00234052||189372|
NCT00233701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPH-US04-001|Normal Pressure Hydrocephalus (NPH) Registry|Normal Pressure Hydrocephalus (NPH) Registry||Codman & Shurtleff|No|Completed|October 2004|September 2008|Actual|September 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|343|||Both|18 Years|N/A|No|Non-Probability Sample|NPH patient who is a candidate for a shunt. Can not be under that age of 18, have a known        contraindication for a shunt, or have an expected life span of less than 24 months.|October 2008|February 5, 2010|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00233701||189398|
NCT00234676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POETRY06032003|POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease|A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Safety, Tolerability and Efficacy of Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily) in Post Menopausal Women With Parkinson's Disease||The Parkinson Study Group||Completed|October 2003|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|23|||Female|N/A|75 Years|No|||December 2007|December 24, 2007|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00234676||189326|
NCT00234689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-99-1897-JZ-CTIL|Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients|||Sheba Medical Center||Completed|January 2002|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|18 Years|65 Years|No|||January 2008|January 28, 2008|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00234689||189325|
NCT00241163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-015-IN|TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN)|An Open, Randomised, Prospective, Multicentre, Parallel-group Trial to Compare Efficacy and Safety of TachoComb S Versus Standard Surgical Treatment in Patients Undergoing Surgical Resection of Superficial Renal Tumour.||Takeda|Yes|Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||170|||Both|18 Years|40 Years|No|||May 2012|August 1, 2012|October 16, 2005||||No||https://clinicaltrials.gov/show/NCT00241163||188844|
NCT00240799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002488|An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (3900 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee.||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|542|||Both|40 Years|N/A|No|||June 2015|June 18, 2015|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240799||188870|
NCT00240812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002497|A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting|A Comparative Study of Coadministered Doses of Ibuprofen and Pseudoephedrine HCl and Each Drug Alone in the Treatment of Primary Nocturnal Enuresis in Children||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||November 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|318|||Both|6 Years|11 Years|No|||June 2011|June 28, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240812||188869|
NCT00241878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334|Preschool Based Obesity Prevention Effectiveness Trial|Preschool Based Obesity Prevention Effectiveness Trial||National Heart, Lung, and Blood Institute (NHLBI)||Active, not recruiting|September 2006|May 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|648|||Both|3 Years|5 Years|No|||December 2007|January 18, 2008|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241878||188790|
NCT00241891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-7-4442|Behavior Change Family Counseling to Reduce Rate of Weight Gain in At-Risk Children|Primary Care Obesity Prevention: One or Multiple Targets||Children's Hospital of Philadelphia|No|Completed|July 2006|February 2015|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|158|||Both|8 Years|12 Years|No|||April 2015|April 6, 2015|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241891||188789|
NCT00241904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|335|Reducing Total Cardiovascular Risk in an Urban Community|Reducing Total Cardiovascular Risk in an Urban Community|COACH|Johns Hopkins University|Yes|Completed|May 2006|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|525|||Both|21 Years|80 Years|No|||February 2014|February 24, 2014|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241904||188788|
NCT00273377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302|The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection|The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection||Outcomes Research Consortium|Yes|Completed|May 2002|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2000|||Both|18 Years|80 Years|No|||October 2008|October 20, 2008|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273377||186423|
NCT00242164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRDA 05-2076|Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis|Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis||University of Michigan||Completed|November 2005|November 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||July 2005|December 8, 2014|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00242164||188768|
NCT00273676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG 99-64|Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia|Costs and Effects of Early Switch of Intravenous to Oral Antibiotics in Severe Community-Acquired Pneumonia: a Multicenter Randomized Trial||UMC Utrecht||Completed|July 2000|March 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||January 2006|January 5, 2006|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273676||186400|
NCT00273910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060069|Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma|Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma||National Institutes of Health Clinical Center (CC)|No|Completed|January 2006|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|104|||Both|7 Years|N/A|No|||October 2012|October 17, 2012|January 7, 2006|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00273910||186382|
NCT00273936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN-944-002|Trial of AVN-944 in Patients With Advanced Hematologic Malignancies|A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies||Vertex Pharmaceuticals Incorporated||Completed|January 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|72|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273936||186381|
NCT00274547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.266|Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Proportion of Patients Experiencing an Exacerbation and Proportion of Patients Hospitalized for an Exacerbation Over 6 Months During Treatment With Tiotropium 18 Mcg Capsule Once Daily in Patients With COPD in a Veterans Affairs Setting||Boehringer Ingelheim||Completed|September 2001|||February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1829|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274547||186335|
NCT00274560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.264|A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.|A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol in a 12 Week, Randomized, Double-Blind, Double-Dummy Parallel Group Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|May 2002|||March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|653|||Both|40 Years|N/A|No|||November 2013|November 8, 2013|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274560||186334|
NCT00274573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.257|Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity|Acute and Long-term Effects of Once Daily Oral Inhalation of Tiotropium 18 Mcg Dry Powder Inhalation Capsules in a Placebo Controlled Parallel Group Design Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity||Boehringer Ingelheim||Completed|March 2002|||October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1639|||Both|40 Years|N/A|No|||November 2013|November 20, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274573||186333|
NCT00225121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471001|Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors|A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of 2 Dosing Schedules Of PF-00299804 In Patients With Advanced Malignant Solid Tumors||Pfizer|No|Completed|October 2005|September 2010|Actual|April 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||April 2012|April 6, 2012|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00225121||190031|
NCT00231374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0489-2005|Measure of Cerebrospinal Fluid (CSF) Pressure Variation With Patient Positioning|In Vivo Analysis of Intradural Pressure Variation With Patient Positioning||Emory University||Withdrawn|September 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Both|18 Years|64 Years|No|||January 2014|January 8, 2014|October 3, 2005|||Difficulty in recruiting patients for the study.|No||https://clinicaltrials.gov/show/NCT00231374||189576|
NCT00225147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1205-01|Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Randomized, Placebo-controlled, Double Blind Phase II/III Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema||Pharming Technologies B.V.|Yes|Completed|July 2005|January 2010|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|77|||Both|12 Years|N/A|No|||February 2013|February 20, 2013|September 20, 2005|Yes|Yes||No|February 22, 2012|https://clinicaltrials.gov/show/NCT00225147||190030|
NCT00225433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803515|Luteal Phase FSH in the IVF Poor Responder|Luteal Phase Recombinant FSH vs. Follicular Phase Recombinant FSH for IVF Stimulation in the Poor Responder||University of Pennsylvania|No|Completed|September 2005|June 2008|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|20 Years|42 Years|No|||December 2015|December 1, 2015|September 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00225433||190008|
NCT00232193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-03-AVX|Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS|Steroid Adjunctive Treatment at Initiation of Avonex Therapy for Patients With Mono-Symptomatic or Relapsing-Remitting Multiple Sclerosis||Providence Multiple Sclerosis Center|No|Completed|December 2003|August 2010|Actual|December 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|55 Years|No|Non-Probability Sample|Treatment-naive MS patients with either RRMS or CIS, of either gender, between 18 to 55        years of age inclusive, with baseline EDSS of 0 to 3.5, fulfilling McDonald criteria for        MS or CHAMPS criteria for CIS, were randomly assigned to one of two treatment groups.|July 2011|July 20, 2011|September 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00232193||189513|
NCT00233038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001745|EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial|EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial||Massachusetts General Hospital|No|Completed|January 2005|March 2008|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233038||189448|
NCT00232180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141079|A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines|The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure|EMPHASIS-HF|Pfizer|Yes|Completed|March 2006|January 2012|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2743|||Both|55 Years|N/A|No|||March 2013|March 28, 2013|September 30, 2005|Yes|Yes||No|May 20, 2011|https://clinicaltrials.gov/show/NCT00232180||189514|
NCT00232739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-6320|Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions|A Multicenter, Non-Randomized Study of the 2.25mm Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions||Cordis Corporation|Yes|Completed|September 2003|August 2009|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||March 2010|March 11, 2010|October 3, 2005|Yes|Yes||No|October 19, 2009|https://clinicaltrials.gov/show/NCT00232739||189471|
NCT00234000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000442931|Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes|A Phase I Multicenter Study of Arsenic Trioxide and Azacitidine in Patients With Myelodysplastic Syndromes||Jonsson Comprehensive Cancer Center|Yes|Terminated|February 2007|||February 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2012|September 30, 2015|October 5, 2005|No|Yes|The study was closed due to poor enrollment|No||https://clinicaltrials.gov/show/NCT00234000||189375|
NCT00234026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 36/03|Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma|Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Gemcitabine for the Treatment of Patients With Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma||Swiss Group for Clinical Cancer Research|Yes|Completed|June 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2012|June 4, 2012|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00234026||189374|
NCT00234663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-003-CF|PTC124 for Cystic Fibrosis|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis||PTC Therapeutics||Completed|September 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|October 5, 2005||||||https://clinicaltrials.gov/show/NCT00234663||189327|
NCT00234702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-206|Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease|A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Lanthanum Carbonate for the Reduction of Serum Phosphorus in Subjects With Stage 3 and 4 Chronic Kidney Disease Who Have Elevated Serum Phosphorus Levels||Shire||Completed|October 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||April 2010|April 29, 2010|October 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00234702||189324|
NCT00234715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNREB#05-0601-CE|Psychosocial Study on Breast Cancer Risk Assessment|A Pilot Study: Psychosocial and Socio-Demographic Determinants of Accepting Breast Cancer Risk Assessment||University Health Network, Toronto|No|Completed|October 2005|August 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|62|||Female|25 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cohort recruited from the University Health Network community.|November 2007|November 13, 2007|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234715||189323|
NCT00240838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002866|An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.|A Randomized, Double-Blind Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.||Johnson & Johnson Consumer and Personal Products Worldwide||Completed|May 2003|June 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|483|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 28, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240838||188867|
NCT00241527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9617C00003|Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo and Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs||AstraZeneca||Completed|December 2000|September 2002|Actual|September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||556|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00241527||188816|
NCT00241540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9617C00001|Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo & Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs||AstraZeneca||Completed|January 2001|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||808|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00241540||188815|
NCT00273689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCP|Exercise Induced Bronchospasm in Children|"Pretreatment With Albuterol vs. Montelukast in Exercise Induced Bronchospasm in Children."||University of New Mexico|Yes|Completed|December 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|13|||Both|7 Years|17 Years|No|||May 2008|May 1, 2008|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273689||186399|
NCT00273390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e1473|A Clinical Trial of Infliximab for Uveitis|The Use of Remicade (Infliximab) in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression||Oregon Health and Science University||Completed|August 2001|December 2006|Actual|December 2006|Actual|N/A|Interventional|N/A||||32|||Both|9 Years|N/A|No|||January 2008|July 1, 2011|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273390||186422|
NCT00274222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-3|The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD|||Inonu University||Terminated|January 2003|October 2005||||N/A|Observational|N/A||||120|||Both|18 Years|80 Years|No|||January 2006|January 9, 2006|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274222||186359|
NCT00275054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455569|Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia|Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression||National Cancer Institute (NCI)||Recruiting|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|N/A|No|||July 2007|August 23, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275054||186296|
NCT00231634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002251|A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|May 2001|November 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|31|||Both|18 Years|75 Years|No|||January 2011|June 6, 2011|September 30, 2005|||Program discontinued|No||https://clinicaltrials.gov/show/NCT00231634||189556|
NCT00231621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003730|A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, One-year Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Dyslipidemia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|May 2001|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|179|||Both|18 Years|75 Years|No|||April 2010|June 6, 2011|September 30, 2005|||The study was terminated prior to completion to focus on the development of a controlled    release formulation.|No||https://clinicaltrials.gov/show/NCT00231621||189557|
NCT00233311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0052|Fast Food Study: Assessment of the Effects of Fast-Food on Inflammatory Markers|Assessment of the Postprandial Effects of a Fast-food on Inflammatory Markers||National Institutes of Health Clinical Center (CC)|No|Completed|March 2004|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|Samples With DNA|Serum, Whole Blood|Both|50 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|General Public|August 2012|August 3, 2012|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233311||189428|
NCT00232505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0403|Cetuximab With or Without Carboplatin in Treating Women With Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer|Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|November 2005|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Female|18 Years|120 Years|No|||January 2016|January 17, 2016|October 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232505||189489|
NCT00233714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-6318|Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions|A Randomized Feasibility Study of the Double Dose or Single Dose Sirolimus-Eluting BX VELOCITY Balloon-Expandable Stent for the Treatment of Diabetic Patients With de Novo Native Coronary Artery Lesions(3D)|3D|Cordis Corporation|No|Completed|May 2003|November 2009|Actual|July 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||November 2009|November 17, 2009|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00233714||189397|
NCT00233740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02-7001|Protection From Pulmonary Embolism With the Permanent OptEase™ Filter (PROOF)|The Cordis Protection From Pulmonary Embolism With the Permanent OptEase™ Filter - A Post Marketing Surveillance Study (PROOF Study)||Cordis Corporation|No|Completed|September 2003|May 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||August 2008|August 4, 2008|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233740||189395|
NCT00233753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USCNVP-01|Study of the Enterprise Self-Expanding Stent System With Endovascular Coil Embolization of Wide- Neck Saccular Intracranial Artery Aneurysms|Cordis Neurovascular Feasibility Study of the Enterprise Self-Expanding Stent System to Facilitate Endovascular Coil Embolization of Wide- Neck Saccular Intracranial Artery Aneurysms||Codman & Shurtleff||Completed|January 2004|December 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||January 2009|January 5, 2009|October 5, 2005||||||https://clinicaltrials.gov/show/NCT00233753||189394|
NCT00235066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC02-04|The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.|A Multicenter, Nonrandomized, Historical Controlled Study In Patients With De Novo Coronary Artery Lesions In Small VessELs Treated With The CYPHER™ STEnt|SVELTE|Cordis Corporation|Yes|Completed|November 2002|April 2006|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||September 2008|September 15, 2008|October 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235066||189296|
NCT00235079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCASL30501-4|Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP 2 Trial: COlchicine for Recurrent Pericarditis.|CORP 2|Azienda Sanitaria Locale 3, Torino|Yes|Completed|November 2005|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235079||189295|
NCT00234364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|permax|Pergolide Treatment and Valvular Heart Disease|||Århus Amt|No|Completed|March 2005|September 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|155|||Both|N/A|N/A|No|||September 2007|September 19, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00234364||189350|
NCT00235651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0509013|Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients|Pharmacokinetic and Deposition Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet®) in Lung Transplant Recipients (Radiotagging Protocol)||University of Pittsburgh||Terminated|October 2005|April 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|60 Years|No|||December 2008|December 16, 2008|October 6, 2005|||study completed|No||https://clinicaltrials.gov/show/NCT00235651||189254|
NCT00272805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS 2005-001|Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg|Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate Release(IR)on Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction||Cardiovascular Clinical Studies||Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|90 Years|No|||February 2013|February 15, 2013|January 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272805||186467|
NCT00272818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-07-042|Study to Identify Non-Invasive Markers of Gastrointestinal Allergy|Non Invasive Markers in the Diagnosis and Interval Assessment of Children and Adults With Known or Suspected Allergic Disease||Children's Hospital Boston||Completed|September 2004|December 2008|Actual|June 2008|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with known or suspected GI allergy.|January 2016|January 26, 2016|January 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00272818||186466|
NCT00241176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12189|Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder|Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder||New York University School of Medicine|Yes|Completed|September 2005|February 2010|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|7 Years|18 Years|No|||December 2012|December 14, 2012|October 14, 2005||No||No|June 7, 2012|https://clinicaltrials.gov/show/NCT00241176||188843|All subjects failed to respond to previous tic medications so could have unique tic symptoms, small sample size, and this was an open-label study, so we did not have a comparison group nor were we blinded to treatment.
NCT00241189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB Number: 01-10-045|Rapamycin Vs Methotrexate in Diffuse SSc|A 48-Week, Double-Blind, Randomized, Parallel Phase I/II Study of Oral Rapamycin Versus Methotrexate in Systemic Sclerosis (Scleroderma)||University of California, Los Angeles||Active, not recruiting|August 2002|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||October 2005|December 28, 2005|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00241189||188842|
NCT00273403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112299|Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA|Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA||The New York Academy of Medicine||Recruiting|November 1999|November 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||5100|||Both|N/A|N/A|No|||September 2006|September 21, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00273403||186421|
NCT00273702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511M77412|An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling|An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling||University of Minnesota - Clinical and Translational Science Institute||Completed|January 2006|September 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2007|April 27, 2007|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273702||186398|
NCT00273962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.45|A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)|A Comparison of Combivent® UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) in a Double-Blind Efficacy and Safety Study in Asthmatic Children With Severe Acute Exacerbation||Boehringer Ingelheim||Completed|May 2002|November 2003||November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|500|||Both|2 Years|10 Years|No|||October 2013|October 28, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00273962||186379|
NCT00274235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR10_01_2005|Intermittent Preventive Treatment During Pregnancy in Benin|Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine||Institut de Recherche pour le Developpement|Yes|Completed|July 2005|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|1600|||Female|N/A|N/A|No|||October 2008|October 30, 2008|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274235||186358|
NCT00232206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPMC-EACRI-IRB-05-032|Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer|A Phase II Study of Cisplatin Plus Docetaxel as Neoadjuvant Therapy for Stages IB Through Selected IIIA NSCLC||Providence Health & Services||Terminated|May 2005|November 2007||April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||May 2011|May 17, 2011|September 30, 2005|||study terminated due to slow accrual|No||https://clinicaltrials.gov/show/NCT00232206||189512|
NCT00231894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04T-584 Stanley Foundation|Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia|Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function||Nathan Kline Institute for Psychiatric Research|No|Completed|May 2005|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||April 2010|July 22, 2011|October 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00231894||189536|
NCT00232518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR076306|Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis|Randomised Controlled Clinical Trial of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis||University of Nottingham||Completed|September 2005|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||April 2005|May 4, 2007|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00232518||189488|
NCT00233324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0033|Surfactant Positive Airway Pressure and Pulse Oximetry Trial|Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants|SUPPORT|NICHD Neonatal Research Network|Yes|Active, not recruiting|February 2005|April 2016|Anticipated|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1316|||Both|24 Weeks|27 Weeks|No|||July 2015|July 21, 2015|October 3, 2005||No||No|November 16, 2014|https://clinicaltrials.gov/show/NCT00233324||189427|
NCT00233350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicentre_3DUS|Clinical Evaluation of Navigated 3D Ultrasound Multicentre Study|Clinical Evaluation of Navigated 3D Ultrasound Multicentre Study||Norwegian University of Science and Technology|No|Completed|January 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|142|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who were operated for intracranial high-grade gliomas (World Health        Organisation(WHO) grade III/IV) in the 3-year period between January 1st 2007 and December        31st 2009 in the Department of Neurosurgery, St. Olavs University Hospital, Trondheim,        Norway|October 2012|September 30, 2015|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00233350||189425|
NCT00233727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB3373|Screen and Treat for Cervical Cancer Prevention|Safety and Efficacy of Two Screen-and-Treat Approaches for the Prevention of Cervical Cancer|SAT|Columbia University|No|Terminated|January 2000|May 2013|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|7123|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|October 4, 2005||No|PI left University|No||https://clinicaltrials.gov/show/NCT00233727||189396|
NCT00233766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02-6314|Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX)|An Evaluation of Two Reduced Sirolimus Doses on the BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions(REDOX)||Cordis Corporation|No|Completed|September 2002|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2008|April 17, 2008|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00233766||189393|
NCT00235365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2005.2.gr|Metacognitive Therapy for Comorbid Insomnia|Metacognitive Therapy for Patients With a Psychiatric Disorder and Comorbid Insomnia.||Norwegian University of Science and Technology|No|Withdrawn|August 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 21, 2012|October 7, 2005||No|problems recruiting patients|No||https://clinicaltrials.gov/show/NCT00235365||189273|
NCT00235664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0504102|Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients|Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients||University of Pittsburgh||Completed|October 2005|December 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|Patients in ICU who are identified as having undergone liver, intestinal or multivisceral        transplantation.|December 2008|December 16, 2008|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235664||189253|
NCT00234377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00147|Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia|A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia||AstraZeneca||Completed|November 2004|May 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||550|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234377||189349|
NCT00234390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004-0299|PreAsthmaControl (PAC)|Prevention of Asthma in Infants/Young Children - PAC||AstraZeneca||Completed|November 1998|December 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|N/A|6 Months|No|||January 2011|January 21, 2011|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234390||189348|
NCT00231465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12905|Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer|Phase II Study of Taxotere® (Docetaxel) + ZD1839 (IRESSA®) in Previously Untreated Elderly Patients (≥70 Years Old) With Stage III-b (With Malignant Pleural Effusion [MPE+]) or Stage IV Non-Small Cell Lung Cancer (NSCLC)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|July 2003|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|70 Years|N/A|No|||August 2012|December 3, 2012|October 3, 2005|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00231465||189569|
NCT00231478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16633|A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy|A Randomized, Double-blind Study of 2 Dose Levels of Kytril on the Prevention of Post-operative Nausea and Vomiting in Pediatric Patients Undergoing Surgery With General Anesthesia||Hoffmann-La Roche||Completed|April 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|2 Years|16 Years|No|||May 2011|May 16, 2011|September 30, 2005|Yes|Yes||No|March 30, 2011|https://clinicaltrials.gov/show/NCT00231478||189568|
NCT00272831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWH 2005-146-T|The Use of Cilostazol in Patients With Diabetic Nephropathy|A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese||Chinese University of Hong Kong|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|20 Years|70 Years|No|||May 2009|May 21, 2009|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00272831||186465|
NCT00273143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1052-05|A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.|Kinetics of Cytomegalovirus (CMV) Replication and CMV-specific Immune Reconstitution After Hematopoietic Stem Cell Transplantation.||Mayo Clinic||Completed|May 2005|April 2007|Actual|April 2007|Actual|Phase 1|Observational|Time Perspective: Prospective||1||50|||Both|18 Years|N/A|No|Probability Sample|rticipants who will be undergoing blood marrow or stem cell transplant and donors that are        18 years of age or older, may be eligible to participate in this study.|May 2011|May 20, 2011|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00273143||186441|
NCT00273416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7771002|A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses|A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses Of PF-00592379 On Erectile Function, Using 100mg Sildenafil As A Positive Control||Pfizer||Completed|January 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Male|18 Years|65 Years|No|||August 2006|August 23, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00273416||186420|
NCT00273429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 04-015|Cosopt Versus Xalatan|||Pharmaceutical Research Network||Completed|April 2005|December 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2007|January 8, 2007|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273429||186419|
NCT00273988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1390|Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults|A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy||Boehringer Ingelheim||Completed|April 2002|October 2003||October 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||October 2013|October 30, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00273988||186377|
NCT00273975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1368|Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients|A Randomised Open Label Multi-centre Trial to Evaluate the Pharmacokinetic, Efficacy and Safety Parameters of Nevirapine 150mg/m2 and Nevirapine 4 or 7 mg/kg When Administered in Combination With AZT and 3TC for 48 Weeks in Antiretroviral naïve Paediatric Patients.||Boehringer Ingelheim||Completed|January 2002|December 2004||December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||123|||Both|3 Months|16 Years|No|||October 2013|October 30, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00273975||186378|
NCT00274586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.155|Headache Study to Compare Aggrenox Full Dose and Reduced Dose|Tolerability of a Four Weeks Treatment With Aggrenox® Modified Release Capsules b.i.d, Compared to Reduced Dose During the First Two Weeks of Treatment in a Double-Blind, Randomized Controlled Parallel Group Comparison Trial Among Taiwanese Patients With Previous TIAs or Ischemic Stroke||Boehringer Ingelheim||Completed|September 2002|April 2003||April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|20 Years|N/A|No|||October 2013|October 30, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274586||186332|
NCT00274599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.392|PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN|A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing MICARDIS® (Telmisartan 40-80-80 mg, QD) and ALTACE® (Ramipril 2.5-5-10 mg, QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring||Boehringer Ingelheim||Completed|October 2002|||December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|812|||Both|19 Years|N/A|No|||November 2013|November 7, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274599||186331|
NCT00274846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450852|Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia|Allogeneic Natural Killer Cells in Patients With Relapsed Acute Myelogenous Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Completed|March 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|2 Years|N/A|No|||November 2012|November 6, 2012|January 10, 2006|Yes|Yes||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00274846||186312|
NCT00275067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04C1|Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery|A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas||Northwestern University|Yes|Active, not recruiting|May 2005|May 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00275067||186295|
NCT00275080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00092|Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia|A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis||National Cancer Institute (NCI)||Completed|February 2006|August 2014|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||June 2014|August 26, 2014|January 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275080||186294|
NCT00232219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.188|Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion|Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.||Melbourne Health||Completed|January 2003|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|October 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00232219||189511|
NCT00232232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.074|Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia|||Melbourne Health||Completed|September 2003|November 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|October 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00232232||189510|
NCT00232752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-6319|Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions|A Multicenter, Non-Randomized Study of the 4.0mm Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions||Cordis Corporation|Yes|Completed|September 2003|November 2009|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||December 2009|December 1, 2009|October 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232752||189470|
NCT00233025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9072|Duloxetine Versus Placebo in the Treatment of FMS|Duloxetine 60/120mg Versus Placebo in the Treatment of Fibromyalgia Syndrome||Eli Lilly and Company||Completed|September 2005|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||320|||Both|18 Years|N/A|No|||August 2007|August 22, 2007|October 3, 2005||||||https://clinicaltrials.gov/show/NCT00233025||189449|
NCT00233051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-1728|Evaluating Genes in Sputum to Measure Drug Response in COPD|Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD||National Jewish Health||Terminated|April 2003|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|40 Years|N/A|No|||September 2014|September 24, 2014|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233051||189447|
NCT00233337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566A2401|Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers|Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients||Novartis||Completed|May 2001|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||April 2012|April 25, 2012|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233337||189426|
NCT00233363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-04-001|Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome|An Exploratory Study of Rebamipide to Evaluate Efficacy and Safety in the Treatment of Dry Mouth in Patients With Sjögren’s Syndrome||Otsuka Pharmaceutical Co., Ltd.||Completed|March 2005|January 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|20 Years|N/A|No|||May 2007|May 25, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233363||189424|
NCT00233376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-1999-11459|Computerized Decision Support System for Antibiotic Treatment|Improving Empirical Antibiotic Treatment Using TREAT,a Computerized Decision Support System. Cluster Randomized Trial||Rabin Medical Center||Completed|May 2004|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1500|||Both|16 Years|N/A|No|||October 2005|July 17, 2006|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233376||189423|
NCT00235378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR043274|Genetic Study of Lupus Patients and Their Families|Gene Mapping in Women With SLE||Oklahoma Medical Research Foundation|No|Completed|July 1996|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2356|Samples With DNA|Blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants include SLE patients, their unaffected family members, and healthy controls.|October 2015|October 13, 2015|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235378||189272|
NCT00235391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2203|Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload|A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators||Novartis||Completed|October 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1683|||Both|2 Years|N/A|No|||June 2011|June 3, 2011|October 6, 2005|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00235391||189271|
NCT00235404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 037-03|Randomized Controlled Trial of Health Care to Elderly Patients.|Specialized Treatment and Care Intervention at a Primary Level in a Nursing Home Compared to Conventional Treatment at a Hospital: a Randomized Controlled Trial.||Norwegian University of Science and Technology|No|Completed|September 2003|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|60 Years|N/A|No|||March 2012|March 27, 2012|October 7, 2005||||No||https://clinicaltrials.gov/show/NCT00235404||189270|
NCT00235352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR43 MH59450|Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia|A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia|CX516|North Suffolk Mental Health Association|Yes|Completed|February 2002|February 2007|Actual|April 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|65 Years||||February 2009|February 25, 2009|October 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00235352||189274|
NCT00231205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA 8524-5|TDI Preejection Velocities and Myocardial Viability|TDI-Derived Myocardial Preejection Velocities in Patients With Chronic Ischemic Left Ventricular Dysfunction Undergoing Surgical Revascularization||Charles University, Czech Republic||Recruiting|January 2005|December 2009||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||200|||Both|18 Years|N/A|No|||September 2005|September 30, 2005|September 30, 2005||||No||https://clinicaltrials.gov/show/NCT00231205||189588|
NCT00273169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-05|Use of the PSA 4000 Monitor in the Post-Operative Period in Patients Undergoing Major Surgery|Use of the PSA 4000 Monitor in the Post-Operative Period in Patients Undergoing Major Surgery||Mayo Clinic||Completed|July 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Detailed Population Description: The study population will include those patients that        have undergone surgery under general anesthesia at St. Marys Hospital, Mayo Clinic        Rochester, admitted to the 7MB D/E Intensive Care Unit and require intubation and        mechanical ventilation for a period of at least 4 hours after admission|January 2010|January 14, 2010|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273169||186439|
NCT00273156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1225-04|A Brief Dental Office Intervention With Tobacco Quitline|A Brief Dental Office Intervention With Tobacco Quitline||Mayo Clinic||Completed|February 2005|December 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 22, 2013|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00273156||186440|
NCT00273715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0715-F2L|Study of Sutures Versus Staples for Skin Closure After Surgical Procedures of Hip|A Comparative Randomized Efficacy Study of Sutures Versus Staples in Hip Surgical Procedures||University of Kentucky|No|Completed|December 2005|October 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273715||186397|
NCT00274001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1362|Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients|An Open, Randomised, Multicentre, Comparative Trial, to Evaluate the Benefit of Switching From a PI-based Regimen to a Nevirapine-based Regimen on the Quality of Life, Patient Adherence, Patient's Perception of Fat Redistribution and Metabolic Changes, in HIV+ Patients Suffering From Fat Abnormalities||Boehringer Ingelheim||Completed|September 2001|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|158|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274001||186376|
NCT00274261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN27500002|Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®|A Phase II/III Multicenter, Randomized, Double-masked, Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®||Health Decisions|Yes|Completed|June 2004|September 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1565|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|February 19, 2016|January 6, 2006|Yes|Yes||No|December 14, 2012|https://clinicaltrials.gov/show/NCT00274261||186356|
NCT00274248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03001|MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia|A Phase 1 Study of MLN518 Given in Combination With Standard Induction Chemotherapy for the Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia||Millennium Pharmaceuticals, Inc.||Completed|March 2005|||May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2008|February 7, 2008|January 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00274248||186357|
NCT00274612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.391|Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM|A Prospective Randomised Open- Label Blinded-Endpoint (PROBE) Trial Comparing Telmisartan (MICARDIS®) (40-80-80mg QD) and Ramipril (2.5-5--10mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. PRISMA = Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM|PRISMA|Boehringer Ingelheim||Completed|October 2002|November 2003||November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||801|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274612||186330|
NCT00274859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454320|Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer|Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes||National Cancer Institute (NCI)||Active, not recruiting|August 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||May 2007|July 23, 2008|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274859||186311|
NCT00275106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-NHL-2004-08|Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma|Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)||National Cancer Institute (NCI)||Terminated|September 2004|August 2012|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|600|||Both|N/A|21 Years|No|||April 2008|July 9, 2013|January 10, 2006|||Withdrawn due to an excess of toxic deaths|No||https://clinicaltrials.gov/show/NCT00275106||186292|
NCT00232531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04.OXA.020|Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function|Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function||University of Oxford||Active, not recruiting|September 2004|February 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||70|||Both|18 Years|N/A|No|||September 2006|January 26, 2007|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232531||189487|
NCT00233779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-7401|Evaluation of Sirolimus-Eluting, Heparin-Coated CoCr Stent in the Treatment of de Novo Coronary Artery Lesions in Small Vessels(EVOLUTION)|Sirolimus-Eluting, Heparin-Coated Cobalt Chromium Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions in Small Vessels (EVOLUTION)||Cordis Corporation|No|Completed|October 2003|December 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||June 2007|June 26, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233779||189392|
NCT00234065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02100-002|Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)|Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin||Otsuka Pharmaceutical Co., Ltd.|Yes|Completed|December 2003|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2800|||Both|20 Years|80 Years|No|||June 2011|June 9, 2011|October 4, 2005||No||No|April 19, 2011|https://clinicaltrials.gov/show/NCT00234065||189371|
NCT00232765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00-6302|Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)|A Multicenter, Randomized, Double-Blind Study of the Sirolimus-Coated BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions||Cordis Corporation|Yes|Completed|February 2001|November 2008|Actual|May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1058|||Both|18 Years|N/A|No|||September 2009|September 15, 2009|October 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232765||189469|
NCT00232778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00-5501|A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis (GAMMA V)|A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis (GAMMA V)||Cordis Corporation||Completed|May 2000|June 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||579|||Both|18 Years|85 Years|No|||April 2008|April 17, 2008|October 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00232778||189468|
NCT00233064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP116|Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)|A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease||MedImmune LLC|No|Completed|October 2005|November 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|417|||Both|N/A|24 Months|No|||January 2010|January 7, 2010|October 3, 2005|Yes|Yes||No|October 2, 2008|https://clinicaltrials.gov/show/NCT00233064||189446|Only serious adverse events were collected as part of the safety evaluation. One death (asphyxia) occurred in the Lyophilized Palivizumab group; this event was judged not related to study drug.
NCT00234741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5326-11|Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease||Synta Pharmaceuticals Corp.||Completed|November 2005|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||12|||Both|18 Years|75 Years||||December 2008|December 3, 2008|October 5, 2005||||||https://clinicaltrials.gov/show/NCT00234741||189321|
NCT00234767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS011620|Study of the Economics of Pulmonary Artery Catheter Use in Patients With Acute Respiratory Distress Syndrome (ARDS)|Economic Analysis of Pulmonary Artery Catheter Use (EA-PAC)||University of Pittsburgh||Completed|September 2001|||August 2007|Actual|Phase 3|Observational|Time Perspective: Prospective||||650|||Both|13 Years|N/A|No|||November 2008|November 5, 2008|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234767||189319|
NCT00235105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01|D2E7-Early AS|Adalimumab in Early Axial Spondyloarthritis (Without Radiological Sacroiliitis): Placebo Controlled Phase Over 3 Months Followed by a 9 Months Open Extension Phase||Charite University, Berlin, Germany||Active, not recruiting|March 2005|June 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||46|||Both|18 Years|N/A|No|||October 2005|December 8, 2005|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235105||189293|
NCT00235118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P98-4601|Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)|An Evaluation of the Safety and Effectiveness of the Cordis Bilateral AAA Device Compared to Open Surgical Repair for the Treatment of Abdominal Aortic Aneurysm||Cordis Corporation||Completed|December 1999|February 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||29|||Both|40 Years|N/A|No|||October 2005|December 8, 2005|October 6, 2005||||||https://clinicaltrials.gov/show/NCT00235118||189292|
NCT00231192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-8-4323|Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes|Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes||Children's Hospital of Philadelphia|Yes|Withdrawn|October 2005|August 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||November 2007|March 11, 2015|October 3, 2005|||Unable to recruit any subjects|No||https://clinicaltrials.gov/show/NCT00231192||189589|
NCT00222079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200308067|Evaluation of Esomeprazole in Treating Gastro-Esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy|Pilot Study to Evaluate Esomeprazole (Nexium) in Treating Gastro-Esophageal Reflux in Patients With Head and Neck Cancer With Prior External Beam Radiation Therapy: a Randomized, Prospective, Placebo-Controlled, Double-Blind Study.||University of Iowa||Recruiting|November 2004|August 2005|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|July 21, 2008|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00222079||190259|
NCT00273468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/15/C|To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)|A Randomised, Active Control, Double-Blind, Double-Dummy, Parallel-Group, Multi-National Study to Assess the Efficacy, Tolerability and Safety of the Granisetron Transdermal Delivery System in Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Administration of Moderately or Highly Emetogenic Multi-Day Chemotherapy||Prostrakan Pharmaceuticals||Completed|January 2006|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||630|||Both|15 Years|N/A|No|||May 2008|May 2, 2008|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273468||186416|
NCT00273481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 05-001|Cosopt Versus Xalacom|||Pharmaceutical Research Network||Completed|September 2005|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||33|||Both|18 Years|N/A|No|||November 2008|November 18, 2008|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273481||186415|
NCT00273442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 05-007|Assessing Cosopt Switch Patients|||Pharmaceutical Research Network||Completed|November 2005|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||November 2008|November 18, 2008|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273442||186418|
NCT00273455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 05-017|Lumigan Versus Cosopt|||Pharmaceutical Research Network||Completed|January 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||34|||Both|18 Years|N/A|No|||November 2008|November 18, 2008|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273455||186417|
NCT00274014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.214|Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders|Effects of Inhaled Tiotropium Bromide on Severity of Airflow Obstruction During Long-term Treatment in Patients With Moderately Severe Copd. Impact on Severity and Incidence of Exacerbations.||Boehringer Ingelheim||Completed|October 2000|October 2003||October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Both|41 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274014||186375|
NCT00274274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1657|Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes|Efficacy and Safety of Insulin Aspart in a Fixed or Flexible Supplementary Insulin Therapy Regimen, With or Without Insulin Detemir in Type 2 Diabetes||Novo Nordisk A/S|No|Completed|September 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|373|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274274||186355|
NCT00274287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412|GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere|A Phase II Pilot Study Investigating the Efficacy and Activity of Single Agent GM-CSF (Leukine) Maintenance Approach in Androgen-independent Prostate Cancer (AIPC) Patients Responding to Taxotere Chemotherapy||Oncology Specialists, S.C.|No|Completed|January 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 19, 2014|January 6, 2006||No||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00274287||186354|
NCT00274638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.387|PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)|A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group 6-week Treatment Study Comparing Telmisartan Combined With Hydrochlorothiazide (40 mg/12.5 mg or 80 mg/12.5 mg) Tablets With Losartan Combined With Hydrochlorothiazide (50 mg/12.5 mg) Tablets Using Ambulatory Blood Pressure Monitoring in Patients With Mild-to-Moderate Hypertension||Boehringer Ingelheim||Completed|July 2002|||July 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|805|||Both|18 Years|N/A|No|||December 2013|December 6, 2013|January 10, 2006||||||https://clinicaltrials.gov/show/NCT00274638||186328|
NCT00274625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1076-05-00|Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery|||Cook|No|Completed|August 2005|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|January 9, 2006|Yes|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00274625||186329|
NCT00274651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-6|A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas|A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas|PXD101-CLN-6|Onxeo|No|Terminated|January 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|January 10, 2006|Yes|Yes|Enrollment stopped prior to reaching expected number of patients, study had accumulated    sufficient data to allow a registration study in PTCL (PXD101-CLN-19)|No|June 30, 2014|https://clinicaltrials.gov/show/NCT00274651||186327|
NCT00274885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454401|Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer|Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin||National Cancer Institute (NCI)||Recruiting|October 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|N/A|No|||May 2007|December 2, 2011|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274885||186309|
NCT00275379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142A4-109|Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|August 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|18 Years|N/A|No|||March 2007|March 14, 2007|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00275379||186271|
NCT00272077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_3509|Insulin Glargine in Type 2 Diabetes Mellitus|Pilot Study on Glycaemic Variability in Type 2 Diabetes Mellitus Patients With Basal Insulin and Fixed Combo Oral Antidiabetic Treatment.||Sanofi||Completed|April 2005|||May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|45 Years|N/A|No|||December 2009|December 4, 2009|January 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00272077||186521|
NCT00233402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC B305/02|Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy|A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer||Photocure|Yes|Completed|January 2005|August 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|789|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|October 4, 2005|Yes|Yes||No|August 5, 2013|https://clinicaltrials.gov/show/NCT00233402||189421|
NCT00233792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P99-6301|FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent|An Evaluation of the Sirolimus Coated Modified BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo or Restenotic Native Coronary Artery Lesions.||Cordis Corporation|Yes|Completed|December 1999|March 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2007|October 11, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00233792||189391|
NCT00234078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037E-04-002|Dose-response Study of OPC-12759 Ophthalmic Suspension|Dose-response Study of OPC-12759 Ophthalmic Suspension||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2005|March 2007|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|290|||Both|20 Years|N/A|No|||January 2014|January 20, 2014|October 4, 2005||No||No|January 20, 2014|https://clinicaltrials.gov/show/NCT00234078||189370|
NCT00234403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0141|A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer|A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer||AstraZeneca||Completed|May 2004|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|18 Years|N/A|No|||April 2009|April 22, 2009|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234403||189347|
NCT00234416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0100|IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer|A Trial to Evaluate ZD1839 (IRESSA) in Combination With Radiotherapy & Gemcitabine as First-Line Treatment in Patients With Locally Advanced Pancreatic Cancer||AstraZeneca||Completed|August 2002|March 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|75 Years|No|||April 2009|April 22, 2009|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234416||189346|
NCT00234728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-2005-02|Study of a New Dressing for Use With Topical Medications|An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Occlusion of Topical Agents With a Hydrophilic Occlusive Dressing to Treatment With Occlusive Dressing Without the Addition of Topical Agents||Teikoku Pharma USA||Completed|September 2005|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 30, 2008|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234728||189322|
NCT00235092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC03-02|The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus|A Prospective, Randomized, Multi-Center Comparison of the Cypher Sirolimus-Eluting and the Taxus Paclitaxel-Eluting Stent Systems.||Cordis Corporation|Yes|Completed|August 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1335|||Both|18 Years|N/A|No|||April 2007|April 25, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00235092||189294|
NCT00225004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-06-002-AJ|Osteoporosis and Colles Fracture|Low-energy Fracture of the Wrist (Colles Fracture) and Osteoporosis. A Ten Year Follow-up and a Prospective Study||Northern Orthopaedic Division, Denmark||Terminated|July 2004|||||N/A|Observational|Time Perspective: Retrospective||1|||||Female|40 Years|N/A|No|Non-Probability Sample|years|April 2014|April 2, 2014|September 21, 2005||No|Recruiting problems|No||https://clinicaltrials.gov/show/NCT00225004||190040|
NCT00225849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPPP-05-07|Japanese Primary Prevention Project With Aspirin|Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP||Ministry of Health, Labour and Welfare, Japan||Recruiting|March 2005|September 2010||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||10000|||Both|60 Years|85 Years|No|||September 2005|September 22, 2005|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00225849||189977|
NCT00225862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100310|A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)|A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS)||GlaxoSmithKline||Completed|January 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|140|||Both|18 Years|79 Years|No|||September 2010|September 29, 2010|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00225862||189976|
NCT00225875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTAI|Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy|Evaluation De l’Efficacité Du Rituximab (Mabthéra) Chez l'Adulte Atteint d'Un Purpura thrombopénique Auto-Immun Chronique Et sévère Et Candidat à La splénectomie||Assistance Publique - Hôpitaux de Paris||Terminated|September 2003|July 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|18 Years|N/A|No|||March 2005|October 25, 2005|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00225875||189975|
NCT00235677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endoplac|Treatment Of Gastroesophageal Reflux Disease By Endoscopic Fundoplication, A Placebo-Controlled Study|A Blinded, Randomized, Sham-Controlled Trial of Endoscopic Gastroplication for the Treatment of Gastroesophageal Reflux Disease||UMC Utrecht||Completed|August 2003|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||July 2005|October 6, 2005|October 6, 2005||||No||https://clinicaltrials.gov/show/NCT00235677||189252|
NCT00235690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0509011|Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)|Pharmacokinetics and Pharmacodynamics of Intravenous Colistin- Pilot Study||University of Pittsburgh|Yes|Completed|June 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00235690||189251|
NCT00225888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS #03-47|Feasibility Study of Digital Photography and Group Discussion for People With Diabetes|Digital Photography and Group Discussion as a Means of Affecting Dietary Change Among People With Type 2 Diabetes: Feasibility Project||Joslin Diabetes Center||Completed|October 2004|October 2005|Actual|October 2005|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||February 2008|February 19, 2008|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225888||189974|
NCT00225901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRC02HG-I/II-1|Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure|Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant and Late-Onset Hepatic Failure||Kyoto University, Graduate School of Medicine||Recruiting|September 2005|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|16 Years|N/A|No|||September 2005|September 22, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225901||189973|
NCT00273195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213|Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG|Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG||Medtronic Cardiac Rhythm Disease Management||Completed|April 2004|June 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||October 2006|October 11, 2006|January 4, 2006||||||https://clinicaltrials.gov/show/NCT00273195||186437|
NCT00273728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swissmedic: 2005DR3123|BaSES Trial: Basel Starch Evaluation in Sepsis|Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BaSES (130;0.4) Trial|BaSES|University Hospital, Basel, Switzerland|No|Completed|May 2005|May 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|231|||Both|18 Years|N/A|No|||August 2011|August 11, 2011|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00273728||186396|
NCT00274040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.244|Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD|A Comparison of 18 μg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 μg, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD).||Boehringer Ingelheim||Completed|July 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||141|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274040||186373|
NCT00274300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJ HSV-001|Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2|A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2||PowderMed||Completed|August 2004|July 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|50 Years|No|||January 2006|January 25, 2007|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274300||186353|
NCT00274872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453890|Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2||National Cancer Institute (NCI)||Active, not recruiting|January 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|80 Years|No|||May 2007|January 29, 2010|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274872||186310|
NCT00274898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454352|Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer|Phase II Randomized Study Evaluting the Effect of Celecoxib as Maintenance Treatment of Stage IIIb Non-Small Cell Lung Cancer That Reponded or is Stable After Radiochemotherapy||National Cancer Institute (NCI)||Active, not recruiting|May 2004|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|75 Years|No|||September 2006|February 6, 2009|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274898||186308|
NCT00272090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_3507|Insulin Glargine in Type 1 Diabetes Mellitus|Italian Experience Trial for the Implementation of the Use of Lantus in Basal - Bolus Regimen in Type I Diabetes Mellitus Patients.||Sanofi||Completed|November 2002|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|489|||Both|18 Years|60 Years|No|||June 2011|June 7, 2011|January 2, 2006||||No||https://clinicaltrials.gov/show/NCT00272090||186520|
NCT00233415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0001|Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer|Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer||Stanford University||Completed|July 2003|May 2007|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|90 Years|No|||June 2010|June 1, 2010|October 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00233415||189420|
NCT00233428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L05-108|Study to Determine Racial and Gender Differences in Platelet Aggregation|Phase 1 Study to Determine Racial and Gender Differences in Platelet Aggregation||Texas Tech University Health Sciences Center||Completed|May 2005|May 2006|Actual|May 2006|Actual|Phase 1|Observational|Time Perspective: Prospective||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 11, 2015|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00233428||189419|
NCT00233805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC00-01|The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.|A Randomized Study With the Sirolimus Coated Modified BX Velocity Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions|RAVEL|Cordis Corporation|Yes|Completed|August 2000|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|85 Years|No|||August 2008|August 5, 2008|October 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00233805||189390|
NCT00234091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA TH001|When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)|An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|1 Year|12 Years|No|||December 2013|December 2, 2013|October 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00234091||189369|
NCT00234104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-03-001|A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of OPC-41061 in Congestive Heart Failure Patients With Extracellular Volume Expansion||Otsuka Pharmaceutical Co., Ltd.|No|Completed|August 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|122|||Both|20 Years|80 Years|No|||November 2013|November 6, 2013|October 4, 2005||No||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00234104||189368|
NCT00234429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0143|A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma|A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma||AstraZeneca||Completed|November 2003|June 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||74|||Both|18 Years|75 Years|No|||December 2007|December 14, 2007|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234429||189345|
NCT00234442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0569|Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer|A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy||AstraZeneca||Terminated|July 2004|February 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||47|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|October 5, 2005|||Closed due to insufficient recruitment.|No||https://clinicaltrials.gov/show/NCT00234442||189344|
NCT00234754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18421|Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women|Surgical Management of Stress Urinary Incontinence in Women: A Randomized Clinical Trial (RCT) of TOT vs TVT||University of Calgary|No|Active, not recruiting|September 2005|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|199|||Female|18 Years|N/A|No|||June 2013|June 25, 2013|October 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00234754||189320|
NCT00234780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6427|In Home Hospital Care Program|In Home Hospital Care Program||University of Rochester||Completed|October 1997|August 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|N/A|18 Years|No|||October 2005|August 15, 2007|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00234780||189318|
NCT00234793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 CA098964-02|Maternal Problem-Solving in Childhood Cancer|Maternal Problem-Solving in Childhood Cancer||University of Rochester||Completed|May 2003|April 2010||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|433|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 11, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00234793||189317|
NCT00225914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000115|Study of Paxil Use in Menopausal Women|Paroxetine Controlled Release in the Treatment of Symptomatic Menopausal Women Following Discontinuation of Hormone Therapy||Massachusetts General Hospital|No|Completed|September 2004|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Female|40 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 23, 2010|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225914||189972|
NCT00225342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlasUniRosiGlic|Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina|Effects of Rosiglitazone and Sulphonylureas on Ischaemic Burden, Blood Pressure and Novel Risk Markers Inclusive of Vascular Function in Patients With Chronic Stable Angina and Type 2 Diabetes Mellitus: A Randomised, Double-Blinded Study.||University of Glasgow||Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2005|September 7, 2006|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225342||190015|
NCT00226148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/0091|Immediate Implant Placement in the Molar Regions|Immediate Implant Placement in the Molar Regions||University of Aarhus|No|Completed|September 2005|September 2009|Actual|September 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 8, 2009|September 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00226148||189956|
NCT00226161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171178|Chronic Pain After Inguinal Herniorrhaphy|||University Hospital, Gentofte, Copenhagen||Terminated|September 2005|September 2013||September 2013||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Male|18 Years|80 Years||||September 2005|January 25, 2013|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00226161||189955|
NCT00222378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20043510|Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease|Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus DNA in Intestinal Mucosa of Patients With Inflammatory Bowel Disease||University of Miami|Yes|Completed|April 2005|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|129|Samples With DNA|Specimens will be discarded upon study completion|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with inflammatory bowel disease (ulcerative colitis and Crohn's Colitis), Other        inflammatory conditions of the colon|May 2015|July 28, 2015|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00222378||190238|
NCT00273533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE498/6007|Ramipril in Rheumatoid Arthritis|Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis||University of Zurich||Completed|June 2004|July 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|60 Years|No|||October 2006|July 21, 2008|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273533||186411|
NCT00273494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgery in NSCLC stage IIIA/N2|Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2|Scandinavian Neoadjuvant Phase III Study of Induction Chemotherapy Followed by Irradiation Alone or Surgery Plus Irradiation in NSCLC Stage IIIA/N2 (T1N2, T2N2, T3/N2).||Rigshospitalet, Denmark||Recruiting|January 1998|January 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|406|||Both|18 Years|75 Years|No|||May 2008|May 21, 2008|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273494||186414|
NCT00273507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neoadjuvant treatment in NSCLC|Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3|Neoadjuvant Chemotherapy in Resectable NSCLC Stages IB, IIA, IIB, and IIIA/T3 But Not IIIA/N2||Rigshospitalet, Denmark||Terminated|January 1998|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|75 Years|No|||September 2009|September 17, 2009|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273507||186413|
NCT00273520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_3503|TELICAST : Telithromycin in Acute Exacerbations of Asthma|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Telithromycin 800 mg (Once Daily for 10 Days) as a Supplement to the Standard of Care for Patients With Acute Exacerbations of Asthma||Sanofi|No|Completed|January 2003|May 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||September 2009|September 14, 2009|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00273520||186412|
NCT00273741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 29|Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients|Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients|Ritaline|University Hospital, Grenoble|Yes|Terminated|January 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|75 Years|No|||December 2009|December 4, 2009|January 6, 2006||No|difficulty of recrutement|No||https://clinicaltrials.gov/show/NCT00273741||186395|
NCT00273754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-03-108|The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).|A Pilot Study to Evaluate if Caffeine Helps Children With Obstructive Sleep Apnea Recover Faster From Anesthesia, and With Less Complications After General Anesthesia for Tonsillectomy and Adenoidectomy.|OSA|The University of Texas Health Science Center, Houston|No|Completed|September 2003|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|30 Months|18 Years|No|||December 2015|December 11, 2015|January 4, 2006|Yes|Yes||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00273754||186394|
NCT00274027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.231|Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)|Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Examine the Effects of Tiotropium on Lung Hyperinflation, Respiratory Mechanics and Dyspnea During Exercise in Patients With COPD||Boehringer Ingelheim||Completed|January 2001|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|19|||Both|40 Years|75 Years|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274027||186374|
NCT00274378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allomatrix radius UCL|Allomatrix Injectable Putty in Distal Radius Fractures|Allomatrix Injectable Putty in Distal Radius Fractures. Protocol for a Randomised, Controlled Clinical Study in Unstable Fractures of the Distal Radius||Université Catholique de Louvain||Completed|June 2005|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|70 Years|No|||July 2009|July 29, 2009|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00274378||186347|
NCT00275145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014514|Effects of Resistance and Aerobic Exercise on Cardiovascular Health|Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE II)|STRRIDE2|Duke University|No|Completed|May 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|261|||Both|18 Years|70 Years|No|||November 2011|May 23, 2013|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275145||186289|
NCT00275405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ajoene|Effect of Garlic on Inflammatory Mediators|Effect of Garlic Oil Macerate on Inflammatory Mediators in Healthy Normal Weight and Obese Subjects.||Albany Medical College||Suspended|April 2006|March 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 19, 2007|January 10, 2006|||Results inconclusive|No||https://clinicaltrials.gov/show/NCT00275405||186269|
NCT00233441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5165|Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter|Placebo Controlled Double Blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200, or 300 mg OD, With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter|MAIA|Sanofi||Completed|December 2004|May 2006|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|673|||Both|21 Years|N/A|No|||May 2012|May 7, 2012|October 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00233441||189418|
NCT00233454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-13704|Phase II Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia|A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 <Midostaurin> Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)||Stanford University|Yes|Active, not recruiting|March 2005|December 2017|Anticipated|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|October 3, 2005|Yes|Yes||No|June 16, 2015|https://clinicaltrials.gov/show/NCT00233454||189417|
NCT00224718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000708|Elective Abdominal Aortic Aneurism - Open Versus Endovascular Repair|ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal " Surgery Versus Endoprosthesis "|ACE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2003|February 2009|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|306|||Both|50 Years|N/A|No|||February 2009|March 31, 2009|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00224718||190062|
NCT00234117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-EMR-4037|Improvement in Bronchial Asthma in Patients With Extraesophageal Reflux After Acid Suppression|Overall Assessment of Improvement in Bronchial Asthma Patients With Extraesophageal Reflux After Effective Acid Suppression||Ponce Gastroenterology Research||Completed|July 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||October 2005|July 20, 2011|October 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00234117||189367|
NCT00234455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC01-02|A Study of the Cypher Sirolimus-Eluting Stent to Treat Bifurcation Lesions.|An Evaluation of the Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With Bifurcation Lesions.|BIFURCATION|Cordis Corporation|Yes|Completed|June 2001|April 2007|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||April 2008|April 28, 2008|October 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00234455||189343|
NCT00225602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH363004|Assertive Community Treatment in Copenhagen|Quasi-Experimental Trial of the Effect of Assertive Community Treatment Among Those With Severe Mental Disorder||Bispebjerg Hospital||Active, not recruiting|January 2004|May 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|No|||September 2005|September 22, 2005|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00225602||189995|
NCT00224731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2549-03|Sleep Disorders in Children With ADHD|Sleep Disorders in Children With ADHD||Hvolby, Allan, M.D.||Recruiting|December 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|5 Years|10 Years||||September 2005|October 25, 2006|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224731||190061|
NCT00225927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers|A Prospective, Randomized, Controlled Trial of Radioguided Seed Localization Versus Standard Needle Localization of Nonpalpable Breast Cancers||McMaster University|No|Completed|June 2004|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|333|||Female|18 Years|N/A|No|||March 2010|February 28, 2011|September 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00225927||189971|
NCT00225966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGU-003|Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control|Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control||MedtronicNeuro||Terminated|August 2004|October 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||153|||Both|16 Years|N/A||||November 2013|November 14, 2013|September 12, 2005||No|Study design was changed and is now InSite trial #1634 - See NCT00547378|No||https://clinicaltrials.gov/show/NCT00225966||189970|
NCT00221871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN02-0233-A|Proper Dosage of Ketamine in Intravenous Regional Anesthesia|Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).||University Health Network, Toronto||Recruiting|January 2004|January 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||September 2005|October 10, 2006|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00221871||190275|
NCT00222131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8777|Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients|Inhibition of Gastric Acid Is the Key To Satisfactory Relief of Symptoms and Restoration of the Quality of Life in Patients With Epigastric Pain Related to Non-Ulcer Dyspepsia During Therapy With Esomeprazole||University of Kansas Medical Center|No|Completed|October 2003|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|55 Years|No|||May 2015|May 1, 2015|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00222131||190255|
NCT00225615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-004|A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels|A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels||BioMarin Pharmaceutical||Completed|November 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|8 Years|N/A|No|||August 2009|August 18, 2009|September 22, 2005||||||https://clinicaltrials.gov/show/NCT00225615||189994|
NCT00222703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F31NR007343|Enhancing Tobacco Abstinence Following Hospitalization|Enhancing Tobacco Abstinence Following Hospitalization||University of Pittsburgh||Completed|May 2002|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||September 2005|September 14, 2005|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00222703||190215|
NCT00273767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 05 04|Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB|Double-blind Phase II Pilot Monocentric Randomized Clinical Trial Evaluating the Effect of a Preliminary Administration of Erythropoietin on Different Markers of Cardiac Ischemia Induced by Cardiopulmonary Bypass|EPOetCEC|University Hospital, Grenoble|Yes|Completed|January 2006|November 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00273767||186393|
NCT00274053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.256|Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD|Effect of a 9-month Treatment of SPIRIVA® on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. Validation of a New HRQoL Questionnaire Appropriate to Common Daily Practice. (TIPHON Study)||Boehringer Ingelheim||Completed|April 2002|April 2004||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|555|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274053||186372|
NCT00274313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parion 552-203|Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients|A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis||Parion Sciences||Completed|January 2006|August 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|14 Years|N/A|No|||January 2009|January 12, 2009|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00274313||186352|
NCT00274755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441015|Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas|Improved Characterization of Brain Tumors By MRI and MRS||University of California, San Francisco||Completed|November 2003|||April 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|250|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274755||186319|
NCT00274664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROTAS-091206|Patching for Lazy Eye: Trial to Evaluate Daily Patching Amounts|Randomised Occlusion Treatment of Amblyopia Study (ROTAS): Trial of Maximal Vs Substantial Doses of Occlusion to Evaluate Visual Outcome for Children With Amblyopia||City University, London||Completed|February 2002|May 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||December 2005|January 9, 2006|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274664||186326|
NCT00274677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA100223|Depression And Bipolar Disorder|A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Major Depression in Patients With Type II Bipolar Disorder||GlaxoSmithKline||Completed|November 2003|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274677||186325|
NCT00274690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT102245|Post-Operative Nausea And Vomiting Study In Female Patients|See Detailed Description||GlaxoSmithKline|No|Completed|February 2005|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|435|||Female|18 Years|55 Years|No|||April 2015|April 14, 2015|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274690||186324|
NCT00276315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-074|Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm|A Phase III, Multicentre, Randomised, Assessor-Blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm||Ipsen||Completed|December 2005|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||348|||Both|18 Years|80 Years|No|||July 2007|July 23, 2007|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276315||186206|
NCT00276328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-31-00250-009|Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults|Efficacy of Diosmectite (Smecta®) in the Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomised, Double Blind, Placebo Controlled, Parallel Groups Study.||Ipsen||Completed|January 2005|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|18 Years|65 Years|No|||January 2007|January 16, 2007|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276328||186205|
NCT00272064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3514|ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.|Optimisation of Insulin Treatment of Type 2 Diabetes Mellitus by Telecare Assistance for Self Monitoring of Blood Glucose (SMBG).||Sanofi||Completed|October 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|352|||Both|35 Years|70 Years|No|||December 2009|December 4, 2009|January 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00272064||186522|
NCT00272376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060058|Clinical and Genetic Studies in Families With Myopia and Related Diseases|Clinical and Molecular Studies in Families With Myopia and Related Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|December 2005|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|2000|||Both|4 Years|N/A|No|||July 2015|August 6, 2015|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00272376||186500|
NCT00272389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tBEB1t-HMO-CTIL|Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile|Prediction of Response to PEGINTERFERON and RIBAVIRIN Treatment in Patients With Chronic HCV Infection by Genetic Profile||Hadassah Medical Organization||Not yet recruiting|March 2006|May 2006|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|150|||Both|18 Years|80 Years|No|||January 2006|January 4, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272389||186499|
NCT00224471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208141/042|Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine|Study to Compare Immunogenicity & Safety of 3 Comercial Lots of GlaxoSmithKline (GSK) Biologicals' Herpes Simplex Candidate Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10-17 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10-17 y With Healthy HSV 1-/2- Adult Females||GlaxoSmithKline||Completed|December 2003|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|671|||Female|10 Years|17 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00224471||190081|
NCT00224484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208141/040|Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old|A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.||GlaxoSmithKline||Completed|April 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|5960|||Female|10 Years|17 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|September 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00224484||190080|
NCT00223925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1263-200|Maribavir for Prevention of CMV After Stem Cell Transplants|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants||Shire||Completed|October 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|111|||Both|18 Years|N/A|No|||March 2014|March 25, 2015|September 13, 2005||||||https://clinicaltrials.gov/show/NCT00223925||190123|
NCT00223938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR02023|Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.|A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin.||Watson Pharmaceuticals|No|Active, not recruiting|May 2004|September 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|291|||Both|18 Years|N/A|No|||February 2008|February 18, 2008|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00223938||190122|
NCT00224991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-06-001-AJ|Osteoporosis School|Effect of Training in Prevention of Falls, Compliance to Treatment and Quality of Life: A Randomized, Prospective Investigation.||Northern Orthopaedic Division, Denmark|No|Completed|June 1999|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||350|||Both|50 Years|N/A|No|||April 2014|April 2, 2014|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224991||190041|
NCT00225316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W05-0041|Maternal Acupuncture for Substance Abuse|Can Maternal Acupuncture for Chemically Dependent Pregnant Women Reduce the Severity of Neonatal Abstinence Syndrome? - A Randomized Controlled Trial||University of British Columbia|No|Completed|August 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2011|May 13, 2011|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00225316||190017|
NCT00225329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C01-0083|Early Labour Assessment and Support at Home|Early Labour Support at Home: RCT of Nurse Visits and Telephone Triage||University of British Columbia||Completed|September 2001|August 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1466|||Female|16 Years|42 Years|Accepts Healthy Volunteers|||September 2005|September 21, 2005|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225329||190016|
NCT00224744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 DIVE 03|Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage|Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage.||Institut Claudius Regaud||Completed|November 2005|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||June 2013|September 11, 2014|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00224744||190060|
NCT00225628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U18HS011046|Improving Quality With Outpatient Decision Support|Improving Quality With Outpatient Decision Support||Agency for Healthcare Research and Quality (AHRQ)||Completed|September 2000|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||3000|||Both|18 Years|N/A|No|||September 2005|September 23, 2005|September 22, 2005||||No||https://clinicaltrials.gov/show/NCT00225628||189993|
NCT00225992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-MDS-04|Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)|A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)||Oncology Specialties, Alabama|No|Terminated|February 2004|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|85 Years||||October 2012|October 10, 2012|September 22, 2005|Yes|Yes|terminated due to lack of accrual.|No||https://clinicaltrials.gov/show/NCT00225992||189968|
NCT00222144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9698|Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer|Phase II Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer||University of Kansas Medical Center|No|Completed|September 2004|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00222144||190254|
NCT00222391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-Anast-04|Influence of Thoracic Epidural Anesthesia on Skin Sympathetic Activity and Heart Rate Variability|Influence of Thoracic Epidural Anesthesia on Skin Sympathetic Activity and Heart Rate Variability in Surgical Patients||University Hospital Muenster||Completed|April 2004|January 2006||||N/A|Observational|Time Perspective: Prospective||||40|||Both|18 Years|N/A|No|||March 2006|January 6, 2009|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00222391||190237|
NCT00222118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-NR007773-01A2|Kansas University Teen Mothers Project|Promoting and Supporting Breastfeeding in Adolescents||University of Kansas Medical Center|No|Completed|October 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|390|||Female|15 Years|18 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222118||190256|
NCT00222417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP-177-04/721170|Audiometric Parameters in Conductive Hearing Loss and Middle Ear Disease|Audiometric Parameters in Conductive Hearing Loss and Middle Ear Disease||University Hospital of North Norway|No|Active, not recruiting|September 2002|December 2014|Anticipated|||Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|12 Years|N/A|No|Non-Probability Sample|Sample of patients scheduled for middle ear surgery at the University Hospital North        Norway in Tromsø.|June 2012|June 20, 2012|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00222417||190235|
NCT00273559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL092005-1|A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids|A Single Center, Open Label, Comparative, Controlled Trial to Assess the Risks and Benefits of Steroid Elimination vs. Steroid Therapy After Renal Transplantation||Florida Hospital Transplant Center|Yes|Active, not recruiting|January 2006|December 2008|Anticipated|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|de novo renal transplant recipients|November 2007|May 8, 2008|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273559||186409|
NCT00276367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/12/02|The Impact of Post Discharge One-Time Home Visit: Bridging the Gap Between Hospital and Home.|||Maimonides Medical Center||Withdrawn|October 2006|||||N/A|Observational|N/A||1|Actual|0|||Both|65 Years|N/A||Non-Probability Sample|Although IRB approval was received, study was not initiated.|May 2015|May 11, 2015|January 11, 2006||No|is involved in NIH study|No||https://clinicaltrials.gov/show/NCT00276367||186202|
NCT00276380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-00240-704|A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke|A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke||Ipsen||Completed|February 2003|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|50 Years|N/A|No|||July 2009|July 23, 2009|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00276380||186201|
NCT00273013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO102141|Study With GW274150 In Patients With Mild Asthma|A Two-centre, Randomised, Double-blind, Double-dummy, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of Treatment With Repeat Doses of GW274150 on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma.||GlaxoSmithKline||Completed|November 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||28|||Both|18 Years|55 Years|No|||February 2011|May 31, 2012|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00273013||186451|
NCT00273026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA103081|Study In Asthma Control|An Open-label, Multi-centre, Randomized, Parallel Group Clinical Effectiveness Study to Determine the Level of Asthma Control in Adolescent and Adult Patients With ADVAIR Versus Usual Care for 24 Weeks.||GlaxoSmithKline||Terminated|November 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||680|||Both|12 Years|N/A|No|||November 2012|November 21, 2012|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273026||186450|
NCT00274066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.258|Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva|The Acute Bronchodilator Effects of a Single Dose (2 Puffs) of the Shortacting Anticholinergic Ipratropium Bromide (40μg) and the Short-acting Beta-adrenergic Fenoterol (200μg) in Comparison to Placebo on Top of Pharmacodynamic Steady State of Once Daily Tiotropium (18μg) Inhalation Capsule in Patients With Chronic Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|October 2002|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||65|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274066||186371|
NCT00274326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5816|DILIPO (DILutIonal HyPOnatremia)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia||Sanofi||Completed|May 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2008|September 12, 2008|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274326||186351|
NCT00274703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEE103226|An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults||GlaxoSmithKline|No|Completed|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||February 2011|May 31, 2012|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274703||186323|
NCT00242411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00008|MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults|A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults. A Randomized, Open, Parallel-group, Multicentre 26-weeks Study||AstraZeneca||Completed|September 2004|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1900|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242411||188749|
NCT00242697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARF1|Double-Blind Comparison of Combined General-Spinal Anesthesia to General Anesthesia for Coronary Artery Surgery|A Randomized Double-Blind Comparison of Combined General-Spinal Anesthesia to General Anesthesia for Coronary Artery Surgery||University of Calgary||Completed|April 2002|July 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||63|||Both|25 Years|80 Years|No|||October 2005|October 19, 2005|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242697||188727|
NCT00272961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1341001|A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.|A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension||Pfizer|No|Terminated|January 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|January 4, 2006|Yes|Yes|See termination reason in detailed description.|No|January 28, 2013|https://clinicaltrials.gov/show/NCT00272961||186455|Results for ‘change from standing to sitting SBP and DBP’ and ‘change from pre-dose to post-dose SBP and DBP’ are reported only at Week 10 as per changes in planned analysis because of early termination of the study and clinical development program.
NCT00272974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9713|Madagascar Female Condom Study|Measuring the Impact of Male and Female Condom Promotion Among Commercial Sex Workers in Madagascar||FHI 360||Completed|February 2001|August 2003||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1000|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2003|January 4, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272974||186454|
NCT00223704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #051171|Bradykinin Receptor Antagonism During Cardiopulmonary Bypass|Bradykinin Receptor Antagonism During Cardiopulmonary Bypass|BRAC|Vanderbilt University|Yes|Completed|May 2006|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Both|18 Years|80 Years|No|||October 2013|October 15, 2013|September 19, 2005|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00223704||190139|This study was conducted in a population that predominantly underwent valve-only surgery. We cannot exclude the possibility that our results may have been different if we studied only coronary artery bypass graft surgery patients.
NCT00224757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0415|Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation - TIARA Pilot Study|Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation|TIARA|The Interuniversity Cardiology Institute of the Netherlands|Yes|Completed|September 2005|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|N/A|No|||September 2011|September 5, 2011|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00224757||190059|
NCT00224250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27269|Ultrasound Study of the Uterine Healing Process After Cesarean Delivery|Ultrasonographic Assessment of the Uterine Scarring Process Following Closure of the Uterus in One Versus Two Layer Technique.||Yale University||Completed|January 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2006|December 7, 2006|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00224250||190098|
NCT00224497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ3100603|A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease|A Phase IIa/b Double-blind, Randomised, Placebo-controlled, Linear Trend Design Dose-ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease||GlaxoSmithKline||Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||380|||Both|50 Years|85 Years|No|||December 2009|December 23, 2009|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224497||190079|
NCT00224510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA30905|A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium|See Detailed Description||GlaxoSmithKline|No|Completed|August 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224510||190078|
NCT00225641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLOFOL|Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer|COLOFOL - A Pragmatic Study to Assess the Frequency of Surveillance Tests After Curative Resection in Patients With Stage II and III Colorectal Cancer - a Randomised Multicentre Trial||Bispebjerg Hospital|Yes|Active, not recruiting|March 2006|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2500|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00225641||189992|
NCT00221910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN02-0771-B|Use of Ultrasound in Lower Extremity Blocks.|Does Ultrasound Guidance Improve the Success of Sciatic Nerve Block at the Popliteal Fossa? A Prospective, Randomized, Controlled Trial.||University Health Network, Toronto||Completed|February 2003|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|85 Years|No|||March 2005|December 4, 2008|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00221910||190272|
NCT00222404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 04 40|Pharmacogenomic Study Realized on "Non-small Cell Lung Carcinoma"|Pharmacogenomic Study Realized Within the Framework of the Common Care to "Non-small Cell Lung Carcinoma" at Any Stages Treated by Chemotherapy.|Pharmacogenos|University Hospital, Grenoble||Completed|July 2005|August 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|556|||Both|18 Years|N/A|No|Non-Probability Sample|Patient older than 18 suffering from Non-Small-Cell Lung Carcinoma          -  Patient treated by chemotherapy with platinum salt          -  Every stage TNM classification          -  No previous chemotherapy          -  One measurable lesion out of nervous central system at least|November 2010|November 4, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00222404||190236|
NCT00222170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE Study|Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)|Esophagoprotection by Rabeprazole Mediated by Restoration of an Impairment in Esophageal Mucin Production: Its Potential Therapeutic Benefit in Patients With Gastroesophageal Reflux Disease (GERD)||University of Kansas Medical Center|No|Completed|May 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|19 Years|79 Years|No|||August 2007|May 7, 2009|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222170||190253|
NCT00222430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11854|Fluoroscopy Guided Femoral Arterial Access|Fluoroscopy Guided Femoral Arterial Access and the Use of Closure Devices: A Randomized Controlled Trial.||University of Oklahoma|No|Completed|March 2005|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|990|||Both|18 Years|N/A|No|||March 2012|March 27, 2012|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00222430||190234|
NCT00276081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO3 HD042609 NIH/NICHD|Gabapentin Versus Estrogen for the Treatment of Hot Flashes|A Randomized Trial of Gabapentin, Estrogen and Placebo for the Treatment of Postmenopausal Hot Flashes||University of Rochester||Completed|May 2002|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||January 2006|November 27, 2006|January 11, 2006||||||https://clinicaltrials.gov/show/NCT00276081||186224|
NCT00272701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00085|Esomeprazole in PPI Failures - IMPROVE|A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks.||AstraZeneca||Completed|December 2005|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|450|||Both|18 Years|65 Years|No|||August 2007|March 5, 2009|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272701||186475|
NCT00275730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9-11-2004|Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers|Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers||Medical University of Vienna||Completed|January 2006|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2007|February 9, 2007|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275730||186246|
NCT00276055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0509C|Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma|Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma||New Mexico Cancer Care Alliance|Yes|Completed|November 2005|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|January 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00276055||186226|
NCT00241787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314|Progression of Sub-Clinical Atherosclerosis|||Tufts Medical Center||Completed|September 2005|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2900|||Both|18 Years|100 Years|No|Non-Probability Sample|Community based in Framingham MA|November 2015|November 30, 2015|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241787||188796|
NCT00241800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1315|Medications and the Risk of Sudden Cardiac Death|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2005|May 2010|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||April 2012|April 26, 2012|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241800||188795|
NCT00242710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-304|Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women|A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women||Pfizer|No|Completed|September 2005|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1083|||Female|40 Years|65 Years|No|||October 2013|October 30, 2013|October 18, 2005|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00242710||188726|
NCT00224523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR104503|Long Term Safety Of GW685698X Via Nasal Biopsy|See Detailed Description||GlaxoSmithKline||Completed|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 13, 2008|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00224523||190077|
NCT00224276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-USA-302|Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics|Prevalence and Incidence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics||Yale University||Completed||||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|N/A|N/A|No|||September 2005|September 16, 2005|September 16, 2005||||No||https://clinicaltrials.gov/show/NCT00224276||190096|
NCT00224783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D153 P800|Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults|Placebo-controlled Double-blind Controlled Trial of Single Intranasal Inoculation of CAIV-T Liquid Formulation in Healthy Japanese Male Adults||MedImmune LLC|No|Completed|August 2002|September 2002|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|45|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|September 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00224783||190057|
NCT00225043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|299|A Randomized, Double-Blind, Trial Comparing Epinephrine Versus Phenylephrine as a Vasoconstrictor in Regional Anesthesia for Upper Extremity Surgery|||New York Methodist Hospital||Completed|June 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 30, 2008|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225043||190037|
NCT00224796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC2001-07|Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot|A Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure® Therapy in the Treatment and Blinded Evaluation of Amputation Wounds of the Diabetic Foot||KCI USA, Inc.||Completed|May 2002|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||146|||Both|18 Years|N/A|No|||September 2005|July 19, 2006|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00224796||190056|
NCT00225017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SABAR|Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study|Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study: Endothelial Function in HIV-Infected Subjects Switched to an Atazanavir Regimen|SABAR|Northwestern University|Yes|Completed|June 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|September 21, 2005|Yes|Yes||No|October 4, 2010|https://clinicaltrials.gov/show/NCT00225017||190039|
NCT00225030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHAP-DK|Observational Study of the Prognosis in Treated Arterial Hypertension|Observational Study of the Prognosis in Treated Arterial Hypertension||Odense University Hospital||Completed|January 1970|July 2004||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||1000|||Both|18 Years|N/A|No|||July 2004|September 13, 2005|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00225030||190038|
NCT00225355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlasUniRosiPlacebo|Rosiglitazone Versus Placebo in Chronic Stable Angina|Insulin Sensitisation as a Novel Mechanism to Lessen Ischaemic Burden in Overweight Non-Diabetic Patients With Chronic Stable Angina: A Pilot Study||University of Glasgow||Terminated|February 2006|November 2006|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||February 2009|February 18, 2009|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225355||190014|
NCT00225368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB 544 D4(1)|Effects of Insecticide Treated Bednets on Child Morbidity and Mortality|Long Term Effects of Insecticide Treated Bednets on the Morbidity and Mortality Caused by Malaria and on the Overall Mortality in Young Children of a Rural Population in Burkina Faso||Heidelberg University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|15 Days||||September 2005|February 5, 2010|September 21, 2005||||No||https://clinicaltrials.gov/show/NCT00225368||190013|
NCT00225979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995B2402|Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly|Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly||Novartis||Completed|November 2002|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|80 Years|No|||April 2012|April 10, 2012|September 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00225979||189969|
NCT00222781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311010|Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus|Three-Tracer PET Quantitation of Insulin Action in Muscle||University of Pittsburgh||Completed|January 2004|December 2006||||N/A|Observational|Time Perspective: Prospective||||24|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 14, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00222781||190209|
NCT00222794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308023|A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia|A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder||University of Pittsburgh||Completed|November 2003|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|18 Years|65 Years|No|||January 2008|August 30, 2010|September 8, 2005||||No||https://clinicaltrials.gov/show/NCT00222794||190208|
NCT00221884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN02-0430-E|Use of Ultrasound in Upper Extremity Blocks.|Does Ultrasound Guidance Improve the Success of Brachial Plexus Block? A Prospective, Randomized, Controlled Trial.||University Health Network, Toronto||Completed|August 2002|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|80 Years|No|||September 2005|December 4, 2008|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00221884||190274|
NCT00222183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM-DE-08|Cutaneous Lupus Erythematosus and Elidel|Evaluation of the Therapeutic Effect and Local Tolerability of Elidel® Cream 1% (Pimecrolimus) in Chronic Discoid Lupus Erythematosus (dLE) or Subacute Cutaneous Lupus Erythematosus (scLE)||University of Leipzig||Recruiting|June 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|No|||February 2007|April 5, 2007|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00222183||190252|
NCT00222196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBACT|Oslo Balloon Angioplasty Versus Conservative Treatment|Oslo Balloon Angioplasty Versus Conservative Treatment||Oslo University Hospital||Completed|November 2000|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|N/A|75 Days|No|||September 2005|July 3, 2011|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00222196||190251|
NCT00222768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502008|PET Imaging of Regional Variation in Insulin Sensitivity of Adipose Tissue in Humans|Three-Tracer PET Quantitation of Insulin Action in Muscle||University of Pittsburgh||Completed|April 2005|December 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||20|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 15, 2008|September 19, 2005||||No||https://clinicaltrials.gov/show/NCT00222768||190210|
NCT00272428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-706|Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.|The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|October 1994|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||13000|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||October 2007|December 16, 2009|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272428||186496|
NCT00273598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019970040|Comparing Two Instrumentation Systems for the Treatment of Adolescent Scoliosis|Comparing the Moss Miami and Universal Spinal Instrumentation Systems for the Treatment of Adolescent Idiopathic Scoliosis||The Hospital for Sick Children||Completed|September 1997|September 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||126|||Both|8 Years|18 Years|No|||December 2013|December 2, 2013|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00273598||186406|
NCT00273611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0799|Vitamin D Levels and Vitamin D Education in Geriatric Patients|Characterization of Vitamin D Levels and Affect of Pharmacist-initiated Vitamin D Education in Geriatric Outpatients.||University of Colorado, Denver|No|Completed|December 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|65 Years|89 Years|No|||November 2013|November 18, 2013|January 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00273611||186405|
NCT00274937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAR0331|Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer|Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study||Children's Oncology Group|Yes|Active, not recruiting|February 2006|||December 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|N/A|18 Years|No|||March 2015|March 3, 2015|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00274937||186305|
NCT00274950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454553|Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors|Protocol for the Treatment of Extracranial Germ Cell Tumours in Children and Adolescents (GC III)||National Cancer Institute (NCI)||Active, not recruiting|May 2005|||May 2010|Anticipated|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|105|||Both|N/A|17 Years|No|||June 2009|September 16, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274950||186304|
NCT00241774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA2906|Coronary Heart Disease Incidence: Depression & Inflammation Risk|Coronary Heart Disease Incidence: Depression & Inflammation Risk||Columbia University|No|Completed|August 2005|May 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3227|Samples With DNA|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the      time of enrollment, epidemiologic data as well as blood samples were obtained. The      participants have since been followed prospectively for a variety of health outcomes. We      plan to assay stored blood samples collected in 1995 for markers of inflammation and link      these results to existing epidemiologic and outcomes data, specifically the 7-year incidence      of CAD events. Buffy coats were also obtained from the blood samples of the SAME      participants for future DNA analysis.|Both|18 Years|N/A|No|Non-Probability Sample|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the        time of enrollment, epidemiologic data as well as blood samples were obtained. The        participants have since been followed prospectively for a variety of health outcomes. We        plan to assay stored blood samples collected in 1995 for markers of inflammation and link        these results to existing epidemiologic and outcomes data, specifically the 7-year        incidence of CAD events.|February 2016|February 4, 2016|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241774||188797|
NCT00242125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0630-AE|Family Studies in Primary Biliary Cirrhosis (PBC)|Family Studies in Primary Biliary Cirrhosis||University Health Network, Toronto||Recruiting|October 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||3000|||Both|18 Years|80 Years|No|||October 2005|January 13, 2006|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242125||188771|
NCT00242450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-02-012|Metoclopramide Use in Very Low Birth Weight Newborns|The Effect of Metoclopramide on Feeding in Very Low Birthweight Newborns : a Randomized, Double Blind, Placebo Controlled Pilot Study and a Proposal for a Multicentre Trial||Lawson Health Research Institute||Completed|March 2002|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|N/A|7 Days|No|||May 2005|December 14, 2005|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242450||188746|
NCT00242762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0504|ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer|A Phase II Study to Evaluate the Safety and Efficacy of the Combination of ZD1839 (IRESSA™), Docetaxel and Cisplatin in Subjects With Recurrent and/or Metastatic Head and Neck Cancer||AstraZeneca||Completed|July 2003|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|70 Years|No|||January 2011|January 25, 2011|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00242762||188722|
NCT00242138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0552-C|Erectile Dysfunction/Prostate/RT/Androgen|A Cross-Sectional Study of Erectile Dysfunction in Patients With Locally Advanced Prostate Cancer Who Have Undergone Radiotherapy and Prolonged Pharmacological Androgen Ablation||University Health Network, Toronto||Completed|March 2000|April 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||50|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242138||188770|
NCT00224770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICH01|Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation|Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation|MISTIE|Johns Hopkins University|Yes|Completed|August 2005|April 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|141|||Both|18 Years|80 Years|No|||June 2015|June 17, 2015|September 21, 2005|Yes|Yes||No|September 21, 2014|https://clinicaltrials.gov/show/NCT00224770||190058|
NCT00225069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPSY1-2005|Thoracoscopic Sympathectomy for Blushing|Thoracoscopic Sympathectomy for Blushing. A Prospective Randomised Trial.||Odense University Hospital||Completed|September 2005|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||August 2012|August 22, 2012|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00225069||190035|
NCT00225056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIBRE02|Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma|Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma||Oncology Specialties, Alabama||Terminated|October 2003|November 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Female|19 Years|85 Years||||April 2007|April 18, 2007|September 21, 2005|||Terminated due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00225056||190036|
NCT00225381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL042637|Gas Kinetics and Metabolism in Anesthesia During Non Steady State|Gas Kinetics and Metabolism in Anesthesia During Non Steady State||University of California, Irvine|No|Recruiting|August 2005|December 2011|Anticipated|||Phase 1|Observational|Observational Model: Case-Only||7|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult patients in the supine position excluding surgeries around the head and neck area|February 2011|February 10, 2011|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00225381||190012|
NCT00225654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505|The ELUTES Clinical Trial|The ELUTES Clinical Trial (European Evaluation of Paclitaxel Eluting Stent)|ELUTES I|Cook||Completed|January 2000|November 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||192|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225654||189991|
NCT00225667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099104|Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers|Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension, Permanent Pacemakers and Risk Factors for Developing Atrial Fibrillation||Connolly, Stuart, M.D.||Not yet recruiting|December 2005|July 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2005|November 22, 2005|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00225667||189990|
NCT00232986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.32.04.02.23.A2|A Comparison of Survey Methodologies to Elicit Sensitive Information From Adolescents in Urban India|A Comparison of Survey Methodologies to Elicit Information on Sexual and Reproductive Health From Adolescents in Urban India||Johns Hopkins Bloomberg School of Public Health||Completed|September 2004|November 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||960|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||October 2005|October 3, 2005|October 3, 2005||||No||https://clinicaltrials.gov/show/NCT00232986||189452|
NCT00232999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-201-04-142|Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma|||Teva Pharmaceutical Industries||Completed|October 2005|January 2006|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|60 Years|No|||September 2008|July 3, 2012|October 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00232999||189451|
NCT00221897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-EY08208; RO1-EY11008|Diagnostic Innovations in Glaucoma Study|Diagnostic Innovations in Glaucoma Study|DIGS|University of California, San Diego|No|Recruiting|April 1995|July 2016|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults|August 2011|August 29, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00221897||190273|
NCT00222443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC Toca One|Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy|Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy||University of Oklahoma||Completed|September 2004|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|1 Year|21 Years|No|||September 2008|September 19, 2008|September 20, 2005||||No||https://clinicaltrials.gov/show/NCT00222443||190233|
NCT00240591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEX104526|Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab|A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH TOSITUMOMAB AND/OR IODINE I 131 TOSITUMOMAB IN STUDIES RIT-I-000, RIT-II-001, RIT-II-002, RIT-II-004, or CP-97-012||GlaxoSmithKline|No|Completed|October 2003|June 2010|Actual|June 2010|Actual|N/A|Observational|N/A||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of patients with NHL previously treated at least 2 years ago        with Tositumomab and/or Iodine I 131 Tositumomab on Study RIT-I-000, RIT-II-001,        RIT-II-002, RIT-II-004, or CP-97-012.|November 2015|November 9, 2015|October 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00240591||188886|
NCT00240604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-29.10.04-HMO-CTIL|Prevention of Corticosteroid-induced Glucose Intolerance|Treatment With Rosiglitazone for the Prevention of Glucose Intolerance in Patients Treated With Corticosteroids||Hadassah Medical Organization||Recruiting|April 2005|October 2015|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|October 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00240604||188885|
NCT00263861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU6Z03|Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors|Impact of Treatment With Taxane or Platinum-Containing Regimens on Peripheral Nerve Functioning in Older Cancer Patients With Diabetes: An Exploratory Study||Case Comprehensive Cancer Center|Yes|Completed|March 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|65 Years|N/A|No|||June 2010|June 10, 2010|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263861||187136|
NCT00264797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0028|Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)|Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)||University of Cincinnati|Yes|Completed|February 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|303|||Both|13 Years|18 Years|No|||May 2013|May 2, 2013|December 10, 2005||No||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00264797||187065|
NCT00264173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R_8740|VALID : VAlproate Versus LIthium in Bipolar Disorders|A Twelve-Week, Open, Randomized Trial Comparing Valproate to Lithium in Bipolar I Patients Suffering From a Manic Episode||Sanofi||Completed|February 2004|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|75 Years|No|||November 2007|November 15, 2007|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264173||187113|
NCT00264771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0082|Hospital Based Incidence of Group A Streptococcal Disease in Fiji|The Hospital Based Incidence of Acute Rheumatic Fever and Rheumatic Heart Disease, Acute Post Streptococcal Glomerulonephritis and Invasive Group A Streptococcal Disease in Fiji||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2005|December 2007||||N/A|Observational|Time Perspective: Prospective||||550|||Both|N/A|N/A|No|||October 2007|May 1, 2008|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264771||187067|
NCT00264784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0081|GAS Epi Study to Measure Age-Related Antibody Titers to J8 Vaccine|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 5: Establishing Natural Age-Related Titers of Antibodies to the J8 Group A Streptococcal Epitope in Fiji||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2005|May 2006||||N/A|Observational|Time Perspective: Prospective||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2007|December 19, 2007|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264784||187066|
NCT00265148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRL-49653/461|Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease|A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD)||GlaxoSmithKline|No|Completed|May 2004|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|85 Years|No|||May 2014|May 22, 2014|December 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265148||187039|
NCT00265161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4180905|The Effectiveness of Influenza Vaccine Among Health Care Workers in a Hospital Setting.|||HaEmek Medical Center, Israel|No|Completed|December 2005|March 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2006|May 31, 2007|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00265161||187038|
NCT00264446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adherex Protocol # AHX-03-101|A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection|Phase 1 Study of the Evaluation of Dihydropyrimidine Dehydrogenase (DPD), Uridine Phosphorylase (UP), Orotate Phosphoribosyl Transferase (OPRT), and Thymidine Phosphorylase (TP) Activity in Tissue Resected From Subjects Undergoing Planned Resection of Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection, Following Administration of Oral ADH300004 (Adherex Protocol Number AHX-03-101)||Adherex Technologies, Inc.||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|19 Years|N/A|No|||August 2007|August 3, 2007|December 12, 2005||||||https://clinicaltrials.gov/show/NCT00264446||187092|
NCT00264732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYC1-004|A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix||Eisai Inc.||Completed|July 2005|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|251|||Female|13 Years|25 Years|No|||May 2012|May 21, 2013|December 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00264732||187070|
NCT00265993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4563A_4001|Enoxaparin in Acute Venous Thromboembolic Disease|The Efficacy of Subcutaneous Enoxaparin Once Daily in the Treatment of Acute Venous Thromboembolic Disease: an Open-labelled, Non-comparative, Multicentric, Phase IV Trial||Sanofi||Completed|December 2004|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|251|||Both|18 Years|N/A|No|||February 2010|February 2, 2010|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265993||186976|
NCT00265122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005287|A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease|A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease||Centocor, Inc.|No|Completed|April 2004|October 2006|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|131|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|December 13, 2005|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00265122||187041|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00266006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7ICH-1602|Factor VIIa in Acute Intracerebral Haemorrhage|Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.||Novo Nordisk A/S|No|Completed|January 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|90|||Both|20 Years|N/A|No|||September 2011|June 26, 2012|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00266006||186975|
NCT00266279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153.05|Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies|Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies||James Graham Brown Cancer Center|Yes|Completed|April 2005|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|December 15, 2005|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00266279||186954|Results data not available, PI not longer at institution
NCT00266292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 267804|The Effect of n-3 LCPUFA on Immune Function and Cardiovascular Risk Factors|||University of Copenhagen||Active, not recruiting|September 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2005|May 27, 2010|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266292||186953|
NCT00242424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05065501|Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age|Safety and Immunogenicity of Fluzone Influenza Virus Vaccine (2005-2006 Formulation) Among Healthy Children 6 to 12 Weeks of Age|GRC28|Seattle Children's Hospital|No|Completed|September 2005|September 2007|Actual|September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1375|||Both|42 Days|84 Days|Accepts Healthy Volunteers|||January 2009|January 27, 2009|October 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00242424||188748|
NCT00243308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Serp-1-01-002|Serp-1 for the Treatment of Acute Coronary Syndrome|A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)||Viron Therapeutics Inc||Terminated|October 2005|December 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|72|||Both|18 Years|80 Years|No|||February 2009|February 5, 2009|October 19, 2005|||Third dose group not recruited due to slow enrollment.|||https://clinicaltrials.gov/show/NCT00243308||188680|
NCT00243542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACZ ACN 01|Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency|ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%.||Allergan||Completed|November 2005|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|64|||Both|12 Years|N/A|No|||May 2011|May 27, 2011|October 21, 2005||||||https://clinicaltrials.gov/show/NCT00243542||188662|
NCT00243555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002H05183|Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut|Molecular Analysis of Immuno-Regulatory Genes Expressed by Mononuclear Cells From Peanut Skin Test Positive Individuals With and Without a History of Peanut Ingestion||McMaster University||Recruiting|September 2002|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|5 Years|N/A|Accepts Healthy Volunteers|||September 2006|January 31, 2007|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00243555||188661|
NCT00243815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9657|Use of Ibuprofen to Prevent IUD Site Effects|Prophylactic Ibuprofen: Effect on IUD Continuation Rates||FHI 360||Completed|June 2002|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2019|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||October 2005|October 16, 2006|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00243815||188641|
NCT00243295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100N7-110|Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies|A Pilot Study to Validate the Feasibility of Injecting and Monitoring Recombinant Human Bone Morphogenetic Protein-2/Calcium Phosphate Matrix (rhBMP-2/CPM) in Subjects With Open Wedge Osteotomies||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2003|March 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||6|||Both|45 Years|70 Years|No|||October 2006|October 5, 2006|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00243295||188681|
NCT00243529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-2917|Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients|In Vivo Responses of DC Vaccines Presenting HLA Class I and II Restricted Tumor Epitopes Either by Peptide-pulsing or mRNA Transfection in Melanoma Patients||Radboud University|No|Completed|April 2004|||February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|75 Years|No|||February 2009|September 28, 2009|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243529||188663|
NCT00244348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC#341-05|Hepatic Artery Infusion With Oxaliplatin|Hepatic Arterial Infusion of Oxaliplatin Clinical Trial||Medical College of Wisconsin||Withdrawn|October 2005|August 2015|Actual|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|October 25, 2005|||Investigator has left institution|No||https://clinicaltrials.gov/show/NCT00244348||188601|
NCT00244088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101316|Study Evaluating the Etiology of Intra-Abdominal Infections|Study of the Etiology of Intra-Abdominal Infections||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2004|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2||340|Samples Without DNA|Intra-abdominal fluid|Both|18 Years|N/A|No|Non-Probability Sample|Surgery units|August 2009|August 31, 2009|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00244088||188621|
NCT00244673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVEK2005-7041-45-DTPMV|Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination|Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination||Bandim Health Project||Completed|October 2005|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|6534|||Both|9 Months|4 Years|No|||February 2012|February 25, 2012|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00244673||188576|
NCT00244335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-00507-1|Examining the Role of Negative Emotional States on Sedative Drug Use in Individuals With Post-Traumatic Stress Disorder|Emotional Control of Sedative Self-Medication in Post-Traumatic Stress Disorder||National Institute on Drug Abuse (NIDA)|Yes|Completed|October 2000|July 2008|Actual|February 2006|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|39|||Both|18 Years|60 Years|No|Non-Probability Sample|PTSD subjects and subjects who have experienced a trauma but never developed PTSD (Trauma        Controls) are being recruited for this study. Recruitment is being conducted through Audie        L. Murphy Veterans Administration Hospital and the University of Texas Health Science        Center at San Antonio.|August 2008|August 22, 2008|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00244335||188602|
NCT00240825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002812|An Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain.|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|222|||Both|15 Years|N/A|No|||June 2015|June 18, 2015|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240825||188868|
NCT00264485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004720|A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump|Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by the E-TRANS Fentanyl HCl Transdermal System Versus Morphine IV Pump for Pain Management After Primary Unilateral Total Hip Replacement||Alza Corporation, DE, USA||Completed|March 2004|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|799|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|December 9, 2005||||||https://clinicaltrials.gov/show/NCT00264485||187089|
NCT00264498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0551|Phase II Iressa & Carbo/Gem in NSCLC|A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2||AstraZeneca||Completed|October 2004|June 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||June 2009|June 11, 2009|December 12, 2005||No||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00264498||187088|No analysis of the efficacy results was performed as the study was prematurely terminated with only 35 out of the planned 122 subjects randomized.Serious and Other adverse event data for Periods 1 and 2 were combined by treatment for this report.
NCT00264511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206/04|Hyperbaric Oxygen in Lower Leg Trauma|Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.||Bayside Health|Yes|Active, not recruiting|February 2006|September 2016|Anticipated|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00264511||187087|
NCT00264524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU93-M-34|DNA Typing of HLA-DR/DQ Alleles in Taiwan Chinese With Rheumatic Heart Disease|||China Medical University Hospital||Completed|January 2004|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|N/A||||January 2004|November 26, 2010|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00264524||187086|
NCT00264472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adherex Protocol # AHX-03-104|A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors|A 2-Part Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ADH300004 (Eniluracil) Administered With 5-Fluorouracil (5-FU), and the Pharmacokinetics of 5-FU Given as: 5.0 mg ADH300004 With Escalating Doses of 5-FU Administered Orally 3 Weeks Out of 4 in Subjects With Refractory Solid Tumors (Part 1); or 5.0 mg ADH300004 With 5 FU Administered Orally as a Split Dose for 3 Weeks Out of 4 in Subjects With Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Gastric Cancer, Cervical Cancer, Prostate Cancer, or Breast Cancer (Part 2) (Adherex Protocol Number AHX-03-104)||Adherex Technologies, Inc.||Suspended|January 2006|||June 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2008|December 12, 2008|December 12, 2005|Yes|Yes|Lack of funds|No||https://clinicaltrials.gov/show/NCT00264472||187090|
NCT00265499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-41|The Internal Thoracic Artery Skeletonization Study: A Paired, Within-Patient Comparison|Skeletonized Versus Non-Skeletonized Internal Thoracic Artery Harvest for Coronary Artery Bypass Grafting||University of Ottawa||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||November 2005|December 13, 2005|December 13, 2005||||No||https://clinicaltrials.gov/show/NCT00265499||187012|
NCT00265200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|565.04|Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer|Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer||James Graham Brown Cancer Center|Yes|Terminated|February 2005|December 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|28|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|December 12, 2005|No|Yes|funding discontinued by sponsor|No||https://clinicaltrials.gov/show/NCT00265200||187035|
NCT00265447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B031120-Proj 2|Exercise and Physical Fitness for Persons With Knee Osteoarthritis|Exercise and Physical Fitness for Persons With Knee Osteoarthritis: Does One Size Fit All||University of Missouri-Columbia||Completed|December 2005|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 30, 2010|December 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00265447||187016|
NCT00265460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tonga.2005.00.|Smoking Cessation in Groups and With Tobacco Pastils|Phase 2 Study of Smoke Free Tobacco and Group Support for Smoking Cessation||University Hospital, Gentofte, Copenhagen||Completed|March 2005|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 14, 2009|December 13, 2005||||No||https://clinicaltrials.gov/show/NCT00265460||187015|
NCT00265772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCNF0105|Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis|Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis||Hôpital Necker-Enfants Malades||Recruiting|November 2005|April 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|6 Years|18 Years|No|||November 2005|December 14, 2005|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00265772||186993|
NCT00266266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|529.03|Human Papilloma Virus DNA Self-Test|Human Papilloma Virus DNA Self-Test|HPV|James Graham Brown Cancer Center|Yes|Completed|January 2004|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|171|||Female|18 Years|N/A|No|Probability Sample|Abnormal pap smear ASCUS or higher        Age 18-postmenopausal|May 2013|May 3, 2013|December 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00266266||186955|
NCT00266656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10088|Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome|Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome||Eli Lilly and Company|No|Completed|December 2005|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Female|4 Years|20 Years|No|||September 2015|September 24, 2015|December 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266656||186925|
NCT00266669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-002|Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon|Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon||MediQuest Therapeutics||Completed|December 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|70 Years|No|||August 2007|August 6, 2007|December 15, 2005||||||https://clinicaltrials.gov/show/NCT00266669||186924|
NCT00243061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03026|AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma|A Phase II Study of AZD2171 in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma||National Cancer Institute (NCI)|Yes|Completed|January 2006|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2013|June 1, 2015|October 20, 2005|Yes|Yes||No|July 9, 2014|https://clinicaltrials.gov/show/NCT00243061||188699|
NCT00243568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04285|Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285)(TERMINATED)|Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E2)||Schering-Plough||Terminated|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||October 2009|October 21, 2009|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00243568||188660|
NCT00243828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC2005/022|Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure|Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure: a Randomized Controlled Trial.||Corporacion Parc Tauli|No|Terminated|November 2005|December 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2007|September 14, 2015|October 24, 2005||No|Very low rate of recruitment anticipated futility of pursuing the study|No||https://clinicaltrials.gov/show/NCT00243828||188640|
NCT00244101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 03-233|Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome|Delivery Room Management of Premature Infants at High Risk of Respiratory Distress Syndrome||Vermont Oxford Network|Yes|Completed|August 2003|June 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|648|||Both|26 Weeks|29 Weeks|No|||August 2012|August 16, 2012|October 24, 2005||No||No|August 16, 2012|https://clinicaltrials.gov/show/NCT00244101||188620|
NCT00244361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND #11,771|Effectiveness of Rituximab in Pediatric OMS Patients.|A Phase I Clinical Trial of Rituximab for Pediatric Opsoclonus-Myoclonus Syndrome||National Pediatric Myoclonus Center|Yes|Completed|June 2005|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|6 Months|19 Years|No|||May 2011|May 6, 2011|October 24, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00244361||188600|
NCT00244686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHE104317|Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)|A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects With Hypereosinophilic Syndrome||GlaxoSmithKline||Recruiting|August 2005|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|12 Years|N/A|No|||February 2016|March 10, 2016|October 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244686||188575|
NCT00244699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200/2005|Integrating Mindfulness-Based Skills Training Into Brief Outpatient Treatment for Substance Abusing Youth|A Mindfulness-Based Intervention for Youth With Concurrent Disorders||Centre for Addiction and Mental Health||Completed|October 2005|April 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|16 Years|24 Years|No|||May 2009|May 9, 2009|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244699||188574|
NCT00244985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447130|Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I/II Pilot Study of the Safety and Efficacy of Rituxan (Chimeric Anti-CD20 Antibody) in Combination With Doxil (Liposomal Doxorubicin) Chemotherapy in Patients With Relapsing or Refractory Indolent or Aggressive B-Cell Lymphoma||Roswell Park Cancer Institute|Yes|Completed|September 2005|||August 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|120 Years|No|||November 2015|November 20, 2015|October 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244985||188552|
NCT00240630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX103632|Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks|A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks||GlaxoSmithKline||Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|646|||Both|18 Years|65 Years|No|||April 2015|April 15, 2015|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00240630||188883|
NCT00264862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOR2008_1|DynaCT Imaging in EVAR: Comparing Clinical Benefit of DynaCT to Multidetector CT as the Current Gold Standard.|Use of DynaCT in Endovascular Treatment of Abdominal Aortic Aneurysm. Evaluation of Image Quality.||Norwegian University of Science and Technology|No|Completed|December 2005|March 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|65 Years|N/A|No|||February 2014|February 27, 2014|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00264862||187061|
NCT00264875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081095|Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy|An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy||Pfizer|No|Completed|February 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|220|||Both|18 Years|N/A|No|||March 2009|March 20, 2009|December 12, 2005|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00264875||187060|
NCT00264888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-004-DMD|Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy||PTC Therapeutics||Completed|December 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Male|5 Years|N/A|No|||January 2009|January 9, 2009|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264888||187059|
NCT00265174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRISL1-HMO-CTIL|Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer.|Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer.||Hadassah Medical Organization||Not yet recruiting|January 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|60|||Both|N/A|N/A|No|||November 2005|December 13, 2005|December 13, 2005||||No||https://clinicaltrials.gov/show/NCT00265174||187037|
NCT00265187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3350105|The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis.|The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis in Northern Israel.||HaEmek Medical Center, Israel|No|Completed|December 2005|March 2006|Actual|March 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|N/A|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children 0-24 months hospitalized with acute bronchiolitis|August 2006|January 2, 2013|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00265187||187036|
NCT00265512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-021|LINK: Aftercare Monitoring Project|Improving Longterm SUD Outcomes With Telephone Case Monitoring||VA Office of Research and Development|Yes|Completed|November 2006|January 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|667|||Both|N/A|N/A|No|||July 2014|April 6, 2015|December 12, 2005||No||No|October 2, 2014|https://clinicaltrials.gov/show/NCT00265512||187011|
NCT00265473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0407M62505|MGA031, Sirolimus and Tacrolimus in Islet Transplantation|hOKT3γ1 (Ala-Ala), Sirolimus and Low Dose Tacrolimus Therapy in Type 1 Diabetic Islet Allograft Recipients||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2005|June 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|December 12, 2005|Yes|Yes||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00265473||187014|
NCT00265486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 271889|Can Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?|Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?||Rigshospitalet, Denmark||Recruiting|August 2005|July 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|12 healthy non-smoking free divers|August 2005|May 23, 2012|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00265486||187013|
NCT00266032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91450|Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles|A Multicenter, Open, Randomized, Parallel Group Comparison to Assess the Safety and Efficacy of the Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Betadex Clathrate and 3 mg Drospirenone) in Two Variations of an Extended Regimen vs. a Standard Regimen (24 + 4 Days) in 1122 Healthy Female Volunteers for One Year, Followed by a One Year Safety Extension||Bayer|No|Completed|December 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1166|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|December 14, 2005||No||No|October 28, 2009|https://clinicaltrials.gov/show/NCT00266032||186973|Data for center no. 1148 was included in “all randomized” set of subjects, but not in FAS, as during medical monitoring of laboratory data a suspicion of potential misconduct was found. An audit was made, but the suspicion could not be resolved.
NCT00266019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK67363 (completed)|Weight Management in Nonalcoholic Steatohepatitis|Weight Management in Nonalcoholic Steatohepatitis (NASH)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 2005|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00266019||186974|
NCT00266682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600|Clinical Investigation of the SelectSecure Pacing Lead|Clinical Investigation of the SelectSecure Pacing Lead||Medtronic Cardiac Rhythm Disease Management||Completed|August 2002|August 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||365|||Both|N/A|N/A|No|||October 2006|October 11, 2006|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00266682||186923|
NCT00266695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10699|Treatment for Completers of the Study B7A-MC-MBCM|Open-Label Treatment for Patients Completing Study B7A-MC-MBCM||Eli Lilly and Company|No|Completed|January 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|203|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 15, 2005|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00266695||186922|A participant could have one or both eyes meet the criteria for a diabetic retinopathy (DR) study eye as defined in study B7A-MC-MBCM.
NCT00243321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-02961|High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer|Phase I Examination of Combination High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Therapy for the Comprehensive Local Treatment of Patients With Locally Confined Adenocarcinoma of the Prostate||Virginia Commonwealth University|No|Completed|February 2003|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|N/A|N/A|No|||April 2013|April 23, 2013|October 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00243321||188679|
NCT00275015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455090|Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia|Pivotal Study for High Dose Therapy and Autologous Stem Cell Transplantation in Early Stages of CLL||National Cancer Institute (NCI)||Completed|January 1998|April 2012|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|60 Years|No|||April 2007|November 5, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275015||186299|
NCT00275275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10161|Pramipexole Conversion to Ropinirole Controlled Release (CR)|An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.||University of Kansas Medical Center|No|Completed|January 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||July 2012|July 21, 2012|January 9, 2006|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT00275275||186279|
NCT00244114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A1-900|Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients|In Vitro Evaluation Of Allergic Reactions In Hemophilia B Subjects Who Have Exhibited A Systemic Allergic Response After Exposure To BeneFIX (Nonacog Alfa; Recombinant Factor IX)||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2006|December 2009|Actual|December 2009|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|20|||Both|N/A|N/A|No|||February 2013|February 14, 2013|October 19, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244114||188619|
NCT00244127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myocet 018|Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.|Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.||Zeneus Pharma||Active, not recruiting|October 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|65 Years|N/A|No|||October 2005|October 26, 2005|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00244127||188618|
NCT00244374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17476-1|A Randomized Trial of Vaccine Adherence in Young Injection Drug Users|A Randomized Trial of Vaccine Adherence in Young IDU|UFO VAX|University of California, San Francisco|No|Completed|August 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|546|||Both|14 Years|29 Years|No|||July 2013|July 25, 2013|October 25, 2005||No||No|April 25, 2013|https://clinicaltrials.gov/show/NCT00244374||188599|
NCT00244712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPZ104057|Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV|A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects|HEAT|GlaxoSmithKline||Completed|July 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|688|||Both|18 Years|N/A|No|||June 2010|June 3, 2010|October 25, 2005|Yes|Yes||No|April 23, 2009|https://clinicaltrials.gov/show/NCT00244712||188573|
NCT00244725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI101711|Odiparcil For The Prevention Of Venous Thromboembolism|A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery||GlaxoSmithKline|No|Completed|September 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|961|||Both|35 Years|N/A|No|||April 2015|April 14, 2015|October 25, 2005||||||https://clinicaltrials.gov/show/NCT00244725||188572|
NCT00244998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 53805|Fulvestrant in Treating Patients With Advanced Prostate Cancer|Phase II Study of Fulvestrant (Faslodex®) in Androgen Independent Prostate Cancer||Roswell Park Cancer Institute|Yes|Completed|September 2005|June 2012|Actual|October 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||March 2013|March 7, 2013|October 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244998||188551|
NCT00240617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX103635|Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks|A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima* (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks (*Treximet)||GlaxoSmithKline|No|Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|623|||Both|18 Years|65 Years|No|||September 2011|May 31, 2012|October 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00240617||188884|
NCT00272519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 045b|Life Skills Intervention for Adolescents Perinatally Infected With HIV|Life Skills Intervention for Young Adolescents Perinatally Infected With HIV and Their Caregivers||Westat|No|Completed|June 2006|October 2006|Actual|October 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|11 Years|14 Years|No|||February 2016|February 29, 2016|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00272519||186489|
NCT00264251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLRHC 02-117|Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance|Effect of Diet, Exercise and Rosiglitazone on Regional Fat and Insulin Resistance in HIV-Infected and Uninfected Men and Women||St. Luke's-Roosevelt Hospital Center|Yes|Completed|July 2005|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2007|October 26, 2007|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264251||187107|
NCT00264264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-101|Arterial Closure vs Direct Compression for Hemostasis After PCI - The ACDC Trial|Arterial Closure vs Direct Compression for Hemostasis After Percutaneous Coronary Interventions||St. Michael's Hospital, Toronto||Completed|July 2006|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|572|||Both|20 Years|N/A|No|||May 2013|May 15, 2013|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00264264||187106|
NCT00265226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-01A/2003-10|Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients|Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters||Ministry of Science and Technology, India|Yes|Completed|March 2005|March 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1020|||Both|18 Years|60 Years|No|||July 2011|January 3, 2014|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00265226||187033|
NCT00264810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP10004|RNS® System Pivotal Study|RNS® System Pivotal-A Clinical Investigation||NeuroPace|Yes|Completed|December 2005|May 2011|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|70 Years|No|||August 2013|August 23, 2013|December 9, 2005|Yes|Yes||No|August 23, 2013|https://clinicaltrials.gov/show/NCT00264810||187064|
NCT00264823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708134|Nursing Intervention for HIV Regime Adherence Among People With Serious Mental Illness (SMI)|Nursing Intervention for HIV Regimen Adherence Among Serious Mental Illness (SMI)||National Institute of Nursing Research (NINR)|Yes|Completed|June 2003|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|N/A|No|||October 2008|October 3, 2008|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264823||187063|
NCT00264849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2425|Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma|A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy||Novartis||Completed|November 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|406|||Both|12 Years|75 Years|No|||June 2011|June 24, 2011|December 12, 2005||No||No|December 3, 2010|https://clinicaltrials.gov/show/NCT00264849||187062|
NCT00265525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBR 4855|Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease.|Evaluation of a Web-Based Intervention to Promote Physical Activity in Patients With Heart Disease: A Randomize Control Trial||Ottawa Heart Institute Research Corporation|Yes|Completed|November 2004|August 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|223|||Both|20 Years|80 Years|No|||March 2009|April 7, 2015|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00265525||187010|
NCT00265785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456424|S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Pemetrexed in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)||Southwest Oncology Group|Yes|Terminated|July 2006|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|December 14, 2005|Yes|Yes|Closed due to poor accrual|No|July 12, 2012|https://clinicaltrials.gov/show/NCT00265785||186992|
NCT00266045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROLONG-TWO STUDY|D-dimer Levels During and After Anticoagulation in Patients With a Previous Venous Thromboembolism: Effects on the Risk of Recurrence|A Multicentre, Prospective, Observational Study on the Predictive Role for Recurrence of D-dimer Levels Measured During and After Anticoagulation in Patients With a First Venous Thromboembolism Episode (the PROLONG-II Study)||St. Orsola Hospital||Completed|August 2005|December 2008|Actual|June 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|355|Samples Without DNA|Plasma samples for D-dimer assays or other coagulation tests|Both|18 Years|82 Years|No|Probability Sample|Subjects with a single previous idiopathic venous thromboembolic event who stop        anticoagulation|August 2012|August 31, 2012|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00266045||186972|
NCT00266305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVL-IHE-D72|Fish Oil Supplementation in Lactation|||University of Copenhagen||Completed|December 1998|January 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3|||150|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2008|August 12, 2008|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266305||186952|
NCT00266708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-08-224|Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.|Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant||Montefiore Medical Center||Completed|October 2002|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|December 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266708||186921|
NCT00243334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HS015226-02|Improving Safety and Quality With Outpatient Order Entry|Improving Safety and Quality With Outpatient Order Entry||Brigham and Women's Hospital|No|Active, not recruiting|July 2007|June 2013|Anticipated|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|800|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243334||188678|
NCT00275301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506M70791|PET Imaging and Olanzapine Treatment in Borderline Personality Disorder|Brain Correlates of Olanzapine Treatment Response in BPD||University of Minnesota - Clinical and Translational Science Institute|No|Completed|December 2005|December 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 25, 2011|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275301||186277|
NCT00244140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91462|Ultravist: Safety and Efficacy in Computed Tomography of Head and Body|Ultravist 370 Milligrams of Iodine Per Milliliter (mg I/mL): Safety and Efficacy in Computed Tomography of Head and Body||Bayer|No|Completed|October 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|435|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|October 24, 2005|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00244140||188617|
NCT00276185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0003|HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke|Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke||University Hospital, Clermont-Ferrand||Recruiting|December 2005|December 2009|Anticipated|January 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00276185||186216|
NCT00276471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC PT TAN2005-013|Evaluation of the Tantalus System in Type 2 Diabetic Subjects|Evaluation of the Tantalus System in Type 2 Diabetic Subjects||Metacure||Completed|December 2005|June 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|21 Years|60 Years|No|||January 2012|January 31, 2012|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276471||186194|
NCT00244738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASTOR- HMO-CTIL|The Use of Castor Oil as a Labor Initiator in Post-date Pregnancies|The Use of Castor Oil as a Labor Initiator in Post-date Pregnancies||Hadassah Medical Organization||Completed|February 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2005|March 18, 2012|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00244738||188571|
NCT00276484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-090|To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)|A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at High Risk for CHD Not Adequately Controlled on Atorvastatin 40 Mg||Merck Sharp & Dohme Corp.||Completed|February 2006|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|579|||Both|18 Years|79 Years|No|||February 2015|February 20, 2015|January 11, 2006|Yes|Yes||No|February 6, 2009|https://clinicaltrials.gov/show/NCT00276484||186193|
NCT00245011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0347 CDR0000447134|Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma|High Dose Samarium-153 With Peripheral Blood Stem Cell Support in High Risk Osteogenic Sarcoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|October 2004|March 2009|Actual|October 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|13 Years|50 Years|No|||April 2015|April 15, 2015|October 25, 2005|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT00245011||188550|"Future work will focus on better understanding the factors that contribute to drug delivery and improving efficacy be combinaiton with chemotherapy, boilogics, or external beam radiotherapy." (See Publication section of this entry).
NCT00272532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9892|EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes|The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study||Sanofi||Completed|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||65|||Both|18 Years|50 Years|No|||February 2008|February 18, 2008|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272532||186488|
NCT00272545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071691|Effectiveness of a Normalization of Eating Intervention Program for Treating Women With Eating Disorders|Adaptation of a CBT Intervention for Eating Disorders||Drexel University||Completed|January 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Female|15 Years|40 Years|No|||September 2013|September 4, 2013|January 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00272545||186487|
NCT00264537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006331|A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive|A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis||Centocor, Inc.|Yes|Completed|December 2005|June 2012|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|637|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|December 11, 2005|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00264537||187085|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in less than or equal to 5% of patients. This information may vary from existing approved labeling and publications.
NCT00265213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-940194|How Breast Conservative Surgery (BCS) Affects Women's Daily Activities On Post-Operation 2 Days?|||Kaohsiung Medical University Chung-Ho Memorial Hospital||Recruiting|May 2005|February 2006|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Female|N/A|N/A|No|||December 2005|February 26, 2008|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00265213||187034|
NCT00266071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC05-08|Study of the Cutaneous Microcirculation in Elderly People|||University Hospital, Angers||Not yet recruiting|December 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|December 14, 2005|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00266071||186970|
NCT00266084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-00-16|Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix|Double-Blinded Multicenter Clinical Study Assessing the Equivalence of the InPath Cervical Cell Collector to the Standard Endocervical Brush and Spatula in Patients Seeking Primary Pap Screening or Follow-Up Screening||University Hospital Case Medical Center||Completed|August 1999|November 2001||||Phase 1/Phase 2|Observational|N/A||||85|||Female|14 Years|N/A|No|||November 2001|December 14, 2005|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00266084||186969|
NCT00266370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-094-CP-01|A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma|A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma||National Health Research Institutes, Taiwan||Recruiting|January 2005|December 2009||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||100|||Both|N/A|N/A|No|||December 2005|December 16, 2005|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266370||186947|
NCT00265798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00116|Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate|A Phase 2 Study of BAY 43-9006 for Imatinib- and Sunitinib Resistant Gastrointestinal Stromal Tumor||National Cancer Institute (NCI)||Active, not recruiting|September 2005|||February 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||December 2014|April 14, 2015|December 14, 2005|Yes|Yes||No|December 6, 2013|https://clinicaltrials.gov/show/NCT00265798||186991|
NCT00266058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAKE99|Drug Interaction Study Between Antimalarial and Anti-HIV Medications|Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine||University of California, San Francisco||Completed|December 2005|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|33|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||May 2013|June 4, 2013|December 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00266058||186971|
NCT00266318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164-04|Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy|A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy||Beth Israel Medical Center||Completed|December 2005|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2008|April 16, 2008|December 14, 2005||||||https://clinicaltrials.gov/show/NCT00266318||186951|
NCT00275028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00036|AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer||National Cancer Institute (NCI)|Yes|Completed|October 2005|January 2011|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|N/A|No|||January 2013|October 9, 2015|January 10, 2006|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT00275028||186298|
NCT00274820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4Y04|Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder|A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders||Case Comprehensive Cancer Center|Yes|Completed|October 2005|October 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00274820||186314|
NCT00275977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020|Treatment of Myocardial Infarction With Bone Marrow Derived Stem Cells|Treatment of Myocardial Infarction With Autologous Bone Marrow Derived Stem Cells||Odense University Hospital||Recruiting|February 2006|March 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|10|||Both|30 Years|75 Years|No|||January 2006|July 22, 2010|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275977||186232|
NCT00276237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0668-2005|Outcomes Following Pulmonary Valve Replacement in Adults|Review of Outcomes Following Pulmonary Valve Replacement for Congenital Heart Disease in Adults||Emory University||Completed|July 2005|November 2005|Actual|||N/A|Observational|Time Perspective: Prospective||||300|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276237||186212|
NCT00275561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1488-05|Topical Steroid Treatment for Eosinophilic Esophagitis|A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis||Mayo Clinic|No|Completed|November 2005|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|60 Years|No|||May 2012|May 1, 2012|January 10, 2006||No||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00275561||186258|The relatively small sample size; unexpected high dropout rate in the placebo group; study commenced before the consensus definition of EoE advising exclusion of gastroesophageal reflux disease (GERD) was established.
NCT00275574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1975-02|Acupuncture for Non-cyclical Breast Pain|Acupuncture for the Treatment of Non-Cyclical Breast Pain||Mayo Clinic|No|Completed|April 2003|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275574||186257|
NCT00275899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701220|Role of DcR3 in T Cell Activation in SLE and RA|Role of DcR3 in T Cell Activation in SLE and RA||National Taiwan University Hospital||Recruiting|January 2006|December 2007||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|January 11, 2006|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275899||186238|
NCT00276198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor395705ctil|Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants|Controlled Clinical Trial to Assess the Effect of Multiple Micronutrient Supplementation (Iron, Vitamins A, C, D, Folic Acid and Zinc) on Nutritional and Health Indicators in Infants in Southern Israel.||Soroka University Medical Center|No|Completed|July 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|771|||Both|5 Months|2 Years|Accepts Healthy Volunteers|||March 2008|April 15, 2008|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00276198||186215|
NCT00276211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20051023|Diffusion Weighted MRI for Lymphnodes in the Axilla|Diffusionsvægtet MR Skanning Med Henblik på axillære Lymfeknudemetastaser Hos Patienter Med primær Mammacancer - et Pilotstudie||Copenhagen University Hospital at Herlev||Completed|January 2006|December 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Female|18 Years|N/A|No|||January 2006|January 27, 2009|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00276211||186214|
NCT00276497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPP2|Role of Pioglitazone in Preventing Diabetes|||M.V. Hospital for Diabetes|Yes|Completed|October 2003|May 2008||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|35 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 3, 2009|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276497||186192|
NCT00272220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9137-G 01|Longitudinal Study of HAART, Social Networks, & Adherence|Longitudinal Randomized Controlled Study of Modified Directly Observed HAART in Mozambique||University of Washington|Yes|Completed|October 2004|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|N/A|No|||November 2007|November 6, 2007|December 30, 2005||||No||https://clinicaltrials.gov/show/NCT00272220||186511|
NCT00272844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-11-189R|Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome|Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome||Children's Hospital Boston|Yes|Completed|January 1998|July 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|N/A|No|||July 2011|July 13, 2011|January 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272844||186464|
NCT00272857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382|Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia|Gene Transfer From Patients With Fanconi Anemia, Genotype A: A Pilot Study||Children's Hospital Boston|Yes|Completed|August 2004|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|1 Year|35 Years|No|||September 2014|September 18, 2014|January 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00272857||186463|
NCT00264901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1720|Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes|Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir® (Insulin Detemir [rDNA Origin] Injection) (PREDICTIVE™ 303)|PREDICTIVE™|Novo Nordisk A/S|No|Completed|October 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5652|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00264901||187058|
NCT00264914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY5904|Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|SIADH Safety|Sanofi||Completed|July 2005|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|57|||Both|18 Years|N/A|No|||January 2009|January 19, 2009|December 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00264914||187057|
NCT00265824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453861|Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)|Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2|DREAM|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Completed|May 2005|||March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|700|||Both|18 Years|80 Years|No|||March 2014|December 10, 2015|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265824||186989|
NCT00265538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMV 04-066|Implementing Evidence Based Treatment of Hypertension|Implementing Evidence-based Treatment of Hypertension||VA Office of Research and Development|No|Completed|July 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|900|||Both|18 Years|80 Years|No|||August 2014|August 6, 2014|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00265538||187009|
NCT00265551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153A1-202|Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Olanzapine-Referenced, Parallel Group Safety, Efficacy, and Tolerability Study of SCA-136 in Subjects With Acute Exacerbations of Schizophrenia||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2006|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||December 2007|December 7, 2007|December 12, 2005||||||https://clinicaltrials.gov/show/NCT00265551||187008|
NCT00266734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 03-543E|Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears|A Prospective Blinded Multi-center Clinical Trial to Evaluate the Efficacy of the Recently FDA Approved RPS Adeno Detector for Detecting Adenoviral Conjunctivitis||Rapid Pathogen Screening|No|Completed|December 2004|September 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||186|||Both|1 Month|N/A|No|||February 2010|February 9, 2010|December 16, 2005||||No||https://clinicaltrials.gov/show/NCT00266734||186919|
NCT00265811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453839|Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery|Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab||Federation Francophone de Cancerologie Digestive|Yes|Completed|November 2005|||November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2564|||Both|18 Years|74 Years|No|||December 2006|April 2, 2012|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265811||186990|
NCT00266955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-111|Retrospective of Children With ADHD and Cardiac Symptoms|A Retrospective Study of Children With ADHD and Cardiac Symptoms||Children's Healthcare of Atlanta||Terminated|January 1999|September 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|10|||Both|N/A|18 Years|No|Non-Probability Sample|retro chart review|September 2007|July 5, 2011|December 19, 2005|||insufficient number of eligible subjects|No||https://clinicaltrials.gov/show/NCT00266955||186903|
NCT00267254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091030|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.|A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030)||Pfizer||Completed|January 2006|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||640|||Both|18 Years|N/A|No|||April 2007|November 20, 2007|December 19, 2005||||||https://clinicaltrials.gov/show/NCT00267254||186880|
NCT00266331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-05TJohn-01|RayGel-An Alternative for Skin Care During External Beam Radiation|Prospective Blinded Randomized Study; RayGel Versus Placebo-an Alternative for Skin Care During External Beam Radiation.||Legacy Health System|Yes|Completed|October 2004|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 27, 2013|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00266331||186950|
NCT00266344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-040|MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)|MK0928 Phase IIb Dose-range Finding Study -Primary Insomnia||H. Lundbeck A/S||Completed|November 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||520|||Both|20 Years|64 Years|No|||January 2015|January 13, 2015|December 14, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00266344||186949|
NCT00266357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-041|Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)|MK0928 Phase II Sleep Laboratory Study - Primary Insomnia||H. Lundbeck A/S||Terminated|November 2005|||March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|20 Years|64 Years|No|||January 2015|January 13, 2015|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00266357||186948|
NCT00275314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 0512007|WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients|WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients, Sponsor Protocol Dated 8/11/2005 and Investigator Brochure Version August 2005||University of Pittsburgh||Terminated|February 2006|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|68 Years|No|||December 2015|December 16, 2015|January 9, 2006|||Study never started at our site Funding issue|||https://clinicaltrials.gov/show/NCT00275314||186276|
NCT00275327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0510165|Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria|Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria||University of Pittsburgh|Yes|Completed|January 2006|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|300|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|N/A|N/A|No|Non-Probability Sample|isolates|December 2015|December 16, 2015|January 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00275327||186275|
NCT00275288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0407M62321|MRI Imaging in Borderline Personality Disorder|"Brain Correlates Of Affect Regulation In BPD"||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2005|June 2007|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 Female subjects ages 18-45 whom meet criteria for BPD will be included in the study. 20        healthy controls will also be females between the ages 18-45.|November 2010|November 1, 2010|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00275288||186278|
NCT00275639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2085-04|The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant|A Randomized, Double-blinded, Placebo-controlled Study of Angiotensin II Receptor Blockade to Prevent Renal Dysfunction Following Liver Transplantation.||Mayo Clinic||Completed|December 2004|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|62|||Both|18 Years|70 Years||||January 2012|January 4, 2012|January 10, 2006||||||https://clinicaltrials.gov/show/NCT00275639||186253|
NCT00275652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207-04|A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.|A Randomized, Double-Blind Trial of Telbivudine (LdT) Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.||Mayo Clinic||Completed|June 2004|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||6|||Both|18 Years|70 Years||||March 2011|March 22, 2011|January 10, 2006||||||https://clinicaltrials.gov/show/NCT00275652||186252|
NCT00275587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164-05|Development of a Hospital Service That Uses Critical Pathway (Protocolized) Care Plans to Provide High-Quality, High-Reliability, Evidence-Based Medical Care|Development of Critical Pathway Care for Hospitalized Patients Using Principles of Patient-Centered Quality Care, Evidence-Based Medicine, and High Reliability Organizational Structure||Mayo Clinic||Completed|January 2005|January 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|348|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized at St. Marys Hospital in Rochester, MN with with one of six medical        diagnoses: community-acquired pneumonia, deep venous thrombosis or pulmonary embolism,        cellulitis, alcohol withdrawal, pyelonephritis, low back pain.|March 2011|March 21, 2011|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275587||186256|
NCT00276250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1136-2005|Islet Transplantation Using Abatacept|Development of Immunosuppression Regimens to Facilitate Single Donor Islet Transplantation Using Abatacept||Emory University|Yes|Completed|December 2005|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||August 2015|August 4, 2015|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276250||186211|
NCT00275912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476BRU02|Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures|A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures||Novartis||Completed|December 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|6 Months|17 Years||||May 2012|May 7, 2012|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275912||186237|
NCT00275925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476BRU01|Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures|A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures||Novartis||Completed|December 2005|March 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|70 Years||||November 2007|November 29, 2007|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275925||186236|
NCT00275938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145R3|Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B|A Pilot Study Of Interferon Alpha 2b Plus Ribavirin In The Treatment Of Patients With Chronic Hepatitis B||National Taiwan University Hospital||Completed|October 1998|June 2001||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|60 Years|No|||January 2006|January 11, 2006|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275938||186235|
NCT00276224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-ZM-VM-04|Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia|Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia||DBL -Institute for Health Research and Development||Completed|September 2005|April 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||480|||Both|9 Years|15 Years|Accepts Healthy Volunteers|||October 2007|October 30, 2007|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276224||186213|
NCT00271947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD Randomized|Crohn's Disease Stem Cell Transplantation|Crohn's Disease Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation (CDNST) Versus Standard Therapy||Northwestern University|Yes|Terminated|April 2005|April 2013|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|55 Years|No|||February 2014|February 10, 2014|January 2, 2006|Yes|Yes|The PI, who was sponsor got retired|No|May 8, 2013|https://clinicaltrials.gov/show/NCT00271947||186531|Potential participants refused to be randomized. Just one participant was enrolled on study, the study is terminated early.
NCT00271960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061175|Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women|Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women||Yale University|No|Completed|April 2001|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1047|||Female|14 Years|25 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|December 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00271960||186530|
NCT00272233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC26414|Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents|Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents||Yale University||Completed|December 2004|June 2005||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2006|March 19, 2007|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272233||186510|
NCT00273182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187|InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry|InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Systems for Cardiac Resynchronization Therapy (CRT) - InSync Registry||Medtronic Cardiac Rhythm Disease Management|No|Completed|March 2002|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1999|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated for use of a cardiac device|July 2013|July 1, 2013|January 4, 2006|Yes|Yes||No|April 13, 2012|https://clinicaltrials.gov/show/NCT00273182||186438|
NCT00265603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-10-009|Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer|Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer||Atlantic Health System|Yes|Terminated|October 2004|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265603||187005|
NCT00265616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSE study, protocol#62/06|Treatment of Refractory Status Epilepticus|A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus||Brigham and Women's Hospital|Yes|Terminated|May 2006|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|16 Years|N/A|No|||April 2013|April 2, 2013|December 13, 2005||No|Insufficient recruitment|No|October 27, 2010|https://clinicaltrials.gov/show/NCT00265616||187004|
NCT00266396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vffr-35|Weight-Bearing Recommendation After Replacement of the Hip or Knee Joint|A Randomized Trial of Weight-Bearing Recommendations After Total Hip or Total Knee Arthroplasty||Verein zur Förderung der Rehabilitationsforschung in Schleswig-Holstein||Active, not recruiting|January 2002|August 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||352|||Both|N/A|N/A|No|||December 2004|December 15, 2005|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266396||186945|
NCT00266409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0851|Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder|A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder||UCB Pharma||Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|418|||Both|18 Years|N/A|No|||December 2009|October 17, 2014|December 15, 2005|No|Yes||No|May 5, 2009|https://clinicaltrials.gov/show/NCT00266409||186944|Originally it was planned to enrol and randomize 848 subjects. The smaller than planned sample size was a result of an unusually high rate of screening failure (results published in Psychiatry 2006, Vol. 3, Issue 12 , pages 39 - 59).
NCT00266383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH94-DC-1009|The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population|The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population||National Health Research Institutes, Taiwan||Completed|January 2005|December 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||250|||Both|N/A|N/A|No|||December 2005|December 16, 2005|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266383||186946|
NCT00266721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355|Efficacy of Pancrelipase on Postprandial Belching and Bloating.|||Minneapolis Veterans Affairs Medical Center||Completed|January 2000|October 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|70 Years|No|||December 2000|December 15, 2005|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266721||186920|
NCT00267280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091031|A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).|A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031)||Pfizer||Terminated|January 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||640|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|December 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267280||186878|
NCT00267267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091035|A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.|Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.||Pfizer||Terminated|January 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1784|||Both|18 Years|N/A|No|||December 2006|December 6, 2007|December 19, 2005||||||https://clinicaltrials.gov/show/NCT00267267||186879|
NCT00275093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03108|Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function|A Phase I Pharmacokinetic and Pharmacodynamic Study of Temsirolimus (CCI-779) in Patients With Advanced Malignancies and Normal and Impaired Liver Function: An NCI Organ Dysfunction Working Group Study||National Cancer Institute (NCI)||Completed|December 2005|||March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|January 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275093||186293|
NCT00275353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9848|Effectiveness of an Individualized Symptom Education Program (ISEP)|Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer.||University of Toronto||Completed|July 2003|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||144|||Female|18 Years|N/A|No|||January 2006|May 25, 2006|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275353||186273|
NCT00276003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101C|INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.|INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.||University of New Mexico|Yes|Completed|August 2002|August 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2009|January 6, 2010|January 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276003||186230|
NCT00271973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-004082-42|OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models|The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models||Odense University Hospital||Completed|February 2006|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||January 2007|January 29, 2007|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00271973||186529|
NCT00275951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941004|Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer|Phase II Study of Cetuximab Plus P-HDFL(Cisplatin and Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin)for the First-line Treatment of Advanced Gastric Cancer|FLAG|National Taiwan University Hospital|Yes|Completed|December 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|75 Years|No|||November 2012|November 15, 2012|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00275951||186234|
NCT00275964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920807|Development of Active Safety Surveillance System for Traditional Chinese Medicine|||National Taiwan University Hospital||Completed|February 2004|September 2004||||Phase 4|Observational|Time Perspective: Prospective|||||||Female|45 Years|55 Years||||June 2005|October 23, 2008|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275964||186233|
NCT00272584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0-0280|CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia|International Study of Improving Treatment for the Most Severely Ill With Schizophrenia||University of British Columbia||Completed|June 2001|January 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||January 2006|May 5, 2006|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272584||186484|
NCT00272558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPM phase II Carbo/VNB|Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma|Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma||Rigshospitalet, Denmark||Completed|September 2004|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|85 Years|No|||September 2009|September 17, 2009|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272558||186486|
NCT00272571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-02-2701-JL-CTIL|The Effects of External Counter Pulsation Therapy on Circulating Endothelial Progenitor Cells|The Effects of External Counter Pulsation Therapy (ECPT) on the Number and Function of Circulating Endothelial Progenitor Cells in Patients With Angina Pectoris||Sheba Medical Center||Completed|August 2004|January 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|40 Years|90 Years|No|||January 2006|January 29, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272571||186485|
NCT00272883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-08-128R|Molecular and Genetic Studies of Congenital Myopathies|Molecular Analysis of Neuromuscular Disease||Children's Hospital Boston|No|Recruiting|August 2003|January 2050|Anticipated|January 2050|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|4000|Samples With DNA|The primary biospecimens retained are blood, saliva and muscle tissue samples. Other      specimens are retained on a case-by-case basis.|Both|N/A|N/A|No|Non-Probability Sample|Individuals with a clinical or suspected diagnosis of a congenital myopathy and their        family members.|October 2015|October 26, 2015|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00272883||186461|
NCT00265863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS043|Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites|Phase II Study of Laparoscopic Hyperthermic Peritoneal Chemotherapy for Malignant Ascites||Masonic Cancer Center, University of Minnesota|Yes|Terminated|August 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|December 14, 2005|Yes|Yes|Withdrawn due to slow accrual|No||https://clinicaltrials.gov/show/NCT00265863||186986|
NCT00266110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0418|Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|Phase II Trial Evaluating the Toxicity and Efficacy of a Multiepitope Dendritic Cell Vaccine Given With Trastuzumab and Vinorelbine Ditartrate for the Treatment of Women With Metastatic Breast Cancer That Express HLA-A0201 and Whose Tumors Overexpress HER-2/NEU||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|December 2005|May 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|December 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00266110||186967|
NCT00266474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF_Sinusitis_QS|Prevalence of Chronic Rhinosinusitis in Cystic Fibrosis|Prevalence of Chronic Rhinosinusitis in Cystic Fibrosis||University of Jena||Completed|December 2005|September 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|187|Samples With DNA|Pseudomonas aeruginosa and Staphylococcus aureus cultures (SNPS)|Both|N/A|N/A|No|||December 2014|December 3, 2014|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266474||186939|
NCT00266097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0405|Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer|A Two-Part Phase I Study of the Addition of Oxaliplatin to Gemcitabine, and Then Erlotinib Plus Oxaliplatin to Gemcitabine as Radiosensitizers for Pancreatic and Biliary Adenocarcinoma||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|August 2004|September 2011|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|December 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00266097||186968|
NCT00266422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3950-JK-CTIL|Neurological Outcome of VLBW Infants With Early Hypotension|||Sheba Medical Center||Completed|January 2005|December 2005||||N/A|Observational|N/A||||250|||Both|N/A|12 Months|No|||January 2006|January 28, 2006|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266422||186943|
NCT00266435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3693-ES-CTIL|The Usefulness of the HyperQ Stress System in Routine Annual Screening Testing|The Usefulness of the HyperQ Stress System in Routine Annual Screening Testing||Sheba Medical Center||Completed|November 2005|August 2007|Actual|August 2007|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|371|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary prevention program|March 2008|March 25, 2008|December 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00266435||186942|
NCT00266968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-005|Outcomes of Children With Congenital Single Ventricle Heart|Assessment of the Outcomes of Children With Congenital Single Ventricle Heart||Children's Healthcare of Atlanta|Yes|Completed|January 2000|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|21 Years|No|Non-Probability Sample|subjects seen at Children's Healthcare of Atlanta with single ventrical heart|November 2014|November 26, 2014|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00266968||186902|
NCT00266981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aposgo-HMO-CTIL|Treatment of Whiplash Associated Disorders by APOS Kit|A Randomized Controlled Trial Which Compare the Effectiveness of an APOS Kit With Short Waves Therapy for Treating Whiplash Associated Disorders||Hadassah Medical Organization||Not yet recruiting|March 2006|December 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|132|||Both|16 Years|70 Years|No|||December 2005|December 19, 2005|December 19, 2005||||No||https://clinicaltrials.gov/show/NCT00266981||186901|
NCT00266994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-00343|HTRS TE Registry (ThromboEmbolism Registry)|HTRS TE Registry (ThromboEmbolism Registry): Prospective Registry of Demographic and Clinical Data for Patients With Thromboembolic Disease||Nationwide Children's Hospital||Completed|December 2005|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2760|||Both|N/A|N/A|No|Non-Probability Sample|Eligible patients diagnosed with a thromboembolic event at any of the participating study        centers will be invited to participate in this study.|February 2013|February 20, 2013|December 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266994||186900|
NCT00262743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454773|Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia|A Phase I/II Study of Daily Oral Polyphenon E in Asymptomatic, Rai Stage 0-II Patients With Chronic Lymphocytic Leukemia||Mayo Clinic||Completed|August 2005|August 2012|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|December 6, 2005|Yes|Yes||No|December 7, 2011|https://clinicaltrials.gov/show/NCT00262743||187217|
NCT00263016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976B_2503|Docetaxel in Non Small Cell Lung Cancer (NSCLC)|A Phase II Pilot Study of Combination of Irinotecan and Cisplatin in Docetaxel/Cisplatin-Responsive Advanced Non-Small Cell Lung Cancer||Sanofi||Terminated|May 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|70 Years|No|||March 2008|March 18, 2008|December 6, 2005|||Slow recruitment|No||https://clinicaltrials.gov/show/NCT00263016||187198|
NCT00275366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3827V|Arm Robotics in Musculoskeletal Rehabilitation|Upper Extremity Robotics in Musculoskeletal Rehabilitation||VA Office of Research and Development|Yes|Completed|July 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|65 Years|No|||March 2008|March 10, 2008|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275366||186272|
NCT00274833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3304|Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Trial of Erlotinib With Temozolomide and Concurrent Radiation Therapy Post-Operatively in Patients With Newly Diagnosed Glioblastoma Multiforme||Case Comprehensive Cancer Center|Yes|Completed|October 2005|September 2012|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00274833||186313|
NCT00275041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0436|Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Concurrent Irinotecan Plus Cetuximab in Patients With Advanced Breast Cancer With Prior Anthracycline and/or Taxane-Containing Therapy||Alliance for Clinical Trials in Oncology|No|Completed|February 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275041||186297|
NCT00276289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509-05|Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics|Spironolactone to Decrease Potassium Wasting in Hypercalciuric Patients Treated With Thiazide Diuretics||Indiana University||Completed|January 2006|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|65 Years|No|||December 2009|December 2, 2009|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00276289||186208|
NCT00275990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JETSTENT|AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction|AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients Undergoing Primary PCI for Acute Myocardial Infarction: [JETSTENT] Study||Boston Scientific Corporation|Yes|Completed|December 2005|August 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|501|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275990||186231|
NCT00276263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heresco 3 CTIL|Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia|Sarcosine (N-methylglycine) Trial for Individuals At Risk for Developing Schizophrenia and Related Disorders||Herzog Hospital|Yes|Withdrawn|August 2006|June 2009||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|45 Years|No|||June 2014|June 3, 2014|January 12, 2006||No|lack of participants|No||https://clinicaltrials.gov/show/NCT00276263||186210|
NCT00272246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYSPAS|Bilateral Internal Pallidum Stimulation in Primary Generalized Dystonia|||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Recruiting|February 2005|December 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|12 Years|60 Years|No|||January 2006|January 4, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272246||186509|
NCT00272259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSF 0238204|Robots for Stroke Survivors|||Carnegie Mellon University||Terminated||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||January 2007|January 4, 2007|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272259||186508|
NCT00272272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-01-01-06-01|Fall Prevention in a Geriatric Nursing Home Setting Using the Music of Nolwenn Leroy|The Nolwenn Effect in a Geriatric Nursing Home Setting||Carrick Institute for Graduate Studies|No|Completed|December 2005|March 2007|Actual|October 2006|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|200|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00272272||186507|
NCT00272285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06003/TnIO01|A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea|A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron Plus Dexamethasone Injection for the Prevention of Chemotherapy-Induced Vomiting and Nausea||Astellas Pharma Inc|No|Completed|January 2006|March 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|287|||Both|20 Years|74 Years|No|||April 2008|April 24, 2008|January 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272285||186506|
NCT00272311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-35|Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome|A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)|PAD|Florida Atlantic University|Yes|Completed|October 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|70|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|January 3, 2006|No|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT00272311||186505|
NCT00272870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMCEH003|Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy|A Pilot Study of Temozolomide and 06Benzylguanine for Treatment of Newly Diagnosed High Grade Glioma, Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection||Children's Hospital Medical Center, Cincinnati|Yes|Terminated|December 2005|August 2012|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|5 Years|55 Years|No|||August 2012|August 28, 2012|January 4, 2006|No|Yes|Slow accrual; drug availability|No||https://clinicaltrials.gov/show/NCT00272870||186462|
NCT00273208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 2005-01|An Intervention to Decrease Fatigue Among Breast Cancer Survivors|Being Well, Staying Healthy: An Integrated Mind-Body Medicine Intervention to Decrease Fatigue Among Breast Cancer Survivors, PILOT STUDY||Mercy Medical Center|No|Completed|September 2005|April 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||25|||Both|N/A|N/A|No|||August 2007|August 1, 2007|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273208||186436|
NCT00273546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6043|Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer|A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progression Free Survival in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Sanofi||Completed|May 1999|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|500|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|January 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00273546||186410|
NCT00274768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0425 CDR0000446286|Capecitabine in Treating Patients With Metastatic Breast Cancer|Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Completed|April 2004|November 2012|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|January 10, 2006|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00274768||186318|The small sample size limited a number of the secondary objectives.
NCT00265837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0165 CDR0000454926|Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer|Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation||Sidney Kimmel Comprehensive Cancer Center||Completed|December 2002|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|72|||Both|N/A|65 Years|No|||April 2014|April 16, 2014|December 14, 2005||||||https://clinicaltrials.gov/show/NCT00265837||186988|
NCT00266487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRC 112812/320|The Norwegian Vitamin Trial (NORVIT)|Randomized Trial of Homocysteine-Lowering With B Vitamins for Secondary Prevention of Cardiovascular Disease After Acute Myocardial Infarction. The Norwegian Vitamin Trial (NORVIT)||University of Tromso||Completed|December 1998|March 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||3750|||Both|30 Years|85 Years|No|||August 2005|May 3, 2006|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266487||186938|
NCT00266448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94/2000|Whole Body Washing With Chlorhexidine for the Eradication of MRSA|The Value of Whole Body Washing With Chlorhexidine for the Eradication of MRSA – a Randomized, Placebo-Controlled, Double-Blinded Clinical Trial||Heidelberg University||Completed|January 2001|April 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||April 2004|December 15, 2005|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266448||186941|
NCT00266461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100P2T1|A Tolerability and Efficacy Study of TU-100 For The Treatment of Postoperative Ileus|A Randomized, Controlled, Open-Label Tolerability And Efficacy Study Of TU-100 For The Treatment Of Postoperative Ileus In Patients Undergoing Laparotomy For Large Bowel Resection||Tsumura USA|No|Completed|December 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||June 2012|July 11, 2013|December 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266461||186940|
NCT00266747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5893|An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder|An Eight-Week,Dble-Blind,Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder|AQUARIUS|Sanofi||Completed|December 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|366|||Both|18 Years|65 Years|No|||March 2009|March 10, 2009|December 16, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00266747||186918|
NCT00267007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003247|A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients Receiving Combination Taxane and Platinum-Based Chemotherapy for Cancer||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|June 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|December 16, 2005|Yes|Yes|Slow enrollment|No|July 31, 2009|https://clinicaltrials.gov/show/NCT00267007||186899|No formal analysis was conducted due to early termination
NCT00275496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSLT-1|Multicenter Selective Lymphadenectomy Trial (MSLT)|A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.||John Wayne Cancer Institute|Yes|Completed|November 1993|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2001|||Both|18 Years|75 Years|No|||May 2014|September 1, 2015|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275496||186263|
NCT00267293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY03-127|Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever|Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever||Penn State University|No|Completed|January 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|6 Months|7 Years|Accepts Healthy Volunteers|||May 2012|May 8, 2012|December 16, 2005||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00267293||186877|Relatively small sample size. Underpowered to evaluate effect oon discomfort and pain. The 6 hour observation allowed for evaluation of single cycle of drug. Did not evaluate the effect of multiple doses over a longer observation period.
NCT00275691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2354-02|Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR|Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR||Mayo Clinic||Completed|October 2005|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Observational|Time Perspective: Prospective||1|Actual|867|||Both|18 Years|N/A|No|Probability Sample|Greater than 18 years of age. Cough present greater than one day and a history of fever        and chills or documented fever in the Emergency Department|January 2010|January 15, 2010|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275691||186249|
NCT00275704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC04C9|Flaxseed for the Treatment of Hot Flashes|Phase II Evaluation of Flaxseed for the Treatment of Hot Flashes||Mayo Clinic||Completed|May 2005|||June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 9, 2011|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275704||186248|
NCT00275600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1957-02|Randomized Clinical Trial of Vitamin E and Evening Oil of Primrose for the Managment of Breast Pain|Randomized Clinical Trial of Vitamin E and Evening Oil of Primrose for the Managment of Cyclical Breast Pain||Mayo Clinic||Completed|January 2003|September 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|82|||Female|18 Years|56 Years|Accepts Healthy Volunteers|||November 2009|November 25, 2009|January 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275600||186255|
NCT00275613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|976-05|Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis|Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis||Mayo Clinic|Yes|Completed|November 2005|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275613||186254|
NCT00275717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|374-05|A Study That Will Look at the Impact of Immunosuppression on Antibody Production in Kidney Transplant Recipients.|The Effects of Thymoglobulin on Antibody Screening Cells.||Mayo Clinic||Completed|March 2005|December 2010|Actual|December 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Three groups will be studied:          1. Non-sensitized renal allograft candidates prior to any therapy;          2. High DSA recipients--Recipients with a positive T or B cell cytotoxicity crossmatch             or a B cell flow cytometric crossmatch assay with a channel shift >350 at baseline             against their living donor at baseline and          3. Low DSA recipients—recipients with a negative T and B cell cytotoxicity assay, but a             positive T or B cell flow cytometric crossmatch with a B cell channel shift <350.|December 2010|December 20, 2010|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275717||186247|
NCT00276276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/478|Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer|An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control Alone or in Combination With Oral Topotecan in Patients With Relapsed Resistant SCLC||GlaxoSmithKline||Completed|November 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||141|||Both|18 Years|N/A|No|||November 2012|April 11, 2013|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00276276||186209|
NCT00272012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3507|OPAL - Insulin Glulisine, Diabetes Mellitus|Efficacy and Safety of Insulin Glulisine Given as a Single Injection at Breakfast + Insulin Glargine+OAD (Oral Antidiabetic Drug) vs Insulin Glulisine Given as a Single Injection at Main Meal+Insulin Glargine+OAD in Type 2 Diabetic Patients for Which Glycemic Control is Suboptimal Using Insulin Glargine+ OAD Alone||Sanofi||Completed|July 2004|||September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|396|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|January 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00272012||186526|
NCT00272025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-207-05|Treatment Resistant Bipolar Depression|Six Week Double Blind, Randomized Trial of Escitalopram Add On for Treatment Resistant Bipolar Depression||Queen's University|No|Terminated|October 2006|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|January 3, 2006||No|Lundbeck withdrew committment - expiring patents and prolonged inactivity|No||https://clinicaltrials.gov/show/NCT00272025||186525|
NCT00272324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA059005-12|Aspirin/Folate Prevention of Large Bowel Polyps|Aspirin/Folate Prevention of Large Bowel Polyps||Dartmouth-Hitchcock Medical Center||Completed|February 1992|January 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1121|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||November 2005|January 3, 2006|January 3, 2006||||||https://clinicaltrials.gov/show/NCT00272324||186504|
NCT00272337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-36|Aspirin Dose and Atherosclerosis in Patients With Heart Disease|A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)|TAD|Florida Atlantic University|Yes|Completed|October 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|37|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|January 3, 2006|No|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT00272337||186503|
NCT00271986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF20050008|Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection (LAR) for Recto-sigmoid Cancer|Intraperitoneal Microdialysis Monitoring of Patients During the Early Postoperative Period After LAR With Reference to Early Diagnosis of Anastomotic Leakage||Odense University Hospital|No|Completed|January 2006|January 2008|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing Loa Anterior Resection (LAR) or rectal cancer|May 2008|July 20, 2011|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00271986||186528|
NCT00271999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beck-night|Frequent Hemodialysis Network: Nocturnal Trial|Frequent Hemodialysis Network: Nocturnal Trial||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|January 2006|January 2010|Anticipated|January 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|January 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00271999||186527|
NCT00272623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 33-2005|Seldinger Technique Versus Venous Cut-Down for Placement of Totally Implantable Venous Access Ports|A Prospective, Randomized Trial Comparing Seldinger Technique Versus Venous Cut-Down for Placement of Totally Implantable Venous Access Ports||University of Zurich||Completed|January 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272623||186481|
NCT00272597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0356|Risperidone LA Study|Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study||University of British Columbia|No|Completed|September 2005|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||April 2011|April 12, 2011|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00272597||186483|
NCT00273247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-98-016|Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis|Adjuvant α-Interferon Treatment After Resection of Hepatocellular Carcinoma in HCV-Related Cirrhosis: a Randomized Trial on Prevention of Cancer Recurrence||National Cancer Institute, Milan||Completed|June 1998|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|75 Years|No|||September 2005|January 5, 2006|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273247||186433|
NCT00273260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI-001|The Effectiveness of Individualised Bone Density Feedback and Osteoporosis Education in Premenopausal Women|The Effect on Behavior and Bone Mineral Density of Individualized Bone Mineral Density Feedback and Educational Interventions in Premenopausal Women: a Randomized Controlled Trial.||Menzies Institute for Medical Research||Completed|January 2000|December 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Female|25 Years|44 Years|Accepts Healthy Volunteers|||January 2006|May 8, 2006|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273260||186432|
NCT00275197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7571001|A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)|An Eight-Week, Double-Blind, Group-Sequential Design, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of The Co- Administration Of Sertraline And Elzasonan (CP-448,187) In Outpatients With Major Depressive Disorder||Pfizer||Completed|December 2005|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|262|||Both|18 Years|N/A|No|||October 2008|October 30, 2008|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00275197||186285|
NCT00275210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC3313|MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer|Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer||Sanofi||Completed|October 1998|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2246|||Both|18 Years|75 Years|No|||April 2009|April 17, 2009|January 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275210||186284|
NCT00265850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB 80405|Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|November 2005|||March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2334|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|December 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265850||186987|
NCT00275184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/CE/94|Bowel Preparation and Prokinetics in Capsule Endoscopy|A Randomised Study of the Optimal Bowel Preparation for Routine Capsule Endoscopy Using Citramag and Senna or Metoclopramide||London North West Healthcare NHS Trust||Recruiting|January 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|150|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275184||186286|
NCT00266773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR052131|A Telephone Feedback System for Prevention of Chronic Pain Relapse|Therapeutic Interactive Voice Response (IVR) for Relapse Prevention in Chronic Pain||University of Vermont|Yes|Completed|November 2005|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|158|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00266773||186916|
NCT00266760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5302|Characteristics of Episodic Ataxia Syndrome|Episodic Ataxia Syndrome: Genotype-phenotype Correlation and Longitudinal Study||Office of Rare Diseases (ORD)||Active, not recruiting|May 2006|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|Samples With DNA|Blood|Both|5 Years|N/A|No|Non-Probability Sample|Individuals with episodic ataxia|July 2010|July 14, 2010|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00266760||186917|
NCT00275769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229|CAPTURE - Complete Automatic Pacing Threshold Utilization Recorded by EnPulse|Complete Automatic Pacing Threshold Utilization Recorded by EnPulse||Medtronic Cardiac Rhythm Disease Management||Completed|March 2004|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label||||860|||Both|N/A|N/A|No|||December 2008|December 10, 2008|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275769||186243|
NCT00267306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-408|Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis|A Phase 1/2, Partially Randomized, Open-Label Study of Visilizumab in Patients With Severe Ulcerative Colitis Refractory to Intravenous Corticosteroids||Facet Biotech||Completed|January 2004|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||144|||Both|16 Years|70 Years|No|||March 2012|March 8, 2012|December 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267306||186876|
NCT00275340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15880|Cardiac Home Education and Support Trial (CHEST): A Pilot Study|A Pilot Trial of a Home-Based Peer Support Program After Coronary Artery Bypass Graft Surgery||University of Toronto|No|Completed|February 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|101|||Both|N/A|N/A|No|||April 2009|June 5, 2009|January 10, 2006||No||No|January 28, 2009|https://clinicaltrials.gov/show/NCT00275340||186274|
NCT00275665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2124-01|The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.|A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.||Mayo Clinic||Completed|November 2001|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|20|||Both|18 Years|N/A||||December 2011|December 16, 2011|January 10, 2006||Yes||||https://clinicaltrials.gov/show/NCT00275665||186251|
NCT00274339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPR-04-01|Prevacid vs Lifestyle Modifications for the Treatment of LPR|A Comparison of Prevacid 30mg BID Plus Lifestyle Modifications Versus Lifestyle Modifications Alone for the Treatment of Laryngopharyngeal Reflux (LPR) in Adults||Hodge, Kenneth M., M.D.|No|Recruiting|December 2005|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|135|||Both|18 Years|N/A|No|||June 2007|June 22, 2007|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00274339||186350|
NCT00272038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI3652S (0513)|Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer|Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer||Oncology Specialists, S.C.|No|Completed|December 2005|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 12, 2013|January 3, 2006||No||No|May 6, 2013|https://clinicaltrials.gov/show/NCT00272038||186524|
NCT00272363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060059|Clinical and Molecular Studies in Families With Glaucoma and Related Diseases|Clinical and Molecular Studies in Families With Glaucoma and Related Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|December 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|4 Years|N/A|No|||August 2014|November 11, 2014|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00272363||186501|
NCT00272350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060063|ZD6474 to Treat Advanced Brain Cancer in Patients|A Phase I/II Trial of ZD6474 for Patients With Recurrent High-Grade and Progressive Low-Grade Gliomas||National Institutes of Health Clinical Center (CC)||Completed|December 2005|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||February 2014|December 16, 2015|January 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00272350||186502|
NCT00272610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 443|Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin|Topical Vitamin A (All-trans Retinol) Versus Vehicle Cream in the Treatment of Aged Skin||University of Michigan||Completed|September 2000|February 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||50|||Both|70 Years|N/A|No|||September 2006|June 23, 2015|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272610||186482|
NCT00272636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0480|Radiofrequency Catheter Ablation for Chronic Atrial Fibrillation|Randomized Comparison of Radiofrequency Catheter Ablation vs. Antiarrhythmic Therapy With Amiodarone for Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation||University of Michigan||Completed|November 2002|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Both|18 Years|70 Years|No|||January 2006|June 2, 2015|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272636||186480|
NCT00272922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1931-A-01 (Institution #)|Randomized, Prospective Controlled Trial of Paraesophageal Hernia Repair With Small Intestinal Submucosa (SIS)|Randomized, Prospective Controlled Trial of Paraesophageal Hernia Repair With Small Intestinal Submucosa (SIS)||Cook||Completed|July 2002|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||October 2007|October 17, 2007|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272922||186458|
NCT00272935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-CEN-301|A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes|A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Demonstrate the Safety and Efficacy of Daily 0.3 mg Synthetic Conjugated Estrogens, A (Cenestin) for the Treatment of Vasomotor Symptoms in Postmenopausal Women||Teva Pharmaceutical Industries|No|Completed|December 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Female|30 Years|80 Years|No|||July 2009|June 29, 2012|January 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272935||186457|
NCT00272896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA04119|Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in Migraineurs|Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide (VIP) in Migraineurs||Danish Headache Center||Completed|October 2004|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||12|||Both|18 Years|40 Years|No|||October 2004|January 4, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272896||186460|
NCT00272909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-103|Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)|A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI||Daiichi Sankyo Inc.|Yes|Terminated|September 2004|January 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|85 Years|No|||October 2015|October 19, 2015|January 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272909||186459|
NCT00275756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-040106|Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans|Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans||Medical University of Vienna|Yes|Withdrawn|September 2008|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|0|||Both|19 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00275756||186244|
NCT00275535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124-01|The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients|A Prospective, Randomized Trial of Calcineurin-Inhibitor Withdrawal in Renal Allograft Recipients||Mayo Clinic|Yes|Completed|April 2001|December 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|75 Years|No|||December 2011|December 6, 2011|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00275535||186260|
NCT00266123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-101497|Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients|A Randomized Open-Label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens With a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2004|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||420|||Both|18 Years|N/A|No|||December 2007|December 18, 2007|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00266123||186966|
NCT00266136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLCG 99|Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)|Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose Chemotherapy With Stem Cell Transplantation||University Hospital Muenster||Completed|June 1999|October 2012|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3500|||Both|16 Years|N/A|No|||October 2012|October 25, 2012|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00266136||186965|
NCT00275821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2302|Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|A Randomized, Double-masked, Active-controlled, Multi-center Study Comparing the Efficacy and Safety of Ranibizumab Administered as Two Dosing Regimens in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|EXCITE|Novartis||Completed|December 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|353|||Both|50 Years|N/A|No|||February 2011|February 22, 2011|January 11, 2006||||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00275821||186241|
NCT00275509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-06-29-03|Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch|Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch||Johns Hopkins University||Recruiting|January 2006|January 2010|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|110|||Both|18 Years|N/A|No|||May 2008|May 7, 2008|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275509||186262|
NCT00275171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019|rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter|The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.||Odense University Hospital|Yes|Completed|February 2006|September 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|January 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00275171||186287|
NCT00276120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1009|Young Women's Breast Cancer Research Program|Identification of Novel Genetic Risk Factors That Contribute to the Risk for Breast Cancer||Washington University School of Medicine|Yes|Recruiting|March 2005|January 2015|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Blood specimens.|Female|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|women diagnosed with invasive breast cancer < 40 years of age|March 2011|March 9, 2011|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00276120||186221|
NCT00276094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-50310|A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women|Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo||Shionogi Inc.||Completed|January 2006|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|826|||Female|40 Years|80 Years|No|||March 2013|May 21, 2013|January 10, 2006|Yes|Yes|||March 20, 2013|https://clinicaltrials.gov/show/NCT00276094||186223|
NCT00276107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101446|Study Evaluating Prevenar Vaccine in Healthy Infants|An Open-Label Trial of the Immunogenicity and Safety of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine [Diphteria CRM197 Protein Conjugate]) in Healthy Infants at 2, 4 and 6 Months of Age||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2004|December 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|42 Days|100 Days|Accepts Healthy Volunteers|||July 2009|July 28, 2009|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00276107||186222|
NCT00275119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454568|Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|Protocole de Phase II: Etude de Faisabilite de L'Oxaliplatine en Association Chimio-Radiotherapie Concomitante Dans le Traitement Des Cancers du Pancreas Localement Avances Non Resecables||National Cancer Institute (NCI)||Active, not recruiting|November 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2006|February 6, 2009|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275119||186291|
NCT00275678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2158-03|Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies|A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From HLA Compatible Unrelated Donors.||Mayo Clinic||Completed|November 2003|||September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|66 Years|No|||June 2010|June 2, 2010|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275678||186250|
NCT00275418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta Carotene 01|Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease|Double-Blind Randomized Prospective Trial of Treatment With Natural Beta Carotene Vs. Placebo for Patients With Crohn's Disease in Remission||Bnai Zion Medical Center||Recruiting|July 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|17 Years|75 Years|No|||January 2006|January 10, 2006|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275418||186268|
NCT00275431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-005|Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies|A Phase II, Open Label, Multicenter Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)||Ascenta Therapeutics||Completed|November 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00275431||186267|
NCT00276029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|etanercept/pr2|TNF Alpha in Refractory Asthma|The Efficacy of a Soluble Ligand Binding Tumour Necrosis Factor Receptor, Etanercept, in Severe, Steroid Dependant Asthma: a Randomised Controlled Study||University Hospitals, Leicester||Completed|December 2003|September 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||September 2004|May 3, 2006|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00276029||186228|
NCT00276042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP-FAR-008|A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media|Prospective, Randomized, Investigator-Blind Trial to Evaluate the Bacteriologic Eradication, Safety and Tolerability, and Pharmacokinetics of Different Dosages of Faropenem Medoxomil BID for 10 Days in the Treatment of Acute Otitis Media||Replidyne|No|Completed|January 2006|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|328|||Both|6 Months|7 Years|No|||February 2008|February 1, 2008|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00276042||186227|
NCT00276302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-02|Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)|A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Either Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) or Advanced or Metastatic Soft Tissue Sarcomas (STS)||Infinity Pharmaceuticals, Inc.|No|Completed|December 2005|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||January 2011|January 5, 2011|January 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00276302||186207|
NCT00272649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-003-004|Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer|A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma||Argos Therapeutics|Yes|Completed|January 2006|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|January 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272649||186479|
NCT00272662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-05|Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy|A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy||Affymax|No|Completed|January 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|80 Years|No|||December 2012|December 19, 2012|January 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272662||186478|
NCT00273819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS0006|Study of Coronary Artery Disease by Two Types of Angiography|Non-Invasive Detection of Revascularizable Cardiomyopathy||VA Connecticut Healthcare System||Completed|October 2005|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|No|||January 2009|January 24, 2009|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273819||186389|
NCT00273221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-A/05/196|Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial|Combined Phacoemulsification and Glaucoma Implant Surgery Versus Combined Phacoemulsification and Trabeculectomy: A Randomized Controlled Trial||National University Hospital, Singapore||Recruiting|July 2005|July 2006|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|21 Years|N/A|No|||May 2008|May 21, 2008|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00273221||186435|
NCT00273234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHC-2006-01|Clinical Effectiveness of Topical Autologous Platelet Gel for the Treatment of Venous Ulcers|Clinical Evaluation of the Safety and Effectiveness of Topical Autologous Platelet Gel (APG) for the Treatment of Lower Extremity Chronic Venous Insufficiency Ulcers. A Multicenter, Randomized, Controlled Clinical Trial||National Healing Corporation||Withdrawn|January 2006|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||March 2007|March 4, 2007|January 4, 2006|||Lack of financial support. Study criteria severly limited enrollment.|||https://clinicaltrials.gov/show/NCT00273234||186434|
NCT00274976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455059|Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine|Subcutaneous Campath-1H in Fludarabine-Refractory CLL||National Cancer Institute (NCI)||Completed|September 2002|August 2009|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||May 2006|November 5, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274976||186302|
NCT00275236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0794|A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|A Multi-center, Double-blind, Randomized, Placebo-controlled, Two-arm, Parallel-group, Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome||UCB Pharma||Completed|November 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|75 Years||||September 2009|September 24, 2014|January 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275236||186282|
NCT00275886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701221|Activation and Recruitment of GIL During Hp Infection|Activation and Recruitment of Gastric Infiltrating Lymphocytes During H. Pylori Infection||National Taiwan University Hospital||Recruiting|January 2006|December 2008||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Both|20 Years|60 Years|No|||December 2005|January 11, 2006|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275886||186239|
NCT00274963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455086|Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM)||National Cancer Institute (NCI)||Active, not recruiting|October 2004|||November 2007|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|N/A|No|||July 2007|November 5, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274963||186303|
NCT00276146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC 03-7-41|Dipyridamole/Magnesium To Improve Sickle Cell Hydration|Dipyridamole/Magnesium To Improve Sickle Cell Hydration||Children's Hospital Medical Center, Cincinnati|Yes|Withdrawn|May 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Actual|0|||Both|12 Years|N/A||||August 2013|August 5, 2013|January 11, 2006|Yes|Yes|The NHLBI BSMB recommended closure due to poor enrollment.|No||https://clinicaltrials.gov/show/NCT00276146||186219|
NCT00276159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05US02IMP-852A|Study of Immune Response Modifier in the Treatment of Hematologic Malignancies|Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||July 2010|July 7, 2010|January 11, 2006|Yes|Yes|Drug was not available.|No|March 2, 2010|https://clinicaltrials.gov/show/NCT00276159||186218|
NCT00276133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7332-1|Effects of Atorvastatin Versus Probucol on Small Dense LDL|Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy||Yokohama City University Medical Center|Yes|Completed|January 2004|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|75 Years|No|||May 2007|May 8, 2007|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00276133||186220|
NCT00275795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAET Testing for Food Allergy|NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®|Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST-NAET®||Nambudripad's Allergy Research Foundation||Completed|July 2005|January 2006||||Phase 1/Phase 2|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||42|||Both|2 Years|78 Years|Accepts Healthy Volunteers|||April 2006|October 31, 2006|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275795||186242|
NCT00272194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-05-0347|Ambu® Laryngeal Mask as an Intubation Conduit|The Ambu® Laryngeal Mask as an Intubation Conduit For Patients Undergoing Routine General Anesthesia||The University of Texas Health Science Center, Houston||Completed|December 2005|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||160|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|January 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00272194||186513|
NCT00272480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIDGE1.0|Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial|Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial||Imperial College London||Completed|November 1999|November 2001||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|16 Years|75 Years|No|||January 2006|May 27, 2015|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272480||186492|
NCT00276406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004037|Use of Pyridostigmine for Constipation in Diabetics|Pyridostigmine in Diabetics With Constipation: Randomized, Placebo-controlled, Double-blind Trial||Mayo Clinic|Yes|Completed|May 2006|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||November 2012|November 2, 2012|January 11, 2006|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT00276406||186199|
NCT00272155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850657|An Intervention to Reduce Inappropriate Prescriptions of Antibiotics for Respiratory Infections in General Practice|Can Antibiotic Prescriptions in Respiratory Tract Infections be Improved? A Cluster Randomized Educational Intervention in General Practice||University of Oslo||Completed|January 2006|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|118621|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2005|April 26, 2010|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00272155||186516|
NCT00275132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000457755|Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy|TOPICAL|University College, London|Yes|Completed|April 2005|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|670|||Both|18 Years|N/A|No|||December 2011|December 1, 2014|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275132||186290|
NCT00276016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04579|The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)|Crossover Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber||Merck Sharp & Dohme Corp.|No|Completed|January 2006|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|39|||Both|18 Years|55 Years|No|||September 2015|September 25, 2015|January 11, 2006|Yes|Yes||No|April 1, 2010|https://clinicaltrials.gov/show/NCT00276016||186229|
NCT00276341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-39-00240-126|Study on the Effectiveness of EGb 761® Vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis|Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-Blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.||Ipsen||Completed|August 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||May 2006|May 15, 2006|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276341||186204|
NCT00276354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-31-52072-003|Study of Long-Term Use of Forlax® in Elderly Patients With Chronic Constipation|Tolerance of Long Term Administration of Forlax® 10g in Elderly Ambulatory or Institutionalized Patients Suffering From Chronic Constipation. Single Blind Randomised Lactulose-Controlled Study With Individual Expected Benefit.||Ipsen||Completed|December 1999|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||240|||Both|70 Years|N/A|No|||May 2006|May 15, 2006|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276354||186203|
NCT00272051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4972|XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy|A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)||Sanofi||Completed|July 2002|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||620|||Both|18 Years|N/A|No|||September 2006|September 11, 2006|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272051||186523|
NCT00274092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.279|Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Comparison of 18 Mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 Mcg) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|September 2002|October 2003||October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|132|||Both|40 Years|N/A|No|||November 2013|November 4, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274092||186369|
NCT00272948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number:2004-000592-33|Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide|Prospective Randomized Study of the Incidence and Outcome of Veno-Occlusive Disease (VOD) With the Prophylactic Use of Defibrotide (DF) in Pediatric Stem Cell Transplantation|VOD-DF|European Group for Blood and Marrow Transplantation|Yes|Completed|December 2005|July 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|N/A|18 Years|No|||June 2011|June 8, 2011|January 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00272948||186456|
NCT00275548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404-04|Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C|A Prospective, Randomized, Multi-center, Open-label, Comparative Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon Alfa-2a(Pegasys) Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C.||Mayo Clinic||Completed|July 2004|April 2009|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|19 Years|N/A|No|||November 2011|November 9, 2011|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275548||186259|
NCT00263497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHM1030375|Temporary Prosthesis in Traumatic Below-knee Amputation|Immediate Temporary Prosthesis Fitting in Traumatic Trans-tibial Amputation: a Controlled Clinical Study in Rural Cambodia||University Hospital of North Norway|Yes|Recruiting|March 2006|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|55 Years|No|||May 2012|May 11, 2012|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263497||187162|
NCT00263523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060042|PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY|PET Imaging of Brain 5-HT1A Receptors Using [11C](-)-RWAY||National Institutes of Health Clinical Center (CC)||Completed|December 2005|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||August 2007|August 16, 2007|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00263523||187161|
NCT00275522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302-04|The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.|A Randomized Open-label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens With a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients.||Mayo Clinic||Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|N/A||||January 2010|January 19, 2010|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275522||186261|
NCT00276458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-079|To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)|A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 Mg||Merck Sharp & Dohme Corp.||Completed|February 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|79 Years|No|||September 2015|September 2, 2015|January 10, 2006|Yes|Yes||No|December 18, 2008|https://clinicaltrials.gov/show/NCT00276458||186195|194 out of 196 randomized patients took at least one dose of blinded study therapy and were included in the safety analysis
NCT00264147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-086|Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)|A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis||Merck Sharp & Dohme Corp.||Completed|January 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|761|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|December 9, 2005|Yes|Yes||No|March 19, 2009|https://clinicaltrials.gov/show/NCT00264147||187115|
NCT00276432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|637-05|Diagnosis and Treatment of Acute Coronary Syndrome in the ED & the Impact of Rapid Bedside cTnl on Outcome.|Diagnosis and Treatment of Acute Coronary Syndrome in the Emergency Department- The Impact of Rapid Bedside cTnl on Outcome.||Mayo Clinic||Completed|November 2005|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|350|||Both|21 Years|N/A|No|||January 2010|January 27, 2010|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00276432||186197|
NCT00276419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-05|Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin|Topical Diclofenac for the Treatment of Noncyclic Breast Pain||Mayo Clinic|No|Terminated|June 2005|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|N/A|No|||December 2012|December 13, 2012|January 11, 2006||No|Lack of funds; FDA approved a topical form of diclofenac during study, no need to continue    study of pharmacy-compounded drug.|No|November 16, 2012|https://clinicaltrials.gov/show/NCT00276419||186198|This study was terminated early due to lack of funds; the FDA approved a topical form of diclofenac during study, therefore there was no need to continue study of pharmacy-compounded drug.
NCT00272766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0722|Macugen for Histoplasmosis|Macugen for Histoplasmosis-An Open-Label, Single-Site, Comparative, Prospective Case Series||Barnes Retina Institute||Terminated|February 2006|May 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||October 2006|October 25, 2006|January 4, 2006||||||https://clinicaltrials.gov/show/NCT00272766||186470|
NCT00272675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO-03.021|Prevention of Nosocomial Infection by Decontamination of the Naso- and Oropharynx With Chlorhexidine (NONI Trial)|Prevention of Nosocomial Infection in Cardiac Surgery by Decontamination of the Naso- and Oropharynx With Chlorhexidine. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Completed|August 2003|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1000|||Both|18 Years|N/A|No|||January 2006|January 6, 2006|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272675||186477|
NCT00275392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4168-P|Vestibular Rehabilitation and Dizziness in Geriatric Patients|Vestibular Rehabilitation and Dizziness in Geriatric Patients||VA Office of Research and Development|No|Completed|April 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|60 Years|N/A|No|||December 2014|December 5, 2014|January 10, 2006||No||No|September 17, 2014|https://clinicaltrials.gov/show/NCT00275392||186270|
NCT00243269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2905|Acupressure and Relaxation for Nausea Control|Acupressure and Relaxation for Nausea Control||University of Rochester|Yes|Completed|November 2005|January 2010|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|83|||Female|18 Years|N/A|No|||March 2010|May 21, 2015|October 19, 2005||No||No|March 22, 2010|https://clinicaltrials.gov/show/NCT00243269||188683|Limitations include a small sample size and the fact that we ceased recruitment to two of the treatment arms and changed our planned primary analysis mid-study based upon an interim analysis that was not specified at the time the study began.
NCT00243282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S05-Shekelle0024|Randomized Controlled Trial of Mind-Body Breathing Therapy (in Chronic Obstructive Pulmonary Disease) To Improve Palliation of Dyspnea and Health-Related Quality of Life|Randomized Controlled Trial of Mind-Body Breathing Therapy (in Chronic Obstructive Pulmonary Disease) To Improve Palliation of Dyspnea and Health-Related Quality of Life||VA Office of Research and Development|No|Completed|October 2005|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||120|||Both|N/A|N/A|No|||March 2008|January 20, 2009|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00243282||188682|
NCT00274911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-CNS-2004-01|Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors|Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours||National Cancer Institute (NCI)||Active, not recruiting|February 2004|||March 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|3 Years|18 Years|No|||June 2009|August 1, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274911||186307|
NCT00274924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455012|Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning||Eastern Cooperative Oncology Group|No|Active, not recruiting|April 2006|March 2019|Anticipated|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||October 2015|October 6, 2015|January 10, 2006|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT00274924||186306|
NCT00272402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308300|Reducing Clinical Inertia in Diabetes Care|Reducing Clinical Inertia in Diabetes Care||HealthPartners Institute|Yes|Completed|February 2006|December 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|61|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00272402||186498|
NCT00272415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-06-2004|A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma|A Phase Ib, Open-Label, Multicenter Trial of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate the Tolerability, Safety, and Pharmacokinetics in Subjects With Newly-Diagnosed or Recurrent Unresectable Stage III or Stage IV Melanoma||Genentech, Inc.||Terminated|October 2005|||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||November 2007|March 9, 2009|January 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272415||186497|
NCT00272688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duo-HRQoL-2|Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit|Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation||University Hospital, Akershus||Completed|January 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||December 2015|December 29, 2015|January 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00272688||186476|
NCT00272987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF104383|ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib|A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer||GlaxoSmithKline||Active, not recruiting|December 2005|June 2016|Anticipated|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|January 4, 2006|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00272987||186453|
NCT00273312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2213|Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma|An Open-label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC)||Novartis||Completed|January 2006|||October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|January 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00273312||186428|
NCT00274742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT103-104|Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL|An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)||Amgen Research (Munich) GmbH|Yes|Completed|June 2004|April 2012|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|January 10, 2006||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT00274742||186320|
NCT00275457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.520|Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients|A Randomised, Double-blind, Placebo-controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Followed by 46 Weeks Open-label or Double-blind Treatment Period||Boehringer Ingelheim||Completed|October 2002|April 2004||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||346|||Both|18 Years|80 Years|No|||October 2013|October 30, 2013|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00275457||186265|
NCT00275483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vital-band 01|Prevention of Postoperative Nausea and Vomiting (PONV) by Acupressure|Prevention of PONV by Acupressure. A Study of the Effect of a Recently Generated Danish Bracelet Vital-Band(R) Which Stimulates the Acupressure Point P6||Herlev Hospital||Completed|May 2005|February 2007|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|132|||Female|18 Years|N/A|No|||May 2008|May 27, 2008|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275483||186264|
NCT00263185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0498 / 201012921|High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status|A Double-Blind, Randomized, Placebo Controlled Trial of High Dose Vitamin D Therapy On Musculoskeletal Symptoms and Bone Mineral Density in Anastrozole-Treated Early Stage Breast Cancer Patients With Marginal Vitamin D Status||Washington University School of Medicine|No|Completed|November 2005|November 2009|Actual|November 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|63|||Female|18 Years|N/A|No|||September 2014|September 18, 2014|December 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00263185||187185|
NCT00263822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55041|Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer|A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|September 2005|||February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|835|||Female|18 Years|N/A|No|||August 2013|August 26, 2013|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263822||187138|
NCT00275834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005514|Zonisamide for Weight Reduction in Obese Adults|Zonisamide for Weight Reduction in Obese Adults||Duke University|Yes|Completed|January 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|65 Years|No|||February 2013|July 9, 2014|January 10, 2006|Yes|Yes||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00275834||186240|
NCT00264160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AIL01|Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy|Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy||Novartis||Completed|May 2006|August 2009|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264160||187114|
NCT00264134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1047791|Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer|A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma||Kentuckiana Cancer Institute||Terminated|June 2003|October 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2010|January 18, 2010|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00264134||187116|
NCT00264394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 3345-062041 SHCS 480|Cardiovascular Risk Factor Management in HIV Infection|Efficacy of a Computerised Physician Reminder System to Control Cardiovascular Risk Factors in HIV-infected Patients Receiving Antiretroviral Therapy: A Nested Randomised Controlled Cluster Trial Within the Swiss HIV Cohort Study||University Hospital, Basel, Switzerland|Yes|Completed|July 2006|February 2010|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4097|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264394||187096|
NCT00272493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5220|Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals|Improving Immune Response to Hepatitis B Vaccine in HIV-positive Subjects Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as a Vaccine Adjuvant: A Phase II Open-Label Pilot Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||September 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|January 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272493||186491|
NCT00272506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|351|Pediatric Asthma Controller Trial (PACT)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2002|September 2004||||Phase 3|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||||||Both|N/A|18 Years|No|||January 2006|July 10, 2006|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272506||186490|
NCT00272779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-138|BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada|A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects||Bristol-Myers Squibb|Yes|Completed|November 2005|October 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1057|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|January 5, 2006|Yes|Yes||No|December 3, 2010|https://clinicaltrials.gov/show/NCT00272779||186469|
NCT00272792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-006|Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet|A Phase 3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet||BioMarin Pharmaceutical||Completed|February 2006|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|45|||Both|4 Years|12 Years|No|||July 2015|July 23, 2015|January 5, 2006||Yes|||January 29, 2009|https://clinicaltrials.gov/show/NCT00272792||186468|
NCT00273130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-01-KAT|Stress Response Using Thin and Standard Size Endoscopy.|Randomised Evaluation of Neuroendocrine Stress Response During Upper Gastrointestinal Endoscopy With Standard or Ultrathin Endoscope.||Hvidovre University Hospital||Terminated|March 1999|August 2002||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|N/A|No|||December 2003|September 11, 2006|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273130||186442|
NCT00273273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 056|PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir|Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection||Westat|No|Completed|February 2006|December 2007|Actual|December 2007|Actual|Phase 4|Observational|N/A||||30|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons with HIV-1 infection between the ages of 18 years, 0 days and 24 years, 364 days        currently on a stable combination antiretroviral regimen (> 28 days) with FDA-approved        antiretroviral combination regimens that include tenofovir plus atazanavir/ritonavir and        at least one other active antiretroviral drug.|February 2016|February 29, 2016|January 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00273273||186431|
NCT00273286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMOD|Family Management of Type 1 Diabetes in Children|Family Management of Childhood Diabetes Study||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|January 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|422|||Both|108 Months|174 Months|No|||April 2011|May 11, 2011|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273286||186430|
NCT00273572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3335-OK-CTIL|Lifestyle Intervention in Obese Arab Women|The Effect of a Lifestyle Intervention Program on Parameters of the Metabolic Syndrome Among Non-Diabetic Obese Arab Women||Sheba Medical Center|No|Completed|December 2004|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|35 Years|54 Years|Accepts Healthy Volunteers|||October 2008|October 27, 2008|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273572||186408|
NCT00274079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.276|SPIRIVA in Ususal Care|A Randomised, Double-blind, Parallel Group, 12 Week Study, Comparing the Effect of Once Daily Tiotropium Lactose Capsule With Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD), naïve to Anticholinergic Agents in Addition to Receiving Their Usual COPD Care||Boehringer Ingelheim||Completed|October 2002|October 2003||October 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||395|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274079||186370|
NCT00243048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446088|Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer|Phase II Randomized Study of Soy Isoflavones in Patients With Localized Prostate Cancer Treated With Radiation Therapy||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 2002|October 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|70|||Male|18 Years|N/A|No|||April 2013|April 3, 2013|October 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00243048||188700|
NCT00275743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004022|Use of MRI for Assessing Stomach Relaxation in Response to a Meal|Dynamic MRI - A Novel Approach for Measuring Gastric Accommodation||Mayo Clinic||Completed|October 2005|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|65 Years|No|||April 2009|April 27, 2009|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275743||186245|
NCT00276068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 RO1 HD040123-03|Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine|Vulvar Vestibulitis Trial: Desipramine-Lidocaine||University of Rochester|Yes|Completed|August 2002|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|128|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2007|November 12, 2007|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00276068||186225|
NCT00273000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-2, MBF|The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans|The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans||Glostrup University Hospital, Copenhagen||Recruiting|January 2006|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2005|September 7, 2006|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273000||186452|
NCT00273299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631D2301|Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension|A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension||Novartis||Completed|November 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|607|||Both|18 Years|80 Years||||November 2011|November 7, 2011|January 4, 2006||||||https://clinicaltrials.gov/show/NCT00273299||186429|
NCT00273585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412524-2|Study of Using Computerized Education to Increase Patients' Confidence in Their Ability to Be Screened for Colon Cancer|Randomized Controlled Trial of Software-Based Enhancement of Colorectal Cancer Screening Self-Efficacy||University of California, Davis||Completed|August 2005|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 6, 2006|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273585||186407|
NCT00274352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM05-006|A Study of Adalimumab to Treat Sarcoidosis of the Skin|A Double-Blind, Randomized, Placebo-Controlled Study of Adalimumab in the Treatment of Cutaneous Sarcoidosis||Pariser, Robert J., M.D.|No|Completed|September 2006|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|89 Years|No|||May 2013|May 20, 2013|January 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00274352||186349|
NCT00272116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERB3514PL950371|Effect of Zinc and Vitamin A Supplementation on Diarrhea, Physical Growth and Immune Response in Malnourished Children|Effect of Zinc and Vitamin A Supplementation on Diarrhea, Physical Growth and Immune Response in Malnourished Children||Society for Applied Studies|No|Completed|February 1998|September 2000|Actual|February 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2482|||Both|6 Months|30 Months|Accepts Healthy Volunteers|||April 2012|April 2, 2012|January 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00272116||186518|
NCT00263198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0970|PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer|Phase II Study of the Combination of PTK787/ZK222584 and Letrozole in Postmenopausal Women With Advanced Hormone Receptor Positive Breast Cancer||Washington University School of Medicine||Terminated|March 2006|November 2006|Actual|October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||May 2013|May 6, 2013|December 6, 2005|No|Yes|unacceptable toxicity|No||https://clinicaltrials.gov/show/NCT00263198||187184|
NCT00263536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060039|Pilot Program for Targeted Prevention of Child or Adolescent Weight Gain|Pilot Program for Targeted Prevention of Child or Adolescent Weight Gain||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2005|September 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|147|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||October 2015|October 17, 2015|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00263536||187160|
NCT00263549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0201NH|Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis|Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity||Allergopharma GmbH & Co. KG|No|Completed|September 2002|February 2006|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||February 2013|February 8, 2013|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00263549||187159|
NCT00263562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17689|Steroid Treatment for Sickle Cell Pain Crisis|Randomized Trial of High-dose Intravenous Methylprednisolone and Steroid Taper for Vaso-occlusive Crises in Sickle Cell Disease||Baylor College of Medicine||Completed|December 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|8 Years|N/A|No|||November 2010|November 30, 2010|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00263562||187158|
NCT00264459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0102st|Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture|A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.||Allergopharma GmbH & Co. KG|No|Completed|February 2003|September 2011|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|60 Years|No|||January 2014|January 23, 2014|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00264459||187091|
NCT00264758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beck-daily|Frequent Hemodialysis Network: Daily Trial|Frequent Hemodialysis Network: Daily Trial||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2006|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|13 Years|N/A|No|||July 2014|July 2, 2014|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00264758||187068|
NCT00264225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S118.3.005|Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)|A Randomized, Double-Blind, Comparative Parallel Group Study of Analgesic Effectiveness and Safety of Three Different Doses of Lamaline® New Formulation vs Dafalgan® Codeine, After 10 Days Administration in Subjects With Painful Gonarthrosis.||Solvay Pharmaceuticals||Completed|December 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|85 Years|No|||February 2008|February 15, 2008|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264225||187109|
NCT00276172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1808|Open-Label Natalizumab Safety Extension Study|An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803||Biogen|No|Completed|December 2003|January 2006|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1615|||Both|18 Years|N/A|No|||June 2009|June 19, 2009|January 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276172||186217|
NCT00276445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-58-2|Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan|Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study||Meiji University of Oriental Medicine||Terminated|January 2004|June 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2004|November 6, 2006|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276445||186196|
NCT00264186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-rhSOD|Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity|Impact of rhCu/Zn SOD on Inflammation-Induced Impairment of Vascular Reactivity||Medical University of Vienna|No|Completed|June 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||43|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2008|May 21, 2008|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264186||187112|
NCT00264433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adherex Protocol # AHX-01-201|A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent|An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201)||Adherex Technologies, Inc.||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2007|August 3, 2007|December 12, 2005||||||https://clinicaltrials.gov/show/NCT00264433||187093|
NCT00272207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WPG2005#1974|A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia|A Randomized Double-blinded Placebo Controlled Trial Assessing the Effect of the Oral Cannabinoid Nabilone on Pain and Quality of Life in Patients With Fibromyalgia||Winnipeg Regional Health Authority|No|Completed|April 2006|March 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||August 2011|August 24, 2011|January 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00272207||186512|
NCT00264121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05.0318L|The Incidence of Congenital Undescended Testis Among Dutch Infants|The Incidence of Congenital Undescended Testis Among Dutch Infants in the Medical Centre Alkmaar||Medical Center Alkmaar||Recruiting|June 2005|June 2008||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3000|||Male|N/A|1 Year|No|||May 2008|May 21, 2008|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264121||187117|
NCT00264719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG-SIG/05011|Metoclopramide to Aid Establishment of Breastfeeding:a Randomised Controlled Trial|Metoclopramide to Aid Establishment of Breastfeeding After Delivery: a Randomized Controlled Trial||National University Hospital, Singapore|Yes|Completed|January 2006|May 2009|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2009|September 18, 2009|December 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00264719||187071|
NCT00264706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lumen-01-CS-1|PolyArginine Treated vEiN grafTs (PATENT)|PolyArginine Treated vEiN grafTs (PATENT)||Lumen Therapeutics||Active, not recruiting|March 2005|April 2008||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|35 Years|85 Years|No|||April 2006|September 5, 2008|December 11, 2005||||No||https://clinicaltrials.gov/show/NCT00264706||187072|
NCT00265096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006340|A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis|GO-REVEAL|Centocor, Inc.|Yes|Completed|December 2005|January 2012|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|407|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|December 12, 2005|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00265096||187043|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00265382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281135|Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia|26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia||Pfizer|Yes|Terminated|June 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Both|13 Years|17 Years|No|||December 2011|December 2, 2011|December 12, 2005|Yes|Yes|Please see Detailed Description for termination reason.|No|April 16, 2010|https://clinicaltrials.gov/show/NCT00265382||187021|The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators.
NCT00265395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03685|Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)|A Study to Assess Treatment With PEG-Intron® and Rebetol® in Naïve Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response||Merck Sharp & Dohme Corp.|No|Completed|December 2004|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1428|||Both|18 Years|70 Years|No|||October 2015|October 7, 2015|December 13, 2005||No||No|May 15, 2009|https://clinicaltrials.gov/show/NCT00265395||187020|
NCT00265408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB #051253|Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection|Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection||University of California, San Diego||Withdrawn|December 2005|March 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2007|December 5, 2014|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00265408||187019|
NCT00273793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-0013-195|Increasing Contingency Management Success in Smoking Cessation|Increasing Contingency Management Success Using Shaping||The University of Texas Health Science Center at San Antonio||Completed|June 2005|November 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|328|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|January 4, 2006||No||No|March 9, 2012|https://clinicaltrials.gov/show/NCT00273793||186391|The study was conducted largely as planned. However the study was not designed to adequately test post-treatment outcomes, as this would not be justifiable unless during treatment differences were observed.
NCT00273806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053766|A Medical Assistant-Based Program to Promote Healthy Behaviors in Primary Care|Engaging the Team: A Multilevel Program to Promote Healthy Behaviors||The University of Texas Health Science Center at San Antonio||Completed|December 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|864|||Both|18 Years|N/A|No|||August 2008|August 26, 2008|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00273806||186390|
NCT00274716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0736-003|Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK0736 and MK0916 in Hypertensive Patients||Merck Sharp & Dohme Corp.|No|Completed|November 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|249|||Both|18 Years|65 Years|No|||June 2015|June 8, 2015|January 10, 2006|Yes|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT00274716||186322|
NCT00274729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-172/03|Mono Unsaturated Fatty Acids in Obesity - Weight Maintenance and Prevention of Lifestyle Diseases in Obese Subjects.|MUFObes: MonoUnsaturated Fatty Acids in Obesity - a Comparison Between 3 Different Diets in Weight Maintenance and the Prevention of Lifestyle Diseases in Obese Subjects. A Randomised, Long-term Intervention Study.||University of Copenhagen||Completed|January 2004|June 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||125|||Both|16 Years|35 Years|Accepts Healthy Volunteers|||January 2006|March 24, 2010|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274729||186321|
NCT00243802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310-2005|Markers of Oxidative Stress Present in Left Atrial Appendage Tissue in Patients With Atrial Fibrillation|Comparison of Markers of Oxidative Stress Present in Left Atrial Appendage Tissue From Subjects With and Without Atrial Fibrillation||Emory University|No|Terminated|May 2005|February 2008|Actual|February 2008|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|65 Years|No|Probability Sample|Male and females between 18 and 65 years of age who have irregular heart beats coming from        the upper chamber of the heart (atrial fibrillation).|September 2013|September 26, 2013|October 24, 2005||No|Terminated.|No||https://clinicaltrials.gov/show/NCT00243802||188642|
NCT00272103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD20003|Itopride in Functional Dyspepsia:a Dose Finding Study|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional Dyspepsia||Royal Adelaide Hospital||Completed|December 2000|January 2002||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|95 Years|No|||November 2005|May 3, 2006|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272103||186519|
NCT00243763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2103|TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma|Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma||Novartis||Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|No|||November 2009|November 20, 2009|October 21, 2005||||||https://clinicaltrials.gov/show/NCT00243763||188645|
NCT00243776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005500|Calcium Current in Human Heart Cells|Calcium Current in Human Atrial Myocytes||Emory University|No|Recruiting|April 2005|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|tissue obtained from surgical waste tissue|Both|N/A|18 Years|No|Probability Sample|children undergoing surgery for repair of congenital heart disease|January 2016|January 8, 2016|October 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00243776||188644|
NCT00274365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4669ctil|Consultations in Psychiatry Through Videoconference|Consultations in Psychiatry Given to GP's Through Videoconference||Sha’ar Menashe Mental Health Center||Completed|November 2005|February 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label||||250|||Both|18 Years|N/A|No|||April 2007|January 28, 2009|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274365||186348|
NCT00244049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA014685-01|CHIPs or College Health Intervention Projects|"Primary Care Alcohol Intervention in College Students"||University of Wisconsin, Madison|No|Completed|May 2004|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 5, 2014|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00244049||188624|
NCT00275158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-52876 (completed)|Glomerular Injury of Preeclampsia|Effect of L-Arginine Therapy on the Glomerular Injury of Pre-Eclampsia: A Randomized Controlled Trial||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|January 2000|December 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||45|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00275158||186288|
NCT00275444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.52|3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study|Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects||Boehringer Ingelheim||Completed|March 2002|||January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|216|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00275444||186266|
NCT00244621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2451C00002|Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age|A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period.||AstraZeneca||Completed|November 2004|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|95|||Both|1 Year|6 Years|No|||August 2011|August 29, 2011|October 25, 2005|Yes|Yes||No|August 7, 2009|https://clinicaltrials.gov/show/NCT00244621||188580|
NCT00244634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2451C00261|Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age|A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study||AstraZeneca||Completed|September 2003|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||238|||Both|6 Years|17 Years|No|||December 2007|December 17, 2007|October 25, 2005||||||https://clinicaltrials.gov/show/NCT00244634||188579|
NCT00264199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050048|Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure|The Effect of 48 Hours GLP-1 Infusion on Left Ventricular Function, Exercise Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure||Aarhus University Hospital Skejby|No|Completed|December 2005|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2007|December 18, 2007|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264199||187111|
NCT00264212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R_8791|AMISH : Aprovel for Management of Isolated Systolic Hypertension|A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension||Sanofi||Completed|August 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||436|||Both|60 Years|90 Years|No|||December 2007|December 17, 2007|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264212||187110|
NCT00264238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUSPO34313|Memantine Augmentation in Obsessive-Compulsive Disorder|An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder||Stanford University||Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2009|April 8, 2009|December 9, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00264238||187108|
NCT00263809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-0028|Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products|Evaluation of the Safety and Performance of Platelet Transfusion Products Treated With MIRASOL® Pathogen Reduction Technology. A Study in Human Thrombocytopenic Subjects.||Terumo BCTbio||Completed|December 2005|October 2007|Actual|October 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|16 Years|N/A|No|||October 2009|October 6, 2009|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263809||187139|
NCT00265135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005278|A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma|A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma||Centocor, Inc.|Yes|Completed|August 2003|February 2006|Actual|February 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00265135||187040|
NCT00264407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10121|Neural Changes in the Aging Auditory System|Age-Related Hearing Loss: Presbycusis & Its Neural Bases||University of Rochester||Completed|January 2001|February 2005||||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||126|||Female|60 Years|86 Years|Accepts Healthy Volunteers|||December 2005|December 8, 2005|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00264407||187095|
NCT00264420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB7743|Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation|A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer||The Cleveland Clinic||Completed|December 2005|March 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2010|December 20, 2010|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00264420||187094|
NCT00264745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-35-6001673-A1|Telephone Assessment and Skill-Building Kit (TASK): A New Program for Family Caregivers of Stroke Survivors|Caregiver Telephone Assessment and Skill-Building Kit||Indiana University||Completed|June 2004|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|January 11, 2011|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264745||187069|
NCT00265759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z1031|Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer|A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|January 2006|||August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|610|||Female|N/A|N/A|No|||July 2015|July 23, 2015|December 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265759||186994|
NCT00265109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0410-001|Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder|Open-Label Study of Levetiracetam in Body Dysmorphic Disorder||Butler Hospital||Completed|December 2004|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||November 2010|November 16, 2010|December 12, 2005||No||No|October 18, 2010|https://clinicaltrials.gov/show/NCT00265109||187042|
NCT00265421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Danish Suture Trial|Study of Different Suturing Techniques for Perineal Repair After Delivery|The Danish Suture Trial: a Randomized Trial on Perineal Sutures Following Vaginal Birth.||University of Aarhus|Yes|Completed|August 2004|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 29, 2009|December 13, 2005||||No||https://clinicaltrials.gov/show/NCT00265421||187018|
NCT00265434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pilot-pulmozyme-nasal-cf|Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis||University of Jena|Yes|Completed|December 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|5 Years|N/A|No|||December 2014|December 3, 2014|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00265434||187017|
NCT00243035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02675|Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma|A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma.||National Cancer Institute (NCI)||Terminated|August 2005|||February 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|October 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00243035||188701|
NCT00242723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060014|Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining|Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|October 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|800|||Both|N/A|100 Years|No|||September 2015|October 6, 2015|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00242723||188725|
NCT00242736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00083|An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)|An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment||AstraZeneca||Completed|October 2005|January 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||350|||Both|18 Years|70 Years|No|||March 2009|March 5, 2009|October 19, 2005||||||https://clinicaltrials.gov/show/NCT00242736||188724|
NCT00242749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0102|IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma|A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable)||AstraZeneca||Completed|December 2002|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||47|||Both|18 Years|70 Years|No|||April 2009|April 22, 2009|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00242749||188723|
NCT00243516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain|Randomized, Controlled Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain||PREtest Consult||Recruiting|October 2005|October 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|400|||Both|18 Years|N/A|No|||September 2006|November 8, 2007|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00243516||188664|
NCT00243789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC0705|Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy|A Double-Blinded Randomized Placebo Controlled Study of Daily Pentoxifylline as a Rescue Treatment in DMD||Cooperative International Neuromuscular Research Group|Yes|Completed|September 2005|January 2008|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|64|||Male|7 Years|N/A|No|||October 2011|October 26, 2011|October 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00243789||188643|
NCT00244062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AA012522-03|Healthy Moms Alcohol Intervention|"Brief Alcohol Intervention: The Healthy Moms Project."||University of Wisconsin, Madison|No|Completed|April 2001|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||250|||Female|18 Years|N/A|No|||April 2011|October 1, 2015|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00244062||188623|
NCT00244075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9458|Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients|Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients||Vanderbilt University|No|Completed|July 1998|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|75 Years|No|||May 2015|May 22, 2015|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00244075||188622|
NCT00244322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9097|Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease|LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease||Eli Lilly and Company||Completed|October 2005|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||45|||Both|50 Years|N/A|No|||May 2007|May 24, 2007|October 24, 2005||||||https://clinicaltrials.gov/show/NCT00244322||188603|
NCT00244647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4126-CL-06|A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis|A Phase 1b, Randomized, Single Blind Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis||Sarepta Therapeutics||Terminated|August 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|19 Years|80 Years|No|||April 2008|April 9, 2008|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244647||188578|
NCT00244660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.504|Blood Pressure Reduction in Danish General Practice (BRIDGE)|Blood Pressure Reduction in Danish General Practice (BRIDGE)||Boehringer Ingelheim||Completed|November 2005|June 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|18 Years|N/A|No|||January 2008|January 17, 2008|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00244660||188577|
NCT00257127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1061s|Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs|Evaluation of Immunologic Memory Following Pneumococcal, Hepatitis B, and Measles Vaccination in HIV Infected Children Treated With Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|6 Years|23 Years|No|||November 2014|November 10, 2014|November 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00257127||187641|
NCT00257114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05004|Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability|Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability||Millennium Pharmaceuticals, Inc.||Completed||||March 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2008|February 7, 2008|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00257114||187642|
NCT00257426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0221|Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer|A Phase II Study of Octreotide Acetate for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma||UNC Lineberger Comprehensive Cancer Center||Completed|July 2005|September 2009|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2012|February 12, 2012|November 18, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00257426||187618|
NCT00251992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-NED-0022|Nexium Dyspepsia/AST|Supportive Test for Acid-Related Symptoms (STARS II) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Uninvestigated Subjects With Upper Gastrointestinal Symptoms.||AstraZeneca||Completed|December 2002|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1200|||Both|18 Years|50 Years|No|||January 2011|January 21, 2011|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251992||188026|
NCT00252005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-017|Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study|Protocol CV185017: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis||Bristol-Myers Squibb||Completed|November 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||520|||Both|18 Years|90 Years|No|||August 2008|February 27, 2010|November 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00252005||188025|
NCT00252291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-A-305|Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics|A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting With Signs and Symptoms Suggestive of Asthma But Without a Definitive Diagnosis||Pharmaxis||Completed|November 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||240|||Both|6 Years|50 Years|No|||November 2009|November 29, 2009|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00252291||188004|
NCT00248794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3251-R|Cognitive Rehabilitation in Schizophrenia|The Effects of Cognitive Rehabilitation on Function in Schizophrenia||VA Office of Research and Development|No|Completed|June 2004|October 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|65 Years|No|||October 2014|October 24, 2014|November 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00248794||188268|
NCT00248781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2777-R|Home-based Exercise Via a Telecommunications System|Home-based Exercise Via a Telecommunications System||VA Office of Research and Development||Completed|September 2003|November 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|103|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|November 2, 2005||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00248781||188269|
NCT00249340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-05|Brief Behavioral Weight Loss Treatment vs. Weight Watchers|Comparison of a Brief Behavioral Weight Loss Intervention With the Weight Watchers Program||The Miriam Hospital||Completed|November 2005|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2005|April 10, 2007|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249340||188228|
NCT00245544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0759-004|Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)|A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Explore the Safety and Preliminary Efficacy of Oral MK0759 in the Treatment of Postherpetic Neuralgia||Merck Sharp & Dohme Corp.||Terminated|November 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|20|||Both|18 Years|85 Years|No|||May 2015|May 20, 2015|October 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00245544||188509|
NCT00245557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-002540|Magnetic Resonance Imaging Study of Geriatric Depression|Nuclear Magnetic Resonance Imaging Study of Treatment With Sertraline in Geriatric Depression||Mclean Hospital|No|Completed|November 2004|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|55 Years|89 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|October 27, 2005|Yes|Yes||No|September 16, 2009|https://clinicaltrials.gov/show/NCT00245557||188508|
NCT00254813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449L00003|Fast Titration Of Quetiapine Versus Currently Approved Titration|Fast Titration Of Quetiapine Versus Currently Approved Titration: A Randomised, Multicentre, Parallel Group Open Trial In Schizophrenia And Schizoaffective Disorder||AstraZeneca||Completed|October 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|60 Years|No|||January 2011|January 25, 2011|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254813||187813|
NCT00255112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP001--68701|TAFF-Psychological Treatment of Separation Anxiety Disorder|Psychological Treatment of Separation Anxiety Disorder||University Hospital, Basel, Switzerland|No|Completed|June 2004|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|5 Years|13 Years|No|||June 2015|June 10, 2015|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00255112||187791|
NCT00255710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449652|Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer|Nonmyeloablative Bone Marrow Transplants in Hematologic Malignancies: Dose Finding Study for Post-Transplant Immunosuppression||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2002|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|60|||Both|18 Years|75 Years|No|||March 2010|March 16, 2010|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00255710||187747|
NCT00255099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006307|TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.|A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treatment to no Treatment Options.||Tibotec Pharmaceuticals, Ireland||Completed|December 2005|July 2008|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|593|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|November 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255099||187792|
NCT00255372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52072-012|To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.|Polyethylene Glycol Laxative (Macrogol 4000;Forlax®) for Treatment of Chronic Constipation in Children : A Phase III, Bicentric, Randomized, Double-Blind, Lactulose Controlled Study.||Ipsen||Completed|April 2005|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|12 Months|36 Months|No|||June 2008|June 3, 2008|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00255372||187772|
NCT00255684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448637|Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer|Non-Myeloablative Conditioning and Unrelated Umbilical Cord Blood Transplantation for Children and Adults With Serious Oncohematologic Diseases||University of Rochester|Yes|Recruiting|December 2003|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|75 Years|No|||October 2013|October 14, 2013|November 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00255684||187749|
NCT00255944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0764b|Effectiveness of an Online Prevention Program in Reducing the Risk of STD Infection in Young Adults|Internet-based Efficacy Trial of an HIV Prevention Program|Youthnet suppl|University of Colorado, Denver||Completed|October 2005|December 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1860|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00255944||187731|
NCT00256269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 04-09|Weekly Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal Carcinoma|A Phase II Study of Weekly Oxaliplatin and Irinotecan in the Treatment of Recurrent or Metastatic Esophageal Carcinoma||University of California, Irvine|Yes|Completed|June 2005|April 2011|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||August 2011|August 15, 2011|November 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256269||187706|
NCT00256802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA-GTN2004|The Diameter of the Middle Cerebral Artery Measured With Magnetic Resonance Angiography|The Diameter of the Middle Cerebral Artery Measured With Magnetic Resonance Angiography (MRA) Under Provocation With Glyceryl Trinitrate in Healthy Volunteers.||Danish Headache Center||Completed|June 2004|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2004|March 30, 2009|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00256802||187666|
NCT00256815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypo 3|Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study|||Clinical Oncology Research Associates||Completed|March 2003|September 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|N/A|N/A|No|||September 2005|February 10, 2014|November 21, 2005||||||https://clinicaltrials.gov/show/NCT00256815||187665|
NCT00249041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050145|Enbrel Liquid Immunogenicity Protocol|Open-label Study to Assess the Antibody Response to Etanercept Liquid in Subjects With Rheumatoid Arthritis (RA)||Amgen||Completed|October 2005|March 2007|Actual|December 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|447|||Both|18 Years|N/A|No|||July 2010|July 29, 2010|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249041||188250|
NCT00249054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF11279577|Prospective Clinical Evaluation of ASR Resurfacing Arthroplasty|||Frederiksberg University Hospital||Active, not recruiting||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2007|July 3, 2007|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249054||188249|
NCT00257452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.302|A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)|A Double-blind, Randomised, Placebo Controlled, Three-way Cross-over Study With an Open Label Positive Control (Moxifloxacin) to Assess the Influence of Inhaled Tiotropium Once Daily Over Twelve Days on the QTC Interval of the ECG in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|October 2004|July 2005||July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257452||187616|
NCT00257790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tobrax1|The Tobramycin Study|Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber||Oslo University Hospital||Completed|September 2001|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||210|||Both|16 Years|70 Years|No|||November 2005|July 3, 2011|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00257790||187590|
NCT00252304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCO-CT-2004-003740-2|Therapeutic Zinc in Childhood Pneumonia|Efficacy of Zinc as Adjuvant Therapy in the Treatment of Severe Pneumonia in Nepalese Children at the Kanti Children's Hospital||Centre For International Health|No|Completed|January 2006|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|641|||Both|2 Months|35 Months|No|||October 2009|October 2, 2009|November 10, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00252304||188003|
NCT00248547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445452|Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant|A Pilot Study of Aprepitant vs. Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplatation(HCT)||OHSU Knight Cancer Institute|Yes|Completed|May 2004|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|November 3, 2005|Yes|Yes||No|November 21, 2011|https://clinicaltrials.gov/show/NCT00248547||188286|
NCT00248560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445589|Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer|Phase II Study of Gemcitabine and Docetaxel (GEMDOC) Combination in Patients With Previously Treated Recurrent or Metatstatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 2005|June 2012|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|November 3, 2005|Yes|Yes||No|August 18, 2014|https://clinicaltrials.gov/show/NCT00248560||188285|The trial design was changed during accrual to allow for study continuation although response rate was lower than predicted. The trial was completed but it did not meet the specified end points.
NCT00252538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-020-04F|Genetic and Biochemical Markers of Interferon-Induced Depression.|Genetic and Biochemical Markers of Interferon-Induced Depression.||VA Office of Research and Development||Completed|April 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|Samples With DNA|Blood samples are being collected to determine the variability in the development of      depressive symptoms induced by interferon. Thus, we plan to measure specific genetic      polymorphisms [i.e., in the serotonin (5-HT) transporter gene-linked polymorphic region      (5-HTTLPR), in the promoter of the 5-HT1A receptor subtype, and an intronic tryptophan      hydroxylase polymorphism]. Tryptophan, 5-HT, and cortisol blood levels will also be      measured.|Both|18 Years|N/A|No|Non-Probability Sample|120 patients initiating interferon therapy will be recruited from the Portland,        Minneapolis, and Long Beach VAMCs. The study is limited to only those participants who are        currently mentally healthy at baseline and eligible to receive interferon therapy.        Research participants are: 1) male or female, 2) age 18 or older, 3) chronically infected        with the hepatitis C virus, 4) candidates for interferon therapy, 4) not on antidepressant        treatment , and 5) not currently abusing any substances such as alcohol or intravenous        drugs, or having abused in the past 6 months|December 2014|December 3, 2014|November 9, 2005||No||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00252538||187985|Limitations include that there are numerous polymorphism in various genes that may influence certain symptoms of depression. The risk for side effects during interferon-alpha treatment likely influenced by many genetic polymorphisms.
NCT00249015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-01-0080 ethics 22148|Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors|Randomized Controlled Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors. The CARE Trial.||AHS Cancer Control Alberta|Yes|Active, not recruiting|January 2008|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|3||Anticipated|300|||Female|18 Years|N/A|No|||June 2014|June 4, 2014|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00249015||188251|
NCT00253071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31/04r|Early Integrated Intervention in Severe Affective Disorders|Early Integrated Intervention in Severe Affective Disorders - a Randomized Controlled Trial.||Hovedstadens Sygehusfaelesskab|No|Completed|December 2005|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|426|||Both|18 Years|70 Years|No|||March 2015|March 18, 2015|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00253071||187944|
NCT00250172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060002|PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram|PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram||National Institutes of Health Clinical Center (CC)||Completed|October 2005|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|65 Years|No|||September 2014|September 16, 2014|November 5, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250172||188165|
NCT00250185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060024|The Role of Nitrite in Preconditioning Mediated Tolerance to Ischemic Stress|The Role of Nitrite in Preconditioning Mediated Tolerance to Ischemic Stress||National Institutes of Health Clinical Center (CC)||Completed|November 2005|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1|||135|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|May 4, 2010|November 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00250185||188164|
NCT00250198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060021|The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease|A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2005|September 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||12|||Both|18 Years|75 Years|No|||September 2006|February 24, 2007|November 5, 2005||||No||https://clinicaltrials.gov/show/NCT00250198||188163|
NCT00250211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-09-0027 / ethics 21780|Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide|Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide||AHS Cancer Control Alberta|Yes|Completed|March 2005|April 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|65 Years|No|||October 2011|February 23, 2016|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00250211||188162|
NCT00249574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15629-1|Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1|HCV Treatment of IDUs After Buprenorphine Stabilization||National Institute on Drug Abuse (NIDA)||Active, not recruiting|June 2003|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||0|||Both|18 Years|80 Years|No|||October 2005|November 3, 2005|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249574||188210|
NCT00255411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060027|Psychiatric Correlates of Psychogenic Movement Disorder and Non-Epileptic Seizure|Neuropsychiatric Correlates of Psychogenic Movement Disorder and Non-Epileptic Seizure||National Institutes of Health Clinical Center (CC)||Completed|November 2005|February 2009||||N/A|Observational|N/A||||190|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|September 26, 2015|November 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00255411||187769|
NCT00255723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-047|Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma|Risk-Adapted High Dose Chemoradiotherapy and Autologous Stem Cell Transplantation for Patients With Relapsed and Primary Refractory Hodgkin's Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|April 2004|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|72 Years|No|||December 2015|December 22, 2015|November 18, 2005|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00255723||187746|
NCT00255385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H22010703A|Efficacy of Bifidus DR10 and Oligo Saccharides / Micronutrient Fortification of Milk|Evaluating Efficacy of Milk Fortified With Bifidus DR10-Oligosaccharides, Zinc and Iron in Reducing Morbidity Due to Diarrhea, Pneumonia and Improving Growth and Development in Children Ages 13-36 Months||Johns Hopkins Bloomberg School of Public Health||Completed|April 2002|April 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Both|12 Months|36 Months|No|||April 2005|November 16, 2005|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255385||187771|
NCT00255697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8Z05|Quality of Life of Older Patients Who Are Undergoing Treatment for Cancer and of Their Family Caregivers|Quality of Life Study Registry for Persons With Cancer and Family Caregivers||Case Comprehensive Cancer Center|Yes|Completed|July 2005|December 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|863|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic|October 2015|October 8, 2015|November 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00255697||187748|
NCT00255957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMS HES 1|Influence of Hydroxyehtyl Starch (HES) on Hemorehology, Coagulation and Elimination Kinetics|Clinical Trial to Study the Effects of HES on Coagulation, Hemorehology and Kinetics Comparing Two Different Products.||Nizam's Institute of Medical Sciences University, India||Completed|October 2005|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|70 Years|No|||November 2005|April 17, 2006|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255957||187730|
NCT00256841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypo 2|Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy|Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study||Clinical Oncology Research Associates||Withdrawn|September 2005|October 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||January 2014|January 27, 2014|November 21, 2005||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00256841||187663|
NCT00256854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX104805|Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)|A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Extended Release (XR) Formulation in Patients With Restless Legs Syndrome (RLS)||GlaxoSmithKline||Completed|November 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|135|||Both|18 Years|79 Years|No|||April 2015|April 15, 2015|November 21, 2005||||||https://clinicaltrials.gov/show/NCT00256854||187662|
NCT00249366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAWEA-K2300222-A|Treatment of Alcohol Withdrawal in Hospital Patients|Acute Drug Withdrawal in a General Medical Setting||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|April 2001|May 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||183|||Both|21 Years|75 Years|No|||November 2005|November 3, 2005|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249366||188226|
NCT00249353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002668|An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder|An Evaluation of the Safety and Effectiveness of CONCERTA® (Methylphenidate Hydrochloride), up to 72 mg Daily, in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed|March 2002|October 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|220|||Both|13 Years|18 Years|No|||April 2010|April 26, 2010|November 4, 2005||||||https://clinicaltrials.gov/show/NCT00249353||188227|
NCT00252044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7609-028|Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder|The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder||Bronx VA Medical Center||Recruiting|October 2000|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|60 Years|No|||November 2005|November 17, 2005|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252044||188022|
NCT00252278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120-05|Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents|The Effect of a Once Daily Evening Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents||Rhode Island Hospital||Recruiting|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|6 Years|17 Years|No|||November 2005|July 5, 2006|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252278||188005|
NCT00252798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913C00073|ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer|A Phase I Trial to Evaluate ZD1839(Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer||AstraZeneca||Completed|July 2002|October 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||44|||Both|18 Years|N/A|No|||December 2007|December 16, 2007|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00252798||187965|
NCT00252811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0509|A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer|A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery||AstraZeneca||Withdrawn|February 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|18 Years|N/A|No|||January 2011|January 27, 2011|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00252811||187964|
NCT00252785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890C00010|Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients|An 8-week, Randomised, Double Blind, Parallel-group, Multi-centre, Phase III Study Comparing the Efficacy and Safety of Symbicort® Turbuhaler® 160/4.5 µg Twice Daily and Pulmicort® Turbuhaler® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Patients With Asthma||AstraZeneca||Completed|October 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||340|||Both|16 Years|N/A|No|||January 2011|January 21, 2011|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00252785||187966|
NCT00253305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MQT-05-001|Topical Gel Anti-Fungal Agent for Tinea Unguium|Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium.||MediQuest Therapeutics||Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|65 Years|No|||May 2007|May 29, 2007|November 13, 2005||||||https://clinicaltrials.gov/show/NCT00253305||187926|
NCT00250770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSF-1|Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis|CSF-1 and Other Cytokines in Human Endometrial Carcinogenesis||University of New Mexico|Yes|Active, not recruiting|January 1998|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|750|Samples Without DNA|We have collected serum and ascites from approximately 200 patients with endometrial      carcinoma and 200 controls. We have long term follow-up serum from approximately 60 of these      patients. Approximately 10% of endometrial carcinoma patients recur. Our goal will be to      eventually have follow-up serum from up to 60 patients with recurrent endometrial carcinoma      in our tissue bank, so that we can determine the role of these assays in predicting      recurrence.|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  All patients undergoing hysterectomy, or who have endometrial cancer, and are under             routine surveillance.          -  Patients may have received prior hormonal, cytotoxic chemotherapy, irradiation or             surgical therapy.          -  Healthy post-menopausal and peri-menopausal women.|July 2009|June 23, 2010|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250770||188119|
NCT00254852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR04-004|Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft|A Single Blind, Multi-Center, Randomized, Prospective Clinical Study Comparing Optecure™ Autograft Extender to Autograft Only in Fusion of the Lumbar Spine||Exactech|No|Terminated|October 2005|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|94|||Both|21 Years|N/A|No|||November 2013|November 20, 2013|November 15, 2005|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00254852||187810|
NCT00255138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4463|Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects|Efficacy of Atomoxetine Therapy Versus Placebo For Ameliorating Cognitive Late Effects Among Survivors of Childhood Cancers||Temple University||Withdrawn|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|6 Years|18 Years|No|||October 2008|October 28, 2008|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00255138||187789|
NCT00255970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RegenF052005|Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects|Regenerative Therapy for Vertical Defects Comparing Demineralized Freeze Dried Bone Allograft (DFDBA) and Regenafil||RTI Surgical|No|Completed|January 2006|November 2007|Actual|November 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 8, 2011|November 16, 2005|Yes|Yes||No|June 9, 2009|https://clinicaltrials.gov/show/NCT00255970||187729|
NCT00256282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 02-23|Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma|A Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in Patients With Metastatic Malignant Melanoma||University of California, Irvine|Yes|Completed|April 2003|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|November 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256282||187705|
NCT00255983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP-FAR-005|A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis|Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo In the Treatment of Acute Exacerbation of Chronic Bronchitis||Replidyne|Yes|Terminated|December 2005|June 2008|Anticipated|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|491|||Both|35 Years|N/A|No|||May 2008|May 30, 2008|November 16, 2005|Yes|Yes|financial reasons|No||https://clinicaltrials.gov/show/NCT00255983||187728|
NCT00256503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33-CA-05|Sleep Homeostasis in Primary Insomnia|Sleep Homeostasis in Primary Insomnia Following Behavioral Treatment||University of Rochester|No|Completed|December 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00256503||187688|
NCT00256516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 05-025|Low Carbohydrate Portfolio or "Eco-Atkins" Diet|Low Carbohydrate Portfolio or "Eco-Atkins" Diet||University of Toronto||Completed|April 2005|December 2006||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2|||30|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00256516||187687|
NCT00256828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA-3903|Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV|A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03)||Clinical Trial Agency of HIV Study Group||Completed|June 2004|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|18 Years|N/A|No|||November 2005|October 15, 2007|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00256828||187664|
NCT00256529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14543|Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia|Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia||University of Utah|No|Completed|November 2005|February 2012|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|483|Samples Without DNA|4 quadrant distal and proximal biopsies of the esophagus|Both|18 Years|90 Years|No|Non-Probability Sample|All patients presenting with dysphagia will be eligibile for enrollment into the study.|December 2014|December 12, 2014|November 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00256529||187686|
NCT00256542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URG-101|Study of U101 for Bladder Pain and/or Urgency|A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin||Urigen||Completed|January 2006|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||August 2006|September 28, 2006|November 17, 2005||||||https://clinicaltrials.gov/show/NCT00256542||187685|
NCT00245284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04K1 - PASA|Predictor of Advanced Subclinical Atherosclerosis|||PreMD||Completed|September 2005|May 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||600|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||June 2006|June 5, 2006|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245284||188529|
NCT00245271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04516|Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction|Double-Blind, Multicenter Study Evaluating the Safety of OMS103HP and Vehicle in Subjects Undergoing Anterior Cruciate Ligament Reconstruction With an Open-Label Phase Containing a PK Analysis in a Subset of Subjects||Omeros Corporation|No|Completed|October 2004|March 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|17 Years|65 Years|No|||June 2011|June 17, 2011|October 26, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00245271||188530|
NCT00252577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-023-05S|Genetic Predictors of Lithium Response in Bipolar Disorder|Genetic Studies of Psychiatric Illness||VA Office of Research and Development|Yes|Recruiting|October 2005|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|DNA from patients with bipolar disorder|Both|21 Years|N/A|No|Non-Probability Sample|Veterans with bipolar disorder|September 2015|September 2, 2015|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00252577||187982|
NCT00252551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0300201|Vertebral Osteosynthesis in Degenerative Lumbar Stenosis With Spondylolisthesis|Vertebral Osteosynthesis in Degenerative Lumbar Stenosis With Spondylolisthesis - CLEOS Study|CLEOS|University Hospital, Toulouse|No|Terminated|March 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||March 2015|March 15, 2015|November 10, 2005||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00252551||187984|
NCT00252824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00014|STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma|A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26 Weeks, Randomised, Open-label, Parallel-group, Multicentre Study||AstraZeneca||Completed|July 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1000|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00252824||187963|
NCT00253097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFE 003|The Post Stroke Preventive Trial (PREVENT). A RCT Nested in a Cohort Study|The Post Stroke Preventive Trial (PREVENT) A Randomised Controlled Trial Nested in a Cohort (RIALTO) Study|PREVENT|Hvidovre University Hospital|No|Active, not recruiting|December 2005|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|353|||Both|15 Years|N/A|No|||July 2009|August 10, 2009|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00253097||187942|
NCT00253084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX054-B04-07|Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease|A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease||IMPAX Laboratories, Inc.|No|Completed|November 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|30 Years|N/A|No|||March 2009|March 13, 2009|November 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00253084||187943|
NCT00253318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0758|RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer|Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Terminated|November 2005|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|November 11, 2005|No|Yes|Toxicity and Lack of Efficacy|No||https://clinicaltrials.gov/show/NCT00253318||187925|
NCT00249379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAWEA-K23-00222-B|Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees|The Use of Acamprosate for Preventing Alcohol Relapse Among Alcohol Dependent Drug Treatment Court Participants||Virginia Commonwealth University|No|Completed|June 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||October 2011|October 10, 2011|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00249379||188225|
NCT00250783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2902C|Pre-Clinical Models in Gynecological Tumors A Tissue Repository|Pre-Clinical Models in Gynecological Tumors: A Tissue Repository||University of New Mexico|Yes|Completed|July 2002|January 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|Tumor and normal tissues, ascites, and/or serum, and/or urine from women with malignant or      premalignant gynecological conditions for which they are undergoing medically-indicated      surgery, and normal tissues from women without malignancy who volunteer to donate serum      and/or tissue at the time of medically indicated surgery|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|tumor and normal tissues, ascites, and/or serum, and/or urine from women with malignant or        premalignant gynecological conditions for which they are undergoing medically-indicated        surgery, and normal tissues from women without malignancy who volunteer to donate serum        and/or tissue at the time of medically indicated surgery.|July 2009|January 6, 2010|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250783||188118|
NCT00251030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4301024|A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects|A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects||Pfizer||Completed|November 2005|January 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 13, 2009|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251030||188099|
NCT00253500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3104|Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer|Prediction of Response or Resistance to Dose Intensified Pre-Operative Epirubicin Therapy of Operable Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|June 2002|December 2010|Actual|September 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||January 2013|January 2, 2013|November 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00253500||187911|
NCT00253513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445306|Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome|A Study of a Reduced-Intensity Conditioning Regimen With Treosulfan and Fludarabine for Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Leukemia||OHSU Knight Cancer Institute|Yes|Completed|June 2005|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|60 Years|No|||February 2011|May 24, 2012|November 11, 2005|Yes|Yes||No|November 16, 2010|https://clinicaltrials.gov/show/NCT00253513||187910|
NCT00249886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN42386710|Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents|||Sunnybrook Health Sciences Centre||Withdrawn|September 2002|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|13 Years|18 Years|No|||November 2005|September 18, 2006|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249886||188186|
NCT00255151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-EE04-087|Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis|A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis||Takeda|No|Completed|January 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|451|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|November 15, 2005|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00255151||187788|
NCT00255437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62745-7|Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients|A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis||AMAG Pharmaceuticals, Inc.||Completed|June 2004|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||304|||Both|18 Years|N/A|No|||October 2007|January 7, 2015|November 17, 2005||||||https://clinicaltrials.gov/show/NCT00255437||187767|
NCT00255450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62745-8|A Crossover Safety Study of Ferumoxytol Versus Placebo|A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared With Placebo||AMAG Pharmaceuticals, Inc.||Completed|January 2005|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|18 Years|N/A|No|||October 2007|November 10, 2008|November 17, 2005||||||https://clinicaltrials.gov/show/NCT00255450||187766|
NCT00255424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62745-6|Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients|A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis||AMAG Pharmaceuticals, Inc.||Completed|May 2004|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||304|||Both|18 Years|N/A|No|||October 2008|January 7, 2015|November 17, 2005||||||https://clinicaltrials.gov/show/NCT00255424||187768|
NCT00255749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449950|Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer|Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy||Jonsson Comprehensive Cancer Center||Completed|August 2005|||April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|89|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|November 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00255749||187745|
NCT00256308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 04-40|Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer|A Phase II Study of Adjuvant Chemoradiation With Weekly Oxaliplatin in Patients With High Risk Resected Squamous Cell Carcinoma of the Head and Neck Region||University of California, Irvine|Yes|Active, not recruiting|April 2005|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2010|May 6, 2010|November 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256308||187703|
NCT00256555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999-M02|Growth Hormone Treatment Study in Children With Cystic Fibrosis|GROWTH HORMONE USE IN CYSTIC FIBROSIS - A MULTICENTER STUDY||University of Texas Southwestern Medical Center||Active, not recruiting|February 2000|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|5 Years|12 Years|No|||November 2005|November 17, 2005|November 17, 2005||||||https://clinicaltrials.gov/show/NCT00256555||187684|
NCT00256295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 04-08|Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of Weekly Oxaliplatin and Gemcitabine Combination Chemotherapy for Recurrent or Metastatic Head and Neck Cancer||University of California, Irvine|Yes|Terminated|April 2005|October 2011|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|November 17, 2005|Yes|Yes|Low accrual|No|June 21, 2013|https://clinicaltrials.gov/show/NCT00256295||187704|
NCT00256893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF102100|Fibromyalgia Study In Adults|A Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Efficacy of Controlled-release Ropinirole (CR) (1-24 mg) Administered Once Daily for 12 Weeks in Subjects With Fibromyalgia||GlaxoSmithKline||Completed|November 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||164|||Both|18 Years|N/A|No|||February 2011|April 11, 2013|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00256893||187659|
NCT00245297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRI Lip-FVIII-05-1|Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.|A Patient-Blinded, Randomized, Comparative, Multicenter, Crossover, (Liposome) Dose Finding Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.||Recoly N.V.|No|Completed|October 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|16|||Male|18 Years|60 Years|No|||October 2007|October 15, 2007|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245297||188528|
NCT00245622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-00|Autologous T Cell Vaccine (TCV) for Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS|TERMS|Opexa Therapeutics, Inc.|Yes|Completed|May 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|55 Years|No|||February 2014|February 6, 2014|October 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00245622||188503|
NCT00253344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Y04|Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors||Case Comprehensive Cancer Center|Yes|Completed|June 2005|June 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|November 11, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00253344||187923|
NCT00252317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3d|Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis|Acute Haemodynamic Effects of Treatment With ACE-Inhibitors in Patients With Symptomatic Aortic Stenosis (ACCESS)||Rigshospitalet, Denmark|Yes|Recruiting|November 2005|October 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||November 2007|September 2, 2008|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00252317||188002|
NCT00252564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-041|Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer|Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer||US Oncology Research|No|Completed|September 2005|June 2009|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|N/A|No|||February 2011|February 15, 2011|November 9, 2005|Yes|Yes||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00252564||187983|
NCT00253110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006013|A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder|A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders||Janssen, LP||Completed|May 1996|September 1998|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|396|||Both|18 Years|65 Years|No|||August 2012|August 3, 2012|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253110||187941|
NCT00253331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MQT 03-001|Lab Study of MQX-503 in Treatment of Raynaud's|Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon||MediQuest Therapeutics||Completed|November 2004|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||36|||Both|18 Years|80 Years|No|||May 2007|May 29, 2007|November 13, 2005||||||https://clinicaltrials.gov/show/NCT00253331||187924|
NCT00249392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP008|Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Ocular Diseases|||Nanjing Medical University||Active, not recruiting|October 2004|||||N/A|Observational|N/A|||Anticipated|800|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||May 2008|May 22, 2008|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249392||188224|
NCT00251043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4830/6040R|Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Site|Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Sites||New York State Psychiatric Institute|Yes|Completed|September 2005|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00251043||188098|
NCT00246857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060015|Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death|Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death||National Institutes of Health Clinical Center (CC)||Recruiting|October 2005|||||N/A|Observational|N/A|||Anticipated|5000|||Both|N/A|N/A|No|||May 2015|February 26, 2016|October 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00246857||188410|
NCT00247156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|narfoundationautismstudy|An Autism Study Using Nambudripad's Food Allergy Elimination Treatments|An Investigation Into the Effectiveness of NAET on Autism Spectrum Disorders||Nambudripad's Allergy Research Foundation||Completed|November 2004|November 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|3 Years|10 Years|No|||April 2006|June 25, 2008|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247156||188388|
NCT00247403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200506744|Safety Study of 2DG With Stereotactic Radiosurgery|Phase I Clinical Trial: 2DG + Stereotactic Radiosurgery (SRS) Protocol for Treatment of Intracranial Metastases||University of Iowa|Yes|Withdrawn|October 2005|June 2008|Anticipated|June 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|N/A|No|||April 2015|April 9, 2015|October 28, 2005|No|Yes|Pharmaceutical company no longer manufactures drug|No||https://clinicaltrials.gov/show/NCT00247403||188369|
NCT00247650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GCA08|Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy|Randomized Multi-Center Study Comparing Prolonged Primary Systemic Endocrine Therapy With Letrozole Alone or in Combination With Zoledronic Acid in Early Breast Cancer (NEOadjuvant Study in CANada)||Novartis||Completed|September 2005|||March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|190|||Female|65 Years|N/A|No|||November 2009|November 20, 2009|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00247650||188351|
NCT00255762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01823|Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients With Unresectable Stage IV Melanoma||National Cancer Institute (NCI)||Completed|December 2005|||December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|November 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00255762||187744|
NCT00247663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345 1601|Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer|Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer||Novartis|No|Completed|December 1999|||December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|20 Years|74 Years|No|||April 2012|April 18, 2012|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00247663||188350|
NCT00255996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951109|Evaluation Of Linezolid Pk Profile In Burns Patients|An Open Label Parallel Group Study To Investigate The Pharmacokinetics Of Intravenous Linezolid, An Oxazolidinone, Administered To Healthy Volunteers And Patients With Major Thermal Injuries||Pfizer||Completed|May 2006|January 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2009|July 13, 2009|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00255996||187727|
NCT00256009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 279545|Treatment of Late Abortion: Evacuatio Uteri or Conservative Treatment|Evacuatio Uteri or Conservtive Treatment After Late Abortion. A Randomize Trial.||Rigshospitalet, Denmark||Not yet recruiting||January 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Female|18 Years|60 Years|No|||November 2005|May 31, 2006|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00256009||187726|
NCT00248313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E-100479|Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus|A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporin Dose Reduction With Cyclosporin Elimination in de Novo Renal Allograft Recipients Receiving Rapamune||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2000|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||470|||Both|18 Years|N/A|No|||November 2007|March 9, 2010|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248313||188302|
NCT00256568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08HS013891|Outpatient Prescription Errors: Detection, Analysis, and Impact on Safety|Outpatient Prescription Errors: Detection, Analysis, and Impact on Safety||University of Vermont|No|Completed|September 2003|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Practices|December 2011|December 14, 2011|November 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00256568||187683|
NCT00248573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0299-2004|Mechanisms of Adaptation in Human Short Bowel Syndrome|||Emory University||Completed|October 2004|July 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|32|Samples With DNA|Intestinal biopsy samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|1) Adults aged 18-75 with less than 200cm small bowel remaining after latest(SBR); 2)        Subject able to enter the study within 2-24 months of latest SBR; 3)(BMI) ≥ 17 kg/m2; 4)        Subject is living at home, clinically stable and expected to survive at least one year; 5)        Subject able to take some oral solid diet and oral medications; 6) Intact stomach and        duodenum and at least 30 cm of in-continuity jejunum and/or ileum (presence of residual        colon is not a specific eligibility criterion); 7) Accurate records available on residual        small bowel/colonic length (accurate tape measurement in operation room or small bowel        follow-through performed within 3 months of entry); 8) Subject has the ability to        understand the requirements of the study, provide written informed consent and agrees to        participate in all assessments.|December 2013|December 16, 2013|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248573||188284|
NCT00248807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3346-V|A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.|Systemic Hemodynamics and Cerebral Blood Flow in Persons With Tetraplegia||VA Office of Research and Development||Completed|October 2005|April 2012|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|November 2, 2005||No||No|September 12, 2013|https://clinicaltrials.gov/show/NCT00248807||188267|Did not assess carbon dioxide levels or the severity of spinal cord injury, which may have contributed to the results.
NCT00245661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-346/050905/Stege|Effects of Temazepam in Patients With Chronic Pulmonary Obstructive Disease|Effects of Temazepam on Dyspnea, Gas Exchange and Sleep Quality in Chronic Obstructive Pulmonary Disease.||Rijnstate Hospital||Completed|October 2005|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|14|||Both|18 Years|N/A|No|||October 2007|October 31, 2007|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00245661||188500|
NCT00245674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0055|SOLIACS: Solian Solution in the Acute Setting|Solian Solution to Treat Schizophrenic Patients During an Acute Episode||Sanofi||Completed|June 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||April 2008|April 8, 2008|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00245674||188499|
NCT00245635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-002613-02|Fluoxetine in Pediatric Body Dysmorphic Disorder|Fluoxetine in Pediatric Body Dysmorphic Disorder|FDA BDD|Montefiore Medical Center|Yes|Completed|November 2004|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|N/A|16 Years|No|||July 2015|July 6, 2015|October 26, 2005||No||No|April 21, 2015|https://clinicaltrials.gov/show/NCT00245635||188502|
NCT00245648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUSTOVsex|Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI|Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial||New York University School of Medicine||Completed|June 2001|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2012|October 3, 2012|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00245648||188501|
NCT00249418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16855-3|Training Therapists to Administer Contingency Management-Patient Phase - 3|Training Therapists to Administer Contingency Management-Patient Phase||University of Connecticut Health Center|No|Completed|January 2004|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249418||188222|
NCT00252837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00055|GALLANT 22 Tesaglitazar vs. Placebo|A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes||AstraZeneca||Terminated|April 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||475|||Both|18 Years|N/A|No|||March 2008|March 14, 2008|November 10, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00252837||187962|
NCT00249626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16855-1|Therapists to Administer Contingency Management-Therapist Phase - 1|Therapists to Administer Contingency Management-Therapist Phase||University of Connecticut Health Center|No|Completed|January 2004|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 17, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249626||188206|
NCT00249639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16855-2|Contingency Management for Attendance - 2|Contingency Management for Attendance||National Institute on Drug Abuse (NIDA)|No|Completed|January 2004|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|N/A|No|||May 2008|May 23, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249639||188205|
NCT00249912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-475-022|Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg, 100 mg or Placebo When Coadministered With Rosuvastatin 10 mg or 20 mg in Subjects With Primary Hypercholesterolemia||Takeda|No|Completed|October 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|415|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00249912||188184|
NCT00250796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1400C|Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma|Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma||University of New Mexico|Yes|Completed|September 2000|March 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||December 2009|January 6, 2010|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250796||188117|
NCT00246870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060022|PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency|PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency||National Institutes of Health Clinical Center (CC)||Completed|October 2005|October 2010||||N/A|Observational|N/A|||Actual|42|||Both|5 Years|55 Years|No|||October 2010|October 20, 2010|October 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00246870||188409|
NCT00246883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060018|Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force|Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force: The NHLBI "Keep the Beat" Program||National Institutes of Health Clinical Center (CC)||Completed|October 2005|April 2009||||Phase 2|Interventional|Primary Purpose: Treatment|1|||120|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2009|September 26, 2015|October 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00246883||188408|
NCT00247416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-0501|Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer|Randomized Phase II Trail of Carboplatin and Gemcitabine Untreated Stage IIIB-pleural Effusion and Stage IV Lung Cancer||University of Kentucky|Yes|Completed|August 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|October 28, 2005||No||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00247416||188368|
NCT00247676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181055|An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer|An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Unresectable Hepatocellular Carcinoma||Pfizer|No|Completed|February 2006|February 2009|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|November 1, 2005|Yes|Yes||No|January 6, 2010|https://clinicaltrials.gov/show/NCT00247676||188349|
NCT00247689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905381|Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics|Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics||National Institutes of Health Clinical Center (CC)||Terminated|December 2004|February 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|21 Years|50 Years|No|||February 2015|March 3, 2015|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247689||188348|
NCT00247949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52/04|Accuracy of Non-invasive Continuous CO2-Monitoring|The Accuracy of Non-invasive Continuous Carbon Dioxide Monitoring by the Sentec V-Sign Digital Monitor System||University Hospital, Basel, Switzerland|Yes|Terminated|July 2004|February 2006|Actual|February 2006|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Probability Sample|patients undergoing surgery in general anesthesia and with clinical indication for        repeated arterial blood gas sampling|November 2009|November 9, 2009|November 1, 2005||No|We had got enough data, therefore we stopped the study and published the data.|No||https://clinicaltrials.gov/show/NCT00247949||188329|
NCT00247962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-402|Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis|A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|566|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|October 31, 2005|Yes|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00247962||188328|
NCT00248300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SToPP-IT|A Peri-intubation Oral Intervention to Reduce Oral Flora and VAP|A Peri-intubation Oral Intervention to Reduce Oral Flora and VAP||Virginia Commonwealth University|Yes|Completed|August 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00248300||188303|
NCT00248586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK67878 (completed 2007)|Development of Limited Contact CBT Treatment for IBS|Development of Limited Contact CBT Treatment for IBS||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|85|||Both|18 Years|70 Years|No|||March 2010|March 17, 2010|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00248586||188283|
NCT00248820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT02-OV|Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses|Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses||University Hospital, Tours|No|Recruiting|September 2002|February 2009|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||November 2007|November 21, 2007|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248820||188266|
NCT00249067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.178|Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients|The Retrospective Evaluation of Carvedilol Versus Captopril and Digoxin/Lasix Therapy in Congestive Heart Failure Due to Left-to-Right Shunt Lesions||Children's Healthcare of Atlanta|No|Terminated|October 2005|October 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||50|||Both|N/A|18 Years|No|||June 2007|June 12, 2007|November 4, 2005|||data collection completed|No||https://clinicaltrials.gov/show/NCT00249067||188248|
NCT00245336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499E01|Study of Recombinant Human Thrombin for Bleeding During Surgery|A Phase 3, Randomized, Double-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Recombinant Human Thrombin (rhThrombin) and Thrombin-JMI (Bovine Thrombin) in Surgical Hemostasis||ZymoGenetics|Yes|Completed|October 2005|July 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||March 2009|March 6, 2009|October 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00245336||188525|
NCT00245908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC Protocol 98-370-277|ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study|||Wisconsin Research Network||Completed|September 1999|September 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||January 2002|October 27, 2005|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00245908||188481|
NCT00253370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02951|Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer|A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma||National Cancer Institute (NCI)|No|Completed|October 2005|September 2010|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||December 2013|November 19, 2014|November 11, 2005|No|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT00253370||187921|
NCT00249405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAANT013957-B|Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)|Predicting Alcoholics' Treatment Responses to an SSRI||University of Cincinnati|Yes|Completed|February 2005|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|65 Years|No|||November 2010|November 2, 2010|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00249405||188223|
NCT00249938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0823|Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.|Evaluation of Plant Sterol and Placebo on Low-density Lipoprotein Concentrations in Hyperlipidemic Patients Treated With Combination Statin and Colesevelam Therapy.||University of Colorado, Denver||Completed|March 2005|August 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|89 Years|No|||August 2015|August 10, 2015|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249938||188182|
NCT00250224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|stent02|Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II|Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II||Aalborg Universitetshospital|Yes|Completed|January 2006|May 2014|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Male|N/A|N/A|No|||September 2005|June 25, 2015|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250224||188161|
NCT00250237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-56|Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery|Randomised Double-blind Placebo-controlled Study of Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery||Bronovo Hospital|Yes|Completed|November 2005|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|220|||Both|75 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 6, 2009|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250237||188160|
NCT00250510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK67357 (completed)|Reimbursement Effects on Enrollment in Obesity Treatment|A Prospective Study to Determine the Effects of a Reimbursement Incentive on Enrollment and Outcomes in a Community Weight Control Program.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|June 2004|December 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|401|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 17, 2010|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250510||188139|
NCT00250835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3304C|Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer|A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer||New Mexico Cancer Care Alliance|Yes|Terminated|April 2005|May 2015|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 4, 2005|Yes|Yes|Low accrual|No|June 19, 2015|https://clinicaltrials.gov/show/NCT00250835||188114|
NCT00250523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 0801232|Mathematical Modeling of the Acute Inflammatory Response Following Injury|Host Response to Injury||National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|February 2003|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|520|Samples With DNA|For trauma injury cohort: The maximum blood volume collected over the 28 day period, if all      samples are obtained, is approximately 90 cc. All standard precautions will be undertaken to      assure minimal risk.      Blood samples will be obtained for genetic analysis of inflammatory gene polymorphisms. We      will collect whole blood, serum and white cells.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects to be recruited will consist of trauma patients and healthy volunteers:|July 2010|July 22, 2010|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250523||188138|
NCT00250536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK56182 (completed)|Anabolic Steroids and Exercise in Hemodialysis Patients|Anabolic Steroids and Exercise in Hemodialysis Patients||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 2000|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00250536||188137|
NCT00247429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101356|Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients|Vandral Retard (Venlafaxine Extended Release) in Depressive Syndrome With Anxiety and Painful Symptoms in Elderly Patients. Observational Study in Primary Care||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2004|October 2005|Actual|October 2005|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|59|None Retained|No specimen retained|Both|60 Years|N/A|No|Non-Probability Sample|Primary care centers|August 2009|August 31, 2009|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00247429||188367|
NCT00247702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940609|The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR|Study of the Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR||National Taiwan University Hospital||Recruiting|July 2005|June 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|80 Years|No|||July 2005|November 1, 2005|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247702||188347|
NCT00247975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR #: 126541|Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy|Primary Prevention of Anthracycline-Induced Cardiotoxicity With L-Carnitine in Patients With Breast Cancer (PPACC)-Pilot Study||Ottawa Heart Institute Research Corporation|Yes|Completed|March 2006|October 2011|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|144|||Female|18 Years|N/A|No|||February 2012|February 6, 2012|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247975||188327|
NCT00247988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP69761/6021|Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers|Phase II Study of Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers||University of Saskatchewan||Terminated|October 2003|April 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Female|N/A|N/A|No|||April 2007|April 20, 2007|November 1, 2005|||Regulatory issues(trial temporarily suspended December 28, 2005. Permanently suspended January    19, 2007. Institutional Reveiw Board informed April 18, 2007|No||https://clinicaltrials.gov/show/NCT00247988||188326|
NCT00248326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405107|The Genetic Basis of Atrial Fibrillation (AF)|The Genetic Basis of Atrial Fibrillation||University of Pittsburgh|Yes|Completed|January 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects must be patients of the UPMC Cardiovascular Institute who are under the medical        care of UPMC cardiologists.|January 2016|January 4, 2016|November 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00248326||188301|
NCT00248833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1178|Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.|Phase 1 Dose Esc Study of Safety and Immun of 3 Injections, Given at 0, 6 and 24 Wks, of Grp B Meningococcal 44/76 MOS NOMV 5D Vaccine Admin to Healthy Subjs IM With and Without Adjuvant||Walter Reed Army Institute of Research (WRAIR)||Completed|December 2005|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 27, 2010|November 2, 2005||||||https://clinicaltrials.gov/show/NCT00248833||188265|
NCT00249080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-IRB-1599|Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease|High Field MRI of Brain Iron in Neurodegenerative Disease||Albany Medical College|Yes|Completed|June 2005|August 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|182|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately equal numbers of subjects with clinically diagnosed Alzheimer's disease,        multiple sclerosis, Parkinson's disease and normal controls (age and gender matched).|August 2009|August 21, 2009|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249080||188247|
NCT00249093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G25-1|Effects of Supplementary Oxygen on Dyspnoea and Exercise Tolerance in COPD Patients Given LTOT|||LHL Helse|No|Completed|October 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||20|||Both|N/A|N/A|No|||April 2007|April 12, 2007|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249093||188246|
NCT00245050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5Y03|Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer|A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome)||Case Comprehensive Cancer Center|Yes|Completed|April 2004|September 2011|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|34|||Female|N/A|N/A|No|||December 2011|December 28, 2011|October 25, 2005|Yes|Yes||No|October 26, 2010|https://clinicaltrials.gov/show/NCT00245050||188547|Interim analysis was conducted after 30 patients were enrolled and had evaluable PPE assessment data. Due to decreased accrual and similar PPE rates between groups, the trial was closed for enrollment after the interim analyses was completed.
NCT00245960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A5-401|Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis|A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|752|||Both|18 Years|N/A|No|||March 2009|March 31, 2009|October 26, 2005||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00245960||188477|
NCT00245687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05U.229|A Research Study to Test (2) Two Different Types of Feeding Tubes Used in the Intensive Care Unit|A Comparative Study of the Tiger Tube Frictional Nasal Jejunal Feeding Tube and the Dubhoff Tube||Thomas Jefferson University||Completed|June 2005|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245687||188498|
NCT00245700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R050017|Adherence of Stalevo, Entacapone and Levodopa|Study of Adherence of Stalevo, Entacapone and Levodopa||South Glasgow University Hospitals NHS Trust||Completed|April 2005|July 2006|Actual|||N/A|Observational|N/A||||14|||Both|18 Years|85 Years||||May 2008|May 22, 2008|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00245700||188497|
NCT00249652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15772-1|Transplant and Addiction Project (TAP) - 1|Drug Treatment for Transplant Candidates||St. Luke's-Roosevelt Hospital Center|Yes|Completed|September 2003|September 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249652||188204|
NCT00249925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ro1AG13687|Project ABLE:Advancing Better Living for Elders|Enhancing Function of Frail Elders At Home||Thomas Jefferson University|Yes|Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind||||319|||Both|70 Years|N/A|No|||March 2015|March 17, 2015|November 4, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00249925||188183|
NCT00249951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG03-157|Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants|||University of Cologne|Yes|Completed|November 2005|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|80|||Both|N/A|8 Weeks|No|||June 2012|June 29, 2012|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249951||188181|
NCT00249964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0100C|Combination Paclitaxel, Carboplatin and Temozolomide|Phase I Dose Finding Clinical Trial of Combination Paclitaxel, Carboplatin and Temozolomide for Subjects With Solid Tumor Malignancies.||New Mexico Cancer Care Alliance|Yes|Completed|November 2003|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|November 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00249964||188180|
NCT00250250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999905 CS002|An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG|An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG (Recombinant Somatropin) Administered by ZomaJet Vision X||Ferring Pharmaceuticals|No|Completed|October 2005|August 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||May 2011|May 19, 2011|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250250||188159|
NCT00247845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04-0098|Evaluation of Atazanavir Substitution Intervention (EASI) Study|Evaluation of Atazanavir Substitution Intervention (EASI) Study: An Observational Phase IV Study to Evaluate the Impact of Atazanavir Substitution on the Quality of Life and Maintenance of Virologic Suppression in HIV-Infected Patients Intolerant to Current Successful HAART||University of British Columbia||Completed|July 2004|September 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|18 years of age or older with a confirmed diagnosis of HIV infection|August 2014|August 20, 2014|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247845||188337|
NCT00248157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995 0804E1|Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)||Novartis||Terminated|November 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|105|||Both|18 Years|70 Years|No|||April 2012|April 30, 2012|November 2, 2005|Yes|Yes|Inconsistent treatment benefit|No||https://clinicaltrials.gov/show/NCT00248157||188314|
NCT00251082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S102.3.119|Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination|A Randomized, Placebo-Controlled, Double-Blind, Multi-National Study to Demonstrate Efficacy of Continuous Combined 0.5 mg Estradiol and 2.5 mg Dydrogesterone in the Treatment of Vasomotor Symptoms in Postmenopausal Women in Comparison to Placebo Over 3 Months, and to Investigate the Bleeding Pattern Over a Double-Blind Treatment Period of One Year Compared With Continuous Combined 1 mg Estradiol and 5 mg Dydrogesterone||Solvay Pharmaceuticals|No|Completed|December 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|391|||Female|45 Years|65 Years|No|||March 2008|March 11, 2008|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251082||188095|
NCT00247169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFK-HEF 4|Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II|Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II: A Phase II Trial||Medical University of Vienna||Completed|August 2004|April 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|60 Years|No|||March 2012|March 8, 2012|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247169||188387|
NCT00247715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-03-052|Comparison of a "Step-Up" Versus a "Step-Down" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)|Comparison of an Antacid/H2-Receptor Antagonist/Proton Pump Inhibitor Versus a Proton Pump Inhibitor/H2-Receptor Antagonist/Antacid Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)||Radboud University|No|Completed|October 2003|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|664|||Both|18 Years|N/A|No|||August 2007|August 28, 2007|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247715||188346|
NCT00248027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB #04-203|Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders Clinic|Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders Clinic||McMaster University||Terminated|January 2004|||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|16 Years|50 Years|No|||September 2006|September 12, 2006|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00248027||188324|
NCT00248014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHODONTICS 1|Response of Individuals With Class II Malocclusion|Cephalometric Indicators of Biological Responsiveness to Orthodontic Treatment of Class II/I in Growing Patients||Aristotle University Of Thessaloniki|Yes|Completed|October 2005|April 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00248014||188325|
NCT00248339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1988 WIRB|Trial of Peg-Interferon Plus Epoetin-Alfa for Treatment of Chronic Hepatitis C Virus Infection|An Open-Label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-Alfa-2b Plus Ribavirin to Peginterferon-Alfa-2b Plus Epoetin-Alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection||Virginia Commonwealth University|Yes|Completed|May 2002|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||November 2005|December 14, 2007|November 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00248339||188300|
NCT00248612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAACIR013727|Psychosocial and Medication Treatment for Anxiety in Alcoholism|CBT And Venlafaxine Treatments For Anxiety In Alcoholism||Boston University||Completed|September 2003|March 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|65 Years|No|||June 2011|June 21, 2011|November 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248612||188282|
NCT00248846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (0203-694)|A Randomized Trial: Changing Behavior in Post-Angioplasty Patients|A Randomized Trial: Changing Behavior in Post-Angioplasty Patients||Weill Medical College of Cornell University|Yes|Active, not recruiting|October 2004|July 2008|Anticipated|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|246|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248846||188264|
NCT00249106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI C001|Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults|Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of Clade C DNA Vaccine ADVAX e/g + ADVAX p/N-t (ADVAX) Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers.|C001|International AIDS Vaccine Initiative|Yes|Completed|December 2003|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2011|February 8, 2013|November 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00249106||188245|
NCT00249119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006043|A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia|Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.||Janssen, LP||Completed||December 1991|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1579|||Both|18 Years|65 Years|No|||February 2011|February 10, 2011|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249119||188244|
NCT00245063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02837|AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer|Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|March 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2013|October 1, 2014|October 25, 2005|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT00245063||188546|The 45 mg PO dose on arm 1 was deemed undeliverable since 7 of 12 patients were unable to complete one cycle due to treatment intolerance. Study was ammended and re-started at 30 mg (arm 2) after discussions with coinvestigators at CTEP.
NCT00245310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiMON|Indocyangreen Elimination in Cirrhosis and Acute Liver Failure|Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure||Heidelberg University||Completed|October 2005|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Probability Sample||November 2008|October 8, 2010|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245310||188527|
NCT00245726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC-8540|Functional Electrical Stimulation (FES) Cycling for Children With Spinal Cord Injuries (SCI)|Lower Extremity Cycling With Functional Electrical Stimulation to Improve the Health and Fitness of Children With Spinal Cord Injuries||Shriners Hospitals for Children|No|Completed|March 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|5 Years|15 Years|No|||January 2009|January 29, 2009|October 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00245726||188495|
NCT00245973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3168A2-307|Study Evaluating Bifeprunox in Bipolar Depression|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients With Bipolar Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2005|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|18 Years|65 Years|No|||December 2007|December 3, 2007|October 27, 2005||||||https://clinicaltrials.gov/show/NCT00245973||188476|
NCT00245986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060006|Effect of Genetics on Metabolism of Efavirenz|Pharmacogenetics of Efavirenz Metabolism: Association of CYP2B6 Genotype and Prolonged Drug Exposure||National Institutes of Health Clinical Center (CC)||Completed|October 2005|May 2008||||Phase 4|Interventional|Primary Purpose: Treatment||||350|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2008|May 21, 2008|October 27, 2005||||No||https://clinicaltrials.gov/show/NCT00245986||188475|
NCT00246233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006073|CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.|A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.||Janssen-Ortho Inc., Canada||Completed|June 2005|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|145|||Both|18 Years|65 Years|No|||April 2010|May 16, 2011|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246233||188457|
NCT00249431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5156R|Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1|A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence||New York State Psychiatric Institute||Terminated|December 2001|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||April 2012|December 10, 2013|November 3, 2005||No|Terminated by the IRB for non-continuation|No||https://clinicaltrials.gov/show/NCT00249431||188221|
NCT00249444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5086 NIDA-09236-13|Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression|A Placebo Controlled Trial of Mirtazapine for Patients With Depression and Cocaine Dependence||New York State Psychiatric Institute|Yes|Completed|May 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|60 Years|No|||October 2013|October 29, 2013|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249444||188220|
NCT00249665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-17182-1|Perindopril-Methamphetamine Interaction Study|Perindopril-Methamphetamine Interaction Study||National Institute on Drug Abuse (NIDA)|Yes|Completed|August 2004|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|45 Years|No|||July 2008|July 9, 2008|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00249665||188203|
NCT00249977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103C|Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan|Phase I Study Of Capecitabine in Combination With Cisplatin and Irinotecan in Patients With Advanced Malignancies.||University of New Mexico|Yes|Completed|April 2003|January 2009|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2009|January 6, 2010|November 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00249977||188179|
NCT00250263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 170/05|A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy|A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy||Bayside Health||Completed|November 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||November 2005|February 11, 2013|November 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00250263||188158|
NCT00248482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445222|Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Imatinib Mesylate Maintenance Therapy in Patients With C-Kit (+) Extensive-Stage Small Cell Lung Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|February 2002|January 2008|Actual|April 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248482||188290|
NCT00247442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-9999999|Australian Screening Mammography Decision Aid Trial (ASMDAT)|An Evaluation of a Decision Aid for Women Aged Over 70 Considering Whether to Stop or Continue Having Mammography Screening.||University of Sydney||Completed|January 2006|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||670|||Female|70 Years|N/A|Accepts Healthy Volunteers|||June 2005|September 27, 2006|October 30, 2005||||No||https://clinicaltrials.gov/show/NCT00247442||188366|
NCT00247728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG 002|PI-88 in Hepatocellular Carcinoma After Hepatectomy|A Randomized, Multi-Centre, Efficacy Evaluation of PI-88 in Patients With Hepatocellular Carcinoma After Hepatectomy - A Phase II Study||Progen Pharmaceuticals||Completed|June 2004|June 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||343|||Both|18 Years|75 Years|No|||October 2007|October 16, 2007|November 1, 2005||||||https://clinicaltrials.gov/show/NCT00247728||188345|
NCT00248365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-ECP-001|Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)|Safety, Biological and Clinical Efficacy of Two Intensity Levels of Theralux Extracorporeal Photochemotherapy in Subjects With Extensive Chronic GvHD Refractory or Intolerant to Standard Therapy: A Randomized, Open-label Phase I/II Clinical Trial||Kiadis Pharma||Completed|November 2005|August 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|November 3, 2005||||||https://clinicaltrials.gov/show/NCT00248365||188298|
NCT00248352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucose 101|A Study Comparing Standard Care for Diabetes to Case-Managed Care for Diabetes in Patients With Coronary Artery Disease|GLUCOSE : Glucose Lowering by Usual Care Or Specialized Endocrinology Team||Ottawa Heart Institute Research Corporation||Completed|February 2005|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|212|||Both|N/A|N/A|No|||October 2007|October 25, 2007|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00248352||188299|
NCT00248638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024944|Efficacy and Mechanisms of GLN Dipeptide in the SICU|Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients|GLND|Emory University|Yes|Completed|September 2006|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|90 Years|No|||August 2015|August 4, 2015|November 3, 2005|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00248638||188280|
NCT00248625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 0608007|A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen.|A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen.||University of Pittsburgh|Yes|Completed|January 2000|October 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|184|||Both|N/A|18 Years|No|||April 2012|May 1, 2012|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248625||188281|
NCT00249132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006067|A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia|Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia||Janssen, LP||Completed||July 1991|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|523|||Both|18 Years|65 Years|No|||February 2011|February 10, 2011|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249132||188243|
NCT00249145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006046|A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia|Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference||Janssen Pharmaceutica N.V., Belgium||Completed|April 1995|December 1996|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|349|||Both|55 Years|N/A|No|||January 2011|January 13, 2011|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249145||188242|
NCT00245076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450773|Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking|Evaluation of the Impact of a Bulletin Board on a Web-Based Smoking Cessation Intervention||National Cancer Institute (NCI)||Completed|April 2005|October 2007|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||April 2006|April 30, 2015|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245076||188545|
NCT00245323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|036798|Checking Smoking Status as a Routine Vital Sign: A Cluster-Randomized Trial of Its Effect on Cessation Counseling|Does Checking Smoking Status as a Vital Sign Increase Physician Counseling? A Practice-Level Randomized Controlled Trial||Virginia Commonwealth University||Completed|November 2003|August 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||2000|||Both|18 Years|N/A|No|||October 2005|October 25, 2005|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245323||188526|
NCT00245089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRSG-UHA-PED03-02|Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma|Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma||National Cancer Institute (NCI)||Recruiting|May 2004|||April 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|41|||Both|N/A|17 Years|No|||July 2009|August 9, 2013|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245089||188544|
NCT00245102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01469|Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma|A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas||National Cancer Institute (NCI)||Completed|September 2005|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|N/A|No|||December 2012|May 7, 2014|October 25, 2005|Yes|Yes||No|November 19, 2013|https://clinicaltrials.gov/show/NCT00245102||188543|
NCT00246532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23GM071400-02|Opiate-Induced Tolerance & Hyperalgesia in Pain Patients|Opiate-Induced Tolerance & Hyperalgesia in Pain Patients||National Institute of General Medical Sciences (NIGMS)|Yes|Completed|October 2005|August 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|139|||Both|18 Years|70 Years|No|||April 2012|April 26, 2012|October 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00246532||188435|
NCT00246012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006004|A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma|A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma||Centocor, Inc.|Yes|Completed|May 2005|February 2009|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|144|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|October 28, 2005|No|Yes||No|May 1, 2013|https://clinicaltrials.gov/show/NCT00246012||188474|
NCT00249691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11578|Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1|Medication Development for Cocaine Dependence||University of Virginia|Yes|Active, not recruiting|October 2005|October 2012|Anticipated|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00249691||188201|
NCT00249704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001116|Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects|Evaluation of the Effect of a 4-Month Intervention of Exercise and/or Vitamin D on Mobility Function and Strength in Frail Elderly Subjects||Pfizer|No|Terminated|October 2005|January 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|64|||Both|75 Years|N/A|No|||January 2009|January 7, 2009|November 3, 2005||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00249704||188200|
NCT00249678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18075-1|Behavioral Therapy Development for Methamphetamine Abusers|Behavioral Therapy Development for Methamphetamine Abuse||University of California, Los Angeles||Suspended|September 2004|May 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||50|||Male|18 Years|65 Years|No|||May 2013|May 31, 2013|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249678||188202|
NCT00250276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104772|Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.|Assess Lot-to-lot Consistency of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Following Manufacturing Adjustments Administered Intramuscularly According to a 0,1,6-mth Schedule in Healthy Female Subjects (18-25 y)||GlaxoSmithKline||Completed|October 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|798|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||January 2012|February 2, 2012|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00250276||188157|
NCT00250549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-190|A Theory Based HIV Prevention Video For Rapid HIV Testing: A Randomized Trial|A Randomized Control Trial Evaluating the Educational Effectiveness of a Rapid HIV Post-Test Counseling Video.||North Bronx Healthcare Network|No|Completed|May 2005|March 2006|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250549||188136|
NCT00248755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFFR883|Assessing Mucociliary Clearance and Airway Liquid Volume in the CF Airway|Pilot Study of a New Technique for Assessing Mucociliary Clearance and Airway Surface Liquid Volume in Cystic Fibrosis||University of Pittsburgh||Completed|November 2005|August 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 17, 2007|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248755||188271|
NCT00248703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBCG9|Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow|Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-containing Treatment||Oslo University Hospital|Yes|Active, not recruiting|October 2003|November 2013|Anticipated|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1128|||Both|18 Years|70 Years|No|||November 2012|November 20, 2012|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248703||188275|
NCT00247455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA1323|Fibre and Appetite Regulation Trial (FART)|Long-term Effect of Cereal Fibre on Abdominal Fat in Insulin Resistant Subjects||University of Toronto|No|Completed|March 2002|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2007|June 20, 2011|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00247455||188365|
NCT00247468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-2-3160|Strict Glucose Control of Pediatric Intensive Care Unit (ICU) Patients|Strict Glucose Control of Pediatric ICU Patients to Reduce Mortality and Morbidity||Children's Hospital of Philadelphia||Suspended|December 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||724|||Both|1 Month|21 Years|No|||April 2005|October 3, 2006|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247468||188364|
NCT00248066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4126-17|Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries|APPRAISAL Trial: A Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of RESTEN-MP® When Used in Conjunction With a Bare Metal Stent in de Novo Native Coronary Artery Lesions||Sarepta Therapeutics||Completed|September 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||February 2007|February 6, 2007|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00248066||188321|
NCT00248079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP069|The Medtronic RESOLUTE Clinical Trial|The Clinical Response Evaluation of the Medtronic Endeavor CR ABT-578 Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions||Medtronic Vascular|Yes|Completed|November 2005|October 2011|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00248079||188320|
NCT00248651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2021-05 (DK065713)|Functional Dyspepsia Treatment Trial|Antidepressant Therapy for Functional Dyspepsia|FDTT|Mayo Clinic|Yes|Completed|October 2006|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|292|||Both|18 Years|75 Years|No|||June 2014|June 26, 2014|November 3, 2005|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00248651||188279|
NCT00248859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL076567-01|Determinants of Cardiac Risk Factor Modification in Latinos With Coronary Artery Disease|Determinants of Cardiac Risk Factors Modification||Weill Medical College of Cornell University|No|Recruiting|August 2004|August 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|213|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiovascular DiSease|November 2010|November 4, 2010|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248859||188263|
NCT00248872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-25196 (0203-704)|A Randomized Trial of Changing Medication Adherence In Hypertensive African-American Patients|A Randomized Trial of Changing Medication Adherence In Hypertensive African-American Patients||Weill Medical College of Cornell University|Yes|Active, not recruiting|October 2004|July 2008|Anticipated|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|262|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248872||188262|
NCT00249158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006010|A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia|Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial||Janssen-Cilag Pty Ltd||Completed|March 1998|February 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|344|||Both|55 Years|N/A|No|||November 2010|November 18, 2010|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249158||188241|
NCT00245713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01085|Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.|9-11 Week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Determine Effects of Adjunctive Levetiracetam on Sleep Architecture of Adults With Partial Onset Epilepsy Receiving a First Generation Anti-epileptic Drug.||UCB Pharma||Completed|March 2003|November 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||40|||Both|18 Years|45 Years||||September 2009|November 25, 2013|October 26, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00245713||188496|
NCT00245947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142A3-102|Study Evaluating ERB-041 in Active Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2004|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|October 26, 2005||||||https://clinicaltrials.gov/show/NCT00245947||188478|
NCT00246792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14596|Enhancing Self-Understanding and Social Integration of Middle School Students With Learning Disabilities|Enhancing Self-Understanding and Social Integration of Middle School Students With Learning Disabilities||University of Toronto||Recruiting|September 2004|December 2006||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|10 Years|15 Years|Accepts Healthy Volunteers|||November 2005|February 16, 2006|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00246792||188415|
NCT00250003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UmU2001:39|Preventive Home Visits for Healthy Pensioners- a Randomized Controlled Trial|Preventive Home Visits for Healthy Pensioners- a Randomized Controlled Trial in Nordmaling||Umeå University||Completed|February 2000|December 2001||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|75 Years|N/A|Accepts Healthy Volunteers|||September 2005|November 22, 2005|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00250003||188177|
NCT00249990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102C|Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)|Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium||University of New Mexico|Yes|Completed|April 2003|September 2007|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||October 2008|January 6, 2010|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00249990||188178|
NCT00250562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631A2302|A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.|A Multicenter, Double-blind, Randomized, Active Controlled, Parallel Group Trial Comparing the Combinations of Valsartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Valsartan 80 mg in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80mg||Novartis||Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1171|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2006|November 7, 2011|November 6, 2005||||No||https://clinicaltrials.gov/show/NCT00250562||188135|
NCT00250575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEX123J1301|A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia|A 24-week, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia||Novartis||Completed|November 2005|||December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|64 Years|No|||May 2012|May 3, 2012|November 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250575||188134|
NCT00250848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2903C|Lung Cancer Case Registry and Tissue Resource|Lung Cancer Case Registry and Tissue Resource||University of New Mexico|No|Recruiting|March 2004|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|750|Samples With DNA|Blood samples, and sputum (phlegm) samples.|Both|N/A|N/A|No|Probability Sample|All patients (male or female) with Lung cancer.|May 2014|May 19, 2014|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00250848||188113|
NCT00248768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3357-R|Accelerated Transcranial Magnetic Stimulation (TMS) for Depression|Accelerated Transcranial Magnetic Stimulation for Depression|ATMS|VA Office of Research and Development|Yes|Completed|February 2005|June 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||September 2014|September 18, 2014|November 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248768||188270|
NCT00248716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor458607ctil|Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations.|||Soroka University Medical Center||Recruiting|February 2007|||April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|9 Months|18 Months|No|||April 2008|April 29, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248716||188274|
NCT00248170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345D2411|Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer|Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer|FACE|Novartis||Completed|December 2005|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4172|||Female|33 Years|96 Years|No|||October 2015|October 14, 2015|November 2, 2005||No||No|September 8, 2015|https://clinicaltrials.gov/show/NCT00248170||188313|
NCT00247741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Articaine|Spinal Anesthesia With Articaine and Lidocaine for Outpatient Surgery.|Spinal Anesthesia With Articaine and Lidocaine for Outpatient Surgery: A Double Blind Randomized Clinical Trial.||St. Antonius Hospital|No|Completed|November 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||80|||Both|18 Years|N/A|No|||October 2005|December 18, 2013|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247741||188344|
NCT00248092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRP104.A03|Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse|A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse||New River Pharmaceuticals||Completed|January 2006|May 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|November 1, 2007|November 1, 2005||||||https://clinicaltrials.gov/show/NCT00248092||188319|
NCT00248040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0204|Reparixin in Prevention of Delayed Graft Dysfunction After Kidney Transplantation|A Phase 2, Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group (3 Arms) Pilot Study to Assess the Efficacy, the Safety and the Pharmacokinetics of Two Treatment Schedules of Reparixin in the Prevention of Delayed Graft Function After Kidney Transplantation in High Risk Patients||Dompé Farmaceutici S.p.A||Completed|October 2005|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|80|||Both|18 Years|65 Years|No|||June 2011|June 7, 2011|November 2, 2005||Yes||||https://clinicaltrials.gov/show/NCT00248040||188323|
NCT00248053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-04-12-04|Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients|Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis (FAP) Patients||Johns Hopkins University|No|Withdrawn|November 2005|||June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|85 Years|No|||September 2012|September 18, 2012|November 1, 2005|Yes|Yes|Subsequent data generated by our collaborators have shown efficacy with curcumin and quercetin    in 5 patients in a non placebo controlled trial.|No||https://clinicaltrials.gov/show/NCT00248053||188322|
NCT00248378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-SD-103|Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis|Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis||Center for Medicinal Cannabis Research||Completed|September 2001|March 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2006|June 21, 2006|November 2, 2005||||||https://clinicaltrials.gov/show/NCT00248378||188297|
NCT00248664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK64880 (completed)|Events Preceding Interstitial Cystitis (EPIC)|A Case Control Study of Interstitial Cystitis|EPIC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 2004|November 2008|Actual|||N/A|Observational|N/A|||Anticipated|400|||Female|18 Years|N/A|No|||March 2010|March 2, 2010|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248664||188278|
NCT00245115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453619|Autologous Peripheral Stem Cell or Bone Marrow Transplant Using Laboratory-Treated Cells in Treating Patients With Acute Leukemia|Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|October 2005|||December 2007|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|N/A|70 Years|No|||April 2011|July 19, 2011|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245115||188542|
NCT00245349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200502799|Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer|Biodistribution and Radiation Dosimetry of F-18 Fluorothymidine (FLT) Imaged With Positron Emission Tomography (PET) in Patients With Head and Neck Cancer: A Radioactive Drug Research Committee (RDRC) Study||University of Iowa|Yes|Completed|October 2005|April 2008|Actual|||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples With DNA|Tumor biopsy, blood samples|Both|21 Years|N/A|No|Non-Probability Sample|Head & Neck Cancer|June 2008|June 9, 2008|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00245349||188524|
NCT00245362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-0011|A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer|A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer||Cell Genesys||Completed|June 2002|June 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||October 2005|October 27, 2005|October 27, 2005||||||https://clinicaltrials.gov/show/NCT00245362||188523|
NCT00246259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005959|A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis|An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis||Janssen-Ortho Inc., Canada|No|Completed|October 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|30 Years|No|||November 2013|November 15, 2013|October 28, 2005|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00246259||188455|
NCT00255905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH067184|Cognitive Behavioral Therapy for the Treatment of Depression-Related Insomnia|Is Insomnia a Modifiable Risk Factor for Major Depressive Disorder||University of Rochester||Completed|July 2004|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|45|||Both|25 Years|65 Years|No|||June 2013|June 27, 2013|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255905||187734|
NCT00255918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0857|Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients|Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine in Schizophrenia||University of Colorado, Denver|Yes|Completed|March 2004|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|60 Years|No|||June 2015|June 30, 2015|November 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255918||187733|
NCT00256191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI 287-02|Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies|A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies||Cortice Biosciences, Inc.|No|Completed|November 2005|February 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|85 Years|No|||November 2005|October 11, 2007|November 16, 2005||||Yes||https://clinicaltrials.gov/show/NCT00256191||187712|
NCT00256204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/500 (ADAGIO)|A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease|A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects|ADAGIO|Teva Pharmaceutical Industries|Yes|Completed|November 2005|June 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1174|||Both|30 Years|80 Years|No|||January 2012|January 10, 2012|November 16, 2005|Yes|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00256204||187711|
NCT00247078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-03/02|The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism|The Efficacy and Safety of Aracmyn® [Antivenin Latrodectus (Black Widow)Equine Immune F(ab)2], in Patients With Systemic Latrodectism: A Phase II, Multi-center, Randomized, Double-Blind Trial||Instituto Bioclon S.A. de C.V.|Yes|Completed|October 2005|December 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|10 Years|N/A|No|||March 2016|March 18, 2016|October 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00247078||188394|
NCT00250289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191055HMO-CTIL|Prevention of Oral Malodor With an Oral Sticker Containing Herbal Formula|Invivo Study of the Efficacy of an Innovative Herbal Formula and Delivery System on Oral Malodor||Hadassah Medical Organization||Completed|March 2006|September 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|15|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2009|January 5, 2010|November 6, 2005||||No||https://clinicaltrials.gov/show/NCT00250289||188156|
NCT00247559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-97-52120-723|Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)|A Phase II, Multi-Centre, Randomised, Double-Blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15 U, 30 U or 45 U of Botulinum Type A Toxin to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow’s Feet)||Ipsen||Completed|May 2004|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|65 Years|No|||May 2006|May 15, 2006|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247559||188357|
NCT00249327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063005|Online HIV Prevention Vignette Evaluation|Online HIV Prevention Vignette Evaluation||Public Health Solutions||Completed|October 2005|February 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1000|||Male|18 Years|90 Years|No|||April 2007|April 18, 2007|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249327||188229|
NCT00248469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MkV1: ITIDRD90|MEMA Kwa Vijana Trial: Impact of an Adolescent Sexual and Reproductive Health Intervention in Mwanza, Tanzania|Strategies for the Prevention of HIV Infection and the Enhancement of Reproductive Health Among Adolescents in Rural Tanzania: MEMA Kwa Vijana Trial||London School of Hygiene and Tropical Medicine||Completed|July 1998|April 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||10000|||Both|14 Years|N/A|Accepts Healthy Volunteers|||November 2005|October 19, 2006|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248469||188291|
NCT00248742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-00093|Psychobiology in Inflammatory Bowel Disease(IBD)|The Impact of Psychobiological Factors in Inflammatory Bowel Disease|INSPIRE|Oslo University Hospital|No|Completed|February 2001|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2009|July 3, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248742||188272|
NCT00247754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B01-0072|VP3: Vancouver Primary Prevention Program (Anxiety Disorders Prevention in School Children)|VP3: Vancouver Primary Prevention Program (Anxiety Disorders Prevention in School Children)||University of British Columbia||Completed|November 2002|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||281|||Both|7 Years|13 Years|No|||October 2005|October 31, 2005|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247754||188343|
NCT00248105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 AR052912-01|Improving Motivation for Physical Activity in Arthritis Clinical Trial|Physical Activity in Persons With Arthritis|IMPAACT|Northwestern University|Yes|Completed|September 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|889|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00248105||188318|
NCT00248118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903382|Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking|Neurocognitive and Affective Correlates of Tobacco Dependence in Adolescent Smokers and Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking||National Institutes of Health Clinical Center (CC)|Yes|Terminated|January 2005|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||September 2009|April 4, 2011|November 1, 2005|Yes|Yes|PI left NIH|No||https://clinicaltrials.gov/show/NCT00248118||188317|
NCT00248391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|avitalbotlitis- HMO-CTIL|The Influence of Feeding Position on Pulmonary Morbidity in Young Children|The Influence of Feeding Position on Pulmonary Morbidity in Young Children||Hadassah Medical Organization||Not yet recruiting||January 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|||Anticipated|2000|||Both|3 Months|12 Months|Accepts Healthy Volunteers|||October 2006|October 25, 2007|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00248391||188296|
NCT00248404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-TSC-001|NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)|A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase||Kiadis Pharma||Completed|September 2005|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|155|||Both|18 Years|N/A|No|||January 2008|September 26, 2012|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00248404||188295|
NCT00248677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71555|Sensible Treatment of Obesity in Rural Youth . . .|Sensible Treatment of Obesity in Rural Youth||University of Florida||Completed|September 2005|August 2008|Actual|August 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Both|8 Years|13 Years|No|||February 2011|December 9, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248677||188277|
NCT00248885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001004169 (Formerly 0100-006)|Peri-Operative Morbidity and Quality of Life After Coronary Artery Bypass Graft (CABG)|Peri-Operative Morbidity and Quality of Life After CABG||Weill Medical College of Cornell University|No|Completed|September 1991|September 1994|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|248|||Both|18 Years|N/A|No|||April 2008|April 10, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248885||188261|
NCT00249171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003175|A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients|Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients||Janssen Pharmaceutica N.V., Belgium||Completed|June 2001|February 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|226|||Both|16 Years|N/A|No|||January 2011|January 13, 2011|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00249171||188240|
NCT00245128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445435|Imatinib Mesylate in Treating Patients With Myelofibrosis|A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia||OHSU Knight Cancer Institute|Yes|Terminated|August 2005|October 2011|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|October 25, 2005|Yes|Yes|Per PI, results from another similar study were published prior to study analysis. Negative    study results were published therefore analysis was not completed|No|October 25, 2011|https://clinicaltrials.gov/show/NCT00245128||188541|Early termination/results were never analyzed due to negative study results from other similar studies.
NCT00245401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-6321|CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)|CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)||Cordis Corporation|Yes|Completed|August 2003|December 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2070|||Both|N/A|N/A|No|||April 2007|April 3, 2007|October 4, 2005||||No||https://clinicaltrials.gov/show/NCT00245401||188520|
NCT00245375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA003|A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery|A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery||Nova Scotia Health Authority||Completed|January 2005|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|17 Years|65 Years|No|||March 2008|March 28, 2008|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00245375||188522|
NCT00256230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 01-01|Disulfiram in Patients With Metastatic Melanoma|Evaluation of Disulfiram in Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy, Phase I/II||University of California, Irvine|Yes|Completed|January 2002|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||December 2011|December 20, 2011|November 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256230||187709|
NCT00256243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 03-70|Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer|A Pilot Study of Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide (AC) With GMCSF Followed by Weekly Carboplatin/Paclitaxel With Plus or Minus Trastuzumab (TC ± H) in the Treatment of Breast Cancer||University of California, Irvine|Yes|Completed|April 2004|July 2012|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||January 2014|January 28, 2014|November 17, 2005|Yes|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00256243||187708|
NCT00256477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY - PTSD|A Controlled Breathing Course for Social & Emotional Health for Vietnam Veterans With Chronic PTSD-RCT|A Controlled Breathing Course Promoting Social and Emotional Health for Vietnam Veterans With Chronic Posttraumatic Stress Disorder - A Randomised Controlled Trial||The University of Queensland||Completed|March 2005|October 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||30|||Male|50 Years|70 Years|Accepts Healthy Volunteers|||March 2005|November 16, 2005|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00256477||187690|
NCT00256776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2005-001628-35|MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation|A Randomized Controlled Study of Velcade (Bortezomib) Plus Thalidomide Plus Dexamethasone Compared to Thalidomide Plus Dexamethasone for the Treatment of Myeloma Patients Progressing or Relapsing After Autologous Transplantation||European Group for Blood and Marrow Transplantation|Yes|Active, not recruiting|July 2005|June 2013|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|November 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00256776||187668|
NCT00257036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005476|A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin|A Multicenter, Active-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Levofloxacin Versus Ciprofloxacin HCl in the Treatment of Mild to Moderate Skin and Skin Structure Infections in Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 1991|February 1993|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|431|||Both|18 Years|N/A|No|||January 2011|June 8, 2011|November 18, 2005||||||https://clinicaltrials.gov/show/NCT00257036||187648|
NCT00247325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144-가-24|RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography|Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Renal Insufficiency Undergoing Coronary Angiography: The RECOVER Study, A Randomized Controlled Trial||Seoul National University Hospital||Completed|January 2004|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|19 Years|N/A|No|||January 2005|November 29, 2006|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247325||188375|
NCT00247572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRP104.A02|Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories|A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse||New River Pharmaceuticals||Completed|September 2005|November 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|November 1, 2007|October 31, 2005||||||https://clinicaltrials.gov/show/NCT00247572||188356|
NCT00247299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|danaCTIL|Evaluation and Optimization of the Technical and Clinical Performance of the Lumenis ONE Platform|Evaluation and Optimization of the Technical and Clinical Performance of the Lumenis ONE Platform||Rambam Health Care Campus||Active, not recruiting|May 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2005|October 30, 2005|October 30, 2005||||No||https://clinicaltrials.gov/show/NCT00247299||188377|
NCT00247312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-8-3|Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial|Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial||Schiffler Cancer Center|Yes|Completed|October 2005|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|319|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00247312||188376|
NCT00248183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX-CP-007|A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)|A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)||Epix Pharmaceuticals, Inc.||Completed|August 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||310|||Both|18 Years|65 Years|No|||April 2008|April 2, 2008|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248183||188312|
NCT00248196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-0045|COOL MI II: Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|COOL MI II: Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction||Radiant Medical||Terminated|October 2005|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|225|||Both|18 Years|N/A|No|||August 2007|March 20, 2008|November 1, 2005||||||https://clinicaltrials.gov/show/NCT00248196||188311|
NCT00245245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBI-1 - 201|Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII|An Open-Label Study of the Hemostatic Activity, Pharmacokinetics and Safety of OBI-1 (B-Domain Deleted Recombinant Porcine FVIII), When Administered by Intravenous Injection, to Control Non-Life and Non-Limb Threatening Bleeding Episodes in Congenital Hemophilia A Patients With an Inhibitor to Human FVIII||Octagen Corporation||Completed|May 2005|June 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|12 Years|N/A|No|||October 2007|October 2, 2007|October 25, 2005||||||https://clinicaltrials.gov/show/NCT00245245||188532|
NCT00248963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A2-315|Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception|A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 Mg and Ethinyl Estradiol 20 Mg in a Continuous 28-Day Regimen for Oral Contraception Versus a Cyclic 21-Day Regimen Oral Contraceptive||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||600|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||May 2006|May 17, 2006|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248963||188255|
NCT00247780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAP-PV-01|Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation|Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation||University of Aarhus||Completed|November 2004|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2008|February 13, 2008|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00247780||188342|
NCT00254111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-OAV3-70505|Study of the Use of Laser Light to Treat Osteoarthritis of the Hand.|Ultra Probe Laser System Osteoarthritis of the Hand Clinical Study.||TriTech Manufacturing||Recruiting|July 2005|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||November 2005|November 14, 2005|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00254111||187867|
NCT00248430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1838.00|Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer|A Phase I-II Trial of Adoptive Immunotherapy Using Haploidentical, Related Donor-Lymphocyte Infusions and IL-2 After Autologous Stem Cell Transplantation for Advanced Lymphoid Malignancies||Fred Hutchinson Cancer Research Center||Completed|August 2003|July 2007|Actual|||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|69 Years|No|||September 2010|September 20, 2010|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00248430||188294|
NCT00248690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-SAHD|ICP Versus Intracranial Compliance Guided Management in SAH|Intracranial Pressure (ICP) Versus Intracranial Compliance (ICC) Guided Management in Subarachnoid Hemorrhage; - a Prospective, Randomized Trial.||Oslo University Hospital||Completed|November 2005|June 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Actual|100|||Both|18 Years|N/A|No|||January 2008|January 17, 2011|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00248690||188276|
NCT00248898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501007700|Quality of Life After Open Heart Surgery in Older Patients|Quality of Life After Open Heart Surgery in Older Patients||Weill Medical College of Cornell University||Active, not recruiting|March 2005|January 2006|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|90 Years|N/A|No|Non-Probability Sample|A (consecutive) series of 49 patients age 90 years or older underwent cardiac operations        between May 1995 and October 2004 at New York Presbyterian Hospital-Weill Medical College        of Cornell University.|March 2008|March 31, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248898||188260|
NCT00249197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005473|A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections|A Multicenter, Randomized, Open-Label Study to Compare the Safety and Efficacy of i.v. And/Or Oral Levofloxacin With That of Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Bacterial Skin and Skin Structure Infections||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 1997|July 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|413|||Both|18 Years|N/A|No|||January 2011|June 8, 2011|November 4, 2005||||||https://clinicaltrials.gov/show/NCT00249197||188239|
NCT00245739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006304|TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.|Early Access of TMC114 in Combination With Low-dose Ritonavir (TMC/r)) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to no Treatment Options.||Tibotec Pharmaceuticals, Ireland|No|Approved for marketing||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||April 2014|April 10, 2014|October 27, 2005|No|Yes||||https://clinicaltrials.gov/show/NCT00245739||188494|
NCT00246025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.50|A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.|A Randomised, Parallel-group, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery||Boehringer Ingelheim||Completed|October 2005|||June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|512|||Both|20 Years|N/A|No|||February 2014|June 3, 2014|October 28, 2005||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00246025||188473|
NCT00256789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypo 1|Once Weekly Radiation for Lung Cancer With Chemotherapy|Combination of Weekly Radiation and Docetaxel for Locally Advanced Non Small Cell Lung Cancer: A Feasibility Study||Clinical Oncology Research Associates||Completed|September 2002|December 2004|Actual|December 2003|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|N/A|N/A|No|||November 2005|February 10, 2014|November 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00256789||187667|
NCT00257049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005491|A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia|A Multicenter, Active-Controlled, Randomized Study To Evaluate The Safety And Efficacy Of Levofloxacin Versus Ceftriaxone Sodium Or Cefuroxime Axetil In The Treatment Of Community-Acquired Pneumonia In Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 1984|January 1995|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|604|||Both|18 Years|N/A|No|||November 2010|June 8, 2011|November 18, 2005||||||https://clinicaltrials.gov/show/NCT00257049||187647|
NCT00247091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR059114MA|Impact of HIV on Measles and Measles Immunisation|Impact of HIV on Measles and Measles Immunisation||Johns Hopkins Bloomberg School of Public Health||Completed|May 2000|September 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||700|||Both|2 Months|15 Months|Accepts Healthy Volunteers|||October 2005|October 28, 2005|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00247091||188393|
NCT00247338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypocaloric PN|The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients|Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study||Sino-Swed Pharmaceutical Corporation||Completed|April 2005|May 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|80 Years|No|||May 2008|May 9, 2008|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247338||188374|
NCT00247585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAHOW12087|Hangover, Congeners, Sleep and Occupational Performance|Hangover, Congeners, Sleep and Occupational Performance||National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|September 2003|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||140|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||December 2006|December 4, 2006|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247585||188355|
NCT00247884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0219|Pender Assisted Therapy (PATh) - Prospective Study of the Treatment of HCV|Directly Observed Therapy for the Treatment of Hepatitis C Virus Infection in Injection Drug Users||University of British Columbia||Completed|June 2005|October 2009|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|19 Years|N/A|No|Probability Sample|Injection drug users|October 2009|October 9, 2009|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247884||188334|
NCT00247858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0247|Analysis of Methicillin Resistant Staphylococcus Aureus (MRSA) Obtained Through the Emergency Department in a Tertiary Care Hospital in Vancouver Canada From 2001-2005|Analysis of Methicillin Resistant Staphylococcus Aureus (MRSA) Obtained Through the Emergency Department in a Tertiary Care Hospital in Vancouver Canada From 2001-2005||University of British Columbia||Active, not recruiting|January 2005|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|97|||Both|N/A|N/A|No|Probability Sample|Patients with a microbiological sample submitted from the emergency department of the        study hospital.|September 2011|September 28, 2011|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00247858||188336|
NCT00247871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0193|Microbiological Characterization and Nasal Carriage Rates of Methicillin Resistant Staphylococcus Aureus (MRSA) in Vancouver Downtown Eastside|The Prevalence of Panton Valentine Leukocidin, Exfoliative Toxin and Agr Genotypes in Staphylococcus Aureus Nasal Colonization in Vancouver's Eastside Community||University of British Columbia||Active, not recruiting|October 2005|December 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|600|||Both|N/A|N/A|No|Probability Sample|Vancouver's Downtown Eastside|September 2011|September 28, 2011|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247871||188335|
NCT00248495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441025|Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Molecular and Genetic Changes in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Cisplatin and Alimta - Phase II Study||Roswell Park Cancer Institute|Yes|Active, not recruiting|June 2005|||April 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248495||188289|
NCT00248521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-PH1/102|17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery|A Cancer Research UK Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|October 2005|||January 2007|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||March 2008|August 1, 2013|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00248521||188288|
NCT00253292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-008281/15|Psychometric Study of Outcomes Instruments|Psychometric Study of Outcomes Instruments||Massachusetts General Hospital|No|Terminated|January 1997|December 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|19 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted to the MGH burn unit for a burn injury between the ages of 19-30 years.|July 2011|July 27, 2011|November 11, 2005||No|Unable to recruit necessary sample size|No||https://clinicaltrials.gov/show/NCT00253292||187927|
NCT00248976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0698-267|Improving Health Behavior and Outcomes After Angioplasty|Improving Health Behavior and Outcomes After Angioplasty||Weill Medical College of Cornell University|No|Completed|April 1999|March 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|660|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248976||188254|
NCT00247793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96.17.066|Immunonutrition in Cardiac Surgery|The Effect of Pre- and Postoperative Supplemental Enteral Nutrition in High-Risk Patients Undergoing Elective Cardiac Surgery. A Prospective Double Blind Study.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Completed|July 1996|December 1998||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||November 2005|November 1, 2005|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00247793||188341|
NCT00247806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0180|Prevalence of Lactose Intolerance Following Stem Cell Transplantation|Prevalence of Lactose Intolerance Following Stem Cell Transplantation in Pediatric Patients.||University of British Columbia||Terminated|October 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 1|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|4 Years|18 Years|No|||October 2005|September 24, 2008|October 31, 2005||No|Too few patients completed the study once enrolled.|No||https://clinicaltrials.gov/show/NCT00247806||188340|
NCT00254124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17585 (Grant ID#)|Use of a Portion Control Food Tool to Induce Weight Loss in Obese Type 2 Diabetics.|Efficacy of a Food Portion Control Tool to Induce Weight Loss and Decrease Hypoglycemic Medication Requirements Amongst Obese Type 2 Diabetics.||University of Calgary||Completed|April 2004|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|18 Years|N/A|No|||November 2005|November 14, 2005|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00254124||187866|
NCT00254137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-02-2004|Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.|A Randomized Phase II-study to Evaluate the Safety and Efficacy of Capecitabine Plus Irinotecan Plus Cetuximab Compared to Capecitabine Plus Oxaliplatin Plus Cetuximab in First-line Treatment of Patients With Metastatic Colorectal Cancer.||Ludwig-Maximilians - University of Munich||Completed|September 2004|November 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||92|||Both|18 Years|75 Years|No|||September 2004|October 27, 2010|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00254137||187865|
NCT00248443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040424|Réa-MiniMax: Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage|Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage. A Multicentric Randomized Controlled Trial||Assistance Publique - Hôpitaux de Paris|Yes|Completed|August 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|206|||Both|18 Years|N/A|No|||March 2007|February 17, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248443||188293|
NCT00248911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0209005792|The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers|The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers:Avon Program for Meditation and Healing||Weill Medical College of Cornell University|No|Active, not recruiting|May 2003|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Female|18 Years|N/A|No|||April 2008|April 10, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00248911||188259|
NCT00248924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101-561|Outcomes Of Social Service Programs For Homebound Older Adults|Outcomes Of Social Service Programs For Homebound Older Adults||Weill Medical College of Cornell University|No|Completed|April 2001|February 2003||||N/A|Observational|Time Perspective: Prospective||||56|||Both|60 Years|N/A|No|||March 2008|March 31, 2008|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00248924||188258|
NCT00245141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRSG-UHA-PED03-01|Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma|Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma||National Cancer Institute (NCI)||Recruiting|May 2004|||April 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|32|||Both|N/A|17 Years|No|||July 2009|August 9, 2013|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245141||188540|
NCT00245154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR24|Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer||Canadian Cancer Trials Group|Yes|Completed|September 2005|January 2013|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|296|||Both|18 Years|N/A|No|||November 2012|January 10, 2013|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00245154||188539|
NCT00245388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV168-008|Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia|A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Trial to Determine the Lipid-Lowering Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia||Bristol-Myers Squibb||Completed|April 2002|July 2002|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|18 Years|70 Years|No|||April 2012|April 20, 2012|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00245388||188521|
NCT00255333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-105-901|INNO-105 in Patients With Solid Tumors|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies||Innovive Pharmaceuticals||Terminated|November 2005|March 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||May 2007|May 11, 2007|November 16, 2005|||Development of this compound was discontinued.|||https://clinicaltrials.gov/show/NCT00255333||187775|
NCT00255658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03164|Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors|Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination With CCI-779 (Temsirolimus) in Advanced Solid Malignancies||National Cancer Institute (NCI)||Completed|September 2005|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2013|April 14, 2015|November 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00255658||187751|
NCT00257062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005479|A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin|A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With That of Ciprofloxacin HCl in the Treatment of Uncomplicated Skin and Skin Structure Infections in Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 1993|April 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|361|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|November 18, 2005||||||https://clinicaltrials.gov/show/NCT00257062||187646|
NCT00257374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gatorade|Pedialyte or Gatorade for Viral Gastroenteritis in Adults: a Randomized, Controlled Trial|||Georgia Regents University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|19 Years|80 Years||||January 2014|January 8, 2014|November 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00257374||187622|
NCT00257387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-101308|Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants|A Nonrandomized, Open-label, Multicenter, Sequential Phase Study to Evaluate the Safety and Efficacy of Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese De Novo Renal Allograft Recipients Receiving Rapamune||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2004|August 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|No|||June 2007|February 1, 2011|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00257387||187621|
NCT00247351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030198|Prevention of Atrial Tachycardia After a Right Atriotomy|Prevention of Atrial Tachycardia After a Right Atriotomy||Aarhus University Hospital Skejby||Completed|September 2003|June 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||15|||Both|18 Years|N/A|No|||September 2003|October 18, 2006|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247351||188373|
NCT00247364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001804|A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)|A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)||Sleep Health Centers||Completed|November 2003|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|85 Years|No|||October 2005|October 28, 2005|October 28, 2005||||No||https://clinicaltrials.gov/show/NCT00247364||188372|
NCT00247611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066684|Improving Treatment Adherence in HIV-Infected Individuals|Changing ART Adherence Behavior: The Lifewindows Project||University of Connecticut|Yes|Completed|October 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|594|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|October 31, 2005||No||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00247611||188354|The only empirical demonstration of LifeWindows outcomes to dateOP sample was defined a posterioriUnder-powered to detect changes in Viral Load
NCT00247897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0389|Comparing Skin Disinfectants Before Labour Epidural Analgesia|What is the Best Skin Preparation Solution for Labour Epidural Analgesia? A Randomized Prospective Trial Comparing ChloraprepTM, DuraprepTM, and Chlorhexidine 0.5% in 70% Alcohol.||University of British Columbia|No|Completed|November 2005|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|195|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2011|April 11, 2011|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00247897||188333|
NCT00247910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C01-0175|Behavioural Treatment of Hypertension|Behavioural Treatment of Hypertension||University of British Columbia|No|Completed|October 2001|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 16, 2011|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247910||188332|
NCT00248209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK FOD|Female Orgasmic Disorder (FOD) and Wellbutrin XL|A Multi-center, Double-blind, Placebo-controlled Study of Bupropion XL in Females With Orgasmic Disorder||Segraves, R., T., M.D., Ph.D.|No|Completed|May 2004|April 2007|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|48|||Female|20 Years|50 Years|No|||April 2007|July 19, 2011|November 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248209||188310|
NCT00248222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3840-DT-CTIL|Early Aerobic Training Program After Ischemic Stroke|||Sheba Medical Center|No|Completed|October 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||October 2009|October 26, 2009|November 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00248222||188309|
NCT00248534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445289|Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma|A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma||National Cancer Institute (NCI)||Completed|September 2005|||September 2012|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|October 11, 2012|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00248534||188287|
NCT00249600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14618-1|Lower-Cost Contingency Management in a Group Setting - 1|Lower-Cost Contingency Management in a Group Setting||University of Connecticut Health Center|No|Completed|March 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249600||188208|
NCT00249873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4912 A|Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)|A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation||Sanofi|Yes|Completed|June 2003|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|7554|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|November 4, 2005|Yes|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00249873||188187|
NCT00248989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-204|Effect of DHEA on Skin Aging in Postmenopausal Women|Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.||Centre Hospitalier Universitaire de Québec, CHU de Québec||Active, not recruiting|November 2004|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Female|60 Years|65 Years|Accepts Healthy Volunteers|||September 2006|September 6, 2006|November 2, 2005||||No||https://clinicaltrials.gov/show/NCT00248989||188253|
NCT00253864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2003658-01H|Functional Outcomes Following Shoulder Surgery: A Prospective Database|Functional Outcome Following Shoulder Surgery: A Prospective Database||Ottawa Hospital Research Institute|No|Recruiting|November 2004|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|October 2015|October 21, 2015|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00253864||187885|
NCT00254449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C115|Effect of NGX-4010 on ENFD and Sensory Function|A Randomized, Controlled, Open-Label Study to Investigate the Effect of NGX-4010 on Epidermal Nerve Fiber Density and Sensory Function in Healthy Volunteers||NeurogesX||Completed|November 2005|May 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2007|February 12, 2009|November 14, 2005||||||https://clinicaltrials.gov/show/NCT00254449||187841|
NCT00254735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077/9059|Quetiapine Augmentation in Severe Obsessive Compulsive Disorder|Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study||AstraZeneca||Completed|April 2002|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|65 Years|No|||December 2007|December 14, 2007|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254735||187819|
NCT00254748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C00003|Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients|The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial||AstraZeneca||Completed|June 2004|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||June 2009|June 9, 2009|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254748||187818|
NCT00255060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0002|Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer|Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer||Stanford University||Completed|November 2001|June 2007|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|25 Years|65 Years|No|Non-Probability Sample|Women with high risk of breast cancer|July 2010|July 16, 2010|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00255060||187795|
NCT00255073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACLOFEN|Does Reducing Spasticity Permit an Increase in Strength?|Does Reducing Spasticity Permit an Increase in Strength?||University of Southern California|No|Completed|January 2005|April 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|5 Years|18 Years|No|||May 2014|May 21, 2014|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00255073||187794|
NCT00255671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4Z05|Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders|Prospective Study on the Short-Term Adverse Effects From Gamma Knife Radiosurgery||Case Comprehensive Cancer Center|Yes|Completed|May 2005|May 2012|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|76|None Retained|Determine the incidence and types of acute complications in patients undergoing stereotactic      radiosurgery for brain tumors or other brain disorders.|Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|October 2015|October 1, 2015|November 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00255671||187750|
NCT00255931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8567|Impact of a Psychological Biofeedback-Relaxation Intervention on Clinical, Physical and Psychological Outcomes in Patients With Heart Failure|Biobehavioral Intervention in Heart Failure||University of Kentucky|No|Completed|July 2004|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|380|||Both|21 Years|N/A|No|||June 2012|June 2, 2012|November 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00255931||187732|
NCT00256217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 03-16|Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women|Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women||University of California, Irvine|Yes|Active, not recruiting|September 2004|December 2018|Anticipated|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Female|18 Years|N/A|No|||January 2014|January 30, 2014|November 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00256217||187710|
NCT00257075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006052|A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder|The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2000|May 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|267|||Both|18 Years|N/A|No|||January 2011|January 13, 2011|November 18, 2005||||||https://clinicaltrials.gov/show/NCT00257075||187645|
NCT00257088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DA15409|The Whole Day First Grade Program|Prevention Services in Schools for Early Drug Abuse Risk||American Institutes for Research||Completed|September 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||2000|||Both|N/A|N/A|No|||August 2005|February 13, 2008|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00257088||187644|
NCT00257101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343|Stepped Intervention for Meds Adherence and Blood Pressure Control|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2001|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||January 2008|February 17, 2016|November 18, 2005||||No||https://clinicaltrials.gov/show/NCT00257101||187643|
NCT00257400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH064528|Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse|Interpersonal Psychotherapy for Depressed Women With Sexual Abuse Histories||University of Rochester|No|Completed|May 2003|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|N/A|No|||December 2013|December 31, 2013|November 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00257400||187620|
NCT00257413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-007|Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension|||Zhejiang University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years||||December 2003|November 21, 2005|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00257413||187619|
NCT00247624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH070821|Improving Sleep and Psychological Functioning in People With Depression and Insomnia|Hypnotics in the Treatment of Psychiatric Disorders||Wake Forest School of Medicine||Active, not recruiting|October 2005|December 2008|Anticipated|October 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|70 Years|No|||March 2009|November 29, 2010|October 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00247624||188353|
NCT00247923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP I/II/III|Endometrial Polyps: Pathophysiology and Clinical Consequences|Endometrial Polyps. Pathophysiology and Clinical Consequences.||Oslo University Hospital||Completed|October 2005|February 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1186|||Female|16 Years|90 Years|Accepts Healthy Volunteers|||February 2009|July 3, 2011|October 31, 2005||||No||https://clinicaltrials.gov/show/NCT00247923||188331|
NCT00248248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEGO_DOXIL_CONS2005|DOXIL for Consolidation Therapy in Ovarian Cancer.|A Phase II Non-randomized Study of DOXIL Consolidation Treatment for Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneal Carcinoma.||Southeastern Gynecologic Oncology|No|Completed|October 2005|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||October 2011|October 7, 2011|November 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00248248||188307|
NCT00248261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZiSe|Ziprasidone and Sertraline in PTSD|Effects of Ziprasidone vs. Placebo During the First Four Weeks of Eight Weeks Sertraline Treatment in Patients With Post-traumatic Stress Disorder (PTSD)||Universitätsklinikum Hamburg-Eppendorf||Terminated|November 2005|June 2010|Actual|August 2009|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Probability Sample|PTSD patients|December 2013|December 12, 2013|November 2, 2005||No|High rate of early drop-outs|No||https://clinicaltrials.gov/show/NCT00248261||188306|
NCT00248235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-4-0023|Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer|Randomized Controlled Trial of Progressive Resistance Exercise Training for Spinal Accessory Neurapraxia/ Neurectomy in Head and Neck Cancer Survivors||University of Alberta, Physical Education||Active, not recruiting|September 2005|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||64|||Both|18 Years|N/A|No|||September 2005|January 31, 2007|November 1, 2005||||No||https://clinicaltrials.gov/show/NCT00248235||188308|
NCT00249002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD001|Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis|A Pilot Phase II Trial Of ABI-007 (A Cremophor El-Free, Protein Stabilized, Nanoparticle Paclitaxel) For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis||Celgene|No|Terminated|November 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Both|18 Years|N/A|No|||April 2012|August 7, 2012|November 3, 2005|Yes|Yes|Terminated due to pipeline prioritization|No|February 21, 2012|https://clinicaltrials.gov/show/NCT00249002||188252|
NCT00249613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-16277-1|Gender-Responsive Treatment for Women Offenders - 1|Gender-Responsive Treatment for Women Offenders||University of California, Los Angeles|Yes|Completed|June 2005|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|291|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|November 3, 2005||No||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00249613||188207|
NCT00245232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH051509-06|Cognitive Processing Therapy Versus Its Individual Components in the Treatment of Post-Traumatic Stress Disorder and Depression in Women Who Have Been Sexually Abused|Cognitive Processes in PTSD: Treatment||University of Missouri, St. Louis||Completed|August 2000|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||228|||Female|18 Years|N/A|No|||March 2015|March 30, 2015|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00245232||188533|
NCT00253877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2003137-01H|A Comparison of a Resurfacing Hip System to Standard Total Hip Arthroplasty|A Prospective, Multi-Centre, Historical Control Trial Comparing the Conserve® Plus Resurfacing Hip System to Standard Total Hip Arthroplasty.||Ottawa Hospital Research Institute|No|Completed|July 2003|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||August 2010|August 19, 2010|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00253877||187884|
NCT00254800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-EW-GWBC|The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females|The Effect of Exenatide on Single and Multiple Doses Oral Contraceptive Pharmacokinetics in Healthy Female Subjects||AstraZeneca|No|Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|November 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254800||187814|
NCT00254761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-DA-114|Effects of Smoked Marijuana on Neuropathic Pain|A Double Blind, Active Placebo Controlled Crossover Trial of the Antinociceptive Effect of Smoked Marijuana on Subjects With Neuropathic Pain; Correlation With Changes in Mood, Cognition, and Psychomotor Performance||Center for Medicinal Cannabis Research|Yes|Completed|November 2003|February 2006|Actual|February 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|70 Years|No|||February 2008|February 27, 2008|November 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00254761||187817|
NCT00254774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077/9061|Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling|Pilot Study of the Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling: an Open Trial||AstraZeneca||Completed|January 2002|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|65 Years|No|||December 2007|December 14, 2007|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254774||187816|
NCT00254787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441L00032|Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients|Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in the Treatment of Patients With Acute Schizophrenia - a Multicentre, Double-Blind, Parallel Group, Randomized Study||AstraZeneca||Completed|June 2005|January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||June 2009|June 9, 2009|November 15, 2005||||No||https://clinicaltrials.gov/show/NCT00254787||187815|
NCT00254462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH066127|Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children|Pharmacological Treatment of ADHD in Young Children||University of Nebraska|Yes|Completed|October 2005|September 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|5 Years|6 Years|No|||December 2015|December 16, 2015|November 14, 2005||No||No|October 3, 2011|https://clinicaltrials.gov/show/NCT00254462||187840|Study design does not allow differentiation between placebo response and psychoeducational treatment effect. Eight-week duration does not allow for examination of long-term effectiveness or assessment of adverse effects over time.
NCT00255086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95722|The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients|The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial||Stanford University||Completed|May 2005|February 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|50 Years|95 Years|No|||October 2010|October 14, 2010|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00255086||187793|
NCT00255346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0817|Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)|Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2005|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|November 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00255346||187774|
NCT00255359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200517-HMO-CTIL|Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Safety and Efficacy of XTL 2125 in Adult HCV-Infected Patients With Compensated Liver Disease, Who Are Interferon-Alpha Non-Responders or Have Relapsed From Interferon-Alpha Therapy||Hadassah Medical Organization||Withdrawn|February 2006|November 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|70 Years|No|||November 2007|November 5, 2007|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00255359||187773|
NCT00256256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0079|The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men|The Effect of GLP-1 on Glucose Uptake in the CNS and Heart in Healthy Subjects During Normoglycaemia Assessed by Positron Emission Tomografi||University of Aarhus||Completed|November 2005|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2007|October 29, 2007|November 16, 2005||||No||https://clinicaltrials.gov/show/NCT00256256||187707|
NCT00256490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 05-020|Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by PET/CT|Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by Positron Emission Tomography Coupled With Computed Tomography (PET/CT)||Université de Sherbrooke||Recruiting|November 2005|November 2009||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||82|||Both|18 Years|70 Years|No|||November 2005|November 17, 2005|November 17, 2005||||No||https://clinicaltrials.gov/show/NCT00256490||187689|
NCT00256867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVS101946|A Study In Patients With Type 2 Diabetes Mellitus|A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|August 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||360|||Both|18 Years|75 Years|No|||February 2013|February 11, 2013|November 18, 2005||||||https://clinicaltrials.gov/show/NCT00256867||187661|
NCT00256880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG20006|Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma|A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma||GlaxoSmithKline|No|Completed|January 2005|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|21 Years|N/A|No|||February 2013|February 20, 2013|November 21, 2005||||No||https://clinicaltrials.gov/show/NCT00256880||187660|
NCT00268463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP C-09|Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer|A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients With Resected or Ablated Liver Metastases From Colorectal Cancer||NSABP Foundation Inc|Yes|Terminated|January 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|December 20, 2005|Yes|Yes|The study was terminated due to low accrual.|No|February 5, 2013|https://clinicaltrials.gov/show/NCT00268463||186792|
NCT00265655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 05-021|Satraplatin for Patients With Metastatic Breast Cancer (MBC)|Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)||Agennix||Completed|November 2005|February 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|December 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265655||187001|
NCT00244296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8672|To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms|A Double-Blind, Stratified, Randomised, Parallel, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Duloxetine (20 mg Bid for 2 Weeks Escalating to 40 mg Bid) for up to 12 Weeks, Compared to Placebo, in Community-Dwelling Elderly Women > or = 65 Years of Age With Symptoms of Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.||Eli Lilly and Company||Completed|October 2005|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||276|||Female|65 Years|N/A|No|||January 2007|January 24, 2007|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00244296||188605|
NCT00244582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060007|Convection-Enhanced Delivery of Glucocerebrosidase to Treat Type 2 Gaucher Disease|Direct Convection-Enhanced Delivery of Glucocerebrosidase for the Treatment of Type 2 (Acute Neuronopathic) Gaucher Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2005|November 2006||||N/A|Observational|N/A||||1|||Male|N/A|5 Years|No|||November 2006|September 26, 2015|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00244582||188583|
NCT00241111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EFR04|Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis|Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis||Novartis||Completed|September 2003|||January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Male|18 Years|N/A|No|||April 2010|April 7, 2010|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00241111||188848|
NCT00241436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5394C00001|Open Label Arimidex in Gynecomastia|An Open-Label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (Arimidex™) Used to Treat Pubertal Boys With Gynecomastia of Recent Onset||AstraZeneca||Completed|June 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Male|11 Years|18 Years|No|||January 2011|January 25, 2011|October 17, 2005||||||https://clinicaltrials.gov/show/NCT00241436||188823|
NCT00241449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238IL/0025|A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer|A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer||AstraZeneca||Completed|November 1998|January 2012|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Female|N/A|N/A|No|||June 2012|June 5, 2012|October 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00241449||188822|
NCT00251095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-8184-1075|Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer|A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer||OncoGenex Technologies||Terminated|September 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|821|||Female|18 Years|N/A|No|||June 2009|June 2, 2009|November 8, 2005|Yes|Yes|Failed primary endpoint|No||https://clinicaltrials.gov/show/NCT00251095||188094|
NCT00251329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRN-004|Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery|Phase II Neoadjuvant Trial of Docetaxel (Taxotere), Carboplatin, and Capecitabine (Xeloda) in the Treatment of Early Stage Locally Advanced and Inflammatory Breast Cancer||Cancer Research Network||Active, not recruiting|May 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||April 2007|April 3, 2007|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251329||188076|
NCT00251888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACIS|CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto|Etude de Recherche de Dose de l'Association Irinotecan (Campto(R)) - Cisplatine (Cisplatyl(R)) Avec la radiothérapie Pelvienne Dans Les Cancers avancés du Col de l'utérus.||ARCAGY/ GINECO GROUP||Completed|November 2002|November 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Female|18 Years|N/A|No|||February 2011|February 24, 2011|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00251888||188034|
NCT00251901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9914C00001|Chest Pain Pilot Study|A Randomized Double-Blind Placebo-Controlled Multi-Centre Pilot Study to Assess Symptom Response in Subjects With Pain or Discomfort in the Chest Receiving Oral Treatment With Esomeprazole 40 mg Bid for 4 Weeks.||AstraZeneca||Completed|May 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|70 Years|No|||January 2011|January 21, 2011|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251901||188033|
NCT00252161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0501|A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer|Randomized Phase III Trial of Surgery Plus Neoadjuvant TS-1 and Cisplatin Compared With Surgery Alone for Type 4 and Large Type 3 Gastric Cancer: Japan Clinical Oncology Group Study (JCOG 0501)||Japan Clinical Oncology Group|Yes|Recruiting|November 2005|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|316|||Both|20 Years|75 Years|No|||June 2010|June 13, 2010|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00252161||188013|
NCT00252174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76,770|MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer|Phase II Dose-response Pilot Study of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Anxiety Associated With Advanced-stage Cancer.||Brigham and Women's Hospital|Yes|Recruiting|February 2007|March 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||July 2010|July 22, 2010|November 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00252174||188012|
NCT00252733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2453C00045|Diabetic Retinopathy Candesartan Trials|Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.|DIRECT|AstraZeneca||Completed|June 2001|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5238|||Both|18 Years|50 Years|No|||April 2014|May 9, 2014|November 10, 2005|Yes|Yes||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00252733||187970|
NCT00270803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-05-EE-03-124-CTIL|The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana|The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana.||Tel-Aviv Sourasky Medical Center|No|Completed|July 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|12|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2005|May 6, 2008|December 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00270803||186617|
NCT00264056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOT-100|Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases|Evaluation of the Safety and Efficacy of Systemic Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Locally Inoperable Progressive Soft Tissue Metastases||Fachklinik Hornheide an der Universität Münster||Recruiting|December 2005|June 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||26|||Both|18 Years|70 Years|No|||November 2005|December 8, 2005|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00264056||187122|
NCT00265070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0093|Trial of Iressa in Prostate Cancer Patients|An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy||AstraZeneca||Completed|January 2003|August 2011|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Male|18 Years|N/A|No|||February 2013|February 4, 2013|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00265070||187045|
NCT00265083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006337|A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis||Centocor, Inc.|Yes|Completed|December 2005|January 2012|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|356|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|December 12, 2005|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00265083||187044|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00270868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 04/1942|Efficacy of Double Wire Technique in Difficult Cases of Common Bile Duct Cannulation in ERCP (UDOGUIA-04)|Double Guide Wire Placement Compared With Conventional Method in Cases of Difficult Common Bile Duct Cannulation in Endoscopic Retrograde Cholangiopancreatography Procedures. A Controlled Multicentred Randomized Trial.||Puerta de Hierro University Hospital||Active, not recruiting|November 2004|November 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||1050|||Both|18 Years|N/A|No|||October 2006|October 17, 2006|December 27, 2005||||No||https://clinicaltrials.gov/show/NCT00270868||186612|
NCT00271167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-05-2004|A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass|A Phase II Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Tolerability, Safety, Pharmacokinetics and Efficacy of Intravenous INO-1001 in High Risk Subjects Undergoing Cardiopulmonary Bypass for Coronary Revascularization and/or Valve Surgery.||Inotek Pharmaceuticals Corporation||Terminated|October 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||162|||Both|18 Years|90 Years|No|||March 2015|March 23, 2015|December 29, 2005|||It was determined that the study was not appropriate for demonstrating therapeutic benefit in    the cardiopulmonary bypass patient population.|No||https://clinicaltrials.gov/show/NCT00271167||186589|
NCT00266825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10186|DHA Supplementation and Pregnancy Outcome|Kansas University DHA Outcome Study (KUDOS)||University of Kansas Medical Center|Yes|Completed|January 2006|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|350|||Female|16 Years|36 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|December 15, 2005|Yes|Yes||No|June 30, 2015|https://clinicaltrials.gov/show/NCT00266825||186912|
NCT00265304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-III-05|A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee|A Double-Blind, Long-Term Evaluation of the Safety of IDEA-033 in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of Osteoarthritis of the Knee||IDEA AG||Completed|July 2005|||July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||550|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|December 13, 2005||||No||https://clinicaltrials.gov/show/NCT00265304||187027|
NCT00265317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181058|A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone|Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer|SUN1058|Pfizer|No|Completed|June 2006|January 2012|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|December 12, 2005|Yes|Yes||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00265317||187026|Due to rounding some percentages will not equal 100%
NCT00265330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281133|Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)|26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)||Pfizer|Yes|Completed|March 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Both|10 Years|17 Years|No|||December 2011|December 2, 2011|December 12, 2005|Yes|Yes||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00265330||187025|The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators.
NCT00265876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I173|AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase I/II Study of AZD0530 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer||Canadian Cancer Trials Group|No|Completed|September 2005|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265876||186985|
NCT00265889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF5386|Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma|Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Poor Risk Recurrent Hodgkin's Disease||Case Comprehensive Cancer Center|No|Completed|February 2002|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|December 14, 2005|Yes|Yes||No|June 10, 2013|https://clinicaltrials.gov/show/NCT00265889||186984|
NCT00244946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446079|Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma|Immune Consolidation With Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphomas||Barbara Ann Karmanos Cancer Institute|No|Completed|March 2004|March 2013|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|15 Years|70 Years|No|||March 2015|March 25, 2015|October 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244946||188555|
NCT00250588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40 MC 00331|Problem-Solving Skills Training to Improve Care for Children With Asthma|Reducing Barriers to Care for Vulnerable Children With Asthma||RAND|No|Completed|October 2003|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|252|||Both|2 Years|12 Years|No|||April 2013|April 25, 2013|November 4, 2005||No||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00250588||188133|Substantial dropout, particularly from CC+PST, is a limitation. Our sample size was not large enough, nor was there sufficient variability in our secondary outcomes, to detect differences in health care utilization despite the odds ratios.
NCT00240539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100449|Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)|Long-term Follow-Up Studies at Years 16-20, to Evaluate the Persistence of Immune Response of GSK Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers in Comparison With a Historical Control Group||GlaxoSmithKline||Completed|October 2003|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|36|||Both|16 Years|20 Years|Accepts Healthy Volunteers|||December 2009|December 10, 2009|October 13, 2005|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00240539||188890|No safety data were collected during this long-term follow-up study.
NCT00240552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV40005|Fosamprenavir Expanded Access|An Open-Label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options||GlaxoSmithKline||No longer available|July 2003|||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||October 2008|October 15, 2008|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240552||188889|
NCT00251108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/052|Fitness Training After Traumatic Brain Injury|The Efficacy of a Supervised Fitness Centre-Based Exercise Programme Compared to an Unsupervised Home-Based Exercise Programme on Improving Fitness and Psychosocial Outcomes in a Traumatic Brain Injured Population||Sydney South West Area Health Service||Completed|October 2003|March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|15 Years|65 Years|No|||February 2007|February 28, 2007|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251108||188093|
NCT00251342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.224-T|Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale|Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale||Chinese University of Hong Kong|No|Recruiting|October 2005|January 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||460|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2007|April 4, 2007|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251342||188075|
NCT00251615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0058|Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging|Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging||National Institutes of Health Clinical Center (CC)||Completed|August 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|18|Samples With DNA|Vascular tissue obtained from the surgical site that would have otherwise been discarded and      Blood Serum|Both|21 Years|N/A|No|Probability Sample|Patients scheduled for vascular surgery|August 2012|August 3, 2012|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251615||188054|
NCT00252720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2453C00046|DIabetic Retinopathy Candesartan Trials.|DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.|DIRECT|AstraZeneca||Completed|August 2001|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1850|||Both|18 Years|55 Years|No|||April 2014|May 9, 2014|November 10, 2005|Yes|Yes||No|March 19, 2012|https://clinicaltrials.gov/show/NCT00252720||187971|
NCT00252486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-266|Omega-3 Fatty Acids in Children and Adolescents With Bipolar Disorder|A Comparison of Omega-3 Fatty Acids vs. Placebo in Children and Adolescents With Bipolar Disorder||University of Rochester|Yes|Completed|November 2001|June 2005|Actual|June 2005|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|65|||Both|6 Years|17 Years|No|||June 2013|June 17, 2013|November 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00252486||187989|
NCT00252746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00039|ZD6474 Phase IIa Dose Finding Multicentre Study|A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]||AstraZeneca||Completed|December 2004|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|53|||Both|20 Years|N/A|No|||April 2015|April 24, 2015|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00252746||187969|
NCT00253045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045905|Motivating HIV+ Women: Risk Reduction and ART Adherence|Motivating HIV+ Women: Risk Reduction and ART Adherence|KHARMA|Emory University|Yes|Completed|August 2004|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|207|||Female|18 Years|85 Years|No|||September 2013|September 13, 2013|November 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00253045||187946|
NCT00263757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1254-05|Atrial Fibrillation Recurrence in Sleep Apnea|A Randomized Trial of Positive Airway Pressure Therapy In Atrial Fibrillation Recurrence In Sleep Apnea||Mayo Clinic|Yes|Completed|October 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|December 7, 2005||No||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00263757||187143|The primary barrier to enrollment was the high rate of subjects who were previously diagnosed with sleep apnea and were already prescribed treatment.
NCT00264069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005755|ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry|Study ADH.E.R.E.: "Therapeutic ADHerence and Treatment Strategies: Mental Health Registry"||Janssen-Cilag, S.A.||Completed|June 2005|June 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2622|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients diagnosed with schizophrenia, bipolar disorder or depression according to the        Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) classification        characteristics who have been given a new therapy plan (that may include drug treatment        for mental illness, visits to a mental health care worker, or other treatments such as        non-medication type of treatments); patients either scheduled for treatment in the next 3        months or already treated for the past 3 months.|April 2010|May 18, 2011|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264069||187121|
NCT00270621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2234e|Family Help Program: Nighttime Enuresis Treatment Program|Family Help Program: Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Enuresis)||IWK Health Centre|No|Completed|June 2003|April 2008|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|December 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00270621||186631|
NCT00270322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKR-1.CTIL|Pain Treatment After Total Knee Replacement - Continuous Epidural Versus Intravenous Patient Controlled Analgesia With Morphine|Pain Treatment After Total Knee Replacement - Continuous Epidural Versus Intravenous Patient Controlled Analgesia With Morphine||Rambam Health Care Campus||Terminated|January 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|55 Years|85 Years|No|||May 2006|April 10, 2007|December 23, 2005|||We believe regional anesth better for TKR,90% patients got epidural. Last year we started    spinal morphine one shot, and found it very promissing.|No||https://clinicaltrials.gov/show/NCT00270322||186653|
NCT00270634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISA05-01|Study of ISA247 (Voclosporin) in De Novo Renal Transplantation|A Phase IIb, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 (Voclosporin) and Tacrolimus (Prograf®) in De Novo Renal Transplant Patients|PROMISE|Aurinia Pharmaceuticals Inc.|Yes|Completed|January 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|334|||Both|18 Years|65 Years|No|||February 2013|February 11, 2013|December 23, 2005|Yes|Yes||No|October 10, 2012|https://clinicaltrials.gov/show/NCT00270634||186630|By limiting access to patients at relatively low risk for rejection and no delayed graft function, the results observed may not be applicable to all renal transplant recipients.
NCT00270647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448630|Physicians' Health Study II|Physicians' Health Study II: Trial of Vitamins in the Chemoprevention of Cancer, CVD, and Eye Disease|PHS II|Brigham and Women's Hospital|Yes|Completed|July 1997|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|14641|||Male|50 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 17, 2012|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270647||186629|
NCT00271427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAIT|Selenium Treatment in Autoimmune Thyroiditis (AIT)|Selenium Treatment in Autoimmune Thyroiditis: Long Term Follow-Up With Variable Doses||Ege University||Completed|December 2004|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|15 Years|70 Years|No|||December 2004|August 22, 2006|December 30, 2005||||No||https://clinicaltrials.gov/show/NCT00271427||186569|
NCT00265681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-119|Telephone Counseling for Snuff Users|Proactive Telephone Counseling With Rural Smokeless Tobacco Users||HealthPartners Institute|No|Completed|November 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||April 2007|April 3, 2007|December 13, 2005||||No||https://clinicaltrials.gov/show/NCT00265681||187000|
NCT00265902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000452799|Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma|Ultra-Sensitive, Infra-Red Thermographic Analysis of Kaposi's Sarcoma Skin Lesions||National Cancer Institute (NCI)||Active, not recruiting|November 2004|||||N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|No|||June 2006|February 6, 2009|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00265902||186983|
NCT00250601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5571|An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder.||Sanofi||Completed|April 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|460|||Both|18 Years|64 Years|No|||February 2012|February 15, 2012|October 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250601||188132|
NCT00250861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-I-IL2-04-029|Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma|A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue||US Oncology Research||Terminated|October 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|18 Years|N/A||||April 2008|April 17, 2008|November 7, 2005|||Study terminated due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00250861||188112|
NCT00250874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myocet 008 (L017)|Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer|Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer||Zeneus Pharma||Recruiting|December 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Female|18 Years|70 Years|No|||November 2005|November 7, 2005|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00250874||188111|
NCT00251914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-NED-0021|Nexium Dyspepsia/AST|Supportive Test for Acid-Related Symptoms (STARS I) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Subjects With Upper Gastrointestinal Symptoms and With Normal Findings at Esophagogastroduodenoscopy.||AstraZeneca||Completed|December 2002|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1500|||Both|18 Years|70 Years|No|||January 2011|January 21, 2011|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251914||188032|
NCT00251927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612C00003|Esomeprazole (NEXIUM) vs. Surgery|An Open, Randomized, Multicenter, Phase IIIB Study During 5 Years to Assess Long-term Efficacy and Tolerability of Esomeprazole Compared to Laparoscopic Anti-reflux Surgery in Adult Subjects With Gastroesophageal Reflux Disease - LOTUS.|LOTUS|AstraZeneca||Completed|October 2001|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|626|||Both|18 Years|70 Years|No|||August 2012|August 7, 2012|November 9, 2005|Yes|Yes||No|July 8, 2010|https://clinicaltrials.gov/show/NCT00251927||188031|
NCT00252187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69-00|Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure|Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strategy|SubqBNP|Mayo Clinic|Yes|Completed|January 2000|June 2010|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|November 10, 2005|No|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00252187||188011|
NCT00252460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 03-0601-CE|CT/MRI Co-registration Prostate Cancer|Evaluation of Planning Computed Tomography Scan and Magnetic Resonance Imaging Simulator Scan Co-Registration for Delineation of Gross Tumour Volume in Radiotherapy Treatment of Localized Prostate Cancer||University Health Network, Toronto||Completed|November 2003|November 2010|Actual|November 2010|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Actual|31|||Male|18 Years|N/A|No|Non-Probability Sample|prostate cancer patients|March 2016|March 24, 2016|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00252460||187991|
NCT00252473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 02-0832-C|S-Frame CT Immobilization Masks For Patients Undergoing Radiation Therapy For Head and Neck Cancer|Evaluation of Setup Accuracy in Med Tec S-Frame Immobilization Masks For Patients Undergoing Radiation Therapy For Head and Neck Cancer||University Health Network, Toronto||Completed|January 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252473||187990|
NCT00252200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|621-03|BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.|Low Dose Continuous Infusion of BNP (Nesiritide) in the Prevention of Renal Insufficiency Post Cardiopulmonary Bypass Cardiac Surgery.||Mayo Clinic|No|Completed|March 2003|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|November 10, 2005||No||No||https://clinicaltrials.gov/show/NCT00252200||188010|
NCT00252213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218-02|BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling|B-Type Natriuretic Peptide (Nesiritide) and Post Myocardial Infarction Left Ventricular Remodeling: Pilot Study Assessing Safety||Mayo Clinic||Terminated|August 2002|January 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 9, 2009|November 10, 2005|||recruitment of subjects was halted prematurely. recruiting subjects halted prematurely|||https://clinicaltrials.gov/show/NCT00252213||188009|
NCT00252759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791AL00002|Iressa Case Control Study in Japan|A Nested Case-control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib||AstraZeneca||Completed|November 2003|February 2006|Actual|||Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|patients|January 2011|January 27, 2011|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00252759||187968|
NCT00253279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001510|Alterations in Protein Synthesis Rates of Burn Patients Measured Over Time Using PET Scans|A Quantitative Study of the Metabolic Alterations in Protein Synthesis Rate That Occur in Burn Patients Over the Time Course of Their Injury Using Positron Emission Tomography.||National Institute of General Medical Sciences (NIGMS)|Yes|Not yet recruiting|November 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|64|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects and burn patients|August 2009|August 12, 2009|November 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00253279||187928|
NCT00263770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1646-05|Treatment Study of Soft Palatal Implants in Obstructive Sleep Apnea|A Randomized, Controlled Treatment Trial of Soft Palatal Implants and Positive Airway Pressure in Mild to Moderate Obstructive Sleep Apnea and Snoring||Mayo Clinic|No|Completed|December 2005|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|80 Years|No|||May 2011|May 18, 2011|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263770||187142|
NCT00264693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMWHplus 3|Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function|Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function||Luzerner Kantonsspital||Completed|January 2006|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Actual|96|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of a medical and surcigal department with all levels of renal function who needs        Dalteparin for prophylaxis or therapy.|August 2009|January 25, 2010|December 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00264693||187073|
NCT00270088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005899|A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.|A Double-Blind, Placebo-Controlled Study to Determine Whether Procrit� (Epoetin Alfa) Can Reduce Peri-Operative Transfusion Requirements in Subjects Undergoing Major Orthopedic Surgery||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 1993|August 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|316|||Both|18 Years|N/A|No|||February 2011|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270088||186671|
NCT00270335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005400-17|Optimizing Propofol in Obese Patients|Optimizing Propofol in Obese Patients||Rigshospitalet, Denmark|No|Completed|January 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|N/A|No|||October 2009|October 15, 2009|December 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00270335||186652|
NCT00270660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06a/2003-04|A Study of the Clinicopathologic Behaviour of the Different Types of Unsafe Chronic Otitis Media|A Cross Sectional Study of Clinicopathologic Behaviour of Primary, Secondary and Mixed Types of Atticoantral Chronic Otitis Media||Karnataka Institute of Medical Sciences||Active, not recruiting|July 2003|December 2005||||Phase 3|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||192|||Both|8 Years|N/A|No|||December 2005|November 29, 2006|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00270660||186628|
NCT00270881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSGCT-CB2005|Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies|Phase 1/2 Study of Cord Blood Transplantation From Unrelated Donor for Adult Patients With Hematologic Malignancies Using Myeloablative Conditioning Regimen||Keio University|Yes|Completed|January 2006|January 2011|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|20 Years|55 Years|No|||April 2012|April 5, 2012|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00270881||186611|
NCT00267072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328.01|Ovarian Screening Study|The University of Louisville Ovarian Screening Study||James Graham Brown Cancer Center|Yes|Completed|June 2001|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Female|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|April 2013|April 22, 2013|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267072||186894|
NCT00267085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0392|Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease|A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease||M.D. Anderson Cancer Center|Yes|Completed|December 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|December 19, 2005|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00267085||186893|
NCT00250887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0526|Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research|A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research||University of Zurich|No|Completed|July 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2007|October 22, 2007|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00250887||188110|
NCT00251121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05116|Routine Mini-invasive Electrophysiology Study for Patients Feeling Tachycardia, With a Negative Holter ECG|Mini-invasive Electrophysiology Study as a Routine Examination for Patients Complaining of Tachycardia, But With a Negative Holter ECG.||Sykehuset Telemark|No|Completed|November 2005|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Both|18 Years|75 Years|No|||February 2012|February 8, 2012|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00251121||188092|
NCT00251628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR #H7097-14918-13|Home Care Management of Pediatric Pain|Home Care Management of Pediatric Pain||University of California, San Francisco|No|Completed|June 2000|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|211|||Both|6 Years|15 Years|No|||June 2012|June 7, 2012|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251628||188053|
NCT00251641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04271|The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)|An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis||Merck Sharp & Dohme Corp.|Yes|Completed|September 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|868|||Both|18 Years|75 Years|No|||January 2015|January 22, 2015|November 8, 2005||No||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00251641||188052|
NCT00251654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA001|Complications and Adverse Effects in Continuous Peripheral Regional Anesthesia|Complications and Adverse Effects in Continuous Peripheral Regional Anesthesia Results of Investigations on 3,491 Catheters||Rechbergklinik Bretten|No|Completed|January 2002|December 2008|Actual|December 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|9000|||Both|1 Year|N/A|No|Non-Probability Sample|All patients receiving perineural blocks via catheter ASA 1 to 4|September 2009|September 30, 2009|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00251654||188051|
NCT00251940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00032|GALLANT 7 Tesaglitazar Add-on to Sulphonylurea|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone||AstraZeneca||Terminated|July 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||555|||Both|18 Years|N/A|No|||March 2008|March 14, 2008|November 9, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00251940||188030|
NCT00252499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-044-08S|Insulin Resistance in Non-alcoholic Fatty Liver Disease|Insulin Resistance in Non-alcoholic Fatty Liver Disease||VA Office of Research and Development|No|Terminated|October 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|13|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|November 9, 2005|No|Yes|Protocol drug change required new clinicaltrails.gov entry|No|November 12, 2013|https://clinicaltrials.gov/show/NCT00252499||187988|Due to recruitment difficulties and concerns about the safety of thiazolidinediones, recruitment was stopped without achieving adequate sample size (16/arm). Thus, no definitive conclusions can be made about the study medications.
NCT00253058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104912|Study Of Perennial Allergic Rhinitis In Pediatrics|Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Perennial Allergic Rhinitis-||GlaxoSmithKline|No|Completed|July 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||286|||Both|3 Years|14 Years|No|||May 2013|May 3, 2013|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253058||187945|
NCT00240851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002881|An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in Treating Muscle Aches and Soreness That Occur After a Marathon Race|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) in the Treatment of Post-Race Muscle Aching and Pain (Soreness)||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|665|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240851||188866|
NCT00264381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10341|Management of Superficial Thrombophlebitis|Management of Superficial Thrombophlebitis||University of Oklahoma|No|Completed|October 2002|September 2011|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|December 8, 2005|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00264381||187097|
NCT00270309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64582|Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms|Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms. A Randomised Controlled Trial Against Standard Therapy||The Royal College of Surgeons of England||Completed|January 2004|October 2006|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||168|||Male|40 Years|N/A|No|||December 2005|May 5, 2015|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270309||186654|
NCT00269854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006256|An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease|A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease||Centocor, Inc.|No|Completed|June 1995|October 1996|Actual|October 1996|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|108|||Both|18 Years|65 Years|No|||November 2014|November 3, 2014|December 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00269854||186689|
NCT00270101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005911|The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma|A Placebo-Controlled Study on the Effect of r-huEPO in Patients With Multiple Myeloma Followed by an Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 1995|September 1996|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|156|||Both|40 Years|80 Years|No|||January 2011|May 17, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270101||186670|
NCT00270673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-334|Early Lactate-Directed Therapy in the Intensive Care Unit (ICU)|Early Lactate-Directed Therapy on the ICU: A Randomized Controlled Trial||Erasmus Medical Center|Yes|Completed|February 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|350|||Both|18 Years|N/A|No|||April 2008|April 24, 2008|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00270673||186627|
NCT00270907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0133|CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer|A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Completed|December 2005|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00270907||186609|
NCT00270920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUS IRB 03003|A Randomised Controlled Trial to Compare Antenatal Preparation and Postnatal Counseling|A Randomised Controlled Trial to Compare Antenatal Preparation and Postnatal Counseling Strategies for Improving Breastfeeding Rates||National University Hospital, Singapore||Completed|February 2004|March 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||450|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2008|July 10, 2008|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00270920||186608|
NCT00270894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN ALSSNBC0401|Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients|Pilot Trial of Sequential Dose-Dense Neoadjuvant Chemotherapy Plus Herceptin in HER2 Positive Stage II-III Breast Cancer Patients||Accelerated Community Oncology Research Network|No|Completed|November 2005|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||March 2012|March 15, 2012|December 28, 2005|Yes|Yes||No|November 18, 2011|https://clinicaltrials.gov/show/NCT00270894||186610|
NCT00271661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-1-0072|Presbyopia in Breast Cancer Survivors|Presbyopia in Breast Cancer Survivors||AHS Cancer Control Alberta|No|Withdrawn|August 2005|May 2006||||N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|45 Years|60 Years|No|Non-Probability Sample|primary care clinic|December 2011|December 8, 2011|December 30, 2005||||No||https://clinicaltrials.gov/show/NCT00271661||186552|
NCT00271674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-275533|YAG Laser Versus Punch Biopsy for the Treatment of Tattoo Skin Markers|||Bispebjerg Hospital||Completed|January 2006|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||June 2008|June 2, 2008|January 3, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00271674||186551|
NCT00250900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WASPYALE2005|Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial|Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial||Yale University||Completed|July 2004|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|6 Months|12 Years||||November 2005|November 29, 2006|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00250900||188109|
NCT00251134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMEGA|OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction|OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.|OMEGA|Stiftung Institut fuer Herzinfarktforschung|Yes|Completed|October 2003|September 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3800|||Both|18 Years|N/A|No|||September 2008|September 11, 2008|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251134||188091|
NCT00251147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10368|A Randomized Clinical Trial Comparing Open to Mini-Open Rotator Cuff Repair for Full-Thickness Rotator Cuff Tears.|Prospective Randomized Study Comparing Open Acromioplasty and Rotator Cuff Repair Versus Arthroscopic Acromioplasty and Mini-Open Rotator Cuff Repair.||University of Calgary|No|Completed|March 1999|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00251147||188090|
NCT00251355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-105|Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer|A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 1998|December 2014|Anticipated|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|72 Years|No|||April 2014|April 29, 2014|November 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00251355||188074|
NCT00251368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-115|Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia|Multicenter Study of 9-AC in Refractory Leukemia||Dana-Farber Cancer Institute|Yes|Completed|January 1995|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|November 8, 2005||||No||https://clinicaltrials.gov/show/NCT00251368||188073|
NCT00251953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00031|GALLANT 8 Tesaglitazar Add-on to Metformin|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Metformin Alone||AstraZeneca||Terminated|July 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||555|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|November 9, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00251953||188029|
NCT00252226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441L00024|Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders|Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders: An Open Prospective Longitudinal Study of the Effectiveness of Quetiapine Monotherapy in Preventing Relapse and Minimizing Neurocognitive Dysfunction Among Adolescents Manifesting Bipolar Spectrum Disorders||Mood Disorders Center of Ottawa||Completed|June 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||June 2008|June 2, 2008|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00252226||188008|
NCT00252239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11231|Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)|Phase 2B Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)||University of Virginia|Yes|Terminated|November 2005|September 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|November 10, 2005|Yes|Yes|Slow enrollment|No|January 12, 2015|https://clinicaltrials.gov/show/NCT00252239||188007|Premature termination limits any conclusions from the trial.
NCT00252772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00026|GALLANT 2 Tesaglitazar vs. Placebo|A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes||AstraZeneca||Terminated|September 2004|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|November 10, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00252772||187967|
NCT00240643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101724|Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke|See Detailed Description||GlaxoSmithKline||Completed|November 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||640|||Both|18 Years|75 Years|No|||February 2013|February 11, 2013|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240643||188882|
NCT00269243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAGINE ID: 906-437|Management With Accupril Post Bypass Graft|The Ischemia Management With Accupril Post Bypass Graft Via Inhibition of the coNverting Enzyme (IMAGINE) Trial||Montreal Heart Institute||Completed|November 1999|May 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||December 2005|February 6, 2006|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00269243||186734|
NCT00269256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1322|Stress, Environment, and Genetics in Urban Children With Asthma|Stress, Environment, and Genetics in Urban Asthma||Brigham and Women's Hospital|No|Completed|September 2005|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|959|Samples With DNA|Maternal DNA Child DNA|Both|18 Years|50 Years|No|Non-Probability Sample|Pregnant women and their children followed over first 5 years.|February 2016|February 2, 2016|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00269256||186733|
NCT00270075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005896|A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery|Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Orthopedic or Cardiovascular Surgery, to Facilitate Presurgical Autologous Blood Donation (A Double-blind, Randomized, Dose Finding Study)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 1990|May 1992|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|80|||Both|18 Years|N/A|No|||February 2011|May 17, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270075||186672|
NCT00269867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006259|Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis|A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment||Centocor, Inc.|No|Completed|March 1997|March 2000|Actual|March 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|428|||Both|18 Years|75 Years|No|||November 2014|November 3, 2014|December 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00269867||186688|
NCT00270348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS6159|Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma|A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 Mg/Day and 200 Mg/Day (Ex-Valve) Administered Once Daily on Growth in Children With Mild Persistent Asthma||Sanofi||Completed|December 2000|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|5 Years|102 Months|No|||December 2005|December 27, 2005|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270348||186651|
NCT00270699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 214|Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2006|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|December 27, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00270699||186625|
NCT00271466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005977|A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief Therapy|A Study to Assess the Safety, Dose Conversion and Titration of DURAGESIC® (Fentanyl Transdermal System) in Pediatric Subjects With Chronic Pain Requiring Opioid Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2000|April 2002|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|199|||Both|2 Years|15 Years|No|||April 2010|May 17, 2011|December 30, 2005||||||https://clinicaltrials.gov/show/NCT00271466||186566|
NCT00271180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602|Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products|Medtronic CRDM Product Performance Report|PPR|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|January 1983|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|N/A|N/A|No|Non-Probability Sample|Subjects implanted with Medtronic qualifying cardiac rhythm product.|September 2014|September 12, 2014|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00271180||186588|
NCT00250666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG 05-146|Procalcitonin-Guided Antimicrobial Discontinuation|Procalcitonin-Guided Antimicrobial Discontinuation Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Sepsis||University Hospital, Geneva||Completed|January 2006|May 2007|Actual|May 2007||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|70|||Both|18 Years|N/A|No|||July 2008|July 7, 2008|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00250666||188127|
NCT00250913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 5626|The Efficacy and Cost-Effectiveness of Behavioral Counseling for Exercise in Men and Women Following Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI)|Efficacy and Cost-Effectiveness of Behavioral Counseling For Exercise Behavior in Men and Women Following AMI and PCI||Ottawa Heart Institute Research Corporation||Completed|August 2005|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|304|||Both|20 Years|85 Years|No|||November 2010|November 5, 2010|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250913||188108|
NCT00251693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-EE04-084|Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis|A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis||Takeda|No|Completed|December 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2038|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|November 8, 2005|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00251693||188049|
NCT00251381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62202-655|Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.|Open Label Randomized Phase II, Multicentre, Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Concomitant-Boost Accelerated Radiotherapy Followed or Not by a Complementary Treatment With Cetuximab in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.||Trial Form Support S.L.||Recruiting|November 2005|November 2009||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|80 Years|No|||October 2006|October 25, 2006|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251381||188072|
NCT00251680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-475/EC304|Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.|A Placebo-Controlled, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in Subjects With Type 2 Diabetes Currently Treated With Lipid-Lowering Therapy||Takeda|No|Completed|October 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|November 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251680||188050|
NCT00252252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LF009B|AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation|Crossover Trial of VPAP (Variable Positive Airway Pressure) Ventilation Versus AutoVPAP in Neuromuscular and Chest Wall Disease: Effects on Nocturnal Hypoventilation, Sleep Quality and Tolerance||ResMed||Completed|November 2005|December 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||June 2008|June 20, 2008|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00252252||188006|
NCT00252512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-120|The Effect of a Contingency Management Intervention on Substance Use|Effectiveness of Contingency Management in VA Addictions Treatment|REAP|VA Office of Research and Development|Yes|Completed|May 2007|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||July 2014|April 6, 2015|November 9, 2005||No||No|August 18, 2014|https://clinicaltrials.gov/show/NCT00252512||187987|
NCT00252525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465B|Correlation of Plasma Endothelial Cell Activity With Cardiovascular Events in Patients With Diabetes Mellitus Type 2|CSP #465B - Correlation of Plasma Endothelial Cell (Basic Fibroblast Growth Factor) Activity With Cardiovascular Events In Patients With Diabetes Mellitus Type 2||VA Office of Research and Development|Yes|Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|400|None Retained|The cohort consisted of patients that participated in the 465 main study.|Both|40 Years|N/A|No|Probability Sample|This is an observational study of patients who are enrolled in the ongoing randomized        clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.|June 2014|June 26, 2014|November 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00252525||187986|
NCT00244751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBX104114|Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects|A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy||GlaxoSmithKline||Completed|November 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|225|||Both|40 Years|70 Years|No|||November 2009|November 5, 2009|October 25, 2005||||||https://clinicaltrials.gov/show/NCT00244751||188570|
NCT00244764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG102616|GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma|A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma||GlaxoSmithKline|Yes|Completed|October 2005|September 2013|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|21 Years|N/A|No|||August 2014|September 24, 2015|October 25, 2005|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00244764||188569|
NCT00244777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDRB 2002-026|Introduction of Hypo-osmolar ORS for Routine Use|Introduction of New Hypo-osmolar ORS Into Routine Use in the Management of Diarrhoeal Disease: a Phase IV Clinical Surveillance.||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|December 2002|February 2004||February 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75000|||Both|N/A|N/A|No|||October 2005|June 11, 2015|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00244777||188568|
NCT00245024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447144|Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer|Phase IB Sulindac Study for Women at High Risk for Breast Cancer||National Cancer Institute (NCI)||Completed|November 2005|January 2010|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|30|||Female|18 Years|65 Years|No|||October 2011|May 1, 2013|October 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00245024||188549|
NCT00245037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447204|Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation|Bu Flu TBI|OHSU Knight Cancer Institute|Yes|Active, not recruiting|June 2005|August 2015|Anticipated|March 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|80 Years|No|||July 2015|July 24, 2015|October 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00245037||188548|
NCT00269568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pittirb0404133|Mifepristone at Same Time Multicenter Study|A Multicenter, Randomized Comparison of Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion Through 63 Days|MAST|University of Pittsburgh|No|Completed|June 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1128|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269568||186709|
NCT00269542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002|Impact of Zinc Supplementation on Mortality and Hospitalizations in Children Aged 1 Months to 23 Months|Impact of Zinc Supplementation on Mortality and Hospitalizations in Children Aged 1 Months to 23 Months||Society for Applied Studies|Yes|Completed|February 2002|August 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|94359|||Both|1 Month|35 Months|Accepts Healthy Volunteers|||June 2008|June 30, 2008|December 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00269542||186711|
NCT00269841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006253|An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease|A Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease||Centocor, Inc.|No|Completed|May 1996|February 1998|Actual|February 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|65 Years|No|||November 2014|November 3, 2014|December 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00269841||186690|
NCT00270114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005914|A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)|Recombinant Human Erythropoietin (r-HuEPO) in Patients With Low Hematocrit Levels to Facilitate Presurgical Autologous Blood Donation in Patients Undergoing Orthopedic Surgery (An Open-label Dose Finding Study)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||March 1991|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270114||186669|
NCT00270946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-VLU-01-CLN|Evaluation of Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers|A Pivotal Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers||Ortec International||Completed|April 2002|December 2003||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|18 Years|85 Years|No|||December 2005|December 28, 2005|December 28, 2005||||||https://clinicaltrials.gov/show/NCT00270946||186606|
NCT00270387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005209|A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy|Prospective Randomized Outcomes Study of Acutely Decompensated Congestive Heart Failure Treated Initially in Outpatients With Natrecor (Nesiritide) - The PROACTION Trial||Scios, Inc.||Completed|January 2001|January 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|250|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270387||186648|
NCT00270712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT DeKAF|A Study of Factors That Affect Long-Term Kidney Transplant Function|Study of Long-term Deterioration of Kidney Allograft Function (DeKAF)|DeKAF|University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|October 2005|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|3175|Samples With DNA|Blood and urine specimens.|Both|N/A|N/A|No|Non-Probability Sample|Kidney transplant recipients|December 2015|December 16, 2015|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270712||186624|
NCT00271206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014537|Effect of Progesterone on Smoking Behavior in Male and Female Smokers|Progesterone and the Effects of Nicotine||Yale University|Yes|Completed|September 2004|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|40 Years|No|||July 2012|July 24, 2012|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00271206||186586|
NCT00271219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA15764-1|RCT Comparing Methadone and Buprenorphine in Pregnant Women|Maternal Opioid Treatment: Human Experimental Research||Johns Hopkins University|Yes|Completed|July 2005|June 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Female|18 Years|41 Years|No|||July 2015|July 30, 2015|December 28, 2005|Yes|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT00271219||186585|
NCT00271479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-04-MEN-04|Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine|Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa||Epicentre||Completed|June 2004|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||720|||Both|2 Years|20 Years|Accepts Healthy Volunteers|||December 2006|December 21, 2006|December 29, 2005||||No||https://clinicaltrials.gov/show/NCT00271479||186565|
NCT00271193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00271193|A Primary Care Intervention for Weight Management|A Primary Care Intervention for Weight Management||University of Colorado, Denver||Completed|September 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271193||186587|
NCT00251160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10650|Electrothermal Arthroscopic Capsulorrhaphy (ETAC) and Open Inferior Capsular Shift in Patients With Shoulder Instability|Arthroscopic Electrothermal Capsulorrhaphy, ETAC, Versus Open Inferior Capsular Shift, ICS in Patients With Shoulder Instability: A Multicentre Randomized Clinical Trial||University of Calgary|Yes|Completed|December 1999|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|14 Years|N/A|No|||July 2015|July 9, 2015|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00251160||188089|
NCT00251394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-411|Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma|A Phase 2, Open-Label Study of the Efficacy, Safety, and Tolerability of Dynavax's Immunostimulatory Phosphorothiolate Oligodeoxyribonucleotide, 1018 ISS, Following Rituxan (Rituximab) Treatment in Patients With CD20+, B-Cell Follicular Non-Hodgkin's Lymphoma.||Dana-Farber Cancer Institute||Completed|July 2004|July 2009|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2009|January 28, 2010|November 8, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00251394||188071|
NCT00243854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507-08 IUCRO-0130|Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer|Pilot Study Using Neoadjuvant Chemo-Radiotherapy and EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer||Indiana University|Yes|Completed|November 2005|October 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|October 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00243854||188638|
NCT00251966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9617C00011|ASTERIX: Low Dose ASA and Nexium|A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.||AstraZeneca||Completed|May 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||960|||Both|60 Years|N/A|No|||March 2009|March 11, 2009|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251966||188028|
NCT00251979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961DC00001|A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer|A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.||AstraZeneca||Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|1312|||Both|18 Years|N/A|No|||May 2011|May 18, 2011|November 9, 2005||||No|December 12, 2008|https://clinicaltrials.gov/show/NCT00251979||188027|
NCT00244387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0515|Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa|A Multi-centre, Multi-national, Phase 3, Randomized, Double-blind, Double-dummy, 3- Arm Parallel Group, Placebo- and Pramipexole- Controlled Trial of the Efficacy and Safety of Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa||UCB Pharma||Completed|March 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|506|||Both|30 Years|N/A||||February 2010|September 24, 2014|October 24, 2005||Yes||||https://clinicaltrials.gov/show/NCT00244387||188598|
NCT00244400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|338|Examine the Possible Association of Hepatic CYP3A Activity and the Susceptibility to Femur Head Necrosis|||Osaka City University||Completed|November 2002|January 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|14 Years|70 Years|Accepts Healthy Volunteers|||October 2006|October 16, 2006|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244400||188597|
NCT00244413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10263|Characteristics of Nondystrophic Myotonias|Nondystrophic Myotonias: Genotype-phenotype Correlation and Longitudinal Study||University of Kansas Medical Center||Completed|February 2006|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|Samples With DNA|Blood samples|Both|6 Years|N/A|No|Non-Probability Sample|Individuals with nondystrophic myotonia|March 2013|March 5, 2013|October 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00244413||188596|
NCT00244790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309-03|The Effects of Obesity and Protein Intake on the Kidney|The Effects of Obesity and Protein Intake on the Kidney||Indiana University|Yes|Completed|April 2004|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 26, 2015|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00244790||188567|
NCT00240396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005p000205|Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture|Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture||Beth Israel Deaconess Medical Center||Recruiting|October 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||November 2005|November 16, 2005|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240396||188901|
NCT00240409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.516|Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease|A Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole Tablets and Bromocriptine Tablets in Patients With Parkinson's Disease.||Boehringer Ingelheim||Completed|July 2003|August 2004||August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|208|||Both|30 Years|80 Years|No|||November 2013|November 1, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240409||188900|
NCT00270127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005917|Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy|Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving Non-Platinum-Containing Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 1996|September 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|375|||Both|18 Years|N/A|No|||January 2011|May 17, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270127||186668|
NCT00269555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412146|Effects of GCP on Prostate Cancer.|Effects of a Genistein Combined Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.||University of California, Davis||Completed|May 2004|September 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||62|||Male|N/A|N/A|No|||June 2010|June 25, 2010|December 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00269555||186710|
NCT00270686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903330|Studies of Heritable Disorders of Connective Tissue|Clinical and Molecular Manifestations of Heritable Disorders of Connective Tissue||National Institutes of Health Clinical Center (CC)||Completed|January 2003|January 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1335|||Both|2 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 3, 2015|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270686||186626|
NCT00270933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232|MAVRIC VR ICD Registry|Marquis/Maximo VR ICD Programming Practices Registry (MAVRIC VR ICD Registry)||Medtronic Cardiac Rhythm Disease Management||Completed|January 2004|December 2005||||N/A|Observational|Time Perspective: Prospective||||742|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|December 28, 2005||||No||https://clinicaltrials.gov/show/NCT00270933||186607|
NCT00270400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005200|A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure|Natrecor (Nesiritide) Versus Dobutamine Therapy for Symptomatic, Decompensated CHF: A Safety Study Using 24-Hour Holter Monitoring - The PRECEDENT Trial: Prospective, Randomized Evaluation of Cardiac Ectopy With Dobutamine or Natrecor Therapy||Scios, Inc.||Completed|August 1998|February 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|255|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270400||186647|
NCT00270998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDN 13|ATLAS: Ambulatory Treatments for Leakage Associated With Stress|ATLAS: Ambulatory Treatments for Leakage Associated With Stress, A Randomized Trial of Pelvic Muscle Exercise Versus Incontinence Pessary Versus Both for Women With Stress or Mixed Urinary Incontinence||NICHD Pelvic Floor Disorders Network|Yes|Completed|June 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|450|||Female|21 Years|N/A|No|||September 2013|September 27, 2013|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270998||186602|
NCT00270959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073613|Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury|Early Combined Intervention After Traumatic Injury||University of Washington|Yes|Active, not recruiting|June 2006|December 2015|Anticipated|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00270959||186605|
NCT00270972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-VLU-02-CLN|The Evaluation of OrCel for the Treatment of Venous Ulcers|A Confirmatory Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (ORCEL) for the Treatment of Venous Ulcers||Ortec International||Active, not recruiting|September 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|85 Years|No|||June 2006|June 2, 2006|December 28, 2005||||||https://clinicaltrials.gov/show/NCT00270972||186604|
NCT00271232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199|InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System|InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System||Medtronic Cardiac Rhythm Disease Management||Completed|March 2003|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||238|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|December 28, 2005||||||https://clinicaltrials.gov/show/NCT00271232||186584|
NCT00271726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTEC Pilot 1 KKS MR|Operative Treatment of Extraarticular Colles' Fractures of the Distal Radius (OTEC)|Prospective, Randomized, Multi-Center Pilot Study on the Treatment of Unstable, Extraarticular Colles Fractures of the Distal Radius by Palmar Locking Plate, External Fixator or Kirschner Wires||Heinrich-Heine University, Duesseldorf||Recruiting|November 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|65 Years|N/A|No|||April 2007|April 25, 2007|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00271726||186547|
NCT00243347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00015|The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer|An Exploratory, Open-Lael Study to Assess the Effects of AZD2171 on Tumors and Biomarkers in Patients With Previously Untreated or Recurrent Non-small Cell Lung Cancer (NSCLC) or Patients With Metastatic or Recurrent Head and Neck Cancer (HNC)||AstraZeneca||Completed|December 2005|July 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|October 21, 2005|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00243347||188677|
NCT00243581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SACCM Ornish Clinical Trial|The Effects of an Intensive Lifestyle Modification Program on Carotid Artery Intima-Media Thickness|The Effects of an Intensive Lifestyle Modification Program on Carotid Artery Intima-Media Thickness||SwedishAmerican Health System||Completed|August 2000|May 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A||||May 2005|October 28, 2005|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00243581||188659|
NCT00243841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0404-20|Dose Escalation Study for Primary Hepatocellular Carcinoma|Multi-institution Phase I/II Dose Escalation Study of Hypofractionated Stereotactic Body Radiation Therapy for Primary Hepatocellular Carcinoma|SBF-HCC|Indiana University|Yes|Active, not recruiting|May 2004|December 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243841||188639|
NCT00243594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-3126|Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection|Active Immunization of Patients With Stage III and IV Melanoma in Whom a Regional Lymph Node Dissection is Planned, With Peptide-Pulsed Dendritic Cells: Evaluation of in Vivo Immune and Clinical Response and Migration||Radboud University|No|Completed|September 1999|||January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||February 2009|February 18, 2009|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243594||188658|
NCT00244153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mor01|Intraarticular Opioids Vs Glucocorticosteroids in Gonarthritis|Intraarticular Application of Opioids Versus Glucocorticosteroids Versus Placebo in Rheumatoid Arthritis||Charite University, Berlin, Germany||Recruiting|June 2004|August 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|19 Years|N/A|No|||February 2004|September 7, 2006|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244153||188616|
NCT00244166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-01|Prednisolone in Active Ankylosing Spondylitis (AS)|Threecenter Placebo Controlled Three Arm Trial in Patients With Active Ankylosing Spondylitis With Prednisolone||Charite University, Berlin, Germany||Recruiting|May 2002|August 2008||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|70 Years|No|||September 2006|September 7, 2006|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244166||188615|
NCT00244439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALG-0506|Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice|A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05%Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis||Taro Pharmaceuticals USA|No|Completed|December 2005|December 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|2 Years|N/A|No|||November 2013|December 19, 2013|October 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244439||188594|
NCT00244803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-07-02-01|Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)|Redistribution and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)||Johns Hopkins University||Active, not recruiting|January 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||101|||Both|18 Years|65 Years|No|||September 2003|October 25, 2005|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244803||188566|
NCT00244816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-04-22|Taxoprexin® Treatment for Advanced Eye Melanoma|Phase II Open-Label Study of Weekly Taxoprexin® (DHA-Paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma||Luitpold Pharmaceuticals||Completed|October 2005|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|13 Years|N/A|No|||January 2009|January 14, 2009|October 25, 2005||||||https://clinicaltrials.gov/show/NCT00244816||188565|
NCT00240422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.398|Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes|A Prospective, Randomized, Double-blind, Double-dummy, Forced Titration, Parallel Group Comparison, Multicenter Trial to Compare the Effects of Either Telmisartan (40-80 mg p.o. Once Daily) or Ramipril (5-10 mg p.o. Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes||Boehringer Ingelheim||Completed|February 2003|July 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|96|||Both|30 Years|80 Years|No|||November 2013|November 7, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240422||188899|
NCT00240682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001098-82|Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR|Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR.|CTXSCC|Centre Hospitalier of Chartres|Yes|Completed|October 2005|June 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||August 2009|February 18, 2012|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00240682||188879|
NCT00269594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510M77009|An Open-Label Study Of Lamictal In Neurotic Excoriation|An Open-Label Study of Lamictal In Neurotic Excoriation||University of Minnesota - Clinical and Translational Science Institute||Completed|January 2006|September 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2007|April 27, 2007|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269594||186707|
NCT00269880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006262|A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Clinical Outcomes Following Percutaneous Coronary Intervention in Patients Treated With an Abciximab Bolus Plus 12-Hour Infusion Given With Either Standard-Dose Weight-Adjusted Heparin or Low-Dose Weight-Adjusted Heparin||Centocor, Inc.||Completed|February 1995|December 1995|Actual|December 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2792|||Both|21 Years|N/A|No|||May 2015|May 22, 2015|December 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00269880||186687|
NCT00270140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005920|A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.|A Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Multiple Doses of R-HuEPO in Facilitating Presurgical Autologous Blood Donation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 1989|August 1991|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|17|||Both|12 Years|N/A|No|||February 2011|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270140||186667|
NCT00270374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005206|A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure||Scios, Inc.||Completed|October 1999|August 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|498|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270374||186649|
NCT00270725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTC-BU-01|Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa|The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS||Boston University||Terminated|July 2005|July 2005|Actual|||N/A|Observational|N/A||1||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|see elig|March 2011|March 29, 2011|December 27, 2005|||Enrollment never initiated, study withdrawn.|No||https://clinicaltrials.gov/show/NCT00270725||186623|
NCT00271297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05146|Pelvic Floor Muscle Training (PFMT) in Treatment and Prevention of POP (POP Study)|Effect of Pelvic Floor Muscle Training (PFMT) in Prevention and Treatment of Female Pelvic Organ Prolapse (POP).||Norwegian School of Sport Sciences||Completed|December 2005|April 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|168|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|December 29, 2005||||No||https://clinicaltrials.gov/show/NCT00271297||186579|
NCT00270985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120050322|The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes|The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes||Rutgers, The State University of New Jersey|No|Active, not recruiting|January 2006|July 2016|Anticipated|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270985||186603|
NCT00271245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK58763-c|Selenium Supplementation of Patients With Cirrhosis|Selenium Supplementation of Patients With Cirrhosis||Vanderbilt University|Yes|Terminated|February 2006|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|December 29, 2005||No|Insufficient funds to complete study.|No||https://clinicaltrials.gov/show/NCT00271245||186583|
NCT00271258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9524|Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents|STUDY OF THE TOLERANCE OF SODIUM DIVALPROATE (DEPAKOTE) IN ADOLESCENTS IN MANIC, MIXED OR HYPOMANIC EPISODES OF BIPOLAR DISORDER|ADOKOT|Sanofi|No|Completed|January 2005|January 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|13 Years|18 Years|No|||January 2011|January 10, 2011|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271258||186582|
NCT00271271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8907|Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients|Phase II Clinical Trial With the Combination Gemcitabine, Oxaliplatin and Vinorelbine as First Line Treatment in Patients With Non-small Cell Bronchopulmonary Cancer|GON|Sanofi|No|Completed|June 2003|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271271||186581|
NCT00271505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0224|Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer|A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2005|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271505||186563|
NCT00271739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5372|Randomized Trial of Telemedicine for Diabetes Care|Informatics for Diabetes Education and Telemedicine (IDEATel)|IDEATel|Columbia University|Yes|Completed|December 2000|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1665|||Both|55 Years|N/A|No|||November 2012|November 19, 2012|December 30, 2005||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00271739||186546|
NCT00271752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASS|The Procalcitonin and Survival Study|The Procalcitonin and Survival Study - A Multicentre Single Blinded Randomized Controlled Trial to Investigate if Treatment Guided by Daily Procalcitonin Measurements Can Reduce Mortality in the Intensive Care Unit|PASS|Danish Procalcitonin Study Group|Yes|Completed|January 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1200|||Both|18 Years|N/A|No|||March 2010|March 3, 2010|January 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00271752||186545|
NCT00243113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000439499|Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx|Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness||National Cancer Institute (NCI)||Completed|June 2004|November 2008|Actual|March 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|N/A|No|||March 2008|March 25, 2013|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00243113||188695|
NCT00243360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U18HS011113-01|Optimizing Antibiotic Use in Long Term Care|Optimizing Antibiotic Use in Long Term Care||Agency for Healthcare Research and Quality (AHRQ)||Completed|January 2001|July 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|N/A|No|||October 2005|October 21, 2005|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00243360||188676|
NCT00243373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS14053-02|Using Barcode Technology to Improve Medication Safety|Using Barcode Technology to Improve Medication Safety||Brigham and Women's Hospital||Completed|April 2005|March 2008|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|6700|||Both|N/A|N/A|No|||January 2012|January 18, 2012|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243373||188675|
NCT00243607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD175-05|Hydrotherapy Against Menopausal Symptoms in Breast Cancer Survivors|Prospective Randomized Feasibility Study on the Self Application of Hydrotherapy to Treat Menopausal Symptoms Caused by Breast Cancer Therapy||Heidelberg University|No|Completed|May 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|N/A|No|||June 2009|June 19, 2009|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243607||188657|
NCT00243867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-04-20|Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer|A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer||Luitpold Pharmaceuticals|No|Completed|November 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|519|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|October 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00243867||188637|
NCT00244192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-073|Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia||Center for Integrated Rehabilitation and Organ Failure Horn||Completed|October 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|40 Years|80 Years|No|||October 2005|December 8, 2005|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244192||188613|
NCT00244426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293-CVD-9010-004|S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation|II Italian Study on Atrial Fibrillation (S.I.F.A. II): Prevention of Thromboembolic Events in Patients With Non Valvular Atrial Fibrillation.|SIFA|Pfizer|No|Completed|December 2000|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1372|||Both|18 Years|N/A|No|||October 2009|October 29, 2009|October 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244426||188595|
NCT00244829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1867.00|Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia|A Multicenter Pilot Study Evaluating the Safety and Efficacy of Imatinib as Post-Transplant Therapy for High- Risk Philadelphia Chromosome-Positive Leukemias||Fred Hutchinson Cancer Research Center||Completed|January 2004|August 2007|Actual|||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2011|November 28, 2011|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244829||188564|
NCT00244842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISA04-03|Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis|A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients|SPIRIT|Aurinia Pharmaceuticals Inc.|Yes|Completed|December 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|451|||Both|18 Years|65 Years|No|||September 2008|September 24, 2008|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00244842||188563|
NCT00240435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.252|12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD|A Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison of 12-week Treatment of Two Doses (5 Mcg and 10 Mcg) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) i||Boehringer Ingelheim||Completed|November 2002|||December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||491|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240435||188898|
NCT00240448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.421|A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension||Boehringer Ingelheim||Completed|September 2003|||June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1109|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240448||188897|
NCT00240695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005947|A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment|An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2003|May 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|724|||Both|50 Years|N/A|No|||April 2010|May 17, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240695||188878|
NCT00240474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.400|A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)|A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)||Boehringer Ingelheim||Completed|December 2002|March 2004||March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|60 Years|N/A|No|||October 2013|October 31, 2013|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240474||188895|
NCT00269607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11899|Naltrexone Implants as Relapse Prevention|Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction.||University of Oslo||Terminated|May 2005|December 2006|Actual|December 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|19 Years|N/A|No|||December 2005|December 10, 2013|December 22, 2005||No|Recruitment difficulties. Reframed as pilot study|No||https://clinicaltrials.gov/show/NCT00269607||186706|
NCT00270361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003316|FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.|Management of Patients With CHF After Hospitalization-Follow up Serial Infusions of NATRECOR (Nesiritide) - FUSION I, A Pilot Study||Scios, Inc.||Completed|December 2001|January 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|214|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270361||186650|
NCT00270153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMCIRBPN03-12-311|The Use of ACE Inhibitors in the Early Renal Post-transplant Period|The Use of ACE Inhibitors in the Early Renal Post-transplant Period||Montefiore Medical Center|No|Completed|September 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|110|||Both|21 Years|80 Years|No|||November 2009|September 15, 2011|December 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00270153||186666|
NCT00271011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005-060|A Study of Mitomycin C, Irinotecan, and Cetuximab|A Phase II Study of Mitomycin C, Irinotecan and Cetuximab in Patients With Previously Treated, Metastatic Colorectal Cancer||University of Michigan Cancer Center|Yes|Terminated|December 2005|July 2009|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|December 27, 2005|Yes|Yes|The study was discontinued due to the death of a co-investigator and a second co-investigator    leaving the institution.|No|June 4, 2014|https://clinicaltrials.gov/show/NCT00271011||186601|The study was discontinued and not completed due to the death of a co-investigator and a second co-investigator leaving the institution.
NCT00271557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005203|A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels|A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF||Scios, Inc.||Completed|January 1997|December 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|305|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|December 30, 2005||||||https://clinicaltrials.gov/show/NCT00271557||186559|
NCT00271284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3516|Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients|A Crossover, Multicentre, Randomised Trial Comparing the Effect on the Control of Blood Glucose Concentration of Insulin Glargine and Insulin Detemir, Combined With Insulin Glulisine, Used as a Bolus, in Type 1 Diabetic Patients|VARIABILITE|Sanofi|No|Completed|October 2005|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271284||186580|
NCT00271531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-072|Bacterial Pulmonary Infection in PICU|Derivation of a Clinical Prediction Rule for Bacterial Pulmonary Infection in Mechanically Ventilated Children||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|Samples With DNA|Nasal aspirate, tracheal aspirate, and non bronchoscopic bronchoalveolar lavage.|Both|2 Months|17 Years|No|Non-Probability Sample|Children, ages > 48 weeks post-conception and < 18 years, requiring mechanical ventilation        in pediatric ICU, presence of abnormal chest x-ray, and initiation of antibiotics (less        than or equal to 12 hours prior to NB-BAL).|October 2009|August 11, 2011|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271531||186561|
NCT00271804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-381|Study of Velcade and Thalidomide in Patients With Myelodysplasia|Phase I Dose Escalation Trial of Bortezomib in Combination With Thalidomide in Patients With Myelodysplasia||Massachusetts General Hospital||Terminated|June 2005|April 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||28|||Both|18 Years|N/A|No|||March 2008|March 7, 2008|December 30, 2005|Yes|Yes|New study with lenalidomide pending|No||https://clinicaltrials.gov/show/NCT00271804||186541|
NCT00271492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48-99|Correlation of Endothelial Function and Early Coronary Artery Disease in Humans|Endothelin in the Coronary Circulation in Early Atherosclerosis in Humans||Mayo Clinic|Yes|Completed|July 2001|January 2008|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|85 Years|No|||April 2010|April 28, 2010|December 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00271492||186564|
NCT00243126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 012|Family-based HIV Prevention for Adolescent Girls|Family-based HIV Prevention for Adolescent Females||Westat|No|Completed|November 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|168|||Female|15 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00243126||188694|
NCT00243386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060201|Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A|Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A||Baxalta US Inc.|Yes|Completed|January 2006|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|7 Years|65 Years|No|||October 2012|June 26, 2015|October 21, 2005|Yes|Yes||No|March 14, 2012|https://clinicaltrials.gov/show/NCT00243386||188674|
NCT00243620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB/jd/01.259|A Randomised Controlled Trial Comparing Vacuum Assisted Closure (V.A.C.®) With Modern Wound Dressings|State-of-the Art Treatment of Chronic Leg Ulcers: a Randomised Controlled Trial Comparing Vacuum Assisted Closure (V.A.C.®) With Modern Wound Dressings||Maastricht University Medical Center||Completed|May 2001|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|85 Years|No|||May 2001|October 21, 2005|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00243620||188656|
NCT00243893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS027713|Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms|Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms||University of California, San Francisco|Yes|Completed|July 2004|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|13 Years|80 Years|No|||October 2013|October 8, 2013|October 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00243893||188635|
NCT00243880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5855|Neuroprotection With Statin Therapy for Acute Recovery Trial (Neu-START)|SPOTRIAS: Neuroprotection With Statin Therapy for Acute Recovery Trial|Neu-START|Columbia University||Completed|September 2005|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||July 2010|January 12, 2011|October 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00243880||188636|
NCT00244179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReA01|New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis|New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis: Immunostimulation Plus Antibiotic Versus Immunosuppression Plus Antibiotic Versus Conventional Standardtherapy||Charite University, Berlin, Germany||Recruiting|January 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|18 Years|70 Years|No|||September 2006|September 7, 2006|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00244179||188614|
NCT00244452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S184.2.101|A Multinational, Randomized, Double-Blind, Placebo‑Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis|A Multinational, Randomized, Double-Blind, Placebo‑Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis||Solvay Pharmaceuticals||Completed|November 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|45 Years|No|||March 2008|March 28, 2008|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244452||188593|
NCT00244465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00302|Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription|Post Marketing Non-interventional Surveillance Pharmacoepidemiology Study (PMSS) to Evaluate Long-term Safety, Tolerability and Compliance in Administration of Xyrem® (Sodium Oxybate) Oral Solution in Patients Who Receive Treatment With This Medication in Regular Clinical Practice.||UCB Pharma|No|Active, not recruiting|May 2006|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|N/A|No|Non-Probability Sample|Patients being treated with Xyrem®.|March 2016|March 1, 2016|October 24, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244465||188592|
NCT00244855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 2002|Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma|Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma||Fred Hutchinson Cancer Research Center|No|Completed|May 2004|||December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||August 2011|August 11, 2011|October 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244855||188562|
NCT00240461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-E002-2005-2|Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors|Efficacy and Safety of COLD-fX in the Prevention of Respiratory Infections in Community-dwelling Seniors: a Multi-center, Randomized, Double-blind, Placebo-controlled Trial||Capital Health, Canada|No|Completed|September 2005|December 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|780|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 6, 2011|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00240461||188896|
NCT00240708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004945|A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia|A Parallel-Group Comparative Open-Label Study of Long-Acting Injectible Risperidone Versus Risperidone Tablets in Patients With Schizophrenia.||Janssen Pharmaceutical K.K.||Completed|June 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|205|||Both|20 Years|N/A|No|||March 2010|May 16, 2011|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240708||188877|
NCT00269932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005497|A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria|A Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With That of Cefuroxime Axetil in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis in Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 1993|May 1994|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|485|||Both|18 Years|N/A|No|||February 2011|June 8, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269932||186683|
NCT00269906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006271|A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty|Chimeric Anti-Platelet Therapy (Abciximab) in Unstable Angina Refractory to Standard Medical Therapy Trial (CAPTURE)||Centocor, Inc.||Completed|May 1993|December 1995|Actual|December 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1265|||Both|21 Years|80 Years|No|||May 2015|May 22, 2015|December 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00269906||186685|
NCT00270413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-004587-23|SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer|A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction||Universitaire Ziekenhuizen Leuven|No|Completed|January 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Female|18 Years|N/A|No|||December 2014|December 8, 2014|December 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00270413||186646|
NCT00270426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SouthernMUC|Benazepril for Advanced Chronic Renal Insufficiency|||Southern Medical University, China||Terminated||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||March 1999|May 4, 2006|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00270426||186645|
NCT00271310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X95-0118B|The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis|The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis||Royal Prince Alfred Hospital, Sydney, Australia||Completed|September 2000|November 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||164|||Both|6 Years|N/A|No|||October 2006|October 6, 2006|December 29, 2005||||No||https://clinicaltrials.gov/show/NCT00271310||186578|
NCT00271323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976B_2507|Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients|A Two Arm Phase II Study Assessing Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-multiple cN2 or IIIB)||Sanofi|No|Terminated|May 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|75 Years|No|||December 2009|December 21, 2009|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271323||186577|
NCT00271843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA019916-01|Smoking and Alcohol Initiation|Predicting Tobacco and Alcohol Initiation||National Institute on Drug Abuse (NIDA)||Active, not recruiting|October 2005|||June 2007|Anticipated|Phase 1|Observational|Time Perspective: Prospective|||Anticipated|2600|||Both|11 Years|15 Years||||December 2008|June 2, 2015|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00271843||186538|
NCT00271544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241|Attain Model 4196 Left Ventricular (LV) Lead|Attain Model 4196 Left Ventricular (LV) Lead||Medtronic Cardiac Rhythm Disease Management|No|Completed|February 2007|December 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|December 28, 2005|Yes|Yes||No|April 30, 2009|https://clinicaltrials.gov/show/NCT00271544||186560|
NCT00271817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-091|To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)|Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|December 2005|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1220|||Both|18 Years|79 Years|No|||September 2015|September 2, 2015|January 3, 2006|Yes|Yes||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00271817||186540|Part 1 population is all patients enrolled in Part 1 of the study. Part 2 is those patients who received either niacin, ezetimibe/simvastatin, or ezetimibe/simvastatin + niacin during Part 1 until they finished the study at week 64 or discontinued.
NCT00267540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLK1-CT-2000-00623|The Effect of Vitamin D on Bone Accretion and Turn-Over in Young Girls|Adolescent Girls-Impact of Vitamin D on Bone Accretion Work Package 1 (Danish Part) of OPTIFORD (Towards A Strategy for Optimal Vitamin D Fortification)||University of Copenhagen||Completed|January 2001|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||225|||Female|10 Years|11 Years|Accepts Healthy Volunteers|||January 2008|January 29, 2008|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00267540||186858|
NCT00271518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPLG-004|Treatment of Children With Insufficient Secretion of Growth Hormone|A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy in Treatment Naive Children With Growth Failure Due to Insufficient Secretion of Endogenous Growth Hormone|BPLG-004|LG Life Sciences|Yes|Active, not recruiting|September 2005|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|144|||Both|3 Years|11 Years|No|||March 2010|March 16, 2010|December 29, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00271518||186562|
NCT00267514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCARB00205|Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients|A Randomized, Cross-over Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer Hydrochloride Tablets Dosed Three Times Per Day in Haemodialysis Patients||Sanofi||Completed|January 2006|May 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|December 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267514||186860|
NCT00243139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNB01|Mandibular Advancement Device for Obstructive Sleep Apnea|A Randomized Controlled Trial of a Mandibular Advancement Device for Obstructive Sleep Apnea||Nykøbing Falster County Hospital||Completed|July 1999|February 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||90|||Both|21 Years|N/A|No|||September 2006|September 14, 2006|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00243139||188693|
NCT00243633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIT 05 - FT / ECUS|Characterization of Focal Liver Lesions by Real-Time Contrast-Enhanced Ultrasound Imaging (CEUS)|Characterization of Focal Liver Lesions by Real-Time Contrast-Enhanced Ultrasound Imaging (CEUS)||University Hospital, Tours|No|Completed|April 2005|August 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|878|||Both|18 Years|N/A|No|||March 2008|March 18, 2008|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243633||188655|
NCT00243906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS039160|Interventional Management of Stroke (IMS) II Study|Interventional Management of Stroke (IMS) II Study||University of Cincinnati|Yes|Completed|January 2003|May 2007|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|80 Years|No|||July 2012|July 18, 2012|October 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00243906||188634|
NCT00243919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006846|Locomotor Experience Applied Post Stroke Trial|Locomotor Experience Applied Post Stroke (LEAPS) Trial|LEAPS|Duke University||Completed|April 2006|June 2012|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|408|||Both|18 Years|N/A|No|||December 2012|July 9, 2014|October 24, 2005||No||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00243919||188633|
NCT00244205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blæretumor PCR projekt|Identifying Methylation Biomarkers for Monitoring Bladder Tumors|Using PCR Technology (Polymerase Chain Reaction Technology) for Monitoring Patients With Bladder Tumors - Optimizing Genanalyses for Clinical Use.||Copenhagen University Hospital at Herlev||Recruiting|November 2005|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||120|||Both|18 Years|N/A|No|||November 2005|November 14, 2005|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00244205||188612|
NCT00244218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-002600-01|Response to Phenylketonuria to Tetrahydrobiopterin (BH4)|Response to Phenylketonuria to Tetrahydrobiopterin (BH4)||FDA Office of Orphan Products Development||Recruiting|April 2005|||March 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|36|||Both|10 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 15, 2009|October 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244218||188611|
NCT00244478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-20-2005-FOCUS|Soy, Bone and Health in College Females|Influence of Soy on Bone Turnover and Body Composition in College Females||University of Georgia|Yes|Completed|October 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|19 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00244478||188591|
NCT00244491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-1036|The Care Transitions Intervention|The Care Transitions Intervention||University of Colorado, Denver||Completed|September 2002|August 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||1400|||Both|65 Years|N/A|No|||August 2015|August 10, 2015|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00244491||188590|
NCT00244504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158/01|Moxonidine in Patients Undergoing Vascular Surgery|The Effects of Small Doses of Moxonidine in Patients Undergoing Vascular Surgery||University Hospital, Basel, Switzerland|Yes|Terminated|November 2002|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|141|||Both|18 Years|N/A|No|||November 2009|November 9, 2009|October 25, 2005||No|Study was stopped after pre-definied interim analysis because of no effects|No||https://clinicaltrials.gov/show/NCT00244504||188589|
NCT00244868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000442928|Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer|Facilitating Decision Making in Advanced Cancer Patients||Fox Chase Cancer Center||Completed|July 2003|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized|||Anticipated|720|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|October 25, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00244868||188561|
NCT00244881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02937|A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)|A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)||National Cancer Institute (NCI)||Completed|September 2005|December 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2013|December 3, 2015|October 25, 2005|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00244881||188560|
NCT00241345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0274|Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant|Randomized Trial of Preemptive Treatment With Oral Valganciclovir Compared With IV Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant||Washington University School of Medicine||Terminated|June 2004|December 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|October 17, 2005|Yes|Yes|Due to low accrual|No||https://clinicaltrials.gov/show/NCT00241345||188830|
NCT00269945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005836|A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||January 1989|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269945||186682|
NCT00269919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002089|An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia|Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia||Janssen Korea, Ltd., Korea|No|Completed|August 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||March 2014|March 25, 2014|December 22, 2005|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00269919||186684|There is limitation in the study that selection or observer bias may occur because this clinical trial was an open, non-comparative, single-arm study and precaution would be necessary for interpreting change in various scales observed in this study.
NCT00270738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700665|Treatment for Female Stress Urinary Incontinence|Treatment for Stress Urinary Incontinence—Indirect Training of Pelvic Floor Muscle Via Transversus Abdominis Muscle Contraction||National Taiwan University Hospital|Yes|Completed|December 2005|March 2010|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|168|||Female|18 Years|70 Years|No|||December 2012|December 4, 2012|December 26, 2005||No||No||https://clinicaltrials.gov/show/NCT00270738||186622|
NCT00271336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chammerman1|Pentoxifylline in the Treatment of NEC in Premature Neonates|Pentoxifylline in the Treatment of Necrotizing Enterocolitis in Premature Neonates||Shaare Zedek Medical Center|Yes|Recruiting|January 2005|March 2010|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||December 2005|May 22, 2008|December 29, 2005||||No||https://clinicaltrials.gov/show/NCT00271336||186576|
NCT00271570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041374|Infliximab (Remicade) for Patients With Acute Kawasaki Disease|Infliximab (Remicade) for Patients With Acute Kawasaki Disease Who Fail to Become Afebrile After Intravenous Gamma Globulin Therapy||University of California, San Diego|Yes|Completed|April 2004|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|18 Years|No|||November 2009|June 11, 2010|December 30, 2005|No|Yes||No|May 1, 2009|https://clinicaltrials.gov/show/NCT00271570||186558|
NCT00271856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AT002024|Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV|Mindfulness-Based Stress Reduction (MBSR), Stress Arousal and Immune Response in Early HIV||University of California, San Francisco|Yes|Completed|May 2005|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|December 30, 2005||No||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00271856||186537|
NCT00271830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMCIRB05-07-184|Sexual Function in Male Renal Transplant Patients|Sexual Function in Male Renal Transplant Patients||Montefiore Medical Center||Terminated|January 2006|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|110|||Male|21 Years|65 Years|No|||December 2007|December 10, 2007|December 30, 2005||||No||https://clinicaltrials.gov/show/NCT00271830||186539|
NCT00267553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomed 777-CLP-32|Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer|Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer||Intarcia Therapeutics||Terminated|November 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|18 Years|N/A|No|||September 2007|September 7, 2007|December 20, 2005|||This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint|||https://clinicaltrials.gov/show/NCT00267553||186857|
NCT00267527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH100-013|A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity||ConjuChem||Terminated|December 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|No|||October 2006|October 12, 2006|December 20, 2005||||||https://clinicaltrials.gov/show/NCT00267527||186859|
NCT00243425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS013645|Patient-Centered Depression Care for African Americans|Patient-Centered Depression Care for African Americans||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|March 2004|March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|75 Years|No|||October 2005|October 21, 2005|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00243425||188671|
NCT00243646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-8-4|Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial|Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial||Schiffler Cancer Center|Yes|Completed|August 2004|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 30, 2013|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00243646||188654|
NCT00244231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBL03-NSR|Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia|A Placebo-Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Nidadd in the Management of Hyperlipidemia||Genovate Biotechnology Co., Ltd.,|No|Completed|October 2003|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|20 Years|75 Years|No|||February 2007|February 27, 2007|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244231||188610|
NCT00244244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALS-001|A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS|A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)||CytRx||Completed|October 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|October 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244244||188609|
NCT00244257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA16100104|Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|Phase I, Open-Label, Multi-center, Single-Dose, Dose-Escalating, Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamic Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)||Sanofi|Yes|Terminated|August 2005|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|October 25, 2005|No|Yes|Study terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00244257||188608|
NCT00240721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002248|A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2000|September 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|363|||Both|16 Years|N/A|No|||November 2010|June 6, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240721||188876|
NCT00240968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0090|H5 Booster After a Two Dose Schedule|Evaluation of a Booster Dose of A/Vietnam/1203/04 (H5N1) Vaccine Administered at 6 Months to Healthy Adult Subjects After a Two Dose Schedule at 0 and 1 Months||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|337|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2008|August 15, 2013|October 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00240968||188858|
NCT00240981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0057|TOM: Testosterone in Older Men With Sarcopenia|Testosterone Replacement for Older Men With Sarcopenia||Boston Medical Center|Yes|Completed|January 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|209|||Male|65 Years|N/A|No|||November 2012|November 20, 2012|October 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00240981||188857|
NCT00241358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0349|Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies|A Phase I/II Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies||Washington University School of Medicine|Yes|Completed|May 2004|February 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|65 Years|No|||August 2013|August 9, 2013|October 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00241358||188829|
NCT00241371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0916|A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma||Washington University School of Medicine||Terminated|March 2005|December 2007|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|October 17, 2005|No|Yes|No response seen in patients|No||https://clinicaltrials.gov/show/NCT00241371||188828|
NCT00241072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2412|Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance|A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt)||Novartis||Completed|September 2002|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 3, 2012|October 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00241072||188851|
NCT00270166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005923|The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy|A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 1995|May 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|201|||Both|18 Years|80 Years|No|||February 2011|May 17, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270166||186665|
NCT00270439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050967|Omentectomy for the Treatment of Diabetes Mellitus Type 2|Omentectomy for Treatment of Diabetes Mellitus Type 2||Vanderbilt University|No|Completed|January 2006|March 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|55 Years|No|||September 2009|September 10, 2009|December 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00270439||186644|
NCT00271024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13976A (R01 DA016834)|Efficacy of Naltrexone in Women's Smoking Cessation|Efficacy of Naltrexone in Women's Smoking Cessation||University of Chicago|No|Completed|December 2005|March 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|333|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|December 28, 2005|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00271024||186600|
NCT00271037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7P01|Colpocleisis for Advanced Pelvic Organ Prolapse|Pelvic Symptoms and Patient Satisfaction After Colpocleisis for Advanced Pelvic Organ Prolapse||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|July 2004|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|||Female|21 Years|N/A|No|Non-Probability Sample|Adult women undergoing colpocleisis for advanced pelvic organ prolapse (pelvic organ        prolapse quantification (POP-Q) stage III-IV)|October 2010|January 9, 2011|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00271037||186599|
NCT00271583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN002|Efficacy Trial of CDB 2914 for Emergency Contraception|A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerance of CDB-2914 With Levonorgestrel as Emergency Contraception||University of Pittsburgh|Yes|Completed|September 1999|September 2001|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1672|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 13, 2007|December 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00271583||186557|
NCT00271869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr. 368/2005|Treatment of Chronic GVHD of Liver or Lungs by ECP|Phase II Study for Treatment of Chronic Graft-Versus-Host Disease of the Liver or Lungs With Adjunct Extracorporeal Photoimmunotherapy||Medical University of Vienna||Recruiting|December 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||December 2005|January 3, 2006|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00271869||186536|
NCT00267566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2234a|Strongest Families (Formerly Family Help Program): Pediatric Anxiety|Strongest Families (Formerly Family Help Program): Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Anxiety)|FHP-ANX|IWK Health Centre|No|Completed|August 2003|April 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267566||186856|
NCT00267839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-ER-OFZ-200501|Effect of Exercise on Risk-factors of Elderly Women|Effects of Exercise on Multiple Risk Factors and Health Costs in Community Living Elderly Women. The Senior Fitness and Prevention Study (SEFIP)||University of Erlangen-Nürnberg Medical School||Terminated|January 2006|March 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|246|||Female|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00267839||186836|
NCT00267800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05.08/A|Database of Interstitial Lung Diseases|Registration of Clinical Data and DNA/Serum of Patients With Interstitial Lung Diseases (ILD)||St. Antonius Hospital||Active, not recruiting|January 2006|||||N/A|Observational|N/A||||100000|||Both|18 Years|N/A|No|||December 2005|August 7, 2008|December 19, 2005||||No||https://clinicaltrials.gov/show/NCT00267800||186839|
NCT00243399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2539|Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia|A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia||Children's Hospital Medical Center, Cincinnati|Yes|Completed|July 2004|January 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||July 2011|July 14, 2011|October 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00243399||188673|
NCT00243412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3377g|A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate|A Double-Blind, Randomized, Multicenter, Phase II Study of the Safety and Efficacy of Two Rituximab Regimens in Subjects With Moderate to Severe Active Rheumatoid Arthritis Receiving Stable Doses of Methotrexate|RUMBA|Genentech, Inc.||Completed|August 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||September 2011|September 6, 2011|October 21, 2005|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00243412||188672|Because of the limited sample size, interpretation of these results should be made with caution and therefore definitive conclusions cannot be made regarding differences between the two retreatment regimens studied.
NCT00243165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LifemelCTIL|Lifemel Honey to Reduce Leucopenia During Chemotherapy|Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia||Rambam Health Care Campus||Not yet recruiting|November 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|60|||Female|18 Years|N/A|No|||October 2005|December 4, 2009|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00243165||188691|
NCT00243672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-Anast-05|Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques|Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques: a Randomised Microarray-Study on Endarterectomy Specimens of Human Carotid Arteries||University Hospital Muenster||Withdrawn|October 2005|October 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||November 2007|November 16, 2007|October 21, 2005|||The study chair changed his employment, the realization of the study was not possible|No||https://clinicaltrials.gov/show/NCT00243672||188652|
NCT00243945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0826|A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease|A Phase 3b, Open-Label, Multicenter, Multinational Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders in Patients With Idiopathic Parkinson's Disease||UCB Pharma||Completed|December 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|58|||Both|18 Years|N/A||||September 2009|September 24, 2014|October 24, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00243945||188631|
NCT00244517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225/03|DIAFAX I+II-Effects of Inhalative Anesthetics on Left Ventricular Diastolic Function|The Effects of Remifentanil, Sevoflurane, Isoflurane and Desflurane on Left Ventricular Diastolic Function in Humans||University Hospital, Basel, Switzerland|Yes|Terminated|June 2004|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|60|||Both|50 Years|N/A|No|||June 2010|June 30, 2010|October 25, 2005||No|Part II was not performed as we could not include enough patients fulfilling the inclusion    criteria.|No||https://clinicaltrials.gov/show/NCT00244517||188588|
NCT00243932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA1536|Clinical Trial of High Dose CoQ10 in ALS|Clinical Trial of High Dose CoQ10 in ALS||Columbia University|Yes|Completed|April 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|185|||Both|21 Years|85 Years|No|||February 2013|January 28, 2014|October 24, 2005|No|Yes||No|March 29, 2010|https://clinicaltrials.gov/show/NCT00243932||188632|
NCT00240487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-9-2088|Nitric Oxide Administration for Acute Respiratory Distress Syndrome|Nitric Oxide Administration for Acute Respiratory Distress Syndrome||Children's Hospital of Philadelphia|No|Completed|September 2000|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|1 Month|18 Years|No|||April 2015|April 23, 2015|October 14, 2005|Yes|Yes||No|January 10, 2013|https://clinicaltrials.gov/show/NCT00240487||188894|There may be some confounding of effects of lung recruitment from high mean airway pressures over the duration of the observation period.
NCT00240734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004597|Treatment of Anemia in Diabetic Subjects With CKD|A Randomized, Double-blind, Placebo-Controlled Study Evaluating Weekly Epoetin Alfa (PROCRIT�) Administration on Hemoglobin Response and Safety in Diabetic Subjects With the Anemia of Chronic Kidney Disease (CKD)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|March 2005|September 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||March 2010|June 8, 2011|October 14, 2005|||This study was stopped for slow enrollment after enrolling only 11 of 180 patients in six    months time.|||https://clinicaltrials.gov/show/NCT00240734||188875|
NCT00240994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT PC01|Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients|A Phase II Exploratory Study to Determine the Safety and Study the Immunomodulatory Functions of Induction Therapy With Campath, Combined With Chronic Immunosuppression With Mycophenolate Mofetil and Sirolimus||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2005|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|1 Year|20 Years|No|||September 2012|October 25, 2012|October 14, 2005|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00240994||188856|
NCT00241007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631C2301E1|A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension|A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension||Novartis||Completed|December 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|836|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2005|November 7, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00241007||188855|
NCT00241020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995BFR04|Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma|Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma||Novartis||Completed|June 2002|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|270|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00241020||188854|
NCT00241085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2417|Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus|A Multi-center, Double Blind, Randomized, Parallel Group Study to Evaluate the Effects of Valsartan on Proteinuria in Hypertensive Subjects With Type 2 Diabetes Mellitus||Novartis||Completed|November 2002|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|392|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2006|November 7, 2011|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00241085||188850|
NCT00242099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0760-AE|Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant|The Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant: A Randomized Trial||University Health Network, Toronto||Completed|February 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||160|||Both|18 Years|N/A|No|||February 2005|April 15, 2008|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242099||188773|
NCT00270179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005926|A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.|A Double-Blind, Placebo-Controlled Study to Determine Whether R-huEPO Can Facilitate Presurgical Autologous Blood Donation and to Determine Its Safety for This Purpose||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||May 1988|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270179||186664|
NCT00270192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG RPR 01101|Antenatal Educational Intervention for Improvement of Breastfeeding|The Effects Of Antenatal Breast Preparation On The Successful Initiation And Continuation Of Breastfeeding In Singaporean Mothers||National University Hospital, Singapore||Completed|May 2002|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||450|||Female|21 Years|55 Years|Accepts Healthy Volunteers|||December 2005|October 23, 2006|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00270192||186663|
NCT00270751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31MD02|Pleural Abrasion Plus Minocycline Versus Apical Pleurectomy for Primary Spontaneous Pneumothorax|Comparison of Pleural Abrasion Plus Minocycline Pleurodesis Versus Apical Pleurectomy After Thoracoscopic Bullectomy for High Recurrent Risk Patients With Primary Spontaneous Pneumothorax: A Prospective Randomized Trial.||National Taiwan University Hospital||Recruiting|April 2005|May 2009||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|15 Years|50 Years|No|||August 2006|August 4, 2006|December 26, 2005||||No||https://clinicaltrials.gov/show/NCT00270751||186621|
NCT00271063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-103|Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia|Phase I/II Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia||Callisto Pharmaceuticals|No|Recruiting|October 2005|April 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|15 Years|N/A|No|||December 2007|December 17, 2007|December 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00271063||186597|
NCT00271596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200509746|Citalopram to Enhance Cognition in HD|A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)|CIT-HD|University of Iowa|Yes|Completed|November 2005|November 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|75 Years|No|||February 2013|February 8, 2013|December 30, 2005|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00271596||186556|Statistical power was limited.
NCT00265044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMV 04-091|Improving Practice Patterns for the Treatment of Hypertension|Innovations to Implementing Evidence-based Clinical Practice||VA Office of Research and Development|No|Completed|January 2004|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1300|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||May 2006|April 6, 2015|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00265044||187047|
NCT00267579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2234b|Strongest Families (Formerly Family Help Program): Pediatric Disruptive Behaviour Disorder|Strongest Families (Formerly Family Help Program):Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Disruptive Behaviour Disorder)||IWK Health Centre|No|Completed|October 2003|April 2008|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267579||186855|
NCT00267852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101749|Study Evaluating the Clinical Remission in Early Aggressive Rheumatoid Arthritis|An Observational Study To Evaluate The Clinical Remission In Early Aggressive Rheumatoid Arthritis (Artrite Reumatoide Precoce Aggressiva Italian Study)|ARPA|Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|April 2006|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with early aggressive RA, who are treated in 15 specialized sites|September 2011|September 14, 2011|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267852||186835|
NCT00267813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-O5-EE-065-CTIL|The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers|The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.||Tel-Aviv Sourasky Medical Center|No|Completed|July 2004|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2008|May 6, 2008|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00267813||186838|
NCT00267826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005 DR 3297|Immunopharmacological Effects of Rituximab in Atopic Dermatitis|Open-Label, Single Center Study to Evaluate the Immunopharmacological Effects of Rituximab in Patients With Atopic Dermatitis||University of Bern|No|Completed|December 2005|December 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2008|June 16, 2008|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00267826||186837|
NCT00243178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4912 W|Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)|A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation||Sanofi||Terminated|July 2003|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6706|||Both|18 Years|N/A|No|||October 2009|October 16, 2009|October 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00243178||188690|
NCT00243191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC004|Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans|Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans||Sarcoma Alliance for Research through Collaboration|Yes|Completed|May 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|October 20, 2005||No||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00243191||188689|Dermatofibrosarcoma protuberans (DFSP)is a rare tumor type. During the the trial the drug manufacturer obtained approval for DSFP indication.The other limitation is limited funding; SARC is actively seeking funding for secondary outcome goal 12/2012.
NCT00244543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003-13|Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis|A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis||Vistakon Pharmaceuticals||Completed|October 2005|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||110|||Both|10 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 26, 2011|October 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244543||188586|
NCT00244894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445180|Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer|Acupuncture for Hot Flashes in Prostate Cancer Patients||OHSU Knight Cancer Institute|Yes|Terminated|September 2002|April 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Male|18 Years|N/A|No|||August 2011|August 29, 2011|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00244894||188559|
NCT00240500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100448|Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers|Long-Term F-U Study at Yrs 16-20, to Evaluate the Persistence of Immune Response of GSK Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers||GlaxoSmithKline||Completed|October 2003|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|109|||Both|16 Years|20 Years|Accepts Healthy Volunteers|||May 2009|May 28, 2009|October 13, 2005|Yes|Yes||No|October 30, 2008|https://clinicaltrials.gov/show/NCT00240500||188893|
NCT00240513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-03|Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin|A Randomized Study to Compare the Acne Relapse Rate After a 3-mo Course of Oral Minocycline, to a 3-mo Course of Oral Minocycline in Combination With a Daily Dose of Topical Tretinoin 0.01% Followed by 3 mo of Topical Tretinoin Alone||Derm Research @ 888 Inc.|No|Terminated|August 2004|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 22, 2012|October 16, 2005||No|Too much difficulty recruiting and retaining patients, PI decided to stop.|No||https://clinicaltrials.gov/show/NCT00240513||188892|
NCT00240747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP59500V-324|Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients|||Pfizer||Terminated|June 2000|January 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|27 Weeks|16 Years|No|||May 2012|May 24, 2012|October 14, 2005||||||https://clinicaltrials.gov/show/NCT00240747||188874|
NCT00240760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCL/DS/MEM/1|Memantine and Down's Syndrome|Efficacy and Safety of Memantine Hydrochloride, a Low Affinity Antagonist to N-Methyl-D-Aspartate (NMDA) Type Receptors, in the Prevention of Cognitive Decline and Disease Progression in Down’s Syndrome||King's College London||Recruiting|October 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|N/A|No|||October 2005|February 17, 2006|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240760||188873|
NCT00241046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345ADE02|Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment|Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment||Novartis||Terminated|April 2002|||March 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||April 2012|April 18, 2012|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00241046||188853|
NCT00241059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405LA01E1|Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients|A Prospective, Open-label, Multicenter, International Follow-up Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients||Novartis||Completed|August 2002|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|183|||Both|18 Years|N/A|No|||January 2011|January 28, 2011|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00241059||188852|
NCT00242112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0387-CE|Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI|Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI||University Health Network, Toronto||Completed|June 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Male|18 Years|N/A|No|||February 2015|February 12, 2015|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00242112||188772|
NCT00252148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI C002|Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults|Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of a Modified Vaccinia Ankara (MVA) Vectored HIV-1 (ADMVA) Vaccine Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers||International AIDS Vaccine Initiative|Yes|Completed|January 2005|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2010|February 8, 2013|November 9, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00252148||188014|
NCT00270764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPFAR 13|Social and Economic Outcomes of HIV/AIDS Care and Treatment in HIV Infected South African Adults|Economic Outcomes of HIV/AIDS Care and Treatment in South Africa||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2005|September 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1065|||Both|18 Years|N/A|No|Probability Sample|Adult ART patients receiving treatment at 3 treatment facilities in South Africa|November 2013|November 19, 2013|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270764||186620|
NCT00270777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178A07|Improving Safety of Antivenom in People Bitten by Snakes|Low Dose Adrenaline, Promethazine, & Hydrocortisone (Alone and in Combination) to Prevent Acute Adverse Reactions to Antivenom in People Bitten by Snakes: Randomised, Double Blind, Placebo-Controlled Trial||University of Kelaniya|Yes|Completed|March 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1000|||Both|12 Years|N/A|No|||June 2008|June 4, 2008|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270777||186619|
NCT00271050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 7883|External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma|The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma||The Cleveland Clinic||Completed|December 2005|June 2010|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2010|December 20, 2010|December 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00271050||186598|
NCT00271349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5257L00017|Budesonide for Eosinophilic Esophagitis|Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study|BEE|Swiss EE Study Group||Completed|December 2005|December 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|28|||Both|14 Years|70 Years|No|||April 2009|May 21, 2015|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271349||186575|
NCT00264654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIR104777|Long-term Study Of Paroxetine in Women and Men|Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- <Phase III Study>|SAD|GlaxoSmithKline|No|Completed|October 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|64 Years|No|||May 2012|April 11, 2013|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264654||187076|
NCT00265031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD12|HD12 for Advanced Stages|||University of Cologne||Completed|January 1999|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|65 Years|No|||August 2007|June 22, 2012|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00265031||187048|
NCT00265057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adherex Protocol # AHX-01-004|Study of ADH-1 Given Intravenously to Patients With Solid Tumors|Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004)||Adherex Technologies, Inc.||Completed|June 2005|January 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2010|December 27, 2010|December 13, 2005||||||https://clinicaltrials.gov/show/NCT00265057||187046|
NCT00267592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-207-21-189 / NABTT 0304|Safety and Efficacy of Talampanel in Glioblastoma Multiforme|A Phase II Trial of Talampanel in Conjunction With Radiation Therapy With Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme||Teva Pharmaceutical Industries||Completed|December 2005|February 2011|Actual|September 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|December 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267592||186854|
NCT00267865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060051|Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma|AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|December 2005|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|99 Years|No|||September 2015|November 7, 2015|December 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267865||186834|
NCT00267891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060048|Brain Changes in Adolescents While Imagining and Observing Aggressive Behavior|Changes in Activation Patterns in the Ventro-Medial Prefrontal Cortex of Healthy Adolescents During the Imagination and Observation of Aggressive Behavior||National Institutes of Health Clinical Center (CC)||Completed|December 2005|August 2010||||N/A|Observational|N/A|||Actual|88|||Male|14 Years|17 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00267891||186833|
NCT00268138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456-HMO-CTIL|Elmex Gel Efficacy in Preventing White Spot Lesions|Phase 4 Study Prevention of Incipient Carious Lesions (White Spot Lesions) in Patients With Fixed Orthodontic Appliances Following the Application of Elmex Gel||Hadassah Medical Organization|Yes|Recruiting|April 2006|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|314|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||December 2005|February 17, 2009|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268138||186814|
NCT00268112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-203|Resynchronization of Left Ventricular Contraction After Reimplantation of Anomalous Left Coronary Artery|Resynchronization of Left Ventricular Contraction After Re-implantation of Anomalous Left Coronary Artery From the Pulmonary Artery (ALCAPA) Evaluated by Tissue Doppler Imaging||Children's Healthcare of Atlanta|No|Terminated|January 2004|December 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|3|||Both|N/A|21 Years|No|Non-Probability Sample|Cardiac pediatric patients|December 2006|March 14, 2012|December 20, 2005|||sufficient data collected for analysis|No||https://clinicaltrials.gov/show/NCT00268112||186816|
NCT00243451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSUHSC H04-049|Early Detection of Mild Cognitive Impairment in Individual Patients|Early Detection of Mild Cognitive Impairment in Individual Patients||Louisiana State University Health Sciences Center Shreveport|No|Completed|September 2003|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|34|||Both|55 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects must have a diagnosis of MCI or mild AD.|September 2011|September 2, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00243451||188669|
NCT00243659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-311|Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery|An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|12 Years|N/A|No|||June 2011|June 2, 2011|October 20, 2005|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00243659||188653|
NCT00244270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P041202|Cystic Fibrosis and Totally Implantable Vascular Access Devices|Cystic Fibrosis and Totally Implantable Vascular Access Devices: Evaluation of the Incidence of Venous Thrombosis Related to the Catheter and Study of the Genetic and Acquired Risk Factors|RITHM|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2005|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|97|||Both|N/A|N/A|No|||September 2005|August 26, 2011|October 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00244270||188607|
NCT00244530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-123|Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery|Postoperative Renal Function After Open-Heart Surgery in Patients With Impaired Renal Function Preoperatively. A Study of the Calcium Channel Blocker Nifedipine's Prophylactic Effect on Further Decline in Renal Function.||University of Oslo School of Pharmacy||Completed|June 2001|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||20|||Both|18 Years|N/A|No|||December 2006|December 20, 2006|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244530||188587|
NCT00244283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gjnh/mccormick/01|A Comparison of Two Anaesthetic Methods of Protecting Heart Tissue During Cardiac Surgery|A Comparison of Myocardial Protection Using Preconditioning With Sevoflurane Against High Thoracic Epidural Analgesia for CABG Surgery||Golden Jubilee National Hospital||Not yet recruiting|January 2006|January 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|40 Years|80 Years|No|||October 2005|October 24, 2005|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00244283||188606|
NCT00244556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101136|Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy|A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2003|May 2004|Actual|May 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A||||February 2013|February 20, 2013|October 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244556||188585|
NCT00244907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AT000477-06|Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women|Metabolism and Bone Health||Purdue University|Yes|Completed|January 2006|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|23|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 7, 2014|October 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00244907||188558|
NCT00244920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446087|Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer|An Open Label Randomized Phase 2 Study To Evaluate The Activity, Tolerability, And Toxicity Of Combined Neoadjuvant Anti-angiogenesis and Androgen Ablation Therapy in Men Undergoing Radical Prostatectomy||OHSU Knight Cancer Institute|No|Withdrawn|January 2002|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Male|18 Years|N/A|No|||May 2011|May 24, 2012|October 25, 2005|No|Yes|Sponsor withdrew drug.|No||https://clinicaltrials.gov/show/NCT00244920||188557|
NCT00241098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489B2402|The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure|A Randomized, Double Blind, Parallel Group Study to Evaluate the Effects of Valsartan Versus Placebo in Patients With Early Stage Heart Failure Due to Diastolic Dysfunction Already Evidenced by an Elevated B-type Natriuretic Peptide Level: the VALIDATE Study||Novartis||Completed|May 2003|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|37|||Both|55 Years|N/A|Accepts Healthy Volunteers|||February 2006|November 7, 2011|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00241098||188849|
NCT00241410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OralvacB2MPL103|Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen|Investigation of the Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen||Allergy Therapeutics|No|Completed|December 2005|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2009|June 16, 2010|October 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00241410||188825|
NCT00241423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-US-GWAW|Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes|Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes Using Metformin or Metformin Plus a Thiazolidinedione||AstraZeneca|No|Completed|October 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||January 2015|February 20, 2015|October 17, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00241423||188824|
NCT00241735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311|Soy Food and Coronary Heart Disease in Women|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2005|May 2009|Actual|May 2009|Actual|N/A|Observational|N/A|||||||Female|N/A|N/A|No|||May 2009|May 1, 2009|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241735||188800|
NCT00241748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310|Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event|Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event||University of Washington|No|Completed|September 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|187|Samples With DNA|DNA is extracted from swish and spit samples. DNA is retained.|Both|30 Years|N/A|No|Non-Probability Sample|Cases: persons suffering cervistatin-associated rhabdomyolysis who sued the manufactorer        and settled their case Control 1: statin users participating in the Heart and Vascular        Health Study Control 2: statin users participating in the Cardiovascular Health Study|January 2012|January 4, 2012|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241748||188799|
NCT00241761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312|Epidemiology of Depression and Heart Failure in Aging|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2005|August 2010|Actual|||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2012|April 26, 2012|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241761||188798|
NCT00270452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060062|Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome|Safety of WT1 and PR1 Peptide Vaccination for Patients With Myeloid Malignancies||National Institutes of Health Clinical Center (CC)||Completed|December 2005|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|85 Years|No|||February 2012|March 14, 2012|December 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00270452||186643|
NCT00270465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060056|Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients|VRC101: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost HIV-1 Vaccination Schedule of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by a Recombinant Multiclade Adenoviral Vector HIV Vaccine||National Institutes of Health Clinical Center (CC)||Completed|December 2005|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1|||17|||Both|18 Years|50 Years|No|||June 2009|September 3, 2009|December 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00270465||186642|
NCT00270478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060054|Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia|Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia||National Institutes of Health Clinical Center (CC)||Completed|December 2005|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00270478||186641|
NCT00271076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHI # 1119|CAPITAL: Carotid Artery Plaque Intravascular Ultrasound Evaluation|Carotid Artery Plaque Intravascular Ultrasound Evaluation||Arizona Heart Institute||Completed|January 2006|September 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|18 Years|N/A|No|||October 2007|October 24, 2007|December 29, 2005||||||https://clinicaltrials.gov/show/NCT00271076||186596|
NCT00271089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|378|Blood Cell Collection for Future Use in Individuals With Fanconi Anemia|Collection of Hematopoietic Cells From Patients With Fanconi Anemia (FA) for Future Autologous Reinfusion and Research||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2004|October 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|1 Year|35 Years|No|||December 2007|December 11, 2007|December 29, 2005||||||https://clinicaltrials.gov/show/NCT00271089||186595|
NCT00271375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E4044-R|Evaluating the Carter Institute Caregiver Education Program at the VA|Evaluating the Carter Institute Caregiver Education Program at the VA||VA Office of Research and Development|No|Completed|October 2005|October 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|1||Anticipated|195|||Both|55 Years|N/A|No|||September 2014|September 30, 2014|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271375||186573|
NCT00264355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeartTx-ARF|Metabolic Pattern of Cyclosporine A and Acute Renal Failure|Metabolic Pattern of Cyclosporine A - Association of Secondary- and Cyclic Metabolites With Acute Renal Failure in Heart Transplant Recipients||University of Oslo School of Pharmacy||Completed|December 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|No|||September 2007|September 5, 2007|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264355||187099|
NCT00264680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM-2003-01|Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For Epilepsy|Validation Of Qolie-10 For Epilepsy, Comparison Of Quality Of Life In Patients Treated With Lamotrigine Or Valproic Acid||GlaxoSmithKline||Completed|October 2003|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|155|||Both|18 Years|50 Years|No|||May 2011|May 5, 2011|December 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00264680||187074|
NCT00265694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INJE05-06|Random Trial for Elderly Patients With NSCLC|A Randomized Phase III Trial of Vinorelbine Versus Gemcitabine and Carboplatin for Elderly Patients With Advanced Non-Small Cell Lung Cancer||Inje University||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|65 Years|N/A|No|||June 2005|December 14, 2005|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00265694||186999|
NCT00265915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0546 CDR0000450145|Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia|A CRC Trial of Rituximab in Combination With Sargramostim (GM-CSF) in Patients With Chronic Lymphocytic Leukemia||Sidney Kimmel Comprehensive Cancer Center||Terminated|July 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|15 Years|N/A|No|||August 2014|August 11, 2014|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00265915||186982|
NCT00266526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0303rB|Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV|A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen||Allergopharma GmbH & Co. KG||Completed|July 2003|July 2005|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||March 2013|March 1, 2013|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00266526||186935|
NCT00265343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05777|6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)|A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed the Protocol 25543 (NCT 00212836; P05817)||Merck Sharp & Dohme Corp.|Yes|Completed|December 2005|January 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|December 12, 2005|Yes|Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00265343||187024|
NCT00266539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004717|A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump|Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by Fentanyl HCl Transdermal System Versus Morphine IV Pump for Pain Management After Non-emergent Abdominal or Pelvic Surgery||Alza Corporation, DE, USA||Completed|April 2004|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|506|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00266539||186934|
NCT00268125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 DIVE 05|Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.|Evaluation of Acupression's Bracelets Associated to an Educational Step Versus Education Only in Nausea and Vomiting's Mastering Induced by FEC100 Chemotherapy's Sort.||Institut Claudius Regaud||Completed|February 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|347|||Female|18 Years|N/A|No|||March 2009|March 17, 2009|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268125||186815|
NCT00268450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454937|Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery|A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder||Medical University of South Carolina|Yes|Completed|September 2005|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|December 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268450||186793|
NCT00243698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT03-FT/SEN|A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions|A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions||University Hospital, Tours|No|Completed|May 2004|May 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|59|||Female|18 Years|N/A|No|||November 2007|November 21, 2007|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00243698||188650|
NCT00243971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0825|A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease|A Phase 3, Randomized, Open-Label, Two-Arm, Parallel-Group, Multicenter, Multinational Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease||UCB Pharma||Completed|November 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||September 2009|September 24, 2014|October 24, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00243971||188629|
NCT00244933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446089|Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer|Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays||Barbara Ann Karmanos Cancer Institute|Yes|Completed|February 2004|October 2009|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||February 2015|February 5, 2015|October 25, 2005|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00244933||188556|Although the study is designed to accrue 18 response evaluable participants in the first stage, the decision was made to close the study after 17 patients because of lack of efficacy.
NCT00244569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBID-2005-VCU|Development of a Breath Test for Monitoring Patients With Liver Disease|Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis||Virginia Commonwealth University||Completed|September 2005|April 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|120|||Both|18 Years|N/A|No|||August 2006|December 14, 2007|October 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244569||188584|
NCT00240526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100450|LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers|Long-Term Follow-up Study at Years 16, 17, 18, 19 and 20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine Administered With or Without HBIG in Newborns of HBeAg+ Mothers||GlaxoSmithKline||Completed|October 2003|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|79|||Both|16 Years|20 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|October 13, 2005|Yes|Yes||No|June 14, 2010|https://clinicaltrials.gov/show/NCT00240526||188891|No safety data were collected during the long-term follow-up study.
NCT00240773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002197|A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee|A Randomized, Double-Blind, Long-Term Comparative Study Evaluating the Safety and Efficacy of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||June 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|581|||Both|40 Years|75 Years|No|||June 2015|June 18, 2015|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240773||188872|
NCT00251602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0059|Analysis of Atropine and Propranolol Induced Changes|Wavelet Transform and Pharmacodynamic Analysis of Atropine and Propranolol Induced Changes in Human Heart Rate Variability||National Institutes of Health Clinical Center (CC)||Completed|March 2003|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Actual|24|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 3, 2012|November 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00251602||188055|
NCT00251875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS013326|Shared Online Health Records for Patient Safety and Care|Shared Online Health Records for Patient Safety and Care||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|July 2005|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||5400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2005|November 9, 2005|November 9, 2005||||No||https://clinicaltrials.gov/show/NCT00251875||188035|
NCT00252993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP225-04-005|12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DDP225 in Patients With Chronic Functional Vomiting||Dynogen Pharmaceuticals||Terminated|November 2005|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||October 2007|October 10, 2007|November 11, 2005||||||https://clinicaltrials.gov/show/NCT00252993||187950|
NCT00253006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA_H_Ka-05104-m|Analysis of Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium|A Quantitative Analysis of Protein- and mRNA-Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium||Copenhagen University Hospital at Herlev||Terminated|January 2006|January 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||60|||Both|18 Years|N/A|No|||October 2006|October 6, 2006|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253006||187949|
NCT00270790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC 0202|EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.|A SINGLE SITE EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CONCURRENT CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH ADVANCED LOCOREGIONAL SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK.||University of Maryland||Completed|May 2002|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||December 2005|December 23, 2005|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00270790||186618|
NCT00271102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0193|Surgical Study Comparing 2 Procedures for the Treatment of a Dropped Bladder|Randomized Trial Comparing Anterior Colporrhaphy to Paravaginal Defect Repair for Anterior Vaginal Wall Prolapse||Geisinger Clinic|No|Active, not recruiting|December 2005|February 2012|Anticipated|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||July 2010|July 9, 2010|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271102||186594|
NCT00271362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3789I|Bone Physiology & Mechanics in Osteomyoplasty Amputation Rehabilitation|Bone Physiology & Mechanics in Osteomyoplasty Amputation Rehabilitation||VA Office of Research and Development|No|Terminated|January 2006|December 2010|Anticipated|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|18 Years|N/A|No|||November 2010|November 4, 2010|December 28, 2005||No|This project is no longer active with DVA.|No||https://clinicaltrials.gov/show/NCT00271362||186574|
NCT00264368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCV-PRISMA|Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy|Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy||University of Oslo School of Pharmacy||Terminated|December 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|6|||Both|18 Years|N/A|No|||June 2007|June 27, 2007|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264368||187098|
NCT00264667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADG103440|Study In Patients With Dyslipidaemia|A Randomised,Double-blind, Parallel Group, Placebo-controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects||GlaxoSmithKline||Completed|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||290|||Both|18 Years|70 Years|No|||August 2009|August 27, 2009|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264667||187075|
NCT00265707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPTYN001CTIL|Evaluation of a New Blood Pressure Measuring Device.|A Study to Evaluate the Safety and Effectiveness (Overall Performance) of the Press-O-Sense Non-Invasive Blood Pressure Measuring Device.||Maaynei Hayesha Medical Center||Recruiting|September 2005|December 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||120|||Both|18 Years|N/A|No|||December 2005|October 6, 2006|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00265707||186998|
NCT00291005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD6562|PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone|A Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer||Sanofi||Completed|August 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Male|20 Years|74 Years|No|||March 2009|March 26, 2009|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291005||185103|
NCT00291018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDC-08122003|Safety and Efficacy Study Comparing ProDisc-C to ACDF Surgery to Treat SCDD|A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc-C to Anterior Cervical Discectomy and Fusion (ACDF) Surgery in the Treatment of Symptomatic Cervical Disc Disease (SCDD)||Synthes USA HQ, Inc.|No|Completed|August 2003|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|60 Years|No|||July 2014|August 4, 2015|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291018||185102|
NCT00291330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.53|Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism|A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.|RE-COVER I|Boehringer Ingelheim||Completed|February 2006|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|2564|||Both|18 Years|N/A|No|||April 2014|June 3, 2014|February 13, 2006||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00291330||185080|
NCT00291343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105239 (mth24-30)|Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study|Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study||GlaxoSmithKline||Completed|February 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|296|||Both|15 Months|24 Months|Accepts Healthy Volunteers|||November 2011|November 3, 2011|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291343||185079|
NCT00291954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN017/HBV-003 (105762)|Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination|A Multicentric, Randomised Study Comparing the Immunogenicity and Safety of Henogen's Adjuvanted Hepatitis B Vaccine Given at 0, 1months to That of Aventis Pasteur MSD's Hepatitis B Given at 0, 1 Months in Pre-Dialysis, and Dialysis Patients Did Not Respond to Previous Hepatitis B Vaccination||Henogen|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|257|||Both|15 Years|N/A|No|||August 2008|August 27, 2008|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00291954||185032|
NCT00293059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91469|Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.||Bayer|No|Completed|December 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Female|18 Years|N/A|No|||November 2013|November 5, 2013|February 15, 2006|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00293059||184956|
NCT00292734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9259|STILDEP: Zolpidem in Depressive and Dysthimic Patients|Additive Beneficial Effect of Zolpidem Onto the Antidepressant Therapy in Depressive and Dysthimic Patients in the Acute Phase of the Disease||Sanofi||Completed|January 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|75 Years|No|||December 2007|December 4, 2007|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292734||184980|
NCT00293020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEN-202|Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy|An Open Label, Long-term Treatment Evaluation of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy||BioDelivery Sciences International|No|Completed|February 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|244|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|February 15, 2006|Yes|Yes||No|February 13, 2012|https://clinicaltrials.gov/show/NCT00293020||184959|
NCT00294008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005071|A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)|Electronic Schizophrenia Treatment Adherence Registry(e-STAR): An Observational, International Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres||Janssen Korea, Ltd., Korea|No|Completed|December 2004|June 2009|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|230|||Both|18 Years|N/A|No|Non-Probability Sample|All patients starting with a new antipsychotic medication, decided after agreement between        the physician and the patient, in accordance with the local label, are eligible for        inclusion in this survey. While patients participating in randomized clinical trials are        not excluded, their participation will be noted.|April 2014|April 2, 2014|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00294008||184886|
NCT00294268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|erie8202|Cognitive Behavioural Therapy for Obesity|A Maintenance-Oriented Cognitive Behavioural Therapy in the Treatment of Obesity||University of Sydney|Yes|Completed|March 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||July 2008|July 1, 2008|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00294268||184867|
NCT00294593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJL-FA-TH01|Efficacy Study of Folinic Acid to Improve Mental Development of Children With Down Syndrome|One-year Double-blind Placebo-controlled Phase 2-3 Study to Evaluate the Effect of Oral Folinic Acid Treatment (1mg/kg/d) on the Psychomotor Development of Young Down Syndrome Patients||Institut Jerome Lejeune||Completed|October 2000|December 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|3 Months|30 Months|No|||December 2009|December 16, 2009|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294593||184843|
NCT00253227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006028|A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease|Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 1997|December 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|387|||Both|18 Years|N/A|No|||November 2010|May 17, 2011|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253227||187932|
NCT00253474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050232|PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma|A Phase I Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas||National Institutes of Health Clinical Center (CC)||Completed|September 2005|January 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|1 Year|21 Years|No|||March 2012|March 28, 2012|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253474||187913|
NCT00249548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13444-3|Low-Cost Contingency Management for Hispanic Outpatients - 3|Low-Cost Contingency Management for Hispanic Outpatients||National Institute on Drug Abuse (NIDA)|No|Completed|August 2004|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2008|May 23, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249548||188212|
NCT00249821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 25735|Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age|Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Efficacy of a Saizen® Treatment at the Same Dose Versus a Lower Maintenance Dose Prolonged During 1 Additional Year.|SGA OPTIMIS|Merck KGaA|No|Completed|February 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|6 Years|11 Years|No|||December 2013|December 2, 2013|November 4, 2005||No||No|June 28, 2012|https://clinicaltrials.gov/show/NCT00249821||188191|Participants’ inclusion period was extended but due to remaining low recruitment rate, it was finally decided to stop enrollment even if only 22 participants were enrolled.
NCT00250692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-04-029-01|A Study to Test the Pain-Relieving Effect of Laughing Gas in Infants|Analgesic Effect of Nitrous Oxide in Neonates Undergoing Heel Stick||University of California, Los Angeles||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind||||52|||Both|N/A|3 Months||||November 2005|November 28, 2005|November 7, 2005||||No||https://clinicaltrials.gov/show/NCT00250692||188125|
NCT00250094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603C|Clinical Benefit of Topoisomerase Downregulation|Clinical Benefit of Topoisomerase Downregulation: A Phase I Pilot Study||New Mexico Cancer Care Alliance|Yes|Completed|May 2004|March 2006|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||September 2011|September 2, 2011|November 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250094||188170|
NCT00250679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-061|Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease|Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease||Sunovion|Yes|Completed|October 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|443|||Both|35 Years|N/A|No|||May 2012|May 29, 2012|November 4, 2005|No|Yes||No|October 3, 2008|https://clinicaltrials.gov/show/NCT00250679||188126|Please see dropout rate in participant group. Sunovion is unaware of any other limitations or caveats associated with this study.
NCT00291356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2104940|GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients|A Double-blind, Randomized, Placebo-controlled, Repeat Dose Study to Compare the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 With GW869682 in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|January 2006|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Both|30 Years|70 Years|No|||April 2015|April 14, 2015|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291356||185078|
NCT00291694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9118|Protocol for Women at Increased Risk of Developing Breast Cancer|A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo||University of Kansas Medical Center|No|Completed|April 2003|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|72|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|February 10, 2006|Yes|Yes||No|June 24, 2013|https://clinicaltrials.gov/show/NCT00291694||185052|
NCT00291707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-005|Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer|A Phase I Trial of Cetuximab (C225) and Pemetrexed With Concurrent Radiation in Head and Neck Cancer||University of Pittsburgh|Yes|Completed|March 2006|January 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291707||185051|
NCT00291941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN014/HBV-001 (105757)|A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.|A Multicentric, Randomised Study Comparing the Immunogenicity and Safety of Henogen's Adjuvanted Hepatitis B Vaccine Given at 0, 1, 6 Months to That of GSK Biologicals' Adjuvanted Hepatitis B Vaccine Given at 0, 1, 2, 6 Moths in Pre-Dialysis, and Dialysis Patients Who Are Hepatitis B Naive.||Henogen|No|Completed|February 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|15 Years|N/A|No|||August 2008|August 27, 2008|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00291941||185033|
NCT00291967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|759346|Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants|Evaluate the Feasibility of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC Vaccine Administered as a 3 Dose Primary Vaccination Course at 6, 10 & 14 Weeks of Age||GlaxoSmithKline||Completed|November 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||525|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||December 2006|December 7, 2006|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00291967||185031|
NCT00293072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot study of Rituximab|Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis|Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Resistant to Conventional Therapy||Cambridge University Hospitals NHS Foundation Trust||Completed|March 2002|May 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|70 Years|No|||October 2005|February 16, 2006|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293072||184955|
NCT00293696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6876C00001|Casodex/Zoladex Biomarkers in Localised Prostate Cancer|A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma||University of Tampere||Completed|October 2004|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Male|18 Years|70 Years|No|||May 2007|May 7, 2007|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293696||184910|
NCT00292747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9134|Drotaverine in Dysmenorrhoea Treatment|Comparison of the Efficacy and Tolerability of Drotaverine 80 mg, Ibuprofen 400 mg and Their Combination in a Calendar Packaging for the Treatment of Primary and Secondary Dysmenorrhoea||Sanofi||Terminated|May 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||480|||Female|18 Years|45 Years|No|||November 2008|November 14, 2008|February 15, 2006||No|early termination due to loss of interest and low enrollment of patient|No||https://clinicaltrials.gov/show/NCT00292747||184979|
NCT00293033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEN-201|Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects|A Double-Blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects||BioDelivery Sciences International|No|Completed|February 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|152|||Both|18 Years|N/A|No|||January 2008|January 16, 2008|February 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293033||184958|
NCT00293046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-10|Assessment of Grazax® Treatment Compliance|A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis||ALK-Abelló A/S||Completed|February 2006|October 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||500|||Both|18 Years|65 Years|No|||September 2008|September 29, 2008|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293046||184957|
NCT00293644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007791|Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy.|A Randomized, Open-Label, Study of Pre-emptive Diclectin® Treatment for Severe Nausea and Vomiting of Pregnancy.||The Hospital for Sick Children|No|Active, not recruiting|February 2006|April 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Female|18 Years|N/A|No|||November 2014|November 19, 2014|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00293644||184914|
NCT00293657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNP-201|Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.|A Randomized, Double-Blind, Single-Dose Study, Placebo-Controlled Evaluation of the Safety and Efficacy of Intravenous Lornoxicam in the Acute Treatment of the Headache of Migraine.||POZEN||Completed|December 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years||||November 2012|November 29, 2012|February 15, 2006||||||https://clinicaltrials.gov/show/NCT00293657||184913|
NCT00294034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197|VIBRANT Registry: Value of Information Based From Pacemaker Recordings and New Technologies|VIBRANT Registry: Value of Information Based From Pacemaker Recordings and New Technologies||Medtronic Cardiac Rhythm Disease Management||Completed|October 2002|May 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||950|||Both|N/A|N/A|No|||March 2007|March 26, 2007|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00294034||184884|
NCT00294021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIH-LTNP|Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage|Long-term Impact of the Pneumococcal Conjugate Vaccine on Pneumococcal Nasopharyngeal Colonization and Immune Correlates for Disease Protection||Johns Hopkins Bloomberg School of Public Health|No|Completed|March 2006|April 2008|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Nasopharyngeal specimens will be collected for isolation of pneumococcus; saliva and serum      specimens will be collected for antibody assays|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults and children living on the Navajo or White Mountain Apache reservations|September 2012|September 25, 2012|February 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00294021||184885|
NCT00294281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR053732|Vagus Nerve Stimulation for Treating Adults With Severe Fibromyalgia|A Pilot Study to Assess the Tolerability and Exploratory Efficacy of Vagus Nerve Stimulation (VNS) Using the VNS Therapy System in Patients With Refractory Fibromyalgia With and Without Major Depression||Rutgers, The State University of New Jersey|Yes|Completed|October 2006|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|60 Years|No|||July 2010|September 19, 2011|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294281||184866|
NCT00294294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6106A1-500|Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa|A Randomized Controlled Open-Label Phase IV Multi Center Study to Assess the Effect of Antipyretic Prophylactic Treatment on the Rate of Febrile Reactions Following Concomitant Contralateral Administration of a 7-Valent Pneumococcal Conjugate Vaccine (Prevenar®) and DTPa-HBV-IPV+Hib Vaccine (Infanrix Hexa®) in Children at 2, 3, 4 and 11-14 Months of Age||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|56 Days|112 Days|Accepts Healthy Volunteers|||February 2013|February 20, 2013|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294294||184865|
NCT00294619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPLG-005|Treatment of Adults With Growth Hormone Deficiency|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.||LG Life Sciences|Yes|Completed|April 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|23 Years|70 Years|No|||October 2012|October 4, 2012|February 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294619||184841|
NCT00253019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|518-2003|A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods|A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods (Oral Contraceptive Pills, Depo Provera and Ortho Evra) Among Women Seeking First Trimester Abortion.||Emory University|No|Completed|October 2004|November 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|321|||Female|13 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants were recruited from a indigent, urban, African American population.|August 2013|August 10, 2013|November 14, 2005||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT00253019||187948|
NCT00253032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F05001|Pain Relief Investigation of NeuroModulation Therapy in Adult Humans|PRIMA Study: Pain Relief Investigation of NeuroModulation Therapy in an Adult Population: A Double Blind, Randomized, Multicenter, Placebo Controlled Trial.||Fralex Therapeutics||Terminated||||||Phase 3|Interventional|N/A|||||||||||||March 2006|March 2, 2006|November 11, 2005||||||https://clinicaltrials.gov/show/NCT00253032||187947|
NCT00249834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25198|Safety and Efficacy of a Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing IVF|A Phase IIIB/IV, Open Label Study to Assess the Efficacy and Safety of a Pre-defined, Fixed Dose of Gonal-f® (Filled-by-Mass in a Prefilled Pen) Based on Subject Baseline Characteristics, for Ovarian Stimulation in Subjects Undergoing in Vitro Fertilization (IVF)|CONSORT in ART|Merck KGaA||Completed|September 2004|March 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Female|18 Years|34 Years|No|||February 2014|February 17, 2014|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00249834||188190|
NCT00250120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402C-T|Pharmacology Study of Aerosolized Liposomal|Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S) - Camptothecin (L9NC)||University of New Mexico|Yes|Completed|April 2003|August 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2008|January 6, 2010|November 3, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250120||188169|
NCT00250393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-0407|A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease|Placebo-Controlled , Crossover , Double-Blind Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Monotherapy]||Kyowa Hakko Kirin Company, Limited|No|Completed|November 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|30 Years|N/A|No|||August 2012|August 28, 2012|November 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00250393||188148|
NCT00242190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2003-082|Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer|Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer||University of Michigan Cancer Center||Completed|June 2004|February 2010|Actual|March 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||November 2010|November 10, 2010|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242190||188766|
NCT00241917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U50/CCU923257|A Video-Based HCV Curriculum for Drug Users|Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training||Organization to Achieve Solutions in Substance Abuse (OASIS)|No|Completed|November 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|450|||Both|18 Years|90 Years|No|||December 2008|December 5, 2008|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00241917||188787|
NCT00242515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP02/28/04|T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)|Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)||National University Hospital, Singapore||Recruiting|March 2005|March 2008||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|16|||Both|21 Years|90 Years|No|||January 2014|January 7, 2014|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00242515||188741|
NCT00242528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EMX03|Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.|Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.||Novartis||Withdrawn|April 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|October 9, 2005||||No||https://clinicaltrials.gov/show/NCT00242528||188740|
NCT00242866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOS103325|Use Of GW274150 In The Prophylactic Treatment Of Migraine|A Multicentre, Two-part, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up to 120mg Daily for 12 Weeks in the Prophylactic Treatment of Migraine.||GlaxoSmithKline|No|Completed|October 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|430|||Female|18 Years|55 Years|No|||October 2014|September 24, 2015|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00242866||188714|
NCT00243100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00091|Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase 1 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Gemcitabine in Patients With Epithelial Tumors||National Cancer Institute (NCI)||Completed|November 2005|||August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|October 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00243100||188696|
NCT00291369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERCY QUATTRO|Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis|PERCY QUATTRO: Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis||Centre Leon Berard||Completed|December 1999|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||456|||Both|18 Years|N/A|No|||February 2006|February 15, 2006|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291369||185077|
NCT00291720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPK2749|Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?|Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?||University Hospital Birmingham|Yes|Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||May 2008|May 20, 2008|February 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00291720||185050|
NCT00292760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2729|A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion|A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion||Royal Marsden NHS Foundation Trust||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2009|December 15, 2009|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292760||184978|
NCT00293709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-102036|Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists|Prospective Post Marketing Surveillance To Evaluate The Safety And Efficacy Of Etanercept Under Usual Care Settings In Patients With Psoriatic Arthritis (Psa) Treated By Dermatologists||Pfizer|No|Completed|January 2006|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|129|||Both|18 Years|N/A|No|Non-Probability Sample|Only patients for whom the decision has already been made to initiate treatment with        Enbrel® can be enrolled in this observational trial. These patients must have a proven        diagnosis of Psoriatic Arthritis.|January 2014|January 10, 2014|February 15, 2006||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT00293709||184909|
NCT00293722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-102064|Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists|Prospective Post Marketing Surveillance to Evaluate the Safety and Efficacy of Etanercept Under Usual Care Settings in Patients With Psoriatic Arthritis (PsA) Treated by Rheumatologists||Pfizer|No|Completed|January 2006|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1308|||Both|18 Years|N/A|No|Non-Probability Sample|Only patients for whom the decision has already been made to initiate treatment with        Enbrel® can be enrolled in this observational trial. These patients must have a proven        diagnosis of Psoriatic Arthritis|January 2014|January 10, 2014|February 15, 2006|No|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT00293722||184908|Results for Psoriasis Area and Severity Index (PASI) was not reported since it was not to be analyzed by rheumatologists as part of this study, as per planned analysis.
NCT00293345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00119|3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of a Prolonged Infusion of Triapine in Combination With a Fixed Dose Rate of Gemcitabine in Patients With Advanced Solid Tumors and Lymphomas||National Cancer Institute (NCI)||Completed|June 2006|||October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|February 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00293345||184935|
NCT00293670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9393FN/0001|FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer|Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer||University of Tampere||Active, not recruiting|May 1997|April 2015||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||573|||Male|N/A|N/A|No|||February 2006|February 16, 2006|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293670||184912|
NCT00293683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04U.498|A Study Comparing Two Different Techniques for Closing the Skin After a Cesarean Delivery|Cesarean Delivery Skin Closure: A Randomized Controlled Trial of Standard Staples Versus Absorbable Staples||Thomas Jefferson University|Yes|Active, not recruiting|December 2004|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Female|12 Years|55 Years|No|||July 2014|July 28, 2014|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293683||184911|
NCT00294047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104820|Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older|A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above||GlaxoSmithKline||Completed|February 2006|January 2014|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5752|||Female|26 Years|N/A|Accepts Healthy Volunteers|||July 2015|November 30, 2015|February 17, 2006|Yes|Yes||No|December 8, 2011|https://clinicaltrials.gov/show/NCT00294047||184883|
NCT00294307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG023116|Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers|Hospital to Home: Cognitively Impaired Elders/Caregivers||University of Pennsylvania|No|Completed|February 2006|August 2012|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|814|||Both|65 Years|N/A|No|Non-Probability Sample|Hospitalized community dwelling older adults with cognitive impairment and a caregiver|January 2016|January 13, 2016|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00294307||184864|
NCT00294645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701|PREFER (Pacemaker Remote Follow-Up Evaluation and Review)|Pacemaker Remote Follow-up Evaluation and Review||Medtronic Cardiac Rhythm Disease Management|No|Completed|April 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|980|||Both|N/A|N/A|No|||October 2010|October 1, 2010|February 20, 2006||No||No|April 1, 2009|https://clinicaltrials.gov/show/NCT00294645||184839|
NCT00253266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2005|Venlafaxine Augmentation in Treatment Resistant Depression|Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression||Max-Planck-Institute of Psychiatry|Yes|Completed|April 2008|August 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|20 Years|70 Years|No|||April 2015|April 7, 2015|November 11, 2005||No||No||https://clinicaltrials.gov/show/NCT00253266||187929|
NCT00241553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9617C00004|Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs||AstraZeneca||Completed|April 2001|February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||276|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00241553||188814|
NCT00241930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H97HA03792|Integrating Buprenorphine Into HIV Treatment|SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model||Organization to Achieve Solutions in Substance Abuse (OASIS)||Recruiting|September 2005|February 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|85 Years|No|||August 2005|October 24, 2005|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241930||188786|
NCT00241943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U50/CCU923257-2|A Video-Based HCV Curriculum for Active Injection Drug Users|Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training||Organization to Achieve Solutions in Substance Abuse (OASIS)|No|Completed|November 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|103|||Both|18 Years|N/A|No|||December 2008|December 8, 2008|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00241943||188785|
NCT00242203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0788 / 201104272|Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer|Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer||Washington University School of Medicine|Yes|Completed|October 2002|May 2011|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|N/A|No|||August 2013|August 9, 2013|October 17, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00242203||188765|
NCT00242541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995BMX02|Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas|Open Label Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas||Novartis||Terminated|March 2003|||August 2005|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||April 2012|April 25, 2012|October 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00242541||188739|
NCT00242554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EMX01|Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases|Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases||Novartis||Completed|October 2002|||July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Male|18 Years|80 Years|No|||April 2012|April 27, 2012|October 9, 2005||||No||https://clinicaltrials.gov/show/NCT00242554||188738|
NCT00242567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446E2432|Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer|A Phase III, Parallel Group, Randomized, Open-label, Multi-centre Clinical Trial of Zoledronic Acid in Males Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer.||Novartis||Completed|December 2005|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|522|||Male|18 Years|N/A|No|||April 2014|April 14, 2014|October 19, 2005||No||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00242567||188737|
NCT00242879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPR20001|A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults|See Detailed Description||ViiV Healthcare||Terminated|August 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|130|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242879||188713|
NCT00291980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN018/HBV-004 (105754)|A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.|A Phase III, Multicentric, Multinational, Controlled, Randomised, Open Study Comparing the Immunogenicity, Reactogenicity and Safety of Henogen's New Adjuvanted Hepatitis B Vaccine, HB-AS02V, to That of Aventis Pasteur MSD's Hepatitis B Vaccine, HBVAXPRO® , Administered as a Booster Dose in Pre-Dialysis, Peritoneal Dialysis and Haemodialysis Subjects (³ 15 Years of Age) Who Previously Responded to Hepatitis B Primary Vaccination But Have Lost Antibody.||Henogen|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|185|||Both|15 Years|N/A|No|||August 2008|August 27, 2008|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00291980||185030|
NCT00291993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2004.01.PHH|Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea and Healthy Controls.|||Regional Hospital Holstebro||Completed|January 2004|||||Phase 4|Observational|Time Perspective: Prospective|||||||Both|20 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 17, 2008|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291993||185029|
NCT00292331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH-88-B251|N-Butyl-2-Cyanoacrylate Injection Versus Band Ligation for Gastric Variceal Hemorrhage|A Randomized Trial of Endoscopic Treatment of Acute Gastric Variceal Hemorrhage: N-Butyl-2-Cyanoacrylate Injection Versus Band Ligation||Taipei Veterans General Hospital, Taiwan||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|80 Years|No|||February 2006|February 14, 2006|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00292331||185004|
NCT00292773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14006|Weight Reduction Surgery and Ovarian Function|The Effect of Weight Reduction Surgery on Ovarian Function in Obese Anovulatory Patients||Sheffield Teaching Hospitals NHS Foundation Trust||Completed|February 2006|February 2008|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|45 Years|No|Non-Probability Sample|Obese anovulatory women.|July 2011|July 19, 2011|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00292773||184977|
NCT00294086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489BUS70|A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure|A 12-Week Multicenter, 2-Arm Regimen, Exploratory Study to Evaluate the Tolerability and Safety of Valsartan Administered Once Daily vs Daily, in Patients With Stable, Chronic Heart Failure (NYHA Class Ll-lll)||Novartis||Completed|December 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A||||June 2011|June 7, 2011|February 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00294086||184880|
NCT00294099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0141|H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults|A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Elderly Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|600|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2008|May 30, 2013|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294099||184879|
NCT00293358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455625|Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain|SIOP Intracranial Germ Cell Tumours Protocol||National Cancer Institute (NCI)||Completed|January 1997|December 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|N/A|N/A|No|||July 2008|September 16, 2013|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293358||184934|
NCT00294320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-IMIQ|Evaluation of Two Different Non-Invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions|Pilot Study to Evaluate Two Different Non-Invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions (Clinical and Sub-Clinical), When Treated With Aldara 5% (Imiquimod) Cream||MEDA Pharma GmbH & Co. KG||Completed|February 2006|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|12|||Both|18 Years|N/A|No|||September 2008|September 24, 2008|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00294320||184863|
NCT00294346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV608-105|Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder|A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Social Anxiety Disorder||Avera Pharmaceuticals||Completed|February 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|65 Years|No|||February 2008|February 15, 2008|February 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294346||184862|
NCT00294658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS050733|Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy|A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone||University of Alabama at Birmingham|Yes|Active, not recruiting|June 2006|March 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00294658||184838|
NCT00290017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH-305|Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy|A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy||Point Therapeutics||Terminated|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||June 2007|June 7, 2007|February 9, 2006|||FDA Hold May 2007|||https://clinicaltrials.gov/show/NCT00290017||185176|
NCT00290030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4428|ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH|A Double-Blind Randomized Parallel Group Study of Alfuzosin 10mg OD Versus Placebo in the Management of Acute Urinary Retention in Patients With a First Episode Due to Benign Prostatic Hyperplasia (BPH)||Sanofi||Completed|May 2001|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|800|||Male|50 Years|N/A|No|||March 2009|March 10, 2009|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290030||185175|
NCT00290043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A/1008|Glulisine Pre- and Postmeal|Glucodynamic Response to Pre- and Postmeal Subcutaneous Injection of 0.15 IU/kg HMR1964 Insulin and RHI in Type 1 Diabetic Subjects in an Open, Randomized, Four-way Crossover Study||Sanofi||Completed|December 2001|March 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|No|||December 2010|December 3, 2010|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290043||185174|
NCT00290316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002|Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver|Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver – A Prospective Study||Central Texas Veterans Health Care System||Active, not recruiting|July 2004|January 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||January 2006|June 5, 2006|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290316||185153|
NCT00253487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC-04660|Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas|A Pilot Study of Temozolomide and O-Benzylguanine for Treatment of High-Grade Glioma, Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection||National Cancer Institute (NCI)||Completed|August 2005|August 2012|Actual|August 2012|Actual|N/A|Interventional|Primary Purpose: Treatment|||||||Both|5 Years|55 Years|No|||January 2006|January 3, 2014|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253487||187912|
NCT00249561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-14370-1|Colorado Women's TC Project|Women's Prison TC: Outcomes, Process & Economic Analysis||National Development and Research Institutes, Inc.|Yes|Completed|September 2001|September 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|610|||Female|18 Years|N/A|No|||July 2011|July 19, 2011|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249561||188211|
NCT00241215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA#03-03-061-03A|Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome|Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome||University of California, Los Angeles||Recruiting|June 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years|No|||June 2005|April 18, 2007|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241215||188840|
NCT00241566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0002|Economic Medical Evaluation of Treatment of the Neuropathic Pain Rebel by Cortical Stimulation|Economic Medical Evaluation of Treatment of the Neuropathic Pain Rebel by Cortical Stimulation||University Hospital, Clermont-Ferrand||Completed|August 2003|December 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||January 2010|January 19, 2010|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241566||188813|
NCT00241579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-SD-107|Analgesic Efficacy of Smoked Cannabis|Analgesic Efficacy of Smoked Cannabis||Center for Medicinal Cannabis Research||Completed|February 2002|January 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2006|June 21, 2006|October 17, 2005||||||https://clinicaltrials.gov/show/NCT00241579||188812|
NCT00241956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.246|Impact of Diabetes and Glucose Control During Rehabilitation After Stroke|Impact of Diabetes and Glucose Control During Rehabilitation After Stroke||Melbourne Health|No|Terminated|October 2005|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|20|||Both|N/A|N/A|No|Probability Sample|Stroke rehab patients|July 2011|July 19, 2011|October 18, 2005||No|poor data collection|No||https://clinicaltrials.gov/show/NCT00241956||188784|
NCT00241969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 54915|Behavioral & Nutritional Treatment to Help CF Preschoolers Grow|A Multi-Site Randomized Clinical Trial of Behavioral and Nutrition Treatment Designed to Help Preschoolers With Cystic Fibrosis Optimize Growth||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|January 2006|December 2015|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|6 Years|No|||January 2014|January 29, 2014|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00241969||188783|
NCT00242216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-03-315|"The Once A Day Protease Inhibitor Regimens"|"PIQD: The Once a Day Protease Inhibitor Regimens." Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients.||The University of Texas Health Science Center, Houston|No|Completed|May 2004|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|October 18, 2005|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00242216||188764|High porportion of subject did not complete the study.
NCT00242229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-307|Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder|A 6 Month, Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Elderly Outpatients With Major Depressive Disorder (MDD)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2004|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|52|||Both|65 Years|N/A|No|||August 2009|August 18, 2009|October 17, 2005||||||https://clinicaltrials.gov/show/NCT00242229||188763|
NCT00242242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060012|Moving a Paralyzed Hand Through Use of a Brain-Computer Interface|Moving a Paralyzed Hand Through a Brain-Computer Interface Controlled by the Affected Hemisphere After Stroke or Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Terminated|October 2005|July 2013||||N/A|Observational|N/A|||Actual|110|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2013|May 21, 2014|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00242242||188762|
NCT00242580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952E2202|A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib|A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne® Plus Intravitreal Pegaptanib(Macugen®) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|VERITAS|Novartis||Completed|September 2005|||January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|111|||Both|50 Years|N/A|No|||April 2011|April 1, 2011|October 19, 2005|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00242580||188736|Secondary outcome measures were to be assessed at Month 6 and at 24 months. However, this study was not completed but terminated after all patients completed 12 months. Original safety was COSTART now mapped to SOC MedDRA.
NCT00242892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P001003|FROST 4: Study of the Optimal Spreading of a Coronary Stent Guided With Pressure Into the Coronary Arteries|Prospective Study Randomized Multicentric On the Optimization Of the Installation Of Stent By Measurement Of the Intra-Coronary Pressure||Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2001|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|800|||Both|18 Years|N/A|No|||March 2007|November 25, 2011|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00242892||188712|
NCT00292006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11955|Computerized Tomography to Help Diagnosis Pediatrics Scaphoid Fractures.|The Efficiency of Computerized Tomography to Aid in the Diagnosis of Pediatrics Scaphoid Fractures||Lawson Health Research Institute||Not yet recruiting|February 2006|January 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||73|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||February 2006|February 14, 2006|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00292006||185028|
NCT00292370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-006-04F|Quetiapine Augmentation for Treatment-resistant PTSD|A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD||VA Office of Research and Development|Yes|Completed|January 2006|May 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|65 Years|No|||June 2014|June 27, 2014|February 13, 2006||No||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00292370||185001|
NCT00292344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-04-01|Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea|Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea||The University of Texas Health Science Center, Houston||Completed|June 2004|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||316|||Both|18 Years|N/A|No|||February 2006|April 17, 2009|February 13, 2006||||||https://clinicaltrials.gov/show/NCT00292344||185003|
NCT00292357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-Med1-01/06|Local Application of Autologous Bone Marrow Cells for Treatment of Chronic Diabetic Ulcers|||Heidelberg University||Recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||April 2007|January 15, 2010|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00292357||185002|
NCT00293371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456195|Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer|A Phase I/II Study of Docetaxel/Prednisone and PTK 787/ZK 222584 in Previously Untreated Metastatic Hormone Refractory Prostate Cancer||University of California, San Francisco||Terminated|February 2005|September 2006|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Male|18 Years|N/A|No|||October 2012|October 9, 2012|February 16, 2006|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00293371||184933|
NCT00292474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2004|TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent|TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent||Boston Scientific Corporation||Completed|March 2002|August 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1326|||Both|18 Years|N/A|No|||October 2008|October 7, 2008|February 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00292474||184993|
NCT00292487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP107|Patients With Renal Impairment Undergoing CT|Isovue and Visipaque in Renally Impaired Patients Undergoing CT||Bracco Diagnostics, Inc||Completed|November 2004|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||150|||Both|18 Years|N/A|No|||August 2006|February 7, 2012|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00292487||184992|
NCT00294060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244|P3: Pacemaker Patient Profiling Study|Pacemaker Patient Profiling (P3) Study||Medtronic Cardiac Rhythm Disease Management|No|Terminated|March 2004|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2013|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|April 2011|April 6, 2011|February 16, 2006||No|Preliminary analysis determined there was sufficient data to support objectives and allow    early completion. The last patient visit occurred on November 6, 2007.|No|July 1, 2009|https://clinicaltrials.gov/show/NCT00294060||184882|Characterization of objectives also encompassed 8 device features (Capture Management, MVP, APP, ARS, PMOP, Rate Response, Mode Switch, Sinus Preference) and 10 additional clinical outcomes. More information is available through the point of contact.
NCT00294073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN#05-002|Defining the Best Approach to Block the Pain After Knee Surgery|Defining the Best Approach to Block the Pain After Knee Surgery||McGill University Health Center||Recruiting|July 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|80 Years|No|||August 2005|June 18, 2007|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294073||184881|
NCT00294671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS051306|The Effect of Diflunisal on Familial Amyloidosis|The Effect of Diflunisal on Familial Amyloidosis||Boston University|Yes|Completed|February 2006|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|75 Years|No|||May 2013|May 12, 2013|February 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294671||184837|
NCT00290056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3494-DL-CTIL|Effect of Supplemental Intake of Omega-3 Polyunsaturated Fatty Acids on the Rate and Complexity of Spontaneously Occurring Ventricular and Supraventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillator (ICD) - A Randomized Clinical Trial|||Sheba Medical Center|No|Active, not recruiting|November 2005|June 2010|Anticipated|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||November 2009|November 3, 2009|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00290056||185173|
NCT00290342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104871|Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants|A Multicentric Study to Compare the Immunogenicity, Safety & Reactogenicity of GSK Biologicals' DTPa-IPV Vaccine vs. Co-administration of GSK's DTPa Vaccine & Sanofi-Pasteurs' IPV Vaccine at Different Injection Sites, to Healthy Children||GlaxoSmithKline||Completed|January 2006|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|452|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290342||185151|
NCT00290355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|249553/004|Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery|A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection||GlaxoSmithKline||Completed|May 2002|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|182|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290355||185150|
NCT00240656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510-A|Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension|Official Title: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease—Focus on Pulmonary Artery Remodeling||Hebei Medical University||Completed|October 2005|May 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|80 Years|No|||October 2005|June 27, 2008|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00240656||188881|
NCT00241202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H642-27289|The Efficacy of the HIV/AIDS Symptom Management Manual|The Efficacy of the HIV/AIDS Symptom Management Manual||University of California, San Francisco|No|Completed|October 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|775|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|October 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00241202||188841|
NCT00241228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9410-04|Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)|Impact of High-volume Veno-venous Continuous Hemofiltration in the Early Management of Septic Shock Patients With Acute Renal Failure|IVOIRE|University Hospital, Bordeaux|Yes|Completed|October 2005|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|80 Years|No|||October 2010|October 12, 2010|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241228||188839|
NCT00241241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVN1|Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera|Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients||PV-Nord||Completed|September 2004|January 2008|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241241||188838|
NCT00241592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03-SF-115|Vaporization as a Smokeless Cannabis Delivery System|Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study||Center for Medicinal Cannabis Research||Completed|August 2004|May 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 12, 2007|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00241592||188811|
NCT00241605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|712753/008|AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus|AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.||GlaxoSmithKline|No|Completed|June 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|75 Years|No|||July 2012|July 11, 2013|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241605||188810|
NCT00242593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0087|Rosiglitazone Effects on Cognition for Adults in Later Life|The Effects of Rosiglitazone on Cognition in Patients With MCI|RECALL|University of Washington|Yes|Active, not recruiting|June 2006|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|55 Years|N/A|No|||August 2011|August 4, 2011|October 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00242593||188735|
NCT00242918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI 8847|Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer|Phase II Trial of Neoadjuvant Docetaxel and ZD 1839 (Iressa) Followed by Radical Prostatectomy in Patients With High Risk, Locally Advanced Prostate Cancer||Benaroya Research Institute||Completed|May 2003|November 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||29|||Male|18 Years|N/A|No|||June 2006|February 3, 2012|October 20, 2005||||||https://clinicaltrials.gov/show/NCT00242918||188710|
NCT00243152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Facial Neuropathy/lamotrigine|Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI|Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI||Pain and Analgesia Imaging and Neuroscience Group|No|Completed|October 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|60 Years|No|||November 2012|November 29, 2012|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00243152||188692|
NCT00242905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040203|Functional Magnetic Resonance Imaging (fMRI) Study of Memory in Children|Anatomical and Functional MRI Study of Episodic Memory in Epileptic Compared to Normal Children||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2005|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Inclusion Criteria:          -  Parents or legal tutors of the children having given written consent to participate             to the study, after having being fully informed.          -  Patients presenting with a temporal and/or frontal epilepsy and being able to perform             the tasks of the protocol.          -  Controls being recruited among brothers, sisters, and friends of the patients and             being right-handlers, without any neurological history or learning disorders.        Exclusion Criteria:          -  Any contra-indication to MRI or being claustrophobia or blind.|March 2007|April 29, 2011|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00242905||188711|
NCT00292786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8520|The Effects of Electrical Stimulation Gait Training on Walking and Posture for Children With Cerebral Palsy|Electrical Stimulation Gait Training to Effect Improvements in Walking Function and Posture for Children With Cerebral Palsy||Shriners Hospitals for Children|No|Completed|June 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||February 2008|February 4, 2008|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292786||184976|
NCT00293085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/ NSCLC 2.2.001|An Open, Randomized, Multicentre, Phase II Pilot Study|An Open, Randomized, Multicentre, Phase II Pilot Study of Docetaxel and Cisplatin in the Adjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC) Stage I-II||Central European Cooperative Oncology Group|No|Completed|December 2001|September 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|19 Years|70 Years|No|||June 2011|June 22, 2011|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293085||184954|
NCT00293748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060097|Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease|Dose-Response Study of Modulation of Gene Expression in Peripheral Blood Mononuclear Cells by Atorvastatin||National Institutes of Health Clinical Center (CC)||Completed|February 2006|December 2008||||N/A|Observational|N/A||||200|||Both|21 Years|N/A|No|||December 2008|September 26, 2015|February 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00293748||184906|
NCT00292864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0007|Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors|Phase 1 Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Select Advanced Solid Tumors||Sunesis Pharmaceuticals||Completed|January 2006|December 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|February 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292864||184970|
NCT00294359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0501CR|The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer|The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer||Australasian Gastro-Intestinal Trials Group||Completed|June 2005|July 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|333|||Both|18 Years|N/A|No|||August 2007|August 21, 2007|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294359||184861|
NCT00294372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1188.31|Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients|Randomised, Double-blind, Placebo-controlled 7 Day Monotherapy Phase IIa Study to Evaluate the Antiviral Activity and Safety of Increasing Doses of Oral Administered RTV-boosted BILR 355 BS (75 mg and 150 mg Twice Daily) in HIV-1-infected, NNRTI-experienced Patients, Followed by 28 Day Combination Therapy With Tipranavir or Lopinavir Based HAART-regimen||Boehringer Ingelheim||Terminated|February 2006|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|February 20, 2006||||No||https://clinicaltrials.gov/show/NCT00294372||184860|
NCT00294112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSIRIS-601-602|Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease|A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants||Mesoblast, Ltd.|No|Completed|February 2006|September 2008|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|70 Years|No|||December 2014|December 2, 2014|February 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294112||184878|
NCT00290368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPJMR0052104|Repeat Nasal Allergen Challenge|Assessment of Inflammatory Mediator and Cellular Changes Following Repeated Nasal Allergen Challenge in Subjects With Allergic Rhinitis Sensitive to Timothy Grass Pollen - a Validation Study||Imperial College London||Completed|February 2006|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2006|October 21, 2015|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290368||185149|
NCT00290875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002174-01H, MOP62795|Implementation of the Canadian C-Spine Rule|Implementation of the Canadian C-Spine Rule: Phase III||Ottawa Hospital Research Institute|No|Completed|January 2003|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11824|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00290875||185113|
NCT00291798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG-17|Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane|Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane||Austrian Breast & Colorectal Cancer Study Group||Completed|September 2000|March 2009||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||98|||Female|59 Years|N/A|No|||February 2006|September 18, 2006|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00291798||185044|
NCT00292422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-RA-201|Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis|A Randomized, Blinded, Placebo-Controlled, Multicenter, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD Therapy||Biogen||Completed|November 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|50|||Both|18 Years|75 Years|No|||December 2007|December 26, 2007|February 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292422||184997|
NCT00240669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.366|RESTIT : Evaluation of Resorbable Osteosynthesis Devices Versus Titanium in Maxillofacial Surgery|RESTIT : Evaluation of Resorbable Osteosynthesis Devices Versus Titanium in Maxillofacial Surgery – A Prospective Randomized Trial in Therapeutic Strategy||Hospices Civils de Lyon||Recruiting|November 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||308|||Both|18 Years|50 Years|No|||April 2007|April 26, 2007|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240669||188880|
NCT00240864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002671|An Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|224|||Both|15 Years|N/A|No|||June 2015|June 18, 2015|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240864||188865|
NCT00241982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liposomal prednisolone|Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis|Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis||Radboud University|No|Completed|October 2005|May 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2008|May 28, 2008|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00241982||188782|
NCT00241995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-RCT_LOND_GAT_AWS_2003|Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome|||St. Petersburg State Pavlov Medical University||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2005|October 17, 2006|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241995||188781|
NCT00242255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060010|Epigenetics in the Aging Process|Remodeling of Chromatin-Based Epigenetic Structures in Development and Aging||National Institutes of Health Clinical Center (CC)||Recruiting|October 2005|||||N/A|Observational|N/A|||Anticipated|240|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00242255||188761|
NCT00242268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST 03-09|A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis|||Alabama Neurology Associates, PC||Recruiting|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||September 2005|December 6, 2005|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242268||188760|
NCT00242281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111.302|APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat|A Phase III, Multicenter Study to Evaluate the Safety/Efficacy of APC-111 MP Tablet QD vs. Penicillin VK QID Both for 10 Days Treatment of Pharyngitis Secondary to S.Pyogenes in Adolescents/Adults||Advancis Pharmaceutical Corporation||Completed|November 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|12 Years|N/A|No|||January 2006|October 23, 2006|October 18, 2005||||||https://clinicaltrials.gov/show/NCT00242281||188759|
NCT00242008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0824|A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease|A Phase 3b, Open-Label, Multicenter, Multinational Trial To Assess The Tolerability Of Switching Subjects From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System And Its Effect On Symptoms In Subjects With Idiopathic Parkinson's Disease||UCB Pharma||Completed|December 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||September 2009|September 24, 2014|October 18, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00242008||188780|
NCT00242021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P6468|The Effect of Fatty Acid Composition on Energy Intake and Satiety|Fatty Acid Composition of a Fat Supplement on Energy Intake, Satiety and Fat Metabolism in Lean and Obese Men||TNO||Completed|October 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00242021||188779|
NCT00242294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTA-2217-06|Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)|A Confirmatory Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease (A Placebo-controlled Double-blind Comparative Study)||Takeda||Completed|November 2004|March 2007|Actual|September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||570|||Both|40 Years|N/A||||December 2008|May 4, 2012|October 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00242294||188758|
NCT00242307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTA-2217-05|Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)|A Confirmatory Study of APTA-2217 in Adult Patients With Bronchial Asthma (A Placebo-controlled Double-blind Comparative Study)||Takeda||Completed|May 2004|June 2007|Actual|September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|20 Years|70 Years||||December 2008|May 4, 2012|October 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00242307||188757|
NCT00242606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LaLiMo|Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy|Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study||Philipps University Marburg Medical Center|Yes|Completed|March 2005|January 2009|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|409|||Both|12 Years|N/A|No|||May 2012|May 8, 2012|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00242606||188734|
NCT00242931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447211|Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy|Pilot Trial of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Hormone-Refractory Prostate Cancer||OHSU Knight Cancer Institute|Yes|Withdrawn|January 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|75 Years|No|||September 2010|May 31, 2012|October 20, 2005|Yes|Yes|Unable to successfully recruit subjects to this study.|No||https://clinicaltrials.gov/show/NCT00242931||188709|
NCT00242944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H17-49|Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)|Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome||Kyoto University|Yes|Completed|November 2005|March 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|307|||Both|20 Years|N/A|No|||June 2008|December 16, 2009|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00242944||188708|
NCT00292799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14007|An RCT of Metformin Vs Orlistat in Obese Anovulatory Women|A Randomised Controlled Clinical Trial of Metformin Versus Orlistat for the Management of Obese Anovulatory Women.||Sheffield Teaching Hospitals NHS Foundation Trust||Completed|February 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Female|18 Years|40 Years|No|||July 2008|July 15, 2008|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00292799||184975|
NCT00293098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-2-4700|Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease|Compassionate Use of Deferiprone in Patients With Thalassemia and Iron-Induced Heart Disease||Children's Hospital of Philadelphia||Approved for marketing|March 2006|||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||February 2012|February 8, 2012|February 16, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00293098||184953|
NCT00293111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDX-101-04|Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)|An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)||Teva Pharmaceutical Industries||Terminated|February 2002|||October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293111||184952|
NCT00293735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28505|Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial|Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET)|LAMPET|Baylor College of Medicine|Yes|Suspended|June 2015|December 2020|Anticipated|June 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|8000|||Female|15 Years|60 Years|No|||January 2016|January 21, 2016|February 16, 2006|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00293735||184907|
NCT00290888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2004:045|Arthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty|Arthroscopic Rotator Cuff Repair With and Without Arthroscopic Acromioplasty in the Treatment of Full Thickness Rotator Cuff||Panam Clinic|No|Completed|April 2004|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|February 10, 2006||No||No|March 5, 2014|https://clinicaltrials.gov/show/NCT00290888||185112|Variation in surgical technique and post-op rehabilitation. We do not have confirmation of cuff healing status as no imaging was carried out post-operatively. Assessment of AC morphology is subjective & based solely on pre-operative radiographs.
NCT00293202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200311904|Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients|The Effect of Etanercept in Suppression of the Systemic Inflammatory Response in Hemodialysis Patients||Kaysen, George A., M.D., Ph.D.||Terminated|March 2005|June 2010|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||April 2012|April 4, 2012|February 15, 2006|Yes|Yes|We were unable to recruit sufficient patients within the confines of our budget|No||https://clinicaltrials.gov/show/NCT00293202||184945|
NCT00293215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2004-015|Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen|A Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen||Ludwig Institute for Cancer Research||Completed|February 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|9|||Both|18 Years|N/A|No|||May 2007|May 11, 2007|February 15, 2006||||||https://clinicaltrials.gov/show/NCT00293215||184944|
NCT00290641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000LS068|Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer|A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Completed|April 2001|January 2006|Actual|January 2006|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|68|||Both|N/A|45 Years|No|||October 2012|October 9, 2012|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290641||185129|
NCT00291525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-01|Randomized On-X Anticoagulation Trial|Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT)|PROACT|On-X Life Technologies, Inc.|Yes|Recruiting|July 2006|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|1200|||Both|18 Years|70 Years|No|||September 2015|September 4, 2015|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291525||185065|
NCT00292435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.10|Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)|A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency.||Boehringer Ingelheim||Completed|March 2006|||October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||202|||||||||October 2013|October 28, 2013|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292435||184996|
NCT00292448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.291|A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Ba 679 BR Respimat® 5 μg and Tiotropium Inhalation Capsule 18 μg in Patients With COPD||Boehringer Ingelheim||Completed|February 2006|March 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||157|||Both|40 Years|N/A|No|||October 2013|October 28, 2013|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292448||184995|
NCT00240903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0043|Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine|Revaccination of Healthy Subjects With Intramuscular Inactivated Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine Representing a Drifted Variant||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2005|March 2006||March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2007|August 11, 2011|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240903||188863|
NCT00240877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV024|Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)||MedImmune LLC|No|Completed|August 2002|April 2004|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|330|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2008|November 19, 2008|October 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00240877||188864|
NCT00241644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102248|Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants|Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants||GlaxoSmithKline||Completed|October 2005|January 2009|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2089|||Both|5 Weeks|10 Weeks|Accepts Healthy Volunteers|||November 2012|April 11, 2013|October 18, 2005|Yes|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00241644||188807|
NCT00241657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS10|Immune Responses to BCG Vaccination in Malawi and the UK|||London School of Hygiene and Tropical Medicine||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|12 Years|25 Years|Accepts Healthy Volunteers|||December 2002|December 14, 2005|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241657||188806|
NCT00242320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-119|Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)|The JADE Study: A 12-week, Double-blind, Randomized Study to Investigate the Effect of 500 Mcg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease||Takeda||Completed|August 2005|August 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|551|||Both|40 Years|N/A|No|||December 2008|May 4, 2012|October 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00242320||188756|
NCT00242333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-AD237-005|A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD|A Multi-Center Randomized, Double-Blind, Parallel Group, Placebo Controlled Study, Including an Additional Open Label Tiotropium Group, to Assess the Efficacy, Safety and Tolerability of 4 Doses of AD 237 Inhaled Once Daily for 28 Days in Subjects With COPD.||Sosei||Completed|October 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|40 Years|N/A|No|||May 2006|May 15, 2006|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242333||188755|
NCT00242619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95552|Insulin Resistance in Patients With Mood Disorder|||Stanford University||Completed|July 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||December 2012|December 13, 2012|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00242619||188733|
NCT00242632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95239|Treatment With Namenda in Women at Risk for Cognitive Decline|||Stanford University||Completed|June 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|October 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00242632||188732|
NCT00242957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M991108; 598; SK/RN - 03PRT/24|The Intervention With Microfinance for AIDS and Gender Equity (IMAGE) Study|||London School of Hygiene and Tropical Medicine||Completed|June 2001|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|14 Years|N/A|Accepts Healthy Volunteers|||December 2008|February 5, 2009|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00242957||188707|
NCT00242970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBC3DS-01|Hypertrophic Scarring After Facial Burn|Hypertrophic Scarring After Facial Burn: A Pilot, Observational Study of Static and Dynamic Measurements of Facial Scars With the 3-D Scanner Through the Scar Maturation Process||Legacy Health System|No|Completed|October 2005|February 2011|Actual|February 2011|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|15|||Both|4 Years|70 Years|No|Non-Probability Sample|Study population includes patients with burn injuries to their face and or neck.|March 2015|March 31, 2015|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00242970||188706|
NCT00243204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH-304|Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy|||Point Therapeutics||Terminated|January 2006|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||June 2007|June 7, 2007|October 19, 2005|||FDA Hold May 2007|||https://clinicaltrials.gov/show/NCT00243204||188688|
NCT00243217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0709|Rotigotine Restless Legs Syndrome Dose Finding Trial|Multi-center, Double-blind, Randomized, Placebo-controlled, Six-arm, Parallel-group, Dose-finding Trial to Determine Efficacy, Safety and Tolerability of Five Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome||UCB Pharma||Completed|April 2003|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|341|||Both|18 Years|75 Years|No|||September 2009|September 24, 2014|October 20, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00243217||188687|
NCT00243438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version vom 18.7.2003|DaVinci Registry(Distinctly Assess Vision in Coronary Intervention)|Distinctly Access Vision In Coronary Interventions||Abbott Vascular|Yes|Completed|July 2003|March 2005|Actual|March 2005|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||1300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diabetes and/or complex coronary artery disease who are treated with a        Multi-Link Vision™ Stent.|January 2009|January 27, 2009|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243438||188670|
NCT00293124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/GIST 1.2.001|Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors|An Open-label Trial of Glivec in Patients With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing C-kit.||Central European Cooperative Oncology Group|Yes|Completed|March 2004|July 2008|Actual|July 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||May 2012|August 11, 2015|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293124||184951|
NCT00293137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORDIC|NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy|Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy|NORDIC|The Cleveland Clinic||Terminated|February 2006|August 2007|Actual|||Phase 4|Observational|N/A||1|Anticipated|60|||Both|18 Years|N/A|No||see inclusion/exclusion|September 2008|September 18, 2008|February 16, 2006|||safety concerns regarding use of rosiglitazone|No||https://clinicaltrials.gov/show/NCT00293137||184950|
NCT00290095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2005.1269|Quality of Life in Patients With Multiple Myeloma|Quality of Life in Patients With Multiple Myeloma||Oslo University Hospital||Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|260|||Both|18 Years|N/A|No|Probability Sample|Patients with Multiple Myeloma in all fases in the south and east of Norway|March 2011|March 7, 2011|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290095||185170|
NCT00291564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239|Ensure Cardiac Resynchronization Therapy Study|Ensure Cardiac Resynchronization Therapy Study||Medtronic Cardiac Rhythm Disease Management||Completed|May 2004|February 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||430|||Both|18 Years|N/A|No|||December 2007|December 17, 2007|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291564||185062|
NCT00290901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191165|Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.|A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in Subjects With Chronic Low Back Pain||Pfizer||Completed|March 2006|||December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||754|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 21, 2008|February 9, 2006||||||https://clinicaltrials.gov/show/NCT00290901||185111|
NCT00290914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI #608|Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder|||Pharmacology Research Institute||Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||May 2012|May 8, 2012|February 9, 2006||Yes||||https://clinicaltrials.gov/show/NCT00290914||185110|
NCT00290927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6168|Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus|Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents (OHA); OHA Therapy Controlled, Open, Randomized, Parallel Group, Comparative (Superiority), 16-week, Multinational, Multicenter Study||Sanofi||Completed|December 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||390|||Both|20 Years|75 Years|No|||March 2009|August 25, 2009|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290927||185109|
NCT00293462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459510|GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer|Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol||University of California, San Francisco|No|Completed|May 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|91|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|February 16, 2006|No|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT00293462||184927|Of 532 potential subjects that were screened, 374 were excluded as they did not meet the inclusion criteria, 45 refused to participate and 22 were no-shows (declined radiation therapy), thereby reducing our original target sample population to 91.
NCT00293384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456201|Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant|Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 2004|February 2012|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|120 Years|No|||February 2016|February 12, 2016|February 16, 2006|Yes|Yes||No|May 12, 2014|https://clinicaltrials.gov/show/NCT00293384||184932|There were no other significant limitations except for the details provided.
NCT00293397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456493|Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Treatment of Patients With Hepatocellular Carcinoma Using Drug-Eluting Bead Embolization||Sidney Kimmel Comprehensive Cancer Center||Completed|November 2005|||April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293397||184931|
NCT00293761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-51|A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research||Completed|January 2006|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|February 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293761||184905|
NCT00293774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABHIP-00001|Alberta Hip Improvement Project|A Provincial Initiative to Examine the Efficacy, Cost-effectiveness and Long-term Safety of Alternative Hip Bearing Surfaces Versus Conventional Therapy for Degenerative Joint Disease of the Hip||Alberta Bone and Joint Health Institute|Yes|Active, not recruiting|June 2004|September 2020|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Blood samples retained for cobalt and chromium metal ion level analysis on select cohort.|Both|18 Years|65 Years|No|Probability Sample|Males between the ages of 18-65 and females between the ages of 18-55|June 2015|June 23, 2015|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293774||184904|
NCT00291148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS_B2005:168|Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain|A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine||University of Manitoba||Completed|March 2006|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|65 Years|No|||March 2011|July 26, 2012|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291148||185092|
NCT00291161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-238|Partners in Dementia Care|Partners in Dementia Care|PDC|VA Office of Research and Development|No|Completed|December 2006|February 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|508|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291161||185091|
NCT00292071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-042|Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)|A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 24 Months With New Onset Fever and Neutropenia||Merck Sharp & Dohme Corp.||Completed|May 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|3 Months|24 Months|No|||November 2015|November 9, 2015|February 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00292071||185023|
NCT00292084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-05-004|An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks||BioWest Therapeutics Inc||Completed|February 2006|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||January 2008|January 17, 2008|February 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00292084||185022|
NCT00293410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0561 CDR0000456431|Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders|Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults and Children With Relapsed or Refractory Acute Leukemias||Sidney Kimmel Comprehensive Cancer Center||Completed|November 2005|||April 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|70|||Both|2 Years|N/A|No|||May 2010|May 5, 2010|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293410||184930|
NCT00240916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11142008-1344|Ontogeny of Measles Immunity in Infants|Ontogeny of Vaccine-Induced Measles Immunity Child Participant-6 and 9 Months||Stanford University||Recruiting|July 1993|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|555|Samples With DNA|white cells, serum|Both|6 Months|N/A|Accepts Healthy Volunteers|Probability Sample|Study populations include infants who are 6, 9, and 12 months of age, and healthy adults        older than 18 years.|November 2009|November 5, 2009|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00240916||188862|
NCT00241254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9408-04|Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis|A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study|PROMESS|University Hospital, Bordeaux|Yes|Completed|December 2005|March 2012|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|65 Years|No|||March 2012|March 14, 2012|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241254||188837|
NCT00241267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT04-FT/ENDO|Bronchial Ultrasonography Via a Fibrescope: Pilot Study in Tumoral Disease|Bronchial Ultrasonography Via a Fibrescope: Pilot Study in Tumoral Disease||University Hospital, Tours||Terminated|March 2005|March 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||20|||Both|18 Years|N/A|No|||May 2006|October 5, 2006|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00241267||188836|
NCT00242346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00006|High Doses of Candesartan Cilexetil on the Reduction of Proteinuria|A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria||AstraZeneca||Completed|April 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|18 Years|80 Years|No|||December 2007|December 17, 2007|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242346||188754|
NCT00242359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2085|A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma|A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma||Bernstein Clinical Research Center|No|Withdrawn|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Both|18 Years|65 Years|No|||January 2009|January 27, 2009|October 17, 2005||No|could not find subject population|||https://clinicaltrials.gov/show/NCT00242359||188753|
NCT00241618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|994058402|Timing and Duration of Acute Hepatitis C Treatment|Phase IV Study of Treatment of Acute Hepatitis C With Pegylated Interferon||Ain Shams University||Completed|January 2002|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|50 Years|No|||September 2006|September 7, 2006|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00241618||188809|
NCT00241631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mitHDAC#1|Enhancement of in−Vitro GC Function in Patients With COPD|Enhancement of In-vitro GC Function in Patients With COPD. A Randomised, Double Blind, Placebo Controlled, Parallel-group Study to Investigate the Effect of Theophylline and Fluticasone on Induced Sputum Cells Obtained Form COPD Patients||Imperial College London|No|Completed|April 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|40 Years|80 Years|No|||September 2007|May 27, 2015|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00241631||188808|
NCT00242983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450163|Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer|Assessment of Quality of Life (QOL) in Patients Registered With "Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer (JMTO LC00-03)"||National Cancer Institute (NCI)||Active, not recruiting|April 2004|||||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||December 2005|December 17, 2013|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00242983||188705|
NCT00243464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0503 INT|Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients With Scalp Psoriasis||LEO Pharma||Completed|September 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|October 21, 2005||||No||https://clinicaltrials.gov/show/NCT00243464||188668|
NCT00243685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050113|Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis|Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors||DiaTech Oncology|No|Completed|September 2006|May 2009|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00243685||188651|
NCT00243958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701003|Aluminum and Auditory Function in ESRD|||National Taiwan University Hospital||Recruiting|October 2005|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||80|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||October 2005|October 23, 2005|October 23, 2005||||No||https://clinicaltrials.gov/show/NCT00243958||188630|
NCT00294723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1573|To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c|Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes|LEAD-3|Novo Nordisk A/S|No|Terminated|February 2006|March 2010|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|746|||Both|18 Years|80 Years|No|||June 2014|June 25, 2014|February 20, 2006|Yes|Yes|The trial was terminated at week 195 due to an insufficient number of subjects remaining to    obtain reasonable statistical power|No|February 23, 2010|https://clinicaltrials.gov/show/NCT00294723||184833|Trial terminated due to an insufficient number of subjects remaining to obtain reasonable statistical power. Efficacy data was not analysed after week 156. Safety data was collected through week 195. No data was available from week 195 to 260
NCT00294736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-107|A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens|A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens||Astellas Pharma Inc|Yes|Completed|November 2005|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|February 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00294736||184832|
NCT00291577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181100|Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer|Exploratory Evaluation Of A Sequential Administration Of Docetaxel And SU011248 In Women With Advanced Breast Cancer||Pfizer|No|Completed|July 2006|February 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||November 2009|November 19, 2009|February 13, 2006|No|Yes||No|October 1, 2009|https://clinicaltrials.gov/show/NCT00291577||185061|
NCT00294164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22388|Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)|Phase 2/3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Safety and Efficacy Trial of Subcutaneously Administered Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Treatment of Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)||EMD Serono||Completed|March 2001|May 2002|Actual|May 2002|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|245|||Both|18 Years|60 Years|No|||March 2014|March 24, 2014|February 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00294164||184875|
NCT00292123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDAIRP 326|Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse|||National Institute on Drug Abuse (NIDA)|No|Completed|June 1999|August 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|65 Years|No|||December 2007|April 30, 2013|February 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292123||185019|
NCT00294684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHILDREN (START) (IND)|A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy|A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants With Biliary Atresia||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|November 2005|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|N/A|6 Months|No|||February 2014|February 26, 2014|February 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294684||184836|
NCT00290069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SATOT42005|Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)|Comparative Study of Tacrolimus and Rapamycin to Evaluate the Renal Function in Patients Older Than 50 Years, Receptors of a Kidney From a Donor Older Than 55 Years in a Mycophenolate Mofetil and Daclizumab Immunosuppressor Regime||Sociedad Andaluza de Trasplantes de Organos y Tejidos||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|94|||Both|50 Years|N/A|No|||February 2006|May 14, 2007|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290069||185172|
NCT00260533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040100|Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder|Double Blind Placebo Controlled Parallel Group Comparison of Atomoxetine (Strattera) for Generalized Social Anxiety Disorder (GSAD)||University of California, San Diego|No|Completed|November 2005|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||January 2014|January 24, 2014|November 29, 2005|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00260533||187383|Small study, with possibility of Type II error. Nonetheless, response rates in both arms were very low, making it unlikely that the failure to see a response to atomoxetine was due to low power compared to placebo.
NCT00260767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRU009|Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution|An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution||Biosyn||Not yet recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Female|18 Years|45 Years|No|||November 2005|November 30, 2005|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260767||187365|
NCT00261027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002521-01H|Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer|A Pilot, Phase II, Single Center, Non-comparative, Open-label Study of Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer||Ottawa Hospital Research Institute|No|Completed|January 2003|September 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Female|20 Years|N/A|No|||March 2010|March 1, 2010|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00261027||187346|
NCT00240929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP097|A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)|A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis), A Humanized Respiratory Syncytial Virus Monoclonal Antibody, in Children With a History of Prematurity||MedImmune LLC||Completed|September 2002|April 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|150|||Both|5 Months|6 Months|No|||November 2010|November 12, 2010|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00240929||188861|
NCT00240942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345ADE04|Letrozole in the Treatment of Severe and Recurrent Endometriosis|Letrozole in the Treatment of Severe and Recurrent Endometriosis||Novartis||Completed|October 2002|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|N/A|No|||April 2012|April 25, 2012|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00240942||188860|
NCT00240955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2404E1|Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients|Efficacy and Safety of Two Immunosuppressive Regimens Mycophenolate Sodium (EC-MPS) With Short-term Steroid Use or Free of Steroids Compared With a Regimen of EC-MPS With Standard Steroids in de Novo Kidney Recipients||Novartis||Completed|March 2004|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|79|||Both|18 Years|75 Years||||January 2011|January 28, 2011|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00240955||188859|
NCT00241280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1480|Study Intended to Evaluate the Safety and Effectiveness of a Johnson & Johnson Vision Care Inc, (JJVCI) Contact Lens for Use on an Extended-wear Basis for up to 7 Days (6 Nights).|||Johnson & Johnson Vision Care, Inc.||Completed|September 2005|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|504|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|October 14, 2005|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT00241280||188835|
NCT00241293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOP-PROMO2003|Influence of Age on Hemispheric Lateralization of Language : a Longitudinal Study|||University Hospital, Tours||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|76 Years|N/A|Accepts Healthy Volunteers|||July 2005|October 14, 2005|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00241293||188834|
NCT00241306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-R2001|Variations of Hemispheric Lateralisation of Language Depending of Gender and Age.|Variations of Hemispheric Lateralisation of Language Depending of Gender and Age.||University Hospital, Tours||Active, not recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2005|October 14, 2005|October 14, 2005||||No||https://clinicaltrials.gov/show/NCT00241306||188833|
NCT00242372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00033|GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin|A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin||AstraZeneca||Terminated|August 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||370|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|October 19, 2005|||The development program has been terminated|||https://clinicaltrials.gov/show/NCT00242372||188752|
NCT00242034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0152-C|Investigation of Cervix Tumor Oxygenation and Microvasculature Using Magnetic Resonance Techniques|Investigation of Cervix Tumor Oxygenation and Microvasculature Using Magnetic Resonance Techniques||University Health Network, Toronto||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|60|||Female|18 Years|N/A|No|||August 2008|September 2, 2008|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242034||188778|
NCT00242996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447158 J0376|Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma|Phase II Trial of Rituximab and Autologous Stem Cell Transplantation for Refractory B Cell Large Cell Lymphoma||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|March 2004|||January 2015|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|44|||Both|18 Years|70 Years|No|||March 2014|March 20, 2014|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00242996||188704|
NCT00243256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSEMDT-2005-2|Treatment of Obesity With Vitamin D (40.000 IE Per Week for 1 Year)|||University of Tromso||Completed|November 2005|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|450|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||May 2008|May 8, 2008|October 20, 2005||||No||https://clinicaltrials.gov/show/NCT00243256||188684|
NCT00243490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33MD01|Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors|Prospective, Open-labeled, Clinical Trial in Compassionate Use to Evaluate the Efficacy and Safety of Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors||National Taiwan University Hospital||Withdrawn||January 2009||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|5|||Both|20 Years|75 Years|No|||January 2010|January 11, 2010|October 20, 2005||No|The Trial could not get permit from Department of Health, Taiwan; Furthermore, no research    fund could support the expensive (photosensitizer) photosan|No||https://clinicaltrials.gov/show/NCT00243490||188666|
NCT00243477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-395|MOTIV Study- Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting|MOTIV Study. Effect of Antidepressive Treatment by Escitalopram Started Preoperatively in Patients Undergoing Coronary Artery Bypass Grafting||Hopital Jean Minjoz|Yes|Completed|January 2006|February 2012|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|368|||Both|30 Years|N/A|No|||March 2012|March 16, 2012|October 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00243477||188667|
NCT00290667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454505|Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma|2-Weekly CHOP Chemotherapy With Dose-Dense Rituximab for the Treatment of Patients Aged 61 to 80 Years With Aggressive CD-20 Positive B-Cell Lymphomas: A Phase-II/Pharmacokinetic Study (CHOP-R-ESC)||German High-Grade Non-Hodgkin's Lymphoma Study Group|Yes|Completed|February 2004|November 2015|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|586|||Both|61 Years|80 Years|No|||November 2015|November 25, 2015|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00290667||185127|
NCT00291187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-3101|VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia||Vanda Pharmaceuticals|No|Completed|February 2006|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|411|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|February 3, 2006|Yes|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT00291187||185089|
NCT00291200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH61282|Enhancing the Prospective Prediction of Psychosis|Enhancing the Prospective Prediction of Psychosis||Yale University||Completed|August 2003|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|268|Samples With DNA|Blood samples for routine laboratory studies|Both|12 Years|35 Years|No|Probability Sample|The study population consists of participants who meet the basic symptoms for psychosis        and control participants recruited at three sites: the PRIME Clinics at University of        North Carolina, Yale University, and the Center for Addiction and Mental Health (CAMH) in        Toronto, Canada.|June 2014|June 9, 2014|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291200||185088|
NCT00291824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHCTF G03-02656|Cardiovascular Lifestyle Study: Effects and Expense of a Cardiovascular Risk Reduction Clinic in Primary Care|A Randomized Controlled Trial of the Effects and Expense of a Primary and Secondary Cardiovascular Risk Reduction Clinic in Primary Care||Caroline Medical Group||Recruiting|August 2004|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||670|||Both|N/A|N/A|No|||February 2006|February 13, 2006|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291824||185042|
NCT00292136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903385|Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study|Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study||National Institutes of Health Clinical Center (CC)||Completed|August 2003|June 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|65 Years|No|||June 2013|February 19, 2014|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00292136||185018|
NCT00259779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5892L00002|Comparison Between Symbicort® and Prednisolone in COPD|A Randomised, Double Blind, Double Dummy, Multicentre Phase III Study Comparing the Efficacy of Budesonide/Formoterol (Symbicort® Forte Turbuhaler®) and Oral Prednisolone + Formoterol (Oxis® Turbuhaler) During Two Weeks, in COPD Patients With an Acute Exacerbation, Followed by Twelve Weeks Open Follow up Period With Budesonide/Formoterol (Symbicort Forte Turbuhaler)|SPACE|AstraZeneca||Completed|September 2005|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|40 Years|N/A|No|||January 2011|January 21, 2011|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00259779||187440|
NCT00260039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V502-001|Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)|A Randomized, International, Double-Blinded (With In-House Blinding), GARDASIL-Controlled, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) L1 Virus-like Particle (VLP) Vaccine Administered to 16- to 23- Year-Old Women||Merck Sharp & Dohme Corp.||Completed|December 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|680|||Female|16 Years|23 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|November 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00260039||187420|
NCT00260312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3827|Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals|Randomized Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba||Pan American Health Organization||Completed|August 2001|January 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Male|6 Weeks|2 Months|Accepts Healthy Volunteers|||January 2004|November 29, 2005|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260312||187399|
NCT00260299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKD dietary study|Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency|Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency||Oregon Health and Science University|Yes|Recruiting|February 2005|December 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|blood samples, cells (fibroblasts) from skin biopsy tissue, DNA, urine and stool|Both|N/A|N/A|No|Non-Probability Sample|children or adults with mevalonic kinase deficiency/mevalonic aciduria/HIDS|March 2012|March 21, 2012|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260299||187400|
NCT00260780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-3728|An STD Prevention Intervention for Men Newly Released From Jail|The MISTERS Project: An STD Prevention Intervention for Men Newly Released From Jail||Centers for Disease Control and Prevention||Completed|June 2001|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2005|December 1, 2005|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00260780||187364|
NCT00292526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S67/500|Prevention of Chemotherapy-Induced Cardiotoxicity in High-Risk Patients|||European Institute of Oncology||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|18 Years|65 Years||||January 2006|February 15, 2006|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292526||184989|
NCT00261040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2003211-01H|Minimally Invasive Surgery of the Hip Versus Standard Approach|Minimally Invasive Surgery of the Hip: A Randomized Study||Ottawa Hospital Research Institute|No|Completed|June 2003|May 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00261040||187345|
NCT00261352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00003|GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy With a Statin||AstraZeneca||Terminated|March 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|December 1, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00261352||187321|
NCT00241670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-ALS.3/GLI|Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid|Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection||medac GmbH||Completed|October 1999|||July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|415|||Both|18 Years|72 Years|No|||April 2012|April 25, 2012|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00241670||188805|
NCT00241319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003-11|Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis||Vistakon Pharmaceuticals||Completed|October 2005|||December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|10 Years|N/A|No|||September 2011|September 26, 2011|October 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00241319||188832|
NCT00241332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510-05165|Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil Based Anesthesia?|Prophylaxis Against Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil/Propofol Based Anesthesia?||Oslo University Hospital||Completed|October 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||September 2005|July 3, 2011|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241332||188831|
NCT00242073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0563-C|The Potential Use of BOLD MRI as a Noninvasive Measure of Tumor Hypoxia in Prostate Cancer|The Potential Use of BOLD MRI as a Noninvasive Measure of Tumor Hypoxia in Prostate Cancer||University Health Network, Toronto||Recruiting|October 2001|October 2005||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Male|18 Years|N/A|No|||August 2008|July 3, 2014|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242073||188775|
NCT00242086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0659-C|Comparison of Triphasic CT, PET and MR Tumour With Pathological Findings in Colorectal Cancer Liver Metastases|Comparison of Triphasic CT, CT/PET and MR Defined Gross Tumour With Pathological Findings in Patients With Colorectal Cancer Liver Metastases||University Health Network, Toronto||Recruiting|October 2004|January 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A||||August 2014|August 28, 2014|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242086||188774|
NCT00242645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04F.244|Computer-Assisted Cancer Risk Behavior Counseling|Computer-Assisted Cancer Risk Behavior Counseling||Thomas Jefferson University|No|Terminated|June 2004|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|200|||Both|21 Years|70 Years|No|||August 2010|August 24, 2010|October 19, 2005||No|Administratively terminated.|No||https://clinicaltrials.gov/show/NCT00242645||188731|
NCT00243009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447207|Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery|Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma||OHSU Knight Cancer Institute|Yes|Terminated|June 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||June 2010|May 24, 2012|October 20, 2005|No|Yes|Due to a lack of a referal base, study was terminated.|No||https://clinicaltrials.gov/show/NCT00243009||188703|
NCT00244010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAAHAP|Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias|Hematopoietic Stem Cell Transplantation (HSCT) From Partially Matched Family Donors for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias: A Pilot Study||St. Jude Children's Research Hospital|No|Completed|October 2005|February 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|21 Years|No|||February 2009|May 1, 2012|October 24, 2005|Yes|Yes||No|February 2, 2012|https://clinicaltrials.gov/show/NCT00244010||188626|This study has terminated due to the PI leaving the institution. An insufficient number of subjects were enrolled to answer the primary objective.
NCT00244023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TADTEST|Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone|Double-Blind, Placebo Controlled Randomized Study of Co-Administering Testosterone With PDE5 Inhibitors in Patients Non-Responders to PDE5 Inhibitors Alone||SELARL du Dr Jacques BUVAT|Yes|Completed|October 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|173|||Male|45 Years|80 Years|No|||August 2008|August 22, 2008|October 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00244023||188625|
NCT00243230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03672|Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1) (Study P03672AM6)|Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1)||Merck Sharp & Dohme Corp.|Yes|Completed|September 2005|March 2011|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|October 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00243230||188686|
NCT00243243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-05-027|Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn|Effect of Recombinant Coagulation Factor VIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn Excision and Grafting||United States Army Institute of Surgical Research|No|Completed|January 2006|July 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||March 2013|March 28, 2013|October 19, 2005||No||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00243243||188685|
NCT00243984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05005|Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome||Northeastern Ohio Universities College of Medicine||Suspended|March 2005|November 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|75 Years|No|||December 2007|December 7, 2007|October 21, 2005|||Study was discontinued because of high drop out rate.|No||https://clinicaltrials.gov/show/NCT00243984||188628|
NCT00243997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-2009-C14|Evaluation of the Efficacy of the Becoming Parents Program|Study of the Effects of the Becoming Parents Program on Couples Becoming Parents for the First Time||University of Washington|Yes|Completed|February 2002|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|940|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 13, 2008|October 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00243997||188627|
NCT00291213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YaleHIC26585|Levetiracetam Treatment of Tardive Dyskinesia|||Yale University||Completed||||April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||June 2014|June 5, 2014|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291213||185087|
NCT00259194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPKAT|Observation and Prediction of Complications After Coronary Angiography|Observation and Prediction of Complications After Coronary Angiography|OPKAT|Herning Hospital|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||June 2009|June 8, 2009|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259194||187485|
NCT00259441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0509-517-158|PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography|Prevention of Radiocontrast Media Induced Nephropathy by Short-Term High-Dose Statin in Renal Insufficiency Undergoing Coronary Angiography (PROMISS)||Seoul National University Hospital||Completed|February 2005|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||320|||Both|19 Years|N/A|No|||July 2007|July 10, 2007|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259441||187466|
NCT00259792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00005|SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults|A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open, Parallel Group Multicentre Study||AstraZeneca||Completed|September 2004|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00259792||187439|
NCT00291603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-192|Short Term Effects of FX Dialysers on QOL and Inflammation|Short-Term Effects of the FX-Class of Haemodialyser on Quality of Life and Inflammatory Markers in Stable Dialysis Patients||Sir Charles Gairdner Hospital|No|Completed|February 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||April 2007|April 24, 2007|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291603||185059|
NCT00291850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/NSCLC.3.2.002|Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC|Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA Non-Small Cell Lung Cancer||Central European Cooperative Oncology Group|No|Terminated|June 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||April 2012|April 30, 2012|February 14, 2006||No|no patient recruitment|No||https://clinicaltrials.gov/show/NCT00291850||185040|
NCT00260546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159/05|An-Art Study: Atrioventricular (AV) Node Ablation in Cardiac Resynchronisation Therapy|An-Art Study: AV-Node Ablation in Cardiac Resynchronisation Therapy||University Hospital, Basel, Switzerland|No|Withdrawn|May 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|90 Years|No|||September 2011|September 29, 2011|November 29, 2005||No|No patients enrolled for 6 months.|No||https://clinicaltrials.gov/show/NCT00260546||187382|
NCT00260559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0522|Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life|Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life||University of Pittsburgh||Recruiting|May 1999|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seeking surgical resection of their esophagus at the University of Pittsburgh        Medical Center.|December 2015|December 1, 2015|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00260559||187381|
NCT00291863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0089/04|Simvastatin Effect on End Stage Renal Failure Patients Treated by Peritoneal Dialysis|Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis||Federal University of São Paulo||Recruiting|February 2006|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||February 2006|February 15, 2006|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00291863||185039|
NCT00292214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.138|Comparing Intravenous and Oral Paracetamol for Cholecystectomy|Comparative Pharmacokinetics of Intravenous and Oral Paracetamol in the Peri-Operative Period of Laparoscopic Cholecystectomy||Melbourne Health||Completed|October 2005|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||February 2006|March 8, 2007|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00292214||185013|
NCT00292890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Kreugel|Which Needle Length for Injecting Insulin|||University Medical Center Groningen||Completed|January 2004|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||January 2005|February 15, 2006|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292890||184968|
NCT00293241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2-Aug 21, 2007|PreFER Managed Ventricular Pacing (MVP) For Elective Replacement|PreFER MVP for Elective Replacement||Medtronic Bakken Research Center|Yes|Completed|February 2006|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|630|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|February 16, 2006||No||No|October 9, 2014|https://clinicaltrials.gov/show/NCT00293241||184942|Atrial pacing % was not collected at implant, device programming in the MVP off arm was more often non-compliant than in MVP on arm, and 25% of the case report forms were sent without device data, possibly influencing device data related objectives
NCT00241683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307|Fetal Growth Restriction & Maternal Cardiovascular Risk|Fetal Growth Restriction & Maternal Cardiovascular Risk||The University of Texas Health Science Center, Houston|No|Completed|August 2005|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|704|||Female|N/A|N/A|No|Non-Probability Sample|Women who were 4 to 12 years postpartum|January 2013|January 18, 2013|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241683||188804|
NCT00241696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308|Air Pollution, Inflammation, and New Onset Asthma|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|August 2005|June 2010|Actual|||N/A|Observational|N/A|||||||Both|8 Years|12 Years|No|||April 2012|December 3, 2015|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241696||188803|
NCT00242047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCT REC 271/2000|Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination.|Randomized, Controlled Trial Comparing Efficacy of Percutaneous and Intradermal Vaccination With Japanese (Tokyo) 172 BCG in the Prevention of Tuberculosis In Infants Vaccinated at Birth||University of Cape Town||Active, not recruiting|March 2001|August 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||12000|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||November 2004|October 18, 2005|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242047||188777|
NCT00243022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1304|Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme|Phase II Randomized Evaluation of 5-Lipoxygenase Inhibition by Herbal Complementary and Alternative Medicine Approach Compared to Control as an Adjuvant Therapy in Newly Diagnosed and Recurrent High-grade Gliomas||Case Comprehensive Cancer Center|Yes|Terminated|September 2004|March 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|October 20, 2005|Yes|Yes|Slow accrual|No|October 11, 2012|https://clinicaltrials.gov/show/NCT00243022||188702|Certain outcome analysis not done due to low patient accrual.
NCT00242658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269|Computerized Health Education to Promote Physical Activity|Computerized Physical Activity Promotion in Primary Care||Milton S. Hershey Medical Center|No|Completed|May 2005|March 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|394|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|October 19, 2005||No||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00242658||188730|
NCT00243737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-P 001-2005|Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria|Open-label, Stratified Study on the Efficacy, Safety and Pharmacokinetic Characteristics of Two Paediatric Formulations of ArtequinTM in Children With Acute Uncomplicated P. Falciparum Malaria||Albert Schweitzer Hospital||Completed|October 2005|April 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|N/A|N/A|No|||January 2013|January 23, 2013|October 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00243737||188647|
NCT00243750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-01|Methotrexate in Ankylosing Spondylitis (MTX in AS)|Open Study for the Evaluation of the Efficacy of Methotrexate 20mg Given Subcutaneously in Patients With Active Ankylosing Spondylitis||Charite University, Berlin, Germany||Active, not recruiting|September 2003|November 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||20|||Both|18 Years|70 Years|No|||August 2003|December 8, 2005|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00243750||188646|
NCT00249483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4706R NIDA-09236-14|Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals|Placebo-Controlled Venlafaxine Treatment for Depressed Cocaine Abusers||New York State Psychiatric Institute|Yes|Completed|October 1999|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|60 Years|No|||October 2013|October 31, 2013|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249483||188217|
NCT00249496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13107-1|Employment-Based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1|Therapeutic Workplace Maintenance Study||National Institute on Drug Abuse (NIDA)|No|Recruiting|October 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|390|||Both|18 Years|N/A|No|||May 2008|May 28, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249496||188216|
NCT00249730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481237|Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.|A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction||Pfizer||Completed|October 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||510|||Male|18 Years|N/A|No|||December 2006|December 18, 2006|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249730||188198|
NCT00243711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9689-001|A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop|||Allergan||Completed|September 2005|April 2006|Actual|April 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|286|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|October 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00243711||188649|
NCT00243724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00078|HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease|An Open-Label, Parallel-Group, Multi-Centre Study to Determine the Effect of Treatment With Esomeprazole for Six Months on Histological Markers of Esophageal Epithelial Acid-Related Disease in Patients With Upper GI Symptoms.||AstraZeneca||Completed|April 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|350|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|October 24, 2005||||No||https://clinicaltrials.gov/show/NCT00243724||188648|
NCT00244595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2451C00001|Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age|A Multicenter, Multinational, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age||AstraZeneca||Completed|September 2003|November 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||235|||Both|6 Years|17 Years|No|||December 2009|December 8, 2009|October 25, 2005||||||https://clinicaltrials.gov/show/NCT00244595||188582|
NCT00244608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890C00003|A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®|A Comparison of the Inflammatory Control of Asthma Provided by One Inhalation of Symbicort® Turbuhaler® 160/4.5 µg/Inhalation b.i.d. Plus As-needed Versus One Inhalation of Symbicort® Turbuhaler® 320/9 µg/Inhalation b.i.d. + One Inhalation of Pulmicort® Turbuhaler® 400 µg/Dose b.i.d. Plus Terbutaline Turbuhaler® 0.4 mg/Inhalation As-needed. A 12-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational, Phase IIIB Study in Adult Patients With Asthma, EOS||AstraZeneca||Completed|May 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||January 2011|January 21, 2011|October 25, 2005||||No||https://clinicaltrials.gov/show/NCT00244608||188581|
NCT00259207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040413|Pulmonary Valve Replacement in Large Right Ventricular Outflow Tract|Pulmonary Valve Replacement : Study of Comparison Between a Standard Surgical Approach With Extracorporeal Circulation and an Off-pump Hybrid Strategy.||Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|6 Years|90 Years|No|||March 2007|September 29, 2009|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259207||187484|
NCT00259220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040427|HDUPE 2004: Gastro-Oesophageal Haemorrhage in Emergency : Gastric Préparation to Endoscopy|In Urgency Hight Digestive Haemorrhage : Gastric Preparation for Endoscopy||Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|N/A|No|||March 2007|September 30, 2008|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259220||187483|
NCT00259454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP 4100027298|Project COPE:Managing Dementia at Home|Managing Problem Behaviors of Alzheimer's Disease||Thomas Jefferson University|Yes|Completed|June 2005|July 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|278|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 15, 2010|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259454||187465|
NCT00290979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6167|Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus|Evaluation of Efficacy and Safety of HMR1964 (Insulin Glulisine) in Subjects With Type 1 Diabetes Mellitus; Insulin Lispro Controlled, Open, Randomized, Parallel Group, Non-inferiority Study, for 28 Weeks||Sanofi||Completed|December 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||March 2009|August 25, 2009|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290979||185105|
NCT00291304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-1-0082|Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma|Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma||AHS Cancer Control Alberta|Yes|Terminated|March 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|72|||Female|18 Years|N/A|No|||December 2011|February 23, 2016|February 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00291304||185082|
NCT00292188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081064|P4 (Pregabalin for Peripheral Posttraumatic Pain)|A 9 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study Of Pregabalin (BID) In Subject With Posttraumatic Peripheral Neuropathic Pain|P4|Pfizer|No|Completed|January 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|80 Years|No|||April 2011|April 22, 2011|February 13, 2006||No||No|May 27, 2009|https://clinicaltrials.gov/show/NCT00292188||185015|
NCT00292513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dermabond Study|Clinical Trial Comparing Tissue Adhesive Vs. Absorbable Suture Vs. Non-Absorbable Suture|A Randomized Clinical Trial Comparing Tissue Adhesive (2-Octylcyanoacrylate) Vs. Absorbable Suture Vs. Non-Absorbable Suture for the Closure of Low Tension Facial and Neck Wounds in Children and Adolescents||Rady Children's Hospital, San Diego||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|18 Years||||May 2005|February 15, 2006|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292513||184990|
NCT00292578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypersensitivity to Cane Sugar|NAET® Testing Devices in Detection of Hypersensitivity to Cane Sugar|NAET® Testing Devices in Detection of Hypersensitivity to Cane Sugar||Nambudripad's Allergy Research Foundation||Completed|January 2005|January 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||75|||Both|22 Years|70 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292578||184986|
NCT00292656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hand washing After NAET|Importance of Hand Washing After Each NAET® Treatment|Importance of Hand Washing After Each NAET® Treatment||Nambudripad's Allergy Research Foundation||Completed|December 2005|December 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||60|||Both|22 Years|70 Years|Accepts Healthy Volunteers|||February 2006|April 2, 2006|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292656||184984|
NCT00292201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120973|Statin Treatment in Patients With Asthma|Pilot Study of Statin Treatment in Patients With Stable Moderate to Severe Asthma||Queen's University|No|Terminated|February 2006|June 2015|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||September 2015|September 14, 2015|February 14, 2006|Yes|Yes|Lack of funding to complete subject recruitment and testing|No||https://clinicaltrials.gov/show/NCT00292201||185014|
NCT00292539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preserve Registry|Prospective Registry of Pacemaker Patients Concerning Percentage of Right Ventricular Pacing, LVEF and NYHA Class|Preserve Registry: Prospective Registry of Pacemaker Patients Concerning Percentage of Right Ventricular Pacing, LVEF and NYHA Class||Guidant Corporation||Completed|February 2006|September 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1||600|||Both|N/A|N/A|No|||April 2009|April 22, 2009|February 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292539||184988|
NCT00292552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO104960|Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints|A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time|ECLIPSE|GlaxoSmithKline|No|Completed|December 2005|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2747|Samples With DNA|Whole blood, serum, plasma, urine sputum|Both|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|COPD subjects and smoking and non-smoking controls|January 2013|January 4, 2013|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00292552||184987|
NCT00292955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-HSR#13748|Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma|An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma||University of Virginia||Recruiting|February 2006|||February 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||May 2011|May 26, 2011|February 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292955||184963|
NCT00241384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-8-10|Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer|Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer||Schiffler Cancer Center|Yes|Completed|January 2005|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|396|||Male|40 Years|80 Years|No|||November 2015|November 16, 2015|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00241384||188827|
NCT00241397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B1-102003|Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety|An Observational Study on the Presence of Depression and/or Anxiety Disorder in Patients Consulting the General Practitioner With Painful Physical Symptoms in Belgium and Luxemburg.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||2560|||Both|18 Years|N/A|No|||March 2007|March 14, 2007|October 17, 2005||||No||https://clinicaltrials.gov/show/NCT00241397||188826|
NCT00242060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0065-C|Functional and Morphologic MRI in the Detection of Prostate Cancer in Patients With Prior Negative Biopsy|The Utility of Functional and Morphologic MRI in the Detection of Prostate Cancer for Patients With Elevated PSA and Prior Negative Biopsy||University Health Network, Toronto||Completed|November 2002|November 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Male|18 Years|N/A|No|||July 2010|July 14, 2010|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242060||188776|
NCT00241709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309|Optimal Approach for Analysis of Case-Control Genetic Association Studies|Case-Control Association Studies and Genetic Confounding|GALA 1|University of California, San Francisco|No|Completed|August 2005|||June 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Actual|800|Samples With DNA|Retrospective genetic analysis of DNA; samples collected between 1998-2001|Both|8 Years|40 Years|No|Non-Probability Sample|Family-based cross sectional analysis|March 2013|March 8, 2013|October 17, 2005||No||No||https://clinicaltrials.gov/show/NCT00241709||188802|
NCT00253201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006025|A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease|Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||October 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|636|||Both|18 Years|N/A|No|||November 2010|May 17, 2011|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253201||187934|
NCT00242385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460501|Pharmacokinetic Study of ARALAST (Human Alpha1- PI)|Single-Dose, Double-Blind, Crossover Study to Evaluate the Pharmacokinetic Comparability of ARALAST Fraction IV-1 Alpha1-Proteinase Inhibitor (ARALAST Fr. IV-1) and ARALAST||Baxalta US Inc.||Completed|December 2005|June 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||July 2011|June 26, 2015|October 19, 2005||Yes||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00242385||188751|
NCT00242671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0299-AE|The Efficacy of Isocapnic Hyperpnoea to Accelerate Recovery After General Anesthesia With Sevoflurane|The Efficacy of Isocapnic Hyperpnoea to Accelerate Recovery After General Anesthesia With Sevoflurane.||University Health Network, Toronto||Completed|October 2005|December 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Female|18 Years|80 Years|No|||September 2006|August 3, 2010|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00242671||188729|
NCT00250042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604C|A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec|A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment||New Mexico Cancer Care Alliance|Yes|Completed|April 2004|March 2006|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2009|September 18, 2011|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250042||188174|
NCT00244309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE14804|Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer|A Randomized Trial of Tamsulosin and/or Dutasteride Versus Placebo to Relieve Urinary Symptoms After Brachytherapy for the Treatment of Localized Prostate Cancer||Case Comprehensive Cancer Center|Yes|Completed|November 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|348|||Male|18 Years|N/A|No|||May 2011|May 3, 2011|October 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00244309||188604|
NCT00250302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMSC-01-HMO-CTIL|Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures|Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures||Hadassah Medical Organization||Completed|April 2009|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|65 Years|No|||October 2010|April 27, 2011|November 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00250302||188155|
NCT00250315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 270675|DOCICAR: Cardiac Dysfunction in Cirrhosis|Cardiac Dysfunction in Cirrhosis: Cirrhotic Cardiomyopathy Evaluated by Dobutamin MRI.||Hvidovre University Hospital||Completed|November 2005|October 2007|Actual|||Phase 3|Observational|Time Perspective: Prospective|||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2007|October 31, 2007|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00250315||188154|
NCT00290966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6044|Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer|Open Label, Randomized Multicentre Phase II/III Study of Docetaxel in Combination With Cisplatin (CDDP) or Docetaxel in Combination With 5-Fluorouracil (5-FU) and CDDP Compared to the Combination of CDDP and 5-FU in Patients With Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease||Sanofi||Completed|October 1998|May 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||610|||Both|18 Years|75 Years|No|||April 2009|April 28, 2009|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290966||185106|
NCT00291642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00412|Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen|Five Parallel Groups, Exploratory Clinical Trial to Compare the Efficacy of Single Dose Levocetirizine 2.5 and 5 mg, Cetirizine 5 mg and 10 mg to Placebo in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen in a EEU.||UCB Pharma||Completed|January 2006|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||541|||Both|16 Years|N/A|No|||September 2009|December 13, 2013|February 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00291642||185056|
NCT00291655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01237|Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).|A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam, for Patients Suffering From Epilepsy and Coming From the Study N01175 (NCT00175903).||UCB Pharma|No|Completed|June 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|16 Years|N/A|No|||April 2015|April 29, 2015|February 10, 2006|Yes|Yes||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00291655||185055|
NCT00291278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060091|Effects of Endometriosis on Bone Mineral Density|The Effects of Endometriosis on Bone Mineral Density||National Institutes of Health Clinical Center (CC)||Completed|February 2006|February 2009||||N/A|Observational|N/A||||80|||Female|40 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|February 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00291278||185083|
NCT00291616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-05-008|Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B|A Multicenter, Randomized, Controlled Trial of Combination Therapy for HBeAg Positive Chronic Hepatitis B: Comparing Thymosin Alpha 1 and Pegylated Interferon-alpha2a With Pegylated Interferon-alpha2a Alone.||Seoul National University Hospital|Yes|Completed|December 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|February 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291616||185058|
NCT00292695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1405|A Phase II Study of Nasal NK/T-cell Lymphoma|A Phase II Study of Concurrent Chemoradiation for The Localized Nasal NK/T-cell Lymphoma||National Health Research Institutes, Taiwan|Yes|Completed|May 2006|December 2010|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|70 Years|No|||October 2013|October 28, 2013|February 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292695||184983|
NCT00292591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD043921|Evaluation of Vitamin D Requirements During Pregnancy|Evaluation of Vitamin D Requirements During Pregnancy||Medical University of South Carolina||Completed|January 2004|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|516|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|February 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00292591||184985|
NCT00292929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1128|Study of the Safety of Intravenous Artesunate|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of Artesunate Administered to Healthy Subjects||Walter Reed Army Institute of Research (WRAIR)||Completed||October 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2007|April 10, 2007|February 14, 2006||||||https://clinicaltrials.gov/show/NCT00292929||184965|
NCT00292942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1142|Study of the Safety of Intravenous Artesunate|A Phase 1 Double-Blind, Placebo-Controlled, Randomized Multiple Dose Escalation Study to Evaluate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of a New GMP Formulation of Intravenous Artesunate if Healthy Subjects||Walter Reed Army Institute of Research (WRAIR)|Yes|Completed||October 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2007|April 10, 2007|February 14, 2006||||||https://clinicaltrials.gov/show/NCT00292942||184964|
NCT00292968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6268|A Comprehensive Practice-Friendly Model for Promoting Healthy Behaviors|A Comprehensive Practice-Friendly Model for Promoting Healthy Behaviors||Virginia Commonwealth University|No|Completed|June 2006|August 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|5670|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 18, 2012|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00292968||184962|
NCT00293267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-018|A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiviral Therapies||Merck Sharp & Dohme Corp.|Yes|Completed|February 2006|May 2011|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|352|||Both|16 Years|N/A|No|||September 2015|September 4, 2015|February 14, 2006|Yes|Yes||No|August 18, 2009|https://clinicaltrials.gov/show/NCT00293267||184940|Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 94 of 118 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.
NCT00242398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDI-FH|Hemodialysis Without Anticoagulation in Intensive Care Unit|Heparin Free Hemodialysis for Patients With Bleeding High Risk in ICU. Randomized Study: Heparin Free Dialysis With Intermittent Saline Flushes Versus Heparin Free Dialysis With Nephral 400ST (AN69ST, Hospal, France)||Centre Hospitalier Départemental|Yes|Recruiting|October 2005|April 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2007|October 2, 2007|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242398||188750|
NCT00241722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-767905/014|Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate Long-Term Safety and Efficacy of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain||Cubist Pharmaceuticals LLC||Completed|August 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|805|||Both|18 Years|N/A|No|||September 2009|September 1, 2015|October 17, 2005||Yes||||https://clinicaltrials.gov/show/NCT00241722||188801|
NCT00253214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006037|Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation|Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2001|July 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|973|||Both|40 Years|N/A|No|||November 2010|May 19, 2011|November 10, 2005||||||https://clinicaltrials.gov/show/NCT00253214||187933|
NCT00243503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181067|Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer|A Phase 2 Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer||Pfizer|No|Completed|February 2006|July 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|October 20, 2005|No|Yes||No|April 20, 2010|https://clinicaltrials.gov/show/NCT00243503||188665|
NCT00253409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448615|Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery|Mesothelioma and Radical Surgery Trial||National Cancer Institute (NCI)||Active, not recruiting|May 2005|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|670|||Both|18 Years|N/A|No|||July 2009|July 11, 2009|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253409||187918|
NCT00253422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448616|Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex™) With or Without Concomitant Anastrozole (Arimidex™) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors||National Cancer Institute (NCI)||Active, not recruiting|March 2004|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|750|||Female|N/A|N/A|No|||May 2011|May 14, 2011|November 11, 2005||||No||https://clinicaltrials.gov/show/NCT00253422||187917|
NCT00253435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450148|N2001-02: I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma|I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma||Children's Hospital Los Angeles|Yes|Active, not recruiting|September 2005|||December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|29 Years|No|||February 2013|February 21, 2013|November 11, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00253435||187916|
NCT00250354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006007|A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation|The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years||Janssen Pharmaceutica N.V., Belgium||Completed|September 1997|August 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|110|||Both|5 Years|12 Years|No|||January 2011|January 20, 2011|November 4, 2005||||||https://clinicaltrials.gov/show/NCT00250354||188151|
NCT00250016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102C-T|Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)|1102C-T. Pharmacology Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium. Tissue Submission for Patients With Endometrial Cancer.||University of New Mexico|Yes|Completed|August 2003|August 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|Samples Without DNA|Blood sample, tumor endometrial tissue, and normal endometrial tissue.|Female|18 Years|N/A|No|Probability Sample|Patients participating in the trial - "Phase II Study of Aerosolized Liposomal-Nitro-20        (S)-Camptothecin (L9NC) in Patients with Metastatic or Recurrent Cancer of the        Endometrium"|March 2008|January 6, 2010|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250016||188176|
NCT00250614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5572|An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder.||Sanofi||Completed|April 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|452|||Both|18 Years|64 Years|No|||June 2010|June 8, 2010|October 18, 2005||No||No||https://clinicaltrials.gov/show/NCT00250614||188131|
NCT00250627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5573|An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder||Sanofi||Completed|December 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|465|||Both|18 Years|64 Years|No|||December 2008|December 22, 2008|November 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250627||188130|
NCT00290680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454922|Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors|Phase I Trial of Bortezomib (VELCADE™) and Celecoxib in Patients With Advanced Solid Tumors||Medical University of South Carolina|Yes|Completed|March 2005|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290680||185126|
NCT00290693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20030652|Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer|A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients "CapTere"||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|June 2004|June 2010|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|February 9, 2006|Yes|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT00290693||185125|The results are for 24 evaluable patients enrolled before June 2007. The study has not been published.
NCT00290706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04H4|A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma|A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma||Northwestern University|Yes|Terminated|September 2005|March 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|February 9, 2006|Yes|Yes|Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients    resulting in poor data.|No||https://clinicaltrials.gov/show/NCT00290706||185124|
NCT00291915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUEPARD-GERCER 2122|Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis|Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis||Goupe d'Etudes et de Recherche Clinique En Rhumatologie||Recruiting|May 2004|March 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||February 2006|February 14, 2006|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00291915||185035|
NCT00291928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112657|HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II|A Double-blind, Randomized, Placebo Controlled, Dose Escalation, Multi-centerphase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20antibody, in Patients With Active Rheumatoid Arthritis Who Have Previously Failedone or More Disease Modifying Anti-rheumatic Drugs||GlaxoSmithKline|No|Completed|February 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|February 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291928||185034|
NCT00291629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUH cardiology|Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES|Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES (MAGIC Cell-3-DES)||Seoul National University Hospital|Yes|Completed|March 2004|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|96|||Both|N/A|80 Years|No|||September 2007|September 6, 2007|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291629||185057|
NCT00291876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100571 (M138)|Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule|Double-blind Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Two Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 12 Month Schedule in Healthy Adult Volunteers||GlaxoSmithKline||Completed|January 2004|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|135|||Both|29 Years|60 Years|Accepts Healthy Volunteers|||April 2014|May 1, 2014|February 14, 2006|Yes|Yes||No|December 10, 2009|https://clinicaltrials.gov/show/NCT00291876||185038|For 5 subjects at Month 234, serum sample tubes were broken. Due to risk of contamination, anti-HAV concentrations analyses were not performed for these subjects, who were excluded in the LT-ATP cohort for immunogenicity analysis at Month 234.
NCT00292994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700-04-2001|Study of How Exercise or Weight Loss Effects Metabolic Syndrome|Exercise and Diet With Weight Loss in Metabolic Syndrome||Yankton Clinical Research Alliance||Active, not recruiting|April 2004|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||130|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2006|February 15, 2006|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292994||184960|
NCT00292981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1145_3003|C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)|Open-label Extension Study of CE1145 (Human Pasteurized C1 Esterase Inhibitor Concentrate) in Subjects With Congenital C1-INH Deficiency and Acute HAE Attacks||CSL Behring||Completed|August 2005|May 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|6 Years|N/A|No|||October 2011|April 20, 2015|February 15, 2006|No|Yes||No|May 25, 2011|https://clinicaltrials.gov/show/NCT00292981||184961|
NCT00293280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0336, CDR0000452787|Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2005|||July 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|42|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293280||184939|
NCT00252694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2453C00047|DIabetic Retinopathy Candesartan Trials|Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.|DIRECT|AstraZeneca||Completed|August 2001|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4717|||Both|37 Years|75 Years|No|||April 2014|May 9, 2014|November 10, 2005|Yes|Yes||No|March 22, 2012|https://clinicaltrials.gov/show/NCT00252694||187973|
NCT00242684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-298|PEU in Elderly TCU Residents|Manifestations, Causes, and Consequences of PEU in Elderly TCU Residents||VA Office of Research and Development|No|Completed|March 2006|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|446|Samples Without DNA|serum and plasma samples|Both|64 Years|N/A|No|Probability Sample|non-terminally ill adults admitted to the TCU|September 2014|April 6, 2015|October 18, 2005||No||No|November 24, 2014|https://clinicaltrials.gov/show/NCT00242684||188728|This was an observational study designed to develop a better understanding of the interrelationships among nutrient intake, weight change, serum concentration of albumins, illness severity, and mortality. For more details, see cited references.
NCT00249509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13191-1|Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals|Marijuana Pharmacotherapies: Controlled Clinical Trials With Nefazodone and Bupropion||National Institute on Drug Abuse (NIDA)||Completed|September 2000|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||132|||Both|18 Years|65 Years|No|||October 2009|October 15, 2009|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249509||188215|
NCT00249743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R44AG022270-02|Clinical Evaluation of a Wireless Monitoring Device to Reduce Falls in the Elderly and Others at High Risk of Falling|NIH-NIA SBIR Phase I/II Study: Clinical Evaluation of a Device to Reduce Patient Falls||NOCwatch International||Completed|December 2004|July 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|N/A|N/A|No|||May 2006|May 25, 2006|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249743||188197|
NCT00250029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104C|Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen|Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy||New Mexico Cancer Care Alliance|Yes|Completed|April 2004|March 2006|Actual|September 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2010|September 23, 2011|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250029||188175|
NCT00250081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83004-278826|Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy|Multi Center Project: Comparison of Functional Outcomes of Tendon Transfer Surgery, Botulinum Toxin Injections and Regular Ongoing Treatment in Hemiplegic Upper Extremity Cerebral Palsy|UECP|Shriners Hospitals for Children|Yes|Terminated|February 2005|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|38|||Both|4 Years|17 Years|No|||November 2014|November 18, 2014|November 3, 2005||No|Accrual is complete.|No||https://clinicaltrials.gov/show/NCT00250081||188171|
NCT00250328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-CLP 52-01- HMO-CTIL|Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-Colectomy|Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-Colectomy||Hadassah Medical Organization||Not yet recruiting|January 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|90 Years|No|||November 2005|November 6, 2005|November 6, 2005||||No||https://clinicaltrials.gov/show/NCT00250328||188153|
NCT00250341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-403-4-196|Non-invasive Measures of Distal Lung Disease in Asthmatics|Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Therapy Directed at the Proximal vs. Distal Lung||Teva Pharmaceutical Industries|No|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|November 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250341||188152|
NCT00258882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD512|Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine|Post-licensure Safety Surveillance Study of Routine Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)||Sanofi|No|Completed|January 2006|December 2012|Actual|July 2011|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|12020|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Passive surveillance by review of Kaiser Permanente Medical Care Program (KPMCP)        computerized records and state mortality tapes|February 2013|February 5, 2013|November 24, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258882||187509|
NCT00258895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3T11|Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®|Safety and Immunogenicity of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL® or Pentacel®||Sanofi||Completed|March 2005|April 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|649|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|November 24, 2005|Yes|Yes||No|August 18, 2009|https://clinicaltrials.gov/show/NCT00258895||187508|
NCT00290459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|608.03|Prognostic Markers of Gynecologic Cancers|Prognostic Markers of Gynecologic Cancers||James Graham Brown Cancer Center||Recruiting|December 2003|||January 2020|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||1|Anticipated|5000|||Female|18 Years|N/A|No|Non-Probability Sample|All female patients undergoing hysterectomy at the Brown Cancer Center|May 2014|May 28, 2014|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00290459||185143|
NCT00291317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5532|The Effect of FES on Children With Spinal Cord Injury|The Effect of FES on Children With Spinal Cord Dysfunction||Children's Specialized Hospital|No|Completed|January 2006|January 2011|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|4 Years|21 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|February 10, 2006||No||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00291317||185081|Difficulty for participants to attend sessions. Difficulties with recruitment.
NCT00292279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL20020004|The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients|The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients: A Randomized, Double Blind, Controlled, Multi-Center Clinical Trial.||Sino-Swed Pharmaceutical Corporation|Yes|Completed|June 2002|February 2004|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|70 Years|No|||May 2008|May 12, 2008|February 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00292279||185008|
NCT00292292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kineflex|Kineflex Artificial Disc System to Treat Degenerative Disc Disease (DDD)|Clinical Study Protocol for the Investigation of the Kineflex Spinal System - a Pivotal Study in Continued Access Stage||SpinalMotion|No|Terminated|January 2005|August 2013|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|514|||Both|18 Years|60 Years|No|||August 2013|August 31, 2013|February 13, 2006|Yes|Yes|Economic and business reasons|No||https://clinicaltrials.gov/show/NCT00292292||185007|
NCT00291889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102039|Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.|Evaluate the Safety, Reactogenicity & Immunogenicity of 2 Antigen Dose Levels of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02 to Healthy PPD-negative Volunteers Aged 18 to 45 Yrs||GlaxoSmithKline||Completed|July 2004|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00291889||185037|
NCT00292227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0864|Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease|Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.||UCB Pharma|No|Completed|January 2006|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||February 2011|October 17, 2014|February 14, 2006|No|Yes||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00292227||185012|
NCT00292240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA018854|Brief Youth Substance Use Intervention for Primary Care|||RAND||Completed|October 2004|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2011|July 20, 2011|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00292240||185011|
NCT00293319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454716|131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma|I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma, A Phase II Study||University of California, San Francisco||Completed|April 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|164|||Both|1 Year|N/A|No|||August 2014|August 14, 2014|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293319||184937|
NCT00293631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNP-202|Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy|A Randomized, Parallel-Group, Double-Blind, Single-Dose Study Evaluating the Efficacy and Safety of Intravenous Lornoxicam (8 mg and 16 mg) Compared to Intravenous Placebo and Ketorolac 30 mg in Management of Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy).||POZEN||Completed|November 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years||||November 2012|November 29, 2012|February 15, 2006||||||https://clinicaltrials.gov/show/NCT00293631||184915|
NCT00293293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000NT790|Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine|Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2005|January 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|43|||Female|N/A|N/A|No|||October 2015|October 6, 2015|February 16, 2006||No||No|August 22, 2011|https://clinicaltrials.gov/show/NCT00293293||184938|
NCT00293618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/288|Implementation Study of the PostOperative Nausea and Vomiting Prediction Rule|IMplementation of a Prediction Rule in Anesthesia Practice to Improve Cost-Effectiveness of Treatment of Postoperative Nausea and Vomiting||UMC Utrecht|No|Completed|March 2006|January 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|11970|||Both|18 Years|N/A|No|||January 2009|January 15, 2009|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293618||184916|
NCT00252980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EB0440|CANDIS - Targeted Treatment for Cannabis Disorders|CANDIS -Targeted Treatment for Cannabis Disorders||Technische Universität Dresden||Active, not recruiting|January 2006|March 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||210|||Both|16 Years|N/A|No|||January 2007|January 15, 2007|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00252980||187951|
NCT00252707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791AL00001|Iressa 2nd Line Phase III Study in Japan|A Multicentre, Randomised, Open-Label, Parallel-Group, Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic (Stage IIIB/IV), or Recurrent Non-Small Cell Lung Cancer, Who Have Failed One or Two Chemotherapy Regimens||AstraZeneca||Completed|September 2003|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|484|||Both|20 Years|N/A|No|||December 2007|December 14, 2007|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00252707||187972|
NCT00253448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1302|Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme|Phase II Trial of Conventional Radiotherapy With Stereotactic Radiosurgery to High Risk Tumor Regions as Determined by Functional Imaging in Patients With Glioblastoma Multiforme||Case Comprehensive Cancer Center|Yes|Completed|December 2002|July 2011|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|November 11, 2005|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00253448||187915|
NCT00249522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13444-1|Vouchers vs. Prizes for Methadone Patients - 1|Vouchers vs. Prizes for Methadone Patients||National Institute on Drug Abuse (NIDA)|No|Completed|August 2003|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|76|||Both|18 Years|N/A|No|||May 2008|May 23, 2008|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249522||188214|
NCT00249756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19982-1|Re-Entry MTC for Offenders With MICA Disorders|Re-Entry MTC for Offenders With MICA Disorders||National Development and Research Institutes, Inc.|Yes|Completed|August 2005|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|610|||Male|18 Years|N/A|No|||August 2013|August 29, 2013|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249756||188196|
NCT00249769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEV01|Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine|Assessment of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine Given Alone||PATH||Completed|November 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||600|||Both|8 Months|11 Months|Accepts Healthy Volunteers|||May 2007|May 5, 2008|November 3, 2005||||No||https://clinicaltrials.gov/show/NCT00249769||188195|
NCT00250055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104C|Non-Invasive, Real-Time Technology for Diagnosis of Cervical Tissue|Non-Invasive, Real-time Technology for Diagnosis of Cervical Tissue||University of New Mexico|Yes|Active, not recruiting|April 2004|January 2010|Anticipated|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||July 2009|March 8, 2010|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00250055||188173|
NCT00250068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402C|Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)|Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)||University of New Mexico|Yes|Completed|April 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2008|May 18, 2010|November 3, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00250068||188172|
NCT00250380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H17-CV(Seishu)-002|The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)|The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)－A Prospective Multicenter Cohort Study-||Ministry of Health, Labour and Welfare, Japan|Yes|Completed|November 2005|March 2011|Actual|June 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|583|Samples With DNA|whole blood, serum, urine|Both|20 Years|N/A|No|Probability Sample|out-patient clinic|December 2011|December 12, 2011|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250380||188149|
NCT00250640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91430|Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years|Open-label, Uncontrolled, Prospective Long-term Observation of Ventavis Inhalation Therapy in the Treatment of Patients With Primary Pulmonary Hypertension up to 4 Years||Bayer|No|Completed|April 2005|July 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Patients with the disease in scope and the prescription of Ventavis mainly from expert        clinics in the participating countries|January 2015|January 30, 2015|November 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00250640||188129|
NCT00250653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS5577|A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression|A Fifty-two-week, Multicenter, Open-label Study Evaluating the Long-term Safety and Tolerability of Saredutant in Adult and Elderly Patients With Major Depressive Disorder||Sanofi||Completed|May 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|365|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|November 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00250653||188128|
NCT00290173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0129111|Ritodrine in Oral Maintenance of Tocolysis After Active Preterm Labor|Ritodrine in Oral Maintenance of Tocolysis After Active Preterm Labor: Randomized Controlled Trial||University of Zagreb||Completed||August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|45 Years|No|||February 2006|May 3, 2006|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00290173||185164|
NCT00290992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT5080|Rasburicase for Hyperuricemia|Open-Label, Multi-Center Study of SR29142 as Uricolytic Therapy/Prophylaxis for Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematological Malignancies at High Risk for Tumor Lysis Syndrome||Sanofi||Completed|June 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|N/A|17 Years|No|||March 2009|March 27, 2009|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290992||185104|
NCT00291668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87037|Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease|A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Active Crohn's Disease||UCB Pharma|No|Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|94|||Both|16 Years|65 Years|No|||March 2015|March 5, 2015|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291668||185054|
NCT00291681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3547-IB-CTIL|Differences in Human Germinal Center B Cell Selection Revealed by Analysis of IgVH Gene Hypermutation and Lineage Trees in Inflammatory Bowel Disease|Studying the Role of B Cells in Inflammatory Bowel Disease (IBD), Using a Combination of Experimental and Bioinformatical Techniques.||Sheba Medical Center||Active, not recruiting|September 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A|No|||January 2006|February 12, 2006|February 12, 2006||||No||https://clinicaltrials.gov/show/NCT00291681||185053|
NCT00291902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK103351|A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention|A 28-day, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Anti-inflammatory Effect and Steady-state Pharmacokinetics of SB-681323 (7.5 mg) in Subjects With Coronary Heart Disease (CHD) Undergoing Elective Percutaneous Coronary Interventions (PCI)||GlaxoSmithKline|No|Completed|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|80 Years|No|||September 2011|May 31, 2012|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291902||185036|
NCT00292305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050116|Nordic Bifurcation Stent Technique Study (BIF II)|Crush- or Culotte Stenting of Bifurcation Lesions Using Drug Eluting Stents? A Randomized Nordic Multicenter Study (BIF II)|BIF II|Aarhus University Hospital Skejby|Yes|Completed|September 2005|December 2012|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|No|||July 2013|July 24, 2013|February 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00292305||185006|
NCT00292318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-013-05S|Treatment of Patients With Fecal Incontinence|Biofeedback Therapy for Fecal Incontinence a Randomized Control Trial||VA Office of Research and Development|No|Terminated|January 2008|September 2014|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|80 Years|No|||August 2015|August 13, 2015|February 13, 2006||No|Unable to continue due to medical equipment necessary for research study was removed from    facility.|No|August 13, 2015|https://clinicaltrials.gov/show/NCT00292318||185005|
NCT00292253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22982|Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects|A Randomized, Multicenter, Parallel Group, Open-label Study Comparing the Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing Remitting MS Patients||EMD Serono||Completed|January 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1883|||Both|18 Years|N/A|No|||August 2013|August 4, 2013|February 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292253||185010|
NCT00292266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21125|A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)|An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif® 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex® 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis||EMD Serono||Completed|November 1999|June 2002|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|677|||Both|18 Years|55 Years|No|||August 2013|August 2, 2013|February 13, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00292266||185009|
NCT00292708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C000000069|Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery|Randomized Multicenter Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery: Single-Dose Vs. Three Doses of Second-Generation Cephalosporin||National Cancer Center, Japan||Completed|May 2004|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|20 Years|80 Years|No|||February 2006|February 15, 2006|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292708||184982|
NCT00292721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134-가-37|Effects of Celecoxib After Percutaneous Coronary Intervention|Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial||Seoul National University Hospital|Yes|Completed|August 2004|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|75 Years|No|||July 2011|July 20, 2011|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00292721||184981|
NCT00293332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455640|Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery|A Phase II Study of Neoadjuvant Therapy With Docetaxel, Carboplatin, and Bevacizumab in Patients With Resectable Early Stage Non-Small Cell Lung Cancer||University of California, San Francisco|Yes|Terminated|December 2005|April 2007|Actual|March 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2007|February 8, 2011|February 16, 2006|Yes|Yes|Terminated due to low subject accrual|No||https://clinicaltrials.gov/show/NCT00293332||184936|
NCT00293969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-360|A Trial Comparing Different Dosing Regimens of Morphine in Patients With Moderate to Severe Pain|A Randomized Clinical Trial Comparing Different Dosing Regimens of Intravenous Morphine in the Treatment of Adult Patients Presenting to the Emergency Department With Moderate to Severe Pain||Montefiore Medical Center||Completed|March 2005|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|21 Years|65 Years|No|||January 2006|February 17, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00293969||184889|
NCT00293982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 04/22, HRRC 086-04|The Influence of Expectations on Patient Satisfaction in the Pediatric Emergency Department|||Medical College of Wisconsin||Completed|June 2004|August 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||948|||Both|N/A|N/A||||February 2005|February 17, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00293982||184888|
NCT00293995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04SG07|Minimal Access Repair of Contralateral Hernias (MARCH Trial)|||Institute of Child Health||Recruiting||December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|N/A|1 Year|No|||December 2006|December 22, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00293995||184887|
NCT00294255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-USA-T290|Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania|Risperidone Plus Mood Stabilizer in the Treatment of Mixed Mania||The University of Texas Health Science Center at San Antonio|Yes|Completed|March 2003|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|September 13, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00294255||184868|
NCT00252434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA018075|Behavioral Therapy Development for Methamphetamine Abuse|Behavioral Therapy Development for Methamphetamine Abuse||University of California, Los Angeles|No|Terminated|August 2004|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|65 Years||||January 2016|January 26, 2016|November 10, 2005||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00252434||187993|
NCT00252447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0483-C|Preop Conformal Radiotherapy - Prostate|A Pilot Study of Pre-Operative Conformal Radiotherapy in Patients With Radical Prostatectomy||University Health Network, Toronto||Completed|May 2000|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Male|18 Years|N/A|No|||August 2010|August 10, 2010|November 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00252447||187992|
NCT00253240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-441|Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population|Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population - An Evaluation Project||Lawson Health Research Institute|No|Completed|September 2004|September 2005|Actual|||Phase 3|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|75|||Both|18 Years|75 Years|No|||July 2007|July 20, 2007|November 10, 2005||||No||https://clinicaltrials.gov/show/NCT00253240||187931|
NCT00253253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05.936L|Long-Term Outcome in Congenital Undescended Testis After Surgical Treatment by Orchidopexy|Long-Term Outcome in Congenital Undescended Testis After Surgical Treatment by Orchidopexy||Medical Center Alkmaar||Completed|August 2006|January 2007||||N/A|Observational|Time Perspective: Retrospective|||Actual|181|||Male|6 Months|25 Years|No|||May 2008|May 21, 2008|November 14, 2005||||No||https://clinicaltrials.gov/show/NCT00253253||187930|
NCT00253461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU6Y02|11C Topotecan PET Imaging|Positron Emission Tomography Using 11C Topotecan in Predicting Response to Treatment in Patients With Brain Metastases Due to Ovarian, Small Cell Lung, or Other Cancer||Case Comprehensive Cancer Center|Yes|Terminated|December 2004|November 2009|Actual|November 2009|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|7|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|November 11, 2005|No|Yes|Drugs unavailable:unable to make radioactive topotecan|No||https://clinicaltrials.gov/show/NCT00253461||187914|
NCT00249535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13444-2|Vouchers vs. Prizes for Cocaine-Dependent Methadone Patients - 2|Vouchers vs. Prizes for Cocaine-Dependent Methadone Patients||University of Connecticut Health Center|No|Completed|March 2005|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|November 3, 2005||No||No||https://clinicaltrials.gov/show/NCT00249535||188213|
NCT00249808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25300|A Study of Efalizumab in Patients With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies|A Multicentre, Open Label Phase IIIb Study of Subcutaneously Admin. Efalizumab (Adult Patients) With Moderate to Severe Chronic Psoriasis Failed to Respond to, or Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Incl. Cyclosporine, Methotrexate and PUVA.||Merck KGaA||Completed|December 2004|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1266|||Both|18 Years|75 Years|No|||March 2009|August 5, 2014|November 4, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00249808||188192|
NCT00249782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACZ ROS 01|A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.|A Phase II, Randomized, Partial-Blind, Parallel-Group, Active- and Vehicle-Controlled, Multicenter Study of the Safety and Efficacy of ACZONE™ (Dapsone) Gel, 5% in Subjects With Papulopustular Rosacea||Allergan||Completed|November 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|400|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|November 3, 2005||||||https://clinicaltrials.gov/show/NCT00249782||188194|
NCT00249795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4912 I|Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)|A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation|ACTIVE I|Sanofi|Yes|Completed|June 2003|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|9016|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|November 4, 2005|Yes|Yes||No|August 24, 2010|https://clinicaltrials.gov/show/NCT00249795||188193|
NCT00242177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol # 2003-0547|Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability|Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability||University of Illinois at Chicago||Completed|October 2003|October 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||October 2005|October 24, 2005|October 18, 2005||||No||https://clinicaltrials.gov/show/NCT00242177||188767|
NCT00242853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA4102651|A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis|An Enabling Study to Investigate the Correlation of Biomarkers of the Activity of Inducible Nitric Oxide Synthase (iNOS) With Disease Activity and Treatment Response in Patients With Rheumatoid Arthritis(RA)||GlaxoSmithKline||Completed|October 2004|||||N/A|Observational|Time Perspective: Prospective||||48|||Both|18 Years|75 Years|No|||October 2008|October 9, 2008|October 19, 2005||||No||https://clinicaltrials.gov/show/NCT00242853||188715|
NCT00250367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006058|A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.|The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder||Janssen Pharmaceutica N.V., Belgium||Completed|October 1997|November 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|151|||Both|18 Years|65 Years|No|||November 2010|November 24, 2010|November 4, 2005||||||https://clinicaltrials.gov/show/NCT00250367||188150|
NCT00290719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456200|Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery|A Phase I/II Study to Evaluate Safety and Efficacy in Patients Who Have Resectable Esophageal Cancer and Are Treated With Neoadjuvant Cisplatin, Irinotecan (CPT-11) ZD1839 (IRESSA), and Radiotherapy Followed by Surgical Resection||University of California, San Francisco|Yes|Terminated|November 2005|June 2008|Actual|April 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|February 9, 2006|No|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT00290719||185123|
NCT00285662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPTi219|Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants|Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants||Papua New Guinea Institute of Medical Research|Yes|Completed|June 2006|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|1100|||Both|2 Months|4 Months|Accepts Healthy Volunteers|||July 2011|July 22, 2011|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285662||185509|
NCT00281476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004933-16|The Effect of High Dose Simvastatine on Multiple Myeloma|The Effect of High Dose Simvastatine on Multiple Myeloma||Vejle Hospital||Completed|February 2006|November 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||October 2011|October 31, 2011|January 23, 2006||||No||https://clinicaltrials.gov/show/NCT00281476||185823|
NCT00281424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-080105|Increasing Walking Following Cardiac Rehabilitation|Increasing Walking Following Completion of Cardiac Rehabilitation||University of Alberta, Physical Education||Recruiting|June 2005|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||225|||Both|N/A|N/A|No|||January 2006|March 8, 2007|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281424||185827|
NCT00282529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05101|Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study|Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study||Sidney Kimmel Comprehensive Cancer Center||Terminated|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|400|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282529||185743|
NCT00282802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS040467|Twins and the Risk of Parkinson's Disease: A Clinical and Imaging Study|Twins and the Risk of PD: A Clinical and Imaging Study||The Parkinson's Institute|No|Active, not recruiting|April 2001|July 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Male|77 Years|88 Years|No|Probability Sample|Participants will be recruited from a closed cohort—the National Academy of        Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort|July 2009|July 1, 2009|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00282802||185723|
NCT00283114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG033-0001|A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome|A Phase 1, Multi-Dose Study of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome||Seattle Genetics, Inc.|No|Completed|November 2005|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|January 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00283114||185700|
NCT00283361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-025|ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure|A Phase II,Randomized, Double-Blind, Flexible Dose Study of ZP120 I.V. Infusion as Add-On Therapy in Patients With Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated With Furosemide||Zealand Pharma||Terminated|January 2006|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|18 Years|N/A|No|||February 2007|February 27, 2007|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00283361||185682|
NCT00283374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9804Z1-900|Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome|A Prospective, Longitudinal Multicenter, Nontreatment, Exploratory Biomarker Study of Metabolic Syndrome in Subjects Undergoing Laparoscopic Roux-En-Y Gastric Bypass Bariatric Syndrome||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|October 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||120|||Both|18 Years|55 Years|No|||May 2006|May 17, 2006|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00283374||185681|
NCT00283400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS049135|Treatment of Subarachnoid Hemorrhage With Human Albumin|Treatment of Subarachnoid Hemorrhage With Human Albumin||Baylor College of Medicine|Yes|Terminated|January 2006|April 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|79 Years|No|||March 2015|March 18, 2015|January 26, 2006|Yes|Yes|Study met safety endpoints|No|February 5, 2013|https://clinicaltrials.gov/show/NCT00283400||185679|Our study has several limitations. ALISAH is an early phase design and we do not have concurrent controls. In addition, the study was neither randomized nor powered to test for efficacy effects.
NCT00283673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350-95|Effect of Exercise Intervention on Various Physiologic Factors That Change With Increasing Age|Impact of Aerobic Exercise Training on Age Related Changes in Insulin Sensitivity and Muscle Oxidative Capacity||Mayo Clinic||Completed|September 1995|January 1998|Actual|January 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||102|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||June 2011|June 3, 2011|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00283673||185658|
NCT00283946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6199-CL-0007|A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia|FK199B (Zolpidem MR Tablet) Phase III Clinical Study -A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia -||Astellas Pharma Inc|No|Completed|February 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|876|||Both|20 Years|64 Years|No|||August 2014|August 19, 2014|January 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00283946||185637|
NCT00284206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-NAP-4008|A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence|An Open-Label Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence||Seattle Institute for Biomedical and Clinical Research||Completed|January 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|65 Years|No|||January 2008|January 3, 2008|January 27, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00284206||185617|
NCT00294632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0461|Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma|Lenalidomide and Rituximab Treatment of Relapsed Mantle Cell Lymphoma and Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Transformed Large Cell Lymphoma, and/or Grade 3 Follicular Lymphoma (Follicular Cleaved Large Cell Lymphoma or Follicular Non-Cleaved Large Cell Lymphoma (RV-LYM-PI-0056)||M.D. Anderson Cancer Center|No|Completed|February 2006|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294632||184840|
NCT00289991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501073|Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)|Prospective, Open-Label, Comparative, Multi-Center Study Of Voriconazole Compared To Itraconazole For The Primary Prophylaxis Of Invasive Fungal Infection (IFI) With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)|IMPROVIT|Pfizer|Yes|Completed|March 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|489|||Both|12 Years|N/A|No|||October 2015|October 16, 2015|February 9, 2006|Yes|Yes||No|February 9, 2010|https://clinicaltrials.gov/show/NCT00289991||185178|Data was excluded from 1 site due to Good Clinical Practices deviations.
NCT00290264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00009|SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma|A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbohaler 160/4.5 μg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open-label, Parallel-group, Multi-centre Study (SALTO)||AstraZeneca||Completed|December 2004|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290264||185157|
NCT00290277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104951|Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years|Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs||GlaxoSmithKline||Completed|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|300|||Female|10 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290277||185156|
NCT00290550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-006|A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)|A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Merck Sharp & Dohme Corp.||Terminated|June 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290550||185136|
NCT00290563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_102|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder|A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK0594 in Patients With Overactive Bladder||Merck Sharp & Dohme Corp.||Completed|February 2006|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|557|||Both|40 Years|74 Years|No|||December 2009|December 14, 2009|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290563||185135|
NCT00290771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571H2201|Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)|A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)||Novartis|No|Terminated|February 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|N/A|No|||April 2011|April 20, 2011|February 10, 2006|Yes|Yes|Lack of efficacy|No|December 20, 2010|https://clinicaltrials.gov/show/NCT00290771||185119|
NCT00291109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9298|An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg|Quantitative Real Time PCR in Cytolytic Formalin Fixed Breast Cells Obtained by Periareolar Fine Needle Aspiration. An Ancillary Protocol to a Chemoprevention Trial of Letrozole||University of Kansas Medical Center||Completed|January 2003|July 2005||||Phase 1/Phase 2|Observational|Time Perspective: Prospective||||40|||Female|18 Years|N/A|No|||September 2008|September 15, 2008|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291109||185095|
NCT00291434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF vs HF and AF|Altered and Conventional Fractionated Radiotherapy in Patients With Head and Neck Cancer|Hyperfractionation and Accelerated Fractionation in Comparison With Conventional Fractionation in Definitive Radiotherapy of Squamous Cell Carcinoma of Larynx, Oropharynx and Hypopharynx||Institute of Radiotherapy and Oncology, Macedonia||Completed|March 1999|June 2005||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||152|||Both|18 Years|75 Years|No|||January 2005|May 3, 2006|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291434||185072|
NCT00291447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2004-001|111-In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen|A Phase 1 Single Dose Escalation Trial of ch806 in Patients With Advanced Tumours Expressing the 806 Antigen||Ludwig Institute for Cancer Research||Completed|May 2005|May 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||August 2006|August 11, 2006|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291447||185071|
NCT00291759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033AU/0002|ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.|Adjuvant Endocrine Therapy in Postmenopausal Patients With HR +ve BC With Good to Moderate Differentiation - ARNO (Arimidex + Nolvadex). Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to: Tamoxifen 3 Years or Anastrozole 3 Years.||AstraZeneca||Completed|January 1996|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3858|||Female|N/A|80 Years|No|||January 2013|January 29, 2013|February 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291759||185047|
NCT00291746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9914C00002|Validation of RDQ Questionnaire|A Single-Blind Single Arm Study to Validate the Reflux Disease Questionnaire (RDQ) for the Diagnosis of Reflux Disease in Primary Care in Patients Treated With Esomeprazole 40 mg o.d.||AstraZeneca||Completed|September 2005|November 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||350|||Both|18 Years|79 Years|No|||March 2009|March 11, 2009|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00291746||185048|
NCT00293839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004570|Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder|Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder||Alza Corporation, DE, USA||Completed||December 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|790|||Female|18 Years|N/A|No|||December 2010|December 7, 2010|February 16, 2006||||||https://clinicaltrials.gov/show/NCT00293839||184899|
NCT00294177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561702010|Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma|Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Persistent Gestational Trophoblastic Tumors Using Atomic Force Microscopy and Dual Polarisation Interferometry||National Taiwan University Hospital||Not yet recruiting|August 2006|July 2008||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Female|N/A|N/A|No|||February 2006|February 17, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294177||184874|
NCT00294450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK140OS|Feasibility Study of a New Fistula Pouching System|Pouching of Fistula - a Non-comparative, Multi-center Investigation||Coloplast A/S|No|Completed|February 2006|March 2007|Actual|March 2007|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|February 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00294450||184854|
NCT00285363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 05-052E|Quality of Life Among Children and Adolescents With Cancer|Quality of Life Among Children and Adolescents With Cancer||Children's Mercy Hospital Kansas City||Active, not recruiting|March 2005|March 2005||||N/A|Observational|Time Perspective: Cross-Sectional||||75|||Both|9 Years|18 Years|No|||March 2005|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285363||185531|
NCT00281450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850652|An Intervention to Reduce Inappropriate Prescriptions for Elderly Patients in General Practice|A Cluster Randomized Educational Intervention to Reduce Inappropriate Prescription Patterns for Elderly Patients in General Practice||University of Oslo||Completed|January 2006|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|85836|||Both|N/A|N/A|No|||December 2005|April 27, 2010|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00281450||185825|
NCT00282542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU124|Hepatocyte Transplantation as a Life Support Bridge|The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure||Virginia Commonwealth University||Suspended|May 2000|January 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2006|January 25, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00282542||185742|
NCT00282815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23NS051202|Sleep Apnea Treatment After Stroke (SATS)|Treatment of Obstructive Sleep Apnea After Stroke||University of Michigan|No|Terminated|September 2004|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||December 2012|January 31, 2013|January 26, 2006|Yes|Yes|Poor recruitment. Funding expired.|No|June 21, 2011|https://clinicaltrials.gov/show/NCT00282815||185722|Attrition pre-randomization and while in randomized treatment led to small numbers.
NCT00283127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2005.1223|Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women.|Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women. - A Randomised Control Trial||Norwegian Institute of Public Health||Completed|February 2006|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||41719|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2009|March 2, 2010|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283127||185699|
NCT00283387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2147-05|Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria|Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria||Mayo Clinic|No|Completed|February 2007|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|6 Years|70 Years|No|||November 2013|November 21, 2013|January 26, 2006|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00283387||185680|
NCT00283413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G980213|Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts|Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts||Boston Scientific Corporation|Yes|Completed|March 2002|March 2009|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|514|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|January 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283413||185678|
NCT00283959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA1565521 (FAB-CL-202)|A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease|A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease||Amicus Therapeutics||Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|65 Years|No|||March 2015|March 25, 2015|January 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283959||185636|
NCT00284219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3401-RA-CTIL|High-Frequency Repetitive Transcranial Magnetic Stimulation Assists In Smoking Cessation|||Sheba Medical Center||Completed|July 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 29, 2011|January 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00284219||185616|
NCT00284570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002022|Pro-Calcitonin Levels Following Pediatric Cardiac Surgery|ProCalcitonin in the Pediatric Surgical Patient, Evaluation of a New Marker of Infection||Emory University|No|Completed|January 2006|March 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|Samples With DNA|Blood samples are collected in order to get the procalcitonin level.|Both|N/A|5 Years|No|Non-Probability Sample|The study patients will be recruited from Children's Healthcare of Atlanta at Egleston.        The patients will be in the pre-operative clinic, Cardiac Intensive Care Unit or the        Cardiac Stepdown Unit.|November 2013|November 26, 2013|January 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00284570||185590|
NCT00290004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0223|Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I/II Trial of Weekly Motexafin Gadolinium (MGd) for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Pharmacyclics||Completed|November 2005|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||September 2008|September 10, 2008|February 8, 2006||||||https://clinicaltrials.gov/show/NCT00290004||185177|
NCT00290290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-14542|Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections|Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical-Site Antisepsis:A Prospective, Randomized, Multicenter Clinical Trial||Baylor College of Medicine|Yes|Completed|September 2003|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|849|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|February 9, 2006||No||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00290290||185155|
NCT00290576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/04/2-Y|Digestive and Nutritional Effects of Probiotics Supplementation in Premature Newborns|Digestive and Nutritional Effects of Probiotics (Bifidobacterium Longum and Lactobacillus GG) Supplementation in Premature Newborns||Nantes University Hospital||Completed|April 2004|June 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|127|||Both|N/A|2 Weeks|No|||June 2008|June 6, 2008|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00290576||185134|
NCT00290589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-05-107|A Trial of Corticosteroids for Low Back Pain|Utility of Intramuscular Corticosteroids for Radicular Low Back Pain||Montefiore Medical Center||Completed|June 2003|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|76|||Both|21 Years|50 Years|No|||October 2009|October 26, 2009|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290589||185133|
NCT00290810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00137|Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)||National Cancer Institute (NCI)||Completed|December 2005|August 2010|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2012|April 21, 2014|February 9, 2006|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00290810||185118|
NCT00291460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKKG IMT 0106|Inspiratory Muscle Training in Hypercapnic COPD|Randomized Controlled Trial of Inspiratory Muscle Training in Patients With Stable Hypercapnic Respiratory Failure Due to COPD||Krankenhaus Kloster Grafschaft||Recruiting|February 2006|March 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||February 2006|August 18, 2006|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291460||185070|
NCT00291473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMT2004-011|Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers|Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers||Ludwig Institute for Cancer Research||Completed|July 2005|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|9|||Both|18 Years|N/A|No|||March 2009|March 2, 2009|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291473||185069|
NCT00292032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-099|Registry of Unexplained Cardiac Arrest|Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER)||University of British Columbia|Yes|Recruiting|May 2004|January 2020|Anticipated|January 2018|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|blood|Both|2 Years|N/A|No|Non-Probability Sample|Unexplained cardiac arrest patients, and first degree relatives of 1) UCA patients 2)        patients with known primary electrical disease or 3) unexplained sudden death before age        60|April 2015|April 13, 2015|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00292032||185026|
NCT00292019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-030|Robotic Laparoscopic Radical Prostatectomy|Robotic Laparoscopic Radical Prostatectomy||Lawson Health Research Institute|No|Recruiting|March 2004|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|40 Years|65 Years|No|Non-Probability Sample|Prostate cancer patients eligible for a radical prostatectomy|July 2009|July 7, 2009|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00292019||185027|
NCT00281788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4950|Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer|A Phase I Study of Oral Capecitabine in Combination With Weekly IV Carboplatin/Paclitaxel and Radiation Therapy for Patients||Duke University||Completed|September 2003|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|18 Years|N/A|No|||April 2008|March 20, 2013|January 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00281788||185800|
NCT00281801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF6330|Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation|Survival in Allogeneic Bone Marrow Transplantation: The Relative Importance of Inpatient Lay Care-Partner Support||Case Comprehensive Cancer Center|No|Completed|February 2006|April 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|168|||Both|18 Years|N/A|No|Non-Probability Sample|Allogeneic Bone Marrow Transplant patients with lay care-partners.|March 2012|March 13, 2012|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00281801||185799|
NCT00281762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2005.01.TGK|Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human|Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human||Regional Hospital Holstebro||Completed||January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2008|May 6, 2008|January 23, 2006||||No||https://clinicaltrials.gov/show/NCT00281762||185801|
NCT00282204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN012605000018617|Hypnosis Antenatal Training for Childbirth (HATCh): a Randomised Controlled Trial|Hypnosis Antenatal Training for Childbirth (HATCh): a Randomised Controlled Trial||Women's and Children's Hospital, Australia|Yes|Completed|December 2005|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|448|||Female|N/A|N/A|No|||December 2010|June 28, 2012|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00282204||185768|
NCT00294463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 217.640/2002/220|Effects of Tibolone Treatment on the Endometrium|Effects of Tibolone Treatment on the Endometrium||Erasmus Medical Center||Completed|February 2003|March 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2006|February 17, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294463||184853|
NCT00294762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-203|Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC|A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With Newly Diagnosed Advanced Non-small Cell Lung Cancer Who Have Tumors With EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers||Astellas Pharma Inc|No|Completed|January 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|February 17, 2006|No|Yes||No|October 5, 2010|https://clinicaltrials.gov/show/NCT00294762||184830|
NCT00282555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC/STU(-Na)05816N/TU 2.05|Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis|Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.||STEBA France||Suspended|February 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|18 Years|75 Years|No|||March 2008|March 18, 2008|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282555||185741|
NCT00283699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS039403|A Pilot Study of Neurocysticercosis Treatment|A Pilot Study of Neurocysticercosis Treatment||National Institute of Neurological Disorders and Stroke (NINDS)|Yes|Completed|February 2001|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|178|||Both|N/A|N/A|No|||March 2008|February 5, 2010|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00283699||185656|
NCT00283712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT APV01|Use of Infliximab for the Treatment of Pemphigus Vulgaris|A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Infliximab in Subjects With Pemphigus Vulgaris Receiving Prednisone||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|January 26, 2006|Yes|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT00283712||185655|
NCT00283153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-050573-BW-2300|Affect Recognition: Enhancing Performance of Persons With Acquired Brain Injury (ABI)|Controlled Study of Affect Recognition Training for Individuals With Acquired Brain Injury||University at Buffalo|No|Completed|October 2008|August 2014|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|65 Years|No|||August 2014|August 1, 2014|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00283153||185698|
NCT00283686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK62401-PKD-TN (IND)|HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A|Polycystic Kidney Disease-Treatment Network||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2006|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|558|||Both|15 Years|64 Years|No|||March 2015|March 18, 2015|January 26, 2006|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00283686||185657|
NCT00284583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0061-05|Comparison of Alcohol and Steroid Injection for Treating Morton's Neuroma|Comparison of Corticosteroid and Ethanol Injection Therapy in the Treatment of Morton's Neuroma||Brown University||Recruiting|May 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2006|January 30, 2006|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00284583||185589|
NCT00284882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0117|Incidence of Group A Strep Pharyngitis in School Children in Fiji|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 3: The Incidence of Group A Streptococcal Pharyngitis and the Prevalence of Pyoderma and Scabies in School Children in Fiji, and Establishing Immunologic Correlates of Protection for a J8 Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2006|November 2006||||N/A|Observational|Time Perspective: Prospective||||1000|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||October 2007|January 24, 2008|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00284882||185566|
NCT00290329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208144/002|Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years|Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged > 2 Yrs When Administered According to the Prescribing Information.||GlaxoSmithKline||Completed|January 2006|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|249|||Both|2 Years|N/A|Accepts Healthy Volunteers|||October 2012|November 1, 2012|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290329||185152|
NCT00290303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100478|Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants|Study to Show Non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- Hepatitis B Vaccine at Birth) vs Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vacc. at Birth for Antibody Response to All Vaccine Antigens Given in Healthy Infants||GlaxoSmithKline||Completed|May 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||996|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290303||185154|
NCT00290602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-04-087|Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome|Prospective Phase II Study of Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome (ARDS) After Thoracic Surgery (E-START)||National Cancer Center, Korea||Completed|February 2004|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2007|January 16, 2007|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290602||185132|
NCT00290823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05IN214|Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients|Treatment of Intraparenchymal Neurocysticercosis: Effect of Increased Dosing of Corticosteroids on Seizure Frequency||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|July 2007|December 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|65 Years|No|||September 2008|September 25, 2008|February 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00290823||185117|
NCT00292058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07911E|Comparing Telepsychiatry and in-Person Outcomes|Comparing Patient Outcomes and Cost of Psychiatric Care Provided Through Videoconferencing With Psychiatric Care Provided in-Person.||Lawson Health Research Institute||Completed|August 2001|August 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||495|||Both|18 Years|65 Years|No|||February 2006|February 14, 2006|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00292058||185024|
NCT00292396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-736|Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs. Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis||AbbVie|Yes|Completed|November 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|180|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|February 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00292396||184999|
NCT00292383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-PASS V.1.2.|Ventricular Pacing Site Selection (V-PASS)|A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy.||Medtronic BRC||Recruiting||December 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|100|||Both|18 Years|N/A|No|||October 2007|August 1, 2011|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00292383||185000|
NCT00282568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0-131|A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients|A Phase 2, Open-Label, Multi-center Study to Assess the Pharmacokinetics, Safety and Tolerability of Tacrolimus in Stable Kidney Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen||Astellas Pharma Inc|No|Completed|August 2002|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|70|||Both|18 Years|65 Years|No|||July 2013|July 25, 2013|January 25, 2006|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT00282568||185740|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00282828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070919|Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder|Improving Outcomes in Pharmacotherapy of Social Phobia||Massachusetts General Hospital|Yes|Completed|March 2006|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|397|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|January 25, 2006|Yes|Yes||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00282828||185721|
NCT00282217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101467|Study Evaluating Sirolimus in the Treatment of Kidney Transplant|Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||March 2007|March 21, 2007|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282217||185767|
NCT00282230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0-165|A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients|A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Prograf®/FK778 and Prograf®/MMF in De Novo Kidney Transplant Recipients||Astellas Pharma Inc||Terminated|November 2003|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|January 24, 2006||||||https://clinicaltrials.gov/show/NCT00282230||185766|
NCT00283725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004636|Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease|Review of Management Strategies in Dementia|REMIND|Ortho-McNeil Neurologics, Inc.|No|Completed|June 2003|December 2006|Actual|December 2006|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|573|||Both|N/A|N/A|No|Non-Probability Sample|Patients with demetia with mild to moderate Alzheimer's disease.|January 2013|January 24, 2013|January 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00283725||185654|
NCT00283972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12242004P|LAP-BAND Observational Cohort|Health Outcome Study of LAP-BAND Adjustable Gastric Banding System||Inamed||Active, not recruiting|June 2005|December 2006||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||240|||Both|18 Years|N/A|No|||January 2006|January 30, 2006|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00283972||185635|
NCT00284232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Measure 2004|Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes|Randomized Controlled Trial Studying the Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes||Helse Stavanger HF|No|Completed|October 2004|December 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||140|||Both|18 Years|70 Years|No|||July 2015|July 27, 2015|January 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00284232||185615|
NCT00284895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJC HS1963|The Effect of Obesity on Lung Functioning|The Effect of Medical and Surgical Weight Loss on Pulmonary Physiology and Airway||National Jewish Health||Completed|November 2005|November 2007|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|N/A|No|||June 2008|June 25, 2008|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284895||185565|
NCT00285168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2003:099|A Randomized Controlled Trial of a Bone Density Decision Aide|A Randomized Controlled Trial of a Bone Density Decision Aide in the Pharmacological Management of Osteoporosis||University of Manitoba||Terminated|May 2005|March 2010|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients of physicians involved in referring patients for DXA bone density testing|July 2012|July 18, 2012|January 30, 2006||No|Inadequate recruitment|No||https://clinicaltrials.gov/show/NCT00285168||185544|
NCT00290849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI-001-IM|ImproveR International (BI-001-IM)|European Registry of Consecutive Patients Undergoing PCI Evaluating the Use of the Thrombin-specific Anticoagulant Bivalirudin With Focus on Patient Selection, Convenience and Safety Aspects.||Nycomed|Yes|Completed|March 2005|September 2007|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1||4000|||Both|18 Years|75 Years|No|Non-Probability Sample|Primary Care Clinic|April 2010|May 4, 2012|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00290849||185115|
NCT00290862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100-0008|A Safety and Efficacy Study for Treatment of Painful Vertebral Compression Fractures Caused by Osteoporosis|A Randomized, Controlled Clinical Study to Evaluate the Safety and Effectiveness of CORTOSS® Synthetic Cortical Bone Void Filler in Vertebral Augmentation||Orthovita d/b/a Stryker||Active, not recruiting|September 2004|March 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 13, 2008|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290862||185114|
NCT00290615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007431 (CDR0000449945)|Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery|Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Bevacizumab in the Treatment of Metastatic Colorectal Cancer||Duke University|Yes|Completed|January 2006|January 2011|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|February 9, 2006|Yes|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT00290615||185131|
NCT00290836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-017-AU|Assess Efficacy and Safety of TachoComb H vs. Standard Surgical Treatment (i.e. Suturing) in Patients Undergoing Prostatectomy (TC-017-AU)|An Open, Randomised, Prospective, Single-centre Phase IV Trial to Assess Efficacy and Safety of TachoComb H Versus Standard Surgical Treatment (i.e. Suture) in Patients Undergoing Prostatectomy||Nycomed|Yes|Completed|May 2004|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|90 Years|No|||May 2012|May 4, 2012|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00290836||185116|
NCT00291122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9380|An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer|Quantitative Real Time PCR in Formalin Fixed Breast Tissue From Biopsy and Re-Excision Specimens: An Ancillary Protocol to a Chemoprevention Trial of Celecoxib||University of Kansas Medical Center||Completed|January 2003|December 2005||||Phase 1|Observational|N/A||||100|||Female|18 Years|N/A|No|||September 2008|September 15, 2008|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291122||185094|
NCT00291772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17339|Continuous Subcutaneous Infusion of Pramlintide and Insulin|Continuous Subcutaneous Infusion of Pramlintide and Insulin: A Randomized, Crossover Design Study||Baylor College of Medicine|Yes|Completed|January 2006|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|13 Years|22 Years|No|||July 2008|July 16, 2008|February 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00291772||185046|
NCT00291785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM201|Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer|Phase I/II Study of CT-2106 in Combination With Infusional 5-fluorouracil/Folinic Acid (5-FU/FA)(de Gramont Schedule) as Second Line in Patients With Metastatic Colorectal Cancer Failing an Oxaliplatin Plus 5-FU/FA Regimen||CTI BioPharma|No|Completed|January 2004|September 2008|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|February 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291785||185045|
NCT00292045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2003-024|Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer|Phase 1 Study of Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With High-Risk Stage D1 or Advanced Prostate Cancer||Ludwig Institute for Cancer Research||Completed|December 2004|January 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||June 2009|June 19, 2009|February 13, 2006||||||https://clinicaltrials.gov/show/NCT00292045||185025|
NCT00293436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000458055|Celecoxib and Erlotinib in Treating Patients With Liver Cancer|A Phase I/II Study of Celecoxib and Erlotinib Hydrochloride as Adjuvant Therapy for High Risk Patients With a History of Hepatocellular Carcinoma||University of California, San Francisco||Withdrawn|January 2005|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293436||184928|
NCT00292409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-125|A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices|A Prospective Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|March 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Both|18 Years|65 Years|No|||May 2008|November 7, 2013|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00292409||184998|
NCT00292812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor4123ctil|Clinical Effects of a Nucleotides-Supplemented Infant Formula|The Clinical Effects of an Infant Formula Supplemented With Various Concentrations of Nucleotides||Soroka University Medical Center||Completed|March 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|150|||Both|N/A|30 Days|Accepts Healthy Volunteers|||May 2007|October 22, 2007|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292812||184974|
NCT00282581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-249-004|Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive|A Phase 1, Double-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia-Naive Human Immunodeficiency Virus (HIV)-Seropositive Subjects||Sanofi|Yes|Terminated|October 2006|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|2|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|January 26, 2006|No|Yes|Senior managemnt decision|No||https://clinicaltrials.gov/show/NCT00282581||185739|
NCT00281996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 02I8|Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer|Phase I/II Study of Gleevec (Imatinib Mesylate, Formerly Known as STI571) and Gemcitabine for Advanced Pancreas Cancer||Northwestern University|Yes|Terminated|March 2005|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||August 2011|August 24, 2011|January 24, 2006|No|Yes|Closed to accrual to allow enrollment on another more promising trial.|No||https://clinicaltrials.gov/show/NCT00281996||185784|
NCT00282243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0-152|A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients|A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen||Astellas Pharma Inc|No|Completed|February 2003|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|70|||Both|18 Years|65 Years|No|||August 2013|August 1, 2013|January 24, 2006|Yes|Yes||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00282243||185765|
NCT00282256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0-160|A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients|A Phase 2, Open-Label, Multi-center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Pediatric Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen||Astellas Pharma Inc|No|Completed|January 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|19|||Both|N/A|12 Years|No|||August 2013|August 12, 2013|January 24, 2006|Yes|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT00282256||185764|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00283426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBG-1-10|Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns|An Open Clinical Feasibility Study to Evaluate Efficacy and Safety of Soluble Beta-1,3/1,6-Glucan in Thermal Burns||Biotec Pharmacon ASA||Terminated|January 2006|March 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||March 2007|March 16, 2007|January 27, 2006|||Slow patient recruitment|No||https://clinicaltrials.gov/show/NCT00283426||185677|
NCT00283439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050144|A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma|An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects With Lymphoma.||Amgen||Completed|October 2005|September 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|39|||Both|18 Years|N/A|No|||June 2011|June 16, 2011|January 26, 2006||||No|August 13, 2010|https://clinicaltrials.gov/show/NCT00283439||185676|
NCT00284245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT-B-011|Evaluation of Pain Location, Pain Quality and Pain Patterns in Subjects With Chronic Pain|Internet-based Study of 10,000 Subjects With Chronic Pain, Including Subject-drawn Pain Diagrams, and Computer-generated Composite Images of Pain Patterns||Taylor MicroTechnology||Recruiting|June 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Volunteers recruited in Internet study.|September 2006|June 24, 2011|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284245||185614|
NCT00284596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10268|Fixation Stability and Bony Healing Following Open Wedge High Tibial Osteotomy|Fixation Stability and Progress of Bony Healing Following Open-Wedge High- Tibial Osteotomy A 24-Subject Clinical Pilot Study Using Radio Stereometric Analysis||Fowler Kennedy Sport Medicine Clinic|No|Completed|February 2005|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|24|||Both|30 Years|70 Years|No|||January 2009|January 28, 2009|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00284596||185588|
NCT00285181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF7808|Effects of Statins on Pro- and Antioxidant Status : Link With Statin-Associated Myopathy.|Effects of Statins on Pro- and Antioxidant Status : Link With Statin-Associated Myopathy. A Randomized, Placebo-Controlled, Double-Blind Study.||University Hospital, Montpellier|No|Completed|November 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2007|August 8, 2007|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285181||185543|
NCT00285194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003M44181|hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients|hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|April 2000|January 2004|Actual|January 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|January 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00285194||185542|
NCT00285493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230859|Low Back Pain and Antibiotic Treatment|Phase 1 Study of Antibiotic Treatment for Low Back Pain||Loewenstein Hospital||Withdrawn|January 2006|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|25 Years|85 Years|No|||June 2011|March 12, 2014|February 1, 2006|||Withdrawn: study halted prematurely, prior to enrollment of first participant|No||https://clinicaltrials.gov/show/NCT00285493||185522|
NCT00290628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000LS017|Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer|Transplantation of Umbilical Cord Blood From Related and Unrelated Donors||Masonic Cancer Center, University of Minnesota|Yes|Terminated|October 1999|April 2007|Actual|April 2007|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|N/A|45 Years|No|||October 2012|October 9, 2012|February 9, 2006|Yes|Yes|Replaced with another study|No||https://clinicaltrials.gov/show/NCT00290628||185130|
NCT00294125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R41AR051232|Flavocoxid, A Plant-Derived Therapy, for the Treatment of Knee Osteoarthritis|Flavocoxid: A Medical Food Therapy for Osteoarthritis||University of Alabama at Birmingham||Completed|February 2006|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|40 Years|75 Years|No|||April 2013|April 19, 2013|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00294125||184877|
NCT00291135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8884|Protocol for Women at Increased Risk of Developing Breast Cancer|Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy||University of Kansas Medical Center|No|Completed|January 2003|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|February 10, 2006|Yes|Yes||No|June 24, 2013|https://clinicaltrials.gov/show/NCT00291135||185093|
NCT00291486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-017|Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer|Phase I Trial of Oral Capecitabine Combined With 131I-huA33 in Patients With Metastatic Colorectal Cancer||Ludwig Institute for Cancer Research|No|Completed|October 2003|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2009|March 2, 2009|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291486||185068|
NCT00291499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03CH/Ct06|Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand|Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study||IBSA Institut Biochimique SA||Completed|June 2005|August 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|162|||Both|40 Years|N/A|No|||November 2012|November 27, 2012|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291499||185067|
NCT00291512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA012116|Promoting Safer Sex in HIV+ Homosexual and Bisexual Men Who Use Methamphetamine|Promoting Safer Sex in HIV+ MSM Methamphetamine Users||University of California, San Diego||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Male|18 Years|N/A|No|||November 2008|October 12, 2011|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291512||185066|
NCT00291811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-CUP001|Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization|Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation|CUP|Sanofi||Approved for marketing|October 2003|||||N/A|Expanded Access|N/A|||||||Both|18 Years|78 Years|No|||February 2014|February 10, 2014|February 13, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00291811||185043|
NCT00293176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-412|The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)|A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)||Eisai Inc.||Completed|December 2003|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|821|||Both|45 Years|90 Years|No|||March 2011|March 31, 2011|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293176||184947|
NCT00293189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 272008|Gene-Polymorphies in the P2X7 Gene in Patients With Osteoporotic Fractures|Gene-Polymorphies in the P2X7 Gene in Patients With Osteoporotic Fractures||Kolding Sygehus||Recruiting|December 2005|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||700|||Both|18 Years|N/A|No|||August 2005|May 19, 2006|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293189||184946|
NCT00293423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05103|GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma|Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma||University of California, San Francisco|Yes|Completed|October 2005|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293423||184929|
NCT00294151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN#05-015|Potential Vertebroplasty Use in the Treatment of Vertebral Metastasis From Breast and Prostate Cancer|Challenging the Paradigm in Pain Relief for Advanced Breast and Prostate Cancer Patients With Vertebral Metastasis: Vertebral Augmentation With Cement Plus Radiotherapy Versus Radiotherapy. A Randomized, Prospective, Double Blind Pilot Study||McGill University Health Center||Recruiting|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|35 Years|75 Years|No|||January 2006|July 12, 2007|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294151||184876|
NCT00294411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4423/03M|Vaginal Birth After Caesarean Section – Effect on Maternal Psychosocial Function|||Chinese University of Hong Kong||Completed|December 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A||||February 2006|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294411||184857|
NCT00283205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5287-26599|Yoga for Treatment of Hot Flashes|Yoga for Treatment of Hot Flashes and Menopausal Symptoms||University of California, San Francisco||Completed|September 2005|December 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2005|January 25, 2006|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00283205||185694|
NCT00282009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465179|Internet and Telephone Counseling for Smoking Cessation|Internet and Telephone Counseling for Smoking Cessation||Georgetown University|Yes|Completed|August 2004|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|2205|||Both|18 Years|90 Years|No|||August 2014|February 9, 2016|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00282009||185783|
NCT00283192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5287-23467-03|Flushes and Sertraline Trial|A Randomized, Double-Blinded, Placebo Controlled, Trial of the Effect of Sertraline Vs. Placebo in Reducing the Incidence and Severity of Hot Flashes in Healthy Women||University of California, San Francisco||Completed|July 2003|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||August 2005|August 2, 2006|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00283192||185695|
NCT00283452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-024|Keep Active Minnesota|Maintaining Physical Activity in Older Adult MCO Members||HealthPartners Institute|Yes|Completed|September 2003|September 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1049|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2010|March 9, 2010|January 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00283452||185675|
NCT00283751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1373|Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2003|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|583|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00283751||185652|
NCT00283985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I05009|Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma|Phase II Study of an Association of L-asparaginase-Methotrexate-Dexamethasone for Relapsing and/or Refractory Nasal and Nasal-type NK-T-cell Lymphoma||University Hospital, Limoges|Yes|Completed|February 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00283985||185634|
NCT00283998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-Odont-02|Comparing Surgical to Conservative Management in the Treatment of Type II Odontoid Fractures Among the Elderly|Phase 4 Study Comparing Surigcal to Conservative Management of Type 2 Odontoid Fractures||AO Clinical Investigation and Documentation|No|Completed|January 2006|March 2012|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|166|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 25, 2014|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00283998||185633|
NCT00284258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023010 / TOP-003|Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer|Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer||Taiho Pharmaceutical Co., Ltd.||Completed|January 2006|August 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|426|||Both|20 Years|75 Years|No|||November 2012|November 1, 2012|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284258||185613|
NCT00284271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACOPP-21|Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma|||University of Cologne||Completed|January 2004|||December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|61 Years|75 Years|No|||July 2011|July 28, 2011|January 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00284271||185612|
NCT00284284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/171|Investigation of the Added Value of a Big Toe Hinged Brace for the Treatment of Hallux Rigidus|Investigation of the Added Value of a Big Toe Hinged Brace for the Treatment of Hallux Rigidus||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|40 Years|75 Years|No|||April 2009|May 11, 2009|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284284||185611|
NCT00284609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 287360|Rehabilitation of Type 2 Diabetes Patients.|"The Effect of Rehabilitation of Type 2 Diabetes Mellitus Versus Standard Outpatient Care." A Randomized Controlled Trial.||Bispebjerg Hospital|No|Completed|August 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2009|March 25, 2010|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00284609||185587|
NCT00293150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICT|PREDICT: Eplerenone in Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure|A Double-Blind, Parallel Design Study to Determine the Effectiveness of Inspra (Eplerenone) in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure (The PREDICT Study)||The Cleveland Clinic||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||September 2008|September 17, 2008|February 16, 2006||||||https://clinicaltrials.gov/show/NCT00293150||184949|
NCT00293163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYLA00204|A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.|||Sanofi||Completed|February 2006|October 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293163||184948|
NCT00294697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K08GM071646-03|Genetic Variation and Immune Responses After Injury|Genetics of Innate Immune Response After Burn Trauma||National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|August 2003|October 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood, Tissue, Fluids|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Burn, Trauma, and Surgical Patients|August 2010|August 23, 2010|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00294697||184835|
NCT00294710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2323E|A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine|A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension||Novartis||Completed|March 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|976|||Both|18 Years|80 Years|No|||November 2011|November 7, 2011|February 18, 2006||||||https://clinicaltrials.gov/show/NCT00294710||184834|
NCT00290654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002LS097|Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ|Twin Cities Brachytherapy Study for Ductal Carcinoma in Situ A Phase II Trial||Masonic Cancer Center, University of Minnesota|Yes|Terminated|December 2002|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||November 2012|April 29, 2015|February 9, 2006|Yes|Yes|Unable to recruit further patients.|No|April 29, 2015|https://clinicaltrials.gov/show/NCT00290654||185128|
NCT00292461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-AS886-202|A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures|A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures||Eisai Inc.||Completed|March 2006|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|16 Years|70 Years|No|||August 2009|May 13, 2013|February 14, 2006|Yes|Yes||No|September 27, 2010|https://clinicaltrials.gov/show/NCT00292461||184994|
NCT00293813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050179|A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density|A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density||Amgen||Completed|May 2006|August 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|247|||Female|50 Years|70 Years|No|||July 2014|July 18, 2014|February 17, 2006||||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00293813||184901|
NCT00293826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050168|A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis.||Amgen||Completed|March 2006|February 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|813|||Both|18 Years|70 Years|No|||March 2010|March 4, 2010|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00293826||184900|
NCT00290407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008.06|Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)|Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)||James Graham Brown Cancer Center|Yes|Terminated|March 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|February 9, 2006|Yes|Yes|terminated due to lack of accrual|No|May 3, 2013|https://clinicaltrials.gov/show/NCT00290407||185146|Study terminated, results data not available
NCT00258856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA23|Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®|Persistence of Bactericidal Antibodies in Children Aged 7 to 15 Years Who Received a Single Dose of Menactra® or Menomune®-A/C/Y/W-135 Five Years Earlier||Sanofi|Yes|Completed|January 2006|November 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|234|||Both|7 Years|15 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|November 24, 2005|Yes|Yes||No|October 19, 2009|https://clinicaltrials.gov/show/NCT00258856||187511|
NCT00281489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1112|Study Evaluating Ways of Preventing Patients From Being Awake During High-Risk Surgery and Anesthesia|B-Unaware Study: Comparison of BIS-guided Anesthesia With End-Tidal Volatile-Guided Anesthesia to Decrease The Incidence of Awareness During High-Risk Surgery||Washington University School of Medicine||Completed|August 2005|||October 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2000|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281489||185822|
NCT00282867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11901|Glucose Regulation in Acute Stroke Patients (GRASP) Study|Glucose Regulation in Acute Stroke Patients (GRASP) Study||University of Virginia|Yes|Completed|May 2006|February 2009|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|N/A|No|||July 2009|July 15, 2009|January 26, 2006|Yes|Yes||No|July 14, 2009|https://clinicaltrials.gov/show/NCT00282867||185718|
NCT00283166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS-KRPC-0609|Coaching to Improve Care of Cancer Pain|Coaching to Improve Care of Cancer Pain||University of California, Davis|Yes|Completed|November 2006|December 2011|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|2||Actual|258|||Both|18 Years|80 Years|No|||December 2011|December 6, 2011|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00283166||185697|
NCT00283179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-02-A01|Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia|Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control||Taiwan Otsuka Pharm. Co., Ltd||Completed|March 2004|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|65 Years|No|||January 2006|May 14, 2008|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283179||185696|
NCT00283738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050119|MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant|A Prospective, Multi-Center, Double-Blinded, Placebo-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With the BioSTAR Septal Repair Implant to Reduce Refractory Migraine Headache With Aura.||NMT Medical|Yes|Active, not recruiting|February 2006|March 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|610|||Both|18 Years|60 Years|No|||January 2008|January 23, 2008|January 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283738||185653|
NCT00283764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111086|Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device|A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device||Pfizer||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283764||185651|
NCT00284323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WD Salvage ML3181|Salvage: Postconditioning With Adenosine for STEMI|Beneficial Effect of Intracoronary Adenosine on Microvascular and Myocardial Salvage in Patients With Acute Myocardial Infarction (SALVAGE)||University Hospital, Gasthuisberg||Recruiting|January 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||January 2006|January 27, 2006|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00284323||185608|
NCT00284011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|677-04|Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels|Effect of the Dietary Supplement S-Adenosyl-L-Methionine on Plasma Homocysteine Levels in Healthy Human Subjects||Mayo Clinic|Yes|Completed|June 2005|May 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284011||185632|
NCT00284297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/213|Follow-up of Patients After Knee Arthrodesis With an Intramedullary Nail|Follow-up of Patients After Knee Arthrodesis With an Intramedullary Nail||University Hospital, Ghent|No|Recruiting|September 2005|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284297||185610|
NCT00284310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/183|Follow-up of Patients After 4-row Arthrodesis or Proximal Row Carpectomy|Follow-up of Patients After 4-row Arthrodesis or Proximal Row Carpectomy||University Hospital, Ghent|No|Recruiting|October 2005|December 2020|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284310||185609|
NCT00284622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTO-1|HTO With and Without Arthroscopy|A Randomized Clinical Trial to Compare the Effectiveness of High Tibial Osteotomy With or Without Arthroscopy of the Knee Joint on Quality of Life, Functional Ability and Pain for Patients With Medical Compartment Osteoarthritis of the Knee||Fowler Kennedy Sport Medicine Clinic||Not yet recruiting|December 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|N/A|No|||January 2009|January 28, 2009|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00284622||185586|
NCT00285532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11261-CP-002|Identifying Residential Hazards Using Home Test Kits|||National Institute of Environmental Health Sciences (NIEHS)||Completed|October 2001|October 2006|Actual|October 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|3 Months|5 Years|Accepts Healthy Volunteers|Probability Sample|Children <5 years receiving care via Babies Milk Fund Clinics|November 2014|November 17, 2014|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00285532||185519|
NCT00284908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPD/STU(-Na) 05819N/TU 1.41|Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers|Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers||STEBA France|No|Completed|September 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|March 21, 2008|January 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00284908||185564|
NCT00284921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AES02|MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive|A Twelve-month, Randomized, Multicenter, Open-label, Exploratory Study to Investigate the Clinical Outcomes of an Immunosuppressive Regimen of Basiliximab, Cyclosporine Microemulsion (CsA-ME) and Enteric-coated Mycophenolate Sodium (EC-MPS) Free of Steroids Compared With a Regimen of EC-MPS With Standard Steroids in de Novo Kidney Recipients Who Are Hepatitis C Positive||Novartis||Terminated|April 2004|||August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|65 Years||||November 2011|November 1, 2011|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00284921||185563|
NCT00293787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-03|A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|June 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|February 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293787||184903|
NCT00293800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-04|A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research||Completed|July 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|N/A|No|||February 2012|February 11, 2012|February 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293800||184902|
NCT00294385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/BC 1.3.002|Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine|A Randomized Phase III Study Comparing Concomitant Docetaxel Plus Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients||Central European Cooperative Oncology Group|No|Completed|June 2002|October 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|430|||Female|18 Years|75 Years|No|||June 2011|June 22, 2011|February 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00294385||184859|
NCT00294398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-8-4458|Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma|Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma||Children's Hospital of Philadelphia|Yes|Completed|March 2006|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|152|||Both|1 Year|18 Years|No|||April 2015|April 23, 2015|February 20, 2006||No||No|May 20, 2013|https://clinicaltrials.gov/show/NCT00294398||184858|
NCT00290394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA03/181|Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients|Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring||Baskent University||Completed|March 2004|August 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|49 Years|65 Years|No|||March 2004|February 9, 2006|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290394||185147|
NCT00291538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/05/9-B|Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma|Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma||Nantes University Hospital||Completed|February 2006|October 2008|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|75 Years|No|||February 2009|February 3, 2009|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291538||185064|
NCT00291551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102.1|Paracor Ventricular Support System (PVSS) for Patients With Heart Failure|Paracor Ventricular Support System: United States Clinical Investigational Plan|PEERLESS-HF|Paracor Medical, Inc|Yes|Terminated|January 2005|April 2011|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|80 Years|No|||May 2012|May 14, 2012|February 10, 2006|No|Yes|Resources unavailable to continue study follow-up.|No|April 14, 2011|https://clinicaltrials.gov/show/NCT00291551||185063|Insufficient resources to continue study follow-up.
NCT00258349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00503|Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer|A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer||National Cancer Institute (NCI)||Completed|August 2006|September 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2013|May 29, 2014|November 22, 2005|Yes|Yes||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00258349||187548|
NCT00258869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests|Plasma Protein Biomarker Based Diagnostics of Outcome in Sepsis & CAP||National Center for Genome Resources|Yes|Recruiting|December 2005|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|PaxGene whole blood tubes (RNA and DNA), EDTA plasma, serum (subset), microbiologic isolates|Both|6 Years|N/A|No|Non-Probability Sample|Emergency department patients > 6 years of age|January 2009|November 5, 2010|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258869||187510|
NCT00282269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTX/06/02/002|Hypothermia in Traumatic Brain Injury in Children (HiTBIC)|Pilot Study of Early and Prolonged Hypothermia in Severe Traumatic Brain Injury in Children||Australia and New Zealand Intensive Care Society|Yes|Completed|November 2006|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|16 Years|No|||June 2009|June 18, 2010|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00282269||185763|
NCT00283504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 05-08-EX-0247|A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy|A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair)||Children's Hospital of The King's Daughters||Completed|January 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|40|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||January 2006|May 25, 2010|January 26, 2006||||||https://clinicaltrials.gov/show/NCT00283504||185671|
NCT00284037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-06-A-0003|Improvement in Baroreflex Sensitivity in OSAS|||Nagoya University||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|70 Years||||May 2005|January 27, 2006|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00284037||185630|
NCT00282841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS44148MATTREY|Visualization of the Cerebral Arterial Circulation Using Contrast-Enhanced Transcranial Ultrasound in Code Stroke Patients|Visualization of the Cerebral Arterial Circulation Using Contrast-Enhanced Transcranial Ultrasound in Code Stroke Patients||University of California, San Diego|Yes|Active, not recruiting|May 2005|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|403|||Both|18 Years|N/A|No|||July 2008|September 10, 2009|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00282841||185720|
NCT00283491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-219/03|The Effect of Lactobacillus Cultures on Iron Bioavailability.|The Effect of a Lactic Acid Fermented Oat Gruel on Iron Absorption in the Proximal and Distal Small Intestine From a Phytate Rich Meal in Healthy Women of Childbearing Age.||University of Copenhagen||Completed|October 2005|November 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|18|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2005|January 20, 2009|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00283491||185672|
NCT00284336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002995-13|Caelyx Adjuvant in Elderly Breast Cancer|An Open Label Phase II Trial to Investigate the Cardiac Effects of Pegylated Liposomal Doxorubicine (Caelyx) in Elderly Breast Cancer Patients With New Imaging and Biochemical Techniques.||Universitaire Ziekenhuizen Leuven||Completed|January 2006|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Female|65 Years|N/A|No|||December 2014|December 8, 2014|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00284336||185607|
NCT00284947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621A2402|Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids|REPLACE: Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids||Novartis|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|18 Years|75 Years|No|||May 2012|May 7, 2012|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284947||185561|
NCT00284635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-231/03|Fast-Track vs Conventional for UKA|||Frederiksberg University Hospital||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||July 2007|July 3, 2007|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284635||185585|
NCT00284648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-36|Operative Versus Non-operative Treatment of Achilles Tendon Rupture|Operative Versus Non-operative Treatment of Achilles Tendon Rupture: A Multicentre, Prospective Randomized Study.||Fowler Kennedy Sport Medicine Clinic|No|Completed|December 2000|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|18 Years|70 Years|No|||November 2015|November 26, 2015|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00284648||185584|
NCT00284934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AFR04|Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients|A Multicenter, National, Open-label, Prospective, Randomized Study to Evaluate Efficacy and Tolerability of Enteric-coated Mycophenolate Sodium 1440 mg/Day With Tacrolimus Reduced Dose Versus Enteric-coated Mycophenolate Sodium 720 mg/Day With Tacrolimus Standard Dose, in Maintenance, Stable, Adult, Kidney Transplant Recipients|OLYMPE|Novartis|No|Completed|December 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|75 Years|No|||March 2011|March 31, 2011|January 30, 2006||No||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00284934||185562|
NCT00285233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0006M55241|Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes|An Open-label Pilot Study of Delayed Mycophenolate Mofetil Instead of Tacrolimus Combined With Anti-thymocyte Globulin, Daclizumab, Etanercept, and Sirolimus in Single-donor, Solitary Islet Allograft Recipients With Type 1 Diabetes||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2000|March 2005|Actual|September 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|January 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00285233||185539|
NCT00281307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 21786|Treatment of Rhinitis With Intranasal Vitamin E|DBPCR Clinical Trial for Treatment of Rhinitis With Intranasal Vitamin E||Penn State University||Suspended|January 2006|October 2008|Anticipated|March 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|149|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|January 23, 2006||No|Due to a substantial response to placebo an interim analysis indicated the need for a larger    than expected study population to achieve the level of significance|No||https://clinicaltrials.gov/show/NCT00281307||185836|
NCT00281281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701147|Pharmacokinetics of Vancomycin in Adults Receiving ECMO|Pharmacokinetics and Posology of Vancomycin in Adults Receiving ECMO||National Taiwan University Hospital||Completed|December 2005|April 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|January 22, 2006||||No||https://clinicaltrials.gov/show/NCT00281281||185838|
NCT00281294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-711|A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis|A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis||Facet Biotech||Terminated|December 2005|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2008|August 2, 2008|January 20, 2006|||Terminated early because the first phase didn't meet the endpoint.|||https://clinicaltrials.gov/show/NCT00281294||185837|
NCT00261339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/UK-506|Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)|PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD||Takeda||Completed|August 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||December 2006|May 4, 2012|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261339||187322|
NCT00290082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/055/HP|Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients|Comparison Between Midazolam and Loxapine in the Treatment of Agitated Patients in the Emergency Department||University Hospital, Rouen|Yes|Terminated|December 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||March 2015|March 10, 2015|February 9, 2006||No|2 complications with midazolam|No||https://clinicaltrials.gov/show/NCT00290082||185171|
NCT00290381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/005/05|The Effects of OC000459 on Nasal Mediators|The Effects of OC000459 on Nasal Th2 Cytokine Release, Eosinophil Responses, and Nasal Symptoms After Nasal Allergen Challenge (NAC) With Timothy Grass Pollen in Subjects With Allergic Rhinitis Out of Season||Imperial College London||Completed|February 2006|June 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2006|May 27, 2015|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290381||185148|
NCT00291174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803272|Measuring Electrical Resistance of Different Tissues on the Outer Surface of the Heart|Impedance Measurement of Epicardial Substrate for Ventricular Arrhythmias: Case Control Series of Patients With and Without Myocardial Scarring||University of Pennsylvania||Terminated|April 2006|January 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients undergoing elective cardiac surgery for coronary artery disease|June 2012|September 12, 2012|February 10, 2006||No|Unforeseen difficulty identifying and enrolling eligible subjects|No||https://clinicaltrials.gov/show/NCT00291174||185090|
NCT00292097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 05-27|A Prospective, Randomized Trial of Early Versus Late Tracheostomy in Trauma Patients With Severe Brain Injury|A Prospective, Randomized Trial of Early Versus Conventional Conversion From Endotracheal Intubation to Percutaneous Tracheostomy for Ventilatory Support of Trauma Patients With Severe Brain Injury||Memorial Medical Center|No|Terminated|February 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|February 13, 2006||No|Difficulty obtaining enrollment|No||https://clinicaltrials.gov/show/NCT00292097||185021|
NCT00292110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904390|Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management|Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management||National Institutes of Health Clinical Center (CC)||Completed|February 2004|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|65 Years|No|||August 2013|February 19, 2014|February 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00292110||185020|
NCT00292825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|skejbyH|Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope|SCANdinavian Vasovagal SYNCope Pacemaker Investigation (SCANSYNC)||Aarhus University Hospital Skejby||Completed|February 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Both|25 Years|N/A|No|||March 2010|March 31, 2010|February 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00292825||184973|
NCT00292838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#01-1929|Relative Potency of Inhaled Corticosteroids|Relative Potency of Inhaled Corticosteroids: Validation of a Clinical Model||St. Joseph's Healthcare Hamilton||Completed|January 2001|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||July 2011|July 19, 2011|February 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00292838||184972|
NCT00292851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#02-2075|Blown Nasal Secretion Measurements in Rhinosinusitis: Repeatability and Validity Compared to Nasal Lavage|Repeatability and Validity of Measurements in Blown Nasal Secretion in Patients With Rhinosinusitis||St. Joseph's Healthcare Hamilton|No|Completed|July 2004|June 2005||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||15|||Both|N/A|N/A|No|Probability Sample|patients with rhinitis|July 2011|July 19, 2011|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00292851||184971|
NCT00262548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-CRESTOR-0001|C-Reactive Protein (CRP) in Obese Diabetic Women|Interventions Study for the Control of Diabetes Mellitus Type 2 in Obese Women||AstraZeneca||Completed|October 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Female|45 Years|N/A|No|||August 2007|August 24, 2007|October 26, 2005||||No||https://clinicaltrials.gov/show/NCT00262548||187232|
NCT00290134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-50204|A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism|Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo||QuatRx Pharmaceuticals Company||Completed|February 2006|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Male|40 Years|N/A|No|||February 2008|February 29, 2008|February 9, 2006||||||https://clinicaltrials.gov/show/NCT00290134||185167|
NCT00290147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC 2004.0002|Safety Study of a Dengue Virus DNA Vaccine|Phase I Clinical Trial of a Dengue-1 DNA Vaccine||Walter Reed Army Institute of Research (WRAIR)||Completed|January 2006|April 2009|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 26, 2009|February 9, 2006||Yes||||https://clinicaltrials.gov/show/NCT00290147||185166|
NCT00290160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-9000-400|Early Protein Supplementation on Prevention of Hyperkalemia|The Effect of Early Protein Supplementation on Prevention of Hyperkalemia in Extremely Low Birth Weight Infants||The University of Texas Health Science Center at San Antonio||Completed|December 2002|July 2007|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||62|||Both|N/A|12 Hours||||December 2012|December 6, 2012|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00290160||185165|
NCT00282282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-362|Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation|Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis After Allogeneic Non-myeloablative Peripheral Blood Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Completed|January 2006|July 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||March 2014|April 29, 2014|January 24, 2006|Yes|Yes||No|January 11, 2013|https://clinicaltrials.gov/show/NCT00282282||185762|This study is a single-institution study, and as such the data are limited by the small study population.
NCT00284050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002D2201|Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement|A Randomized, Double-masked, Multi-center, Phase II Study Assessing the Safety and Efficacy of Two Concentrations of Ranibizumab (Intravitreal Injections) Compared With Non-treatment Control for the Treatment of Diabetic Macular Edema With Center Involvement|RESOLVE|Novartis||Completed|October 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|N/A|No|||February 2011|February 22, 2011|January 30, 2006||No||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00284050||185629|
NCT00284063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01AT000123-03|Z-Joint Changes in Low Back Pain Following Adjusting|Z-Joint Changes in Low Back Pain Following Adjusting||National University of Health Sciences|Yes|Completed|October 2005|September 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|112|||Both|21 Years|69 Years|No|||April 2015|April 14, 2015|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284063||185628|
NCT00283465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002047|A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy|An Open-label, Randomized Study to Evaluate the Effect of Early Treatment of Anemia With Epoetin Alfa on Hemoglobin, the Incidence of Blood Transfusions and Quality of Life in Patients Receiving Platinum-containing Chemotherapy||Janssen-Cilag B.V.||Completed|November 1999|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|316|||Both|18 Years|N/A|No|||January 2011|January 13, 2011|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00283465||185674|
NCT00283478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1056757|Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer|Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.||Kentuckiana Cancer Institute||Completed|May 2004|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|January 26, 2006||||||https://clinicaltrials.gov/show/NCT00283478||185673|
NCT00284024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|r05-60|Effectiveness of Domperidone to Increase Breastmilk Supply in Mothers With Low Supply|Assessing the Feasibility of Testing Domperidone's Effect on Breastfeeding in Women With Insufficient Breast Milk: An RCT Pilot Study||McMaster University|No|Terminated|September 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|45|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|October 11, 2007|January 27, 2006|||Unable to recruit participants|No||https://clinicaltrials.gov/show/NCT00284024||185631|
NCT00285259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB01-202|Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)|A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT)||Astellas Pharma Inc|Yes|Completed|January 2006|November 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||July 2013|July 31, 2013|January 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00285259||185537|
NCT00285246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-296|Prospective Study of Veteran Health in Previously Deployed Soldiers|Prospective Study of Functional Status in Veterans at Risk for Unexplained Illnesses||VA Office of Research and Development|No|Completed|December 2005|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|838|None Retained|Saliva|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Army National Guard & Reserves Soldiers deploying to either Iraq or Afghanistan. Outcome        measures assessed at all 4 time points (pre-deployment, immediately post-deployment, 3        months post-return, 1 year post-return)|April 2015|April 23, 2015|January 30, 2006||No||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00285246||185538|The sample was comprised of only Army National Guard and Reserve military personnel, and therefore results may not generalize to the broader population of military personnel from other Service branches or components.
NCT00285545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK58197|Biomagnetic Signals of Intestinal Ischemia|Biomagnetic Signals of Intestinal Ischemia II||University of South Alabama|No|Completed|January 2000|January 2013|Actual|January 2013|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic|June 2013|June 29, 2013|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285545||185518|
NCT00285558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK62916 (completed)|Peer-enhanced Intervention to Support Teen Weight Loss|Peer-Enhanced Intervention to Support Teen Weight Loss||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 2002|April 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|13 Years|16 Years|No|||January 2010|January 12, 2010|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285558||185517|
NCT00281658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF104535|Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer||GlaxoSmithKline|Yes|Active, not recruiting|January 2006|December 2015|Anticipated|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|444|||Both|18 Years|N/A|No|||August 2015|November 5, 2015|January 23, 2006|Yes|Yes||No|May 5, 2011|https://clinicaltrials.gov/show/NCT00281658||185809|Some participants (PAR) are captured as withdrawing from the study due to death. Per protocol, PAR who died were considered to be study completers and did not withdraw from the study; for the purposes of this report, they are classified as withdrawn.
NCT00281645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOV-075-022|Long-Term Safety Study of Bicifadine for the Treatment of Chronic Low Back Pain|A Multicenter Standard of Care-Controlled Study to Evaluate the Long-Term Safety of Bicifadine for the Treatment of Chronic Low Back Pain||DOV Pharmaceutical, Inc.||Completed|December 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1250|||Both|18 Years|N/A|No|||March 2007|March 26, 2007|January 23, 2006||||||https://clinicaltrials.gov/show/NCT00281645||185810|
NCT00281918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454560|Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia|Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia|CLL-8|Hoffmann-La Roche||Completed|July 2003|October 2011|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|817|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|January 24, 2006|Yes|Yes||No|December 21, 2009|https://clinicaltrials.gov/show/NCT00281918||185790|
NCT00261599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0522|An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy|A Phase 3, Randomized, Double-Blind, Dose-Controlled Study to Assess the Efficacy and Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal to Moderate Sedation in Patients Undergoing Colonoscopy||Eisai Inc.||Completed|March 2006|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||November 2008|November 6, 2008|December 1, 2005|Yes|Yes||||https://clinicaltrials.gov/show/NCT00261599||187302|
NCT00261586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002500|A Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach|Effect of Analgesics on the Irreversible Inactivation of Cyclooxygenase-1 Activity by Low Dose Aspirin and Endoscopic Evaluation of the Gastric Mucosal Effect||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||March 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|92|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261586||187303|
NCT00261846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-200|Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias|A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias||Pfizer|No|Completed|March 2006|July 2015|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|571|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|December 2, 2005|Yes|Yes||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00261846||187284|Analyses of progression free survival and overall survival was based on all-treated population, instead of evaluable population which was the primary efficacy population as per planned analyses.
NCT00262236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2304|Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension|A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension||Novartis||Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|693|||Both|18 Years|N/A|No|||June 2006|November 7, 2011|December 2, 2005||||||https://clinicaltrials.gov/show/NCT00262236||187255|
NCT00262223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6266R-NIAAAHIE014341|Combined Treatment for Alcohol-Dependent Individuals With PTSD|Combined Treatment for Alcohol-Dependent Individuals With PTSD||New York State Psychiatric Institute|Yes|Completed|May 2006|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||November 2013|September 3, 2014|December 5, 2005|Yes|Yes||No|August 14, 2014|https://clinicaltrials.gov/show/NCT00262223||187256|
NCT00258362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS021|Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer|A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer||Masonic Cancer Center, University of Minnesota|Yes|Completed|July 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|November 22, 2005|Yes|Yes||No|August 20, 2010|https://clinicaltrials.gov/show/NCT00258362||187547|
NCT00294515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT18435|IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients|IMPACT|Hoffmann-La Roche||Completed|March 2006|August 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|326|||Both|16 Years|N/A|No|||July 2010|July 30, 2010|February 21, 2006|Yes|Yes||No|June 2, 2010|https://clinicaltrials.gov/show/NCT00294515||184849|
NCT00294814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMBO_CTIL|TCD Detection of Gas and Solid Micro-Emboli in Patients Undergoing Coronary Artery Bypass Grafting (CABG): The Influence of Proximal Anastomosis Technique|Gas and Solid Brain Microembolization Detected by the EmbodopR TCD System During Proximal Coronary Graft Anastomosis Done With Aortic Cross Clamping, Partial Occlusion or the HeartstringR Device and Their Effect on Neurocognitive Performance After Coronary Bypass Operation||Rambam Health Care Campus||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|N/A|N/A|No|||May 2006|March 19, 2007|February 20, 2006||||No||https://clinicaltrials.gov/show/NCT00294814||184826|
NCT00258596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2002-01-PRISON II|Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions|Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions: A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Chronic Total Coronary Occlusions (PRISON II)||R&D Cardiologie||Completed|January 2003|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||January 2007|March 5, 2007|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258596||187530|
NCT00258609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-007|Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study|A 12-Week Prospective, Double-Blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis.||Rajavithi Hospital||Completed|February 2003|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||128|||Both|18 Years|65 Years|No|||December 2005|December 22, 2005|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258609||187529|
NCT00258622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS1209-008|NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain|NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study||Danish Pain Research Center||Completed|November 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||November 2007|November 15, 2007|November 24, 2005||||No||https://clinicaltrials.gov/show/NCT00258622||187528|
NCT00258635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RagweedMATAMPL203|Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test|A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL® With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen.||Allergy Therapeutics||Completed|November 2005|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|69|||Both|18 Years|50 Years||||June 2010|June 16, 2010|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00258635||187527|
NCT00282854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4727|Genetics of Rolandic Epilepsy|Genetics of Rolandic Epilepsy||King's College London|No|Recruiting|January 2005|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1000|Samples With DNA|whole blood|Both|3 Years|N/A|No|Non-Probability Sample|Community Sample|August 2011|December 5, 2011|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00282854||185719|
NCT00284427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10006|Safety of Antioxidants During GYN Cancer Care|Safety of Oral Antioxidants and Intravenous Vitamin C During GYN Cancer Care||University of Kansas Medical Center|Yes|Completed|September 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|N/A|N/A|No|||February 2016|February 9, 2016|January 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00284427||185600|
NCT00284674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-287.591|Prospective Clinical Evaluation of Three Prosthesis Re-cap, M2a-Magnum and C2a-taper.|||Frederiksberg University Hospital||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|70 Years|No|||September 2006|March 17, 2015|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284674||185582|
NCT00283218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asp-BIAsp-2005/0109|A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.|A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. - A Randomised, Quadruple Cross-Over Trial||University of Aarhus||Completed|January 2006|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||August 2006|August 7, 2006|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283218||185693|
NCT00284661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11125|Meniscal Repair: A Randomized Prospective Trial of FAST-FIX vs. Meniscal Suturing|Meniscal Repair: A Randomized Prospective Trial of FAST-FIX vs. Meniscal Suturing||Fowler Kennedy Sport Medicine Clinic|No|Completed|June 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|16 Years|50 Years|No|||November 2015|November 26, 2015|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00284661||185583|
NCT00284986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osiris 270|Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients|A Phase II Open Label Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Salvage of Treatment-Refractory Acute GVHD Patients||Mesoblast, Ltd.|No|Completed|November 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|6 Months|70 Years|No|||December 2014|December 2, 2014|January 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00284986||185558|
NCT00285571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK62400 (completed 2007)|Dietary Variety Versus Dietary Fat Effects in Energy Intake|Dietary Variety vs Dietary Fat Effects on Energy Intake||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2005|September 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285571||185516|
NCT00281320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05717|Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)|A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis.||Merck Sharp & Dohme Corp.|Yes|Completed|February 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|65 Years|N/A|No|||February 2015|February 20, 2015|January 23, 2006|Yes|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00281320||185835|
NCT00281333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-02-2708-UM-CTIL|The Influence of "Karate" on Bleeding in Hemophilic Patients.|The Influence of "Karate" on Bleeding in Hemophilic Patients.||Sheba Medical Center|No|Terminated||October 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|12|||Male|11 Years|19 Years|No|||August 2011|August 28, 2011|January 23, 2006||No|logistics|No||https://clinicaltrials.gov/show/NCT00281333||185834|
NCT00281671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-12-160|Nesiritide Use Following Cardiac Surgery in Infants|Pilot Study of the Effects of Nesiritide on Hemodynamics and Urine Output Following Cardiopulmonary Bypass in Infants||Children's Hospital Boston|Yes|Terminated|February 2006|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Both|N/A|1 Year|No|||January 2009|January 28, 2009|January 23, 2006|Yes|Yes|Slow patient enrollment.|No||https://clinicaltrials.gov/show/NCT00281671||185808|
NCT00281931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454581|Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia|Phase II Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients With B-PLL||National Cancer Institute (NCI)||Active, not recruiting|September 1999|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|21|||Both|18 Years|75 Years|No|||July 2007|November 5, 2013|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00281931||185789|
NCT00293488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463738|SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma|An Open Label Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of SL-11047 in Patients With Refractory Lymphoma||National Cancer Institute (NCI)||Completed|January 2006|||September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||September 2008|September 22, 2008|February 16, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00293488||184925|
NCT00293501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459794|Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery|A Phase I/II Trial of Tinzaparin (Innohep), a Low Molecular Weight Heparin (LMWH) for Treatment of Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|December 2005|||February 2007|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||February 2007|November 5, 2013|February 16, 2006||||||https://clinicaltrials.gov/show/NCT00293501||184924|
NCT00261859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25116|Enhancing Emergency Practitioner (EP)-Performed Alcohol Interventions in the Emergency Department (ED)|Enhancing EP-Performed Alcohol Interventions in the ED||Yale University|No|Completed|October 2005|November 2009|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|900|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|December 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00261859||187283|
NCT00262249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGH-2051|Effect of Growth Hormone in Children With Growth Hormone Deficiency|Effect of Growth Hormone in Children With Growth Hormone Deficiency and Idiopathic Short Stature||Novo Nordisk A/S|No|Completed|August 2000|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|173|||Both|3 Years|15 Years|No|||October 2014|October 24, 2014|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262249||187254|
NCT00262561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-003844-68|Resistance to Aspirin and/or Clopidogrel Among Patients With PAD.|Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin||Aalborg Universitetshospital|Yes|Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|263|||Both|18 Years|N/A|No|||January 2014|January 25, 2014|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262561||187231|
NCT00294788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProFlu2006|Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines|Phase I/II Placebo-Controlled Study of Consumption of a Probiotic on HAI Titre Following Influenza Vaccination of Healthy Adult Subjects||Probiomics Ltd||Active, not recruiting|March 2006|January 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2007|January 8, 2007|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294788||184828|
NCT00294801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|flex-a-new|Effect of Flex-a-New on Osteoarthritis of the Knee|||Rabin Medical Center||Recruiting|January 2006|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|85 Years|No|||February 2006|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294801||184827|
NCT00290186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03038007|An Evaluation of Hyperbaric Treatments for Children With Cerebral Palsy|An Evaluation of the Therapeutic Effectiveness of Hyperbaric Oxygen Treatments and Hyperbaric Air Treatments for Children With Cerebral Palsy||Dayton Children's Hospital|Yes|Terminated|August 2005|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|3 Years|8 Years|No|||August 2014|August 13, 2014|February 8, 2006|Yes|Yes|Terminated for futility.|No|February 27, 2014|https://clinicaltrials.gov/show/NCT00290186||185163|
NCT00290433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0004|Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma|A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma||M.D. Anderson Cancer Center|No|Completed|September 2003|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00290433||185144|
NCT00294827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05409 (SECA I)|Liver Transplantation and Metastatic Colo-rectal Cancer.|Liver Transplantation and Metastatic Colo-rectal Cancer.||Oslo University Hospital||Active, not recruiting|February 2006|May 2020|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00294827||184825|
NCT00282607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA 2005-001|A Study of DA-8159 in Subjects With Erectile Dysfunction|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 2 Dose Ranging Trial To Assess The Safety and Efficacy of DA-8159 Tablets in Male Subjects With Erectile Dysfunction.||Dong-A PharmTech Co., Ltd.|Yes|Completed|May 2005|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Male|19 Years|75 Years|No|||February 2007|February 27, 2007|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282607||185737|
NCT00283816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB-00012501|Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy|Metabolic Impact of Oral Contraceptives With or Without Metformin in Obese Adolescents With Polycystic Ovary Syndrome (PCOS)||University of Rochester|Yes|Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||April 2011|April 28, 2015|January 27, 2006|Yes|Yes||No|April 8, 2011|https://clinicaltrials.gov/show/NCT00283816||185647|
NCT00283777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R55DK060126|Chromium and Insulin Action|Effect of Chromium Picolinate on Metabolic and Physiologic Parameters in Type 2 Diabetes||Pennington Biomedical Research Center||Completed|August 1998|April 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|25 Years|75 Years|No|||January 2006|January 26, 2006|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283777||185650|
NCT00284349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/043|Study to Investigate the Added Value of a Rehabilitation Brace in the Treatment at Home After a Fracture of the Ankle|Study to Investigate the Added Value of a Rehabilitation Brace in the Treatment at Home After a Fracture of the Ankle||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||April 2009|May 18, 2009|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284349||185606|
NCT00284960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18805|The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction|The Incidence and Treatment of Insulin Resistance Among Men With Erectile||Penn State University||Recruiting|July 2005|June 2006||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||June 2005|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284960||185560|
NCT00284973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WanMal002|A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate|Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers||PATH||Completed|January 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2007|April 13, 2015|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00284973||185559|
NCT00285298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11010(1)|Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients|Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients: a Pilot Randomized, Placebo-controlled, Double-blind Trial.||Walter Reed Army Medical Center||Completed|January 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||September 2009|July 28, 2011|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285298||185535|
NCT00285285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25448|Point of Care Device Use in the Pediatric Emergency Department|A Randomized Trial to Assess the Efficacy of Point-of-Care Testing in Decreasing Length of Stay in a Pediatric Emergency Department||Yale University||Completed|January 2004|August 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Both|N/A|21 Years|Accepts Healthy Volunteers|||January 2006|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285285||185536|
NCT00285584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15303-1|Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)|Drug Abuse, Depression and Responses to HIV Counseling||New York University|Yes|Completed|September 2002|September 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Male|18 Years|N/A|No|||May 2012|May 17, 2012|January 31, 2006||No||No|March 13, 2012|https://clinicaltrials.gov/show/NCT00285584||185515|We achieved substantially lower recruitment than needed to adequately test the study hypothesis. We also experienced substantial losses-to-follow-up.
NCT00281346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29 FU-71-05|Non-Invasive Diagnosis of Coronary Artery Stenoses by Doppler Echocardiography|Non-Invasive Evaluation of Coronary Pathology by Transthoracic Doppler Echocardiography. A Comparative Study to Coronary Angiography.||Norwegian University of Science and Technology|No|Completed|December 2005|August 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|110|||Both|18 Years|90 Years|No|||January 2009|January 9, 2009|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00281346||185833|
NCT00281359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL1 230|A Comparative Study of the Effectiveness of Treatment of Contractures With Mechanically Applied Stretch and Heat.|A Comparative Study of the Effectiveness of Treatment of Contractures With Mechanically Applied Stretch and Heat.||Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust|No|Completed|April 2003|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|16 Years|No|||November 2014|November 4, 2014|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00281359||185832|
NCT00281684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRA105345|SB-705498 Dental Pain Study After Tooth Extraction|A Multi-centre, Randomised, Single Blind, Placebo Controlled, Parallel Group Study to Examine the Effect of Single Doses of SB-705498, a TRPV1 Receptor Antagonist, on Pain Following Third Molar Tooth Extraction||GlaxoSmithKline|No|Completed|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|137|||Both|18 Years|50 Years|No|||March 2011|March 10, 2011|January 23, 2006||||No||https://clinicaltrials.gov/show/NCT00281684||185807|
NCT00281697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3693g|A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)|A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer||Genentech, Inc.||Completed|February 2006|September 2012|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|684|||Both|18 Years|N/A|No|||July 2013|July 5, 2013|January 23, 2006|Yes|Yes||No|August 23, 2012|https://clinicaltrials.gov/show/NCT00281697||185806|
NCT00281944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01051|Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors|A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination With Fluorouracil and Leucovorin in Pediatric Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|September 2005|||May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|N/A|21 Years|No|||May 2013|May 1, 2013|January 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00281944||185788|
NCT00292903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH30915|Evaluating the Effectiveness of Brief Interpersonal Psychotherapy for Pregnant Women With Depression|Culturally Relevant Brief Interpersonal Psychotherapy (IPT-B) for Perinatal Depression||University of Pittsburgh||Completed|March 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 6, 2012|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00292903||184967|
NCT00292916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-ER-OFZ-200501-Vib|Effect of Whole Body Vibration on Bone and Fall Related Parameters|Effect of Whole Body Vibration on Bone and Fall Related Parameters - the Erlangen Longitudinal Vibration Study (ELVIS)||University of Erlangen-Nürnberg Medical School||Terminated|January 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||150|||Female|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292916||184966|
NCT00293852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18155|Collaborative Care for Heart Failure Patients With the Metabolic Syndrome|Collaborative Care for Heart Failure Patients With the Metabolic Syndrome||Baylor College of Medicine||Recruiting|February 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|380|||Both|18 Years|N/A|No|||December 2010|December 2, 2010|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00293852||184898|
NCT00294190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 120|Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer|A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|February 2006|July 2009|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||May 2011|December 6, 2012|February 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00294190||184873|
NCT00293527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-05030|Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma|A Phase II Dose Escalation Study of Continuous Daily Subcutaneous Administration of Interferon Alpha-2b in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn||November 2006||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|February 15, 2006|Yes|Yes|Withdrawn in October 2006, no longer of interest|No||https://clinicaltrials.gov/show/NCT00293527||184922|
NCT00294476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCan-01|IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma|A One Arm, Open Label,Multi - Center Phase II Study to Evaluate the Safety and Efficacy of IVIG in the Treatment of Various Metastatic Solid Tumors for Which There is no Better Alternate Treatment||GammaCan||Recruiting|July 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||September 2006|October 11, 2006|February 19, 2006||||No||https://clinicaltrials.gov/show/NCT00294476||184852|
NCT00294489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORHCV1-HMO-CTIL|Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT|Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT||Hadassah Medical Organization||Recruiting|February 2006|December 2006|Anticipated|||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|500|||Both|18 Years|N/A|No|||February 2006|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294489||184851|
NCT00294203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOSUR|Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer|Placebo-Controlled Pilot Study to Assess the Post-Operative Administration of Epoetin Alfa on Patients Undergoing Abdominal or Pelvic Surgery for Malignancy||University of Florida|No|Completed|February 2006|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|February 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294203||184872|
NCT00294502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3008|Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia|||Henry Ford Health System||Completed|September 2003|May 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2003|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294502||184850|
NCT00290498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0054|Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma|Rituximab-HCVAD Alternating Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2005|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|16 Years|60 Years|No|||September 2015|September 8, 2015|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00290498||185140|
NCT00294840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETDCTIL|Dynamic PET acquisition-a Quantitative Technique for Grading of Malignant Tumors and Prediction of Response to Treatment|Dynamic FDG-PET in Aggressive Lymphoma and Pancreas Cancer||Rambam Health Care Campus||Completed|August 2006|April 2010|Actual|September 2009|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with pancreatric cancer|May 2008|July 28, 2010|February 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00294840||184824|
NCT00290472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00047|CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase II Study of CCI-779 in B-cell Lymphoma and CLL||National Cancer Institute (NCI)||Completed|March 2004|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||February 2013|May 7, 2014|February 10, 2006|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00290472||185142|
NCT00282893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1NS038484|Balloon Prophylaxis of Aneurysmal Vasospasm|Balloon Prophylaxis of Aneurysmal Vasospasm||University of California, Davis|Yes|Completed|October 2000|December 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|170|||Both|17 Years|N/A|No|||March 2014|March 12, 2014|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00282893||185717|
NCT00284453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510087|Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm|Gene Expression in ICD Patients With Electrical Storm||University of Pittsburgh|No|Active, not recruiting|October 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|75|Samples With DNA|6 RNA samples are obtained and kept frozen on-site to be evalauted at a later date. A      portion of this DNA will be used to analyze the structure of certain genes that are known to      play a role in cardiac arrhythmias. We cannot at this time know exatly what genes will be      tested.|Both|18 Years|N/A|No|Probability Sample|Thirty men and women over age 18 with electrical strom that we hope will volunteer to        participate in this genetic research study|January 2016|January 11, 2016|January 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00284453||185598|
NCT00284362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/095|Prospective and Comparative Analysis of Arthroscopic and Open Surgery for Hallux Rigidus|Prospective and Comparative Analysis of Arthroscopic and Open Surgery for Hallux Rigidus||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|40 Years|60 Years|No|||February 2009|May 18, 2009|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284362||185605|
NCT00284375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/016|Systematic Registration of All Big Toe Prostheses Placed in Ghent University Hospital|Systematic Registration of All Big Toe Prostheses Placed in Ghent University Hospital||University Hospital, Ghent|No|Recruiting|January 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|500 patients will be included.|December 2014|December 4, 2014|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284375||185604|
NCT00284388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/056|Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs|Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|40 Years|70 Years|No|||February 2009|February 13, 2009|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284388||185603|
NCT00284440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072-Leh-2005-001|Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma|Relationship Between Visual Field Progression in Glaucoma and Choroidal Blood Flow Response to the Hand-grip Test||University Hospital, Basel, Switzerland|No|Withdrawn|March 2006|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|30 Years|80 Years|No|Non-Probability Sample|patients with glaucoma|March 2015|March 9, 2015|January 30, 2006||No|enrollment problems|No||https://clinicaltrials.gov/show/NCT00284440||185599|
NCT00284700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDRB 97-004|Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh?|Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh?||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|December 1997|May 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|2 Years|5 Years||||January 2006|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284700||185580|
NCT00285623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-018-IN|Observational Cohort Study of TachoSil (TC-018-IN)|An Non-interventional, Prospective, Non-controlled Study of the Use of TachoSil in Supportive Treatment in Surgery for Improvement of Haemostasis Where Standard Techniques Are Insufficient.||Nycomed|Yes|Completed|December 2005|July 2008|Actual|April 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3000|||Both|18 Years|90 Years|No|Probability Sample|Patients exposed to TachoSil® of all thromboembolic events, immunological events and drug        interactions leading to thromboembolic events or major bleeding.|July 2009|May 4, 2012|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00285623||185512|
NCT00281398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-31|Attitudes of Medical Trainees Towards Homeless Persons Presenting for Care in the Emergency Department|Attitudes of Medical Trainees Towards Homeless Persons Presenting for Care in the Emergency Department||St. Michael's Hospital, Toronto|Yes|Completed|August 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|||Anticipated|100|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2013|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00281398||185829|
NCT00285597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-080|Ursodeoxycholic Acid in Chronic Heart Failure|Ursodeoxycholic Acid Therapy in Chronic Heart Failure: A Placebo-controlled Study Evaluating the Effects of Ursodeoxycholic Acid on Peripheral Blood Flow and Immune Function||National Heart and Lung Institute||Active, not recruiting|May 2004|January 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||October 2009|October 8, 2009|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285597||185514|
NCT00281372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3982-ES-CTIL|Sexual Dysfunction and Dental Care|Association Between Sexual Dysfunction in Adults and Behavioral Dysfunctions in Achieving Proper Dental Care||Sheba Medical Center||Completed|February 2006|June 2008|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|448|||Both|18 Years|88 Years|No|Non-Probability Sample|Men and women, over 18 years old, who come for sexual therapy/ counseling to the Sexual        Medical Center, in Sheba Medical Center, Israel Partners or spouses of the above.|July 2008|July 28, 2008|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00281372||185831|
NCT00281385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0422-02|Health and Psychological Outcomes of Lifestyle Versus Traditional Physical Activity|Health and Psychological Outcomes of Lifestyle Versus Traditional Physical Activity- Study 1||University of Alberta, Physical Education||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||January 2006|October 10, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281385||185830|
NCT00281957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00774|Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery|A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) With Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma||National Cancer Institute (NCI)||Completed|August 2007|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||April 2013|May 2, 2014|January 24, 2006|Yes|Yes||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00281957||185787|
NCT00282165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/187-E|Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order|Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order||UMC Utrecht|No|Terminated|November 2006|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|8|||Male|18 Years|65 Years|No|||January 2015|January 23, 2015|January 24, 2006||No|Required number of subjects to be included could not be accomplished|No||https://clinicaltrials.gov/show/NCT00282165||185771|
NCT00293553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK67275 (completed 2007)|Clinical Approaches to Ileal Pouch Dysfunction|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||December 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|No|||March 2010|March 17, 2010|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00293553||184920|
NCT00293579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0482|Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer|A Phase II Study of Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|February 2006|November 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 15, 2006|Yes|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT00293579||184919|
NCT00293254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-019|A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies||Merck Sharp & Dohme Corp.||Completed|February 2006|May 2011|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|351|||Both|16 Years|N/A|No|||July 2015|July 16, 2015|February 15, 2006|Yes|Yes||No|August 20, 2009|https://clinicaltrials.gov/show/NCT00293254||184941|Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 83 of 119 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.
NCT00293514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-021-IM|TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)|An Open, Randomised, Prospective, Multi-centre, Parallel-group Trial of TachoSil Versus Standard Surgical Treatment in Patients Undergoing Pulmonary Lobectomy for Lung Malignancy and Requiring Treatment for Air Leakage||Nycomed|Yes|Completed|February 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|90 Years|No|||February 2008|May 4, 2012|February 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00293514||184923|
NCT00293540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0476|Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer|Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer||International Breast Cancer Research Foundation|Yes|Completed|February 2006|March 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|249|||Female|18 Years|N/A|No|||March 2015|March 30, 2015|February 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293540||184921|
NCT00293865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 05/11-M|Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast Cancer|Prospective Multicentric Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast Cancer||Centre René Gauducheau||Recruiting|March 2006|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|203|||Female|18 Years|N/A|No|||October 2010|October 11, 2010|February 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00293865||184897|
NCT00293878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2005-001|Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of FM-VP4 in Subjects With Primary Hypercholesterolemia||Forbes Medi-Tech||Completed|November 2005|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|75 Years||||February 2007|February 22, 2007|January 17, 2006||||||https://clinicaltrials.gov/show/NCT00293878||184896|
NCT00293891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0-206|A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis|||Astellas Pharma Inc||Completed||January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|658|||Both|12 Years|N/A|No|||December 2007|December 19, 2007|February 16, 2006||||||https://clinicaltrials.gov/show/NCT00293891||184895|
NCT00294528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC|Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex and AGC||Hvidovre University Hospital||Recruiting|January 2004|January 2010||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|75 Years|No|||October 2003|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294528||184848|
NCT00289874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-336|Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)|A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients With Seasonal Aeroallergen Sensitivity||Merck Sharp & Dohme Corp.||Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|6 Years|14 Years|No|||January 2016|January 20, 2016|February 7, 2006|Yes|Yes||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00289874||185187|Safety is reported in the literature.
NCT00289887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-315|Obese Hypertension Study (0954-315)|A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination With Hydrochlorothiazide Versus Placebo in Obese Patients With Elevated Systolic and Diastolic Blood Pressure||Merck Sharp & Dohme Corp.||Completed|February 2006|March 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|261|||Both|21 Years|75 Years|No|||July 2015|July 21, 2015|February 8, 2006|Yes|Yes||No|September 21, 2009|https://clinicaltrials.gov/show/NCT00289887||185186|
NCT00290511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0287|Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma|A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2004|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|60 Years|N/A|No|||December 2015|December 18, 2015|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290511||185139|
NCT00290485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-CTG-01-V7.0-A1|Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)|A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor||Maisonneuve-Rosemont Hospital||Recruiting|August 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||April 2006|April 6, 2006|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290485||185141|
NCT00283517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005548|A Registry of Treatment Adherence for Patients With Schizophrenia|Electronic Schizophrenia Treatment Adherence Registry, eSTAR||Janssen-Cilag, S.A.||Completed|September 2003|May 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2046|||Both|18 Years|N/A|No|Non-Probability Sample|Patients starting treatment with a new antipsychotic medication, in accordance with        product labeling in the local area; permitted by their physician to participate in a        clinical trial|April 2010|April 26, 2010|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00283517||185670|
NCT00283530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1050203|Tumor Phenotypes and Correlation to Clinical Outcomes in Cancer|Identification of Tumor Phenotypes and Correlation to Clinical Outcomes in Patients Diagnosed With Cancer||Kentuckiana Cancer Institute||Terminated|May 2003|July 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer subjects who have or will have tissue and or blood collected.|January 2010|January 18, 2010|January 26, 2006|||The PI is no longer with Kentuckiana Cancer Institute. All current subjects completed. No    further subjects will be enrolled. Terminated with IRB.|No||https://clinicaltrials.gov/show/NCT00283530||185669|
NCT00283790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0289|Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo|Investigation of Psycliomotor and Cognitive Residual Effects After Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopielone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Plurazepam 30 mg As An External Comparator||Sanofi||Completed|January 2006|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 1, 2008|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00283790||185649|
NCT00284739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI-03HYoon-02|Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses|Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses||Kaiser Permanente|No|Completed|February 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|January 31, 2006|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00284739||185577|
NCT00284687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-02-HMO-CTIL|Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients|Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients||Hadassah Medical Organization||Completed|July 2006|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||August 2009|June 9, 2010|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00284687||185581|
NCT00284999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 05-034|Soothe Versus Refresh|||Pharmaceutical Research Network||Completed||August 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||33|||Both|18 Years|N/A|No|||August 2006|August 21, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284999||185557|
NCT00285012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051054|Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease||Pfizer|No|Completed|May 2006|April 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|504|||Both|35 Years|N/A|No|||April 2010|April 15, 2010|January 30, 2006|Yes|Yes||No|October 30, 2009|https://clinicaltrials.gov/show/NCT00285012||185556|
NCT00285025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5286|Study of the Effect of SR57667B in Patients With Alzheimer's Disease|A Phase II, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease||Sanofi||Completed|March 2005|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|50 Years|N/A|No|||January 2006|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285025||185555|
NCT00282178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00007|Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo|A 36 Week Three-Center Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo||Umeå University|No|Completed|April 2005|April 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|70 Years|No|||June 2008|October 15, 2008|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00282178||185770|
NCT00281411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC.2005.01.291E|Follow-up of Endovascular Aneurysm Treatment - The FEAT Trial|Follow-up Study of Endovascular Abdominal Aortic Aneurysm Treatment||UMC Utrecht||Active, not recruiting|January 2006|January 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Patient planned for endovascular abdominal aortic aneurysm repair|November 2008|November 17, 2008|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281411||185828|
NCT00281710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2005.02.TGK|Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans|Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans||Regional Hospital Holstebro||Completed|October 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind||||20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2008|May 6, 2008|January 23, 2006||||No||https://clinicaltrials.gov/show/NCT00281710||185805|
NCT00281723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-12.2.06-HMO-CTIL|Efficacy of Adhesive Tablets in Treating Oral Ulcers (Aphthous)|Phase 2 Study of Efficacy of Adhesive Tablets in Treating Oral Ulcers (Aphthous)||Hadassah Medical Organization|No|Suspended||May 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A||||May 2007|May 6, 2007|January 24, 2006|||The company which holds the patent was not interested.|No||https://clinicaltrials.gov/show/NCT00281723||185804|
NCT00283036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8793|APROVE : Irbesartan in Hypertension|Efficacy and Tolerability of Posology Adaptation of Irbesartan in Ambulatory Hypertensive Patients||Sanofi||Completed|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|N/A|N/A|No|||April 2008|April 1, 2008|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283036||185706|
NCT00283049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4052|Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control|Safety and Efficacy of Insulin Glargine Injection [rDNA Origin] Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control||Sanofi||Terminated|February 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|390|||Both|18 Years|79 Years|No|||January 2011|January 7, 2011|January 26, 2006|Yes|Yes|Due to technical issues relating to the Electronic diary data.|No|December 16, 2009|https://clinicaltrials.gov/show/NCT00283049||185705|The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.
NCT00283322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-0312|Heparin Antibodies in Intensive Care Unit Patients (HAICU)|Heparin Antibodies in Intensive Care Unit Patients (HAICU)||The University of Texas Health Science Center, Houston|No|Completed|November 2004|May 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|185|Samples Without DNA|Plasma. Patients consented for use to look for heparin antibodies in this study only.|Both|18 Years|N/A|No|Probability Sample|Consecutive consenting patients admitted to neurotrauma, surgical-trauma or medical        intensive care unit meeting enrollment criteria.|December 2007|December 3, 2007|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00283322||185685|
NCT00293592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECS|Dexamethasone for Cardiac Surgery Trial|Dexamethasone for Cardiac Surgery Trial||UMC Utrecht|Yes|Completed|May 2006|December 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4500|||Both|18 Years|N/A|No|||April 2015|April 18, 2015|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293592||184918|
NCT00293605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS200361715|Effect of Cemented Stem Design on Periprosthetic Bone Mass Following Primary Total Hip Arthroplasty|Effect of Cemented Stem Design on Periprosthetic Bone Mass Following Primary Total Hip Arthroplasty||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|January 2004|April 2011|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|120|Samples Without DNA|Blood and Urine only|Both|60 Years|N/A|No|Non-Probability Sample|Pre-assessment clinics at Sheffield Hospitals, patients booked for hip replacements.|May 2011|May 6, 2011|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293605||184917|
NCT00293904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT005-AllQbG10 02|Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy|Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy||Cytos Biotechnology AG||Completed|February 2006|February 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|65 Years|No|||September 2007|September 19, 2007|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00293904||184894|
NCT00293917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0-207|A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis|A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis||Astellas Pharma Inc|No|Completed|January 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|658|||Both|12 Years|N/A|No|||February 2008|February 11, 2008|February 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00293917||184893|
NCT00293930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0-205|A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis|||Astellas Pharma Inc||Completed||November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|645|||Both|12 Years|N/A|No|||December 2007|December 19, 2007|February 16, 2006||||||https://clinicaltrials.gov/show/NCT00293930||184892|
NCT00294216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN K85 02025|Omacor and Placebo in Carotid Plaque Stability|A Double Blind Comparison of Omacor and Placebo in Patients Awaiting Endarterectomy to Investigate the Effect on Carotid Plaque Stability||Pronova BioPharma||Completed|August 2003|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||121|||Both|18 Years|N/A|No|||February 2006|February 17, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294216||184871|
NCT00294541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-17043-12|A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy|An Open-Label Extension Study Evaluating the Long-Term Safety of ICA-17043 With or Without Hydroxyurea Therapy in Subjects With Sickle Cell Disease||Icagen|Yes|Terminated|February 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|17 Years|66 Years|No|||September 2007|September 10, 2007|February 21, 2006|||Lack of efficacy demonstrated in study ICA-17043-10|No||https://clinicaltrials.gov/show/NCT00294541||184847|
NCT00290199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F051021005|Foley Catheter for Labor Induction in Women With Term and Near Term Membrane Rupture|A Randomized Controlled Trial of Foley Catheter for Labor Induction in Women With Term and Near Term Prelabor Rupture of Membranes (PROM)||University of Alabama at Birmingham|Yes|Terminated|December 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Female|12 Years|55 Years|No|||September 2012|September 29, 2012|February 9, 2006||No|Gathering information from the PI records to provide this response.|No|June 1, 2012|https://clinicaltrials.gov/show/NCT00290199||185162|
NCT00290732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0503 CDR0000459502|Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer|A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Completed|November 2005|October 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||October 2013|October 7, 2013|February 9, 2006|No|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00290732||185122|Duct cannulation was not successful in all participants; possibly due to extensive disease or prior excisional biopsy (2 subjects).
NCT00284076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|357|L-Arginine in the Treatment of Peripheral Arterial Disease|||Stanford University||Completed|February 2000|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||March 2014|March 4, 2014|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00284076||185627|
NCT00284401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/102|Prosthetic Component Relationship of the Reversed Delta III Total Shoulder Prosthesis in the Transverse Plane of the Body|Prosthetic Component Relationship of the Reversed Delta III Total Shoulder Prosthesis in the Transverse Plane of the Body||University Hospital, Ghent|No|Completed|February 2004|July 2004|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00284401||185602|
NCT00284414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/199|Is Ultrasonography Comparable to MRI for the Detection of Morton Neuroma of the Foot?|Is Ultrasonography Comparable to MRI for the Detection of Morton Neuroma of the Foot?||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|20 Years|80 Years|No|||February 2009|May 18, 2009|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284414||185601|
NCT00283569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mrbt1-03-132|Genetic Epidemiology of Adult Onset Glioma|Genetic Epidemiology of Adult-Onset Glioma||Kentuckiana Cancer Institute||Completed|May 2004|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Saliva, Toe Nail Clippings|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Glioma and a Control|January 2010|January 18, 2010|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00283569||185666|
NCT00285350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2154|Mycophenolate Mofetil in Myasthenia Gravis|A Trial of Mycophenolate Mofetil in Myasthenia Gravis||FDA Office of Orphan Products Development||Completed|September 2002|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||March 2007|March 24, 2015|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285350||185532|
NCT00285636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-0217-C|Long Term Follow-Up of Burn Injuries|Long Term Follow-Up of Burn Injuries||National Institute of General Medical Sciences (NIGMS)|No|Completed|June 1992|September 2008|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|85 Years|No|Non-Probability Sample|burn patients|September 2009|May 6, 2013|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285636||185511|
NCT00284089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A1201|Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Open-label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)||Novartis||Completed|April 2005|January 2009|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|88|||Both|50 Years|N/A|No|||February 2011|February 22, 2011|January 30, 2006||No||No|January 20, 2011|https://clinicaltrials.gov/show/NCT00284089||185626|
NCT00285337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-CSM-03|Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy|An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy|CSM|AOSpine North America Research Network|No|Completed|December 2005|November 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|321|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285337||185533|
NCT00285610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11261-CP-003|Early Exposure to Lead and Adult Antisocial Outcomes|||National Institute of Environmental Health Sciences (NIEHS)||Completed|November 2001|October 2006|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Both|18 Years|N/A|No|Non-Probability Sample|Pregnant women were recruited from four prenatal clinics in Cincinnati, Ohio if they        resided in areas of the city with a high concentration of older, lead-contaminated housing|November 2014|November 17, 2014|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285610||185513|
NCT00294424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF51871|Study on Costs and Effects of Waiting Time in Total Hip and Knee Replacements|A Prospective, Multi-Centre Study on Costs and Effects of Waiting Time in Patients Undergoing Total Hip and Knee Replacement Surgery. A Randomized Controlled Trial.||Academy of Finland||Active, not recruiting|September 2002|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||833|||Both|16 Years|N/A|No|||January 2006|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294424||184856|
NCT00294437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/prostate 1.2.001|ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases|Randomised Open-label Multicenter Prosp. Clinical Study to Show the Efficacy of IV ZOMETA® 4mg for Prevention of Bone Metastases in Hormone-naïve High Risk Patients With Locally Advanced Prostate Cancer||Central European Cooperative Oncology Group|No|Terminated|December 2003|November 2007|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|376|||Male|18 Years|N/A|No|||April 2012|April 30, 2012|February 20, 2006||No|underfunding|No||https://clinicaltrials.gov/show/NCT00294437||184855|
NCT00282464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281139|A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.|A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression||Pfizer|Yes|Completed|February 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|392|||Both|18 Years|N/A|No|||June 2009|June 1, 2009|January 24, 2006|Yes|Yes||No|March 3, 2009|https://clinicaltrials.gov/show/NCT00282464||185748|
NCT00282477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-4031-IM-CTIL|Trial to Evaluate Erectile Function, Fertility and Sperm Count in Male Cyclists Compared to Age Matched Controls|Prospective Controlled Trial to Evaluate Erectile Function, Fertility and Sperm Count in Male Cyclists Compared to Age Matched Controls||Sheba Medical Center||Recruiting|February 2006|||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2007|August 6, 2007|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282477||185747|
NCT00282724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT0500INT001|Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis|A Randomized, Double-blind, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg od and 150 mg od) Given During 12 Weeks in Lamellar Ichthyosis||GlaxoSmithKline||Completed|January 2006|April 2007|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|98|||Both|14 Years|N/A|No|||September 2011|September 23, 2011|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00282724||185728|
NCT00290420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRD/Prevmal/Bol/06|Prevention of P. Vivax Malaria During Pregnancy in Bolivia|Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine.||Institut de Recherche pour le Developpement|No|Withdrawn|March 2006|November 2007|Anticipated|November 2007|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 21, 2013|February 9, 2006||No|important delays and malaria season missed, due to political changes|No||https://clinicaltrials.gov/show/NCT00290420||185145|
NCT00290940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0917-A-U205|Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of CS-917 as Monotherapy for Type 2 Diabetes||Daiichi Sankyo Inc.||Completed|January 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|70 Years|No|||September 2007|September 10, 2007|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00290940||185108|
NCT00290953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC3679|Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide|A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide|SESAME|Sanofi||Completed|October 2002|March 2006|Actual|March 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|432|||Both|18 Years|N/A|No|||December 2008|December 22, 2008|February 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00290953||185107|
NCT00293956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25190|Thyroid Function in Term Infants With Respiratory Distress|Thyroid Function in Term and Near Term Infants With Respiratory Distress and Its' Relation to Severity of Illness||Christiana Care Health Services|No|Completed|January 2006|July 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Whole blood, serum|Both|N/A|6 Days|No|Probability Sample|Full-term and near-term infants with respiratory distress during the first 24 hours of        life.|January 2008|January 16, 2008|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293956||184890|
NCT00293943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET-B04-1|Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation|A Randomized Trial to Investigate the Significance of Complete Versus Incomplete Electrical Isolation of Pulmonary Veins by Radiofrequency-induced Linear Lesions||German Atrial Fibrillation Network||Completed|February 2006|August 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|232|||Both|50 Years|85 Years|No|||September 2012|September 7, 2012|February 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00293943||184891|
NCT00294229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK220_02|Spinal Manipulative Therapy for Low Back Pain|Spinal Manipulative Therapy for Low Back Pain: Randomised Controlled Trial||University of Bern|No|Completed|March 2003|October 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|104|||Both|20 Years|55 Years|No|||September 2011|September 30, 2011|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00294229||184870|
NCT00294554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-08-20-03|Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia|Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia||Johns Hopkins University|No|Completed|April 2005|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|N/A|No|||April 2008|April 2, 2012|February 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00294554||184846|
NCT00289900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524B-024|Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)|A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|January 2006|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|2340|||Both|18 Years|80 Years|No|||December 2015|December 17, 2015|February 7, 2006|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00289900||185185|
NCT00290212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK V 77/2005|Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause|Phase II Study of Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause: a Randomised Double Blind Placebo-Controlled Trial||University Hospital of North Norway||Completed|January 2006|June 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|304|||Female|50 Years|60 Years|Accepts Healthy Volunteers|||December 2006|January 23, 2008|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00290212||185161|
NCT00291070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0605|Effects of L-Theanine in Boys With ADHD|A Double Blind, Randomized Placebo Controlled Clinical Trial Examining the Effects of L-Theanine (Suntheanine®) in Male Child Subjects With Attention Deficit Hyperactivity Disorder||University of British Columbia||Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|100|||Male|8 Years|12 Years|No|||April 2008|April 28, 2008|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00291070||185098|
NCT00290745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465205|Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ|Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer||University of California, San Francisco||Completed|January 2004|June 2011|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|N/A|N/A|No|||March 2014|March 28, 2014|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290745||185121|
NCT00290758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 04B3|Phase IIb Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer|Phase IIb Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer||Northwestern University|Yes|Active, not recruiting|January 2006|May 2011|Anticipated|August 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|126|||Female|25 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 20, 2010|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00290758||185120|
NCT00291031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO-SG-114NM|Study of the Effect of Imagery Rehearsal Therapy (IRT) of Nightmares|A Randomised Controlled Trial of Imagery Rehearsal Therapy (IRT) of Nightmares in a Psychiatric Population||GGZ Centraal|Yes|Completed|February 2006|August 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|65 Years|No|||October 2013|October 16, 2013|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291031||185101|
NCT00284115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 2005/10/006|Efficacy of a Mechanical Gait Repetitive Training Technique in Hemiparetic Stroke Patients (AVC)|Efficacy of a Mechanical Gait Repetitive Training Technique Compared With a Usual Rehabilitation Program on Gait Recovery in Hemiparetic Stroke Patients||Rennes University Hospital|No|Terminated|March 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284115||185624|
NCT00284713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPCARE-DCM|Progenitor Cell Therapy in Dilative Cardiomyopathy|Transplantation Of Progenitor Cells And Recovery Of Left Ventricular Function In Patients With Nonischemic Dilatative Cardiomyopathy||Johann Wolfgang Goethe University Hospitals|No|Completed|May 2004|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|80 Years|No|||February 2009|February 17, 2009|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284713||185579|
NCT00284726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-10-25-03|The Effect of Cold Storage Solutions on Ischemic Injury in Lung Transplantation|A Prospective, Controlled, Randomized Study on the Effect of Cold Storage Solutions on Complement Activation and Other Mediators of Ischemic Injury in Lung Transplantation||Johns Hopkins University||Active, not recruiting|December 2000|September 2005||||Phase 3|Interventional|N/A|||||||Both|N/A|N/A||||August 2005|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284726||185578|
NCT00281437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0503-03|Health First-Study 2|Health First: Health and Psychological Outcomes of Physical Activity- Study 2||University of Alberta, Physical Education||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||January 2006|October 11, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281437||185826|
NCT00281463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01103, 010842|Impact of Pushrim Activated Power Assist Wheelchairs on Mobility Among People With Tetraplegia|Impact of Pushrim Activated Power Assist Wheelchairs on Mobility Among People With Tetraplegia||VA Pittsburgh Healthcare System|No|Completed|November 2001|January 2008|Actual|March 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|January 23, 2006||No||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00281463||185824|
NCT00290121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0503|Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics|Cerebral Mechanism Involved in Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics (IIT)||Université de Montréal||Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2005|March 13, 2013|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00290121||185168|
NCT00294749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005959-17|Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy|Comparison Between Short and Long Schemes of Antibiotic Prophylaxis for Transrectal Prostate Biopsy. A Multicentre Prospective Randomised Study||Poitiers University Hospital|No|Terminated|February 2006|April 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|300|||Male|18 Years|N/A|No|||January 2009|January 26, 2009|February 19, 2006||||No||https://clinicaltrials.gov/show/NCT00294749||184831|
NCT00290108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257/99|The Influence of Injection Rate on EEG Propofol Peak Effect as Measured by Bispectral Index|The Influence of Injection Rate on EEG Propofol Peak Effect as Measured by Bispectral Index||Technische Universität München||Completed|March 2003|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||99|||Both|18 Years|60 Years|No|||June 1998|February 9, 2006|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290108||185169|
NCT00283062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976J_3501|Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy|A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- Leuprolide Acetate) in Combination With TAXOTERE® (Docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients With Prostate Cancer at High Risk of Relapse After Radical Prostatectomy||Sanofi||Completed|December 2005|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|228|||Male|18 Years|N/A|No|||December 2010|January 25, 2012|January 26, 2006|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00283062||185704|The study had difficulties in meeting enrollment goals within a reasonable time frame. The final sample size allowed for the safety analyses but was underpowered for drawing conclusions regarding efficacy and quality of life (QoL) endpoints.
NCT00283075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0407007343|Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer|Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer||The Rogosin Institute|Yes|Completed|January 2005|February 2015|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|January 26, 2006|Yes|Yes||No|October 26, 2015|https://clinicaltrials.gov/show/NCT00283075||185703|
NCT00283088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS44148LYDEN|Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke|Phase 1 Study of Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke||University of California, San Diego|Yes|Completed|October 2003|May 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|130|||Both|18 Years|80 Years|No|||January 2009|January 11, 2011|January 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283088||185702|
NCT00283335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363|The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol|CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol|HIT|VA Office of Research and Development|Yes|Completed|June 1991|August 1999|Actual|September 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2531|||Male|N/A|73 Years|No|||October 2015|October 20, 2015|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00283335||185684|
NCT00283348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cell 500|New Strategies for Non-Invasive Detection of Chronic Allograft Nephropathy|New Strategies for Non-Invasive Detection of Chronic Allograft Nephropathy||Virginia Commonwealth University|No|Completed|January 2006|December 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|121|Samples With DNA|Blood, Urine|Both|18 Years|70 Years|No|Probability Sample|Patients Diagnosis of Chronic Allograft Nephropathy at VCUHS Clinic|March 2009|March 19, 2009|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00283348||185683|
NCT00294580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC-795-835|Early Childhood Malaria Prevention With Maloprim in The Gambia|Comparison of Two Strategies for Control of Malaria Within A Primary Health Care Programme in the Gambia||Imperial College London||Completed|April 1982|September 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2253|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||March 2006|May 27, 2015|February 20, 2006||||No||https://clinicaltrials.gov/show/NCT00294580||184844|
NCT00294242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6H06|Safety Study of Membrane Sweeping in Pregnancy|Does Routine Membrane Sweeping in Uncomplicated Term Pregnancies Increase the Rate of Prelabour Rupture of Membranes||Tripler Army Medical Center||Not yet recruiting|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2006|February 17, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294242||184869|
NCT00289939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA012572|Reducing HIV & Domestic Violence Risk in Women Offenders|Reducing HIV & Domestic Violence Risk in Women Offenders||Multnomah County Health Department||Completed|September 2000|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||530|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2005|February 27, 2006|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00289939||185182|
NCT00294567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHF-17NOV2005|Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)|Azelnidipine and Amlodipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Junten Medical University (ALPS-J)||Juntendo University Hospital|No|Completed|December 2005|January 2011|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|20 Years|79 Years|No|||October 2008|June 2, 2011|February 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00294567||184845|
NCT00289913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V251-068|Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)|An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age||Merck Sharp & Dohme Corp.||Completed|April 2006|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|1274|||Both|12 Months|17 Months|Accepts Healthy Volunteers|||February 2016|February 2, 2016|February 8, 2006|Yes|Yes||No|June 9, 2011|https://clinicaltrials.gov/show/NCT00289913||185184|
NCT00289926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHP 200501|Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms|A Randomised, Double-blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms||Monash University|Yes|Completed|February 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00289926||185183|
NCT00291083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8427|Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer|Study of Manual Nipple Fluid Aspiration IN Post-Menopausal Women||University of Kansas Medical Center|No|Completed|October 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|229|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical center|February 2012|February 6, 2012|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291083||185097|
NCT00291382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM49071|Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product|See Detailed Description||GlaxoSmithKline|No|Completed|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291382||185076|
NCT00291044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL R116|HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women|HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women||Stony Brook University||Completed|September 2005|September 2009|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|300|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant subjects|November 2010|November 18, 2010|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00291044||185100|
NCT00291057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALG-0508|Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice|Phase II, Multi-center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis||Taro Pharmaceuticals USA|No|Terminated|February 2006|December 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|6 Months|24 Months|No|||November 2013|December 19, 2013|February 10, 2006|No|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00291057||185099|
NCT00284466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-IRB 2005-0377|Comparing Angiography: Multislice CT Versus Invasive Heart Catheterization (CACTI)|Comparing Angiography: Multislice CT vs. Invasive Heart Catheterization (CACTI)||University of Wisconsin, Madison|No|Completed|January 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|January 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00284466||185597|
NCT00284752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK001|Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer|Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer||Kaiser Permanente||Completed|August 2005|December 2011|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Male|18 Years|N/A|No|||September 2012|September 28, 2012|January 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00284752||185576|
NCT00285051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rafa protocol THC002/NVP|Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy|Study to Compare the Safety and Efficacy of 2 Different Doses of Inhaled D8-THC to Standard Therapy With Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy||Rafa Laboratories||Suspended|November 2005|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|18 Years|85 Years|No|||February 2007|February 27, 2007|January 31, 2006|||Study drug expiry date not extended|No||https://clinicaltrials.gov/show/NCT00285051||185553|
NCT00285064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ram1099_CTIL|Assessment of Myocardial Viability Using Multidetector Computed Tomography|Non-Invasive Assessment of Myocardial Viability Using Multidetector Computed Tomography Post Acute Myocardial Infarction||Rambam Health Care Campus||Completed|January 2006|May 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|20|||Both|18 Years|N/A|No|||February 2007|October 11, 2008|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00285064||185552|
NCT00285038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRACTIL|Ultrasound (US)-Doppler for the Diagnosis of Asymptomatic Deep Vein Thrombosis (DVT) in Gynecologic Cancer Patients|US-Doppler for the Diagnosis of Asymptomatic DVT in Gynecologic Cancer Patients||Rambam Health Care Campus||Completed|March 2006|December 2010|Actual|December 2010|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Gynecological Ambulatory cancer patients|January 2006|December 13, 2010|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00285038||185554|
NCT00285324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060085|Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis|Two-Compartment Model of Diffusion Tensor Magnetic Resonance Imaging (DT-MRI) for the Diagnosis of Glioma Tumor Recurrence Versus Radiation Necrosis||National Institutes of Health Clinical Center (CC)||Completed|January 2006|August 2013||||N/A|Observational|N/A|||Actual|29|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2013|December 6, 2013|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285324||185534|
NCT00285649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19P3|Predicting Patients' Response to Spinal Manipulation|Predicting Patients' Response to Spinal Manipulation||Palmer College of Chiropractic|Yes|Completed|July 2004|March 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|240|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285649||185510|
NCT00294775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2005-001930-34|Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis|Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis - Effect of Blockade of the Angiotensin-II Receptor||Odense University Hospital||Active, not recruiting|February 2006|June 2009|Anticipated|January 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|140|||Both|18 Years|N/A|No|||June 2009|June 26, 2009|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294775||184829|
NCT00282776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH071825|Identification and Therapy of Postpartum Depression|Identification and Therapy of Postpartum Depression||University of Pittsburgh|No|Completed|August 2006|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|628|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 30, 2013|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00282776||185725|
NCT00282789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-06-A-0002|BiPAP for Cardiomyopathy With Central Sleep Apnea|||Nagoya University||Completed|June 2000|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|70 Years|No|||June 2000|January 27, 2006|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00282789||185724|
NCT00283101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG040-0003|A Safety Study in Patients With Chronic Lymphocytic Leukemia|A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia||Seattle Genetics, Inc.|No|Completed|July 2005|October 2006|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|January 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00283101||185701|
NCT00282516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28H01|Asthma In-Home Monitoring (AIM) Trial|“Internet-Based Home Monitoring and Education of Children With Asthma is Comparable to Ideal, Office-Based Care: Results of a One-Year, Asthma In-Home Monitoring (AIM) Trial”||Tripler Army Medical Center||Active, not recruiting|April 2003|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||120|||Both|6 Years|17 Years|No|||January 2006|January 25, 2006|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282516||185744|
NCT00282750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002344|The Bar Coded Sponge Study|A Randomised Clinical Trial of a Bar-Coded Safety Sponge System||Brigham and Women's Hospital||Completed|March 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 13, 2010|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00282750||185727|
NCT00282763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0686-005|A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)|Proprietary Information - Exploratory (Non-confirmatory) Trial||Merck Sharp & Dohme Corp.||Terminated|December 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|80 Years|No|||November 2015|November 20, 2015|January 24, 2006||||||https://clinicaltrials.gov/show/NCT00282763||185726|
NCT00283660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045755|Zinc, Mental Health, and School Performance in Guatemalan Schoolchildren|Zinc, Mental Health, and School Performance||Emory University|Yes|Completed|January 2006|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|750|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00283660||185659|
NCT00283933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA1565522 (FAB-CL-203)|A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease|A Phase 2, Open-Label, Single Dose Level, 24-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease||Amicus Therapeutics||Completed|January 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|65 Years|No|||April 2015|April 8, 2015|January 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283933||185638|
NCT00294606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-941|Comparison of the Effects of Phenylephrine and Norepinephrine on Cardiac Function During Carotid Artery Surgery|Comparison of the Effects of Phenylephrine and Norepinephrine on Cardiac Function During Carotid Cross-Clamping During Carotid Endarterectomy Under General Anesthesia||Lawson Health Research Institute||Recruiting|February 2006|February 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||86|||Both|18 Years|N/A|No|||February 2006|February 17, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294606||184842|
NCT00289965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAACAR012518-06|Substance Use Risk Education (SURE) Project|Brief Alcohol Interventions by Counselor vs Computer||Syracuse University|Yes|Completed|September 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|703|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00289965||185180|
NCT00289952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB#05-018 (CTN-205)|Valproic Acid and Its Effects on HIV Latent Reservoirs|Use of Valproic Acid to Purge HIV From Resting CD4+ Memory Cells/ A Proof-of-Concept Study||McGill University Health Center|Yes|Active, not recruiting|June 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||January 2008|March 30, 2009|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00289952||185181|
NCT00289978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2301|Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis|A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis|FREEDOMS|Novartis||Completed|January 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1272|||Both|18 Years|55 Years|No|||April 2012|April 9, 2012|February 9, 2006|Yes|Yes||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00289978||185179|
NCT00290225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSCIAHVNIMHANS|Yoga Breath Program and Client-Centered Exposure for Relief of PTSD in Tsunami Victims|Controlled Trial of Yoga Breath Based Group Intervention and Client-Centered Exposure Treatment for Relief of Traumatic Stress and Depression in Tsunami Victims||Victim Services Center, Miami|No|Completed|June 2005|December 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2007|May 2, 2007|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00290225||185160|
NCT00290238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSMED-K011702-PNT02|Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients|Percutaneous Neuromodulation Therapy With Chronic Low Back Pain Patients With or Without Lower Extremity Pain - A Randomized, Controlled, Parallel Groups Study||RS Medical|No|Terminated|December 2005|September 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||May 2009|May 8, 2009|February 8, 2006|Yes|Yes|Slow recruitment and high dropout rates|No|November 25, 2008|https://clinicaltrials.gov/show/NCT00290238||185159|
NCT00290251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060090|Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914|Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2006|August 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Female|25 Years|50 Years|No|||November 2012|November 14, 2012|February 10, 2006|Yes|Yes||No|October 28, 2011|https://clinicaltrials.gov/show/NCT00290251||185158|
NCT00290524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCTG-02-V5|Early Alimentation Following Colorectal Surgery|Prospective, Multicentric, Randomized Phase III Study Comparing Early Oral Alimentation to Nil Per Os Diet After Colorectal Surgery||Maisonneuve-Rosemont Hospital||Recruiting|January 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||800|||Both|18 Years|N/A|No|||April 2006|April 6, 2006|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00290524||185138|
NCT00290537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0635|Phase II Study of ZD6474 in Advanced NSCLC|A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC||M.D. Anderson Cancer Center|No|Terminated|January 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||August 2009|August 31, 2009|February 10, 2006|No|Yes|Accrual was suboptimal and increasing the number of patients was not feasible.|No|March 18, 2009|https://clinicaltrials.gov/show/NCT00290537||185137|
NCT00291096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4601|Protocol for Women at Increased Risk of Developing Breast Cancer|High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer||University of Kansas Medical Center|No|Recruiting|January 1989|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples Without DNA|RPFNA specimens, serum, NAF|Female|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Self-identified women at high risk for development of breast cancer|October 2015|October 29, 2015|February 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00291096||185096|
NCT00291395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05055|PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers|||Danish Headache Center||Terminated|September 2005|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2005|October 25, 2006|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291395||185075|
NCT00291408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0403/171|Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD|A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Symbicort® and Pulmicort® on HAT and HDAC Expression and Activity in Induced Sputum Cells Obtained From COPD Patients.||Imperial College London||Completed|April 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|48|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||April 2008|May 28, 2015|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291408||185074|
NCT00291421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003937|A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease|International Outcomes Survey In Dementia (IOSID)||Janssen Pharmaceutica N.V., Belgium||Completed|July 2002|May 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|2360|||Both|N/A|N/A|No|||April 2013|April 15, 2013|February 10, 2006||||No||https://clinicaltrials.gov/show/NCT00291421||185073|
NCT00291733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALID-PD|Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease|Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial||1st Hospital of Social Security Services||Active, not recruiting|May 2006|October 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|50|||Both|30 Years|80 Years|No|||November 2007|November 14, 2007|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00291733||185049|
NCT00284765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-20050182|Management of the Sprained Ankle by Help of NSAID-Plaster|Optimation of Treatment of the Sprained Ankle by Help of NSAID-Plaster (Flector). A Questionnaire.||Kolding Sygehus||Recruiting|February 2006|May 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||200|||Both|18 Years|N/A|No|||January 2006|March 10, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284765||185575|
NCT00264277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROLONG STUDY|D-Dimer to Establish Duration of Anticoagulation After Venous Thromboembolism|D-Dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized “Prolong” Study||St. Orsola Hospital||Completed|September 2002|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||December 2004|December 1, 2006|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264277||187105|
NCT00267774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3933|Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)|||Stanford University||Completed|January 2006|September 2015|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1005|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267774||186841|
NCT00267787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAL0001|Molecular Genetic and Pathological Studies of Anal Tumors|Molecular Genetic and Pathological Studies of Anal Tumors||Stanford University|Yes|Recruiting|September 2004|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with anal cancer or high risk for anal cancer refered to Stanford.|July 2012|July 5, 2012|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267787||186840|
NCT00267475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-3-15|Data Bank for Eosinophilic Disorders|Clinical and Immunological Evaluation of Eosinophil Associated Gastrointestinal Disorders (EGID)||Children's Hospital Medical Center, Cincinnati||Completed|May 2001|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with an eosinophilic disorder and patients without an eosinophilic        disorder to serve as normal controls|January 2013|September 17, 2013|December 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00267475||186863|
NCT00267488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100414|Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer|An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer||GlaxoSmithKline|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|70|||Female|18 Years|N/A|No|||June 2012|June 28, 2012|December 20, 2005|||||December 5, 2008|https://clinicaltrials.gov/show/NCT00267488||186862|As there was only 1 responder, time to response, and duration of response were not calculated.
NCT00267501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-8|Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders|Eosinophils and Inflammation, an Expanded Study||Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2005|January 2050|Anticipated|January 2050|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with eosinophilic disorders and patients without eosinophilic disorders to serve        as normal controls|September 2014|November 10, 2015|December 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00267501||186861|
NCT00268723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-925|Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB|An Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Versus Placebo in Prevention of EIB in Subjects 18 Years of Age and Older With EIB||Sunovion|No|Completed|December 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|December 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268723||186772|
NCT00268749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02T-175|Glycine Treatment of Prodromal Symptoms|Glycine Treatment of Prodromal Symptoms||Yale University||Completed|July 2002|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|14 Years|35 Years|No|||March 2012|March 28, 2012|December 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00268749||186771|
NCT00269126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO100646|Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)|See Detailed Description||GlaxoSmithKline||Completed|February 2005|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|150|||Both|40 Years|80 Years|No|||May 2012|April 11, 2013|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269126||186743|
NCT00269100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jaul1CTIL|Prevention of Bacteremia Induced by Debridement of Pressure Ulcer|||Herzog Hospital||Terminated||||||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||60|||Both|N/A|N/A|No|||April 2007|April 19, 2007|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269100||186745|
NCT00269113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M39023|A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma|A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma||Hoffmann-La Roche||Completed|September 1998|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|75 Years|No|||July 2015|July 21, 2015|December 22, 2005||No||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00269113||186744|
NCT00269659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC 2003/147|Evaluating Effects of a Left Bundle Branch Block|Serial Evaluation of Left Bundle Branch Block; Role of New Imaging Techniques. Three-Dimensional Echocardiography, Tissue Doppler Imaging, and Magnetic Resonance Imaging||VU University Medical Center|No|Completed|January 2004|July 2007|Actual|July 2007|Actual|Phase 3|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2009|February 23, 2009|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269659||186702|
NCT00270010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005842|A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||August 1989|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|72|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270010||186677|
NCT00270231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800810|Effects of Naltrexone on Nicotine Reinforcement|Pharmacogenetic Investigation of Naltrexone||University of Pennsylvania|No|Completed|March 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|64|||Both|18 Years|65 Years|No|||November 2013|November 12, 2013|December 23, 2005|Yes|Yes||No|February 18, 2009|https://clinicaltrials.gov/show/NCT00270231||186660|
NCT00270491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAXEL|Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.|A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.||ARCAGY/ GINECO GROUP||Completed|December 2005|October 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|130|||Female|18 Years|N/A|No|||February 2011|February 24, 2011|December 26, 2005||||No||https://clinicaltrials.gov/show/NCT00270491||186640|
NCT00263432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/245|Reparation of Cartilage Injuries in the Human Knee by Implantation of Fresh Human Allogenic Chondrocytes|Reparation of Cartilage Injuries in the Human Knee by Implantation of Fresh Human Allogenic Chondrocytes||University Hospital, Ghent|No|Recruiting|August 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|December 4, 2005||No||No||https://clinicaltrials.gov/show/NCT00263432||187167|
NCT00263445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-07-052-02|Constructing an Insulin-Like Growth Factor-based Prediction Model|Constructing an Insulin-Like Growth Factor-based Prediction Model||University of California, Los Angeles||Terminated|August 2004|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|3 Years|14 Years|No|Non-Probability Sample|GH-treated chlidren|December 2014|December 1, 2014|December 7, 2005||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00263445||187166|
NCT00266617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005845|A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy|The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||June 1990|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|86|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00266617||186928|
NCT00266903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-118|Eisenmenger's Syndrome in Adults With CHD|Treatment of Eisenmenger's Syndrome in Adults With Congenital Heart Disease With Pulmonary Arterial Vasodilators||Children's Healthcare of Atlanta||Completed|January 1996|January 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|48|||Both|18 Years|N/A|No|Non-Probability Sample|Congenital heart disease (unoperated, palliated or repaired) Eisenmenger's syndrome Age 18        to 80|November 2014|November 26, 2014|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00266903||186907|
NCT00267150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ADE10|Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants|Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients||Novartis||Completed|November 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A||||May 2011|May 17, 2011|December 16, 2005||||No|December 9, 2010|https://clinicaltrials.gov/show/NCT00267150||186888|
NCT00262951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS060|Chemoradiation in Locally Advanced Pancreatic Cancer|A Phase II Pilot Study of Multi-Agent Neo-Adjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Adenocarcinoma||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2005|August 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|December 6, 2005|Yes|Yes|Closed at a planned interim analysis by meeting a predefined toxicity endpoint|No|November 14, 2011|https://clinicaltrials.gov/show/NCT00262951||187203|
NCT00263276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-008|A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Control on Diet and Exercise||AstraZeneca|No|Completed|December 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|385|||Both|18 Years|79 Years|No|||March 2015|March 20, 2015|December 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00263276||187179|
NCT00263627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0204AV|Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens||Allergopharma GmbH & Co. KG|No|Completed|June 2005|March 2010|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|60 Years|No|||November 2013|July 2, 2014|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00263627||187153|
NCT00263263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCUBATE-001|RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.|Phase 2 Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Degenerated Saphenous Vein Grafts||Antwerp Cardiovascular Institute Middelheim|Yes|Completed|September 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|85 Years|No|||March 2007|March 12, 2007|December 7, 2005||||No||https://clinicaltrials.gov/show/NCT00263263||187180|
NCT00263601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0101av|Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis|A Multicentre, Placebo Controlled, Double-Blind Study for Evaluation of Safety and Efficacy of Preseasonal Specific Immunotherapy With an Allergoid Preparation of an Extract of a 6 Grass Pollen Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity||Allergopharma GmbH & Co. KG|No|Completed|November 2001|August 2010|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|65 Years|No|||June 2014|June 4, 2014|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00263601||187155|
NCT00263614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-103-0143|Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.|A Cross Sectional and Retrospective Evaluation in HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)Patients With Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases(The MELT Study).||Gilead Sciences||Completed|December 2005|June 2007|Actual|||Phase 4|Observational|Time Perspective: Retrospective|||Anticipated|100|||Both|18 Years|N/A|No|||January 2009|January 30, 2009|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00263614||187154|
NCT00264550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006343|An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Subjects With ActiveRheumatoid Arthritis Despite Methotrexate Therapy|GO-FORWARD|Centocor, Inc.|Yes|Completed|December 2005|May 2012|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|444|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|December 11, 2005|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00264550||187084|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00264563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80/05|"Iatrogenesis Imperfecta"- Extent and Characteristic in NICU in Israel.|||Bnai Zion Medical Center||Completed|November 2005|April 2006||||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|6 Months|No|Non-Probability Sample|Ifants admitted to NICU during the study period|August 2005|June 16, 2011|December 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00264563||187083|
NCT00268086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-123|Constrictive Pericarditis in the Adult Congenital Cardiac Population|Constrictive Pericarditis in the Adult Congenital Cardiac Population||Children's Healthcare of Atlanta||Terminated||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||15|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268086||186818|
NCT00268073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-067|Incidence of Neo-Aortic Insufficiency|Comparison of the Incidence of Neo-Aortic Insufficiency After Classic Norwood I and Norwood I-Sano Procedures||Children's Healthcare of Atlanta||Terminated|January 2002|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|21 Years|No|||May 2007|May 3, 2007|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268073||186819|
NCT00269139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|719371|Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder|Study of Outcome With an Intervention From the Cape Cod Model of Psychotherapy for Subjects in a Behavioral Crisis and With the Diagnosis of Borderline Personality Disorder (BPD) or Post-Traumatic Stress Disorder (PTSD)||Laddis, Andreas, M.D.||Not yet recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|19 Years|65 Years|No|||December 2005|February 17, 2006|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269139||186742|
NCT00269386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLBUHT R&D 1558|Clarithromycin in Active Crohn's Disease|Randomised Controlled Trial of Clarithromycin in Active Crohn's Disease||Royal Liverpool University Hospital|Yes|Completed|April 2000|May 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||January 2009|January 6, 2009|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269386||186723|
NCT00269672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-500|Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects|A Randomized, Open Label, Controlled Phase II Study to Evaluate Safety, Tolerability and Immunogenicity After Two Different 13-Valent Pneumococcal Conjugate Vaccine Formulations in Elderly Subjects Aged 65 Years and Older Who Are Naive to Previous 23vPS Immunization||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|915|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 4, 2010|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269672||186701|
NCT00269685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-33-R2|Comparison of Vasopressin and Other Pressors in Septic Shock|Comparative Prospective Study of Vasopressin and Catecholamine in Septic Shock||Université de Sherbrooke||Completed|July 2000|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||August 2005|May 26, 2006|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269685||186700|
NCT00270023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005890|A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.|Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Selective Orthopedic and Vascular Surgery or Reductive Mammoplasty to Facilitate Presurgical Autologous Blood Donation Combined With Normo-Volemic Hemodilution (NVHD)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||November 1991|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|112|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00270023||186676|
NCT00270244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH73640, #5037|Group Interpersonal Psychotherapy for Depressed Adolescents in School-based Clinics|Group Interpersonal Psychotherapy for Depressed Adolescents (IPT-AG) in School-based Clinics||New York State Psychiatric Institute|Yes|Completed|December 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Female|12 Years|18 Years|No|||December 2011|December 27, 2011|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00270244||186659|
NCT00270257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 058|Drug Treatment Combined With Drug and Risk Reduction Counseling in the Prevention of HIV Infection and Death Among Injection Drug Users|A Phase III Randomized Controlled Trial to Evaluate the Efficacy of Drug Treatment in Prevention of HIV Infection and Death Among Opiate Dependent Injectors||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2007|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1252|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 4, 2014|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00270257||186658|
NCT00264082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|419.04|Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis|"Tartrate-Resistant Acid Phosphatase as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis During Zometa Treatment: A Pilot Study"||James Graham Brown Cancer Center||Completed|September 2004|||May 2006|Actual|Phase 2|Observational|N/A|||Anticipated|30|||Female|18 Years|N/A|No|||April 2013|April 8, 2013|December 9, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00264082||187120|
NCT00266630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9637|Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder|Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder||Eli Lilly and Company||Completed|November 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|20 Years|65 Years|No|||December 2010|December 10, 2010|December 15, 2005|Yes|Yes||No|May 26, 2010|https://clinicaltrials.gov/show/NCT00266630||186927|Identified errors were corrected.
NCT00266643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8952|Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain|A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain||Eli Lilly and Company||Completed|December 2005|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||205|||Both|18 Years|N/A|No|||August 2007|August 1, 2007|December 15, 2005||||||https://clinicaltrials.gov/show/NCT00266643||186926|
NCT00267163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0090|Brain Imaging and Mental Disorders of Aging Intervention|Brain Imaging and Mental Disorders of Aging Intervention||National Institute on Aging (NIA)||Completed|September 2000|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|64|||Both|40 Years|90 Years|No|||August 2008|August 28, 2008|December 16, 2005||||No||https://clinicaltrials.gov/show/NCT00267163||186887|
NCT00267189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001H2401|RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency|A 6-month, Multicenter, Randomized, Open-label Study of Safety and Efficacy of Everolimus-based Regimen Versus Calcineurin Inhibitor (CNI)-Based Regimen in Maintenance Liver Transplant Recipients||Novartis|Yes|Completed|November 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|70 Years||||April 2011|April 11, 2011|December 19, 2005||No||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00267189||186885|
NCT00262665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 05-0384|Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder|Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder||Icahn School of Medicine at Mount Sinai|Yes|Withdrawn|March 2005|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|55 Years|No|||December 2012|December 10, 2012|December 6, 2005|Yes|Yes|protocol cancelled|No||https://clinicaltrials.gov/show/NCT00262665||187223|
NCT00262678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3267-005|Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.||Prostrakan Pharmaceuticals||Completed|December 2005|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|17 Years|N/A|No|||June 2009|June 2, 2009|December 6, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00262678||187222|
NCT00262964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK37948|Obesity and Nonalcoholic Fatty Liver Disease|Obesity and Nonalcoholic Fatty Liver Disease||Washington University School of Medicine|Yes|Completed|October 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|45 Years|No|||July 2010|July 2, 2010|December 6, 2005||No||No|March 15, 2010|https://clinicaltrials.gov/show/NCT00262964||187202|
NCT00263289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|n20kup-HMO-CTIL|Preprocedural Fasting and Nitrous Oxide -Oxygen Inhalation Analgesia for Dental Treatment of Children|The Effect of Preprocedural Fasting on Vomiting Frequency in Children Administered Nitrous Oxide -Oxygen Inhalation Analgesia for Dental Treatment||Hadassah Medical Organization||Not yet recruiting|January 2006|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|4 Years|17 Years||||December 2005|December 7, 2005|December 7, 2005||||No||https://clinicaltrials.gov/show/NCT00263289||187178|
NCT00263640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0104av|Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis||Allergopharma GmbH & Co. KG|No|Completed|May 2005|August 2012|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|6 Years|40 Years|No|||January 2015|January 14, 2015|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00263640||187152|
NCT00263887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100533|Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)|Multi-center, Randomized Trial With I.V. Prolastin® to Evaluate Frequency of Exacerbations and Progression of Emphysema by Means of Multi-slice CT Scans in Patients With Congenital Alpha-1-antitrypsin Deficiency.||Grifols Therapeutics Inc.|No|Completed|December 2003|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|September 12, 2005|No|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00263887||187134|
NCT00265564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-175|SUPER Study (Substance Use and PTSD Treatment Effectiveness Research Study)|Effectiveness of Screening and Treatment for PTSD in SUD Patients||VA Office of Research and Development|No|Completed|July 2006|July 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|125|||Male|18 Years|N/A|No|||November 2014|November 6, 2014|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00265564||187007|
NCT00268099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-121|Optimal Timing for Repair of Right-to-Left Shunt Lesions|Optimal Timing for Repair of Right-to-Left Shunt Lesions||Children's Healthcare of Atlanta|No|Terminated|May 2005|November 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|75|||Both|N/A|18 Years|No|Non-Probability Sample|patients in the congenital surgery database who have undergone repair of a Tetralogy of        Fallot defect|June 2007|March 15, 2012|December 20, 2005|||study not started|No||https://clinicaltrials.gov/show/NCT00268099||186817|
NCT00268385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00675|Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas|A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2005|||October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||December 2015|March 11, 2016|December 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00268385||186797|
NCT00269152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10105|Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer|A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients With Completely Resected Stage Ib or II Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|December 2005|July 2013|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|December 21, 2005|Yes|Yes||No|November 12, 2008|https://clinicaltrials.gov/show/NCT00269152||186741|A protocol amendment was approved after the trial original completed to allow for collection of additional overall survival data due to number of participants surviving at 3 years.
NCT00269165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-187|Adjuvant Radiation in Aortic Valvuloplasty - ARAVA|||Medstar Research Institute||Terminated|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|75 Years|N/A|No|||May 2010|May 28, 2010|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269165||186740|
NCT00269399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFCL3001|A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)|A Double-Blind, Randomized, Controlled Trial of Rifaximin Compared to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)||Valeant Pharmaceuticals International, Inc.||Completed|December 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||July 2011|July 17, 2011|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269399||186722|
NCT00269724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005971|A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence|Open-Label Safety And Dose Conversion/Determination Study of OROS® Oxybutynin Chloride for Urge Urinary Incontinence||Alza Corporation, DE, USA||Completed|March 1997|September 1997||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269724||186699|
NCT00269737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005980|Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer|Efficacy of TTS Fentanyl in the Management of Pain in Patients With Malignancy - Study III||Alza Corporation, DE, USA||Completed|May 1986|February 1988||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||7|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269737||186698|
NCT00262795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455042|Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia|Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Active, not recruiting|September 2003|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|205|||Both|65 Years|79 Years|No|||December 2007|November 5, 2013|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00262795||187214|
NCT00263094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3395-MD-CTIL|An End to the Yom Kippur (and Ramadan) Headache|: An End to the Yom Kippur (and Ramadan) Headache: A Double Blind Placebo Controlled Trial of Prophylactic Rofecoxib in Preventing Ritual Fasting Headache.||Sheba Medical Center||Completed|September 2004|November 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||220|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2006|January 25, 2006|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00263094||187192|
NCT00269815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006001|Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder|Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD||Alza Corporation, DE, USA||Completed||December 1999|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|6 Years|13 Years|No|||June 2011|June 13, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269815||186692|
NCT00269828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGT305|A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.|Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.||CTI BioPharma||Terminated|December 2005|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Female|18 Years|N/A|No|||February 2007|February 13, 2007|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269828||186691|
NCT00266916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-138|Percutaneous Interventions in Adults With CHD|Percutaneous Interventions in Adults With Complex Cyanotic Congenital Heart Disease||Children's Healthcare of Atlanta||Terminated|January 1996|August 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||9|||Both|18 Years|N/A|No|||May 2007|May 22, 2007|December 19, 2005|||data collection sufficient|No||https://clinicaltrials.gov/show/NCT00266916||186906|
NCT00267202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AUS23|Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma|A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids||Novartis||Completed|December 2005|April 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|275|||Both|18 Years|55 Years|No|||October 2011|October 27, 2011|December 19, 2005||Yes||No|November 22, 2010|https://clinicaltrials.gov/show/NCT00267202||186884|
NCT00262691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-05-G-0001|Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study|Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study, the Kitanagoya Genome (KING) Study for the Local Residents of Kitanagoya, Japan||Nagoya University|No|Recruiting|May 2005|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||Anticipated|7000|||Both|50 Years|N/A|No|||September 2007|September 20, 2007|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00262691||187221|
NCT00267228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018|Funen Anorexia Nervosa Study - Retrospective Cohort Study and 10 Year Follow-up Study|||Odense University Hospital|No|Active, not recruiting|February 2006|||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||March 2007|March 22, 2007|December 19, 2005||||No||https://clinicaltrials.gov/show/NCT00267228||186882|
NCT00262704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001600|SimCare: Physician Intervention to Improve Diabetes Care|SimCare: Physician Intervention to Improve Diabetes Care||HealthPartners Institute|No|Completed|December 2001|September 2002|Actual|August 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|2020|||Both|18 Years|80 Years|No|||August 2014|August 20, 2014|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262704||187220|
NCT00262717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVRP9901|Can Resistance Enhance Selection of Treatment? (CREST)|A Randomised Comparator Study to Assess the Relative Efficacy of Genotypic Versus Virtual Phenotypic Resistance Tests in Treatment Experienced Patients With HIV Infection for Whom a Change in Therapy is Indicated||Kirby Institute||Completed|March 2001|August 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Both|18 Years|N/A|No|||June 2006|June 8, 2006|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00262717||187219|
NCT00262990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2303|Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer|A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer||Novartis||Completed|November 2005|||February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|829|||Female|18 Years|N/A|No|||May 2012|May 2, 2012|December 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00262990||187200|
NCT00263302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512-e|Diuretic Efficacy of Dexamethasone in Heart Failure|Diuretic Efficacy of Dexamethasone in Congestive Heart Failure Patients||Hebei Medical University||Suspended|March 2006|December 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|80 Years|No|||January 2005|July 2, 2008|December 7, 2005||||No||https://clinicaltrials.gov/show/NCT00263302||187177|
NCT00263666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/022|A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa|A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine||GlaxoSmithKline||Completed|March 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|6 Weeks|10 Weeks|No|||July 2015|July 6, 2015|December 8, 2005|Yes|Yes||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00263666||187150|
NCT00263679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100406/004|Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.|A Phase III, Double-blinded, Randomized, Multicenter, Clinical Study to Assess the Safety and Immunogenicity of GSK Biologicals' Tdap 0.3 mg Candidate Vaccine When Given as a Booster Dose to Healthy School Children and Adolescents (9-13 Years of Age), Previously Vaccinated With a 5th Consecutive Dose of Acellular Pertussis-containing Vaccine, in Studies APV-118 or APV-120||GlaxoSmithKline||Completed|November 2003|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|321|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||February 2012|March 1, 2012|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00263679||187149|
NCT00263653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103954|Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197|Study to Evaluate the Safety, Reactogenicity & Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™, vs Hib-MenC or Priorix™ Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) & MenC-CRM197 Conjugate Vaccines.||GlaxoSmithKline||Completed|March 2005|September 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|297|||Both|13 Months|14 Months|Accepts Healthy Volunteers|||June 2014|June 26, 2014|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00263653||187151|
NCT00263900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/078/HP|TGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit|Exploratory Study of the Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit and Their Impact on the Assumption of Responsibility of the Suspect Children of a Viral Infection||University Hospital, Rouen|No|Completed|December 2005|June 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|377|||Both|N/A|5 Years|No|||April 2011|April 20, 2011|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00263900||187133|
NCT00263926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al1000ig|Efficacy and Safety of a Purified Standardised Wasp Venom Preparation|Immunotherapy of Wasp Venom Allergy: Comparison of a Purified Preparation to Conventional Aqueous Wasp Venom in an Open Controlled Study||Allergopharma GmbH & Co. KG||Completed|March 2001|November 2010|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 2013|March 8, 2013|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00263926||187132|
NCT00265590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060044|Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia|Phenotype-Genotype Correlation in Aniridia||National Institutes of Health Clinical Center (CC)||Completed|December 2005|October 2008||||N/A|Observational|N/A||||100|||Both|4 Years|N/A|No|||October 2008|September 26, 2015|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265590||187006|
NCT00268411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453849|Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer|Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX]||National Cancer Institute (NCI)||Active, not recruiting|September 2004|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||May 2007|May 23, 2008|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268411||186795|
NCT00268398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453815|Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases|Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX|MIROX|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)||Completed|July 2002|||December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|284|||Both|18 Years|75 Years|No|||May 2012|May 21, 2012|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00268398||186796|
NCT00268762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Argatroban+TPA 02-121B|Argatroban Stroke Treatment - A Pilot Safety Study|A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke||The University of Texas Health Science Center, Houston|Yes|Completed|February 2003|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|85 Years|No|||November 2014|November 3, 2014|December 20, 2005|Yes|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00268762||186770|Possible selection bias and investigators unblinded to treatment. In addition, although 60/65 patients had 24 hour recanalization data, only 47 were available at 2 hours.
NCT00269425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THIS-A20010724157261|The Heart Institute of Spokane Diet Study|The Heart Institute of Spokane Diet Intervention and Evaluation Trial (THIS DIET)||Providence Health & Services|No|Completed|October 2000|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|202|||Both|18 Years|N/A|No|||December 2005|August 23, 2010|December 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00269425||186720|
NCT00269438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZUC3002|New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis|Phase 3 Study to Establish the Efficacy and Safety of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium Dosed Twice Daily in Achieving Clinical Improvement in Subjects With Mildly to Moderately Active Ulcerative Colitis After 8 Weeks of Therapy||Valeant Pharmaceuticals International, Inc.||Completed|December 2005|June 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||225|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2009|December 21, 2009|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269438||186719|
NCT00269451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSD Turkey|Assessing PTSD After Earthquake in Turkey|||Sheba Medical Center||Active, not recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||December 2005|December 22, 2005|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269451||186718|
NCT00269464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-8888-JZ-CTIL|Chronic Schizophrenia With Obsessive-Compulsive Symptoms: Comorbidity or a Subtype?|||Sheba Medical Center||Completed||March 2007||||N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|65 Years||||December 2007|December 18, 2007|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269464||186717|
NCT00269412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFIB2001|Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome||Valeant Pharmaceuticals International, Inc.||Completed|December 2005|September 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|525|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269412||186721|
NCT00267020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10463|Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Patients With Advanced or Metastatic Pancreatic Cancer|A Randomized, Open-Label Phase 2 Study of 2 Regimens, Gemcitabine Plus Enzastaurin and Single-Agent Gemcitabine, in Patients With Locally Advanced or Metastatic Pancreatic Cancer||Eli Lilly and Company|Yes|Completed|December 2005|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|December 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267020||186898|
NCT00267319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4002A_4002|FOCUS Fatigue Outcome in Copaxone USers|Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis||Sanofi||Completed|June 2003|||October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267319||186875|
NCT00262808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448633|GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer|A PHASE II Study of GM-CSF As Pre- And Post-operative Adjuvant Therapy For Stage II And III Colon Cancer||University of Rochester||Completed|March 2004|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00262808||187213|
NCT00262821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00591|Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer|A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis||National Cancer Institute (NCI)||Completed|February 2006|||August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|402|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|December 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00262821||187212|
NCT00263107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|teleround-01|Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction.|Remote Post-Operative Rounding and the Physician Ability to Identify Morbidity||University of California, Davis||Completed|August 2004|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||270|||Both|18 Years|N/A|No|||December 2005|May 30, 2006|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00263107||187191|
NCT00263120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-12-003Halnon|Effects of Thymectomy During Cardiothoracic Surgery|||University of California, Los Angeles||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|35 Years|No|||November 2005|September 7, 2006|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00263120||187190|
NCT00263133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEP-1|Modulation of Visually Evoked Potentials by an Antidepressant|Modulation of Visually Evoked Potentials by an Antidepressant||University Hospital Freiburg||Completed|December 2005|January 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|June 1, 2007|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00263133||187189|
NCT00269529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050003|Intraarticular Analgesia After Total Knee Arthroplasty, a Randomised Study|Postoperative Analgesia After Total Knee Arthroplasty. A Comparison of Continuous Femoral Block and Extensive Intraoperative Infiltration With Local Anesthetic Supplemented With Intraarticular Bolus the Following Day.||University of Aarhus||Completed|February 2005|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||October 2006|October 12, 2006|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269529||186712|
NCT00266929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-GOF-05|Treatment of Type II Odontoid Fractures Among the Elderly|Comparing Surgical to Conservative Management in the Treatment of Type II Odontoid Fractures Among the Elderly||AOSpine North America Research Network|No|Completed|December 2005|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|159|||Both|64 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects receiving care for acute Type II Odontoid Fracture in participating        investigational sites|April 2015|May 19, 2015|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00266929||186905|
NCT00267176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2428|Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension|A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to Ibuprofen 600 mg Three Times a Day in Osteoarthritis Patients With Controlled Hypertension||Novartis||Completed|November 2005|||September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1020|||Both|50 Years|N/A||||May 2012|May 18, 2012|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00267176||186886|
NCT00267241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1600|Effects of Different Assisted Mechanical Ventilation in Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) Patients|Effects of Different Assisted Mechanical Ventilation in ALI/ARDS Patients||Policlinico Hospital|No|Completed|December 2005|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267241||186881|
NCT00263315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 191.137/2000/088|Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis|Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial.||Erasmus Medical Center||Completed|January 2000|May 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||320|||Both|18 Years|N/A|No|||August 2006|August 17, 2006|December 7, 2005||||No||https://clinicaltrials.gov/show/NCT00263315||187176|
NCT00262977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402-001|Improving Aspirin Use in Diabetes: A Cluster Randomized Trial|Improving Appropriate Aspirin Use Among Adults With Diabetes in a Primary Care Setting: Using an Electronic Medical Record to Target a Physician-supervised Nurse Practitioner Intervention||Northwestern University||Completed|September 2004|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||300|||Both|40 Years|N/A|No|||July 2010|July 21, 2010|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262977||187201|
NCT00263965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C09999|ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity|A 16-Week Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes||AstraZeneca||Terminated|August 2005|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||105|||Both|30 Years|70 Years|No|||March 2008|March 14, 2008|December 9, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00263965||187129|
NCT00264303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00394|CUTE (Chronic Urticaria Treatment Evaluation)|A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU)||UCB Pharma||Completed|December 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|886|||Both|18 Years|N/A|No|||June 2011|August 30, 2011|December 8, 2005|No|Yes||No|May 18, 2009|https://clinicaltrials.gov/show/NCT00264303||187103|
NCT00264576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P5|Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults|A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs||Novartis|No|Completed|October 2005|May 2006|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|613|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2012|December 20, 2012|December 9, 2005|Yes|Yes|||December 20, 2012|https://clinicaltrials.gov/show/NCT00264576||187082|
NCT00264927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4489|Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|SIADH|Sanofi||Completed|May 2004|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|77|||Both|18 Years|N/A|No|||December 2008|December 9, 2008|December 12, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00264927||187056|
NCT00263939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS013603|Homing in on Health: Study of a Home Delivered Chronic Disease Self Management Program|A Randomized Trial of Home Self-Efficacy Enhancement||Agency for Healthcare Research and Quality (AHRQ)|Yes|Completed|July 2004|October 2007|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|415|||Both|40 Years|N/A|No|||February 2010|October 4, 2010|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00263939||187131|
NCT00263952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0202ig|Efficacy and Safety of a Purified Standardised Bee Venom Preparation|Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.||Allergopharma GmbH & Co. KG|No|Completed|March 2003|April 2010|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 2013|March 1, 2013|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00263952||187130|
NCT00264940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-05-ZH-315-CTIL|Diagnosis of Insulin Resistance: 13C-Glucose Breath Test Vs HOMA Index.|||Tel-Aviv Sourasky Medical Center||Not yet recruiting||||||N/A|Observational|N/A|||||||Both|18 Years|80 Years||||December 2005|December 12, 2005|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00264940||187055|
NCT00264290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10775-26933-01|Valganciclovir to Reduce T Cell Activation in HIV Infection|Valganciclovir to Reduce T Cell Activation in HIV Infection||University of California, San Francisco|No|Completed|August 2006|November 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|December 9, 2005|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00264290||187104|
NCT00265291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01GM061394|Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group|||National Institute of General Medical Sciences (NIGMS)|Yes|Completed|November 1999|October 2008|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|700|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2008|October 9, 2008|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00265291||187028|
NCT00268437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N044E|Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery|A Phase II Trial of Preoperative Radiation and Chemotherapy (Pemetrexed and Carboplatin) for Locally Advanced Esophageal Cancer||Alliance for Clinical Trials in Oncology|Yes|Terminated|April 2006|March 2015|Actual|January 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|December 20, 2005|Yes|Yes|Trial closed early because, during an interim analysis, the primary endpoint fell short.|No|March 9, 2015|https://clinicaltrials.gov/show/NCT00268437||186794|
NCT00268775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOK/WINAp/CZ-01|Implementation Strategies for a Simple Intervention to Reduce Longterm Benzodiazepine Use in Dutch Community Pharmacies|Implementation Strategies Aimed at a Simple Patient-directed Intervention to Reduce Long-term Use of Benzodiazepines in Dutch Community Pharmacies||Radboud University||Completed|November 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||20000|||Both|18 Years|N/A|No|||August 2009|August 17, 2009|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268775||186769|
NCT00266786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2005-01|Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery|A Phase 3, Double-Blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain Following Major Abdominal Surgery||Luitpold Pharmaceuticals||Completed|December 2005|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|321|||Both|18 Years|64 Years|No|||May 2011|May 9, 2011|December 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266786||186915|
NCT00269750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005968|A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.|The Maximum Tolerated Dose and Minimum Effective Dose of OROS® Oxybutynin Compared to Ditropan® (Immediate-release Oxybutynin) in the Treatment of Patients With Urge or Mixed Urinary Incontinence||Alza Corporation, DE, USA||Completed|July 1996|February 1997||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|40 Years|75 Years|No|||April 2010|May 18, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269750||186697|
NCT00269763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005983|Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer|The Clinical Use and Safety of TTS (Fentanyl) in the Management of Pain in Patients With Cancer||Alza Corporation, DE, USA||Completed|October 1987|April 1988||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269763||186696|
NCT00267332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0502|Modafinil in Opioid Induced Sedation|A Randomized Double-Blinded, Placebo Controlled, Crossover Trial Examining the Effectiveness of Modafinil in Opioid Induced Sedation||Sidney Kimmel Comprehensive Cancer Center||Terminated|January 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|No|||April 2007|April 23, 2007|December 16, 2005|||Low accrual|No||https://clinicaltrials.gov/show/NCT00267332||186874|
NCT00263159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/320|Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study|Pharmaceutical Care for Asthma Control Improvement||University Ghent|No|Completed|January 2006|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|221|||Both|18 Years|50 Years|No|||December 2007|December 19, 2007|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00263159||187187|
NCT00263458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H97HA03799|Integrating Buprenorphine Into the SFGH AIDS Program|Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study)|BHIVES-SF|University of California, San Francisco|Yes|Completed|December 2005|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|19 Years|N/A|No|||September 2011|September 8, 2011|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00263458||187165|
NCT00263471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-2320|Myopia Progression and the Effect of 7-Methylxanthine|Phase 2 Study of the Effect of 7-Methylxanthine on the Progression of Childhood Myopia||Trier Research Laboratories||Active, not recruiting|October 2003|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||90|||Both|8 Years|13 Years|No|||October 2003|December 13, 2005|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00263471||187164|
NCT00263783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP065|Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors|Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors||MedImmune LLC||Completed|March 2001|June 2002|Actual|April 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||24|||Both|18 Years|18 Years|No|||January 2009|January 28, 2009|December 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00263783||187141|
NCT00269217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524B-022|Lipid Efficacy Study (0524B-022)(COMPLETED)|A Multicenter, Randomized, Double-Blind, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|January 2006|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1400|||Both|18 Years|85 Years|No|||January 2016|January 21, 2016|December 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269217||186736|
NCT00262730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0501 CDR0000454915|Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|January 2006|April 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|December 6, 2005|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00262730||187218|"Other Adverse Events" not reported for this study. Only serious(grade 3/4)related to either TMZ and/or Poly were reported. Subjects may have experienced grade 1 and grade 2 other adverse event but they have no bearing on clinical outcome of agent
NCT00266942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-109|Intra-Atrial vs. Extra-Cardiac Technique During Fontan Operation|The Determination of Differences Between Intr-Atrial vs. Extra-Cardiac Technique During the Fontan Operation: A Retrospective Review||Children's Healthcare of Atlanta|No|Terminated|January 1990|January 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||400|||Both|N/A|18 Years|No|||May 2007|May 22, 2007|December 19, 2005|||data collection ended|No||https://clinicaltrials.gov/show/NCT00266942||186904|
NCT00267215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2301|Efficacy and Safety of Lumiracoxib|A One-week Multicenter, Multiple-dose, Randomized, Double-blind, Double-dummy, Parallel-group Comparison of the Analgesic Efficacy and Safety of Lumiracoxib (COX189), Celecoxib, and Placebo in the Treatment of Osteoarthritis of the Knee||Novartis||Completed|November 2000|||February 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|50 Years|N/A||||May 2012|May 18, 2012|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00267215||186883|
NCT00263705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elderly capecitabine 1|Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study|Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study||Jules Bordet Institute|No|Completed|January 2003|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|70 Years|N/A|No|||February 2011|February 23, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00263705||187147|
NCT00263692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213503/047|Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety|Open, Randomized, Phase II, Clinical Trial to Compare the Immunogenicity and Safety of a Booster Dose of GSK Biologicals' DTaP-IPV Vaccine (Infanrix®-IPV) Co-administered With a Booster Dose of Merck and Company's M-M-R®II, to That of Separate Injections of GSK Biologicals' DTaP Vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II Administered as Booster Doses to Healthy Children 4 to 6 Years of Age.||GlaxoSmithKline||Completed|November 2002|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|401|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||February 2012|June 21, 2012|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00263692||187148|
NCT00264316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-CAR-ML2170|Bone Marrow-Derived Stem Cell Transfer in Acute Myocardial Infarctions|A Double-blind, Randomised, Controlled Study of Autologous Bone Marrow-Derived Stem Cell Transfer In Patients With ST-Segment Elevation Myocardial Infarction.||Universitaire Ziekenhuizen Leuven||Completed|May 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind||||68|||Both|18 Years|75 Years|No|||December 2005|January 16, 2013|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264316||187102|
NCT00264589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2004/APM|Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes|Effects of an Individualized Training Program on Cardiovascular Function at Rest and During Exercise in Obese and in Type 2 Diabetic Subjects||Centre Hospitalier Universitaire de Nīmes|No|Completed|December 2005|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00264589||187081|
NCT00264953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD11|HD11 for Intermediate Stages|||University of Cologne||Completed|May 1998|||January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1395|||Both|16 Years|75 Years|No|||July 2011|August 3, 2011|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00264953||187054|
NCT00265239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310|Pilot Study of Edaravone to Treat Acute Myocardial Infarction|Effects of Edaravone in Patients With Acute Myocardial Infarction||Kumamoto University||Completed|April 2001|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|N/A|N/A|No|||November 2007|September 12, 2014|December 13, 2005||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00265239||187032|
NCT00265252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fosamax 01|Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis|Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis||Kaohsiung Medical University Chung-Ho Memorial Hospital||Active, not recruiting|June 2005|June 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|20 Years|85 Years|No|||April 2007|February 26, 2008|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00265252||187031|
NCT00265629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEP-4405|RF Ablation of Atrial Fibrillation|A Clinical Investigation of Radiofrequency Ablation for the Treatment of Atrial Fibrillation Using the High Density Mesh Bard Ablation System||C. R. Bard|No|Completed|August 2005|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|85 Years|No|||June 2013|June 18, 2013|December 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00265629||187003|
NCT00265642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-006027-37|Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C|Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C|Fibrosar|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|October 2006|November 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|75 Years|No|||July 2012|February 6, 2014|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265642||187002|
NCT00268814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIS-HV9-0701|The German Project of Heroin Assisted Treatment of Opiate Dependent Patients|Phase III Study of Maintenance Treatment for Opiate Dependence With Heroin (Diamorphine) Compared to Methadone||Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|March 2002|December 2007|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|1015|||Both|23 Years|N/A|No|||September 2015|September 7, 2015|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268814||186767|
NCT00268827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70-1002-070|A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort|A Comparison of Adverse Events and Quality of Life Before and After Switching From Kaletra Soft-Gel Capsules (SGC) to Kaletra Tablets in an African American Cohort||AIDS Arms Inc.|Yes|Completed|December 2005|February 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2007|April 4, 2007|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00268827||186766|
NCT00268788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-130|Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy|A Controlled Cross-Over Trial of Subcutaneous Versus Intravenous Immunoglobulin for Multifocal Motor Neuropathy||University of Aarhus|Yes|Completed|August 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||February 2008|February 19, 2008|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268788||186768|
NCT00267046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0511|Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma|A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide||M.D. Anderson Cancer Center|Yes|Completed|December 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|49|||Both|15 Years|65 Years|No|||April 2012|April 17, 2012|December 19, 2005|Yes|Yes||No|January 18, 2012|https://clinicaltrials.gov/show/NCT00267046||186896|
NCT00267059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0175|Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)|Lenalidomide (Revlimid) in Patients With Previously Treated Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|December 2005|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|December 19, 2005|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00267059||186895|
NCT00267345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3927-JK-CTIL|Measurement of Hormonal Concentration in Chylothorax Fluid in Infants With Congenital Chylothorax|||Sheba Medical Center|Yes|Recruiting|March 2005|October 2007||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||15|||Both|N/A|10 Weeks|No|||January 2006|February 28, 2007|December 19, 2005||||No||https://clinicaltrials.gov/show/NCT00267345||186873|
NCT00267033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040426|Evaluation of Vertebroplasty Associated With Radiotherapy for Spine Metastases (EVAR)|Randomized Trial of Vertebroplasty and Radiotherapy Versus Radiotherapy Alone for Osseous Spine Metastases||Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2005|August 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|186|||Both|18 Years|N/A|No|||March 2007|December 1, 2008|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267033||186897|
NCT00262847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00590|Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer||National Cancer Institute (NCI)|Yes|Completed|September 2005|July 2015|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1873|||Female|18 Years|N/A|No|||February 2015|August 18, 2015|December 6, 2005|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00262847||187210|
NCT00263146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAMIS|Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers.|Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory (ARAMIS: Apport d'un Recrutement Alveolaire Sur Les Marqueurs de l'Inflammation Dans le SDRA)||University Hospital, Tours|Yes|Terminated|September 2005|February 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||February 2010|February 2, 2010|December 5, 2005|||Lack of inclusion due to changed medical practice|No||https://clinicaltrials.gov/show/NCT00263146||187188|
NCT00268918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-020|Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients|A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients||Dana-Farber Cancer Institute|Yes|Completed|September 2005|January 2011|Actual|January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||April 2015|April 8, 2015|December 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268918||186759|
NCT00269516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.3.001|SLV308 for Treatment of Patients With Early Parkinson's Disease|A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease||Solvay Pharmaceuticals|Yes|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|468|||Both|30 Years|N/A|No|||August 2008|August 28, 2008|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269516||186713|
NCT00263029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8479|Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer|Pre-operative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer (PROCTFUL)|PROCTFUL|Sanofi||Completed|June 2002|||March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|75 Years|No|||September 2008|September 17, 2009|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00263029||187197|
NCT00263003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0094|Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension|A Randomized, Open Label Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension||Sanofi||Completed|June 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|20 Years|70 Years|No|||December 2007|December 6, 2007|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00263003||187199|
NCT00263367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDRC-22.2005|Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism|Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism: A Pilot Study||The International Child Development Resource Center|Yes|Completed|October 2005|February 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|5 Years|12 Years|No|||June 2011|June 21, 2011|November 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00263367||187172|
NCT00263380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD IL8|Investigation on the Role of Corticosteroids and Beta-Agonists on Cytokine Production in COPD Patients|Experimental Study on the Role of Corticosteroids and Beta-Agonists on Cytokine Production in COPD Patients||St. Antonius Hospital||Recruiting|October 2005|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||90|||Both|40 Years|N/A|Accepts Healthy Volunteers|||July 2005|September 8, 2006|December 7, 2005||||No||https://clinicaltrials.gov/show/NCT00263380||187171|
NCT00263978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-2005|Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver|Defibrotide Compassionate Use Protocol for Patients With Life Threatening Veno-Occlusive Disease of the Liver||Emory University|No|No longer available|November 2005|June 2009|Actual|June 2009|Actual|N/A|Expanded Access|N/A|||||||Both|1 Year|22 Years|No|||June 2014|June 27, 2014|December 9, 2005||No|poor enrollment|No||https://clinicaltrials.gov/show/NCT00263978||187128|
NCT00263991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 05085|Cortical Reorganisation in Patients With Primary Headache Disorders|Cortical Reorganisation in Patients With Primary Headache Disorders||Danish Headache Center||Active, not recruiting||||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2005|December 9, 2005|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00263991||187127|
NCT00264004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00038|Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours|A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients With Advanced Solid Tumours||AstraZeneca||Completed|November 2005|April 2011|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|December 9, 2005|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT00264004||187126|
NCT00264017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L0087|Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis|Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis||Dattoli Cancer Center and Brachytherapy Research Institute||Completed|November 2005|November 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||60|||Male|45 Years|80 Years||||November 2005|December 6, 2005|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00264017||187125|
NCT00264329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DA016211|Transitional Case Management Study|Transitional Case Management Study||University of California, Los Angeles||Completed|November 2004|May 2008|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|812|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|December 8, 2005||No||No||https://clinicaltrials.gov/show/NCT00264329||187101|
NCT00264966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASM8-003|Multiple Dose ASM8 in Mild Asthmatics|A Double-blind, Placebo-controled, Crossover Study To Evaluate the Efficacy, Safety and Tolerability of Inhaled ASM8-003 in Subjects With Mild Allergic Asthma.||Pharmaxis|No|Completed|December 2005|April 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||November 2012|November 30, 2012|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00264966||187053|
NCT00265265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0010-1|Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1|Phase 1, Double-Blind, Placebo-Controlled Multiple Dose Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine||National Institute on Drug Abuse (NIDA)||Completed|August 2005|||September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|45 Years|No|||January 2013|January 23, 2013|December 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265265||187030|
NCT00265278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0008-1|Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1|Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil||National Institute on Drug Abuse (NIDA)||Active, not recruiting|March 2005|March 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|45 Years|No|||December 2005|October 25, 2007|December 13, 2005||||||https://clinicaltrials.gov/show/NCT00265278||187029|
NCT00274391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DONALDS00A0|Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis|Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis||University of North Carolina, Chapel Hill||Completed|July 2001|April 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||24|||Both|14 Years|N/A|No|||December 2005|January 9, 2006|January 9, 2006||||||https://clinicaltrials.gov/show/NCT00274391||186346|
NCT00266149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMS: j.nr. 2612-2188|Lamotrigine and Oral Contraceptives|Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives||University of Aarhus||Terminated|June 2003|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Female|18 Years|40 Years|No|||December 2005|April 23, 2008|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00266149||186964|
NCT00266162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 3.2|Bosentan in Treatment of Pulmonary Arterial Hypertension|Therapy of Pulmonary Arterial Hypertension (PAH) With Bosentan in Patients With Eisenmenger Syndrome||Competence Network for Congenital Heart Defects|No|Completed|August 2004|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266162||186963|
NCT00269178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC L2002.69|Cluster Randomized Trial of Peer Health Education in Malaria in The Gambia|Cluster Randomized Trial of the Impact of a Peer-Health Education Programme on Malaria Knowledge Attitudes and Practice in Students and Their Families||London School of Hygiene and Tropical Medicine||Completed|August 2003|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||960|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2003|January 31, 2006|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269178||186739|
NCT00263484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQMM01(dtZ)|Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma|An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma|dtZ|Gleneagles Hospital|Yes|Completed|December 2005|October 2010|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|21 Years|N/A|No|||July 2011|July 19, 2011|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263484||187163|
NCT00267358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-1291-205|Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.|||Helsinn Therapeutics (U.S.), Inc||Completed|November 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||||||Both|18 Years|N/A|No|||August 2013|August 30, 2013|December 19, 2005||||||https://clinicaltrials.gov/show/NCT00267358||186872|
NCT00262834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00098|Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer|A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer||National Cancer Institute (NCI)||Completed|October 2005|May 2013|Actual|October 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||June 2014|August 28, 2014|December 6, 2005|No|Yes||No|July 10, 2013|https://clinicaltrials.gov/show/NCT00262834||187211|The main limitation of the trial is the unexpectedly low proportion of matched evaluable samples available for the biomarkers studied, ranging from 44% to 92%.
NCT00264095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003460|An Observational Study of Blood Management Techniques in Oncology Surgical Treatment|Blood Management Observation in Oncology Surgical Treatment (BOOST)||Janssen-Cilag B.V.||Completed|July 2004|February 2006|Actual|February 2006|Actual|Phase 4|Observational|Time Perspective: Cross-Sectional||1|Actual|488|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a malignant tumour for which surgery is the primary treatment and a minimal        blood loss of 500 ml. and a maximum blood loss of 3000 ml. is expected.|April 2014|April 25, 2014|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264095||187119|
NCT00264108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002455|Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia|EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE).||Janssen-Cilag B.V.||Completed|June 2005|February 2011|Actual|February 2011|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|492|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients receiving epoetin- or darbepoetin alfa as anemia treatment during        chemotherapy, as part of the common practice of participating physicians. Patients may        enter the study as soon as either their epoetin alfa or their darbepoetin alfa treatment        starts.|May 2014|May 6, 2014|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264108||187118|
NCT00268931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24098|Development Training in Babies Born Preterm|Enhanced Developmental Training Experiences in Babies Born Preterm||Christiana Care Health Services|No|Completed|August 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|32|||Both|6 Weeks|11 Weeks|No|||April 2013|April 12, 2013|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268931||186758|
NCT00268567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLLNT-2002HL0133|Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone|Phase 3 Study of Leflunomide Combined With Prednisone Treatment of Proliferative Lupus Nephritis as Induction Therapy||Peking University||Completed|October 2002|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||October 2004|December 21, 2005|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268567||186784|
NCT00269230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234|Attain StarFix™ Model 4195 Left Ventricular Lead|Attain StarFix™ Model 4195 Left Ventricular Lead||Medtronic Cardiac Rhythm Disease Management|No|Completed|July 2004|July 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|441|||Both|18 Years|N/A|No|||October 2008|November 18, 2008|December 21, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00269230||186735|
NCT00262769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455013|Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors|Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study|ABC-02|University College, London|Yes|Completed|May 2005|||August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|324|||Both|16 Years|N/A|No|||July 2012|July 16, 2012|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262769||187216|
NCT00263328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921021|Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient|A Multicenter, Phase 2, Open-label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 Versus Tacrolimus, When Co-administered With Mycophenolate Mofetil In Renal Allograft Recipients||Pfizer|No|Completed|December 2005|June 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|46|||Both|18 Years|70 Years|No|||June 2015|June 16, 2015|December 6, 2005|Yes|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT00263328||187175|
NCT00263341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 300|Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol|A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150 ug of Nestorone® and 15 ug of Ethinyl Estradiol||Population Council||Active, not recruiting|December 2005|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|December 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00263341||187174|
NCT00263354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8915|Oxaliplatin in Gastric Cancer|Oxaliplatin Phase II Trial in Association With 5FU and Folinic Acid in the Treatment of Advanced Unresectable or Metastatic Gastric Cancer.||Sanofi||Completed|October 2003|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||August 2010|November 5, 2010|December 7, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00263354||187173|
NCT00263393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-CA-RAP-A|Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)|Evaluation of a Primary Health Care Intervention for the Prevention of Cardiovascular Disease in Rural Andhra Pradesh|RAPCAPS|The George Institute||Completed|December 2005|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3712|||Both|30 Years|N/A|No|||June 2012|June 21, 2012|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00263393||187170|
NCT00263718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0202 INT|Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle Alone in Psoriasis Vulgaris||LEO Pharma||Completed|December 2005|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|December 8, 2005||||No||https://clinicaltrials.gov/show/NCT00263718||187146|
NCT00264030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC00-02|Distal Protection Combined With PTCA in AMI Patients|Distal Protection Combined With PTCA in AMI Patients -- The DIPLOMAT Study.|DIPLOMAT|Cordis Corporation|Yes|Completed|March 2002|August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||January 2008|January 4, 2008|December 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00264030||187124|
NCT00264043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC99-09|The Study to Evaluate Patient Outcome Using Distal Protection Combined With the BX Velocity.|Distal Protection Combined With Velocity in Coronary Arteries and SVBG Registry.|DISCOVER|Cordis Corporation|Yes|Completed|May 2000|June 2002|Actual|February 2002|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||August 2008|August 5, 2008|December 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00264043||187123|
NCT00264342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA078603-05A1|Effectiveness of Using Reduced Nicotine Cigarettes in Men and Women Smokers to Combat Nicotine Addiction|Safety of Nicotine Reduction Strategy||University of California, San Francisco|Yes|Completed|July 2005|July 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|135|Samples Without DNA|Tissue (blood) and urine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Health adults 18 and over|May 2013|May 21, 2013|December 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00264342||187100|
NCT00264602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-219|Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer|Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer||Dana-Farber Cancer Institute|No|Recruiting|January 2009|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|114|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00264602||187080|
NCT00264615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEP103944|Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa|An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa||GlaxoSmithKline||Completed|October 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment||||45|||Both|13 Years|N/A|No|||April 2015|April 14, 2015|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264615||187079|
NCT00264979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2005/0193|Evaluation of 2 Resection Strategies of Synchronous Colorectal Cancer Metastases|Prospective Randomized Study Comparing the Morbidity and Mortality After Liver Resection for Synchronous Colorectal Cancer Metastases When Performed Either During or 12 to 14 Weeks After the Primary Resection|METASYNC|Rennes University Hospital|Yes|Recruiting|December 2005|December 2019|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00264979||187052|
NCT00274781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF6818|Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes|A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome||The Cleveland Clinic|No|Completed|February 2004|November 2010|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|January 10, 2006|Yes|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT00274781||186317|
NCT00266513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060049|Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States|Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States||National Institutes of Health Clinical Center (CC)||Terminated|December 2005|July 2013||||N/A|Observational|N/A|||Actual|119|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2013|October 4, 2014|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00266513||186936|
NCT00266500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060038|Body Heat Content and Dissipation in Obese and Normal Weight Adults|Body Heat Content and Dissipation in Obese and Normal Weight Adults||National Institutes of Health Clinical Center (CC)||Completed|December 2005|October 2014||||N/A|Observational|N/A|||Actual|80|||Both|18 Years|70 Years|No|||October 2014|October 29, 2014|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00266500||186937|
NCT00266799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04445|The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)|A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (PELICAN Trial)||Merck Sharp & Dohme Corp.|No|Completed|January 2006|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Female|18 Years|N/A|No|||February 2015|February 6, 2015|December 15, 2005|No|Yes||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00266799||186914|
NCT00267969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006328|A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis|PHOENIX1|Centocor Research & Development, Inc.|Yes|Completed|December 2005|May 2011|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|766|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|December 20, 2005|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00267969||186827|The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.
NCT00263796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 04-0749 (2)|An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism|An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism||Anagnostou, Evdokia, M.D.|Yes|Completed|March 2006|September 2012|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|50 Years|No|||April 2014|April 28, 2014|December 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00263796||187140|
NCT00268541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03BI004|Physical Activity, Insulin Resistance and Function of Fat Tissue in the Offspring of Patients With Type 2 Diabetes|Physical Activity, Insulin Resistance and Adipose Tissue Gene Expression in the Offspring of Patients With Type 2 Diabetes||NHS Greater Glasgow and Clyde||Completed|September 2004|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268541||186786|
NCT00268554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PORH-dipy|Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole|Enhancement of Postocclusive Reactive Hyperaemia||Radboud University|Yes|Completed|December 2005|July 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 27, 2008|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268554||186785|
NCT00268970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT2-05-05|Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer|Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-small Cell Lung Cancer (NSCLC)||Agennix||Completed|December 2005|September 2009|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268970||186755|
NCT00268983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/028|Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma|A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma||GlaxoSmithKline|No|Completed|October 2004|June 2013|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2014|June 26, 2014|December 21, 2005|Yes|Yes||No|June 29, 2010|https://clinicaltrials.gov/show/NCT00268983||186754|
NCT00269269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|348|Conditioned Placebo Effects and Treatment of Hypertension|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|N/A|100 Years|No|||January 2008|February 17, 2016|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269269||186732|
NCT00268944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03105|Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support|Prospective, Open-label, Single-arm, Exploratory Study of the Effect and Safety of rhGAA in Patients With Advanced Late-onset Pompe Disease Who Are Receiving Respiratory Support||Sanofi||Completed|December 2005|June 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268944||186757|
NCT00262782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455035|Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia|Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Active, not recruiting|April 1997|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||December 2007|November 5, 2013|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00262782||187215|
NCT00263042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5826|Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes|Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors|CRESCENDO|Sanofi|Yes|Terminated|December 2005|April 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18695|||Both|55 Years|N/A|No|||August 2009|August 27, 2009|December 6, 2005|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00263042||187196|
NCT00263055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R_9262|MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV|Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV||Sanofi||Completed|August 2004|||June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00263055||187195|
NCT00272441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350|Prevention of Early Asthma in Kids (PEAK)|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 2001|September 2004||||N/A|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||||||Both|N/A|18 Years|No|||January 2008|January 18, 2008|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00272441||186495|
NCT00272454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOP-PLT-0501|Cilostazol in Acute Ischemic Stroke Treatment (CAIST)|The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke||Korea Otsuka Pharmaceutical Co.,Ltd.||Completed|January 2006|September 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|468|||Both|30 Years|85 Years|No|||December 2009|December 15, 2009|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00272454||186494|
NCT00272740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238SZ/0001|SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer|An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors||AstraZeneca||Completed|March 2000|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||93|||Female|N/A|N/A|No|||February 2007|February 8, 2007|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272740||186472|
NCT00263731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|523.05|Metabolomic Analysis of Lung Cancer|Preoperative Metabolomic Analysis of Primary Lung Cancer: A Translational Clinical Trial of the Brown Cancer Center||James Graham Brown Cancer Center|Yes|Recruiting|December 2005|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|750|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Group 1 (experimental group): 250 lung cancer patients undergoing surgery, with             13-C-glucose infusion);          -  Group 2 (control group): 250 lung cancer patients undergoing surgery, without             13-C-glucose infusion); and          -  Group 3 (healthy subjects): 250 subjects to provide 1 blood sample and 1 urine             sample.|January 2016|February 29, 2016|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263731||187145|
NCT00263744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP058|Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive|A Phase I/II Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus (HPV) Types 16 and 18, in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive||MedImmune LLC||Completed|November 1999|June 2001|Actual|April 2001|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||January 2009|January 7, 2009|December 8, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00263744||187144|
NCT00273039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKF100110|A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder||GlaxoSmithKline||Completed|August 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|242|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|January 5, 2006||||||https://clinicaltrials.gov/show/NCT00273039||186449|
NCT00273052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR103561|COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension|A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) With Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients||GlaxoSmithKline|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|514|||Both|18 Years|80 Years|No|||July 2012|July 11, 2013|January 5, 2006|||||December 19, 2008|https://clinicaltrials.gov/show/NCT00273052||186448|
NCT00273338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-007|DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])|A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)||Novacea||Terminated|January 2006|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1200|||Male|18 Years|N/A|No|||November 2007|November 2, 2007|December 14, 2005|||DSMB|||https://clinicaltrials.gov/show/NCT00273338||186426|
NCT00273624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Olanzapine Augmentation|Olanzapine Augmentation Therapy in Treatment-Resistant Depression: a Double-Blind Placebo-Controlled Trial|Olanzapine Augmentation Therapy in Treatment-Resistant Depression: a Double-Blind Placebo-Controlled Trial||University Hospital Freiburg|No|Recruiting|June 2005|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2009|February 17, 2009|January 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00273624||186404|
NCT00264628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SND103929|GW679769 In Fibromyalgia|An Outpatient, Randomised, Double-blind, Placebo Controlled, Parallel Group Exploratory Study to Evaluate Safety, Tolerability and Efficacy of GW679769 in Patients With Fibromyalgia Syndrome Comorbid With Depression.||GlaxoSmithKline||Completed|October 2005|September 2006|Actual|September 2006|Actual|N/A|Observational|N/A||1|Actual|8|||Both|18 Years|65 Years|No|||April 2015|April 15, 2015|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264628||187078|
NCT00264641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-2-15|The Impact of Renin-Angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study|The Impact of Renin-Angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study||Hypoglycaemia Research Group||Active, not recruiting|January 2006|December 2006||||N/A|Observational|Time Perspective: Cross-Sectional||||20|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2006|March 27, 2006|December 12, 2005||||No||https://clinicaltrials.gov/show/NCT00264641||187077|
NCT00264992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE-STUDY|Implantation and Cytokine Expression|The Cytokine Paired Footprint of Successful Implantation||UMC Utrecht||Completed|January 2006|November 2007|Actual|November 2007|Actual|N/A|Observational|Time Perspective: Prospective||||160|||Female|N/A|N/A|No|||May 2008|May 27, 2008|December 9, 2005||||No||https://clinicaltrials.gov/show/NCT00264992||187051|
NCT00265005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tPA 255-04|Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants|Dose-Ranging, Safety And Efficacy Of Cathflo(TM) Activase(R) (Alteplase) For The Treatment Of Central Catheter Occlusion In Neonates And Infants; Phase I||University of Louisville|Yes|Terminated|June 2005|December 2012|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|28 Weeks|66 Weeks|No|||December 2015|March 8, 2016|December 12, 2005|Yes|Yes|difficulty in recruiting subjects|No||https://clinicaltrials.gov/show/NCT00265005||187050|
NCT00265018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD10|HD10 for Early Stages|||University of Cologne||Completed|May 1998|||January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1370|||Both|16 Years|75 Years|No|||July 2011|July 28, 2011|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00265018||187049|
NCT00266175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 1|Pulmonary Arteriopathy-Diagnostics and Therapy|Pulmonary Arteriopathy; Evaluation of Invasive Treatments of Peripheral Pulmonary Stenosis in Terms of Right Ventricular Function and Patient Exercise Tolerance||Competence Network for Congenital Heart Defects|No|Completed|May 2005|July 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|53|||Both|6 Years|N/A|No|||October 2008|October 14, 2008|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266175||186962|
NCT00262860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448635|Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma||University of Rochester|Yes|Completed|April 2005|||May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262860||187209|
NCT00266812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04071|Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)|Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy Followed by Sequential TMZ in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Central Nervous System (CNS) Metastasis Versus Radiotherapy Alone||Merck Sharp & Dohme Corp.|No|Terminated|March 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|December 16, 2005||No|Patient target could not be reached within the planned timeframe.|No|July 29, 2009|https://clinicaltrials.gov/show/NCT00266812||186913|
NCT00263172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS# 03-022|Weight Loss on the Web: A Pilot Study Comparing a Commercial Website to a Structured Behavioral Intervention|||University of Vermont||Completed|February 2003|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|January 21, 2010|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00263172||187186|
NCT00267657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0006-1|A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1|Assessment of Interactions Between IV Methamphetamine and Reserpine||National Institute on Drug Abuse (NIDA)||Active, not recruiting|January 2004|November 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|21 Years|45 Years|No|||December 2005|October 25, 2007|December 20, 2005||||||https://clinicaltrials.gov/show/NCT00267657||186849|
NCT00267670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 1347-001|Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH|The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH)||Northwestern University|No|Completed|March 2005|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||August 2014|August 27, 2014|December 12, 2005|Yes|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00267670||186848|The most significant limitation of this study is the small sample size, thus the lack of statistical significance may be due to low power.
NCT00268229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-6441|Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML||The Cleveland Clinic||Completed|July 2003|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|December 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00268229||186808|
NCT00268242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-7725|Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse||The Cleveland Clinic|No|Terminated|January 2006|July 2011|Actual|August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 30, 2015|December 20, 2005||No|If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients    (21%) of 24 enrolled patients had a CR so the study was terminated.|No|June 3, 2015|https://clinicaltrials.gov/show/NCT00268242||186807|If </= 5 of 1st 18 pts had a CR, study would stop (otherwise, another 22 pts would be accrued). Study would stop if >4 of 1st 10 or 10 of 1st 25 pts had unacceptable toxicity per protocol & Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0
NCT00269581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9578|Headstrong Intervention for Pediatric Headache|Headstrong Intervention for Recurrent Pediatric Headache||University of Kansas Medical Center|Yes|Completed|August 2004|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|7 Years|12 Years|No|||September 2012|September 24, 2012|December 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00269581||186708|
NCT00269282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|321|Increasing Adherence to Asthma Medication in Urban Teens|Motivating Asthma Adherence in Urban Teens||Johns Hopkins University|Yes|Completed|May 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|10 Years|15 Years|No|||January 2013|January 11, 2013|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00269282||186731|
NCT00269295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-084|TY800 Dose Escalation (Typhoid)|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, In-Patient Phase I/II Study to Determine the Safety and Immunogenicity of Ty800 in Healthy Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2006|January 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|47|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|June 9, 2011|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269295||186730|
NCT00276393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70-02|Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes|Randomized Trial Comparing Insulin Glargine to Ultra-Lente Insulin in Type I Diabetes||Mayo Clinic||Completed|July 2002|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||22|||Both|18 Years|80 Years|No|||May 2011|May 20, 2011|January 11, 2006||||No||https://clinicaltrials.gov/show/NCT00276393||186200|
NCT00263068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0793|An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome|An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome||UCB Pharma||Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|279|||Both|18 Years|N/A||||September 2009|September 24, 2014|December 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00263068||187194|
NCT00263081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-475-016|Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia|A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia.||Takeda|No|Terminated|November 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|8 Years|N/A|No|||May 2012|May 23, 2012|December 6, 2005|Yes|Yes|Overall profile of the compound does not offer significant clinical advantage to patients over    currently available lipid lowering agents|No||https://clinicaltrials.gov/show/NCT00263081||187193|
NCT00272753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN-00S-0022|Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations|A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler (Budesonide/Formoterol Combination), Formoterol, Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma. Investigating the Supplementary Value of the Budesonide Component Within Symbicort When Tested in a Model of Slow Onset Acute Asthma||AstraZeneca|No|Completed|April 2004|November 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|55 Years|No|||May 2011|May 31, 2011|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272753||186471|
NCT00272714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-4OHT-02|Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women|A Phase II, Randomized, Double-Blind, Two-Dose, Placebo-Controlled Multicentre Study of 4-Hydroxy Tamoxifen Gel for Cyclical Mastalgia in Otherwise Healthy Pre-Menopausal Women With Regular Menstrual Cycles.||ASCEND Therapeutics|No|Completed|March 2003|April 2005|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|146|||Female|18 Years|N/A|No|||July 2013|July 11, 2013|January 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00272714||186474|
NCT00272727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RDK-DUM-2005/1|Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver|Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver||AstraZeneca||Completed|February 2006|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||100|||Both|18 Years|40 Years|No|||January 2011|January 21, 2011|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00272727||186473|
NCT00273637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STVincentH|Registry and Survey of Women With Pregnancy Related Cardiomyopathy|Pregnancy Related Cardiomyopathy Enrollment and Lessons in Web-Based Recruitment (PRiCELESS)||St. Vincent's Medical Center||Recruiting|October 2005|January 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||175|||Female|18 Years|50 Years|No|||October 2005|May 25, 2006|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273637||186403|
NCT00273858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101695|Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis|Open Label Study To Evaluate The Safety Profile And The Quality Of Life In Patients Receiving Etanercept For The Treatment Of Rheumatoid Arthritis, Ankylosing Spondylitis And Psoriatic Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|March 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|880|||Both|18 Years|N/A|No|Non-Probability Sample|Rheumatoid Arthritis Patients, Psoriatic Arthritis Patients, Ankylosing Spondylitis        Patients|September 2011|September 8, 2011|January 4, 2006||No|The study was terminated because at least one year follow-up was achieved for each patient and    the achievement of 965 exposure years to the drug.|No|June 30, 2011|https://clinicaltrials.gov/show/NCT00273858||186386|
NCT00273845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-407-10|Reducing Barriers to Drug Abuse Treatment Services|Reducing Barriers to Drug Abuse Treatment Services|RBP|Wright State University|Yes|Completed|May 2003|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|678|||Both|18 Years|N/A|No|||February 2009|February 23, 2009|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273845||186387|
NCT00274144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.385|Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism|Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism||Boehringer Ingelheim||Completed|December 2001|May 2004||March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|19 Years|N/A|No|||October 2013|October 31, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274144||186365|
NCT00274131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.506|Long-term Administration Study of SND 919 Tablets in Parkinson's Disease|Long-term Administration Study of SND 919 Tablets in Parkinson's Disease||Boehringer Ingelheim||Completed|December 1998|February 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||170|||Both|20 Years|N/A|No|||May 2012|May 18, 2012|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274131||186366|
NCT00267371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202-001|ESCAPE Migraine Trial|Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial||St. Jude Medical|Yes|Terminated|November 2005|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|70 Years|No|||May 2014|May 19, 2014|December 16, 2005|Yes|Yes|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00267371||186871|
NCT00267644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-09-VA03|Ultrasound of the Inferior Vena Cava (IVC) and Dehydration Status in Pediatric Emergency Patients|Ultrasound of the Inferior Vena Cava (IVC) and Dehydration Status in Pediatric Emergency Patients||Maimonides Medical Center|Yes|Completed|December 2005|September 2009|Actual|September 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|76|||Both|1 Month|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Any ED patient 1-month to 41 months of age presenting to the ED with a History or        vomiting, Diarrhea or decreased PO intake|April 2013|April 18, 2013|December 19, 2005||No||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00267644||186850|
NCT00267683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1667|Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes|A Clinical Trial to Study the Efficacy and Safety of Insulin Aspart Three Times Per Day Compared to Glibenclamide Once or Twice Daily in Type 2 Diabetes by Comparison of Ability to Control Blood Glucose||Novo Nordisk A/S|No|Terminated|December 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|9|||Both|20 Years|N/A|No|||March 2016|March 3, 2016|December 20, 2005|||This trial was terminated due to low recruitment|No||https://clinicaltrials.gov/show/NCT00267683||186847|
NCT00268008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-033|Children and Adolescents Receiving Mechanical and Prosthetic Valves|Retrospective Review of Children and Adolescents Receiving Mechanical and Prosthetic Valves in the Aortic and Mitral Position 1976-2002||Children's Healthcare of Atlanta||Terminated|January 1976|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|21 Years|No|||May 2007|May 3, 2007|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268008||186824|
NCT00267982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-064|Radiofrequency Ablation of Ectopic Atrial Tachycardia|A Retrospective Review of Outcomes Related to Radiofrequency Ablation of Ectopic Atrial Tachycardia||Children's Healthcare of Atlanta|No|Terminated|August 1992|February 2008|Actual|August 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Both|N/A|21 Years|No|Non-Probability Sample|The study population is subjects received RFA for treatment of EAT between August 2992 and        August 2003 at Children's Healthcare of Atlanta|June 2011|July 5, 2011|December 20, 2005||No|significant conclusive data has been collected|No||https://clinicaltrials.gov/show/NCT00267982||186826|
NCT00267995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-047|Ross Aortic Valve Replacement Patients|Proposal for Retrospective Review of Ross Aortic Valve Replacement Patients||Children's Healthcare of Atlanta|No|Terminated|December 1994|||||N/A|Observational|Time Perspective: Retrospective||1|Actual|75|||Both|N/A|21 Years|No|Non-Probability Sample|Retro chart review|May 2007|July 5, 2011|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00267995||186825|
NCT00268580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-782-04|Evaluation of the Emergency Department Asthma Care Project|Evaluation of the Emergency Department Asthma Care Project||Queen's University|No|Completed|January 2006|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||300|||Both|19 Years|N/A|No|||January 2006|June 1, 2007|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268580||186783|
NCT00268957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD3-199-301|Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis|A Randomized, Parallel, Open-Label Study to Compare Once Per Day Sevelamer Carbonate Powder Dosing With Three Times Per Day Sevelamer Hydrochloride Tablet Dosing in Chronic Kidney Disease Patients on Hemodialysis||Sanofi||Completed|January 2006|May 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|December 22, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00268957||186756|
NCT00269022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-705498/008|Use Of SB-705498 In The Acute Treatment Of Migraine|A Single Blind, Placebo Controlled, Multi-Centre Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of the TRPV1 Antagonist SB-705498 Against the Pain of Acute Migraine.||GlaxoSmithKline||Completed|January 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|1|||70|||Both|18 Years|65 Years|No|||May 2009|May 15, 2009|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269022||186751|
NCT00269893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006268|A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty|A Phase III Double-Blind, Placebo-Controlled Multicenter Study of Abciximab In Patients Undergoing High Risk Coronary Angioplasty (EPIC)||Centocor, Inc.|Yes|Completed|November 1991|November 1992|Actual|November 1992|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2038|||Both|18 Years|80 Years|No|||June 2015|June 1, 2015|December 22, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00269893||186686|
NCT00272168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3437-R|The Use of Skills Training to Augment CWT/VI for Veterans With SMI|The Use of Skills Training to Augment CWT/VI for Veterans With SMI|MPROVE|VA Office of Research and Development||Completed|October 2005|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||April 2015|April 27, 2015|December 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00272168||186515|
NCT00272181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB4-845-01-IIA|Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer|A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease||Viventia Bio|No|Terminated|January 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|January 3, 2006|No|Yes|Slow accrual in North America|No||https://clinicaltrials.gov/show/NCT00272181||186514|
NCT00273091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version vom 10.07.2003|MODULA Modul 5 BEAT-HF|MODULA-Study: Modul 5 / BEAT HF: Detektion and Registration of Atrial Tachyarrhythmias at Patients With Heart Failure||Guidant Corporation||Completed|August 2003|May 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Elegible patients comprise the investiagators standard CRT-D population.|April 2009|March 9, 2015|January 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00273091||186445|
NCT00272142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNI 04002|Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial|Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial||Society for Applied Studies|No|Completed|January 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|2000|||Both|N/A|28 Days|Accepts Healthy Volunteers|||September 2009|September 2, 2009|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00272142||186517|
NCT00273065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCUCH-AR-NEOSAX-0001|Local Anesthetic Properties of Neosaxitoxin|Phase 1 Study of Local Infiltration of Neosaxitoxin as a Local Anesthetic||University of Chile||Completed|May 2005|September 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2007|February 16, 2007|January 4, 2006||||No||https://clinicaltrials.gov/show/NCT00273065||186447|
NCT00273078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.390|Tongue Pressure Recording During Speech|Experimental Study About Tongue Interactions With Teeth and Palate During Speech, Using Strain Gauge Transducer and Complete Denture. Comparison of Adaptation Phenomenon’s Between Patients With New Complete Denture.||Hospices Civils de Lyon||Recruiting|January 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||20|||Both|18 Years|90 Years||||April 2007|April 26, 2007|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273078||186446|
NCT00274170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2006.014|Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache|Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache||C.R.Darnall Army Medical Center||Recruiting|January 2006|February 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274170||186363|
NCT00274183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94034|Nonalcoholic Fatty Liver Disease in Taiwanese Children|Prevalence, Clinicopathological Characteristics, Biomarkers and Genetics of Nonalcoholic Steatohepatitis in Taiwanese Children||Far Eastern Memorial Hospital|Yes|Recruiting|January 2006|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Serum, WBC DNA|Both|6 Years|18 Years|No|Probability Sample|Obese children will be enrolled from elementary school and high school in Taiwan|September 2015|October 12, 2015|January 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00274183||186362|
NCT00274417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVA-001|Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)|A Randomized, Placebo-Controlled, Double-Blind Study of the Use of Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP Study)||Urology of Virginia||Active, not recruiting|January 2006|May 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Male|50 Years|N/A|No|||April 2007|April 17, 2007|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274417||186344|
NCT00274430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|margherita03|Prevention of High Altitude Pulmonary Edema|A Randomized Controlled Trial of the Effects of Tadalafil and Dexamethasone Versus Placebo on Pulmonary Edema Formation and Cerebral Blood Flow Autoregulation in High Altitude Newcomers With a Previous History of High Altitude Pulmonary Edema||University of Zurich||Completed|July 2003|September 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2003|November 30, 2006|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274430||186343|
NCT00274157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRE-PAD|FIRE-PAD: Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease|Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease (FIRE-PAD). Effects of Catheter-Based Revascularization on Functional Capacity, Quality of Life, and the Cardiovascular Risk Profile of Patients With Intermittent Claudication||The Cleveland Clinic||Terminated|March 2007|March 2008|Actual|March 2008|Actual|Phase 2|Observational|Time Perspective: Prospective|||Anticipated|37|||Both|40 Years|85 Years|No|||June 2008|June 26, 2008|January 9, 2006||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT00274157||186364|
NCT00274404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311M53430|Controlled Trial of Valacyclovir in Infectious Mononucleosis|Randomized Study Assessing the Antiviral Activity and Safety of Valacyclovir in Primary Infectious Mononucleosis||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2004|September 2005|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|January 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00274404||186345|
NCT00271440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-HD44004-2|Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal|Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal|NNIPS-SFS|Johns Hopkins Bloomberg School of Public Health|No|Completed|January 2006|April 2006|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|286|||Both|N/A|3 Days|Accepts Healthy Volunteers|||April 2010|April 2, 2010|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271440||186568|
NCT00271908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 040b|C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions|Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation||Westat|Yes|Completed|February 2007|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|4472|||Both|12 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Each site's population of focus was determined during C2P's Phase I (ATN 016a) and is one        of the following: young women who have sex with men (YWSM), young men who have sex with        men (YMSM), or young users of drugs. For each population, the age range must fall between        12 and 24 years, inclusive.|March 2016|March 1, 2016|December 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00271908||186534|
NCT00271921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK66033 (completed)|Does Metabolic Syndrome Exist in Anorexia Nervosa?|Does Metabolic Syndrome Exist in Anorexia Nervosa?||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|September 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|December 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00271921||186533|
NCT00271934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU95LU1|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Poor Prognostic Indicators and Systemic Lupus Erythematosus:A Phase II Study||Northwestern University|No|Completed|September 2002|April 2012|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|60 Years|No|||April 2012|April 9, 2012|January 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00271934||186532|
NCT00268593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR88206|Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer|A Randomised Phase II Study of Two Dose Schedules of PI-88 in Combination With Docetaxel in Patients With Androgen-independent Prostate Cancer||Progen Pharmaceuticals||Completed|August 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|N/A|No|||June 2011|June 13, 2011|December 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268593||186782|
NCT00268255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447160|Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer|Phase I/II Study of Induction Gefitinib and Concurrent Radiotherapy in Patients With Previously Untreated, Medically Inoperable Stage I or II Non-Small Cell Lung Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|December 20, 2005|Yes|Yes|Study never moved forward with accrual.|No||https://clinicaltrials.gov/show/NCT00268255||186806|
NCT00268281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238|Left Ventricular Capture Management (LVCM) Software Download Clinical Trial|Left Ventricular Capture Management (LVCM) Software Download Clinical Trial||Medtronic Cardiac Rhythm Disease Management||Completed|December 2004|July 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||107|||Both|18 Years|N/A|No|||October 2006|October 11, 2006|December 21, 2005||||||https://clinicaltrials.gov/show/NCT00268281||186805|
NCT00269308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP01425|Chiropractic and Exercise for Seniors With Neck Pain|Randomized Clinical Trial of Chiropractic Manual Therapy Plus Home Exercise, Supervised Exercise Plus Home Exercise and Home Exercise Alone For Individual 65 and Over With Chronic Mechanical Neck Pain||Northwestern Health Sciences University||Completed|October 2003|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|241|||Both|65 Years|N/A|No|||August 2011|August 22, 2011|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00269308||186729|
NCT00269035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|773812/007|SPECT Study With SB-773812 In Schizophrenic Patients|A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts.||GlaxoSmithKline|No|Completed|June 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|95|||Both|18 Years|55 Years|No|||September 2012|September 13, 2012|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269035||186750|
NCT00269321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R18HP01424|Chiropractic and Exercise for Seniors With Low Back Pain|Randomized Clinical Trial of Chiropractic Manual Therapy Plus Home Exercise, Supervised Exercise Plus Home Exercise and Home Exercise Alone For Individuals 65 and Over With Chronic Mechanical Low Back Pain||Northwestern Health Sciences University||Completed|October 2003|March 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|65 Years|N/A|No|||June 2013|June 27, 2013|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269321||186728|
NCT00273104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05175|The Effect of Lifestyle Intervention Versus Gastric Bypass on Various Comorbidities in Morbidly Obese Subjects|The Effect of Lifestyle Intervention vs Gastric Bypass on Various Comorbidities||The Hospital of Vestfold|No|Completed|December 2005|December 2014|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|65 Years|No|||February 2015|February 17, 2015|January 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00273104||186444|
NCT00273117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-01-GLO|Transnasal and Oral Gastroscopy.|Transnasal and Conventional Oral Diagnostic Gastroscopy. A Prospective Randomised Study.||Hvidovre University Hospital||Terminated|February 2002|August 2003||||Phase 3|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|18 Years|N/A|No|||January 2006|January 6, 2006|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00273117||186443|
NCT00272467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OIAAMCTIVK205|Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy|A Comparative Study on the Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy||Korea Otsuka International Asia Arab|Yes|Completed|July 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|20 Years|N/A|No|||April 2015|April 27, 2015|January 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00272467||186493|
NCT00273351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSPECT|Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families|Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.||Institute for Neurodegenerative Disorders|No|Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|62|||Both|21 Years|N/A|No|||April 2014|April 21, 2014|January 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00273351||186425|
NCT00273650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB12-AUT|Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism|Double-Blind Placebo Controlled, Cross-over Trial of Subcutaneous B12 on Behavioral and Metabolic Measures in Children With Autism.||University of California, Davis|Yes|Completed|July 2005|August 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|3 Years|8 Years|No|||October 2012|October 30, 2012|January 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00273650||186402|
NCT00273871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-100535|Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients|A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2002|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||190|||Both|18 Years|N/A|No|||May 2007|March 7, 2011|January 5, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00273871||186385|
NCT00273884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001A3-200-GL|Amonafide in Combination With Cytarabine in Secondary AML|Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)||Xanthus Pharmaceuticals, Inc.||Completed|August 2005|April 2009||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||February 2007|February 16, 2007|January 5, 2006||||||https://clinicaltrials.gov/show/NCT00273884||186384|
NCT00274456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA024|Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer|A Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 Versus Every 3 Weeks Taxotere as First Line Therapy of Stage IV (Metastatic) Breast Cancer||Celgene|No|Completed|November 2005|July 2011|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|302|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|January 10, 2006|Yes|Yes||No|February 7, 2011|https://clinicaltrials.gov/show/NCT00274456||186341|
NCT00274469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6995C00006|A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer|A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Anastrozole (ARIMIDEX™) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer|FIRST|AstraZeneca||Active, not recruiting|February 2006|December 2016|Anticipated|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|233|||Female|45 Years|100 Years|No|||February 2016|February 3, 2016|January 10, 2006|Yes|Yes||No|January 27, 2009|https://clinicaltrials.gov/show/NCT00274469||186340|One patient in the ITT population was randomized to Fulvestrant 500 but did not receive drug and was excluded from the safety population. Hence, the safety population for Fulvestrant contained 101 patients.
NCT00274807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-4409|Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Intensive Induction for Newly Diagnosed Acute Myelogenous Leukemia||The Cleveland Clinic||Completed|June 2001|May 2008|Actual|April 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|16 Years|N/A|No|||February 2011|February 9, 2011|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00274807||186315|
NCT00274794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-3600|VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL|A Prospective Randomized Trial of VP-16 Plus G-CSF Plus Rituximab vs VP-16 Plus G-CSF Alone for Peripheral Blood Progenitor Cell Mobilization Prior to Autologous Stem Cell Transplantation for B Cell Lymphoid Malignancies||The Cleveland Clinic|No|Completed|February 2000|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|January 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00274794||186316|
NCT00274989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455087|Bendamustine and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|Multicenter Phase II Trial of Bendamustine in Combination With Rituximab for Patients With Relapsed Chronic Lymphocytic Leukemia. CLL2M Protocol of the German CLL-Study Group (GCLLSG)||National Cancer Institute (NCI)||Completed|November 2005|||March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|61|||Both|18 Years|N/A|No|||July 2007|August 23, 2013|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00274989||186301|
NCT00275223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK67167 (completed)|Insulin Resistance in Severely Obese Patients|Insulin Resistance in Severely Obese Patients||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|September 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|48|||Female|18 Years|65 Years|No|||March 2010|March 17, 2010|January 10, 2006||||No||https://clinicaltrials.gov/show/NCT00275223||186283|
NCT00271453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005950|A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief Therapy|A Study to Assess the Safety, Efficacy and Pharmacokinetics of Durogesic (Fentanyl Transdermal Drug Delivery System) in the Treatment of Pediatric Patients With Chronic Pain Requiring Long-term Opioid Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 1996|October 1998|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|41|||Both|2 Years|18 Years|No|||April 2010|May 17, 2011|December 30, 2005||||No||https://clinicaltrials.gov/show/NCT00271453||186567|
NCT00271687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-14-0049 / 22262|A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer|A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer||AHS Cancer Control Alberta|Yes|Completed|February 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||March 2012|February 24, 2016|December 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00271687||186550|
NCT00271700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001880/1|Improving Glycemic Control on GMS: A Quality Improvement Study|Improving Glycemic Control on GMS: A Quality Improvement Study||Brigham and Women's Hospital||Not yet recruiting|May 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|1100|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|December 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00271700||186549|
NCT00267410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-4869|Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center|Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center||Centers for Disease Control and Prevention|No|Completed|November 2005|June 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|33|||Male|18 Years|24 Years|No|||September 2012|September 10, 2012|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00267410||186868|
NCT00267423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-040|Biventricular Pacing in the Pediatric Population|A Single Center, Retrospective Study of the Safety and Feasibility of Epicardial Biventricular Pacing in the Pediatric Population||Children's Healthcare of Atlanta||Terminated|January 2002|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||12|||Both|N/A|21 Years|No|||May 2007|May 2, 2007|December 19, 2005||||No||https://clinicaltrials.gov/show/NCT00267423||186867|
NCT00268996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-480848/026|Integrated Biomarker And Imaging Study - 2|See Detailed Description||GlaxoSmithKline||Completed|November 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||300|||Both|18 Years|80 Years|No|||May 2009|May 15, 2009|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268996||186753|
NCT00269009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61-9165|CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change|CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change||Great Lakes Research Into Practice Network||Recruiting|January 2006|February 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training|||||||Both|18 Years|N/A|No|||September 2006|January 10, 2007|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269009||186752|
NCT00268606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60-00636-98-028|Tailored Cognitive-Behavioral Therapy for Fibromyalgia Patients at Risk|Tailored Cognitive-Behavioral Therapy for Fibromyalgia Patients at Risk: A Randomized, Controlled Trial||Radboud University||Completed|December 2003|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268606||186781|
NCT00269048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPL104884|SB-480848 In Subjects With Coronary Heart Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2, Eff||GlaxoSmithKline|No|Completed|November 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|920|||Both|18 Years|80 Years|No|||March 2015|March 20, 2015|December 21, 2005||||||https://clinicaltrials.gov/show/NCT00269048||186749|
NCT00269334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC0931204|Clinical Pharmacogenomics of Antidepressant Response|Phase 4 Study of Clinical Pharmacogenomics of Antidepressant Response||National Health Research Institutes, Taiwan||Not yet recruiting|December 2005|November 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||December 2005|December 22, 2005|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269334||186727|
NCT00273364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI MS.Randomized2004|Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study|Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study||Northwestern University|Yes|Recruiting|January 2006|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|55 Years|No|||March 2016|March 21, 2016|January 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00273364||186424|
NCT00273663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9376-03|Transcranial Electrical Stimulation (TCES) / Cerebral Blood Flow (CBF) / Xenon Under Computerized Tomography (Xe/CT)|The Effects of Transcranial Electrical Stimulation (TCES) on Cerebral Blood Flow (CBF) With Xenon Under Computerized Tomography (Xe/CT)||University Hospital, Bordeaux|Yes|Completed|January 2006|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2007|June 28, 2007|January 6, 2006||||No||https://clinicaltrials.gov/show/NCT00273663||186401|
NCT00273897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060067|Electrical Polarization of the Brain in Corticobasal Syndrome|Direct Current Brain Polarization for Apraxia in Corticobasal Syndrome||National Institutes of Health Clinical Center (CC)||Completed|December 2005|||December 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1|||20|||Both|40 Years|90 Years|No|||December 2008|May 5, 2010|January 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00273897||186383|
NCT00274196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28-17.02.06-HMO-CTIL|Ultrasound as a Diagnostic Tool for Occult Hip Fractures|A Prospective Study of the Specificity and Sensitivity of Ultrasound in Diagnosing Occult Hip Fractures||Hadassah Medical Organization|No|Recruiting|February 2006|June 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|40 Years|N/A|No|||November 2007|November 12, 2007|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00274196||186361|
NCT00274443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA028|An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin|An Open -Label, Phase II Trial of Increasing Doses of ABI-007 and Carboplatin in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)||Celgene|No|Completed|March 2005|September 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|18 Years|N/A|No|||February 2011|April 2, 2012|January 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00274443||186342|
NCT00266188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 4.1|Follow up of Post-repair Tetralogy of Fallot|Non-invasive Imaging and Exercise Tolerance Tests in Post-repair Tetralogy of Fallot - Intervention and Course in Patients Over 8 Years Old||Competence Network for Congenital Heart Defects|No|Completed|January 2005|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|406|||Both|8 Years|N/A|No|Non-Probability Sample|Patient with tetralogy of Fallot|September 2011|September 20, 2011|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266188||186961|
NCT00266552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006019|A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation|The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years||Janssen Pharmaceutica N.V., Belgium||Completed||October 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|118|||Both|5 Years|12 Years|No|||January 2011|January 20, 2011|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00266552||186933|
NCT00266565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-9-18|Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome|A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes||Children's Hospital Medical Center, Cincinnati|Yes|Completed|December 2001|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||July 2015|July 27, 2015|December 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00266565||186932|
NCT00275002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03050|O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors|A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients With Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors||National Cancer Institute (NCI)|Yes|Completed|February 2006|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|N/A|21 Years|No|||February 2013|July 25, 2014|January 10, 2006|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00275002||186300|
NCT00275249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5612-23841|Evolution of Analgesic Tolerance With Opioids|Evolution of Analgesic Tolerance During Long Term Treatment of Chronic Pain With Opioids||University of California, San Francisco||Completed|March 2001|December 2005|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||60|||Both|21 Years|80 Years|No|||March 2011|April 12, 2011|January 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00275249||186281|
NCT00275262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-BT04-093|A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation|Leuprolide Acetate to Enhance Immune Function Post-Autologous Stem Cell Transplantation||Abbott|No|Terminated|February 2006|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||April 2010|April 9, 2010|January 9, 2006|Yes|Yes||No|February 5, 2010|https://clinicaltrials.gov/show/NCT00275262||186280|The study was terminated early because of slow enrollment. For the primary endpoint, changes from baseline within each treatment group were analyzed. Between treatment group comparisons were not performed because the sample size was too small.
NCT00267436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-U65/CCU523908|Adopting and Demonstrating the Adaptation of Prevention Techniques: Community PROMISE PLUS|Adopting and Demonstrating the Adaptation of Prevention Techniques: Community PROMISE Positives Leading and Utilizing Strategies (ADAPT CP PLUS)||Centers for Disease Control and Prevention|No|Completed|July 2006|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|574|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 12, 2012|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00267436||186866|
NCT00271713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 19472|Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)|Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures||Charite University, Berlin, Germany|No|Completed|March 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|60 Years|75 Years|No|||January 2009|January 27, 2009|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00271713||186548|
NCT00268294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221|Restoring Sinus Rhythm With Cardiac Resynchronization in Patients With Atrial Fibrillation (ReSync AF)|Restoring Sinus Rhythm With Cardiac Resynchronization in Patients With Atrial Fibrillation||Medtronic Cardiac Rhythm Disease Management||Completed|May 2003|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268294||186804|
NCT00268307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|opt001|Bone Marrow Stem Cell Infusion Following a Heart Attack|Cellular Transplantation of Autologous Bone Marrow-Derived Stem Cells Following Myocardial Infarction||Minneapolis Heart Institute Foundation|No|Completed|December 2005|September 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|41|||Both|21 Years|N/A|No|||December 2013|December 3, 2013|December 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268307||186803|
NCT00268021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-082|Automated Cardioverter Defibrillator in Children|The Use of Automated Cardioverter Defibrillator in Children (AICD)||Children's Healthcare of Atlanta|No|Completed|January 1998|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|34|||Both|N/A|21 Years|No|Non-Probability Sample|Subjects with AICD or BiV insertions|November 2014|November 26, 2014|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00268021||186823|
NCT00268034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-073|Left Ventricular Aneurysms in Children|Left Ventricular Aneurysms in Children||Children's Healthcare of Atlanta||Terminated|June 2002|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||5|||Both|N/A|21 Years|No|||May 2007|May 3, 2007|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268034||186822|
NCT00268320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230|Clinical Investigation of the Medtronic Concerto™ Device|Clinical Investigation of the Medtronic Concerto™ Cardiac Resynchronization Therapy (CRT) and Implantable Cardioverter Defibrillator (ICD) Therapies (CRT+ICD Device)||Medtronic Cardiac Rhythm Disease Management||Completed|January 2006|July 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|N/A|No|||September 2008|September 22, 2008|December 21, 2005||||||https://clinicaltrials.gov/show/NCT00268320||186802|
NCT00268619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE498_3501|FOCUS:Focus On Coronary Unstable Syndromes|A Placebo-controlled, Double-blind, Randomized, Multicenter Study of Ramipril 5 and 10 mg Capsules and Insulin Infusion in Subjects With Unstable Coronary Syndromes||Sanofi||Completed|June 2004|||July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2011|January 10, 2011|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268619||186780|
NCT00268632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_4001|IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)|A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.||Sanofi||Completed|August 1999|||February 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|65 Years|80 Years|No|||January 2011|January 10, 2011|December 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268632||186779|
NCT00269620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pittirb0503164|PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra|An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra|PARIS|University of Pittsburgh|No|Completed|June 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2008|October 20, 2008|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269620||186705|
NCT00265720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H57/CCH420680-05|Colorectal Cancer Screening Intervention Trial|Research on Community Cancer Control: Study of Colorectal Cancer Screening in the African American Population||Morehouse School of Medicine|No|Completed|March 2003|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|360|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 3, 2009|December 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00265720||186997|
NCT00265928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459747|Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma|VELCADE (Bortezomib) for Injection - Phase II Study of Bortezomib and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Terminated||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||January 2007|January 24, 2008|December 14, 2005|||Withdrawn for poor accrual|No||https://clinicaltrials.gov/show/NCT00265928||186981|
NCT00266227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3384g|A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate|SUNRISE|Genentech, Inc.||Completed|January 2006|||October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|559|||Both|18 Years|80 Years|No|||September 2013|September 20, 2013|December 14, 2005|Yes|Yes||No|October 24, 2008|https://clinicaltrials.gov/show/NCT00266227||186958|
NCT00266591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005470|A Study of the Efficacy and Safety of Topiramate Treatment in Patients With Epilepsy|Single Center TOPAMAX� (Topiramate) Monotherapy Trial in Subjects With Refractory Partial Onset Seizures||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 1992|April 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|51|||Both|14 Years|N/A|No|||January 2011|June 6, 2011|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00266591||186930|
NCT00266201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 5.1|Right Ventricular Failure in Congenital Heart Defects|Evaluation of Biochemical Markers of Neurohumoral Activity and Correlation With Clinically Significant Parameters in Patients With Right Ventricular Failure and Congenital Heart Defects||Competence Network for Congenital Heart Defects|No|Completed|June 2003|July 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1||150|||Both|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient group:        - Adolescents (at least14 years old)/adults with a surgically treated congenital heart        Control group:        - Healthy population, comparable to the patient sample with respect to age and gender|April 2007|August 17, 2011|December 15, 2005||||No||https://clinicaltrials.gov/show/NCT00266201||186960|
NCT00267111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0086-E|Topical Amethocaine Gel for Intramuscular Injection in Term Neonates|Local Anaesthesia [Topical Amethocaine Gel (Ametop)] for Intramuscular Injection in Term Neonates: A Randomized Controlled Trial.||Mount Sinai Hospital, Canada|No|Completed|July 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|N/A|N/A|No|||March 2012|March 28, 2012|December 15, 2005||No||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00267111||186891|
NCT00266838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZL OFT-ML 3386|Prevention of Docetaxel Induced Dacryostenosis|A Double Blind Interventional Study of the Efficacy of Topical Eye Treatment in the Prevention of Docetaxel Induced Dacryostenosis||Universitaire Ziekenhuizen Leuven|No|Completed|July 2006|May 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2005|June 24, 2010|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00266838||186911|
NCT00267098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215|Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)|Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)|BLOCK HF|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|December 2003|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|918|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|December 19, 2005|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00267098||186892|
NCT00267384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor407205ctil|N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity|||Soroka University Medical Center||Completed|March 2006|September 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|90 Years||||June 2012|June 19, 2012|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00267384||186870|
NCT00262873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449689|Bortezomib in Treating Patients With Myelodysplastic Syndromes|A Phase II Pilot Study of VELCADE in Patients With MDS||University of Rochester||Completed|May 2005|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|December 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00262873||187208|
NCT00267449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC-311|Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System|Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System||ART Advanced Research Technologies Inc.||Recruiting|November 2005|||||Phase 3|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|950|||Female|20 Years|80 Years|Accepts Healthy Volunteers|||September 2007|September 10, 2007|December 19, 2005||||No||https://clinicaltrials.gov/show/NCT00267449||186865|
NCT00267696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-05070|Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Phase II Study of Gemcitabine/Carboplatin/Bevacizumab in Platinum Sensitive Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.||Ohio State University Comprehensive Cancer Center|Yes|Completed|November 2005|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|December 19, 2005||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00267696||186846|
NCT00267722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-412|Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease|A Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's Disease||Facet Biotech||Completed|February 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|70 Years|No|||March 2012|March 6, 2012|December 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267722||186844|
NCT00267735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03HS013959-01A1|Measuring Preferences for Childbirth After Cesarean|Measuring Preferences for Childbirth After Cesarean||Oregon Health and Science University||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|September 8, 2006|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00267735||186843|
NCT00268047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-068|Pulmonary Resistance in Fontan Who Have Undergone Heart Transplantation|Retrospective Assessment of Pulmonary Vascular Resistance in Fontan Patients Who Have Undergone Orthotopic Heart Transplantation||Children's Healthcare of Atlanta||Terminated||||||N/A|Observational|Time Perspective: Retrospective||1|Actual|50|||Both|N/A|21 Years|No|Non-Probability Sample|retro chart review|July 2011|July 5, 2011|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00268047||186821|
NCT00268333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453784|Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer|Phase II Study of Recurrent Ganglionic Colorectal Cancer Not Accessible By Surgery Treated Using Chemotherapy With Simplified FOLFOX7 Followed By Radiotherapy Combined With 5FU and Oxaliplatin||National Cancer Institute (NCI)||Completed|August 2005|||January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|80 Years|No|||May 2007|February 6, 2009|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268333||186801|
NCT00268645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_5036|Insulin Glargine in Type 2 Diabetes|Open Trial of the Safety and Efficacy of Lantus for Insulin Naive Type 2 Diabetes Mellitus Patients or Patients Who Use Insulin Combined With 1 or More Oral Antidiabetic Drugs and Don't Have Good Glycemic Control.||Sanofi||Completed|September 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||534|||Both|18 Years|N/A|No|||January 2011|January 10, 2011|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268645||186778|
NCT00268658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor412805ctil|Clinical Use of Andante SmartStep System in Gait Rehabilitation|Clinical Use of Andante SmartStep System in Gait Rehabilitation||Soroka University Medical Center||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|85 Years|No|||November 2005|February 26, 2007|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268658||186777|
NCT00269347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP10009|Manipulation, Exercise, and Self-Care for Low Back Pain|Manipulation, Exercise, and Self-Care for Low Back Pain||Northwestern Health Sciences University||Completed|January 2001|April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2005|December 22, 2005|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269347||186726|
NCT00269360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP10013|Manipulation, Exercise, and Self-Care for Neck Pain|Manipulation, Exercise, and Self-Care for Neck Pain||Northwestern Health Sciences University||Completed|March 2001|February 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|65 Years|No|||November 2007|November 19, 2007|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269360||186725|
NCT00269633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080-19000-J11401|Research Study of Treatment for Winter Depression With Different Colors of Light|Optimizing Light Wavelength for Treatment of Seasonal Affective Disorder||Thomas Jefferson University|Yes|Active, not recruiting|November 2006|November 2015|Anticipated|December 2014||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269633||186704|
NCT00265356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-098389|Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases|The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial|PETCAM|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|November 2005|April 2013|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|404|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|December 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00265356||187023|
NCT00265369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C_9240|TEDDY: Spores of Bacillus Clausii in Acute Diarrhoea in Children|Comparative Efficacy and Safety of a Bacillus Clausii Probiotic Strain Versus Placebo in the Treatment of Acute Diarrhoea in Children||Sanofi||Completed|May 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||420|||Both|6 Months|36 Months|No|||January 2011|January 10, 2011|November 4, 2005||||No||https://clinicaltrials.gov/show/NCT00265369||187022|
NCT00265954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK56746|Internet Assisted Obesity Treatment|A Randomized Trial of an Internet Versus In-person Behavioral Weight Loss Treatment Program.|iReach|University of Vermont||Completed|February 2006|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|488|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 21, 2010|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265954||186979|
NCT00266214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3272-301|Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome|A Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine Patch 5% With Placebo in Patients With Pain From Carpal Tunnel Syndrome||Endo Pharmaceuticals||Terminated|November 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|December 15, 2005|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00266214||186959|
NCT00266578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-9-9|A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders|Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial||Children's Hospital Medical Center, Cincinnati||Completed|October 2002|October 2012|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|3 Years|30 Years|No|||April 2013|April 10, 2013|December 15, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00266578||186931|
NCT00266253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM18249|A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin|A Randomized Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.||Hoffmann-La Roche||Completed|November 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|220|||Both|30 Years|75 Years|No|||March 2016|March 1, 2016|December 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266253||186956|
NCT00266864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2648-C|Testosterone Replacement Therapy in Chronic Spinal Cord Injury|Testosterone Replacement Therapy in Chronic Spinal Cord Injury||VA Office of Research and Development|No|Completed|August 2003|December 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Male|18 Years|49 Years|No|||April 2014|April 8, 2014|December 15, 2005||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00266864||186909|Compared to similar trials our trial was relatively small. Although there was statistical and clinical changes associated with testosterone replacement therapy, the translation of these findings with regard to functional gain was not addressed.
NCT00266851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2005-0258|AZMATICS: AZithroMycin/Asthma Trial In Community Settings|AZMATICS: Azithromycin Asthma Trial In Community Settings||University of Wisconsin, Madison|Yes|Completed|January 2006|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|December 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00266851||186910|
NCT00262626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGS1|The Canadian Glaucoma Study|A Multicentre Study on the Risk Factors for the Progression of Open-Angle Glaucoma||Dalhousie University||Terminated|February 1995|June 1995||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||430|||Both|N/A|N/A|No|||June 2003|December 5, 2005|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262626||187226|
NCT00267397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-107|Prevalence and Clinical Spectrum of the 22q11 Deletion|Prevalence and Clincial Spectrum of the 22q11 Deletion: A Population Based Study of Children and Congenital Heart Defects||Children's Healthcare of Atlanta|No|Terminated|January 1967|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|6 Years|No|||May 2007|May 2, 2007|December 19, 2005|||sufficient data collected|No||https://clinicaltrials.gov/show/NCT00267397||186869|
NCT00262886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449939|Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer|Non-Myeloablative HLA-Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma||University of Rochester||Completed|August 2001|||July 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|70 Years|No|||June 2013|June 5, 2013|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00262886||187207|
NCT00271765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-15-2003|A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention|A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention||Inotek Pharmaceuticals Corporation||Completed|January 2004|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||40|||Both|18 Years|N/A|No|||November 2006|November 27, 2006|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00271765||186544|
NCT00267709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-411|Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease|A Phase 2a, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients With Crohn's Disease||Facet Biotech||Completed|February 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|70 Years|No|||March 2012|March 6, 2012|December 19, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00267709||186845|
NCT00267748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181065|Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)|A Randomized Phase II Study Of The Efficacy And Safety Of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (Renal EFFECT Trial)||Pfizer|Yes|Completed|December 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|December 20, 2005|Yes|Yes||No|June 23, 2011|https://clinicaltrials.gov/show/NCT00267748||186842|
NCT00268372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459847|S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx|A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, With and Without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients With Advanced Oropharyngeal Squamous Cell Cancer||Southwest Oncology Group|Yes|Terminated|December 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|December 21, 2005|Yes|Yes|SWOG eliminated its head and neck committee|No||https://clinicaltrials.gov/show/NCT00268372||186798|
NCT00268060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-050|Infant Medical Records: Case Report Proposal|Baby R. Case Report Proposal||Children's Healthcare of Atlanta||Terminated|September 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1|||Male|N/A|21 Years|No|||May 2007|May 3, 2007|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268060||186820|
NCT00268697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-475/EC303|Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.|A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia||Takeda|No|Completed|October 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1267|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|December 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268697||186774|
NCT00268346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF5538|Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer|A Phase II Trial of ZD1839 (IRESSA®) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction||Case Comprehensive Cancer Center|Yes|Completed|October 2005|August 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|December 20, 2005|Yes|Yes||No|October 27, 2011|https://clinicaltrials.gov/show/NCT00268346||186800|
NCT00268359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004091|Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas|Bevacizumab in Combination With Irinotecan for Malignant Gliomas||Duke University||Completed|May 2005|October 2009|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|68|||Both|18 Years|N/A|No|||February 2013|July 18, 2014|December 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00268359||186799|
NCT00269646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC11487|Comparison of Two Different Diets on Health Outcomes|Effect of a Low-Carbohydrate and High-Carbohydrate, High-Fiber Diet on Insulin Sensitivity and Risk Markers for Cardiovascular Disease in Men and Women With the Metabolic Syndrome||University of Virginia|No|Active, not recruiting|November 2004|August 2009|Anticipated|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2009|February 16, 2009|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00269646||186703|
NCT00269984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005833|A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Efficacy of r-HuEPO, Administered Subcutaneously, in Chronic Anemia Induced by Advanced Cancer||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||June 1990|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|56|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269984||186679|
NCT00269958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005887|A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery|A Double-Blind, Phase II, Placebo-Controlled Study to Determine the Safety and Efficacy of r-HuEPO in Reducing Transfusion Requirements in Patients Undergoing Total Hip Joint Replacement Surgery||Janssen-Ortho Inc., Canada||Completed||December 1991|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|208|||Both|18 Years|85 Years|No|||April 2010|May 16, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269958||186681|
NCT00269971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005908|A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.|A Parallel Group Placebo-Controlled Study to Determine an Effective Dose Regimen for EPREX� (Epoetin Alfa) Sterile Solution to Reduce Transfusion Requirements in Patients Undergoing Major Elective Orthopedic Surgery||Janssen-Ortho Inc., Canada||Withdrawn|May 1996|April 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|214|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269971||186680|
NCT00270504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-044TWUS|Memokath® 044TW Stent for Treatment of Urethral Stricture|Prospective, Randomized, Controlled, Multicenter Trial of the Memokath® 044TW Thermo-Expandable Stent for Maintaining Urethral Patency in Patients After Dilation or Internal Urethrotomy of Recurrent Stricture of the Bulbar Urethra||Pnn Medical DK|No|Completed|December 2002|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Male|21 Years|N/A|No|||December 2008|November 17, 2009|December 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00270504||186639|
NCT00270517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDP420-05-006|Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia|A Randomized, Double-Blinded, Parallel Group, Multicenter Study of EDP-420 Versus Telithromycin for the Treatment of Community Acquired Pneumonia||Enanta Pharmaceuticals||Recruiting|December 2005|July 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|18 Years|65 Years|No|||September 2006|September 18, 2006|December 23, 2005||||||https://clinicaltrials.gov/show/NCT00270517||186638|
NCT00265733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0437|Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer|Phase II Trial of CT-2103 (Xyotax™) With Capecitabine as First-Line Chemotherapy for Patients With Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|February 2006|May 2013|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|December 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265733||186996|
NCT00265941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0522|Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas||Radiation Therapy Oncology Group|Yes|Active, not recruiting|November 2005|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|December 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265941||186980|
NCT00265967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9917|Irbesartan in Hypertension|Missed Dose Effect of Irbesartan in Hypertensive Patients and Cardiovascular Risk Profile Monitoring Under Irbesartan Treatment||Sanofi||Completed|September 2005|||February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|December 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00265967||186978|
NCT00265980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5988|Leptin in Human Energy and Neuroendocrine Homeostasis|Leptin in Human Energy and Neuroendocrine Homeostasis||Columbia University|Yes|Active, not recruiting|July 2002|June 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|60|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|December 14, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00265980||186977|
NCT00266240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM18248|A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus||Hoffmann-La Roche||Completed|November 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|267|||Both|30 Years|75 Years|No|||March 2016|March 1, 2016|December 15, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266240||186957|
NCT00266604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002869|A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy|TOPAMAX� (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX� as Monotherapy in the Treatment of Epilepsy in Clinical Practice||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|409|||Both|10 Years|N/A|No|||April 2010|June 8, 2011|December 16, 2005||||||https://clinicaltrials.gov/show/NCT00266604||186929|
NCT00262639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15844|Prometa Protocol for Alcohol Dependence|A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention||Medical University of South Carolina|Yes|Completed|December 2005|March 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||December 2009|December 9, 2009|December 5, 2005|Yes|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00262639||187225|
NCT00267124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0089|Brain Aging Project--Kansas University|KU Brain Aging Project||National Institute on Aging (NIA)||Active, not recruiting|November 2004|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Blood samples are collected analyzed and banked as whole blood, serum, white blood cells|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|KU memory clinic patients, volunteers from the community, and the states of Kansas and        Missouri|April 2009|April 28, 2009|December 16, 2005||No||No||https://clinicaltrials.gov/show/NCT00267124||186890|
NCT00263211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0427 / 201107340|A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients|The Impact Of Platelet Function Inhibition On Circulating Cancer Cells In Metastatic Breast Cancer Patients||Washington University School of Medicine|No|Completed|January 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|N/A|No|||August 2013|August 9, 2013|December 6, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00263211||187183|
NCT00263575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3267-007|Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients|A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients||Prostrakan Pharmaceuticals|No|Completed|January 2005|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|17 Years|N/A|No|||January 2013|January 31, 2013|December 7, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00263575||187157|
NCT00263835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK59527 (completed)|A Self-care Intervention for Latino Adults With Diabetes|A Self-care Intervention for Latino Adults With Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|October 2004|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 1, 2010|December 7, 2005||||No||https://clinicaltrials.gov/show/NCT00263835||187137|
NCT00271778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06b/2003-04|A Comparative Study of the Outcomes of 2 Surgical Procedures for Safe Type of Chronic Otitis Media|A Randomized Control Study of the Outcomes of Mastoidotympanoplasty Versus Tympanoplasty in Quiescent Tubotympanic Otitis Media||Karnataka Institute of Medical Sciences||Active, not recruiting|July 2003|June 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|10 Years|50 Years|No|||December 2005|January 3, 2006|January 3, 2006||||No||https://clinicaltrials.gov/show/NCT00271778||186543|
NCT00271791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42352|Prednisone Treatment for Vestibular Neuronitis|Prednisone Treatment for Vestibular Neuronitis||Carmel Medical Center|No|Completed|September 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||July 2007|November 4, 2007|January 1, 2006||||No||https://clinicaltrials.gov/show/NCT00271791||186542|
NCT00267462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-034|Hypertrophic Myopathy in Children|Retrospective Review of Hypertrophic Myopathy in Children||Children's Healthcare of Atlanta||Terminated|January 1996|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||75|||Both|N/A|21 Years|No|||May 2007|May 3, 2007|December 19, 2005||||No||https://clinicaltrials.gov/show/NCT00267462||186864|
NCT00268671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976G_2501|Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)|Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Sanofi||Completed|August 2003|April 2006||April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|75 Years|No|||December 2009|December 4, 2009|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268671||186776|
NCT00268684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-05-FB-05235-CTIL|Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC|A Phase III Trial Comparing Whole Brain Radiation (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases||Tel-Aviv Sourasky Medical Center||Recruiting|May 2005|||||Phase 3|Interventional|N/A||||381|||Both|18 Years|N/A|No|||December 2005|February 27, 2006|December 21, 2005||||||https://clinicaltrials.gov/show/NCT00268684||186775|
NCT00268710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976J_2503|Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]|Multicenter Phase II Study of Taxotere (Docetaxel) Administered Weekly or Every Three Weeks in Combination With Prednisone as Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer (HRPC)||Sanofi||Completed|February 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|75 Years|No|||December 2009|December 4, 2009|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00268710||186773|
NCT00269061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADG104148|Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin|An Exploratory MRI Study in Type 2 Diabetic Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Measurement of Fluid Volumes by MRI in the Lower Extremities of Subjects Receiving Pioglitazone||GlaxoSmithKline||Completed|January 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|18 Years|70 Years|No|||October 2008|October 15, 2008|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269061||186748|
NCT00269087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO100648|GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)|Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)" A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -||GlaxoSmithKline||Completed|January 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|122|||Both|40 Years|80 Years|No|||May 2014|May 22, 2014|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269087||186746|
NCT00269074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-070-II-02|Effect of IDEA-070 on Pain and Inflammation Induced by PDT|Safety and Efficacy of IDEA-070 for the Treatment of Pain and Inflammation Induced by Photodynamic Therapy of Actinic Keratosis||IDEA AG||Completed|January 2006|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|85 Years|No|||March 2009|March 19, 2009|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269074||186747|
NCT00269373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 283694|Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors|PET-CT Scan as a Diagnostic Method in Unknown Primary Tumors||Rigshospitalet, Denmark|No|Completed|December 2005|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|136|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with unknown tumors|February 2012|February 20, 2012|December 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00269373||186724|
NCT00269997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005839|A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug|The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Cisplatin Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||July 1990|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|72|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00269997||186678|
NCT00270205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5176|Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART|A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, in HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2006|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|28|||Both|18 Years|50 Years|No|||March 2014|March 5, 2014|December 21, 2005|Yes|Yes||No|September 7, 2011|https://clinicaltrials.gov/show/NCT00270205||186662|This is a Phase I/II small sample study that was not powered for the secondary efficacy endpoints.
NCT00270218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 068|Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate Immune Response Kinetics and Safety of Two Different Primes, Adenoviral Vector Vaccine (VRC-HIVADV014-00-VP) and DNA Vaccine (VRC-HIVDNA009-00-VP), Each Followed by Adenoviral Vector Boost in Healthy, HIV-1 Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2006|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|December 21, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00270218||186661|
NCT00263406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/055|Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation|Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation||University Hospital, Ghent|No|Completed|December 2002|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|1 Month|18 Years|No|||December 2007|December 19, 2007|December 4, 2005||||No||https://clinicaltrials.gov/show/NCT00263406||187169|
NCT00263419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-Med1-01/05|Stress-relief Management for Treatment of Late Complications in Type 2 Diabetes|Psychosoziale Intervention Zur Reduktion Diabetischer Spätschäden Bei Diabetes Mellitus Typ 2|HEIDIS|Heidelberg University||Active, not recruiting|January 2005|June 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|30 Years|70 Years|No|||October 2011|October 26, 2011|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263419||187168|
NCT00265746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBN Nr 2 P05001 28|Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes|Program for the Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes. Evaluation of the Efficacy of the Life-Style Modification and the Life-Style Modification in Conjunction With Metformin, in the Prevention of Diabetes Mellitus Development in a Population of Women Who Had Expired a Gestational Diabetes - a Multicenter, Randomized, Double Blind Study.||Medical Universtity of Lodz||Recruiting|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Female|18 Years|50 Years|No|||December 2005|February 27, 2006|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00265746||186995|
NCT00266877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-200|Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer||Puma Biotechnology, Inc.|No|Completed|December 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|172|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|December 16, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00266877||186908|
NCT00267137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190|Study for Atrial Fibrillation Reduction (SAFARI)|Study for Atrial Fibrillation Reduction (SAFARI)||Medtronic Cardiac Rhythm Disease Management||Completed|September 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||540|||Both|N/A|N/A|No|||May 2006|May 19, 2006|December 19, 2005||||||https://clinicaltrials.gov/show/NCT00267137||186889|
NCT00262652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI-UCLA-ASTHMA-01|Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics|Sodium Pyruvate Bronchodilation in Asthmatics||Emphycorp|Yes|Terminated|January 2006|September 2006|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2005|June 24, 2011|December 6, 2005|Yes|Yes|Patients did not respond to therapy|No||https://clinicaltrials.gov/show/NCT00262652||187224|
NCT00262938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5804|Lifestyle Change and Quality of Life in Obese Patients With Stage I/II Endometrial Cancer in Remission|Lifestyle Change and Quality of Life in Obese Endometrial Cancer Survivors||Case Comprehensive Cancer Center|Yes|Completed|February 2005|August 2011|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|47|||Female|18 Years|N/A|No|||January 2012|January 17, 2012|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262938||187204|
NCT00262899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450155|Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions|Genetic Counseling for Newly Diagnosed Breast Cancer Patients||Georgetown University|No|Completed|August 2005|July 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|331|||Female|18 Years|N/A|No|||January 2013|January 4, 2013|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262899||187206|
NCT00262925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00518|Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL)||National Cancer Institute (NCI)|No|Terminated|June 2006|February 2013|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2013|April 14, 2015|December 6, 2005|Yes|Yes|slow accrual|No|April 25, 2014|https://clinicaltrials.gov/show/NCT00262925||187205|
NCT00263237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060037|STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency|A Pilot Study of Safety and Efficacy of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency||National Institutes of Health Clinical Center (CC)||Completed|December 2005|July 2008||||Phase 1|Interventional|Primary Purpose: Treatment|1|||10|||Both|18 Years|75 Years|No|||July 2008|July 24, 2008|December 7, 2005||No||No||https://clinicaltrials.gov/show/NCT00263237||187182|
NCT00263250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HS 09860|Watchful Waiting Versus Open Tension-free Repair of Inguinal Hernia in Asymptomatic or Minimally Symptomatic Men|Watchful Waiting Versus Open Tension-free Repair of Inguinal Hernia in Asymptomatic or Minimally Symptomatic Men||Creighton University|No|Completed|February 1999|February 2005|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||724|||Male|18 Years|N/A|No|||June 2013|June 28, 2013|December 6, 2005||||No||https://clinicaltrials.gov/show/NCT00263250||187181|
NCT00263588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF105084|Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer|A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy||Novartis|No|Active, not recruiting|December 2005|December 2016|Anticipated|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|242|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00263588||187156|
NCT00263874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5641009|Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of UK-500,001 Dry Powder For Inhalation (DPI) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).||Pfizer||Terminated|November 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||324|||Both|40 Years|80 Years|No|||July 2007|July 20, 2007|December 8, 2005|||The decision to terminate was completely related to efficacy and there were no safety    concerns.|No||https://clinicaltrials.gov/show/NCT00263874||187135|
NCT00260572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#99-0355|Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease|Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease||University of Pittsburgh||Recruiting|April 1999|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of reflux seeking treatment in a physician's office.|December 2015|December 1, 2015|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00260572||187380|
NCT00261053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1202-01|Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Phase II Exploratory, Open-label Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema||Pharming Technologies B.V.|Yes|Completed|June 2003|December 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||April 2013|April 24, 2013|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261053||187344|
NCT00261625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940706|Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?|Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients?||National Taiwan University Hospital||Completed|August 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|20 Years|80 Years|No|||December 2008|January 2, 2009|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261625||187300|
NCT00261924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|451-P-A-NIV|Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days|Clinical Trial to Evaluate the Therapeutic Efficacy and Safety of INTERCEPT Platelets Stored for up to Seven Days After Collection|TESSI|Cerus Corporation|Yes|Completed|October 2005|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|211|||Both|16 Years|N/A|No|||December 2005|April 13, 2010|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00261924||187279|
NCT00261937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67/05|Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants|Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants||Bnai Zion Medical Center||Completed|December 2005|April 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|12 Months|No|||December 2005|February 5, 2013|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00261937||187278|
NCT00262275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 01/624|Optimum Platelet Inhibition After Coronary Bypass Surgery|Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel||Papworth Hospital NHS Foundation Trust||Completed|July 2002|||July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00262275||187252|
NCT00262288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1203-01|Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema||Pharming Technologies B.V.||Completed|April 2004|January 2007|Actual|January 2007|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|16 Years|70 Years|No|||February 2013|February 21, 2013|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00262288||187251|
NCT00258401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Z05|Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.|The Effectiveness of a Low-Residue Diet on Diarrhea in Cancer Patients Receiving Pelvic Radiation Therapy||Case Comprehensive Cancer Center|Yes|Completed|May 2005|June 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|11|||Both|20 Years|80 Years|No|||January 2011|January 11, 2011|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00258401||187544|
NCT00258687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-115|Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma|A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients||Dana-Farber Cancer Institute||Active, not recruiting|January 2005|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|N/A|No|||May 2015|May 8, 2015|November 23, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258687||187524|
NCT00259558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC3|Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis|Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa||Heidelberg University||Completed|April 2003|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|16 Years|90 Years|No|||February 2007|February 7, 2007|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259558||187457|
NCT00259272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9675|Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine|Phase IIIb, Multicenter, Single-Arm Open-Label Study, Supporting the Development and the Validation of the MATHYS Scale (Multidimensional Assessment of THYmic States) in a Population of Bipolar Patients Treated With Olanzapine, Either in-Label (Manic and Mixed Patients) and Off-Label (Hypomanic and Bipolar Depression)||Eli Lilly and Company|No|Completed|November 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Both|18 Years|N/A|No|||April 2009|April 30, 2009|November 28, 2005|Yes|Yes||No|April 30, 2009|https://clinicaltrials.gov/show/NCT00259272||187479|Fewer patients than planned were enrolled in the study. Not all the analyses (Principal Component Analysis, scree plot to define the structure) could be provided due to the specific formatting of the clinicaltrials.gov databank.
NCT00287586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24192|Testosterone Replacement in Older Men and Atherosclerosis Progression|Effects of Testosterone Replacement on Atherosclerosis Progression in Older Men With Low Testosterone Levels||Boston University|Yes|Active, not recruiting|March 2003|December 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|360|||Male|60 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 6, 2012|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00287586||185362|
NCT00287599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWHO510134|Rapid Identification of Key Pathogens in Wound Infection by Molecular Means|Rapid Identification of Key Pathogens in Wound Infection by Molecular Means||Brentwood Biomedical Research Institute|No|Completed|October 2006|August 2011|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|400|Samples With DNA|Pus and tissue specimens|Both|18 Years|N/A|No|Probability Sample|Community sample|February 2012|February 7, 2012|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287599||185361|
NCT00287820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FiD-MC-x226(7524)|Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism|Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism||Nathan Kline Institute for Psychiatric Research|No|Completed|February 2004|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|65 Years|No|||December 2007|July 22, 2011|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287820||185344|
NCT00288756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|The V-Tachogram:Decreasing Ventricular Arrythmias When Injecting Contrast in the Left Ventricle|||Trillium Health Centre||Active, not recruiting|July 2006|August 2006||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||156|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2006|September 11, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288756||185272|
NCT00289055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE04-01NL|The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions.|A Clinical Investigation of the SMART™ Nitinol Self-Expandable Stent Versus Balloon Angioplasty for the Treatment of Superficial Femoral Artery Occlusions|DURAVEST|Cordis Corporation|Yes|Terminated|November 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|30 Years|N/A|No|||February 2009|February 20, 2009|February 7, 2006|Yes|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00289055||185249|
NCT00261092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0126|GEMOX: Oxaliplatin in Pancreatic Cancer|Phase II Multicenter, Open Label Study of Oxaliplatin Combined With Gemcitabine(GEMOX) in Advanced and Metastatic Pancreatic Cancer||Sanofi||Completed|October 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|18 Years|75 Years|No|||April 2008|April 14, 2008|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261092||187341|
NCT00261105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4026|Telithromycin in Respiratory Tract Infections|An Open, Multicenter, Non-comparative, Phase IV Trial of Efficacy and Safety of Ketek(Telithromycin) 800mg||Sanofi||Completed|February 2005|December 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2009|September 24, 2009|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261105||187340|
NCT00261118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLBUHT R&D 2709|Rituximab in Active Ulcerative Colitis|Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis||Royal Liverpool University Hospital|Yes|Completed|April 2004|October 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00261118||187339|
NCT00261391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-04-052R|Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.|Phase I Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Marimastat in Patients With Disabling Malformations and No Other Treatment Options||Children's Hospital Boston||Completed|October 2000|October 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||9|||Both|2 Years|N/A|No|||May 2005|January 8, 2008|December 2, 2005||||||https://clinicaltrials.gov/show/NCT00261391||187318|
NCT00261404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-001.008|TNFerade™ Biologic Plus Radiation for Metastatic Melanoma|A Phase II, Open Label, Single Arm, "Proof of Concept" Study of TNFerade™ Plus Radiation in Patients With Metastatic Melanoma||GenVec||Completed||||||Phase 2|Interventional|N/A|||||||Both|18 Years|N/A|No|||May 2011|May 11, 2011|December 2, 2005||||||https://clinicaltrials.gov/show/NCT00261404||187317|
NCT00261638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701123|A Study of the Effect of Mental Health Promotion on Mental Health Index|A Study of the Effect of Mental Health Promotion on Mental Health Index||National Taiwan University Hospital||Recruiting|October 2005|May 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2005|December 2, 2005|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261638||187299|
NCT00261963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-187-03|The Effect of UV-Irradiation on Cutaneous Cicatrices|The Effect of UV-Irradiation on Cutaneous Cicatrices -A Randomised, Controlled Study With Clinical, Skin Reflectance, Histological and Biochemical Evaluations||Bispebjerg Hospital||Completed|February 2004|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2007|June 4, 2007|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261963||187276|
NCT00261950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050104|Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease|Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease|BONAFIDE|Amgen|No|Completed|May 2006|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|December 2, 2005|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00261950||187277|
NCT00262301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1304-01|Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Randomized, Placebo-controlled, Double-blind Phase III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema||Pharming Technologies B.V.|Yes|Completed|June 2004|October 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|16 Years|N/A|No|||September 2012|September 27, 2012|December 1, 2005||No||No|July 27, 2012|https://clinicaltrials.gov/show/NCT00262301||187250|
NCT00258700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103974 (primary study)|Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine|Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix™-IPV Versus a Licensed Men-C Vaccine With Pediacel™ When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months||GlaxoSmithKline||Completed|February 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|478|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2011|October 2, 2014|November 24, 2005||||No||https://clinicaltrials.gov/show/NCT00258700||187523|
NCT00259298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9917|Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis|The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|November 2005|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|50 Years|85 Years|No|||July 2010|July 14, 2010|November 28, 2005|Yes|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00259298||187477|
NCT00259597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Morphology|Nuclear Morphology of Breast Cells in Ductal Lavage|Morphometry of Breast Cells in Ductal Lavage||University of Michigan|Yes|Completed|June 2004|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|women with a previous biopsy of proliferative breast disease|November 2008|December 19, 2012|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259597||187454|
NCT00259571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC4|Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.|Prospektive, Randomisierte, Doppelblinde, Mesalazin-kontrollierte ("Double-dummy Verfahren) Multizenter-Studie Zur Beurteilung Der Annahme Der äquivalenten Wirkung Von Intestinal Retardiert Freigesetztem Phosphatidylcholin gegenüber Mesalazin (Non-inferiority Study) in Der Remissionserhaltung Der Colitis Ulcerosa.||Heidelberg University||Withdrawn||March 2010||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|0|||Both|15 Years|80 Years|No|||November 2005|December 12, 2013|November 28, 2005|||Missing financial sponsorship|No||https://clinicaltrials.gov/show/NCT00259571||187456|
NCT00259584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0770-C|Superior Vena Caval Obstruction (SVCO) - Management and Outcome|A Prospective Longitudinal Study of the Management and Outcome of Superior Vena Caval Obstruction (SVCO)||University Health Network, Toronto||Completed|October 2001|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259584||187455|
NCT00259857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01FD001847-05|Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis|A Randomized, Double-Blind, Placebo-Controlled, Prospective, Cross-Over Phase II Clinical Trial to Determine the Safety and Efficacy of Alendronate (Fosamax) in Juvenile Osteoporosis (IND#60,017)||Medical University of South Carolina|Yes|Completed|October 2003|August 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|5 Years|15 Years|No|||December 2010|December 29, 2010|November 29, 2005|Yes|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00259857||187434|
NCT00259870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAA104606|SB-773812 Administered In Adults With Schizophrenia|A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia||GlaxoSmithKline|No|Completed|September 2005|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|338|||Both|18 Years|65 Years|No|||November 2012|November 21, 2012|November 30, 2005||||||https://clinicaltrials.gov/show/NCT00259870||187433|
NCT00287807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-06-02-SL|Effect of Self-monitoring of Blood Glucose in Patients With Type 2 Diabetes Mellitus Not Using Insulin|Self-monitoring of Blood Glucose in Patients With Type 2 Diabetes Mellitus Who Are Not Using Insulin. A Randomized Controlled Trial||Medical Research Foundation, The Netherlands||Completed|February 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||September 2011|September 23, 2011|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00287807||185345|
NCT00288548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeFCo2|Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD||Martini Hospital Groningen||Recruiting|February 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||February 2006|February 17, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288548||185288|
NCT00288028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455585|Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant|A Phase I Study of Bortezomib During Maintenance Phase After High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma||Barbara Ann Karmanos Cancer Institute|No|Completed|July 2005|June 2012|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288028||185328|
NCT00288041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00138|Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma|A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for the Treatment of Metastatic Melanoma||National Cancer Institute (NCI)||Completed|October 2005|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00288041||185327|
NCT00288782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mirtazapine_Occupancy_01_2005|PET Neuroimaging of [11C]Mirtazapine|Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans||University of Aarhus|No|Completed|February 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||24|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2007|April 18, 2007|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288782||185270|
NCT00288769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR415705CTIL|Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis|||Soroka University Medical Center||Completed|March 2006|January 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||||||Both|65 Years|N/A|No|||January 2008|January 22, 2009|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288769||185271|
NCT00289068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phacoemulsification Sleeves|Phacoemulsification Sleeves|Determination of Surgical Efficacy and Most Efficient Surgical Parameters for Use With the 2.2, 2.8, and 3.0mm Phacoemulsification Sleeves Used With the Alcon Infinity 1.1mm ABS Flared Tip||University of Oklahoma|Yes|Completed|January 2006|September 2007|Actual|April 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|44|||Both|18 Years|N/A|No|Non-Probability Sample|Dean A. McGee Eye Institute|July 2011|July 8, 2011|February 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00289068||185248|
NCT00261430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002893|A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.|Schizophrenia Treatment Acceptance Response Trial: a 20-week, Open-label, Multicenter, Randomized Study Comparing the Effect of the "GAIN Acceptance Approach Verses the "Approach-as-usual" in Supporting Patient Acceptance of Long-acting Risperidone (Risperdal� CONSTA�) in Adults With Schizophrenia||Janssen, LP||Completed||October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|650|||Both|18 Years|70 Years|No|||April 2010|May 16, 2011|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261430||187315|
NCT00261417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160L00001|Dose Response Study in Japanese Patients|A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes||AstraZeneca||Terminated|May 2004|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|30 Years|80 Years|No|||April 2009|April 21, 2009|December 1, 2005|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00261417||187316|
NCT00261976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004780|A Long-term Safety Study of Infliximab (Remicade)|Long-term Safety Follow-up of REMICADE (RESULTS)||Centocor, Inc.|Yes|Completed|February 2002|March 2012|Actual|March 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2971|||Both|N/A|N/A|No|Non-Probability Sample|All patients enrolled in ongoing and future Centocor sponsored infliximab clinical        studies.|March 2014|March 15, 2014|December 2, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00261976||187275|
NCT00262314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24293|Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients|Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients|RENEW|EMD Serono||Completed|October 2000|September 2008|Actual|January 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|509|||Both|18 Years|65 Years|No|Non-Probability Sample|Male and female patients with a clinically definite or laboratory supported diagnosis of        MS and having secondary (chronic) progressive, progressive relapsing, or worsening        relapsing-remitting disease (i.e., patients whose neurologic status is significantly        abnormal between relapses). Patients with primary progressive disease will not be included        in this study.|October 2013|October 21, 2013|December 5, 2005||No||No|May 21, 2010|https://clinicaltrials.gov/show/NCT00262314||187249|
NCT00258453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPOH-CRANIOPHARYNGIOMA-2000|Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma|Prospective, Multi-Center Survey Study of Children and Adolescents With Craniopharyngioma||National Cancer Institute (NCI)||Completed|May 2001|September 2009|Actual|September 2007|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|120|||Both|N/A|18 Years|No|||October 2007|August 1, 2013|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258453||187541|
NCT00258193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol MCP-103-005|Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS|A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Pharmacodynamic Effects of Orally Administered 100ug and 1000ug QD MD-1100 Acetate on Gastrointestinal Transit in Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)||Ironwood Pharmaceuticals, Inc.||Completed|January 2006|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|65 Years|No|||October 2006|October 19, 2006|November 22, 2005||||||https://clinicaltrials.gov/show/NCT00258193||187559|
NCT00258427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002LS014|Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia|Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|March 2002|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|44 Years|No|||January 2016|January 21, 2016|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258427||187543|
NCT00258440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445450|Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer|A Pilot Trial of Extended Interval Dosing of Epoetin Alfa (Procrit®) for the Treatment of Anemia in Oncology Patients||OHSU Knight Cancer Institute|Yes|Terminated|May 2003|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|7|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|November 23, 2005|Yes|Yes|Sponsor discontinued funding of the study|No|June 10, 2010|https://clinicaltrials.gov/show/NCT00258440||187542|Due to low accruals the sponsor decided to discontinue the study early. A full analysis was not completed.
NCT00259285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9901|Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer|Alimta (Pemetrexed) and Cisplatin Treatment as Neoadjuvant Therapy in Non Small Cell Lung Cancer||Eli Lilly and Company|No|Terminated|November 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2009|April 7, 2009|November 28, 2005|Yes|Yes|Trial was stopped early due to low enrollment.|No|December 19, 2008|https://clinicaltrials.gov/show/NCT00259285||187478|Trial was stopped early due to low enrollment and the relapse-free survival outcome measure was not analyzed.
NCT00259610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X031030004|Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)|Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)|TEAR|University of Alabama at Birmingham|Yes|Completed|May 2004|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|755|||Both|18 Years|N/A|No|||October 2013|July 16, 2014|November 28, 2005|Yes|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT00259610||187453|
NCT00259909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPL104226|Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Prospective Observational Study for the Psychometric Validation of a Patient-Reported Questionnaire in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD).||GlaxoSmithKline||Completed|November 2005|||||N/A|Observational|Time Perspective: Prospective||||740|||Both|40 Years|N/A|No|||October 2008|October 15, 2008|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00259909||187430|
NCT00259922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-767905/013|Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain||Cubist Pharmaceuticals LLC||Completed|August 2005|||June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|485|||Both|18 Years|N/A|No|||September 2009|September 1, 2015|November 29, 2005||Yes||||https://clinicaltrials.gov/show/NCT00259922||187429|
NCT00259883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104228|Combination Of PAXIL Tablet And Benzodiazepines|Post-marketing Clinical Study on PAXIL Tablet in Patients With Depression or Depressive Mood - A Study on Combination of PAXIL Tablet and Benzodiazepines||GlaxoSmithKline||Completed|June 2005|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|64 Years|No|||August 2011|April 11, 2013|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00259883||187432|
NCT00259896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP105330|In-patient Study in Patients With Type 2 Diabetes Mellitus|A Randomized, Open-label, Placebo-controlled, Repeat-dose Study to Assess the Pharmacokinetics and Pharmacodynamics of 5 Micrograms Exenatide Administered Subcutaneously Twice Daily for 7 Days in Healthy Normal Volunteers and in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|October 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||January 2011|May 31, 2012|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00259896||187431|
NCT00287625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/ko/2006/001|Early Pulmonary Rehabilitation for Hospitalized Patients With Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|To Study the Effect of Early Pulmonary Rehabilitation on Exacerbations, Hospitalization Rates and Quality of Life in Patients Admitted to Hospital With Acute Exacerbation of Chronic Obstructive Pulmonary Disease.||Chinese University of Hong Kong||Completed|January 2006|June 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|N/A|No|||June 2011|June 22, 2011|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00287625||185359|
NCT00287833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01479|Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men|Phase I Single Dose Safety and Pharmacokinetic Study of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age||National Cancer Institute (NCI)||Completed|January 2006|||April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287833||185343|
NCT00288561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002B2201|Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration|Open-Label, Multicenter, Phase II Study Assessing the Safety of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Occult or Predominately Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD)||Novartis||Completed|November 2004|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||June 2008|June 18, 2008|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288561||185287|
NCT00289393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB #151-2004|Response Shift in Patient Expectations and Functional Outcome|Response Shift in Patient Expectations and Functional Outcome Following Posterior Lumbar Spinal Surgery for Degenerative Spinal Disorders||Sunnybrook Health Sciences Centre||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A||||September 2006|September 11, 2006|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289393||185223|
NCT00288795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC U4104|A Randomized Study of Polarity or Massage Therapy to Reduce Fatigue in Breast Cancer Patients During Radiation Therapy|A Randomized Study of Polarity or Massage Therapy to Reduce Fatigue in Breast Cancer Patients During Radiation Therapy||University of Rochester||Completed|January 2006|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Female|21 Years|N/A|No|||November 2011|November 30, 2011|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288795||185269|
NCT00288808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11787|Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.|Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements for Pediatric Patients on Anticoagulation Therapy.||University of Rochester||Terminated|October 2005|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|200|||Both|N/A|18 Years|No|||April 2015|April 24, 2015|February 6, 2006|||insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00288808||185268|
NCT00289107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-3|Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA|Multi-center, Prospective, Clinical Evaluation of the P.F.C.® Sigma™ Rotating Platform Cruciate Substituting vs P.F.C.® Sigma™ Cruciate Substituting Knee Primary Cases||DePuy Orthopaedics|No|Completed|April 2001|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|75 Years|No|||August 2013|August 6, 2013|February 7, 2006|Yes|Yes||No|September 29, 2010|https://clinicaltrials.gov/show/NCT00289107||185245|
NCT00289120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0133-2003|Effect of Cola on Urinary Stone Risk Factors|Effect of Cola on Urinary Stone Risk Factors||Emory University|No|Completed|November 2003|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 5, 2014|February 7, 2006||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00289120||185244|
NCT00288535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-BK-2005-1|Treatment of Bifurcated Coronary Lesions With Cypher™-Stent|Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions||Heart Center Bad Krozingen||Recruiting|March 2005|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2005|September 17, 2007|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288535||185289|
NCT00289367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-075|Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery|Randomized Prospective Study of T3 on the Incidence of Post-Operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery||Northwell Health||Completed|February 2006|May 2008|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|280|||Both|18 Years|85 Years|No|||May 2008|May 19, 2008|February 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00289367||185225|
NCT00289666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23011|The Effect of Positive Airway Pressure on Heart Rate Variability|A Prospective Study to Determine the Effect of Positive Airway Pressure on Heart Rate Variability in Individuals With Obstructive Sleep Apnea||Christiana Care Health Services|No|Completed|July 2003|September 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|38|Samples Without DNA|Serum, Plasma, Urine|Both|18 Years|75 Years|No|Non-Probability Sample|Tertiary Care|September 2008|September 29, 2008|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00289666||185202|
NCT00261989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-198|Pulse Oximetry Readings and Hourly Variation in Oximetry Readings With CHD|The Retrospective Analysis of Presenting Pulse Oximetry Readings and Hourly Variation in Oximetry Readings in Patients With Known Congenital Heart Disease||Children's Healthcare of Atlanta|No|Terminated|November 2005|September 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|1000|||Both|N/A|N/A|No|Non-Probability Sample|retro chart review|September 2007|July 5, 2011|December 2, 2005|||data insignificant, study terminated|No||https://clinicaltrials.gov/show/NCT00261989||187274|
NCT00262002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P5|Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants|A Phase II, Randomized, Open Label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory After Two or Three Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants at 2, 3, 4 or 2, 4, 6 Months of Age||Novartis||Completed|September 2004|October 2006|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|601|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||June 2014|June 16, 2014|December 2, 2005|Yes|Yes||No|September 2, 2013|https://clinicaltrials.gov/show/NCT00262002||187273|
NCT00261664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49150|Empowering Elders Through Technology|Empowering Elders Through Technology||Robert Wood Johnson Foundation||Completed|September 2003|July 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||290|||Both|N/A|N/A|No|||July 2011|July 25, 2011|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261664||187298|
NCT00261677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002296|A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) on Anemia and Quality of Life in Children With Cancer Undergoing Myelosuppressive Chemotherapy||Ortho Biotech Products, L.P.||Completed|August 2000|October 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|224|||Both|5 Years|18 Years|No|||April 2010|May 19, 2011|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261677||187297|
NCT00262327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB-101|Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor|Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Human Endostatin for Advanced Solid Tumors||Sun Yat-sen University||Active, not recruiting|May 2005|February 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||December 2005|June 15, 2006|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00262327||187248|
NCT00258206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0478 CDR0000441169|Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma|Phase II Study of High Dose Cyclophosphamide and Rituximab in Multiple Myeloma||Sidney Kimmel Comprehensive Cancer Center||Completed|December 2004|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|November 22, 2005|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00258206||187558|
NCT00258466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447161|Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer|Phase III Trial of Neutron + Photon Radiation Versus Photon + Hypofractionated Intensity Modulated Radiation Therapy in Localized Prostate Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|May 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|0|||Male|N/A|N/A|No|||April 2013|April 5, 2013|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258466||187540|
NCT00258713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISA05-02|A 36-Week Extension to Protocol ISA04-03|A 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients With Plaque Psoriasis|SPIRIT|Aurinia Pharmaceuticals Inc.|Yes|Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|309|||Both|18 Years|66 Years|No|||September 2008|September 24, 2008|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258713||187522|
NCT00258986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCG/166.478/RvB|Efficacy Study Comparing Hand-Assisted Laparoscopic and Mini-Incision Muscle Splitting Incision Living Donor Nephrectomy|||University Medical Center Groningen||Recruiting|March 2004|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||November 2005|January 31, 2006|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258986||187501|
NCT00258999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2005-0342|Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study|Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study||University of Wisconsin, Madison||Completed|October 2005|November 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||600|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||December 2007|October 1, 2015|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258999||187500|
NCT00260195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072591|A School Program for Children Exposed to Violence|A School Program for Children Exposed to Violence||RAND|No|Completed|July 2005|July 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|10 Years|14 Years|No|||April 2014|April 28, 2014|November 29, 2005||No||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00260195||187408|
NCT00260442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0187|Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy|Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy||Texas A&M University||Active, not recruiting|November 2005|May 2017|Anticipated|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|36|||Both|50 Years|69 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260442||187389|
NCT00260689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060034|Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia|A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2005|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|136|||Both|2 Years|N/A|No|||May 2015|May 19, 2015|December 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00260689||187371|
NCT00260182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061686-02|Genetics of Recurrent Early Onset Major Depression|Genetics of Recurrent Early Onset Major Depression||National Institute of Mental Health (NIMH)||Active, not recruiting|October 2005|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1500|Samples With DNA|Blood samples with DNA|Both|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will include participants with a family history of depression.|May 2009|January 3, 2011|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00260182||187409|
NCT00260429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUPY 303|Collagenase in the Treatment of Dupuytrens Disease|Double-blind, Randomized Placebo Controlled Study of the Relative Safety and Efficacy of Collagenase Therapy in the Treatment of Residual-type Dupuytren's Disease.||Stony Brook University|No|Completed|June 2003|April 2008|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||November 2010|November 5, 2010|November 29, 2005|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00260429||187390|
NCT00288067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00104|Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma|A Phase I-II Trial of Fenretinide (4-HPR) + Rituximab in Patients With B-cell Lymphoma||National Cancer Institute (NCI)|Yes|Terminated|October 2005|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2014|September 30, 2014|February 6, 2006|Yes|Yes|NCI stopped supplying fenretinide in November of 2012.|No|January 8, 2014|https://clinicaltrials.gov/show/NCT00288067||185325|
NCT00288301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00893-05|North Carolina WISEWOMAN: Weight-Wise Pilot Study|North Carolina WISEWOMAN Study - Weight-Wise Program||University of North Carolina, Chapel Hill|No|Completed|February 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|151|||Female|40 Years|64 Years|No|||June 2010|June 9, 2010|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288301||185307|
NCT00289406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK310_III_2006|Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension|An 8 Weeks, Multi-Center, Randomized, Double Blinded, Comparative Phase 3 Clinical Trial to Assess the Efficacy and Safety of S-Amlodipine Gentisate Compared to Amlodipine Besylate in Patients With Mild-to-Moderate Hypertension||SK Chemicals Co.,Ltd.||Completed|January 2006|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||110|||Both|18 Years|75 Years|No|||September 2006|March 5, 2007|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00289406||185222|
NCT00289705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU523-04|Surgical Intervention for Morbidly Obese Adolescents|Surgical Intervention With Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity in Adolescence - a Matched Control Study||Göteborg University|Yes|Active, not recruiting|February 2006|February 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|13 Years|17 Years|No|||January 2016|January 7, 2016|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00289705||185200|
NCT00289159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM0110|Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up|Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).||Groupe Hospitalier Pitie-Salpetriere||Active, not recruiting||||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|50 Years|No|||September 2005|February 8, 2006|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289159||185241|
NCT00285805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-49653-3|The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride|The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride. A Double-blind Placebo Controlled Cross Over Study.||Radboud University|No|Completed|February 2006|November 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||October 2008|August 23, 2010|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285805||185498|
NCT00289081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-1|Primary TKA Cruciate Retaining vs Cruciate Substituting With Rotating Platform Knee Prostheses|Multi-center Prospective Clinical Evaluation of the P.F.C.® Sigma™ Rotating Platform Knee Primary Cases Cruciate Retaining Versus Cruciate Substituting||DePuy Orthopaedics|No|Terminated|February 2001|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|399|||Both|18 Years|75 Years|No|||May 2014|May 12, 2014|February 7, 2006|No|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT00289081||185247|
NCT00289094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-2|Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA|Multi-center, Prospective, Clinical Evaluation of the PFC Sigma Rotating Platform Cruciate Retaining Versus PFC Sigma Cruciate Retaining Knee Primary Cases||DePuy Orthopaedics|No|Completed|March 2001|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|75 Years|No|||August 2013|August 6, 2013|February 7, 2006|Yes|Yes||No|September 29, 2010|https://clinicaltrials.gov/show/NCT00289094||185246|
NCT00289679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kf 01059/04|Cytokine Profile and Metal Ion Concentrations at Patients Undergoing a Revision THR|||Frederiksberg University Hospital||Recruiting||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||July 2007|March 17, 2015|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00289679||185201|
NCT00285779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20041132|Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus|A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus||Stanford University|Yes|Terminated|August 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|January 31, 2006|Yes|Yes|Slow recruitment|No|January 28, 2015|https://clinicaltrials.gov/show/NCT00285779||185500|Trial was terminated early due to low recruitment rates.
NCT00261703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976F_2503|Docetaxel in Head and Neck Cancer|Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck Cancer (LAHNC).||Sanofi||Completed|December 2002|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|439|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|December 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00261703||187295|
NCT00262015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14P2|Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine|A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate®||Chiron Corporation||Active, not recruiting|September 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||264|||Both|13 Years|15 Years||||December 2005|December 2, 2005|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00262015||187272|
NCT00262028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P8|Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children|A Phase 2, Randomized, Single-blind, Controlled, Single-Center Study to Compare the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Children 2-10 Years of Age and an Open-label Study to Assess the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine Administered to Healthy Toddlers 12-23 Months of Age||Novartis|No|Completed|April 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|5||Actual|910|||Both|12 Months|10 Years||||January 2016|January 12, 2016|December 2, 2005|No|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00262028||187271|
NCT00262340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0404/30|The Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma|Prospective, Randomised Controlled Trial of the Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|December 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|55|||Both|8 Years|18 Years|No|||October 2015|October 28, 2015|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00262340||187247|
NCT00258232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445439|Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer|Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 2002|August 2007|Actual|March 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2013|April 5, 2013|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258232||187557|
NCT00258479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15413|Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents|Modafinil and Nicotine in Adolescents: Phase I Trial||University of Kentucky|Yes|Completed|June 2003|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00258479||187539|
NCT00258726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-073|Immune Responses to Two Dose Varivax +/- MMR-II|Immunogenicity and Safety of Live Attenuated Varicella Vaccine in 12 and 18 Month-old Children, With and Without Concomitant Administration of Measles-Mumps-Rubella Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|October 2005|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||105|||Both|12 Months|12 Months|Accepts Healthy Volunteers|||April 2010|August 26, 2010|November 23, 2005||||No||https://clinicaltrials.gov/show/NCT00258726||187521|
NCT00259311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9951|Efficacy Study of LY2422347 to Treat Insomnia|A Randomized, Double-Blind Comparison of 5 mg of LY2422347, 15 mg of LY2422347, and Placebo in the Treatment of Patients With Primary Insomnia||Eli Lilly and Company||Completed|November 2005|November 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|24 Years|75 Years|No|||January 2007|January 24, 2007|November 28, 2005||||||https://clinicaltrials.gov/show/NCT00259311||187476|
NCT00259324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-R21-DK07491901|Childhood Obesity Treatment Targeting Specific Behaviors|Childhood Obesity Treatment Targeting Specific Behaviors||The Miriam Hospital||Completed|September 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|81|||Both|4 Years|9 Years|Accepts Healthy Volunteers|||December 2007|April 19, 2012|November 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00259324||187475|
NCT00260962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000210-01H|Olanzapine in the Treatment of Patients With Anorexia Nervosa|Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study||Ottawa Hospital Research Institute||Completed|September 2000|September 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||September 2009|September 30, 2009|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260962||187351|
NCT00261235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0007|Trial of Supported Employment Versus USES Supported Employment|A Randomized Trial of Supported Employment Versus USES Enhanced Supported Employment in Veterans With Serious Mental Illness||VA Connecticut Healthcare System||Completed|March 2005|January 2007|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||January 2009|January 24, 2009|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261235||187330|
NCT00261248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1996-295|Vaccine for Recurrent Urinary Tract Infections in Women|Phase 2 Clinical Trial of Vaginal Mucosal Immunization for Recurrent Urinary Tract Infections||University of Wisconsin, Madison||Completed|November 1996|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||75|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||September 2003|October 1, 2015|November 30, 2005||||||https://clinicaltrials.gov/show/NCT00261248||187329|
NCT00260975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999232-01H|Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer|A Prospective, Longitudinal Investigation of the Neuropsychological and Psychosocial Effects of Cancer Therapy||Ottawa Hospital Research Institute|No|Completed|June 2001|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3||150|||Female|50 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Breast Cancer|August 2010|August 23, 2010|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260975||187350|
NCT00287846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441039|Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis|Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy||National Cancer Institute (NCI)||Recruiting|August 2004|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|N/A|No|||December 2006|July 15, 2010|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00287846||185342|
NCT00288054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456381|S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer||Southwest Oncology Group|Yes|Terminated|April 2006|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|February 6, 2006|Yes|Yes|Study closed early due to poor accrual.|No|November 26, 2012|https://clinicaltrials.gov/show/NCT00288054||185326|
NCT00288314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRR04-WEH/METRAPI|fMRI in Posttraumatic Stress Disorder (PTSD) During Working Memory Updating|Working Memory Updating in Posttraumatic Stress Disorder (PTSD): Study of Neural Correlates Using fMRI|METRAPI|University Hospital, Tours|Yes|Completed|January 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|34|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|PTSD related to sexual abuse vs controls, in right-handed females.|March 2010|March 16, 2010|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00288314||185306|
NCT00288834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSF NA 4992|Outcomes of Swallowing Rehabilitation After Stroke|Outcomes of Swallowing Rehabilitation After Stroke||University of Canterbury||Completed|August 2001|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||February 2006|February 6, 2006|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288834||185266|
NCT00289172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103792|Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India|A Multicenter Study of the Immunogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8 Wks at the Time of the First Dose||GlaxoSmithKline||Completed|February 2006|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||360|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||October 2010|October 14, 2010|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289172||185240|
NCT00289419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040199|Intraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study|Postoperative Analgesia After Total Hip Arthroplasty. A Comparison of Continuous Epidural Infusion and Wound Infiltration With Intraarticular Bolus Injection.||University of Aarhus||Completed|February 2005|March 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00289419||185221|
NCT00289380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMA2005CSPEN|Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk|1. Prevalence of Nutritional Risk-undernutrition-support in China-Euro-USA. 2. Impact of Nutrition Support on Outcome for Patient at Risk. 3. Impact of Nutrition Support on Outcome,Cost/Effectiveness for Patient at Risk.||Peking Union Medical College|No|Recruiting|January 2005|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|80 Years|No|Non-Probability Sample|Continuing sampling in 6 clinical Departments of large, middle & small size hospitals in        15 large cities from West, Middle & East China.        Also, data from Denmark and USA will be collected and analysed.|February 2014|February 11, 2014|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00289380||185224|
NCT00261716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3176-R|Motivational Interviewing to Improve Work Outcomes in Schizophrenia|Motivational Interviewing to Improve Work Outcomes in Schizophrenia||VA Office of Research and Development||Active, not recruiting|January 2005|February 2015|Anticipated|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|No|||October 2014|October 14, 2014|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261716||187294|
NCT00262379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 2005-01|Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C|Multicenter Study, Randomized and Pragmatic, Comparing Two Therapeutic Strategies : Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C and Treated by Combination Therapy Peginterferon Alfa-2a Plus Ribavirin||University Hospital, Angers|Yes|Completed|December 2005|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00262379||187244|
NCT00262041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P6|Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents|A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age||Novartis||Completed|October 2004|March 2006||March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|3||Actual|524|||Both|11 Years|17 Years||||September 2013|September 9, 2013|December 2, 2005|Yes|Yes||No|September 9, 2013|https://clinicaltrials.gov/show/NCT00262041||187270|
NCT00262353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/416|Elimination of Protein-bound Uremic Retention Solutes by Prometheus Artificial Hepatic System Versus Conventional Dialysis|Elimination of Protein-bound Uremic Retention Solutes by Prometheus Artificial Hepatic System Versus Conventional Dialysis||University Hospital, Ghent|No|Suspended||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||June 2010|June 28, 2010|December 4, 2005||No|study never started because of safety alerts in literature regarding the topic to be examined|No||https://clinicaltrials.gov/show/NCT00262353||187246|
NCT00262366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/099|Comparison of Automatic CPAP to Fixed CPAP for OSAS Following a Prediction Formula|Titration Efficacy of Automatic CPAP Versus Fixed CPAP, Following a Prediction Formula in Patients With OSAS||University Hospital, Ghent|No|Completed|May 2005|March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|December 4, 2005||||No||https://clinicaltrials.gov/show/NCT00262366||187245|
NCT00258245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445464|Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia|A Phase I Study of Arsenic Trioxide and Ascorbic Acid (ATO/AA) in Combination With Low Dose Velcade-Thalidomide-Dexamethasone (VTD) in Relapsed/Refractory Multiple Myeloma (MM)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258245||187556|
NCT00259337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I41|Immunogenicity and Safety of Pentaxim™ in an Indian Population|Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India.||Sanofi|No|Completed|February 2006|December 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|226|||Both|42 Days|56 Days|Accepts Healthy Volunteers|||April 2012|April 13, 2012|November 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00259337||187474|
NCT00258739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_ES1_209|Docetaxel in Non Small Cell Lung Cancer (NSCLC)|A Phase II, Randomized Study With Docetaxel-gemcitabine Followed by Radiotherapy vs Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) Followed by Docetaxel-gemcitabine Versus Docetaxel-gemcitabine Followed by Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) in Stage III NSCLC||Sanofi||Completed|October 2001|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258739||187520|
NCT00259012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B3-333, 3001B3-335|Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD|A Multicenter, Randomized, Open Label, Single and Multiple Dose Study of the Pharmacokinetics and Pharmacodynamics of 2 Dose Levels of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged 1 Through 11 Months With Presumed GERD||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|1 Month|11 Months|No|||April 2010|April 19, 2010|November 23, 2005|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00259012||187499|
NCT00259935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/692|A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors|A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors||GlaxoSmithKline|No|Completed|October 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||106|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|November 30, 2005||||||https://clinicaltrials.gov/show/NCT00259935||187428|
NCT00259948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cva-mi-HMO-CTIL|Aerobic Exercise Training & the Autonomic System In Patients After Myocardial Infarction or Stroke|The Effect of Aerobic Exercise Training On the Function of the Autonomic System In Patients That Have Suffered Myocardial Infarction or Stroke||Hadassah Medical Organization||Not yet recruiting|January 2006|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|230|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2005|November 30, 2005|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00259948||187427|
NCT00260715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4133|A Community-Based Intervention With Popular Opinion Leaders (C-POL) in Texas|A Community-Based Intervention With Popular Opinion Leaders (C-POL) in Texas to Achieve Syphilis Elimination||Centers for Disease Control and Prevention||Completed|October 2002|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|December 1, 2005|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00260715||187369|
NCT00261261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANCE|Family-Centered Behavioral Preparation for Surgery|Study of the ADVANCE Behavioral Preparation Program for Children and Their Parents||Yale University||Completed|January 2001|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||400|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||November 2005|November 30, 2005|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00261261||187328|
NCT00261287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-416|Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 Mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age||Takeda||Completed|November 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||102|||Both|2 Years|5 Years|No|||June 2011|May 4, 2012|December 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00261287||187326|
NCT00288080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0521|Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer|A Phase III Protocol of Androgen Suppression (AS) and 3DCTR/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|December 2005|||April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|612|||Male|18 Years|120 Years|No|||March 2016|March 3, 2016|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288080||185324|
NCT00289133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03111|Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study|Prospective, Comparative, Randomized Study of GVF Versus Cross-linked Polyethylene in Total Knee Arthroplasty||DePuy Orthopaedics|No|Active, not recruiting|February 2005|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|937|||Both|18 Years|80 Years|No|||April 2013|April 3, 2013|February 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00289133||185243|
NCT00289146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0021-2005|Comparison of Immune Response Following Surgical Management of Renal Tumors|Comparison of Immune Response Following Surgical Management of Renal Tumors||Emory University|No|Terminated|November 2005|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Probability Sample|Patients undergoing open or laparoscopic surgeries for the treatment of kidney tumors.|September 2013|September 23, 2013|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00289146||185242|
NCT00288847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOB_00001_patella|Functional Surface Electromyogram of Knee Extensors in Healthy Humans and Patients With Patella-dislocation.|Functional Surface Electromyogram of Knee Extensors in Healthy Humans and Patients With Patella-dislocation.||University Hospital, Basel, Switzerland|No|Completed|November 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Retrospective|||Actual|15|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00288847||185265|
NCT00288860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEL 03-135|Telephone Case Monitoring (TCM) for Veterans With Post-Traumatic Stress Disorder (PTSD)|Telephone Case Monitoring for Veterans With PTSD|TCM-PTSD|VA Office of Research and Development|Yes|Completed|October 2006|December 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|926|||Both|18 Years|N/A|No|||September 2014|October 1, 2014|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288860||185264|
NCT00289185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104298|Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants|A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region.||GlaxoSmithKline||Completed|September 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|340|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||July 2014|July 3, 2014|February 8, 2006|Yes|Yes||No|November 8, 2012|https://clinicaltrials.gov/show/NCT00289185||185239|
NCT00289432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAM|Hospital Based Group Intervention for Breast Cancer Patients.|Effects of Group Intervention on Anxiety, Depression and Quality of Life Among Women Operated for Breast Cancer. A Randomized, Prospective Study.||Oslo University Hospital|Yes|Completed|April 2006|December 2014|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|450|||Female|18 Years|74 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00289432||185220|
NCT00289718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100556 (Y11)|Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule|Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers||GlaxoSmithKline||Completed|November 2004|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 6, 2014|February 9, 2006|Yes|Yes||No|January 11, 2010|https://clinicaltrials.gov/show/NCT00289718||185199|
NCT00286104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC-PWS-002|Impact of Ventricular Catheter Used With Antimicrobial Agents on Patients With a Ventricular Catheter|The Impact of Ventricular Catheter Impregnated With Antimicrobial Agents on Infection in Patients With Ventricular Catheter: A Prospective Randomized Study||Chinese University of Hong Kong|Yes|Completed|April 2004|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|184|||Both|18 Years|80 Years|No|||July 2009|December 21, 2009|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286104||185475|
NCT00286117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033IT/0002|ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years|An Open Randomised Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ as Adjuvant Therapies in Post-Menopausal Women With Breast Cancer Already Being Treated With NOLVADEX for at Least Two Years||AstraZeneca||Completed|March 1998|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|448|||Female|N/A|75 Years|No|||April 2009|April 30, 2009|February 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00286117||185474|
NCT00262392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PamidronateforHO271005|Study of Pamidronate for the Prevention of Heterotopic Ossification|Study Into the Effect of Pamidronate for the Prevention of Heterotopic Ossification in High-risk Patients: A Randomized Controlled Trial||University Hospital, Basel, Switzerland|No|Withdrawn|June 2005|June 2010|Anticipated|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|20 Years|N/A|No|||March 2015|March 9, 2015|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262392||187243|
NCT00262054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01005|Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)|Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3||Deutsches Herzzentrum Muenchen|Yes|Completed|November 2005|May 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4570|||Both|18 Years|N/A|No|||August 2008|March 12, 2010|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00262054||187269|
NCT00258492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-03-1-0082|Restless Legs Syndrome Exercise Intervention|The Prevalence and Outcomes of Restless Legs Syndrome Among Veterans - Exercise Intervention||Northeastern Ohio Universities College of Medicine||Active, not recruiting|December 2005|January 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|40 Years|N/A|No|||July 2006|January 25, 2007|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258492||187538|
NCT00259025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVN3DIALYSE|Intravenous n-3 Fatty Acids and Sudden Cardiac Death in Hemodialysis Patients|The Effect of Intravenous n-3 Polyunsaturated Fatty Acids on Risk Markers for Sudden Cardiac Death in Hemodialysis Patients||Aalborg Universitetshospital||Completed|September 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|90 Years|No|||April 2008|August 8, 2008|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259025||187498|
NCT00260208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400A2426|Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus|A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus||Novartis||Terminated|January 2006|||September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|361|||Both|18 Years|75 Years|No|||December 2011|December 2, 2011|November 30, 2005|Yes|Yes|Study was prematurely terminated due to poor recruitment.|No|September 14, 2011|https://clinicaltrials.gov/show/NCT00260208||187407|This study was prematurely discontinued due to poor recruitment. Since only a small patient group could be analyzed for primary outcome measure, robust conclusions on the effect of the two calcineurin inhibitors on the fibrosis score cannot be drawn.
NCT00260221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19635-B|VRH Pain Reduction During Burn Wound Care and Physical Therapy|Testing Interactions to Adjunctive Pain Control Techniques|VRH|National Institute of General Medical Sciences (NIGMS)|No|Completed|January 2002|November 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|77|||Both|7 Years|85 Years|No|||March 2011|May 6, 2013|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260221||187406|
NCT00259623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406902|Cardiac Surgical Treatment by Radiofrequency Ablation on Valvular Patients: Efficacy at 3 Months|Efficacy at 3 Months on Permanent Atrial Fibrillation in Patients Candidates to Cardiac Surgical Treatment by Epicardial, or Possibly Endocardial, Radiofrequency Ablation||University Hospital, Toulouse|No|Completed|December 2005|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||July 2009|July 16, 2009|November 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00259623||187452|
NCT00259636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EISAI 51-345-749|Zonisamide for Fibromyalgia & Migraine|Zonisamide for Fibromyalgia & Migraine||University of Pittsburgh|Yes|Withdrawn|August 2004|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||May 2011|May 31, 2011|November 26, 2005|Yes|Yes|Logistical problems prevented enrollment|No||https://clinicaltrials.gov/show/NCT00259636||187451|
NCT00260702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060032|Omalizumab to Treat Hyper-IgE (Job's) Syndrome|Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome||National Institutes of Health Clinical Center (CC)||Completed|November 2005|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|1|||Both|6 Years|76 Years|No|||March 2010|March 20, 2010|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00260702||187370|
NCT00260988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003391-01H|A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery|Tinzaparin Versus Dalteparin for Perioperative Thromboembolic Prophylaxis in Patients With Dialysis Dependent Renal Disease- A Canadian Multicentre Trial||Ottawa Hospital Research Institute|No|Completed|October 2003|November 2008|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|N/A|No|||July 2009|September 8, 2014|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260988||187349|
NCT00261001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORVACS 005|Safety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular Route|A Randomized Comparative Phase I Study to Evaluate and to Compare the Safety and Immunogenicity of a Transcutaneous Mode of Administration of a Licensed Tetanus/Influenza Vaccine to the Conventional Intramuscular Route of Vaccine Administration in Healthy Volunteers and HIV-infected Patients|MANON-05|Objectif Recherche Vaccins SIDA|No|Completed|October 2005|September 2009|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 24, 2009|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261001||187348|
NCT00288821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DINGO study|Diagnostic Imaging of Lymph Nodes in Gynaecologic Oncology|The Diagnostic Accuracy of Non-invasive Lymph Node Imaging in Gynaecologic Malignancies||UMC Utrecht||Completed|February 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Female|18 Years|N/A|No|Non-Probability Sample|patients with histologically proven cervical, vulvar, ovarian, endometrial cancer which        are planned to have a regional lymph node dissection.|February 2012|February 8, 2012|February 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00288821||185267|
NCT00288587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0007|Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)|CP0007: Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)||NxStage Medical||Completed|October 2003|January 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|February 6, 2006|Yes|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT00288587||185285|
NCT00289198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR106080|Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR)||GlaxoSmithKline||Completed|February 2006|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|301|||Both|12 Years|N/A|No|||March 2015|March 12, 2015|February 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00289198||185238|
NCT00289445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jth_003|Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)|Open, Multi-center Phase I/II Trial With Mitomycin C in Combination With 5-Fluorouracil and Folinic Acid in Pretreated Patients With Metastatic Gastrointestinal Cancer||University Hospital Tuebingen||Completed|September 1999|March 2006||March 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2013|January 25, 2013|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289445||185219|
NCT00289744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100561 (Y6)|Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule|Long-Term Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Children||GlaxoSmithKline||Completed|February 2004|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|171|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||October 2011|October 2, 2014|February 9, 2006|Yes|Yes||No|April 8, 2010|https://clinicaltrials.gov/show/NCT00289744||185197|
NCT00285844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDK071309|Integrating the Genetic and Metabolic Faces of Obesity|Integrating the Genetic and Metabolic Faces of Obesity||Stanford University||Completed|October 2005|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|88|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285844||185495|
NCT00286156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7736|Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease||The Cleveland Clinic|Yes|Completed|October 2006|December 2014|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|75 Years|No|||March 2014|March 31, 2015|February 1, 2006||No||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00286156||185471|
NCT00289731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100382|Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc|Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals' Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines||GlaxoSmithKline||Completed|November 2003|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|577|||Both|41 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 27, 2011|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00289731||185198|
NCT00285818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2HSE450|Mifepristone Used to Treat Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT)|A Double-blind, Placebo-controlled Study of Mifepristone in Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT)||Stanford University||Completed|January 2003|April 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||September 2010|September 15, 2010|January 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00285818||185497|
NCT00258258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 38504|Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders|An Open Label Dose Escalation Study of Intravenous Paricalcitol (ZEMPLAR™) [19-NOR-1 ALPHA, 25 - (OH)D] With Zoledronic Acid (Zometa™) in Patients With Multiple Myeloma||Roswell Park Cancer Institute|No|Terminated|August 2005|||March 2009|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|November 22, 2005||No|Withdrawn due to low accrual|No||https://clinicaltrials.gov/show/NCT00258258||187555|
NCT00259363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8330|Oxaliplatin in Rectal Cancer|Phase I-II Study of Preoperative Oxaliplatin-FU and Radiotherapy for Patients With Rectal Cancer||Sanofi||Terminated|October 2002|||June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|46|||Both|18 Years|80 Years|No|||December 2009|December 4, 2009|November 28, 2005||No|Study cancelled because recruitment rate was too slow|No||https://clinicaltrials.gov/show/NCT00259363||187472|
NCT00259649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901423|Prospective Survey of Menstrual Migraine & Prevention With Eletriptan|Assessment and Prevention of Menstrual Migraine: Phase 1-prospective Survey of Self-identified Menstrual Migraine. Phase 2-prevention of Menstrual Migraine With Relpax||University of Pittsburgh||Completed|August 2004|||August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|71|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|July 1, 2011|November 26, 2005|Yes|Yes||No|May 26, 2011|https://clinicaltrials.gov/show/NCT00259649||187450|Relatively small sample size and open-label treatment limit Menstrual regulation by hormonal therapy might have affected treatment response;
NCT00259662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0507000393|High-Dose Periop Statins for Prevention of DVT|High-Dose Statin Therapy in the Perioperative Period and DVT Prevention.||Yale University||Recruiting|November 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||150|||Female|18 Years|N/A|No|||November 2005|November 30, 2005|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259662||187449|
NCT00259961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05SG29|Clinical Outcome of Laparoscopic Versus Open Nissen Fundoplication in Children: 3−Year Follow-up Study of Randomized Controlled Trial.|||Institute of Child Health||Completed||December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|3 Years|20 Years|No|||December 2006|December 22, 2006|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00259961||187426|
NCT00259974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040409|RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy|Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2006|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|82 Years|No|||March 2007|May 5, 2011|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00259974||187425|
NCT00260468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20051050|Brain Abnormalities in Late-Onset Major Depression|Structural and Functional Cerebral Findings in Late-Onset Major Depression||University of Aarhus|No|Completed|November 2005|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|44|Samples With DNA|Apolipoprotein|Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|1. Subjects with first-episode late-onset major depression from psychiatric hospital or             clinic          2. Healthy controls|October 2009|October 21, 2009|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260468||187388|
NCT00260481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-01-076-01|Prometa Pharmacotherapy for Methamphetamine Dependence|Double-Blind, Placebo Controlled Trial of Prometa Pharmacotherapy for the Treatment of Methamphetamine Abuse||University of California, Los Angeles|Yes|Completed|January 2006|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260481||187387|
NCT00260741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00-DA-112|Cannabis for Spasticity in Multiple Sclerosis|Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study||Center for Medicinal Cannabis Research||Terminated|March 2003|January 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|21 Years|N/A|No|||April 2007|April 3, 2007|November 30, 2005|||Discontinued due to non-enrollment.|||https://clinicaltrials.gov/show/NCT00260741||187367|
NCT00261326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Statin-01|Simvastatin Treatment of Patients With Acute Optic Neuritis|Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial||Glostrup University Hospital, Copenhagen|Yes|Active, not recruiting|September 2006|May 2011|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|59 Years|No|||March 2009|January 7, 2011|December 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00261326||187323|
NCT00288340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050978|Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging|Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging||Vanderbilt University|No|Completed|January 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 12, 2008|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288340||185304|
NCT00288600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ivig01|Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease|Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants||Oswaldo Cruz Foundation|Yes|Completed|October 2006|August 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|N/A|6 Hours|No|||December 2015|December 2, 2015|February 6, 2006||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT00288600||185284|We calculated the sample size using a expected rate of 30% reduction in exchange using incidence of exchange transfusion at our department and data from a meta-analysis (relative risk, 0.21; 95% CI 0.10-0.45).
NCT00285857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0010|Phase II Trial - Breast Cancer Chemoprevention by Lovastatin|A Phase II Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer||Stanford University|Yes|Terminated|November 2005|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|65 Years|No|||June 2014|June 5, 2014|January 31, 2006||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00285857||185494|
NCT00285870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPPER EXTREMITY HYPERTONIA|Quantification of Upper Extremity Hypertonia|Quantification of Upper Extremity Hypertonia||University of Southern California||Completed|January 2006|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|60|||Both|4 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children with cerebral palsy and/or dystonia.|March 2013|March 11, 2013|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285870||185493|
NCT00286182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB3037|Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)|Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status||Columbia University|Yes|Completed|July 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|55 Years|N/A|No|||February 2015|February 25, 2015|February 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00286182||185469|
NCT00286468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-SULF-007|Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes||Takeda|No|Completed|April 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|500|||Both|18 Years|80 Years|No|||February 2012|February 1, 2012|February 1, 2006|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00286468||185447|
NCT00286169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0702002|Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)|Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer||Sumitomo Dainippon Pharma Co., Ltd.||Terminated|April 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|130|||Both|70 Years|N/A|No|||August 2010|August 9, 2010|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286169||185470|
NCT00286455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-PLC-010|Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared With Placebo in Subjects With Type 2 Diabetes||Takeda|No|Completed|February 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|329|||Both|18 Years|80 Years|No|||February 2012|February 1, 2012|February 1, 2006|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00286455||185448|
NCT00285831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95879|Mild Depression 2 Week Observational Study|Dysphoric-Like Disorder of Epilepsy, Is it Unique?||Stanford University||Active, not recruiting|December 2005|||||N/A|Observational|Time Perspective: Prospective||||120|||Both|18 Years|N/A|No|||October 2008|October 23, 2008|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285831||185496|
NCT00258752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH071320|Comparison of Three Therapy-Based Interventions for Preventing Depression in Adolescents|Prevention of Depression in Adolescents||Rutgers University|No|Completed|November 2005|June 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|57|||Both|11 Years|17 Years|No|||April 2013|April 11, 2013|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258752||187519|
NCT00258765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GAU15|Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.|A Phase IIb Randomised Clinical Trial of the Tolerability, Safety and Efficacy of Adjuvant Docetaxel-Zoledronic Acid After Prostatectomy for High-risk Early Prostate Cancer (AD-ZAP).||Novartis|Yes|Terminated|May 2006|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1|||Male|30 Years|N/A|No|||April 2010|April 23, 2010|November 24, 2005||No|Poor recruitment & not feasible to continue|No||https://clinicaltrials.gov/show/NCT00258765||187518|
NCT00259038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0-162|Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure|||Daiichi Sankyo Inc.||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 28, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00259038||187497|
NCT00259051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9587C00002|A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population|A Double-blind, Randomised, Parallel-group, Multicentre, Phase III Study to Investigate the Pharmacodynamic Effect by Assessment of the 24 Hours Intraesophageal pH Level, the Efficacy and Safety of Omeprazole 10mg and 20mg od in Patients With Non-erosive Reflux Disease (NERD).||AstraZeneca||Completed|January 2004|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|20 Years|N/A|No|||January 2011|January 21, 2011|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259051||187496|
NCT00259350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anticath|Chlorhexidine vs Povidone Iodine in Alcoholic Solutions for Prevention of Central Venous Catheter Infection|Prevention of Central Venous Catheter Infections : Comparison of the Efficacy of Skin Disinfection With 5% Povidone Iodine in Alcoholic Solution Versus 0.25% Chlorhexidine, 0.025 Benzalkonium and 4% Benzylic Alcohol||Poitiers University Hospital||Completed|May 2004|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||520|||Both|18 Years|N/A|No|||January 2009|January 26, 2009|November 27, 2005||||No||https://clinicaltrials.gov/show/NCT00259350||187473|
NCT00259376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4788|American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm|American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)|ADONIS|Sanofi||Completed|November 2001|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|629|||Both|21 Years|N/A|No|||February 2010|February 12, 2010|November 25, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00259376||187471|
NCT00259675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB 04-99|Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC|Treatment of Stages IIIB and IV, Non Small Cell Lung Cancer With Alternating Cycles of Carboplatin/Taxol and Carboplatin/Gemcitabine.||University of Saskatchewan||Completed|May 2004|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|19 Years|75 Years|No|||May 2007|November 10, 2007|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259675||187448|
NCT00260247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-315|Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine.|Induction of Drug Metabolism: A Comparative, Pharmacokinetic in Vivo Study of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4.||Odense University Hospital||Completed|April 2005|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2005|April 21, 2015|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00260247||187404|
NCT00260234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-PCIA-04-001|Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients|A Single-Center Phase I/II Study Of Peg-Encapsulated Islet Allografts Implanted In Patients With Type I Diabetes||Novocell||Terminated|November 2005|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||12|||Both|20 Years|N/A|No|||September 2014|September 8, 2014|November 28, 2005|Yes|Yes|Stopped in December 2007|No||https://clinicaltrials.gov/show/NCT00260234||187405|
NCT00260728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2100|The Boston Scientific ACCESS Trial|ACCESS: Prospective, Multi-center Trial of the Fusion Vascular Access Graft for Patients Who Require Early Vascular Access for Hemodialysis|ACCESS|Maquet Cardiovascular||Terminated|December 2005|December 2008|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|November 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00260728||187368|
NCT00261014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002452-01H|Understanding Risk Factors Involved in Developing a Second Blood Clot.|REcurrent VEnous Thromboembolism Risk Stratification Evaluation A Study to Develop a Clinical Prediction Rule to Predict Low Recurrence Risk in Patients With Idiopathic Venous Thromboembolism.||Ottawa Hospital Research Institute|No|Active, not recruiting|October 2002|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|patients diagnosed with idiopathic blood clots|November 2015|November 17, 2015|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00261014||187347|
NCT00271115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25165|Kangaroo Holding and Maternal Stress|The Effect of Kangaroo Holding on Maternal Stress Levels||Christiana Care Health Services|No|Completed|September 2005|January 2008|Actual|October 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00271115||186593|
NCT00271128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hymc34/2005|NT-proBNP for Evaluation of the Dyspneic Patient in the Emergency Room and the Medical Ward|NT-proBNP for Evaluation of the Dyspneic Patient in the Emergency Room and the Medical Ward (BNP4EVER)||Hillel Yaffe Medical Center||Active, not recruiting|October 2005|September 2007|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|N/A|No|||December 2005|March 19, 2008|December 29, 2005||||No||https://clinicaltrials.gov/show/NCT00271128||186592|
NCT00288353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050943|Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes|Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes||Vanderbilt University|No|Terminated|January 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||January 2009|January 23, 2009|February 6, 2006|Yes|Yes|unable to secure additional funding|No||https://clinicaltrials.gov/show/NCT00288353||185303|
NCT00288873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509008122|Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity|Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity||Weill Medical College of Cornell University||Active, not recruiting|February 2006|July 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2007|July 19, 2007|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288873||185263|
NCT00289783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103813|Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine|A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.||GlaxoSmithKline||Completed|February 2006|August 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|4441|||Both|6 Weeks|15 Months|Accepts Healthy Volunteers|||October 2012|October 18, 2012|February 9, 2006|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00289783||185194|
NCT00285896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0172|GLP-1 Infusion and Long-Time Fasting|The Effect of 48 Hours of GLP-1 Infusion During Long-Time Fasting on Glycaemia and Counterregulatory Hormones||University of Aarhus|Yes|Completed|December 2005|May 2007|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||July 2008|July 10, 2008|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285896||185491|
NCT00285883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/03|Directly Observed Therapy in High Risk Populations in Newark, NJ|Directly Observed Therapy in High Risk Populations in Newark, NJ||Saint Michael's Medical Center||Completed|April 2004|May 2006||||Phase 3|Interventional|N/A||||30|||Male|18 Years|N/A|No|||January 2006|February 27, 2006|January 31, 2006||||||https://clinicaltrials.gov/show/NCT00285883||185492|
NCT00286195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Frontier Registry II|Frontier Registry II Bifurcation Stent System Registry|The Abbott Vascular MULTI -LINK FRONTIER Coronary Bifurcation Stent System Registry II||Abbott Vascular||Withdrawn|December 2004|December 2006||December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||May 2015|May 12, 2015|February 2, 2006||No|Study was withdrawn due to a business decision.|No||https://clinicaltrials.gov/show/NCT00286195||185468|
NCT00286975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDLead:Patel et al.|Growing Future Physician Leaders: A Randomized Trial of an Educational Intervention in Postgraduate Trainees|Growing Future Physician Leaders: A Randomized, Controlled Trial of an Educational Intervention in Postgraduate Trainees||McGill University Health Center||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2005|October 16, 2008|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286975||185409|
NCT00286676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-045|The Use of Nutropin Depot in HIV-Infected Adult Males|||University of Texas Southwestern Medical Center||Active, not recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Male|18 Years|N/A|No|||January 2006|February 1, 2006|February 1, 2006||||||https://clinicaltrials.gov/show/NCT00286676||185431|
NCT00258778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-01-2005|Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)|A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers||Protalix||Completed|November 2005|January 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2006|December 4, 2006|November 23, 2005||||||https://clinicaltrials.gov/show/NCT00258778||187517|
NCT00259064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0711|Iressa v BSC (Best Supportive Care) in First Line NSCLC|A Phase II Multicentre Randomised, Parallel Group, Double-Blind, Placebo-Controlled Study of ZD1839 (IRESSATM) (250MG Tablet) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Chemotherapy-Naive Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status|INSTEP|AstraZeneca||Active, not recruiting|September 2004|December 2016|Anticipated|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|130 Years|No|||February 2016|February 1, 2016|November 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00259064||187495|
NCT00259077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9587C00001|Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population|A Double-blind, Randomised, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy of Omeprazole 20mg and 10mg od for the Four-week Treatment of Non-erosive Reflux Disease (NERD) With That of Placebo od and to Investigate Safety||AstraZeneca||Completed|October 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|20 Years|N/A|No|||January 2011|January 21, 2011|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259077||187494|
NCT00259688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB 05-110|Prevalence Study of Sleep Apnea in Women With Preeclampsia|Sleep Disordered Breathing and Preeclampsia||University of Saskatchewan||Completed|February 2006|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 7, 2010|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259688||187447|
NCT00259701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC-12397-1|Microvascular Reactivity.|Transdermal Application of Acetylcholine and Nitroglycerin Without Iontophoresis.||Yale University||Completed|June 2005|September 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2005|October 5, 2006|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259701||187446|
NCT00259987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF102980|Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus|A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients With Relapsed Adenocarcinoma of the Esophagus, Including Tumors of the Gastroesophageal Junction and Gastric Cardia||GlaxoSmithKline||Completed|November 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2009|May 15, 2009|November 30, 2005||||||https://clinicaltrials.gov/show/NCT00259987||187424|
NCT00260000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-2706-BH4-1|Study of BH4, a New and Simple Treatment of Mild PKU|Study of the Response of Tetrahydrobiopterin on S-Phenylalanine in Patients With PKU Housing the Y414C Mutation||The Kennedy Institute-National Eye Clinic||Completed|April 2005|December 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|8 Years|N/A|No|||April 2006|April 12, 2006|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260000||187423|
NCT00260494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7546-25444|Acupuncture and Post-Surgical Wound Healing|Acupuncture and Post-Surgical Wound Healing in Coronary Artery Bypass Graft Patients Undergoing Open Saphenous Vein Graft Harvest||University of California, San Francisco|Yes|Terminated|March 2005|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|65|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|November 29, 2005||No|No difference in primary outcomes at interim analysis.|No||https://clinicaltrials.gov/show/NCT00260494||187386|
NCT00260507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D40921|The Impact of Vocational Rehabilitation for Mentally Ill Veterans|The Impact of Vocational Rehabilitation on Mentally Ill Veterans|VocRehab|Tuscaloosa Research & Education Advancement Corporation|No|Active, not recruiting|August 2006|May 2014|Anticipated|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|100|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260507||187385|
NCT00270816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU - CYC - 06|Interferon ß-1b Treatment by Cyclical Administration|Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose.||S. Andrea Hospital|Yes|Completed|November 2005|November 2013|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|No|||December 2013|February 10, 2014|December 27, 2005||No||No||https://clinicaltrials.gov/show/NCT00270816||186616|
NCT00270829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26854|Renal Effects of Intrarenal Nesiritide|Renal Effects of Intrarenal Nesiritide||University of Maryland||Terminated|December 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2008|February 8, 2008|December 23, 2005||No|Funding not available|No||https://clinicaltrials.gov/show/NCT00270829||186615|
NCT00288613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0009|FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study|FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study||NxStage Medical|Yes|Completed|January 2006|November 2013|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|501|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with ESRD who are candidates for daily hemodialysis with the NxStage System        One and have Medicare as the primary payor.|July 2014|July 22, 2014|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288613||185283|
NCT00289757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100576 (Y11)|Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule|Double-blind, Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Three Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 6 Month Schedule in Healthy Adult Subjects||GlaxoSmithKline||Completed|January 2004|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|78|||Both|29 Years|60 Years|Accepts Healthy Volunteers|||May 2014|July 24, 2014|February 9, 2006|Yes|Yes||No|December 10, 2009|https://clinicaltrials.gov/show/NCT00289757||185196|
NCT00286234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61486 (completed)|Niacin, N-3 Fatty Acids and Insulin Resistance|Niacin, N-3 Fatty Acids and Insulin Resistance||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2007|December 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|10|||Both|40 Years|69 Years|No|||April 2013|April 30, 2013|February 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00286234||185465|
NCT00286208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1.5|Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation|A Randomized Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation||Gynuity Health Projects||Completed|August 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1443|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286208||185467|
NCT00286221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001283|IVPCA in the Management of Pain Following Major Intracranial Surgery|The Safety and Efficacy of IVPCA in the Management of Adult Postoperative Craniotomy Pain: A Prospective, Randomized Controlled Trial||Johns Hopkins University||Not yet recruiting|March 2006|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||128|||Both|18 Years|N/A|No|||January 2006|February 1, 2006|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286221||185466|
NCT00286494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-TZD-009|Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus||Takeda|No|Completed|February 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|493|||Both|18 Years|80 Years|No|||February 2012|February 1, 2012|February 1, 2006|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00286494||185445|
NCT00286481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-475-020|Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia|A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of Lapaquistat and Simvastatin Alone and in Combination in Subjects With Hypercholesterolemia||Takeda|No|Completed|March 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1362|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|February 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00286481||185446|
NCT00287001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/2005|Effect of Cold Air Cooling on the Incidence of Post Inflammatory Hyperpigmentation Following Laser Treatment|Effect of Cold Air Cooling on the Incidence of Post Inflammatory Hyperpigmentation Following a Q-Switched Nd:YAG Laser Treatment of Acquired Bilateral Nevus of Ota-Like Macules||Mahidol University|No|Completed|December 2005|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2007|May 21, 2008|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00287001||185407|
NCT00259103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLX.CR.001|Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Pharmacokinetics and Efficacy of Intravenous Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labour||Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies||Completed|November 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|72|||Female|18 Years|40 Years|No|||May 2014|May 6, 2014|November 15, 2005||No||No||https://clinicaltrials.gov/show/NCT00259103||187492|
NCT00259389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACTG P1036B|Directly Observed Therapy for HIV Infected Adolescents|Directly Observed Therapy (DOT) in HIV-1 Infected Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|16 Years|25 Years|No|||September 2012|September 17, 2012|November 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00259389||187470|
NCT00259402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC_7127|Oxaliplatin in Esophagus Cancer (Advanced) 1st Line|Phase II Open-label Single Arm Study of Oxaliplatin Combined With Cisplatin and 5FU in Advanced Esophagus Cancer Patients||Sanofi||Completed|February 2000|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|75 Years|No|||December 2009|December 4, 2009|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259402||187469|
NCT00259727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCD-005-05S|The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism|The Effects of HIV Protease Inhibitors on Glucose Metabolism||VA Office of Research and Development||Completed|January 2006|September 2008|Actual|||N/A|Observational|N/A||1|Anticipated|80|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||March 2009|September 28, 2009|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259727||187444|
NCT00259714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509000646|Dialysate Sodium Individualization in Hemodialysis|Hemodynamic and Hormonal Responses to Dialysate Sodium Individualization in Hemodialysis Patients||Yale University|No|Terminated|March 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|90 Years|No|||October 2008|October 3, 2008|November 28, 2005||No|Protocol was not feasible - only 1 of 18 enrollees completed procedures.|No||https://clinicaltrials.gov/show/NCT00259714||187445|
NCT00260286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Excalibur X|Effects of Gynecological Age on LH Sensitivity to Energy Availability|Dietary Energy Requirements in Physically Active Men and Women, Objective 4B: Effects of Gynecological Age on LH Sensitivity to Energy Availability||Ohio University||Completed|August 2001|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||18|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||November 2005|December 2, 2005|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260286||187401|
NCT00260260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-001145-42|OXY-1: The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain|The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain||Odense University Hospital||Completed|June 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|80 Years|No|||January 2008|January 3, 2008|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260260||187403|
NCT00260273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107/2004|Access, Detection and Psychological Treatments|Access, Detection and Psychological Treatments||Ontario Mental Health Foundation|No|Active, not recruiting|August 2004|August 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|56|||Both|12 Years|30 Years|No|||October 2007|November 7, 2007|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00260273||187402|
NCT00260754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4087|Utilization of the Community Popular Opinion Leader (C-POL) Model in Alabama|Utilization of the Community Popular Opinion Leader (C-POL) Model to Achieve Syphilis Elimination in Alabama||Centers for Disease Control and Prevention||Completed|October 2002|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|May 30, 2006|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00260754||187366|
NCT00271882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 053|PTSD and Risk Behavior in HIV Positive Female Adolescents|PTSD and Risk Behavior in HIV Positive Female Adolescents||Westat|No|Completed|March 2006|September 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Female|18 Years|24 Years|No|Non-Probability Sample|English speaking women, 18-24 years old with behaviorally- acquired HIV through        heterosexual intercourse or injection drug use after the age of 9 years, who report a        history of sexual and/or physical abuse prior to age 18, and who have engaged in vaginal        or anal intercourse in the 4 months prior to screening.|February 2016|February 29, 2016|December 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00271882||186535|
NCT00289458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB 05-158|Aquatic Exercise and Efficacy Enhancement to Decrease Fall Risk in Older Adults With Hip Osteoarthritis|The Effect of Aquatic Exercise and Aquatic Exercise Combined With Education and Efficacy Enhancement on Improving Indices of Fall Risk in Older Adults With Hip Osteoarthritis: a Randomized Controlled Clinical Trial||University of Saskatchewan||Completed|October 2005|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|79|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 6, 2010|February 7, 2006||No||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00289458||185218|
NCT00289770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100551 (EXT Y11)|Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults|A Double Blind Randomised, Comparative Study of the Immunogenicity and Reactogenicity of Three Different Lots of GlaxoSmithKline Biologicals' Combined Hepatitis A - Hepatitis B Vaccine When Administered in Healthy Adults||GlaxoSmithKline||Completed|November 2004|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|June 26, 2014|February 9, 2006|Yes|Yes||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00289770||185195|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following complete retesting and reanalysis.
NCT00289796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210602-002|Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine|Assess the Feasibility of an Investigational Vaccination Regimen, Compared to a 3-dose Primary Vaccination With GSK Bio's Infanrix Hexa™ (DTPa-HBV-IPV/Hib Vaccine) Following Hepatitis B Vaccination at Birth. Primary Vaccination is Followed in the 2nd Year of Life by a Booster Dose of Infanrix-hexa||GlaxoSmithKline||Completed|July 2004|December 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|121|||Both|N/A|5 Days|Accepts Healthy Volunteers|||November 2011|October 9, 2014|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00289796||185193|
NCT00287560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBMDE-0312|Effect of a Modified Propofol Preparation on Injection Pain During Induction of Anesthesia in Children|A Comparison of Venous Tolerability and Injection Pain of a Modified Propofol Preparation and Standard Propofol in the Induction of Anesthesia in Children||B. Braun Melsungen AG||Completed|August 2003|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||64|||Both|2 Years|6 Years|No|||February 2008|February 22, 2008|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00287560||185364|
NCT00286507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/235|Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study|Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study: Randomised Comparison of Macular Hole Surgery With or Without Internal Limiting Membrane Peeling|FILMS|University of Aberdeen||Completed|July 2005|September 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00286507||185444|
NCT00286741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-084|Can Group Visits Improve Outcomes of Veterans With Diabetes|Can Group Visits Improve Outcomes of Veterans With Diabetes||VA Office of Research and Development|Yes|Completed|June 2006|January 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|N/A|N/A|No|||May 2014|April 6, 2015|February 1, 2006||No||No|July 31, 2014|https://clinicaltrials.gov/show/NCT00286741||185427|
NCT00286728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-014|Dual Diagnosis Self-Help Referral|Dual Diagnosis Self-Help Group Referral: Outcomes and Services Use||VA Office of Research and Development|No|Completed|April 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|287|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|February 1, 2006||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT00286728||185428|
NCT00277927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-035|Mild Valvar Pulmonary Stenosis|Clinical Management of Children With Mild Valvar Pulmonary Stenosis||Children's Healthcare of Atlanta|No|Terminated|January 1984|December 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|146|||Both|N/A|2 Years|No|Non-Probability Sample|Children at Children's Healthecare of Atlanta between the dates of 1984 and 2003 with mild        valvar pulmonary stenosis that were less than 2 years old|November 2007|July 5, 2011|January 13, 2006|||sufficient data collected for significant study results|No||https://clinicaltrials.gov/show/NCT00277927||186089|
NCT00258804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4055|Insulin Glargine During and After the Period of Fasting in Ramadan|Evaluation (Safety and Efficacy) of Treatment With Insulin Glargine and Glimepiride in Patients With Type 2 Diabetes Before, During and After the Period of Fasting in Ramadan||Sanofi||Completed|May 2005|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|35 Years|N/A|No|||June 2011|June 7, 2011|November 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00258804||187515|
NCT00259116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLX.CHF.001|A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure|A Pilot Safety and Dose-Finding Trial of Intravenous Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure||Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies||Completed|November 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|90 Years|No|||April 2009|April 13, 2009|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259116||187491|
NCT00259129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100561|Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients|Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients||Bayer|No|Completed|August 2005|March 2008|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|53|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|November 28, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00259129||187490|
NCT00259142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGA.5.2RNA2005|Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies|Community Acceptability and Cost-effectiveness of Two Drug Distribution Methods for Home Based Management of Fevr in Kayunga District, Uganda||DBL -Institute for Health Research and Development||Terminated|November 2005|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1314|||Both|N/A|59 Months|No|||May 2015|May 12, 2015|November 25, 2005|||Study never started|No||https://clinicaltrials.gov/show/NCT00259142||187489|
NCT00259740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050134|Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab|An Open-Label, Multi-Center Phase 2 Trial of Denosumab in the Treatment of Relapsed or Plateau-Phase Multiple Myeloma||Amgen|No|Completed|November 2005|December 2011|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|November 29, 2005|Yes|Yes||No|December 9, 2010|https://clinicaltrials.gov/show/NCT00259740||187443|
NCT00260013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-093|Transition Into Primary-care Psychiatry (TIPP)|Transition Into Primary-care Psychiatry (TIPP): A Mental Health Demonstration Project.||Lawson Health Research Institute|No|Completed|January 2005|January 2006|Actual|January 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|65 Years|No|||March 2010|March 22, 2010|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260013||187422|
NCT00270036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005902|A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.|A Double-Blind, Placebo-Controlled Study to Determine the Safety of r-HuEPO and Whether r-HuEPO Can Reduce Post-Operative Transfusion Requirements in Subjects Undergoing Major Orthopedic Surgery||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 1991|October 1991|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|N/A|No|||November 2010|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270036||186675|
NCT00260520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-03-1942|LMWH to Prevent Preeclampsia and Fetal Growth Restriction|Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation||University of Florence||Terminated|January 2002|December 2003||||Phase 4|Observational|N/A|||||||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2003|March 3, 2006|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260520||187384|
NCT00270530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1954-21/22-2|Intermittent Preventive Treatment of Malaria in HIV-Seropositive Pregnant Women in Zambia|Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia||Center for International Health and Development||Completed|November 2002|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||454|||Female|18 Years|50 Years|No|||November 2004|January 30, 2006|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00270530||186637|
NCT00271622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060065|Screening for Studies on Autism Spectrum Disorders|Screening Protocol for Studies of the Pediatrics and Developmental Neuroscience Branch||National Institutes of Health Clinical Center (CC)||Recruiting|December 2005|||||N/A|Observational|N/A|||Anticipated|5000|||Both|N/A|20 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|December 31, 2005||No||No||https://clinicaltrials.gov/show/NCT00271622||186554|
NCT00271635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/320|Ascorbic Acid Treatment in CMT1A Trial (AATIC)|Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A|AATIC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|January 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|12 Years|25 Years|No|||July 2008|July 2, 2008|January 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00271635||186553|
NCT00267631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-02-VA10|Impact of Body Weight on the Immediate Health of the Pediatric Population|The Influence of Childhood Obesity on Presentation to a Pediatric Emergency Department||Maimonides Medical Center|No|Completed|April 2005|March 2007|Actual|March 2007|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5392|||Both|2 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric Emergency Medicine Patients|July 2013|July 29, 2013|December 19, 2005||No||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00267631||186851|
NCT00289471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-112|Identifying Patients With Dementia in Primary Care|Dementia in Primary Care: Setting the Stage for Quality Improvement|GEMS|VA Office of Research and Development|No|Completed|October 2009|October 2010|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|630|||Both|65 Years|N/A|No|Probability Sample|Veterans' who have previously completed GEMS-Phase 1 testing, continues to be a VA clinic        patient and identifies a key family member or friend who will answer questions about the        veteran's memory and daily activities.|April 2015|April 10, 2015|February 8, 2006||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT00289471||185217|
NCT00289809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2005-001|TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients|A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma||Istituto Clinico Humanitas|No|Completed|September 2006|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2009|December 17, 2009|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00289809||185192|
NCT00287313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-MED-491|Daily Vitamin K in Patients on Warfarin With Unstable INRs|Use of Daily Vitamin K Supplementation in Patients on Warfarin With a History of Frequent Dose Changes or Variable INRs||University of North Carolina, Chapel Hill|No|Completed|October 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287313||185383|
NCT00287014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0042|Rift Valley Fever in Kenya|Late Outcomes of Rift Valley Fever in Kenya: Ijara Clinical Survey||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|April 2006||||N/A|Observational|Time Perspective: Prospective||||250|||Both|1 Year|N/A|Accepts Healthy Volunteers|||October 2007|August 26, 2010|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287014||185406|
NCT00288184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK64587-DENA (completed)|Uric Acid in Essential Hypertension in Children|Randomized Double-blinded, Placebo-controlled, Cross-over Trial of Allopurinol for the Treatment of Newly Diagnosed Essential Hypertension in Adolescents||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|December 2003|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|12 Years|18 Years|No|||January 2010|January 12, 2010|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288184||185316|
NCT00288431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-015|Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)|A Phase 1B, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin||Merck Sharp & Dohme Corp.|No|Completed|February 2006|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00288431||185297|
NCT00259155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4166|Rifaximin for the Treatment of Irritable Bowel Syndrome|Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth and IBS: Double Blind Randomized Controlled Trial (Multicenter Trial)||Cedars-Sinai Medical Center||Completed|July 2003|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||92|||Both|18 Years|65 Years|No|||July 2003|March 17, 2008|November 25, 2005||||||https://clinicaltrials.gov/show/NCT00259155||187488|
NCT00259415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIRG-00-1998|Telesupport: Evaluation of Professionally Led Support Groups for Caregivers|Evaluation of Professionally Led Support Groups for Caregivers||Thomas Jefferson University||Completed|September 2000|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind|||||||Female|55 Years|N/A||||July 2015|July 6, 2015|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259415||187468|
NCT00259753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU201|Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration|A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration||OPKO Health, Inc.|Yes|Completed|July 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|50 Years|N/A|No|||July 2008|August 4, 2008|November 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00259753||187442|
NCT00259766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00001|SHARE - Symbicort and Health Economics in a Real Life Evaluation|Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months||AstraZeneca||Completed|April 2004|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1970|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259766||187441|
NCT00260026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-010|Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer|Safety and Pharmacokinetic Study of Jin Fu Kang In Combination With Docetaxel for Patients With Previously Treated Non-Small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|November 2004|January 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2007|January 25, 2007|November 29, 2005||||||https://clinicaltrials.gov/show/NCT00260026||187421|
NCT00270556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-02-1008|Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.|Phase II, Open-Label,Randomised, Comparator Study of Substitution w/Tenofovir or Abacavir in HIV-1 Infected Individuals, w/Viral Load Less 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of HAART.||Gilead Sciences||Completed|January 2003|October 2004||||Phase 2|Interventional|N/A||||100|||Both|18 Years|N/A|No|||April 2008|April 7, 2008|December 23, 2005||||No||https://clinicaltrials.gov/show/NCT00270556||186635|
NCT00270842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O4006-R|Effect of Exercise on Gait and Balance in Peripheral Neuropathy|Effect of Exercise on Gait and Balance in Peripheral Neuropathy||VA Office of Research and Development|No|Completed|January 2006|September 2012|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|101|||Both|N/A|N/A|No|||April 2015|April 7, 2015|December 23, 2005||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT00270842||186614|Due to the large number of drop outs following the 10 week data point, maintenance of gait and balance changes is uncertain.
NCT00270270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006070|A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||July 1989|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|63|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270270||186657|
NCT00271141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hy11/2005|Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease|Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease||Hillel Yaffe Medical Center||Recruiting|May 2005|December 2015||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2005|December 29, 2005|December 29, 2005||||No||https://clinicaltrials.gov/show/NCT00271141||186591|
NCT00271401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006265|A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab|A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percutaneous Coronary Intervention||Centocor, Inc.|No|Completed|July 1996|September 1997|Actual|September 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2399|||Both|21 Years|N/A|No|||May 2015|May 22, 2015|December 30, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00271401||186571|
NCT00258375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I164|OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer|A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer||Canadian Cancer Trials Group||Completed|June 2005|September 2008|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|42|||Female|18 Years|N/A|No|||March 2010|November 7, 2010|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258375||187546|
NCT00258908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD521|Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan|Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age.||Sanofi|No|Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|115|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|November 24, 2005|Yes|Yes||No|April 7, 2009|https://clinicaltrials.gov/show/NCT00258908||187507|
NCT00258921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-9511|RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment|An International Registry in Essential Hypertension|RIAT|Sanofi||Completed|March 2004|July 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||31870|||Both|N/A|N/A|No|||November 2007|November 21, 2007|November 24, 2005||||No||https://clinicaltrials.gov/show/NCT00258921||187506|
NCT00259233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B208, 2|The Role of Peptide YY (PYY)in Inhibiting Food Intake.|The Effects of Peripheral Administration of Saline, PYY1-36 and PYY3-36 on ad Libitum Energy Intake and Appetite.||University of Copenhagen||Completed|March 2005|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2007|January 20, 2009|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259233||187482|
NCT00289484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05156|A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression|A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acid as an Augmentor of Antidepressant Medication for Major Depression.||The University of New South Wales||Recruiting|February 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|65 Years|No|||September 2006|September 11, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00289484||185216|
NCT00289822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158/02|Cell Therapy for Coronary Heart Disease|Cell Therapy for Coronary Heart Disease: Infusion of Autologous Ex Vivo Cultivated Endothelial Progenitor Cells (EPCs)” and Autologous Bone Marrow Progenitor Cells in Crossover Design for Improvement of Vascularization and Cardiac Function||Johann Wolfgang Goethe University Hospitals||Terminated|January 2002|January 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|80 Years|No|||February 2006|November 29, 2006|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289822||185191|
NCT00287027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS#17558|Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication|Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication||National Alliance on Mental Illness New Hampshire||Terminated|February 2006|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2007|January 4, 2007|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287027||185405|
NCT00287040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408-03B|Breast Cancer Screening Via Computer V. Phone|Breast Cancer Screening Via Computer V. Phone||Indiana University|Yes|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1686|||Female|41 Years|75 Years|Accepts Healthy Volunteers|||August 2008|May 16, 2012|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287040||185404|
NCT00288210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183/2003|Sirolimus Eluting Stenting in Acute Myocardial Infarction|Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI||San Camillo Hospital, Rome||Active, not recruiting|March 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|February 9, 2006|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288210||185314|
NCT00287768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JACCRO GC-03|Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer|A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer||Japan Clinical Cancer Research Organization|Yes|Completed|March 2006|October 2010|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|628|||Both|20 Years|79 Years|No|||June 2011|June 27, 2011|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287768||185348|
NCT00287976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454758|Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma|Irinotecan Single-Drug Treatment For Children With Refractory or Recurrent Hepatoblastoma||National Cancer Institute (NCI)||Active, not recruiting|April 2003|||December 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|20 Years|No|||June 2009|September 16, 2013|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00287976||185332|
NCT00288197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501066|A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections|An Open, Prospective, Uncontrolled, Multi-Center Study To Evaluate The Efficacy And Safety Of Voriconazole In Chinese Subjects With Proven Or Probable Serious Invasive Fungal Infections||Pfizer||Completed|January 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|77|||Both|18 Years|75 Years|No|||June 2008|June 10, 2008|February 6, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00288197||185315|
NCT00288470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYLA-001-01|A Double-blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast.|||Sanofi||Completed|June 2002|August 2003||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|30 Years|55 Years||||March 2015|March 17, 2015|February 7, 2006||||||https://clinicaltrials.gov/show/NCT00288470||185294|
NCT00288483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC53W0.01|Cholesterol-Lowering Effects of Policosanol|Placebo-Controlled, Randomised, Double-Blind, Multi-Centre Clinical Trial on Dose-Dependent Cholesterol-Lowering Effects of Policosanol in Patients With Hypercholesterolaemia With 10 to 80 Mg Policosanol for 12 Weeks||Drug Commission of the German Medical Association||Terminated|September 2000|July 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||November 2005|July 20, 2006|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288483||185293|
NCT00259168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-005/03|Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?|Insulin Resistance and Postprandial Endothelial Function: Does Early Intervention Make a Difference?||Bispebjerg Hospital||Recruiting|June 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||70|||Both|25 Years|75 Years||||November 2005|November 28, 2005|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259168||187487|
NCT00259181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191058HMO-CTIL|A Protocol for the Use of Chlorhexidine Gluconate Saturation for the Reduction of Dental Biofilm Formation on Polymethylmethacrylate Restoration|Examination of the Immersion of Provisional Crown Material in Chlorhexidine Gluconate on Dental Plaque Formation in Vivo||Hadassah Medical Organization||Completed|January 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||12|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2007|January 5, 2010|November 24, 2005||||No||https://clinicaltrials.gov/show/NCT00259181||187486|
NCT00259428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC3153|EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)|EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)|EURIDIS|Sanofi|Yes|Completed|November 2001|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|615|||Both|21 Years|N/A|No|||February 2010|February 8, 2010|November 25, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00259428||187467|
NCT00269776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005989|An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder|Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD||Alza Corporation, DE, USA||Completed|November 1998|January 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||||||Both|6 Years|12 Years|No|||July 2011|July 8, 2011|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269776||186695|
NCT00270049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005905|Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia|The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 1990|January 1994|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|195|||Both|18 Years|N/A|No|||January 2011|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270049||186674|
NCT00270582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-94015|A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer|A Randomized Phase II Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small Cell Lung Cancer||Far Eastern Memorial Hospital||Recruiting|November 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|75 Years|No|||September 2005|February 6, 2009|December 26, 2005||||No||https://clinicaltrials.gov/show/NCT00270582||186633|
NCT00270283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006076|A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 1988|April 1990|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|102|||Both|18 Years|75 Years|No|||July 2009|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270283||186656|
NCT00270543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-93006|An Effective and Well-Tolerated Regimen of Docetaxel Plus High-Dose 5-Fluorouracil and Leucovorin(HDFL)to Treat Inoperable Advanced or Metastatic Gastric Cancer|A Phase II Study of Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin(HDFL)for Inoperable Advanced or Metastatic Gastric Cancer||Far Eastern Memorial Hospital||Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|75 Years|No|||September 2004|February 6, 2009|December 26, 2005||||No||https://clinicaltrials.gov/show/NCT00270543||186636|
NCT00271154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233|REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)|REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)||Medtronic Cardiac Rhythm Disease Management|Yes|Completed|September 2004|November 2011|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|684|||Both|18 Years|N/A|No|||January 2012|January 26, 2012|December 21, 2005|Yes|Yes||No|December 24, 2008|https://clinicaltrials.gov/show/NCT00271154||186590|
NCT00271414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005962|A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy|A 15-day Trial to Document the Safety, Clinical Utility and Pharmacokinetics of Duragesic (TTS Fentanyl) in the Treatment of Pediatric Subjects With Continuous Pain Requiring Opioid Therapy||Janssen Pharmaceutica N.V., Belgium||Completed|March 1999|March 2001|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|53|||Both|2 Years|12 Years|No|||April 2010|May 16, 2011|December 30, 2005||||||https://clinicaltrials.gov/show/NCT00271414||186570|
NCT00262587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-061|Elite Sport and Development of Asthma|Elite Sport and Development of Asthma||Bispebjerg Hospital||Completed|September 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262587||187229|
NCT00262600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.26|Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate|Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)||Boehringer Ingelheim||Completed|November 2005|||April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|3||Actual|18113|||Both|18 Years|N/A|No|||April 2014|November 5, 2014|December 6, 2005||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00262600||187228|
NCT00258934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID15|Immunogenicity Study of the Influenza Vaccine in Adults|||Sanofi|Yes|Completed|September 2005|September 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|978|||Both|18 Years|57 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|November 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00258934||187505|
NCT00258947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VVL04|Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults|Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults.||Sanofi|No|Completed|September 2005|January 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|230|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2012|January 30, 2012|November 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00258947||187504|
NCT00259519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N041000314|Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes|Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial||University of Alberta|Yes|Terminated|January 2006|September 2011|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Female|N/A|N/A|No|||April 2010|April 5, 2010|November 25, 2005||No|The DSMB supported termination of the trial due to slow recruitment.|No||https://clinicaltrials.gov/show/NCT00259519||187460|
NCT00289497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44DK054559|TempTouch IR Thermometry & Diabetic Patient Self-Care|Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home||Diabetica Solutions Inc.||Completed|June 2000|July 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||180|||Both|18 Years|80 Years|No|||February 2006|February 8, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00289497||185215|
NCT00289510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|710501|Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)|Single-Blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) With a License Egg Derived Influenza Vaccine||Nanotherapeutics, Inc.||Completed|January 2006|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||423|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|October 7, 2015|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00289510||185214|
NCT00287300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-EPID-153|Efficacy and Safety of Azithromycin and Artesunate in Pregnant Women|A Pilot Randomized Controlled Trial of Azithromycin or Artesunate Added to Sulphadoxine Pyrimethamine as Therapy for Malaria in Pregnancy||University of North Carolina, Chapel Hill||Completed|September 2003|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||141|||Female|15 Years|49 Years|No|||January 2006|February 3, 2006|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00287300||185384|
NCT00288002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455125|Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer|A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer||National Cancer Institute (NCI)||Completed|January 2005|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1500|||Female|18 Years|N/A|No|||July 2009|August 23, 2013|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288002||185330|
NCT00288236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5593|Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin||Sanofi||Completed|January 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|368|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00288236||185312|
NCT00288509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-47-52120-731|Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia|A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia||Ipsen|No|Completed|February 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|February 7, 2006|No|Yes||No|January 6, 2010|https://clinicaltrials.gov/show/NCT00288509||185291|
NCT00287573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S5442|Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis|A Prospective, Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis|TAXUS V ISR|Boston Scientific Corporation||Completed|June 2003|January 2010|Actual|December 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|488|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|February 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00287573||185363|
NCT00287781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#04028|A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache|A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache||Kern Medical Center||Completed|January 2002|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00287781||185347|
NCT00287989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0432, CDR0000455116|Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Randomized Phase II Trial Comparing Two Doses of Pulsed Erlotinib Prechemotherapy (PEP-C) in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|November 2004|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|February 6, 2006||||||https://clinicaltrials.gov/show/NCT00287989||185331|
NCT00269802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005995|A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder|Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD||Alza Corporation, DE, USA||Completed||February 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||||||Both|6 Years|12 Years|No|||June 2011|June 9, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269802||186693|
NCT00269191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-071|A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)|A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)||Merck Sharp & Dohme Corp.||Completed|February 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|528|||Both|40 Years|N/A|No|||February 2015|February 24, 2015|December 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269191||186738|
NCT00269477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA35|Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®|Persistence of Bactericidal Antibodies in Adolescents and Adults Aged 15 to 23 Years Who Received a Single Dose of Menactra® or Menomune®-A/C/Y/W-135 Five Years Earlier||Sanofi|Yes|Completed|December 2005|December 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|145|||Both|15 Years|23 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|December 22, 2005|Yes|Yes||No|November 10, 2009|https://clinicaltrials.gov/show/NCT00269477||186716|
NCT00269789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005992|A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children|Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD||Alza Corporation, DE, USA||Completed|March 1998|May 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||||||Both|6 Years|12 Years|No|||June 2011|June 9, 2011|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00269789||186694|
NCT00270296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHP 016|Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV|Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2006|September 2010|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|730|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 9, 2015|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00270296||186655|
NCT00270608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-17.02.06-HMO-CTIL|How Does Early Age Life Style Affect Bone Strength and General Health Parameters at Middle Age?|How Does Early Age Life Style Affect Bone Strength and General Health at Middle Age? Twenty-Five Year Follow-up Health Status Comparison of a Sedentary Versus Extremely Physically Active Population From an Early Age||Hadassah Medical Organization|Yes|Recruiting|March 2007|November 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|whole blood|Male|40 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Israeli males who were 17-22 years-old and received a military profile of either 82 or 97        in 1983|November 2007|November 25, 2007|December 26, 2005||||No||https://clinicaltrials.gov/show/NCT00270608||186632|
NCT00261066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2003209-01H|Outcome Following Orthopaedic Surgery|A Prospective Database for Orthopaedic Surgery||Ottawa Hospital Research Institute|No|Recruiting|September 2001|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are scheduled to undergo orthopaedic surgery at The Ottawa Hosptial.|July 2015|July 29, 2015|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00261066||187343|
NCT00270855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3918-R|Exercise to Reduce Obesity in Spinal Cord Injury|Exercise to Reduce Obesity in Spinal Cord Injury||VA Office of Research and Development||Completed|May 2008|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||May 2012|May 21, 2012|December 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00270855||186613|
NCT00261872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060004|Treatment of Patients With Alcoholism and Attention Deficit Disorder|Treatment of Patients With Alcoholism and Attention Deficit Disorder||National Institutes of Health Clinical Center (CC)||Completed|December 2005|April 2007||||Phase 4|Interventional|Primary Purpose: Treatment||||100|||Both|21 Years|65 Years|No|||April 2007|April 10, 2007|December 3, 2005||||No||https://clinicaltrials.gov/show/NCT00261872||187282|
NCT00261898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060036|Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity|Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity||National Institutes of Health Clinical Center (CC)||Terminated|November 2005|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|239|||Both|18 Years|50 Years|No|||November 2015|November 3, 2015|December 4, 2005||No|This study has been terminated. (Interim analysis of preliminary results indicated the need    for protocol re-design).|No||https://clinicaltrials.gov/show/NCT00261898||187281|
NCT00261911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB238|A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.|A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents||Abbott|No|Completed|July 2000|February 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|498|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||August 2007|August 30, 2007|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261911||187280|
NCT00262262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIIS|The Effect of Levetiracetam on the Postmastectomy Pain Syndrome|The Effect of Levetiracetam on the Postmastectomy Pain Syndrome||Odense University Hospital|No|Completed|March 2004|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||November 2007|November 21, 2007|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262262||187253|
NCT00262574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020474-Hasin-BNP.CTIL|Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty|Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1||The Baruch Padeh Medical Center, Poriya|No|Recruiting|July 2005|June 2013|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|500|||Both|N/A|N/A|No|||December 2010|August 8, 2011|December 6, 2005||No||No||https://clinicaltrials.gov/show/NCT00262574||187230|
NCT00258960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2004-05|Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer|Phase IV.II, Clinical Trial, With the Combination of Pegylated Liposomal Doxorubicin (Caelyx), Cyclophosphamide and Trastuzumab (Herceptin) in Patients With Metastatic Breast Cancer With Overexpression of HER2/Neu||Spanish Breast Cancer Research Group||Completed|February 2006|July 2008|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|49|||Female|18 Years|70 Years|No|||September 2009|September 25, 2009|November 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00258960||187503|
NCT00258661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501-202|Is Osteopathic Manipulative Treatment (OMT) Beneficial for Elderly Patients Hospitalized With Pneumonia?|Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE)|MOPSE|A.T. Still University of Health Sciences|Yes|Completed|March 2004|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|406|||Both|50 Years|N/A|No|||July 2011|July 22, 2011|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258661||187526|
NCT00258674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #000-113|Improving Diabetes Care:Effectiveness of Physician Profiling and Care Coordination by a Diabetes Resource Nurse|A Randomized Trial of Strategies to Improve Diabetes Care: Effectiveness and Costs of Physician Profiling and Care Coordination by a Diabetes Resource Nurse||Baylor Research Institute|Yes|Completed|January 2000|December 2001|Actual|December 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1891|||Both|65 Years|N/A|No|||July 2013|July 22, 2013|November 23, 2005||No||No|October 21, 2011|https://clinicaltrials.gov/show/NCT00258674||187525|All participating practices belonged to the same network of fee-for-service practices, which may reduce generalizability.Neither physicians nor patients could be blinded; but data were collected by individuals blinded to study arm assignments.
NCT00259532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 268342|Three New Methods for Diagnosing Pancreas Cancer|Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer||University of Copenhagen||Recruiting|February 2005|January 2009||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|80|||Both|N/A|N/A|No|||February 2009|February 25, 2009|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259532||187459|
NCT00282490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHTENS2006|Surface Nerve Stimulation Treatment for OAB in Children|Sacral Transcutaneous Nerve Stimulation Treatment for Functional Daytime Incontinence in Children With Over Active Bladder Syndrome||University of Aarhus|No|Completed|February 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|15 Years|No|||June 2008|June 13, 2008|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282490||185746|
NCT00282503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute GvHD-1|Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease|A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease||Therakos||Terminated|January 2006|||June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|January 24, 2006|No|Yes|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00282503||185745|
NCT00287794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sshiozawah180206|Quality of Sleep in Patients With Rheumatoid Arthritis|Study on the Quality of Sleep in Patients With Rheumatoid Arthritis||Kobe University||Recruiting|February 2006|December 2010|Anticipated|December 2010|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Samples for Western blot for inflammatory cytokines and transcription factors responsible      for arthritis.|Both|17 Years|N/A|No|Non-Probability Sample|All the patients with rheumatoid arthritis with or without sleep disturbance.|March 2009|March 13, 2009|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00287794||185346|
NCT00288249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91464|Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer|Prospective, Multicenter, Randomized, Independent-group, Open-label Phase II Study to Investigate the Efficacy, Safety and Tolerability of 4 Regimen With 3 Doses of ZK 219477 (16 and 12 mg/m2 Body Surface Area as 3-hour Infusion or 22 mg/m2 Body Surface Area as 30-minute or 3-hour Infusion) in Patients With Metastatic Breast Cancer||Bayer|No|Completed|December 2005|January 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Female|18 Years|N/A|No|||November 2014|November 27, 2014|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288249||185311|
NCT00288522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52030-164|Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment|A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.||Ipsen||Terminated|January 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||April 2007|September 29, 2015|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288522||185290|
NCT00288496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCON trial|Mechanical Bowel Preparation for Elective Colorectal Surgery|Mechanical Bowel Preparation for Elective Colorectal Surgery. A Multicenter Randomized Study||Ikazia Hospital, Rotterdam||Completed|April 1998|February 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1400|||Both|18 Years|N/A|No|||April 2000|February 7, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288496||185292|
NCT00289029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP104|A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography|Visipaque and Isovue in Cardiac Angiography in Renally Impaired Patients||Bracco Diagnostics, Inc||Completed|July 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||400|||Both|18 Years|N/A|No|||August 2006|August 17, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00289029||185251|
NCT00289042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2879|Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)|The Use of Enoxaparin Compared to Unfractionated Heparin for Short Term Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing TEE Guided Cardioversion: Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Randomized Multicenter Study||The Cleveland Clinic||Completed|December 1999|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||May 2005|January 30, 2007|February 8, 2006||||||https://clinicaltrials.gov/show/NCT00289042||185250|
NCT00260325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70,328-01|Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy Volunteers|Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia: a Randomized Controlled Trial in Healthy Volunteers||Penn State University||Completed|August 2004|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 29, 2007|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260325||187398|
NCT00261079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455_4125|Fexofenadine in Pruritic Skin Disease|The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease||Handok Pharmaceuticals Co., Ltd.|No|Completed|April 2005|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|435|||Both|12 Years|70 Years|No|||November 2007|November 5, 2007|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261079||187342|
NCT00270062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005893|A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.|A Double-Blind, Placebo-Controlled Study to Determine Whether R-HuEPO Can Facilitate Presurgical Autologous Blood Donation in Patients With Low Hematocrit Levels||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 1989|July 1991|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|77|||Both|12 Years|N/A|No|||February 2011|May 17, 2011|December 22, 2005||||||https://clinicaltrials.gov/show/NCT00270062||186673|
NCT00270569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-94012|An Effective and Compliance Regimen of Paclitaxel Plus Cisplatin to Treat Metastatic Breast Cancer|A Phase II Study of Weekly Low-Dose Paclitaxel Plus 24-Hour Infusion of Cisplatin as First-Line Chemotherapy for Metastatic Breast Cancer||Far Eastern Memorial Hospital||Recruiting|October 2005|||February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|75 Years|No|||August 2005|February 6, 2009|December 26, 2005||||No||https://clinicaltrials.gov/show/NCT00270569||186634|
NCT00260793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103911|Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease|Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease||Colorado Neurology||Recruiting|November 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|25 Years|N/A|No|||November 2005|February 2, 2006|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00260793||187363|
NCT00261365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-004|Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)|An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients With Unresectable Stage III or IV Malignant Melanoma Randomized and Treated With Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels||Bristol-Myers Squibb|Yes|Completed|November 2005|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2008|February 27, 2010|December 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00261365||187320|
NCT00261378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA1008|Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation|Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)|PRECISIONV|Biocompatibles UK Ltd||Completed|November 2005|January 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|N/A|No|||June 2010|June 14, 2010|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261378||187319|
NCT00261612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-002150-64|Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma|||Medical University of Vienna||Active, not recruiting|January 2005|January 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|19 Years|75 Years|No|||October 2006|October 17, 2006|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261612||187301|
NCT00262613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI-NII5-021|Sodium Pyruvate Therapy in COPD Patients|Long-Term Use of Inhaled Sodium Pyruvate for the Treatment of Chronic Obstructive Pulmonary Disease||Emphycorp||Completed|September 2004|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|85 Years|No|||May 2006|May 25, 2006|December 6, 2005||||||https://clinicaltrials.gov/show/NCT00262613||187227|
NCT00258388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I165|Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy|A Randomized Phase II Study of OGX-011 in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate Cancer||Canadian Cancer Trials Group|No|Completed|June 2005|January 2011|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Male|18 Years|N/A|No|||September 2011|September 27, 2011|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00258388||187545|
NCT00258973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2005-1281|Office Practice Assessment of Carotid Atherosclerosis Using Handheld Ultrasound (OPACA) Study|Office Practice Assessment of Carotid Atherosclerosis Using Handheld Ultrasound (OPACA) Study||University of Wisconsin, Madison||Completed|April 2006|September 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|375|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258973||187502|
NCT00259259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 275625|Functional Lipids and Appetite Regulation|The Effect of Functional Lipids on Appetite Regulation in Man||University of Copenhagen||Completed|October 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||22|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2006|January 20, 2009|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259259||187480|
NCT00259545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC2|Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis|Prospektive, Randomisierte Doppelblinde Studie Zur Wirksamkeit Von Intestinal Retardiert Freigesetztem Phosphatidylcholine Bei therapierefraktärer Colitis Ulcerosa Mit Chronisch Aktivem Verlauf Unter Corticosteroiden||Heidelberg University|No|Completed|February 2003|February 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|16 Years|90 Years|No|||June 2008|June 4, 2008|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259545||187458|
NCT00260117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66738 (completed)|Long-Term Exercise Maintenance Via Internet Support|Long-Term Exercise Maintenance Via Internet Support||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|16000|||Both|18 Years|N/A|No|||February 2010|February 24, 2010|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260117||187414|
NCT00286754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-170|A Behavioral Intervention To Improve Hypertension Control In Veterans|A Behavioral Intervention to Improve Hypertension Control in Veterans||VA Office of Research and Development|No|Completed|July 2006|September 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|533|||Both|21 Years|N/A|No|||May 2015|May 8, 2015|February 1, 2006||No||No|January 21, 2015|https://clinicaltrials.gov/show/NCT00286754||185426|
NCT00286767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060086|Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy|A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2006|||||N/A|Observational|Time Perspective: Prospective|||Actual|225|||Both|18 Years|99 Years|No|||January 2016|January 16, 2016|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00286767||185425|
NCT00288015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04S1|Bevacizumab in Treating Patients With Angiosarcoma|An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma||Northwestern University|Yes|Active, not recruiting|October 2005|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288015||185329|
NCT00288223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4022|Telithromycin in Acute Exacerbation of Chronic Bronchitis|Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults||Sanofi||Terminated|January 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|35 Years|N/A|No|||December 2009|December 8, 2009|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288223||185313|
NCT00288262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-101 (Scripps SOPRS #)|Melatonin Effects on Luteinizing Hormone|Melatonin Effects on Luteinizing Hormone||Scripps Health||Terminated|June 2004|February 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|50 Years|70 Years|No|||October 2005|February 6, 2006|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00288262||185310|
NCT00288275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-301|Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer|A Non-Interventional Prospective Study of the Correlation of the Precision Therapeutics, Inc. Chemoresponse Assay With Progression-Free Survival in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer.||Precision Therapeutics||Terminated|July 2004|October 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|256|Samples With DNA|Leftover tumor cells from the test, pathology slides, and blood samples will be collected      and stored to look for potential genetic variations related to drug pathway genes to      identify patterns associated with clinical outcome.|Female|18 Years|N/A|No|Non-Probability Sample|Approximately 500 patients will be enrolled at 20-30 US sites. Patients have been        diagnosed with persistent, refractory, or recurrent epithelial ovarian, peritoneal, or        fallopian tube cancer.|October 2012|October 4, 2012|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00288275||185309|
NCT00288288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPEL|Prospective Registry of Epicardial LV Leads Placed During Cardiac Surgery Procedures|Prospective Registry of Epicardial LV Leads Placed During Cardiac Surgery Procedures||University of Kansas Medical Center|No|Completed|March 2006|May 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Medical Center|September 2012|September 24, 2012|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00288288||185308|
NCT00309803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|872|EPIC European Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting|Evaluating the Use of the FiberNet® Embolic Protection Device in Carotid Artery Stenting: The EPIC European Study||Lumen Biomedical|No|Completed|March 2006|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||October 2008|October 20, 2008|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309803||183703|
NCT00310063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466312|Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy|Acupressure for the Prevention of Chemotherapy-Associated Nausea and Vomiting in Children||Comprehensive Cancer Center of Wake Forest University|No|Completed|April 2005|||May 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|2 Years|21 Years|No|||July 2012|July 11, 2012|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00310063||183684|
NCT00310076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466311|Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer|Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer||Comprehensive Cancer Center of Wake Forest University|No|Completed|October 2002|September 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|March 29, 2006||No||No|July 24, 2012|https://clinicaltrials.gov/show/NCT00310076||183683|
NCT00311025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03054|Stroke: Reduction of Physical Performance Post Stroke. Inactivity or Secondary Complications?|Stroke: Reduction of Physical Performance Post Stroke. Inactivity or Secondary Complications? How to Cope Daily Life Activities for as Long as Possible.||Oslo University College||Completed|September 2003|September 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||60|||Both|N/A|N/A|No|||September 2005|April 3, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311025||183612|
NCT00311051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMONA-4022229|Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite|A Randomized Double-blind and Placebo-controlled Study to the Influence of Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Patients With Mild to Moderate Atopic Asthma (House Dust Mite)||Research Center Borstel||Withdrawn|April 2005|April 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||April 2012|April 13, 2012|April 1, 2006||||No||https://clinicaltrials.gov/show/NCT00311051||183610|
NCT00311870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 92126|Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy|||Steno Diabetes Center||Completed|March 1993|April 1999||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||52|||Both|18 Years|55 Years|No|||April 1999|April 4, 2006|April 4, 2006||||No||https://clinicaltrials.gov/show/NCT00311870||183547|
NCT00312416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-121203B|Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise|Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise||Medical University of Vienna||Completed|February 2004|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||February 2007|February 9, 2007|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312416||183505|
NCT00308997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073673-01|Transcranial Magnetic Stimulation for "Voices"|Transcranial Magnetic Stimulation Guided by Neuroimaging for Patients With Persistent "Voices"||Yale University|Yes|Completed|February 2006|April 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|55 Years|No|||December 2012|December 13, 2012|March 28, 2006||No||No|November 14, 2012|https://clinicaltrials.gov/show/NCT00308997||183764|
NCT00309322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA 05-PEDS|Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures|A Phase 2, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Mandibular and Maxillary Procedures||Novalar Pharmaceuticals, Inc.||Completed|March 2006|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|4 Years|11 Years|No|||November 2006|November 16, 2006|March 30, 2006||||||https://clinicaltrials.gov/show/NCT00309322||183740|
NCT00310752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-1|Evaluation of DermStream(tm) - an Irrigation Product for Chronic Wound Management|||EnzySurge||Completed|March 2006|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|80 Years|No|||July 2008|July 31, 2008|April 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310752||183633|
NCT00311064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 285157|Inflammatory Response and Pregnancy Outcome in Women With Type 2 Diabetes or Overweight|Inflammatory Response and Pregnancy Outcome in Women With Type 2 Diabetes or Only Overweight. The Influence of Physical Activity||Rigshospitalet, Denmark||Withdrawn|March 2006|January 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|280|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 20, 2007|April 4, 2006|||because of lack of funding and recruitment problems the study has been closed.|No||https://clinicaltrials.gov/show/NCT00311064||183609|
NCT00261222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB544-A8-AQ2005|Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso|Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso||Heidelberg University||Completed|September 2005|November 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|6 Months|59 Months|No|||October 2006|February 2, 2010|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00261222||187331|
NCT00260403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95/00|TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration|Transpupillary Thermotherapy Versus Photodynamic Therapy Treatment of Occult and Minimally Classic Choroidal Neovascularization in Age-Related Macular Degeneration.||St. Erik Eye Hospital||Recruiting|June 2003|January 2008||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||140|||Both|50 Years|85 Years|No|||June 2004|February 2, 2006|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260403||187392|
NCT00260650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 04-252|Patient Activation in High-Risk Patients With Heart Failure|Heart PACT: Patient Activation in High-Risk Patients With Heart Failure|Heart PACT|VA Office of Research and Development|Yes|Completed|September 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|84|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260650||187374|
NCT00260910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC9003003|Progression Evaluation and Genetic Determinants of Hypertension in Chinese - A Follow-up Study of Taiwan SAPPHIRe|Progression Evaluation and Genetic Determinants of Hypertension in Chinese - A Follow-up Study of Taiwan SAPPHIRe||National Health Research Institutes, Taiwan||Completed|May 2001|||||N/A|Observational|Observational Model: Family-Based||1|||||Both|30 Years|70 Years||Non-Probability Sample|A follow-up genetic study of Taiwan SAPPHIRe Cohort|August 2009|August 12, 2009|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00260910||187355|
NCT00261729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-025-05S|Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees|Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees||VA Office of Research and Development|Yes|Completed|July 2004|December 2009|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|50 Years|No|||December 2009|December 2, 2009|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261729||187293|
NCT00261469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005686|An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans|Efficacy of Topiramate Prophylaxis as add-on to Triptan Therapy for Migraine||Janssen-Ortho Inc., Canada||Completed|April 2003|November 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|38|||Both|18 Years|65 Years|No|||January 2011|May 16, 2011|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261469||187312|
NCT00309504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22307|Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy|Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy||AHS Cancer Control Alberta|Yes|Completed|March 2006|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Local Healthy volunteers|March 2012|February 24, 2016|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00309504||183726|
NCT00309517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABSCG 92|Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C|A Prospectively Randomized Study on Neoadjuvant Radio-Chemotherapy in Patients With Operated Rectal Carcinoma Dukes B and C (pT2, pN1-3; pT3-4, pN0-3; M0.||Austrian Breast & Colorectal Cancer Study Group||Terminated|July 1997|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||700|||Both|18 Years|80 Years|No|||October 2000|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309517||183725|
NCT00310115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS01-178|Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy|Smoking Relapse Prevention Among Postpartum Women||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2005|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|650|||Female|18 Years|N/A|No|Non-Probability Sample|Women, 18 years of age or older, who quit smoking while pregnant.|June 2015|June 25, 2015|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00310115||183681|
NCT00310089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466185|AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer|A Pilot Study to Evaluate The Effects of Neoadjuvant AZD2171, a VEGF Receptor Tyrosine Kinase Inhibitor With Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy in Previously Untreated Locally Advanced Breast Cancer||National Cancer Institute (NCI)||Completed|January 2006|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|33|||Female|18 Years|N/A|No|||January 2007|June 18, 2013|March 29, 2006||||||https://clinicaltrials.gov/show/NCT00310089||183682|
NCT00302822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004722-12|Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)|Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|April 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00302822||184224|
NCT00302835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001_1|Case-Control Study on Analgesics and Nephropathy (SAN)|Case-Control Study on Analgesics and Nephropathy (SAN)||Center for Epidemiology and Health Research, Germany||Completed|January 2001|December 2004||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||||4200|||Both|N/A|50 Years|No|||April 2006|April 21, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00302835||184223|
NCT00303160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15344|Effect of Helicobacter Pylori on the Availability of Vitamin E and C|Effect of Helicobacter Pylori on the Availability of Vitamin E and C||University of Toronto||Active, not recruiting|March 2006|September 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 13, 2007|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303160||184199|
NCT00312156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1379|Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|August 2002|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|347|||Both|6 Years|17 Years|No|||March 2009|June 25, 2009|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312156||183525|
NCT00312702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1249|Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America|A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS02A Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States||U.S. Army Medical Research and Materiel Command|Yes|Completed|April 2006|April 2007|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|April 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00312702||183483|
NCT00308477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX4001|A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|79 Years|No|||February 2012|February 9, 2012|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308477||183804|
NCT00308724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15958|Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care|Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care||Baylor College of Medicine|No|Completed|March 2004|April 2015|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|60 Years|N/A|No|||January 2015|July 21, 2015|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308724||183785|
NCT00309868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-p-001736|Study of Nesiritide in Diastolic Heart Failure.|A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure.||Massachusetts General Hospital||Completed|December 2002|December 2003|Actual|December 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|March 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309868||183699|
NCT00310401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3 UO1 HL081332-01S1|The Effect of Nebulized Albuterol on Donor Oxygenation|The Effect of Nebulized Albuterol on Donor Oxygenation||Vanderbilt University|Yes|Completed|April 2007|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|506|||Both|14 Years|N/A|No|||August 2013|August 30, 2013|March 1, 2006||No||No|June 24, 2013|https://clinicaltrials.gov/show/NCT00310401||183660|
NCT00311272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-1970|Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer|Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate (MelCancerVac) for Treatment of Patients With Advanced Colorectal Cancer||University Hospital, Gentofte, Copenhagen||Completed|November 2004|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|40|||Both|25 Years|75 Years|No|||February 2009|February 17, 2009|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311272||183593|
NCT00310466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHX0712|Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever|A Multicentre, Randomised, Double-blind, Placebo-controlled Parallel Group Clinical Trial to Investigate the Efficacy and Safety of Specific Sublingual Immunotherapy With SLITone Birch in Patients With Seasonal Birch Pollen Induced Rhinoconjunctivitis||ALK-Abelló A/S|No|Completed|June 2005|January 2007|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|65 Years|No|||April 2013|April 29, 2013|April 2, 2006||No||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00310466||183655|Clinical improvement following SLIT is thought to be due to immunological mechanisms that develop over time. Even though clear immunological changes were observed in this trial it appears that the treatment was too short to reach full clinical effect
NCT00311597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466064|Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors|A Phase I/II Dose-Escalation/Efficacy Study of Palliative Extracranial Radiosurgery Using the Elektra Stereotactic Body Frame System||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|June 2002|November 2016|Anticipated|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|120 Years|No|||September 2015|September 30, 2015|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00311597||183568|
NCT00260416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEMI-12|Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours|Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours||Aarhus University Hospital Skejby||Completed|May 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||May 2008|May 21, 2008|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260416||187391|
NCT00260663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLI 04-265|The Hearing Aid Effectiveness After Aural Rehabilitation (HEAR) Trial|The Hearing Aid Effectiveness After Aural Rehabilitation (HEAR) Trial||VA Office of Research and Development|No|Completed|February 2006|June 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|660|||Both|N/A|N/A|No|||January 2008|April 6, 2015|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260663||187373|
NCT00260897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 9206002|Molecular Genetic Study of Avascular Necrosis of the Femoral Head|Molecular Genetic Study of Avascular Necrosis of the Femoral Head-Revealing ANFH Pathogenesis Mechanism by Cell and Animal Models||National Health Research Institutes, Taiwan||Recruiting|May 2003|April 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2007|May 7, 2007|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00260897||187356|
NCT00261209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tendon 101|Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand|Study of Collagenase Injection Therapy for Treatment of Zone II Flexor Tendon Adhesions in the Hand||Stony Brook University|No|Completed|January 2005|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||December 2012|December 11, 2012|November 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00261209||187332|
NCT00261482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002905|Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.|An Open Label, Multicentre Study of the EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch in Europe: Evaluation of Women's Experience With EVRA� and Comparison With Previously Used Methods of Contraception.||Janssen Pharmaceutica N.V., Belgium||Completed|July 2003|December 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|778|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 15, 2010|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261482||187311|
NCT00258505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor402605ctil|Monitoring Brain Activity in Human Brain Injury|Incidence, Nature and Consequences of Cortical Depolarizations in Human Brain Injury From Trauma and Ischemia: The COSBID Study||Soroka University Medical Center||Not yet recruiting||September 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|100|||Both|18 Years|N/A|No|||October 2005|July 31, 2007|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258505||187537|
NCT00258518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1500|Respiratory Mechanics and Pleural Effusion|Estimation of Respiratory Mechanics (Respiratory System, Chest Wall and Lung Elastance) and Pleural Effusion at the Bedside With CT Scan.||Policlinico Hospital|No|Completed|November 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|16 Years|90 Years|No|Non-Probability Sample|ALI/ARDS patients|March 2012|March 7, 2012|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258518||187536|
NCT00262067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3694g|A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)|A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer||Genentech, Inc.||Active, not recruiting|December 2005|December 2013|Anticipated|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1237|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|December 2, 2005|Yes|Yes||No|August 20, 2013|https://clinicaltrials.gov/show/NCT00262067||187268|
NCT00262080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDEMA3 (DX-88/14)|Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)|A Double-blind, Placebo-controlled Study (72 Patients, Randomized 1:1) Followed by a Repeat-dosing Phase to Assess the Efficacy and Safety of DX-88 (Ecallantide; Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema||Dyax Corp.|Yes|Completed|December 2005|February 2007|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|10 Years|N/A|No|||April 2010|April 9, 2010|December 5, 2005|Yes|Yes||No|December 30, 2009|https://clinicaltrials.gov/show/NCT00262080||187267|
NCT00309530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG 90|Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C|A Prospectively Randomized Phase III Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Patients With Operated Colon Carcinoma Dukes C (Stage III; T1-4, N1-30, M0).||Austrian Breast & Colorectal Cancer Study Group||Completed|October 1990|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||598|||Both|18 Years|80 Years|No|||April 1999|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309530||183724|
NCT00309543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG 91|Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B|A Prospectively Randomized Study on Adjuvant Chemotherapy in Patients With Operated Colon Carcinoma Dukes B (Stage II; T3-4, N0, M0).||Austrian Breast & Colorectal Cancer Study Group||Completed|November 1993|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||636|||Both|18 Years|80 Years|No|||March 2006|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309543||183723|
NCT00300105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6160C00047|GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes|A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar Therapy in Patients With Type 2 Diabetes||AstraZeneca||Terminated|October 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||March 2008|March 14, 2008|March 7, 2006|||The development program has been terminated|No||https://clinicaltrials.gov/show/NCT00300105||184427|
NCT00310375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX-RET-E22-303|Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial|A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)||GlaxoSmithKline|No|Active, not recruiting|May 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|181|||Both|18 Years|75 Years|No|||November 2015|November 5, 2015|March 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00310375||183662|
NCT00310700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14P5|Kinetics of B Cell Response in Infants Menjugate Vaccination|A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age||Novartis||Completed|May 2005|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||75|||Both|8 Weeks|11 Weeks|Accepts Healthy Volunteers|||September 2014|September 18, 2014|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310700||183637|
NCT00310388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX-RET-E22-304|Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial|A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)||GlaxoSmithKline|No|Active, not recruiting|July 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|376|||Both|18 Years|75 Years|No|||March 2015|March 9, 2015|March 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00310388||183661|
NCT00310726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD039611|Zambia Exclusive Breastfeeding Study|Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission||Boston Medical Center|Yes|Completed|May 2001|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1435|||Female|18 Years|40 Years|No|||July 2011|July 26, 2011|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00310726||183635|
NCT00310739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-50|Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury|||Hamamatsu University||Recruiting||||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||April 2005|November 6, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310739||183634|
NCT00308464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6391003|A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency|A Double Blind Parallel Group Randomised Multiple Dose Study To Evaluate The Pharmacodynamic Response And Safety Of PHA-794428 In Adult Growth Hormone Deficient Patients||Pfizer||Terminated|July 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||136|||Both|18 Years|65 Years|No|||May 2011|May 17, 2011|March 27, 2006|||See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00308464||183805|
NCT00309608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.6|Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS (1 mg, 5 mg and 10 mg Administered Orally Once Daily) Over 12 Weeks as add-on Therapy in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Metformin Therapy, Including an Open-label Glimepiride Treatment Arm.||Boehringer Ingelheim||Completed|April 2006|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|333|||Both|21 Years|75 Years|No|||December 2013|June 24, 2014|March 31, 2006||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00309608||183718|
NCT00309335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA 04-200|Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures|A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Dental Patients Undergoing Maxillary Procedures||Novalar Pharmaceuticals, Inc.||Completed|February 2006|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||240|||Both|12 Years|N/A|No|||November 2006|November 16, 2006|March 30, 2006||||||https://clinicaltrials.gov/show/NCT00309335||183739|
NCT00309582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIR2405|Nevirapine Levels and Fluconazole|Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole||Bamrasnaradura Infectious Diseases Institute||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|15 Years|N/A|No|||November 2005|March 30, 2006|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309582||183720|
NCT00310414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060128|fMRI Studies of Task Specificity in Focal Hand Dystonia|fMRI Studies of Task Specificity in Focal Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|March 2006|March 2012||||N/A|Observational|N/A|||Actual|51|||Both|18 Years|65 Years|No|||March 2012|March 21, 2012|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00310414||183659|
NCT00310778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051201|Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker|Effects of Sodium Intake on Pharmacokinetic/Pharmacodynamic Relationship of a Single Dose of a Renin Angiotensin System-Blocker, or a Beta-Blocker in Normotensive Sodium-Depleted or Replated Volunteers in a Cross-Over Study||Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2008|September 19, 2008|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00310778||183631|
NCT00312169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL105034 (EVITA)|Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)|Evolution of L74V or K65R Mutations in VIremic Subjects on TDF or ABC (EVITA)||Orlando Immunology Center||Completed|April 2006|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312169||183524|
NCT00312182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4301023|Thorough QT Study of Nelfinavir|Evaluation Of The Effect Of Nelfinavir On QT Intervals At Steady-State After Twice-Daily Administration Of Nelfinavir Tablets To Healthy Volunteers||Pfizer||Completed|March 2006|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 9, 2009|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312182||183523|
NCT00261495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002374|A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.|Randomized, Open-Label, Comparative Parallel Group Study to Assess Efficacy and Safety on Flexible Dosages of OROS Hydromorphone Once-Daily Compared to Sustained Release Oxycodone Twice Daily in Subjects With Chronic Non-malignant Pain Requiring Continuous Opioid Therapy.||Janssen Pharmaceutica N.V., Belgium|No|Completed|March 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|504|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|December 2, 2005||No||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00261495||187310|
NCT00261508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006106|A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)|Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study||Janssen-Ortho Inc., Canada||Completed|August 1999|December 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|80|||Both|5 Years|12 Years|No|||January 2011|January 20, 2011|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261508||187309|
NCT00260923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2328|A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg, 150 mg and 300 mg to Placebo in Patients With Essential Hypertension||Novartis||Completed|November 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|641|||Both|18 Years|N/A||||November 2011|November 7, 2011|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260923||187354|
NCT00260936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 021b|Metabolic Abnormalities - HIV Infected and Uninfected Males|Prevalence of Morphologic and Metabolic Anormalities in HIV Infected and Uninfected Young Men||Westat|No|Completed|March 2006|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|250|||Male|12 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 250 subjects will be enrolled in the study. The number of subjects enrolled        in each study group will be as follows: 50 HIV-negative subjects; 100 HIV-positive        subjects who are antiretroviral therapy (ART) naïve; and two groups of up to 50        HIV-positive subjects each, one on an NNRTI-based regimen and the other on a PI-based        regimen.|February 2016|February 29, 2016|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260936||187353|
NCT00262106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDP301|Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection|An International Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 0.5% and 2% PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection||Endo Pharmaceuticals|Yes|Completed|October 2005|September 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|9404|||Female|16 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 5, 2012|December 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00262106||187265|
NCT00262405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1995-0304|Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis|Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis||University of Michigan|No|Completed|January 2001|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|35 Years|80 Years|No|||December 2015|December 2, 2015|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00262405||187242|
NCT00258271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448638|Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia|A Phase I Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Leukemias||University of Rochester|Yes|Completed|March 2005|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|November 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00258271||187554|
NCT00258284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445613|Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer|Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma||Barbara Ann Karmanos Cancer Institute|Yes|Completed|August 2003|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||March 2014|March 5, 2014|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258284||187553|
NCT00258297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000447159|Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery|A Phase II Safety, Efficacy, and Feasibility Study of Neoadjuvant ZD1839 (IRESSA) in Resectable Esophageal Cancer||University of Rochester|Yes|Terminated|April 2004|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|November 22, 2005||No|Withdrawn for lack of funding and accrual|No||https://clinicaltrials.gov/show/NCT00258297||187552|
NCT00258531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHF Gastro 01|Evaluation of 3-Dimensional Magnetic Imaging During Colonoscopy|Evaluation of 3-Dimensional Magnetic Imaging During Colonoscopy for Visualisation of Endoscope Localisation||Sykehuset Telemark||Completed|June 2003|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||360|||Both|18 Years|N/A|No|||June 2005|July 27, 2006|November 22, 2005||||No||https://clinicaltrials.gov/show/NCT00258531||187535|
NCT00258791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVS-2005|Effects of Pretreatment With Ibuprofen in Post-Electroconvulsive Therapy (ECT) Headache|Effects of Pretreatment With Ibuprofen in Post- ECT Headache||Norwegian University of Science and Technology|No|Withdrawn|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|November 24, 2005||No|first postponed then cancelled as national drug authority changed requirements|No||https://clinicaltrials.gov/show/NCT00258791||187516|
NCT00309842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS043|Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases|Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|July 2005|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|N/A|55 Years|No|||January 2016|January 21, 2016|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309842||183701|
NCT00301080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05CC2|D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain|A Phase III Study of D-Cycloserine in the Management of Paclitaxel-Induced Peripheral Neuropathic Pain in Breast Cancer Patients||Northwestern University|Yes|Terminated|February 2006|May 2008|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|5||Actual|7|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|March 8, 2006|Yes|Yes|Funding for the study fell through.|No|November 25, 2013|https://clinicaltrials.gov/show/NCT00301080||184353|Early termination resulted from a change in funding source (which ultimately fell through) along with drug manufacturing delays. Data could not be analyzed based on only 7 patients, all of whom were enrolled under the original design version.
NCT00301353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phytos QLRT-2000-00431-WP3|Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women|Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women||TNO||Completed|October 2002|July 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||October 2002|May 20, 2015|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00301353||184333|
NCT00301366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11815|The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency|Multi-center, Open-label Trial to Evaluate the Safety and Tolerability of Alpha-1 MP in Subjects With Alpha-1-antitrypsin (AAT) Deficiency|STAMP|Grifols Therapeutics Inc.|No|Completed|June 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|March 8, 2006|No|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00301366||184332|
NCT00301626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA13333-02|ROSCAP: Reduction of Smoking in Cardiac Patients Study|||Minneapolis Veterans Affairs Medical Center||Completed|October 2000|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||180|||Both|18 Years|80 Years|No|||April 2005|October 23, 2008|March 10, 2006||||||https://clinicaltrials.gov/show/NCT00301626||184312|
NCT00311259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-3108|Melatonin Treatment and Inflammation, Oxidative Stress and Autonomic Function in Connection With Surgery|||University Hospital, Gentofte, Copenhagen||Not yet recruiting|May 2006|November 2006||||Phase 2|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional||||40|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||February 2006|April 3, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311259||183594|
NCT00311584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL0421|Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma|A Phase II Study of Irinotecan + Temozolomide in Children With Recurrent Neuroblastoma||Children's Oncology Group|Yes|Completed|April 2006|December 2013|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|N/A|21 Years|No|||September 2014|September 16, 2014|April 5, 2006|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00311584||183569|
NCT00309036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0403rP|Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Cocktail of Recombinant Derivatives of Major Allergens of Timothy Grass (Phleum Pratense).||Allergopharma GmbH & Co. KG||Completed|January 2004|May 2008|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||March 2013|March 8, 2013|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309036||183761|
NCT00309049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-088|Ixabepilone Administered as an Enteric Coated Formulation.|An Exploratory Study of Ixabepilone Administered as an Enteric Coated Formulation in Patients With Advanced Cancer.||Bristol-Myers Squibb||Completed|April 2006|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||30|||Both|18 Years|N/A|No|||June 2008|February 3, 2010|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309049||183760|
NCT00309062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al0103rB|Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1||Allergopharma GmbH & Co. KG|No|Completed|December 2003|June 2009|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||March 2013|March 8, 2013|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309062||183759|
NCT00309894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456193|Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy|Phase II Trial to Assess the Activity of Ketoconazole Plus GM-CSF in Patients With Prostate Cancer Progressive After Androgen Deprivation||University of California, San Francisco|Yes|Completed|April 2004|December 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|49|||Male|N/A|N/A|No|||October 2012|October 9, 2012|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309894||183697|
NCT00309361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVA 04-100|Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures|A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Dental Patients Undergoing Mandibular Procedures||Novalar Pharmaceuticals, Inc.||Completed|February 2006|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||240|||Both|12 Years|N/A|No|||November 2006|November 16, 2006|March 30, 2006||||||https://clinicaltrials.gov/show/NCT00309361||183737|
NCT00310167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/05/84|Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma|A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma|FoRT|University College, London|Yes|Active, not recruiting|October 2005|July 2016|Anticipated|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|614|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00310167||183677|
NCT00309907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCT0521|Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant|Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation||Children's Oncology Group|Yes|Active, not recruiting|April 2006|||September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|1 Year|17 Years|No|||February 2016|February 23, 2016|March 29, 2006|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00309907||183696|
NCT00310791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anorexia04|Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa|Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa||Children's Hospital Boston|Yes|Completed|April 2004|December 2010|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|15 Years|30 Years|No|||December 2012|December 27, 2012|April 3, 2006|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00310791||183630|
NCT00310180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00707|Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)|Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial|TAILORx|National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2006|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|11248|||Female|18 Years|75 Years|No|||February 2016|March 24, 2016|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00310180||183676|
NCT00261768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3011R|Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial|Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial||VA Office of Research and Development|Yes|Completed|June 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|288|||Both|18 Years|85 Years|No|||March 2010|March 19, 2010|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261768||187290|
NCT00261742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214/05|Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis|Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Dermatitis - an Open, Randomized, Controlled Trial||University Children's Hospital Basel||Terminated|October 2005|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||194|||Both|1 Year|16 Years|No|||January 2007|January 16, 2007|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261742||187292|
NCT00262093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIMIMULTI-HMO-CTIL|Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence|Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence||Hadassah Medical Organization||Recruiting|November 2005|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|200|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2005|March 19, 2007|December 4, 2005||||No||https://clinicaltrials.gov/show/NCT00262093||187266|
NCT00262119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNV-20-171005|MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure|MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure||Medtronic Bakken Research Center||Completed|February 2006|April 2013|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|1300|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|December 4, 2005||No||No|May 9, 2014|https://clinicaltrials.gov/show/NCT00262119||187264|
NCT00262418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/212|Comparison of the Efficacy and Safety of Ivermectin to Permethrin|A Randomised, Double Blind, Double Dummy Study to Compare the Efficacy and Safety of a Single Administration of Ivermectin to a Single Administration of Permethrin for the Treatment of Scabies||University Ghent|No|Completed|July 2004|May 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|160|||Both|5 Years|N/A|No|||December 2007|December 19, 2007|December 4, 2005||||No||https://clinicaltrials.gov/show/NCT00262418||187241|
NCT00258544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010462|Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)|Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis|MAA|University of Pittsburgh|Yes|Recruiting|October 2001|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|150|Samples With DNA|Lung Tissue from a Lung Biopsy ordered by the patients physician. Also, a blood sample may      be collected at the researchers discretion as listed in the addendum consent form.|Both|18 Years|N/A|No|Non-Probability Sample|Population includes any patients seen at the Simmons Center for Interstitial Lung Disease        with the possibility of having the diagnosis of Idiopathic Pulmonary Fibrosis who's        physician has ordered an open Lung Biopsy. To check for the disease also known as IPF.|December 2015|January 4, 2016|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258544||187534|
NCT00259090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997C00057|Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer|A Double-blind, Randomized, Multicentre Trial to Compare the Anti-tumour Effects and Tolerability of a 500 mg Dose of Faslodex (Fulvestrant) Plus Arimidex (Anastrozole) With a 500 mg Dose of Faslodex(Fulvestrant) Alone and With Arimidex(Anastrozole) Alone, in Postmenopausal Women Prior to Surgery for Primary Breast Cancer||AstraZeneca||Completed|April 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Female|N/A|N/A|No|||July 2012|July 9, 2012|November 25, 2005|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00259090||187493|
NCT00309855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|319-03|Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men|Mechanisms of Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men: Modulation of GHRH, GHRP and Somatostatin Action by Estrogenic Versus Androgenic Steroids||Mayo Clinic||Completed|December 2005|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|80|||Male|50 Years|80 Years|Accepts Healthy Volunteers|||July 2012|July 27, 2012|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00309855||183700|
NCT00301938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00149|7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes|A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS||National Cancer Institute (NCI)||Completed|December 2005|||May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|March 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00301938||184291|
NCT00303433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB-00012460|Namenda to Prevent Post-Operative Delirium|Namenda as Prevention for Post-Operative Delirium||University of Rochester||Terminated|March 2006|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|50 Years|N/A|No|||December 2009|June 2, 2015|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303433||184178|
NCT00302510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0608|Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy|Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein||Nanjing University School of Medicine|Yes|Completed|January 2000|August 2003|Actual|March 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||July 2008|May 25, 2010|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00302510||184248|
NCT00309348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44DK067775|Ultrasound Instrument to Prevent Dialysis Graft Failure|New Doppler Instrument for Preventing Impending Access-Graft Failure Randomized Trial||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Active, not recruiting|February 2006|September 2008|Anticipated|September 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|220|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309348||183738|
NCT00309387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-110|Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)|Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)|CTNS|National Eye Institute (NEI)|Yes|Completed|May 1995|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1020|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|March 29, 2006|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00309387||183735|
NCT00309374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK291/2005Version2.0|Anti-Inflammatory Effect of Statins in the Human Endotoxin Model|Anti-Inflammatory Effect of Statins in the Human Endotoxin Model||Medical University of Vienna||Completed|March 2006|July 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2007|January 4, 2007|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309374||183736|
NCT00309621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP00626|Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis|Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis||Basilea Pharmaceutica||Completed|April 2006|May 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|75 Years|No|||July 2010|July 16, 2010|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309621||183717|
NCT00310492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHX0556|Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis|Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Demonstrate the Efficacy of a 12-month Subcutaneous Specific Immunotherapy With ALK-depot SQ Milbenmischung in Patients With Atopic Dermatitis and Proven IgE-mediated Sensitization to House Dust Mites||ALK-Abelló A/S|No|Completed|April 2006|November 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|55 Years|No|||December 2015|December 28, 2015|April 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00310492||183653|
NCT00310505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS01MZP03|Amphotericin B Treatment in Visceral Leishmaniasis|Randomised Double Blind Dose Ranging Study of Amphotericin B in Visceral Leishmaniasis||Banaras Hindu University||Completed|January 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1500|||Both|2 Years|65 Years|No|||September 2008|September 11, 2008|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310505||183652|
NCT00260949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2003534-01H|Outcome Following Surgery to Repair Rotator Cuff Tears|Functional and Anatomical Results Following Arthroscopic Cuff Repair||Ottawa Hospital Research Institute|No|Completed|November 2004|September 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|November 30, 2005||No||No||https://clinicaltrials.gov/show/NCT00260949||187352|
NCT00261274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152-1001|Safety Study of ECO Conversion System For Red Blood Cells.|Evaluation of the Safety of Repeated Autologous Infusions of Enzyme-Converted A-to-O (A-ECO) Red Cells Into Group A Volunteers.||ZymeQuest|Yes|Completed|November 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 22, 2009|November 30, 2005||Yes||No||https://clinicaltrials.gov/show/NCT00261274||187327|
NCT00261755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akupunktur2001-41-1305|Acupuncture as Pain Relief and Relaxation During Childbirth|Acupuncture as Pain Relief and Relaxation During Childbirth. A Randomized Controlled Study||University of Aarhus|No|Completed|March 2001|May 2004|Actual|February 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|607|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2008|May 6, 2008|December 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00261755||187291|
NCT00262132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL401|Mycophenolate for Pulmonary Sarcoidosis|Mycophenolate for Pulmonary Sarcoidosis||Medical University of South Carolina||Terminated|September 2003|August 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||20|||Both|18 Years|N/A|No|||January 2007|January 4, 2007|December 5, 2005||||||https://clinicaltrials.gov/show/NCT00262132||187263|
NCT00262145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA051001|Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption|Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Uptake in Human||NatureGen||Completed|October 2005|November 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2005|December 5, 2005|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262145||187262|
NCT00262431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1431/28.3|Efficacy of Early Tracheostomy to Reduce Incidence of Ventilator Acquired Pneumonia (VAP)|||University of Turin, Italy||Completed|June 2004|October 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00262431||187240|
NCT00258310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445467|Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy|A Phase II Study Examining the Feasibility of Long Term and Low Dose Oral Capecitabine (Xeloda®) in Newly Diagnosed Head and Neck Squamous Cell Carcinoma (HNSCC) After Surgery, Radiation and/or Chemotherapy||Barbara Ann Karmanos Cancer Institute|Yes|Completed|December 2003|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|November 22, 2005|Yes|Yes||No|November 20, 2014|https://clinicaltrials.gov/show/NCT00258310||187551|There were no significant limitations.
NCT00262444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/084|Effectivity and Efficiency of Turning Frequencies: a Randomised Controlled Trial|Effectivity and Efficiency of Turning Frequencies: a Randomised Controlled Trial||University Ghent|No|Completed|September 2003|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|500|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|December 4, 2005||||No||https://clinicaltrials.gov/show/NCT00262444||187239|
NCT00258323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF5848|Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer|A Phase II Trial of Pre- and Postoperative Chemoradiotherapy and ZD1839 (IRESSA) Followed by Maintenance ZD1839 in Patients With Locoregionally Advanced Esophageal and Gastroesophageal Junction Carcinoma||Case Comprehensive Cancer Center|Yes|Completed|October 2005|February 2010|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258323||187550|
NCT00258557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002800|TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.|Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients.||Tibotec Pharmaceuticals, Ireland|Yes|Completed|September 2005|May 2012|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|692|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258557||187533|
NCT00258817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC26|Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2005-2006 Formulation)||Sanofi|No|Completed|October 2005|August 2007|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||January 2014|January 16, 2014|November 24, 2005|Yes|Yes||No|January 21, 2009|https://clinicaltrials.gov/show/NCT00258817||187514|
NCT00299793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.08.110|Observational Study of Lamotrigine|Observational Study of Lamotrigine||Northwell Health||Completed|October 2001|||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||60|||Both|18 Years|N/A|No|||March 2007|March 22, 2007|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299793||184451|
NCT00299806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A1304|SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension|A Multi-center, Open-label Study Assessing the Safety and Efficacy of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension||Novartis||Completed|April 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|20 Years|80 Years|No|||November 2011|November 7, 2011|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299806||184450|
NCT00302263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF11-282523|B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)|B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)||University of Copenhagen||Completed|January 2005|April 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||22|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2005|March 13, 2006|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302263||184267|
NCT00310128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-044|Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma|Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma||AIDS Malignancy Consortium||Withdrawn|February 2006|||||Phase 2|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 29, 2006|||Drug supply unavailable|No||https://clinicaltrials.gov/show/NCT00310128||183680|
NCT00308516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 65|5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer|A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer||SCRI Development Innovations, LLC|No|Completed|March 2006|February 2012|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|March 28, 2006|No|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00308516||183801|
NCT00308763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|376|Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals|Clinical Trial of Two Medications on Smoking Cessation||University of Tennessee|Yes|Completed|January 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|594|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308763||183782|
NCT00308750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10651|First Line Chemotherapy Treatment of Advanced NSCLC|A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|No|Completed|March 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|217|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|March 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308750||183783|
NCT00309634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106750|Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years|Observer-blind Monocentric Study in Adults Aged b/w 18-60 Yrs to Evaluate Reactogenicity and Immunogenicity of 1 and 2 Administrations of Pandemic Monovalent Influenza Vaccines Administered at Different Antigen Doses & Adjuvanted or Not.||GlaxoSmithKline||Completed|March 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309634||183716|
NCT00310219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0515|Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer|Comparative Study of Gross Tumor Volume Definition With or Without PET Fusion for Patients With Non-Small Cell Lung Carcinoma||Radiation Therapy Oncology Group|Yes|Completed|February 2006|November 2013|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00310219||183674|
NCT00310869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-02-021|Adolescents Born Preterm; Nurtured Beginnings|Adolescents Born Preterm: Nurtured Beginnings||Children's Hospital Boston|Yes|Recruiting|January 2005|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|70|||Both|14 Years|18 Years|No|||October 2011|October 3, 2011|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00310869||183624|
NCT00261300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/VMG-708|Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)|Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints||Takeda||Completed|October 2000|July 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||December 2008|May 4, 2012|December 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00261300||187325|
NCT00261313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040137|ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer|An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer||Amgen||Completed|December 2005|December 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|N/A|No|||February 2010|February 25, 2010|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261313||187324|
NCT00261521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004420|A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients|Double-blind Study to Assess the Impact of Normalization of Hemoglobin Compared to Partial Correction of Hemoglobin With EPREX�/ERYPO� on Left Ventricular Structure in Early Hemodialysis Patients (RWJ-22512)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2000|May 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|596|||Both|18 Years|N/A|No|||December 2010|December 2, 2010|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261521||187308|
NCT00261534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-057|Cancer Related Fatigue in Patients Receiving Chemotherapy|Outcomes Research on the Course of Cancer Related Fatigue Throughout Five Chemotherapy Treatments||Medical Center Alkmaar||Active, not recruiting|January 2006|July 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||90|||Both|18 Years|N/A|No|||September 2006|September 13, 2006|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261534||187307|
NCT00261547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2928S|Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients|Pilot Study of Rituximab Treatment to Inhibit HLA Antibodies in Renal Allograft Recipients||Massachusetts General Hospital|Yes|Completed|December 2005|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|64 Years|No|||February 2008|February 15, 2008|December 1, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00261547||187306|
NCT00262158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 0930704|Analysis of 'Tobacco and Alcohol Tax Law' and Its Impact on Cigarette Consumption|The Survey of Cigarette Consumption||National Health Research Institutes, Taiwan||Completed|August 2004|September 2004||||N/A|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional||||4000|||Both|18 Years|N/A|No|||December 2005|December 5, 2005|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262158||187261|
NCT00262171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC9012005|Hereditary Nonpolyposis Colorectal Cancer in Taiwan－Related Genetic Study and Clinical Applications|Hereditary Nonpolyposis Colorectal Cancer in Taiwan－Related Genetic Study and Clinical Applications||National Health Research Institutes, Taiwan||Recruiting|May 2002|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|800|||Both|20 Years|N/A|No|Non-Probability Sample|The HNPCC patients and their families from the collaborative hospitals and relate the        information to the risk of CRC in order to provide sound disease control system in Taiwan|August 2009|August 12, 2009|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00262171||187260|
NCT00262184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-PP02|A Taiwan Isoflavone Multicenter Study (TIMS)|A Taiwan Isoflavone Multicenter Study (TIMS)||National Health Research Institutes, Taiwan||Recruiting|December 2004|December 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||420|||Female|45 Years|65 Years|No|||December 2005|December 5, 2005|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262184||187259|
NCT00262457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3259-R|BIONs, for Improved Tissue Health and Pressure Sore Prevention|BIONs, for Improved Tissue Health and Pressure Sore Prevention||VA Office of Research and Development|No|Withdrawn|April 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||September 2013|September 16, 2013|December 2, 2005||No|It was found that the devices were not suitable for the application.|No||https://clinicaltrials.gov/show/NCT00262457||187238|
NCT00262470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008397|Treatment of Orthostatic Intolerance|Treatment of Orthostatic Intolerance||Vanderbilt University|No|Active, not recruiting|April 1997|||January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|20||Anticipated|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|December 5, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00262470||187237|
NCT00258570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020123|Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)|Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis|GP|University of Pittsburgh|Yes|Recruiting|January 2003|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|Samples With DNA|Blood samples retained for multitude of testing. Consent allows for unrestricted use of      samples.|Both|18 Years|N/A|No|Non-Probability Sample|Patient population includes patients who have been diagnosed with a fibrotic interstitial        lung disease who have been seen by a Simmons Center Physician.|January 2016|January 4, 2016|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258570||187532|
NCT00258830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC25|Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine|Annual Study of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2005-2006 Formulation)||Sanofi|No|Completed|September 2005|March 2007|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 16, 2014|November 24, 2005|Yes|Yes||No|March 5, 2009|https://clinicaltrials.gov/show/NCT00258830||187513|
NCT00300716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-13|Trial of Memantine for Cognitive Impairment in Multiple Sclerosis|Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis||Oregon Health and Science University||Recruiting|April 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|146|||Both|18 Years|65 Years|No|||April 2007|August 27, 2009|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300716||184381|
NCT00312767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL03505|A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.|A Multicenter, Open-Label, Cross-Over Trial to Evaluate the Pharmacokinetics of Fabrazyme During Simultaneous Fabrazyme Infusion and Chronic Hemodialysis in Patients With Fabry Disease.||Sanofi||Withdrawn|April 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||February 2014|February 4, 2014|April 7, 2006||Yes||||https://clinicaltrials.gov/show/NCT00312767||183478|
NCT00308529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 110|Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer|Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|March 2006|January 2009|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||55|||Both|18 Years|N/A|No|||January 2009|June 18, 2010|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308529||183800|
NCT00309114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD043943-03|Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)|Prevention of UTI in Persons With Spinal Cord Injury||Baylor College of Medicine|Yes|Completed|February 2004|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|160|||Both|15 Years|64 Years|No|||November 2010|November 30, 2010|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309114||183755|
NCT00309075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91251|Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries|Multicenter, Open-label Study of the Safety (Open-label) and Efficacy (Open-label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients With Known or Suspected Disease of the Calf and/or Pedal Arteries Undergoing MRA of the Calf and Pedal Arteries With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as the Standard of Reference.||Bayer|No|Completed|December 2003|November 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|126|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|March 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00309075||183758|
NCT00309088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0601|FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients|FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients||Astellas Pharma Inc||Completed|April 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|16 Years|64 Years|No|||August 2014|August 22, 2014|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309088||183757|
NCT00309920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000458037|Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer|Adjuvant Therapy of Breast Cancer: Impact of Erythropoiesis Stimulating Factors on Event Free Survival High Risk Breast Cancer Treatment||National Cancer Institute (NCI)||Recruiting|January 2004|||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1234|||Female|18 Years|65 Years|No|||April 2006|February 6, 2009|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00309920||183695|
NCT00309933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000460234|Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance|Quality of Life in Younger Breast Cancer Survivors||National Cancer Institute (NCI)||Active, not recruiting|October 2005|||||N/A|Observational|N/A|||Anticipated|2697|||Female|18 Years|78 Years|No|||March 2010|March 9, 2010|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00309933||183694|
NCT00310232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-076080|Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)|Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20)||Ontario Clinical Oncology Group (OCOG)|Yes|Terminated|February 2001|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||March 2006|June 29, 2007|March 31, 2006|||Recommendation of DSMB for safety issue, increased mortality with study drug.|No||https://clinicaltrials.gov/show/NCT00310232||183673|
NCT00310245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG01|BASTA Study on STI in HIV Infected Patients|Strategic Long Term, Immunologically Driven Treatment Interruptions in Patients on Effective HAART: a Controlled, Randomized Study||A.O. Ospedale Papa Giovanni XXIII||Completed|November 2000|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|18 Years|80 Years|No|||November 2005|July 21, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00310245||183672|
NCT00310518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 501-221|Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma|A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma||ArQule||Completed|February 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00310518||183651|
NCT00310856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P9|Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)|A Phase 2, Partially Randomized, Open Label, Multicenter Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Young Children||Novartis||Completed|June 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|175|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||August 2013|August 29, 2013|April 3, 2006|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT00310856||183625|
NCT00261573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006034|A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia|The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 1998|December 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|593|||Both|40 Years|N/A|No|||November 2010|May 17, 2011|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261573||187304|
NCT00261560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002824|A Safety and Effectiveness Study of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Pain Associated With Ankle Sprains.|A Randomized, Double-Blind, Parallel-Group Study Comparing the Safety and Effectiveness of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Ankle Sprains.||Johnson & Johnson Consumer and Personal Products Worldwide||Completed||February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|260|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|December 2, 2005||||||https://clinicaltrials.gov/show/NCT00261560||187305|
NCT00261781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3189|Walking Capacity in Parkinson's Disease (PD-Walk)|Does Home-based Treadmill Training Improve Walking Capacity and Quality of Life in People With Early to Mid-stage Parkinson's Disease?||University of Sydney|No|Terminated|May 2005|September 2012|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|80 Years|No|||May 2015|May 27, 2015|December 1, 2005||No|20 subjects completed for a pilot, further funding required to continue study|No||https://clinicaltrials.gov/show/NCT00261781||187289|
NCT00262197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105300|Patient Based Strategy to Reduce Errors in Diabetes Care|Patient Based Strategy to Reduce Errors in Diabetes Care||HealthPartners Institute|No|Completed|December 2001|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||10000|||Both|18 Years|75 Years|No|||September 2012|September 4, 2012|December 5, 2005||No||No||https://clinicaltrials.gov/show/NCT00262197||187258|
NCT00262483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX05-950-102|Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C|A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C||Vertex Pharmaceuticals Incorporated||Completed|December 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||12|||Both|18 Years|65 Years|No|||December 2007|December 17, 2007|December 2, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00262483||187236|
NCT00262496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3216-01|Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.|Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.||VA Office of Research and Development||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|80 Years|No|||June 2015|June 25, 2015|December 2, 2005||||||https://clinicaltrials.gov/show/NCT00262496||187235|
NCT00258843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV17|Safety of Imovax Polio in Chinese Infants and Children|Clinical Safety Evaluation Study of the Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered as a Single Booster Dose at 18 Months of Age in Healthy Chinese Children, and as the First Dose of Primary Vaccination at 2 Months of Age in Healthy Chinese Infants.||Sanofi||Completed|November 2005|April 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|2 Months|18 Months|Accepts Healthy Volunteers|||January 2014|January 20, 2014|November 24, 2005||No||No||https://clinicaltrials.gov/show/NCT00258843||187512|
NCT00301639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-p-002189|A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults|A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults||Massachusetts General Hospital||Completed|March 2005|December 2005||December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00301639||184311|
NCT00301925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463447|Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery|Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer (TACT2)||National Cancer Institute (NCI)||Active, not recruiting|December 2005|||September 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|4400|||Both|18 Years|N/A|No|||July 2009|November 25, 2010|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301925||184292|
NCT00308282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11055|A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Patients With Rheumatoid Arthritis|Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate||Eli Lilly and Company||Completed|March 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|75 Years|No|||September 2008|September 17, 2008|March 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308282||183819|
NCT00308295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512-13|A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients|A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients||Indiana University||Completed|April 2006|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||27|||Both|18 Years|82 Years|No|||October 2007|October 15, 2007|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308295||183818|
NCT00309400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20057601|The Early History of Universal Screening for Metabolic Disorders|The Early History of Universal Screening for Metabolic Disorders||University of Miami|No|Completed|January 2006|June 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians and scientists knowledgeable about history of newborn screening|August 2014|August 19, 2014|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309400||183734|
NCT00309946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00126|Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery|Phase II Study of AZD2171 (NSC#732208) in Patients With Malignant Mesothelioma||National Cancer Institute (NCI)|Yes|Completed|December 2005|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||October 2013|July 25, 2014|March 29, 2006|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00309946||183693|
NCT00309647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106378|Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years|A Partially-blind Multi-centric Study in Adults Aged Between 18-60 Yrs Designed to Evaluate the Reactogenicity & Immunogenicity of 1 & 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses & Adjuvanted or Not||GlaxoSmithKline||Completed|March 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|September 8, 2014|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309647||183715|
NCT00310531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91213|3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women|A Multicenter, Double-Blind, Double-Dummy, Randomized, Active- Controlled, 3-Year Study to Evaluate the Antiresorptive Efficacy, Safety and Tolerability of a Ultra-Low Dose Estradiol Transdermal Delivery System Releasing 0.014 mg / Day Versus Oral Raloxifene Hydrochloride 60 mg / Day - as a Therapy for the Prevention of Osteoporosis in Postmenopausal Female Osteopenic Patients.||Bayer|No|Completed|February 2004|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|500|||Female|55 Years|80 Years|No|||December 2014|December 29, 2014|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00310531||183650|
NCT00310544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91230|Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction|Multicenter, Single-blind, Randomized, Intraindividual Study of the Safety and Efficacy of Magnevist Gadopentetate Dimeglumine (Magnevist® Injection) at 0.1 and 0.2 mmol/kg for the Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction||Bayer|No|Completed|March 2006|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|73|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|March 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310544||183649|
NCT00310882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297-31.3-06-HMO-CTIL|Involvement of Endogenous Digitalis-like Compounds in Breast Cancer|Involvement of Endogenous Digitalis-like Compounds in Breast Cancer||Hadassah Medical Organization|No|Withdrawn|May 2006|May 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|blood samples|Female|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Women with first diagnosis of Breast Cancer or a benign Breast Disease|May 2008|April 7, 2011|April 4, 2006||No|the PI is no longer work at Hadassah|No||https://clinicaltrials.gov/show/NCT00310882||183623|
NCT00311142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-3126-AM-CTIL|Actigraphic Sleep Patterns in Newborns Delivered Via Vacuum Extraction vs. Partum Spontaneous and Cesarean Section|Actigraphic Sleep Patterns in Newborns Delivered Via Vacuum Extraction vs. Partum Spontaneous and Cesarean Section.||Sheba Medical Center|No|Completed|March 2003|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|N/A|2 Days||||April 2008|April 15, 2008|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00311142||183603|
NCT00311389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-28|A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension|A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|January 2003|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|408|||Both|18 Years|N/A|No|||February 2012|February 11, 2012|April 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00311389||183584|
NCT00311402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.178|JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme|JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily||Boehringer Ingelheim||Completed|April 2006|||March 2009|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||Actual|1295|||Both|50 Years|N/A|No|||January 2014|January 21, 2014|March 28, 2006||||No|February 16, 2010|https://clinicaltrials.gov/show/NCT00311402||183583|
NCT00311415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14P6|Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children|A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Infants as One Dose Given at 2 or 6 Months of Age With a Booster at 12-16 Months of Age, in Comparison to Two Doses in the First Year of Life, Given Two Months Apart, With a Booster at 12-16 Months of Age; and in Comparison to One Dose Given at 12-16 Months of Age||Novartis|No|Completed|October 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|257|||Both|7 Weeks|16 Weeks|Accepts Healthy Volunteers|||February 2012|February 6, 2012|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00311415||183582|
NCT00311155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-OLM-03-05|Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension|Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension|OLMETREAT|Daiichi Sankyo Inc.|No|Completed|March 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|694|||Both|18 Years|N/A|No|||November 2010|November 23, 2010|April 3, 2006|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00311155||183602|
NCT00311688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRP 030/OPTICA|Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies|An Omnibus Proleukin (IL-2) Trial in HIV Infected Patients Including Interrupted Versus Continuous Antiretrovirals (OPTICA)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2003|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||November 2013|November 19, 2013|April 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00311688||183561|
NCT00271388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3868-R|Vestibular Stimulation to Treat Hemispatial Neglect|Noise Enhanced Galvanic Vestibular Stimulation in Hemispatial Neglect||VA Office of Research and Development||Completed|January 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|2|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 1, 2014|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00271388||186572|
NCT00261820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E1-100194|Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients|A Randomized Study To Compare The Safety And Efficacy Of Two Immunosuppressive Regimens In De Novo Renal Allograft Recipients:Sirolimus Plus Mycophenolate Mofetil Plus Corticosteroids Following A Rabbit Anti-Human Thymocyte Globulin Induction (RATG) Vs Tacrolimus Plus Mycophenolate Mofetil Plus Corticosteroids||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|65 Years|No|||May 2006|May 17, 2006|December 2, 2005||||No||https://clinicaltrials.gov/show/NCT00261820||187286|
NCT00261833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1226_4001|Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency|A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to Compare the Efficacy and Safety of 60mg/kg Body Weight of Zemaira® Weekly I.V. Administration With Placebo Weekly I.V. Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency||CSL Behring|Yes|Completed|March 2006|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|65 Years|No|||January 2015|January 11, 2015|December 2, 2005|Yes|Yes||No|November 2, 2014|https://clinicaltrials.gov/show/NCT00261833||187285|
NCT00261794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3153R|Cognitive Remediation for Schizophrenia|Computer Assisted Cognitive Remediation for Schizophrenia||VA Office of Research and Development||Completed|November 2004|September 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|64 Years|No|||January 2010|January 5, 2010|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261794||187288|
NCT00261807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26386|Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections|Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.||University of Maryland||Completed|June 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||May 2008|May 30, 2008|December 1, 2005||Yes||||https://clinicaltrials.gov/show/NCT00261807||187287|
NCT00262522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-730|Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects|A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects||Abbott|No|Completed|November 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|664|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 3, 2012|December 5, 2005|Yes|Yes||No|July 9, 2009|https://clinicaltrials.gov/show/NCT00262522||187233|
NCT00268151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|562.04|Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer|Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer||James Graham Brown Cancer Center||Terminated|February 2005|||February 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|December 20, 2005|No|Yes|Study was terminated due to lack of funding.|No||https://clinicaltrials.gov/show/NCT00268151||186813|
NCT00268476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455008|STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial|STAMPEDE: Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer|STAMPEDE|Medical Research Council|Yes|Recruiting|September 2005|||September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|8100|||Male|N/A|N/A|No|||July 2014|July 24, 2014|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268476||186791|
NCT00258336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449719|Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma|Phase II Trial of Maintenance Rituximab Plus FavId® and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma||National Cancer Institute (NCI)||Recruiting|August 2004|||November 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||August 2008|January 9, 2014|November 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00258336||187549|
NCT00258583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0307127|UPMC Simmons Center for Interstitial Lung Disease Pennsylvania Statewide Research Registry|UPMC Simmons Center for Interstitial Lung Disease Pennsylvania Statewide Research Registry|ILDRR|University of Pittsburgh|Yes|Recruiting|October 2003|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Study population can be described as any adult being seen by a physician at the Simmons        Center for interstitial lung disease who has been diagnosed with an Interstitial Lung        Disease.|December 2015|January 4, 2016|November 23, 2005||No||No||https://clinicaltrials.gov/show/NCT00258583||187531|
NCT00268840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIO PANCREAS|The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer|National Trial Phase II to Study the Combination of Gemcitabine and Docetaxel in Patients With Locally Advanced or Metastatic Pancreatic or Biliary Adenocarcinoma That Cannot be Removed by Surgery||ARCAGY/ GINECO GROUP|No|Completed|August 2001|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|60 Years|No|||June 2011|June 29, 2011|December 22, 2005||No||No||https://clinicaltrials.gov/show/NCT00268840||186765|
NCT00268853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIX203|A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin|Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial|RAPID|CTI BioPharma|Yes|Completed|November 2005|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||July 2012|January 15, 2015|December 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268853||186764|
NCT00312455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA015360-03|Effects of Fatty Acid Supplementation on Substance Dependent Individuals|Cholesterol and Fatty Acids in Cocaine Addiction Relapse||National Institute on Drug Abuse (NIDA)|No|Completed|July 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||||||Both|25 Years|55 Years|No|||August 2008|August 26, 2008|April 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00312455||183502|
NCT00312468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1334|Examining the Link Between Heart Disease and HIV Infection in Women|Mechanisms of Atherosclerosis and CVD in HIV+ Women||National Heart, Lung, and Blood Institute (NHLBI)||Active, not recruiting|October 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1000|||Female|13 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 18, 2006|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312468||183501|
NCT00308776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4736|Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa|Effect of Cholecystokinin on Binge Eating in Bulimia Nervosa||New York State Psychiatric Institute|No|Terminated|October 2003|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|6|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 25, 2012|March 28, 2006||No|Unable to recruit subjects|No||https://clinicaltrials.gov/show/NCT00308776||183781|
NCT00309101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0602|An Open Study for Steroid Resistant, Non-Thymectomized MG Patients|FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients||Astellas Pharma Inc||Completed|February 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|16 Years|64 Years|No|||June 2009|June 2, 2009|March 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00309101||183756|
NCT00309959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0127V|ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix||Gynecologic Oncology Group||Completed|November 2006|||February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Female|N/A|N/A|No|||December 2014|December 29, 2014|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309959||183692|
NCT00309426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2006003|Effect of Fetuin A in Hemodialysis Patients|The Effect of Serum Fetuin A Concentration on the 5-Year Prognosis in Hemodialysis Patients||University of Shizuoka||Active, not recruiting|March 2001|March 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|70 Years|No|||March 2006|May 18, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00309426||183732|
NCT00310258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|girls & drugs|Drug Use Prevention Among Girls Through a Mother-Daughter Intervention|Drug Abuse Prevention: A Mother-Daughter Intervention||National Institute on Drug Abuse (NIDA)||Completed|April 2005|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||2000|||Female|11 Years|13 Years|Accepts Healthy Volunteers|||March 2006|March 30, 2006|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00310258||183671|
NCT00309972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465629|Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Randomized Phase III Trial of Sequential Chemotherapy Followed By Radical Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Chemotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer and Good Performance Status|SOCCAR|University College, London|Yes|Completed|December 2005|February 2012|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||March 2012|December 1, 2014|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00309972||183691|
NCT00310271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM HSD-001 P|A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects|A Phase I Study Assessing Safety and Tolerability of a DNA Vaccine With a DNA Encoded Immunostimulator , Administered by Particle Mediated Epidermal Delivery Using the PowderMed ND10 Delivery System in HSV-2 Seronegative Healthy Volunteers||PowderMed||Completed|April 2006|December 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2008|November 20, 2008|March 31, 2006||||||https://clinicaltrials.gov/show/NCT00310271||183670|
NCT00310557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90940|Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries|Multicenter, Open-label Study of the Safety (Open-label) and Efficacy (Open-label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients With Known or Suspected Renal Artery Disease Undergoing MRA of the Renal Arteries With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as the Standard of Reference||Bayer|No|Completed|December 2003|December 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|116|||Both|18 Years|N/A|No|||December 2014|December 28, 2014|March 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310557||183648|
NCT00310895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRN163L CP05-101|Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies||Geron Corporation|No|Completed|March 2006|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|April 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310895||183622|
NCT00311467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG RCC 1.3.001|Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma|Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma: a Prospective, Randomized, Multi-center phaseIII-Trial||Central European Cooperative Oncology Group|No|Terminated|March 2004|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|19 Years|75 Years|No|||May 2012|May 15, 2012|April 5, 2006||No|no patient recruitment|No||https://clinicaltrials.gov/show/NCT00311467||183578|
NCT00311428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M71P1|Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months|A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months.||Novartis||Completed|October 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||270|||Both|6 Months|35 Months||||September 2006|September 13, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311428||183581|
NCT00311441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M48P3|Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children|A Phase IV, Randomized, Controlled, Single-Blind, Multi-Center Study in Children to Evaluate the Safety, Tolerability and Immunogenicity of Two TBE Vaccines Administered According to Two Different Schedules.||Novartis||Completed|March 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||300|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||March 2008|March 14, 2008|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311441||183580|
NCT00267618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2234d|Family Help Program: Pediatric Recurrent Headache and Abdominal Pain|Family Help Program: Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Recurrent Headache and Abdominal Pain)||IWK Health Centre|No|Completed|June 2004|April 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267618||186852|
NCT00271609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060064|Bevacizumab for Recurrent Malignant Glioma|A Phase II Trial of Bevacizumab for Patients With Recurrent High-Grade Gliomas||National Institutes of Health Clinical Center (CC)|No|Completed|December 2005|February 2014|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||April 2014|April 13, 2014|December 31, 2005|Yes|Yes||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00271609||186555|
NCT00267917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215.1365|Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.|A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique.||Boehringer Ingelheim||Completed|January 2006|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||13|||Both|40 Years|N/A|No|||October 2013|October 28, 2013|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00267917||186831|
NCT00262210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1495|A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers|A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers||National Health Research Institutes, Taiwan||Completed|June 1995|December 1999||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2005|December 5, 2005|December 5, 2005||||No||https://clinicaltrials.gov/show/NCT00262210||187257|
NCT00262509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3905-R|Emergency Egress and Information System for Persons With Vision Loss|Emergency Egress and Information System for Persons With Vision Loss||VA Office of Research and Development|No|Terminated|September 2008|April 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 14, 2014|December 2, 2005||No|Intervention worsened performance for first 17 of 24 planned participants.|No|September 17, 2013|https://clinicaltrials.gov/show/NCT00262509||187234|Trials were terminated early with just 17 Participants of the planned 24, as the intervention was NOT providing measurable benefit.
NCT00267904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060047|Reference Values for Plasma Catechols|Reference Values for Plasma Catechols||National Institutes of Health Clinical Center (CC)||Recruiting|December 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 10, 2015|December 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00267904||186832|
NCT00268866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.367|Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung Clinics|Danish Quality Assurance Project on Diagnosis and Treatment of COPD in Outpatient Lung Clinics||Boehringer Ingelheim||Completed||January 2007||||Phase 4|Observational|N/A||||1820|||Both|35 Years|N/A|No|||April 2008|April 15, 2008|December 22, 2005||||No||https://clinicaltrials.gov/show/NCT00268866||186763|
NCT00268879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL1251/038/CL|Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)|A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (c-IBS)||Alizyme|Yes|Completed|December 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1821|||Female|18 Years|65 Years|No|||February 2008|February 13, 2008|December 22, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00268879||186762|
NCT00268489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0426|Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Pemetrexed Disodium (ALIMTA®) Plus Bevacizumab in Patients With Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment)||Alliance for Clinical Trials in Oncology|No|Completed|May 2006|April 2010|Actual|May 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|December 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00268489||186790|
NCT00269490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU# 05-89014|Yoga as a Therapy for Traumatic Experiences|Yoga as an Adjunctive Therapy for Post-Traumatic Stress Disorder: A Feasibility Study||Samueli Institute for Information Biology||Completed|December 2005|August 2007|Actual|October 2006|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|7|||Both|18 Years|N/A|No|||January 2008|January 24, 2008|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269490||186715|
NCT00269503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#B04-091|Chiropractic Prone Distraction for Lower Back Pain|A Pilot Study of Chiropractic Prone Distraction for Subacute Back Pain With Sciatica||Samueli Institute for Information Biology||Terminated|March 2006|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|45 Years|No|||May 2008|May 7, 2008|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00269503||186714|
NCT00312481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL994-02-2004|MOVIPREP® Versus PICOLAX® Pilot Study|A Randomised, Single-Centre, Parallel-Group, Pilot Study to Assess the Efficacy, Safety and Patient Acceptability of a New 2-Litre Bowel Preparation Agent (MOVIPREP®) Compared With a Standard Bowel Preparation Agent (PICOLAX®)||Norgine|No|Completed|July 2005|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|80 Years|No|||December 2007|December 12, 2007|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312481||183500|
NCT00308542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX4002|A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|79 Years|No|||February 2012|February 9, 2012|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308542||183799|
NCT00309660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPAR2005|Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis|||Herlev Hospital||Recruiting|November 2005|June 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||September 2006|September 20, 2006|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309660||183714|
NCT00309673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC05001|Local Anesthesia and Tuberculin Skin Test in Infants and Children|Local Anesthesia Effect on Tuberculin Skin Test Results in Infants and Children||Assistance Publique - Hôpitaux de Paris||Not yet recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|1 Month|15 Years|No|||March 2006|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309673||183713|
NCT00309439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB15636|ALA and Prostate Cancer|Studies of Serum PSA to Help Resolve the Current Implication of Alpha-linolenic Acid (ALA) and Prostate Cancer||University of Toronto||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|77 Years||||June 2012|June 12, 2012|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00309439||183731|
NCT00309985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3805|Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer|CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer|CHAARTED|Eastern Cooperative Oncology Group|Yes|Active, not recruiting|July 2006|December 2022|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|790|||Male|18 Years|N/A|No|||February 2016|February 1, 2016|March 29, 2006|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00309985||183690|
NCT00309686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010855|A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stabilizers in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2006|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|300|||Both|18 Years|65 Years|No|||March 2010|May 17, 2011|March 31, 2006||||||https://clinicaltrials.gov/show/NCT00309686||183712|
NCT00310570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 58/06|Comparison of Splinting Interventions for Treating Mallet Finger Injuries|Comparison of Splinting Interventions for Minimising Extensor Lag in Mallet Finger Injuries||Bayside Health||Not yet recruiting|May 2006|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||April 2006|April 2, 2006|April 2, 2006||||No||https://clinicaltrials.gov/show/NCT00310570||183647|
NCT00310908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234567-HMO-CTIL|Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic|Efficacy of Tramadol Hcl in the Treatment of Renal Colic||Hadassah Medical Organization|No|Completed|September 2006|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||September 2006|February 15, 2009|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00310908||183621|
NCT00311168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD343|Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)|Reduce Ventricular Pacing Using Ventricular Intrinsic Preference: VIP™ Study||St. Jude Medical|No|Completed|February 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|100|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311168||183601|
NCT00311454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mekos 05 UseQ 001|Quaternium-15, Use Test|An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15||Mekos Laboratories AS||Not yet recruiting|April 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||10|||Both|18 Years|N/A|No|||April 2006|April 4, 2006|April 4, 2006||||||https://clinicaltrials.gov/show/NCT00311454||183579|
NCT00311181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 324|POWER (Pulse Width Optimized Waveform Evaluation Trial)|Phase 4 Study That Compares the DFT (Defibrillation Threshold) Efficacy of 3 Different Membrane Time Constant Based Biphasic Defibrillation Waveforms||St. Jude Medical|No|Completed|August 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|217|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|April 3, 2006||No||No|July 24, 2011|https://clinicaltrials.gov/show/NCT00311181||183600|
NCT00311727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0006|Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine|Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Prevention|1||Actual|339|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|August 15, 2013|April 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00311727||183558|
NCT00267956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006322|An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis||Centocor, Inc.|Yes|Completed|December 2005|September 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|December 20, 2005|No|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00267956||186828|The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.
NCT00268203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEX104545|Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma|Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma||GlaxoSmithKline||Completed|September 1998|February 2013|Actual|March 2000|Actual|Phase 2|Interventional|N/A|||Actual|765|||Both|18 Years|N/A||||January 2014|March 20, 2014|December 20, 2005|Yes|Yes|||October 10, 2013|https://clinicaltrials.gov/show/NCT00268203||186810|
NCT00267930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235-SR-1005|Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence|A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF||Cardiome Pharma|No|Completed|December 2005|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|221|||Both|18 Years|85 Years|No|||December 2008|December 17, 2008|December 20, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00267930||186830|
NCT00267943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.491|Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients|An Open-label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80 mg + Hydrochlorothiazide 25 mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.||Boehringer Ingelheim||Completed|January 2006|January 2007||January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||639|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00267943||186829|
NCT00268216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO30003|Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)|See Detailed Description||GlaxoSmithKline||Completed|September 2000|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|6228|||Both|40 Years|80 Years|No|||April 2015|April 15, 2015|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268216||186809|
NCT00267605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2234c|Strongest Families (Formerly Family Help Program): Pediatric Attention Deficit/Hyperactivity Disorder|Strongest Families (Formerly Family Help Program): Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Attention Deficit/Hyperactivity Disorder)|FHPADHD|IWK Health Centre|No|Completed|June 2003|April 2008|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|December 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00267605||186853|
NCT00268502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUMC-0209-08B|Quality of Life in African-American or Caucasian Female Breast Cancer Survivors|Survey of the Quality of Life of Women||Indiana University|No|Completed|December 2005|April 2014|Actual|November 2007|Actual|N/A|Observational|N/A|||Anticipated|195|||Female|18 Years|120 Years|No|||November 2015|November 12, 2015|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00268502||186789|
NCT00268515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|349|Aerosol Cyclosporine for Prevention of Lung Rejection|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|April 1998|March 2003|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|N/A|100 Years|No|||December 2005|February 23, 2016|December 21, 2005||||No||https://clinicaltrials.gov/show/NCT00268515||186788|
NCT00259805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPMC-IRB25.102|A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis|A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis||California Pacific Medical Center Research Institute|No|Completed|January 2005|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|5 Years|25 Years|No|||March 2008|March 20, 2013|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00259805||187438|
NCT00259818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-1421 #101|Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors|An Open-Label Phase I Dose Escalation Study of Intravenous Infusion of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Refractory Malignant Tumors||Erimos Pharmaceuticals||Completed|December 2005|January 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|November 30, 2005||||||https://clinicaltrials.gov/show/NCT00259818||187437|
NCT00269204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-020|Lipid Efficacy/Tolerability Study (0524A-020)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|December 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1620|||Both|18 Years|85 Years|No|||July 2015|July 24, 2015|December 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00269204||186737|
NCT00312234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007434|Qigong vs. Aerobic Exercise in the Treatment of Childhood Chronic Musculoskeletal Pain|Feasibility and Impact of Qigong as Compared to Aerobic Exercise in the Treatment of Childhood Chronic Musculoskeletal Pain: A Pilot Randomized Controlled Trial.||The Hospital for Sick Children||Completed|August 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|8 Years|18 Years|No|||December 2013|December 17, 2013|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312234||183519|
NCT00308308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-009|Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes|A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up||Mannkind Corporation||Completed|February 2006|August 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|589|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|March 27, 2006|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00308308||183817|
NCT00308555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC # 064|Opioid and Cannabinoid Pharmacokinetic Interactions|Opioid and Cannabinoid Pharmacokinetic Interactions: A Pilot Study||University of California, San Francisco||Completed|May 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|March 27, 2006|No|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00308555||183798|Small number of participants, powered to detect a 25% change in AUC(12).Further research is needed to determine how cannabis delivery systems other than vapor affect metabolism of opioids and other drugs.
NCT00309998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465498|Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer||University of Rochester||Completed|September 2005|||May 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|70 Years|N/A|No|||September 2014|September 16, 2014|March 29, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00309998||183689|
NCT00309712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-009|Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study|Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease||Intermountain Health Care, Inc.||Completed|August 2002|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309712||183710|
NCT00310284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44HL065893|A Treatment Study Comparing Two Non-Drug, Self-Help Treatment of Chronic Insomnia.|Computerized Self-Help Treatment for Primary Insomnia||PICS, Inc.||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2006|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00310284||183669|
NCT00310297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_1505|Insulin Glulisine in Type 2 Diabetes Mellitus|A Randomized, Open Label, Two-arm, Cross-over Design Study to Compare the Pharmacodynamics and Pharmacokinetics of Insulin Glulisine and Insulin Lispro in Obese Patients With Type 2 Diabetes.||Sanofi||Completed|November 2004|||December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||July 2008|January 10, 2011|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00310297||183668|
NCT00310596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91024|Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects|Cardiovascular Safety Study of 0.1 and 0.3 mmol/kg Magnevist® Injection at Two Injection Rates (Bolus and 10 mL/15 Sec.) in Normal Subjects Following a Randomized, Cross-over Design Using Placebo and a Concurrent Positive Control||Bayer||Completed|January 2004|March 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|6||Actual|71|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|March 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310596||183645|
NCT00310583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000411-10|Effects of Pregabalin on Mechanical Hyperalgesia|Effects of Pregabalin on Mechanical Hyperalgesia - EPOM||Professional Associations Clinic Bergmannsheil||Recruiting|July 2006|April 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2006|April 4, 2007|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310583||183646|
NCT00310921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-00SFeig-04-B|A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination|A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination: Effects on Pain, Ease of Procedure and Complications||Kaiser Permanente||Completed|May 2001|May 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2005|April 10, 2007|April 3, 2006||||||https://clinicaltrials.gov/show/NCT00310921||183620|
NCT00311506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z1943n|A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease|A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease||Genentech, Inc.||Completed||||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||25|||Both|14 Years|N/A|No|||April 2006|April 4, 2006|March 25, 2006||||No||https://clinicaltrials.gov/show/NCT00311506||183575|
NCT00311480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P1|Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects|A Phase II, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 7.5 mg or 15 mg of H5N1 Influenza Antigen, in Non-Elderly Adult and Elderly Subjects||Novartis||Completed|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||520|||Both|18 Years|N/A||||March 2007|March 12, 2007|April 4, 2006||||No||https://clinicaltrials.gov/show/NCT00311480||183577|
NCT00311493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V48P2E3|Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults|A Phase IV, Randomized, Open-Label, Multi-Center Study in Adults: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer) in Study V48P2E1, 5 Years After First Booster Immunization and Evaluation of Booster Kinetics in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer), 5 Years After First Booster Immunization||Novartis||Completed|February 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||179|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 12, 2007|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311493||183576|
NCT00259493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Graft Patency in Beating Heart Vs. Conventional CABG Using Cardiac CT|Graft Patency Following Off-Pump CABG Vs. On-Pump CABG Using 64 MDCT Bypass Graft CT Angiography||Trillium Health Centre||Recruiting|December 2005|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||September 2005|September 7, 2006|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259493||187462|
NCT00268528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL03N1|Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission|Understanding the Ethnic and Racial Differences in Survival in Children With Acute Lymphoblastic Leukemia||Children's Oncology Group|Yes|Active, not recruiting|May 2005|||October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|755|||Both|N/A|21 Years|No|||March 2016|March 7, 2016|December 20, 2005||No||No||https://clinicaltrials.gov/show/NCT00268528||186787|
NCT00268164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB coul|Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis|Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis||Hvidovre University Hospital||Terminated|June 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||September 2006|May 5, 2015|December 21, 2005|||Inclusion was difficult and to slow|No||https://clinicaltrials.gov/show/NCT00268164||186812|
NCT00268177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO30005|Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease|A 13-week, Double-blind, Parallel Group, Multi-centre Study to Compare the Bronchial Anti-inflammatory Activity of the Combination of Salmeterol/Fluticasone Propionate 50/500mcg Twice Daily Compared With Placebo Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|October 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|40 Years|80 Years|No|||February 2011|April 11, 2013|December 20, 2005||||No||https://clinicaltrials.gov/show/NCT00268177||186811|
NCT00259467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH069425|Project TAP: Tailored Activities Project|Tailored Activity to Improve Affect in Dementia||Thomas Jefferson University|No|Completed|February 2004|January 2007||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind||||60|||Both|21 Years|N/A|No|||August 2010|August 24, 2010|November 28, 2005||||No||https://clinicaltrials.gov/show/NCT00259467||187464|
NCT00259480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 AG22254|Project ACT: Advancing Caregiving Techniques|Reducing Family Caregiver Upset With Disruptive Behavior||Thomas Jefferson University||Completed|August 2001|March 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|272|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 12, 2015|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259480||187463|
NCT00260585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990507|Esophageal Cancer Risk Registry|Esophageal Cancer Risk Registry||University of Pittsburgh||Recruiting|June 1999|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|4500|Samples With DNA|blood, tissue, lymph nodes|Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients will be selected from the investigator's clinic.|December 2015|December 1, 2015|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00260585||187379|
NCT00260052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-264|Erythropoietin Effects After Traumatic Brain Injury|Phase II Study of the Effects of Erythropoietin on Neuronal Cell Death in Traumatic Brain Injury Patients||Medical College of Wisconsin||Withdrawn|July 2003|January 2010|Actual|January 2010|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|November 29, 2005||No|PI has left institution|No||https://clinicaltrials.gov/show/NCT00260052||187419|
NCT00308321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03NU13|Long Term Tapering or Standard Steroids for Nephrotic Syndrome|Long Term Tapering or Standard Steroids for Nephrotic Syndrome||Institute of Child Health||Recruiting|September 2003|October 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|15 Years|No|||November 2007|November 28, 2007|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308321||183816|
NCT00308789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0258-A|A Trial of Infant Flow Biphasic Nasal Continuous Airway Pressure (NCPAP) Versus Infant Flow NCPAP for the Facilitation of Extubation in Infants </= 1250 Grams|Infant Flow Biphasic NCPAP Versus Infant Flow NCPAP for the Facilitation of Successful Extubation in Infants </= 1250 Grams: A Randomized Controlled Trial||Mount Sinai Hospital, Canada|No|Terminated|April 2006|December 2009|Anticipated|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|N/A|6 Months|No|||May 2009|May 4, 2009|March 28, 2006|||Poor enrollment|No||https://clinicaltrials.gov/show/NCT00308789||183780|
NCT00309413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBD-PT 04-153|A Clinical Trial on the Antipsychotic Properties of Cannabidiol|A Placebo-Controlled Randomized Cross-Over Clinical Trial on the Antipsychotic Properties of the Endocannabinoid Modulator Cannabidiol||University of Cologne|No|Completed|March 2006|July 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||July 2008|July 23, 2008|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309413||183733|
NCT00309127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.226-T|Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy|A Multicentre, Randomised Study to Examine the Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy||Chinese University of Hong Kong||Completed|May 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|205|||Both|35 Years|75 Years|No|||August 2015|August 21, 2015|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309127||183754|
NCT00309140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10287|An Open Label Study of Oral Enzastaurin in Patients With Cancer|An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies||Eli Lilly and Company|No|Completed|March 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309140||183753|
NCT00309166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/011|Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.|An Observer-blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years||GlaxoSmithKline||Completed|April 2006|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||270|||Male|10 Years|18 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|March 28, 2006||||No||https://clinicaltrials.gov/show/NCT00309166||183752|
NCT00309725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012118|A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.|Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||October 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|139|||Both|N/A|N/A|No|||January 2011|May 17, 2011|March 31, 2006||||||https://clinicaltrials.gov/show/NCT00309725||183709|
NCT00310011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-88197|Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium|A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium||Comprehensive Cancer Center of Wake Forest University||Completed|June 1998|August 2009|Actual|October 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|71|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00310011||183688|
NCT00310609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90941|Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches|Multicenter, Open-label Study of the Safety (Open-label) and Efficacy (Open-label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients With Known or Suspected Disease of the Aortic Arch and Cerebral Branches Who Are Undergoing MRA of These Vessels With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as the Standard of Reference.||Bayer|No|Completed|December 2003|October 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|123|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|March 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310609||183644|
NCT00310934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KarolinskaUH Regional 373/03|A Stepwise Strategy Utilizing Buprenorphine and Methadone|Graded Strategy for Pharmacological Treatment of Heroin Dependence||Karolinska University Hospital||Completed|August 2005|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||96|||Both|20 Years|N/A|No|||March 2006|October 23, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310934||183619|
NCT00310947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coronary flow reserve|Impact of Patient-Prosthesis-Mismatch on Coronary Flow Reserve|Impact of Patient-Prosthesis-Mismatch and Aortic Valve Design on Coronary Flow Reserve Following Aortic Valve Replacement||Johann Wolfgang Goethe University Hospitals||Completed|March 2005|January 2006||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||48|||Both|18 Years|80 Years|No|||March 2003|April 4, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00310947||183618|
NCT00311194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABLM|Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure|A Randomised, Controlled Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure||Swedish Heart Lung Foundation||Completed|February 1998|July 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||206|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2002|April 3, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311194||183599|
NCT00311519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-05-04|A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects|A Phase IIIB Double Blind, Randomized, Placebo-Controlled, Dose-Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects||Halozyme Therapeutics||Completed|November 2005|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2006|April 5, 2006|April 4, 2006||||||https://clinicaltrials.gov/show/NCT00311519||183574|
NCT00311766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSEB|A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa||RegeneRx Biopharmaceuticals, Inc.|No|Terminated|February 2006|November 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|2 Years|N/A|No|||April 2014|April 25, 2014|April 4, 2006|Yes|Yes|Lack of patient availability and expiration of study drug|No|May 22, 2013|https://clinicaltrials.gov/show/NCT00311766||183555|Early termination of the study leading to randomizing 30 of the 36 participants planned. This was due to the small pool of participants and therefore resulting in low availability of eligible participants.
NCT00259246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B208,1|The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.|Fasting and Postprandial Response After Infusion of Saline, PYY1-36 and PYY3-36 and Effects on Appetite, Energy Intake and Energy Expenditure in Overweight/Obese Compared to Normalweight Subjects||University of Copenhagen||Completed|June 2004|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2005|January 20, 2009|November 25, 2005||||No||https://clinicaltrials.gov/show/NCT00259246||187481|
NCT00259831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-E002-2005-3|Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults|Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adult Employees in Continuing Care Facilities||Afexa Life Sciences Inc||Completed|December 2005|August 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00259831||187436|
NCT00268892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS15A|Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer|An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens in Patients With Prostate Cancer||Ferring Pharmaceuticals|No|Completed|January 2006|December 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|278|||Male|18 Years|N/A|No|||December 2010|December 8, 2010|December 21, 2005|Yes|Yes||No|November 17, 2010|https://clinicaltrials.gov/show/NCT00268892||186761|
NCT00268905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-104|A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors|A Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors||Eisai Inc.||Completed|October 2006|||November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|December 21, 2005|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00268905||186760|
NCT00260338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jens Kastrup|Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia|Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia||Rigshospitalet, Denmark||Completed|December 2005|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|30 Years|80 Years|No|||May 2013|May 30, 2013|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260338||187397|
NCT00260598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-1030|LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer|LIFE-Lung Fluorescence Endoscopic Surveillance in Patients at High Risk For Developing Lung Cancer||University of Pittsburgh||Terminated|August 1998|||January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|142|||Both|18 Years|85 Years|No|||April 2015|April 6, 2015|November 29, 2005||No|LIFE Bronchoscopy equipment no longer functioning and cannot be repaired.|No||https://clinicaltrials.gov/show/NCT00260598||187378|
NCT00260611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-011|Study of Oxaliplatin and Taxotere in Prostate Cancer|Study of Oxaliplatin and Taxotere in Androgen Independent Prostate Cancer||University of Pittsburgh|Yes|Completed|November 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Male|18 Years|N/A|No|||March 2015|March 24, 2015|November 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00260611||187377|
NCT00260806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1318|Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children|HAART Associated Cardiotoxicity in HIV-Infected Children||University of Miami|Yes|Completed|August 2004|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|71|Samples With DNA|Peripheral blood mononuclear cells (PBMCs) were collected from the WITS cohort to      investigate the presence of mitochondrial DNA (mtDNA) mutations.|Both|2 Years|18 Years|No|Non-Probability Sample|Study participants will be children perinatally infected with HIV who were enrolled in the        Women and Infants Transmision Study (WITS).        This cohort will be compared to the historical Pediatric Pulmonary and Cardiovacular        Complications Study (P2C2 HIV) cohort of perinatally HIV-infected children not exposed to        HAART.|March 2014|March 17, 2014|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00260806||187362|
NCT00308802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-01|Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients|Noninvasive Monitoring to Predict Outcome in De Novo Kidney Transplant Recipients||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|280|Samples With DNA|Blood samples may be retained|Both|N/A|N/A|No|Non-Probability Sample|People who are candidates for kidney transplant|August 2013|August 29, 2013|March 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00308802||183779|
NCT00308815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701098|Comparison of Manual Cardiopulmonary Resuscitation (CPR) Versus Automatic CPR Machine During Ambulance Transport.|Comparison of Manual Cardiopulmonary Resuscitation (CPR) Versus Automatic CPR Machine on the CPR Performance for Out-of-Hospital Cardiac Arrest During Ambulance Transport.||National Taiwan University Hospital||Recruiting|January 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|16 Years|N/A|No|||October 2004|March 28, 2006|March 28, 2006||||No||https://clinicaltrials.gov/show/NCT00308815||183778|
NCT00309452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601001013|Specialized Treatment Early in Psychosis (STEP)|Randomized Trial of Usual Care Versus Specialized, Phase-specific Care in the Public Sector for First Episode Psychosis.|STEP|Yale University|Yes|Completed|March 2006|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|16 Years|45 Years|No|||September 2013|September 17, 2013|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00309452||183730|
NCT00309699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010858|A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder|Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes in Bipolar Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2006|November 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|493|||Both|18 Years|65 Years|No|||June 2014|June 19, 2014|March 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309699||183711|
NCT00310024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02693|Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|November 2005|||February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|March 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310024||183687|
NCT00310310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 02-275|Effect of Self-Management on Improving Sleep Apnea Outcomes|Effect of Self-Management on Improving Sleep Apnea Outcomes||VA Office of Research and Development|No|Completed|April 2006|December 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|240|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00310310||183667|
NCT00310622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHZ01|Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG|An Assessment of the HyperQ Signal for Detecting Ischemia During Dobutamine Stress Echocardiography (DSE)||BSP Biological Signal Processing Ltd.||Recruiting|March 2006|February 2007||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||150|||Both|N/A|N/A|No|||February 2007|February 28, 2007|April 2, 2006||||No||https://clinicaltrials.gov/show/NCT00310622||183643|
NCT00310635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14P1E1|Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age|A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age||Novartis||Completed|June 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||241|||Both|32 Months|40 Months|Accepts Healthy Volunteers|||October 2006|October 25, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310635||183642|
NCT00310960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-102|An Observational Study of Infantile, Acquired Non-accommodative, and Acquired Partially-accommodative Esotropia|An Observational Study of Infantile, Acquired Non-accommodative, and Acquired Partially-accommodative Esotropia||Jaeb Center for Health Research|Yes|Completed|June 2004|May 2008|Actual|October 2007|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|293|||Both|N/A|4 Years|No|Non-Probability Sample|Community sample|August 2011|August 31, 2011|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00310960||183617|
NCT00310973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064410|HIV Prevention Within High-Risk Bulgarian and Hungarian Social Networks|HIV Prevention Within High-Risk Social Networks||Medical College of Wisconsin|No|Completed|February 2003|November 2005|Actual|November 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|320|||Both|15 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00310973||183616|
NCT00311220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCVGH-940117/439|Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers|Phase IV Study of the Quantiferon-RD1 Test||Taichung Veterans General Hospital||Recruiting|January 2004|November 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2006|April 3, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311220||183597|
NCT00311207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940601/C05098|Development of Tuberculosis Diagnostic Kit|Development of Tuberculosis Diagnostic Kit||Taichung Veterans General Hospital||Recruiting|December 2005|November 2006||||Phase 3|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|18 Years|N/A|No|||April 2006|April 3, 2006|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00311207||183598|
NCT00311805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00023438/STU00000487|Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)|Injection of Autologous CD34-Positive Stem Cells for Neovascularization and Symptom Relief in Patients With Severe Intermittent Claudication||Losordo, Douglas, M.D.|Yes|Active, not recruiting|April 2006|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|24|||Both|21 Years|N/A|No|||March 2015|March 30, 2015|April 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00311805||183552|
NCT00311779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-202-06|A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis|Phase 2 Study of Efficacy and Safety of Different Strengths of Spinosad Topical Creme Rinse (0%, 0.5% or 1.0%) in Subjects 2 Years of Age or Older With Pediculosis Capitis - A Dose Ranging Study||ParaPRO LLC||Completed|March 2006|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|2 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 11, 2006|April 4, 2006||||||https://clinicaltrials.gov/show/NCT00311779||183554|
NCT00311792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01283756|Transfer of Skills From VR-Trainer to Operation Room|Transfer of Skills From LapSimGyn VR-Simulator to a Laparoscopic Salpingectomy||Rigshospitalet, Denmark|Yes|Completed|August 2006|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|2||Actual|24|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||August 2007|August 29, 2007|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311792||183553|
NCT00260130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63185 (completed)|Food Rheology and Feeding in Lean and Obese Humans|Study 1: Viscosity Study Study 2: Meal Timing Study Study 3:Chronic Fluid and Solid Food Intake in Lean and Overweight Individuals||Purdue University||Completed|February 2005|July 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|34|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260130||187413|
NCT00259506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/195|Implementation and Evaluation of "Mindfulness-Based Cognitive Therapy" in a Health Care Region in Flanders: a Randomized Clinical Trial|Implementation and Evaluation of "Mindfulness-Based Cognitive Therapy" in a Health Care Region in Flanders: a Randomized Clinical Trial||University Hospital, Ghent|No|Completed|March 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|405|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|November 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00259506||187461|
NCT00260065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACO-020|A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes|A Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Advanced-Stage Myelodysplastic Syndromes||Eisai Inc.||Completed|May 2005|December 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|N/A|No|||June 2010|May 13, 2013|November 28, 2005|Yes|Yes||No|April 13, 2009|https://clinicaltrials.gov/show/NCT00260065||187418|Not Specified
NCT00260351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB28|Immunogenicity and Safety of Verorab™ in Indian Population|Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV, Verorab™) Administered for Rabies Post-exposure Treatment. Comparison of Essen-IM, Zagreb-IM, and Thai Red Cross (TRC)-ID Regimens in the Indian Population.||Sanofi|Yes|Completed|December 2004|October 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|405|||Both|2 Years|N/A|No|||January 2014|January 10, 2014|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260351||187396|
NCT00260858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL5047|GI Interlab 2 Study: Measuring the Glycaemic Index (GI) of Foods|Measuring the Glycaemic Index of Foods: Interlaboratory Study #2||Glycaemic Index Testing, Inc.||Completed|November 2005|April 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||280|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2006|June 7, 2006|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260858||187359|
NCT00261144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cell 101|Collagenase in the Treatment of Cellulite|Collagenase in the Treatment of Cellulite||Stony Brook University|No|Not yet recruiting|February 2013|March 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|November 30, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00261144||187337|
NCT00260819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050502|Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia|Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia||Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2006|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2007|October 16, 2008|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00260819||187361|
NCT00260832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACO-016|Trial of Decitabine in Patients With Acute Myeloid Leukemia|Randomized Phase 3 Trial of Decitabine Versus Patient's Choice With Physician's Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia||Eisai Inc.||Completed|November 2005|December 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|485|||Both|65 Years|N/A|No|||September 2011|September 20, 2011|December 1, 2005|Yes|Yes||No|April 13, 2011|https://clinicaltrials.gov/show/NCT00260832||187360|
NCT00309179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7820-A001-204|A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors|A Single Arm Phase II Study of the Efficacy, Safety, and Biomarkers of Activity of E7820 Plus Cetuximab in Advanced Solid Tumors Preceded by a Run-In Study to Determine Safety of the Combination||Eisai Inc.||Active, not recruiting|September 2007|||December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||December 2015|January 27, 2016|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309179||183751|
NCT00309192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001385-14|Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema|Efficacy and Safety of Intravitreal Triamcinolone as Treatment of the Diffuse Diabetic Macular Edema||Instituto Universitario de Oftalmobiología Aplicada||Recruiting|April 2006|April 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||292|||Both|50 Years|75 Years|No|||September 2006|September 13, 2006|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309192||183750|
NCT00308867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK 04|PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK|Photodynamic Therapy With PD P 506 A or Its Placebo Compared With Cryosurgery for the Treatment of Mild to Moderate Actinic Keratosis||photonamic GmbH & Co. KG|No|Completed|March 2006|November 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|349|||Both|18 Years|N/A|No|||April 2008|April 10, 2008|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00308867||183774|
NCT00309205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM005B|A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium|A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.||International Partnership for Microbicides, Inc.||Completed|December 2005|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||36|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309205||183749|
NCT00309465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2005-080|Perioperative Insulin Glargine Dosing Study|A Study of the Relationship Between the Proportional Insulin Glargine Evening Dose and the Perioperative Serum Glucose Values in Patients With Diabetes Undergoing Surgery||William Beaumont Hospitals|No|Completed|October 2005|October 2009|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|402|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|March 30, 2006||No||No|October 1, 2012|https://clinicaltrials.gov/show/NCT00309465||183729|Limitations include use of point-of-care glucometers, which are less precise than central laboratory testing; estimated 75% power in the insulin glargine only group; and varying fasting lengths, usual glycemic control and surgery starting times.
NCT00310037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50403|Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma|A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|June 2006|||December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|151|||Both|18 Years|69 Years|No|||June 2015|June 22, 2015|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00310037||183686|
NCT00310050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466320|Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase I Dose-Escalating Study of Induction Gemcitabine/Pemetrexed Followed by Pemetrexed and Concurrent Upper Abdominal Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer||Comprehensive Cancer Center of Wake Forest University|No|Terminated|October 2005|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|March 29, 2006||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00310050||183685|
NCT00310323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAS 003-03|Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea|Effect of Chronic Intermittent Nocturnal Hypoxia on Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea||Virginia Commonwealth University|No|Completed|January 2003|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|69|||Both|4 Years|16 Years|No|||March 2009|March 17, 2009|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00310323||183666|
NCT00310336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 37/06|Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine|Chronic Hepatitis C: Treatment of (Peg)Interferon Alpha - Ribavirin Non-Responders With Pegylated Interferon alpha2b, Ribavirin, AdoMet and Betaine||University Hospital, Basel, Switzerland||Completed|August 2006|September 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|65 Years|No|||October 2010|October 27, 2010|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00310336||183665|
NCT00310986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE490230|Breathing Meditation With Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder|Breathing Meditation With Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder Children: A Randomized Controlled Trial||Khon Kaen University||Recruiting|April 2006|May 2011|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|22|||Both|7 Years|12 Years|No|||August 2009|May 27, 2010|April 4, 2006||||No||https://clinicaltrials.gov/show/NCT00310986||183615|
NCT00310999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-400|C-Spine Movement - Shikani Optical Scope vs Macintosh Laryngoscope for Patients With Cervical Spine Injury|Comparison of Shikani Optical Scope to Macintosh Laryngoscope for Intubation of Patients With Potential Cervical Spine Injury||Lawson Health Research Institute||Completed|March 2006|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2006|April 12, 2007|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310999||183614|
NCT00311532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10245|Observational Study of Pergolide Mesylate and Cardiac Valvulopathy|Observational Study to Determine the Incidence of New-Onset Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinson's Disease||Eli Lilly and Company||Completed|March 2006|May 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|200|||Both|18 Years|N/A|No|||July 2007|July 16, 2007|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311532||183573|
NCT00311545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462096|S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Advanced or Metastatic Renal Cell Cancer||Southwest Oncology Group|Yes|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|April 5, 2006|Yes|Yes|withdrawal of support for drug supply|No||https://clinicaltrials.gov/show/NCT00311545||183572|
NCT00311818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4040|Insulin Glargine in Type 2 Diabetes Mellitus|44-week, Parallel, Open, Randomized, Multinational, Multi-center Clinical Trial to Compare Efficacy and Safety of the Combination Therapy of an Oral Anti-diabetic Drug Treatment With Either HOE901 Insulin Once Daily or Lispro Insulin Analogue at Mealtime in Type 2 Diabetes Mellitus Patients Poorly Controlled With Oral Anti-diabetic Drug Treatment.||Sanofi||Completed|June 2003|||May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00311818||183551|
NCT00311831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008727|The Implementation of a Gastroenteritis Education Program|The Implementation of a Gastroenteritis Education Program||The Hospital for Sick Children|No|Completed|March 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|105|||Both|16 Years|N/A|No|||December 2013|December 10, 2013|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00311831||183550|
NCT00311844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04209|A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)|A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms||Merck Sharp & Dohme Corp.||Completed|March 2005|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|41|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 4, 2006||||||https://clinicaltrials.gov/show/NCT00311844||183549|
NCT00312117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4353|Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate|A Randomized Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate||Kaiser Permanente|Yes|Completed|January 2006|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||300|||Both|18 Years|N/A||||March 2015|March 10, 2015|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312117||183528|
NCT00260143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK49296 (completed)|Testosterone and Physical Function in HIV+ Men|Testosterone and Physical Function in HIV Associate Weight Loss||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|May 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|100|||Male|18 Years|60 Years|No|||January 2010|January 14, 2010|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260143||187412|
NCT00260156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2381|A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes|A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|November 2005|||December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|59|||Both|30 Years|N/A|No|||January 2013|January 2, 2013|November 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00260156||187411|
NCT00260078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1058|Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children|Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2006|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|8 Years|17 Years|No|||February 2015|February 23, 2015|November 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00260078||187417|
NCT00260091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD038561|Conventional Infertility Treatment vs. Fast Track to IVF|Conventional Infertility Therapy vs. Fast Track to IVF|FASTT|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|August 1999|April 2006|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|503|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||January 2009|November 15, 2013|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260091||187416|
NCT00260624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP MD 43|Escitalopram Treatment of Patients With Agitated Dementia|Escitalopram in the Treatment of Patients With Agitated Dementia||University of Rochester||Completed|February 2003|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|61 Years|N/A|No|||February 2012|February 23, 2012|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260624||187376|
NCT00261157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412323-1|Use of Robotic Telerounding After Operative Procedures|Use of Robotic Telerounding After Operative Procedures: Does It Affect Patient Outcomes?||University of California, Davis||Completed|April 2004|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||72|||Both|18 Years|72 Years|No|||November 2005|November 30, 2005|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00261157||187336|
NCT00261131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9199|Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy|Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial||Shriners Hospitals for Children||Completed|March 2006|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|250|||Both|3 Years|18 Years|No|||February 2009|February 4, 2009|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00261131||187338|
NCT00308880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCVGH-957001A|Tranexamic Acid and Head and Neck Surgery Patients|If Tranexamic Acid Could Reduce the Duration of Drainage Tube Placement ? —A Prospective Randomized Study in Head and Neck Surgery Patients||Taichung Veterans General Hospital||Recruiting|March 2006|March 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|20 Years|80 Years|No|||March 2006|March 29, 2006|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00308880||183773|
NCT00309478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG-5|Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients|A Randomized Phase III Study Comparing Cyclophosphamide + Methotrexate + Fluorouracil Vs. Goserelin + Tamoxifen in Premenopausal, Hormone Receptor-Positive, Lymph Node-Positive or -Negative Patients||Austrian Breast & Colorectal Cancer Study Group||Completed|December 1990|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1099|||Female|19 Years|N/A|No|||June 1999|May 18, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309478||183728|
NCT00309244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-102|Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up|A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere /Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up||Mannkind Corporation||Completed|February 2006|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|677|||Both|18 Years|80 Years|No|||October 2014|October 9, 2014|March 27, 2006|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00309244||183746|
NCT00309738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-304|Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin|Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease||Kowa Research Europe|No|Completed|September 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|75 Years|No|||March 2010|March 9, 2010|December 8, 2005||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00309738||183708|
NCT00309751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-305|Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia|Study of Pitavastatin Vs. Atorvastatin (Following Up-Titration) in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia||Kowa Research Europe|No|Completed|December 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|418|||Both|18 Years|75 Years|No|||February 2010|February 17, 2010|December 8, 2005||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00309751||183707|
NCT00310349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 November 2005|PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease|PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease||University of Melbourne||Not yet recruiting|March 2006|January 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|210|||Female|16 Years|39 Years|Accepts Healthy Volunteers|||March 2006|December 12, 2007|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00310349||183664|
NCT00310648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M70P1|Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)|Part 1:Phase I Open-Label, Single-Center to Evaluate the Safety of a Commercially Available Adjuvanted Influenza Vaccine When Administered to Elderly Subjects Part 2: A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Immunogenicity and Safety of a Commercially Available Influenza Vaccine and a Conventional Commercially Available Influenza Vaccine When Administered to Elderly Subjects||Novartis||Completed|January 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||600|||Both|60 Years|N/A||||September 2006|September 13, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310648||183641|
NCT00310661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/2004|Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia|A Dual-centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine the Effects of Various Adjunctive Doses of Sarizotan in the Treatment of Patients With Neuroleptic-induced Tardive Dyskinesia||Centre for Addiction and Mental Health|No|Terminated|December 2004|March 2008||September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||July 2015|July 22, 2015|April 3, 2006||No|Funding|No||https://clinicaltrials.gov/show/NCT00310661||183640|
NCT00311012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A1201|SPP100 Dose Finding Study in Japan|Dose-finding Study of SPP100 in Essential Hypertension||Novartis||Completed|August 2004|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|445|||Both|20 Years|80 Years|No|||June 2006|November 7, 2011|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00311012||183613|
NCT00311233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150063|Recurrent Abdominal Pain in Childhood -Characteristics and Course|Recurrent Abdominal Pain in Childhood, Characteristics and Course||Sykehuset Innlandet HF||Completed|February 2006|April 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|Samples Without DNA|All patients have blood tests for hemoglobin, total leucocyte and differential count,      sedimention rate, C-reactive protein, total IgE and IgE screen for food allergies, and      antiendomysial and antigliadin antibodies (IgG and IgA) and anti-tissue transglutaminase      antibodies for celiac disease. Furthermore, urine analyses for protein, blood and and      leucocytes, three stool specimen for occult blood and one stool specimen for quantification      of calprotectin.|Both|4 Years|15 Years|Accepts Healthy Volunteers||Consecutive new pediatric patients (4-15 years) referred by their general practitioners to        four pediatric out-patient clinics in Innlandet Hospital Health Authorities for evaluation        of recurrent abdominal pain.|May 2008|May 22, 2008|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00311233||183596|
NCT00311558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-7509|Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma|Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b for Solid Tumors, Lymphoma or Myeloma||The Cleveland Clinic|Yes|Active, not recruiting|October 2005|May 2012|Anticipated|May 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2011|March 29, 2011|April 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00311558||183571|
NCT00312143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AEG01|Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients|A Prospective, Open Label, Multicenter Study to Assess the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients||Novartis||Completed|February 2004|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|35|||Both|18 Years|75 Years||||February 2011|February 1, 2011|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00312143||183526|
NCT00312130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2345|A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes|A Single-blind, Single-treatment Study to Evaluate the Effects of Vildagliptin on Response to an Intravenous Glucose Load in Pre-diabetic Subjects With Impaired Fasting Glucose||Novartis||Completed|April 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|No|||May 2012|May 4, 2012|April 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00312130||183527|
NCT00312390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-070503|Amblyopia and Neurovascular Coupling in the Retina of Humans|Amblyopia and Neurovascular Coupling in the Retina of Humans||Medical University of Vienna|Yes|Withdrawn|July 2003|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|December 5, 2014|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312390||183507|
NCT00260169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067949|Determining Depression Treatment Preferences of Low-Income Latinos in Primary Care Settings|Patient-Centered Depression Care in the Public Sector||University of Southern California||Completed|November 2005|January 2009|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|432|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|November 29, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00260169||187410|
NCT00259844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH2/048|Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed|A Phase 2 Study Immunologically Evaluating 5T4-MVA (TroVax) in Patients Undergoing Surgical Resection of Colorectal Liver Metastases||Cancer Research UK||Completed|June 2004|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||November 2005|July 17, 2006|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00259844||187435|
NCT00260104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP058|Risk Factors of Individuals With Coronary Artery Disease|||Nanjing Medical University||Recruiting|November 2005|||||N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|89 Years|Accepts Healthy Volunteers|||May 2008|May 23, 2008|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260104||187415|
NCT00260364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2631|Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer|A Phase I-II Dose Finding and Early Efficacy Study of Combination Therapy With Erlotinib (Tarceva), Gemcitabine, Bevacizumab (Avastin), and Capecitabine in Advanced Pancreatic Cancer|TARGET|Royal Marsden NHS Foundation Trust|Yes|Active, not recruiting|November 2005|December 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2010|January 5, 2010|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260364||187395|
NCT00260871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94LCP005|Genetic Epidemiological Study of Lung Cancer in Taiwan and Clinical Applications|Genetic Epidemiological Study of Lung Cancer in Taiwan and Clinical Applications-focusing on Female Lung Adenocarcinoma (GEFLAC)||National Health Research Institutes, Taiwan|Yes|Active, not recruiting|May 2002|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|The program project intend to identify susceptible genes for lung cancer, especially for        female lung adenocarcinoma.|July 2011|July 27, 2011|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00260871||187358|
NCT00261170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12RT-0148|Bupropion for Hospital-Based Smoking Cessation|Bupropion for Hospital-Based Smoking Cessation||University of California, San Francisco|No|Completed|July 2003|February 2007|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|80 Years|No|||May 2008|May 22, 2008|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261170||187335|
NCT00261443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-189|A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania|Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|September 2005|October 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1270|||Both|18 Years|N/A|No|||April 2011|November 7, 2013|December 1, 2005|Yes|Yes||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00261443||187314|
NCT00261690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13289-C|Virtual Reality Pain Control During Burn Wound Care|Use of Virtual Reality for Adjunctive Treatment of Burn Pain|VRPT/H2O/RT|National Institute of General Medical Sciences (NIGMS)|No|Completed|February 2002|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|184|||Both|6 Years|60 Years|No|||June 2012|April 17, 2013|December 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00261690||187296|
NCT00309218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BToenshoff001|Steroid Withdrawal in Pediatric Renal Transplant Recipients Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)|Multicenter, Open-label, Randomized Study on Steroid-free Immunosuppression, in Comparison With Daily Steroid Therapy, in Children With Stable Renal Transplant Function Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)||Klinik für Kinder- und Jugendmedizin|Yes|Completed|March 1999|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|42|||Both|N/A|18 Years|No|||April 2015|April 22, 2015|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309218||183748|
NCT00309491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG-6|Randomized Study Comparing Tamoxifen Vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-Positive Patients|A Randomized Phase III Study Comparing Tamoxifen Vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-Positive Patients||Austrian Breast & Colorectal Cancer Study Group||Completed|December 1990|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Female|50 Years|80 Years|No|||December 1995|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309491||183727|
NCT00309764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project # 041873|CHF Management Using Telemedicine|Improving CHF Outcomes Through Interactive Voice Recognition (IVR) Data Acquisition and Targeted Nurse Follow-Up||Kaiser Permanente||Completed|November 2001|August 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||106|||Both|30 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309764||183706|
NCT00310362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-295|Use of Telehealth In-home Messaging to Improve GI (Gastrointestinal) Endoscopy Completion Rates|Use of Telehealth In-Home Messaging to Improve GI Endoscopy Completion Rates|GIVER|VA Office of Research and Development|No|Completed|July 2007|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|3610|||Both|N/A|N/A|No|||July 2014|April 6, 2015|March 30, 2006||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT00310362||183663|
NCT00310713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14P5E1|Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine|A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age||Novartis||Completed|April 2006|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|33|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||September 2014|September 18, 2014|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00310713||183636|
NCT00310674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14P3|Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age|A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine||Novartis||Completed|September 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|11 Weeks|15 Weeks|Accepts Healthy Volunteers|||March 2007|March 12, 2007|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310674||183639|
NCT00310687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M14P2E1|Persistence of Immune Response After Vaccination With MCC|A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign||Novartis||Completed|October 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||1244|||Both|11 Years|20 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00310687||183638|
NCT00311246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14093A|Trial of Adalimumab in Progressive Sarcoidosis|A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis||University of Chicago|Yes|Terminated|April 2006|September 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|85 Years|No|||June 2011|June 28, 2011|April 3, 2006|Yes|Yes|Difficulty in recruiting subjects|No||https://clinicaltrials.gov/show/NCT00311246||183595|
NCT00311038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-1101-24|Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT|Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice Computed Tomography (CT) Due to Suspected Coronary Artery Disease||Ono Pharmaceutical Co. Ltd||Completed|April 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|90|||Both|20 Years|74 Years|No|||June 2012|June 12, 2012|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311038||183611|
NCT00311571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDES/00-433|Toulouse Male Long Term Bed Rest 2001-2002|Simulation of a Mission Aboard the International Space Station by a Long Duration Anti-Orthostatic Bed Confinement at – 6° (90 Days) on Healthy Subjects:1/Perfecting of Preventive Methods (Muscular Exercise and Biphosphonates) and Evaluation of the Effects on the Locomotion and Cardiovascular Systems and on the Lipid and Energy Metabolisms. 2/Pharmacokinetic Assessment: Effects of Position on the Absorption Mechanisms: Pharmacokinetics of Paracetamol Used as Model to Study Oral Absorption in Simulated Weightlessness||Centre National d'Etudes Spatiales||Completed|August 2001|June 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||28|||Male|25 Years|45 Years|No|||April 2006|September 1, 2006|April 4, 2006||||No||https://clinicaltrials.gov/show/NCT00311571||183570|
NCT00311857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract-2005-003911-63|Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)|Treatment of Primary Glioblastoma Multiforme With Cetuximab, Radiotherapy and Temozolomide (GERT) – Phase I/II Trial||Heidelberg University||Recruiting|February 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Both|18 Years|70 Years|No|||September 2006|September 7, 2006|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311857||183548|
NCT00310141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-234|Computer-Assisted Counseling in Helping African American Smokers Stop Smoking|Treatment of Nicotine Dependence Among African Americans||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2002|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|500|||Both|21 Years|65 Years|No|||June 2015|June 25, 2015|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00310141||183679|
NCT00312403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-300505|Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?|Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?||Medical University of Vienna|Yes|Completed|November 2005|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 14, 2010|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312403||183506|
NCT00260676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|396|Protective Ventilatory Strategy in Potential Organ Donors|a Randomised Control Trial on Protective Ventilatory Strategy in Potential Organ Donors||University of Turin, Italy||Recruiting|September 2004|January 2010|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||June 2009|June 16, 2009|November 29, 2005||No||No||https://clinicaltrials.gov/show/NCT00260676||187372|
NCT00260377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-3107-JL-CTIL|Aspirin Resistance Following Coronary Bypass Surgery|||Sheba Medical Center|No|Terminated|January 2005|December 2006||June 2006||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|30 Years|90 Years|No|||September 2008|September 8, 2008|November 29, 2005|||The researcher had left the hospital and the project was stopped|No||https://clinicaltrials.gov/show/NCT00260377||187394|
NCT00260390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3222-GO-CTIL|Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial|The Efficacy of Testosterone Replacement in Treating Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial||Sheba Medical Center||Recruiting|September 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|40 Years|80 Years||||October 2006|October 3, 2006|November 30, 2005||||No||https://clinicaltrials.gov/show/NCT00260390||187393|
NCT00260637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACUCP|Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis|A Double Blind, Sham Controlled Trial Evaluating the Efficacy of Acupuncture in Relieving Symptoms of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome||University of Science Malaysia||Completed|February 2004|August 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||86|||Male|20 Years|65 Years|No|||November 2005|October 25, 2006|November 29, 2005||||No||https://clinicaltrials.gov/show/NCT00260637||187375|
NCT00260884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1293|Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer|Phase III Study of the Effect of Radical Gastric Surgery Versus Conventional Surgery on Recurrence and Survival in Patients With Advanced Stage Gastric Cancer.||National Health Research Institutes, Taiwan||Completed|October 1993|August 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2005|December 1, 2005|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00260884||187357|
NCT00261183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-05-SS-03186-CTIL|The Contribution of Melatonin Vs. Placebo in Benzodiazepine Withdrawal in Methadone Maintenance Treatment Patients|||Tel-Aviv Sourasky Medical Center||Recruiting|December 2004|December 2006||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||November 2005|December 1, 2005|December 1, 2005||||No||https://clinicaltrials.gov/show/NCT00261183||187334|
NCT00261196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shoulder 202|Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)|||Stony Brook University||Withdrawn|January 2006|January 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|80 Years|No|||August 2011|August 11, 2011|November 30, 2005|||IND moved to sponsor.|||https://clinicaltrials.gov/show/NCT00261196||187333|
NCT00261456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/MRE07/25|The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer|The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer: Targeted Screening in BRCA1/2 Mutation Carriers & Controls||Institute of Cancer Research, United Kingdom|Yes|Recruiting|October 2005|December 2021|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1700|Samples With DNA|Whole blood, Serum, Plasma, Urine, Prostate tissue.|Male|40 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|Any patient that meets the eligibility criteria and maybe attending a genetics clinic at a        number of international centres that have gone through ethical approval.|February 2016|February 22, 2016|December 1, 2005||No||No||https://clinicaltrials.gov/show/NCT00261456||187313|
NCT00308919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC/WST03 658 N/WST 2.08|Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy|Phase II Study of Photodynamic Therapy With WST-09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure : Effect of the Light Dose and the Number of Fibres||STEBA France||Completed|April 2004|November 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|N/A|No|||May 2010|June 18, 2010|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308919||183770|
NCT00309231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-873|Clinical Islet Transplantation Using the Edmonton Protocol|Clinical Islet Transplantation Using the Edmonton Protocol||Lawson Health Research Institute|No|Withdrawn||January 2008||||Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with type 1 diabetes of at least 5 years duration, with either severe        hypoglycemia with unawareness, or severe glycemic lability|June 2010|June 8, 2010|March 29, 2006||No|no funding|No||https://clinicaltrials.gov/show/NCT00309231||183747|
NCT00309777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-302|Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin|Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia||Kowa Research Europe|No|Completed|September 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|857|||Both|18 Years|75 Years|No|||January 2010|January 7, 2010|November 11, 2005||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00309777||183705|
NCT00309790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-p-0003994|Study of Sildenafil in Advanced Heart Failure.|Phase 3 Study of the Effects of Chronic Sildenafil Citrate Therapy on Exercise Tolerance and Hemodynamics in Patients With Advanced Heart Failure.||Massachusetts General Hospital||Completed|May 2003|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|March 30, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00309790||183704|
NCT00299260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-107|CMV Glycoprotein B Vaccine in Allograft Recipients|A Phase II Immunogenicity Trial of Cytomegalovirus Glycoprotein B Vaccine in Allograft Candidate Recipients||University College, London|Yes|Active, not recruiting|August 2006|September 2011|Anticipated|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||January 2008|April 16, 2010|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299260||184492|
NCT00299559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK222122005|Kinetics of Etheric Oils, Smart Textiles vs. Ointment|An Open Clinical Cross-Over Trial to Compare the Kinetics of Etheric Oils Applied Onto the Skin or Via Smart Textiles||Technische Universität Dresden|No|Completed|March 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2007|February 12, 2009|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299559||184469|
NCT00299884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-816-04|Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-Lowering Strategy|The Comparison of the Efficacy of Ezetimibe and Fenofibrate Versus Atorvastatin Alone in the Lowering of LDL Cholesterol||Queen's University|No|Completed|January 2005|July 2006|Actual|July 2006|Actual|Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|45|Samples Without DNA|Apo-lipo B|Both|18 Years|85 Years|No|Probability Sample|Subjects aged 18-85 with elevated LDL-C levels 3.0 mmol/L and greater.|May 2008|May 13, 2008|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299884||184444|
NCT00299936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02314|Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects|Comparison of PEG Interferon Alfa-2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects||Weill Medical College of Cornell University||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||5000|||Both|18 Years|70 Years|No|||March 2006|March 3, 2006|March 3, 2006||||||https://clinicaltrials.gov/show/NCT00299936||184440|
NCT00300196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI-ASP-0503|ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke|ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke||Neurobiological Technologies|Yes|Terminated|March 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|311|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|March 6, 2006|Yes|Yes|Futility|No||https://clinicaltrials.gov/show/NCT00300196||184421|
NCT00300183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2H97 HA 00247-03-02|Evaluation of an HIV Outreach Program|Evaluation of an Outreach and Intervention Program to Reach HIV- Positive Persons Living in Bronx, NY Single Room Occupancy Hotels||Montefiore Medical Center||Completed|October 2003|July 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|18 Years|N/A|No|||September 2005|March 31, 2006|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300183||184422|
NCT00300482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-748|Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia||Abbott|No|Completed|March 2006|||December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|1445|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|March 7, 2006|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00300482||184399|
NCT00300495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P000376|Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection|Phase III Study of Preoperative Amiodarone for Prevention of Atrial Fibrillation After Lung Resection||Beth Israel Deaconess Medical Center||Recruiting|February 2006|March 2011|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2008|May 5, 2008|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00300495||184398|
NCT00300833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aggrastat in AMI.CTIL|Treating Acute MI Patients With Aggrastat on Their Way to Hospital|||The Baruch Padeh Medical Center, Poriya||Recruiting|January 2006|||January 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2009|August 10, 2011|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00300833||184372|
NCT00300846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-170|A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients|A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|December 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||200|||Both|18 Years|65 Years|No|||June 2008|November 7, 2013|March 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00300846||184371|
NCT00300859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-0681|Brief Intervention to Increase Safety Belt Use Among ED Patients|Brief Intervention to Increase Safety Belt Use Among ED Patients||Centers for Disease Control and Prevention||Not yet recruiting|February 2006|October 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 9, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300859||184370|
NCT00301158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455588|Promoting Physical Activity In After-School Programs for Urban Adolescents|Involving Adolescents in Physical Activity Promotion||National Cancer Institute (NCI)||Recruiting|September 2004|||August 2008|Anticipated|N/A|Interventional|Primary Purpose: Prevention|||Anticipated|420|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||June 2009|September 16, 2013|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00301158||184348|
NCT00301470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 2005 - 01|Functional MR Urography|Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults||Central Hospital, Nancy, France|No|Completed|March 2006|March 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|550|||Both|1 Month|N/A|No|||October 2006|July 21, 2011|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00301470||184324|
NCT00301769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00100|SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia|A Phase I Study of SJG-136 in Patients With Advanced Leukemia||National Cancer Institute (NCI)||Terminated|December 2005|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|March 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00301769||184304|
NCT00302380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-p-001975|An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD|An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD||Massachusetts General Hospital|Yes|Completed|October 2000|March 2006|Actual|March 2006|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|Samples With DNA|A sample of blood (2 tablespoons) will be drawn from all subjects.|Both|18 Months|55 Years|Accepts Healthy Volunteers|Probability Sample|200 un-medicated subjects with ADHD and 100 subjects without ADHD will be recruited        sequentially. No individual will be excluded based on gender, race, or ethnicity.|June 2011|June 27, 2011|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302380||184258|
NCT00302692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA 0465044Y|Use of Beta Blockers in Elderly Trauma Patients|"Effects of Beta-Blockade on Cardiovascular Morbidity and Mortality in Elderly Trauma Patients: A Prospective Randomized Clinical Trial"||University of Texas Southwestern Medical Center||Recruiting|December 2005|September 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|148|||Both|55 Years|N/A|No|||May 2007|May 9, 2007|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00302692||184234|
NCT00311883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060051|Hydroxychloroquine in Cystic Fibrosis|Phase 1 Study of Hydroxychloroquine in Cystic Fibrosis||Vanderbilt University|Yes|Completed|March 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|16 Years|N/A|No|||January 2008|January 25, 2008|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00311883||183546|
NCT00308490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/31-1-2005|Changes in Iron Markers Following Iron Loading in Hemodialysis Patients|Phase IV Study of Iron Indices' Kinetics in Hemodialysis Patients||Papageorgiou General Hospital||Completed|September 2005|January 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||160|||Both|18 Years|N/A|No|||September 2006|March 12, 2007|March 28, 2006||||No||https://clinicaltrials.gov/show/NCT00308490||183803|
NCT00308503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6220|Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia|Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study|EPOCH|Sanofi||Completed|February 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|608|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|March 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00308503||183802|
NCT00300677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501079|To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days|Assessment Of Voriconazole Penetration Into The Brain By Fluorine-Magnetic Resonance Spectroscopy||Pfizer|No|Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 5, 2009|March 7, 2006|No|Yes||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00300677||184384|
NCT00301912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463168|Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation||University of California, San Francisco||Withdrawn|January 2002|||November 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|16 Years|60 Years|No|||October 2012|October 1, 2012|March 9, 2006|Yes|Yes|Withdrawn because study never opened to accrual|No||https://clinicaltrials.gov/show/NCT00301912||184293|
NCT00311649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0129|Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities|Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2005|September 2006||September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|83|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|August 11, 2011|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311649||183564|
NCT00311662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TON/01/05-CLIN|Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache|Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache||Minster Research Ltd|No|Completed|April 2006|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|124|||Both|18 Years|55 Years|No|||August 2009|August 28, 2009|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00311662||183563|
NCT00300365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803751|Pioglitazone Vs Placebo in Combination With Niacin Extended Release on Low HDL|A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-Diabetic Patients With Metabolic Syndrome||University of Pennsylvania||Recruiting|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||84|||Both|18 Years|75 Years|No|||March 2006|May 19, 2006|March 6, 2006||||No||https://clinicaltrials.gov/show/NCT00300365||184408|
NCT00303472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050159|Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)|An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)||Amgen||Completed|February 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|72|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|March 16, 2006|Yes|Yes||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00303472||184175|
NCT00303485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19334|A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)|A Randomized Double-blind Study to Determine the Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once-monthly Boniva (Ibandronate) Versus Placebo in the Treatment of Post-menopausal Osteoporosis||Hoffmann-La Roche||Completed|February 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Female|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|March 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303485||184174|
NCT00303511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-2006|Pacemaker Therapy in Adults With Congenital Heart Defects|Pacemaker Therapy in Adults With Congenital Heart Defects||Emory University|No|Completed|January 1996|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|||Both|19 Years|N/A|No|Non-Probability Sample|Adults with congenital heart disease requiring epicardial pacemaker leads|July 2014|July 16, 2014|March 16, 2006||No||No|November 8, 2013|https://clinicaltrials.gov/show/NCT00303511||184172|
NCT00303784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455583|Hormone Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer|Prostate Adenocarcinoma: TransCutaneous Hormones [PATCH] A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Analogues in Prostate Cancer||National Cancer Institute (NCI)||Recruiting|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|200|||Male|N/A|N/A|No|||June 2008|August 23, 2013|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303784||184153|
NCT00303797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00124|Sorafenib and Bortezomib in Treating Patients With Advanced Cancer|A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination With the Proteasome Inhibitor PS-341 in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|December 2005|||May 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|March 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303797||184152|
NCT00299273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBR-0583|High Fat - High Protein Diet in the Treatment of Obesity|Exploratory Feasibility Study: High Fat/Protein Diet in the Treatment of Obesity||Rockefeller University|Yes|Terminated|March 2006|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|March 2, 2006||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00299273||184491|
NCT00299572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94040|Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?|Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients?||Far Eastern Memorial Hospital||Not yet recruiting|March 2006|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|80 Years|No|||March 2006|March 5, 2006|March 5, 2006||||No||https://clinicaltrials.gov/show/NCT00299572||184468|
NCT00299585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191059 HMO-CTIL|A Clinical Study of the Use of Brushite as Primary Stabilizer in Immediate Dental Implantation|Phase 2 Clinical Study on the Efficacy of Injectable Brushite Bone Cement in Bone Augmentation and Dental Implant Stabilization||Hadassah Medical Organization||Suspended|December 2007|November 2008|Anticipated|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2007|January 5, 2010|March 5, 2006|Yes|Yes|manufacturer could not finance the study|No||https://clinicaltrials.gov/show/NCT00299585||184467|
NCT00300547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05030-MA|Preoperative Assessment for Synchronous Carcinoma or Polyps With Magnetic Resonance (MR) Colonography|Preoperative Assessment for Synchronous Carcinoma or Polyps With MR Colonography in Patients With Obstructing Cancer. A Prospective Study.||Herlev Hospital||Completed|March 2007|||April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||March 2006|August 17, 2010|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00300547||184394|
NCT00300911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA04/164|Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction|A Study of PPAR-Gamma Agonist-Rosiglitazone for Determining Cardiac Adverse Effects in Type 2 Diabetic Patients||Baskent University||Completed|December 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|45 Years|65 Years|No|||November 2005|March 9, 2006|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00300911||184366|
NCT00300508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033AU/0001|3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer|A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.||AstraZeneca||Completed|January 1996|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||856|||Female|N/A|80 Years|No|||April 2009|April 30, 2009|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300508||184397|
NCT00300521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2000-09|Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma|Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma||Beijing Chao Yang Hospital||Completed|September 2000|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||September 2000|March 8, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300521||184396|
NCT00300872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/hui/2006/002|Effect of Nasal Continuous Positive Airway Pressure (CPAP) Blood Pressure and Vascular Endothelial Growth Factor in Obstructive Sleep Apnea Syndrome|A Randomized, Placebo-controlled Study of the Medium-term Effect of Nasal CPAP on 24 Hour Blood Pressure and Vascular Endothelial Growth Factor in Obstructive Sleep Apnea Syndrome||Chinese University of Hong Kong|Yes|Recruiting|January 2005|December 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|80 Years|No|||June 2011|June 22, 2011|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00300872||184369|
NCT00300885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11961|A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)||Bayer|No|Terminated|February 2006|February 2009|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|926|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|March 8, 2006|Yes|Yes|Based on the results of the interim analysis, it was determined that the study would not meet    its primary efficacy endpoint and the study was terminated early.|No|November 4, 2009|https://clinicaltrials.gov/show/NCT00300885||184368|Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early. The planned biomarker analysis was suspended due to early termination.
NCT00301184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 065|Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA Vaccine and Recombinant Modified Vaccinia Ankara/HIV62 Vaccine in Healthy, HIV-1-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|December 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|March 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00301184||184346|
NCT00301457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5392NL003|Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer|A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.|DATA|AstraZeneca||Active, not recruiting|June 2006|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1900|||Female|45 Years|99 Years|No|||February 2016|February 9, 2016|March 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00301457||184325|
NCT00301782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456203|Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors|Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors||National Cancer Institute (NCI)||Completed|June 2005|June 2010|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|88|||Male|16 Years|N/A|No|||May 2007|August 23, 2013|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301782||184303|
NCT00302393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-p-001811|Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults|A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy of Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults||Massachusetts General Hospital||Completed|June 2006|February 2008|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302393||184257|
NCT00312715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060133|Thyroid and Fat Tissue Metabolism|Thyroid Hormone-Induced Lipolysis: An In Vivo Microdialysis Study||National Institutes of Health Clinical Center (CC)||Completed|April 2006|July 2014||||N/A|Observational|N/A|||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|December 11, 2015|April 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00312715||183482|
NCT00312728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3752g|A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)|A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer||Genentech, Inc.||Completed|March 2006|||June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|April 7, 2006|Yes|Yes||No|March 18, 2011|https://clinicaltrials.gov/show/NCT00312728||183481|
NCT00301067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05M1|Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma|A Phase I/II Study of High-Dose Calcitriol in Combination With Temozolomide for Patients With Metastatic Melanoma||Northwestern University|Yes|Active, not recruiting|May 2005|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|March 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00301067||184354|
NCT00302497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621ACA07|EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function|12 Month, Prospective, Randomised, Open-Label Comparative Study to Evaluate the Protection of Kidney Function by Basiliximab in a CNI-Free Regimen in Newly Kidney Transplanted Patients (Three Months Post-Transplant) Who Are Recipient of One Kidney From Expanded Donor Criteria (UNOS Criteria)||McGill University Health Center||Not yet recruiting|April 2007|April 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|40 Years|75 Years|No|||February 2006|April 11, 2007|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00302497||184249|
NCT00312247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC-DMD-79115|Biomechanical Analysis of Gait in Individuals With Duchenne Muscular Dystrophy|Biomechanical Analysis of Gait in Individuals With Duchenne Muscular Dystrophy||Shriners Hospitals for Children|No|Completed|April 2006|March 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|85|||Male|4 Years|21 Years|No|Non-Probability Sample|Boys with DMD who are ambulatory starting at the age of 4 until ambulation ceases|May 2015|May 18, 2015|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00312247||183518|
NCT00312221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3019|Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain|Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain||Purdue Pharma LP|No|Terminated|April 2004|August 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|418|||Both|40 Years|N/A|No|||September 2012|September 5, 2012|April 6, 2006|Yes|Yes|terminated early for administrative reasons unrelated to safety or efficacy|No|July 15, 2010|https://clinicaltrials.gov/show/NCT00312221||183520|This study was terminated early for administrative reasons not related to safety or efficacy. Low enrollment at termination led to reduced power.
NCT00303524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8664C00004|Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients|An Open-label, Randomized, Parallel Group, Multicentre Study to Compare Oestradiol Suppression Between ZOLADEX 10.8 mg Depot Given 3 Monthly and ZOLADEX 3.6 mg Depot Given Monthly in Pre-menopausal Patients With ER Positive Early Breast Cancer||AstraZeneca||Completed|February 2006|February 2009|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Female|20 Years|N/A|No|||December 2009|December 20, 2009|March 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303524||184171|
NCT00303810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455572|Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma|Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma||Universitätsklinikum Hamburg-Eppendorf||Completed|January 2001|||December 2013|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|567|||Both|N/A|21 Years|No|||July 2009|January 27, 2014|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303810||184151|
NCT00299286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2737|Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer|A Double Blind Short-Term Presurgical Study Assessing the Molecular Antiproliferative Predictors of Lapatinib's Effects in Breast Cancer|MAPLE|Institute of Cancer Research, United Kingdom|Yes|Completed|June 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Female|18 Years|80 Years|No|||August 2012|August 3, 2012|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299286||184490|
NCT00299299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 2736|Modelling Internal Hepatic Movement With an External Abdominal Marker|Modelling Internal Hepatic Movement With an External Abdominal Marker Block for Use With a Real Time Position Monitoring System for Respiratory Gating||Royal Marsden NHS Foundation Trust||Recruiting|June 2006|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|10 RMH patients aged over 18 years with single or multiple hepatic metastases secondary to        colorectal cancer. Metastases at other sites will not be an exclusion criterion. WHO        performance status 0, 1 or 2.|January 2010|January 11, 2010|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299299||184489|
NCT00299598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191060HMO-CTIL|Clinical Study of Antibacterial Nanoparticles Incorporated in Composite Restorations|phase2 Safety and Efficacy of Antibacterial Nano Particles Incorporated in Dental Composite.||Hadassah Medical Organization||Completed|September 2006|December 2009|Actual|December 2009|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|personal of Hadassah MO|October 2009|January 5, 2010|March 5, 2006||||No||https://clinicaltrials.gov/show/NCT00299598||184466|
NCT00299923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 18545 (TRELA)|Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy|Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy.||Universitätsklinikum Hamburg-Eppendorf||Active, not recruiting|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2007|March 8, 2007|March 6, 2006||||No||https://clinicaltrials.gov/show/NCT00299923||184441|
NCT00300924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck 075-00|A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine|A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Co-Administered With Acetaminophen for the Treatment of Acute Migraine.||Diamond Headache Clinic|Yes|Completed|March 2006|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||May 2008|May 27, 2008|March 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00300924||184365|
NCT00300937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFN-03-053|Coenzyme Q10 Supplementation and Development of Preeclampsia|Coenzyme Q10 Supplementation in Pregnant Women as Strategy to Reduce Maternal Morbidity Due to Preeclampsia||Teran, Enrique, MD, PhD|No|Completed|July 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|235|||Female|14 Years|25 Years|No|||November 2007|November 21, 2007|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300937||184364|
NCT00300898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8006|Radiofrequency Nucleoplasty Vs Percutaneous Nucleotomy (Dekompressor) Vs Decompression Catheter for the Treatment of Painful Contained Lumbar Disc Herniation|Radiofrequency Nucleoplasty Vs Percutaneous Nucleotomy (Dekompressor) Vs Decompression Catheter for the Treatment of Painful Contained Lumbar Disc Herniation: A Prospective Randomized Controlled Study||The Cleveland Clinic||Not yet recruiting|July 2006|July 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|18 Years|54 Years|No|||September 2005|March 8, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300898||184367|
NCT00301197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD036904|Childhood Obesity Treatment: A Maintenance Approach|Childhood Obesity Treatment: A Maintenance Approach||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|August 1999|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||216|||Both|7 Years|12 Years|No|||March 2006|March 8, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00301197||184345|
NCT00301483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM-0125|A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects|A Single-Center, Study to Evaluate the Safety and Tolerability of Hemoglobin-Based Oxygen Carrier-201 (HBOC 201) in Trauma Subjects. (Phase II - Safety and Tolerability)||Biopure Corporation|Yes|Recruiting|July 2004|December 2008|Anticipated|September 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|53|||Both|18 Years|65 Years|No|||February 2008|March 5, 2008|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00301483||184323|
NCT00301496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-010302|Randomized Controlled 8-Week Crossover Evaluation of Compression Bandage Systems for Venous Leg Ulcers|Randomized Controlled Eight Week Cross-Over Clinical Evaluation of the 3M Coban 2-Layer Compression System to Evaluate the Product Performance in Patients With Venous Leg Ulcers||3M||Completed|March 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|21 Years|N/A|No|||October 2007|October 10, 2007|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00301496||184322|
NCT00302120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC Utrecht|The MONET - Study: MR Mammography of Nonpalpable Breast Tumors|MR Mammography: Randomized Controlled Trial to Study Efficiency of MR Mammography in Reducing the Number of Invasive Interventions in Nonpalpable Suspicious Breast Lesions. The MONET - Study|MONET|UMC Utrecht||Recruiting|February 2006|March 2010|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|440|||Female|18 Years|75 Years|No|||June 2008|June 9, 2008|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302120||184278|
NCT00302406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000038|Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate|Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate||Massachusetts General Hospital||Completed|July 2003|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|55 Years|No|||July 2011|July 11, 2011|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00302406||184256|
NCT00300690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C124|Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp)|Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex).||University Hospital, Gentofte, Copenhagen||Completed|October 1993|January 1999||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||March 2006|March 8, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300690||184383|
NCT00300703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19975760-01H|OPALS Cardiac Arrest Database (OCAD)|Ontario Prehospital Advanced Life Support (OPALS) Study Cardiac Arrest Database||Ottawa Hospital Research Institute|No|Completed|January 2006|September 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1538|||Both|16 Years|N/A|No|Probability Sample|Inclusion Criteria:          -  Ages 16 years and above        Exclusion Criteria:        under 16 yrs|October 2010|October 13, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00300703||184382|
NCT00301613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0605|Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN|MMF Versus Intravenous CTX Pulses in the Treatment of Adult Severe Henoch-Schonlein Purpura Nephritis||Nanjing University School of Medicine|Yes|Completed|January 2003|January 2006|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|16 Years|50 Years|Accepts Healthy Volunteers|||July 2008|May 25, 2010|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00301613||184313|
NCT00311636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM-6|Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery|Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression With Triptorelin Vs. Control in Young Breast Cancer Patients. A Randomized Phase III Multicenter Study [PROMISE]||National Cancer Institute (NCI)||Completed|September 2003|April 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|280|||Female|18 Years|45 Years|No|||April 2008|June 25, 2013|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311636||183565|
NCT00308334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2498|Effect of Domperidone on the Nutrient Composition of Preterm Mother's Breast Milk|A Double Blind Placebo Controlled Trial Examining the Effect of Domperidone on the Composition of Breast Milk||IWK Health Centre||Completed|October 2003|January 2008|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Female|N/A|N/A|No|||June 2009|June 10, 2009|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00308334||183815|
NCT00311935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hernia repair study|Laparoscopic vs Open Hernia Mesh Repair for Inguinal Hernia|Randomized Controlled Trial of Laparoscopic vs. Open Mesh Inguinal Hernia Repair in Men Under the Age of 60||Waitemata District Health Board|No|Recruiting|April 2006|May 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|350|||Male|15 Years|60 Years|No|||February 2009|February 2, 2009|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311935||183542|
NCT00303225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060114|SIGA-246 to Treat Smallpox|A Double-Blind, Randomized, Placebo-Controlled, Ascending Single-Dose, Phase I Trial of the Anti-Orthopoxvirus Compound SIGA-246 in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2006|August 2006||||Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2006|November 16, 2011|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303225||184194|
NCT00303238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lakeside 3a|Study to Evaluate the Effect of Botanical Dietary Supplements on Inflammation in Healthy People|Double-Blind Trial to Evaluate the Effect of Botanical Dietary Supplements on C-Reactive Protein, Ex-Vivo IL-1 Production, and In-Vivo IL-1 Gene Expression in Healthy Human Subjects||Access Business Group||Completed|October 2004|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 14, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303238||184193|
NCT00303537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AkerU3|Metformin in Non-Alcoholic Fatty Liver Disease|Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)||University Hospital, Aker|No|Active, not recruiting|November 2004|June 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|70 Years|No|||June 2007|June 29, 2007|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00303537||184170|
NCT00299611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008596|Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder|A Double-Blind Augmentation Study of LEvetiracetam in Obsessive Compulsive Disorder||Duke University|Yes|Terminated|November 2005|April 2008|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||June 2010|April 9, 2013|March 6, 2006|No|Yes|Sponsor decided to terminate the study due to budget consideration|No||https://clinicaltrials.gov/show/NCT00299611||184465|
NCT00299351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2742|A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.|||Royal Marsden NHS Foundation Trust||Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|N/A|N/A|No|||November 2005|March 3, 2006|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299351||184485|
NCT00299949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0012|Thrombin Generation and Thromboelastography in Non-overt DIC|Use of Whole Blood and Cell-rich Coagulation Assays for the Detection of Non-Overt DIC in Sepsis||The University of Texas Health Science Center, Houston|No|Terminated|October 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|Samples Without DNA|Samples will be discarded after the study is completed.|Both|N/A|N/A|No|Non-Probability Sample|Patients arriving in Emergency Department with sepsis (systemic inflammatory response        syndrome).|February 2013|February 6, 2013|March 3, 2006||No|Insufficient subject enrollment|No||https://clinicaltrials.gov/show/NCT00299949||184439|
NCT00300209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 98-0477|Manhattan HIV/Hepatology Brain Bank|Manhattan HIV/Hepatology Brain Bank||Icahn School of Medicine at Mount Sinai||Completed|September 1998|June 2002|Actual|June 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|187|Samples Without DNA|plasma and serum blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with HIV infection with advanced disease who display signs of distal sensory        polyneuropathy, and who consent to postmortem organ donation.|March 2016|March 16, 2016|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300209||184420|
NCT00300534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-2875|Multi-site Study of Rapid Diagnostic Syphilis Assays|Multi-site Study of Rapid Diagnostic Syphilis Assays of Persons Attending STD Clinics in High Syphilis Morbidity Areas||Centers for Disease Control and Prevention||Completed|August 2002|July 2009|Actual|December 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 6, 2012|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00300534||184395|
NCT00300976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-DOIT3|The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases|A Randomized Controlled Study of the Intensive Therapy and the Conventional Therapy for the Suppression of the Vascular Complications in the Type 2 Diabetic Patients|J-DOIT3|Japan Foundation for the Promotion of International Medical Research Cooperation|Yes|Active, not recruiting|May 2006|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2542|||Both|45 Years|69 Years|No|||October 2015|October 16, 2015|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00300976||184361|
NCT00301262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481238|Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied|A Multi-Center, Parallel Group, Flexible Dose Trial With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Assess The Impact Of Viagra On The Sexual Satisfaction Of Men With Mild Erectile Dysfunction||Pfizer||Completed|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|183|||Male|18 Years|N/A|No|||December 2008|December 8, 2008|March 7, 2006||||No|November 12, 2008|https://clinicaltrials.gov/show/NCT00301262||184340|
NCT00301210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18125-2|Assessment of Tramadol as a Treatment for Opioid Addiction|Assessment of the Level of Physical Dependence and Blockade Efficacy Produced by Tramadol||Johns Hopkins University|No|Completed|January 2006|November 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|55 Years|No|||April 2015|April 16, 2015|March 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00301210||184344|
NCT00301509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630/DS|Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis|Outcome of Decompensated Hepatitis C Virus-Related Cirrhotic Patients Treated With Peginterferon Alfa-2b and Ribavirin: Results of a Controlled Study||Casa Sollievo della Sofferenza IRCCS||Completed|January 2002|December 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2005|March 10, 2006|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00301509||184321|
NCT00301795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03080|Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma|A Phase II Trial of Rituximab + Oblimersen Sodium (GenasenseTM, G3139, NSC #683428, IND #58842) in Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)||National Cancer Institute (NCI)||Terminated|March 2006|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|March 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00301795||184302|
NCT00302133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-AA015385-01 -Salloum|Optimizing Pharmacotherapy for Bipolar Alcoholics|Optimizing Pharmacotherapy for Bipolar Alcoholics||University of Miami|No|Completed|May 2006|July 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|March 9, 2006||No||No|October 20, 2014|https://clinicaltrials.gov/show/NCT00302133||184277|High early drop-out rate leading to small number of subjects analyzed.
NCT00302419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5737|Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction|Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction||Istanbul University||Completed|October 2004|February 2008|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|20 Years|75 Years|No|||July 2008|July 30, 2008|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302419||184255|
NCT00302432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH16/2005.CTIL|The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study|The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study||Lev-Hasharon Mental Healtlh Center||Completed|March 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|65 Years|No|||July 2010|July 21, 2010|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00302432||184254|
NCT00311090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5945|Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs|International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds During a 6-month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity|EQUINOX|Sanofi|Yes|Completed|April 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|757|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|April 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00311090||183607|
NCT00311298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMR-UC-2006-01|Nutrition, Diabetes and Pulmonary TB/HIV|The Role of Nutritional Support and Diabetes During Treatment of Pulmonary TB: Two Randomized Nutritional Supplementation Trials in Tanzania||University of Copenhagen||Completed|April 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1250|||Both|15 Years|N/A|No|||August 2009|August 3, 2009|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00311298||183591|
NCT00310817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P7|Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.|A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.||Novartis||Completed|March 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|623|||Both|12 Months|59 Months|Accepts Healthy Volunteers|||October 2015|October 6, 2015|April 3, 2006|Yes|Yes|||August 29, 2013|https://clinicaltrials.gov/show/NCT00310817||183628|
NCT00311311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-319|Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients|A Prospective, Randomized, Open-Label, Pilot Study To Compare The Effect On Carotid Atherosclerosis Of A Tacrolimus-Based Regimen With Conversion From A Tacrolimus- To A Sirolimus-Based Regimen At 3-4 Months Post-Transplant In De Novo Renal Transplant Recipients||Pfizer|No|Terminated|April 2006|January 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|35 Years|N/A|No|||July 2013|July 19, 2013|April 3, 2006|Yes|Yes|See termination reason in detailed description.|No|December 12, 2011|https://clinicaltrials.gov/show/NCT00311311||183590|
NCT00311324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0960|A Church Based Intervention to Improve Diabetes Care|A Church Based Intervention to Improve Diabetes Care||University of North Carolina, Chapel Hill|No|Completed|February 2001|August 2003|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|201|||Both|20 Years|N/A|No|||December 2015|December 3, 2015|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00311324||183589|
NCT00312494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281143|3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects|A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex||Pfizer|No|Completed|April 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|680|||Both|18 Years|65 Years|No|||February 2010|February 2, 2010|April 6, 2006|Yes|Yes||No|December 17, 2009|https://clinicaltrials.gov/show/NCT00312494||183499|
NCT00308568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0038|RCT of Mailed Brochure to Boost Adherence to Screening Colonoscopy|Randomized Controlled Trial of a Mailed Brochure to Increase Adherence to Referrals for Screening Colonoscopy||University of Colorado, Denver||Completed|February 2006|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||628|||Both|50 Years|N/A||||April 2014|April 28, 2014|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00308568||183797|
NCT00303251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2105|Safety of TKI258 in Advanced/Metastatic Melanoma Subjects|A Phase I/II Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TKI258 (CHIR-258) in Patients With Locally Advanced or Metastatic Melanoma||Novartis||Completed|April 2006|||September 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||February 2013|February 9, 2013|March 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303251||184192|
NCT00303823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00893|Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia|A Phase II Trial of Polyphenon E for Cervical Cancer Prevention||National Cancer Institute (NCI)|No|Completed|September 2005|February 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|98|||Female|18 Years|N/A|No|||April 2013|April 14, 2015|March 15, 2006|Yes|Yes||No|July 13, 2012|https://clinicaltrials.gov/show/NCT00303823||184150|
NCT00299312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5201|Genetic and Physical Characteristics of Rett Syndrome|Rett Syndrome Natural History: Genetic and Physical Characteristics of Rett Syndrome||University of Alabama at Birmingham|Yes|Completed|March 2006|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Individuals fulfilling consensus clinical criteria for Classic or Variant Rett Syndrome,        individuals with MECP2 mutations who do not meet the clinical criteria, or individuals who        have a duplication of Xq28 including the MECP2 locus or individuals who have mutations in        CDKL5 or FOXG1.|November 2015|November 6, 2015|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299312||184488|
NCT00299624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAPH|Effect of Aging on Haemostasis Parameters|Identifying Morphological and Biological Biomarkers of the Venous Thromboembolic Risk Risk Related to Aging||Hopital Lariboisière|Yes|Completed|October 2005|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Stable patients without overt acute clinical event, not receiving antiplatelet or        anticoagulant treatment|September 2010|September 13, 2010|March 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00299624||184464|
NCT00299637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCA chorioamnionitis HMO-CTIL|Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis|Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis During Labor Comparing to Fetuses to Healthy Mothers.||Hadassah Medical Organization||Recruiting|October 2006|December 2007|Anticipated|||Phase 0|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Anticipated|34|||Female|20 Years|45 Years|No|||March 2006|November 29, 2006|March 5, 2006||||No||https://clinicaltrials.gov/show/NCT00299637||184463|
NCT00299962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803776|Gene Therapy for Pleural Malignancies|A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-beta (BG00001, Ad.hIFN-β for Pleural Malignancies||University of Pennsylvania|No|Active, not recruiting|March 2006|April 2023|Anticipated|April 2023|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|March 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299962||184438|
NCT00300222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C117|Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia||NeurogesX||Completed|March 2006|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|90 Years|No|||March 2008|March 4, 2008|March 6, 2006||||No||https://clinicaltrials.gov/show/NCT00300222||184419|
NCT00300560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajCEU49-004|Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli|Efficacy and Safety of Colistin for Therapy of Infections Caused by Extended Spectrum Beta-Lactamase(ESBL) Producing Klebsiella Pneumoniae or Escherichia Coli||Mahidol University||Recruiting|February 2006|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||152|||Both|18 Years|80 Years|No|||March 2006|May 19, 2006|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300560||184393|
NCT00300989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D93-701 - 002|Inion OTPS Biodegradable Fixation System for the Ankle|A Double-Blind,Randomised,Prospective Clinical Investigation to Compare Post-Operative Fracture Healing Using the Inion OTPS Biodegradable Fixation System Versus Conventional Metal Screws and Plates in the Treatment of Ankle Fractures.||Inion Oy||Completed|December 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|43|||Both|18 Years|60 Years|No|||October 2007|October 4, 2007|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00300989||184360|
NCT00301002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST 92|Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis|A Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92)||The Guenther Dermatology Research Centre||Completed|June 2005|October 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||November 2006|November 21, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00301002||184359|
NCT00301223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081081|A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain|An 8-Week Multi-Center, Randomized, Double Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150mg-600mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Symptoms Of Neuropathic Pain||Pfizer||Completed|February 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|309|||Both|18 Years|75 Years|No|||May 2011|May 4, 2011|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00301223||184343|
NCT00301236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124E2305|Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder|A 5-Week Treatment, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules Administered Once Daily in Pediatric Children With Attention-Deficit/Hyperactivity Disorder||Novartis||Completed|February 2006|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||252|||Both|6 Years|12 Years||||December 2007|December 17, 2007|March 8, 2006||||||https://clinicaltrials.gov/show/NCT00301236||184342|
NCT00301249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK57292 (completed)|Linkage Consortium for End-Stage Renal Disease|The Family Investigation of Nephropathy and Diabetes (FIND) Study||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|October 1999|November 2005||||Phase 4|Observational|N/A||||7000|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301249||184341|
NCT00301522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAXUS V De novo|Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions|TAXUS V: De Novo Lesion: A Randomized, Double-blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, in the Treatment of De Novo Coronary Lesions||Boston Scientific Corporation|No|Completed|February 2003|April 2009|Actual|December 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1108|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|March 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00301522||184320|
NCT00301535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOEU003|A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery|Enhancement of Tissue Preservation During Cardiopulmonary Bypass With HBOC-201 (Registry Study)||Biopure Corporation|Yes|Recruiting|February 2006|September 2008|Anticipated|July 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||May 2008|May 15, 2008|March 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00301535||184319|
NCT00301808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000461591|Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer|Phase II Study of Concurrent Cisplatin/Pemetrexed and RT Followed by Docetaxel in Stage III NSCLC (Non Small Cell Lung Cancer)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|November 2005|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|March 9, 2006|Yes|Yes||No|April 12, 2014|https://clinicaltrials.gov/show/NCT00301808||184301|Study being a single institution, single arm study.
NCT00302146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060055|Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations|Functional Imaging in Subjects With Glucocerebrosidase Mutations||National Institutes of Health Clinical Center (CC)||Completed|March 2006|||||N/A|Observational|N/A|||Actual|64|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|March 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00302146||184276|
NCT00310206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0015|H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults|A Randomized, Open-Label, Phase I Clinical Trial Comparing the Safety, Reactogenicity, and Immunogenicity of Immunization With Inactivated Influenza A/H5N1 Vaccine Administered by the Intradermal or the Intramuscular Route Among Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2005|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2009|May 30, 2013|March 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310206||183675|
NCT00310830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-368|Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)|Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease||Actelion||Terminated|March 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|12 Years|N/A|No|||February 2010|February 11, 2010|April 3, 2006|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00310830||183627|
NCT00310479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-6-0062 / 22281|Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer|Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer||AHS Cancer Control Alberta|No|Completed|June 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Male|40 Years|N/A|No|||March 2012|February 24, 2016|April 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00310479||183654|
NCT00310804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P9|Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)|A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Or of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult Subjects Aged >=18 to <=60||Novartis|No|Completed|September 2005|April 2006|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|1200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|April 3, 2006|No|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00310804||183629|Because of potential issues related to Good Clinical Practice (GCP), data from one of the sites were not used in the analyses.
NCT00311103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI/041582|Disability of Musculoskeletal Origin in Community-dwelling Elderly|Disability of Musculoskeletal Origin in Community-dwelling Elderly: Efficacy of a Specific Clinical Intervention.|DIME|Spanish Foundation of Rheumatology|Yes|Completed|October 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|214|||Both|65 Years|N/A|No|||September 2014|September 12, 2014|April 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00311103||183606|
NCT00311337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSMM VIII|VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)|Evaluation of Safety and Efficacy of VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following High-Dose Melphalan Treatment and Autologous PBSCT (Minimal Residual Disease, Partial Remission or Stable Disease)||University of Wuerzburg||Recruiting|October 2005|October 2010||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||61|||Both|18 Years|N/A|No|||March 2006|April 4, 2006|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311337||183588|
NCT00311948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1 CA098685-02|Telephone and Web-based Teen Tobacco Cessation in HMOs|Telephone and Web-based Teen Tobacco Cessation in HMOs|QWIThelper|Kaiser Permanente|Yes|Completed|March 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|600|||Both|15 Years|18 Years|No|||September 2006|September 27, 2012|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00311948||183541|
NCT00311961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-001|Intravenous Versus Oral Administration of Prednisolone in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease||Isala||Completed|June 2001|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||256|||Both|40 Years|N/A||||August 2009|August 25, 2009|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311961||183540|
NCT00312507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007730|Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration|Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration||The Hospital for Sick Children||Recruiting|April 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|N/A|24 Hours|No|||October 2006|October 16, 2006|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312507||183498|
NCT00312520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020020166|Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy|The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial||The Hospital for Sick Children||Completed|July 2002|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|1 Month|4 Months|No|||August 2013|August 1, 2013|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312520||183497|
NCT00308347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-147|A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy||Merck Sharp & Dohme Corp.||Completed|May 1996|April 2001|Actual|February 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1513|||Both|31 Years|70 Years|No|||February 2015|February 18, 2015|March 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308347||183814|
NCT00308581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87042|Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab|Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab||UCB Pharma|No|Completed|April 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|539|||Both|18 Years|N/A|No|||April 2011|August 30, 2011|March 28, 2006|Yes|Yes||No|July 7, 2009|https://clinicaltrials.gov/show/NCT00308581||183796|
NCT00303836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02684|Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma|A Phase II Study Using a Peptide Vaccine With or Without Aldesleukin Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma||National Cancer Institute (NCI)||Terminated|November 2005|||January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|March 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303836||184149|
NCT00299325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_C_0172|VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt|A Randomized, Double Blind, Two-arm Placebo Controlled, 12-Month Study of the Effects of Rimonabant 20mg Once Daily on the Amount and the Activity of Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome.|VICTORIA|Sanofi||Completed|March 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|254|||Both|35 Years|70 Years|No|||December 2010|December 9, 2010|March 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299325||184487|
NCT00299338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP01A-SII-101|A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients|A Pharmacokinetic and Safety Study of Procaine HCl in HIV-1 Infected Patients||Samaritan Pharmaceuticals, Inc||Completed|September 1997|September 2001||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||March 2006|March 31, 2006|March 2, 2006||||||https://clinicaltrials.gov/show/NCT00299338||184486|
NCT00299975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PID-001|A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation|A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation||Hong Kong Baptist University|Yes|Completed|October 2006|October 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|97|||Both|18 Years|65 Years|No|||April 2015|April 8, 2015|March 6, 2006||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00299975||184437|
NCT00300235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1319|Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence|The Epidemiology of Priapism (Sickle Cell Disease)||University of Texas Southwestern Medical Center|Yes|Completed|August 2005|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Actual|1464|||Male|5 Years|N/A|No|Non-Probability Sample|Males receiving care in any Comprehensive Sickle Cell Center.|December 2015|December 22, 2015|March 7, 2006||No||No|March 13, 2009|https://clinicaltrials.gov/show/NCT00300235||184418|
NCT00300573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 08721-204|Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs|A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimized Background Therapy in HIV-1 Infected Subjects Who Have Failed and/or Harbor HIV With Resistance Mutations to NRTIs, PIs, and NNRTIs|DECLARE|Incyte Corporation|Yes|Terminated|April 2006|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|16 Years|75 Years|No|||June 2012|June 1, 2012|March 7, 2006|Yes|Yes|Development program ended due to inability to pair with other cytidine analogs and higher risk    of hyperlipasemia when not used with 3TC/FTC.|No||https://clinicaltrials.gov/show/NCT00300573||184392|
NCT00301028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0919|Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer|Phase II Trial of Induction Therapy With Cetuximab (C225) and Carboplatin/Paclitaxel Chemotherapy in Previously Untreated Patients With Advanced (Stage IV) Head & Neck Squamous Cell Carcinoma||M.D. Anderson Cancer Center|No|Completed|April 2006|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|16 Years|N/A|No|||February 2013|February 26, 2013|March 8, 2006|Yes|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT00301028||184357|
NCT00301275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2123|Assessing Free Immunoglobulin Light Chains in Patients With Myeloma|||Royal Marsden NHS Foundation Trust||Completed|June 2002|December 2005||||Phase 2|Observational|Allocation: Random Sample, Time Perspective: Longitudinal|||||||Both|18 Years|N/A||||March 2006|March 9, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00301275||184339|
NCT00301548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S31/499|Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer|Primary Chemotherapy Combined With Perioperative Chemotherapy In Operable Breast Cancer||European Institute of Oncology||Completed|February 2000|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||172|||Female|18 Years|70 Years|No|||January 2006|March 9, 2006|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301548||184318|
NCT00301821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0489|Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma||Alliance for Clinical Trials in Oncology|Yes|Completed|January 2006|April 2015|Actual|October 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|March 9, 2006|Yes|Yes||No|March 13, 2015|https://clinicaltrials.gov/show/NCT00301821||184300|
NCT00302159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060112|Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors|A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial||National Institutes of Health Clinical Center (CC)|Yes|Active, not recruiting|March 2006|October 2016|Anticipated|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|90 Years|No|||July 2015|July 7, 2015|March 11, 2006|Yes|Yes||No|May 22, 2014|https://clinicaltrials.gov/show/NCT00302159||184275|
NCT00310843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1452|Case-Control Viramune (Nevirapine) Toxicogenomics Study|A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy||Boehringer Ingelheim||Completed|February 2006|||September 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|889|||Both|18 Years|N/A|No|Non-Probability Sample|Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity        Within the First 8 Weeks of Nevirapine Therapy|July 2013|July 31, 2013|March 28, 2006||||No||https://clinicaltrials.gov/show/NCT00310843||183626|
NCT00311116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020010130|Vitamin E to Prevent Mucositis in Children With Cancer|Serial Controlled N-of-1 Trials of Topical Vitamin E as Prophylaxis for Chemotherapy-induced Oral Mucositis in Pediatric Patients||The Hospital for Sick Children||Completed|July 2002|February 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||16|||Both|6 Years|18 Years|No|||December 2013|December 17, 2013|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311116||183605|
NCT00311350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-100|Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects|Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of MOA-728 Administered Orally to Healthy Subjects||Valeant Pharmaceuticals International, Inc.||Completed|March 2006|August 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double-Blind||||48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|April 3, 2006||||||https://clinicaltrials.gov/show/NCT00311350||183587|
NCT00311675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0130|St. Jude Open Label H5 Trial|A Single Center, Open-Label, Phase I/II Study of Two 90-µg Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|August 26, 2010|April 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00311675||183562|
NCT00312260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008259|Comparing Gabapentin and Amitriptyline for the Treatment of Neuropathic Pain in Children and Adolescents|Randomized Controlled Trial Comparing Gabapentin and Amitriptyline for the Treatment of Neuropathic Pain in Children and Adolescents||The Hospital for Sick Children|No|Active, not recruiting|April 2006|December 2010|Anticipated|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|17 Years|No|||December 2010|December 13, 2010|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00312260||183517|
NCT00308607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 18580|Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma|Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma||University of Turku|No|Completed|August 2005|April 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||April 2009|April 2, 2009|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308607||183794|
NCT00308594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2006:027|Oral Dexamethasone for the Treatment of Cervical Radiculopathy|Oral Dexamethasone for the Treatment of Cervical Radiculopathy: A Double Blinded, Randomized, Placebo Controlled Trial||University of Manitoba|No|Terminated|November 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|60 Years|No|||April 2011|April 27, 2011|March 28, 2006|||Study terminated due to withdrawl of participating co-investigators.|No||https://clinicaltrials.gov/show/NCT00308594||183795|
NCT00299364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-FEM0401|Comparison of the Efficacy and Tolerability of Black Cohosh Vs Tibolone in Patients With Menopausal Symptoms|Multi-Center, Randomized, Double-Blind, Parallel-Controlled Study on the Efficacy and Tolerability of Black Cohosh Vs Tibolone in Patients With Menopausal Symptoms||Schaper & Bruemmer GmbH & Co KG||Completed|September 2004|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Female|40 Years|60 Years|No|||March 2006|March 2, 2006|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00299364||184484|
NCT00299377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Thiele|Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI|Randomized Comparison of Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI and Effects on Infarct Size and Microvascular Obstruction||University of Leipzig||Completed|January 2006|February 2008|Actual|November 2007||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||June 2008|July 2, 2008|March 2, 2006||||No||https://clinicaltrials.gov/show/NCT00299377||184483|
NCT00299650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACURASYS|Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients|Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients||Assistance Publique Hopitaux De Marseille|Yes|Completed|March 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|90 Years|No|||October 2008|October 9, 2008|March 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00299650||184462|
NCT00299663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-HMO-CTIL|Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract|Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract||Hadassah Medical Organization|Yes|Completed|February 2006|October 2011|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|61|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The population that participate in the study are women who were udentified with positive        culture of group A streptoccoci in the genital tracts, starting from 2003 and on.|January 2012|January 15, 2012|March 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00299663||184461|
NCT00299988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512008265|Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease|A Placebo-controlled, Randomized, Double-Blind Phase II Clinical Study of Gammagard Intravenous Immunoglobulin (IVIg) for Treatment of Mild to Moderate Alzheimer's Disease||Weill Medical College of Cornell University|Yes|Completed|February 2006|April 2010|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|50 Years|N/A|No|||November 2010|November 8, 2010|March 3, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00299988||184436|
NCT00300248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1329|Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome|The Improving Care of Acute Lung Injury Patients (ICAP) Study||Johns Hopkins University|No|Completed|October 2004|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|520|||Both|18 Years|N/A|No|Non-Probability Sample|13 critical care units at 4 academic hospitals in Baltimore, MD|August 2015|August 31, 2015|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300248||184417|
NCT00300586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.386|IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer|A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer Not Progressing on First Line Cisplatin-gemcitabine Chemotherapy Maintenance Chemotherapy With Gemcitabine or Sequential Treatment With Erlotinib||Hospices Civils de Lyon|Yes|Completed|June 2006|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|842|||Both|18 Years|70 Years|No|||December 2011|December 28, 2011|March 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00300586||184391|
NCT00300599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/hui/2006/001|Effect of Continuous Positive Airway Pressure (CPAP) on Systemic Blood Pressure, Coagulability and Carotid Intima-media Thickness in Patients With Sleep Apnea|A Randomized Controlled Study of the Long-term Effects of Nasal Continuous Positive Airway Pressure on Systemic Blood Pressure, Coagulability and Carotid Intima-media Thickness in Obstructive Sleep Apnea Syndrome||Chinese University of Hong Kong|No|Recruiting|January 2006|December 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||June 2011|June 22, 2011|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00300599||184390|
NCT00300950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-4000-02|Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer|A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With a Gemcitabine Regimen Versus a Gemcitabine Regimen With Placebo, in Patients With Post-resection R0/R1 Pancreatic Cancer With Tumor Sequence Confirmation of Ras Mutations.||GlobeImmune||Completed|January 2006|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|March 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00300950||184363|
NCT00300963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223412/093|Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients|A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia||GlaxoSmithKline||Completed|December 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||275|||Both|18 Years|65 Years|No|||February 2013|February 13, 2013|March 7, 2006||||||https://clinicaltrials.gov/show/NCT00300963||184362|
NCT00301587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002377|A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives|A Randomized, Double-Blind, Two-Part, Parallel-Group, Comparative Study to Evaluate Blood Folate Levels in Women Taking an Oral Contraceptive With and Without Folic Acid||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Withdrawn||December 2004|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|March 10, 2006|||Company decision to not fund further development of women's health new drug development    programs.|||https://clinicaltrials.gov/show/NCT00301587||184315|
NCT00301288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2657|A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).|||Royal Marsden NHS Foundation Trust||Completed||||||N/A|Observational|Time Perspective: Retrospective||1||152|||Both|18 Years|N/A|No|Non-Probability Sample|152 participants with Non-Hodgkin's Lymphoma who have received an autologous stem cell        trandplant in the past and have written informed consent.|January 2010|January 11, 2010|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301288||184338|
NCT00301561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12110 STRATALL|Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL)|Expanded Access to Antiretroviral Therapy in Africa: Assessment of the Patients' Management in District Hospitals With a Simplified Follow-up Approach (ANRS 12110 STRATALL)||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|May 2006|October 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|459|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00301561||184317|
NCT00301834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462406|Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders|Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia||University of California, San Francisco||Completed|January 2005|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|21 Years|No|||May 2013|May 15, 2013|March 9, 2006|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00301834||184299|
NCT00301847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02689|Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain|A Phase 2 Study of Sorafenib (BAY 43-9006) in Metastatic Renal Cell Cancer to the Brain||National Cancer Institute (NCI)||Completed|November 2005|||June 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||April 2006|February 8, 2013|March 9, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00301847||184298|
NCT00302185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCAVIC Pal 1|Acupuncture in Palliative Cancer Care|A Feasibility Study in Acupuncture for Symptom Management in Palliative Care.||British Columbia Cancer Agency|No|Completed|June 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2010|October 19, 2010|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00302185||184273|
NCT00302445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD3588s|A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis|An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Raptiva (Efalizumab)in Combination With Narrow Band Phototherapy for the Treatment of Moderate to Severe Plaque Psoriasis.||Derm Research, PLLC|Yes|Completed|March 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 12, 2007|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00302445||184253|
NCT00311129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309123|Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL|A Multicenter Study to Assess the Antitumor Effect and Safety of Fludarabine Phosphate Tablet (SH T 586) in Combination With Rituximab Administered in 6 Treatment Cycles (1 Treatment Cycle: Rituximab 375 mg/m2 iv on Day 1 Along With 5-Consecutive Day Oral Dosing of SH T 586 40 mg/m2/Day From Day 1 to Day 5, Followed by an Observation Period of 23 Days) in Patients With Indolent Lymphoma||Sanofi||Completed|December 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|74 Years|No|||December 2013|December 2, 2013|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00311129||183604|
NCT00311363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111461|Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.|A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.||XenoPort, Inc.|No|Completed|April 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|327|||Both|18 Years|N/A|No|||May 2011|July 15, 2013|April 3, 2006|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00311363||183586|
NCT00311376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-515|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder|||Allergan||Completed|August 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|416|||Both|18 Years|80 Years|No|||November 2015|November 5, 2015|April 4, 2006|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT00311376||183585|
NCT00311974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2006.01.HV|The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals|The Effect of Dihydralazine on Renal Tubular Function and Vasoactive Hormones in Healthy Individuals||Regional Hospital Holstebro||Completed|April 2006|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||16|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2010|February 17, 2010|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311974||183539|
NCT00311987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001376|Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients|A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients||Johns Hopkins University|No|Terminated|April 2006|April 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||April 2006|April 1, 2013|April 5, 2006||Yes|Curtailment of funding by sponsor|||https://clinicaltrials.gov/show/NCT00311987||183538|
NCT00312533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHRF2006-01|Outcome Following Hylan F- 20 (Synvisc) + Corticosteroid Injections for the Treatment of Osteoarthritis of the Knee|Outcome Following Hylan F- 20 (Synvisc) + Corticosteroid Injections for the Treatment of Osteoarthritis of the Knee||Steadman Hawkins Research Foundation||Completed|April 2006|February 2008|Actual|February 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|80 Years|No|||August 2008|August 22, 2008|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312533||183496|
NCT00308828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47/31-1-2005|The Prevalence of Osteoporosis in Hemodialysis Patients|Prevalence of Osteoporosis in Hemodialysis Patients and Relevance With Renal Bone Disease||Papageorgiou General Hospital||Completed|January 2005|August 2007|Actual|August 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|166|||Both|18 Years|N/A|No|Non-Probability Sample|Patients on hemodialysis|June 2008|June 5, 2008|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00308828||183777|
NCT00308841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.SDÜ.0.01.00.01.301.01|Anesthetic Efficacy of Intrauterine Lidocaine for Removal of a "Lost" Intrauterine Device|||Suleyman Demirel University||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|N/A|N/A||||September 2005|October 17, 2008|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00308841||183776|
NCT00308854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK 03|Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK|PD P 506 A or Its Placebo in Combination With Red Light for Photodynamic Therapy of Mild to Moderate Actinic Keratosis||photonamic GmbH & Co. KG|No|Completed|March 2006|December 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||April 2008|April 10, 2008|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00308854||183775|
NCT00299390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91375|Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer|Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)||Bayer||Terminated|April 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|March 3, 2006||No|Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop    the trial due to lack of efficacy .|No||https://clinicaltrials.gov/show/NCT00299390||184482|
NCT00299676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004816|An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period|An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period||Janssen-Cilag Pty Ltd||Completed|May 2005|March 2008|Actual|March 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Alzheimer's disease, who are currently not in permanent residential care. A        convenience sampling method was applied.|May 2014|May 22, 2014|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299676||184460|
NCT00300001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0186|Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes|Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes||Community Cancer Care||Recruiting|March 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||300|||Both|18 Years|N/A|No|||August 2006|August 23, 2006|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00300001||184435|
NCT00300261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003907|Testing the Effects of Telehealth Monitoring on Rehospitalization and Self Care for Heart Failure Patients in Home Care|Promoting Self Care Using Telehomecare: Impact on Outcomes||University of Pennsylvania|No|Completed|September 2005|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|216|||Both|55 Years|N/A|No|||March 2010|November 30, 2015|March 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00300261||184416|
NCT00300612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0104|Vaccine Treatment for Advanced Malignant Melanoma|A Phase I/II Study of Dorgenmeltucel-L (HyperAcute Melanoma) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Malignant Melanoma||NewLink Genetics Corporation|No|Completed|March 2006|September 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|March 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00300612||184389|
NCT00302224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIO-501|A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus|A Phase 1/2a, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Study of Safety, Tolerability, Pharmacokinetics and Activity of 14 Days of Oral Dosing With the 2S,4R Enantiomer of Ketoconazole (DIO-902) in Subjects With Type 2 Diabetes Mellitus||DiObex||Completed|February 2005|August 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|70 Years|No|||February 2008|February 20, 2008|March 10, 2006||||||https://clinicaltrials.gov/show/NCT00302224||184270|
NCT00301301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2656|A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)|||Royal Marsden NHS Foundation Trust||Completed||||||N/A|Observational|Time Perspective: Retrospective||1||39|||Both|18 Years|N/A|No|Non-Probability Sample|39 participants aged over 18 with histological diagnosid of diffuse large B cell lymphoma        and written informed consent. Patients who have received Gemcitabine-cisplatin,        methylprednisolone (GEM-P) as per standard unit guidelines with or without Rituximab for        relapsed/refractory DLBCL.|January 2010|January 11, 2010|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301301||184337|
NCT00301574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003301|An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.|Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.||Janssen Pharmaceutical K.K.||Completed|April 2001|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|398|||Both|45 Years|N/A|No|||January 2011|May 16, 2011|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00301574||184316|
NCT00301860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462439|Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer|Feasibility of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions for Children at High Risk for Complications With Conventional Transplantation||University of California, San Francisco|Yes|Terminated|January 2003|November 2007|Actual|March 2007|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|8|||Both|N/A|21 Years|No|||July 2013|July 11, 2013|March 9, 2006||No|lack of efficacy|No||https://clinicaltrials.gov/show/NCT00301860||184297|
NCT00301873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010125|Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma|Phase II Study of Zometa (Zoledronic Acid) to Prevent Osteoporosis in Patients With Brain Tumors||Duke University|Yes|Completed|May 2006|September 2012|Actual|February 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|March 9, 2006|Yes|Yes||No|October 15, 2012|https://clinicaltrials.gov/show/NCT00301873||184296|Limitations include early pt termination leading to small numbers of subjects analyzed (eg no BMD study at 6 and/or 12 mos)secondary to the poor overall survival (eg median survival 3-9 mos)associated with recurrent glioblastoma multiforme(GBM) pts.
NCT00302172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-101|ARQ 197 in Subjects With Metastatic Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Metastatic Solid Tumors||ArQule|No|Completed|January 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||August 2009|August 25, 2009|March 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00302172||184274|
NCT00302796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005500-17|Antibiotic Treatment to Patients With Low Back Pain|Antibiotic Treatment to Patients With Low Back Pain Associated With Modic Changes Following Disc Herniation. A Randomized Clinical Controlled Trial||The Back Research Center, Denmark|Yes|Completed|March 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|162|||Both|18 Years|65 Years|No|||July 2009|May 26, 2010|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00302796||184226|
NCT00312000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIRO1|Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma|A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma||Dutch Colorectal Cancer Group|Yes|Completed|January 2003|December 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|820|||Both|18 Years|N/A|No|||September 2008|September 5, 2008|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00312000||183537|
NCT00312013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRX106365|Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer|The INPACT Study (Improving With Nadroparin the Prognosis in Advanced Cancer Treatment). A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate||GlaxoSmithKline||Completed|May 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|503|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00312013||183536|
NCT00312026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD3753g|A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet|A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet||Genentech, Inc.||Completed|April 2006|November 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312026||183535|
NCT00312273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20F35869|Aminophylline in Bradyasystolic Cardiac Arrest|Aminophylline in Bradyasystolic Cardiac Arrest: A Randomized Placebo-Controlled Trial||Vancouver General Hospital||Completed|January 2001|July 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||966|||Both|16 Years|N/A|No|||September 2003|July 26, 2006|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312273||183516|
NCT00312585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G0418|Acupuncture for the Prevention of Postdates Pregnancy|A Randomized Controlled Trial of Acupuncture to Prevent Postdates Pregnancy||University of North Carolina, Chapel Hill|No|Completed|February 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|89|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 4, 2011|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312585||183492|
NCT00308360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-189|Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility|Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility||Nathan Kline Institute for Psychiatric Research||Completed|September 1999|April 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||46|||Both|18 Years|65 Years|No|||March 2006|March 28, 2006|March 28, 2006||||No||https://clinicaltrials.gov/show/NCT00308360||183813|
NCT00308620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510M77007|Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine|A Randomized, Pilot Study of the Anti-Viral and Anti-Inflammatory Effects of Chloroquine in Early HIV Infection||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|March 2006|June 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|No|||May 2012|July 9, 2012|March 27, 2006||No|Insufficient financial support; lack of efficacy for primary endpoint|No|September 26, 2011|https://clinicaltrials.gov/show/NCT00308620||183793|
NCT00299403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010072|The Antidepressant Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)Compared to ECT|The Antidepressant Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)Compared to Electroconvulsive Therapy (ECT).An Open Randomized Noninferiority Trial.||University of Aarhus|No|Completed|May 2002|May 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||June 2008|June 30, 2008|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299403||184481|
NCT00299416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC- MS-02-188|Caffeinol Hypothermia Protocol|Combined Neuroprotective Modalities Coupled With Thrombolysis in Acute Ischemic Stroke: A Pilot Study of Caffeinol and Mild Hypothermia||The University of Texas Health Science Center, Houston|Yes|Completed|February 2003|August 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||April 2011|April 5, 2011|March 2, 2006|Yes|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT00299416||184480|
NCT00299689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|076.06|Phase II Trial of Ontak With Metastatic Melanoma|Phase II Trial of ONTAK With Metastatic Melanoma||James Graham Brown Cancer Center|Yes|Completed|March 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||May 2013|August 26, 2014|March 3, 2006|Yes|Yes||No|August 26, 2014|https://clinicaltrials.gov/show/NCT00299689||184459|
NCT00299702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006121|Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia|A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|February 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|March 3, 2006||No||No|January 26, 2010|https://clinicaltrials.gov/show/NCT00299702||184458|15% of subjects did not meet stability inclusion criteria; many received supplemental antipsychotics post-randomization; biweekly visits may have increased aripiprazole adherence; numerous early dropouts may have led to dependent censoring and bias.
NCT00300014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVT in vitreous hemorrhage|Efficacy and Safety of Intravitreal Triamcinolone Acetonide in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage|Comparative,Randomized Study Between Intravitreal Triamcinolone Acetonide and Air-Fluid Exchange in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage||Asan Medical Center||Recruiting|January 2006|May 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|20 Years|N/A|No|||June 2007|June 12, 2007|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300014||184434|
NCT00300274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2310|Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection|A 24-month, Multi-center, Randomized, Open-label, Non-inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-controlled Everolimus With Reduced Cyclosporine Versus 3.0 g Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Heart Transplant Recipients||Novartis||Completed|January 2006|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|721|||Both|18 Years|70 Years|No|||July 2012|July 10, 2012|March 6, 2006|Yes|Yes||No|July 6, 2012|https://clinicaltrials.gov/show/NCT00300274||184415|
NCT00300287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2307E1|A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia|A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia||Novartis||Completed|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|19 Years|N/A||||July 2007|July 16, 2007|March 6, 2006||||No||https://clinicaltrials.gov/show/NCT00300287||184414|
NCT00300625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-05-109C|Validation of the San Francisco Syncope Rule|Validation of the San Francisco Syncope Rule||Albert Einstein College of Medicine of Yeshiva University||Completed|January 2005|||||N/A|Observational|Time Perspective: Prospective|||||||Both|21 Years|N/A|No|||March 2006|February 17, 2009|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300625||184388|
NCT00301015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RapAct 28-02-2006|Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers|Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers||Karolinska University Hospital||Completed|March 2006|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|3005|||Both|N/A|N/A|No|||October 2007|October 31, 2007|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00301015||184358|
NCT00306670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2688|Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A|A Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia A||Georgetown University|No|Terminated|April 2006|August 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|March 23, 2006|No|Yes|Sponsor no longer funding study.|No||https://clinicaltrials.gov/show/NCT00306670||183941|
NCT00306930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIN|Clinical Study Evaluating an Acetabular Cup System After Total Hip Replacement|Multi-center, Prospective, Clinical Evaluation of Pinnacle Acetabular Implants in Total Hip Arthroplasty||DePuy Orthopaedics|No|Completed|July 2000|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1593|||Both|N/A|N/A|No|||July 2014|July 28, 2014|March 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00306930||183921|
NCT00301886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463758|S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone|A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer||Southwest Oncology Group|Yes|Withdrawn|May 2006|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|N/A|No|||November 2013|November 11, 2013|March 9, 2006|Yes|Yes|withdrawn support for study|No||https://clinicaltrials.gov/show/NCT00301886||184295|
NCT00302198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23.112|Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org|Amyotrophic Lateral Sclerosis Web Based Patient Care Database||Forbes Norris MDA/ALS Research Center||Completed|January 2006|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15000|||Both|N/A|N/A|No|Non-Probability Sample|Any patient diagnosed with ALS by a licensed physician.|February 2010|March 1, 2010|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302198||184272|
NCT00302211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C200-006|The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension|A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients With Pulmonary Arterial Hypertension Receiving Oral Sildenafil|VISION|Actelion||Terminated|February 2006|November 2009|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|67|||Both|12 Years|85 Years|No|||May 2011|May 12, 2011|March 10, 2006|Yes|Yes|Terminated due to slow enrollment|No|May 27, 2010|https://clinicaltrials.gov/show/NCT00302211||184271|Primary purpose was to evaluate the efficacy of iloprost in PAH patients. Slow patient recruitment led to early study closure. In addition there were factors regarding the conduct of the study which preclude conclusions from this limited dataset.
NCT00302458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001812|A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults|A Double-blind, Randomized, Placebo-controlled, Crossover Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults||Massachusetts General Hospital|No|Completed|January 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|March 13, 2006||No||No|November 18, 2013|https://clinicaltrials.gov/show/NCT00302458||184252|
NCT00308035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10144|Foot Posture in People With Paralysis on One Side After Stroke|Foot Posture in People With Hemiplegia After Stroke||University of Kansas Medical Center|No|Completed|November 2005|June 2006|Actual|||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|People with hemiplegia from chronic stroke and limited ankle mobility|June 2008|June 12, 2008|March 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00308035||183838|
NCT00311701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0111|Chart Review of Antivirals for Influenza in Infants|A Retrospective Chart Review to Assess the Safety of Oseltamivir (Tamiflu®) Compared to Alternate Antiviral Therapy (Amantadine or Rimantadine) Administered to Children Less Than 12 Months of Age With Diagnosed or Suspected Influenza (CASG 113)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2005|December 2006||||N/A|Observational|Time Perspective: Retrospective||||200|||Both|N/A|11 Months|No|||October 2007|May 12, 2011|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311701||183560|
NCT00311714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0077|Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958|CS-8958 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects||Biota Scientific Management Pty Ltd||Completed|April 2007|December 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|January 11, 2009|April 5, 2006||||||https://clinicaltrials.gov/show/NCT00311714||183559|
NCT00312039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-014A|Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation|A 14 Day Randomized, Double Blind, Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation|Resistance|Achillion Pharmaceuticals|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||January 2014|January 20, 2014|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312039||183534|
NCT00312286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1547-851B|Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.|A Randomized, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection||Takeda|No|Terminated|April 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|538|||Female|18 Years|45 Years|No|||January 2012|January 31, 2012|April 6, 2006|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00312286||183515|
NCT00312559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10214|The Therapeutics Effects of Yoga in Individuals With Parkinson's Disease|The Therapeutic Effects of Yoga in Individuals With Parkinson's Disease||University of Kansas Medical Center||Completed|February 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||18|||Both|18 Years|N/A|No|||August 2007|August 17, 2007|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312559||183494|
NCT00308659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAP FOB|Study to Evaluate Two Diagnostic Strategies for the Treatment of Severe Community Acquired Pneumonia (SCAP)|Diagnostic Strategy Evaluation Study of Two Diagnostic Strategies for the Treatment of SCAP : Noninvasive Strategy and Semiinvasive Strategy Including FOB Distal Samplings||Assistance Publique - Hôpitaux de Paris||Recruiting|March 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||March 2006|March 28, 2006|March 28, 2006||||No||https://clinicaltrials.gov/show/NCT00308659||183790|
NCT00308633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060122|Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants|Mechanism and Vascular Effects of Endothelial Progenitor Cell Mobilization in Patients With Coronary Artery Disease Undergoing Cardiac Rehabilitation||National Institutes of Health Clinical Center (CC)||Completed|March 2006|||December 2007|Actual|N/A|Observational|N/A||||55|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2009|September 26, 2015|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308633||183792|
NCT00308893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOHP05-WEH/BDNF|BDNF Gene Polymorphism and Antidepressants Treatment|Brain Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Response to Antidepressants Treatment in Major Depression||University Hospital, Tours|No|Completed|July 2006|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|188|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308893||183772|
NCT00299429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Thiele|MIDCAB Versus DES in Proximal LAD Lesions|Randomised Comparison of Minimally Invasive Direct Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Proximal Stenosis of the Left Anterior Descending Coronary Artery||University of Leipzig|Yes|Completed|January 2003|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||March 2007|July 7, 2008|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00299429||184479|
NCT00299715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010834|A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release Paliperidone in the Treatment of Subjects With Acute Manic and Mixed Episodes Associated With Bipolar I Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|473|||Both|18 Years|65 Years|No|||June 2011|June 2, 2011|March 3, 2006||||||https://clinicaltrials.gov/show/NCT00299715||184457|
NCT00299728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2003-022;NYU05-120;CUMC9147|NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors|A Phase I Study Using Vaccination With NY-ESO-1 Recombinant Protein Mixed With CpG7909 and Montanide® ISA-51 in Patients With Cancers That Often Express NY-ESO-1.||Ludwig Institute for Cancer Research||Completed|March 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||January 2009|January 28, 2009|March 6, 2006||||||https://clinicaltrials.gov/show/NCT00299728||184456|
NCT00299741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-05-1-0439|Study of SU11248 in Men With Advanced Prostate Cancer|A Phase II Study of SU011248 in Men With Advanced Prostate Cancer||Massachusetts General Hospital|No|Completed|March 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|N/A|No|||December 2012|December 14, 2012|March 3, 2006||No||No|May 9, 2012|https://clinicaltrials.gov/show/NCT00299741||184455|
NCT00300638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAABER007112|Alcoholism: Emotion and Thinking|Affective and Conative Changes in Alcoholism||Boston University||Recruiting|August 2001|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|700|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study populations include alcoholics and demographically equivalent healthy controls.        Potential participants who have participated in one or more of our prior studies are        contacted by telephone to determine whether or not they would like to participate again.        Potential participants who have not previously been enlisted in any of our studies are        recruited through fliers placed in the Boston Veterans Affairs Healthcare System, Boston        University School of Medicine, and after-care programs in the Boston area, and through        advertisements placed with local newspapers and web sites. For these "new" participants,        subject selection procedures include an initial prescreening telephone interview to        determine identifying information such as age, level of education, health history, and        history of alcohol and drug use. Those eligible are invited to the laboratory for further        screening and neuropsychological evaluations.|November 2012|November 8, 2012|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300638||184387|
NCT00301041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465214|Radiation Therapy in Treating Women With Invasive Breast Cancer|The Relationship Between Plasma Transforming Growth Factor-beta 1 (TGF-β) and Fractionation in Radiotherapy for Breast Cancer: A Randomized Study||University of California, San Francisco||Completed|April 2004|May 2004|Actual|May 2004|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00301041||184356|
NCT00301314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2655|A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).|||Royal Marsden NHS Foundation Trust||Completed||||||N/A|Observational|Time Perspective: Retrospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|219 participants aged over 18 with Hodgkin Lymphina who have received an autologous stem        cell transplant and written informed consent.|January 2010|January 11, 2010|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301314||184336|
NCT00307216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071252|Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis|Randomized Controlled Trial of the Graduated Recovery Intervention Program for First-Episode Psychosis||University of North Carolina, Chapel Hill|Yes|Completed|April 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00307216||183899|
NCT00307229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-100643|Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)|A Phase I Trial Investigating the Safety and Immunogenicity of an Adenovirus Encoding Rat HER-2 Administered Intradermally to Patients With Metastatic or Locally Recurrent Breast Cancer||Ontario Clinical Oncology Group (OCOG)||Completed|March 2006|May 2012|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|March 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00307229||183898|
NCT00302471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0429-011|MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)|A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease||Merck Sharp & Dohme Corp.||Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|29|||Male|18 Years|N/A|No|||April 2015|April 24, 2015|March 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00302471||184251|
NCT00302484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTX-BISPHO-01|Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation|Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation, a Prospective Randomised Study||Medical University of Vienna||Active, not recruiting|April 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||96|||Both|18 Years|N/A|No|||January 2006|July 25, 2006|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302484||184250|
NCT00302809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24568|Blood Pressure Lowering Effects of Grape Juice|Effect of Concord Grape Juice on Blood Pressure and Vascular Function in Subjects With Pre-Hypertension and Stage 1 Hypertension||Boston University|No|Completed|March 2006|May 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||June 2009|June 16, 2009|March 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00302809||184225|
NCT00303082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDTP2/PDTSP-SUS|Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity|Clinical Trial for the Prevention of Premature Birth and Neonatal Related Morbidity||Oswaldo Cruz Foundation|Yes|Terminated|January 2006|August 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|645|||Female|14 Years|N/A|No|||October 2009|June 14, 2011|March 13, 2006|Yes|Yes|Limitation of funding|No||https://clinicaltrials.gov/show/NCT00303082||184204|
NCT00303108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04111|Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer|Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer||US Oncology Research||Completed|December 2005|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|March 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303108||184203|
NCT00303121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0631-AE|Compliance and Administration Technique in Topical Drug Therapy of Glaucoma|||University of Toronto||Completed|November 2005|June 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||120|||Both|18 Years|N/A|No|||June 2006|October 10, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303121||184202|
NCT00308269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-006|Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)|Protocol EC-FV-01: A Phase 1 Study of EC145 Administered in Weeks 1 and 3 of a 4-Week Cycle||Endocyte|No|Completed|March 2006|July 2008|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|March 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00308269||183820|
NCT00312052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5555-G000-201|Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease||Eisai Inc.||Completed|September 2007|||March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|600|||Both|45 Years|80 Years|No|||December 2012|June 30, 2014|April 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00312052||183533|
NCT00312299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PR1210608|Posterior Capsule Opacification Study|Posterior Capsule Opacification After Implantation of Square Edge PMMA, Round Edge PMMA and Acrysof Intraocular Lenses: Randomized Controlled Study||Aurolab|No|Completed|April 2006|January 2012|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|40 Years|65 Years|No|||July 2012|July 11, 2012|April 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00312299||183514|
NCT00312546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AI067854-02|Study of Valproic Acid to Treat HIV Infected Adults|Inhibiting Histone Deacetylase: Toward Eradication of HIV||University of North Carolina, Chapel Hill||Terminated|June 2006|October 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|N/A|No|||May 2012|May 11, 2012|April 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00312546||183495|
NCT00312312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITNO|Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide|Does Specific Immunotherapy Possess Immunomodulative Effects at the Bronchial Mucosa Level Among Adults With Atopic Diseases?||Bispebjerg Hospital||Recruiting|March 2006|December 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|40|||Both|18 Years|45 Years|No|||September 2006|June 11, 2007|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312312||183513|
NCT00312572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3018|Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain|A Randomized, Double-Blind Study Evaluating the Dose Conversion From Vicodin® to Buprenorphine Transdermal System (BTDS) in Subjects With Osteoarthritis (OA) Pain||Purdue Pharma LP||Completed|June 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|40 Years|85 Years|No|||August 2012|August 27, 2012|April 7, 2006|Yes|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT00312572||183493|
NCT00308672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC94-2314-B-039-024|The Prevalence of Metabolic Syndrome and Its Associated Factors in an Urban City|The Study for the Prevalence of Metabolic Syndrome and Its Associated Factors in an Urban City- Comparison of Agreement for Prevalence of Metabolic Syndrome Among the WHO, NCEP ATP III and Taiwan Definitions||China Medical University Hospital||Recruiting|August 2005|July 2006||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||3000|||Both|40 Years|N/A|No|||March 2006|March 29, 2006|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00308672||183789|
NCT00308685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-303-25-167|Chronic-dose Safety and Efficacy Study of a Bronchodilator Inhaler in Pediatric Asthmatics|||Teva Pharmaceutical Industries||Completed|July 2007|||July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|4 Years|11 Years|No|||October 2015|October 29, 2015|March 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308685||183788|
NCT00308646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC93-2314-B-039-025|Instrument Development of Screening Prediabetes Patients|Instrument Development of Screening Prediabetes Patients||China Medical University Hospital||Terminated|October 2004|July 2005||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||3000|||Both|40 Years|N/A|No|||March 2006|March 29, 2006|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00308646||183791|
NCT00308906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aminoglycoside Waste Specimen|Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children|Assessment of Gene and Urinary Protein Expression in Aminoglycoside-treated and Untreated Infants, Children and Adolescents||Virginia Commonwealth University|No|Completed|June 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|166|Samples With DNA|Waste blood samples will be collected in order to evaluate potential genetic mechanisms of      aminoglyoside induced renal injury. Waste urine samples will be collected in order to      evaluate candidate protein biomarkers of aminoglycoside induced renal injury.|Both|N/A|18 Years|No|Non-Probability Sample|Aminoglycoside treated and untreated newborns, infants and children.|January 2016|January 30, 2016|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00308906||183771|
NCT00300040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOSA001/BIOEU001|Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia|Phase II, Multi-Center,Single-Blind,Placebo-Controlled Study,Evaluating Safety & Feasibility of HBOC-201 (Wound Healing Patients With Peripheral Vascular Disease & Undergoing Lower Limb Amputation Due to Critical Lower Limb Ischemia||Biopure Corporation|No|Terminated|May 2006|June 2008|Anticipated|June 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|75 Years|No|||May 2008|May 15, 2008|March 6, 2006||No|Very slow enrollment.Study entry criteria not in line w/local standards of care|No||https://clinicaltrials.gov/show/NCT00300040||184432|
NCT00300300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bard0105|Anterior Cruciate Ligament (ACL) Reconstruction Using Different Grafts and Surgical Techniques|Anterior Cruciate Ligament Reconstruction: Comparison of Patellar With Hamstring Tendon Using a Computer-assisted Versus a Conventional Surgical Technique.||Queen's University|No|Terminated|September 2009|January 2029|Anticipated|January 2028|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|125|||Both|18 Years|40 Years|No|||September 2015|September 9, 2015|March 6, 2006||No|Study temporarily suspended until funding can be secured.|No||https://clinicaltrials.gov/show/NCT00300300||184413|
NCT00300313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-3913-JZ-CTIL|PTSD Prevention Using Escitalopram|||Sheba Medical Center||Completed|June 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|65 Years|No|||December 2013|December 30, 2013|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300313||184412|
NCT00301054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/GD/23|Study on Preventing Anemia in Children in Ghana|Preventing Anemia in Children (6months-30months) in a Malaria Endemic Rural Area in Ghana - A Randomized Double Blind Study||Ghana Health Services||Completed|June 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||872|||Both|6 Months|30 Months|Accepts Healthy Volunteers|||July 2005|May 26, 2006|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301054||184355|
NCT00301327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01-2005|Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice.|A Multi-Center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice.||Summers Laboratories||Completed|January 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|6 Months|N/A|No|||May 2007|May 25, 2007|March 8, 2006||||||https://clinicaltrials.gov/show/NCT00301327||184335|
NCT00301600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0606|Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy|Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy||Nanjing University School of Medicine|Yes|Completed|January 2003|January 2006|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|12 Years|65 Years|No|||July 2008|May 25, 2010|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00301600||184314|
NCT00301899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060035|Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab|A Phase II Study to Evaluate the Efficacy and Safety Using Combined Monoclonal Antibodies, Trastuzumab and Pertuzumab in Subjects With Her-2 Overexpressed Locally Advanced and Metastatic Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|December 2005|October 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|37|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|March 9, 2006||||||https://clinicaltrials.gov/show/NCT00301899||184294|
NCT00307203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA000510|Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke|Nicotine and Smoking Cessation in Schizophrenia||National Institute on Drug Abuse (NIDA)|No|Completed|August 1998|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 2, 2008|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00307203||183900|
NCT00307502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-TRANSVERSAL|Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV|Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects||Germans Trias i Pujol Hospital|No|Completed|January 2005|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Anticipated|675|||Both|18 Years|80 Years|No|||February 2010|February 22, 2010|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00307502||183879|
NCT00307762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5772732|Gait Trainer vs Traditional Physiotherapy in Acute Stroke|Body-weight Supported Therapy Using Gait Trainer Versus Traditional Gait-oriented Physiotherapy in Acute Phase of Stroke. The Effectiveness of Gait Training and Brain Networks Using NBS (Navigating Brain Stimulation)||Kuopio University Hospital|No|Completed|May 2003|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|85 Years|No|||January 2008|March 30, 2015|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307762||183859|
NCT00300391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505051|ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium|ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium||University of Pittsburgh|Yes|Terminated|March 2006|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|March 6, 2006||No|Insufficient recruitment to meet aims.|No||https://clinicaltrials.gov/show/NCT00300391||184406|
NCT00311740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631B1303|A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)|A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients With Essential Hypertension (Factorial Study)||Novartis||Completed|March 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|582|||Both|20 Years|80 Years||||November 2011|November 7, 2011|April 4, 2006||||No||https://clinicaltrials.gov/show/NCT00311740||183557|
NCT00311753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEX839BDE02|Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients|An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients||Novartis||Completed|February 2006|||December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|342|||Both|40 Years|N/A||||June 2010|June 7, 2010|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00311753||183556|
NCT00312065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#03/10/VA03|Study of the Need for Temperature Probe Covers for Newborn Babies on Radiant Warmers|Servocontrolled Radiant Warmers and the Role of Thermistor Probe Reflective Shields in Neonates||Maimonides Medical Center|No|Completed|October 2003|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|1 Week|No|||April 2015|April 6, 2015|April 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00312065||183532|
NCT00312598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 70,111|Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine|Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole||University of North Carolina, Chapel Hill|Yes|Completed|August 2005|April 2010|Actual|April 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|serum collected at baseline and end of study to be assayed in the future for related      metabolic tests which are not specified at this time.|Both|18 Years|65 Years|No|Non-Probability Sample|Psychiatry outpatient clinic|January 2014|January 10, 2014|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312598||183491|
NCT00308971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051000|Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)|Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)||Vanderbilt University|No|Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|75 Years|No|||July 2009|July 8, 2009|March 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308971||183766|
NCT00308373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104-04|Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus|Effects of Elevated Free Fatty Acids on Endogenous Glucose Production in People With and Without Type 2 Diabetes Mellitus||Mayo Clinic||Completed|July 2004|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|73|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308373||183812|
NCT00308386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18 67495 (completed)|DYNAMIC Study: (Diabetes Nurse Case Management And Motivational Interviewing for Change)|Impact of Nurse Case Management on Diabetes Co-morbidities||Milton S. Hershey Medical Center|Yes|Active, not recruiting|August 2006|August 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|820|||Both|18 Years|N/A|No|||February 2011|February 28, 2011|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00308386||183811|
NCT00308399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1099-05|A Study to Evaluate the Effect of a Medicine on Gastric Functions in Healthy Volunteers.|A Double Blind, Randomized, Placebo-controlled, Single Center, Parallel Group Study to Evaluate the Effects of Itopride (100 mg and 200 mg t.i.d.) on Gastric Motor and Sensory Functions in Healthy Volunteers.||Mayo Clinic||Completed|November 2005|June 2007|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|March 27, 2006||||||https://clinicaltrials.gov/show/NCT00308399||183810|
NCT00309257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVA01|Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome|Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome||Mario Negri Institute for Pharmacological Research|No|Completed|January 2004|October 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|15 Years|70 Years|No|||October 2009|October 5, 2009|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309257||183745|
NCT00300326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURG-130-04|Computer-Assisted Total Knee Arthroplasty (TKA) With Zimmer LPS Flex Knee System|An Investigation of Total Knee Arthroplasty Kinematics on Patient Performance - The Zimmer Legacy® LPS Flex Knee System||Queen's University|Yes|Withdrawn|January 2006|January 2012|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|50 Years|80 Years|No|||April 2009|April 28, 2009|March 7, 2006|Yes|Yes|problems with planned computer|No||https://clinicaltrials.gov/show/NCT00300326||184411|
NCT00300651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhilippsU|Trial of Cognitive Behavioral Therapy for Schizophrenia|Phase 3 Randomized Controlled Trial of Cognitive Behavioural Therapy for Patients With Schizophrenia||Philipps University Marburg Medical Center||Recruiting|March 2006|August 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Both|16 Years|69 Years|No|||March 2006|March 8, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300651||184386|
NCT00305799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3Y05|Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors|Auditory and Vestibular Function Evaluation in Patients With Solid Tumors Treated With Oxaliplatin-Containing Chemotherapy||Case Comprehensive Cancer Center|No|Completed|November 2005|November 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|November 2014|November 20, 2014|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305799||184007|
NCT00306046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.4528.03 F|18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone|Use of 18F-Fluoride Positron Emission Tomography in the Assessment and Evaluation of Therapy in Monostotic Paget's Disease of Bone||Université Catholique de Louvain||Completed|February 2002|March 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||March 2006|March 20, 2006|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00306046||183989|
NCT00306059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/096|Early Goal Directed Therapy for Acute Kidney Injury|Early Goal Directed Therapy for Acute Kidney Injury||University Hospital, Ghent|No|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|340|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00306059||183988|
NCT00306345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Outreach: A Programme for Timely Treatment of Critically Ill Patients in a University Hospital|Outreach: A Programme for Early Recognition, Quick Response and Timely Treatment of Critically Ill Patients in a University Hospital||Radboud University||Recruiting|January 2006|December 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|1500|||Both|18 Years|N/A|No|||February 2007|July 11, 2007|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306345||183966|
NCT00303745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453857|Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Randomized Study of Second-Line Therapy Comprising Irinotecan With or Without Capecitabine in Patients Aged At Least 75 Years With Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2006|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|78|||Both|75 Years|N/A|No|||December 2006|July 23, 2008|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303745||184156|
NCT00303979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258|IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting|Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting|IMPROVE-HF|Medtronic Cardiac Rhythm Disease Management|No|Completed|May 2005|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|34810|||Both|18 Years|N/A|No|Probability Sample|Heart failure patients in outpatient cardiology practices|November 2012|November 21, 2012|March 15, 2006||No||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00303979||184138|
NCT00307515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-05-006|Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery|A Prospective, Randomized, Controlled Evaluation of Fibrin Sealant 2 (FS2) as an Adjunct to Hemostasis for Soft Tissue Bleeding During Retroperitoneal or Intra-Abdominal Surgery||Ethicon, Inc.|No|Completed|February 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|N/A|N/A|No|||January 2009|January 8, 2009|March 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307515||183878|
NCT00307528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100409|Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population|A Study to Evaluate the Safety, Reactogenicity & Immunogenicity of the GSK Biologicals Candidate Pneumococcal Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations, in Healthy Elderly Subjects||GlaxoSmithKline||Completed|January 2004|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|146|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 27, 2011|March 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307528||183877|
NCT00307775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/VO1/6|Vaginal Estrogen for the Treatment of Faecal Incontinence in Women|A Pilot Study to Examine the Efficacy of Vaginally Administered Oestradiol in the Treatment of Faecal Incontinence in Post Menopausal Women||London North West Healthcare NHS Trust||Terminated|March 2006|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Female|45 Years|N/A|No|||February 2007|April 28, 2012|March 27, 2006|||Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00307775||183858|
NCT00299819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP126|Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)|A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lupus Erythematosus (SLE)||MedImmune LLC||Completed|March 2006|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|45|||Both|18 Years|80 Years|No|||December 2007|December 17, 2007|March 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00299819||184449|
NCT00308048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03720|14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response|14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response||Oslo University Hospital||Completed|March 2004|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||435|||Male|18 Years|70 Years|No|||March 2006|July 3, 2011|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308048||183837|
NCT00301418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501007705|Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma|Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma||Northwell Health|No|Completed|March 2006|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|March 9, 2006||No||No|January 12, 2016|https://clinicaltrials.gov/show/NCT00301418||184328|
NCT00312078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC protocol 810; HRRC 360-05|Effect of Yogurt on Minimal Hepatic Encephalopathy|Effect of Yogurt Supplementation on Psychometric Test Performance in Cirrhotic Patients With Minimal Hepatic Encephalopathy. A Prospective Pilot Trial.||Medical College of Wisconsin|No|Completed|November 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|24 Years|65 Years|No|||October 2007|October 31, 2007|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312078||183531|
NCT00312091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1056|Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children|A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months and Older to Less Than 13 Years of Age in Thailand||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2006|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Both|6 Months|13 Years|No|||September 2012|September 10, 2012|April 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00312091||183530|
NCT00312104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1372|Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes.||Novo Nordisk A/S|No|Completed|April 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|325|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00312104||183529|
NCT00312325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-030602|Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans|Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans||Medical University of Vienna||Completed|July 2005|August 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|19 Years|65 Years|No|||March 2006|April 7, 2006|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312325||183512|
NCT00312338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMS-05-11|Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora|Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora||Alcon Research||Completed|June 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|2||Actual|137|||Both|1 Year|13 Years|No|||February 2010|October 31, 2012|April 4, 2006|Yes|Yes||No|July 15, 2009|https://clinicaltrials.gov/show/NCT00312338||183511|Limited source documents.
NCT00312611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801287|Screened Health Assessment & Pacer Evaluation|Screened Health Assessment & Pacer Evaluation||University of Pennsylvania||Active, not recruiting|August 2004|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||200|||Both|18 Years|65 Years|No|||April 2006|April 6, 2006|September 1, 2005||||||https://clinicaltrials.gov/show/NCT00312611||183490|
NCT00308412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 215|Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants|Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2006|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|45|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||July 2010|July 15, 2010|March 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00308412||183809|
NCT00308984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225|CARE--Childhood Awareness and Recall Evaluation|Multi-Center Study on the Incidence of Intra-operative Awareness and Recall in the Pediatric Population Undergoing General Anesthesia: CARE--Childhood Awareness and Recall Evaluation||Medtronic - MITG|No|Completed|January 2006|May 2008|Actual|December 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1784|||Both|5 Years|15 Years|No|Non-Probability Sample|Children 5-15 years of age scheduled for a surgical procedure that requires general        anesthesia|March 2012|March 6, 2012|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308984||183765|
NCT00308932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-2002|Effect of Age and Device on Delivery of Fluticasone|Relative Amount of Fluticasone Delivered by HFA-MDI Through Chamber/Mask to Young Children With Asthma||University of Florida||Completed|February 2003|April 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|1 Year|18 Years|No|||August 2004|September 16, 2011|March 28, 2006||||||https://clinicaltrials.gov/show/NCT00308932||183769|
NCT00309270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMPATH|Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation|A Prospective, Randomized Study to Compare the Effect of Campath-1,Low Dose Sirolimus Versus Campath-1H, Low Dose CsA Both in Addition to Low Dose Mycophenolate Mofetil on Phenotypic and Functional Profiles of PBMCs in Kidney Transplant Recipients in a Steroid-Free Regimen||Mario Negri Institute for Pharmacological Research||Completed|February 2003|April 2010||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||21|||Both|18 Years|75 Years|No|||March 2006|May 18, 2006|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309270||183744|
NCT00309283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALADIN|Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study|Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study|ALADIN|Mario Negri Institute for Pharmacological Research|No|Completed|April 2006|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|75 Years|No|||April 2013|April 23, 2013|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309283||183743|
NCT00305331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCDOM2006|Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease|Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease||University Health Network, Toronto||Terminated|March 2006|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|25|||Both|30 Years|90 Years|No|||July 2012|July 26, 2012|March 20, 2006||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT00305331||184042|
NCT00305552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031008|SARCOTHAL. Thalidomide in Skin Sarcoidosis|Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis||Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2007|April 29, 2011|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305552||184025|
NCT00305565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-21-US|Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses|Randomized Comparison of Outcomes in Patients With Treatment-Resistant Depression Who Receive VNS Therapy Administered at Different Amounts of Electrical Charge||Cyberonics, Inc.|Yes|Completed|January 2006|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|331|||Both|18 Years|N/A|No|||December 2013|December 6, 2013|March 20, 2006|Yes|Yes||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00305565||184024|
NCT00306358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050067|Plasma Holotranscobalamin as Compared to Plasma Cobalamins for Assessment of Vitamin B12 Absorption|Plasma Holotranscobalamin as Compared to Plasma Cobalamins for Assessment of Vitamin B12 Absorption. Optimisation of a Non-Radioactive Vitamin B12 Absorption Test (CobaSorb)||University of Aarhus||Completed|May 2005|October 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 22, 2006|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306358||183965|
NCT00306683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040701|Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions|Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|6 Years|18 Years|No|||April 2007|February 17, 2011|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00306683||183940|
NCT00306943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104745|Annual Study for Fluarix Registration|Phase III Vaccination Study for Evaluation of Immunogenicity and Reactogenicity of Influsplit SSW 2004/2005 in People Age 18 or Beyond||GlaxoSmithKline||Completed|July 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 21, 2012|September 15, 2005||||No||https://clinicaltrials.gov/show/NCT00306943||183920|
NCT00299520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. ICLA-08-CSI1|Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)|Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections.(ASSIST-1)||Arpida AG||Completed|June 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2008|April 2, 2008|March 3, 2006||||||https://clinicaltrials.gov/show/NCT00299520||184472|
NCT00299494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K3-101|Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)|A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma||Pfizer|No|Completed|May 2006|June 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|119|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|March 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299494||184474|
NCT00299507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-59|Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)|Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)||Alcon Research|Yes|Completed|March 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|240|||Both|50 Years|N/A|No|||September 2009|November 27, 2012|March 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299507||184473|
NCT00299832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A1303|SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction|A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction||Novartis|No|Completed|April 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|20 Years|80 Years|No|||November 2011|November 7, 2011|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299832||184448|
NCT00300404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOXO-KI-TT|Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression|Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study||Zentrum für Integrative Psychiatrie||Completed|January 2002|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2006|May 19, 2006|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300404||184405|
NCT00300417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060110|Phase I Study of West Nile Virus Vaccine|A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects||National Institutes of Health Clinical Center (CC)||Completed|March 2006|December 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 29, 2007|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300417||184404|
NCT00300118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-52/CDA|Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)|Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients||Dr. Falk Pharma GmbH|Yes|Completed|September 2004|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|311|||Both|18 Years|70 Years|No|||May 2014|May 16, 2014|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300118||184426|
NCT00300378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-333|Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|480|||Both|18 Years|N/A|No|||December 2007|December 3, 2007|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300378||184407|
NCT00301730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455626|Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung|Adoptive Immunotherapy With Costimulated Tumor-Derived T Cells After Allogeneic Hematopoietic Stem Cell Transplantation||National Cancer Institute (NCI)||Completed|October 2005|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|1|||Both|18 Years|75 Years|No|||April 2006|April 27, 2015|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301730||184306|
NCT00312351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1014|A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)|An Exploratory Randomized, Double-Masked, Multi-Center Comparative Trial, in Parallel Groups, to Explore the Safety and Efficacy of Three Different Doses of Intravitreous Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 102 Weeks, in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (AMD)||Eyetech Pharmaceuticals||Terminated|April 2006|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||262|||Both|50 Years|N/A|No|||January 2007|January 12, 2007|April 6, 2006||||||https://clinicaltrials.gov/show/NCT00312351||183510|
NCT00312364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRE0094P-201|Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers|||Pfizer||Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|322|||Both|18 Years|85 Years|No|||May 2012|May 24, 2012|April 6, 2006||||||https://clinicaltrials.gov/show/NCT00312364||183509|
NCT00308425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2405IT02|Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS|Effect of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Valsartan as Part of Intensified Multi-factorial Intervention Compared to EC-MPS Plus Standard Practice of Care on Development of Transplant Nephropathy in Cadaver Donor Kidney Recipients Given Basiliximab, Cyclosporine Microemulsion (CsA-ME) and Short-term Steroids: a 12-month, Prospective, Randomized, Open-label Multicentre Study (MYTHOS)||Novartis||Completed|October 2002|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|119|||Both|18 Years|70 Years||||January 2011|January 28, 2011|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00308425||183808|
NCT00302237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-716|CAPTURE 2 Post-Marketing Registry|Second Phase of "Carotid RX ACCULINK/RX ACCUNET Post-Approval Trial to Uncover Unanticipated or Rare Events"|CAPTURE 2|Abbott Vascular|No|Completed|March 2006|May 2010|Actual|March 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|6426|||Both|N/A|N/A|No|Non-Probability Sample|Open-ended enrollment at approximately 400 clinical sites in the United States.|December 2012|December 12, 2012|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302237||184269|
NCT00302250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0217 (Amended)|The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension|Study of The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension Before and After Receiving Oral Alagebrium or Placebo for 8 Weeks (STRETCH)||Synvista Therapeutics, Inc||Completed|February 2006|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|50 Years|N/A|No|||March 2006|March 21, 2006|March 13, 2006||||||https://clinicaltrials.gov/show/NCT00302250||184268|
NCT00308945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-ZAC-2004-001|Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients|Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients||University Hospital, Basel, Switzerland|No|Completed|November 2003|February 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|55 Years|85 Years|No|||January 2008|January 14, 2008|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00308945||183768|
NCT00308958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510M75246|Comparison of Airway Clearance Efficacy of Two High Frequency Chest Wall Oscillation (HFCWO) Devices in Cystic Fibrosis|Comparison of Airway Clearance Efficacy of Sine Wave and Triangular Wave High Frequency Chest Wall Oscillation (HFCWO) Devices in Patients With Cystic Fibrosis||University of Minnesota - Clinical and Translational Science Institute||Completed|February 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||15|||Both|19 Years|N/A|No|||May 2013|May 28, 2013|March 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308958||183767|
NCT00309556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG-24|Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer|A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastuzumab to Epirubicin and Docetaxel + G-CSF ± Trastuzumab as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer||Austrian Breast & Colorectal Cancer Study Group|No|Completed|February 2005|November 2011|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|536|||Female|19 Years|80 Years|No|||December 2011|December 29, 2011|March 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00309556||183722|
NCT00309816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-p-001039|Study of Sildenafil in Patient With Heart Failure.|Measurement of the Effect of Sildenafil Citrate (Viagra) on the Hemodynamics of Exercise Tolerance in Advanced Congestive Heart Failure.||Massachusetts General Hospital||Completed|December 2001|February 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|No|||March 2006|March 30, 2006|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309816||183702|
NCT00305812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MY11|Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma|A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma||Canadian Cancer Trials Group||Completed|December 2005|June 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|92|||Both|18 Years|N/A|No|||March 2010|November 7, 2010|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00305812||184006|
NCT00306072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-SRDB28|Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes|Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes||Ross Products||Completed|June 2005|September 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||82|||Both|18 Years|75 Years|No|||March 2006|January 26, 2010|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00306072||183987|
NCT00306085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Autologous Bone Marrow Cell Treatment in Peripheral Atherosclerosis|Autologous Bone Marrow Cell Treatment in Patients With Peripheral Atherosclerosis||University of Naples||Recruiting|April 2005|April 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|45 Years|90 Years|No|||March 2006|March 21, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00306085||183986|
NCT00306098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/0196|Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression|Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression||University of Miami|Yes|Active, not recruiting|December 2000|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||June 2015|June 11, 2015|March 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00306098||183985|
NCT00306371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040308|Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser|Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser||Skincare Physicians of Chestnut Hill||Completed|July 2004|February 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2004|March 22, 2006|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306371||183964|
NCT00306696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/342|Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.|See Detailed Description||GlaxoSmithKline||Completed|October 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||388|||Both|35 Years|80 Years|No|||March 2011|October 25, 2012|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306696||183939|
NCT00299234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4Z-MC-X040|Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL|Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia||Monarch Medical Research|No|Terminated|June 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|6 Years|18 Years|No|||April 2007|April 25, 2012|March 2, 2006||No|Insufficient number of interested potentital subjects|No||https://clinicaltrials.gov/show/NCT00299234||184494|
NCT00299845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-ped-LPZ-01|Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children|||Osaka University||Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|1 Year|15 Years|No|||September 2006|October 10, 2012|March 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00299845||184447|
NCT00299858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006036-01H|Theophylline in Chronic Obstructive Pulmonary Disease|Effect of Theophylline on Exercise Capacity and Lung Function in COPD Patients Receiving Long-acting Inhaled Bronchodilator Therapy||Ottawa Hospital Research Institute|No|Completed|October 2006|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|90 Years|No|||November 2010|November 10, 2010|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299858||184446|
NCT00300755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B3-328|Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)|A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD)||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|1 Year|5 Years|No|||April 2010|April 14, 2010|March 7, 2006|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00300755||184378|
NCT00300781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-201|Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer|Phase 2 Study of HKI-272 In Subjects With Advanced Breast Cancer||Puma Biotechnology, Inc.|No|Active, not recruiting|August 2006|December 2017|Anticipated|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|March 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00300781||184376|
NCT00300768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRC-33 - 980819(B)|Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection|A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection||World Health Organization|Yes|Completed|September 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|172|||Both|18 Years|60 Years|No|||February 2012|February 13, 2012|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300768||184377|
NCT00301444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI P05-A008|A Study to Test the Effectiveness of Mirror-Box and Mental Visualization Treatments on Phantom Limb Pain|A Pilot Study to Assess the Efficacy of Mirror-Box and Mental Visualization Treatments on Phantom Limb Pain||Walter Reed Army Medical Center|No|Recruiting|March 2006|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2007|June 13, 2007|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301444||184326|
NCT00312377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00032|ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer|A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC|ZODIAC|AstraZeneca||Completed|May 2006|March 2014|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1690|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|April 6, 2006|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00312377||183508|
NCT00312624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602085|Morphological Predictors of Sudden Cardiac Death in Patients With Known Cardiomyopathies|Morphological Predictors of Sudden Cardiac Death in Patients With Known Cardiomyopathies||University of Pittsburgh|Yes|Completed|April 2006|December 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with cardiomyopathy|June 2011|June 9, 2011|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312624||183489|
NCT00312637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0426|Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease|High-Resolution Axillary MRI With Magnetic Resonance Spectroscopy as a Non-Invasive Test for Determining Pathologic Lymph Node Status in Patients With Invasive Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Withdrawn|March 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|25 Years|N/A|No|||April 2012|April 27, 2012|April 6, 2006||No|Lack of funding.|No||https://clinicaltrials.gov/show/NCT00312637||183488|
NCT00308698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808|Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning Hemodialysis (HD)|Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis||Hamamatsu University||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||July 2004|March 29, 2006|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00308698||183787|
NCT00303134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105004956|Islet Cell Transplants for Diabetes|Human Islet Cell Transplantation in Type 1 Diabetic Patients||Weill Medical College of Cornell University||Suspended|August 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|8|||Both|18 Years|65 Years|No|||September 2007|December 4, 2008|March 13, 2006||||||https://clinicaltrials.gov/show/NCT00303134||184201|
NCT00303147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11438|Cognitive and Health Benefits of Expressive Writing for Family Caregivers Under Stress|||University of Toronto||Active, not recruiting|May 2003|July 2005||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 14, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303147||184200|
NCT00309296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC|Longitudinal Care: Smoking Reduction to Aid Cessation|Longitudinal Care: Smoking Reduction to Aid Cessation; Part of Hatsukami's Tobacco Exposure Reduction||Minneapolis Veterans Affairs Medical Center|No|Completed|November 2005|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|443|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2011|February 11, 2011|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00309296||183742|
NCT00309569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG-7|Randomized Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment in Receptor-Negative Patients|A Randomized Phase III Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment Hormone Receptor-Negative Breast Cancer Patients||Austrian Breast & Colorectal Cancer Study Group||Completed|October 1991|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||480|||Female|18 Years|80 Years|No|||October 1999|March 31, 2006|March 31, 2006||||No||https://clinicaltrials.gov/show/NCT00309569||183721|
NCT00305591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0406/161|Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.|Functional Magnetic Resonance Imaging and Spectroscopy of the Brain in Patients With Chronic Hepatic Encephalopathy||Imperial College London||Completed|March 2006|October 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|May 28, 2015|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00305591||184022|
NCT00305825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465198|Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery|A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer||University of California, San Francisco|Yes|Active, not recruiting|August 2004|November 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||January 2015|January 9, 2015|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00305825||184005|
NCT00303446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060113|Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)|Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy)||National Institutes of Health Clinical Center (CC)|Yes|Completed|March 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Male|18 Years|N/A|No|||January 2011|January 25, 2011|March 15, 2006||No||No|December 9, 2009|https://clinicaltrials.gov/show/NCT00303446||184177|
NCT00303459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-414|Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)|Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study|Compass-2|Actelion|Yes|Completed|May 2006|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|334|||Both|12 Years|N/A|No|||October 2015|October 16, 2015|March 16, 2006|Yes|Yes||No|January 2, 2015|https://clinicaltrials.gov/show/NCT00303459||184176|
NCT00303758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453841|Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression||Federation Francophone de Cancerologie Digestive||Completed|October 2005|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||December 2006|March 3, 2014|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00303758||184155|
NCT00300170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U65/CCU223363-02|Engagement in HIV Primary Care Services|Determinants of Engagement in HIV Primary Care Services Among Black and Hispanic Single Room Occupancy Hotel Residents in New York City||Montefiore Medical Center||Completed|October 2004|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||500|||Both|18 Years|N/A|No|||September 2005|March 31, 2006|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300170||184423|
NCT00300131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-370|ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation|Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions|ABSORB A|Abbott Vascular|Yes|Completed|March 2006|July 2011|Actual|July 2011|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary artery disease|September 2011|September 9, 2011|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300131||184425|
NCT00300157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-06|Left Main Coronary Artery Stenosis and Angioplasty With Taxus Stent|French Multicenter Study Assessing Angioplasty With Taxus Drug Eluting Stent in Unprotected Left Main Coronary Artery Associated to Other Coronary Lesions or Not||French Cardiology Society|Yes|Completed|December 2005|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|N/A|No|||January 2011|January 3, 2011|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300157||184424|
NCT00300430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-758|Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.|A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia||Abbott|No|Completed|September 2006|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1911|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|March 7, 2006|Yes|Yes||No|March 10, 2009|https://clinicaltrials.gov/show/NCT00300430||184403|This was an open-label study designed to assess the longer-term safety of the combination therapies. Evaluation of efficacy outcomes was a secondary objective.
NCT00300443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-031|Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|December 2005|June 2007|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|561|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|March 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00300443||184402|
NCT00300807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XTL2005-16|Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection|A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection||XTL Biopharmaceuticals||Active, not recruiting|October 2005|April 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|65 Years|No|||March 2007|March 6, 2007|March 7, 2006||||||https://clinicaltrials.gov/show/NCT00300807||184374|
NCT00300794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT N1 V1_5|Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia|||Vilnius University||Completed|February 2003|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|35 Years|No|||November 2006|November 13, 2006|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00300794||184375|
NCT00301119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456198|Lung Cancer Biomarkers and Screening|NYU Lung Cancer Biomarker Center|NYULCBC|New York University School of Medicine|Yes|Recruiting|May 2000|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|6860|Samples With DNA|blood serum, plasma, urine, sputum, BAL, lung tissue, buccal swab|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects at risk for lung cancer and controls from community, private physician        referrals, local trade unions, employee health fairs, word of mouth and print        advertisements.        patient referrals from physician outpatient offices and inpatients with CT findings        suspicious for lung cancer.|September 2015|September 23, 2015|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00301119||184350|
NCT00302081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03548|Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)|Comparison of Three Regimens of PEG-Intron and Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients||Merck Sharp & Dohme Corp.|No|Completed|August 2003|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|696|||Both|18 Years|70 Years|No|||April 2015|April 7, 2015|March 10, 2006||No||No|April 29, 2009|https://clinicaltrials.gov/show/NCT00302081||184281|
NCT00302094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 11-107/03|Image Fusion PET, CT and 3D-ultrasound Examinations|Image Fusion PET, CT and 3D-ultrasound Examinations in Treatment of Anal Cancer||Rigshospitalet, Denmark||Completed|June 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Probability Sample|Patients with anal cancer|November 2012|November 29, 2012|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302094||184280|
NCT00312650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0120|Doxil and Gemcitabine in Recurrent Ovarian Cancer|A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer||Women and Infants Hospital of Rhode Island||Terminated|April 2006|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Female|18 Years|N/A|No|||January 2015|January 9, 2015|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312650||183487|
NCT00312663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1250|Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America|A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS01B Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States||U.S. Army Medical Research and Materiel Command|Yes|Completed|April 2006|April 2007|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|April 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00312663||183486|
NCT00308438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-009|Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008|An Open Label Extension Study of the Safety and Efficacy of ALX-0600 in Subjects With Crohn's Disease Who Completed the Pilot Study Protocol CL0600-008||Shire|No|Completed|March 2004|June 2006|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||January 2015|November 10, 2015|September 13, 2005|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00308438||183807|
NCT00308711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso-Obs-004|Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor|A Multi-center, Randomized, Double-blind Phase III Study of the Efficacy and Safety of the Misoprostol Vaginal Insert Compared to Cervidil for Women Requiring Cervical Ripening and Induction of Labor (The MVP Study).||Ferring Pharmaceuticals|Yes|Completed|April 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1308|||Female|18 Years|N/A|No|||June 2012|June 15, 2012|March 27, 2006|Yes|Yes||No|July 29, 2009|https://clinicaltrials.gov/show/NCT00308711||183786|
NCT00303966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02688|Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|A Phase II Study of BAY 43-9006 in Relapsed Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Terminated|November 2005|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2014|April 17, 2014|March 15, 2006|Yes|Yes|Slow accrual|No|November 8, 2013|https://clinicaltrials.gov/show/NCT00303966||184139|Early termination leading to small number of subjects
NCT00309309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLITA-TX|Metabolic and Renal Effects of Rosiglitazone in Kidney Transplant|A Prospective, Longitudinal Study to Assess the Metabolic and Renal Effects of Rosiglitazone in Albuminuric Kidney Transplant Recipients||Mario Negri Institute for Pharmacological Research|No|Completed|April 2005|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|18 Years|70 Years|No|||July 2007|July 2, 2007|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00309309||183741|
NCT00302848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG 2000_1|European Active Surveillance Study (EURAS)|The European Active Surveillance Study on OC Prescribing Practice, Benefits and Safety (EURAS)||Center for Epidemiology and Health Research, Germany|Yes|Completed|November 2000|December 2005||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|59510|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women prescribed hormonal contraceptives|November 2009|November 6, 2009|March 13, 2006||||No|June 23, 2009|https://clinicaltrials.gov/show/NCT00302848||184222|This is an observational study. The possibility of bias and residual confounding cannot be entirely eliminated.
NCT00303173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16081|The Relaxation and Blood Pressure in Pregnancy (REBIP) Study|A Randomized Controlled Trial of The Effectiveness of Guided Imagery on Blood Pressure in Hypertensive Pregnant Women: The Relaxation and Blood Pressure in Pregnancy (REBIP) Pilot Study||University of Toronto|No|Completed|August 2004|February 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Female|N/A|N/A|No|||June 2008|June 23, 2008|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00303173||184198|
NCT00299533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000025/14|Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy|A Randomized, Double-blind, Placebo-controlled, Prospective Study Evaluating the Usefulness of Polyunsaturated Fatty Acids (PUFA) in Patients Wtih Uncontrolled Epilepsy||Brigham and Women's Hospital||Completed|February 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299533||184471|
NCT00299546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006334|A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)||Centocor, Inc.|Yes|Completed|February 2006|May 2012|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|461|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|March 3, 2006|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00299546||184470|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00299871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6012|Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus|A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus||Sanofi||Completed|February 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|542|||Both|30 Years|75 Years|No|||January 2014|January 27, 2014|March 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00299871||184445|
NCT00299897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP01A-111-05|SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Orally Administered SP01A for 28 Days as Monotherapy Treatment in HIV-Infected Patients With Evidence of Resistance to Currently Available Antiretroviral Therapy||Samaritan Pharmaceuticals, Inc||Active, not recruiting|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|60 Years|No|||October 2006|October 25, 2006|March 3, 2006||||||https://clinicaltrials.gov/show/NCT00299897||184443|
NCT00299910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor388505ctil|Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing|Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing||Soroka University Medical Center||Recruiting|March 2005|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|2 Years|10 Years||||May 2008|May 20, 2008|March 6, 2006||||No||https://clinicaltrials.gov/show/NCT00299910||184442|
NCT00300456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-749|Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia||Abbott|No|Completed|March 2006|||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|657|||Both|18 Years|N/A|No|||May 2009|May 29, 2009|March 7, 2006|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00300456||184401|
NCT00300469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-750|Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia||Abbott|No|Completed|March 2006|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|613|||Both|18 Years|N/A|No|||June 2009|June 1, 2009|March 7, 2006|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00300469||184400|
NCT00300820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060108|Perspectives of Individuals With Bipolar Disorder and Siblings of Individuals With Bipolar Disorder; A Telephone Interview Study|Seeking Genetic Counseling: What Motivates Families At Risk For Psychiatric Illness?||National Institutes of Health Clinical Center (CC)||Completed|March 2006|February 2008||||N/A|Observational|N/A||||50|||Both|18 Years|N/A|No|||February 2008|September 26, 2015|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300820||184373|
NCT00301145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455745|Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking|Treatment of Nicotine Dependence in a Health Care Setting||National Cancer Institute (NCI)||Completed|October 2005|November 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|1200|||Both|18 Years|N/A|No|||September 2007|December 18, 2013|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00301145||184349|
NCT00301431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A4-327|Study Evaluating the Efficacy of DVS-233 in Fibromyalgia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design, Efficacy and Tolerability Study of 4 Fixed Doses of DVS-233 in Adult Outpatients With Fibromyalgia Syndrome||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|August 2006|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1050|||Both|18 Years|N/A|No|||December 2007|December 3, 2007|March 8, 2006||||||https://clinicaltrials.gov/show/NCT00301431||184327|
NCT00301171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|370|Treatment of Persistent Wheezing in Infants and Children|Respiratory Function in Infants With Persistent Wheezing||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2003|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|54|||Both|N/A|36 Months|No|||December 2007|December 12, 2007|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301171||184347|
NCT00302107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-019-05F|A Placebo-Controlled Study of Mirtazapine for PTSD|A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans||VA Office of Research and Development|Yes|Completed|April 2006|June 2012|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|March 9, 2006|Yes|Yes||No|January 3, 2014|https://clinicaltrials.gov/show/NCT00302107||184279|Small sample of predominantly male combat veterans limits generalizability of findings.
NCT00312676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7332.55b|Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote|Conversion From Multiple-Daily Dose Enteric-Coated Depakote to Once-Daily Depakote ER in Elderly Outpatients With Epilepsy or Behavioral Disturbances:||Veterans Affairs Medical Center, Miami||Recruiting|March 2006|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|60 Years|90 Years|No|||March 2006|April 6, 2006|April 6, 2006||||No||https://clinicaltrials.gov/show/NCT00312676||183485|
NCT00312689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Record 1|Microbiological Examination of Children Operated for Congenital Lacrimal Stenosis|Microbiological Examination of Children Operated for Congenital Lacrimal Stenosis||University Hospital Muenster||Active, not recruiting|March 2006|April 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||120|||Both|N/A|14 Years|No|||April 2007|April 11, 2007|April 7, 2006||||No||https://clinicaltrials.gov/show/NCT00312689||183484|
NCT00308451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N21 CPB-03001|A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM|”A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Study to Evaluate the Improvement in Glycemic Control After Daily Administration of Chromium Picolinate and Biotin in Patients With Type 2 Diabetes Mellitus”||Nutrition 21, Inc.||Completed|November 2003|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||March 2006|March 27, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308451||183806|
NCT00301340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03-2005|Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice|An Open Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice||Summers Laboratories||Completed|March 2006|||||Phase 3|Interventional|Primary Purpose: Treatment||||200|||Both|6 Months|N/A|No|||May 2007|May 25, 2007|March 8, 2006||||||https://clinicaltrials.gov/show/NCT00301340||184334|
NCT00311922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 060128|Improving Care for Patients With Diabetes and Poor Numeracy Skills|Improving Care for Patients With Diabetes and Poor Numeracy Skills||Vanderbilt University|No|Completed|March 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|106|||Both|18 Years|80 Years|No|||February 2008|February 15, 2008|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00311922||183543|
NCT00303420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2003:119|Alteplase for Blood Flow Restoration in Hemodialysis Catheters|Alteplase for Blood Flow Restoration in Hemodialysis Catheters: A Randomized Prospective Clinical Trial||University of Manitoba|Yes|Terminated|September 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||December 2008|December 17, 2008|March 15, 2006||No|Unable to enrol enough people to achieve the full sample size|No||https://clinicaltrials.gov/show/NCT00303420||184179|
NCT00299468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290-00-0013|The Effect of the Patient Activation Measure on Chronic Care|Using the Patient Activation Measure (PAM) to Improve Patient Self-Management of Hypertension||Weill Medical College of Cornell University||Completed|April 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|283|||Both|21 Years|N/A|No|||May 2006|March 12, 2008|March 2, 2006||||No||https://clinicaltrials.gov/show/NCT00299468||184476|
NCT00299481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-44017|Tissue Bank of Biological Specimens From Patients With Gynecologic Disease|Tissue and Data Acquisition Activity for the Study of Gynecological Disease||Walter Reed Army Medical Center||Recruiting|March 2006|January 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|7000|||Female|18 Years|N/A|No|||June 2008|June 26, 2008|March 2, 2006||||No||https://clinicaltrials.gov/show/NCT00299481||184475|
NCT00303199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL2001|Study of ZIO-101 in Multiple Myeloma|A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma||Ziopharm||Completed|January 2006|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|March 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303199||184196|
NCT00303771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453855|Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer||Federation Francophone de Cancerologie Digestive|Yes|Completed|June 2003|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|282|||Both|75 Years|N/A|No|||December 2006|March 3, 2014|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00303771||184154|
NCT00299247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-246|SP Resistance and Falciparum Malaria Transmission|SP Resistance Markers and Falciparum Malaria Transmission||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||December 2006|Anticipated|December 2006|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|5 Years|N/A|No|||January 2010|August 26, 2010|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299247||184493|
NCT00289289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217|Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)|Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)||Medtronic Cardiac Rhythm Disease Management|No|Completed|February 2004|July 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|400|||Both|N/A|N/A|No|||June 2012|June 25, 2012|February 7, 2006|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00289289||185231|The effect of ON programming was not consistent across randomized study period, violating a key assumption of the cross-over study design.
NCT00289549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-Bo-05-204|Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)|Phase II Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)||BioCryst Pharmaceuticals||Completed|June 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|February 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00289549||185211|
NCT00289562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-Bi-04-106|Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia|A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride||BioCryst Pharmaceuticals||Completed|September 2004|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2012|January 19, 2012|February 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00289562||185210|
NCT00289848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-040|MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|March 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|530|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|February 7, 2006|Yes|Yes||No|March 18, 2010|https://clinicaltrials.gov/show/NCT00289848||185189|
NCT00289861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-000584|Risperidone Augmentation in Patients With Schizophrenia|Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine||Massachusetts General Hospital|No|Completed|February 2003|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||October 2013|October 29, 2013|February 8, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00289861||185188|
NCT00286286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABHN0635|Intraperitoneal Aerosolized Delivery of a Local Anesthetic for Post Operative Pain Management. A Double Blind, Randomised Controlled Clinical Trial.|Clinical Protocol for the Prospective Double Blind Randomised Controlled Trial for the Use of Intraperitoneal Aerosolized Local Anesthetic||Northgate Technologies||Active, not recruiting|February 2006|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||January 2007|January 9, 2007|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286286||185461|
NCT00286299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2005.1507|Treatment Effects From Aerobic Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia|Physiological and Psychiatric Effects From Aerobic High Intensity Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia: A Controlled Clinical Trial.||Norwegian University of Science and Technology|No|Completed|October 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|20 Years|65 Years|No|||March 2016|March 15, 2016|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00286299||185460|
NCT00286832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG PET Study|Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV|Evaluation of Response to Treatment Using 18F-FDG Positron Emission Tomography Imaging (PET) With Special Emphasize on the Prognostic Significance of Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV||Copenhagen University Hospital at Herlev|Yes|Completed|August 2005|January 2011|Actual|January 2011|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample according to the area covered by the participating centers|July 2011|July 2, 2011|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00286832||185420|
NCT00287131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3518-JS-CTIL|Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients|Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients||Sheba Medical Center|No|Recruiting|January 2006|November 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00287131||185397|
NCT00287144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|399702|Post Partum Thyroiditis 2: Long Term Observations|Observations of Leng Term Effects From Post Partum Thyroiditis.||Sykehuset Telemark||Active, not recruiting|November 2002|December 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2005|February 2, 2006|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287144||185396|
NCT00287079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 26222|A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome|A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebif®) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS)|CIS-ON|Merck KGaA||Completed|October 2005|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Months|65 Years|No|||December 2013|December 2, 2013|February 2, 2006|No|Yes||No|February 2, 2012|https://clinicaltrials.gov/show/NCT00287079||185401|
NCT00287092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5I15|Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants|A Randomised, Controlled, Double-Blind Study of the Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Compared To Infanrix®-IPV+Hib When Both Vaccines Are Given to Infants Using a Three Dose Immunisation Schedule ("Nordic Schedule" 3-5-12 Months)||Sanofi||Completed|February 2006|September 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|807|||Both|80 Days|120 Days|Accepts Healthy Volunteers|||January 2015|January 6, 2015|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287092||185400|
NCT00287612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 12-150|Necessity of Esophageal Dissection During Laparoscopic Fundoplication|Prospective Trial Comparing Utility of Esophageal Crural Dissection During Laparoscopic Fundoplication in Children||Children's Mercy Hospital Kansas City|Yes|Completed|February 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|177|||Both|N/A|18 Years|No|||March 2009|September 21, 2009|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00287612||185360|
NCT00284557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|416-2005|A Primary Care Behavioral Approach for Addressing Childhood Overweight|Evaluation of a Primary Care-Based Behavioral Intervention for Improving Physical Activity and Nutrition Behaviors Among High-Risk African-American Youth||Emory University|No|Completed|January 2006|July 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|7 Years|11 Years|No|||June 2012|June 29, 2012|January 30, 2006||No||No|May 25, 2012|https://clinicaltrials.gov/show/NCT00284557||185591|
NCT00284843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0118|Prevalence of RHD, Pyoderma and Scabies in Children in Fiji|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 1: The Prevalence of Rheumatic Heart Disease, Pyoderma and Scabies in School Children in Fiji||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2006|June 2007||||N/A|Observational|Time Perspective: Prospective||||5200|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||October 2007|January 24, 2008|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00284843||185569|
NCT00284856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-332|Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes||Merck Sharp & Dohme Corp.|No|Completed|May 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1640|||Both|18 Years|55 Years|No|||March 2015|March 27, 2015|January 31, 2006|Yes|Yes||No|April 6, 2011|https://clinicaltrials.gov/show/NCT00284856||185568|
NCT00285129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/338|Primary Ceramic-on-Ceramic Total Hip Replacement Versus Metal-on-Metal Hip Resurfacing in Young Active Patients|Primary Ceramic-on-Ceramic Total Hip Replacement Versus Metal-on-Metal Hip Resurfacing in Young Active Patients||University Hospital, Ghent|No|Completed|January 2004|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|No|||December 2007|December 19, 2007|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285129||185547|
NCT00285103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC2996-101|SPC2996 in Chronic Lymphocytic Leukaemia|An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia||Santaris Pharma A/S|Yes|Completed|June 2005|December 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||February 2011|February 1, 2011|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00285103||185549|
NCT00285116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/204|The Correlation Between Fasicitis Plantaris and Hallux Rigidus|The Correlation Between Fasicitis Plantaris and Hallux Rigidus||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|60|||Both|40 Years|65 Years|No|||February 2009|May 18, 2009|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285116||185548|
NCT00281567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.250|Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|August 2002|||July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|76|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00281567||185816|
NCT00281580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.1|Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension|A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study||Boehringer Ingelheim||Completed|April 2006|||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|16||Actual|1461|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|January 24, 2006||||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00281580||185815|
NCT00281151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1198|Center for Reducing Asthma Disparities - Meharry/Vanderbilt Centers|Center for Reducing Asthma Disparities - Meharry/Vanderbilt Centers||Vanderbilt University|Yes|Completed|September 2002|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|180|||Female|N/A|60 Years|No|Non-Probability Sample|This study will enroll pregnant women with asthma, children requiring intensive care unit        (ICU) admission for asthma, and asthmatics requiring emergency care.|February 2009|December 10, 2014|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281151||185847|
NCT00281177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199|Center for Reducing Asthma Disparities - Northwestern University/Cook County Hospital Centers|Center for Reducing Asthma Disparities - Northwestern University/Cook County Hospital Centers||National Heart, Lung, and Blood Institute (NHLBI)||Active, not recruiting|September 2002|July 2007||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2006|June 30, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281177||185846|
NCT00281541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-008|A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma|A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma||Astellas Pharma Inc|No|Completed|November 2005|June 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|January 23, 2006||||No||https://clinicaltrials.gov/show/NCT00281541||185818|
NCT00281554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-7-012|Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation|A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation|ACT 4|Astellas Pharma Inc|No|Completed|October 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|254|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|January 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00281554||185817|
NCT00282295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105753|US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease|Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents||GlaxoSmithKline||Completed|January 2006|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Actual|1376|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282295||185761|
NCT00282308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3374g|A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate|A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate|SIERRA|Genentech, Inc.||Completed|January 2006|February 2009|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|65 Years|No|||August 2013|August 19, 2013|January 24, 2006|Yes|Yes||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00282308||185760|
NCT00289328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK60030 (completed)|Glucocorticoid-induced Osteopenia in Children|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|November 2001|April 2006|Actual|||N/A|Observational|Time Perspective: Prospective||||550|||Both|5 Years|21 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289328||185228|
NCT00289003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-907-SBG-1-02-HN|The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients|An Exploratory, Randomised, Parallel Group Study, Comparing the Protective Effect of Soluble Beta-1,3/1,6-Glucan or Placebo in Oral Mucositis in Head and Neck Cancer Patients Receiving Radiation Therapy or Chemoradiotherapy||Biotec Pharmacon ASA||Completed|October 2003|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||May 2006|January 15, 2007|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289003||185253|
NCT00289016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002/03|A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma|A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma||BioVex Limited|Yes|Completed|December 2005|May 2009|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|February 8, 2006|Yes|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT00289016||185252|
NCT00289302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196|InSync Implantable Cardioverter Defibrillator Registry: Cardiac Resynchronization Therapy|InSync Implantable Cardioverter Defibrillator Registry: Cardiac Resynchronization Therapy||Medtronic Cardiac Rhythm Disease Management||Completed|January 2003|December 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||600|||Both|18 Years|N/A|No|||September 2006|October 3, 2007|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00289302||185230|
NCT00289315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA Health|LA Health Project HIPTeens Project (a Secondary Prevention Program) and the Wise Mind Project (a Primary Prevention Program).|LA Health: A Prospective Study of Primary and Secondary Obesity Prevention in Children and Adolescents||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|August 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2709|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00289315||185229|
NCT00289575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63|MBCP Safety and Performance in the Osteonecrosis of Femur Head|Evaluation of Safety and Performance of Macroporous Biphasic Calcium Phosphate Granules Combined With Cellulosic-Derived Gel, in Filling Bones Gap After Aseptic Osteonecrosis Biopsy of Femur Head.||Biomatlante|No|Recruiting|February 2006|February 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|50 Years|No|||March 2007|March 1, 2007|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00289575||185209|
NCT00285688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-CMR-002|Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital|Antibiotic Resistance Helicobacter Pylori and Clarithromycin Resistance Mutation in Helicobacter Pylori in Rajavithi Hospital||Rajavithi Hospital|Yes|Recruiting|June 2006|December 2008|Anticipated|||Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Gastric Biopsy tissue and H. pylori DNA|Both|15 Years|N/A|No|Non-Probability Sample|Dydpepsia patient with gastroscopic examination|August 2008|August 2, 2008|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285688||185507|
NCT00286312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2005-02|Myocardial Infarction Size Reduction With Atorvastatin|Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study||R&D Cardiologie|No|Completed|February 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00286312||185459|
NCT00286559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/05|Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)|Feasibility and Accuracy of Transoesophageal Harmonic Contrast Echocardiography in Assessing Myocardial Blood Flow and Blood Flow Reserve||University Hospital, Basel, Switzerland|Yes|Withdrawn|August 2006|December 2008||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|February 2, 2006||No|echo contrast agents no longer allowed in CAD patients.|No||https://clinicaltrials.gov/show/NCT00286559||185440|
NCT00287157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol C2/5/TZ-TBI-01|Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)|A Double-Blind, Randomized, Two-Way Crossover, Comparative Study to Evaluate the Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl Versus Placebo in Children With Chronic Traumatic Brain Injury||Teva GTC||Completed|December 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|5|||Both|8 Years|18 Years|No|||September 2007|January 20, 2009|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287157||185395|
NCT00287378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC-2423|Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab|Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab||University of North Carolina, Chapel Hill|Yes|Terminated|March 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|1|||Both|18 Years|50 Years|No|||February 2009|June 26, 2009|February 3, 2006|Yes|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00287378||185378|
NCT00287365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC-2371|Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers|Glutathione S Transferase M1 (GSTM1) Genotype Associated Susceptibility to Airway Response to Ozone in Mild Asthmatic Volunteers.|Glutoz|University of North Carolina, Chapel Hill|No|Active, not recruiting|January 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|50 Years|No|||June 2015|July 16, 2015|February 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00287365||185379|
NCT00284869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK255/2005|Ethnic Differences in the Inflammatory Response in Systemic Inflammation|Ethnic Differences in the Inflammatory Response in Systemic Inflammation||Medical University of Vienna||Completed|January 2006|April 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||32|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2006|September 11, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284869||185567|
NCT00285142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF7715|Effect of Rosiglitazone|Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers||University Hospital, Montpellier||Completed|June 2004|November 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2006|October 5, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285142||185546|
NCT00285415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EndoRT|A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation|A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation for Stage III/IV Endometrial Carcinoma||Carilion Clinic||Completed|April 2005|June 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|18 Years|N/A|No|||October 2013|October 24, 2013|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285415||185527|
NCT00285428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hA20-01|Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma|A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma||Immunomedics, Inc.|No|Completed|September 2004|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|January 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00285428||185526|
NCT00285441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-278477|Identification of Cytokine Profiles and T Cell Subsets Among Immunosuppressed Patients at Risk of Developing Active Tuberculosis|||Hvidovre University Hospital||Recruiting|November 2005|September 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||60|||Both|18 Years|N/A|No|||December 2005|February 27, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285441||185525|
NCT00281840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6304|Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase II Study of Bevacizumab in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck||Case Comprehensive Cancer Center|Yes|Completed|September 2005|December 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|January 24, 2006|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT00281840||185796|
NCT00281827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002LS013|Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer|Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer||Masonic Cancer Center, University of Minnesota|Yes|Terminated|May 2002|July 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|January 24, 2006|Yes|Yes|Due to drug unavailability|No|June 23, 2009|https://clinicaltrials.gov/show/NCT00281827||185797|
NCT00282620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLUG001817HE|Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.|The Adjuvant Magnesium Trial (AdMag): Assessment if the Impact of Oral Magnesium on ICD Firing and Quality of Life||Hartford Hospital||Recruiting|January 2006|June 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|N/A|No|||March 2007|November 16, 2007|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282620||185736|
NCT00289341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA 0466|Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.|A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/LNCaP) Administered Subcutaneously to Prostate Cancer Patients.||Rockefeller University|No|Completed|March 2002|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|N/A|No|||January 2013|January 11, 2013|February 7, 2006|Yes|Yes||No|August 8, 2011|https://clinicaltrials.gov/show/NCT00289341||185227|
NCT00289588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2004.163|An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers|An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial||Brooke Army Medical Center||Completed|January 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3000|||Both|17 Years|60 Years|Accepts Healthy Volunteers|||December 2005|February 13, 2006|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00289588||185208|
NCT00285701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCCO101/05|Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study|Early Detection of Pre-malignant and Malignant Conditions in the Colon by Means of Fluorescence Endoscopy Using Local and Oral Sensitisation With Hexaminolevulinate (HAL) - a Dose Finding Study||Photocure||Completed|July 2006|March 2008|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|38|||Both|18 Years|85 Years|No|||January 2010|January 14, 2010|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285701||185506|
NCT00285714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3D_MKC590_JP01|3D Imaging of Hard and Soft Tissue in Orthognathic Surgery|An Analysis of the Clinical Applicability of a Three-Dimensional Imaging Platform Used to Register the Influence of Orthognathic Surgery on Facial Hard and Soft Tissue in Patients With Congenital Maxillofacial Deformities.||Radboud University||Recruiting|February 2006|December 2010|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|450|||Both|15 Years|N/A|No|||July 2007|July 26, 2007|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00285714||185505|
NCT00286013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/196|Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma|Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma||University Hospital, Ghent|No|Suspended|May 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|February 1, 2006|||Study suspended because of safety reasons|No||https://clinicaltrials.gov/show/NCT00286013||185482|
NCT00286026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1079-17254|Azithromycin in Control of Trachoma II|Azithromycin in Control of Trachoma II||University of California, San Francisco|No|Withdrawn|June 2005|August 2009|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2012|April 12, 2012|January 31, 2006||No|Prevalence of infection for screened population too low (<7%) to enroll anyone.|No||https://clinicaltrials.gov/show/NCT00286026||185481|
NCT00286338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|des.prost-1|Comparison of Monitors of Fluid Therapy|Comparison of Monitors of Fluid Therapy||Rigshospitalet, Denmark||Completed|February 2006|April 2006|Actual|||Phase 4|Observational|Time Perspective: Prospective||||12|||Male|18 Years|70 Years|No|||January 2009|January 13, 2009|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286338||185457|
NCT00286364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 01.2005-05-20|Short-Term Androgen Priming Before COS Using Aromatase Inhibitor and hCG During Early-Follicular-Phase GnRH Antagonist Administration - a Randomized Controlled Trial|||Rigshospitalet, Denmark||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|39 Years|No|||April 2007|April 20, 2007|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286364||185455|
NCT00286572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129/03|Long-term Mortality in Diabetics Undergoing Major Surgery|Comparison in Survival in Patients With Insulin-dependent and Non-insulin-dependent Diabetes Mellitus With Known or Suspected Coronary Artery Disease Undergoing Major Non-cardiac Surgery||University Hospital, Basel, Switzerland|Yes|Completed|January 2004|August 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|380|||Both|18 Years|N/A|No|Probability Sample|Patients with treated diabetes mellitus undergoing surgery with major risk or patients        with treated diabetes mellitus and known coronary artery disease undergoing surgery with        major or intermediate risk|March 2015|March 9, 2015|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00286572||185439|
NCT00287391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLEEP|Sleep Disorders and Gastroesophageal Reflux Disease (GERD)|The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia.||University of North Carolina, Chapel Hill|No|Completed|September 2004|December 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2007|April 25, 2007|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00287391||185377|
NCT00287664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAHRS|Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin|Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study||Hospital Clinic of Barcelona||Suspended|February 2002|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|75 Years|No|||April 2007|April 10, 2007|February 3, 2006|||because in a preliminary analysis we would need 1000 patients per group to achieve    significative differences in the main end point.|No||https://clinicaltrials.gov/show/NCT00287664||185356|
NCT00287651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-06|Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus|Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy||Florida Atlantic University|Yes|Terminated|November 2005|June 2012|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||August 2009|August 25, 2009|February 6, 2006||No|Administrative|No||https://clinicaltrials.gov/show/NCT00287651||185357|
NCT00287339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ COUGH|The Utility of Nexium in Chronic Cough and Reflux Disease|Chronic Cough and Reflux Disease: A Randomized, Double-Blinded, Placebo Controlled Trial of High Dose Proton Pump Inhibition||University of North Carolina, Chapel Hill|No|Completed|September 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 6, 2012|February 3, 2006|Yes|Yes||No|May 11, 2011|https://clinicaltrials.gov/show/NCT00287339||185381|This study was performed at a single center, and participants were mostly female and white, which may limit generalizability. The number of subjects in some patient subgroups was small.
NCT00287352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1D-MC-X273|Study of Amantadine for Weight Stabilization During Olanzapine Treatment|Double Blind Placebo Controlled Investigation of Amantadine for Retarding Weight Gain in First Episode Adlt Psychotic Subjects Beginning Therapy With Olanzapine.||University of North Carolina, Chapel Hill|Yes|Completed|May 2005|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||April 2011|April 29, 2011|February 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287352||185380|
NCT00285155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF7759|Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers|Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers||University Hospital, Montpellier||Completed|November 2004|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2007|August 8, 2007|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285155||185545|
NCT00285454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amanda Heinl-Green|Cell Repair in Heart Failure|A Phase I/II, Randomised, Double-blind, Placebo Controlled, Single-centre Study of Bone Marrow Mononuclear Cells by Percutaneous Retrograde Coronary Venous Delivery to Patients With Ischaemic Heart Failure and no Standard Revascularisation Options.||Imperial College London||Withdrawn|January 2006|December 2008|Anticipated|February 2006|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|80 Years|No|||March 2015|March 30, 2015|January 27, 2006|||no funding|No||https://clinicaltrials.gov/show/NCT00285454||185524|
NCT00281203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1327|Comparison of Alveolar Macrophages in Healthy Individuals Versus Individuals With COPD|Innate and Adaptive Immunity in COPD Exacerbations: Bronchoscopies on Healthy Volunteers||University of Michigan|No|Completed|September 2005|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|July 2013|July 15, 2013|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281203||185844|
NCT00282074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3945-JK-CTIL|Evaluating Changes in Spermatogram Following Bilateral Laparoscopic Inguinal Hernia Repair in Fertile Males|Prospective Trial to Evaluate Changes in Spermatogram Following Bilateral Laparoscopic Inguinal Hernia Repair in Males in the Fertility Age||Sheba Medical Center||Terminated|January 2006|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Male|18 Years|40 Years|No|||January 2007|January 23, 2007|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282074||185778|
NCT00282048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061023|Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer|Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer||Pfizer|No|Completed|March 2006|June 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|January 23, 2006|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00282048||185780|Population pharmacokinetics was not presented, as the data was not available for the single study and data of other axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.
NCT00282061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3497-YD-CTIL|Synchronization and Desynchronization Between Circadian Rhythms in Patients With Delayed Sleep Phase Syndrome (DSPS)|||Sheba Medical Center||Recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|22 Years|50 Years|No|||January 2006|December 14, 2006|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282061||185779|
NCT00289354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N 21 CPB-02003|Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM|Randomized, Double Blinded, Placebo Controlled, Study to Evaluate Improvements in Glycemic Control, Lipid Levels, Quality of Life and Healthcare Costs After Daily Administration of Chromium Picolinate and Biotin in Patients With T2DM||Nutrition 21, Inc.||Completed|March 2003|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|70 Years|No|||February 2006|February 7, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00289354||185226|
NCT00289614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP 105|Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)|Patients With Renal Impairment and Diabetes Undergoing Computed Tomography||Bracco Diagnostics, Inc||Completed|January 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|350|||Both|18 Years|N/A|No|||January 2008|January 3, 2008|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289614||185206|
NCT00289601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESISTOR|Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty|Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance||Brigham and Women's Hospital|Yes|Terminated|March 2006|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1200|||Both|21 Years|N/A|No|||July 2007|July 19, 2007|February 8, 2006|||Sponsor support withdrawn|No||https://clinicaltrials.gov/show/NCT00289601||185207|
NCT00285727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2969|Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression|Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression||Stanford University||Completed|January 2006|October 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||May 2008|May 16, 2008|January 31, 2006||||||https://clinicaltrials.gov/show/NCT00285727||185504|
NCT00286039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/163|Plasma Citrulline Level in Relation to Absorptive Surface|Plasma Citrulline Level in Relation to Absorptive Surface||University Hospital, Ghent|No|Completed|August 2005|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|18 Years|No|||September 2011|September 29, 2011|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286039||185480|
NCT00286052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB File: 1002-605|Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients|The Impact of Concomitant Ultra Low Dose Infusion Naloxone and Therapeutic Infusion Opioid on Opioid Requirements in Pediatric ICU Patients||University of Texas Southwestern Medical Center||Completed|December 2002|August 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||128|||Both|N/A|18 Years||||September 2005|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00286052||185479|
NCT00286325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013763|Rituximab in the Treatment of Patients With Bullous Pemphigoid|Rituximab in the Treatment of Patients With Bullous Pemphigoid||Duke University|No|Completed|March 2005|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||September 2012|April 9, 2013|February 1, 2006|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00286325||185458|Open label trial of rituximab in the treatment of 7 patients with the autoimmune blistering disease bullous pemphigoid.
NCT00286585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261/05|TEAM-Project: Trial on the Effect of Anesthetics on Morbidity and Mortality|Multi-Center Trial on the Effect of Anesthetics on Morbidity and Mortality in Patients Undergoing Major Non-cardiac Surgery||University Hospital, Basel, Switzerland|Yes|Completed|February 2006|November 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|385|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00286585||185438|
NCT00286845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diatech Leuk II Vand|Use of the MiCK Assay for Apoptosis in AML|Use of the MiCK Assay for Apoptosis to Predict Complete Remission in Acute Myeloid Leukemia||DiaTech Oncology|No|Completed|January 2006|December 2009|Actual|||Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patient population will include newly diagnosed AML patients with both de novo AML and AML        arising from a previously diagnosed myelodysplastic syndrome. The study will not include        patients with previously treated leukemia that has relapsed|January 2012|January 25, 2012|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00286845||185419|
NCT00287677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIHCREC01|Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients|Double Strategy to Induce and Expand the T Cell Repertoire by the Administration of Growth Hormone and Vaccination in HIV-1 Infected Patients||Germans Trias i Pujol Hospital|No|Completed|January 2006|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||November 2009|November 3, 2009|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00287677||185355|
NCT00288327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U48/CCU409660|NC Enhanced WISEWOMAN Project|Testing Lifestyle Interventions for CVD Risk Reduction in Older, Underserved Women; Enhanced WISEWOMAN Project||University of North Carolina, Chapel Hill|No|Completed|March 2003|January 2005|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|258|||Female|40 Years|64 Years|No|||March 2009|March 12, 2009|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288327||185305|
NCT00287859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS039|Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|Phase I Study of Weekly Topotecan in Women With Progressive or Recurrent Ovarian Cancer and a Poor Performance Status||Masonic Cancer Center, University of Minnesota|Yes|Terminated|August 2004|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||January 2010|January 20, 2010|February 6, 2006|No|Yes|Withdrawn due to low accrual|No||https://clinicaltrials.gov/show/NCT00287859||185341|
NCT00287638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/ko/2006/002|Markers in Exhaled Breath Condensate in Obstructive Sleep Apnoea (OSA) Patients|To Assess the Differences in Chemokines and Oxidative Stress Markers in Exhaled Breath Condensate of Obstructive Sleep Apnoea Patients||Chinese University of Hong Kong||Completed|January 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||January 2010|January 21, 2010|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00287638||185358|
NCT00285467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508-06|Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease Stage Three and Four|Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease Stage Three and Four||Indiana University||Completed|January 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|82 Years|No|||October 2011|October 12, 2011|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285467||185523|
NCT00281216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1324|Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations|Innate and Adaptive Immunity in COPD Exacerbations: Prospective Cohort Study||University of Michigan|No|Completed|September 2005|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|serum, sputum|Both|40 Years|80 Years|No|Non-Probability Sample|Recruited from pulmonary and general medicine clinics|January 2016|January 28, 2016|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281216||185843|
NCT00281593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1236.1|Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension|A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study||Boehringer Ingelheim||Completed|April 2006|||April 2007|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|1354|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|January 24, 2006||||||https://clinicaltrials.gov/show/NCT00281593||185814|
NCT00282087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC005|Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma|Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial||Sarcoma Alliance for Research through Collaboration|Yes|Completed|January 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|N/A|No|||November 2014|November 23, 2014|January 24, 2006||No||No|July 19, 2013|https://clinicaltrials.gov/show/NCT00282087||185777|
NCT00282321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2006.01.TGK|High-protein and High-carbohydrate Diets' Effect on Urinary Concentrating Ability|||Regional Hospital Holstebro||Completed|May 2007|June 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 19, 2010|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282321||185759|
NCT00282334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.2004.01.LBM|A Comparison of Telemedical and Conventional Antihypertensive Treatment|A Comparison of Telemedical and Conventional Antihypertensive Treatment||Regional Hospital Holstebro|No|Completed|May 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Both|20 Years|80 Years|No|||July 2011|July 29, 2011|January 24, 2006||No||No|February 18, 2010|https://clinicaltrials.gov/show/NCT00282334||185758|Technical difficulties with telemedical equipment,referral bias,unblinded study
NCT00283231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5287-27101|RESPeRATE for Treatment of Hot Flashes|RESPeRATE (Paced Respiration) for Treatment of Hot Flashes and Menopausal Symptoms||University of California, San Francisco||Completed|October 2005|February 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||July 2005|May 6, 2008|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00283231||185692|
NCT00289653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205/2005|Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation|Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation||Centre for Addiction and Mental Health||Completed|September 2005|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|19 Years|N/A|No|||May 2009|May 9, 2009|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289653||185203|
NCT00289627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-008|A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma|A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma||Bristol-Myers Squibb||Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||June 2010|September 23, 2010|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00289627||185205|
NCT00289640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-022|Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma|A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma||Bristol-Myers Squibb||Completed|April 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Both|16 Years|N/A|No|||January 2009|February 27, 2010|February 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00289640||185204|
NCT00285740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2903|Group Cognitive Behavioral Therapy to Treat Depression in an Epilepsy Clinic Setting|||Stanford University||Active, not recruiting|August 2005|January 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||December 2007|December 14, 2007|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285740||185503|
NCT00286065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLXLEF-AP4|Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-op Pain in Adult Patients Undergoing Elective Orthopedic Surgery|Multi-Centre Placebo-Controlled Randomized 2 Part Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-Op Pain in Adult Patients Undergoing Elective Orthopedic Surgery||YM BioSciences||Completed|January 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||123|||Both|18 Years|70 Years|No|||June 2007|June 26, 2007|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00286065||185478|
NCT00286078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EI0105|Treatment for Migraines With an Implantable Device|Precision Implantable Stimulator for Migraine (PRISM) Study- Occipital Nerve Stimulation (ONS) for Migraine||Boston Scientific Corporation|No|Active, not recruiting|February 2006|December 2016|Anticipated|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00286078||185477|
NCT00286351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endo 220604|Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis|||Rigshospitalet, Denmark||Completed|January 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|20 Years|40 Years|No|||April 2007|April 20, 2007|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286351||185456|
NCT00286598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMHS IRB 1040047|Feet First: Promoting Physical Activity Among People With Diabetes Mellitus and Insensate Feet|Feet First: Increasing Activity Without Increasing the Risk of Foot Ulcers in People With Diabetes and Insensate Feet||University of Missouri-Columbia|Yes|Active, not recruiting|January 2005|June 2008|Anticipated|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|50 Years|N/A|No|||December 2007|December 21, 2007|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286598||185437|
NCT00286858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beluga|Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing|Clinical Observations of Automatic Algorithms for Cardiac Pacing||Boston Scientific Corporation|No|Completed|September 2006|December 2010|Actual|September 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|903|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with indication for a dual chamber pacemaker and not having a        complete AV-block are invited to participate.|February 2011|January 5, 2016|February 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00286858||185418|
NCT00286871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6538|Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen|Steroid Avoidance in Hep C OLT||Duke University||Completed|February 2006|February 2009||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|60 Years|No|||February 2006|September 18, 2014|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00286871||185417|
NCT00287898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450959|Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation|Telephone-Based Genetic Counseling; An Equivalence Trial||Georgetown University|No|Active, not recruiting|May 2005|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|600|||Female|21 Years|85 Years|No|||February 2015|February 12, 2015|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00287898||185338|
NCT00288574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4703R|Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa|Fluoxetine After Weight Restoration in Anorexia Nervosa||New York State Psychiatric Institute||Completed|January 2000|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|16 Years|45 Years|No|||March 2015|March 24, 2015|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288574||185286|
NCT00285506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 15813|The Effect of Contrast Media on Erythrocytes in Healthy Volunteers|The Effect of Low-Osmolar and Iso-Osmolar Contrast Media on Erythrocytes in Healthy Volunteers.||Medical University of South Carolina||Completed|January 2006|January 2006||||N/A|Observational|Time Perspective: Cross-Sectional||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2006|May 25, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285506||185521|
NCT00285207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-001|Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix||Tigris Pharmaceuticals|No|Completed|January 2006|June 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|147|||Female|18 Years|N/A|No|||September 2010|September 23, 2010|January 30, 2006|Yes|Yes||No|August 30, 2010|https://clinicaltrials.gov/show/NCT00285207||185541|
NCT00281229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1328|T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Innate and Adaptive Immunity in COPD Exacerbations: Surgical Volunteers||University of Michigan|No|Completed|September 2005|January 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|481|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects undergoing clinically indicated lung resections.|January 2016|January 28, 2016|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281229||185842|
NCT00285519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHF-03-143|Japan Morning Surge-1 Study|The Effects of Controlling Morning Hypertension on Target Organ Damage With Adrenergic Blockers, Based on Self-Measured Morning Blood Pressure Readings||Japan Heart Foundation||Completed|August 2003|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|N/A|N/A|No|||February 2006|February 1, 2006|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00285519||185520|
NCT00281606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 585|A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules|A Phase IV, Randomized, Open-label Study of the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules||California Collaborative Treatment Group||Completed|February 2006|||October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00281606||185813|
NCT00281853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE13Z04|Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer|Characterization of Chemotherapy/Biotherapy-Induced Peripheral Neuropathy: Refinement of Clinical Measures||Case Comprehensive Cancer Center|Yes|Completed|March 2005|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|21 Years|85 Years|No|Probability Sample|Patients who are receiving chemotherapy or biological therapy for cancer.|June 2010|June 10, 2010|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00281853||185795|
NCT00282633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHN001820HU|Wound Closure Techniques|A Comparison of Skin Closure Techniques After Primary Cesarean Delivery||Hartford Hospital||Recruiting|November 2005|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|120|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||October 2007|October 30, 2007|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282633||185735|
NCT00283543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1068016|Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma|A Phase II Study of Radiation With Concomitant and Then Sequential Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Who Have Undergone Surgery With Gliadel Wafer Insertion||Kentuckiana Cancer Institute||Active, not recruiting|September 2002|April 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|72 Years|No|||October 2007|October 30, 2007|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283543||185668|
NCT00283556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1068114|High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma|Phase I/II Study of High Dose Irinotecan (Camptosar, CPT-11) in Patients With Recurrent Unresectable Malignant Glioma on Steroids/Anti-epileptics||Kentuckiana Cancer Institute||Completed|August 2001|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||January 2010|January 18, 2010|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283556||185667|
NCT00283803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-9710-A04|To Lengthen the Duration of the Off-Treatment of Intermittent Androgen Suppression|Evaluation of the Effect of Exisulind on the Duration of the "Off-Treatment" Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression||University of Washington|No|Active, not recruiting|October 2001|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Male|21 Years|N/A|No|||February 2008|February 20, 2008|January 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283803||185648|
NCT00285792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96534|Stanford Preschool Physical Activity Project|Stanford Preschool Physical Activity Project||Stanford University||Completed|December 2005|March 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||July 2006|October 4, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285792||185499|
NCT00286403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCAT-1|Vasodilators and Anti-Oxidant Therapy in Early ATN|Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial||Southeast Renal Research Institute|Yes|Withdrawn|August 2008|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|630|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|February 1, 2006|No|Yes|The study was terminated due to logistics at a local hospital.|No||https://clinicaltrials.gov/show/NCT00286403||185452|
NCT00285753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-2002-018|Support Groups for Patients With Mild Cognitive Impairment and Their Partners|Development and Evaluation of Support Groups for Patients With Mild Cognitive Impairment and Their Partners||Radboud University|Yes|Completed|November 2003|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|110|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||May 2008|May 20, 2008|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285753||185502|
NCT00285766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9303-P0204|Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression|A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression||Somerset Pharmaceuticals||Completed|August 2002|July 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|65 Years|N/A|No|||April 2008|April 21, 2008|January 31, 2006||||||https://clinicaltrials.gov/show/NCT00285766||185501|
NCT00286091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050147|Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer||Amgen|Yes|Completed|February 2006|April 2014|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1435|||Male|18 Years|N/A|No|||May 2015|May 20, 2015|February 2, 2006|Yes|Yes||No|March 25, 2015|https://clinicaltrials.gov/show/NCT00286091||185476|
NCT00286377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0603|Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of Prosaptide Over 6 Weeks of Treatment for the Relief of Neuropathic Pain Associated With HIV-1||Savient Pharmaceuticals||Terminated|September 2003|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Both|18 Years|N/A|No|||January 2006|February 2, 2006|June 30, 2005||||||https://clinicaltrials.gov/show/NCT00286377||185454|
NCT00286390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-04-01|Acupuncture for Acute and Chronic Pain in Air Force Personnel|Outcomes and Cost Assessment of Acupuncture in the Treatment (OCAT) of Pain Patients at Malcolm Grow USAF Medical Center||Samueli Institute for Information Biology||Completed|March 2005|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Both|18 Years|N/A|No|||September 2007|September 4, 2007|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286390||185453|
NCT00287404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC-2395|Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes|A Comparison of NMR and Chemical Lipid Analysis in the Fasting and Postprandial State in Patients With Type 2 Diabetes||University of North Carolina, Chapel Hill||Completed|October 2005|September 2006||||N/A|Observational|Time Perspective: Prospective||||30|||Both|20 Years|75 Years|No|||December 2007|December 19, 2007|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00287404||185376|
NCT00287417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3032|Early Ultrasound and Maternal Biochemical Markers to Evaluate the Risk of Down Syndrome During the First Trimester|Nuchal Translucency Study - PAPP-A||University Hospital, Strasbourg, France||Completed|July 2003|February 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinics, public hospitals|May 2011|May 13, 2011|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00287417||185375|
NCT00287872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0456 CDR0000450772|Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma|VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|September 2004|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|February 6, 2006||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00287872||185340|
NCT00287885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003LS034|Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer|Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer||Masonic Cancer Center, University of Minnesota|Yes|Completed|March 2004|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287885||185339|
NCT00288119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1DK070863|Familial Barrett's Esophagus|Familial Barrett's Esophagus|FBE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|October 2005|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|Blood Samples are required to be sent to our NIH approved Biorepository and this repository      is designed to help all researchers performing studies on the genetic basis of diseases.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with Barrett's esophagus or adenocarcenoma of the esophagus whose medical care        is at the participating institutions, are referred from outside institutions, or who        contact the participating institutions.|January 2013|January 15, 2013|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288119||185321|
NCT00285220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00011552|Safety and Efficacy of Laparoscopic Truncal Vagotomy for the Treatment of Obesity|A Prospective, Multi-Center Study to Evaluate the Safety and Effectiveness of Laparoscopic Truncal Vagotomy for the Treatment of Obesity||University of Rochester|Yes|Completed|September 2005|December 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|25 Years|55 Years|No|||February 2009|February 17, 2009|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285220||185540|
NCT00281242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1325|Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Innate and Adaptive Immunity in COPD Exacerbations: Severe AE-COPD Clinical Course Study||University of Michigan|No|Completed|September 2005|July 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|40 Years|80 Years|No|Non-Probability Sample|Emergency room and clinics|January 2016|January 28, 2016|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281242||185841|
NCT00281255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353|Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy|Allopurinol and Cardiac Function Pilot Study in Idiopathic Dilated Cardiomyopathy||University of Pennsylvania|No|Withdrawn|June 2003|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|January 20, 2006|Yes|Yes|Infeasible|No||https://clinicaltrials.gov/show/NCT00281255||185840|
NCT00281268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356|Fluids and Catheters Treatment Trial (FACTT) - ARDS Clinical Research Network|||National Heart, Lung, and Blood Institute (NHLBI)||Completed||October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Intervention Model: Factorial Assignment, Primary Purpose: Treatment|||||||Both|13 Years|N/A|No|||January 2008|January 18, 2008|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281268||185839|
NCT00281866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000452784|Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer|Genotypic-Based Pharmacodynamic Evaluation of Erlotinib (Erlotinib (Tarceva™, OSI Pharmaceuticals, Uniondale, NY) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|37|||Both|18 Years|N/A|No|||March 2010|March 16, 2010|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00281866||185794|
NCT00283582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM00-435|Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy|Randomized Double-blind Placebo-controlled Trial of Primary Prophylaxis With Recombinant Human Thrombopoietin Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy||M.D. Anderson Cancer Center||Completed|June 2001|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|50|||Both|13 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 22, 2012|January 27, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00283582||185665|
NCT00286416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xolair AERD|Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma|Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With the Co-Morbid Conditions of Aspirin Exacerbated Respiratory Disease(AERD) and Allergic Asthma and Rhinitis.||Scripps Health||Recruiting|January 2006|July 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|90 Years|No|||January 2006|November 6, 2006|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286416||185451|
NCT00286624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0207M29841|Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation|A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients|NITA|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2003|August 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||May 2008|May 2, 2008|February 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00286624||185435|
NCT00286611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200406002|Determination of Amifostine Levels During Radiation Therapy|Serial Blood and Salivary Sampling for Validation of Quantitative Amifostine Assays||University of Iowa|Yes|Completed|October 2004|May 2008|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients receiving amifostine as a part of their standard cancer therapy.|June 2008|June 9, 2008|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00286611||185436|
NCT00286884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2003.01.LBM|Heart Rate Variability in White Coat Hypertension and Essential Hypertension|||Regional Hospital Holstebro||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||65|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||September 2006|September 8, 2006|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00286884||185416|
NCT00286897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-E044-301|The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations||Eisai Inc.||Completed|February 2006|August 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|702|||Both|30 Years|N/A|No|||November 2015|November 2, 2015|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00286897||185415|
NCT00287196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 02.01|Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes|Randomised Clinical Trial of Surgery Versus Surgery Plus Adjuvant Radiotherapy for Regional Control in Patients With Completely Resected Macroscopic Nodal Metastatic Melanoma||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|March 2002|December 2011|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||September 2009|June 23, 2013|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287196||185392|
NCT00287430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102-035|Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis|||University of Texas Southwestern Medical Center||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|6 Years|40 Years|No|||January 2006|February 2, 2006|February 2, 2006||||||https://clinicaltrials.gov/show/NCT00287430||185374|
NCT00287170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2/13/6MP:CAL-01|Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease|Pilot, Open-Label, Randomized, Parallel Group Study to Evaluate Clinical/ and Immunological Efficacy/Safety of Locally Delivered 6-MP or Calcitriol vs Purinethol in Non-Steroid Dependent Patients With Active CD||Teva GTC||Completed|July 2006|December 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|75 Years|No|||July 2008|July 3, 2008|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287170||185394|
NCT00287183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0341001|6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria|Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488||Pfizer|No|Completed|February 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|31 Years|N/A|No|||September 2009|September 30, 2009|January 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00287183||185393|
NCT00287443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0303-161|Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis|||University of Texas Southwestern Medical Center||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||48|||Both|7 Years|17 Years|No|||January 2006|February 2, 2006|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287443||185373|
NCT00287703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Final version 26 Oktober 2005|Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression|Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression||Hillerod Hospital, Denmark|Yes|Completed|March 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00287703||185353|
NCT00288899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAF 05-308|Benefits of 'Repeat Back' Protocols Within A Computer-Based Informed Consent Program|Benefits of 'Repeat Back' Protocols Within A Computer-Based Informed Consent Program||VA Office of Research and Development|Yes|Completed|August 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|575|||Both|18 Years|N/A|No|||September 2014|April 6, 2015|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288899||185261|
NCT00288912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-016|Self-Management of Osteoarthritis|Self-Management of Osteoarthritis: A Tailored, Telephone-based Intervention|SeMOA|VA Office of Research and Development|No|Completed|October 2006|September 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|523|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|February 6, 2006||No||No|August 1, 2014|https://clinicaltrials.gov/show/NCT00288912||185260|
NCT00288093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00120|3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase I Study of Triapine® in Combination With Radiation Therapy in Locally Advanced Pancreas Cancer||National Cancer Institute (NCI)||Active, not recruiting|December 2006|||May 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00288093||185323|
NCT00282113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004122333-1|Effects of Probiotic and Prebiotic Combinations on Premature Infants|Efficacy of a Prebiotic and Probiotic Combination in Preterm Infants||University of California, Davis|Yes|Completed|October 2004|August 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|90|||Both|N/A|7 Days|Accepts Healthy Volunteers|||December 2009|December 31, 2009|January 23, 2006||No||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00282113||185775|Smaller sample size than anticipated due to the number of infants enrolled who were discharged home prior to completing five weeks of treatment.
NCT00281619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL420 MPA (PK-PD)|PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients|Development of Population Pharmacokinetic-Pharmacodynamic (PK-PD) Models of Mycophenolic Acid for Bayesian Dose Individualization in Pediatric Kidney Transplant Patients||Children's Hospital Medical Center, Cincinnati|No|Completed|January 2006|February 2010|Actual|February 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29|||Both|2 Years|17 Years|No|Probability Sample|Male subjects and non-pregnant female subjects aged 2-17 years who are about to receive a        kidney transplant and will be on post transplant MMF containing immunosuppressive therapy,        per clinical care.|December 2013|December 18, 2013|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00281619||185812|
NCT00281632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104450|A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer|This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.||GlaxoSmithKline||Completed|March 2006|October 2010|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|21 Years|N/A|No|||February 2011|March 17, 2011|January 23, 2006||||Yes|November 25, 2009|https://clinicaltrials.gov/show/NCT00281632||185811|
NCT00281879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000452794|Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer|Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies||OHSU Knight Cancer Institute|Yes|Terminated|February 2006|March 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|200|||Both|N/A|60 Years|No|||May 2012|July 2, 2012|January 24, 2006|Yes|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00281879||185793|Early termination
NCT00282100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS0414|A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma|||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|December 2005|December 2012|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|40|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282100||185776|
NCT00282347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2970g|A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis|LUNAR|Genentech, Inc.|No|Completed|January 2006|January 2013|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|144|||Both|16 Years|75 Years|No|||January 2015|January 6, 2015|January 24, 2006|Yes|Yes||No|February 1, 2010|https://clinicaltrials.gov/show/NCT00282347||185757|
NCT00282360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR05-1-5|Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease|Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease||IRCCS San Raffaele||Completed|February 1999|October 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|85 Years|No|||May 2004|January 24, 2006|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282360||185756|
NCT00282906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-05-1|FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer|[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer||University of Southern California||Completed|October 2005|August 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|257|||Male|21 Years|N/A|No|||December 2014|December 14, 2014|January 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00282906||185716|
NCT00282919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661154|A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria|A Phase 2, Open Label, Non-Comparative Trial Of Azithromycin 2000 mg Plus Chloroquine 600 Mg Base Daily For Three Days For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria||Pfizer|Yes|Completed|March 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|January 26, 2006|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00282919||185715|
NCT00282932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121127|Detrol LA In Men With Overactive Bladder.|A Randomized, Double Blind, Placebo Controlled Detrol LA "Add-On" To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker.||Pfizer||Completed|January 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Male|40 Years|N/A|No|||September 2007|September 5, 2007|January 26, 2006||||||https://clinicaltrials.gov/show/NCT00282932||185714|
NCT00283855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B031120-Proj 1|RAHelp.Org: An Online Self Management Program for Adults With Rheumatoid Arthritis|An Online Self Management Program for Adults With Rheumatoid Arthritis||University of Missouri-Columbia||Completed|October 2003|September 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2008|July 9, 2009|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00283855||185644|
NCT00283868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS44148MEYER|Stroke Team Remote Evaluation Using a Digital Observation Camera|A Prospective Study to Evaluate the Efficacy of a Remote Digital Observation Camera Protocol in the Evaluation and Thrombolytic Treatment of Acute Stroke Patients in the Remote Hospital Setting|STRokE DOC|University of California, San Diego|Yes|Completed|January 2004|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|234|||Both|18 Years|N/A|No|Probability Sample|Acute Stroke Patients|September 2009|June 2, 2015|January 26, 2006||No||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00283868||185643|
NCT00283881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060080|Tactile Learning in Stroke Patients|Implicit Tactile Learning in Chronic Stroke Enhanced by Non-Invasive Brain Stimulation of the Somatosensory Cortex||National Institutes of Health Clinical Center (CC)||Completed|January 2006|||October 2009|Actual|N/A|Observational|N/A||||70|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2009|October 22, 2009|January 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00283881||185642|
NCT00283244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0512|Gemcitabine and/or Erlotinib as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Randomized Phase II Study of First-Line Treatment With Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|March 2006|March 2016|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|147|||Both|70 Years|N/A|No|||June 2014|June 16, 2014|January 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283244||185691|
NCT00283257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI CA 95260|Simultaneous Care: Linking Palliation to Clinical Trials|A Randomized Control Trial That Teaches Oncology Clinical Trial Patients and Their Caregivers Problem Solving Skills.||University of California, Davis||Recruiting|February 2002|June 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||600|||Both|18 Years|N/A|No|||January 2006|January 25, 2006|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00283257||185690|
NCT00286130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/Core 1.2.001|Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer|A Randomised, Open-label Phase II Study Evaluating the Efficacy and Safety of Folfox6 + Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer||Central European Cooperative Oncology Group|No|Completed|July 2005|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00286130||185473|
NCT00286637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-EY013178-06|Novel Diagnostics for Ocular Structure|Optical Coherence Tomography Domain Reflectometry & Optical Coherence Tomography Measurements of Intraocular Structure||University of Pittsburgh|Yes|Recruiting|January 1995|June 2017|Anticipated|May 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Recruiting subjects male or female, ages beginning at 18 with Macular dgegeneration,        diabetic retinopathy, and/or glaucoma. Can also be a normal/healthy subject.|September 2015|September 17, 2015|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00286637||185434|
NCT00286910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2005.05/ IMT|Urinary Aquaporin 2 and Expression of the NPHS2 Gene in Adults Suffering From Nephrotic Syndrome|Urinary Aquaporin 2 and Expression of the NPHS2 Gene in Adults Suffering From Nephrotic Syndrome||Regional Hospital Holstebro||Completed|May 2005|||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|adult patients with nephrotic syndrome healthy volunteers|March 2010|March 17, 2010|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00286910||185414|
NCT00286923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS 347|Does Topiramate Adjust the Excitability of the Brain in Migraine Sufferers?|Modulation of the Excitability of the Occipital Cerebral Cortex Using Topiramate||Emerald City Headache Organization||Not yet recruiting|February 2006|August 2006||||N/A|Observational|N/A||||10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2006|February 13, 2006|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00286923||185413|
NCT00286936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSG-RCT-05|Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo|Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo||Hvidovre University Hospital||Terminated|February 2004|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|96|||Both|70 Years|N/A|No|||September 2006|August 29, 2011|February 3, 2006|||Slow inclusion resulting in premature termination due to logistics|No||https://clinicaltrials.gov/show/NCT00286936||185412|
NCT00287209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003 0245|Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)|Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)||University of Aarhus||Completed|January 2004|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||250|||Both|18 Years|N/A|No|||February 2006|February 3, 2006|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00287209||185391|
NCT00287690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-170|Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease|The Effect of Genistein (Supro®) on Coronary Artery Diameter and Blood Flow in Men and Women With Coronary Heart Disease||Imperial College London|No|Completed|October 1999|April 2003||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|30 Years|75 Years|No|||February 2006|October 21, 2015|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00287690||185354|
NCT00287716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPF-004|Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis||InterMune|Yes|Completed|June 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|435|||Both|40 Years|80 Years|No|||May 2011|May 12, 2011|February 6, 2006|Yes|Yes||No|June 2, 2010|https://clinicaltrials.gov/show/NCT00287716||185352|
NCT00287911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000452043|Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer|A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer||Masonic Cancer Center, University of Minnesota|Yes|Completed|February 2005|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287911||185337|
NCT00288925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01010106E|Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment|Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment||Zeria Pharmaceutical||Completed|September 2005|||December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|20 Years|N/A|No|||May 2009|May 29, 2009|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288925||185259|
NCT00288106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466341|S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT|Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed With Prostate Cancer||Southwest Oncology Group|Yes|Terminated|September 2005|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|961|||Male|55 Years|120 Years|No|Non-Probability Sample|Men diagnosed with prostate cancer on or before 12/31/03 after participation in the        Prostate Cancer Prevention Trial (SWOG-9217)|September 2015|September 28, 2015|February 6, 2006||No|Poor accrual resulted in lack of feasibility to evaluate endpoints.|No||https://clinicaltrials.gov/show/NCT00288106||185322|
NCT00282373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCUE|Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients|Randomized Controlled Pilot Study: Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients Using Traditional Surface Cooling Techniques vs. the Medivance® Arctic Sun® System||Medivance, Inc.|Yes|Completed|November 2004|September 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|No|||September 2007|September 10, 2007|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00282373||185755|
NCT00282386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-122|A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)|A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas||Merck Sharp & Dohme Corp.||Completed|December 1999|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|2586|||Both|40 Years|N/A|No|||September 2015|September 15, 2015|January 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00282386||185754|
NCT00282646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000968-33|Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)|(Intraarterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells for Induction of Neovascularization in Patients With Peripheral Arterial Occlusive Disease)||Johann Wolfgang Goethe University Hospitals|No|Completed|October 2005|March 2011|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2011|August 23, 2011|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00282646||185734|
NCT00282659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHIT001799HI|The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control|The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag||Hartford Hospital||Recruiting|January 2006|June 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|N/A|No|||March 2007|November 2, 2007|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282659||185733|
NCT00282672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-204|Ablation of Intestinal Metaplasia Containing Dysplasia|Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years||Medtronic - MITG|Yes|Completed|February 2006|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|127|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|January 25, 2006|Yes|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT00282672||185732|
NCT00282945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001289|Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone|Analyzing Beta Cell Function Tests Over Time In Patients With Type 2 Diabetes Mellitus Randomized To Metformin Or Rosiglitazone||Pfizer||Terminated|January 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|29|||Both|45 Years|70 Years|No|||October 2008|October 9, 2008|January 25, 2006|||See statement in Detailed Description.|No||https://clinicaltrials.gov/show/NCT00282945||185713|
NCT00283270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCEP|Effectiveness of Screening and Counselling for Elderly With Psychological Problems|A Randomised Controlled Trial on the Effectiveness of Screening and Brief Counselling for Elderly Patients With Psychological Problems in Primary Care.||The University of Hong Kong||Completed|November 2002|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||450|||Both|60 Years|N/A|No|||December 2005|January 26, 2006|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00283270||185689|
NCT00283894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060079|Body Weight Regulation in Patients With Narcolepsy|The Role of the Orexin System in Body Weight Regulation: Patients With Narcolepsy||National Institutes of Health Clinical Center (CC)||Completed|January 2006|June 2013||||N/A|Observational|N/A|||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|December 7, 2013|January 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00283894||185641|
NCT00283829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-3017-A-04|Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer|Immunotherapy With Low Dose Interleukin-2 After Cytoreductive Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer: A Phase I/II Study||University of Washington|No|Completed|September 2002|July 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||November 2007|November 28, 2007|January 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00283829||185646|
NCT00283842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A5-322|Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, 13-Week, Adaptive-Design Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|March 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|408|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|January 26, 2006|Yes|Yes|business reasons|No|June 30, 2009|https://clinicaltrials.gov/show/NCT00283842||185645|
NCT00284102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1700|PEEP Test and Gas Exchange in ALI/ARDS Patients|Positive End Expiratory Pressure (PEEP) Test and Gas Exchange in ALI/ARDS Patients||Policlinico Hospital|No|Completed|January 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|16 Years|90 Years|No|||September 2008|September 24, 2008|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284102||185625|
NCT00286143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-10-3988|Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates|Evaluation of Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates on Perioperative Outcome||Children's Hospital of Philadelphia|No|Completed|February 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|N/A|6 Months|No|||September 2009|September 14, 2009|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286143||185472|
NCT00286429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-INS-011|Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes||Takeda|No|Completed|February 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|390|||Both|18 Years|80 Years|No|||February 2012|February 1, 2012|February 1, 2006|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00286429||185450|
NCT00286650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paracetamol|Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief|Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief||University of Otago||Completed|May 2005|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2004|February 2, 2006|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286650||185433|
NCT00287235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARS HE Study|Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)|A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy||Gambro Renal Products, Inc.|Yes|Completed|September 2000|April 2004|Actual|November 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|February 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287235||185389|
NCT00287222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2005-13|Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma|Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma||University of Arkansas|No|Completed|February 2006|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2011|June 17, 2011|February 3, 2006|Yes|Yes||No|March 22, 2011|https://clinicaltrials.gov/show/NCT00287222||185390|Two subjects withdrew consent.
NCT00288379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00007|SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma|A Comparative, Placebo-controlled, Double Blind, Double Dummy, Cross-over, Single Centre, Phase IIIb Study Between Formoterol Alone (Oxis® Turbuhaler® 4.5 µg) and the Fixed Combination of Formoterol and Budesonide (Symbicort® Turbuhaler®160/4.5 µg) on Airway Responsiveness and Airway Inflammation Induced by Repeated Low-dose Allergen Challenge in Allergic Patients With Mild Asthma||AstraZeneca||Completed|October 2004|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|55 Years|No|||January 2011|January 21, 2011|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288379||185301|
NCT00288626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN033AI|High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study|A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) and Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2006|November 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|February 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288626||185282|
NCT00288639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081088|Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).|Lyrica (Pregabalin) Administered As An Add-On Therapy For Partial Seizures (LEADER) An Open-Label, Multicenter Add-On Therapy Trial|LEADER|Pfizer|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||August 2009|August 28, 2009|February 7, 2006||No||No|December 16, 2008|https://clinicaltrials.gov/show/NCT00288639||185281|
NCT00288886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-267|Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment|Reinforcement of Abstinence and Attendance in Substance Abuse Treatment||VA Office of Research and Development|Yes|Completed|March 2007|June 2011|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||July 2014|April 6, 2015|February 6, 2006||No||No|October 17, 2014|https://clinicaltrials.gov/show/NCT00288886||185262|
NCT00288678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-PP08|A Prospective Study on Diabetes Management Through an Integrated Delivery System|A Prospective Study on Diabetes Management Through an Integrated Delivery System|DMIDS|National Health Research Institutes, Taiwan|No|Completed|July 2003|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|1222|||Both|30 Years|70 Years|No|||February 2008|January 26, 2010|February 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00288678||185278|
NCT00288366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050942|Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome|Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome||Vanderbilt University|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||January 2009|January 23, 2009|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288366||185302|
NCT00281892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454570|Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia|Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity||National Cancer Institute (NCI)||Recruiting|September 2004|||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|348|||Both|N/A|N/A|No|||July 2007|August 23, 2013|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00281892||185792|
NCT00281905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454575|Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors|Management of Children Aged Less Than 3 Years With Brain Tumors||National Cancer Institute (NCI)||Active, not recruiting|June 1992|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|3 Years|No|||June 2007|September 19, 2013|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00281905||185791|
NCT00282126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 AR052275|Potassium Citrate to Prevent Age Related Bone Loss|Potassium Citrate to Prevent Age Related Bone Loss: Pilot Study||University of California, San Francisco|No|Completed|January 2006|||January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|52|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00282126||185774|
NCT00282399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACO-019|A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome|Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.||Eisai Inc.|No|Terminated|October 2006|February 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|January 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00282399||185753|
NCT00282958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAT0014|The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain|The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain||Palo Alto Veterans Institute for Research||Completed|February 2003|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years||||March 2015|March 4, 2015|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282958||185712|
NCT00283283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13205|Half vs Full Dose Influenza Vaccine|Clinical Study to Compare the Immune Response of Half Dose Trivalent Inactivated Influenza Vaccine (TIV) to Full Dose||U.S. Army Medical Research and Materiel Command|No|Completed|November 2004|May 2006|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|1316|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|January 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00283283||185688|
NCT00283296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02331, 0408063|Development of a Collapsible Folding Manual Wheelchair|Development of a Collapsible Folding Manual Wheelchair||VA Pittsburgh Healthcare System|No|Completed|January 2004|April 2011|Actual|July 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 23, 2014|January 24, 2006||No||No|June 11, 2013|https://clinicaltrials.gov/show/NCT00283296||185687|Limited number of Endeavor prototypes.
NCT00284492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P REK NORD 102/2005|Acupuncture for Hot Flushes in Menopause|Effectiveness of Acupuncture-care for Treatment of Hot Flushes Among Postmenopausal Women|ACUFLASH|University Hospital of North Norway||Completed|February 2006|May 2008|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Female|40 Years|80 Years|Accepts Healthy Volunteers|||May 2012|May 11, 2012|January 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00284492||185595|
NCT00284128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI6032|AVE7688 in Patients With Mild to Moderate Blood Pressure|Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With Mild to Moderate Hypertension|RAVEL-1|Sanofi||Completed|December 2005|March 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1940|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|January 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00284128||185623|
NCT00286962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-06-01-SL|Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus|A Randomized Cross-Over Single Centre Study Comparing the Effects of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus Patients||Medical Research Foundation, The Netherlands||Completed|February 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||April 2008|April 10, 2008|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00286962||185410|
NCT00286442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-MET-008|Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes||Takeda|No|Completed|March 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|527|||Both|18 Years|80 Years|No|||February 2012|February 1, 2012|February 1, 2006|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00286442||185449|
NCT00286663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 12494|Autoimmune Hepatitis Study|Evaluation of the Cellular Immune Response in Patients With Anti-SLA/LP- or Anti-LKM-Positive Autoimmune Hepatitis||University of Rochester||Terminated|January 2006|June 2008|Actual|||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 8, 2008|February 1, 2006||No|Principal Investigator moving out of state, no other staff to lead research.|No||https://clinicaltrials.gov/show/NCT00286663||185432|
NCT00286949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB#20040223|Treatment of Executive Dysfunction in Parkinson's Disease|Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-Label Study||Johns Hopkins University||Active, not recruiting|September 2004|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|21 Years|65 Years|No|||November 2005|July 25, 2006|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00286949||185411|
NCT00287924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454548|High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma|Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma||National Cancer Institute (NCI)||Active, not recruiting|March 2005|||March 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|29|||Both|N/A|2 Years|No|||June 2009|September 16, 2013|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00287924||185336|
NCT00287456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901-466|Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.|||University of Texas Southwestern Medical Center||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|12 Years|32 Years|No|||January 2006|February 2, 2006|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287456||185372|
NCT00288392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBG-1-11|Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients|A Double-Blind Therapeutic Exploratory Clinical Study to Evaluate the Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients||Biotec Pharmacon ASA||Completed|June 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||May 2006|October 17, 2006|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288392||185300|
NCT00288652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061026|[S,S]-Reboxetine Dose-Range Finding Trial|[S,S]-Reboxetine Dose-Range Finding Trial: A 16-Week, Randomized, Double-Blind, Placebo And An Active Comparator Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN)||Pfizer||Completed|March 2006|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|February 7, 2006||||||https://clinicaltrials.gov/show/NCT00288652||185280|
NCT00288665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Versie 1.0 d.d. 1-7-2004|Thrombectomy and Improvement of Left Ventricular Function in AMI|Thrombectomy Before Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Improves Left Ventricular Function at 3 Months||R&D Cardiologie||Completed|April 2004|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||February 2006|February 6, 2006|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288665||185279|
NCT00289211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVP2005-1/Part A|C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks|LEVP2005-1/Part A: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) for the Treatment of HAE in Acute Attacks||Shire|Yes|Completed|June 2005|September 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|6 Years|N/A|No|||March 2014|March 19, 2014|February 7, 2006|Yes|Yes||No|March 17, 2010|https://clinicaltrials.gov/show/NCT00289211||185237|
NCT00282139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSARIP703 / WIRB #20031378|Aripiprazole in the Treatment of Tourette's Syndrome|Aripiprazole in the Treatment of Tourette's Syndrome||University of Florida||Terminated|January 2004|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|6 Years|17 Years||||October 2011|October 4, 2011|January 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00282139||185773|
NCT00282412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD RA ALLO|Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism|Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism||Northwestern University|Yes|Recruiting|September 2002|September 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|60 Years|No|||March 2016|March 21, 2016|January 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00282412||185752|
NCT00282685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000969-19|Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy|(Restoration of Nerve Functions by Intra-Arterial Transplantation of Bone Marrow Progenitor Cells in Patients With Diabetic Poly Neuropathy (PNP)||Johann Wolfgang Goethe University Hospitals|No|Recruiting|October 2005|October 2008|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||November 2007|November 21, 2007|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282685||185731|
NCT00282971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171063|A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus|A Six Month, Open-Label Outpatient, Parallel Group Trial Assessing The Impact Of Inhaled Insulin (Exubera) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On Two Oral Anti-Diabetic Agents.||Pfizer|No|Terminated|March 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|354|||Both|35 Years|80 Years|No|||July 2009|September 11, 2009|January 26, 2006|Yes|Yes|See termination reason in detailed description.|No|February 11, 2009|https://clinicaltrials.gov/show/NCT00282971||185711|Study terminated prematurely since the sponsor stopped marketing and manufacturing of EXUBERA and withdrew Market Authorization in Europe in September 2008. No efficacy, safety, or quality reason was associated with the premature halt of this study.
NCT00282984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051049|Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking|A 12-Week, Double-Blind, Placebo-Controlled, Multicenter Study With A 40 Week Follow Up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 Milligram (Mg) Twice Daily (BID) for Smoking Cessation in Subjects With Cardiovascular Disease||Pfizer|Yes|Completed|February 2006|August 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|714|||Both|35 Years|75 Years|No|||August 2009|August 27, 2009|January 26, 2006|Yes|Yes||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00282984||185710|
NCT00283595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001443/3; MGH|Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa|Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa||Massachusetts General Hospital|Yes|Completed|January 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Female|14 Years|45 Years|No|||September 2012|September 15, 2012|January 27, 2006||No||No|August 16, 2012|https://clinicaltrials.gov/show/NCT00283595||185664|
NCT00293228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137|Treatment of Latent Tuberculosis Infection With Isoniazid|Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB||Instituto Nacional de Salud Publica, Mexico|Yes|Completed|February 2007|June 2009|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|200|||Both|10 Years|85 Years|No|||May 2010|May 25, 2010|February 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00293228||184943|
NCT00285077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS5283|Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease|Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease||Sanofi||Completed|March 2004|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|390|||Both|50 Years|N/A|No|||December 2008|December 22, 2008|January 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00285077||185551|
NCT00284479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Murtagh/Murphy 2004|The Effect of Walking on Cardiovascular Risk|The Effect of a Worksite Based Walking Programme on Cardiovascular Risk in Previously Sedentary Civil Servants||University of Ulster||Completed|May 2002|January 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2003|July 20, 2006|January 27, 2006||||No||https://clinicaltrials.gov/show/NCT00284479||185596|
NCT00287469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 749|A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.|A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal.||Walter Reed Army Institute of Research (WRAIR)||Completed|February 2000|January 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|February 2, 2006||||||https://clinicaltrials.gov/show/NCT00287469||185371|
NCT00287729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPF-006|Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis||InterMune|Yes|Completed|April 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|344|||Both|40 Years|80 Years|No|||May 2011|May 12, 2011|February 6, 2006|Yes|Yes||No|June 2, 2010|https://clinicaltrials.gov/show/NCT00287729||185351|
NCT00287937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02676|Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors|Phase I Study Of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) in Combination With Paclitaxel /Carboplatin for Advanced and Refractory Solid Malignancies||National Cancer Institute (NCI)||Completed|July 2005|||June 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|February 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287937||185335|
NCT00288132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18 67312 (completed)|The Diabetes TeleCare Study|Bridging Barriers to Diabetes Care With Telemedicine: The Diabetes TeleCare Study (DTC)|DTC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|August 2005|November 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|165|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 3, 2011|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288132||185320|
NCT00288158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71223 (completed)|Primary Prevention of Hypertension in Obese Adolescents|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|February 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|128|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||April 2011|April 25, 2011|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00288158||185318|
NCT00288405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN-03-01|The ENTERPRISE Study - Study of the Enterprise Self-Expanding Stent System|Cordis Neurovascular Feasibility Study of the Enterprise Self-Expanding Stent System to Facilitate Endovascular Coil Embolization of Wide- Neck Saccular Intracranial Artery Aneurysms||Codman & Shurtleff|Yes|Completed|June 2004|December 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|80 Years|No|||April 2012|April 30, 2012|October 5, 2005||||No||https://clinicaltrials.gov/show/NCT00288405||185299|
NCT00288938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060060|Natural History Study of Moles and Suspicious Melanoma|Dermoscopic Diagnosis, Histopathological Correlation, and Cellular Immortalization of Melanocytic Nevi and Primary Cutaneous Melanoma||National Institutes of Health Clinical Center (CC)||Completed|February 2006|October 2011||||N/A|Observational|N/A|||Actual|20|||Both|5 Years|N/A|No|||October 2011|September 26, 2015|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00288938||185258|
NCT00288951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-17|Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients|||Alcon Research||Completed|October 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|690|||Both|18 Years|N/A|No|||September 2009|August 16, 2012|February 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288951||185257|
NCT00289224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C8phIII|Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata|A Randomized Controlled Trial of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India||International Vaccine Institute|Yes|Completed|July 2006|May 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|69329|||Both|12 Months|N/A|Accepts Healthy Volunteers|||March 2012|July 30, 2014|February 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00289224||185236|
NCT00289237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCPH - 99-1|Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease|A Randomised Non-pharmacological Intervention Study for Prevention of Ischaemic Heart Disease Inter99||Glostrup University Hospital, Copenhagen||Completed|March 1999|March 2011|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|61301|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|September 19, 2005||No||No||https://clinicaltrials.gov/show/NCT00289237||185235|
NCT00282152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040797|Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)|Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease||Vanderbilt University|Yes|Completed|March 2006|October 2015|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|30|||Both|50 Years|75 Years|No|||January 2016|January 25, 2016|January 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00282152||185772|
NCT00282425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD Scl.Allo2005|Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis|Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis||Northwestern University|Yes|Terminated|May 2005|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|No|||December 2012|December 14, 2012|January 24, 2006|Yes|Yes|No subject enrolled since 2009|No||https://clinicaltrials.gov/show/NCT00282425||185751|
NCT00282438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA SARC.2003|Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis|Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial||Northwestern University|No|Terminated|December 2003|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|60 Years|No|||March 2016|March 21, 2016|January 24, 2006|Yes|Yes|No plan to continue enrollment|No||https://clinicaltrials.gov/show/NCT00282438||185750|
NCT00282698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322-04|Outcomes With Tight Control of Hyperglycemia in Cardiac Surgery Patients|Outcomes With Use Of Intensive Insulin Therapy In Intraoperative Management Of Hyperglycemia In Adult Patients Undergoing Cardiac Surgery||Mayo Clinic||Completed|July 2004|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00282698||185730|
NCT00283309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042005-018|Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes|||University of Texas Southwestern Medical Center||Terminated|November 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|70 Years|No|||April 2013|April 19, 2013|January 24, 2006|No|Yes|Study finished enrollment but data was never sent for publishing.|No||https://clinicaltrials.gov/show/NCT00283309||185686|
NCT00283608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583001|Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer|Pharmacogenetics of Aromatase Inhibitors||Mayo Clinic|Yes|Completed|July 2005|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Anastrozole treatment group samples will be used as described for this study, and then will      be destroyed.      Exemestane treatment group samples of blood will be stored at Mayo Clinic Rochester.|Female|18 Years|N/A|No|Probability Sample|Diagnosis of breast cancer. Stage I, II, or III disease.        Planning to undergo treatment with anastrozole at the clinically approved dose of 1 mg/day        OR Mayo Clinic Cancer Center Rochester patient who will be enrolled on or has been        enrolled on CAN-NCIC-MA27 and has not started taking the study medication (anastrozole or        exemestane)|May 2011|May 13, 2011|January 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00283608||185663|
NCT00285675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-016|Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004|A Continuation Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004||Novacea||Active, not recruiting|April 2006|January 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||January 2006|May 30, 2006|January 31, 2006||||||https://clinicaltrials.gov/show/NCT00285675||185508|
NCT00284778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I05026|Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer|A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Français de Pneumo-Cancérologie (GFPC).||University Hospital, Limoges||Completed|February 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|70 Years|No|||March 2010|March 26, 2010|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00284778||185574|
NCT00284791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-2571|Lamotrigine in Treatment Resistant Depression in Adolescents|Lamotrigine Use in Treatment Refractory Depression in Adolescents||Maine Medical Center||Suspended|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|13 Years|18 Years|No|||September 2005|March 29, 2006|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00284791||185573|
NCT00287248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMYLOID001|Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain|Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease||Institute for Neurodegenerative Disorders|No|Completed|February 2006|March 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|38|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 6, 2014|February 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287248||185388|
NCT00287261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446G2422|A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)|A Prospective Multicentre Phase II Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)||Universitaire Ziekenhuizen Leuven|No|Completed|February 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00287261||185387|
NCT00287482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIH042005|Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.|A Pilot Study of the Herbal Remedy Essiac (ESIAK ®) Versus Placebo in Improving the Quality of Life in Women Completing Adjuvant Treatment for Breast or Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers.||Women and Infants Hospital of Rhode Island||Terminated|October 2005|July 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|18 Years|90 Years|No|||February 2007|February 8, 2007|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00287482||185370|
NCT00287495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060083|BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma|Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma||National Institutes of Health Clinical Center (CC)||Completed|February 2006|January 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|110 Years|No|||November 2015|December 2, 2015|February 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287495||185369|
NCT00287742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003172|A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease|Double-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease||Janssen Pharmaceutical K.K.|No|Terminated|March 2002|March 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|33|||Both|N/A|N/A|No|||November 2010|May 20, 2011|February 3, 2006|||A decision was made to discontinue the study due to a change in the strategic direction of the    company.|No||https://clinicaltrials.gov/show/NCT00287742||185350|
NCT00287755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JACCRO GC-04|Clinical Trial of Chemosensitivity Test|Chemosensitivity Test to Evaluate the Effect of Adjuvant Cancer Chemotherapy (S-1) After Gastric Surgery||Japan Clinical Cancer Research Organization|Yes|Completed|March 2006|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|300|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287755||185349|
NCT00288145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK071946|Statewide (Rhode Island and Neighboring States) Partnerships for Worksite Weight Management|Statewide Partnerships for Worksite Weight Management||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|June 2006|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 30, 2013|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00288145||185319|
NCT00288691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90955|Menorrhagia Study in Women With Treatment-resistant Menorrhagia|A Multi-center, Double-blind, Placebo-controlled, Randomized, Parallel Group Study to Evaluate the Effects of Different Doses of SH T 00127B in Women With Treatment-resistant Menorrhagia Aged 30 to 55 Years After Daily Oral Administration of Multiple Doses for 35 up to 50 Days||Bayer|No|Completed|November 2001|January 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|26|||Female|30 Years|55 Years|No|||December 2014|December 29, 2014|February 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00288691||185277|
NCT00288704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-AI-0505|Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)|IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs||Regeneron Pharmaceuticals|Yes|Completed|December 2005|August 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|7 Years|N/A|No|||December 2011|December 1, 2011|February 6, 2006|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00288704||185276|Cryopyrin Associated Periodic Syndrome (CAPS) is a rare disease with only a few hundred cases in the US.
NCT00289250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC867|Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum|Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum: A Randomized Controlled Trial||London School of Hygiene and Tropical Medicine||Completed|May 2001|December 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|6 Months|N/A|Accepts Healthy Volunteers|||December 2002|February 28, 2006|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289250||185234|
NCT00282451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3024|Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes|Comparison of Biphasic Insulin Aspart 30 Twice Daily With Biphasic Insulin Aspart 30 Twice Daily Plus Lunchtime Injection of Insulin Aspart, in Combination With or Without Metformin (for Both Treatment Groups) in Subjects With Type 2 Diabetes. A Multi-center, Randomized, Open-labeled, Two-armed Parallel Group Trial in Subjects With Type 2 Diabetes Previously Treated With Conventional Biphasic Human Insulin 30/70||Novo Nordisk A/S|No|Completed|February 2006|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|79|||Both|18 Years|18 Years|No|||October 2013|October 21, 2013|January 25, 2006||||No||https://clinicaltrials.gov/show/NCT00282451||185749|
NCT00282711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELL001524HE|The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?|The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?"A Multi-Center, Prospective, Randomized Study to Establish the Optimal Method for Detection of CAD Risk in Women at an Intermediate-High Pre-Test Likelihood CAD"||Hartford Hospital|Yes|Completed|June 2004|December 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|824|||Female|60 Years|N/A|No|Probability Sample|Females age 60 and above with suspected heart disease|July 2012|July 31, 2012|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00282711||185729|
NCT00282997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081078|A Safety Study Of Pregabalin In Fibromyalgia|A 12-Week, Open-Label, Safety Trial Of Pregabalin In Patients With Fibromyalgia||Pfizer||Completed|February 2006|October 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||October 2007|March 21, 2008|January 26, 2006||||||https://clinicaltrials.gov/show/NCT00282997||185709|
NCT00283010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUT-105-2005|Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT)|Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT)|IMPACT|Posit Science Corporation||Completed|January 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|487|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00283010||185708|
NCT00283023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-CMR-003|Oligodendrocyte Progenitor Cell Culture From Human Brain|Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain||Rajavithi Hospital|Yes|Recruiting|December 2007|||December 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|20 Years|65 Years|No|||August 2008|August 2, 2008|January 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00283023||185707|
NCT00292500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP2004-06|Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II|Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II||Cardica, Inc|No|Terminated|January 2006|December 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|50 Years|85 Years|No|||August 2013|August 19, 2013|February 14, 2006||No|Cardica has terminated the development of the product for Business Reason.|No||https://clinicaltrials.gov/show/NCT00292500||184991|
NCT00281502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salix-RifaxPSE-BactOvrGrwth-01|The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy|The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy||Weill Medical College of Cornell University|No|Recruiting|December 2005|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||November 2010|November 4, 2010|January 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00281502||185821|
NCT00281515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 15|Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer|An Open-label, Multicenter, Randomized Phase II Study to Compare the Effects of Paclitaxel/Carboplatin and Lonafarnib to Those of Paclitaxel/Carboplatin for First-line Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages IIB-IV||AGO Study Group||Completed|January 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Female|18 Years|N/A|No|||June 2012|June 28, 2012|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00281515||185820|
NCT00293475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012|Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|A Phase I/II Study of Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen||OHSU Knight Cancer Institute|Yes|Recruiting|October 2005|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|18 Years|75 Years|No|||February 2016|February 12, 2016|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00293475||184926|
NCT00286988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPMAT-EME-4001|Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children|Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children||Monarch Medical Research||Terminated|March 2006|June 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|12|||Both|4 Years|12 Years|No|||April 2007|January 5, 2011|February 1, 2006|Yes|Yes|Insufficient potential subjects|No||https://clinicaltrials.gov/show/NCT00286988||185408|
NCT00287274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/002|Impact of Computerized Physician Order Entry on Medication Prescription Errors in the Intensive Care Unit: a Controlled Cross-Sectional Trial.|Impact of Computerized Physician Order Entry on Medication Prescription Errors in the Intensive Care Unit: a Controlled Cross-Sectional Trial.||University Hospital, Ghent|No|Completed|March 2004|April 2004|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00287274||185386|
NCT00287508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD-640-0063|Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)|Emboshield and Xact Post Approval Carotid Stent Trial Using the Emboshield® BareWire™ Rapid Exchange Embolic Protection System and Xact® Rapid Exchange Carotid Stent System||Abbott Vascular||Completed|November 2005|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label||||1500|||Both|N/A|N/A|No|||October 2008|October 16, 2008|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00287508||185368|
NCT00287521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-68|A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research||Completed|November 2005|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|87|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|February 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00287521||185367|
NCT00288171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK64587-POST (terminated)|Allopurinol for Renal Transplant Associated Hypertension in Children|Randomized Double-blinded, Placebo-controlled, Cross-over Trial of Allopurinol for the Treatment of Post-renal-transplant Hypertension in Children||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Terminated|February 2006|June 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|6 Years|18 Years|No|||June 2011|June 6, 2011|February 6, 2006||No|insufficient number of eligible subjects|No||https://clinicaltrials.gov/show/NCT00288171||185317|
NCT00287950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454726|Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma|Protocol for Infants With Neuroblastoma Diagnosed Under the Age of One Year||National Cancer Institute (NCI)||Active, not recruiting|September 1992|||||N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|N/A|1 Year|No|||December 2006|September 16, 2013|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00287950||185334|
NCT00286520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK021CC|Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury|Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury - a Prospective, Randomized, Controlled, Multicentre Trial of Transanal Irrigation Vs. Conservative Bowel Management||University of Aarhus||Completed|December 2003|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||February 2006|February 2, 2006|January 30, 2006||||No||https://clinicaltrials.gov/show/NCT00286520||185443|
NCT00286533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/414|Evaluation of Implants Placed in the Regular Dentist's Practice|Retrospective Evaluation of Implants Placed in the Regular Dentist's Practice. A Study to Evaluate Implant Success, Prosthetic Complications, Opinion of the Patient, and Quality of Care||University Hospital, Ghent|No|Recruiting|January 2006|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286533||185442|
NCT00286780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-008|Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia|A Phase 2, Open Label Study of AT-101 in Combination With Rituximab in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia||Ascenta Therapeutics|No|Completed|January 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|February 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00286780||185424|
NCT00281970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455112|Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery|Phase II Trial of Weekly Docetaxel (Taxotere®) and Monthly Cisplatin Chemotherapy as Adjuvant Treatment for Patients With Completely Resected Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||July 2007|February 6, 2009|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00281970||185786|
NCT00281983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455092|Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia|Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|June 2000|July 2010|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|65 Years|No|||April 2007|November 5, 2013|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00281983||185785|
NCT00289263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANTA1|Maintenance Chemotherapy in Metastatic Breast Cancer|Maintenance Paclitaxel Vs Control After Anthracycline/Paclitaxel Combined First-Line Chemotherapy in Metastatic Breast Cancer||MANTA 1 Study Italian Collaborative Group||Active, not recruiting|April 1998|October 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||524|||Female|18 Years|70 Years|No|||November 2003|February 8, 2006|February 8, 2006||||No||https://clinicaltrials.gov/show/NCT00289263||185233|
NCT00283621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-326|Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide|A Pilot Study of Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta) in Patients With Sarcoma Receiving Adriamycin and Ifosfamide||M.D. Anderson Cancer Center|No|Completed|November 2002|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|January 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00283621||185662|
NCT00291226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glytech|Glycine vs Placebo for the Schizophrenia Prodrome|Glycine vs Placebo for the Schizophrenia Prodrome||Yale University|Yes|Completed|March 2006|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|13 Years|35 Years|No|||January 2010|January 13, 2010|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00291226||185086|
NCT00283634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05005|A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer|A Randomized, Non-comparative, Multicenter, Open-Label, Phase 2 Study of Tarceva™ (Erlotinib) Alone and of Tarceva Plus VELCADE* (Bortezomib) for Injection in Patients With Relapsed or Refractory, Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Millennium Pharmaceuticals, Inc.||Terminated|August 2005|August 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2011|February 16, 2011|January 27, 2006|||insufficient efficacy|||https://clinicaltrials.gov/show/NCT00283634||185661|
NCT00283907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060084|Brain Networks Responsible for Sense of Agency|Brain Networks Responsible for Sense of Agency: An EEG Study||National Institutes of Health Clinical Center (CC)||Completed|January 2006|December 2008||||N/A|Observational|N/A||||20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2008|December 17, 2008|January 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00283907||185640|
NCT00284505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG0678|Use of Thalidomide in Patients With Arachnoiditis|Prospective Study of the Use of Thalidomide in Patients With Arachnoiditis||Washington University School of Medicine||Completed|July 2005|July 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|3|||Both|18 Years|85 Years|No|||December 2008|December 4, 2008|January 30, 2006||Yes||||https://clinicaltrials.gov/show/NCT00284505||185594|
NCT00284518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-517|Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia|||Allergan|Yes|Completed|December 2005|May 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|380|||Male|50 Years|N/A|No|||November 2012|November 16, 2012|January 31, 2006|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00284518||185593|
NCT00284141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD6123|Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma|A Multicenter, Open-label, Single-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-resistant Locally Advanced or Metastatic Non-small-cell Lung Adenocarcinoma||Sanofi|Yes|Completed|January 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||July 2011|November 12, 2012|January 30, 2006|Yes|Yes||No|August 17, 2012|https://clinicaltrials.gov/show/NCT00284141||185622|
NCT00284154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 122|Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer|A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|January 2006|November 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|January 27, 2006|No|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT00284154||185621|
NCT00281814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-6950|Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant|Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support||The Cleveland Clinic|No|Active, not recruiting|February 2006|||December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Local patients receiving allogeneic bone marrow transplant.|March 2011|March 28, 2011|January 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00281814||185798|
NCT00282022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456623|VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer|A Phase II Trial of Cloretazine™ (VNP40101M) for Patients With Relapsed or Refractory Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2005|||May 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|18 Years|N/A|No|||January 2009|November 5, 2013|January 24, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00282022||185782|
NCT00285376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNSC-04-DP-02|Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response|A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder||Genaissance Pharmaceuticals|No|Completed|February 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|65 Years|No|||February 2008|February 12, 2008|January 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00285376||185530|
NCT00286689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403-239|Effects of Growth Hormone in Chronically Ill Children|||University of Texas Southwestern Medical Center||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|3 Years|17 Years|No|||January 2006|February 1, 2006|February 1, 2006||||||https://clinicaltrials.gov/show/NCT00286689||185430|
NCT00286702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC 01/166|Does Splinting Prevent Contractures Following Stroke?|||University of Western Sydney||Completed|October 2002|September 2004||||N/A|Interventional|N/A||||63|||Both|18 Years|N/A|No|||January 2006|February 1, 2006|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286702||185429|
NCT00287534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033GR/0001|Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.|A Prospective, Multi-Centre, Randomised, Open Parallel Group Study to Compare the Effectiveness and Compatibility of ARIMIDEX (ZD 1033) With NOLVADEX After a Prior 2 Years' Treatment With Tamoxifen in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.|ARNO-95|AstraZeneca||Completed|November 1996|September 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1059|||Female|N/A|75 Years|No|||June 2009|June 7, 2009|February 6, 2006||||No||https://clinicaltrials.gov/show/NCT00287534||185366|
NCT00287547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-005|Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris|Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris||Bristol-Myers Squibb||Completed|March 1997|January 1998|Actual|January 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||144|||Both|18 Years|70 Years|No|||April 2011|April 11, 2011|February 6, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00287547||185365|
NCT00287963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454919|Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer|A Phase I Study of Topotecan in Combination With Vinorelbine in Recurrent Lung Cancer||Medical University of South Carolina|Yes|Completed|February 2004|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00287963||185333|
NCT00278746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-5268/PID/20/198/2004|Addition of Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting|An Effectiveness Trial Examining the Addition of Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting.||Society for Applied Studies|No|Completed|January 2005|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20032|||Both|1 Month|5 Years|No|||June 2015|June 15, 2015|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00278746||186030|
NCT00279292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK69947 (completed)|Randomized Trial of EUS Neurolysis in Pancreas Cancer|Phase III Randomized Placebo Controlled Trial of EUS Guided Celiac Plexus Neurolysis for Pancreatic Cancer Pain||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|26|||Both|18 Years|100 Years|No|||October 2015|October 13, 2015|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279292||185988|
NCT00288418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-ACVC05|Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization|A Controlled, Randomized, Single-Blind, Multi-Center Pivotal Clinical Study Using Angiotech CVC to Prevent Bacterial Colonization on Short-Term Central Venous Catheters||Angiotech Pharmaceuticals|No|Completed|December 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|960|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288418||185298|
NCT00281736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441205|Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer|A Phase II Study of HPPH Photodynamic Therapy for Treatment of High Grade Dysplasia, Carcinoma In-Situ or Early Intramucosal Adenocarcinoma in Barrett's Esophagus. Randomization to Two PDT Treatment Regimens of HPPH (2-1 [Hexyloxyethyl]-2devinylpyropheophorbide-a) and Light||Roswell Park Cancer Institute|Yes|Completed|February 2004|December 2013|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|January 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00281736||185803|
NCT00281749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/12/VA03|Telephone Call From Acute Care Physicians to Long Term Care Physicians: Impact on Transitional Care of Elderly Patients|||Maimonides Medical Center||Completed||October 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|65 Years|N/A||||August 2011|August 17, 2011|January 23, 2006||||No||https://clinicaltrials.gov/show/NCT00281749||185802|
NCT00282191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051220|Prevalence of Spasticity in Adults With Mental Retardation Living in the Community|Prevalence of Spasticity in Adults With Mental Retardation Residing in a Community Setting||Vanderbilt University|No|Completed|August 2006|August 2007|Actual|August 2007|Actual|Phase 1|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|7|||Both|18 Years|N/A|No|Probability Sample|Adults with mental retardation living in community homes in Davidson County, TN.|March 2008|March 26, 2008|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00282191||185769|
NCT00291239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WADE|Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression|Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression||Zentrum für Integrative Psychiatrie||Active, not recruiting|February 2006|July 2009|Anticipated|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||April 2009|April 2, 2009|February 9, 2006||||No||https://clinicaltrials.gov/show/NCT00291239||185085|
NCT00291265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060096|Measures of Motor Impairment in Early Parkinson's Disease|Testing Objective Measures of Motor Impairment in Early Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|February 2006|February 2010||||N/A|Observational|N/A|||Actual|10|||Both|30 Years|85 Years|No|||February 2010|February 3, 2010|February 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00291265||185084|
NCT00291590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHEP001|Diabetes Health Enhancement Program to Improve Health of People With Diabetes|Phase 3 Randomized Controlled Trial of the Diabetes Health Enhancement Program for Medicaid and Dual Eligibles in South King County, Washington||VA Puget Sound Health Care System||Completed|July 2001|August 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||146|||Both|40 Years|85 Years|No|||June 2005|February 13, 2006|February 13, 2006||||No||https://clinicaltrials.gov/show/NCT00291590||185060|
NCT00291837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM203|CT-2106 for the Second Line Treatment of Ovarian Cancer|Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen||CTI BioPharma||Completed|November 2004|December 2007|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|N/A|No|||February 2010|February 24, 2010|February 14, 2006||Yes||||https://clinicaltrials.gov/show/NCT00291837||185041|
NCT00292162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/S0704/47|Curing Atrial Fibrillation in Heart Failure|Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure||NHS Greater Glasgow and Clyde||Completed|January 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|16 Years|N/A|No|||May 2012|May 29, 2012|February 14, 2006||No||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00292162||185017|
NCT00292175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/NBI2/10|NBI With Magnification for Dysplasia Detection in Ulcerative Colitis|Randomised,Controlled Trial of Narrow Band Imaging With Magnification (NBI) Versus White Light Endoscopy for Dysplasia Detection in Ulcerative Colitis Surveillance||London North West Healthcare NHS Trust||Recruiting|February 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|110|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|February 14, 2006||||No||https://clinicaltrials.gov/show/NCT00292175||185016|
NCT00285090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001850/4|Bone Mineral Density, Body Composition and Growth Following Severe Burn Injury|Bone Mineral Density, Body Composition and Growth Following Severe Burn Injury||Shriners Hospitals for Children||Terminated|February 2005|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|60|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||December 2011|December 19, 2011|January 31, 2006||No|Lack of volunteers|No||https://clinicaltrials.gov/show/NCT00285090||185550|
NCT00292877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#02-2115|The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)|The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control||St. Joseph's Healthcare Hamilton|No|Completed|January 2005|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|70 Years|No|||January 2011|January 21, 2011|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00292877||184969|
NCT00282035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2005-RAPID|RAPID: Randomized Trial of Accelerated Partial Breast Irradiation|A Multi-centre Randomized Trial to Determine if Accelerated Partial Breast Irradiation, Utilizing 3D CRT, is as Effective as Whole Breast Irradiation Following Breast Conserving Surgery in Women With Ductal Carcinoma in Situ or Invasive Breast Cancer With Negative Axillary Lymph Nodes||Ontario Clinical Oncology Group (OCOG)|Yes|Active, not recruiting|January 2006|December 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2128|||Female|40 Years|N/A|No|||September 2015|September 21, 2015|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00282035||185781|
NCT00288990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-05-AVX|A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis|Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response.||Biogen|No|Completed|January 2006|August 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|whole blood and serum|Both|18 Years|65 Years|No|Non-Probability Sample|MS patients on interferon beta|December 2007|December 20, 2007|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00288990||185254|
NCT00287287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-701-F3R|REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas|Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas||University of Kentucky|Yes|Active, not recruiting|February 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00287287||185385|
NCT00278447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAI-010870-06A2|Addiction Health Evaluation And Disease Management (AHEAD) Study|Linkage of Alcohol Abusers to Primary Care||Boston Medical Center|No|Completed|April 2006|April 2012|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|569|||Both|18 Years|N/A|No|||October 2012|October 1, 2014|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00278447||186052|
NCT00279071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Modlock|Use of Acupuncture for Stimulation of Labour|Use of Acupuncture for Stimulation of Labour||Herning Hospital|No|Terminated|October 2002|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2008|July 1, 2008|January 18, 2006|||exhausted personel after a long recruiting period|No||https://clinicaltrials.gov/show/NCT00279071||186005|
NCT00289276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228|FAST (Fluid Accumulation Status Trial)|FAST (Fluid Accumulation Status Trial)||Medtronic Cardiac Rhythm Disease Management|No|Completed|November 2003|||April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|156|||Both|18 Years|N/A|No|||October 2010|October 5, 2010|February 7, 2006|Yes|Yes||No|April 1, 2009|https://clinicaltrials.gov/show/NCT00289276||185232|This was a characterization study with no descriptive statistical analysis. The results reported were counts of subjects with impedance data available as applicable for each objective.
NCT00285961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/364|Evaluation of Cork Splint Materials Instead of Plaster Splint for Children|Evaluation of Cork Splint Materials Instead of Plaster Splint for Children||University Hospital, Ghent|No|Completed||April 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|11 Years|No|||February 2009|May 11, 2009|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285961||185486|
NCT00289523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|227|EEG Biomarkers for Predicting Response to Antidepressant Therapy|Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD), a Prospective, Randomized, Multi-center Study to Determine the Efficacy of Selected EEG and Genotype Biomarkers for Predicting Response to Antidepressant Therapy With Escitalopram, Bupropion XL, or a Combination Treatment Regimen.||Medtronic - MITG|Yes|Completed|January 2006|July 2007|Actual|July 2007|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|375|||Both|21 Years|75 Years|No|Probability Sample|A total of 375 subjects with major depressive disorder (MDD) between the ages of 18 - 75        with no other primary neuropsychiatric illnesses were recruited from the population        presenting for ongoing treatment in a primary care clinic, or for depression in a        psychiatric clinic at each site.|April 2010|March 6, 2012|February 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00289523||185213|
NCT00289536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060403|Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A|Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM||Baxalta US Inc.|Yes|Completed|February 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|12 Years|65 Years|No|||May 2011|June 26, 2015|February 9, 2006|No|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00289536||185212|
NCT00289835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laval-VG-01|Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI Trial|Sealing Moderate Coronary Saphenous VEin Graft LEsions With the Paclitaxel-eluting Stent (Taxus) as a New Approach to Maintain Vein Graft Patency and Reduce Cardiac Events: a Pilot Intravascular Ultrasound Study.|VELETI|Laval University|No|Completed|February 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||October 2008|November 23, 2011|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00289835||185190|
NCT00286546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Testosterone and Major Depression|The Role of Testosterone in Major Depression||University Health Network, Toronto||Completed|January 2001|August 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||August 2005|September 8, 2006|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286546||185441|
NCT00286806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-006|A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer|An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy||Ascenta Therapeutics||Completed|December 2005|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Male|18 Years|N/A|No|||August 2010|August 20, 2010|February 3, 2006||||||https://clinicaltrials.gov/show/NCT00286806||185422|
NCT00285909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P6689|Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation|Effect of Moderate Alcohol Consumption on PPAR-γ Activity and Risk Markers of Metabolic Disease: Influence of Genetic Variation in Alcohol Oxidation||TNO||Completed|March 2006|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||36|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||August 2006|August 15, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285909||185490|
NCT00285922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HL69758-10|Novel Method to Diagnose Acute Myocardial Ischemia|Comparison of Estimated Body Surface Potential Mapping With Standard Electrocardiography in Patients Presenting to the Emergency Department With Chest Pain||University of California, San Francisco||Completed|August 2001|December 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1320|||Both|21 Years|N/A|No|||July 2005|January 31, 2006|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00285922||185489|
NCT00285935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00825|Cellular Aging and Neurobiology of Depression Study|Neurosteroid Metabolism and the Antidepressant Effects of Serotonin Specific Reuptake Inhibitors (SSRI's)|CAN-D|University of California, San Francisco|Yes|Recruiting|December 2010|February 2020|Anticipated|February 2020|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|228|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00285935||185488|
NCT00285948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/339|Primary Birmingham Hip Resurfacing Arthroplasty Using a Metal-on-Metal Couple in the Young Active Patient|Primary Birmingham Hip Resurfacing Arthroplasty Using a Metal-on-Metal Couple in the Young Active Patient||University Hospital, Ghent|No|Completed|November 1998|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|250|||Both|18 Years|65 Years|No|||February 2009|February 17, 2009|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285948||185487|
NCT00286247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 201-010|Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer|||Introgen Therapeutics||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|February 1, 2006||||||https://clinicaltrials.gov/show/NCT00286247||185464|
NCT00286260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|keppra2|Levetiracetam for Painful Polyneuropathy|Double-blind, Randomised, Placebo-controlled Trial of the Effect of Levetiracetam on Painful Polyneuropathy||Odense University Hospital||Completed|January 2006|October 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|80 Years|No|||January 2006|December 17, 2009|February 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00286260||185463|
NCT00283647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11261-CP-004|MR Assessment of Brain Function Altered by Lead Exposure|MR Assessment of Brain Function Altered by Lead Exposure||National Institute of Environmental Health Sciences (NIEHS)||Completed|October 2002|September 2006|Actual|September 2006|Actual|N/A|Observational|N/A||||150|||Both|19 Years|26 Years|No|||April 2015|April 13, 2015|January 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00283647||185660|
NCT00283920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060073|PET Imaging of Brain Peripheral Benzodiazepine Receptors|PET Imaging of Brain Peripheral Type Benzodiazepine Receptors||National Institutes of Health Clinical Center (CC)||Completed|January 2006|October 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 3, 2007|January 29, 2006||||No||https://clinicaltrials.gov/show/NCT00283920||185639|
NCT00284167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49147|Efficacy of a Web-based Tailored Weight Management Program|Efficacy of a Web-based Tailored Weight Management Program With and Without Tailored Nutrition and Goal Setting Support||Robert Wood Johnson Foundation||Completed|September 2003|July 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind||||1848|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|January 24, 2006||||No||https://clinicaltrials.gov/show/NCT00284167||185620|
NCT00284180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 89|Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer|Phase II Trial of Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|January 2006|November 2010|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|N/A|No|||July 2013|July 9, 2013|January 27, 2006|No|Yes||No|March 25, 2013|https://clinicaltrials.gov/show/NCT00284180||185619|
NCT00285402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARPH-Cl-03|Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine|Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study||Ariston Pharmaceuticals, Inc.|No|Active, not recruiting|May 2007|June 2008|Anticipated|June 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|198|||Both|18 Years|74 Years|No|||February 2008|February 6, 2008|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285402||185528|
NCT00284804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX060-05/05E|A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease|An Open-label, Randomized, Multicenter, Phase II Study of MDX-060 in Combination With Gemcitabine, MDX060 in Combination With Dexamethasone, and Gemcitabine Monotherapy in Patients With Relapsed or Refractory Hodgkin's Disease||Bristol-Myers Squibb|No|Completed|November 2005|October 2009|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|January 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00284804||185572|
NCT00284817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP068|Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer|Phase I Study of MEDI522, a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer or Other Solid Tumors Refractory to Standard Therapy||MedImmune LLC||Completed|July 2001|May 2005|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|17|||Both|18 Years|N/A|No|||May 2008|May 27, 2008|January 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00284817||185571|
NCT00282594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRMC 050023|The Effect of Intensive Insulin Therapy in the Surgical Critical Care Unit|No Outcome Benefit for the Use of Intensive Insulin Therapy in the Critically Ill General and Vascular Surgical Patient. A Randomized Prospective Trial.||Genesys||Completed|July 2003|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||317|||Both|18 Years|N/A|No|||November 2005|January 26, 2006|January 26, 2006||||No||https://clinicaltrials.gov/show/NCT00282594||185738|
NCT00278187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453542|Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Open-Label Study of Volociximab (M200) in Combination With Erlotinib (Tarceva™) in Previously Treated Patients With Locally Advanced (Stage IIIb) or Metastatic (Stage IV) Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|December 18, 2013|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278187||186069|
NCT00288444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174-2004|Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer|Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies||Emory University||Terminated|January 2006|March 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|38|||Both|N/A|N/A|No|||December 2012|December 17, 2012|February 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00288444||185296|
NCT00288717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUJIYAMA-Study|Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients|A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System||Saitama Medical University||Recruiting|February 2006|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|20 Years|N/A|No|||January 2007|January 9, 2007|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288717||185275|
NCT00288964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0104/125|Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure|Compassionate Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure - A Clinical Trial||Alung Technologies||Withdrawn|November 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 7, 2006|||Sponsor no longer pursuing regulatory approval of investigational device|No||https://clinicaltrials.gov/show/NCT00288964||185256|
NCT00288977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P.001702|Islet Transplantation in Type 1 Diabetic Recipients of Kidney Transplants|Islet Transplantation in Type 1 Diabetic Recipients of Renal Allografts, Using the Edmonton Protocol||Beth Israel Deaconess Medical Center||Completed|September 2000|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||September 2006|October 22, 2008|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288977||185255|
NCT00285974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/398|Dosage of Metal Ions in the Blood of Different Metal-on-metal Prostheses, in Correlation With Physical Activity|Dosage of Metal Ions in the Blood of Different Metal-on-metal Prostheses, in Correlation With Physical Activity||University Hospital, Ghent|No|Active, not recruiting|December 2003|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|25 Years|65 Years|No|||December 2014|December 4, 2014|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00285974||185485|
NCT00285987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/282|Quality of Life After an Ambulatory Reconstruction of the Cruciate Ligament|Quality of Life After an Ambulatory Reconstruction of the Cruciate Ligament||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|50 Years|No|||December 2007|December 19, 2007|February 1, 2006|||Study has never started|No||https://clinicaltrials.gov/show/NCT00285987||185484|
NCT00286000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/195|High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study|High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study||University Hospital, Ghent|No|Completed|June 2004|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||106|||Both|18 Years|69 Years|No|||December 2007|December 19, 2007|February 1, 2006||||No||https://clinicaltrials.gov/show/NCT00286000||185483|
NCT00286273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WON 03.1|Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration|Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin||Onze Lieve Vrouwe Gasthuis|Yes|Completed|March 2003|March 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|N/A|No|||August 2009|August 25, 2009|February 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00286273||185462|
NCT00286819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/Breast.2.2.005|Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer|Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin 75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin 90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer||Central European Cooperative Oncology Group|No|Completed|April 2005|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|75 Years|No|||May 2012|May 15, 2012|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00286819||185421|
NCT00287105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2004-001647-30|Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children|An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)|ESPHALL|Rennes University Hospital|Yes|Active, not recruiting|February 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|1 Year|18 Years|No|||March 2016|March 21, 2016|February 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00287105||185399|
NCT00287118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25161|A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Patients With Moderate to Severe Plaque Psoriasis|||Merck KGaA||Completed|October 2004|October 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Both|17 Years|75 Years|No|||February 2014|February 17, 2014|February 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00287118||185398|
NCT00286793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-202|Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC|An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)||Ascenta Therapeutics|No|Completed|February 2006|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Male|18 Years|N/A|No|||June 2011|June 27, 2011|February 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00286793||185423|
NCT00287053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 25031|Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation|Phase IV Study of the Effects of Divalproex Sodium on Food Intake and Energy Expenditure.|VPA|Pennington Biomedical Research Center|No|Completed|February 2006|October 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|57|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|February 2, 2006||No||No|April 21, 2009|https://clinicaltrials.gov/show/NCT00287053||185403|This was a short-term study; the long-term effects of this compound on energy balance require further study.
NCT00287066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171060|A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition|Open-Label Randomized Two-Way Crossover Pilot Study To Estimate The Effects Of Inhaled Versus IV Infusion Of Human Insulin With Regards To Glucose Disposal In Subjects With Type 1 Diabetes Mellitus||Pfizer||Terminated|February 2006|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2007|February 20, 2008|February 2, 2006|||See termination reason in detailed description.|||https://clinicaltrials.gov/show/NCT00287066||185402|
NCT00287326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-Anes-231|Comparison of Low-Dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone|Comparison of Epidural Bupivacaine-Clonidine With Intravenous Morphine Versus Intravenous Morphine Alone for Post-Operative Pain Relief in Pediatric Patients Undergoing Lower Extremity or Pelvic Osteotomy.||University of North Carolina, Chapel Hill||Terminated|January 2006|June 2006|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|4 Years|16 Years|No|||June 2009|June 23, 2009|February 3, 2006|||terminated by PI|No||https://clinicaltrials.gov/show/NCT00287326||185382|
NCT00284193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3768-UM-CTIL|Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII|Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII||Sheba Medical Center|No|Completed|January 2005|November 2009|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|16 Years|65 Years|No|||July 2012|July 26, 2012|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00284193||185618|
NCT00284531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEN122|Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients|Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100||Baylor College of Medicine|No|Terminated|October 2003|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|1 Month|18 Years|No|||October 2015|October 14, 2015|January 31, 2006|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00284531||185592|
NCT00284830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191|SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction|Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction (SAVE PACe)|SAVEPACe|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|January 2003|February 2008|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1070|||Both|18 Years|N/A|No|||February 2008|February 26, 2008|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00284830||185570|
NCT00281190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1326|Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function|Innate and Adaptive Immunity in COPD Exacerbations: Clinically-Indicated Bronchoscopies||University of Michigan|No|Completed|September 2005|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Smokers with COPD or smokers with normal pulmonary function will be recruited from among        subjects scheduled to undergo bronchoscopy for clinical indications.|December 2014|December 12, 2014|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281190||185845|
NCT00281528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA023|Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer|A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.||Celgene|No|Terminated|February 2006|March 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|208|||Female|18 Years|N/A|No|||March 2012|March 19, 2012|January 24, 2006|Yes|Yes|sufficient mature data to complete a final analysis|No|February 17, 2012|https://clinicaltrials.gov/show/NCT00281528||185819|
NCT00285389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANTEAU 2001|Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years|Treatment in First Line of Mantle Cell Lymphoma for Patients Under 66 Years by the VAD-CHLORAMBUCIL -Rituximab Regimen Followed by Intensification and Autologous PBSC Transplantation After Marrow Purging With Rituximab||French Innovative Leukemia Organisation|Yes|Completed|February 2002|December 2008|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|65 Years|No|||February 2009|February 11, 2009|January 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00285389||185529|
NCT00281138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1197|Center for Reducing Asthma Disparities - Rhode Island/Puerto Rico Centers|Pediatric Asthma Disparities: Perceptions and Management||Rhode Island Hospital|No|Completed|September 2002|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|983|||Both|7 Years|15 Years|No|Non-Probability Sample|Children with asthma or a history of breathing problems, from Non-Latino white, Puerto        Rican or Dominican ethnicities. Participant recruitment occurred in Rhode Island and in        island Puerto Rico.|July 2008|November 5, 2013|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00281138||185848|
NCT00288730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005197|A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest|A Randomized, Double-Blinded, Placebo-Controlled Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in Subjects With Decompensated CHF||Scios, Inc.||Completed|October 1996|August 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|127|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00288730||185274|
NCT00288743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/087|Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study|Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study||University Hospital, Ghent|No|Completed|September 2002|December 2002|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|16 Years|N/A|No|||December 2007|December 19, 2007|February 7, 2006||||No||https://clinicaltrials.gov/show/NCT00288743||185273|
NCT00288457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0758-2003|Ureteral Stent Length and Patient Symptoms|||Emory University||Terminated|February 2006|October 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Probability Sample|Male or female over 18 years of age, will be receiving electro-shock wave therapy for        kidney stones|December 2013|December 23, 2013|February 6, 2006||No|Because no staff to consent or enroll subjects|No||https://clinicaltrials.gov/show/NCT00288457||185295|
NCT00280982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2005-269|Dendritic Cell-based Immunotherapy in Mesothelioma|Vaccination With Autologous Dendritic Cells Pulsed With Tumor Lysate for Treatment of Patients With Malignant Pleural Mesothelioma||Erasmus Medical Center||Completed|January 2006|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2010|November 15, 2010|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280982||185860|
NCT00276692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-ET-2003-04|Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma|Phase II Study of Irinotecan (CPT-11) in Children and Adolescents With High Risk Ewing's Sarcoma||National Cancer Institute (NCI)||Completed|August 2003|July 2009|Actual|September 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|N/A|19 Years|No|||June 2009|June 25, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276692||186179|
NCT00280930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-183|Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer|A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density||Dana-Farber Cancer Institute||Active, not recruiting|October 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Female|18 Years|N/A|No|||January 2007|January 18, 2007|January 23, 2006||||||https://clinicaltrials.gov/show/NCT00280930||185864|
NCT00280943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4686-05-7R2ER|Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities|Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities Written for FDA Approved Medications for Osteoporosis Treatment.||Duke University||Completed|January 2005|March 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention||||64|||Both|N/A|N/A|No|||October 2007|October 16, 2007|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00280943||185863|
NCT00280956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD351|Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease|A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies||Elan Pharmaceuticals||Completed|July 2002|September 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|2000|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|January 21, 2006||||No||https://clinicaltrials.gov/show/NCT00280956||185862|
NCT00276679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454577|Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma|Phase II Study of Temozolomide (Temodal) in Children Over 1 Year of Age With Relapsed or Refractory High Risk Neuroblastoma||National Cancer Institute (NCI)||Completed|April 2003|November 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|1 Year|16 Years|No|||January 2006|September 16, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276679||186180|
NCT00277511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR355/3036|Levofloxacin, Chronic Bacterial Prostatitis|Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP)||Sanofi||Completed|March 2003|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Male|18 Years|N/A|No|||October 2007|October 11, 2007|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277511||186119|
NCT00278382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02682|Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|A Phase 2 Study of BAY 43-9006 (IND 69896) in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphomas||National Cancer Institute (NCI)||Completed|October 2005|||December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|January 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00278382||186057|
NCT00277446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0456-035|Dietary Supplementation With Soy Isoflavones in Asthma|Dietary Supplementation With Soy Isoflavones in Asthma||Northwestern University|No|Completed|January 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|50 Years|No|||February 2011|February 23, 2011|January 13, 2006||No||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00277446||186122|
NCT00277472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BUS04|Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension|A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy||Novartis||Completed|November 2005|||November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||March 2008|June 6, 2011|January 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00277472||186121|
NCT00278122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11782|Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction With Paclitaxel in Patients With Advanced Melanoma||University of Virginia||Suspended|July 2005|||December 2015|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|January 16, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00278122||186074|
NCT00279253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-141003|Effects of Intravenous Clonidine on Ocular Blood Flow and Intraocular Pressure|||Medical University of Vienna||Completed|March 2004|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||January 2006|January 18, 2006|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279253||185991|
NCT00279591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48082|Near-Continuous, Noninvasive Blood Pressure Monitoring to Improve Outcomes in Pediatric Transport|Near-Continuous, Noninvasive Blood Pressure Monitoring to Improve Outcomes in Pediatric Transport||University of Arkansas|No|Terminated|June 2006|January 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|1 Year|17 Years|No|||April 2012|April 3, 2012|January 17, 2006||No|Lack of technical support and supplies|No|March 28, 2011|https://clinicaltrials.gov/show/NCT00279591||185966|Small Sample Size. Halted prior to projected enrollment secondary to lack of technical support and supplies for near continuous BP measuring device.
NCT00279890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-05|Topical Agent for Treatment of Red Skin|Proof of Concept Trial:SR-01 for the Treatment of Rosacea||Mayo Clinic||Completed|July 2005|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||May 2011|May 20, 2011|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279890||185943|
NCT00307424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.258-T|Comparison Between Auto CPAP and Fixed CPAP in Chinese Patients With OSA|Comparison of Auto-Continuous Positive Airway Pressure Device(Auto-CPAP) With Conventional Fixed CPAP in Chinese Patients With Obstructive Sleep Apnea (OSA)||Chinese University of Hong Kong||Completed|August 2004|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Both|18 Years|65 Years|No|||August 2004|March 27, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307424||183885|
NCT00307437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006325|A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.||Centocor Research & Development, Inc.|Yes|Completed|May 2005|October 2011|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1230|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|March 24, 2006|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00307437||183884|The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.
NCT00307450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-LELEDY-007|Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease|Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study|LeLeDys|Technische Universität Dresden|Yes|Completed|March 2006|July 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|34|||Both|30 Years|80 Years|No|||July 2009|July 31, 2009|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00307450||183883|
NCT00298389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0404/111|Macrophage Phagocytosis in COPD|Macrophage Phagocytosis in Chronic Obstructive Pulmonary Disease||Imperial College London||Completed|October 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|90|||Both|21 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects, smokers without COPD and COPD patients|March 2006|March 19, 2014|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298389||184557|
NCT00298402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0404/87|Macrophages in Smokers' Lung|The Role of Macrophages in the Pathophysiology of Smokers' Lung||Imperial College London||Withdrawn|October 2005|October 2007||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||March 2006|May 27, 2015|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298402||184556|
NCT00307996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2006001|The Effect of CoQ10 Administration on Hemodialysis Patients|The Effect of CoQ10 Administration on the Oxidative and Antioxidative Markers in Hemodialysis Patients||University of Shizuoka||Completed|March 2004|December 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|85 Years|No|||March 2006|March 27, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307996||183841|
NCT00308009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVT Prolapse study|Comparison of the Result of TVT Performed at the Time of Prolapse Surgery or 3 Months After|Multicenter Prospective Randomized Trial Comparing to Strategies When Incontinence Surgery is Needed in Addition to Prolapse Surgery||Oslo University Hospital|Yes|Completed|February 2002|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Female|N/A|N/A|No|||November 2007|April 27, 2015|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00308009||183840|
NCT00308243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI-N115-I-010-01|Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.|Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study. Stage 1)||Emphycorp||Completed|March 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||July 2011|July 17, 2011|March 27, 2006||Yes||||https://clinicaltrials.gov/show/NCT00308243||183822|
NCT00304213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79-06|Does Testosterone Improve Function in Hypogonadal Older Men|Does Testosterone Improve Function in Hypogonadal Older Men||North Florida Foundation for Research and Education||Withdrawn|March 2006|April 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Male|60 Years|80 Years||||February 2015|February 12, 2015|March 16, 2006|||Study never started, PI relocation|No||https://clinicaltrials.gov/show/NCT00304213||184124|
NCT00280501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-160905|Dopaminergic Modulation of Choroidal Blood Flow Changes During Dark/Light Transitions|Dopaminergic Modulation of Choroidal Blood Flow Changes During Dark/Light Transitions||Medical University of Vienna|Yes|Completed|August 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|21|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2008|July 8, 2008|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280501||185897|
NCT00280137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220044879|Health-related Quality of Life Measure in Pediatric Lupus|Health-related Quality of Life Measure in Pediatric Lupus||Rutgers, The State University of New Jersey|No|Active, not recruiting|June 2004|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|2 Years|18 Years|No|Non-Probability Sample|The population will consist of outpatients during clinics visits and inpatients during        hospitalizations.|June 2015|June 11, 2015|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00280137||185925|
NCT00280722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4858|RAW Study Version 3.4|Does Increasing Research Awareness Impact on Accrual? A Feasibility Study. Protocol Version 3.4 Dated April 2005.||Oxford University Hospitals NHS Trust||Not yet recruiting|January 2006|November 2006||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Educational/Counseling/Training||||400|||Both|18 Years|N/A|No|||January 2006|January 20, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00280722||185880|
NCT00280995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012CS8|Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy|A Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects||Sanofi||Completed|January 2006|August 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|January 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00280995||185859|
NCT00281008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012CS9|Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy|A Phase 2, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects||Sanofi||Completed|February 2006|December 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|January 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00281008||185858|
NCT00276705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454579|Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer|Hepatocellular Carcinoma Family of Tumours In Children / Adolescents and Young Adults||National Cancer Institute (NCI)||Active, not recruiting|June 2005|||April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|47|||Both|N/A|29 Years|No|||June 2009|September 16, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276705||186178|
NCT00280969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QD001|Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment|Open-label Randomized Multicenter Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir Boosted Atazanavir to Efavirenz||International Medical Center of Japan|Yes|Completed|September 2005|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Male|20 Years|N/A|No|||March 2015|March 27, 2015|January 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00280969||185861|
NCT00277238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1211002|CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects|CPG 10101 Combination Therapy for the Treatment of Hepatitis C: A Phase II Randomized, Open Label, Multi-Center, Parallel Arm, Controlled Trial of CPG 10101 at Two Different Dose Levels With Pegylated-Interferon-Alpha 2B (PEG-IFN) Plus Ribavirin (RBV) or PEG-IFN Plus RBV Without CPG 10101 in the Treatment of Non-Responder (Null and Partial Responder) HCV Genotype 1 Infected Subjects||Pfizer|Yes|Completed|February 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|113|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|January 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277238||186138|
NCT00277251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-187R|Alendronate Osteoporosis Study|Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis||Children's Hospital Boston||Active, not recruiting|March 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|8 Years|22 Years|No|||January 2006|January 13, 2006|July 7, 2005||||||https://clinicaltrials.gov/show/NCT00277251||186137|
NCT00277498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641044|A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma|A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States.||Pfizer||Completed|December 2005|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||528|||Both|18 Years|N/A|No|||June 2008|March 15, 2011|January 13, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00277498||186120|
NCT00278395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00087|Vorinostat in Treating Patients With Kidney Cancer|A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Renal Cell Carcinoma (RCC)||National Cancer Institute (NCI)||Completed|October 2005|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2013|June 3, 2015|January 16, 2006|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00278395||186056|
NCT00278148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF5876|Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer|A Phase I/II Trial of Neoadjuvant Paclitaxel, Carboplatin and OSI-774 (Tarceva) With Concurrent Accelerated Hyperfractionation Radiation Followed by Maintenance Therapy With OSI-774 for Stage III Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Active, not recruiting|October 2005|December 2012|Anticipated|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278148||186072|
NCT00277849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060074|Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research|Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research||National Institutes of Health Clinical Center (CC)||Completed|January 2006|July 2010||||N/A|Observational|N/A|||Anticipated|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|January 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00277849||186095|
NCT00279006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-12006|Adhesiveness of Coronary Drug-Eluting Stents to the Delivery Balloon-Catheter: A Randomized Comparison|Adhesiveness of Coronary Drug-Eluting Stents to the Delivery Balloon-Catheter: A Randomized Comparison||Foundation for Cardiovascular Research, Zurich||Not yet recruiting|January 2006|March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|18 Years|80 Years|No|||January 2006|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279006||186010|
NCT00279266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55288|Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy|A Randomized Double Blinded Pilot Study of Oral Thiamine in the Symptomatic Treatment of Painful Diabetic Peripheral Neuropathy||Loma Linda University|Yes|Withdrawn|January 2006|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|January 18, 2006||No|inadequate recruitment|No||https://clinicaltrials.gov/show/NCT00279266||185990|
NCT00279604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EB0432|INCA - Intervention and Neuropsychology in Cannabis Abuse|Targeted Interventions in Cannabis Abuse: Focus on Decision Making (INCA)||University Hospital, Bonn||Recruiting|July 2005|October 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|16 Years|36 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279604||185965|
NCT00307112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0093|Rheumatic Heart Disease Prevalence in Leon, Nicaragua|Study of the Prevalence of Rheumatic Heart Disease in Leon, Nicaragua||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|August 2006|August 2008||||N/A|Observational|Time Perspective: Prospective||||3600|||Both|5 Years|15 Years|Accepts Healthy Volunteers|||September 2007|August 26, 2010|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00307112||183907|
NCT00307125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-02|Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies|B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|757|||Both|5 Years|70 Years|No|||March 2015|March 11, 2015|March 23, 2006|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT00307125||183906|Slow accrual. In order to ensure the study was completed within the time frame allotted, randomization to the control arm (Pilot Phase-Placebo plus immunosuppression) was suspended. Enrollment continued to lag. The study was stopped early.
NCT00307710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0340|Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma|Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma: A Phase II, Double-Blind Pilot Study - Version 4||M.D. Anderson Cancer Center|Yes|Completed|August 2004|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|March 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307710||183863|
NCT00307723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-233|Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer|A Tolerability and Efficacy Study of the Angiogenesis Inhibitor Bevacizumab in Combination With 5-Fluorouracil, Oxaliplatin, and External Beam Radiation Therapy Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer||Massachusetts General Hospital|Yes|Terminated|May 2006|July 2009|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|March 24, 2006|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00307723||183862|
NCT00298415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0501|Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)|Phase III Study of Monotherapy by Gemcitabine or Vinorelbine Comparing to Doublet by Carboplatin and Paclitaxel Among Elderly Patients With Stage IIIB/IV NSCLC (Obligatory Second-line by Erlotinib)||Intergroupe Francophone de Cancerologie Thoracique|Yes|Completed|March 2006|December 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|451|||Both|70 Years|89 Years|No|||October 2013|October 24, 2013|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298415||184555|
NCT00308022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW IRB 022005-052|Comparison Study of High Frequency Percussive Ventilation With Conventional Ventilation|A Prospective Randomized Controlled Trial Comparing High Frequency Percussive Ventilation With Conventional Mechanical Ventilation Utilizing Protective Lung Strategies in Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome||University of Texas Southwestern Medical Center||Recruiting|January 2006|December 2009||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|18 Years|65 Years|No|||March 2006|September 8, 2006|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00308022||183839|
NCT00298649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8739-CP-001|Reducing Farmworkers Exposure to Agricultural Chemicals|||National Institute of Environmental Health Sciences (NIEHS)||Terminated|July 2002|October 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|October 5, 2015|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298649||184537|
NCT00299208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-149|Azithromycin Combination Therapy for Malaria|Phase II, Open Label, Randomized Study of Azithromycin Combination Therapy for the Treatment of Acute, Uncomplicated Falciparum Malaria||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|20 Years|65 Years|No|||March 2010|August 26, 2010|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299208||184496|
NCT00280735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0320|Carboplatin and Docetaxel After Surgery in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Phase II Trial Exploring the Feasibility of Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA Non-Small Cell Lung Cancer|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|May 2004|||July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|120 Years|No|||January 2016|January 20, 2016|January 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00280735||185879|
NCT00281021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|629.05|Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer|Phase II Trial of Second Line Erlotinib + Digoxin in Patients With Non-Small Cell Lung Cancer||James Graham Brown Cancer Center|Yes|Terminated|February 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|January 23, 2006||No|Interim analysis revealed that only 1 patient had a partial response.|No|April 12, 2013|https://clinicaltrials.gov/show/NCT00281021||185857|
NCT00276939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRM GWU DM Study|Plant-Based Dietary Intervention in Type 2 Diabetes|Plant-Based Dietary Intervention in Type 2 Diabetes||Physicians Committee for Responsible Medicine|Yes|Completed|September 2003|July 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00276939||186160|
NCT00276900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH053735|Sertraline for the Prevention of Recurrent Postpartum Depression|Prevention of Recurrent Postpartum Depression||University of Pittsburgh|No|Completed|December 2003|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 30, 2013|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00276900||186163|
NCT00277225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-003|A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris|A Phase I,Randomized, Double Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris||Bristol-Myers Squibb||Completed|November 1995|June 1996|Actual|June 1996|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|18 Years|65 Years|No|||April 2011|April 11, 2011|January 12, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00277225||186139|
NCT00278135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.1002|Memory Improvement With Docosahexaenoic Acid Study (MIDAS)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in the Elderly|MIDAS|DSM Nutritional Products, Inc.|No|Completed|December 2005|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|485|||Both|55 Years|N/A|No|||May 2014|May 16, 2014|January 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00278135||186073|
NCT00278408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459796|Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study]||German High-Grade Non-Hodgkin's Lymphoma Study Group|No|Completed|November 2005|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|700|||Both|18 Years|60 Years|No|||November 2015|January 20, 2016|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278408||186055|
NCT00278681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRN-A-96-90006-00|Effectiveness of Adding Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting|An Effectiveness Trial Examining the Addition of Zinc to the Current Case Management Package of Diarrhoea in a Primary Health Care Setting. Phase I||Society for Applied Studies|No|Completed|August 2003|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2364|||Both|1 Month|5 Years|No|||July 2008|July 1, 2008|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00278681||186034|
NCT00278694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05059|Oxaliplatin and 5-FU Based Preoperative Chemoradiation|Oxaliplatin and 5-FU Based Preoperative Chemoradiation|LARC-RRP|Oslo University Hospital||Active, not recruiting|September 2005|May 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278694||186033|
NCT00278421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459685|Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma|Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study]||German High-Grade Non-Hodgkin's Lymphoma Study Group|Yes|Recruiting|November 2005|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|592|||Both|18 Years|60 Years|No|||November 2015|November 25, 2015|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278421||186054|
NCT00279019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2103473|Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double Blind, Placebo-Controlled, Double Dummy, 4-Way Cross-Over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Inhaled Doses of GSK233705 and Tiotropium Bromide (18µg) Via DPI in COPD Patients||GlaxoSmithKline||Completed|December 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|40 Years|75 Years|No|||October 2008|October 9, 2008|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279019||186009|
NCT00279032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA10006|GW406381 In Patients With Peripheral Nerve Injury|A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Study to Investigate the Effects of Chronic Dose Oral GW406381 on Pain and Areas of Hyperalgesia and Allodynia in Patients With Peripheral Nerve Injury as a Result of Trauma or Surgery.||GlaxoSmithKline||Completed|September 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|80 Years|No|||February 2009|February 19, 2009|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279032||186008|
NCT00279617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Miefert|Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks|Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks||Lindner Center of HOPE||Completed|January 2006|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2011|December 12, 2011|January 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00279617||185964|
NCT00279929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|669-02|DHEA Replacement in Adrenalectomized/Hypoadrenal Patients|Assessing the Effects of Dehydroepiandrosterone Replacement on the Mood of Adrenalectomised/Hypoadrenal Subjects||Mayo Clinic||Completed|July 2002|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Female|18 Years|75 Years|No|||May 2011|May 20, 2011|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279929||185940|
NCT00307463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ege1336|Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation|Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation: a Randomised, Prospective and Controlled Study||Ege University|Yes|Completed|September 2005|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|70 Years|No|||September 2013|September 6, 2013|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00307463||183882|
NCT00307476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24200|Comparison of Rectal Trumpet and Standard Care|A Clinical Comparison of the Rectal Trumpet and Standard Care in Acutely Ill Patients With Fecal Incontinence||Christiana Care Health Services||Terminated|September 2005|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|March 24, 2006|||Unable to recruit target enrollment numbers|No||https://clinicaltrials.gov/show/NCT00307476||183881|
NCT00298987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-033|A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate|Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate||Bristol-Myers Squibb||Completed|February 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||June 2008|February 4, 2010|March 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298987||184512|
NCT00294853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05099|Multi Detector-Row Computed Tomography (MDCT) Calcium Score of Heart Transplanted Patients|MDCT Calcium Score of Heart Transplanted Patients||Oslo University Hospital||Completed|December 2005|June 2007||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|240|||Both|18 Years|N/A|No|||April 2008|July 3, 2011|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00294853||184823|
NCT00298961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TelepsychiatryCTIL|Psychiatric Consultation Through Videoconference in a Primary Care Setting|Telepsychiatry: Cost Analysis, Quality of Life, Satisfaction and Effectiveness of Psychiatric Consultation Through Videoconference in a Primary Care Setting||Sha’ar Menashe Mental Health Center||Not yet recruiting|May 2006|November 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|March 2, 2006||||No||https://clinicaltrials.gov/show/NCT00298961||184514|
NCT00298974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-697|A Study of Pain Relief in Osteoarthritis|A Phase 3, Randomized, Multicenter, Double-blind Study Comparing the Analgesic Efficacy of Extended Release Hydrocodone/Acetaminophen Tablets (Vicodin CR) to Placebo in Subjects With Osteoarthritis||Abbott|No|Completed|February 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|873|||Both|21 Years|80 Years|No|||January 2011|January 24, 2011|March 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298974||184513|
NCT00276718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454749|Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors|Germ Cell Tumour Study II||National Cancer Institute (NCI)||Active, not recruiting|April 1989|||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|N/A|15 Years|No|||February 2006|September 16, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276718||186177|
NCT00276952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCUCH-NL-GTX-002|Gonyautoxin in the Treatment of Chronic Tension-Type Headache|Phase 2 Study of Treatment of Chronic Tension-Type Headache Using Gonyautoxins||University of Chile||Terminated|September 2004|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||27|||Both|18 Years|80 Years|No|||September 2005|January 12, 2006|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276952||186159|
NCT00280748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0409|Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer|A Phase II Study of Treatment of Brain Metastases From Non-Small Cell Lung Cancer With Concurrent Whole Brain Radiation Therapy and Pemetrexed|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|May 2005|April 2009|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00280748||185878|
NCT00277537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-B-301|Safety and Efficacy of Bronchitol in Bronchiectasis|A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis.||Pharmaxis|Yes|Completed|March 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|354|||Both|15 Years|80 Years|No|||August 2008|August 27, 2008|January 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277537||186117|
NCT00277888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-Cathedia|Comparison of Femoral Versus Jugular Routes for Temporary Hemodialysis in Seriously Ill Patients|Complications of Jugular and Femoral Venous Catheterization in Critically Ill Patients Requiring Hemodialysis: A Randomized Controlled Trial|CATHEDIA|University Hospital, Caen||Completed|April 2004|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|750|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277888||186092|
NCT00276913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5312-02|A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors|A Phase I Study of STA-5312 Administered Weekly in Subjects With Advanced or Metastatic Solid Tumors||Synta Pharmaceuticals Corp.||Completed|June 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|January 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00276913||186162|
NCT00276926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HES0203|Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias|Open Label Pilot Phase II Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias||University of Bologna||Recruiting|March 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||September 2009|September 14, 2009|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276926||186161|
NCT00278733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B05 0636|Campus Health Intervention Projects UBC Site|Campus Health Intervention Projects to Reduce High Risk Drinking Among University Students by Means of Brief Physician Advice||University of British Columbia||Completed|February 2006|May 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 7, 2007|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278733||186031|
NCT00278707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3968-YA-CTIL|GTA-Glyceryltriacetate for Canavan Disease|Phase 1 Treatment With GTA in Two Infant With Canavan Disease||Sheba Medical Center||Active, not recruiting|January 2006|July 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|N/A|15 Months|No|||August 2006|August 11, 2006|January 15, 2006||||No||https://clinicaltrials.gov/show/NCT00278707||186032|
NCT00279045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/048|Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide|A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|January 2000|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|4426|||Both|30 Years|75 Years|No|||April 2015|April 10, 2015|January 17, 2006||||||https://clinicaltrials.gov/show/NCT00279045||186007|
NCT00279279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223|PREPARE - Primary Prevention Parameters Evaluation|PREPARE - Primary Prevention Parameters Evaluation||Medtronic Cardiac Rhythm Disease Management||Completed|October 2003|May 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||700|||Both|18 Years|N/A|No|||October 2006|October 25, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279279||185989|
NCT00310440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003|An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation|An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation||CeraPedics, Inc|Yes|Active, not recruiting|January 2006|May 2019|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|April 3, 2006|No|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT00310440||183657|
NCT00310765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3727|Pregabalin for Abdominal Pain From Adhesions|Pregabalin for the Treatment of Abdominal Pain From Adhesions: Placebo Controlled Trial||Henry Ford Health System|No|Terminated|March 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|March 31, 2006||No|Study was terminated by the sponsor due to low accrual.|No||https://clinicaltrials.gov/show/NCT00310765||183632|
NCT00311077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_1502|Insulin Glulisine in Healthy Lean and Obese Subjects|Pharmacodynamic and Pharmacokinetic Properties of Insulin Glulisine (Apidra) in Comparison to Insulin Lispro (Humalog) in Healthy Lean and Obese Subjects||Sanofi||Completed|April 2004|||October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00311077||183608|
NCT00307177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-036|Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma|Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma: A Phase II, Double-Blind Pilot Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2004|April 2005||April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|28|||Both|18 Years|N/A|No|||November 2006|December 4, 2014|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00307177||183902|
NCT00307489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0106|Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil|A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adefovir Dipivoxil for Chronic Hepatitis B and Having Persistent Viral Replication||Gilead Sciences|No|Completed|March 2006|October 2010|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|69 Years|No|||October 2011|October 4, 2011|March 24, 2006|Yes|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00307489||183880|The randomized and treated (RAT) analysis set includes all subjects who were ongoing at the time of analysis (i.e., those on blinded therapy and those who switched to open-label FTC/TDFdue to persistent viremia).
NCT00305123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0002|Molecular Epidemiology of Streptococcus Pyogenes Among Children in Bamako, Mali|The Molecular Epidemiology of Streptococcus Pyogenes Among Children in Bamako, Mali (Bamako BGAS2000)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1757|Samples With DNA|GAS isolates.|Both|5 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|5-16 year old children with complaints consistent with pharyngitis attending 4 public        schools in Bamako, Mali.|October 2009|February 14, 2013|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00305123||184057|
NCT00305604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-047|Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Sitagliptin in Elderly Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|March 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|65 Years|N/A|No|||February 2015|February 3, 2015|March 20, 2006|Yes|Yes||No|February 24, 2009|https://clinicaltrials.gov/show/NCT00305604||184021|
NCT00298662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-020826|Combination Therapy of Betaseron-Prograf in Multiple Sclerosis|A Pilot Safety and Tolerability Open-Label Study of Interferon Beta-1b in Combination With Tacrolimus in Patients Suffering From Multiple Sclerosis Who Have Failed Treatment With Approved Disease Modifying Agents||Clinique de sclérose en plaques et neuromusculaire de l'Outaouais||Active, not recruiting|February 2003|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|55 Years|No|||September 2005|March 2, 2006|March 2, 2006||||No||https://clinicaltrials.gov/show/NCT00298662||184536|
NCT00295386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK Vest nr. 186.03|Cognitive-Behavioural and Hypnotic Treatment of Chronic Primary Insomnia Among the Elderly|||University of Bergen||Completed|January 2004|December 2007|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|55 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 2, 2009|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295386||184783|
NCT00276965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074707|Bipolar II Depression: Lithium, SSRI, or the Combination|Comparing the Safety and Effectiveness of a Mood Stabilizing Medication, an Antidepressant Medication, and a Combination of Both Medications to Treat Symptoms of Bipolar Type II Depression||Lindner Center of HOPE|Yes|Completed|September 2006|July 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|139|||Both|18 Years|65 Years|No|||May 2013|May 8, 2013|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276965||186158|
NCT00277290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-202|Study of XL999 in Patients With Previously Treated Ovarian Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer||Symphony Evolution, Inc.|Yes|Terminated|January 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||February 2010|February 18, 2010|January 12, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subjects|Yes||https://clinicaltrials.gov/show/NCT00277290||186134|
NCT00277264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.259|Spiriva® Assessment of FEV1 (SAFE)|Spiriva® Assessment of FEV1 (SAFE). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Long-term Treatment in Patients With COPD. A One-year Parallel Group, Double-blind, Randomised, Placebo-controlled Study||Boehringer Ingelheim||Completed|January 2002|May 2004||May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||914|||Both|40 Years|N/A|No|||November 2013|November 5, 2013|January 9, 2006||||No||https://clinicaltrials.gov/show/NCT00277264||186136|
NCT00277901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-122|MRI Assessment of RV Function: Patients With TOF or Aortic Coarctation|MRI Assessment of Two Congenital Heart Disease States: Assessment of Right Ventricular Function: Predictor of Optimal Timing of Pulmonary Valve Replacement in Patients With TOF; Assessment of Flow Dynamics in Patients With Aortic Coarctation||Children's Healthcare of Atlanta|No|Completed|March 2002|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|390|||Both|N/A|21 Years|No|Non-Probability Sample|The study population is Patients with the diagnosis of Tetralogy of Fallot or Aortic        Coarctation being Treated at Children's Healthcare of Atlanta at Egleston|November 2014|November 26, 2014|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00277901||186091|
NCT00277524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601|OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.|OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.|OMNI|Medtronic Cardiac Rhythm Disease Management|No|Terminated|August 2005|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3032|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving a specified Medtronic Implantable Pulse Generator(IPG), Implantable        Cardioverter Defibrillator(ICD), or Cardiac Resynchronization Therapy-Defibrillator(CRT-D)        device where informed consent and/or authorization to use and disclose health information        permission has been granted.|May 2013|May 21, 2013|January 12, 2006|Yes|Yes|Ended follow-up after four years|No|July 13, 2012|https://clinicaltrials.gov/show/NCT00277524||186118|
NCT00277862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G43230832638|Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4|Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4||Ain Shams University|Yes|Completed|April 2002|April 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|280|||Both|18 Years|55 Years|No|||February 2008|February 25, 2008|January 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277862||186094|
NCT00277875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0217|STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH|The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.||Synvista Therapeutics, Inc|No|Completed|February 2004|January 2006|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||25|||Both|50 Years|N/A|No|||January 2006|August 26, 2009|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277875||186093|
NCT00309881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455040|Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia That Did Not Respond to Fludarabine (Closed to Entry as of 10/2006), Chronic Lymphocytic Leukemia With Autoimmune Hemolytic Anemia, or Richter Transformation|CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)||National Cancer Institute (NCI)||Recruiting|April 2003|||||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||January 2010|August 23, 2013|March 29, 2006||||No||https://clinicaltrials.gov/show/NCT00309881||183698|
NCT00279058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pepDCIL2- HMO-CTIL|The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2|The Role of Autologous Dendritic Cells Pulsed by Melanoma Associated Peptides to Augment the Therapeutic Effect of Interleukin-2||Hadassah Medical Organization||Completed|December 2005|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|65 Years|No|||April 2007|April 19, 2015|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00279058||186006|
NCT00310453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-09|Tolerability of ALK Grass Tablet in Children|A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of ALK Grass Tablet in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)||ALK-Abelló A/S||Completed|March 2006|May 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||32|||Both|5 Years|12 Years|No|||May 2006|May 3, 2006|April 2, 2006||||No||https://clinicaltrials.gov/show/NCT00310453||183656|
NCT00280800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1187|Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Sleep Apnea|Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Obstructive Sleep Apnea Syndrome||University of Zurich|No|Completed|January 2006|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|75 Years|No|||May 2014|May 14, 2014|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280800||185874|
NCT00281099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240|Managed Ventricular Pacing ("MVP") Trial|MVP Trial (Managed Ventricular Pacing ("MVP") Versus Backup Ventricular Pacing at a Rate of 40 Beats Per Minute ("VVI 40") Pacing Trial)|MVP|Medtronic Cardiac Rhythm Disease Management|Yes|Terminated|October 2004|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1031|||Both|18 Years|N/A|No|||July 2010|July 30, 2010|January 20, 2006|Yes|Yes|Inability to reach statistical significance toward primary endpoint|No|June 30, 2009|https://clinicaltrials.gov/show/NCT00281099||185851|
NCT00306891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00021|Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)|Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin™), Followed by an Assessment of the Safety & Tolerability of Fixed and Individualised Daily Dosing||AstraZeneca||Completed|June 2006|September 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|March 23, 2006|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT00306891||183924|
NCT00306904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU211|Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema|A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Diabetic Macular Edema||OPKO Health, Inc.|Yes|Completed|January 2006|December 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|21 Years|N/A|No|||July 2008|July 24, 2008|March 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00306904||183923|
NCT00306917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD|Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement|A Prospective, Randomized Study of Summit™ Porocoat® Versus Summit™ DuoFix™ HA in Cementless Total Hip Arthroplasty||DePuy Orthopaedics|No|Terminated|November 2002|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|N/A|75 Years|No|||December 2011|December 1, 2011|March 23, 2006|Yes|Yes|Terminated due to limited enrollment and follow up.|No|January 29, 2010|https://clinicaltrials.gov/show/NCT00306917||183922|The protocol called for 400 subjects to be followed for 5 years, but due to slow enrollment the study closed early. 245 subjects were enrolled & study endpoint was modified to 2 years. Enrollment closed on June 30, 2006; study closed on Jan 29, 2009.
NCT00307190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4735/#5797R|Hormone Release and Stomach Disturbances in People With Binge Eating Disorder|Postprandial Cholecystokinin Release and Gastric Emptying in Binge Eating Disorder||New York State Psychiatric Institute|No|Completed|October 2004|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|Samples Without DNA|Blood serum|Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, obese women between ages 18 and 60 with and without Binge Eating Disorder|May 2012|May 25, 2012|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00307190||183901|
NCT00298090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-1502-319|Evaluation of a Radial Arterial Line's Effect on StO2 Monitoring|An Evaluation of a Radial Arterial Line's Effect on StO2 Monitoring Using the InSpectra® Tissue Spectrometer||The University of Texas Health Science Center at San Antonio|No|Completed|January 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients wiht arterial lines|November 2014|November 14, 2014|February 27, 2006||No||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00298090||184580|Eighteen subjects were not included in final analysis due to incomplete data sets; unsuccessful arterial line placement, technical problems in applying StO2 device, unreliable data or partial data.
NCT00298103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0602065|Antibiotic Resistant Community-Acquired E. Coli|Antibiotic Resistant Community-Acquired E. Coli||University of Pittsburgh|Yes|Completed|February 2006|December 2015|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|N/A|N/A|No|Non-Probability Sample|patients with e coli infections|December 2015|December 16, 2015|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00298103||184579|
NCT00295100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278100|Tamoxifen-MRI Study|Cancer Risk and Biomarkers of Tamoxifen Chemoprevention||University of Pennsylvania||Completed|September 2000|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||78|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 20, 2007|February 20, 2006||||No||https://clinicaltrials.gov/show/NCT00295100||184804|
NCT00295113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2398|Interest of a 30 Minutes' Intermittent Work Exercise Test in Patients With Chronic Obstructive Pulmonary Disease: Cardiac and Pulmonary Functions|Interest of a 30 Minutes' Intermittent Work Exercise Test in Patients With Chronic Obstructive Pulmonary Disease: Cardiac and Pulmonary Functions||University Hospital, Strasbourg, France||Completed|November 2001|June 2003||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|10|||Both|18 Years|65 Years|No|||November 2007|November 28, 2007|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00295113||184803|
NCT00306111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rpm_001|Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma|Pegfilgrastim Versus Filgrastim - Intraindividual Comparison of Quantity and Quality of Mobilized Peripheral Blood Stem Cells in Patients With Non Hodgkin-lymphoma||University Hospital Tuebingen|No|Completed|January 2006|December 2011|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2012|May 28, 2014|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00306111||183984|
NCT00276744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0507, CDR0000455000|Individualized Drug Treatment Selection Process for Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|October 2005|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276744||186175|
NCT00276978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aripiprazole Augmentation|Aripiprazole Augmentation Therapy in Treatment-resistant Depression|Aripiprazole Augmentation Therapy in Treatment-resistant Depression||University Hospital Freiburg|No|Recruiting|June 2005|November 2009|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||February 2009|January 12, 2010|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00276978||186157|
NCT00277277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 EG002311-02|In-Home Weight Loss Program for Adults With Type 2 Diabetes Delivered by Interactive Cable Television Technology|Telehealth Delivery of a Weight Loss Program in Diabetes||Bastyr University||Completed|August 2004|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||19|||Both|18 Years|N/A|No|||October 2007|October 29, 2007|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277277||186135|
NCT00277576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM HBV-001|Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection|Phase I, Multi-Centre, Randomised, Placebo-Controlled, Dose Escalation Study to Assess Local & Systemic Tolerability of Therapeutic DNA Plasmid pdpSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using PowderJect ND10 Delivery System in Subjects With Chronic Hepatitis B Infection||PowderMed||Completed|January 2006|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|50 Years|No|||November 2008|November 20, 2008|January 13, 2006||||||https://clinicaltrials.gov/show/NCT00277576||186114|
NCT00277589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9133|LISA-study : Levothyroxin in Nodular Goiter|TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter||Sanofi||Completed|May 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|1024|||Both|18 Years|65 Years|No|||December 2009|December 3, 2009|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00277589||186113|
NCT00278161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0260 CDR0000451458|Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma|Phase II Study of High Dose Cyclophosphamide and Rituximab in Low Grade and Mantle Cell Lymphoma||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2005|July 2011|Actual|December 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|70 Years|No|||April 2014|April 16, 2014|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278161||186071|
NCT00278174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE15804|Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer|A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma||Case Comprehensive Cancer Center|Yes|Completed|February 2005|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278174||186070|
NCT00278434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000460044|Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3|An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3||University of California, San Francisco|Yes|Terminated|April 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Female|18 Years|N/A|No|||August 2013|August 2, 2013|January 16, 2006||No|Accrual was insufficient to meet study endpoints|No||https://clinicaltrials.gov/show/NCT00278434||186053|
NCT00280241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-136|Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia|Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia||University of Pittsburgh|Yes|Completed|June 2004|January 2013|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 19, 2006|Yes|Yes||No|January 5, 2016|https://clinicaltrials.gov/show/NCT00280241||185917|
NCT00280254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA-ICC01|A Hemodynamically Oriented Echocardiography-Based Strategy in the Treatment of Congestive Heart Failure|A Hemodynamically Oriented Echocardiography-Based Strategy in the Treatment of Congestive Heart Failure||Federal University of Rio Grande do Sul||Terminated|November 1999|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||102|||Both|18 Years|N/A|No|||January 2006|January 19, 2006|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00280254||185916|
NCT00310154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466391|Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study||Comprehensive Cancer Center of Wake Forest University|No|Completed|November 2003|August 2010|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||November 2011|November 30, 2011|March 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00310154||183678|
NCT00310427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060129|Effect of LY686017 on Alcohol Craving|NK1 Receptor Antagonism for Treatment of Anxiety and Craving in Anxious Alcohol Dependent Subjects During Early Abstinence||National Institutes of Health Clinical Center (CC)|No|Completed|March 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|21 Years|65 Years|No|||April 2010|April 13, 2010|April 1, 2006|No|Yes||No|March 5, 2010|https://clinicaltrials.gov/show/NCT00310427||183658|
NCT00276770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455011|Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas|NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy Using [F18] Fluorothymidine (FLT) As a Marker of Proliferation in Patients With Primary Brain Tumors||University of Washington||Completed|February 2006|||May 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00276770||186173|
NCT00277017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1500C|Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma|A Phase I/II Trial of Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, and Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma.||New Mexico Cancer Care Alliance|Yes|Completed|September 2000|August 2005|Actual|August 2005|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||December 2009|September 23, 2011|January 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277017||186154|
NCT00277030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOUC022005|Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams|Comparative Trial of Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams||Pontificia Universidad Catolica de Chile||Recruiting|January 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|N/A|1 Day|No|||December 2005|August 22, 2006|January 5, 2006||||No||https://clinicaltrials.gov/show/NCT00277030||186153|
NCT00276510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-31-00240-011|A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints|Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70||Ipsen||Completed|February 2002|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2878|||Both|70 Years|N/A|No|||December 2009|December 14, 2009|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00276510||186191|
NCT00297752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO/PO.109|Treatment of Facial Burns With Flammacerium Compared to Flammazine and the Impact of Facial Burns on Psychosocial Wellbeing|A Randomised Multicentre Clinical Trial on the Efficacy of Flammacerium in the Treatment of Facial Burns and the Impact of Facial Burns on Psychosocial Wellbeing||Association of Dutch Burn Centres||Completed|March 2006|December 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|180|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00297752||184605|
NCT00297765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-02-002|Optimizing Prograf® Therapy in Renal Transplant Patients|OPTIMA (Optimizing Prograf® Therapy in Renal Transplant Patients)|OPTIMA|Astellas Pharma Inc|Yes|Completed|January 2003|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|323|||Both|18 Years|N/A|No|||December 2007|August 25, 2008|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00297765||184604|
NCT00297778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.596|Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms|A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms||Boehringer Ingelheim||Completed|March 2006|||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|296|||Both|30 Years|80 Years|No|||April 2014|June 3, 2014|February 28, 2006|Yes|Yes||No|May 22, 2009|https://clinicaltrials.gov/show/NCT00297778||184603|
NCT00298675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11483|Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors|A Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors||Sanofi||Completed|March 2006|May 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|March 1, 2006|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00298675||184535|
NCT00298688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0559|A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer|Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer||AstraZeneca||Completed|September 2004|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||June 2008|June 11, 2008|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298688||184534|
NCT00305370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG03-325b|Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD|Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial||Federal University of Rio Grande do Sul||Completed|August 2005|March 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|8 Years|17 Years|No|||March 2006|August 6, 2008|March 19, 2006||||No||https://clinicaltrials.gov/show/NCT00305370||184039|
NCT00305838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463518|CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen|Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen||National Cancer Institute (NCI)||Recruiting|March 2004|||December 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|200|||Female|N/A|N/A|No|||June 2009|August 9, 2013|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00305838||184004|
NCT00305851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANUR0631|Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant|Music Video and Adolescent/Young Adult Resilience During Transplant||Children's Oncology Group|Yes|Completed|April 2006|||April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|118|||Both|11 Years|24 Years|No|||February 2016|February 19, 2016|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305851||184003|
NCT00305864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01092|Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME||National Cancer Institute (NCI)||Completed|February 2006|March 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|118|||Both|18 Years|N/A|No|||October 2011|April 29, 2014|March 21, 2006|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00305864||184002|
NCT00312741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pneumonia1|Usefulness of Microbiological Tests in Community-Acquired Pneumonia|Prospective Study on Benefits Derived From Microbiological Tests in Community-Acquired Pneumonia||Hospital Arnau de Vilanova|No|Recruiting|April 2006|May 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|No|||February 2009|February 26, 2009|April 7, 2006||||No||https://clinicaltrials.gov/show/NCT00312741||183480|
NCT00312754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-108|A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome|A Phase IV, One-arm, Open-label, Multicenter Study Evaluating Effect of Treatment Change to Atazanavir/Ritonavir on Brachial Endothelial Function of HIV Infected Patient Receiving Function in HIV Infected Patient Receiving Potent Antiretroviral Combination Therapy||Bristol-Myers Squibb||Terminated|June 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||June 2008|February 3, 2010|November 14, 2005|Yes|Yes|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00312754||183479|
NCT00277550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919EUS42|The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia|A Randomized, Double-blind, Placebo-controlled Evaluation of the Effects of Tegaserod (6 mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia||Novartis||Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 13, 2006||||||https://clinicaltrials.gov/show/NCT00277550||186116|
NCT00277563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Weintraub|Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome|Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome (Cts): A Randomized, Placebo-Controlled Trial With Secondary Bayesian Modification||Weintraub, Michael I., MD, FACP, FAAN||Completed|June 2004|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||September 2007|September 20, 2007|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277563||186115|
NCT00309010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060126|Neurophysiology of Task-Specificity of Focal Hand Dystonia|Neurophysiology of Task-Specificity of Focal Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|March 2006|February 2009||||N/A|Observational|N/A||||115|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 25, 2009|March 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00309010||183763|
NCT00309023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-001|Study of BMS-663513 in Patients With Advanced Cancer|A Phase I/II, Ascending Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients With Metastatic or Locally Advanced Solid Malignancies||Bristol-Myers Squibb|No|Terminated|December 2005|September 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309023||183762|
NCT00277914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.74|Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women|12-month Sustained Efficacy of Flibanserin v Placebo n Younger Women With HSDD in NA||Sprout Pharmaceuticals, Inc||Completed|January 2006|||July 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|749|||Female|18 Years|45 Years|No|||March 2012|March 14, 2012|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277914||186090|
NCT00309595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE04-03|The Study to Compare SMART Nitinol Stent and Balloon Angioplasty|A Multi-Center Prospective, Randomized, Two-Arm Clinical Investigation of the Cordis SMARTTM Nitinol Self Expandable Stent Versus Balloon Angioplasty Only for the Treatment of Superficial Femoral Artery Occlusions.|SIT-UP|Cordis Corporation|Yes|Completed|December 2005|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|N/A|No|||June 2009|June 10, 2009|March 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00309595||183719|
NCT00280553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2399|A Pilot Study of Bupivacaine Infusion in Abdominal Surgery|A Pilot Study of Bupivacaine Infusion in Abdominal Surgery||McMaster University||Recruiting|April 2005|April 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||May 2012|May 14, 2012|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280553||185893|
NCT00281112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1196|Center for Reducing Asthma Disparities - Howard/Hopkins Centers|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||July 2008|July 23, 2008|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281112||185850|
NCT00280540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BUS05|Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension|A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension||Novartis||Completed|December 2005|||August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||648|||Both|18 Years|N/A||||March 2008|November 5, 2010|January 19, 2006||||||https://clinicaltrials.gov/show/NCT00280540||185894|
NCT00276783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05C2|Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases|A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases||Northwestern University|Yes|Active, not recruiting|November 2005|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276783||186172|
NCT00297427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002175-01A1|Acupuncture for Urinary Incontinence|Efficacy of Acupuncture in Treating Urinary Incontinence||University of Pittsburgh|Yes|Completed|October 2005|July 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Female|25 Years|N/A|No|||June 2012|June 22, 2012|February 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00297427||184629|
NCT00298428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051004|Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)|Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)|SPACE|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2006|December 2008|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|159|||Both|18 Years|N/A|No|||June 2011|September 23, 2011|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298428||184554|
NCT00304863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17937|Addition of Lactobacillus to Metronidazole in Treatment of CDAD|Addition of a Probiotic (Lactobacillus GG) to Metronidazole for the Treatment of Clostridium Difficile Associated Disease||VA Medical Center, Houston||Completed|January 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304863||184076|
NCT00305383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA003142-202|Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C|Analysis of Hepatitis C Viral Kinetics and Viramidine Pharmacokinetics Utilizing Two Treatment Regimens in Therapy-Naive Patients With Chronic Hepatitis C||Valeant Pharmaceuticals International, Inc.||Terminated|November 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||June 2012|June 21, 2012|March 17, 2006|Yes|Yes|Dose levels were determined to be subtherapeutic|No||https://clinicaltrials.gov/show/NCT00305383||184038|
NCT00305617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-6503|Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer|Evaluation of CSF Levels of Tarceva (OSI-774) in Patients With Stage III Non-Small Cell Lung Cancer and No CNS Involvement Undergoing Treatment With Tarceva||The Cleveland Clinic||Completed|January 2004|||December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Diagnostic|||Anticipated|10|||Both|N/A|N/A|No|||July 2009|May 13, 2011|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00305617||184020|
NCT00279097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0038|Safety Study to Evaluate Intracranial Pressure During High Frequency Chest Wall Oscillation|A Safety Study to Evaluate Intracranial Pressure With the Utilization of High Frequency Chest Wall Oscillation (HFCWO) Using the Vest™ on Mechanically Ventilated Neurosurgical Patients||Hill-Rom||Terminated|January 2006|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||November 2006|November 15, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279097||186003|
NCT00312429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2166|Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer|Cord Blood Transplantation in Adult Recipients||Duke University|No|Completed|January 2002|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|70 Years|No|||April 2012|April 2, 2012|April 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00312429||183504|
NCT00312442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC/WST0512 66N/WST 2.21|Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy|Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy||STEBA France|Yes|Terminated|May 2006|December 2009|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|N/A|No|||May 2010|May 31, 2010|March 30, 2006||No|STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11    make it safer and better candidate for therapeutic applications.|No||https://clinicaltrials.gov/show/NCT00312442||183503|
NCT00278759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0501|Unclogging the Pediatric Emergency Room: Impact of Rapid Viral Diagnostics|Unclogging the Pediatric Emergency Room: Impact of Rapid Viral Diagnostics. A Randomized Controlled Trial of Decision Making Based Upon Early (at Triage) Rapid Diagnosis of Respiratory Viral Infections (VIRAP) in Children 3-36 Months of Age Presenting to the Emergency Department (ED) With a Flu-Like Illness.||University of British Columbia|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|275|||Both|3 Months|36 Months|Accepts Healthy Volunteers|||August 2008|February 17, 2009|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278759||186029|
NCT00277303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-206|Study of XL999 in Patients With Metastatic Colorectal Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer||Symphony Evolution, Inc.|Yes|Terminated|December 2005|February 2007|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|January 12, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subjects|No||https://clinicaltrials.gov/show/NCT00277303||186133|
NCT00279955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|235|PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure|Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure||Medtronic Cardiac Rhythm Disease Management||Completed|June 2004|June 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1024|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving a specified Medtronic Implantable Cardiac Resynchronization Therapy        Defibrillator device where informed consent and/or authorization to use and disclose        health information permission has been granted.|June 2012|June 11, 2012|January 18, 2006||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00279955||185938|
NCT00279968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231|INSIGHTS ICD Registry|Investigating Significant ICD Heart Therapies Registry Study (INSIGHTS ICD Registry)||Medtronic Cardiac Rhythm Disease Management||Completed|February 2004|January 2006||||N/A|Observational|Time Perspective: Prospective||||1326|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00279968||185937|
NCT00279630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022051|Exercise and Shoe Orthoses in Treatment of Posterior Tibial Tendon Dysfunction|Phase 1 Study on Effectiveness of Exercise on Function, Quality of Life and Disability in Patients With Posterior Tibial Tendon Dysfunction||University of Southern California||Completed|June 2002|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|70 Years|No|||December 2014|December 2, 2014|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00279630||185963|
NCT00279942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2155-05|Effect of Revival Soy on Fibromyalgia Pain|Effect of Revival Soy on Fibromyalgia Pain||Mayo Clinic|Yes|Completed|May 2006|September 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|76 Years|No|||January 2012|January 4, 2012|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00279942||185939|
NCT00280566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281137|Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)|A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment With Both Agents||Pfizer|No|Completed|December 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|584|||Both|18 Years|N/A|No|||January 2010|January 5, 2010|January 19, 2006|Yes|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00280566||185892|This is a maintenance of effect design using a survival analysis methodology. In such a design it may be difficult to interpret timepoint by timepoint treatment group comparisons in MRS, CGI-S, CGI-I, MADRS, and PANSS.
NCT00280579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-277/99|Cyanide Poisoning in Fire Victims|||Rigshospitalet, Denmark||Withdrawn|January 2006|January 2007||||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|January 20, 2006|||Not sufficient time to conduct the study|No||https://clinicaltrials.gov/show/NCT00280579||185891|
NCT00281125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVCI05-14|Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer|A Two-Cohort Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin in Patients With Advanced Non-Small Cell Lung Cancers and Malignant Pleural Mesotheliomas||Nevada Cancer Institute|Yes|Terminated|January 2006|August 2008|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|January 6, 2006||Yes|Suspended due to data issues revealed at DSMB meeting. Planned amendment but was never    submitted. Study was then closed.|No||https://clinicaltrials.gov/show/NCT00281125||185849|
NCT00280813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21942|Alcohol Use Disorders in Schizophrenia|Treatment of Alcohol Use Disorders in Schizophrenia||University of Maryland|No|Completed|March 2004|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|22 Years|60 Years|No|||October 2008|October 24, 2008|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280813||185873|
NCT00280826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060046|Efalizumab to Treat Uveitis|Treatment of Non-Infectious Intermediate and Posterior Uveitis Associated Macular Edema With Humanized Anti-CD11a Antibody Therapy||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2006|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2011|January 28, 2011|January 21, 2006|No|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00280826||185872|
NCT00280839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-298|Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation|A Double-Blind, Placebo-Controlled, 11-Week Trial of Topiramate as an Aid to Smoking Cessation||Lindner Center of HOPE||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|65 Years|No|||April 2012|April 11, 2012|September 13, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00280839||185871|
NCT00280852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18940|Review of Multimodality Management of Anaplastic Thyroid Cancer|A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer||AHS Cancer Control Alberta||Completed|January 2006|June 2006|Actual|June 2006|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|5|||Both|N/A|N/A|No|Probability Sample|anaplastic thyroid cancer|July 2011|November 18, 2011|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00280852||185870|
NCT00277069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2899C|Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer|INST: Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer||University of New Mexico|Yes|Completed|May 2000|March 2006|Actual|March 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|75 Years|No|||October 2008|January 6, 2010|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277069||186150|
NCT00298116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502108|Molecular Associations With Reproductive Failure|Molecular Associations With Reproductive Failure||University of Pittsburgh||Completed|September 2000|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|475|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Patients are recruited through Genetics during a counseling session.|December 2014|December 5, 2014|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00298116||184578|
NCT00304590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-203|Study of XL999 in Patients With Multiple Myeloma|A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma||Symphony Evolution, Inc.|Yes|Terminated|February 2006|May 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|March 16, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subjects|No||https://clinicaltrials.gov/show/NCT00304590||184097|
NCT00306150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12002|Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy|A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy.||Bayer||Terminated|December 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|March 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00306150||183981|
NCT00306423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#025027|Rehabilitation Post Lumbar Microdiscectomy|||University of Southern California||Active, not recruiting|June 2003|September 2012|Anticipated|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|60 Years|No|||June 2012|June 15, 2012|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00306423||183960|
NCT00306436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9286-01|Comprehensive Management of Diabetic Patients With Renal Impairment : Impact on Blood Pressure and Glycemic Control|Evaluation of the Impact of a Comprehensive Clinical Management on the Quality of Blood Pressure and Glycemic Control in Diabetic Uremic Patients||University Hospital, Bordeaux|Yes|Recruiting|May 2006|May 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2007|June 12, 2007|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00306436||183959|
NCT00306761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSU_Thrasher|Effects of Dynamic Wheelchair Seating on Spasticity and Functional Mobility in Children|Effects of Dynamic Wheelchair Seating on Spasticity and Functional Mobility in Children||Montana State University|No|Completed|April 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|4 Years|12 Years|No|||September 2014|September 15, 2014|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00306761||183934|
NCT00306774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR051361|Vitamin D to Slow Progression of Knee Osteoarthritis|Trial of Vitamin D to Reduce the Progression of Knee Osteoarthritis: A Double-Blind, Placebo-Controlled Once Daily Dosing Regimen||Tufts Medical Center|Yes|Completed|March 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|45 Years|90 Years|No|||September 2011|September 21, 2011|March 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00306774||183933|
NCT00278811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09541|Emergency Linkage to Outpatient Psychiatric Services|Emergency Linkage to Outpatient Psychiatric Services||University of Rochester|Yes|Completed|April 2003|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278811||186025|
NCT00278460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462116|Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer||Comprehensive Cancer Center of Wake Forest University|No|Completed|November 2000|September 2007|Actual|February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278460||186051|
NCT00278473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071721|Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults|Treatment of Meta-Cognitive Deficits in Adults With ADHD||National Institute of Mental Health (NIMH)|No|Active, not recruiting|May 2005|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|65 Years|No|||November 2008|December 30, 2008|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00278473||186050|
NCT00308737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-030|Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes|Pulmonary Outcomes Within a 2-Year Period in Subjects With Diabetes Mellitus Treated With Technosphere /Insulin or Usual Antidiabetic Treatment and in Subjects Without Abnormalities in Glucose Control.||Mannkind Corporation||Completed|June 2005|October 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2053|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|March 28, 2006|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00308737||183784|
NCT00280267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AG023716|Testosterone Therapy After Hip Fracture in Elderly Women|Testosterone Therapy After Hip Fracture in Elderly Women||Washington University School of Medicine|Yes|Completed|August 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|15|||Female|65 Years|N/A|No|||February 2009|February 3, 2009|January 19, 2006||Yes||||https://clinicaltrials.gov/show/NCT00280267||185915|
NCT00280280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050935|Botox vs. Baclofen for Upper Limb Spasticity|Double-blind Comparison of Botox Versus Baclofen for the Treatment of Subjects With Upper Limb Spasticity - Pilot Study||Vanderbilt University|No|Terminated|February 2006|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|January 18, 2006||No|low patient accrual|No||https://clinicaltrials.gov/show/NCT00280280||185914|
NCT00280865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-SBD-0001|GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes|Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes||AstraZeneca||Completed|April 2002|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|30 Years|50 Years|No|||July 2006|July 27, 2006|January 20, 2006||||||https://clinicaltrials.gov/show/NCT00280865||185869|
NCT00276523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000441020|PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery|A Randomized Phase II Study of SCH 54031 in Surgically Resectable Squamous Cell Tumors of the Head and Neck||M.D. Anderson Cancer Center|No|Completed|February 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|3|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00276523||186190|
NCT00276796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456248|Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix||Gynecologic Oncology Group||Completed||||January 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Female|18 Years|N/A|No|||February 2009|May 24, 2013|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276796||186171|
NCT00277082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302C|Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung|Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung (NSCLC)||University of New Mexico|Yes|Completed|August 2003|June 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|Samples Without DNA|Blood, lung tissue, lung cancer tissue.|Both|18 Years|N/A|No|Probability Sample|All patients, 18 years of age or older, with metastatic and/or recurrent endometrial        cancer or with mixed mesenchymal malignant tumors whose epithelial component is recurring,        who have failed standard chemotherapy or hormonal regimens for their disease or who refuse        recommended standard chemotherapy.|April 2008|January 6, 2010|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277082||186149|
NCT00304278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAO-OSI-3601S|Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)|Phase II Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)||Southern Illinois University|Yes|Active, not recruiting|March 2006|December 2015|Anticipated|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|March 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00304278||184119|
NCT00305136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thoracotomyCTIL|Advancement of Psychophysics of Pain Modulation From Lab to Clinic: Constructing Susceptibility Profile for Appearance of Postoperative Neuropathic Pain|Advancement of Psychophysics of Pain Modulation From Lab to Clinic: Constructing Susceptibility Profile for Appearance of Postoperative Neuropathic Pain||Rambam Health Care Campus|No|Active, not recruiting|December 2005|June 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|130|||Both|18 Years|70 Years|No|||June 2007|July 8, 2007|March 19, 2006||||No||https://clinicaltrials.gov/show/NCT00305136||184056|
NCT00306163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/NL-101|Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)|Nebulizer Trial: Evaluation of the Influence of Particle Size of Aerosolized AMP on Bronchial Responsiveness in Patients With Asthma and the Effects of Treatment With Ciclesonide Versus Fluticasone.||Takeda|No|Completed|May 2006|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|60 Years|No|||April 2010|May 4, 2012|March 22, 2006|Yes|Yes||No|April 6, 2010|https://clinicaltrials.gov/show/NCT00306163||183980|
NCT00306176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1975|Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus|Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus||Aristotle University Of Thessaloniki||Completed|January 2005|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||April 2007|April 3, 2007|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306176||183979|
NCT00306449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-48|Prevention of Weight Gain in Young Adults|Prevention of Weight Gain in Young Adults||Université de Sherbrooke||Completed|September 2002|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||110|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2006|March 21, 2006|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00306449||183958|
NCT00306462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-12-27-01|Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor|Randomized Double-Blinded Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor Between 24 to 32 6/7 Weeks' Gestation||University of Cincinnati|No|Terminated|March 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|33|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||November 2009|November 6, 2009|March 21, 2006|No|Yes|No enrollment in past year, lack of interest|No||https://clinicaltrials.gov/show/NCT00306462||183957|
NCT00306787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810A2308|Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes|A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes||Novartis||Completed|March 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1179|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|March 22, 2006|Yes|Yes||No|August 20, 2009|https://clinicaltrials.gov/show/NCT00306787||183932|
NCT00278824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZCM-201|Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain|A Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy of CHADD™ Applied Over a Transdermal Fentanyl Patch for the Treatment of Breakthrough Pain in Patients With Moderate to Severe Non-malignant Chronic Pain||ZARS Pharma Inc.|No|Terminated|January 2006|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|70 Years|No|||June 2012|June 4, 2012|January 16, 2006|No|Yes|Difficulty identifying and enrolling eligible patients|No||https://clinicaltrials.gov/show/NCT00278824||186024|
NCT00279110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018577|Directly Administered HIV Therapy in Methadone Clinics|Directly Administered vs. Self-administered Antiretroviral Therapy in Methadone Clinics||Johns Hopkins University||Completed|April 2006|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||May 2011|April 14, 2015|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00279110||186002|
NCT00279305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ritux|Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||December 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|8 Years|45 Years|No|||January 2009|January 5, 2009|January 17, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00279305||185987|
NCT00279318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63790|TEDDY - The Environmental Determinants of Diabetes in the Young|Consortium for Identification of Environmental Triggers of Type 1 Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|September 2004|September 2025|Anticipated|September 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8668|Samples With DNA|Serum, plasma, PBMCs, stool, urine, saliva, nasal swabs, nail clippings, water|Both|N/A|4 Months|Accepts Healthy Volunteers|Non-Probability Sample|Childen up to 4 months of age with specified HLA are enrolled and followed longitudnally        until 15 years of age|November 2014|November 19, 2014|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00279318||185986|
NCT00279084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003.315|NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels|Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels (110- 129 g/L and 130 - 149 g/L) on Progression of Chronic Kidney Disease in Patients With Type 2 Diabetes and With Chronic Kidney Disease||Hospices Civils de Lyon||Active, not recruiting|January 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||204|||Both|18 Years|80 Years|No|||October 2007|October 3, 2007|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279084||186004|
NCT00279643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 543|The Effect of Laser Hair Removal on Permanent Hair Reduction|The Effect of Laser Hair Removal on Markers of Follicular Stem Cells||University of Michigan|No|Completed|January 2005|June 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 29, 2015|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279643||185962|
NCT00279656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|om050-40/2003|Benefit of a Collaborative Approach to Improve the Quality of Medicines Use in Elderly Inpatients|Collaborative Approach to Improve the Quality of Medicines Use in Elderly Inpatients - Randomized Controlled Trial||Université Catholique de Louvain||Completed|November 2003|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||180|||Both|70 Years|N/A|No|||June 2004|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279656||185961|
NCT00279981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219|TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics|TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics||Medtronic Cardiac Rhythm Disease Management||Completed|November 2003|June 2007|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Prospective||||3100|||Both|18 Years|N/A|No|||December 2008|December 10, 2008|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279981||185936|
NCT00280293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05T-704|Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency|A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence||University of Texas Southwestern Medical Center|No|Completed|March 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|70 Years|No|||July 2013|July 30, 2013|January 19, 2006|Yes|Yes||No|May 13, 2013|https://clinicaltrials.gov/show/NCT00280293||185913|The weekly UDS (rather than thrice weekly as is customary in cocaine trials) design feature decreased our number of observations and statistical power, and did not provide us with a complete picture of cocaine use between weekly visits.
NCT00280878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH204/05|Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma|A Pilot Study of Rituximab in Combination With Out-patient Based VGF/F-GIV Salvage Therapies for Relapsed/Refractory CD20+ Lymphomas||Bayside Health||Completed|January 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||October 2007|January 13, 2016|January 22, 2006||||No||https://clinicaltrials.gov/show/NCT00280878||185868|
NCT00276536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-3575|Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma|Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma|IFNa|The Cleveland Clinic|Yes|Completed|January 2001|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|120 Years|No|||October 2015|October 11, 2015|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276536||186189|
NCT00276549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF7143|Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer|Phase II Trial of Gemcitabine And Docetaxel In Androgen-Independent Metastatic Prostate Cancer||Case Comprehensive Cancer Center|No|Completed|October 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|N/A|No|||January 2013|January 24, 2013|January 12, 2006|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00276549||186188|
NCT00276809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455093|Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia|Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Active, not recruiting|June 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|60 Years|No|||April 2007|November 5, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276809||186170|
NCT00276822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05B4|Improving Communication With Patients With Breast Cancer|Facilitating Caring Communication for People With Cancer: The Case of Breast Cancer||Northwestern University||Terminated|October 2005|||November 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|30 Years|80 Years|No|||June 2012|June 8, 2012|January 12, 2006||No|Preliminary findings did not support purpose.|No||https://clinicaltrials.gov/show/NCT00276822||186169|
NCT00277108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD80|Lexapro in the Treatment of Patients With Postpartum Depression|Open Label Variable Dose Escitalopram (Lexapro) in the Treatment of Patients With Postpartum Major Depression: A Pilot Study||University of Rochester||Completed|February 2004|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|N/A|No|||November 2008|November 5, 2008|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277108||186147|
NCT00277121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03150 (REK)|Genetic Origin of Lipid Disorders|Genetic Origin of Lipid Disorders||University of Oslo||Not yet recruiting|January 2006|||||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Retrospective/Prospective|||||||Both|18 Years|54 Years|Accepts Healthy Volunteers|||January 2006|January 12, 2006|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277121||186146|
NCT00304876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18158|Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea|Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea||VA Medical Center, Houston|No|Completed|October 2005|January 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patients positive for C. difficile|September 2010|September 9, 2010|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304876||184075|
NCT00305877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02969|Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery|An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination With Gemcitabine and in Combination With Chemoradiation (Capecitabine and Radiation) in Patients With Completely-Resected Pancreatic Carcinoma||National Cancer Institute (NCI)||Completed|February 2006|February 2012|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||December 2012|May 6, 2014|March 21, 2006|Yes|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00305877||184001|
NCT00306202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-018|Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia|Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005||Bristol-Myers Squibb|No|Active, not recruiting|March 2006|October 2022|Anticipated|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|58|||Both|12 Months|20 Years|No|||August 2015|August 11, 2015|March 21, 2006|Yes|Yes||No|June 11, 2012|https://clinicaltrials.gov/show/NCT00306202||183977|
NCT00306215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL004_282|A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease|A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease||ChemoCentryx|Yes|Completed|March 2006|June 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|436|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00306215||183976|
NCT00306813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSMM VII|Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma|A Multicenter Phase I/II Trial Evaluating the Safety and Efficacy of Lenalidomide (Revlimid, CC-5013) in Combination With Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma||University of Wuerzburg||Completed|September 2004|December 2008||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|53|||Both|18 Years|N/A|No|||March 2006|August 3, 2009|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00306813||183930|
NCT00306475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051231|Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?|Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?||Vanderbilt University|No|Completed|March 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2010|January 6, 2010|March 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00306475||183956|
NCT00306800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC T404/05|Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp|A Multicenter, Double Blind, Vehicle-Controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 Mg/g Cream and Aktilite CL128 LED Light in Patients With Multiple Actinic Keratosis on the Face and/or Scalp||Galderma||Completed|September 2007|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306800||183931|
NCT00279383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-022-IT|OSHES - Observational Study on Hemostasis in Surgery (TC-022-IT)|OSHES (Observational Study on Hemostasis in Surgery ). A Non Interventional Study on the Hemostasis Supportive Methods in Surgery||Nycomed|Yes|Completed|August 2005|April 2008|Actual|April 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|800|||Both|18 Years|90 Years|No|Probability Sample|Patients who are candidates for a specific type of surgery where a supportive hemostyptic        agent will be used and who issued an informed consent. A special procedure will be        implemented for use in emergency situations.|January 2009|May 4, 2012|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00279383||185981|
NCT00279409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5064|Treatment of Children With ADHD Who do Not Fully Respond to Stimulants|Developing More Efficacious Treatments for Children With ADHD Who Are "Partial" or "Non-responders" to Stimulants|TREAT|New York State Psychiatric Institute|Yes|Terminated|July 2006|February 2009|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|6 Years|17 Years|No|||September 2013|September 20, 2013|January 18, 2006|No|Yes|Recruitment Rate too slow|No||https://clinicaltrials.gov/show/NCT00279409||185980|
NCT00279422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-415|A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis|A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis||Facet Biotech|Yes|Terminated|February 2006|August 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|January 17, 2006|Yes|Yes|DMC recommendation, no efficacy|No||https://clinicaltrials.gov/show/NCT00279422||185979|
NCT00279123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI Trial|Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers|||Kwong Wah Hospital||Completed|January 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A||||January 2006|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279123||186001|
NCT00279136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF 3.2.02.34, DIACON|Towards Restoring the Physiological Inhibition of Airway Narrowing in Asthma|Towards Restoring the Physiological Inhibition of Airway Narrowing in Asthma||Leiden University Medical Center||Recruiting|September 2004|March 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2005|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279136||186000|
NCT00279331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA PE 002|Estimating the Incidence of HIV Infection Among Men Who Have Sex With Men in Peru and Ecuador|Implementation of a Third Generation Sentinel Surveillance Approach Among Men Who Have Sex With Men at High Risk for HIV, Type-1 Acquisition in the Andean Region||National Institute of Allergy and Infectious Diseases (NIAID)||Completed||November 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|2608|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 20, 2013|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279331||185985|
NCT00279344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-015-IN|Efficacy and Safety of FITpatch Compared to Standard Opioid Treatment in Cancer Pain (FT-015-IN)|A Randomised, Open, Parallel-group, Multi-centre Trial to Investigate Analgesic Efficacy and Safety of Transdermal Fentanyl (FITpatch) Compared to Standard Opioid Treatment in Cancer Pain.||Nycomed|No|Completed|September 2004|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|18 Years|75 Years|No|||May 2012|May 4, 2012|December 14, 2005||||No||https://clinicaltrials.gov/show/NCT00279344||185984|
NCT00279669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROP|Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity|Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity||Weill Medical College of Cornell University|No|Suspended|December 2004|July 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Premature babies with Retinopathy of Prematurity|May 2008|May 7, 2008|January 17, 2006||No|Studies are suspended until a new ultrasound scanner is acquired.|No||https://clinicaltrials.gov/show/NCT00279669||185960|
NCT00279994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-06-252|(Cost) Effectiveness Study of Exercise Therapy in Patients With Peripheral Arterial Disease|Exercise Therapy in Patients With Peripheral Arterial Disease: the Costs and Effectiveness of Physiotherapeutic Supervision With or Without Therapy Feedback Versus a "go Home and Walk" Advice|EXITPAD|Atrium Medical Center||Active, not recruiting|December 2005|May 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|N/A|N/A|No|||May 2008|May 6, 2008|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00279994||185935|
NCT00280306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Voss|White Matter Fiber Tracking and Assessment of White Matter Integrity in the Cervical Spinal Cord|White Matter Fiber Tracking and Assessment of White Matter Integrity in the Cervical Spinal Cord - Pilot Study||Weill Medical College of Cornell University||Completed|November 2005|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|35|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cervical spinal cord compression|June 2015|June 2, 2015|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00280306||185912|
NCT00280319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUWVRCT2|Study of Treatments for Depression Among Displaced Adolescents in Northern Uganda.|Randomized Controlled Study of Non-Pharmacologic Treatments for Depression Among Displaced Adolescents in Northern Uganda.||Boston University||Active, not recruiting|July 2005|February 2006||||N/A|Interventional|N/A||||600|||Both|14 Years|17 Years|No|||January 2006|January 20, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00280319||185911|
NCT00280592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 051016|Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients|Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.|CANNEBERGE|Rennes University Hospital|Yes|Completed|January 2006|October 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|171|||Both|18 Years|70 Years|No|||May 2008|May 18, 2012|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280592||185890|
NCT00276835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04V1|Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer|A Pilot Study of the Effect of Genistein in Combination With High-Dose Interleukin-2 on Cell Expansion and Gene Expression in Patients With Metastatic Melanoma or Renal Cell Carcinoma||Northwestern University||Completed|November 2005|January 2014|Actual|July 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|January 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00276835||186168|
NCT00277095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM02|ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males|Clinical Investigation of the ProACT Adjustable Continence Therapy for Treatment of Post-Prostatectomy Stress Urinary Incontinence|ProACT|Uromedica|No|Active, not recruiting|August 2005|December 2016|Anticipated|February 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Male|45 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|January 11, 2006|No|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT00277095||186148|
NCT00277381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002248|Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology|Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology||Massachusetts General Hospital||Completed|July 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|||Actual|84|||Both|45 Years|65 Years|No|||February 2013|February 27, 2013|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00277381||186127|
NCT00277394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 0401 INT|Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis|Safety Profile of Innohep Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis||LEO Pharma|Yes|Completed|December 2005|July 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|541|||Both|70 Years|N/A|No|||March 2015|March 25, 2015|January 13, 2006||No||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00277394||186126|
NCT00278031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qolrb-HMO-CTIL|Quality of Life in Children Cured of Retinoblastoma|Quality of Life in Children Cured of Retinoblastoma||Hadassah Medical Organization|No|Recruiting|March 2006|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|35|||Both|1 Year|18 Years|No|Non-Probability Sample|Long term survivors of childhood retinoblastoma|March 2015|March 17, 2015|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00278031||186081|
NCT00278044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94028|Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children|Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children||Far Eastern Memorial Hospital||Recruiting|January 2006|July 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|20|||Both|N/A|N/A|No|||January 2006|February 6, 2009|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278044||186080|
NCT00305396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031041|Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation|Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplant Recipients.||Vanderbilt University||Completed|April 2004|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|75 Years|No|||March 2006|March 20, 2006|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00305396||184037|
NCT00305630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 64263|Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)|Neovascular Age Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy||Johns Hopkins University||Completed|July 2002|November 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|50 Years|N/A|No|||March 2006|March 20, 2006|March 20, 2006||||||https://clinicaltrials.gov/show/NCT00305630||184019|
NCT00305890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008156|Weight Management and Coping Skills Training For Patients With Knee Osteoarthritis|Duke University Pain Prevention: Weight Management and Coping Skills Training For Patients With Osteoarthritis of the Knee||Duke University|Yes|Completed|January 2004|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|412|||Both|18 Years|85 Years|No|||August 2013|July 11, 2014|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305890||184000|
NCT00307073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201|Adapta Pacing System Clinical Study|Adapta Clinical Study to Evaluate the Overall System Safety and Clinical Performance of the Adapta Pacing System||Medtronic Cardiac Rhythm Disease Management||Completed|May 2005|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|N/A|N/A|No|||October 2006|October 11, 2006|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00307073||183910|
NCT00306488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060116|OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration|A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)|Yes|Completed|March 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|60 Years|N/A|No|||August 2011|August 16, 2011|March 22, 2006|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00306488||183955|
NCT00306501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060120|Volitional Swallowing in Stroke Patients With Chronic Dysphagia|Induction of Volitional Swallowing in Chronic Dysphagia Post Stroke: A Novel Mechanism-Based Intervention||National Institutes of Health Clinical Center (CC)||Completed|March 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|75 Years|No|||October 2010|October 30, 2010|March 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00306501||183954|
NCT00307671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040425|Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years|Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants|CORTAGE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2005|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|65 Years|N/A|No|||March 2007|September 9, 2011|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00307671||183866|
NCT00279175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/04|REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)|Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR - AMI)||Johann Wolfgang Goethe University Hospitals||Completed|April 2004|December 2010|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|80 Years|No|||September 2012|September 19, 2012|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00279175||185997|
NCT00279461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21562|Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis|Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells||Indiana University|No|Withdrawn|May 2009|May 2011|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|January 17, 2006||No|Dr. Levy terminated from IU in December 2009. Indiana University has no record that this study    was initiated prior to his termination.|No||https://clinicaltrials.gov/show/NCT00279461||185976|
NCT00279721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18916|Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.|Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.||AHS Cancer Control Alberta||Completed|January 2006|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||July 2011|January 18, 2012|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279721||185956|
NCT00279734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-049|Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers|An Exploratory Study to Evaluate the Effect of Abatacept (BMS-188667) on the Antibody Response Following Tetanus Toxoid and 23-Valent Pneumococcal Vaccinations in Healthy Subjects||Bristol-Myers Squibb||Completed|August 2004|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 11, 2011|January 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00279734||185955|
NCT00279357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/NBI/121|Randomised Trial of NBI for Adenoma Detection|Randomised, Controlled Trial of Narrow Band Imaging (NBI) Versus Standard Endoscopy for Adenoma Detection||London North West Healthcare NHS Trust||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|214|||Both|18 Years|N/A|No|||June 2007|June 28, 2007|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279357||185983|
NCT00279370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060335|Antidepressant Use During Pregnancy|Antidepressant Use During Pregnancy||University of Pittsburgh|No|Completed|September 1999|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|283|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with or without active depression and with or without SSRI use in pregnancy|September 2013|September 30, 2013|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00279370||185982|
NCT00279682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059366|Prevention of Suicide in Primary Care Elderly: Collaborative Trial (PROSPECT)|Prevention of Suicide in Primary Care Elderly: Collaborative Trial||Weill Medical College of Cornell University||Completed|May 1999|August 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1200|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2006|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279682||185959|
NCT00279695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB00238|Ultrasonic Evaluation of Ocular Tissues|Ultrasonic Evaluation of Ocular Tissues||Weill Medical College of Cornell University|No|Active, not recruiting|January 1996|June 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|150|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ophthalmology practice referrals|January 2010|January 19, 2010|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00279695||185958|
NCT00279708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060072|Atorvastatin to Treat Pulmonary Sarcoidosis|Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial||National Institutes of Health Clinical Center (CC)||Completed|January 2006|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||March 2016|March 11, 2016|January 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00279708||185957|
NCT00280007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR-2|Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma|AVATACE-1: Bevacizumab (Avastin®) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial||Medical University of Vienna|No|Terminated|January 2006|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|85 Years|No|||September 2009|April 21, 2010|January 19, 2006||No|Safety concerns in the treatment arm|No||https://clinicaltrials.gov/show/NCT00280007||185934|
NCT00280020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0061|Behavioral Treatment of Insomnia in Aging|Aging: Cytokine Mechanisms and Treatment of Insomnia||University of California, Los Angeles|Yes|Completed|April 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|123|||Both|55 Years|90 Years|No|||July 2012|July 9, 2012|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00280020||185933|
NCT00280332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUC|A Follow-up Colonoscopy Examination in Patients Who Had Previously Undergone Screening Colonoscopy|A Follow-up Colonoscopy Examination in Patients Who Had Previously Undergone Screening Colonoscopy||Chinese University of Hong Kong|No|Completed|March 2006|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|560|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who are previously participated in one of our two screening colonoscopy studies        [Sung, Gastroenterol 2003; Leung, AJG 2004]|May 2008|May 9, 2008|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280332||185910|
NCT00280891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18882|Review of Palliative Radiotherapy in the Management of Advanced Head and Neck Cancer|Review of Palliative Radiotherapy in the Management of Advanced Head and Neck Cancer||AHS Cancer Control Alberta||Completed|January 2006|June 2006|Actual|||N/A|Observational|Time Perspective: Retrospective|||Anticipated|100|||Both|N/A|N/A|No|||July 2006|January 24, 2013|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00280891||185867|
NCT00280605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0168|ALF-ONE : ALFuzosin ONcE Daily|Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China||Sanofi||Completed|August 2005|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Male|N/A|N/A|No|||August 2010|August 30, 2010|January 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00280605||185889|
NCT00280618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9202|Oxaliplatin in Unresectable Hepatocellular Carcinoma|Phase II Study of Eloxatin + 5-Fluorouracil/Leucovorin in Patients With Unresectable Hepatocellular Carcinoma||Sanofi||Completed|July 2004|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280618||185888|
NCT00276575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008048|Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors|Phase I Study of Bevacizumab in Combination With Everolimus and Erlotinib in Advanced Cancer||Duke University||Completed|March 2005|September 2014|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|January 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00276575||186187|
NCT00280917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-202RA|Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis||Can-Fite BioPharma||Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|254|||Both|18 Years|75 Years|No|||June 2011|March 10, 2015|January 23, 2006|||||February 24, 2015|https://clinicaltrials.gov/show/NCT00280917||185865|
NCT00276601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0442, CDR0000449985|Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia|A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia||Sidney Kimmel Comprehensive Cancer Center||Completed|October 2004|June 2013|Actual|December 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||||||Both|5 Years|74 Years|No|||April 2014|April 16, 2014|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00276601||186185|
NCT00276848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455094|Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia|Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL)||National Cancer Institute (NCI)||Completed|July 1999|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|375|||Both|18 Years|65 Years|No|||April 2007|November 5, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276848||186167|
NCT00278057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED. RES. HOS.2003.01|STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE|PHASE 4 STUDY OT THE EFFECT OF GLUCOSE ADDED TO THE DIALYSIS FLUID ON BLOOD PRESSURE, BLOOD GLUCOSE AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS.||Regional Hospital Holstebro||Completed|May 2003|May 2003||||Phase 4|Interventional|N/A||||55|||Both|18 Years|N/A|No|||January 2006|January 16, 2006|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278057||186079|
NCT00278070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 50/05|Metronomic Oral Vinorelbine in Patients With Metastatic Tumors|Metronomic Vinorelbine in Patients With Metastatic Tumors: Phase II Translational Study||Hellenic Cooperative Oncology Group|Yes|Completed|January 2006|February 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||||||Both|16 Years|75 Years|No|||February 2008|February 27, 2008|January 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00278070||186078|
NCT00305643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0328|Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer|A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer||M.D. Anderson Cancer Center|Yes|Terminated|February 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|March 21, 2006|Yes|Yes|Terminated due to low accrual. No data analyzed.|No|January 25, 2012|https://clinicaltrials.gov/show/NCT00305643||184018|Due to low accrual in this trial, no outcome measures were evaluable.
NCT00305903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BUS32|Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease|A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20)||Novartis||Completed|March 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Both|50 Years|85 Years|No|||December 2007|December 17, 2007|March 20, 2006||||||https://clinicaltrials.gov/show/NCT00305903||183999|
NCT00306189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050172|A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects|Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects -||Amgen||Completed|January 2006|November 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|212|||Female|N/A|80 Years|No|||June 2013|June 13, 2013|March 21, 2006||||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00306189||183978|
NCT00307086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14184|Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants|An Evaluation of Bortezomib (VelcadeR ) Followed by High-Dose Melphalan and Bortezomib (VelcadeR) as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants in Patients With Primary Refractory Multiple Myeloma and Plasma Cell Leukemia||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|June 2005|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|March 23, 2006|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00307086||183909|per protocol subjects are followed for 2 years post transplant; however, subjects are followed on our long-term follow-up protocol(MCC12567/IRB6101) to assess overall and disease free survival. additional data available at time manuscript was written
NCT00307385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060127|Transcranial Direct Current Stimulation to Improve Hand Movement in Stroke Patients|Modulation of Motor Learning After Stroke Using Principles of Metaplasticity||National Institutes of Health Clinical Center (CC)||Completed|March 2006|March 2008||||N/A|Observational|N/A||||82|||Both|18 Years|80 Years|No|||March 2008|March 28, 2008|March 25, 2006||||No||https://clinicaltrials.gov/show/NCT00307385||183888|
NCT00307346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060125|Physiology of Weakness in Movement Disorders|Physiology of Weakness With Movement Disorders||National Institutes of Health Clinical Center (CC)||Completed|March 2006|January 2011||||N/A|Observational|N/A|||Actual|6|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2011|January 26, 2011|March 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00307346||183889|
NCT00307957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-08-14-1|Study to Determine the Effectiveness of Pillar Palatal Implants to Treat Obstructive Sleep Apnea|Pillar Palatal Implant System Multi-Institutional, Randomized Placebo-Controlled Study for Obstructive Sleep Apnea||University of Cincinnati||Completed|October 2005|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 10, 2007|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307957||183844|
NCT00280085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001280|The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.|Pancreatic Beta-Cell Mass And Function Quantification By Means Of Perfusion Imaging||Pfizer||Terminated|December 2005|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|August 6, 2009|January 18, 2006|||Explanation provided in detailed descriptiong section of record.|No||https://clinicaltrials.gov/show/NCT00280085||185928|
NCT00280098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976J_4001|Docetaxel in the Treatment of Hormone Refractory Prostate Cancer|Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment||Sanofi||Completed|January 2006|||October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2009|December 4, 2009|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00280098||185927|
NCT00279799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00041131|HIV Prevention for African American Teens|HIV Prevention Maintenance for African American Teens||Emory University|Yes|Completed|February 2005|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|701|||Female|14 Years|20 Years|Accepts Healthy Volunteers|||September 2013|November 18, 2013|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00279799||185950|
NCT00280033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-062|H5 Adult - Chiron Study of Bird Flu Vaccine|A Randomized, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or Combined With Adjuvants in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2006|November 2006|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|9||Actual|394|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2009|September 12, 2013|January 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00280033||185932|
NCT00280046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1554|Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Biphasic Insulin Aspart 30 on Glycaemic Control in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|November 2003|July 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|307|||Both|40 Years|70 Years|No|||June 2012|June 15, 2012|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00280046||185931|
NCT00280345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pigmentary Glaucoma|Autoimmune Dysregulation in Pigmentary Glaucoma|Autoimmune Dysregulation in Pigmentary Glaucoma||University of Oklahoma|Yes|Completed|February 2006|May 2009|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|23|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2011|July 8, 2011|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280345||185909|
NCT00280358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-072|A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.|||Dey||Completed||December 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2008|March 5, 2008|January 19, 2006||||||https://clinicaltrials.gov/show/NCT00280358||185908|
NCT00280631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.1101|Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)|Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)||Telik|No|Completed|February 2006|June 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||June 2011|May 30, 2012|January 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00280631||185887|
NCT00280644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWA486_4022|Leflunomide in Rheumatoid Arthritis|Efficacy of Leflunomide on Joint Inflammation and Destruction of Joint Integrity in Active Rheumatoid Arthritis (RA) Patients||Sanofi|No|Completed|April 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|75 Years|No|||January 2011|January 10, 2011|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00280644||185886|
NCT00280904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI-IN04-001|A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus|A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus||Codman & Shurtleff|No|Completed|January 2006|April 2008|Actual|April 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|433|||Both|N/A|N/A|No|Non-Probability Sample|Subjects of any age, gender and ethnicity, with hydrocephalus|February 2013|February 5, 2013|January 20, 2006||No||No|November 17, 2010|https://clinicaltrials.gov/show/NCT00280904||185866|
NCT00280397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-J081-103|An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors|An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors||Eisai Inc.||Completed|January 2006|November 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|20 Years|75 Years|No|||October 2014|March 16, 2015|January 20, 2006||No||No|February 21, 2015|https://clinicaltrials.gov/show/NCT00280397||185905|
NCT00276588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0428, CDR0000450843|Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel) in Patients With Performance Status = 2,3 or Other Significant Co-Morbidity (HIV Infection or s/p Organ Transplantation) in Advanced Non-Small Cell Lung Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2005|||March 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276588||186186|
NCT00276861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20030655|Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer|Phase II Study of Oxaliplatin And Fixed Rate Infusion Gemcitabine as Second Line Therapy for Patients With Metastatic Colon Cancer||University of Miami Sylvester Comprehensive Cancer Center|Yes|Terminated|September 2005|May 2008|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|January 12, 2006||Yes|Low Accrual|No|January 22, 2013|https://clinicaltrials.gov/show/NCT00276861||186166|Protocol closed prematurely due to low accrual. Only 10 of 27 anticipated patients were enrolled.
NCT00277147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060070|Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine|Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine, Phase 1 Trial in Adults at NIH CC||National Institutes of Health Clinical Center (CC)||Completed|January 2006|September 2008||||Phase 1|Interventional|Primary Purpose: Treatment|1|||25|||Both|18 Years|45 Years|No|||September 2008|September 18, 2008|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00277147||186145|
NCT00277160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020122|A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer|A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer||Amgen||Completed|June 2002|January 2005|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|852|||Both|65 Years|N/A|No|||October 2010|October 7, 2010|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277160||186144|
NCT00277173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HS014867|Improving Geriatric Drug Safety in Underserved Practices|Improving Geriatric Drug Safety in Underserved Practices||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||4800|||Both|65 Years|N/A|No|||January 2006|January 13, 2006|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277173||186143|
NCT00277420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#CHW 05/75, HRRC 214-05|Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children|A Randomized Controlled Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children||Medical College of Wisconsin||Withdrawn|August 2005|August 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|6 Years|17 Years|No|||August 2015|August 21, 2015|January 12, 2006|||PI has left institution after losing funding for this PI-initiated study|No||https://clinicaltrials.gov/show/NCT00277420||186124|
NCT00277784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIUM #1-2005|High-Resolution Ultrasound Imaging of the Retina and Choroid for Detection on Age Related Macular Degeneration|High-Resolution Ultrasound Imaging of the Retina and Choroid||Weill Medical College of Cornell University|No|Completed|July 2005|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|45 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ophthalmology practice|March 2008|March 4, 2008|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00277784||186100|
NCT00278603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVD.HSCT2003|Stem Cell Injection for Peripheral Vascular Disease|Hematopoietic Stem Cell Injection for Peripheral Vascular Disease: Induction of Neoangiogenesis. A Phase I Study||Northwestern University|Yes|Completed|October 2004|June 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|January 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278603||186040|
NCT00278616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU APS AUTO 2004|Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome|High Dose Cyclophosphamide & CAMPATH-1H With Hematopoietic Stem Cell Transplantation in Patients With Refractory Antiphospholipid Syndrome (APS): A Phase I Trial||Northwestern University|No|Withdrawn|August 2005|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|No|||April 2012|April 9, 2012|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278616||186039|
NCT00305656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00127|AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase II Study of AZD2171 in Recurrent Glioblastoma||National Cancer Institute (NCI)|Yes|Completed|January 2006|||April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||July 2013|August 14, 2013|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00305656||184017|
NCT00305916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 2005/06/004|Multislice Spiral Computed Tomography and Cardiomyopathy|Accuracy of Multislice Spiral Computed Tomography in Diagnosis of Coronary Artery Disease Associated to Idiopathic Cardiomyopathy in Sinus Rhythm ("MSCT-IC Study").|CMD-scanner|Rennes University Hospital|No|Completed|February 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|No|||February 2008|February 22, 2008|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305916||183998|
NCT00307970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|582-2002|Impact of Anti-static Chamber/Mask|The Impact of an Anti-static Valved-holding Chamber on Bioavailability of Inhaled Fluticasone Propionate in Young Children With Asthma||University of Florida||Completed|April 2003|September 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|1 Year|6 Years|No|||June 2004|September 16, 2011|March 24, 2006||||||https://clinicaltrials.gov/show/NCT00307970||183843|
NCT00307983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2006002|Effect of Malnutrition on the Prognosis in Hemodialysis Patients|Effect of Malnutrition on the Prognosis in Hemodialysis Patients||University of Shizuoka||Recruiting|April 2004|February 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||600|||Both|N/A|70 Years|No|||March 2006|March 27, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307983||183842|
NCT00307398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-60|Anecortave Acetate Risk-Reduction Trial (AART)|||Alcon Research||Terminated|March 2004|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2596|||Both|50 Years|N/A|No|||May 2009|November 27, 2012|March 24, 2006|Yes|Yes|Management decision|No||https://clinicaltrials.gov/show/NCT00307398||183887|
NCT00307411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK 4470/05M|Effect of Growth Hormone in Metabolic Syndrome|Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome||Chinese University of Hong Kong||Not yet recruiting|August 2006|July 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Male|35 Years|50 Years|No|||March 2006|April 3, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307411||183886|
NCT00279812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR02/2005|Selenium and Immune Function|Selenium and Immune Function||Institute of Food Research||Completed|April 2005|August 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|144|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||March 2011|March 18, 2011|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00279812||185949|
NCT00279149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 030443|TRUST-tPA: Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) of Patients With Acute Stroke|Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) in the Management of Patient With Acute Stroke Within 3-hour After Their Symptom Onset Who Are Admitted to a Remote Hospital With no Stroke Unit Facility||Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2006|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|18 Years|N/A|No|||February 2007|February 16, 2011|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00279149||185999|
NCT00279162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0502 US|Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis|Calcipotriene Plus Betamethasone Dipropionate Gel Compared to the Gel Vehicle in Scalp Psoriasis, in Patients Receiving Calcipotriene Plus Betamethasone Dipropionate Ointment for Psoriasis Vulgaris of Trunk/Limbs||LEO Pharma||Completed|December 2005|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|January 17, 2006||||||https://clinicaltrials.gov/show/NCT00279162||185998|
NCT00279435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-417|Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study|A Randomized, Double-blind, Multicenter Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study||Facet Biotech|Yes|Terminated|August 2006|August 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|January 17, 2006|Yes|Yes|company decision based on other studies|No||https://clinicaltrials.gov/show/NCT00279435||185978|
NCT00279448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXEAPO-0028-118|Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer|Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+ Post-Menopausal Patients With Non-Metastatic Breast Cancer|TEAM|Pfizer|Yes|Completed|January 2002|June 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9779|||Female|50 Years|N/A|No|||December 2011|December 22, 2011|January 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00279448||185977|
NCT00279773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2102|Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia|A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia||Novartis||Terminated|September 2004|||October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|January 18, 2006|Yes|Yes|Study was stopped due to time dependent drug accumulation|No||https://clinicaltrials.gov/show/NCT00279773||185952|
NCT00279747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.208|A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)|A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.||Boehringer Ingelheim||Completed|September 2000|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||226|||Both|2 Years|16 Years|No|||October 2013|October 31, 2013|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00279747||185954|
NCT00280059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081046|Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy|A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures||Pfizer|No|Completed|August 2006|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|660|||Both|16 Years|N/A|No|||March 2015|March 4, 2015|January 18, 2006|Yes|Yes||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00280059||185930|Cox proportional hazards model for time to event (TTE) analyses; three summary statistics were not generated as median TTE will not exist if survival function (Kaplan-Meier product limit estimates) does not fall below 0.5 (post-hoc analysis).
NCT00280371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-069|A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD|A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg/0.5 mL Delivered by OMRON MicroAir NE-U22V Nebulizer in the Treatment of Patients With Chronic Obstructive Pulmonary Disease||Dey||Completed|January 2006|May 2007|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||345|||Both|40 Years|N/A|No|||February 2008|November 9, 2010|January 19, 2006||||||https://clinicaltrials.gov/show/NCT00280371||185907|
NCT00280384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2014-J081-133|An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects|An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects||Eisai Inc.||Completed|January 2006|||August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|44 Years|No|||April 2013|April 23, 2013|January 20, 2006||||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00280384||185906|
NCT00280410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7337-J081-151|Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver|Multicenter, Randomized, Open-Label Study Investigating The Superiority Of The Contrast Enhancement Effect Of E7337 On Tumor Like Lesion In The Dynamic CT Of The Liver Of Patients With Tumor Like Lesions In The Liver||Eisai Inc.||Completed|February 2006|||October 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||192|||Both|20 Years|80 Years|No|||January 2010|January 28, 2010|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00280410||185904|
NCT00280657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91299|Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa|Multicenter, Double-blind, Double-dummy, Randomized Parallel Group Study to Evaluate the Safety and Efficacy of SH D 00659 E for 6 Treatment Cycles in Female Patients With Acne Papulopustulosa in Comparison to SH D 00659 G and Placebo.||Bayer|No|Completed|March 2004|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1326|||Female|16 Years|45 Years|No|||December 2014|December 17, 2014|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280657||185885|
NCT00280670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH075806-01|CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS||BIACA|University of California, Los Angeles|Yes|Completed|January 2005|August 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|7 Years|11 Years|No|||March 2012|March 28, 2012|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280670||185884|
NCT00276614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453541|Bortezomib in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients||Jonsson Comprehensive Cancer Center|Yes|Completed|April 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|January 12, 2006|Yes|Yes||No|March 27, 2012|https://clinicaltrials.gov/show/NCT00276614||186184|Approval of several agents for management of renal cell carcinoma rendered accrual to this trial quite difficult.
NCT00277186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTH-00001|Alberta Hip and Knee Replacement Project|A Randomized Controlled Prospective Study to Examine the Effectiveness of a New Evidence Based Arthroplasty Care Model for Patients With Severe Degenerative Joint Disease (DJD) of the Hip or Knee in Alberta||Alberta Bone and Joint Health Institute|Yes|Completed|April 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3434|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00277186||186142|
NCT00277433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10744|Histamine Pharmacogenetics in Children With Atopic Dermatitis|Histamine Pharmacogenetics in Children With Atopic Dermatitis||Virginia Commonwealth University|No|Completed|June 2004|December 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|751|Samples With DNA|buccal-derived DNA|Both|6 Months|5 Years|Accepts Healthy Volunteers|Probability Sample|Caucasian,AfricanAmerican and Hispanic children with a medical diagnosis of atopic        dermatitis and healthy, age matched controls|April 2010|April 28, 2010|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00277433||186123|
NCT00277797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102004819|Non-Invasive Targeted Electronic Pain Control Device ("Biowave System") Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain|A Randomized, Single-Blinded, Comparative Crossover Trial of the Safety and Efficacy of a Non-Invasive Targeted Electronic Pain Control Device ("Biowave System") Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain.||Weill Medical College of Cornell University|No|Completed|February 2001|October 2008|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||June 2013|June 13, 2013|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00277797||186099|
NCT00278083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0168T42|TNF-alpha Directed Therapy in Asthma|A Randomised, Double Blind, Placebo-controlled, Parallel Group Pilot Study to Determine the Effect of REMICADE on Safety, Efficacy and Biomarkers of Inflammation in Patients With Asthma Receiving Inhaled Corticosteroids||Imperial College London||Completed|October 2001|April 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|60 Years|No|||January 2006|February 23, 2016|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00278083||186077|
NCT00305669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455649|GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer|A Pilot Study of Two Dose Schedules of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer||University of California, San Francisco|Yes|Completed|July 2006|June 2014|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|N/A|N/A|No|||June 2014|June 24, 2014|March 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00305669||184016|
NCT00306514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT004-MelQbG10 01|Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients|A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma||Cytos Biotechnology AG||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||September 2007|September 19, 2007|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00306514||183953|
NCT00306527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P4E1|Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly|A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity (in a Subset) Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before in the V58P4 Study.||Novartis||Completed|September 2005|April 2006|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|2235|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|March 22, 2006||Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00306527||183952|
NCT00306540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-SEA-0006|Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder|A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder||AstraZeneca|No|Completed|December 2004|August 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||December 2010|December 8, 2010|March 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00306540||183951|
NCT00306553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT004-MelQbG10 03|Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients|||Cytos Biotechnology AG||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||September 2006|September 18, 2006|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00306553||183950|
NCT00307736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-345|Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer|A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer||Massachusetts General Hospital|Yes|Completed|May 2006|July 2011|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|March 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307736||183861|
NCT00308204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD3433s|Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva|Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva||The Cleveland Clinic||Terminated|March 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|70 Years|No|||May 2007|May 22, 2007|March 28, 2006|||inadequate number of enrolled study subjects|||https://clinicaltrials.gov/show/NCT00308204||183825|
NCT00308217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604-2005|Single Ventricle Outcome|The Examination of Outcome in Children With Single Ventricle Physiology||Emory University||Completed|June 2005|June 2005||||N/A|Observational|Time Perspective: Prospective||||30|||Both|N/A|N/A|No|||December 2013|December 11, 2013|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00308217||183824|
NCT00280475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0504|A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis|Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504)||Japan Clinical Oncology Group|Yes|Recruiting|January 2006|January 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|20 Years|79 Years|No|||June 2010|June 13, 2010|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280475||185899|
NCT00279474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1951CTIL|The Effect of Cognitive Behavior Intervention on Psychological Distress of Cancer Patients and Their Family Members|Evaluation of the Effect of Cognitive Behavior Intervention on Psychological Distress of Cancer Patients and Their Family Members||Rambam Health Care Campus||Recruiting|July 2004|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||320|||Both|20 Years|70 Years|No|||October 2005|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279474||185975|
NCT00279760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-002|Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis|A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis||Bristol-Myers Squibb||Completed||||March 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|18 Years|65 Years|No|||April 2010|April 29, 2010|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279760||185953|
NCT00280696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01221|A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures|A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)||UCB Pharma|No|Completed|November 2005|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|352|||Both|16 Years|65 Years|No|||February 2015|February 10, 2015|January 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00280696||185882|
NCT00280072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-003|Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure|A Multi-Center, Randomized, Controlled, Double-Blind, Phase II Study To Assess Safety and Efficacy With the Renal Assist Device (RAD) in Patients With Acute Renal Failure||RenaMed Biologics||Terminated|January 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||November 2012|November 29, 2012|January 18, 2006||||||https://clinicaltrials.gov/show/NCT00280072||185929|
NCT00280423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD103894|Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia|A 28 Day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.||GlaxoSmithKline||Completed|January 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|342|||Both|18 Years|64 Years|No|||April 2015|April 14, 2015|January 19, 2006||||||https://clinicaltrials.gov/show/NCT00280423||185903|
NCT00280436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD105514|Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia|A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of GW679769 on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Non-elderly Subjects With Primary Insomnia||GlaxoSmithKline||Completed|January 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|122|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|January 19, 2006||||||https://clinicaltrials.gov/show/NCT00280436||185902|
NCT00280683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K30-04-Z001|Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma|Phase 2 Study: GCRC: Effects of L-arginine Supplementation on Exhaled Nitric Oxide and Clinical Exacerbations in Adults With Moderate to Severe Asthma||University of California, Davis|Yes|Completed|December 2004|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|90 Years|No|||April 2013|April 26, 2013|January 19, 2006||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00280683||185883|
NCT00276627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010216|Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer|Enhancing Patient-Oncologist Communication||Duke University|No|Completed|February 2003|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|800|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00276627||186183|
NCT00276874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA020429|Aripiprazole to Reduce Cocaine Relapse|Preventing Cocaine Relapse: Developing Pharmacotherapies||University of Kentucky|Yes|Completed|January 2006|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|50 Years|No|||October 2011|March 1, 2012|January 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00276874||186165|
NCT00277199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-017|Comparability DE vs CD-CHO1|Study to Compare the Pharmacokinetics of CD-CHO1 Process BMS-188667 to DE Process BMS188667 in Healthy Subjects||Bristol-Myers Squibb||Completed|September 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 11, 2011|January 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00277199||186141|
NCT00277212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-392 ST|A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode|A Multicenter, Double-blind, Study of the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|December 2005|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1169|||Both|18 Years|N/A|No|||November 2010|November 7, 2013|January 13, 2006|Yes|Yes||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00277212||186140|
NCT00277810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098B1-203, 3098B1-204|Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease|A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|March 2006|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|250|||Both|50 Years|N/A|No|||July 2008|February 14, 2013|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277810||186098|
NCT00277823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-332|Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277823||186097|
NCT00278096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMC P 92/99|Randomised Controlled Trial of Unsolicited Occupational Therapy in Community-Dwelling Elderly|Randomised Controlled Trial of Unsolicited Occupational Therapy in Community-Dwelling Elderly||Leiden University Medical Center||Completed|March 2000|May 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|85 Years|85 Years|Accepts Healthy Volunteers|||January 2006|January 13, 2006|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00278096||186076|
NCT00278330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00077|Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia|Phase I Trial of Vorinostat (SAHA) in Combination With Alvocidib (Flavopiridol) in Patients With Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia With Excess Blasts-2||National Cancer Institute (NCI)||Completed|January 2006|||October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|January 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00278330||186060|
NCT00278343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03027|Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer|A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2006|||June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Female|19 Years|N/A|No|||August 2014|August 5, 2014|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278343||186059|
NCT00278655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD MS.Auto2002|Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis|Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Interferon Therapy: A Phase II Multi-Center Trial||Northwestern University|No|Terminated|June 2003|May 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|50 Years|No|||March 2014|March 31, 2014|January 16, 2006|Yes|Yes||No|April 9, 2013|https://clinicaltrials.gov/show/NCT00278655||186036|The study had following limitations: small number of enrolled participants and no randomization.
NCT00306228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRACIA 3|Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty|A Randomised Trial to Evaluate the Role of Paclitaxel Eluting Stent and Tirofiban to Improve the Results of Facilitated PCI in the Treatment of Acute ST- Segment Elevation Myocardial Infarction|GRACIA3|GRACIA Group|Yes|Completed|October 2004|January 2009|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|436|||Both|18 Years|N/A|No|||September 2009|September 25, 2009|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00306228||183975|
NCT00306826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leipzig-01|Pioglitazone in Impaired Glucose Tolerance|Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance||University of Leipzig||Withdrawn||May 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|40 Years|75 Years|No|||June 2008|February 1, 2010|March 23, 2006|||financial support withdrawn|No||https://clinicaltrials.gov/show/NCT00306826||183929|
NCT00307749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-257-A03|Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy|A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy||Mitsubishi Tanabe Pharma Corporation||Completed|March 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|420|||Both|18 Years|70 Years|No|||December 2007|December 26, 2007|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307749||183860|
NCT00308178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-249|Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer|Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study||Dana-Farber Cancer Institute||Completed|March 2006|June 2008|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|March 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308178||183827|
NCT00308191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-070|A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD|A 6-Week Double-Blind, Parallel-Group, Active-Controlled Trial to Compare the Efficacy and Safety of Concomitant Treatment of Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease||Dey||Completed|April 2006|December 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||128|||Both|40 Years|N/A|No|||March 2008|March 5, 2008|March 27, 2006||||||https://clinicaltrials.gov/show/NCT00308191||183826|
NCT00308230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045884|Pilot Study of B-Type Natrieutic Peptide (BNP) Levels in Patients With Congenital Heart Disease(BNP)|A Pilot Study of B-Type Natriuretic Peptide (BNP) Levels in Patients With Congenital Heart Disease and Systemic Right Ventricles or Volume Overloaded Pulmonic Right Ventricles||Emory University|No|Completed|December 2001|September 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|34|||Both|18 Years|89 Years|No|||July 2014|July 16, 2014|March 27, 2006||No||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00308230||183823|
NCT00280176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0209|Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer|Phase I Study of PS-341 in Combination With 5-Fluorouracil and External Beam Radiotherapy For The Treatment Of Locally Advanced And Metastatic Rectal Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|April 2003|September 2010|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2012|February 12, 2012|January 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00280176||185922|
NCT00280488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMON-009892-11A1|Enhanced Motivational Interviewing With Alcohol Positive Trauma Patients|Enhanced MI With Alcohol Positive Trauma Patients||Brown University|Yes|Active, not recruiting|May 2005|April 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||June 2010|June 24, 2010|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280488||185898|
NCT00280449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-357|Two Approaches to Providing HIV/AIDS Services in the Community to People Living With HIV/AIDS|Two Approaches to Providing HIV/AIDS Services in the Community to People Living With HIV/AIDS (PHAs): The Comparative Impact on Quality of Life, Access to and Expenditures for All Health and Social Services||McMaster University||Not yet recruiting|March 2006|February 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2005|January 20, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00280449||185901|
NCT00280111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-153|Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants|Reactogenicity and Immunogenicity of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Healthy Non-Malnourished Infants 8-12 Weeks of Age||Society for Applied Studies|Yes|Completed|January 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||July 2008|July 1, 2008|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00280111||185926|
NCT00280462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-110705|Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade|Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade||Medical University of Vienna|Yes|Completed|August 2005|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|21|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||July 2008|July 8, 2008|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280462||185900|
NCT00280709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELLA|Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction|Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study.||University Hospital, Linkoeping|Yes|Completed|January 2006|August 2010|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|20 Years|N/A|No|||December 2010|August 9, 2011|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280709||185881|
NCT00276640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454506|Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas|Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma|SIOP-LGG-2004|Societe Internationale d'Oncologie Pediatrique|Yes|Active, not recruiting|April 2004|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|3000|||Both|N/A|18 Years|No|||November 2014|June 14, 2015|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00276640||186182|
NCT00276666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454549|Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery|Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma||National Cancer Institute (NCI)||Active, not recruiting|November 2001|||March 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|29|||Both|3 Years|21 Years|No|||June 2009|September 16, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276666||186181|
NCT00276887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08MH001662|Cognitive Behavior Therapy for Somatization Disorder|Cognitive Behavior Therapy for Somatization Disorder||Rutgers, The State University of New Jersey|No|Completed|September 1999|April 2004|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|84|||Both|18 Years|70 Years|No|||February 2014|February 19, 2014|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00276887||186164|
NCT00277836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3161K1-101|Study Evaluating MST-997 in Advanced Malignant Solid Tumors|A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2006|December 7, 2006|January 13, 2006||||||https://clinicaltrials.gov/show/NCT00277836||186096|
NCT00278109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0381 CDR0000446085|Radiation Therapy, Cyclophosphamide, and Doxorubicin in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery|Phase I/II Partial Breast Irradiation With Concurrent Chemotherapy||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|July 2004|||May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Female|39 Years|N/A|No|||March 2014|March 28, 2014|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278109||186075|
NCT00278369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04U1|Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer|A Pilot Study of Denileukin Diftitox in Combination With High-Dose IL-2 for Patients With Metastatic Renal Cell Carcinoma||Northwestern University|Yes|Completed|April 2005|September 2010|Actual|June 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|January 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00278369||186058|
NCT00278668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123.ctil|ECT Schizophrenia Serotonin Study|Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy||Sha’ar Menashe Mental Health Center||Not yet recruiting|October 2006|October 2006|Anticipated|||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|15|||Both|18 Years|55 Years|No|||May 2008|May 20, 2008|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278668||186035|
NCT00306254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5571010|Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery|A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessing the Safety and Efficacy of PD 0348292 in the Prevention of Venous Thromboembolic Events (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee Replacement||Pfizer||Completed|March 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1225|||Both|18 Years|N/A|No|||October 2007|October 5, 2007|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00306254||183973|
NCT00306566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT004-MelQbG10 02|Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients|A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage II Malignant Melanoma||Cytos Biotechnology AG||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||September 2007|September 19, 2007|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00306566||183949|
NCT00306579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054B26A43722225|Myocardial Damage In Patients With Cerebral Infarction|Myocardial Damage In Patients With Cerebral Infarction. Prevalence and Characteristics as Measured by Troponins, Electrocardiographic Changes and Myocardial Perfusion Imaging.||Danish Heart Foundation||Completed|August 2003|May 2005||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||250|||Both|18 Years|N/A|No|||March 2006|March 23, 2006|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00306579||183948|
NCT00307944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-06-24-04|Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea|Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing||University of Cincinnati||Completed|August 2004|August 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 10, 2007|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307944||183845|
NCT00307684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011068|Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder||Janssen-Cilag International NV|No|Completed|January 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|65 Years|No|||April 2014|April 2, 2014|March 24, 2006|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00307684||183865|Planned sample size for DB phase was 80 subjects. Of 99 subjects at the end of OL phase only 45 subjects consented. No cutoffs for key efficacy assessments in DB entry criteria.
NCT00307697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMHT-01/06|A Letter Intervention in Primary Care Patients to Improve Depression and Anxiety Disorders|A Randomised Controlled Trial of a Letter Intervention in Primary Care Patients to Improve Depression and Anxiety Disorders||Bayside Health|No|Completed|June 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|November 26, 2013|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00307697||183864|
NCT00329056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTQ-PD-001|A Trial of MitoQ for the Treatment of People With Parkinson's Disease|A Double-Blind, Prospective, Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients With Parkinson's Disease||Antipodean Pharmaceuticals, Inc.|Yes|Completed|May 2006|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|128|||Both|30 Years|N/A|No|||July 2010|July 19, 2010|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329056||182250|
NCT00319527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-078|Long-Term Study of Living Kidney Donors|Long-Term Medical and Psychological Implications of Becoming a Living Kidney Donor: A Historical Matched Cohort Study||Lawson Health Research Institute|No|Completed|May 2004|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|311|Samples Without DNA|Serum and urine samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Living Kidney Donors|July 2009|July 6, 2009|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319527||182964|
NCT00329667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSD 0206|Observational Study of Prosthetic Tissue Aortic and Mitral Heart Valve|An Observational, Prospective Evaluation of the SJM Epic Valve|EPIC|St. Jude Medical||Completed|January 2003|September 2008|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|761|||Both|18 Years|N/A|No|||September 2010|September 9, 2010|May 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00329667||182203|
NCT00329992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200BO-102204|Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial|Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial||University of Zurich|No|Completed|April 2004|December 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||January 2010|January 19, 2010|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329992||182180|
NCT00329680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILAS-04-ABT|The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis|Investigating Nutritional Therapy With EPA, GLA and Antioxidants Role in Sepsis Treatment-INTERSEPT STUDY||Fernandes Tavora Hospital|Yes|Completed|June 2007|October 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||October 2009|December 30, 2009|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329680||182202|
NCT00330005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFPR-001|A Pilot Study of Psychodynamic Psychotherapy for Bipolar Disorder|A Pilot Study of Psychodynamic Psychotherapy for Bipolar Disorder||The University of Texas Health Science Center at San Antonio||Completed|July 2002|January 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|75 Years|No|||May 2006|May 24, 2006|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330005||182179|
NCT00330577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A594|24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients|24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients||Aristotle University Of Thessaloniki||Completed|April 2006|July 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|29 Years|80 Years|No|||May 2014|May 9, 2014|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00330577||182137|
NCT00330538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 08-085|Osteoporosis in Children With ALL|Incidence of Osteoporosis in Children With Acute Lymphoblastic Leukemia Undergoing Therapy||Children's Mercy Hospital Kansas City||Completed|March 2004|October 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||20|||Both|4 Years|18 Years|No|||April 2007|April 5, 2007|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00330538||182140|
NCT00330785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841018|Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia|An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)|JEWEL I|Pfizer||Completed|October 2004|September 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1250|||Both|18 Years|80 Years|No|||April 2007|January 6, 2010|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00330785||182121|
NCT00330525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1723-04|Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity|Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity||Mayo Clinic||Completed|January 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330525||182141|
NCT00330759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050244|Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.||Amgen|Yes|Completed|June 2006|October 2011|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|1779|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|May 25, 2006||Yes||No|December 9, 2010|https://clinicaltrials.gov/show/NCT00330759||182123|
NCT00330772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-091|Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study|Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery|PAPA CABG|McMaster University|No|Recruiting|July 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||May 2007|May 25, 2007|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00330772||182122|
NCT00326989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005709-50|Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium|Extracorporal Shock Wave Therapy for Induction of Therapeutic Neovascularization and Homing of Bone Marrow Progenitor Cells in Patients With Chronic Ischemic Heart Disease||Johann Wolfgang Goethe University Hospitals|No|Completed|May 2006|November 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|103|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|May 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00326989||182406|
NCT00279903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1565-05|Is Botox Effective in Relieving Pain From Knee Osteoarthritis?|Intra-articular Botulinum Toxin Type-A in Knee Osteoarthritis - a Randomized, Cortisone Controlled, Double Blind Study.||Mayo Clinic|Yes|Completed|November 2005|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|62|||Both|40 Years|N/A|No|||November 2012|November 6, 2012|January 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00279903||185942|
NCT00279916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103-04|Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays|Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays: a Randomized Placebo-controlled Study||Mayo Clinic|Yes|Completed|September 2005|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|6 Years|N/A|No|||July 2011|July 20, 2011|January 18, 2006|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00279916||185941|
NCT00280202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9502100|Detection of Genetic Markers of Lung Cancer|Detection of Genetic Markers of Lung Cancer Initiation and Progression||University of Pittsburgh||Recruiting|June 1996|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Blood, tissue, and lymph nodes|Both|18 Years|85 Years|No|Non-Probability Sample|Eligible patients will be selected from investigator's clinic.|December 2015|December 1, 2015|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00280202||185920|
NCT00280514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abscess-cef-moxi|Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration|Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration||Medical University of Vienna|No|Completed|January 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study|||Anticipated|20|||Both|18 Years|90 Years|No|||November 2005|August 3, 2010|January 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00280514||185896|
NCT00280774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102005-076|Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes|Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes: A Pilot Study||University of Texas Southwestern Medical Center||Completed|March 2006|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|70 Years|No|||July 2007|January 23, 2008|January 19, 2006||||No||https://clinicaltrials.gov/show/NCT00280774||185876|
NCT00281034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OASIS-2005|OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)|Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS Study)||Kyorin Pharmaceutical Co.,Ltd|Yes|Completed|September 2005|July 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2069|||Both|N/A|N/A|No|Probability Sample|Univercity, Main hospital, general Hospital,0pen|April 2012|April 10, 2012|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00281034||185856|
NCT00281073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-01|Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study|A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation|ICE-CHIP|EP MedSystems|Yes|Completed|March 2005|July 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|January 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00281073||185853|
NCT00281086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1195|Center for Reducing Asthma Disparities - Harvard University/Boston Area Community Health Centers|||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2002|July 2007|Actual|July 2007|Actual|N/A|Observational|N/A|||||||Both|N/A|N/A|No|||April 2008|April 22, 2008|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281086||185852|
NCT00317278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001872-01A2|Effects of Massage on the Immune System of Preterm Infants|Effects of Massage on Immune System of Preterm Infants||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|October 2005|July 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|120|||Both|28 Weeks|33 Weeks|No|||December 2009|December 4, 2009|April 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00317278||183134|
NCT00328731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAR Foundation study 120|Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques).|The Effectiveness of Milk Allergy Elimination Through NAET Treatments||Nambudripad's Allergy Research Foundation||Completed|January 2005|January 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||26|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||January 2005|May 19, 2006|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00328731||182275|
NCT00328744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK074721-01|Reducing Snack Variety in Weight Loss Treatment|Reducing Snack Food Variety During Obesity Treatment||The Miriam Hospital||Completed|July 2006|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2008|April 19, 2012|May 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00328744||182274|
NCT00328757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OF-01|Safety of Regular Diet as the First Meal in Patients Who Underwent Surgical Treatment for Gynecologic Cancer|Regular Versus Liquid Diet as the First Meal in Patients Undergoing Major Abdominal Gynecologic Cancer Operation: A Randomized Controlled Trial||Chiang Mai University||Withdrawn|May 2006|April 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|240|||Female|18 Years|75 Years|No|||June 2011|June 27, 2011|May 19, 2006|||Before starting the recruitment process, new data from literature were available. The    investigators considered that this study was no longer needed.|No||https://clinicaltrials.gov/show/NCT00328757||182273|
NCT00329394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-008|Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient|Study of the Efficacity of the Systemic Ketamine for the Improvement of Post-Operative Analgesia After ORL Carcinological Surgery at the Alcohol-Dependent Patient.||University Hospital, Clermont-Ferrand||Suspended|April 2006|September 2008|Anticipated|September 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|70 Years|No|||October 2008|October 7, 2008|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329394||182224|
NCT00329407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22296|The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects|||Boston University||Completed|September 2003|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 30, 2010|May 22, 2006||No||No|July 7, 2010|https://clinicaltrials.gov/show/NCT00329407||182223|Limitation of this trial include the small number of subjects included and lack of blinding, and inculsion of a placebo control group. An other limitation was the testing the active medication topiramate at om=nly one dose level (i.e. 400 mg daily).
NCT00329420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87048|Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)|A Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed no Clinical Efficacy in a Remission Induction Study (Study C87037) But Showed Clinical Efficacy After Additional Remission Induction Therapy Was Applied, at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals||UCB Pharma|No|Completed|May 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|16 Years|64 Years|No|||February 2015|February 27, 2015|May 22, 2006|Yes|Yes||No|May 1, 2009|https://clinicaltrials.gov/show/NCT00329420||182222|Due to the small number of subjects in this study, the percentages of subjects with adverse events may be misleading.
NCT00329693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999051 CS01|Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide|A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.||Ferring Pharmaceuticals|Yes|Completed|June 2006|May 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|182|||Female|21 Years|37 Years|No|||May 2011|May 18, 2011|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329693||182201|
NCT00330590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512052|Central Venous Access Catheter Placement Using the Sonic Flashlight|Central Venous Access Catheter Placement by Interventional Radiologists Using the Sonic Flashlight for Real Time Ultrasound Guidance||University of Pittsburgh||Completed||December 2006|Actual|||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|18 Years|N/A||||February 2008|February 7, 2008|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00330590||182136|
NCT00330291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975|Xyrem for Treatment Refractory Insomnia Due to PTSD|Xyrem for Treatment Refractory Insomnia Due to PTSD||State University of New York - Upstate Medical University||Withdrawn|August 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|May 24, 2006|Yes|Yes|terminated due to inability to recruit subjects|||https://clinicaltrials.gov/show/NCT00330291||182159|
NCT00330798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20060020H|A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief|A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief of Patients Status Post-Photorefractive Keratectomy: A Double-Masked Randomized Prospective Study||Alcon Research||Completed|February 2006|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|N/A|No|||May 2012|May 22, 2012|May 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330798||182120|
NCT00330551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH066286|Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia|Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia||University of California, Los Angeles||Completed|March 2006|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 2, 2013|May 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330551||182139|
NCT00326638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005242-01H|3D-Conformal Radiation vs Helical Tomotherapy in Prostate Cancer|Randomized Phase III Trial of 3D Conformal Radiotherapy Versus Helical Tomotherapy IMRT in High-Risk Prostate Cancer||Ottawa Hospital Research Institute|No|Active, not recruiting|November 2005|May 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Male|18 Years|N/A|No|||July 2015|July 21, 2015|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326638||182430|
NCT00326651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Conception Kit|Home Usage of Conception Kit Instructions|Home Usage of Conception Kit Instructions||Conceivex||Active, not recruiting|May 2006|May 2007||||Phase 4|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||60|||Female|16 Years|55 Years|Accepts Healthy Volunteers|||January 2007|January 31, 2007|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326651||182429|
NCT00326664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00709|AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors|A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors||National Cancer Institute (NCI)||Completed|March 2006|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|21 Years|No|||March 2016|March 4, 2016|May 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00326664||182428|
NCT00280228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA016631|Home Based Treatment for Drug Use in Early Adolescents|Home-based Behavioral Therapy (HBT): Psychosocial Intervention Project for Early Adolescents With Pre- or Early Substance Use Disorder: Phase II||University of Pittsburgh|Yes|Completed|January 2006|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|11 Years|14 Years|No|||May 2011|May 25, 2011|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00280228||185918|
NCT00280215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2203-05|Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria|Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria||Mayo Clinic|No|Withdrawn|December 2007|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|10 Years|80 Years|No|||April 2015|April 6, 2015|January 19, 2006||No|Inadequate number of patients, lack of funding|No||https://clinicaltrials.gov/show/NCT00280215||185919|
NCT00281047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hp.FP-10.01|The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy|The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin||Hamamatsu University||Recruiting|January 2006|May 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||138|||Both|15 Years|90 Years|No|||January 2006|January 26, 2006|January 23, 2006||||No||https://clinicaltrials.gov/show/NCT00281047||185855|
NCT00278200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445433 J0216|Vaccine Therapy in Treating Patients Who Are Being Considered For a Solid Organ Transplant and Are at Risk For Post-Transplant Lymphoproliferative Disorder|Vaccination of Patients at High Risk for Post-Transplant Lymphoproliferative Disorder With a Photochemically Inactivated EBV-Infected B-Cell Vaccine||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|September 2002|December 2022||December 2021|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|120 Years|No|||October 2015|October 30, 2015|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278200||186068|
NCT00320151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blood Collection Protocol|Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases|Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases||Weill Medical College of Cornell University|No|Recruiting|April 2006|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|600|||Both|18 Years|90 Years|No|Non-Probability Sample|General admission criteria for this project will require at least one of the following:        (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung        disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy        consistent with lung disease; (5) family history of lung disease; and (6) patients with        diseases of organs with known association with lung disease.|April 2015|April 20, 2015|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00320151||182916|
NCT00320385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF104900|Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer|A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens||GlaxoSmithKline|No|Completed|November 2005|October 2010|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|296|||Female|18 Years|N/A|No|||April 2015|January 28, 2016|May 1, 2006|Yes|Yes||No|October 20, 2011|https://clinicaltrials.gov/show/NCT00320385||182898|
NCT00320398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR3106333|Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery||GlaxoSmithKline||Completed|January 2006|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|20 Years|N/A|No|||October 2010|October 1, 2010|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320398||182897|
NCT00320411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF104911|GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer|Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer||GlaxoSmithKline||Completed|November 2005|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|20 Years|74 Years|No|||May 2012|April 11, 2013|May 1, 2006||No||No|November 10, 2009|https://clinicaltrials.gov/show/NCT00320411||182896|
NCT00317564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308740|Betaseron Pregnancy Registry|Betaseron Pregnancy Registry||INC Research|Yes|Completed|April 2006|June 2012|Actual|April 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Female|N/A|N/A|No|Non-Probability Sample|US only|December 2013|December 5, 2013|April 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00317564||183112|
NCT00329082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6649|Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers|LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers||Eli Lilly and Company|Yes|Completed|May 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|25|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 5, 2009|May 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00329082||182248|
NCT00329095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMED-01|An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance|An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures||Robin, Alan L., M.D.||Completed|December 2005|April 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||60|||Both|18 Years|N/A|No|||May 2006|May 22, 2006|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00329095||182247|
NCT00329069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATV-D-01-007 G|The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia|Vascular Endothelial Receptor Activity in Patients With Coronary Artery Disease on Medication With Statins||University of Ulm||Completed|May 2002|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|May 22, 2006|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329069||182249|
NCT00329706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-10-079, 03-04-026|Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)|Early and Long-Term Value of Imaging Brain Metabolism||University of California, Los Angeles|Yes|Recruiting|June 2006|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|710|||Both|65 Years|N/A|No|||January 2016|January 13, 2016|May 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00329706||182200|
NCT00329719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00652|Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma|A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|March 2006|||February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|115|||Both|18 Years|N/A|No|||June 2013|May 29, 2015|May 23, 2006|Yes|Yes||No|June 2, 2014|https://clinicaltrials.gov/show/NCT00329719||182199|
NCT00330304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|299/2005|Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children|Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With Concomitant Cotrimoxazole (CTX) in HIV-infected Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of Tuberculosis||University of Cape Town||Active, not recruiting|January 2003|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|450|||Both|8 Weeks|15 Years|No|||September 2010|September 7, 2010|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330304||182158|
NCT00330317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345EGB07|Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer|Neoadjuvant Hormone Therapy for Postmenopausal Women With HR+ Primary Breast Cancer: A Multi-center Study to Determine the Optimum Length of Treatment With Letrozole on Tumour Regression to Permit Breast Conserving Surgery.||Novartis|No|Completed|February 2006|||March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|18 Years|80 Years|No|||September 2011|September 22, 2011|May 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00330317||182157|
NCT00330330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 113715-CS7|Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment|A Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 in Patients With Type 2 Diabetes Mellitus Who Have Not Received Prior Therapy||Ionis Pharmaceuticals, Inc.||Completed|February 2003|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|18 Years|65 Years|No|||February 2008|February 4, 2008|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330330||182156|
NCT00330824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRA-05-02|Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Post Operative Inflammation in LASIK Surgery|Efficacy of Antibiotic Steroid Combination Compared With Individual Administration in Prevention of Post Operative Inflammation in Patients Having LASIK Surgery||Federal University of São Paulo|Yes|Completed|April 2006|December 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|50 Years|No|||August 2009|August 6, 2009|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00330824||182118|
NCT00330564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0463|Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow|A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome||M.D. Anderson Cancer Center|No|Terminated|May 2006|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|May 26, 2006|Yes|Yes|Slow accrual.|No|June 1, 2011|https://clinicaltrials.gov/show/NCT00330564||182138|Limitations include the conclusion of the study before maximum enrollment and the use of archival tissue that was not related to the participants in the clinical trial.
NCT00330811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1409-2005|B-type Natriuretic Peptide in the Non-Cardiac Pediatric Patient|B-type Natriuretic Peptide in the Non-Cardiac Pediatric Patient||Emory University|No|Completed|April 2006|May 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|N/A|5 Years|No|Non-Probability Sample|Any child who is less than 6 years old seen in the Emergency Department evaluated for        respiratory and/or infectious disease with order/s to have blood draw.|May 2012|May 22, 2012|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00330811||182119|
NCT00327262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571AAT06|Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase|Multicenter, Phase III Study Comparing Imatinib (STI571, Glivec®) Standard Dose (400 Mg/Day) With Imatinib High Dose Induction (800 Mg/Day) Followed by Standard Dose Maintenance (400 Mg/Day) in Pretreated CML Patients in Chronic Phase||Central European Leukemia Study Group||Recruiting|January 2004|December 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||September 2005|June 16, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327262||182385|
NCT00311285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-001-G-2006|Physical and Mental Load in the Surgeon Performing Laparoscopic Tasks|Physical and Mental Load During Laparoscopic Tasks. A Prospective Randomized Trial of the Ergonomics in a Black Box Model||University Hospital, Gentofte, Copenhagen||Not yet recruiting||March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|12|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||March 2006|June 28, 2007|April 3, 2006||||No||https://clinicaltrials.gov/show/NCT00311285||183592|
NCT00311610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000467234|Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer|Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin||Alliance for Clinical Trials in Oncology|No|Completed|January 2006|June 2010|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|April 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00311610||183567|
NCT00311623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000468942|Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer|A Pharmacodynamic Study of Pre-Prostatectomy Rapamycin in Men With Advanced Localized Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 2006|||January 2008|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Male|18 Years|N/A|No|||February 2009|February 18, 2011|April 5, 2006||||No||https://clinicaltrials.gov/show/NCT00311623||183566|
NCT00280527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1347-004|Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.|Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.||Northwestern University|No|Completed|September 2006|September 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|43|||Both|18 Years|65 Years|No|Non-Probability Sample|This will be a prospective trial of obese patients with presumed NAFLD undergoing        bariatric surgery. Patients will be enrolled at Northwestern Memorial Hospital through the        bariatric surgery clinic.|December 2011|December 16, 2011|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280527||185895|
NCT00280787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0215|Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim|LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|November 2003|October 2010|Actual|January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|January 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00280787||185875|
NCT00281060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK164/2003|Vienna Absolute Trial: Balloon Angioplasty Versus Stenting in the Superficial Femoral Artery|Balloon Angioplasty Versus Stenting With Nitinol Stents in the Superficial Femoral Artery||Medical University of Vienna||Completed|June 2003|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||August 2005|July 26, 2006|January 20, 2006||||No||https://clinicaltrials.gov/show/NCT00281060||185854|
NCT00278785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513815-1|Brief Intervention for Alcohol Use Among Injured Patients|Brief Intervention for Alcohol Use Among Injured Patients: A Prospective, Randomized Trial||University of California, Davis|No|Active, not recruiting|March 2006|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|830|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00278785||186027|
NCT00278798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0591|TRAIL-CC: Trachelectomy, Radical Hysterectomy, and Intimate Life After Cervical Cancer Study|||University of British Columbia|No|Completed|January 2006|December 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|33|||Female|19 Years|65 Years|No|Non-Probability Sample|Women diagnosed with cervical or endometrial cancer|July 2012|July 10, 2012|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278798||186026|
NCT00321230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL994-02/2000|Clinical Evaluation of a New Reduced Volume Bowel Preparation|A Pilot Monocentric, Open Phase II Study to Investigate the Efficacy and Safety of a New Oral Gut Cleansing Solution ("Low Dose Bowel Prep") in 30 Patients Submitted to Colonoscopy||Norgine|No|Completed|January 2001|May 2001||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||April 2008|April 15, 2008|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321230||182835|
NCT00328718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM103848|Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets|See Detailed Description||GlaxoSmithKline|No|Completed|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||526|||Both|6 Years|14 Years|No|||November 2012|November 21, 2012|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00328718||182276|
NCT00329459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX105850|Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea|See Detailed Description||GlaxoSmithKline|No|Completed|May 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|354|||Female|18 Years|65 Years|No|||April 2015|April 15, 2015|May 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00329459||182219|
NCT00329433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0969|Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery|The Use of Desirudin Versus Heparin for Thrombosis Prophylaxis in Cardiothoracic Surgery Patients||Washington University School of Medicine|Yes|Completed|May 2006|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||June 2011|June 14, 2011|May 22, 2006|No|Yes||No|March 11, 2011|https://clinicaltrials.gov/show/NCT00329433||182221|The study size was small and a surrogate end point was the primary outcome. The study was not powered to show statistical differences in clinical outcomes. Many patients received both desirudin and heparin during the study.
NCT00329745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107070|Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)|A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants.||GlaxoSmithKline||Completed|January 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|8687|||Both|2 Years|3 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|May 24, 2006|Yes|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00329745||182197|
NCT00330070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPL512,602-2002|Control of Asthma Patients Symptomatic on Inhaled Corticosteroids|An 8 Week, Randomized, Double-Blind, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of Oral IPL512,602 to Placebo in Subjects With Moderate to Severe Persistent Asthma Inadequately Controlled on Inhaled Corticosteroids||Inflazyme Pharmaceuticals Ltd||Completed|May 2006|January 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|50 Years|No|||February 2007|February 14, 2007|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00330070||182176|
NCT00330850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-513301|An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack|||ProEthic Pharmaceuticals||Completed|May 2006|December 2006||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||650|||Both|18 Years|65 Years|No|||March 2007|March 30, 2007|May 26, 2006||||||https://clinicaltrials.gov/show/NCT00330850||182116|
NCT00330603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12302|Serial Exhaled Breath pH Monitoring|Serial Exhaled Breath pH Monitoring||University of Virginia||Recruiting|April 2006|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|99|||Both|5 Years|N/A|No|Non-Probability Sample|patients with chronic cough for whom their doctor is planning to begin an empiric trial of        proton pump inhibitor as a diagnostic trial of therapy.|March 2011|March 4, 2011|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00330603||182135|
NCT00326677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601117|Primary Prevention of Major Depression in Later Life|Primary Prevention of Major Depression in Later Life||University of Pittsburgh|No|Active, not recruiting|May 2006|December 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|306|||Both|50 Years|N/A|No|||February 2011|February 17, 2011|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326677||182427|
NCT00327015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-039|A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control||AstraZeneca|Yes|Completed|May 2006|December 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1306|||Both|18 Years|77 Years|No|||March 2015|April 8, 2015|May 15, 2006|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00327015||182404|
NCT00326690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioVentrix - Blue Egg Trial™|Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity|A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart||BioVentrix||Recruiting|November 2005|July 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|June 8, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326690||182426|
NCT00327028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTP-DP-0505-1205|Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Phenytoin Efficacy in Bronchial Asthma Therapy||Centre of Chinese Medicine, Georgia||Completed|September 2005|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||61|||Both|18 Years|65 Years|No|||February 2009|February 18, 2009|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00327028||182403|
NCT00276991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAM10|Traditional CAM Therapy in the Treatment of HIV/AIDS|Modest Phase 1 and Phase II Clinical Studies on Traditional CAM Therapy in the Treatment of HIV/AIDS||Traditional Alternative Medicine Research, India|Yes|Terminated|November 2007|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|8 Years|65 Years|No|||November 2015|November 2, 2015|January 12, 2006||No|Lack of funding prevented the recruitment of 1000 HIV Patients all over India|No||https://clinicaltrials.gov/show/NCT00276991||186156|
NCT00277004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0399C|Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.|Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.||University of New Mexico|Yes|Completed|February 1999|March 2005|Actual|March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Female|N/A|N/A|No|Probability Sample|Females with breast cancer undergoing cancer treatment.|March 2008|January 6, 2010|January 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277004||186155|
NCT00277316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-201|Study of XL999 in Patients With Metastatic Renal Cell Carcinoma|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma||Symphony Evolution, Inc.|Yes|Terminated|December 2005|June 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|January 12, 2006|Yes|Yes|Development of XL999 was stopped due to cardiac toxicities in the subjects|No||https://clinicaltrials.gov/show/NCT00277316||186132|
NCT00277602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIL_DE1_201|Riluzole in Huntington's Disease|A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease||Sanofi||Completed|November 1999|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|537|||Both|25 Years|65 Years|No|||February 2012|February 15, 2012|January 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00277602||186112|
NCT00311896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-BEM-2004-02|Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)|Multicentric, Randomized, Placebo Controlled and Double-blind Study to Evaluate the Efficacy and Safety of Antithrombotic Prophylaxis With Bemiparin (3,500 UI/Day) in Cancer Patients With a Central Venous Catheter (CVC)(BECAT)||Clinica Universidad de Navarra, Universidad de Navarra|No|Terminated|July 2005|December 2010|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|402|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|April 5, 2006||No|Sponsor stopped due to difficulties to recruit 402 patients required by protocol|No||https://clinicaltrials.gov/show/NCT00311896||183545|
NCT00311909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHC DBS TS|Thalamic Deep Brain Stimulation for Tourette Syndrome|Thalamic Deep Brain Stimulation for Tourette Syndrome: A Prospective Clinical Trial||University Hospital Case Medical Center||Completed|June 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||5|||Both|18 Years|N/A|No|||April 2006|April 5, 2006|April 5, 2006||||||https://clinicaltrials.gov/show/NCT00311909||183544|
NCT00312195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3201|Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain|An Open-label Run-in, Followed by a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Show the Effectiveness of Buprenorphine Transdermal System in Management of Patients With Chronic Nonmalignant Pain Syndromes||Purdue Pharma LP||Completed|March 2001|July 2001|Actual|July 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|267|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|April 5, 2006|Yes|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT00312195||183522|
NCT00312208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_GMA_301|Docetaxel in Breast Cancer|A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes||Sanofi||Completed|November 2001|October 2013|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3299|||Female|18 Years|70 Years|No|||December 2013|December 4, 2013|April 5, 2006|Yes|Yes||No|October 29, 2009|https://clinicaltrials.gov/show/NCT00312208||183521|
NCT00327951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-109|Infant Weight Gain With Trisomy 21 and CAVC|The Impact of Weight Gain in the Pre-operative Infant With Trisomy 21 (Down Syndrome) and Complete Atrioventricular Canal (CAVC)||Children's Healthcare of Atlanta|No|Terminated|January 2001|February 2008|Actual|March 2006|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|46|||Both|N/A|1 Year|No|Non-Probability Sample|patients' charts from Children's Healthcare of Atlanta|February 2008|March 14, 2012|May 18, 2006||No|sufficient data collected for significant conclusion|No||https://clinicaltrials.gov/show/NCT00327951||182332|
NCT00328458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03C.275|EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients|A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer||Thomas Jefferson University|Yes|Completed|February 2004|July 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||March 2011|March 11, 2011|May 19, 2006||Yes||Yes||https://clinicaltrials.gov/show/NCT00328458||182296|
NCT00328185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-217|Allograft Fibrosis Following Pediatric Cardiac Transplantation|Allograft Fibrosis: Its Regulation and Significance Following Pediatric Cardiac Transplantation||Children's Healthcare of Atlanta||Terminated|January 2006|December 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|100|||Both|N/A|18 Years|No|Non-Probability Sample|Children who underwent heart transplantation prior to age 18|January 2006|March 14, 2012|May 18, 2006|||unable to gather sufficient data|No||https://clinicaltrials.gov/show/NCT00328185||182315|
NCT00328471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS041333-01A1|A Post Discharge Intervention to Improve Stroke Outcomes|A Post Discharge Intervention to Improve Stroke Outcomes||Summa Health System|Yes|Completed|June 2002|June 2009|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|380|||Both|18 Years|N/A|No|||January 2012|January 6, 2012|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328471||182295|
NCT00329121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-008|Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ|Multi-centre, Open-label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)||Peplin||Completed|May 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329121||182245|
NCT00329134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/177|Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria|Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria||University Ghent|No|Completed|July 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|6 Months|59 Months|No|||April 2009|April 16, 2009|May 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00329134||182244|
NCT00329732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GON-DBPC/WBY|Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks|Double-Blind, Placebo Controlled Trial Of Greater Occipital Nerve Block For The Treatment Of Migraine Status||Thomas Jefferson University||Terminated|March 2006|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|80 Years|No|||April 2015|April 16, 2015|May 24, 2006||No|Study terminated due to inadequate recruitment|No|May 24, 2011|https://clinicaltrials.gov/show/NCT00329732||182198|
NCT00330018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-03-HMO-CTIL|Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)|An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation||Hadassah Medical Organization|Yes|Completed|February 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|14 Years|70 Years|No|||August 2009|April 19, 2015|May 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00330018||182178|
NCT00330044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05C.276|Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer|A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.||Thomas Jefferson University|Yes|Completed|April 2006|October 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|N/A|No|||August 2010|August 24, 2010|May 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00330044||182177|
NCT00330083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-01|Safety of ALK Ragweed Tablet|A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY||ALK-Abelló A/S||Completed|May 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|50 Years|No|||September 2007|September 20, 2007|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00330083||182175|
NCT00330863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH070007-01|Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy|Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)|PROACTIVE|Northwell Health|Yes|Completed|May 2006|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|65 Years|No|||July 2014|July 14, 2014|May 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330863||182115|
NCT00326729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD06-004|Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation|||Montreal Burn Centre||Recruiting|May 2006|||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|18 Years|80 Years|No|||May 2006|June 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326729||182423|
NCT00326703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boeing001|Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort|Investigation to Determine the Effects of Aircraft Cabin Altitudes on Passenger Comfort and Discomfort||The Boeing Company||Completed|October 2002|April 2003||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||500|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||May 2006|October 16, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326703||182425|
NCT00326716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-182|Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women|A Study of the Pharmacokinetics of Atazanavir (ATV)/Ritonavir(RTV) Administered as Part of Highly Active Antiretroviral Therapy (HAART) in HIV-1 Infected Pregnant Women||Bristol-Myers Squibb|No|Completed|June 2006|August 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Female|18 Years|N/A|No|||November 2011|November 4, 2011|May 15, 2006|No|Yes||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00326716||182424|
NCT00330837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512116|Ultrasound Scanning of Vascular Access Sites|Ultrasound Scanning of Vascular Access Sites||University of Pittsburgh||Completed|February 2006|February 2007|Actual|||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 7, 2008|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00330837||182117|
NCT00327288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-010|Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients|A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Taxotere® (Docetaxel) in Previously Treated Inoperable Stage III and Stage IV Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic Previously Treated Breast Cancer or Hormone Refractory Prostate Cancer||AmpliMed Corporation|No|Completed|October 2005|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327288||182383|
NCT00276757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454768|Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis|Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis||National Cancer Institute (NCI)||Completed|April 2001|June 2013|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|376|||Both|N/A|17 Years|No|||May 2007|January 9, 2014|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276757||186174|
NCT00277654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-PAD-402|Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder||Lindner Center of HOPE||Completed|February 2004|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||December 2011|December 12, 2011|January 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277654||186109|
NCT00277667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET0302|Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms|A Randomized, Double-Blind, Placebo-Controlled Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms||Lindner Center of HOPE||Completed|February 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00277667||186108|
NCT00277953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-047|MRI Review of Tracheal Dimensions|A Review of Tracheal Dimensions in the Pediatric Population Using MRI||Children's Healthcare of Atlanta||Terminated||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||75|||Both|N/A|21 Years|No|||May 2007|May 2, 2007|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277953||186087|
NCT00277615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHUL2006|Evaluation Study of Ultrasound Bladder Scanner for Monitoring Bladder Function|Clinical Evaluation of a Portable Ultrasound Bladder Scanner for Continuous Monitoring of Bladder Function in Children.||University of Aarhus|No|Active, not recruiting|October 2005|December 2012|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|4 Years|15 Years|No|Probability Sample|Children with OAB|January 2012|January 20, 2012|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00277615||186111|
NCT00277641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106531|Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity|Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients||Lindner Center of HOPE||Completed|March 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||June 2011|June 21, 2011|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00277641||186110|
NCT00277940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-042|Aortic Arch Reconstruction|Neoaortic Elastic Properties After Aortic Arch Reconstruction||Children's Healthcare of Atlanta||Terminated||||||N/A|Observational|Time Perspective: Retrospective||1|Actual|36|||Both|N/A|6 Years|No|Non-Probability Sample|retro chart review|May 2007|July 5, 2011|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00277940||186088|
NCT00328211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK68463|Intralumenal Effects on Cholesterol Absorption/Synthesis|Intralumenal Effects on Cholesterol Absorption/Synthesis||Children's Hospital Medical Center, Cincinnati|Yes|Completed|September 2005|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|35|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328211||182313|
NCT00328224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230606-HMO-CTIL|Oral Status and Prevalence of Dental Trauma in Children Treated With Ritalin Due to Attention-Deficit Hyperactivity Disorder (ADHD)|Oral Status and Prevalence of Dental Trauma in Children Treated With Ritalin Due to Attention-Deficit Hyperactivity Disorder (ADHD)||Hadassah Medical Organization||Completed|May 2006|October 2007|Actual|||N/A|Observational|Observational Model: Case Control||2|Actual|50|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|healthy children children with adhd treated with ritalin|May 2006|October 31, 2007|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328224||182312|
NCT00328198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM203|Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia||Sanofi|Yes|Completed|May 2006|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|May 18, 2006|Yes|Yes||No|June 25, 2012|https://clinicaltrials.gov/show/NCT00328198||182314|
NCT00328484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|387|Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease|Exercise and Disability in COPD Patients||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|January 2002|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|318|||Both|N/A|N/A|No|||February 2009|February 17, 2009|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00328484||182294|
NCT00328770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4279|De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma|De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects||University of Alberta|No|Completed|December 1996|March 2006|Actual|March 2006|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|70 Years|No|||June 2013|June 18, 2013|May 19, 2006||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00328770||182272|
NCT00328783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02U.282|Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer|A Pilot Study Investigating Active Breathing Coordinator (ABC) to Reduce Radiation Dose to Normal Structures in Breast Cancer Patients||Thomas Jefferson University|Yes|Completed|October 2002|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|112|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|May 19, 2006||No||No|January 27, 2014|https://clinicaltrials.gov/show/NCT00328783||182271|
NCT00330109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-9-0032 / 22151-22523|Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology|Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology||AHS Cancer Control Alberta|Yes|Recruiting|June 2006|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00330109||182173|
NCT00329472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-09-027|Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer|Randomized Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Plus Adjuvant Chemotherapy Versus Surgery Plus Adjuvant Chemotherapy in Stage IB, IIA, IIB and T3N1 Non-small Cell Lung Cancer (ICON)||Samsung Medical Center||Withdrawn|April 2006|July 2010|Anticipated|July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2010|August 26, 2010|May 22, 2006||No|poor enrollment|No||https://clinicaltrials.gov/show/NCT00329472||182218|
NCT00330343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-03-31-02|Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents|The Optimal Dose of Prophylactic Naloxone in Ameliorating Opioid Induced Side Effects in Children and Adolescents Receiving IVPCA Morphine for Moderate to Severe Pain: A Pharmacodynamic, Pharmacokinetic, and Pharmacogenetic Study||Johns Hopkins University||Recruiting|May 2004|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||99|||Both|7 Years|17 Years|No|||July 2005|May 25, 2006|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330343||182155|
NCT00330356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074825/Z/04/Z|Effects of Low Salt Diet Versus High Salt Diet on Blood Pressure|Effects of Low Salt Diet Versus High Salt Diet on Blood Pressure||Aga Khan University||Active, not recruiting|September 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|40 Years|N/A|Accepts Healthy Volunteers|||April 2006|May 25, 2006|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330356||182154|
NCT00330369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAR-311|DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension|DORADO - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311)||Gilead Sciences|Yes|Completed|June 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|352|||Both|35 Years|80 Years|No|||February 2014|February 19, 2014|May 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330369||182153|
NCT00330096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.12NRC|Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women|||Nestlé||Completed|March 2006|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|110|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2015|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330096||182174|
NCT00330616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK1102369|Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan|Clinical Evaluation of Bupropion SR (323U66)in Patients With Depression - Investigation in Elderly Patients With Depression||GlaxoSmithKline||Completed|May 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|65 Years|N/A|No|||June 2009|April 13, 2015|May 26, 2006||||No|November 26, 2008|https://clinicaltrials.gov/show/NCT00330616||182134|
NCT00327106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401129|Tranexamic Acid in HIp Fracture Surgery (THIF Study)|Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.|THIF|Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|April 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327106||182397|
NCT00327067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060166|Iron Replacement in Blood Donors|Iron Replacement in Blood Donors||National Institutes of Health Clinical Center (CC)||Completed|May 2006|March 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|1820|||Both|18 Years|N/A|No|||March 2012|September 26, 2015|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327067||182400|
NCT00327080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060165|Sildenafil to Treat HIV-Associated Pulmonary Hypertension|Evaluation of Endothelial and Hemodynamic Function in HIV Associated Pulmonary Hypertension and a Phase I/II Safety and Efficacy Trial of Sildenafil in HIV Associated Pulmonary Hypertension||National Institutes of Health Clinical Center (CC)||Terminated|May 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2012|August 20, 2013|May 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00327080||182399|
NCT00327041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rgoodtrial001|Monitoring Response to Antiplatelet Therapy|Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy||NHS Greater Glasgow and Clyde||Recruiting|January 2006|September 2006||||Phase 4|Observational|N/A||||40|||Both|18 Years|80 Years|No|||May 2006|May 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00327041||182402|
NCT00327054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05201MED(Grant Fund#1VJ)|Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia|Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia: A Randomized Controlled Trial||Aga Khan University|No|Completed|February 2006|March 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2007|June 30, 2015|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327054||182401|
NCT00327795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-010|Surgical Outcomes in Pediatric Patients With Coarctation and VSD|Staged Approach to Coarctation and VSD Can Offer Optimal Outcomes||Children's Healthcare of Atlanta||Terminated|January 2006|November 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1||32|||Both|N/A|N/A|No|Non-Probability Sample|diagnosis of coarctation and VSD|January 2006|March 14, 2012|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00327795||182344|
NCT00277329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-204|Study of XL999 in Patients With Non-small Cell Lung Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer||Symphony Evolution, Inc.|Yes|Terminated|December 2005|July 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|January 12, 2006|Yes|Yes|Study was terminated due to cardiac toxicities in the subejcts|No||https://clinicaltrials.gov/show/NCT00277329||186131|
NCT00277342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOW_MM_LFABP|Potential Association of a Common L-FABP Polymorphism With Lipid-induced Hepatic Insulin Resistance|||German Institute of Human Nutrition||Completed|January 2006|April 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2006|May 3, 2012|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277342||186130|
NCT00277680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU22200105|Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids|A Randomized Trial Comparing Laparoscopic Bilateral Occlusion of Uterine Vessels to Uterine Fibroid Embolization for the Treatment of Symptomatic Uterine Fibroids||Oslo University Hospital||Active, not recruiting|December 2000|April 2010||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|30 Years|N/A|No|||January 2006|July 3, 2011|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277680||186107|
NCT00278213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454588|Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia|Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Active, not recruiting|September 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|17|||Both|18 Years|65 Years|No|||July 2007|November 5, 2013|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278213||186067|
NCT00278486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI ARRON 04|Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)|Immune Ablation and Hematopoietic Stem Cell Transplantation in Patients With Autoimmune-Related Retinopathy and Optic Neuropathy (ARRON) Syndrome (Not Associated With Cancer)||Northwestern University|No|Terminated|August 2004|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|60 Years|No|||April 2013|April 4, 2013|January 15, 2006|Yes|Yes|First subject over five years after the transplant. The second subject is not in compliance    with follow ups. We do not plan to enroll more subjects.|No||https://clinicaltrials.gov/show/NCT00278486||186049|
NCT00278772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Miefert|Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania|"A Randomized, Double-Blind, Placebo-Controlled Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania"||Lindner Center of HOPE||Completed|August 2003|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||May 2010|May 24, 2010|January 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00278772||186028|
NCT00328510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04U.534|Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy|A Randomized Trial Comparing Two Forms of Immobilization of the Head for Fractioned Stereotactic Radiotherapy||Thomas Jefferson University|Yes|Completed|February 2005|September 2009|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|May 19, 2006||No||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00328510||182292|
NCT00328497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CLN-002|A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors|A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors||CASI Pharmaceuticals, Inc.||Completed|May 2006|December 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||March 2010|March 9, 2010|May 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00328497||182293|
NCT00328796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11295|Acupuncture for Pain Relief During Perineal Repair After Childbirth|Acupuncture or Local Anaesthetics for Pain Relief During Perineal Repair After Vaginal Delivery: A Randomised Controlled Trial||Sonderborg Hospital||Completed|May 2006|February 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Actual|207|||Female|15 Years|50 Years|No|||September 2008|October 3, 2008|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00328796||182270|
NCT00329108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281147|Ziprasidone And Olanzapine's Outcomes In Mania|A Multicenter, Randomized, Double-Blind, Parallel Group Study, Comparing The Efficacy And Tolerability Of Ziprasidone (Zeldox, Geodon) vs. Olanzapine (Zyprexa) In The Treatment And Maintenance Of Response In Patients With Acute Mania|ZOOM|Pfizer|No|Terminated|November 2006|January 2008|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||April 2009|April 1, 2009|May 5, 2006|Yes|Yes|Please see Brief Summary for Termination Reason.|No|December 22, 2008|https://clinicaltrials.gov/show/NCT00329108||182246|The study was terminated due to poor recruitment. No efficacy data were summarized due to very low sample size. Only safety data were summarized.
NCT00329446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00010|Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder|GOLD|AstraZeneca||Completed|April 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|800|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329446||182220|
NCT00330642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HandyLab #VVP00103|Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study|Rapid Detection of Group B Streptococcus Using a Bedside Microfluidics Device: Labor and Delivery Study||University of Michigan|No|Withdrawn|July 2006|||July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients 18 years or older who present for induction of labor.|December 2015|December 14, 2015|May 26, 2006|Yes|Yes|HandyLab device did not work for the science|No||https://clinicaltrials.gov/show/NCT00330642||182132|
NCT00330876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-308EU|Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Open-Label, Long-Term (> 1 Year) Extension Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia||Kowa Research Europe|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|545|||Both|65 Years|N/A|No|||March 2010|March 9, 2010|May 26, 2006||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00330876||182114|
NCT00330889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999920/040|Effects Of Prednisolone On Rheumatoid Arthritis Patients|A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients||GlaxoSmithKline|No|Completed|February 2004|December 2006|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|32|||Both|25 Years|75 Years|No|Probability Sample|A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene        Expression in Rheumatoid Arthritis Patients and pharmacodynamic effects on whole blood        gene and protein expression.|October 2012|October 18, 2012|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00330889||182113|
NCT00326742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGFN 2 01 GS 0475|Validation in Humans of Genes Involved in Alcohol Drinking, Stress-Induced Alcohol Drinking and Relapse|Validation in Humans of Genes Involved in Alcohol Drinking, Stress-Induced Alcohol Drinking and Relapse||Central Institute of Mental Health, Mannheim||Completed|July 2005|March 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|281|||Both|18 Years|19 Years|Accepts Healthy Volunteers|||May 2007|May 9, 2007|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00326742||182422|
NCT00330629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000674|Preference and Vegetarian Diet in Weight Loss Treatment|Preference and Vegetarian Diet in Weight Loss Treatment||University of Pittsburgh||Completed|January 2002|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||195|||Both|18 Years|55 Years||||March 2006|May 26, 2006|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00330629||182133|
NCT00327327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-004|Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma|A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma||AmpliMed Corporation|Yes|Completed|February 2004|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||September 2010|September 14, 2010|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327327||182380|
NCT00327522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106962|Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.|An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.||GlaxoSmithKline||Completed|June 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00327522||182365|
NCT00327548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 5P50-AT00008|Use of Guided Imagery for Functional Abdominal Pain in Children:|Treatment of Functional Abdominal Pain in Children:Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities||Children's Mercy Hospital Kansas City||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|5 Years|18 Years||||July 2002|October 4, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327548||182363|
NCT00328029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2999|Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population|Assessment of Respiratory Functions After a Conditioning Regimen With Busulfan for Allograft or Autograft in a Unicenter Pediatric and Prospective Population||University Hospital, Strasbourg, France||Recruiting|July 2006|June 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|3 Years|18 Years|No|||February 2009|February 24, 2009|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328029||182327|
NCT00328042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAC 05-067|Hepatitis C Self-Management|A Self-Management Intervention for Veterans With Hepatitis C||VA Office of Research and Development|No|Completed|May 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|134|||Both|N/A|N/A|No|||July 2014|April 6, 2015|May 17, 2006||No||No|August 26, 2014|https://clinicaltrials.gov/show/NCT00328042||182326|
NCT00277043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902C|A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes|A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes||New Mexico Cancer Care Alliance|Yes|Completed|June 2002|September 2005|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||December 2009|September 23, 2011|January 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00277043||186152|
NCT00277056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1602C|Dysregulated Tyrosine Kinase Signaling in Leukemia|Dysregulated Tyrosine Kinase Signaling in Leukemia||University of New Mexico|Yes|Completed|May 2002|October 2005|Actual|October 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples With DNA|blood bone marrow|Both|18 Years|N/A|No|Non-Probability Sample|people with leukemia|April 2008|January 6, 2010|January 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00277056||186151|
NCT00277693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040338|Cardiovascular Protective Effect of Spironolactone in Hemodialysis|Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies||Universidad Los Andes, Chile||Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years||||December 2005|January 12, 2006|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277693||186106|
NCT00277706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-03|Impact of Parathyroid Hormone (PTH) on Osseous Cavity|Impact of Parathyroid Hormone (1-34) on Osseous Regeneration in the Oral Cavity||University of Michigan||Completed|August 2004|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|75 Years|No|||October 2009|October 6, 2009|January 12, 2006||Yes||||https://clinicaltrials.gov/show/NCT00277706||186105|
NCT00277732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/340|Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial|Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial||University Ghent|No|Completed|January 2006|November 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|288|||Both|45 Years|75 Years|No|||December 2007|December 19, 2007|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277732||186104|
NCT00277979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-058|3D Echocardiography Managing Infantile Pompe's Disease|Utilization of 3D Echocardiography in the Management of Infantile Pompe's Disease: Two Case Reports||Children's Healthcare of Atlanta|No|Terminated|January 2005|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|2|||Both|N/A|N/A|No|Non-Probability Sample|Subject with Infantile Pompe's Disease seen at Children's between Jan. and February, 2005.|December 2007|March 14, 2012|January 13, 2006||No|project withdrawn|No||https://clinicaltrials.gov/show/NCT00277979||186085|
NCT00277966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-051|Cath Lab Performance Improvement|Cardiac Catheterization Laboratory Radiology Performance Improvement||Children's Healthcare of Atlanta||Terminated|January 2004|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|21 Years|No|||May 2007|May 3, 2007|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277966||186086|
NCT00278226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000452798|Motivational Program for Smokers Enrolled in a Methadone Maintenance Program|Smoking Cessation Among Methadone Maintained Patients||Butler Hospital|No|Completed|June 2001|October 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|398|||Both|18 Years|75 Years|No|||March 2010|March 23, 2010|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278226||186066|
NCT00278499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA CH 005|Prevalence of HIV and Other Sexually Transmitted Infections Among Female Sex Workers and Miners in Honghe Prefecture, Yunnan Province, China|Epidemiology of HIV-1 and Other Sexually Transmitted Infections in Honghe Prefecture, Yunnan Province, China||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3800|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female sex workers and their clients in Hinghe Prefecture, Yunnan Province, China|January 2011|January 12, 2011|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278499||186048|
NCT00278512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD Vasculitis.Auto2002|Hematopoietic Stem Cell Support in Vasculitis|High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome||Northwestern University|No|Recruiting|August 2003|August 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|16 Years|60 Years|No|||March 2016|March 21, 2016|January 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278512||186047|
NCT00328250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12232|Effectiveness of Internet Cognitive Behavioral Therapy Intervention for Treating Insomnia|Internet Insomnia Intervention: Development and Feasibility||University of Virginia|No|Completed|October 2006|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||January 2012|January 11, 2012|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00328250||182310|
NCT00328523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-060|TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)|Ezetimibe Together With Any Statin Cholesterol Enhancement||Merck Sharp & Dohme Corp.||Completed|June 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1496|||Both|18 Years|80 Years|No|||January 2015|January 11, 2015|May 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00328523||182291|
NCT00328536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMACOR-D-01/06|Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus|Effects of Treatment With Omacor for 6 Weeks on Preprandial and Postprandial Endothelial Function Following a High Fat Meal in Patients With Type 2 Diabetes Mellitus||Ruhr University of Bochum|No|Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|34|||Both|35 Years|70 Years|No|||May 2009|May 7, 2009|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00328536||182290|
NCT00328809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1045057|Spironolactone Safety in Dialysis Patients|Subjects With Severe Heart Failure and End-Stage Renal Disease on Hemodialysis: A Pilot Study to Assess Safety and Tolerability of Spironolactone||State University of New York - Upstate Medical University||Withdrawn||||||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|May 19, 2006||No|personnel shortage|No||https://clinicaltrials.gov/show/NCT00328809||182269|
NCT00330655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000296/1|An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder|An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity||Mclean Hospital|No|Completed|May 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|16 Years|65 Years|No|||August 2007|August 10, 2007|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330655||182131|
NCT00330902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGS64|Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan|Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan||London School of Hygiene and Tropical Medicine|No|Completed|January 2004|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|3 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 30, 2007|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330902||182112|
NCT00326768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.516|Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension|An Open-Label, Long-term (52-week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation||Boehringer Ingelheim||Completed|May 2006|August 2007||August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|184|||Both|20 Years|80 Years|No|||November 2013|November 11, 2013|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00326768||182421|
NCT00327093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-401|Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases|Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases||Hospices Civils de Lyon||Terminated|May 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||February 2009|February 6, 2009|May 17, 2006||No|The scientific commitee decided to stop the inclusions and exploit the results.|No||https://clinicaltrials.gov/show/NCT00327093||182398|
NCT00327301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-WUK-2006-001|Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease|Systematic Characterization of the Cellular Proteome From Human Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease||University Hospital, Basel, Switzerland|No|Withdrawn|October 2006|||May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|None Retained|plasma|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|glaucoma patients|March 2015|March 9, 2015|May 17, 2006||No|was replaced by an other study|No||https://clinicaltrials.gov/show/NCT00327301||182382|
NCT00327535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH19960|A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.|A Multicenter, Randomized, Open Label Dose Finding Study of Mircera in Anemic Patients With Stage IIIB or IV Non-small Cell Lung Cancer Receiving First Line Myelosuppressive Chemotherapy||Hoffmann-La Roche||Completed|May 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|153|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327535||182364|
NCT00327808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI 1020-202|Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma|Multi-Center, Randomized, Double-Blind, Repeated Doses Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma||Pharmaxis|No|Completed|May 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||November 2012|November 30, 2012|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327808||182343|
NCT00327821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107189 BBC|The Effectiveness of Commercial Weight Loss Programmes|A Randomised Control Trial of Commercial Weight Loss Programme in a Community Based Sample of Obese Adults.||University of Surrey||Completed|July 2002|March 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2003|July 20, 2006|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00327821||182342|
NCT00327834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4Z-US-X009|Atomoxetine in the Treatment of Binge Eating Disorder|Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients||Lindner Center of HOPE||Completed|May 2006|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|65 Years|No|||June 2011|June 21, 2011|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327834||182341|
NCT00277355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-002588|Pilot Study of Minocycline in Huntington's Disease|A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease||Huntington Study Group|Yes|Completed|April 2006|November 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|January 12, 2006|No|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00277355||186129|
NCT00277992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-107|Growth in Children With HLHS|Growth in Children With HLHS||Children's Healthcare of Atlanta||Terminated|January 2001|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|N/A|21 Years|No|||May 2007|May 22, 2007|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277992||186084|
NCT00278252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-CNS-2001-4|Etoposide in Treating Young Patients With Relapsed Ependymoma|Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma||National Cancer Institute (NCI)||Recruiting|July 2001|||July 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|14|||Both|N/A|21 Years|No|||June 2009|August 6, 2013|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278252||186064|
NCT00278239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454509|Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors|Study of Outcome of Children Previously Enrolled in European Trials of Treatment for Primitive Neuroectodermal Tumour (PNET)||National Cancer Institute (NCI)||Active, not recruiting|June 2002|||||Phase 3|Observational|N/A|||||||Both|3 Years|24 Years|No|||April 2006|September 19, 2013|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278239||186065|
NCT00278837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0209005792(RCT)|Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors|Contemplative Self-Healing to Improve Quality of Life in Breast Cancer Survivors: the Avon Foundation Program to Reach Medically Underserved Populations||Weill Medical College of Cornell University|No|Active, not recruiting|May 2003|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|160|||Female|18 Years|N/A|No|||April 2008|April 22, 2008|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00278837||186023|
NCT00278850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0592|"Vestibulitis Educational Seminar Trial" Study|"Vestibulitis Educational Seminar Trial" Study||University of British Columbia|No|Completed|January 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|500|||Female|18 Years|65 Years|No|Non-Probability Sample|women diagnosed with vulvar vestibulitis|June 2015|June 11, 2015|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278850||186022|
NCT00329147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-900|Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects|A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 6, 2007|May 23, 2006||||||https://clinicaltrials.gov/show/NCT00329147||182243|
NCT00329160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3565L00002|Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease|A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease as Measured by Intravascular Ultrasonography||AstraZeneca||Completed|October 2005|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|214|||Both|20 Years|75 Years|No|||August 2011|August 29, 2011|May 22, 2006|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00329160||182242|Because there was no placebo arm the net effect of rosuvastatin was not clarified. This study examined only single measurable plaques, which might not represent pan-coronary nature of plaque.
NCT00329485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200602-WA|The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients|The Effect of Ribose on B-Type Natriuretic Peptide Levels in Congestive Heart Failure Patients||Valen Labs|No|Terminated|June 2006|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||120|||Both|18 Years|80 Years|No|||August 2007|August 1, 2007|May 23, 2006|||Poor recruitment and through put|No||https://clinicaltrials.gov/show/NCT00329485||182217|
NCT00329758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-06ROHI|Effect of Rosuvastatin on Amnesia and Orientation Through Galveston Outcome Amnesia Test in Moderate Head Injury|Phase II Study of Rosuvastatin´s Effect on Amnesia and Orientation Through Galveston Outcome Amnesia Test in Humans With Moderate Head Injury||Universidad Autonoma de San Luis Potosí|Yes|Completed|July 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|50 Years|No|||March 2009|June 23, 2010|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329758||182196|
NCT00330382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00888|Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia|Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial||National Cancer Institute (NCI)||Completed|January 1999|May 2013|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|325|||Both|18 Years|N/A|No|||February 2014|December 16, 2014|May 25, 2006|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00330382||182152|
NCT00330395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-058|Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)|A Multicenter, Sequential-Panel, Open-Label, Noncomparative Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Caspofungin Acetate in Neonates and Infants Less Than 3 Months of Age.||Merck Sharp & Dohme Corp.||Completed|May 2006|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|N/A|3 Months|No|||November 2015|November 9, 2015|May 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330395||182151|
NCT00330421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03122|Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)|A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma||National Cancer Institute (NCI)||Completed|June 2006|July 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||November 2013|April 1, 2014|May 25, 2006|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT00330421||182149|No Grade 4 toxicities were noted (15 patients). IFP measurements were obtained in only 6 of 15 patients at baseline. Only 2 of these 6 patients had SD at 28 and 56 days and therefore, second IFP measurements were only obtained in those 2 patients.
NCT00330915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9732|A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.|A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer||Eli Lilly and Company|No|Completed|June 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|May 26, 2006|Yes|Yes||No|June 3, 2009|https://clinicaltrials.gov/show/NCT00330915||182111|
NCT00326794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P011022|Efficacy of Shoulder Mobilisation Versus Conventional Immobilisation for Nonsurgically Proximal Humerus Fracture|Effectiveness at 3 Months of Immediate Shoulder Mobilisation Versus Conventional Immobilisation for Impacted Nonsurgically Treated Proximal Humerus Fracture: a Randomised Controlled Trial.||Assistance Publique - Hôpitaux de Paris||Terminated|October 2002|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||76|||Both|20 Years|N/A|Accepts Healthy Volunteers|||June 2005|May 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326794||182419|
NCT00326807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095/2001|Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling|A Randomized, Double-Blind, Placebo-Controlled Trial of Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling||Centre for Addiction and Mental Health||Completed|June 2001|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||May 2006|May 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326807||182418|
NCT00326781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|703294|Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)|Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center (TTURC), Project 2||University of Pennsylvania|No|Completed|December 1999|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|674|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2010|August 16, 2010|May 15, 2006|Yes|Yes||No|May 15, 2009|https://clinicaltrials.gov/show/NCT00326781||182420|
NCT00327574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR 070854|Population Based Strategies for Effective Control of High Blood Pressure in Pakistan|||Aga Khan University||Active, not recruiting|June 2004|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|5 Years|N/A|No|||May 2006|May 25, 2006|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00327574||182361|
NCT00327587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVEA489A2302|8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension|An 8-week, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension.||Novartis||Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|2279|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327587||182360|
NCT00327600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-005|Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma|A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma||AmpliMed Corporation|Yes|Completed|July 2005|December 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|N/A|N/A|No|||September 2010|September 14, 2010|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327600||182359|
NCT00327314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM 1641|Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma|||Azienda Ospedaliera San Giovanni Battista||Recruiting|December 2002|October 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||December 2006|December 27, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327314||182381|
NCT00327561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLH03/E007|Effect of Intensive Periodontal Therapy on Vascular Function|Effects of Non-Surgical Periodontal Therapy on Endothelial Function A Randomized Controlled Clinical Trial||Eastman Dental Insitute and Hospital||Completed|September 2003|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|35 Years|60 Years|No|||March 2005|May 16, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327561||182362|
NCT00328341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6693-19472-05|The Use of Tissue Oxygen Monitoring in Critically Injured Patients|The Use of Tissue Oxygen Monitoring in Critically Injured Patients||University of California, San Francisco|No|Terminated|April 2006|December 2011|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|Inclusion Criteria:          -  Age 18 years and older          -  Intubated and assisted mechanical ventilation          -  Traumatic brain injury requiring advanced neuromonitoring          -  Abbreviated injury scale 3 or more in torso. abdomen, or extremities|September 2013|September 18, 2013|May 17, 2006|No|Yes|Slow to enroll.|No||https://clinicaltrials.gov/show/NCT00328341||182304|
NCT00277368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003613|A Study of the Prevalence of Headache in Epileptic Patients|Headache in Epileptic Patients||Janssen Korea, Ltd., Korea||Completed|July 2005|March 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|719|||Both|13 Years|85 Years|No|Non-Probability Sample|Patients with a recent diagnosis epilepsy; able to describe their symptoms by themselves;        have had at least 2 episodes of seizures during the previous year; have had at least 1        headache during the previous year.|April 2010|April 26, 2010|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00277368||186128|
NCT00278005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-134|Infection in DiGeorge Following CHD Surgery|Incidence of Infection in the Patient With DiGeorge Syndrome Following Surgery for Congenital Heart Disease||Children's Healthcare of Atlanta|No|Terminated|January 1998|March 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|400|||Both|N/A|15 Years|No|Non-Probability Sample|DiGeorge Syndrome Cardiac Surgery|March 2008|March 14, 2012|January 13, 2006||No|completed|No||https://clinicaltrials.gov/show/NCT00278005||186083|
NCT00278265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454596|Methotrexate as First-Line Therapy and Fludarabine as Second-Line Therapy in Treating Patients With T-Cell Large Granular Lymphocytic Leukemia|First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL)||National Cancer Institute (NCI)||Recruiting|June 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||July 2007|August 23, 2013|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278265||186063|
NCT00278525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI Scl.Randomized2004|Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma|Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial||Northwestern University|No|Completed|September 2005|December 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|60 Years|No|||March 2014|March 28, 2014|January 15, 2006|Yes|Yes||No|April 9, 2013|https://clinicaltrials.gov/show/NCT00278525||186046|
NCT00278863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0415|Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial|Randomized Multicenter Phase II Trial of Capecitabine Versus S-1 as First-line Treatment in Elderly Patients With Advanced or Recurrent Unresectable Gastric Cancer||Asan Medical Center|No|Completed|November 2004|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|65 Years|85 Years|No|||January 2014|January 13, 2014|January 17, 2006||No||No|January 13, 2014|https://clinicaltrials.gov/show/NCT00278863||186021|
NCT00329498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMCIRB-98-04-02|L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes|Manipulation of L-Ascorbic Acid Level For The Treatment of Selected Cases Of Acute Myeloid Leukemia and Myelodysplastic Syndromes||Samsung Medical Center||Suspended|May 1998|August 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|N/A|N/A|No|||October 2006|October 25, 2006|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329498||182216|
NCT00329771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-BA/AAA|Research Study to Determine Sensitivity to Gentle Touch and Pressure During an Active Migraine Attack.|Brush Allodynia in Patients With Episodic Migraine During an Acute Attack.||Thomas Jefferson University|No|Completed|March 2006|March 2008|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with episodic migraine, as defined by the International Headache        Society,recruited from our office practice and the communitiy|March 2014|March 14, 2014|May 24, 2006||No||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00329771||182195|
NCT00330122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-05-01|Restoration of the Radial Length in Compound Wrist Fractures Using Anterior Locking Plates|Restoration of the Radial Length in Compound Wrist Fractures Using Anterior Locking Plates||University Hospital, Angers||Recruiting|March 2006|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|40 Years|80 Years|No|||May 2006|May 24, 2006|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330122||182172|
NCT00330135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA 2003-01|The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis|Multicentre, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Investigate the Efficacy of Sodium Hyaluronate in Patients With Symptomatic Hip Osteoarthritis||Daiichi Sankyo Inc.|No|Terminated|January 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|30 Years|80 Years|No|||January 2008|January 7, 2008|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00330135||182171|
NCT00330161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03067|Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer|Phase II Evaluation of Suberoylanilide Hydroxamic Acid (NSC 701852) in Patients With Advanced Prostate Cancer That Has Progressed on One Prior Chemotherapy||National Cancer Institute (NCI)||Completed|March 2006|May 2011|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|18 Years|N/A|No|||December 2012|April 25, 2014|May 25, 2006|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00330161||182169|The primary objective was to determine the number of patients wtih progression-free survival at 6 months. Unfortunately all eligible patients were off therapy before the 6 month time point.
NCT00330668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS306|Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency|Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study||Ipsen|Yes|Terminated|November 2005|March 2010|Actual|February 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|4 Years|15 Years|No|||May 2011|May 31, 2011|May 26, 2006|Yes|Yes|Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day|No|February 28, 2011|https://clinicaltrials.gov/show/NCT00330668||182130|The study was terminated by the sponsor on identification of an unacceptable frequency of hypoglycemia which was reported at doses of ≥200 mcg/kg once daily. Only safety results are presented as efficacy data were not analyzed according to protocol.
NCT00327145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2401|A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy|A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy||Novartis||Completed|March 2006|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|894|||Both|18 Years|N/A||||November 2011|November 7, 2011|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327145||182394|
NCT00319202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fcv193|Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects|A Randomized, Double Blind, Cross-Over, Placebo-Controlled Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism, of Non Diabetic, Non Hypertensive Subjects With Dysglycemia and Abdominal Obesity."ARAMIA"|ARAMIA|Fundación Cardiovascular de Colombia|Yes|Terminated|June 2006|February 2012|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|April 26, 2006||No|Difficulties in completing the required sample size|No||https://clinicaltrials.gov/show/NCT00319202||182989|
NCT00327340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGX-011-07|Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC|Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer||OncoGenex Technologies|No|Completed|July 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|N/A|No|||October 2012|October 2, 2012|May 16, 2006|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT00327340||182379|
NCT00327119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050216|Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer|A Phase 2 Multicenter Single Arm Clinical Trial of ABX EGF (Panitumumab) Monotherapy in Japanese Subjects With Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy||Amgen||Completed|April 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||50|||Both|20 Years|N/A|No|||September 2009|September 11, 2009|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327119||182396|
NCT00327132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3206|Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome|Multicentre,Prospective Study of First-line Antibiotic Therapy for Early-stage Low-grade and High-grade Gastric Mucosa-associated Lymphoid Tissue-type Lymphoma and Potential Predicting Factor for Treatment Outcome||National Health Research Institutes, Taiwan||Completed|July 2006|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|N/A|N/A|No|||March 2016|March 23, 2016|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327132||182395|
NCT00320307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAL102120|Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects|An Open-Label, Two-Period, Crossover, Pharmacokinetic Study of Abacavir and Its Intracellular Anabolite Carbovir Triphosphate Following Once-Daily and Twice-Daily Administration of Abacavir in HIV-Infected Subjects.||GlaxoSmithKline||Completed|September 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|May 1, 2006||||||https://clinicaltrials.gov/show/NCT00320307||182904|
NCT00327847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol #04037|Optimizing Vitamin D Nutrition in Healthy Adults|Optimizing Vitamin D Nutrition in Healthy Adults||Winthrop University Hospital||Completed|December 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 23, 2008|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00327847||182340|
NCT00328068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASAS-class-crit-1|Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)|Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA||Charite University, Berlin, Germany|Yes|Recruiting|July 2006|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|992|Samples With DNA|DNA and RNA will be collected in selected centres for analysis of candidate gene variants in      ankylosing spondylitis/ spondyloarthritis. Serum and plasma sample will be collected for      biomarker analysis with special focus on markers of bone metabolism|Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic back pain of unknown origin or peripheral arthritis / enthesitis /        dactylitis of unknown origin who are referred to a rheumatologist for diagnostic work-up|February 2013|February 12, 2013|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328068||182324|
NCT00328354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 EB 0019-83 Mammography|Mammography SPECT With Rotating Slant Hole Collimator|||Johns Hopkins University||Not yet recruiting||||||N/A|Observational|N/A||||20|||Female|35 Years|80 Years|Accepts Healthy Volunteers|||January 2006|May 18, 2006|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328354||182303|
NCT00328367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYS-2006-05209|Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia|A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia||Seoul National University Hospital|Yes|Completed|December 2005|February 2008|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||April 2008|October 28, 2008|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00328367||182302|
NCT00277771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507098|Improving Self-Monitoring in Weight Loss With Technology|Improving Self-Monitoring in Weight Loss With Technology||University of Pittsburgh|No|Completed|February 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|January 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00277771||186101|
NCT00278018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|immatureDC- HMO-CTIL|Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors|Peritumoral Injection of Immature Dendritic Cels to Irradiated Metastases of Solid Tumors||Hadassah Medical Organization||Terminated|December 2005|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||April 2007|April 19, 2015|January 16, 2006||No|Because there were no responses|No||https://clinicaltrials.gov/show/NCT00278018||186082|
NCT00278278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454723|Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas|Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma||National Cancer Institute (NCI)||Active, not recruiting|September 2003|||March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|3 Years|18 Years|No|||November 2008|December 18, 2013|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00278278||186062|
NCT00278538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI SLE.Auto2003|Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus|Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial||Northwestern University|Yes|Recruiting|August 2005|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|15 Years|60 Years|No|||March 2016|March 21, 2016|January 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278538||186045|
NCT00278876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0501|Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation|Phase II Study of Imatinib Mesylate as Adjuvant Treatment in High-relapse Risk Localized Gastrointestinal Stromal Tumors With C-kit Mutation||Asan Medical Center|No|Completed|April 2005|March 2011|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|January 17, 2006||No||No|November 19, 2013|https://clinicaltrials.gov/show/NCT00278876||186020|
NCT00278889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00041|Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)|A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer|HORIZON I|AstraZeneca||Completed|January 2006|October 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|January 17, 2006|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT00278889||186019|
NCT00329784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN032AD|Promoting Tolerance to Peanut in High-Risk Children|Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD)|LEAP|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2006|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|640|||Both|4 Months|10 Months|No|||March 2016|March 8, 2016|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329784||182194|
NCT00329797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0518|Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy|A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer||Radiation Therapy Oncology Group|Yes|Completed|March 2006|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|109|||Male|18 Years|N/A|No|||March 2015|March 17, 2015|May 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00329797||182193|
NCT00330148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICENTRE-BTT|Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis|Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase||Epicentre||Terminated|March 2001|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||435|||Both|N/A|N/A|No|||May 2006|May 24, 2006|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330148||182170|
NCT00330408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05GS002MSC|Impact of Training of GPs on Adherence of Hypertensive Individuals to Antihypertensive Medication|Impact of Training of GPs on Adherence of Hypertensive Individuals to Antihypertensive Medication||Aga Khan University||Active, not recruiting|September 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||178|||Both|40 Years|N/A|No|||April 2006|May 25, 2006|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330408||182150|
NCT00330928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101|SPECTACL: SPECTroscopic Assessment of Coronary Lipid|Coronary Artery Plaque Characterization by NIR Spectroscopy in Patients Undergoing Elective Percutaneous Coronary Intervention|SPECTACL|InfraReDx|Yes|Completed|January 2006|October 2008|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|106|||Both|18 Years|N/A|No|||July 2009|July 14, 2009|May 26, 2006|No|Yes||No|January 28, 2009|https://clinicaltrials.gov/show/NCT00330928||182110|Technical limits of the prototype device factored into the data set reduction(28 patients).Data made available to evaluate handling of the device(30 patients) could not be prospectively evaluated for the primary endpoint of Spectral Similarity.
NCT00326820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000478864|Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer|Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases||Wales Cancer Trials Unit|Yes|Active, not recruiting|January 2006|October 2015|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1404|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|May 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00326820||182417|
NCT00319501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K826-05-3001|Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.|A Phase III, Randomized Double-Blind, Parallel, Placebo-Controlled, Multicenter Study, With Optional Open-Label Continuation, of the Safety and Efficacy of Vanquix Auto-Injector (Diazepam Injection) for the Management of Selected, Refractory Patients With Epilepsy Who Require Intermittent Medical Intervention to Control Episodes of Acute Repetitive Seizures||Pfizer|Yes|Completed|January 2006|July 2014|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|234|||Both|2 Years|N/A|No|||August 2014|August 6, 2014|April 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319501||182966|
NCT00319774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-01|Hemocontrol and Blood Pressure Control in Dialysis Patients|Assessment of Hemocontrol Biofeedback System Efficiency on Long Term Blood Pressure Control, Nursing Interventions, and Quality of Life in Hemodialysis Patients: a Randomized Controlled Trial||Université de Montréal||Completed|December 2002|July 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2003|April 27, 2006|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319774||182945|
NCT00319787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0129|Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer|A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical & Metabolic Changes in the Prostate Determined by MRI/3D-MRS & Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Casodex® (Bicalutamide) Alone or the Combination of Casodex® & ZD1839 (Iressa™)||AstraZeneca||Completed|December 2003|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||102|||Male|18 Years|80 Years|No|||January 2011|January 24, 2011|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319787||182944|
NCT00320099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM04100|Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock|Phase 3 Study of Corticotherapy (Hydrocortisone Alone Versus Hydrocortisone Plus Fludrocortisone) Versus Corticotherapy Plus Intensive Insulin Therapy for Septic Shock|COIITSS|University of Versailles|Yes|Completed|January 2006|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|508|||Both|18 Years|N/A|No|||April 2010|April 5, 2010|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00320099||182920|
NCT00320112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-239|Improving Insulin Therapy With Enhanced Care Management|Improving Insulin Therapy With Enhanced Care Management and Peer Support||VA Office of Research and Development|No|Completed|February 2007|March 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|244|||Both|21 Years|N/A|No|||August 2014|April 6, 2015|April 27, 2006||No||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00320112||182919|study only included male patients.intervention only lasted six months.the nature of the intervention prevented blinding to treatment group.A final limitation is the relatively low rate of uptake of the intervention.
NCT00320125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8818-01|Effects of Dairy Foods on Adolescent Pregnant Mothers and Their Newborns|Effects of Dairy Foods on Adolescent Pregnant Mothers and Their Newborns||University of Utah||Completed|March 2002|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|72|||Female|15 Years|18 Years|Accepts Healthy Volunteers|||October 2008|May 1, 2015|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00320125||182918|
NCT00327860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66116|Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)|Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)|CKiD|Johns Hopkins Bloomberg School of Public Health|Yes|Active, not recruiting|October 2003|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|891|Samples With DNA|Blood and urine specimens will be collected at the baseline visit and at each annual      follow-up visit. Nail clippings and hair samples will be collected at baseline.Specimens      will be stored at the NIDDK Biosample Repository, which is Fisher BioServices Corporation in      Rockville, MD.      The genetics repository will receive blood samples and process them to create immortalized      cell lines, and DNA samples. Whole blood for the genetic repository will be collected at      baseline. The genetics repository is at Rutgers, the State University of New Jersey in New      Brunswick, NJ.|Both|1 Year|16 Years|No|Non-Probability Sample|The CKiD Study is a multi-center, prospective cohort study of children aged 1 to 16 years        with mild to moderate impaired kidney function. The study population consist of two        cohorts.|March 2015|February 29, 2016|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00327860||182339|
NCT00328081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOCCER|State of Obesity Care in Canada Evaluation Registry|State of Obesity Care in Canada Evaluation Registry An Observational Study of Clinical Care of Patients With Obesity||McMaster University||Terminated|May 2006|August 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|1906|||Both|18 Years|N/A|No|||September 2007|September 13, 2007|May 18, 2006|||Principal Investigator left the institution|No||https://clinicaltrials.gov/show/NCT00328081||182323|
NCT00321178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BURULICODRUGTRIAL|BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA|Randomised Trial for Early Lesions Caused by M. Ulcerans - Comparison Between 8 Weeks Streptomycin and Rifampicin (SR), or 4 Weeks SR Followed by 4 Weeks R Plus Clarithromycin|BURULICO|University Medical Center Groningen|Yes|Completed|May 2006|February 2009|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|5 Years|N/A|No|||April 2010|June 29, 2010|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321178||182839|
NCT00277745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-00003522|Integrated Microfluidic System for Oral Diagnostics|Integrated Microfluidic System for Oral Diagnostics||University of Michigan|Yes|Completed|June 2005|June 2007|Actual|February 2007|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Saliva, serum, dental plaque and gingival crevicular fluid|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 Adult subjects comprised of two populations: 1) disease susceptible (n=50) and 2)        low-risk disease (n=50)|December 2015|December 11, 2015|January 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00277745||186103|
NCT00277758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-092|Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I|A Phase I Study of Low Dose Interleukin 2 (IL-2)Monotherapy, Followed by IL-2 Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I Infection||Weill Medical College of Cornell University|Yes|Terminated|March 2004|August 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||March 2008|March 6, 2008|January 12, 2006|Yes|Yes|Insufficient rate of volunteer accrual.|No||https://clinicaltrials.gov/show/NCT00277758||186102|
NCT00278902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRY-0501|A Study of ARRY-334543 in Patients With Advanced Cancer|||Array BioPharma||Completed|January 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|January 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00278902||186018|
NCT00279188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF 3.2.92.45, AMPUL|Asthma Management Project University Leiden|Asthma Management Project University Leiden||Leiden University Medical Center||Completed|May 1992|September 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||75|||Female|18 Years|60 Years|No|||September 2004|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279188||185996|
NCT00278551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 96RA1|Stem Cell Support in Patients With Rheumatoid Arthritis|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Rheumatoid Arthritis and High Risk Factors||Northwestern University|No|Terminated|June 1997|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||April 2013|April 4, 2013|January 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278551||186044|
NCT00279487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P768|Preanalgesic Effect of Gabapentin in Total Knee Repair|||Texas Health Resources||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2006|February 27, 2007|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00279487||185974|
NCT00279786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-001|B2-Adrenergic Receptor Polymorphisms|B2-Adrenergic Receptor Polymorphisms: Implications For The Treatment Of Status Asthmaticus In Children||Connecticut Children's Medical Center|No|Completed|December 2005|January 2009|Actual|January 2009|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|126|||Both|2 Years|18 Years|No|Probability Sample|Children admitted to the ICU with severe asthma exacerbations|July 2009|July 27, 2009|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00279786||185951|
NCT00329524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51817|Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus|Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus||University of Arkansas|No|Completed|June 2006|August 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|May 22, 2006||No||No|June 17, 2009|https://clinicaltrials.gov/show/NCT00329524||182214|Study was ended early and analysis was limited to only 5 subjects. A follow up study using a revised protocol is underway.
NCT00329810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-166|Effect on Cognitive Function of a Treatment With Aripiprazole|A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|March 2005|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|18 Years|65 Years|No|||February 2012|November 7, 2013|September 12, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00329810||182192|
NCT00329823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004555-19|Etanercept in Hidradenitis Suppurativa|A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa||University of Athens||Completed|September 2005|May 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|17 Years|N/A|No|||May 2006|May 23, 2006|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329823||182191|
NCT00330681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI186-16|Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)|A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner.||Mitsubishi Tanabe Pharma Corporation|No|Completed|May 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|20 Years|75 Years|No|||September 2014|September 16, 2014|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00330681||182129|
NCT00318864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBarrTaylor|Biological CVD Risk Factors in Older Depressed Patients|Stress, the HPA and Health in Aging||Stanford University||Completed|June 2002|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|55 Years|N/A|Accepts Healthy Volunteers|||April 2006|April 25, 2006|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318864||183014|
NCT00319189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Starlix in RTR|Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients|Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance||University of Oslo School of Pharmacy||Completed|November 2002|November 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||April 2006|May 9, 2006|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319189||182990|
NCT00319215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/316|Effects of Ramelteon on Driving Ability|A Study to Investigate the Residual Effects of Ramelteon (8 mg), Zopiclone (7.5 mg) and Placebo on Actual Driving, Memory, Psychomotor Performance and Mood||Utrecht Institute for Pharmaceutical Sciences||Completed|March 2006|July 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2007|April 24, 2007|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00319215||182988|
NCT00319514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-LU-42|Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC|Randomized Phase II Trial of Two Different Schedules of Docetaxel Plus Cisplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer||Gachon University Gil Medical Center||Completed|April 2004|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||78|||Both|18 Years|75 Years|No|||March 2008|March 10, 2008|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00319514||182965|
NCT00319228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG-401|Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.|A Phase II/III Pivotal Trial Evaluating the Safety, Pharmacokinetic Properties and Efficacy of a Plasma-Derived Anti-thrombin III Concentrate With Administration in Surgery, Pregnancy and Thromboembolic or Thrombotic Events.||Grifols Biologicals Inc.|Yes|Recruiting|January 2006|March 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|12 Years|N/A|No|||February 2014|February 17, 2014|April 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319228||182987|
NCT00319800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-LU-62|Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC|A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response||Gachon University Gil Medical Center||Active, not recruiting|February 2006|March 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|No|||March 2008|March 10, 2008|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00319800||182943|
NCT00319813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.376|General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment|General Practice Quality Assurance Project. COPD Diagnosis and Treatment||Boehringer Ingelheim||Completed||September 2007||||Phase 4|Observational|N/A||||8000|||Both|35 Years|N/A|No|||April 2008|April 15, 2008|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00319813||182942|
NCT00321204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002175|A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias|A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias in Patients After Cardiac Surgery||Emory University|No|Terminated|December 2005|February 2007|Actual|February 2007|Actual|Phase 2|Observational|N/A||||600|||Both|18 Years|65 Years|No|||April 2014|April 21, 2014|May 1, 2006||No|Terminated: We are no longer recruiting.|No||https://clinicaltrials.gov/show/NCT00321204||182837|
NCT00320619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360|Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery|Aminocaproic Acid and Bleeding in Spinal Surgery||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|April 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00320619||182880|
NCT00320905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#05094|Smart Heart Study: Cognitive Benefits of Cardiac Rehabilitation|Smart Heart Study: Cognitive Benefits of Cardiac Rehabilitation||Summa Health System|No|Completed|March 2006|March 2008|Actual|February 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|70|||Both|50 Years|85 Years|No|Non-Probability Sample|Those with cardiovascular disease|July 2010|July 19, 2010|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00320905||182859|
NCT00320918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4504C|Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib|Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib||University of New Mexico|Yes|Completed|November 2005|October 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|||Both|N/A|N/A|No|Probability Sample|Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer Center        with a combination of irinotecan, capecitabine and celecoxib.|December 2007|January 6, 2010|April 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00320918||182858|
NCT00320931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27314 (LR-05-003)|Assessment of Coronary Artery Disease by Hybrid PET/CT|Assessment of Coronary Flow Reserve and CT Angiography By Hybrid PET/CT: Relation to Clinically Indicated SPECT Studies||University of Maryland||Completed|March 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|No|||April 2008|April 16, 2008|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00320931||182857|
NCT00277407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MulticlinicalAutism Study|Treatment of Autistic Children Using NAET Procedures|An Investigation Into the Outcome of NAET Treatment on Children With Allergy-Related Autism Spectrum Disorders in a Multi-Clinical Setting.||Nambudripad's Allergy Research Foundation|Yes|Completed|June 2006|May 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|3 Years|10 Years|No|||May 2007|May 4, 2007|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00277407||186125|
NCT00278915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6992C00044|Faslodex in McCune Albright Syndrome|An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome|FMAS|AstraZeneca||Active, not recruiting|January 2006|July 2023|Anticipated|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|1 Year|10 Years|No|||February 2016|February 3, 2016|January 17, 2006|Yes|Yes||No|December 6, 2010|https://clinicaltrials.gov/show/NCT00278915||186017|
NCT00278928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000275|Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic|Prospective, Randomized Study of Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic Containers.||Beth Israel Deaconess Medical Center||Terminated|January 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|82|||Both|N/A|10 Days|No|||May 2007|May 16, 2007|January 18, 2006|||Manufacturing change in one of the two lipid emulsion products being studied.|No||https://clinicaltrials.gov/show/NCT00278928||186016|
NCT00279500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0002|Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa|Chronic Retinal Electrodes to Provide Electrical Stimulation of the Retina to Elicit Visual Percepts in Blind Subjects||Second Sight Medical Products|No|Completed|February 2002|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|January 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00279500||185973|
NCT00279513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV-2006|TRAUMEEL S in Reducing Pain After Correction of Hallux Valgus-Clinical Trial|A Randomised, Double- Blind, Placebo Controlled, Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Reducing Pain After Surgical Correction of Hallux Valgus||Shaare Zedek Medical Center||Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2011|April 3, 2011|January 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00279513||185972|
NCT00330174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-MD-04|Acamprosate in Alcoholics With Comorbid Anxiety or Depression|The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression||Medical University of South Carolina|No|Completed|April 2006|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|60 Years|No|||April 2015|April 10, 2015|May 25, 2006||No||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00330174||182168|
NCT00330434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAGRE15647|Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism|Human CYP2B6: Induction by Ethanol and Polymorphisms||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|No|Completed|December 2005|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2008|April 7, 2008|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330434||182148|
NCT00330941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joris, Lidocaine Outcomes|Intravenous Lidocaine and Acute Rehabilitation|Intravenous Lidocaine Infusion Improves Outcome After Laparoscopic Colectomy||Outcomes Research Consortium||Completed|January 2003|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||45|||Both|N/A|70 Years|No|||February 2009|February 4, 2009|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00330941||182109|
NCT00318552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3591/9014|Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.|Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.||AstraZeneca||Completed|January 2002|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318552||183038|
NCT00318877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31487|Sports to Prevent Obesity|Sports to Prevent Obesity Randomized Trial||Stanford University|No|Completed|May 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|April 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00318877||183013|
NCT00318084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25N54|PPI Test in GP Patients|The Proton Pump Inhibitor Test in Reflux Disease: a Study Using Nexium in General Practice Patients||AstraZeneca||Completed|January 2003|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||August 2007|August 15, 2007|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318084||183073|
NCT00318955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-401|Post-Marketing Clinical Study to Assess Efficacy and Safety of Dexmedetomidine in Post-Operative Patients|A Post-Marketing, Open-Label, Randomized, Comparative Study Comparing the Usefulness of Dexmedetomidine at the Time of Extubation and Post Extubation Period to Other Sedative Management in Post-Operative Patients||Hospira, Inc.|No|Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|20 Years|N/A|No|||June 2015|June 29, 2015|April 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00318955||183008|
NCT00318968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00076|Nexium RESPONSE Trial|Development of an Algorithm for Identification of Responders to Short Term Treatment With Esomeprazole (Nexium) in Primary Care||AstraZeneca||Completed|May 2006|November 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|1000|||Both|18 Years|N/A|No|||January 2009|January 23, 2009|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00318968||183007|
NCT00319241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA011498|Relational Parenting Group for Opioid-Addicted Mothers|Relational Parenting Group for Opioid-Addicted Mothers||Yale University||Completed|January 1998|November 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Female|18 Years|65 Years|No|||June 2008|June 16, 2008|April 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00319241||182986|
NCT00320346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-PAN-05-18|Phase II Study of Pandemic Influenza Vaccine|A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (≤18 Years to ≥64 Years of Age).||CSL Limited||Completed|July 2006|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2008|November 6, 2008|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320346||182901|
NCT00320359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864-A/479|Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer|An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer||GlaxoSmithKline||Completed|August 2002|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|700|||Both|18 Years|75 Years|No|||March 2011|July 19, 2012|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320359||182900|
NCT00317226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT05005|Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease|Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT45 in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease||Luitpold Pharmaceuticals|No|Completed|June 2005|September 2007|Actual|March 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|12 Years|N/A|No|||June 2015|June 8, 2015|April 20, 2006|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00317226||183138|
NCT00317239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT04004|VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease|Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease||Luitpold Pharmaceuticals|No|Completed|May 2005|August 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Both|12 Years|N/A|No|||September 2013|September 16, 2013|April 20, 2006|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00317239||183137|
NCT00320320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-GI-53|Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer|A Pilot Phase II Trial of Irinotecan Discontinuation and Reintroduction in Patients With Previously Untreated Advanced Colorectal Cancer||Gachon University Gil Medical Center|No|Terminated|April 2005|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|18 Years|75 Years|No|||November 2008|November 24, 2008|May 1, 2006|||Poor accrual|No||https://clinicaltrials.gov/show/NCT00320320||182903|
NCT00320333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-53-1071|COPD Rehabilitation in Primary and Secondary Health Care|Comparison of Pulmonary Rehabilitation of Patients With Chronic Obstructive Pulmonary Disease in Primary and Secondary Health Care||Glostrup University Hospital, Copenhagen||Recruiting|December 2004|December 2007||||N/A|Observational|N/A||||120|||Both|N/A|N/A|No|||May 2006|May 17, 2006|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320333||182902|
NCT00320632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH015413|Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression|Psychopharmacology of Biogenic Amines in Depression||Harvard Medical School||Completed|August 1990|July 1993||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00320632||182879|
NCT00319254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A2-201|Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer|Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer||Pfizer|No|Completed|May 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Female|18 Years|N/A|No|||December 2012|December 21, 2012|April 24, 2006|Yes|Yes||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00319254||182985|
NCT00319267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-365|Bosentan in Children With Pulmonary Arterial Hypertension|An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension||Actelion||Completed|May 2005|February 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|33|||Both|2 Years|12 Years|No|||February 2010|February 11, 2010|April 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00319267||182984|
NCT00319280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-01-004-ML|Proximal Tibial Open Wedge Osteotomy. A Clinical Prospective, Randomized RSA-trial.|Proximal Tibial Open Wedge Osteotomy. Stability and Healing Evaluated in a Clinical Prospective, Randomized Trial Using RSA.||Northern Orthopaedic Division, Denmark|No|Completed|December 2004|December 2008|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|No|||March 2014|March 28, 2014|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319280||182983|
NCT00278564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA IIM.Auto2003|Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases|High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial||Northwestern University|No|Recruiting|September 2005|September 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|65 Years|No|||March 2016|March 21, 2016|January 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278564||186043|
NCT00278304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454997|Radiation Therapy in Treating Patients With Cervical Cancer|A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer||National Cancer Institute (NCI)||Completed|September 2005|June 2006|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|N/A|No|||April 2006|June 18, 2013|January 16, 2006||||No||https://clinicaltrials.gov/show/NCT00278304||186061|
NCT00278577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 97CD1|Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease||Northwestern University|No|Terminated|April 2001|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|60 Years|No|||April 2013|February 4, 2014|January 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278577||186042|
NCT00278590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI SLE.Allo2004|Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus|Allogeneic Stem Cell Transplantation in Patients With Systemic Lupus Erythematosus||Northwestern University|No|Withdrawn|July 2004|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|50 Years|No|||July 2015|July 13, 2015|January 16, 2006|Yes|Yes|No participants enrolled|No||https://clinicaltrials.gov/show/NCT00278590||186041|
NCT00279526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor417105ctil|Depression and Increased Health Services Utilization Among Elderly Primary Care Patients|||Soroka University Medical Center||Completed|April 2006|December 2006|Actual|||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||450|||Both|65 Years|N/A|No|||May 2007|May 24, 2007|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279526||185971|
NCT00279539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND 10442|Stem Cell Mobilization and VEGF Gene Transfer for Heart Failure|phVEGF165 GENE TRANSFER TO PROMOTE ANGIOGENESIS IN PATIENTS WITH ISCHEMIC HEART FAILURE||Losordo, Douglas, M.D.|No|Withdrawn|July 2008|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|21 Years|N/A||||June 2009|March 30, 2015|January 17, 2006|||Study never started.|||https://clinicaltrials.gov/show/NCT00279539||185970|
NCT00279201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10455|The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)|The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control|IOOV|Eli Lilly and Company|Yes|Completed|December 2005|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|2091|||Both|30 Years|79 Years|No|||January 2011|January 24, 2011|December 15, 2005|Yes|Yes||No|November 11, 2010|https://clinicaltrials.gov/show/NCT00279201||185995|
NCT00280150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0511|Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer|Phase I/II Trial of Induction Carboplatin/Paclitaxel With Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy With Carboplatin/Paclitaxel, Bevacizumab and Erlotinib in Stage IIIA/B Non-Small Cell Lung Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|January 2006|January 2013|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|January 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00280150||185924|
NCT00280163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506010|Genomics and Postoperative Atrial Fibrillation|Genomics and Postoperative Atrial Fibrillation||University of Pittsburgh||Completed|November 2005|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|336|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Hospital patients about to undergo or have undergone Coronary Artery Bypass surgery|February 2016|February 11, 2016|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00280163||185923|
NCT00330187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA17460|Combined Pharmaco/Behavior Therapy in Adolescent Smokers|Combined Pharmaco/Behavior Therapy in Adolescent Smokers||Medical University of South Carolina||Recruiting|March 2004|September 2008||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment||||216|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||April 2006|May 25, 2006|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330187||182167|
NCT00330447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cancer in pregnancy|Effects of Oncological Treatment During Pregnancy|Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring||University Hospital, Gasthuisberg|No|Recruiting|August 2005|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|None Retained|serum and sediment of blood; from 2010 on we collect umbilical cord blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women diagnosed with cancer|December 2015|December 2, 2015|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00330447|5 Years|182147|
NCT00330460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050141|A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.|A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Denisty||Amgen||Completed|May 2006|January 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1189|||Female|18 Years|N/A|No|||January 2011|January 20, 2011|April 6, 2006||||No|June 18, 2010|https://clinicaltrials.gov/show/NCT00330460||182146|
NCT00318565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWI30031|Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter|Navistar Thermocool Evaluation of the Catheter With the Stockert 70 Radiofrequency Generator for Endocardial Ablation in Patients With Typical Atrial Flutter||Biosense Webster, Inc.|No|Completed|January 2006|February 2008|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|291|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|April 25, 2006|Yes|Yes||No|July 8, 2009|https://clinicaltrials.gov/show/NCT00318565||183037|
NCT00320996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3002C|SGO Society of Gynecologic Oncologists Data Outcomes Project|SGO Society of Gynecologic Oncologists Data Outcomes Project||University of New Mexico|Yes|Completed|March 2002|February 2005|Actual|July 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Female|N/A|N/A|No|Non-Probability Sample|Females with a pelvic mass who will have surgery|October 2008|January 6, 2010|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00320996||182853|
NCT00318331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glutamine|Enteral Glutamine in Critical Illness|Randomized Clinical Trial Comparing Enteral Glutamine Supplementation to Standard of Care Enteral Feeding in Critical Illness||Christiana Care Health Services|Yes|Terminated|May 2006|September 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2008|March 10, 2008|April 24, 2006||No|Unable to meet enrollment numbers|No||https://clinicaltrials.gov/show/NCT00318331||183054|
NCT00318344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170-06|Evaluation of Atuna Racemosa Toxicity|Evaluation of Atuna Racemosa Toxicity||Mayo Clinic||Completed|April 2006|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 1, 2010|April 24, 2006||||||https://clinicaltrials.gov/show/NCT00318344||183053|
NCT00318890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F020522012|Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Trial of Induction Cisplatin and Docetaxel Followed by Concomitant Docetaxel/Radiotherapy With Subcutaneous Amifostine for Locally Advanced Squamous Cell Carcinoma of the Head and Neck||University of Alabama at Birmingham|Yes|Completed|October 2002|December 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|19 Years|N/A|No|||February 2011|February 11, 2011|April 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318890||183012|
NCT00320138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO0001-051-0002|Acupuncture for the Treatment of Posttraumatic Stress Among Military Personnel|Acupuncture for the Treatment of Trauma Survivors||Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|60 Years|No|||January 2012|January 11, 2012|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00320138||182917|
NCT00320957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking0503|Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital|Study of the Safety and Effectiveness of the Ologen (OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery||Pro Top & Mediking Company Limited||Completed|January 2006|December 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||May 2008|May 23, 2008|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320957||182856|
NCT00317785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998.00|Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases|A Phase II Trial of Total Body Irradiation Plus Metabolism-Based Cyclophosphamide Dosing as Preparative Therapy for Allogeneic Hematopoietic Cell Transplant for Patients With Hematological Malignancy||Fred Hutchinson Cancer Research Center||Completed|May 2005|||November 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|70 Years|No|||May 2010|May 5, 2010|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00317785||183095|
NCT00317525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X050314015|Effects of Different Add Powers on the Comfort and Productivity of Computer Users With Fixed or Free Head Movement|Effects of Different Add Powers on the Comfort and Productivity of Computer Users With Fixed or Free Head Movement||American Optometric Association||Completed|May 2005|June 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|40 Years|N/A|Accepts Healthy Volunteers|||May 2005|September 7, 2006|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317525||183115|
NCT00318305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392-05|Patient Preference With Visicol Tablet Preparation for Colonoscopy|Patient Preference and Acceptance With Sodium Phosphate Tablet Preparation for Colonoscopy: A Prospective Study||Mayo Clinic|No|Completed|March 2005|April 2006|Actual|April 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Scheduled colonoscopy list will be reviewed to identify potential subjects for        recruitment. A cover letter will be sent to the potential study subject with tablet        preparation as an alternative to Golytely preparation ( PEG). For subjects who are willing        to participate, a prescription for 28 tablet sodium phosphate bowel preparation as        outlined in appendix: A will be mailed. A questionnaire will be given to the patients        prior to their colonoscopy to identify their preferences regarding bowel preparation and        their acceptance ( see appendix: B).        A separate validated questionnaire will be given to participating physicians after the        procedure, to quantitate the colonic cleansing (appendix : C). Adverse events will be        documented. A statistical analysis of the results will be done at the end of the study.|December 2009|December 1, 2009|April 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318305||183056|
NCT00319852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I28|Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV|||Sanofi||Completed|April 2006|July 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|442|||Both|56 Days|70 Days|Accepts Healthy Volunteers|||April 2012|April 13, 2012|April 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00319852||182939|
NCT00278941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00005|Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) As Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder|AMETHYST|AstraZeneca||Completed|December 2005|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||3000|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00278941||186015|
NCT00278629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU FDA CIDP.AUTO2003|Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy|Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial||Northwestern University|No|Recruiting|March 2005|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|January 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00278629||186038|
NCT00279214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9944|Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock|An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock||Eli Lilly and Company||Completed|November 2005|November 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|18 Years|N/A|No|||August 2009|August 26, 2009|December 15, 2005|||||October 31, 2008|https://clinicaltrials.gov/show/NCT00279214||185994|
NCT00279227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICARD Study|Role of Epicardial Adipose Tissue in Coronary Artery Disease|Role of Epicardial Adipose Tissue in Coronary Artery Disease||McMaster University||Recruiting|January 2006|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||50|||Both|18 Years|N/A|No|||January 2006|August 9, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279227||185993|
NCT00279825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX054-B05-01|Comparison of IPX054, Immediate-Release Carbidopa-Levodopa, and Controlled-Release Carbidopa-Levodopa in Subjects With Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to Carbidopa-Levodopa Immediate-Release 200 (2x100) mg Tablets and Carbidopa-Levodopa Controlled-Release 200 mg Tablet in Subjects With Parkinson's Disease||IMPAX Laboratories, Inc.|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Both|30 Years|N/A|No|||March 2009|March 13, 2009|January 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00279825||185948|
NCT00279838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|957-04|Computer Assisted Total Knee Replacement|Computer Assisted Navigation in Total Knee Arthroplasty||Mayo Clinic||Completed|June 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||March 2011|March 22, 2011|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279838||185947|
NCT00279851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05046|Blood Sugars in Children With Idiopathic Seizures.|Prevalence of Hypoglycemia and/or Hyperinsulinism/Hyperammonemia Syndrome in Patients With Idiopathic Seizures.||Children's Mercy Hospital Kansas City||Recruiting|February 2006|August 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||225|||Both|N/A|17 Years|No|||September 2006|September 6, 2006|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279851||185946|
NCT00318019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804315|Effect of OPC Factor on Energy Levels|The Effect of OPC Factor on Energy Levels in Healthy Individuals Aged 45-65: A Randomized Controlled Trial||University of Pennsylvania||Completed|June 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 16, 2011|April 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00318019||183078|
NCT00318253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-704|The Effects of Cranberry Juice on Bacterial Adhesion|The Effects of Cranberry Juice on Urine and Bacterial Adhesion to Cells||Lawson Health Research Institute|No|Completed|March 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|12|||Female|19 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|April 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00318253||183060|
NCT00318266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-885|NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.|NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers||Lawson Health Research Institute|No|Recruiting|January 2006|January 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with a history og pTis, pT1, larger ( >2 cm) pTa or multiple pTa bladder tumors.|November 2008|November 12, 2008|April 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00318266||183059|
NCT00321009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 59673|LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin|A Prospective Randomized Trial Comparing Enoxaparin to Warfarin for the Prevention of LV Thrombus Formation After Anterior Wall Myocardial Infarction: A 60 Patient Pilot Study||William Beaumont Hospitals||Completed|March 2000|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|80 Years|No|||May 2006|May 1, 2006|May 1, 2006||||||https://clinicaltrials.gov/show/NCT00321009||182852|
NCT00319319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-02-006|Nicotinic Receptor Augmentation of SSRI Antidepressants|A Double-Blind,Randomized,Placebo-Controlled Trial of Mecamylamine Hydrochloride for the Treatment of SSRI-Refractory Major Depressive Disorder.||Yale University|No|Completed|January 2003|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||April 2007|April 18, 2007|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00319319||182980|
NCT00319332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/029|A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen|A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients With Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma||GlaxoSmithKline||Withdrawn|September 2005|February 2021|Anticipated|February 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|April 26, 2006|||This study has been cancelled prior to enrollment|No||https://clinicaltrials.gov/show/NCT00319332||182979|
NCT00318643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-05-01|A Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Superficial Bladder Cancer|A Phase I-IIa, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer||Halozyme Therapeutics|No|Active, not recruiting|March 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|27|||Both|18 Years|N/A|No|||April 2008|April 3, 2008|April 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318643||183031|
NCT00318656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104988|24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes|Comparison of the Effects of Rosiglitazone and Glimepiride, Both Given in Combination With Metformin, on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone. A 3-Month Multicentre, Randomized, Parallel-Group, Open-Label Study.||GlaxoSmithKline||Completed|November 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|40 Years|80 Years|No|||April 2009|April 10, 2009|April 25, 2006||||No|October 17, 2008|https://clinicaltrials.gov/show/NCT00318656||183030|
NCT00319826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014073|Virulence Determinants in S Aureus Bacteremia|Virulence Determinants in Staphylococcus Aureus Bacteremia||Duke University|No|Recruiting|March 2004|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|10000|Samples With DNA|Blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bacterial strains are used from patients with particular syndromes (e.g. nasal carraige,        endocarditis, osteomylitis) that were be identified using the Bloodstream Infections        Registry. No new subjects was or will be enrolled within the current investigation.|October 2015|October 25, 2015|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319826||182941|
NCT00319839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 05-46|Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab|UCI 05-46:A Phase II Study of AlbuminBound-Paclitaxel (AbraxaneTM) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression||University of California, Irvine|Yes|Active, not recruiting|March 2006|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|April 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319839||182940|
NCT00320658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 212|Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant|Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 18, 2008|May 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00320658||182878|
NCT00320671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060004-02|Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis|Preventing Morbidity in First Episode Schizophrenia, Part II||Northwell Health|Yes|Completed|December 2005|December 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|198|||Both|15 Years|40 Years|No|||January 2016|January 6, 2016|May 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00320671||182877|
NCT00321516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-402|Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder|Effects of Aripiprazole on the Steady-State Pharmacokinetics of Lamotrigine in Subjects With Bipolar I Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1|||20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|November 7, 2013|May 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00321516||182813|
NCT00321529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0327060002|Comparison of the ProAdjuster Analysis to the Penning Method of Determining Intersegmental Motion of the Cervical Spine|||Logan College of Chiropractic||Completed||October 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2007|May 23, 2007|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00321529||182812|
NCT00318058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104540|Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population|A Phase I/II, Open, Controlled Study in Order to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals Influenza Candidate Adjuvanted Vaccine in an Elderly Population Aged Over 65 Years Previously Vaccinated in 2004 With the Same Candidate Vaccine||GlaxoSmithKline||Completed|October 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|84|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318058||183075|
NCT00318903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F001130016|Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer|A Phase II Study of Irinotecan and Taxotere With Concurrent Radiotherapy as a Preoperative Treatment in Resectable Esophageal Cancer||University of Alabama at Birmingham|Yes|Completed|January 2002|April 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|19 Years|N/A|No|||December 2010|December 30, 2010|April 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318903||183011|
NCT00318929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCUHM10204|Tolerability and Efficacy of Depakote-extended Release in the Elderly|Tolerability and Efficacy of Depakote-ER in the Elderly||Virginia Commonwealth University|No|Completed|April 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|60 Years|N/A|No|||June 2010|February 21, 2012|April 25, 2006|Yes|Yes||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00318929||183010|
NCT00320684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4625/5767R|Serotonin Transporter Concentrations in Women With a History of Anorexia Nervosa|A Positron Emission Tomography Study of the Serotonin Transporter in Weight-Restored Women With Anorexia Nervosa||New York State Psychiatric Institute|No|Completed|July 2003|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be women who have recovered from anorexia nervosa and are currently        living in the local community.|June 2012|June 28, 2012|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00320684||182876|
NCT00320697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC 15-2005|Smoking Relapse Prevention in Schizophrenia|A Trial of the Effects of Bupropion, Nicotine Replacement Therapy and CBT on Smoking Cessation and Smoking Relapse in Patients With Schizophrenia||North Suffolk Mental Health Association||Completed|April 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|April 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00320697||182875|
NCT00278642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD Derm.Auto2001|Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders|High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial||Northwestern University|No|Terminated|September 2002|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|60 Years|No|||April 2013|April 4, 2013|January 16, 2006|Yes|Yes|sponsor stopped the study because of lack of elligible participants|No||https://clinicaltrials.gov/show/NCT00278642||186037|
NCT00278954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMX01|Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.|A Phase III, Multicenter, Open-Label Study To Evaluate The Efficacy, Safety, and Pharmacokinetics of Gammaplex® in Primary Immunodeficiency Diseases||Bio Products Laboratory|No|Completed|January 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|3 Years|N/A|No|||January 2013|January 23, 2013|January 18, 2006|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00278954||186014|
NCT00278967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F38-26|An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects||Braintree Laboratories||Completed|February 2006|August 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||450|||Both|18 Years|N/A|No|||October 2006|October 18, 2006|January 13, 2006||||||https://clinicaltrials.gov/show/NCT00278967||186013|
NCT00279578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050184|Clot Formation and Clot Stability in Patients With Severe Haemophilia A|Clot Formation and Clot Stability in Patients With Severe Haemophilia A - Effect of Recombinant Factor VIII and Tranexamic Acid||University of Aarhus||Completed|January 2006|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Male|18 Years|N/A|No|||November 2006|November 15, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279578||185967|
NCT00279552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030267|Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?|Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?||University of Aarhus||Completed|April 2004|December 2004||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||37|||Both|18 Years|N/A|No|||January 2006|January 17, 2006|January 17, 2006||||No||https://clinicaltrials.gov/show/NCT00279552||185969|
NCT00280189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0302108|Study of Outcomes of Radiofrequency Ablation of Lung Tumors|A Prospective Study of Outcomes of Radiofrequency Ablation of Lung Tumors||University of Pittsburgh||Suspended|September 2003|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|72|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seeking minimally invasive treatment for pulmonary malignancies.|February 2014|April 3, 2015|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00280189||185921|
NCT00318032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9320|A Study to Investigate the Benefits of the Early Detection and Intensive Treatment of Type 2 Diabetes|A Randomised Trial of the Cost Effectiveness of Screening and Intensive Multi-factorial Intervention for Type 2 Diabetes|ADDITION|University Hospitals, Leicester||Active, not recruiting|August 2004|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8579|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 1, 2014|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00318032||183077|
NCT00318045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X050208014|Effects of Optical Blur on Performance and Comfort of Computer Users|Effects of Optical Blur on Performance and Comfort of Computer Users||Vision Council of America||Active, not recruiting|October 2005|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||35|||Both|19 Years|N/A|Accepts Healthy Volunteers|||April 2006|April 21, 2006|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00318045||183076|
NCT00319865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMM55|PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma|PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma||Korean Multiple Myeloma Working Party||Recruiting|November 2005|September 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||47|||Both|N/A|75 Years|No|||April 2006|April 28, 2006|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00319865||182938|
NCT00320424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR3106335|Hip Fracture Study of GSK576428 (Fondaparinux Sodium)|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery||GlaxoSmithKline||Completed|February 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|20 Years|N/A|No|||October 2010|October 1, 2010|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320424||182895|
NCT00317811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000479708|Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma||National Cancer Institute (NCI)||Completed|November 2005|||February 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||June 2011|November 5, 2013|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00317811||183093|
NCT00318578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEGRIEL stephane|Prognosis Factors Associated With Convulsive Status Epilepticus in Adults|Prognosis Factors Associated With Convulsive Status Epilepticus in Adults: A Multicenter Cohort Study||Central Hospital, Versailles||Completed|March 2005|January 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|100|||Both|18 Years|N/A|No|||August 2007|August 13, 2007|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318578||183036|
NCT00329654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/067|James EMBAR® Light Therapy in the Treatment of Burn Wounds of Intermediate Depth|A Prospective, Randomized, Single Blinded, Controlled Clinical Investigation of James Embar® Light Therapy in the Treatment of Burn Wounds With Little Healing Potential||University Hospital, Ghent|No|Completed|March 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|40|||Both|2 Years|75 Years|No|||July 2015|July 30, 2015|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329654||182204|
NCT00329979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-18|Femoral vs Radial Approach and MRI Evaluation of Strokes|Silent Cerebral Infarction After Heart Catheterization: A Randomized Comparison of Radial and Femoral Arterial Access.||University Hospital, Caen||Completed|May 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|152|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with aortic stenosis|June 2010|June 9, 2010|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329979||182181|
NCT00330265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT 20051320|Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers|A Prospective, Randomized, Controlled, Unmasked, Multiple Treatment, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of an Interactive Wound Dressing Containing Cultured Keratinocytes Versus Conventional Wound Therapy for the Treatment of Diabetic Foot Ulcers|KC-002PT|KeraCure|Yes|Recruiting|January 2006|September 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2008|August 25, 2008|May 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330265||182161|
NCT00330278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 11120|Timing of Prophylactic Antibiotics for Cesarean Sections|A Randomized, Double-Blind, Placebo Controlled Trial of Cefazolin Given Either 30 Minutes Prior to Cesarean Section or at Cord Clamping||Medical University of South Carolina||Completed|January 2003|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||350|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2006|September 26, 2007|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330278||182160|
NCT00330239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPMS-857|Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence|Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence||Medical University of South Carolina||Completed|January 2003|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|No|||October 2007|October 2, 2007|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330239||182163|
NCT00330252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-404|Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL|Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2006|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|May 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330252||182162|
NCT00318591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK046CC|Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections|A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters.||Coloplast A/S|Yes|Completed|April 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|219|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|April 26, 2006||No||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00318591||183035|
NCT00319540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2906|RCT of Psychoeducational Program of Depression|A Randomized Controlled Trial of a Psychoeducational Group Program for Unipolar Depression in Adults in Norway||Norwegian Institute of Public Health||Completed|March 2001|March 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||155|||Both|18 Years|N/A|No|||January 2001|April 28, 2006|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00319540||182963|
NCT00319553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td516|Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®|Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX®||Sanofi|No|Completed|May 2006|December 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|647|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|April 28, 2006|No|Yes||No|September 28, 2010|https://clinicaltrials.gov/show/NCT00319553||182962|
NCT00326625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-GA-201|Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)|A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)||Teva Pharmaceutical Industries||Completed|July 2006|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|366|||Both|18 Years|70 Years|No|||August 2013|August 29, 2013|May 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00326625||182431|
NCT00278980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPSp201|Effect of C-Peptide on Diabetic Peripheral Neuropathy|Effect of C-Peptide on Diabetic Peripheral Neuropathy, a 6 Months Randomized Double-Blind, Placebo Controlled, Dose-Finding, Multicenter Study, With Parallel Groups||Creative Peptides Sweden Inc.||Completed|October 2003|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|55 Years|No|||January 2006|January 12, 2006|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00278980||186012|
NCT00278993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-204|Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy|A Phase II, Multicenter, Open Label, Two Stage Design Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy||Eisai Inc.||Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Male|18 Years|N/A|No|||April 2012|June 30, 2014|January 17, 2006|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00278993||186011|
NCT00279240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPP1|Life Style Modifications Prevents Type 2 Diabetes in Asian Indians|The Indian Diabetes Prevention Programme Shows That Lifestyle Modification and Metformin Prevent Type 2 Diabetes in Asian Indian Subjects With Impaired Glucose Tolerance (IDPP1)||M.V. Hospital for Diabetes||Completed|March 2001|December 2004||||Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Prevention|||||||Both|35 Years|55 Years|Accepts Healthy Volunteers|||July 2002|January 23, 2006|January 18, 2006||||No||https://clinicaltrials.gov/show/NCT00279240||185992|
NCT00279565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04279|Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)|Randomized, Controlled Study of Buprenorphine and Methadone in Hepatitis C Patients in Need of Treatment||Indivior Inc.|No|Terminated|August 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||128|||Both|18 Years|65 Years|No|||February 2007|November 21, 2012|January 17, 2006||No|The trial was terminated because of deviations from the protocol.|No||https://clinicaltrials.gov/show/NCT00279565||185968|
NCT00280761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0216|Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy|A Biologic Study of Global Gene Expression, NF-Kappa B and p53 in Adenocarcinoma of the Rectum.||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|December 2003|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Adenocarcinoma of the Rectum|Both|18 Years|N/A|No|Non-Probability Sample|All patients (male, female, any ethnic background) with rectal (inferior margin of the        tumor less than 15cms from anal verge by rigid sigmoidoscopy or below the level of S1-2 at        operation) or sigmoid-rectal junction carcinomas confirmed by sigmoidoscopy and pathologic        diagnosis of biopsy sample.|January 2015|January 30, 2015|January 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00280761||185877|
NCT00279864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415-05|The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection|Prolonged Oral Levofloxacin-Rifampin for Staphylococcus Aureus Prosthetic Joint Infection (PJI) Treated With Debridement And Retention Of Components: A Prospective Observational Cohort Study. Mayo PJI Study Group (MPSG)*||Mayo Clinic||Completed|September 2005|January 2007|Actual|January 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|A maximum of 15 adult participants with total hip or total knee arthroplasty are approved        for enrollment in this protocol at Mayo Clinic Rochester.|April 2015|April 29, 2015|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00279864||185945|
NCT00279877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12031|Cost Effectiveness and Efficacy of Kyphoplasty and Vertebroplasty Trial|Cost Effectiveness and Efficacy of Kypho and Vertebro Plasty Trial||University of Virginia||Completed|May 2005|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|112|||Both|50 Years|N/A|No|||December 2013|December 2, 2013|January 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00279877||185944|
NCT00276731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454725|Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma|Randomized Study of Radiotherapy in Patients With Stage 2B/3 (INSS) Neuroblastoma in Children Over 1 Year of Age||National Cancer Institute (NCI)||Active, not recruiting|March 1995|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|1 Year|N/A|No|||January 2006|September 16, 2013|January 12, 2006||||No||https://clinicaltrials.gov/show/NCT00276731||186176|
NCT00319566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|713B-401-US|Heart and Estrogen-Progestin Replacement Study (HERS)|Heart and Estrogen-Progestin Replacement Study (HERS)||University of California, San Francisco||Completed|July 1992|July 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2430|||Female|55 Years|75 Years|No|||January 2002|April 27, 2006|April 27, 2006||||||https://clinicaltrials.gov/show/NCT00319566||182961|
NCT00320710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446E2352|Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer|A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer||Novartis|Yes|Completed|February 2006|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|416|||Female|18 Years|N/A|No|||August 2014|August 18, 2014|April 28, 2006|Yes|Yes||No|July 8, 2014|https://clinicaltrials.gov/show/NCT00320710||182874|
NCT00320723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMH CORRC 20-01|Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia|Nicotine Replacement Therapy Added to Cognitive Behavioral Therapy for Smoking Cessation in Patients With Major Mental Illness||North Suffolk Mental Health Association||Completed|July 2001|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||May 2009|May 15, 2009|April 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00320723||182873|
NCT00318279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-826|Evaluation of Surgical Simulator for Practicing a Vascular Anastomosis|Benefits of a Surgical Skills Lab Vascular Anastomosis Simulator: A Randomized Controlled Trial||Lawson Health Research Institute||Not yet recruiting|May 2006|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2006|April 24, 2006|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00318279||183058|
NCT00318292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63-06|Preemptive Local Anesthesia in Vaginal Surgery|Preemptive Local Anesthesia in Vaginal Surgery, A Prospective, Randomised Trial||Mayo Clinic|No|Completed|April 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|N/A|No|||October 2010|October 22, 2010|April 24, 2006|Yes|Yes||No|February 18, 2009|https://clinicaltrials.gov/show/NCT00318292||183057|
NCT00320801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3014 and BUP3014S|Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.|A Randomized, Double-Blind, Multicenter Study Evaluating The Safety and Efficacy of BTDS in Subjects With Moderate to Severe Osteoarthritis Pain. Includes a 52-Week Extension Phase.||Purdue Pharma LP|Yes|Terminated|January 2004|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|188|||Both|40 Years|N/A|No|||August 2012|August 27, 2012|April 28, 2006|Yes|Yes|This study was terminated early due to administrative reasons.|No|July 28, 2010|https://clinicaltrials.gov/show/NCT00320801||182867|Study terminated due to administrative reasons. The primary objective was changed to a safety study prior to unblinding.
NCT00320814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0512|Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema|An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intravitreal Administration of VEGF Trap in Patients With Diabetic Macular Edema||Regeneron Pharmaceuticals|No|Completed|April 2006|August 2007|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|April 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00320814||182866|
NCT00321152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P000604|A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)|A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF Among SSRI-Resistant Outpatients With Major Depressive Disorder (MDD)||Massachusetts General Hospital|No|Completed|November 2006|June 2010|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||June 2010|June 7, 2010|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00321152||182841|
NCT00321334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLC0501|Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC|Survival Study of Neo-adjuvant Versus Adjuvant Chemotherapy With Docetaxel Combined Carboplatin in Resectable Stage IB to IIIA Non-small Lung Cancer||Chinese Society of Lung Cancer|Yes|Completed|March 2006|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|410|||Both|18 Years|75 Years|No|||August 2014|August 4, 2014|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00321334||182827|
NCT00321711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050232|Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim (AMG 531) Treatment of Subjects With Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents||Amgen||Completed|October 2006|October 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|5||Actual|69|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|May 2, 2006||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00321711||182799|
NCT00317395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6624|Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome|A Randomized, Double-blind, Triple-dummy, Dose-ranging Study, Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban, in Patients With Non-ST Elevation Acute Coronary Syndrome and Planned Early Invasive Strategy|SEPIA-ACS1|Sanofi|Yes|Completed|June 2006|March 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|3241|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|April 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00317395||183125|
NCT00317681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG 001|Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)|The Efficacy of Topical Tacrolimus in the Treatment of Cutaneous Lupus Erythematosus - a Multi-Center-Trial||Heinrich-Heine University, Duesseldorf||Completed|August 2005|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||September 2007|September 7, 2007|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317681||183103|
NCT00317915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC2481|Irbesartan in Type 2 Diabetes|The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)||Steno Diabetes Center||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|70 Years|No|||April 2006|April 24, 2006|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00317915||183086|
NCT00317928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160350-1|Efficacy of Metformin in PCOS: Metabolic and Hormonal Factors|||Aarhus University Hospital Skejby||Active, not recruiting|August 2001|September 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Female|20 Years|45 Years|No|||August 2001|October 10, 2006|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00317928||183085|
NCT00318474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04PE116|Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy|A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy||St. Joseph's Hospital and Medical Center, Phoenix|Yes|Terminated|January 2002|March 2010|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|184|||Both|7 Years|70 Years|No|||February 2016|February 4, 2016|April 24, 2006|Yes|Yes|DSMB recommended stopping the trial because of lack of effect.|No|June 3, 2014|https://clinicaltrials.gov/show/NCT00318474||183043|
NCT00319761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC-2006.120|Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy|The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy||Chinese University of Hong Kong||Completed|May 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||January 2009|January 29, 2009|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319761||182946|
NCT00327236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA-0148|The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes|Killer T Cell Activity in the Paraneoplastic Neurologic Syndromes||Rockefeller University|No|Recruiting|January 1995|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|serum, cells)|Both|16 Years|N/A|No|Non-Probability Sample|Patients with paraneoplastic neurologic disease, diagnosed through the research lab of the        PI, or from third party referrals in the NYC area.|October 2015|October 30, 2015|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327236||182387|
NCT00327249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-007|Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients|A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma||AmpliMed Corporation|No|Completed|October 2005|January 2008|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2009|August 7, 2009|May 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00327249||182386|
NCT00327444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6125|Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites||Sanofi|Yes|Completed|July 2006|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|N/A|No|||July 2011|November 30, 2012|May 16, 2006|Yes|Yes||No|August 17, 2012|https://clinicaltrials.gov/show/NCT00327444||182371|
NCT00327457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1796-21/23 (NCE)|Coordinated Endoscopic Colorectal Cancer Screening|Coordinated Endoscopic Colorectal Cancer Screening||University of Pittsburgh||Completed|June 2002|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|||Actual|599|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||February 2011|February 18, 2011|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327457||182370|
NCT00327964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/DMID 05-0110|Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda|Utility of Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda||University of California, San Francisco|No|Completed|October 2005|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|Samples With DNA|Dried blood spots on filter paper|Both|1 Year|11 Years|No|Probability Sample|601 children enrolled in a longitudinal antimalarial treatment efficacy trial in Kampala,        Uganda.|October 2008|October 1, 2008|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00327964||182331|
NCT00328237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMBMT-149|Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation|Treatment of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed by Single-Unit or Double-Unit Cord Blood Transplantation: A Phase II Study||Colorado Blood Cancer Institute||Recruiting|November 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|49 Years|No|||November 2005|June 23, 2006|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00328237||182311|
NCT00320021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYR-205/207|Effect of Pyridorin in Patients With Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled, Escalating Dose, Pilot Study to Evaluate the Safety, Tolerability and Biologic Activity of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes||BioStratum||Completed|July 2002|September 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|70 Years|No|||April 2006|April 27, 2006|April 27, 2006||||||https://clinicaltrials.gov/show/NCT00320021||182926|
NCT00320229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCX-LD|Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen|||Azienda Sanitaria Ospedaliera||Terminated|December 2004|July 2005||||Phase 4|Interventional|N/A||||84|||Both|50 Years|N/A|No|||January 2006|May 15, 2006|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00320229||182910|
NCT00320541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10663|A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer|A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer||Eli Lilly and Company|Yes|Completed|May 2006|August 2012|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|187|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|April 28, 2006|Yes|Yes||No|April 26, 2010|https://clinicaltrials.gov/show/NCT00320541||182886|Of 191 randomized patients, 4 patients were disqualified from inclusion in any efficacy or safety analyses due to significant Good Clinical Practice (GCP) violations; data is reported for the remaining 187 randomized patients.
NCT00320515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7461|Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer|Phase 1/2 Study of Pemetrexed Plus Cisplatin in Unresectable, Advanced Gastric Carcinoma.||Eli Lilly and Company|No|Completed|March 2004|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|70 Years|No|||August 2009|August 19, 2009|April 28, 2006|Yes|Yes||No|July 9, 2009|https://clinicaltrials.gov/show/NCT00320515||182888|
NCT00320528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9867|Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder With or Without Comorbid Conditions||Eli Lilly and Company|No|Completed|April 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|269|||Both|6 Years|15 Years|No|||December 2009|December 2, 2009|April 28, 2006|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00320528||182887|The original intent was to also calculate change and 95% confidence intervals at end of Period III; however, due to low number of patients completing Period III, variations from baseline (LOCF), are not suitable for further analysis or description.
NCT00320840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4131-JK-CTIL|Internal and Familial Resources and Motherhood. Follow Up of Mothers With Twins and Preterm Infants Versus Mothers With Single Full Term Infants|The Contribution of Internal and Familial Resources to the Development of Motherhood. Long Term Follow Up of Mothers With Twins and Preterm Infants Versus Mothers With Single Full Term Infants||Sheba Medical Center||Not yet recruiting|May 2006|May 2012||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|N/A|3 Months|No|||April 2006|April 30, 2006|April 30, 2006||||No||https://clinicaltrials.gov/show/NCT00320840||182864|
NCT00321126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-020|Zinc Supplementation in Shigella Patients|Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|January 1999|April 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|12 Months|59 Months|No|||May 2006|May 2, 2006|May 2, 2006||||No||https://clinicaltrials.gov/show/NCT00321126||182843|
NCT00317447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral Steroid Tx Acute Sciatica|The Efficacy of Oral Steroids in the Treatment of Acute Sciatica|Oral Steroids in the Treatment of Acute Sciatica A Randomized Controlled Study||Kaiser Permanente||Completed|February 2002|April 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|20 Years|60 Years|No|||April 2006|April 20, 2006|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00317447||183121|
NCT00321347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPS-05-002-MI|Intravenous (IV) Lidocaine for Opioid-refractory Pain|A Randomized, Placebo Controlled Phase II Study of Parenteral Lidocaine's Ability To Acutely Relieve Opioid Refractory Pain||San Diego Hospice & Palliative Care|Yes|Withdrawn|May 2006|May 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|May 1, 2006|Yes|Yes|No patients enrolled and clinician no longer at institution.|No||https://clinicaltrials.gov/show/NCT00321347||182826|
NCT00321360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9813|Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Healthy Volunteers|Reaction Time Monitored Patient Maintained Propofol Sedation: a Volunteer Safety Study||University of Glasgow|Yes|Completed|May 2006|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 4, 2012|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00321360||182825|
NCT00317421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JO-02|Effect of Regular Sildenafil on Blood Pressure and Arterial Function in Hypertension|Effects of Regular Treatment With Sildenafil on Blood Pressure and Endothelial Function in Untreated Hypertensives||University of Edinburgh||Completed|March 2004|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||February 2004|April 20, 2006|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00317421||183123|
NCT00317408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466639|Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma|Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence||National Cancer Institute (NCI)||Active, not recruiting|April 2004|||February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|96|||Both|N/A|21 Years|No|||September 2015|September 24, 2015|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00317408||183124|
NCT00317967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Sheldon|Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart|Statin Induced Regression of Cardiomyopathy Trial - SirCat||University of Calgary|Yes|Completed|April 2007|November 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|April 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00317967||183082|
NCT00317941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91489|Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif|The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®).||Bayer|No|Completed|March 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|220|||Both|18 Years|55 Years|No|||August 2013|August 15, 2013|April 24, 2006|Yes|Yes||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00317941||183084|
NCT00317954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-2233|Spironolactone in Diabetic Nephropathy|Spironolactone in Diabetic Nephropathy||Steno Diabetes Center||Completed|September 2003|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||August 2005|April 21, 2006|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317954||183083|
NCT00318201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 0412-09|The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers|The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers||Indiana University|Yes|Completed|April 2006|December 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|April 5, 2012|April 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00318201||183064|
NCT00318487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/126|Bilateral Sinus Floor Augmentation in Conjunction With Immediate Implant Loading - Study on 3i Dental Implants|Bilateral Sinus Floor Augmentation in Conjunction With Immediate Implant Loading - A Clinical and Histomorphometric Follow-Up Study on 3i Dental Implants||University Hospital, Ghent|No|Active, not recruiting|September 2007|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00318487||183042|
NCT00323791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539400|Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Trial of Gemzar (Gemcitabine) and Gleevec (Imatinib Mesylate) in Patients With Metastatic Renal Cell Carcinoma||Rutgers, The State University of New Jersey|Yes|Terminated|April 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||December 2009|December 10, 2009|May 8, 2006|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00323791||182643|
NCT00323804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC15 NRfi|Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.|Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients.||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|May 2006|March 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|372|||Both|18 Years|N/A|No|||August 2014|September 3, 2014|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00323804||182642|
NCT00327002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804137 PALMS|A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism|A Mechanistic Study of the Effects of LY518674 on HDL C Metabolism||University of Pennsylvania||Completed|January 2006|November 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|80 Years|No|||December 2009|December 9, 2015|May 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00327002||182405|
NCT00327730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0646-AS91-301|Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial|Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain||Eisai Inc.||Completed|April 2006|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|240|||Both|18 Years|60 Years|No|||April 2014|April 17, 2014|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327730||182349|
NCT00327470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751017|An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD|A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV).|PERSPECTIVES|Pfizer|No|Terminated|July 2006|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|288|||Both|50 Years|N/A|No|||January 2011|April 2, 2012|May 17, 2006||No|See termination reason in detailed description.|No|April 13, 2010|https://clinicaltrials.gov/show/NCT00327470||182369|
NCT00327691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0981-117|A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels|The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD|TNT|Pfizer||Completed|April 1998|August 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||8600|||Both|35 Years|75 Years|No|||May 2007|May 1, 2007|May 16, 2006||||||https://clinicaltrials.gov/show/NCT00327691||182352|
NCT00327977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-128|Hypoxemia in Infants After Palliative Surgery|A Retrospective Study of Hypoxemia in Infants After Palliative Neonatal Surgery for Congenital Heart Disease||Children's Healthcare of Atlanta|No|Completed|January 2001|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|375|||Both|N/A|3 Years|No|Probability Sample|patients'charts only from Children's Healthcare of Atlanta|November 2014|November 25, 2014|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00327977||182330|
NCT00320034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC 192|Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma|Double-blind, Crossover, Placebo-controlled Evaluation of the Effect of Levalbuterol (R-albuterol) on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma||McMaster University||Completed|April 2006|November 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|55 Years|No|||July 2009|February 28, 2011|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00320034||182925|
NCT00320567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR008332|The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa|The Effect of Ortho Tri-Cyclen on Bone Mineral Density in Pediatric Subjects With Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed||April 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|123|||Female|N/A|17 Years|No|||June 2011|June 30, 2011|April 28, 2006||||||https://clinicaltrials.gov/show/NCT00320567||182884|
NCT00320554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR040406008|Motion Characteristics of the Foot and Ankle as Measured by Durometer Readings|||Logan College of Chiropractic||Completed||September 2006|Actual|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2007|May 23, 2007|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320554||182885|
NCT00320827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1008-A-U101|Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)|Phase 1 Study of CS-1008, a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)||Daiichi Sankyo Inc.||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||September 2007|September 10, 2007|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00320827||182865|
NCT00321139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1189-2005|Assessment of Translesional Markers and Metabolomics|An Assessment of Translesional Markers and Metabolomics||Emory University||Completed|April 2006|||January 2007|Actual|Phase 4|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|21 Years|N/A|No|||September 2014|December 12, 2014|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00321139||182842|
NCT00321724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01825|AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase II Trial of AZD2171 in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Patients||National Cancer Institute (NCI)||Completed|May 2006|||May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|May 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00321724||182798|
NCT00321737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-EE05-135|Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis|A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.||Takeda|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|445|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|May 2, 2006|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00321737||182797|
NCT00317694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH 001 (ACT 2)|Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients|A Multicentre Phase II Study With Magnesium Iron Hydroxycarbonate: an Open-label, Dose-ranging Phase Followed by a Placebo-controlled, Double-blind, Parallel-group Comparison in Haemodialysis Subjects With Hyperphosphataemia||Ineos Healthcare Limited|Yes|Completed|March 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|April 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00317694||183102|
NCT00317707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&P|Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk|Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk||Mario Negri Institute for Pharmacological Research|Yes|Completed|February 2004|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12513|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|April 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00317707||183101|
NCT00318188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM04023|Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis|Effects of a Personalized Standardized Rehabilitation Program on the Quality of Life of Patients With Systemic Sclerosis Patients : a Randomized Controlled Trial|SCLEREDUC|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2005|January 2014|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|220|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|April 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00318188||183065|
NCT00319488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|386|Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)|Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)|AIMS|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|February 2004|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|238|||Both|12 Months|59 Months|No|||April 2012|April 30, 2012|April 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319488||182967|
NCT00324454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005846|Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease|A Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease||Duke University|No|Completed|May 2006|June 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2009|June 17, 2013|May 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00324454||182593|
NCT00324727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000468944|Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma|A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver||Delcath Systems Inc.||Completed|February 2006|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|May 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324727||182573|
NCT00325104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060163|Cinacalcet to Treat Familial Primary Hyperparathyroidism|Cinacalcet Actions in Familial Primary Hyperparathyroidism||National Institutes of Health Clinical Center (CC)||Completed|May 2006|March 2007||||Phase 3|Interventional|Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||March 2007|September 26, 2015|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325104||182547|
NCT00327483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-HS15038-03|Web Based Renal Transplant Patient Medication Education|Web Based Renal Transplant Patient Medication Education||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|July 2005|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||250|||Both|14 Years|N/A|No|||May 2006|May 16, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327483||182368|
NCT00327717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-AS086-311|Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures|A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures||Eisai Inc.||Completed|September 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|16 Years|70 Years|No|||August 2014|August 14, 2014|May 17, 2006||No||No|October 28, 2010|https://clinicaltrials.gov/show/NCT00327717||182350|
NCT00327496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-166|Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells|||Mackay Memorial Hospital||Active, not recruiting|June 2005|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|30 Years|80 Years|No|||June 2005|May 16, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327496||182367|
NCT00327743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD6511|Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer|A Dose-escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy||Sanofi||Completed|August 2006|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|18 Years|N/A|No|||August 2011|August 9, 2011|May 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327743||182348|
NCT00327756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060162|Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder|An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder||National Institutes of Health Clinical Center (CC)||Withdrawn|May 2006|||May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|November 22, 2011|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00327756||182347|
NCT00327769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997L00004|Faslodex Advanced Breast Cancer Local Chinese Study|A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer||AstraZeneca||Completed|November 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|234|||Female|18 Years|N/A|No|||January 2011|January 24, 2011|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00327769||182346|
NCT00328549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005116|A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)|A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN||Ortho Biotech Products, L.P.||Completed|October 2001|December 2002|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|105|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00328549||182289|
NCT00328822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE490424|Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial|Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial||Khon Kaen University||Completed|December 2006|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|65 Years|No|||October 2006|March 17, 2008|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00328822||182268|
NCT00320242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000085|Laser Light Cues for Gait Freezing in Parkinson's Disease|An Open Label Study to Assess the Efficacy of Visual Cues in the Form of the Laser Cane or the U-Step Walker With Laser Accessory in Parkinson's Disease Patients Who Experience Freezing of Gait.||Beth Israel Deaconess Medical Center|No|Completed|April 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2009|July 31, 2009|April 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00320242||182909|
NCT00320255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-027|A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer|A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study||Bristol-Myers Squibb|Yes|Completed|June 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|129|||Both|18 Years|90 Years|No|||February 2012|February 28, 2012|April 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00320255||182908|
NCT00320268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00001|Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD|MOONSTONE|AstraZeneca||Completed|April 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320268||182907|
NCT00320853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBISR/2006/02|A Study to Evaluate the Effect of Vitamin D Supplementation on Insulin Sensitivity and Secretion|A Pilot Study to Evaluate the Effect of Vitamin D Supplementation on Insulin Secretion and Peripheral Insulin Sensitivity||Sitaram Bhartia Institute of Science and Research||Completed|April 2006|May 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Male|30 Years|N/A|Accepts Healthy Volunteers|||May 2006|May 1, 2006|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320853||182863|
NCT00320866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR316302CTIL|Evaluation of Symptoms, Complications and Side Effects of Adding Medications Continuously To Subcutaneous Infusion (Hypodermoclysis) In Home Care Hospice Patients|||Soroka University Medical Center||Completed|February 2002|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||27|||Both|N/A|N/A|No|||May 2006|April 29, 2008|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320866||182862|
NCT00321750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CFR01|Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream|Phase 2 Study of the Treatment of Oral Erosive Lichen Planus With 1% Pimecrolimus Cream: a Double Blind Randomized Prospective Trial With Measurement of Pimecrolimus Levels in the Blood||Centre Hospitalier Universitaire de Nice||Terminated|December 2004|April 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||14|||Both|18 Years|N/A|No|||May 2006|October 17, 2006|May 2, 2006||||No||https://clinicaltrials.gov/show/NCT00321750||182796|
NCT00321763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107192|Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate|Demonstrate the Lot-to-lot Consistency of 3 Consecutive Production Lots of an Adjuvanted Influenza Vaccine Candidate & Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate vs Fluarix™ Administered Intramuscularly in Elderly||GlaxoSmithKline||Completed|April 2006|December 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|3124|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 18, 2013|May 3, 2006|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00321763||182795|
NCT00321399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARC|Study of Perfusion and Anatomy's Role in Coronary Artery (CAD)|SPARC, Including Its Pilot CT Angiographic Study, is a Prospective, Open-label, Multicenter, Sequentially Sampled, Observational Registry to Define the Clinical Value of Stress Perfusion (Stress SPECT, Stress PET), Noninvasive Angiography (CTA) and Combined Perfusion-anatomy (PET/CT) Studies in Patients With Known or Suspected CAD With Respect to Post-test Resource Utilization and Prediction of Cardiac Death and Non-fatal Myocardial Infarction|SPARC|Brigham and Women's Hospital|No|Completed|June 2006|July 2014|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3019|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known coronary artery disease and patients with suspected CAD and an        intermediate-High Likelihood of disease|July 2014|July 15, 2014|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00321399||182822|
NCT00321412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST001|Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas|A Double-blind, Randomized, Placebo-controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Mild to Moderately Active Crohn's Patients With Fistulas||Ocera Therapeutics|No|Completed|March 2006|September 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|70 Years|No|||May 2014|May 27, 2014|May 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00321412||182821|
NCT00317993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZE04-003|LDL Receptor Under Ezetimibe and Simvastatin|Effects of Ezetimibe and Simvastatin on LDL Receptor Protein Expression and on LDL Receptor and HMG-CoA Reductase mRNA Expression in Mononuclear Cells: a Randomized Controlled Study in Healthy Men||University of Cologne||Completed|April 2004|July 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||60|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00317993||183080|
NCT00317434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 0538 - F051025014|Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer|A Phase I Trial of Lapatinib in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer||University of Alabama at Birmingham||Terminated|November 2005|April 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|19 Years|90 Years|No|||December 2009|December 10, 2009|April 20, 2006|No|Yes|Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited    clinical responses.|||https://clinicaltrials.gov/show/NCT00317434||183122|
NCT00318838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006022|Effect of Azimilide Dihydrochloride on Renal Function|A Double-blind, Randomized, Parallel-group, Placebo-controlled, Multiple-dose Study to Assess the Effect of 125 mg/Day Orally Administered Azimilide Dihydrochloride on Renal Function and Hemodynamics in Healthy Volunteers||Warner Chilcott|No|Completed|April 2006|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 22, 2010|April 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318838||183016|
NCT00318851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI473|Carotid Artery Stenting With Protection Registry|Treatment of Carotid Stenosis With Carotid Stenting and Neurologic Protection With Pre-Procedure and Follow-Up With MRI DIffusion Imaging and Neuropsychological Testing||Providence Health & Services|No|Completed|September 2003|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|90 Years|No|||March 2006|August 25, 2010|April 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318851||183015|
NCT00317980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMT-LD-CP-2006|Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis|Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis|Lowdosesb|University of Brasilia|No|Completed|February 2006|December 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|7 Years|50 Years|Accepts Healthy Volunteers|||January 2009|January 20, 2009|April 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00317980||183081|
NCT00323492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-FR-164-0109|TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada|Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients.|TOTEM|Gilead Sciences|No|Completed|September 2005|March 2008|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|92|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|May 5, 2006||No||No|March 20, 2009|https://clinicaltrials.gov/show/NCT00323492||182666|Comparison of adverse events between Truvada and maintain baseline regimen groups is inappropriate since numbers at risk (and exposure to study drug) are not balanced, as described in the adverse event treatment group descriptions.
NCT00325117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1302|To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin to Placebo as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy||Novartis||Completed|April 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|20 Years|N/A||||May 2007|May 10, 2007|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00325117||182546|
NCT00325130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-025|Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)|An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V501 Given Concomitantly With Menactra™ and ADACEL™ in Healthy Adolescents 11-17 Years of Age||Merck Sharp & Dohme Corp.|No|Completed|April 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1042|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|May 11, 2006|Yes|Yes||No|May 19, 2009|https://clinicaltrials.gov/show/NCT00325130||182545|
NCT00327275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080192|The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis|The Strength Training and Remicade Study||University of Arizona||Completed|March 2004|January 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|May 16, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327275||182384|
NCT00327990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBN104125|Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate|See Detailed Description||GlaxoSmithKline|No|Completed|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Female|60 Years|N/A|No|||March 2011|March 17, 2011|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00327990||182329|
NCT00328263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1285-AAD-M01|Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients|A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy and Safety of BIO-K*+ CL-1285* in the Prevention of Antibiotic-associated Diarrhea in Adult Patients Exposed to Nosocomial Infection.||Bio-K Plus International Inc.|Yes|Completed|March 2006|October 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|472|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|May 17, 2006||No||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00328263||182309|
NCT00329186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-901|Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects|A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|February 6, 2013|May 23, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00329186||182240|
NCT00319722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000868/3|EEG Studies of Sensory Processing in Autistic Children|Electrophysiologic Indicators of Gating and Timing Abnormalities in Autism||Massachusetts General Hospital||Recruiting|February 2006|March 2011|Anticipated|March 2011|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|130|||Both|3 Months|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|autistic children meeting criteria for autism based on ADOS and ADI and clinical DSM IV or        their siblings between the ages of 3 months to 13 years.|May 2010|May 3, 2010|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319722||182949|
NCT00320060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYR-206|Effect of Pyridorin in Patients With Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes||BioStratum||Completed|October 2001|January 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||128|||Both|18 Years|70 Years|No|||April 2006|April 27, 2006|April 27, 2006||||||https://clinicaltrials.gov/show/NCT00320060||182923|
NCT00320593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-123|Correction of Myopia Evaluation Trial 2|Correction of Myopia Evaluation Trial 2 (COMET2): A Randomized Trial of the Effect of Progressive Addition Lenses Versus Single Vision Lenses on Low Myopia Associated With Large Accommodative Lags and Near Esophoria in Children|COMET2|Jaeb Center for Health Research|Yes|Completed|April 2005|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|8 Years|11 Years|No|||January 2012|January 25, 2012|April 28, 2006||No||No|May 17, 2011|https://clinicaltrials.gov/show/NCT00320593||182882|Limitations include: differential loss to follow up , differential compliance between the groups, power of near addition was not customized in PAL group, and we have no data on whether PAL group was looking through the near addition.
NCT00320580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR008335|An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen|A Randomized, Open-Label, Multicenter Study Comparing the Bleeding Profile of Ortho Evra (Norelgestromin/Ethinyl Estradiol) Continuous Regimen vs. Ortho Evra Cyclic Regimen||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed||March 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|239|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|April 28, 2006||||||https://clinicaltrials.gov/show/NCT00320580||182883|
NCT00321438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR104629|Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus|Prospective, Observational Study of Subjects With CXCR4-Tropic or Non-Phenotypeable HIV to Assess Changes in Tropism Over Time||GlaxoSmithKline||Terminated|July 2005|||||N/A|Observational|Time Perspective: Prospective||1||150|||Both|18 Years|N/A|No|||May 2009|May 15, 2009|May 1, 2006||||||https://clinicaltrials.gov/show/NCT00321438||182819|
NCT00326560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN/06/03/021|Comparison of Glue With Sutures for Pterygium Surgery|Comparison of Cut and Paste With Sutured Autograft Pterygium Excision||Wellington Hospital||Recruiting|May 2006|September 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2006|June 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326560||182436|
NCT00317720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0471|Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer|Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy||M.D. Anderson Cancer Center|No|Completed|April 2006|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|April 21, 2006|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00317720||183100|Trial Results were combined for the 2 trials at MDACC & BIDMC/DFCI with US Food & Drug Administration approval for completion with adequate power. As results were pooled for analytic purposes, BIDMC/DFCI protocol was amended to match MDACC protocol.
NCT00318006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00000253|Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms|A Randomized Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms||University of Michigan||Completed|December 2005|August 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|127|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00318006||183079|
NCT00322582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN/ICM|The Genetic Basis for Familial Cardiomyopathy in Patients With Idiopathic Cardiomyopathy|Open Labeled of the Study the Genetic Basis for Familial Cardiomyopathy in Patients With Idiopathic||Carmel Medical Center||Terminated|May 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|41|Samples With DNA|Blood samples|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|History of cardiomyopathy|January 2007|January 24, 2012|May 5, 2006||No|no financial resources were available to complete the study|No||https://clinicaltrials.gov/show/NCT00322582||182735|
NCT00318214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRE0094P-202|Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers|||Pfizer|No|Terminated|June 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|85 Years|No|||May 2012|May 24, 2012|April 24, 2006|Yes|Yes|The study had poor enrollment with only 16 patients randomized across 19 study centers over an    18-month period.|No||https://clinicaltrials.gov/show/NCT00318214||183063|
NCT00318513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3251s|Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema|Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema||Premiere Oncology of Arizona||Not yet recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Female|N/A|N/A|No|||April 2006|May 9, 2006|April 24, 2006||||||https://clinicaltrials.gov/show/NCT00318513||183040|
NCT00318539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C09907|Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study|Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder, a Double-blind, Placebo-controlled Study||AstraZeneca||Completed|December 2003|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|70 Years|No|||January 2011|January 20, 2011|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318539||183039|
NCT00319176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162-04|Evaluation of Pre-dose and Post-dose Anti-factor Xa Levels With Enoxaparin Use During Pregnancy|||University of California, Irvine||Completed|April 2004|December 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obstetrics clinic|February 2013|February 6, 2013|April 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00319176||182991|
NCT00324181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.060|Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient|Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient||Chinese University of Hong Kong|Yes|Active, not recruiting|June 2006|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Glaucoma patients from a tertiary University Ophthalmic clinic setting|August 2009|August 3, 2009|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00324181||182613|
NCT00327509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-KAR-2004-001|mRNA Expression in Lymphocytes of Glaucoma Patients|Messenger Ribonucleic Acid Expression in Lymphocytes of Glaucoma Patients||University Hospital, Basel, Switzerland|No|Completed|January 2004|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|60|Samples With DNA|white cells|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|glaucoma patients, healthy subjects|August 2009|August 19, 2009|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327509||182366|
NCT00327782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-114|Palliative Care of Children With End-Stage Heart Failure|Palliative Care of Children With End-Stage Heart Failure||Children's Healthcare of Atlanta||Terminated|January 1995|April 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|1 Year|18 Years|No|||May 2007|May 2, 2007|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00327782||182345|
NCT00328562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03C.225|ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer|A Phase I Study of ZD1839 (Iressa) and Hypofractionated Thoracic Radiotherapy With Stereotactic Body Frame Immobilization for Patients With Advanced Non-Small Cell Lung Cancer||Thomas Jefferson University|Yes|Completed|December 2003|September 2010|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 19, 2006|Yes|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT00328562||182288|
NCT00328835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCS|Optic Nerve Compliance Study|Optic Nerve Compliance Study||Capital Vision Research Trust||Completed|March 2006|April 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label||||100|||Both|18 Years|N/A||||May 2006|October 16, 2006|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328835||182267|
NCT00329173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0102|PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.|A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) With Atorvastatin (20 mg) in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD||AstraZeneca||Completed|November 2003|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329173||182241|
NCT00329511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-04|A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy|A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy||University of California, Irvine|No|Terminated|September 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|May 22, 2006||No|Inadequate Enrollment|No||https://clinicaltrials.gov/show/NCT00329511||182215|
NCT00320281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2691|Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.|Botulinum Toxin A for the Treatment of Cervical/Shoulder Pain Following Acute Spinal Cord Injury.||Craig Hospital|Yes|Completed|April 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|15 Years|N/A|No|||June 2013|June 22, 2013|April 28, 2006||No||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00320281||182906|
NCT00320879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26122284|Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria|Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria||Steno Diabetes Center||Completed|September 2003|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|N/A|No|||July 2003|May 17, 2006|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320879||182861|
NCT00321425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05240|Ultrasound Guidance Vs. Electrical Nerve Stimulation for Infraclavicular Brachial Plexus Block|||Rikshospitalet University Hospital||Completed|May 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|80|||Both|18 Years|70 Years|No|||October 2007|May 20, 2008|May 2, 2006||||No||https://clinicaltrials.gov/show/NCT00321425||182820|
NCT00326287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011407|Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia|A Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Placebo in the Treatment of Subjects Hospitalized With Community-Acquired Pneumonia||Basilea Pharmaceutica|Yes|Completed|June 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|638|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|May 12, 2006||Yes||||https://clinicaltrials.gov/show/NCT00326287||182456|
NCT00322608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI-2358-100|Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma|Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients With Advanced Solid Tumor Malignancies or Lymphoma||Nereus Pharmaceuticals, Inc.|No|Completed|April 2006|December 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2011|January 6, 2011|May 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00322608||182733|
NCT00322621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10258|Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)|Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain||Eli Lilly and Company||Completed|April 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|18 Years|N/A|No|||February 2011|February 3, 2011|May 5, 2006|Yes|Yes||No|October 30, 2008|https://clinicaltrials.gov/show/NCT00322621||182732|
NCT00317460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS05NSC|Buprenorphine and Integrated HIV Care|On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings||Yale University|No|Completed|September 2005|October 2012|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|April 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00317460||183120|
NCT00317473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1030|Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children|Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine.||U.S. Army Medical Research and Materiel Command|No|Completed|June 2003|July 2005|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||135|||Both|12 Months|47 Months|Accepts Healthy Volunteers|||June 2015|June 4, 2015|April 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00317473||183119|
NCT00317486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-405|Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology||Actelion||Completed|September 2003|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|54|||Both|12 Years|N/A|No|||February 2010|February 11, 2010|April 21, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00317486||183118|
NCT00322595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00011|Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder|An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER)|SILVER|AstraZeneca||Completed|May 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|800|||Both|18 Years|65 Years|No|||December 2007|December 18, 2008|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00322595||182734|
NCT00318227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-03-043|Randomized Trial of a Liberal Versus a Restrictive Transfusion Strategy in Elderly Cardiac Surgery Patients|Evaluation of a Liberal Versus Restrictive Blood Transfusion Strategy in Elderly Patients Following Coronary Bypass or Aortic Valve Surgery||Lawson Health Research Institute|No|Recruiting|June 2005|May 2009|Anticipated|April 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|74|||Both|70 Years|90 Years|No|||April 2009|April 15, 2009|April 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00318227||183062|
NCT00318240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-877|Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound (HIFU)|Feasibility Study for Locally Recurrent Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound (HIFU)||Lawson Health Research Institute|No|Recruiting|April 2006|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|40 Years|80 Years|No|||February 2009|February 10, 2009|April 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00318240||183061|
NCT00323193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4219-R|Using MOVE! With Seriously Mentally Ill Veterans|Using MOVE! With Seriously Mentally Ill Veterans||VA Office of Research and Development|Yes|Completed|July 2006|August 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|109|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|May 5, 2006||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00323193||182689|
NCT00323206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13224|Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma|Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|June 2004|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00323206||182688|
NCT00323167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5902|Rare Genetic Disorders of the Breathing Airways|Rare Genetic Disorders of the Airways: Cross-sectional Comparison of Clinical Features, and Development of Novel Screening and Genetic Tests||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|May 2006|January 2019|Anticipated|October 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|360|Samples With DNA|Respiratory cultures, nasal samples, and blood samples|Both|N/A|N/A|No|Non-Probability Sample|Individuals with suspected primary ciliary dyskinesia, non-classical or variant cystic        fibrosis, and pseudohypoaldosteronism|March 2016|March 7, 2016|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323167||182691|
NCT00323180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 03-376|Investigation of Protein Biomarkers of Prostate Cancer|Investigation of Protein Biomarkers of Prostate Cancer||University of New Mexico|Yes|Completed|August 2005|February 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|||||Male|18 Years|N/A|No|Non-Probability Sample|Patients with prostate cancer|November 2009|January 6, 2010|May 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323180||182690|
NCT00324740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00095|Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer|A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)|Yes|Terminated|March 2006|May 2014|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|N/A|No|||June 2014|October 22, 2015|May 10, 2006|Yes|Yes||No|July 20, 2015|https://clinicaltrials.gov/show/NCT00324740||182572|
NCT00328016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0067|Breathe: Slow Paced Breathing to Lower Blood Pressure|Respiratory Adaptations to Behavioral Interventions in Elevated Blood Pressure||National Institutes of Health Clinical Center (CC)||Completed|April 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 2, 2012|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328016||182328|
NCT00328289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12006|Effect of Intradialytic Electrical Muscle Stimulation and Passive Leg Mobilisation on Blood Pressure and Dialysis Efficacy|Effect of Intradialytic Electrical Muscle Stimulation and Passive Leg Mobilisation on Blood Pressure and Dialysis Efficacy||University Hospital Inselspital, Berne||Completed|May 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|90 Years|No|||January 2011|January 12, 2011|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328289||182307|
NCT00328276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR93-IRB-119|Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia|NMDA Enhancers in the Treatment of Schizophrenia||China Medical University Hospital||Completed|December 2004|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||May 2006|May 18, 2006|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328276||182308|
NCT00328848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS014539-01A1|After Discharge Management of Low Income Frail Elderly|After Discharge Management of Low Income Frail Elderly (AD-LIFE)||Summa Health System|Yes|Completed|October 2005|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|530|||Both|66 Years|N/A|No|||July 2014|July 16, 2014|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328848||182266|
NCT00328861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060169|Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer|Phase II Study in Metastatic Melanoma or Kidney Cancer Using Autologous Natural Killer Cells Plus Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy||National Institutes of Health Clinical Center (CC)|No|Completed|May 2006|April 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|May 20, 2006|Yes|Yes||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00328861||182265|
NCT00328874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2005-000574-40|Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy|Mono-Center, Prospective, Double-Blind, Placebo-Controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy||German Parkinson Study Group (GPS)|No|Completed|May 2006|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||March 2008|March 25, 2008|May 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00328874||182264|
NCT00329199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP#4100027295|Pennsylvania Adolescent Intervention Research Study (PAIRStudy)|TRIAD Project: Pennsylvania Adolescent Intervention Research Study (PAIRStudy; Project 3a)||Pennsylvania Department of Health||Terminated|December 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|240|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||August 2007|August 16, 2007|May 22, 2006|||Trial was rewritten and will no longer focus on the link between smoking and depression.|No||https://clinicaltrials.gov/show/NCT00329199||182239|
NCT00329225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/347|Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin||GlaxoSmithKline|No|Completed|September 2002|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||630|||Both|18 Years|70 Years|No|||November 2012|April 11, 2013|May 22, 2006||||||https://clinicaltrials.gov/show/NCT00329225||182237|
NCT00329238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.47|Secondary Prevention of Venous Thrombo Embolism (VTE).|A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.|RE-MEDY|Boehringer Ingelheim||Completed|May 2006|||October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|2867|||Both|18 Years|N/A|No|||December 2013|May 8, 2014|May 23, 2006||||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00329238||182236|
NCT00325377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMRI-LBP-002|The Effects of the MME Procedure on Chronic Low Back Pain|A Randomized Sham-Controlled Clinical Study to Evaluate the Effects of the Magnetic Molecular Energizer (MME)on Chronic Low Back Pain||Advanced Magnetic Research Institute International|No|Active, not recruiting|April 2006|January 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|30 Years|79 Years|No|||July 2007|July 8, 2007|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00325377||182526|
NCT00325390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6720|Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation|Double-Blind Parallel Comparison Study of SR25990C Versus Standard Therapy in Japan(Ticlopidine) in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Who Are Planned for Percutaneous Coronary Intervention||Sanofi||Completed|July 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||800|||Both|20 Years|N/A|No|||March 2009|March 24, 2009|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325390||182525|
NCT00321165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOT-trial|The AOT (Acridine Orange and Taurolidine) Trial|The AOT (Acridine Orange and Taurolidine) Trial: a Survey on Diagnosis and Prevention of Catheter-Related Infections in Patients on Home Parenteral Nutrition||Radboud University||Completed|June 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|60|||Both|18 Years|N/A|No|||February 2009|February 10, 2009|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321165||182840|
NCT00321451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011861|Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia|Behavioral Insomnia Therapy With Fibromyalgia||Duke University|Yes|Completed|May 2006|February 2011|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|111|||Both|21 Years|65 Years|No|||January 2016|January 28, 2016|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321451||182818|
NCT00321464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050136|A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer||Amgen|Yes|Completed|April 2006|April 2012|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|2049|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|May 2, 2006||Yes||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00321464||182817|
NCT00325936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNL-MS-01|The Effects of Cilnidipine on Metabolic Syndrome Improvement|A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS]||Boryung Pharmaceutical Co., Ltd|No|Completed|July 2005|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|30 Years|65 Years|No|||August 2008|August 26, 2008|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00325936||182483|
NCT00322361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V232-056|Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)(COMPLETED)|A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process||Merck Sharp & Dohme Corp.|No|Completed|May 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|566|||Both|N/A|10 Days|Accepts Healthy Volunteers|||June 2015|June 1, 2015|May 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00322361||182752|
NCT00322894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0552C|Expanded Breast Cancer Registry and Tissue Repository|Expanded Breast Cancer Registry and Tissue Repository||New Mexico Cancer Care Alliance|Yes|Recruiting|February 2006|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|500|Samples With DNA|Sample of tumor, buccal cells and blood collected at the time of study enrollment.|Both|18 Years|N/A|No|Probability Sample|All patients diagnosed with breast cancer during the study period commencing January 2006,        regardless of gender, ethnicity/race, stage of disease or treatment.|January 2016|January 15, 2016|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322894|20 Years|182711|
NCT00322075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_00722|LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous|Comparison of Glycaemic Fluctuations During 3 Days Subcutaneous Continuous Monitoring in Patients With Basal Substitution Human Insulin NPH vs Insuline Glargine||Sanofi||Completed|April 2006|November 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|65 Years|No|||September 2007|September 11, 2007|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00322075||182773|
NCT00322348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8664C00008|Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women|An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer||AstraZeneca||Completed|April 2006|November 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Female|18 Years|N/A|No|||December 2010|December 22, 2010|May 3, 2006|Yes|Yes||No|November 11, 2010|https://clinicaltrials.gov/show/NCT00322348||182753|The criteria for non-inferiority were not met for the primary efficacy endpoint (PFS at Week 24). However, since recruitment was terminated prematurely, the study was no longer adequately powered to detect non-inferiority.
NCT00323518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG53135-CLN-12|A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis|A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant||Celldex Therapeutics|Yes|Completed|May 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|390|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323518||182664|
NCT00322881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-402|Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer|A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer||Dana-Farber Cancer Institute|Yes|Terminated|April 2006|April 2010|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|70 Years|N/A|No|||June 2015|June 12, 2015|May 5, 2006|Yes|Yes|Early closure based on audit by study investigators after 3 patients died on study.|No|January 6, 2015|https://clinicaltrials.gov/show/NCT00322881||182712|This study terminated early due to 3 deaths on study and consequently results are limited.
NCT00324194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-004|A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes|A Phase I Study of MGCD0103 Given as a Twice Weekly Oral Dose in Patients With Leukemia or Myelodysplastic Syndromes||Mirati Therapeutics Inc.|No|Completed|February 2005|August 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|May 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00324194||182612|
NCT00324207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006028|Molecular Quantification of Insulin mRNA|Prediction of Type 1 Diabetes: Molecular Quantification of Insulin mRNA in the While Cell Fraction of Whole Blood||Children's Mercy Hospital Kansas City|No|Completed|February 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|1 Year|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hospital and clinic patients and their siblings.|March 2010|March 3, 2010|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00324207||182611|
NCT00323505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1871|A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma|||Royal Marsden NHS Foundation Trust||Completed|March 2001|December 2004||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||May 2006|May 8, 2006|May 8, 2006||||No||https://clinicaltrials.gov/show/NCT00323505||182665|
NCT00323817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99010206E|To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia|||Zeria Pharmaceutical||Completed|April 2006|October 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|282|||Both|18 Years|70 Years|No|||May 2015|May 26, 2015|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323817||182641|
NCT00324753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 03-252|Quality Improvement of Patient-Provider Communication For Colorectal Cancer Screening|Improving Patient-Provider Communication For Colorectal Cancer Screening||VA Office of Research and Development|No|Completed|April 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|450|||Both|50 Years|74 Years|No|||April 2015|April 24, 2015|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00324753||182571|
NCT00328302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-AHM-0044-01|Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy|Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB||Karolinska University Hospital||Active, not recruiting|September 2000|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||13|||Both|17 Years|30 Years|No|||June 2000|May 18, 2006|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328302||182306|
NCT00328575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05U.443|Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases|Phase I Dose Escalation Trial in Patients With Brain Metastases Using IMRT||Thomas Jefferson University|Yes|Completed|October 2005|June 2011|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00328575||182287|
NCT00328601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-20557-3258|Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)|Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-Blind,Placebo-Controlled Multicentre Trial With 4 Parallel Groups||MEDA Pharma GmbH & Co. KG||Completed|February 2005|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||170|||Both|18 Years|74 Years|No|||July 2008|July 29, 2008|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00328601||182285|
NCT00328887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0011004683|Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma|Phase I, Initial Safety/Toxicity Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdCUCD40L) to Patients With Stage III or IV Esophageal Carcinoma||Weill Medical College of Cornell University|Yes|Withdrawn|July 2011|June 2029|Anticipated|June 2029|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||August 2015|August 3, 2015|May 22, 2006|No|Yes|No funding was obtained for this study. No subject were receruited.|No||https://clinicaltrials.gov/show/NCT00328887||182263|
NCT00328900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03113|Measurement of Stress During Anesthesia With "Pain Detector" on Patients Receiving Atropine|||Rikshospitalet University Hospital|No|Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|24|||Both|18 Years|N/A|No|||April 2007|May 31, 2012|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00328900||182262|
NCT00329212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMP95-RD-010|The Pharmacokinetics Study of Concentrated Herbal Formula and Traditional Herbal Decoctions in Humans|Bioequivalence of Bioactive Markers Between Concentrated Herbal Formula and Traditional Herbal Decoctions in Humans||Committee on Chinese Medicine and Pharmacy||Completed||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|20 Years|35 Years|Accepts Healthy Volunteers|||November 2006|November 14, 2006|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329212||182238|
NCT00329836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA/CH/01|A Research Study to Examine Cutaneous Allodynia and Cluster Headache|||Thomas Jefferson University|No|Completed|August 2006|February 2008|Actual|February 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects with cluster headache|July 2011|July 21, 2011|May 24, 2006|No|Yes||No|July 21, 2011|https://clinicaltrials.gov/show/NCT00329836||182190|
NCT00329849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P10|Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age|A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With That of a Licensed Meningococcal ACWY Polysaccharide Vaccine (Menomune®) Administered to Healthy Children 2 to 10 Years of Age||Novartis|No|Completed|May 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1500|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|May 23, 2006||No||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00329849||182189|
NCT00326300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011557|A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder|An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed|April 2006|August 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|560|||Both|18 Years|65 Years|No|||April 2010|May 20, 2011|May 12, 2006||||||https://clinicaltrials.gov/show/NCT00326300||182455|
NCT00325702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018084-01A2|Addressing Young Men's Substance Use and HIV Risk|Addressing Young Men's Substance Use and HIV Risk|Get REAL|Public Health Management Corporation|No|Completed|October 2006|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|761|||Male|15 Years|29 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|May 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00325702||182501|
NCT00325715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201904-006|AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers|||Allergan||Completed|April 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|May 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00325715||182500|
NCT00325949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-790|A Study of Pain Relief in Low Back Pain|A Phase 3, Open-Label Period Followed By a Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) Compared to Placebo in Subjects With Chronic Low Back Pain||Abbott|No|Completed|May 2006|June 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|770|||Both|21 Years|75 Years|No|||July 2011|July 22, 2011|May 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325949||182482|
NCT00322920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104799|Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer|A Phase I Study of Weekly Topotecan With Cisplatin for the Management of Advanced Stage or Recurrent Carcinoma of the Cervix||University of Alabama at Birmingham||Terminated|July 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Female|19 Years|N/A|No|||February 2008|February 13, 2008|May 5, 2006|||Low accrual|No||https://clinicaltrials.gov/show/NCT00322920||182709|
NCT00322907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fatol 1|Cotrifazid Safety and Efficacy Against Malaria|A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea||Policlinique Médicale Universitaire||Terminated|April 2000|January 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||330|||Both|6 Months|N/A|No|||October 1999|May 5, 2006|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00322907||182710|
NCT00323219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO3-0153|Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department|Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department||University of British Columbia|No|Recruiting|January 2004|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|390|||Both|N/A|18 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323219||182687|
NCT00323531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 01-019|Thoracoscopy Versus Fibrinolysis in Children With Empyema|Thoracoscopy Versus Fibrinolysis in Children With Empyema||Children's Mercy Hospital Kansas City|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|N/A|18 Years|No|||May 2008|May 6, 2008|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323531||182663|
NCT00323830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-08-10|Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma|Phase III Randomized Controlled Trial of Adjuvant Capecitabine/Cisplatin Chemotherapy and Chemoradiation Therapy for Gastric Adenocarcinoma||Samsung Medical Center||Completed|October 2004|April 2011|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|458|||Both|18 Years|75 Years|No|||November 2011|November 8, 2011|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323830||182640|
NCT00324220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-005|A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia|A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome or Acute Myelogenous Leukemia||Mirati Therapeutics Inc.|No|Completed|January 2006|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324220||182610|
NCT00324233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK052CC|Evaluation of Residual Urine After Intermittent Catheterisation|Evaluation of Residual Urine After Intermittent Catheterisation - Comparison of 2 Hydrophilic Coated, Intermittent Catheters||Coloplast A/S||Completed|April 2006|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 29, 2012|May 9, 2006||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00324233||182609|
NCT00324480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00090|Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Flavopiridol in Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|March 2006|||April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||October 2011|February 21, 2014|May 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00324480||182591|
NCT00324467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-00017|Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment|Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results|LYTPET|British Columbia Cancer Agency|No|Active, not recruiting|August 2006|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00324467||182592|
NCT00324493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSFIH2004|Musculoskeletal Function in Hemophilia|Musculoskeletal Function in Hemophilia in Developing Countries||Christian Medical College, Vellore, India||Active, not recruiting|June 2004|June 2009||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||250|||Male|5 Years|15 Years|No|||June 2005|November 29, 2006|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324493||182590|
NCT00325143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/100|Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine|Assess Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Admnd at 3 & 4 Mths & DTPa-HBV-IPV/Hib Vaccine Admnd at 5 Mths, Followed by DTPa-IPV/Hib Vaccine at 18 Mths in Infants Who Received hepatitisB Vaccine at Birth & at One Month of Age||GlaxoSmithKline||Completed|December 2003|||February 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|702|||Both|11 Weeks|17 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325143||182544|
NCT00328055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0066|Comparison of an Easy to Read Advance Directive Versus a Standard Advance Directive|Effects of an Easy to Read Advance Directive on Acceptability, Knowledge, and Self-efficacy Compared to a Standard Advance Directive||National Institute on Aging (NIA)||Completed|August 2004|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind||||200|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 21, 2011|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328055||182325|
NCT00328315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 EB 0019-83|Cardiac SPECT With Rotating Slant Hole Collimator|||Johns Hopkins University||Recruiting|October 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2007|January 3, 2007|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328315||182305|
NCT00328588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-006|LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy|||Astellas Pharma Inc||Completed|December 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00328588||182286|
NCT00329251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0490; EARTH-06|Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV|Study of the Influence of Immunological Repeated Stimuli With Commercial Vaccines Over the Viral Load (VL), Resistance Development and Specific Immunological Response Against HIV in Early Stage HIV Patients With Undetectable VL After HAART||Hospital Clinic of Barcelona||Completed|April 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||26|||Both|18 Years|N/A|No|||May 2006|May 22, 2006|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329251||182235|
NCT00329264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00009|Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder|TITANIUM|AstraZeneca||Completed|April 2006|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|876|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00329264||182234|
NCT00329537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309240|Study of Sargramostim in Moderately to Severely Active Crohn's Disease|Open-Label Phase 1 Study to Assess the Tolerability, Pharmacokinetics and Safety of 2 and 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 4 Weeks, and Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease (Sargramostim Phase 1/2 Study)||Sanofi|No|Terminated|June 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|May 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00329537||182213|
NCT00329862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAGBTV|Laparoscopic Adjustable Gastric Banding With Truncal Vagotomy|Pilot Study Assessing Advantage of Adding Truncal Vagotomy to LAGB||Central Carolina Surgery, PA||Terminated|May 2006|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 14, 2011|May 23, 2006|||study size reached|No||https://clinicaltrials.gov/show/NCT00329862||182188|
NCT00322114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000468031|Lycopene in Preventing Prostate Cancer in Healthy Participants|Mechanism of Prostate Cancer Prevention by Lycopene||National Cancer Institute (NCI)||Recruiting|February 2006|||February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|3||Anticipated|150|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|September 19, 2013|May 3, 2006||||No||https://clinicaltrials.gov/show/NCT00322114||182771|
NCT00326573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCUA008|Trial of Motivational Interviewing in Adolescents With Diabetes|A Multicentre, Randomised Controlled Trial of Motivational Interviewing in Adolescents With Diabetes||Cardiff University||Terminated|October 2001|June 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||80|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||October 2004|May 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326573||182435|
NCT00322101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1992.00|Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia|A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia||Fred Hutchinson Cancer Research Center|Yes|Completed|January 2006|October 2014|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|N/A|65 Years|No|||October 2014|October 23, 2014|May 2, 2006|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00322101||182772|
NCT00322933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHARF4|Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure|Multicentre Randomised Trial of Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure||Ziekenhuis Netwerk Antwerpen (ZNA)||Terminated|April 2001|March 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1628|||Both|18 Years|N/A|No|||April 2005|October 25, 2006|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00322933||182708|
NCT00323284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-003|A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma|A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.||Glaukos Corporation|No|Completed|June 2005|March 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|May 6, 2006|Yes|Yes||No|September 4, 2012|https://clinicaltrials.gov/show/NCT00323284||182682|Open label given no way to mask treatment group to surgeon and visibility of iStent device upon gonioscopy.
NCT00323258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005018|Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease|PILOT-EBM: Patient Focused Intervention to Improve Long-term Adherence to Evidence Based Medications|PILOT-EBM|Duke University|No|Completed|June 2006|March 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|143|||Both|18 Years|N/A|No|||May 2012|January 11, 2013|May 5, 2006||No||No|March 19, 2012|https://clinicaltrials.gov/show/NCT00323258||182684|
NCT00323271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4150-R|Cognitive-behavior Therapy for MS-Related Chronic Pain|Cognitive-behavior Therapy for MS-Related Chronic Pain||VA Office of Research and Development|No|Completed|July 2006|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|N/A|No|||August 2015|August 25, 2015|May 5, 2006||No||No|July 21, 2015|https://clinicaltrials.gov/show/NCT00323271||182683|
NCT00323232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0441|Comparison of Treatment Outcomes in Hip Fractures Surgically Fixed With Either a Two or Four Hole Device.|Two-Hole Versus Four-Hole Dynamic Hip Screw (DHS) for the Treatment of Intertrochanteric Fractures: A Prospective Randomized Trial||University of British Columbia|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|65 Years|N/A|No|||April 2011|April 26, 2011|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323232||182686|
NCT00323245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0608|Regaining Bladder Control in Postmenopausal Women With Osteoporosis|Regaining Urinary Continence in Postmenopausal Women With Osteoporosis: A Randomized Controlled Trial.||University of British Columbia|No|Completed|March 2006|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|48|||Female|55 Years|80 Years|Accepts Healthy Volunteers|||April 2011|April 12, 2011|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323245||182685|
NCT00323869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-03730|Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell)|Phase II Trial of Bevacizumab in Combination With Gemcitabine and Carboplatin in Patients With Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell Carcinoma)||Stanford University|Yes|Completed|June 2006|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323869||182637|
NCT00323882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-017 ST|Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase I/II, Open-label, Dose-escalation Study of MDX-010 Administered Every 3 Weeks for 4 Doses in Patients With Metastatic Hormone-Refractory Prostate Cancer||Bristol-Myers Squibb|No|Completed|January 2006|July 2013|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Male|18 Years|N/A|No|||August 2014|August 14, 2014|May 8, 2006|Yes|Yes||No|July 23, 2014|https://clinicaltrials.gov/show/NCT00323882||182636|Due to the small number of participants who underwent more than 4 doses of treatment (induction period) and the exploratory nature of this study, not all of the secondary objectives were completed.
NCT00323843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005972-34|Retrograde Intrarenal Stone Surgery - A Method of Treating the ESWL Resistant Kidney Stone|RIRS - A Method of Treating the ESWL Resistant Kidney Stone||Fredericia Hosptial||Active, not recruiting|June 2006|February 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||January 2007|January 29, 2007|May 8, 2006||||No||https://clinicaltrials.gov/show/NCT00323843||182639|
NCT00323856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBI 04-01|Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A|Phase IV A Study of Immunologic Safety for Alphanate in Previously Treated Patients Diagnosed With Severe Hemophilia A||Grifols Biologicals Inc.|No|Recruiting|January 2003|March 2020|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|6 Years|65 Years|No|||February 2014|February 17, 2014|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323856||182638|
NCT00324506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT 355349|Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis|A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis||University of Texas Southwestern Medical Center|Yes|Completed|May 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|55 Years|No|||June 2013|June 17, 2013|May 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00324506||182589|
NCT00324519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2005|Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester|Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester||University of Florida|No|Completed|February 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 1, 2012|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00324519||182588|
NCT00324766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105|Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.|Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.||Oslo University Hospital|Yes|Completed|June 2006|March 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|20 Years|N/A|No|||June 2012|June 25, 2012|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00324766||182570|
NCT00325481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP134|Study To Evaluate the Safety of Bivalent Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults||MedImmune LLC||Completed|June 2006|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2007|July 17, 2007|May 11, 2006||||||https://clinicaltrials.gov/show/NCT00325481||182518|
NCT00325494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-009-001|A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer|A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects With Advanced Mesothelin-expressing Tumors||Morphotek||Completed|May 2006|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|May 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325494||182517|
NCT00325507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-B2/001/05|Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma|Safety, Immunology, and Biological Activity Evaluation of TroVax® in Treatment of Patients With Locally Advanced or Metastatic Renal Carcinoma||Oxford BioMedica||Completed|November 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||July 2008|July 31, 2008|May 10, 2006||||||https://clinicaltrials.gov/show/NCT00325507||182516|
NCT00328614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02C.172|Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer|A Phase I Pilot Study of Samarium-153 Combined With Neoadjuvant Hormonal Therapy and Radiation Therapy in Men With Locally Advanced Prostate Cancer||Thomas Jefferson University|Yes|Completed|March 2003|June 2011|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|32|||Male|18 Years|N/A|No|||November 2013|November 11, 2013|May 19, 2006|No|Yes||No|June 24, 2013|https://clinicaltrials.gov/show/NCT00328614||182284|
NCT00328627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-322OPI-001|Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes||Takeda|No|Completed|May 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|1554|||Both|18 Years|80 Years|No|||February 2013|February 19, 2013|May 19, 2006|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00328627||182283|
NCT00328913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P6880|The Effect of 5-Hydroxytryptophan (5-HTP) on Satiety|Effectiveness of 5-Hydroxytryptophan on Satiety in a Randomised, Placebo Controlled, Time Blinded Study, in Overweight Women||TNO||Completed|March 2006|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2007|January 8, 2007|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00328913||182261|
NCT00328926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26109|Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])|A Phase IV, Multicenter, Randomized, Double-blinded, Clinical Trial to Confirm the Efficacy of the 75 IU Dose of Luveris® vs. Placebo When Administered With Follitropin Alfa for Induction of Follicular Development and Pregnancy in Hypogonadotropic Hypogonadal Women With Profound LH Deficiency, as Defined by a Baseline LH Level <1.2 IU/L||EMD Serono||Terminated|March 2006|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|11|||Female|18 Years|40 Years|No|||August 2013|August 4, 2013|May 20, 2006|Yes|Yes|Please see "Purpose" statement|No|May 22, 2013|https://clinicaltrials.gov/show/NCT00328926||182260|
NCT00329277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNM200601|Detection of Topographic Residual Acuity in Patients With Age Related Macular Degeneration|||University Health Network, Toronto||Completed|April 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|N/A|N/A|No|||November 2006|May 22, 2008|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329277||182233|
NCT00329290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068-02|Evaluation of Maternal and Fetal Outcomes in Pregnancies in Women With Prosthetic Heart Valves|||University of California, Irvine||Completed|February 2002|April 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Female|15 Years|45 Years|No|Non-Probability Sample|Questionare|February 2013|February 6, 2013|May 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00329290||182232|
NCT00329550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87047|Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease|A 26-week, Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed Clinical Efficacy in a Remission Induction Study (Study C87037 [NCT00291668]), at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals||UCB Pharma|No|Completed|May 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|16 Years|64 Years|No|||February 2015|February 27, 2015|May 22, 2006|Yes|Yes||No|April 7, 2009|https://clinicaltrials.gov/show/NCT00329550||182212|Due to the small number of subjects in this study, the percentages of subjects with adverse events may be misleading.
NCT00322127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060156|An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers|A Pilot Study of the Safety and Activity of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|May 2006|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|50 Years|No|||January 2016|January 15, 2016|May 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00322127||182770|
NCT00322140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060151|CDDO to Treat Solid Tumors and Lymphomas|Phase I Study of CDDO in Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|May 2006|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||August 2011|September 26, 2015|May 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00322140||182769|
NCT00322374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-104|Phase I Combination w/ Epirubicin|A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer||R-Pharm|No|Completed|August 2006|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|May 1, 2006|No|Yes||No|July 6, 2010|https://clinicaltrials.gov/show/NCT00322374||182751|
NCT00322634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0535C|Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors|Investigator Initiated Trial: Prospective Study of Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors||New Mexico Cancer Care Alliance|Yes|Completed|February 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic solid tumors.|August 2011|September 17, 2012|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322634||182731|
NCT00323921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052603|Determination of Safety and Efficacy of a Laser With Cooling for Treatment of Skin|||Candela Corporation|No|Completed|August 2005|January 2007|Actual|December 2006|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|30 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 2, 2012|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00323921||182633|
NCT00323934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-002|Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma||Mirati Therapeutics Inc.|No|Completed|April 2004|October 2008|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|May 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00323934||182632|
NCT00323947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH066835|Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy|Double Blind, Placebo Controlled, Crossover Study of Extended Release Methylphenidate for Treatment of ADHD in Children With Epilepsy||Children's Hospital Boston|Yes|Completed|May 2003|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|6 Years|18 Years|No|||July 2013|July 31, 2013|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323947||182631|
NCT00323297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481243|Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension|A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah)||Pfizer|Yes|Completed|September 2006|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|May 5, 2006|Yes|Yes||No|August 23, 2013|https://clinicaltrials.gov/show/NCT00323297||182681|
NCT00323570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7TRAUMA-1648|Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma|A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ NiaStase®) in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients||Novo Nordisk A/S|No|Withdrawn|May 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||March 2012|June 26, 2012|May 8, 2006||||No||https://clinicaltrials.gov/show/NCT00323570||182660|
NCT00323544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-MC-164-0111|SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection|A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Twice Daily co-Formulated Zidovudine and Lamivudine (Combivir®) or Zidovudine and Lamivudine, in Virologically Suppressed, HIV Infected Patients Taking Efavirenz||Gilead Sciences|No|Completed|October 2004|October 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|18 Years|N/A|No|||June 2008|June 30, 2008|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00323544||182662|
NCT00323557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0605|Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients|Immuno-Augmentation With GM-CSF in Patients Receiving Pneumococcal Vaccine While Undergoing Treatment for Advanced Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Completed|June 2004|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|N/A|N/A|No|||December 2012|December 3, 2012|May 5, 2006||No||No|April 6, 2012|https://clinicaltrials.gov/show/NCT00323557||182661|
NCT00324259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0412 / 201108392|Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer|A Phase II Randomized Study of Physiological (6 mg Daily) and High Dose (30 mg Daily) Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer||Washington University School of Medicine|No|Completed|August 2004|August 2014|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|18 Years|N/A|No|||January 2015|January 29, 2015|May 8, 2006|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT00324259||182607|The slight imbalance in numbers assigned to the 2 groups was a because of yearly data and safety monitoring, which led to early closure of the 30mg group for toxicity concerns after 32 patients had been enrolled.
NCT00320437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|terror HMO-CTIL|Intergenerational Transmission of Terror|The Intergenerational Transmission of Trauma From Terror: A Developmental Perspective||Hadassah Medical Organization||Not yet recruiting|May 2007|December 2008|Anticipated|||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|300|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2006|November 29, 2006|April 30, 2006||||No||https://clinicaltrials.gov/show/NCT00320437||182894|
NCT00324246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-7-28-1 CTIL|Feasibility Study of the NEW NORMA-SENSE|Feasibility Study of the NEW NORMA-SENSE Indicator Strip and Vaginal Secretion Buffer Capacity Measurement - IN-VITRO Study.||Carmel Medical Center|Yes|Completed|September 2006|December 2007|Actual|||Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|160|None Retained|Vaginal secretions.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Women, age between 18 years and 45 years with or without symptoms of vaginal infection.|January 2007|June 19, 2008|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00324246||182608|
NCT00324779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466643|Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia|Multicenter Therapy Study for Children With Mature B-NHL or B-ALL With a Rituximab - Window Before Chemotherapy||National Cancer Institute (NCI)||Completed|March 2004|||April 2011|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|79|||Both|N/A|18 Years|No|||September 2015|September 24, 2015|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00324779||182569|
NCT00325156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100917|Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants|An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants.||GlaxoSmithKline||Completed|November 2004|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2590|||Both|11 Weeks|17 Weeks|Accepts Healthy Volunteers|||November 2012|November 8, 2012|February 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325156||182543|
NCT00317317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002651-01A1|The Effect of Acupuncture on Infertility With In-Vitro Fertilization (IVF) Patients|Acupuncture for Infertility Patients: The Effect on IVF||National Center for Complementary and Integrative Health (NCCIH)|Yes|Active, not recruiting|October 2005|November 2009|Anticipated|November 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Female|21 Years|N/A|No|||August 2009|August 27, 2009|April 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00317317||183131|
NCT00318396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-002a-SKO|Compaction Femur Preparation for Cementless Total Hip Arthroplasty (THA) Unilateral|Compaction Femur Total Hip Arthroplasty (THA) Uni-lateral||Northern Orthopaedic Division, Denmark|Yes|Active, not recruiting|June 2004|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|70 Years|No|||March 2015|March 19, 2015|April 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00318396||183049|
NCT00328640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM 0620 0404|Quality Improvement in Stroke Prevention (QUISP)|Secondary Prevention After Ischemic Stroke: A Trial of an Evidence-Based System-Wide Intervention||University of California, San Francisco|Yes|Completed|December 2005|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||1500|||Both|50 Years|N/A|No|||April 2007|April 25, 2007|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328640||182282|
NCT00328939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI105316|ARIXTRA Local Study For Registration In China.|Randomized, Single Blind, Parallel Study to Compare the Safety and Efficacy of ARIXTRA to Enoxaparine in Patients Undergoing Elective Major Hip or Knee Replacement or a Revision of Components.||GlaxoSmithKline||Completed|May 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||240|||Both|18 Years|75 Years|No|||February 2011|May 31, 2012|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00328939||182259|
NCT00317499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021630|Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis|Double-Blind, Randomized, Placebo-Controlled Study of Etanercept (ENBREL) in the Treatment of Psoriatic Arthritis (PsA) and Psoriasis||Amgen||Completed|April 2000|July 2002|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|205|||Both|18 Years|70 Years|No|||December 2010|December 22, 2010|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317499||183117|
NCT00317512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-0001|Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization|A Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Dose Finding Pilot Study, to Evaluate Safety/Feasibility of HBOC-201 in Elective Percutaneous Coronary Revascularization of Subjects With Acute Coronary Syndromes||Biopure Corporation|Yes|Completed|December 2003|July 2007|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|75 Years|No|||May 2008|May 15, 2008|April 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00317512||183116|
NCT00317733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-II-03|Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee|A Double-Blind, Placebo-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 (Ketoprofen in Transfersome) in Comparison to Oral Celecoxib for the Treatment of Pain Associated With Osteoarthritis of the Knee||IDEA AG||Completed||January 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|40 Years|N/A|No|||March 2009|March 19, 2009|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317733||183099|
NCT00322153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-50|A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type||Forest Laboratories|No|Completed|June 2005|January 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|677|||Both|50 Years|N/A|No|||August 2010|August 25, 2010|May 3, 2006|Yes|Yes||No|July 20, 2010|https://clinicaltrials.gov/show/NCT00322153||182768|
NCT00322166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402639|The FREEDOM Study: a Randomised Controlled Trial of Sunlight and Calcium in Older People|A Randomised Controlled Trial of Sunlight and Calcium Supplementation to Reduce Vitamin D Deficiency and Falls in Older People in Residential Care||University of Sydney|No|Completed|July 2006|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|70 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 20, 2009|May 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00322166||182767|
NCT00322387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-2104|Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients|Treatment With Plerixafor in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given With A Mobilizing Regimen of Chemotherapy and G-CSF||Sanofi|Yes|Completed|April 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|May 4, 2006|No|Yes||No|June 15, 2010|https://clinicaltrials.gov/show/NCT00322387||182750|The number and complexity of the cohorts make generalizations regarding the data problematic. Each cohort was small, and mobilizing and high-dose conditioning regimens varied across sites. AEs may include residual effects of chemotherapy.
NCT00322647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4904C|Cancer Center Trials: Reasons for Low Accrual Rates at One Academic Institution Vs. The Community Setting|Cancer Center Trials: Reasons for Low Accrual Rates at One Academic Institution Vs. The Community Setting||University of New Mexico|Yes|Completed|January 2005|June 2007|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|20|||Female|18 Years|N/A|No|Probability Sample|Patients with cancer.|April 2008|January 6, 2010|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322647||182730|
NCT00319592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-040-008|A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX|Randomized, Double-blind, Phase II Study of the Safety, Tolerability and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax™ JE) Compared With Mouse Brain-derived Inactivated JE Vaccine (JE VAX®).||Sanofi|No|Completed|May 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|48 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|April 28, 2006|Yes|Yes||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00319592||182959|
NCT00319605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01242|Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam|Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)||UCB Pharma||Completed|April 2006|July 2006|Actual|July 2006|Actual|Phase 4|Observational|Time Perspective: Retrospective||1|Anticipated|600|||Both|16 Years|N/A|No|Non-Probability Sample|Study populaton is defined. See Eligibility Criteria.|May 2012|May 24, 2012|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00319605||182958|
NCT00319579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-204|A Prospective Study of Living Kidney Donation|The Long Term Medical and Psychological Implications of Becoming a Living Kidney Donor: A Prospective Pilot Study||Lawson Health Research Institute|No|Active, not recruiting|January 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Serum and urine samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Living Kidney Donors|March 2015|March 31, 2015|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319579||182960|
NCT00323895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC05-02|The Intra-Drug Eluting Stent (DES) Restenosis Study|A Prospective, Randomized, Multi-Center Comparison of the CYPHER Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients With Intra-Des Restenosis|CRISTAL|Cordis Corporation|Yes|Completed|March 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|320|||Both|18 Years|N/A|No|||July 2010|July 28, 2010|May 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323895||182635|
NCT00323908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9933|Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer|QM-MSP, Ki-67, and Cytomorphology of RPFNA Specimens From High Risk Women||University of Kansas Medical Center|No|Completed|June 2005|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|281|||Female|18 Years|N/A|No|Non-Probability Sample|medical center|February 2012|February 6, 2012|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323908||182634|
NCT00320450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA1100849|SB-681323 In Subjects With Rheumatoid Arthritis|A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA)||GlaxoSmithKline|No|Completed|November 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|78|||Both|18 Years|N/A|No|||May 2012|October 31, 2013|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00320450||182893|
NCT00324532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB 07 2005|to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD|An Open Label, Non Comparative, Prospective Pilot Study, to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD||BioBalance Corporation||Completed|May 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|80 Years|No|||May 2006|January 26, 2015|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324532||182587|
NCT00321022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-020|Transient Ischemic Attack (TIA) Accelerated Diagnostic Protocol|Costs and Outcomes of an Emergency Department-based Accelerated Diagnostic Protocol vs Hospitalization for Patients With Transient Ischemic Attack: a Randomized Controlled Trial.||William Beaumont Hospitals||Completed|August 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||154|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|March 16, 2012|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00321022||182851|
NCT00321243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 05-213|Evaluation of Emergency Triage Using a Computerized Simulator|Evaluation of a Four-Level Triage Scale (the Geneva Emergency Triage Scale) Using a Computer Triage Simulator||University Hospital, Geneva||Completed|May 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||150|||Both|18 Years|65 Years|No|||June 2008|June 3, 2008|February 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00321243||182834|
NCT00317889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-002b-SKO|Compaction Total Hip Arthroplasty (THA) Bilateral|Compaction THA Bilateral||Northern Orthopaedic Division, Denmark||Active, not recruiting|May 2001|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||January 2016|January 21, 2016|April 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00317889||183088|
NCT00318136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3744g|A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)|A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer||Genentech, Inc.||Completed|September 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||May 2010|May 5, 2010|April 24, 2006|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00318136||183069|
NCT00321477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKB105022|A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder|See Detailed Description||GlaxoSmithKline|No|Completed|December 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Female|18 Years|75 Years|No|||March 2011|May 31, 2012|May 1, 2006||||||https://clinicaltrials.gov/show/NCT00321477||182816|
NCT00321789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-273|A Patient-Spouse Intervention for Self-Managing High Cholesterol|A Patient-Spouse Intervention for Self-Managing High Cholesterol|CouPLES|VA Office of Research and Development|No|Completed|September 2007|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|255|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2014|April 6, 2015|May 3, 2006||No||No|September 2, 2014|https://clinicaltrials.gov/show/NCT00321789||182794|The dietary measure underestimates dietary intake but should not invalidate differences between groups or across time. Sample size for dietary analyses was reduced due to missing data, but non-responders did not differ on measured characteristics.
NCT00321490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00002|Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD|DIAMOND|AstraZeneca||Completed|April 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00321490||182815|
NCT00321802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18108|Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins|Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins|PAFRIOSIES|University of Calgary|No|Completed|April 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 30, 2014|May 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00321802||182793|
NCT00321815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8501006|Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer|A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen||Pfizer|No|Completed|August 2006|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||December 2010|December 16, 2010|May 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00321815||182792|
NCT00318318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-710|Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed by Human Genome Array|Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed by Human Genome Array||Lawson Health Research Institute|No|Completed|March 2006|February 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Female|35 Years|95 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|April 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00318318||183055|
NCT00318604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94042|Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker|||Far Eastern Memorial Hospital||Not yet recruiting||||||N/A|Observational|Time Perspective: Longitudinal|||||||Both|18 Years|90 Years|No|||April 2006|May 11, 2006|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318604||183034|
NCT00317746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN194|Trial of Citalopram for the Prevention of Depression|A Randomized, Placebo Controlled Trial of Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Co-infected Individuals Initiating Pegylated Interferon/Ribavirin Therapy|PICCO|McGill University Health Center|Yes|Completed|November 2006|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|76|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|April 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00317746||183098|
NCT00322686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC-MD-03|Study of Oglemilast for the Treatment of Asthma|Efficacy and Safety of Oglemilast in the Prevention of Allergen-induced Bronchospasm||Forest Laboratories|No|Completed|May 2006|||December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|50 Years|No|||March 2012|March 16, 2012|May 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00322686||182727|
NCT00322699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBPDT-577-04|Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer|Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer||North Florida/South Georgia Veterans Health System|Yes|Completed|February 2005|March 2011|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|October 25, 2012|May 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00322699||182726|
NCT00322400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050200|Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer|An Open-label, Dose-finding Study to Evaluate the Safety of AMG 706 in Combination With Paclitaxel or Docetaxel as Treatment for Locally Recurrent or Metastatic Breast Cancer||Amgen|No|Completed|March 2006|January 2012|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|46|||Female|18 Years|N/A|No|||July 2013|July 30, 2013|May 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00322400||182749|
NCT00322660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005091|Adrenaline Injections to Children Born at Elective CS|Can the Risk of RD and Hypoglycemia in Children Born at Elective CS be Reduced by Injection of Adrenaline||Hvidovre University Hospital|Yes|Completed|June 2006|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|270|||Both|N/A|1 Day|Accepts Healthy Volunteers|||June 2007|June 27, 2007|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00322660||182729|
NCT00322673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-207|Study of XL999 in Patients With Acute Myeloid Leukemia (AML)|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia||Symphony Evolution, Inc.|Yes|Terminated|May 2006|May 2007|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|May 4, 2006|Yes|Yes|Study was terminated due to cardiac toxicities|No||https://clinicaltrials.gov/show/NCT00322673||182728|
NCT00320177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040050|Eating Behavior in Children|Eating Behavior in Children||National Institutes of Health Clinical Center (CC)||Completed|November 2003|October 2014||||N/A|Observational|N/A|||Actual|263|||Both|8 Years|17 Years|No|||October 2014|October 29, 2014|April 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00320177||182914|
NCT00319904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000560|The Partners Genetics Collaborative Study of Schizophrenia|The Partners Genetics Collaborative Study of Schizophrenia||Massachusetts General Hospital|No|Active, not recruiting|March 2001|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|DNA is extracted and stored for future anaysis of genes that may be associated with      schizophrenia|Both|18 Years|70 Years|No|Non-Probability Sample|Adults with Schizophrenia|March 2016|March 16, 2016|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319904||182935|
NCT00319917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-506-RA05|A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients|FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients||Astellas Pharma Inc||Completed|April 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|20 Years|64 Years|No|||August 2014|August 19, 2014|April 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00319917||182934|
NCT00319930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNF1010-CLL-05001|Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(Allylamino)-17-demethoxy-geldanamycin [17-AAG]) in Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL)||Biogen||Terminated|May 2005|May 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|18 Years|N/A|No|||March 2010|March 4, 2010|April 27, 2006|||Discontinuation of program|||https://clinicaltrials.gov/show/NCT00319930||182933|
NCT00319878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5403|Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia|A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia||Office of Rare Diseases (ORD)||Recruiting|May 2006|December 2009|Anticipated|July 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|21 Years|N/A|No|||October 2008|October 6, 2008|April 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319878||182937|
NCT00319891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUT-109-2005|Computer-Based Training for Mild Alzheimer's Disease|Computer-Based Training for Mild Cognitive Impairment and Mild Alzheimer's Disease||Posit Science Corporation||Completed|September 2004|October 2006||October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|60 Years|90 Years|No|||May 2013|May 13, 2013|April 27, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00319891||182936|
NCT00320164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dendritic Cells|Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals|Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals||Weill Medical College of Cornell University|No|Withdrawn|January 2006|January 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group A is for leukapheresis and Group B is for buffy coats collection. We will use either        Group A or Group B or both to collect mononuclear cells. The source of potential subjects        in both groups will be normal individuals recruited from the population of healthy        individuals in the New York metropolitan area and elsewhere. Accrual will be random with        no bias as to gender or racial/ethnic group. Nevertheless, because the accrual process        will be random, it is possible that among the study individuals there may be differences        in the proportion of males and females, and racial/ethnic groups. The study volunteers        will be recruited through IRB approved advertisements placed in local newspapers and on        fliers to be circulated throughout the New York Metropolitan area and elsewhere. All        efforts will be made to recruit women and minorities.|September 2010|September 24, 2010|April 27, 2006||No|research priority change|No||https://clinicaltrials.gov/show/NCT00320164||182915|
NCT00320736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC 20-01|Galantamine for Cognition in People With Schizophrenia|Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder||North Suffolk Mental Health Association||Completed|January 2004|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00320736||182872|
NCT00321035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking0501-1|Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital|Study of the Safety and Effectiveness of the OculusGen Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery||Pro Top & Mediking Company Limited||Completed|December 2005|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||May 2008|May 21, 2008|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00321035||182850|
NCT00321256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011226/DGS-2001/0195|Human Islet Transplantation in Brittle Type 1 Diabetes Mellitus. The GRAGIL 2 Study.|Transplantation d'Ilots Pancreatiques Allogeniques Adultes Pour le Traitement du Diabete Insulino-dependant: Etude GRAGIL 2.||University Hospital, Grenoble||Completed|July 2003|July 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|18 Years|65 Years|No|||March 2012|March 1, 2012|May 2, 2006||||No||https://clinicaltrials.gov/show/NCT00321256||182833|
NCT00321594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00141|Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|A Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation||National Cancer Institute (NCI)|Yes|Completed|May 2006|||August 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||December 2012|January 30, 2013|May 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00321594||182807|
NCT00321620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050103|Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer||Amgen|Yes|Completed|April 2006|February 2012|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|1904|||Male|18 Years|N/A|No|||February 2016|February 19, 2016|May 2, 2006||Yes||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00321620||182806|
NCT00318747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN031AD|Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug|Asthma Immunotherapy With a Ragweed Allergen Immunostimulatory Sequence Conjugate||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|April 2006|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|65 Years|No|||February 2013|February 1, 2013|April 25, 2006|||Poor enrollment|||https://clinicaltrials.gov/show/NCT00318747||183023|
NCT00321191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02531|Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients|Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients||Austin Health||Completed|May 2006|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|N/A|No|||August 2008|June 23, 2015|May 2, 2006||||No||https://clinicaltrials.gov/show/NCT00321191||182838|
NCT00321503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1345-2005|Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)|Diagnosis and Response to Treatment of Laryngopharyngeal Reflux Using an Oropharyngeal Aerosolized pH Probe||Emory University||Completed|May 2006|May 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pos controls: Subjects visiting the Emory Clinic/Emory Voice center with LPR symptoms.        Neg controls: Random subjects in Atlanta without LPR symptoms. See other descriptions for        more details.|December 2013|December 6, 2013|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321503||182814|
NCT00321217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pharmacogenomics of anti-TNF|Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis|Pharmacogenomics of Anti-TNF Treatment in Patients With Rheumatoid Arthritis||Radboud University|No|Recruiting|May 2004|April 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Probability Sample|Patients with RA according to the ACR criteria who are treated with monoclonal anti-TNF        antibodies.|November 2011|August 15, 2012|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321217||182836|
NCT00317551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VisionCRC-ARU|Cambridge Anti-Myopia Trial: Accommodation Training and Aberration Control in Myopia Development|Accommodation Training and Aberration Control in Myopia Development||Anglia Ruskin University||Completed|April 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||December 2005|October 16, 2006|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317551||183113|
NCT00318942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM01020|Efficacy and Safety of Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients|CRISTAL: Colloids Compared to Crystalloids in Fluid Resuscitation of Critically Ill Patients: A Multinational Randomised Controlled Trial||University of Versailles|Yes|Completed|February 2003|November 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2857|||Both|18 Years|N/A|No|||June 2014|June 29, 2014|September 2, 2005||No||No||https://clinicaltrials.gov/show/NCT00318942||183009|
NCT00317759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1796.00|Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Fludarabine Lymphodepletion for Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center||Completed|May 2003|October 2008|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|75 Years|No|||May 2010|September 30, 2015|April 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00317759||183097|
NCT00317772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0322|Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I/II Study of Weekly Topotecan and Gefitinib (Iressa) in Patients With Platinum-Resistant Ovarian, Peritoneal, of Fallopian Tube Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2004|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Female|N/A|N/A|No|||October 2015|October 22, 2015|April 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00317772||183096|
NCT00318669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIR104776|Social Anxiety Disorder Study Of Paroxetine|Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study>||GlaxoSmithKline|No|Completed|December 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|390|||Both|18 Years|64 Years|No|||July 2012|April 11, 2013|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318669||183029|
NCT00322946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 221|Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2007|||August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2008|August 5, 2009|May 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00322946||182707|
NCT00323310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 110|Safety and Efficacy of MultiHance in Pediatric Patients|A Phase III Multi-Center Open Label Study to Evaluate Safety and Efficacy of MultiHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients||Bracco Diagnostics, Inc|No|Terminated|April 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|92|||Both|2 Years|17 Years|No|||October 2010|October 13, 2010|May 5, 2006|Yes|Yes|Adequate statistical power at 92 dosed pts to meet study objectives.|No|August 16, 2010|https://clinicaltrials.gov/show/NCT00323310||182680|
NCT00323323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0303|CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas|A Phase I Study of CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|March 2004|||August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323323||182679|
NCT00321308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8501004|Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer|A Randomized Phase II Trial Of Pemetrexed With Or Without PF-3512676 For The Treatment Of Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer After Failure Of One Prior Chemotherapy Regimen For Advanced Disease||Pfizer|No|Terminated|September 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|May 2, 2006|Yes|Yes|See Termination Reason in Detailed Description.|No||https://clinicaltrials.gov/show/NCT00321308||182829|
NCT00321321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-05011|The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes|Phase 2 Study of The Beta Cell Responsiveness to GIP With and Without Sulfonylurea in Patients With Type 2 Diabetes||University Hospital, Gentofte, Copenhagen|Yes|Completed|May 2006|April 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||September 2008|June 23, 2015|May 2, 2006||No||No|September 29, 2008|https://clinicaltrials.gov/show/NCT00321321||182828|
NCT00320476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMM52|VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates|Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed By Melphalan, Prednisone, Thalidomide (MPT) Maintenance As a First Line Treatment For The Patients With Multiple Myeloma Who Are Non-Transplant Candidates||Korean Multiple Myeloma Working Party|Yes|Completed|April 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|65 Years|75 Years|No|||April 2006|May 5, 2008|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00320476||182891|
NCT00320762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking0501-2|Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital|Study of the Safety and Effectiveness of the Ologen (OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery||Pro Top & Mediking Company Limited||Completed|January 2006|||December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||May 2008|May 21, 2008|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320762||182870|
NCT00321269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-082|Depression and Congestive Heart Failure in Outpatients.|Depression and CHF in Outpatients||VA Office of Research and Development|No|Completed|October 2007|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|134|||Both|45 Years|N/A|No|||November 2015|November 23, 2015|May 1, 2006||No||No|November 12, 2014|https://clinicaltrials.gov/show/NCT00321269||182832|
NCT00320463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105910|Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants|Compare Immunogenicity & Reactogenicity of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (New vs Current) Given in Healthy Infants. The DTPa-HBV-IPV Vaccine (New Formulation) Will Also be Assessed in a 3rd Group of Subjects||GlaxoSmithKline||Completed|April 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||415|||Both|11 Weeks|17 Weeks|Accepts Healthy Volunteers|||November 2012|November 21, 2012|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00320463||182892|
NCT00320749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-05058|Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer|A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|December 2005|January 2011|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|April 28, 2006|Yes|Yes||No|September 15, 2015|https://clinicaltrials.gov/show/NCT00320749||182871|
NCT00317876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.00|Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia|Dose-Finding Study for Cyclophosphamide as Conditioning Regimens for Bone Marrow Transplantation From Related Donors in Patients With Fanconi Anemia||Fred Hutchinson Cancer Research Center||Completed|June 1998|||July 2003|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|N/A|N/A|No|||April 2012|April 18, 2012|April 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00317876||183089|
NCT00318123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAKE|Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients|Multicentre, Open Label, Prospective, Randomised Clinical Trial to Evaluate the Effectiveness of Abacavir 600 mg+ Lamivudine 300 mg as QD+ Efavirenz 600 mg QD Versus Kaletra 400/100 mg BID as Initial Antiretroviral Treatment||Germans Trias i Pujol Hospital|No|Completed|April 2004|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|80 Years|No|||January 2008|January 25, 2008|April 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00318123||183070|
NCT00318448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6820|Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia|Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study|Zolkids|Sanofi||Completed|April 2006|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|201|||Both|6 Years|17 Years|No|||April 2009|April 6, 2009|March 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00318448||183045|
NCT00320372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRD Registry|Treatment-Resistant Depression Registry|A Long-term, Prospective, Observational, Multi-center Patient Outcome Registry to Collect Data in Patients With Treatment-resistant Depression (TRD) Who Are Currently in a Major Depressive Episode.||Cyberonics, Inc.|No|Completed|January 2006|May 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|795|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic depression that is at least two years in duration or a recurrent        depression that includes at least three lifetime episodes including the current major        depressive episode (MDE); and an inadequate response to four or more adequate        antidepressant treatments.|December 2015|December 22, 2015|May 1, 2006|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT00320372||182899|
NCT00321542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-DM|Coronary CT Angiography in Asymptomatic Diabetes Mellitus|Assessment of the Additive Value of Multislice Computed Tomographic Angiography of the Coronary Arteries in the Prediction of Acute Cardiac Events in Asymptomatic Individuals With Type II Diabetes Mellitus||Carmel Medical Center|Yes|Active, not recruiting|September 2006|September 2017|Anticipated|September 2015|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|793|||Both|55 Years|74 Years|No|Non-Probability Sample|Type 2 diabtes mellitus, age 55-74 yrs, no known coronary artery disease|February 2015|July 28, 2015|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321542||182811|
NCT00317252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005|Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization|Angiotensin Converting Enzyme Inhibitors and Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization "The CAPTAIN Trial"||McMaster University|No|Completed|July 2006|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Both|N/A|N/A|No|||October 2012|October 19, 2012|April 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00317252||183136|
NCT00317265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK NR-348/98|Coronary Bypass Surgery Trial: Complete Arterial Revascularization and Conventional Coronary Artery Surgery|Complete Arterial Revascularization and Conventional Coronary Artery Surgery Study (CARACCASS)-European Multicenter Study||Medical University of Vienna||Terminated|January 1999|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Both|18 Years|71 Years|No|||March 2006|October 12, 2006|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00317265||183135|
NCT00318071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-LR-001|Multi MERCI (Mechanical Embolus Removal in Cerebral Ischemia [MERCI™])|A Multinational Controlled Registry to Evaluate the Concentric Merci Retriever System (Mechanical Embolus Removal in Cerebral Ischemia [MERCI™])|Multi-MERCI|Stryker Neurovascular|Yes|Completed|January 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|164|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|July 14, 2005|No|Yes||No||https://clinicaltrials.gov/show/NCT00318071||183074|
NCT00328159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030435|Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids|Dietary Therapy of Mitochondrial Fatty Acids Oxidation. A Clinical Study of Treatment With Odd Carbons Medium-chain Fatty Acids||Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||March 2007|February 16, 2011|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328159||182317|
NCT00328172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.5|Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients|A Randomized, Double-blind, Placebo-controlled, Five Parallel Group Study Investigating the Efficacy and Safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg Administered Orally Once Daily) Over 12 Weeks in Drug Naive and Treated Patients With Type 2 Diabetes With Insufficient Glycemic Control (Study Includes an Open-label Metformin Treatment Arm)||Boehringer Ingelheim||Completed|May 2006|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|302|||Both|21 Years|75 Years|No|||February 2014|February 15, 2014|May 18, 2006|||||May 13, 2011|https://clinicaltrials.gov/show/NCT00328172||182316|
NCT00319293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160350-2|Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome|||Aarhus University Hospital Skejby||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|20 Years|35 Years|No|||October 2006|October 10, 2006|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00319293||182982|
NCT00319306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00012|Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy|Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy|RELEASE|AstraZeneca||Completed|September 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||550|||Both|18 Years|N/A|No|||March 2009|March 16, 2009|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319306||182981|
NCT00319007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23266|Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis|Adenoma-Carcinoma Sequence in the Ileal Pouch Anal Anastomosis in Patients With Familial Adenomatous Polyposis: Studies on Luminal and Mucosal Risk Factors and Chemoprevention||Radboud University||Recruiting|April 2006|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|30|||Both|16 Years|N/A|No|||August 2007|August 9, 2007|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319007||183004|
NCT00319358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR-131|Role of Antioxidants Supplementation in Chronic Pancreatitis|Effect of Antioxidant Supplementation on Pain, Antioxidant Profile and Oxidative Stress in Patients With Chronic Pancreatitis||All India Institute of Medical Sciences, New Delhi|Yes|Completed|October 2003|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|12 Years|70 Years|No|||January 2009|January 28, 2009|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00319358||182977|
NCT00318981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-2003-023|Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD|Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD||University of Maryland||Active, not recruiting|December 2004|December 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Female|N/A|N/A|No|||September 2006|September 8, 2006|April 25, 2006||||||https://clinicaltrials.gov/show/NCT00318981||183006|
NCT00318994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3591/9010|Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis|Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis||AstraZeneca||Completed|February 2002|May 2007|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|N/A|N/A|No|||January 2008|January 11, 2008|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00318994||183005|
NCT00319345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUN-LM-0001|Sodium-Lactate and Traumatic Brain Injury|Sodium-Lactate Versus Mannitol in the Treatment of Intracranial Hypertensive Episodes in Severe Traumatic Brain Injured Patients||Institut d'Anesthesiologie des Alpes Maritimes||Terminated|November 2003|November 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||34|||Both|18 Years|65 Years|No|||April 2006|June 22, 2010|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319345||182978|
NCT00321100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-GI-002|Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab|Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer||Fox Chase Cancer Center|Yes|Terminated|April 2006|December 2013|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|May 1, 2006||No|Enrollment closed 10/15/2008 based on data about KRAS.|No||https://clinicaltrials.gov/show/NCT00321100||182845|
NCT00321282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|076-2006|A Retrospective Analysis of the Predictive Potential of Pre-operative|A Retrospective Analysis of the Predictive Potential of Pre-operative Data on Post-operative Atrial Fibrillation||Emory University|No|Terminated|February 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|65 Years|No|||September 2013|September 26, 2013|May 1, 2006||No|The study never started.|No||https://clinicaltrials.gov/show/NCT00321282||182831|
NCT00321295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2004-083|Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery|Prospective Evaluation Of Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery||William Beaumont Hospitals||Completed|August 2004|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2011|April 2, 2011|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00321295||182830|
NCT00321646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-438|Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy|A Phase II Study of Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy||Dana-Farber Cancer Institute|Yes|Completed|June 2006|December 2012|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|18 Years|N/A|No|||November 2013|November 6, 2013|May 2, 2006|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT00321646||182804|
NCT00321633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000467994|Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer|A Randomized Phase II Pilot Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic Genetic Breast Cancer [BRCA Trial]||National Cancer Institute (NCI)||Completed|September 2005|||September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|148|||Female|N/A|N/A|No|||July 2009|August 23, 2013|May 2, 2006||||No||https://clinicaltrials.gov/show/NCT00321633||182805|
NCT00317603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-111|Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients|A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Metastatic Breast Cancer Patients||Dana-Farber Cancer Institute||Active, not recruiting|November 2005|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|April 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00317603||183109|
NCT00317616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1369-2005|The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study|The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study|Pre-fALS|University of Miami|No|Recruiting|April 2006|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Serum, Plasma, CSF, DNA, Urine, Cell lines|Both|18 Years|N/A|No|Non-Probability Sample|Healthy individuals who harbor a mutation in a gene associated with ALS.|March 2016|March 9, 2016|April 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00317616||183108|
NCT00320970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI831|Angiotensin II Antagonism of TGF-Beta 1|Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study||Providence Health & Services||Completed|August 2002|September 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|August 1, 2007|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00320970||182855|
NCT00320983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1601C|Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer|A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer||University of New Mexico|Yes|Completed|March 2002|December 2005|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|N/A|N/A|No|||October 2008|January 6, 2010|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00320983||182854|
NCT00317538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003136|Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept|Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept||Centocor Ortho Biotech Services, L.L.C.||Completed|June 2003|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|April 21, 2006||||||https://clinicaltrials.gov/show/NCT00317538||183114|
NCT00318617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD100964|Effect Of GW501516X On How The Heart Obtains And Uses Energy|A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects||GlaxoSmithKline||Terminated|December 2005|||||N/A|Observational|N/A||1||30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|April 25, 2006||||||https://clinicaltrials.gov/show/NCT00318617||183033|
NCT00318630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104385|The Effect Of AVANDIA On The Late Asthmatic Response|A Randomised Double-blind Two-period Crossover Study to Investigate the Effect of Treatment With Repeat Doses of a PPAR Gamma Agonist on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma Compared With Repeat Doses of Placebo.||GlaxoSmithKline||Completed|July 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||34|||Both|18 Years|55 Years|No|||December 2009|December 10, 2009|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318630||183032|
NCT00327678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAALL 2005|Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults|Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph||Group for Research in Adult Acute Lymphoblastic Leukemia|No|Recruiting|May 2006|January 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1080|||Both|18 Years|59 Years|No|||January 2013|January 29, 2013|May 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00327678||182353|
NCT00319020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-367|Bosentan in Children With Pulmonary Arterial Hypertension Extension Study|An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed AC-052-365 (Future 1)||Actelion||Completed|August 2005|March 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|2 Years|12 Years|No|||April 2013|April 8, 2013|April 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319020||183003|
NCT00320190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-043|Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib|An Open-label, Randomized Study of Dasatinib vs High-dose (800-mg) Imatinib in the Treatment of Subjects With Chronic Phase Chronic Myeloid Leukemia Who Have Had a Suboptimal Response After at Least 3 Months of Therapy With 400 mg Imatinib||Bristol-Myers Squibb|No|Terminated|August 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||July 2011|October 1, 2013|May 1, 2006|Yes|Yes|Terminated due to slow participant accrual|No|June 6, 2011|https://clinicaltrials.gov/show/NCT00320190||182913|Enrollment terminated prematurely on September 5, 2008, due to slow accrual. Only 32 of 156 planned participants were randomized from August 2, 2006. Per BMS standards, findings were reported in a synopsis format, with only safety results included.
NCT00319618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0128|Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer|A Randomised Phase II Study: Treatment With Daily p.o. Iressa™ (ZD1839) or Placebo in Combination With Weekly IV Infusion of Docetaxel in Patients With Metastatic Breast Cancer||AstraZeneca||Completed|June 2003|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Female|18 Years|N/A|No|||December 2007|December 14, 2007|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319618||182957|
NCT00319631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGF in ARDS|Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)|Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)||Weill Medical College of Cornell University|Yes|Recruiting|January 2006|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|32|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects for the study will be drawn from endotracheally intubated inpatients of The New        York Presbyterian Hospital-Weill Cornell Medical Center diagnosed with ALI or ARDS or who        are at risk for developing ARDS.|February 2011|February 18, 2011|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319631||182956|
NCT00319943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUT-108-2005|Computer-Based Therapy for Mild Cognitive Impairment|Computer-Based Therapy for Mild Cognitive Impairment||Posit Science Corporation||Completed|September 2004|July 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|65 Years|90 Years|No|||April 2006|April 27, 2006|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319943||182932|
NCT00321113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-02-IT-01|Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys|An Open, Multicentre, Randomised, Parallel Group Study to Compare in Marginal Old-for-Old Renal Transplant Patients the Safety and Efficacy of Two Treatments: Sequential Mycophenolate Mofetil/Delayed Tacrolimus Plus Steroids vs Tacrolimus Plus Mycophenolate Mofetil in Patients Requiring Induction With Anti-IL2 Antibody|TIGRE|Astellas Pharma Inc|No|Completed|September 2004|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|60 Years|N/A|No|||April 2009|April 7, 2009|May 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00321113||182844|
NCT00321048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0609|Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator|Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|June 2006|October 2017|Anticipated|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|November 25, 2014|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00321048||182849|
NCT00321061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060149|Phase I Study of Vaccination Schedule of Experimental HIV Vaccines|VRC 011: A Phase I Clinical Trial of Intramuscular, Subcutaneous and Intradermal Administration of an HIV-1 Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, and an HIV-1 Multiclade Adenoviral Vector Vaccine,VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|April 2006|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|50 Years|No|||December 2009|December 3, 2009|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321061||182848|
NCT00321074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-01-IT-02|Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts|AN OPEN, MULTICENTRE, RANDOMISED PARALLEL GROUP CLINICAL STUDY TO COMPARE SAFETY AND EFFICACY OF TACROLIMUS (FK506) WITH MONOCLONAL ANTI-IL2R ANTIBODIES (DACLIZUMAB) VS TACROLIMUS (FK506) WITH STEROIDS AND EVALUATE PHARMACOKINETICS IN LIVER ALLOGRAFT RECIPIENTS RECEIVING SUBOPTIMAL LIVERS|PANTERA|Astellas Pharma Inc|No|Completed|May 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|May 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00321074||182847|
NCT00317356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-05-002|A Dose-Finding Study of OPC-6535 in Patients With Active Ulcerative Colitis|A Dose-Finding Study of OPC-6535 in Patients With Active Ulcerative Colitis||Otsuka Pharmaceutical Co., Ltd.|No|Terminated|May 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|65 Years|No|||April 2008|April 28, 2008|April 21, 2006||No|Efficacy was not cleared at US study|No||https://clinicaltrials.gov/show/NCT00317356||183128|
NCT00317369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-05-001|A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease|A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease||Otsuka Pharmaceutical Co., Ltd.|No|Terminated|May 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|16 Years|65 Years|No|||April 2008|April 28, 2008|April 21, 2006||No|Efficacy was not cleared at US study|No||https://clinicaltrials.gov/show/NCT00317369||183127|
NCT00321659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR048305|Optimizing Fibromyalgia Self-Management|Short and Long-Term Effects of Exercise and Education as Self-Management in Women With Fibromyalgia||Beth Israel Deaconess Medical Center||Active, not recruiting|October 2002|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|25 Years|75 Years|No|||September 2006|September 29, 2006|May 3, 2006||||No||https://clinicaltrials.gov/show/NCT00321659||182803|
NCT00317902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005131|An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)|An Open-Label Study to Evaluate The Effect of Every Other Week PROCRIT (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients||Ortho Biotech Products, L.P.||Completed|October 2002|May 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|292|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317902||183087|
NCT00317330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-581|A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis|A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||6400|||Both|N/A|N/A|No|||August 2006|August 26, 2010|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00317330||183130|
NCT00317343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI-006-IT|RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)|RIAPRE - A Non-interventional Registry on the Anticoagulation Treatment in High Risk Elective Percutaneous Coronary Interventions||Nycomed|Yes|Withdrawn|March 2006|February 2008|Anticipated|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|90 Years|No|Non-Probability Sample|Primary care clinic|May 2012|May 4, 2012|March 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00317343||183129|
NCT00318422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1436|Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.|LEAD-1|Novo Nordisk A/S|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1041|||Both|18 Years|80 Years|No|||October 2014|October 29, 2014|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318422||183047|
NCT00318435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2646|Fluency Stent-Graft Versus Luminex Stent for Angioplasty of Recurrent Stenosis of the Cephalic Arch in Autogenous Arteriovenous (AV) Access for Hemodialysis|||Shaare Zedek Medical Center||Completed|May 2006|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|15 Years|N/A|No|||April 2006|August 17, 2008|April 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00318435||183046|
NCT00318175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG 002|Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis|Study to Assess the Effect of Bosentan on the Treatment of Skin Fibrosis in Patients With Systemic Sclerosis (BTSF)||Heinrich-Heine University, Duesseldorf||Completed|June 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||September 2007|September 7, 2007|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00318175||183066|
NCT00321555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060150|LMB-2 to Treat Hairy Cell Leukemia|A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia||National Institutes of Health Clinical Center (CC)||Recruiting|April 2006|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|100 Years|No|||January 2016|March 2, 2016|May 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00321555||182810|
NCT00317798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000480087|Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma|A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)||University of Rochester||Completed|April 2006|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|April 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00317798||183094|
NCT00327938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2005.2354|Genetic Variation – The Need for Opioids During Surgery|Genetically Variation – May the Need of Opioids During Surgery be Known Beforehand by Giving Noxious Stimulation and Measure the Skin Conductance Response Before Surgery?||Rikshospitalet University Hospital|No|Completed|May 2006|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Female|18 Years|65 Years|No|||April 2007|April 19, 2007|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00327938||182333|
NCT00327704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFB N°ALBU-0503|Early Albumin Resuscitation During Septic Shock|Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline||Laboratoire français de Fractionnement et de Biotechnologies||Completed|July 2006|January 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|794|||Both|18 Years|80 Years|No|||April 2011|April 5, 2011|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327704||182351|
NCT00319956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0436|Trial II of Lung Protection With Azithromycin in the Preterm Infant|Trial II of Lung Protection With Azithromycin in the Preterm Infant||University of Kentucky|Yes|Completed|September 2004|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Both|N/A|72 Hours|No|||June 2012|June 7, 2012|April 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319956||182931|
NCT00319969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNF3140-SCLC-05004|Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.|A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy||Celgene|No|Completed|April 2006|January 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||September 2009|September 28, 2009|April 27, 2006|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00319969||182930|
NCT00320203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-62|Anecortave Acetate in Patients With Open-angle Glaucoma|A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma||Alcon Research||Completed|March 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|N/A|No|||February 2008|November 27, 2012|May 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00320203||182912|
NCT00320502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BXT-203|A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effects of BXT-51072 on CK-MB in High-Risk Type 2 Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention||Synvista Therapeutics, Inc|No|Completed|May 2006|August 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|30 Years|75 Years|No|||August 2008|August 21, 2008|April 30, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00320502||182889|
NCT00320489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6390|Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia|A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia||Eli Lilly and Company|No|Completed|April 2006|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|524|||Both|18 Years|65 Years|No|||January 2012|January 19, 2012|April 28, 2006|Yes|Yes||No|September 29, 2010|https://clinicaltrials.gov/show/NCT00320489||182890|Results for Outcome Measures 17 and 18 were corrected as a result of an identified programming error.
NCT00320775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0502|Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD|An Exploratory Study of the Safety, Tolerability and Biological Effect of Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration||Regeneron Pharmaceuticals|No|Completed|June 2005|August 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|50 Years|N/A|No|||March 2015|March 16, 2015|April 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00320775||182869|
NCT00321373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107022|Study to Evaluate an Influenza Vaccine Candidate|A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years Old and Above||GlaxoSmithKline||Completed|May 2006|December 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|1220|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 9, 2013|March 16, 2006|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00321373||182824|
NCT00321386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE 05-0169/ER-1|Analysis of Clinical Profiles of Chinese Patients With Normal Tension Glaucoma|Parameters for Disease Progression in Chinese Patients With Normal Tension Glaucoma||Chinese University of Hong Kong|Yes|Recruiting|December 2003|December 2012|Anticipated|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood taking for glaucoma genetics analysis shall be performed.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Normal Tension Glaucoma recruited from a teritary University Eye Hospital        setting.|June 2011|June 27, 2011|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00321386||182823|
NCT00321672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C119|Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy|A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy||NeurogesX|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|494|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|May 2, 2006|Yes|Yes||No|June 16, 2010|https://clinicaltrials.gov/show/NCT00321672||182802|Differences between the 60- and 30-minute Control groups prevented pooling according to prespecified criteria resulting in treatment comparisons between 60- and 30-minute NGX-4010 groups and their respective Control groups with relatively low power.
NCT00321685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01081|Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer|Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|July 2006|May 2020|Anticipated|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||November 2015|February 23, 2016|May 2, 2006|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT00321685||182801|
NCT00321698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000467219|Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer|Phase I/II Study of Preoperative Radiation and Docetaxel Activity in High Risk Localized Prostate Cancer||OHSU Knight Cancer Institute|Yes|Active, not recruiting|January 2006|||October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|N/A|No|||April 2013|April 30, 2013|May 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00321698||182800|
NCT00317629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fcv137|Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis|Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis||Fundación Cardiovascular de Colombia|Yes|Terminated|May 2006|March 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|50 Years|No|||November 2010|November 23, 2010|April 21, 2006||No|An interim analysis showed that nitric oxide patches are not enough effective|No||https://clinicaltrials.gov/show/NCT00317629||183107|
NCT00317382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-148|Does Static Ultrasound-Preview Reduce the Incidence of Difficult Lumbar Puncture?|Does Static Ultrasound-Preview Reduce the Incidence of Traumatic and/or Difficult Lumbar Puncture? A Randomized Control Trial||St. Luke's-Roosevelt Hospital Center|Yes|Terminated|December 2004|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|April 20, 2006||No|We could not get physicians in the ED to enroll patients.|No||https://clinicaltrials.gov/show/NCT00317382||183126|
NCT00317642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO34100405|A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)|A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens||Sanofi|Yes|Completed|August 2006|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|326|||Both|55 Years|N/A|No|||March 2014|March 17, 2014|April 24, 2006|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00317642||183106|
NCT00317655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jointcare/Fe/1/DK|Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain|Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain - a Randomized, Double Blind, Placebo-Controlled Clinical Investigation With Parallel Groups for 3 Months to Enlighten Joint Health||Ferrosan AS||Completed|April 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|175|||Both|30 Years|85 Years|No|||May 2007|May 16, 2007|April 23, 2006||||No||https://clinicaltrials.gov/show/NCT00317655||183105|
NCT00317668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|autoimmunepi-HMO-CTIL|Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients|||Hadassah Medical Organization||Recruiting|November 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|250|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2006|April 29, 2007|April 23, 2006||||No||https://clinicaltrials.gov/show/NCT00317668||183104|
NCT00318149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104886|Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population|Demonstrate the Non-inferiority in Term of Cellular Mediated Immune Response of GSK Biologicals' Influenza Candidate Vaccines Containing Various Adjuvants Administered in Elderly Population (Aged 65 Years &Amp; Older) vs Fluarix™ (Known as Alpha-Rix™ in Belgium) Administered in Adults (18-40 Years)||GlaxoSmithKline||Completed|October 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|425|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 22, 2015|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318149||183068|
NCT00318162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDDLDN-HMO-CTIL|Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)|Randomized Double-Blind Trial of Low-Dose Naltrexone for Children With PDD||Hadassah Medical Organization||Not yet recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|3 Years|6 Years|No|||April 2006|May 2, 2006|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318162||183067|
NCT00318500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142A2-203|Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 75 mg and 150 mg Doses of ERB-041 on the Reduction of Symptoms Associated With Endometriosis During Treatment and Post Treatment in Reproductive-Aged Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Female|18 Years|45 Years|No|||December 2007|December 7, 2007|April 24, 2006||||||https://clinicaltrials.gov/show/NCT00318500||183041|
NCT00318812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005840-01H|Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure|Heme Iron Polypeptide for the Treatment of Iron Deficiency Anemia in Pre-Dialysis Patients: A Pilot Randomized Controlled Study||Ottawa Hospital Research Institute|No|Completed|May 2007|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|April 25, 2006||No||No|June 26, 2013|https://clinicaltrials.gov/show/NCT00318812||183018|Recruitment for the trial was a challenge; over 1100 patients screened - 55 consented - 40 randomized
NCT00326963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19712|BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.|An Open-label Study to Evaluate the Effect on Viral Load of a New Investigational Protease Inhibitor With Fuzeon Plus a Background Antiretroviral Regimen in Triple-class Treatment-experienced Patients With HIV-1 Infection||Hoffmann-La Roche||Completed|February 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|May 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00326963||182408|
NCT00326976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX06AQ-II-01|Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury|A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 (a Fibrin Derived Peptide Bbeta15-42) on Ischemia Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The "F.I.R.E." Study||Fibrex Medical Research & Development GmbH|Yes|Completed|August 2006|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|80 Years|No|||December 2007|December 3, 2007|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00326976||182407|
NCT00327223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-011|Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy|A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy||AmpliMed Corporation|No|Completed|November 2005|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2008|March 12, 2008|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327223||182388|
NCT00327665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106068|Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population|A Study to Compare the Safety, Reactogenicity & Immunogenicity of GSK Biologicals Pneumococcal Vaccines vs the Licensed 23-valent Pneumococcal Polysaccharide Vaccine, in Healthy Elderly Subjects||GlaxoSmithKline||Completed|May 2006|June 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|335|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327665||182354|
NCT00319982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001936|Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem|Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem||Brigham and Women's Hospital|Yes|Completed|January 2006|December 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|5 Years|39 Years|No|||March 2015|March 24, 2015|April 27, 2006|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00319982||182929|Small number of participants and short follow-up duration. Currently available tools to monitor treatment response/ phenotypic progression are may lack adequate resolution. The penetrance of sarcomere mutations is variable and may not be complete.
NCT00319995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04095|Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)|Efficacy and Safety of Combination Loratadine/Montelukast QD vs Pseudoephedrine and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|March 2006|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1095|||Both|15 Years|N/A|No|||October 2015|October 19, 2015|April 28, 2006||||No||https://clinicaltrials.gov/show/NCT00319995||182928|
NCT00320216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005416|A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis|A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis||Centocor, Inc.|No|Completed|November 2003|March 2005|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|320|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|April 28, 2006|No|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00320216||182911|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.
NCT00320788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0508|Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)|A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration||Regeneron Pharmaceuticals|No|Completed|April 2006|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|159|||Both|50 Years|N/A|No|||January 2012|January 27, 2012|April 28, 2006|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00320788||182868|This is a phase 2 study with small numbers of patients per group limiting the conclusions that can be drawn from the resulting data.
NCT00321087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2000-0533|A Study of T2000 in Essential Tremor|Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study||Taro Pharmaceuticals USA|Yes|Terminated|August 2006|December 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|75 Years|No|||January 2014|January 19, 2014|May 1, 2006||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00321087||182846|
NCT00307619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003667|An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.|Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder||Janssen-Cilag Farmaceutica Ltda.||Completed|November 2003|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|73|||Both|18 Years|60 Years|No|||January 2011|January 27, 2011|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00307619||183870|
NCT00307606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|seromprotocol|Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma|Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma||Herlev Hospital|Yes|Recruiting|December 2005|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||December 2005|September 5, 2007|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307606||183871|
NCT00307879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-MAGIC1|Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion|Phase 2 MAGIC Cell (Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion) Trial||Seoul National University Hospital||Terminated|March 2004|February 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|80 Years|No|||March 2004|March 27, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307879||183850|
NCT00304369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16175|Response of Clostridium Difficile Infection to Metronidazole Therapy|The Response of Clostridium Difficile Infection to Metronidazole Therapy||VA Medical Center, Houston|No|Completed|June 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|N/A|||Anticipated|290|||Both|18 Years|64 Years|No|||February 2013|February 14, 2013|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304369||184113|
NCT00304096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11992|Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer|Evaluation of the Safety and Immunogenicity of Vaccination With Multiple Synthetic Peptides in Participants With Advanced Breast Cancer||University of Virginia|Yes|Completed|December 2005|April 2008|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|March 15, 2006|Yes|Yes||No|January 15, 2013|https://clinicaltrials.gov/show/NCT00304096||184131|
NCT00304330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0602123|Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients|Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients; a Comparative Study With a Non-transplant Population||University of Pittsburgh|Yes|Recruiting|September 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|N/A|N/A|No|Non-Probability Sample|gram negative organisms|December 2015|December 16, 2015|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00304330||184115|
NCT00304681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003112|An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children|The Effectiveness of CONCERTA® vs. Usual Clinical Care With Immediate Release Methylphenidate (IR MPH) in Children (6-12 Years) With Attention Deficit Hyperactivity Disorder (ADHD): A Randomized, Open-Label Trial||Janssen-Ortho Inc., Canada||Completed||February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|6 Years|12 Years|No|||April 2010|May 16, 2011|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304681||184090|
NCT00305474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XYMHI001|Identification and Treatment of the Liability to Develop Schizophrenia|Identification and Treatment of the Liability to Develop Schizophrenia||Central South University||Recruiting|December 2003|||January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|19 Years|59 Years|Accepts Healthy Volunteers|||June 2009|June 23, 2009|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305474||184031|
NCT00305695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462217|Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries|A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery That Results in Removal of Both Ovaries||National Cancer Institute (NCI)||Active, not recruiting|November 2005|||March 2013|Anticipated|Phase 2|Observational|N/A||2|Anticipated|222|||Female|N/A|N/A|No|||April 2010|May 5, 2010|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00305695||184014|
NCT00305942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 117|Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer|A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|March 2006|November 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|March 20, 2006|No|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00305942||183996|
NCT00306241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106001|A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years|A Phase III, Double-blind, Randomized, Controlled Study to Evaluate Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly (0, 1, 6 Month Schedule) in Healthy Females Aged 18 - 35 Years||GlaxoSmithKline||Completed|March 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|||Actual|300|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2011|November 23, 2011|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00306241||183974|
NCT00302354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002212|A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults|A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults||Massachusetts General Hospital||Completed|December 2004|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302354||184260|
NCT00302627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI497|Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation|Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation||Providence Health & Services|No|Completed|January 1999|November 2002|Actual|November 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||December 2002|August 25, 2010|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302627||184239|
NCT00302640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM02-3021|Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children|Multi-center, Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children||Romark Laboratories L.C.||Completed|February 2005|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|11 Years|No|||May 2012|May 30, 2012|March 13, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00302640||184238|
NCT00302653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9436|Rasburicase in Tumor Lysis Syndrome|Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.||Sanofi||Completed|February 2006|||November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|18 Years|No|||September 2009|September 24, 2009|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00302653||184237|
NCT00302926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01-107/02|B195: Effect of Diet-Induced Energy Deficit and Body Fat Reduction on Inflammatory Markers in Obese Subjects|B195: Effect of Diet-Induced Energy Deficit and Body Fat Reduction on Inflammatory Markers in Obese Subjects||University of Copenhagen||Completed|September 2002|June 2003||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2006|March 14, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00302926||184216|
NCT00303277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21974|Do HMG CoA Reductase Inhibitors Affect Abeta Levels?|Do HMG CoA Reductase Inhibitors Affect Abeta Levels?||Seattle Institute for Biomedical and Clinical Research|Yes|Completed|August 2002|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|90 Years|No|||April 2010|April 12, 2010|March 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303277||184190|
NCT00303563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA18604|A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis|A Randomized, Double-blind Study to Compare the Effect of RO4402257 Monotherapy and Methotrexate Monotherapy on Disease Response in Patients With Active Rheumatoid Arthritis.||Hoffmann-La Roche||Completed|April 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|204|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303563||184168|
NCT00303849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOL-04058-L|Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors|Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma||OHSU Knight Cancer Institute|Yes|Recruiting|September 2005|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|March 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303849||184148|
NCT00307047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-368|SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System|SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions||Abbott Vascular|Yes|Completed|August 2006|May 2012|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3687|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|March 23, 2006|Yes|Yes||No|August 30, 2010|https://clinicaltrials.gov/show/NCT00307047||183912|
NCT00307008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|513026/004|Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.|An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23™ (MSD Aventis Pasteur) in Elderly Population.||GlaxoSmithKline||Completed|October 2003|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1198|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2011|April 11, 2013|March 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307008||183915|
NCT00307632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002962|An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol|An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol||Janssen-Cilag Farmaceutica Ltda.||Completed|February 2003|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|580|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|March 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00307632||183869|
NCT00307892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arth 06 CTIL|Traumeel S for Reduction of Post Operative Pain Following Arthroscopy|A Randomised, Double- Blind, Placebo Controlled, Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Reducing Pain After Arthroscopy||Shaare Zedek Medical Center||Suspended|January 2011|||January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|40 Years|No|||October 2010|October 28, 2010|March 27, 2006||No|Inability to recruit patients|No||https://clinicaltrials.gov/show/NCT00307892||183849|
NCT00304694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940601|Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients|Whole-Body 18F-FDG PET in Evaluating Induction Chemotherapeutic Response for Locally Advanced Nasopharyngeal Cancer Patients and Correlating With Histopathology: a Prospective Study||National Taiwan University Hospital||Recruiting|March 2006|||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||50|||Both|18 Years|80 Years|No|||March 2006|March 16, 2006|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00304694||184089|
NCT00304356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15601|Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection|Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy||VA Medical Center, Houston||Recruiting||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||February 2006|February 8, 2007|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00304356||184114|
NCT00304980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02 52 5 406|Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status|Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia||Institute of Tropical Medicine, Belgium||Terminated|March 2003|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||3000|||Both|15 Years|45 Years|No|||September 2010|September 12, 2010|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00304980||184068|
NCT00305201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-29/05|Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease|Cardiovascular Risk Markers Before and After Therapy With Statins in Patients With History of Kawasaki Disease||Pontificia Universidad Catolica de Chile|No|Withdrawn|April 2006|May 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|22|||Both|8 Years|25 Years|No|||March 2008|March 11, 2008|March 20, 2006||No|Withdrawn due to lack of study participants|No||https://clinicaltrials.gov/show/NCT00305201||184051|
NCT00306592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-MS-322|Natalizumab Re-Initiation of Dosing|An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation||Biogen|No|Completed|March 2006|February 2008|Actual|December 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|404|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|January 31, 2006|Yes|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00306592||183947|
NCT00306839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMELI 001|Efficacy Study of Tissucol/Tisseel Fibrin Sealant to Treat Inguinal Hernia|Prospective, Controlled, Randomized Study to Evaluate Pain and Further Disabling Complications in Patients Undergoing Lichtenstein Technique for Primary Inguinal Hernia Repair by Fixing the Mesh With Fibrin Sealant Versus Sutures||University of Milan|Yes|Completed|February 2006|May 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|325|||Male|18 Years|80 Years|No|||February 2009|February 12, 2009|March 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00306839||183928|
NCT00307099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-216|Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU|Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU): Impact on Antimicrobial Resistance, Superinfections, Length of ICU Stay and Hospitalization, and Mortality||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|October 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||February 2007|June 6, 2013|March 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00307099||183908|
NCT00302367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-p-002058|An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects|An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects||Massachusetts General Hospital||Completed|January 2004|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00302367||184259|
NCT00302666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91227|Bleeding Pattern Study|Comparative, Prospective, Multi-Center, Open, Randomized Study to Investigate Bleeding Patterns, Metabolic Effects, Contraceptive Efficacy, Acceptance, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 2 mg Dienogest, in Two Different Regimens of Intake (Four Extended Cycles of 84 Days Each Versus the Conventional Regimen of 21 Days) in Healthy Volunteers||Bayer||Completed|June 2003|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1315|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00302666||184236|
NCT00302679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701245|Comparison of Colonoscopy and Sigmoidoscopy in Terms of Pain, Acceptance and Procedure Time|Comparison of Colonoscopy and Sigmoidoscopy in Terms of Pain, Acceptance and Procedure Time||National Taiwan University Hospital||Recruiting|January 2006|June 2006||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||400|||Both|18 Years|N/A|No|||February 2006|March 13, 2006|March 12, 2006||||No||https://clinicaltrials.gov/show/NCT00302679||184235|
NCT00302939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0062|Etiology of Anemia|Studies in the Etiology of Anemia in an Unselected Sequential Referral Population||National Institutes of Health Clinical Center (CC)||Terminated|January 2006|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Bone marrow aspirate, urine, blood serum|Both|18 Years|N/A|No|Non-Probability Sample|Community|April 2010|April 21, 2010|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00302939||184215|
NCT00303576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM003|A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel|A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.||International Partnership for Microbicides, Inc.||Completed|October 2005|July 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||112|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2006|July 28, 2006|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303576||184167|
NCT00303862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02686|AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer|A Phase 2 Study of AZD2171 in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Terminated|March 2006|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2013|May 5, 2014|March 15, 2006|Yes|Yes||No|July 8, 2013|https://clinicaltrials.gov/show/NCT00303862||184147|
NCT00307060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-264|MK0954A-264 Filter Study (0954A-264)(COMPLETED)|A Randomized, Double-Blind, Parallel-Filter Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan-HCTZ Combination as Compared to Losartan Monotherapy in Patients With Essential Hypertension||Merck Sharp & Dohme Corp.||Completed|December 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|274|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00307060||183911|
NCT00307307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARMA|Carotid Atherosclerosis Regression at Magnetic Resonance Assessment.|Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology||University of Pennsylvania||Completed|January 2000|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||69|||Both|18 Years|90 Years|No|||March 2006|May 18, 2006|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00307307||183892|
NCT00307905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NoF 06 CTIL|TRAUMEEL for Pain After Fracture of Neck of Femur|A Randomised, Double - Blind, Placebo Controlled Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Controlling Post-operative Pain After Fracture of Neck of Femur||Shaare Zedek Medical Center||Withdrawn|January 2011|||June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||October 2010|October 28, 2010|March 27, 2006||No|Anticipation of inadequate recruitment according to current format.|No||https://clinicaltrials.gov/show/NCT00307905||183848|
NCT00308152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/05.851|Intravenous Saline Pre-Hydration in Patients Undergoing Outpatient Colonoscopy|Randomised, Controlled Trial of Intravenous Saline Pre-Hydration in Patients Undergoing Outpatient Colonoscopy||The Canberra Hospital||Completed|February 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308152||183829|
NCT00304135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000470411|Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery|Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract||Federation Francophone de Cancerologie Digestive|Yes|Completed|October 2005|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||December 2006|March 3, 2014|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00304135||184130|
NCT00304382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16562|Humoral Determinants of Immunity to Pneumococcal Infection|Humoral Determinants of Immunity to Pneumococcal Infection||VA Medical Center, Houston|Yes|Completed|January 2003|June 2012|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|114|||Both|N/A|N/A|No|||February 2013|February 14, 2013|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304382||184112|
NCT00304707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017370|Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence|Bupropion Treatment for Smokers in Recovery||National Institute on Drug Abuse (NIDA)||Recruiting|April 2005|February 2010|Anticipated|July 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 4, 2009|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304707||184088|
NCT00304993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNARED|Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia|Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia||Foundation Research, Florida||Completed|January 2001|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 17, 2006|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304993||184067|
NCT00305214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220b|MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients|Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients (MASTER II)||Medtronic Cardiac Rhythm Disease Management||Completed|October 2003|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||405|||Both|N/A|N/A|No|||February 2008|February 11, 2008|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305214||184050|
NCT00306280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lmrx01|Feasibility Study of Phototherapy System to Treat H Pylori|Phase 1 Study of Phototherapy System to Treat H Pylori||LumeRx||Recruiting|March 2006|March 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2006|September 19, 2006|March 21, 2006||||||https://clinicaltrials.gov/show/NCT00306280||183971|
NCT00306605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26047|Emotional Experiences in Fathers of NICU Infants|Emotional Experiences in Fathers of NICU Babies: A Comparison of Fathers in Medical and Surgical NICUs.||Christiana Care Health Services|No|Completed|March 2006|November 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Fathers of preterm infants who are hospitalized in a newborn intensive care unit.|November 2008|November 6, 2008|March 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00306605||183946|
NCT00306852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19990167|Tube Versus Trabeculectomy (TVT) Study|Tube Versus Trabeculectomy (TVT) Study||University of Miami|Yes|Completed|October 1999|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|85 Years|No|||October 2015|October 22, 2015|March 23, 2006||No||No|July 24, 2015|https://clinicaltrials.gov/show/NCT00306852||183927|
NCT00307151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1060|Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV|Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-to-Child HIV Transmission|P1060|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Active, not recruiting|December 2005|December 2016|Anticipated|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|452|||Both|2 Months|36 Months|No|||December 2015|December 3, 2015|March 24, 2006||No||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00307151||183904|Accrual to Cohort I was terminated early by the Data Safety Monitoring Committee after enrollment of 164 of the planned 288 subjects.
NCT00302705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-489A2425|Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose|Prospective, Randomized, Open-Label Study in Patients With Mild-to-Moderate Essential Hypertension to Compare the Antihypertensive Efficacy Determined by Ambulatory Blood Pressure Monitoring of Valsartan and Enalapril After Missing One Dose||University of Vigo|Yes|Completed|January 2005|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||January 2009|January 2, 2009|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00302705||184233|
NCT00302952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ARA02|Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis|A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2006|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|70 Years|No|||February 2014|February 12, 2014|March 13, 2006|No|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00302952||184214|Enrollment was slow and the full sample size was not obtained.
NCT00303290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM99-127|PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C)||M.D. Anderson Cancer Center|No|Completed|January 2000|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|12 Years|N/A|No|||November 2015|November 25, 2015|March 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303290||184189|
NCT00303303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01-12B|The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations|The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations||Carolinas Healthcare System|Yes|Terminated|April 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|25|||Both|12 Months|N/A|No|||July 2008|July 16, 2008|March 14, 2006||No|Study terminated due to declining enrollment; data analysis proceeding.|No||https://clinicaltrials.gov/show/NCT00303303||184188|
NCT00303589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI18274|A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections|A Phase II Prospective, Open Label, Randomized, Active-controlled, Parallel Group, Multi-center 'Proof of Concept' Trial in Adult Patients With Complicated Skin or Skin Structure Infections Requiring Hospitalization.||Hoffmann-La Roche||Completed|December 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|313|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303589||184166|
NCT00303602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10268|Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)|BMI Evaluation: Placebo and Active Comparator Trial of Olanzapine Zydis Pills Used Sublingually (PLATYPUS)||Eli Lilly and Company||Completed|March 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|65 Years|No|||June 2009|June 5, 2009|March 15, 2006|Yes|Yes||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00303602||184165|
NCT00303875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012963|Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight|RENEW: Reach Out to Enhance Wellness in Older Survivors||Duke University|Yes|Completed|December 2003|May 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|641|||Both|65 Years|N/A|No|||February 2013|April 9, 2013|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00303875||184146|
NCT00307320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 12234|Study Examining Stress During Pregnancy|Coping With Stress During Pregnancy||University of Virginia||Active, not recruiting|March 2006|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|40 Years|No|||August 2008|December 29, 2009|March 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00307320||183891|
NCT00308165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA4229|Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors|A Phase I Study of Topotecan by Intracerebral Clysis for the Treatment of Recurrent Primary Malignant Brain Tumors||Columbia University|Yes|Active, not recruiting|March 2004|December 2015|Anticipated|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|1 Year|N/A|No|||January 2015|January 13, 2015|March 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00308165||183828|
NCT00305006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08126|Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy|Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy|CIMT|Columbia University|No|Recruiting|July 2007|February 2011|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Months|14 Years|No|||January 2011|January 12, 2011|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305006||184066|
NCT00305019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-201|Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus|A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus||Bukwang Pharmaceutical||Terminated|July 2002|March 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|60 Years|No|||April 2006|April 11, 2006|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00305019||184065|
NCT00305227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28552-B|Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection|Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infections||University of Washington|Yes|Completed|March 2006|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|50 Years|No|||January 2016|January 13, 2016|March 20, 2006|Yes|Yes||No|June 3, 2014|https://clinicaltrials.gov/show/NCT00305227||184049|
NCT00305487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-417|Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age||Takeda||Completed|March 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||660|||Both|6 Years|11 Years|No|||June 2011|May 4, 2012|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305487||184030|
NCT00305708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462443|Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission|Bone Marrow Stem Cell Transplantation for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myeloid Leukemia in 1Remission||University of California, San Francisco||Completed|August 2000|July 2004|Actual|July 2004|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|17 Years|No|||November 2012|November 8, 2012|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305708||184013|
NCT00305734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02690|Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer|Phase II Trial of PS-341 (Bortezomib, NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma||National Cancer Institute (NCI)||Completed|August 2006|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|March 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00305734||184012|
NCT00305955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-101|Bilateral Refractive Amblyopia Treatment Study|Bilateral Refractive Amblyopia Treatment Study|ATS7|Jaeb Center for Health Research|No|Completed|August 2004|October 2006|Actual|July 2006|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|3 Years|10 Years|No|Non-Probability Sample|Community sample|October 2009|March 23, 2010|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305955||183995|
NCT00306267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010540|A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy|A Pilot Study to Evaluate the Safety and Efficacy of PROCRIT (Epoetin Alfa) 80,000 Units Once Every Four Weeks (Q4W) vs. 40,000 Units Once Every Two Weeks (Q2W) in Cancer Subjects With Non-Chemotherapy Anemia (NCA)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|March 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|61|||Both|18 Years|N/A|No|||March 2010|May 17, 2011|March 21, 2006|||Study stopped as it would not address important survival concerns raised in other recently    conducted clinical studies.|||https://clinicaltrials.gov/show/NCT00306267||183972|
NCT00306618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CLN-005|Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma|A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients With Recurrent Glioblastoma Multiforme||CASI Pharmaceuticals, Inc.||Completed|January 2006|December 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2008|December 9, 2008|March 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00306618||183945|
NCT00306631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-101|A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1|A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer||CASI Pharmaceuticals, Inc.|Yes|Completed|January 2006|November 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|March 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00306631||183944|
NCT00306865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060031|Brain Changes in Patients With Focal Hand Dystonia|Evaluation of Density and Pattern of Distribution of GABA A Receptors in the Brain of Patients With Focal Hand Dystonia Studied With PET Using [11C] Flumazenil||National Institutes of Health Clinical Center (CC)||Completed|March 2006|October 2010||||N/A|Observational|N/A|||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 15, 2010|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00306865||183926|
NCT00307138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hetastarch_Off-pump_CABG|Hetastarch and Bleeding Complications After Off-Pump Coronary Bypass Surgery|Hetastarch (Hextend) and Bleeding Complications After Off-Pump Coronary Bypass Surgery||Kaiser Permanente||Completed|September 2004|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||330|||Both|20 Years|80 Years|No|||August 2005|May 19, 2006|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00307138||183905|
NCT00307164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5229|Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy|A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2006|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|March 23, 2006|Yes|Yes||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00307164||183903|
NCT00306878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-001|Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris|Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris||Bristol-Myers Squibb||Completed|August 1995|May 1997|Actual|May 1997|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|50 Years|No|||April 2011|April 11, 2011|March 23, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00306878||183925|
NCT00302718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-349|Financial Incentives to Translate ALLHAT Into Practice: A Randomized Trial|RCT of Financial Incentives to Translate ALLHAT Into Practice||VA Office of Research and Development|No|Completed|February 2007|September 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|83|||Both|N/A|N/A|No|||October 2014|April 6, 2015|March 10, 2006||No||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00302718||184232|
NCT00302731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9941|Bioidentical 'Natural' Hormone Evaluation in Early Menopause|Prospective Double Blind Evaluation of Bioidentical Hormones||University of Kansas Medical Center|Yes|Completed|February 2006|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|March 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00302731||184231|
NCT00302965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004341-01|Effectiveness of Plasma Transfusions in Critical Care Patients|Effectiveness of Fresh Frozen Plasma in Critical Care (EPICC) Trial||Ottawa Hospital Research Institute||Completed|April 2005|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|70|||Both|N/A|N/A|No|||October 2008|October 17, 2008|September 13, 2005||||No||https://clinicaltrials.gov/show/NCT00302965||184213|
NCT00302978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5215|Changes in Brain Activity (Functional MRI Study) Before and After Behavioral Therapy of Height Phobia|The Effects of in Vivo Exposure Therapy on the Neural Correlates of Height Phobia: a Functional Magnetic Resonance Imaging Study Using a Fear Provocation Paradigm.||New York State Psychiatric Institute||Completed|March 2006|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2007|December 14, 2011|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00302978||184212|
NCT00303316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L16|Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants|Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants||Sanofi||Completed|February 2006|September 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|458|||Both|510 Days|578 Days|Accepts Healthy Volunteers|||January 2013|January 18, 2013|March 13, 2006||No||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00303316||184187|
NCT00303329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0108E1|Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients|Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload||Novartis|Yes|Completed|March 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|184|||Both|2 Years|N/A|No|||April 2011|April 15, 2011|October 14, 2005|Yes|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00303329||184186|
NCT00303615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200.3540|Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer|Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer, Phase II Study||Legacy Health System||Terminated|June 2005|July 2007|Actual|June 2007|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Female|18 Years|N/A|No|||October 2008|October 17, 2008|March 16, 2006||No|Low accrural|No||https://clinicaltrials.gov/show/NCT00303615||184164|
NCT00303888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462103|Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|A Randomized Placebo-Controlled Phase Ib/IIa Safety, Tolerability and Efficacy Study of Oral Phenoxodiol in Combination With Docetaxel Versus Docetaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer||National Cancer Institute (NCI)||Recruiting|April 2006|||June 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||June 2009|October 28, 2010|March 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303888||184145|
NCT00307645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P991003|IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis|Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis||Assistance Publique - Hôpitaux de Paris||Terminated|May 2003|August 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||March 2003|April 7, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307645||183868|
NCT00307658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P991006|Intravenous Immunoglobulin After Relapse in Vasculitis|Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial||Assistance Publique - Hôpitaux de Paris||Terminated|March 2001|July 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2003|May 18, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307658||183867|
NCT00307333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10845|Impact of Heart Rate Characteristics Monitoring in Neonates|Impact of Heart Rate Characteristics Monitoring in Neonates|HeRO|University of Virginia|Yes|Completed|August 2005|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|3003|||Both|N/A|32 Weeks|No|||May 2013|May 16, 2013|March 24, 2006|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT00307333||183890|
NCT00304720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMBMT-124-A|Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor|Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Family Donor Hematopoietic Cell Transplants||Colorado Blood Cancer Institute||Recruiting|March 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|50 Years|70 Years|No|||March 2004|February 6, 2008|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304720||184087|
NCT00304733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2024|Wound Healing: Total Contact Cast Vs. Custom-Made Temporary Footwear for Patients With Diabetic Foot Ulceration|Wound Healing: Total Contact Cast Vs. Custom-Made Temporary Footwear for Patients With Diabetic Foot Ulceration||Rehabilitation Centre Amsterdam||Active, not recruiting|August 2001|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||43|||Both|18 Years|80 Years|No|||August 2001|March 16, 2006|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00304733||184086|
NCT00305032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.399|Effect of Endoscopic Gastric Balloon Insertion on Obstructive Sleep Apnea in Patients With Morbid Obesity|Effect of Endoscopic Gastric Balloon Insertion on Obstructive Sleep Apnea in Patients With Morbid Obesity||Chinese University of Hong Kong|Yes|Completed|March 2006|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|N/A|No|||February 2016|February 26, 2016|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305032||184064|
NCT00305240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220a|MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients|Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients (MASTER I)||Medtronic Cardiac Rhythm Disease Management||Completed|October 2003|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||656|||Both|N/A|N/A|No|||February 2008|February 11, 2008|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305240||184048|
NCT00305500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EscitaHD001|Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)|Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults||Abarbanel Mental Health Center||Completed|March 2006|December 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|75 Years|No|||March 2006|July 25, 2006|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00305500||184029|
NCT00305747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462637|Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy|Phase I Study of Bioresponse-dim in Non-Metastatic, Hormone-Refractory Prostate Cancer Patients With Rising Serum PSA||Barbara Ann Karmanos Cancer Institute|Yes|Completed|August 2005|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||January 2014|January 14, 2014|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00305747||184011|
NCT00305968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHFIBS-1|Evaluation of Patient Education in Irritable Bowel Syndrome|Evaluation of Patient Education in Patients With Irritable Bowel Syndrome - a Randomized Multi Center Study||Sorlandet Hospital HF||Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2011|December 20, 2011|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305968||183994|
NCT00305981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1665-26922|The ICU Care Knowledge Study|The ICU Care Knowledge Study: A Prospective Study of Family Members' Knowledge of ICU Care and Prognosis||University of California, San Francisco||Completed|October 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||154|||Both|N/A|N/A|No|||October 2005|April 17, 2007|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00305981||183993|
NCT00306319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 05.02|Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia|Pharmacokinetic Interaction Study of Rifampicin, Isoniazid and Moxifloxacin in Tuberculosis Patients in Bandung, Indonesia||Radboud University||Completed|January 2006|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||23|||Both|18 Years|55 Years|No|||May 2008|May 20, 2008|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306319||183968|
NCT00306644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/334|Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes|See Detailed Description||GlaxoSmithKline||Completed|May 2002|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||556|||Both|35 Years|80 Years|No|||October 2008|October 13, 2008|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306644||183943|
NCT00302783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-12-37X|Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents|Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents: The Formative Value of an ACGME Competency-Based Assessment Tool.||Children's Hospital Medical Center, Cincinnati||Completed|June 2004|September 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||36|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 14, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00302783||184227|
NCT00303043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000|Hemodynamic Monitoring With Mixed Venous Saturation|Hemodynamic Monitoring. The Continuous Measurement of Mixed Venous Saturation Compared to Clinical Valuation: A Pilot Study||Policlinico Hospital|No|Completed|March 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|16 Years|80 Years|No|Probability Sample|Critically ill patients with a central venous catheter|March 2009|December 29, 2009|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00303043||184207|
NCT00302744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEFFTER11287-01|Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety|Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety||Los Angeles Biomedical Research Institute|Yes|Completed|April 2004|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||January 2013|January 28, 2013|March 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00302744||184230|
NCT00302991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01247|Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)|Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA)||UCB Pharma|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||||180|||Both|18 Years|N/A||||January 2008|January 29, 2008|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302991||184211|
NCT00303004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01000|Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome|Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome||Rigshospitalet, Denmark|Yes|Completed|March 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303004||184210|
NCT00303342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT002490|Neuroendocrine Mechanisms in Behavioral Treatment of Insomnia|Neuroendocrine Mechanisms in Behavioral Treatment of Insomnia||Brigham and Women's Hospital|No|Completed|March 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|59 Years|No|||January 2010|January 12, 2010|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00303342||184185|
NCT00303355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11803B|Measurement of Jugular Venous Pulse in Critically Ill Patients.|An Evaluation of the Utility of Clinical Examination for the Measurement of Jugular Venous Pulse in Critically Ill Patients.||University of Chicago||Terminated|September 2002|September 2004||||N/A|Observational|Time Perspective: Prospective||||36|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|March 14, 2006|||Study completed|No||https://clinicaltrials.gov/show/NCT00303355||184184|
NCT00303628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5204|Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer|Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation||Eastern Cooperative Oncology Group|Yes|Terminated|February 2006|April 2019|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 15, 2006|Yes|Yes|The study was terminated before reaching its accrual goal due to slow accrual.|No|January 28, 2016|https://clinicaltrials.gov/show/NCT00303628||184163|
NCT00303641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-424|Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients|A Prospective Randomized Study of the Safety and Effectiveness of the Medtronic Resting Heart System||Lawson Health Research Institute||Completed|November 2004|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|30 Years|85 Years|No|||September 2006|September 6, 2006|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303641||184162|
NCT00303901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462091|Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery|Percutaneous Thoracic Cryotherapy (PTC) for Inoperable Primary Lung Cancer and Metastatic Management||Barbara Ann Karmanos Cancer Institute|Yes|Completed|November 2005|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|March 15, 2006|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00303901||184144|There were no study limitations.
NCT00307931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87055|Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab|Certolizumab Pegol in the Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Have Been Previously Treated Successfully With Infliximab But Who Have Subsequently Lost Response or Developed Intolerance to Infliximab||UCB Pharma|No|Terminated|April 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2009|August 30, 2011|March 24, 2006|Yes|Yes|Study was terminated early because of slow recruitment|No|September 8, 2009|https://clinicaltrials.gov/show/NCT00307931||183846|This study was terminated early due to slow recruitment, namely only 17 subjects were recruited although the sample size had planned for approximately 50 subjects. As a consequence, the majority of secondary outcome measures were not summarized.
NCT00307918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP GL 01 06 CTIL|Acupuncture for Elevated Intraocular Pressure|Acupuncture Treatment for Elevated Intraocular Pressure: A Pilot Study||Shaare Zedek Medical Center||Terminated|May 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|21 Years|N/A|No|||September 2007|September 30, 2007|March 27, 2006|||lack of patients|No||https://clinicaltrials.gov/show/NCT00307918||183847|
NCT00304746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-001667|AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment|A Parallel-Group, Placebo-Controlled Trial of AndroGel in Men With Major Depressive Disorder Who Display an Incomplete Response to Standard Antidepressant Treatment||Mclean Hospital|No|Completed|April 2006|April 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Male|30 Years|65 Years|No|||November 2010|November 17, 2010|March 16, 2006|Yes|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00304746||184085|The small number of participants limited statistical power. Also, the study recruited “treatment-resistant” men, who are often poorly responsive. For a detailed discussion, see the published report of the study.
NCT00305045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237/2004|Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation|Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation: A Double-blind, Sham-controlled, Longitudinal Study.||Centre for Addiction and Mental Health|No|Completed|March 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|73|||Both|18 Years|85 Years|No|||January 2012|January 23, 2012|March 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00305045||184063|
NCT00305253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-84956-000-GSS|Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt|Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt||University of California, San Francisco|Yes|Completed|April 2006|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|990|||Female|18 Years|N/A|No|||May 2013|May 9, 2013|March 17, 2006||No||No|July 7, 2009|https://clinicaltrials.gov/show/NCT00305253||184047|Non-randomized, non-blinded pre-intervention/intervention design
NCT00305760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0501|Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer|A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Erbitux (Cetuximab) for the Treatment of Advanced Pancreatic Adenocarcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|December 2005|||February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|March 21, 2006|Yes|Yes||No|June 18, 2015|https://clinicaltrials.gov/show/NCT00305760||184010|
NCT00306007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1179-27236-01A|Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women|Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women|LMUP|University of California, San Francisco|No|Completed|November 2005|August 2007|Actual|August 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|320|||Female|15 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|target population for this study is pregnant women who present to san Francisco General        Hospital (SFGH) Women's Options Center (WOC) for abortion and to the Women's Health Center        for prenatal care. The population is racially and ethnically diverse, and the majority are        financially challenged and have no insurance or Medicaid.|June 2013|June 23, 2013|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00306007||183992|
NCT00306293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLX105832|VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2|The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection||GlaxoSmithKline|No|Completed|February 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|70|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|March 21, 2006||||||https://clinicaltrials.gov/show/NCT00306293||183970|
NCT00306306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-0212|COOL RCN: Cooling to Prevent Radiocontrast Nephropathy|COOL RCN: Cooling to Prevent Radiocontrast Nephropathy in Patients Undergoing Diagnostic or Interventional Catheterization||Radiant Medical||Terminated|March 2006|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|400|||Both|18 Years|N/A|No|||August 2007|August 4, 2008|March 21, 2006||||||https://clinicaltrials.gov/show/NCT00306306||183969|
NCT00306332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSCT10|T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation|T-cel and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation by Using Immunomagnetic Negative and Positive Selection Procedures||Radboud University||Terminated|March 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|250|||Both|18 Years|65 Years|No|||August 2009|August 17, 2009|March 22, 2006|||Interim analysis has shown that the objectives of this study can not be reached|No||https://clinicaltrials.gov/show/NCT00306332||183967|
NCT00306657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/057|Normal Tension and Chronic Open Angle Glaucoma and Cerebrospinal Fluid Composition|Normal Tension and Chronic Open Angle Glaucoma, Cerebrospinal Fluid Composition in Subarachnoid Space of Affected Optic Nerves||Kantonsspital Aarau||Recruiting|March 2006|December 2012|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|N/A|No|||April 2007|June 23, 2011|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00306657||183942|
NCT00303069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V710-001|V710 First-In-Man (FIM) Study (V710-001)|A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age||Merck Sharp & Dohme Corp.|Yes|Completed|November 2005|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|124|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|March 13, 2006|No|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00303069||184205|
NCT00302757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002206-37|Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma|Multicenter Phase I/II Study of Radioimmunotherapy With 90Y-ibritumomab Tiuxetan in a Nonmyeloablative Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation From HLA-identical Donors in Patients With Advanced Non-Hodgkin Lymphoma||University Hospital Tuebingen||Completed|March 2006|July 2011|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|70 Years|No|||May 2014|May 28, 2014|March 10, 2006||||No||https://clinicaltrials.gov/show/NCT00302757||184229|
NCT00302770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449C00008|Efficacy of Quetiapine in Generalised Social Anxiety Disorder|Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study||AstraZeneca||Terminated|June 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|65 Years|No|||January 2011|January 25, 2011|March 13, 2006|||This study was terminated due to poor enrollment|No||https://clinicaltrials.gov/show/NCT00302770||184228|
NCT00303017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primus Protocol #OAPS|Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study|Safety, Efficacy and Acceptability of Flavocoxid (Limbrel) Compared With Naproxen in Subjects With Osteoarthritis of the Knee. A Pilot Study||Primus Pharmaceuticals|No|Completed|March 2006|September 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|85 Years|No|||November 2008|October 19, 2015|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00303017||184209|
NCT00303030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biofeedback or injections|A Randomized, Controlled, Clinical Trial of Biofeedback and Anal Injections as First Treatment of Fecal Incontinence|A Randomized, Controlled, Clinical Trial of Biofeedback and Anal Injections as First Treatment of Fecal Incontinence.||University Hospital of North Norway|No|Completed|May 2006|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00303030||184208|
NCT00303368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9165|Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia|Multicenter Study of Tibial Dysplasia in Neurofibromatosis Type I (NF1) Patients|NF1TD|Shriners Hospitals for Children|Yes|Recruiting|March 2004|December 2008|Anticipated|||N/A|Observational|N/A||1|Anticipated|420|Samples With DNA|If the enrollee's private physician includes surgery in the management of his/her disorder,      and if tissue is removed to be discarded, permission is obtained to store the specimen in a      tissue repository for future research.|Both|N/A|N/A|No|Non-Probability Sample|Adults and children with NF1, with or without Tibial Dysplasia, ages 3+ and individuals        ages birth through 18 with Tibial Dysplasia, with or without NF1.|May 2008|May 20, 2008|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00303368||184183|
NCT00299442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q1606/57|Self-Help Parent Training for Conduct Problems in Children|Can Self−Help Parent Training Reduce Conduct Problems in Children on NHS Waiting Lists for Child Mental Health Services?||University of Oxford||Recruiting|July 2007|February 2009|Anticipated|February 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||November 2008|March 10, 2009|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299442||184478|
NCT00299754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCTan001|Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)|The Randomised-Controlled Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)||KK Women's and Children's Hospital||Completed|January 2003|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||171|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2005|March 6, 2006|March 6, 2006||||No||https://clinicaltrials.gov/show/NCT00299754||184454|
NCT00300027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-007|Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With 5-Fluorouracil/Leucovorin and Irinotecan or Oxaliplatin for Patients With Advanced or Metastatic Cancer||Bristol-Myers Squibb||Terminated|April 2006|||December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||September 2007|February 27, 2010|March 6, 2006||||||https://clinicaltrials.gov/show/NCT00300027||184433|
NCT00304395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17555|Pulmonary Infections Masquerading as Community-Acquired Pneumonia|Pulmonary Infections Masquerading as Community-Acquired Pneumonia||VA Medical Center, Houston|No|Completed|January 2004|January 2007|Actual|January 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40|||Both|18 Years|64 Years|No|Non-Probability Sample|Patients with Pulmonary infections.|September 2010|September 9, 2010|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304395||184111|
NCT00304759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2005-PROFIT|PROFIT - Prostate Fractionated Irradiation Trial|A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer||Ontario Clinical Oncology Group (OCOG)|Yes|Active, not recruiting|May 2006|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1204|||Male|N/A|N/A|No|||September 2015|September 21, 2015|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304759||184084|
NCT00305058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 04-08-225E|Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain|A Randomized Clinical Trial Comparing Intravenous Morphine and Intravenous Hydromorphone in the Treatment of Adult ED Patients With Moderate to Severe Pain||Montefiore Medical Center||Recruiting|July 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||178|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2005|March 17, 2006|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00305058||184062|
NCT00305266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0018|Study of CIDP Patients During IVIG Treatment|"Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy"||University of Aarhus|No|Completed|August 2005|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|11|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2007|November 30, 2007|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00305266||184046|
NCT00305279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H40550-27771|The Effects of Dietary Phosphate Intake on Calciotropic Hormones and FGF23.|The Effects of Dietary Phosphate Intake on Calciotropic Hormones and FGF23||University of California, San Francisco||Withdrawn|February 2006|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|0|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00305279||184045|
NCT00305773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01470|Vorinostat in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)||Completed|January 2006|January 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||December 2012|April 30, 2014|March 21, 2006|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00305773||184009|
NCT00306020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR394105CTIL|Analgesia and Wound Healing Assessment Following Topical Morphine Applied to Patients With Cutaneous Cancer Related Pain|Analgesia and Wound Healing Assessment Following Topical Morphine Applied to Patients With Cutaneous Cancer Related Pain||Soroka University Medical Center||Withdrawn|January 2006|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|75 Years|No|||July 2012|July 3, 2012|March 21, 2006||No|The study was withdrawn due to difficulties in recruiting appropriate patients in community    clinic setting|No||https://clinicaltrials.gov/show/NCT00306020||183991|
NCT00297219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGE99803466003-2|Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry|The Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry: Prospective, Randomized, Controlled Study||Ege University|Yes|Completed|November 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|457|||Both|18 Years|80 Years|No|||August 2009|August 3, 2009|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297219||184645|
NCT00297414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004240|An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine|An Analysis of Mortality in Subjects Who Participated in Three Studies of Galantamine in Mild Cognitive Impairment||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2004|January 2005|Actual|January 2005|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1083|||Both|N/A|N/A|No|Non-Probability Sample|Study population included patients randomized and treated with galantamine or placebo in 3        previous studies (CR003145, CR002014, and CR005947)|April 2012|April 11, 2012|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00297414||184630|
NCT00303056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6091|Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis|Efficacy and Safety of Intra-articular Multiple Doses of 500 µg Icatibant Including 40 mg Triamcinolone as Calibrator in a Randomized, Double-blind, Parallel-group, Placebo-controlled 13-week Multi-centre Study in Patients With Symptomatic Knee Osteoarthritis||Sanofi||Completed|February 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|590|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|March 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303056||184206|
NCT00303381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22648|Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis|A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding Phase II Study of Subcutaneously Administered IFN-beta-1a in the Treatment of Patients With Moderately Active Ulcerative Colitis||EMD Serono||Completed|December 2001|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|194|||Both|18 Years|N/A|No|||August 2013|August 4, 2013|March 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303381||184182|
NCT00303654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446284|Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection|Quality Assessment of the Roei Loop Resectoscope for Transurethral Resection of Bladder Neoplasm and BPH||National Cancer Institute (NCI)||Completed|August 2005|June 2007|Actual|||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|N/A|N/A|No|||June 2007|March 25, 2013|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303654||184161|
NCT00303667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS042|Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant|Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2005|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||November 2011|June 11, 2015|March 15, 2006|Yes|Yes|Replaced by another study|No|June 11, 2015|https://clinicaltrials.gov/show/NCT00303667||184160|
NCT00303914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462104|Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer|A Survey of Disease and Treatment-Related Symptoms in Patients With Invasive Cancer: Prevalence, Severity and Treatment||National Cancer Institute (NCI)||Active, not recruiting|April 2006|||||N/A|Observational|N/A|||Anticipated|2310|||Both|18 Years|N/A|No|||August 2009|July 19, 2012|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303914||184143|
NCT00299767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-061|Phase I Study of Sequential Cord Blood Transplants|Phase I Study of Sequential Cord Blood Transplants||Massachusetts General Hospital||Completed|May 2003|May 2009|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|65 Years|No|||May 2013|May 22, 2013|March 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299767||184453|
NCT00300053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24779|ACT34-CMI -- Adult Autologous CD34+ Stem Cells|A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)||Baxter Healthcare Corporation|Yes|Completed|March 2006|March 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|150|||Both|21 Years|80 Years|No|||September 2010|September 1, 2010|March 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00300053||184431|
NCT00300066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN-20050065MCH|Assessment of Serum Cystatin C as a Marker of Kidney Function in Children|Prediction Equations for Glomerular Filtration Rate in Children Based on Serum Cystatin C and Body Cell Mass||Aalborg Universitetshospital||Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|2 Years|14 Years|No|Non-Probability Sample|Children aged 2-14 years referrede for GFR measurement|May 2010|May 27, 2010|March 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00300066||184430|
NCT00304148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK60990|SDCC - Prospective Cohort Study of Chronic Renal Insufficiency|Prospective Cohort Study of Chronic Renal Insufficiency|CRIC|University of Pennsylvania|Yes|Active, not recruiting|July 2003|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5112|Samples With DNA|DNA, urine, serum, blood|Both|45 Years|79 Years|No|Probability Sample|The CRIC Study population will include a racially and ethnically diverse group of adult        patients with mild-to-moderate CRI. The 1,500 new cohort members will be recruited into        the study, compared with participants recruited in Phase I, these individuals will have        higher ranges of age and more preserved kidney function, and most will have proteinuria.        The population of 1500 new recruits will have similar characteristics as the current CRIC        cohort: ~50% with Diabetes, ~50% female, ~45% white and ~45% African-American.|August 2015|August 17, 2015|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00304148||184129|
NCT00304408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16383|Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody|Association Between Clinical Response of Clostridium Difficile Colitis to Treatment and Emergence of Anti-C.Difficile Toxin Antibody||VA Medical Center, Houston|No|Completed|January 2005|January 2008|Actual|January 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Patients positive for C. difficile.|September 2010|September 9, 2010|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304408||184110|
NCT00304772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCRID0502|Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients|A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients||Kyoto University|No|Withdrawn|August 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|N/A|N/A|No|||March 2009|March 24, 2009|March 17, 2006||No|Subjects were not recruited as intended.|No||https://clinicaltrials.gov/show/NCT00304772||184083|
NCT00304785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 03-026|Latanoprost Versus Fotil|||Pharmaceutical Research Network||Completed|May 2005|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||October 2007|October 23, 2007|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304785||184082|
NCT00305071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMJE IRB NO：950113-1|Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets in Acute Bacterial Cystitis.|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets (UmayC) in Acute Bacterial Cystitis.||Min-Sheng General Hospital||Not yet recruiting|April 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Female|20 Years|65 Years|No|||March 2006|March 19, 2006|March 19, 2006||||No||https://clinicaltrials.gov/show/NCT00305071||184061|
NCT00305305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-PCRC #2206|Brain Development Research Program|Disorders of Cerebral Development: A Phenotypic and Genetic Analysis||University of California, San Francisco||Recruiting|August 2003|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Individuals with agenesis or dysgenesis of the corpus callosum, polymicrogyria, or        cerebellar hypoplasia.|December 2015|December 2, 2015|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00305305||184043|
NCT00305513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-17.02.06-HMO-CTIL|Effectiveness of Rehabilitation on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect|Effectiveness of Rehabilitation (Phasic Alerting and Visual Spatial Scanning Training) on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect: Using Functional Imaging PET and Standardized Neurobehavioral and Functional Tests||Hadassah Medical Organization||Not yet recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|6|||Both|25 Years|85 Years|No|||March 2006|June 2, 2010|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00305513||184028|
NCT00305786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20043597|Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|August 2005|May 2010|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00305786||184008|
NCT00306033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0712-B|Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis|IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial||University Health Network, Toronto||Completed|March 2004|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2005|March 31, 2006|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00306033||183990|
NCT00296673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-06-01|Reactive Neuromuscular Training Effects on Side Bridge Endurance Test|||Logan College of Chiropractic||Completed||October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||October 2006|October 25, 2006|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00296673||184686|
NCT00297232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-MS-321|Natalizumab (Tysabri) Re-Initiation of Dosing|An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation|STRATA|Biogen|No|Terminated|March 2006|April 2014|Actual|December 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1094|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|February 27, 2006|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT00297232||184644|Sponsor decided to terminate the study prior to all subjects reaching Week 480 as the primary objective was deemed to have been met and only approximately 45% of the original STRATA population remained in the study at the time of study termination.
NCT00303394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1000-ZH|Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist|Phase 2 Study of IL-1Ra in Patients With Type 2 Diabetes||University of Zurich||Completed|April 2004|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|20 Years|N/A|No|||March 2007|March 2, 2007|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00303394||184181|
NCT00303407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOT 99/54|Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care|||University Hospital, Geneva||Terminated|January 2001|July 2002||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||December 2005|March 15, 2006|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303407||184180|
NCT00303732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012347|Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors|PTK787/ZK222584 and RAD001 for Patients With Advanced Solid Tumors|PTK/RAD|Duke University|Yes|Completed|December 2004|August 2012|Actual|August 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00303732||184157|
NCT00303706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-053|Study of Endoscopic Versus Open Harvest of the Radial Artery in Coronary Artery Bypass Surgery|A Prospective Randomized Trial of Endoscopic Versus Conventional Harvesting of the Radial Artery in Coronary Artery Bypass||Lawson Health Research Institute||Completed|April 2005|August 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|80 Years|No|||September 2007|September 27, 2007|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00303706||184159|
NCT00303719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001LS058|Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy|Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|March 2002|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|75 Years|No|||January 2016|January 21, 2016|March 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303719||184158|
NCT00303927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462118|Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene|Thymidylate Synthase (TS) Genotype-Directed Phase II Trial of Oral Capecitabine for 2-Line Treatment of Advanced Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|December 2005|||September 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||March 2010|March 18, 2010|March 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303927||184142|
NCT00303940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050239|Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors|A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 2005|February 2010|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|26|||Both|2 Years|18 Years|No|||March 2012|March 14, 2012|March 15, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00303940||184141|
NCT00299455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRR-60|Amoxicillin Clavulanate in Treatment of Acute Otitis Media|Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children||University of Turku|No|Active, not recruiting|March 2006|March 2009|Anticipated|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|6 Months|35 Months|No|||February 2009|February 10, 2009|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299455||184477|
NCT00300339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT4791|Mixed Antagonist of Serotonin for Claudication Optimal Therapy|Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel|MASCOT|Sanofi||Completed|February 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|599|||Both|40 Years|N/A|No|||December 2008|December 18, 2008|March 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00300339||184410|
NCT00300352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04.OXB.004|Effect of Folic Acid Treatment in Coronary Artery Disease|Effect of Folic Acid Treatment in Coronary Artery Disease||University of Oxford||Recruiting|May 2004|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|60|||Both|18 Years|N/A|No|||January 2007|August 6, 2008|March 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00300352||184409|
NCT00300664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2128|A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.|||Royal Marsden NHS Foundation Trust||Completed|July 2002|April 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||150|||Both|18 Years|N/A||||March 2006|October 12, 2006|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00300664||184385|
NCT00304161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067894|Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease|Depression Diagnosis and Treatment in Parkinson Disease||University of Pennsylvania|No|Completed|July 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|30 Years|79 Years|No|||March 2015|March 10, 2015|March 15, 2006|Yes|Yes||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00304161||184128|First, the sample size was relatively small. Second, the diagnostic criteria for depression which are typically used in clinical trials were not used as an inclusion criterion. Third, antidepressant use at baseline was common in our population.
NCT00304421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028|Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD|Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD||VA Greater Los Angeles Healthcare System||Completed|January 2004|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|65 Years|No|||September 2007|September 14, 2007|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00304421||184109|
NCT00304434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDA-014-05F|Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.|Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01)||VA Office of Research and Development||Completed|February 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 21, 2009|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304434||184108|
NCT00304447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903X-100863|Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia|A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2002|January 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||July 2009|July 28, 2009|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00304447||184107|
NCT00304798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB #051272|Study of Admission Versus Discharge After Transient Ischemic Attack (TIA)|Pilot Study of Admission Versus Discharge After Transient Ischemic Attack (TIA)||University of California, San Diego||Withdrawn|March 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2007|February 3, 2015|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00304798||184081|
NCT00304811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17556|Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection|Vancomycin Versus Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)||VA Medical Center, Houston||Completed|January 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|160|||Both|18 Years|64 Years|No|||September 2009|September 25, 2009|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00304811||184080|
NCT00305084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR003|Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors|A Phase IB Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Solid Tumors||MolMed S.p.A.|No|Completed|January 2006|April 2008|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00305084||184060|
NCT00305292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5612-27941-01|Modafinil-Alcohol Interactions in Healthy Volunteers|"Modafinil-Alcohol Interactions Assessed Using Tests of Thermal Stimulation, Cognition, Mood, and Motor Function in Healthy Volunteers"||University of California, San Francisco||Terminated|March 2006|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research||||32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 23, 2011|March 17, 2006|||This study should be terminated as the study closed prior to 2007 and the investigator has    since retired. No records are available.|No||https://clinicaltrials.gov/show/NCT00305292||184044|
NCT00296166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAT-SKOPI study|Catheter Ablation Versus Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation|A Randomized Study That Will Show the Effects of Catheter Ablation Compared to the Effects of Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation.||Rigshospitalet, Denmark|Yes|Terminated|November 2006|November 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||July 2007|September 1, 2010|February 23, 2006|||Patients with permanent AF are seldomly symptomatic enough to justify intervention. We decided    to stop inclusion due to low recruitment rate.|No||https://clinicaltrials.gov/show/NCT00296166||184725|
NCT00296179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0166|Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro|Comparison of Zolpidem Tartrate Extended-Release vs. Placebo in Treatment of Insomnia Associated With Newly Diagnosed Major Depressive Disorder(MDD) or Untreated MDD Relapse, When Used Concomitantly With Escitalopram||Sanofi||Completed|February 2006|||June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||372|||Both|21 Years|64 Years|No|||July 2008|July 25, 2008|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00296179||184724|
NCT00305526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REBEAT 1.5|REBEAT Resynchronisation and Beta-Blocker European Trial|Resynchronisation and Beta-Blocker European Trial||Guidant Corporation||Terminated|April 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|354|||Both|18 Years|N/A|No|||August 2007|August 8, 2007|March 21, 2006|||lack of enrolment|No||https://clinicaltrials.gov/show/NCT00305526||184027|
NCT00305539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P041203|HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis|HECTHOR: A Pilot Multicenter Double-blind Randomised Study of 3 Months Treatment With Humira Added to Steroids in Giant Cell Arteritis||Assistance Publique - Hôpitaux de Paris|No|Completed|May 2006|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|50 Years|N/A|No|||July 2012|July 6, 2012|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305539||184026|
NCT00296413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000379|A Study to Look at Hormone Levels While on Lamictal or Depakote With or Without an Oral Contraceptive|Variation of Serum Valproate and Lamotrigine Levels in Relation to The Menstrual Cycle and Oral Contraceptive Use||Beth Israel Deaconess Medical Center|No|Completed|February 2006|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|48|Samples Without DNA|Serum Samples for hormone testing|Female|13 Years|45 Years|No|Non-Probability Sample|Two regional epilepsy centers|March 2010|March 15, 2010|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00296413||184706|
NCT00296426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002458/1|Implementation and Evaluation of a Medical Reconciliation Protocol at Brigham and Women's Hospital|Implementation and Evaluation of a Medical Reconciliation Protocol||Brigham and Women's Hospital||Active, not recruiting|May 2006|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|500|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296426||184705|
NCT00297245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21124941|Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass|||Huazhong University of Science and Technology||Recruiting|February 2006|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|18 Years|65 Years|No|||January 2006|February 27, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297245||184643|
NCT00296920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0118-B|Deep Brain Stimulation for Refractory Major Depression|Deep Brain Stimulation for Refractory Major Depression||University Health Network, Toronto||Completed|June 2002|||November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|30 Years|70 Years|No|||September 2005|February 16, 2009|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296920||184667|
NCT00297440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03CA119712|Exercise, Smoking Cessation and Adolescents|Exercise to Aid Smoking Cessation in Adolescent Girls||Temple University|No|Active, not recruiting|March 2006|August 2011|Anticipated|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|13 Years|19 Years|Accepts Healthy Volunteers|||July 2010|July 22, 2010|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297440||184628|
NCT00297791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA007|COLOR II: Laparoscopic Versus Open Rectal Cancer Removal|A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer.|COLORII|Nova Scotia Health Authority|Yes|Active, not recruiting|June 2004|October 2017|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1100|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297791||184602|
NCT00308256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.395|Effects of Nurse-counselling in the Improvement of the type1 Diabetes Control in Adolescents|Effects of Nurse-counselling in the Improvement of the type1 Diabetes Control in Adolescents: a Randomized Controlled Trial||Hospices Civils de Lyon||Completed|March 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|77|||Both|13 Years|18 Years|No|||December 2011|December 28, 2011|March 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00308256||183821|
NCT00303953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01096|PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma|Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas||National Cancer Institute (NCI)||Completed|January 2006|August 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||April 2013|April 23, 2014|March 15, 2006|Yes|Yes||No|February 28, 2012|https://clinicaltrials.gov/show/NCT00303953||184140|
NCT00299780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-109|Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.|Phase I Study of Parathyroid Hormone in Combination With G-CSF in Patients Requiring Additional Stem Cell Mobilization||Massachusetts General Hospital|Yes|Completed|July 2004|April 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|75 Years|No|||April 2007|April 23, 2007|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299780||184452|
NCT00300079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-05-13|Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension|A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension||Alcon Research||Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2008|April 7, 2012|March 6, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00300079||184429|
NCT00300092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI 99.156|Pediatric Fingertip Injuries:Are Antibiotics Required?|Pediatric Fingertip Injuries: Do Prophylactic Antibiotics Alter Infection Rates?||Children's Hospital Los Angeles|No|Completed|September 2000|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|N/A|18 Years|No|||April 2015|April 16, 2015|March 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00300092||184428|
NCT00305344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2005-362|Umbilical Cord Blood Infusion to Treat Type 1 Diabetes|Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study||University of Florida|Yes|Completed|April 2005|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|1 Year|N/A|No|||July 2012|July 3, 2012|March 17, 2006|Yes|Yes||No|March 2, 2012|https://clinicaltrials.gov/show/NCT00305344||184041|Small sample size. No randomized control group
NCT00305578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-43|Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression|Memantine Augmentation of Lamotrigine Incomplete Response in Bipolar Depression: A Randomized Placebo Controlled Clinical Trial||Indiana University|Yes|Completed|August 2005|December 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||October 2015|October 2, 2015|September 14, 2005||No||No|June 30, 2015|https://clinicaltrials.gov/show/NCT00305578||184023|
NCT00304174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5049/#6178R|Motivating Factors That Play a Role in Bulimia Nervosa|Translational Research on Eating Disorders: Behavioral Assessment of Motivation to Eat||New York State Psychiatric Institute|No|Active, not recruiting|May 2005|June 2017|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Participants who meet DSM-IV criteria for bulimia nervosa and control participants who        weigh between 80 and 120% of ideal weight|October 2013|March 24, 2015|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00304174||184127|
NCT00304460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060115|Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer|Studies on the Mechanism of Action of High-Dose IL-2 in Metastatic Melanoma and Renal Cell Cancer||National Institutes of Health Clinical Center (CC)||Completed|March 2006|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|138|||Both|18 Years|N/A|No|||February 2014|October 23, 2014|March 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00304460||184106|
NCT00304473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449C00001|Fast Titration in the Treatment of Schizophrenia, Taiwan|Fast Titration of Quetiapine Versus Conventional Titration in the Treatment of Schizophrenia/Schizoaffective Disorder: a Randomised, Parallel Group Open Trial||AstraZeneca||Completed|August 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304473||184105|
NCT00304499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005965|Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence|Efficacy and Safety of OROS® Oxybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence||Alza Corporation, DE, USA||Completed|December 1995|December 1996||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||176|||Female|40 Years|N/A|No|||April 2010|May 18, 2011|March 17, 2006||||||https://clinicaltrials.gov/show/NCT00304499||184104|
NCT00304512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAB-CL-204|A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease|A Phase 2, Open-Label, Multiple Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Female Patients With Fabry Disease||Amicus Therapeutics|No|Completed|May 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Female|18 Years|65 Years|No|||April 2015|April 8, 2015|March 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00304512||184103|
NCT00304824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-Guk-2004-002|Assessment of the Ability to Distinguish Odors in Glaucoma Patients|Olfactory Function in Glaucoma Patients||University Hospital, Basel, Switzerland|No|Completed|October 2004|November 2005|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|17 Years|70 Years|No|Non-Probability Sample|glaucoma patients|September 2008|September 25, 2008|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304824||184079|
NCT00295880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS072|Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer|A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25)||Masonic Cancer Center, University of Minnesota|Yes|Terminated|June 2005|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|12 Years|45 Years|No|||November 2012|November 6, 2012|February 23, 2006|Yes|Yes|Time to engraftment would not be improved compared to historical controls.|No|March 25, 2009|https://clinicaltrials.gov/show/NCT00295880||184746|This study was terminated early based on interim statistical analysis that indicated time to engraftment will not be improved compared to historical controls. While safe, lack of faster marrow recovery supports early discontinuation.
NCT00296192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0873|Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms|A Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Trial to Assess the Tolerability, Safety, and Efficacy of Rotigotine Nasal Spray for the Acute Treatment of "OFF" Symptoms in Subjects With Advanced-Stage, Idiopathic Parkinson Disease||UCB Pharma|No|Completed|February 2006|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|82|||Both|30 Years|N/A|No|||February 2011|September 24, 2014|February 22, 2006|No|Yes||No|July 30, 2009|https://clinicaltrials.gov/show/NCT00296192||184723|
NCT00296153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN K85 05026|Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment|Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids||Pronova BioPharma|No|Completed|February 2006|October 2007|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||March 2008|March 10, 2008|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00296153||184726|
NCT00296686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4213|Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression|A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine.||New York State Psychiatric Institute|No|Terminated|September 2001|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||April 2012|April 26, 2012|February 23, 2006|No|Yes|Study is no longer funded.|No||https://clinicaltrials.gov/show/NCT00296686||184685|
NCT00307788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P001139|Acupuncture Analgesia in Relation to Psychiatric Comorbidity|The Association Amongst Acupuncture Analgesia, Expectancy, and Psychiatric Comorbidity in Patients With Low Back Pain|LBP|Brigham and Women's Hospital|Yes|Completed|May 2004|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 24, 2012|March 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00307788||183857|
NCT00307801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91470|Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.||Bayer|No|Completed|February 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|231|||Female|18 Years|N/A|No|||December 2014|December 8, 2014|March 27, 2006||No||No|March 2, 2011|https://clinicaltrials.gov/show/NCT00307801||183856|
NCT00297453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA 09253-7|Smoking Treatment in HIV Clinical Care Settings|||University of California, San Francisco|No|Completed|January 2006|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|207|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 25, 2012|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00297453||184627|
NCT00308061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1029|Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali|Dbl Blind Randomized Controlled Phase I Trial to Eval the Safety and Immunogenicity of WRAIR’s MSP1 Candidate Malaria Vaccine (FMP1) Adjuvant in GSK Bio's AS02A vs. Rabies Vaccine in Semi-Immune Adults in Bandiagara, Mali.||Walter Reed Army Institute of Research (WRAIR)||Completed|July 2003|July 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2006|December 1, 2006|March 24, 2006||||||https://clinicaltrials.gov/show/NCT00308061||183836|
NCT00303992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465211|Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer|Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial||University of California, San Francisco|Yes|Completed|May 2004|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|N/A|No|||March 2015|March 13, 2015|March 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303992||184137|
NCT00304265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI05|Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine|Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination||Sanofi|Yes|Completed|March 2006|October 2007|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|215|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|March 16, 2006||No||No|February 10, 2011|https://clinicaltrials.gov/show/NCT00304265||184120|
NCT00304239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC T405/05|Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp|A Multicenter, Double Blind, Vehicle-controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream and Aktilite CL128 LED Light in Patients With Multiple Actinic Keratosis on the Face and/or Scalp||Galderma|No|Completed|March 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|March 16, 2006||||||https://clinicaltrials.gov/show/NCT00304239||184122|
NCT00304252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22916|Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease|A Phase II, Multicenter, Randomised, Double-blind, Placebo Controlled, Dose Finding Study of Subcutaneously Administered Interferon Beta-1a for Maintenance of Remission in Patients With Crohn's Disease||EMD Serono||Terminated|November 2001|September 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||192|||Both|18 Years|N/A||||August 2013|August 4, 2013|March 14, 2006|||Lack of Efficacy|No||https://clinicaltrials.gov/show/NCT00304252||184121|
NCT00304564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-02-01-06-02|Study of the Effect of the Music of Nolwenn Leroy in Fall Prevention Strategies in Texas Nursing Homes|Fall Prevention and The Nolwenn Effect in Texas Geriatric Nursing Home Settings||Carrick Institute for Graduate Studies|No|Completed|February 2006|March 2007|Actual|April 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|100|||Both|50 Years|N/A|No|||January 2016|January 26, 2016|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00304564||184099|
NCT00304837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND 11948|VEGF Gene Transfer for Critical Limb Ischemia|||Losordo, Douglas, M.D.||Completed||April 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|21 Years|N/A||||April 2008|October 18, 2010|March 16, 2006||||||https://clinicaltrials.gov/show/NCT00304837||184078|
NCT00305357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5612-16138|Evolution of Pain From Herpes Zoster|Evolution of Pain and Neural Dysfunction From Acute Herpes Zoster to Post-Herpetic Neuralgia||University of California, San Francisco||Completed|November 2001|December 2006|Actual|November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|50 Years|N/A|No|Non-Probability Sample|Males and females aged 50 or older with outbreak of herpes zoster occurring less than 6        weeks prior to study entry.|March 2011|April 12, 2011|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00305357||184040|
NCT00304187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4902|Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa|Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa||New York State Psychiatric Institute|No|Completed|September 2004|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|June 21, 2013|March 15, 2006||No||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00304187||184126|
NCT00304200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Temodar/Sutent|Temodar and Sutent as Therapy for Melanoma|Temodar and Sutent as Therapy for Patients With Malignant Melanoma, a Phase I/II Study||Northern California Melanoma Center|Yes|Terminated|March 2006|January 2009|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|March 12, 2006||No|Funding was inadequate to continue; Companies requested closure.|No||https://clinicaltrials.gov/show/NCT00304200||184125|
NCT00304525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAF265A2101|A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma|A Phase I/II, Open-label, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265)Administered Orally to Patients With Locally Advanced or Metastatic Melanoma.|CHIR-265-MEL01|Novartis|No|Completed|April 2006|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|104|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|March 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00304525||184102|
NCT00295607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-01-28|Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients|Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in HCV Positive in Liver Transplantation|CHASE|Astellas Pharma Inc|Yes|Completed|June 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|138|||Both|18 Years|65 Years|No|||September 2011|April 9, 2013|February 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295607||184767|
NCT00295620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033AU/0003|Secondary Adjuvant Long Term Study With Arimidex|A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy|SALSA|AstraZeneca|Yes|Active, not recruiting|March 2004|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3500|||Female|N/A|80 Years|No|||March 2016|March 21, 2016|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295620||184766|
NCT00306956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUNDASAMIN101|Influence of Pacifiers on Breastfeeding Duration|Influence of Pacifiers on Breastfeeding Duration: a Multicentre, Randomised Controlled Trial||Fundacion para la Salud Materno Infantil|Yes|Completed|March 2006|May 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|1021|||Both|N/A|18 Days|Accepts Healthy Volunteers|||September 2008|September 18, 2008|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00306956||183919|
NCT00306969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-391G|Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma|Phase I/II Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma||Boston University||Completed|December 2001|April 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||September 2004|March 23, 2006|March 23, 2006||||No||https://clinicaltrials.gov/show/NCT00306969||183918|
NCT00296439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0034|Nutrition Counseling to Lower Serum Phosphorus Levels|Comparison of Different Counseling Methods on Serum Phosphorus Levels in Renal Patients at Hines VA Hospital||Edward Hines Jr. VA Hospital||Recruiting|February 2006|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||44|||Both|19 Years|85 Years|No|||February 2006|February 23, 2006|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296439||184704|
NCT00296452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033|Effect of a Nutritional Supplement on H&N Cancer Patients|The Effect of an Enhanced Nutritional Supplement on Head and Neck Cancer Patients||Edward Hines Jr. VA Hospital||Recruiting|February 2006|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|30 Years|80 Years|No|||February 2006|February 23, 2006|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296452||184703|
NCT00296699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4943|A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression|A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression||New York State Psychiatric Institute||Completed|March 2005|||June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||January 2008|January 14, 2008|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296699||184684|
NCT00304005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VION-CLI-041|VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders|A Phase I/II Study of Cloretazine in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia or Richter's Syndrome||National Cancer Institute (NCI)||Completed|July 2005|August 2008|Actual|October 2005|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||August 2008|July 17, 2013|March 15, 2006||||||https://clinicaltrials.gov/show/NCT00304005||184136|
NCT00304291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNI-NMO-101|A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)|A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)||State University of New York at Buffalo||Completed|August 2001|May 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|55 Years|No|||March 2006|November 27, 2006|March 15, 2006||||No||https://clinicaltrials.gov/show/NCT00304291||184118|
NCT00304603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003409|Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus|A Study to Evaluate the Mode of Action of Topiramate in the Treatment of Obese Subjects With and Without Type 2 Diabetes Mellitus Using DNA Samples From Subjects Who Were Randomized Within Select Previous Topiramate Studies||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2004|April 2005|Actual|April 2005|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1145|Samples With DNA|Whole blood|Both|18 Years|75 Years|No|Probability Sample|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or        PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within        the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study).|November 2012|November 27, 2012|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304603||184096|
NCT00300729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLCSG0501|Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy|Cox-2-Inhibitor and Chemotherapy in Non-Small Cell Lung Cancer. A Prospective Randomized Double-Blind Study|CYCLUS|University Hospital, Linkoeping|Yes|Active, not recruiting|May 2006|September 2010|Anticipated|May 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00300729||184380|
NCT00300742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12069|Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals|Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual||University of Virginia|Yes|Completed|March 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|March 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00300742||184379|
NCT00304577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662720|Bilateral Recession or Unilateral Recession-Resection as Surgery for Infantile Esotropia|A Randomized Comparison of Bilateral Recession With Unilateral Recession-Resection as Surgery for Infantile Esotropia||Erasmus Medical Center||Completed|January 1998|December 2001||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|3 Years|8 Years|Accepts Healthy Volunteers|||September 2005|March 17, 2006|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304577||184098|
NCT00304850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9258-03|Polyamine-free Diet to Prevent Post Surgery Hyperalgesia|Efficacy of a Polyamine-free Diet Associated or Not With Ketamine on Early and Late Hyperalgesia After Breast Cancer Surgery|PoLyDOL|University Hospital, Bordeaux|Yes|Completed|March 2006|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Female|18 Years|75 Years|No|||December 2009|December 24, 2009|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304850||184077|
NCT00301951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465362|Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer|Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies||University of California, San Francisco|Yes|Completed|September 2004|July 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||June 2015|June 30, 2015|March 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00301951||184290|
NCT00301964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02692|Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC# 704865, IND # 7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|October 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|18 Years|N/A|No|||October 2013|November 19, 2014|March 9, 2006|Yes|Yes||No|November 19, 2014|https://clinicaltrials.gov/show/NCT00301964||184289|
NCT00305097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK46200 (completed)|Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance|Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Active, not recruiting|March 2006|September 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 10, 2011|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305097||184059|
NCT00305110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 0511307|Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain|Safety and Speed of Onset of a Fixed Dose of Intravenous Hydromorphone in the Treatment of Adult Patients Presenting to the Emergency Department With Acute Severe Pain||Montefiore Medical Center||Completed|January 2006|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00305110||184058|
NCT00302523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0603|Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy|Tacrolimus Treatment of Patients With Idiopathic||Nanjing University School of Medicine|Yes|Completed|March 2006|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00302523||184247|
NCT00304226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631B2406|Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy|A 14 Week Study to Evaluate Effectiveness of a Valsartan Versus an Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy||Novartis||Completed|February 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1288|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00304226||184123|
NCT00304538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIO-103|A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus|A Phase 1b, Single-Blind Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Three Separate Dose Levels of Very Low Dose-Glucagon Administered Subcutaneously Overnight for 6, 9 or 12 Hours in Subjects With Type 1 Diabetes Mellitus||DiObex||Completed|March 2006|July 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||10|||Both|18 Years|55 Years|No|||August 2006|August 21, 2006|March 16, 2006||||||https://clinicaltrials.gov/show/NCT00304538||184101|
NCT00304551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JV19595|A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)|A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC||Chugai Pharmaceutical|No|Completed|June 2006|June 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|20 Years|75 Years|No|||June 2010|June 1, 2010|March 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00304551||184100|
NCT00295373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0HQ01|Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?|Phase 4 Clinical Trial to Examine the Role of Rosuvastatin and Exercise Treatment in Modulating Inflammatory Response in Hypercholesterolemic Subjects||Purdue University||Active, not recruiting|February 2006|August 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||48|||Both|40 Years|65 Years|No|||April 2007|April 19, 2007|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295373||184784|
NCT00296205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20055203|Phase II High-Dose Cyclophosphamide for Multiple Sclerosis|Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis||Stony Brook University||Withdrawn|October 2003|February 2006|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|75 Years|No|||October 2006|July 21, 2009|February 23, 2006|||I am changing locations to Johns Hopkins Medical Center|||https://clinicaltrials.gov/show/NCT00296205||184722|
NCT00307567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105555|Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488|Evaluate Booster Vaccination With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or to Evaluate the Immune Memory Following a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children, Previously Vaccinated in Infancy in the Primary Study 103488||GlaxoSmithKline||Completed|November 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||689|||Both|11 Months|18 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00307567||183874|
NCT00296465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-05|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Administered Intravenously or Subcutaneously (Via Portable Infusion Pump) Compared to Oral Treatment With Clomiphene Citrate in Anovulatory or Oligoovulatory Infertile Females||Ferring Pharmaceuticals|Yes|Completed|February 2005|November 2005|Actual|November 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|132|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 18, 2011|February 23, 2006|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00296465||184702|
NCT00307541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105554|Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine|Phase IIIa Randomized, Controlled Study to Assess the Immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered as a 3-dose Primary Immunization Course Before 6 Months of Age||GlaxoSmithKline||Completed|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||120|||Both|8 Weeks|16 Weeks|Accepts Healthy Volunteers|||September 2011|September 21, 2011|March 7, 2006||||No||https://clinicaltrials.gov/show/NCT00307541||183876|
NCT00307554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105553|A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study|Assess Lot-to-lot Consistency of 3 Lots (Double Blind Design) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Vaccine and Evaluate Non-inferiority to Prevenar™ (Single Blind Design) When Administered as 3-dose Primary Immunization Course Before 6 Months of Age||GlaxoSmithKline||Completed|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1600|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2014|September 8, 2014|March 8, 2006||||No||https://clinicaltrials.gov/show/NCT00307554||183875|
NCT00304616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOP-010402|SWitching to Abilify Trial (SWAT)|A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients||Korea Otsuka Pharmaceutical Co.,Ltd.||Completed|October 2004|October 2007|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|65 Years|No|||December 2009|December 15, 2009|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304616||184095|
NCT00304629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012070|Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease|Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2000|March 2002|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|241|||Both|45 Years|N/A|No|||January 2011|January 31, 2011|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304629||184094|
NCT00304889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18736|Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis|Vancomycin Vs. Nitazoxanide to Treat Clostridium Difficile Colitis That Has Failed Therapy With Metronidazole||VA Medical Center, Houston||Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated for C. difficile.|February 2013|June 1, 2015|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304889||184074|
NCT00304902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18867|Chart Review of Outcome of Treatment for S. Aureus Bacteremia|Retrospective Chart Review of the Outcome of Treatment for Staphylococcus Aureus Bacteremia||VA Medical Center, Houston|No|Completed|February 2006|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|120|||Both|18 Years|64 Years|No|Non-Probability Sample|All patients with Staphylococcus aureus in a blood culture.|September 2010|September 9, 2010|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304902||184073|
NCT00305149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|riskadapted beacopp/CTIL|Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma|Use of Risk Factors for Initiation Therapy With Beacopp or Escalated Beacopp and Interim Evaluation and Modification of Therapy Based on Scintigraphy Results.||Rambam Health Care Campus||Completed|July 1999|December 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||130|||Both|18 Years|65 Years|No|||March 2006|March 20, 2006|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00305149||184055|
NCT00301379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0651 / 201102096|Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients|Prospective Registry Study of Neoadjuvant Chemoradiation in Conjunction With Liver Transplantation for Cholangiocarcinoma With Induction Gemcitabine, Followed by 3D Conformal Radiation With 5-FU as a Radiosensitizer, and Maintenance Xeloda Therapy Until Liver Transplantation||Washington University School of Medicine|No|Recruiting|August 2005|October 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Non-Probability Sample|Primary care clinic.|December 2015|December 17, 2015|March 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00301379||184331|
NCT00301392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-PREDICT|Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)|Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)||Tokyo University|No|Completed|April 2006|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1240|||Both|30 Years|74 Years|No|||September 2013|September 5, 2013|March 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00301392||184330|
NCT00301652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0607|MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis|Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Treatment of ANCA Associated Vasculitis||Nanjing University School of Medicine|Yes|Completed|June 2003|December 2005|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||March 2009|June 7, 2010|March 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00301652||184310|
NCT00302003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD0431|Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma|A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease||Children's Oncology Group|Yes|Active, not recruiting|February 2006|||March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|287|||Both|N/A|21 Years|No|||August 2015|August 21, 2015|March 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00302003||184287|
NCT00302289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01-188/00|B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients|B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients||University of Copenhagen||Completed|January 2000|December 2000||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2000|March 13, 2006|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302289||184265|
NCT00302276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF11-150/03|Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)|Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)||University of Copenhagen||Completed|January 2004|July 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2004|January 20, 2009|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302276||184266|
NCT00302861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-11|A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Phase 1/2 Study to Evaluate the Feasibility and Tolerability of Treatment of Previously Untreated B-CLL Chronic Lymphocytic Leukemia (B-CLL) Patients With Recombinant Idiotype Conjugated to KLH (Id-KLH) Administered With GM-CSF||Genitope Corporation||Terminated|March 2006|||||Phase 1/Phase 2|Interventional|N/A||||86|||Both|18 Years|N/A||||March 2008|March 14, 2008|March 13, 2006||||||https://clinicaltrials.gov/show/NCT00302861||184221|
NCT00303186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101750|Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy|An Observational Study to Evaluate the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy||Pfizer|No|Completed|February 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with PsA who are failure to the conventional treatments according to the local        recommendations, will be enrolled in the study through tertiary referrals centers (HRCs        i.e., Hospital Rheumatolgic Centers).|June 2012|June 25, 2012|March 14, 2006||No||No|June 25, 2012|https://clinicaltrials.gov/show/NCT00303186||184197|Results were not summarized for Month 6, 18 and 24 due to insufficient data collected and small sample size achieved at the time points.
NCT00295074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402095|The Effect of Mild Traumatic Brain Injury on Recovery From Injury|The Effect of Mild Traumatic Brain Injury on Recovery From Injury||University of Pittsburgh||Completed|October 2004|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|800|||Both|18 Years|N/A|No|||February 2008|February 7, 2008|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00295074||184806|
NCT00295360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDR-108-03|Expression of BCRP in Icteric Patients|Influence of Cholestasis on Intestinal BCRP Expression||University Hospital, Basel, Switzerland||Completed|June 2003|August 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2005|February 22, 2006|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00295360||184785|
NCT00307255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0520|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors|Phase I Trial of Abraxane in Combination With Gemcitabine in Patients With Solid Tumors||UNC Lineberger Comprehensive Cancer Center||Completed|August 2006|October 2008|Actual|September 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|March 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00307255||183896|
NCT00307840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/4-2-2005|Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism|Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism||Papageorgiou General Hospital||Completed|February 2005|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2005|March 27, 2006|March 27, 2006||||No||https://clinicaltrials.gov/show/NCT00307840||183853|
NCT00307242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05U.164|Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B|A Single Center Open-Label, Randomized Study Comparing the Safety of Immediately Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir for 12 Weeks Before Instituting Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B||Thomas Jefferson University|Yes|Completed|May 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|March 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307242||183897|
NCT00308074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0119/06/05|An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders|A Prospective Open-Label Trial of Aripiprazole Monotherapy in the Autism Spectrum Disorders (ASD)||Cambridge Health Alliance|No|Completed|February 2006|February 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|6 Years|17 Years|No|||December 2010|December 2, 2010|March 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00308074||183835|
NCT00304642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM004|A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel|A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel in Healthy HIV-Negative Women.||International Partnership for Microbicides, Inc.||Completed|November 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||18|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2006|June 1, 2006|March 16, 2006||||||https://clinicaltrials.gov/show/NCT00304642||184093|
NCT00304655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOP-010401|Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)|Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder.||Korea Otsuka Pharmaceutical Co.,Ltd.||Completed|July 2004|October 2007|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|65 Years|No|||December 2009|December 15, 2009|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304655||184092|
NCT00304915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNT 05-152|HIV Translating Initiatives for Depression Into Effective Solutions|HIV Translating Initiatives for Depression Into Effective Solutions|HI-TIDES|VA Office of Research and Development|Yes|Active, not recruiting|February 2007|June 2016|Anticipated|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|249|||Both|18 Years|75 Years|No|||October 2015|October 23, 2015|March 16, 2006||No||No|September 10, 2014|https://clinicaltrials.gov/show/NCT00304915||184072|
NCT00304941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060119|Insulin Resistance and Breast Cancer|Breast Cancer and Insulin Resistance: Implications for Preventive Counseling in Familial and Sporadic Cases||National Institutes of Health Clinical Center (CC)||Completed|March 2006|September 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|25|||Female|30 Years|70 Years|No|||September 2010|September 18, 2010|March 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00304941||184071|
NCT00305162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CAN-05-02|A Clinical Trial to Demonstrate the Efficacy of Cangrelor|A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).|PCI|The Medicines Company|Yes|Terminated|April 2006|June 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8882|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|March 17, 2006|No|Yes|Insufficient evidence of the clinical effectiveness of cangrelor|No|April 22, 2013|https://clinicaltrials.gov/show/NCT00305162||184054|Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely to meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified.
NCT00305409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZB/4/335|Synbiotic Treatment in Crohn's Disease Patients|Synbiotic Treatment in Crohn's Disease Patients||University of Dundee||Completed|June 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|79 Years|No|||February 2009|February 10, 2009|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00305409||184036|
NCT00301093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-126|Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2005|||May 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00301093||184352|
NCT00301106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456626|Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver|Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patients With Metastatic Breast Cancer to the Liver||National Cancer Institute (NCI)||Active, not recruiting|October 2005|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Female|18 Years|85 Years|No|||February 2009|February 27, 2009|March 8, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00301106||184351|
NCT00301405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-149 IND #74,062|Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain|Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain||William Beaumont Hospitals|No|Terminated|March 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 1, 2013|March 9, 2006|Yes|Yes|Study closed. Difficult enrollment of patients with prostatitis.|No||https://clinicaltrials.gov/show/NCT00301405||184329|
NCT00301665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52120-715|Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis|A Phase II, Multicentre, Randomised, Double-Blind, Parallel Groups, Placebo Controlled Clinical Study of Efficacy and Safety of Dysport® for Migraine Prophylaxis||Ipsen||Completed|February 2003|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||120|||Both|18 Years|65 Years|No|||September 2007|September 12, 2007|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301665||184309|
NCT00301678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453539|Personalized Nutrition Education in Improving Eating Habits of Healthy Participants Who Eat an Unhealthy Diet|Innovative Video Tailoring for Dietary Change||National Cancer Institute (NCI)||Active, not recruiting|June 2001|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|2520|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|September 16, 2013|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301678||184308|
NCT00301990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000460074|Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study||National Cancer Institute (NCI)||Recruiting|September 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||April 2007|January 9, 2014|March 10, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00301990||184288|
NCT00302874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gil362-HMO-CTIL|In-Hospital Hyperglycemia: Effects of Treatment on Glycemic Control and Clinical Outcome|In-Hospital Hyperglycemia: Effects of Treatment on Glycemic Control and Clinical Outcome||Hadassah Medical Organization||Completed|February 2003|October 2004||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||400|||Both|N/A|N/A|No|||October 2002|March 23, 2007|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00302874||184220|
NCT00302536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0604|Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis|Tacrolimus Treatment of Patients With Idiopathic Focal Segmental||Nanjing University School of Medicine|Yes|Withdrawn|March 2006|September 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||September 2010|February 8, 2012|March 13, 2006||No|There was less patients recruited.|No||https://clinicaltrials.gov/show/NCT00302536||184246|
NCT00306124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL_001 Project on Dementia/MCI|Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment|Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI)||University Hospital Muenster||Recruiting|January 2006|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2007|October 24, 2007|March 21, 2006||||No||https://clinicaltrials.gov/show/NCT00306124||183983|
NCT00306137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11800|Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung Cancer or Esophageal Cancer||Bayer|No|Terminated|December 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|March 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00306137||183982|
NCT00299221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TICTAC|Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients|Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients|TICTAC|Newark Beth Israel Medical Center|No|Completed|April 2004|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|March 2, 2006||No||No|September 10, 2010|https://clinicaltrials.gov/show/NCT00299221||184495|This trial enrolled 150 patients, but cannot be used to generalize care to other patients without careful consideration of risks and benefits. All patients had corticosteorids weaned so this trial doesn't assess the risk of steroid weaning.
NCT00295087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511043|X-Chromosome Inactivation Status and Premature Ovarian Failure|X-Chromosome Inactivation Status and Premature Ovarian Failure||University of Pittsburgh|Yes|Completed|November 2005|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|13|Samples With DNA|DNA that is extracted from the blood specimen|Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will include women diagnosed with POF through clinics. Women diagnosed        with POF may also inquire about this study through the Clinical Trials website.|December 2014|December 5, 2014|February 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00295087||184805|
NCT00295893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05015|Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer|Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer||City of Hope Medical Center|Yes|Active, not recruiting|September 2005|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|120 Years|No|||February 2016|February 10, 2016|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295893||184745|
NCT00295906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454721|Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control|Efficacy of Web-Based Instruction on Skin Cancer Triage||National Cancer Institute (NCI)||Recruiting|June 2004|||January 2008|Anticipated|N/A|Interventional|Allocation: Randomized|||Anticipated|4550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|December 17, 2013|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00295906||184744|
NCT00307580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2404g|Cathflo Activase Pediatric Study|Cathflo Activase (Alteplase) Pediatric Study (CAPS)||Genentech, Inc.||Completed|April 2002|May 2003|Actual|||Phase 4|Interventional|Primary Purpose: Treatment||||300|||Both|N/A|17 Years|No|||April 2014|April 8, 2014|March 25, 2006||||No||https://clinicaltrials.gov/show/NCT00307580||183873|
NCT00307827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-418|Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)|A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis||Abbott|Yes|Terminated|April 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|March 24, 2006|Yes|Yes|Study Canceled|No||https://clinicaltrials.gov/show/NCT00307827||183854|
NCT00308100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFP502|Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation|A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation||Fresenius Kabi|Yes|Terminated|October 2005|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||January 2009|January 14, 2009|March 28, 2006||No|Study is prematurely ended due to poor patient recruitment rate.|No||https://clinicaltrials.gov/show/NCT00308100||183833|
NCT00307814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005101|A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)|A Randomized, Open-Label Clinical Evaluation of PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease||Ortho Biotech Products, L.P.||Completed|January 2002|January 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|519|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00307814||183855|
NCT00304031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0525|Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma|Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|January 2006|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1173|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|March 15, 2006|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00304031||184134|This was a two-stage study in which participants were registered, received concomitant RT and TMZ, and then were randomized to standard or dose-dense adjuvant TMZ. Some patients were not randomized, resulting in the third arm (No adjuvant TMZ).
NCT00304304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20057395|HealthSpark 2: Improving Asthma Care for Preschool Children|Community - Based Asthma Intervention in Subsidized Preschools||University of Miami|No|Completed|February 2006|June 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|2000|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|March 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00304304||184117|
NCT00304954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060111|Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration|Treatment of Choroidal Subretinal Neovascularization With Agents Directed Against the Immune Response|AMDB1|National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Both|55 Years|92 Years|No|||April 2011|April 13, 2011|March 17, 2006|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00304954||184070|
NCT00305175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUSTLE|Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease|Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease||St. Jude Children's Research Hospital|No|Active, not recruiting|March 2006|January 2026|Anticipated|January 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Whole Blood|Both|N/A|30 Years|No|Non-Probability Sample|Study participants will be patients with sickle cell disease who receive medical care from        the Department of Hematology staff of St. Jude Children's Research Hospital. All patients        on hydroxyurea therapy or patients who are initiating hydroxyurea therapy will be invited        to participate.|May 2015|October 6, 2015|March 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00305175||184053|
NCT00305422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077/9007|Effect of Quetiapine on Negative Symptoms and Cognition|Efficacy of Quetiapine Compared to Risperidone on Negative Symptoms and Cognition With Regard to Underlying Neurobiological Mechanisms and Brain Activation.||AstraZeneca||Completed|November 2001|January 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|65 Years|No|||June 2009|June 9, 2009|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00305422||184035|
NCT00305435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050162|Safety Study of AMG 531 in Japanese Subjects With ITP|An Open Label Phase 2 Study Evaluating the Safety of Starting Dose of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura||Kyowa Hakko Kirin Company, Limited|No|Completed|February 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||September 2014|September 11, 2014|March 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00305435||184034|
NCT00301691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUSM-R01-CA81828|Nutrition Education for Low-Income Healthy Participants Who Eat an Unhealthy Diet|Tailoring Nutrition Education for Low-Income Audiences||National Cancer Institute (NCI)||Completed|September 2000|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|July 9, 2013|March 9, 2006||||No||https://clinicaltrials.gov/show/NCT00301691||184307|
NCT00302016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2109|Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia|An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.||Novartis||No longer available|January 2006|||November 2008|Actual|Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||August 2011|August 25, 2011|March 9, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00302016||184286|
NCT00302302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 270121|The Effects of L-arabinose on Intestinal Sucrase Activity in Man|The Effects of Increasing Doses of L-arabinose in a Sucrose Rich Meal on Intestinal Sucrase Activity in Man||University of Copenhagen|No|Completed|September 2005|January 2006|Actual|November 2005|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Actual|15|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2014|February 25, 2014|September 21, 2005||No||No||https://clinicaltrials.gov/show/NCT00302302||184264|
NCT00302315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.T02.102.003|Effectiveness of Physiotherapy on Postcesarean Pain and Functional Activities|Effectiveness of Physiotherapy on Postcesarean Pain and Functional Activities||Hacettepe University||Completed|December 2004|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2006|March 13, 2006|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302315||184263|
NCT00302549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0602|To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN|To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class||Nanjing University School of Medicine|Yes|Completed|May 2004|February 2006|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||July 2008|May 25, 2010|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00302549||184245|
NCT00302562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701234|The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma|||National Taiwan University Hospital||Not yet recruiting|August 2006|July 2007||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|30 Years|75 Years|No|||December 2005|March 12, 2006|March 12, 2006||||No||https://clinicaltrials.gov/show/NCT00302562||184244|
NCT00302887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEK06/12-39|Connective Tissue Manipulation and Combined Ultrasound Therapy in Patients With Fibromyalgia|Short and Long Term Results of Connective Tissue Manipulation and Combined Ultrasound Therapy in Patients With Fibromyalgia||Hacettepe University||Completed|August 2003|December 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||20|||Female|19 Years|68 Years|Accepts Healthy Volunteers|||March 2006|March 14, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00302887||184219|
NCT00302900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|371|Preventing Negative Reactions in First Time Blood Donors to Encourage Subsequent Blood Donations|Preventing Adverse Reactions in Novice Blood Donors||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|January 2006|March 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 17, 2009|March 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00302900||184218|
NCT00303212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-HL-080228|Tele-HF: Yale Heart Failure Telemonitoring Study|A Study of Telemonitoring to Improve Heart Failure Outcomes||Yale University|Yes|Completed|March 2006|July 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1660|||Both|18 Years|N/A|No|||September 2010|September 16, 2010|March 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00303212||184195|
NCT00303498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321006|A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure|A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure||Pfizer|Yes|Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|March 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00303498||184173|
NCT00295633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-013|A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone|A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone||AstraZeneca||Completed|March 2006|October 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|565|||Both|18 Years|77 Years|No|||March 2015|March 18, 2015|February 22, 2006|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00295633||184765|
NCT00306709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH-04PMurp-01|Take HEED (Healthy Eating and Exercise Decisions)|Take HEED (Healthy Eating and Exercise Decisions)||Kaiser Permanente|No|Completed|February 2005|June 2010|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|223|||Female|40 Years|65 Years|No|||September 2010|September 17, 2010|March 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00306709||183938|
NCT00306982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106622|Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™|An Observational Study to Investigate the Incidence of Influenza, Downstream Complications of Influenza and Hospitalizations, in Elderly Subjects Vaccinated With GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly.||GlaxoSmithKline||Completed|March 2006|||||N/A|Observational|Time Perspective: Prospective||||2000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 9, 2008|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00306982||183917|
NCT00307853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP 06|TRAUMEEL for Pain After Total Knee/Hip Arthroplasty|A Randomised, Double - Blind, Placebo Controlled Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Controlling Pain After Total Knee and Total Hip Arthroplasty.||Shaare Zedek Medical Center||Terminated|August 2008|||August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||October 2009|October 18, 2009|March 27, 2006||No|lack of patients|No||https://clinicaltrials.gov/show/NCT00307853||183852|
NCT00307866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90956|Identification of Hepatic Lesions|A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.||Bayer||Completed|April 2001|May 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|218|||Both|18 Years|N/A|No|||May 2009|May 15, 2009|March 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00307866||183851|
NCT00308113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITT0503|CoQ10 and Prednisone in Non-Ambulatory DMD|PITT0503: Clinical Trial of Coenzyme Q10 and Prednisone in Duchenne Muscular Dystrophy||Cooperative International Neuromuscular Research Group|Yes|Terminated|April 2007|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3|||Male|10 Years|18 Years|No|||October 2013|October 16, 2013|March 27, 2006|Yes|Yes|New enrollment has been suspended, currently following previously enrolled participants|No|August 7, 2013|https://clinicaltrials.gov/show/NCT00308113||183832|In December 2007 the CINRG Data Safety and Monitoring Board (DSMB) met and recommended to close the study as the AAN had released practice parameters recommending that all patients with DMD should be offered treatment with corticosteroids.
NCT00308087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310421|Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma|Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-cell Lymphoma|PREMIER|Sanofi|Yes|Terminated|May 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|March 28, 2006|Yes|Yes|Terminated by sponsor due to low enrollment; see details below|No|June 11, 2010|https://clinicaltrials.gov/show/NCT00308087||183834|One hundred ninety-six patients were planned and 75 enrolled prior to termination. The study was terminated early due to low enrollment, and the extent of changes needed to the protocol to keep pace with therapeutic changes for indolent lymphoma.
NCT00304018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463370|Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer|Pilot Study of Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies||University of California, San Francisco||Completed|October 2002|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|55 Years|No|||August 2013|August 13, 2013|March 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00304018||184135|
NCT00304317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405M60562|Celecoxib (Celebrex) in the Management of Acute Renal Colic|Celecoxib in the Management of Acute Renal Colic||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|March 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|March 16, 2006||No|PI is no longer at the University of Minnesota|No||https://clinicaltrials.gov/show/NCT00304317||184116|
NCT00304967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060117|Dynamic Light Scattering to Study Crystalline Proteins in Young Normal Lenses|A Study of Crystalline Proteins in Young Normal Lenses Using the NASA-NEI Dynamic Light Scattering (DLS) Device||National Institutes of Health Clinical Center (CC)||Completed|March 2006|March 2007||||N/A|Observational|N/A||||30|||Both|5 Years|21 Years|Accepts Healthy Volunteers|||March 2007|March 5, 2008|March 18, 2006||||No||https://clinicaltrials.gov/show/NCT00304967||184069|
NCT00305188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5505|Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.|A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV||Sanofi||Completed|December 2005|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|879|||Both|18 Years|N/A|No|||December 2010|December 16, 2010|March 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00305188||184052|
NCT00305448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997C00004|A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg|Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy|FINDER I|AstraZeneca||Completed|March 2006|February 2012|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|143|||Female|N/A|N/A|No|||February 2012|February 14, 2012|March 20, 2006|Yes|Yes||No|March 17, 2009|https://clinicaltrials.gov/show/NCT00305448||184033|
NCT00302029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0126|CMV Infection in Adolescent Males|Seroprevalence and Prospective Risk Factor Analysis of Cytomegalovirus (CMV) Infection in Adolescent Males||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|June 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|411|Samples With DNA|Blood, urine and salvia samples.|Male|12 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|1000 males aged 12 - 17 years will be recruited from participating adolescent clinics at        Cincinnati Children's Hospital Medical Center (CCHMC), Vanderbilt University Medical        Center, and the University of Texas Medical Branch Galveston.|November 2009|November 10, 2011|March 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00302029||184285|
NCT00302328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMAH|Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes|A Randomised Clinical Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes||Glostrup University Hospital, Copenhagen|No|Completed|August 2005|January 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|N/A|N/A|No|||March 2014|March 13, 2014|March 13, 2006||No||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00302328||184262|non-closure of macular hole after surgical procedure in 18 patients led to re-operation. Data included in main published papers.
NCT00302575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01DA016191|Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved Parolees|Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved Parolees||National Institute on Drug Abuse (NIDA)||Recruiting|February 2005|August 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2006|February 1, 2010|March 13, 2006||||No||https://clinicaltrials.gov/show/NCT00302575||184243|
NCT00302601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70|Study of Diagnosis and Pathophysiology of Pulmonary Embolism (APE 1 Trial)|The Acute Pulmonary Embolism 1 (APE 1) Trial: Prospective Investigation of Scintigraphic Diagnosis and Pathophysiology of Right Heart Strain||Odense University Hospital||Suspended|April 2006|June 2009|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Diagnostic|||Anticipated|500|||Both|18 Years|N/A|No|||February 2009|February 4, 2009|March 13, 2006|||Logistics failure and staff/scanner shortage|No||https://clinicaltrials.gov/show/NCT00302601||184241|
NCT00302614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701256|The Role of Clinical Parameters in Predicting the Severity of Obstructive Sleep Apnea|||National Taiwan University Hospital||Recruiting|January 2006|June 2006||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|20 Years|60 Years|No|||December 2005|March 12, 2006|March 12, 2006||||No||https://clinicaltrials.gov/show/NCT00302614||184240|
NCT00302913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-BK-2005-2|Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition|Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition After Elective Coronary Stenting||Heart Center Bad Krozingen||Completed|December 2005|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||February 2006|June 29, 2006|March 14, 2006||||No||https://clinicaltrials.gov/show/NCT00302913||184217|
NCT00306722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0524|An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy|A Phase 3, Randomized, Double-Blind, Dose-Controlled Study To Assess The Efficacy And Safety Of AQUAVAN® (Fospropofol Disodium) Injection For Minimal-To-Moderate Sedation In Patients Undergoing Flexible Bronchoscopy||Eisai Inc.||Completed|April 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||November 2008|November 6, 2008|March 22, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00306722||183937|
NCT00306735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-05-05|Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.|A Double-blind Phase 2 Study to Assess the Safety and Efficacy of Aloxi (Palonosetron HCl) for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving High-dose Melphalan as Conditioning Chemotherapy for Stem Cell Transplantation||Eisai Inc.|No|Completed|March 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00306735||183936|
NCT00306748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-004|Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation|A Randomized, Multicenter, Double-Blind, Parallel-Design, Phase 2 Trial of Oral MD-1100 Acetate Administered for 14 Days Once Daily at 100 ug, 300 ug, 1000 ug, or Placebo to Patients With Chronic Constipation||Ironwood Pharmaceuticals, Inc.||Completed|March 2006|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||March 2009|March 22, 2009|March 20, 2006||||||https://clinicaltrials.gov/show/NCT00306748||183935|
NCT00306384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-OLE-012|Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus|A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes||Takeda|No|Completed|March 2006|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3323|||Both|18 Years|80 Years|No|||February 2013|February 17, 2013|March 21, 2006|Yes|Yes||No|February 17, 2013|https://clinicaltrials.gov/show/NCT00306384||183963|
NCT00306995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102499|Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population|A Phase III, Open, Randomized, Multicenter, Comparative Vaccination Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of a Monovalent Candidate Pandemic Influenza A Vaccine in Individuals Over 60 Years of Age||GlaxoSmithKline||Completed|May 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||385|||Both|60 Years|N/A|No|||February 2012|February 23, 2012|February 16, 2006||||No||https://clinicaltrials.gov/show/NCT00306995||183916|
NCT00307268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70361|Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD|Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adolescents With ADHD: An Observational, Long-Term Follow-up Study of Routine Clinical Care||University of British Columbia|No|Completed|March 2008|December 2012|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|195|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children and adolescents with a diagnosis of ADHD, aged 6 to 18 inclusive (at baseline),        referred to the Provincial ADHD Program for clinical assessment.|January 2013|January 21, 2013|March 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00307268||183895|
NCT00307593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020931|RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides|Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies||Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2004|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2007|November 16, 2007|March 24, 2006||||No||https://clinicaltrials.gov/show/NCT00307593||183872|
NCT00308126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFP501|Study to Evaluate the Effect of Hydroxyethyl Starch (HES) in Complications of Patients After Abdominal Surgery|Phase IV, Open-Label, Randomized, Albumin-Controlled, Parallel Group, Multicenter Study to Evaluate the Effect of Medium Molecule HES (130/0.4) in Complications for Patients After Abdominal Surgery||Fresenius Kabi|No|Completed|June 2005|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||624|||Both|18 Years|75 Years|No|||March 2006|December 7, 2007|March 28, 2006||||No||https://clinicaltrials.gov/show/NCT00308126||183831|
NCT00308139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2993LAR-105 (DURATION - 1)|Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)|A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications||AstraZeneca|No|Completed|April 2006|August 2014|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|16 Years|N/A|No|||July 2015|July 29, 2015|March 27, 2006|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00308139||183830|
NCT00304083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC006|Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors|Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors||Sarcoma Alliance for Research through Collaboration|No|Completed|December 2005|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|N/A|N/A|No|||December 2014|December 15, 2014|March 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00304083||184132|
NCT00304070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAR0332|Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor|Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study||Children's Oncology Group||Active, not recruiting|September 2006|||December 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|N/A|21 Years|No|||March 2016|March 17, 2016|March 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00304070||184133|
NCT00304668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM005A|A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa|A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel (TMC120 Gel-002) vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.||International Partnership for Microbicides, Inc.||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|0|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2006|December 8, 2015|March 17, 2006||||No||https://clinicaltrials.gov/show/NCT00304668||184091|
NCT00305461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/AR-101|Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)|A Pilot Study on the Impact of Two Different Doses of Ciclesonide (160 Mcg/Day and 320 Mcg/Day) Administered in the Evening on Quality of Life in Patients With Moderate Persistent Asthma.||Takeda||Completed|February 2006|February 2008|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|21 Years|65 Years|No|||June 2009|May 4, 2012|March 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00305461||184032|
NCT00305682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS036|Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant|Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|June 2005|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|320|||Both|N/A|75 Years|No|||January 2016|January 21, 2016|March 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00305682||184015|
NCT00305929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC/WST041251N/WST2.18|Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure|Phase II Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure - Repeat Procedure||STEBA France|No|Completed|March 2006|December 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Male|N/A|N/A|No|||May 2010|May 31, 2010|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00305929||183997|
NCT00301756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00144|Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors|A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors||National Cancer Institute (NCI)||Active, not recruiting|September 2006|||August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Female|18 Years|N/A|No|||April 2013|April 11, 2013|March 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00301756||184305|
NCT00302042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK70702 (completed)|Translating the DPP Into the Community|Translating the DPP Into the Community||Northwestern University|No|Completed|May 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|March 10, 2006||No||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00302042||184284|
NCT00302055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71527 (completed)|Feasibility of a Partnered Approach to Prevent Diabetes|Feasibility of a Partnered Approach to Prevent Diabetes||Northwestern University|No|Completed|March 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Both|25 Years|N/A|No|||December 2014|December 10, 2014|March 10, 2006||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT00302055||184283|
NCT00302068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011980|Exercise to Treat Depression in Individuals With Coronary Heart Disease|Understanding the Prognostic Benefits of Exercise and Anti-depressant Therapy (UPBEAT)|UPBEAT|Duke University|Yes|Completed|July 2006|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|101|||Both|35 Years|N/A|No|||May 2015|June 1, 2015|March 9, 2006|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00302068||184282|Relatively small sample size. Participants had to be willing to accept the condition to which they were randomly assigned, and patients who were not interested in exercise or taking an antidepressant were unlikely to have volunteered.
NCT00302341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-009|DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)|International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS||Immtech Pharmaceuticals, Inc|Yes|Terminated|May 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|13 Years|65 Years|No|||March 2013|March 6, 2013|March 10, 2006|Yes|Yes|FDA Clinical Hold as of 12/21/07 due to safety concerns|No||https://clinicaltrials.gov/show/NCT00302341||184261|
NCT00302588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701257|The Final Diagnosis and Treatment Result of Metastatic Cervical Carcinoma of Unknown Primary|||National Taiwan University Hospital||Recruiting|January 2006|February 2006||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||100|||Both|20 Years|75 Years|No|||December 2005|March 12, 2006|March 12, 2006||||No||https://clinicaltrials.gov/show/NCT00302588||184242|
NCT00303264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-MD-20|The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.|A Phase II Study to Investigate the Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.||Forest Laboratories||Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|75 Years|No|||March 2012|March 1, 2012|March 14, 2006||||||https://clinicaltrials.gov/show/NCT00303264||184191|
NCT00303550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. ICLA-09-CSI2|Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)|Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections (ASSIST-2)||Arpida AG||Completed|March 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|90 Years|No|||March 2006|March 26, 2007|March 15, 2006||||||https://clinicaltrials.gov/show/NCT00303550||184169|
NCT00307021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105874|Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children|Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years||GlaxoSmithKline||Completed|April 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|180|||Both|18 Months|48 Months|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307021||183914|
NCT00307034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105539|Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule|An Open, Randomized, Phase IIIa Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly According to a 2-4-11 Months Vaccination Schedule||GlaxoSmithKline||Completed|January 2006|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|351|||Both|8 Weeks|16 Weeks|Accepts Healthy Volunteers|||October 2012|November 21, 2012|March 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00307034||183913|
NCT00306397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL-080-CH02|Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients|Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression||University Hospital, Basel, Switzerland|No|Completed|January 2005|December 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|75 Years|No|||June 2010|June 29, 2010|March 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00306397||183962|
NCT00306410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIDI trial|The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients|The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients||Radboud University||Recruiting|January 2006|July 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||85|||Both|18 Years|N/A|No|||February 2007|February 28, 2007|March 22, 2006||||No||https://clinicaltrials.gov/show/NCT00306410||183961|
NCT00307281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofP ERC Registry|Emphysema Research Registry|Emphysema Research Registry; Screening Study and Genetic Testing||University of Pittsburgh|No|Recruiting|August 2000|July 2030|Anticipated|July 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort||1|Anticipated|3000|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Current and former smokers with a 10 pack year tobacco history.|December 2015|December 1, 2015|March 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00307281|2 Years|183894|
NCT00307294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-078|Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)|Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy||University of Pittsburgh|Yes|Completed|March 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||January 2016|January 14, 2016|March 24, 2006|Yes|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT00307294||183893|
NCT00328094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000299|Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery|Impact of Tight Control of Perioperative Blood Glucose in Patients Undergoing Vascular Surgery on Their Perioperative Cardiovascular and Overall Morbidity and Mortality||Beth Israel Deaconess Medical Center|Yes|Terminated|March 2006|May 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|May 18, 2006||No|The recruitment rate slowed considerably|No|February 28, 2013|https://clinicaltrials.gov/show/NCT00328094||182322|A trial to adequately address mortality would require 5000 to 6000 patients. The alpha levels for significance were not adjusted for the interim analyses because of the unplanned issues with subject recruitement as surgery became percutaneous.
NCT00328393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000570-52|Effect of Pioglitazone on Ambulatory Blood Pressure|Effect of Pioglitazone on Ambulatory Blood Pressure||University of Erlangen-Nürnberg Medical School||Completed|March 2007|January 2011|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Male|18 Years|75 Years|No|||July 2012|July 6, 2012|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00328393||182300|
NCT00328380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFID3004|Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States||Valeant Pharmaceuticals International, Inc.||Completed|December 2005|September 2008|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|660|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 21, 2009|May 17, 2006||||||https://clinicaltrials.gov/show/NCT00328380||182301|
NCT00328965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC103842|Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea|An Open Label, Multi-centre, Single Arm Phase IV Study to Evaluate the Antihypertensive Effect of Lacidipine in Mild to Moderate Essential Hypertension Patients With Type 2 Diabetes in Korea||GlaxoSmithKline|No|Completed|November 2004|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|35 Years|75 Years|No|||August 2010|August 12, 2010|May 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00328965||182257|
NCT00296387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00052|Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome|Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS||AstraZeneca||Completed|January 2006|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1160|||Both|18 Years|75 Years|No|||December 2007|December 12, 2007|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296387||184708|
NCT00296400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3569C00011|Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease|Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Non-diabetic Patients With Moderate Proteinuria|PLANET II|AstraZeneca||Completed|February 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|237|||Both|18 Years|N/A|No|||June 2011|June 14, 2011|February 23, 2006|Yes|Yes||No|March 22, 2010|https://clinicaltrials.gov/show/NCT00296400||184707|
NCT00328952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYS-2006-05018|Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Patients With Schizophrenia|Naturalistic Multicenter Study of Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Schizophrenia||Seoul National University Hospital|Yes|Completed|August 2004|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|routine lab tests for changes in medical condition|Both|15 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|voice-hearing patients with schizophrenia|September 2009|September 15, 2009|May 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00328952||182258|
NCT00329914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|predict2006|Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?|Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial||Rigshospitalet, Denmark|Yes|Completed|June 2006|September 2010|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|677|||Female|18 Years|N/A|No|||February 2009|July 22, 2011|May 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00329914||182185|
NCT00330213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLF-RW-06|Effects of Red Wine and Cognac on Coronary Circulation|Effects of Red Wine and Cognac on Coronary Circulation||University of Turku||Completed|October 2004|April 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||25|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||September 2004|May 24, 2006|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00330213||182165|
NCT00329901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P11|Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years|A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis (Tdap) Vaccine and Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Acellular Pertussis (Tdap) Vaccine, or One Dose of Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years||Novartis|No|Completed|April 2006|December 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|1072|||Both|11 Years|25 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|May 23, 2006|Yes|Yes||No|August 27, 2013|https://clinicaltrials.gov/show/NCT00329901||182186|
NCT00330200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 113715-CS11|Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of ISIS 113715 Monotherapy on Insulin Sensitivity, Glucose and Lipid Metabolism and Energy Expenditure in Subjects With Type 2 Diabetes Mellitus||Ionis Pharmaceuticals, Inc.|No|Terminated|November 2006|May 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|70 Years|No|||April 2008|April 25, 2008|May 24, 2006|No|Yes|Due to poor enrollment|No||https://clinicaltrials.gov/show/NCT00330200||182166|
NCT00330473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9628|A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare Insulin Use and Its Effect on Glycemic Control in Patients With Type 2 Diabetes Mellitus: Two Populations With Different Insulin Treatment Options||Eli Lilly and Company||Completed|June 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1019|||Both|18 Years|N/A|No|||January 2010|January 22, 2010|May 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330473||182145|
NCT00326911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP02-0555|Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer|A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas||ImClone LLC|Yes|Terminated|May 2006|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|May 15, 2006|Yes|Yes|The planned enrollment was 130 patients and the study was halted prematurely due to lack of    efficacy in both arms. Enrolled patients continued treatment.|No|November 3, 2009|https://clinicaltrials.gov/show/NCT00326911||182411|Accrual on the trial was stopped earlier than planned due to insufficient efficacy in both arms.
NCT00314990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHS94.141|VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis|Homocysteine Lowering by B Vitamins and the Secondary Prevention of Deep-Vein Thrombosis and Pulmonary Embolism. A Randomized, Placebo-Controlled, Double Blind Trial.||Radboud University||Completed|January 1996|January 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||620|||Both|20 Years|80 Years|No|||April 2006|April 14, 2006|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00314990||183310|
NCT00315757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1012-C1055|Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 2, Multi-Center, Open-Label, Randomized Study of Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma||Human Genome Sciences Inc.|No|Completed|May 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|April 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00315757||183251|
NCT00316277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0030|Prescription Opioid Addiction Treatment Study (POATS)|A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence||Mclean Hospital|Yes|Completed|May 2006|January 2013|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|653|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|April 18, 2006||No||No|May 8, 2012|https://clinicaltrials.gov/show/NCT00316277||183211|A treatment providing infrequent or no medical management was not included. It is not known if less intensive medical management would affect outcomes. Length of the trial may have also affected results. Pain severity was only moderate on average.
NCT00316550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV608-107|Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study to Assess the Effects of AV608 on Central Processing of Visceral Stimuli in Subjects With Irritable Bowel Syndrome||Avera Pharmaceuticals|No|Terminated|April 2006|September 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|65 Years|No|||February 2008|February 15, 2008|April 19, 2006|Yes|Yes|Animal Safety Data|No||https://clinicaltrials.gov/show/NCT00316550||183190|
NCT00327912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU688-02|Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity|Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial|ASGARD|Göteborg University||Active, not recruiting|April 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|50 Years|No|||February 2016|February 4, 2016|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00327912||182335|
NCT00328107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC01|Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults|Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years.||Protein Sciences Corporation|No|Completed|November 2004|August 2005|Actual|August 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|459|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2010|January 8, 2010|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00328107||182321|
NCT00328120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6995C00004|Faslodex 500mg Multiple Dose Tolerability Study in BC Patients|An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer||AstraZeneca||Completed|April 2004|June 2010|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||November 2010|November 16, 2010|May 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00328120||182320|
NCT00328419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.358|Consequences of Parenteral Nutrition Photoprotection on Oxidant Related Diseases Among Extremely Low Birth Weight Infants|Consequences of Parenteral Nutrition Photoprotection on the Oxidant Related Diseases Among Extremely Low Birth Weight Infants : A Randomized Controlled Study||Hospices Civils de Lyon|Yes|Completed|May 2006|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|591|||Both|N/A|6 Days|No|||December 2011|December 28, 2011|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00328419||182299|
NCT00328666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802058 LIMBS|The Penn Lifestyle Modification and Blood Pressure Study|Cardiovascular Effects of Iyengar Yoga vs. Enhanced Usual Care in Patients With High-normal to Stage I Hypertension||University of Pennsylvania||Completed|February 2005|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|70 Years|No|||November 2015|November 24, 2015|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328666||182280|
NCT00328978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-990-0165|Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects|A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day in Schizophrenic or Schizoaffective Subjects.||AstraZeneca||Completed|October 2003|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00328978||182256|
NCT00328653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOVATIVE - NVG05L101|Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)|Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC||Novagali Pharma||Completed|May 2006|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|114|||Both|4 Years|N/A|No|||August 2008|August 20, 2008|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00328653||182281|
NCT00329589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05C.255|A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients|A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients||Thomas Jefferson University|Yes|Completed|September 2005|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Both|18 Years|N/A|No|||August 2010|August 19, 2010|May 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00329589||182209|
NCT00329602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROR104836|Long-term Study Of Ropinirole In Restless Legs Syndrome|A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome.||GlaxoSmithKline|No|Completed|March 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|404|||Both|18 Years|79 Years|No|||March 2012|April 24, 2014|May 23, 2006|Yes|Yes||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00329602||182208|
NCT00330226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYS-2006-05318|Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders|Naturalistic Prospective Follow-Up of Patients With Schizophrenia or Bipolar Disorders Receiving Atypical Antipsychotics and/or Mood Stabilizers||Seoul National University Hospital|Yes|Recruiting|January 2006|December 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|regular lab tests for evaluating the changes in medical condition|Both|18 Years|65 Years|No|Probability Sample|patients with schizophrenia or bipolar disorder receiving pharmacotherapy|July 2010|July 21, 2010|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00330226||182164|
NCT00330499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 02.03|Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.|A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|October 2002|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00330499||182143|
NCT00330486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR15882|Open Label Trial of Acamprosate in Bipolar Alcoholics|The Use of Acamprosate in Alcohol-Dependent Individuals With Bipolar Disorder||Medical University of South Carolina||Completed|April 2006|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||September 2008|September 18, 2008|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00330486||182144|
NCT00330720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205-2002|Impact of An Emergency Response System on Anxiety and Health-Care Use|A Randomized Clinical Trial To Asses The Impact of An Emergency Response System on Anxiety and Health-Care Use Among Older Emergency Patients After A Fall||Sunnybrook Health Sciences Centre||Completed|November 2002|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|70 Years|N/A|No|||September 2004|May 26, 2006|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00330720||182126|
NCT00326599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0528|Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|June 2007|February 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00326599||182433|
NCT00298441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU-Neph-05-001|Efficacy of Intravenous Iron Administration in Hemodialysis Patients|Effect of IVIR Frequency on Anemia Correction and Oxidative Stress Formation and in Hemodialysis Patients||Kumamoto University|Yes|Completed|June 2005|March 2007|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|90 Years|No|||May 2008|May 8, 2008|February 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00298441||184553|
NCT00315484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004609|Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia|A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) To Evaluate Hematologic Response Rate In Anemic Cancer Patients Receiving Chemotherapy||Ortho Biotech Products, L.P.||Completed|February 2003|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|358|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00315484||183272|
NCT00316030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12403|Study of Bexarotene in Patients With Acute Myeloid Leukemia|A Phase I Study of Bexarotene in Patients With Acute Myeloid Leukemia||University of Pennsylvania||Completed|January 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|April 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316030||183230|
NCT00322192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Health Foundation 224/1960|Evaluation of Whether Functional Strength Training Can Enhance Recovery of Mobility After Stroke|The Effects of Functional Strength Training on Weakness and Function of the Lower Limb After Stroke||St George's, University of London||Completed|January 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||May 2006|June 8, 2015|May 4, 2006||||No||https://clinicaltrials.gov/show/NCT00322192||182765|
NCT00321932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005NT018|Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant|A Randomized Phase II of Zoledronic Acid (Zometa) in the Prevention of Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2005|March 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|May 2, 2006|Yes|Yes||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00321932||182784|
NCT00322205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|703463|Bio-Behavioral Lung Cancer Prevention Program|Bio-Behavioral Lung Cancer Prevention Program||National Institute on Drug Abuse (NIDA)||Completed|June 1999|March 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||555|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|May 18, 2006|May 4, 2006||||No||https://clinicaltrials.gov/show/NCT00322205||182764|
NCT00328146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-105|A Technique for Sternal Re-Entry|Re-Operative Surgery in Children: A Technique for Sternal Re-Entry||Children's Healthcare of Atlanta||Active, not recruiting|February 2001|February 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||450|||Both|N/A|18 Years|No|||April 2006|May 18, 2006|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00328146||182318|
NCT00328133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6693-27309-01|The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry|The Use of rFVIIa in Trauma Patients: A WTA/AAST Multi-Center Case Registry||University of California, San Francisco|No|Completed|June 2006|June 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|380|||Both|18 Years|N/A|No|Non-Probability Sample|Retrospective and prospective observational case review study on traumatically injured        adult patients.|May 2012|May 9, 2012|May 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00328133||182319|
NCT00328432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9061|A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy|Phase IB Study of Biomarker Modulation by Celecoxib vs. Placebo in Women With Newly-Diagnosed Breast Cancer||University of Kansas Medical Center||Completed|June 2003|December 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Female|18 Years|N/A|No|||September 2008|September 15, 2008|May 19, 2006||||No||https://clinicaltrials.gov/show/NCT00328432||182298|
NCT00328991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3482-A|Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts|Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris||Minneapolis Veterans Affairs Medical Center||Completed|October 2004|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2006|May 22, 2006|May 22, 2006||||No||https://clinicaltrials.gov/show/NCT00328991||182255|
NCT00329355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX105852|Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)|See Detailed Description||GlaxoSmithKline|No|Completed|May 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|351|||Female|18 Years|65 Years|No|||April 2015|April 15, 2015|May 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00329355||182227|
NCT00329615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kl450112|Insulin Treatment in Cancer Cachexia|Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism and Physical Functioning. A Randomized Prospective Study.||Göteborg University||Completed|January 2000|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||135|||Both|25 Years|85 Years|No|||August 2009|August 20, 2009|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329615||182207|
NCT00329329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT1-05-02|Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies|Phase 1 Study of the Oral Platinum Agent Satraplatin in Combination With Capecitabine for the Treatment of Patients With Advanced Solid Malignancies||Agennix||Terminated|May 2006|February 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|May 22, 2006|Yes|Yes|Sponsor decided to discontinue study drug development|No||https://clinicaltrials.gov/show/NCT00329329||182229|
NCT00329342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTW-LBP-1|Return to Work Interventions for Patients With Low Back Pain|Return to Work Interventions for Patients With Low Back Pain During Inpatient Rehabilitation: a Quasi-Experimental Study||Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster|No|Completed|April 2006|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|60 Years|No|||November 2007|November 26, 2007|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329342||182228|
NCT00329940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345DFR04|Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer|Assessment of Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Having Discontinued Anastrozole Adjuvant Treatment Due to Musculoskeletal Disorders||Novartis||Completed|November 2005|||January 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Female|18 Years|N/A|No|||August 2012|August 6, 2012|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00329940||182183|
NCT00329641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00777|Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye|Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma||National Cancer Institute (NCI)||Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2013|July 25, 2014|May 23, 2006|Yes|Yes||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00329641||182205|
NCT00329966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71P4S|Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects||Novartis||Completed|June 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|18 Years|N/A||||September 2006|September 13, 2006|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329966||182182|
NCT00297466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA017812|Strategies to Help Adult ED Patients Quit Smoking|Strategies to Help Adult ED Patients Quit Smoking||National Institute on Drug Abuse (NIDA)||Recruiting|January 2006|April 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||336|||Both|21 Years|N/A|No|||February 2006|February 24, 2006|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297466||184626|
NCT00330733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-011-05F|Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk|Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk||VA Office of Research and Development|Yes|Completed|January 2007|September 2010|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|71|||Both|21 Years|75 Years|No|||April 2014|April 15, 2014|May 26, 2006|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00330733||182125|Since we did not measure endogenous glucose production and lipolysis, the effects on hepatic glucose and lipid metabolism deserve further study. Sufficient numbers of women were not included, with which to confidently extend these results to women
NCT00326586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA185-002|A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer|A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer||Bristol-Myers Squibb||Completed|May 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|54|||Male|18 Years|N/A|No|||July 2009|January 24, 2011|May 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00326586||182434|
NCT00326885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-REM-AC-02-US|Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites|A Single-Arm, Open-Label, Phase II Study to Assess the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites||Neovii Biotech||Completed|June 2006|August 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|18 Years|N/A|No|||October 2011|November 14, 2012|May 15, 2006|Yes|Yes||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00326885||182413|
NCT00298740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU|Medtronic MiniMed Implantable Insulin Pump|Reimplantation of Subjects With Implantable Insulin Pump Therapy||Johns Hopkins University||Active, not recruiting|February 2003|December 2011||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A||||February 2006|March 1, 2006|March 1, 2006||||||https://clinicaltrials.gov/show/NCT00298740||184530|
NCT00315770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FQS-506359|Health of Young European Families and Fish Consumption|Health of Young European Families and Fish Consumption||Landspitali University Hospital||Active, not recruiting|January 2004|April 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||320|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||April 2006|April 20, 2006|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00315770||183250|
NCT00321906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14467B|Comparison of Sirolimus and Azathioprine in Lung Transplantation|Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen Versus Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation||University of Chicago|Yes|Completed|April 2002|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|181|||Both|18 Years|65 Years|No|||June 2015|June 11, 2015|May 2, 2006|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00321906||182786|
NCT00321919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16169|A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia|A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy.||Hoffmann-La Roche||Completed|July 2000|April 2005|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|605|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|May 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00321919||182785|
NCT00322218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307940/106-20|Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R|A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy||CTI BioPharma||Active, not recruiting|May 2006|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|60 Years|N/A|No|||October 2008|October 22, 2008|May 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00322218||182763|
NCT00322231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-014|A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)|A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Subjects With a History of Herpes Zoster||Merck Sharp & Dohme Corp.||Completed|May 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|101|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|May 2, 2006|Yes|Yes||No|May 12, 2010|https://clinicaltrials.gov/show/NCT00322231||182762|
NCT00295945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459963|Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer|Outcomes of Perioperative Epidural Analgesia in Gynecologic Oncology Patients: A Parallel Prospective Cohort and Randomized Clinical Study||University of California, San Francisco||Completed|March 2005|December 2009|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|240|||Female|N/A|N/A|No|Non-Probability Sample|DISEASE CHARACTERISTICS:          -  Diagnosis of a gynecologic malignancy          -  Scheduled to undergo open abdominal/pelvic surgery (i.e., laparotomy) on the             gynecologic oncology service at the University of California San Francisco Medical             Center          -  No failed epidural catheters (for patients choosing epidural analgesia)          -  No lumbar epidurals (for patients choosing epidural analgesia)|May 2014|May 19, 2014|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00295945||184741|
NCT00295399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTRS001|Telerehabilitation for the Hand and Arm After Stroke and Traumatic Brain Injury|||Ono Academic College||Not yet recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|80 Years|No|||August 2008|August 11, 2008|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00295399||184782|
NCT00328445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA013474|Randomized Trial of the Positive Action Program in Hawaii Schools|The Positive Action Program: Outcomes and Mediators||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2001|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2500|||Both|6 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00328445||182297|
NCT00328705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209|D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management|D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management||Medtronic Cardiac Rhythm Disease Management|No|Completed|May 2006|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||February 2008|February 11, 2008|May 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00328705||182277|
NCT00329030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|384|Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT)|Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401)|BMT CTN 0401|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|December 2005|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|80 Years|No|||October 2013|October 31, 2013|May 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00329030||182252|
NCT00329043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0903|Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy|A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2006|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Male|N/A|N/A|No|||September 2015|September 11, 2015|May 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00329043||182251|
NCT00329381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CiGE025AUS23|Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy|A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab)on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids||University of Mississippi Medical Center|Yes|Completed|May 2006|October 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|No|||January 2007|June 3, 2008|May 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00329381||182225|
NCT00329628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11354|Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin|RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement||Bayer||Completed|February 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4541|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|May 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00329628||182206|
NCT00329927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P4S|Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2006-2007, When Administered to Elderly Subjects.||Novartis||Completed|June 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|65 Years|N/A||||September 2006|September 13, 2006|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329927||182184|
NCT00329368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-FI-003|Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer|A Phase I Study of EC90 With GPI-0100 Adjuvant Followed by EC17 With Cytokines (Interleukin-2 [IL-2] and Interferon-alpha [IFN-alpha]) in Patients With Refractory or Metastatic Cancer||Endocyte|No|Completed|September 2005|June 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|May 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00329368||182226|
NCT00297479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0988|Group Therapy for Nicotine Dependence: Mindfulness and Smoking|Group Therapy for Nicotine Dependence||M.D. Anderson Cancer Center|Yes|Recruiting|May 2005|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|750|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00297479||184625|
NCT00330512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4117-AM-CTIL|Maternal Hypotension During Cesarean Section and Short Term Neonatal Outcome.|Maternal Hypotension During Elective Cesarean Section and Short Term Neonatal Outcome.||Sheba Medical Center|No|Terminated|May 2006|July 2007|Actual|July 2007|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|1 Day|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|June 2009|June 28, 2009|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00330512||182142|
NCT00330746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALC-1|CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer|Randomized Phase II Study of Cetuximab in Combination With Gemcitabine or Gemcitabine Followed by Cetuximab in Advanced Non Small-cell Lung Cancer Patients Who Are Not Candidates for Platinum Based Therapy.|CALC-1|National Cancer Institute, Naples|No|Completed|November 2005|June 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00330746||182124|
NCT00326391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011560|A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder|A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day.||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed|April 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|229|||Both|18 Years|65 Years|No|||April 2010|May 20, 2011|May 12, 2006||||||https://clinicaltrials.gov/show/NCT00326391||182448|
NCT00326404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008437|Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents|Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents||The Hospital for Sick Children|No|Recruiting|May 2006|May 2009|Anticipated|May 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Female|15 Years|18 Years|No|||July 2008|July 17, 2008|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00326404||182447|
NCT00322751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0529C|Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer|Phase I Study of Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer (NSCLC) (Stage I to IIIA)||University of New Mexico|Yes|Completed|April 2006|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2009|January 6, 2010|May 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00322751||182722|
NCT00322764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG2417-01|Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression|Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression||Repligen Corporation||Completed|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|65 Years||||November 2007|November 8, 2007|May 4, 2006||||||https://clinicaltrials.gov/show/NCT00322764||182721|
NCT00296244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AUS29|Steroid Free Immunosuppression in Liver Transplantation|Steroid Free Immunosuppression in Liver Transplantation||Thomas Jefferson University|No|Completed|February 2006|June 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|72 Years|No|||October 2012|October 18, 2012|February 23, 2006||No||No|July 21, 2011|https://clinicaltrials.gov/show/NCT00296244||184719|
NCT00296231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200508714|Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study|Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study||University of Iowa||Completed|February 2006|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|3 Months|No|||November 2010|November 23, 2010|February 22, 2006||No||No|October 29, 2010|https://clinicaltrials.gov/show/NCT00296231||184720|
NCT00295646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG-12|Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid|Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)||Austrian Breast & Colorectal Cancer Study Group|Yes|Active, not recruiting|June 1999|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1803|||Female|19 Years|59 Years|No|||August 2015|August 3, 2015|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00295646||184764|
NCT00295919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000459787|N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma|Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma||Children's Hospital Los Angeles|Yes|Completed|December 2005|May 2015|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|N/A|30 Years|No|||February 2016|February 11, 2016|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295919||184743|
NCT00295932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-103|Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2005|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295932||184742|
NCT00296218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_C_0024|ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation|Randomized Comparison of a Two-month Regimen of Irbesartan Versus Enalapril on Cardiovascular Markers in Patients With Acute Coronary Syndrome Without ST Segment Elevation.||Sanofi||Completed|February 2006|||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|18 Years|N/A|No|||October 2009|October 14, 2009|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00296218||184721|
NCT00296504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV30005|A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects|An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects||ViiV Healthcare|No|Completed|November 2001|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|753|||Both|13 Years|N/A|No|||June 2012|April 11, 2013|February 24, 2006|Yes|Yes|||September 30, 2011|https://clinicaltrials.gov/show/NCT00296504||184699|
NCT00296517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK1102365|Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors|Clinical Evaluation of 323U66 SR in Patients With Depression - Placebo-controlled, Double-blind, Comparative Study in Patients With Depression Who Did Not Respond Sufficiently to Selective Serotonin Re-uptake Inhibitors||GlaxoSmithKline||Completed|January 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|325|||Both|18 Years|65 Years|No|||November 2009|November 25, 2009|February 23, 2006||||No|March 19, 2009|https://clinicaltrials.gov/show/NCT00296517||184698|
NCT00328679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604-068|Evaluation of Food Hypersensitivity in Children/Adolescents With Functional Dyspepsia|Food-Specific IgE, IgG, IgG4, Skin Prick Testing and Atopy Patch Testing in Children/Adolescents With Functional Dyspepsia: A Pilot Study||Children's Mercy Hospital Kansas City|No|Completed|June 2006|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|41|||Both|8 Years|17 Years|No|||October 2008|October 6, 2008|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00328679||182279|
NCT00328692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKI-301|PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy||NovaCardia, Inc.|Yes|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|932|||Both|18 Years|N/A|No|||October 2009|October 8, 2009|May 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00328692||182278|
NCT00329004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-002|A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors|A Phase I Dose Escalation Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb||Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||August 2009|January 24, 2011|May 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00329004||182254|
NCT00329017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9814|Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer|Correlation of SNP Patterns With Fine Needle Aspiration Cytomorphology in High Risk Postmenopausal Women||University of Kansas Medical Center|No|Active, not recruiting|May 2005|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Fine needle aspirate|Female|18 Years|N/A|No|Non-Probability Sample|Post menopausal women, on or off hormone replacement therapy, at high risk of developing        breast cancer|August 2015|August 13, 2015|May 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00329017||182253|
NCT00297271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004819|Prospective Research in Memory Clinics (PRIME)|Prospective Research in Memory Clinics (PRIME)||Janssen-Cilag Pty Ltd|No|Completed|August 2005|August 2011|Actual|August 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|970|||Both|N/A|N/A|No|Non-Probability Sample|Consenting patients with mild cognitrive impairement or dementia recruited at 12        participating sites accross Australia.|November 2013|November 28, 2013|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00297271||184641|
NCT00296933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB #05-0464-A|Memory Functioning and Antidepressant Treatment|Memory Functioning and Antidepressant Treatment: A Randomized Controlled Trial Comparing Escitalopram and Bupropion XL||University Health Network, Toronto||Completed|December 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|50 Years|No|||February 2009|February 16, 2009|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296933||184666|
NCT00296946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FY2005|Ipratropium Spray for Drooling Saliva in Parkinson's Disease|Phase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's Disease||University Health Network, Toronto||Completed|November 2004|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|30 Years|N/A|No|||October 2004|November 15, 2006|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296946||184665|
NCT00297258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG20002|Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma|Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma||GlaxoSmithKline|No|Completed|November 2005|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|148|||Both|21 Years|N/A|No|||December 2015|January 4, 2016|February 24, 2006|Yes|Yes||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00297258||184642|
NCT00297830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2324|Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation|Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation|CTX|Columbia University|No|Active, not recruiting|November 2005|January 2014|Anticipated|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|84|||Both|20 Years|70 Years|No|||February 2013|February 11, 2013|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297830||184599|
NCT00297804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2009|A Randomized, Double-Blind Study to Assess Paclitaxel-Eluting Stents in Treatment of Longer Lesions|TAXUS VI - A Randomized, Double-Blind Study to Assess Paclitaxel-Eluting Stents in Treatment of Longer Lesions|TAXUS VI|Boston Scientific Corporation|Yes|Completed|May 2002|February 2008|Actual|October 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|448|||Both|18 Years|N/A|No|||February 2008|March 11, 2009|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297804||184601|
NCT00297817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P3|Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents|A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age||Novartis|No|Completed|February 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|203|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||January 2012|January 3, 2012|February 27, 2006||Yes||||https://clinicaltrials.gov/show/NCT00297817||184600|
NCT00298129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7332-3|Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease|Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease||Yokohama City University Medical Center|Yes|Completed|February 2004|December 2006|Actual|||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal|||Actual|278|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||May 2007|May 8, 2007|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00298129||184577|
NCT00298454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200601|Forced Diuresis Versus Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients|Forced Diuresis Vs Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients (Fodorefh)||Medical Centre Leeuwarden||Terminated|December 2005|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|18 Years|N/A|No|||April 2007|April 18, 2007|March 1, 2006|||Number included has been reached|No||https://clinicaltrials.gov/show/NCT00298454||184552|
NCT00326066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-007|A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients.|A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Newly Diagnosed Open Angle Glaucoma and Subjects Diagnosed With Ocular Hypertension||Glaukos Corporation|Yes|Active, not recruiting|February 2005|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00326066||182473|
NCT00326079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-005|A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2|A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents||Glaukos Corporation|Yes|Active, not recruiting|August 2004|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00326079||182472|
NCT00326105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00006|Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment (PEARL STUDY)|PEARL|AstraZeneca||Completed|April 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|450|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326105||182470|
NCT00326417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0301|Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)|Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)||Medical College of Wisconsin|Yes|Active, not recruiting|January 2006|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|94|||Both|N/A|65 Years|No|||January 2016|January 7, 2016|May 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00326417||182446|
NCT00321945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002174|A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers|A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers on Post-Operative Atrial Fibrillation||Emory University|No|Completed|December 2005|October 2009|Actual|October 2009|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|546|||Both|18 Years|65 Years|No|Probability Sample|All patients, 18 years or older up to and including 65 years of age, who underwent        elective cardiac surgery in the Emory University Hospital, Crawford Long Hospital, or the        VA Medical Center between 2000-2005.|September 2013|September 26, 2013|May 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00321945||182783|
NCT00323674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/080|Minimally Invasive Open Preperitoneal Surgery With Polysoft Mesh Versus a Classic Open Surgery With Light Weight Mesh|Prospective Randomized Study to Evaluate the Recovery of a Hernia Inguinalis by a Minimally Invasive Open Preperitoneal Surgery With Polysoft Mesh Versus a Classic Open Surgery According to Modified Lichtenstein Procedure With Light Weight Mesh||University Hospital, Ghent|No|Active, not recruiting|March 2006|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00323674||182652|
NCT00323687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-DE-164-0106|SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada|Switch to a Completely ONce Daily Regimen Containing Emtricitabine/Tenofovir - Fixed Dose Combination Plus Third QD Partner: "SONETT"||Gilead Sciences|No|Completed|September 2004|January 2007|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2008|June 6, 2008|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00323687||182651|
NCT00324077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-011|Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase|A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase||Bristol-Myers Squibb||Withdrawn|August 2006|||February 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A||||April 2011|February 16, 2016|May 9, 2006|No|Yes|Insufficient Enrollment|No||https://clinicaltrials.gov/show/NCT00324077||182621|
NCT00296569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0686-006|A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)|A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MK0686 in Patients With Osteoarthritis of the Knee or Hip||Merck Sharp & Dohme Corp.||Completed|September 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|150|||Both|40 Years|65 Years|No|||December 2014|December 23, 2014|February 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00296569||184694|
NCT00296582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65-06|Gastric Motor Function Measurement in Dyspepsia and Normal Subjects|Simultaneous Gastric Motor Function Measurement in Dyspepsia And Normal Subjects Ingesting a Solid-Liquid Meal||Mayo Clinic|No|Completed|January 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 20, 2011|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296582||184693|
NCT00296556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRC05PG-II-1|Therapeutic Study of ONO-4819CD for Ulcerative Colitis|A Randomized, Placebo-Controlled Trial of ONO-4819CD for Treatment of Mild to Moderate Ulcerative Colitis.||Kyoto University, Graduate School of Medicine|Yes|Terminated|February 2006|March 2008|Actual|December 2007|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|7|||Both|20 Years|N/A|No|||April 2009|April 27, 2009|February 24, 2006||No|terminated|No||https://clinicaltrials.gov/show/NCT00296556||184695|
NCT00296530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA103578|Study Of Patients With Allergic Rhinitis And Asthma|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID||GlaxoSmithKline|No|Completed|September 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|600|||Both|15 Years|N/A|No|||August 2013|September 5, 2013|February 23, 2006||||||https://clinicaltrials.gov/show/NCT00296530||184697|
NCT00296543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508-02|T Wave Alternans in Hemodialysis|Pilot Study of a Noninvasive Predictor of Sudden Cardiac Death in Hemodialysis Patients||Indiana University||Completed|October 2005|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Hemodialysis patients with heart disease and/or poor cardiac function|June 2011|June 17, 2011|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00296543||184696|
NCT00296738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIBGCTIL|123I-MIBG SPECT/CT for Assessment of Cardiac Sympathetic Innervation|Quantitative 123I-MIBG SPECT/CT Assessment of Cardiac Sympathetic Innervation||Rambam Health Care Campus||Completed|May 2007|May 2010|Actual|August 2009|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|40 Years|N/A|No|Non-Probability Sample|Patients refered for neuroendocrine diseases|August 2011|August 17, 2011|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296738||184681|
NCT00296751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|epiduralCTIL|Epidural Analgesia Versus IV Meperidine for Labor Pain Control|Epidural Analgesia Versus IV Meperidine for Labor Pain Control. Objective Evaluation of the Pain Intensity Influence on the Autonomic Nervous System.||Rambam Health Care Campus||Completed|March 2006|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|60|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2008|June 30, 2010|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296751||184680|
NCT00297284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25085|Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil|Pilot and Feasibility Study of Modafinil Treatment to Improve Cognitive Efficiency in SLE Patients||Hospital for Special Surgery, New York||Terminated|February 2006|February 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||September 2006|January 27, 2009|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297284||184640|
NCT00297297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH-FB-10|Improved Preoperative Selection of Cold Thyroid Nodules|Preoperative Selection of Solitary Solid Cold Thyroid Nodules - A Prospective Study on the Value of Sonography, Cytology, Immunostaining and Molecular Profiling||Herlev Hospital||Enrolling by invitation|December 2008|March 2011|Anticipated|||Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Tertiary referral center (Endocrine outpatient - University Hosiptal - clinic). Patients        referred with a solitary thyroid nodule|October 2007|February 24, 2010|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297297||184639|
NCT00296478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999913 2004-02|Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet (Endometrin®) Compared to Crinone 8% Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization (IVF)|Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet (Endometrin®) Compared to Crinone 8% Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization (IVF)||Ferring Pharmaceuticals||Completed|July 2005|July 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1211|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||May 2011|May 18, 2011|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296478||184701|
NCT00296491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA103575|Study Of Allergic Rhinitis In Patients Who Also Have Asthma|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID||GlaxoSmithKline||Completed|September 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|725|||Both|15 Years|N/A|No|||June 2015|June 11, 2015|February 23, 2006|Yes|Yes||No|October 31, 2008|https://clinicaltrials.gov/show/NCT00296491||184700|
NCT00296712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4653|Are Two Antidepressants a Good Initial Treatment for Depression?|Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.||New York State Psychiatric Institute|No|Completed|February 2005|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|65 Years|No|||April 2012|April 26, 2012|February 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296712||184683|
NCT00298168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSPSL-0001-PF Part B|YSPSL for Prevention of Delayed Graft Function Part B|Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation||Y's Therapeutics, Inc.|Yes|Completed|May 2006|December 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|N/A|No|||January 2008|January 24, 2008|February 27, 2006|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00298168||184574|
NCT00297492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA011557-07|Gradual vs. Abrupt Cessation Treatment for Smoking|Gradual vs. Abrupt Cessation Treatment for Smoking||University of Vermont|No|Completed|January 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|750|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 17, 2013|February 24, 2006||No||No|May 31, 2012|https://clinicaltrials.gov/show/NCT00297492||184624|Our projected incidence of abstinence was higher than what was actually observed, leading to lower statistical power than expected.
NCT00298753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2005.04/IMT|Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine|Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine||Regional Hospital Holstebro||Withdrawn|May 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 14, 2015|March 1, 2006|||no patients could be recruited|No||https://clinicaltrials.gov/show/NCT00298753||184529|
NCT00298766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-CAN-2007|Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis|An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain (AL)-Amyloidosis||Millennium Pharmaceuticals, Inc.||Completed|June 2005|September 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|March 1, 2006|Yes|Yes||No|July 16, 2010|https://clinicaltrials.gov/show/NCT00298766||184528|
NCT00298142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Headache Trial|Management of Headache Disorders: A Clinical Trial Screening for Prognostic Patient Characteristics|A Prospective Randomised Clinical Trial to Investigate the Management of Headache Disorders. Study to Identify Prognostic Patient Characteristics and to Investigate the Additional Value of Physio-/Manual Therapy||Vrije Universiteit Brussel||Terminated|February 2006|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|February 27, 2006|||Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00298142||184576|
NCT00298727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152239|The Effect and Mediators of Two Knowledge Translation Strategies|Defining the Effect and Mediators of Two Knowledge Translation Strategies Designed to Alter Knowledge, Intent and Clinical Utilization of Rehabilitation Outcome Measures||McMaster University|No|Completed|January 2007|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|131|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 3, 2011|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298727||184531|
NCT00325819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC Protocol #4665|Acetaminophen Before Vaccines for Infants Study (AVIS)|A Randomized Placebo-controlled Trial of Acetaminophen for Prevention of Post-vaccination Fever in Infants||Group Health Cooperative|Yes|Completed|May 2006|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|374|||Both|6 Weeks|9 Months|Accepts Healthy Volunteers|||February 2014|February 25, 2014|May 11, 2006|Yes|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00325819||182492|
NCT00326092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-49|A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|May 2006|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||88|||Both|18 Years|N/A|No|||September 2007|June 3, 2012|May 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00326092||182471|
NCT00322244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120020367|Massage Therapy for Osteoarthritis of the Knee|Massage Therapy for Osteoarthritis of the Knee||Rutgers, The State University of New Jersey||Completed|January 2003|October 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|35 Years|N/A|No|||January 2011|January 31, 2011|May 3, 2006||||No||https://clinicaltrials.gov/show/NCT00322244||182761|
NCT00322478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRB1-2006-1|Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes|Non-Significant Risk Investigational Device Study of the Wireless GlucoMON™ Glucose Meter Accessory and Real-time Blood Glucose Alerts as an Enabling Technology for People Who Team Manage Diabetes||Diabetech|Yes|Completed|April 2006|October 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|432|||Both|N/A|N/A|No|||October 2015|October 30, 2015|May 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00322478||182743|
NCT00323700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0448|A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD)|A Naturalistic Prospective Study of Treatment Effectiveness for ADHD||University of British Columbia|No|Withdrawn|December 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|16 Years|18 Years|No|Probability Sample|Children between ages of 6-18; one-year prospective observational study designed to        evaluate and compare outcomes effectiveness between OROS-MPH and IR MPH in ADHA and ODD        symptoms at the ADHD Clinic of the British Columbia Children's and Women's Health Centre.|April 2009|April 17, 2009|May 8, 2006||No|Merged with the study NCT00307268|No||https://clinicaltrials.gov/show/NCT00323700||182650|
NCT00297011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50301066|Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis|Valacyclovir+Temovate Gel for the Episodic Treatment of Herpes Labialis: A Patient-Initiated Double-Blind, Placebo-Controlled Study, Randomized Study.||University of Utah|No|Completed|September 2004|January 2008|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 30, 2008|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00297011||184661|
NCT00296777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4781|Treatment of Depression Following Multiple Brain Tests|Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment||New York State Psychiatric Institute|No|Completed|December 2004|December 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|65 Years|No|||April 2012|April 26, 2012|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296777||184678|
NCT00296790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0167|Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)|||Sanofi||Completed|February 2006|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||372|||Both|21 Years|64 Years|No|||October 2007|October 11, 2007|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296790||184677|
NCT00296764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5203|Characterization of Angelman Syndrome|Angelman Syndrome Natural History Study||University of California, San Diego|No|Recruiting|February 2006|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood and cheek swab samples|Both|N/A|60 Years|No|Non-Probability Sample|Patients with Angelman syndrome (molecular or clinical diagnosis) between the ages of 1        day and 60 years.|September 2015|September 27, 2015|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296764||184679|
NCT00297557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2733|Dual Time Point PET Imaging in Lymphoma|||Royal Marsden NHS Foundation Trust||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|16 Years|N/A|No|||January 2006|October 10, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297557||184619|
NCT00297895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSLT-II|Multicenter Selective Lymphadenectomy Trial II (MSLT-II)|A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node||John Wayne Cancer Institute|Yes|Active, not recruiting|September 2004|September 2022|Anticipated|September 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1925|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297895||184594|
NCT00297908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2006.041|Alcohol Based Hand Sanitizer: Can Frequent Use Cause an Elevated Blood Alcohol Level?|Alcohol Based Hand Sanitizer: Can Frequent Use Cause an Elevated Blood Alcohol Level?||C.R.Darnall Army Medical Center||Completed|February 2006|February 2006||||N/A|Observational|Time Perspective: Prospective||||5|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2007|June 2, 2015|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297908||184593|
NCT00297921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03002|A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy|||Millennium Pharmaceuticals, Inc.||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|February 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00297921||184592|
NCT00296725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4217R/#5294R|Dichotic Listening as a Predictor of Medication Response in Depression|Dichotic Listening as a Predictor of Placebo and Medication Response in Depression||New York State Psychiatric Institute|No|Completed|April 1994|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|65 Years|No|||April 2012|April 26, 2012|February 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296725||184682|
NCT00296959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCTOP2005|Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease|Anti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced Dyskinesias||University Health Network, Toronto||Terminated|September 2004|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|30 Years|75 Years|No|||August 2007|September 19, 2007|February 23, 2006|||early termination due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00296959||184664|
NCT00297843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/01 Nabio ITEM|A Pilot Monocenter Study to Assess Cellular and Soluble Biomarkers in Nasal Secretions|A Pilot Monocenter Study to Assess the Reproducibility and Specificity of Cellular and Soluble Biomarkers in Nasal Secretions in Patients With Allergic Rhinitis and Healthy Volunteers Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC)||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|March 2006|May 2006||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2007|June 18, 2007|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00297843||184598|
NCT00298181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSPSL-0001-PF Part A|YSPSL for Prevention of Delayed Graft Function Part A|Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation||Y's Therapeutics, Inc.|Yes|Completed|October 2005|December 2007|Actual|November 2006|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|15|||Both|18 Years|N/A|No|||January 2008|January 24, 2008|February 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298181||184573|
NCT00298467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX060-04|MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma|An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma||Bristol-Myers Squibb||Withdrawn|February 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|12 Years|N/A|No|||April 2010|April 23, 2010|March 1, 2006|||sponsor decision|||https://clinicaltrials.gov/show/NCT00298467||184551|
NCT00298779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-CAN-1001|Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.|An Open-Label Study to Assess the Effect of Omeprazole Administration on the Pharmacokinetics of VELCADE in Subjects With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma||Millennium Pharmaceuticals, Inc.||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|March 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298779||184527|
NCT00299026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAXUS II|A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent|TAXUS II: A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent||Boston Scientific Corporation||Completed|June 2001|February 2007|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||532|||Both|18 Years|N/A|No|||August 2008|August 28, 2008|March 3, 2006||||No||https://clinicaltrials.gov/show/NCT00299026||184509|
NCT00294892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITA1|Pharmacokinetics Study on Nevirapine Resistance in Tanzania|The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)||Radboud University|No|Completed|February 2006|June 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Female|18 Years|40 Years|No|||May 2012|May 30, 2012|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00294892||184820|
NCT00326118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106445|Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.|Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix™, Versus MenC-CRM197 Vaccine With Hiberix™ & Priorix™ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination.||GlaxoSmithKline||Completed|June 2006|October 2012|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|433|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||October 2013|November 5, 2015|May 12, 2006|Yes|Yes||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00326118||182469|
NCT00326131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA165-017|A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer|Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer||Bristol-Myers Squibb||Terminated|April 2006|||March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|N/A||||August 2007|February 27, 2010|May 15, 2006||||||https://clinicaltrials.gov/show/NCT00326131||182468|
NCT00322491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-2105|Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients|Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF||Sanofi|No|Completed|March 2004|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|May 4, 2006|No|Yes||No|October 30, 2010|https://clinicaltrials.gov/show/NCT00322491||182742|
NCT00323050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102547|Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects|Evaluate Immunogenicity,Safety & Reactogenicity of a Booster Dose of Hib-MenC Conjugate Vaccine When Given to Healthy Subjects Aged 13-14 Mths Who Were Primed With 3 Doses of Hib-MenC vs a Booster Dose of Infanrix Hexa Given to Subjects Primed With 3 Doses of Infanrix Hexa and Meningitec||GlaxoSmithKline||Completed|November 2004|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||468|||Both|13 Months|14 Months|Accepts Healthy Volunteers|||May 2009|May 21, 2009|August 26, 2005||||No||https://clinicaltrials.gov/show/NCT00323050||182700|
NCT00323427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4185-R|Clinical Trial of the "Living Well With Hearing Loss Workshop"|Clinical Trial of the "Living Well With Hearing Loss Workshop"||VA Office of Research and Development|No|Completed|May 2007|September 2010|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|85 Years|No|||January 2014|January 17, 2014|May 5, 2006||No||No|September 26, 2013|https://clinicaltrials.gov/show/NCT00323427||182671|
NCT00323713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA1-1425|Very Low Protein Diet and Renal Death in Chronic Kidney Disease (CKD)-ERIKA Study|Effects of Very Low Protein Diet Supplemented With Ketoanalogs on Renal Death in Phase 4/5 Chronic Kidney Disease (CKD) - ERIKA Study||Azienda Sanitaria ASL Avellino 2|Yes|Active, not recruiting|February 2005|December 2012|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||June 2011|June 23, 2011|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00323713||182649|
NCT00323726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 02-579|Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study|Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study||New Mexico Cancer Care Alliance||Withdrawn|December 2005|December 2006|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Female|N/A|N/A|No|Non-Probability Sample|Patients with ovarian germ cell tumors|June 2015|June 16, 2015|May 5, 2006|No|Yes|The study was limited to IRB Exempt chart review; not an applicable trial.|No||https://clinicaltrials.gov/show/NCT00323726||182648|
NCT00297024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 04-0750-C|Radiotherapy - Cerebrovascular Reactivity (RT-CVR Study)|MRI Changes With Administered Oxygen and Carbon Dioxide in Patients With Brain Tumors Receiving Radiotherapy: A Pilot Study||University Health Network, Toronto||Completed|February 2005|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00297024||184660|
NCT00297037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12589|Pimecrolimus Cream for Oral Lichen Planus|A 6-week Randomized, Double-blind, Vehicle-controlled Pilot Study With a 6-week Open Label Extension to Assess the Efficacy and Safety of Pimecrolimus 1% Cream in the Treatment of Oral Lichen Planus||University of Utah|No|Completed|August 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|September 14, 2012|February 23, 2006|Yes|Yes||No|March 1, 2011|https://clinicaltrials.gov/show/NCT00297037||184659|
NCT00297947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET0348|High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder|A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder|HDQ|Manhattan Psychiatric Center|Yes|Completed|December 2004|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|64 Years|No|||April 2015|April 16, 2015|February 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00297947||184590|
NCT00297570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4015-IH-CTIL|Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy|||Sheba Medical Center|No|Recruiting|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||October 2007|October 7, 2007|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297570||184618|
NCT00297583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_1501|Insulin Glulisine in Type 1 Diabetes Mellitus|A Single-center, Randomized, Double-blind, 3-period Cross-over Trial to Compare the Effect of Insulin Glulisine, Insulin Lispro and Unmodified Human Insulin on the Endogenous Glucose Production in Type 1 Diabetic Patients.||Sanofi||Completed|April 2004|||May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||December 2009|December 4, 2009|February 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00297583||184617|
NCT00298220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWAZO/GPA-01|Engaging General Practice in the Prevention of Patients With Alcohol Problems|Engaging General Practice in the Prevention of Patients With Alcohol Problems||Radboud University||Completed|July 2005|April 2009|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|77|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2009|September 21, 2009|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00298220||184570|
NCT00298233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 001|High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza|High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|326|||Both|1 Year|N/A|No|||May 2014|May 26, 2014|March 1, 2006|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT00298233||184569|
NCT00296972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 18562A|Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication|A Randomized, Multicenter, phaseIIIB, Two Arm Study Evaluating the Tolerability of Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection co-Infected With Human Immunodeficiency Virus Receiving HAART Versus Not Receiving HAART||University Health Network, Toronto||Terminated|July 2005|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||April 2007|April 19, 2007|February 23, 2006|||not funded|No||https://clinicaltrials.gov/show/NCT00296972||184663|
NCT00296985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 01-0420-B|Continuous Cellsaver and Neurocognitive Decline Post Cardiac Surgery|The Impact of Continuous Flow Cellsaver on Neurocognitive Decline After Cardiac Surgery||University Health Network, Toronto||Completed|December 2001|January 2007|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||312|||Both|60 Years|N/A|No|||November 2013|November 25, 2013|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00296985||184662|
NCT00297310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005020|Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation|Pre-transplant Pharmacokinetics as a Predictor of the Tacrolimus Dose Requirement Post Renal Transplantation||Janssen-Cilag Pty Ltd||Completed|May 2004|April 2007|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|89|||Both|14 Years|N/A|No|||April 2010|June 6, 2011|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297310||184638|
NCT00297505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA008425|Serotonin, Impulsivity, and Cocaine Dependence Treatment|Serotonin, Impulsivity, and Cocaine Dependence Treatment||National Institute on Drug Abuse (NIDA)||Completed|April 2001|November 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|50 Years|No|||February 2006|February 27, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297505||184623|
NCT00297518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-0605-5|Study of Scaling and Root Planing (SRP) With PerioWave vs. SRP Alone in Chronic Periodontitis|A Multicenter, Randomized, Examiner Blinded Study of Photoactivated Disinfection With Scaling and Root Planing in the Treatment of Chronic Periodontitis||Ondine Research Laboratories||Completed|March 2006|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||May 2007|May 17, 2007|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297518||184622|
NCT00297856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104154|Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine|Open, Prospective Study of the Safety of GSK Biologicals' Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO)||GlaxoSmithKline||Completed|March 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10000|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Subjects enrolled in the Northern California Kaiser-Permanente Health Care Plan|January 2014|January 9, 2014|February 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00297856||184597|
NCT00298155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01253 - Committee 1|Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer|Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer|TAPS|University of Washington|Yes|Active, not recruiting|July 2006|February 2012|Anticipated|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Male|18 Years|N/A|No|||January 2012|January 6, 2012|February 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298155||184575|
NCT00297869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311-04B|Using Informatics to Enhance Care of Older Emergency Department Patients|Computer-Assisted Decision Support to Increase the Safety of Prescribing to Older Emergency Department Patients||Indiana University|No|Active, not recruiting|January 2005|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|954|||Both|N/A|N/A|No|||March 2010|March 31, 2010|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297869||184596|
NCT00299052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1272-2005|Efficacy of DBM on Fractures of the Shinbone (Tibia)|The Efficacy of Demineralized Bone Matrix and Autogenous Bone Graft in Accelerated Fracture Healing in Closed Tibia Fracture||Emory University|No|Completed|March 2006|September 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00299052||184507|
NCT00299065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-04-C05-201|Safety Study of Zileuton Injection in Patients With Asthma|Assessment of Safety, Tolerability, and Pharmacokinetics of Zileuton Injection in Patients With Asthma||Critical Therapeutics||Completed|January 2006|June 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|12 Years|N/A|No|||September 2007|September 24, 2007|March 2, 2006||||||https://clinicaltrials.gov/show/NCT00299065||184506|
NCT00298480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230-04s|Dynamic Cervical Change: Prediction of Preterm Labor in Symptomatic Patients|||Memorial Health Services Research Council||Recruiting|February 2005|July 2007|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||220|||Female|18 Years|45 Years||||April 2007|April 18, 2007|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298480||184550|
NCT00295464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACG Trial|Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth|Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial)||University of Oulu||Terminated|May 2001|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||440|||Both|N/A|N/A|No|||February 2006|May 1, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295464||184778|
NCT00299039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA008|T3AI-Pain After Breast Surgery|A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery.|T3AI|Nova Scotia Health Authority||Completed|May 2006|September 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||September 2008|January 30, 2009|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00299039||184508|
NCT00295984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462444|Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma|Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial||National Cancer Institute (NCI)||Completed|March 2006|August 2006|Actual|||Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|78 Years|No|||August 2006|June 18, 2013|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00295984||184738|
NCT00321958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27406|Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer|Cryotherapy Ablation of Barrett's Esophagus and Early Esophageal Cancer||CSA Medical, Inc.|Yes|Terminated|April 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|May 3, 2006|Yes|Yes|The sponsor determined that adequate data had been acquired.|No||https://clinicaltrials.gov/show/NCT00321958||182782|
NCT00321971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH070719|Prevention of Depression in Spouses of People With Cognitive Impairment|Prevention of Psychiatric Morbidity in AD Caregivers||National Institute of Mental Health (NIMH)|Yes|Recruiting|February 2007|April 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 25, 2009|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321971||182781|
NCT00323063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040504|Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer|Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer||Rutgers, The State University of New Jersey|No|Active, not recruiting|May 2006|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|120 Years|No|||December 2015|December 16, 2015|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323063||182699|
NCT00323739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 32|Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma|Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma||SCRI Development Innovations, LLC|No|Completed|May 2006|March 2011|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||July 2013|July 18, 2013|May 5, 2006|No|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00323739||182647|
NCT00323752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-0510|Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.|Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.||University of British Columbia||Completed|October 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|12 Years|18 Years|No|||September 2008|September 24, 2008|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323752||182646|
NCT00297609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-0000-AV-CTIL|Prevention of Errors in Resuscitation Medications Orders by Means of a Computerized Physician Order Entry|Prevention of Potential Errors in Resuscitation Medications Orders by Means of a Computerized Physician Order Entry With Clinical Decision Support System in Pediatric Critical Care – a Prospective Cohort Study.||Sheba Medical Center||Completed|January 2002|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|18 Years|No|||February 2006|February 27, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297609||184615|
NCT00297635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06C.07|Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy|||Thomas Jefferson University||Withdrawn|March 2006|December 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|N/A|No|||March 2011|March 18, 2011|February 23, 2006|||Decided not to participate in study per Leslie Padron-Massaro|No||https://clinicaltrials.gov/show/NCT00297635||184614|
NCT00297986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040|Evaluation of Different Interfaces for Noninvasive Positive Pressure Ventilation (NPPV)|Evaluation of Different Interfaces for NPPV||Policlinico Hospital|No|Completed|June 2004|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|April 2015|April 27, 2015|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297986||184587|
NCT00297323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002119|An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy|An Open Observational Safety Study During Administration of Topamac, as Monotherapy in Epileptic Patients With no Prior Treatment or Unsuccessfully Treated With Other Antiepileptic Drug||Janssen Cilag Pharmaceutica S.A.C.I., Greece||Completed|June 2005|February 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Both|2 Years|N/A|No|Probability Sample|In this study a total number of 75 patients will be enrolled. Adults and children over 2        years of age who are eligible according to the approved SmPC of topiramate and their        seizures are not manageable. Patients with new exposure to an AE treatment for epilepsy or        lack of response to the previous treatment. Patients who will agree to sign the written        informed consent for the anonymous and confidential use of their medical data with their        participation in the study or a relative or a legal authorised representative.|April 2010|April 26, 2010|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297323||184637|
NCT00298519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPR/NHG/03025|Maternal Ethnic Group,Diet,Breast Milk Fatty Acid and Potential Effect Development of Allergy in the Offspring|The Influence of Maternal Ethnic Group and Diet on Breast Milk Fatty Acid Content and Its Potential Effect on Development of Allergy in the Offspring.||National University Hospital, Singapore||Completed|June 2003|February 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|21 Years|50 Years|No|Non-Probability Sample|Pregnant women with the intention of breastfeeding their babies|September 2009|September 18, 2009|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298519||184547|
NCT00298532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 64269|OPALS Pediatric Study|The Ontario Prehospital Advanced Life Support (OPALS) Study for Critically Ill and Injured Pediatric Patients||Ottawa Hospital Research Institute|No|Completed|July 1992|January 2008|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1|||9000|||Both|N/A|15 Years|No|||October 2010|October 13, 2010|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298532||184546|
NCT00298194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99010205E|The Effects of Z-338 in Subjects With and Without Functional Dyspepsia|The Effects of Z-338 on the Symptomatic Response to a Nutrient Challenge and Gastric Nutrient Distribution and Emptying in Subjects With and Without Functional Dyspepsia||Zeria Pharmaceutical|No|Completed|February 2006|||July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|52|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2009|January 12, 2009|February 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00298194||184572|
NCT00298207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-0012|Walking Intervention in African American Adults With Newly Diagnosed Hypertension|Walking Intervention in African American Adults With Newly Diagnosed Hypertension||University of Illinois at Chicago||Completed|April 2001|February 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||20|||Both|25 Years|59 Years|No|||April 2001|February 27, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00298207||184571|
NCT00297531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-0605-4|Study of Scaling and Root Planing With PerioWave Versus Scaling and Root Planing Alone in Chronic Periodontitis|Photodynamic Disinfection in Combination With Scaling and Root Planing in the Treatment of Chronic Periodontitis||Ondine Research Laboratories||Active, not recruiting|April 2006|October 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2007|May 17, 2007|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297531||184621|
NCT00297544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1777-CTIL|Effect of Sildenafil on Endothelial Function|Effect of Sildenafil on Endothelial Function||Rambam Health Care Campus||Recruiting|October 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||60|||Male|40 Years|70 Years|No|||November 2005|February 27, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297544||184620|
NCT00297882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG46|Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon|Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon||Gates Malaria Partnership|Yes|Completed|July 2006|July 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|900|||Both|12 Months|120 Months|No|||April 2013|April 28, 2013|February 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00297882||184595|
NCT00294918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23056|An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome|Multicenter Open-label, Randomized, Dose-finding, Parallel-group, Safety and Efficacy Trial of Subcutaneous Administration of Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)||EMD Serono||Completed|September 2001|February 2003|Actual|February 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|142|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|February 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00294918||184818|
NCT00294905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-16-104|Implementation of an Evidence Based Smoking Cessation Strategy (SMOCC) for Patients With COPD in Primary Care|Implementation of an Evidence Based Smoking Cessation Strategy (SMOCC) for Patients With COPD in Primary Care||Radboud University||Terminated|March 2006|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|2700|||Both|40 Years|N/A|No|||February 2007|September 22, 2010|February 21, 2006||No|recruitment of patients did not reach sufficient numbers|No||https://clinicaltrials.gov/show/NCT00294905||184819|
NCT00295711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOV-075-020|Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain|A Multi-Center Double-Blind, Placebo-Controlled Randomized Study of Bicifadine 200 Mg BID, Bicifadine 300 Mg BID, and Bicifadine 400 Mg BID in the Treatment of Chronic Low Back Pain||DOV Pharmaceutical, Inc.||Completed|September 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||532|||Both|18 Years|75 Years|No|||June 2006|June 22, 2006|February 23, 2006||||||https://clinicaltrials.gov/show/NCT00295711||184759|
NCT00295724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOV-075-021|Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain|A Multi-Center, Double-Blind, Placebo-Controlled Randomized Study of Bicifadine 200 mg BID in the Treatment of Chronic Low Back Pain||DOV Pharmaceutical, Inc.||Completed|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2007|January 26, 2007|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00295724||184758|
NCT00321997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1003 and EOP1004|A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.|A PHASE II/III RANDOMIZED, DOUBLE-MASKED, CONTROLLED, DOSE-RANGING, MULTI-CENTER COMPARATIVE TRIAL, IN PARALLEL GROUPS, TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTIONS OF EYE001 (ANTI-VEGF PEGYLATED APTAMER) GIVEN EVERY 6 WEEKS FOR 54 WEEKS, IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD)||Eyetech Pharmaceuticals||Completed|May 2001|October 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||540|||Both|50 Years|N/A|No|||May 2006|May 2, 2006|May 2, 2006||||||https://clinicaltrials.gov/show/NCT00321997||182779|
NCT00322257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-2076|Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes|Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy||Novo Nordisk A/S|No|Terminated|May 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|596|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|May 3, 2006|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00322257||182760|
NCT00322777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spirit II|Spirituality Teaching Program for Depressed Adults|A Spirituality Teaching Program for Depression in Adults: A Randomized Controlled Trial||Canadian Institute of Natural and Integrative Medicine|No|Completed|January 2005|December 2008|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|May 4, 2006||No||No|June 17, 2015|https://clinicaltrials.gov/show/NCT00322777||182720|
NCT00322790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0549C|Differences in Trends Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study|INST 0549C Differences in 30-year Trends in Incidence and Survival for Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study||New Mexico Cancer Care Alliance|Yes|Withdrawn|January 2006|September 2013|Actual|January 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Individuals diagnosed with malignant germ cell tumors at University of New Mexico        facilities|March 2015|April 2, 2015|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322790||182719|
NCT00322803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELB139202-05|ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment|International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment||elbion AG||Terminated|May 2006|October 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|No|||September 2006|September 27, 2006|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00322803||182718|
NCT00324142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-06JGunt-01-B|A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis|A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis||Kaiser Permanente||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|45 Years|No|||July 2012|July 31, 2012|May 9, 2006||Yes|Study Terminated Prematurely|No||https://clinicaltrials.gov/show/NCT00324142||182616|
NCT00297349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003472|A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures|An Open-label Observation Study of Topiramate Administration as Adjuvant Therapy for Focal Epilepsy, Lennox-Gastaut Syndrome Epileptic Seizures and Generalized Tonoclonic Seizures in Adults and Children Aged 2 Years and Older||Janssen Cilag Pharmaceutica S.A.C.I., Greece||Completed|November 2003|June 2005|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|153|||Both|2 Years|N/A|No|Probability Sample|225 adult patients and children aged 2 years or older will be enrolled in the study. Study        participants should demonstrate focal epilepsy or epileptic seizures of the LENNOX-GASTAUT        syndrome or generalized tonoclonic seizures, who should have undergone treatment with one        or more antiepileptic drugs and whose treatment should be judged by the inverstigator as        non-satisfactory.|April 2010|April 26, 2010|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297349||184635|
NCT00298012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001202-60|Methotrexate in the Treatment of Axial Spondyloarthritis|Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study.||Rheumatism Foundation Hospital||Withdrawn|March 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|50 Years|No|||January 2009|January 2, 2009|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00298012||184586|
NCT00297596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 77|Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer|A Phase II Trial of Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|February 2006|October 2010|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||January 2013|January 24, 2013|February 24, 2006||No||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00297596||184616|
NCT00297934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-06-02|Spinal Manipulative Therapy: Dual-Task Performance|Influence of Instrument-Applied Spinal Manipulative Therapy on Dual-Task Performance Involving Complex Postural and Cognitive Tasks||Logan College of Chiropractic||Completed|March 2006|March 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||October 2006|December 17, 2008|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297934||184591|
NCT00298285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABRIDGE|ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement|ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement. A Pilot Study||The Cleveland Clinic||Completed||October 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||January 2006|November 7, 2007|February 28, 2006||||||https://clinicaltrials.gov/show/NCT00298285||184565|
NCT00298298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/100/0601|DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer|L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer||AVAX Technologies|Yes|Terminated|January 2006|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Both|N/A|N/A|No|||December 2015|December 2, 2015|February 28, 2006|Yes|Yes|Suspended until capitalization is completed|No||https://clinicaltrials.gov/show/NCT00298298||184564|
NCT00298506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0601|Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)|An Open, Prospective Study to Assess the Efficacy and Safety of FK506 Combined MMF in the Treatment of Class III，IV，V + IV or V + III Lupus Nephritis||Nanjing University School of Medicine|Yes|Completed|September 2005|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Female|12 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 28, 2011|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298506||184548|
NCT00298493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH REB#00-0032-A|Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol|A Randomized Trial of Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol - A Pilot Study||Mount Sinai Hospital, Canada||Completed|February 2001|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||65|||Both|18 Years|N/A|No|||February 2006|February 28, 2006|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00298493||184549|
NCT00298792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAALIT014202-02|Individualized Treatment Program for Alcohol Problems|Individualized Treatment Program for Alcohol Problems|IATP|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|No|Completed|January 2006|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||April 2009|April 14, 2009|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298792||184526|
NCT00295230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512098|Effects of Volume Guarantee With Pressure Supported vs. Synchronized Intermittent Mandatory Ventilation in VLBW Infants|The Effects of Volume Guarantee Combined With Pressure Supported Ventilation (PSV+VG) Versus Synchronized Intermittent Mandatory Ventilation (SIMV+VG) in Very Low Birth Weight Infants||Children's Hospitals and Clinics of Minnesota||Suspended|February 2006|September 2007|Anticipated|||Phase 1|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|16|||Both|N/A|120 Hours|No|Probability Sample|premature infants weighing </= 1500 grams and needing mechanical ventilation at 72-120        hours of age.|November 2007|November 6, 2007|February 21, 2006|||suboptimal enrollment after 18 months.|No||https://clinicaltrials.gov/show/NCT00295230||184794|
NCT00294970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3918-JZ-CTIL|Cognitive Characteristics of PTSD Patients With OCD|Cognitive Characteristics of PTSD Patients With OCD||Sheba Medical Center|No|Completed|February 2006|August 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|76|||Both|18 Years|70 Years|No|Non-Probability Sample|Eligible patients from each group were invited to participate in the study from the        inpatient, outpatient and public clinic populations of the Chaim Sheba Medical Center        Psychiatric Division|January 2010|January 31, 2010|February 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00294970||184814|
NCT00295490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|devilclaw1|Trial Evaluating Devil's Claw for the Treatment of Hip and Knee Osteoarthritis|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Two- Centre Study to Evaluate the Efficacy and Safety of Devil's Claw in the Treatment of Knee and Hip Osteoarthritis||University of Southampton|No|Terminated|December 2004|June 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|67|||Both|40 Years|N/A|No|||September 2011|September 9, 2011|February 21, 2006||No|unexpected withdrawal of funding|No|June 19, 2009|https://clinicaltrials.gov/show/NCT00295490||184776|
NCT00295503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3442S|Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma|A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma||University of Texas Southwestern Medical Center|Yes|Completed|February 2006|August 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||February 2006|August 16, 2010|February 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295503||184775|
NCT00295204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-002|Evaluation of a Mobile Cardiac Outpatient Telemetry System Versus Standard Loop Event Monitor|Evaluation of a Mobile Cardiac Outpatient Telemetry System (CardioNet) Versus Standard Loop Event Monitor: A Multi-Center Randomized Study||Cardionet||Active, not recruiting|April 2005|October 2006||||N/A|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional||||300|||Both|18 Years|N/A|No|||February 2006|August 2, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295204||184796|
NCT00295217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF017|MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation|MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device||InSightec||Completed|February 2006|October 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 13, 2009|February 21, 2006||||||https://clinicaltrials.gov/show/NCT00295217||184795|
NCT00295477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tebas 066290 - Protocol 802456|Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV|A Phase I/II, Open-label, Single Center Study to Evaluate the Tolerability, Trafficking and Therapeutic Effects of Repeated Doses of Autologous T Cells Transduced With VRX496 in HIV Infected Subjects||University of Pennsylvania|Yes|Active, not recruiting|January 2006|December 2020|Anticipated|September 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2013|March 14, 2013|February 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295477||184777|
NCT00296309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-02-42|Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.|A Multicentre, Randomised, Open Clinical Study to Compare the Efficacy and Safety of a Combination of Tacrolimus and Mycophenolate Mofetil Based Regimen With or Without Induction in Elderly Recipients Undergoing Kidney Transplantation|SENIOR|Astellas Pharma Inc|Yes|Completed|October 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|267|||Both|60 Years|N/A|No|||August 2014|August 28, 2014|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296309||184714|
NCT00323076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-14-0050/DX-FAZ-001/22390|Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours|A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head & Neck, Small Cell and Non-Small Cell Carcinoma of the Lung, Lymphoma, Glioblastoma Multiforme, Neuroendocrine Tumours or Renal Cell Carcinoma||AHS Cancer Control Alberta|No|Recruiting|September 2004|April 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|16 Years|N/A|No|||January 2014|October 1, 2014|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00323076||182698|
NCT00323089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-0562|Removal of Lung Nodules After Being Marked With a Microcoil|Thoracoscopic Resection of Subcentimetre Lung Nodules After Localization Using Percutaneous Inserted Platinum Microcoil Under CT Guidance: a Pilot Study||University of British Columbia||Recruiting|April 2003|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323089||182697|
NCT00323115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0536|Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme|A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme||Dartmouth-Hitchcock Medical Center|No|Completed|May 2006|July 2013|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||June 2014|October 8, 2015|May 4, 2006|Yes|Yes||No|August 24, 2012|https://clinicaltrials.gov/show/NCT00323115||182695|
NCT00323479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5392L00013|Arthralgia During Anastrozole Therapy for Breast Cancer|A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer||AstraZeneca||Completed|June 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Female|18 Years|N/A|No|||March 2012|March 13, 2012|May 8, 2006|Yes|Yes||No|January 26, 2010|https://clinicaltrials.gov/show/NCT00323479||182667|
NCT00323440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4126-AL-CTIL|Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission|Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission||Sheba Medical Center|Yes|Withdrawn||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 18, 2008|May 7, 2006||No|Collaboration could not be established|No||https://clinicaltrials.gov/show/NCT00323440||182670|
NCT00314886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0009|Effect of Butyrogenic Fibers in IBS Patients|Effect of an Enriched Butyrogenic Fibres Diet on Rectal Sensitivity in Healthy Control and IBS Patients.||University Hospital, Clermont-Ferrand||Recruiting|January 2005|July 2005|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2011|January 18, 2011|April 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00314886||183318|
NCT00297648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87043|Mucosal Healing Study in Crohn's Disease (CD)|A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.|MUSIC|UCB Pharma|No|Completed|February 2006|December 2009|Actual|January 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||February 2011|August 30, 2011|February 27, 2006|Yes|Yes||No|December 10, 2009|https://clinicaltrials.gov/show/NCT00297648||184613|
NCT00297661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-33/2003|Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization|Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization: SIRTAX Trial||University of Bern||Completed|April 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||1012|||Both|18 Years|N/A|No|||February 2006|October 19, 2006|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00297661||184612|
NCT00298584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008396|Comparison of Infant Pain Responses Between Two Different Methods of Urine Collection|Comparison of Infant Pain Responses Between Two Different Methods of Urine Collection for Diagnosis of Infection: Suprapubic Aspiration and Urinary Catheterization||The Hospital for Sick Children||Recruiting|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||50|||Both|N/A|6 Months|No|||August 2006|February 22, 2007|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00298584||184542|
NCT00298246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060102|Clinical and Immunological Investigations of Subtypes of Autism|Clinical and Immunological Investigations of Subtypes of Autism||National Institutes of Health Clinical Center (CC)||Completed|February 2006|||||N/A|Observational|Time Perspective: Prospective|||Actual|557|||Both|1 Year|7 Years|No|||April 2015|May 6, 2015|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298246||184568|
NCT00298259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/06|Trial of Operative Fixation of Fractured Ribs in Patients With Flail Chest|Prospective Randomised Trial of Operative Fixation of Fractured Ribs in Patients With Flail Chest||The Alfred|No|Completed|January 2007|March 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|75 Years|No|||December 2012|December 9, 2012|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298259||184567|
NCT00298272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-RA-201|Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis|A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis||Biogen|No|Terminated|May 2006|July 2011|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|March 1, 2006|Yes|Yes|Sponsor decided to end long term extension phase for business reasons unrelated to safety.|No|April 20, 2010|https://clinicaltrials.gov/show/NCT00298272||184566|Sponsor made a business decision to terminate study on 28 July 2011, after completion of the primary endpoint and during the long-term extension phase. One participant was still in extended safety follow-up and was referred for appropriate care.
NCT00298558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0091|ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly|Trial of a Cognitive Intervention for Older Adults|ACTIVE|New England Research Institutes|Yes|Completed|March 1998|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|2832|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2014|March 24, 2014|February 28, 2006||No||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00298558||184544|
NCT00298571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212|Cesarean Delivery and Post-operative Pain Management With Local Anesthesia|||University of South Florida||Completed|February 2006|October 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2006|June 14, 2012|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00298571||184543|
NCT00298818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.08.035|Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation|Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation / Developmental Disabilities||Northwell Health|No|Completed|August 2002|March 2008|Actual|December 2005|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Epilepsy center|May 2008|May 19, 2008|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00298818||184524|
NCT00298805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.02.073|A Quality of Life Study in Patients With Migraines|Dysphoric-like Disorder of Epilepsy, Is It Unique?||Northwell Health|No|Terminated|January 2006|April 2013|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|Migraine patients will be recruited from the outpatient neurology clinics / offices.|August 2013|August 8, 2013|March 1, 2006||No|Study terminated due to expiration of IRB approval|No||https://clinicaltrials.gov/show/NCT00298805||184525|
NCT00299091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|startTDM-EFV|Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients|Open, Parallel and Randomised Pilot Clinical Trial to Evaluate the Utility of the Therapeutic Monitoring of Plasma Levels of Efavirenz in Hiv-Infected Patients Initiating an Antiretroviral Treatment Regimen With Sustiva||Germans Trias i Pujol Hospital|No|Completed|September 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||October 2008|October 14, 2008|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299091||184505|
NCT00294983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3912-JZ-CTIL|OCD Among Patients With Burns|||Sheba Medical Center||Withdrawn||||||N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|70 Years|No|||January 2008|January 28, 2008|February 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00294983||184813|
NCT00294996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STM01-102|Trial of Myocet in Metastatic Breast Cancer|A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer||Sopherion Therapeutics||Active, not recruiting|January 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|363|||Female|18 Years|N/A|No|||March 2009|March 30, 2009|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00294996||184812|
NCT00295282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1100-01|A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis|A Phase I, Multicenter, Dose-escalation Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Patients With Active Ulcerative Colitis||Bristol-Myers Squibb|No|Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|February 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295282||184790|
NCT00295243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1073-04|Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies|A Phase I Trial of the Dual Kinase Inhibitor GW572016 in Combination With Topotecan in Patients With Advanced Solid Malignancies||Mayo Clinic|Yes|Completed|September 2004|November 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||January 2011|January 12, 2011|February 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295243||184793|
NCT00295256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M630-430-2029|Randomized Trial to Evaluate the Effectiveness of Nurse Case Management|Randomized Trial to Evaluate the Effectiveness of Nurse Case Management on High-Risk Pregnancy Outcomes||Johns Hopkins University||Recruiting|February 2006|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|15 Years|N/A|No|||September 2006|September 13, 2006|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00295256||184792|
NCT00295737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/04 IMHOTEP-1 FHG|Effect of an Immunotoxin on Activated Human Macrophages in Those With Allergic Rhinitis or Mild Intermittent Asthma|05/04 IMHOTEP-1 FHG: Ex Vivo Effect of an Immunotoxin on Activated Human Macrophages From Atopics After Segmental Instillation of Allergen and Endotoxin||Fraunhofer-Institute of Toxicology and Experimental Medicine||Terminated|February 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|8|||Both|18 Years|55 Years|No|||January 2008|January 15, 2008|February 22, 2006|||proof of mechanism achieved with fewer subjects than anticipated|No||https://clinicaltrials.gov/show/NCT00295737||184757|
NCT00296023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463724|Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer|Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies||University of California, San Francisco|Yes|Completed|January 1999|June 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||October 2012|October 2, 2012|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00296023||184735|
NCT00295763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYR01605|A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.|Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method.||Sanofi||Completed|May 2006|September 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|February 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295763||184755|
NCT00296036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000464246|Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer|A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome||National Cancer Institute (NCI)||Completed|June 2006|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|6||Anticipated|132|||Both|18 Years|N/A|No|||January 2009|November 17, 2010|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00296036||184734|
NCT00322829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0107|Development and Optimization of a GBS Diagnostic Test|Development and Optimization of a GBS Micro Total Analysis System (µTAS) Prototype for the Direct Detection of Group B Streptococci in Vaginal/Anal Specimens From Intrapartum Maternity Patients||Laval University|Yes|Suspended|May 2006|February 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|320|Samples With DNA|Vaginal/anal swab samples taken from pregnant women admitted for delivery to the Centre      Hospitalier Universitaire de Québec (CHUQ).|Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women admitted for delivery at the Centre Hospitalier Universitaire de Québec        (CHUQ)|September 2008|September 18, 2008|May 4, 2006||No|Temporarily suspended in between validating test systems.|No||https://clinicaltrials.gov/show/NCT00322829||182716|
NCT00323102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 130|A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain|Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain|ENHANCE|Bracco Diagnostics, Inc|No|Completed|May 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||114|||Both|18 Years|N/A|No|||January 2008|January 18, 2008|May 5, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00323102||182696|
NCT00323765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060157|Plasticity in Cervical Dystonia|Plasticity in Cervical Dystonia||National Institutes of Health Clinical Center (CC)||Completed|May 2006|May 2008||||N/A|Observational|N/A||||44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|September 26, 2015|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00323765||182645|
NCT00323453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-06|Wound Infection Alexis Wound Retractor|Rate of Surgical Wound Infection After Open Appendectomy Using the Alexis Wound Retractor||Santa Barbara Cottage Hospital|Yes|Completed|March 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||May 2009|December 18, 2012|May 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323453||182669|
NCT00323466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/164|A Study of the Effect on Oro-dental Complications of Intensity Modulated Radiotherapy (IMRT) Versus Conventional Radiotherapy in Patients With Cancer of the Head or Neck|A Study of the Effect on Oro-dental Complications of Intensity Modulated Radiotherapy (IMRT) Versus Conventional Radiotherapy in Patients With Cancer of the Head or Neck||University Hospital, Ghent|No|Recruiting|May 2007|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00323466||182668|
NCT00314626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELA|Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily|Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC Once Daily||Germans Trias i Pujol Hospital|No|Completed|November 2004|March 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|80 Years|No|||November 2007|January 25, 2008|April 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00314626||183338|
NCT00298337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T101060058;T1040A0002;T110612|Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008|||Helsinki University||Active, not recruiting|October 1999|December 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|37 Weeks|42 Weeks||||March 2006|October 17, 2006|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298337||184561|
NCT00298350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-183-0105|Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.|Phase 2 Study of the Treatment of Antiretroviral Treatment-Experienced Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) vs. a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination With Background ART.||Gilead Sciences|Yes|Completed|February 2006|July 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|278|||Both|18 Years|65 Years|No|||July 2008|July 28, 2008|February 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298350||184560|
NCT00299156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0536|Oral Clofarabine Study in Patients With Myelodysplastic Syndrome|Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Completed|March 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|N/A|N/A|No|||August 2015|October 8, 2015|March 3, 2006|Yes|Yes||No|August 19, 2015|https://clinicaltrials.gov/show/NCT00299156||184500|
NCT00297960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|olanz/zipra|Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle|Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle||Medical University of Vienna||Completed|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2005|October 17, 2006|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00297960||184589|
NCT00297973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841038|Cardiovascular Risk Assessment in Patients Treated With Caduet|Cardiovascular Risk Assessment In Patients With Hypertension And At Least Three Other Risk Factors, Treated With Caduet Compared To Usual Care: The Right Study|RIGHT|Pfizer||Completed|February 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|1442|||Both|18 Years|N/A|No|||April 2008|March 27, 2009|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297973||184588|
NCT00299143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM 04-24|Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes|Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes|REACS|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|June 2005|June 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|97|Samples Without DNA|serum, plasma, urines|Both|18 Years|85 Years|No|Non-Probability Sample|patients admitted in the intensive care unit with acute coronary syndrome|December 2011|December 27, 2011|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00299143||184501|
NCT00298545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUH IRB # PHO-0554|Effect of Vitamin D and Calcium on Genes in the Colon|High vs. Low Calcium Intake in the Presence of High Vitamin D: Effect on Gene Expression in the Colon||Rockefeller University|No|Completed|November 2005|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|10|||Both|48 Years|72 Years|Accepts Healthy Volunteers|||November 2011|November 17, 2011|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298545||184545|
NCT00299104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3373g|A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis|A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis|IMAGE|Genentech, Inc.||Completed|January 2006|July 2013|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|755|||Both|18 Years|80 Years|No|||August 2013|August 20, 2013|March 2, 2006|Yes|Yes||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00299104||184504|
NCT00298831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05943|Use of Sugammadex at the End of Case in Routine Anesthesia (19.4.311)(P05943)(COMPLETED)|A Multicenter, Open Label, Phase IIIa Trial to Evaluate the Efficacy and Safety of Org 25969 When Used at the End of Surgical Procedure to Reverse the Neuromuscular Block Induced by Rocuronium Following Routine Anesthesia||Merck Sharp & Dohme Corp.|No|Completed|October 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|March 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00298831||184523|
NCT00294931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 90|Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer|A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer||SCRI Development Innovations, LLC||Completed|February 2006|January 2009|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||January 2009|June 24, 2010|February 20, 2006||||No||https://clinicaltrials.gov/show/NCT00294931||184817|
NCT00294944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3911-JZ-CTIL|The Effectiveness of Idazoxan in Treating TRD|||Sheba Medical Center||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|65 Years||||January 2008|January 28, 2008|February 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00294944||184816|
NCT00295529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0109-E|GenetiKiT: Evaluation of an Educational Intervention on the Delivery of Genetics Services by Family Physicians|GenetiKiT: Evaluation of the Impact of a Multifaceted Intervention to Enhance the Delivery of Genetics Services by Family Physicians.||University of Toronto|No|Completed|April 2005|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|125|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00295529||184773|
NCT00296062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1205|Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer|Dose-Dense and Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in Solid Tumors and Phase II With Bevacizumab a First-Line Therapy of Advanced Colorectal Cancer||Case Comprehensive Cancer Center|Yes|Terminated|March 2006|May 2011|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|February 23, 2006|Yes|Yes|Trial did not move to Phase II portion due to poor tolerance of treatment|No||https://clinicaltrials.gov/show/NCT00296062||184732|
NCT00295789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCOG0505|Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)|A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Carboplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)||Japan Clinical Oncology Group|Yes|Active, not recruiting|February 2006|November 2011|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|253|||Female|20 Years|75 Years|No|||June 2010|June 13, 2010|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00295789||184753|
NCT00295802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050103|Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer|Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer||EDAP TMS S.A.|No|Active, not recruiting|April 2006|September 2014|Anticipated|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Male|50 Years|N/A|No|||February 2014|February 6, 2014|February 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295802||184752|
NCT00295516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH-REB 01-0266-U|Doppler or Amniocentesis to Predict Fetal Anemia|Minimally Invasive Management of Rh Alloimmunization: Can Amniotic Fluid DeltaOD450 Measurements Be Replaced by Doppler Studies?||University of Toronto||Completed|October 2000|August 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||157|||Both|N/A|N/A|No|||February 2006|May 19, 2006|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00295516||184774|
NCT00295750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS21|The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer|An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy||Ferring Pharmaceuticals|Yes|Completed|February 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|620|||Male|18 Years|N/A|No|||December 2012|December 17, 2012|February 22, 2006|No|Yes||No|January 5, 2009|https://clinicaltrials.gov/show/NCT00295750||184756|
NCT00295776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lamictal PHN|Lamictal in the Treatment of Post-Herpetic Neuralgia|Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study||George Washington University||Terminated|February 2005|||December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|18 Years|85 Years||||February 2005|March 11, 2013|February 22, 2006|Yes|Yes|enrollment difficult due to inclusion/exclusion criteria/protocol requirements|No||https://clinicaltrials.gov/show/NCT00295776||184754|
NCT00296634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0127|H5 Vaccine Alone or With Adjuvant in Healthy Adults|A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|600|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2008|August 26, 2010|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00296634||184689|
NCT00298064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0548C|Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer|Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer||University of New Mexico|Yes|Completed|December 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|N/A|||Actual|300|||Female|N/A|N/A|No|||November 2009|January 6, 2010|February 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00298064||184582|
NCT00323128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/037|Validation of Serum Creatinine Dosage and Renal Clearance|Validation of Serum Creatinine Dosage and Renal Clearance||University Hospital, Ghent|No|Completed|May 2006|December 2010|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|60 Years|No|||June 2011|June 1, 2011|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323128||182694|
NCT00323141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/079|Intraperitoneal Mesh With 3cm Overlap Versus a Rives-Stoppa Repair With a 6cm Overlap in Hernia Umbilicalis|Prospective Randomized Trial to Study the Effectiveness of an Intraperitoneal Mesh With an Overlap of 3cm Versus a Rives-Stoppa Repair With an Overlap of 6cm With Patients With a Hernia Umbilicalis||University Hospital, Ghent|No|Active, not recruiting|March 2006|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00323141||182693|
NCT00314327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.04.161|Optimizing Response in Psychosis Study|Optimizing Response in Psychosis Study|ORP|Northwell Health|Yes|Terminated|April 2006|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|15 Years|40 Years|No|||June 2015|June 10, 2015|April 11, 2006|Yes|Yes|Recruitment for the study was limited.|No|April 13, 2015|https://clinicaltrials.gov/show/NCT00314327||183361|
NCT00323778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25107|Prospective Assessment of the Efficacy of Hyaluronate Knee Injections in Patients With Osteoarthritis|Prospective Assessment of the Efficacy of Intra-Articular Hyaluronate to Affect Extracellular Matrix Changes in Patients With Osteoarthritis||Hospital for Special Surgery, New York||Terminated|May 2006|||September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|40|||Both|45 Years|90 Years|No|||February 2008|February 4, 2008|May 8, 2006||||||https://clinicaltrials.gov/show/NCT00323778||182644|
NCT00314613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7858|Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal|Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal||Duke University||Terminated|April 2006|||December 2006||Phase 4|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|40 Years|No|||May 2010|June 19, 2013|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314613||183339|
NCT00314925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N05-10564|Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features|Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Patients With Advanced Solid Tumors With Neuroendocrine Features||Neotropix||Active, not recruiting|April 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|April 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00314925||183315|
NCT00314938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6391004|A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency|A Double Blind, Single Dose Study To Explore The Safety, Pharmacokinetics And Pharmacodynamics Of PHA-794428 In Pediatric Patients With Growth Hormone Deficiency||Pfizer|No|Terminated|April 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|6 Years|12 Years|No|||May 2011|May 12, 2011|April 13, 2006|||See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00314938||183314|
NCT00298909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leipzig-02|Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)|Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function||University of Leipzig||Completed|March 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|35 Years|75 Years|No|||July 2012|July 29, 2012|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00298909||184517|
NCT00295568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060095|Interaction of Right and Left Brain Hemispheres in Learning Precision Hand Movements|Contribution of Interhemispheric Inhibition to Motor Learning||National Institutes of Health Clinical Center (CC)||Completed|February 2006|January 2009||||N/A|Observational|N/A||||46|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2009|January 13, 2009|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00295568||184770|
NCT00295581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050118|PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria|Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria||National Institutes of Health Clinical Center (CC)||Completed|March 2005|June 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 18, 2008|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00295581||184769|
NCT00298311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPD MOD|Trial to Evaluate the Effect of Home-Based Peer Support on Maternal-Infant Interaction, Infant Health Outcomes, and Postpartum Depression (PPD)|An RCT to Evaluate the Effect of Home-Based Peer Support on Maternal-Infant Interaction, Infant Health Outcomes, and Postpartum Depression||Canadian Research Institute for Social Policy|No|Recruiting|November 2005|July 2009|Anticipated|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|104|||Female|N/A|N/A|No|||February 2009|February 6, 2009|March 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00298311||184563|
NCT00298324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-006178-86|Myfortic - Treatment for Extensive cGvHD|A Randomized Double Blinded Placebo-Controlled Phase III Trial Comparing Cyclosporine Plus Steroids With or Without Myfortic as Primary Treatment for Extensive Chronic Graft Versus Host Disease||European Group for Blood and Marrow Transplantation|Yes|Terminated|September 2006|November 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||April 2015|April 2, 2015|March 1, 2006|||Due to slow accrual|No||https://clinicaltrials.gov/show/NCT00298324||184562|
NCT00298857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.02.045|A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights|An Open-label, Prospective Trial to Determine the Effect(s) of Obesity on the Pharmacokinetic Parameters of Valproic Acid||Northwell Health||Terminated|March 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 29, 2012|March 2, 2006|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00298857||184521|
NCT00298870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-MRT-TB-01|Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)|||Osaka University|Yes|Completed|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|20 Years|75 Years|No|||May 2011|October 17, 2012|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00298870||184520|
NCT00298844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021|Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus|Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus: Left Ventricular Diastolic Dysfunction, Myocardial Ischemia and Peripheral Vascular Insufficient||Odense University Hospital||Recruiting|January 2006|January 2010|Anticipated|||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||350|||Both|20 Years|N/A|No|||March 2007|March 22, 2007|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298844||184522|
NCT00299117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060007|Brief Smoking Intervention for Women Undergoing Breast Cancer Surgery|Effect of a Brief Preoperative Smoking Intervention on Postoperative Complications in Women Undergoing Breast Cancer Surgery: A Randomised Clinical Trial||Herlev Hospital|Yes|Completed|April 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|130|||Female|18 Years|N/A|No|||January 2009|January 30, 2009|March 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00299117||184503|
NCT00294957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3910-JZ-CTIL|Psychological and Physiological Status of Former Prisoners of War|||Sheba Medical Center||Withdrawn||||||N/A|Observational|Time Perspective: Retrospective|||||||Male|N/A|N/A||||January 2008|January 28, 2008|February 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00294957||184815|
NCT00296348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-02-43|Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation|An Open, Randomised, Multicentre Clinical Study to Investigate the Safety and Efficacy of Steroid Withdrawal With Tacrolimus, Mycophenolate Mofetil and Daclizumab Against Tacrolimus, Mycophenolate Mofetil and Steroids in Children After Kidney Transplantation|TWIST|Astellas Pharma Inc|Yes|Completed|November 2005|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|198|||Both|2 Years|18 Years|No|||June 2015|June 25, 2015|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296348||184711|
NCT00296049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466308|Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy|An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients||Comprehensive Cancer Center of Wake Forest University|No|Withdrawn|July 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|N/A|N/A|No|||July 2012|July 12, 2012|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00296049||184733|
NCT00296335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0204|Trial of Adjuvant Chemotherapy for Gastric Cancer|A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma||Asan Medical Center|Yes|Completed|February 2002|December 2009|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|855|||Both|18 Years|69 Years|No|||January 2014|January 13, 2014|February 24, 2006||No||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00296335||184712|
NCT00298376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.389|Oral Tolerance in Cow’s Milk Allergy in the Infant|Oral Tolerance in Cow’s Milk Allergy in the Infant: Role of CD4+CD25+ T Cells and Intestinal Microflora||Hospices Civils de Lyon||Recruiting|March 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||50|||Both|1 Month|15 Months|Accepts Healthy Volunteers|||April 2007|April 26, 2007|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298376||184558|
NCT00323154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02-0589|Nalbuphine for the Treatment of Opioid Induced Pruritus in Children|Nalbuphine for the Treatment of Opioid Induced Pruritus in Children||University of British Columbia||Completed|March 2004|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|134|||Both|N/A|7 Years|No|||September 2008|September 24, 2008|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323154||182692|
NCT00313976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91449|Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)|A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis||Bayer|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2008|March 9, 2015|April 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00313976||183388|
NCT00313989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/125|Evaluation of Osseo-integration After Placement of Dental Implants With Patients Receiving Radiotherapy for Buccopharyngeal Oncology|Evaluation of Osseo-integration After Placement of Dental Implants With Patients Receiving Radiotherapy for Buccopharyngeal Oncology||University Hospital, Ghent|No|Recruiting|September 2007|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313989||183387|
NCT00314340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513430|A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine|A CTSC Clinical Research Center Study: A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine||University of California, Davis|No|Completed|November 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|April 11, 2006|No|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00314340||183360|
NCT00315991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12202|Blood Glucose Awareness Training for Parents|Parent-Child Co-Regulation of Pediatric Diabetes, Phase 2||University of Virginia||Completed|April 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|77|||Both|6 Years|11 Years|No|||January 2013|January 14, 2013|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00315991||183233|
NCT00295334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250505|Moderate Alcohol Intake Among Patients With Type 2 Diabetes|||The S. Daniel Abraham International Center for Health and Nutrition||Active, not recruiting|February 2006|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||100|||Both|40 Years|75 Years|No|||September 2006|September 11, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295334||184787|
NCT00296140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMV 04-096|Implementing Evidence in the Detection and Treatment of Post Stroke Depression|||Richard L. Roudebush VA Medical Center||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|February 22, 2006|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00296140||184727|
NCT00298883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|584-2004|Desensitization of Renal Transplant Candidates|Desensitization of Renal Transplant Candidates||University of Florida|No|Completed|February 2006|December 2008|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||July 2012|July 24, 2012|March 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00298883||184519|
NCT00298896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0006|Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer|Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)||Sunesis Pharmaceuticals||Completed|February 2006|June 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||March 2009|March 5, 2009|March 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298896||184518|
NCT00295035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tasmc-05-na-05160-ctil|Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer|Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer||Tel-Aviv Sourasky Medical Center||Not yet recruiting|March 2006|March 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||February 2006|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295035||184809|
NCT00295308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906407|Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients|Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients||National Institutes of Health Clinical Center (CC)||Completed|November 2005|July 2014|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|February 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295308||184788|
NCT00295555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7332-2|Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy|Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy||Yokohama City University Medical Center|Yes|Completed|January 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|20 Years|79 Years|No|||April 2007|May 8, 2007|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295555||184771|
NCT00295295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AR051564|Vibration Intervention to Improve Bone and Muscle in Children With Cerebral Palsy|Mechanical Intervention in Children With Cerebral Palsy||Children's Hospital Los Angeles||Completed|September 2004|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||34|||Both|6 Years|12 Years|No|||May 2013|June 19, 2013|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295295||184789|
NCT00299130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2973g|A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis|A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis|SERENE|Genentech, Inc.||Completed|October 2005|July 2013|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|511|||Both|18 Years|80 Years|No|||January 2016|January 11, 2016|March 3, 2006|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT00299130||184502|
NCT00295009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDL-07272001|Safety and Effectiveness Study of Prodisc to Spinal Fusion Surgery|A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc to Spinal Fusion Surgery in the Treatment of Discogenic Pain Associated With DDD in the Lumbosacral Spine|PDL|Synthes USA HQ, Inc.|No|Completed|September 2001|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|852|||Both|18 Years|60 Years|No|||July 2014|July 31, 2014|February 20, 2006|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT00295009||184811|
NCT00295022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00414|Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects|Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEU.||UCB Pharma||Completed|August 2006|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||403|||Both|19 Years|N/A||||September 2009|December 13, 2013|February 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295022||184810|
NCT00295269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|355|Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome|Late Steroid Rescue Study (LaSRS): The Efficacy of Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome||National Heart, Lung, and Blood Institute (NHLBI)||Completed|March 1997|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|13 Years|N/A|No|||April 2006|May 8, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295269||184791|
NCT00296647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0462|Smoking Cessation Intervention: Effectiveness in Primary Care|Tobacco Dependence: Treatment and Outcomes; Pharmacotherapies: Effectiveness in Primary Care||University of Wisconsin, Madison|No|Completed|September 2004|December 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|1346|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|February 24, 2006||No||No|October 21, 2011|https://clinicaltrials.gov/show/NCT00296647||184688|The present study is limited to some extent by the fact that self-reported abstinence was not biochemically confirmed. However, there is evidence that self-reported abstinence rates are generally accurate in low-contact effectiveness studies.
NCT00296881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-0605-3|SRP in Combination With PERIOWAVE in Comparison to SRP Alone in Chronic Periodontitis|Clinical Outcomes Following Non-Surgical Treatment of Chronic Periodontitis, Using Scaling and Root Planing (SRP) in Conjunction With PerioWave, Compared to SRP Alone||Ondine Research Laboratories||Active, not recruiting|April 2006|December 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2007|May 17, 2007|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296881||184670|
NCT00296894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/072|Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints|TNF-Blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints: Randomized, Double Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of Adalimumab 40 mg SC Every Other Week in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints||University Hospital, Ghent|No|Completed|May 2006|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2009|February 6, 2009|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296894||184669|
NCT00297180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGO105858|Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks|A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor||GlaxoSmithKline|No|Completed|January 2006|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|136|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|February 24, 2006||||||https://clinicaltrials.gov/show/NCT00297180||184648|
NCT00296868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRvB/2001-290/JV|Prophylactic Administration of Vitamin C in Wrist Fractures|Prophylactic Administration of Vitamin C in Wrist Fractures; a Randomized Placebo Controlled Multicentre Dose-Finding Study of the Incidence of Complex Regional Pain Syndrome||Stichting Achmea Slachtoffer en Samenleving||Completed|January 2001|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||300|||Both|18 Years|N/A|No|||December 2005|February 24, 2006|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00296868||184671|
NCT00297167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUR-1008-M|Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency||Forest Laboratories||Completed|May 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|34|||Both|7 Years|N/A|No|||February 2014|February 24, 2014|February 27, 2006|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT00297167||184649|
NCT00298636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADO-122|Dose-Response of Adenosine for Perioperative Pain|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Escalating Dose-Response Trial of Intravenous Adenosine for Perioperative Analgesia in Females Undergoing Abdominal Hysterectomy or Myomectomy||Xsira Pharmaceuticals||Completed|October 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Female|18 Years|65 Years|No|||August 2006|August 1, 2006|February 28, 2006||||||https://clinicaltrials.gov/show/NCT00298636||184538|
NCT00313677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U54NS053672-06|Clinical Trial Readiness for the Dystroglycanopathies|Clinical Trial Readiness for the Dystroglycanopathies||University of Iowa|No|Recruiting|April 2006|March 2020|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|fibroblasts, whole blood|Both|N/A|N/A|No|Non-Probability Sample|neuromuscular care clinic|May 2012|May 7, 2012|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00313677||183411|
NCT00314353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FC-BV-003|Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon|Randomized Phase II Clinical Trial of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Line Treatment for Metastatic Colorectal Cancer||NSABP Foundation Inc|No|Terminated|March 2006|June 2010|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||June 2010|June 8, 2010|April 11, 2006|Yes|Yes|The study was closed early due to low enrollment and new information regarding the benefit of    the study regimen.|No|November 7, 2008|https://clinicaltrials.gov/show/NCT00314353||183359|The study was closed early due to low enrollment and new information regarding the benefit of the study regimen.
NCT00314639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4764|Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia|The Impact of Modafinil as an Adjunctive to a Second Generation Antipsychotic on Cognitive Functioning in Schizophrenia and Schizophrenia Spectrum Psychosis.||Laval University||Completed|September 2005|||June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2007|February 11, 2009|April 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00314639||183337|
NCT00295867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000465216|Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer|Pilot Study to Evaluate the Effect of Zoledronic Acid (Zometa) on Occult Malignant Bone Marrow Cells in Patients With High Risk Early Stage Breast Cancer||University of California, San Francisco||Active, not recruiting|December 2005|December 2013|Anticipated|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Female|18 Years|N/A|No|||October 2012|October 9, 2012|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295867||184747|
NCT00327613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066-WUK-2005-001|Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma|Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG)||University Hospital, Basel, Switzerland|No|Completed|June 2005|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with pseudoexfoliation|September 2008|September 25, 2008|May 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00327613||182358|
NCT00327873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0064|Palliative Oxygen for the Relief of Breathlessness|A Multi-center Randomized Double-blind Controlled Trial of Oxygen Versus Medical Air for the Relief of Breathlessness in Patients With Intractable Dyspnea and PaO2>55mmHg||National Institute on Aging (NIA)|Yes|Completed|May 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2009|December 10, 2009|May 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00327873||182338|
NCT00296088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1330|Effects of Obesity on Care and Outcomes in Mechanically Ventilated Individuals in the Intensive Care Unit|A Prospective Observational Study of the Association Between Excess Body Weight and Outcome and Process Measures in Mechanically Ventilated Medical Intensive Care Unit Patients||Ohio State University||Terminated|February 2006|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|582|||Both|18 Years|N/A|No|Probability Sample|patients requiring mechanical ventilation admitted to the OSUMC MICU|July 2013|July 29, 2013|February 23, 2006||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00296088||184731|
NCT00295542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIDIT03-PXIB-32201PR|Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy|Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study).|MAPEC|University of Vigo|Yes|Completed|March 2000|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3344|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 27, 2009|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00295542||184772|
NCT00295815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9817|Enzastaurin Versus Lomustine in Glioblastoma|Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma||Eli Lilly and Company|Yes|Completed|January 2006|May 2014|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|397|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|February 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295815||184751|
NCT00295828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEF-0510|A Pilot Study for the Treatment of Iris Neovascularization With Macugen|A Pilot Study for the Treatment of Iris Neovascularization With Macugen||Hermann Eye Center|No|Completed|January 2006|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 3, 2008|February 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295828||184750|
NCT00296907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIGO-1|Psychological Interventions in Siblings of Children With Cancer|Psychological Interventions in Siblings of Children With Cancer: a Randomized Controlled Study||University Children's Hospital, Zurich||Completed|April 2006|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|30|||Both|7 Years|16 Years|No|||July 2012|July 27, 2012|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296907||184668|
NCT00297193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT2005-003337-40|ASTIC Autologous Stem Cell Transplantation for Crohn's Disease|Autologous Stem Cell Transplantation for Crohn's Disease: ASTIC||European Group for Blood and Marrow Transplantation|Yes|Terminated|June 2006|March 2017|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||August 2013|August 29, 2013|February 27, 2006||No|For safety reasons the recruitment was halted prematurely. Patients on the trial continute to    receive treatment and are being followed up as part the protocol.|No||https://clinicaltrials.gov/show/NCT00297193||184647|
NCT00297206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS210914|A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children|An Open-label, Single-dose, Multicenter, Pharmacokinetic, Safety and Tolerability Study of Valaciclovir Oral Suspension in Infants and Children.||GlaxoSmithKline|No|Completed|January 2003|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|1 Month|6 Years|No|||March 2011|March 17, 2011|February 24, 2006||||||https://clinicaltrials.gov/show/NCT00297206||184646|
NCT00297401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8023|Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus|The Effect of Protein Kinase C Inhibition on Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|February 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00297401||184631|
NCT00297388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002899|A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder|A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|70 Years|No|||April 2010|May 17, 2011|February 24, 2006||||||https://clinicaltrials.gov/show/NCT00297388||184632|
NCT00297726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-OA-00001|A Study to Examine the Efficacy of the Arthritis Self Management Program|A Prospective Study to Examine the Efficacy of the Arthritis Self Management Program (ASMP) in Patients With Osteoarthritis (OA) in Alberta||Alberta Bone and Joint Health Institute||Completed|October 2004|April 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||64|||Both|18 Years|N/A|No|||February 2006|February 27, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297726||184607|
NCT00330967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-029-05F|Mechanisms of Insulin Resistance in Humans|Mechanisms of Insulin Resistance in Humans||VA Office of Research and Development|No|Completed|April 2006|August 2014|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|25|Samples Without DNA|Blood samples, muscle biopsies|Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|March 2015|March 17, 2015|May 26, 2006||No||No|January 22, 2015|https://clinicaltrials.gov/show/NCT00330967||182107|The study's original Principal Investigator left the VA prior to the completion of data acquisition and no further subjects were enrolled. The data entered were analyzed based solely on study files in the system.
NCT00314002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APE1|Catheter Thrombectomy in Patients With Massive Pulmonary Embolism|Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism||Straub Medical AG||Terminated|October 2005|April 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||August 2009|August 6, 2009|April 11, 2006|||After treatment of 7 patients, it was decided that the handling characteristics of the test    device should be upgraded before continuing the trial as planned.|No||https://clinicaltrials.gov/show/NCT00314002||183386|
NCT00314015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/121|Evaluation of the Success Rate of Immediately Loaded Implants|Evaluation of the Success Rate of Immediately Loaded Implants||University Hospital, Ghent|No|Recruiting|January 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314015||183385|
NCT00315250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Query 3C|Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease|Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease||Institute for Neurodegenerative Disorders|No|Completed|January 2006|June 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|225|||Both|22 Years|N/A|No|||April 2014|April 21, 2014|April 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00315250||183290|
NCT00315731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/027|A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma|A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma||GlaxoSmithKline||Completed|March 2003|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2014|May 29, 2014|April 17, 2006|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT00315731||183253|
NCT00315471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5503|Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis|VCRC Longitudinal Protocol for Takayasu's Arteritis||University of Pennsylvania|Yes|Recruiting|April 2006|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Blood (serum and plasma), urine, and DNA|Both|N/A|N/A|No|Non-Probability Sample|Individuals with Takayasu's arteritis. Enrollment will be sequential and participants will        have disease in various stages and of different duration.|September 2015|September 4, 2015|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315471||183273|
NCT00315744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102318|Viapaed Study In Children And Adolescents With Asthma|Steroid-sparing Management of the Salmeterol/Fluticasone 50/100µg b.i.d. Combination Compared to Fluticasone 200µg b.i.d. in Children and Adolescents With Moderate Asthma||GlaxoSmithKline|No|Completed|November 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|4 Years|16 Years|No|||March 2011|March 17, 2011|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00315744||183252|
NCT00327353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101182|Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol|Single-Centre Randomised Open Crossover Study to Examine the Influence of Different Internal Resistances of Discus and Turbohaler Respectively on the Effects of Salmeterol and Formoterol in Asthmatic Subjects||GlaxoSmithKline||Completed|January 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||77|||Both|18 Years|N/A|No|||May 2009|May 21, 2009|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327353||182378|
NCT00327366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-s3|Effect of Bright Light on Sex Hormones and Ovulation in Humans|||Russian Academy of Medical Sciences|No|Completed|September 2003|April 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|27|||Female|19 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 18, 2009|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00327366||182377|
NCT00327886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-029|Managing Cyanosis Following Bidirectional Glenn Operation|A Retrospective Review of Postoperative Management of Cyanosis Following Bidirectional Glenn Operation||Children's Healthcare of Atlanta||Terminated|February 2006|February 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|N/A|1 Year|No|||June 2007|June 12, 2007|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00327886||182337|
NCT00295841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466307|Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|February 2005|||November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|120 Years|No|||September 2015|September 22, 2015|February 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00295841||184749|
NCT00295854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-001-CL-002|Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis|A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis||MediciNova|Yes|Completed|May 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|296|||Both|18 Years|N/A|No|||December 2011|December 16, 2011|February 22, 2006|No|Yes||No|February 16, 2011|https://clinicaltrials.gov/show/NCT00295854||184748|
NCT00296101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|359|School-Based Intervention to Increase Physical Activity Among Adolescent Females|Interventions to Increase Adolescent Physical Activity||National Heart, Lung, and Blood Institute (NHLBI)||Completed|February 2000|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Female|13 Years|15 Years|Accepts Healthy Volunteers|||February 2006|March 6, 2006|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296101||184730|
NCT00296114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRT 03 001|Pancreatic Cancer Serum and DNA Repository|Pancreatic Cancer Serum and DNA Repository||Pancreatic Cancer Research Team||Completed|February 2004|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|690|Samples With DNA|Whole Blood and Serum Samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Samples are collected on: Pancreatic Cancer, Liver Disease, Pancreatitis, Healthy and        Healthy at Risk Subjects.|December 2011|April 29, 2013|February 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00296114||184729|
NCT00296127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191202|Study of Celecoxib Bioavailability in Healthy Subjects|A Relative Bioavailability Study Of Celecoxib Administered As Capsule Contents Sprinkled On Applesauce In Healthy Adult Volunteers||Pfizer||Completed|February 2006|March 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2006|February 1, 2007|February 22, 2006||||||https://clinicaltrials.gov/show/NCT00296127||184728|
NCT00296361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-02-40|To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.|A Multicentre, Randomised, Open Clinical Study to Compare the Efficacy and Safety of a Combination Therapy of Tacrolimus With Sirolimus Versus Tacrolimus With Mycophenolate Mofetil in Kidney Transplantation.|RESTORE|Astellas Pharma Inc|Yes|Completed|October 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|634|||Both|18 Years|60 Years|No|||August 2014|August 28, 2014|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296361||184710|
NCT00296374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3569C00007|Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease|Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria|PLANET 1|AstraZeneca||Completed|February 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|353|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|February 23, 2006|Yes|Yes||No|March 3, 2010|https://clinicaltrials.gov/show/NCT00296374||184709|
NCT00296660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAVI 001|Acute HIV Infection Observational Study|Acute HIV-1 Infection Prospective Cohort Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2006|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Up to 1300 with either an acute HIV-1 infection, established HIV-1 infection, or without        HIV-1 infection will be enrolled. Sexual partners of those with an acute infection will        also be enrolled.|November 2013|November 18, 2013|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296660||184687|
NCT00329303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87044|Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis|Efficacy and Safety of Re-treatment With Cimzia® at 2 Dose Regimens for 12 Weeks in Subject Suffering From Moderate to Severe Chronic Plaque Psoriasis Having Relapsed After Response to First Treatment||UCB Pharma||Completed|April 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||75|||Both|N/A|18 Years|No|||September 2009|September 6, 2013|May 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00329303||182231|
NCT00329316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL Progesterone Perlitz.CTIL|Prevention of Recurrent Preterm Delivery by a Natural Progesterone Agent|||The Baruch Padeh Medical Center, Poriya||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Female|N/A|N/A|No|||June 2007|June 26, 2008|May 23, 2006|||Study withdrawn for financial problems. We didnwt get a grant we needed for purchesing the    medication for the study.|No||https://clinicaltrials.gov/show/NCT00329316||182230|
NCT00329563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9863-B03|Pilot Community Clinical Study of Hypothermia in Cardiac Arrest|Pilot Community Clinical Study of Hypothermia in Cardiac Arrest||University of Washington||Completed|November 2004|March 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||December 2007|December 18, 2007|May 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00329563||182211|
NCT00329576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106640|Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine|Evaluate the Anti-HBs Antibody Persistence, in Subjects Who Received GSK Biologicals' Preservative-free or Thiomersal-free Engerix™-B or Engerix™-B Containing Thiomersal, Approximately 5 to 6 Yrs Earlier||GlaxoSmithKline||Completed|May 2006|||||Phase 4|Interventional|N/A||||632|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00329576||182210|
NCT00297739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-ATT-401|Risperidone Augmentation for Treatment-Resistant Aggression in ADHD|Risperidone Augmentation for Treatment-Resistant Aggression in ADHD||Armenteros, Jorge L., M.D., P.A.||Completed|January 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|7 Years|12 Years|No|||March 2006|March 15, 2006|February 28, 2006||||No||https://clinicaltrials.gov/show/NCT00297739||184606|
NCT00329888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561703024|Comparison of Papillary Balloon Dilatation Vs.Sphincterotomy for Lithotripsy in Difficult Sphincterotomy or Distal CBD Tapering|Comparison of Endoscopic Papillary Balloon Dilatation and Sphincterotomy for CBD Stones With Difficult Sphincterotomy or Distal CBD Tapering||National Taiwan University Hospital||Active, not recruiting|March 2006|May 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A|No|||April 2006|May 24, 2006|May 24, 2006||||No||https://clinicaltrials.gov/show/NCT00329888||182187|
NCT00298077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0602053|A Retrospective Review of Infections Usually Observed in Transplant Recipients|A Retrospective Review of Infections Usually Observed in Transplant Recipients||University of Pittsburgh|Yes|Active, not recruiting|August 2006|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|500|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|N/A|N/A|No|Non-Probability Sample|transplant recipients with infections|December 2015|December 16, 2015|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00298077||184581|
NCT00326898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00534|Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery|ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma|ASSURE|National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2006|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1923|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|May 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00326898||182412|
NCT00326612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15275|Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures|Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy||University of Utah|No|Completed|June 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|358|||Both|N/A|17 Years|No|||September 2011|September 19, 2011|May 15, 2006|Yes|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00326612||182432|
NCT00314964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4291023|Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Evaluating PD-0299685 for Treatment of Vasomotor Symptoms Associated With Menopause||Pfizer||Completed|August 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|527|||Female|40 Years|70 Years|No|||March 2011|March 14, 2011|April 13, 2006||||||https://clinicaltrials.gov/show/NCT00314964||183312|
NCT00314977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKO 2005-01 / BOOG 2007-02|Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.|Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable and/or Locally Advanced Breast Cancer. The INTENS Study|INTENS|Radboud University|No|Completed|February 2006|||April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|70 Years|No|||March 2010|March 17, 2010|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00314977||183311|
NCT00315263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.3965|Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology|Genomics, SNPs, and Clinical Neonatology||Children's Mercy Hospital Kansas City|No|Completed|April 2006|July 2011|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|63|Samples With DNA|Whole Blood|Both|N/A|N/A|No|Non-Probability Sample|Intensive Care Nursery|August 2011|August 25, 2011|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315263||183289|
NCT00315276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/2027/AD/US|Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD|A 9-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With Attention Deficit/Hyperactivity Disorder||Teva Pharmaceutical Industries||Completed|May 2006|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||370|||Both|18 Years|65 Years|No|||November 2007|August 22, 2012|April 17, 2006||||||https://clinicaltrials.gov/show/NCT00315276||183288|
NCT00316017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28226-A - IND 12506|Hypertonic Resuscitation Following Traumatic Injury|Phase 3 Study of Hypertonic Resuscitation Following Traumatic Injury With Hypovolemic Shock||University of Washington|Yes|Terminated|May 2006|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|895|||Both|15 Years|N/A|No|||February 2011|February 25, 2011|April 17, 2006|Yes|Yes|Futility & potential safety concern (increased early mortality in the HS/HSD arms for those    with no PRBC in 1st 24 hr, post-randomization subgp)|No|September 2, 2010|https://clinicaltrials.gov/show/NCT00316017||183231|The trial was stopped early for futility in the presence of a potential safety concern regarding increased mortality among patients receiving hypertonic solutions and no blood transfusions. This was no longer evident 6 hr after hospital admission.
NCT00316264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP127|Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season|A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season||MedImmune LLC|Yes|Completed|April 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|260|||Both|N/A|24 Months|No|||November 2012|November 13, 2012|April 18, 2006|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00316264||183212|
NCT00316537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG002-121|Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers|A Multicenter, Randomized Study of the Safety and Preliminary Efficacy of Low-Dose Nicotine Gel (ATG002) in Patients With Plantar Diabetic Foot Ulcers||CoMentis||Terminated|October 2006|July 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||August 2007|August 7, 2007|April 17, 2006|||Sponsor Decision|No||https://clinicaltrials.gov/show/NCT00316537||183191|
NCT00337428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-024|Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)|An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With REPEVAX™ in Healthy Adolescents 11-17 Years of Age||Merck Sharp & Dohme Corp.||Completed|May 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|843|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|June 14, 2006|Yes|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00337428||181636|Safety results have been previously reported in the literature.
NCT00345267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/S1103/16|Effect of an Integrated Care Pathway on Asthma Care in Hospital|Cluster Randomised Controlled Trial of the Effect of the Introduction of an Acute Wheeze/Asthma Integrated Care Pathway on Patient Outcome||University of Edinburgh||Completed|August 2004|March 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|2 Years|16 Years|No|||June 2006|June 26, 2006|June 26, 2006||||No||https://clinicaltrials.gov/show/NCT00345267||181063|
NCT00340158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903214|Establishing an Inflammatory Breast Cancer Registry|The Establishment of an Inflammatory Breast Cancer Registry and Biospecimen Repository||National Institutes of Health Clinical Center (CC)||Completed|June 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|164|||Female|18 Years|N/A|No|||April 2009|April 22, 2010|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340158||181434|
NCT00336479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX05-950-104|Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C|A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment||Vertex Pharmaceuticals Incorporated|Yes|Completed|June 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|263|||Both|18 Years|65 Years|No|||June 2014|June 25, 2014|June 9, 2006|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00336479||181704|
NCT00346047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3802|Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain|A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Determine the Efficacy and Safety of BTDS Compared to Placebo in Subjects With Moderate to Severe Low Back Pain||Mundipharma Pte Ltd.||Completed|May 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|238|||Both|20 Years|N/A|No|||April 2008|April 11, 2008|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00346047||181005|
NCT00338273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-149|A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode||Otsuka Pharmaceutical Development & Commercialization, Inc.||Withdrawn|December 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years||||February 2012|November 7, 2013|June 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338273||181574|
NCT00346333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-126|Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A|Randomized Clinical Trial for Retinitis Pigmentosa||National Eye Institute (NEI)|Yes|Completed|July 2003|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|60 Years|No|||December 2013|December 12, 2013|June 27, 2006|Yes|Yes||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00346333||180985|
NCT00346060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050380|Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.|Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.||Radtke, Norman D., M.D.||Completed|February 2002|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|55 Years|N/A|No|||March 2014|March 12, 2014|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00346060||181004|
NCT00346346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906147|Analysis of the Immune Response to the Malaria Parasite in Mali, West Africa|Longitudinal Analysis of the B-Cell Immune Response to Plasmodium Falciparum in Mali||National Institutes of Health Clinical Center (CC)||Completed|April 2006|January 2013||||N/A|Observational|N/A|||Anticipated|237|||Both|2 Years|25 Years|No|||January 2013|August 20, 2013|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00346346||180984|
NCT00346619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1298-05|Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults|Investigating the Time of Nelfinavir Treatment Necessary for an Increase in Thymic Naive T Cells in Adults.||Mayo Clinic||Completed|October 2005|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 19, 2010|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346619||180963|
NCT00326872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00128|AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine|A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas||National Cancer Institute (NCI)||Active, not recruiting|May 2006|||October 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||December 2015|January 11, 2016|May 16, 2006|Yes|Yes||No|July 10, 2013|https://clinicaltrials.gov/show/NCT00326872||182414|
NCT00327379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11799|Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery||Bayer||Completed|February 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|May 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00327379||182376|
NCT00327392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-0523|A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.|A Phase 3 Open-Label, Single Arm Study to Assess the Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal-to-Moderate Sedation in Patients Undergoing Minor Surgical Procedures||Eisai Inc.||Completed|May 2006|December 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|123|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|May 16, 2006|Yes|Yes|||March 1, 2012|https://clinicaltrials.gov/show/NCT00327392||182375|
NCT00295347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT 209/3-1|Mineralocorticoid Receptor in the Treatment of Severe Depression|Mineralocorticoid Receptor in the Treatment of Severe Depression: A Randomized, Double Blind, and Placebo Controlled Trial||Universitätsklinikum Hamburg-Eppendorf||Completed|December 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|65|||Both|18 Years|70 Years|No|||June 2008|June 9, 2008|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00295347||184786|
NCT00326833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0198|How Many Patients Are in Need of Vitamin B12 Injections?|How Many Patients Are in Need of Vitamin B12 Injections?||University of Aarhus||Active, not recruiting|January 2006|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2008|August 7, 2008|May 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00326833||182416|
NCT00326859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD05-043|Comparison of Monitored Anesthesia Care Using Remifentanil or Fentanyl for Major Dressing Changes in Burns|||Montreal Burn Centre||Terminated|August 2005|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|85 Years|No|||October 2006|October 12, 2006|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00326859||182415|
NCT00327158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0296-F1V|A Prospective Study to Determine the Effectiveness of Reaming in Reducing Fat Emboli to the Lungs|Using Transesophageal Echocardiography To Assess Fat Emboli As A Result Of Reaming In A Prospective Randomized Control Trial To Determine The Effectiveness Of Reaming In Diminishing Fat Emboli To The Lungs||University of Kentucky|No|Completed|May 2006|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2010|January 27, 2010|May 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00327158||182393|
NCT00338780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUC30934|Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)|A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)||Chinese University of Hong Kong||Completed|November 2000|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||October 2006|October 27, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00338780||181535|
NCT00339924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905196|Physicians' Understanding of Human Genetic Variation|Physicians' Understanding of Human Genetic Variation||National Institutes of Health Clinical Center (CC)||Completed|July 2005|||||N/A|Observational|N/A|||Anticipated|2000|||Both|21 Years|N/A|No|||January 2016|February 12, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339924||181449|
NCT00336219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/M3-343|Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)|COMPETITION: Investigation of Clinical Endpoints for Treatment-induced Gastroesophageal Reflux Disease (GERD) Symptom Changes||Takeda||Completed|August 2006|April 2007|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|628|||Both|18 Years|N/A|No|||October 2008|May 4, 2012|June 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336219||181723|
NCT00338299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005098|Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia|An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of PROCRIT� (Epoetin Alfa) in the Treatment of Patients With Cancer and Chemotherapy Induced Anemia (60,000 Units Weekly for Four Weeks Followed by 60,000 Units Every Two Weeks)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2003|April 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|51|||Both|18 Years|N/A|No|||April 2010|May 19, 2011|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00338299||181572|
NCT00337688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512006|Power Wheelchair Joystick Use in Spastic Cerebral Palsy|Joystick Use for Virtual Electric Power Wheelchair Driving in Individuals With Spastic Cerebral Palsy||University of Pittsburgh|No|Completed|July 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|12 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with CP and controls|September 2011|September 13, 2011|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337688||181616|
NCT00348959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY04MCC|An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation|An Evaluation of the Effect of 'Open Window', an Art Intervention, on Psychological Well-being and Experience of Stem Cell Transplantation for the Treatment of Haematological Malignancies||St. James's Hospital, Ireland|No|Completed|August 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|198|||Both|16 Years|N/A|No|||June 2012|June 12, 2012|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00348959||180784|
NCT00345540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV002- IS21 -OC|Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer|Phase 2 Trial of NOV-002 With Carboplatin in Women With Recurrent and Platinum Resistant Tumors of Mullerian Origin||Cellectar Biosciences, Inc.|No|Completed|July 2006|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||January 2009|February 25, 2015|June 26, 2006|No|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00345540||181043|The criterion for continuing to Stage II of the study (≥ 2 responses) was not met.
NCT00345761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JO19380|Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer|Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer||Chugai Pharmaceutical|No|Completed|February 2006|July 2010|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|20 Years|74 Years|No|||August 2010|August 13, 2010|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345761||181026|
NCT00346034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081101|This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia|A 12 Week, Open-Label, Safety Trial Of Pregabalin In Patients With Fibromyalgia||Pfizer|No|Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|357|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|June 28, 2006|Yes|Yes||No|February 12, 2009|https://clinicaltrials.gov/show/NCT00346034||181006|
NCT00345280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8789|Ocular Surface Changes in Patients With Cystic Fibrosis|Chosen Parameters of the Immune Response in the Origin of Ocular Changes in Patients With Cystic Fibrosis||University of Bialystok|No|Recruiting|August 2006|September 2008|Anticipated|||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|26|||Both|3 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|26 male and female patients aged 3-25 with clinically definite diagnosis of cystic        fibrosis|June 2008|June 16, 2008|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345280||181062|
NCT00345293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA-0537|Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer|A Phase I/II Study of Autologous Dendrtitic Cells Pulsed With Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate Cancer Patients.||Rockefeller University|Yes|Active, not recruiting|June 2006|June 2015|Anticipated|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||September 2013|March 17, 2015|June 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00345293||181061|
NCT00345774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX-CP-017|Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Short-Term Efficacy and Safety of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease||Epix Pharmaceuticals, Inc.|No|Completed|June 2006|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Both|25 Years|79 Years|No|||May 2008|May 27, 2008|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345774||181025|
NCT00346073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106316|Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years|A Study to Evaluate Immunogenicity and Safety of Boostrix Compared to Adacel When Administered as a Booster Vaccination in Adults Aged 19 to 64 Years of Age||GlaxoSmithKline||Completed|July 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Actual|2337|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||September 2012|October 4, 2012|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346073||181003|
NCT00346359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2041.00|Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer|Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies||Fred Hutchinson Cancer Research Center||Completed|March 2006|November 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|65 Years|No|||May 2010|May 12, 2010|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346359||180983|
NCT00346632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2449-US-001|An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia|Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)||Kyowa Hakko Kirin Pharma, Inc.|Yes|Terminated|June 2006|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|June 28, 2006|Yes|Yes|Terminated due to suboptimal dosing schedule|No||https://clinicaltrials.gov/show/NCT00346632||180962|
NCT00346931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-PTO-2004-AKH|Phacotrabeculotomy Versus CCI+Phaco in Patients With Borderline Control of Intraocular Pressure|Phacotrabeculotomy vs. CCI+Phaco in Patients With Borderline Control of Intraocular Pressure||Medical University of Vienna||Terminated|December 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|50 Years|80 Years|No|||June 2006|July 22, 2010|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00346931||180939|
NCT00326924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004706-01H|Age of Red Blood Cells in Premature Infants Study (ARIPI)|Age of Red Blood Cells in Premature Infants Study (ARIPI)||Ottawa Hospital Research Institute|Yes|Completed|May 2006|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|377|||Both|N/A|37 Weeks|No|||November 2014|November 2, 2014|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326924||182410|
NCT00326950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-J081-105|Phase I Clinical Study of E7389|Phase I Clinical Study of E7389 in Patients With Solid Tumors||Eisai Inc.||Completed|June 2006|February 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|74 Years|No|||March 2012|March 6, 2012|May 16, 2006||No||No|November 16, 2011|https://clinicaltrials.gov/show/NCT00326950||182409|
NCT00327197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES100769|Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma|A Study to Assess Disease Pathology and Key Therapeutic Targets in Severe Asthma||GlaxoSmithKline||Terminated|August 2005|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|65 Years|No|||December 2012|December 19, 2012|May 17, 2006||No|The study was truncated due to the long period of enrollment and the collection of a    sufficient amount of data that allowed the scientific objectives to be met|No||https://clinicaltrials.gov/show/NCT00327197||182390|
NCT00327626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 113715-CS12|Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 Administered Daily in Patients With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea||Ionis Pharmaceuticals, Inc.||Withdrawn|May 2006|March 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|18 Years|70 Years|No|||May 2007|May 18, 2007|May 16, 2006|||study was never started due to regional geopolitical conflict|No||https://clinicaltrials.gov/show/NCT00327626||182357|
NCT00327899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-129|Home Inotropic Therapy in Children|Home Inotropic Therapy in Children||Children's Healthcare of Atlanta|No|Terminated|March 2006|May 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|13|||Both|N/A|18 Years|No|Non-Probability Sample|Choa patients' medical charts between 2.2.04 and 12.31.05 with Coram Healthcare only.        These patients would have received inotropic support at home.|November 2007|November 18, 2011|May 18, 2006|||Per PI instruction.|No||https://clinicaltrials.gov/show/NCT00327899||182336|
NCT00339664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903242|Analyses of Human Samples Collected in Clinical Trials|Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute||National Institutes of Health Clinical Center (CC)||Recruiting|June 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|5000|||Both|N/A|N/A|No|||June 2015|June 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339664||181467|
NCT00339677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904043|Recontacting Participants in the Observing Protein and Energy Nutrition (OPEN) Study: Re-OPEN|Recontacting Participants in the Observing Protein and Energy Nutrition Study: ReOPEN||National Institutes of Health Clinical Center (CC)||Completed|November 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|484|||Both|19 Years|69 Years|No|||February 2016|March 10, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339677||181466|
NCT00336232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK069341|Determinants of Vitamin K Metabolism|Dietary and Non-dietary Components of Vitamin K Metabolism||Tufts University|No|Completed|May 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 17, 2013|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336232||181722|
NCT00336505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL05-001|Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)|A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults||Advanced Life Sciences, Inc.|No|Completed|December 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|584|||Both|18 Years|N/A|No|||January 2010|January 29, 2010|June 9, 2006|Yes|Yes||No|September 3, 2009|https://clinicaltrials.gov/show/NCT00336505||181702|
NCT00336791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0321|Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer|Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression Profile-Based Test to Select Patients for Preoperative Taxane/Anthracycline Chemotherapy for Stage I-III Breast Cancer||M.D. Anderson Cancer Center|No|Completed|September 2003|September 2010|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|N/A|N/A|No|||February 2012|February 13, 2012|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336791||181680|
NCT00337103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-301|E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes|A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes||Eisai Inc.||Active, not recruiting|June 2006|||March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1102|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|June 13, 2006|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT00337103||181659|
NCT00338234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAIRe|Observational Study of Iron Metabolism in Anemia in ICU and Post-Operative Patients|Observational Study of Iron Metabolism in Anemia in ICU and Post-Operative Patients, Role of Hepcidin|FAIRe|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|153|Samples Without DNA|Blood serum|Both|20 Years|88 Years|No|Non-Probability Sample|-  For the surgery :population 20 yers to 88 years old          -  For the reanimation : population to the 41 years to 85 years old|April 2007|May 5, 2008|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338234||181577|
NCT00338247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF103659|EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer|An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer||GlaxoSmithKline|No|Active, not recruiting|July 2006|February 2016|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4732|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|June 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338247||181576|
NCT00339079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH071688|Comparing Cognitive Behavioral Therapy, Antidepressant Medication, and Combined Treatment in Individuals With Hypochondriasis|Treatment of Hypochondriasis With CBT and/or SSRI||Brigham and Women's Hospital|Yes|Completed|June 2006|December 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|94|||Both|21 Years|N/A|No|||August 2012|August 14, 2012|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00339079||181512|
NCT00345020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032005-027|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique||University of Texas Southwestern Medical Center|No|Completed|May 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|N/A|||Actual|0|||Both|21 Years|95 Years|Accepts Healthy Volunteers|||May 2007|June 19, 2008|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00345020||181082|
NCT00349245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0173|Dexmedetomidine vs. Remifentanil for Sedation During AFI|A Randomized, Double-Blind Comparison Of Dexmedetomidine And Remifentanil For Sedation During Awake Fiberoptic Intubations||The University of Texas Health Science Center, Houston||Completed|June 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|July 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00349245||180763|
NCT00345007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R414/09/2005|Macular Function After Scleral Buckle|Assessment of Recovery of Macula Function After Successful Scleral Buckling Surgery for Rhegmatogenous Retinal Detachment||Singapore National Eye Centre||Completed|June 2005|October 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||27|||Both|18 Years|N/A|No|||May 2005|June 26, 2006|June 26, 2006||||No||https://clinicaltrials.gov/show/NCT00345007||181083|
NCT00345787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3801|Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain|A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Determine the Efficacy and Safety of BTDS Compared to Placebo in Subjects With Moderate to Severe Osteoarthritic Pain of the Hip or Knee||Mundipharma Pte Ltd.||Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|262|||Both|40 Years|N/A|No|||April 2008|April 11, 2008|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345787||181024|
NCT00345800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00301|Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes|Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy.||UCB Pharma|No|Completed|April 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|No|||June 2015|June 18, 2015|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00345800||181023|
NCT00346372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB#03-11-052|Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy|||University of California, Los Angeles||Recruiting|March 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who meet the following Eligibility Criteria|February 2009|June 17, 2010|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00346372||180982|
NCT00346645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VELCADE|A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer|A Phase II Study of Velcade® (Bortezomib) in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|June 2006|December 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||January 2012|February 5, 2013|June 29, 2006|||stopped after planned interim analysis for lack of efficacy|No||https://clinicaltrials.gov/show/NCT00346645||180961|
NCT00346957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-98-03|A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration|||Alcon Research||Completed|April 1999|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|128|||Both|50 Years|N/A|No|||March 2012|March 3, 2012|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346957||180937|
NCT00346970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005694-30|The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)|Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.||Hannover Medical School||Completed|July 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||May 2008|May 5, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00346970||180936|
NCT00298701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-11|Tolerability of Grazax-R in Children|A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of GRAZAX-R in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)||ALK-Abelló A/S||Completed|February 2006|April 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||50|||Both|5 Years|12 Years|No|||May 2006|May 3, 2006|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298701||184533|
NCT00298714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAHEPC|Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C|Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.||Hospital Clinic of Barcelona||Completed|March 2003|January 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|35 Years|65 Years|No|||November 2007|November 21, 2007|March 2, 2006||||No||https://clinicaltrials.gov/show/NCT00298714||184532|
NCT00327171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD6122|Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer|A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer||Sanofi|No|Completed|May 2006|March 2010|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|218|||Female|18 Years|N/A|No|||September 2011|September 17, 2012|May 16, 2006|Yes|Yes||No|August 17, 2012|https://clinicaltrials.gov/show/NCT00327171||182392|
NCT00327184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106388|Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine|Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC Given With Infanrix™ Penta Versus NeisVac-C™ Given With Infanrix™ Hexa at 3,5m of Age & Persistence Prior to a Hib-MenC Booster at 11m & Immunogenicity of the Booster||GlaxoSmithKline||Completed|April 2006|June 2007|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|709|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2011|June 7, 2012|May 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00327184||182391|
NCT00327405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCJSC001|Results of Ocular Compression and Suture Release in Trabeculectomy and Combined Surgery|A Retrospective Study of Surgical Outcomes.||University of Cincinnati||Completed||||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2006|May 17, 2006|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00327405||182374|
NCT00327418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0981-430-102|CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events|A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)|CARDS|Pfizer||Completed|January 1997|February 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2800|||Both|40 Years|75 Years|No|||May 2007|May 8, 2007|May 16, 2006||||||https://clinicaltrials.gov/show/NCT00327418||182373|
NCT00327639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000|Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto|Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto||University Health Network, Toronto||Recruiting|July 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||50|||Both|18 Years|N/A||||July 2005|May 17, 2006|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00327639||182356|
NCT00335920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL DEX-ISSNHL|Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss|A Prospective, Randomized, Double Blind, Placebo Controlled, Multicenter Study on the Safety and Efficacy of Continuous Infusion of Corticosteroid Delivered Via Catheter in Patients With Idiopathic Sudden Sensorineural Hearing Loss||University Hospital Tuebingen||Completed|October 2003|July 2007|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|No|||February 2008|February 4, 2008|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00335920||181745|
NCT00336518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBA 1/2005|Continuing Treatment With Pegasys and Copegus|Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24||Májbetegekért Alapítvány||Recruiting|June 2006|July 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||August 2005|June 12, 2006|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336518||181701|
NCT00337896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0005|T and B Cell Response to Avian Flu Vaccine|T and B Cell Immune Responses to Influenza A/H5N1 Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|blood|Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults male and female ages 18-64 years, participating in another clinical trial        (DMID Protocol 04-062)|April 2011|August 15, 2013|June 15, 2006||||No||https://clinicaltrials.gov/show/NCT00337896||181602|
NCT00339092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064388|Modified Directly Observed Therapy for Improving Antiretroviral Therapy Adherence in People With HIV|Project Title: A RCT of HIV Adherence Case Management and Modified Directly Observed Therapy||Massachusetts General Hospital|No|Completed|January 2003|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00339092||181511|
NCT00339391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901244|Socioenvironmental Determinants of Psychological Functioning, Mental Health and AIDS in Mali|Socio-Environmental Determinants of Psychological Functioning, Mental Health and AIDS in Mali||National Institutes of Health Clinical Center (CC)||Completed|August 2001|||||N/A|Observational|N/A|||Anticipated|1002|||Both|16 Years|50 Years|No|||November 2015|December 2, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339391||181488|
NCT00348686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00012|Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)|A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy||AstraZeneca||Completed|June 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|315|||Both|18 Years|75 Years|No|||March 2012|March 5, 2012|July 3, 2006|Yes|Yes||No|June 8, 2009|https://clinicaltrials.gov/show/NCT00348686||180805|
NCT00345033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072635|Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia|Aripiprazole for Clozapine Associated Medical Morbidity||Massachusetts General Hospital|Yes|Completed|March 2005|October 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||June 2014|June 10, 2014|June 23, 2006||No||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00345033||181081|The limitations of this study include the relatively small sample size, short intervention period (8 weeks) and the lack of generalizability of our findings to patients with schizophrenia treated by antipsychotic agents other than clozapine.
NCT00345306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EndoUtro-HMO-CTIL|Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan|Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan - a Clinical Comparative Study||Hadassah Medical Organization|No|Suspended|March 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Female|18 Years|35 Years||||June 2006|May 6, 2008|June 27, 2006|||no patient was recruited till 1/2008|No||https://clinicaltrials.gov/show/NCT00345306||181060|
NCT00345319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M49P7|Purified Rabies Vaccine for Human Use (Chick-embryo Cell)|Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years.||Novartis||Completed|March 2006|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|630|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 12, 2011|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345319||181059|
NCT00345592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005_TH|TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients|TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients|TRADE HF|Guidant Corporation|Yes|Completed|October 2006|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|June 27, 2006|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT00345592||181039|
NCT00345553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASIC|Biliary Atresia Study in Infants and Children|Biliary Atresia Study in Infants and Children (BASIC)|BASIC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|May 2006|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1265|Samples With DNA|Samples of blood and urine will be collected for research purposes.|Both|6 Months|N/A|No|Non-Probability Sample|The parents or guardians of all eligible subjects at each BARC center, or the subjects        themselves if 18 years of age or older, will receive a letter of introduction, followed by        a telephone call and, if willing, arrangement of an appointment at which time informed        consent will be obtained. New patients who are at least one year of age and not        participating in the BARC PROBE study will also be approached.|August 2015|August 27, 2015|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345553||181042|
NCT00345566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUSKBK28200706|Effect of Protein Composition on Gastric Emptying|Effect of the Protein Composition on the Gastric Emptying Rate in Children With Cerebral Paresis||Ullevaal University Hospital||Not yet recruiting|August 2006|December 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|1 Year|16 Years|No|||June 2006|June 27, 2006|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345566||181041|
NCT00346086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAC01-03-27-01|DNA Vaccine for Ragweed Allergic Adults|A Phase II Observer-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, Tolerability, and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults (Sponsor's Protocol NRH01)||Johns Hopkins University||Completed|May 2001|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|60 Years||||June 2006|June 27, 2006|June 27, 2006||||||https://clinicaltrials.gov/show/NCT00346086||181002|
NCT00346658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR16047|Magnesium Supplementation to Prevent Bone Loss|Magnesium Supplementation to Prevent Bone Loss||University of Tennessee||Completed|July 2002|September 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||74|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||December 2008|December 12, 2008|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346658||180960|
NCT00346983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001385|Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics|Pilot Study of the Effect of Pegaptanib Sodium to Prevent Worsening of Cystoid Macular Edema Following Cataract Surgery in Diabetics||Johns Hopkins University|No|Terminated|June 2006|May 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||May 2008|May 8, 2008|June 29, 2006|Yes|Yes|Difficulty enrolling eligible subjects|No||https://clinicaltrials.gov/show/NCT00346983||180935|
NCT00347204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5225|Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK|Double Masked Evaluation of Acular LS Versus Nevanac for Postoperative Pain Control in Eyes Undergoing PRK||Center For Excellence In Eye Care||Completed|January 2006|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2006|June 29, 2006|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347204||180918|
NCT00299013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL2502/020/CL|Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis|A Multicentre, Randomised, Double Blind, Double Dummy, Active Comparator Controlled, Parallel Group Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis||Alizyme|No|Completed|March 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|796|||Both|18 Years|75 Years|No|||April 2008|April 24, 2008|March 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00299013||184510|
NCT00295165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310187|Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease|Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease||Sanofi||Terminated|January 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|February 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295165||184799|
NCT00327210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVAIRB# 11593|Feasibility and Efficacy of Delivering Blood Glucose Awareness Training Over the Internet|Blood Glucose Awareness Training Delivered Over the Internet (BGATHome.Com): Feasibility and Efficacy||University of Virginia||Active, not recruiting|May 2005|July 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||100|||Both|21 Years|N/A|No|||August 2008|August 6, 2008|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00327210||182389|
NCT00327431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009109|Relationship of Genes and Life Events to Blood Pressure|||Sunnybrook Health Sciences Centre||Completed|November 2006|December 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2008|May 21, 2008|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00327431||182372|
NCT00327652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC05001|Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases|Phase 1 Dose-Escalation Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases||Anza Therapeutics, Inc.|Yes|Completed|October 2006|||February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||April 2008|April 22, 2008|May 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00327652||182355|
NCT00327925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD-OC-CAAb|Blood Test for Ovarian Cancer Associated Antibodies (CAAb)|Study to Assess the Effectiveness of the CAAb Test With Ovarian Cancer Patients||Lab Discoveries Ltd.||Recruiting|July 2006|June 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|March 1, 2007|May 18, 2006||||No||https://clinicaltrials.gov/show/NCT00327925||182334|
NCT00348400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5099|Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost|Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||May 2007|May 30, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348400||180827|
NCT00348413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R272/16/2002|Thyroid Treatment Trial|Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.||Singapore National Eye Centre||Completed|June 2003|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|21 Years|60 Years|No|||May 2010|May 11, 2010|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348413||180826|
NCT00348387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV13|Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV|||Sanofi|No|Completed|June 2006|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|600|||Both|60 Days|70 Days|Accepts Healthy Volunteers|||January 2014|January 20, 2014|July 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00348387||180828|
NCT00348673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271010|A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061|A Randomised, Double Blind, Placebo-controlled, Multicenter Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061||Pfizer|No|Completed|February 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Male|18 Years|55 Years|No|||August 2013|August 14, 2013|July 5, 2006|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00348673||180806|
NCT00349258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-277|The Use of GnRH Agonist Trigger in the Prevention of OHSS|A Prospective Randomized Study Comparing the Use of hCG or GnRH Agonist to Trigger Final Oocyte Maturation in High Responders Undergoing in-Vitro Fertilization Treatment||University of Connecticut Health Center||Completed|August 2004|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||66|||Female|20 Years|39 Years|Accepts Healthy Volunteers|||February 2006|July 5, 2006|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349258||180762|
NCT00345046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201-28|A Comparison of Three Different Formulations of Prednisolone Acetate 1%|A Comparison of Three Different Formulations of Topical Prednisolone Acetate 1% for Control of Post Glaucoma and/or Cataract Surgery Inflammation.||Indiana University|No|Completed|September 2002|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||March 2014|June 2, 2015|June 26, 2006||No||No|December 24, 2013|https://clinicaltrials.gov/show/NCT00345046||181080|
NCT00345332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12299|A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of Botox for Severe Refractory Urge Urinary Incontinence||University of Rochester|Yes|Completed|October 2005|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|21 Years|90 Years|Accepts Healthy Volunteers|||September 2010|August 2, 2011|June 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345332||181058|
NCT00345579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105987|Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age|A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.||GlaxoSmithKline||Completed|September 2006|March 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|4432|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||February 2013|February 7, 2013|June 26, 2006|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00345579||181040|Solicited symptoms and unslocited AEs were not collected during this study. Only information about specific categories of AEs (SAEs, NOCIs, rash and AEs resulting in ER visits) were collected in this study.
NCT00345605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5102|Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder|A Randomized, Double-Blind, Crossover Study of Sodium Phenylbutyrate and Low-Dose Arginine Compared to High-Dose Arginine Alone on Liver Function, Ureagenesis and Subsequent Nitric Oxide Production in Patients With Argininosuccinic Aciduria||Baylor College of Medicine|Yes|Completed|February 2008|November 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|5 Years|N/A|No|||October 2015|October 6, 2015|June 26, 2006||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT00345605||181038|
NCT00345813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466317|Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer|Randomized Phase IIb Preprostatectomy Study of Dietary Supplementation With Soy and Biomarkers of Prostate Cancer Risk and Progression||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|October 2003|November 2016|Anticipated|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Male|18 Years|120 Years|No|||September 2015|September 30, 2015|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00345813||181022|
NCT00346385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491231|BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901||ImmunoGen, Inc.||Completed|March 2002|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346385||180981|
NCT00346671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001884-01|Effects of Reiki on Stress|Effects of Reiki on Physiological Consequences of Acute Stress||The Cleveland Clinic|Yes|Completed|January 2006|June 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|257|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00346671||180959|
NCT00346684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPL|Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)|Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.||University of Cologne||Completed|July 2006|||November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||August 2008|August 11, 2008|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346684||180958|
NCT00294879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBCH 0601|Effects of Inspiration Rise Time on Work of Breathing and Comfort of Conscious Patients on Mechanical Ventilation|||Radboud University||Completed|February 2006|March 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind|||Anticipated|10|||Both|18 Years|N/A|No|||May 2008|May 30, 2008|February 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00294879||184821|
NCT00295152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDO project|Effects of Community Occupational Therapy in Older Patients With Dementia and Their Caregivers.|Effects of Community Occupational Therapy on the Daily Performance of Older Patients With Mild to Moderate Dementia and on the Sense of Competence of Their Primary Caregivers.||Radboud University||Active, not recruiting|April 2001|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||135|||Both|65 Years|N/A|No|||February 2006|November 16, 2011|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295152||184800|
NCT00295425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TALSB002|CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.|Open, Multicenter, Randomized Clinical Trial in Patients With Moderate-Severe Psoriasis (PASI > 10) to Compare the Efficacy of Mycophenolate Mofetil Versus Cyclosporine A.||University Hospital Muenster||Active, not recruiting|May 2000|October 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|No|||October 2006|October 4, 2006|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00295425||184780|
NCT00299000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB-008|A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI|A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI)||BioMarin Pharmaceutical|No|Completed|May 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4|||Both|N/A|1 Year|No|||July 2011|July 19, 2011|March 2, 2006|Yes|Yes||No|May 7, 2010|https://clinicaltrials.gov/show/NCT00299000||184511|Given the small number of patients (4) represented in this study, the outcomes observed in this study may not reflect or predict outcomes observed by physicians in clinical practice.
NCT00294866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005002|Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients|An Open Label, Multi-Center Study of the Effect of Paricalcitol on Markers of Inflammation in Patients With Stage 5 Chronic Kidney Disease on Hemodialysis.||Fresenius Medical Care North America|No|Completed|March 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|N/A|No|||April 2010|April 7, 2010|February 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00294866||184822|
NCT00295126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 01 12|REPI : a Randomized Open Label Trial Evaluating the Use of APC in Pre-Implantation Reconstruction of Maxilla|Use of Autologous Platelet Concentrate in Pre-Implantation Reconstruction of Maxilla.||University Hospital, Grenoble|No|Terminated|May 2003|November 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1|||20|||Both|18 Years|N/A|No|||March 2008|March 11, 2008|February 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00295126||184802|
NCT00295672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 05-110|Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.|Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy With Cisplatin-docetaxel in Patients With Locally Advanced Non-small-cell Lung Cancer. A Multicenter Phase II Trial|VINCR|University Hospital, Brest|No|Completed|February 2006|June 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|70 Years|No|||July 2009|July 24, 2009|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00295672||184762|
NCT00348088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05122|Melanoma Biomarker Study|CXCL1 Biomarker Study in Metastatic Melanoma||Sidney Kimmel Comprehensive Cancer Center||Completed|May 2006|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Malignant Melanoma|December 2012|December 12, 2012|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00348088||180851|
NCT00348049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R277/21/2002|Efficacy of LASIK Versus PRK in Asians With Mild and Moderate Myopia|A Prospective, Randomized Trial Evaluating the Operational Efficacy of LASIK vs. PRK for the Correction of Low and Moderate Myopia in the Singapore Armed Forces||Singapore National Eye Centre||Completed|November 2002|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|21 Years|40 Years|No|||October 2002|October 23, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348049||180854|
NCT00348062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5177|A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension|A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||May 2007|May 30, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348062||180853|
NCT00348374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171093|Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes|A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Trial Assessing The Efficacy Of Exubera Vs. Lispro Introduced Into A Lantus Based Regimen In Suboptimally Controlled Patients With Type 2 Diabetes Mellitus||Pfizer|No|Completed|June 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|80 Years|No|||July 2009|March 2, 2010|June 30, 2006|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00348374||180829|Due to cancellation of the EXUBERA program the sample size was too small to adequately address the inferential objectives of this study. Descriptive statistics for the PSIT Questionnaire and the markers of cardiovascular risk were not provided.
NCT00348985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01052|PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas|A Phase 1 Study of PXD101 in Combination With Bortezomib (PS-341) in Patients With Advanced Solid Tumors and Lymphoma||National Cancer Institute (NCI)||Completed|March 2006|||January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|16 Years|N/A|No|||May 2013|May 1, 2013|July 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00348985||180782|
NCT00349271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRTCC-CHG|Cell Therapy in Chagas Cardiomyopathy|Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Chagas Cardiomyopathy||Ministry of Health, Brazil||Terminated|January 2006|December 2009|Actual|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|65 Years|No|||January 2010|January 24, 2010|July 5, 2006||No|Change the sample size due to smaller variance than expected|No||https://clinicaltrials.gov/show/NCT00349271||180761|
NCT00345059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISTAL-2|The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer|Single Agent Chemotherapy With Weekly Docetaxel vs Combination Chemotherapy in Second-line Treatment of Advanced Non Small Cell Lung Cancer|DISTAL-2|National Cancer Institute, Naples|No|Terminated|May 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|84|||Both|N/A|75 Years|No|||January 2016|January 13, 2016|June 26, 2006||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00345059||181079|
NCT00345345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060190|Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia|Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath)||National Institutes of Health Clinical Center (CC)||Recruiting|June 2006|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|85 Years|No|||November 2015|November 20, 2015|June 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345345||181057|
NCT00345618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6034|Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach|An International, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Study of 3-month or 6-month Treatment With SSR126517E (3.0 mg s.c. Once-weekly) Versus Oral INR-adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis|CASSIOPEA|Sanofi|Yes|Completed|June 2006|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3202|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345618||181037|
NCT00345826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000480396|Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia|Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Subjects Who Experienced Clinical Benefit on Protocol CA 180-002||Jonsson Comprehensive Cancer Center|Yes|Completed|November 2005|||July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|June 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00345826||181021|
NCT00346112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-KARE-01|Rehabilitation, Quality of Life, and Exercise Tolerance in Patients With an ICD|Rehabilitation, Quality of Life, and Exercise Tolerance in Internal Cardioverter-Defibrillator-patients, RELAX-ICD Trial||University Hospital Inselspital, Berne||Terminated|June 2006|December 2009||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||November 2010|November 5, 2010|June 28, 2006|||insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00346112||181000|
NCT00346099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FR-1|Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum|A Phase II Study to Determine the Efficacy and Safety of Panitumumab in Combination With Chemoradiotherapy for Unresectable or Locally Recurrent Adenocarcinoma of the Rectum With or Without Metastatic Disease||NSABP Foundation Inc|No|Withdrawn|June 2006|May 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2007|December 21, 2007|June 27, 2006|Yes|Yes|Protocol closed based on new (and as yet unpublished) information from a phase II clinical    trial.|No||https://clinicaltrials.gov/show/NCT00346099||181001|
NCT00346398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN025AD|Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study|A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease (ITN025AD)|GPAC|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2006|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|51|||Both|12 Months|30 Months|No|||April 2015|April 30, 2015|June 27, 2006|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT00346398||180980|One participant in the placebo group could not be included in intent-to-treat analyses because a sibling was also in the study
NCT00346710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001397|Patient Experiences in Rheumatology|Communication Skills in Rheumatology Fellows||Johns Hopkins University||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||60|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2005|June 28, 2006|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346710||180956|
NCT00347009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF104070|Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis|An Open Label Study of Adefovir Dipivoxil for the Treatment of Patients With Chronic Hepatitis B Related Advanced Fibrosis or Cirrhosis.||GlaxoSmithKline||Completed|May 2005|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|N/A|No|||March 2011|May 31, 2012|June 30, 2006||||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00347009||180933|
NCT00295178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-4CELL-05-02|Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas|A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas||Cubist Pharmaceuticals LLC||Completed|March 2006|August 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||December 2006|December 14, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295178||184798|
NCT00295191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGE99803466003|Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in HD Patients(EGESTUDY)|Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Prospective, Randomized, Controlled Study||Ege University|Yes|Completed|November 2005|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|704|||Both|18 Years|80 Years|No|||October 2011|October 3, 2011|February 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00295191||184797|
NCT00295438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 05 52|Robot-Based Tele-Echography II - A Comparative Study|Robot-Based Tele-Echography II - A Comparative Study Using Two Echographic Modalities for Diagnosis of Thoracoabdominal Injuries at the Trauma Center of the Grenoble University Hospital.||University Hospital, Grenoble|Yes|Terminated|February 2006|March 2009|Actual|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|February 21, 2006||No|No diagnosis of visceral lesion was placed on 18 included patients. The study is thus stopped    prematurely for ethical reasons.|No||https://clinicaltrials.gov/show/NCT00295438||184779|
NCT00295139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041195|Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients|Behavioral Treatment of Drug Abuse in SPMI Patients||University of Maryland|No|Active, not recruiting|January 2005|March 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|307|||Both|18 Years|55 Years|No|||December 2009|December 17, 2009|February 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00295139||184801|
NCT00295412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077-99904|The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients|The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients||Université de Montréal||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|55 Years||||September 2005|February 21, 2006|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00295412||184781|
NCT00295659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA 200665|An RCT to Evaluate Incidence, Cost and Clinical Outcomes Using 75 vs 100g. Screening Methods for Gestational Diabetes|What is the Optimal Method for Screening and Diagnosis of Gestational Diabetes? An RCT to Evaluate Incidence, Cost-Effectiveness and Clinical Outcomes Using Three Methods||Canadian Diabetes Association||Completed|January 2001|September 2004||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||5800|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2005|October 17, 2006|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00295659||184763|
NCT00348075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R330/23/2003|A Singapore Study to Assess How Neurovision Improve the Vision of Adults With Low to Moderate Myopia|A Singapore Study To Evaluate The Efficacy OF Neurovision'S NVC™- Vision Correction Technology For The Visual Improvement In Subjects With Low Or Moderate Adult Myopia||Singapore National Eye Centre||Completed|January 2004|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||||||Both|17 Years|55 Years|No|||May 2010|May 11, 2010|July 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00348075||180852|
NCT00348738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OEGRO54|Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome|The Influence of the Pre-Therapeutic Increase in the Hemoglobin Level in the Blood Through Erythropoietin to the Therapy Results of the Primary Radiation Therapy for Carcinoma of the Cervix||Medical University of Vienna|No|Active, not recruiting|July 2000|July 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|19 Years|80 Years|No|||October 2007|October 31, 2007|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00348738||180801|
NCT00348699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00164|AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery|A Phase I Study and Pharmacological Trial of Once Weekly Aminoflavone Prodrug (AFP464) Administered 3 Out of Every 4 Weeks in Solid Tumor Patients||National Cancer Institute (NCI)||Completed|July 2006|||January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||December 2011|February 21, 2014|July 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00348699||180804|
NCT00348972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901/1021|Lantus in Prediabetes|Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)||Sanofi||Completed|February 2002|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2006|July 4, 2006|July 4, 2006||||||https://clinicaltrials.gov/show/NCT00348972||180783|
NCT00348712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1390|Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes|Efficacy and Safety of Inhaled Pre-prandial Human Insulin Plus Metformin Versus Rosiglitazone Plus Metformin in Type 2 Diabetes||Novo Nordisk A/S|No|Terminated|October 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|July 5, 2006|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00348712||180803|
NCT00348725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF23-0121 04 02|Acceptability of a Fixed Combination of Fenofibrate and Metformin|An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia||Solvay Pharmaceuticals||Completed|April 2005|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||69|||Both|20 Years|80 Years|No|||August 2007|August 31, 2007|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00348725||180802|
NCT00349284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF 178P 04 01|A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome|A Randomised, Double-Blind Study Comparing the Efficacy and Safety of 145 mg Fenofibrate, 10 mg Ezetimibe and Their Combination in Patients With Type IIb Dyslipidemia and Features of the Metabolic Syndrome||Solvay Pharmaceuticals||Completed|January 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||181|||Both|18 Years|70 Years|No|||August 2007|August 31, 2007|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349284||180760|
NCT00349297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R325/18/2003|The Microbiological Spectrum in Acute Dacryocystitis|||Singapore National Eye Centre||Completed|November 2003|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Acute dacryocystitis patients|May 2010|May 11, 2010|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349297||180759|
NCT00345072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS013329-02|A Menopause Interactive Decision Aid System|A Menopause Interactive Decision Aid System||Rhode Island Hospital||Active, not recruiting|July 2003|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||296|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||June 2006|June 26, 2006|June 26, 2006||||No||https://clinicaltrials.gov/show/NCT00345072||181078|
NCT00345358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107058|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine|Evaluate Immunogenicity, Safety & Reactogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-dose Primary Immunization in Children Before 6 mo of Age||GlaxoSmithKline||Completed|September 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|600|||Both|9 Weeks|60 Months|Accepts Healthy Volunteers|||August 2012|September 6, 2012|June 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345358||181056|
NCT00345371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CSP-1025-1|Topiramate for the Treatment of Methamphetamine Dependence - 1|Phase 2, Double-Blind, Placebo-Controlled Trial of Topiramate for the Treatment of Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)||Completed|April 2006|December 2007|Actual|August 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||December 2007|December 21, 2007|June 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00345371||181055|
NCT00345644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_3507|Risedronate in Osteopenic Postmenopausal Women|A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 24 Month, Monocenter Study Comparing Weekly Oral Risedronate 35 mg and Placebo|OSMAUSE|Sanofi|No|Completed|March 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|156|||Female|55 Years|75 Years|No|||December 2009|December 4, 2009|March 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00345644||181035|
NCT00345839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050182|E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events|EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events|EVOLVE|Amgen|Yes|Completed|August 2006|May 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3883|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 27, 2006||||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00345839||181020|
NCT00346723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201.3.125|Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.|Immunogenicity and Reactogenicity of Trivalent Influenza Subunit Vaccine Influvac® for the Season 2006/2007. An Open, Baseline-Controlled Study in Two Groups of Healthy Subjects: Adults and Elderly.||Solvay Pharmaceuticals||Completed|July 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 29, 2009|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346723||180955|
NCT00346411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001359|Health Outcomes in Rheumatoid Arthritis|Health Outcomes in Rheumatoid Arthritis||Johns Hopkins University||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||260|||Both|19 Years|N/A|No|||May 2006|June 28, 2006|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346411||180979|
NCT00346697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT002862-01|Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients|A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy||Brown, Todd, M.D., Ph.D.|No|Completed|October 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|June 29, 2006|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00346697||180957|
NCT00347243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP012/06|Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical Intraocular Lenses|Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical||Federal University of São Paulo||Completed|September 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|80 Years|Accepts Healthy Volunteers|||March 2006|October 25, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347243||180915|
NCT00347256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASBS-PNS001|Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer|Preoperative Radiotherapy and Concomitant Chemotherapy Followed by Surgery for Advanced Paranasal Sinus Carcinoma||University of Tennessee||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||December 2008|December 9, 2008|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347256||180914|
NCT00296270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIR13914|Memory for Flu Facts and Myths and Effects on Vaccine Intentions|"Myths and Facts" About the Flu: Health Education Campaigns Can Reduce Vaccination Intentions||University of Michigan||Completed|March 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||175|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||February 2006|February 23, 2006|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296270||184717|
NCT00296283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20051107|Family Workshops for Bipolar Disorder|An Acceptance Based Psychoeducation Intervention to Reduce Expressed Emotion in Family Members of Bipolar Patients||University of Miami||Completed|August 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|64 Years||||May 2007|May 22, 2007|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296283||184716|
NCT00296595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-64438|Effects of n-3 Polyunsaturated Fatty Acids and Antioxidants on Postprandial Hyperlipidemia and Vascular Function in Men|Physiological Mechanisms Underlying the Effects of PUFA and Antioxidants on Postprandial Lipemia, Oxidative Stress, Endothelial Dysfunction and Inflammation in Men||Laval University||Completed|February 2006|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|99|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00296595||184692|
NCT00295685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSESOM0159|Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD|Single Dose Nexium 40MG QAM vs Lansoprazole 30mg BID for Control of Symptomatic GERD-A Double Blind Cross-Over Study||Digestive & Liver Disease Specialists||Completed|October 2005|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|80 Years|No|||February 2009|February 24, 2009|February 22, 2006||||||https://clinicaltrials.gov/show/NCT00295685||184761|
NCT00295958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060041|LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery|Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)||Completed|December 2005|July 2008|Actual|June 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|February 23, 2006||||||https://clinicaltrials.gov/show/NCT00295958||184740|
NCT00347789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11111|Effectiveness of a Procedure for Previously Failed Glaucoma Surgery|Efficacy of Transconjunctival Mitomycin-C in Needle Revisions of Failing Trabeculectomy||Glaucoma Research & Education Group||Completed|May 1997|June 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||100|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2006|June 30, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347789||180874|
NCT00347802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5176|Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%|Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||May 2007|May 30, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347802||180873|
NCT00348426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH_CER_002|Botulism Outbreak in Thailand (Episode II)|Clinical Manifestations of Botulism Outbreak in Northern Thailand: A Case Series of Botulism Treated With Botulinum Anti-Toxin.||Rajavithi Hospital||Completed|June 2006|September 2006||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||200|||Both|N/A|N/A|No|||November 2006|November 7, 2006|July 2, 2006||||No||https://clinicaltrials.gov/show/NCT00348426||180825|
NCT00348439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437|Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment|A Multicenter, Randomized, Double Masked, Placebo Controlled, Sequential Dose Response Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)||Bausch & Lomb Incorporated|Yes|Terminated|April 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|June 30, 2006|Yes|Yes|Lack of Efficacy|No||https://clinicaltrials.gov/show/NCT00348439||180824|
NCT00349310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.597|Profile of Depressive Symptoms in Parkinsons Disease|Profile of Depressive Symptoms in Parkinson's Disease (PRODEST-PD)||Boehringer Ingelheim||Completed|April 2006|October 2006|Actual|October 2006|Actual|Phase 4|Observational|N/A||||1018|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349310||180758|
NCT00349323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-7041-83/hah|Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia|Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia||DBL -Institute for Health Research and Development|No|Completed|August 2006|September 2007|Actual|August 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|12 Months|59 Months|No|||February 2008|May 7, 2008|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349323||180757|
NCT00345397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4203-R|A Colonic Tube to Improve Bowel Function in Spinal Cord Injury|Percutaneous Colostomy for Bowel Management in Spinal Cord Injury||VA Office of Research and Development|No|Active, not recruiting|May 2006|July 2016|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 27, 2006|Yes|Yes||No|February 26, 2015|https://clinicaltrials.gov/show/NCT00345397||181053|Difficulty in recruitment from a limited population reduced our intended enrollment and prolonged our study.This also reduced our statistical significance and limited our conclusions.
NCT00345657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHI-A001|Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care|Extended-Release Niacin/Lovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting (EXTEND Study)||In His Image||Completed|July 2003|May 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||June 2006|June 27, 2006|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345657||181034|
NCT00345384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-201|Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients|Post-Operative Infusion of Low-Dose Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients: A Randomized, Double-Blind, Controlled Pilot Study||Baylor Research Institute|No|Completed|May 2008|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|85 Years|No|||January 2016|January 12, 2016|June 27, 2006|No|Yes||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00345384||181054|Pilot study with small numbers of participants.
NCT00345631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM0501|Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device|ECLIPSE Trial - Ensure's Vascular Closure Device Speeds Hemostasis Trial||Cordis Corporation|Yes|Completed|February 2007|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|488|||Both|18 Years|85 Years|No|||May 2012|May 25, 2012|June 26, 2006|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00345631||181036|
NCT00346125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS080|PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma|An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma||Masonic Cancer Center, University of Minnesota|No|Active, not recruiting|April 2006|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|70|||Both|16 Years|N/A|No|||January 2016|January 21, 2016|June 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00346125||180999|
NCT00345852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD041149|Fetoscopic Selective Laser Photocoagulation in Twin-Twin Transfusion Syndrome|A Prospective, Randomized Multicenter Trial of Amnioreduction Vs Selective Fetoscopic Laser Photocoagulation for the Treatment of Severe Twin-Twin Transfusion Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|March 2002|May 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2006|June 28, 2007|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345852||181019|
NCT00338663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-20041|A Study on Knee Immobilization and Pain Levels After an Anterior Cruciate Ligament (ACL) Reconstruction Surgery|The Effect of Knee Immobilization on Postoperative Pain Following an Anterior Cruciate Ligament (ACL) Reconstruction: A Randomized Clinical Trial||LifeMark Health Research Group|Yes|Completed|May 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||88|||Both|18 Years|40 Years|No|||August 2007|August 22, 2007|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00338663||181544|
NCT00347022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-44-008|A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications|||Guerbet||Completed|May 2006|June 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|145|||Both|1 Year|16 Years|No|||April 2013|April 8, 2013|June 30, 2006||No||No|December 23, 2011|https://clinicaltrials.gov/show/NCT00347022||180932|
NCT00339560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997028|A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China|A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China||National Institutes of Health Clinical Center (CC)||Completed|May 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3200|||Both|18 Years|75 Years|No|||January 2016|February 2, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339560||181475|
NCT00295997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463522|Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia|Non-myeloablative Allogeneic Stem Cell Transplantation With Match Unrelated Donors for Treatment of Hematologic Malignancies and Renal Cell Carcinoma and Aplastic Anemia||National Cancer Institute (NCI)||Active, not recruiting|May 2005|||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|N/A|74 Years|No|||April 2007|January 3, 2014|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00295997||184737|
NCT00296010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000463710|Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer|Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (Age 66 Years or Older) With Endocrine Nonresponsive Breast Cancer Who Are Not Suitable for Being Offered a " Standard Chemotherapy Regimen"|CASA|International Breast Cancer Study Group|Yes|Terminated|August 2005|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|77|||Female|66 Years|N/A|No|||August 2015|August 25, 2015|February 23, 2006||No|Accrual rate was too low|No||https://clinicaltrials.gov/show/NCT00296010||184736|
NCT00296296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95442|Immunosuppression Impact on the Metabolic Control of First Kidney Transplant Recipients With Pre-Existing Type 2 Diabetes (DM)|Randomized Open Label Study Comparing the Metabolic Control of First Kidney Transplant Recipients With Pre-Existing Type 2 Diabetes (DM) Receiving Either Prograf or Neoral as Part of a Thymoglobulin Induction, Prednisone Free and Blood Monitored Cellcept Immunosuppressive Drug Regimen.||Stanford University||Recruiting|June 2005|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||January 2007|January 23, 2007|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00296296||184715|
NCT00295698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUF 91088|Interaction Between HIV and Lymphatic Filariasis|Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine||DBL -Institute for Health Research and Development||Completed|August 2001|November 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2006|February 23, 2006|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00295698||184760|
NCT00296803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9842|PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome|PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome||Sanofi||Completed|November 2005|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 10, 2011|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00296803||184676|
NCT00295971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000462168|Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease|Stem Cell Enriched, T Cell Depleted Haplocompatible Peripheral Blood Transplantation for Children With Myelodysplastic Disease, Leukemia, Marrow Failure Syndromes, or Severe Immunodeficiency Diseases||University of California, San Francisco|Yes|Completed|April 2005|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|1 Year|17 Years|No|||November 2012|November 8, 2012|February 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295971||184739|
NCT00296257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2450174|Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114|A Phase 2, Multi-Centre, Randomised, Double Blind, Placebo Controlled Study Evaluating the Efficacy, Safety and Pharmacokinetics of Two Doses of a Candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg Once Daily), Administered in Combination With Ongoing Methotrexate Treatment in Patients With Active Rheumatoid Arthritis.||Dainippon Sumitomo Pharma Europe LTd.|Yes|Terminated|February 2006|April 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|312|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|February 22, 2006||||No||https://clinicaltrials.gov/show/NCT00296257||184718|
NCT00348101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPEKLILU05|Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation|The Influence of Continuous Perioperative Beta-Blocker Therapy in Combination With Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation and Myocardial Ischaemia in High-Risk Vascular Surgery Patients||Klinikum Ludwigshafen|No|Completed|June 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|75|||Both|18 Years|N/A|No|||April 2007|May 29, 2007|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348101||180850|
NCT00348452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B02.CT3.021.TRA P03|A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA)|Double-blind, Randomized, Dose-ranging, Parallel-group Comparison of the Efficacy and Safety of Extended Release Tramadol Hydrochloride (Tramadol HCl ER) 100 mg, 200 mg, 300 mg, Celecoxib 200 mg and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip.||Valeant Pharmaceuticals International, Inc.||Completed|September 2002|August 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Both|18 Years|80 Years|No|||June 2012|June 20, 2012|July 3, 2006||||||https://clinicaltrials.gov/show/NCT00348452||180823|
NCT00348751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000B161|CholGate - The Effect of Alerting Versus on Demand Computer Based Decision Support on Treatment of Dyslipidaemia by General Practitioners|The Effect of Alerting Versus on Demand Computer Based Decision Support on Treatment of Dyslipidaemia by General Practitioners - The CholGate Randomized Trial||Erasmus Medical Center||Completed|June 2004|November 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|70 Years||||June 2006|May 7, 2008|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00348751||180800|
NCT00348998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000480370|Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer|Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2006|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||November 2008|November 5, 2013|July 5, 2006||||||https://clinicaltrials.gov/show/NCT00348998||180781|
NCT00349011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Komen BCTR0100202|Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer|Menopausal Therapy in Women at Increased Risk for Breast Cancer: Does a Personalized Risk Assessment and Counseling Intervention Aid in Decision-Making?||Yale University||Completed|August 2002|March 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||60|||Female|40 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 5, 2006|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349011||180780|
NCT00349336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO20254|A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.|A Randomized, Open Label Trial to Assess the Steady State Pharmacokinetics of Avastin Given With Either XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|August 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|July 6, 2006|Yes|Yes||No|June 2, 2009|https://clinicaltrials.gov/show/NCT00349336||180756|
NCT00349349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111773|HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab|A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab||GlaxoSmithKline||Completed|June 2006|June 2012|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|223|||Both|18 Years|N/A|No|||June 2013|May 29, 2014|July 6, 2006|Yes|Yes||No|October 20, 2011|https://clinicaltrials.gov/show/NCT00349349||180755|
NCT00345865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS048|Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|Autologous Peripheral Blood Stem Cell Transplant for Patients With Lymphoma||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|August 2005|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|325|||Both|N/A|75 Years|No|||January 2016|January 21, 2016|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345865||181018|
NCT00345878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105926|Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years|Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine Administered Intramuscularly ( 0, 1, 6 Month Schedule) in Healthy Women From Malaysia.||GlaxoSmithKline||Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|271|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|June 28, 2006|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00345878||181017|
NCT00337805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMA-04-016|Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery|A Randomized Trial of Synthetic vs Normal Saline for the Flow-based Algorithmic Hemodynamic Resuscitation of Patients Post-cardiac Surgery||McGill University Health Center|No|Completed|September 2004|April 2008|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|N/A|N/A|No|||September 2009|September 17, 2009|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337805||181607|
NCT00338130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00003|Randomised Study to Compare the Efficacy of AZD6244 vs TMZ|A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma||AstraZeneca||Completed|July 2006|July 2013|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|June 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338130||181584|
NCT00346424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA006|Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters|Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Occluded Central Venous Access Devices||ARCA Biopharma, Inc.|Yes|Completed|September 2005|December 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||August 2008|August 12, 2008|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346424||180978|
NCT00338676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM05003 - P051042|Aortic Stenosis in Elderly : Determinant of Progression|Aortic Stenosis in Elderly : Determinant of Progression. COFRASA (French Cohort)||Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|November 2006|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|273|Samples With DNA|blood samples|Both|70 Years|N/A|No|Probability Sample|Patients diagnosed with an at least mild aortic stenosis with no indication for surgery|February 2016|February 24, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00338676||181543|
NCT00338962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 11637|Naltrexone & SSRI in Alcoholics With Depression/PTSD|Naltrexone & SSRI in Alcoholics With Depression/PTSD||Yale University|Yes|Completed|October 2001|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|88|||Both|21 Years|75 Years|No|||January 2016|January 6, 2016|June 15, 2006||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00338962||181521|
NCT00338975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH071410|Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia|Cognitive Behavioral Skills Training for Schizophrenia||Veterans Medical Research Foundation|Yes|Completed|June 2005|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338975||181520|
NCT00339339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904253|Levels of Bisphenol A in Urine and Saliva Following Placement of Composite Restorations|Bisphenol A and Metabolites in Urine and Saliva Associated With Placement of Composite Restorations||National Institutes of Health Clinical Center (CC)||Completed|July 2004|January 2013||||N/A|Observational|N/A|||Actual|76|||Both|20 Years|60 Years|No|||January 2013|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339339||181492|
NCT00296322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0102|Trial of Adjuvant Chemotherapy for Gastric Cancer|A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin||Asan Medical Center|No|Completed|October 2001|March 2010|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|528|||Both|18 Years|69 Years|No|||August 2013|August 7, 2013|February 24, 2006||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT00296322||184713|
NCT00296816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0239|TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary|A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel With Bevacizumab as First Line Therapy in Patients With FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma|TEACO|Sanofi|No|Completed|March 2006|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Female|18 Years|N/A|No|||August 2011|July 20, 2012|February 23, 2006|Yes|Yes||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00296816||184675|One site closed prematurely during the study. Every effort was made to collect, at minimum, any outstanding safety data for the participants at this site. As a result, participants from this site were included only in the safety analysis.
NCT00297050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060105|Safety and Dose Study of Peramivir for Influenza Treatment|A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Intravenous Peramivir in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Completed|February 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1|||100|||Both|18 Years|50 Years|No|||August 2009|August 27, 2009|February 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00297050||184658|
NCT00297336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002116|An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine|An Open-label Observational Safety Study During Administration of Topiramate, for the Prophylaxis of Migraine||Janssen Cilag Pharmaceutica S.A.C.I., Greece||Completed|March 2005|February 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Probability Sample|In this study a total number of 80 patients with diagnosed migraine according to the        criteria of the International Headache Society HIS (Cephalalgia 1998; 8 (Suppl7) :1-98)        will participate. Patients who will be enrolled should be either male or female over 18        years of age, they should satisfy the migraine prophylactic medication criteria, and will        agree to sign the written informed consent for the anonymous and confidential use of their        medical data with their participation in the study.|April 2010|April 26, 2010|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297336||184636|
NCT00348140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA102670|Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease|A 54-week, Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE e4-stratified Subjects With Mild to Moderate Alzheimer's Disease (REFLECT-3)|REFLECT-3|GlaxoSmithKline|Yes|Completed|July 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1450|||Both|50 Years|90 Years|No|||September 2014|September 25, 2014|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00348140||180847|
NCT00348465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYM-353|Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds|An Observational Study to Evaluate the Changes in Prostate Volume Over Time With The Use of Transrectal Ultrasound and Computed Tomography Following Permanent Prostate Brachytherapy With Iodine-125 Seeds.||New York Methodist Hospital|Yes|Completed|May 2006|March 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29|||Male|18 Years|80 Years|No|Non-Probability Sample|Prostate Cancer patients|May 2008|May 20, 2008|July 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00348465||180822|
NCT00348478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00001455|Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger|Determination of the Impact of Water and Health Education on Trachoma and Ocular C. Trachomatis in Niger||Johns Hopkins University||Completed|December 2005|January 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||720|||Both|6 Months|65 Months|Accepts Healthy Volunteers|||November 2005|October 27, 2011|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348478||180821|
NCT00348764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 38|ESGVS: Sclerotherapy With Lauromacrogol|Treatment of Greater Saphenous Vein (GSV) Insufficiency Using Echo-Guided Sclerotherapy With Lauromacrogol 400 Foam –Comparative Study of 3% Versus 1% Concentration.||University Hospital, Grenoble||Completed|March 2004|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|25 Years|75 Years|No|||July 2006|July 5, 2006|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00348764||180799|
NCT00349024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481526|Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer|Efficacy of Gelclair™ in Reducing the Pain of Oral Mucositis in Children and Young People With Cancer (SC 2005 07)||National Cancer Institute (NCI)||Active, not recruiting|July 2005|||December 2009|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|50|||Both|4 Years|19 Years|No|||June 2009|September 19, 2013|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349024||180779|
NCT00345085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052006-029|Comparison of Higher Order Aberrations and Contrast Sensitivity Between Acrysof SN60AT, SN60WF and Restore Intraocular Lenses|Comparison of Higher Order Aberrations and Contrast Sensitivity Between Acrysof SN60AT, SN60WF and Restore Intraocular Lenses||University of Texas Southwestern Medical Center||Completed|March 2005|April 2007|Actual|||N/A|Observational|N/A|||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|July 24, 2014|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00345085||181077|
NCT00337246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRU-NCRI-UKCLL01-FCM/FCM-R|Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia|A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Completed|July 2005|March 2011|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|56|||Both|N/A|N/A|No|||May 2007|August 1, 2013|June 13, 2006||||No||https://clinicaltrials.gov/show/NCT00337246||181648|
NCT00337571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-179|Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)|A Multicenter Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|June 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|218|||Both|6 Years|17 Years|No|||November 2009|November 7, 2013|June 13, 2006|Yes|Yes||No|June 3, 2009|https://clinicaltrials.gov/show/NCT00337571||181625|
NCT00337558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-003|A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)|Solifenacin Succinate in a Flexible Dose Regimen With Simplified Bladder Training Versus Solifenacin Succinate in a Flexible Dose Regimen Alone in a Prospective, Randomized, Parallel Group, Overactive Bladder Symptom Study|SOLAR|Astellas Pharma Inc|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|643|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|June 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00337558||181626|
NCT00338156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StaHF461302|Observational Study of the Remodelling Process Following Myocardial Infarct|Assessment of the Relationship Between Collagen Turnover, Left Ventricular Remodelling and Myocardial Scarring Assessed by Cardiac Magnetic Resonance and Neurohumoral Activation in Patients With Previous Myocardial Infarction||Helse Stavanger HF|No|Completed|August 2003|September 2003|Actual|September 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|119|Samples Without DNA|Serum Plasma|Both|N/A|N/A|No|Probability Sample|Patients with risk of heart failure secondary to myocardial infarct.|July 2010|July 27, 2015|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338156||181582|
NCT00338143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD2782g|A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies|A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned From Systemic Therapies||Genentech, Inc.||Completed|October 2003|May 2004|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||1200|||Both|18 Years|75 Years|No|||February 2014|February 28, 2014|June 15, 2006||||||https://clinicaltrials.gov/show/NCT00338143||181583|
NCT00338416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004612|An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks|An Open-Labeled Pilot Study to Evaluate the Effects of High Dose PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a Every Three Week Regimen||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2003|January 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|115|||Both|19 Years|N/A|No|||April 2010|June 8, 2011|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00338416||181563|
NCT00338689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00389|European Childhood Obesity Project: Early Programming by Infant Nutrition?|Childhood Obesity - Programming by Infant Nutrition|CHOP|Ludwig-Maximilians - University of Munich|No|Active, not recruiting|October 2002|September 2015|Anticipated|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1678|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||September 2015|September 14, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00338689||181542|
NCT00338988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0340|Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma|A Phase II Study of Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma, Including Carcinoma of the Gallbladder and Biliary Tract||M.D. Anderson Cancer Center|No|Completed|August 2003|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|June 16, 2006||No||No|November 3, 2010|https://clinicaltrials.gov/show/NCT00338988||181519|
NCT00339001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4128-JK-CTIL|Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity|The Possible Influence of Erythropoietin and Early Iron Supplements on the Prevalence and Severity of Retinopathy of Prematurity and Other Short Term Outcome of Prematurity||Sheba Medical Center||Recruiting|April 2006|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||400|||Both|N/A|3 Months|No|||June 2006|June 19, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339001||181518|
NCT00339014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZB 201|Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity|A Dose Parallel, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Multiple Regimens of the Combination of Zonisamide CR Plus Bupropion SR in the Treatment of Subjects With Uncomplicated Obesity||Orexigen Therapeutics, Inc|Yes|Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|611|||Both|18 Years|60 Years|No|||April 2008|April 18, 2008|June 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00339014||181517|
NCT00339612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902270|NISDI Pediatric Latin American Countries Epidemiologic Study (PLACES): A Prospective Observational Study of HIV-Infected Children at Clinical Sites in Latin American Countries|NISDI Pediatric Latin American Countries Epidemiologic Study (PLACES): A Prospective Observational Study of HIV-Infected Children at Clinical Sites in Latin American Countries||National Institutes of Health Clinical Center (CC)||Completed|July 2002|||||N/A|Observational|N/A|||Anticipated|2500|||Both|N/A|21 Years|No|||July 2015|July 25, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339612||181471|
NCT00339625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999910159|Polyp Prevention Trial|Polyp Prevention Trial||National Institutes of Health Clinical Center (CC)||Completed|June 1991|April 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2440|||Both|35 Years|99 Years|No|||March 2016|March 18, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339625||181470|
NCT00296855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91463|Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease|Intra-individual Open-label Multicenter Comparison Study of Magnetic Resonance Angiography (MRA) With the Blood Pool Contrast Agent Vasovist® and a Conventional Extracellular Contrast Agent With Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients With Peripheral Artery Disease||Bayer||Completed|February 2006|February 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|261|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296855||184672|
NCT00296608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466625|Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer|Preoperative Radiotherapy With or Without Concurrent Chemotherapy (5-Fluorouracil and Leucovorin) in T3-4 Rectal Cancers - Randomized Trial||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|762|||Both|N/A|75 Years|No|||April 2012|May 1, 2012|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00296608||184691|
NCT00297063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD104742|BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-|Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo -||GlaxoSmithKline||Completed|January 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|350|||Both|20 Years|75 Years|No|||October 2010|October 1, 2010|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297063||184657|
NCT00297076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR104456|Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-Containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.||GlaxoSmithKline||Terminated|July 2005|October 2007|Anticipated|October 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||406|||Both|18 Years|N/A|No|||May 2009|May 15, 2009|February 24, 2006||||||https://clinicaltrials.gov/show/NCT00297076||184656|
NCT00297089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-780|A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer|A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT 751 in Combination With Pemetrexed Versus Pemetrexed Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer||AbbVie|No|Completed|November 2006|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|February 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00297089||184655|
NCT00348491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2474|Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib|A Randomized, Double-blind, Double-dummy, Parallel Group, Single-center Study Evaluating the Analgesic Effect of Single Doses of Lumiracoxib 400 mg, Celecoxib 400 mg and Placebo in the Treatment of Post-dental Surgery Pain||Novartis||Completed|February 2006|||May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||364|||Both|17 Years|N/A||||May 2012|May 18, 2012|June 30, 2006||||||https://clinicaltrials.gov/show/NCT00348491||180820|
NCT00348504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001077|Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.|Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.||Abbott||Completed|March 2003|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1300|||Both|18 Years|N/A|No|||November 2007|November 16, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348504||180819|
NCT00348517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-45|Safety/Efficacy of Systane Free vs Refresh Liquigel|An Evaluation of the Safety and Efficacy of Systane Free FID 105783||Alcon Research||Completed|July 2006|November 2006||November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00348517||180818|
NCT00348777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 06 06|THERMARTHROSE: Gonarthrosis and Water Cure|Evaluation of the Effects of a Water Cure on Gonarthrosis: Randomized Clinical Study Including Water Cure Versus Continuation of the Usual Treatment||Association Francaise pour la Recherche Thermale|No|Completed|June 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|462|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|July 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00348777||180798|
NCT00349050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23NS050485-01A2|Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception|Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception||Medical University of South Carolina|Yes|Withdrawn|July 2006|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||October 2010|April 26, 2012|July 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00349050||180777|
NCT00349063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/217/05/L|Contact Lens Wettability|The Impact of Short Term Wearing Time on In Vivo and Ex Vivo Wettability||University of Waterloo||Completed|July 2005|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||55|||Both|16 Years|N/A||||July 2006|July 17, 2006|July 4, 2006||||No||https://clinicaltrials.gov/show/NCT00349063||180776|
NCT00349037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM FLS-002|Study of the Ability of a Flu Vaccine to Prevent Flu Infection|A Prospective, Randomised, Double Blind, Placebo-Controlled Study to Assess the Efficacy of a Trivalent (A/New Caledonia/20/99, A/Panama/2007/99, B/Jiangsu/10/20) DNA Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) Against a Controlled Influenza Virus Challenge.||PowderMed||Completed|September 2006|January 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||105|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2007|January 25, 2007|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349037||180778|
NCT00337259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2006-60|Gemcitabine for Marginal Zone Lymphoma|Phase II Study of Gemcitabine in Patients With Advanced Stage Marginal Zone B-cell Lymphoma||Asan Medical Center|Yes|Terminated|June 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|June 14, 2006||No|poor accrual and response less than expected on interim analysis|No||https://clinicaltrials.gov/show/NCT00337259||181647|
NCT00337272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN AEJSINS0601|Treating Chronic Insomnia in Breast Cancer Patients|Phase IV: Treatment of Chronic Insomnia in Patients With Breast Cancer Following Completion of Chemotherapy||Accelerated Community Oncology Research Network|No|Terminated|August 2006|January 2009|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Female|21 Years|60 Years|No|||August 2011|August 18, 2011|June 13, 2006|Yes|Yes|Lack of enrollment.|No|June 2, 2009|https://clinicaltrials.gov/show/NCT00337272||181646|Early study termination due to slow enrollment; Small sample size analyzed; Some IVRS and Patient Care Monitor (PCM) data were lost and could not be retrieved; Some subject non-compliance with study requirements
NCT00337285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRP104.304|An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||New River Pharmaceuticals|No|Completed|July 2006|June 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|349|||Both|18 Years|55 Years|No|||August 2012|August 16, 2012|June 9, 2006|No|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00337285||181645|
NCT00337584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24003|A Pre-Operative Screening Questionnaire (AMS-Q) for Ambulatory Orthopedic Surgery Patients|||Hospital for Special Surgery, New York||Completed|December 2005|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||August 2007|August 7, 2007|June 14, 2006||||No||https://clinicaltrials.gov/show/NCT00337584||181624|
NCT00337818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107476 (M18)|Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women|A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study||GlaxoSmithKline||Completed|June 2006|January 2009|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|770|||Female|10 Years|25 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|June 15, 2006|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00337818||181606|
NCT00338182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00002|AZD1152 in Patients With Advanced Solid Malignancies|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 48-hour Intravenous Infusion in Patients With Advanced Solid Malignancies||AstraZeneca||Active, not recruiting|May 2006|January 2013|Anticipated|January 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|June 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00338182||181581|
NCT00338195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPR01-05-04-03|Assessment and Treatment of Caffeine Dependence|||Johns Hopkins University||Completed|May 2001|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338195||181580|
NCT00338429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3104|Better Days, Better Nights: Treatment for Sleep Difficulties (Telephone Coached)|Better Days, Better Nights: Treatment for Sleep Difficulties (A Sleep Intervention Module of the Family Help Program)|Sleep|IWK Health Centre|No|Completed|April 2005|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338429||181562|
NCT00339053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04.01 TAA|Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair|The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta||St. Antonius Hospital||Recruiting|September 2004|January 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||142|||Both|18 Years|N/A|No|||October 2006|October 20, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339053||181514|
NCT00339027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0116|HealthSpark: Health Access for Children in Federally-Subsidized Child Care|||University of Miami||Completed|May 2004|March 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||960|||Both|3 Years|5 Years||||March 2005|September 7, 2006|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00339027||181516|
NCT00339040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1047|Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children|Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|130|||Both|7 Years|12 Years|No|||December 2014|December 30, 2014|June 19, 2006|Yes|Yes||No|September 7, 2011|https://clinicaltrials.gov/show/NCT00339040||181515|
NCT00340132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999820136|Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians|Cross-Sectional and Longitudinal Studies of "Pre-Diabetes"||National Institutes of Health Clinical Center (CC)||Recruiting|August 1982|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 24, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340132||181435|
NCT00335855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0073|Pharma-Pen (Formerly Innoject) Auto-injectory TIV|Demonstration of Safety, Effectiveness, and Ease-of-Use of an Advanced Self-Delivery System (Pharma-Pen™) for IM and SC Administration of Vaccines by Untrained Users - Phase I||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||October 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2009|August 26, 2010|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00335855||181750|
NCT00296621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030420|Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy|Efficacy Study of Oral Glutamine Supplementation in Duchenne Muscular Dystrophy|MDB-GLN|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2006|November 2007|Actual|February 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|N/A|N/A|No|||December 2007|December 20, 2007|February 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00296621||184690|
NCT00297115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-125|Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)|Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study||Takeda||Completed|March 2006|August 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1568|||Both|40 Years|N/A|No|||June 2011|May 4, 2012|February 27, 2006|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00297115||184653|
NCT00297362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003559|A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease|Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type||Janssen Cilag Pharmaceutica S.A.C.I., Greece||Completed|June 2004|October 2005|Actual|||Phase 4|Observational|Time Perspective: Prospective||1|Actual|344|||Both|N/A|N/A|No|Probability Sample|247 patients with diagnosed with mild to moderate Alzheimer's disease with a score of        10-26 on the Mini Mental Status Exam. Patients switching from an acetylcholinesterase        inhibitor treatment due to lack of efficacy or poor tolerability.|March 2012|March 23, 2012|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00297362||184634|
NCT00348790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05C4|Vatalanib in Treating Patients With Recurrent or Progressive Meningioma|A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas||Northwestern University|Yes|Completed|May 2006|July 2013|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|July 5, 2006|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT00348790||180797|
NCT00348803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Gene Mutations in Secondary Pulmonary Hypertension|||Medical University of Vienna||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A||||June 2006|July 5, 2006|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00348803||180796|
NCT00349076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAO/ARO/AIO-04|Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer|Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rectal Cancer||University of Erlangen-Nürnberg Medical School||Active, not recruiting|July 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349076||180775|
NCT00349089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAT|Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy|Adjuvant Chemotherapy With Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin in NSCLC IB, IIA, IIB, T3N1: a Randomized Phase II Study||Thoraxklinik am Universitätsklinikum Heidelberg|Yes|Active, not recruiting|October 2006|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|74 Years|No|||May 2011|May 2, 2011|July 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00349089||180774|
NCT00336388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-4701|Use of Rapid Diagnostic Tests for Malaria Case Management in Kenya|Introduction of Malaria Rapid Diagnostic Tests, Artemisinin-based Combination Therapy, and Malaria Case Management Guidelines at Health Facilities in Kenya: A Cluster Randomized Trial to Evaluate Adherence and Acceptance by Health Care Workers, Impact on Antimalarial Prescription Practices, and Patient Perceptions||Centers for Disease Control and Prevention||Completed|July 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||3600|||Both|5 Years|N/A|No|||March 2010|March 8, 2010|June 10, 2006||||No||https://clinicaltrials.gov/show/NCT00336388||181710|
NCT00349375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF0242780-01 05 01|Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy|A Multicenter, Double-Blind, Randomized, Active Comparator, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 20 mg Simvastatin Alone||Solvay Pharmaceuticals||Completed|November 2005|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1040|||Both|18 Years|75 Years|No|||July 2009|July 7, 2009|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349375||180753|
NCT00349388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-11-010|Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients|A Randomized Trial Comparing Once Daily Dosing vs. Multiple Doses a Day of Mesalamine in Pediatric Patients With Quiescent Ulcerative Colitis||Atlantic Health System|No|Terminated|July 2006|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|6 Years|18 Years|No|||August 2014|August 13, 2014|July 5, 2006|Yes|Yes|none enrolled in second arm, therfore no analysis|No|July 24, 2014|https://clinicaltrials.gov/show/NCT00349388||180752|No subjects were analysed due to lack of enrollment. No subject was enrolled into the once a day dosing arm to answer our primary or secondary outcomes.
NCT00349362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDGH 264|Testosterone for Men With Insulin Treated Type 2 Diabetes|A Randomised Double Blind Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Replacement on Glycaemic Control and Arterial Wall Properties of Hypogonadal Men With Type 2 Diabetes Treated With Insulin||Barnsley Hospital||Completed|July 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|40|||Male|40 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 29, 2010|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349362||180754|
NCT00336947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCU-BRI-HN-05-01|S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer|Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study||National Cancer Institute (NCI)||Active, not recruiting|April 2006|||March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|500|||Both|20 Years|75 Years|No|||December 2008|May 14, 2013|June 13, 2006||||No||https://clinicaltrials.gov/show/NCT00336947||181669|
NCT00337870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3416|Painful Procedures in the Emergency Department: A Distraction Intervention (3-5 Year Olds)|Painful Procedures in the Emergency Department: Does a Formal Program in Distracting Techniques for Parents and Children Reduce Pain and Anxiety in Children (3-5 Year Olds)?|ERPain|IWK Health Centre|No|Completed|March 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00337870||181604|
NCT00337597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 05/7-F|Continuous Regional Analgesia After Total Knee Arthroplasty|Continuous Regional Analgesia After Total Knee Arthroplasty. Normal Saline or Dextrose 5% in Water as Fluid Medium for Pre-Placement Expansion in Order to Facilitate the Catheter Passing||Nantes University Hospital||Completed|May 2006|December 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||July 2008|July 18, 2008|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00337597||181623|
NCT00337831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/127|Clinical Study on Optimised Removal of Protein-bound Uremic Toxins With Convective Dialysis Treatment.|Clinical Study on Optimised Removal of Protein-bound Uremic Toxins With Convective Dialysis Treatment.||University Hospital, Ghent|No|Completed|May 2006|May 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|85 Years|No|||June 2011|June 29, 2011|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00337831||181605|
NCT00338455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003649|Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC|Investigation of the Use of Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC||Scios, Inc.|Yes|Terminated|September 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|June 16, 2006|Yes|Yes|DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated    due to slow enrollment|No|October 22, 2008|https://clinicaltrials.gov/show/NCT00338455||181560|Early termination of the study due to enrollment difficulties (change in standard of care for patient population as well as changing organ allocation rules by United Network for Organ Sharing); efficacy not analyzed due to limited sample size (n=16).
NCT00338442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VZ-009|Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection|Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection||Cangene Corporation|No|Approved for marketing|February 2006|December 2009|Anticipated|December 2009|Anticipated|N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||April 2013|April 1, 2013|June 15, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00338442||181561|
NCT00339378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900025|Incidence and Mortality of Childhood Cancer Among Children of Farmer Pesticide Applications|Incidence and Mortality of Childhood Cancer Among Children of Farmer Pesticide Applicators||National Institutes of Health Clinical Center (CC)||Completed|June 2000|June 2007||||N/A|Observational|N/A||||21985|||Both|N/A|N/A|No|||June 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339378||181489|
NCT00339352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999013|A Family Study of Adults With Glioma|A Family Study of Adults With Glioma||National Institutes of Health Clinical Center (CC)||Completed|February 1999|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|3000|||Both|18 Years|100 Years|No|||September 2015|October 6, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339352||181491|
NCT00339365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077329|Promoting Infant Mental Health in Foster Care|Promoting Infant Mental Health in Foster Care||University of Washington|No|Completed|April 2007|July 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|236|||Both|10 Months|24 Months|Accepts Healthy Volunteers|||May 2012|May 16, 2012|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339365||181490|
NCT00339651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903053|Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer|Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2002|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|2000|||Female|40 Years|N/A|No|||April 2015|April 23, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339651||181468|
NCT00297375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002821|A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache|A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Acute Treatment of Migraine Headache Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2003|August 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|375|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|February 24, 2006||||||https://clinicaltrials.gov/show/NCT00297375||184633|
NCT00297700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 RO1 DA017974|Implementing Tobacco Control in Dental Practice|Implementing Tobacco Control in Dental Practice||National Institute on Drug Abuse (NIDA)||Active, not recruiting|May 2004|April 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||2800|||Both|18 Years|N/A|No|||July 2006|July 13, 2006|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297700||184609|
NCT00297713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230-00009|Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety|A Phase II, Multi-Center, Multi-Dose, Randomized, Open-Label, Parallel Group Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety||Altus Pharmaceuticals||Completed|July 2005|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|60 Years|No|||December 2006|December 11, 2006|February 27, 2006||||||https://clinicaltrials.gov/show/NCT00297713||184608|
NCT00297128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG R03 (96) / TAKO 06|Preoperative Chemoradiation With Capecitabine and Cetuximab|Preoperative Chemoradiation With Capecitabine and Cetuximab Within a Multidisciplinary Therapeutic Approach in Patients With Operable T3-T4 Rectal Cancer: a Phase II Study||Austrian Breast & Colorectal Cancer Study Group|No|Completed|October 2005|November 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|80 Years|No|||December 2011|December 29, 2011|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297128||184652|
NCT00297141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG 95 / TAKO 05|Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma|Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum||Austrian Breast & Colorectal Cancer Study Group|No|Completed|October 2004|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|No|||December 2013|December 30, 2013|February 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00297141||184651|
NCT00297154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16557|The Effect of Diet and Exercise in Heart Failure|Lifestyle Modification in the Treatment of Heart Failure||Baylor College of Medicine||Recruiting|March 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|75 Years|No|||December 2010|December 2, 2010|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297154||184650|
NCT00296829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID16|Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly|||Sanofi|No|Completed|January 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1080|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|February 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00296829||184674|
NCT00298025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24688|A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation|A Phase IV, Multicenter, Open-label, Randomized Study to Compare the Safety and Efficacy of Cetrotide® 3 mg Versus Antagon™ in the Inhibition of a Premature LH Surge in a r-hFSH/hMG Stimulation Cycle With OCP Programming in Women Undergoing Ovarian Stimulation Prior to ART||EMD Serono||Completed|September 2003|May 2004|Actual|May 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|185|||Female|18 Years|39 Years|No|||March 2014|March 24, 2014|February 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00298025||184585|
NCT00298038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFHE3001|A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy||Valeant Pharmaceuticals International, Inc.|Yes|Completed|December 2005|April 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|299|||Both|18 Years|N/A|No|||July 2011|July 17, 2011|February 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298038||184584|
NCT00336089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466676|Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors|The Effects of Cross Training on Fatigue and Pain Levels in Breast Cancer Survivors||National Cancer Institute (NCI)||Recruiting|January 2006|||December 2008|Anticipated|N/A|Interventional|Allocation: Randomized|||Anticipated|54|||Both|18 Years|60 Years|No|||July 2009|September 16, 2013|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00336089||181733|
NCT00336401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0011-B|Peri-Operative And Long-Term Cardioprotective Properties Of Sevoflurane In High Risk Patients Undergoing Non-Cardiac Surgery|Peri-Operative And Long-Term Cardioprotective Properties Of Sevoflurane In High Risk Patients Undergoing Non-Cardiac Surgery||University Health Network, Toronto||Completed|October 2006|February 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|45 Years|N/A|No|||September 2006|July 29, 2010|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00336401||181709|
NCT00336674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INIT II|Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes|A Randomised, Double-blind, Placebo-controlled Trial of Intranasal Insulin (440 IU) in Children and Young Adults at Risk of Type 1 Diabetes: Intranasal Insulin Trial II|INITII|Melbourne Health|Yes|Active, not recruiting|December 2006|December 2024|Anticipated|August 2024|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|110|||Both|4 Years|30 Years|No|||May 2015|May 11, 2015|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336674||181689|
NCT00345098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTE5376|A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder|A Double-Blind, Multi-Center, Multinational, Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A (350mg q12) Versus Placebo in the Prevention of Depression Relapse up to 1 Year in Patients With Major Depressive Disorder Improved After 12 Weeks of Open Treatment With SR58611A (350mg q12)|CALYPSO|Sanofi||Completed|May 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|704|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|June 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345098||181076|
NCT00337610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-053|Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy||Merck Sharp & Dohme Corp.||Completed|June 2006|August 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|78 Years|No|||February 2016|February 4, 2016|June 14, 2006|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00337610||181622|
NCT00338221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-039|Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition|Prospective Double Blinded Randomized Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition||University of Virginia|No|Withdrawn|August 2004|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|3 Months|36 Months|No|||October 2008|October 27, 2008|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338221||181578|
NCT00338208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vanderbilt IRB #030642|Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot|Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot|PAVE|Vanderbilt University|No|Completed|October 2003|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 19, 2015|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338208||181579|
NCT00338728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0384|Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients|Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2003|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|N/A|N/A|No|||October 2015|October 22, 2015|June 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338728||181539|
NCT00338702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1_James L Mahoney|A Randomized, Controlled Trial of Autologous Platelet Gel Treatment in Diabetic Foot Ulcers|||St. Michael's Hospital, Toronto|No|Withdrawn|March 2008|October 2009|Anticipated|October 2009||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|June 16, 2006||No|Industry support and funding not forthcoming|No||https://clinicaltrials.gov/show/NCT00338702||181541|
NCT00338715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-035|Effectiveness of Pulmonary Vein Isolation in Prevention of Atrial Fibrillation Following Heart Bypass Surgery|A Randomized Controlled Trial of Prophylactic Pulmonary Vein Isolation as Adjunct to Coronary Artery Bypass Grafting||Lawson Health Research Institute|No|Completed|July 2006|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|193|||Both|18 Years|85 Years|No|||February 2011|February 7, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00338715||181540|
NCT00337909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUT-107-2005|Computer-Based Training for Cognitive Enhancement: Classroom Study|Computer-Based Training for Cognitive Enhancement: Classroom Study||Posit Science Corporation|No|Completed|September 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|94|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00337909||181601|
NCT00339885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995030|Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus|Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus||National Institutes of Health Clinical Center (CC)||Recruiting|March 1995|||||N/A|Observational|N/A|||Anticipated|60000|||Both|12 Months|N/A|Accepts Healthy Volunteers|||September 2015|October 27, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339885||181452|
NCT00340171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997068|Fetal Growth Evaluation by Three-Dimensional Ultrasound|Fetal Growth Evaluation by Three-Dimensional Ultrasound||National Institutes of Health Clinical Center (CC)||Completed|November 1997|||||N/A|Observational|N/A|||Anticipated|4518|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|November 11, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340171||181433|
NCT00298623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110963|XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.||XenoPort, Inc.|Yes|Completed|March 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||May 2011|May 10, 2013|February 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298623||184539|
NCT00298051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02817-8|Umbilical Cord Clamping and Infant Iron Status|Umbilical Cord Clamping and Infant Iron Status||University of California, Davis||Completed|October 2003|February 2005|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|476|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2013|September 26, 2013|February 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00298051||184583|
NCT00296842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICARTA-1|Prevention of Posttraumatic Stress Symptoms and Behavioral Problems in Children After Road Traffic Accidents: a Randomized Controlled Trial|Prevention of Posttraumatic Stress Symptoms and Behavioral Problems in Children and Adolescents After Road Traffic Accidents: a Randomized Controlled Trial||University Children's Hospital, Zurich||Completed|November 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|99|||Both|7 Years|16 Years|No|||December 2011|December 8, 2011|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00296842||184673|
NCT00297102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-124|Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)|Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study||Takeda|No|Completed|February 2006|September 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1523|||Both|40 Years|N/A|No|||June 2011|May 4, 2012|February 27, 2006|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00297102||184654|
NCT00298597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSFEPO_01|Influence of G-CSF and EPO on Associative Learning and Motor Skills|Influence of G-CSF and EPO on Associative Learning and Motor Skills||University Hospital Muenster||Completed|March 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|180|||Both|18 Years|N/A|No|||April 2007|April 22, 2009|March 1, 2006||||No||https://clinicaltrials.gov/show/NCT00298597||184541|
NCT00298610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1168|Safety and Efficacy Study of IV Artesunate to Treat Malaria|A Phase II, Open Label, Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Artesunate in Adults With Uncomplicated Malaria||Walter Reed Army Institute of Research (WRAIR)||Completed|March 2006|||October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||September 2008|September 2, 2008|March 1, 2006||||||https://clinicaltrials.gov/show/NCT00298610||184540|
NCT00340392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906140|Isolation and Characterization of Mammary Stem Cells|Isolation and Characterization of Mammary Stem Cells||National Institutes of Health Clinical Center (CC)||Completed|April 2006|March 2011||||N/A|Observational|N/A|||Anticipated|400|||Both|N/A|N/A|No|||March 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340392||181418|
NCT00340405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999920168|Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China|Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China||National Institutes of Health Clinical Center (CC)||Completed|April 1992|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|11000|||Both|40 Years|100 Years|No|||December 2015|December 24, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340405||181417|
NCT00336102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0502|Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers|Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed With Breast Cancer and the Magnitude of Change in Thyroid Function Post-Chemotherapy||University of South Florida|Yes|Completed|April 2006|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|541|Samples Without DNA|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine      (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in      12 months and again 24 months after enrollment. All thyroid function marker assays will be      performed by LabCorp.|Female|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a pilot study with a planned accrual of 270 patients (cases) and 280 healthy        volunteers (controls). Patients between the ages of 25 and 75, diagnosed with primary,        operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin /        Cytoxan (AC) plus a taxane are trial candidates. Participants will be asked to nominate 2        women to serve as their healthy control. In the event the first woman is not eligible or        decides not to participate, the second woman will be evaluated. Controls will be women        from the same general demographic area, have no prior history of cancer and be within 5        years of the patient's age (+/- 5 years).|July 2015|July 7, 2015|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00336102||181732|
NCT00336414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGG-PRINTO-003|Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis|Five-Year Single-Blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis: Oral Cyclophosphamide Versus High Dose Intravenous Cyclophosphamide Versus Intermediate Dose Intravenous Cyclophosphamide||Istituto Giannina Gaslini||Withdrawn|June 2006|June 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||159|||Both|1 Year|18 Years|No|||June 2007|June 27, 2007|June 12, 2006|||the study is withdrawn due to low and unexpected enrollment rate|No||https://clinicaltrials.gov/show/NCT00336414||181708|
NCT00336934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000480402|Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled Study of The Effects of Pomegranate Extract On Rising Prostate-Specific Antigen Levels In Men Following Primary Therapy||Roll International Corporation|Yes|Completed|November 2005|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Male|18 Years|N/A|No|||August 2011|August 8, 2011|June 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336934||181670|
NCT00336687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0013|Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation.|Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation.||University Hospital, Clermont-Ferrand||Completed|July 2005|November 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|322|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of Reanimation|March 2010|March 26, 2010|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00336687||181688|
NCT00337623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0011|Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.|Corticosteroids and Cataracts : Prospective Study of the Impact of Systemic Corticosteroid Therapy on Lens Transparency Evaluated by Scheimpflug Photography and Quantification of Lens Autofluorescence.||University Hospital, Clermont-Ferrand||Completed|June 2000|July 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2006|June 22, 2006|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00337623||181621|
NCT00337883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI2691g|A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)|A Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)||Genentech, Inc.||Completed|July 2003|October 2005|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|June 15, 2006||||||https://clinicaltrials.gov/show/NCT00337883||181603|
NCT00338741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23888|Rebif® Pregnancy Registry|Rebif® Pregnancy Registry||EMD Serono||Completed|December 2002|February 2008|Actual|October 2007|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant MS patients|August 2011|August 2, 2013|June 16, 2006|No|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00338741||181538|Despite a consistent and exhaustive expenditure of resources over 5 years only 36 subjects were enrolled into the Registry, a number which precludes meaningful statistical analysis of the potential risks of Rebif® during pregnancy.
NCT00338754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-688|Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 2/3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Adalimumab in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis||Abbott||Completed|November 2005|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|20 Years|N/A|No|||September 2007|September 10, 2007|June 18, 2006||||No||https://clinicaltrials.gov/show/NCT00338754||181537|
NCT00338468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004606|A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)|An Open-Label Pilot Study to Assess Disability in Anemic Elderly Patients With Chronic Kidney Disease Receiving PROCRIT (Epoetin Alfa)||Ortho Biotech Products, L.P.|No|Terminated|November 2003|September 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|65 Years|N/A|No|||March 2010|May 17, 2011|June 16, 2006|||The study was stopped early due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT00338468||181559|
NCT00336180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017491|Adolescent Drug and HIV Prevention in South Africa|Adolescent Drug and HIV Prevention in South Africa||Penn State University|Yes|Completed|September 2003|April 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|7695|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2013|March 19, 2013|June 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00336180||181726|
NCT00339066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2524|Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression|Treatment Outcomes of Vascular Depression||Duke University||Completed|August 2001|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|131|||Both|60 Years|N/A|No|||February 2008|August 7, 2013|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00339066||181513|
NCT00338507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERD-CB-01-2005|Phase 2 Study - Erdosteine in Patients With CB/COPD|A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Dose_Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated With Chronic Obstructive Pulmonary Disease||Adams Respiratory Therapeutics||Completed|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|40 Years|N/A|No|||December 2007|December 5, 2007|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00338507||181556|
NCT00338520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14617|Hyperphenylalaninemia in Cerebral Malaria|Hyperphenylalaninemia in Cerebral Malaria||University of Utah|No|Completed|October 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|285|Samples With DNA|urine, CSF, blood|Both|6 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|The study is a prospective cohort study involving Tanzanian children 6 months to 6 years        old admitted with UM and CM as defined by World Health Organization (WHO) criteria        (Section 5.2). Healthy children who are not acutley ill (healthy control, HC) and children        with coma and/or CNS illnesses not attributed to malaria (NMC) will serve as controls.        Children will be recruited from 2 hospitals in Dar es Salaam (AHID,MDH).|October 2012|October 19, 2012|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338520||181555|
NCT00338767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063011|Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy|Depression Treatment to Improve Antiretroviral Adherence||Massachusetts General Hospital|No|Completed|January 2001|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338767||181536|
NCT00336193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-4537|Competency Training, Staff Performance, & Family Outcomes|University of Colorado Health Sciences Center: Competency Training, Staff Performance, & Family Outcomes||Centers for Disease Control and Prevention|No|Completed|August 2005|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Anticipated|1075|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2011|February 10, 2011|June 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00336193||181725|
NCT00336206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39338|Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia|Subcutaneous Injection, Low Dose Alemtuzumab for Consolidation and Maintenance of Patients in Clinical Response After Having Achieved Partial or Complete Remission After 1st or 2nd Line Anti-Tumor Therapy for B-Cell CLL||Tawam Hospital||Not yet recruiting|July 2006|October 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|75 Years|No|||June 2006|July 21, 2006|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336206||181724|
NCT00298935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-102|Study of the Effectiveness of Osteopathic Manipulative Treatment in Pregnant Women|Pilot Clinical Trial of Osteopathic Manipulative Treatment (OMT) in Pregnancy||University of North Texas Health Science Center||Completed|July 2003|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||146|||Female|18 Years|N/A|No|||June 2013|June 21, 2013|March 2, 2006||||No||https://clinicaltrials.gov/show/NCT00298935||184515|
NCT00299182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0146|Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma|Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX||M.D. Anderson Cancer Center|No|Completed|March 2006|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|50|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|March 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299182||184498|
NCT00298922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ 0003|Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex|Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Azithromycin in Patients With CF, Chronically Infected With Burkholderia Cepacia Complex||St. Michael's Hospital, Toronto|Yes|Active, not recruiting|February 2006|October 2009|Anticipated|February 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|19 Years|N/A|No|||July 2009|July 30, 2009|March 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00298922||184516|
NCT00299195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-099|A Randomized Study of Sulindac in Oral Premalignant Lesions|A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2006|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|March 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00299195||184497|
NCT00297674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA-GREC-2004-01|Intravenous Clarithromycin in Septic Syndrome|Clarithromycin as Immunomodulatory Therapy for the Management of Septic Syndrome by Ventilator-Associated Pneumonia||University of Athens||Completed|June 2004|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||July 2004|February 27, 2006|February 27, 2006||||No||https://clinicaltrials.gov/show/NCT00297674||184611|
NCT00297687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-500|Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults|A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||108|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|February 24, 2006||||No||https://clinicaltrials.gov/show/NCT00297687||184610|
NCT00295048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24292|Cognitive Remediation for Schizophrenia|Cognitive Remediation for Schizophrenia||University of Maryland|No|Completed|November 2004|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||May 2007|June 26, 2007|February 19, 2006||||No||https://clinicaltrials.gov/show/NCT00295048||184808|
NCT00336427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORMC-MRSA-Pregnancy|MRSA Colonization in Peripartum Women and Their Offspring|A Prospective Study of MRSA Colonization in Peripartum Women and Their Offspring||Orlando Regional Medical Center||Completed|September 2005|May 2006||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||600|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2006|June 9, 2006|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00336427||181707|
NCT00336141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-05-3|Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer|Phase I/II Clinical Trial With Vorinostat and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU-Based Chemotherapy||University of Southern California||Completed|June 2006|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|June 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336141||181729|
NCT00336713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5576|A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)|A Multicenter, 24-52-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder||Sanofi||Completed|May 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|430|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|June 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336713||181686|
NCT00336960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0173|Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery|Phase II Pilot Study of Pre-Operative Celecoxib (Celebrex) in Combination With Prolonged Venous Infusion 5FU and Radiation Therapy for Patients With Stage II/III Resectable Rectal Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|July 2002|March 2008|Actual|November 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2013|March 2, 2013|June 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336960||181668|
NCT00336700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-016|A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer|A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer||University of Pittsburgh|Yes|Terminated|June 2006|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|June 12, 2006|Yes|Yes|Study published November 2010 and no further work will be done|No||https://clinicaltrials.gov/show/NCT00336700||181687|
NCT00337948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004615|An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks|An Open-Labeled Pilot Study to Evaluate the Effects of High Dose PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a Weekly or Every Four Week Regimen||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2003|February 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|129|||Both|19 Years|N/A|No|||January 2011|June 8, 2011|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00337948||181598|
NCT00337961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990379|Optic Nerve Sheath Fenestration|Optic Nerve Sheath Fenestration||Vanderbilt University|No|Completed|July 2000|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2013|January 6, 2013|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00337961||181597|
NCT00339898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904135|Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma|Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma||National Institutes of Health Clinical Center (CC)||Completed|March 2004|January 2015||||N/A|Observational|N/A|||Anticipated|500|||Both|2 Years|30 Years|No|||January 2015|October 2, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339898||181451|
NCT00336765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL647-002|Study of XL647 Administered Orally Daily to Patients With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors||Kadmon Corporation, LLC|Yes|Completed|July 2006|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|June 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336765||181682|
NCT00337350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000014|Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment|A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis||Massachusetts General Hospital||Completed|September 2003|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|65 Years|No|||April 2015|April 15, 2015|June 13, 2006||No||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00337350||181641|Our findings in this study were limited by the small sample size. It is possible that with a larger sample, significant improvements might be observed not only in glucose metabolism but also in lipid metabolism.
NCT00337051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9413-04|Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN)|Sevoflurane-induced Prevention of Ischemia-reperfusion Lesions in Renal Allograft Transplants Recipients|SévoRein|University Hospital, Bordeaux|Yes|Completed|June 2006|June 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337051||181663|
NCT00337064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC0601|Partial Breast Radiation to the Lumpectomy Cavity With IMRT in Elderly Women|Phase I/II Trial to Evaluate Partial Breast Radiation to the Region of the Lumpectomy Cavity Using Intensity Modulated Radiation in Elderly Women With Breast Cancer||University of Vermont||Recruiting|June 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Female|65 Years|N/A|No|||May 2006|June 13, 2006|June 13, 2006||||No||https://clinicaltrials.gov/show/NCT00337064||181662|
NCT00339105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4114-SM-CTIL|The Usefulness of HyperQ Recordings for the Early Diagnosis of Acute Coronary Syndrome in Patients Presenting With Chest Pain|The Usefulness of HyperQ Recordings for the Early Diagnosis of Acute Coronary Syndrome in Patients Presenting With Chest Pain||Sheba Medical Center||Recruiting|June 2006|January 2007||||Phase 3|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||50|||Both|18 Years|N/A|No|||January 2007|January 14, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339105||181510|
NCT00339118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4013-IK-CTIL|EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children|||Sheba Medical Center||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|6 Months|21 Years|No|||June 2006|June 19, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339118||181509|
NCT00339404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999012|Genetic Analysis of Familial Melanoma|Genetic Analysis of Familial Melanoma||National Institutes of Health Clinical Center (CC)||Completed|March 1999|March 2011||||N/A|Observational|N/A|||Anticipated|3000|||Both|N/A|N/A|No|||March 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339404||181487|
NCT00295061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11816|Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults|Multi-center, Randomized, Double-blind, Crossover Trial to Evaluate the Pharmacokinetic Comparability of Alpha-1 MP to Prolastin in Subjects With Alpha1-antitrypsin Deficiency.|ChAMP|Grifols Therapeutics Inc.|No|Completed|May 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|February 20, 2006|No|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00295061||184807|
NCT00298363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0108|Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.|A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation||Gilead Sciences|Yes|Completed|April 2006|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|112|||Both|18 Years|69 Years|No|||April 2013|April 19, 2013|February 28, 2006|Yes|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00298363||184559|
NCT00295594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-01-27|Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.|An Open, Randomised, Multicenter, Clinical Study to Compare the Safety and Efficacy of Tacrolimus and Minimal Steroids in Combination With Either a Monoclonal Anti-IL2R Antibody (Daclizumab) or Mycophenolate Mofetil in Liver Allograft Transplantation.|MARSILEA|Astellas Pharma Inc|Yes|Completed|March 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|627|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|February 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00295594||184768|
NCT00336154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2140CTIL|Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa|Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa||Rambam Health Care Campus||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|13 Years|60 Years|No|||June 2006|June 12, 2006|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336154||181728|
NCT00336453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC02|Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics|Evaluation of the Safety, Reactogenicity and Immunogenicity of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly to Healthy Children Aged 6 To 59 Months||Protein Sciences Corporation|Yes|Completed|October 2006|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|156|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||December 2009|December 16, 2009|June 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336453||181706|
NCT00336726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-735|Neuroendocrine Dysfunction in Traumatic Brain Injury: Correlation With Cognitive Dysfunction and Repair|||Denver Research Institute||Terminated||||||N/A|Observational|Time Perspective: Prospective||1|||||Male|21 Years|65 Years|No|Probability Sample|Male subjects having had a recent traumatic brain injury|December 2004|March 23, 2011|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00336726||181685|
NCT00336739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2455|The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects|||Tufts University|No|Completed|April 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|2||Actual|17|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||June 2007|July 20, 2007|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336739||181684|
NCT00336973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD3780g|A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent|A Phase IV Open-Label Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Raptiva (Efalizumab) in Adult Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent||Genentech, Inc.||Completed|May 2006|||February 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||April 2009|July 1, 2015|June 13, 2006|Yes|Yes||No|April 15, 2009|https://clinicaltrials.gov/show/NCT00336973||181667|
NCT00337298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jmehl01|The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes|Lack of Effect of Antihypertensive Treatment With Amlodipine and Lisinopril on Retinal Autoregulation in Patients With Type 1 Diabetes and Mild Diabetic Retinopathy. A Prospective Randomized Clinical Trial.||University of Aarhus|No|Completed|July 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|25|||Both|18 Years|35 Years|No|||June 2009|June 22, 2009|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337298||181644|
NCT00338481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-060-version1a|"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer|"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study||Sankt Lukas Hospice|Yes|Completed|April 2006|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2011|July 26, 2011|June 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338481||181558|
NCT00338494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506000158|Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma|Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermed.Grade B-Cell/T-Cell Lymphoma||Yale University|No|Completed|October 2005|April 2011|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|June 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00338494||181557|
NCT00339638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905068|Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1|Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study||National Institutes of Health Clinical Center (CC)||Completed|December 2004|May 2011||||N/A|Observational|N/A|||Anticipated|228|||Both|N/A|N/A|No|||May 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339638||181469|
NCT00335868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000486219|PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy|A Pilot Phase II Study of PHA-739358 in Patients With Chronic Myeloid Leukemia Relapsing on Gleevec or c-ABL Therapy||National Cancer Institute (NCI)||Active, not recruiting|March 2007|||December 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||July 2009|December 17, 2013|June 8, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00335868||181749|
NCT00335881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106745|Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib|Multicentre Study to Assess Persistence of Antibodies Against Hepatitis B & Immune Response to a Hepatitis B Challenge Dose in Healthy Children 4 to 6 Yrs Old Previously Vaccinated With 4 Doses of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine||GlaxoSmithKline||Completed|June 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||April 2012|November 21, 2012|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00335881||181748|
NCT00337376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511000860|A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers|A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Solid Cancers||Yale University|No|Terminated|February 2006|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|June 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00337376||181640|
NCT00337389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510-05|Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.|A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma||Mast Therapeutics, Inc.||Active, not recruiting|May 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||November 2007|November 15, 2007|June 14, 2006||||No||https://clinicaltrials.gov/show/NCT00337389||181639|
NCT00337649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO17328|A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer.|An Open -Label Study to Evaluate the Effect of Combination Therapy With Epothilone D and Herceptin on Tumor Response in Patients With HER-2 Overexpressing Locally Advanced or Metastatic Breast Cancer.||Hoffmann-La Roche||Completed|May 2004|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|June 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00337649||181619|
NCT00338260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-133|Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)|A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy||Merck Sharp & Dohme Corp.||Completed|June 1995|November 2001|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|496|||Both|55 Years|80 Years|No|||July 2015|July 29, 2015|June 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338260||181575|
NCT00346593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03 010|Investigation of the Clinical Performance of Silicone Hydrogel Contact Lenses During Continuous Wear|||University of Melbourne||Completed|May 2004|December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|45 Years||||February 2007|February 8, 2007|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346593||180965|
NCT00346606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187CL1|The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria|A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Desloratadine 5mg (Denosin®) With Levocetirizine 5mg (Xyzal®) in the Treatment of Chronic Idiopathic Urticaria Patients||Lotus Pharmaceutical||Recruiting|January 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|12 Years|N/A|No|||May 2006|June 29, 2006|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346606||180964|
NCT00339911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999046|Collection and Distribution of Blood Samples From Healthy Donors for In Vitro Research at the NCI Frederick Cancer Research and Development Center|Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick||National Institutes of Health Clinical Center (CC)||Recruiting|October 1999|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339911||181450|
NCT00346879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602-26|Study to Determine Effective Dosing of Fondaparinux in Obese Persons|Thromboprophylaxis in the Morbidly Obese With Weight Based Dosing of Fondaparinux: A Pharmacodynamic Study||Indiana University|Yes|Withdrawn|August 2006|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 28, 2006|Yes|Yes|Funding withdrawn; study closed due to lack of accrual.|No||https://clinicaltrials.gov/show/NCT00346879||180943|
NCT00346892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/014|To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV|Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa||GlaxoSmithKline||Completed|November 2001|||March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||450|||Both|5 Weeks|10 Weeks|Accepts Healthy Volunteers|||October 2015|October 29, 2015|February 3, 2006||||No||https://clinicaltrials.gov/show/NCT00346892||180942|
NCT00346905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Number: 320 - 1001|Endoscopic Implantation of Enteryx for the Treatment of GERD|Endoscopic Implantation of Enteryx for the Treatment of Gastroesophageal Reflux Disease (GERD): Post Market Study||Beth Israel Deaconess Medical Center||Active, not recruiting|October 2003|February 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|N/A|N/A|No|||June 2006|March 19, 2008|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346905||180941|
NCT00330694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-04-357|Efficiency of Physiotherapeutic Care in Parkinson's Disease|Efficiency of Physiotherapeutic Care in Parkinson's Disease||Radboud University|No|Completed|May 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|708|||Both|20 Years|80 Years|No|||September 2008|September 1, 2008|May 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00330694||182128|
NCT00330707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/0085/1995|Combined Use of BCG and Interferon Alpha in Bladder Cancer|A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer||National University Hospital, Singapore||Completed|October 1995|June 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||March 2011|March 2, 2011|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00330707||182127|
NCT00330954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 05-087E|Gene Expression Profiling in Type 1 Diabetes|Gene Expression Profiling in Type 1 Diabetes||Children's Mercy Hospital Kansas City|No|Completed|June 2006|April 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|64|Samples With DNA|Whole Blood saved frozen for 1 year|Both|7 Years|14 Years|No|Non-Probability Sample|Male and female subjects 7-14 years of age          -  New onset T1DM          -  Five years post onset of T1DM|March 2010|March 3, 2010|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00330954||182108|
NCT00299169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-135|Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes|Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes||Lawson Health Research Institute|No|Terminated|September 2006|November 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|80 Years|No|||September 2006|January 4, 2008|March 2, 2006|||insufficient recruitment/enrollment|No||https://clinicaltrials.gov/show/NCT00299169||184499|
NCT00337636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N001-05|Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)|A Phase I Study of the Safety and Preliminary Effectiveness of Human CNS Stem Cells (HuCNS-SC) in Patients With Neuronal Ceroid Lipofuscinosis Caused by Palmitoyl Protein Thioesterase 1 (PPT1) or Tripeptidyl Peptidase 1 (TPP-I) Deficiency||StemCells, Inc.|Yes|Completed|May 2006|September 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Months|12 Years|No|||January 2015|January 13, 2015|June 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00337636||181620|
NCT00339131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-IB11|ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid|Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid||Molecular Insight Pharmaceuticals, Inc.|No|Completed|June 2006|January 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|24|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|June 17, 2006||||No||https://clinicaltrials.gov/show/NCT00339131||181508|
NCT00339144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-058|Study of Dasatinib (BMS-354825) in Patients With Solid Tumors|A Phase I Study of BMS-354825 in Patients With Solid Tumors||Bristol-Myers Squibb|Yes|Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|20 Years|N/A|No|||November 2010|November 19, 2010|June 19, 2006|No|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00339144||181507|
NCT00340184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG1001|A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients|A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel/Carboplatin Chemotherapy in High-risk Cervical Cancer Patients After Radical Hysterectomy||Korean Gynecologic Oncology Group||Completed|August 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||55|||Female|20 Years|75 Years||||January 2006|October 17, 2010|June 20, 2006||||No||https://clinicaltrials.gov/show/NCT00340184||181432|
NCT00340210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999002|Extended Follow-up of Columbia, MO Serum Bank Participants|Extended Follow-up of Columbia, MO Serum Bank Participants||National Institutes of Health Clinical Center (CC)||Completed|December 1998|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|6720|||Female|18 Years|N/A|No|||August 2015|September 16, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340210||181431|
NCT00336986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN028-1614|Efficacy Study of IL-21 to Treat Metastatic Melanoma|An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma||Novo Nordisk A/S|No|Completed|September 2004|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00336986||181666|
NCT00337324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LORENZ/01|Electromagnetic Stimulation (FREMS) in Patients With Painful Diabetic Neuropathy|Clinical Assessment of Transcutaneous Neurostimulation and Biofeedback (FREMS)in Patients With Diabetic Neuropathy||IRCCS San Raffaele||Completed|March 2002|May 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||38|||Both|18 Years|70 Years|No|||March 2002|June 14, 2006|June 14, 2006||||No||https://clinicaltrials.gov/show/NCT00337324||181643|
NCT00341211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999996013|Specimens From Normal Controls|Specimens From Normal Controls||National Institutes of Health Clinical Center (CC)||Completed|April 1996|December 2010||||N/A|Observational|N/A|||Actual|27|||Both|18 Years|N/A|No|||December 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341211||181356|
NCT00341939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904279|Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data|Retrospective Analysis of Drug Disposition and Response-related Genotypes in Cancer Patients and Correlation With Pharmacokinetics and Pharmacodynamics Data||National Institutes of Health Clinical Center (CC)||Completed|September 2004|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1587|||Both|18 Years|100 Years|No|||November 2015|November 11, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341939||181301|
NCT00342225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903073|Mother-Child Relationships During Pregnancy Among Bofi Foragers|Mother-Child Relationships During Pregnancy Among the Bofi Foragers in the Northern Congo||National Institutes of Health Clinical Center (CC)||Completed|December 2002|December 2006||||N/A|Observational|N/A||||60|||Both|N/A|N/A|No|||December 2006|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342225||181279|
NCT00341705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901170|The Second Multicenter Hemophilia Cohort Study|The Second Multicenter Hemophilia Cohort Study||National Institutes of Health Clinical Center (CC)||Completed|April 2001|April 2013||||N/A|Observational|N/A|||Anticipated|5000|||Both|13 Years|N/A|No|||April 2013|February 19, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341705||181318|
NCT00341718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906130|Experiences of Genetics Patients With Visible Abnormalities Who Facilitate Teaching in Genetics Clinics|The Experiences of Genetics Patients With Visible Differences Who Facilitate Teaching in Genetics Clinics||National Institutes of Health Clinical Center (CC)||Completed|March 2006|March 2007||||N/A|Observational|N/A||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341718||181317|
NCT00341679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905200|Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases|Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases||National Institutes of Health Clinical Center (CC)||Completed|July 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|719|||Both|N/A|N/A|No|||December 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341679||181320|
NCT00343369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455738|Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia|Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Recruiting|January 2003|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|550|||Both|1 Year|18 Years|No|||June 2006|August 23, 2013|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00343369||181202|
NCT00343629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000473167|Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers|Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations||National Cancer Institute (NCI)||Completed|April 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|28|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2006|April 27, 2015|June 22, 2006||||||https://clinicaltrials.gov/show/NCT00343629||181183|
NCT00343642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001628-01A2|Dietary Treatment of Crohn's Disease|Dietary Treatment of Crohn's Disease||Rush University Medical Center|Yes|Completed|September 2006|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|73|||Both|18 Years|80 Years|No|||January 2014|January 24, 2014|June 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00343642||181182|
NCT00343655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581152|Evaluation of Atorvastatin Treatment on Carotid Plaque.|A Randomized Clinical Trial Of Atorvastatin 10 Mg And 80 Mg In The Reversal Of Or Stabilization Of Carotid Atheroma Lipid Pool||Pfizer||Terminated|January 2007|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 20, 2006|||The study was terminated on June 22, 2007 for inability to enroll patients within an    appropriate timeframe. There were no efficacy/safety concerns.|No||https://clinicaltrials.gov/show/NCT00343655||181181|
NCT00346918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1246|Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study.||University of Zurich|Yes|Completed|June 2006|June 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|40 Years|No|||February 2014|February 26, 2014|June 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346918||180940|
NCT00347178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R358/16/2004|Asymptomatic Narrow Angles - Laser Iridotomy Study; Multicentric RCT|Prophylactic Laser Iridotomy for Eyes With Narrow Drainage Angles; A Randomised Controlled Trial||Singapore National Eye Centre||Recruiting|January 2005|January 2013||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||544|||Both|50 Years|N/A|No|||June 2006|June 30, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347178||180920|
NCT00348114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R260/05/2002|Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency|Transplantation of Ex-Vivo Expanded Human Limbal Epithelial Stem Cells (LSC) on Amniotic Membrane (AM) for Limbal Stem Cell Deficiency (LSCD).||Singapore National Eye Centre||Suspended|May 2002|May 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|N/A|N/A|No|||January 2002|July 3, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348114||180849|
NCT00348127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R313/06/2003|A Singapore Pilot Study to Assess Neurovision in Treatment of Low Myopia|A Singapore Pilot Study To Evaluate The Efficacy Of A Computerized System For The Vision Improvement Of People With Low Myopia||Singapore National Eye Centre||Completed|March 2003|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|15 Years|55 Years|No|||January 2010|June 23, 2010|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348127||180848|
NCT00339794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905055|Clinical Integration of Genetic Risk Assessment in Family Medicine|Clinical Integration of Genetic Risk Assessment in Family Medicine||National Institutes of Health Clinical Center (CC)||Completed|December 2004|July 2010||||N/A|Observational|N/A|||Anticipated|1500|||Both|21 Years|N/A|No|||July 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339794||181458|
NCT00344201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R389/47/2004|Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery|Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction||Singapore National Eye Centre|Yes|Completed|November 2004|January 2008|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 11, 2010|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344201||181143|
NCT00340678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995037|Renoprotection in Early Diabetic Nephropathy in Pima Indians|Renoprotection in Early Diabetic Nephropathy in Pima Indians||National Institutes of Health Clinical Center (CC)|Yes|Completed|August 1995|March 2014|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|170|||Both|18 Years|65 Years|No|||October 2013|July 16, 2014|June 19, 2006|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00340678||181396|
NCT00340691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905053|Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis|Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline||National Institutes of Health Clinical Center (CC)||Completed|December 2004|||October 2007|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1|||1500|||Both|14 Years|65 Years|Accepts Healthy Volunteers|||November 2008|June 1, 2012|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340691||181395|
NCT00341991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902035|Molecular Epidemiology of Cutaneous Malignant Melanoma|Molecular Epidemiology of Cutaneous Malignant Melanoma||National Institutes of Health Clinical Center (CC)||Completed|October 2001|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|17500|||Both|18 Years|100 Years|No|||May 2015|October 2, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341991||181297|
NCT00342004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998006|A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women|A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|76000|||Female|40 Years|70 Years|No|||March 2016|March 22, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342004||181296|
NCT00341445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904265|Cockroach Allergen Reduction by Extermination Alone in Low-Income, Urban Homes: A Randomized Control Trial|Cockroach Allergen Reduction by Extermination Alone in Low-Income, Urban Homes-A Randomized Control Trial||National Institutes of Health Clinical Center (CC)||Completed|August 2004|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|21 Years|N/A|No|||September 2013|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341445||181338|
NCT00341731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901047|Environmental Factors in the Development of Polycystic Ovary Syndrome|Environmental Factors in the Development of Polycystic Ovary Syndrome||National Institutes of Health Clinical Center (CC)||Completed|December 2000|||||N/A|Observational|N/A|||||||Female|18 Years|N/A|No|||October 2008|November 25, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341731||181316|
NCT00341432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905227|Effectiveness of Nicotine Replacement Therapy in Reducing the Risk of Nicotine Exposure in Pregnant Minority Smokers|Nicotine Replacement Therapy Methods for Pregnant Women||National Institutes of Health Clinical Center (CC)||Completed|August 2005|April 2011|Actual|||Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|300|||Female|21 Years|N/A|Accepts Healthy Volunteers|||April 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341432||181339|
NCT00343408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I175|AZD2171 and Standard Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer or Colorectal Cancer|A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer||Canadian Cancer Trials Group||Completed|August 2005|September 2008|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2010|November 7, 2010|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00343408||181199|
NCT00342433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999025|Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study|Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study||National Institutes of Health Clinical Center (CC)||Completed|April 1999|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|850|||Male|18 Years|100 Years|No|||December 2015|December 19, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342433||181265|
NCT00342732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999019|The Food Intake Phenotype: Assessing Eating Behavior and Food Preferences as Risk Factors for Obesity|The Food Intake Phenotype: Assessing Eating Behavior and Food Preferences as Risk Factors for Obesity||National Institutes of Health Clinical Center (CC)||Recruiting|April 1999|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|600|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342732||181246|
NCT00342758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902005|Early Life Factors and Respiratory Health in Mexico City Children|Early Life Factors and Respiratory Health in Mexico City Children||National Institutes of Health Clinical Center (CC)||Completed|October 2001|October 2007||||N/A|Observational|N/A||||6800|||Both|N/A|N/A|No|||October 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342758||181245|
NCT00342771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905021|An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males|A Case-Control Study of Prostate Cancer in the Greater Baltimore Area: An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males||National Institutes of Health Clinical Center (CC)||Recruiting|October 2004|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|2000|||Male|40 Years|90 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342771||181244|
NCT00343031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901177|Effect of the Antiandrogen DDE on Anthropometric Measures at Birth|Effect of the Antiandrogen DDE on Anthropometric Measures at Birth||National Institutes of Health Clinical Center (CC)||Completed|May 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2300|||Both|N/A|20 Years|No|||December 2015|December 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00343031||181227|
NCT00343057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXP0001A_9001|DISCO - Influence of a Simple Information Booklet on the Evolution of Acute Low Back Pain (LBP)|Influence of a Simple Information Booklet on the Evolution of Acute Low Back Pain (LBP): a Quasi-experimental Study in a Primary Care Setting.||Sanofi||Completed|September 2003|June 2004|Actual|||N/A|Observational|N/A||2|Actual|2830|||Both|18 Years|N/A|No|Probability Sample|Subjects presenting with acute common low back pain.|September 2009|September 3, 2009|June 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00343057||181225|
NCT00343070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/176|Functional Neuroimaging in Depression|Functional Neuroimaging in Depression: Longitudinal Study of PET Metabolism in Correlation With Changes in Attentional Bias, Autobiographical Memory, Future Fluency and Facial Recognition in Depressed Patients Treated With Escitalopram.||University Hospital, Ghent|No|Completed|March 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||August 2010|August 30, 2010|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00343070||181224|
NCT00343382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N04CA|Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer|Pilocarpine for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study||Alliance for Clinical Trials in Oncology|Yes|Completed|December 2006|December 2012|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|201|||Female|18 Years|N/A|No|||September 2014|September 24, 2014|June 22, 2006|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT00343382||181201|
NCT00343668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-ST05-02|S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer|A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy||Korean Cancer Study Group|No|Recruiting|September 2005|July 2008|Anticipated|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|70 Years|No|||June 2006|May 25, 2010|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00343668||181180|
NCT00346944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK III 24.01|Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam|Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam - A Study of Patients Examined at the Dental Biomaterials Adverse Reaction Unit in 1993 to 1999||University of Bergen|Yes|Completed|September 2002|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|25 Years|55 Years|No|||August 2012|August 27, 2012|June 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346944||180938|
NCT00347477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12080|Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest|Fluid Shift in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest, and How do They Manage Life Afterwards?||Haukeland University Hospital||Completed|September 2005|March 2009||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|23|||Both|18 Years|80 Years|No|||March 2009|April 30, 2009|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347477||180897|
NCT00347490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXA_L_00821|HENOX: Enoxaparine in Hemodialysis|Efficacy and Safety in Hemodialysis With Enoxaparine||Sanofi||Completed|May 2006|June 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|70 Years|No|||January 2008|January 22, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347490||180896|
NCT00347854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-06|Fluorophotometry Evaluation of Lubricant Eye Drops|Fluorophotometry Evaluation of Lubricant Eye Drops FID 105783||Alcon Research|No|Completed|April 2006|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 1, 2012|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347854||180869|
NCT00348153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2006-001732-53|Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)|Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients With Different Forms of Refractory Uveitis Acronym: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)||Heidelberg University||Active, not recruiting|August 2006|March 2013|Anticipated|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|July 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00348153||180846|
NCT00344214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061146|STD Risk Reduction for Heterosexual Methamphetamine Users|Reducing HIV/STD Risk, Methamphetamine Use, and Depression Among Heterosexuals||University of California, San Diego||Completed|October 2006|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|432|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344214||181142|
NCT00340418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905182|Mechanisms of Lung Allograft Rejection|Mechanisms of Lung Allograft Rejection||National Institutes of Health Clinical Center (CC)||Completed|June 2005|April 2007||||N/A|Observational|N/A||||120|||Both|18 Years|80 Years|No|||April 2007|March 5, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340418||181416|
NCT00340704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.66|PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder|An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges.||Boehringer Ingelheim|No|Completed|April 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|143|||Both|2 Years|16 Years|No|||January 2016|January 20, 2016|June 19, 2006|No|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT00340704||181394|In Group D-527.51 Rollover study, due to the early termination caution should be used in interpreting these results due to the impact of the early termination, as well as the impact of the study design on interpretation of results by dose.
NCT00342017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901261|The Effect of Parasitic Worm Infections on the Immune Response to Tuberculosis Bacteria|Immunological Consequences of Helminth and Mycobacterial Coinfection||National Institutes of Health Clinical Center (CC)||Completed|May 2002|||September 2008|Actual|N/A|Observational|N/A||||5200|||Both|6 Years|65 Years|No|||August 2009|September 5, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342017||181295|
NCT00342030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903044|Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans|Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans||National Institutes of Health Clinical Center (CC)||Completed|November 2002|April 2012||||N/A|Observational|N/A|||Anticipated|63257|||Both|45 Years|74 Years|No|||April 2012|April 13, 2012|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342030||181294|
NCT00340990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904009|Immune Responses to Mycobacterium Tuberculosis|Pilot Study of CD4+ T Cell Immune Responses to Mycobacterium Tuberculosis||National Institutes of Health Clinical Center (CC)||Completed|October 2003|November 2015||||N/A|Observational|N/A|||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 28, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340990||181373|
NCT00341003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905210|Severe Malaria and Anti-malarial Drug Resistance in Cambodia|Multidisciplinary Studies of Severe Malaria and Antimalarial Drug Resistance in Cambodia||National Institutes of Health Clinical Center (CC)||Completed|July 2005|January 2011||||N/A|Observational|N/A|||Anticipated|2090|||Both|N/A|N/A|No|||January 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341003||181372|
NCT00341016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999996030|Scientific Protocol for the Study of Leukemia and Other Hematologic Diseases Among Clean-up Workers in Ukraine Following the Chernobyl Accident|Scientific Protocol for the Study of Leukemia and Other Hematologic Diseases Among Clean-up Workers in Ukraine Following the Chernobyl Accident||National Institutes of Health Clinical Center (CC)||Recruiting|July 1996|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|4000|||Both|18 Years|70 Years|No|||February 2016|March 4, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341016||181371|
NCT00342537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904076|Genetics of Familial Testicular Cancer|Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Studies of Familial Testicular Germ Cell Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 2003|||||N/A|Observational|N/A|||Anticipated|2600|||Male|4 Years|100 Years|No|||August 2015|October 2, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342537||181258|
NCT00342823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904024|Immunogenetics of Visceral Leishmaniasis|Immunogenetics of Visceral Leishmaniasis||National Institutes of Health Clinical Center (CC)||Completed|October 2003|June 2010||||N/A|Observational|N/A|||Anticipated|7000|||Both|1 Year|N/A|Accepts Healthy Volunteers|||June 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342823||181240|
NCT00341744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7633|Providing Access to the Visual Environment|Providing Access to the Visual Environment||Vanderbilt University|No|Recruiting|July 2001|December 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|795|||Both|3 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children age 3 to 21 years of age, enrolled in a TN school, with visual impairment|December 2015|December 8, 2015|June 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00341744||181315|
NCT00341757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900214|Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)|Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)||National Institutes of Health Clinical Center (CC)||Completed|September 2000|July 2011||||N/A|Observational|N/A|||Anticipated|5190|||Both|18 Years|N/A|No|||July 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341757||181314|
NCT00343759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803893|Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy|||University of Pennsylvania||Withdrawn|June 2006|December 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|June 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00343759||181174|
NCT00343785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2054.00|Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant|Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation From HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Trial||Fred Hutchinson Cancer Research Center|Yes|Completed|February 2006|||May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|65 Years|No|||September 2012|September 18, 2012|June 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00343785||181173|
NCT00341952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998022|Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma|Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|January 1998|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|2400|||Both|20 Years|74 Years|No|||January 2016|January 29, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341952||181300|
NCT00341965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999006|Pesticide Exposure and Health Status in North Carolina African American Male Farmers and Farm Workers|Pesticide Exposure and Health Status in NC African American Male Farmers and Farm Workers||National Institutes of Health Clinical Center (CC)||Completed|January 1999|November 2013||||N/A|Observational|N/A|||Anticipated|389|||Male|18 Years|N/A|No|||November 2013|January 27, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341965||181299|
NCT00342251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903235|Investigating Age-Related Macular Degeneration|Age-Related Macular Degeneration: A Genetic Epidemiology Study in the Amish||National Institutes of Health Clinical Center (CC)||Completed|June 2003|April 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3000|||Both|50 Years|N/A|No|||April 2012|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342251||181278|
NCT00342485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999993010|In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients|In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients||National Institutes of Health Clinical Center (CC)||Completed|April 1993|March 2008||||N/A|Observational|N/A||||5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342485||181262|
NCT00342498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999994012|Estrogen Receptor Gene Mutations|Estrogen Receptor Gene Mutations||National Institutes of Health Clinical Center (CC)||Completed|January 1994|June 2008||||N/A|Observational|N/A||||0|||Both|18 Years|N/A|No|||June 2008|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342498||181261|
NCT00343044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3040200|Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers|Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers||Benaroya Research Institute|No|Completed|June 2006|August 2011|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||April 2015|April 29, 2015|June 20, 2006|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00343044||181226|
NCT00343395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-013|Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Combined Rosiglitazone/Metformin (Avandamet®) vs. Placebo on Serological Outcomes in Non-Diabetic Patients With Stable Coronary Syndromes||Intermountain Health Care, Inc.|No|Terminated|June 2006|January 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|June 21, 2006|No|Yes|FDA concerns regarding Avandamet|No||https://clinicaltrials.gov/show/NCT00343395||181200|
NCT00343707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP102280|PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients|See Detailed Description||GlaxoSmithKline|No|Completed|November 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|18 Years|65 Years|No|||March 2011|May 31, 2012|June 21, 2006||||No||https://clinicaltrials.gov/show/NCT00343707||181178|
NCT00347191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006IOP|Relationship Between Central Corneal Thickness and Intraocular Pressure Measures Instruments.|Phase 4 Study Evaluating the Relationship Between Intraocular Pressure and Central Corneal Thickness Using Various Instruments in Ocular Hypertension, Normal-tension Glaucoma, Primary Open Angle Glaucoma, Keratoconus and Normal Eyes.||Aston University|No|Completed|January 2006|June 2006|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||1000|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical diagnosis of glaucoma, open angle; ocular hypertension; glaucoma (low-tension);        keratoconus and other healthy volunteers.|June 2011|June 22, 2011|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347191||180919|
NCT00347828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allergan/Z101|Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose|Prospective Study Comparing the Effectiveness of Zymar and Vigamox for Preoperative Antibiotic Sterilization of the Ocular Surface After Loading Dose||Ophthalmic Consultants of Boston||Active, not recruiting|June 2006|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|25 Years|N/A|Accepts Healthy Volunteers|||June 2006|July 3, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347828||180871|
NCT00348166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAU/085/2005|Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children?|Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten||KK Women's and Children's Hospital||Withdrawn|December 2005|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind|||Anticipated|180|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||October 2011|October 3, 2011|July 3, 2006|||Stringent eligibility criterion caused difficulties in recruiting patients.|No||https://clinicaltrials.gov/show/NCT00348166||180845|
NCT00348530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CavsBe.2006|Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy|Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy||Medical University of Silesia||Recruiting|January 2006|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|No|||January 2006|October 17, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348530||180817|
NCT00340431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904216|Experimental Vaccine for Plasmodium Falciparum Malaria|Phase 1 Study of the Safety and Immunogenicity of MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, Asexual Blood-Stage Vaccines for Plasmodium Falciparum Malaria||National Institutes of Health Clinical Center (CC)||Completed|June 2004|February 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2008|August 24, 2009|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340431||181415|
NCT00340444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904045|Genetic Studies of Inflammatory Bowel Disease|Genetic Study of Inflammatory Bowel Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2003|September 2007||||N/A|Observational|N/A||||10000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340444||181414|
NCT00341237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040053|Environmental Polymorphisms Registry|Environmental Polymorphism Registry (EPR)||National Institutes of Health Clinical Center (CC)||Recruiting|November 2003|||||N/A|Observational|N/A|||Anticipated|20000|||Both|8 Years|N/A|Accepts Healthy Volunteers|||August 2015|January 7, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341237||181354|
NCT00341250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906081|Malaria Vaccine in Children in Mali|Randomized, Controlled, Phase 1/2 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria in Children in Doneguebougou and Bancoumana, Mali||National Institutes of Health Clinical Center (CC)||Completed|January 2006|December 2006||||Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1|||900|||Both|2 Years|3 Years|Accepts Healthy Volunteers|||April 2009|November 26, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341250||181353|
NCT00340717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903187|Markers for Early Detection of Prostate Cancer|Multi-Institutional Pilot Study to Evaluate Molecular Markers in Urine and Serum in the Early Detection of Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|May 2003|||||N/A|Observational|N/A||||100|||Male|40 Years|75 Years|No|||September 2006|March 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340717||181393|
NCT00341224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903261|Steppin' Up: Positive Youth Development Program|Steppin' Up: Positive Youth Development Program||National Institutes of Health Clinical Center (CC)||Completed|July 2003|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|12 Years|N/A|No|||December 2009|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341224||181355|
NCT00342836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905146|Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer|Immunohistochemical Analysis of Human Transbronchial Biopsy Specimens Collected in a Phase I Chemoprevention Trial of Myo-Inositol in Heavy Smokers Conducted Outside the Intramural NCI Program||National Institutes of Health Clinical Center (CC)||Completed|April 2005|||||Phase 1|Interventional|Primary Purpose: Treatment||||20|||Both|40 Years|74 Years|Accepts Healthy Volunteers|||February 2006|March 22, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342836||181239|
NCT00343096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The BIVIN Trial|Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.|Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial||University of Malawi College of Medicine||Terminated|June 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|800|||Both|2 Months|15 Years|No|||July 2012|July 9, 2012|June 21, 2006||No|The buccal arm of the study was 30% less effective in stopping seizures within 10 minutes    compared with the IV dose. This met a stopping rule for the study|No||https://clinicaltrials.gov/show/NCT00343096||181222|
NCT00344045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN145-010|Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty|A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy And Safety of IV Paracetamol Versus Placebo in Subjects With Postoperative Pain After Total Hip Arthroplasty||Bristol-Myers Squibb|No|Completed|April 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|80 Years|No|||October 2015|October 12, 2015|June 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00344045||181155|
NCT00344318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107007|Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine|To Assess the Safety, Reactogenicity and Immunogenicity of GSK Bio Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-admin With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 mo of Age||GlaxoSmithKline||Completed|August 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|806|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2011|September 21, 2011|June 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00344318||181134|
NCT00341978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998049|Genetic Analysis of Brain Disorders|Genetic Analysis of Brain Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|October 1998|||||N/A|Observational|N/A||||5000|||Both|N/A|N/A|No|||September 2007|March 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341978||181298|
NCT00342264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999003|A Nested Case-Control Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners|Diesel Exhaust Among Miners Study||National Institutes of Health Clinical Center (CC)||Completed|January 1999|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1000|||Both|18 Years|85 Years|No|||July 2015|October 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342264||181277|
NCT00342511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906075|Pilots of Self-Collection for HPV DNA Detection|Pilots of Self-Collection Devices for HPV DNA Detection||National Institutes of Health Clinical Center (CC)||Completed|January 2006|December 2011||||N/A|Observational|N/A|||Anticipated|300|||Female|21 Years|N/A|Accepts Healthy Volunteers|||December 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342511||181260|
NCT00342524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905192|Collection of Convalescent SARS Plasma by Apheresis|Collection of Convalescent SARS Plasma by Apheresis||National Institutes of Health Clinical Center (CC)||Completed|July 2005|February 2007||||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||February 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342524||181259|
NCT00342810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903232|Analyses of Existing Framingham Data|Continued Analyses of Epidemiologic Risk Factors Using Existing Framingham Eye and Heart Study Data||National Institutes of Health Clinical Center (CC)||Completed|June 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|6061|||Both|30 Years|N/A|No|||May 2015|May 20, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342810||181241|
NCT00342784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905034|Identification of Prostate Cancer Genes|Genetic Analysis of Cases, Controls, and Families With Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|November 2004|||||N/A|Observational|N/A|||Anticipated|5118|||Both|18 Years|N/A|No|||June 2015|June 20, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342784||181243|
NCT00342797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999993033|Retinoblastoma Biomarker Study|Retinoblastoma Biomarker Study||National Institutes of Health Clinical Center (CC)||Completed|November 1993|||||N/A|Observational|N/A|||Anticipated|700|||Both|8 Years|80 Years|No|||August 2015|September 16, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342797||181242|
NCT00341055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005110|A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.|A Pilot Study to Evaluate the Hematologic Response Rate of PROCRIT� (Epoetin Alfa) at 80,000 Units Once Weekly in Anemic Cancer Patients Receiving Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2003|May 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|69|||Both|18 Years|N/A|No|||March 2010|June 8, 2011|June 19, 2006||||||https://clinicaltrials.gov/show/NCT00341055||181368|
NCT00347503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2601|Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients|Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||July 2007|July 12, 2007|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347503||180895|
NCT00347516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R430/25/2005|Comparative Study of Three IOL Power Calculation Formulae for Asian Eyes Shorter Than 22mm or Longer Than 25mm|Comparative Study of Three Intraocular Lens Power Calculation Formulae for Asian Eyes With Axial Lengths Less Than 22mm and Greater Than 25mm||Singapore National Eye Centre||Completed|December 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|210|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 11, 2010|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347516||180894|
NCT00347529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM FLP-001|Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu|A Randomised Double Blind Dose-Ranging Study to Assess the Safety, Tolerability and Immunogenicity of a Monovalent H5 DNA Influenza Vaccine (A Vietnam/1194/2004) Administered by Particle Mediated Epidermal Delivery (PMED) to Healthy Adults||PowderMed||Completed|August 2006|January 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2007|January 25, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347529||180893|
NCT00347841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5178|Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost|Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||May 2007|May 30, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347841||180870|
NCT00348543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 97346|Prophylactic Laser Treatment of Drusen Maculopathy|Prophylactic Laser Treatment of Drusen Maculopathy in Age-related Macular Degeneration.||University Hospital, Linkoeping||Completed|December 1999|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|55 Years|N/A|No|||October 1999|August 3, 2011|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348543||180816|
NCT00342303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999993027|Activity of Essential Fatty Acid Elongation/Desaturation Pathway During Early Life in Human Infants, In Vivo|Essential Fatty Acid Metabolism in the Newborn: Equivalence of Precusors and Mediators in the Synthesis of Long Chain Polyunsaturated Fatty Acids of the n-6 and n-3 Series||National Institutes of Health Clinical Center (CC)||Completed|June 1993|July 2010||||N/A|Observational|N/A|||Anticipated|110|||Both|N/A|N/A|No|||July 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342303||181274|
NCT00341458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999040|Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics|Breast, Ovarian and Endometrial Cancer Case-Control Study in Poland||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 1999|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|6600|||Female|20 Years|74 Years|No|||April 2015|March 2, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341458||181337|
NCT00342550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998016|Cervical Volume by Three-Dimensional Ultrasound as a Predictor of Preterm Delivery|Cervical Volume by Three-Dimensional Ultrasound as a Predictor of Preterm Delivery||National Institutes of Health Clinical Center (CC)||Completed|March 1998|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|680|||Female|15 Years|N/A|No|||October 2015|October 27, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342550||181257|
NCT00342849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999994037|Treatment of Lead-Exposed Children Trial|Treatment of Lead-Exposed Children (TLC) Trial||National Institutes of Health Clinical Center (CC)||Completed|July 1994|June 2015|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1332|||Both|12 Months|33 Months|No|||June 2015|June 11, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342849||181238|
NCT00342277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999056|Microarray Expression Profiling to Identify Stereotypic mRNA Profiles for Preterm Delivery in Order to Unravel the Biological Mechanisms|Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition||National Institutes of Health Clinical Center (CC)||Recruiting|December 1999|||||N/A|Observational|N/A|||Anticipated|11128|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 16, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342277||181276|
NCT00343434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-98904|Soy-Based Meal Replacement in Helping Women With Stage I, Stage II, or Stage III Breast Cancer in Complete Remission Lose Weight|Use of a Soy-Based Meal Replacement Weight Loss Intervention for Survivors of ER/PR Negative Breast Cancer||Comprehensive Cancer Center of Wake Forest University||Completed|January 2005|||July 2007|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||Anticipated|25|||Both|21 Years|N/A|No|||June 2013|June 4, 2013|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00343434||181197|
NCT00343109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6166|Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer|Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer||University of Washington|No|Active, not recruiting|March 2004|||June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|38|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|June 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00343109||181221|
NCT00343421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5I16|Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers|Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix®-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age||Sanofi|No|Completed|July 2006|June 2009|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|588|||Both|55 Days|75 Days|Accepts Healthy Volunteers|||January 2015|January 6, 2015|June 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00343421||181198|
NCT00344331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060186|Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C|Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C||National Institutes of Health Clinical Center (CC)||Recruiting|June 2006|||||N/A|Observational|N/A|||Anticipated|300|||Both|N/A|N/A|No|||September 2015|September 12, 2015|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344331||181133|
NCT00343720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNJ-26866138-LUC-2001|Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy|A Randomized, Open-Label, Multicenter Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy||Millennium Pharmaceuticals, Inc.||Completed||||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2008|March 11, 2008|June 22, 2006||||||https://clinicaltrials.gov/show/NCT00343720||181177|
NCT00343733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3052/BP/US|Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain|A 12-Week Open-Label Study With 3 Within-Patient Double-Blind Placebo-Controlled Periods to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain||Teva Pharmaceutical Industries||Completed|August 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|80 Years|No|||May 2014|May 8, 2014|June 21, 2006||||||https://clinicaltrials.gov/show/NCT00343733||181176|
NCT00343746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309021|Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging|Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging||University of Pittsburgh|Yes|Recruiting|October 2005|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Observational|N/A||1|Anticipated|1500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects can be 18 to 90 years of age. They can be male or female. Recruiting for normal        and diseased subjects.|September 2015|September 17, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00343746||181175|
NCT00344006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA 714703/005|Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria|A Multi-Centre, Randomised, Double-Blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-Dapsone-Artesunate Versus Artemether-Lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adolescents in Africa.||GlaxoSmithKline||Completed|June 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||1395|||Both|12 Months|14 Years|No|||May 2009|May 15, 2009|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00344006||181158|
NCT00344292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1333|Understanding the Genetic and Hereditary Basis of Atherosclerosis|SNPs and Extent of Atherosclerosis (SEA) Study||Wake Forest Baptist Health|Yes|Completed|March 2006|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|2763|Samples With DNA|DNA|Both|15 Years|34 Years|No|Non-Probability Sample|Subject enrolled in the Pathobiologic Determinants of Atherosclerosis in Youth (PDAY)        study|January 2013|January 23, 2013|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344292||181136|
NCT00344279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905220|Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis|Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection||National Institutes of Health Clinical Center (CC)||Completed|August 2005|January 2012||||N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|N/A|No|||January 2012|September 26, 2015|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344279||181137|
NCT00343083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042712|Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)|A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck||University of Maryland|Yes|Completed|December 2004|May 2012|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 20, 2006|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00343083||181223|
NCT00341536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904219|Feasibility Study for Prospective Diet and Lifestyle Cohorts in Delhi, Kerala, and Kolkota, India|A Feasibility Study for Prospective Cohort in India||National Institutes of Health Clinical Center (CC)||Completed|June 2004|November 2013||||N/A|Observational|N/A|||Anticipated|4044|||Both|35 Years|70 Years|No|||November 2013|October 9, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341536||181331|
NCT00341796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902214|Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India|A Prospective Cohort Study of the Seroprevalence of, and Interventions to Decrease the Risk of Mother-to-Child Transmission of, Human Immunodeficiency Virus Type 1 (HIV) in Tamil Nadu, India||National Institutes of Health Clinical Center (CC)||Completed|June 2002|August 2006||||N/A|Observational|N/A||||400|||Female|N/A|N/A|No|||August 2006|March 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341796||181311|
NCT00346996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HypoAna|Insulin Analogues and Severe Hypoglycaemia|The Effect of Insulin Analogues and Human Insulin on the Incidence of Severe Hypoglycaemia in Hypoglycaemia Prone Type 1 Diabetic Patients||Steno Diabetes Center|No|Completed|May 2007|August 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00346996||180934|
NCT00347217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL401345|Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event|An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event.||AstraZeneca||Completed|February 2006|January 2009|Actual|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3840|||Both|N/A|N/A|No|Non-Probability Sample|Clinic|August 2011|August 29, 2011|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347217||180917|
NCT00347867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Viagra.CTIL|Viagra for the Treatment of IUGR|Improvement of Utero-Placental Perfusion and Fetal Growth in IUGR and PET by Administration of Sildenafil Citrate in Pregnancy||Rambam Health Care Campus||Not yet recruiting|July 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2006|July 3, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00347867||180868|
NCT00342563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 26364|Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients|Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients||Yale University|Yes|Completed|May 2004|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|60 Years|No|||November 2015|November 5, 2015|June 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00342563||181256|
NCT00343161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00109|Symptom Adapted Therapy in GERD Patients|A Randomized, Open, Parallel-group, Multi-national, Multi-centre, Phase IV Study to Evaluate the Efficacy of Three Different Patient Management Strategies With and Without Esomeprazole 20 mg During a 3 Months Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related|SYMPATHY|AstraZeneca||Completed|August 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||441|||Both|18 Years|55 Years|No|||January 2011|January 21, 2011|June 20, 2006||||No||https://clinicaltrials.gov/show/NCT00343161||181217|
NCT00343174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR-CC-0101|Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms|Multicenter Parallel Randomized Double-Blind Placebo Controlled Study of Efficacy and Safety of Intravenous Ancrod ( Arvin ) Given Within 6 Hours After the Onset of Acute Ischemic Stroke: European Stroke Treatment With Ancrod Trial ESTAT||Heidelberg University||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||January 2002|June 20, 2006|June 20, 2006||||No||https://clinicaltrials.gov/show/NCT00343174||181216|
NCT00342290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998018|Early Pregnancy Evaluation by Three-Dimensional Ultrasound|Early Pregnancy Evaluation by Three-Dimensional Ultrasound||National Institutes of Health Clinical Center (CC)||Terminated|March 1998|June 2012||||N/A|Observational|N/A|||Anticipated|2000|||Female|15 Years|N/A|Accepts Healthy Volunteers|||June 2012|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342290||181275|
NCT00343122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 4462005|Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline|Evaluation of Two Methods for the Echocardiographic Assessment of Intrapulmonary Vasodilatation in Patients With Liver Cirrhosis: Agitated Saline Versus Polygelatine||Medical University of Vienna||Recruiting|June 2006|||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|100|||Both|18 Years|N/A|No|||September 2007|September 14, 2007|June 20, 2006||||No||https://clinicaltrials.gov/show/NCT00343122||181220|
NCT00343811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/3048/AD/US|Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment|A 6-week, Double-Blind, Placebo-Controlled, Parallel Group Randomized Withdrawal Study to Evaluate the Continued Efficacy of Modafinil Treatment in Dosages up to 425mg/Day in Patients With Attention-Deficit/Hyperactivity Disorder Who Are Responders to Modafinil Treatment, Followed by a 12-Month Open-Label Extension Period||Teva Pharmaceutical Industries||Completed|June 2006|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|6 Years|17 Years|No|||May 2014|May 8, 2014|June 21, 2006||||||https://clinicaltrials.gov/show/NCT00343811||181171|
NCT00344058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 01001-OBG-01|Abbreviated MgSO4 Therapy in Post-Partum Preeclampsia|Abbreviated Post-Partum Magnesium Sulfate Seizure Prophylaxis in Preeclampsia: A Comparison of 12 and 24 Hour Regimens||Case Western Reserve University||Completed|January 2001|August 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Female|18 Years|N/A|No|||August 2005|June 23, 2006|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344058||181154|
NCT00343798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2044.00|A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies|A Pilot Study to Evaluate the Co-infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies||Fred Hutchinson Cancer Research Center|No|Completed|April 2006|||July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|6 Months|45 Years|No|||February 2015|February 10, 2015|June 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00343798||181172|
NCT00344032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104479|Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women|Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV-16/18 VLP/AS04 Vaccine Administered Intramuscularly at 0, 1, 6 Months in Healthy Indian Female Subjects Aged 18-35 Yrs||GlaxoSmithKline||Completed|July 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|354|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|June 23, 2006|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00344032||181156|
NCT00339170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061493|Cognitive Training and Enhanced Supported Employment in Schizophrenia|Cognitive Training and Enhanced Supported Employment||Yale University||Active, not recruiting|April 2000|July 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||July 2012|July 23, 2012|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00339170||181505|
NCT00339183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050181|Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone|A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer||Amgen||Completed|June 2006|November 2010|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1186|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 16, 2006||||No|April 3, 2014|https://clinicaltrials.gov/show/NCT00339183||181504|
NCT00336271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010|The Effects of Coffee|The Effects of Coffee||American University||Completed|April 2006|March 2007||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2007|March 14, 2007|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00336271||181719|
NCT00344019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000035/1|Effects of Atorvastatin on Myonecrosis|Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study||Beth Israel Deaconess Medical Center||Not yet recruiting|July 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|150|||Both|18 Years|N/A|No|||March 2008|March 10, 2008|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00344019||181157|
NCT00344305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP129|A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children|A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to Less Than 60 Months of Age||MedImmune LLC|Yes|Completed|May 2006|December 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||September 2012|September 5, 2012|June 22, 2006|Yes|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT00344305||181135|
NCT00344656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4850|Appetite-Related Brain Activity in Women With Anorexia Nervosa|The Study of Appetite-Related Brain Activity With Functional Magnetic Resonance Imaging in Women With Anorexia Nervosa||New York State Psychiatric Institute|Yes|Completed|October 2004|October 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with AN between 18 and 45 years of age hospitalized for treatment of anorexia        nervosa.|April 2012|April 18, 2012|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344656||181110|
NCT00344643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0202-112|A Comparison of 12 Month Daily Wear of Two Novel O2 Permeable Silicone Hydrogel CLs (HOP/SiH) and A Control, Standard O2 Lens|A Comparison of 12 Month Daily Wear of Two Novel Hyper-Oxygen Permeable Silicone Hydrogel Contact Lenses (HOP/SiH) and A Control, Standard Oxygen Permeable Lens; and, 30-Night Versus 6-Night Immediate Extended Wear of Two HOP/SiH Lenses.||University of Texas Southwestern Medical Center|No|Completed|October 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|187|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2008|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344643||181111|
NCT00347230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R419/14/2005|Intacs for Keratoconus|Intacs for Keratoconus||Singapore National Eye Centre||Recruiting|October 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2005|July 3, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347230||180916|
NCT00347542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBISR/2006/03|A Trial to Study the Effect of Vitamin D Supplementation on Glucose and Insulin Metabolism in Centrally Obese Men|A Double Blind Randomized Control Trial to Study the Effect of Vitamin D Supplementation on Peripheral Insulin Sensitivity in Centrally Obese Men||Sitaram Bhartia Institute of Science and Research||Completed|July 2006|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Male|35 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 31, 2013|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347542||180892|
NCT00348179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 04-036E|Vascular Function in Adolescent, Diabetic Children|Vascular Function in Adolescent, Diabetic Children||Children's Mercy Hospital Kansas City|No|Completed|April 2004|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|85|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||April 2007|January 23, 2008|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00348179||180844|
NCT00340366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904068|Influence of Genetics on Vitamin Metabolism in Pregnant Women|Investigation Into the Influence of Genetic Variation on Folate, Cobalamin and Related Metabolites||National Institutes of Health Clinical Center (CC)||Completed|December 2003|December 2007||||N/A|Observational|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340366||181420|
NCT00340379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008437|Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression|A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol||Duke University|No|Completed|April 2003|August 2005|Actual|August 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||February 2012|August 15, 2014|June 20, 2006|Yes|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00340379||181419|
NCT00342875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902143|The New England Bladder Cancer Study|The New England Bladder Cancer Study||National Institutes of Health Clinical Center (CC)||Completed|February 2002|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|2681|||Both|30 Years|79 Years|No|||June 2015|June 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342875||181236|
NCT00342888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902030|Case-Control Study of Pesticides and Childhood Leukemia|A Case-Control Study of Pesticides and Childhood Leukemia||National Institutes of Health Clinical Center (CC)||Completed|October 2001|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|629|||Both|N/A|8 Years|No|||May 2015|May 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342888||181235|
NCT00341770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999910107|Assessment of Sympathetic Nervous System Activity by Microneurography Recording Technique|Assessment of Sympathetic Nervous System Activity by Microneurography Recording Technique||National Institutes of Health Clinical Center (CC)||Completed|April 1991|November 2010||||N/A|Observational|N/A|||Anticipated|600|||Both|4 Years|N/A|No|||November 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341770||181313|
NCT00343824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/224|Bacterial Control in Partial Thickness Burns Using Silver-containing Wound Dressings|Bacterial Control in Partial Thickness Burns Using Silver-containing Wound Dressings||University Hospital, Ghent|No|Active, not recruiting|August 2006|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|80 Years|No|||December 2014|December 4, 2014|June 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00343824||181170|
NCT00343135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103997|AUGMENTIN 1gm In Skin And Soft Tissue Infection|An Open, Non-comparative Study to Evaluate the Efficacy and Safety of AUGMENTIN 1gm (875mg Amoxicillin/125mg Clavulanic Acid) po q 12 Hours in the Treatment of Uncomplicated Skin and Soft Tissue Infections in Pakistan||GlaxoSmithKline||Completed|December 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|195|||Both|12 Years|N/A|No|||November 2012|November 21, 2012|June 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00343135||181219|
NCT00343148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4126-21a|Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid|Pharmacokinetic Study of AVI-4126 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration||Sarepta Therapeutics||Completed|June 2006|June 2009|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||July 2009|July 6, 2009|June 20, 2006||||No||https://clinicaltrials.gov/show/NCT00343148||181218|
NCT00338546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2RO1DA01006409|Study to Improve Scientific Understanding of the Cardiovascular Actions of Cocaine|Cocaine and Sympathetic Nerve Activity in Humans||University of Texas Southwestern Medical Center||Recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|440|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 19, 2009|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00338546||181553|
NCT00339443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902040|Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different Methods|Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different Methods||National Institutes of Health Clinical Center (CC)||Completed|November 2001|May 2010||||N/A|Observational|N/A|||Anticipated|120|||Both|N/A|N/A|No|||May 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339443||181484|
NCT00339456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902288|Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda|A Randomized, Controlled Trial of Short Cycle Intermittent Versus Continuous HAART for the Treatment of Chronic HIV Infection in Uganda||National Institutes of Health Clinical Center (CC)||Completed|August 2002|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339456||181483|
NCT00339469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905215|Effect of High-Legume Diet on Colorectal Cancer Risk|The Effects of a High Legume Low Glycemic Index Diet on Insulin Resistance and Inflammation in Patients at High Risk for Colorectal Adenoma Recurrence||National Institutes of Health Clinical Center (CC)||Completed|August 2005|May 2008|Actual|May 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|65|||Male|35 Years|75 Years|No|||February 2016|February 26, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339469||181482|
NCT00344071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904284|Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia|Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia||National Institutes of Health Clinical Center (CC)||Completed|September 2004|||April 2007|Actual|N/A|Observational|N/A||||250|||Both|N/A|N/A|No|||September 2009|September 26, 2015|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344071||181153|
NCT00344084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906121|Surveillance for Leishmaniasis Skin Lesions in Mali|Active Surveillance for Cutaneous Leishmaniasis in Mali||National Institutes of Health Clinical Center (CC)||Completed|March 2006|September 2012||||N/A|Observational|N/A|||Anticipated|2000|||Both|1 Year|N/A|No|||September 2012|October 23, 2014|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344084||181152|
NCT00338793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shi-TB-01|Corticosteroids in the Treatment of Tuberculous Pleurisy|A Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Corticosteroids for Treatment of Patients With Tuberculous Pleurisy||Guangxi Medical University|Yes|Completed|July 2006|August 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1500|||Both|18 Years|N/A|No|||August 2008|August 25, 2008|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00338793||181534|
NCT00336284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20052069|TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up|TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up|TRUST|Biotronik, Inc.|No|Completed|November 2005|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1450|||Both|18 Years|N/A|No|||July 2010|July 28, 2010|June 9, 2006||No||No|January 12, 2010|https://clinicaltrials.gov/show/NCT00336284||181718|
NCT00344669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05267|Effect of Mass Deworming on Child Growth|Increased Weight Gain in Preschool Children Due to Mass Albendazole Treatment Given During "Child Health Days" in Uganda||Makerere University||Completed|August 2000|November 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||10000|||Both|1 Year|7 Years|No|||June 2006|October 16, 2006|June 14, 2006||||No||https://clinicaltrials.gov/show/NCT00344669||181109|
NCT00340483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904206|Smoking Cessation Aid for Young Smokers|X-Pack: A Smoking Cessation Aid for Young Smokers||National Institutes of Health Clinical Center (CC)||Completed|May 2004|December 2006||||Phase 1|Interventional|Primary Purpose: Treatment||||291|||Both|18 Years|22 Years|Accepts Healthy Volunteers|||December 2006|February 24, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340483||181411|
NCT00340795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905197|Media-Smart Youth Program Evaluation Study|Media-Smart Youth Program Evaluation Study||National Institutes of Health Clinical Center (CC)||Completed|August 2005|March 2007||||N/A|Observational|N/A||||0|||Both|11 Years|13 Years|Accepts Healthy Volunteers|||March 2007|March 5, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340795||181387|
NCT00340470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903262|Michigan Driver Education Study|Michigan Young Drivers Intervention Study||National Institutes of Health Clinical Center (CC)||Completed|July 2003|February 2007||||Phase 3|Interventional|Primary Purpose: Treatment||||0|||Both|15 Years|16 Years|No|||February 2007|October 25, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340470||181412|
NCT00340782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906145|Influence of Social and Environmental Factors on Women's Reproductive Function in a Maya Community of Guatemala|The Influence of Social and Environmental Factors on Fecundability in a Maya Community of Guatemala||National Institutes of Health Clinical Center (CC)||Completed|April 2006|April 2008||||N/A|Observational|N/A||||0|||Female|16 Years|42 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340782||181388|
NCT00341068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999053|Genetic Analysis of Neural Tube and Orofacial Cleft Defects in the Irish Population|Genetic Analysis of Neural Tube and Orofacial Cleft Defects in the Irish Population||National Institutes of Health Clinical Center (CC)||Completed|December 1999|||||N/A|Observational|N/A|||Anticipated|8000|||Both|N/A|N/A|No|||October 2015|November 3, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341068||181367|
NCT00336245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGPAF PG-51161|A Randomized Trial of IUD Versus Hormonal Contraception in HIV-infected Women in Zambia|A Randomized Trial of IUD Versus Hormonal Contraception in HIV-infected Women in Zambia||University of Alabama at Birmingham||Completed|June 2002|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2|||600|||Female|16 Years|N/A|No|||August 2009|March 5, 2015|June 11, 2006||||No||https://clinicaltrials.gov/show/NCT00336245||181721|
NCT00347555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-059|Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly|Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2006|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|April 11, 2013|June 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00347555||180891|
NCT00347880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 359-2004|Atrial and Brain Natriuretic Peptides in Bronchiolitis|Atrial and Brain Natriuretic Peptides in Bronchiolitis||University of Florida|Yes|Completed|September 2004|July 2007|Actual|||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|37 Weeks|2 Years|No|Probability Sample|Children between the ages of 37 weeks and 2 years old with evidence of bronchiolitis.|March 2012|March 1, 2012|July 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00347880||180867|
NCT00347893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22222|The Efficacy of Selective Laser Trabeculoplasty|Clinical Results of Selective Laser Trabeculoplasty in Treatment of Open Angle Glaucoma||Glaucoma Research & Education Group||Recruiting|May 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2006|June 30, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347893||180866|
NCT00339833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903121|The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers|The Effect of Salsalate Treatment on Insulin Sensitivity and Insulin Secretion in Obese Non-Diabetic Individuals||National Institutes of Health Clinical Center (CC)|No|Completed|March 2003|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|45 Years|No|||January 2013|January 29, 2013|June 19, 2006||No||No|December 29, 2010|https://clinicaltrials.gov/show/NCT00339833||181456|
NCT00340093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902290|Diabetes Management Personal Trainer|The Diabetes Management Study||National Institutes of Health Clinical Center (CC)||Completed|August 2002|March 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|11 Years|16 Years|No|||March 2007|March 7, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340093||181438|
NCT00338312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002005 and Yr 2-4 OL|Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido|A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.||Warner Chilcott|No|Completed|June 2002|July 2006|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|610|||Female|40 Years|70 Years|No|||April 2013|April 15, 2013|June 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338312||181571|
NCT00338325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3317|Reading Preoperatively to Reduce Anxiety in Day Surgery|A Randomized Trial Of Reading Preoperatively To Day Surgery Children To Reduce Anxiety and Pain||IWK Health Centre|No|Completed|June 2005|April 2006|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||June 2015|June 15, 2015|June 15, 2006||||No||https://clinicaltrials.gov/show/NCT00338325||181570|
NCT00342862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0485-CL-0002|AMEVIVE® Pregnancy Registry|Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry||Astellas Pharma Inc|Yes|Terminated|December 2003|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to        conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown        prospectively|December 2013|December 10, 2013|June 19, 2006|No|Yes|The Sponsor has made a decision, driven by business needs, to cease promotion, manufacturing,    distribution and sales of Amevive|No||https://clinicaltrials.gov/show/NCT00342862||181237|
NCT00343187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACZ EGFR 01|A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash|A Phase II, Randomized, Double-Blind, Parallel Design Study to Evaluate ACZONE™ (Dapsone) Gel, 5% As a Treatment For Rash Related to the Human Epidermal Growth Factor Receptor 1 (HER1)/Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor Tarceva® (Erlotinib)||Allergan||Terminated|June 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|2|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|June 20, 2006|||Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00343187||181215|
NCT00338806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH071530|Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder|Prevention for Symptomatic Offspring of Bipolar Parents||National Institute of Mental Health (NIMH)|Yes|Recruiting|November 2006|November 2009|Anticipated|November 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|12 Years|17 Years|No|||March 2009|March 25, 2009|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338806||181533|
NCT00338819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC06SP156CTIL|ActiveCare+SFT Hemodynamic Profile Compare to SCD Express in Ventilated Patients|ActiveCare+SFT Hemodynamic Profile Compare to SCD Express in Ventilated Patients||Tel-Aviv Sourasky Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|No|||June 2006|June 18, 2006|June 18, 2006||||No||https://clinicaltrials.gov/show/NCT00338819||181532|
NCT00343447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0579 CDR0000481362|Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia|Phase II Randomized Trial of Early Versus Late Vaccination in Patients With High Risk CLL||Sidney Kimmel Comprehensive Cancer Center|No|Withdrawn|August 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|June 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00343447||181196|
NCT00339963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902042|Genome Expression in Lymphoma, Leukemia and Multiple Myeloma|Expression of the Genome in Lymphoid Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|November 2001|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|3000|||Both|1 Year|100 Years|No|||November 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339963||181446|
NCT00339157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-40|Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS|ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS)||Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|June 2006|July 2008|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|2 Years|20 Years|No|||July 2010|July 19, 2010|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00339157||181506|
NCT00344682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-34|Memantine Augmentation of Antidepressants|A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders||University of Massachusetts, Worcester|No|Completed|June 2006|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|85 Years|No|||January 2014|January 9, 2014|June 22, 2006|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00344682||181108|Early termination due to slow enrollment, leading to small numbers of subjects enrolled.
NCT00340496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999996027|Analysis of NF2 Mutations in Radiation-Related Neural Tumors|Analysis of NF2 Mutations in Radiation-Related Neural Tumors||National Institutes of Health Clinical Center (CC)||Completed|August 1996|July 2006||||N/A|Observational|N/A||||112|||Both|N/A|N/A|No|||July 2006|March 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340496||181410|
NCT00340509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902016|A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study|A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study||National Institutes of Health Clinical Center (CC)||Completed|October 2001|July 2013||||N/A|Observational|N/A|||Anticipated|99999999|||Both|N/A|N/A|No|||July 2013|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340509||181409|
NCT00340522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904282|Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development|Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development||National Institutes of Health Clinical Center (CC)||Completed|September 2004|August 2014||||N/A|Observational|N/A|||Anticipated|20|||Both|N/A|25 Years|No|||August 2014|September 10, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340522||181408|
NCT00340808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904144|Molecular Staging of Endometrial Cancer|Integration of an Epidemiologic Questionnaire Into Gynecologic Oncology Group Trials: First Project, Protocol 210||National Institutes of Health Clinical Center (CC)||Completed|March 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|6000|||Female|18 Years|120 Years|No|||September 2015|October 6, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340808||181386|
NCT00341289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903141|Environmental and Behavioral Risk Factors for Childhood Drowning|Environmental and Behavioral Risk Factors for Childhood Drowning||National Institutes of Health Clinical Center (CC)||Completed|March 2003|||January 2007|Actual|N/A|Observational|N/A||||1430|||Both|1 Year|20 Years|No|||September 2009|September 3, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341289||181350|
NCT00341510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906017|Health Behaviors in School-Age Children: A World Health Organization Cross-National Study|U.S. Health Behavior in School Children Survey||National Institutes of Health Clinical Center (CC)||Completed|October 2005|November 2006||||N/A|Observational|N/A||||14350|||Both|7 Years|16 Years|No|||November 2006|March 5, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341510||181333|
NCT00341523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995026|Early Detection of Esophageal Cancer|Early Detection of Esophageal Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 1994|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|8000|||Both|21 Years|80 Years|No|||November 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341523||181332|
NCT00336531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-02-069|Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation|Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors||Samsung Medical Center||Completed|April 2006|October 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Both|N/A|15 Years|No|||November 2008|November 17, 2008|June 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00336531||181700|
NCT00336557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM028|Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy|A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns Versus Usual Care in High-Dose Interferon Treated Patients||Teva Pharmaceutical Industries|No|Completed|July 2006|July 2009|Actual|April 2009|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1230|Samples Without DNA|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.|Both|18 Years|N/A|No|Probability Sample|Subjects who have been on high-dose Interferon (IFN) for 1 to 4 years|October 2013|October 29, 2013|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336557||181698|
NCT00339807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902112|Natural History of HTLV-I Infection: Prospective Follow-up of a Cohort of Blood Donors in Jamaica|Natural History of HTVL-I: A Cross-Sectional Study of a Cohort of Blood Donors in Jamaica||National Institutes of Health Clinical Center (CC)||Completed|January 2002|August 2011||||N/A|Observational|N/A|||Anticipated|1500|||Both|18 Years|N/A|No|||August 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339807||181457|
NCT00340080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNA106030|Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity|A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity||GlaxoSmithKline||Completed|April 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||1806|||Both|18 Years|N/A|No|||January 2010|January 21, 2010|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340080||181439|
NCT00339586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIELT|First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene|Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene||AZ-VUB||Recruiting|January 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2006|June 19, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339586||181473|
NCT00335816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mskcc 12-201|Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer|Timing of Rectal Cancer Response to Chemoradiation||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2008|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|248|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335816||181752|
NCT00336115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qeii|The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients|Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults||Queen Elizabeth II Health Sciences Centre|No|Enrolling by invitation|July 2006|May 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|10|||Both|18 Years|64 Years|No|||October 2007|October 22, 2007|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00336115||181731|
NCT00336128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGV 03050904006|Population Based Intervention to Prevent Obesity in Kindergartens (TigerKids)|||Ludwig-Maximilians - University of Munich||Active, not recruiting|October 2003|July 2009|Anticipated|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30000|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||May 2008|May 6, 2008|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336128||181730|
NCT00338338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106357|The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients|A Randomized, Double-blind, Parallel Group, Single-Centre Study to Evaluate the Efficacy and Safety of Lacidipine and Amlodipine Once-daily Treatment in Hypertensive Adult Patients||GlaxoSmithKline|No|Completed|November 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|40 Years|80 Years|No|||May 2011|May 26, 2011|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00338338||181569|
NCT00343200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481247|A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study To Assess The Efficacy And Safety Of Viagra (Sildenafil Citrate) In Men With Erectile Dysfunction (ED) Who Do Not Self Identify.||Pfizer|No|Completed|July 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|371|||Male|30 Years|N/A|No|||September 2008|September 9, 2008|June 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00343200||181214|
NCT00343460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000489413|APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer|A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens||National Cancer Institute (NCI)||Completed|April 2006|May 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|3||Anticipated|1338|||Both|18 Years|N/A|No|||August 2008|November 5, 2013|June 22, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00343460||181195|
NCT00338832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071539|Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia|Adapting a Physical Activity Intervention for Schizophrenia||Veterans Medical Research Foundation|Yes|Completed|June 2006|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|21 Years|64 Years|No|||August 2013|August 6, 2013|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338832||181531|
NCT00338845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065849|Share Safer Sex Counseling Program for Changing Sexual Risk Behaviors in Mexican Female Sex Workers|Safer Sex Intervention for At-risk Women in Mexico||University of California, San Diego||Completed|December 2003|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1800|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 9, 2013|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338845||181530|
NCT00338858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alyn2CTIL|The Connection Between Gait Variability Parameters and Balance Performance in Children With Physical Disability|The Connection Between Gait Variability Parameters and Balance Performance in Children With Physical Disability||Alyn Pediatric & Adolecent Rehabilitation Center|Yes|Completed|June 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|3 Years|16 Years|Accepts Healthy Volunteers|||June 2006|February 14, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00338858||181529|
NCT00344097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 AT003613|The Effects of Soy Protein on Post-thoracotomy Pain|The Effects of Soy Protein Supplementation on Post-thoracotomy Pain||National Center for Complementary and Integrative Health (NCCIH)|Yes|Withdrawn|March 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344097||181151|
NCT00344110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A1301|Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Placebo and Active-controlled, Multicenter, Parallel-group Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy, Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension||Novartis||Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|768|||Both|20 Years|75 Years||||November 2011|November 7, 2011|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00344110||181150|
NCT00339976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902275|Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis|Ascertainment of Death in ALS Patients||National Institutes of Health Clinical Center (CC)||Completed|August 2002|April 2008||||N/A|Observational|N/A||||0|||Both|N/A|N/A|No|||April 2008|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339976||181445|
NCT00339703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20040210H|Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.|Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.||Wilford Hall Medical Center||Active, not recruiting|November 2004|May 2006||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2006|June 19, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339703||181464|
NCT00340275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999023|Longitudinal Study of Vaginal Flora|Longitudinal Study of Vaginal Flora||National Institutes of Health Clinical Center (CC)||Completed|April 1999|November 2010||||N/A|Observational|N/A|||Anticipated|5500|||Female|15 Years|44 Years|No|||November 2010|November 19, 2010|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340275||181427|
NCT00340288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901209|Fibroid Growth Study|Fibroid Growth Study||National Institutes of Health Clinical Center (CC)||Completed|June 2001|||||N/A|Observational|N/A|||Anticipated|300|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340288||181426|
NCT00339430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902253|HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)|HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)||National Institutes of Health Clinical Center (CC)||Completed|July 2002|August 2010||||N/A|Observational|N/A|||Anticipated|3500|||Female|N/A|N/A|No|||August 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339430||181485|
NCT00339690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905166|Dust Mite Allergen Reduction Study|Dust Mite Allergen Reduction Study||National Institutes of Health Clinical Center (CC)||Completed|June 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|1||Anticipated|100|||Both|5 Years|15 Years|No|||November 2015|November 28, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339690||181465|
NCT00340223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905237|HLA-B35 Alleles and AIDS|Comparison of HIV-1 Epitopes That May be Recognized by HLA-B*3501 (PY) and -B*3503 (Px) Early After Seroconversion and After Development of AIDS||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2005|September 2007|Actual|||N/A|Observational|N/A|||Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 9, 2012|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340223||181430|
NCT00335933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0045|Safety and Efficacy of Gabapentin in Postherpetic Neuralgia|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia||Depomed||Completed|May 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|378|||Both|18 Years|N/A|No|||June 2006|August 1, 2007|June 8, 2006||||||https://clinicaltrials.gov/show/NCT00335933||181744|
NCT00335946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0602060019|A Pilot Investigational Study: Treatment of Anxiety With Non-Needle Electro-Acupuncture|||Logan College of Chiropractic|No|Completed|June 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2007|October 16, 2008|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335946||181743|
NCT00337727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-130|Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)|A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC)||Merck Sharp & Dohme Corp.||Completed|January 2007|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|848|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|June 14, 2006|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00337727||181613|
NCT00340106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905211|Prevention of Environmental Tobacco Smoke Exposure in Children 0-12 Months Old|Prevention of Environmental Tobacco Smoke (ETS) Exposure to Children, Ages 0-12 Months||National Institutes of Health Clinical Center (CC)||Completed|July 2005|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|375|||Female|18 Years|N/A|No|||May 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340106||181437|
NCT00340119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905125|Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis|Prospective Study of Inflammatory Markers and Genes as Predictors of Atherosclerotic Cardiovascular Disease in Dialysis Patients||National Institutes of Health Clinical Center (CC)||Completed|March 2005|March 2012||||N/A|Observational|N/A|||Anticipated|871|||Both|19 Years|N/A|No|||March 2012|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340119||181436|
NCT00337012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001079-39|The Effect of Duloxetine on Interoceptive Awareness|The Effect of Duloxetine on Interoceptive Awareness, Thermal Heat Pain Perception, and Bodily Symptoms in Major Depressive: a Pilot Study With fMRI.||University Hospital, Bonn||Recruiting|July 2007|||||Phase 4|Observational|Time Perspective: Prospective|||Anticipated|36|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2008|November 28, 2008|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00337012||181665|
NCT00335829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0598 CDR0000483104|Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|May 2006|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335829||181751|
NCT00339248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905061|Markers for Breast Cancer|Risk of Breast Cancer and Hyperplastic Conditions in the Breast Cancer Serum Bank in Relation to Inherited Genetic Variants||National Institutes of Health Clinical Center (CC)||Completed|December 2004|||||N/A|Observational|N/A||||2632|||Female|15 Years|N/A|No|||October 2007|March 12, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339248||181499|
NCT00338559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0059|Does LMA Instead of ET Tube Affect Incidence of Postoperative Vomiting in Children Undergoing Strabismus Correction?|Does Using Laryngeal Mask Airway (LMA) Instead of an Endotracheal Tube (ET Tube) Affect the Incidence of Postoperative Vomiting in Children Undergoing Strabismus Correction? - An Observational Study||The University of Texas Health Science Center, Houston|No|Completed|May 2006|November 2013|Actual|November 2013|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|71|||Both|1 Year|12 Years|No|Probability Sample|Two hundred six children between the ages of 1 and 12 years are expected to take part in        this study.|December 2014|December 2, 2014|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338559||181552|
NCT00339196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050202|5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS|Multi Centers, Open-trial Phase II Study Evaluating 5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®) in Patients With Acute Myelogenous Leukemia and High Risk Myelodysplasia.||Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2007|May 6, 2011|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00339196||181503|
NCT00339209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905184|Prospective Lung Transplant Database for Genetic Research|Prospective Lung Transplant Database for Genetic Research||National Institutes of Health Clinical Center (CC)||Completed|June 2005|April 2007||||N/A|Observational|N/A||||400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2007|March 5, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339209||181502|
NCT00339989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903302|Cervical Cancer Early Endpoints and Determinants|A Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2003|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|3500|||Female|18 Years|120 Years|Accepts Healthy Volunteers|||February 2016|March 5, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339989||181444|
NCT00335985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0998-12|Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)|A Randomized, Double-blind, Controlled Clinical Study of GB-0998 for the Steroid-resistant Polymyositis and Dermatomyositis||Japan Blood Products Organization|No|Completed|June 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|16 Years|75 Years|No|||February 2012|November 3, 2014|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335985||181740|
NCT00335998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03126|Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies|Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies.||National Cancer Institute (NCI)||Completed|March 2006|||October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|June 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00335998||181739|
NCT00336024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0334|Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma|A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children &lt;36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate||Children's Oncology Group|Yes|Active, not recruiting|August 2007|||March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|N/A|2 Years|No|||March 2016|March 22, 2016|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336024||181737|
NCT00340249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995040|Use of the Perinatal Database and Biologic Tissue Bank at The Perinatology Research Branch (PRB)|Use of a Perinatal Database and Biologic Tissue Bank at the Perinatology Research Branch (PRB)||National Institutes of Health Clinical Center (CC)||Completed|July 1995|||||N/A|Observational|N/A||||0|||Female|N/A|N/A|No|||June 2012|June 13, 2012|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340249||181429|
NCT00340262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900019|Bone Mineral Density and Subsequent Cancer Risk|Bone Mineral Density and Subsequent Cancer Risk||National Institutes of Health Clinical Center (CC)||Completed|April 2000|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|22695|||Female|55 Years|80 Years|No|||March 2016|March 19, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340262||181428|
NCT00335959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000476577|S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery|Neoadjuvant Chemoradiation Therapy With Oxaliplatin and Capecitabine for Patients With Surgically Resectable Gastric Cancer: A Pilot Phase II Trial With Molecular Correlates||Southwest Oncology Group|Yes|Terminated|May 2006|||April 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|June 8, 2006|Yes|Yes|Closed due to slow accrual|No|July 12, 2012|https://clinicaltrials.gov/show/NCT00335959||181742|
NCT00335972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-27-05|The Effects of DexMed and Desflurane on Carotid Patients|Phase 4: The Effects of Dexmedetomidine and Desflurane on Postoperative Cognitive Dysfunction in Patients Undergoing Carotid Endarterectomy||The Cleveland Clinic|Yes|Terminated|June 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|4|||Both|50 Years|80 Years|No|||May 2014|May 19, 2014|June 8, 2006||No|Closed due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT00335972||181741|
NCT00336258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BECKCTIL|US-Doppler and Procoagulant Microparticles for the Diagnosis of Asymptomatic DVT in Advanced Cancer Patients With Poor Performance Status|US-Doppler and Procoagulant Microparticles for the Diagnosis of Asymptomatic DVT in Advanced Cancer Patients With Poor Performance Status||Rambam Health Care Campus||Completed|June 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients with an advanced stage of the disease, hospitalized in the oncology department.|April 2007|December 13, 2010|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336258||181720|
NCT00337181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-11048|Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial|Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E.||U.S. Army Medical Research and Materiel Command||Active, not recruiting|May 2006|June 2017|Anticipated|December 2006|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|130|||Both|18 Years|31 Years|No|||December 2015|December 30, 2015|June 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00337181||181653|
NCT00339326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902282|Risk Factors for Non-HIV-Related Kaposi s Sarcoma|Cofactors for Classical Kaposi's Sarcoma and for Kaposi's Sarcoma-Associated Herpesvirus Infection: A Case-Control Study in Sicily||National Institutes of Health Clinical Center (CC)||Completed|August 2002|||||N/A|Observational|N/A|||Anticipated|2000|||Both|N/A|99 Years|No|||January 2016|February 4, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339326||181493|
NCT00339573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998033|National Survey of Lead and Allergen Hazards in Housing|National Survey of Lead Hazards and Allergens in Housing||National Institutes of Health Clinical Center (CC)||Completed|June 1998|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|2000|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339573||181474|
NCT00337038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor431706ctil|Endothelial Function as a Marker for Blood Pressure Control Among Hypertensive Diabetic Patients|||Soroka University Medical Center||Completed|June 2006|July 2010|Actual|July 2010|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337038||181664|
NCT00337662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10769|Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia|Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.||Eli Lilly and Company||Completed|May 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|628|||Both|18 Years|65 Years|No|||February 2010|February 8, 2010|June 14, 2006|Yes|Yes||No|December 3, 2008|https://clinicaltrials.gov/show/NCT00337662||181618|
NCT00337337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKU-94-032|Multiple Grain in Type 2 Diabetes|Effect of Reconstitute Multiple Grain on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes||National Cheng-Kung University Hospital||Recruiting|April 2005|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|25 Years|75 Years|No|||June 2006|October 17, 2006|June 14, 2006||||No||https://clinicaltrials.gov/show/NCT00337337||181642|
NCT00338598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 20915|Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism|Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism||Yale University|Yes|Active, not recruiting|June 2003|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|46|||Both|21 Years|60 Years|No|||July 2015|July 14, 2015|June 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00338598||181549|
NCT00338572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380|Effect of Exercise and Diet on Inflammation in Hypertensive Individuals|Sympathetic Nervous System Regulation of Cell Adhesion||University of California, San Diego|Yes|Completed|June 2006|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|185|||Both|25 Years|60 Years|No|||June 2012|June 7, 2012|June 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00338572||181551|
NCT00339482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999760256|Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community|Prospective Studies of Diabetes Mellitus and Its Complications in the Gila River Indian Community||National Institutes of Health Clinical Center (CC)||Completed|September 1976|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|5 Years|N/A|No|||December 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339482||181481|
NCT00339261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904063|Disease Progression and Activity in Patients With Systemic Lupus Erythematosus|Disease Progression and Activity in the Carolinas Lupus Study - MUSC Medical University of South Carolina Follow up||National Institutes of Health Clinical Center (CC)||Completed|December 2003|October 2006||||N/A|Observational|N/A||||716|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2006|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339261||181498|
NCT00339222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902038|Family Study of Melanoma in Italy|Family Study of Melanoma in Italy||National Institutes of Health Clinical Center (CC)||Recruiting|November 2001|||||N/A|Observational|N/A|||Anticipated|1600|||Both|10 Years|N/A|Accepts Healthy Volunteers|||May 2015|September 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339222||181501|
NCT00339235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998001|Establishment of a Perinatal Database and a Bank of Biological Materials|Establishment of a Clinical Perinatal Database and Bank of Biological Materials||National Institutes of Health Clinical Center (CC)||Recruiting|December 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|43000|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339235||181500|
NCT00339716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995021|Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident|Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident||National Institutes of Health Clinical Center (CC)||Recruiting|March 1994|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|21000|||Both|N/A|46 Years|No|||January 2016|January 29, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339716||181463|
NCT00336895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A-US27|Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients|Conversion of CellCept to Myfortic: A Prospective Study on the Tolerability and Safety of Myfortic in Liver Transplant Recipients||University of Pittsburgh|Yes|Recruiting|November 2006|November 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||October 2008|October 2, 2008|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336895||181673|
NCT00340301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903210|Exposure to Neurotoxins as Risk Factors for ALS|Exposure to Neurotoxins as Risk Factors for ALS: Measurement of Genes, Proteins, Neurotoxicants, and Other Factors Potentially Associated With ALS||National Institutes of Health Clinical Center (CC)||Completed|June 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|397|||Both|N/A|N/A|No|||February 2016|February 17, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340301||181425|
NCT00340314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAF/02|A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF)|A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial|APAF2|IRCCS San Raffaele||Completed|January 2005|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||198|||Both|18 Years|70 Years|No|||May 2006|July 27, 2010|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340314||181424|
NCT00336882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2005-006213-40|Anaesthesia With Propofol Versus Midazolam : Effect on Oxidative Stress in the Brain of Head Trauma Patients|Anaesthesia With Propofol Versus Midazolam : Effect on Oxidative Stress in the Brain of Head Trauma Patients|PROMIS|Rennes University Hospital|No|Terminated|June 2006|February 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00336882||181674|
NCT00337545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD0012467|Phase II Trial of RAD001 in Refractory Colorectal Cancer|Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer||Swedish Medical Center||Completed|May 2006|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|No|||October 2007|October 5, 2007|June 15, 2006||||No||https://clinicaltrials.gov/show/NCT00337545||181627|
NCT00339937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998035|Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily|Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily||National Institutes of Health Clinical Center (CC)||Completed|April 1998|||||N/A|Observational|N/A|||Anticipated|8000|||Both|N/A|99 Years|No|||February 2016|February 23, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339937||181448|
NCT00339950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900010|Colorectal Neoplasia Screening With Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Centers: The CONCeRN Trial|Diet, Other Risk Factors, Genetics and the Risk of Colorectal Neoplasia in a Screening Trial of Asymptomatic Women: A Sub-Study of the CONCeRN Trial||National Institutes of Health Clinical Center (CC)||Completed|February 2000|||||N/A|Observational|N/A|||Anticipated|1500|||Female|40 Years|79 Years|No|||August 2015|September 16, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339950||181447|
NCT00336843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2005-276|Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma|Combining 90Y-ibritumomab Tiuxetan With High-dose Chemotherapy of BuCyE and Autologous Stem Cell Transplantation in Patients With B-cell Non-Hodgkin's Lymphoma - an Open-labeled Phase II Study||Asan Medical Center|Yes|Completed|November 2005|May 2010|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|64 Years|No|||February 2016|February 13, 2016|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00336843||181677|
NCT00337142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4266-AM-CTIL|Follow up Glucose Levels Among Infants of Diabetic Mothers|||Sheba Medical Center||Completed|June 2006|December 2006|Actual|December 2006|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|1 Day|No|Non-Probability Sample|primary care clinic|June 2009|June 28, 2009|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00337142||181656|
NCT00337155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15304|BAY88-8223, Dose Finding Study in Patients With HRPC|A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases||Bayer|No|Completed|May 2006|December 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|122|||Male|18 Years|N/A|No|||December 2014|December 23, 2014|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00337155||181655|
NCT00337168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0530|S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase II Trial of Cytarabine and Clofarabine in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)||Southwest Oncology Group|Yes|Completed|October 2006|January 2013|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|16 Years|N/A|No|||March 2015|March 5, 2015|June 13, 2006|Yes|Yes||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00337168||181654|
NCT00337467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-227|Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression|Phase IIIb Multicenter, Single Arm, Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY (Only REYataz) Study|OREY|Bristol-Myers Squibb|No|Completed|June 2006|May 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||June 2010|June 18, 2010|June 14, 2006|Yes|Yes||No|May 21, 2010|https://clinicaltrials.gov/show/NCT00337467||181633|
NCT00337753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0503M68191|Cognitive Behavioral Therapy for Pathological Gambling|Cognitive Behavioral Therapy for Pathological Gambling||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|June 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|75 Years|No|||January 2010|January 4, 2010|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337753||181611|
NCT00339599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905247|Genetic Predictors of Cardiovascular Disease|Study of Chemokine Markers and Genes as Predictors of Cardiovascular Disease||National Institutes of Health Clinical Center (CC)||Completed|September 2005|August 2015||||N/A|Observational|N/A|||Anticipated|2306|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339599||181472|
NCT00336167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-05-19|Bezafibrate Trial in CPT2 Deficiency|Clinical Trial on the Effect of Bezafibrate in the Muscular Form of Carnitine Palmitoyltransferase 2 Deficiency||Assistance Publique - Hôpitaux de Paris||Recruiting|June 2006|July 2007|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||April 2007|April 6, 2007|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00336167||181727|
NCT00339846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905029|Genetic Analysis of Craniofrontonasal Syndrome|Genetic Analysis of Craniofrontonasal Syndrome||National Institutes of Health Clinical Center (CC)||Completed|January 2005|September 2008||||N/A|Observational|N/A||||152|||Both|N/A|N/A|No|||September 2008|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339846||181455|
NCT00339859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998027|DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer|DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|June 1995|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|5000|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|November 17, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339859||181454|
NCT00339872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3174K1-100|Study Evaluating IMA-638 in Asthma|Randomized, Double-Blind, Placebo-Controlled, Sequential-Group, Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-638 Administered Subcutaneously and Intravenously to Subjects With Asthma||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2006|April 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|50 Years|No|||December 2007|December 3, 2007|June 20, 2006||||||https://clinicaltrials.gov/show/NCT00339872||181453|
NCT00337675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-302|Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared With Placebo in the Treatment of Episodic Asthma in Children Aged 6 Months to 5 Years||Merck Sharp & Dohme Corp.||Completed|October 2006|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1771|||Both|6 Months|5 Years|No|||February 2015|February 6, 2015|June 14, 2006|Yes|Yes||No|February 19, 2010|https://clinicaltrials.gov/show/NCT00337675||181617|
NCT00338286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005143|A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy|A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy||Janssen Research & Development, LLC|Yes|Active, not recruiting|March 2006|June 2017|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2098|||Female|18 Years|99 Years|No|||February 2016|February 23, 2016|June 16, 2006|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00338286||181573|
NCT00338533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vanderbilt IRB # 8542|Endoscopic Goniotomy for Infantile Glaucoma|Endoscopic Goniotomy for Infantile Glaucoma||Vanderbilt University|No|Completed|April 1997|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|3 Years|No|||January 2013|January 6, 2013|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338533||181554|
NCT00339274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900024|International Cooperation for Post-Cherynobyl NIS Thyroid Tissue and Data Banks|The Chernobyl Tissue Bank||National Institutes of Health Clinical Center (CC)||Completed|October 1999|March 2012||||N/A|Observational|N/A|||Anticipated|4000|||Both|N/A|N/A|No|||March 2012|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339274||181497|
NCT00338897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5664|Dose Ranging Study in Elective Total Hip Replacement Surgery|A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery|DRIVE|Sanofi||Completed|May 2006|May 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|1090|||Both|18 Years|N/A|No|||December 2008|December 9, 2008|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00338897||181526|
NCT00338910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-58/BIO|Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy Volunteers|Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy Volunteers||University Hospital Tuebingen|Yes|Completed|May 2006|June 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 10, 2007|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00338910||181525|
NCT00339495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997041|Early Marker and Etiologic Studies in the PLCO Trial|Etiologic and Early Marker Studies in the PLCO Trial||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|156000|||Both|55 Years|74 Years|Accepts Healthy Volunteers|||May 2015|November 10, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339495||181480|
NCT00339781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905109|Predictive and Protective Factors in the Cause of Diabetes - A Study in Twins|Predictive and Protective Factors in the Cause of Diabetes: A Study in Twins||National Institutes of Health Clinical Center (CC)||Completed|February 2005|||September 2007|Actual|N/A|Observational|N/A||||240|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2009|September 22, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339781||181459|
NCT00339729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997029|Johnston County ADHD Study: Environmental, Reporductive, and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD)|Johnston County ADHD Study: Environmental, Reproductive and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD)||National Institutes of Health Clinical Center (CC)||Completed|May 1997|May 2007||||N/A|Observational|N/A||||8000|||Both|8 Years|N/A|Accepts Healthy Volunteers|||May 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00339729||181462|
NCT00337792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002284/1|Comparing the Effectiveness of Oral Versus Intravenous Pain Medicine for Suction Curettage (D&C)|A Randomized Clinical Trial Comparing Oral Conscious Sedation With Intravenous Conscious Sedation for First Trimester Surgical Abortion||Planned Parenthood League of Massachusetts|Yes|Terminated|June 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|132|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|June 15, 2006||No|DSMB review at 50% recruitment, further recruitment unlikely to change result|No||https://clinicaltrials.gov/show/NCT00337792||181608|
NCT00336570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024767|Predictive Medicine Research. (PRE MED)|Predictive Medicine Research (PRE MED) :Investigation of Predictors of Health, Sub-clinical and Clinical Organ System Diseases in Healthy Adult Population.||Emory University|No|Completed|February 2006|October 2010|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|288|Samples With DNA|Whole Blood and Urine were collected. Samples of Serum, Plasma and Urine are stored.|Both|30 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normal subjects between the ages of 30-90.|November 2013|November 15, 2013|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336570||181697|
NCT00336297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MacMillan_VAW_Testing_Trial|Testing Methods of Screening for Woman Abuse in Health Care Settings.|Testing Screening Formats for Indicator-Based and Universal Screening Measurements in the Identification of Woman Abuse.||McMaster University||Completed|May 2004|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||2000|||Female|18 Years|64 Years||||February 2005|November 28, 2006|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00336297||181717|
NCT00336310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSRE0001|A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients|A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients||National Cheng-Kung University Hospital||Not yet recruiting|July 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|30 Years|75 Years|No|||June 2006|June 12, 2006|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336310||181716|
NCT00336583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2006-130|Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)|Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOX) for Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma||Asan Medical Center|Yes|Completed|June 2006|January 2008|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|N/A|75 Years|No|||September 2009|May 25, 2010|June 13, 2006||No||No|May 5, 2009|https://clinicaltrials.gov/show/NCT00336583||181696|
NCT00336856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-006|Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy|A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer||University of Pittsburgh|Yes|Completed|June 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336856||181676|
NCT00338390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUROPA|Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC|Study of Changes in CD4 Lymphocyte Count in Patients With a HAART Regimen Including DDI + Tenofovir and With Viral Suppression Following the Replacement of Tenofovir With Abacavir Once Daily or Following the Double Replacement of DDI + Tenofovir With Abacavir + Lamivudine in a Single Tablet||Hospital de Granollers|No|Completed|April 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|80 Years|No|||October 2008|March 19, 2015|June 15, 2006||||No||https://clinicaltrials.gov/show/NCT00338390||181565|
NCT00336466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17747|The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)|The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial.||University of Calgary||Completed|September 2004|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|45 Years|75 Years|No|||November 2007|November 26, 2007|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336466||181705|
NCT00335894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04I/HMG10|Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).|A Prospective, Randomized, Investigator-blind, Controlled, Clinical Study of Phase III on the Efficacy and Tolerability of hMG-IBSA (IBSA) vs Menopur (Ferring) Administered s.c. in Women Undergoing COH in an ART Programme (IVF)||IBSA Institut Biochimique SA||Completed|May 2005|March 2009||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|144|||Female|18 Years|36 Years|No|||December 2008|March 9, 2010|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00335894||181747|
NCT00336752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-03-113|Operative Versus Non Operative Treatment for Unstable Ankle Fractures|A Prospective Randomized Multi-Centre Study to Compare Operative Versus Non Operative Functional Treatment in Patients With Unstable Isolated Fibula Fractures||Lawson Health Research Institute|No|Completed|June 2003|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00336752||181683|
NCT00339417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906107|Effect of Albendazole Dose on Clearance of Filarial Worms|Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study||National Institutes of Health Clinical Center (CC)||Completed|February 2006|August 2011|Actual|August 2008|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|1000|||Both|14 Years|65 Years|No|||August 2011|August 18, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339417||181486|
NCT00337714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60% MURST no. 7020119-1|Comparison of Central Venous Catheters With Silver Nanoparticles Versus Conventional Catheters|A Parallel, Randomized Multicenter Comparison of Triple Lumen Central Venous Catheters Impregnated With Silver Nanoparticles (AgTive®) Versus Conventional Catheters in Intensive Care Unit Patients|NanoAgCVC|Catholic University of the Sacred Heart|No|Completed|July 2006|September 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|472|||Both|18 Years|N/A|No|||September 2008|May 13, 2011|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337714||181614|
NCT00337987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507000369|A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma|A Pilot Phase II Study to Determine the Safety of the Combination of ONTAK (DAB389IL-2), an Interleukin-2 Fusion Toxin, in Combination With CHOP in Peripheral T-Cell Lymphoma||Yale University||Completed|November 2005|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|June 15, 2006|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00337987||181595|
NCT00339508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902152|Exploratory Data Analysis for Disease Pedigrees and Cancer Genetics|Exploratory Data Analysis for Disease Pedigrees and Cancer Genetics||National Institutes of Health Clinical Center (CC)||Completed|March 2002|||||N/A|Observational|N/A|||Anticipated|25000|||Both|N/A|N/A|No|||September 2015|October 27, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339508||181479|
NCT00340327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3174K1-101|Study Evaluating IMA-638 in Healthy Japanese|An Ascending Single Dose Study of the Safety and Pharmacokinetics of IMA-638 Administered to Healthy Japanese Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2006|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00340327||181423|
NCT00339742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903146|Stomach and Esophageal Cancers in Northern Iran|Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Phase I: Case-Control Study||National Institutes of Health Clinical Center (CC)||Completed|March 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1200|||Both|18 Years|99 Years|No|||February 2016|February 24, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339742||181461|
NCT00339768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995029|A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province|Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province, China||National Institutes of Health Clinical Center (CC)||Completed|May 1995|June 1996|Actual|June 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|3600|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 17, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339768||181460|
NCT00336362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|464|Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major|A Pilot Study to Assess the Safety and Efficacy of G-CSF Mobilization With and Without Hydroxyurea Pretreatment in Adults With Beta Thalassemia Major||University of Washington|Yes|Completed|July 2006|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|50 Years|No|||December 2012|December 18, 2012|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336362||181712|
NCT00336336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G105|GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF|A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure||Gruppo di Ricerca GISSI|Yes|Completed|August 2002|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|6975|||Both|18 Years|N/A|No|||September 2010|August 13, 2015|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336336||181714|
NCT00336349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMUH20060504|A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Neuropathic Foot Pain|A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Neuropathic Foot Pain||Taipei Medical University Hospital|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|30|||Both|30 Years|N/A|No|||July 2011|July 25, 2011|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336349||181713|
NCT00336908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2030001 71860000074|Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery|Inflammatory Responses of Intravenous Fish Oil, Soybean Oil and Medium Chain Triglyceride Fat Emulsions in Young Children Before and After Open Heart Surgery||University of Alberta||Completed|November 2005|November 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|32|||Both|N/A|3 Months|No|||November 2007|November 26, 2007|June 13, 2006||||No||https://clinicaltrials.gov/show/NCT00336908||181672|
NCT00336921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9645|Alfuzosin for Treating Acute Urinary Retention|A Double-blind, Randomized,Placebo Controlled Study of Alfuzosin 10mg od in the Return to Successful Voiding in Patients With a First Episode of Acute Urinary Retention Due to Benign Prostatic Hyperplasia||Sanofi||Completed|February 2006|||April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|156|||Male|50 Years|80 Years|No|||September 2009|September 14, 2009|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00336921||181671|
NCT00336011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186/02|Safety of Cardiac Pacemakers in 1.5T Tesla MRI|Studie Zur Sicherheit Von Medtronic Schrittmachern Bei Magnetresonanz-Bildgebungsverfahren an 1,5 Tesla-Systemen Study to Evaluate Safety Medtronic Pacemakers in MR Imaging at 1.5T Tesla)||University Hospital, Bonn||Completed|December 2002|January 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||75|||Both|N/A|N/A|No|||January 2006|June 9, 2006|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00336011||181738|
NCT00336869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024856|Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership|Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership|Meta-Health|Emory University||Completed|December 2005|January 2010|Actual|January 2010|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|680|Samples Without DNA|Blood samples metabolic testing|Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|African American and White residents age 30-65|November 2013|November 15, 2013|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336869||181675|
NCT00337194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02822|SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Randomized Double-Blinded Placebo Controlled Phase II Study of the Anti-CD30 Antibody, SGN-30 (NSC #731636), in Combination With Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD) for Patients With Relapsed/Refractory Hodgkin Lymphoma||National Cancer Institute (NCI)||Completed|April 2006|October 2014|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2014|February 10, 2015|June 13, 2006|Yes|Yes||No|February 10, 2015|https://clinicaltrials.gov/show/NCT00337194||181652|
NCT00337207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05C3|Bevacizumab in Treating Patients With Recurrent or Progressive Glioma|A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas||Northwestern University|Yes|Active, not recruiting|March 2006|December 2016|Anticipated|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|June 13, 2006|Yes|Yes||No|October 21, 2012|https://clinicaltrials.gov/show/NCT00337207||181651|
NCT00337506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 03/6-E|Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|A Multicenter Open-Label Phase II Study of Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma||Nantes University Hospital||Terminated|August 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|No|||August 2004|June 15, 2006|June 14, 2006||||No||https://clinicaltrials.gov/show/NCT00337506||181630|
NCT00339313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900005|Food Intake and Appetite in the Children of Mothers With Diabetes|Food Intake and Appetite in the Children of Mothers With Diabetes||National Institutes of Health Clinical Center (CC)||Completed|January 2000|June 2011||||N/A|Observational|N/A|||Anticipated|240|||Both|7 Years|10 Years|No|||June 2011|June 25, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339313||181494|
NCT00335907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-23 NIGMS 2005|Protocol-driven Hemodynamic Support for Patients With Septic Shock|Protocol-driven Hemodynamic Support for Patients With Septic Shock||National Institute of General Medical Sciences (NIGMS)||Recruiting|September 2006|January 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||August 2010|August 23, 2010|June 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00335907||181746|
NCT00336778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22675|Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression|A Phase I Pilot Study Of An Antiretroviral Bridging Regimen In Highly Experienced Patients Unable To Achieve Viral Suppression.||University of Maryland|Yes|Completed|January 2004|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2010|May 21, 2010|June 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00336778||181681|
NCT00337402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0001|Effects of Gastrostomy on Amyotrophic Lateral Sclerosis|Effects of Gastrostomy on Quality of Life and Survival in Patients With Amyotrophic Lateral Sclerosis||University Hospital, Clermont-Ferrand||Completed|January 2002|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||380|||Both|18 Years|N/A|No|||June 2006|November 20, 2006|June 15, 2006||||No||https://clinicaltrials.gov/show/NCT00337402||181638|
NCT00347750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2006.CTIL|Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations|Pharmacokinetics and Pharmacodynamics of Lopinavir an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations||Rambam Health Care Campus||Withdrawn|September 2006|September 2007|Actual|September 2007|Actual|Phase 3|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|60 Years|No|||April 2007|November 1, 2015|July 3, 2006|||lack of participants|No||https://clinicaltrials.gov/show/NCT00347750||180877|
NCT00347763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WellcomeTrust 059134|Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania|Strategies for the Control of Blinding Trachoma: Effect of Fly Spray||Johns Hopkins University||Completed|June 2000|October 2002|Actual|September 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2|||350|||Both|12 Months|8 Years|Accepts Healthy Volunteers|||May 2004|April 12, 2013|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347763||180876|
NCT00338871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alyn1CTIL|Home Based Exercise Program for Brain Injury Children|||Alyn Pediatric & Adolecent Rehabilitation Center||Completed|June 2006|April 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|6 Years|18 Years|No|||April 2007|February 14, 2011|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00338871||181528|
NCT00338884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181110|Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer|A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer||Pfizer||Completed|September 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|N/A|N/A|No|||August 2012|August 22, 2012|June 16, 2006|Yes|Yes||No|April 20, 2010|https://clinicaltrials.gov/show/NCT00338884||181527|
NCT00340002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997065|Fetal Anatomy by Three-Dimensional Ultrasound|Fetal Anatomy by Three-Dimensional Ultrasound||National Institutes of Health Clinical Center (CC)||Recruiting|November 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|7000|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340002||181443|
NCT00340015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995025|A Prospective Study of Diet and Cancer in Members of the American Association of Retired Persons|NCI-AARP Diet and Health Study||National Institutes of Health Clinical Center (CC)||Completed|October 1995|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|566401|||Both|50 Years|69 Years|No|||February 2016|February 23, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340015||181442|
NCT00340028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905087|Hormonal Changes in Early Pregnancy|Hormonal Changes in Early Pregnancy: Pilot Study to Evaluate Stored Urine Specimens||National Institutes of Health Clinical Center (CC)||Completed|January 2005|||||N/A|Observational|N/A|||Anticipated|80|||Female|25 Years|35 Years|No|||February 2016|March 2, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340028||181441|
NCT00336063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00089|Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma|A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|March 2006|||October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|N/A|No|||March 2016|March 10, 2016|June 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00336063||181735|
NCT00340340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901211|Genetic Epidemiology of Lung Cancer and Smoking|Genetic Epidemiology of Lung Cancer and Smoking Current Title: Environmental And Genetic Lung Cancer Etiology (EAGLE)||National Institutes of Health Clinical Center (CC)||Completed|June 2001|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|4500|||Both|35 Years|79 Years|No|||January 2016|February 12, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340340||181422|
NCT00336050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1341|Effect of Air Pollution on Long-Term Asthma Severity and Lung Function in Children|Fresno Asthmatic Children's Environment Study|FACES|National Heart, Lung, and Blood Institute (NHLBI)|No|Active, not recruiting|November 2000|September 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|315|Samples With DNA|Password-protected database and storage facility that is part of the UCB SPH biorepository|Both|6 Years|11 Years|No|Non-Probability Sample|Convenience sample of children ages 6-11 at intake with proven asthma. All live within a        radius of 20 km from the EPA Super Site in Fresno, CA|February 2009|February 11, 2009|June 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00336050||181736|
NCT00336375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/04/2006|Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping|Treatment of Uncomplicated Childhood Malaria by an Artemisinin Derivative in Combination With Lumefantrine. Efficacy, Safety and Genotyping.||Karolinska University Hospital||Completed|June 2006|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|1 Year|10 Years|No|||October 2007|October 31, 2007|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336375||181711|
NCT00337233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481279|Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer|Restorative Yoga for Symptom Management and Stress Reduction in Women With Ovarian Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|January 2004|November 2016|Anticipated|November 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|106|||Female|18 Years|120 Years|No|||September 2015|September 30, 2015|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00337233||181649|
NCT00337532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-384|A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer|A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer||Bristol-Myers Squibb||Completed|May 2005|June 2007|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||50|||Both|18 Years|75 Years||||June 2008|February 2, 2010|June 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00337532||181628|
NCT00342212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906131|Actigraph Accelerometer Validation Study|Actigraph Accelerometer Validation Study||National Institutes of Health Clinical Center (CC)||Completed|March 2006|April 2008|Actual|||N/A|Observational|N/A|||||||Both|18 Years|74 Years|Accepts Healthy Volunteers|||May 2011|May 24, 2011|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342212||181280|
NCT00336323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-129|A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)|A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)|Bevacizumab|Diabetic Retinopathy Clinical Research Network|Yes|Completed|June 2006|February 2008|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|121|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|June 9, 2006|Yes|Yes||No|March 16, 2011|https://clinicaltrials.gov/show/NCT00336323||181715|
NCT00336596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-031/2004|Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion|Transcranial Ultrasound Enhanced Thrombolysis (TRUST)||University of Zurich|Yes|Recruiting|June 2006|June 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|N/A|N/A|No|||April 2007|April 25, 2007|June 13, 2006||||No||https://clinicaltrials.gov/show/NCT00336596||181695|
NCT00336609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 200509024|TRIAD Burden of Illness Mucositis Study|Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-Small Cell Lung Cancers or Non-Hodgkin's Lymphoma||TRIAD Burden of Illness||Recruiting|November 2005|May 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1600|||Both|18 Years|N/A|No|||April 2007|April 19, 2007|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336609||181694|
NCT00337519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL #02|Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia|Chemo-Immunotherapy With Allogeneic Blood Stem Cell Transplantation in Patients With Chronic Lymphocytic Leukemia (Study #02)||Charite University, Berlin, Germany||Active, not recruiting|January 2003|April 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|N/A|65 Years|No|||January 2009|January 28, 2009|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00337519||181629|
NCT00337766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS/URC/ER/mm 151/DG|Desmopressin in Cardiac Surgery|Efficacy of Desmopressin (1-deamin0-8-D-arginine-vasopressin) in Reducing Active Microvascular Bleeding After Cardiac Surgery||Università Vita-Salute San Raffaele||Completed|June 2006|September 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|18 Years|100 Years|No|||May 2013|October 20, 2015|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00337766||181610|
NCT00337779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA/9016 (FORTE)|Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).|A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)||Teva Pharmaceutical Industries||Completed|August 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1155|||Both|18 Years|55 Years|No|||October 2011|October 6, 2011|June 14, 2006|Yes|Yes||No|January 18, 2010|https://clinicaltrials.gov/show/NCT00337779||181609|
NCT00338078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241/98, dnr 98-165|Nocturnal Oxygen Treatment in Heart Failure and Cheyne-Stokes Respiration|Nocturnal Oxygen Treatment in Heart Failure and Cheyne-Stokes Respiration. A Randomized Double-Blind Placebo Controlled Cross-Over Study||Umeå University||Completed|March 1999|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|19 Years|90 Years|No|||June 2008|July 1, 2008|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00338078||181588|
NCT00338091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROAD|Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency|||Southern Medical University, China||Terminated|January 2002|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2002|June 16, 2006|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00338091||181587|
NCT00336492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012388|A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis|A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE�) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis||Centocor, Inc.||Completed|September 2006|April 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|6 Years|17 Years|No|||July 2013|July 24, 2013|June 9, 2006|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00336492||181703|
NCT00337415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0354-004|MK0354 Clinical Efficacy and Tolerability Study (0354-004)|Proprietary Information - Exploratory (Non-Confirmatory) Trial||Merck Sharp & Dohme Corp.||Terminated|May 2006|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|65|||Both|18 Years|75 Years|No|||May 2015|May 15, 2015|June 14, 2006||||||https://clinicaltrials.gov/show/NCT00337415||181637|
NCT00337922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104807|Pharmacokinetic Study Of EPZICOM Tablet|Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) - Pharmacokinetic Study in HIV-Infected Patients -||GlaxoSmithKline||Completed|July 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|20 Years|64 Years|No|||October 2008|October 15, 2008|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00337922||181600|
NCT00337935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012229|A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.|An Open-Label, Randomized, Multi-center, Controlled Study of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease in the Long Term Care Setting||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|June 16, 2006|Yes|Yes||No|July 16, 2010|https://clinicaltrials.gov/show/NCT00337935||181599|Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment.
NCT00347776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01EY013878|Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia|Trial of Antibiotics to Reduce Recurrent Trichiasis (STAR)|STAR|Johns Hopkins University|Yes|Completed|August 2001|December 2006|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3|||1450|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|July 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00347776||180875|
NCT00338364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3202|Painful Procedures in the Emergency Department: A Distraction Intervention|Painful Procedures in the Emergency Department:Does a Formal Program in Distracting Techniques for Parents and Children Reduce Pain and Anxiety in Children?|ERPain|IWK Health Centre|No|Completed|January 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|189|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338364||181567|
NCT00340054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99906013|Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields|Assessment of Occupational EMF Exposure - Validation of Interview Procedures Used in Brain Tumor Study||National Institutes of Health Clinical Center (CC)||Completed|October 2005|March 2007|Actual|||N/A|Observational|N/A|||Anticipated|108|||Both|18 Years|65 Years|No|||March 2012|March 7, 2012|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340054||181440|
NCT00344825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306003|Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)|Observational Study for Evaluation of Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia.||Sanofi|No|Completed|January 2004|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, aged >/= 18 years, either sex with B-CLL, who are starting a new pharmacological        treatment for B-CLL (1st, 2nd, 3rd, 4th), duration of CLL therapy </= 6 months, WHO        Performance Status &#8804; 2, life expectancy >/= 6 months|December 2013|December 2, 2013|June 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00344825||181097|
NCT00344838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903-556|Customized Laser Ablation: Comparing Results of LADAR Vision and VISX Platforms|Customized Laser Ablation: Comparing Results of LADAR Vision and VISX Platforms||University of Texas Southwestern Medical Center||Recruiting|September 2003|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||June 2006|June 23, 2006|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344838||181096|
NCT00340353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905138|Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research|Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development||National Institutes of Health Clinical Center (CC)||Completed|April 2005|April 2012||||N/A|Observational|N/A|||Anticipated|99999|||Both|4 Years|N/A|Accepts Healthy Volunteers|||April 2012|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340353||181421|
NCT00336076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0246|Molecular Mechanisms and Diagnosis of Mastocytosis|Investigation of Cellular and Molecular Pathologic Mechanisms in Mast Cell Disorders.||University of Michigan|No|Recruiting|July 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Plasma and nucleic acid.|Both|N/A|N/A|No|Probability Sample|Patients with confirmed or suspected mast cell disease|February 2009|February 12, 2009|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00336076||181734|
NCT00341406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903290|Fat Cell Size in Insulin Resistance|Adipose Cell Size In Human Insulin Resistance||National Institutes of Health Clinical Center (CC)||Recruiting|September 2003|||||N/A|Observational|N/A|||Anticipated|9999999|||Both|18 Years|N/A|No|||September 2015|October 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341406||181341|
NCT00336661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-0605-2|PerioWave Re-Treatment Protocol Compared to Scaling and Root Planing (SRP) and a Single Treatment With PerioWave|A Multicenter, Randomized, Blinded Study of Two Treatments of Photoactivated Disinfection With SRP Against One Treatment of Photoactivated Disinfection With SRP Against SRP Alone in the Treatment of Chronic Periodontitis||Ondine Research Laboratories||Completed|January 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||May 2007|May 17, 2007|June 12, 2006||||No||https://clinicaltrials.gov/show/NCT00336661||181690|
NCT00342446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999996019|A Follow-up Study of Women Evaluated and Treated for Infertility|Follow-Up Study of Women Evaluated and Treated for Infertility||National Institutes of Health Clinical Center (CC)||Completed|June 1996|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|12193|||Female|18 Years|50 Years|No|||November 2015|November 18, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342446||181264|
NCT00342472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998008|Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China|Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China||National Institutes of Health Clinical Center (CC)||Completed|July 1998|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|19 Years|N/A|No|||August 2015|September 16, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342472||181263|
NCT00337220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-04|Urine Testing to Detect Kidney Transplant Rejection|Noninvasive Diagnosis of Renal Allograft Rejection by Urinary Cell mRNA Profiling||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|492|Samples With DNA|Blood and urine collection|Both|N/A|80 Years|No|Non-Probability Sample|Patients who have recently undergone kidney transplant|August 2013|August 13, 2013|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337220||181650|
NCT00338403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14357A|Effects of Continuous Airway Pressure on the Ability to Heat and Humidify Air|Effects of Continuous Airway Pressure on the Ability to Heat and Humidify Air||University of Chicago||Completed|June 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label||||10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338403||181564|
NCT00338637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4127-AA-CTIL|Measuring the Balance Improvement on Multiple Sclerosis Patients After a Short Training Period With an APOS (All Phase Of Step Cycle) Kit|||Sheba Medical Center||Recruiting|April 2006|October 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||June 2006|June 19, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00338637||181546|
NCT00338650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-808|Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)|A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab||Abbott||Completed|June 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|18 Years|75 Years|No|||November 2007|November 28, 2007|June 19, 2006||||||https://clinicaltrials.gov/show/NCT00338650||181545|
NCT00342186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902323|Genes Involved in Resistance or Susceptibility to Hepatitis B Virus|Human Genes Involved in Susceptibility or Resistance to Hepatitis B Virus||National Institutes of Health Clinical Center (CC)||Completed|September 2002|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|3400|||Both|8 Years|90 Years|No|||January 2016|March 10, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342186||181282|
NCT00338949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH074540|Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes|The Metabolic Syndrome in Patients With Schizophrenia||Veterans Medical Research Foundation|No|Completed|June 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|65 Years|No|||August 2013|August 6, 2013|June 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338949||181522|
NCT00342407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902039|The Incidence of Breast and Other Cancers Among Female Flight Attendants|The Incidence of Breast and Other Cancers Among Female Flight Attendants||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2001|||||N/A|Observational|N/A|||Anticipated|10000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 6, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342407||181266|
NCT00337077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00566|Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of E7389 (Halichondrin B Analog), in Patients With Metastatic Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)|No|Completed|November 2006|November 2013|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Male|18 Years|N/A|No|||April 2014|May 21, 2014|June 13, 2006|Yes|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00337077||181661|
NCT00337090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-044|A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)|A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder||Astellas Pharma Inc||Completed||March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1108|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|June 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00337090||181660|
NCT00347425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.3.020|Switch Study of Existing Atypical Antipsychotics to Bifeprunox|A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder||Solvay Pharmaceuticals|No|Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|65 Years|No|||May 2008|May 20, 2008|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00347425||180901|
NCT00347438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14201B|Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer|A Phase II Study to Evaluate the Efficacy, Safety, and Genomic Markers of Response of Capecitabine as NeoAdjuvant Therapy in Women With Newly Diagnosed Locally Advanced Breast Cancer||University of Chicago|Yes|Terminated|September 2006|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||November 2015|November 5, 2015|June 29, 2006|Yes|Yes|a result of slow accrual|No|October 5, 2015|https://clinicaltrials.gov/show/NCT00347438||180900|
NCT00347165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AvastinDMRE|Intravitreal Bevacizumab for Age-Related Macular Degeneration|Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot Study||Asociación para Evitar la Ceguera en México||Recruiting|September 2005|September 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|50 Years|N/A|No|||June 2006|June 30, 2006|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347165||180921|
NCT00347464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-295|Adaptive Behavior Assessment of Men With 49, XXXXY, Klinefelter Syndrome|Adaptive Behavior Assessment of Men With 49, XXXXY, Klinefelter Syndrome||University of Wisconsin, Madison|No|Withdrawn|June 2006|August 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Male|2 Years|21 Years|No|Non-Probability Sample|Klinefelter males ages 2-21 with proven 49,XXXXY karyotype|December 2015|December 1, 2015|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00347464||180898|
NCT00338923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO-01-05|Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.|Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.||HealOr||Completed|June 2006|May 2007|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2007|August 16, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00338923||181524|
NCT00344513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105517/358|Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)|Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients||GlaxoSmithKline||Completed|December 2002|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50000|||Both|N/A|N/A|No|||October 2010|October 1, 2010|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344513||181121|
NCT00344526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I00001|Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis|Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial .||University Hospital, Limoges||Completed|January 2000|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||June 2007|June 27, 2007|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00344526||181120|
NCT00341198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902166|Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study|Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study||National Institutes of Health Clinical Center (CC)||Completed|April 2002|December 2006||||N/A|Observational|N/A||||700|||Both|N/A|N/A|No|||December 2006|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341198||181357|
NCT00340964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905173|Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences|Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences||National Institutes of Health Clinical Center (CC)||Completed|June 2005|January 2014||||N/A|Observational|N/A|||Anticipated|70|||Both|12 Years|20 Years|No|||January 2014|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340964||181375|
NCT00340977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999996006|Svangerskap, Arv, og Miljo (Pregnancy, Heredity and Environment)|Svangerskap, Arv, Og Miljo (Pregnancy, Heredity and Environment)||National Institutes of Health Clinical Center (CC)||Completed|September 1995|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|6000|||Both|N/A|1 Year|No|||January 2016|January 9, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340977||181374|
NCT00336622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402010|Efficacy of Wrist/Hand Splints and Tendon/Nerve Gliding Exercises for Carpal Tunnel Syndrome: A RCT|The Efficacy of a Wrist and Hand Splint in Conjunction With Tendon and Nerve Gliding Exercise for the Treatment of Carpal Tunnel Syndrome: A Randomized Clinical Trial||University of Pittsburgh|No|Completed|June 2004|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||February 2011|February 18, 2011|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336622||181693|
NCT00336635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_SPX_101|Safety and Immunogenicity of CJ-50300|Randomized, Double Blind, Placebo Control Study to Evaluate the Safety and Immunogenicity of CJ-50300 in Healthy Volunteers : Phase I||Seoul National University Hospital|Yes|Completed|June 2006|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||24|||Both|20 Years|28 Years|Accepts Healthy Volunteers|||April 2007|April 17, 2007|June 13, 2006||||No||https://clinicaltrials.gov/show/NCT00336635||181692|
NCT00336648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0784|Preop Chemoradiation Resectable Pancreas|A Phase II Pilot Study of Preoperative Gemcitabine and Bevacizumab-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreas||M.D. Anderson Cancer Center|No|Completed|June 2006|July 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|June 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00336648||181691|
NCT00341692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903158|Studying Normal Breast Tissue and Cancer Risk|Pilot Study to Collect Normal Breast Tissue From Organ and Tissue Donors||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 2003|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|20|||Female|11 Years|N/A|No|||April 2015|August 29, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341692||181319|
NCT00338104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0361-028|Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin|Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin||Northwestern University|No|Completed|July 2004|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|80 Years|No|||March 2009|April 3, 2009|June 15, 2006||No||No|December 1, 2008|https://clinicaltrials.gov/show/NCT00338104||181586|not all patients were analyzed in each group because insulin not given appropriately to those patients
NCT00338117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005884|Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease|A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 1995|May 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|554|||Both|45 Years|N/A|No|||April 2010|April 26, 2010|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00338117||181585|
NCT00341900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902043|Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews|Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews||National Institutes of Health Clinical Center (CC)||Completed|November 2001|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|140|||Male|25 Years|60 Years|No|||April 2015|May 5, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341900||181303|
NCT00341913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900012|Network on Antimicrobial Resistance in Staphylococcus Aureus|Network on Antimicrobial Resistance in Staphylococcus Aureus||National Institutes of Health Clinical Center (CC)||Completed|March 2000|June 2008||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||June 2008|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341913||181302|
NCT00342173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999030|Costa Rican Natural History Study of HPV and Cervical Neoplasia|Costa Rican Natural History Study of HPV and Cervical Neoplasia||National Institutes of Health Clinical Center (CC)||Completed|May 1999|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|12000|||Female|18 Years|100 Years|No|||January 2016|February 17, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342173||181283|
NCT00342199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901190|Surveillance of Streptococcal Infections in Children in India|Epidemiological Surveillance in India of Group A Streptococcal Infections Including Pharyngitis and Impetigo Supported by Indo-US Vaccine Action Program||National Institutes of Health Clinical Center (CC)||Completed|July 2001|February 2014||||N/A|Observational|N/A|||Anticipated|663|||Both|N/A|20 Years|No|||February 2014|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342199||181281|
NCT00343356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LanZhou University|Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder|Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management||LanZhou University||Completed|June 1996|July 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||138|||Both|26 Years|72 Years|No|||May 1996|June 21, 2006|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00343356||181203|
NCT00343616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000482396|Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98|Investigating Cognitive Function for Patients Participating in the BIG Trial 1-98 in Select Centers||International Breast Cancer Study Group|Yes|Completed|April 2005|May 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|135|||Female|30 Years|N/A|No|||July 2012|July 26, 2012|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00343616||181184|
NCT00347152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10399|Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability|Overnight Versus Progressive Conversion of Multiple Daily Dose Enteric-Coated Divalproex to Once-Daily Divalproex Extended Release: Which Strategy is Better Tolerated by Patients With Intellectual Disabilities?||University of Kansas Medical Center|No|Completed|November 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||September 2008|September 10, 2008|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00347152||180922|
NCT00347412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV002-C301|Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer|Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)||Cellectar Biosciences, Inc.|Yes|Completed|November 2006|February 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|880|||Both|18 Years|N/A|No|||March 2010|November 7, 2011|June 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00347412||180902|
NCT00347451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R415/10/2005|Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.|Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.||Singapore National Eye Centre||Completed|October 2005|June 2006|Actual|June 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Myopic subjects|May 2010|May 11, 2010|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347451||180899|
NCT00347815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-001-ML|Pharmacokinetics and Pharmacodynamics of Buprenorphine in Healthy Volunteers|Pharmacokinetics and Pharmacodynamics of Buprenorphine After Intravenous Administration in Healthy Volunteers||Danish University of Pharmaceutical Sciences||Recruiting|June 2006|August 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2006|July 3, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00347815||180872|
NCT00341029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906045|Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate|Measurement of Cytogenetic Endpoints in Lymphocytes of Children Diagnosed With Attention Deficit/Hyperactivity Disorder (ADHD) and Treated With Methylphenidate or Adderall||National Institutes of Health Clinical Center (CC)||Completed|December 2005|September 2007|Actual|September 2007|Actual|N/A|Observational|N/A||||84|||Both|6 Years|12 Years|No|||June 2009|August 27, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341029||181370|
NCT00341419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905106|Genetic Analysis of Patients With Pseudoxanthoma Elasticum|Genetic Analysis of Patients With Pseudoxanthoma Elasticum (PXE)||National Institutes of Health Clinical Center (CC)||Completed|February 2005|May 2013||||N/A|Observational|N/A|||Anticipated|200|||Both|12 Years|N/A|No|||May 2013|February 19, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341419||181340|
NCT00341172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905023|The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis|Discovery of Genetic Variants Contributing to the Incidence or Course of CMV Disease in AIDS Patients||National Institutes of Health Clinical Center (CC)||Completed|October 2004|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|2500|||Both|13 Years|100 Years|No|||April 2015|March 18, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341172||181359|
NCT00341185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998014|Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing|Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing||National Institutes of Health Clinical Center (CC)||Completed|March 1998|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|3000|||Both|63 Years|71 Years|No|||October 2015|November 17, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341185||181358|
NCT00315926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-3109|Melatonin and Cardiac Outcome After Major Surgery|Melatonin and Cardiac Morbidity After Elective Abdominal Aortic Aneurism Repair||University Hospital, Gentofte, Copenhagen|Yes|Completed|January 2007|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|80 Years|No|||November 2006|June 29, 2010|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00315926||183238|
NCT00315939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12126|Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes|Improving Metabolic Control and Reducing Hypoglycemic Risk in Type 1 Diabetes Mellitus With Biological and Behavioral Feedback|BPK002|University of Virginia|No|Completed|January 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|N/A|No|||August 2014|September 9, 2014|April 18, 2006||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT00315939||183237|
NCT00315952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06020777|Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes|Open-Label Randomized Two-Way Crossover Pilot Study to Estimate the Effects of Inhaled vs. IV Infusion of Human Insulin With Regards to Glucose Disposal in Subjects With Type 1 Diabetes Mellitus||University of Pittsburgh||Completed|April 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|50 Years|No|||February 2008|February 15, 2008|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00315952||183236|
NCT00316186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/903|First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin|An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer||GlaxoSmithKline||Completed|June 2005|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 19, 2006|Yes|Yes||No|April 29, 2009|https://clinicaltrials.gov/show/NCT00316186||183218|
NCT00316199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9803|Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer|Phase II Study of Gemcitabine-Paclitaxel 3-Weekly Schedule as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure||Eli Lilly and Company|No|Completed|April 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||June 2009|June 12, 2009|April 18, 2006|Yes|Yes||No|April 22, 2009|https://clinicaltrials.gov/show/NCT00316199||183217|
NCT00316459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142A2-110|Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects|A Randomized, Double-Blind, Placebo and Moxifloxacin (Open-Label) Controlled, 4-Period, Crossover Study of the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2007|April 11, 2007|April 18, 2006||||||https://clinicaltrials.gov/show/NCT00316459||183197|
NCT00326274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN.750.04|Clinical Safety Trial of Long-Term Intermittent Use of Helioblock® SX Cream|||Loreal USA||Completed|May 2006|November 2006||November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|6 Months|12 Years||||February 2009|February 10, 2009|May 15, 2006||Yes||||https://clinicaltrials.gov/show/NCT00326274||182457|
NCT00316719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF105220|Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients|Phase III Study of Adefovir Dipivoxil Tablets in Patients With Compensated Chronic Hepatitis B -Comparative Study Against Lamivudine-||GlaxoSmithKline||Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|16 Years|64 Years|No|||October 2009|October 1, 2009|April 19, 2006||||No|June 15, 2009|https://clinicaltrials.gov/show/NCT00316719||183177|
NCT00316966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor323202ctil|A Clinical Trial to Determine Outcomes and Cost Effectiveness of Nutritional Intervention in Elderly Patients|||Soroka University Medical Center||Completed|June 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|65 Years|95 Years|No|||May 2005|August 9, 2010|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00316966||183158|
NCT00313443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATACA-URT04/06|Concentrations of Amiodarone in Fat Tissue During Chronic Treatment|Study of Concentrations of Amiodarone in Fat Tissue Obtained by Needle Aspiration in Patients on Chronic Treatment|ATACA|Hopital Lariboisière|No|Completed|April 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||June 2009|July 6, 2011|April 10, 2006||No||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00313443||183426|Small number of patients included. High variability of amiodarone concentrations in fat tissue between the 2 simultaneous samples for some patients. Incidence of amiodarone-related adverse effects probably overestimated.
NCT00314678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 99-25|Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer|Cisplatin Induction Followed by Paclitaxel Consolidation for the Treatment of Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer With In Vitro Correlates of Response||University of California, Irvine||Completed|September 2005|April 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||December 2007|December 7, 2007|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314678||183334|
NCT00314691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3612|Development of New Prenatal Diagnostic Tests From Maternal Blood|Development of New Prenatal Diagnostic Tests From Maternal Blood||University Hospital, Strasbourg, France||Terminated|April 2006|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 27, 2011|April 12, 2006|||Leaving of the person responsible for the data collection|No||https://clinicaltrials.gov/show/NCT00314691||183333|
NCT00314652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP99-0203|Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.|A Double-Blind Placebo-Controlled Study of Buprenorphine Transdermal System (BTDS) in Patients With Osteoarthritis of the Hip or Knee||Purdue Pharma LP||Completed|June 1999|October 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|18 Years|N/A|No|||April 2006|April 29, 2006|April 12, 2006||||||https://clinicaltrials.gov/show/NCT00314652||183336|
NCT00314951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101.1.C.003|Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)|||Merck Sharp & Dohme Corp.|Yes|Completed|May 2006|August 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|629|||Both|16 Years|N/A|No|||September 2011|April 27, 2015|April 13, 2006|Yes|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00314951||183313|
NCT00318825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-05225|Nitrous Oxide for Analgesia During Colonoscopy|Use of Nitrous Oxide for Analgesia During Colonoscopy - A Randomised Trial||Rikshospitalet University Hospital||Completed|April 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|90 Years|No|||April 2006|November 30, 2010|April 25, 2006||||No||https://clinicaltrials.gov/show/NCT00318825||183017|
NCT00319163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A2-108|Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women|An Open-label, Single-dose, Randomized, 2-period, Crossover, Bioequivalence Study to Compare Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||26|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2009|August 5, 2009|April 26, 2006||||||https://clinicaltrials.gov/show/NCT00319163||182992|
NCT00319462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-260|Localization of Point A in Cervical Cancer|Localization of Anatomic Point A in Cervical Cancer Patients||Mackay Memorial Hospital|Yes|Recruiting|November 2006|April 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||20|||Female|30 Years|75 Years|No|||April 2006|April 18, 2007|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319462||182969|
NCT00324441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBH-FM-1|Mild Water-Filtered Near Infrared Whole-Body-Hyperthermia as an Adjunct in the Treatment of Fibromyalgia|A Randomized Controlled Trial on the Effectiveness of Mild Water-Filtered Near Infrared Hyperthermia as an Adjunct to a Standard Multimodal Rehabilitation in the Treatment of Fibromyalgia||Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster||Completed|January 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||132|||Both|18 Years|70 Years|No|||August 2003|May 9, 2006|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324441||182594|
NCT00325728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-375-061|Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects||Takeda|No|Completed|March 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|55 Years|N/A|No|||February 2012|February 27, 2012|May 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325728||182499|
NCT00325962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTN-001|A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension||BioMarin Pharmaceutical||Completed|May 2006|December 2008|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|18 Years|N/A|No|||July 2009|July 17, 2009|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325962||182481|
NCT00320892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR416506CTIL|"Death Rattle" - A Double Blind, Randomly Controlled, Crossover Trial|"Death Rattle" - A Double Blind, Randomly Controlled, Crossover Trial||Soroka University Medical Center||Terminated|January 2007|June 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||July 2012|July 3, 2012|May 1, 2006||No|Difficulties in recruiting appropriate participants to the study|No||https://clinicaltrials.gov/show/NCT00320892||182860|
NCT00325026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|594-2004|Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation|Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation||University of Florida||Completed|April 2005|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|130|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 1, 2012|May 10, 2006||||||https://clinicaltrials.gov/show/NCT00325026||182552|
NCT00315198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-114|Trial Comparing Near Versus Distance Activities While Patching for Amblyopia in Children 3 to <7 Years Old|A Randomized Trial Comparing Near Versus Distance Activities While Patching for Amblyopia in Children 3 to <7 Years Old|ATS6|Jaeb Center for Health Research|Yes|Completed|February 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|425|||Both|3 Years|6 Years|No|||May 2009|March 23, 2010|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315198||183294|
NCT00315432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005134|NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection|)A Study to Evaluate the Erythropoietic Response in HCV/HIV Co-Infected Patients Receiving Combination Ribavirin/Interferon Therapy||Ortho Biotech Products, L.P.||Completed|September 2000|November 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|91|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00315432||183276|
NCT00315679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHT01|A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis|||Central Manchester University Hospitals NHS Foundation Trust||Completed|June 1996|November 1998||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|16 Years|65 Years|No|||March 2006|April 18, 2006|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00315679||183257|
NCT00315692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-03 Pelvic Mass Study|Risk of Ovarian Cancer in Patients With a Pelvic Mass|Evaluation of a Multiple Biomarker Assay to Estimate the Risk of Ovarian Cancer in Patients Presenting With a Pelvic Mass.||Fujirebio Diagnostics, Inc.|No|Completed|December 2005|February 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|566|Samples Without DNA|Serum, plasma and urine|Female|18 Years|N/A|No|Probability Sample|Women undergoing surgery for the removal of a pelvic mass.|November 2011|November 7, 2011|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00315692||183256|
NCT00315705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO21800205|A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.|A Phase 1/2 Dose-Escalation Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Pediatric Patients With Refractory or Relapsed Acute Leukemias.||Sanofi|No|Completed|March 2006|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|1 Year|21 Years|No|||March 2014|March 17, 2014|April 18, 2006|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00315705||183255|
NCT00316472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC05-0958|The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients|The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients||Washington University School of Medicine||Completed|April 2006|December 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2009|January 14, 2009|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316472||183196|
NCT00316771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA18439|A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy|A Randomized, Double-blind, Placebo-controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.||Hoffmann-La Roche||Completed|November 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|374|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316771||183173|
NCT00316979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS_Migraine_VGHTPE|Efficacy of rTMS in the Treatment of Patients With Migraine|Therapeutic Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Migraine Using Somatosensory Evoked High-Frequency Oscillations as a Parameter: A 3-year Study.||Taipei Veterans General Hospital, Taiwan|No|Recruiting|April 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|65 Years|No|||June 2010|June 6, 2010|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00316979||183157|
NCT00316732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103500|Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS|An Observational Study to Assess the Effectiveness of Avodart™(Dutasteride)in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice||GlaxoSmithKline||Completed|October 2004|||||Phase 4|Interventional|N/A||||530|||Male|N/A|N/A|No|||October 2012|October 18, 2012|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00316732||183176|
NCT00316745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCSG0601|IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer|Irinotecan Combined With S-1( IRIS ) Followed by mFOLFOX6 Regimen Versus mFOLFOX6 Followed by IRIS Regimen in Advanced Colorectal Cancer||Hokkaido Gastrointestinal Cancer Study Group|Yes|Suspended|April 2006|March 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||October 2007|October 31, 2007|April 19, 2006|||Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line    setting.|No||https://clinicaltrials.gov/show/NCT00316745||183175|
NCT00313105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004626-10|Smoking Cessation With Smokeless Tobacco, Nicotine Tablets and Nicotine Patches|Smoking Cessation by Nurses With Smokeless Tobacco Buccal Tablets, Nicotine Buccal Tablets, Nicotine Patches With Repeated Therapy Every 6 Months for 2 Years||University Hospital, Gentofte, Copenhagen|No|Active, not recruiting|April 2006|August 2010|Anticipated|April 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 14, 2009|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00313105||183452|
NCT00313755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/NBI5/15|Magnification Narrow Band Imaging Colonoscopy for Hereditary Non-Polyposis Colorectal Cancer Surveillance|Back-to Back Trial of Narrow Band Imaging (NBI) With Magnification Versus Standard Colonoscopy for Colonic Neoplasia Surveillance in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients||London North West Healthcare NHS Trust||Completed|April 2006|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||60|||Both|18 Years|N/A|No|||November 2006|November 15, 2007|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00313755||183405|
NCT00314054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-105|Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults|An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of HCV-796 in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2008|April 10, 2008|April 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00314054||183382|
NCT00314392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Placebo|Gender, Pain, and Placebo Analgesia|Effect of Participant Gender, Experimenter Gender, and Drug-Related Information on Placebo Analgesia||University Hospital of North Norway||Completed|September 2006|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|74|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2008|February 4, 2008|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00314392||183356|
NCT00314717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol reference 16929|The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Women With Gestational Hyperglycemia|The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Women With Gestational Hyperglycemia||University of Toronto|No|Completed|April 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|45 Years|No|||August 2007|June 20, 2011|April 13, 2006||||No||https://clinicaltrials.gov/show/NCT00314717||183331|
NCT00314366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT-H-GEN-05-0599|Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)|Phase IB Randomized Controlled Double-Blind Trial of Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells Under Electromechanical Guidance for Therapeutic Angiogenesis||Texas Heart Institute|Yes|Active, not recruiting|April 2006|April 2021|Anticipated|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|70 Years|No|||October 2015|October 20, 2015|April 10, 2006|No|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT00314366||183358|The study is a preliminary study based on a small sample size which limits the statistical rigor of the analysis.
NCT00314665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-08-28-05|Use of Thalidomide in Chronic Uveitis|Use of Thalidomide in Chronic Uveitis||University of Cincinnati||Terminated|January 2004|August 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||15|||Both|18 Years|N/A|No|||December 2007|December 3, 2007|April 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00314665||183335|
NCT00320086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC MO1RROO997|Microalbuminuria in Children With and Without Diabetes|Microalbuminuria in Children With and Without Diabetes||University of New Mexico||Recruiting|August 2005|November 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|220|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Primary care/specialty clinincs and community|September 2008|January 13, 2009|April 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00320086||182921|
NCT00325403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-302|FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)|A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension||United Therapeutics|Yes|Completed|October 2006|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|349|||Both|12 Years|75 Years|No|||February 2013|February 12, 2013|May 11, 2006|Yes|Yes||No|January 3, 2013|https://clinicaltrials.gov/show/NCT00325403||182524|
NCT00326313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4132-TS-CTIL|Clinical Outcome of Neonates With GBS Positive Culture-12 Year Retrospective Study|Clinical Outcome of Neonate With GBS Positive Culture-12 Year Retrospective Study||Sheba Medical Center||Not yet recruiting|June 2006|||||N/A|Observational|N/A||||74|||Both|N/A|2 Weeks|No|||May 2006|May 15, 2006|May 14, 2006||||No||https://clinicaltrials.gov/show/NCT00326313||182454|
NCT00326326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5561005|Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus||Pfizer||Completed|July 2006|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|30 Years|70 Years|No|||May 2009|May 6, 2009|May 12, 2006||||||https://clinicaltrials.gov/show/NCT00326326||182453|
NCT00325039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK58229|TOMUS-Trial Of Mid-Urethral Slings|TOMUS-Trial Of Mid-Urethral Slings|TOMUS|New England Research Institutes|Yes|Completed|April 2006|June 2013|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|597|||Female|21 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 12, 2013|May 10, 2006||No||No|March 26, 2012|https://clinicaltrials.gov/show/NCT00325039||182551|
NCT00325975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030090|Immune Responses to Smallpox Vaccination|Immune Responses to Vaccinia Virus Vaccination||National Institutes of Health Clinical Center (CC)||Completed|February 2003|March 2016||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|69|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00325975||182480|
NCT00314899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0074|Fetal Immunity to Falciparum Malaria|Fetal Immunity to Plasmodium Falciparum Malaria||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|May 2007|September 2011||||N/A|Observational|N/A||||1020|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2007|August 26, 2010|April 13, 2006||||No||https://clinicaltrials.gov/show/NCT00314899||183317|
NCT00314912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-758017|Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease|An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease||Bellus Health Inc||Active, not recruiting|May 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||650|||Both|50 Years|N/A|No|||July 2007|July 13, 2007|April 13, 2006||||||https://clinicaltrials.gov/show/NCT00314912||183316|
NCT00315211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hycamtin study #102143|Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer|Phase 2 Study of Weekly Topotecan With Docetaxel for Recurrent Small Cell Lung Cancer||Aultman Hospital||Terminated|November 2004|June 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 31, 2007|April 17, 2006|||Slow Accrual|No||https://clinicaltrials.gov/show/NCT00315211||183293|
NCT00315224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/019/2004|Sports in Hypertension of the Elderly|The Impact of Pulse Pressure on Cardiovascular Effects of Exercise Training in Hypertension of the Elderly||Charite University, Berlin, Germany||Completed|February 2005|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|61 Years|N/A|No|||March 2005|April 14, 2006|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00315224||183292|
NCT00315445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP96-0604|The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.|A Comparative Study of Buprenorphine TDS, Oxycodone/ Acetaminophen Tablets Qid and Placebo in Patients With Chronic Back Pain|BP96-0604|Purdue Pharma LP||Completed|December 1997|May 1998|Actual|May 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|134|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|April 17, 2006|Yes|Yes||No|May 17, 2011|https://clinicaltrials.gov/show/NCT00315445||183275|There was a large percentage of discontinuations across treatment groups.
NCT00315965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESNOD-01|Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects|Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects||University Hospital Tuebingen|Yes|Recruiting|July 2006|September 2007|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|107|||Both|6 Years|45 Years|Accepts Healthy Volunteers|||May 2007|June 13, 2007|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00315965||183235|
NCT00316212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025-102|Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass|Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel Group Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Graft Surgery Involving Cardiopulmonary Bypass||Merck Sharp & Dohme Corp.||Terminated|April 2006|||August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||160|||Both|18 Years|75 Years||||May 2013|May 24, 2013|April 18, 2006||||||https://clinicaltrials.gov/show/NCT00316212||183216|
NCT00316225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10426|Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen|A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid||Eli Lilly and Company|No|Completed|December 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|April 18, 2006|Yes|Yes||No|March 10, 2010|https://clinicaltrials.gov/show/NCT00316225||183215|
NCT00312806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/M3-341|Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)|Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks||Takeda||Completed|May 2006|July 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|N/A|No|||December 2008|May 4, 2012|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00312806||183475|
NCT00313131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUS 03-32|Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments|A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge||Université de Sherbrooke||Completed|January 2004|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1524|||Female|11 Years|N/A|No|||September 2005|April 7, 2006|April 7, 2006||||No||https://clinicaltrials.gov/show/NCT00313131||183450|
NCT00313118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067-KOA-2005-001|Mean Values of Oxidative Stress Parameters in Healthy Subjects|Determination of the Mean Values of Oxidative Stress Parameters in the Plasma of Healthy Subjects||University Hospital, Basel, Switzerland|No|Suspended|January 2006|September 2016|Anticipated|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|None Retained|plasma|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy persons|October 2015|October 1, 2015|April 10, 2006||No|Problems with recruiting|No||https://clinicaltrials.gov/show/NCT00313118||183451|
NCT00316758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC19794|A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.|A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249||Hoffmann-La Roche||Completed|February 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|259|||Both|30 Years|75 Years|No|||March 2016|March 1, 2016|April 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316758||183174|
NCT00312780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL784-201|Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects With Albuminuria Due to Diabetic Nephropathy||Symphony Evolution, Inc.|Yes|Completed|March 2006|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||February 2010|February 22, 2010|April 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00312780||183477|
NCT00314041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6029A1 D110 P500|Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants|A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 1997|April 1998|Actual|April 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||240|||Both|7 Weeks|10 Weeks|Accepts Healthy Volunteers|||February 2013|February 20, 2013|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00314041||183383|
NCT00314080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH_CER_001|Treatment of Survivors After Botulism Outbreak|An Outbreak of Botulism in Thailand: Clinical Manifestations and Management of Severe Respiratory Failure||Rajavithi Hospital||Completed|March 2006|April 2006||||N/A|Observational|N/A||||18|||Both|1 Year|N/A|No|||August 2007|October 23, 2008|March 30, 2006||||No||https://clinicaltrials.gov/show/NCT00314080||183380|
NCT00314405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3157|Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope|Identification of Sentinel Lymph Node (SLN) in Breast Cancer Care: Clinical and Economical Evaluation of a Double Method Using Isotope and Methylene Blue Dye Injection.||University Hospital, Strasbourg, France||Completed|April 2006|||April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|N/A|No|||February 2008|August 7, 2008|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00314405||183355|
NCT00325520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5984R|A Neurocognitive Model of Anorexia Nervosa|A Neurocognitive Model of Anorexia Nervosa||New York State Psychiatric Institute|Yes|Completed|May 2006|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|152|||Both|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Anorexia Nervosa or Healthy Volunteers|July 2013|August 14, 2014|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00325520||182515|
NCT00314379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP1980|Endothelial Function in a Sample Group of Patients From the ICARE Study|Vitamin E Treatment and Endothelial Function in Type 2 Diabetic Patients With Hp 2-2 Phenotype From the I CARE Study (EFI)||Technion, Israel Institute of Technology||Completed|April 2006|December 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|50|||Both|55 Years|N/A|No|||January 2009|January 20, 2009|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00314379||183357|
NCT00315289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-116|Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old|A Prospective Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old|NLD1|Jaeb Center for Health Research|Yes|Completed|February 2005|September 2006|Actual|||Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|973|||Both|6 Months|47 Months|No|Non-Probability Sample|community sample|January 2010|February 26, 2010|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315289||183287|
NCT00324155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-024|Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma|A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo||Bristol-Myers Squibb|Yes|Completed|August 2006|October 2013|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|681|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|May 8, 2006|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT00324155||182615|
NCT00324168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9332-21899-05|Steroids for Corneal Ulcers Trial|Steroids for Corneal Ulcers Trial|SCUT|University of California, San Francisco|Yes|Completed|September 2006|December 2012|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|16 Years|N/A|No|||December 2013|December 12, 2013|May 5, 2006|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00324168||182614|
NCT00325741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|368|Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus|Allogeneic Hematopoietic Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus Using a Non-Myeloablative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|June 2004|July 2010|Anticipated|July 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|64 Years|No|||August 2009|August 6, 2009|May 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00325741||182498|
NCT00325988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050063|Biomarkers in Multiple Sclerosis|NINDS Biomarkers in Multiple Sclerosis Study (BioMS)||National Institutes of Health Clinical Center (CC)||Completed|December 2004|February 2014||||N/A|Observational|N/A|||Actual|858|||Both|18 Years|60 Years|No|||February 2014|November 3, 2015|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00325988||182479|
NCT00326339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-006|Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate||Rigel Pharmaceuticals|Yes|Completed|August 2006|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|189|||Both|18 Years|75 Years|No|||March 2008|April 16, 2009|May 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00326339||182452|
NCT00326352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/1/13|Comparison of Sedation/Analgesia: Midazolam/Morphine Vs Propofol/Remifentanil|Comparison of Sedation/Analgesia: Midazolam/Morphine Vs Propofol/Remifentanil||University of Edinburgh||Terminated|July 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|16 Years|65 Years|No|||May 2006|May 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326352||182451|
NCT00321828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP C-10|Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery|A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients With Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor||NSABP Foundation Inc|Yes|Completed|March 2006|December 2012|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|May 2, 2006|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT00321828||182791|
NCT00315237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L0070 IN 302 P1|Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract|Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract||Bristol-Myers Squibb|Yes|Completed|July 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|364|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|April 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00315237||183291|
NCT00315458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3011 and BUP3011S|Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.|Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Determine Efficacy and Safety of Buprenorphine Transdermal System in Subjects With Moderate To Severe Osteoarthritis Pain Requiring Daily Treatment With Opioids||Purdue Pharma LP||Terminated|December 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|40 Years|N/A|No|||August 2012|August 27, 2012|April 17, 2006|Yes|Yes|Administrative reasons.|No|July 28, 2010|https://clinicaltrials.gov/show/NCT00315458||183274|This study was terminated early for administrative reasons. The efficacy data are not presented since the primary objective of this study was changed identifying it as a safety study.
NCT00315718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPC-02/1998|Long-Term Effects of Sucontral(TM) on Mild and Moderate Cases of Diabetes Mellitus (Type 2)|Controlled Clinical Trial on Long Term Effects of Hintonia Latiflora Extract in Mild to Moderate Type 2 Diabetes||Harras Pharma Curarina GmbH||Completed|June 2002|June 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|45 Years|80 Years|No|||April 2006|April 18, 2006|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00315718||183254|
NCT00315978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-MED-221|The Impact of Patient Involvement in Decision-Making About Heart Disease Prevention|Decision Aid to Improve Coronary Heart Disease Risk Modification: a Pilot Randomized Trial||University of North Carolina, Chapel Hill||Completed|June 2003|February 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||120|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||April 2006|July 9, 2007|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00315978||183234|
NCT00316992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-375-068|Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease|A Study of the Safety of Ramelteon in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease||Takeda|No|Completed|April 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|40 Years|N/A|No|||May 2010|May 31, 2010|April 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316992||183156|
NCT00313469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSERM|Sources of the Variability of the Response to Fluindione in Elderly Patients (PREPA)|Sources of the Variability of the Response to Fluindione in Elderly Patients (PREPA) [Etude Des Sources de variabilité de la réponse à la Fluindione Chez Les Personnes âgées de 80 Ans et Plus (PREPA) ]||Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2005|April 2008|Actual|April 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|152|Samples With DNA|Blood samples for the measure of drug concentrations Blood samples with DNA measurements|Both|80 Years|N/A|No|Non-Probability Sample|Elderly people (>80 years) initiating a treatment with fluindione|August 2011|August 24, 2011|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00313469||183424|
NCT00317044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9618C00001|Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma|A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma|RELAX|AstraZeneca||Completed|April 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|961|||Both|18 Years|70 Years|No|||May 2014|May 9, 2014|April 20, 2006|Yes|Yes||No|April 23, 2009|https://clinicaltrials.gov/show/NCT00317044||183152|Numbers of patients analyzed in each of the Outcome Measures varies due to the amount of qualifying data captured for the patients.
NCT00313482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-05-011|PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC|A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer||Veeda Oncology|No|Terminated|April 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|90 Years|No|||May 2012|May 9, 2012|April 10, 2006||No|Low accrual|No||https://clinicaltrials.gov/show/NCT00313482||183423|
NCT00313768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8501003|Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC|A Randomized Phase 2 Trial Of Paclitaxel, Carboplatin And Bevacizumab With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer||Pfizer|No|Terminated|December 2005|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|April 10, 2006|Yes|Yes|See Termination Reason in Detailed Description.|No||https://clinicaltrials.gov/show/NCT00313768||183404|
NCT00312793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST02-HMO-CTIL|The Efficacy and Safety of Electronic Stimulation in Patients Who Underwent Reconstruction of the Anterior Cruciate Ligament|Phase 2 Study to Evaluate the Efficacy and Safety of Electronic Stimulation of the Quadriceps Muscle in the Thigh by the MyoSpare Device, in Patients Who Underwent Reconstruction of the Anterior Cruciate Ligament (ACL)||Hadassah Medical Organization||Terminated||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|40 Years|No|||June 2009|June 21, 2009|April 10, 2006|||the study stopped becaust the sponsor did not wish to proceede with the study|No||https://clinicaltrials.gov/show/NCT00312793||183476|
NCT00314093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060137|RFT-5-dgA in Patients With Metastatic Melanoma|Phase II Evaluation of RFT5-dgA in Patients With Metastatic Melanoma||University of Texas Southwestern Medical Center||Completed|April 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314093||183379|
NCT00314119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060134|Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1|Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1||National Institutes of Health Clinical Center (CC)||Completed|April 2006|||||N/A|Observational|Time Perspective: Prospective|||Actual|17|||Both|20 Years|N/A|No|||August 2015|September 10, 2015|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314119||183377|
NCT00314132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-040-010|Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.|Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)||Sanofi|No|Completed|October 2005|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2004|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 4, 2012|April 11, 2006|Yes|Yes||No|November 6, 2012|https://clinicaltrials.gov/show/NCT00314132||183376|
NCT00314418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV0001|Patient Position and Impact on Colonoscopy Time|Patient Position and Impact on Colonoscopic Cecal Intubation Time||VA Connecticut Healthcare System||Completed|September 2005|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||120|||Male|18 Years|N/A|No|||April 2006|April 11, 2006|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00314418||183354|
NCT00314704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOAP vasopressors|Dopamine and Norepinephrine in Shock Patients|Comparison of Dopamine and Norepinephrine as the First Vasopressor Agent in the Management of Shock||Sepsis Occurrence in Acutely Ill Patients||Completed|December 2003|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1679|||Both|18 Years|N/A|No|||April 2006|January 29, 2010|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314704||183332|
NCT00325195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0405 & C0406|Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout|Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout||Savient Pharmaceuticals|No|Completed|May 2006|December 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|May 10, 2006|Yes|Yes||No|October 13, 2010|https://clinicaltrials.gov/show/NCT00325195||182540|
NCT00325208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06NT01|Feeding Bottle Design, Milk Intake and Infant Growth|||Institute of Child Health||Recruiting||December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||152|||Both|N/A|7 Days|Accepts Healthy Volunteers|||December 2006|December 22, 2006|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325208||182539|
NCT00315003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6132|TELI COM - Telithromycin in Children With Otitis Media|Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/kg od for 4 Days, in Children With Acute Otitis Media||Sanofi||Terminated|January 2006|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1500|||Both|6 Months|6 Years|No|||April 2009|April 2, 2009|April 13, 2006|||Pediatric development program terminated by sponsor|No||https://clinicaltrials.gov/show/NCT00315003||183309|
NCT00315016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRG 2005-316|Eplerenone, ACE Inhibition and Albuminuria|Eplerenone, ACE Inhibition and Albuminuria||Radboud University|No|Completed|January 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|75 Years|No|||May 2012|May 25, 2012|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315016||183308|
NCT00315302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-115|Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old|A Randomized Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye As Prescribed Treatments for Amblyopia in Children 3 to <7 Years Old|ATS8|Jaeb Center for Health Research|Yes|Completed|February 2005|January 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|3 Years|6 Years|No|||May 2012|May 16, 2012|April 14, 2006|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00315302||183286|
NCT00325065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060155|Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders|Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders||National Institutes of Health Clinical Center (CC)||Completed|May 2006|April 2010||||N/A|Observational|N/A|||Actual|71|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||April 2010|April 17, 2010|May 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00325065||182550|
NCT00325078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060160|Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease|Tumor Necrosis Factor Alpha Inhibitor (Lnfliximab, Adalimumab) Treatment for Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences||National Institutes of Health Clinical Center (CC)|Yes|Terminated|May 2006|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|10 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 19, 2015|May 11, 2006|Yes|Yes|Insufficient patient participation|No|March 18, 2014|https://clinicaltrials.gov/show/NCT00325078||182549|Due to limited subject participation and lack of sustained clinical benefits (1 year), there is insufficient complete data to generate meaningful statistics for the outcome measures. Instead, this data are reported as a case series.
NCT00325091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060161|Long-Term Motor Learning in Focal Hand Dystonia|Long-Term Motor Learning in Focal Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|May 2006|January 2014||||N/A|Observational|N/A|||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 7, 2014|May 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00325091||182548|
NCT00325754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|396|Benefits of Lightweight Ambulatory Oxygen Systems for Individuals With COPD|Benefits of Ambulatory Oxygen in Hypoxemic COPD Patients||University of Minnesota - Clinical and Translational Science Institute||Completed|March 2005|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment||||100|||Both|40 Years|N/A|No|||May 2014|May 22, 2014|May 11, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00325754||182497|
NCT00321854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.595|Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.||Boehringer Ingelheim||Completed|May 2006|||April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|535|||Both|30 Years|79 Years|No|||March 2014|May 7, 2014|May 3, 2006|Yes|Yes||No|December 18, 2009|https://clinicaltrials.gov/show/NCT00321854||182790|
NCT00321867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0086|Graft-Augmented Rectocele Repair-A Randomized Surgical Trial|Porcine-Derived Small Intestine Submucosa Graft-Augmented Rectocele Repair-A Randomized Trial||Women and Infants Hospital of Rhode Island|No|Completed|January 2004|January 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Female|21 Years|N/A|No|||May 2014|May 27, 2014|May 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00321867||182789|
NCT00316238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5294|A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia|A Double-Blind Dose-Response Study Comparing Rapid Acting Intramuscular Olanzapine and Intramuscular Placebo in Agitated Patients With Schizophrenia||Eli Lilly and Company||Completed|April 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|20 Years|65 Years|No|||June 2007|June 6, 2007|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00316238||183214|
NCT00316485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060144|Diagnosis, Evaluation and Treatment of Patients in Need of Third Molar Removal|Diagnosis, Evaluation and Treatment of Patients in Need of Third Molar Removal||National Institutes of Health Clinical Center (CC)||Completed|April 2006|January 2013||||N/A|Observational|N/A|||Actual|718|||Both|18 Years|50 Years|No|||January 2013|February 19, 2014|April 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00316485||183195|
NCT00316784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-III-02/E|IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA|A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee||IDEA AG||Completed|July 2005|May 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||704|||Both|18 Years|75 Years|No|||March 2009|March 19, 2009|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316784||183172|
NCT00312819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVC1.03-HMO-CTIL|Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer|Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine||Hadassah Medical Organization||Completed|March 2006|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||February 2009|August 30, 2010|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00312819||183474|
NCT00312832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D40-30|Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy|A Randomized Open Label Study Comparing the Impact of Reducing the Dose of Stavudine Versus Switching to Tenofovir on Plasma Lipids, Body Composition and Mitochondrial Function in HIV-Infected Patients Receiving Antiretroviral Therapy||Hospital Clinic of Barcelona||Completed|January 2004|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||January 2004|October 23, 2006|April 7, 2006||||No||https://clinicaltrials.gov/show/NCT00312832||183473|
NCT00323960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGG-PRINTO-002|Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis|Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate|PRINTOJDMTR|Istituto Giannina Gaslini|No|Recruiting|May 2006|May 2011|Anticipated|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|1 Year|18 Years|No|||February 2011|February 16, 2011|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00323960||182630|
NCT00312845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-LYM-3001|Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma||Millennium Pharmaceuticals, Inc.||Completed|March 2006|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|676|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|April 7, 2006|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00312845||183472|
NCT00313144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|450501|Aralast alpha1-proteinase Inhibitor Surveillance Study|ARALAST alpha1-proteinase Inhibitor (α1-PI) Surveillance Study||Baxalta US Inc.|No|Terminated|June 2006|May 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|18 Years|N/A|No|||August 2011|June 26, 2015|April 10, 2006|Yes|Yes|Study terminated early due to Aralast being phased out of the market.|No|March 4, 2011|https://clinicaltrials.gov/show/NCT00313144||183449|Study was terminated early due to Aralast being phased out of the market.
NCT00313456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT1-05-09|A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel|A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel||Agennix||Terminated|March 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|April 10, 2006|Yes|Yes|Sponsor decided to discontinue study drug development|No||https://clinicaltrials.gov/show/NCT00313456||183425|
NCT00313742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1724|The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins|An Assessment of the Impact of Performing Physical Exercise on the Maximum Plasma Glucose Decline in Subjects With Type 1 Diabetes Managed on a Basal Bolus Insulin Regimen: A Comparison of 3 Basal Insulin Treatments - Insulin Detemir, Insulin Glargine and NPH Insulin||Novo Nordisk A/S|No|Completed|April 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|51|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00313742||183406|
NCT00324792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 05 54|I3LTE4: Intensive Insulin Therapy and Production of LTE4 in Patients With Diabetes|Effect of an Intensive Insulin Therapy on the Production of LTE4 in Patients With Diabetes||University Hospital, Grenoble||Completed|May 2006|October 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|45|||Both|18 Years|N/A|No|||June 2008|June 11, 2008|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00324792||182568|
NCT00325169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO104962|SERETIDE Plus Tiotropium Versus Individual Components|See Detailed Description||GlaxoSmithKline|No|Completed|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|40 Years|80 Years|No|||February 2011|May 31, 2012|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00325169||182542|
NCT00325182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23008|The Effects of Levetiracetam on Alcohol Dependent Subjects|The Effects of Levetiracetam on Alcohol Dependent Subjects||Boston University||Active, not recruiting|January 2006|July 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||April 2007|April 4, 2007|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325182||182541|
NCT00325546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6001|Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities||Sanofi||Completed|April 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|643|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|May 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00325546||182513|
NCT00315029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITS2006|Patient-Centered Implementation Trial for Single Embryo Transfer|Patient-Centered Implementation of Elective Single Embryo Transfer (eSET) in in Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection (ICSI)||Radboud University||Completed|November 2006|October 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|230|||Both|18 Years|39 Years|No|||October 2008|October 24, 2008|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315029||183307|
NCT00325455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-003|MK0859 Dose-Ranging Study (0859-003)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of MK-0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Terminated|June 2006|March 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|500|||Both|18 Years|75 Years|No|||February 2015|February 27, 2015|May 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325455||182520|
NCT00325468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050233|An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density|An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density||Amgen|No|Completed|May 2006|August 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Female|N/A|N/A|No|||December 2013|December 4, 2013|May 10, 2006|Yes|Yes||No|January 3, 2013|https://clinicaltrials.gov/show/NCT00325468||182519|
NCT00325416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12733|Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.|A Study of Intensive-Dose Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|November 2001|July 2016|Anticipated|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|N/A|No|||November 2015|December 4, 2015|May 11, 2006|Yes|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT00325416||182523|Data on presence of chromosomal abnormalities at time of diagnosis were not available for majority of patients. The cancer center will continue to collect information about the participant's disease and its treatment for the rest of their life.
NCT00325429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1304|Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes|A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes||Novartis||Completed|April 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|20 Years|N/A||||January 2009|January 6, 2009|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00325429||182522|
NCT00326378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-08-066|Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer|A Multinational, Multicenter, Phase III Open Randomized Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-small Cell Lung Cancer (CCheIN)||Samsung Medical Center||Completed|October 2005|May 2015|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|434|||Both|18 Years|N/A|No|||November 2012|June 3, 2015|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326378||182449|
NCT00326001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP016|Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8)|AURUM 8 - Ablation of the Cavotricuspid Isthmus in Patients With Atrial Flutter Using an 8 mm Gold Alloy Tip Electrode||Biotronik SE & Co. KG||Completed|June 2004|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|N/A|No|||August 2009|February 3, 2010|May 12, 2006||No||No|May 13, 2009|https://clinicaltrials.gov/show/NCT00326001||182478|
NCT00326014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-002|A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.|A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.||Glaukos Corporation|Yes|Completed|April 2003|December 2009|Actual|March 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00326014||182477|
NCT00326027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/DE-004|Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)|Profi-Study: Symptom Reduction in Hospitalized Patients Suffering From Symptomatic Non-erosive or Erosive Gastroesophageal Reflux Disease Treated With Pantoprazole 20 or 40 mg o.d. for 7 Days||Nycomed|No|Completed|October 2006|November 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326027||182476|
NCT00326365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAL.ICU.2006|Effect of Homeopathic Remedy Kalium Bichromicum on Viscosity and Amount of Sputum Mechanically Ventilated ICU Patients.|A Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Investigate the Efficacy and Safety of the Homeopathic Remedy Kalium Bichromicum (Potassium Dichromate) to Decrease Viscosity and Amount of Sputum as Well as Time to Extubation, in Intubated Mechanically Ventilated ICU Patients.||Shaare Zedek Medical Center||Not yet recruiting|June 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|N/A|No|||May 2006|October 30, 2007|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326365||182450|
NCT00321880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000471996|Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia|Healing Touch as a Supportive Intervention for Adult Acute Leukemia Patients: A Pilot Study||Comprehensive Cancer Center of Wake Forest University|No|Completed|February 2006|October 2008|Actual|February 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00321880||182788|
NCT00316004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28226-A - IND 12505|Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)|Phase 3 Study of Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)||University of Washington|Yes|Terminated|May 2006|January 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1331|||Both|15 Years|N/A|No|||May 2011|May 16, 2011|April 17, 2006|Yes|Yes|Futility|No|February 11, 2011|https://clinicaltrials.gov/show/NCT00316004||183232|The trial was stopped early for futility at a planned data and safety monitoring board review. The futility boundary was crossed for each of the 2 group comparisons (hypertonic saline/dextran vs normal saline and hypertonic saline vs normal saline).
NCT00316251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0403060006|Application of Specific Frequencies to Stimulate the Spinocerebellar Tract in Subjects With Unilateral Dysafferentation|||Logan College of Chiropractic||Completed|April 2006|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||April 2006|November 20, 2006|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00316251||183213|
NCT00317005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEL/CPG/Nefro/Hcy|Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events|Randomized Clinical Trial of Folate Therapy/Placebo for Reduction of Homocysteine Serum Levels in Uremic Patients and Influence on Cardiovascular Mortality||Universidade Estadual de Londrina||Completed|April 2003|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||186|||Both|18 Years|N/A|No|||May 2005|April 20, 2006|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00317005||183155|
NCT00317018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMV 04-360|Implementing Telemedicine-Based Collaborative Care for MDD in Contract CBOCs|Implementing Telemedicine-Based Collaborative Care for MDD in Contract CBOCs||VA Office of Research and Development|No|Withdrawn|May 2008|September 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||April 2014|April 25, 2014|April 19, 2006||No|This study was withdrawn prior to enrollment.|No||https://clinicaltrials.gov/show/NCT00317018||183154|
NCT00324272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C02.240|Post-Operative Drainage Following Lymph Node Dissection|Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial.||Oxford University Hospitals NHS Trust|No|Completed|January 2003|June 2010|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|N/A|No|||May 2006|July 18, 2011|May 8, 2006||No||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00324272||182606|
NCT00324285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-007|Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children.|Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children With Watery Diarrhoea Due to Vibrio Cholerae||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|July 2001|October 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||180|||Both|6 Months|36 Months|No|||May 2006|March 20, 2013|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00324285||182605|
NCT00323973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fcv059|Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity|A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy.||Fundación Cardiovascular de Colombia|Yes|Completed|July 2003|July 2006|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|70 Years|No|||November 2010|November 23, 2010|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00323973||182629|
NCT00323986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39/2004|Azithromycin Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and Tracheostomy|Azithromycin Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and Tracheostomy. Effects on Recurrent Respiratory Infections, Inflammatory Parameters and Bacterial Persistence||University of Milan||Terminated|October 2004|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|45 Years|80 Years|No|||April 2006|May 8, 2006|May 8, 2006||||No||https://clinicaltrials.gov/show/NCT00323986||182628|
NCT00313781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021011|Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)|A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of CP-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer||Pfizer|No|Completed|May 2006|December 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Male|18 Years|N/A|No|||March 2013|March 5, 2013|April 10, 2006|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00313781||183403|
NCT00314067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF-01EB0412|Evaluation of Case Management to Improve the Outpatient Care of Alcohol-related Disorders|Comprehensive Quality Management in Out-patient Care for Alcohol-related Disorders (AQAH). Transfer and Dissemination Into Routine Practice||University Hospital Freiburg||Completed|July 2006|August 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|112|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2008|October 17, 2013|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00314067||183381|
NCT00313794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671014|Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment|Phase 2, Single Arm Study Of Ticilimumab In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum||AstraZeneca|No|Completed|May 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|April 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313794||183402|
NCT00324558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-BEM-2004-01|Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)|Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer||Clinica Universidad de Navarra, Universidad de Navarra|No|Terminated|June 2005|September 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|May 9, 2006||No|Sponsor stopped due to difficulties to recruit 130 patients required by protocol|No||https://clinicaltrials.gov/show/NCT00324558||182585|
NCT00324805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00509|Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery|A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)|Yes|Active, not recruiting|June 2007|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||February 2016|March 24, 2016|May 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324805||182567|
NCT00324818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI048044|Treatment of Bacterial Vaginosis|Therapy and Prevention for Sexually Associated Bacterial Vaginosis||University of Alabama at Birmingham||Completed|July 2002|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 13, 2009|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324818||182566|
NCT00326144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00003|Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Mono-Therapy in the Treatment of Adult Patients With Major Depressive Disorder|OPAL|AstraZeneca||Completed|April 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|310|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326144||182467|
NCT00326157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-IT-131-0151|PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation|Phase II Pilot Study on Safety of Administration of 3mg/kg/Day Three Times a Week Until Day 22 (21 Days After Transplantation Day) and 7 mg/kg Weekly From Day 29 to the End of Treatment (Day 50-8th Week) of AmBisome® in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem-cell Transplantation||Gilead Sciences|No|Completed|June 2006|November 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|34|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00326157||182466|
NCT00325793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012003|IV Double and Triple Concentrated Nicardipine for Stroke and ICH|An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage||OSF Healthcare System||Recruiting|January 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2006|May 12, 2006|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00325793||182494|
NCT00325780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-307|Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Open-Label, Long-Term (1 Year) Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia||Kowa Research Europe|No|Completed|July 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1355|||Both|18 Years|75 Years|No|||January 2010|January 25, 2010|February 10, 2006||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00325780||182495|
NCT00326040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-001A|A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects|A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects.||Glaukos Corporation|Yes|Completed|April 2003|August 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||July 2008|July 23, 2008|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00326040||182475|
NCT00325442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-301|FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)|A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension||United Therapeutics||Completed|October 2006|December 2010|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|354|||Both|12 Years|70 Years|No|||May 2013|May 6, 2013|May 11, 2006|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00325442||182521|
NCT00317577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCVR-0020|Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma|A Multicenter, Double-Masked, 2-Arm Parallel Group Study Comparing the Effect of Brimonidine 0.2% Versus Timolol 0.5% on Visual Field Stability in Patients With Low-Pressure Glaucoma||Chicago Center for Vision Research||Completed|December 1998|May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|30 Years|N/A|No|||April 2006|April 23, 2006|April 23, 2006||||No||https://clinicaltrials.gov/show/NCT00317577||183111|
NCT00317837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-005-LAM|Bipolar Versus Unipolar Hemiarthroplasty for Patients With a Hip Fracture|Bipolar vs. Unipolar Hemiarthroplasty for Patients Aged 70 Years or Above, With a Dislocated Medial Femoral Neck Fracture||Northern Orthopaedic Division, Denmark||Withdrawn|October 2004|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|70 Years|N/A|No|||March 2014|March 28, 2014|April 23, 2006||No|Recruitment was too slow, primary investigator has left the organisation|No||https://clinicaltrials.gov/show/NCT00317837||183092|
NCT00321893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-02166|Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer|Randomized Phase II Trial of Budesonide Turbuhaler® 800 Micrograms/Twice Daily Versus Placebo in High-Risk Population With Undetermined Lung Nodules Detected at Screening Low Dose CT Scan||National Cancer Institute (NCI)|Yes|Completed|January 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|225|||Both|50 Years|N/A|No|||October 2014|December 21, 2015|May 2, 2006|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT00321893||182787|
NCT00322179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR0036|Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C|Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C||Palo Alto Veterans Institute for Research||Completed|November 2005|November 2008|Actual|November 2007|Actual|N/A|Observational|N/A||2|Actual|22|||Both|18 Years|N/A|No||Inclusion Criteria:          -  obese (weight > 85kg and BMI>30) or non-obese patients (<75kg and BMI <25) with             chronic Hepatitis C          -  Chronic Hepatitis C infection with documented HCV RNA          -  Body habitat either as obese or non-obese as defined above          -  Currently not under IFN therapy          -  Non-African American|March 2015|March 4, 2015|May 4, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00322179||182766|
NCT00316823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456480|Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules|Gene Expression Analysis in Thyroid Nodule FNA Samples||National Cancer Institute (NCI)||Completed|July 2005|||December 2009||N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|400|||Both|18 Years|N/A|No|||December 2008|February 21, 2014|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316823||183169|
NCT00317057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05756|Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease|Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease||Glostrup University Hospital, Copenhagen||Recruiting|April 2006|January 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1500|||Both|N/A|N/A|No|||January 2007|January 4, 2007|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00317057||183151|
NCT00313157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004221-26|RATe Control in Atrial Fibrillation|Rate Control in Atrial Fibrillation|RATAF|Asker & Baerum Hospital|No|Completed|April 2006|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|N/A|No|||May 2014|May 11, 2014|April 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313157||183448|
NCT00316797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01_INER_001/002|Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects|Phase 1 Assessment of the Biodistribution and Safety of 123-I INER in Healthy Subjects||Institute for Neurodegenerative Disorders|Yes|Completed|April 2006|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00316797||183171|
NCT00316810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPATICO|Simultaneous Pancreas-kidney Transplantation With Campath Protocol|An Open-label, Randomized, Prospective Study to Investigate the Safety and Efficacy of Campath-1H as an Induction Agent in Combination With Tacrolimus Monotherapy Compared to Short-course ATG-induction in Combination With Tacrolimus, Mycophenolate Mofetil and Short-term Steroids Application in de Novo SPK Transplanted Diabetic Patients||Medical University Innsbruck||Completed|April 2006|June 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|No|||June 2012|June 18, 2012|April 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00316810||183170|
NCT00317031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICT|Individually Adapted Therapy of Alcoholism|Individually Adapted Therapy of Alcoholism: Clinical Studies||Central Institute of Mental Health, Mannheim||Completed|November 2002|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|435|||Both|18 Years|65 Years|No|||June 2008|June 26, 2008|April 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00317031||183153|
NCT00323999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB170262|Hysteroscopic Monopolar and Bipolar Resection|A Randomised Trial to Compare the Differences Between Monopolar Surgery (Loop Resection) With Glycine 1,5% and Bipolar Surgery With Saline (Olympus,Versapoint) on Hysteroscopic Surgery.||Ullevaal University Hospital||Recruiting|December 2004|December 2007||||N/A|Interventional|N/A|||||||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2006|May 9, 2006|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00323999||182627|
NCT00324025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYC123A2202|Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS||Novartis||Terminated|March 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||December 2008|December 11, 2008|May 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324025||182625|
NCT00314106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060136|Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma|Phase II Study Using a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution With CD34+ Stem Cells in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)|No|Completed|April 2006|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|April 11, 2006|Yes|Yes||No|September 18, 2012|https://clinicaltrials.gov/show/NCT00314106||183378|
NCT00324545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-1-1|Cardiovascular Outcomes Of Diet Counseling|Long-Term Adherence and Cardiovascular Outcomes of a Randomized Controlled Trial of Medium-Intensity Minimally-Directive Counseling for Different Diets||The Camelot Foundation||Completed|January 2000|December 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|30 Years|59 Years|Accepts Healthy Volunteers|||May 2006|May 9, 2006|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324545||182586|
NCT00324831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466677|GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|Phase III, Double-Blind, Randomized, Placebo-Controlled Trial of FavID® (Id/KLH) and GM-CSF Following CHOP/Rituximab as First-Line Therapy in Subjects With High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma||National Cancer Institute (NCI)||Suspended||||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|480|||Both|18 Years|N/A|No|||March 2007|December 17, 2013|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00324831||182565|
NCT00325221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS033|Psychosomatic Effects of Implantable Cardioverter Defibrillator With Home Monitoring Function (QUANTUM)|QUANTUM - Quality-of-Life, Anxiety and Depression in ICD Patients Using Home Monitoring||Biotronik SE & Co. KG|No|Completed|August 2006|October 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|May 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00325221||182538|
NCT00326170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0799|Phase II 5-Azacytidine Plus VPA Plus ATRA|Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Completed|July 2005|December 2007|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|3 Years|N/A|No|||June 2012|June 12, 2012|May 12, 2006||No||No|June 6, 2011|https://clinicaltrials.gov/show/NCT00326170||182465|
NCT00326183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_023|Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study|An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age||Merck Sharp & Dohme Corp.||Completed|May 2006|January 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1800|||Both|12 Months|17 Months|Accepts Healthy Volunteers|||January 2009|February 19, 2009|May 12, 2006|Yes|Yes||No|October 21, 2008|https://clinicaltrials.gov/show/NCT00326183||182464|
NCT00325533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|470|Effectiveness of a Barbershop-Based Program to Improve High Blood Pressure Control and Awareness in Black Men|Group Randomized Trial of a Barber-Based Intervention to Improve Hypertension Control in Black Men||Cedars-Sinai Medical Center|No|Completed|May 2006|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2319|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|June 11, 2014|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00325533||182514|
NCT00325806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE498_3E03|Ramipril - Hypertension|Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.||Sanofi||Completed|May 2000|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1008|||Both|50 Years|85 Years|No|||March 2013|March 7, 2013|April 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00325806||182493|
NCT00325767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPN 04-03-19-11|Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol|Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol||Johns Hopkins University||Completed|May 2004|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2006|May 12, 2006|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00325767||182496|
NCT00326053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00017|Prevention of Asthma Relapse After Discharge From Emergency|A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse|PARADE|AstraZeneca||Completed|May 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|65 Years|No|||January 2011|January 21, 2011|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00326053||182474|
NCT00318110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T00008|Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma|Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma||Center for International Blood and Marrow Transplant Research|Yes|Terminated|April 2006|January 2009|Anticipated|January 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||September 2008|September 29, 2008|April 24, 2006|Yes|Yes|Unable to meet subject enrollment goal.|No||https://clinicaltrials.gov/show/NCT00318110||183071|
NCT00318097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 11-116|Histamine Responsiveness in McCune-Albright Syndrome|Histamine Responsiveness in Patients With McCune-Albright Syndrome||Children's Mercy Hospital Kansas City||Recruiting|November 2003|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Both|N/A|39 Years|Accepts Healthy Volunteers|||November 2004|May 1, 2006|April 24, 2006||||No||https://clinicaltrials.gov/show/NCT00318097||183072|
NCT00318357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE-HF Long-term follow-up|CARE-HF LTFU: CArdiac REsynchronization in Heart Failure Long-Term Follow-up|CARE-HF LTFU: CArdiac REsynchronization in Heart Failure Long-Term Follow-up||Medtronic Bakken Research Center|Yes|Active, not recruiting|September 2006|July 2010|Anticipated|July 2010|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|None Retained|No biospecimens are retained|Both|18 Years|N/A|No|Non-Probability Sample|Chronic heart failure patients with NYHA class III-IV,with a LVEF of less than or equal to        35%, who are on optimal medical treatment, and documented evidence of ventricular        dyssynchrony as evidenced by QRS or Echo prior enrollment in the CARE-HF main study.        Patients who have participated in the CARE-HF program and were reported to be alive in May        2005 (study closure of the main study) are asked to participate in the CARE-HF LTFU study.|May 2008|May 30, 2008|April 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00318357||183052|
NCT00318370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-003-002|Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy|A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse||Morphotek|No|Completed|May 2006|June 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|N/A|No|||September 2015|September 4, 2015|April 24, 2006|Yes|Yes||No|January 27, 2012|https://clinicaltrials.gov/show/NCT00318370||183051|
NCT00316498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030011|Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease|A Phase I/II Randomized, Controlled Study of OGT 918 in Adult and Juvenile Patients With Niemann Pick C Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2002|August 2007||||Phase 1|Interventional|Primary Purpose: Treatment||||30|||Both|12 Years|N/A|No|||August 2007|September 26, 2015|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316498||183194|
NCT00316511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-726-05|Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma|A Phase 1 Multi-Center, Dose Escalation and Pharmacokinetic Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma||Agenus, Inc.||Completed|March 2006|||June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|21|||Both|18 Years|N/A|No|||October 2008|October 24, 2008|April 19, 2006||||||https://clinicaltrials.gov/show/NCT00316511||183193|
NCT00316524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-005|A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects|A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects||Bavarian Nordic||Completed|May 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|745|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316524||183192|
NCT00323336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77-05|Markers of Bone Turnover in Saliva and How This Compares to Urine and Blood|Salivary Markers of Bone Turnover Compared to Urine and Blood||Mayo Clinic||Completed|May 2006|November 2007|Actual|November 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|100|||Female|25 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|The subject population will be limited to pre-menopausal and post-menopausal females who        are in good systemic health in an attempt to determine whether salivary levels of bone        turnover markers hold valuable promise as a replacement or partner biofluid for serum        and/or urine. In addition, proper selection of the subject population will minimize the        effect of confounding variables. The specific inclusion criteria and exclusion criteria        are listed below.|January 2010|January 22, 2010|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00323336||182678|
NCT00323349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-0931|A Study of Attitudes About the Risk of Developing Type 2 Diabetes|Cues to Action in Diabetes Risk Education (CADRE): Randomized Study Assessing the Impact of Knowledge of Impaired Glucose Tolerance on Perceived Risk and Behavior Change Motivation||Eastern Virginia Medical School||Completed|April 2003|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label||||276|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|June 27, 2007|May 6, 2006||||No||https://clinicaltrials.gov/show/NCT00323349||182677|
NCT00323375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Don Krogstad, K 0154 (Phase 1)|Phase 1 Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine|Randomized Controlled Trial of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine||Tulane University Health Sciences Center||Completed|August 1999|August 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||122|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2005|May 5, 2006|May 5, 2006||||||https://clinicaltrials.gov/show/NCT00323375||182675|
NCT00323583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCA06-02|Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer|Phase II Study of Paclitaxel, Oxaliplatin, Leucovorin and 5-Fluorouracil (POLF) in Gemcitabine-Refractory Advanced Pancreatic Cancer||Seattle Cancer Treatment and Wellness Center||Recruiting|May 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|65 Years|No|||May 2007|May 7, 2007|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00323583||182659|
NCT00323596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0171|Trial of a Home Based Strength and Balance Retraining Program in Reducing Falls Risk Factors|Action Seniors!: A 12-month Randomized Controlled Trial of a Home Based Strength and Balance Retraining Program in Reducing Falls Risk Factors||University of British Columbia|No|Completed|September 2004|December 2008|Actual|||N/A|Observational|N/A||1|Anticipated|71|None Retained|None retained|Both|70 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Seniors aged 70 years and older, presenting to a health care provider with a fall.|October 2009|October 23, 2009|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323596||182658|
NCT00323609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0601-KAVIAR|KAVIAR Study - Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures|A Multicenter, Randomized, Prospective Clinical Trial to Compare the Short- and Long-term Safety and Effectiveness of Balloon Kyphoplasty to Vertebroplasty in the Treatment of Painful, Acute Osteoporosis-related Vertebral Body Compression Fractures (VCFs).||Medtronic Spine LLC||Terminated|August 2006|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|404|||Both|21 Years|N/A|No|||June 2012|March 18, 2013|May 5, 2006||No|Due to high number of patients terminating study early, low patient enrollment and difficulty    in patient/investigator willingness for randomization|No|June 29, 2012|https://clinicaltrials.gov/show/NCT00323609||182657|The original study design required n=1,234 randomized patients; however, the study was stopped early with only n=404 enrolled patients, due to low enrollment, difficulty in willingness to randomize patients and a high proportion of early terminations
NCT00324311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW2004-11-02|Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care|Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)||MediWound Ltd|Yes|Completed|December 2005|February 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|4 Years|55 Years|No|||July 2009|May 8, 2011|May 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324311||182603|
NCT00324857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-234|Educational Intervention for Knee Pain|Knee Replacement Disparity: A Randomized, Controlled Intervention||VA Office of Research and Development|No|Completed|September 2006|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|663|||Both|50 Years|N/A|No|||December 2015|December 15, 2015|May 9, 2006||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00324857||182564|
NCT00324298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARTS-TE3|Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles|A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3||National Cancer Institute (NCI)||Completed|July 2003|March 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|210|||Male|18 Years|50 Years|No|||January 2007|August 9, 2013|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00324298||182604|
NCT00325559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1122|The Effect of Hyperglycaemia on Local Energy Stores in the Working Muscle in Patients With Type 1 Diabetes Mellitus|The Effect of Hyperglycaemia on Local Energy Stores in the Working Muscle in Patients With Type 1 Diabetes Mellitus||University Hospital Inselspital, Berne||Completed|June 2006|||March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind|||Anticipated|10|||Male|20 Years|40 Years||||January 2011|January 12, 2011|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00325559||182512|
NCT00325845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050253|Synvisc Injections for Lumbar Facet Joint Pain|Efficacy and Safety of Intra-Articular Synvisc Injections as Treatment of Painful Lumbar Facet Joint Arthrosis||Sheltering Arms Physical Rehabilitation Hospitals||Recruiting|May 2006|May 2008||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|30 Years|N/A|No|||September 2006|September 12, 2006|May 12, 2006||||||https://clinicaltrials.gov/show/NCT00325845||182490|
NCT00322270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA008|Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters|Phase 3, Multicenter, Multinational, Open-Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects With Occluded Central Venous Access Devices (SONOMA-3)||ARCA Biopharma, Inc.|No|Completed|January 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2008|August 12, 2008|May 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00322270||182759|
NCT00322283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC-MD-01|Study of Oglemilast for the Prevention of Asthma.|Efficacy and Safety of Oglemilast in the Prevention of Exercise-Induced Bronchospasm||Forest Laboratories||Completed|May 2006|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|50 Years|No|||April 2012|April 7, 2012|May 4, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00322283||182758|
NCT00325832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392-2005|Conventional Versus Automated Measurement of Blood Pressure in the Office (The CAMBO Study)||CAMBO|Sunnybrook Health Sciences Centre|No|Completed|January 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|||Anticipated|750|||Both|N/A|N/A|No|||May 2008|August 20, 2010|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00325832||182491|
NCT00321568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060154|Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis|An Exploratory Study on Detection of Cortical and White Matter Damage in Patients With Multiple Sclerosis Using Magnetic Resonance Imaging at 7 Tesla||National Institutes of Health Clinical Center (CC)||Completed|May 2006|April 2011||||N/A|Observational|N/A|||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 21, 2011|May 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00321568||182809|
NCT00321581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060152|AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia|Phase I Trial of CEDIRANIB (AZD2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|May 2006|October 2011|Actual|||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|13|||Both|2 Years|18 Years|No|||June 2012|October 9, 2014|May 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00321581||182808|
NCT00317291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003092|Acupuncture/Moxibustion for Peripheral Neuropathy in HIV|Acu/Moxa for Peripheral Neuropathy in Persons With HIV||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|November 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||September 2009|September 16, 2009|April 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00317291||183133|
NCT00317304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002910-01|Mindfulness Based Stress Reduction for Hot Flashes|Mindfulness Based Stress Reduction for Hot Flashes||University of Massachusetts, Worcester|Yes|Completed|January 2005|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Female|40 Years|69 Years|Accepts Healthy Volunteers|||October 2012|October 3, 2012|April 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00317304||183132|
NCT00319371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074-GOB-2006-001|Registration of Skin-Temperatures and Sleep-Wake Behaviour|Registration of Skin-Temperatures and Sleep-Wake Behaviour in the Daily Life of Women With Vasospasm in Comparison to Controls||University Hospital, Basel, Switzerland|No|Completed|November 2005|June 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|women with vasospasm and difficulties of initiating sleep and women without vasospasm and        no difficulties of initiating sleep|September 2008|September 25, 2008|April 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00319371||182976|
NCT00318383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi - 4512|Efficacy of NicVAX in Smokers Who Want to Quit Smoking|A Phase 2, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking||National Institute on Drug Abuse (NIDA)|Yes|Active, not recruiting|May 2006|November 2008|Anticipated|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|313|||Both|18 Years|N/A|No|||November 2008|November 3, 2008|April 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318383||183050|
NCT00318682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC0504|Evaluation and Medico-Economic Study of FIBROSCAN in Patients With Viral Hepatitis|Evaluation and Medico Economic Study of FIBROSCAN in Patients With Viral Hepatitis|FIBROSTIC|Assistance Publique - Hôpitaux de Paris|No|Terminated|May 2006|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|Samples Without DNA|biological samples to evaluate the hepato-fibrosis|Both|18 Years|N/A|No|Non-Probability Sample|patient with hepatitis B or C|September 2006|February 11, 2009|April 25, 2006||No|enough patients have been enrolled for the statistic analysis|No||https://clinicaltrials.gov/show/NCT00318682||183028|
NCT00322413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epo-Comp-00-01|Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial|Efficacy and Safety of Epoetin Omega in Patients Undergoing Regular Dialysis. Part II: Comparative Trial Versus Epoetin Alfa||General Hospital Sveti Duh||Completed|January 1997|April 1997||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|85 Years|No|||May 2006|July 20, 2006|May 4, 2006||||No||https://clinicaltrials.gov/show/NCT00322413||182748|
NCT00322426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Schoffer|Sensory Cues for Freezing in Parkinson's Disease|Effect of Randomized Patient-Triggered Sensory Cues for Freezing of Gait in Parkinson's Disease||Austin Health||Not yet recruiting|July 2006|January 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|40 Years|95 Years|No|||May 2006|June 22, 2006|May 3, 2006||||No||https://clinicaltrials.gov/show/NCT00322426||182747|
NCT00322439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040210|Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis|Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis||Amgen|No|Completed|May 2006|February 2013|Actual|December 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2511|Samples With DNA|Whole blood, serum, plasma.|Both|18 Years|N/A|No|Probability Sample|Patients with plaque psoriasis, who are currently receiving Enbrel or who are intending to        start or restart Enbrel therapy at multi-centers.|February 2016|February 19, 2016|May 5, 2006|No|Yes||No|February 11, 2014|https://clinicaltrials.gov/show/NCT00322439|5 Years|182746|
NCT00317070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA010|Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)|A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC)||Nova Scotia Health Authority||Terminated|April 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||May 2008|May 8, 2009|April 20, 2006||No|Poor recruitment, poor patient compliance, lack of funding|No||https://clinicaltrials.gov/show/NCT00317070||183150|
NCT00312858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V251-067|Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)|An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age||Merck Sharp & Dohme Corp.|No|Completed|April 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|653|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||October 2015|October 29, 2015|April 7, 2006|Yes|Yes||No|March 24, 2009|https://clinicaltrials.gov/show/NCT00312858||183471|
NCT00323362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539557|Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer|Phase II Study of Imatinib Mesylate and Gemcitabine for Recurrent/Metastatic Non-small Cell Lung Cancer (NSCLC)||Rutgers, The State University of New Jersey|No|Terminated|April 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|March 7, 2006|Yes|Yes|Toxicity|No|November 18, 2013|https://clinicaltrials.gov/show/NCT00323362||182676|
NCT00324038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004279-39|Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly|An Open, Randomised, Multicentre Study to Compare Buprenorphine Transdermal Delivery System (BTDS) With Standard Treatment in Elderly Subjects With OA of the Hip and/or Knee||Napp Pharmaceuticals Limited||Completed|March 2006|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|65 Years|N/A|No|||June 2011|June 13, 2011|May 9, 2006||||No|July 17, 2009|https://clinicaltrials.gov/show/NCT00324038||182624|
NCT00324324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000472877|Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant|Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation||OHSU Knight Cancer Institute|Yes|Terminated|May 2006|December 2012|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|May 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324324||182602|
NCT00323622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104297|Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine|An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose.||GlaxoSmithKline||Completed|April 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|1737|||Both|33 Months|69 Months|Accepts Healthy Volunteers|||March 2014|July 3, 2014|September 8, 2005|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00323622||182656|
NCT00324012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02 262098|Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma|Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma||Rigshospitalet, Denmark|No|Completed|April 2006|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00324012||182626|
NCT00324870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00093|Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer|Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With the VEGF Inhibitor Bevacizumab in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|February 2006|November 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||October 2013|December 10, 2015|May 10, 2006|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT00324870||182563|
NCT00324571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC-68-401|Dialysis Clinical Outcomes Revisited (DCOR) Trial|A Randomized, Open Label, Parallel Design Study of Renagel® Phosphate Binder Versus Calcium-Based Phosphate Binders in Hemodialysis Patients||Sanofi||Completed|March 2001|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|May 9, 2006||||||https://clinicaltrials.gov/show/NCT00324571||182584|
NCT00324584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 01|Web-Based Follow-Up Using Cellular Phone in Type 1 Diabetic Patients Under Insulin Pump Therapy : The PumpNet Study|Surveillance Des données De l’Autosurveillance glycémique Via Internet Et Le réseau téléphonique GSM Chez Le diabétique De Type 1 Sous Traitement Insulinique Par Pompe Externe : Etude Prospective randomisée PumpNet.||University Hospital, Grenoble||Completed|April 2003|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||July 2006|July 4, 2006|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00324584||182583|
NCT00325260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201.3.121|Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China|A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China.||Solvay Pharmaceuticals||Completed|March 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||900|||Both|3 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 31, 2006|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325260||182535|
NCT00325273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG84025|Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonatal Period|Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonate||Chang Gung Memorial Hospital|Yes|Completed|April 2005|April 2010|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|180|||Female|N/A|N/A|No|||June 2011|March 16, 2015|May 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00325273||182534|
NCT00325572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23275|Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism|Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism||Penn State University|Yes|Completed|November 2006|December 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||January 2013|January 13, 2013|May 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325572||182511|
NCT00322517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6191007|Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer|A Phase 2 Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer||Pfizer|No|Completed|April 2006|July 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Female|18 Years|N/A|No|||May 2011|May 10, 2011|April 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00322517||182740|
NCT00326430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Residential Cognitive and Interpersonal Therapy for Social Phobia|Residential Cognitive Therapy Versus Residential Interpersonal Therapy for Social Phobia: A Randomized Controlled Trial||Modum Bad||Completed|October 2001|June 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|65 Years|No|||May 2006|May 15, 2006|May 15, 2006||||No||https://clinicaltrials.gov/show/NCT00326430||182445|
NCT00317590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnKaHeresoRDT|Effectiveness and Cost-Effectiveness of a Rapid Diagnostic Test for Malaria|Evaluation de l'utilité et du coût-efficacité du Test Rapide Paracheck® Pour la Prise en Charge Des Cas de Paludisme Dans Les régions Des Hauts Bassins et Des Cascades, au Burkina Faso||Centro per le Malattie Tropicali||Completed|April 2006|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|4000|||Both|6 Months|N/A|No|||October 2007|October 30, 2007|April 23, 2006||||No||https://clinicaltrials.gov/show/NCT00317590||183110|
NCT00317850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC006253-01|Gabapentin for the Treatment of Tinnitus|Gabapentin for the Relief of Idiopathic Subjective Tinnitus||Washington University School of Medicine||Terminated|April 2004|February 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|April 21, 2006||||No||https://clinicaltrials.gov/show/NCT00317850||183091|
NCT00317863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-003-JO|Zink and Bone Strength|Zink and Bone Strength||Northern Orthopaedic Division, Denmark|Yes|Suspended|January 2004|December 2006||||N/A|Observational|Observational Model: Cohort||||0|||Female|18 Years|80 Years|No|Probability Sample|blood- and urine samples collected from 20 OA patients and 20 osteoporosis patients who        all had a hip-replacement. All patients were evaluated by DEXA-scanning.|March 2014|March 28, 2014|April 23, 2006||No|The researcher has left the organization|No||https://clinicaltrials.gov/show/NCT00317863||183090|
NCT00319059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMPD-Annexin|The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance|The Influence of the 34C>T Variant in the AMPD1 Gene on Individual Susceptibility for Ischemia-Reperfusion.||Radboud University||Active, not recruiting|March 2006|April 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2006|October 12, 2006|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319059||183000|
NCT00319644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27831-01|Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia|Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia||University of California, San Francisco|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|37|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|April 27, 2006||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00319644||182955|
NCT00322452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791AC00007|First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia|Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia|IPASS|AstraZeneca||Completed|March 2006|June 2010|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1329|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|May 5, 2006|Yes|Yes||No|April 29, 2009|https://clinicaltrials.gov/show/NCT00322452||182745|
NCT00322725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0604C|Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review|Bevacizumab(Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review||University of New Mexico|Yes|Completed|February 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with bevacizumab, with or without chemotherapy, with a wide variety of        metastatic malignancies.        Patients with and without pre-existing hypertension treated with bevacizumab plus or minus        chemotherapy with a wide variety of metastatic malignancies.|February 2016|February 24, 2016|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322725||182724|
NCT00322712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0603C|INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer|INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer||University of New Mexico|Yes|Completed|September 2006|January 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|12|||Both|18 Years|N/A|No|Probability Sample|Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research        and Treatment Center.|February 2015|March 2, 2015|May 5, 2006||No||No|February 11, 2015|https://clinicaltrials.gov/show/NCT00322712||182725|
NCT00322959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-056|Tai-Chi-Chuan on Differentiation and Maturation of Dendritic Cells|Effect of Tai-Chi-Chuan on Differentiation and Maturation of Human Dendritic Cells||Mackay Memorial Hospital|Yes|Completed|August 2004|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|TCC practitioner and Healthy subjects as controls|September 2008|September 19, 2008|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322959||182706|
NCT00324051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10960|Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet|PREFERENCE: 12-Week Open Label Trial On Olanzapine Orodispersible Tablet Vs. Oral Olanzapine Preference Study|PREFERENCE|Eli Lilly and Company||Completed|May 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|284|||Both|18 Years|65 Years|No|||January 2008|January 21, 2008|May 8, 2006||||No||https://clinicaltrials.gov/show/NCT00324051||182623|
NCT00324064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 03-053|Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing|Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing||Children's Mercy Hospital Kansas City|No|Completed|July 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|5 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00324064||182622|
NCT00324597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481095|AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase Ib, Open-Label, Sequential, Dose-Finding, Study of AMG 706 in Combination With Gemcitabine to Treat Subjects With Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|October 2005|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||April 2007|September 16, 2013|May 10, 2006||||||https://clinicaltrials.gov/show/NCT00324597||182582|
NCT00324610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP 5/7|Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen|Phase I/II Study of Tolerance and Pharmacokinetics With Capecitabine Given 5 Days Out of 7 in Metastatic Breast Cancer||Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie||Recruiting|March 2006|||||Phase 1/Phase 2|Interventional|N/A||||46|||Female|18 Years|N/A|No|||May 2006|May 16, 2006|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324610||182581|
NCT00325234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10826|Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer|A Randomized Phase II Study of Two Chemotherapy Regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxanes Pretreated Advanced Breast Cancer Patients||Eli Lilly and Company|No|Completed|June 2006|August 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Female|18 Years|N/A|No|||April 2011|April 26, 2011|May 10, 2006|Yes|Yes||No|April 26, 2011|https://clinicaltrials.gov/show/NCT00325234||182537|
NCT00325247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-018|Efficacy of Zinc Therapy in Acute Diarrhoea in Young Children|Efficacy of Short Course Zinc Therapy (5 vs 10 d) With 20 mg Elemental Zinc Daily in the Treatment of Acute Diarrhoea: A Double-blind Individually Randomized Controlled Community Trial.||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|February 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|2050|||Both|1 Month|59 Months|No|||May 2006|July 11, 2011|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325247||182536|
NCT00326456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-2|MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer|Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer||National Cancer Institute, Naples|Yes|Active, not recruiting|January 2003|May 2016|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|820|||Female|N/A|75 Years|No|||January 2016|January 22, 2016|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326456||182443|
NCT00322010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13766B|Early Directed Physical Therapy in the Management of Mechanically Ventilated Patients in a Medical Intensive Care Unit|A Randomized Trial of Early Physical and Occupational Therapy in Mechanically Ventilated, Critically Ill Patients||University of Chicago|No|Completed|June 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00322010||182778|
NCT00322309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22530|Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects|The Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects||Boston University|Yes|Active, not recruiting|September 2005|September 2010|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2010|August 30, 2010|May 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00322309||182756|
NCT00326443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0009|CVD 909 Vi Prime Boost Study|Phase I Randomized, Double-Blind, Heterologous Prime-Boost Study of the Safety and Immunogenicity of Vi Polysaccharide Typhoid Vaccine After Priming by Live Attenuated Oral Vi+ Salmonella Typhi Strain CVD 909||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2006|August 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|21|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2010|May 8, 2014|May 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00326443||182444|
NCT00321984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-GD05-137|Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease|A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)||Takeda|No|Completed|June 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|947|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|May 2, 2006|Yes|Yes||No|February 26, 2009|https://clinicaltrials.gov/show/NCT00321984||182780|
NCT00318695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNU01|Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses|Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses- A Randomized Double-Blind Placebo Controlled Trial||National University Hospital, Singapore|Yes|Completed|May 2004|January 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|253|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2009|January 21, 2009|April 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00318695||183027|
NCT00319033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-332|Open-label Study With Bosentan in Interstitial Lung Disease|Long-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330.|BUILD 2 OL|Actelion||Completed|July 2004|February 2006|Actual|February 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||132|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00319033||183002|
NCT00319046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGT 918-011|Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease|Open-label, Non Comparative, Multi-center Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Oral Miglustat as a Maintenance Therapy After a Switch From Enzyme Replacement Therapy in Adult Patients With Stable Type 1 Gaucher Disease||Actelion||Completed|February 2006|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2012|May 24, 2012|April 26, 2006|Yes|Yes||No|April 24, 2012|https://clinicaltrials.gov/show/NCT00319046||183001|
NCT00318708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|377|Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)|Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)|MIA|Milton S. Hershey Medical Center|Yes|Completed|June 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|60 Years|No|||December 2012|December 28, 2012|April 25, 2006|Yes|Yes||No|April 27, 2012|https://clinicaltrials.gov/show/NCT00318708||183026|Participants underwent endobronchial biopsy for characterization of lower airway status for M pneumoniae or C pneumoniae. The target sample size was 72 positives and 72 negatives. Only 80 and 12 were recruited, respectively.
NCT00319410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWMCgyn-1|Comparison of Two Hysteroscopy Approaches|A New Approach to Office Hysteroscopy Compared With Traditional Hysteroscopy||Wolfson Medical Center||Completed|July 2005|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||130|||Female|N/A|N/A|No|||April 2006|November 27, 2006|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319410||182973|
NCT00319384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 06-2642|Outpatient Ultrafiltration Therapy in Heart Failure Patients Trial|Outpatient Ultrafiltration Therapy in Heart Failure Feasibility Trial||Minneapolis Medical Research Foundation|No|Withdrawn|April 2006|May 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|90 Years|No|||October 2012|October 3, 2012|April 26, 2006|||Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00319384||182975|
NCT00322465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0120|NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)|Phase II Randomized, Placebo-Controlled Double-Blind 4-Arm Trial for the Treatment of Non-Gonococcal Urethritis (NGU): Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|305|||Male|16 Years|45 Years|No|||May 2011|November 13, 2014|May 4, 2006|Yes|Yes||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00322465||182744|
NCT00322738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0067|Time to Infection With Malaria Parasites|Time to Infection With Malaria Parasites in Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|June 2006|January 2007||||N/A|Observational|Time Perspective: Prospective||||552|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2008|August 26, 2010|May 4, 2006||||No||https://clinicaltrials.gov/show/NCT00322738||182723|
NCT00322985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22409|A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma|A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma||AHS Cancer Control Alberta|No|Completed|June 2006|July 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322985||182704|
NCT00322972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02576|Trachoma Amelioration in Northern Amhara (TANA)|Eliminating Trachoma With Repeat Mass Drug Treatment|TANA|University of California, San Francisco|Yes|Completed|June 2006|May 2014|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|33000|||Both|1 Year|N/A|Accepts Healthy Volunteers|||September 2015|September 5, 2015|May 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00322972||182705|
NCT00325585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA015641|HIV Prevention Intervention for Couples|Couples HIV Intervention Randomized Controlled Trial||National Development and Research Institutes, Inc.||Completed|April 2005|June 2008|Actual|December 2007|Actual|Phase 2|Interventional|N/A|||Anticipated|780|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|May 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00325585||182510|
NCT00325598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1053 / 201103235|Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer|Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer: A Phase I/II Feasibility Study||Washington University School of Medicine|No|Active, not recruiting|February 2006|April 2017|Anticipated|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||September 2014|September 19, 2014|May 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325598||182509|
NCT00324350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK069514|Intensive Glycemic Control and Skeletal Health Study|Intensive Glycemic Control and Skeletal Health Study - Ancillary Study to the Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD-BONE)|ACCORD-BONE|University of California, San Francisco|Yes|Completed|October 2003|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|7287|||Both|40 Years|79 Years|No|||September 2012|September 5, 2012|May 10, 2006||No||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00324350||182601|The initial identification of a possible fracture event relied on self-report at annual visits with the possibility of under- or over-reporting of fractures.
NCT00324883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601008328|Urine Chloride/Creatinine Ratio for Estimation of Urine Sodium|Urine Chloride/Creatinine Ratio for Estimation of Urine Sodium||Weill Medical College of Cornell University|No|Completed|March 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|Samples Without DNA|urine|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|volunteers from patient population including hypertensive and normotensive individuals,        and hypertensive and normotensive volunteers recruited by advertising. Age >21 excluding        individuals with unstable changes in renal function.|July 2013|July 8, 2013|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00324883||182562|
NCT00326482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060153|Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy|A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients With Chronically Elevated Transaminases on Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|May 2006|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|180|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|May 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00326482||182441|
NCT00326495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060164|BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer|A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC)||National Institutes of Health Clinical Center (CC)|No|Completed|May 2006|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|May 16, 2006|Yes|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT00326495||182440|
NCT00322023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH074356|Safety and Effectiveness of D-Serine in Schizophrenia|PK/PD Study of Escalating Dose D-Serine as Adjunctive Treatment in Schizophrenia||National Institute of Mental Health (NIMH)|Yes|Active, not recruiting|March 2006|June 2008|Anticipated|June 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||October 2008|October 27, 2008|May 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00322023||182777|
NCT00322296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-031|Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis|A Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis: a Topical Chemoprevention Strategy for Cutaneous T-cell Lymphoma.||Fox Chase Cancer Center||Terminated|April 2001|August 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|April 15, 2013|May 4, 2006|Yes|Yes|The response rate (5/8) had reached a statistical significant endpoint.|||https://clinicaltrials.gov/show/NCT00322296||182757|
NCT00322543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID (Genesis) Registry CP-02|Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)|Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID) A Multi-Center Study of the Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System (Corio™) in Patients With De Novo Lesions of the Native Coronary Arteries||Conor Medsystems|No|Terminated|May 2006|May 2008|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||September 2008|October 16, 2008|May 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00322543||182738|
NCT00322504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0520C|Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study|||University of New Mexico||Completed|January 2006|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Female|18 Years|N/A|No|||November 2006|January 6, 2010|May 5, 2006||||No||https://clinicaltrials.gov/show/NCT00322504||182741|
NCT00322816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0068|Malaria Prevalence in Children|Malaria Prevalence, Incidence and Mortality in Children||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|June 2006|January 2007||||N/A|Observational|Time Perspective: Prospective||||2000|||Both|6 Months|10 Years|Accepts Healthy Volunteers|||February 2008|August 26, 2010|May 4, 2006||||No||https://clinicaltrials.gov/show/NCT00322816||182717|
NCT00318409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA021090-1|Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM|Pilot Study of Acceptability of Bupropion Treatment for Methamphetamine Dependence Among Men Who Have Sex With Men.||San Francisco Department of Public Health|Yes|Completed|September 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|April 24, 2006||No||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00318409||183048|
NCT00318721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-2005-015374|Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar|Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar|KALANET|London School of Hygiene and Tropical Medicine|Yes|Completed|June 2006|November 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20000|||Both|2 Years|N/A|Accepts Healthy Volunteers|||June 2009|November 3, 2009|April 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00318721||183025|
NCT00318734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1335|Examining the Link Between Trace Elements and Cardiovascular Disease Risk Factors in Young Adults|Trace Elements and CVD Risk Factors Among Young Adults||University of North Carolina, Chapel Hill||Completed|May 2006|April 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4362|||Both|20 Years|32 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participating in the CARDIA study.|December 2011|December 9, 2011|April 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00318734||183024|
NCT00319709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4846|An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression|An Eight-Week, Double-Blind Placebo Controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Elderly Patients With Major Depressive Disorder (MDD)|ZEPHIR|Sanofi||Completed|April 2006|August 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|288|||Both|65 Years|N/A|No|||March 2009|March 10, 2009|April 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00319709||182950|
NCT00323024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX1011:201|Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension|An Open-Label, Dose-Determination Safety, Tolerability, and Activity Study of Inhaled NX1011 in Patients With Pulmonary Arterial Hypertension||NITROX, LLC||Withdrawn|September 2006|May 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|18 Years|75 Years|No|||July 2006|August 29, 2007|May 5, 2006||||||https://clinicaltrials.gov/show/NCT00323024||182702|
NCT00323037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104852|A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure|A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure|COMPARE|CTI-1, LLC|No|Completed|March 2006|June 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|318|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|May 5, 2006|Yes|Yes||No|January 16, 2009|https://clinicaltrials.gov/show/NCT00323037||182701|
NCT00323414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61732|Polyunsaturated Fatty Acids (PUFA) in the Treatment of Non-Alcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes Mellitus (PUFA)|Randomized Controlled Trial of Omega-3 Fatty Acids in the Treatment of Non-Alcoholic Steatohepatitis in Patients With Type 2 Diabetes Mellitus||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|April 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|May 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323414||182672|
NCT00323011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-05-2|FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer|A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer||University of Southern California||Terminated|May 2006|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|May 5, 2006|Yes|Yes|drug not available|No||https://clinicaltrials.gov/show/NCT00323011||182703|
NCT00323388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 04-458|Identification of Risk Allels for Prostate Cancer|Identification of Risk Allels for Prostate Cancer||University of New Mexico|Yes|Completed|November 2005|September 2007|Actual|September 2007|Actual|N/A|Observational|N/A||1|||||Male|N/A|N/A|No|Non-Probability Sample|Patients with prostate cancer|November 2009|January 6, 2010|May 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00323388||182674|
NCT00323401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDM2006|The Influence of Antenatal Classes on Pregnancy, Birth and Parenthood|The Influence of Antenatal Classes on Pregnancy, Birth and Parenthood||University of Aarhus|No|Active, not recruiting|May 2006|December 2011|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|52 Years|No|||November 2011|November 4, 2011|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323401||182673|
NCT00323635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000960|A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.|A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.||Brigham and Women's Hospital|Yes|Terminated|April 2006|January 2011|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 5, 2006|Yes|Yes|New department chairman instructed PI to discontinue study.|No|August 9, 2013|https://clinicaltrials.gov/show/NCT00323635||182655|
NCT00323648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/111|Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis|Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis||University Hospital, Ghent|No|Completed|May 2006|August 2013|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00323648||182654|
NCT00323661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA079|Closed Loop Stimulation, Cognitive Performance, and Quality of Life in Pacemaker Patients|COGNITION - Cognitive Performance & Closed Loop Stimulation|COGNITION|Biotronik SE & Co. KG||Completed|May 2006|March 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|405|||Both|55 Years|N/A|No|||February 2012|February 10, 2012|May 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00323661||182653|
NCT00325299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFAS-02|Magnesium After Alcohol Withdrawal Treatment|Magnesium After Alcohol Withdrawal Treatment||Finnish Foundation for Alcohol Studies||Completed||September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||178|||Both|20 Years|64 Years|No|||May 2006|May 11, 2006|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325299||182532|
NCT00325611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-02GGade-01 - H|Multidisciplinary Inpatient Palliative Care Intervention|A Multi-Site Replication of an Inpatient Palliative Care Program||Kaiser Permanente||Completed|April 2002|July 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||550|||Both|18 Years|N/A|No|||May 2006|May 12, 2006|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00325611||182508|
NCT00325858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B02.CT3.023.TRA P03|A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip|Double-Blind, Randomized,Dose-Ranging, Parallel-Group Comparison Of The Efficacy And Safety Of Extended-Release Tramadol Hydrochloride(Tramadol HCl ER)100 Mg, 200 Mg, 300 Mg, And 400 Mg With Placebo In The Treatment Of Osteoarthritis Of Knee And/Or Hip||Valeant Pharmaceuticals International, Inc.|No|Completed|January 2002|December 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1000|||Both|18 Years|74 Years|No|||September 2006|August 24, 2012|May 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325858||182489|
NCT00326196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|557|Coronary Artery Revascularization in Diabetes|CSP #557 - Coronary Artery Revascularization in Diabetes (VA CARDS)|VA CARDS|VA Office of Research and Development|Yes|Terminated|July 2006|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|May 12, 2006|No|Yes|Lack of participant enrollment|No|July 1, 2013|https://clinicaltrials.gov/show/NCT00326196||182463|Low participant recruitment led to the study being terminated early.
NCT00326508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060066|Combination Daclizumab/Denileukin Diftitox to Treat Uveitis|Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis||National Institutes of Health Clinical Center (CC)||Completed|May 2006|December 2006||||Phase 2|Interventional|Primary Purpose: Treatment||||5|||Both|18 Years|65 Years|No|||December 2006|February 24, 2007|May 16, 2006||||No||https://clinicaltrials.gov/show/NCT00326508||182439|
NCT00322036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-7869-05-010.01|Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's|Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type||Myrexis Inc.|Yes|Terminated|May 2006|December 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|800|||Both|55 Years|N/A|No|||August 2008|August 1, 2008|May 2, 2006|Yes|Yes|Myriad has discontinued the development of Flurizan.|No||https://clinicaltrials.gov/show/NCT00322036||182776|
NCT00322556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB05_006CR|Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)|A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)||CSL Behring||Completed|November 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|4 Years|71 Years|No|||September 2012|September 27, 2012|May 5, 2006|Yes|Yes||No|September 27, 2012|https://clinicaltrials.gov/show/NCT00322556||182737|
NCT00322569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01|A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)|A Randomized, Multi-Center Study of the Pimecrolimus-Eluting (Corio™) and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (SymBio™) in Patients With De Novo Lesions of the Native Coronary Arteries||Cordis Corporation|Yes|Completed|July 2006|May 2012|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|246|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|May 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00322569||182736|
NCT00322530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-Dialysis-2006|Comparison of Dialysis Strategies in Critically Ill Patients With Acute Renal Failure|Comparison of Dialysis Strategies in Critically Ill Patients With Acute Renal Failure on the Intensive Care Unit|rescue|Heidelberg University|No|Completed|April 2006|February 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|May 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00322530||182739|
NCT00319072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0065|Hormone Replacement Therapy (HRT) Website Tool|Testing an Interactive Website for Hormone Replacement||National Institute on Aging (NIA)||Completed|March 2004|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||280|||Female|45 Years|74 Years|Accepts Healthy Volunteers|||April 2006|April 26, 2006|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00319072||182999|
NCT00319397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0063|Effects of Age and Exercise on Blood Pressure Regulation|Arterial Stiffness With Age: Part 1 and 2||National Institute on Aging (NIA)||Recruiting|April 2004|March 2007||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||January 2009|December 10, 2009|April 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00319397||182974|
NCT00319657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|367|Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs|Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-Cell Transfusion in HLA-Matched Living Donor Kidney Transplantation||Stanford University|Yes|Recruiting|July 2004|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|April 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00319657||182954|
NCT00319670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851-201|A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children|A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children||Braintree Laboratories||Completed|March 2006|||May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|4 Years|16 Years|No|||February 2013|February 6, 2013|April 27, 2006||||||https://clinicaltrials.gov/show/NCT00319670||182953|
NCT00320008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA92071gm-KA99035g-KA99035gs|Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria|||Steno Diabetes Center||Active, not recruiting|January 1992|March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|40 Years|65 Years|No|||April 2006|October 12, 2006|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00320008||182927|
NCT00324090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01-249/01|Glycemic Index, Body Weight and Health|Glycemic Index, Body Weight and Health||University of Copenhagen||Completed|March 2002|July 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||43|||Female|20 Years|41 Years|Accepts Healthy Volunteers|||February 2002|January 20, 2009|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324090||182620|
NCT00324363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWBA|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin||AstraZeneca|No|Completed|January 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|466|||Both|21 Years|75 Years|No|||January 2015|February 20, 2015|May 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324363||182600|
NCT00324623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000468827|Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma|Phase I Study of In Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma||Centre Hospitalier Universitaire Vaudois|No|Completed|September 2005|||November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||November 2012|November 19, 2012|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00324623||182580|
NCT00324896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5581|Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone|Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone||Rutgers, The State University of New Jersey|No|Completed|May 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|85 Years|No|||April 2013|April 24, 2013|May 9, 2006|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00324896||182561|This was only a 6-week trial with small group of participants.
NCT00324909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBA-1|Effects of Hyperbaric Oxygen Therapy in Autistic Children: A Pilot Study|Effects of Hyperbaric Oxygen Therapy on Clinical Symptoms and Markers of Inflammation and Oxidative Stress in Autistic Children: A Pilot Study||International Hyperbarics Association||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|2 Years|18 Years||||April 2007|April 9, 2007|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324909||182560|
NCT00324389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-014|Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes|A Pilot Study to Characterize Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes Using High Density Oligonucleotide Microarray Expression Analysis in Caucasian and African American Patients With Chronic Hepatitis C||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2006|June 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2|||Male|18 Years|65 Years|No|||April 2009|August 26, 2010|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00324389||182598|
NCT00325286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-13934|Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder|Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder||Creighton University|No|Active, not recruiting|May 2006|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|65 Years|No|||December 2007|December 13, 2007|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00325286||182533|
NCT00325312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-2|Subcutaneous Carbon Dioxide Insufflations for Acute Non Specific Neck Pain|Evaluation of the Efficacy of Subcutaneous Carbon Dioxide Insufflations for Treating Acute Non Specific Neck Pain in General Practice||Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster||Completed|January 2001|March 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||114|||Both|18 Years|64 Years|No|||May 2006|May 12, 2006|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325312||182531|
NCT00325624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-04|Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel)|Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel)|DREAM-Tel|Sunnybrook Health Sciences Centre||Completed|November 2006|April 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00325624||182507|
NCT00325637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNL-BR3-01-02|Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients With Hypertension|A Multi-Center, Double Blind, Randomized and Non-Inferiority Clinical Study of Cilnidipine to Compare the Effects on Cerebral Blood Flow With Losartan in Patients With Ischemic Stroke Hypertension||Boryung Pharmaceutical Co., Ltd|Yes|Completed|January 2005|August 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|250|||Both|35 Years|80 Years|No|||December 2008|December 11, 2008|May 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00325637||182506|
NCT00325871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-243|Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer|The Effect of Concurrent Chemoradiation on Circulating Endothelial Progenitor Cells in Colorectal Cancer||Mackay Memorial Hospital||Recruiting|April 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||30|||Both|30 Years|60 Years|No|||March 2006|May 12, 2006|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00325871||182488|
NCT00326222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASOPP1|Patient Education in NorthTrondelag Hospital Trust|Patient Education in NorthTrondelag Hospital Trust - Interventions, Effects and Patient Experience||Norwegian University of Science and Technology|No|Completed|May 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|146|||Both|18 Years|90 Years|No|||September 2010|September 8, 2010|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326222||182461|
NCT00326469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52030-166|Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours|Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy||Ipsen||Completed|May 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|May 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00326469||182442|
NCT00326521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297-05|Evaluation of Fever Occurring in Labor in Patients Receiving Epidural Anesthesia|Evaluation of Intrapartum Fever in Patients Receiving Epidural Anesthesia||MemorialCare|No|Recruiting|October 2006|May 2009|Anticipated|||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Maternal serum, amniotic fluid, and umbilical cord blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women >18 years of age that present to labor and delivery and are in active labor.|June 2008|June 5, 2008|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326521||182438|
NCT00322049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 824|A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants|A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants||U.S. Army Medical Research and Materiel Command|Yes|Completed|February 2004|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|51|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||May 2012|May 22, 2012|May 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00322049||182775|
NCT00322322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050316|Early Administration of L-carnitine in Hemodialysis Patients|Early Administration of L-carnitine in Hemodialysis Patients: Double Blind Randomized Trial Versus Placebo||Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2006|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||March 2007|May 3, 2011|May 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00322322||182755|
NCT00322842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-EU21|Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients|Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF||Sanofi||Completed|September 2004|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|May 4, 2006|No|Yes||No|October 30, 2010|https://clinicaltrials.gov/show/NCT00322842||182715|
NCT00322855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0517C|Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma|Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma||New Mexico Cancer Care Alliance|Yes|Terminated|August 2005|August 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Probability Sample|Patients with soft tissue sarcoma treated with chemotherapy form 2004 and 2005.|July 2015|July 10, 2015|May 5, 2006||No|Low accrual|No|June 16, 2015|https://clinicaltrials.gov/show/NCT00322855||182714|
NCT00318760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905403|Effect of Clonidine on Responses to Imagery Scripts|Effect of Clonidine on Responses to Imagery Scripts||National Institutes of Health Clinical Center (CC)||Completed|June 2005|August 2013|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|55 Years|No|||July 2014|July 9, 2014|April 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00318760||183022|
NCT00319085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-008a-JPE|Preheating of Femur Component in Hybrid Total Hip Arthroplasty|Comparison Between Preheated and Non-preheated Femur Component in Hybrid Total Hip Arthroplasty (THA) A Prospective Randomized Study of the 80 THA Using Radiostereometry.||Northern Orthopaedic Division, Denmark|Yes|Completed|May 2006|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|80|||Both|70 Years|85 Years|No|||April 2015|April 9, 2015|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319085||182998|
NCT00319098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107064|Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above|A Phase III, Observer-blind, Randomised Study to Evaluate the Safety and Immunogenicity of One and Two Administrations of Pandemic Monovalent (H5N1) Influenza Vaccine (Adjuvanted Split Virus Formulation ) in Adults Aged 18 Years and Older||GlaxoSmithKline||Completed|May 2006|February 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5075|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 28, 2012|April 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00319098||182997|
NCT00319111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-370|Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT, NCT00313222)|BENEFIT OL|Actelion||Completed|January 2006|April 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|18 Years|80 Years|No|||November 2012|November 29, 2012|April 26, 2006|No|Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00319111||182996|
NCT00319124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03b-2005-NAR|Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis of the Hip. A Case-Control Study|Evaluation of Function and Effect of Exercise in Patients With Osteoarthritis of the Hip.A Case-control Study.||Oslo University Hospital|No|Completed|April 2005|October 2010|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|52|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with hip osteoarthritis and mild to moderate pain. Matched controls with no hip        pain.|May 2012|March 1, 2016|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319124||182995|
NCT00319137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOS102512|An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine|A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of Doses of 5-180 mg of the iNOS Inhibitor GW274150 in the Treatment of Acute Migraine During the Mild Headache Phase||GlaxoSmithKline|No|Completed|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||126|||Both|18 Years|65 Years|No|||February 2011|May 31, 2012|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00319137||182994|
NCT00319150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-852-05|REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial|Resistance to ErythroPoietin Effectiveness Algorithm Trial||Queen's University|Yes|Terminated|October 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|April 26, 2006||No|New evidence and trouble recruiting|No||https://clinicaltrials.gov/show/NCT00319150||182993|
NCT00319683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHX-03-103|A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma|A Phase 1/2 Study in Subjects With Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma, Evaluating the Safety, and Anti-Tumor Activity of ADH300004 (Eniluracil) With Escalating Doses of 5 Fluorouracil Administered Orally Once Weekly for 3 Weeks Out of Every 4 (Adherex Protocol Number AHX-03-103)||Adherex Technologies, Inc.||Terminated||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2008|December 12, 2008|April 27, 2006|Yes|Yes|Lack of funds|Yes||https://clinicaltrials.gov/show/NCT00319683||182952|
NCT00319696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-333|Bosentan in Digital Ulcers|Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers|RAPIDS 2 OL|Actelion|No|Completed|July 2004|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|April 27, 2006|No|Yes||No|June 29, 2012|https://clinicaltrials.gov/show/NCT00319696||182951|
NCT00324103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS PART|Structured Treatment Interruptions in Chronic HIV Infection|Antiretroviral Treatment With Structured Treatment Interruptions (STI) Versus Continuous Antiretroviral Treatment in HIV+ Patients With Persistent Suppression of Viral Replication||Istituto Superiore di Sanità||Completed|June 2001|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||October 2005|May 8, 2006|May 8, 2006||||No||https://clinicaltrials.gov/show/NCT00324103||182619|
NCT00324376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC-68-209|Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing|A Randomized, Cross-Over Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing||Sanofi||Completed|March 2003|May 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|May 9, 2006||||||https://clinicaltrials.gov/show/NCT00324376||182599|
NCT00324649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-ES-164-0154|Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada|Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study).|RECOMB|Gilead Sciences|Yes|Completed|May 2006|September 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|May 9, 2006||No||No|March 30, 2009|https://clinicaltrials.gov/show/NCT00324649||182579|
NCT00324922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27915-B|Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus (MRSA) Osteomyelitis (VOTSMO)|A Prospective, Randomized Trial Comparing Vancomycin With Trimethoprim/Sulfamethoxazole for the Treatment of MRSA Osteomyelitis||University of Washington|Yes|Active, not recruiting|May 2006|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||July 2009|July 27, 2009|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00324922||182559|
NCT00325325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVEROTAC|Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus|A Pilot Study to Investigate Pharmacokinetic Characteristics of Everolimus in Patients Treated With Tacrolimus-Based Immunosuppression in De Novo Kidney Transplantation||Hospital Universitario Ramon y Cajal||Recruiting|January 2006|June 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||May 2006|October 25, 2006|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325325||182530|
NCT00325338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RagweedMATAMPL205|Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis|Follow-up Study to Evaluate the Sustained Clinical Efficacy of Ragweed MATA MPL (Allergy Therapeutics®) in Patients With Ragweed-induced Seasonal Allergic Rhinitis Upon Re-exposure to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Model, Approximately One Year After Pre-seasonal Treatment in 2005||Allergy Therapeutics||Completed|May 2006|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||June 2010|June 16, 2010|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325338||182529|
NCT00325650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5107|Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes (RAPSODI)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of Long-Term Administration of Rimonabant in the Prevention of Type 2 Diabetes in Patients With Prediabetic Status (i.e., Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Both)||Sanofi||Terminated|May 2006|March 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2420|||Both|35 Years|75 Years|No|||June 2009|June 12, 2009|May 12, 2006|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00325650||182505|
NCT00325663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKOK1|Acupuncture in Osteoarthritis of the Knee|Specific and Non-Specific Effects of Acupuncture: A Double-Blinded, Randomized, Controlled Trial in Patients With Osteoarthritis of the Knee||Heidelberg University||Completed|April 2004|April 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Both|35 Years|90 Years|No|||April 2004|May 12, 2006|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00325663||182504|
NCT00325884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VABHS-IRB-1934|Long-term Outcomes of Patients After Coronary Bifurcation Stenting|Long-term Outcomes of Patients After Coronary Bifurcation Stenting||VA Boston Healthcare System|No|Completed|August 2001|August 2005|Actual|August 2005|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|160|||Both|N/A|N/A|No|Non-Probability Sample|Patient receiving drug eluting or bare metal coronary stents for coronary bifurcation        lesions|August 2011|August 25, 2011|May 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00325884||182487|
NCT00326209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPUC3005|Long-Term Safety and Tolerability of Mesalamine Pellets in Patients With Ulcerative Colitis in Remission|A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation||Valeant Pharmaceuticals International, Inc.||Completed|December 2005|July 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|394|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|May 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00326209||182462|
NCT00326235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA013264|Effects of Buspirone in Opiate Withdrawal|Effects of Buspirone in Withdrawal From Opiates||National Institute on Drug Abuse (NIDA)||Completed|January 2002|July 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|25 Years|55 Years|No|||March 2005|May 12, 2006|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00326235||182460|
NCT00326248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT102553|Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women|A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis||GlaxoSmithKline|No|Completed|March 2006|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|482|||Female|18 Years|N/A|No|||March 2011|May 31, 2012|May 12, 2006||||||https://clinicaltrials.gov/show/NCT00326248||182459|
NCT00322062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL994-02/2001|MOVIPREP® Versus NaP Pivotal Phase III Study|A Prospective Randomised Single-Blinded Multicentric and Pivotal Phase III Study Comparing the Efficacy, Safety and Acceptability of a New 2 Litres Gut Lavage Solution NRL994 Versus a Sodium Phosphate Solution for Colonoscopy Preparation||Norgine|No|Completed|April 2002|March 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|75 Years|No|||April 2008|April 15, 2008|May 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00322062||182774|
NCT00322335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106672|Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC|Phase III, Open, Multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC Compared to a Booster Dose of Infanrix™ Hexa When Given to 14 Month-old Subjects Primed in Study DTPa-HBV-IPV-097 & Boosted in Study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097||GlaxoSmithKline||Completed|May 2006|September 2010|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|230|||Both|31 Months|33 Months|Accepts Healthy Volunteers|||November 2011|November 10, 2011|May 4, 2006|Yes|Yes||No|September 17, 2010|https://clinicaltrials.gov/show/NCT00322335||182754|
NCT00313040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79940|Study to Promote Physical Activity Among Overweight Persons|Promoting Increased Physical Activity as the Main Outcome of Treatment for Overweight Persons: A Pilot Randomized Controlled Trial||Stanford University||Completed|March 2004|June 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|April 7, 2006||||No||https://clinicaltrials.gov/show/NCT00313040||183457|
NCT00313053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSMAB216|Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia|A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Pediatric Patients With Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia||Stanford University||Completed|September 2004|July 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Months|18 Years|No|||October 2010|May 31, 2011|April 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313053||183456|
NCT00313066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940513/C05092|Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion|Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Among Tuberculous Pleurisy and Malignant Pleural Effusion Patients||Taichung Veterans General Hospital||Recruiting|November 2005|November 2006||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||80|||Both|18 Years|N/A|No|||April 2006|April 9, 2006|April 9, 2006||||No||https://clinicaltrials.gov/show/NCT00313066||183455|
NCT00322868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFFTI-Pio001|Safety and Efficacy of Pioglitazone as an Anti-Inflammatory for the Treatment of CF Lung Disease|A Pilot Study Assessing the Safety and Efficacy of Pioglitazone as an Anti-Inflammatory Agent for the Treatment of CF Lung Disease in Patients With Cystic Fibrosis||University Hospital Case Medical Center||Completed|April 2006|April 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||September 2007|September 20, 2007|May 4, 2006||||No||https://clinicaltrials.gov/show/NCT00322868||182713|
NCT00318461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1572|To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together|Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes|LEAD-2|Novo Nordisk A/S|No|Completed|May 2006|November 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1091|||Both|18 Years|80 Years|No|||October 2014|October 14, 2014|April 25, 2006|Yes|Yes||No|February 23, 2010|https://clinicaltrials.gov/show/NCT00318461||183044|
NCT00319423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03a-2005-NAR|Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis. a RCT.|Evaluation of Function and Effect of Exercise Therapy in Patients With Osteoarthritis of the Hip. A Randomized Controlled Trial.||Ullevaal University Hospital||Completed|April 2005|||February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|40 Years|80 Years|No|||April 2006|February 4, 2010|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319423||182972|
NCT00319735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GI05-92|Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas|A Pilot Study With Cetuximab and Radiation Therapy for Patients With Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group Study (GI05-92)||Hoosier Cancer Research Network|Yes|Completed|April 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|April 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00319735||182948|
NCT00319748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06US03IMP-852A|Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers|Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers||Masonic Cancer Center, University of Minnesota|Yes|Completed|April 2006|December 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||January 2010|January 4, 2010|April 27, 2006|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00319748||182947|Other Adverse Events that occurred were noted as targeted toxicities and not captured as adverse events.
NCT00320047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5017|Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder|Effects of Baclofen on Binge Eating in Bulimia Nervosa and Binge Eating Disorder||New York State Psychiatric Institute|No|Completed|April 2005|June 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|55 Years|No|||September 2008|August 8, 2013|April 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00320047||182924|
NCT00324116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751016|Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions|A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions||Pfizer|No|Completed|July 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|50 Years|N/A|No|||March 2010|March 15, 2010|May 8, 2006||No||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00324116||182618|
NCT00324402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005008|Plasma Brain Natriuretic Peptide Levels in Pregnancy|Plasma Brain Natriuretic Peptide Levels in Pregnancy||Oklahoma State University Center for Health Sciences|No|Completed|August 2006|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy pregnant women, 18-40|July 2008|July 8, 2008|May 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00324402||182597|
NCT00324662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA044|Study to Verify Proper Detection of Supraventricular Tachyarrhythmia With Single-Lead Dual-Chamber Implantable Cardioverter-Defibrillators (ADRIA)|ADRIA - Belos A+ vs DR Clinical Investigation of Arrhythmia Discrimination||Biotronik SE & Co. KG||Completed|August 2003|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|260|||Both|18 Years|N/A|No|||September 2008|September 29, 2008|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00324662||182578|
NCT00324948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vivus-FSD-10|Topical Alprostadil for Female Sexual Arousal Disorder|A Double-Blind, Randomized, 6-Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women With Female Sexual Arousal Disorder (FSAD)||VIVUS, Inc.||Completed|September 2004|November 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Female|21 Years|60 Years|No|||March 2009|March 9, 2009|May 9, 2006||Yes||||https://clinicaltrials.gov/show/NCT00324948||182558|
NCT00324961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF106632|Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B|A 2-year Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B||GlaxoSmithKline||Completed|January 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|533|||Both|18 Years|65 Years|No|||October 2009|October 26, 2009|May 9, 2006||No||No|August 27, 2009|https://clinicaltrials.gov/show/NCT00324961||182557|
NCT00325676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/M3-342|Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)|CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD||Takeda||Completed|June 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|639|||Both|18 Years|N/A|No|||June 2007|May 4, 2012|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00325676||182503|
NCT00325689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-397 ST|Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.|A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy.||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||April 2011|November 7, 2013|May 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325689||182502|
NCT00325923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-06-03-01|Impact of a Decision Aid Regarding Natural Health Products for Menopausal Symptoms|A Patient Decision Aid Regarding Natural Health Products for Menopausal Symptoms:a Randomized Controlled Trial||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|April 2006|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||70|||Female|45 Years|64 Years|Accepts Healthy Volunteers|||April 2006|March 24, 2010|May 11, 2006||||No||https://clinicaltrials.gov/show/NCT00325923||182484|
NCT00325897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397|Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease|Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2006|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1142|||Both|40 Years|N/A|No|||April 2015|April 7, 2015|May 12, 2006||No||No|August 18, 2011|https://clinicaltrials.gov/show/NCT00325897||182486|
NCT00326261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0126-AE|Randomized Controlled Trial of Ultrasound Guided Needle Placement Versus Nerve Stimulation for Coracoid Infraclavicular Brachial Plexus Block|Randomized Controlled Trial of Ultrasound Guided Needle Placement Versus Nerve Stimulation for Coracoid Infraclavicular Brachial Plexus Block||University Health Network, Toronto||Completed||||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|80 Years|No|||April 2006|December 17, 2008|May 12, 2006||||No||https://clinicaltrials.gov/show/NCT00326261||182458|
NCT00317200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LUN05-99|A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer|Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study||Hoosier Cancer Research Network|Yes|Completed|April 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|April 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00317200||183140|
NCT00313092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-LEJ-2004-002|Obstructive Sleep Apnea Syndrome in Glaucoma|Does Plasma Matrix-metalloproteinase Activity Predict Glaucomas in Patients With OSAS (Obstructive Sleep Apnea Syndrome) and Does the Level of Plasma Matrix-metalloproteinase Activity Decrease After One Month of nCPAP-treatment||University Hospital, Basel, Switzerland|No|Terminated|January 2005|September 2005|Actual|September 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|None Retained|plasma|Both|18 Years|95 Years|No|Non-Probability Sample|Patients with sleep apnoe syndrom|October 2015|October 1, 2015|April 10, 2006||No|recruiting problems|No||https://clinicaltrials.gov/show/NCT00313092||183453|
NCT00313430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED. RES.HOS 2004 03/IT|Urinary Concentration and Diluting Ability in Patients With Chronic Renal Disease and/ or Hypertension|Urinary Concentration and Diluting Ability in Patients With Chronic Renal Disease or Hypertension||Regional Hospital Holstebro||Completed|May 2004|||March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Healthy participants were recruited by advertisements in public and private institutions        Patients with primary hypertension or chronic renal failure were recruited from the        Out-patients' Clinic, Department of Medicine, Section of Nephrology, Holstebro Hospital|August 2015|August 19, 2015|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313430||183427|
NCT00313690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2N-05-2|Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer|Phase I/II Study of Neoadjuvant Bortezomib in Combination With Docetaxel and Cisplatin Followed by Surgery in Early Stage Non-Small Cell Lung Cancer.||University of Southern California||Withdrawn|April 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|April 10, 2006|Yes|Yes|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00313690||183410|
NCT00313404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0584-2002|Infectivity of Norovirus in Groundwater-Human Challenge Study|Assessment of Calicivirus Survival in Surface Water and Subsurface Water||Emory University|No|Completed|February 2006|April 2011|Actual|January 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00313404||183429|
NCT00313417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shapira1CTIL|Creatine as a New Therapeutic Strategy in Depression|A Double-blind, Parallel, Randomized, add-on Clinical Trial of Creatine Versus Placebo Added to Antidepressant Treatment of Patients With Major Depressive Episode.||Herzog Hospital|Yes|Terminated|January 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|75 Years|No|||April 2013|April 3, 2013|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313417||183428|
NCT00319475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-DE 006|Evaluation of Mechanical Stapler for Aortic Anastomoses|Evaluation of Mechanical Stapler for Aortic Anastomoses||SVSE 2000 Ltd.||Active, not recruiting|February 2006|July 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|21 Years|85 Years|No|||October 2006|October 8, 2006|April 27, 2006||||No||https://clinicaltrials.gov/show/NCT00319475||182968|
NCT00320606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN029ST|Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients|Immunosuppression Withdrawal for Pediatric Living-donor Liver Transplant Recipients (ITN029ST)|WISP-R|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|May 2006|March 2017|Anticipated|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|4 Years|18 Years|No|||June 2015|June 15, 2015|April 28, 2006||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00320606||182881|
NCT00319436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017294|Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers|Fostering Mothers' Emotionally Responsive Parenting||Yale University|Yes|Completed|August 2004|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Female|18 Years|65 Years|No|||January 2014|January 20, 2014|April 26, 2006||No||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00319436||182971|Sample most representative of addicted mothers in mid-30’s, Caucasian, high school educated, unemployed, moderate involvement with child welfare. Caution in generalizing to higher risk mothers (adolescent mothers, ethnic minority,less educated).
NCT00319449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04060|Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)|A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population.||Merck Sharp & Dohme Corp.||Completed|September 2005|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|75 Years|No|||October 2015|October 9, 2015|April 28, 2006|Yes|Yes||No|April 14, 2011|https://clinicaltrials.gov/show/NCT00319449||182970|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.
NCT00324129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-003|A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes|A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose In Patients With Leukemia Or Myelodysplastic Syndromes||Mirati Therapeutics Inc.|No|Completed|February 2005|December 2008|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|May 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00324129||182617|
NCT00324415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-045|Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer|Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma||AIDS Malignancy Consortium|No|Active, not recruiting|September 2006|April 2016|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|May 10, 2006|Yes|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT00324415||182596|
NCT00324675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN 2|Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy|Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy||Technische Universität Dresden|Yes|Completed|August 2006|December 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|75 Years|No|||October 2011|October 27, 2011|May 9, 2006||No||No|September 15, 2011|https://clinicaltrials.gov/show/NCT00324675||182577|
NCT00324974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-GI05-109|The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux|A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux||Takeda|No|Completed|June 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|1 Month|11 Months|No|||July 2010|July 20, 2010|May 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324974||182556|
NCT00324987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00776|Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor|A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors||National Cancer Institute (NCI)|Yes|Completed|April 2008|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2015|August 28, 2015|May 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324987||182555|
NCT00316160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100368|Sexual Functioning Study With Antidepressants|See Detailed Description||GlaxoSmithKline|No|Completed|September 2004|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||344|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|April 18, 2006||||||https://clinicaltrials.gov/show/NCT00316160||183220|
NCT00316173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/902|Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer|An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer||GlaxoSmithKline|Yes|Completed|March 2005|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Female|18 Years|N/A|No|||November 2012|November 21, 2012|April 19, 2006||||No|October 20, 2009|https://clinicaltrials.gov/show/NCT00316173||183219|As only 17 of 55 participants had CR/PR, the treatment was not effective. The follow up of participants for survival was thus stopped early (original plan: every 3 months for 2 years; then every 6 months for 3-5 years; then annually/until death).
NCT00316446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF1|Study to Determine Incidence of Hypoventilation in Patients Who Have Undergone Gastric Bypass|A Prospective Double Blind Pilot Study to Determine the Incidence of Postoperative Hypoventilation in Patients With Clinically Significant Obesity Who Have Undergone Gastric Bypass Procedures Under General Anesthesia||University of South Florida|No|Completed|January 2006|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include male and female adult patients (age 18-65) with        clinically significant obesity (body mass index (BMI) between 40-85 kg/m2), who are        approved for gastric bypass surgery for weight loss. Patients must have documented        obstructive sleep apnea and use continuous positive airway pressure (CPAP) or bilevel        positive airway pressure (BiPAP), and have an American Society of Anesthesiologists (ASA)        Physical Status Classification I-III.|September 2012|September 18, 2012|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316446||183198|
NCT00325910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Approval J-2865|Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study|Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study||University of Alberta||Terminated|May 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2008|May 12, 2008|May 12, 2006|||Insufficient study participants|No||https://clinicaltrials.gov/show/NCT00325910||182485|
NCT00326534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 303797|Rickettsial Genesis to Sarcoidosis in Denmark|Rickettsial Genesis to Sarcoidosis in Denmark||Statens Serum Institut|No|Completed|September 2006|March 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|Samples With DNA|Buffy coats, serum, bronchoalveolar lavage fluid and transbronchial biopsies|Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to fiberoptic bronchoscopy in the department either because of        sarcoidosis, hemoptysis, chronic cough, or cancer suspicion|March 2009|March 6, 2009|May 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00326534||182437|
NCT00316953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01824|Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate|A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (BMS Trial CA180038)||National Cancer Institute (NCI)||Completed|March 2006|||September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|1 Year|21 Years|No|||January 2013|February 4, 2013|April 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00316953||183159|
NCT00317213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIB-05-2001|Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture|Phase IIB Study of the Efficacy and Safety of LIBERTAL, A Phosphatidic-Acid-Enriched Phospholipid, on Smoking Cessation||Kaplan Medical Center||Completed|February 2002|July 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||April 2008|April 9, 2008|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00317213||183139|
NCT00313079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMALL0003|Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia|A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Adult Patients With Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia||Stanford University|Yes|Completed|May 2006|July 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|April 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313079||183454|
NCT00313716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01NS038660|Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury|Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury||Baylor College of Medicine|Yes|Completed|April 2006|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|200|||Both|15 Years|N/A|No|||September 2014|September 2, 2014|April 10, 2006|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00313716||183408|
NCT00313729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000448883|Temozolomide in Treating Patients With Low-Grade Glioma|A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma||University of California, San Francisco|Yes|Completed|May 1999|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|April 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313729||183407|
NCT00314028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH066682|Effectiveness of HIV Risk Reduction Program Among African American Men|Promoting HIV Risk Reduction Among African American Men||University of Kentucky||Completed|April 2003|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|270|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00314028||183384|
NCT00313703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-03-077E|Prospective ED Headache Cohort Study|Predicting Poor Pain and Functional Outcomes After Discharge From the Emergency Department With a Primary Headache||Montefiore Medical Center||Completed|March 2005|May 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|477|||Both|21 Years|N/A|No|Non-Probability Sample|Convenience sample of ED patients|April 2011|April 15, 2011|April 10, 2006||No||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00313703||183409|
NCT00318773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1HD18633|Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS)|Short-Term Versus Long-Term Treatment for Severe PMS||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|February 2002|February 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|174|||Female|18 Years|45 Years|No|||April 2006|February 26, 2009|April 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00318773||183021|
NCT00318786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1598|Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes|Trial to Investigate the Efficacy and the Safety of Thrice-Daily NN2000-Mix70 (NovoRapid 70 Mix) Compared to Twice-Daily NN-X14Mix30 (NovoRapid 30 Mix) in Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|April 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|289|||Both|20 Years|N/A|No|||November 2014|November 3, 2014|April 26, 2006||||No||https://clinicaltrials.gov/show/NCT00318786||183020|
NCT00318799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91477|Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters|A Single-centre, Open-label, Crossover, Controlled, Randomized Study to Investigate the Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters in 30 Healthy Female Volunteers Over 3 Treatment Cycles||Bayer||Completed|April 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 20, 2013|April 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00318799||183019|
NCT00320294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-GI-52|ILF With/Without Cisplatin for Advanced Gastric Cancer|A Randomized Trial of Irinotecan, Leucovorin, 5-FU (ILF) Versus ILF Plus Cisplatin (PILF) Combination Chemotherapy in Patients With Advanced Gastric Cancer||Gachon University Gil Medical Center||Active, not recruiting|February 2005|March 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||86|||Both|18 Years|75 Years|No|||March 2007|March 9, 2007|May 1, 2006||||No||https://clinicaltrials.gov/show/NCT00320294||182905|
NCT00324714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000474949|Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS|A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women||International Breast Cancer Study Group||Withdrawn|February 2003|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Actual|0|||Female|40 Years|70 Years|No|||November 2012|November 28, 2012|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00324714||182574|
NCT00320073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0509|Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors|A Two Arm Phase I Dose Escalation Trial of Vinflunine With Erlotinib or Pemetrexed in Refractory Solid Tumors||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|August 2006|January 2010|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|April 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00320073||182922|
NCT00324428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000311|TMS for the Treatment of Pancreatic Cancer Pain|The Effect of a 10-day Course of Transcranial Magnetic Stimulation on Abdominal Pain in Patients With Locally Advanced and Advanced Pancreatic Cancer, a Randomized Phase II Study.||Beth Israel Deaconess Medical Center||Active, not recruiting|May 2006|February 2008|Anticipated|February 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|65 Years|No|||February 2010|February 3, 2010|May 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00324428||182595|
NCT00324688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-MC-104-1015|Safety Study of Once a Day ART and Opiate Substitute.|Open-label Multicenter Study to Assess the Efficacy, the Tolerability and the Adherence of a Once Daily (QD) Taken Antiretroviral Therapy (ART) Containing the NtRTI Tenofovir DF 300 mg in Combination With the Best Suitable Once a Day Regimen Being 1 NRTI Plus 1 PI or 1 NRTI Plus 1 NNRTI in HIV-1-infected IVDU- Patients With Opiate Substitution Being Either Antiretroviral-naive or With Suppressed Viral Load and Without a History of Virological Failure|3OD|Gilead Sciences|No|Completed|March 2003|June 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00324688||182576|
NCT00324701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-421|Telepsychology-Service Delivery for Depressed Elderly Veterans|Telepsychology-Service Delivery for Depressed Elderly Veterans||VA Office of Research and Development|No|Completed|September 2006|October 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|241|||Both|60 Years|N/A|No|||September 2014|April 6, 2015|May 9, 2006||No||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00324701||182575|
NCT00325000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHR443/4-1|Interpersonal Psychotherapy for Severely Depressed Inpatients|An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Severely Depressed Inpatients||German Research Foundation||Terminated|November 2000|August 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||October 2000|December 19, 2006|May 9, 2006||||No||https://clinicaltrials.gov/show/NCT00325000||182554|
NCT00325013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000259 (DK71851)|Evaluation of DHA for the Treatment of PSC|Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC)||Beth Israel Deaconess Medical Center|No|Completed|December 2005|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||March 2015|March 10, 2015|May 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00325013||182553|
NCT00325351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91476|ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer|Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer||Bayer|No|Completed|August 2006|March 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||October 2014|October 31, 2014|May 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00325351||182528|
NCT00325364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9626|Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Insulin-Naive Patients With Type 2 Diabetes Mellitus.||Eli Lilly and Company||Completed|April 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|415|||Both|18 Years|N/A|No|||July 2008|July 3, 2008|May 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00325364||182527|
NCT00348907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 05 45|EVENT: Hydrotherapy and Deep Venous Thrombosis|Evaluation of the Efficacy of the Thermal Cure in the Prevention of the Post-Thrombotic Syndrome After a Deep Venous Thrombosis of Lower Limbs.||Association Francaise pour la Recherche Thermale|No|Terminated|July 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||October 2007|October 31, 2007|July 4, 2006|||decision to stop the study because of enrollment difficulties.|No||https://clinicaltrials.gov/show/NCT00348907||180788|
NCT00349193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAQ/5062|A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod|A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects||Teva Pharmaceutical Industries|No|Completed|March 2005|August 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|306|||Both|18 Years|50 Years|No|||April 2011|April 7, 2011|June 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00349193||180767|
NCT00344903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHS-2-001|Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort|Longitudinal Cohort Study of Dallas County Residents to Identify Novel Determinants of Atherosclerotic Heart Disease: The DHS 2||University of Texas Southwestern Medical Center|Yes|Completed|September 2007|December 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3400|Samples With DNA|Plasma Serum DNA|Both|35 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Adults who participated in DHS-1. The study will include equal numbers of men and women        and will include 50% African Americans|February 2009|July 7, 2010|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344903||181091|
NCT00345228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R347/05/2004|Myopic Macular Haemorrhages|Myopic Macular Haemorrhages||Singapore National Eye Centre||Completed|June 2004|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||30|||Both|18 Years|N/A|No|||May 2004|June 26, 2006|June 26, 2006||||No||https://clinicaltrials.gov/show/NCT00345228||181066|
NCT00345488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSG-DT-01|Fast Track Admittance of Hip Fracture Patients|Fast Track ER Admittance of Hip Fracture Patients||Hvidovre University Hospital||Active, not recruiting|September 2002|June 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|N/A||||May 2006|June 27, 2006|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345488||181047|
NCT00345501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS IEC 265|Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention|Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients With Preexisting Renal Dysfunction Undergoing a Coronary Procedure||Onassis Cardiac Surgery Centre|Yes|Completed|November 2005|July 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|208|||Both|18 Years|90 Years|No|||August 2007|August 22, 2007|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345501||181046|
NCT00345735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-017-IM|Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)|Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients. A Randomised, Double-blind, Placebo-controlled, Cross-over Confirmatory Trial Testing Fentanyl and Placebo in Eight Breakthrough Pain Episodes||Nycomed||Completed|May 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|80 Years|No|||May 2012|May 4, 2012|June 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00345735||181028|
NCT00315341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0027|Starting Treatment With Agonist Replacement Therapies (START)|Starting Treatment With Agonist Replacement Therapies (START)||National Institute on Drug Abuse (NIDA)|Yes|Active, not recruiting|April 2006|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1250|||Both|18 Years|N/A|No|||October 2009|October 29, 2009|April 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00315341||183283|
NCT00315354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK072428|Popular Diets Study|Popular Diets, Metabolism, and CVD Risk||Children's Hospital Boston||Completed|April 2006|April 2013|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315354||183282|
NCT00315315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-117|Study of Surgical Procedures for Treatment of Persistent Nasolacrimal Duct Obstruction in Children < 4 Years Old|A Prospective Study of Surgical Procedures for the Treatment of Persistent Nasolacrimal Duct Obstruction in Children Less Than Four Years Old|NLD2|Jaeb Center for Health Research|Yes|Completed|February 2005|February 2008|Actual|February 2008|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|194|||Both|6 Months|47 Months|No|Non-Probability Sample|Community sample|May 2012|May 16, 2012|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315315||183285|
NCT00316069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060142|Stem Cell Collection|Peripheral Blood Collection of Adult Stem Cells||National Institutes of Health Clinical Center (CC)||Recruiting|April 2006|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 25, 2015|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316069||183227|
NCT00315809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0080|Molecular Epidemiology of Leprosy - Philippines|Molecular Epidemiology of Leprosy - Philippines||Colorado State University|No|Completed|April 2006|December 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|310|||Both|18 Years|N/A|No|Non-Probability Sample|Blood, nasal swabs, slit skin smears and biopsies will be obtained prospectively from        individuals greater than 18 years of age, representing newly diagnosed and relapse leprosy        patients. The study participants will be obtained from LWM clinic. DNA and RNA based        methodologies will be developed and applied to obtain data necessary for substantiation of        a number of factors implicated in transmission of leprosy in Philippines.|June 2011|June 22, 2011|April 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00315809||183247|
NCT00315822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-O|Supplemental Postoperative Oxygen and Wound Infection in Morbidly Obese Patients|Supplemental Postoperative Oxygen & Wound Infection in Morbidly Obese Patients||Outcomes Research Consortium|No|Terminated|May 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1276|||Both|18 Years|80 Years|No|||February 2009|February 5, 2009|April 17, 2006||No|Study was terminated due to futility|No||https://clinicaltrials.gov/show/NCT00315822||183246|
NCT00342589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990084|New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia|Studies of Human Pneumocystis Infection||National Institutes of Health Clinical Center (CC)||Recruiting|April 1999|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1500|||Both|3 Years|99 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342589||181254|
NCT00342940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V78P4S|Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older|A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects||Novartis||Suspended|October 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||125|||Both|18 Years|N/A||||March 2007|March 7, 2007|June 20, 2006|||Lack of Vaccine Supplies|No||https://clinicaltrials.gov/show/NCT00342940||181233|
NCT00343239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_00072|Docetaxel in Locally Advanced Gastric Adenocarcinoma|Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study|NEOTAX|Sanofi||Completed|June 2006|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|70 Years|No|||November 2014|November 3, 2014|June 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00343239||181211|
NCT00343213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3454|Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix.|Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Immunohistochemical Study on Biopsies (Retrospective and Prospective Analysis) and on Liquid Based (SurePath) Cervical Cytology (Prospective Analysis). Correlation With HPV Typing and Clinical Outcome.||University Hospital, Strasbourg, France||Recruiting|June 2006|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|300|||Female|18 Years|N/A|No|||August 2011|August 29, 2011|June 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00343213||181213|
NCT00343226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621ABE02|An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.|An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.||Novartis||Completed|May 2002|||April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|75 Years||||August 2010|August 24, 2010|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00343226||181212|
NCT00348660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 04-095|Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic|The Seroprevalence of Hepatitis C and Course of Infection Among Pregnant Women Attending a Toronto Inner City Antenatal Care Clinic||St. Michael's Hospital, Toronto||Active, not recruiting|August 2005|June 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|16 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Females are 16 years of age and over who present to the inner city health clinic for        antenatal care who give their informed consent to participate in this study.|December 2009|September 2, 2011|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00348660||180807|
NCT00348946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS050597-01A2|Androgen Effect on Klinefelter Syndrome Motor Outcome|Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome||Thomas Jefferson University|Yes|Active, not recruiting|July 2006|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Male|4 Years|12 Years|No|||April 2015|April 30, 2015|July 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00348946||180785|
NCT00348036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH068450|Group Intervention for Interpersonal Trauma|Trauma Interventions for Low-income Women in Primary Care||Georgetown University|No|Completed|September 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|70 Years|No|||April 2013|April 29, 2013|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00348036||180855|
NCT00348322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-22|Safety/Efficacy of Systane Free vs Refresh Tears|An Evaluation of the Safety and Efficacy of Systane Free FID 105783 - II||Alcon Research||Completed|July 2006|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||September 2008|September 23, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348322||180833|
NCT00344981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22407|Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression|A Study to Probe The Safety And Durability of Tenofovir And a Cell Cycle Agent to Maintain Viral Suppression|HADIT|University of Maryland|Yes|Completed|June 2003|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2010|May 21, 2010|June 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00344981||181085|
NCT00344994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gskswitch|SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole|An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose||Georgia Regents University||Completed|May 2006|April 2010|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||May 2011|May 12, 2011|June 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00344994||181084|
NCT00348920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOTSA1|The Effects of High Spinal Anesthesia on Heart Function, Stress Response and Pain Control in Aortic Valve Surgery|The Effects of High Spinal Anesthesia on Hemodynamics, Stress Response, Renal Function and Post-operative Pain Control in Patients Undergoing Aortic Valve Replacement for Aortic Stenosis||University of Manitoba|Yes|Completed|February 2007|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00348920||180787|
NCT00349206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00131|Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma|Phase 1 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|April 2006|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||February 2013|April 9, 2014|July 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00349206||180766|
NCT00344916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.1996.04.JNB|Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis|NO-Synthesis in Patients With Liver Cirrhosis: Effect of L-NMMA on Renal Hemodynamics, Sodium Excretion and Plasma Levels of Vasoactive Hormones||Regional Hospital Holstebro||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind||||30|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2006|July 10, 2006|June 24, 2006||||No||https://clinicaltrials.gov/show/NCT00344916||181090|
NCT00344929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITHAGORE 6|Severe Post Partum Haemorrhage (PPH): A Randomized Trial on Transversal Intervention in 6 French Perinatal Networks|Severe Post Partum Haemorrhage (PPH): A Randomized Trial on Transversal Intervention in 6 French Perinatal Networks||Hospices Civils de Lyon||Recruiting|November 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|6500|||Female|15 Years|45 Years|No|||April 2007|April 26, 2007|June 26, 2006||||No||https://clinicaltrials.gov/show/NCT00344929||181089|
NCT00344942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICA_L_00872|Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults|A Randomised, Double-blind, French Multi-centre Study, to Evaluate the Efficacy and Tolerance, in Comparison With Placebo, of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults|RhiCNANI|Sanofi|No|Terminated|April 2006|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|65 Years|No|||December 2009|December 4, 2009|June 26, 2006||No|patient's recruitment too difficult|No||https://clinicaltrials.gov/show/NCT00344942||181088|
NCT00345514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 RO1 HL70785|The Provider and Organization in Asthma Guidelines|The Provider and Organization in Asthma Guidelines||University of Connecticut Health Center|No|Completed|September 2002|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|36|||Both|N/A|N/A|No|||November 2012|November 8, 2012|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345514||181045|
NCT00345527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004/2006|A Randomized Control Trial Examining Two Treatments for Problem Gambling|A Randomized Control Trial Examining Two Treatments for Problem Gambling||Centre for Addiction and Mental Health|No|Withdrawn||||November 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|June 27, 2006|||Study moved to British Columbia|No||https://clinicaltrials.gov/show/NCT00345527||181044|
NCT00345748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-071|A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate|A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate||Bristol-Myers Squibb|No|Completed|June 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|194|||Both|20 Years|N/A|No|||April 2011|April 11, 2011|June 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345748||181027|
NCT00314743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-1192|Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation|A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation||Washington University School of Medicine||Completed|October 2005|December 2008|Actual|December 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|48|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|April 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00314743||183329|
NCT00315848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP96-0101|The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.|A Multi-Center, Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Buprenorphine Transdermal Delivery System Vs. Oxycodone/Acetaminophen Tablets Vs. Placebo in Patients With Chronic Pain Due to Osteoarthritis||Purdue Pharma LP||Completed|November 1996|December 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||225|||Both|18 Years|N/A|No|||April 2006|April 29, 2006|April 18, 2006||||||https://clinicaltrials.gov/show/NCT00315848||183244|
NCT00315328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-119|Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds|A Randomized Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds|ATS9|Jaeb Center for Health Research|Yes|Completed|August 2005|January 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|233|||Both|7 Years|12 Years|No|||May 2012|May 16, 2012|April 14, 2006|Yes|Yes||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00315328||183284|
NCT00315536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/042|Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children|Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children||University Hospital, Ghent|No|Completed|May 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|63|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||January 2012|January 3, 2012|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315536||183268|
NCT00316342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95050341|Workplace Based Rehabilitation for Low Back Disorders|Workplace Based Rehabilitation for Low Back Disorders||Rush University Medical Center||Completed|January 1997|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||433|||Both|N/A|N/A|No|||November 2007|November 28, 2007|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316342||183206|
NCT00316329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0164|ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria|Multinational, Randomized, Comparative Study of the Efficacy and Safety of Three Therapeutic Regimens: Coarsucam™ (Artesunate + Amodiaquine Fixed-Dose Combination) Administered in 1 or 2 Intakes Per Day Versus Coartem® (Artemether + Lumefantrine) in the Treatment of Uncomplicated Plasmodium Falciparum Malaria||Sanofi||Completed|March 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||1032|||Both|N/A|N/A|No|||April 2008|April 21, 2008|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00316329||183207|
NCT00316615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71P3S|Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, When Administered to Non-Elderly Adult and Elderly Subjects||Novartis||Completed|June 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|18 Years|N/A||||September 2006|September 13, 2006|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316615||183185|
NCT00342602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905218|Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome|Influence of Host Genetic Factors in Development of PML in an AIDS Cohort||National Institutes of Health Clinical Center (CC)||Completed|August 2005|||||N/A|Observational|N/A||||450|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2006|March 16, 2009|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342602||181253|
NCT00344149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3114|Rituximab as Second Line Treatment for ITP|Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study"||Ostfold Hospital Trust|Yes|Completed|June 2006|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00344149||181147|
NCT00343252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9041|Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis|The Effect of Teriparatide Compared With Risedronate on Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures||Eli Lilly and Company|No|Completed|June 2006|June 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|712|||Female|45 Years|N/A|No|||May 2011|May 20, 2011|June 20, 2006|Yes|Yes||No|June 8, 2010|https://clinicaltrials.gov/show/NCT00343252||181210|
NCT00312884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006EP001B|Home-HF: Evaluation of Patients With Heart Failure Using Home Telemonitoring|Home-HF: a Randomised Controlled Evaluation of Home Telemonitoring of Patients With Heart Failure Recently Discharged From Hospital.||Imperial College London||Active, not recruiting|May 2006|December 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||November 2007|November 7, 2007|April 7, 2006||||No||https://clinicaltrials.gov/show/NCT00312884||183469|
NCT00316563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-8-0008|Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study|A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study||AHS Cancer Control Alberta|Yes|Completed|August 2006|November 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2007|February 8, 2010|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316563||183189|
NCT00349232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA-KINE-2006-001|Lifestyle Intervention in Obese Children Attending Special Primary Education.|Prevalence of Overweight and Obesity in Children Attending Special Primary Education and the Effect of a Lifestyle Intervention.||University College of Antwerp||Not yet recruiting|July 2006|July 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||July 2006|July 6, 2006|July 4, 2006||||No||https://clinicaltrials.gov/show/NCT00349232||180764|
NCT00312871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003181|Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency|Effect of Early Correction of Anemia on the Progression of Chronic Renal Insufficiency (ECAP)||Janssen Cilag S.A.S.|No|Terminated|February 2001|June 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|217|||Both|18 Years|75 Years|No|||April 2010|May 16, 2011|April 7, 2006|||Study was stopped due to restrictions in labeling for the subcutaneous route of administration    of EPREX.|No||https://clinicaltrials.gov/show/NCT00312871||183470|
NCT00349219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORCH|TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer|An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer|TORCH|National Cancer Institute, Naples|Yes|Completed|December 2006|June 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|760|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00349219||180765|
NCT00344955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2004.01.LP|Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects|Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects||Regional Hospital Holstebro||Completed|January 2003|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 14, 2008|June 24, 2006||||No||https://clinicaltrials.gov/show/NCT00344955||181087|
NCT00344968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-05-001|Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema|A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/Day and ASI-001B 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Edema|FAME|Alimera Sciences||Completed|September 2007|December 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|956|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|June 26, 2006|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00344968||181086|
NCT00345241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012006-021|Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points|Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points||University of Texas Southwestern Medical Center|No|Completed|January 2006|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2008|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00345241||181065|
NCT00345254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-SL-001|Severing Nuchal Cord at the Time of Delivery.|Study That Clarifies Whether Cord Around the Neck Should Be Severed at Delivery.||Wolfson Medical Center||Completed|September 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A||||September 2003|June 26, 2006|June 26, 2006||||No||https://clinicaltrials.gov/show/NCT00345254||181064|
NCT00314431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG99547|Post-Hospitalization Nursing Effectiveness (PHONE) Study|Randomized Comparison of Two Models of Post-NICU Care for Preterm Infants With Neonatal Chronic Lung Disease||Wake Forest School of Medicine||Completed|May 1996|August 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|N/A|483 Days|No|||April 2006|April 11, 2006|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00314431||183353|
NCT00314730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16402|Outcomes in the Palm of Your Hand: Improving the Quality and Continuity of Patient Care|Outcomes in the Palm of Your Hand: Improving the Quality and Continuity of Patient Care||University of Toronto||Active, not recruiting|May 2006|June 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||400|||Both|18 Years|N/A|No|||April 2007|April 18, 2007|April 13, 2006||||No||https://clinicaltrials.gov/show/NCT00314730||183330|
NCT00314769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060138|Long-Term Improvement in Motor Learning by Transcranial Direct Current Stimulation|Long-Term Improvement in Training Effects by Transcranial DC Stimulation||National Institutes of Health Clinical Center (CC)||Completed|April 2006|December 2013||||N/A|Observational|N/A|||Actual|196|||Both|18 Years|80 Years|No|||December 2013|November 4, 2014|April 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00314769||183327|
NCT00314782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00020|Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC|A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer||AstraZeneca||Completed|March 2006|March 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Male|18 Years|N/A|No|||March 2010|March 11, 2013|April 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00314782||183326|
NCT00316888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000470269|Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer|Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma||National Cancer Institute (NCI)||Recruiting|January 2007|||June 2016|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||July 2012|August 22, 2012|April 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316888||183164|
NCT00317135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|759346/004|Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.|Assess Reactogenicity & Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Compared to Tritanrix™-HepB/Hiberix™ (Control) in Healthy Infants (2,4,6 Mths Age), After a Hepatitis B Birth Dose||GlaxoSmithKline||Completed|December 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Both|N/A|3 Days|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00317135||183145|
NCT00315562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB #060323|Study of Early Versus Delayed Carotid Endarterectomy (CEA) for Small to Medium-sized Ischemic Stroke Caused by High-grade Carotid Stenosis|Pilot Study of Early Versus Delayed Carotid Endarterectomy (CEA) for Small to Medium-sized Ischemic Stroke Caused by High-grade Carotid Stenosis||University of California, San Diego||Withdrawn|April 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2007|February 3, 2015|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00315562||183266|
NCT00315835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP96-0104|Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.|A Single Dose, Randomized, Double-Blind, Parallel Group Study of the Safety and Pharmacokinetics of Buprenorphine TDS (12.5, 25, 50 Mcg/Hour) Vs. Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery||Purdue Pharma LP||Completed|October 1996|November 1997||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||April 2006|April 17, 2006|April 17, 2006||||||https://clinicaltrials.gov/show/NCT00315835||183245|
NCT00313313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-040|A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas|A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone||AstraZeneca||Completed|April 2006|September 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|768|||Both|18 Years|77 Years|No|||March 2015|April 14, 2015|April 10, 2006|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00313313||183436|
NCT00312962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068725|Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia|Neuroscience-Guided Remediation of Cognitive Deficits in Schizophrenia|CRIS|University of California, San Francisco|Yes|Completed|April 2004|March 2013|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|April 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00312962||183463|
NCT00316628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P3S|Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects.||Novartis||Completed|June 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|65 Years|N/A|No|||September 2006|September 13, 2006|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316628||183184|
NCT00343512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0368|Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer|Pilot Study of Neoadjuvant Dose Dense Docetaxel With Correlative Molecular Studies in Stage II/III Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|February 2004|March 2011|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|18 Years|N/A|No|||April 2012|April 21, 2012|June 22, 2006|Yes|Yes|closed due to competing neoadjuvant studies for a small patient population|No|October 11, 2010|https://clinicaltrials.gov/show/NCT00343512||181191|All adverse events have been included in the "other adverse event" section. They are not differentiated by causality (eg. related to disease, con-meds).
NCT00343876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-012|Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial|A Single Center, Double-Blind, Randomized Trial to Evaluate the Effects of Aspirin 325 mg + Clopidogrel 75 mg v. Aspirin 325 mg + Placebo on Plasma Concentration of C-Reactive Protein: The CATER Trial Protocol||Intermountain Health Care, Inc.||Completed|July 2005|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|June 21, 2006||||||https://clinicaltrials.gov/show/NCT00343876||181167|
NCT00343889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL203|Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine|Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix-HepB/Hib™, Both Given Concomitantly With the Oral Polio Vaccine at 6, 10, and 14 Weeks of Age in Healthy Infants in the Philippines||Sanofi|Yes|Completed|August 2006|April 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|379|||Both|42 Days|50 Days|Accepts Healthy Volunteers|||November 2013|November 11, 2013|June 21, 2006||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT00343889||181166|
NCT00344461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23783|A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine|Cell Cycle Independent Antiretroviral Therapy: Combination of Nevirapine, FTC, and Tenofovir||University of Maryland|Yes|Completed|March 2004|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|75 Years|No|||August 2012|August 3, 2012|June 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00344461||181125|
NCT00317096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL-1998-1|FCM Versus R-FCM Followed by R-Maintenance or Observation Only|Treatment of Relapsed CBCC, CC and LPIC Lymphoma With FCM Chemotherapy Alone or in Combination With the Monoclonal Anti CD 20 Antibody Rituximab Followed by Anti-CD 20 Maintenance or Observation Only||Ludwig-Maximilians - University of Munich|No|Active, not recruiting|November 1998|June 2021|Anticipated|June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|319|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|April 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00317096||183148|
NCT00312897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 12-1321|Omega-3 Fatty Acids in Adolescent Depression|Omega-3 Fatty Acids in Adolescent Depression||Icahn School of Medicine at Mount Sinai|Yes|Completed|December 2005|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|12 Years|19 Years|No|||October 2015|October 23, 2015|April 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00312897||183468|
NCT00316836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0434|Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole|The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|April 2006|||October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|550|Samples With DNA|blood samples|Female|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosed with breast cancer.|July 2015|July 13, 2015|April 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00316836||183168|
NCT00317083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JG-2006-BCH|Cough Reflex and Obstructive Sleep Apnea Syndrome|Effect of Obstructive Sleep Apnea Syndrome Associated With Obesity on Cough Reflex Threshold to Citric Acid||Bichat Hospital||Completed|November 2001|February 2003||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|18 Years|N/A|No|||January 2004|April 21, 2006|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00317083||183149|
NCT00313807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|contrst2006|Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage|CoNTRST - Contrast Nephropathy and Travasol for Renal Safety Trial: Intravenous Amino Acid Infusion for the Prevention of Contrast-mediated Acute Renal Failure Following Coronary Catheterization||Queen's University|Yes|Withdrawn|November 2005|September 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|April 11, 2006|Yes|Yes|Abandoned due to lack of recruitment Oct 2006|No||https://clinicaltrials.gov/show/NCT00313807||183401|
NCT00314145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-040-009|A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX|A Multicentre, Randomized, Double-blind, Phase III Study of The Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (ChimeriVax™-JE and JE-VAX®)||Sanofi|No|Completed|November 2005|November 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|820|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 4, 2012|April 11, 2006|Yes|Yes||No|November 6, 2012|https://clinicaltrials.gov/show/NCT00314145||183375|
NCT00314158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-24|A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research||Completed|November 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|523|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|April 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00314158||183374|
NCT00314444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060139|Treatment for Psychogenic Disorders|Treatment for Psychogenic Movement Disorders||National Institutes of Health Clinical Center (CC)||Completed|April 2006|April 2009||||N/A|Observational|N/A||||15|||Both|18 Years|N/A|No|||April 2009|September 26, 2015|April 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00314444||183352|
NCT00314756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG04-484|Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage|Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage||Wake Forest School of Medicine||Completed|March 2005|November 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2005|April 12, 2006|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314756||183328|
NCT00315081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-05|Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine|Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia||University Hospital, Bonn||Not yet recruiting|May 2006|May 2008||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Male|18 Years|60 Years|No|||November 2005|April 13, 2006|April 13, 2006||||No||https://clinicaltrials.gov/show/NCT00315081||183303|
NCT00316901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060099|Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial|PET/CT Evaluation of Subjects Treated on Surgery Branch Adoptive Cell Therapy Protocols||National Institutes of Health Clinical Center (CC)||Completed|April 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|April 19, 2006||||||https://clinicaltrials.gov/show/NCT00316901||183163|
NCT00316082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-038|Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise||AstraZeneca||Completed|June 2006|November 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|365|||Both|18 Years|77 Years|No|||March 2015|April 8, 2015|April 18, 2006|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00316082||183226|
NCT00312936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003102-01|A Mindfulness Based Approach to HIV Treatment Side Effects|A Mindfulness Based Approach to HIV Treatment Side Effects||University of California, San Francisco|Yes|Completed|July 2006|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|76|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|April 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00312936||183465|
NCT00312975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671015|Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)|Phase 2 Randomized, Non-Comparative Study Of CP-675,206 Or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy In Patients With Stage IIIB (With Effusion) Or Stage IV Non-Small Cell Lung Cancer That Has Responded Or Remained Stable||AstraZeneca|No|Completed|May 2006|February 2010|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|April 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00312975||183462|
NCT00313352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0293-2006|Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function|Effects of Beta-adrenergic Blocking Agents in Adult Patients With Transposition of the Great Arteries on Systemic Ventricular Function||Emory University|No|Completed|January 1997|March 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|110|||Both|18 Years|N/A|No|Probability Sample|A retrospective study analysis of medical records of patients age 18yrs and up, who had        systemic RV dysfunction late after atrial inflow correction for d-TGA.|November 2013|November 8, 2013|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00313352||183433|
NCT00313573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000466348|Telemedicine or Standard Care in Treating Patients With Depression and/or Pain Caused By Cancer|TeleCare Management of Pain and Depression in Cancer||National Cancer Institute (NCI)||Active, not recruiting|February 2006|||January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized|||Anticipated|480|||Both|18 Years|N/A|No|||May 2009|September 19, 2013|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313573||183416|
NCT00343525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0601|Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C|A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients With Chronic Hepatitis C||Peregrine Pharmaceuticals|No|Completed|May 2006|||January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|N/A|No|||April 2008|April 28, 2008|June 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00343525||181190|
NCT00343551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2351|Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.|A Nine-Week, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension||Novartis||Completed|May 2006|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||654|||Both|18 Years|N/A||||July 2008|July 15, 2008|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00343551||181189|
NCT00344773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00056|First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation|An Open-label, Multi-centre Study to Evaluate Efficacy and Safety of Gefitinib as the First-line Treatment for Locally Advanced (IIIB), Metastatic (IV) or Recurrent Pulmonary Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation.||AstraZeneca||Completed|March 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|19 Years|N/A|No|||June 2010|June 24, 2010|June 26, 2006||No||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00344773||181101|
NCT00344786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNF2024-CLL-05002|Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL|A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL)||Biogen|No|Terminated|February 2006|September 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2009|June 4, 2009|June 23, 2006|No|Yes|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT00344786||181100|
NCT00317109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104756|Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects|Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007||GlaxoSmithKline||Completed|April 2006|May 2007||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|168|||Both|15 Months|18 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|February 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00317109||183147|
NCT00312923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003077-01|Preliminary Study of Safety and Efficacy of Policosanol|Preliminary Study of Safety and Efficacy of Policosanol||Rush University Medical Center|Yes|Completed|September 2005|September 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||July 2013|July 19, 2013|April 7, 2006|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00312923||183466|It is possible that other constituents underlie policosanol’s lipid-lowering activity. One study found that triacontanol inhibited HMG-CoA reductase in rat liver cells. Triacontanol was not detected in either lot of policosanol used in this study.
NCT00313287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-301|Safety and Antiviral Activity Study of Clevudine 30 Mg QD in Patient With Chronic HBV|A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD in Patients Chronically Infected With Hepatitis B Virus||Bukwang Pharmaceutical||Terminated|June 2003|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|60 Years|No|||April 2006|April 11, 2006|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00313287||183438|
NCT00313300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-023|Safety Study of Apixaban in Recent Acute Coronary Syndrome|A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.||Bristol-Myers Squibb|Yes|Completed|May 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1741|||Both|18 Years|90 Years|No|||November 2015|November 25, 2015|April 10, 2006|Yes|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT00313300||183437|
NCT00313560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0534 CDR0000465208|Erlotinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer That Can Be Removed By Surgery|Phase II Study of Erlotinib (Tarceva) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2006|||December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|120 Years|No|||January 2016|January 13, 2016|April 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313560||183417|
NCT00313196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-369|Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)|Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease|ASSET-2|Actelion||Terminated|April 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|12 Years|N/A|No|||January 2012|January 11, 2012|April 10, 2006|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00313196||183445|
NCT00313209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-127|Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)|Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study|EOS|Takeda||Completed|April 2006|February 2008|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|933|||Both|40 Years|N/A|No|||April 2011|May 4, 2012|April 11, 2006|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00313209||183444|
NCT00313547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHI 05740|High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients|Impact of High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine on Autonomic Regulation and on Sympathetic Activation in Response to Cold Exposure in Hypertensive Patients With Impaired Glucose Tolerance, Diabetes or Coronary Artery Disease||Montreal Heart Institute||Terminated|April 2006|March 2008|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||August 2007|May 2, 2008|April 10, 2006|||Very difficult to recruit patients/slow recruitment(2 patients in nearly 2 years).|No||https://clinicaltrials.gov/show/NCT00313547||183418|
NCT00313521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454503|Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors|Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups||National Cancer Institute (NCI)||Active, not recruiting|June 1995|||November 1997|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|3 Years|20 Years|No|||December 2006|September 19, 2013|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00313521||183420|
NCT00313534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455645|Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer|A Phase I Study of NDGA in Patients With Non-Metastatic Biochemically Relapsed Prostate Cancer||University of California, San Francisco|Yes|Terminated|June 2005|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|15|||Male|18 Years|N/A|No|||October 2012|October 9, 2012|April 11, 2006|No|Yes|Ran out of drug|No||https://clinicaltrials.gov/show/NCT00313534||183419|
NCT00313495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COHORT|Cooperative Huntington's Observational Research Trial|Cooperative Huntington's Observational Research Trial||HP Therapeutics Foundation|No|Recruiting|February 2006|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Blood, DNA and Urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. An individual of any age that is affected by Huntington's disease          2. An individual 18 years of age or older, who has tested positive for the HD gene          3. An individual 18 years of age or older who is a parent, sibling or child of an             individual affected by HD          4. An older adolescent 15 to 17 years of age, who has a parent affected by HD enrolled             in COHORT, or a parent who has tested positive for the HD gene enrolled in COHORT (at             select sites)          5. Grandparents and grandchildren of anyone participating in COHORT who fulfills the             requirements of (the above) category (1) or (2)          6. HD family members who have no risk for HD due to no family history (spouses or             caregivers)          7. HD family members who have undergone DNA testing and does not carry the genetic             mutation responsible for HD.|March 2011|March 4, 2011|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00313495||183422|
NCT00313508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13649|Dendritic Cell Vaccination During Lymphoid Reconstruction|A Dose Ranging Trial of MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Using Cytokines With Autologous Lymphocyte Infusion With or Without Escalating Doses of Fludarabine for Patients With Chemotherapy-naive Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|February 2006|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|16 Years|N/A|No|||December 2012|February 20, 2014|April 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00313508||183421|
NCT00313820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081063|Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain|A 13-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150-600 Mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Central Post-Stroke Pain (CPSP)||Pfizer|No|Completed|August 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||October 2009|October 9, 2009|April 10, 2006|Yes|Yes||No|September 8, 2009|https://clinicaltrials.gov/show/NCT00313820||183400|
NCT00313833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3002|Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.|A Randomized, Double Blind, Pilot Evaluation of the Effectiveness of BTDS Versus Placebo on Health Outcomes Associated With Analgesic Management of Elderly Residents in Supervised Living Environments||Purdue Pharma LP||Completed|December 2000|November 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|55 Years|N/A|No|||April 2006|April 29, 2006|April 10, 2006||||||https://clinicaltrials.gov/show/NCT00313833||183399|
NCT00314171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-10|A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|October 2005|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|April 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00314171||183373|
NCT00314184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1447C00144|Quetiapine Fumarate Bipolar Maintenance Monotherapy|Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 Weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients|SPaRCLe|AstraZeneca||Completed|March 2005|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|1255|||Both|18 Years|N/A|No|||December 2008|December 19, 2008|April 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00314184||183372|
NCT00314795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-06|Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease|An Open-Label Study to Investigate the Efficacy and Safety of Peginesatide in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease||Takeda|No|Active, not recruiting|April 2006|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00314795||183325|
NCT00315575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0092|Memory Imaging of Normal Aging|BOLD and Perfusion fMRI of Alzheimer's Disease Risk||National Institute on Aging (NIA)|No|Completed|August 2005|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|90|||Both|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults from the community|January 2009|January 22, 2009|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315575||183265|
NCT00317161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100480|Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.|Study to Show Consistency Hib-MenAC(3 Lots) Mixed With Tritanrix™-HBV, Non-inferiority of Study Vaccine to Tritanrix™-HBV/Hiberix™ (+/-) Meningitec™ & MenA Response in Infants (2,4,6M) With Hepatitis B Birth Dose||GlaxoSmithKline||Completed|August 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1000|||Both|56 Days|83 Days|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00317161||183143|
NCT00312949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067189|Effectiveness of an Interactive Educational Website for Improving the Quality of Mental Health Care for People With Schizophrenia|Consumer Internet Education About Mental Health Quality||Johns Hopkins Bloomberg School of Public Health|No|Completed|April 2006|December 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|56|||Both|13 Years|N/A|No|||April 2015|April 15, 2015|April 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00312949||183464|
NCT00313365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218-2006|Surgical Lavage vs Serial Needle Aspiration for Infected Joints|Arthrotomy With Irrigation and Debridement Versus Serial Arthrocentesis as Treatment for Septic Arthritis in Adults||Emory University||Withdrawn|April 2006|July 2013|Anticipated|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|April 10, 2006||No|Study was never started because Dr. Hammerberg left before it could be started.|No||https://clinicaltrials.gov/show/NCT00313365||183432|
NCT00344474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAJTXVA|Personality-targeted Interventions for Adolescent Alcohol Misuse|A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness|Preventure|King's College London||Completed|November 2003|July 2008|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|710|||Both|13 Years|16 Years|Accepts Healthy Volunteers|||February 2006|June 24, 2011|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00344474||181124|
NCT00344799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB#04-12-084|Cytogenetic Study of Ocular Melanoma|Molecular and Cytogenetic Studies of Ocular Melanoma||University of California, Los Angeles||Recruiting|April 2005|||July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been diagnosed with ocular melanoma, and underwent melanoma treatment at        our facility.|July 2015|July 6, 2015|June 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00344799||181099|
NCT00344812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPR-95-07-24-03|Opioid Maintenance Medications Comparison Study|||Johns Hopkins University||Completed|January 1996|June 1998||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|21 Years|55 Years|No|||March 2006|June 26, 2006|June 26, 2006||||||https://clinicaltrials.gov/show/NCT00344812||181098|
NCT00313261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-203|Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group|An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group||Bukwang Pharmaceutical||Terminated|June 2003|February 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2012|October 16, 2012|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00313261||183440|
NCT00313274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-302|Safety and Antiviral Activity Study of Clevudine 30 Mg QD in Patients With HBeAg(-) Chronic HBV|A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine (L-FMAU) 30 Mg QD in Patients With HBeAg Negative Chronic Hepatitis B||Bukwang Pharmaceutical||Terminated|July 2003|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|60 Years|No|||April 2006|April 11, 2006|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00313274||183439|
NCT00314522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-0003|Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe|Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe||AHS Cancer Control Alberta||Completed|September 2005|March 2006||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|5|||Male|18 Years|N/A|No|Non-Probability Sample|primary care clniic|December 2011|February 23, 2016|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314522||183346|
NCT00314535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-0002 / 22073|Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe|Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe||AHS Cancer Control Alberta|Yes|Completed|July 2005|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|40|||Male|18 Years|N/A|No|Non-Probability Sample|Local Healthy Volunteers|March 2012|February 24, 2016|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314535||183345|
NCT00314834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZUS-A1244|Effect of Intradialytic Parenteral Nutrition on Morbidity and Mortality of Malnourished Hemodialysis Patients|Effect of Intradialytic Parenteral Nutrition on Morbidity and Mortality of Malnourished Hemodialysis Patients||EZUS-LYON 1||Terminated|January 2001|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||204|||Both|18 Years|82 Years|No|||March 2005|April 14, 2006|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00314834||183322|
NCT00313222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-366|Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)||Actelion||Completed|October 2005|March 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|80 Years|No|||February 2010|February 11, 2010|April 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313222||183443|
NCT00313235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #006-025-01|Combined Modality Treatment for Patients With Stage IV Melanoma|Combined Modality Treatment for Patients With Stage IV Melanoma: Cyclophosphamide and a Dendritic Cell Vaccine Loaded With Killed Allogeneic Melanoma Cells||Baylor Research Institute|Yes|Completed|March 2006|June 2012|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|21 Years|75 Years|No|||June 2013|June 12, 2013|April 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313235||183442|
NCT00313248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91466|Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer|Phase 2 Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients With Metastatic Breast Cancer||Bayer|No|Completed|April 2006|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Female|18 Years|N/A|No|||November 2015|November 11, 2015|April 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313248||183441|
NCT00314223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR94-IRB-167|Identification of Gene Polymorphism in Patients With Sick Sinus Syndrome in Chinese Population in Taiwan|||China Medical University Hospital||Recruiting|February 2006|December 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2006|April 12, 2006|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314223||183369|
NCT00313859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2005-08-011|Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC|Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic Colorectal Cancer||Samsung Medical Center||Completed|September 2005|August 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00313859||183397|
NCT00314210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00012|Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.|A Multi-Centre,Double-Blind,Randomised-Withdrawal,Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine SR as Monotherapy in the Maintenance Treatment of Patients With GAD Following an Open-Label Stabilisation Period|PLATINUM|AstraZeneca||Completed|March 2006|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||575|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00314210||183370|
NCT00313170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997C00006|A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg|Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy|FINDER II|AstraZeneca||Active, not recruiting|May 2006|December 2016|Anticipated|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|161|||Female|45 Years|130 Years|No|||February 2016|February 3, 2016|April 10, 2006|Yes|Yes||No|June 10, 2009|https://clinicaltrials.gov/show/NCT00313170||183447|
NCT00313183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-162|A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus|A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SYMLIN in Adolescent Subjects With Type 1 Diabetes Mellitus||AstraZeneca|No|Completed|April 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|12 Years|17 Years|No|||January 2015|March 5, 2015|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00313183||183446|
NCT00314197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005|Improving Health Behaviors Through Telephone Linked Care|Study That Examines Integration of the Telephone Linked Care Behavioral Change (Automated Counseling) System Into Primary Care||American Academy of Family Physicians|No|Completed|April 2006|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||September 2007|September 24, 2007|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00314197||183371|
NCT00314457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-5-4294|Efficacy Study of Continuous Intraarticular Infusion in Patients Undergoing Arthroscopic Knee and Shoulder Operations|A Randomized, Double-blind Trial Comparing the Analgesic Efficacy and Side Effects of Continuous Intraarticular Infusion of Bupivacaine Versus Normal Saline in Patients Undergoing Knee and Shoulder Operations||Children's Hospital of Philadelphia|No|Terminated|August 2005|April 2009|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|11 Years|19 Years|No|||July 2009|July 10, 2009|April 12, 2006||No|Bupivacaine has recently been shown to inhibit osteoclast formation in vitro.|No||https://clinicaltrials.gov/show/NCT00314457||183351|
NCT00314470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-0001/ethics 21312|Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute|Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute||AHS Cancer Control Alberta|Yes|Completed|January 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Representative selection from the database (images) of clinical research patients approved        for other protocols.|April 2012|February 24, 2016|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314470||183350|
NCT00315367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA1-904|A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties|A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function||Neurognostics||Completed|September 2004|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|26|||Both|18 Years|65 Years|No|||October 2007|October 15, 2007|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00315367||183281|
NCT00316641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR93-IRB-71|The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles|||China Medical University Hospital||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|20 Years|65 Years||||March 2006|November 6, 2006|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00316641||183183|
NCT00316654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V14P38E1|Persistence of Antibody Response to N. Meningitidis Group C in Children|A Phase IV, Multi-Center, Open-Label, Unrandomized Study to Evaluate the Persistence of Antibody Response to N. Meningitidis Group C, Before and After 2 Doses of the Conjugate Pneumococcal Vaccine, in Children Seven Months and Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine and a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule||Novartis||Completed|February 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||573|||Both|7 Months|N/A|Accepts Healthy Volunteers|||September 2006|September 13, 2006|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316654||183182|
NCT00317148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-205|Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women|Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women||Centre Hospitalier Universitaire de Québec, CHU de Québec||Active, not recruiting|August 2005|September 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||September 2006|September 6, 2006|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00317148||183144|
NCT00313014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3015|Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain|A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain||Purdue Pharma LP|No|Terminated|February 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|660|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|April 10, 2006|Yes|Yes|Terminated early due to administrative reasons unrelated to efficacy or safety.|No|July 28, 2010|https://clinicaltrials.gov/show/NCT00313014||183459|BUP3015 was terminated early due to administrative reasons unrelated to efficacy or safety.
NCT00313027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0011|Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation|Cervical Nodal Metastasis in Squamous Cell Carcinoma of the Head and Neck - Novel MRI, FDG-PET, and Histopathologic Correlation||Stanford University||Completed|November 2002|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|March 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00313027||183458|
NCT00344162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905097|Family Study on Preeclampsia|A Familial Genetic Study on Preeclampsia: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|January 2005|September 2006||||N/A|Observational|N/A||||1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2006|September 26, 2015|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344162||181146|
NCT00344175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-309|Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors|Double-blind follow-on Study of Pitavastatin (4mg) Versus Simvastatin (40mg and 80mg) With a Single-blind Extension of Treatment in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease||Kowa Research Europe|No|Completed|June 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||January 2010|January 25, 2010|June 22, 2006||No||No|September 1, 2009|https://clinicaltrials.gov/show/NCT00344175||181145|
NCT00344487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27050|Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study|The Effect of Kaletra on CD4 Immune Reconstitution in HIV-infected Patients With Long-term Virologic Suppression on a Non-Kaletra Containing ART Regimen, But With a Blunted Immune Response||University of Maryland|Yes|Terminated|December 2005|September 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|June 22, 2006|Yes|Yes|Inability to enroll subjects.|No|August 3, 2012|https://clinicaltrials.gov/show/NCT00344487||181123|
NCT00344500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3925-R|Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications|Management of Antipsychotic Medication Associated Obesity|MAMAO|VA Office of Research and Development|Yes|Completed|October 2005|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|70 Years|No|||May 2015|May 12, 2015|June 22, 2006||No||No|April 3, 2015|https://clinicaltrials.gov/show/NCT00344500||181122|Limitations to our study were its single-site recruitment yielding subjects mostly male and all veterans, limiting of statistical power by control subjects allowed to join treatment group resulting in exclusion from data, and a high dropout rate.
NCT00335478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000476568|Daptomycin in Treating Neutropenia and Fever in Patients With Cancer|Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever||OHSU Knight Cancer Institute|Yes|Completed|December 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|54|||Both|18 Years|99 Years|No|||October 2015|October 20, 2015|June 8, 2006|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00335478||181776|
NCT00314249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-03|Study of Milnacipran for the Treatment of Fibromyalgia|A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.||Forest Laboratories||Completed|April 2006|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1025|||Both|18 Years|70 Years|No|||January 2010|January 14, 2010|April 11, 2006||Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00314249||183367|
NCT00314262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024922|Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor|Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers||Emory University|Yes|Completed|October 2006|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|18 Years|65 Years|No|||October 2014|October 21, 2014|April 11, 2006|Yes|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT00314262||183366|One limitation is the small number of patients who were evaluable for response.
NCT00314275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-061|The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System|Evaluation of Pharmacokinetics (PK) and Safety of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|ENDEAVOR PK|Medtronic Vascular|Yes|Completed|January 2006|August 2011|Actual|May 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|April 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00314275||183365|
NCT00314548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-22-3/05/RDC/AKU/3479|Inhaled Prostacyclin for Adult Respiratory Distress Syndrome (ARDS) and Pulmonary Hypertension|Trial of Inhaled Alprostadil to Improve Hypoxia and Pulmonary Hypertension||Aga Khan University|Yes|Completed|May 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|16 Years|N/A|No|||November 2009|May 18, 2010|April 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00314548||183344|
NCT00313872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2005-03-044|Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer|Phase III Randomized Trial of Taxotere/Cisplatin Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer||Samsung Medical Center||Completed|May 2003|January 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313872||183396|
NCT00315146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30-AG021332-2006|Optimizing Body Composition for Function in Older Adults|Optimizing Body Composition for Function in Older Adults (OPTIMA) - A Pepper Pilot Study||Wake Forest Baptist Health|Yes|Completed|April 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|88|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|April 13, 2006||No||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00315146||183298|
NCT00314496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-0004|Development of Magnetic Resonance (MR) Simulation for Treatment Planning|Development of MR Simulation for Treatment Planning||AHS Cancer Control Alberta|Yes|Completed|September 2005|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patient with conform histological diagnosis of glioblastoma multiforme signed the        consent forms and were willing to go for curative radiation treatment with temozolomide|January 2012|February 24, 2016|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314496||183348|
NCT00314509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-506|Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)|ADVICE: A Dose Range Finding Study of Formoterol Administered Once Daily in the Evening in Combination With Ciclesonide Using the Ultrahaler™ Versus Monotherapy of Each Drug in Asthmatic Patients||Takeda||Completed|July 2005|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Both|18 Years|75 Years|No|||July 2008|May 4, 2012|April 11, 2006||||No||https://clinicaltrials.gov/show/NCT00314509||183347|
NCT00313846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3012|Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of the Buprenorphine Transdermal Delivery System in Subjects With Moderate to Severe Osteoarthritic Pain of Hip or Knee||Purdue Pharma LP||Completed|April 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|529|||Both|40 Years|75 Years|No|||August 2012|August 27, 2012|April 11, 2006|Yes|Yes||No|July 28, 2010|https://clinicaltrials.gov/show/NCT00313846||183398|
NCT00314808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007559|A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas|A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas||Duke University|No|Completed|April 2006|April 2012|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2013|July 10, 2014|April 13, 2006|No|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00314808||183324|
NCT00315120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02-20-1|The OSTEOPATHIC Trial: The OSTEOPAThic Health Outcomes In Chronic Low Back Pain Trial|A Randomized Controlled Trial of Osteopathic Manipulative Treatment and Ultrasound Physical Therapy for Chronic Low Back Pain||University of North Texas Health Science Center|Yes|Completed|August 2006|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|488|||Both|21 Years|69 Years|No|||May 2011|May 9, 2011|April 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00315120||183300|
NCT00315094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9655|Technological Home Care: Improving HPN Care With Videophone And Internet Education|Prevention of Home Parenteral Nutrition (HPN) Infection, Depression and Improving Caregiving Problem Solving||University of Kansas Medical Center|Yes|Completed|April 2006|November 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|172|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|April 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00315094||183302|
NCT00316095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1228.1|Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia|Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia||Boehringer Ingelheim||Completed|April 2006|August 2007||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1695|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316095||183225|
NCT00316355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071464|Stepped Care for Treating Obsessive-Compulsive Disorder|Stepped Care for Obsessive-Compulsive Disorder||Hartford Hospital|Yes|Completed|June 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|69 Years|No|||February 2014|February 24, 2014|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316355||183205|
NCT00316667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA20060011|Health2006 - an Observational Study of Cardiovascular Disease, Diabetes, Asthma and Allergy|Health2006 - an Observational Population-based Study of Cardiovascular Disease, Type 2 Diabetes, Asthma and Allergy||Glostrup University Hospital, Copenhagen||Completed|June 2006|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3471|Samples With DNA|Extracted DNA, urine, serum|Both|18 Years|69 Years|Accepts Healthy Volunteers|Probability Sample|Random sample of citizens living in 11 municipalities in Copenhagen. Age 18-69 years.|October 2012|October 2, 2012|April 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00316667||183181|
NCT00316914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000471238|Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery|A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity||Alliance for Clinical Trials in Oncology|Yes|Completed|January 2006|November 2012|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|104|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|April 19, 2006|Yes|Yes||No|November 26, 2012|https://clinicaltrials.gov/show/NCT00316914||183162|Data cutoff was done after 127 days because of premature study closure and because of the protocol modification mandating that the Ca/Mg therapy be discontinued.
NCT00316927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARTS-DAVDAS|Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer|A Randomized Phase III Trial of Dexamethasone and Aspirin (DA) Versus Dexamethasone, Diethylstilbestrol and Aspirin (DAS) in Locally Advanced or Metastatic Cancer of the Prostate - Immediate Versus Deferred Diethylstilbestrol||National Cancer Institute (NCI)||Completed|December 2002|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|260|||Male|18 Years|N/A|No|||April 2007|June 25, 2013|April 19, 2006||||No||https://clinicaltrials.gov/show/NCT00316927||183161|
NCT00312988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031000|Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy|Topotecan-Monotherapy Vs. Topotecan + Etoposide Vs. Topotecan + Gemcitabine in Therapy in Patients With Recurrent Ovarian Cancer||North Eastern Germany Society of Gynaecologic Oncology||Completed|January 2000|December 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Female|18 Years|N/A|No|||September 2005|April 10, 2006|September 9, 2005||||No||https://clinicaltrials.gov/show/NCT00312988||183461|
NCT00313001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1714|Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.|Effects of NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea||Novo Nordisk A/S|No|Completed|April 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|373|||Both|18 Years|80 Years|No|||October 2014|October 24, 2014|April 8, 2006||||No||https://clinicaltrials.gov/show/NCT00313001||183460|
NCT00313625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2018.00|Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma|A Phase II Study of Intravenous Melphalan and Busulfan Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma||Fred Hutchinson Cancer Research Center||Completed|September 2005|||July 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||September 2010|September 20, 2010|April 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313625||183412|
NCT00344188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010238|Diagnosis and Treatment of Leishmanial Infections|Diagnosis and Treatment of Leishmanial Infections||National Institutes of Health Clinical Center (CC)||Recruiting|August 2001|||||N/A|Observational|N/A|||Anticipated|100|||Both|2 Years|80 Years|No|||November 2015|December 2, 2015|June 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00344188||181144|
NCT00335192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRANUCS|To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir|Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients Treated With Abacavir and/or Lamivudine Given With or Without TDF.||Germans Trias i Pujol Hospital|No|Completed|January 2005|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|80 Years|No|||September 2008|September 5, 2008|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335192||181797|
NCT00335790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBA-2|A Controlled Trial of the Clinical Effects of Hyperbaric Therapy in Autistic Children|A Prospective, Randomized, Double-Blind, Controlled Study on the Clinical Effects of Hyperbaric Therapy in Autistic Children||International Hyperbarics Association||Completed|June 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|2 Years|7 Years|No|||April 2007|April 9, 2007|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00335790||181754|
NCT00335803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBY/NDPH-TM/001|A Research Study To Compare Two Kinds Of Daily Headache|A Comparison Of Subjects With New Daily Persistent Headache (NDPH) And Subjects With Transformed Migraine (TM)||Thomas Jefferson University||Completed|March 2006|September 2007|Actual|||N/A|Observational|N/A|||||||Both|14 Years|65 Years|No|||January 2009|January 22, 2009|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00335803||181753|
NCT00314574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q3662g|A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)|A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists||Genentech, Inc.||Completed|December 2005|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|850|||Both|12 Years|75 Years|No|||February 2012|February 8, 2012|April 12, 2006|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00314574||183342|
NCT00314860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/204|RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole|A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)||GlaxoSmithKline|No|Completed|February 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|568|||Both|18 Years|79 Years|No|||May 2015|May 8, 2015|April 13, 2006||||||https://clinicaltrials.gov/show/NCT00314860||183320|
NCT00315159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0031|Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients.|Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients With Sentinel Lymph Nodes Determined to be Negative for Metastatic Disease.||Women and Infants Hospital of Rhode Island|Yes|Completed|August 2003|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Female|18 Years|N/A|No|||January 2015|January 9, 2015|April 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00315159||183297|
NCT00315172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060141|Non-Exercise Activity Thermogenesis (NEAT) in Children|Non-Exercise Activity Thermogenesis (NEAT) in Children||National Institutes of Health Clinical Center (CC)||Completed|April 2006|November 2008||||Phase 1|Interventional|Primary Purpose: Treatment|1|||120|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||November 2008|November 8, 2008|April 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00315172||183296|
NCT00315133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCFMRPUSP|Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus|Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes Mellitus- a Phase I/II Study||University of Sao Paulo||Recruiting|December 2003|December 2012|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|12 Years|35 Years|No|||November 2010|November 15, 2010|April 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00315133||183299|
NCT00314483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCMSC_GVHD012006|Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease|Evaluation of Potential Mesenchymal Stem Cells for the Treatment of Graft Versus Host Disease Following an Allogeneic Stem Cell Transplant||Christian Medical College, Vellore, India|Yes|Recruiting|June 2007|June 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|2 Years|60 Years|Accepts Healthy Volunteers|||July 2007|July 3, 2007|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314483||183349|
NCT00315588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/0329|Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation|Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation||University of Miami|Yes|Active, not recruiting|December 2000|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||June 2015|June 11, 2015|April 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00315588||183264|
NCT00315861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 72|Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies|A Phase I Study of Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies||SCRI Development Innovations, LLC||Completed|March 2006|January 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||January 2009|January 22, 2009|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00315861||183243|
NCT00316368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-318|A Study to Determine the Effect of Bi-Ventricular Pacing on Cardiac Hemodynamics After Coronary Artery Bypass Graft|A Study to Determine the Effect of Bi-Ventricular Pacing on Cardiac Hemodynamics After Coronary Artery Bypass Graft||St. Michael's Hospital, Toronto||Completed|October 2006|October 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|60|||Both|18 Years|N/A|No|||December 2009|December 22, 2009|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00316368||183204|
NCT00316940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000479712|Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|December 2005|February 2011|Actual|June 2008|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||December 2007|September 19, 2013|April 19, 2006||||||https://clinicaltrials.gov/show/NCT00316940||183160|
NCT00317187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100791|Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.|Partially Blinded Study to Assess Reactogenicity & Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ in Healthy Infants After a Hepatitis B Birth Dose||GlaxoSmithKline||Completed|June 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Both|56 Days|83 Days|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 17, 2006||||No||https://clinicaltrials.gov/show/NCT00317187||183141|
NCT00317174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|759346/002|A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.|Assess Immune Persistence & Memory by Giving Plain PRP,PSA & PSC (10 Mths Age), & Immunogenicity & Safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 Booster (15-18 Mths Age) in Previously Primed Subjects||GlaxoSmithKline||Completed|July 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||450|||Both|10 Months|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 15, 2006||||No||https://clinicaltrials.gov/show/NCT00317174||183142|
NCT00345410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6412|Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Three Doses of AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia||Sanofi||Completed|June 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|345|||Both|18 Years|N/A|No|||December 2008|December 18, 2008|June 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00345410||181052|
NCT00334919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002374-01A1|RCT of the Naturopathic Anti-Inflammatory Diet|Randomized Clinical Trial of the Naturopathic Anti-Inflammatory Diet||National College of Natural Medicine|Yes|Completed|May 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||May 2009|June 23, 2010|June 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00334919||181817|
NCT00335205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-02-2690-LG-CTIL|A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.|A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression.||Sheba Medical Center||Recruiting|April 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||June 2006|June 8, 2006|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00335205||181796|
NCT00314301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94023|Motion Analysis of Sit-to-Stand Movements in Children With Spastic Diplegia|Motion Analysis of Sit-to-Stand Movements in Children With Spastic Diplegia Before and After Loaded Sit-to-Stand Training||Far Eastern Memorial Hospital||Not yet recruiting|April 2006|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||20|||Both|5 Years|12 Years|No|||April 2006|April 14, 2006|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314301||183363|
NCT00314587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colaris01|Treatment of Unstable Both-Bone Midshaft Forearm Fractures in Children|Treatment of Unstable Both-Bone Midshaft Forearm Fractures in Children: A Randomized Trial Between 1 and 2 Elastic Stable Intramedullary Nails||Colaris, Joost, M.D.||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|15 Years|Accepts Healthy Volunteers|||November 2006|February 23, 2007|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314587||183341|
NCT00314600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colaris02|Treatment of Non-Dislocated Midshaft Both-Bone Fractures|Above Elbow Cast in Non-Dislocated Both-Bone Midshaft Forearm Fractures in Children: Necessity or Needless Cruelty? A Randomized Trial||Colaris, Joost, M.D.||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|15 Years|Accepts Healthy Volunteers|||November 2006|February 23, 2007|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314600||183340|
NCT00314847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECLS|Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock|National Multicenter Randomized Trial, Comparing Two Treatments of Myocardial Infarction Complicated With Cardiogenic Shock: Standard Treatment vs Standard Treatment Plus ECLS (Extracorporeal Life Support)||University Hospital, Caen|Yes|Terminated|June 2005|October 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||July 2010|July 30, 2010|April 13, 2006||No|The study was stopped prematurely due to insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00314847||183321|
NCT00315406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5504|Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa|Longitudinal Protocol of Polyarteritis Nodosa||University of Pennsylvania|Yes|Recruiting|April 2006|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Blood (serum and plasma), urine, and DNA|Both|N/A|N/A|No|Non-Probability Sample|Individuals with polyarteritis nodosa. Enrollment will be sequential and participants will        have disease in various stages and of different duration.|September 2015|September 4, 2015|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315406||183278|
NCT00315640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-03|Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation|A Study of the Safety and Efficacy of Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation||Alcon Research||Completed|December 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|70|||Both|18 Years|N/A|No|||January 2010|November 27, 2012|April 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00315640||183260|
NCT00315380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5506|Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)|Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)||University of Pennsylvania|Yes|Recruiting|April 2006|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Blood (serum and plasma), urine, and DNA|Both|N/A|N/A|No|Non-Probability Sample|Individuals with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Enrollment        will be sequential and participants will have disease in various stages and of different        duration.|September 2015|September 4, 2015|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315380||183280|
NCT00315393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5505|Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis|Determining Disease Activity Biomarkers in Individuals With Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis||University of Pennsylvania|Yes|Recruiting|April 2006|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Blood (serum and plasma), urine, and DNA|Both|N/A|N/A|No|Non-Probability Sample|Individuals with granulomatosis with polyangiitis (Wegener's)and microscopic polyangiitis.        Enrollment will be sequential and participants will have disease in various stages and of        different duration.|September 2015|September 4, 2015|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315393||183279|
NCT00314821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0116/05/05|Ropinirole in the Treatment of Bipolar Depression|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder||Cambridge Health Alliance||Recruiting|February 2006|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|64 Years|No|||October 2006|October 19, 2006|April 13, 2006||||||https://clinicaltrials.gov/show/NCT00314821||183323|
NCT00315107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HND01|Estrogen Treatment in Acromegalic Women|||Université de Montréal||Recruiting|May 2006|August 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||30|||Female|18 Years|N/A|No|||May 2006|May 25, 2006|April 13, 2006||||No||https://clinicaltrials.gov/show/NCT00315107||183301|
NCT00315874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP96-0102|The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.|Safety and Efficacy of Buprenorphine TDS (Transdermal Delivery System) 5, 10 and 20 Applied Every 7 Days for Sixty Days vs. 5 mg Oxycodone/325 mg Acetaminophen Tablets q6h Prn vs. Placebo in Patients With Chronic Low Back Pain||Purdue Pharma LP||Completed|April 1997|January 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||225|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|April 18, 2006||||||https://clinicaltrials.gov/show/NCT00315874||183242|
NCT00316108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S5385|Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)|Boston Scientific EPI: A Carotid Stenting Trial for High-Risk Surgical Patients|BEACH|Boston Scientific Corporation|Yes|Completed|February 2002|November 2007|Actual|May 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|747|||Both|N/A|N/A|No|||August 2014|August 26, 2014|April 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316108||183224|
NCT00316680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104489|Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.|Study to Assess Immunogenicity & Safety of GSK Bio Kft's DTPw-HBV/Hib vs DTPwCSL-HBV/Hib Kft & vs Concomitant Administration of CSL's Triple Antigen & Hiberix (GSK Bio), to Infants 2,4,6 Mths of Age, After a Birth Dose of Hep B||GlaxoSmithKline||Terminated|March 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||288|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|April 20, 2006||||No||https://clinicaltrials.gov/show/NCT00316680||183180|
NCT00349102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATING 2006|Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer|Evaluation of the Interest of Breath Holding for the Prevention of Radiation Pneumonitis Following Conformal Radiation Therapy||Centre Leon Berard|Yes|Active, not recruiting|July 2006|July 2013|Anticipated|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2013|March 5, 2013|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349102||180773|
NCT00349401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01NS041386_TRIAL3|Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation|Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation||Wake Forest School of Medicine||Withdrawn|December 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|70 Years|No|||May 2009|June 2, 2015|July 5, 2006|||Study was not initiated. No subjects were screened or enrolled.|||https://clinicaltrials.gov/show/NCT00349401||180751|
NCT00313391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|731-2005|Risperdal Consta and Health Care Utilization in Patients With Schizophrenia|The Effects of Risperdal Consta on Health Care Utilization Costs in Chronically Ill Schizophrenic Patients||Emory University||Completed|December 2005|||December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|55 Years||||September 2014|September 23, 2014|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00313391||183430|
NCT00345111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062005-060|ACRYSOF® Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance RESTOR IOL SN60WF IOL (Control Group)|ACRYSOF® Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance With RESTOR IOL Compared With SN60WF IOL (Control Group)||University of Texas Southwestern Medical Center||Withdrawn|July 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 26, 2014|June 23, 2006||Yes|Verified with former investigator that recruitment activity did not take place|No||https://clinicaltrials.gov/show/NCT00345111||181075|
NCT00345917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050137|Safety Study in Retinal Transplantation for Retinitis Pigmentosa.|Safety Study in Retinal Transplantation for Retinitis Pigmentosa.||Radtke, Norman D., M.D.||Completed|February 2002|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|N/A|No|||April 2012|April 10, 2012|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345917||181014|
NCT00345930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017208_1|DILIN's Prospective Study|A Multi-Center, Longitudinal Study of Drug-and CAM-Induced Liver Injury||Duke University|Yes|Recruiting|September 2004|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1600|Samples With DNA|Samples with DNA|Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have suffered a drug induced liver injury and meet inclusion and exclusion        criteria|August 2015|August 3, 2015|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345930||181013|
NCT00334932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000471769|Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma|Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma||National Cancer Institute (NCI)||Recruiting|February 2006|||January 2010|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||August 2008|January 9, 2014|June 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00334932||181816|
NCT00330993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601001|Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation|Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation||University of Pittsburgh||Completed|March 2006|August 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|January 24, 2007|May 26, 2006||||||https://clinicaltrials.gov/show/NCT00330993||182105|
NCT00335491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14551|Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors|A RENEW Intervention for Elderly Cancer Survivors||University of Utah|Yes|Completed|March 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|49|||Both|60 Years|N/A|No|||September 2011|September 28, 2011|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335491||181775|
NCT00330980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|394|Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels|Statins and Noncardiovascular Endpoints||University of California, San Diego||Completed|April 2000|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1000|||Both|20 Years|N/A|Accepts Healthy Volunteers|||July 2008|March 19, 2014|May 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00330980||182106|
NCT00346450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R198/24/2000|Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation|Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface||Singapore National Eye Centre||Completed|October 2001|December 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||January 2010|January 11, 2010|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346450||180976|
NCT00346736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 04-096 T/418|Use of Acupuncture In Children With Autistic Spectrum Disorder|Use of Acupuncture In Autistic Spectrum Disorder||The University of Hong Kong||Completed|May 2005|March 2007|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|3 Years|18 Years|No|||September 2008|September 1, 2008|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346736||180954|
NCT00314873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603-21/ IUCRO-0147|Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma|Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma||Indiana University||Completed|April 2006|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|April 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00314873||183319|
NCT00315185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-TH-017|Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer|Phase II Study as First Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer||Fox Chase Cancer Center|Yes|Completed|December 2004|June 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|53|||Both|18 Years|N/A|No|||September 2010|September 22, 2010|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00315185||183295|
NCT00347269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH057858-05|Primary Care Intervention Strategy for Anxiety Disorders|Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes||University of Washington|Yes|Completed|June 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1004|||Both|18 Years|75 Years|No|||October 2014|October 17, 2014|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347269||180913|
NCT00315614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/0024|Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus|Islet Cell Transplantation Alone and CD34+ Enriched Donor Bone Marrow Cell Infusion in Patients With Type 1 Diabetes Mellitus; Steroid Free Regimen||University of Miami|Yes|Completed|December 2000|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||March 2014|April 16, 2014|April 14, 2006|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00315614||183262|
NCT00315627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0205|Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation|Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation||University of Miami|No|Active, not recruiting|July 2005|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||June 2015|June 11, 2015|April 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00315627||183261|
NCT00315601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0748|Intrapulmonary Pharmacokinetics of Antibiotics|Comparison of the Intrapulmonary and Plasma Concentrations of Telithromycin and Azithromycin in Healthy Adult Subjects||University of Illinois at Chicago|No|Terminated|January 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|April 14, 2006||No|Sanofi-Aventis wanted the study terminated.|No||https://clinicaltrials.gov/show/NCT00315601||183263|
NCT00316121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-HEALOS-01|Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease|A Prospective, Multicenter, Randomized Study Comparing the Use of HEALOS® to Autograft in a Transforaminal Lumbar Interbody Fusion (TLIF) Approach||Advanced Technologies and Regenerative Medicine, LLC (ATRM)||Completed|April 2006|||January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|70 Years|No|||February 2011|February 8, 2011|April 18, 2006|Yes|Yes||No|January 19, 2011|https://clinicaltrials.gov/show/NCT00316121||183223|Stringent criteria for endpoint.Minimum sample size not reached; no hypothesis testing.High portion of current/prior smokers in both groups may impact fusion success.Product usage was appropriate and not low.This study is not on label for HEALOS.
NCT00316381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGENT|Stem Cell Therapy to Improve Myocardial Function in Patients With Acute Myocardial Infarction|Myocardial REGeneration by Intracoronary Infusion of Selected Population of stEm Cells in Acute Myocardial iNfarcTion. Randomized Multicenter Trial||Silesian School of Medicine|Yes|Completed|November 2004|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|75 Years|No|||May 2008|May 20, 2008|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00316381||183203|
NCT00316693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104798|Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine|A Phase II Study to Assess the Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Japanese Female Subjects Aged 20 - 25 Years.||GlaxoSmithKline||Completed|April 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1046|||Female|20 Years|25 Years|Accepts Healthy Volunteers|||February 2011|April 11, 2013|April 19, 2006|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00316693||183179|
NCT00345124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|med.res.hos.2006.cc.02|The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential Hypertension|The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential Hypertension, During Basal Conditions and After Hypertonic Saline Infusion.||Regional Hospital Holstebro|No|Completed|May 2006|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00345124||181074|
NCT00345137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.1995.02.JNB|Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis|Phase 1 Study of Systemic Effects of Ng-Monomethyl-L-Arginine on Renal Hemodynamics in Patients With Polycystic Kidney Disease and Chronic Glomerulonephritis||Regional Hospital Holstebro||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind||||75|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2006|June 24, 2006|June 24, 2006||||No||https://clinicaltrials.gov/show/NCT00345137||181073|
NCT00345436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906094|Exercise in Insulin-Resistant Minority Adolescents|An Exercise Intervention in Insulin-Resistant Minority Adolescents||National Institutes of Health Clinical Center (CC)||Completed|February 2006|May 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|14 Years|18 Years|No|||May 2011|May 12, 2011|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345436||181051|
NCT00345683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105988|Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.|Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.||GlaxoSmithKline||Completed|July 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|4021|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|June 26, 2006|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00345683||181032|Only information about specific categories of AEs (SAEs, NOCIs, rash and AEs resulting in ER visits) were collected in this study.
NCT00345943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5606R/6679R|An fMRI Study of Self-regulation in Adolescents With Bulimia Nervosa|An fMRI Study of Self-regulation in Adolescents With Bulimia Nervosa||New York State Psychiatric Institute|Yes|Active, not recruiting|October 2004|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Female|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents (ages 12-17 years) with bulimia nervosa and age, gender, and weight-matched        controls|March 2015|March 20, 2015|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00345943||181012|
NCT00335218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91161|Fat Distribution in Healthy Early Postmenopausal Women|A Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled, Two-arm, Phase IV Study to Investigate the Influence of a Continuous Combined Estrogen-progestin Regimen Containing 2 mg Estradiol Valerate and 2 mg Dienogest (Climodien® / Lafamme®) on the Fat Distribution in Otherwise Healthy Early Postmenopausal Women||Bayer|No|Completed|July 2002|August 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Female|48 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|February 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00335218||181795|
NCT00331552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6139|Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer|Phase I - II Study of Doxil® In Combination With Daily Oral Cyclophosphamide and Herceptin for Patients With HER-2/Neu Positive Disease In Patients With Metastatic Breast Cancer||University of Washington|No|Completed|February 2006|||February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00331552||182066|
NCT00331240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1457|24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination|24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination||Aristotle University Of Thessaloniki|No|Completed|March 2006|February 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|29 Years|80 Years|No|||May 2014|May 9, 2014|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00331240||182086|
NCT00331253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/04/i-MP|Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).|A 54-WEEK, PHASE 2, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INDOCYANINE GREEN-MEDIATED PHOTOTHROMBOSIS (i-MP) FOR THE TREATMENT OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.||Opto Eletronica S.A.|Yes|Recruiting|April 2007|December 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|50 Years|N/A|No|||April 2007|April 25, 2007|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00331253||182085|
NCT00346749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC105931|ADVAIR DISKUS (Fluticasone Propionate/Salmeterol) Versus SEREVENT DISKUS (Salmeterol) On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared With Salmeterol DISKUS 50mcg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Terminated|December 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||180|||Both|40 Years|N/A|No|||October 2010|October 1, 2010|June 28, 2006|||The study was terminated due to difficulties with finding sites and subjects willing to    participate.|||https://clinicaltrials.gov/show/NCT00346749||180953|
NCT00347048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-1107|Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients|Tacrolimus (FK506) P-III Placebo-Controlled Double-Blind Study in Moderate to Severe Refractory Ulcerative Colitis Patients||Astellas Pharma Inc|Yes|Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|16 Years|64 Years|No|||August 2014|August 25, 2014|June 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00347048||180930|
NCT00347035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0771/04|INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE|INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE||Federal University of São Paulo||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|90 Years||||June 2006|October 25, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347035||180931|
NCT00347594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVC2-03-052|A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)|A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)||Bausch & Lomb Incorporated|No|Completed|August 2005|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|76|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|June 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00347594||180888|
NCT00347607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI01-033|Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania|Cost-effectiveness of Three Alternative Azithromycin Treatment Strategies for Trachoma Control in Tanzania||Johns Hopkins University||Completed|April 2002|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2700|||Both|12 Months|7 Years|Accepts Healthy Volunteers|||March 2002|October 27, 2011|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00347607||180887|
NCT00347945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMS2040|Randomized Trial of Treatments for Convergence Insufficiency|A Randomized Clinical Trial of Pencil Push-Ups Versus Office Based Vision Therapy For the Treatment of Convergence Insufficiency||Pennsylvania College of Optometry||Completed|October 2000|November 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||90|||Both|9 Years|30 Years|Accepts Healthy Volunteers|||January 2002|July 3, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00347945||180862|
NCT00315653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-01 Sure Study|Survivin Urine mRNA Assay Risk of Bladder Cancer Study|Evaluation of the Survivin Urine mRNA Assay to Estimate Risk of Bladder Cancer Found on Cystoscopy||Fujirebio Diagnostics, Inc.||Completed|September 2005|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||600|||Both|50 Years|N/A|No||Subjects scheduled to undergo cystoscopy|March 2008|March 12, 2008|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00315653||183259|
NCT00315887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP98-1201|The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.|A Double-Blind Comparative Study of Buprenorphine Transdermal System (BTDS) and Hydrocodone/Acetaminophen Tablets in Patients With Chronic Back Pain||Purdue Pharma LP||Completed|April 1999|October 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||April 2006|May 1, 2006|April 18, 2006||||||https://clinicaltrials.gov/show/NCT00315887||183241|
NCT00316134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-02 Pleural Effusion Study|Multiple Biomarkers in Undiagnosed Pleural Effusion|Evaluation of Multiple Biomarkers in Serum and Pleural Fluid to Estimate the Probability of Cancer in Patients Presenting With an Undiagnosed Pleural Effusion||Fujirebio Diagnostics, Inc.|No|Terminated|March 2006|February 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|Serum and pleural fluids|Both|18 Years|N/A|No|Probability Sample|N/A - study was closed|November 2011|November 7, 2011|April 18, 2006||No|The study was terminated on completion of the Pilot Study phase.|No||https://clinicaltrials.gov/show/NCT00316134||183222|
NCT00316394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-178|Improving Preventive Service Delivery at Adult Complete Health Check-Ups|Improving Preventive Service Delivery at Adult Complete Health Check-Ups: the Preventive Health Evidence-Based Recommendation Form (PERFORM) Cluster Randomized Controlled Trial||St. Michael's Hospital, Toronto||Completed|November 2002|March 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|21 Years|N/A|No|||April 2006|October 10, 2006|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00316394||183202|
NCT00316407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 0503|Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients|Phase I/II Lapatinib Plus Carboplatin and Paclitaxel in Stage III or IV Relapsed Ovarian or Stage IV Breast Cancer Patients||Swedish Medical Center|No|Completed|August 2005|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||March 2010|February 16, 2011|April 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316407||183201|
NCT00316706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104896 (month 18 FU)|Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine|A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013||GlaxoSmithKline||Completed|October 2005|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1245|||Female|10 Years|14 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|April 19, 2006|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00316706||183178|
NCT00345150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.1995.01.JNB|Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls|Phase 1 Study of the Effects of Systemic Nitric Oxide Inhibition With Ng-Monomethyl-L-Arginine on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls||Regional Hospital Holstebro||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind||||30|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2006|June 24, 2006|June 24, 2006||||No||https://clinicaltrials.gov/show/NCT00345150||181072|
NCT00345163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3708g|A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)|A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse|BRAIN|Genentech, Inc.||Completed|July 2006|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|June 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00345163||181071|
NCT00345449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004776-01|Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation|Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation||Ottawa Hospital Research Institute||Completed|September 2006|September 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|200|||Both|18 Years|N/A|No|||July 2009|July 8, 2009|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345449||181050|
NCT00345696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XELOXAVBISEMANAL|1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.|Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients.||Unidad Integral de Investigación en Oncología S.L.|No|Completed|June 2006|January 2011|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345696||181031|
NCT00345956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105722|To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)|A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Bio Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam||GlaxoSmithKline||Completed|September 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|375|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||November 2012|November 21, 2012|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00345956||181011|
NCT00346515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|864|EPIC US Feasibility Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting|Evaluating the Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting: The EPIC US Feasibility Study||Lumen Biomedical|Yes|Completed|June 2006|January 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|18 Years|N/A|No|||October 2008|October 20, 2008|June 29, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00346515||180971|
NCT00346528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-64|Safety of NGOIS Compared to BSS Plus in Pediatric Patients|Safety of NGOIS Compared to BSS Plus in Pediatric Patients||Alcon Research|No|Completed|July 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|N/A|17 Years|No|||March 2012|March 1, 2012|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346528||180970|
NCT00335504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00837|Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia|Randomized, Phase II Trial of Atorvastatin, RAFTILOSE Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia||National Cancer Institute (NCI)||Completed|March 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|85|||Both|40 Years|N/A|No|||April 2013|April 23, 2014|June 8, 2006|Yes|Yes||No|November 26, 2012|https://clinicaltrials.gov/show/NCT00335504||181774|Variation in endpoint measurement across sites, relatively small sample size, and rectal biomarker assessments only may have contributed to challenges in full data interpretation.
NCT00331292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRB100706|A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients|A Study to Identify a Transcriptomic Profile Indicative of Cycle AMP Pathway Activation in the Lung||GlaxoSmithKline||Terminated|August 2006|||||N/A|Observational|Time Perspective: Prospective||||30|||Both|18 Years|45 Years|No|||October 2008|October 15, 2008|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00331292||182083|
NCT00332202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9823|PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin|A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin||Eli Lilly and Company|Yes|Completed|June 2006|July 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|709|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|May 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00332202||182021|
NCT00331799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008715|Pilot Study of Duloxetine in Psychological Resilience|A Pilot Study of Duloxetine in Psychological Resilience and Its Correlation With Blockade of Serotonin and Norepinephrine Transporter||Duke University|Yes|Completed|April 2007|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||June 2013|July 1, 2013|May 30, 2006|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT00331799||182050|
NCT00347061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS5235|Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH|A Long-term Safety and Efficacy of SL77.0499-10 10mg Once-daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH).A Multicenter, 52-week, Open Label, Uncontrolled Study.||Sanofi||Completed|May 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|148|||Male|50 Years|N/A|No|||October 2009|October 1, 2009|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347061||180929|
NCT00347074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R317/10/03|A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients|||Singapore National Eye Centre||Completed|September 2003|March 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||120|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2003|July 3, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347074||180928|
NCT00347295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263.510|Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.|A Randomised, Double-blinded, Double-dummy, Multi-center, Paralleled Study to Investigate the Safety and Efficacy of Brotizolam (Lendormin) Compared With Estazolam in Insomnia Outpatients.||Boehringer Ingelheim||Completed|June 2006|January 2007||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||253|||Both|18 Years|65 Years|No|||October 2013|October 31, 2013|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347295||180911|
NCT00347282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R440/35/2005|Post Enucleation Socket Syndrome Study|Post-enucleation Socket Syndrome Study (PESSS): Part 1 - Three Dimensional Volumetric Assessment of Anophthalmic Sockets With the New Multi-detector Computed Tomographic Technology||Singapore National Eye Centre||Completed|March 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who had enucleation surgery with primary orbital implant|May 2010|May 11, 2010|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347282||180912|
NCT00347971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|494E03|Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma|Phase 1, Open-Label, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered in Combination With Rituxan (Rituximab) in Subjects With B-Cell Non Hodgkin's Lymphoma||ZymoGenetics||Completed|June 2006|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||September 2008|September 4, 2008|June 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00347971||180860|
NCT00315419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5401|Identifying Characteristics of Bone Marrow Failure Syndromes|Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias||Office of Rare Diseases (ORD)||Active, not recruiting|April 2006|July 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Residual samples from peripheral blood and bone marrow aspiration/biopsies|Both|11 Years|N/A|No|Non-Probability Sample|Individuals with bone marrow failure syndromes|July 2009|April 19, 2010|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315419||183277|
NCT00315900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAC00081|Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia|Depakote ER vs. Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia||Tuscaloosa Research & Education Advancement Corporation|No|Completed|May 2006|March 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|55 Years|N/A|No|||August 2012|August 30, 2012|April 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00315900||183240|
NCT00315666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-000060-82|Prophylactic Effect of Memantine in Chronic Tension-Type Headache|Prophylactic Effect of Memantine in Chronic Tension-Type Headache||Danish Headache Center|Yes|Completed|May 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years|No|||February 2009|February 19, 2009|April 18, 2006||||No||https://clinicaltrials.gov/show/NCT00315666||183258|
NCT00316147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104005|Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules|Phase IIIb, Open, Randomized, Multicenter Study to Assess the Immunogenicity & Safety of GSK Biologicals' Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants When Given at 6-10-14 Weeks of Age or at 2-4-6 Months of Age||GlaxoSmithKline||Completed|December 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||224|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 21, 2006||||No||https://clinicaltrials.gov/show/NCT00316147||183221|
NCT00316420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TI027 PG/HK|Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer|Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma||Swedish Medical Center|No|Completed|December 2003|August 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2010|March 4, 2010|April 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316420||183200|
NCT00316433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-03-099|Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer|Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer||Swedish Medical Center||Terminated|February 2005|January 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||April 2007|April 4, 2007|April 18, 2006||||||https://clinicaltrials.gov/show/NCT00316433||183199|
NCT00348556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004007|Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure|Efficacy of Intra-renal Infusion of BNP in Enhancing Renal Function in Human CHF With Cardiorenal Syndrome: A Pilot Study||Mayo Clinic|Yes|Terminated|December 2005|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|90 Years|No|||September 2012|September 14, 2012|June 30, 2006|No|Yes|Company providing catheter bought out, funding and supplies terminated|No|September 14, 2012|https://clinicaltrials.gov/show/NCT00348556||180815|The study was terminated early because the company providing catheter was bought out, and funding and supplies were terminated.
NCT00348829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMW 01|Mitral Valve Reconstruction in Chronic Heart Failure (CHF): Identification of Predictors for a Successful Therapy|Mitral Valve Reconstruction in Patients With Chronic Heart Failure and Secondary Mitral Insufficiency: Identification of Predictors for a Successful Therapy||University of Leipzig|No|Suspended|June 2006|December 2008|Anticipated|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|70 Years|No|||May 2009|May 11, 2009|July 5, 2006||No|not enough patients to e recruited, problems with the conductance catheter|No||https://clinicaltrials.gov/show/NCT00348829||180794|
NCT00345176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-120|Age-Related Eye Disease Study 2 (AREDS2)|Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration|AREDS2|National Eye Institute (NEI)|Yes|Completed|September 2006|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|4203|||Both|50 Years|85 Years|No|||April 2015|April 13, 2015|June 14, 2006|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00345176||181070|
NCT00345189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNF2024-ST-05003|Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, PK, and PD Study of CNF2024 Administered Orally Twice Weekly for 3 Weeks of a 4 Week Course or Twice Weekly for 4 Weeks of a 4 Week Course to Patients With Advanced Solid Tumors||Biogen|Yes|Completed|February 2006|April 2009|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2009|July 10, 2009|June 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00345189||181069|
NCT00345462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S206.3.012|Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.|Immunogenicity and Reactogenicity of Trivalent Virosomal Influenza Vaccine Invivac® for the Season 2006/2007. An Open, Baseline-controlled Study in Two Groups of Healthy Subjects: Adults and Elderly.||Solvay Pharmaceuticals||Withdrawn|June 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 5, 2010|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00345462||181049|
NCT00346242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EGR05|Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events|Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events||Novartis||Completed|March 2004|||March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||60|||Both|18 Years|N/A|No|||April 2012|April 29, 2012|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00346242||180991|
NCT00346255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491241|BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma|IMGN901|ImmunoGen, Inc.|No|Completed|April 2005|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346255||180990|
NCT00331279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA8837|The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study|The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study||Columbia University|No|Completed|August 2005|February 2006|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Female|23 Years|47 Years|Accepts Healthy Volunteers|||January 2011|December 6, 2012|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00331279||182084|
NCT00332592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-20060037|Intragastric and Peritoneal Microdialysis in Infants With Necrotizing Enterocolitis (NEC)|Intragastric and Intraperitoneal Microdialysis in Infants With NEC||Odense University Hospital|No|Completed|October 2006|May 2010|Actual|January 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|N/A|6 Months|No|Non-Probability Sample|Premature children with NEC|May 2008|July 20, 2011|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332592||181996|
NCT00331565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATORVA-06|Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin|Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin||University of Oslo School of Pharmacy||Completed|August 2006|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|May 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00331565||182065|
NCT00347087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS HF 7/04|Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure|Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure||Charite University, Berlin, Germany||Completed|July 2004|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|36|||Both|21 Years|N/A|No|||October 2007|October 30, 2007|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347087||180927|
NCT00347308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Photographic Assessment of Eyebrow Position and Range of Motion|Photographic Assessment of Eyebrow Position and Range of Motion||The New York Eye & Ear Infirmary|No|Completed|July 2007|January 2009|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults, between the ages of 18- 85|April 2012|April 29, 2012|June 29, 2006||No||No|August 10, 2009|https://clinicaltrials.gov/show/NCT00347308||180910|
NCT00347620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-072|Improving Vision and Quality of Life in the Nursing Home|Improving Vision and Quality of Life in the Nursing Home||University of Alabama at Birmingham||Completed|August 2000|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 12, 2010|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347620||180886|
NCT00347646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|484|A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)|An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)||Bausch & Lomb Incorporated|Yes|Terminated|September 2006|June 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|June 30, 2006|Yes|Yes|Lack of Efficacy|No||https://clinicaltrials.gov/show/NCT00347646||180885|
NCT00347984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004-09|Product Preference With Systane Compared to Artificial Tears on Frequency of Drop Use|The Effect of Systane® Compared to Marketed Artificial Tears on Frequency of Drop Use||Alcon Research||Completed|December 2005|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||August 2008|April 7, 2012|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347984||180859|
NCT00347997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385|A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix for Lasik|||Bausch & Lomb Incorporated|No|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|June 30, 2006|Yes|Yes|Decision made by B&L to cancel the study, no subjects enrolled.|No||https://clinicaltrials.gov/show/NCT00347997||180858|
NCT00347568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0312-05|BC-DAISY: A Breast Cancer Decision Aid System|BC-DAISY: A Breast Cancer Decision Aid System||Rhode Island Hospital||Completed|July 2006|December 2009|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|195|||Female|21 Years|75 Years|Accepts Healthy Volunteers|||June 2012|June 4, 2012|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00347568||180890|
NCT00347581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hms0304|A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children|A Randomized Clinical Trial of the Effectiveness of Base-in Prism Reading Glasses Vs. Placebo Reading Glasses for Symptomatic Convergence Insufficiency in Children||Pennsylvania College of Optometry||Completed|May 2003|August 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||January 2005|July 3, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00347581||180889|
NCT00347958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD518|Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine|Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose||Sanofi|No|Completed|August 2006|October 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|545|||Both|15 Years|69 Years|Accepts Healthy Volunteers|||November 2013|November 11, 2013|July 3, 2006|Yes|Yes||No|May 14, 2010|https://clinicaltrials.gov/show/NCT00347958||180861|
NCT00315913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS #2004-3997|Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor|Placebo-Controlled Randomized Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Dysfunctional Labor||University of California, Irvine|No|Terminated|January 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 5, 2014|April 17, 2006||No|Low study enrollment|No||https://clinicaltrials.gov/show/NCT00315913||183239|
NCT00347906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 00052|Photodynamic Therapy (PDT) Versus Transpupillary Thermotherapy (TTT) in Occult Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (AMD)|Photodynamic Therapy Versus Transpupillary Thermotherapy in Occult CNV in Age-related Macular Degeneration||University Hospital, Linkoeping|No|Terminated|November 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|55 Years|N/A|No|||November 2003|January 11, 2010|July 3, 2006|No|Yes|Difficulties in recruiting patients|No||https://clinicaltrials.gov/show/NCT00347906||180865|
NCT00347919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG20007|Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer|A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors||GlaxoSmithKline|No|Completed|July 2006|March 2015|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|189|||Female|21 Years|N/A|No|||January 2016|January 28, 2016|June 30, 2006|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00347919||180864|In 2008 at primary completion, study was terminated. In 2011, protocol amendment 4 (Am4), allowed continuation of treatment until PD for the 1 par. This par. completed the study per Am 4. Par. last visit occurred, the study is considered completed.
NCT00348192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ3106242|SB-742457 And Donepezil In Alzheimer's Disease|A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease||GlaxoSmithKline||Completed|May 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||200|||Both|50 Years|85 Years|No|||May 2009|May 28, 2009|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348192||180843|
NCT00348205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|369|A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia|||Bausch & Lomb Incorporated|No|Completed|June 2005|March 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00348205||180842|
NCT00348218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R462/11/2006|Pilot Study of Neurovision to Improve Vision and Slow Myopia Progression in Children With Myopia|Pilot Study To Evaluate The Efficacy Of Neurovision'S NVC™- Vision Correction Technology For The Improvement In Visual Acuity In Myopic Children And Slowing Down Of Myopia Progression||Singapore National Eye Centre||Completed|June 2006|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|7 Years|9 Years|No|||May 2010|May 10, 2010|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348218||180841|
NCT00348569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-189-002|A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain|A Prospective, Multicenter Study of GE LightSpeed Volume Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain Patients Suspected of Coronary Artery Disease||GE Healthcare||Completed|May 2006|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||304|||Both|18 Years|N/A|No|||August 2007|August 15, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348569||180814|
NCT00348816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000486733|Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer|A Phase II Study to Assess the Feasibility and Activity of Concomitant Radiation and Docetaxel Chemotherapy Followed by Docetaxel Chemotherapy in Prostate Cancer Patients With a Persistent or Rising PSA After Radical Prostatectomy||The University of Texas Health Science Center at San Antonio||Active, not recruiting|May 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||January 2016|January 25, 2016|July 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00348816||180795|
NCT00349414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Reference Code: A/06/164|Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma|A Comparison of the Safety and Efficacy of Conventional Versus Micropulse Transscleral Diode Laser Cyclophotocoagulation in Refractory Glaucoma||National University Hospital, Singapore||Recruiting|July 2006|December 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Both|22 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 13, 2008|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349414||180750|
NCT00345722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 03-043C|The Effect of Strawberries in a Cholesterol-Lowering Dietary Portfolio|The Long-Term Effect of Viscous Fibers, Soy Protein, and Plant Sterol Foods in Combination on Serum Cholesterol and Other Risk Factors for Cardiovascular Disease||University of Toronto||Completed|June 2006|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 7, 2007|June 26, 2006||||No||https://clinicaltrials.gov/show/NCT00345722||181029|
NCT00345969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 02-1108|Exercise and Testosterone Therapy in Elderly Men With Physical Frailty|Exercise and Testosterone Therapy in Elderly Men With Physical Frailty||Washington University School of Medicine||Completed|November 2004|August 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Male|65 Years|N/A|No|||April 2012|April 17, 2012|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345969||181010|
NCT00346554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.01.008|To Study the Prevalence of Insomnia in Geriatric COPD Patients Who Are Enrolled in a Pulmonary Rehabilitation Program.|To Study the Prevalence of Insomnia in Geriatric COPD Patients Who Are Enrolled in a Pulmonary Rehabilitation Program.||Hackensack University Medical Center|Yes|Completed|April 2006|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|60 Years|N/A|No|Non-Probability Sample|Greitric COPD patients who are enrolled in Pulmonary Rehabilitation at HUMC|February 2014|February 1, 2014|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00346554||180968|
NCT00346567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|comtru|Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)|Clinical Trial: Backup With Combivir (AZT/3TC) or Single Dose (sd) Truvada (FTC/TDF) in Order to Avoid NNRTI Resistance After sd Nevirapine for the Prevention of Mother-to-child Transmission (MTCT)||Rigshospitalet, Denmark||Completed|June 2006|April 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|566|||Female|18 Years|55 Years|No|||February 2009|February 22, 2016|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346567||180967|
NCT00331019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HandyLab #VVP00056|Rapid Detection of Group B Strep- 35-37 Week Study|Rapid Detection of Group B Streptococcus Using a Bedside Microfluidics Device: 35-37 Week Study||University of Michigan|No|Withdrawn|July 2006|||July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients 18 years or older who present for prenatal cultures in clinic at 35-37 weeks.|December 2015|December 14, 2015|May 26, 2006|Yes|Yes|HandyLab device determined to not work for the science|No||https://clinicaltrials.gov/show/NCT00331019||182103|
NCT00332605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601M80486|N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence|A Double-Blind Study of N-Acetyl Cysteine Plus Naltrexone in the Treatment of Methamphetamine Dependence||University of Chicago|Yes|Completed|June 2006|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|May 30, 2006|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00332605||181995|
NCT00332891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5891|An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder|An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD|ELECTRA|Sanofi||Completed|March 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|508|||Both|18 Years|65 Years|No|||March 2009|March 6, 2009|June 1, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00332891||181973|
NCT00347672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 217|Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults|Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|June 2006|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|42|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2008|January 18, 2008|July 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00347672||180883|
NCT00347685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B00.CTOL.003.TRA P03|A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.|Open-label Assessment of the Safety and Effectiveness of Extended Release Tramadol (Tramadol ER) in the Treatment of Chronic Non-malignant Pain.||Valeant Pharmaceuticals International, Inc.||Completed|October 2000|February 2003||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||650|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|July 1, 2006||||||https://clinicaltrials.gov/show/NCT00347685||180882|
NCT00348010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B00.CT3.015.TRA PO3|A Study Comparing the Effectiveness and Safety of Extended Release Tramadol Versus Placebo for the Treatment of Osteoarthritis (OA) of the Knee|Double-blind, Randomized, Dose-titration, Parallel-group Comparison of the Efficacy and Safety of Extended Release Tramadol Hydrochloride (Tramadol HCl ER) and Placebo in the Treatment of Osteoarthritis of the Knee.||Valeant Pharmaceuticals International, Inc.||Completed|November 2000|July 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||245|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|July 2, 2006||||||https://clinicaltrials.gov/show/NCT00348010||180857|
NCT00348270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R367/25/2004|Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses|Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 Three-piece Silicone Posterior Chamber Intraocular Lens and Alcon Laboratories MA60 Acrysof Three-piece Acrylic Posterior Chamber Intraocular Lens||Singapore National Eye Centre||Completed|July 2005|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|50 Years|80 Years|No|||May 2010|May 11, 2010|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348270||180837|
NCT00347659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-C06-001|US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study|Phase 1 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema||Aeris Therapeutics|Yes|Completed|June 2006|September 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|40 Years|N/A|No|||February 2008|February 27, 2008|June 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00347659||180884|
NCT00348621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1AG15812|A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents|Clinical Trial of Interventions for Visual Loss in Nursing Home Residents||Johns Hopkins University||Active, not recruiting|June 1999|June 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1600|||Both|65 Years|N/A|No|||January 2006|July 3, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348621||180810|
NCT00348634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919EUS51|Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients|The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation||Novartis||Terminated|July 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|65 Years|N/A||||March 2016|March 2, 2016|July 3, 2006|||Terminated early due to regulatory action suspending tegaserod use in 2007|||https://clinicaltrials.gov/show/NCT00348634||180809|
NCT00348231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-195(4220)|Jikei Optimal Insulin Therapy in Type 2 Diabetes|||Jikei University School of Medicine||Recruiting|November 2004|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|20 Years|80 Years|No|||June 2006|August 31, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348231||180840|
NCT00347932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|433|A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.|A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.||Bausch & Lomb Incorporated|No|Completed|June 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|957|||Both|1 Year|N/A|No|||March 2015|March 4, 2015|June 30, 2006|Yes|Yes||No|June 29, 2009|https://clinicaltrials.gov/show/NCT00347932||180863|
NCT00348582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5217|Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery|Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||June 2007|June 21, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348582||180813|
NCT00348842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397231205-HMO-CTIL|Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer Modalities|Phase II: Safety and Primary Efficacy of Clinical Application of Newcastle Disease Virus for the Treatment of Patients Resistant to All Conventional Modalities||Hadassah Medical Organization||Withdrawn|March 2006|June 2006|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||February 2006|April 7, 2011|July 4, 2006||||No||https://clinicaltrials.gov/show/NCT00348842||180793|
NCT00348855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNGE20060702|Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice|Effects of a Series of Intensified Prevention Consultations on the Changes in Goals and Risk Factors in Hypertensive Patients at High Cardiovascular Risk|ESCAPE|Collège National des Généralistes Enseignants|Yes|Completed|November 2006|March 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|1836|||Both|40 Years|75 Years|No|||November 2011|November 12, 2011|July 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00348855||180792|
NCT00349115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMM53|TCD Followed by autoSCT for Newly Diagnosed MM Patients|Induction Therapy With TCD Regimen (Thalidomide, Cyclophosphamide, Dexamethasone) Followed by Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients||Korean Multiple Myeloma Working Party||Recruiting|June 2006|June 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|43|||Both|18 Years|75 Years|No|||July 2006|May 5, 2008|July 4, 2006||||No||https://clinicaltrials.gov/show/NCT00349115||180772|
NCT00344864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sanchez001|A Prospective Clinical Research Project Evaluating The Effects of Soft Contact Lenses on Higher Order Visual Aberrations|A Prospective Clinical Research Project Evaluating The Effects of Soft Contact Lenses on Higher Order Visual Aberrations||University of Texas Southwestern Medical Center|No|Terminated|January 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|All patients of any race and sex between the ages of 18-35 years of age who are not        currently wearing contact lenses at their initial presentation.|May 2007|March 22, 2011|June 23, 2006||No|Terminated due to lack of patient recruitment|No||https://clinicaltrials.gov/show/NCT00344864||181094|
NCT00344877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060187|Electrical Brain Stimulation to Reduce Epileptic Seizures|Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|June 2006|May 2009||||N/A|Observational|N/A||||56|||Both|18 Years|80 Years|No|||May 2009|May 6, 2009|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344877||181093|
NCT00346021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ro1CA 103965-01|Sun Protection for Florida's Children|Sun Protection for Florida's Children||University of South Florida|No|Completed|February 2005|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2984|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00346021||181007|
NCT00345709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0359|Elizabeth Registry for Low Grade Ovarian Cancer|The Elizabeth Registry for Low Grade Ovarian Cancer||M.D. Anderson Cancer Center|No|Completed|September 2003|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|60|||Female|N/A|N/A|No|Non-Probability Sample|M.D. Anderson Cancer Center Patient, living or deceased, with a pathologically-confirmed        diagnosis of either low grade ovarian carcinoma or LMP ovarian carcinoma.|October 2015|October 5, 2015|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345709||181030|
NCT00345982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/150|Augmenting Clozapine With Sertindole - SERCLOZ|Augmenting Clozapine With Sertindole - a Double Blinded Randomized Placebo Study||University of Aarhus|Yes|Completed|September 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||September 2010|September 24, 2010|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00345982||181009|
NCT00346268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3481066|Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy|Randomized, Double-Blind Study Of The Morphine-Sparing Efficacy And Safety Of Parecoxib Sodium 40 Mg IV Followed By 20 Mg IV Every 12 Hours In The Treatment Of Pain Following Radical Prostatectomy|PROSTATECTOMY|Pfizer|Yes|Terminated|December 2006|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|105|||Male|18 Years|N/A|No|||September 2011|September 21, 2011|June 28, 2006|Yes|Yes|See termination reason in detailed description.|No|September 21, 2011|https://clinicaltrials.gov/show/NCT00346268||180989|This study was terminated prematurely due to slow recruitment.
NCT00346281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB2-201|32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer|A Phase IIa, Safety Study of the Active Implantable(Radiological) Medical Device 32P BioSilicon, Administered Intratumourally to Patients With Advanced, Unresectable Pancreatic Cancer, in Addition to Standard IV Gemcitabine Chemotherapy||pSiMedica Limited||Recruiting|June 2006|June 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||June 2006|June 28, 2006|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00346281||180988|
NCT00347139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C106093|Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients|Multi-centre, Randomised, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study, to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (25, 100 and 400 Mcg Once Daily) of GW642444||GlaxoSmithKline||Completed|May 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||March 2011|May 31, 2012|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347139||180923|
NCT00347386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCO-CT-2004-003740-3|Therapeutic Zinc in Infant Bacterial Illness|Zinc as an Immunomodulator in the Treatment of Possible Serious Bacterial Infections in Infants 7 Days and up to 4 Months of Age||Centre For International Health|Yes|Completed|July 2005|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|700|||Both|N/A|4 Months|No|||December 2010|December 6, 2010|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347386||180904|
NCT00331825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH-890010|Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism|A Randomized Controlled Trial Study of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism||Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan||Completed|July 2000|July 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Both|18 Years|65 Years|No|||February 2000|May 30, 2006|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331825||182048|
NCT00332241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-178|Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)|A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|June 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|6 Years|17 Years|No|||December 2009|November 7, 2013|May 31, 2006|Yes|Yes||No|June 3, 2009|https://clinicaltrials.gov/show/NCT00332241||182018|
NCT00332904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-0606-HH-UH-DK|Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis|Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems|PEKASYS|Hvidovre University Hospital|Yes|Active, not recruiting|August 2006|December 2010|Anticipated|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|75 Years|No|||June 2010|June 3, 2010|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332904||181972|
NCT00332917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.3.006|An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients|An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients||Solvay Pharmaceuticals|Yes|Completed|February 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|30 Years|N/A|No|||January 2009|January 23, 2009|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00332917||181971|
NCT00347698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-007|Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy|Intravitreal Bevacizumab Vs Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A One-Year Prospective, Contralateral Eye Study||Asociación para Evitar la Ceguera en México||Recruiting|March 2006|August 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||June 2006|June 30, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347698||180881|
NCT00347711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0020|Bevacizumab and Retinal Vascular Occlusions|||Asociación para Evitar la Ceguera en México||Recruiting||||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|40 Years|90 Years||||June 2006|July 3, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347711||180880|
NCT00348023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5179|Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension|Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||February 2007|February 7, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348023||180856|
NCT00348283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-769|Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon||Abbott|No|Completed|August 2006|||September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|75 Years|No|||April 2011|April 7, 2011|June 30, 2006|Yes|Yes||No|September 15, 2009|https://clinicaltrials.gov/show/NCT00348283||180836|
NCT00348296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0998-A1|Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis|A Randomized, Double-blind, Placebo-controlled Multi-center Study of GB-0998 for Treatment of Systemic Sclerosis||Benesis Corporation||Completed|July 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|16 Years|N/A|No|||July 2010|July 28, 2010|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348296||180835|
NCT00348647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1-62|Prevention of Injuries by an Exercise Program – a RCT|Can Lower Extremity Overuse Injuries Be Prevented by an Exercise Program Aiming at Muscular Strength, Flexibility and Coordination – a RCT||Amager Hospital||Active, not recruiting|December 2004|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|July 3, 2006|July 3, 2006||||No||https://clinicaltrials.gov/show/NCT00348647||180808|
NCT00348244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5152|Ketorolac vs. Steroid in the Prevention of CME|A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||January 2007|January 15, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348244||180839|
NCT00348595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0798|Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer|Phase I/II Double Blinded Randomized Study to Determine the Tolerability and Efficacy of 2 Different Doses of Revlimid (CC-5013, Lenalidomide) in Biochemically Relapsed Prostate Cancer Patients (M0) After Local Treatment||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|May 2006|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00348595||180812|
NCT00348868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A007|Buprenorphine HIV Care Integration Project|Miami Buprenorphine HIV Care Integration Project||University of Miami|No|Completed|July 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2007|March 14, 2008|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00348868||180791|
NCT00349128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF23-0121 03 01|Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes|A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.||Solvay Pharmaceuticals||Completed|January 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||382|||Both|20 Years|80 Years|No|||August 2007|August 31, 2007|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349128||180771|
NCT00349141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810501|Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)|A Phase I/II Dose Escalation Study of a Vero Cell-Derived, Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 45 Years||Nanotherapeutics, Inc.||Completed|June 2006|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||270|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|October 7, 2015|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349141||180770|
NCT00349180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6770|Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)|Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement||Sanofi||Completed|June 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||156|||Both|20 Years|N/A|No|||March 2009|March 26, 2009|July 4, 2006||||No||https://clinicaltrials.gov/show/NCT00349180||180768|
NCT00344890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR06-001|Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy|A Safety and Efficacy Comparison of Preservon Treated Allograft Bone Dowels Versus Traditional Freeze-Dried Allograft Bone Dowels for Fusion of Degenerated Cervical Intervertebral Discs in the Treatment of Cervical Radiculopathy or Myelopathy||LifeNet Health|Yes|Completed|September 2006|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|65 Years|No|||April 2015|April 3, 2015|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344890||181092|
NCT00315042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6133|TELI TON - Telithromycin in Tonsillitis|Multinational, Randomized, Double-Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 10 Days Penicillin V 13.3 mg/kg Tid in Children 6 Months to Less Than 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis||Sanofi||Terminated|March 2006|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|314|||Both|6 Months|13 Years|No|||April 2009|April 2, 2009|April 13, 2006|||Pediatric development program terminated by sponsor|No||https://clinicaltrials.gov/show/NCT00315042||183306|
NCT00315055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L10|Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule|Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2, 3, and 4 Months Primary Schedule in Healthy Turkish Infants||Sanofi|Yes|Completed|July 2006|February 2008|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|310|||Both|50 Days|71 Days|Accepts Healthy Volunteers|||September 2014|September 4, 2014|April 13, 2006||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT00315055||183305|
NCT00346008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBCI-03-033-CM|Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members|Genetic Epidemiologic Studies of Melanoma in Iceland||National Cancer Institute (NCI)||Completed|October 2005|February 2009|Actual|December 2008|Actual|N/A|Observational|N/A|||Anticipated|2500|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2008|May 29, 2013|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00346008||181008|
NCT00346294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050207|An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-Injector in Subjects With Rheumatoid Arthritis|An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-Injector in Subjects With Rheumatoid Arthritis||Amgen||Completed|January 2006|July 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||February 2009|February 19, 2009|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00346294||180987|
NCT00346580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1254-03|The Effects of HIV Protease Inhibitors in Severe Sepsis|The Effects of HIV Protease Inhibitors in Severe Sepsis||Mayo Clinic||Completed|June 2003|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346580||180966|
NCT00315497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5502|Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis|Longitudinal Protocol for Giant Cell Arteritis||University of Pennsylvania|Yes|Recruiting|April 2006|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood (serum and plasma), urine, and DNA|Both|50 Years|N/A|No|Non-Probability Sample|Adults with giant cell arteritis. Enrollment will be sequential and participants will have        disease in various stages and of different duration.|September 2015|September 4, 2015|April 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00315497||183271|
NCT00332215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511M77511|A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.|Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study.||University of Minnesota - Clinical and Translational Science Institute||Terminated|February 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||November 2008|November 26, 2008|May 30, 2006|||Dr. Milla has left University of Minnesota. The study is no longer being conducted at this    site.|||https://clinicaltrials.gov/show/NCT00332215||182020|
NCT00332228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5004-R|Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence|Study Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence||New York State Psychiatric Institute|Yes|Completed|June 2002|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|125|||Both|18 Years|60 Years|No|||October 2012|October 25, 2012|May 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00332228||182019|
NCT00333229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GDE13|A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss|Influence of Zoledronic Acid on Bone Mineral Density and Bone Ultrasonometry in Premenopausal Women With Hormone Receptor Negative Breast Cancer and Adjuvant Chemotherapeutic Treatment||Novartis||Terminated|March 2006|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Female|18 Years|N/A|No|||November 2014|November 17, 2014|May 31, 2006||No|Due to rare patient population, planned number of patients could not be recruited in a    reasonable timeframe. Recruitment was stopped prematurely.|No|November 17, 2014|https://clinicaltrials.gov/show/NCT00333229||181947|
NCT00332618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laboratoires CARILENE|Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia|Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia||Laboratoires CARILENE||Completed|September 2003|April 2004||||Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||74|||Both|18 Years|N/A|No|||March 2003|June 6, 2006|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00332618||181994|
NCT00347373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC2166|Effect of Conjugated Linoleic Acid Supplement on Body Composition|Conjugated Linoleic Acid and Body Fat Mass in Obese Humans||University of North Carolina, Chapel Hill||Completed|August 2004|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2006|June 30, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347373||180905|
NCT00347724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B00.CT3.014.TRA P03|A Study Comparing the Effectiveness and Safety of Extended-release Tramadol Versus Placebo in the Treatment of Chronic Low Back Pain|Double-blind, Randomized, Placebo-controlled, Parallel Group Comparison of the Efficacy and Safety of Extended Release Tramadol (Tramadol ER) 300 mg and 200 mg to Placebo in the Treatment of Chronic Low Back Pain||Valeant Pharmaceuticals International, Inc.||Completed|November 2000|November 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|80 Years|No|||June 2012|June 20, 2012|July 2, 2006||||||https://clinicaltrials.gov/show/NCT00347724||180879|
NCT00348309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA102672|Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease|A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.|REFLECT-2|GlaxoSmithKline|Yes|Completed|July 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1496|||Both|50 Years|90 Years|No|||July 2013|August 8, 2013|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00348309||180834|
NCT00348335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32,133|Efficacy of Topical Cyclosporin for Ocular Rosacea|Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea||Ophthalmic Consultants of Long Island|Yes|Completed|June 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00348335||180832|
NCT00348933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5204|Dietary Supplements for the Treatment of Angelman Syndrome|Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome||University of California, San Diego|Yes|Completed|July 2006|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|N/A|5 Years|No|||September 2012|September 21, 2012|July 3, 2006||No||No|June 16, 2011|https://clinicaltrials.gov/show/NCT00348933||180786|
NCT00348257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEORTC-HR-001|Safety and Efficacy of Using LEORTEC-300 System For Hair Removal Treatment|Safety and Efficacy of Using LEORTEC-300 System For Hair Removal Treatment||Leortec Medical Systems Ltd|Yes|Completed|July 2006|September 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|July 2, 2006||||No||https://clinicaltrials.gov/show/NCT00348257||180838|
NCT00348608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXV302|Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast–Enhanced CT Angiography of Arteries of the Heart|||GE Healthcare||Completed|June 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||540|||Both|18 Years|N/A|No|||June 2007|June 28, 2007|June 30, 2006||||||https://clinicaltrials.gov/show/NCT00348608||180811|
NCT00348881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL201|Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants|Large Scale Safety and Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix HepB/Hib™, Both Given Concomitantly With OPV at 6, 10, and 14 Weeks of Age in Healthy Filipino Infants||Sanofi|Yes|Completed|June 2006|June 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2133|||Both|42 Days|50 Days|Accepts Healthy Volunteers|||August 2013|August 15, 2013|July 5, 2006||No||No|June 10, 2013|https://clinicaltrials.gov/show/NCT00348881||180790|
NCT00348894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061031|[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.|A Phase 2b Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Chronic Painful Diabetic Peripheral Neuropathy (DPN).||Pfizer|No|Terminated|July 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|July 4, 2006|Yes|Yes|- Study was terminated due to insufficient clinical efficacy observed in previous studies    conducted in postherpetic neuralgia.|No||https://clinicaltrials.gov/show/NCT00348894||180789|
NCT00349167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-1001|PR-104 in Treating Patients With Advanced Solid Tumors|A Phase I, Multi-Center, Open Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR-104 Given Every 3 Weeks in Patients With Solid Tumors||Proacta, Incorporated|No|Completed|December 2005|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|July 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00349167||180769|
NCT00345202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2004.02.LP|Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects|Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects.||Regional Hospital Holstebro||Completed|September 2004|February 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind||||20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 14, 2008|June 24, 2006||||No||https://clinicaltrials.gov/show/NCT00345202||181068|
NCT00345215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|med.res.hos.2006.cc.01|The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Healthy Humans.|The Effect of High and Low Sodium Intake on Aquaporin-2 in Healthy Humans, During Basal Conditions and After Hypertonic Saline Infusion.||Regional Hospital Holstebro|No|Completed|May 2006|May 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00345215||181067|
NCT00345475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01326|UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)|A Prospective Study Of Pregnancies Exposed to UCB Antiepileptic Drugs to Determine if There is a Potential Increase in the Risk of Major Birth Defects||UCB Pharma|Yes|Active, not recruiting|December 2004|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|516|||Female|N/A|N/A|No|Non-Probability Sample|See Inclusion Criteria        - Women who have been diagnosed with Epilepsy and continued their UCB AED medication while        pregnant|December 2015|December 22, 2015|June 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00345475||181048|
NCT00315068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRD-03-I-03|Usefulness of Markers to Predict Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation|The Value of Amino-Terminal Brain Natriuretic Peptide and C-Reactive Protein Serum Levels for Predicting Recurrence of Atrial Fibrillation and/or Atrial Flutter After Radiofrequency Catheter Ablation||University Hospital, Geneva||Active, not recruiting|April 2004|August 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||180|||Both|18 Years|80 Years|No|||April 2007|April 19, 2007|April 13, 2006||||No||https://clinicaltrials.gov/show/NCT00315068||183304|
NCT00346320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR25|Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) For Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC)||Canadian Cancer Trials Group|Yes|Completed|April 2006|August 2014|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||August 2014|October 19, 2015|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00346320||180986|
NCT00315549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6134|TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults|Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis||Sanofi||Terminated|February 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|233|||Both|13 Years|N/A|No|||April 2009|April 2, 2009|April 14, 2006|||Pediatric development program terminated by sponsor|No||https://clinicaltrials.gov/show/NCT00315549||183267|
NCT00315510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QPhT05_131005-Rosuvastatine|Rosuvastatin and Ischemia Reperfusion|Does Rosuvastatin Reduce Ischemia/Reperfusion Injury in Humans In-Vivo? A Randomized Double Blind Placebo Controlled Trial||Radboud University||Completed|April 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 22, 2008|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00315510||183270|
NCT00315523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00415|Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen|Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEC.||UCB Pharma||Completed|July 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||403|||Both|18 Years|N/A||||May 2012|December 13, 2013|April 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00315523||183269|
NCT00331851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1697|Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.|LEAD-5|Novo Nordisk A/S|No|Completed|May 2006|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|584|||Both|18 Years|80 Years|No|||November 2014|November 17, 2014|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331851||182046|
NCT00332956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rF1V-02(a)|Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers|A Phase 2 (a), Dose-Blinded, Block-Randomized, Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers||DynPort Vaccine Company LLC, A CSC Company|Yes|Completed|May 2006|October 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|400|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00332956||181968|
NCT00342927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901117|Family Investigation of Nephropathy and Diabetes (F.I.N.D.)|Family Investigation of Nephropathy and Diabetes (F.I.N.D.)||National Institutes of Health Clinical Center (CC)||Recruiting|March 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 25, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342927||181234|
NCT00333593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2003/01440|Super High-Flux - High Volume Dialysis in Sepsis-Induced Acute Renal Failure|Randomized, Cross Over Study Comparing Standard Hemodialysis to Hemodialysis With a Novel Polyamide Membrane (P2SH) in Patients With Sepsis and Acute Renal Failure||Austin Health||Completed|June 2006|November 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||December 2006|December 26, 2006|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00333593||181919|
NCT00333606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III UV 12/06|Acupuncture and Auditory Evoked Potentials|Effects of Acupuncture on the Auditory Evoked Potentials: a Randomized Volunteer Crossover Study||University Medicine Greifswald||Recruiting|January 2005|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||10|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2006|June 3, 2006|June 3, 2006||||No||https://clinicaltrials.gov/show/NCT00333606||181918|
NCT00354250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02928|Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Advanced Renal Cell Cancer||National Cancer Institute (NCI)||Completed|May 2006|||February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|N/A|No|||June 2013|June 4, 2013|July 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00354250||180387|
NCT00354263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P001|Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen|IMP321 Phase I Study of Four Increasing Doses (3, 10, 30 and 100 µg) of a New Immunostimulatory Factor (IMP321) Given Alone or as an Adjuvant to a Reference Flu Antigen in Healthy Young Male Volunteers||Immutep S.A.|No|Completed|April 2005|February 2006|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|60|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2008|April 23, 2008|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354263||180386|
NCT00358254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILS-04-262|Noninvasive Skin Spectroscopy for Diabetes Screening|Noninvasive Skin Spectroscopy for Diabetes Screening||InLight Solutions||Completed|October 2004|December 2007|Actual|||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Those at risk for diabetes|November 2007|July 21, 2010|July 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00358254||180088|
NCT00358566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX115.1.1-302|GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer|"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.||Pharmexa A/S|Yes|Terminated|June 2006|August 2008|Anticipated|August 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|75 Years|No|||May 2008|May 16, 2008|July 14, 2006|Yes|Yes|Preliminary data showed no survival benefit in the GV1001 group compared to the gemcitabine    group.|Yes||https://clinicaltrials.gov/show/NCT00358566||180064|
NCT00354237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS2005/0130|DARE: Diabetes in cArdiac REhabilitation|Effect of Strict Glycemic Control on Improvement of Exercise Capacities (VO2 Peak, Peak Workload After Cardiac Rehabilitation, in Patients With Type 2 Diabetes Mellitus With Coronary Artery Disease.||Centre Hospitalier Universitaire Dijon|Yes|Completed|July 2005|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|95 Years|No|||November 2014|November 17, 2014|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354237||180388|
NCT00367445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171094|A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus|A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents||Pfizer||Completed|September 2006|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||January 2008|January 25, 2008|August 21, 2006||||||https://clinicaltrials.gov/show/NCT00367445||179400|
NCT00367458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060197|A Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Medications With the Specific Aims of Studying the Effects of Atorvastatin on HIV Viral Load and Immune Activation Markers|A Randomized Placebo Controlled Trial of Atorvastatin in HIV Positive Patients Not on Antiretroviral Medications With the Specific Aims of Studying the Effects of Atorvastatin on HIV Viral Load and Immune Activation Markers||National Institutes of Health Clinical Center (CC)||Completed|July 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|N/A|No|||April 2009|November 25, 2009|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367458||179399|
NCT00367471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF103892|Combination Of Lapatinib With Carboplatin, Paclitaxel and Trastuzumab In Metastatic Breast Cancer|A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, and Herceptin in Patients With Metastatic Breast Cancer||Novartis|No|Active, not recruiting|December 2006|June 2016|Anticipated|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|August 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00367471||179398|
NCT00367484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24810|Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis|Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis||Merck KGaA||Completed|May 2004|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|460|||Both|18 Years|60 Years|No|||January 2014|January 26, 2014|August 21, 2006||No||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00367484||179397|
NCT00355680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PR1210511|Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy|Comparative Study of Indigenous Green Laser With Already Available Green Laser in Proliferative Diabetic Retinopathy||Aurolab|No|Completed|December 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||February 2009|February 10, 2009|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00355680||180280|
NCT00355693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9812/A|Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients|Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol A) in Oral Surgery Patients B) in General Dentistry Patients C) in Colonoscopy Patients||University of Glasgow||Not yet recruiting|October 2006|February 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||April 2006|August 23, 2006|July 21, 2006||||No||https://clinicaltrials.gov/show/NCT00355693||180279|
NCT00356265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00000261|Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide|Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide||University of Michigan||Recruiting|July 2006|June 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2006|December 1, 2006|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356265||180235|
NCT00356278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024846|D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD|A Cognitive Enhancer May Facilitate Behavioral Exposure Therapy for Veterans With PTSD||Emory University|No|Completed|September 2006|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|156|||Both|21 Years|65 Years|No|||January 2016|January 6, 2016|July 24, 2006|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT00356278||180234|The study had a high dropout rate. 31 participants dropped out before the first treatment session. Although disheartening, the dropout rate is similar to rates in other studies with veterans and active duty personnel.
NCT00356252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNRCA1860|Biological Functions of Carotenoids in Humans|Functional Bioavailability of Carotenoids in Humans||Tufts University||Completed|April 2002|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||July 2008|July 23, 2008|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356252||180236|
NCT00316589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-011|Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients|A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl.||Bavarian Nordic|Yes|Completed|June 2006|October 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|581|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|April 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00316589||183187|
NCT00316602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-008|A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis|A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis||Bavarian Nordic|Yes|Completed|July 2006|April 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|632|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|April 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00316602||183186|
NCT00316043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOK_PNKU_01|Prevention of Renal Failure in Children With Urinary Tract Infections|Prevention of Renal Failure in Children With Urinary Tract Infections in General Practice: Current Clinical Management, Possibilities for Improvement and Potential Cost-Efficiency||Radboud University|No|Completed|May 2006|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|124|||Both|N/A|12 Years|No|||July 2007|July 30, 2007|April 14, 2006||||No||https://clinicaltrials.gov/show/NCT00316043||183229|
NCT00316576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-130|Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)|Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients||University Hospital, Caen||Terminated|May 2006|November 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients admitted to ICU fore more than 48 hours|January 2008|January 16, 2008|April 19, 2006|||The study was stopped on november 2006 after inclusion was fulfilled|No||https://clinicaltrials.gov/show/NCT00316576||183188|
NCT00316849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00642|Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I Study of CCI-779, and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|May 2006|||November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|April 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00316849||183167|
NCT00363870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108134|A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults|A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults||GlaxoSmithKline||Completed|September 2006|||December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||7632|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363870||179670|
NCT00364143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHL-PRT001|Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors|A Phase I Study of IHL-305 (Irinotecan Liposome Injection) in Patients With Advanced Solid Tumors||Yakult Honsha Co., LTD||Recruiting|September 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|August 11, 2006||||Yes||https://clinicaltrials.gov/show/NCT00364143||179649|
NCT00364403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03DK073335|A Low Glycemic Load Diet During Pregnancy in Overweight Women|Glycemic Load and Infant Birth Weight in Pregnant Overweight/Obese Women||Children's Hospital Boston|Yes|Completed|February 2007|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|25 Years|N/A|No|||August 2010|August 27, 2010|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364403||179630|
NCT00364663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950307|The Utility and Cost-Effectiveness Analysis of 18F-FDG PETin Staging Potential Operable Non-Small Cell Lung Cancer|The Utility and Cost-Effectiveness Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in Staging Potential Operable Non-Small Cell Lung Cancer||National Taiwan University Hospital||Recruiting|August 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|18 Years|90 Years|No|||August 2006|August 15, 2006|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00364663||179610|
NCT00365833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-2006|CEC/EPC and Cardiovascular Risk in Renal Transplant Recipients|Circulating Endothelial Cell and Endothelial Progenitor Cell Evaluation of Kidney Transplant Patients|CEC|University of Florida|No|Terminated|July 2006|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|80 Years|No|Non-Probability Sample|de novo renal transplant recipients|September 2011|September 28, 2011|August 17, 2006||No|difficulty obtaining required data|No||https://clinicaltrials.gov/show/NCT00365833||179523|
NCT00355173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB001-HMO-CTIL|Pilot Study to Assess the Efficacy and Safety of the Lubo Cervical Collar|Pilot Study to Assess the Efficacy and Safety of the Lubo Cervical Collar||Hadassah Medical Organization||Completed|May 2006|November 2010|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2010|May 11, 2011|July 20, 2006||||No||https://clinicaltrials.gov/show/NCT00355173||180319|
NCT00354497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000485428|Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men|Prostate Cancer Screening and Dietary HA Exposure in African-Americans: Phase II||National Cancer Institute (NCI)||Recruiting|March 2002|||||Phase 2|Interventional|Primary Purpose: Screening|1||Anticipated|800|||Male|50 Years|70 Years|Accepts Healthy Volunteers|||August 2008|September 19, 2013|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354497||180369|
NCT00354822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2005-000699-41|Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.|Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas.|Z0105|A.O. Ospedale Papa Giovanni XXIII|No|Terminated|August 2005|August 2009|Actual|August 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|No|||September 2009|September 17, 2009|July 19, 2006||No|Inability to recruit in time a sufficient number of patients|No||https://clinicaltrials.gov/show/NCT00354822||180345|
NCT00354835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST0531|Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma|Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)||Children's Oncology Group|Yes|Active, not recruiting|December 2006|||September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|481|||Both|N/A|49 Years|No|||February 2016|February 1, 2016|July 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00354835||180344|
NCT00355719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEVIATAZ|Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients|Clinical Pilot Trial to Evaluate the Influence of Nevirapine in Exposure to Atazanavir in Steady State Equilibrium in HIV-Infected Adult Patients.||Germans Trias i Pujol Hospital|No|Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||June 2009|June 16, 2009|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00355719||180277|
NCT00355147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAB 05-297|Adapting Tools to Implement Stroke Risk Management to Veterans|Adapting Tools to Implement Stroke Risk Management to Veterans|TOOLS|VA Office of Research and Development|No|Completed|January 2009|December 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|174|||Both|18 Years|N/A|No|||February 2014|April 6, 2015|July 18, 2006||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00355147||180321|Both our intervention and control groups experienced attrition during the study period but the rate between groups did not differ significantly.
NCT00355160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23218EP|Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting|Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting||Penn State University|No|Completed|July 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Pateints presenting to our clinic with a diagnosis of "sinusitis" by referring physicians        with facial pain and/or headache as key complaint, ut who have no clincal evidence of        sinusitis by CT scan or examination|May 2013|May 13, 2013|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00355160||180320|
NCT00355407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-420|Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation|A Pilot Study of Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation||Dana-Farber Cancer Institute||Completed|June 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||31|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00355407||180301|
NCT00355966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Chaudhuri|Comparison of Misoprostol and PGE2 Gel for Induction of Labour in Women With Premature Rupture of Membranes at Term|Comparison of Misorostol & PGE2 Gel for Immediate Induction of Labour for Premature Ropture of Membranes at Term||Nilratan Sircar Medical College|Yes|Completed|August 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Female|N/A|N/A|No|||November 2008|March 24, 2010|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00355966||180258|
NCT00356525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9934|Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor|Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs. Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy||Eli Lilly and Company|No|Terminated|September 2006|April 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|N/A|No|||August 2010|August 9, 2010|July 24, 2006|Yes|Yes|Stopped early due to low enrollment|No|June 8, 2009|https://clinicaltrials.gov/show/NCT00356525||180216|The trial terminated early due to slow enrollment. Secondary outcomes were not analyzed due to insufficient data. Original results reported were interim analyses. Results have now been updated with final data.
NCT00356590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021623|Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012|Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012||Amgen||Completed|December 1998|April 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|468|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|July 24, 2006||||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00356590||180213|
NCT00356603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STA106711|Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan|Clinical Evaluation of Sumatriptan Succinate Injection Kit Product in Patients With Migraine or Cluster Headache||GlaxoSmithKline|No|Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|65 Years|No|||May 2013|May 13, 2013|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356603||180212|
NCT00357123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28-08 ROAS|Effect of Rosuvastatin in Abdominal Sepsis|Use of Rosuvastatin in Integral Management of Abdominal Sepsis||Universidad Autonoma de San Luis Potosí|Yes|Recruiting|August 2006|September 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||September 2010|February 18, 2011|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357123||180174|
NCT00316875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05B5|Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer|A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer||Northwestern University|Yes|Completed|May 2006|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|April 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00316875||183165|
NCT00316316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5124|Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder|Cognitive Behavioral Therapy Plus Motivational Interviewing for Obsessive Compulsive Disorder||New York State Psychiatric Institute|No|Completed|March 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||March 2012|March 15, 2012|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316316||183208|
NCT00363623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06 009|Comparison of Contact Lens Maintenance Systems for Silicone Hydrogel Lenses|||University of Melbourne||Completed|August 2006|December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2007|March 20, 2008|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363623||179689|
NCT00363636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-NH-301|A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)|A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma||Biogen|Yes|Terminated|September 2006|April 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|N/A|No|||March 2011|September 17, 2015|August 11, 2006|Yes|Yes|Enrollment challenges due to changes in standards of care resulted in premature termination.    No safety or efficacy events factored into this action.|No||https://clinicaltrials.gov/show/NCT00363636||179688|
NCT00364416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005212|Longitudinal Registry for Advanced Heart Failure Patients|ADHERE (Acute Decompensated Heart Failure National Registry) Longitudinal Module-Registry of Advanced Heart Failure Patients at High Risk for Rehospitalization||Scios, Inc.||Completed|October 2002|April 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1466|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with HF who present with severe symptoms limiting their physical activities at        rest|April 2010|April 26, 2010|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364416||179629|
NCT00365313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7NB study|Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib|A Phase 3 Double Blinded, Randomized, Placebo Controlled Trial of Proton Pump Inhibitor for the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor||Chinese University of Hong Kong||Completed|August 2002|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||273|||Both|18 Years|95 Years|No|||October 2006|October 26, 2006|August 16, 2006||||No||https://clinicaltrials.gov/show/NCT00365313||179562|
NCT00357409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020124|GABA Levels in the Brains of Blind People|GABA Levels in the Occipital Cortex of Blind Human Subjects||National Institutes of Health Clinical Center (CC)||Completed|February 2002|March 2008||||N/A|Observational|N/A||||39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|March 7, 2008|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357409||180153|
NCT00357643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AG010353|Effect of Calcium and Vitamin D on Bone Loss From the Hip|Effect of Calcium and Vitamin D on Bone Loss From the Hip||Tufts University||Completed|October 1992|February 1996||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||450|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2005|July 26, 2006|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357643||180135|
NCT00357656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060402|Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery|Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusion (CI) Versus Intermittent Bolus Infusion (BI) in Subjects With Severe or Moderately Severe Hemophilia A Undergoing Major Orthopedic Surgery||Baxalta US Inc.|Yes|Completed|June 2006|December 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|July 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357656||180134|
NCT00354016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V44P10S|Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects|A Phase III, Multicenter, Uncontrolled, Open-Label Study to Demonstrate Safety and Immunogenicity of a Commercially Available Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 When Administered to Non-Elderly Adult and Elderly Subjects||Novartis||Completed|July 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 12, 2007|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354016||180404|
NCT00355433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMC 11H06|Comparison of Body and Room Temperature Saline in Urodynamics|Comparison of Urodynamic Volume Measurements Using Room and Body Temperature Saline||Tripler Army Medical Center||Recruiting|July 2006|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2006|July 20, 2006|July 20, 2006||||No||https://clinicaltrials.gov/show/NCT00355433||180299|
NCT00354900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0540|Phase I Study of Aprotinin in Advanced Breast Cancer|Phase I Study of Aprotinin in Advanced Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Terminated|July 2006|April 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Female|18 Years|90 Years|No|||August 2009|August 3, 2009|July 18, 2006||No|The FDA changed the labeling for this agent, and we felt we could not offer it to patients on    a non-surgical study.|No||https://clinicaltrials.gov/show/NCT00354900||180340|
NCT00354913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006768|Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma|A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma||Duke University|Yes|Completed|May 2005|October 2010|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2012|January 14, 2013|July 19, 2006|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00354913||180339|
NCT00355186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWISS-AMI|SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI)|SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI)||University of Zurich||Completed|August 2006|November 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|90 Years|No|||November 2012|November 8, 2012|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355186||180318|
NCT00355446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0106-24|Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.|Bioavailabilty of Bimatoprost Ophthalmic Solution in Human Aqueous.||Indiana University||Completed|July 2001|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||October 2007|October 16, 2007|July 20, 2006||||No||https://clinicaltrials.gov/show/NCT00355446||180298|
NCT00355420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLD01-HMO-CTIL|Evaluation of the Change in Length of the Leg in Children After Treatment of Femur Fractures.|Evaluation of the Change in Length of the Femur and Tibia in Children After Treatment of Femur Fractures With External Fixators, Plaster of Paris or Internal Fixation||Hadassah Medical Organization||Withdrawn|October 2006|||||Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|children that sufferinf from LLD|March 2013|March 3, 2014|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355420||180300|
NCT00355979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.084|Comparative Study of Intragastric Balloon and Pharmacotherapy for Non-Morbid Obesity|Randomized Trial of Intragastric Balloon and Pharmacotherapy for Non-Morbid Obesity||Chinese University of Hong Kong||Recruiting|March 2006|March 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2006|October 17, 2006|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00355979||180257|
NCT00355992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA-0106-001.04|The Ischemia Modified Albumin In Diagnosing Ischemic New Events|The Ischemia Modified Albumin In Diagnosing Ischemic New Events (IMAGINE Study).|IMAgine|Inverness Medical Innovations||Terminated|September 2006|December 2007|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1250|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who present in the emergency department at the listed institutions with suspected        ischemic signs and or symptoms (chest pain) will be eligible for participation in the        study as long as they meet inclusion and exclusion criteria and sign an informed consent.|May 2009|May 11, 2009|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00355992||180256|
NCT00355706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 5|Effectiveness of Thoracic Facet Joint Nerve Blocks|Effectiveness of Thoracic Facet Joint Nerve Blocks: A Randomized, Prospective, Double-Blind Controlled Evaluation||Pain Management Center of Paducah|Yes|Completed|August 2003|July 2011|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|July 24, 2006||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00355706||180278|
NCT00355953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002067398|Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women|||University of Messina||Completed|January 2003|June 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Female|45 Years|70 Years|No|||April 2008|April 18, 2008|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00355953||180259|
NCT00356018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3D20-2006|Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:|Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy: A Randomized, Parallel, Prospectively-Controlled Outpatient Comparison||Orlando Health, Inc.|No|Completed|July 2006|February 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective||1|Actual|5|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The population includes both patients whose seizures are relatively well controlled on        their present conventional, enteric-coated twice-daily or three-times daily Divalproex        sodium regimen.|May 2012|May 31, 2012|July 21, 2006||||No||https://clinicaltrials.gov/show/NCT00356018||180254|
NCT00356291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH075644|Improving HIV Prevention Skills in People With Serious Mental Illnesses|HIV Prevention for the Mentally Ill: Motivation-Skills||Boston Medical Center||Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|19 Years|N/A|No|||July 2013|July 23, 2013|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00356291||180233|
NCT00356616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TETRIZ|Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients|Open-Label, Single-Centre, Randomised Pilot Study to Evaluate Immunovirological and Clinical Evolution of a Combination With Nucleoside Analogues/Nucleotides (Trizivir +Tenofovir) in Multiresistant Patients With Virological Failure||Germans Trias i Pujol Hospital|No|Terminated|September 2005|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||November 2007|January 25, 2008|July 24, 2006||No|terminated|No||https://clinicaltrials.gov/show/NCT00356616||180211|
NCT00356629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOHP06-PD Air Exhalé|Development of a Noninvasive Method of Evaluation of Pulmonary Inflammation in the Condensates of Exhaled Air|Development of a Noninvasive Method of Evaluation of the Pulmonary Inflammation in the Condensates of Exhaled Air||University Hospital, Tours|No|Terminated|July 2006|July 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ubjects suffering from CF, COPD, asthma and tobacco exposure|November 2008|November 13, 2008|July 25, 2006||No|Technical problem|No||https://clinicaltrials.gov/show/NCT00356629||180210|
NCT00356551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 UDI SPO9588|Family Spirit Study|Family Strengthening in Native Communities Project||Johns Hopkins University||Completed|May 2002|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||320|||Both|12 Years|24 Years|Accepts Healthy Volunteers|||June 2006|July 25, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356551||180215|
NCT00356564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106744|Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib|Multicentre Study to Assess Persistence of Antibodies Against Hepatitis B & Immune Response to a Hepatitis B Challenge Dose in Healthy Children 7 to 9 Yrs Old Previously Vaccinated With 4 Doses of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine||GlaxoSmithKline||Completed|July 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||350|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356564||180214|
NCT00313885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT5400|Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia|Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-center, Randomized, Double-blind, Placebo-controlled Study.||Sanofi||Completed|April 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|205|||Both|18 Years|64 Years|No|||November 2010|November 29, 2010|April 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00313885||183395|
NCT00316862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-80302|Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery|A Phase II Trial of Preoperative Irinotecan, Cisplatin and Radiation in Esophageal Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|February 2006|||December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|April 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00316862||183166|
NCT00364156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801851|Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation|Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation||University of Pennsylvania|No|Completed|June 2004|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|568|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 1, 2010|August 14, 2006|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00364156||179648|
NCT00364962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561703040|Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients|||National Taiwan University Hospital||Recruiting|April 2006|June 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||20|||Both|20 Years|75 Years|No|||August 2006|August 15, 2006|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00364962||179587|
NCT00357968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10635|Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting|Protocol H7T-MC-TABL(a) PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation (PRINCIPLE) - TIMI 44|PRINCIPLE|Eli Lilly and Company|Yes|Completed|August 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||August 2010|August 25, 2010|July 26, 2006|No|Yes||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00357968||180110|
NCT00357981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10857-25721-01|Continuous Use of the Contraceptive Patch and the Personal Economic Impact.|Patient Experiences Using Evra for Management of Menstrual Related Symptoms.||University of California, San Francisco||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|July 26, 2006|Yes|Yes|Both sponsor and UCSF decided this study was not clinical relevant at this time|No||https://clinicaltrials.gov/show/NCT00357981||180109|
NCT00358267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603008446|Randomized Trial Comparing Partial Resection of Inferior Turbinate(PRIT) and Radiofrequency Ablation(RFA) for Inferior Turbinate Reduction|A Randomized Trial Comparing Two Surgical Techniques for Inferior Turbinate Reduction||Weill Medical College of Cornell University||Withdrawn|July 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|July 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00358267||180087|
NCT00358579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQCA01|Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest|A Randomised, Double-blinded Multi-centre Trial Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest at the Emergency Department. (Preadmission Intravenous Vasopressin, Adrenaline Outcome Trial: PIVOT vII)|PIVOT|Singapore General Hospital|Yes|Completed|March 2006|January 2010|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|727|||Both|17 Years|N/A|No|||July 2011|July 12, 2011|July 30, 2006||No||No|August 3, 2010|https://clinicaltrials.gov/show/NCT00358579||180063|As the study was conducted over a relatively long period, results may be affected by secular trends.Variations in post-resuscitation care can affect survival to discharge status and variations between institutions are difficult to account for.
NCT00354861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P002|A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321|A Phase I, Single-Blind Study to Determine the Safety, Tolerability and Pharmacodynamic Profiles of a Hepatitis B Antigen Combined With IMP321 Versus the Hepatitis B Antigen Alone and a Reference Vaccine in Healthy Young Male Volunteers||Immutep S.A.|No|Completed|May 2005|February 2006|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354861||180343|
NCT00354536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP106073|In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus|A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injections of GSK 716155 in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|February 2006|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||February 2011|May 31, 2012|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354536||180366|
NCT00354926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AME 06.133v.A|Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma|Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY 2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin's Lymphoma||Applied Molecular Evolution|No|Completed|July 2006|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||January 2013|January 5, 2016|July 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00354926||180338|
NCT00354939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4049|Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement|10-week, Open, National, Multicenter Clinical Trial to Evaluate the Safety of Insulin Glargine in Type 2 Diabetes Mellitus Patients, on Intensified Conventional Therapy (ICT)|SAFIR|Sanofi||Completed|October 2003|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||480|||Both|18 Years|75 Years|No|||August 2010|August 30, 2010|July 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00354939||180337|
NCT00355199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT: 2005-00700-14|Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.|Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas||Gruppo Italiano Terapie Innovative nei Linfomi|No|Recruiting|May 2005|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||June 2011|June 22, 2011|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355199||180317|
NCT00355472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-0501|Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL|Phase I Dose Escalation Study of KW-0761 in Patients With Relapsed Adult T-Cell Lymphoma (ATL) and Peripheral T-Cell Lymphoma (PTCL)||Kyowa Hakko Kirin Company, Limited|No|Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|69 Years|No|||October 2012|October 17, 2012|July 20, 2006||No||No|August 7, 2012|https://clinicaltrials.gov/show/NCT00355472||180296|
NCT00355459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082005-026|A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease|A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease||University of Texas Southwestern Medical Center||Terminated|August 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||May 2007|March 21, 2011|July 20, 2006|||The PI has elected to terminate study at this time|No||https://clinicaltrials.gov/show/NCT00355459||180297|
NCT00356005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICDDRB #2006-024|Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh|Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open Label Randomized Controlled Trial||Medical University of Vienna||Completed|August 2006|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Both|8 Years|65 Years|No|||October 2012|October 31, 2012|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00356005||180255|
NCT00356304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH074860|Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression|Antidepressant Adherence Among Hispanics: A Motivational Interviewing Approach||Rutgers, The State University of New Jersey|No|Completed|April 2006|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||April 2014|April 10, 2014|July 21, 2006||No||No|February 24, 2014|https://clinicaltrials.gov/show/NCT00356304||180232|
NCT00356889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00115|Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors|A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors||National Cancer Institute (NCI)|Yes|Completed|May 2006|June 2010|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||April 2013|May 12, 2014|July 26, 2006|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00356889||180192|
NCT00356902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT732656|Comparison of Different Oxygen Delivery Strategies During Resuscitation of Babies|Effect of Titrating Oxygen Concentration During Resuscitation of the Newborn on Achieving Normoxemia||University of Calgary||Completed|July 2005|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|215|||Both|23 Weeks|32 Weeks|No|||September 2007|September 14, 2007|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356902||180191|
NCT00313586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01077|Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia|A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2006|April 2016|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||January 2016|February 18, 2016|April 11, 2006|Yes|Yes||No|November 18, 2014|https://clinicaltrials.gov/show/NCT00313586||183415|
NCT00317122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|759346/007|Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth|Demonstrate Non-inferiority of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ With Respect to Anti-HBs Immune Response, When Given to Healthy Infants at 6,10 & 14 Wks Age, After a Birth Dose of Hepatitis B Vaccine||GlaxoSmithKline||Completed|October 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||192|||Both|N/A|10 Days|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 23, 2006||||No||https://clinicaltrials.gov/show/NCT00317122||183146|
NCT00312910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc-05DP2907-CTIL|Probiotics for the Prevention of Major Complications of Cirrhosis|Probiotics for the Prevention of Major Complications of Cirrhosis||Meir Medical Center||Completed|April 2005|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|50|||Both|N/A|N/A|No|||April 2007|May 21, 2008|April 9, 2006||||No||https://clinicaltrials.gov/show/NCT00312910||183467|
NCT00364676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS501|Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Phase 1 Study of Vinorelbine Liposomes Injection (VLI) for Treatment in Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease||Spectrum Pharmaceuticals, Inc||Completed|July 2006|August 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|August 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00364676||179609|
NCT00356798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PanFlu-1001|Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects|The Phase-I Clinical Trial Protocol for the Pandemic Inactivated Influenza Vaccine||Sinovac Biotech Co., Ltd||Completed|December 2005|April 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2007|November 8, 2007|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356798||180198|
NCT00357071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030122|Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases|Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2003|||||N/A|Observational|N/A|||Actual|213|||Both|6 Years|N/A|No|||August 2015|August 6, 2015|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357071||180178|
NCT00354276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000492755|VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia||National Cancer Institute (NCI)||Active, not recruiting|May 2006|||December 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|60 Years|N/A|No|||May 2009|January 9, 2014|July 19, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00354276||180385|
NCT00354510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPD103280|Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis|Randomised, Double-blind, Placebo-controlled Study of Topical GW842470X Formulation in Adults With Moderate Atopic Dermatitis||GlaxoSmithKline||Completed|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||190|||Both|18 Years|65 Years|No|||March 2011|May 31, 2012|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354510||180368|
NCT00354523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0475|Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma|A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma||M.D. Anderson Cancer Center|No|Terminated|December 2004|August 2013|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|16 Years|N/A|No|||December 2014|December 16, 2014|July 18, 2006||No|Study closed following Phase I portion, insufficient activity to continue to Phase II.|No||https://clinicaltrials.gov/show/NCT00354523||180367|
NCT00354874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C101762|Investigation Of A New Medication (GW642444) In Asthmatic Patients|A Multi-centre, Randomised, Double-blind, Placebo Controlled, Dose Ascending, Four Way Crossover Study to Examine Efficacy (FEV1), Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Doses of GW642444||GlaxoSmithKline||Completed|January 2005|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|28|||Both|18 Years|70 Years|No|||February 2011|March 15, 2012|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354874||180342|
NCT00354887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0827|Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater|A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater||M.D. Anderson Cancer Center|No|Completed|November 2004|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|July 18, 2006||No||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00354887||180341|
NCT00354302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA27B|Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27|The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer||Canadian Cancer Trials Group|Yes|Completed|April 2006|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|497|||Female|45 Years|N/A|No|||January 2012|January 9, 2012|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354302||180384|
NCT00354315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCHUQ-5-05-12-03|DÉCISION+, a Continuous Professional Development Program to Improve Optimal Drug Prescription : a Feasibility Study|DÉCISION+, a Continuous Professional Development Program to Improve Optimal Drug Prescription : a Feasibility Study||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|September 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|642|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2008|February 13, 2009|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354315||180383|
NCT00354549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 19/05|Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC|Bevacizumab and Erlotinib First-Line Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (Stage IIIB/IV) Followed by Platinum-Based Chemotherapy at Disease Progression. A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|January 2006|September 2010|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354549||180365|
NCT00354562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-782|A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer|A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer||Abbott|No|Terminated|February 2007|||February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||September 2010|January 5, 2011|July 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00354562||180364|
NCT00355758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-3561|UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling|Prostate Cancer Detection by Serum Proteomic Profiling||University of California, Irvine|No|Terminated|April 2005|June 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Whole blood is collected from subjects. The whole blood is spun down by centrifugation and      only serum is retained and stored.|Male|50 Years|N/A|No|Non-Probability Sample|Those who have prostate cancer and are scheduled for robotic prostatectomy to treat the        disease and are seen at the Urology Clinic of the University of California, Irvine.|August 2010|August 31, 2010|July 24, 2006||No|Lack of personnel|No||https://clinicaltrials.gov/show/NCT00355758||180274|
NCT00356044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEICG 2004/063|Arterial Access for Coronary Intervention in Myocardial Infarction|Femoral Versus Radial Access for Coronary Intervention in the Acute Phase of ST-Elevation Myocardial Infarction||Hospital Juan Canalejo|No|Completed|May 2004|December 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|80 Years|No|||July 2007|July 10, 2007|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356044||180252|
NCT00355745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBUS -RA-001|Safety and Efficacy of Using CBUS™ System for Ultrasound Breast Imaging Designed for Breast Tumor Diagnosis|||Helix Medical Systems||Terminated|July 2006|July 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||May 2008|June 8, 2011|July 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00355745||180275|
NCT00355732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients|Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients; Randomized Prospective Study||Dr. Josip Benčević General Hospital||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|October 25, 2006|July 23, 2006||||No||https://clinicaltrials.gov/show/NCT00355732||180276|
NCT00356668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606-051|Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure|Observational, Cross-over Study of the Positive Distending Pressure Generated by Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure||Children's Hospitals and Clinics of Minnesota||Completed|July 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||July 2015|July 13, 2015|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356668||180207|
NCT00357240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-288|Drug Interaction Study With Proton Pump Inhibitor|Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Omeprazole 20 mg on the Pharmacokinetics of Atazanavir Administered With Ritonavir in Healthy Subjects||Bristol-Myers Squibb||Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|8|||56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|April 7, 2011|July 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357240||180166|
NCT00357253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000484429|Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma|A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas and High Grade Gliomas||Pediatric Brain Tumor Consortium|Yes|Completed|January 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|3 Years|21 Years|No|||January 2013|January 8, 2013|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357253||180165|
NCT00356915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT0300-302-INT|Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.|A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail.||GlaxoSmithKline|No|Completed|July 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|1381|||Both|16 Years|75 Years|No|||April 2015|May 18, 2015|July 25, 2006|Yes|Yes||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00356915||180190|
NCT00357214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR052322|Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults|Effect of Potassium Bicarbonate on Bone and Muscle||Tufts University|No|Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|171|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 8, 2011|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357214||180168|
NCT00313326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-005|Comparative Study of Duration of Respiratory Weaning Between Adaptive Support Ventilation and Succession of Controlled Ventilation Then Spontaneous Ventilation for Patients After Surgery|Comparative Study of Duration of Respiratory Weaning Between Adaptive Support Ventilation and Succession of Controlled Ventilation Then Spontaneous Ventilation for Patients After Surgery||University Hospital, Clermont-Ferrand||Terminated|February 2005|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||October 2008|October 7, 2008|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313326||183435|
NCT00313339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0076-2006|Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction|AMORCYTE MYOCARDIAL REPAIR STUDY- A Phase I Trial of Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction. (AMRS)|AMR-1|Emory University|Yes|Completed|March 2006|March 2013|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||November 2013|November 15, 2013|April 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00313339||183434|
NCT00313924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oab.CTIL|Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome|The Applicability of the OAB Assessment Tool for Evaluation of Treatment Efficacy of Overactive Bladder.||Rambam Health Care Campus||Recruiting|February 2006|March 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|20 Years|80 Years|No|||February 2007|February 19, 2007|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00313924||183392|
NCT00314236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG-CIP01-P|Trial Comparing BST-CarGel and Microfracture in Repair of Articular Cartilage Lesions in the Knee|A Randomized, Comparative Multicenter Clinical Trial Evaluating BST-CarGel™ and Microfracture in Repair of Focal Articular Cartilage Lesions on the Femoral Condyle||Piramal Healthcare Canada Ltd|No|Completed|December 2005|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|55 Years|No|||December 2015|December 17, 2015|April 11, 2006||No||No|November 5, 2015|https://clinicaltrials.gov/show/NCT00314236||183368|
NCT00356811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF105764|Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer|An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients||GlaxoSmithKline|No|Completed|May 2006|December 2013|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Female|18 Years|N/A|No|||May 2014|June 19, 2014|July 25, 2006||No||No|May 8, 2014|https://clinicaltrials.gov/show/NCT00356811||180197|
NCT00356824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AI062677-01|Relationship Between HIV and Malaria in Ugandan Children|Prospective Longitudinal Study of Interactions Between HIV and Malaria in Ugandan Children: A UCSF/Makerere University "Children With HIV and Malaria Project"||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2005|May 2010|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood samples|Both|1 Year|10 Years|No|Probability Sample|HIV-infected children in Ugana at risk for malaria infection|July 2010|July 30, 2010|July 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00356824||180196|
NCT00357097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRL106721|The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome|A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany||GlaxoSmithKline|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|240|||Both|18 Years|79 Years|No|||May 2011|May 31, 2012|July 25, 2006||||No|December 12, 2008|https://clinicaltrials.gov/show/NCT00357097||180176|
NCT00357422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2007-006|Comparison Study of Operation and PEIT for Small, Solitary Hepatocellular Carcinoma (HCC)|Prospective Randomized Trial of the Effective Therapy for Small, Solitary HCC Comparing Operation and Percutaneous Ethanol Injection Therapy||Seoul National University Hospital|Yes|Completed|October 2005|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|70 Years|No|||December 2013|December 2, 2013|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357422||180152|
NCT00357669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01187|Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht-Lundborg Disease||UCB Pharma|No|Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|16 Years|N/A|No|||May 2015|May 15, 2015|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00357669||180133|
NCT00357682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491649|A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia|A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia|AspECT|University of Oxford|Yes|Active, not recruiting|March 2005|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|2513|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357682||180132|
NCT00357708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03088|Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases|A Phase I Trial of SAHA (NSC 701852) and Decitabine (IND 50733, NSC 127716) in Patients With Relapsed, Refractory or Poor Prognosis Leukemia||National Cancer Institute (NCI)||Completed|June 2006|||October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357708||180130|
NCT00357721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-286|Atazanavir Twice Daily|Randomized, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics of Atazanavir Administered Twice-Daily in Health Subjects||Bristol-Myers Squibb||Completed|June 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3|||18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2011|April 5, 2011|July 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357721||180129|
NCT00358007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.195|Use of Cone Beam Kilovoltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer|Evaluation of Cone Beam Kilovoltage Imaging During Radiation Therapy for Tumors of the Head and Neck||Thomas Jefferson University|Yes|Terminated|March 2007|September 2010|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|July 27, 2006||No|Administratively Terminated by PI|No|June 12, 2014|https://clinicaltrials.gov/show/NCT00358007||180107|
NCT00358020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05141|Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients|A Phase II, Multi-Center, Open Label Study Of Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients||University of Turin, Italy||Completed|November 2004|December 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||November 2006|November 30, 2006|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358020||180106|
NCT00358293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol C2/5/TZ-MS-05|Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity|A Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS Patients||Teva GTC||Completed|December 2006|February 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|20 Years|65 Years|No|||April 2007|January 20, 2009|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358293||180085|
NCT00355212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3909/562/35/2000|Comparison Between Radiofrequency Versus Ethanol Injection for the Treatment of Hepatocellular Carcinoma|Comparative Study Between Radiofrequency and Ethanol Injection for the Ablation of Small Hepatocellular Carcinoma Associated With Liver Cirrhosis||Azienda Ospedaliera San Giovanni Battista||Terminated|January 2001|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|N/A|N/A|No|||March 2006|July 21, 2006|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00355212||180316|
NCT00355485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 563|Microdermabrasion for Acne|Microdermabrasion for Acne Vulgaris||University of Michigan|No|Completed|September 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|13 Years|N/A|No|||July 2015|July 8, 2015|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00355485||180295|
NCT00355225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB544D4|Community-Effectiveness of the Distribution of Insecticide-Treated Bed Nets Through Social Marketing Antenatal Care Services in Malaria Control in Rural Burkina Faso|||Heidelberg University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|N/A||||July 2006|October 6, 2006|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00355225||180315|
NCT00355498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0093|Amyloid Plaque and Tangle Imaging in Aging and Dementia|Amyloid Plaque and Tangle Imaging in Aging and Dementia||University of California, Los Angeles|Yes|Completed|September 2005|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|194|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is selected from UCLA primary care clinics, UCLA memory clinic,        residents from the California counties of Orange and Los Angeles who answer ads placed in        newspapers in these areas.|December 2015|December 2, 2015|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355498||180294|
NCT00355511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICORE2006-002|Heart Failure Evaluation Acute Referral Team Trial (HEARTT)|Heart Failure Evaluation Acute Referral Team Trial (HEARTT)||University of Alberta|No|Withdrawn|July 2007|February 2009|Anticipated|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 25, 2015|July 18, 2006||No|unable to recruit patients|No||https://clinicaltrials.gov/show/NCT00355511||180293|
NCT00356317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071250|Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia|A Culturally Based Family Therapy for Schizophrenia||University of Miami|Yes|Completed|March 2015|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|13 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00356317||180231|
NCT00356031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-090|Bevacizumab and Radiation Therapy for Sarcomas|A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas||Massachusetts General Hospital|Yes|Recruiting|July 2006|March 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||April 2010|April 27, 2010|July 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00356031||180253|
NCT00355823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFI and wounds|Bioelectric Field Imaging Near Human Skin Wounds|Phase I Study of the Electric Field Near Human Skin Wounds||National Institute of General Medical Sciences (NIGMS)|No|Completed|August 2006|April 2007|Actual|April 2007|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Two age groups will be studied: 1. Young adults 18-19 years old; and 2. older adults 65-80        years old.|November 2006|May 20, 2008|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00355823||180269|
NCT00357500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-343|Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer|Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer||Dana-Farber Cancer Institute|Yes|Completed|January 2005|December 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|N/A|21 Years|No|||September 2014|September 19, 2014|July 26, 2006|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00357500||180146|
NCT00313599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC#05591|Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors||University of California, San Francisco|Yes|Completed|February 2006|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|April 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00313599||183414|
NCT00313612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00053|Oxaliplatin and Topotecan in Advance Ovarian Cancer|A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer||National Cancer Institute (NCI)|Yes|Terminated|January 2006|December 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||May 2013|October 27, 2015|April 11, 2006|Yes|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00313612||183413|
NCT00313898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|viagracommCTIL|Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males|The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction||Rambam Health Care Campus|No|Recruiting|September 2005|June 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Male|35 Years|70 Years|No|||April 2006|May 16, 2007|April 10, 2006||||No||https://clinicaltrials.gov/show/NCT00313898||183394|
NCT00313911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L04|Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.|Large Scale Safety Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine, in Comparison to Tritanrix-Hep B/Hib™ and OPV Administered at 2, 4, and 6 Months of Age in Latin American Infants||Sanofi|Yes|Completed|July 2006|February 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2133|||Both|50 Days|71 Days|Accepts Healthy Volunteers|||April 2014|April 2, 2014|April 11, 2006||No||No|September 18, 2012|https://clinicaltrials.gov/show/NCT00313911||183393|
NCT00357110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6990C00001|Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer|A Randomised Phase II Study Comparing Anastrozole and Fulvestrant to Anastrozole for Adjuvant Treatment of Postmenopausal Patients With Early Breast Cancer and Disseminated Tumour Cells in Bone Marrow|@FAME|AstraZeneca||Completed|April 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Female|N/A|N/A|No|||December 2010|December 3, 2010|July 20, 2006|Yes|Yes||No|December 18, 2009|https://clinicaltrials.gov/show/NCT00357110||180175|
NCT00353990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002803-15|Bioavailability of Insulin Administered in Duodenum|Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart Administered in the Duodenum in Healthy Volunteers – an Open Single Blinded and Uncontrolled Explorative Trial||University of Aarhus|No|Completed|August 2006|December 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2007|April 24, 2007|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00353990||180406|
NCT00354003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAG-DIS 01|The Study of the Impact of Disclosing Imaging Study Information to Trial Participants|Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials||Institute for Neurodegenerative Disorders|Yes|Completed|July 2006|August 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Both|21 Years|N/A|No|Non-Probability Sample|Research participants who previously underwent ß-CIT imaging|April 2009|April 17, 2009|July 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00354003||180405|
NCT00358306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070309010|The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)|The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)||University of Alabama at Birmingham|Yes|Completed|April 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|36|||Both|2 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children 2-20 years old with history of acute kidney injury|February 2010|February 16, 2010|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358306||180084|
NCT00354029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001082-41|Effect of Perioperative i.v. Low-dose S(+) Ketamine|Effect of Perioperative i.v. Low-dose S(+) Ketamine in Patients Undergoing Hemorrhoidectomy||Asker & Baerum Hospital||Completed|August 2006|May 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|July 18, 2006||No||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00354029||180403|
NCT00354952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA-Med Micro-2002|Selection of Antibiotic Resistance by Azithromycin and Clarithromycin in the Oral Flora|Impact of Azithromycin and Clarithromycin Therapy on Pharyngeal Carriage of Macrolide-Resistant Streptococci Among Healthy Volunteers: A Randomised, Double-Blind, Placebo-Controlled Trial||Universiteit Antwerpen||Completed|July 2002|October 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||203|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2003|July 19, 2006|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354952||180336|
NCT00354965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUG102821|Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients|An Open-label Study to Determine the Pharmacokinetic Profiles of Amoxicillin and Clavulanate in Adolescent Patients Weighing at Least 40 kg and no More Than 16 Years of Age Receiving Augmentin XR (Amoxicillin 2000 mg/Clavulanate 125 mg) Orally Twice Daily for 10 Days.||GlaxoSmithKline||Completed|January 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|16 Years|No|||January 2012|May 31, 2012|July 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00354965||180335|
NCT00356954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0509-517-158-2|NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization|N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization: NASPI Study-A Randomized Controlled Trial||Seoul National University Hospital||Completed|February 2005|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||250|||Both|19 Years|N/A|No|||November 2006|November 24, 2006|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00356954||180187|
NCT00355771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-1-2005|Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis|Placebo Controlled Pilot Study on the Efficacy of Levocetirizine 5 mg in Reducing Symptoms, Airway Resistance, and Sleep Impairment in Patients With Persistent Allergic Rhinitis||Institut für Atemwegsforschung GmbH|No|Completed|June 2006|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|50 Years|No|||January 2008|January 12, 2008|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00355771||180273|
NCT00356642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPD102031|Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis|A Randomised, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Ten Day Repeat Topical Applications of GW842470X Cream on the Skin of Patients With Atopic Dermatitis||GlaxoSmithKline||Completed|June 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||42|||Both|18 Years|67 Years|No|||February 2011|May 31, 2012|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356642||180209|
NCT00356655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Gardner|The ACHIEVA Study of Enhanced Pharmacist Care on Antidepressant Use and Response|A COHORT AND INTERVENTION STUDY EVALUATING ANTIDEPRESSANT EPIDEMIOLOGY AND ADHERENCE: The ACHIEVA Study||University of Alberta||Terminated|July 2006|January 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|106|||Both|18 Years|N/A|No|||May 2008|May 12, 2008|July 24, 2006|||Low recruitment|No||https://clinicaltrials.gov/show/NCT00356655||180208|
NCT00356369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107386|Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine|Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age)||GlaxoSmithKline||Completed|December 2006|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|11 Years|55 Years|Accepts Healthy Volunteers|||July 2012|March 28, 2013|July 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00356369||180227|
NCT00356382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-291|Decreasing Rates of Illness in Kids (DRINK)|Decreasing Rates of Illnesses in Kids (DRINK)||Georgetown University|Yes|Completed|September 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||638|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||April 2007|May 12, 2008|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356382||180226|
NCT00313378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0004|Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy|Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy.||University Hospital, Clermont-Ferrand||Completed|April 2004|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|20 Years|75 Years|No|||April 2013|April 2, 2013|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313378||183431|
NCT00314314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Insulin|The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder|A Randomized, Double-Blind Controlled Trial Evaluating the Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder||University Health Network, Toronto|No|Completed|May 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||May 2008|July 9, 2009|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00314314||183362|
NCT00346138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000-03|A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema|Deep Lamellar Endothelial Keratoplasty as Surgical Treatment for Corneal Endothelial Decompensation||Mayo Clinic||Completed|June 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|21 Years|N/A|No|||January 2010|January 14, 2010|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00346138||180998|
NCT00314288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62225-006|Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia|A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia||EMD Serono||Completed|July 2002|July 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|30 Years|N/A|No|||October 2013|October 22, 2013|April 12, 2006||||||https://clinicaltrials.gov/show/NCT00314288||183364|
NCT00314561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreaUAnanmH|The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome|The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome: A Prospective, Randomized, Open-label, Crossover Trial||Korea University Anam Hospital||Completed|May 2006|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||September 2008|June 30, 2011|April 12, 2006||||No||https://clinicaltrials.gov/show/NCT00314561||183343|
NCT00358280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0695L00002|Ropivacaine Versus Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery|A Randomised, Double-Blind, Multi-Centre, Parallel Group Study Comparing Efficacy and Safety of 5 mg/ml Ropivacaine and 5 mg/ml Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery||AstraZeneca||Completed|April 2006|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|70 Years|No|||March 2009|March 25, 2009|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00358280||180086|
NCT00353977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040198|Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors|A Pilot Trial of an Accelerated Immunization Schedule With ALVAC-pp65 (vCP260) for Inducing CMV-Specific Immunity in Stem Cell Allotransplant Donors and Healthy Volunteers||National Institutes of Health Clinical Center (CC)|Yes|Completed|May 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Both|18 Years|80 Years|No|||June 2014|June 5, 2014|July 18, 2006|No|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00353977||180407|
NCT00354042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2A100517|Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects|A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 4 Period Crossover Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of GW597901X in Asthmatic Subjects||GlaxoSmithKline||Completed|August 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||24|||Both|18 Years|65 Years|No|||May 2009|May 15, 2009|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354042||180402|
NCT00354328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050163|Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy|Relationship of Diastolic Function and Functional Capacity in Hypertrophic Cardiomyopathy: A Post-Hoc Analysis of Protocols 01-H-0066 and 96-H-0144||National Institutes of Health Clinical Center (CC)||Completed|May 2005|||||N/A|Observational|N/A||||0|||Both|20 Years|75 Years|No|||November 2012|November 20, 2012|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354328||180382|
NCT00355238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-006|A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer|A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy||Bristol-Myers Squibb|Yes|Completed|December 2006|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355238||180314|
NCT00354575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941216|Effect of Chinese Herb on Chronic Constipation for Residents in Long-Term Care Units|A Randomized, Placebo-Controlled, Double-Blind, Parallel Study on the Efficacy and Safety of Traditional Chinese Medicines for Chronic Constipation Residents in Long-Term Care Units||National Taiwan University Hospital|Yes|Completed|September 2006|June 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|168|||Both|20 Years|N/A|No|||July 2008|August 14, 2008|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354575||180363|
NCT00354588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WelsEK 206|Arterial Stiffness, Wave Reflections and Renal Failure|Observational Study on the Prognostic Significance (Renal and Cardiovascular) of Arterial Stiffness and Arterial Wave Reflections in Patients With Mild to Moderate Renal Impairment||Klinikum Wels-Grieskirchen||Completed|January 2006|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|19 Years|N/A|No|Non-Probability Sample|patients with chronic renal failure|November 2010|November 3, 2010|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354588||180362|
NCT00355784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK071955-01|Growth Hormone as a Determinant of Weight Regulation|Growth Hormone as a Determinant of Weight Regulation.||University of Michigan||Completed|September 2005|December 2015|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|July 24, 2006||No||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00355784||180272|The short duration of our intervention was a limitation. The metabolic measurements that were performed in the postabsorptive state was a limitation.
NCT00357526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10857-19674-04|Oral Contraceptive Pills Compared to Vaginal Rings|YOUNG WOMEN’S EXPERIENCES: ORAL CONTRACEPTIVE PILLS VS The VAGINAL RING||University of California, San Francisco||Completed|April 2003|August 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Female|15 Years|21 Years|Accepts Healthy Volunteers|||March 2006|April 19, 2007|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357526||180144|
NCT00356057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G040150|Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace|AVAIL CLS/CRT: AV-node Ablation With CLS and CRT Pacing Therapies for the Treatment of AF|AVAIL|Biotronik, Inc.|No|Terminated|December 2004|June 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|153|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|July 21, 2006|Yes|Yes|Slow enrollment.|No|December 2, 2008|https://clinicaltrials.gov/show/NCT00356057||180251|Early termination due lack of enrollment.
NCT00356070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH 4.2005.147|Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison|Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison||Norwegian University of Science and Technology||Completed|January 2006|December 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2006|August 9, 2011|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356070||180250|
NCT00356083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|188-03REK|Opioid Rotation From Morphine to Methadone in Treatment of Non-malignant Pain|Opioid Switching From Oral Slow Release Morphine to Oral Methadone May Improve Pain Control in Chronic Non-malignant Pain: a Nine-month Follow-up Study.||Norwegian University of Science and Technology|No|Completed|January 2004|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||April 2015|April 7, 2015|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00356083||180249|
NCT00356343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD043859|Strength Training Using Neuromuscular Electrical Stimulation For Children With Cerebral Palsy|Strength Training Using NMES for Children With Cerebral Palsy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|July 2004|||September 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|7 Years|12 Years|No|||January 2011|January 9, 2011|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356343||180229|
NCT00356330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116/06|Safety of Cardiac Pacemakers in 3 Tesla MRI|Study to Evaluate Safety of Cardiac Pacemakers in MR Imaging at 3T Tesla||University Hospital, Bonn||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||75|||Both|N/A|N/A|No|||April 2007|April 9, 2007|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356330||180230|
NCT00356967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5515|Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation|An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers|EURODIAN|Sanofi||Completed|June 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|602|||Both|18 Years|N/A|No|||December 2008|December 18, 2008|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00356967||180186|
NCT00356980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060167|TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors|A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) by Intravenous Administration in Subjects With Advanced Solid Organ Malignancies||National Institutes of Health Clinical Center (CC)||Completed|May 2006|April 2009|Actual|February 2009|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|July 26, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00356980||180185|
NCT00356928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0551 CDR0000483771|Cyclophosphamide Plus Transplantation of Partially HLA-mismatched, CD8+ T Cell-depleted Peripheral Blood Cells for Patients With Myelodysplastic Syndrome , Refractory Acute Myeloid Leukemia, Refractory Lymphoma or Myeloproliferative Disorders|Cyclophosphamide Plus Transplantation of Partially HLA-Mismatched (Haploidentical), CD8+ T Cell-Depleted Peripheral Blood Cells (PBCs) for Patients With Myelodysplastic (MDS) or Myeloproliferative Disorders (MPD)||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|May 2006|December 2017|Anticipated|May 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|120 Years|No|||October 2015|October 30, 2015|July 26, 2006|Yes|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00356928||180189|
NCT00356941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS073|Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC|Phase I Study of Oxaliplatin in Combination With Docetaxel and Radiotherapy in Patients With Unresectable or Recurrent Non-Small Cell Lung Cancer (NSCLC)||Masonic Cancer Center, University of Minnesota|Yes|Terminated|April 2006|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|July 26, 2006|No|Yes|Withdrawn due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00356941||180188|
NCT00313963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008367|MAST - Magnesium for Sickle Cell Acute Crisis in Children|MAST - Magnesium for Sickle Cell Acute Crisis in Children||The Hospital for Sick Children|Yes|Completed|April 2006|July 2013|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|4 Years|18 Years|No|||August 2013|August 9, 2013|April 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00313963||183389|
NCT00345904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107507|Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2006/2007 in People Aged 18 Years or Above||GlaxoSmithKline||Completed|July 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00345904||181015|
NCT00346164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST0332|Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma|Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age||Children's Oncology Group|Yes|Active, not recruiting|February 2007|||September 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|588|||Both|N/A|29 Years|No|||September 2014|September 8, 2014|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346164||180996|
NCT00346177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND-11196-02|Stem Cell Study for Patients With Heart Failure|Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40%||Losordo, Douglas, M.D.|Yes|Withdrawn|September 2010|September 2012|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||September 2010|September 10, 2010|June 27, 2006|Yes|Yes|Funding not obtained. No subjects enrolled.|No||https://clinicaltrials.gov/show/NCT00346177||180995|
NCT00313937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4028|SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1|Single Centre, Open, Controlled, Randomised (1:1), Parallel Group: Insulin Glargine vs. NPH: FPG (Fasting Plasma Glucose) in Patients With DM Type 1 Who Skip the Morning Meal During Treatment With MDI (Multiple Daily Injection) Basal/Bolus Insulin||Sanofi||Completed|November 2001|||June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313937||183391|
NCT00313950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAF65|Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine|Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children||Sanofi|No|Completed|September 2006|April 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|470|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||January 2014|January 17, 2014|April 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00313950||183390|
NCT00357734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0555|Iressa Follow-up Trial|Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials||AstraZeneca|No|Completed|January 2005|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357734||180128|
NCT00357747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I166|AEG35156 and Docetaxel in Treating Patients With Solid Tumors|A Phase I Study of AEG35156 in Combination With Docetaxel in Patients With Solid Tumors||Canadian Cancer Trials Group|No|Completed|April 2005|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357747||180127|
NCT00357435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040008|Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases|Clinical and Molecular Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|October 2003|||||N/A|Observational|N/A|||Anticipated|2000|||Both|4 Years|N/A|No|||July 2015|August 12, 2015|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357435||180151|
NCT00358033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12712|Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic|Effectiveness of Different Strategies in Maintaining Target Goals of Cardiovascular Risk Factors in Patients Discharged From Cardiovascular Risk Reduction Clinic||Providence VA Medical Center|Yes|Completed|July 2003|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00358033||180105|
NCT00354068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004364|Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma|A Phase I Study of Imatinib Mesylate in Combination With Temozolomide in Patients With Malignant Glioma||Duke University||Completed|July 2004|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|65|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|July 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00354068||180401|
NCT00354341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA16620|(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy|A Randomized, Open-Label Study of the Effect of Anemia Correction With NeoRecormon on Cardiac Structure and Function in Anemic Patients With Early Diabetic Nephropathy.||Hoffmann-La Roche||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2006|July 19, 2006|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354341||180381|
NCT00354991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-950|Hyzaar Asia HEAALTH (0954A-950)|An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients With Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy||Merck Sharp & Dohme Corp.||Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|437|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|July 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00354991||180333|
NCT00354653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUC 30956|A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone|AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-Core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.||GlaxoSmithKline||Active, not recruiting|February 2002|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|15 Years|N/A|No|||July 2007|July 24, 2007|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354653||180357|
NCT00354666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2E101312|Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma|A Randomised, Double-blind, Placebo-controlled, Dose Ascending Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled GSK159797 Delivered by Dry Powder Inhaler in Mild to Moderate Asthmatic Subjects||GlaxoSmithKline||Completed|September 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||20|||Both|18 Years|65 Years|No|||October 2010|October 1, 2010|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354666||180356|
NCT00355524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002797|A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents|A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/Rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents||Tibotec Pharmaceuticals, Ireland|Yes|Completed|June 2006|March 2011|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|80|||Both|6 Years|17 Years|No|||July 2013|July 5, 2013|July 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355524||180292|
NCT00356109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9627|Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes|A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company||Completed|August 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|494|||Both|18 Years|N/A|No|||February 2009|February 6, 2009|July 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00356109||180247|
NCT00358124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4014|Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy|||Sanofi||Completed|January 2001|June 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|18 Years|80 Years|No|||January 2011|January 10, 2011|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00358124||180098|
NCT00357838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR95-IRB-64|Pulse Waves and Tongue Diagnosis Differences Between Follicular and Luteal Phase in Normal Healthy Women|||China Medical University Hospital||Recruiting|July 2006|||||N/A|Observational|Time Perspective: Cross-Sectional|||||||Female|21 Years|40 Years|Accepts Healthy Volunteers|||July 2006|October 17, 2006|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00357838||180120|
NCT00354133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 121/06|Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease|The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)||German Parkinson Study Group (GPS)|Yes|Active, not recruiting|July 2006|June 2012|Anticipated|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|60 Years|No|||August 2011|January 27, 2012|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354133||180396|
NCT00356681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050225|A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer|A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer||Amgen|Yes|Terminated|December 2006|August 2012|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|282|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|July 24, 2006|Yes|Yes|Sponsor decision to close study|No||https://clinicaltrials.gov/show/NCT00356681||180206|
NCT00363376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-06-14-01|A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain|A Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain||Lindner Center of HOPE|No|Completed|January 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|August 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363376||179707|
NCT00363389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001201-28|Hysteroscopy and Misoprostol Project|Self-Administered Vaginal Misoprostol at Home for Cervical Ripening Prior to Outpatient Hysteroscopy: a Randomised Placebo-Controlled Trial.||Ullevaal University Hospital|Yes|Completed|September 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|73 Years|No|||April 2007|August 6, 2007|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363389||179706|
NCT00356720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PIII-10/03|Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma|Clinical Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% (Instilled Twice Daily for 2 or 3 Days) Versus Oral Azithromycin in Treatment of Trachoma||Laboratoires Thea||Completed|January 2004|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|1 Year|10 Years|No|||July 2006|July 25, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356720||180204|
NCT00345670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP130|Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy RSV and PIV3 Seropositive 1-9 Year-Old Children||MedImmune LLC|Yes|Completed|June 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3|||120|||Both|1 Year|9 Years|Accepts Healthy Volunteers|||September 2008|September 2, 2008|June 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00345670||181033|
NCT00345891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008930|Quit Smoking Program for Lung Cancer Patients' Families (The Family Ties Project)|Quite Smoking Program for Lung Cancer Patients' Families||Duke University|No|Completed|June 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|496|||Both|18 Years|N/A|No|||May 2010|July 23, 2014|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00345891||181016|
NCT00346476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA-SA Project 3B|Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa|A Study of the Effects of Antiretroviral Therapy on Rates and Transmission of Tuberculosis||CIPRA SA|No|Completed|April 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1250|Samples With DNA|Sputum, Saliva|Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|HIV and TB infected and uninfected individuals|February 2011|February 9, 2011|June 28, 2006||No||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00346476||180974|
NCT00346151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN023ST|Belatacept to Prevent Organ Rejection in Kidney Transplant Patients|The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)|BESTT|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|December 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||December 2014|December 30, 2014|June 27, 2006|Yes|Yes|Stopping rule-acute rejection threshold-was met based on local biopsy results|No|June 8, 2011|https://clinicaltrials.gov/show/NCT00346151||180997|The trial was stopped early due to meeting an acute rejection threshold of three acute rejections based on local pathology reads in the first five participants enrolled.
NCT00346437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304386|Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients With Stable Angina||Cardium Therapeutics|Yes|Completed|October 2001|November 2008|Actual|January 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|416|||Both|30 Years|75 Years|No|||November 2008|February 8, 2012|June 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00346437||180977|
NCT00358046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILY-1201|Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia|A Phase 2, Randomized, Dose-Ranging, Single-Blind, Efficacy and Tolerability Study of ILY101 in Patients With Chronic Kidney Disease With Hyperphosphatemia on Hemodialysis||Ilypsa||Active, not recruiting|June 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|18 Years|80 Years|No|||February 2007|February 5, 2007|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00358046||180104|
NCT00358319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13991|Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma|Phase I/II Trial of Valproic Acid and Karenitecin for Metastatic Malignant Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|March 2005|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||February 2011|November 21, 2013|July 27, 2006|Yes|Yes|PI left Moffitt|No||https://clinicaltrials.gov/show/NCT00358319||180083|
NCT00354601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-83203|Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer|A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum||Comprehensive Cancer Center of Wake Forest University||Terminated|January 2006|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|120 Years|No|||January 2012|September 29, 2015|July 19, 2006|Yes|Yes|funding withdrawn|No|March 9, 2009|https://clinicaltrials.gov/show/NCT00354601||180361|Early closure due to discontinuation of funding
NCT00354978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0614|Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients|Phase II Study of Irinotecan, Leucovorin, 5-Fluorouracil (FOLFIRI) Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer||M.D. Anderson Cancer Center|No|Completed|January 2005|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|July 18, 2006||No||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00354978||180334|
NCT00354172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN-2005LS058|Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.|Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells||Masonic Cancer Center, University of Minnesota|Yes|Terminated|February 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|45 Years|No|||November 2012|November 6, 2012|July 19, 2006|Yes|Yes|Competing study was started.|No|November 30, 2009|https://clinicaltrials.gov/show/NCT00354172||180393|
NCT00354367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87058|Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas|A Phase IIIB Multicenter, Open Label, Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor (TNF) in Crohn's Disease Patients With Draining Fistulas.||UCB Pharma||Withdrawn|January 2007|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A||||May 2012|May 25, 2012|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354367||180379|
NCT00354614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-09-05|Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)|Validation of the ApneaLink Sleep Screener in a Suspected Sleep Disordered Breathing Population||ResMed|No|Completed|June 2006|July 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|N/A|No|Probability Sample|Pts. with suspected OSA.|July 2008|July 2, 2008|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354614||180360|
NCT00355004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000486405|Computerized and Mailed Reminders in Increasing the Rate of Colorectal Cancer Screening in Adults With an Average Risk for Colorectal Cancer|Improving Systems for Colorectal Cancer Screening||National Cancer Institute (NCI)||Completed|March 2005|February 2009|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Screening|||Anticipated|21860|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2007|December 18, 2013|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00355004||180332|
NCT00355017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF: 05.05.2003|BNP Guided Care in Addition to Multidisciplinary Care|NT-BNP Guided Care in Addition to Multidisciplinary Care in Patients With Chronic Heart Failure A Three-Arm, Prospective, Randomised Study||Medical University of Vienna||Terminated|September 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|19 Years|N/A|No|||July 2006|October 17, 2006|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00355017||180331|
NCT00356707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1343|Evaluating the Link Between Neighborhood Environments and Obesity Among African American Women|Effect of Urban Form on Exercise and BMI in Black Women||Boston University|No|Completed|June 2006|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23000|||Female|21 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|The Black Women's Health Study cohort comprises 59,000 African American women recruited        mainly from subscribers to Essence magazine who returned the baseline 1995 survey.|March 2012|March 27, 2012|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356707||180205|
NCT00366730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM02-3014|Study of Nitazoxanide in the Treatment of Amebiasis in Children|Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children||Romark Laboratories L.C.||Completed|February 2004|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|1 Year|11 Years|No|||August 2006|August 18, 2006|August 18, 2006||||No||https://clinicaltrials.gov/show/NCT00366730||179455|
NCT00366743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-05-001|Evaluation of Visual Outcomes After Myopic LASIK|Analysis of Visual Outcomes, Contrast Sensitivity, Glare, Induction of High Order Aberrations and Wavefront Technology, Following LASIK Surgery||Medical University of South Carolina||Completed|May 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|21 Years|60 Years|No|||June 2005|August 17, 2006|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366743||179454|
NCT00358410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW679769/904|An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia|See Detailed Description||GlaxoSmithKline||Completed|January 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||January 2011|January 27, 2011|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358410||180076|
NCT00354627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002743|The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs|Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options||Tibotec Pharmaceuticals, Ireland|No|Completed|January 2006|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5178|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|July 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00354627||180359|
NCT00355030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9861|Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature|Efficacy and Safety of Somatropin in Combination With Leuprorelin Compared to Somatropin Alone in Pubertal Children With Idiopathic Short Stature|Phoenix|Eli Lilly and Company|No|Completed|June 2006|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|8 Years|171 Months|No|||August 2015|August 6, 2015|July 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355030||180330|
NCT00367042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513516-1|Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks|Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery||University of California, Davis|Yes|Completed|July 2005|July 2008|Actual|July 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|98|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|August 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00367042||179431|
NCT00367055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101765|Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes|Comparison of the Action of the Rosiglitazone-metformin Fixed-dose Combination and of a Metformin-sulfonylurea Free Combination on the B-cell Function in Type 2 Diabetic Patients Not Controlled With Metformin Alone.||GlaxoSmithKline||Completed|October 2004|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|84|||Both|40 Years|75 Years|No|||July 2010|July 20, 2010|August 21, 2006||||No|October 2, 2009|https://clinicaltrials.gov/show/NCT00367055||179430|
NCT00357318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00185|Bevacizumab and Sunitinib in Treating Patients With Solid Tumors|A Phase I Study of Bevacizumab in Combination With SU11248||National Cancer Institute (NCI)||Completed|June 2006|||July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2013|February 21, 2014|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357318||180160|
NCT00346216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191172|Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen|A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen|PRECISION|Pfizer|Yes|Active, not recruiting|October 2006|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|24200|||Both|18 Years|N/A|No|||March 2016|March 12, 2016|June 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00346216||180993|
NCT00346489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0409-60|Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C|Intermediate Term Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin c in Trabeculectomy Surgery.||Indiana University||Completed|September 2004|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|N/A|N/A|No|||December 2007|December 21, 2007|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346489||180973|
NCT00346502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0811|Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)|Phase I/II Evaluation of Topical Application of 20% Betulinic Acid Ointment in the Treatment of Dysplastic Nevi With Moderate to Severe Dysplasia||University of Illinois at Chicago||Suspended|January 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|June 29, 2006|No|Yes|The study has been temporarily suspended due to funding issues|No||https://clinicaltrials.gov/show/NCT00346502||180972|
NCT00346190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-16|The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.|A Six Month Double-Blind, Placebo-Controlled Trial Followed by Six Month Open-Label Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.||McGill University Health Center||Recruiting|January 2003|April 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||10|||Both|55 Years|N/A|No|||January 2006|April 11, 2007|June 27, 2006||||No||https://clinicaltrials.gov/show/NCT00346190||180994|
NCT00346463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC UMCU 05-207K|Antenatal Allopurinol in Intrauterine Growth Restriction|Does Antenatal Allopurinol Administration Improve Maternal and Neonatal Outcome in Intrauterine Growth Restriction?||UMC Utrecht||Not yet recruiting|July 2006|July 2013|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|N/A|No|||June 2006|April 25, 2008|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346463||180975|
NCT00358059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK043802|Behavior Therapy for Families of Diabetic Adolescents|Behavior Therapy for Families of Diabetic Adolescents||Nemours Children's Clinic||Completed|October 2000|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|12 Years|16 Years|No|||October 2005|July 26, 2006|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00358059||180103|
NCT00358072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILG-ALL 09/00|Treatment of Adult ALL With an MRD-directed Programme.|Treatment of Adult Acute Lymphoblastic Leukemia Using a Post-remission Programme Whose Intensity Varies Depending on the Risk Class Defined on the Basis of Minimal Residual Disease.||Northern Italy Leukemia Group|No|Completed|May 2000|September 2008|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|15 Years|65 Years|No|||December 2010|December 28, 2010|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00358072||180102|
NCT00358332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0146|Phase I Pediatric FMP2.1/AS02A Trial in Mali|Randomized, Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali||U.S. Army Medical Research and Materiel Command||Completed|November 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|100|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||October 2011|October 18, 2011|July 27, 2006|No|Yes||No|December 9, 2008|https://clinicaltrials.gov/show/NCT00358332||180082|
NCT00358345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP C9|PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization|PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization||Notal Vision Ltd|Yes|Completed|October 2003|September 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|347|||Both|50 Years|N/A|No|Probability Sample|At least 200 subjects with intermediate AMD in at least one (1) eye based on medical        record review and/or clinical diagnosis and at least 200 subjects with neovascular AMD in        at least one (1) eye.|January 2008|January 10, 2008|July 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00358345||180081|
NCT00356733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHS-2005B192|Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome|Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome||UMC Utrecht||Completed|January 2007|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|80 Years|No|||November 2011|November 30, 2011|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356733||180203|
NCT00356993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81/2005|Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)|The STOP (Stop Smoking Therapy for Ontario Patients) Study: The Effectiveness of Nicotine Replacement Therapy in Ontario Smokers.||Centre for Addiction and Mental Health|No|Recruiting|October 2005|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10000|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356993||180184|
NCT00354406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-DCT-200601|Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty|A Randomized Trial Comparing the Efficacy on Myocardial Infarct Size Reduction of Early vs. Late Abciximab Administration During Primary Percutaneous Coronary Angioplasty||University of Pisa|No|Completed|April 2006|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||November 2011|November 13, 2011|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354406||180376|
NCT00355537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDGH 237|Testosterone Replacement in Diabetes With Vascular Disease (Version 2)|A Randomised, Double Blind, Placebo-controlled Parallel Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus||Barnsley Hospital|No|Completed|February 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Male|18 Years|N/A|No|||March 2010|March 29, 2010|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00355537||180291|
NCT00355797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060536|Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response|CLEAR: Cylos Pacemaker Responds With Physiologic Rate Changes During Daily Activities|CLEAR|Biotronik, Inc.|No|Completed|May 2006|December 2010|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|1491|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|July 21, 2006||No||No|June 6, 2011|https://clinicaltrials.gov/show/NCT00355797||180271|
NCT00355810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 4.2005.2284|Probiotics for Irritable Bowel Syndrome|Lactobacillus Plantarum MF 1298 vs Placebo for Irritable Bowel Syndrome.||Norwegian University of Science and Technology|No|Completed|January 2006|December 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||September 2011|September 29, 2011|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00355810||180270|
NCT00356096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.604|Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances|A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances||Boehringer Ingelheim||Completed|July 2006|||June 2007|Actual|Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|404|||Both|18 Years|80 Years|No|||May 2012|May 18, 2012|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356096||180248|
NCT00357292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PI1-09/01(AS)|Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers|Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers||Laboratoires Thea||Completed|March 2002|April 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2006|July 26, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357292||180162|
NCT00357305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00088|Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders|Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders||National Cancer Institute (NCI)||Completed|May 2006|||November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357305||180161|
NCT00366080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3A106104|Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy|An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.||GlaxoSmithKline|No|Terminated|November 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|65 Years|No|||March 2011|March 10, 2011|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366080||179505|
NCT00366093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-054|Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause|The Efficacy of Eszopiclone 3 mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause||Sunovion|No|Completed|February 2004|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|410|||Female|40 Years|60 Years|No|||February 2012|February 21, 2012|August 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366093||179504|
NCT00354380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB544-A8-ASMB2006|Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study|||Heidelberg University||Completed|September 2006|November 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|6 Years|10 Years||||September 2006|October 23, 2006|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354380||180378|
NCT00355277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0014|Local Anaesthetic Effects of Transcutaneous Amitriptyline|Local Anaesthetic Effects of Transcutaneous Amitriptyline in Human Volunteers : a Controlled, Double-blinded, Randomised Study Versus Placebo and Transcutaneous Local Anaesthetic (EMLA(R))||University Hospital, Clermont-Ferrand||Completed|November 2005|December 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|July 20, 2006||||No||https://clinicaltrials.gov/show/NCT00355277||180311|
NCT00355550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0094|Ketasyn In Age-Associated Memory Impairment|A Double-Blind, Placebo-Controlled Study of Ketasyn (AC-1202) Administered For Ninety Days In Subjects With Age-Associated Memory Impairment||National Institute on Aging (NIA)||Completed|July 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|50 Years|85 Years|No|||June 2007|December 10, 2009|July 20, 2006||||No||https://clinicaltrials.gov/show/NCT00355550||180290|
NCT00367393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CDE20|Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis|An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage||Novartis||Completed|March 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|60 Years|No|||March 2016|March 20, 2016|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367393||179404|
NCT00367406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/280|Comparison Between Gamma 3 Nail and ACE Trochanteric Nail|Comparison Between Gamma 3 Nail and ACE Trochanteric Nail||University Hospital, Ghent|No|Recruiting|November 2006|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367406||179403|
NCT00357851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2003-029|Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery|||Nemours Children's Clinic||Completed|March 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|120|||Both|N/A|18 Years|No|||October 2010|October 13, 2010|July 26, 2006||||||https://clinicaltrials.gov/show/NCT00357851||180119|
NCT00358137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404|Effect of Aerobic Exercise on Blood Pressure Changes|Psychophysiologic Stress, Exercise, & Autonomic Control||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 1997|January 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|February 17, 2016|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358137||180097|
NCT00346229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014340|Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer|A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin (ThermoDox™) and Hyperthermia in Patients With Local-Regionally Recurrent Breast Cancer||Duke University||Terminated|April 2006|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||October 2013|March 18, 2016|June 28, 2006|No|Yes|Funding|No||https://clinicaltrials.gov/show/NCT00346229||180992|
NCT00347100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_01051|Insulin Glargine in Type 2 Diabetic Patients|Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy|TARGET|Sanofi||Completed|June 2006|||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|387|||Both|18 Years|80 Years|No|||September 2009|September 14, 2009|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347100||180926|
NCT00346762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA CH 003|Evaluating Host and Viral Factors Among HIV Infected Former Commercial Blood Donors in Fuyang, Anhui Province, China|Host and Viral Factors in HIV-1-Infected Typical Progressors and Long-Term Survivors Among Former Blood Donors in Anhui Province, China||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2005|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|186|Samples With DNA|Whole blood and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample of HIV infected and uninfected blood donors|May 2014|May 16, 2014|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00346762||180952|
NCT00346775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR105693|Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)|A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects With Seasonal Allergic Rhinitis During a Three-week Cross-over Study||GlaxoSmithKline||Completed|May 2006|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|97|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|June 28, 2006||||No||https://clinicaltrials.gov/show/NCT00346775||180951|
NCT00354094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061030|[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.|A Phase 2B Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Postherpetic Neuralgia (PHN).||Pfizer||Terminated|November 2006|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||November 2007|November 7, 2007|July 18, 2006|||The study was stopped due to business/operational issues.|No||https://clinicaltrials.gov/show/NCT00354094||180399|
NCT00354354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-926-06|Bronchodilators and Oxygen Kinetics With Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients|Bronchodilator Effect on O2 Deficit and V'O2 Kinetics During Moderate Intensity Exercise in Normoxemic COPD.||Queen's University|Yes|Completed|March 2006|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|80 Years|No|||April 2011|April 18, 2011|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354354||180380|
NCT00355056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-010|Premium Migraine Trial|Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management.||St. Jude Medical|Yes|Completed|January 2006|December 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|July 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355056||180328|
NCT00355316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0435 / 201109033|A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients|Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients||Washington University School of Medicine|No|Completed|November 2005|February 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|224|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 19, 2013|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00355316||180308|
NCT00354107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00407|Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma|A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC# 731636, IND#) in Children With CD30+ Recurrent Anaplastic Large Cell Lymphoma||National Cancer Institute (NCI)|Yes|Terminated|January 2007|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|1 Year|21 Years|No|||October 2011|May 5, 2014|July 19, 2006|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00354107||180398|Number of participants analyzed = 4. One patient was not evaluable for response.
NCT00354120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT:2005-000805-68|Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant|Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors|GLOBAL|Gruppo Italiano Trapianto di Midollo Osseo|No|Completed|March 2005|August 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|65 Years|No|||March 2014|March 20, 2014|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354120||180397|
NCT00365547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS083|Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy|Phase II Clinical Study of Weekly Topotecan in Combination With Avastin™ in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy||Masonic Cancer Center, University of Minnesota|Yes|Completed|September 2006|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|August 16, 2006|Yes|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT00365547||179544|
NCT00356356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021640|16.0040 Ankylosing Spondylitis Study|Open-label, Long-term Extension Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis Who Participated in Protocol 16.0037||Amgen||Completed|April 2002|September 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|257|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356356||180228|
NCT00366106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN ALJBMM0502|Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma|A Phase II, Open Label Study Evaluating an Alternative Schedule of Velcade/Dexamethasone Plus Doxil in the Treatment of Multiple Myeloma||Accelerated Community Oncology Research Network|No|Terminated|July 2006|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2012|April 4, 2012|August 16, 2006|Yes|Yes|Study was closed to enrollment when it became clear that enrollment was too slow to complete    full enrollment target within time frame allowed.|No|September 26, 2011|https://clinicaltrials.gov/show/NCT00366106||179503|The study was closed to enrollment when it became clear that enrollment was too slow to complete the planned enrollment target of 45 patients within the time frame allowed. Response rate was unable to be assessed due to missingness of required data.
NCT00366119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMN-P01|Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension|Phase 4 Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Ramiprin Tab. in Essential Hypertension||Pacific Pharmaceuticals||Active, not recruiting|June 2006|June 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||86|||Both|18 Years|N/A|No|||March 2007|March 8, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366119||179502|
NCT00367029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|408|Individualized Motivational Print Materials to Encourage More Physical Activity|Achieving Physical Activity Guidelines Through an Enhanced Print Intervention||The Miriam Hospital|Yes|Completed|August 2006|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2009|May 6, 2014|August 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00367029||179432|
NCT00367354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00041134|Respiratory Motion Analysis in Children With MRI|Respiratory Motion Analysis in Children for Improvement of MR (Magnetic Resonance) Imaging of Congenital Heart Disease||Emory University|No|Terminated|August 2006|July 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|6|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|35 healthy volunteers (21 years or older) and 25 cardiac MRI patients of different age        groups.|December 2014|December 8, 2014|August 18, 2006||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00367354||179407|
NCT00356122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCOX_L_00716|Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase II Multicenter Study of Docetaxel and Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Chemotherapy-Naïve Subjects With Unresectable Locally Advanced and/or Recurrent (Stage IIIB) or Metastatic (Stage IV) Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC)||Sanofi||Completed|July 2006|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||August 2011|October 7, 2011|July 24, 2006|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00356122||180246|
NCT00363090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491451|Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma|Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study||National Cancer Institute (NCI)||Recruiting|September 2006|||December 2010|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|84|||Both|18 Years|N/A|No|||June 2009|September 19, 2013|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363090||179728|
NCT00363662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01NS034866-08A1|Diagnostic Utility of MRI in Intracerebral Hemorrhage|Diagnostic Utility of MRI in Intracerebral Hemorrhage||Stanford University||Recruiting|June 2006|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A total of 180 ICH or IVH patients will be studied. All patients will be inpatients        admitted to the Stanford Stroke Center, a multidisciplinary referral center for the        treatment of acute stroke. Consecutive patients will be enrolled provided they meet the        inclusion and exclusion criteria and that they or a legally authorized representative give        informed consent.|June 2012|June 12, 2012|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00363662||179686|
NCT00363909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N05C9|Citalopram in Treating Postmenopausal Women With Hot Flashes|Phase III Randomized, Double-Blind, Placebo-Controlled Evaluation of Citalopram for the Treatment of Hot Flashes||Alliance for Clinical Trials in Oncology|Yes|Completed|November 2006|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|254|||Female|18 Years|N/A|No|||July 2015|July 4, 2015|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363909||179667|
NCT00363610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZ-002-001|A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma|A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of Intravenous Pegaspargase in Combination With Intravenous Gemcitabine HCl in the Treatment of Advanced and/or Metastatic Solid Tumors and Lymphoma||Enzon Pharmaceuticals, Inc.|No|Terminated|July 2006|June 2008|Anticipated|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2008|May 16, 2008|August 9, 2006|No|Yes|No recommended Phase II dose was determined.|No||https://clinicaltrials.gov/show/NCT00363610||179690|
NCT00346801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0352|CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Completed|September 2003|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||October 2012|October 19, 2012|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00346801||180949|
NCT00346814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-001|Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome|Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome||Asociación para Evitar la Ceguera en México||Recruiting|July 2006|November 2006|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|1 Month|12 Months|No|||June 2006|June 28, 2009|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346814||180948|
NCT00346827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20102D05|Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.|||Britannia Pharmaceuticals Ltd.||Not yet recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|85 Years|No|||June 2006|June 29, 2006|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346827||180947|
NCT00347113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAN.5.2.SAF|Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania|The Effect of Schistosome and Soil-transmitted Helminth Infections on Malaria,Infection, Morbidity and Antibody Response Among School and Pre-school Children in Mwanza, Tanzania||DBL -Institute for Health Research and Development||Completed|July 2006|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|620|||Both|5 Years|15 Years|No|||January 2011|September 22, 2014|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347113||180925|
NCT00346788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RL-001|The Subvastus Approach in Total Knee Arthroplasty|The Subvastus Approach in Total Knee Arthroplasty||Nova Scotia Health Authority|No|Completed|January 2005|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|N/A|N/A|No|||May 2008|June 27, 2011|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00346788||180950|
NCT00358098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-1-0093|Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer|For Women With Estrogen Positive Metastatic Breast Cancer Discordance of Pre-treatment FDG-PET and FES-PET in Addition to Presence of Ki-67 and Human Epidermal Growth Factor 2 (HER-2) Overexpression Will Predict for Hormone Refractory Disease When Compared to Standard Response Criteria||AHS Cancer Control Alberta|No|Terminated|August 2006|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|51|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|September 2014|September 26, 2014|July 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00358098||180100|
NCT00358111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302925|Study of LUMA Cervical Imaging System as Adjunct to Colposcopy|A Single Arm Multi-Center Post Approval Study of LUMA as Adjunct to Colposcopy||SpectraScience|Yes|Terminated|July 2006|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|10|||Female|18 Years|N/A|No|||May 2014|May 12, 2014|July 27, 2006||No|PMA withdrawn|No||https://clinicaltrials.gov/show/NCT00358111||180099|
NCT00355290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA2006.01|Changes in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial|Changes in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial||Hospital de Clinicas de Porto Alegre||Completed|August 2006|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|114|||Both|18 Years|N/A|No|||May 2008|May 5, 2008|July 20, 2006||||No||https://clinicaltrials.gov/show/NCT00355290||180310|
NCT00355303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Chaudhuri|Comparison of Misoprostol and Prostaglandin E2 (PGE2) Gel for Induction of Labour in Premature Rupture of Membranes at Term|Comparison of Misoprostol and PGE2 Gel for Induction of Labour in in Premature Rupture of Membranes at Term- A Randomized Comparative Trial||Nilratan Sircar Medical College|Yes|Completed|August 2006|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|932|||Female|N/A|N/A|No|||July 2015|July 21, 2015|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00355303||180309|
NCT00355563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP2005-07|Study of the PAS-Port® Proximal Anastomosis System in Coronary Bypass Surgery|Use of the PAS-Port Proximal Anastomosis System for Creation of Aorto-Venous Proximal Anastomoses in Coronary Bypass Surgery|EPIC|Cardica, Inc|Yes|Completed|June 2006|April 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|220|||Both|50 Years|85 Years|No|||January 2009|January 8, 2009|July 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355563||180289|
NCT00358436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT000742|Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)|||Almirall, S.A.||Completed|July 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|804|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|July 28, 2006|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00358436||180074|
NCT00358449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEE103219|Intravenous Mepolizumab In Children With Eosinophilic Esophagitis|A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219)||GlaxoSmithKline|No|Completed|September 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|77|||Both|2 Years|17 Years|No|||February 2016|February 11, 2016|July 27, 2006|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT00358449||180073|
NCT00358462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26995-D|Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)|Mycoplasma Genitalium Antibiotic Susceptibility and Treatment: A Randomized Double-blind Trial of the Efficacy of Azithromycin and Doxycycline for Clinical and Microbiological Cure of M. Genitalium in Men With Nongonococcal Urethritis||University of Washington|Yes|Completed|January 2007|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|606|||Male|16 Years|N/A|No|||February 2013|February 1, 2013|July 27, 2006|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT00358462||180072|
NCT00355251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE-ATOR|Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption|Study of the Influence of Atorvastatin in Plasma Viral Replication Given Prior to Antiretroviral Treatment Interruption in Patients With HIV-1 Infection and Viral Suppression.||Germans Trias i Pujol Hospital|No|Terminated|July 2006|February 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||February 2014|March 19, 2014|July 19, 2006||No|On the basis of published results of SMART study, it has been observed that the results are    worse in patients who have interrupted their treatments.|No||https://clinicaltrials.gov/show/NCT00355251||180313|
NCT00355264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-007|Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency|Phase 2, Multicenter, Open Label Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to Primary BH4 Deficiency||BioMarin Pharmaceutical||Completed|August 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||August 2014|August 11, 2014|July 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355264||180312|
NCT00365261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 060340|Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer|Effect of Eszopiclone (Lunesta) on Sleep Disturbance and Pain in Cancer||University of California, San Diego|No|Completed|September 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|75 Years|No|||December 2015|December 16, 2015|August 15, 2006|Yes|Yes||No|August 24, 2011|https://clinicaltrials.gov/show/NCT00365261||179566|
NCT00365560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.341|An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma|A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 Mcg (2 Actuations of 2.5 Mcg) and 10 Mcg (2 Actuations of 5 Mcg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler® as Add-on Therapy in Patients With Severe Persistent Asthma||Boehringer Ingelheim||Completed|August 2006|||November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||115|||Both|18 Years|75 Years|No|||July 2013|July 10, 2013|August 16, 2006||||||https://clinicaltrials.gov/show/NCT00365560||179543|
NCT00365573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USTF001-HMO-CTIL|Doppler Ultrasonography Evaluation of Tibial Fracture Site Vascularity|Doppler Ultrasonography Evaluation of Tibial Fracture Site Vascularity||Hadassah Medical Organization||Suspended|February 2008|||||Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|17 Years|65 Years|No|Non-Probability Sample|patient witj tibial fracture.|October 2010|November 4, 2010|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365573||179542|
NCT00365781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 113715-CS13|Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715|A Phase 1, Open-Label Examination of the Dermatologic Effects From Subcutaneous Administration of ISIS 113715, and Antisense Oligonucleotide Inhibitor of Protein Tyrosine Phosphatase 1B, in Healthy Volunteers||Ionis Pharmaceuticals, Inc.||Completed|August 2006|September 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 15, 2007|August 15, 2006||||||https://clinicaltrials.gov/show/NCT00365781||179527|
NCT00366067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTPZ-P-CH-0806-0107|Study of Efficacy of Phenytoin in Therapy of Children With Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Phenytoin Efficacy in Children for Therapy of Bronchial Asthma||Centre of Chinese Medicine, Georgia|Yes|Completed|August 2006|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|4 Years|14 Years|No|||February 2009|February 18, 2009|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366067||179506|
NCT00366470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-VitaminD|A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients|A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy||Christian Medical College, Vellore, India|Yes|Completed|November 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|75 Years|No|||July 2012|July 4, 2012|August 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00366470||179475|
NCT00366483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098B1-130|Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Lecozotan SR Administered Orally to Healthy Young and Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 15, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366483||179474|
NCT00366457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-234|Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer|Phase II Study of Gemcitabine, Bevacizumab and Erlotinib in Locally Advanced and Metastatic Pancreatic Cancer||Massachusetts General Hospital|Yes|Completed|August 2006|July 2011|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|August 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366457||179476|
NCT00366756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI-06-001|Evaluation of VisionQuest 20/20, a Visual Acuity Testing Software|Evaluation of a Visual Acuity Testing Software for Children, VisionQuest 20/20||Medical University of South Carolina|No|Completed|July 2006|November 2008|Actual|November 2008|Actual|Phase 3|Observational|Time Perspective: Prospective||1|Actual|97|||Both|8 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|Healthy children ages 8-5 years with myopia.|December 2010|August 4, 2011|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366756||179453|
NCT00366769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-05-005|Evaluation of Outcomes Following LASIK Surgery Using CustomVue|Evaluation of Visual Outcomes, Contrast Sensitivity, Glare, and Induction of High Order Aberrations Following LASIK Surgery Using CustomVue||Medical University of South Carolina||Completed|September 2005|February 2006||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||March 2006|August 17, 2006|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366769||179452|
NCT00355394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-4-4755|Treatment of Acute Migraine Headache in Children|Treatment of Acute Migraine Headache in Children||Children's Hospital of Philadelphia|No|Completed|August 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|8 Years|18 Years|No|||October 2015|October 30, 2015|July 19, 2006||No||No|January 8, 2013|https://clinicaltrials.gov/show/NCT00355394||180302|Study was performed in tertiary care setting and may not be generalizable to all settings. Small number of subjects (n=31). None admitted or received additional rescue medication, suggesting most severely affected may not have been enrolled.
NCT00367367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3280105|Endometrial Curettage Before Embryo Transfer|Endometrial Hysteroscopy and Curettage Prior to Embryo Transfer||HaEmek Medical Center, Israel||Recruiting|December 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2006|August 20, 2006|August 20, 2006||||No||https://clinicaltrials.gov/show/NCT00367367||179406|
NCT00367380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVDC-2006-004|Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers|Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers||Malaria Vaccine and Drug Development Center|Yes|Completed|December 2006|March 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 2, 2014|August 19, 2006||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00367380||179405|
NCT00346541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R423/18/2005|Role of Polymorphisms in the IL-1 Gene Cluster|Investigating the Genetic Basis of Glaucoma: Role of Polymorphisms in the IL-1 Gene Cluster||Singapore National Eye Centre||Completed|July 2005|June 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||400|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2006|June 29, 2006|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00346541||180969|
NCT00347321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051013|Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC)|Evaluation of Early Percutaneous Tracheostomy in Patients Undergoing Cardiovascular Surgery and Requiring Prolonged Mechanical Ventilation|ETOC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2006|June 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|212|||Both|18 Years|N/A|No|||March 2007|December 2, 2009|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00347321||180909|
NCT00347334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-209|Is Home Positioning Time Associated With Torticollis Rate of Recovery?|Is Home Positioning Time Associated With Torticollis Rate of Recovery?||The Cleveland Clinic||Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 1|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|N/A|6 Months|No|||January 2014|January 27, 2016|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00347334||180908|
NCT00355043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-027|Efficacy of Zinc in the Treatment of Bronchiolitis and Prevention of Wheezing Respiratory Illness in Children Less Than Two Years Old|||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|February 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|330|||Both|2 Months|23 Months|No|||July 2006|July 11, 2011|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355043||180329|
NCT00356395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-008|Safety and Effects of Ramipril Combined With Candesartan|Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients||Gachon University Gil Medical Center||Completed|August 2003|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|35 Years|75 Years|No|||March 2006|July 25, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356395||180225|
NCT00356408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87065|Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease|An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).|COSPAR II|UCB Pharma|No|Completed|January 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||April 2011|August 26, 2014|July 25, 2006|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00356408||180224|
NCT00358384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES104031|Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034|A Randomised (With Respect to Microplaque Treatment Positions), Single-Blind, Placebo-Controlled, Positive-Controlled, Microplaque Study to Assess the Effectiveness of a Topical Formulation of GW786034 in Patients With Chronic Plaque Psoriasis||GlaxoSmithKline||Completed|September 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||February 2011|May 31, 2012|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358384||180078|
NCT00358397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0590|One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy|Phase I Safety Study of Clostridium Novyi-NT Spores in Patients With Treatment-Refractory Solid Tumor Malignancies||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|July 2006|September 2008|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2008|February 1, 2011|July 27, 2006|No|Yes|Design Problem|No||https://clinicaltrials.gov/show/NCT00358397||180077|
NCT00365274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00162|SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma|A Phase II Study of SGN-30 in Combination With CHOP in Anaplastic Large Cell Lymphoma||National Cancer Institute (NCI)|No|Terminated|August 2006|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2013|May 29, 2014|August 16, 2006|Yes|Yes||No|September 13, 2013|https://clinicaltrials.gov/show/NCT00365274||179565|
NCT00365586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3269-303|Ketoprofen Topical Patch, 20% in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee|A Phase III Study of the Efficacy, Tolerability and Safety of the Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee, Including a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase Followed by an Open-Label Treatment Phase||Endo Pharmaceuticals||Completed|August 2006|May 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|August 16, 2006||||No||https://clinicaltrials.gov/show/NCT00365586||179541|
NCT00365794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USC GCRC#1156|Investigator Initiated Study of the Effects of Androgen Therapy on Carbohydrate and Lipid Metabolism In Elderly Men|||University of Southern California|No|Completed|August 2006|December 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|60 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365794||179526|
NCT00367081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH-CTR_001|Treatment of Cerebral Toxoplasmosis in HIV/AIDS|Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial.||Rajavithi Hospital||Completed|May 2003|August 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|16 Years|N/A|No|||July 2007|July 29, 2007|August 18, 2006||||No||https://clinicaltrials.gov/show/NCT00367081||179428|
NCT00366418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060228|Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia|A Pilot Study of Fractionated Dose Subcutaneous Rituximab (RTX, Rituxan(Registered Trademark)) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia||National Institutes of Health Clinical Center (CC)||Completed|August 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|21 Years|N/A|No|||February 2011|February 25, 2011|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366418||179479|
NCT00366431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-200|Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Non-Malignant Pain||Valeant Pharmaceuticals International, Inc.||Completed|August 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||420|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|August 18, 2006||||||https://clinicaltrials.gov/show/NCT00366431||179478|
NCT00366444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP21L-301|Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery|Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery||Xanodyne Pharmaceuticals||Completed|August 2006|||October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|65 Years|No|||April 2011|April 12, 2011|August 17, 2006||Yes|||March 22, 2010|https://clinicaltrials.gov/show/NCT00366444||179477|
NCT00366782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 231|Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults|A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2007|June 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|51|||Both|6 Months|49 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|August 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00366782||179451|
NCT00367068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF-147|Dutch National ITB Study in Children With Cerebral Palsy|Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy||Maastricht University Medical Center|No|Completed|January 2002|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||18|||Both|4 Years|16 Years|No|||November 2007|November 15, 2007|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367068||179429|
NCT00355940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STO-NTNU/DMF-SINTEF-1|Comparing Fluoroscopy and Technological Methods for Guidance During Endovascular Procedures|Comparing Fluoroscopy and Technological Methods for Guidance During Endovascular Procedures Traditional Fluoroscopy Navigation Based on Preoperative CT and Intraoperative DynaCT||Norwegian University of Science and Technology|No|Completed|August 2007|April 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|60 Years|N/A|No|||April 2013|April 26, 2013|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00355940||180260|
NCT00363129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N05C3|Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer|The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study||Alliance for Clinical Trials in Oncology|No|Completed|December 2006|August 2014|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|207|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|August 10, 2006||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT00363129||179726|
NCT00363415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9691|Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer|A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer||Eli Lilly and Company|Yes|Completed|August 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|908|||Both|18 Years|N/A|No|||October 2009|October 20, 2009|August 10, 2006|Yes|Yes||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00363415||179704|
NCT00347399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AvastinTFD|Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration|Effects of Intravitreal Injection of Bevacizumab in Combination With Verteporfin Photodynamic Therapy||Asociación para Evitar la Ceguera en México||Recruiting|March 2006|June 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|55 Years|N/A|No|||June 2006|June 30, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347399||180903|
NCT00347737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10386|The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL|The Effects of Therapy With Teriparatide (Recombinant Parathyroid Hormone (1-34) on Vascular Compliance and Osteoprotegerin/RANKL||University of Kansas Medical Center|No|Withdrawn|June 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|40 Years|N/A|No|||January 2013|January 14, 2013|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00347737||180878|
NCT00346840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso-Obs-002|Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour|Controlled-Release Misoprostol Vaginal Insert in Parous Women for Labor Induction: Randomized Trial||Ferring Pharmaceuticals|No|Completed|June 2003|March 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|124|||Female|18 Years|N/A|No|||June 2012|June 15, 2012|June 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00346840||180946|
NCT00347347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R456/05/2006|Comparative Study of Cycloplegic Refraction and Subjective Refraction With Fogging in School Age Children|||Singapore National Eye Centre||Completed|February 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|4 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 4-13 years old.|May 2010|May 11, 2010|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00347347||180907|
NCT00356135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10631|Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event|A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndrome Who Are Receiving Clopidogrel|SWAP|Eli Lilly and Company||Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|139|||Both|18 Years|74 Years|No|||October 2010|October 20, 2010|July 21, 2006|Yes|Yes||No|December 10, 2009|https://clinicaltrials.gov/show/NCT00356135||180245|
NCT00357552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5230|Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy|A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens||AIDS Clinical Trials Group|Yes|Completed|January 2008|May 2012|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 25, 2006|Yes|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00357552||180142|
NCT00364650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL346 (Main)|Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation|Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation: a Single Center Randomized Controlled Trial||Swedish Medical Center|Yes|Completed|July 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00364650||179611|
NCT00364910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH071249|Safety and Efficacy of Cognitive Behavior Therapy for People With Post-Traumatic Stress and Cardiovascular Illness|PTSD Treatment in Cardiac Patients||National Institute of Mental Health (NIMH)|No|Completed|April 2006|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||September 2008|September 8, 2008|August 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00364910||179591|
NCT00364923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-008|Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|PROPEL|Spectrum Pharmaceuticals, Inc|Yes|Completed|August 2006|February 2012||January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|August 14, 2006|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00364923||179590|Outcome Measure (primary and secondary), Serious Adverse Event and Adverse Event data presented have a cut-off date of August 2009.
NCT00365599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14662|Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer|Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination With Tamoxifen for Patients With Advanced Breast Cancer Who Have Failed Prior Anti-hormonal Therapy.||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|February 2006|August 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|August 15, 2006|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00365599||179540|
NCT00366158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR06001LV|EVITA: Evaluation of VIP Feature in Pacemaker Patients|EVITA: Evaluation of VIP Feature in Pacemaker Patients||St. Jude Medical|No|Completed|August 2006|September 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|461|||Both|18 Years|N/A|No|||October 2010|October 8, 2010|August 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00366158||179499|
NCT00365820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919N2201|Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain|A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain||Novartis||Terminated|July 2006|April 2007|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||670|||Both|18 Years|N/A||||April 2012|April 19, 2012|August 17, 2006|Yes|Yes|This study was terminated early as a result of regulatory action suspending tegaserod use in    2007|No||https://clinicaltrials.gov/show/NCT00365820||179524|
NCT00366132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050198|Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers|DermaGold Indicated for Use of Shockwave Treat of Diabetic Foot Ulcers in Patients With Diabetes Mellitus||Tissue Regeneration Technologies||Recruiting|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||August 2006|August 17, 2006|August 17, 2006||||||https://clinicaltrials.gov/show/NCT00366132||179501|
NCT00365807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC06631-01-00|Examination of a Treatment Program for Overweight Children, Adolescents, and Their Families|Effectiveness of a Treatment Program for Pediatric Obesity||University of Kansas Medical Center|No|Completed|July 2006|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|7 Years|17 Years|No|||November 2012|November 2, 2012|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00365807||179525|
NCT00366808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-06-003|Mechanical vs. Alcohol Separation of the Corneal Epithelium During Surface Ablation Refractive Procedures|Mechanical vs. Alcohol Separation of the Corneal Epithelium During Surface Ablation Refractive Procedures||Medical University of South Carolina||Completed|February 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||July 2006|October 1, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366808||179449|
NCT00366821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-141|Retrospective Review of the Outcomes of Newborns With Genetic Abnormalities|Retrospective Review of the Outcomes of Newborns With Genetic Abnormalities||Children's Healthcare of Atlanta|No|Completed|January 2002|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1000|||Both|N/A|30 Days|No|Non-Probability Sample|Patients' charts will be reviewed from Children's Healtcare of Atlanta between January 1,        2002 through December 31, 2006 of all neonates who underwent cardiac surgery.|November 2014|November 26, 2014|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366821||179448|
NCT00367094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLHT344ACN01|Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension|Efficacy and Safety of the Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Benazepril||Novartis||Completed|July 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||296|||Both|18 Years|N/A|No|||March 2007|July 6, 2007|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367094||179427|
NCT00367107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4169-RG-CTIL|Autism in Adult Patients and the Effects on Caregivers|Autism: Long Term Course and Impact||Sheba Medical Center||Not yet recruiting|August 2008|||August 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|30 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|autisem|February 2008|February 4, 2008|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367107||179426|
NCT00366795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6682|Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver|Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo in the Absence of Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.|SPARe-2|Sanofi||Terminated|August 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||July 2009|July 17, 2009|August 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366795||179450|
NCT00363142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEX106430|A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects|See Detailed Description.||GlaxoSmithKline||Completed|May 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Both|18 Years|N/A|No|||October 2010|October 21, 2010|August 11, 2006|Yes|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00363142||179725|
NCT00356850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PI2-03/02(F)|Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers|Ocular Pharmacokinetics After a Single Drop Instillation, in Each Eye of One of Three Different Concentrations of T1225 (0.5% - 1% - 1.5% Dihydrate) in 91 Healthy Volunteers||Laboratoires Thea||Completed|May 2002|June 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2006|July 25, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356850||180194|
NCT00363922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.2070|Rehabilitation After Coronary Bypass Grafting. Comparison of Different Types of Rehabilitation Programs|Rehabilitation After Coronary Bypass Grafting: Home Based Rehabilitation Versus Rehabilitation in Institution and Rehabilitation in Institution Versus Out-patient Rehabilitation at the Hospital||Norwegian University of Science and Technology|No|Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00363922||179666|
NCT00364169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 308399|Prevention of Constipation: Systematic Nursing Interventions to Reduce Postoperative Constipation After Thoracic Surgery|Systematic Nursing Interventions to Reduce Postoperative Constipation After Thoracic Surgery||Rigshospitalet, Denmark||Completed|September 2006|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|58|||Both|18 Years|N/A|No|||June 2008|June 27, 2008|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364169||179647|
NCT00315783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006102|Comparison of Data Obtained by Echocardiography and Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy|Comparison of Data Obtained by Echocardiography and Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy||Assistance Publique - Hôpitaux de Paris||Recruiting|April 2006|June 2006||||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||||30|||Both|18 Years|N/A|No|||April 2006|April 17, 2006|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00315783||183249|
NCT00315796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0387|Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy|Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy||Johns Hopkins University||Completed|August 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||January 2005|March 31, 2015|April 17, 2006||||No||https://clinicaltrials.gov/show/NCT00315796||183248|
NCT00346853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-MP Dark Adaptation Inhib.|Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy|Clinical Interventions Against Stargardt Macular Dystrophy: Phase 1 Pilot Study of 4-MP as an Inhibitor of Dark Adaptation||University of Utah|No|Completed|November 2005|September 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2008|July 9, 2008|June 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00346853||180945|
NCT00346866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-00-07|Anecortave Acetate Versus Placebo in AMD Patients Following PDT|Anecortave Acetate Versus Placebo in AMD Patients Following PDT||Alcon Research||Completed|May 2000|December 2001|Actual|December 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||136|||Both|50 Years|N/A|No|||August 2008|August 4, 2008|June 28, 2006||||||https://clinicaltrials.gov/show/NCT00346866||180944|
NCT00347126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R463/12/2006|Results of Mass Switch From Latanoprost to Travoprost|Efficacy and Safety of a Systematic Switch From Latanoprost to Travoprost in Patients With Glaucoma||Singapore National Eye Centre||Completed|April 2006|April 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|372|||Both|N/A|N/A|No|Non-Probability Sample|Patients on treatment with latanoprost who are switched to travoprost therapy|May 2010|May 11, 2010|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00347126||180924|
NCT00347360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD105453|The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial|See Detailed Description||GlaxoSmithKline||Completed|July 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|654|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|June 29, 2006|Yes|Yes||No|April 22, 2009|https://clinicaltrials.gov/show/NCT00347360||180906|
NCT00357331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604008486|The Effects of Potassium Citrate on Bone Metabolism|A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia||Weill Medical College of Cornell University||Recruiting|July 2006|||December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|75|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||November 2010|November 4, 2010|July 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357331||180159|
NCT00357344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906173|Study of Effects From Gastric Bypass Weight Loss on Brain Tissue|Weight Changes and the Brain (Study of the Effects of a Large and Intentional Weight Loss Induced by Roux-en-Y Gastric Bypass on Brain Tissue Composition of Obese Patients Using Magnetic Resonance Imaging and Voxel-Based Morphometry)||National Institutes of Health Clinical Center (CC)||Completed|May 2006|October 2008||||N/A|Observational|N/A||||80|||Both|18 Years|45 Years|No|||October 2008|October 4, 2008|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357344||180158|
NCT00357357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF0220/003|European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients|Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease||Hunter-Fleming Ltd|Yes|Completed|July 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|55 Years|N/A|No|||August 2008|August 20, 2008|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357357||180157|
NCT00357864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002462-19|Carbachol´s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow|Basic Research on Carbachol´s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow in a Humane Experimental Headache Model||Danish Headache Center|Yes|Completed|July 2006|April 2007|Actual|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2007|August 29, 2007|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357864||180118|
NCT00358163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-046|Trial of PTK787/ZK 222584 Plus Paclitaxel|Phase I Study of the Oral Vascular Endothelial Growth Factor Inhibitor PTK787/ZK 222584 in Combination With Paclitaxel in Patients With Advanced Solid Tumors.||Dana-Farber Cancer Institute||Active, not recruiting|April 2006|April 2010|Anticipated|April 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|July 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00358163||180095|
NCT00364949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50HD044405|Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands|Genes, Androgens and Intrauterine Environment in PCOS||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|January 2003|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|70|Samples With DNA|blood|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with PCOS and control women and their offspring|April 2013|April 3, 2013|August 15, 2006||No||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00364949||179588|
NCT00364936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS Society 676/01|Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS)|Proposal to Create a Flagship Neurology and Palliative Care Service for South London||King's College London|Yes|Completed|March 2004|December 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|N/A|N/A|No|||June 2009|June 10, 2009|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364936||179589|
NCT00366171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3168A1-312|Open Label Extension Study of Bifeprunox|An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2006|October 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|66 Years|No|||December 2007|December 18, 2007|August 17, 2006||||||https://clinicaltrials.gov/show/NCT00366171||179498|
NCT00366184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060225|Influence of Theta Burst Stimulation and Carbidopa-Levodopa on Motor Performance in Stroke Patients|Influencing Motor Performance in Patients With Stroke by Combined Theta Burst Stimulation and Carbidopa-Levodopa||National Institutes of Health Clinical Center (CC)||Completed|August 2006|May 2010||||N/A|Observational|N/A|||Actual|20|||Both|18 Years|90 Years|No|||May 2010|May 27, 2010|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366184||179497|
NCT00366496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-05-004|Surgical Outcomes After Routine Cataract Extraction & Implantation of a Conventional or Spheric Intraocular Lens|Comparison of Visual Outcomes, Wavefront Analysis, Contrast Sensitivity and Glare Testing Following Cataract Extraction Between Acrysof Single-Piece IOL and Acrysof WF||Medical University of South Carolina||Completed|July 2004|May 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|50 Years|80 Years|No|||July 2005|August 17, 2006|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366496||179473|
NCT00366509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060222|Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases|Role of Helicobacter Pylori and Its Toxins in Pulmonary and Oropharyngeal Disease||National Institutes of Health Clinical Center (CC)||Recruiting|August 2006|||||N/A|Observational|N/A|||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 15, 2015|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366509||179472|
NCT00366145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280|Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease|A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal(Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid Refractory Acute GVHD||Osiris Therapeutics|Yes|Completed|July 2006|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|6 Months|70 Years|No|||October 2011|October 11, 2011|August 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366145||179500|
NCT00354471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2000 115|Uterine Artery Embolization for Symptomatic Fibroids|Short and Long Term Outcomes of Uterine Artery Embolization.||University of Manitoba||Completed||||||Phase 3|Observational|Time Perspective: Prospective|||||||Female|18 Years|60 Years||||July 2006|February 4, 2009|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354471||180371|
NCT00354484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT06011|Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients|Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients||Luitpold Pharmaceuticals|No|Completed|May 2006|January 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|291|||Female|N/A|N/A|No|||October 2013|October 8, 2013|July 13, 2006|Yes|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00354484||180370|
NCT00354796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|enoxap-HMO-CTIL|The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin|The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin||Hadassah Medical Organization|No|Recruiting|July 2006|October 2015|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|patients admitted to tertiary hospital|June 2011|July 3, 2011|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354796||180347|
NCT00354809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD105516|Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Morning Administration of GW679769 (10mg and 30 mg) on Polysomnograph Sleep Recordings, Subjective Sleep Assessment, Daytime Cognition and Psychomotor Function in Subjects With Primary Insomnia||GlaxoSmithKline|No|Completed|May 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|68|||Both|18 Years|64 Years|No|||April 2015|April 14, 2015|July 18, 2006||||||https://clinicaltrials.gov/show/NCT00354809||180346|
NCT00367419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-340-14-6-1-PU-02|Use of Erythromycin in Mustard-Induced Bronchiolitis|Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans||Baqiyatallah Medical Sciences University||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|N/A|N/A||||March 2006|November 4, 2008|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367419||179402|
NCT00367432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01222|A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures|A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in Subjects From 16 to 65 Years With Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized Who Completed in a Previous Study||UCB Pharma|No|Completed|July 2006|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|398|||Both|16 Years|65 Years|No|||April 2015|April 1, 2015|August 21, 2006|Yes|Yes||No|December 2, 2011|https://clinicaltrials.gov/show/NCT00367432||179401|
NCT00363155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN7000/02-B01|KRN7000 in Chronic Hepatitis B|Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis B Infection||Foundation for Liver Research||Completed|March 2003|July 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||28|||Both|18 Years|70 Years|No|||August 2006|August 10, 2006|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363155||179724|
NCT00355654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5I19|Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®|Safety and Immunogenicity of Booster Vaccination With PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination With Infanrix® Hexa When Both Vaccines Are Co-Administered With Prevenar® to Toddlers 11-18 Months of Age||Sanofi|No|Completed|September 2006|July 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|847|||Both|11 Months|18 Months|Accepts Healthy Volunteers|||January 2015|January 6, 2015|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355654||180282|
NCT00355667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H18-Junkanki(seishu)-ippan-046|Comparison of Long- and Short-Acting Diuretics in Congestive Heart Failure|Japanese Multicenter Evaluation of Long- Versus Short-Acting Diuretics in Congestive Heart Failure|J-MELODIC|Hyogo College of Medicine|Yes|Active, not recruiting|June 2006|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||January 2009|January 28, 2009|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00355667||180281|
NCT00316056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060143|Use of Virtual Reality to Communicate Concepts of Genomics to the General Public|Using Virtual Reality to Test Communication Strategies for Genomic Concepts||National Institutes of Health Clinical Center (CC)||Completed|April 2006|||October 2007|Actual|N/A|Observational|N/A||||346|||Both|18 Years|40 Years|No|||August 2009|August 26, 2009|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316056||183228|
NCT00316303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072556|Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder|The STIRR Intervention for Dually Diagnosed Clients||Dartmouth-Hitchcock Medical Center||Completed|February 2006|August 2012|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|April 18, 2006||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00316303||183209|
NCT00348348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|434|A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis||Bausch & Lomb Incorporated|No|Completed|June 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1161|||Both|1 Year|N/A|No|||March 2015|March 4, 2015|June 30, 2006|Yes|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00348348||180831|
NCT00348361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELR100710|Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)|A Study to Validate Key Therapeutic Targets and Biomarkers During Allergen Exposure in Subjects With Allergic Rhinitis||GlaxoSmithKline||Completed|April 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||48|||Both|18 Years|65 Years|No|||October 2008|October 9, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00348361||180830|
NCT00316290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH073567|Integrated Parent Training for Treating Depression in Mothers of Children With Attention Deficit Hyperactivity Disorder|Integrated Treatment for Depressed Mothers of ADHD Children||University of Maryland||Completed|April 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|6 Years|N/A|No|||February 2013|February 22, 2013|April 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00316290||183210|
NCT00364390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITT-101|A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|A Phase I Open Label Pilot Study to Evaluate the Safety, Efficacy and Tolerability of Anginera for Adults With Left Ventricular Dysfunction AND Reversible Myocardial Ischemia Undergoing CABG Surgery||Theregen, Inc.|Yes|Active, not recruiting|April 2006|February 2009|Anticipated|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|35 Years|80 Years|No|||March 2009|March 27, 2009|August 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00364390||179631|
NCT00364624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR/06-008|Adrenal Function in Patients With Newly Diagnosed Lung Cancer|Adrenal Cortical Function in Patients With Newly Diagnosed Lung Cancer||Princess Margaret Hospital, Hong Kong|No|Completed|August 2006|May 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed, histologically confirmed primary lung cancer|January 2009|January 15, 2009|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364624||179613|
NCT00364637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS/URC/ER/mm 51/DG|Volatile Anesthetics in Cardiac Protection|Pharmacological Preconditioning Properties of Volatile Anesthetics||Università Vita-Salute San Raffaele||Recruiting|January 2005|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|18 Years|100 Years|No|||March 2016|March 9, 2016|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00364637||179612|
NCT00365612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266073|Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients|Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen||Gilead Sciences|No|Completed|July 2006|January 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|80 Years|No|||April 2008|April 9, 2008|August 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00365612||179539|
NCT00365287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000LS039|Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer|Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen||Masonic Cancer Center, University of Minnesota|Yes|Completed|June 2000|December 2005|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|148|||Both|N/A|69 Years|No|||October 2012|October 9, 2012|August 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00365287||179564|
NCT00365300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B3-329|Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study of the Efficacy and Safety of Pantoprazole Sodium Enteric-Coated Granules in Infants (1 Through 11 Months) With Symptomatic GERD.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|N/A|11 Months|No|||April 2010|April 26, 2010|August 16, 2006|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00365300||179563|
NCT00357942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102010|Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy|Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children||Danish University of Pharmaceutical Sciences|Yes|Completed|September 2006|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|N/A|N/A|No|||February 2014|February 20, 2014|July 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00357942||180112|
NCT00357955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12733|Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients|Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients||Providence VA Medical Center|Yes|Completed|August 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|July 24, 2006||No||No|January 14, 2014|https://clinicaltrials.gov/show/NCT00357955||180111|
NCT00362661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSD-06|Low-dose Cortisol in Chronic Posttraumatic Stress Disorder|Low-dose Cortisol in Chronic Posttraumatic Stress Disorder||University of Zurich||Terminated|June 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||January 2010|January 11, 2010|August 9, 2006||No|Recruitment: Insufficient number of patients eligible for enrollment|No||https://clinicaltrials.gov/show/NCT00362661||179760|
NCT00358943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICGG Gaucher Registry|International Collaborative Gaucher Group (ICGG) Gaucher Registry|International Collaborative Gaucher Group (ICGG) Gaucher Registry||Sanofi|No|Recruiting|April 1991|January 2030|Anticipated|January 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12000|||Both|N/A|N/A|No|Non-Probability Sample|Gaucher disease|February 2016|February 18, 2016|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00358943||180035|
NCT00358956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00068|A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer|A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer||AstraZeneca||Completed|August 2006|May 2014|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|July 28, 2006|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00358956||180034|
NCT00359190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF10027|Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer|A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients With Treatment- Naive Breast Cancer||GlaxoSmithKline|No|Completed|June 2004|January 2008|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|July 28, 2006||||||https://clinicaltrials.gov/show/NCT00359190||180016|
NCT00359697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.132|Comparison of Two Different Medications Used to Treat Elevated Intracranial Pressure|Prospective, Randomized Clinical Trialto Compare Mannitol and Hypertonic Saline for Treatment of Increased Intracranial Pressure||Thomas Jefferson University||Not yet recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|August 1, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00359697||179979|
NCT00359996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9886 (AHRQ R01 HS10479)|Improving Diabetes Care Collaboratively in the Community|Improving Diabetes Care Collaboratively in the Community||University of Chicago|No|Active, not recruiting|June 2000|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2720|||Both|18 Years|75 Years|No|||August 2007|August 9, 2007|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00359996||179958|
NCT00360282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602009|Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?|Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs||University of Pittsburgh|No|Completed|August 2006|March 2010|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|36|||Both|21 Years|45 Years|No|||December 2014|December 4, 2014|August 2, 2006||No||No|November 7, 2012|https://clinicaltrials.gov/show/NCT00360282||179938|
NCT00360607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1891002|A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections|A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections||Pfizer||Completed|July 2004|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|307|||Both|12 Years|N/A|No|||December 2008|December 1, 2008|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360607||179914|
NCT00357370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-009|A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes|A Pilot Study of the Efficacy and Safety of BMS-512148 on Glycemic Control in Subjects With Type 2 Diabetes Treated Aggressively But Not Controlled on Combination Antihyperglycemic Therapy With Metformin and/or Thiazolidinedione (TZD) and Insulin.||AstraZeneca|No|Completed|October 2006|March 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|67|||Both|18 Years|75 Years|No|||March 2015|March 20, 2015|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357370||180156|
NCT00358514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-0063|Continuous Pressure Monitoring In Lower Leg Fractures|Continuous Compartment Pressure Monitoring (Ccpm) Following Tibial Fracture: A Prospective Randomized Trial||University of British Columbia|No|Terminated|September 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|16 Years|N/A|No|||March 2010|March 26, 2010|July 28, 2006||No|Large sample size and change in Orthopaedic practice to use of CCPM in conjunction with    Clinical Monitoring rendered project less timely.|No||https://clinicaltrials.gov/show/NCT00358514||180068|
NCT00358527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04608|Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|May 2006|November 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|July 31, 2006|Yes|Yes||No|February 18, 2010|https://clinicaltrials.gov/show/NCT00358527||180067|
NCT00361933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30618-A|Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease|Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir||University of Washington|Yes|Withdrawn|December 2008|May 2009|Anticipated|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||June 2009|June 16, 2009|August 8, 2006|Yes|Yes|Research never begun.|No||https://clinicaltrials.gov/show/NCT00361933||179815|
NCT00356512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060188|Physiologic Regulation of FGF-23|Physiologic Regulation of FGF-23||National Institutes of Health Clinical Center (CC)||Completed|July 2006|||September 2009|Actual|N/A|Observational|N/A||||20|||Both|18 Years|N/A|No|||September 2009|September 26, 2015|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356512||180217|
NCT00356837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-06-004|Diagnosing Extremity Fractures and/or Dislocations Using Ultrasound Presenting to the Emergency Department|Diagnosing Extremity Fractures and/or Dislocations Using Ultrasound in Adult Patients Presenting to the Emergency Department||United States Army Institute of Surgical Research|No|Terminated|August 2006|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|323|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|July 24, 2006||No|IRB terminated study due to non compliance with continuing review date.|No||https://clinicaltrials.gov/show/NCT00356837||180195|
NCT00357084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1978.00|Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant|A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation||Fred Hutchinson Cancer Research Center||Completed|May 2006|||August 2007|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|1||Anticipated|53|||Both|N/A|N/A|No|||September 2010|September 10, 2010|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357084||180177|
NCT00361621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-012|Ph II CHOP+Velcade in Mediastinal LBCL|Phase II Study of CHOP/Rituxan Plus VELCADE in Mediastinal Large B-cell Lymphoma||Dana-Farber Cancer Institute||Terminated|July 2006|May 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2009|November 30, 2012|August 7, 2006|Yes|Yes|Closed due to slow accrual|No||https://clinicaltrials.gov/show/NCT00361621||179838|
NCT00361829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880032|The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development|Specificity of Mother-Infant Interaction: The Influence of Maternal Age, Employment Status, and Parenthood Status||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 1988|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5970|||Both|5 Months|50 Years|Accepts Healthy Volunteers|||May 2015|November 7, 2015|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00361829||179823|
NCT00361309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-348|SU011248 in Advanced Hepatocellular Carcinoma|A Phase II Study of SU011248 in Advanced Hepatocellular Carcinoma||Massachusetts General Hospital|Yes|Completed|April 2006|March 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||March 2014|March 16, 2014|August 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361309||179862|
NCT00362063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304-C03/L3301n|Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency|Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency||Baylor College of Medicine||Recruiting|January 2006|August 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|1 Month|17 Years|Accepts Healthy Volunteers|||December 2010|December 21, 2010|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362063||179805|
NCT00362674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-304|Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial|An Open-label, Observation Study to Evaluate the Durability of Antiviral Activity in Chronic Hepatitis B Patients Who Showed Complete Response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 Trial||Bukwang Pharmaceutical||Completed|June 2005|||||Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A||Non-Probability Sample|the patients who completed the previous 301, 302 and 303 studies with clevudine|December 2010|December 21, 2010|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362674||179759|
NCT00361816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020195|Human MATER and Idiopathic Infertility|Human MATER and Idiopathic Infertility||National Institutes of Health Clinical Center (CC)||Completed|May 2002|March 2011||||N/A|Observational|N/A|||Anticipated|100|||Female|N/A|N/A|No|||March 2011|September 26, 2015|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00361816||179824|
NCT00358891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701282|Follow-Up of VLBW Infants With Chronic Lung Disease: Respiratory Health and Neurodevelopment|Follow-Up of Very Low Birth Weight Preterm Infants With Chronic Lung Disease at Preschool Ages: Respiratory Health and Neurodevelopment||National Taiwan University Hospital||Not yet recruiting|August 2006|July 2009||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||98|||Both|N/A|3 Years|No|||July 2006|August 1, 2006|July 30, 2006||||No||https://clinicaltrials.gov/show/NCT00358891||180039|
NCT00358904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0678|Assessment of Weber Humeral Derotational Osteotomy Using CT Scan|Assessment of Weber Humeral Derotational Osteotomy Using CT Scan||University of British Columbia|No|Completed|May 2006|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects who have had the Weber osteotomy for Hill-Sachs lesions.|April 2011|April 26, 2011|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358904||180038|
NCT00359203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS3|ISSUE3: International Study on Syncope of Uncertain Etiology 3|ISSUE3: International Study on Syncope of Uncertain Etiology 3 Pacemaker Therapy for Patients With Asystolic Neurally-mediated Syncope||Medtronic Bakken Research Center||Completed|September 2006|November 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|511|||Both|40 Years|N/A|No|||September 2015|September 28, 2015|July 31, 2006||No||No|May 22, 2013|https://clinicaltrials.gov/show/NCT00359203||180015|
NCT00360633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605008534|Psychiatric and Cognitive Manifestations of Parkinson's Disease|Psychiatric and Cognitive Manifestations of Parkinson's Disease: A Prospective Cohort Study||New York University School of Medicine|Yes|Recruiting|June 2006|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Patients with Parkinson's Disease who are seen for their routine medical care at the             NYU Parkinson's and Movement Disorders Center.          2. Matched healthy control subjects.|November 2015|November 18, 2015|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360633||179913|
NCT00360932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL6049-0417|Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)|An Open-Label Registry Study of the Facial Lipoatrophy Correction Experience With SCULPTRA® in Subjects With Human Immunodeficiency Virus (FACES Study)|FACES|Sanofi|No|Completed|October 2005|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|290|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|August 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360932||179891|
NCT00361140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14178|Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)|Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|August 2005|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|16 Years|65 Years|No|||June 2013|April 24, 2013|August 3, 2006|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT00361140||179875|
NCT00357578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000114|Genetic Study of Age-Related Macular Degeneration|A Case Control Study of Age-Related Macular Degeneration (AMD) Examining Gene Expression Patterns in Circulating Monocytes From Peripheral Blood Samples||National Institutes of Health Clinical Center (CC)||Completed|April 2000|September 2007||||N/A|Observational|N/A||||150|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 26, 2015|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357578||180140|
NCT00354458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKI-302|PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy||NovaCardia, Inc.|Yes|Completed|October 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1102|||Both|18 Years|N/A|No|||October 2009|October 8, 2009|July 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00354458||180372|
NCT00357877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE017753-01|Prevention of Adult Caries Study (PACS)|Prevention of Adult Caries Study||Tufts University|Yes|Active, not recruiting|July 2006|June 2010|Anticipated|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|983|||Both|18 Years|N/A|No|||November 2009|December 10, 2009|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357877||180117|
NCT00357695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040047|Role of the Brain in Processing Visually Presented Objects|Role of the Parieto-Frontal Network in Automatic Processing of Visually Presented Objects||National Institutes of Health Clinical Center (CC)||Completed|November 2003|October 2008||||N/A|Observational|N/A||||45|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 29, 2008|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357695||180131|
NCT00357994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S187.3.001|Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects|A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations||AbbVie|Yes|Completed|January 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|30 Years|N/A|No|||January 2015|January 12, 2015|July 27, 2006|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00357994||180108|
NCT00361374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P002337|Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression|Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters||Massachusetts General Hospital|Yes|Completed|July 2006|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|196|||Both|18 Years|80 Years|No|||July 2014|July 17, 2014|August 4, 2006|Yes|Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT00361374||179857|The study was underpowered due to lower than expected recruitment. The high placebo response rate may have impeded signal detection. The n-3 preparations were not pure, but “enriched” for one n-3 or the other, and contained other FAs.
NCT00361842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol CLTR0105-201|Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer|Multicenter, Open-Label, Phase 2 Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Carcinoma||Celator Pharmaceuticals|No|Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|August 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361842||179822|
NCT00362362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060224|Collection of Blood Samples for DNA in Motor Neuron Disease|Collection of Blood Samples for DNA Analysis in Motor Neuron Diseases||National Institutes of Health Clinical Center (CC)||Completed|August 2006|September 2013||||N/A|Observational|N/A|||Actual|23|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362362||179783|
NCT00362687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-ES-164-0151|GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance|GMB: Phase IV, Multicenter, Randomized, Open-Label Pilot Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients Who Need to Interrupt HAART and Who Are Infected With HIV Isolates Containing at Least 2 TAMs (or K65R) and M184V||Gilead Sciences|No|Completed|November 2006|October 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362687||179758|
NCT00362700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-204|Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201|An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of Retreated Clevudine in Chronic Hepatitis B Patients Who Received Clevudine in L-FMAU-201||Bukwang Pharmaceutical||Terminated|July 2003|October 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||33|||Both|N/A|N/A|No|||June 2006|August 8, 2006|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362700||179757|
NCT00362713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-027|Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection|A Phase 1b Safety and Dose-Assessment Study of Neoadjuvant Ipilimumab Monotherapy in Patients With Urothelial Carcinoma Undergoing Surgical Resection||Bristol-Myers Squibb|No|Completed|March 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2009|January 24, 2011|August 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362713||179756|
NCT00362349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-ITP-05-21|Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients|A Single-Arm, Open Label, Multi-Centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP)||CSL Limited|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2009|February 5, 2009|August 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362349||179784|
NCT00362648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-015|Developing World Study for RotaTeq™ (V260-015)(COMPLETED)|Efficacy, Safety, and Immunogenicity of RotaTeq™ Among Infants in Asia and Africa||Merck Sharp & Dohme Corp.||Completed|March 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|7504|||Both|N/A|12 Weeks|Accepts Healthy Volunteers|||October 2015|October 8, 2015|August 8, 2006|Yes|Yes||No|March 11, 2010|https://clinicaltrials.gov/show/NCT00362648||179761|
NCT00358696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0218|Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients|TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus.||University of British Columbia|No|Completed|July 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|N/A|No|||October 2009|October 19, 2009|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358696||180054|
NCT00359411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960085|Genetic Studies of X-linked Lymphoproliferative Disease|Genetic Studies of the X-Linked Lymphoproliferative Disease||National Institutes of Health Clinical Center (CC)||Completed|May 1996|February 2010||||N/A|Observational|N/A|||Actual|12|||Both|N/A|N/A|No|||February 2010|September 26, 2015|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359411||179999|
NCT00359424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS052220|Interventional Management of Stroke (IMS) III Trial|Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone|IMSIII|University of Cincinnati|Yes|Terminated|August 2006|April 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|656|||Both|18 Years|82 Years|No|||November 2013|November 19, 2013|July 31, 2006|Yes|Yes|NINDS/NIH-DSMB recommended halting trial due to futility, no safety concerns.|No|July 4, 2013|https://clinicaltrials.gov/show/NCT00359424||179998|The IMS III trial was stopped early because of futility, according to the prespecified rules. A limitation of our trial is that it did not compare the efficacy of the new stent retrievers with that of intravenous t-PA alone.
NCT00359710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060148|Patients' Perspectives on Identity, Ancestry and Genetics|Identity, Ancestry and Genetics: Patients' Perspectives||National Institutes of Health Clinical Center (CC)||Completed|April 2006|February 2011||||N/A|Observational|N/A|||Actual|22|||Both|21 Years|N/A|No|||February 2011|September 26, 2015|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359710||179978|
NCT00356421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171035|A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®|A 52-Week Multicenter, Open-Label, Randomized, Parallel, Two - Arm Study Comparing Exubera® (Inhaled Human Insulin) Vs. Humalog® (Insulin Lispro), Both In Combination With Insulin Glargine In Subjects With Type 1 Diabetes Mellitus||Pfizer|No|Terminated|November 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||January 2009|August 25, 2009|July 24, 2006|Yes|Yes|See termination reason in detailed description.|No|June 24, 2009|https://clinicaltrials.gov/show/NCT00356421||180223|As a result of Pfizer’s decision to stop marketing Exubera ®, this study was terminated. Due to the early termination of the study and the low number of subjects who completed, no descriptive statistics for efficacy endpoints are provided.
NCT00356434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|foot pump vs SCD|A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population|Study of Patient Compliance and Comfort Using Sequential Compression Devices and Foot Pumps for DVT Prevention||Johns Hopkins University|No|Terminated|November 2008|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 21, 2012|July 24, 2006||No|PI assigned to a different hospital;difficulty recruiting patients|No||https://clinicaltrials.gov/show/NCT00356434||180222|
NCT00356746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-05/261-E|Inflammatory Response During Anesthesia and Surgery|A Prospective, Randomized Trial to Study the Effects of Different Anesthetic Agents on the Perioperative Immune Response|IRAS|UMC Utrecht|No|Completed|March 2006|March 2009|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|Samples Without DNA|Full blood smaples|Both|18 Years|N/A|No|Non-Probability Sample|specific surgical patients receiving general anesthesia of university teaching hospital|June 2008|June 23, 2015|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00356746||180202|
NCT00357006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202/04|A Definitive Estrogen Patch Study (ADEPT)|Multisite Double-Blind Randomized Controlled Study of Estradiol Plus Antipsychotic Versus Placebo Plus Antipsychotic in the Treatment of Psychotic Symptoms in Women With Schizophrenia||The Alfred|Yes|Completed|July 2006|December 2013|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Female|18 Years|50 Years|No|||May 2015|May 7, 2015|July 26, 2006||No||No|March 1, 2015|https://clinicaltrials.gov/show/NCT00357006||180183|
NCT00358215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050222|RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia||Amgen|Yes|Completed|June 2006|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2278|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|July 27, 2006|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00358215||180091|
NCT00358800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C04-0474|REMStar Auto With C-Flex – In-Laboratory Performance v. Conventionally Titrated CPAP Therapy: Performances and Preferences|A Randomized Cross Over Study to Compare REMStar Auto With C-Flex to Standard CPAP Therapy in Patients With OSAHS, and to Assess Its Safety, Tolerability and Efficacy and Preference Over CPAP.||University of British Columbia||Completed|February 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||July 2006|July 28, 2006|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00358800||180046|
NCT00358202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUR0300202A|Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia|Phase 4 Study of Once-Daily Intramuscular Cefepime Versus Ceftriaxone for In-Home Treatment of Nursing Home-Acquired Pneumonia||CPL Associates||Completed|March 2002|April 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|60 Years|N/A|No|||October 2007|October 29, 2007|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358202||180092|
NCT00356863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-2374-RD-CTIL|Effect of an Educational Intervention on Cardiac Patients' Participation Rate in Cardiac Rehabilitation Programs|The Influence of Increasing Awareness of Cardiac Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery to Cardiac Rehabilitation (CR) on Actual Participation Rates and; Patients' Related Barriers to CR Programs Participation|MECRIS|Sheba Medical Center|No|Completed|February 2004|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1024|||Both|N/A|N/A|No|||November 2015|November 16, 2015|July 25, 2006||No||No|June 8, 2010|https://clinicaltrials.gov/show/NCT00356863||180193|Lack of randomizationNo biochemical tests were performed by the study and information regarding biochemical parameters was drawn from the medical records during baseline and from medical documents during follow up.
NCT00357136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|888|Online Survey on Computer Password Usage.|||Towson University||Completed|July 2006|July 2007|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|50|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357136||180173|
NCT00357149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976F_2501|Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)|Randomized Phase II Trial of Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.||Sanofi||Completed|January 2003|||February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357149||180172|
NCT00362414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2005-4800|Beta-hCG + Erythropoietin in Acute Stroke|Safety of Beta-hCG + Erythropoietin in Acute Stroke|BETAS|University of California, Irvine|No|Completed|August 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|21 Years|85 Years|No|||April 2008|April 24, 2008|August 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362414||179779|
NCT00362427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR504|Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®|A Randomized Trial to Assess the Immunogenicity and Safety of PR5I With an Adjuvant Composition Enhancement to the Hepatitis B Component and When Given Concomitantly With Prevnar®||Sanofi|Yes|Completed|August 2006|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|460|||Both|42 Days|89 Days|Accepts Healthy Volunteers|||January 2014|January 10, 2014|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362427||179778|
NCT00361855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-05-018|Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle|A Phase 1 Open Label Dose Escalation Study Evaluate The Safety Of a Single Escalating Dose Of NX-CP105 (Human Adult Bone Marrow Derived Somatic Cells [hABM-SC] Administered by Endomyocardial Injection To Cohorts Of Adults 30-60 Days Following Acute Myocardial Infarction||Neuronyx||Completed|April 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|30 Years|75 Years|No|||September 2008|September 9, 2008|August 7, 2006||||||https://clinicaltrials.gov/show/NCT00361855||179821|
NCT00361868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF23-0121 05 01|Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI|A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia||Solvay Pharmaceuticals|Yes|Terminated|June 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|75 Years|No|||June 2008|June 26, 2008|August 8, 2006||No|The study was discontinued prematurely at the end of March 2007 due to slow enrolment.|No||https://clinicaltrials.gov/show/NCT00361868||179820|
NCT00361881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-04|Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis|A Randomized, Double-Blind, Active Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis||Medivir|No|Completed|July 2006|December 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|1443|||Both|18 Years|N/A|No|||August 2008|August 14, 2008|August 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361881||179819|
NCT00361894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11356|Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.|RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.|RECORD 3|Bayer||Completed|February 2006|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2531|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|August 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361894||179818|
NCT00358670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04563|Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)|A Long-Term Efficacy and Safety Study of Infliximab in the Treatment of Moderate to Severe Plaque-Type Psoriasis||Merck Sharp & Dohme Corp.|Yes|Terminated|May 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|441|||Both|18 Years|75 Years|No|||January 2015|January 22, 2015|July 31, 2006||No|Infusion reactions during re-induction cycles after a period of no treatment. Please see    "Purpose" section.|No|April 8, 2010|https://clinicaltrials.gov/show/NCT00358670||180056|
NCT00358683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87069|A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease|Open Label Long Term Clinical Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87055 Study.||UCB Pharma||Withdrawn|November 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A||||May 2012|May 25, 2012|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00358683||180055|
NCT00358709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B02-0769|Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Two State-of-the-Art Interventions|Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Cognitive-Behavioral Therapy and Skills Training Symptom Management on Measures of Symptoms and on Other Indices of Well-Being||University of British Columbia||Completed|June 2002|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|129|||Both|18 Years|35 Years|No|||June 2008|June 18, 2008|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358709||180053|
NCT00359723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS021062|Methylphenidate and Parkinson's Disease|Subacute Trial of Methylphenidate in Parkinson's Disease||Oregon Health and Science University||Completed|July 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|21 Years|N/A|No|||September 2009|September 3, 2009|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00359723||179977|
NCT00360295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661174|A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults|A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults||Pfizer||Completed|September 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|153|||Both|16 Years|80 Years|No|||May 2008|May 19, 2008|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360295||179937|
NCT00356759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI-06-21|Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients|A Randomized Double-blind Study of 4-weekly Versus 12-weekly Monitoring of Stable Patients on Long-term Anticoagulation With Warfarin||McMaster University|Yes|Completed|December 2006|February 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||December 2008|February 26, 2010|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00356759||180201|
NCT00357019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 09/99 NAAXIA SINE Phase IV|Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis|Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis||Laboratoires Thea||Completed|April 2001|October 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|4 Years|N/A|No|||July 2006|July 26, 2006|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357019||180182|
NCT00357032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02838|PXD101 in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of PXD101 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or Patients Over 60 With Newly-Diagnosed Acute Myelogenous Leukemia||National Cancer Institute (NCI)||Completed|May 2006|July 2010|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2013|October 8, 2014|July 26, 2006|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT00357032||180181|
NCT00357383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PI3-07/02(F)|Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers|Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers||Laboratoires Thea||Completed|October 2002|October 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2006|July 26, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357383||180155|
NCT00354224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000484638|Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer|A Phase II Study of XELOX in Locally Advanced or Metastatic Gastric Cancer||National Cancer Institute (NCI)||Completed|January 2005|||August 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||January 2008|January 23, 2009|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354224||180389|
NCT00354211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study # 2005-06, Revision B|Using Minimally Invasive Cardiac Output Data vs. Standard Care for Patients Emergently Admitted to the Intensive Care Unit Who Are Hemodynamically Unstable|TREASURE: Treatment With Minimally-Invasive Cardiac Output for Assessment of User Derived Results Evaluating Economic Benefit||Edwards Lifesciences|Yes|Completed|July 2006|December 2007|Actual|September 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|392|||Both|18 Years|N/A|No|Probability Sample|The study population will include patients emergently admitted to the Intensive Care Unit        who develop hemodynamic instability within 6 hours of admission.|February 2013|February 8, 2013|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354211||180390|
NCT00354445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP1023|A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD|A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement||Eyetech Pharmaceuticals||Recruiting|June 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1000|||Both|50 Years|N/A|No|||January 2007|January 12, 2007|July 18, 2006||||||https://clinicaltrials.gov/show/NCT00354445||180373|
NCT00357162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00143|Belinostat in Treating Patients With Myelodysplastic Syndromes|Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome||National Cancer Institute (NCI)||Completed|May 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2011|May 2, 2014|July 26, 2006|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00357162||180171|
NCT00357188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-283|Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects|Open-Label, Multiple Dose Study to Determine the Relative Bioavailability of Atazanavir (ATV) 400 mg Administered With Ritonavir (RTV) and Efavirenz (EFV) Compared to Atazanavir 300 mg Administered With Ritonavir Alone in Healthy Subjects||Bristol-Myers Squibb||Completed|July 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2|||22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|April 7, 2011|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357188||180170|
NCT00357448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6193|Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer|Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer||University of Washington|Yes|Active, not recruiting|April 2005|||November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||May 2015|May 1, 2015|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357448||180150|
NCT00357461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000486705|Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma|A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma||Bristol-Myers Squibb||Withdrawn|May 2006|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|16 Years|N/A|No|||May 2013|May 14, 2013|July 26, 2006||||||https://clinicaltrials.gov/show/NCT00357461||180149|
NCT00362791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-1112.1|Project RESPECT: The Efficacy of HIV/STD Prevention Counseling|Multicenter Randomized Controlled Trial Evaluating the Efficacy of HIV/STD Prevention Counseling and Testing in Preventing High Risk Behaviors and New Sexually Transmitted Diseases (Project RESPECT)||Centers for Disease Control and Prevention||Completed|April 2003|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||6000|||Both|14 Years|N/A|Accepts Healthy Volunteers|||July 2005|August 9, 2006|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362791||179750|
NCT00358748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0006|Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants|Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants||University of British Columbia|No|Completed|July 2005|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|30 Weeks|No|||April 2011|April 11, 2011|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358748||180050|
NCT00361634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060118|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis|DCE-MRI of the Wrist to Measure Short-Term Responses in Rheumatoid Arthritis Subjects Treated With Etanercept||Amgen||Completed|September 2006|March 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|August 4, 2006||||Yes|August 13, 2010|https://clinicaltrials.gov/show/NCT00361634||179837|
NCT00362752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-120|A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome|A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome||St. Michael's Hospital, Toronto|No|Completed|October 2006|December 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||January 2010|January 26, 2010|August 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362752||179753|
NCT00362765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF23-0121 05 03|Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study|Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination.||Solvay Pharmaceuticals|No|Terminated|October 2006|July 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|8|||Both|40 Years|75 Years|No|||August 2008|August 12, 2008|August 9, 2006||No|The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients    who are not under statin therapy at inclusion.|No||https://clinicaltrials.gov/show/NCT00362765||179752|
NCT00362076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980155|The Role of Motion in Infants' Ability to Categorize|Categorization Based on Motion-Carried Information in Infancy||National Institutes of Health Clinical Center (CC)||Completed|September 1998|April 2012||||N/A|Observational|N/A|||Actual|941|||Both|3 Months|6 Years|Accepts Healthy Volunteers|||April 2012|May 3, 2012|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362076||179804|
NCT00362089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKFZ001_CN|Fatty Acids During Pregnancy and Lactation and Body Fat Mass in Newborns|The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development||Technische Universität München|Yes|Completed|June 2006|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|208|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||February 2014|February 3, 2014|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362089||179803|
NCT00362102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-259|A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma|A Multi-center, Open Label, Non-randomized, Phase II Study to Assess the Activity and Safety of Cetuximab Plus Irinotecan in Subjects With EGFR-detectable Metastatic Colorectal Carcinoma||Eli Lilly and Company||Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Both|20 Years|75 Years|No|||October 2015|October 26, 2015|August 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362102||179802|
NCT00362375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-1927-4768|Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women|Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women by SisterLove, Inc. in Atlanta, GA||Centers for Disease Control and Prevention|No|Completed|May 2006|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|313|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 27, 2010|August 8, 2006||No||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00362375||179782|
NCT00362726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-106|Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone|Effect of Atazanavir Administered With and Without Ritonavir on the Pharmacokinetics of the Cytochrome P450 2C8 Substrate Rosiglitazone in Healthy Subjects||Bristol-Myers Squibb||Completed|September 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5|||14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|April 7, 2011|August 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362726||179755|
NCT00359437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4493|Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver|Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo With Concomitant Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.|SPARe-1|Sanofi||Terminated|July 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|501|||Both|18 Years|N/A|No|||July 2009|July 17, 2009|August 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00359437||179997|
NCT00359450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA165-026|Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)|A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients||Bristol-Myers Squibb||Terminated|July 2006|||March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||186|||Both|18 Years|N/A|No|||September 2007|February 27, 2010|August 1, 2006||||||https://clinicaltrials.gov/show/NCT00359450||179996|
NCT00355849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9632|Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients With Type 2 Diabetes Treated With Once-Daily Insulin Glargine||Eli Lilly and Company||Completed|August 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|555|||Both|18 Years|N/A|No|||October 2008|October 13, 2008|July 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355849||180267|
NCT00356161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVK-HAI 1|HAI Via Interventionally Implanted Port Catheter Systems|Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms.||Charite University, Berlin, Germany||Recruiting|April 2002|April 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||July 2006|July 24, 2006|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356161||180243|
NCT00356148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAR-YC-2003-0111|The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.|Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25.||Marmara University|Yes|Completed|October 2003|May 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|372|||Female|18 Years|N/A|No|||December 2012|December 19, 2012|July 24, 2006||No||No|April 20, 2012|https://clinicaltrials.gov/show/NCT00356148||180244|
NCT00357396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-059|Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors|A Phase II Trial of a Chemotherapy Based Regimen of Intravenous Busulfan (Busulfex), Melphalan and Thiotepa as Myeloablative Regimen Followed by a T- Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant From and HLA-Compatible Donor in the Treatment of High Risk Ewing's Sarcoma Family Tumors||Memorial Sloan Kettering Cancer Center||Completed|June 2005|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|40 Years|No|||October 2015|October 22, 2015|July 26, 2006|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00357396||180154|
NCT00357591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEG020301|Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation|MOMENTUM: Multicenter Trial of the Orqis Medical CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy||Orqis Medical Corporation|Yes|Terminated|September 2004|January 2008|Actual|January 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|90 Years|No|||August 2009|December 24, 2009|July 25, 2006|Yes|Yes|Projected neutral significance for primary composite efficacy endpoint.|No||https://clinicaltrials.gov/show/NCT00357591||180139|
NCT00357604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-285|Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females|The Effect of the Co-administration of Atazanavir (ATV) and Ritonavir (RTV) on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects||Bristol-Myers Squibb||Completed|July 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2|||22|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|April 7, 2011|July 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00357604||180138|
NCT00357903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021618|Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials|Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials||Amgen||Completed|April 1997|April 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|639|||Both|4 Years|N/A|No|||February 2016|February 5, 2016|July 26, 2006||||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00357903||180115|
NCT00357916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-005|Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of PEP005 Topical Gel (0.01% Concentration) in Healthy Volunteers Using a Repeat Insult Patch Test Design||Peplin||Completed|June 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2008|December 22, 2008|July 26, 2006||||||https://clinicaltrials.gov/show/NCT00357916||180114|
NCT00362882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00123|Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer|Randomized Phase II Trial of Sequential Versus Concurrent Docetaxel and PS-341 (NSC 681239) in Previously Treated Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)|Yes|Completed|July 2006|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||November 2012|October 3, 2014|August 10, 2006|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT00362882||179743|
NCT00359567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10037030-01|Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy|Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy||Taiho Pharmaceutical Co., Ltd.||Completed|July 2006|August 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|1140|||Both|20 Years|N/A|No|||July 2011|July 6, 2011|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359567||179989|
NCT00357201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1675-PIICA-04/04 PHASE II|Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome|Evaluation of the Efficacy of T1675, a Per Os Omega 3 and Omega 6 Polyunsaturated Essential Fatty Acid Dietary Formulation Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome||Laboratoires Thea||Completed|November 2004|May 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|90 Years|No|||July 2006|July 26, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357201||180169|
NCT00357474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2006-010|Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs|A Multicenter, Randomized, Controlled Trial of the Effective Therapy for Multiple, Small Hepatocellular Carcinomas: Comparing Transarterial Chemoembolization With Percutaneous Ethanol Injection Therapy.||Seoul National University Hospital|Yes|Completed|October 2005|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|20 Years|70 Years|No|||December 2013|December 2, 2013|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357474||180148|
NCT00357760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00559|Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2007|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|March 24, 2016|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357760||180126|
NCT00354185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00006|PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma|A Phase I Study of PXD101 in Combination With 17-AAG in Advanced Malignancies||National Cancer Institute (NCI)||Terminated|May 2006|||February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|July 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00354185||180392|
NCT00358735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedicalCS06CC001|Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)|Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty (THA): Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)|SAFE|Medical Compression Systems|Yes|Completed|June 2006|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|411|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|July 30, 2006|Yes|Yes||No|September 14, 2014|https://clinicaltrials.gov/show/NCT00358735||180051|
NCT00362115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-491-005|Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension||Takeda|No|Completed|May 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|449|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|August 7, 2006|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00362115||179801|
NCT00362128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1338|Cardiovascular Disease Risk Factors in Chinese American Immigrants|Chinese American Cardiovascular Health Assessment CHA-CHA|CHA-CHA|Albert Einstein College of Medicine of Yeshiva University|No|Completed|January 2007|October 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2072|Samples With DNA|Biospecimens are being analyzed to evaluate the relationship between biomarker, behaviors      and sociodemographic variables. Stored specimens will permit future analysis that may      involve genetic variables related to biomarker findings.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample from Chinatown region of NYC.|August 2015|August 5, 2015|August 8, 2006||No||No|July 6, 2015|https://clinicaltrials.gov/show/NCT00362128||179800|
NCT00362739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508008095|Blood Collection From Individuals With Lung Disease for Genetic Studies|Collection of Blood for Gene Expression/Genomic Studies in Individuals With Chronic Lung Disease||Weill Medical College of Cornell University|Yes|Recruiting|September 2005|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|In this study, a small amount of blood for extraction of DNA for the study of the genetic      basis of lung disease will be obtained from each subject. The collected blood (cells and      serum) will be used for genetic testing in studies relating to the genetic material and/or      gene expression, and/or studies of proteins or other substances in serum (the liquid portion      of the blood after it has been allowed to clot). Because these latter protein studies will      occur at a future date, the serum will be stored for use in these studies.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals visiting the Starr-5 Pulmonary, Critical Care Unit, and 5 West floor for        standard clinical care will be recruited. Controls will be obtained from volunteers        without a history of lung disease.|April 2015|April 20, 2015|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362739||179754|
NCT00355576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB6334|Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis|Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis||Columbia University|Yes|Completed|July 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|21 Years|85 Years|No|||January 2011|January 31, 2011|July 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355576||180288|
NCT00356174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CoFAR2|An Observational Study of Childhood Food Allergy|A Prospective Cohort Study of Immune Mechanisms, Genetic Factors, and Clinical and Environmental Characteristics Associated With the Occurrence and Clinical Outcome of Food Allergy (CoFAR2)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|July 2006|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|515|Samples With DNA|Buccal swab (DNA)|Both|3 Months|15 Months|No|Non-Probability Sample|Children with milk or egg allergy who are at risk for peanut allergy|January 2016|January 20, 2016|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00356174||180242|
NCT00356447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91442|Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.|A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq® (Drospirenone 2mg and Estradiol 1mg) in Postmenopausal Chinese Women With Vasomotor Symptoms Over Four 28-day Treatment Cycles.||Bayer|No|Completed|May 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|249|||Female|45 Years|65 Years|No|||September 2014|September 30, 2014|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356447||180221|
NCT00357045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1002|Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine|Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine; THE HEPDEP II STUDY||Portland VA Medical Center||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||December 2003|July 25, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357045||180180|
NCT00357929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23214|Weaning From Mechanical Ventilation Using Permissive Hypercarbia|Weaning From Mechanical Ventilation Using Permissive Hypercarbia||Penn State University||Terminated|August 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||May 2007|May 29, 2007|July 27, 2006|||insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00357929||180113|
NCT00358228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4964|Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)|Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US, EFC4964) - A Randomized, Double-blind, 3-arm, Placebo-controlled, Parallel-group, Fixed-dose, 52-week, Multi-center Study.||Sanofi||Completed|September 2002|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|787|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|July 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00358228||180090|
NCT00358241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-03-05-05|Effects of Nerve Block on Knee Function After Knee Replacement|Effects of Continuous Lumbar Plexus Nerve Block on Functional Restoration and Outcome After Unilateral Total Knee Arthroplasty||Johns Hopkins University||Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|21 Years|80 Years||||July 2006|July 27, 2006|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358241||180089|
NCT00362258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0256|I PREVENT - Irbesartan In Hypertensive Diabetic Patients|Irbesartan In Hypertensive Diabetic Patients||Sanofi|No|Completed|February 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|797|||Both|35 Years|75 Years|No|||March 2011|April 1, 2011|August 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362258||179791|
NCT00358540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRC105499|Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide|An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen||GlaxoSmithKline||Completed|June 2006|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|48|||Both|18 Years|N/A|No|||May 2011|March 15, 2012|July 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00358540||180066|
NCT00358553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 101-002|A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin|||Baxter Healthcare Corporation||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2007|March 12, 2007|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00358553||180065|
NCT00359333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1706|Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST|Multiple Centers, Prospective, Phase II Trial of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Locally Advanced/Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced/Metastatic Malignant Gastrointestinal Stromal Tumor|STS|National Health Research Institutes, Taiwan|Yes|Completed|December 2006|March 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|70 Years|No|||October 2013|October 28, 2013|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359333||180005|
NCT00359580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|970192|Genetic Studies in the Amish and Mennonites|Genetic Studies in the Amish and Mennonites||National Institutes of Health Clinical Center (CC)||Completed|September 1997|||||N/A|Observational|Time Perspective: Retrospective|||Actual|157|||Both|N/A|N/A|No|||June 2015|July 8, 2015|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359580||179988|
NCT00357227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 GI 0204|Atrial Fibrillation and the Risk for Neurological Complications|Atrial Fibrillation and the Risk for Neurological Complications||University Hospital Muenster||Recruiting|January 2004|||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1000|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||April 2007|April 18, 2007|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357227||180167|
NCT00357487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3704|Evaluation of Two New Medical Instruments Dedicated to the Sentinel Lymph Node Technique in Case of Breast Cancer|Sentinel Lymph Node Identification in Case of Breast Cancer. Clinical Evaluation of a New Intra-operative Probe and a Mini Gamma Camera||University Hospital, Strasbourg, France||Completed|June 2006|December 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Female|18 Years|N/A|No|||August 2011|August 29, 2011|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357487||180147|
NCT00358085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unknown|NExT ERA: National Expertise Based Trial of Elective Repair of Abdominal Aortic Aneurysms: A Pilot Study|Expertise Based Randomized Controlled Trial of Open Versus Endovascular Repair of Abdominal Aortic Aneurysms: A Pilot Study||McMaster University||Not yet recruiting|September 2006|January 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||July 2006|July 26, 2006|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00358085||180101|
NCT00357773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PIII-11/03|Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis|Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis||Laboratoires Thea||Completed|May 2004|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||July 2006|July 26, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357773||180125|
NCT00354705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0383|Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients|Prognostic Molecular and Environmental Factors in High-Risk Stage II and Stage III Colon Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2006|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|20 ml of blood for genomic analysis collected at baseline, at completion of adjuvant      chemotherapy ( <28 days after its completion) if applicable, at each subsequent surveillance      visit (every 3 months after discontinuation of adjuvant chemotherapy, continuing for 2      years), and at time of disease recurrence, if applicable.      20 ml of blood for proteomic analysis studies collected at baseline, at completion of      adjuvant chemotherapy, if applicable ( <28 days after its completion), and at time of      disease recurrence, if applicable.      Tissue (0.2gm of tissue) from primary resection obtained at time of study enrollment. A      tissue sample (0.2gm of tissue) also obtained, if possible, from patients that require      surgical intervention at M.D. Anderson Cancer Center, for recurrent disease.|Both|14 Years|N/A|No|Non-Probability Sample|Patients 14 years of age and up with colon cancer recently removed by surgery and        receiving chemotherapy to try to prevent cancer from returning.|October 2015|October 22, 2015|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354705||180353|
NCT00354731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941103|Efficacy of Pentoxifylline on Primary Nephrotic Syndrome|Clinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic Syndrome||National Taiwan University Hospital|Yes|Completed|August 2006|April 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|20 Years|80 Years|No|||October 2012|November 12, 2012|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354731||180352|
NCT00362388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRTCC-ISQ|Cell Therapy in Chronic Ischemic Heart Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery||Ministry of Health, Brazil|Yes|Terminated|January 2006|November 2008|Actual|November 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|30 Years|75 Years|No|||November 2008|January 26, 2010|August 8, 2006||No|low enrollling|No||https://clinicaltrials.gov/show/NCT00362388||179781|
NCT00362401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050213|Patients Perception of Mechanical Heart Valve Sounds: Psychoacoustics and Quality of Life|Patients Perception of Mechanical Heart Valve Sounds: Psychoacoustics and Quality of Life||University of Aarhus|No|Completed|November 2005|January 2009|Actual|||Phase 0|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|150 patients are expected to be included. They all must have a mechanical heart valve in        the aortic position implanted between 3 months and 4,5 years prior to the investigation.        The patients will be divided into tree main groups, which correspond to the type of valve        they have acquired - ATS (ATS Medical Inc, Minneapolis, MN, USA), Medtronic-Hall™        (Medtronic, Minneapolis, MN, USA) and St. Jude Medical Standard (St. Jude Medical Inc, St.        Paul, MN, USA). With the purpose of recruiting a greater number of patients than those        available in the geographic region of Denmark, we have established an agreement with The        Heart Center in Bad Oeynhausen, Germany, who will contribute to the study with all 150        patients.|August 2009|August 3, 2009|August 9, 2006||No||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00362401||179780|
NCT00359242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22165EP|The SLeeping and Intake Methods Taught to Infants and Mothers Early in Life (SLIMTIME) Project|Primary Prevention of Obesity Through Infancy Interventions||Penn State University||Completed|June 2006|December 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|160|||Both|N/A|12 Months|Accepts Healthy Volunteers|||November 2008|March 9, 2011|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00359242||180012|
NCT00358722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH 002 (ALCON)|An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate|A Long-term, Open-label Continuation Study to Assess the Safety of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia|ALCON|Ineos Healthcare Limited|Yes|Terminated|July 2006|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|July 31, 2006|Yes|Yes|Limited number of subjects|No||https://clinicaltrials.gov/show/NCT00358722||180052|
NCT00358969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-0518|Guanfacine to Treat Borderline Personality Disorder|Guanfacine in the Treatment of Borderline Personality Disorder||Bronx VA Medical Center||Recruiting|July 2006|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||July 2006|July 31, 2006|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00358969||180033|
NCT00359216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04726|The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)|A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Sleep-disordered Breathing Associated With Perennial Allergic Rhinitis (PAR) Using Home-Monitored Cardio-Respiratory Methodology.||Merck Sharp & Dohme Corp.|No|Completed|May 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||May 2015|May 28, 2015|July 31, 2006||No||No|January 23, 2009|https://clinicaltrials.gov/show/NCT00359216||180014|
NCT00355589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K749-06-3001|Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension|A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Efficacy and Safety of a Combination of Ramipril Plus Hydrochlorothiazide Versus the Component Monotherapies in Subjects With Essential Hypertension||Pfizer||Completed|July 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||October 2012|October 8, 2012|July 20, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00355589||180287|
NCT00355862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SiLVER05|Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma|A Prospective Randomised, Open-labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma||University of Regensburg|Yes|Completed|January 2006|May 2014|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|525|||Both|18 Years|N/A|No|||July 2009|July 29, 2014|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00355862||180266|
NCT00356772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PI4-11/02(F)|Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers|Comparison of Azithromycin Level in Tears and in Conjunctiva After Repeated Instillations of T1225 1.5% Eye Drops or After a Single Per Os Administration of Zithromax® (Azithromycin 1g), in 36 Healthy Volunteers||Laboratoires Thea||Completed|February 2003|March 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2006|July 25, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356772||180200|
NCT00357617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000490047|Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery|Evaluation of the Effect of Celecoxib on Angiogenesis Markers in Patients With Operable Head and Neck Squamous Cell Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|June 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||January 2008|December 23, 2010|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357617||180137|
NCT00357630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000486704|Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary|Phase II Protocol: Gemcitabine for Metastatic Cancer With Unknown Primary Site - Analysis of Symptom Benefit||National Cancer Institute (NCI)||Completed|June 2006|||February 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||October 2008|April 11, 2009|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357630||180136|
NCT00361478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/2004|Effect of the 'Mother and Baby' Program on Well-Being|Effect of the 'Mother and Baby' Program on New Mothers' Psychological and Physical Well-Being.||University of Melbourne|No|Completed|July 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2006|August 11, 2008|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00361478||179849|
NCT00361985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511008254|Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery|Randomized, Prospective, Double-blind Trial of PPI vs Placebo in Prevention of Gastrojejunal Strictures After Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity||Weill Medical College of Cornell University|No|Withdrawn|January 2008|July 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 7, 2010|August 7, 2006||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00361985||179811|
NCT00362271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-462 ST|Aripiprazole and Effexor XR Drug Interaction Study|Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1|||38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|November 7, 2013|August 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362271||179790|
NCT00362518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-319|Vitamins C and Vitamin E and Cardiovascular Risk|Vitamin C and Vitamin E Therapy in Type 2 Diabetes and Cardiovascular Risk||University of New Mexico|Yes|Completed|July 2004|March 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2008|September 2, 2008|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362518||179771|
NCT00359320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.198|A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy|A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy||Thomas Jefferson University||Recruiting|July 2006|December 2015||July 2015||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00359320||180006|
NCT00359346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060209|Plasma Exchange for Autoimmune Autonomic Failure|Plasma Exchange for Autoimmune Autonomic Failure||National Institutes of Health Clinical Center (CC)||Completed|July 2006|April 2009||||N/A|Observational|N/A||||3|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359346||180004|
NCT00359593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSNscore|Stroke Canada Optimization of Rehabilitation by Evidence Implementation Trial SCORE-IT)|Stroke Canada Optimization of Rehabilitation by Evidence Implementation Trial (SCORE IT)||Toronto Rehabilitation Institute||Recruiting|September 2006|April 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|2000|||Both|18 Years|N/A|No|||July 2006|March 19, 2008|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00359593||179987|
NCT00357786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040027|An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease|An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal® (Registered Trademark) in Patients With Fabry Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2003|||December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||3|||Male|39 Years|45 Years|No|||December 2008|August 16, 2011|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357786||180124|
NCT00358358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO104925|Chronic Obstructive Pulmonary Disease Endpoints Study|See Detailed Description||GlaxoSmithKline|No|Completed|March 2006|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|163|||Both|40 Years|N/A|No|||April 2015|April 15, 2015|July 27, 2006||||||https://clinicaltrials.gov/show/NCT00358358||180080|
NCT00358371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103811|Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)|See Detailed Description||GlaxoSmithKline||Completed|January 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 21, 2009|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358371||180079|
NCT00354081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD-14154|WENBIT - Western Norway B Vitamin Intervention Trial|A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography|WENBIT|Haukeland University Hospital|Yes|Completed|April 1999|February 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3096|||Both|18 Years|N/A|No|||May 2010|July 11, 2013|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00354081||180400|
NCT00362778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The INSUCOR study|Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia|Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia|INSUCOR|Hospital Clinic of Barcelona||Completed|January 2006|June 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362778||179751|
NCT00354679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-013|Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer|Phase II Trial of Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Completed|April 2006|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|120 Years|No|||January 2016|January 14, 2016|July 19, 2006|Yes|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT00354679||180355|
NCT00354692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER0601|Effect of Two Iron Preparations on Protein in the Urine|A Randomized Cross-over Pilot Study of the Effect of Sodium Ferric Gluconate Complex vs. Iron Sucrose on Proteinuria in Non-dialysis Chronic Kidney Disease Patients||Watson Pharmaceuticals||Completed|June 2006|||November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|July 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00354692||180354|
NCT00358982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-010|Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma||Mirati Therapeutics Inc.|No|Terminated|August 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|July 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00358982||180032|
NCT00359229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOLPI_L_01540|Stilnox Treatment in Elderly Patients With Insomnia|A Multicentre Prospective, Open Label ,3 Weeks Phase IV Study to Evaluate the Efficacy and Safety in Elder Patients With Insomnia in China|STEP|Sanofi||Completed|July 2006|||September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|65 Years|N/A|No|||September 2009|September 14, 2009|July 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00359229||180013|
NCT00356460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC100800305|Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma|A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFβ) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma||Sanofi|Yes|Completed|September 2006|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|29|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|July 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00356460||180220|
NCT00357058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020079|Role of Brain Region Changes in Tactile (Touch) Ability Following Nerve Block|Substrates Mediating Deafferentiation-Induced Enhancement of Tactile Spatial Acuity||National Institutes of Health Clinical Center (CC)||Completed|December 2001|December 2007||||N/A|Observational|N/A||||90|||Both|18 Years|N/A|No|||December 2007|September 26, 2015|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357058||180179|
NCT00361725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCAS|Comparative Study of the Protein C Pathway in Septic and Non Septic Patients With Organ Failure|Comparative Study of the Protein C Pathway in Septic and Non Septic Patients||Assistance Publique - Hôpitaux de Paris||Terminated|March 2003|October 2003||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2006|August 9, 2006|August 7, 2006||||No||https://clinicaltrials.gov/show/NCT00361725||179830|
NCT00362908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29854-B|Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome|Diets for Dyslipidemia in the Metabolic Syndrome||University of Washington|No|Completed|September 2006|June 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||October 2010|October 27, 2010|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362908||179741|
NCT00358813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT102783|Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment||GlaxoSmithKline||Completed|September 2006|||||Phase 1|Interventional|N/A|||Anticipated|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|July 28, 2006||||||https://clinicaltrials.gov/show/NCT00358813||180045|
NCT00359060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU 2003-2793|Physical Activity and Breast Cancer Risk in Postmenopausal Women:the SHAPE Study|Physical Activity and Breast Cancer Risk in Postmenopausal Women: the SHAPE Study||UMC Utrecht||Completed|January 2005|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||180|||Female|50 Years|69 Years|Accepts Healthy Volunteers|||July 2006|October 12, 2006|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00359060||180026|
NCT00359073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31799|Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma|Effect of Montelukast on Experimentally-Induced RV16 Infection in Volunteers With Mild Asthma||University of Wisconsin, Madison|No|Completed|October 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|65 Years|No|||February 2009|February 17, 2009|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00359073||180025|
NCT00359905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMD3213-IT-CL 0215|Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH|Evaluation of the Efficacy and Safety of Silodosin vs. Tamsulosin and Placebo in the Treatment of the Signs and Symptoms of BPH. Multicentre, Randomised, Double-Blind, Controlled Trial With an Optional Long-Term, Open-Label Extension Phase.||Recordati Industria Chimica e Farmaceutica S.p.A.|No|Completed|May 2006|January 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1228|||Male|50 Years|N/A|No|||February 2009|February 18, 2009|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00359905||179965|
NCT00359606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98127|5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer|Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine||City of Hope Medical Center|Yes|Completed|April 1999|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|August 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00359606||179986|
NCT00357266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020099|Differences in Genes and Proteins in Active and Controlled Uveitis|Analysis of Differential Gene Expression Profiles in Patients With Defined Ocular Inflammatory Diseases Using CDNA Microarrays and Proteomics||National Institutes of Health Clinical Center (CC)||Completed|February 2002|October 2007||||N/A|Observational|N/A||||60|||Both|6 Years|N/A|No|||October 2007|September 26, 2015|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357266||180164|
NCT00357279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-108|Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease|A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease||Merck Sharp & Dohme Corp.||Completed|July 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|352|||Both|5 Years|N/A|No|||October 2015|October 9, 2015|July 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357279||180163|
NCT00357513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020221|Genetic Studies to Identify Stroke Subtypes and Outcome|Stroke Genomics - A Correlative Study of Stroke Subtypes, Neuroimaging, Therapy and Outcome Measures||National Institutes of Health Clinical Center (CC)||Completed|June 2002|December 2008||||N/A|Observational|N/A||||840|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2008|September 26, 2015|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357513||180145|
NCT00357799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/139, GC 185|VeinViewer for Peripheral IV Placement in Children With Difficult Intravenous (IV) Access|VeinViewer for Peripheral IV Placement in Children With Difficult IV Access||Children's Hospital and Health System Foundation, Wisconsin|No|Completed|October 2006|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|N/A|19 Years|No|||August 2011|August 22, 2011|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357799||180123|
NCT00357812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/NIR03/20|The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)|A Study to Compare the Efficacy of Two Potential Diagnostic Assays: a Fluorescein Conjugated Monoclonal Antibody in Vivo Assay and Nested Real Time PCR Assay to Rapidly and Accurately Diagnose Herpes Simplex Keratitis.||University of Ulster||Completed|September 2006|November 2012|Actual|||Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients over the age of 16 years in which the cause of keratitis is difficult to diagnose        and in which HSK has to be excluded will be enrolled for this study|November 2012|January 14, 2013|July 26, 2006||||No||https://clinicaltrials.gov/show/NCT00357812||180122|
NCT00357825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061034|A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia|An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of [S,S]-Reboxetine Administered Once Daily in Patients With Fibromyalgia||Pfizer||Completed|August 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||246|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|July 26, 2006||||||https://clinicaltrials.gov/show/NCT00357825||180121|
NCT00355108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.405|ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome|ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome. Beneficial or Iatrogenic Effects.||Hospices Civils de Lyon|Yes|Completed|September 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|170|||Both|18 Years|90 Years|No|||December 2010|December 22, 2010|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355108||180324|
NCT00355121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA43|Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®|Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.||Sanofi|No|Completed|October 2006|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|882|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|July 20, 2006|Yes|Yes||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00355121||180323|
NCT00358995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H02-80132|A Cognitive Behavioral Therapy of Primary Obsessions in Obsessive Compulsive Disorder|A New Cognitive Behavioral Therapy to Target Distorted Appraisals Characteristic of Primary Obsessions in Obsessive Compulsive Disorder||University of British Columbia|No|Completed|July 2002|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|65 Years|No|||February 2014|February 17, 2014|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358995||180031|
NCT00355602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tenovus 134/03|Antibiotics for the Treatment of Ulcerative Colitis|Use of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis Patients||University of Dundee||Completed|July 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|79 Years|No|||February 2009|February 10, 2009|July 21, 2006||||No||https://clinicaltrials.gov/show/NCT00355602||180286|
NCT00359463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA103452|Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment|An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers With Mild, Moderate or Severe Hepatic Impairment||GlaxoSmithKline|No|Completed|April 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 25, 2012|July 28, 2006||||||https://clinicaltrials.gov/show/NCT00359463||179995|
NCT00359736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-009-05F|Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis|Vasodilator Therapy and Exercise Tolerance in IPF Patients||VA Office of Research and Development|Yes|Completed|July 2006|June 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|40 Years|85 Years|No|||September 2014|September 29, 2014|July 31, 2006|No|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00359736||179976|
NCT00355329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-001|Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation|Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation||The University of Hong Kong||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|3 Years|16 Years|No|||July 1999|October 19, 2006|July 20, 2006||||No||https://clinicaltrials.gov/show/NCT00355329||180307|
NCT00355342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO40041|Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Via DISKUS Versus Salmeterol 50mcg BID Via DISKUS on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|April 2004|||September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|40 Years|N/A|No|||March 2013|March 1, 2013|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00355342||180306|
NCT00356785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230/01|Changes in Body Composition and Metabolic Risk Parameters by Life Style Intervention.|Body Compositional and Endocrine-Metabolic Changes by Long-Term Lifestyle Intervention With Health Education, Diet (Almased®), Physical Activity or a Combination of Diet and Physical Activity in Overweight and Obese Persons.||University Hospital Freiburg||Completed|January 2001|December 2001||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|34 Years|65 Years|Accepts Healthy Volunteers|||April 2006|July 25, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00356785||180199|
NCT00361218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P000413|Biological Markers of Response to Treatment in Major Depressive Disorder|Serum Brain-Derived Neurotrophic Factor (BDNF) and QEEG as Biological Markers of Response to (Es)Citalopram Treatment in Major Depressive Disorder||Massachusetts General Hospital|Yes|Completed|October 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|65 Years|No|||July 2013|July 24, 2013|August 4, 2006||No||No|July 24, 2013|https://clinicaltrials.gov/show/NCT00361218||179869|
NCT00362531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGNSCN01-0|Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome|Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome||Peking University||Completed|November 2004|January 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2006|August 9, 2006|August 9, 2006||||No||https://clinicaltrials.gov/show/NCT00362531||179770|
NCT00362895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-23|A Bioequivalence Study of Tobradex AF|A Double-Masked, Parallel-Group, Randomized, Single-Dose Bioequivalence Study of Tobradex AF Suspension and TOBRADEX Ophthalmic Suspension||Alcon Research||Completed|April 2006|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|995|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|August 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362895||179742|
NCT00358592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06C.78|Comparison of Tissue Retractors During Cesarean Delivery in Obese Women|Randomized Controlled Trial of the Efficacy of the Mobius ™ Retractor in Performing Cesarean Sections in Patients With BMI ≥35kg/m2||Thomas Jefferson University||Recruiting|July 2006|June 2014|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|60|||Female|15 Years|N/A|No|||May 2013|May 20, 2013|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00358592||180062|
NCT00358826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIA-2291-01|Study Effect of VIA-2291 on Vascular Inflammation|Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event||Tallikut Pharmaceuticals, Inc.|Yes|Completed|July 2006|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|191|||Both|30 Years|80 Years|No|||July 2012|July 19, 2012|July 28, 2006|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00358826||180044|
NCT00359099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0762-2006|Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening|Proposal for Retrospective Review of the Prevalence of Hepatitis C Infection in Adult Patients Who Underwent Congenital Heart Surgery Before Screening||Emory University||Terminated|January 1980|July 2006||||N/A|Observational|Time Perspective: Retrospective||||1000|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00359099||180023|
NCT00360477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-3515|FloSeal Tubeless Exit Versus Cope Loop Nephrostomy Versus Fascial Stitch Following Percutaneous Nephrolithotripsy|Prospective Randomized Trial of Floseal Tubeless Exit vs. Cope Loop Nephrostomy vs. Fascial Stitch Following Percutaneous Nephrolithotripsy||University of California, Irvine|No|Enrolling by invitation|June 2004|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||August 2013|August 21, 2013|August 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00360477||179923|
NCT00360490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91518|Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)|A Multicenter, Randomized, Open Label, Parallel Group, Active Control Study to Evaluate the Efficacy and Safety of LNG IUS (Mirena®) as Compared to Medroxyprogesterone Acetate During 6 Cycles of Treatment in Patients With Idiopathic Menorrhagia||Bayer|No|Completed|July 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Female|18 Years|N/A|No|||November 2013|November 14, 2013|August 2, 2006|Yes|Yes||No|October 13, 2009|https://clinicaltrials.gov/show/NCT00360490||179922|
NCT00360178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BDE13|Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide|An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combination of an Angiotensin Receptor Blocker (Candesartan 32 mg) Plus HCTZ 25 mg||Novartis||Completed|July 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|198|||Both|18 Years|N/A||||November 2011|November 7, 2011|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00360178||179946|
NCT00360191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA015440|A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence|A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence||Medical University of South Carolina||Completed|April 2004|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|81|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|January 10, 2012|August 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360191||179945|
NCT00357539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PI1-09/01(F)|Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers|Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers||Laboratoires Thea||Completed|February 2002|March 2002||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2006|July 26, 2006|July 25, 2006||||No||https://clinicaltrials.gov/show/NCT00357539||180143|
NCT00358423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001702|The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema|Pilot Study of the Effect of Pegaptanib Sodium in Patients With Chronic, Post-Operative Cystoid Macular Edema||Johns Hopkins University|No|Terminated|July 2006|February 2007|Actual|February 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||May 2008|May 8, 2008|July 27, 2006|Yes|Yes|Difficulty enrolling eligible subjects|No||https://clinicaltrials.gov/show/NCT00358423||180075|
NCT00354640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05100, CDR0000485361|Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer|A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole||Sidney Kimmel Comprehensive Cancer Center|No|Completed|June 2006|November 2011|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||May 2013|May 15, 2013|July 19, 2006|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00354640||180358|Small sample size, difficulty in recruiting due to women either already taking a statin or on a different aromatase inhibitor.
NCT00354419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2030.00|Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant|A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood||Fred Hutchinson Cancer Research Center|No|Terminated|February 2006|||December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|40 Years|No|||January 2011|January 3, 2011|July 19, 2006|No|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00354419||180375|
NCT00355901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-420|An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis|An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis||Facet Biotech|Yes|Terminated|September 2006|November 2012||||Phase 2|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|N/A|No|||August 2008|August 2, 2008|July 21, 2006||||||https://clinicaltrials.gov/show/NCT00355901||180263|
NCT00355914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol3|Effectiveness of Lumbar Facet Joint Nerve Blocks|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Lumbar Facet Joint Nerve Blocks||Pain Management Center of Paducah|Yes|Completed|August 2003|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|July 24, 2006||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00355914||180262|
NCT00355069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U18HS011068-01|Better Pediatric Asthma Outcomes Through Chronic Care|Better Pediatric Asthma Outcomes Through Chronic Care||University of Connecticut Health Center|Yes|Completed|August 2001|May 2003|Actual|May 2003|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|548|||Both|5 Years|17 Years|No|||May 2014|May 27, 2014|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00355069||180327|
NCT00355082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM30055|Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy|A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures||GlaxoSmithKline|No|Completed|May 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|226|||Both|13 Years|N/A|No|||May 2013|October 30, 2014|July 19, 2006|Yes|Yes||No|September 8, 2009|https://clinicaltrials.gov/show/NCT00355082||180326|
NCT00355355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSO-OL005|A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)|A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC)||Light Sciences Oncology|Yes|Completed|July 2006|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|July 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00355355||180305|
NCT00356187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK73349 (completed)|Beta Blockade in Critical Injury|Beta-blockade Reduces Catabolism in Severely Injured Trauma Patients||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||March 2010|March 17, 2010|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356187||180241|
NCT00360984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4044|Prevention of Severe Hypoglycemia in Type 1 Diabetes|Can Hypoglycaemia Awareness Be Restored in Individuals With Type 1 Diabetes and Severe Hypoglycaemia Employing Optimised Subcutaneous Insulin Regime or Continuous Subcutaneous Insulin Infusion Pump||Newcastle University||Completed|May 2003|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||21|||Both|18 Years|74 Years|No|||July 2006|August 4, 2006|August 4, 2006||||No||https://clinicaltrials.gov/show/NCT00360984||179887|
NCT00362284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0095|Comprehensive Support for Alzheimer's Disease Caregivers|Expanded Counseling and Support for Adult Children Caring for Parents With Alzheimer's Disease or Similar Disorders||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2005|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|161|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362284||179789|
NCT00362544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-FR-131-104|PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia|Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia||Gilead Sciences||Completed|October 2003|March 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|May 10, 2006||||No||https://clinicaltrials.gov/show/NCT00362544||179769|
NCT00362557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-07-05|Imaging Techniques in Body MRI|Imaging Techniques in Body MRI||Johns Hopkins University||Active, not recruiting|September 2001|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who may require a body MRI examination|August 2015|August 31, 2015|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362557||179768|
NCT00358605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0075|The Use of Oral Appliances as an Adjunct to Continuous Positive Airway Pressure (C-PAP) in the Treatment of Obstructive Sleep Apnoea|A Randomized Study to Compare Oral Appliances to Standard CPAP Therapy in Patients With OSAHS, and to Assess Its Safety, Tolerability and Efficacy and Preference Over CPAP for Its Short-term Use.||University of British Columbia|No|Recruiting|August 2005|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|No|||November 2011|November 15, 2011|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358605||180061|
NCT00358839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHM-CGRP|Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.|Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.||Danish Headache Center||Completed|July 2006|October 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||20|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2006|November 9, 2006|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00358839||180043|
NCT00359086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-008|Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma|A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma||Mirati Therapeutics Inc.|No|Completed|August 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|July 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00359086||180024|
NCT00359619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108052 (FU month 18)|Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine|A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study||GlaxoSmithKline||Completed|September 2006|August 2009|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|383|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||January 2015|February 12, 2015|July 18, 2006|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00359619||179985|
NCT00359632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951110|Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater|Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater||Pfizer|No|Terminated|November 2008|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|34|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|July 28, 2006|Yes|Yes|Study was stopped due to poor enrollment on 28 Feb 2012. Reason for termination was not due to    safety concerns.|No|December 16, 2014|https://clinicaltrials.gov/show/NCT00359632||179984|This pilot study was exploratory and not designed to be powered for safety or efficacy. Controls were not followed post-baseline whereas linezolid patients returned for multiple study visits. The study was terminated early due to slow enrollment.
NCT00359931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060218|Brain Imaging of Tinnitus|Neural Modeling and Brain Imaging of Tinnitus||National Institutes of Health Clinical Center (CC)||Completed|July 2006|March 2016||||N/A|Observational|N/A|||Actual|58|||Both|30 Years|65 Years|No|||March 2016|March 8, 2016|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00359931||179963|
NCT00359944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-3933-271|Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease||Sunovion|No|Completed|February 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|171|||Both|55 Years|N/A|No|||May 2013|May 28, 2013|August 1, 2006|Yes|Yes||No|April 11, 2011|https://clinicaltrials.gov/show/NCT00359944||179962|
NCT00360789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR070116MA|Evaluation of Whether Functional Strength Training Can Enhance Motor Recovery of the Upper Limb After Stroke|The Effects of Standardized Physical Therapy and Functional Strength Training on Upper Limb Function and Neuromuscular Weakness After Stroke: a Pilot Study||St George's, University of London||Completed|June 2005|December 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||August 2006|June 5, 2015|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360789||179901|
NCT00360802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-FIS-22|Effectiveness of Cognitive Behavioral Treatment and Mindfulness Based Stress Reduction (MBSR) for Chronic Low Back Pain|The Effectiveness of Cognitive Behavioral Treatment and Mindfulness Based Stress Reduction for Chronic Low Back Pain Treated in Pain Clinics||Kovacs Foundation||Completed|May 2006|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|330|||Both|18 Years|70 Years|No|||May 2009|May 27, 2009|August 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00360802||179900|
NCT00358150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD00304|A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients|A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients||Sanofi||Active, not recruiting|June 2006|December 2015|Anticipated|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|65 Years|No|||October 2015|October 16, 2015|July 27, 2006|Yes|Yes||No|August 22, 2014|https://clinicaltrials.gov/show/NCT00358150||180096|The results include data from the start of the first participant's assessments (16 June 2006) through each participant's safety data cut-off, defined as the date of the Month 48 assessment plus 7 days.
NCT00354393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000486304|Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma|Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Active, not recruiting|August 2002|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|N/A|75 Years|No|||October 2007|February 6, 2009|July 19, 2006||||No||https://clinicaltrials.gov/show/NCT00354393||180377|
NCT00354432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cccwfu97405|Soy Protein/Isoflavones and Venlafaxine in Treating Hot Flashes in Patients Receiving Hormone Therapy for Prostate Cancer|Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer||Wake Forest School of Medicine|Yes|Completed|February 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|120|||Male|21 Years|N/A|No|||June 2010|June 26, 2012|July 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00354432||180374|
NCT00355381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU 04-09-03-01|Evaluating Patient Information Prescriptions|Evaluating Patient Information Prescriptions in Different Service Environments||Johns Hopkins University|No|Active, not recruiting|September 2004|September 2009|Anticipated|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|299|||Both|N/A|N/A|No|||January 2009|January 27, 2009|July 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00355381||180303|
NCT00360087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-371|A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study|Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients With Pulmonary Hypertension Associated With Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369)|ASSET-3|Actelion||Terminated|March 2006|December 2007|Actual|August 2007|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1|||236|||Both|16 Years|N/A|No|||February 2010|February 11, 2010|August 2, 2006|No|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00360087||179951|
NCT00355095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0026|Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis|Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT)||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Completed|August 2006|July 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|50 Years|No|||September 2012|September 12, 2012|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00355095||180325|
NCT00355368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 145/05|Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care|Phase 4 Study of Succinylcholine Versus Rocuronium as Neuromuscular Blocking Agent for Emergency Intubation in Intensive Care||University Hospital, Basel, Switzerland|Yes|Completed|August 2006|July 2010|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|N/A|No|||November 2011|November 10, 2011|July 20, 2006||No||No|August 8, 2011|https://clinicaltrials.gov/show/NCT00355368||180304|
NCT00360061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECCRA/2001|CBT in Adolescents With Type 1 Diabetes|Randomised Controlled Trial of Cognitive Behaviour Therapy: Efficacy and Acceptability for Adolescents With Type 1 Diabetes.||University of Bristol||Completed|September 2001|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|11 Years|16 Years|No|||June 2001|August 1, 2006|August 1, 2006||||No||https://clinicaltrials.gov/show/NCT00360061||179953|
NCT00355875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT754957|The Effect of Oxygen Exposure During Newborn Resuscitation on Lung Injury|Oxygen Exposure During Newborn Resuscitation and Pulmonary Oxidative Stress||University of Calgary||Completed|July 2005|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|23 Weeks|32 Weeks|No|||November 2006|November 6, 2006|July 22, 2006||||No||https://clinicaltrials.gov/show/NCT00355875||180265|
NCT00355888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-10070|Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors|A Phase I, Open Label Study of MBP-426 Given by Intravenous Infusion in Patients With Advanced or Metastatic Solid Tumors||Mebiopharm Co., Ltd|No|Completed|June 2006|April 2009|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||September 2009|November 27, 2014|July 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00355888||180264|
NCT00356200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-CL1|Fluphenazine Decanoate for Psoriasis|Ascending-Dose, Double-Blind, Placebo-Controlled, Bilateral Study of Intralesional Fluphenazine Decanoate in Psoriasis||Tufts Medical Center|No|Terminated|July 2006|September 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||December 2010|December 20, 2010|July 24, 2006|No|Yes|Enrollment criteria met|No|November 15, 2010|https://clinicaltrials.gov/show/NCT00356200||180240|
NCT00356473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-07-061-02|Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis|Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis||University of California, Los Angeles|No|Completed|March 2003|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2006|June 21, 2012|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356473||180219|
NCT00361998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0706|Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated Cystitis|Nitrofurantoin Macrocrystals 3 Days Vs. 7 Days in the Treatment of Women With Uncomplicated Cystitis||HaEmek Medical Center, Israel||Withdrawn|September 2006|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2007|March 1, 2007|August 8, 2006|||recruitment failed|No||https://clinicaltrials.gov/show/NCT00361998||179810|
NCT00361751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK34817 (completed)|Substrate Cycling in Energy Metabolism|Phase 2 Trial to Examine the Metabolic Effects of Fenofibrate in Burned Patients||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|May 2003|May 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|4 Years|18 Years|No|||February 2010|February 12, 2010|August 7, 2006||||No||https://clinicaltrials.gov/show/NCT00361751||179828|
NCT00362011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-062|Effect of Chia Seeds (Salvia Hispanica L.) on Glucose Control in Patients With Type 2 Diabetes|Effect of Chia Seeds (Salvia Hispanica L.) on Glucose Control in Patients With Type 2 Diabetes||St. Michael's Hospital, Toronto||Completed|March 2001|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|35 Years|75 Years||||February 2001|August 8, 2006|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362011||179809|
NCT00362570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0222|Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma|Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|May 2005|March 2011|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|August 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362570||179767|
NCT00359112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVM100264|AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes|A Randomised, Multi-Centre, Phase IV, Double-Blind, Parallel Group Study Comparing the Effects of 52 Weeks Administration of AVANDAMET and Metformin Plus Sulphonylurea on Change in HbA1c From Baseline in Overweight Type 2 Diabetics Poorly Controlled on Metformin.||GlaxoSmithKline||Completed|February 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||544|||Both|18 Years|75 Years|No|||May 2009|May 15, 2009|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00359112||180022|
NCT00359372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060216|Predicting Response to Cardiac Resynchronization Therapy in Heart Failure|Predicting Response to Cardiac Resynchronization Therapy in Heart Failure||National Institutes of Health Clinical Center (CC)||Completed|July 2006|May 2007||||N/A|Observational|N/A||||180|||Both|18 Years|N/A|No|||May 2007|September 26, 2015|August 1, 2006||||No||https://clinicaltrials.gov/show/NCT00359372||180002|
NCT00359359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91495|A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer|Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC)||Bayer|No|Completed|July 2006|August 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|July 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00359359||180003|
NCT00360204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22163|Improving Health Outcomes for New Mothers and Babies|Improving Health Outcomes for New Mothers and Babies||Penn State University||Completed|September 2006|February 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1154|||Both|N/A|7 Months|Accepts Healthy Volunteers|||August 2009|March 9, 2011|August 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00360204||179944|
NCT00360256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP450 Antidepressant study|Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants|Pharmacogenetic Study of CYP450 2D6 and 2C19 in Patients With Significant Adverse Effects From Antidepressants||Georgia Regents University|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 3|Observational|Time Perspective: Retrospective||2|Actual|46|||Both|18 Years|65 Years|No|Non-Probability Sample|Depressed patients|April 2012|April 18, 2012|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360256||179940|
NCT00360217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes|The Efficacy and Short-Term Safety of Docosahexaenoic Acid (DHA) and Statin Therapy for Subjects With Coronary Artery Disease or Cardiac Risk Equivalents With Moderate Hypertriglyceridemia (IIb)||Maine Center for Lipids and Cardiovascular Health||Completed|January 2006|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|21 Years|80 Years|No|||July 2006|November 17, 2011|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00360217||179943|
NCT00354146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004036|A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.|A Phase 2 Study Evaluating the Efficacy of the Farnesyl Transferase Inhibitor (FTI) R115777 in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2001|July 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|252|||Both|18 Years|N/A|No|||January 2011|January 31, 2011|July 18, 2006||||||https://clinicaltrials.gov/show/NCT00354146||180395|
NCT00354159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103|Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)|Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic HF (REDUCEhf)|REDUCEhf|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|April 2006|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|442|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|July 19, 2006|Yes|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT00354159||180394|The study was terminated early after 400 of an estimated 1300 subjects required were randomized. The study was terminated due to a pressure lead integrity issue based on analysis of pressure leads from other clinical trials.
NCT00355836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/153|Recovery of Hand Function Through Mental Practice.|Can Motor Imagery Enhance Recovery of Hand Function After Stroke? Evaluation of Motor Imagery Training.||University of Aberdeen||Completed|November 2004|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|135|||Both|N/A|N/A|No|||November 2015|November 4, 2015|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00355836||180268|
NCT00359307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000143|Genetic Factors in Atherosclerosis|Chemokine System Polymorphisms and Risk of Atherosclerosis (CAD)||National Institutes of Health Clinical Center (CC)||Completed|June 2000|March 2013||||N/A|Observational|N/A|||Anticipated|2000|||Both|N/A|N/A|No|||March 2013|August 20, 2013|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359307||180007|
NCT00355615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3561C00087|PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin|A Phase IIIb, Efficacy, and Safety Study of Rosuvastatin in Children 10-17 Years of Age With Heterozygous Familial Hypercholesterolemia: a 12-week, Double-blind, Randomized, Multicenter, Placebo-controlled Study With a 40-week, Open-label, Follow-up||AstraZeneca||Completed|July 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|173|||Both|10 Years|17 Years|No|||August 2011|August 29, 2011|July 20, 2006|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00355615||180285|
NCT00355628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2246-0401|Clinical Study of KW-2246 in Patients With Cancer Pain|Phase II Clinical Study of KW-2246 in Patients With Cancer Pain - Maintenance Switch Study in Oral Morphine or Oral Oxycodone-treated Patients||Kyowa Hakko Kirin Company, Limited|No|Completed|July 2006|||July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|80 Years|No|||August 2012|August 30, 2012|July 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00355628||180284|
NCT00355641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/206|Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome|A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)||GlaxoSmithKline|No|Completed|October 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|450|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|July 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00355641||180283|
NCT00360997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSA 2005/03|Investigation of Acceptable Dose of Mobilisation and Tactile Stimulation to Enhance Upper Limb Recovery After Stroke|Mobilisation and Tactile Stimulation to Enhance Upper Limb Recovery After Stroke: Phase I Investigation of Acceptable Dose, Efficacy and Underlying Mechanisms||St George's, University of London||Recruiting|March 2006|September 2008||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||August 2006|October 19, 2006|August 4, 2006||||No||https://clinicaltrials.gov/show/NCT00360997||179886|
NCT00361231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-349|Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer|Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer||Massachusetts General Hospital|Yes|Completed|May 2006|August 2012|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||March 2014|March 15, 2014|August 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361231||179868|
NCT00356213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peterli1|Comparison of Laparoscopic Sleeve Gastrectomy and Roux-Y-gastric Bypass in the Treatment of Morbid Obesity|Laparoscopic Sleeve Gastrectomy or Laparoscopic Proximal Roux-Y-gastric Bypass in the Treatment of Morbid Obesity||University Hospital, Basel, Switzerland|No|Enrolling by invitation|July 2006|August 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||January 2016|January 19, 2016|July 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00356213||180239|
NCT00356226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP-05-1550.R2|The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients|The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients With Ascites and Activation of Sympathetic Nervous System: a Randomized Double-Blind Placebo Controlled Study.||CHU de Charleroi||Completed|October 2000|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|18 Years|N/A|No|||October 2000|November 30, 2006|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356226||180238|
NCT00360698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_4002|Insulin Glulisine in Type 2 Diabetic Patients|Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study.|Basal Plus|Sanofi||Completed|July 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|75 Years|No|||August 2011|August 1, 2011|August 3, 2006|Yes|Yes||No|August 20, 2009|https://clinicaltrials.gov/show/NCT00360698||179908|
NCT00362583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-018-IM|Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)|A Double-blind, Randomised, Placebo-controlled Trial Confirming the Efficacy of Intranasal Fentanyl Titrated to 50, 100 or 200 µg With an Open Long-term Safety Follow-up in Cancer Patients With Breakthrough Pain||Nycomed||Completed|June 2006|March 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|80 Years|No|||May 2012|May 4, 2012|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362583||179766|
NCT00362596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-4178|A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand|A Randomized Controlled Crossover Trial of Acylcovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand||Centers for Disease Control and Prevention||Completed|January 2005|August 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||67|||Female|18 Years|49 Years|No|||August 2006|August 9, 2006|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362596||179765|
NCT00358852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011989|Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia|Scale Validation of Prediction of Relapse and Rehospitalization Short Term in Patients With Schizophrenia|PRE-COG|Janssen-Cilag, S.A.|No|Completed|August 2006|September 2008|Actual|September 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|2339|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with schizophrenia, schizoaffective / schizophreniform more than 2 years of        evolution and who are admitted to inpatient psychiatric units for short stay acute care        setting.|March 2014|March 18, 2014|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358852||180042|
NCT00359645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPISTORL - THANCS|Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population|DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality.||Gustave Roussy, Cancer Campus, Grand Paris||Terminated|August 2006|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1993|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 27, 2012|August 1, 2006||No|Too low accrual|No||https://clinicaltrials.gov/show/NCT00359645||179983|
NCT00359151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191225|Celebrex Total Knee Arthroplasty Study|Multicenter, Double Blind, Randomized, Placebo Controlled Trial Of The Efficacy And Safety Of Usual Care Plus Celecoxib Compared To Placebo For Peri-Operative And Rehabilitation Pain Control And Return To Function In Osteoarthritis Patients Undergoing Total Knee Arthroplasty||Pfizer|No|Terminated|November 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|80 Years|No|||May 2008|May 22, 2008|July 28, 2006|Yes|Yes|This study was terminated early due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT00359151||180019|
NCT00359918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reg.-Nr. 008/2006|Randomized Multicenter Trial of Prehospital Initiated Facilitated Percutaneous Coronary Intervention (PCI) Versus Primary PCI in ST-segment-Elevation MI (STEMI)|Randomized, Controlled Multicenter Trial of Prehospital Initiated Facilitated PCI Versus Primary PCI in Patients With STEMI LIPSIA-STEMI Trial|LIPSIA STEMI|University of Leipzig|Yes|Completed|August 2006|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||August 2009|August 6, 2009|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359918||179964|
NCT00359658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-94/2004|Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation|Conversion Study to Optimize Immunosuppressive Regimen by Withdrawal of Steroids, Cyclosporine A Dose Reduction and a Switch to Mycophenolatmofetile for Patients After Heart Transplantation in the Long-Term.||Hannover Medical School|No|Completed|November 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||February 2009|February 12, 2009|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359658||179982|
NCT00360854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481539|Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma|Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma||National Cancer Institute (NCI)||Active, not recruiting|May 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|1 Year|21 Years|No|||June 2007|September 19, 2013|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360854||179896|
NCT00361114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIF 35|IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.|Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Uncomplicated Malaria and in 2-10 Month Old Asymptomatic Infants.||Gates Malaria Partnership|Yes|Terminated|July 2006|October 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|112|||Both|2 Months|59 Months|No|||May 2008|May 1, 2008|August 3, 2006||No|SP arms were stopped due to high levels of treatment failure.CD not available.|No||https://clinicaltrials.gov/show/NCT00361114||179877|
NCT00363857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/249|A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome|A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)||GlaxoSmithKline||Completed|August 2003|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||360|||Both|18 Years|79 Years|No|||April 2015|April 13, 2015|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00363857||179671|
NCT00364130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004906|Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial|Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial||Children's Hospital of Philadelphia|Yes|Completed|February 2007|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|8 Years|21 Years|No|||August 2014|August 20, 2014|August 14, 2006||No||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00364130||179650|
NCT00359853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-pbe-mnjf-2|Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis|Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis||Hospital Clinic of Barcelona||Completed|September 2000|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||70|||Both|18 Years|80 Years|No|||June 2004|August 1, 2006|August 1, 2006||||No||https://clinicaltrials.gov/show/NCT00359853||179969|
NCT00360074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH 326/03|Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation|A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism||University Hospital Freiburg||Completed|February 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|18 Years|75 Years|No|||June 2008|June 6, 2008|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00360074||179952|
NCT00360360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI UNKPRI 19|Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site|A Phase II Study of Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Patients With Carcinoma of Unknown Primary Site||SCRI Development Innovations, LLC|No|Completed|July 2006|March 2009|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|August 2, 2006|No|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00360360||179932|
NCT00360373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK68228|Adolescent Gastric By-pass and Diabetic Precursors|Adolescent Gastric By-pass and Diabetic Precursors||Children's Hospital Medical Center, Cincinnati|Yes|Completed|August 2005|February 2012|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|15 Years|45 Years|No|Non-Probability Sample|Adolescents undergoing weight loss surgery|January 2014|January 3, 2014|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360373||179931|
NCT00360737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA24424 BT-001|Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses|Pharmacokinetics of a Heptavalent Equine-derived Botulinum Antitoxin (NP-018)||Cangene Corporation|Yes|Completed|July 2006|April 2010|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|July 19, 2006|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00360737||179905|
NCT00359814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-95/2004|Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction After Heart Transplantation|Conversion Study to Optimize Immunosuppressive Regimen by Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction for Patients After Heart Transplantation in Lon-Term||Hannover Medical School|No|Completed|November 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|No|||February 2009|February 13, 2009|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359814||179971|
NCT00359840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN321-SC/05-A55|A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor|A Randomized, Dose - Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor||Kyowa Hakko Kirin Company, Limited||Completed|July 2006|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|20 Years|74 Years|No|||August 2012|August 30, 2012|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359840||179970|
NCT00361010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KeppraCAE|A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy|A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy||The Cleveland Clinic||Completed|December 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|4 Years|10 Years|No|||July 2011|July 27, 2011|August 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361010||179885|
NCT00360347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16558|A Study of Mircera in Anemic Patients With Multiple Myeloma|Open Label, Randomized, Exploratory Study to Investigate the Hemoglobin Dose-Response, the Safety and the Pharmacokinetic Profile Following Subcutaneous Administration of Mircera Once Every Three Weeks to Anemic Patients With Multiple Myeloma||Hoffmann-La Roche||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2008|January 23, 2008|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360347||179933|
NCT00361738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6738|Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Response, Multicentre, Multinational Study Evaluating the Efficacy and Safety of AVE2268 Administered Either Twice Daily (Breakfast and Lunch) at a Dose of 300, 600 and 1200 mg or Once Daily (Breakfast) at a Dose of 1200 mg, in Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled||Sanofi||Completed|July 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|317|||Both|18 Years|74 Years|No|||February 2009|February 6, 2009|August 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361738||179829|
NCT00362609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B3-331, 3001B3-335|Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD|A Multicenter, Open-Label, PK, PD and Safety Study of Pantoprazole Delayed-Release Granules Administered as a Suspension in Neonates and Preterm Infants With a Clinical Diagnosis of GERD||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|N/A|28 Days|No|||April 2010|April 22, 2010|August 8, 2006|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00362609||179764|
NCT00362622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X050826003|Determinants of Compliance With Glaucoma Therapy|Determinants of Compliance With Glaucoma Therapy||University of Alabama at Birmingham|No|Completed|October 2005|January 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|19 Years|N/A|No|Non-Probability Sample|Glaucoma patients.|August 2012|August 14, 2012|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362622||179763|
NCT00362635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-310|Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection|A Double-blinded and Randomised Study to Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30 mg qd Versus Lamivudine 100 mg qd for Chronic Hepatitis B Infection||Bukwang Pharmaceutical||Completed|August 2006|||December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|92|||Both|18 Years|60 Years|No|||July 2012|July 24, 2012|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362635||179762|
NCT00362297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30520-D - Phase 1|Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2|A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults||University of Washington|No|Completed|September 2006|September 2011|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|August 8, 2006|Yes|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT00362297||179788|The trial was performed at a single site, and enrolled mostly white, healthy, sexually active adults with high rates of genital HSV-2 recurrence. The results may not be generalizable to other populations.
NCT00362310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKS/IND/02|Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir|A Phase II Trial With the HIV Protease Inhibitor Indinavir for the Treatment of Classical Kaposi's Sarcoma||Istituto Superiore di Sanità||Completed|June 2003|July 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||April 2008|April 11, 2008|August 9, 2006||||No||https://clinicaltrials.gov/show/NCT00362310||179787|
NCT00359125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-0327|RU-486 in the Treatment of Bipolar Depression|Efficacy of Mifepristone (RU-486) in the Treatment of Bipolar Depression.||University of British Columbia||Withdrawn|July 2006|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00359125||180021|
NCT00360230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106367|Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children|A Partially-blind (Observer-blind) Study to Evaluate the Safety and Immunogenicity of 3 Different Vaccination Schedules With 2 GSK Biologicals' Candidate Plasmodium Falciparum Vaccines in Children Aged 5 to 17 Months Living in Ghana||GlaxoSmithKline||Completed|August 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|540|||Both|5 Months|17 Months|Accepts Healthy Volunteers|||September 2009|September 3, 2009|July 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360230||179942|
NCT00360243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.70|6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA|6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA||Sprout Pharmaceuticals, Inc||Completed|July 2006|||April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1392|||Female|18 Years|50 Years|No|||March 2012|March 14, 2012|August 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360243||179941|
NCT00360516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8748-27380-02|Paleolithic Diet and Exercise Study|Paleolithic Diets, Exercise Physiology and Metabolism||University of California, San Francisco|No|Completed|November 2005|December 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360516||179920|
NCT00359385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8202|The Effects of Alendronate After Cure of Primary Hyperparathyroidism|The Effects of Alendronate After Cure of Primary Hyperparathyroidism|AlenPostPara|Columbia University|No|Withdrawn|July 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|August 1, 2006||No|incomplete enrollment|No||https://clinicaltrials.gov/show/NCT00359385||180001|
NCT00359970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-02-082|Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea|Loperamide Plus Azithromycin More Effectively Treats Travelers' Diarrhea In Mexico Than Azithromycin Alone||The University of Texas Health Science Center, Houston|No|Completed|June 2002|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|176|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|August 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00359970||179960|
NCT00361127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCM S65/206|Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure|Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-inhibitors||Centro Cardiologico Monzino||Completed|August 2006|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|20 Years|80 Years|No|||January 2016|January 27, 2016|August 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00361127||179876|
NCT00361400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD045480-03|Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study|Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study||University of California, San Francisco||Completed|August 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1387|Samples Without DNA|urine for pregnancy testing|Female|15 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Planned Parenthood patients who present to start a hormonal birth control for the first        time.|August 2013|August 1, 2013|August 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00361400||179855|
NCT00361075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23RR016067-05|Midlife Cholesterol Study|Mentored Patient Oriented Research Career Development Award||Northwestern University||Completed|July 1998|May 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Female|47 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00361075||179880|
NCT00361088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13971|A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma|A Dose Escalation of Zarnestra (R115777) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|August 2005|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||May 2011|November 21, 2013|August 3, 2006|Yes|Yes|Initial Principal Investigator left Moffitt|No||https://clinicaltrials.gov/show/NCT00361088||179879|
NCT00363116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEN049|A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients|An Open-Label, Comparative Trial of Two Daclizumab Dosing Strategies Versus No Induction Treatment in Combination With Tacrolimus, Mycophenolate Mofetil, and Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients||University of Cincinnati||Completed|April 1999|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|298|||Both|18 Years|65 Years|No|||October 2013|October 24, 2013|August 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00363116||179727|
NCT00363402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETCT-HMO-CTIL|18FDG- PET/CT Contribution to the Assessment of Lesion Severity in Cystic Fibrosis (CF)|18FDG- PET/CT Contribution to the Assessment of Lesion Severity in Cystic Fibrosis (CF||Hadassah Medical Organization||Completed|August 2006|December 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|20|||Both|10 Years|N/A|No|||August 2006|May 19, 2009|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00363402||179705|
NCT00360386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C_9108|ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"|Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.||Sanofi||Completed|March 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|18 Years|85 Years|No|||August 2010|August 30, 2010|August 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00360386||179930|
NCT00360399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024975|Identifying Factors That Predict Antidepressant Treatment Response|Predictors of Antidepressant Treatment Response: The Emory CIDAR||Emory University|Yes|Completed|August 2006|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|344|||Both|18 Years|65 Years|No|||July 2015|July 16, 2015|August 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360399||179929|
NCT00361023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LISS|Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy|Effects of Angiotensin Type 1 Receptor Blockade With Losartan on Insulin Sensitivity and Secretion in Subjects With Type 2 Diabetes and Nephropathy||Shanghai Jiao Tong University School of Medicine||Completed|January 2006|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|17 Years|N/A|No|||January 2006|August 4, 2006|August 1, 2006||||No||https://clinicaltrials.gov/show/NCT00361023||179884|
NCT00361270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4421-I|Treatment of Veterans With Chronic Low Back Pain|Treatment of Veterans With Chronic Low Back Pain|CLBP|VA Office of Research and Development|No|Active, not recruiting|October 2006|December 2016|Anticipated|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|161|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|August 4, 2006||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT00361270||179865|The study is done on a population of Veterans and may not generalize to the larger population. The same provider administered treatment for all four groups.
NCT00360711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906179|Genetic Counselors' Experiences of Moral Value Conflicts With Clients|Genetic Counselors' Experiences of Moral Value Conflicts With Clients||National Institutes of Health Clinical Center (CC)||Completed|June 2006|March 2007||||N/A|Observational|N/A||||0|||Both|N/A|N/A|No|||March 2007|September 26, 2015|August 4, 2006||||No||https://clinicaltrials.gov/show/NCT00360711||179907|
NCT00361530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-STARS echo|Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo)|Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon Carotid Intima-media Complex Thickness in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.||Translational Research Informatics Center, Kobe, Hyogo, Japan||Active, not recruiting|March 2004|||July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|854|||Both|45 Years|80 Years|No|||March 2015|March 19, 2015|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00361530||179845|
NCT00361491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI5879|An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder|An Eight-Week, Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled Study Evaluating the Efficacy, and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Patients With Major Depressive Disorder|LENA|Sanofi||Completed|August 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|324|||Both|18 Years|64 Years|No|||January 2009|January 15, 2009|August 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361491||179848|
NCT00361504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011074|A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain|A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|November 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1123|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|August 4, 2006|Yes|Yes||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00361504||179847|
NCT00361517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/0984/2005|To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early|Using Serum Galactomannan Levels in a Prospective, Randomised, Non-Blinded Trial to Guide Early Anti-Fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis.||Singapore General Hospital|Yes|Terminated|June 2006|June 2009|Anticipated|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|47|||Both|12 Years|N/A|No|||June 2009|June 23, 2009|August 6, 2006||No|Gm test became routinely available. We could not compare the two arms anymore.|No||https://clinicaltrials.gov/show/NCT00361517||179846|
NCT00358657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2032.00|Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders|HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide||Fred Hutchinson Cancer Research Center|Yes|Recruiting|May 2006|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|54 Years|No|||December 2015|December 3, 2015|July 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00358657||180057|
NCT00359164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-0202|Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.|A Randomized, Controlled, Double-Masked, Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab (Avastin), in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD)||University of British Columbia||Completed|July 2006|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|50 Years|N/A|No|||August 2008|August 12, 2008|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00359164||180018|
NCT00358618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-0219|The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats|The Effects of Three Effect-site-targeted Propofol Concentrations on Dispersion of Myocardial Repolarization in Children||University of British Columbia|No|Completed|September 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||August 2009|August 17, 2009|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358618||180060|
NCT00358865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3847-AB-CTIL|Checking the Usability of a Virtual Reality System in Children With Brain Injury|Checking the Usability of Video Projected Virtual Reality Sytem in Children With Acquired Brain Injury||Sheba Medical Center|No|Completed|December 2005|December 2006|Actual|December 2006|Actual|Phase 1|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study sample consisted of 33 children, and was divided into study and control groups:        16 children with ABI from the Pediatric Rehabilitation department at the Sheba Medical        Center, Tel Hashomer in the study group (mean age = 7.91, S.D. = 1.43, range from 6 to        11.4 years old), and 17 healthy participants in the control group (mean age = 7.94, S.D. =        1.57, range from 6 - 11.33 years).|April 2008|April 30, 2008|July 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00358865||180041|
NCT00360529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.71|24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder|A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Every Evening and Flibanserin 100 Milligrams Every Evening in Women With Hypoactive Sexual Desire Disorder in North America||Boehringer Ingelheim||Completed|July 2006|||April 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|886|||Female|18 Years|N/A|No|||April 2009|April 24, 2009|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360529||179919|
NCT00360555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.75|A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder|Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America||Sprout Pharmaceuticals, Inc||Completed|July 2006|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1584|||Female|18 Years|55 Years|No|||March 2012|March 6, 2012|August 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360555||179918|
NCT00360841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561702041|Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting|Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting: A Prospective Randomized Double-blind Cross-over Study||National Taiwan University Hospital|No|Completed|June 2006|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|N/A|No|||November 2012|December 4, 2012|August 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00360841||179897|
NCT00360906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD-10842|Omega-3 Fatty Acid Treatment in Multiple Sclerosis|Omega-3 Fatty Acid Treatment in Multiple Sclerosis||Haukeland University Hospital||Completed|December 2004|July 2008||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|55 Years|No|||August 2006|August 4, 2006|August 4, 2006||||No||https://clinicaltrials.gov/show/NCT00360906||179893|
NCT00361673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0264|Evaluating the Effect of Neighborhood Environments on Cardiovascular Risk Factors|Reducing CVD (Cardiovascular Disease) Risk and Health Disparities Through Active Living Communities||University of Colorado, Denver|No|Completed|September 2006|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1140|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of one of the following five neighborhoods in the Greater Stapleton Community:        Northeast Park Hill, Greater Park Hill, East Montclair, Stapleton, or Original Aurora|December 2013|December 23, 2013|August 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00361673||179834|
NCT00360568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S187.3.003|Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects|Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects||AbbVie|Yes|Completed|June 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|30 Years|N/A|No|||January 2015|January 12, 2015|August 3, 2006|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00360568||179917|
NCT00360581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603012|Preventing Postpartum Relapse to Smoking Using Yoga and Cognitive Behavioral Therapy: A Randomized Pilot Study|Preventing Postpartum Relapse to Smoking Using Yoga and Cognitive Behavioral Therapy: A Randomized Pilot Study||University of Pittsburgh||Completed|April 2006|January 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 7, 2008|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00360581||179916|
NCT00363649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05121 CDR0000492005|Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI|A Randomized Phase II Trial of Interferon + GM-CSF Versus K562/GM-CSF Vaccination in CML Patients Achieving a Complete Cytogenetic Response to Frontline Tyrosine Kinase Inhibitor Therapy||Sidney Kimmel Comprehensive Cancer Center||Recruiting|September 2006|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363649||179687|
NCT00363883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02844|Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium|Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium||National Cancer Institute (NCI)||Terminated|June 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||January 2014|January 28, 2015|August 10, 2006|Yes|Yes|Trial stopped early for futility|No|January 28, 2015|https://clinicaltrials.gov/show/NCT00363883||179669|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.
NCT00363896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT000740|A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)|Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients||Almirall, S.A.||Completed|August 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|843|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|August 10, 2006||No||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00363896||179668|
NCT00360412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-303|A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations||Eisai Inc.||Terminated|October 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|997|||Male|30 Years|N/A|No|||August 2013|June 26, 2014|August 2, 2006|Yes|Yes|Study stopped due to lack of efficacy.|No|October 23, 2012|https://clinicaltrials.gov/show/NCT00360412||179928|Due to early termination, a limited number of subjects (only 2) completed this open-label extension study. The majority of subjects did not reach the scheduled Week 56 assessment. Many outcomes could only be analyzed to Week 68 as a result.
NCT00360425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62,745-9|A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women|A Phase 1 Active- and Placebo-Controlled Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women||AMAG Pharmaceuticals, Inc.||Completed|May 2006|August 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||174|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|November 17, 2011|August 2, 2006||||||https://clinicaltrials.gov/show/NCT00360425||179927|
NCT00360750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481598|Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye|A Data Collection Study to Compare the Outcome for Children With Advanced Unilateral Retinoblastoma Treated With or Without Post-Enucleation Chemotherapy ± Radiotherapy on RB 2005 11 With Historical Controls Receiving no Additional Therapy||National Cancer Institute (NCI)||Active, not recruiting|September 2005|||July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|15 Years|No|||June 2009|September 16, 2013|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360750||179904|
NCT00360724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 4967/6363R|Duloxetine for Chronic Depression: a Double-blind Study|Duloxetine for Chronic Depression: a Double-blind Study||New York State Psychiatric Institute|No|Completed|August 2006|December 2013|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|20 Years|75 Years|No|||October 2013|October 5, 2015|August 3, 2006|Yes|Yes||No|October 1, 2013|https://clinicaltrials.gov/show/NCT00360724||179906|
NCT00361543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPrc 94/06|Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia|Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?|SERM|The Alfred||Completed|August 2006|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Female|45 Years|70 Years|No|||January 2015|January 28, 2015|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00361543||179844|
NCT00361244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-439|SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer|A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer||Massachusetts General Hospital||Active, not recruiting|July 2006|||December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2007|December 28, 2007|August 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361244||179867|
NCT00361257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5235|Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults|Phase II, Randomized, Placebo-Controlled, Double-Blind Study of Minocycline in the Treatment of HIV-Associated Cognitive Impairment||AIDS Clinical Trials Group|Yes|Terminated|March 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|August 4, 2006|Yes|Yes|This study was terminated early due to futility.|No|January 28, 2011|https://clinicaltrials.gov/show/NCT00361257||179866|Originally, 100 participants were expected to enroll. As of the early termination notice, 107 participants were randomized, yet not all subjects could complete the 24 week assessment.
NCT00362024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0952-004|MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)|MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease||Merck Sharp & Dohme Corp.||Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||||||Both|55 Years|N/A|No|||July 2015|July 31, 2015|August 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362024||179808|
NCT00362037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0255|I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy|Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy||Sanofi|No|Completed|March 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|281|||Both|30 Years|75 Years|No|||May 2011|May 27, 2011|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362037||179807|
NCT00359177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT102785|Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Hepatic Impairment||GlaxoSmithKline||Completed|December 2005|||||Phase 1|Interventional|N/A||||24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|July 28, 2006||||||https://clinicaltrials.gov/show/NCT00359177||180017|
NCT00358631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI5878|An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder|An Eight-Week, Multicenter, Double-Blind, Placebo- and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Major Depressive Disorder||Sanofi||Completed|July 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|319|||Both|18 Years|64 Years|No|||April 2009|April 10, 2009|July 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00358631||180059|
NCT00358644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACO-017|Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)|A Phase II Study of Decitabine For the Front-line Treatment of Older Patients With Acute Myeloid Leukemia||Eisai Inc.||Completed|March 2005|December 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|60 Years|N/A|No|||June 2010|May 13, 2013|July 31, 2006|Yes|Yes||No|April 13, 2009|https://clinicaltrials.gov/show/NCT00358644||180058|
NCT00358878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4492|Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)|Satavaptan Cirrhotic Ascites Treatment Study: a Double-blind, Randomised, Parallel-group Comparison of Treatment With Satavaptan at 5 to 10 mg Daily Versus Placebo on Top of Conventional Treatment in Patients With Ascites Due to Cirrhosis of the Liver|CATS|Sanofi||Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|N/A|No|||July 2009|July 17, 2009|July 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00358878||180040|
NCT00359138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04441|The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)|A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation||Merck Sharp & Dohme Corp.|No|Completed|February 2006|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|July 31, 2006||Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00359138||180020|
NCT00359398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006IC003B|Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac Surgery|Post-operative Administration of Platelet Rich Plasma Sequestered Prior to Cardiopulmonary Bypass Reduces the Coagulopathy Associated With Complex Cardiac Surgery||Royal Brompton & Harefield NHS Foundation Trust|Yes|Terminated|August 2006|July 2009|Actual|July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|16 Years|N/A|No|||September 2009|September 18, 2009|August 1, 2006||No|Funding expired, low recruitment|No||https://clinicaltrials.gov/show/NCT00359398||180000|
NCT00359684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|780093|Use of Cysteamine in the Treatment of Cystinosis|Natural History Study of the Use of Cysteamine in the Treatment of Cystinosis||National Institutes of Health Clinical Center (CC)||Recruiting|July 1978|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|N/A|No|||November 2015|December 2, 2015|August 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00359684||179980|
NCT00360919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCCR-01|Assessing the Presence of Casomorphins in Human Plasma After Dairy Ingestion|Assessing the Presence of Casomorphins in Human Plasma After Dairy Ingestion||Physicians Committee for Responsible Medicine|Yes|Completed|September 2006|December 2010|Actual|December 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 6, 2012|August 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00360919||179892|
NCT00357565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS075|Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia|Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|December 2005|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|3 Years|No|||February 2016|February 18, 2016|July 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00357565||180141|
NCT00361387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02-23-03|Use of Focalin for Fatigue in Sarcoidosis|Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.||University of Cincinnati|No|Completed|June 2006|January 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|August 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361387||179856|
NCT00364182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A1-400|Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B|A Multicenter, Open-Label Study To Compare On-Demand Treatment With 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX (BeneFIX) Reformulated Drug Product (rFIX-R) In Subjects With Severe Hemophilia B||Pfizer|No|Completed|May 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Male|6 Years|65 Years|No|||August 2011|August 30, 2011|August 14, 2006|Yes|Yes||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00364182||179646|Although the protocol-defined endpoint was days lost from work or school after hemarthrosis, data was collected and reported in hours.
NCT00364429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102747|SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia|Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study||GlaxoSmithKline|No|Terminated|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|55|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|August 11, 2006|No|Yes|terminated|No||https://clinicaltrials.gov/show/NCT00364429||179628|
NCT00361582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011218|A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|669|||Both|18 Years|80 Years|No|||April 2010|June 3, 2011|August 4, 2006||||||https://clinicaltrials.gov/show/NCT00361582||179841|
NCT00361595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HUS120|Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women|Open Label Proof of Concept Study of IV Zoledronic Acid (ZA) 5 mg After Forteo in Postmenopausal Women||The Cleveland Clinic|No|Completed|August 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|N/A|85 Years|No|||October 2010|December 14, 2010|August 4, 2006|Yes|Yes||No|October 13, 2010|https://clinicaltrials.gov/show/NCT00361595||179840|
NCT00361283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0435278B|Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis|Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis||University of Florida|No|Completed|June 2004|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 16, 2012|August 4, 2006|Yes|Yes||No|March 9, 2012|https://clinicaltrials.gov/show/NCT00361283||179864|
NCT00361556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-11|Treatment for Nonspecific Low Back Pain in Primary Care: a Trial on Different Health Education Booklets|Treatment for Nonspecific Low Back Pain in Primary Care With Standardized Health Education Booklets: A Randomized Controlled Clinical Trial||Kovacs Foundation|Yes|Completed|October 2005|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|240|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|August 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00361556||179843|
NCT00361569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-CEN-302|A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Compare the Effects of 12 Weeks of Treatment With DR-2041(Synthetic Conjugated Estrogens, A) Vaginal Cream vs. Placebo Vaginal Cream on Vulvovaginal Atrophy in Healthy Postmenopausal Women||Teva Pharmaceutical Industries|No|Completed|August 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|622|||Female|30 Years|80 Years|No|||March 2015|March 30, 2015|August 3, 2006|Yes|Yes||No|December 22, 2008|https://clinicaltrials.gov/show/NCT00361569||179842|
NCT00361777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020309|Diagnostic Performance of Screening Tests for Cushing s Syndrome|The Diagnostic Performance of Screening Tests for the Diagnosis of Cushing's Syndrome||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2002|||||N/A|Observational|N/A|||Anticipated|500|||Both|18 Years|75 Years|No|||December 2015|January 22, 2016|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00361777||179827|
NCT00362050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBx/MMV05-06|RBx11160 Phase II Dose Ranging Study RBx/MMV05-06|A Phase II, Double-Blind, Parallel-Group, Randomized, Dose-Ranging Study Assessing the Antimalarial Activity and Safety of RBx 11160 Administered for 7 Days in Patients With Acute Uncomplicated Plasmodium Falciparum Malaria||Medicines for Malaria Venture||Completed|June 2006|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||255|||Both|13 Years|65 Years|No|||August 2007|August 28, 2007|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362050||179806|
NCT00362323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF23-0121 06 01|Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO|A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin.||Solvay Pharmaceuticals|No|Completed|October 2006|March 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|482|||Both|18 Years|75 Years|No|||April 2010|April 15, 2010|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362323||179786|
NCT00358917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-802|Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects|A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir (LPV/r) Tablets 800/200 Milligram (mg) Once-Daily (QD) Versus 400/100 mg Twice-Daily (BID) When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-Experienced, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects||Abbott|Yes|Completed|August 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|599|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|July 28, 2006|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00358917||180037|
NCT00358930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 501-208|A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Study of ARQ 501 in Patients With Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||ArQule||Completed|July 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00358930||180036|
NCT00359671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6592-001|Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)|Phase I Study Evaluating MK6592 in Combination With Docetaxel in Adult Patients With Relapsed or Refractory Advanced Solid Tumors||Merck Sharp & Dohme Corp.||Terminated|March 2007|July 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||38|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|August 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00359671||179981|
NCT00359957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK60476 (completed)|Efficacy of Increasing Physical Activity to Reduce Children's Visceral Fat|Activity, Diet, and Visceral Adiposity: New Care Emerging (ADVANCE) Project|ADVANCE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|July 2006|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|7 Years|12 Years|No|||March 2010|March 1, 2010|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359957||179961|
NCT00359983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107824|Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB|A Study to Evaluate the Long-term Antibody Persistence at 1, 3 & 5 Years After the Administration of a Fourth Dose of Hib-MenCY-TT Vaccine Compared to ActHIB in Subjects Boosted in a Previous Study.||GlaxoSmithKline||Completed|September 2006|May 2011|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|270|||Both|22 Months|60 Months|Accepts Healthy Volunteers|||August 2012|September 6, 2012|July 31, 2006|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00359983||179959|
NCT00360269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA018221|Atomoxetine Treatment for ADHD and Marijuana Dependence|Atomoxetine Treatment for ADHD and Marijuana Dependence||Medical University of South Carolina|Yes|Completed|November 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||December 2014|December 8, 2014|August 2, 2006|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00360269||179939|Small sample size and poor retention
NCT00360594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804481|Acamprosate Initiated During Alcohol Detoxification|Initiating Acamprosate Within Versus Post-detoxification in the Rehabilitative Treatment of Alcohol Dependence.||National Institute on Drug Abuse (NIDA)|Yes|Completed|October 2006|November 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||December 2009|December 2, 2009|August 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360594||179915|
NCT00361413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-01-HMO-CTIL|Alefacept for Prevention of Graft Versus Host Disease (GVHD)|An Investigator Initiated Double Blind Randomized Study of Alefacept Treatment Prevention of Graft Versus Host Disease in Myeloablative Stem Cell Transplantation||Hadassah Medical Organization|No|Terminated|June 2006|December 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|26|||Both|14 Years|75 Years|No|||December 2010|April 19, 2015|July 31, 2006||No|company withdrawal of the drug|No||https://clinicaltrials.gov/show/NCT00361413||179854|
NCT00361426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022-05B|EarlySense Monitoring Device Evaluation on COPD, CHF and Pneumonia Patients|EarlySense Monitoring Device Evaluation on Patients in Med / Surg||EarlySense Ltd.|Yes|Recruiting|January 2008|||February 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Months|N/A|No|Probability Sample|Patients hospitalized in Med/Surg unit|January 2008|January 24, 2008|August 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00361426||179853|
NCT00357890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-03890-002|Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)|A Pilot Study of the Effect of Continuous Subcutaneous Insulin Infusion in Adolescents With Newly-diagnosed Type 1 Diabetes on Insulin Resistance, Beta-cell Function and the Honeymoon Period.||Nemours Children's Clinic|No|Completed|December 2005|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|12 Years|17 Years|No|||April 2015|April 14, 2015|July 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00357890||180116|
NCT00361660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|407-2005A|The Effect of Different Schedules of Functional Task Practice for Improving Hand and Arm Function After Stroke|The Impact of Functional Task Practice Dosing on Motor Control in Hemiplegia From Chronic Stroke||VA Office of Research and Development|No|Withdrawn|August 2006|December 2007|Anticipated|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||June 2015|June 25, 2015|August 7, 2006||No|project was only internally funded and would complete for subjects with 2 newer externally    funded projects|No||https://clinicaltrials.gov/show/NCT00361660||179835|
NCT00355927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBSsed1-HMO-CTIL|Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.|Changes of the Neuronal Activity in the Subthalamic Nucleus Under Propofol Sedation During Stereotactic Electrode Implantation.||Hadassah Medical Organization|No|Enrolling by invitation|September 2006|July 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||August 2006|November 1, 2007|July 23, 2006||||No||https://clinicaltrials.gov/show/NCT00355927||180261|
NCT00356239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201/05|Implantable Cardioverter Defibrillators And Magnetic Resonance Imaging of the Heart at 1.5 Tesla|Evaluation of Safety and Feasibility Magnetic Resonance Imaging of the Heart at 1.5 Tesla In Patients With Implantable Cardioverter Defibrillators||University Hospital, Bonn|Yes|Recruiting|July 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||25|||Both|N/A|N/A|No|||April 2007|April 9, 2007|July 24, 2006||||No||https://clinicaltrials.gov/show/NCT00356239||180237|
NCT00356486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORAL-2|Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV|Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a (40 KD) (270 μg/Week) and Ribavirin (1600 mg/Day) With Epoetin β Support (450 IU/kg/Week)||Germans Trias i Pujol Hospital|No|Completed|October 2005|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|80 Years|No|||September 2009|September 2, 2009|July 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00356486||180218|
NCT00361608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-CI 03|Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device|Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device||EarlySense Ltd.||Completed||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|12 Years|18 Years|No|||April 2008|April 22, 2008|August 6, 2006||||No||https://clinicaltrials.gov/show/NCT00361608||179839|
NCT00361036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060030|Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent|Feasibility Evaluation of the Embolic Agent BeadBlock™ in the Treatment of Uterine Fibroids With Uterine Artery Embolization With Comparison of Study Endpoints to Embosphere®||Worthington-Kirsch, Robert L., M.D.|No|Completed|August 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Female|30 Years|50 Years|No|||April 2011|April 14, 2011|August 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361036||179883|
NCT00361049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3Y03|Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant|Donor Mesenchymal Stem Cell Infusion for Treatment of Graft Versus Host Disease: A Phase I Trial||Case Comprehensive Cancer Center|Yes|Completed|September 2004|November 2010|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||November 2010|November 4, 2010|August 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361049||179882|
NCT00361296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05115, CDR0000491987|Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes|K562/GM-CSF Vaccination in Patients With Myelodysplastic Syndrome||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|August 2006|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|120 Years|No|||October 2015|October 30, 2015|August 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361296||179863|
NCT00361790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-463 ST|Aripiprazole and Lexapro Drug Interaction Study|Effects on Aripiprazole on the Steady-State Pharmacokinetics of Escitalopram in Healthy Subjects||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|August 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1|||25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|November 7, 2013|August 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361790||179826|
NCT00361803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYT104152|Topotecan Pharmacokinetic Characterization Study|A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer||GlaxoSmithKline|No|Completed|September 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||March 2011|May 31, 2012|August 7, 2006||||||https://clinicaltrials.gov/show/NCT00361803||179825|
NCT00362336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L15|Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV|Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to CombAct-HIB® Concomitantly Administered With Engerix B® Paediatric and OPV at 6, 10, and 14 Weeks of Age in South African Infants||Sanofi|Yes|Completed|August 2006|August 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|622|||Both|N/A|3 Days|Accepts Healthy Volunteers|||April 2014|April 1, 2014|August 8, 2006||No||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00362336||179785|
NCT00334438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0525|Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma|A Phase I Study Evaluating Combined Zevalin (Ibritumomab Tiuxetan) and Valcade (Bortezomib) in Relapsed/Refractory Low-Grade or Follicular B-Cell and Mantle Cell Lymphoma||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|July 2006|October 2011|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|June 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00334438||181854|
NCT00334763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05L1|Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Radiation Followed by Paclitaxel, Carboplatin, and Bevacizumab (PCA) in Patients With Stage IIIB and IV Squamous Non-Small Cell Lung Cancer||Northwestern University||Terminated|May 2006|November 2007|Actual|May 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|June 7, 2006|Yes|Yes|Principal Investigator felt risk to patients was too high.|||https://clinicaltrials.gov/show/NCT00334763||181829|
NCT00335036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB-05-11-147|Pediatric Lead Extractability and Survival Evaluation (PLEASE)|Pediatric Lead Extractability and Survival Evaluation (PLEASE)Study: A Prospective Assessment of Implantable Cardioverter Defibrillator (ICD) Lead Extractability and Survival in Children and Congenital Heart Disease Patients||Children's Hospital Boston|Yes|Terminated|June 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|1 Year|55 Years|No|||August 2009|August 3, 2009|June 6, 2006||No|Lead was recalled and manufacturing halted|No||https://clinicaltrials.gov/show/NCT00335036||181808|
NCT00335309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT-1/2005|Maxillary Sinus Irrigation in the Management of Chronic Rhinosinusitis|Effectiveness of Maxillary Sinus Saline Irrigation in Conjunction With Systemic Antibiotic Therapy Versus Systemic Antibiotic Therapy Alone in the Management of Chronic Rhinosinusitis, a Prospective Randomized Controlled Trial||Carmel Medical Center|Yes|Completed|October 2005|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||October 2013|October 6, 2013|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335309||181788|
NCT00335322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-ALTAIR|ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens|A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection.||Kirby Institute|Yes|Completed|February 2007|November 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|329|||Both|16 Years|N/A|No|||April 2012|April 17, 2012|June 8, 2006||No||No|April 17, 2012|https://clinicaltrials.gov/show/NCT00335322||181787|Inadequate sample size for true comparison of non-inferiority
NCT00341328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-01C-1/2003-10|Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.|Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters||Ministry of Science and Technology, India|Yes|Completed|March 2007|March 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|60 Years|No|||April 2013|April 25, 2013|June 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00341328||181347|
NCT00341341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905054|Impact of Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk and Receptivity to Quit Smoking|Impact of a Patient's Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk Information and Receptivity to Quit Smoking||National Institutes of Health Clinical Center (CC)||Completed|December 2004|July 2010||||N/A|Observational|N/A|||Anticipated|757|||Both|18 Years|55 Years|No|||July 2010|July 17, 2010|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341341||181346|
NCT00331097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELDA|ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment|Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF||National Cancer Institute, Naples|No|Active, not recruiting|July 2003|March 2017|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Female|65 Years|80 Years|No|||November 2015|November 27, 2015|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00331097||182097|
NCT00341562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905234|Genomics of In-Stent Restenosis|Genomics of In-Stent Restenosis: Endarterectomy Study||National Institutes of Health Clinical Center (CC)||Completed|September 2005|July 2006||||N/A|Observational|N/A||||30|||Both|18 Years|N/A|No|||July 2006|March 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341562||181329|
NCT00341575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905249|Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer|Psychosocial Aspects of Genetic Testing for HNPCC||National Institutes of Health Clinical Center (CC)||Completed|September 2005|August 2010||||N/A|Observational|N/A|||Anticipated|80|||Both|18 Years|82 Years|No|||August 2010|August 3, 2010|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341575||181328|
NCT00331864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2303|SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovasculariza-tion Secondary to Age-related Macular Degeneration||Novartis||Completed|April 2006|April 2008||April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|531|||Both|50 Years|N/A|No|||February 2011|February 15, 2011|April 11, 2006||No||No|December 9, 2010|https://clinicaltrials.gov/show/NCT00331864||182045|
NCT00342342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903067|Family Studies of Eye Traits|Family Studies of Ocular Traits||National Institutes of Health Clinical Center (CC)||Completed|December 2002|||||N/A|Observational|N/A|||Anticipated|8000|||Both|45 Years|84 Years|No|||July 2015|August 25, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342342||181271|
NCT00343681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT63|A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)||Sanofi|No|Completed|July 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 16, 2014|June 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00343681||181179|
NCT00343980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1682|Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes|Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes||Novo Nordisk A/S|No|Terminated|October 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|363|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|June 22, 2006|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00343980||181160|
NCT00344617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R452/01/2006|Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy|Off-Label Use of AVASTIN (BEVACIZUMAB)Intravitreal Injection For the Treatment of Serosanguinous Maculopathy||Singapore National Eye Centre||Active, not recruiting|June 2006|May 2008|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|50 Years|N/A|No|||September 2007|September 25, 2007|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344617||181113|
NCT00344630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S5572|TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?|TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?||Boston Scientific Corporation||Completed|May 2006|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||2500|||Both|18 Years|N/A|No|||October 2008|October 7, 2008|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344630||181112|
NCT00332137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1696-05|Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects|Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects||Mayo Clinic||Completed|September 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2011|March 21, 2011|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00332137||182026|
NCT00333164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHA STROKE04-01|Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis|Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis (CATHARSIS)||Translational Research Informatics Center, Kobe, Hyogo, Japan||Completed|May 2006|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|45 Years|85 Years|No|||August 2012|August 2, 2012|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00333164||181952|
NCT00333177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH037705-06|Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia|Developmental Processes in Schizophrenic Disorders: Cognitive Remediation, Medication Adherence, and Work Outcome in Recent-Onset Schizophrenia||University of California, Los Angeles|Yes|Completed|March 2006|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|153|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333177||181951|
NCT00333515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuBChE-01|Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously|A Phase 1, Randomized, Observer-blinded, Single Dose, Placebo Controlled Dosage-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Plasma-Derived Human Butyrylcholinesterase (HuBChE) Administered Intravenously (IV)||Baxalta US Inc.|Yes|Completed|January 2007|August 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|June 26, 2015|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333515||181925|
NCT00332579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602M82626|Double-Blind Naltrexone in Kleptomania|A Double-Blind, Placebo-Controlled Study of Naltrexone in Kleptomania||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|May 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|21 Years|75 Years|No|||April 2012|April 9, 2012|May 30, 2006|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00332579||181997|
NCT00332865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060059|Swallow Exercise as Prophylaxis of Dysphagia After Radiotherapy|Swallow Exercise as Prophylaxis of Dysphagia After Radiotherapy||University of Aarhus|No|Completed|June 2006|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|June 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00332865||181975|
NCT00334100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3603-P|Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness|Treadmill Training in Chronic MS: Efficacy and Cost-Effectiveness||VA Office of Research and Development|Yes|Withdrawn|April 2006|December 2014|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||October 2014|October 7, 2014|June 2, 2006||No|Difficulty with recruiting|No||https://clinicaltrials.gov/show/NCT00334100||181880|
NCT00334113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4202-I|Telerehabilitation Intervention to Promote Exercise for Diabetes|Telerehabilitation Intervention to Promote Exercise for Diabetes||VA Office of Research and Development|No|Completed|January 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|June 2, 2006||No||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00334113||181879|
NCT00334139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EDE28|Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer|A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis||Novartis||Completed|June 2006|||July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|411|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00334139||181877|
NCT00334451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-030206-H|RAPID-RF: Remote Active Monitoring in Patients With Heart Failure|Remote Active Monitoring in Patients With Heart Failure||Boston Scientific Corporation|No|Completed|May 2006|July 2008|Actual|July 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|891|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinics, heart failure clinics, hospitals|February 2014|February 20, 2014|June 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00334451||181853|
NCT00344344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901016|A Pilot Study to Evaluate the Efficacy of Refined Methods to Mitigate Indoor Allergens in North Carolina and Boston, Massachusetts Homes|A Pilot Study to Evaluate the Efficacy of Refined Methods to Mitigate Indoor Allergens in North Carolina and Boston, Massachusetts Homes||National Institutes of Health Clinical Center (CC)||Completed|October 2000|September 2006||||N/A|Observational|N/A||||88|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 26, 2015|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344344||181132|
NCT00344370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-310|Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia|Double-Blind, Follow-On Study of Pitavastatin (4 mg) Versus Atorvastatin (20 mg and 40 mg), With a Single-Blind Extension of Treatment, in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia||Kowa Research Europe|No|Completed|August 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|N/A|N/A|No|||January 2010|January 25, 2010|June 23, 2006||No||No|September 1, 2009|https://clinicaltrials.gov/show/NCT00344370||181131|
NCT00334776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10M-03-1|Vaccine Therapy in Treating Patients With Metastatic Melanoma|A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma||University of Southern California||Completed|October 2003|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|16 Years|N/A|No|||May 2014|May 19, 2014|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334776||181828|
NCT00334789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00142|Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery|A Phase 1 Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies||National Cancer Institute (NCI)||Active, not recruiting|June 2006|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00334789||181827|
NCT00335049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0157|Study of Theories About Myopia Progression (STAMP)|Study of Theories About Myopia Progression (STAMP)||Ohio State University|Yes|Completed|December 2006|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|6 Years|11 Years|No|||October 2010|October 7, 2010|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00335049||181807|
NCT00340821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999996018|A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis|A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica||National Institutes of Health Clinical Center (CC)||Completed|May 1993|March 2011||||N/A|Observational|N/A|||Anticipated|1800|||Both|2 Years|N/A|No|||March 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340821||181385|
NCT00342628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999050|Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants|Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP||National Institutes of Health Clinical Center (CC)|Yes|Completed|July 2006|January 2011|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|301|||Both|N/A|N/A|No|||May 2012|May 22, 2012|June 19, 2006|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00342628||181252|
NCT00342355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904094|Antiretroviral Therapy for Advanced HIV Disease in South Africa|Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2004|August 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1771|||Both|14 Years|N/A|No|||April 2013|April 29, 2013|June 19, 2006||No||No|September 14, 2009|https://clinicaltrials.gov/show/NCT00342355||181270|
NCT00343993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y0905001040291|Noninvasive Positive Pressure Ventilation for ALI/ARDS:a Multicentre Randomized Controlled Trial|||Beijing Chao Yang Hospital|Yes|Recruiting|June 2006|December 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|18 Years|70 Years|No|||April 2007|April 3, 2007|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00343993||181159|
NCT00344266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060183|Gene Expression and Inflammation in Overweight Subjects|Gene Expression and Release of Inflammatory Mediators in Overweight Subjects Before and After Weight Loss||National Institutes of Health Clinical Center (CC)||Completed|June 2006|||||N/A|Observational|Time Perspective: Prospective|||Actual|144|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344266||181138|
NCT00341484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998026|Genetic Susceptibility to Oncogenic Viruses|Genetic Susceptibility to Oncogenic Viruses||National Institutes of Health Clinical Center (CC)||Completed|May 1998|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|2600|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341484||181335|
NCT00341497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998040|Biomarkers for Oral Cancer|Biomarkers for Oral Cancer||National Institutes of Health Clinical Center (CC)||Completed|August 1996|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|110 Years|No|||June 2015|January 21, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341497||181334|
NCT00341042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905028|Collection of Tissue Specimens in Mali, West Africa, for HIV and Tuberculosis Research|Establishment of Normal Parameters for Blood and Sputum With Samples Obtained From Volunteers in Bamako||National Institutes of Health Clinical Center (CC)||Terminated|January 2005|May 2013||||N/A|Observational|N/A|||Anticipated|480|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|January 14, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341042||181369|
NCT00341471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906078|Building Futures for Youth - Phase III|Adolescent Pregnancy Prevention: Building Futures for Youth||National Institutes of Health Clinical Center (CC)||Completed|January 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||Anticipated|2500|||Both|N/A|N/A|No|||May 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341471||181336|
NCT00331812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0007|Mitochondrial Functions and Oxidative Stress in ALS Patients|Study of Mitochondrial Functions and Oxidative Stress in ALS Patients.||University Hospital, Clermont-Ferrand||Recruiting|February 2006|February 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of patients will be studied : 20 hypermetabolic ALS patients, 20        normometabolic ALS patients and 20 healthy volunteers paired for age and sex.|January 2011|January 18, 2011|May 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00331812||182049|
NCT00333541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD045480-03|Evaluation of Internet Access and Use in Adolescent Women Initiating Contraception|Internet Access and Use in Women at High Risk for Unintended Pregnancy: A Randomized Clinical Trial||University of California, San Francisco|No|Completed|June 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|100|||Female|15 Years|24 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333541||181923|
NCT00333554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIP (IND)|Nutritional Intervention to Prevent Diabetes|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|June 2006|April 2013|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|99|||Both|N/A|5 Months|No|||May 2013|May 30, 2013|June 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333554||181922|
NCT00333567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2427|Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy of a Single Dose of Lumiracoxib 400 mg Given Pre-Emptively Versus Post-Operatively, in Reducing Pain Associated With Ambulatory Arthroscopic Knee Surgery||Novartis||Completed|August 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||110|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00333567||181921|
NCT00333528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuBChE-02|A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly|A Phase 1, Randomized, Observer-Blinded, Single Dose, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Plasma-Derived Human Butyrylcholinesterase (HuBChE) Administered Intramuscularly (IM)||Baxalta US Inc.|Yes|Completed|December 2007|August 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|June 26, 2015|June 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00333528||181924|
NCT00333788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87046|Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease|Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.|Welcome2|UCB Pharma|No|Completed|October 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|233|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|June 2, 2006|Yes|Yes||No|April 13, 2011|https://clinicaltrials.gov/show/NCT00333788||181904|
NCT00333814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-014|A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis|||Allergan||Completed|May 2006|April 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|229|||Both|18 Years|N/A|No|||March 2011|March 11, 2011|June 2, 2006|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00333814||181902|
NCT00334126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010501|Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Paliperidone ER Compared to Quetiapine in Subjects With an Acute Exacerbation of Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|399|||Both|18 Years|65 Years|No|||March 2010|May 17, 2011|June 2, 2006||||||https://clinicaltrials.gov/show/NCT00334126||181878|
NCT00344708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0399-090|Transplantation of Tissue Cultured Human Amniotic Epithelial Cells Onto Damaged Ocular Surfaces|Transplantation of Tissue Cultured Human Amniotic Epithelial Cells Onto Damaged Ocular Surfaces||University of Texas Southwestern Medical Center|No|Recruiting|September 2000|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|88 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2008|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344708||181106|
NCT00344695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3R01CA077081-04S1|Bupropion Treatment for Youth Smoking Cessation|||University of Arizona||Completed||April 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|14 Years|17 Years|Accepts Healthy Volunteers|||June 2006|June 23, 2006|June 23, 2006||||||https://clinicaltrials.gov/show/NCT00344695||181107|
NCT00340535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904228|Effect of Genetic Differences on Levels of Water Disinfection Byproducts in Blood After Showering|Levels of Selected Potentially Carcinogenic Drinking Water Disinfection Byproducts in Whole Blood After Showering||National Institutes of Health Clinical Center (CC)||Completed|June 2004|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|18 Years|90 Years|No|||March 2016|March 19, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340535||181407|
NCT00340548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902173|Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)|Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)||National Institutes of Health Clinical Center (CC)||Completed|March 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|333|||Both|4 Years|100 Years|No|||December 2015|January 1, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340548||181406|
NCT00341848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902075|Postpartum Uterine Regression|Postpartum Uterine Regression||National Institutes of Health Clinical Center (CC)||Completed|December 2001|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Female|18 Years|45 Years|No|||July 2015|July 10, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341848||181307|
NCT00342095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997002|Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study|Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus Study (CLU) and Disease Progression and Activity in the Carolina Lupus Study||National Institutes of Health Clinical Center (CC)||Completed|December 1996|March 2007||||N/A|Observational|N/A||||640|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342095||181289|
NCT00341302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902261|A Prospective, Observational Study of HIV-Infected Pregnant Women and Their Infants at Clinical Sites in Latin American and Caribbean Countries|A Prospective, Observational Study of HIV-Infected Pregnant Women and HIV-Exposed, Uninfected Children at Clinical Sites in Latin American Countries||National Institutes of Health Clinical Center (CC)||Completed|July 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Female|N/A|50 Years|No|||May 2015|December 3, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341302||181349|
NCT00341315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904196|Breast Cancer, Breast Disease, and Pesticides|A Study of Breast Cancer, Breast Disease, Mammographic Density and Pesticides Among a Population From Triana, Alabama||National Institutes of Health Clinical Center (CC)||Completed|May 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|228|||Female|35 Years|80 Years|No|||April 2015|May 5, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341315||181348|
NCT00342641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905172|Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers|Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans||National Institutes of Health Clinical Center (CC)||Completed|June 2005|December 2011||||N/A|Observational|N/A|||Anticipated|815000|||Both|N/A|N/A|No|||December 2011|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342641||181251|
NCT00342654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999031|Nutrition Intervention Trials in Linxian Follow-up Study|Nutritional Intervention Trials in Linxian China- Continued Follow-up||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 1999|||||N/A|Observational|N/A|||Anticipated|34000|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342654||181250|
NCT00342069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905067|Prevalence of Ambivalence Regarding Prenatal Testing|Facilitating Informed for Prenatal Testing: The Role of Ambivalence||National Institutes of Health Clinical Center (CC)||Completed|December 2004|December 2007||||N/A|Observational|N/A|||||||Female|18 Years|N/A|No|||December 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342069||181291|
NCT00343265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18589|Vaginal Progesterone Versus Placebo in Multiple Pregnancy|Pilot Randomized Trial of Vaginal Progesterone to Prevent Preterm Birth in Multiple Pregnancy||University of Calgary|No|Completed|June 2006|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|84|||Female|18 Years|N/A|No|||August 2013|August 14, 2013|June 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00343265||181209|
NCT00343499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-011|The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)|A Single Center, Randomized Trial to Evaluate the Effects of Diovan to Maintain Sinus Rhythm in Patients With Persistent Atrial Fibrillation||Intermountain Health Care, Inc.||Terminated|November 2004|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|June 21, 2006|||Inability to recruit|No||https://clinicaltrials.gov/show/NCT00343499||181192|
NCT00340756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903274|Evaluating Serum Sex Steroid Hormones|Reproducibility of Serum Sex Steroid Measurement: A Proof of Performance Study||National Institutes of Health Clinical Center (CC)||Completed|August 2003|February 2011||||N/A|Observational|N/A|||Anticipated|60|||Both|20 Years|75 Years|No|||February 2011|February 26, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340756||181390|
NCT00340769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901160|Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic|Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic||National Institutes of Health Clinical Center (CC)||Completed|April 2001|December 2006||||N/A|Observational|N/A||||0|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2006|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340769||181389|
NCT00341783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902248|Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali|Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Doneguebougou, Mali||National Institutes of Health Clinical Center (CC)||Terminated|July 2002|July 2005||||N/A|Observational|N/A||||515|||Both|N/A|45 Years|Accepts Healthy Volunteers|||July 2005|January 6, 2009|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341783||181312|
NCT00333190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-151|CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation|CD8+ T Cell Depletion as Graft Versus Host Disease Prophylaxis After HLA-Matched Unrelated Donor Non-myeloablative Peripheral Blood Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Completed|September 2005|March 2009|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|May 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333190||181950|
NCT00333203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-18|Next Generation Ophthalmic Irrigating Solution Posterior Segment Study|Clinical Evaluation of the Safety of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for Use During Surgery for Removal of Epimacular Membrane and Vitrectomy||Alcon Research|No|Completed|October 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|369|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333203||181949|
NCT00333216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-30|Anecortave Acetate Risk-Reduction Trial (AART)|Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)||Alcon Research|No|Terminated|May 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|24|||Both|50 Years|N/A|No|||December 2011|November 27, 2012|May 31, 2006|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00333216||181948|
NCT00334152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKT102552|Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women|A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis||GlaxoSmithKline|No|Completed|March 2006|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|515|||Female|18 Years|N/A|No|||April 2015|April 14, 2015|June 2, 2006||||||https://clinicaltrials.gov/show/NCT00334152||181876|
NCT00333801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4092-I|The Impact of Vocational Rehabilitation on Mentally III Veterans|The Impact of Vocational Rehabilitation on Mentally III Veterans||VA Office of Research and Development|No|Completed|April 2006|July 2012|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|60 Years|No|||March 2015|March 6, 2015|June 2, 2006||No||No|November 25, 2014|https://clinicaltrials.gov/show/NCT00333801||181903|The elements of the study that limit generalizability include the single-site design, the small number of IPS interventionists, low number of women in the sample, and the exclusion of nonveterans.
NCT00340587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997039|Human Sperm Binding to Transgenic Mouse Eggs|Human Sperm Binding to Transgenic Mouse Eggs||National Institutes of Health Clinical Center (CC)||Completed|May 1997|February 2016||||N/A|Observational|N/A|||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340587||181403|
NCT00340561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905070|Effect of Experience on Driving Performance in New Teenage Drivers|Effects of Experience on the Driving Performance of Novice Teen Drivers||National Institutes of Health Clinical Center (CC)||Completed|January 2005|July 2006||||N/A|Observational|N/A||||48|||Both|7 Years|55 Years|Accepts Healthy Volunteers|||July 2006|March 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340561||181405|
NCT00340574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905117|Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)|Phase I Study of the Safety and Immunogenicity of AMA-1-C1/Alhydrogel + CPG 7909, An Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria||National Institutes of Health Clinical Center (CC)||Completed|March 2005|July 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|45 Years|No|||July 2008|July 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340574||181404|
NCT00340834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2302|Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|TRANSFORMS|Novartis||Completed|May 2006|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1292|||Both|18 Years|55 Years|No|||January 2014|January 14, 2014|June 19, 2006|Yes|Yes||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00340834||181384|
NCT00341081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903029|Validation of Self-Reported Needle Sharing Among Injection Drug Users|Validation of Self-Reported Needle Sharing Among Injection Drug Users||National Institutes of Health Clinical Center (CC)||Completed|October 2002|June 2007|Actual|||N/A|Observational|N/A||||442|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341081||181366|
NCT00341094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995020|Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Ukraine Following the Chernobyl Accident|Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Diseases in Ukraine Following the Chernobyl Accident||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 1995|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|70000|||Both|18 Years|48 Years|No|||October 2015|November 17, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341094||181365|
NCT00342108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4162-AB-CTIL|Cortical Visual Impairment and Visual Attentiveness|Cortical Visual Impairment and Visual Attentiveness: The Effect of Visual and Cross-Modal Environments on Children Diagnosed With Cerebral Palsy and Cortical Visual Impairment||Sheba Medical Center|No|Completed|September 2007|October 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|2 Years|21 Years|No|||November 2010|November 2, 2010|June 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00342108||181288|
NCT00342121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902197|Influence of Corn Farming on the Immune System|Influence of Corn Farming on the Immune System||National Institutes of Health Clinical Center (CC)||Completed|May 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Male|18 Years|100 Years|No|||September 2015|November 13, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342121||181287|
NCT00342134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902196|Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis|Immunological Mechanisms of Immune Ablation and Autologous Hematopoietic Stem Cell Transplantation in Secondary Progressive Multiple Sclerosis||National Institutes of Health Clinical Center (CC)||Completed|May 2002|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|70 Years|No|||May 2011|May 5, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342134||181286|
NCT00342368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot.pdc181(A.295)/C.E./2004|Helmet CPAP vs Venturi O2 to Treat Early ALI/ARDS|A Comparison of CPAP Delivered by Helmet and O2 Therapy With a Venturi Mask as First Line Intervention in Early ALI/ARDS|HelmetCPAP|Catholic University of the Sacred Heart|No|Recruiting|June 2005|March 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||October 2007|October 31, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342368||181269|
NCT00343902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AT000011|Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial|Randomized Clinical Trial of a Crataegus Oxycantha Extract in Chronic Heart Failure||National Center for Complementary and Integrative Health (NCCIH)||Completed|January 2000|May 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||June 2006|June 21, 2006|June 21, 2006||||||https://clinicaltrials.gov/show/NCT00343902||181165|
NCT00342082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904242|Effects of Anti-HIV Therapy on Red Blood Cells of HIV-infected Mothers and Their Infants|A Pilot Study to Investigate Micronucleated Erythrocyte Frequencies in Infants Exposed to Nucleoside Antiretrovial Drugs in Utero and for 6 Weeks Postnatally||National Institutes of Health Clinical Center (CC)||Completed|June 2004|December 2007||||N/A|Observational|N/A||||0|||Both|N/A|N/A|No|||December 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342082||181290|
NCT00343278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104689|Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets|Post-Marketing Clinical Study of Valaciclovir Hydrochloride Tablets -Single Oral Dose Study in Hemodialysis Patients-||GlaxoSmithKline||Completed|July 2005|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|20 Years|N/A|No|||April 2015|April 13, 2015|June 21, 2006||||No||https://clinicaltrials.gov/show/NCT00343278||181208|
NCT00343291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13421|A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC|Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|December 2006|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|June 20, 2006|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00343291||181207|
NCT00342043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905214|Examination of Protective Factors Against Severe Malaria|Multidisciplinary Studies of Malaria Protection by Hemoglobinopathies and G6PD Deficiency in Mali||National Institutes of Health Clinical Center (CC)||Completed|August 2005|April 2009||||N/A|Observational|N/A||||4850|||Both|N/A|10 Years|No|||April 2009|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342043||181293|
NCT00342056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905090|Role of Gene Variation in Effectiveness of Gleevec Treatment|Analysis of ABCG2 Genotype in Gleevec Treated Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (C421A) in ABCG2 and Response to Treatment||National Institutes of Health Clinical Center (CC)||Completed|January 2005|October 2008|Actual|||N/A|Observational|N/A||||100|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342056||181292|
NCT00342316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRALG1/02|Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia|Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation With Reduced Conditioning (RICT) Versus Best Standard of Care in Acute Myeloid Leukemia (AML)in First Complete Remission (CR)||Vastra Gotaland Region|Yes|Recruiting|December 2003|December 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|352|||Both|51 Years|70 Years|No|||November 2015|January 14, 2016|June 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00342316||181273|
NCT00332930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIR-NCHR-02|ITV Extension Study|An Extension Study to Protocol VIR-NCHR-01 to Assess the Antiretrovirological Properties of a Therapeutic HIV Vaccine Candidate Based on Recombinant Fowlpox Virus (rFPV) (ITV Extension Study)||Kirby Institute||Completed|September 2002|September 2003||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||35|||Both|18 Years|N/A|No|||June 2006|February 26, 2007|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00332930||181970|
NCT00334165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|III UV 13/05|Auricular Acupuncture for Analgesia During Total Hip Arthroplasty|Auricular Acupuncture (AA) vs. Sham Acupuncture for Complementary Analgesia During Elective Total Hip Arthroplasty: a Randomized Controlled Trial||University Medicine Greifswald||Completed|June 2005|June 2008||March 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|360|||Both|45 Years|85 Years|No|||February 2011|February 25, 2011|June 3, 2006||||No||https://clinicaltrials.gov/show/NCT00334165||181875|
NCT00333580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O4052-X|Veteran-Centered Outcomes Using Qualitative and Quantitative Methods|Veteran-Centered Outcomes Using Qualitative and Quantitative Methods||VA Office of Research and Development|No|Completed|July 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Veteran and non-veteran male/females with stroke or incomplete spinal cord injury        currently enrolled in locomotor/gait training studies.|April 2015|April 7, 2015|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333580||181920|
NCT00334464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-120|A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"|A Controlled Clinical Pharmacogenetic Study of a CYP2C9 Plus VKORC1 Polymorphism-Based Individualized Dosing Algorithm for Warfarin to Increase Efficiency of Achieving Therapeutic Dosing||Intermountain Health Care, Inc.||Completed|February 2006|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334464||181852|
NCT00341120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903076|Genetic Causes of Male Infertility|Methylenetetrahydrofolate Reductase C677T Mutation, Other Variant Genotypes, and Male Infertility||National Institutes of Health Clinical Center (CC)||Completed|January 2003|August 2012||||N/A|Observational|N/A|||Anticipated|400|||Male|20 Years|45 Years|No|||August 2012|February 19, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341120||181363|
NCT00341107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999010|Physicians Survey on Genetic Testing|Physicians Survey on Genetic Testing||National Institutes of Health Clinical Center (CC)||Completed|February 1999|||||N/A|Observational|N/A||||1350|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2006|March 3, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341107||181364|
NCT00341354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906087|Coated Endotracheal Tube and Mucus Shaver to Prevent Hospital-Acquired Infections|Evaluation of Silver-Sulfadiazine Tracheal Tubes / Mucus Shaver in Intubated Patients Expected to Have a Prolonged Mechanical Ventilation||National Institutes of Health Clinical Center (CC)||Completed|January 2006|September 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||September 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341354||181345|
NCT00341588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902113|A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen|A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen||National Institutes of Health Clinical Center (CC)||Completed|January 2002|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|3600|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341588||181327|
NCT00341861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999038|Interdisciplinary Case-Control Study of Bladder Cancer in Spain|Interdisciplinary Case-Control Study of Bladder Cancer in Spain||National Institutes of Health Clinical Center (CC)||Completed|June 1998|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|3000|||Both|21 Years|80 Years|No|||November 2015|November 19, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341861||181306|
NCT00343304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-357|Pilot Study - Comparison of Upper Body Ergometer Vs. Robot in Upper Extremity Motor Recovery Post-Stroke|||Burke Rehabilitation Hospital||Completed|April 2005|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|19 Years|90 Years|No|||April 2005|June 20, 2006|June 20, 2006||||No||https://clinicaltrials.gov/show/NCT00343304||181206|
NCT00342381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060003|Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation|Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation||University of Aarhus|Yes|Completed|June 2006|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 12, 2007|June 20, 2006||||No||https://clinicaltrials.gov/show/NCT00342381||181268|
NCT00343577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X050202007|Antiproteinuric Agents and Fabry Disease|Observational Study of Antiproteinuric Agents in Patients With Fabry Disease Treated With Enzyme Replacement Therapy||University of Alabama at Birmingham||Completed|January 2001|December 2006||||N/A|Observational|Time Perspective: Prospective||||12|||Both|14 Years|95 Years|No|||June 2006|November 17, 2013|June 21, 2006||||No||https://clinicaltrials.gov/show/NCT00343577||181187|
NCT00334295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238GR/0002|Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.|An Open, Non-randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 mg Monthly Dose of i.m. Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.||AstraZeneca||Completed|December 2002|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||June 2012|June 11, 2012|June 5, 2006|Yes|Yes||No|January 11, 2012|https://clinicaltrials.gov/show/NCT00334295||181865|
NCT00342953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903082|Study of Health Effects of Cosmetic Breast Augmentation|Extended Mortality Follow-Up of Women With Augmentation Mammoplasty||National Institutes of Health Clinical Center (CC)||Completed|January 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|17424|||Female|21 Years|69 Years|No|||April 2015|April 22, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342953||181232|
NCT00340457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902051|Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States|Case-Control Study of Renal Cell Cancer Among Caucasians and African Americans in the United States||National Institutes of Health Clinical Center (CC)||Completed|November 2001|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|2424|||Both|20 Years|79 Years|No|||January 2016|February 17, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340457||181413|
NCT00340743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904169|Diet and Genetic Damage|Inhibition of Fried Meat-Induced DNA Damage: A Dietary Intervention Study||National Institutes of Health Clinical Center (CC)||Completed|April 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|16|||Both|18 Years|45 Years|No|||September 2015|October 6, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340743||181391|
NCT00341263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904052|Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies|Study of Maternal and Umbilical Cord Hormone Concentrations in Monochorionic and Dichorionic Pregnancies||National Institutes of Health Clinical Center (CC)||Completed|November 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Female|N/A|N/A|No|||January 2016|January 29, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341263||181352|
NCT00341276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995027|Esophageal Cancer Genetics Studies|Esophageal Cancer Genetics Studies||National Institutes of Health Clinical Center (CC)||Recruiting|June 1995|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|8000|||Both|18 Years|100 Years|No|||March 2016|March 22, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341276||181351|
NCT00342329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901154|Lupus Nephritis: Role of Environmental and Occupational Exposures|Lupus Nephritis: Role of Environmental and Occupational Exposures||National Institutes of Health Clinical Center (CC)||Completed|April 2001|March 2007||||N/A|Observational|N/A||||0|||Both|N/A|N/A|No|||March 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00342329||181272|
NCT00342576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999890048|Host Response to Infection and Treatment in Lymphatic Filarial Disease in India|Host Response to Infection and Treatment in Lymphatic Filarial Disease in India||National Institutes of Health Clinical Center (CC)||Recruiting|April 1994|||||N/A|Observational|N/A|||Anticipated|1500|||Both|18 Years|75 Years|No|||December 2011|November 20, 2012|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342576||181255|
NCT00333827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRTCC-MCD|Cell Therapy In Dilated Cardiomyopathy|Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Dilated Cardiomyopathy||Ministry of Health, Brazil||Recruiting|January 2006|February 2009|Anticipated|December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||June 2006|November 19, 2008|June 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00333827||181901|
NCT00343850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14515A|Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis|Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis: A Randomized Pilot Trial||University of Chicago||Completed|September 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|June 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00343850||181169|
NCT00344123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00003633|Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects|Pharmacokinetic Evaluation of Single-dose Rosuvastatin 10 mg When Co-administered With Steady-state Tipranavir 500 mg/Ritonavir 200 mg TPV/r) B.I.D. in Healthy Adult Volunteers||Johns Hopkins University|Yes|Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00344123||181149|
NCT00344383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR008344|An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen|An Open-Label Study Evaluating the Bleeding Profile of Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) Administered as an Extended Regimen||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed|November 2003|July 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|61|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 3, 2011|June 23, 2006||||||https://clinicaltrials.gov/show/NCT00344383||181130|
NCT00342147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995046|Family Study of Head and Neck Cancers in Taiwan|Family Study of Head and Neck Cancers in Taiwan||National Institutes of Health Clinical Center (CC)||Completed|November 1995|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|4000|||Both|18 Years|N/A|No|||July 2015|August 8, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342147||181285|
NCT00341367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903070|Blood Sample Donations to Study the Role of Genes in Pain|Genetic Risk of Chronic Pain After Acute Sciatica||National Institutes of Health Clinical Center (CC)||Completed|December 2002|March 2010||||N/A|Observational|N/A|||Actual|320|||Both|N/A|N/A|No|||March 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341367||181344|
NCT00341601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905069|Multi-Drug Resistant Tuberculosis in Korea|A Natural History Study of Multidrug-Resistant Tuberculosis Strains and Host Susceptibility Genes in Korean Patients With Pulmonary Tuberculosis||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2004|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2040|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 24, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341601||181326|
NCT00341614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDF-05-06|Exercise Training in Older Diabetic Women|The Effects of an Exercise and Diet Intervention on Cardiovascular Risk Factors in Postmenopausal Type 2 Diabetics||University of San Francisco|No|Completed|June 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||August 2007|August 14, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341614||181325|
NCT00341627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999005|Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families|Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families||National Institutes of Health Clinical Center (CC)||Completed|January 1999|||||N/A|Observational|N/A|||Anticipated|140|||Both|N/A|N/A|No|||August 2015|September 16, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341627||181324|
NCT00342992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995012|Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study|Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC Study) Population||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 1985|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|29133|||Male|50 Years|69 Years|No|||September 2015|October 6, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342992||181230|
NCT00342693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906103|Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine|Thyroid Abnormalities Associated With Protracted Childhood I-131 Exposure From Atmospheric Emissions From the Mayak Nuclear Plant in Russia||National Institutes of Health Clinical Center (CC)||Terminated|February 2006|September 2013||||N/A|Observational|N/A|||Anticipated|360|||Both|51 Years|52 Years|No|||September 2013|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342693||181248|
NCT00343005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904175|Experimental Vaccine for Malaria in Adults in Mali|Double-Blind, Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria, in Semi-Immune Adults in Doneguebougou, Mali||National Institutes of Health Clinical Center (CC)||Completed|April 2004|January 2008||||Phase 1|Interventional|Primary Purpose: Treatment||||54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|September 25, 2013|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00343005||181229|
NCT00343564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 2121|A Study of SB-743921 in Non-Hodgkin's Lymphoma|A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma||Cytokinetics||Completed|April 2006|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|June 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00343564||181188|
NCT00343018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904108|Interviewing Children About Past Events: Evaluating the NICHD Interview Protocol|Evaluating the NICHD Interview Protocol in an Analog Study||National Institutes of Health Clinical Center (CC)||Completed|January 2004|October 2006||||N/A|Observational|N/A||||150|||Both|5 Years|N/A|Accepts Healthy Volunteers|||October 2006|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00343018||181228|
NCT00334308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 02-113C|Barley Protein and CVD|Barley Protein and Coronary Heart Disease Risk Reduction||University of Toronto||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 16, 2009|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00334308||181864|
NCT00342966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999032|Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation|Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation||National Institutes of Health Clinical Center (CC)||Completed|June 1999|July 2010||||N/A|Observational|N/A|||Anticipated|34|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2010|July 24, 2010|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342966||181231|
NCT00341809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904255|Genetic Analysis of Psoriasis and Psoriatic Arthritis|Role of HLA and KIR in the Natural History of Psoriasis||National Institutes of Health Clinical Center (CC)||Completed|July 2004|September 2012||||N/A|Observational|N/A|||Anticipated|5000|||Both|1 Year|N/A|No|||September 2012|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341809||181310|
NCT00341822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906132|Invasive Prenatal Testing Decisions in Pregnancy After Infertility|Prenatal Testing Decisions in Pregnancy After Infertility||National Institutes of Health Clinical Center (CC)||Completed|March 2006|December 2007||||N/A|Observational|N/A||||200|||Female|35 Years|N/A|No|||December 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341822||181309|
NCT00337701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19849|BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection|Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection||Hoffmann-La Roche||Completed|June 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|326|||Both|16 Years|N/A|No|||November 2015|November 2, 2015|June 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00337701||181615|
NCT00337974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUT-106-2005|Computer-Based Training for Cognitive Enhancement: In Home Study|Computer-Based Training for Cognitive Enhancement: In Home Study||Posit Science Corporation|No|Completed|March 2005|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|182|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00337974||181596|
NCT00343473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309020|Novel Diagnostics With Optical Coherence Tomography: Imaging the Anterior Eye|Novel Diagnostics With Optical Coherence Tomography: Imaging of the Anterior Eye||University of Pittsburgh|Yes|Recruiting|October 2005|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Observational|N/A||1|Anticipated|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will range form 18 years to 90 years. Gender can be male or female. Will include        100 normals and 100 diseased patients that include diabetic retinopathy, macular        degeneration, and glaucoma.|September 2015|September 17, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00343473||181194|
NCT00344136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1344|Identifying Genes That May Increase the Risk for Heart Disease in African Americans|Health Disparities and CVD: Admixture Mapping in the Jackson Heart Study||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|March 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||5302|||Both|21 Years|95 Years|Accepts Healthy Volunteers|||October 2006|October 11, 2006|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344136||181148|
NCT00344409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN321-SC/05-A54|A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients|A Double-blind, Placebo Controlled, Randomized Study of KRN321 for the Treatment of Anemia in Cancer Patients||Kyowa Hakko Kirin Company, Limited||Completed|March 2006|||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|20 Years|74 Years|No|||August 2012|August 30, 2012|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00344409||181129|
NCT00344422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002434|Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|A Multi-Center Randomized Study of Vincristine, Doxil and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Multiple Myeloma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2000|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|198|||Both|18 Years|N/A|No|||April 2010|June 8, 2011|June 23, 2006||||||https://clinicaltrials.gov/show/NCT00344422||181128|
NCT00344721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082004-008|A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome|A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome||University of Texas Southwestern Medical Center||Recruiting|September 2004|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2006|June 23, 2006|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344721||181105|
NCT00342394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902049|Fungicide Exposure Assessment Among Apple and Peach Farmers in the Argicultural Health Study|Fungicide Exposure Assessment Among Apple and Peach Farmers in the Agricultural Health Study||National Institutes of Health Clinical Center (CC)||Completed|November 2001|May 2013||||N/A|Observational|N/A|||Anticipated|75|||Both|N/A|N/A|No|||May 2013|October 23, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342394||181267|
NCT00342667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997066|Clinical, Biochemical, Histological and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients With Preterm Labor and Premature Rupture of Membranes|Clinical, Biochemical, Histological and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients With Preterm Labor and Premature Rupture of Membranes||National Institutes of Health Clinical Center (CC)||Completed|December 1997|||||N/A|Observational|N/A|||Anticipated|5000|||Female|15 Years|45 Years|No|||October 2015|October 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342667||181249|
NCT00342160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906100|Viral and Immunologic Factors Contributing to the Lack of HIV Transmission Among Couples in Rakai, Uganda|Virologic and Immunologic Factors Contributing to the Lack of HIV-1 Transmission in HIV-Discordant Couples in Rakai, Uganda||National Institutes of Health Clinical Center (CC)||Completed|February 2006|November 2012||||N/A|Observational|N/A|||Anticipated|100|||Both|18 Years|65 Years|No|||November 2012|January 14, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342160||181284|
NCT00333684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-BA-001|Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid|A Prospective Study Evaluating the Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid Soft Tissue Endoprosthesis||Canadian Immunodeficiency Research Collaborative||Completed|December 2004|May 2010|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|50 Years|No|||June 2012|June 4, 2012|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333684||181912|
NCT00343317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES112/02|Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women|Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women||University of KwaZulu||Completed|February 2003|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1372|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2005|June 21, 2006|June 21, 2006||||No||https://clinicaltrials.gov/show/NCT00343317||181205|
NCT00334321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0297 / 201106410|Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients|Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients||Washington University School of Medicine|Yes|Completed|April 2006|September 2015|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|N/A|No|||October 2015|October 1, 2015|June 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00334321||181863|
NCT00343915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101695 Ext. Mth30|Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs|Long-term Study of Immune Response Persistence of GSK Biologicals' 2-dose Thiomersal-free Engerix™-B and 3-dose Preservative-free Engerix™-B Vaccines in Subjects Aged 11-15 Yrs||GlaxoSmithKline||Completed|April 2004|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|267|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||November 2011|October 2, 2014|September 14, 2005|Yes|Yes||No|December 23, 2008|https://clinicaltrials.gov/show/NCT00343915||181164|
NCT00334581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBES_L_00907|Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria|A Study of Irbesartan 150mg Verses 300mg in Chinese Hypertensive Patients With Diabetes and Microalbuminuria||Sanofi||Completed|May 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|30 Years|65 Years|No|||September 2009|September 14, 2009|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00334581||181843|
NCT00341549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902191|Family Myopia Study|Family Myopia Study||National Institutes of Health Clinical Center (CC)||Completed|April 2002|||||N/A|Observational|N/A|||Anticipated|10000|||Both|4 Years|N/A|No|||January 2016|February 3, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341549||181330|
NCT00336544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL06-001|Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia|A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults||Advanced Life Sciences, Inc.|No|Completed|June 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|522|||Both|18 Years|N/A|No|||January 2010|January 29, 2010|June 9, 2006|Yes|Yes||No|September 3, 2009|https://clinicaltrials.gov/show/NCT00336544||181699|
NCT00337441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR02-32-031|Treatment of Chronic Anemia With Epoetin Alfa in Elderly|Chronic Anemia And Fatigue In Elderly Patients: A Randomized Double-Blind Placebo-Controlled Cross-Over Study With Epoetin Alfa.||Research and Education Foundation of Michael Reese Hospital||Active, not recruiting|January 2003|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||62|||Both|65 Years|N/A|No|||June 2006|June 14, 2006|June 14, 2006||||No||https://clinicaltrials.gov/show/NCT00337441||181635|
NCT00337454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-031|Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan|A Phase I/II Study of BMS-354825 in Subjects With Imatinib Resistant or Intolerant Philadelphia Chromosome Positive Chronic Myelogenous Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Treatment||Bristol-Myers Squibb||Completed|July 2005|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6|||48|||Both|20 Years|75 Years||||April 2011|April 7, 2011|June 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00337454||181634|
NCT00343863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6140|Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer|Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients||University of Washington|No|Completed|January 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|41|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|June 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00343863||181168|
NCT00340613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16630|Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes|A School Intervention: Lunch Time Insulin Injections in Children With Poorly Controlled Type 1 Diabetes||Baylor College of Medicine|Yes|Completed|June 2006|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|10 Years|19 Years|No|||July 2008|July 16, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340613||181401|
NCT00341640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905074|Metabolism of Nicotine and Cotinine in Pregnant African-American Women|Pharmacokinetics of Nicotine and Cotinine in Pregnant African-American Women and Implications for Pharmacological Interventions||National Institutes of Health Clinical Center (CC)||Completed|January 2005|December 2006||||Phase 1|Interventional|Primary Purpose: Treatment||||50|||Female|18 Years|30 Years|No|||December 2006|February 24, 2007|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341640||181323|
NCT00341380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902319|Prevention of Tumor Spread Due to Lung Cancer Surgery|Venous or Arterial Ligation and Intraoperative Dissemination (VALID) of Cancer Cells: A Randomized Clinical Trial For Patients With Resectable Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)||Completed|September 2002|||||N/A|Observational|N/A|||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341380||181343|
NCT00332397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02206|The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis|Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis|ISAR-TEST-2|Deutsches Herzzentrum Muenchen|Yes|Completed|March 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1007|||Both|18 Years|N/A|No|||June 2008|June 16, 2008|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00332397||182007|
NCT00341653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998054|A Cohort Study of Smoking Prevention and Health Promotion for Middle School Students in Wuhan, China|A Cohort Study of Smoking Prevention and Health Promotion for Middle School Students in Wuhan, China||National Institutes of Health Clinical Center (CC)||Completed|July 1998|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|7000|||Both|12 Years|13 Years|No|||September 2015|October 6, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341653||181322|
NCT00341887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904096|Epidemiological Study of HIV in the South African National Defense Force|PHIDISA I: A Prospective, Observational Cohort Study of HIV Infection (Both Treated and Untreated) and Risk-Related Co-Infections in the South African National Defence Force (SANDF)||National Institutes of Health Clinical Center (CC)||Terminated|January 2004|November 2012||||N/A|Observational|N/A|||Anticipated|50000|||Both|N/A|N/A|No|||November 2012|October 9, 2014|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341887||181304|
NCT00333359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111490|XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.|An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.||XenoPort, Inc.|No|Completed|June 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|581|||Both|18 Years|N/A|No|||May 2011|July 15, 2013|June 1, 2006|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00333359||181937|
NCT00333372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99010207|To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia|To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms||Zeria Pharmaceutical||Completed|April 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||440|||Both|20 Years|79 Years|No|||January 2009|January 12, 2009|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333372||181936|
NCT00333697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.2033|Single Comprehensive Ultrasound to Rule Out DVT in High-risk Patients|Ultrasound-sparing Strategy for Suspected DVT: A Prospective Clinical Cohort Study||Intermountain Health Care, Inc.|No|Completed|November 2005|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|199|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333697||181911|
NCT00333957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|will001-HMO-CTIL|Capsule Endoscopy in Cystic Fibrosis|Capsule Endoscopy in Cystic Fibrosis-Screening for Small Bowel Disease in Cystic Fibrosis Patient.||Hadassah Medical Organization||Recruiting|July 2006|July 2007||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|10 Years|N/A|No|||October 2007|November 5, 2007|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00333957||181891|
NCT00334620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-3I_1998|Effectiveness of Radon Spa Therapy in Multimodal Rehabilitative Treatment of Rheumatoid Arthritis|||Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster||Completed|July 1998|May 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|N/A|No|||November 2005|June 7, 2006|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334620||181840|
NCT00334594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 17/04|Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma|Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma (MPM) With or Without Hemithoracic Radiotherapy. A Randomized Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Terminated|November 2005|June 2018|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|69 Years|No|||March 2015|March 10, 2015|June 7, 2006||No|1. Lower accrual due to new less extensive suregery techniques.      2. Patients exposed to asbestos increases in age leading to a lower accrual rate.|No||https://clinicaltrials.gov/show/NCT00334594||181842|
NCT00334607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107531|Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA|Assess the Immunogenicity of 3 Doses of Pediarix®, Prevnar® & ActHIB® Given to Healthy Infants When Administered With GSK Biologicals' 2 Dose Oral Live Attenuated Human Rotavirus Vaccine Given During the Same Vaccination Visit or Separately||GlaxoSmithKline||Completed|June 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|484|||Both|6 Weeks|16 Weeks|Accepts Healthy Volunteers|||January 2012|February 2, 2012|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334607||181841|
NCT00336817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A-US26|A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients|A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients||University of Pittsburgh|Yes|Recruiting|November 2006|November 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||October 2008|October 2, 2008|June 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00336817||181679|
NCT00338351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106208|Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.|To Assess Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (Infanrix™ Hexa) at 2, 4 and 6 Months of Age.||GlaxoSmithKline||Completed|April 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||240|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2012|November 21, 2012|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00338351||181568|
NCT00337740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCPSVECE/9/01PD|Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding|Randomized Study Comparing Ligation With Propranolol for Primary Prophylaxis of Variceal Bleeding in Candidates for Liver Transplantation||University of Padova||Terminated||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|120|||Both|18 Years|65 Years|No|||September 2006|April 20, 2012|June 14, 2006|||From the interim analysis resulted that more than 1000 patients were required to demonstrate a    significant difference between the 2 treatments.|No||https://clinicaltrials.gov/show/NCT00337740||181612|
NCT00337116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor435006ctil|Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients|Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients||Soroka University Medical Center|No|Withdrawn|January 2007|January 2008|Anticipated|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A||||January 2007|January 27, 2010|June 14, 2006||No|LOGISTIC DIFFICULTIES|No||https://clinicaltrials.gov/show/NCT00337116||181658|
NCT00337129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03046|S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)|No|Completed|May 2006|July 2011|Actual|August 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||July 2012|August 11, 2015|June 13, 2006|Yes|Yes||No|July 20, 2012|https://clinicaltrials.gov/show/NCT00337129||181657|
NCT00343486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3P104833|Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms|An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as Well as the Pharmacokinetic Profile of Oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women With Overactive Bladder||GlaxoSmithKline||Completed|May 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||240|||Female|18 Years|80 Years|No|||May 2009|May 15, 2009|June 21, 2006||||No||https://clinicaltrials.gov/show/NCT00343486||181193|
NCT00344734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.1997.03.JNB|Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure|Effects of Acute L-NMMA Treatment on Renal Hemodynamics, Sodium and Water Excretion and Plasma Levels of Vasoactive Hormones in Patients With Congestive Heart Failure and Healthy Controls||Regional Hospital Holstebro||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind||||30|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||June 2006|June 24, 2006|June 24, 2006||||No||https://clinicaltrials.gov/show/NCT00344734||181104|
NCT00344747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR433806CTIL|Multidisciplinary Ambulatory Intervention Program in Family of Children and Adolescents With Obesity|Multidisciplinary Ambulatory Intervention Program (Dietary Behavioral Physical Activity) in Family of Children and Adolescents With Obesity||Soroka University Medical Center||Completed|September 2006|August 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|6 Years|18 Years||||September 2010|September 19, 2010|June 25, 2006||||No||https://clinicaltrials.gov/show/NCT00344747||181103|
NCT00340600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998017|Continuation of Follow-up of DES-Exposed Cohorts|Continuation of Follow-up of DES-Exposed Cohorts||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 1998|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|12735|||Both|N/A|100 Years|No|||October 2015|October 28, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340600||181402|
NCT00341133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999054|Genetic Analysis of Left-Right Axis Formations|Genetic Analysis of Left-Right Axis Malformations||National Institutes of Health Clinical Center (CC)||Completed|December 1999|||November 2006|Actual|N/A|Observational|N/A||||900|||Both|N/A|N/A|No|||August 2009|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341133||181362|
NCT00341146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902056|Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)|Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NPC Susceptibility Gene(s)||National Institutes of Health Clinical Center (CC)||Completed|November 2001|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|9100|||Both|7 Years|90 Years|No|||April 2015|March 9, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341146||181361|
NCT00340847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901233|Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer|Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer||National Institutes of Health Clinical Center (CC)||Completed|August 2001|May 2010||||N/A|Observational|N/A|||Anticipated|500|||Both|N/A|N/A|No|||May 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340847||181383|
NCT00340860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902206|The Norwegian Mother and Child Study - Environmental Specimen Collection|The Norwegian Mother and Child Study - Environmental Specimen Collection||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2002|||||N/A|Observational|N/A|||Anticipated|85000|||Both|N/A|N/A|No|||January 2016|January 16, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340860||181382|
NCT00340873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995038|Molecular Epidemiology of Dioxin-Related Illness in Seveso|Molecular Epidemiology of Dioxin-Related Illness in Seveso||National Institutes of Health Clinical Center (CC)||Completed|December 1994|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340873||181381|
NCT00340886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902004|NIEHS/UNC Environmental Polymorphism Study|Environmental Polymorphism Study (EPS)||National Institutes of Health Clinical Center (CC)||Completed|October 2001|May 2010||||N/A|Observational|N/A|||Anticipated|485|||Both|18 Years|N/A|No|||May 2010|September 26, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340886||181380|
NCT00332722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol4|Effectiveness of Cervical Facet Joint Nerve Blocks|Effectiveness of Cervical Facet Joint Nerve Blocks: A Randomized, Prospective, Double-Blind Controlled Evaluation||Pain Management Center of Paducah|Yes|Completed|September 2003|March 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|May 31, 2006||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00332722||181986|The study limitations include the lack of a placebo group.
NCT00332735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-nr 06-010|Spinal Anesthesia With Articaine and Bupivacaine for Outpatient Lower Limb Surgery|Spinal Anesthesia With 5% Articaine and 0.5% Bupivacaine for Outpatient Lower Limb Surgery. A Double-Blind Randomised Clinical Trial||Reinier de Graaf Groep||Completed|May 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|70 Years|No|||April 2007|April 18, 2007|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00332735||181985|
NCT00332748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA165-030|A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer|Effect of Esomeprazole on the Pharmacokinetics of BMS-275183 in Patients With Advanced Malignancies||Bristol-Myers Squibb||Terminated|December 2006|||December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A||||September 2007|February 27, 2010|May 31, 2006||||||https://clinicaltrials.gov/show/NCT00332748||181984|
NCT00333060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-551-002|Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal|Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients||Othera Pharmaceuticals||Terminated|November 2005|January 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|164|||Both|50 Years|N/A|No|||March 2008|March 31, 2008|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00333060||181960|
NCT00333073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONSUI-EU02|Effectiveness and Safety of Bulkamid® as Bulking Agent for the Treatment of Female Urinary Incontinence|Effectiveness and Safety of Bulkamid® as Bulking Agent for the Treatment of Female Urinary Incontinence||Contura||Completed|March 2006|May 2010|Actual|October 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Female|18 Years|N/A|No|||July 2013|February 14, 2014|June 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00333073||181959|
NCT00333385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01648|Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis|||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||Terminated|October 2001|April 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|8 Years|N/A|No|||March 2001|June 2, 2006|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333385||181935|
NCT00333983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3833-R|Evaluation of Robotic Arm Rehabilitation in Stroke Patients|Evaluation of Robotic Arm Rehabilitation in Stroke Patients||VA Office of Research and Development|Yes|Completed|June 2006|February 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|June 2, 2006||No||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00333983||181889|This study was terminated early with the current number of subjects analyzed. A midstudy futility analysis showed a need for 99 participants per group to determine signifcance between the robotic training over the intensive conventional exercise.
NCT00333996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-015|A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis|||Allergan||Terminated|May 2006|March 2007|Actual|March 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|5|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|June 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00333996||181888|
NCT00333970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F3460-V|Predictors of Response to Cognitive Remediation in Schizophrenia|Predictors of Response to Cognitive Remediation in Schizophrenia||VA Office of Research and Development|No|Completed|August 2004|July 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|June 2, 2006||No||No|October 2, 2014|https://clinicaltrials.gov/show/NCT00333970||181890|
NCT00334971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001354|Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women|Aromatase Activity and Ovarian Growth Factors in Preovulatory Follicles||Massachusetts General Hospital|Yes|Active, not recruiting|September 2004|January 2018|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|116|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00334971||181813|
NCT00334945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X041104010|Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent|Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23 (a Known Phosphaturic Agent)||University of Alabama at Birmingham|No|Completed|April 2006|August 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|35|||Both|3 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children attending Endocrinology clinics of Children's Hospital of Alabama. Ages are 3-14        years of age.|November 2011|November 11, 2011|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00334945||181815|
NCT00334958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2080-A001-301|Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures||Eisai Inc.|No|Completed|February 2006|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|356|||Both|12 Years|80 Years|No|||January 2013|January 2, 2013|June 7, 2006|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00334958||181814|
NCT00336830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-02-037|Improving Cardiac Rehabilitation Participation in Women and Men|Improving Cardiac Rehabilitation Participation in Women and Men||Lawson Health Research Institute|No|Completed|May 2003|December 2009|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|1035|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 26, 2014|June 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00336830||181678|
NCT00338026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECO-4601-101|A Phase I Study of ECO-4601 in Patients With Advanced Cancer|A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose||Thallion Pharmaceuticals|Yes|Completed|February 2006|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2008|July 10, 2008|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338026||181592|
NCT00338377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0069|Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma|Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|Yes|Recruiting|February 2006|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|189|||Both|12 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|February 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338377||181566|
NCT00338585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA007|Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery|Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)||ARCA Biopharma, Inc.|Yes|Terminated|April 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|June 15, 2006|Yes|Yes|Based upon preliminary safety and efficacy results from a similar study.|No||https://clinicaltrials.gov/show/NCT00338585||181550|
NCT00344435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905160|Genetic Susceptibility to Factor VIII Inhibitors|Factor VIII Inhibitor Formation: Identifying Predisposing Genetic Factors||National Institutes of Health Clinical Center (CC)||Completed|May 2005|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|3500|||Both|1 Year|100 Years|No|||April 2015|March 11, 2016|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344435||181127|
NCT00344448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060181|Pilot Study of Raptiva to Treat Sjogren's Syndrome|A Randomized, Placebo Controlled, Proof of Concept, Study of Raptiva, a Humanized Anti-CD-11a Monoclonal Antibody, in Patients With Sjogren's Syndrome||National Institutes of Health Clinical Center (CC)|Yes|Terminated|June 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 23, 2006||No|Increased risk of PML associated with raptiva in other studies|No|February 14, 2011|https://clinicaltrials.gov/show/NCT00344448||181126|Early termination due to serious adverse event described in psoriasis which led to the withdrawal of the drug from market.
NCT00340626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997035|Genetic Analysis of Hereditary Non-Syndromic Oral Clefts|Genetic Analysis of Hereditary Non-Syndromic Oral Clefts||National Institutes of Health Clinical Center (CC)||Recruiting|June 1997|||||N/A|Observational|N/A|||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340626||181400|
NCT00340639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903088|Management of Type 1 Diabetes Among Adolescents|Developmental Influences on Management of Type I Diabetes||National Institutes of Health Clinical Center (CC)||Completed|January 2003|November 2006||||N/A|Observational|N/A||||240|||Both|7 Years|N/A|No|||November 2006|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340639||181399|
NCT00341393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906101|Validation of System for Monitoring the Effectiveness of Antiretroviral Therapy in HIV-Infected Patients in Africa|Validation of Algorithm for Monitoring the Virological Efficacy of Antiretroviral Therapy in Africa||National Institutes of Health Clinical Center (CC)||Completed|February 2006|November 2007||||N/A|Observational|N/A||||0|||Both|18 Years|N/A|No|||November 2007|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00341393||181342|
NCT00341874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999993016|Non-Syndrome Hereditary Hearing Impairment - Gene Mapping: India/Pakistan Protocol|Non-Syndromic Hereditary Hearing Impairment - Gene Mapping: India/Pakistan Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|July 1992|||||N/A|Observational|N/A|||Anticipated|24000|||Both|2 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 19, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341874||181305|
NCT00332410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0605055|Intravenous Voriconazole in Patients With Renal Compromise|Intravenous Voriconazole in Patients With Renal Compromise||University of Pittsburgh|Yes|Completed|May 2006|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|solid organ transplant receiving voriconazole with serum creatinine level >2|December 2015|December 16, 2015|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00332410||182006|
NCT00332436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-013T|Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|December 1999|November 2001|Actual|November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|586|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332436||182005|
NCT00332761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841046|Caduet in an Untreated Subject Population|An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untreated Subject Population)|CUSP|Pfizer||Completed|June 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|21 Years|N/A|No|||August 2008|August 19, 2008|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00332761||181983|
NCT00333086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345ADE03|A Study of Letrozole in the Treatment of Endometrial Cancer|A PHASE II STUDY OF LETROZOLE IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER||Novartis||Completed|January 2000|||June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|N/A|No|||April 2012|April 18, 2012|June 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00333086||181958|
NCT00333398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0016|Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults|A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults Greater Than or Equal to 18 to Less Than 65 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|1359|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2008|August 26, 2010|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333398||181934|
NCT00333710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4120-V|Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD|Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD||VA Office of Research and Development|No|Completed|September 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|53|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|June 2, 2006||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT00333710||181910|Small sample size, all male, reliance on self-report measures.
NCT00334347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000671|A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR|A Comparison Study of the Efficacy and Tolerability Between Depakote ER and Depakote in the Acute Treatment of Mania and Mixed Mania||Massachusetts General Hospital|No|Completed|June 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|19 Years|65 Years|No|||December 2007|December 3, 2007|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334347||181861|
NCT00334334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107005|Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.|To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With DTPa-combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.||GlaxoSmithKline||Completed|June 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|1572|||Both|6 Weeks|16 Weeks|Accepts Healthy Volunteers|||November 2012|June 12, 2014|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00334334||181862|
NCT00334984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANUR0532|Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma|Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study||Children's Oncology Group||Withdrawn|January 2007|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Actual|0|||Both|5 Years|30 Years|No|||July 2013|July 9, 2013|June 7, 2006|||Withdrawn due to inability to reach an acceptable agreement with industry sponsor|||https://clinicaltrials.gov/show/NCT00334984||181812|
NCT00335517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11678|Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients|Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients|DepoDur|University of Rochester|No|Completed|June 2006|November 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||December 2012|December 3, 2014|June 8, 2006|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00335517||181773|
NCT00335231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUEENS-SRE-3|Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery|The Effect of Preoperative Topical Gatifloxacin on Anterior Chamber Sample Cultures After Cataract Surgery.||Queen's University||Suspended|June 2006|May 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2006|May 17, 2007|June 8, 2006|||Protocol changes underway.|No||https://clinicaltrials.gov/show/NCT00335231||181794|
NCT00338000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012034|EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure|An Open-Label Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure||Janssen Pharmaceutica N.V., Belgium||Completed|June 2001|May 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|292|||Both|18 Years|N/A|No|||January 2011|January 31, 2011|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00338000||181594|
NCT00338013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vanderbilt IRB # 000832|Patient Sleep Position Questionnaire|Patient Sleep Position Questionnaire||Vanderbilt University|No|Completed|February 2001|March 2007|Actual|March 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary Care Clinic|January 2013|January 6, 2013|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338013||181593|
NCT00338936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631B1303E1|Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)|A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) -||Novartis||Completed|May 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|362|||Both|20 Years|80 Years||||November 2011|November 7, 2011|June 16, 2006||||No||https://clinicaltrials.gov/show/NCT00338936||181523|
NCT00339287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901055|Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens|Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens||National Institutes of Health Clinical Center (CC)||Recruiting|February 2001|||||N/A|Observational|N/A|||Anticipated|200|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339287||181496|
NCT00338039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0983|Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients|Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Completed|September 2005|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|January 27, 2006||No||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00338039||181591|
NCT00338052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-02306|Study of Bleeding With Extended Administration of an Oral Contraceptive|Open-Label Study of Cycle Control With Extended Administration of Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 Mcg Oral Tablets||Warner Chilcott|No|Completed|June 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|207|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||May 2008|May 7, 2008|June 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00338052||181590|
NCT00344760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26280|A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy|Viral Decay Kinetics During Induction Therapy With or Without the Use of Enfuvirtide in HAART-naÃ-ve Patients With Advanced HIV||University of Maryland|Yes|Completed|January 2005|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|70 Years|No|||February 2013|February 7, 2013|June 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00344760||181102|
NCT00340951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905183|Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?|Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?||National Institutes of Health Clinical Center (CC)||Completed|June 2005|April 2007||||N/A|Observational|N/A||||400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2007|March 5, 2008|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340951||181376|
NCT00340899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997067|Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study|Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Restriction: A Longitudinal Study||National Institutes of Health Clinical Center (CC)||Recruiting|December 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|27778|||Both|15 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 3, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340899||181379|
NCT00340912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999880215|Use of Biopsy Punch for Skin Biopsies for Fibroblasts Culturing|Use of Biopsy Punch for Skin Biopsies for Fibroblasts Culturing||National Institutes of Health Clinical Center (CC)||Completed|December 1988|||December 1988|Actual|N/A|Observational|N/A||||500|||Both|18 Years|50 Years|No|||October 2009|October 2, 2009|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340912||181378|
NCT00340938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905030|Family Management of Childhood Diabetes Study|Family Management of Childhood Diabetes Study||National Institutes of Health Clinical Center (CC)||Completed|November 2004|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|1540|||Both|9 Years|70 Years|No|||December 2015|January 13, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340938||181377|
NCT00331747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3985-UG-CTIL|Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate|Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate||Sheba Medical Center||Recruiting|May 2006|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||July 2006|July 5, 2006|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331747||182054|
NCT00332046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKF10015|fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder|A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD).||GlaxoSmithKline||Completed|January 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||57|||Both|18 Years|50 Years|No|||October 2008|October 15, 2008|May 30, 2006||||||https://clinicaltrials.gov/show/NCT00332046||182033|
NCT00341666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906135|Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites|Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites||National Institutes of Health Clinical Center (CC)||Completed|April 2006|July 2011||||N/A|Observational|N/A|||Anticipated|360|||Both|1 Year|65 Years|No|||July 2011|July 16, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341666||181321|
NCT00332787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH039188|Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents|Childhood Depression: Remission and Relapse||University of Texas Southwestern Medical Center||Completed|June 2000|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|7 Years|18 Years|No|||January 2014|January 7, 2014|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00332787||181981|
NCT00333125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-25|A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research||Completed|April 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|May 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333125||181955|
NCT00333099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0012|INEC Study: Immuno-modulating Enteral Nutrition in Cancer|Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer||University Hospital, Clermont-Ferrand||Completed|May 2006|September 2011|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|250|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|June 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00333099||181957|
NCT00333411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206.5|Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis|A 12 Week Double-blind, Randomised, Placebo-controlled, Modified Dose-escalation Trial to Investigate Safety, Efficacy, and Pharmacokinetics of BIRT 2584XX Tablets at Doses of 100, 300 and 500 mg Administered Once Daily in Patients With Moderate to Severe Psoriasis With a 12 Week Treatment Extension||Boehringer Ingelheim||Completed|June 2006|||June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|360|||Both|18 Years|75 Years|No|||June 2014|June 13, 2014|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333411||181933|
NCT00333736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roche-B1.0|Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration|Prospective Study to Assess Patient Satisfaction, Quality of Life and Adverse Events of Patients Using the Biojector Versus Standard Needles for Enfuvirtide Administration||Canadian Immunodeficiency Research Collaborative|Yes|Completed|May 2005|September 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|337|||Both|18 Years|50 Years|No|||June 2012|June 4, 2012|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333736||181908|
NCT00334009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2005/02320|Catecholamine-O-Methyl-Transferase(COMT)-Polymorphism in Cardiac Surgery|Impact of Catecholamine-O-Methyl-Transferase Enzyme Activity on Clinical and Biological Parameters in Patients After Cardiac Surgery.||Austin Health||Completed|June 2006|November 2006||||N/A|Observational|Time Perspective: Prospective||||250|||Both|18 Years|N/A|No|||March 2008|March 3, 2008|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334009||181887|
NCT00334360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexmed/Buspirone|Dexmed/Buspirone Synergism on Shivering|Do Dexmedetomidine and Buspirone Synergistically Reduce the Threshold, Gain, and Maximum Intensity of Shivering?||Outcomes Research Consortium|No|Completed|September 2004|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|June 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00334360||181860|
NCT00334633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040329003|Treatment of Bacterial Vaginosis (BV) With Tinidazole|Tinidazole for the Treatment of Bacterial Vaginosis||University of Alabama at Birmingham||Completed|November 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|593|||Female|18 Years|45 Years|No|||February 2011|May 24, 2011|June 7, 2006||No||No|March 3, 2011|https://clinicaltrials.gov/show/NCT00334633||181839|
NCT00335543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAGTDK-70-3046-Ho2|Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery|Preoperative Chemoradiation in Locally Resectable Adenocarcinoma of Pancreatic Head Without Metastasis||National Cancer Institute (NCI)||Completed|June 2003|October 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|254|||Both|18 Years|N/A|No|||August 2009|August 9, 2013|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00335543||181772|
NCT00331006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|374|Rituximab to Treat Severe Hemophilia A|Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study)|RICH|New England Research Institutes|Yes|Completed|June 2006|January 2012|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Months|N/A|No|||June 2013|June 7, 2013|May 26, 2006|Yes|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT00331006||182104|The study was terminated before reaching its target sample size of 50 subjects due to low enrollment rates. Therefore, confidence intervals for proportions are wide.
NCT00337480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resicard Prevention|Study of the Efficiency of Education About Cardiovascular Risk Factors in Patients After an Acute Coronary Syndrome|A Network to Control Risk Factors After Acute Coronary Syndrome||Resicard|Yes|Completed|July 2006|September 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|504|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00337480||181632|
NCT00337493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19199|Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.|A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation||Hoffmann-La Roche||Completed|December 2005|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|155|||Both|13 Years|75 Years|No|||September 2012|September 14, 2012|June 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00337493||181631|
NCT00338611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-107|Convergence Insufficiency Treatment Trial (CITT)|Convergence Insufficiency Treatment Trial (CITT)||National Eye Institute (NEI)||Active, not recruiting|July 2005|September 2009|Anticipated|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|221|||Both|9 Years|18 Years|No|||October 2008|March 24, 2010|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338611||181548|
NCT00340652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903287|Effects of Infant Diets on Estrogen Activity and Development|Study of Estrogen Activity & Development (SEAD) - SEAD 1 Sonography||National Institutes of Health Clinical Center (CC)||Completed|August 2003|August 2012||||N/A|Observational|N/A|||Anticipated|156|||Both|N/A|1 Year|No|||August 2012|August 20, 2013|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340652||181398|
NCT00331201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402|SAFEstart Feeding Intolerance Study Phase II|SAFEstart Treatment for NICU Patients With Feeding Intolerance; a Phase II Randomized, Controlled Trial||Intermountain Health Care, Inc.||Completed|July 2005|April 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||November 2006|November 27, 2006|May 25, 2006||||No||https://clinicaltrials.gov/show/NCT00331201||182089|
NCT00331513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00094|Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes|A Phase 1 Study of Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) in Combination With Idarubicin in Relapsed or Refractory Leukemia||National Cancer Institute (NCI)||Completed|March 2006|||January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00331513||182069|
NCT00341159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905089|Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study|Genetic Analysis of Cancer Susceptibility Alleles in the CARE Case-Control Study||National Institutes of Health Clinical Center (CC)||Completed|January 2005|February 2015||||N/A|Observational|N/A|||Anticipated|9257|||Both|35 Years|64 Years|No|||February 2015|February 25, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341159||181360|
NCT00332085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190|Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes|Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes: Impact on Blood Sugar Control and Insulin Resistance||Bastyr University||Terminated|January 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||October 2007|October 29, 2007|May 30, 2006|||Issues w/recruitment|No||https://clinicaltrials.gov/show/NCT00332085||182030|
NCT00332098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073871|Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents|Family-Focused Treatment for Bipolar Adolescents||University of California, Los Angeles|Yes|Completed|August 2006|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|13 Years|17 Years|No|||May 2014|May 16, 2014|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00332098||182029|
NCT00332449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4112-AM-CTIL|Early Breast Feeding and Glucose Levels in High Risk Newborns|Does Early Breast Feeding Prevents Neonatal Hypoglycemia in High Risk Newborns||Sheba Medical Center|No|Recruiting|June 2007|December 2008|Anticipated|June 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|1 Day|No|Non-Probability Sample|primary clinic clinic|April 2008|April 14, 2008|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332449||182004|
NCT00332059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-026T|Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|May 2003|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|445|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332059||182032|
NCT00332072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-021T|Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension|||Allergan||Completed|August 2001|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|541|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332072||182031|
NCT00332462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400ADE01|A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients|A Multicenter, Open-label, Exploratory Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine During the First 7 Days Post Transplant Followed by Treatment With Cyclosporine Micro Emulsion in de Novo Liver Transplant Recipients||Novartis||Completed|May 2006|January 2009|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|75 Years|No|||March 2011|March 1, 2011|May 30, 2006||No||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00332462||182003|
NCT00333424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-AE1|Thai Prophylactic HIV Vaccine Phase I Study|A Randomised, Placebo-Controlled, Double-Blind, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS-HIV-AE DNA Prime and rFPV-HIV-AE Boost HIV Vaccination Strategy||Kirby Institute|Yes|Terminated|August 2007|February 2009|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|June 1, 2006||No|Vaccines safe but not immunogenic in 8 participants; trial closed to further recruitment by    the protocol steering committee & DSMB.|No||https://clinicaltrials.gov/show/NCT00333424||181932|
NCT00333437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL371|Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement|Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients||University of California, San Francisco|No|Completed|May 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|21 Years|70 Years|No|||September 2013|September 23, 2013|June 2, 2006|Yes|Yes||No|May 6, 2013|https://clinicaltrials.gov/show/NCT00333437||181931|
NCT00333723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/143|AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone|A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg Once Daily) in Combination With Glyburide in African American and Hispanic Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Glyburide Monotherapy||GlaxoSmithKline||Completed|July 2000|January 2003|Actual|January 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|245|||Both|21 Years|N/A|No|||February 2013|February 11, 2013|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333723||181909|
NCT00333749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3870505|The Effectiveness of Pasteurized Goat Milk in the Treatment of Childhood Oral Ulcer Diseases|Phase 1 1 Study Assesing the Benefit of Pasteurized Goat Milk in Reducing Disease Severity of Young Children With Oral Ulcer Diseases||HaEmek Medical Center, Israel|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|January 13, 2006||||No||https://clinicaltrials.gov/show/NCT00333749||181907|
NCT00334022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roche-FVD-1|Fuzeon Viral Decay Pilot Study|A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA||Canadian Immunodeficiency Research Collaborative||Completed|February 2006|January 2010|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|60 Years|No|||June 2012|June 4, 2012|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00334022||181886|
NCT00334997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000478790|Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis|Early Stage Glottic Cancer: Endoscopic Excision or Radiotherapy [EaStER]||National Cancer Institute (NCI)||Completed|September 2005|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||March 2009|December 18, 2013|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334997||181811|
NCT00334646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV103444|Cyclophosphamide Drug Interaction Study In Cancer Patients|An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 and Intravenous Cyclophosphamide in Cancer Patients||GlaxoSmithKline||Terminated|August 2005|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|June 6, 2006|No|Yes|compound terminated|No||https://clinicaltrials.gov/show/NCT00334646||181838|
NCT00334659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-101|A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects|A Double-blind, Placebo-controlled, Positive Controlled, Randomized, Crossover Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects||Avexa|No|Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|37|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|June 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00334659||181837|
NCT00334672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481605|Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis|Hemophagocytic Lymphohistiocytosis||National Cancer Institute (NCI)||Active, not recruiting|March 2006|||November 2010|Anticipated|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|288|||Both|N/A|17 Years|No|||June 2009|September 16, 2013|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334672||181836|
NCT00335244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409|Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery|A Phase III Single-Blind, Randomized, Placebo Controlled, Clinical Trial to Determine the Safety and Efficacy of Intravenous L-Citrulline Versus Placebo in Children Undergoing Cardiopulmonary Bypass||Asklepion Pharmaceuticals, LLC|Yes|Completed|May 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|77|||Both|N/A|17 Years|No|||January 2015|January 26, 2015|June 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335244||181793|
NCT00335257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG 2005-2|International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC)|International Active Surveillance Study of Women Taking Oral Contraceptives (INAS OC)||Center for Epidemiology and Health Research, Germany|Yes|Completed|August 2005|March 2013|Actual|January 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|85109|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women using oral contraceptives|November 2014|November 14, 2014|June 8, 2006||No||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00335257||181792|In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.
NCT00335556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN0321|Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors|Treatment of High Risk Renal Tumors: A Groupwide Phase II Study||Children's Oncology Group|Yes|Completed|June 2006|||September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|294|||Both|N/A|29 Years|No|||February 2015|December 11, 2015|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335556||181771|
NCT00335569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04CH/HCG02|Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation|A Prospective, Randomized, Controlled Clinical Study on the Assessment of Tolerance and Clinical Equivalence of hCG- IBSA (IBSA) Versus Ovitrelle (Serono), Both Administered Sub-cutaneously in Women Undergoing in Vitro Fertilization (IVF).||IBSA Institut Biochimique SA|No|Completed|August 2005|December 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|144|||Female|18 Years|40 Years|No|||May 2011|May 31, 2011|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00335569||181770|
NCT00338065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vanderbilt IRB# 010436|External Influences Upon Ocular Homeostasis|External Influences Upon Ocular Homeostasis||Vanderbilt University|No|Recruiting|June 2006|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|||Both|10 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be selected from the GCRC, the glaucoma clinic, and healthy subjects invited        to participate.        involuntary (autonomic) nervous system, blood pressure in the arteries and the|December 2015|December 30, 2015|June 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00338065||181589|
NCT00339521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999028|Genetic Susceptibility to Childhood Respiratory IIlness in Mexico City|Genetic Susceptibility to Childhood Respiratory Illness in Mexico City||National Institutes of Health Clinical Center (CC)||Completed|October 1998|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|2400|||Both|4 Years|17 Years|No|||December 2015|December 19, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339521||181478|
NCT00339534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902240|Survey of Prostate Cancer in Accra, Ghana|Survey of Prostate Cancer in Accra, Ghana||National Institutes of Health Clinical Center (CC)||Completed|June 2002|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1950|||Male|18 Years|125 Years|No|||November 2015|November 19, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339534||181477|
NCT00339547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999995048|Risk Factors for Uterine Fibroids: A Case Control Study|Risk Factors for Uterine Fibroids: A Case Control Study and Follow-up Amendment to Study Disease Progression||National Institutes of Health Clinical Center (CC)||Completed|November 1995|||||N/A|Observational|N/A|||Anticipated|2000|||Female|35 Years|50 Years|No|||July 2015|August 5, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339547||181476|
NCT00339300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999994036|A Case-Referent Study of Brain Tumors in Adults|A Case-Referent Study of Brain Tumors in Adults||National Institutes of Health Clinical Center (CC)||Completed|August 1994|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1600|||Both|18 Years|90 Years|No|||February 2016|March 9, 2016|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00339300||181495|
NCT00343928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH071689|Amino Acids, Serotonin, and Body Weight Regulation|Amino Acids, Serotonin, and Body Weight Regulation||Beth Israel Deaconess Medical Center|No|Completed|June 2006|||June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|40 Years|No|||February 2013|February 19, 2013|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00343928||181163|
NCT00340665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903184|Study of Infant Diets on Estrogen Activity and Development|Study of Estrogen Activity & Development (SEAD) SEAD2: Physical Exam and Ballard Markers; Sead 3: Biochemistry||National Institutes of Health Clinical Center (CC)||Completed|May 2003|August 2012||||N/A|Observational|N/A|||Anticipated|456|||Both|N/A|1 Year|No|||August 2012|November 27, 2013|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00340665||181397|
NCT00335764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00676|Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma||National Cancer Institute (NCI)||Completed|April 2006|September 2012|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||December 2013|May 21, 2014|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335764||181756|
NCT00331526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000471241|Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme|Phase II Trial of Intralesional Adoptive Cellular Therapy of Glioblastoma With Interleukin-2-Stimulated Lymphocytes||Hoag Memorial Hospital Presbyterian||Completed|February 1999|April 2012|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|16 Years|N/A|No|||March 2013|March 22, 2013|May 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00331526||182068|
NCT00331474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N06/04/071|The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants|The Effect of BCG Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants||University of Stellenbosch||Active, not recruiting|May 2006|August 2009|Anticipated|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|N/A|48 Hours|No|||February 2009|February 13, 2009|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00331474||182072|
NCT00331487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6E-US-GLAI|Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia|Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia||Takeda|No|Completed|September 2000|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|719|||Both|35 Years|N/A|No|||February 2012|February 27, 2012|May 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00331487||182071|
NCT00332488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-103|Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes|A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and a Secretagogue) in Subjects With Type 2 Diabetes Mellitus Sub-optimally Controlled on Combination Metformin and a Secretagogue.||Mannkind Corporation||Completed|December 2004|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|547|||Both|18 Years|80 Years|No|||October 2014|October 9, 2014|May 31, 2006|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00332488||182002|Wks 12–24 was a non-randomized treatment period of the trial; outcomes were not analyzed for Wks 12–24. Safety results include entire trial; patients counted in multiple treatments for safety.
NCT00332774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-20|Nevanac 3-Month Safety Study With QID Dosing|A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehicle Following Cataract Surgery||Alcon Research||Completed|February 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|149|||Both|10 Years|N/A|No|||March 2012|March 1, 2012|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00332774||181982|
NCT00332800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-343|Study Impact of Nutritional Supplementary Treatment of Undernourished Stroke Patient on Functional Outcome Measures|What Impact Does Intensive Vs. Standard Nutritional Supplementary Treatment of Undernourished Stroke Patient Have on Functional Outcome Measures on an Acute Rehabilitation Unit – a Pilot Study||Burke Rehabilitation Hospital||Completed|October 2003|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|95 Years|No|||June 2005|May 31, 2006|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00332800||181980|
NCT00333138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2201|Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis|Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase||Novartis||Completed|May 2003|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|281|||Both|18 Years|60 Years|No|||December 2013|December 24, 2013|June 1, 2006||No||No|April 5, 2012|https://clinicaltrials.gov/show/NCT00333138||181954|
NCT00333450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106623|Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.|Multicentre Immune Memory Study in Healthy Children Following a 3 Dose Primary Vaccination With Prevenar or GSK Biologicals' Pneumococcal Conjugate Vaccine Via the Administration of a Single Booster Dose of Pneumovax 23||GlaxoSmithKline||Completed|August 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|11 Months|14 Months|Accepts Healthy Volunteers|||February 2012|March 1, 2012|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333450||181930|
NCT00333463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMS-06-03|Compliance With Once Daily Glaucoma Medication|Compliance With Once Daily Glaucoma Medication||Alcon Research||Completed|June 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|700|||Both|N/A|N/A|No|||March 2010|April 7, 2012|June 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00333463||181929|
NCT00334035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441C09906|Antipsychotic Therapy and First Episode|Duration of Maintenance Anti-psychotic Therapy After First -Episode Schizophrenia: a Double-blind Randomized Placebo-control Relapse Prevention Study||The University of Hong Kong||Completed|August 2003|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|||Actual|169|||Both|18 Years|65 Years|No|||June 2008|February 17, 2011|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00334035||181885|
NCT00334373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethics ID E-20039|Post Conditioning in PCI for Acute ST Elevation Myocardial Infarction|Post Conditioning in PCI for Acute ST Elevation Myocardial Infarction||University of Calgary|No|Completed|June 2006|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|June 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00334373||181859|
NCT00334685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061021|[S,S]-Reboxetine Add-On Trial|[S,S]-Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN) Concomitantly Treated With Pregabalin.||Pfizer|Yes|Terminated|July 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||354|||Both|18 Years|N/A|No|||July 2008|July 15, 2008|June 7, 2006|||The DMC terminated the study on the basis of futility (insufficient clinical response).|No||https://clinicaltrials.gov/show/NCT00334685||181835|
NCT00334698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/02 Nacon ITEM|Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic Rhinitis|A Randomized, Double Blind, Placebo-controlled, Four Way Cross-over Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms Scores and Rhinomanometry in Patients With Allergic Rhinitis Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC)||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|July 2006|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|51|||Both|18 Years|55 Years|No|||May 2007|February 2, 2010|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334698||181834|
NCT00334711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/10/196|Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations|A Prospective Study of Sulfonylureas in Patients With Diabetes Due to Kir6.2 Mutations||Royal Devon and Exeter NHS Foundation Trust||Completed|January 2004|January 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||June 2006|November 28, 2006|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334711||181833|
NCT00335010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2004-160|Intravenous NTG to Preserve Gastric Microcirculation During Gastric Tube Reconstruction|A Prospective Double Blinded Study on the Effect of Intravenously Administrated Nitroglycerine on Gastric Tissue Microvascular Bloodflow and Microvascular Hemoglobin Saturation During Gastric Tube Reconstruction||Erasmus Medical Center||Completed|May 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||32|||Both|18 Years|N/A|No|||June 2006|June 7, 2006|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00335010||181810|
NCT00335270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6692-05-12R1|A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination|A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination||Duke University||Completed|March 2006|December 2007||December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|June 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00335270||181791|
NCT00331032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0121|VivaGel™ in Healthy Young Women|An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3 Percent w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2006|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|56|||Female|18 Years|24 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|May 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00331032||182102|
NCT00331045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABD102965|Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid|Clinical Evaluation of Alvimopan (SB767905) on Constipation and Related Symptoms Associated With Opioid -A Placebo-controlled Double-blind Study in Cancer Patients-||Cubist Pharmaceuticals LLC||Terminated|April 2006|December 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|21|||Both|20 Years|N/A|No|||September 2009|September 1, 2015|May 26, 2006||No|Subject registration did not proceed as expected; difficult to complete within scheduled time    frame; prematurely terminated w/ 21 subjects randomized.|No||https://clinicaltrials.gov/show/NCT00331045||182101|
NCT00331305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010275|Exercise Training Versus Drug Therapy for Treating Depression in Older Adults|Exercise Training and Depression in Older Adults II||Duke University|Yes|Completed|August 1999|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|457|||Both|40 Years|N/A|No|||December 2007|August 28, 2013|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00331305||182082|
NCT00331318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060171|Improving Hand Movement Training Through Electrical Stimulation of the Brain|Encoding a Motor Memory Through Metaplasticity||National Institutes of Health Clinical Center (CC)||Completed|May 2006|April 2008||||N/A|Observational|N/A||||31|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|May 27, 2006||||No||https://clinicaltrials.gov/show/NCT00331318||182081|
NCT00331578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-06-6|Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent|Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent|CREATE|JW Medical Systems Ltd|Yes|Completed|June 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2077|||Both|N/A|N/A|No|||January 2009|January 19, 2009|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331578||182064|
NCT00331604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-2161|Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes|Inhaled Pre-prandial Human Insulin With the AERx® iDMS Versus s.c. Insulin Aspart in Type 2 Diabetes: A 104 Week, Open-label, Multicenter, Randomised, Trial Followed by a 12 Week Re-randomised Extension to Investigate Safety and Efficacy||Novo Nordisk A/S|No|Terminated|August 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|618|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|May 24, 2006|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00331604||182063|
NCT00338624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004675|An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.|A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride) for the Treatment of Lower Urinary Tract Symptoms.||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed|May 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|420|||Male|45 Years|N/A|No|||April 2010|May 20, 2011|June 16, 2006||||||https://clinicaltrials.gov/show/NCT00338624||181547|
NCT00343590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-06-03|Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study|Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study||Logan College of Chiropractic||Completed|June 2006|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|25 Years|65 Years||||October 2008|October 16, 2008|June 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00343590||181186|
NCT00343603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309019|Tracking Optical Coherence Tomography|Tracking Optical Coherence Tomography||University of Pittsburgh|No|Suspended|October 2004|||December 2010|Actual|Phase 2|Observational|N/A||1|Anticipated|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subject can range between 18 to 85 years old. They can be healthy or diseased. Recruiting        males and females.|July 2011|July 25, 2011|June 19, 2006||No|Waiting for new device|No||https://clinicaltrials.gov/show/NCT00343603||181185|
NCT00344851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP06-010|Exenatide and Metformin Therapy in Overweight Women With PCOS|Comparison of the Effects of Monotherapy With Exenatide or Metformin to Combined Exenatide and Metformin Therapy on Menstrual Cyclicity in Overweight Women With Polycystic Ovary Syndrome||Metabolic Center of Louisiana Research Foundation|No|Completed|June 2006|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2007|July 10, 2007|June 23, 2006||||No||https://clinicaltrials.gov/show/NCT00344851||181095|
NCT00335777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/MIG-CA/ 01|A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine|An Open-Label Pilot Trial To Collect And Evaluate Data On The Use Of Migranal® In The Treatment Of Two Acute Migraine Attacks Associated With Cutaneous Allodynia||Thomas Jefferson University||Completed|August 2006|April 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||March 2014|March 21, 2014|June 9, 2006||No||No|October 26, 2010|https://clinicaltrials.gov/show/NCT00335777||181755|
NCT00331214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001134 and Yr 2-4 OL|Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido|Study to Evaluate the Efficacy and Safety of Transdermal Testosterone in Women With Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy||Warner Chilcott|No|Completed|June 2002|July 2006|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|533|||Female|20 Years|70 Years|No|||April 2013|April 15, 2013|May 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00331214||182088|
NCT00331786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000473094|Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer|Phase I Multiple-Dose Safety, Pharmacokinetic and Pharmacodynamic Clinical Study of Nitric Oxide Releasing Aspirin (NCX 4016)||National Cancer Institute (NCI)||Completed|July 2006|||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|240|||Both|50 Years|N/A|No|||May 2007|February 6, 2009|May 30, 2006||||||https://clinicaltrials.gov/show/NCT00331786||182051|
NCT00331760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0418|Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery|A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|March 2006|||February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|May 30, 2006|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00331760||182053|
NCT00332514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23071|Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care|Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care||Boston Medical Center|No|Completed|March 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|February 19, 2016|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332514||182001|
NCT00332540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-018T|Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|August 2001|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|520|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332540||182000|
NCT00333112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-008|A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare® In Combination With Tamsulosin in OAB Residual Symptoms|VICTOR|Astellas Pharma Inc|Yes|Completed|May 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|398|||Male|45 Years|N/A|No|||September 2014|September 17, 2014|June 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00333112||181956|
NCT00332813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA020930|Reducing HIV Risk Among Pregnant Women in Drug Treatment|Reducing HIV Risk Among Pregnant Women in Drug Treatment||Rhode Island Hospital||Completed|February 2006|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|98|||Female|18 Years|N/A|No|||January 2006|March 26, 2013|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00332813||181979|
NCT00333762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4065-X|Use of "Smart Wheelchairs" to Provide Independent Mobility to Visual and Mobility Impairments|Use of "Smart Wheelchairs" to Provide Independent Mobility to Visual and Mobility Impairments||VA Office of Research and Development|No|Completed|June 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|June 2, 2006||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00333762||181906|Only four subjects actually tested the chair. It was decided to stop after these four subject tests because the chairs were clearly not viable for this population of persons who were totally blind, and thus there was no need for further testing.
NCT00334048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-036|Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo|Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants||St. Luke's-Roosevelt Hospital Center|No|Completed|June 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||February 2015|February 18, 2015|June 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00334048||181884|
NCT00334386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030089-01|Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.|Multicentre, Multinational, Parallel, Randomised, Double Blind Clinical Trial, to Evaluate the Non-inferiority of PR Torasemide Versus IR Torasemide in Patients With Mild or Moderate Arterial Hypertension.||Ferrer Internacional S.A.||Completed|April 2005|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||388|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00334386||181858|
NCT00334399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1008|Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|69 Years|No|||October 2008|October 8, 2008|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00334399||181857|
NCT00334724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-136|Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study|Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study||Kyoto University, Graduate School of Medicine|Yes|Withdrawn|October 2006|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|65 Years|80 Years|No|||December 2015|December 28, 2015|June 7, 2006||No|Patients were not appropriately enrolled|No||https://clinicaltrials.gov/show/NCT00334724||181832|
NCT00331058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES100767|Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects|A Study To Validate Key Therapeutic Targets and Characterise Their Response to Corticosteroids in Multiple Asthma Phenotypes||GlaxoSmithKline|No|Terminated|February 2006|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|58|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|May 26, 2006||No|The study was truncated due to the long period of enrollment and the collection of a    sufficient amount of data that allowed the scientific objectives to be met|No||https://clinicaltrials.gov/show/NCT00331058||182100|
NCT00331071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012025|Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks|Postmarketing Study of ORTHO EVRA in Relation to Venous Thromboembolism, Ischemic Stroke, and Myocardial Infarction||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Active, not recruiting|April 2002|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|334|||Female|15 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Data collected from PharMetrics, a United States based, ongoing longitudinal database of        data contributed by managed care plans that contains information on unpaid claims for        pharmaceuticals, medical diagnoses and procedures|June 2010|May 18, 2011|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00331071||182099|
NCT00331630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05B2|Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer|Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)||Northwestern University|Yes|Active, not recruiting|May 2006|August 2015|Anticipated|August 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00331630||182062|
NCT00331838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6243|Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, Dose Response Study of Subcutaneous AVE5026 With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery|TREK|Sanofi|Yes|Completed|May 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|705|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|May 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00331838||182047|
NCT00342706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905083|Building Healthy Teen Relationships and Reproductive Practices to Increase Intervals Between Pregnancies|Building Healthy Teen Relationships and Reproductive Practices to Increase Interpregnancy Intervals||National Institutes of Health Clinical Center (CC)||Completed|January 2005|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|750|||Female|15 Years|19 Years|No|||April 2011|April 30, 2011|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00342706||181247|
NCT00343343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS322-1749|Comparison of NovoFine® Needles (4 mm vs. 6 mm)|A Comparative, Randomised Study With NovoFine® 4 mm Needle Versus NovoFine® 6 mm Needle in Regard to Anatomical Deposition of Sterile Air in Children and Thin Adults With Diabetes and Backflow of Test Medium (Only Adults) After Injection in Thigh and Abdomen||Novo Nordisk A/S|No|Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|62|||Both|6 Years|75 Years|No|||June 2012|June 20, 2012|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00343343||181204|
NCT00344539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-075|AMA1-C1/Alhydrogel + CpG 7909 for Malaria|Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2005|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|75|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|May 30, 2013|June 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00344539||181119|
NCT00344552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-540|Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer|Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.||Bristol-Myers Squibb|No|Completed|June 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|20 Years|N/A|No|||November 2009|November 12, 2009|June 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00344552||181118|
NCT00344565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 5148|A Placebo-Controlled Double-Blind Combined Treatment of Modafinil and CBT for Cocaine Dependence|Combined Treatment of Modafinil and Cognitive Behavioral Therapy for Cocaine Dependence||Research Foundation for Mental Hygiene, Inc.|Yes|Completed|November 2005|March 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|55 Years|No|||November 2012|November 30, 2012|June 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00344565||181117|
NCT00344578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fedyk001|Clinical Outcomes After AcrySof® ReStor IOL Surgery in Faculty Practice at UTSW Medical Center at Dallas: A Retrospective Review|Clinical Outcomes After AcrySof® ReStor IOL Surgery in Faculty Practice at UTSW Medical Center at Dallas: A Retrospective Review||University of Texas Southwestern Medical Center|No|Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|120|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|All patients of any race and sex between the ages of 18-90 years of age who have undergone        ReSTOR® IOL cataract surgery will be recruited in this retrospective project.|June 2006|March 22, 2011|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344578||181116|
NCT00331500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-60|Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis|A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis||Alcon Research||Completed|August 2006|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|250|||Both|10 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 11, 2008|May 30, 2006||||||https://clinicaltrials.gov/show/NCT00331500||182070|
NCT00332150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4076-AM-CTIL|Mothers' Approach to Clinical Research Amongst Their Preterm or Healthy Newborns|Mothers' Approach to Clinical Research Amongst Their Preterm or Healthy Newborns||Sheba Medical Center||Completed|March 2006|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332150||182025|
NCT00332553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5546|Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen|Study of Vasomotor Symptoms in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen||Eli Lilly and Company||Completed|February 2002|May 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||May 2007|May 11, 2007|May 30, 2006||||||https://clinicaltrials.gov/show/NCT00332553||181999|
NCT00331773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0415|Radiation Therapy in Treating Patients With Stage II Prostate Cancer|A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 2006|||July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1115|||Male|18 Years|120 Years|No|||March 2016|March 3, 2016|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00331773||182052|
NCT00332111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0603103|Infectious Outcomes Following Pancreas Transplantation|Infectious Outcomes Following Pancreas Transplantation||University of Pittsburgh|Yes|Completed|April 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|patients with pancreatic and kidney transplants|January 2013|January 15, 2013|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00332111||182028|
NCT00332852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345DDE10|Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer|An Open Phase III Trial With Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer||Novartis||Completed|March 2006|||July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|655|||Female|18 Years|N/A|No|||July 2011|July 7, 2011|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332852||181976|
NCT00332878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064882|Stepping Stones Program for Preventing HIV Infection in Residents of Rural South African Communities|RCT of Stepping Stones Behavioural Intervention for HIV||Medical Research Council, South Africa|Yes|Completed|March 2003|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2801|||Both|16 Years|23 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|June 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00332878||181974|
NCT00332826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-105|Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma|A Phase 3, 12-month Treatment, Multicenter, Randomized, Open-Label, Parallel Group Clinical Trial Comparing Prandial Subcutaneous Insulin With Prandial Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma||Mannkind Corporation||Terminated|June 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|3|||Both|18 Years|N/A|No|||May 2012|May 3, 2012|June 1, 2006|No|Yes|Non-safety related business decision to combine special population protocols|||https://clinicaltrials.gov/show/NCT00332826||181978|
NCT00333151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1574|Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes|LEAD-4|Novo Nordisk A/S|No|Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|576|||Both|18 Years|80 Years|No|||November 2014|November 17, 2014|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00333151||181953|
NCT00333775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17708|A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer|A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer.||Hoffmann-La Roche||Completed|March 2006|October 2013|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|736|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|June 5, 2006||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT00333775||181905|
NCT00334061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 0676|Study to Assess the Safety and Effectiveness of the Penumbra System|Evaluation of the Penumbra™ Stroke System in the Revascularization of Patients With Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease||Penumbra Inc.|Yes|Completed|June 2006|November 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|79 Years|No|||December 2008|January 9, 2009|June 2, 2006||Yes|||November 20, 2008|https://clinicaltrials.gov/show/NCT00334061||181883|
NCT00334074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-145|Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in Selected Elderly Patients at High Risk of Anthracycline Toxicity||Baylor Research Institute|No|Completed|August 2005|February 2008|Actual|February 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|85 Years|No|||July 2013|July 15, 2013|June 2, 2006|Yes|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT00334074||181882|
NCT00335283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051169|Efficacy of Lansoprazole in Chronic Post Nasal Drip|Randomized Placebo-Controlled Trial of BID Lansoprazole in Isolated Chronic Post Nasal Drip|PND|Vanderbilt University|No|Completed|August 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||June 2012|July 17, 2012|June 7, 2006|No|Yes||No|March 28, 2011|https://clinicaltrials.gov/show/NCT00335283||181790|Sample size of 75 participants is small. Lack of an objective measure of postnasal drainage limited the study outcome to be symptom based.
NCT00335634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-05-0813|Sexual Dysfunction and Adaptation in Couples Affected by Prostate Cancer Surgery|Sexual Dysfunction and Adaptation in Couples Affected by Prostate Cancer Surgery: Steps Towards a Bio-Psychosocial Model of Treatment||University Health Network, Toronto||Completed|June 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|35 Years|70 Years|No|Non-Probability Sample|Men with prostate cancer who have had a radical prostatectomy, and their intimate        partners.|December 2015|December 9, 2015|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335634||181766|
NCT00335582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#05-0146-B|EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine)|The EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Study: A Randomized, Double-blinded Trial of Clonidine for Reducing Cardiac Morbidity and Mortality Following Non-cardiac Surgery.||University Health Network, Toronto||Active, not recruiting|June 2006|December 2009|Anticipated|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|165|||Both|45 Years|N/A|No|||May 2009|October 8, 2009|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335582||181769|
NCT00335595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-05-02|Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients|Randomized, Multicenter, Phase III Study, to Evaluate the Efficacy and Safety of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy After Initial Chemotherapy Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|July 2006|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|June 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00335595||181768|
NCT00335621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN05RM001|Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)|Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable COPD||NHS Greater Glasgow and Clyde||Withdrawn|June 2006|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|35 Years|80 Years|No|||May 2006|July 27, 2010|June 8, 2006|||Study terminated prior to recruitment - recruitment proved impossible|No||https://clinicaltrials.gov/show/NCT00335621||181767|
NCT00331344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00155|Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy and Chemotherapy|Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer Patients Previously Treated With Chemotherapy||National Cancer Institute (NCI)|Yes|Completed|April 2006|||November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Male|18 Years|N/A|No|||September 2012|September 19, 2012|May 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00331344||182079|
NCT00341835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903288|Genetic Epidemiology of Lung Cancer|Genetic Epidemiology of Lung Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|August 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|9999|||Both|5 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|June 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00341835||181308|
NCT00331643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01826|Ixabepilone in Treating Young Patients With Refractory Solid Tumors|Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|April 2006|June 2009|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|1 Year|35 Years|No|||January 2014|November 13, 2014|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00331643||182061|
NCT00343941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100438|Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults|A Phase II Multicentre, Randomized, Double Blind, Parallel Group, Placebo Controlled Pilot Study of Tucaresol at Two Dosing Levels (25,50 mg) in HIV-1 Infected Adult Subjects With Plasma HIV-1 RNA < 50 Copies/ml on Stable Highly Active Antiretroviral Therapy Regimen for at Least 3 Months||GlaxoSmithKline||Completed|November 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|64 Years|No|||October 2008|October 9, 2008|June 22, 2006||||No||https://clinicaltrials.gov/show/NCT00343941||181162|
NCT00344227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-FVF3102s|Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)|Prospective Optical Coherence Tomography (OCT) Imaging of Patients With Neovascular Age-Related Macular Degeneration (AMD) Treated With Intra-Ocular Lucentis™ (Ranibizumab): PrONTO Study||University of Miami||Completed|August 2004|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|50 Years|N/A|No|||June 2006|June 23, 2006|June 23, 2006||||||https://clinicaltrials.gov/show/NCT00344227||181141|
NCT00344240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0966|Exercise and Activity Guidance in Older Adults With Diabetes|Aerobic Performance,Mobility Limitations and Exercise in Older Adults With Diabetes||University of Michigan||Completed|August 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|240|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2007|February 2, 2010|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344240||181140|
NCT00344591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067495|Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison|Ecosystems Therapy for Men Reintegrating Into Their Family||University of California, San Francisco||Completed|January 2005|||June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|162|||Male|18 Years|N/A|No|||July 2015|July 22, 2015|June 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00344591||181115|
NCT00344604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032004-028|The Role of Psychosocial and Other Quality of Life Parameters in Evaluating Functional Changes Prior to and Following Laser in-Situ Keratomileusis (LASIK)Changes Laser in-Situ Keratomileusis (LASIK)|The Role of Psychosocial and Other Quality of Life Parameters in Evaluating Functional Changes Prior to and Following Laser in-Situ Keratomileusis (LASIK)||University of Texas Southwestern Medical Center|No|Terminated|March 2004|June 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2008|June 23, 2006||No|PI decided to terminate the study at this time|No||https://clinicaltrials.gov/show/NCT00344604||181114|
NCT00331227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202021|Flavonoid Supplementation and Endothelial Function|Effect of Supplemental Flavonoids on Endothelial Function, Lipids, and Markers of Inflammation||Carolinas Healthcare System||Completed|May 2006|December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 14, 2007|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00331227||182087|
NCT00332163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050184|Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy|A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab|STEPP|Amgen|No|Completed|April 2006|September 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|90 Years|No|||January 2016|January 26, 2016|May 31, 2006|Yes|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT00332163||182024|
NCT00332176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-06-001|A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C|A Phase II Randomized, Active-Controlled Study to Assess the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin Over 12 Weeks in Treatment-Naïve Patients With Chronic Hepatitis C||BioWest Therapeutics Inc||Recruiting|June 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|65 Years|No|||April 2008|April 3, 2008|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00332176||182023|
NCT00332189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-008|Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006|A Phase 3b, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006||BioMarin Pharmaceutical||Completed|July 2006|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|4 Years|N/A|No|||October 2012|October 17, 2012|May 30, 2006|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00332189||182022|
NCT00332124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0678|Safety and Effectiveness of Taking Choline Supplements During Pregnancy for Improving Infant Brain Development|Double-blind Trial of Phosphatidylcholine During Pregnancy and Infant Serum Choline Levels||University of Colorado, Denver|Yes|Suspended|June 2006|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|900|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|May 30, 2006|No|Yes|reconsidering study design|No||https://clinicaltrials.gov/show/NCT00332124||182027|
NCT00333489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ABR02|Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension|A National, Multicentric and Comparative Study to Evaluate Efficacy and Tolerability of the Association of Valsartan and Amlodipine Versus Amlodipine Alone in the Treatment of Essential Arterial Hypertension - Stages I and II (Mild to Moderate).||Novartis||Completed|March 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|551|||Both|21 Years|70 Years||||June 2006|November 7, 2011|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00333489||181927|
NCT00333476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-1256F-212|A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration|A Phase 2, Randomized, Open Label, Safety, and Pharmacodynamic Study of Squalamine Lactate for Injection for the Treatment of Minimally Classic or Active Occult Choroidal Neovascularization Associated With Age-Related Macular Degeneration||Genaera Corporation||Terminated|May 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||140|||Both|50 Years|N/A|No|||November 2007|November 27, 2007|June 1, 2006||||||https://clinicaltrials.gov/show/NCT00333476||181928|
NCT00333502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX-001|Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors|A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors||Cerulean Pharma Inc.||Completed|May 2006|April 2012|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333502||181926|
NCT00334737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-139|Darbepoetin Administration to Preterm Infants|A Randomized, Masked, Placebo Controlled Study to Assess the Safety and Efficacy of Darbepoetin Alfa Administered to Preterm Infants||University of New Mexico|Yes|Active, not recruiting|June 2006|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|N/A|49 Hours|No|||September 2013|November 6, 2013|June 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00334737||181831|
NCT00334750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111125|Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada|Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada||Pfizer|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|410|||Both|18 Years|N/A|No|Non-Probability Sample|Canadian population|September 2010|September 8, 2010|June 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00334750||181830|
NCT00335023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-021b|Well Being of Obstetric Patients on Minimal Blood Transfusions|Well Being of Obstetric Patients on Minimal Blood Transfusions|WOMB|Sanquin Research & Blood Bank Divisions|No|Completed|May 2004|||March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 19, 2011|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00335023||181809|
NCT00335296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA0005/09|PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)|The Paradigm IIca/III Trial: PFx Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness||Cierra||Suspended|May 2006|December 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|65 Years|No|||December 2007|December 18, 2007|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00335296||181789|
NCT00335647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000486281|Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma|A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in Patients With Advanced Multiple Myeloma||National Cancer Institute (NCI)||Completed|January 2006|||April 2008|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2008|November 5, 2013|June 8, 2006||||||https://clinicaltrials.gov/show/NCT00335647||181765|
NCT00335660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV608-106|Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity||Avera Pharmaceuticals||Terminated|June 2006|September 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|62|||Female|18 Years|65 Years|No|||February 2008|February 15, 2008|June 8, 2006|||Animal Safety Data|No||https://clinicaltrials.gov/show/NCT00335660||181764|
NCT00331084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRA-05-01|Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery|Efficacy of Antibiotic Steroid Combination Compared With Individual Administration in Prevention of Postoperative Inflammation in Patients Having Cataract Surgery||Federal University of São Paulo|Yes|Completed|April 2006|March 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|132|||Both|18 Years|N/A|No|||August 2009|August 6, 2009|May 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00331084||182098|
NCT00331331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060068|The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease|The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 2006|||||N/A|Observational|N/A|||Actual|63|||Both|18 Years|80 Years|No|||September 2015|October 1, 2015|May 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00331331||182080|
NCT00332631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2004/01899|High-Dose N-Acetylcysteine in Cardiac Surgery|High-Dose N-Acetylcysteine in Cardiac Surgery Patients at High-Risk of Postoperative Renal Dysfunction.||Austin Health||Completed|August 2004|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|N/A|No|||July 2009|July 6, 2009|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00332631||181993|
NCT00332943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060039 MA|MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil|MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil||Herlev Hospital||Completed|December 2005|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|20|||Both|18 Years|N/A|No|||September 2007|September 19, 2007|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00332943||181969|
NCT00343954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGX-3227-01|PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease|Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease||Angiogenix||Not yet recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|10 Years|N/A|No|||June 2006|June 21, 2006|June 21, 2006||||||https://clinicaltrials.gov/show/NCT00343954||181161|
NCT00344253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-Number: 2004-004403-37|Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis|A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)||Heidelberg University|Yes|Completed|March 2006|January 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00344253||181139|
NCT00340730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902070|Community Based Youth Injury Prevention Program|Community Based Youth Injury Prevention Program||National Institutes of Health Clinical Center (CC)||Completed|December 2001|November 2006||||N/A|Observational|N/A||||392|||Both|7 Years|N/A|No|||November 2006|September 26, 2015|June 19, 2006||||No||https://clinicaltrials.gov/show/NCT00340730||181392|
NCT00331539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BnaiZionMC-06-ML-002-CTIL|Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant|Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant||Bnai Zion Medical Center||Recruiting|May 2006|June 2008||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|12 Years|N/A|Accepts Healthy Volunteers|||July 2005|October 6, 2006|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331539||182067|
NCT00332566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106602|Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib|Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.||GlaxoSmithKline||Completed|June 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|148|||Both|18 Months|24 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|May 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00332566||181998|
NCT00332839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE02|Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-coated Mycophenolate Sodium and Everolimus in Comparison to Standard Therapy With Enteric-coated Mycophenolate Sodium and Ciclosporin Microemulsion in Stable Renal Transplant Patients||Novartis||Terminated|November 2005|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|93|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|May 31, 2006|Yes|Yes|The trial was terminated early due to slow enrollment. It was determined that the planned    sample size of 300 could not be achieved.|No|March 14, 2014|https://clinicaltrials.gov/show/NCT00332839||181977|Adverse Events data were not collected during the Follow-up period.
NCT00334087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|boquita HMO-CTIL|The Relation Between Pregnancy,Birth Outcome, Feeding , Oral Hygiene Habits and Early Childhood Caries Development.|Assessment of Pregnancy History, Birth Outcome, Feeding and Oral Practices With Development of Early Childhood Caries in Offspring of Women Who Have Not Participated in Previous Birth Preparation Class||Hadassah Medical Organization||Not yet recruiting|June 2007|September 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|200|||Both|36 Months|48 Months|Accepts Healthy Volunteers|||April 2007|April 15, 2007|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334087||181881|
NCT00334412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-FR-131-0106|COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis|AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study.||Gilead Sciences||Completed|March 2004|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|10 Years|N/A|No|||July 2015|July 7, 2015|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334412||181856|
NCT00334425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2005|The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.|The Effect of LH-Priming During Early Follicular Phase on Ovarian Response and Pregnancy Outcome in GnRHa Down-Regulated Women, Stimulated With Exogenous Gonadotrophins in IVF Treatment||Central Jutland Regional Hospital||Recruiting|April 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Female|18 Years|38 Years|No|||June 2006|June 9, 2006|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00334425||181855|
NCT00335400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUEENS-SRE-1|Anesthetic and Dilating Gel for Cataract Surgery|Comparison of an Anesthetic and Dilating Gel Cocktail Versus the Standard Pre-operative Pharmacologic Regimen for Cataract Surgery on Corneal Anesthesia and Pupil Dilation.||Queen's University||Completed|March 2006|May 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00335400||181782|
NCT00335699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00053|Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome|A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C||AstraZeneca||Completed|August 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||370|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|June 9, 2006||||No||https://clinicaltrials.gov/show/NCT00335699||181761|
NCT00335361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050215|Implantable Device for Male Reproductive Sterilization|The Intra Vas Device (IVD) As A Means of Male Reproductive Sterilization A Single Armed Feasibility Study||Shepherd Medical Company||Active, not recruiting|September 2006|September 2009|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 5, 2007|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00335361||181784|
NCT00335374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.3.008|An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients|An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients||Solvay Pharmaceuticals|Yes|Completed|August 2007|November 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|30 Years|N/A|No|||February 2009|February 5, 2009|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335374||181783|
NCT00331448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-57508 / HL-74814|Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults|Fat Redistribution and Metabolic Change in HIV Infection (FRAM)||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|June 2000|July 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1483|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2006|August 10, 2006|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331448||182073|
NCT00331721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN06-CLD-01001|Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST|A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke||PAION Deutschland GmbH|Yes|Terminated|May 2006|May 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|85 Years|No|||May 2008|May 21, 2008|May 30, 2006||No|Scientific data called into question the viability of the substance class|No||https://clinicaltrials.gov/show/NCT00331721||182055|
NCT00331708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEACAT2.1|Artesunate Plus Sulfadoxine-Pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria|An Open-Label in Vivo Drug Study to Evaluate Artesunate Plus Sulfadoxine-Pyrimethamine (ASSP) Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes in Pregnant Women With Uncomplicated Falciparum Malaria||University of Cape Town||Active, not recruiting|April 2006|June 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|N/A|No|||April 2007|April 3, 2007|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331708||182056|
NCT00332007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TON/02/05-CLIN|Tonabersat in the Prophylaxis of Migraine With Aura|A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura||Minster Research Ltd|No|Completed|May 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|65 Years|No|||August 2009|August 28, 2009|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00332007||182036|
NCT00331994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0161|EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth|Efficacy Evaluation of Enterogermina, 2 Billion Bacillus Clausii Spores, on Eradication of Small Intestinal Bacterial Overgrowth: a Randomised, Parallel-group, Open Study.||Sanofi||Completed|April 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|65 Years|No|||July 2009|July 17, 2009|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00331994||182037|
NCT00332306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|trc23|Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment|Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis||Tuberculosis Research Centre, India|Yes|Active, not recruiting|June 2006|December 2011|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|61 Years|No|||January 2009|October 7, 2009|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00332306||182013|
NCT00333294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0530|Phase II Iressa + Irradiation Followed by Chemo in NSCLC|A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSA™) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non Small Cell Lung Cancer||AstraZeneca||Completed|September 2004|January 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|No|||December 2007|December 16, 2007|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333294||181942|
NCT00333307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLX.PE.001|Evaluation of the Safety of Relaxin in Preeclampsia|A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia||Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies||Suspended|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|18|||Female|18 Years|40 Years|No|||March 2010|March 12, 2010|June 1, 2006||||||https://clinicaltrials.gov/show/NCT00333307||181941|
NCT00332280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMT/P2CA/001|Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo|A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo||Auron Healthcare GmbH||Terminated|May 2006|March 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|79 Years|No|||March 2013|March 19, 2013|May 31, 2006||No|Lack of efficacy. Stopped at first interim evaluation point|No||https://clinicaltrials.gov/show/NCT00332280||182015|
NCT00332293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-40|AL-15469A for the Treatment of Bacterial Conjunctivitis|An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India||Alcon Research||Completed|May 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|695|||Both|1 Month|N/A|No|||March 2012|March 1, 2012|May 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00332293||182014|
NCT00333892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8737|Leukapheresis to Obtain Lymphocytes for Studies on Antiretroviral Naive HIV-infected Patients|Leukapheresis Procedures to Obtain Lymphocytes for Research Studies on Antiretroviral Naive HIV-infected Patients||Canadian Immunodeficiency Research Collaborative||Completed|August 2003|December 2008|Actual|||Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|Samples With DNA|Obtain lymphocytes for research studies on anti-retroviral naive HIV-infected patients.|Both|18 Years|50 Years|No|Probability Sample|HIV-infected adults who have a positive ELISA and a confirmatory western blot HIV test.|June 2012|June 4, 2012|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333892||181896|
NCT00334230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060175|Gait Training and Brain Changes in Stroke Patients|Mechanisms of Training Induced Improvements in Gait Function After Stroke||National Institutes of Health Clinical Center (CC)||Completed|June 2006|April 2008||||N/A|Observational|N/A||||58|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00334230||181870|
NCT00359021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002740|An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).|An Open-label Trial With TMC125 as Part of an ART Including TMC114/Rtv and an Investigator-selected OBR in HIV-1 Infected Subjects Who Participated in a DUET Phase III Trial (TMC125-C206 or TMC125-C216).||Tibotec Pharmaceuticals, Ireland|No|Completed|June 2006|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|503|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|July 28, 2006||No||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00359021||180029|
NCT00359268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010161|Identification of Viruses Associated With Diseases of Unknown Cause|Identification of Novel Viruses||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2001|||||N/A|Observational|N/A|||Actual|56|||Both|N/A|N/A|No|||July 2015|August 5, 2015|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359268||180010|
NCT00333944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRH/IERC/2000/12|Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.|Effectiveness of High Dose Pralidoxime in the Treatment of Organophosphorus Pesticide Poisoning – a Randomised Controlled Trial||Giriraj Hospital||Completed|May 2000|June 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|12 Years|N/A|No|||May 2000|June 5, 2006|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00333944||181892|
NCT00334269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT64076|Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Action Toward Obesity Prevention (SHARE-AP Action)|Study of Health Assessment and Risk Evaluation (SHARE) in Aboriginal Peoples (AP) Action Toward Obesity Prevention (SHARE-AP Action)||Population Health Research Institute||Completed|May 2004|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||174|||Both|5 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 27, 2009|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00334269||181867|
NCT00334282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG105192|Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma|A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma||GlaxoSmithKline|Yes|Completed|April 2006|December 2014|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|435|||Both|18 Years|N/A|No|||August 2015|January 11, 2016|June 5, 2006|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00334282||181866|
NCT00366223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0607092|Changing Patterns of Candida Infections in Urban Medical Centers|Changing Patterns of Candida Infections in Urban Medical Centers: Emphasis on the Emergence of Non-albicans Species and Their Influence on Clinical Outcomes||University of Pittsburgh|Yes|Active, not recruiting|August 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|80|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|N/A|N/A|No|Non-Probability Sample|candida blood culture|December 2015|December 16, 2015|August 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00366223||179494|
NCT00335153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S187.3.004|Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease|An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications||AbbVie|Yes|Completed|January 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|354|||Both|30 Years|N/A|No|||January 2015|January 12, 2015|June 8, 2006|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00335153||181800|
NCT00335426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0601060018|Influence of Spinal Manipulative Therapy Upon Stroop Task Performance|||Logan College of Chiropractic||Completed|June 2006|December 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2009|August 28, 2009|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00335426||181780|
NCT00331149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROP105323|A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's|A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.||GlaxoSmithKline|No|Completed|June 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|344|||Both|30 Years|N/A|No|||March 2012|March 7, 2013|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00331149||182093|
NCT00331422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS070|Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced||Masonic Cancer Center, University of Minnesota|Yes|Terminated|October 2005|March 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|May 30, 2006|Yes|Yes|Study was terminated due to lack of available funding.|No|November 23, 2009|https://clinicaltrials.gov/show/NCT00331422||182075|1 of the 2 evaluable patients was switched from Paclitaxel to Taxotere during the course of her treatment due to toxicity (adverse effects), but since it remains a platinum-based chemotherapy she is included in the evaluable group.
NCT00335101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-012-091|Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography|||GE Healthcare||Terminated|June 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||384|||Both|18 Years|N/A|No|||May 2007|May 14, 2007|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00335101||181803|
NCT00335114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F051025017|Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers|Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers||University of Alabama at Birmingham||Completed|November 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|19 Years|N/A|No|||June 2006|June 8, 2006|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00335114||181802|
NCT00335712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5129-03|Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus|Phase II Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus||Ono Pharmaceutical Co. Ltd||Completed|June 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|81|||Both|45 Years|74 Years|No|||June 2012|June 12, 2012|June 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00335712||181760|
NCT00331136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-003-05|Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria|An Open-Label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) In Children With Acute Uncomplicated Plasmodium Falciparum Malaria||Medicines for Malaria Venture||Completed|June 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|2 Years|14 Years|No|||May 2008|May 19, 2008|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00331136||182094|
NCT00363688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|756497|Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin|Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin: Is It Safe?||Meir Medical Center||Terminated|January 1998|May 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|4 Years|90 Years||||December 1997|August 10, 2006|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363688||179684|
NCT00332020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11357|Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement|RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Hip Replacement.|RECORD 2|Bayer||Completed|February 2006|June 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2457|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332020||182035|
NCT00332033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060029|Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)|Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)||National Institutes of Health Clinical Center (CC)||Completed|May 2006|February 2007||||Phase 2|Interventional|Primary Purpose: Treatment||||32|||Female|35 Years|50 Years|No|||February 2007|March 30, 2007|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00332033||182034|
NCT00332371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4817|COMPACT - COMbining Plasma-filtration and Adsorption Clinical Trial|COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU||Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva|Yes|Terminated|December 2006|July 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|May 31, 2006||No|The study was prematurely interrupted for futility.|No||https://clinicaltrials.gov/show/NCT00332371||182009|
NCT00332384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-012T|Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|January 2000|November 2001|Actual|November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|573|||Both|18 Years|N/A|No|||May 2011|May 27, 2011|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332384||182008|
NCT00333320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSTCONDITIONING|Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction|Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction||French Cardiology Society|Yes|Completed|September 2006|November 2011|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333320||181940|
NCT00333645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESITRA-01|Prophylaxis With Caspofungin in High-Risk Liver Transplantation|Prophylaxis With Caspofungin for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients||Grupo de Estudio de Infecciones en Transplantados||Recruiting|October 2003|March 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||70|||Both|18 Years|N/A|No|||December 2006|April 12, 2007|June 4, 2006||||No||https://clinicaltrials.gov/show/NCT00333645||181915|
NCT00333905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4096R|The Effect of Ischemic Training on Exercise Endurance|The Effect of Ischemic Training on Exercise Endurance||VA Office of Research and Development||Completed|March 2006|February 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|30 Years|71 Years|No|||June 2006|February 3, 2009|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333905||181895|
NCT00333918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-BR-CS02|Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery|Efficacy and Safety Study of Topical Bromfenac Ophthalmic Solution vs. Placebo for Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery||Bausch & Lomb Incorporated||Completed|June 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|522|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|June 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333918||181894|
NCT00359034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-70016|Fetal Aortic Pulsewave Velocity: A Novel Doppler Ultrasound Method of Measuring the Biophysical Properties of the Fetal Aorta|Fetal Aortic Pulsewave Velocity: A Novel Doppler Ultrasound Method of Measuring the Biophysical Properties of the Fetal Aorta||University of British Columbia|No|Withdrawn|May 2006|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Singleton pregnancy between 20-36 weeks GA presenting at British Columbia Women's        Hospital.|January 2013|February 4, 2014|July 28, 2006||No|Could not resolve technical difficulties|No||https://clinicaltrials.gov/show/NCT00359034||180028|
NCT00365625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244/06|Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris|Patient Orientated Basic Science Investigation: Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris||Johann Wolfgang Goethe University Hospitals||Recruiting|July 2005|December 2007|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|psoriasis patients|August 2009|February 1, 2010|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365625||179538|
NCT00365846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-032|"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"|"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation||University of Wisconsin, Madison|No|Completed|August 2000|July 2006|Actual|July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Both|18 Years|60 Years|No|||September 2012|September 21, 2012|August 16, 2006|Yes|Yes||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00365846||179522|
NCT00365859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-180|Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)|A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|September 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|330|||Both|6 Years|17 Years|No|||June 2010|November 7, 2013|August 15, 2006|Yes|Yes||No|December 17, 2009|https://clinicaltrials.gov/show/NCT00365859||179521|
NCT00334906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-15|Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)|An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type||Forest Laboratories||Completed|July 2005|||November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|50 Years|N/A|No|||January 2008|January 3, 2008|June 6, 2006||||||https://clinicaltrials.gov/show/NCT00334906||181818|
NCT00366522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3201A1-100|Study Evaluating LXR-623 in Healthy Subjects|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 6, 2009|August 17, 2006||||||https://clinicaltrials.gov/show/NCT00366522||179471|
NCT00335439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUEENS-SRE-2|Effect of Prophylactic Ketorolac on CME After Cataract Surgery|Effect of Prophylactic NSAID Drops on Cystoid Macular Edema After Cataract Surgery Using Optical Coherence Tomography||Queen's University||Completed|June 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|98|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|June 8, 2006||||No||https://clinicaltrials.gov/show/NCT00335439||181779|
NCT00335166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.3.003|SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease|A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.||Solvay Pharmaceuticals|Yes|Completed|November 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|30 Years|N/A|No|||April 2008|April 1, 2008|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335166||181799|
NCT00335738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARET0332|Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma|A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy||Children's Oncology Group|Yes|Completed|December 2005|||September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|331|||Both|N/A|6 Years|No|||June 2013|June 10, 2013|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335738||181758|
NCT00331695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040438|Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery|Evaluation of the Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery||Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2006|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|560|||Female|18 Years|49 Years|No|||March 2007|May 6, 2011|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00331695||182057|
NCT00331981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8968|Amisulpride in Schizophrenic Patients|Study of the Efficacy and Safety After Long-Term Treatment With Amisulpride in Schizophrenic Patients||Sanofi|No|Completed|February 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||138|||Both|18 Years|N/A|No|||April 2008|April 8, 2008|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331981||182038|
NCT00332319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKB104846|Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients|See Detailed Description||GlaxoSmithKline|No|Terminated|January 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|65 Years|No|||March 2011|April 15, 2015|May 30, 2006||||||https://clinicaltrials.gov/show/NCT00332319||182012|
NCT00364260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002056|A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.|A Study to Determine the Impact of Hemoglobin Maintenance and Other Interventional Strategies to Prevent or Delay the Progression of Left Ventricular Mass Growth in Subjects With Early Renal Insufficiency.||Janssen-Ortho Inc., Canada||Completed|December 1997|August 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|172|||Both|18 Years|80 Years|No|||January 2011|January 31, 2011|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364260||179641|
NCT00363935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072005-020|Bariatric Dose-Ranging Study With Dexmedetomidine|A Randomized, Double-Blind, Controlled Study of Dexmedetomidine (Precedex) Infusion for Improving Control of Acute Autonomic Response During Laparoscopic Bariatric Surgery||University of Texas Southwestern Medical Center||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|70 Years||||April 2007|April 17, 2007|August 10, 2006||||||https://clinicaltrials.gov/show/NCT00363935||179665|
NCT00363948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5435-08|Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus|MK-0431/ONO-5435 Phase III Clinical Study - Metformin Add-On Study for Patients With Type 2 Diabetes Mellitus||Ono Pharmaceutical Co. Ltd||Completed|August 2006|||February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Both|20 Years|74 Years|No|||June 2012|June 12, 2012|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00363948||179664|
NCT00333008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY-012006|A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.|Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status||The Alvin and Lois Lapidus Cancer Institute||Recruiting|May 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||27|||Both|18 Years|N/A|No|||September 2006|September 25, 2006|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00333008||181964|
NCT00333021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR3106116|Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) After Abdominal Surgery||GlaxoSmithKline||Completed|May 2006|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|127|||Both|40 Years|N/A|No|||July 2009|July 9, 2009|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00333021||181963|
NCT00333034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-318|Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis|A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 4, 2007|May 23, 2006||||No||https://clinicaltrials.gov/show/NCT00333034||181962|
NCT00332696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995AFR08|Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis|Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis||Novartis|No|Completed|September 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|June 1, 2006||No||No|January 17, 2011|https://clinicaltrials.gov/show/NCT00332696||181988|Study was terminated prematurely due to low enrollment
NCT00332709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345DDE09|Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer|An Open Phase III Trial With Letrozole Alone or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer||Novartis||Completed|January 2006|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||October 2011|October 10, 2011|May 31, 2006||No||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00332709||181987|
NCT00333658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3108R|A Behavioral Intervention to Improve Work Outcomes|A Behavioral Intervention to Improve Outcomes in VA Work Programs||VA Office of Research and Development|No|Completed|December 2003|September 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|N/A|N/A|No|||June 2009|June 24, 2009|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333658||181914|
NCT00333333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC# 26075|Mechanism of Thrombocytopenia in Infants|Mechanism of Thrombocytopenia in Small for Gestational Age Infants Versus Infants With Maternal Preeclampsia Exposure||Christiana Care Health Services|No|Completed|June 2006|June 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Cord blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In utero infants who are small for gestational age or who are exposed to maternal        pre-eclampsia|June 2008|June 12, 2008|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333333||181939|
NCT00333346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/195|Tramadol iv. : Influence of Dose and Dose Intervals on Therapeutic Accuracy and Side Effects When Used for Postoperative Pain Relief in Ambulatory Surgery|Tramadol iv. : Influence of Dose and Dose Intervals on Therapeutic Accuracy and Side Effects When Used for Postoperative Pain Relief in Ambulatory Surgery||University Hospital, Ghent|No|Completed|September 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|70 Years|No|||August 2010|August 30, 2010|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333346||181938|
NCT00353951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRACE-01|An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care|Genomics to Combat Resistance Against Antibiotics in Community-Acquired LRTI in Europe: GRACE. Workpackage 8. An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care||Cardiff University||Completed|September 2006|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective|||Actual|3402|||Both|18 Years|N/A|No|||May 2008|May 19, 2008|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353951||180409|
NCT00353964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVOL-PRO-06-024|Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery|A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery||Evolutec Group||Recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A|No|||July 2006|July 27, 2006|July 17, 2006||||||https://clinicaltrials.gov/show/NCT00353964||180408|
NCT00365638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|636/04|Simvastatin Therapy in Women With Polycystic Ovary Syndrome.|Effects of Simvastatin on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Prospective, Randomized Trial.||Poznan University of Medical Sciences||Completed|April 2004|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|40 Years|No|||September 2004|August 15, 2006|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00365638||179537|
NCT00365651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEA2006|Nutrition and Soccer for Pediatric Overweight and Obesity|Multi Intervention Approach to Pediatric Overweight and Obesity: A Randomized Control Group Trial||Leach Chiropractic Clinic|Yes|Completed|June 2006|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|22|||Female|9 Years|12 Years|Accepts Healthy Volunteers|||May 2007|May 18, 2007|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00365651||179536|
NCT00365872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14497|External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma|Combination of External Beam Radiation With Intratumoral Injection of Dendritic Cells as Neo-adjuvant Treatment of High-risk Soft Tissue Sarcoma Patients||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|May 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2013|February 10, 2014|August 17, 2006|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT00365872||179520|
NCT00365885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006833|Showing Health Information Value in a Community Network|Showing Health Information Value in a Community Network||Duke University||Completed|August 2006|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|20108|||Both|N/A|N/A|No|||December 2012|July 9, 2014|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365885||179519|
NCT00366860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC Protocol #1971|Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease|Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease||University of Michigan|Yes|Completed|January 2004|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366860||179445|
NCT00366873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3374-1151|Evaluation of Mineral Absorption in Infants Fed Infant Formula|Evaluation of Mineral Absorption in Infants Fed Infant Formula||Mead Johnson Nutrition|No|Completed|September 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|44|||Both|56 Days|70 Days|Accepts Healthy Volunteers|||March 2009|March 4, 2009|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366873||179444|
NCT00366834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV102549|Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting|A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron and Dexamethasone for the Prevention of Nausea||GlaxoSmithKline|No|Completed|July 2006|October 2009|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1840|||Both|18 Years|N/A|No|||June 2012|September 6, 2012|August 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366834||179447|
NCT00335179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1467-IMIQ|Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream|Double-Blind, Vehicle-Controlled Study to Evaluate Cellular and Molecular Events During Four Weeks of Treatment for Actinic Keratosis With Aldara (Imiquimod) Cream, 5%||Graceway Pharmaceuticals, LLC|No|Completed|January 2003|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|N/A|No|||July 2010|July 22, 2010|June 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335179||181798|
NCT00335452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5965|Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS|Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.|CURRENT/OASIS7|Sanofi|Yes|Completed|June 2006|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|25086|||Both|18 Years|N/A|No|||November 2010|November 9, 2010|June 8, 2006|Yes|Yes||No|September 15, 2010|https://clinicaltrials.gov/show/NCT00335452||181778|
NCT00335465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4053|Lantus Effect on Myocardial Glucose Metabolism in T2|Pilot Study for the Evaluation of the Effects of Insulin Treatment on Myocardial Function, Perfusion, and Glucose Metabolism in Patients With Primary Left Ventricular Dysfunction and Type 2 Diabetes.||Sanofi||Completed|September 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||December 2009|December 4, 2009|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335465||181777|
NCT00331162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG04-498|Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation|Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation||Wake Forest Baptist Health|No|Active, not recruiting|February 2005|June 2015|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|275|||Both|18 Years|65 Years|No|||December 2009|January 10, 2011|May 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00331162||182092|
NCT00331435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCV-PDT-1|PDT Study for Exudative AMD With PCV|Clinical Research of Photodynamic Therapy for Exudative Age-related Macular Degeneration Accompanied With Polypoidal Choroidal Vasculopathy||Ophthalmic PDT Study Group|Yes|Completed|June 2006|January 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|113|||Both|50 Years|N/A|No|||March 2011|March 30, 2011|May 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00331435||182074|
NCT00363987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFP503|Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)|A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy||Fresenius Kabi||Completed|May 2006|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|75 Years|No|||August 2010|September 1, 2010|August 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00363987||179661|
NCT00363428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0825|Lung Rehabilitation in Treating Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Surgery for Lung Cancer|A Randomized Trial of Pulmonary Rehabilitation in Patients With Moderate to Severe COPD Who Require Lung Resection for Lung Cancer||Mayo Clinic|Yes|Active, not recruiting|August 2006|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|40 Years|120 Years|No|||March 2015|January 7, 2016|August 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00363428||179703|
NCT00363441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20313|A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck|A Randomized Phase II Study of Conventional 3D Radiation (3DCRT) Versus Intensity-Modulated Radiation (IMRT) in Squamous Cell Cancer of the Head and Neck (SCCHN): Pilot Feasibility Study||AHS Cancer Control Alberta||Withdrawn||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A||||January 2011|January 18, 2012|August 9, 2006||||No||https://clinicaltrials.gov/show/NCT00363441||179702|
NCT00363675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P000388/3|Evaluation of Hand Assessments in Children With Severe Hand Burns|Evaluation of Hand Assessments in Children With Severe Hand Burns||Massachusetts General Hospital|No|Terminated|August 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|5 Years|18 Years|No|||February 2012|February 29, 2012|August 9, 2006||No|This was a pilot study, but the larger study was not funded.|No|February 29, 2012|https://clinicaltrials.gov/show/NCT00363675||179685|This pilot study was discontinued secondary to lack of grant funding for the project.
NCT00364247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011215|A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety.|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy Followed by a Voluntary Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|602|||Both|18 Years|80 Years|No|||June 2011|June 2, 2011|August 11, 2006||||||https://clinicaltrials.gov/show/NCT00364247||179642|
NCT00332332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050180|Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis|Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis||Amgen||Completed|March 2006|February 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|246|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|May 30, 2006||||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00332332||182011|
NCT00332345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-011T|Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|July 1999|August 1999|Actual|August 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|73|||Both|21 Years|N/A|No|||May 2011|May 27, 2011|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332345||182010|
NCT00364442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS10019|Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics|A Repeat Dose, Randomised, Double Blind, 2-Way Crossover Study to Assess the Safety and Systemic Exposure of SERETIDE/VIANI 50/50 COA Compared to Concurrent Administration of Individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS Inhalers in Subjects Aged 18 - 55 Years With Mild Asthma||GlaxoSmithKline||Completed|January 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|55 Years|No|||October 2008|October 9, 2008|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364442||179627|
NCT00364455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006118|Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.|Randomized Trial of Epoetin Alfa in Men With Hormone-refractory Prostate Cancer and Anemia.||Janssen-Ortho Inc., Canada||Completed|December 2002|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|56|||Male|18 Years|N/A|No|||April 2010|April 26, 2010|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364455||179626|
NCT00333047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345ADE07|Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy|A Study of Letrozole in the Treatment of Metastatic Breast Cancer in Combination With Chemotherapy||Novartis||Completed|July 2002|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Female|65 Years|N/A|No|||November 2009|November 18, 2009|May 31, 2006||||No||https://clinicaltrials.gov/show/NCT00333047||181961|
NCT00364689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPROST #200060006|RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial|RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial||University of Miami||Recruiting|August 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||April 2007|June 23, 2010|August 15, 2006||||||https://clinicaltrials.gov/show/NCT00364689||179608|
NCT00364975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31150906-HMO-CTIL|Development of Gourmet Healthy Cooking Workshop for Cancer Patients|Development of Gourmet Healthy Cooking Workshop for Cancer Patients||Hadassah Medical Organization||Withdrawn|December 2006|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Female|N/A|N/A|No|||August 2006|September 20, 2015|August 15, 2006|||Was not funded|No||https://clinicaltrials.gov/show/NCT00364975||179586|
NCT00364988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAN|Pioglitazone and Losartan Provides Additional Renoprotection|Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy||Shanghai Jiao Tong University School of Medicine|Yes|Completed|January 2005|January 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|32 Years|75 Years|No|||October 2014|October 23, 2014|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364988||179585|
NCT00349726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0036-1|Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants|Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants|INS-1|NICHD Neonatal Research Network|Yes|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|74|||Both|N/A|6 Days|No|||July 2015|July 27, 2015|July 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00349726||180727|
NCT00349739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIOWA200101096|Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate|Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension||University of Iowa||No longer available|January 2003|August 2008|Anticipated|||N/A|Expanded Access|N/A|||||||Both|55 Years|N/A|No|||January 2010|January 14, 2010|July 6, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00349739||180726|
NCT00366548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-009|Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy Infants Given in a 2-, 3-, 4-, and 12-Month Schedule With Routine Pediatric Vaccinations||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|500|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||July 2012|July 6, 2012|August 17, 2006|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00366548||179469|
NCT00366561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-139|Neonates With Neurological Complications|Retrospective Review of Neonates With Neurological Complications Following Cardiac Surgery||Children's Healthcare of Atlanta|No|Completed|January 2002|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|810|||Both|N/A|30 Days|No|Non-Probability Sample|All neonates (newborns < 30 days of age) from January 1, 2002 through June 20, 2006 at        Children's Healthcare of Atlanta who have suffered neurological complications following        cardiac surgery.|November 2014|November 26, 2014|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366561||179468|
NCT00367211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN200-301|Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.|A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.||POZEN||Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||400|||Both|18 Years|N/A|No|||April 2008|April 21, 2008|August 18, 2006|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00367211||179418|
NCT00366886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-140|Patients With NMDA Biomarker Data Following Cardiac Surgery|Retrospective Review of 22 Patients With NMDA Biomarker Data Following Cardiac Surgery||Children's Healthcare of Atlanta||Terminated||July 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||22|||Both|N/A|18 Years|No|||June 2007|June 12, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366886||179443|
NCT00366899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-500|Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|605|||Both|75 Days|105 Days|Accepts Healthy Volunteers|||January 2013|January 17, 2013|August 17, 2006|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00366899||179442|
NCT00366535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060229|Neurotropin to Treat Fibromyalgia|Neurotropin Treatment of Fibromyalgia||National Institutes of Health Clinical Center (CC)||Completed|August 2006|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|August 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366535||179470|
NCT00366847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-149|Computer Modeling of Congenital Heart Disease|Computer Modeling of Congenital Heart Disease||Children's Healthcare of Atlanta||Completed|June 2001|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|This is a chart review of patients with heart defects associated with Right Ventricle        dysfunction who have received a cardiac MRI at Children's Healthcare of Atlanta between        January 1, 1990 and March 14, 2007.|May 2014|May 7, 2014|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366847||179446|
NCT00367120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661180|Zmax Compared to Augmentin in Sinusitis|A Multicenter, Randomized, Open Label Comparative Study Of Azithromycin Extended Release (ZMAX) Versus Amoxicillin/Clavulanate Potassium In Subjects With Acute Bacterial Sinusitis (ABS) In A Physician Practice Environment||Pfizer||Completed|June 2006|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|762|||Both|18 Years|N/A|No|||March 2010|March 15, 2010|August 21, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00367120||179425|
NCT00335751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000480348|PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma|Glucose Metabolic Response by PET/CT to Sarcoma Treatments||Jonsson Comprehensive Cancer Center|No|Completed|January 2006|October 2011|Actual|July 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335751||181757|
NCT00331175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001292|Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults|A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects||Pfizer||Completed|July 2006|December 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2006|December 14, 2006|May 26, 2006||||||https://clinicaltrials.gov/show/NCT00331175||182091|
NCT00331188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBV-VAP/EVB-301|Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding|The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension||Debiovision|No|Completed|May 2006|July 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|75 Years|No|||July 2008|July 7, 2008|May 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00331188||182090|
NCT00364806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine 3|A Clinical Trial Comparing Two Different Medications to Determine Which One is Better for Patients With an Acute Migraines in the Emergency Department|Prochlorperazine Verus Metoclopramide for the Treatment of Acute Migraine in the Emergency Department Setting||Montefiore Medical Center||Completed|August 2006|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||76|||Both|18 Years|N/A|No|||May 2008|May 19, 2008|August 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364806||179599|
NCT00365131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC96-1101|A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.|||Sanofi||Completed|December 1997|July 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|10 Years|65 Years|No|||March 2015|March 4, 2015|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00365131||179576|
NCT00363961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03DK064825|Resistance Training During Maintenance Dialysis|Resistance Training During Maintenance Dialysis||Tufts University|Yes|Completed|April 2004|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|51|||Both|30 Years|80 Years|No|||December 2009|December 9, 2009|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00363961||179663|
NCT00364195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB1002 203|Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer|A Pharmacokinetic Interaction and Safety and Efficacy Phase II, Open Label Study With a Safety Lead-in Evaluating Docetaxel Plus Tesmilifene (YMB1002) in Patients With Metastatic Breast Cancer Suitable for Treatment With Docetaxel||YM BioSciences||Completed|June 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|33|||Female|18 Years|65 Years|No|||January 2009|January 8, 2009|August 14, 2006||||||https://clinicaltrials.gov/show/NCT00364195||179645|
NCT00364221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0447|Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome|The Effect of Rosiglitazone on Adipocyte-derived Cytokines in Nondiabetics With the Metabolic Syndrome||University of Colorado, Denver||Completed|November 2004|October 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|55 Years|No|||November 2012|November 20, 2012|August 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364221||179644|
NCT00364468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN125/05-A04|Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients|A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma||Kyowa Hakko Kirin Company, Limited||Completed|March 2006|||March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|107|||Both|20 Years|74 Years|No|||August 2012|August 23, 2012|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364468||179625|
NCT00364728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561701025|Efferocytosis and Genomic Polymorphism in Autoimmune Diseases|Efferocytosis (Clearance of Apoptotic Cells by Phagocytosis) and Autoimmune Diseases in Human||National Taiwan University Hospital|No|Recruiting|January 2006|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|450|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Taiwan autoimmune diseases case control study|May 2010|May 20, 2010|August 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00364728||179605|
NCT00364702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45/04|Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder|Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder||Shaare Zedek Medical Center||Completed|August 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|40|||Both|10 Years|20 Years|Accepts Healthy Volunteers|||July 2006|August 16, 2011|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00364702||179607|
NCT00364715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561702012|Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer|Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer||National Taiwan University Hospital||Completed|January 2005|December 2005||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|26 Years|85 Years|No|||August 2006|August 16, 2006|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00364715||179606|
NCT00350051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91500|ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer|Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer||Bayer|No|Completed|August 2006|December 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Male|18 Years|N/A|No|||December 2014|December 2, 2014|July 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00350051||180702|
NCT00350389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350855|VISIBLE Study (Visual Intervention Strategy Incorporating Bifocal & Long-distance Eyewear)|Randomised Controlled Falls Prevention Trial of Plain Distance Glasses in Elderly Multifocal Wearers.|VISIBLE|The University of New South Wales|Yes|Completed|June 2005|December 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|606|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00350389||180677|
NCT00366275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17165|Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma|Phase II of Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Patients With Relapsed or Refractory Follicular Lymphoma||IRCCS Policlinico S. Matteo|No|Completed|January 2002|September 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|60 Years|No|||October 2012|October 26, 2012|August 17, 2006||No||No|February 18, 2009|https://clinicaltrials.gov/show/NCT00366275||179490|
NCT00366925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ada-UC-05-102|CESA 5.10 Investigation to Compare the Efficacy and Safety of the Adacolumn® Apheresis Device in Patients With Active Ulcerative Colitis|Randomized Controlled Multicenter Investigation to Compare the Efficacy and Safety of Adacolumn® Granulocytes, Monocytes/Macrophage Apheresis Device, 5 Versus 10 Treatments, in Patients With Active Ulcerative Colitis||Otsuka Frankfurt Research Institute GmbH||Completed|April 2006|July 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|174|||Both|18 Years|75 Years||||April 2009|April 27, 2009|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00366925||179440|
NCT00362960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-866/29|Olmesartan Medoxomil and Diabetic Nephropathy|Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy||Daiichi Sankyo Inc.||Completed|May 2003|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|30 Years|N/A|No|||August 2006|October 6, 2006|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00362960||179737|
NCT00362973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6213|PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer|Early Assessment of Response to Targeted Breast Cancer Therapy||University of Washington||Completed|May 2006|||November 2009|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Actual|42|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|August 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362973||179736|
NCT00363233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04DZ14007|The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus|The Effects of Flax Lignans on Lipid Profile and Glucose Management in Type 2 Diabetes: a Randomized Double-Blind Cross-Over Study||Chinese Academy of Sciences||Completed|March 2006|December 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|50 Years|79 Years|No|||January 2007|January 8, 2007|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363233||179718|
NCT00363246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E4460-R|Characterizing Wheelchair-Related Falls in Elderly Veterans|Characterizing Wheelchair-Related Falls in Elderly Veterans||VA Office of Research and Development|Yes|Completed|June 2007|December 2012|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|766|||Both|62 Years|N/A|No|Probability Sample|Elderly wheelchair users|July 2015|July 27, 2015|August 10, 2006||No||No|June 5, 2015|https://clinicaltrials.gov/show/NCT00363246||179717|
NCT00367159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3490|Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children|Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children||University Hospital, Strasbourg, France|No|Recruiting|January 2007|February 2021|Anticipated|August 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|3 Years|15 Years|No|||February 2009|February 24, 2009|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367159||179422|
NCT00367133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-105|Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema|A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema|IVT|Diabetic Retinopathy Clinical Research Network|Yes|Completed|July 2004|October 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|840|||Both|18 Years|N/A|No|||March 2011|March 18, 2011|August 3, 2006|Yes|Yes||No|July 14, 2009|https://clinicaltrials.gov/show/NCT00367133||179424|
NCT00367146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH3474MMF|MMF After Pediatric Liver Transplantation|||Hannover Medical School|No|Completed|November 2004|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|17 Years|No|||July 2007|May 19, 2011|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367146||179423|
NCT00367523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906189|Pulmonary Hypertension in Patients With Sickle Cell Disease in Nigeria|Prevalence of Secondary Arterial Hypertension (PAH) in Patients With Sickle Cell Disease in Nigeria and the Role of HIV/AIDS and Endemic Parasitic Infections in the Natural History of Pulmonary Hypertension in Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2006|||||N/A|Observational|N/A|||Anticipated|1000|||Both|5 Years|N/A|No|||October 2015|October 17, 2015|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367523||179395|
NCT00367497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-40|Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma|Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma||Keio University||Terminated|August 2005|November 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|69 Years|No|||November 2007|November 19, 2007|August 22, 2006|||The stopping rule was applied because of low response rates.|No||https://clinicaltrials.gov/show/NCT00367497||179396|
NCT00363168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001650|Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial|Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial||Johns Hopkins University|No|Completed|August 2006|May 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|7|||Both|50 Years|N/A|No|||September 2012|September 18, 2012|August 9, 2006|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT00363168||179723|
NCT00365456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-001-IM|Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)|An Open Label, International, Multi Centre, Parallel Group, Phase III b, Randomised Trial, Investigating Lumbar Spine Bone Mineral Density (BMD) Changes in Postmenopausal Women With Primary Osteoporosis Initially Treated With 12 Months of Full Length Parathyroid Hormone (PTH 1-84) Followed by 12 Months of Treatment With Risedronate Followed by Either 12 Months Treatment With PTH (1-84) or Risedronate.|PEAK|Takeda|Yes|Completed|July 2006|August 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|407|||Female|50 Years|N/A|No|||August 2012|August 16, 2012|August 9, 2006||No||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00365456||179551|
NCT00364273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2F104300|GSK159802 In Healthy Male Subjects And Asthmatics|A Randomised, Double-Blind, Placebo Controlled Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Dry Powder Doses of GSK159802 in Healthy Male Subjects and Asthmatics||GlaxoSmithKline||Completed|August 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||45|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 15, 2009|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364273||179640|
NCT00364481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYEE IRB 06.06|Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome|Effectiveness of Tongue Exercises and Laryngopharyngeal Reflux Therapy on Upper Airway Resistance Syndrome||West Side ENT||Withdrawn|August 2006|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|August 11, 2006||No|Not enough subjects enrolled|No||https://clinicaltrials.gov/show/NCT00364481||179624|
NCT00364494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS/URC/ER/mm 556/DG|Hemodilution and Outcome in Cardiac Surgery|Effect of Moderate Hemodilution During Cardiopulmonary Bypass on Postoperative Outcome Following Cardiac Surgery||Università Vita-Salute San Raffaele|Yes|Terminated|November 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||||||Both|18 Years|N/A|No|||August 2009|August 13, 2009|August 11, 2006||No|difficult enrollment after the primary investigator left the centre|No||https://clinicaltrials.gov/show/NCT00364494||179623|
NCT00364507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGF1-HMO-CTIL|Serum Levels of Insulin- Like Growth Factor and Fertility|Serum Levels of Insulin-Like Growth Factor in Fertile and Infertile Women Over 40 Years Old||Hadassah Medical Organization||Not yet recruiting|January 2007|December 2007|Anticipated|||Phase 0|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Anticipated|60|||Female|40 Years|55 Years|Accepts Healthy Volunteers|||August 2006|August 14, 2006|August 14, 2006||||No||https://clinicaltrials.gov/show/NCT00364507||179622|
NCT00364234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 DK74105 (completed)|Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD|Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|May 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|65 Years|No|||April 2015|April 13, 2015|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364234||179643|
NCT00365365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_00714|Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer|A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab ± Trastuzumab for the Adjuvant Treatment of Patients With Node-Positive & High-Risk Node-Negative Breast Cancer||Sanofi|Yes|Completed|August 2006|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|214|||Female|18 Years|N/A|No|||January 2012|August 16, 2012|August 16, 2006|Yes|Yes||No|August 16, 2012|https://clinicaltrials.gov/show/NCT00365365||179558|The study was originally designed to last for 6-10 years. Based on a protocol amendment, the study was shortened to about 3 years, and the endpoint Overall Survival (OS) was deleted.
NCT00365378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-005|Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)|Study of Pilot Manufacturing Lot of HPV 16 Virus-Like Particle (VLP) Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females||Merck Sharp & Dohme Corp.|No|Completed|September 1999|July 2009|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2409|||Female|16 Years|23 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|August 16, 2006|Yes|Yes||No|March 22, 2010|https://clinicaltrials.gov/show/NCT00365378||179557|Of note, the number of subjects reported in the results posting is slightly different than that specified in the publication by Koutsky, et al (2002). The data provided here is based on final data.
NCT00364741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001710-32|Supplemental Oxygen and Complications After Abdominal Surgery (The PROXI-trial)|PeRioperative OXygen Fraction - Effect on Surgical Site Infection and Pulmonary Complications After Abdominal Surgery (The PROXI-trial)||Rigshospitalet, Denmark|Yes|Completed|October 2006|November 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1400|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|August 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00364741||179604|
NCT00365677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|441|A Study to Investigate the Safety and Effectiveness of Aspheric Laser Refractive Surgery Treatments for Myopia|Compare the Safety and Effectiveness of Two Versions of the Bausch & Lomb Zyoptix™ Tissue Saving Aspheric Algorithm to the Current Zyoptix™ Tissue Saving Algorithm When Used for Myopia and Myopic Astigmatism Lasik Treatment||Bausch & Lomb Incorporated|No|Completed|October 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|June 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00365677||179535|
NCT00351195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|etoxel-01-2005|Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)|A Phase II Study of Etoposide, Oxaliplatin and Capecitabine in Patients With Advanced HCC||Rigshospitalet, Denmark||Terminated|February 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|75 Years|No|||August 2008|August 25, 2008|July 11, 2006|||Did not meet the criteria for continuation to second stage|No||https://clinicaltrials.gov/show/NCT00351195||180617|
NCT00350701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1911|Effect of Androgel on Type 2 Diabetic Males With Hypogonadism|Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism||Kaleida Health|No|Active, not recruiting|July 2006|July 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|3||Anticipated|36|||Male|35 Years|75 Years|No|||December 2012|December 17, 2012|July 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00350701||180654|
NCT00350987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB87/06|Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The "ProHOSP" Study|Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The "ProHOSP" Study||University Hospital, Basel, Switzerland||Completed|October 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1002|||Both|18 Years|N/A|No|||September 2008|September 22, 2008|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00350987||180633|
NCT00367198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060587|Protein Supplementation in Dialysis Patients|Protein Supplementation in Dialysis Patients||Vanderbilt University|No|Terminated|August 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|August 18, 2006||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00367198||179419|
NCT00362986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N05C4|Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash]||Alliance for Clinical Trials in Oncology|No|Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|116|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362986||179735|
NCT00363259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV01-01|Pegintron Induction Therapy in HCV Non-Responders|Pegintron Induction Therapy in Previous Non-Responders With Chronic HCV: A Dutch Multicenter Randomized Controlled Trial. (PIT-Study)||Foundation for Liver Research||Completed|July 2002|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|18 Years|70 Years|No|||August 2006|August 10, 2006|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363259||179716|
NCT00363272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01828|Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma|A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS||National Cancer Institute (NCI)||Completed|June 2006|||October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|1 Year|21 Years|No|||January 2013|January 15, 2013|August 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00363272||179715|
NCT00367172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA013805|Directly Observed Antiretroviral Therapy Among Active Drug Users|Directly Observed Antiretroviral Therapy Among Active Drug Users||Yale University|Yes|Completed|June 2001|December 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||125|||Both|18 Years|65 Years|No|||August 2009|August 3, 2009|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367172||179421|
NCT00367185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFM 99-06|Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma|Comparison of Melphalan-Prednisone(MP),MP-THALIDOMIDE,and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma.||University Hospital, Lille||Completed|May 2000|October 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|65 Years|75 Years|No|||April 2006|August 21, 2006|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367185||179420|
NCT00362921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004127|Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme|Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme||Duke University|No|Completed|April 2004|July 2008|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||February 2013|July 9, 2014|August 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362921||179740|
NCT00362934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF0242780-01 05 03|Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin|A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With Atorvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 10 mg Atorvastatin Alone||Solvay Pharmaceuticals||Completed|October 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|516|||Both|18 Years|75 Years|No|||July 2009|July 7, 2009|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00362934||179739|
NCT00363207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STDI-HMO-CTIL|Behavior of Children Related to Numbness After Dental Local Anesthesia|Behavior of Children in the Following Appointment Related to Numbness Perception After Dental Local Anesthesia||Hadassah Medical Organization|Yes|Completed|May 2007|May 2008|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|100|||Both|4 Years|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|children receiving routine dental treatment at the hadassah school of dental medicine|April 2007|May 19, 2008|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00363207||179720|
NCT00363467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14604|Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation|A Pilot Study of Intravenous, Targeted-Dose Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk AML||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|May 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|56 Years|74 Years|No|||August 2011|August 24, 2011|August 10, 2006||No|Low accrual|No|August 9, 2010|https://clinicaltrials.gov/show/NCT00363467||179700|Two patients enrolled and transplanted out of 24 targeted transplant accrual goal. Due to poor enrollment study closed and no further analyses were conducted.
NCT00363181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1DMC-X280|Side Effects of Antipsychotic Medications|Does Olanzapine Inhibit the Secretory Response to Insulin Resistance?||Stanford University||Recruiting|April 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||120|||Both|30 Years|66 Years|No|||March 2007|March 19, 2007|August 9, 2006||||No||https://clinicaltrials.gov/show/NCT00363181||179722|
NCT00363194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG10005|A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients|An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Single Doses of Pazopanib in Cancer Patients||GlaxoSmithKline||Completed|September 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|21 Years|N/A|No|||March 2010|March 17, 2010|August 11, 2006||||||https://clinicaltrials.gov/show/NCT00363194||179721|
NCT00363454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14675|Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer|Phase I Pharmacokinetic and Pharmacodynamic, Open-Label, Dose Escalation Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer Which Have Activated Akt Demonstrated by Immunohistochemistry||Prescient Therapeutics, Ltd.|Yes|Completed|April 2006|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363454||179701|
NCT00365755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-ENSG-5|Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma|Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year||National Cancer Institute (NCI)||Completed||March 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|1 Year|18 Years|No|||March 2008|August 1, 2013|August 16, 2006||||No||https://clinicaltrials.gov/show/NCT00365755||179529|
NCT00365742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00005390-Chestnut Hill Hosp|Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements|Simvastatin Vs Therapeutic Lifestyle Changes and Supplements: A Primary Prevention Randomized Trial||Chestnut Hill Health System||Completed|April 2006|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2006|August 16, 2006|August 16, 2006||||No||https://clinicaltrials.gov/show/NCT00365742||179530|
NCT00364520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0037|Molecular Epidemiology of Benzene-exposed Workers.|Molecular Epidemiology of Benzene-exposed Workers in Shanghai,China||University of Colorado, Denver|No|Completed|August 2003|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2000|||Both|18 Years|67 Years|Accepts Healthy Volunteers|Non-Probability Sample|Shanghai Workers|May 2007|May 19, 2015|August 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00364520||179621|
NCT00364780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL647-201|Study of XL647 in Subjects With Non-Small-Cell Lung Cancer|A Phase 2 Study of XL647 in Subjects With Non-Small-Cell Lung Cancer||Kadmon Corporation, LLC|Yes|Completed|July 2006|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|August 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364780||179601|
NCT00364793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-922|Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children|An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age.||Bristol-Myers Squibb|No|Completed|February 2007|July 2013|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|56|||Both|3 Months|6 Years|No|||April 2014|April 11, 2014|August 15, 2006|No|Yes||No|March 6, 2014|https://clinicaltrials.gov/show/NCT00364793||179600|
NCT00364754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB1002 202|Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer|A PHARMACOKINETIC INTERACTION PHASE I, MULTI-CENTRE, OPEN-LABEL, CROSS-OVER Study Evaluating the Effect of Tesmilifene on the Plasma Pharmacokinetics of Epirubicin and Cyclophosphamide in Patients With Metastatic/Recurrent Breast Cancer||YM BioSciences||Completed|May 2004|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|55 Years|No|||April 2014|April 18, 2014|August 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364754||179603|
NCT00365027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5040706|Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.|||HaEmek Medical Center, Israel||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|N/A|No|||September 2015|September 3, 2015|August 15, 2006|||Enrollment difficulties|No||https://clinicaltrials.gov/show/NCT00365027||179582|
NCT00365040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWMC|Customized PRK With Mitomycin Versus Customized Lasik for Myopic Astigmatism|Customized PRK With Mitomycin Versus Customized Lasik for Myopic Astigmatism||Federal University of São Paulo||Completed|December 2004|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2006|August 15, 2006|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00365040||179581|
NCT00365053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02839|PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery|Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Completed|June 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2013|December 17, 2014|August 16, 2006|Yes|Yes||No|July 9, 2014|https://clinicaltrials.gov/show/NCT00365053||179580|
NCT00365391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00136|Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer|Phase II Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer (HCC)||National Cancer Institute (NCI)||Completed|August 2006|June 2010|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||March 2013|June 10, 2015|August 16, 2006|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00365391||179556|
NCT00365690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078749|Effectiveness of a Telephone-Delivered Behavioral Treatment to Improve the Quality of Life of Older Adults With HIV|Telephone-Delivered Coping Improvement Intervention for HIV Infected Older Adults||Ohio University|Yes|Completed|February 2007|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|360|||Both|50 Years|N/A|No|||May 2013|May 6, 2013|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365690||179534|
NCT00365404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01802-03-C|Activity, Rheumatoid and Osteoarthritis, and Weight Management|Weight Management, Physical Activity, Less Disability in Rheumatoid and Osteoarthritis||HealthPartners Institute||Completed|October 2003|February 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind||||465|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2006|November 25, 2015|August 16, 2006||||No||https://clinicaltrials.gov/show/NCT00365404||179555|
NCT00351000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2005|Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus|An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia||North Suffolk Mental Health Association||Completed|January 2005|March 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|July 11, 2006||||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00351000||180632|The sample size in this study may not have been adequate to demonstrate the effectiveness of ziprasidone as an adjuvant therapy. The receptor-binding profile of ziprasidone may not significantly counteract the mechanisms of metabolic disturbances.
NCT00366938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2360|Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).|A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator||Novartis||Completed|September 2003|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1464|||Both|18 Years|N/A||||May 2012|May 18, 2012|August 18, 2006||||||https://clinicaltrials.gov/show/NCT00366938||179439|
NCT00367224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB3701|Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo|Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo||Henry Ford Health System|No|Completed|January 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|N/A|||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 28, 2009|August 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367224||179417|
NCT00367237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04422|Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)|A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis||Merck Sharp & Dohme Corp.|No|Completed|May 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|August 18, 2006||No||No|March 19, 2009|https://clinicaltrials.gov/show/NCT00367237||179416|
NCT00363545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107077|To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)|A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Bio Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV||GlaxoSmithKline||Completed|September 2006|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1270|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2012|November 21, 2012|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00363545||179695|
NCT00364052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL109|Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients|Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients: A Single Center Experience With Oral Ganciclovir Versus Valganciclovir||Oregon Health and Science University||Not yet recruiting|August 2006|January 2007||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||200|||Both|18 Years|80 Years|No|||August 2006|August 16, 2006|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364052||179656|
NCT00363506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHR-757962-7081|American Migraine Prevention Study|Nutritional Based Protocol to Balance Serotonin for the Prevention or Reduced Frequency/Duration/Intensity of Migraines||Dynamic Health Resources||Recruiting|January 2006|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|1000|||Both|18 Years|72 Years|No|||April 2008|April 22, 2008|August 9, 2006||||No||https://clinicaltrials.gov/show/NCT00363506||179698|
NCT00363519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5435-09|Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus|MK-0431/ONO-5435 Phase III Clinical Study - Glimepiride add-on Study for Patients With Type 2 Diabetes Mellitus||Ono Pharmaceutical Co. Ltd||Completed|August 2006|||January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|195|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00363519||179697|
NCT00362947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Steflux study|Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis|Randomized Clinical Study of Different Treatment Doses and Duration of Low Molecular Weight Heparin (Parnaparin) in Superficial Vein Thrombosis||St. Orsola Hospital||Completed|August 2006|February 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|664|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00362947||179738|
NCT00363220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0607059|Community - Associated Extended-spectrum Beta-lactamases (ESBL)|Community - Associated Extended-spectrum Beta-lactamases (ESBL)||University of Pittsburgh|Yes|Completed|August 2006|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|N/A|N/A|No|Non-Probability Sample|ESBL infections|December 2015|December 16, 2015|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00363220||179719|
NCT00363701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice|With-Drawal Study of Proton-Pump-Inhibitors in Patients From Primary Care Who Have Previously Been Treated on a Long-Term Basis||Glostrup University Hospital, Copenhagen||Recruiting|August 2006|February 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||August 2006|August 14, 2006|August 14, 2006||||No||https://clinicaltrials.gov/show/NCT00363701||179683|
NCT00363974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-103|Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML|An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy||Aegera Therapeutics|No|Completed|October 2005|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||November 2009|November 30, 2009|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363974||179662|
NCT00363714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRNA 0401|A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|||Allergan||Completed|November 2004|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|26|||Both|50 Years|N/A|No|||August 2008|August 14, 2008|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363714||179682|
NCT00365482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.02.029|Bipolar Disorder in Epilepsy|Bipolar Disorder in Epilepsy||Northwell Health|No|Completed|August 2006|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|N/A|No|Non-Probability Sample|Epilepsy patients at the Long Island Jewish Comprehensive Epilepsy Center|May 2012|May 15, 2012|August 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00365482||179549|
NCT00366002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328A2404|Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder|A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy||Novartis||Completed|June 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|18 Years|N/A||||January 2008|January 14, 2008|August 17, 2006||||||https://clinicaltrials.gov/show/NCT00366002||179510|
NCT00364767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P5805|Moderate Alcohol Consumption, Fat and Carbohydrate Metabolism and Insulin Sensitivity|The Effect of Moderate Alcohol Consumption on Markers of Oxidative Phosphorylation and Lipid Oxidation and on Postprandial Glycemic Control in Healthy, Lean and Overweight, Young Men||TNO|Yes|Completed|October 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|19|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2008|May 22, 2008|August 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00364767||179602|
NCT00365716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-007|Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)|A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women||Merck Sharp & Dohme Corp.||Completed|May 2000|September 2009|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|1158|||Female|16 Years|23 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|August 16, 2006|Yes|Yes||No|May 19, 2010|https://clinicaltrials.gov/show/NCT00365716||179532|
NCT00365950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS DVT/PE Study|3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE|Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism||British Thoracic Society||Completed|September 1999|December 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2400|||Both|18 Years|N/A|No|||January 2004|August 17, 2006|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00365950||179514|
NCT00365963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-191X|Web-based Intervention for Lung Cancer Patients and Their Informal Caregivers|Clinician Integration Study||University of Wisconsin, Madison||Completed|April 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|252|||Both|18 Years|110 Years|No|||February 2016|February 3, 2016|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365963||179513|
NCT00366288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3186A1-100|Study Evaluating PAZ-417 in Healthy Young/Elderly|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAZ-417 Administered Orally to Healthy Young and Healthy Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|March 2008|Actual|March 2008|Actual|Phase 1|Observational|Observational Model: Cohort||7|Anticipated|56|Samples With DNA|plasma and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of a certain town|July 2009|July 8, 2009|August 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00366288||179489|
NCT00350402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS050633|Masked Faces in Parkinson Disease: Mechanism and Treatment|Masked Faces in Parkinson Disease: A Randomized Double-blind Sham-treatment Controlled Clinical Trial of High Intensity Respiratory Muscle Strength Training (MST) for Treatment of Reduced Facial Expression in Parkinson Disease||University of Florida|Yes|Completed|December 2004|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|45 Years|80 Years|No|||April 2012|April 4, 2012|July 5, 2006||No||No|February 6, 2012|https://clinicaltrials.gov/show/NCT00350402||180676|
NCT00350415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006444|A Double Blind Study for the Treatment of Acute Ulcerative Colitis|A Double-blind, Randomized, 6-week, Parallel-group Design Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day for the Treatment of Moderately Active Ulcerative Colitis.||Warner Chilcott|No|Completed|June 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|772|||Both|18 Years|75 Years|No|||April 2013|April 15, 2013|July 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00350415||180675|
NCT00351013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFT2006/2|The Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities|A Pilot Study of the Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities||Malamed|Yes|Completed|June 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Actual|731|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 3, 2009|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351013||180631|
NCT00363285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000495321|Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer|Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer||National Cancer Institute (NCI)||Recruiting|January 2003|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|900|||Male|N/A|79 Years|No|||October 2006|August 23, 2013|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363285||179714|
NCT00363558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4133|Fixation of Skin Grafts in Patients With Burns: Comparison Between Cyanoacrylate Glue and Skin Staples|Fixation of Skin Grafts in Patients With Burns: Comparison Between Cyanoacrylate Glue and Skin Staples||Rabin Medical Center||Completed|January 2002|May 2003||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||44|||Both|N/A|N/A|No|||May 2003|August 10, 2006|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363558||179694|
NCT00364078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0601|Transitoriness in Cancer Patients, Psychosocial Issues in Cancer Care|Transitoriness in Cancer Patients: a Cross-Sectional Study of Uncertainty, Locus of Control, Quality of Life and Existentials Views on Finality of Life in Cancer Patients||Sidney Kimmel Comprehensive Cancer Center|No|Completed|June 2006|August 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|193|||Both|21 Years|N/A|No|Probability Sample|Patients of the Johns Hopkins University Medical Institutions|May 2008|May 19, 2008|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364078||179654|
NCT00364091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003-09|Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis||Vistakon Pharmaceuticals||Completed|August 2006|||October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|365|||Both|10 Years|N/A|No|||September 2011|September 26, 2011|August 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364091||179653|
NCT00363532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060083|Functional MRI (fMRI) in CGRP Induced Migraine|Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by||Danish Headache Center||Completed|September 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|55 Years|No|||January 2009|January 27, 2009|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00363532||179696|
NCT00363740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR100652|Study of GW685698X In Patients With Seasonal Allergic Rhinitis|Clinical Evaluation of GW685698 for Seasonal Allergic Rhinitis -A Placebo-controlled Study to Determine the Non-inferiority of GW685698 Over Fluticasone Propionate Using a Double-blind Manner-||GlaxoSmithKline||Completed|February 2005|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|38|||Both|16 Years|N/A|No|||May 2012|April 11, 2013|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00363740||179680|
NCT00363753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB #060452|Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack|Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack||University of California, San Diego||Withdrawn|August 2006|March 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||20|||Both|18 Years|N/A|No|||March 2007|March 30, 2007|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363753||179679|
NCT00364000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02_2006|Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate|Arterial Stiffness and Arterial Calcifications Evolution in ESRD Haemodialysis Patients Treated by Sevelamer or Calcium Acetate||Romanian Society of Nephrology|Yes|Not yet recruiting|January 2012|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|60 Years|No|||November 2011|November 12, 2011|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00364000||179660|
NCT00364013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050203|PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy|A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer||Amgen|Yes|Completed|August 2006|March 2013|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1183|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|August 10, 2006|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT00364013||179659|
NCT00364026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol DAR-201|A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs|A Phase II Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-201)||Gilead Sciences||Completed|June 2004|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|35 Years|85 Years|No|||August 2006|January 17, 2007|August 10, 2006||||||https://clinicaltrials.gov/show/NCT00364026||179658|
NCT00363480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM 106538|Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data|Reaching Asthma Control With Salmeterol/Fluticasone 50/250 µg bd Combination in Steroid Naive or Low Dose Inhaled Corticoid Steroid Patients by Using Asthma Control Test (ACT) Comparison of Patient Self Rating With Diary Card Data.||GlaxoSmithKline|No|Completed|May 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|250|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363480||179699|
NCT00363727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/228|Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's|A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.||GlaxoSmithKline|No|Completed|December 2003|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|209|||Both|30 Years|70 Years|No|||April 2015|April 13, 2015|August 7, 2006||||||https://clinicaltrials.gov/show/NCT00363727||179681|
NCT00366015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-158|Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room|Same Procedure Cardiac Hybrid Surgery in a Specialty Built OR-- A Pilot Study||Lawson Health Research Institute|No|Recruiting|August 2003|June 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|30 Years|85 Years|No|||August 2011|August 3, 2011|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00366015||179509|
NCT00365092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD042080|Middle Ear Disease Before Age 3, Treatment With Ear Tubes, and Literacy and Attentional Abilities at Ages 9 to 11|Early Otitis and Literacy and Attention at 9 to 11 Years||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|April 2002|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||400|||Both|N/A|61 Days|Accepts Healthy Volunteers|||August 2006|August 15, 2006|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00365092||179579|
NCT00365105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0517|Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer|Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|July 2006|||January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|261|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|August 16, 2006|Yes|Yes||No|November 3, 2014|https://clinicaltrials.gov/show/NCT00365105||179578|This study stopped accrual early with 261 accrued out of 352 planned, due to a lower than expected rate of skeletal related events in the control arm.
NCT00365118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-278867|Treatment of Naevus Flammeus Using Intense Pulsed Light and Pulsed Dye Laser|||Bispebjerg Hospital||Completed|November 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|2 Years|N/A||||June 2008|June 2, 2008|August 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00365118||179577|
NCT00365417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-4|Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer|A Phase II Clinical Trial of Bevacizumab Beginning Concurrently With a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy Followed by Postoperative Bevacizumab Alone for Women With Locally Advanced Breast Cancer||NSABP Foundation Inc|No|Completed|August 2006|November 2009|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|August 15, 2006|Yes|Yes||No|August 21, 2009|https://clinicaltrials.gov/show/NCT00365417||179554|
NCT00365430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SoS245119|SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes|SAFE or SORRY? Development and Testing of an Evidence Based Inpatient Safety Program for the Prevention of Common Complications.||Radboud University|Yes|Completed|September 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 22, 2009|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365430||179553|
NCT00365729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 KI 0211|Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men|Evaluation of Viral Load Determination and Other Biomarkers of High Risk HPV-Types as a Marker for Progression of Perianal HPV-infections in HIV-positive Men Who Have Sex With Men||Deutsche Luft und Raumfahrt||Recruiting|October 2003|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Anogenital smears|Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|HIV-positive men who have sex with men|January 2016|January 20, 2016|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365729||179531|
NCT00365976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011697|Study of the Insomnia in Patients With Low Back Pain|Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain||Duke University|No|Completed|August 2006|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|21 Years|64 Years|No|||June 2015|July 2, 2015|August 16, 2006|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00365976||179512|We obtained only self-reported sleep outcomes.The period of double-blind treatment was relatively short.We excluded all subjects who might have required opioid therapy to manage their pain which limits study generalizability.
NCT00350714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBVH-0706|BreathID Multi-center HCV Liver Breath Test Study|Validation of a Breath Test for Assessment of Liver Fibrosis in Patients With Chronic Hepatitis C Viral Infection||Exalenz Bioscience LTD.|No|Terminated|July 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|No|||June 2011|June 19, 2011|July 10, 2006||No|Due to FDA comments, protocol changed; new trial will be proposed shortly|No||https://clinicaltrials.gov/show/NCT00350714||180653|
NCT00350727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG102857|Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma|Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma|VEG102857|GlaxoSmithKline|No|Completed|December 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||May 2012|April 11, 2013|July 10, 2006|No|Yes||No|December 26, 2010|https://clinicaltrials.gov/show/NCT00350727||180652|
NCT00351026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA021073|Methadone Maintenance & HIV Risk in Ukraine|Methadone Maintenance & HIV Risk in Ukraine||University of Pennsylvania|Yes|Completed|June 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|July 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00351026||180630|
NCT00363792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060085|Effect of GTN and Diamox Measured by BOLD-Response.|The Effect of Glyceryl Trinitrate and Diamox on Blood-Oxygenation-Level-Dependent.Signal (BOLD-Signal) and Cerebral Haemodynamics With the Use of a 3-Tesla MRI-Scan.||Danish Headache Center||Recruiting||May 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2006|August 11, 2006|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00363792||179676|
NCT00364104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-06-0374|Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children|Randomized Field Intervention Trial of H. Pylori Eradication to Reduce Iron Deficiency Among Children in El Paso, Texas|HEIDC|The University of Texas Health Science Center, Houston|Yes|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|125|||Both|36 Months|120 Months|Accepts Healthy Volunteers|||June 2009|June 26, 2009|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364104||179652|
NCT00363779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060177|Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia|Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia||National Institutes of Health Clinical Center (CC)|No|Terminated|June 2006|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|August 10, 2006||No|Study terminated due to low accrual and the investigator left the NIH.|No|March 30, 2012|https://clinicaltrials.gov/show/NCT00363779||179677|As there were only 5 patients treated, the primary endpoints of this protocol were not met and there is not enough data generated for statistical analysis. This protocol is being terminated due to low accrual and the investigator leaving the NIH.
NCT00364312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK062942|Lifestyle Interventions for Long Term Diabetes Control|Improving Control With Activity and Nutrition||University of Virginia||Active, not recruiting|May 2004|December 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||390|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2006|August 11, 2006|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364312||179637|
NCT00363766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9813|Study of LY573636 in Patients With Metastatic Non-Small Cell Lung Cancer|A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|September 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||October 2009|October 16, 2009|August 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363766||179678|
NCT00364039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV650-012|Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650|A Phase 1 Double-Blind, Placebo-Controlled Single Center Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Dose and Multiple Dose Escalations of AV650 in Healthy Subjects||Avigen||Completed|August 2006|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind||||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|August 14, 2006||||||https://clinicaltrials.gov/show/NCT00364039||179657|
NCT00364299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS 020744|Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure|Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure||Hospital Clinic of Barcelona||Completed|October 2002|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||142|||Both|18 Years|N/A|No|||May 2006|October 19, 2006|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364299||179638|
NCT00364832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA16286|A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.|A Randomized, Open-label Study of Dose Conversion Factors for Maintenance Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia||Hoffmann-La Roche||Completed|October 2001|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|137|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|August 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364832||179597|
NCT00364286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0497|Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)|Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)||M.D. Anderson Cancer Center|No|Completed|August 2006|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|N/A|No|||June 2013|June 12, 2013|August 14, 2006|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00364286||179639|
NCT00364533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011221|A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|October 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|367|||Both|18 Years|80 Years|No|||April 2014|April 3, 2014|August 11, 2006|Yes|Yes|Slow enrollment|No|December 19, 2008|https://clinicaltrials.gov/show/NCT00364533||179620|Sponsor terminated study, sample size not reached. The protocol section describes 4 study arms defining the treatment groups in the study design. The participant flow module describes the 5 treatment groups analyzed for the primary endpoint
NCT00365768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6806|Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors|A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer||Columbia University|Yes|Completed|October 2004|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|56|||Both|5 Years|21 Years|No|||February 2014|February 3, 2014|August 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00365768||179528|
NCT00366028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMV 04-055|Increasing Evidence-based Clinical Practices in VA|Strengthening Organization to Implement Evidence-based Clinical Practice||VA Office of Research and Development|No|Completed|January 2006|January 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|1624|||Both|N/A|N/A|No|||May 2014|April 6, 2015|August 16, 2006||No||No|June 6, 2014|https://clinicaltrials.gov/show/NCT00366028||179508|
NCT00366392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI-05-001|Project Magnify - A Comparison of Two Strategies to Improve Reading Ability|Project Magnify - A Comparison of Two Strategies (Large Print Versus Optical Aids) for Helping Visually Impaired Students Improve Reading Abilities||Medical University of South Carolina||Completed|May 2005|July 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|5 Years|17 Years|No|||July 2006|October 2, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366392||179481|
NCT00366704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3168A1-313|Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint|A Multicenter, Randomized, Double-blind, Parallel-group Fixed-dose Study of the Effect on Weight of Bifeprunox Versus Risperidone in the Treatment of Outpatients With Schizophrenia.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|November 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|65 Years|No|||April 2008|February 7, 2013|August 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366704||179457|
NCT00365989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF018|MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication|A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques||InSightec||Completed|October 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 13, 2012|August 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00365989||179511|
NCT00365443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V502-003|Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)|Proprietary Information - Exploratory (Non-Confirmatory) Trial||Merck Sharp & Dohme Corp.||Withdrawn|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|0|||Female|16 Years|26 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|August 16, 2006||||No||https://clinicaltrials.gov/show/NCT00365443||179552|
NCT00366626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AA010761|Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.|Alcohol Research Center Grant. Component #1: Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response||Medical University of South Carolina|Yes|Completed|April 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|21 Years|65 Years|No|||November 2012|November 2, 2012|August 17, 2006||No||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00366626||179463|
NCT00366951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA#: 03111102|A Randomized Study on Comparing the Efficacy of Foley Catheter and Extraamniotic Saline Infusion for Labor Induction|A Randomized Clinical Trial Comparing the Efficacy and Safety of Foley Catheter Balloon With Oxytocin and Extraamniotic Saline Infusion (EASI) With Oxytocin for Induction of Labor Requiring Cervical Ripening||Rush University Medical Center||Completed|April 2004|November 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Female|N/A|N/A|No|||December 2007|December 28, 2007|August 18, 2006||||No||https://clinicaltrials.gov/show/NCT00366951||179438|
NCT00350753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-UGI-01|Avastin and Tarceva for Upper Gastrointestinal Cancers|A Phase II Study of Erlotinib and Bevacizumab in Patients With Advanced Upper Gastrointestinal Carcinomas, Refractory or Intolerable to Standard Systemic Therapy||Rigshospitalet, Denmark||Completed|June 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|126|||Both|18 Months|N/A|No|||July 2009|July 14, 2009|July 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00350753||180651|
NCT00351273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AR053646|Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria|Phase 3 Trial to Assess the Efficacy of Long-Term (6 Months) Combination Antibiotics as a Treatment for Chlamydia-Induced Reactive Arthritis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||Completed|May 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|70 Years|No|||January 2009|January 29, 2009|July 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351273||180611|
NCT00351845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203470|Clinical Study to Test the Effects of a Low-Carbohydrate Diet on Body Weight|A Clinical Study to Evaluate the Effect of a Modified Carbohydrate Diet on Body Weight in Overweight or Obese Men and Women||Provident Clinical Research|No|Completed|April 2004|December 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2009|April 21, 2009|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351845||180567|
NCT00363805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000487501|Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease|Chemoprevention of Lung Carcinogenesis Using Green Tea: Phase IIb Randomized, Double-Blinded, Placebo Controlled Trial of Green Tea and Polyphenon E in Former Smokers With Chronic Obstructive Lung Disease (COPD)||University of Arizona||Completed|May 2004|||March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|178|||Both|40 Years|80 Years|No|||September 2013|September 27, 2013|August 10, 2006|Yes|Yes||No|July 2, 2013|https://clinicaltrials.gov/show/NCT00363805||179675|
NCT00363818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3919-MS-CTIL|The Association of Platelet Function and Endothelial Function of the Brachial Artery|The Association Between Platelet Function and Endothelial Function of the Brachial Artery in Healthy Subjects and in Patients With Coronary Artery Disease||Sheba Medical Center|No|Completed|January 2006|March 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|151|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited from the Heart Institute Coronary care Unit and outpatient        clinic|April 2008|April 8, 2008|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00363818||179674|
NCT00364377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002673|Incretins in Impaired Fasting Glucose|The Role of Incretins in the Pathogenesis of Fasting and Postprandial Glucose Metabolism in People With Impaired Fasting Glucose||Mayo Clinic|No|Completed|August 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|35 Years|70 Years|No|||November 2011|November 1, 2011|August 14, 2006|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00364377||179632|
NCT00364338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30-150906-HMO-CTIL|Development of Gourmet Medical Cooking Workshop for Lifestyle Changing and Its Affect on Perimenopausal Women|Development of Gourmet Medical Cooking Workshop for Lifestyle Changing and Its Affect on Perimenopausal Women||Hadassah Medical Organization||Withdrawn|January 2007|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||August 2006|September 20, 2015|August 14, 2006||||No||https://clinicaltrials.gov/show/NCT00364338||179635|
NCT00364351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00057|Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy|A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy||AstraZeneca||Active, not recruiting|August 2006|March 2016|Anticipated|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1574|||Both|18 Years|130 Years|No|||December 2015|December 2, 2015|August 14, 2006|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00364351||179634|
NCT00364065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00003008|Study to Evaluate Ferris PainWrap in the Treatment of Chronic Low Back Pain|A Randomized, Controlled, Double-Blind, Pilot Study to Evaluate Ferris PainWrap, a Semipermeable Hydrophilic Polymeric Membrane, in the Treatment of Chronic Low Back Pain||Pain and Rehabilitation Medicine||Completed|September 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years||||April 2007|April 17, 2007|August 14, 2006||||No||https://clinicaltrials.gov/show/NCT00364065||179655|
NCT00364559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29-09 ROICH|Effect of Rosuvastatin in Intracerebral Hemorrhage|Effect of Rosuvastatin on Outcome by NIHSS After Intracerebral Hemorrhage||Universidad Autonoma de San Luis Potosí||Completed|August 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|75|||Both|16 Years|80 Years|No|||March 2009|March 25, 2009|August 14, 2006||||No||https://clinicaltrials.gov/show/NCT00364559||179618|
NCT00364845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050122|STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients|A Randomised Single-Blind Study to Improve Health-related Quality of Life as Measured by the Short-Form 36 (SF-36) Vitality Score by Correcting Anemia With Aranesp (Darbepoetin Alfa) in the Elderly.||Amgen|No|Terminated|September 2006|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|51|||Both|70 Years|N/A|No|||April 2014|April 23, 2014|August 14, 2006||No|The reason for the discontinuation of the study is difficulty with recruitment and timely    enrolment and is not related to safety concerns|No|December 2, 2010|https://clinicaltrials.gov/show/NCT00364845||179596|
NCT00364546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011212|A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain|A Randomized, Double-Blind, Active-Control, Parallel-Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2006|July 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|877|||Both|18 Years|N/A|No|||April 2010|June 2, 2011|August 11, 2006||||||https://clinicaltrials.gov/show/NCT00364546||179619|
NCT00364819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-14025|Initial Study of Rituximab to Treat Primary Biliary Cirrhosis|Effects of Rituximab (Rituxan) on B Cell and AMA Response in Patients With Primary Biliary Cirrhosis||University of California, Davis|Yes|Completed|January 2007|December 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|65 Years|No|||March 2014|March 4, 2014|August 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364819||179598|
NCT00366405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-06-001|Comparison of the Torsional Handpiece to Conventional Handpiece During Routine Phacoemulsification|Comparison of the Torsional Handpiece to Conventional Handpiece During Routine Phacoemulsification||Medical University of South Carolina|No|Completed|February 2006|September 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|30|||Both|50 Years|N/A|No|Probability Sample|Bilateral senile cataracts. Cataract density up to 3+. 50 years of age or older. Patient        must desire cataract extraction. Expected maximum of 4 weeks and minimum of 1 week        interval between first and second eye surgeries.        Willing and able to comply with scheduled visits and other study procedures.|October 2010|October 1, 2010|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00366405||179480|
NCT00366717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-144|Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy|||Mackay Memorial Hospital||Completed|June 2005|January 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||20|||Both|20 Years|N/A|No|||January 2006|August 18, 2006|August 18, 2006||||No||https://clinicaltrials.gov/show/NCT00366717||179456|
NCT00366366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/075|To Evaluate Immunogenicity & Safety of GSK Bio’s DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines|To Assess Interchangeability b/w GSK Bio’s DTPa-HBV-IPV/Hib (Mixed Vaccine) & DTPa-IPV/Hib + HBV at 3rd Dose of Primary Vaccination Course in Children Who Received HBV Vaccine at Birth & 1 Mth & DTPa-IPV/Hib Vaccine at 3 & 4 Mths of Age||GlaxoSmithKline||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|11 Weeks|17 Weeks|Accepts Healthy Volunteers|||September 2006|October 18, 2006|August 18, 2006||||No||https://clinicaltrials.gov/show/NCT00366366||179483|
NCT00366353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-10|Sedation Versus No Sedation in a Spontaneous Breathing Trial|A Randomized Trial Comparing Sedation Versus No Sedation For Patients Undergoing a Spontaneous Breathing Trial.||Memorial Medical Center|No|Terminated|June 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|August 18, 2006||No|Difficulty obtaining enrollment|No||https://clinicaltrials.gov/show/NCT00366353||179484|
NCT00366964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412776-1|The Efficacy Of The Wavelight Mydon Laser for Hair Removal And Treatment of Leg Veins|Determine The Efficacy Of The Wavelight Mydon Laser For Hair Removal And Treatment of Leg Veins||University of California, Davis|No|Completed|October 2004|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|August 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00366964||179437|
NCT00367289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ctosteolysis-HMO-CTIL|CT for Diagnosis of Implant Stability in Revision Arthroplasty|CT for Diagnosis of Implant Stability in Revision Arthroplasty||Hadassah Medical Organization|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Revision hip and knee arthroplasty patients|August 2006|April 27, 2011|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367289||179412|
NCT00367263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICLE-L-01335|Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary|A Randomized Cross-Over Design Study Evaluating a Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary in Subjects 12 Years and Older With Mild to Moderate Persistent Asthma Receiving Ciclesonide MDI (Alvesco) 80 ug BID||Allergy & Asthma Medical Group & Research Center|No|Completed|October 2006|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|12 Years|N/A|No|||April 2007|April 30, 2007|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367263||179414|
NCT00367276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91070|Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.|A Multicentre, Open, Uncontrolled Study to Assess Quality of Life During Six Cycles (24 Weeks) of Treatment With an Oral Contraceptive Containing 30 µg of Ethinylestradiol and 3 mg of Drospirenone (Yasmin).||Bayer|No|Completed|December 2002|May 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Female|18 Years|35 Years|No|||October 2013|October 10, 2013|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00367276||179413|
NCT00350766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRTCC-IAM|Cell Therapy in Myocardial Infarction|Multicenter Prospective Randomized Double Blind Trial of Bone Marrow Mononuclear Cells Transplantation Through Intracoronary Injection in Patients With Acute Myocardial Infarction.|EMRTCC|Ministry of Health, Brazil|Yes|Recruiting|July 2006|July 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|30 Years|80 Years|No|||August 2006|September 19, 2007|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00350766||180650|
NCT00350779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-052|Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and a PPARg Agonist||Merck Sharp & Dohme Corp.|No|Completed|June 2006|June 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|78 Years|No|||February 2016|February 3, 2016|July 7, 2006|Yes|Yes||No|May 13, 2009|https://clinicaltrials.gov/show/NCT00350779||180649|Non-serious adverse event results represent those events included in the primary safety analysis for this study (events occurred prior to initiation of glycemic rescue therapy). Site 0520039 was non-compliant with GDP, data was removed from analyses.
NCT00351858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBT-IVREXBC 02|Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer|Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer|IV REXBC 02|Neovii Biotech||Terminated|July 2006|February 2009|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|N/A|No|||April 2015|April 30, 2015|July 12, 2006||No|company focus on other projects|No||https://clinicaltrials.gov/show/NCT00351858||180566|
NCT00351871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03851|Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy|Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy||Louisiana State University Health Sciences Center in New Orleans||Completed|April 2002|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|18 Years|70 Years|No|||February 2009|February 3, 2009|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351871||180565|
NCT00364117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.01.052|Remote Presence Timely Discharge Management|Remote Presence Timely Discharge Management||Hackensack University Medical Center||Withdrawn|August 2006|August 2008|Actual|August 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|August 11, 2006||No|No patients were enrolled|No||https://clinicaltrials.gov/show/NCT00364117||179651|
NCT00333840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A 0106|Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia|A Phase III Study of STI571 Versus Interferon-α (IFN-α) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||Novartis||Completed|June 2000|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1106|||Both|18 Years|70 Years|No|||August 2013|August 7, 2013|June 2, 2006|Yes|Yes||No|March 15, 2013|https://clinicaltrials.gov/show/NCT00333840||181900|
NCT00333853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDI 70-97017-17|Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)|Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm) to Improve Glycemic Control Through Behavioral and Therapeutic Changes||LifeScan|No|Completed|August 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||250|||Both|N/A|N/A|No|||May 2008|May 12, 2008|June 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333853||181899|
NCT00364364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0473|Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.|Pharmacokinetics, Biodistribution and Targeting of 111 In- Labeled Humanized PAM4IgG in Pre-Surgical Pancreatic Cancer Patients.An Examination of Protein Dose||Sidney Kimmel Comprehensive Cancer Center||Terminated|May 2007|June 2008|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|9|||Both|21 Years|N/A|No|||December 2008|December 16, 2008|August 14, 2006|||Loss of funding|No||https://clinicaltrials.gov/show/NCT00364364||179633|
NCT00364585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604008494|A Prospective Evaluation of the GreenLight Model 120 Laser|A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia||Weill Medical College of Cornell University||Completed|May 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Male|40 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 16, 2008|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364585||179616|
NCT00364325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005215|Registry for Acute Decompensated Heart Failure Patients Admitted to the ER|Acute Decompensate Heart Failure National Registry ( ADHERE) Emergency Module (EM)||Scios, Inc.||Completed|July 2004|March 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18920|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of all consecutive adults patients seen in the Emergency        department of an acute care hospital and treated actively for Acute Decompensated Heart        Failure (ADHF) where the condition is defined clinically as new onset of Heart Failure        with decompensation or chronic heart failure with decompensation. Patient eligibility is        based upon the presence of a hospital discharge and/or Emergency department diagnosis of        ADHF and is not tied to the use of any specific therapeutic agent or regimen.|April 2010|April 26, 2010|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00364325||179636|
NCT00364572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU#06-20009A|Efficacy of Epidural Etanercept in the Treatment of Sciatica|Efficacy of Epidural Etanercept in the Treatment of Sciatica||Johns Hopkins University|Yes|Completed|May 2006|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||January 2009|January 21, 2009|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00364572||179617|
NCT00365144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491225|Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine|A Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Metastatic Gemcitabine-Refractory Pancreatic Cancer||University of California, San Francisco|Yes|Completed|February 2006|March 2010|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|August 16, 2006|Yes|Yes||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00365144||179575|
NCT00365469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNU01 (Phase II)|Influence of Probiotics on Atopy, Immunological Responses and Gut Microflora - Follow-up to 5 Years|A Follow-up Study to 5 Years of a Randomized, Double-blinded, Placebo-controlled Study on the Influence of Probiotics on Atopy, Immunological Responses and Gut Microflora||National University Hospital, Singapore|Yes|Completed|May 2006|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|253|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 7, 2014|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365469||179550|
NCT00366379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC19800|A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.|An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.||Hoffmann-La Roche||Completed|July 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|127|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|August 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366379||179482|
NCT00366665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-05-002|Comparison of the Performance of the Infiniti Vision and the Series 20000 Legacy Phacoemulsification Systems|Comparison of the Infiniti Vision and the Series 20000 Legacy Systems||Medical University of South Carolina||Completed|March 2005|May 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|50 Years|N/A|No|||May 2005|August 17, 2006|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366665||179460|
NCT00366639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005194|Registry for Acute Decompensated Heart Failure Patients|ADHERE Core III - Acute Decompensated Heart Failure Registry||Scios, Inc.||Completed|October 2001|February 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24118|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive adult patients admitted to an acute care hospital and treated actively for        acute HF, where acute HF is defined clinically as a new onset with HF decompensation|October 2009|October 29, 2009|August 18, 2006||||No||https://clinicaltrials.gov/show/NCT00366639||179462|
NCT00366652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-401|Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects|A Randomized, Open-Label, Crossover, Drug Interaction Study to Evaluate the Effects of DVS SR And Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2007|May 25, 2007|August 17, 2006||||||https://clinicaltrials.gov/show/NCT00366652||179461|
NCT00367302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA020583|Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release|Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release||National Development and Research Institutes, Inc.|No|Completed|August 2006|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367302||179411|
NCT00363025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFA-9803|A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.|A Randomized Multicenter Study of More Intensive Versus Less Intensive Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia (AML) or Transformed Refractory Anemia With Excess Blasts (RAEB-t).||Acute Leukemia French Association||Terminated|November 1999|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||465|||Both|65 Years|N/A|No|||August 2006|February 20, 2008|August 11, 2006||||No||https://clinicaltrials.gov/show/NCT00363025||179732|
NCT00351052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CDE10|Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis|A 24-Week, Randomized, Multicenter, Parallel-Group, Double-Blind, Vehicle-Controlled Study on Pimecrolimus Cream 1% Assessing the Steroid-Sparing Effect in the Long Term Management of Pediatric Patients With Severe Atopic Dermatitis||Novartis||Completed|December 2001|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|184|||Both|2 Years|18 Years||||January 2008|January 15, 2008|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00351052||180628|
NCT00350805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3494|Measuring Time Windows in Patients With Schizophrenia and Healthy Controls|Relating the 'Experienced Present' With the Mechanisms of Neuronal Function: A Comparative Study in Patients With Schizophrenia and Healthy Controls Using Psychophysical and Neurophysiological Methods||University Hospital, Strasbourg, France|No|Recruiting|September 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|228|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic, residents of Strasbourg|March 2016|March 2, 2016|July 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00350805||180647|
NCT00351884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23103|Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes|A Multicenter, Double-blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 MG QD to Placebo as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy||Novartis||Completed|May 2006|||November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|370|||Both|18 Years|78 Years|No|||February 2011|February 28, 2011|July 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351884||180564|
NCT00351897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-ost-1358|The Efficacy of Pulsed Dye Laser in Dermatophytosis|The Efficacy of Pulsed Dye Laser in Dermatophytosis||hahid Beheshti University of Medical Sciences||Completed|April 2006|September 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2007|February 19, 2008|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351897||180563|
NCT00333619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-321|Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation|Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation||VA Office of Research and Development|No|Completed|January 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|60 Years|N/A|No|||October 2014|April 6, 2015|June 2, 2006||No||No|October 23, 2014|https://clinicaltrials.gov/show/NCT00333619||181917|
NCT00334204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0092|Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?|Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?||University of Mississippi Medical Center|No|Terminated|August 2004|December 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|58|||Both|18 Years|80 Years|No|||June 2013|June 26, 2013|June 2, 2006||No|run out of independent funding|No|April 11, 2013|https://clinicaltrials.gov/show/NCT00334204||181872|Early termination leading to lesser-than-planned numbers of subjects analyzed
NCT00334217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O3108R|Cognitive Remediation in Early Substance Abuse Treatment|Cognitive Remediation in the Initial Phase of Substance Abuse Treatment: Feasibility and Efficacy||VA Office of Research and Development||Terminated|August 2005|December 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||June 2009|June 17, 2009|June 2, 2006|||The intervention could not be successfully carried out in the SADP setting because of issues    independent of the cognitive training intervention.|No||https://clinicaltrials.gov/show/NCT00334217||181871|
NCT00364611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_00712|Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer|A Pilot, Phase II, Multicenter, Open-Label, Prospective Evaluation of Docetaxel and Bevacizumab ± Trastuzumab in the First-Line Treatment of Patients With Metastatic Breast Cancer||Sanofi||Completed|August 2006|April 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Female|18 Years|N/A|No|||April 2012|July 20, 2012|August 14, 2006|Yes|Yes||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00364611||179614|
NCT00364598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TI-102|Study of Anginera in Adults With a Left Ventricular Assist Device (LVAD) as Bridge to Transplant|A Phase I Open Label Pilot Study to Obtain Tissue for Histological Analysis After Application of Anginera™ in Adults With A Left Ventricular Assist Device As A Bridge To Transplant||Theregen, Inc.|No|Active, not recruiting|December 2006|February 2009|Anticipated|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2009|March 27, 2009|August 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00364598||179615|
NCT00364884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941213|Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease|Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease||National Taiwan University Hospital||Not yet recruiting|August 2006|August 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|20 Years|65 Years|No|||August 2006|August 15, 2006|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00364884||179593|
NCT00365183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0228|Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer|Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer||Pharmacyclics||Terminated|June 2006|June 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|August 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00365183||179572|
NCT00365196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|399|Hostility Reduction Program to Improve Autonomic Regulation of the Heart|Hostility Reduction and Autonomic Control of the Heart||National Heart, Lung, and Blood Institute (NHLBI)||Completed|December 1999|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2007|February 17, 2016|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365196||179571|
NCT00364858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZ-011-01|Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease|A Phase IV, Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every Four Weeks Versus Every Two Weeks in the Maintenance Therapy of Patients With Type 1 Gaucher Disease||Sanofi||Completed|December 2001|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 15, 2006|Yes|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00364858||179595|
NCT00364871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB201|Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity|Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study of Combination Therapy for Safety and Efficacy in Subjects With Uncomplicated Obesity||Orexigen Therapeutics, Inc|Yes|Completed|April 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|410|||Both|18 Years|60 Years|No|||April 2008|April 18, 2008|August 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00364871||179594|
NCT00365157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00170|Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction|A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency||National Cancer Institute (NCI)||Active, not recruiting|October 2006|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||November 2015|February 15, 2016|August 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00365157||179574|
NCT00365170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1474|Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes|A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes||Novo Nordisk A/S|No|Completed|September 2002|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|419|||Female|18 Years|N/A|No|||May 2012|May 21, 2012|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00365170||179573|
NCT00331370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHCPP00493|Hypertension Related Damage to the Microcirculation in South Asian: Emergence, Predictive Power and Reversibility|Hypertension Related Damage to the Microcirculation in South Asian: Emergence,Predictive Power and Reversibility||Aga Khan University||Not yet recruiting|May 2006|June 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||2880|||Both|9 Years|N/A|No|||May 2006|May 30, 2006|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331370||182077|
NCT00331409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000479150|Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma||OHSU Knight Cancer Institute|Yes|Completed|January 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|100 Years|No|||February 2016|February 17, 2016|May 30, 2006|Yes|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00331409||182076|Our phase II study closed after the first stage of accrual due to an insufficient number of participants who remained progression-free at 3 months, per the study design.
NCT00331656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIVCOMPARE-HMO-CTIL|Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure.|Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study.||Hadassah Medical Organization||Not yet recruiting|June 2008|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||May 2006|May 6, 2008|May 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00331656||182060|
NCT00331669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBS and tardive dystonia|Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia|Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia||Charite University, Berlin, Germany|Yes|Recruiting|May 2006|December 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||February 2009|March 3, 2009|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00331669||182059|
NCT00366691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-06-002|Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation|Comparison of Acular LS With Lotemax to Prevent Anterior Segment Inflammation After Phacoemulsification and Intraocular Lens Implantation||Medical University of South Carolina||Completed|February 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||June 2006|October 1, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366691||179458|
NCT00366678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-008|Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|613|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||July 2012|July 6, 2012|August 17, 2006|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00366678||179459|
NCT00366977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1-CA86242-1|Efficacy and Cost of State Quitline Policies|Efficacy and Cost of State Quitline Policies||Kaiser Permanente||Completed|June 2000|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|4614|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 28, 2011|August 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00366977||179436|
NCT00367328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513081-1|To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa|To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa||University of California, Davis|No|Terminated|April 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|August 19, 2006|No|Yes|Terminated: recruiting or enrolling participants has halted.|No||https://clinicaltrials.gov/show/NCT00367328||179409|
NCT00363038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1253-015|Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising|Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising||Northwestern University|No|Completed|July 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|August 10, 2006||No||No|November 29, 2010|https://clinicaltrials.gov/show/NCT00363038||179731|As only laser-induced bruising on the inner arm was studied, it remains to be seen if this result can be generalized to other postoperative bruises and at other anatomical sites.
NCT00351065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK3530_II_2004|Phase II Trial of SK3530 in Erectile Dysfunction|an 8week, Multi-Center, Randomized, Double Blind, Placebo-Controlled,Parallel Group, Fixed Dose, Dose-Finding Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction.||SK Chemicals Co.,Ltd.||Terminated|September 2004|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Male|19 Years|70 Years|No|||July 2006|July 11, 2006|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351065||180627|
NCT00351286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGX-1039-02|Efficacy Study of Oral L-Citrulline in Patients Taking Simvastatin With Peripheral Arterial Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral L-Citrulline Compared to Placebo in Patients Taking Background Simvastatin 40 mg qD and With Peripheral Arterial Disease Including Intermittent Claudication||Angiogenix||Active, not recruiting|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|40 Years|75 Years|No|||July 2006|October 17, 2006|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00351286||180610|
NCT00358761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060207|Investigation of Southern Tick-Associated Rash Illness (STARI)|Investigation of Southern Tick-Associated Rash Illness (STARI)||National Institutes of Health Clinical Center (CC)||Terminated|July 2006|December 2012||||N/A|Observational|N/A|||Actual|3|||Both|14 Years|N/A|No|||December 2012|October 9, 2014|July 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00358761||180049|
NCT00333866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081100|Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.|A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.||Pfizer|No|Completed|July 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|747|||Both|18 Years|N/A|No|||March 2009|April 25, 2013|June 2, 2006|Yes|Yes||No|November 20, 2008|https://clinicaltrials.gov/show/NCT00333866||181898|
NCT00333879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4188-R|Virtual Reality Mobility Training System for Veterans With Vision Loss|Virtual Reality Mobility Training System for Veterans With Vision Loss||VA Office of Research and Development|No|Completed|March 2009|April 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 20, 2013|June 2, 2006||No||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00333879||181897|Early termination leading to small numbers of subjects analyzed. Technical problems with Virtual Sound System. None of the first 4 Subjects could distinguish between sounds in front versus sounds beside them.
NCT00335413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001453-10|Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy|Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy||Steno Diabetes Center||Completed|June 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|70 Years|No|||June 2008|June 4, 2008|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00335413||181781|
NCT00334178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAXY-P001-R-2003|Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine|A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine||Lotus Pharmaceutical|No|Completed|November 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|74|||Both|18 Years|65 Years|No|||September 2007|September 6, 2007|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334178||181874|
NCT00334191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2005/02249|Sodium Bicarbonate in Cardiac Surgery|A Randomised, Double Blind, Placebo Controlled Pilot Study of the Effect of Sodium Bicarbonate on Postoperative Renal Function and Oxidative Stress in Patients Undergoing Elective Cardiopulmonary Bypass.||Austin Health||Completed|June 2006|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|N/A|No|||July 2009|July 6, 2009|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334191||181873|
NCT00365235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348|Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals|Genetic Susceptibility to Common Lipid Disorders in Mexico||University of California, Los Angeles||Completed|July 2006|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|998|Samples With DNA|Whole blood sample is taken from all participants and adipose tissue sample from a subgroup.|Both|10 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects are Mexicans visiting the Dyslipidemia Clinic at the Instituto Nacional de        Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, and their family members|January 2012|January 11, 2012|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365235||179568|
NCT00365248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-019-IN|TachoSil Paediatric Liver Trial (TC-019-IN)|A Prospective, Multi-centre Phase III-b Study of TachoSil in Paediatric Patients Scheduled for Resection of the Liver With or Without Segmental Liver Transplantation.||Nycomed|Yes|Completed|October 2005|May 2008|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|6 Years|No|||July 2008|May 4, 2012|August 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00365248||179567|
NCT00364897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACL001-HMO-CTIL|Investigation of Clinical Outcome of ACL Reconstruction Utilizing Two Tibial Fixation Techniques, Concentric Tapered Interference Screws and Interference Screw and Sheath|Comparison Between Two Tibial Fixation Techniques in ACL Reconstruction||Hadassah Medical Organization||Withdrawn||||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||140|||Both|21 Years|40 Years|No|||February 2007|April 10, 2007|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00364897||179592|
NCT00365209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00449|Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)|Phase IIA Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)||National Cancer Institute (NCI)||Completed|October 2006|January 2011|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2014|July 30, 2015|August 16, 2006|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT00365209||179570|
NCT00365222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14714|Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma|Phase II Study of Dose Intensive Temozolomide in Elderly Adults With Newly Diagnosed Glioblastoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|July 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|70 Years|N/A|No|||January 2009|January 21, 2009|August 15, 2006|Yes|Yes|IRB Study Closure|No||https://clinicaltrials.gov/show/NCT00365222||179569|
NCT00365521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-314759|Prophylactic Photodynamic Therapy to Organ Transplant Patients|||Bispebjerg Hospital||Not yet recruiting|April 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|||Anticipated|50|||Both|40 Years|70 Years|No|||May 2008|May 30, 2008|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00365521||179546|
NCT00365495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022|Influence of Physical Training on Mitochondrial Function in Type 2 Diabetic Patients|||Odense University Hospital||Active, not recruiting|August 2006|June 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||April 2007|April 3, 2007|August 15, 2006||||No||https://clinicaltrials.gov/show/NCT00365495||179548|
NCT00365508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491296|Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking|Comparing the Lozenge to the Patch for Smoking Cessation||Fox Chase Cancer Center|No|Completed|February 2006|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|642|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|August 16, 2006||No||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00365508||179547|The study was an effectiveness trial so external vs. internal validity was emphasized. Many participants were lost to follow-up.
NCT00366041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03F/DE01|Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries|Multicentre Clinical Study to Compare the Efficacy and the Tolerance of Cellularised LG002 With the Efficacy and Tolerance of Uncellularised LG002 in the Treatment of Severe Burn Injury||Laboratoires Genévrier|Yes|Terminated|February 2006|December 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||January 2010|January 20, 2010|August 17, 2006||No|not appropriate to carry on the study|No||https://clinicaltrials.gov/show/NCT00366041||179507|
NCT00367003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024883|Deep Brain Stimulation for Treatment Resistant Depression|Deep Brain Stimulation for Treatment Resistant Depression||Emory University|Yes|Recruiting|September 2006|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|August 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367003||179434|
NCT00367016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200312064-4|Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)|Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)|Xolair|University of California, Davis|No|Completed|February 2004|December 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|55 Years|No|||May 2011|May 25, 2011|August 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367016||179433|
NCT00366990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415|Low Sodium Diet and Behavioral Intervention for Reversing Arterial Stiffening in Overweight Individuals|Clinical Trial to Reverse Early Arterial Stiffening|SAVE|University of Pittsburgh|Yes|Completed|January 2007|June 2013|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|349|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 5, 2016|August 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00366990||179435|
NCT00367315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2361|Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)|A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator||Novartis||Completed|September 2003|||February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1684|||Both|18 Years|N/A||||May 2012|May 18, 2012|August 18, 2006||||||https://clinicaltrials.gov/show/NCT00367315||179410|
NCT00363077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107975|Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate|A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ (GlaxoSmithKline Biologicals) Administered Intramuscularly in Elderly Aged 60 Years and Older.||GlaxoSmithKline||Completed|October 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|150|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|May 16, 2013|August 7, 2006|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00363077||179729|
NCT00363363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008413|Physical Activity in Fontan Patients|Identifying Determinants and Optimizing Rehabilitation of Physical Activity for Children After the Fontan Procedure||The Hospital for Sick Children|Yes|Completed|August 2006|May 2009|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|6 Years|10 Years|No|||August 2013|August 25, 2013|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00363363||179708|
NCT00351585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2344|A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Effects of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes Mellitus||Novartis||Completed|July 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|39|||Both|30 Years|65 Years|No|||May 2012|May 4, 2012|July 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351585||180587|
NCT00359281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|733-002|Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents|A Phase II, Fixed-sequenced, Open- Label, Research Study to Assess Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Therapies in Healthy Volunteers||Aegerion Pharmaceuticals, Inc.|No|Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|125|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|July 31, 2006|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00359281||180009|
NCT00359515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010095|Genetic Analysis of Oculocerebrorenal Syndrome of Lowe|Mutation Detection for Lowe Syndrome||National Institutes of Health Clinical Center (CC)||Completed|February 2001|February 2009||||N/A|Observational|N/A||||120|||Male|N/A|N/A|No|||February 2009|September 26, 2015|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359515||179992|
NCT00335140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000475776|Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma||National Cancer Institute (NCI)||Suspended|December 2006|||June 2016|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||February 2010|July 11, 2012|June 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335140||181801|
NCT00334893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00169|Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer|A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer||National Cancer Institute (NCI)||Completed|April 2006|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Female|18 Years|N/A|No|||December 2011|April 29, 2014|June 7, 2006|Yes|Yes||No|October 16, 2013|https://clinicaltrials.gov/show/NCT00334893||181819|
NCT00334490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091532|Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?|A Phase II, Double Blind Randomized Controlled Trial to Determine the Safety and Efficacy of 12.5mg of Oral Sildenafil (Viagra) Compared to Placebo to Decrease Pulmonary Hypertension in Cardiac Patients After Cardiopulmonary Bypass||St. Michael's Hospital, Toronto|Yes|Completed|March 2005|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|June 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00334490||181850|
NCT00334503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1009|Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|69 Years|No|||October 2008|October 8, 2008|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334503||181849|
NCT00334477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acbc01|Efficacy and Safety of Tadalafil in Hemodialysis Patients|Efficacy and Safety of Tadalafil 20mg for the Treatment of Erectile Dysfunction in Chronic Renal Patients in Hemodialysis.||University of Pernambuco||Not yet recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Male|18 Years|70 Years|No|||April 2006|June 6, 2006|June 6, 2006||||No||https://clinicaltrials.gov/show/NCT00334477||181851|
NCT00334828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5564-G000-301|ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis|ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis||Eisai Inc.||Completed|June 2006|||January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2000|||Both|18 Years|N/A|No|||January 2013|June 30, 2014|June 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00334828||181824|
NCT00334802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9066|Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer|Combination Study of LY188011 and Paclitaxel in Patients With Metastatic/Recurrent Breast Cancer After Neo-adjuvant/Adjuvant Chemotherapy With Anthracycline||Eli Lilly and Company|Yes|Completed|June 2006|March 2010|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|20 Years|74 Years|No|||March 2010|March 10, 2010|June 6, 2006|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00334802||181826|
NCT00334815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01097|Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2006|||July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|N/A|No|||April 2014|January 29, 2016|June 7, 2006|Yes|Yes||No|September 22, 2015|https://clinicaltrials.gov/show/NCT00334815||181825|
NCT00335062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S05-05-066|TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease|TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease||Children's Hospital Boston|Yes|Completed|August 2005|February 2010|Actual|February 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|Samples With DNA|whole blood, serum, white cells.|Both|2 Years|21 Years|No|Non-Probability Sample|Children and adolescents referred to a tertiary medical center with hyperthyroidism.|July 2014|July 24, 2014|June 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00335062||181806|
NCT00365534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIC|Use of Magnetic Imaging to Asses the Efficacy of Cap Assisted Colonoscopy in Reducing Looping and Improving Patient Acceptance for the Colonoscopy Procedure|A Double-Blinded Randomized Study Comparison the Mechanism of Looping Formation and Subject's Acceptance During CAC and Regular Colonoscopy by MEI (MIC Study)||Chinese University of Hong Kong||Withdrawn|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|20|||Both|N/A|N/A||||March 2010|March 25, 2010|August 16, 2006||No|The study was incorporated in another study.|No||https://clinicaltrials.gov/show/NCT00365534||179545|
NCT00335673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBES_L_00165|I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients|Irbesartan in Mild to Moderate Hypertensive Patients||Sanofi||Completed|February 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1630|||Both|30 Years|75 Years|No|||March 2011|March 31, 2011|June 9, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00335673||181763|
NCT00331357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-05-06|Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire|Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire||University Hospital, Angers||Not yet recruiting|June 2006|December 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|N/A|18 Years|No|||May 2006|May 29, 2006|May 29, 2006||||No||https://clinicaltrials.gov/show/NCT00331357||182078|
NCT00332683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-225|Reducing Dysphagia Associated With Anterior Cervical Spine Surgery by Maintaining Low Endotracheal Tube Cuff Pressure|Endotracheal Tube Cuff Pressure Protocol to Reduce Dysphagia Following Anterior Cervical Spine Surgery: A Prospective Randomized Pilot Study||Lawson Health Research Institute|No|Recruiting|September 2006|December 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|21 Years|65 Years|No|||June 2010|June 2, 2010|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332683||181989|
NCT00331110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200501707|Study of How An Ankle Strap Changes Effects of Insole Treatment for Knee Osteoarthritis|Immediate and Short-Term Analgesic and Biomechanical Effects of a Laterally Wedged Insole With Ankle Strapping for Medial Compartment Knee Osteoarthritis||University of Iowa||Completed|May 2006|August 2006|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Both|45 Years|N/A|No|||April 2007|December 20, 2007|May 26, 2006||||No||https://clinicaltrials.gov/show/NCT00331110||182096|
NCT00331123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001133 and Yr 2-4 OL|Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido|Study to Evaluate Efficacy and Safety of Transdermal Testosterone and Safety for an Open-label Period in Women With Hypoactive Sexual Desire Disorder on Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy.||Warner Chilcott|No|Completed|May 2002|July 2006|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|562|||Female|20 Years|70 Years|No|||April 2013|April 15, 2013|May 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00331123||182095|
NCT00331877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|famirea VIII|A Communication Strategy for Families of Patients Dying in the ICU|A Proactive Communication Strategy for Family Members of Patients Dying in the ICU: A Multicenter Randomized Controlled Trial||Famirea Study Group||Terminated|May 2005|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||136|||Both|18 Years|N/A|No|||May 2006|May 30, 2006|May 30, 2006||||No||https://clinicaltrials.gov/show/NCT00331877||182044|
NCT00331890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GF-ICTUS-04|ICTUS Study: International Citicoline Trial on Acute Stroke|Citicoline in the Treatment of Acute Ischemic Stroke. An International Randomized Multicenter Placebo-controlled Study|ICTUS|Ferrer Internacional S.A.|Yes|Terminated|October 2006|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2298|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|May 30, 2006||No|With 2078 patients, a statistical stopping boundary has now been crossed|No||https://clinicaltrials.gov/show/NCT00331890||182043|
NCT00331916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-38|AL-15469A for the Treatment of Bacterial Conjunctivitis|AL-15469A for the Treatment of Bacterial Conjunctivitis||Alcon Research||Completed|November 2005|||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|600|||Both|1 Month|N/A|No|||September 2009|September 25, 2009|May 30, 2006||||||https://clinicaltrials.gov/show/NCT00331916||182042|
NCT00367341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026176|Imaging Predictors of Treatment Response in Depression|Imaging Predictors of Treatment Response in Depression||Emory University|Yes|Completed|August 2006|July 2013|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|21 Years|60 Years|No|||November 2013|November 21, 2013|August 18, 2006|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT00367341||179408|
NCT00363051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2239|Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy|An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy||Novartis||Completed|June 2006|April 2012|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|August 2, 2006|Yes|Yes||No|December 2, 2011|https://clinicaltrials.gov/show/NCT00363051||179730|
NCT00332644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA19706-1|Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms|Pharmacotherapies: Efficacy, Mechanisms and Algorithms||University of Wisconsin, Madison|No|Completed|September 2004|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|1504|||Both|18 Years|N/A|No|||October 2011|October 21, 2011|June 1, 2006||No||No|October 21, 2011|https://clinicaltrials.gov/show/NCT00332644||181992|
NCT00351598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 99.05|Lung Tumour Volume Database|Tumour Volume as an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer - A Protocol for a Prospective Database.||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|September 1999|November 2012|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|531|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with loco-regional non-small cell lung cancer|July 2014|July 31, 2014|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351598||180586|
NCT00333632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007964|Effect of Dexmedetomidine Upon Sleep Postoperatively|Restorative Sleep: Effect of Dexmedetomidine||Duke University||Withdrawn|June 2006|June 2011|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|21 Years|50 Years|No|||June 2011|July 11, 2014|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333632||181916|
NCT00334555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F020508005|Control of Trichomoniasis|Control of Trichomoniasis - A Paradigm for STD Control||University of Alabama at Birmingham||Completed|May 2003|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|599|||Both|18 Years|65 Years|No|||August 2009|August 11, 2009|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00334555||181845|
NCT00334568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA100930|Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease|A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilisation and Cognition in Subjects With Mild to Moderate Alzheimers Disease (AD)||GlaxoSmithKline||Terminated|December 2004|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|50 Years|85 Years|No|||January 2013|January 10, 2013|June 6, 2006||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00334568||181844|
NCT00335725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GBF/FSH08|Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.|Multicentric Prospective, Randomised, Controlled Clinical Study on Clinical Efficacy and Tolerability of Urinary FSH (Fostimon® , IBSA) Versus r-FSH (Gonal-F®, Serono) in ICSI.||IBSA Institut Biochimique SA||Completed|March 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|151|||Female|18 Years|40 Years|No|||March 2015|March 23, 2015|June 9, 2006||||No|February 12, 2015|https://clinicaltrials.gov/show/NCT00335725||181759|
NCT00334854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-EPSSG-NRSTS-2005|Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma|Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas||National Cancer Institute (NCI)||Recruiting|March 2006|||May 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|250|||Both|N/A|20 Years|No|||July 2009|August 9, 2013|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334854||181822|
NCT00334841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507874356- HMO-CTIL|Leptin and Cytokines in Diabetic Pregnancy - Physiologic or Pathogenic Role|Leptin and Cytokines in Diabetic Pregnancy - Physiologic or Pathogenic Role||Hadassah Medical Organization||Recruiting|July 2006|||||N/A|Observational|N/A|||Anticipated|30|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2006|November 5, 2007|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00334841||181823|
NCT00335075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03644|Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)|A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma||Merck Sharp & Dohme Corp.|No|Completed|March 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|June 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00335075||181805|
NCT00335088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4780506|Local Moxifloxacin and Povidone Iodine Versus Povidone Iodine Alone as a Prophylaxis Before Eye Operations|||HaEmek Medical Center, Israel|No|Recruiting|June 2006|May 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|500|||Both|20 Years|N/A|No|||March 2007|May 31, 2007|June 5, 2006||||No||https://clinicaltrials.gov/show/NCT00335088||181804|
NCT00335335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXV301|Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast–Enhanced CT Angiography of Arteries of the Heart|||GE Healthcare||Completed|May 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||540|||Both|18 Years|N/A|No|||June 2007|June 28, 2007|June 7, 2006||||||https://clinicaltrials.gov/show/NCT00335335||181786|
NCT00335348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/69|Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse|Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse An Australian Myeloma Forum Multi-Centre Phase II Trial||Peter MacCallum Cancer Centre, Australia||Completed|June 2006|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|80 Years|No|||August 2011|January 7, 2013|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00335348||181785|
NCT00335686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MULTINEKA|Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients|Randomised, Prospective Multicentre Clinical Study on the Effect of the Combination of Lopinavir/Rtv + Nevirapine as Maintenance Bitherapy (Without Nucleoside Analogues) in Comparison With a Triple Therapy Including Lopinavir/Rtv + Nucleoside Analogues in HIV-Infected Patients||Germans Trias i Pujol Hospital|No|Completed|October 2003|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|80 Years|No|||June 2007|February 19, 2008|June 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00335686||181762|
NCT00331942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD-BC-CAAb|Breast Cancer Associated Antibodies|Study of Breast Cancer Associated Antibodies||Lab Discoveries Ltd.||Recruiting|July 2006|May 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2006|March 1, 2007|May 27, 2006||||No||https://clinicaltrials.gov/show/NCT00331942||182040|
NCT00331955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02695|Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors|Phase I Trial of Vorinostat (NSC-701852, Suberoylanilide Hydroxamic Acid) and Doxorubicin (NSC-123127, Adriamycin)||National Cancer Institute (NCI)||Completed|March 2006|||June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00331955||182039|
NCT00331682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01471|Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer|An Open-Label, Non-Randomized Phase II Study of Alvocidib (Flavopiridol) in Combination With Docetaxel in Refractory, Metastatic Pancreatic Cancer (NCI #6366)||National Cancer Institute (NCI)||Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2013|May 12, 2014|May 30, 2006|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT00331682||182058|
NCT00331929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped-2/2006|Respiratory Health Study of Children in Kiryat Tivon|Respiratory Health Study of Children in Kiryat Tivon||Carmel Medical Center|Yes|Completed|September 2006|December 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|638|||Both|6 Years|18 Years|No|||December 2007|June 18, 2008|May 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00331929||182041|
NCT00332254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014439|Study to Prevent Cartilage Damage Following Acute Knee Injury.|IL-1ra for Prevention of Chondropathy Following Knee Injury||Duke University|Yes|Completed|March 2006|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|30 Years|No|||January 2008|May 29, 2013|May 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00332254||182017|
NCT00332267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-HYP/ETX|Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia|Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia||Rigshospitalet, Denmark|No|Completed|May 2006|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2008|September 2, 2008|May 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00332267||182016|
NCT00332657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-34|Anecortave Acetate Risk Reduction Trial (AART)|||Alcon Research||Terminated|September 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|36|||Both|50 Years|N/A|No|||September 2009|November 27, 2012|May 31, 2006|Yes|Yes|Management Decision|No||https://clinicaltrials.gov/show/NCT00332657||181991|
NCT00332670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOW 014-91-049|Light Therapy for Elderly Depression|High Cortisol Levels as a Risk Factor for Depression in the Elderly and the Effect of Bright Light Treatment on Mood, Sleep-Wake Pattern and Self-Sufficiency||GGZ Buitenamstel|No|Terminated|January 2003|June 2007|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|60 Years|N/A|No|||August 2008|August 12, 2008|May 31, 2006|||End of research time, time-resources|No||https://clinicaltrials.gov/show/NCT00332670||181990|
NCT00362804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240/2001|Tetrabenazine for Partial Responders|Augmentation of Antipsychotic Partial Responders With Tetrabenazine||Centre for Addiction and Mental Health|No|Completed|February 2002|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|41|||Both|18 Years|65 Years|No|||July 2012|July 4, 2012|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362804||179749|
NCT00362817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0428|Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases|Phase I/II Multicenter Trial of Intra-Arterial Carboplatin and Oral Temozolomide for the Treatment of Recurrent and Symptomatic Residual Brain Metastases.||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2004|February 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|August 8, 2006|Yes|Yes||No|February 26, 2015|https://clinicaltrials.gov/show/NCT00362817||179748|
NCT00334867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS0531|Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma|A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma||Children's Oncology Group||Withdrawn|December 2005|||January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|50 Years|No|||June 2013|June 27, 2013|June 7, 2006|Yes|Yes|withdrawn|No||https://clinicaltrials.gov/show/NCT00334867||181821|
NCT00334880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRP104.303|Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)||New River Pharmaceuticals|No|Completed|May 2006|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|420|||Both|18 Years|55 Years|No|||July 2009|July 1, 2009|June 7, 2006||||No||https://clinicaltrials.gov/show/NCT00334880||181820|
NCT00333931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 18342|Pilot Trial of Neural Correlates of Response to Treatment of PTSD-Associated Impulsive Aggression|Pilot Trial of Neural Correlates of Response to Treatment of PTSD-Associated Impulsive Aggression||VA Medical Center, Houston||Recruiting|June 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|65 Years|No|||June 2006|June 2, 2006|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00333931||181893|
NCT00334516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060174|Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis|Cortical Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis||National Institutes of Health Clinical Center (CC)||Completed|June 2006|August 2015||||N/A|Observational|N/A|||Actual|77|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00334516||181848|
NCT00334529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060180|Alternative Oseltamivir Dosing Strategies|Evaluation of Alternative Oseltamivir (Tamiflu[R]) Dosing Strategies for Use During Influenza Prophylaxis||National Institutes of Health Clinical Center (CC)||Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||48|||Both|18 Years|N/A|No|||September 2009|September 26, 2015|June 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00334529||181847|
NCT00334542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0485, CDR0000477214|Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer|A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|March 2006|November 2011|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Female|18 Years|N/A|No|||July 2013|July 3, 2013|June 7, 2006|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00334542||181846|
NCT00366197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rapid Shallow Breathing Index|Prediction of Weaning Outcomes by Using Rate of Change of Rapid Shallow Breathing Index|Prediction of Weaning Outcomes by Using Rate of Change of Rapid Shallow Breathing Index||Atlantic Health System||Terminated|January 2005|July 2008|Actual|||Phase 0|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Male and Female|January 2014|January 15, 2014|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366197||179496|
NCT00366210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060112013|Constraint-Induced Therapy Modified for Rehabilitating Arm Function in Stroke Survivors w/Plegic Hands|Constraint-Induced Therapy Modified for Rehabilitating Arm Function in Stroke Survivors w/Plegic Hands||University of Alabama at Birmingham|Yes|Completed|October 2005|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|19 Years|N/A|No|||August 2010|December 24, 2014|August 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00366210||179495|
NCT00373386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peds15|Growth Hormone and Endothelial Function in Children|Growth Hormone and Endothelial Function in Children||Ohio State University|No|Completed|January 2005|December 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|8 Years|18 Years|No|||June 2008|June 27, 2008|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373386||178953|
NCT00373659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-FVF3102|An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD|Prospective Optical Coherence Tomography (OCT) Imaging of Patients With Neovascular AMD Treated With Intra-Ocular Ranibizumab (Lucentis) (PrONTO) Study||University of Miami|No|Completed|August 2004|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|50 Years|N/A|No|||June 2012|June 12, 2012|September 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00373659||178932|
NCT00373932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29494-V2|Real-Time Support for Exercise Persistence in COPD|Real-Time Support for Exercise Persistence in COPD||University of Washington|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|17|||Both|40 Years|85 Years|No|||December 2009|December 3, 2009|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373932||178911|
NCT00373958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-004|Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States||Pfizer||Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|666|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||January 2013|January 17, 2013|September 7, 2006|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00373958||178909|
NCT00374205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KA22062006|Randomized Trial on Effectiveness of ACTs in Ghana|A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria||Bernhard Nocht Institute for Tropical Medicine|Yes|Terminated|September 2006|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|6 Months|59 Months|No|||November 2007|November 26, 2007|September 8, 2006|||Interim analysis showed more LCFs in one of the treatment arms|No||https://clinicaltrials.gov/show/NCT00374205||178890|
NCT00374465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CavsBe.06|Therapy With Verapamil or Carvedilol in Chronic Heart Failure|Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy||Medical University of Silesia||Recruiting|January 2006|May 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||September 2006|September 8, 2006|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374465||178870|
NCT00374751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYM-354|Effect of Samarium on the Relief of Pain Due to Vertebral Metastases|Phase I/II Study of the Use of Vertebral Intracavitary Cement and Samarium (VICS) for Painful Vertebral Metastases||New York Methodist Hospital|Yes|Completed|May 2006|||January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|80 Years|No|||April 2015|April 27, 2015|September 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00374751||178848|
NCT00375583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906244|Effect of Albendazole Dose on Clearance of Filarial Worms|Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study||National Institutes of Health Clinical Center (CC)||Completed|September 2006|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|55 Years|No|||April 2011|April 29, 2011|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00375583||178786|
NCT00375596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-06-001|A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis|Study Withdrawn Prior to Determining Official Title||Bausch & Lomb Incorporated|No|Withdrawn||||||Phase 2|Interventional|Intervention Model: Parallel Assignment|||Actual|0|||Both|6 Years|N/A|No|||February 2015|February 19, 2015|September 12, 2006||No|Study withdrawn without starting or enrolling subjects due to a business decision to not    proceed with the project.|No||https://clinicaltrials.gov/show/NCT00375596||178785|
NCT00372359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAR1400CTIL|Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions|Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions||Barzilai Medical Center|Yes|Recruiting|August 2006|December 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|8 Years|18 Years|No|Non-Probability Sample|Children aged 8-18 that are at least 5 years on methylphenidates|September 2012|September 19, 2012|September 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00372359||179029|
NCT00334243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Purcell-01|Protocols for Improved in Vitro Fertilization (IVF) Outcomes|Protocol Evaluation for Improved In Vitro Fertilization Outcomes||University of California, San Francisco|Yes|Terminated|June 2006|November 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|45 Years|No|||October 2011|October 5, 2011|June 6, 2006||No|stopped due to limited enrollment. 2 subjects were enrolled. There was NO enrollment after    November 2007.|No||https://clinicaltrials.gov/show/NCT00334243||181869|
NCT00376363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20057138|Ahmed Versus Baerveldt Comparison Study|Ahmed Versus Baerveldt Comparison Study|ABC|University of Miami|Yes|Completed|November 2005|October 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|85 Years|No|||July 2015|July 25, 2015|September 13, 2006||No||No|May 17, 2015|https://clinicaltrials.gov/show/NCT00376363||178726|
NCT00376337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG463-21-20|Micafungin Salvage Mono-therapy in Invasive Aspergillosis|A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis||Astellas Pharma Inc|Yes|Terminated|June 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||October 2011|September 4, 2013|September 13, 2006|No|Yes|Study was stopped due to difficulties in recruitment and changes in standard care for invasive    aspergillosis|No||https://clinicaltrials.gov/show/NCT00376337||178728|
NCT00376350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT001908|Dose of Spinal Manipulation for Chronic Low Back Pain|Dose-Response/Efficacy of Manipulation for Chronic LBP||University of Western States|Yes|Completed|March 2007|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|400|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00376350||178727|
NCT00372255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106252|Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years|An Open, Phase IV Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years||GlaxoSmithKline||Completed|November 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||240|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372255||179037|
NCT00372489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-09|Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD|An Open-Label, Multi-Center, Extension Study to Evaluate the Safety and Tolerability of Peginesatide for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease||Affymax|No|Terminated|September 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|September 5, 2006|Yes|Yes|Due to more robust long-term data generated in other active-controlled studies|No|April 26, 2012|https://clinicaltrials.gov/show/NCT00372489||179019|Early termination of study due to generation of controlled long-term data in Phase 3 studies. Amended dosing guidelines during the trial to reflect label changes for ESAs; the primary outcome was assessed after the dosing guideline change.
NCT00372502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23GM076652|Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation|Lactate Assessment in the Treatment of Early Sepsis: The LactATES Trial|LactATES|National Institute of General Medical Sciences (NIGMS)|Yes|Completed|January 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||January 2009|January 12, 2009|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372502||179018|
NCT00372515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-403|High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations|Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations||Dana-Farber Cancer Institute|Yes|Active, not recruiting|June 2006|February 2015|Anticipated|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|September 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372515||179017|
NCT00372788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00012|AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen|A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen||AstraZeneca||Completed|August 2006|December 2008|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|September 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372788||178997|
NCT00372801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COX103843|Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of The Knee|A Double-Blind, Randomised, Placebo-Controlled, Cross-Over Pilot Study to Investigate the Efficacy of Ibuprofen in Patients With Osteoarthritis of the Knee Following Administration of a Single Dose||GlaxoSmithKline||Completed|August 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|N/A|80 Years|No|||October 2008|October 15, 2008|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372801||178996|
NCT00373100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD1120041349X|The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children|The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children Admitted to Mulago Hospital, Uganda.||Makerere University|Yes|Completed|September 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|328|||Both|6 Months|59 Months|No|||July 2009|July 3, 2009|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373100||178974|
NCT00373399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5204|Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks|Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks||New York State Psychiatric Institute||Recruiting|May 2006|November 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||November 2006|November 16, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373399||178952|
NCT00373672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060567|Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder|Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder||Vanderbilt University|No|Completed|August 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2010|February 22, 2010|September 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00373672||178931|
NCT00374231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSWD Liver|Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients|A Single Center, Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients Utilizing a Tacrolimus/Mycophenolate Mofetil Based Maintenance Immunosuppression Protocol||University of Cincinnati|No|Completed|October 2002|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||November 2015|November 23, 2015|September 8, 2006|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00374231||178888|
NCT00374504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 2745584|Prediction of Postoperative Pain by an Electrical Pain Stimulus|||Rigshospitalet, Denmark||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||46|||Female|18 Years|N/A|No|||February 2006|September 8, 2006|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374504||178867|
NCT00374218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTREB17491|Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference|Effect of Replacing HFCS With Sucromalt on Glucose Tolerance, Blood Lipids and Inflammatory Markers in Subjects With Raised Waist Circumference||University of Toronto|No|Completed|September 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||August 2007|August 13, 2007|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374218||178889|
NCT00374478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC R49/CCR115279-5|Effects of Transdermal Scopolamine on Occupational Performance|Effects of Transdermal Scopolamine on Occupational Performance||Boston University|No|Completed|April 2005|April 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||33|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2007|April 6, 2007|February 2, 2006||||No||https://clinicaltrials.gov/show/NCT00374478||178869|
NCT00375089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5202|Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity|Prader-Willi Syndrome and Early-onset Morbid Obesity Natural History Clinical Protocol||University of Florida|Yes|Completed|September 2006|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|392|Samples With DNA|Blood samples for both DNA and RNA|Both|N/A|60 Years|No|Non-Probability Sample|Individuals with Prader-Willi syndrome and Early-onset Morbid Obesity|September 2014|September 18, 2014|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375089||178823|
NCT00372632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05 34 5 520|IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda|Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda||Institute of Tropical Medicine, Belgium|No|Completed|December 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1717|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 12, 2010|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372632||179009|
NCT00372645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR001/2005|Increasing Folate Status of a General Population(FOLSUPP STUDY)|Effects Of A Mixed Diet Intervention Versus Folic Acid Supplementation And Metafolin® Supplementation On Folate Status And Cardiovascular Disease Risk Factors In Healthy Adults||Institute of Food Research|No|Completed|May 2005|January 2012|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|180|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|March 23, 2015|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372645||179008|
NCT00372931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-15|A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension|A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|May 2006|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||April 2008|April 21, 2008|September 6, 2006||||||https://clinicaltrials.gov/show/NCT00372931||178987|
NCT00372944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00008|AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy|A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy||AstraZeneca||Completed|August 2006|October 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|September 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372944||178986|
NCT00334256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12109 TEmAA|Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)|Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia|TEmAA|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|October 2006|December 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|72|||Female|18 Years|N/A|No|||December 2011|December 2, 2011|June 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00334256||181868|
NCT00376116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA056|Home Monitoring in Cardiac Resynchronisation Therapy|Home CARE - Home Monitoring in CArdiac REsynchronisation Therapy|HomeCARE|Biotronik SE & Co. KG||Completed|March 2005|November 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|513|||Both|18 Years|N/A|No|||November 2008|November 14, 2008|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376116||178745|
NCT00376675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N05C7|Methylphenidate in Treating Patients With Fatigue Caused by Cancer|Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study||Alliance for Clinical Trials in Oncology|Yes|Completed|February 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|148|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 13, 2006|Yes|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT00376675||178703|
NCT00372268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3621|Effects of Insufflated Gas on Core Temperature and Post-operative Pain During Laparoscopic Surgery|Evaluation of the Effects of Conditioning of Insufflated Gas on the Core Temperature and the Post-operative Pain During Laparoscopic Surgery||University Hospital, Strasbourg, France|No|Completed|January 2006|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|248|||Female|18 Years|N/A|No|||April 2012|April 12, 2012|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372268||179036|
NCT00372281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3780|Cliavist in Infectious and Degenerative Diseases of the Spine|Comparison of Cliavist Enhancement in Infectious and Degenerative Diseases of the Spine||University Hospital, Strasbourg, France|No|Recruiting|March 2007|December 2009|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2009|February 24, 2009|September 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00372281||179035|
NCT00372528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081140|An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures|An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164||Pfizer|No|Terminated|March 2007|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|September 5, 2006|Yes|Yes|This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug.    No efficacy or safety concerns factored into this decision.|No|September 21, 2012|https://clinicaltrials.gov/show/NCT00372528||179016|This was a compassionate use study and no formal primary outcome measure was specified a priori. Descriptive safety data were collected, subsequently safety outcome was designated as primary outcome as per National Institute of Health (NIH) criteria.
NCT00372775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181092|Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases|A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases||Pfizer|No|Completed|March 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|September 5, 2006|Yes|Yes||No|December 8, 2010|https://clinicaltrials.gov/show/NCT00372775||178998|
NCT00372814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK59067A (completed)|Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes|Adherence to IDDM Regimen in Urban Youth||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|March 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|10 Years|17 Years|No|||December 2014|December 15, 2014|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372814||178995|
NCT00373113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181107|A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine|Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated||Pfizer|Yes|Terminated|November 2006|June 2011|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|482|||Female|18 Years|N/A|No|||June 2012|June 15, 2012|September 5, 2006|Yes|Yes|See termination reason in detailed description.|No|October 20, 2010|https://clinicaltrials.gov/show/NCT00373113||178973|Due to patient enrollment termination, PFS/OR/TTP/DR were done by investigator assessment due to lack of central review data and TTR/EORTC QLQ-C30/QLQ BR23 analyses were not done. Those enrolled could receive capecitabine or enter an extension trial.
NCT00373412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jacobson VCL CT-02 TC|Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge|Randomized, Phase 1 Trial to Evaluate Safety and CMV-Specific Immune Response to a pDNA CMV Trivalent Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge in Healthy, CMV- Seronegative Adults||University of California, San Francisco|No|Completed|October 2006|||February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2006|May 5, 2008|September 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00373412||178951|
NCT00373685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191331|GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)|Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In Osteoarthritis Patients|GI-REASONS|Pfizer|Yes|Completed|October 2006|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8067|||Both|55 Years|N/A|No|||February 2012|February 2, 2012|September 7, 2006|Yes|Yes||No|October 26, 2011|https://clinicaltrials.gov/show/NCT00373685||178930|
NCT00373945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC107442|HLA-B*5701 And Hypersensitivity To Abacavir|A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir.||GlaxoSmithKline||Completed|August 2006|August 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|280|||Both|18 Years|N/A|No|||May 2009|May 15, 2009|September 7, 2006||||||https://clinicaltrials.gov/show/NCT00373945||178910|
NCT00374790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604015|Iron Supplementation of Lead-Exposed Infants|Pilot Study to Determine the Efficacy of Iron Supplementation in Preventing the Elevation of Blood Lead Concentrations in Young Children||Cornell University||Not yet recruiting|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||50|||Both|6 Months|9 Months|Accepts Healthy Volunteers|||May 2006|September 8, 2006|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374790||178845|
NCT00375115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360HMO-CTIL|Efficacy of Sambucol in the Treatment of Influenza|Efficacy of Sambucol on the Length of Time to Resolution of Influenza Illness||Hadassah Medical Organization||Active, not recruiting|September 2006|September 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Female|20 Years|65 Years|No|||October 2007|November 5, 2007|September 10, 2006||||No||https://clinicaltrials.gov/show/NCT00375115||178821|
NCT00374491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0506JM|The Long-term Degradation Outcome of Bilok Screws Used for ACL Reconstruction|The Long-term Degradation Outcome of Bilok Biodegradable Interference Fixation Screws Used for Bone-Patellar Tendon-Bone ACL Reconstruction||ArthroCare Corporation||Withdrawn|September 2006|||||Phase 4|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|55 Years|No|||January 2016|January 4, 2016|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00374491||178868|
NCT00374764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND #58033|Comparison of Applied Behavioral Analysis (ABA) Versus ABA and Risperidone|Randomized Double Blind Comparison of Applied Behavioral Analysis Versus ABA and Risperidone||Washington University School of Medicine||Completed|July 2000|June 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|30 Months|5 Years|Accepts Healthy Volunteers|||June 2002|February 15, 2007|September 7, 2006||||||https://clinicaltrials.gov/show/NCT00374764||178847|
NCT00374777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6199-CL-0008|A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients|FK199B (Zolpidem MR Tablet) Phase III Clinical Study -A Double-Blind, Placebo- and Nitrazepam-Controlled, Group-Comparison Study in Patients With Insomnia Associated With Schizophrenia and Manic-Depressive Psychosis||Astellas Pharma Inc|No|Completed|August 2006|June 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|450|||Both|20 Years|64 Years|No|||August 2014|August 19, 2014|September 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00374777||178846|
NCT00375362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004083|The Analgesic Effect of Nitroglycerin Patch for Postoperative Pain After Total Knee Replacement|The Analgesic Efficacy of Nitroglycerin Patches for Postoperative Pain in Patients Undergoing Total Knee Arthroplasty||Rabin Medical Center||Recruiting|July 2006|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2006|September 12, 2006|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375362||178802|
NCT00375908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|861|Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury|Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury||Johns Hopkins University|No|Completed|October 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4|||Both|N/A|N/A|No|Probability Sample|This study looked at umbilical cord blood from normal neonates and neonates with risk        factors for neurological injury.|August 2015|August 31, 2015|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375908||178761|
NCT00375921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-4-0028 23026|Evaluating Taste and Smell Function and Food and Taste Preferences of Head and Neck Cancer Patients During Radiation Therapy/Chemotherapy|Evaluation of Chemosensory Function and Taste Preference of Head and Neck Cancer Patients Prior to, On Completion of and Six Weeks After Oncology Treatment||AHS Cancer Control Alberta|Yes|Completed|November 2006|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|diagnosed with head and neck cancer including the lip, oral cavity, salivary glands,        paranasal sinuses, oropharynx, hypopharynx, larynx and thyroid|March 2012|February 24, 2016|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375921||178760|
NCT00375934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP21L-302|Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery|Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery||Xanodyne Pharmaceuticals||Completed|September 2006|||January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||May 2010|September 17, 2010|September 11, 2006||Yes|||March 22, 2010|https://clinicaltrials.gov/show/NCT00375934||178759|
NCT00372658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20010125H|Intracervical Block Versus Placebo to Assess Pain Control During Hysterosalpingogram|Intracervical Block and Pain Perception During the Performance of a Hysterosalpingogram: A Randomized Controlled Trial||Wilford Hall Medical Center||Completed|July 2002|October 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2005|September 6, 2006|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372658||179007|
NCT00374959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TABASCO|Prevention of Pneumonia Comparing Ceftriaxone With Subglottic Aspiration|The Prevention of Primary Endogenous Ventilator-Associated Pneumonia: A Multicenter Randomized Trial Comparing Continuous Aspiration of Subglottic Content and a 3-Day Course of Ceftriaxone.||Hospital Universitario Principe de Asturias||Completed|October 2000|October 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||80|||Both|18 Years|N/A|No|||September 2006|September 25, 2006|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00374959||178833|
NCT00374972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40106|Combined Hormonal Versus Progestin Only Contraception During Lactation|||Shaare Zedek Medical Center||Not yet recruiting||||||N/A|Observational|Allocation: Random Sample, Time Perspective: Longitudinal||||40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2006|September 11, 2006|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00374972||178832|
NCT00333671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dorte Nellemann, glycerol|Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema)|Diabetic Macular Oedema: the Retinal Thickness as a Function of Changes in Plasma Osmolality Evaluated by OCT.||Glostrup University Hospital, Copenhagen|No|Completed|December 2004|April 2007|Actual|February 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|June 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00333671||181913|
NCT00376129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-EU-098-04-AME|Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis|Open-Label,Singel Center Study to Evaluate the Safety and Efficacy of an Intramuskcular 12 Week-Course of Alefacept in Patients With Atopic Dermatitis||University Hospital Inselspital, Berne|No|Completed|January 2006|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|65 Years|No|||December 2007|December 7, 2007|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376129||178744|
NCT00376142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIME2005|Translating Clinicians' Beliefs Into Implementation Interventions (TRACII)|Translating Clinicians' Beliefs Into Implementation Interventions (TRACII): a Modelling Experiment to Change Clinicians' Intentions to Implement Evidence-Based Practice.||Newcastle University||Completed|April 2005|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||1200|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2006|September 13, 2006|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376142||178743|
NCT00376376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSU 06-496F|Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli|Urinary Bactericidal Activity of 4 Doses of Levofloxacin (250, 500, &750, and 1000 mg) Against Fluoroquinolone-Resistant E. Coli||Michigan State University||Completed|September 2006|November 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2008|November 25, 2008|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376376||178725|
NCT00376402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-PAN-05-24|Study of a Pandemic Influenza Vaccine in Elderly Participants|Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants||CSL Limited||Completed|October 2006|June 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 6, 2008|September 11, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00376402||178724|
NCT00372294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8415|To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis|||hahid Beheshti University of Medical Sciences||Active, not recruiting|July 2005|November 2008|Anticipated|August 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||||||Both|N/A|N/A|No|||June 2008|July 28, 2008|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372294||179034|
NCT00372307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/275|Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris|Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris||University Hospital, Ghent|No|Completed|May 2004|November 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||26|||Both|6 Years|N/A|No|||December 2007|December 19, 2007|September 4, 2006||||No||https://clinicaltrials.gov/show/NCT00372307||179033|
NCT00372541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD1120041348U|Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children|Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children Aged Less Than Five Years at Mulago Hospital: A Randomized Controlled Trial||Makerere University||Completed|September 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|348|||Both|6 Months|59 Months|No|||July 2010|July 23, 2010|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372541||179015|
NCT00372840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-FCRB-04-002-P|Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer|Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment||Fox Chase Cancer Center||Active, not recruiting|May 2006|||November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|332|||Both|18 Years|120 Years|No|||March 2016|March 1, 2016|September 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00372840||178993|
NCT00373126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC 06-05|The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia|A Double-Blind, Placebo-Controlled Trial of Reward Responsivity During Nicotine Withdrawal in Smokers With Schizophrenia and Normal Controls||North Suffolk Mental Health Association||Completed|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2009|May 14, 2009|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00373126||178972|
NCT00373698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAC 06-073|Re-Engineering Systems for the Primary Care Treatment for PTSD|Reengineering Systems for the Primary Care Treatment of PTSD|RESPECT-PTSD|VA Office of Research and Development|Yes|Completed|March 2008|April 2012|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|N/A|No|||June 2014|April 6, 2015|September 6, 2006||No||No|July 31, 2014|https://clinicaltrials.gov/show/NCT00373698||178929|
NCT00373971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1995-1-62|Preventing Loss of Weight, Fat Free Mass and Activities of Daily Living|Nutritional Care – Preventing Loss of Weight, Fat Free Mass and Activities of Daily Living Four Months After Surgery.||University of Aarhus||Completed|November 1995|July 1998||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||252|||Both|65 Years|N/A|No|||September 2006|September 7, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373971||178908|
NCT00375128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC027.2|Sporozoite Challenge of Polyprotein Vaccinees|Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Polyprotein Malaria Vaccines 'FP9−PP, MVA−PP' and Control Non−Vaccinated Volunteers||European Malaria Vaccine Initiative|No|Completed|September 2006|April 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2007|October 18, 2007|September 10, 2006||||No||https://clinicaltrials.gov/show/NCT00375128||178820|
NCT00374803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyforticINVINT|Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal|A 12-month, Prospective, Randomized, Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal||University of Cincinnati|No|Completed|April 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|75 Years|No|||April 2012|April 10, 2012|September 8, 2006||No||No|March 9, 2012|https://clinicaltrials.gov/show/NCT00374803||178844|
NCT00375102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 EA-0000041|Acupuncture and the Relaxation Response for Substance Abuse|Acupuncture and the Relaxation Response for Homeless Veterans With Substance Abuse||VA Boston Healthcare System|No|Completed|November 2006|November 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375102||178822|
NCT00375947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIA-0001|Study of Effectiveness of Hand Exercises to Treat Symptoms of Hand Osteoarthritis|Efficacy of a Home-Based Hand Range-of-Motion and Strength Training Exercise Program for Improvement of Hand Function in Older Adults With Hand Osteoarthritis: a Randomized Controlled Trial||The Arthritis Research Institute of America||Completed|November 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2|||65|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2007|August 22, 2007|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375947||178758|
NCT00372372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HARECCTR0500019|The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment|||Tuen Mun Hospital|Yes|Completed|January 2004|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||September 2007|September 27, 2007|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372372||179028|
NCT00376207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK-0102200601|Physical Activity After Stroke: How Does it Effect Chronical Inflammation and Insulin Sensitivity|||Bispebjerg Hospital||Completed|January 2006|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|200|||Both|40 Years|N/A|No|||October 2007|October 16, 2007|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376207||178738|
NCT00374088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBMED No.: 2004-851|N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)|Attenuation of Myocardial Dysfunction by N-Acetylcysteine in Infants Undergoing Arterial Switch Procedure||University of Michigan|Yes|Completed|February 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|N/A|3 Months|No|||December 2011|December 14, 2011|September 7, 2006|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00374088||178899|
NCT00376597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-70305|Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection|A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|June 2006|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|877|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376597||178709|
NCT00365326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFM-705|Safety and Efficacy of Autologous, Intracoronary Stem Cell Injections in Total Coronary Artery Occlusions|Safety and Efficacy of Autologous, Intracoronary Stem Cell Injections in Total Coronary Artery Occlusions||Case Western Reserve University||Completed|January 2006|June 2008|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2006|March 8, 2011|August 15, 2006||||||https://clinicaltrials.gov/show/NCT00365326||179561|
NCT00365339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-287|Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir|Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Famotidine on the Pharmacokinetics of Atazanavir/Ritonavir/Tenofovir in Healthy Subjects||Bristol-Myers Squibb||Completed|April 2006|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5|||40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|April 7, 2011|August 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00365339||179560|
NCT00376155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG47|Comparison of Two Strategies for the Delivery of IPTc|Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission||Gates Malaria Partnership|Yes|Completed|May 2006|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14000|||Both|3 Months|5 Years|Accepts Healthy Volunteers|||February 2008|February 7, 2008|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376155||178742|
NCT00376415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001944|A Safety Study of Lessertia Frutescens in Adults.|A Randomized, Double-blind Placebo-controlled Phase 1 Trial of Lessertia Frutescens in Adults.||University of Missouri-Columbia||Completed|September 2004|January 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Screening||||24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 6, 2010|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00376415||178723|
NCT00373152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS006|MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer|Breast MRI Assessment of Tumor Viability After Radiofrequency Ablation (RFA)||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|March 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|No|||August 2011|August 11, 2011|September 6, 2006|Yes|Yes|No patient accrual|No||https://clinicaltrials.gov/show/NCT00373152||178970|
NCT00372567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181112|Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors|A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib||Pfizer|Yes|Terminated|June 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|September 5, 2006|Yes|Yes|See termination reason in detailed description.|No|October 27, 2010|https://clinicaltrials.gov/show/NCT00372567||179014|On 18 June 2009, the study was prematurely stopped for operational reasons (poor recruitment, lack of interest, and change of clinical practice) and not related to safety concerns
NCT00373139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/08/VA11|Accuracy of Whole-Blood Testing for Rapid Detection of Pregnancy|Accuracy of Whole-Blood Testing for Rapid Detection of Pregnancy||Maimonides Medical Center|No|Completed|July 2006|August 2008|Actual|August 2008|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|633|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy ED adult women of child bearing age.|December 2013|December 27, 2013|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373139||178971|
NCT00373984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shoulderpain|A Study of the Incidence of Post-Thoracotomy Shoulder Pain|A Study of the Incidence of Post-Thoracotomy Shoulder Pain||University Health Network, Toronto||Completed|January 2005|||January 2006|Actual|N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|No|||October 2013|October 4, 2013|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373984||178907|
NCT00373997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060725|Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux|Role of Esophageal and Laryngeal Biopsies in Suspected Laryngopharyngeal Reflux|biopsy I|Vanderbilt University|No|Completed|September 2006|December 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2011|April 29, 2014|September 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00373997||178906|
NCT00374244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02T-251|Efficacy of Pimozide Augmentation for Clozapine Partial Response|Efficacy of Pimozide Augmentation for Clozapine Partial Response||Yale University|No|Completed|January 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|60 Years|No|||February 2016|February 4, 2016|September 7, 2006||No||No|January 10, 2013|https://clinicaltrials.gov/show/NCT00374244||178887|
NCT00375141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-316279|Long-Pulsed Dye Laser and Intense Pulsed Light for Skin Rejuvenation.|||Bispebjerg Hospital||Terminated||May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind|||||||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2007|June 4, 2007|September 11, 2006|||Inclusion, treatments and follow-up are finished|No||https://clinicaltrials.gov/show/NCT00375141||178819|
NCT00375375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minimal hepatic encephalopathy|Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life|||Postgraduate Institute of Medical Education and Research||Completed|January 2004|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|N/A|N/A|No|||March 2007|March 1, 2007|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375375||178801|
NCT00375609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT05-003|Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)|Evaluation of the Factor Xa Inhibitor, PRT054021, Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events After Unilateral Total Knee Replacement (EXPERT)||Portola Pharmaceuticals||Completed|May 2006|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|200|||Both|18 Years|75 Years|No|||September 2007|September 10, 2007|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375609||178784|
NCT00375622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3393|Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial|||Rabin Medical Center||Completed|February 2005|June 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2006|September 12, 2006|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375622||178783|
NCT00376545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060243|Brain Connectivity Between Visual Input and Movement|Brain Connectivity Between Visual Input and Motor Output||National Institutes of Health Clinical Center (CC)||Completed|September 2006|||November 2008|Actual|N/A|Observational|N/A||||25|||Both|18 Years|N/A|No|||November 2009|September 26, 2015|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00376545||178713|
NCT00372385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX05-950-104EU|Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C|A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects With Hepatitis C||Vertex Pharmaceuticals Incorporated|Yes|Completed|August 2006|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|334|||Both|18 Years|65 Years|No|||June 2014|June 25, 2014|September 1, 2006|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00372385||179027|
NCT00372398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTWC/CREC/429/06|Premature Coronary Atherosclerosis in Scleroderma|Premature Coronary Atherosclerosis in Scleroderma: A Case Control Study||Tuen Mun Hospital|Yes|Completed|October 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|scleroderma patients|September 2010|September 15, 2010|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372398||179026|
NCT00374634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|indvFSH2006|Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination|Individual Versus Standard rFSH Dose for Controlled Ovarian Stimulation and Intrauterine Insemination. A Prospective Randomised Multi Centre Study||Rigshospitalet, Denmark|Yes|Completed|September 2006|October 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|234|||Female|25 Years|39 Years|No|||September 2011|September 30, 2011|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374634||178857|
NCT00374647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STN INV INT|Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts|Open Label Randomized Single Study to Evaluate the Safety & Efficacy of Early CNI Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil; MMF (CellCept) and Sirolimus (Rapamune)||University of Cincinnati|No|Completed|March 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|75 Years|No|||June 2008|June 5, 2008|September 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00374647||178856|
NCT00365001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP18663|A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.|A Randomized, Open-label Study to Assess the Pharmacokinetics of Simvastatin and Methotrexate in Combination With Tocilizumab in Patients With Rheumatoid Arthritis.||Hoffmann-La Roche||Completed||April 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|75 Years|No|||June 2010|June 10, 2010|August 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00365001||179584|
NCT00365014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0036|Progression of Hematopoietic Diseases in Shanghai, China|Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.||University of Colorado, Denver||Completed|August 2003|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10757|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with blood diseases|July 2013|July 19, 2013|August 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00365014||179583|
NCT00365352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111460|XP13512 vs. Placebo in Patients With Restless Legs Syndrome.|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.||XenoPort, Inc.|No|Completed|August 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|325|||Both|18 Years|N/A|No|||May 2011|July 15, 2013|August 15, 2006|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00365352||179559|
NCT00376168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-06-001|A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease|A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease||Protalix|Yes|Completed|August 2007|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|September 12, 2006|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00376168||178741|
NCT00376428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-03-10|Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients|Application of Functional Electrophysiological Tests to Evaluate Pharmacological Treatments in Patients With Cystic Fibrosis||Assistance Publique - Hôpitaux de Paris||Terminated|January 2003|June 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||September 2006|February 24, 2015|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376428||178722|
NCT00373451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01106|Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome|Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)|ISAR-REACT-4|Deutsches Herzzentrum Muenchen|Yes|Completed|July 2006|July 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1721|||Both|18 Years|80 Years|No|||May 2012|May 7, 2012|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373451||178948|
NCT00372580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701271|Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis|Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis||National Taiwan University Hospital||Recruiting|August 2006|December 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||110|||Both|N/A|N/A|No|||September 2006|September 5, 2006|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372580||179013|
NCT00372827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-03-06|Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension|Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|February 2004|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||245|||Both|18 Years|N/A|No|||May 2008|April 5, 2012|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372827||178994|
NCT00373425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-302|A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors|A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors|RADIANT|Astellas Pharma Inc|Yes|Completed|September 2006|June 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1252|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|September 7, 2006|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT00373425||178950|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.
NCT00373438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDH-ECMO/BALLOON-TRIAL-135/06|Fetoscopic Tracheal Balloon Occlusion in Left Diaphragmatic Hernia|Randomized Clinical Trial in Order to Assess the Effect of Fetoscopic Tracheal Balloon Occlusion on the Postnatal Disease Course in Neonates With Left Congenital Diaphragmatic Hernia - FDH-ECMO/BALLOON-TRIAL||University Hospital, Bonn|Yes|Recruiting|January 2009|July 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|January 5, 2009|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373438||178949|
NCT00373711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|END0003|Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA|Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection||Stanford University|Yes|Withdrawn|May 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with Thyroid cancer|April 2011|April 7, 2011|September 6, 2006||No|Abandoned|No||https://clinicaltrials.gov/show/NCT00373711||178928|
NCT00374517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906241|Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs|A Phase II Clinical Trial of Pimonidazole Hydrochloride as a Hypoxia Marker in Subjects Undergoing Elective Lung Resection for Treatment-Refractory Pulmonary Tuberculosis||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2006|February 2010|Anticipated|February 2010|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|N/A|No|||February 2010|September 26, 2015|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374517||178866|
NCT00374829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA 0530008|Impact of an IT-Based and Healthcare Professional Support Program on Patients With High Blood Pressure|The Impact of a Multidisciplinary, Information Technology Supported Program on Blood Pressure Control in Primary Care (The Loyal Study)||Université de Montréal|No|Active, not recruiting|May 2004|June 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|N/A|No|||May 2007|May 6, 2009|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374829||178843|
NCT00375674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181109|A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer|Sunitinib Treatment Of Renal Adjuvant Cancer (S-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC|S-TRAC|Pfizer|Yes|Active, not recruiting|August 2007|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00375674||178779|
NCT00375960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V3381-2DPNP01|A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Crossover Study of the Safety, Efficacy and Pharmacokinetics of Two Escalating, Oral Doses of V3381 (200 mg BID and 400 mg BID) for 28 Days in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)||Vernalis (R&D) Ltd||Completed|June 2006|April 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|75 Years|No|||March 2007|March 30, 2007|September 11, 2006||||||https://clinicaltrials.gov/show/NCT00375960||178757|
NCT00375388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET/NL/97.01|The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial|Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial||Bethesda General Hospital, Hoogeveen||Completed|January 1998|October 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|30 Years|80 Years|No|||September 2006|September 12, 2006|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375388||178800|
NCT00375635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBD2006|Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis|Removal of Protein Bound Uremic Toxins in Chronic Hemodialysis Patients by Modified Plasma Separation and Adsorption Combined With Hemodialysis||Rigshospitalet, Denmark||Recruiting|March 2006|October 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||10|||Both|18 Years|70 Years|No|||September 2006|September 12, 2006|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375635||178782|
NCT00375648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EFR08|Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer|Assessment of the Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer|TRAPEZE|Novartis||Completed|June 2005|||July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Male|18 Years|N/A|No|||June 2011|June 9, 2011|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375648||178781|
NCT00376272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G106|GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence|Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence||Gruppo di Ricerca GISSI|Yes|Completed|November 2004|March 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1442|||Both|40 Years|N/A|No|||April 2009|April 17, 2009|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00376272||178733|
NCT00376285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5431015|Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033|A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects||Pfizer||Withdrawn|November 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|September 13, 2006||||||https://clinicaltrials.gov/show/NCT00376285||178732|
NCT00372983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV205-C101|Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy|A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin||Cellectar Biosciences, Inc.|No|Completed|August 2006|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|65 Years|No|||December 2007|December 17, 2007|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372983||178983|
NCT00372996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021004|Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer|A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer||Pfizer|No|Terminated|February 2007|June 2014|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|September 5, 2006|Yes|Yes|This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature    closure was not prompted by any safety or efficacy concerns.|No|June 3, 2015|https://clinicaltrials.gov/show/NCT00372996||178982|
NCT00375219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGX-635-CML-202|Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation|A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation||Teva Pharmaceutical Industries|Yes|Completed|September 2006|September 2013|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|September 8, 2006|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00375219||178813|
NCT00365898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP3011|Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain|A Study of the Efficacy and Safety of 8 Mg Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain||Purdue Pharma LP||Terminated|July 2005|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|18 Years|N/A|No|||August 2006|August 16, 2006|August 16, 2006||||||https://clinicaltrials.gov/show/NCT00365898||179518|
NCT00365911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/038|Prevalence of Renal Failure and Risk Factors in an Unreferred Healthy Population|Prevalence of Renal Failure and Risk Factors in an Unreferred Healthy Population||University Hospital, Ghent|No|Completed|March 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|August 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00365911||179517|
NCT00366236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-3017|Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents|Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents||Romark Laboratories L.C.||Completed|February 2004|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|12 Years|N/A|No|||August 2006|August 18, 2006|August 18, 2006||||No||https://clinicaltrials.gov/show/NCT00366236||179493|
NCT00366249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074K5-319|Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.|A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|January 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1061|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|August 17, 2006|Yes|Yes||No|July 14, 2009|https://clinicaltrials.gov/show/NCT00366249||179492|
NCT00372320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060206|Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer|Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of AdhAQP1, an Adenoviral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction||National Institutes of Health Clinical Center (CC)||Completed|August 2006|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2016|February 13, 2016|September 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00372320||179032|
NCT00376441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-119|Evaluate Women After Vaginal Surgery for Urinary Symptoms and Sexual Function|Study of Sexual Function and Urinary Symptoms in Women Having Vaginal Surgeries||William Beaumont Hospitals|No|Completed|August 2006|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|41|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women at least 18 years of age having urinary incontinence or pelvic organ prolapse.|August 2011|August 19, 2011|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376441||178721|
NCT00373464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-003078-92|Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Surgery|Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Gynaecologic Surgery With Expected Need of Post-operative Opioids||Oslo University Hospital||Completed|March 2006|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||126|||Female|18 Years|70 Years|No|||August 2005|June 30, 2011|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00373464||178947|
NCT00373724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-03-23-05|A Placebo-Controlled Study Assessing Lateral Branch Radiofrequency Denervation for Sacroiliac (SI) Joint Pain|||Johns Hopkins University|Yes|Completed|November 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||May 2008|May 7, 2008|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373724||178927|
NCT00373737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0005|Microarray Analysis of Gene Expression in Liver Tumors|Microarray Analysis of Gene Expression in Liver Tumors||Stanford University||Completed|May 1999|December 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|liver tumor|Both|18 Years|N/A|No|Non-Probability Sample|Patients with liver tumors undergoing partial liver resection, open liver biopsy, and        patients undergoing liver transplantation with or without liver tumors at Stanford        University|July 2010|July 23, 2010|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373737||178926|
NCT00374010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412044|Improving Patient-Clinician Communication About End-of-Life Care|Improving Patient-Clinician Communication Among End-Stage Renal Disease African Patients and Their Families||University of Pittsburgh|No|Active, not recruiting|January 2005|June 2008|Anticipated|June 2007|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00374010||178905|
NCT00374257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-054|UVB Phototherapy Treatment of Oral Chronic GVHD|Narrow-Band UVB Phototherapy for Treatment of Oral Chronic Graft-versus-Host Disease||Brigham and Women's Hospital|Yes|Terminated|August 2006|August 2010|Anticipated|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|4 Years|N/A|No|||March 2010|March 17, 2010|September 8, 2006||No|Low/slow accrual|No||https://clinicaltrials.gov/show/NCT00374257||178886|
NCT00374530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060026|Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2|Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2||Danish Headache Center||Completed|August 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2007|July 31, 2007|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374530||178865|
NCT00374543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000142|Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder|Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder||Massachusetts General Hospital|Yes|Terminated|February 2006|November 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|75 Years|No|||March 2014|March 20, 2014|September 8, 2006||No|Recruitment goal could not be achieved|No|May 20, 2013|https://clinicaltrials.gov/show/NCT00374543||178864|This study was terminated due to extreme difficulties in participant recruitment. Therefore, the sample size is extremely low, leaving inconclusive data.
NCT00374842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108656|Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate|A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidates Compared to Fluarix™ Administered Intramuscularly in Subjects Aged 18-59 Years.||GlaxoSmithKline||Completed|October 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|300|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||February 2013|March 7, 2013|September 8, 2006|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00374842||178842|
NCT00374855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9593|A Study in People With Mild Hypertension|Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension||Eli Lilly and Company||Completed|September 2006|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||153|||Both|18 Years|70 Years|No|||May 2007|May 11, 2007|September 8, 2006||||||https://clinicaltrials.gov/show/NCT00374855||178841|
NCT00375700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-4-0029 / 23027|Effect of an Oral Supplement on the Total Energy and Protein Intake of Head and Neck Cancer Patients in the Last 2 Weeks of Radiation Therapy|Efficacy of an Oral Nutrition Supplement on the Total Caloric and Protein Intake of Head and Neck Cancer Patients During the Last 2 Weeks of Radiation Therapy||AHS Cancer Control Alberta|Yes|Withdrawn|November 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|February 24, 2016|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375700||178777|
NCT00376220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-04-23-10|Bipolar Depression Research Study|A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression||Johns Hopkins University|Yes|Completed|May 2004|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|75 Years|No|||January 2011|June 22, 2011|September 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00376220||178737|
NCT00376532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJU 06U.282|Extracellular Matrix Marker of Arrhythmia Risk (EMMA)|Role of Matrix Metaloproteinase(MMP)9 and MMP 2 in Risk Stratification for Ventricular Tachycardia/Fibrillation in Patients With Implanted Cardioverter Defibrillator (ICD) Devices.|EMMA|Thomas Jefferson University|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|63|Samples Without DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Inpatients or outpatients with the cardiac device of interest implanted prior to        enrollment.|May 2014|May 5, 2014|September 14, 2006||No||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00376532||178714|
NCT00372450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000489157|Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer|A Quality of Life Comparison in Patients With Malignant Dysphagia Treated With Either Self-Expanding Plastic Stents (SEPS) or Self-Expanding Metal Stents (SEMS)||National Cancer Institute (NCI)||Active, not recruiting|June 2006|||June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|90|||Both|18 Years|N/A|No|||November 2008|May 9, 2009|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00372450||179022|
NCT00373841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610029|Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)|Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis|GAP|University of Pittsburgh|Yes|Recruiting|October 2005|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|500|Samples With DNA|Blood samples necessary to analyze disease progression in patient with idiopathic pulmonary      fibrosis over a long period of time.|Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 and older who have been diagnosed with IPF and referred by a Simmons        Center doctor.|January 2016|January 4, 2016|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373841||178918|
NCT00383474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00147|Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase|A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias||National Cancer Institute (NCI)||Completed|August 2006|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2013|April 14, 2015|September 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00383474||178188|
NCT00365703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17/2006-1-HY-CTIL|Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best?|Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best?||Hillel Yaffe Medical Center|Yes|Completed|September 2006|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|115|||Both|N/A|4 Months|No|||December 2007|December 15, 2007|August 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00365703||179533|
NCT00365924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001294|A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo|A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo)||Pfizer|No|Completed|December 2006|April 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Female|55 Years|70 Years|No|||June 2008|March 20, 2009|August 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00365924||179516|
NCT00365937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUC 05-003|Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides|Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Terminated|August 2006|August 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|August 17, 2006||No|New regulatories of the peptides by the pharmaceutical company (the seller)|No||https://clinicaltrials.gov/show/NCT00365937||179515|
NCT00366262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3175A1-103|Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen|A Randomized, Double-Blind, Parallel Group Study To Compare The 7-Day Gastrointestinal Safety of 2 Doses of PLA-695 To That Of Placebo And Naproxen||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2008|August 1, 2008|August 17, 2006||||||https://clinicaltrials.gov/show/NCT00366262||179491|
NCT00366600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-107|Study Evaluating HKI-272 Administered to Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects.||Puma Biotechnology, Inc.||Completed|July 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|August 17, 2006||||||https://clinicaltrials.gov/show/NCT00366600||179465|
NCT00372879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-451|Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS|Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis.||Lawson Health Research Institute|No|Completed|December 2006|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372879||178991|
NCT00372593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML0531|Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults||Children's Oncology Group|Yes|Active, not recruiting|August 2006|||August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1070|||Both|N/A|29 Years|No|||March 2016|March 10, 2016|September 6, 2006|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT00372593||179012|
NCT00372853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671025|Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma|A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma||AstraZeneca|No|Completed|November 2006|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|September 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372853||178992|
NCT00373763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH-EUROTRIAL I - 093/06|Fetoscopic Tracheal Balloon Occlusion in Unborns With Severe Congenital Diaphragmatic Hernia - EUROTRIAL I|Randomized Clinical Trial for the Assessment of the Life-Saving Potential of Fetoscopic Tracheal Balloon Occlusion in Fetuses With Severe Congenital Diaphragmatic Hernia - EUROTRIAL I||University Hospital, Bonn||Withdrawn|January 2007|||January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|98|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2008|August 22, 2008|September 6, 2006||No|No patients could be recruited and randomized due to other center offering backdoor for    treatment.|No||https://clinicaltrials.gov/show/NCT00373763||178924|
NCT00373776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04--01|Miltefosine for Mucosal Leishmaniasis|||AB Foundation||Completed|April 2004|May 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|12 Years|N/A|No|||September 2006|September 7, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373776||178923|
NCT00373750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA019042-01A1|Cradling Our Future Through Family Strengthening Study|In-home Prevention of SA Risks for Native Teen Families||Johns Hopkins Bloomberg School of Public Health|No|Completed|June 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|322|||Female|12 Years|19 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373750||178925|
NCT00374023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-012|A Study on Immunological Effect of Vitamin A and Zinc in a Placebo Controlled 4 Cell Trial|||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|July 1993|November 1995||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||147|||Both|1 Year|3 Years|No|||May 1993|September 7, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374023||178904|
NCT00374270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICORE-GG5130000107|Improving Blood Pressure Management in Patients With Diabetes|Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN|SCRIP-HTN|University of Alberta|No|Completed|May 2005|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|||Actual|227|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 7, 2007|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374270||178885|
NCT00374868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8679|Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)|Phase 1/2 Study of Biweekly ALIMTA Plus Cisplatin in Patients With Locally, Advanced, Non-Resectable or Metastatic Urothelial Cancer||Eli Lilly and Company|No|Completed|August 2006|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||October 2010|October 20, 2010|September 11, 2006|Yes|Yes||No|April 29, 2009|https://clinicaltrials.gov/show/NCT00374868||178840|
NCT00375154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URGPROT1|HERMES STUDY: Study on the Feasibility and Efficiency of Noninvasive Positive-Pressure Ventilation (NPPV) in Prehospital Care|Noninvasive Positive-pressure Ventilation (NPPV) for Acute Respiratory Failure in Out-of-hospital Patients: a Multicenter, Prospective, Randomized Controlled Trial||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Withdrawn|August 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|September 11, 2006|||major difficulties in training investigators in other centers|No||https://clinicaltrials.gov/show/NCT00375154||178818|
NCT00375401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351025|A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety|A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects||Pfizer|Yes|Terminated|October 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2536|||Both|18 Years|70 Years|No|||November 2012|November 5, 2012|September 11, 2006|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00375401||178799|
NCT00375414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastropexy|Role of Prophylactic Antibiotics in New Introducer PEG-Gastropexy|New Introducer PEG-Gastropexy Does Not Need Prophylactic Antibiotics: Prospective Randomised Double Blind Placebo Controlled Trial||Johann Wolfgang Goethe University Hospitals||Completed|October 2003|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|97|||Both|16 Years|88 Years|No|||May 2007|May 4, 2007|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375414||178798|
NCT00375661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O2006-415|Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC|Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma||Kyoto University||Completed|September 2006|March 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|25 Years|75 Years|No|||September 2015|September 1, 2015|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00375661||178780|
NCT00373542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRL103660|12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome|A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep|(CR-RLS)|GlaxoSmithKline|No|Completed|October 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|79 Years|No|||April 2015|April 15, 2015|September 7, 2006||||||https://clinicaltrials.gov/show/NCT00373542||178941|
NCT00375973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-05-01-02|Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome|A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome|CFS|University of Cincinnati|No|Completed|September 2006|March 2014|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||July 2015|July 31, 2015|September 12, 2006|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT00375973||178756|
NCT00375986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00014248|A Comparison of Manual vs. Spontaneous Removal of the Placenta at Cesarean Section|A Comparison of Manual vs. Spontaneous Removal of the Placenta at Cesarean Section||University of Rochester|No|Completed|September 2006|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|150|||Female|18 Years|N/A|No|||November 2007|November 12, 2007|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375986||178755|
NCT00376233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMCANNIACIN|Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia|First Detailed Study on Effects of Long Term Regular Cannabis Use on Arachidonic Acid-Prostaglandine Pathways in Schizophrenia||University of Jena||Completed|February 2004|June 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2006|October 11, 2006|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376233||178736|
NCT00373555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-20269|Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis|Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis||University of Calgary|No|Completed|September 2006|August 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|50|||Both|16 Years|N/A|No|||August 2008|September 30, 2008|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373555||178940|
NCT00373568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05--01|Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis|Miltefosine (42 Days) for Mucosal Leishmaniasisi||AB Foundation||Completed|April 2005|December 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|12 Years|80 Years|No|||May 2010|May 29, 2010|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373568||178939|
NCT00374348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH-PSY-Aripiprazole/Schiz/OCD|Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)|"Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)".||Jamaica Hospital Medical Center||Completed|March 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||January 2009|September 15, 2011|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374348||178879|
NCT00375258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN86750102|Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage|A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement||London School of Hygiene and Tropical Medicine|Yes|Completed|May 2005|March 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20211|||Both|16 Years|N/A|No|||June 2011|June 29, 2011|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375258||178810|
NCT00366301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000823|The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes|The LANCET Trial: A Randomized Clinical Trial of Lantus for C-reactive Protein Reduction in Early Treatment of Type 2 Diabetes||Brigham and Women's Hospital|Yes|Terminated|August 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|500|||Both|18 Years|79 Years|No|||October 2010|October 26, 2010|August 17, 2006||No|Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.|No|October 26, 2010|https://clinicaltrials.gov/show/NCT00366301||179488|
NCT00366574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-05-003|Comparison of a Laser Keratome to a Mechanical Microkeratome|Comparison of INTRALASE® to AMADEUS™ Microkeratome||Medical University of South Carolina||Completed|September 2004|February 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||March 2005|August 17, 2006|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366574||179467|
NCT00366587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-06-004|Comparison of Visual Outcomes and Patient Satisfaction After Cataract Surgery and Implantation of ReSTOR and ReZoom IOLs|Contralateral Eye Comparison of Visual Outcomes and Patient Satisfaction After Routine Phacoemulsification and Implantation of ReSTOR and ReZoom IOLs||Medical University of South Carolina||Completed|February 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||July 2006|October 1, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366587||179466|
NCT00366912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aladin 2006|Unloading Respiratory Muscles During NIV: Comparison of a Spontaneous and Auto-adjusting Controlled Mode|||Krankenhaus Kloster Grafschaft||Terminated|August 2006|April 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2009|August 18, 2006|||No longer recruiting: participants are no longer being recruited or enrolled|No||https://clinicaltrials.gov/show/NCT00366912||179441|
NCT00372346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|419000－X90305|Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension|||Zhejiang University||Recruiting|June 2006|December 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|60 Years|No|||August 2006|September 5, 2006|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372346||179030|
NCT00372619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML0523|Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia||Children's Oncology Group|Yes|Active, not recruiting|March 2007|||August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|74|||Both|1 Year|30 Years|No|||October 2015|October 5, 2015|September 6, 2006|Yes|Yes||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00372619||179010|
NCT00373165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19827|Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients|Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load||Lower Saxony Center for Nephrology||Completed|August 2000|October 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|18 Years|N/A|No|||September 2006|September 12, 2006|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00373165||178969|
NCT00373789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDN 12|Refractory Urge Incontinence and Botox Injections|Refractory Urge Incontinence and Botox Injections||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Terminated|June 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Female|21 Years|N/A|No|||October 2010|January 9, 2011|September 6, 2006|Yes|Yes|higher than anticipated rate of increased post-void residual in subjects who received    botulinum toxin A injection|No||https://clinicaltrials.gov/show/NCT00373789||178922|
NCT00373802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASAL #9579|The Use of Nasal Phenylephrine in Infants With Bronchiolitis|A Randomized, Double-Blinded Placebo Control Trial of Nasal Phenylephrine in Infants With Bronchiolitis||Akron Children's Hospital||Completed|January 2005|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|N/A|12 Months||||January 2009|January 9, 2009|September 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00373802||178921|
NCT00374036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0305603|Metastatic Gastric Cancer FFCD 03-07|Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach||University Hospital, Toulouse|No|Completed|June 2005|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|416|||Both|18 Years|N/A|No|||October 2011|October 10, 2011|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00374036||178903|
NCT00374283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLYOMA|Monitoring of Biopsy-Proven Interstitial Polyomavirus Nephritis in Kidney and Kidney Pancreas Transplant Recipients|Monitoring of Biopsy-Proven Interstitial Polyomavirus Nephritis in Kidney and Kidney Pancreas Transplant Recipients||University of Cincinnati|No|Completed|June 2001|October 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|70 Years|No|||December 2007|December 20, 2007|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374283||178884|
NCT00374556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001703|Insomnia and Osteoarthritis Study|The Efficacy of Eszopiclone (Lunesta) for Chronic Insomnia Associated With Osteoarthritis.||Johns Hopkins University||Completed|January 2006|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|64 Years|No|||March 2014|March 10, 2014|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374556||178863|
NCT00374569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-05-05|Dynamic Posturographic Testing and Motor Learning Predictability in Gymnasts|Dynamic Posturographic Testing and Motor Learning Predictability in Gymnasts||Carrick Institute for Graduate Studies|No|Completed|June 2005|September 2006|Actual|July 2006|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|10 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374569||178862|
NCT00374881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-3010|A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects|A Randomized, Double-Blind, Single-Center, 5 Way Cross-Over Study to Assess the Effect of Adding Oral Phenylephrine and Oral Sorbitol to Low Dose (1.5 mg) Plain Oral Morphine in Human Volunteers: Analgesia and Side Effect Assessment.||BioLineRx, Ltd.|No|Completed|September 2006|August 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|9|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00374881||178839|
NCT00374894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20032063 - 2001102049|The Combined Effect of 2,3-Dimercaptosuccinic Acid and Multi-Nutrients on Children in Lead Poisoning|||China Medical University, China||Completed|March 2004|August 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||500|||Both|3 Years|6 Years||||April 2004|September 11, 2006|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00374894||178838|
NCT00375167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Efficacy of the Recovery Workbook as a Psychoeducational Tool for Facilitating Recovery|Efficacy of the Recovery Workbook as a Psychoeducational Tool for Facilitating Recovery in Persons With Severe and Persistent Mental Illness||Queen's University||Completed|September 2006|May 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 14, 2008|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375167||178817|
NCT00375427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EIT14|Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions|A Prospective, Randomized, Multi-center Comparative 2-arm Trial of Efficacy and Safety of Zoledronic Acid (Every 3-months vs. Every 4 Weeks) Beyond Approximately 1 Year of Treatment With Zoledronic Acid in Patients With Bone Lesions From Breast Cancer||Novartis||Completed|February 2006|||February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|430|||Female|18 Years|N/A|No|||July 2011|April 9, 2012|September 12, 2006||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00375427||178797|
NCT00375687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-Urol1|Investigation of Early Hormonotherapy Efficacy of Prostate Cancer|Investigation of Early Hormonotherapy Efficacy of High Risk Patients for Progression of Prostate Cancer After Radical Prostatectomy||Kaunas University of Medicine||Recruiting|August 2005|January 2020||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||61|||Male|40 Years|80 Years|No|||November 2005|September 12, 2006|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375687||178778|
NCT00372424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181113|Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive|An Explorative Study Of The Tolerability Of SU011248 In Combination With Docetaxel And Trastuzumab As First-Line Treatment In Patients With Breast Cancer Over-Expressing HER-2||Pfizer|No|Completed|December 2006|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||December 2012|December 21, 2012|September 5, 2006|No|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00372424||179024|
NCT00374075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11893|Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy|In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy||University of Utah||Completed|September 2003|February 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|2 Years|N/A|No|||September 2006|September 11, 2006|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00374075||178900|
NCT00374335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 02 029E|Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas|Multiple Hemangiomas and Large Cutaneous Hemangiomas of Infancy: Incidence of Hepatic Hemangiomatosis||Children's Mercy Hospital Kansas City|Yes|Completed|September 2006|December 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|261|||Both|N/A|6 Months|No|||September 2011|September 12, 2011|September 7, 2006||No||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00374335||178880|
NCT00375206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM FLS-001|A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine|A Phase I Study to Assess Safety, Tolerability and Immunogenicity of a Trivalent Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) to Healthy Subjects||PowderMed||Completed|September 2006|January 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||189|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2007|January 25, 2007|September 11, 2006||||||https://clinicaltrials.gov/show/NCT00375206||178814|
NCT00382564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060249|Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease|Magnetic Resonance Angiography (MRA) in the Diagnosis of Atherosclerotic Disease Using High Field (3T) MRI Scanners: A Pilot Technical Development Study||National Institutes of Health Clinical Center (CC)||Completed|September 2006|May 2012||||N/A|Observational|N/A|||Actual|216|||Both|18 Years|N/A|No|||May 2012|May 30, 2015|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382564||178258|
NCT00383162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX106571|A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)|A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)||GlaxoSmithKline|No|Completed|November 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|65 Years|No|||March 2011|May 31, 2012|September 29, 2006|Yes|Yes||No|October 3, 2008|https://clinicaltrials.gov/show/NCT00383162||178212|
NCT00375297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99321|Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women|Randomized Double Blind Placebo Controlled Study of Sildenafil for Treatment of Serotonergic Reuptake Inhibitor Associated Sexual Dysfunction in Women With Major Depression Treated to Remission||University of New Mexico||Completed|January 2001|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|18 Years|50 Years|No|||September 2006|September 8, 2006|September 11, 2005||||||https://clinicaltrials.gov/show/NCT00375297||178807|
NCT00366314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-142|Frequency of Accessing Central Lines for Blood Samples|Frequency of Accessing Central Lines for Blood Samples and Medication Administration: A Comparison Between CICU, PICU and NICU||Children's Healthcare of Atlanta||Terminated|June 2003|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||320|||Both|N/A|18 Years|No|||June 2007|June 12, 2007|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00366314||179487|
NCT00366327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3168A1-314|Study Evaluating Bifeprunox in Patients With Schizophrenia.|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|January 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|66 Years|No|||April 2008|February 7, 2013|August 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00366327||179486|
NCT00366340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-006|Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.|A Phase 3, Randomized, Active-Controlled, Double-blind Trial of the Safety, Tolerability, and Immunologic Non-Inferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Germany.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|604|||Both|56 Days|112 Days|Accepts Healthy Volunteers|||June 2012|June 28, 2012|August 17, 2006|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00366340||179485|
NCT00366613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI-06-002|Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation|Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation||Medical University of South Carolina||Withdrawn|July 2005|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|4 Years|18 Years|No|||August 2007|October 2, 2007|August 17, 2006|||We wish to wait until there is more data available using this substance.|No||https://clinicaltrials.gov/show/NCT00366613||179464|
NCT00372892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-105|Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)|A Randomized, Double Blind, Placebo Controlled Pilot Trial of Rituximab for Non-splenectomized Adults With Acute Immune Thrombocytopenic Purpura Receiving Standard Treatment (R-ITP)||McMaster University|Yes|Completed|September 2006|June 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|80 Years|No|||June 2012|June 6, 2012|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372892||178990|
NCT00373178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020401975|Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes|Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes||Aristotle University Of Thessaloniki||Completed|January 2005|June 2008|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|40 Years|70 Years|No|||November 2012|November 1, 2012|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373178||178968|
NCT00374049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-086|MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer|A Pilot Dose Finding Study of MUC1 Vaccine in Conjunction With Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM in Patients With Recurrent and/or Advanced Prostate Cancer||University of Pittsburgh|Yes|Active, not recruiting|June 2006|December 2015|Anticipated|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 23, 2015|September 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00374049||178902|
NCT00374296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-007|MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease|A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease||Mirati Therapeutics Inc.|No|Terminated|September 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|September 7, 2006|Yes|Yes|The Clinical Development Program for MGCD0103 is being re-evaluated|No||https://clinicaltrials.gov/show/NCT00374296||178883|
NCT00374582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA|End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)|End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)||University of Cincinnati|No|Completed|September 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|September 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00374582||178861|
NCT00374907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-041|A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients||AstraZeneca||Completed|September 2006|December 2009|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|70 Years|No|||March 2015|April 20, 2015|September 7, 2006|Yes|Yes||No|December 26, 2010|https://clinicaltrials.gov/show/NCT00374907||178837|
NCT00375713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00410|Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema|A Multi-centre, Double-blind, Double-dummy, Randomized, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Xyzal® 5mg od vs Zyrtec® 10mg od in Subjects Aged 15 Years and Above With Dermatitis and Eczema||UCB Pharma|No|Completed|October 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|466|||Both|15 Years|N/A|No|||December 2009|August 30, 2011|September 12, 2006|No|Yes||No|July 8, 2009|https://clinicaltrials.gov/show/NCT00375713||178776|
NCT00375999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-232|Docetaxel and Epirubicin in Advanced Gastric Cancer|A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.||Yonsei University||Completed|September 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|September 13, 2006||No||No|January 14, 2014|https://clinicaltrials.gov/show/NCT00375999||178754|
NCT00372437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-006|A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine|A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine||Mirati Therapeutics Inc.|No|Completed|September 2006|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|September 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372437||179023|
NCT00372970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4204|Placebo Controlled Trial of Botulinum Toxin for Gastroparesis|Randomized Placebo-Controlled Double Blind Study of Botulinum Toxin Versus Placebo for the Treatment of Gastroparesis||Temple University|No|Completed|July 2003|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|September 5, 2006||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT00372970||178984|
NCT00374608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-2006|Exercise in Chronically Paced Children|A Single Center, Prospective, Pilot Study Examining the Evaluation of Exercise Capacity in Chronically RV Paced Children and Young Adults||Emory University|No|Completed|January 2007|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|10 Years|21 Years|No|Non-Probability Sample|pt who have congenital complete heart block with no other preexisting condition that        precludes the patient from exercise|May 2012|May 30, 2012|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374608||178859|
NCT00374621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97274|Trial of Cervical Ripening and Labor Induction Using Misoprostol With or Without Intravaginal Isosorbide Mononitrate|Randomized Clinical Trial of Cervical Ripening and Labor Induction Using Stepwise Oral Misoprostol With or Without Intravaginal Isosorbide Mononitrate||Stanford University|No|Completed|September 2006|January 2010|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Female|18 Years|N/A|No|||June 2011|June 13, 2011|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00374621||178858|
NCT00374933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08405|Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation|Non-Myeloablative Conditioning With Allogeneic Peripheral Blood Progenitor Cell Transplantation Followed by Prophylactic Activated Donor Lymphocyte Infusion (DLI) for the Treatment of High Risk Acute Leukemia/MDS||University of Pennsylvania||Completed|April 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|70 Years|No|||January 2016|January 29, 2016|September 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00374933||178835|
NCT00374946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-355/98|A Clinical Evaluation of Wear Couples in THA|||Frederiksberg University Hospital||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|N/A|N/A||||November 2007|November 26, 2007|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00374946||178834|
NCT00376012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|trc20A|Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis|Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis||Tuberculosis Research Centre, India||Active, not recruiting|February 2001|September 2008|Anticipated|September 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|15 Years|60 Years|No|||May 2008|June 10, 2008|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376012||178753|
NCT00374374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19990156|Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn’s Disease.|Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn’s Disease.||Odense University Hospital||Completed|May 2001|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||April 2006|September 7, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374374||178877|
NCT00374686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL015 HSC02-0140|Study of Prophylactic Vs Preemptive Valganciclovir|Prophylactic Vs Preemptive Oral Valganciclovir for Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients: A Clinical and Pharmacoeconomic Study||Washington University School of Medicine||Completed|March 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|85 Years|No|||September 2005|September 7, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374686||178853|
NCT00374998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC027.1|Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP|A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates FP9 PP and MVA PP in Healthy Adults Using a Prime-Boost Delivery Schedule||European Malaria Vaccine Initiative||Completed|April 2006|January 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||35|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2007|February 28, 2007|September 10, 2006||||No||https://clinicaltrials.gov/show/NCT00374998||178830|
NCT00367250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETRA 01|Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer|Phase I Study Investigating the Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer With High and Moderate HER2 Expression||Medical University of Vienna|No|Recruiting|July 2006|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Female|18 Years|N/A|No|||September 2010|September 27, 2010|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367250||179415|
NCT00362999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603042|Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism|Histamine Pharmacodynamics in Patients With Allergic Rhinitis: Validation of Laser Doppler Flowmetry as a Surrogate Endpoint||Children's Mercy Hospital Kansas City|No|Recruiting|August 2006|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|blood|Both|7 Years|18 Years|No|Non-Probability Sample|Pediatric patients with allergic rhinitis|July 2011|July 6, 2011|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00362999||179734|
NCT00373191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0575 CDR0000485360|Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery|Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|May 2006|December 2013|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples With DNA|Serum|Female|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed ductal carcinoma in situ or invastive breast cancer.|October 2015|October 9, 2015|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373191||178967|
NCT00373477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-fam/med-161|A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid Recipients|A Randomized Trial of the Cost Effectiveness of Generalist Care Managers for the Treatment of Depression in Medicaid Recipients||University of North Carolina, Chapel Hill||Completed|July 2003|February 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||September 2006|September 6, 2006|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00373477||178946|
NCT00373490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-048|A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)|MK0683 Phase1 Clinical Study - Solid Tumor -||Merck Sharp & Dohme Corp.||Completed|July 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|N/A|No|||August 2015|August 26, 2015|September 7, 2006|Yes|Yes||No|October 20, 2008|https://clinicaltrials.gov/show/NCT00373490||178945|
NCT00372684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051063|PALUREA: Severe Imported Malaria in Adults|PALUREA: Severe Falciparum Imported Malaria in Adults: Clinical and Physiopathological Study|PALUREA|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2006|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|302|Samples With DNA|physiopathologic|Both|18 Years|N/A|No|Probability Sample|Patients with severe malaria and patients with uncomplicated malaria|July 2007|June 18, 2010|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372684||179005|
NCT00372697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995BIT12|Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly|A Randomised, Open-label, Multicenter Study Comparing the Efficacy and Safety of Medical Treatment With Octreotide Acetate 30 mg Administered Every 21 Days for 6 Months With That of Octreotide Acetate 60 mg Administered Every 28 Days for 6 Months in Acromegalic Patients With Uncontrolled Disease||Novartis||Completed|December 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||April 2011|April 19, 2011|September 6, 2006||No||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00372697||179004|
NCT00374101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18/2004|High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding|Proton Pump Inhibitors in Conjunction to Endoscopic Therapy for Bleeding Peptic Ulcers: a Randomized Clinical Trial of High vs Standard Doses||Casa Sollievo della Sofferenza IRCCS|No|Completed|January 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||450|||Both|18 Years|90 Years|No|||April 2007|April 4, 2007|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374101||178898|
NCT00374673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-chronic pain 1|Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders|Efficacy of Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Idiopathic Pain Syndromes : a Double Blind Sham Controlled Study||Hospital Ambroise Paré Paris|No|Completed|October 2006|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374673||178854|
NCT00374595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053-95-FB|Vascular Risk After Kidney Transplantation|Vascular Risk After Kidney Transplantation||University of Nebraska|Yes|Completed|April 2006|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|342|||Both|19 Years|N/A|No|Probability Sample|Transplant Clinic patients|June 2012|June 18, 2012|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374595||178860|
NCT00376558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020855-02|Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence|Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence||National Institute on Drug Abuse (NIDA)||Recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||May 2006|September 14, 2006|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00376558||178712|
NCT00376571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040136|Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?|Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions? A Strategy of Routine Stenting Both Main Vessel and Side Branch Versus a Strategy of Routine Main Vessel Stenting and Optional Treatment of Side Branch|BIFI|Aarhus University Hospital Skejby|Yes|Completed|October 2004|March 2011|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|413|||Both|N/A|N/A|No|||July 2013|July 24, 2013|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00376571||178711|
NCT00372411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|558|Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients|CSP #558 - Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients|VA ROBOTICS|VA Office of Research and Development|Yes|Completed|December 2005|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|127|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|September 5, 2006||No||No|September 4, 2013|https://clinicaltrials.gov/show/NCT00372411||179025|
NCT00373256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181094|A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer|A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer||Pfizer|Yes|Completed|November 2006|August 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|488|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|September 7, 2006|Yes|Yes||No|June 1, 2010|https://clinicaltrials.gov/show/NCT00373256||178962|
NCT00381784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 041|C2P - Phase III: MPowerment and Community Promise|Connect-To-Protect® Phase III: Local Evaluation of Community Promise Connect-To-Protect® Phase III: Local Evaluation of Mpowerment||Westat|Yes|Completed|July 2006|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Both|12 Years|24 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381784||178317|
NCT00375453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91526|Dose Escalation Study of SH U04722 in Solid Tumors|Phase I, Open-label, Dose Escalation Study for Evaluation of Safety, Tolerability, Pharmacokinetics, and Tumor-suppressive Efficacy of SH U04722 in Patients With Solid Tumors||Bayer||Terminated|January 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|74 Years|No|||December 2014|December 30, 2014|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375453||178795|
NCT00382018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000504319|S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy|A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment||Southwest Oncology Group|Yes|Active, not recruiting|October 2006|May 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|651|||Female|18 Years|N/A|No|||September 2015|September 15, 2015|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382018||178300|
NCT00376584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-023|Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin||Merck Sharp & Dohme Corp.||Completed|July 2006|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|825|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|September 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00376584||178710|
NCT00382291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078594|Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder|SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder||University of Florida|Yes|Completed|February 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|56|||Both|7 Years|17 Years|No|||December 2012|February 6, 2013|September 28, 2006|Yes|Yes||No|December 14, 2012|https://clinicaltrials.gov/show/NCT00382291||178279|Temporary study suspension led to smaller number of subjects enrolled than initially planned and resulted in smaller number of subjects analyzed, reducing power.
NCT00375505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GDE21|The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss|Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss||Novartis||Completed|October 2005|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|September 11, 2006||No||No|May 18, 2015|https://clinicaltrials.gov/show/NCT00375505||178792|
NCT00375804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|357.03|Racial Disparity in Endometrial Cancer|Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer||James Graham Brown Cancer Center|Yes|Terminated|June 2003|June 2010|Actual|||N/A|Observational|Observational Model: Cohort||1|Actual|43|||Female|N/A|N/A|No|Probability Sample|Chart review of subjects diagnosed with endometrial cancer|April 2012|April 27, 2012|September 11, 2006||No|Funding and logistical difficuties resulted in the withdrawl of the study.|No||https://clinicaltrials.gov/show/NCT00375804||178769|
NCT00375817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMI-EU-02-008|Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial|A Phase II, Open-Label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)||Bioheart, Inc.|Yes|Active, not recruiting|November 2005|January 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||October 2007|October 11, 2007|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375817||178768|
NCT00375531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB ID #00890|Use of Mindfulness Meditation With Iraqi/Afghanistan War Veterans|Use of Mindfulness Meditation With Iraqi/Afghanistan War Veterans With Post Traumatic Stress Disorder||Philadelphia Veterans Affairs Medical Center||Withdrawn|October 2006|August 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|55 Years|No|||October 2007|April 27, 2015|September 12, 2006|||protocol revisions were deemed unable to be completed by 8/2007|No||https://clinicaltrials.gov/show/NCT00375531||178790|
NCT00363012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6271|Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2|Development of HER-2/Neu (HER2) ICD Memory Immunity After Vaccination With a Plasmid Encoding HER2 ICD in Patients With Advanced Stage HER2 Overexpressing Breast and Ovarian Cancers||University of Washington|No|Completed|April 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|56|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|August 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00363012||179733|
NCT00363298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97134|Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD|Double-blind Trial of Acute and Intermediate-term Dextro-amphetamine Versus Caffeine Augmentation in Treatment Resistant OCD||Stanford University|No|Completed|August 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|No|||June 2012|June 5, 2012|August 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363298||179713|
NCT00363311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVO105948|Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men|A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management||GlaxoSmithKline|Yes|Completed|July 2006|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|302|||Male|50 Years|80 Years|No|||June 2011|March 15, 2012|August 11, 2006|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00363311||179712|
NCT00373204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0229|Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)|Phase II Trial of Motexafin Gadolinium and Docetaxel for Second Line Treatment of Patients With Advanced Non-small Cell Lung Cancer||Pharmacyclics||Terminated|May 2006|May 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|September 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00373204||178966|
NCT00373217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10134|Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Evaluation of the Immunogenicity of Vaccination With Synthetic Peptides in Adjuvant in Patients With Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||University of Virginia||Active, not recruiting|April 2006|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Female|18 Years|N/A|No|||December 2014|December 18, 2014|September 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00373217||178965|
NCT00373503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4942|Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse|Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse||New York State Psychiatric Institute|No|Completed|August 2005|September 2008|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|8|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|September 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00373503||178944|
NCT00374985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-DOR-2004|Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction|Prospective, Open, Multicentre Phase I/II Study to Evaluate the Safety and Efficacy of a Neoadjuvant Radiochemotherapy With Docetaxel and Oxalipaltin in Patients With Adenocarcinoma of the Gastric-oesophageal Junction||Johannes Gutenberg University Mainz|Yes|Completed|October 2005|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||November 2014|November 27, 2014|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00374985||178831|
NCT00374361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO 203|Study of the Relationship Between Blood Vessels and Insulin Response in Adolescents|Relationship of Endothelial Function to Insulin Sensitivity in African American and Caucasian Adolescents||Ohio State University||Completed|July 2003|June 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||66|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||September 2006|September 8, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374361||178878|
NCT00374660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IROF-017|Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors|Phase I-II Clinical and Pharmacokinetic Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors||Eisai Inc.||Active, not recruiting|June 2003|||August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|September 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00374660||178855|
NCT00374309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060237|Experimental Vaccine for Prevention of Ebola Virus Infection|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|September 2006|May 2009||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1|||48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2009|May 6, 2009|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374309||178882|
NCT00374322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF105485|Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer|A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer||GlaxoSmithKline|Yes|Completed|August 2006|July 2013|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3166|||Female|18 Years|N/A|No|||July 2014|August 14, 2014|September 7, 2006|Yes|Yes||No|July 17, 2014|https://clinicaltrials.gov/show/NCT00374322||178881|
NCT00375440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L05-063|Tranexamic Acid Study|Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty||Texas Tech University Health Sciences Center||Withdrawn|February 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|September 11, 2006|||Study halted prematurely as investigator left the institution.|No||https://clinicaltrials.gov/show/NCT00375440||178796|
NCT00372671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-02-144|Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation|Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation, the CR$P-2 Pilot Study.||Lawson Health Research Institute||Completed|June 2005|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|September 6, 2006|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00372671||179006|
NCT00372957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPB106653|Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus|PK/PD Study of GW823093 in Japanese Subjects With T2DM A Single-blind, Placebo Controlled, Randomized, Multi-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GW823093C Administered Orally for 7 Days in Japanese Subjects With Type 2 Diabetes||GlaxoSmithKline||Completed|March 2006|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|20 Years|64 Years|No|||October 2010|October 1, 2010|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372957||178985|
NCT00373828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 73 (NUA)|Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 1: Diagnosis.|Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 1: Diagnosis||Clinical Locomotion Science||Completed|June 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|302|||Both|18 Years|75 Years|No|Non-Probability Sample|Three hundred consecutive patients with an episode of suspected non-cardiac acute chest        pain will be recruited from among patients discharged from an acute chest pain clinic        situated at a large specialized cardiology department.|February 2013|February 19, 2013|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373828||178919|
NCT00373607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTEKINPERU|Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru|Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region||Institute of Tropical Medicine, Belgium|No|Completed|July 2003|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|522|||Both|5 Years|60 Years|No|||September 2010|September 13, 2010|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373607||178936|
NCT00373620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG2001|A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients|A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy in High-Risk Endometrial Cancer Patients After Operation.||Korean Gynecologic Oncology Group||Recruiting|January 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|20 Years|75 Years|No|||December 2005|September 6, 2006|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00373620||178935|
NCT00382031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-EGFr-202|Zalutumumab in Patients With Non-curable Head and Neck Cancer|An Open-Labeled Randomized Parallel Group Trial of Zalutumumab, a Human Monoclonal Anti-EGFr Antibody, in Combination With Best Supportive Care (BSC) vs BSC, in Pts With Non-Curable SCCHN Who Have Failed Standard Platinum-Based Chemotherapy||Genmab|Yes|Completed|November 2006|August 2011|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|September 27, 2006|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT00382031||178299|
NCT00382304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOL26700606|A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea|A Study of the Pharmacokinetics of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea||Sanofi||Completed|September 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 27, 2006||||||https://clinicaltrials.gov/show/NCT00382304||178278|
NCT00374114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|d34c09|A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia|A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia||University of Tennessee||Completed|January 2004|December 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||December 2008|December 12, 2008|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00374114||178897|
NCT00374712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P031010|Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia|Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients||Assistance Publique - Hôpitaux de Paris|No|Terminated|January 2005|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|40|Samples With DNA|DNA|Both|18 Years|80 Years|No|Non-Probability Sample|Adult, end-stage renal disease patients treated by standard hemodialysis|November 2007|November 6, 2007|September 12, 2005|||terminated|No||https://clinicaltrials.gov/show/NCT00374712||178851|
NCT00375024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14718|Patient Navigator Project|Patient Navigator Project||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|May 2007|November 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1267|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375024||178828|
NCT00375544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C00011|Study to Evaluate the Safety and Efficacy of a Low Level Light Device in Patients With Knee Osteoarthritis|A Phase I Single Center Open Label Study to Evaluate the Safety and Efficacy of a Low Level Light Device in Patients With Knee Osteoarthritis||Light Sciences LLC||Completed|September 2006|November 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|40 Years|N/A|No|||August 2009|August 12, 2009|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375544||178789|
NCT00363324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82/04|Bone Marrow Cells in Myocardial Infarction|Effects of Autologous Bone Marrow Celss on Acute ST-Elevation Myocardial Infarction||University of Oulu||Completed|January 2005|November 2007|Actual|November 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||December 2007|December 27, 2007|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363324||179711|
NCT00363337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Parker|A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression|||Lindner Center of HOPE||Completed|August 2006|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|August 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363337||179710|
NCT00363571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060084|The Effect of Glyceryl Trinitate and Diamox on Cerebral Haemodynamics.|The Effect of Glyceryl Trinitrate (GTN) and Diamox on Cerebral Haemodynamics Judged With the Help of 3-Tesla MRI.||Danish Headache Center||Not yet recruiting|August 2006|May 2007||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2006|August 14, 2006|August 14, 2006||||No||https://clinicaltrials.gov/show/NCT00363571||179693|
NCT00373516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRX-101-CLIN-003|Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Study of the Safety and Efficacy of Two Dosing Regimens of QRX-101 (Becocalcidiol) Ointment in the Treatment of Plaque-Type Psoriasis||QuatRx Pharmaceuticals Company||Completed|September 2004|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2006|September 6, 2006|September 6, 2006||||||https://clinicaltrials.gov/show/NCT00373516||178943|
NCT00373529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO24300606|A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)|A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients With Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit||Sanofi|Yes|Completed|October 2006|May 2010|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|60 Years|N/A|No|||March 2014|March 17, 2014|September 7, 2006|Yes|Yes||No|February 24, 2011|https://clinicaltrials.gov/show/NCT00373529||178942|
NCT00376298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-050|Urology Database to Evaluate Clinical Information and Improve Patient Care.|Urology Database for Outcomes Research||William Beaumont Hospitals|No|Completed|February 2004|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|215|||Both|18 Years|N/A|No|Non-Probability Sample|Men and Women with conditions including radical prostatectomy, pelvic organ prolapse and        neurostimulator implantation at William Beaumont Hospital|December 2015|December 22, 2015|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376298||178731|
NCT00373854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo 208|Study of How Low Blood Sugar Affects the Way Blood Vessels Work|Hypoglycemia and Endothelial Function||Ohio State University|No|Completed|September 2005|September 2006|Actual|||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2007|April 4, 2007|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373854||178917|
NCT00374062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1253-017|Effect of the Subconscious on Mohs Micrographic Surgery|Effect of the Subconscious on Mohs Micrographic Surgery||Northwestern University|No|Completed|December 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|25 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 14, 2014|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00374062||178901|
NCT00375180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-4-0030 / 23028|Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients|Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients Prior to, on Completion of and Six Weeks After Oncology Treatment||AHS Cancer Control Alberta|Yes|Completed|November 2006|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Diagnosed with head and neck cancer including the lip, oral cavity, salivary glands,        paranasal sinuses, oropharynx, nasopharynx, hypopharynx, larynx, and thyroid|March 2012|February 24, 2016|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375180||178816|
NCT00375193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNF3140-SCLC-002|Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy|A Phase 2 Trial of Single-Agent Amrubicin in Patients With Extensive Disease Small Cell Lung Cancer That is Refractory or Progressive Within 90 Days of Completion of First Line Platinum-based Chemotherapy||Celgene|No|Completed|November 2006|March 2009|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||September 2009|September 29, 2009|September 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00375193||178815|
NCT00376246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050714|Effect of Ezetimibe on Flow-Mediated Brachial Artery Reactivity in Healthy Subjects|Effect of Ezetimibe on Flow-Mediated Brachial Artery Reactivity in Healthy Subjects||University of California, San Diego||Completed|September 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 2, 2008|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376246||178735|
NCT00376259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2304|Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone|An Open-label, Multicenter, Randomized Study of Combination Therapy With Oral LDT600 (Telbivudine) Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant||Novartis||Terminated|January 2007|||August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|70 Years|No|||June 2011|June 28, 2011|September 13, 2006|Yes|Yes|The study was not completed as planned and was terminated early with agreement from the    European Medicines Agency (EMEA)|No|December 20, 2010|https://clinicaltrials.gov/show/NCT00376259||178734|The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA).
NCT00385723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0087|Fish Oil (Omega 3), Immune Function, and Mood|Omega-3 Dietary Supplementation, Immune Function, and Mood||Ohio State University|Yes|Completed|September 2006|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|138|||Both|40 Years|88 Years|Accepts Healthy Volunteers|||November 2012|November 13, 2012|October 10, 2006||No||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00385723||178018|
NCT00385736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-826|Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis|A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis||Abbott|No|Completed|November 2006|March 2010|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|576|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|October 9, 2006|Yes|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00385736||178017|
NCT00381433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4065-21c|Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid|Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration||Sarepta Therapeutics||Completed|September 2006|June 2009|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||July 2009|July 6, 2009|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00381433||178341|
NCT00374699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-07-021|Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas|A Phase I/II Study of Bortezomib + CHOP in Patients With Advanced Stage Aggressive T Cell or NK/T Cell Lymphomas||Samsung Medical Center||Completed|April 2006|October 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|55|||Both|18 Years|65 Years||||June 2007|October 12, 2009|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00374699||178852|
NCT00373867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03AR051128|Effectiveness of Adding Behavioral Therapy to Physical Therapy to Treat Low Back Pain|Behavioral Interventions for Low Back Pain||University of Florida|Yes|Completed|January 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|108|||Both|15 Years|60 Years|No|||January 2013|January 24, 2013|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373867||178916|
NCT00375271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP 12523|Perioperative Hemodynamic Optimization in High-Risk Patients Using Less-Invasive Monitoring Methods|Multicenter Randomized Controled Trial of Perioperative Hemodynamic Optimization in High-Risk Patients Using Less-Invasive Monitoringng Methods||Centro de Estudos Mário César de Rezende||Recruiting|August 2006|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|N/A|No|||September 2006|September 11, 2006|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375271||178809|
NCT00375284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.616|A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS|A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome||Boehringer Ingelheim||Completed|September 2006|||July 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|404|||Both|18 Years|80 Years|No|||October 2013|October 30, 2013|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375284||178808|
NCT00375037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-277|A Multifaceted Intervention to Improve Hand Hygiene|Cluster Randomized Controlled Trial of a Multifaceted Intervention to Improve Hand Hygiene Among Healthcare Workers||McMaster University|No|Completed|January 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1500|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2008|September 19, 2008|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375037||178827|
NCT00375050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01T-432|Treatment of Refractory Schizophrenia With Riluzole|Neuroprotective Treatment of Refractory Schizophrenia With Riluzole||Yale University|No|Suspended|May 2002|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|September 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00375050||178826|
NCT00375310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607-09; IUCRO-0155|Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer|Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma||Indiana University|Yes|Completed|September 2006|November 2014|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375310||178806|
NCT00375895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2006-002714-35|Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation|Prospective, Open-label, Single Arm Pilot Study Evaluating the Effect on Virological Response of the Switch From Tacrolimus to Cyclosporin Associated With a Peginterferon Alfa-2a / Ribavirin Bitherapy, in Non-responder or With Recurrent VHC+ Disease Liver Transplanted Patients.||Rennes University Hospital|No|Terminated|June 2006|December 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|September 12, 2006||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00375895||178762|
NCT00376181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-OPI536-003|Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus|A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes||Takeda|No|Terminated|June 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|September 12, 2006|Yes|Yes|Combination formulation concerns|No||https://clinicaltrials.gov/show/NCT00376181||178740|
NCT00363350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2005.229|Rituximab Treatment in Sjogren's Syndrome|Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial||University Medical Center Groningen||Completed|August 2006|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||February 2009|February 23, 2009|August 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00363350||179709|
NCT00363584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000492266|Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer|A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer||National Cancer Institute (NCI)||Completed|March 2006|||August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|360|||Both|18 Years|N/A|No|||October 2011|August 23, 2013|August 10, 2006||||No||https://clinicaltrials.gov/show/NCT00363584||179692|
NCT00376025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB001|Antioxidant Supplementation in Patients With Kashin-Beck Disease|Study of the Effects of Antioxidant Supplementation in Patients Suffering From Kashin-Beck Disease||Innovative Humanitarian Solutions|Yes|Recruiting|July 2007|April 2009|Anticipated|January 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|300|||Both|9 Years|18 Years|No|||February 2008|February 12, 2008|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00376025||178752|
NCT00376038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2105246|Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes|A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.||GlaxoSmithKline||Completed|August 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|30 Years|64 Years|No|||February 2011|May 31, 2012|September 12, 2006||||||https://clinicaltrials.gov/show/NCT00376038||178751|
NCT00373815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002577-44|Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease|A Phase I Dose Escalation Study With Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Acute GVHD After Allogeneic Hematopoietic Stem Cell Transplantation||University Hospital Tuebingen||Terminated|September 2006|October 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|70 Years|No|||May 2014|May 28, 2014|September 6, 2006|||high incidence of TTP, poor recrual|No||https://clinicaltrials.gov/show/NCT00373815||178920|
NCT00374920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM 1003-101|Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder|A Multicenter, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 1003 for the Treatment of Patients With Bipolar I Disorder Suffering Acute Manic or Mixed Episodes||Memory Pharmaceuticals|No|Completed|September 2006|March 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||May 2008|May 5, 2008|September 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00374920||178836|
NCT00385125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSHO #73|Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL|Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation.||University of Magdeburg||Recruiting|August 2004|August 2010||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2006|October 5, 2006|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00385125||178062|
NCT00385398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030601|QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC|Phase II Quality of Life Study of Stereotactic RadioSurgery, Temozolomide and Erlotinib Chemotherapy for the Treatment of 1-3 Brain Metastases in Non-small Cell Lung Cancer||Rutgers, The State University of New Jersey|Yes|Withdrawn|July 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|October 5, 2006|Yes|Yes|lack of funding and drug supply|No||https://clinicaltrials.gov/show/NCT00385398||178041|
NCT00385749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVLeadSelectSite|Right Ventricular Defibrillation Lead Select Site Study|Right Ventricular Defibrillation Lead Select Site Study||Associates in Cardiology, PA||Recruiting|October 2006|December 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|21 Years|N/A|No|||October 2007|October 30, 2007|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00385749||178016|
NCT00381446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS005|Evaluation of Corneal Staining With Various Contact Lens/Solution Combinations|Evaluation of Corneal Staining With Market Contact Lens/Solution Combinations||Andrasko, Gary, OD, LLC||Recruiting|July 2005|March 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 26, 2007|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00381446||178340|
NCT00381472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/169|Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa||GlaxoSmithKline||Completed|June 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|393|||Both|30 Years|N/A|No|||April 2015|April 16, 2015|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381472||178339|
NCT00375011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BID CIRR|Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics|Use of the BreathID to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients With Cirrhosis in Need of Liver Transplantation||Exalenz Bioscience LTD.||Terminated|September 2008|October 2011|Actual|||Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Cirrhosis determined by liver histology or clinical findings|February 2010|February 15, 2012|September 10, 2006|||Company restructured and protocol restructured. Resubmitted with IDE approval under new    company name-Exalenz|No||https://clinicaltrials.gov/show/NCT00375011||178829|
NCT00374413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kineflex/C|Kineflex/C Artificial Disc System to Treat Cervical Degenerative Disc Disease (DDD)|Clinical Study Protocol for the Investigation of the Kineflex/C Spinal System - a Pivotal Study in Continued Access Stage||SpinalMotion|No|Terminated|July 2005|August 2013|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|343|||Both|18 Years|60 Years|No|||August 2013|August 31, 2013|September 7, 2006|Yes|Yes|Economic and business factors|No||https://clinicaltrials.gov/show/NCT00374413||178874|
NCT00374426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-0806 (completed)|Preventing Depression Recurrence in Diabetes|Preventing Depression Recurrence in Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|March 1998|October 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||262|||Both|18 Years|80 Years|No|||March 2010|March 1, 2010|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374426||178873|
NCT00375063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6 P05B 132 21|Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)|Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery||Ministry of Science and Higher Education, Poland||Completed|January 2001|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|18 Years|80 Years|No|||September 2006|September 11, 2006|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375063||178825|
NCT00375323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NovoSeven 1|Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation|Effects of Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation in Patients With Hemophilia A and Antibodies to Factor VIII||Medical University of Vienna||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|||||||Male|18 Years|N/A||||April 2007|April 19, 2007|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375323||178805|
NCT00375336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA MH NR/8306-5|Risk Factors Associated With Calcification of the Aortic Valve|Risk Markers of Coronary Artery Disease Associated With Calcific Aortic Valve Disease||Charles University, Czech Republic|No|Active, not recruiting|January 2005|December 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|Samples Without DNA|serum and plasma specimens retained at -80 deg. C|Both|18 Years|N/A|No|Probability Sample|Consecutive patients admitted to hospital for evaluation due to common causes like        dyspnea, chest pain, fatigue or syncope, who fulfilled the two inclusion criteria: 1/        angiographically significant CAD, and 2/ AS (mean transvalvular aortic gradient ≥30 mm Hg)        or nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) or had normal aortic valve as        diagnosed by echocardiography.|December 2008|December 31, 2008|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375336||178804|
NCT00372333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-III-01|IDEA-033 Open Label Study|A Multiple-Dose, Open-Label Safety, Compliance, and Usage Evaluation Study of Epicutaneously Applied IDEA-033 in Joint / Musculoskeletal Pain or Soft Tissue Inflammation||IDEA AG||Completed|August 2004|April 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|491|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|September 4, 2006||||No||https://clinicaltrials.gov/show/NCT00372333||179031|
NCT00363597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606-104|Intestinal Permeability in Children/Adolescents With Functional Dyspepsia|Intestinal Permeability and Serum Zonulin Concentration in Children/Adolescents With Functional Dyspepsia||Children's Mercy Hospital Kansas City|No|Completed|August 2006|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|42|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00363597||179691|
NCT00363831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9863|Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma|A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC)||The University of Hong Kong||Recruiting|July 2006|||December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|75 Years|No|||July 2010|July 27, 2010|August 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00363831||179673|
NCT00363844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5435-10|Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus|MK-0431/ONO-5435 Phase III Clinical Study - Long-term Treatment Study for Patients With Type 2 Diabetes Mellitus||Ono Pharmaceutical Co. Ltd||Completed|August 2006|||February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|209|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|August 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00363844||179672|
NCT00333242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA015463-04|Hyperalgesia in Methadone Patients: Can it be Treated?|||National Institute on Drug Abuse (NIDA)||Active, not recruiting|September 2002|||August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|55 Years|No|||August 2008|August 11, 2008|June 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00333242||181946|
NCT00372463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49148|Internet Diabetes Self-Management|Internet Diabetes Self-Management: A Randomized Trial||Robert Wood Johnson Foundation||Completed|February 2006|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|||Anticipated|700|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00372463||179021|
NCT00373269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3866|The Effect of Insulin on Infarct Size and Neurologic Outcome After Acute Stroke|The Effect of Insulin on Infarct Size and Neurologic Outcome After Acute Stroke||Temple University|No|Completed|January 2004|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|September 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00373269||178961|
NCT00373282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8116|Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy|||hahid Beheshti University of Medical Sciences||Completed|June 2001|June 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||August 2006|October 11, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373282||178960|
NCT00384306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES11086|Effects Of Oral Prednisolone On Bone Metabolism In Patients With Chronic Obstructive Pulmonary Disease|Investigation of the Side Effects of Orally Administered Glucocorticoids. An Open Label Study to Investigate the Effects of Orally Administered Prednisolone on Bone Metabolism in Patients With COPD.||GlaxoSmithKline||Completed|June 2004|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|9|||Both|40 Years|75 Years|No|||April 2015|April 15, 2015|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384306||178124|
NCT00384566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-03/04|A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure|The CAMERA Study: CArvedilol MEtoprolol Respiratory Assessment Investigator Trial||The Alfred||Withdrawn|June 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|October 5, 2006|No|Yes|In order to join forces with another study already running which aims to answer the same    question.|No||https://clinicaltrials.gov/show/NCT00384566||178104|
NCT00384852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100N7-212|A Study of rhBMP-2/CPM in Closed Fractures of the Humerus|A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy in Closed Fractures of the Humerus||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|139|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|October 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384852||178082|
NCT00384865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458|A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension|A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension||University of Pennsylvania|Yes|Terminated|September 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|N/A|No|||July 2009|January 31, 2013|September 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00384865||178081|
NCT00384878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-95011|Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer|A Phase II Study of Cetuximab Plus P-HDFL (Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) for the First-Line Treatment of Advanced Gastric Cancer||Far Eastern Memorial Hospital||Recruiting|June 2006|||March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||June 2006|February 6, 2009|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384878||178080|
NCT00385138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CAN-05-03|Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.|A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).|Platform|The Medicines Company|Yes|Terminated|September 2006|June 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|5364|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|October 4, 2006|No|Yes|Insufficient evidence of the clinical effectiveness of cangrelor|No|April 22, 2013|https://clinicaltrials.gov/show/NCT00385138||178061|Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely not meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified.
NCT00385411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8971|Study of Valproate in Young Patients Suffering From Epilepsy|Therapeutic Follow-up Observational Study and Population Kinetics Ancillary Study of Valproate Microgranules (Micropakine® SR) in Patients Aged Between 6 Months and 15 Years Suffering From Epilepsy.|VAPOP|Sanofi|No|Completed|March 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|6 Months|15 Years|No|||October 2009|October 2, 2009|October 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00385411||178040|
NCT00374127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4683|Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper|Comparison Between Marijuana Smoked in Cigarette Paper (Joints) Versus Cigar Paper (Blunts)||New York State Psychiatric Institute||Completed|December 2004|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||36|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2008|July 26, 2010|September 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00374127||178896|
NCT00374140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-049|Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer|Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer||University of Pittsburgh|Yes|Completed|October 2006|July 2012|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2013|January 8, 2014|September 6, 2006|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00374140||178895|
NCT00374387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/309|Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire|Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire||University Hospital, Ghent|No|Completed|September 2006|March 2011|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 30, 2011|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374387||178876|
NCT00374400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDC|The Paired Donation Consortium Paired Donation Program|The Paired Donation Consortium Paired Donation Program||University of Cincinnati||Completed|September 2004|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 20, 2007|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374400||178875|
NCT00373880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4741|Effects of Aripiprazole on Cocaine Craving and Self-Administration|Effects of Aripiprazole on Cocaine Craving and Self-Administration||New York State Psychiatric Institute||Completed|April 2005|August 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 26, 2008|September 7, 2006||||||https://clinicaltrials.gov/show/NCT00373880||178915|
NCT00373893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051252|Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia|Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia||University of California, San Diego||Completed|December 2005|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2005|September 7, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373893||178914|
NCT00374153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-06-0310|Southern Methodist Alcohol Research Trial (SMART)|Dismantling Motivational Interviewing and Feedback for College Drinkers||The University of Texas Health Science Center, Houston||Completed|September 2006|January 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|363|||Both|18 Years|N/A|No|||March 2010|March 9, 2010|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00374153||178894|
NCT00374725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF 20020197|Treatment of Ulcerative Colitis With a Combination of Lactobacillus Rhamnosus and Lactobacillus Acidophilus.|Treatment of Ulcerative Colitis With a Combination of Lactobacillus Rhamnosus and Lactobacillus Acidophilus. A Randomised Placebo Controlled Trial||Odense University Hospital||Completed|February 2003|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||130|||Both|18 Years|N/A|No|||November 2002|September 8, 2006|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374725||178850|
NCT00375076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODEXA1|Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients|Prevention of Venous Thrombosis in Cancer Patients: A Prospective, Randomized, Double-blind Study Comparing Two Different Dosages of Low-molecular Weight Heparin||Medical University of Vienna||Completed|June 2006|May 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A|No|||September 2009|September 17, 2009|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375076||178824|
NCT00375570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-07|Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents|An Open Label, Multi-Centre, Phase III, Subject Initiated Safety Study of ME-609 in Treatment of Recurrent Herpes Simplex Labialis in Adolescents||Medivir|No|Completed|October 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|254|||Both|12 Years|17 Years|No|||August 2008|August 14, 2008|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00375570||178787|
NCT00376480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491633|Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases|Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia||National Cancer Institute (NCI)||Recruiting|March 2005|||June 2010|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|50 Years|No|||July 2009|November 10, 2009|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376480||178718|
NCT00332969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995ADE13|Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma|Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size||Novartis||Completed|September 2005|||October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2011|November 23, 2011|June 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00332969||181967|
NCT00332982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCCTKN|Ontario ICU Clinical Best Practices Demonstration Project|Ontario ICU Clinical Best Practices Demonstration Project||Sunnybrook Health Sciences Centre||Completed|November 2005|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|N/A|N/A|No|||June 2005|November 20, 2006|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00332982||181966|
NCT00333255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-41|Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery|Preoperative and Postoperative Nevanac 0.1% Compared to Acular LS for the Treatment of Ocular Inflammation Associated With Cataract Surgery||Alcon Research||Completed|September 2005|||March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|267|||Both|10 Years|N/A|No|||July 2009|July 7, 2009|June 1, 2006||||||https://clinicaltrials.gov/show/NCT00333255||181945|
NCT00333281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9520|A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months|A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Effects of 5 mg Tadalafil (IC351, LY450190) and 50 mg Sildenafil Administered Once Daily for 6 Months on Visual Function in Healthy Subjects or Subjects With Mild Erectile Dysfunction||Eli Lilly and Company||Completed|June 2005|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||198|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 23, 2007|May 31, 2006||||||https://clinicaltrials.gov/show/NCT00333281||181943|
NCT00373009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR054098|Prevention of Low Back Pain in the Military|Prevention of Low Back Pain in the Military. A Randomized Clinical Trial|POLM|University of Florida|Yes|Completed|February 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|4325|||Both|18 Years|35 Years|No|||March 2015|March 12, 2015|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00373009||178981|
NCT00373022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491199|Moderate Physical Activity in Helping Patients Recover Physically and Emotionally From Stage II Or Stage III Colorectal Cancer|The Effect of Moderate Physical Activity on the Physical and Emotional Recovery of Patients With a History of Colorectal Cancer||University of Arizona||Completed|January 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|45|||Both|18 Years|N/A|No|||December 2006|May 26, 2010|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373022||178980|
NCT00376649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-031106-HMO-CTIL|Development of Workshop for Lifestyle Changing for Crohn's Disease Patients and Its Affect on the Disease's Indexes|Development of Workshop for Lifestyle Changing for Crohn's Disease Patients and Its Affect on the Disease's Indexes||Hadassah Medical Organization||Withdrawn|January 2007|December 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Both|18 Years|N/A|No|||September 2006|September 20, 2015|September 14, 2006|||funding was not granted|No||https://clinicaltrials.gov/show/NCT00376649||178705|
NCT00376662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS HRT and Etidronate Study|HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids.|HRT and/or Etidronate in the Prevention and Treatment of Osteoporosis and Fractures in Post-Menopausal Patients With Asthma Receiving Long-Term Oral and/or Inhaled Glucocorticoids:a Randomised Factorial Trial||British Thoracic Society||Completed|August 1992|October 2000||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||750|||Female|N/A|59 Years|No|||September 2006|September 13, 2006|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376662||178704|
NCT00372736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I166B|AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors|A Phase I Study of AEG35156 Given as a 2 Hour Intravenous Infusion in Combination With Docetaxel in Patients With Solid Tumours||Canadian Cancer Trials Group|No|Completed|June 2006|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||January 2012|October 5, 2015|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372736||179001|
NCT00372749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051058|Does the Threat of an Aversive Reaction Affect Craving of Alcohol During Cue Exposure in Alcohol Dependent Patients?|Does the Threat of an Aversive Reaction Affect Craving of Alcohol During Cue Exposure in Alcohol Dependent Patients?||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||February 2007|March 25, 2011|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372749||179000|
NCT00373048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mefloquine HIV zambia|Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial|Mefloquine Malaria Prophylaxis in HIV-1 Infected Individuals and Its Influence on the Evolution Towards AIDS: a Randomized Placebo-controlled Trial||Institute of Tropical Medicine, Belgium|No|Completed|October 2005|May 2011|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 23, 2011|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00373048||178978|
NCT00373061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q2952g|An Observational Study of the Use and Safety of Xolair During Pregnancy|The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (Omalizumab) During Pregnancy|EXPECT|Genentech, Inc.||Active, not recruiting|October 2006|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|304|||Female|N/A|N/A|No|Non-Probability Sample|Enrollment in the Xolair Pregnancy Registry is voluntary and must be initiated by the        pregnant woman. A healthcare provider (HCP) cannot enroll a patient but can suggest that        the pregnant woman call the Registry Center to enroll herself.|March 2016|March 8, 2016|September 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00373061||178977|
NCT00373308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0012|Quality of Life Following Radical Prostatectomy|Quality of Life Following Radical Prostatectomy||Stanford University|Yes|Recruiting|September 2002|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Male|18 Years|N/A|No|Non-Probability Sample|Patients scheduled to undergo radical prostatectomy at Stanford|November 2015|November 16, 2015|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373308||178958|
NCT00373334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI-AX-001|Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)|A Double-Blind, Randomized, Parallel, Multicenter Study of Axid (Nizatidine) Oral Solution in the Treatment of Gastroesophageal Reflux Disease (GERD) Symptoms in Infants Age 30 Days-1 Year||Braintree Laboratories||Completed|August 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|138|||Both|N/A|1 Year|No|||November 2009|November 17, 2009|September 7, 2006|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00373334||178957|
NCT00373633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU 011906|Extrapleural Intercostal Catheter vs. Thoracic Epidural for Thoracotomy Pain|A Prospective Randomized Trial Comparing Extrapleural Intercostal Local Anesthesia Versus Thoracic Epidural for the Managment of Acute Post Thoracotomy Pain||Virginia Commonwealth University||Terminated|September 2006|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|26|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|September 6, 2006|No|Yes|terminated due to diminishing frequency of thorocotomies and slow enrollment|No||https://clinicaltrials.gov/show/NCT00373633||178934|
NCT00373646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thalidomide-MALT|Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients|Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)||Medical University of Vienna||Completed|June 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373646||178933|
NCT00373906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Velcade-MALT-Lymphoma|Velcade in MALT Lymphoma Patients|Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type||Medical University of Vienna||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|16|||Both|18 Years|N/A|No|||May 2008|November 26, 2013|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373906||178913|
NCT00373919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|erythro-esophagus|The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal Esophagectomy|||Kaplan Medical Center||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A|No|||August 2006|March 2, 2007|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00373919||178912|
NCT00374166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI5880|An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder|An Eight-week, Multicenter, Double-blind, Placebo- and Paroxetine-controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder||Sanofi||Completed|August 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|325|||Both|18 Years|64 Years|No|||July 2011|July 25, 2011|September 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00374166||178893|
NCT00374179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-322.001|CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma|A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma||Adnexus, A Bristol-Myers Squibb R&D Company|No|Completed|August 2006|February 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2009|February 23, 2009|September 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00374179||178892|
NCT00374192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P000194|The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women|The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women||Massachusetts General Hospital|No|Completed|February 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Female|40 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 7, 2009|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374192||178891|
NCT00374439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Horowitz Dis|Cognitive Behavioral vs. Interpersonal Therapy (IPT) Prevention of Depression in Adolescents|Promoting Well-being in Teens||Vanderbilt University||Completed|January 2004|April 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|September 8, 2006||||No||https://clinicaltrials.gov/show/NCT00374439||178872|
NCT00374452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMV 04-062|VISN Collaborative for Improving Hypertension Management With ATHENA-HTN|VISN Collaborative for Improving Hypertension Management With ATHENA-HTN||VA Office of Research and Development|No|Completed|January 2007|March 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|103|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2014|April 25, 2014|September 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00374452||178871|
NCT00374738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC181BO-1 (IRB #01012)|Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function|Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function||Samueli Institute for Information Biology||Completed|November 2006|September 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|65 Years|No|||February 2009|February 27, 2009|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00374738||178849|
NCT00375349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20173CTIL|Non Alcoholic Fatty Liver Disease Influence of Statin Therapy|||Shaare Zedek Medical Center||Not yet recruiting|September 2006|September 2009||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|18 Years|85 Years|No|||August 2006|September 11, 2006|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375349||178803|
NCT00375557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-08-25-06|Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients|An Open Label, Randomized, Flexible Dose, 6-week Clinical Trial of the Safety and Efficacy of Divalproex ER vs Quetiapine in the Treatment of Behavioral Symptoms in the Elderly With Moderate to Severe Alzheimer's Dementia||University of Cincinnati|No|Withdrawn|October 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00375557||178788|
NCT00376519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN-2005LS011|Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases|Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells||Masonic Cancer Center, University of Minnesota|Yes|Terminated|May 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|45 Years|No|||November 2012|November 6, 2012|September 13, 2006|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00376519||178715|
NCT00376194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060238|Mercury Chelation to Treat Autism|An Investigation of the Efficacy of Mercury Chelation as a Treatment for Autism Spectrum Disorder||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2006|March 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|4 Years|10 Years|No|||September 2013|September 17, 2013|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376194||178739|
NCT00332995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM008, TMC120-C131|Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium|Double-blind, Randomized, Placebo Controlled Trial to Study Safety, Local and Systemic Availability of TMC120 From a Vaginal Ring.||International Partnership for Microbicides, Inc.||Completed|July 2005|August 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||13|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|June 1, 2006||||No||https://clinicaltrials.gov/show/NCT00332995||181965|
NCT00333268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-14|Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus|Clinical Evaluation of the Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for Use During Cataract Extraction and IOL Implantation||Alcon Research||Completed|September 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|369|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|June 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00333268||181944|
NCT00375778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004139-74|Parkinson's Disease Evaluated by PET and the Effect of Memantine|Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine||University of Aarhus||Completed|April 2005|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|50 Years|70 Years|No|||September 2006|September 12, 2006|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375778||178771|
NCT00375791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 212|Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma|An Open-Label Phase II Study of the Safety and Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Relapsed or Relapsed/Refractory Multiple Myeloma||AEterna Zentaris|No|Completed|December 2005|October 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||February 2012|February 11, 2014|September 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00375791||178770|
NCT00384020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-095-PP-01|Clinical Pharmacogenomics of Antidepressant Response|Phase 4 Clinical Pharmacogenomics of Antidepressant Response||National Health Research Institutes, Taiwan||Completed|January 2006|January 2010|Actual|January 2010|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|402|||Both|18 Years|N/A|No|Non-Probability Sample|depressive patients in Taiwan|January 2010|January 29, 2010|October 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00384020||178146|
NCT00372229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19313|A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation|A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration||Hoffmann-La Roche||Completed|May 2006|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|301|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372229||179039|
NCT00372242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-041|Feasible Means to Address Moderately Malnourished Children Within BINP Communities|||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|December 2000|September 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||1231|||Both|6 Months|24 Months|No|||April 2003|September 4, 2006|September 4, 2006||||No||https://clinicaltrials.gov/show/NCT00372242||179038|
NCT00372762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-415|Bumetanide Versus Furosemide in Heart Failure|Bumetanide Has a More Favourable Effect on Insulin Resistance Than Furosemide in Patients With Heart Failure - A Pilot Study||Lawson Health Research Institute|No|Withdrawn|January 2011|June 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|September 6, 2006||No|Due to changes within the research program this study is not feasible at this time|No||https://clinicaltrials.gov/show/NCT00372762||178999|
NCT00373074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0220|Epidural Blood Patch on the Resolution of Postdural Puncture Headache (PDPH)|A Multi-Center, Randomized Controlled Study Trial to Investigate the Effect of Varying Volumes of Blood Patch on the Resolution of Postdural Puncture Headache (PDPH)||The University of Texas Health Science Center, Houston||Terminated|September 2006|July 2008|Actual|July 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|0|||Female|18 Years|65 Years|No|||February 2009|February 4, 2009|September 5, 2006||No|Lack of subject population for PI|No||https://clinicaltrials.gov/show/NCT00373074||178976|
NCT00373087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051034|COMT Polymorphism and Entacapone Efficacy|Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease|COMT|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2006|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|N/A|No|||July 2007|April 28, 2010|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373087||178975|
NCT00373347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0006|Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma|Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma||Stanford University|Yes|Recruiting|November 2004|December 2025|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with liver cancer|February 2015|February 4, 2015|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373347||178956|
NCT00373360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-PH-411|Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin|Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction||United Therapeutics|No|Completed|September 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||January 2013|January 3, 2013|September 7, 2006|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT00373360||178955|
NCT00373373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS/INNERE_A/AML2006|Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML|A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML||University Hospital Muenster|Yes|Completed|September 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|61 Years|N/A|No|||August 2009|August 18, 2009|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373373||178954|
NCT00378482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4881C00024|A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.|A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols||AstraZeneca|No|Active, not recruiting|March 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|N/A|N/A|No|||November 2015|November 5, 2015|September 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00378482||178565|
NCT00379041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20931|Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma|Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|September 1993|||October 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1158|||Both|15 Years|70 Years|No|||February 2015|February 10, 2015|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379041||178524|
NCT00380224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3168A1-311|Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.|A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Befeprunox Versus Olanzapine in the Treatment of Outpatients With Schizophrenia.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|65 Years|No|||December 2007|December 18, 2007|September 21, 2006||||||https://clinicaltrials.gov/show/NCT00380224||178433|
NCT00379314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42/E8/04|Randomized, Multicenter Trial Comparing TVT With TVT-O for Treatment of Female Urinary Incontinence|A Randomized, Prospective, Multicenter Trial Comparing TVT With TVT-O Procedures in Treatment of Female Primary Urinary Stress Incontinence||Helsinki University||Active, not recruiting|April 2004|December 2010||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||260|||Female|18 Years|N/A|No|||September 2006|October 31, 2006|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00379314||178503|
NCT00379600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARA102198|The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis||GlaxoSmithKline|No|Completed|November 2004|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|96|||Both|18 Years|N/A|No|||January 2012|May 31, 2012|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00379600||178481|
NCT00379964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-053|A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)|A Noncomparative, Multicenter, Open-Label, Study to Evaluate the Safety, Tolerability and Efficacy of MK0991 as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia||Merck Sharp & Dohme Corp.||Completed|June 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00379964||178453|
NCT00376636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP635CRD04|Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension|A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-Week Study to Investigate the Safety and Efficacy of the Oral Renin Inhibitor SPP635 Once Daily in Patients With Mild to Moderate Hypertension||Speedel Pharma Ltd.|No|Completed|October 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|70 Years|No|||September 2006|October 29, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00376636||178706|
NCT00380198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS068645-305|A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.|A Randomized, Double-Blind Comparison of Apadenoson and Adenosine to Treadmill Exercise Stress for Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)||Forest Laboratories||Terminated|July 2006|November 2006||November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||1500|||Both|18 Years|N/A||||April 2008|January 18, 2011|September 21, 2006|||Business decision to end program|No||https://clinicaltrials.gov/show/NCT00380198||178435|
NCT00380536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047631|Medical Self-Management for Improving Health Behavior Among Individuals in Community Mental Health Settings|Adapting a Medical Self-Management Program for a Community Mental Health Center||Emory University|No|Completed|September 2006|July 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|111|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380536||178410|
NCT00380549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2005884-01H|A Comparison of an Advanced Metal Hip System to a Resurfacing Hip System|A Prospective Case Series (Pilot Study) Comparing Ion Levels and Clinical Outcomes of the CONSERVE® A-Class Type Hip System With BFH™ Technology to the CONSERVE® Plus Total Hip Resurfacing System||Ottawa Hospital Research Institute|No|Completed|June 2006|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2010|August 19, 2010|September 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00380549||178409|
NCT00373295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5232|Effect of Baclofen on Marijuana Withdrawal and Relapse|Effect of Baclofen on Marijuana Withdrawal and Relapse||New York State Psychiatric Institute|No|Completed|May 2006|January 2010|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|13|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|September 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00373295||178959|
NCT00377377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 67/04|Oral Ghrelin Agonist in Healthy Subjects|Pharmacokinetics and Pharmacodynamic Effects of an Oral Ghrelin Agonist in Healthy Subjects||University Hospital, Basel, Switzerland|No|Completed|November 2005|July 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||July 2006|May 2, 2007|September 15, 2006||||No||https://clinicaltrials.gov/show/NCT00377377||178650|
NCT00379847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-080|An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia|A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia||Cumberland Pharmaceuticals|No|Completed|February 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|September 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00379847||178462|
NCT00379860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3201A1-101|Study Evaluation LXR-623 in Healthy Adults|A Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of LXR-623 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|October 2006|January 2007||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2007|March 8, 2007|September 21, 2006||||||https://clinicaltrials.gov/show/NCT00379860||178461|
NCT00379873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0606060021|Chiropractic Adjustment on Physiological Measurements|||Logan College of Chiropractic||Completed|October 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2007|July 31, 2007|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00379873||178460|
NCT00380497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008846|Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children|Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in children-a Single Blinded Randomized Controlled Trial||The Hospital for Sick Children|Yes|Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|4 Years|18 Years|No|||July 2013|July 25, 2013|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00380497||178413|
NCT00380809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK 106|Rotational Atherectomy Prior to Taxus Stent|Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.||Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH||Completed|August 2006|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00380809||178389|
NCT00379067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|617-EC-006|A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.|A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia||Astellas Pharma Inc||Completed|October 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|882|||Male|45 Years|N/A|No|||October 2014|October 8, 2014|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379067||178522|
NCT00376844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000502033|External-Beam Radiation Therapy or Implant Radiation Therapy Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage I Endometrial Cancer|PORTEC-2, Postoperative Radiation Therapy for Endometrial Carcinoma - A Multicenter Randomised Phase III Trial Comparing External Beam Radiation and Vaginal Brachytherapy||National Cancer Institute (NCI)||Active, not recruiting|May 2006|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|104|||Female|N/A|N/A|No|||December 2011|September 16, 2013|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376844||178690|
NCT00378755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMM51|Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM|Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM||Korean Multiple Myeloma Working Party||Recruiting|March 2006|July 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||62|||Both|15 Years|65 Years|No|||September 2006|September 21, 2006|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00378755||178544|
NCT00375765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104274|Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer|See Detailed Description||GlaxoSmithKline||Completed|April 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||40|||Male|50 Years|N/A|No|||May 2009|May 21, 2009|September 12, 2006||||No||https://clinicaltrials.gov/show/NCT00375765||178772|
NCT00376051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218-2006|Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia|Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia||Sunnybrook Health Sciences Centre|No|Completed|September 2006|September 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||November 2009|November 20, 2009|September 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00376051||178750|
NCT00380913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB1 Study 001|Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy|A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy||NEMA Research, Inc.||Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|75 Years|No|||February 2008|February 14, 2008|September 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00380913||178381|
NCT00379613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05942|Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)|A Multi-Center Randomized Safety Assessor-Blinded Placebo-Controlled Parallel and Dose Escalating Dose-Finding Trial in Subjects of ASA 1 - 2 to Assess the Safety, Efficacy and PK of Sugammadex Administered at 5 Min. After Administration of 1.2 mg/kg Esmeron||Merck Sharp & Dohme Corp.|Yes|Completed|November 2003|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|45|||Both|18 Years|64 Years|No|||May 2015|May 19, 2015|September 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379613||178480|
NCT00372476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BDE28|Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer|Open-label Trial of Imatinib in Combination With Vinorelbine for Patients With Advanced Breast Carcinoma: ICON|INV181|Novartis||Completed|June 2006|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||May 2013|May 20, 2013|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372476||179020|
NCT00380211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDB-200-001|Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults|A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine With Reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in Subjects Between 18-60 and Over 60 Years of Age.||GlaxoSmithKline||Completed|September 2006|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 14, 2010|September 21, 2006||||||https://clinicaltrials.gov/show/NCT00380211||178434|
NCT00373035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-85A03|Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy|Biomarkers of Prostate Cancer||Comprehensive Cancer Center of Wake Forest University||Completed|February 2006|||July 2006|Actual|N/A|Observational|N/A|||Anticipated|60|||Male|18 Years|N/A|No|||June 2013|June 4, 2013|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00373035||178979|
NCT00377143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131-2006|PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care|PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care||University of Florida||Withdrawn|July 2006|||August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||September 2011|February 14, 2012|September 13, 2006||No|similar large study planned by NHLBI|No||https://clinicaltrials.gov/show/NCT00377143||178668|
NCT00378547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM4-05|Effect of Paracetamol, Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Having a Tonsillectomy|Effect of Paracetamol Versus Paracetamol Combined With Pregabalin Versus Paracetamol Combined With Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for Tonsillectomy||Glostrup University Hospital, Copenhagen|Yes|Terminated|January 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|147|||Both|18 Years|50 Years|No|||December 2009|December 31, 2009|September 19, 2006||No|ENT surgery stopped at the recruiting hospital|No||https://clinicaltrials.gov/show/NCT00378547||178560|
NCT00378560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-027|V501 Efficacy Study in Women Aged 18 to 26 (V501-027)|V501 Phase II Efficacy Study in Women Aged 18 to 26||Merck Sharp & Dohme Corp.||Completed|June 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1021|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|September 18, 2006|Yes|Yes||No|April 21, 2010|https://clinicaltrials.gov/show/NCT00378560||178559|
NCT00372905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05H9|Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma|A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE®) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma||Northwestern University|Yes|Active, not recruiting|August 2006|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372905||178989|
NCT00372918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060713|Interpretation of Transnasal Esophagoscopy Findings|An Interdisciplinary Interpretation of Transnasal Esophagoscopy Findings|TNE|Vanderbilt University|No|Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|98|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372918||178988|
NCT00377104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00161|Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I Dose-Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Following Cytoreduction With Chemotherapy||National Cancer Institute (NCI)||Terminated|September 2006|||November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|September 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00377104||178671|
NCT00377117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-470|Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II|Diabetes Screening, Risk Management, and Disease Management in a High-Risk Mental Health Population.||Lawson Health Research Institute|No|Completed|May 2006|July 2007|Actual|||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|39|||Both|18 Years|75 Years|No|||July 2007|July 20, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377117||178670|
NCT00380172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-03-02|Long-Term Efficacy in AMD of Rheopheresis in North America|A Multicenter, Open Label, Prospective Study to Determine Safety and Efficacy Over an Additional 12-Month Period With Non-Exudative Age-Related Macular Degeneration (With Follow-on to 12-Months)||OccuLogix||Active, not recruiting|October 2005|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|N/A|N/A|No|||September 2006|September 21, 2006|September 21, 2006||||||https://clinicaltrials.gov/show/NCT00380172||178437|
NCT00380822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1001|Double-Blind Study of Miglitol in Japanese With type2 Diabetes|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|69 Years|No|||September 2006|September 25, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380822||178388|
NCT00376857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03123|Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.|Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green: a Randomised Controlled Clinical Trial||University of Regensburg||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||September 2006|September 13, 2006|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376857||178689|
NCT00376870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPER|PIoglitazone for PrEvention of Restenosis in Diabetic Patients|Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent||University of Rome Tor Vergata|Yes|Recruiting|July 2008|April 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||June 2008|July 30, 2008|September 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00376870||178688|
NCT00377611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107564|Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™|An Observational Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™||GlaxoSmithKline||Completed|October 2006|||June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||3000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 15, 2006||||No||https://clinicaltrials.gov/show/NCT00377611||178632|
NCT00377624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8229|HUPS: Hyalgan Use in Painful Shoulder|Sodium Hyaluronate for Treatment of Chronic Painful Shoulder With Limitation of Motion Due to Glenohumeral Joint Osteoarthritis, Rotator Cuff Tear and/or Primary or Secondary Adhesive Capsulitis||Sanofi||Completed|January 2002|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||602|||Both|35 Years|N/A|No|||January 2011|January 10, 2011|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377624||178631|
NCT00377637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX17801|A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.|A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.||Hoffmann-La Roche||Completed|July 2005|March 2010|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|370|||Both|12 Years|75 Years|No|||October 2011|October 31, 2011|September 15, 2006|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00377637||178630|For many of the Maintenance Phase Outcomes, the total number of events precluded a meaningful time to event statistical analysis, therefore, only events numbers are reported.
NCT00379652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410|Community Partnership to Examine Racial and Ethnic Differences in Health Care for Hypertension and Diabetes|Community, Health Center, and Academic Medicine Partnership Project (CHAMPP)|CHAMPP|Harvard Medical School|Yes|Completed|October 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|1204|||Both|18 Years|N/A|No|||August 2009|May 19, 2015|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00379652||178477|
NCT00378222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO96|Autologous Transplantation for Multiple Myeloma|A Prospective, Randomized Study of Single Versus Double Autologous Stem Cell Transplantation for Multiple Myeloma||University of Bologna||Completed|January 1996|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||324|||Both|18 Years|60 Years|No|||September 2006|September 18, 2006|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378222||178585|
NCT00379990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA4104917|A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Synovial Thickness and Vascularity of 28 Days Repeat Dosing of GW274150 or 7.5mg Prednisolone in RA Subjects.||GlaxoSmithKline|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|September 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379990||178451|
NCT00380575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-027|Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia|A 4-Day, Double-Blind, Placebo-Controlled, Multicenter Study of IV YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia||Cumberland Pharmaceuticals||Completed|August 2000|February 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|September 22, 2006||||||https://clinicaltrials.gov/show/NCT00380575||178407|
NCT00380588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10298|Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer|A Randomized Study of Gemcitabine/Cisplatin Versus Single-Agent Gemcitabine in Patients With Biliary Tract Cancer||Eli Lilly and Company|No|Completed|September 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|20 Years|N/A|No|||November 2009|November 18, 2009|September 22, 2006|Yes|Yes||No|October 15, 2009|https://clinicaltrials.gov/show/NCT00380588||178406|
NCT00376324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-119|Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone|An Open-Label, Multiple-Dose Study of the Pharmacokinetics of Tigecycline in Human Bone||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2006|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 8, 2009|September 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00376324||178729|
NCT00376610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF1127957|Prospective Clinical Evaluation of ASR/Re-Cap Resurfacing Arthroplasty|Prospective Clinical Evaluation of ASR/Re-Cap Resurfacing Arthroplasty||Frederiksberg University Hospital||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2007|July 3, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00376610||178708|
NCT00376623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.9|Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer|An Open, Randomised Clinical Phase II Trial to Investigate the Efficacy, Safety and Pharmacokinetics of a Single Dose of 200 mg of i.v. BI 2536 in Comparison to 50 mg of i.v. BI 2536 Administered on Days 1, 2 and 3 in Patients With Advanced or Metastatic Non Small Cell Lung Cancer||Boehringer Ingelheim||Completed|July 2006|||April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|96|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00376623||178707|
NCT00380874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081124|Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial Of The Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy Symptoms In Subjects With Advanced Colorectal Cancer||Pfizer|Yes|Terminated|January 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|80 Years|No|||October 2009|October 1, 2009|September 25, 2006|Yes|Yes|See detailed description for termination reason|No|March 10, 2009|https://clinicaltrials.gov/show/NCT00380874||178384|Due to lack of symptom emergence, enrollment was halted, and endpoint modified because primary assumptions upon which it was powered (emergence of symptomatology) were not met, and not all endpoints were able to be reliably analyzed.
NCT00380887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713E1-133, 0713E1-135|Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2005|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||54|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||September 2006|September 26, 2006|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00380887||178383|
NCT00372710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EDE03|Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions|Efficacy and Tolerability of Intravenous Zoledronic Acid 4mg as an Adjunct to Standard Therapies Including Conversion From Pamidronate in Breast Cancer Patients With Metastatic Bone Lesions. A Prospective, Randomised, Open-label, Clinical Study||Novartis||Terminated|August 2002|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|N/A|No|||November 2009|November 20, 2009|September 6, 2006||||No||https://clinicaltrials.gov/show/NCT00372710||179003|
NCT00372723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108983|Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)|Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis||Loyola University||Withdrawn|July 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|September 5, 2006||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT00372723||179002|
NCT00376909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450797|A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women|New York Prevention Care Manager Project||Dartmouth-Hitchcock Medical Center|No|Completed|November 2001|||April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2729|||Female|40 Years|69 Years|Accepts Healthy Volunteers|||September 2006|November 26, 2014|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376909||178685|
NCT00378274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVA2006LG|Descriptive Study of Pain, Anxiety and Depression|Pain, Anxiety and Depression in Chronic Pain Patients With and Without Neuropathic Pain Compared With Healthy Volunteers||Danish Pain Research Center|Yes|Completed|September 2006|September 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|75|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2007|November 15, 2007|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378274||178581|
NCT00378573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_00730|Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II, Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Sanofi||Terminated|January 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2010|January 21, 2010|September 19, 2006|Yes|Yes|Incidence of GI Perforation|No|September 17, 2009|https://clinicaltrials.gov/show/NCT00378573||178558|Due to early termination of the study only 17/90 subjects enrolled. Efficacy analysis of Progression Free Survival and Overall Survival were not performed. Efficacy results limited to a descriptive summary of best overall response for each subject.
NCT00378833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-054|Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)|A Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK0524A Versus Niacin Extended-Release||Merck Sharp & Dohme Corp.||Completed|July 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1300|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|September 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00378833||178540|
NCT00378092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011992|A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode|A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia||Janssen Cilag N.V./S.A.|No|Completed|April 2006|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|17 Years|47 Years|No|||May 2014|May 7, 2014|September 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00378092||178595|
NCT00373230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005NFGrantTemple|Treating Obesity in Underserved Overweight Populations|Treating Obesity and Its Consequences in Underserved Overweight Populations||Temple University|Yes|Recruiting|October 2007|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00373230||178964|
NCT00373243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXA100754|A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment|An Open-Label, Non-Randomised Study of 20 mg GW406381 Single Dose Pharmacokinetics in Healthy Subjects and in Volunteers With Moderate Hepatic Impairment||GlaxoSmithKline||Completed|October 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00373243||178963|
NCT00377130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0501|Stress Management Therapy in Patients Receiving Chemotherapy for Cancer|Stress Management Therapy for Patients Undergoing Chemotherapy||University of South Florida|Yes|Completed|December 2006|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|442|||Both|18 Years|N/A|No|||September 2010|January 30, 2014|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00377130||178669|
NCT00380835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNF3140-MBC-001|Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer|A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer||Celgene||Withdrawn||December 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|66|||Both|18 Years|N/A|No|||September 2008|September 22, 2008|September 26, 2006|||Study Never Initiated|No||https://clinicaltrials.gov/show/NCT00380835||178387|
NCT00381121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 4729|University of Michigan "Nephrology Research BioBank"|Michigan Nephrology Research BioBank for Molecular Analysis of Renal Disease "Nephrology Research BioBank"||University of Michigan|No|Recruiting|September 2006|August 2056|Anticipated|August 2056|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|420|Samples With DNA|Tissue, blood, urine|Both|N/A|N/A|No|Non-Probability Sample|Renal disease patients undergoing diagnostic workup|December 2015|December 1, 2015|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381121||178365|
NCT00381134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK063010-04 (completed)|Improving Outcomes in Patients With Kidney Disease Due to Diabetes|Improving Outcomes in Diabetic Nephropathy||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 2003|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|92|||Both|21 Years|65 Years|No|||March 2010|March 1, 2010|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381134||178364|
NCT00377650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JagiellonianU|Polish-Italian-Hungarian RAndomized ThrombEctomy Trial|Polish-Italian-Hungarian RAndomized ThrombEctomy Trial. PIHRATE Trial.||Jagiellonian University||Recruiting|September 2005|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||January 2007|January 16, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377650||178629|
NCT00380601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA225JP|PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)|An Open-label, PhaseⅢ Study to Evaluate the Efficacy and Safety of MRA in Patients With RA||Chugai Pharmaceutical||Completed|May 2006|February 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|No|||December 2009|December 22, 2009|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00380601||178405|
NCT00380614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethical/Path/GBPH/805|A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B|||Maulana Azad Medical College||Completed|January 2002|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|5 Years|75 Years|No|||September 2006|September 25, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380614||178404|
NCT00378495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-18506-Z019|Miltefosine for Brazilian Visceral Leishmaniasis|||AB Foundation||Terminated|April 2005|October 2007|Anticipated|April 2007|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|2 Years|65 Years|No|||January 2011|January 18, 2011|September 18, 2006|||accrual criteria being reviewed|No||https://clinicaltrials.gov/show/NCT00378495||178564|
NCT00375466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.1285|Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.|Phase 4 Study of Tranexamic Acid for Elderly Patients Undergoing Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.||St. Olavs Hospital|No|Completed|September 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|70 Years|N/A|No|||December 2012|December 12, 2012|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00375466||178794|
NCT00375752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GDE19|Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer|Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks)|FEMZONE|Novartis||Active, not recruiting|June 2006|December 2015|Anticipated|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Female|18 Years|N/A|No|||August 2015|August 21, 2015|September 11, 2006|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00375752||178773|
NCT00379626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH 048-01|Cognitive and Hormonal Treatment of Sex Offenders|Cognitive Group and Hormonal Treatment of Sex Offenders.||Norwegian University of Science and Technology|No|Terminated|August 2003|August 2010|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 30, 2012|September 21, 2006||No|too few patients participated|No||https://clinicaltrials.gov/show/NCT00379626||178479|
NCT00380900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3189A1-102|Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Test Article or Placebo Administered Orally to Healthy and Osteoarthritis Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|September 26, 2006||||||https://clinicaltrials.gov/show/NCT00380900||178382|
NCT00380939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0981-400-314|This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.|A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL)||Pfizer||Completed|April 1999|December 2000||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|30 Years|75 Years|No|||November 2006|November 29, 2006|September 26, 2006||||||https://clinicaltrials.gov/show/NCT00380939||178379|
NCT00377156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0574|Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients With One to Three Cerebral Metastases||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|July 2006|||October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00377156||178667|
NCT00377169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 065H|Collection of Blood Samples From SMART Study Participants for Future Genetic Studies|Genomics: A Substudy of a Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting||||||N/A|Observational|N/A|||Anticipated|3261|||Both|13 Years|N/A|No|||September 2006|November 9, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377169||178666|
NCT00380562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0069|The Baltimore Experience Corps Study|Experience Corps Trial: Improving Health of Older Populations Through Generativity||Johns Hopkins University|Yes|Completed|July 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|702|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 18, 2013|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00380562||178408|
NCT00376922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000495315|Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases|Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy||Comprehensive Cancer Center of Wake Forest University|No|Completed|June 2006|May 2010|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|65|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376922||178684|
NCT00381173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYC3-002|A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing|A Phase 1 Open-Label Study of the Safety and Feasibility of ZYC300 Administration With Cyclophosphamide Pre-Dosing||Eisai Inc.|No|Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2011|May 13, 2013|September 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00381173||178361|
NCT00377728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPR101987|Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber|A 14 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in an Environmental Exposition Unit (Vienna Challenge Chamber) in Subjects With Seasonal Allergic Rhinitis (SAR)||GlaxoSmithKline|No|Completed|March 2006|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|50 Years|No|||April 2015|April 14, 2015|September 14, 2006||||||https://clinicaltrials.gov/show/NCT00377728||178623|
NCT00378066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0277|Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer|A Phase II Study of Combination Chemotherapy With Bevacizumab, Capecitabine and Oxaliplatin in Patients With Previously Untreated Metastatic or Recurrent Colorectal Cancer||Asan Medical Center|Yes|Completed|August 2006|October 2008|Actual|August 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|70 Years|No|||January 2013|January 21, 2013|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00378066||178597|
NCT00378586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-05037|Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock|Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock||Herlev Hospital||Not yet recruiting|January 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Septic shock patients.|June 2009|June 22, 2009|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00378586||178557|
NCT00378599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04590|Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)|PROTECT - Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy||Merck Sharp & Dohme Corp.|No|Completed|May 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|70 Years|No|||April 2015|April 7, 2015|September 18, 2006|No|Yes||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00378599||178556|
NCT00378612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007965|ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial|Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial||Duke University|Yes|Completed|June 2005|September 2012|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|September 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00378612||178555|
NCT00378014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001HDE10|Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy|Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients||Novartis|Yes|Completed|August 2006|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|70 Years|No|||January 2015|January 19, 2015|September 15, 2006|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00378014||178601|
NCT00378027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arixtra PE Study 05-202|Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux|Phase IV, Single Arm Study to Obtain Information Regarding the Safety and Efficacy of Fondaparinux Given Outpatient for Treatment of Acute Pulmonary Embolism||The Cleveland Clinic|Yes|Terminated|October 2006|November 2008|Anticipated|||Phase 4|Observational|Time Perspective: Prospective||||100|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|September 18, 2006|||enrollment criteria not met by PI patient population|No||https://clinicaltrials.gov/show/NCT00378027||178600|
NCT00377364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022006-009|Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy|Acetaminophen for Mood and Memory Changes Associated With Prednisone Therapy||University of Texas Southwestern Medical Center|No|Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||December 2013|December 13, 2013|September 14, 2006||No||No|August 19, 2011|https://clinicaltrials.gov/show/NCT00377364||178651|Limitations include the small sample size and relatively small changes in mood and memory in both groups that limited our ability to detect between-group differences.
NCT00377663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|431|Internet-Based Program to Improve Asthma Management in Children|Internet-Based Patient-Centered Asthma Management System||Seattle Children's Hospital||Completed|July 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|600|||Both|2 Years|10 Years|No|||March 2014|March 24, 2014|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00377663||178628|
NCT00377351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906247|Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort|Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort||National Institutes of Health Clinical Center (CC)||Completed|September 2006|August 2010||||N/A|Observational|N/A|||Actual|21|||Both|50 Years|80 Years|No|||August 2010|August 4, 2010|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00377351||178652|
NCT00377676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-AD-04-03-US-1|Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability During Treatment of Type 2 Diabetes (T2DM) With Usual Diabetes Therapy (UDT) and Either Cycloset or Placebo||VeroScience|Yes|Completed|July 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3095|||Both|30 Years|80 Years|No|||October 2011|October 27, 2011|September 14, 2006|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT00377676||178627|Thus HbA1c was only performed on a subset of patients defined as failing (HbA1c >= 7.5) and who were on oral diabetes medications. Forced titration of study drug may have lead to a greater number of discontinuations.
NCT00378768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2029.00|Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma|A Phase II Study of Thymoglobulin in Patients With Multiple Myeloma Who Are Candidates for Allogeneic or Autologous Stem Cell Transplant||Fred Hutchinson Cancer Research Center||Completed|November 2005|June 2007|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|N/A|N/A|No|||November 2011|November 28, 2011|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00378768||178543|
NCT00379340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN0533|Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor|Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors||Children's Oncology Group|Yes|Active, not recruiting|February 2007|||July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|395|||Both|N/A|29 Years|No|||October 2015|October 20, 2015|September 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379340||178501|
NCT00379353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0980|The Effects of Thalidomide on Symptom Clusters|The Effects of Thalidomide on Symptom Clusters||M.D. Anderson Cancer Center|Yes|Completed|September 2006|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|September 19, 2006|No|Yes||No|July 3, 2012|https://clinicaltrials.gov/show/NCT00379353||178500|Limited accrual and attrition led to small sample size.
NCT00379639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPI-06-0003|A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors|A Phase I/II Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors.||Celgene||Completed|July 2006|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|September 20, 2006|No|Yes||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00379639||178478|
NCT00379977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106345|Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age|Open, Primary Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Administered to Healthy Chinese Infants at 3, 4 and 5 Months of Age.||GlaxoSmithKline||Completed|September 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|90 Days|120 Days|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00379977||178452|
NCT00380952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-02-001|Intraoperative Use of the BP Device for Detecting Positive Margins During Lumpectomy Procedure|MAST Study Protocol||Dune Medical Devices|No|Completed|November 2006|April 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|N/A|No|||May 2008|May 25, 2008|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00380952||178378|
NCT00376727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000506089|Cetuximab in Treating Patients With Advanced Solid Tumors|A Phase I Study of the Safety and Tolerability of Four Doses of Cetuximab (C225) in Patients With Advanced Solid Tumors||University of California, Davis|Yes|Completed|December 2004|December 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||March 2010|March 25, 2010|September 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00376727||178699|
NCT00376740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor440006ctil|Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole|Phase 3 Study of the Effect of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving the Aromatase Inhibitor, Letrozole, in the Adjuvant Setting||Soroka University Medical Center|No|Completed|September 2005|||November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Female|18 Years|82 Years|No|||August 2011|August 22, 2011|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00376740||178698|
NCT00376701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-441|Combination Therapy for Age-Related Macular Degeneration.|Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin.||Lawson Health Research Institute|Yes|Completed|September 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|103|||Both|50 Years|N/A|No|||September 2011|September 27, 2011|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00376701||178701|
NCT00376714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2105333|Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects.||GlaxoSmithKline||Completed|August 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||45|||Both|40 Years|75 Years|No|||May 2009|May 15, 2009|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376714||178700|
NCT00381186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWO 2200.0139|Impact of 3-Year Lifestyle Intervention on Postprandial Glucose Metabolism: the SLIM Study|Impact of 3-Year Lifestyle Intervention on Postprandial Glucose Metabolism: the SLIM Study||Maastricht University Medical Center||Completed|February 1999|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||September 2006|September 25, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00381186||178360|
NCT00381199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN#05-017|Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia|Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia||McGill University Health Center|No|Completed|April 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|N/A|No|||May 2007|May 16, 2007|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00381199||178359|
NCT00377741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP18046|A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.|Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis||Hoffmann-La Roche||Completed|December 2004|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|14 Years|N/A|No|||November 2015|November 26, 2015|September 15, 2006|Yes|Yes||No|November 26, 2015|https://clinicaltrials.gov/show/NCT00377741||178622|
NCT00377390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-09|ICATA Asthma Mechanistic Study|Inner-City Anti-IgE Therapy for Asthma Mechanistic Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|224|Samples With DNA|Blood samples, sputum, and nasal secretions|Both|6 Years|20 Years|No|Non-Probability Sample|Inner-city children and adolescents ages 6 to 20 with asthma who are currently enrolled in        the ICATA Clinical Study|February 2013|February 6, 2013|September 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00377390||178649|
NCT00378287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005824|A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole|A Randomized, Controlled, Double-blind, Cross-over Study of the Effect of Oral Rabeprazole 20mg and Intravenous Pantoprazole 40mg on Intragastric pH in Patients||Janssen-Ortho Inc., Canada||Completed|October 2005|December 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 7, 2012|September 15, 2006||||No||https://clinicaltrials.gov/show/NCT00378287||178580|
NCT00377754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0013|Prospective Study of Infant Dengue|A Prospective Study of Dengue Virus Infections During Infancy to Define Correlates of Protective Immunity||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|September 2006|September 2010||||N/A|Observational|Time Perspective: Prospective||||20000|||Both|6 Weeks|N/A|Accepts Healthy Volunteers|||October 2007|August 26, 2010|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377754||178621|
NCT00377767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1HD050966|Improving Primary Care to Prevent Childhood Obesity|Improving Primary Care to Prevent Childhood Obesity||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|September 2006|September 2009||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Both|2 Years|6 Years|No|||September 2006|September 15, 2006|September 15, 2006||||No||https://clinicaltrials.gov/show/NCT00377767||178620|
NCT00383734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 132|Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE|Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|December 2006|September 2010|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|October 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00383734||178168|
NCT00375726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 228|Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2006|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|58|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 13, 2010|September 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00375726||178775|
NCT00375739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-006|Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses|A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.||Peplin||Completed|September 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 11, 2006||||||https://clinicaltrials.gov/show/NCT00375739||178774|
NCT00378261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004807|APART Advanced Profiling of Anti-Rheumatic Therapies|A Multicenter, Randomized, Open Study to Evaluate the Impact of an Electronic Data Capture System on the Care of Patients With Rheumatoid Arthritis||Centocor Ortho Biotech Services, L.L.C.||Completed|January 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|1079|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|September 15, 2006||||No||https://clinicaltrials.gov/show/NCT00378261||178582|
NCT00378248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPP|Ullevål PersonalityProject|Ullevål PersonalityProject. A Randomized Controlled Trial of Intensive Daytreatment Followed by Outpatient Long-term Combined Treatment Compared With Eclectic Individual Therapy for Patients With Personality Disorders||Oslo University Hospital||Active, not recruiting|May 2004|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|50 Years|No|||November 2013|November 26, 2013|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00378248||178583|
NCT00378508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delay-Study 5|Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes|Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes||Yale University|Yes|Active, not recruiting|September 2006|August 2013|Anticipated|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|8 Years|30 Years|No|||October 2012|October 31, 2012|September 18, 2006|Yes|Yes||No|September 4, 2012|https://clinicaltrials.gov/show/NCT00378508||178563|
NCT00378521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-001|Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon|Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon||MediQuest Therapeutics||Completed|July 2006|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|75 Years||||May 2007|May 29, 2007|September 18, 2006||||||https://clinicaltrials.gov/show/NCT00378521||178562|
NCT00379366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9443-05|External Ionizing Radiation to Prevent Restenosis on Haemodialysis Vascular Access|Efficacy and Tolerance of Transcutaneous Ionizing Radiations to Prevent Restenosis Caused by Intimal Hyperplasia on Prosthetic Haemodialysis Vascular Access|RASTA|University Hospital, Bordeaux|Yes|Terminated|December 2006|January 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 20, 2006||No|lack of patients|No||https://clinicaltrials.gov/show/NCT00379366||178499|
NCT00380016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060203|Catheter-Based Treatment of Cardiovascular Disease|Catheter-Based Treatment of Cardiovascular Disease in Patients||National Institutes of Health Clinical Center (CC)||Completed|September 2006|March 2009||||N/A|Interventional|Primary Purpose: Treatment|1|||150|||Both|18 Years|N/A|No|||March 2009|September 26, 2015|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380016||178449|
NCT00380003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004|Efficacy Study of EVT 201 to Treat Insomnia|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy of Two Doses of EVT 201 in the Treatment of Primary Insomnia in Adult Patients||Evotec Neurosciences GmbH||Completed|September 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|21 Years|64 Years|No|||January 2008|January 29, 2008|September 22, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00380003||178450|
NCT00380237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 211 (Study B)|Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)|Phase 1 Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study B)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|October 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 18, 2008|September 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00380237||178432|
NCT00380978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-009|Neuraxial Versus Systemic Analgesia for Latent Phase Labor Effect on Rate of Operative Delivery|Early Compared With Late Neuraxial Analgesia in Nulliparous Labor Induction||Northwestern University|No|Completed|October 2001|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1026|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 17, 2014|September 25, 2006||No||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00380978||178376|The study was not powered to detect a small difference between groups in the cesarean delivery rate. It was not blinded. Different obstetric providers have different management styles, and different triggers for performing cesarean delivery.
NCT00376948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000495776|Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 2005|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|120 Years|No|||December 2015|December 7, 2015|September 13, 2006|Yes|Yes||No|August 8, 2014|https://clinicaltrials.gov/show/NCT00376948||178682|Stopped after 1st stage completed due to failure to meet preset efficacy endpoints; Lack of randomization in the design, which impaired the ability to detect whether the lack of activity is due to patient selection or in-activity of the regimen.
NCT00377403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0140|Treatment of Acute Sinusitis|Randomized Clinical Trial to Evaluate Guidelines for Acute Rhinosinusitis (Phase IV Study)||Washington University School of Medicine|Yes|Completed|October 2006|August 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|70 Years|No|||December 2012|December 24, 2012|September 14, 2006||No||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00377403||178648|
NCT00378079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 DA 16237-03|Methadone Maintenance for Prisoners|Methadone Maintenance for Prisoners|MMP|Friends Research Institute, Inc.|Yes|Completed|September 2003|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|211|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|September 15, 2006||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00378079||178596|See 2009 manuscript published in the Journal of Substance Abuse Treatment for the a discussion of study limitations. The study was conducted only on males from Baltimore. For results regarding HIV risk behaviors see manuscript by Wilson et. al.
NCT00377416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|366|Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency|Preclinical & Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults||University of Massachusetts, Worcester||Active, not recruiting|March 2004|October 2021|Anticipated|October 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00377416||178647|
NCT00378326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA-0572|Immunotherapy of the Paraneoplastic Syndromes|Immunotherapy of the Paraneoplastic Syndromes||Rockefeller University|Yes|Completed|April 2006|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|14 Years|N/A|No|||January 2016|January 26, 2016|September 18, 2006|Yes|Yes||No|November 2, 2015|https://clinicaltrials.gov/show/NCT00378326||178577|
NCT00378339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-015-MBL|Gold Against Pains From Osteoarthrosis in the Knee|Clinical Effects From Implants of Gold Around the Arthrotic Knee Joint. A Randomized, Double Blind, Placebo Controlled Investigation.||Northern Orthopaedic Division, Denmark||Withdrawn|January 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|80 Years|No|||March 2014|March 28, 2014|September 19, 2006|||Withdrawn because of lack of approvement from local medical authorities|No||https://clinicaltrials.gov/show/NCT00378339||178576|
NCT00375492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-US-GWBM|Effect on Weight Loss of Exenatide Versus Placebo|Effect on Weight Loss of Exenatide Versus Placebo in Subjects With Type 2 Diabetes Participating in a Lifestyle Modification Program||AstraZeneca|No|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|75 Years|No|||March 2015|March 19, 2015|September 11, 2006|Yes|Yes||No|February 25, 2009|https://clinicaltrials.gov/show/NCT00375492||178793|
NCT00378040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-541S|Systematic Assessment of Vascular Risk|Toronto Vascular Disease Risk Factor Assessment Program: Systematic Assessment of Vascular Risk||University Health Network, Toronto|No|Active, not recruiting|June 2004|December 2014|Anticipated|December 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Both|30 Years|N/A|No|Non-Probability Sample|Those with confirmend PAD|May 2014|May 20, 2014|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00378040||178599|
NCT00378053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060829|A Prospective Study of Radiation Exposure to Surgeons|A Prospective Study of Radiation Exposure to Surgeons||Vanderbilt University||Completed|September 2006|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||4|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2007|August 14, 2007|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378053||178598|
NCT00378534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060248|Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants|Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back||National Institutes of Health Clinical Center (CC)|No|Completed|September 2006|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|10 Years|75 Years|No|||December 2014|October 5, 2015|September 19, 2006|Yes|Yes||No|December 22, 2014|https://clinicaltrials.gov/show/NCT00378534||178561|
NCT00379080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00681|Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma|A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma||National Cancer Institute (NCI)||Completed|January 2007|||September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|September 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379080||178521|
NCT00379093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-MOO-013937|Healthy Living as You Age|Preventing Harm From Alcohol Use in Older Adults|HLAYA|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Completed|August 2003|July 2008|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|631|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 10, 2009|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379093||178520|
NCT00379106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002C|Arm Function and Quality of Life Following Mastectomy.|Arm Function and Quality of Life Following Mastectomy.||University of New Mexico|Yes|Completed|October 2003|September 2007|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|N/A|N/A|No|||March 2008|January 6, 2010|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379106||178519|
NCT00380250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0211SIB-0431|Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation|Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation||Sucampo Pharma Americas, LLC||Completed|May 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|590|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|September 21, 2006|No|Yes||No|October 7, 2008|https://clinicaltrials.gov/show/NCT00380250||178431|
NCT00380029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0521|Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer|A Phase II Study of Erlotinib (Tarceva®) in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|May 2006|August 2016|Anticipated|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00380029||178448|
NCT00380926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAFES-2004-07|Fish Oil and Asthma in House Dust Mite Allergy|Anti-Inflammatory Effect of Polyunsaturated Fatty Acids in Allergic Asthma After Allergen Challenge||Johann Wolfgang Goethe University Hospitals||Completed|April 2004|November 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||23|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2006|September 28, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380926||178380|
NCT00376688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02703|Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer|Phase II Trial of CCI-779 (Temsirolimus) in Patients With Locally Advanced or Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2006|||June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|September 13, 2006|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00376688||178702|
NCT00380627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-094|Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)|Quality of Life With Arcoxia in Women With Dysmenorrhea||Merck Sharp & Dohme Corp.||Completed|September 2005|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||337|||Female|18 Years|25 Years|No|||March 2015|March 16, 2015|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00380627||178403|
NCT00376987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000495325|Zinc Supplements in Lowering Cadmium Levels in Smokers|Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?||Comprehensive Cancer Center of Wake Forest University|No|Completed|December 2003|June 2015|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|61|||Both|21 Years|120 Years|No|||September 2015|September 30, 2015|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376987||178679|
NCT00377000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL6021-0505|A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.|||Sanofi||Completed|November 2005|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|12 Years|30 Years|Accepts Healthy Volunteers|||October 2007|October 5, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377000||178678|
NCT00376753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060242|Muscle Contraction in Patients With Focal Hand Dystonia|The Effect of Surround Inhibition During Phasic Compared to Tonic Voluntary Finger Movement in Focal Hand Dystonia||National Institutes of Health Clinical Center (CC)||Completed|September 2006|May 2011||||N/A|Observational|N/A|||Actual|84|||Both|18 Years|N/A|No|||May 2011|September 26, 2015|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00376753||178697|
NCT00377208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|424|Individually Tailored Web-Based Program to Improve Blood Pressure Control|Efficacy of Web-Based Feedback to Improve Blood Pressure Control||Milton S. Hershey Medical Center|No|Completed|January 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|500|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 18, 2013|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00377208||178663|
NCT00376935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5212|Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults|A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2006|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|September 14, 2006|Yes|Yes||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00376935||178683|
NCT00377182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV18369|A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.|A Randomized, Double-blind Study to Evaluate the Safety and Tolerability of the HCV Polymerase Inhibitor Pro-drug in Combination With Pegasys, With or Without Copegus, Versus Pegasys Plus Copegus, in Treatment-naïve Patients With Chronic Hepatitis C, Genotype 1||Hoffmann-La Roche||Completed|September 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|107|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|September 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00377182||178665|
NCT00377195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 05.02|Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma|A Prospective Single Arm Trial of Involved Field Radiotherapy Alone for Stage I-II Low Grade Non-gastric Marginal Zone Lymphoma||Trans-Tasman Radiation Oncology Group (TROG)|No|Active, not recruiting|July 2007|April 2019|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00377195||178664|
NCT00378105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-150|Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma|An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma||Dana-Farber Cancer Institute||Active, not recruiting|September 2006|February 2016|Anticipated|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 18, 2006|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00378105||178594|
NCT00378352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905255|REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction|Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions||National Institutes of Health Clinical Center (CC)||Completed|September 2005|January 2011|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|250|||Both|21 Years|N/A|No|||October 2010|June 28, 2012|September 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00378352||178575|
NCT00378625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00096/990954|Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia|Randomised, Double Blind Clinical Trial of the Efficacy, Effect on Gametocytes and Tolerability of Amodiaquine Vs Amodiaquine Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Quibdo, Colombia||Centro Internacional de Entrenamiento e Investigaciones Médicas||Completed|April 2000|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||360|||Both|1 Year|65 Years|No|||September 2006|September 19, 2006|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378625||178554|
NCT00378781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID93-004|Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection|Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions||M.D. Anderson Cancer Center|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|N/A|N/A|No|||February 2012|February 22, 2012|September 19, 2006||No|Study withdrawn.|No||https://clinicaltrials.gov/show/NCT00378781||178542|
NCT00378820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-072/04|The Effect of Whey and Casein on IGFs in Prepubertal Boys|The Effect of Whey and Casein With and Without Milk Minerals on IGFs in Prepubertal Boys||University of Copenhagen||Active, not recruiting|July 2004|April 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Male|8 Years|8 Years|Accepts Healthy Volunteers|||September 2006|January 20, 2009|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00378820||178541|
NCT00379379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR93-IRB-127|Study of Improving Insulin Sensitivity by Electroacupuncture Therapy|Study of Improving Insulin Sensitivity by Combined Both Electroacupuncture and Drug Therapy||China Medical University Hospital||Completed|January 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||26|||Both|30 Years|65 Years|No|||September 2006|September 20, 2006|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379379||178498|
NCT00379392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|338-2003|Mental Imagery to Reduce Motor Deficits in Stroke|Mental Imagery to Reduce Motor Deficits in Stroke||Emory University|Yes|Completed|January 2003|August 2011|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|N/A|No|||April 2015|April 10, 2015|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379392||178497|
NCT00379665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCT 05-01|Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy|Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy||Southwestern Regional Medical Center|No|Completed|October 2005|September 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|80 Years|No|||December 2012|December 10, 2012|September 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379665||178476|
NCT00379678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2042|Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis|A Pilot Ex-vivo Study to Evaluate the Effect of Pimecrolimus on Antimicrobial Peptide Expression and Vaccinia Virus Growth in Perilesional Skin Cultures of Patients With Atopic Dermatitis||National Jewish Health||Completed|September 2006|March 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|28|||Both|18 Years|65 Years|No|||September 2014|September 24, 2014|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379678||178475|
NCT00379704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060307|TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects.|TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects. Relationship With Circulating Tissue Factor and Coagulation Activation Markers||Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2006|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|85|Samples Without DNA|samples of plasma and serum and greasy fragments|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Inclusion Criteria:          -  BMI > 35          -  Stable obesity          -  Abdominal or pelvic surgery          -  Agree to participate to the study        Exclusion Criteria:          -  malignancy,          -  infectious or inflammatory disease, notably HIV infection          -  pregnancy          -  history of ischemic cardio or neurovascular event, lower limb arteritis|March 2007|December 7, 2011|September 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00379704||178473|
NCT00380042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0479|Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder|Feasibility Study of the Safety and Effectiveness of Cortical Stimulation for Subjects With Major Depressive Disorder|PROSPECT|Northstar Neuroscience|Yes|Terminated|September 2006|March 2009|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||September 2008|December 30, 2009|September 21, 2006|No|Yes|Study terminated as a result of the dissolution of the Sponsor.|No||https://clinicaltrials.gov/show/NCT00380042||178447|
NCT00380263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060087|PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow|Basic Scientific Research Investigating PACAP38 Headache Inducing Effects in Migraine Patients||Danish Headache Center|Yes|Completed|November 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|N/A|||Actual|12|||Both|18 Years|50 Years|No|||May 2008|May 29, 2008|September 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00380263||178430|
NCT00380276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-7869-05-009|Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol|Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type||Myrexis Inc.||Terminated|September 2006|December 2008|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|55 Years|N/A|No|||August 2008|August 1, 2008|September 21, 2006|Yes|Yes|Myriad has discontinued the development of Flurizan.|No||https://clinicaltrials.gov/show/NCT00380276||178429|
NCT00380640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009064|The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa|The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa: A Randomized, Double Blinded, Placebo Controlled, Cross-over Pilot Study||The Hospital for Sick Children|No|Completed|September 2006|September 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|20 Years|No|||August 2013|August 1, 2013|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00380640||178402|
NCT00380653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC682-05-04|Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes|A Phase I Pharmacologic Study of Oral Sapacitabine in Patients With Advanced Leukemias or Myelodysplastic Syndromes||Cyclacel Pharmaceuticals, Inc.||Completed|January 2006|June 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2006|October 18, 2009|September 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00380653||178401|
NCT00377897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIPEC|Cell Therapy With Bone Marrow Mononuclear Cells in Critical Leg Ischemia (CLI)|Optimisation d'un Produit de thérapie Cellulaire Autologue Par Cellules mononucléées médullaires Dans l'ischémie Critique Des Membres inférieurs liée à l'athérosclérose||University of Paris 5 - Rene Descartes||Recruiting|January 2005|December 2009|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2009|February 13, 2009|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00377897||178610|
NCT00377221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19-AI060614:P3 Aim1|Anorectal Microbicide Project(AMP): Rectal Health, Behaviors and Microbicide Acceptability|Rectal Health, Behaviors and Microbicide Acceptability||University of California, Los Angeles||Recruiting|September 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||896|||Both|18 Years|N/A||||September 2006|September 15, 2006|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377221||178662|
NCT00377234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA19547|A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.|Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study.||Hoffmann-La Roche||Completed|May 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|356|||Female|55 Years|80 Years|No|||July 2015|July 31, 2015|September 15, 2006|Yes|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT00377234||178661|
NCT00377429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-CAT-OC-01|Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy|An Open-Label, Single-Arm, Phase II Safety and Tolerability Study of Catumaxomab (Anti-EpCAM x Anti-CD3) in Women With Advanced Epithelial Ovarian Cancer After a Complete Response to Chemotherapy||Neovii Biotech|Yes|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|N/A|No|||July 2012|July 16, 2012|September 15, 2006|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00377429||178646|
NCT00377780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYOHERTAX|Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer|Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer|MYOHERTAX|Catharina Ziekenhuis Eindhoven|No|Terminated|August 2006|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|September 14, 2006||No|wothdrawal of sponsor|No||https://clinicaltrials.gov/show/NCT00377780||178619|
NCT00377793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12146|Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II|A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II||Bayer||Completed|July 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|352|||Male|18 Years|64 Years|No|||December 2014|December 23, 2014|September 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00377793||178618|
NCT00377819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050234|Study of Transitioning From Alendronate to Denosumab|A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density||Amgen||Completed|September 2006|July 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|504|||Female|55 Years|N/A|No|||June 2011|June 30, 2011|September 14, 2006||||No|July 1, 2010|https://clinicaltrials.gov/show/NCT00377819||178616|
NCT00378118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThrasherRF|Use of OraQuick for Screening HIV in Children Less Than Eighteen Months Old|Evaluation of the Use of OraQuick in Children Less Than Eighteen Months Old||Thrasher Research Fund|Yes|Completed|December 2006|September 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|N/A|18 Months|No|Non-Probability Sample|Children admitted to the University Teaching Hospital,Lusaka,Zambia with various illnesses        and aged less than 18 months old|November 2007|November 5, 2007|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378118||178593|
NCT00378365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050604|Acute Promyelocytic Leukemia 2006 (APL)|A Randomized Trial Assessing the Role of Arsenic Trioxide and/or ATRA During Consolidation Course in Newly Diagnosed Acute Promyelocytic Leukemia (APL)||Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2006|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||March 2007|April 15, 2014|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00378365||178574|
NCT00378378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04292|Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)|Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old||Merck Sharp & Dohme Corp.|No|Completed|July 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|127|||Both|6 Years|17 Years|No|||May 2015|May 27, 2015|September 18, 2006|Yes|Yes||No|June 24, 2009|https://clinicaltrials.gov/show/NCT00378378||178573|The standard deviation is pooled for Primary and Secondary Outcome Measures.
NCT00376077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000006180|A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.|A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Rapidly Augmenting Platelet Counts in Childhood ITP.||The Hospital for Sick Children|Yes|Recruiting|August 2005|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|1 Year|17 Years|No|||November 2014|November 19, 2014|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00376077||178748|
NCT00376090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 158|Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults|A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVA-CMDR (HIV-1 CM235 Env/ CM240 Gag/Pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV-Uninfected Adults||U.S. Army Medical Research and Materiel Command|No|Completed|July 2005|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 2, 2011|September 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00376090||178747|
NCT00376103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHIRB 2006-032|Radiation Boost for Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Maximal Resection, Local Radiation Boost With Concomitant Temozolomide, Followed by External Radiation Therapy With Concomitant Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Multiforme||Methodist Healthcare|Yes|Terminated|August 2006|||March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|September 13, 2006||No|Loss of funding from sponsor|No||https://clinicaltrials.gov/show/NCT00376103||178746|
NCT00378638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3359s|Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study|Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymp Node Positive Breast Cancer: A Pilot Study||Chap, Linnea I., M.D.|No|Recruiting|June 2006|October 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||October 2007|October 23, 2007|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378638||178553|
NCT00379119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455646|Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer|Androgen Blockade Therapy and Thymic Function in Individuals Over 50 Years of Age With Adenocarcinoma of the Prostate: A Cross-Sectional Study||University of California, San Francisco|No|Terminated|January 2005|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Male|50 Years|N/A|No|Probability Sample|Individuals >50 years of age with prostate cancer|October 2012|October 9, 2012|September 19, 2006||No|low accrual|No||https://clinicaltrials.gov/show/NCT00379119||178518|
NCT00379405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQV/RTV-MONOTERAPIA|Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment|Open-Label, Comparative and Randomised Pilot Study to Evaluate the Efficacy and Safety of Saquinavir/Ritonavir in Single Therapy vs Standard HAART Therapy as Maintenance Therapy.||Germans Trias i Pujol Hospital|No|Completed|June 2006|July 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||October 2008|October 10, 2008|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00379405||178496|
NCT00379691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01|Ideal Dose of Phenylephrine to Treat Low Blood Pressure During Cesarean Section|Phenylephrine Dose-Finding Study to Minimize Hypotension Due to Spinal Anesthesia for Cesarean Section||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|August 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 19, 2007|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00379691||178474|
NCT00379717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUB06-001|Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)|Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): a Phase I/II Trial of Radiation Dose Escalation and Fixed Dose Chemotherapy.||AZ-VUB||Recruiting|November 2006|April 2008||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|75 Years|No|||September 2006|March 12, 2008|September 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00379717||178472|
NCT00379730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES106087|Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind Study of Treatment With a Known Anti-inflammatory (Prednisolone) to Evaluate Novel Endpoints in Patients With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|March 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|40 Years|80 Years|No|||February 2011|May 31, 2012|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379730||178471|
NCT00380055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18388|Reducing Cancer Disparities for American Indians in the Rural Intermountain West|Reducing Cancer Disparities for American Indians in the Rural Intermountain West||University of Utah|No|Completed|October 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|1800|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 19, 2011|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380055||178446|
NCT00380289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGTT1|Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension|Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension||University of Cambridge||Recruiting|September 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||66|||Both|18 Years|75 Years|No|||September 2006|September 22, 2006|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00380289||178428|
NCT00380302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT10019|Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.|A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease||Sanofi||Completed|September 2006|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|162|||Both|50 Years|N/A|No|||December 2008|December 18, 2008|September 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00380302||178427|
NCT00380965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB1 Study 003|Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy|A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer||NEMA Research, Inc.||Completed|October 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|75 Years|No|||February 2008|February 14, 2008|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380965||178377|
NCT00376961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000494646|S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade®) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma||Southwest Oncology Group|Yes|Active, not recruiting|August 2006|October 2015|Anticipated|January 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|September 13, 2006|Yes|Yes||No|January 2, 2013|https://clinicaltrials.gov/show/NCT00376961||178681|
NCT00377247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-178|Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor|Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor (Phase I/II Study)||University of Pittsburgh|Yes|Terminated|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|37 Years|N/A|No|||January 2016|January 28, 2016|September 14, 2006|Yes|Yes|study closed to accrual due to slow accrual|No||https://clinicaltrials.gov/show/NCT00377247||178660|
NCT00377442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP20413|A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.|A Randomized, Open-label Crossover Study to Investigate the Potential Interaction Between GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes||Hoffmann-La Roche||Completed|August 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00377442||178645|
NCT00377806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVOL458UDE01|Topical Diclofenac Gel in Patients With Superficial Inflammation of the Veins|A One Week, Double-Blind, Adaptive, Randomized, Multicenter Study to Compare the Efficacy, Safety and Tolerability of Topical Diclofenac Gel Versus Placebo in Patients With Superficial Thrombophlebitis||Novartis||Completed|January 2003|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|85 Years|No|||December 2007|December 7, 2007|September 15, 2006||||No||https://clinicaltrials.gov/show/NCT00377806||178617|
NCT00377832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605008549|Acetaminophen for Fetal Tachycardia: a Randomized Pilot Trial|Acetaminophen for Fetal Tachycardia: a Randomized Pilot Trial||Weill Medical College of Cornell University|No|Terminated|July 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|September 14, 2006||No|Poor recruitment and lack of funding|No|December 22, 2010|https://clinicaltrials.gov/show/NCT00377832||178615|Poor recruitment and lack of funding led to early termination of the trial
NCT00378131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-1291-206|Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia|A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of RC-1291 and Placebo in Patients With Cancer Anorexia/Cachexia||Helsinn Therapeutics (U.S.), Inc|Yes|Completed|September 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|September 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00378131||178592|
NCT00378937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-ON/2003/1772|Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain|An Open, Randomized, Parallel Group Study in Patients With Cancer Pain, To Compare a Two-Step Analgesic Ladder (Non-Opioid to Oxycodone) With Conventional Management Using A Three-Step Approach||National Cancer Institute (NCI)||Completed|January 2004|February 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|30|||Both|18 Years|N/A|No|||July 2007|August 1, 2013|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00378937||178532|
NCT00378950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|439|Educational Program for Various Health Literacy Levels to Improve the Health of Individuals With Heart Failure|Health Literacy and Self-Management in Heart Failure||University of North Carolina, Chapel Hill|Yes|Completed|March 2007|February 2011|Actual|February 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|605|||Both|21 Years|N/A|No|||February 2012|February 1, 2012|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00378950||178531|
NCT00379236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-01D|A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee, With an Open-Label Safety Extension||Ferring Pharmaceuticals|No|Completed|October 2006|May 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|588|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 20, 2011|September 20, 2006|Yes|Yes||No|August 12, 2009|https://clinicaltrials.gov/show/NCT00379236||178509|
NCT00375518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-079|Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery|Double-Blind Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery||Memorial Sloan Kettering Cancer Center||Completed|July 2006|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 11, 2006|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00375518||178791|
NCT00378872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GJNH-06-01|Tranexamic Acid vs. Quixil - Reducing Blood Loss in Joint Replacement|Prospective Randomised Trial Comparing Intraoperative Topical Quixil and Intravenous Tranexamic Acid, in Reduction of Blood Loss Following Primary Hip & Knee Joint Replacement Surgery.||Golden Jubilee National Hospital|No|Completed|June 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|132|||Both|N/A|N/A|No|||May 2008|May 13, 2008|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00378872||178537|
NCT00379132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM601-003|131-I-TM-601 Study in Adults With Solid Tumors|A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labeled Chlorotoxin in Patients With Recurrent or Refractory Somatic and/or Cerebral Metastatic Solid Tumors||TransMolecular||Completed|August 2006|August 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|September 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00379132||178517|
NCT00379145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0087M|Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus|A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas||Gynecologic Oncology Group|Yes|Completed|June 2007|||January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|September 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379145||178516|
NCT00379158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200210085-5|Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana|Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements Added to Complementary Foods for Infants in Ghana||University of California, Davis||Completed|October 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||393|||Both|5 Months|6 Months|Accepts Healthy Volunteers|||September 2006|September 20, 2006|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379158||178515|
NCT00379418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021864|Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients|Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)|AIR|Emory University|No|Completed|January 2003|December 2009|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with coronary artery disease undergoing left heart catheterization|September 2013|September 11, 2013|September 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379418||178495|
NCT00379431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/257|A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab|A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab||University Hospital, Ghent|No|Active, not recruiting|November 2006|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00379431||178494|
NCT00380068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB-323|Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension|ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension||Gilead Sciences|Yes|Completed|August 2006|May 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|September 21, 2006|Yes|Yes||No|July 10, 2009|https://clinicaltrials.gov/show/NCT00380068||178445|
NCT00380341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0803050033|Effects of Instrument-Applied Spinal Manipulative Therapy on Postureal Control and Autonomic Balance|||Logan College of Chiropractic||Completed|September 2006|November 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|19 Years|30 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00380341||178424|
NCT00380354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA101985|Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma|A Two-centre, Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With Repeat Doses of Inhaled GSK256066 on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma||GlaxoSmithKline|No|Completed|September 2006|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||February 2011|May 31, 2012|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00380354||178423|
NCT00380315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG1321001_P302|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study||Ahn-Gook Pharmaceuticals Co.,Ltd||Completed|March 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|396|||Both|18 Years|70 Years|No|||June 2009|June 30, 2009|September 21, 2006||||||https://clinicaltrials.gov/show/NCT00380315||178426|
NCT00380328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-106|HKI-272 Ketoconazole Drug Interaction Study|An Open-label, Randomized, 2-period Crossover, Drug Interaction Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Ketoconazole and a Single Dose of HKI-272 Administered Orally to Healthy Subjects||Puma Biotechnology, Inc.||Completed|October 2006|November 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|September 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00380328||178425|
NCT00380666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060021|The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer|||University of Aarhus|No|Withdrawn|June 2007|July 2010|Anticipated|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||July 2010|July 9, 2010|September 25, 2006||No|Technical problems.|No||https://clinicaltrials.gov/show/NCT00380666||178400|
NCT00377299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052006-27|A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence|A Double-blind, Placebo-controlled Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence||University of Texas Southwestern Medical Center|No|Completed|October 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 5, 2013|September 14, 2006||No||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00377299||178656|
NCT00377312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606127|7 Day Continuous Parathyroid Hormone IV Infusion|Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation||University of Pittsburgh|Yes|Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|11|||Both|24 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|September 14, 2006|No|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00377312||178655|Small number of subjects in each group Study limited to Caucasians Only one timepoint for follow-up was measure Study did not include saline infused controls
NCT00376974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1|The Effect of Education on Patient Compliance|The Effect of Patient Education on Glaucoma Medication Compliance||Michael Debakey Veterans Affairs Medical Center||Active, not recruiting|March 2005|May 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||40|||Male|40 Years|90 Years|No|||September 2006|September 13, 2006|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376974||178680|
NCT00377260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0142|Acute Otitis Media (AOM) Therapy Trial in Young Children|Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM)||University of Pittsburgh|Yes|Completed|November 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|291|||Both|6 Months|23 Months|No|||December 2014|December 3, 2014|September 14, 2006|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT00377260||178659|Long-term implications of abnormal otoscopic findings (bulging) without symptoms, and persistent middle-ear effusion without findings of acute inflammation as forerunners of subsequent acute otitis media episodes remains uncertain.
NCT00377273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL6025-0201|An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses|||Sanofi||Completed|November 2003|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 8, 2008|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377273||178658|
NCT00377455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 06-043|Placebo Controlled Trial of Bosentan in Scleroderma Patients|Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension||Georgetown University|No|Terminated|September 2006|March 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|September 14, 2006|No|Yes|Study was terminated due to inadequate enrolment|No|March 28, 2011|https://clinicaltrials.gov/show/NCT00377455||178644|
NCT00377845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP06-2351|Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.|Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.||University of Aarhus|No|Completed|September 2006|March 2008|Actual|December 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Screening|||Anticipated|100|||Female|23 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 26, 2008|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00377845||178614|
NCT00377858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10936|Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)|Comparison of Two Approaches to Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Oral Therapy: Comparison of Premixed Insulin Lispro Mid Mixture With Separate Basal and Bolus Insulin Injections|IOOX|Eli Lilly and Company|No|Completed|August 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|484|||Both|30 Years|80 Years|No|||December 2009|December 4, 2009|September 11, 2006|Yes|Yes||No|September 16, 2009|https://clinicaltrials.gov/show/NCT00377858||178613|
NCT00378144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7801002|Efficacy and Safety of Sinutab on Subjects in the Setting of a Common Cold|A Community Pharmacy Based Investigation in the Self-Medication Area Efficacy and Safety of Sinutab and Pseudoephedrine on Subjects With Nasal Congestion Accompanied by Headache in the Setting of a Common Cold||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|469|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00378144||178591|
NCT00378885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGD 4013|Effect Study of a Theory-Based Internet Intervention on Safe-Sex Practices|The Effect of a Theory Based Tailored Intervention Online on the Reduction of Risk Behavior for HIV Transmission Among Men Who Have Sex With Men - a Randomized, Single-Blind, Active (Waiting-List) Controlled Trial||Public Health Service of Amsterdam||Terminated|January 2003|August 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||642|||Male|N/A|N/A|Accepts Healthy Volunteers|||September 2006|September 20, 2006|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00378885||178536|
NCT00378846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060118|Three Different Types of Thermometers in Measuring Temperature in Young Patients With Fever and Without Fever|A Study Evaluating the Agreement of Devices for Measuring Temperature in Children||National Institutes of Health Clinical Center (CC)||Completed|March 2006|November 2009|Actual|||N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|32|||Both|4 Years|17 Years|No|||March 2012|March 14, 2012|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00378846||178539|
NCT00379171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 02-014/03|Milk Types and Fish Oil in 9- to 12-Month-Old Infants|The Importance of Complementary Feeding on Growth, Nutritional Status and Markers for Disease. An Intervention Study With Milk Types and LC-PUFA Supplements in 9- to 12-Month-Old Infants||University of Copenhagen||Completed|May 2003|March 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||100|||Both|8 Months|12 Months|Accepts Healthy Volunteers|||August 2008|August 13, 2008|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379171||178514|
NCT00379184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-014-MBL|Sensitization in Osteoarthritic Knees|Quantitative Assessment of Central Sensitization in Osteoarthritis Patients||Northern Orthopaedic Division, Denmark|No|Completed|September 2006|June 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with knee OA|March 2014|March 28, 2014|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379184||178513|
NCT00379444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1711-05|Tobacco Cessation Treatment for Pregnant Alaska Natives|Tobacco Cessation Treatment for Pregnant Alaska Natives||Mayo Clinic|Yes|Completed|November 2006|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|March 8, 2012|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379444||178493|
NCT00379457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-EPSSG-RMS-2005|Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma|A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005]||National Cancer Institute (NCI)||Recruiting|June 2006|||May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|600|||Both|N/A|20 Years|No|||July 2009|August 9, 2013|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00379457||178492|
NCT00380081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZI-06-010|A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia|A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Efficacy and Safety of Sublingual Zolpidem Tartrate Tablet in Adult Patients With Insomnia Characterized by Difficulty Returning to Sleep After Middle-of-the-Night (MOTN) Awakening||Transcept Pharmaceuticals|No|Completed|April 2006|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|82|||Both|18 Years|64 Years|No|||February 2012|February 10, 2012|September 21, 2006|No|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT00380081||178444|Scheduled nocturnal awakening is an established method used to evaluate treatments for naturally occurring middle-of-the-night awakenings. Additional studies are needed to determine the generalizability of the findings to 'real world' conditions.
NCT00380094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0024|Triage Now: an Observational, Prospective Multimarker Study of Biomarkers in Patients Presenting With Chest Pain|TRIAGE NOW: Triage in Acute General Chest Pain Patients Evaluation||Biosite||Completed|August 2006|December 2007|Actual|||Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients presenting with chest pain and ACE in differential diagnosis.|December 2009|December 17, 2009|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00380094||178443|
NCT00380367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-029|Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)|Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India||Merck Sharp & Dohme Corp.||Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Female|9 Years|15 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 22, 2006|Yes|Yes||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00380367||178422|
NCT00380380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2378|A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.|A Randomized, Single-blind, Placebo Controlled, Cross-over Study to Evaluate the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.||Novartis||Completed|January 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||18|||Both|30 Years|65 Years||||May 2012|May 6, 2012|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00380380||178421|
NCT00380679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5800|Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department|Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department||Louisiana State University Health Sciences Center in New Orleans||Active, not recruiting|December 2005|March 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||September 2006|September 25, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380679||178399|
NCT00380991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO_L_01840|Topic Compatibility Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene|Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensitivity) of Dermacyd Delicata (New Fragrance)||Sanofi||Completed|May 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2008|May 15, 2008|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380991||178375|
NCT00381004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0267|FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia|Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|September 2006|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|N/A|No|||December 2015|December 14, 2015|September 25, 2006||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT00381004||178374|
NCT00381017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04371|Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)|A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg Interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus - The ENDURE Study||Merck Sharp & Dohme Corp.||Withdrawn|September 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|69 Years|No|||August 2014|August 11, 2014|September 26, 2006|Yes|Yes|Non-protocol feasibility|||https://clinicaltrials.gov/show/NCT00381017||178373|
NCT00377585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104888|Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population|A Phase II/III, Observer-blind, Multi-Country, Multi-Centre, Randomized Study to Demonstrate the Superiority in Terms of Immunogenicity of Adjuvanted Influenza Vaccine Administered in Adults Aged 50 Years and Older Compared to Fluarix™||GlaxoSmithKline||Completed|September 2006|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||3350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377585||178634|
NCT00377936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT4001|EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas|A Controlled, Randomized, Open Label Phase II Trial to Evaluate Safety and Efficacy of a 1st Line Combination Treatment With Weekly Infusions of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG-1) in Three Dose Levels Compared With Gemcitabine Monotherapy in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas||MediGene|Yes|Completed|September 2005|October 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|212|||Both|18 Years|N/A|No|||November 2008|November 13, 2008|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00377936||178607|
NCT00376766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTCIC 05 24|Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)|Rapid Oral Treatment of Cluster Epileptic Seizures. Efficacy Assessment of Levetiracetam in Cluster Seizures.||University Hospital, Grenoble|No|Terminated|February 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|112|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|September 14, 2006||No|recruitment recruitment recruitment recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00376766||178696|
NCT00376779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106786|Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age|A Study to Evaluate the Immunogenicity and Safety of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine as Compared to the Currently Licensed Infanrix Hexa in Healthy Infants (2,3,4 M)||GlaxoSmithKline||Completed|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||450|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00376779||178695|
NCT00377507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2006004|Catechin Mouth-washing for Removal of Intraoral Bacteria|A Clinical Trial of Tea Catechin Mouth-washing for Removal of Intraoral Bacteria in the Elderly||University of Shizuoka|No|Terminated|October 2006|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|36|||Both|65 Years|95 Years|No|||July 2013|July 14, 2013|September 14, 2006||No|difficult to achieve the sufficient subjects|No||https://clinicaltrials.gov/show/NCT00377507||178640|
NCT00377871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-218/2-14|Hemodynamic Performance in Stentless Heart Valves|Hemodynamic Performance in Stentless Heart Valves||University of Aarhus|No|Completed|May 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|65 Years|N/A|No|||February 2008|May 31, 2015|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00377871||178612|
NCT00377468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2310106|Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)|Low Dose Administration of Delta9-Tetrahydrocannabinol for the Prevention of Hyperalgesia and Chronic Pain in Patients With Acute Complex Regional Pain Syndrome (CRPS) of the Upper Limb||Ludwig-Maximilians - University of Munich||Recruiting|September 2006|December 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|100|||Both|18 Years|N/A|No|||June 2008|June 26, 2008|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377468||178643|
NCT00377481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20339|COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.|A Randomised, Cross-Over Study to Investigate the Comfort of Injection of Renal Anaemia Patients Receiving Subcutaneous NeoRecormon® Compared to Darbepoetin Alfa.||Hoffmann-La Roche||Completed|September 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00377481||178642|
NCT00378391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4S-PL-O067|European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry|European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab||Jagiellonian University||Completed|November 2005|February 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||1800|||Both|18 Years|N/A|No|||June 2007|June 19, 2007|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00378391||178572|
NCT00378690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGD-EC-003|A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD|A Phase IIIb Randomized Study of Intermittent Versus Continuous Androgen Deprivation Therapy Using ELIGARD 22.5 mg 3-month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy|ICELAND|Astellas Pharma Inc|No|Completed|March 2006|December 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|706|||Male|18 Years|80 Years|No|||June 2014|June 2, 2014|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00378690||178549|
NCT00378924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000343|Cardiology Biobank Registry|Cardiology Biobank Registry||Emory University|No|Recruiting|December 2003|April 2020|Anticipated|March 2020|Anticipated|Phase 1|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|12000|Samples With DNA|60 cc of blood will be obtained from the participant. Blood will be processed and stored in      -80F freezers as plasma, serum, extracted DNA and whole blood.|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General population & patients presenting to the hospital|January 2016|January 7, 2016|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00378924||178533|
NCT00379522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitris|Vasopressin in Traumatic Hemorrhagic Shock Study|A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-study)||Medical University Innsbruck|Yes|Completed|July 2010|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|September 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00379522||178487|
NCT00379535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501101|Preventing Lack of Iodine During Pregnancy|Phase III : Preventing Lack of Iodine During Pregnancy. Effect of Supplying Woman With Potassium Iodine to the Neuro-Cognitive Children Development Until Two Years||University Hospital, Toulouse|No|Terminated|December 2006|June 2010|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|374|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|September 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00379535||178486|
NCT00375830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BONE0001|PET/CT and Whole-Body MRI for Detection of Skeletal and Soft Tissue Metastases|PET/CT and Whole-Body MRI for Detection of Skeletal and Soft Tissue Metastases||Stanford University|Yes|Recruiting|January 2006|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00375830||178767|
NCT00375843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069217|Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication|Response Variability in Treatment Resistant Depression - an Ancillary Study to "Sequenced Treatment Alternatives to Relieve Depression (STAR*D)"||National Institute of Mental Health (NIMH)|No|Completed|January 2005|March 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|75 Years|No|||September 2008|February 5, 2013|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00375843||178766|
NCT00378898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060724|Feasibility of Placing Bravo PH Capsule in Proximal Esophagus|DUAL BRAVO PH MONITORING: A Feasibility Trial|bravo|Vanderbilt University|No|Completed|September 2006|July 2009|Actual|March 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||July 2013|December 11, 2014|September 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00378898||178535|
NCT00378911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02702|Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus|A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||National Cancer Institute (NCI)||Completed|October 2006|January 2010|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||December 2012|June 11, 2014|September 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00378911||178534|
NCT00378859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-097/00|The Effect of Milk and Meat on IGFs in Prepubertal Boys|The Effect of Milk and Meat on IGFs in Prepubertal Boys||University of Copenhagen||Completed|November 2000|March 2001||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||24|||Male|8 Years|8 Years|Accepts Healthy Volunteers|||September 2006|January 20, 2009|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00378859||178538|
NCT00379470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-11|Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)|A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM||NovoCure Ltd.|Yes|Completed|September 2006|January 2011|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||April 2012|April 29, 2012|September 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379470||178491|
NCT00379743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000063|Partnership for Healthy Seniors|Cancer Prevention and Treatment Among African American Older Adults: Screening Trial||Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|October 2006|December 2012|Anticipated|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2874|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 18, 2012|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00379743||178470|
NCT00379756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106718|A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia||GlaxoSmithKline|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|510|||Male|18 Years|64 Years|No|||March 2011|June 7, 2012|September 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379756||178469|
NCT00380107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opt. medium 1|Volume Deficit Prior to Surgery|Estimation of Volume Deficit in Patients Prior to Surgery||Rigshospitalet, Denmark||Completed|October 2006|August 2007|Actual|August 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||4|Actual|4|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients for surgery in 3 procedures:          -  mastectomy          -  rad. prostatectomy          -  open adb. surgery        And 20 healthy subjects|August 2009|August 5, 2009|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380107||178442|
NCT00380393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106464|Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.|A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Bio's Candidate Vaccine RTS,S/AS01, Administered According to a 0,1,2-mths Schedule in Children Aged 5 to 17 Mths Living in Tanzania & Kenya||GlaxoSmithKline||Completed|January 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|855|||Both|5 Months|17 Months|Accepts Healthy Volunteers|||September 2009|September 3, 2009|September 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00380393||178420|
NCT00380406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006603-01H|PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial|PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial: A Randomized Controlled Trial of Gonadotropin Releasing Hormone Agonist (GnRHa) for Fertility Preservation in Oncology Patients|PROOF|Ottawa Hospital Research Institute|Yes|Completed|January 2007|April 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|38 Years|No|||August 2010|August 19, 2010|September 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00380406||178419|
NCT00380692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10483|Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder|A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder||Eli Lilly and Company||Completed|October 2006|October 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|6 Years|17 Years|No|||May 2010|May 5, 2010|September 22, 2006|Yes|Yes||No|May 18, 2009|https://clinicaltrials.gov/show/NCT00380692||178398|
NCT00380705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-365|Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)|Quality of Life in Asthma and Rhinitis Allergic With Singulair||Merck Sharp & Dohme Corp.||Completed|March 2005|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|91|||Both|6 Years|N/A|No|||December 2015|December 17, 2015|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00380705||178397|
NCT00380718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10720|Chemotherapy for Patients With Non-Small Cell Lung Cancer|Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy||Eli Lilly and Company|No|Completed|November 2006|November 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||November 2010|November 1, 2010|September 22, 2006|Yes|Yes||No|September 2, 2009|https://clinicaltrials.gov/show/NCT00380718||178396|
NCT00381030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKF105517/379|Effects of Carvedilol on Health Outcomes in Heart Failure|Effects of Inpatient Initiation of Carvedilol and Nurse Management on Health Outcomes in Vulnerable Heart Failure Patients (ECHO Study): a Randomized Trial||Denver Health and Hospital Authority||Completed|October 2002|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||September 2006|September 25, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00381030||178372|
NCT00377598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-583-EC201|Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia|A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo||Takeda|No|Completed|October 2006|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|399|||Both|50 Years|N/A|No|||January 2012|January 31, 2012|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00377598||178633|
NCT00377962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIC01|Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation|Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation: Results at 24 Months|NOCTET|Novartis||Completed|December 2005|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|282|||Both|18 Years|65 Years|No|||May 2011|May 12, 2011|September 15, 2006|Yes|Yes||No|March 23, 2011|https://clinicaltrials.gov/show/NCT00377962||178605|
NCT00377286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604099|Effect of Glucosamine on Joint Structure and Quality of Life (JOG)|Development of Biomarker and Functional Assessment Tools to Evaluate the Effect of Glucosamine on Joint Structure and Quality of Life||University of Pittsburgh|Yes|Completed|September 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|201|||Both|35 Years|65 Years|No|||June 2011|June 12, 2011|September 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00377286||178657|
NCT00377494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-070|CS DNA MVA Trial in Mampong, Ghana|A Phase I Trial of PFCSP DNA/MVA.CSO Prime/Boost Vaccine in Mampong, Ghana||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||July 2008||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2007|August 26, 2010|September 14, 2006||||||https://clinicaltrials.gov/show/NCT00377494||178641|
NCT00378417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL69-0|Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes|Efficacy Trial in Finnish Children of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Pneumococcal Serotypes in the Vaccines||National Institute for Health and Welfare, Finland||Completed|March 1995|March 1999||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3075|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2006|September 19, 2006|September 19, 2006||||||https://clinicaltrials.gov/show/NCT00378417||178570|
NCT00377884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-018-MBL|Serologic Characterization of Bone-healing|Serologic Based Molecular Characterization of Bone-healing After Cementless Total Hip Arthroplasty||Northern Orthopaedic Division, Denmark||Withdrawn|January 2004|June 2009|Anticipated|June 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|40 Years|80 Years|No|Probability Sample|patients planned for cementless THR for OA in the hip|April 2014|April 2, 2014|September 18, 2006|||Lack of patients, lack of funding for analysis|No||https://clinicaltrials.gov/show/NCT00377884||178611|
NCT00378157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUS 29560105|Joint Attention Intervention and Young Children With Autism|Effectiveness of Joint Attention Intervention in Young Children With Autism - a Randomized Study||Oslo University Hospital||Completed|September 2006|January 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|24 Months|60 Months|No|||February 2011|February 21, 2011|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00378157||178590|
NCT00379262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-0501 Trial|Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma|Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma||Hong Kong Nasopharyngeal Cancer Study Group Limited|Yes|Active, not recruiting|September 2006|December 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|798|||Both|18 Years|70 Years|No|||March 2015|March 30, 2015|September 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00379262||178507|
NCT00378716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP C-06|Combination Chemotherapy in Treating Patients With Resected Colon Cancer|A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon||NSABP Foundation Inc|Yes|Completed|February 1997|April 2009|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1608|||Both|N/A|N/A|No|||January 2010|January 8, 2010|September 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00378716||178547|
NCT00378976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21760-A|HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.|A Randomized, Double-blind, Placebo-controlled Crossover Trial of Valacyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Men Who Have Sex With Men (MSM).||University of Washington|No|Completed|August 2003|July 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|N/A|No|||August 2013|August 21, 2013|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00378976||178529|
NCT00375856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DepuyRP06|Computer-Assisted Total Knee Replacement Kinematics: DePuy Sigma Posterior Cruciate Substituting Knee and the DePuy Sigma RP Rotating Platform Knee|An Investigation of Computer-Assisted Total Knee Replacement Kinematics on Patient Performance: An Examination of the DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee and the DePuy P.F.C.® Sigma RP Rotating Platform Knee Systems||Queen's University|Yes|Completed|October 2006|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|91|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00375856||178765|
NCT00379808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06011312|Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease|Role of the Arachidonate 5-Lipoxygenase Pathway in Coronary Heart Disease||University of Florida|No|Completed|July 2006|August 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|September 20, 2006|No|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00379808||178465|Because there were no order effects, the placebo groups were combined and the montelukast groups were combined. Therefore results from each of these are not reported by arm.
NCT00379197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006LS016|Naltrexone in Treating Women With Metastatic Breast Cancer That Did Not Respond to Hormone Therapy|Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer||Masonic Cancer Center, University of Minnesota|Yes|Terminated|July 2006|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||July 2013|July 25, 2013|September 19, 2006|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00379197||178512|
NCT00379483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0105E1|Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload|Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload||Novartis||Completed|July 2002|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|October 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00379483||178490|
NCT00379769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRL-049653/231|RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes|A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia|RECORD|GlaxoSmithKline|Yes|Completed|April 2001|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|4447|||Both|40 Years|75 Years|No|||November 2014|September 24, 2015|September 21, 2006||No||No|August 24, 2009|https://clinicaltrials.gov/show/NCT00379769||178468|
NCT00381082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOOV-1 Version 1 22 Sep 2004|A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.|A Randomised, Controlled and Blinded Assessment Study of the Efficacy of MOOV Head Lice Treatment (Ego Pharmaceutical Pty. Ltd.) in the Treatment of Head Lice in Primary School Children.||Uniquest Pty Ltd||Completed|September 2004|November 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||152|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||December 2006|December 8, 2006|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381082||178368|
NCT00380731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH076074|Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia|fMRI of Emotional Reactivity Cognitive Regulation and CBT for Social Phobia||Stanford University|Yes|Completed|September 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|21 Years|55 Years|No|||November 2011|November 29, 2011|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380731||178395|
NCT00380744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8705|A Safety and Pharmacokinetics Study in Patients With Rheumatoid Arthritis|A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis||Eli Lilly and Company|No|Completed|November 2005|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|104|||Both|18 Years|75 Years|No|||October 2009|October 5, 2009|September 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00380744||178394|
NCT00376792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456773|Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer|An Open Randomized Phase III Trial of Six Cycles of Docetaxel Versus Surveillance After Radical Prostatectomy in High Grade Prostate Cancer Patients With Margin Positive T2 or T3 Tumours||National Cancer Institute (NCI)||Recruiting|October 2005|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|396|||Male|18 Years|70 Years|No|||June 2009|August 23, 2013|September 13, 2006||||No||https://clinicaltrials.gov/show/NCT00376792||178694|
NCT00378170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prototype vs Macintosh|Laryngoscope Prototype Tested Against the Traditional Macintosh Blade|||Herlev Hospital||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||210|||Both|18 Years|N/A|No|||November 2006|December 1, 2006|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378170||178589|
NCT00378404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-LUN-69-UKY|Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC|A Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)||University of Kentucky|No|Terminated|November 2004|January 2010|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|September 18, 2006||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00378404||178571|
NCT00377910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-02-012-OSi|The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy|Placebo Controlled Trial, Testing the Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles Tendinopathy.||Northern Orthopaedic Division, Denmark|Yes|Completed|March 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00377910||178609|
NCT00377923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05A/Prg05|Endometrial Effects of Daily Progesterone s.c. 25 and 50 Mg Aqueous Formulation to Female Healthy Volunteers|||IBSA Institut Biochimique SA||Completed|August 2005|March 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2006|September 19, 2006|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00377923||178608|
NCT00378703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00533|Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer|The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2007|December 2015|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|361|||Both|18 Years|N/A|No|||October 2014|April 14, 2015|September 19, 2006|Yes|Yes||No|April 14, 2015|https://clinicaltrials.gov/show/NCT00378703||178548|
NCT00378963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0606060022|Instrument Applied and Manual Manipulation Induced EMG Response in Asymptomatic Subjects|||Logan College of Chiropractic||Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|20 Years|60 Years||||May 2007|July 31, 2007|September 18, 2006||||No||https://clinicaltrials.gov/show/NCT00378963||178530|
NCT00378430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200654|" Patients Attitude Towards Physicians and Health Screening Issues Among First Generation Asian-Indian Immigrants to United States".|||University of California, San Francisco||Terminated|September 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 23, 2013|September 18, 2006|||poor response to questionnaire|No||https://clinicaltrials.gov/show/NCT00378430||178569|
NCT00378989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVA2XRCT|The Effectiveness of Health Advice and Occupational Health Intervention on Work Ability|The Effectiveness and Cost-effectiveness of Health Advice and Occupational Health Intervention on Work Ability. Two Randomised Trials.||Evalua International|No|Completed|September 2004|October 2006|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|418|||Both|18 Years|60 Years|No|||February 2015|February 9, 2015|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00378989||178528|
NCT00379002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-095|The Women's Urology Center/WISH Database Project|The Women's Urology Center/WISH Database Project||William Beaumont Hospitals|No|Enrolling by invitation|July 2006|July 2016|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|||Female|18 Years|N/A|No|Non-Probability Sample|All Women's Urology Center or WISH patients|September 2013|September 13, 2013|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379002||178527|
NCT00379288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04139|Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)|A 1-Year Safety Study of Medium and High Doses of Mometasone Furoate/Formoterol Combination Formulation and Medium and High Doses of Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Medium to High Doses of Inhaled Glucocorticosteroids||Merck Sharp & Dohme Corp.|No|Completed|June 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|404|||Both|12 Years|N/A|No|||January 2015|January 12, 2015|September 19, 2006|No|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00379288||178505|
NCT00379899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060111|ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis|A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis||Amgen||Completed|September 2006|November 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|360|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|September 21, 2006||||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00379899||178458|
NCT00375869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBI2006|Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury|A Prospective Randomized Placebo Controlled Study of the Efficacy and Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury||Royal Alexandra Hospital|No|Completed|November 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|70 Years|No|||March 2012|March 1, 2012|September 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00375869||178764|
NCT00375882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060088|Safety Study to Evaluate the Effect of Lowering Body Temperature During Cochlear Implantation|Mild Hypothermia During Cochlear Implantation||University of Miami|No|Terminated|March 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|70 Years|No|||August 2014|August 14, 2014|September 11, 2006||No|as specified in the protocol|No||https://clinicaltrials.gov/show/NCT00375882||178763|
NCT00380146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEACAT2.2|Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-Pyrimethamine Intermittent Presumptive Treatment in Pregnant Women|An Open-Label in Vivo Drug Study to Evaluate the Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes Following Sulfadoxine-Pyrimethamine Intermittent Presumptive Treatment (SP IPT) in Pregnant Women||University of Cape Town|Yes|Active, not recruiting|September 2006|March 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Female|18 Years|N/A|No|||April 2007|April 23, 2007|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00380146||178439|
NCT00379210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002761-01A1|Neural Effects of Mindfulness Training on Attention|Neural Effects of Mindfulness Training on Attention||University of Pennsylvania|Yes|Completed|September 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|65 Years|No|||November 2007|December 20, 2011|September 20, 2006||No||No|July 20, 2010|https://clinicaltrials.gov/show/NCT00379210||178511|
NCT00379496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|843/99|Trial of Acupuncture Added to Usual Treatment for Fibromyalgia|A Randomized Controlled Trial of Acupuncture Added to Usual Treatment for Fibromyalgia||University of Sao Paulo||Completed|April 2000|May 2002||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||58|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||September 2006|September 21, 2006|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00379496||178489|
NCT00379509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0411|Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer|Phase I Radiosensitization Study of GW572016 With Biologic Correlates in Locoregionally Recurrent Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|April 2006|August 2012|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|120 Years|No|||January 2016|January 17, 2016|September 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00379509||178488|
NCT00379782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2006-025|Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project|||Queen's Medical Centre||Completed|October 2006|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|628|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 26, 2011|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00379782||178467|
NCT00381095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081128|A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer|A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain|COPE|Pfizer|Yes|Terminated|December 2006|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||August 2011|October 21, 2011|September 25, 2006|Yes|Yes|See termination reason in detailed description.|No|August 18, 2011|https://clinicaltrials.gov/show/NCT00381095||178367|Efficacy parameters baseline=the last non-missing observation, up to the baseline visit for that efficacy parameter. Baseline mBPI scores=average score in week preceding randomization, minimum 4 datapoints. No formal hypothesis testing conducted.
NCT00381108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4373|Study of the Effects of Pomegranate Tablets on Enlarged Prostates|A Randomized, Double Blinded, Controlled Clinical Trial of Pomegranate Tablets vs Placebo: Effects on Symptoms of Benign Prostatic Hyperplasia||University of California, Irvine|No|Active, not recruiting|September 2005|June 2010|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|N/A|No|||January 2010|January 4, 2010|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381108||178366|
NCT00381043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-MD-06|Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic|Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study||University of North Carolina, Chapel Hill|No|Completed|August 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|65 Years|No|||February 2013|February 18, 2013|September 26, 2006|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00381043||178371|
NCT00381056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-000044|The Labor and Delivery Teamwork Intervention Trial|The Labor and Delivery Teamwork Intervention Trial||Beth Israel Deaconess Medical Center||Completed|July 2000|March 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||30000|||Female|N/A|N/A|No|||September 2006|September 26, 2006|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381056||178370|
NCT00377026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M051633|FirstWIND: Weight Loss Interventions After Delivery|FirstWIND: Weight Loss Interventions After Delivery||Johns Hopkins University|No|Completed|September 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Female|18 Years|N/A|No|||June 2009|June 18, 2009|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00377026||178677|
NCT00377039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD337-021|A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia|A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study to Investigate the Efficacy, Safety and Tolerability of AD 337 in the Treatment of Fibromyalgia in Female Subjects.||Sosei||Completed|August 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|65 Years|No|||September 2007|September 30, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377039||178676|
NCT00377520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8368|A Trial for Patients With Advanced/Recurrent Endometrial Cancer|A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma||Eli Lilly and Company|Yes|Completed|September 2006|September 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|N/A|N/A|No|||November 2009|November 13, 2009|September 14, 2006|Yes|Yes||No|October 21, 2008|https://clinicaltrials.gov/show/NCT00377520||178639|
NCT00377533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA013|Wheelchair Handling Skills of Caregivers: Comparison Between Anti-tip Devices and a New Design|Wheelchair Handling Skills of Caregivers: Comparison Between Conventional Rear Anti-tip Devices and a New Design||Nova Scotia Health Authority||Completed|December 2004|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|April 1, 2010|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377533||178638|
NCT00377546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5264|Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|N/A|N/A||||September 2008|September 23, 2008|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377546||178637|
NCT00378742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060236|Repository for Inherited Eye Diseases|National Ophthalmic Genotyping and Phenotyping Network, Stage 1 - Creation of DNA Repository for Inherited Ophthalmic Diseases||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2006|||||N/A|Observational|Time Perspective: Prospective|||Actual|959|||Both|2 Years|N/A|No|||May 2015|January 12, 2016|September 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00378742||178545|
NCT00379028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5892C00012|Airway Clearance Study|A Randomized, Double-blind, Two-way Cross-over Study Evaluating Systemic Bioavailability and Airway Clearance of SymbicortTurbuhaler 320/9mcg vs SeretideDiskus 50/500mcg After Single Inhalations in Patients With COPD and Healthy Volunteers||AstraZeneca||Completed|September 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 21, 2011|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379028||178525|
NCT00377559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYOTAX|Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer|Phase II Multicentre Open Label Trial Evaluating the Efficacy and Safety of the Liposomal Doxorubicin (Myocet®) and Docetaxel (Taxotere®) Combination as First-line Treatment of Patients With Metastatic HER2/Neu Negative Breast Cancer|MYOTAX|Catharina Ziekenhuis Eindhoven|No|Completed|May 2006|July 2011|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||August 2011|October 5, 2015|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00377559||178636|
NCT00377572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-08|Inner-City Anti-IgE Therapy for Asthma|Inner-City Anti-IgE Therapy for Asthma (ICAC-08)|ICATA|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|419|||Both|6 Years|20 Years|No|||June 2013|June 6, 2013|September 14, 2006|Yes|Yes||No|January 11, 2013|https://clinicaltrials.gov/show/NCT00377572||178635|
NCT00378196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00002686|Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial|Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial||Johns Hopkins University|No|Completed|September 2006|December 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||November 2012|November 12, 2012|September 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00378196||178587|
NCT00378183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012520|A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.|A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine||Janssen, LP||Completed|February 2001|May 2002|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|65 Years|No|||April 2010|April 26, 2010|September 15, 2006||||No||https://clinicaltrials.gov/show/NCT00378183||178588|
NCT00378729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051008|Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS)|PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment|PERCING|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2006|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Female|18 Years|36 Years|No|||October 2007|October 3, 2011|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00378729||178546|
NCT00379587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-377|Rituximab for Prevention of Chronic GVHD|A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation||Dana-Farber Cancer Institute||Completed|September 2006|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|65|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|September 21, 2006|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00379587||178482|
NCT00379912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG MDS04-85|Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes|Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts)||Hoosier Cancer Research Network|Yes|Terminated|September 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|September 21, 2006||No|Insufficient response rate|No||https://clinicaltrials.gov/show/NCT00379912||178457|
NCT00376454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1A20004|The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects With Peripheral Neuropathic Pain||GlaxoSmithKline||Completed|November 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||113|||Both|18 Years|80 Years|No|||February 2013|February 11, 2013|September 13, 2006||||||https://clinicaltrials.gov/show/NCT00376454||178720|
NCT00376467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL0201|STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia|STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201.||Gruppo Italiano Malattie EMatologiche dell'Adulto||Completed|December 2001|February 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376467||178719|
NCT00379548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-47|Changes in Inflammatory State in Asian Americans Changing From Traditional Asian Diets to American Diet - a Pilot Study|A Pilot Study of the Changes in Inflammatory State in Asian Americans Changing From Traditional Asian Diet to Typical American Diets||Joslin Diabetes Center|Yes|Active, not recruiting|November 2005|December 2014|Anticipated|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|September 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00379548||178485|
NCT00379561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX302|PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer|A Phase 1 Trial of PSA-Activated PSA-PAH1 Therapy for Locally Recurrent Prostate Cancer Without Metastases After Primary Radiation Therapy||Sophiris Bio Corp||Completed|March 2006|July 2008|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|October 27, 2009|September 20, 2006||||||https://clinicaltrials.gov/show/NCT00379561||178484|
NCT00379223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9418-04|Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial|Multicenter Trial to Investigate the Safety and Efficacy of Vitrectomy With Radial Optic Neurotomy for the Preservation of Visual Function in Subjects With Central Retinal Vein Occlusion (CRVO)|OVCR|University Hospital, Bordeaux|Yes|Terminated|October 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|50 Years|N/A|No|||August 2008|March 3, 2011|September 20, 2006||No|lack of recruting|No||https://clinicaltrials.gov/show/NCT00379223||178510|
NCT00380419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00007344|Effects of Interpersonal Psychotherapy on Depression During and After Pregnancy|Infant Outcomes and Depression Treatment in Pregnancy||University of Michigan|Yes|Completed|October 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Female|21 Years|45 Years|No|||May 2013|May 29, 2013|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380419||178418|
NCT00380445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2379|Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes|Effect of Vildagliptin on Adipose Tissue and Skeletal Muscle Metabolism in Obese Patients With Type 2 Diabetes||Novartis||Completed|January 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|21|||Both|30 Years|65 Years||||May 2012|May 4, 2012|September 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00380445||178417|
NCT00380757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006347-01H|Comparison of Bystander Fatigue and CPR Quality When Using Two Different CPR Ratios.|Comparison of Bystander Fatigue and CPR Quality When Using the New 30:2 Versus the Old 15:2 Chest Compression to Ventilation International Guidelines: A Randomised Crossover Trial||Ottawa Hospital Research Institute|No|Completed|October 2006|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|55 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 16, 2012|September 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00380757||178393|
NCT00377975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 22021|"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat|Synergistic Induction of UCP-1 by Ephedrine/Caffeine and Pioglitazone: A Rationale for Combination Therapy of Obesity||Pennington Biomedical Research Center||Completed|January 2003|November 2004||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|September 17, 2006||||||https://clinicaltrials.gov/show/NCT00377975||178604|
NCT00377052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I172|Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma|A Phase II Study of Bortezomib and Gemcitabine in Patients With Relapsed Mantle Cell Lymphoma||Canadian Cancer Trials Group|Yes|Completed|June 2006|June 2011|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00377052||178675|
NCT00377065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-023|Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)|Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options||Merck Sharp & Dohme Corp.||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|16 Years|N/A|No|||March 2016|March 22, 2016|September 14, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00377065||178674|
NCT00377325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR050100|The Effectiveness of Lower Cyclosporine Doses for Psoriasis|Cyclosporine in the Pharmacotherapy of Psoriasis||University of Rochester|Yes|Withdrawn|June 2007|September 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|70 Years|No|||November 2014|November 20, 2014|September 15, 2006|Yes|Yes|Study terminated by the DSMB due to low recruitment|No||https://clinicaltrials.gov/show/NCT00377325||178654|
NCT00379327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuPTD-100|Acupuncture for Promotion of Timely Delivery|Acupuncture for Promotion of Timely Delivery||University of Pennsylvania|No|Completed|January 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Female|15 Years|50 Years|No|||October 2010|November 17, 2010|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00379327||178502|
NCT00376064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995BDE16|Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly|A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy||Novartis||Completed|March 2006|||January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376064||178749|
NCT00377949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 04-227|Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients|The Natural History and Outcome of Patients With Scleroderma at High Risk for or With Early Pulmonary Hypertension||Georgetown University|No|Active, not recruiting|February 2005|||January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|75 Years|No|Non-Probability Sample|Primary care, rheumatology and pulmonary hypertension clinics.|September 2015|September 23, 2015|September 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00377949||178606|
NCT00378469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2006/0415|Study of the Effects of Muscular Activity on Iron Metabolism|Study of the Effects of Muscular Activity on Iron Metabolism: A Pilot Study on Healthy Volunteers||Rennes University Hospital|No|Recruiting|September 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2007|July 11, 2007|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00378469||178566|
NCT00379925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|426|Effectiveness of a Church-Based Program at Increasing Physical Activity and Healthy Dietary Habits in African Americans|A Partnership to Promote Physical Activity and Healthy Eating in AME Churches||University of South Carolina|No|Completed|July 2006|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|1600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 5, 2013|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00379925||178456|
NCT00378443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2006]022|ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT|||Peking University||Active, not recruiting|January 2006|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|65 Years|No|||September 2006|September 21, 2006|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00378443||178568|
NCT00379301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn805173|Efficacy of Different Ablation Strategies for Controlling Atrial Fibrillation|Efficacy of Different Ablation Strategies in Achieving Long-Term Arrhythmia Control in Patients With Persistent or Permanent Atrial Fibrillation|RASTA|University of Pennsylvania||Completed|October 2006|October 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|166|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|September 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00379301||178504|
NCT00381147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-340-14-6-1-PU-11|Use of Clarithromycin in Mustard-Induced Bronchiolitis|Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard||Baqiyatallah Medical Sciences University||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|N/A|N/A||||September 2006|January 6, 2009|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381147||178363|
NCT00376883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG 08/00|Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month|The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.||Nordic Myeloma Study Group||Completed|January 2000|October 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||500|||Both|18 Years|N/A|No|||January 2007|January 3, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00376883||178687|
NCT00372606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51759|An Evaluation of a Culturally- and Linguistically-Appropriate Online Diet Program for U.S Hispanics|An Evaluation of a Culturally- and Linguistically-Appropriate eHealth Portal to Facilitate Improved Diets, Increased Fitness-Levels, and Weight-Loss Among U.S. Hispanics||Robert Wood Johnson Foundation||Completed|September 2004|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|1000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2009|October 6, 2009|September 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00372606||179011|
NCT00379886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECT-Jan2004-Jan2007|Comparison of Thiopental and Propofol as Anaesteticum During ECT|Comparison of Thiopental and Propofol as Anaesteticum During ECT||Rigshospitalet, Denmark||Recruiting|January 2003|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||November 2007|November 13, 2007|September 21, 2006||||No||https://clinicaltrials.gov/show/NCT00379886||178459|
NCT00380120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/98|Ultrasound Findings to Adjust the Duration of Anticoagulation|The AESOPUS Study: Ultrasound Findings to Adjust the Duration of Anticoagulation in Patients With Deep Vein Thrombosis|AESOPUS|University of Padova|Yes|Completed|January 1999|June 2006|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|538|||Both|18 Years|N/A|No|||March 2008|March 17, 2008|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380120||178441|
NCT00380133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI100477|Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Five-way Crossover Study to Assess the Effects of Single Oral Doses of SB-681323 (7.5 mg and 25 mg) and Prednisolone (10 mg and 30 mg) on Biomarkers in Induced Sputum and Blood in COPD Patients.||GlaxoSmithKline||Completed|June 2005|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|75 Years|No|||March 2012|May 31, 2012|September 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00380133||178440|
NCT00380770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H029/02|HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT|A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT)|KAART|University of KwaZulu|Yes|Completed|January 2003|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||March 2009|July 20, 2010|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00380770||178392|
NCT00380783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203818-005|Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis|||Allergan||Terminated|October 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|2|||Female|18 Years|N/A|No|||May 2011|May 27, 2011|September 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00380783||178391|
NCT00381069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72994|SDSU MOVE/Me Muevo Project|Obesity Prevention and Control in Community Recreation Centers||San Diego State University|Yes|Active, not recruiting|October 2006|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|541|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381069||178369|
NCT00378235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL13PEI-151|Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma|Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma||INSYS Therapeutics Inc||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|3 Years|21 Years|No|||November 2014|November 11, 2014|September 18, 2006|||There was a change of sponsor. The new sponsor company did not wish to conduct the study after    all.|||https://clinicaltrials.gov/show/NCT00378235||178584|
NCT00375232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMOEBA Trial|Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes|Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes||Indiana University||Withdrawn|October 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|September 11, 2006||||No||https://clinicaltrials.gov/show/NCT00375232||178812|
NCT00376805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN-2005LS033|Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer|Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer||Masonic Cancer Center, University of Minnesota|Yes|Terminated|April 2006|January 2010|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|September 13, 2006|Yes|Yes|Withdrawn due to toxicity|No|July 13, 2010|https://clinicaltrials.gov/show/NCT00376805||178693|
NCT00376818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2306|Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers|Evaluation of a Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers||Case Comprehensive Cancer Center|Yes|Completed|June 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|September 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00376818||178692|
NCT00377078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-VB-04-02|Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.|Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes to Manage Post-Antibiotic Colonization and Infection With Clostridium Difficile||Johns Hopkins University||Recruiting|October 2005|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|N/A|No|||September 2006|September 14, 2006|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377078||178673|
NCT00377338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/102/HP|Safety and Accuracy of Alveoscopy in Interstitial Lung Diseases|Phase II Study of Broncho-Alveoscopy Using Fibered Confocal Fluorescence Microscopy|ALVEOLE|University Hospital, Rouen|Yes|Completed|May 2006|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|Samples Without DNA|distal lung biopsy if of tumoral nature (fixed or frozen sample)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy smoker and non-smoker subjects, patients with no peripheral lung disease on CT        scan, Patients with focal parenchymal lung diseases, patients with diffuse parenchymal        lung diseases|July 2013|July 29, 2013|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00377338||178653|
NCT00376311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Daniel H Manicourt|Effects of Oral Salmon Calcitonin in Human Osteoarthritis|Phase IIa Study of the Effects of a New Oral Formulation of Salmon Calcitonin in Human Osteoarthritis||Université Catholique de Louvain||Terminated|September 2002|May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||54|||Both|50 Years|80 Years|No|||June 2002|September 13, 2006|December 30, 2005||||No||https://clinicaltrials.gov/show/NCT00376311||178730|
NCT00378209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-147|Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma|Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma||Dana-Farber Cancer Institute||Active, not recruiting|August 2006|December 2016|Anticipated|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 18, 2006|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00378209||178586|
NCT00378456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98CH11|Vitamins and Minerals for Children With Downs Syndrome|||Institute of Child Health||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|N/A|7 Months||||September 2006|September 19, 2006|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00378456||178567|
NCT00379938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0078|B-19 Parvovirus Vaccine Study|A Phase I/II Study of the Safety and Immunogenicity of a Recombinant Human Parvovirus B-19 Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|August 2006|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|43|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|August 11, 2011|September 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379938||178455|
NCT00379951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-048|A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)|A Prospective, Multicenter, Noncomparative, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections||Merck Sharp & Dohme Corp.||Completed|June 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|September 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00379951||178454|
NCT00379015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000496448|Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer|Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer||National Cancer Institute (NCI)||Completed|January 2006|September 2012|Actual|June 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|20 Years|65 Years|No|||July 2009|December 17, 2013|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00379015||178526|
NCT00380848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHC BMB 05-009|Impact of Different Dialysis on Sleep Apnea in Patients With Renal Failure|Effect of Hemodiafiltration on Sleep-Disordered Breathing in Patients With End-Stage Renal Disease||McGill University Health Center||Recruiting|March 2006|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||May 2006|April 11, 2007|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380848||178386|
NCT00380861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04092|Does Implant Design Improve Postoperative Flexion?|Does Implant Design Improve Postoperative Flexion?A Prospective, Randomized, Comparative, Multi-center Study Comparing PFC® Sigma™ RP Knee Versus PFC® Sigma™ RP-F Implanted in Simultaneous Bilateral Subjects||DePuy Orthopaedics|No|Completed|March 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|40 Years|70 Years|No|||August 2013|August 6, 2013|September 26, 2006|Yes|Yes||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00380861||178385|
NCT00381160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK73025A|Reducing Sugar-sweetened Beverage Consumption in Overweight Adolescents|Reducing Sugar-Sweetened Beverage Consumption in Overweight Adolescents|BASH|Children's Hospital Boston||Completed|September 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||August 2012|August 8, 2012|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00381160||178362|
NCT00376493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APA 05-452|Prolonged Treatment for Infected Abortion After Hospital Discharge.|Prolonged Treatment for Infected Abortion After Hospital Discharge.|APA|Hospital de Clinicas de Porto Alegre|Yes|Terminated|May 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Female|14 Years|50 Years|No|||December 2007|March 10, 2008|September 14, 2006||No|The rate of cure in both arms was higher than expected|No||https://clinicaltrials.gov/show/NCT00376493||178717|
NCT00376506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060212|A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia|A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia||National Institutes of Health Clinical Center (CC)||Completed|July 2006|January 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|90 Years|No|||September 2012|September 25, 2012|September 14, 2006|No|Yes||No|November 1, 2011|https://clinicaltrials.gov/show/NCT00376506||178716|
NCT00380510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP000016-02|The Safe Teen Study|The SAFE TEEN Study: Family Physicians' Reports of Facilitators of and Barriers to Preventive Care for Adolescents.||The University of Texas Health Science Center at San Antonio||Completed|June 2004|February 2005||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2006|September 25, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380510||178412|
NCT00380523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-093|Analgesic Treatment Mediated by Arcoxia (0663-093)|Analgesic Treatment Mediated by Arcoxia||Merck Sharp & Dohme Corp.||Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|237|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|September 22, 2006||||No||https://clinicaltrials.gov/show/NCT00380523||178411|
NCT00380458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-0406JM|Study to Evaluate Recovery From Postoperative Pain After Sleep Apnea Surgery|Prospective, Randomized, Controlled Clinical Trial to Evaluate Recovery From Post-operative Pain in Adults After Sleep Apnea Surgery Using a Coblation Device Compared to Electrocautery||ArthroCare Corporation|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|September 22, 2006||No|No patients enrolled. Study did not start.|No||https://clinicaltrials.gov/show/NCT00380458||178416|
NCT00380471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-pts-968|Treatment and Complication of Bath PUVA in Vitiligo|Treatment and Complication of Bath PUVA in Vitiligo||hahid Beheshti University of Medical Sciences||Recruiting|January 2006|August 2006|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2008|January 22, 2008|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380471||178415|
NCT00380159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-018|Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A|An Open-Label,48 Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Subjects Who Have Completed 14 Days of Treatment in Protocol ACH443-014A.||Achillion Pharmaceuticals|No|Completed|September 2006|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|60 Years|No|||February 2014|February 18, 2014|September 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00380159||178438|
NCT00380484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKR-KNAST-06|Short- and Long Term Growth in Children With Asthma|Short- and Long Term Growth in Children With Asthma Treated With Budesonide or Montelukast||Children´s Clinic, Randers||Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|6 Years|11 Years|No|||February 2008|February 19, 2008|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00380484||178414|
NCT00380796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012292|A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).|A Multicenter, Observational Study of the Long-term Safety of Infliximab (REMICADE) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). RESULTS COPD: REMICADE Safety Under Long Term Study in COPD||Centocor, Inc.|Yes|Completed|April 2006|December 2009|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|88|||Both|N/A|N/A|No|Non-Probability Sample|The study population consists of patients who had at least one dose of study drug in        clinical studies of infliximab in the treatment of COPD, that are targeted for long-term        safety follow-up and were asked to participate in this long-term safety follow-up study.|September 2013|September 3, 2013|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380796||178390|
NCT00375245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14435B|Rapamycin With Grapefruit Juice for Advanced Malignancies|A Phase Ib Study Administering Rapamycin (Sirolimus) With Grapefruit Juice in Patients With Advanced Malignancies||University of Chicago|Yes|Completed|September 2006|May 2012|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|September 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00375245||178811|
NCT00379054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1928-04|Intervention for Support Persons to Help Smokers Quit|Intervention for Support Persons to Help Smokers Quit||Mayo Clinic||Completed|September 2005|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 18, 2010|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00379054||178523|
NCT00376831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR440806CTIL|The Efficacy of Midazolam & Ketamine Versus Midazolam & Fentanyl for Sedation in Ambulatory Colonoscopies|||Soroka University Medical Center||Completed|January 2007|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2007|August 9, 2007|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00376831||178691|
NCT00377091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510M76771|Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy|Pilot Pharmacoeconomic Evaluation of Fondaparinux Treatment of Pulmonary Embolism (PE) Compared to Treatment With Unfractionated Heparin||University of Minnesota - Clinical and Translational Science Institute||Withdrawn|June 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|September 13, 2006|||Study pulled due to a grant disagreement between the U of M and SMDC|No||https://clinicaltrials.gov/show/NCT00377091||178672|
NCT00351637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20145|Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients|Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients: a Phase II Multicenter, Open Label, Feasibility Study||AHS Cancer Control Alberta||Terminated|December 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|July 11, 2006|||Study suspended due to low accrual|No||https://clinicaltrials.gov/show/NCT00351637||180583|
NCT00360958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCM S67/306|Treatment of Severe Heart Failure by Ultrafiltration|Ultrafiltration for the Chronic Treatment of Severe Congestive Heart Failure||Centro Cardiologico Monzino||Completed|August 2006|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|90 Years|No|||January 2016|January 27, 2016|August 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360958||179889|
NCT00361166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-008|Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone|A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects||ACADIA Pharmaceuticals Inc.||Completed|August 2005|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|No|||March 2007|March 20, 2007|August 3, 2006||||||https://clinicaltrials.gov/show/NCT00361166||179873|
NCT00361699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-STARS hsCRP|hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)|Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon the Serum High Sensitive CRP in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.||Translational Research Informatics Center, Kobe, Hyogo, Japan||Active, not recruiting|March 2004|||July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1095|||Both|45 Years|80 Years|No|||March 2015|March 19, 2015|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00361699||179832|
NCT00362466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-044|A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy|An Open-Label Randomized Phase III Study of Dasatinib vs. High-Dose (600 mg) Imatinib Mesylate in the Treatment of Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Are Imatinib Failures or Who Have Had a Suboptimal Response After 3-18 Months of Therapy With 400 mg Imatinib||Bristol-Myers Squibb|No|Terminated|April 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|August 9, 2006|Yes|Yes|Insufficient Enrollment|No|July 24, 2009|https://clinicaltrials.gov/show/NCT00362466||179775|Study was terminated early due to insufficient enrollment.
NCT00362830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA183-008|A Study of the Alternative Administration of Ixabepilone and Vinflunine|A Study of the Alternating Administration of Ixabepilone and Vinflunine Every Three Weeks in Patients With Advanced Cancer||Bristol-Myers Squibb|No|Completed|August 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|August 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362830||179747|
NCT00362505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-303|Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials|An Open-Label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials||Bukwang Pharmaceutical||Terminated|June 2004|March 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||June 2006|August 8, 2006|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362505||179772|
NCT00362869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-209|Enteroaggregative E.Coli (EAEC)|Pathogenicity of Enteroaggregative E. Coli in Adult Volunteers; Dose-Escalation Study||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|February 2008|December 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|5|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2010|May 30, 2013|August 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00362869||179744|
NCT00358787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-70532|Management of Displaced Supracondylar Fractures of the Humerus Using Lateral vs. Crossed K-wires|Management of Displaced Supracondylar Fractures of the Humerus Using Lateral Versus Cross K Wires: A Prospective Randomized Clinical Trial||University of British Columbia|No|Recruiting|July 2008|September 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|3 Years|7 Years|No|||November 2015|November 30, 2015|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00358787||180047|
NCT00358176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6063|Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women|A Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Noninferiority Study Comparing 75mg Risedronate Dosed on 2 Consecutive Days Monthly With 5mg Daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed Over 24 Months.||Sanofi||Completed|July 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1231|||Female|50 Years|N/A|No|||December 2009|December 11, 2009|July 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00358176||180094|
NCT00358189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4061I|Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease|Deep Brain Stimulation and Motor Function in Parkinson's Patients||VA Office of Research and Development||Completed|October 2006|May 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|30 Years|75 Years|No|||July 2006|February 3, 2009|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00358189||180093|
NCT00358488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2E106359|Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients|A Multi-enter, Randomized, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (10, 15, and 20 Mcg) of GSK159797||GlaxoSmithKline||Completed|April 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|54|||Female|18 Years|70 Years|No|||November 2013|November 7, 2013|July 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00358488||180070|
NCT00354198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941008|Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis|Clinical Efficacy of Combined Pentoxifylline and Conventional Immunosuppressive Regimens on Patients With Rapidly Progressive Glomerulonephritis||National Taiwan University Hospital|No|Terminated|August 2006|June 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2012|November 12, 2012|July 18, 2006||No|short of participants|No||https://clinicaltrials.gov/show/NCT00354198||180391|
NCT00352183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF0242780-01 05 02|Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy|A Multicenter, Double-Blind, Randomized Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Simvastatin Alone.||Solvay Pharmaceuticals|No|Completed|January 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|75 Years|No|||July 2009|July 7, 2009|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352183||180542|
NCT00352456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040271|Psychological Mechanisms of Behavioral Dysregulation|Psychobiological Mechanisms of Behavioral Dysregulation||National Institutes of Health Clinical Center (CC)||Completed|August 2004|April 2008||||N/A|Observational|N/A||||160|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352456||180522|
NCT00352729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-06-002|Evaluation of ACell Hydrated Wound Dressing for Autogenous Skin Donor Sites|Evaluation of ACell Hydrated Wound Dressing for Autogenous Skin Donor Sites|ACell|United States Army Institute of Surgical Research|No|Withdrawn|November 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|July 13, 2006|Yes|Yes|PI decided to use another product|No||https://clinicaltrials.gov/show/NCT00352729||180501|
NCT00359476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA183-023|A Study of Vinflunine in Patients With Gastric Cancer|A Multicenter, Single-Arm, Phase II Study of Single-Agent Vinflunine in the Second-line Treatment of Patients With Gastric Cancer||Bristol-Myers Squibb|No|Terminated|March 2007|November 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||December 2007|February 27, 2010|August 1, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00359476||179994|
NCT00359489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001336|Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.|A Randomized, Open-Label, Methodology Trial To Investigate The Utility Of Echocardiography In Assessment Of Cardiac Valvular Regurgitation In Adult Subjects||Pfizer||Completed|April 2007|July 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 13, 2007|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00359489||179993|
NCT00360685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14418|Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX|Safety of Tacrolimus And Methotrexate (MTX) Versus Tacrolimus And Mycophenolate Mofetil (MMF) As Graft Versus Host Disease Prophylaxis In Allogeneic Hematopoietic Cell Transplants (HCT)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2005|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|N/A|N/A|No|||March 2013|March 22, 2013|August 3, 2006|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00360685||179909|
NCT00350909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308S51681|Brief Intervention for Drug Abusing Adolescents|Brief Intervention for Drug Abusing Students||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2005|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350909||180639|
NCT00351143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE104325|A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control|A Randomized, Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50/250 Mcg b.i.d. Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only.||GlaxoSmithKline|No|Completed|July 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||550|||Both|18 Years|N/A|No|||November 2011|November 10, 2011|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351143||180621|
NCT00361465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610|DYSCAR: Characterization of Dystonia|Characterization of Dystonia and Influence of Cognitive-attentional Factors||University Hospital, Grenoble|No|Completed|August 2006|December 2010|Actual|||N/A|Observational|Time Perspective: Prospective||4|Anticipated|75|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parkinsonian patients, Dystonia patients,Major depression, Dementia, Acute psychosis,        Clinical motor deficit making the movements impossible, joint or muscle pathology|March 2011|March 25, 2011|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00361465||179850|
NCT00361712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003692|Effect of Preemptive Epidural Analgesia in Labor on Cytokine Production|Effect of Preemptive Epidural Analgesia in Labor on Pro and Anti-Inflammatory Cytokine Production in a Mother and a Newborn||Rabin Medical Center||Active, not recruiting|January 2006|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A||||July 2006|August 6, 2006|August 6, 2006||||No||https://clinicaltrials.gov/show/NCT00361712||179831|
NCT00352209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060158|Cardiomyopathy Following Stem Cell Transplantation|Retrospective Review of Cardiomyopathy Patient Cases Post Allogeneic Hematopoietic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Completed|May 2006|May 2007||||N/A|Observational|N/A|||||||Both|18 Years|80 Years|No|||May 2007|March 5, 2008|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352209||180540|
NCT00351962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20131|Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours|Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours||AHS Cancer Control Alberta||Recruiting|September 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351962||180558|
NCT00352495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0515|Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma|A Phase I Study of Vinblastine in Combination With Carboplatin for Children With Newly Diagnosed and Recurrent Low-Grade Gliomas||Children's Oncology Group|Yes|Completed|June 2006|March 2012|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|21 Years|No|||February 2014|February 11, 2014|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352495||180519|
NCT00362219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-2468.CTIL|Topical Morphine for Analgesia in Patients With Skin Grafts|Topical Morphine for Analgesia in Patients With Skin Grafts||Rambam Health Care Campus||Completed|December 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|75 Years|No|||October 2011|October 27, 2011|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362219||179794|
NCT00362232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11355|Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.|RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-blind, Randomized Study of BAY59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement|RECORD 4|Bayer|Yes|Completed|June 2006|January 2008|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|3148|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|August 8, 2006|Yes|Yes||No|May 10, 2012|https://clinicaltrials.gov/show/NCT00362232||179793|
NCT00362245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/2006_CTIL|Amikacin Penetration Into the Cerebrospinal Fluid|Amikacin Penetration Into the Cerebrospinal Fluid: Pharmacokinetic/Pharmacodynamic Analysis in Adults With Hospital Acquired Gram-negative Meningitis Associated With Intracranial Pressure Monitoring and Draining Devices||Rambam Health Care Campus||Withdrawn|September 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|75 Years|No|||November 2015|November 1, 2015|August 8, 2006|||lack of participants|No||https://clinicaltrials.gov/show/NCT00362245||179792|
NCT00362479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-DSG-301|Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive|A Prospective, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of the 28-Day Oral Contraceptive DR-1021||Teva Pharmaceutical Industries|No|Completed|August 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1347|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|August 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362479||179774|
NCT00353379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-650|Pharmacology of Cognition in Schizotypal Personality Disorder|Pharmacology of Cognition in Schizotypal Personality Disorder: Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2007|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00353379||180453|
NCT00353392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-ost-1359|Q-Switched Nd:YAG in Macular Amyloidosis|||hahid Beheshti University of Medical Sciences||Completed|March 2006|August 2006||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2006|December 18, 2013|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353392||180452|
NCT00353639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060082|Telomere Repair Gene Mutation in Inflammatory Bowel Disease|Telomere Repair Gene Mutations in Inflammatory Bowel Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2006|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|95|||Both|2 Years|80 Years|No|||June 2015|June 19, 2015|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353639||180433|
NCT00358501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-01|Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients|Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy||Jazz Pharmaceuticals|Yes|Completed|July 2006|March 2015|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|N/A|N/A|No|||June 2011|February 2, 2016|July 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00358501||180069|
NCT00359541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060077|Voriconazole Blood Levels and Toxicity|Voriconazole Plasma Concentration and Toxicity||National Institutes of Health Clinical Center (CC)||Completed|January 2006|June 2010||||N/A|Observational|N/A|||Actual|98|||Both|12 Years|N/A|No|||June 2010|September 26, 2015|August 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00359541||179991|
NCT00359294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM104-A-002-05|A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma|A Phase I Multicenter, Open-Label, Dose-Escalating Clinical and Pharmacokinetic Study of PM00104 Administered Intravenously Over 1 Hour Daily for 5 Days, Every 3 Weeks, to Subjects With Advanced Malignant Solid Tumors or Lymphoma.||PharmaMar|Yes|Terminated|May 2006|September 2008|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2008|April 20, 2009|August 1, 2006|Yes|Yes|Considered not necessary to continue with this trial; recommended dose was reached in other    phase I trials|No||https://clinicaltrials.gov/show/NCT00359294||180008|
NCT00359008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP V3|PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)|PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)||Notal Vision Ltd|Yes|Completed|July 2006|September 2007|Actual|||Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|336|||Both|50 Years|N/A|No|Probability Sample|At least 200 subjects with intermediate AMD in at least one (1) eye based on medical        record review and/or clinical diagnosis and at least 200 subjects with neovascular AMD in        at least one (1) eye in all sites.|January 2008|January 10, 2008|July 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00359008||180030|
NCT00359255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-0680|The Effect of Additional Arm Therapy on Arm Function After Stroke|The Effect of a Supplementary Exercise Program for Upper Extremity Function in Stroke Rehabilitation||University of British Columbia|Yes|Completed|July 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|120|||Both|19 Years|N/A|No|||July 2009|July 8, 2009|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00359255||180011|
NCT00360334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-BP-GWBG|A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients|An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone||AstraZeneca|No|Completed|June 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|235|||Both|30 Years|N/A|No|||March 2015|March 19, 2015|August 2, 2006|Yes|Yes||No|April 14, 2009|https://clinicaltrials.gov/show/NCT00360334||179934|
NCT00351130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631B2406E1|Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy|An 8 Week Extension to a Randomized, Double-blind, Parallel Group, Active-controlled, Multi-center, 14 Week Study to Evaluate the Effectiveness of a Valsartan Versus and Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy||Novartis||Completed|June 2006|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|79|||Both|18 Years|75 Years||||November 2011|November 7, 2011|March 16, 2006||||No||https://clinicaltrials.gov/show/NCT00351130||180622|
NCT00350610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0207017894|Computer-Based Training in Cognitive Behavior Therapy|Computer-Based Training in Cognitive Behavior Therapy|CBT4CBT|Yale University|Yes|Completed|November 2007|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 28, 2013|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350610||180661|
NCT00351156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAU-CL-001|Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease|A Multicenter Study to Evaluate and Characterize the Ex Vivo Effect of Pharmacological Chaperone Therapy in Blood Cell Lines Derived From Patients With Gaucher Disease||Amicus Therapeutics||Completed|July 2006|March 2007|Actual|March 2007|Actual|N/A|Observational|N/A||1||50|Samples With DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Patients with Gaucher disease|August 2010|August 17, 2010|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00351156||180620|
NCT00351390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001447/12|Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.|The Use of Pro-Brain Natriuretic Peptide Targeted Therapy to Tailor Medical Management of Patients With Congestive Heart Failure Followed in an Outpatient Setting: the ProBNP Outpatient Tailored CHF Therapy (PROTECT) Study|PROTECT|Massachusetts General Hospital||Active, not recruiting|September 2005|December 2017|Anticipated|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||April 2015|April 26, 2015|July 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00351390||180602|
NCT00351936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-2005|A Placebo-Controlled, Cross-Over Trial of Aripiprazole|A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia||North Suffolk Mental Health Association|No|Completed|December 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|July 12, 2006||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00351936||180560|The small sample size and the short duration of active treatment and washout period may have prevented detection of other metabolic benefits, including possible reductions in fasting insulin and insulin resistance (measured by HOMA-IR).
NCT00351949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P003|IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)|IMP321 Phase 1 Study in Advanced or Metastatic Renal Cell Carcinoma Patients (P003)||Immutep S.A.||Completed|September 2005|October 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351949||180559|
NCT00351650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060195|Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan|Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan||National Institutes of Health Clinical Center (CC)||Completed|July 2006|February 2008||||N/A|Observational|N/A||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|September 26, 2015|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351650||180582|
NCT00351663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|einav-1-ctil|The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients|Prospective Randomised Study of the Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients||Shaare Zedek Medical Center|No|Withdrawn|February 2007|May 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 30, 2015|July 12, 2006||No|Study was not executed|No||https://clinicaltrials.gov/show/NCT00351663||180581|
NCT00351975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00146|Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases|A Phase I Study of PXD101 in Combination With Azacitidine (5-Aza) for Advanced Hematologic Malignancies||National Cancer Institute (NCI)||Completed|June 2006|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||October 2013|December 22, 2014|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00351975||180557|
NCT00352222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2015|Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries|A Prospective, Multicenter, Single Arm Study to Obtain Additional Data on the Safety and Efficacy of the Express Vascular LD Implantation in the Treatment of Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries|MELODIE|Boston Scientific Corporation||Completed|January 2004|February 2007|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00352222||180539|
NCT00352781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064/2006|Stop Smoking Therapy for Ontario Patients|The STOP (Stop Smoking Therapy for Ontario Patients) Study: The Effectiveness of Nicotine Replacement Therapy in Ontario Smokers PHASE II|STOP|Centre for Addiction and Mental Health|No|Completed|July 2006|August 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1767|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|July 13, 2006||No||No|February 15, 2012|https://clinicaltrials.gov/show/NCT00352781||180497|Many participants could not be reached 6 and 12 months after treatment to complete the follow-up questionnaires. Data pertaining to smoker and provider satisfaction and healthcare utilization were not collected.
NCT00353080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6064|Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women|A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)||Sanofi||Completed|December 2002|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|171|||Female|45 Years|N/A|No|||December 2009|December 11, 2009|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00353080||180474|
NCT00353093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/01|The ERASMUS Study: Limited vs Extended US for DVT Diagnosis|Limited Versus Extended Ultrasonography for the Diagnosis of Clinically Symptomatic Deep Vein Thrombosis of the Lower Extremities. A Randomized Study||University of Padova||Completed|January 2003|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||2000|||Both|18 Years|N/A||||July 2005|October 19, 2006|July 14, 2006||||No||https://clinicaltrials.gov/show/NCT00353093||180473|
NCT00353106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0727|Experience of Having Chronic Graft-Versus-Host Disease|The Experience of Having Chronic Graft-Versus-Host Disease||M.D. Anderson Cancer Center|No|Completed|February 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|187|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study participants with chronic graft-versus-host disease (cGVHD) following allogeneic        blood or marrow transplantation, the patient's primary family caregiver, and content        expert panel.|July 2012|July 27, 2012|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00353106||180472|
NCT00353405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH066809|HIV and STD Prevention for High-Risk, Inner-City, African American Youth|A Multilevel HIV Prevention Strategy for High-Risk Youth||University of Pennsylvania|Yes|Completed|October 2006|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1650|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00353405||180451|
NCT00353418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV18209|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection|A Randomized, Multicenter, Double Blinded Study Comparing the Safety and Efficacy of Pegasys® 180 ug Plus Copegus® 1000 or 1200 mg to the Currently Approved Combination of Pegasys® 180 ug Plus Copegus® 800 mg in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection and HIV-1||Hoffmann-La Roche||Completed|June 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|415|||Both|18 Years|N/A|No|||July 2010|July 30, 2010|July 17, 2006|Yes|Yes||No|May 14, 2010|https://clinicaltrials.gov/show/NCT00353418||180450|
NCT00353652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|413|Evaluating the Link Between Thiazide Medications, the Nervous System, and Diabetes in Individuals With High Blood Pressure|Neural Mechanisms of Thiazide-induced Insulin Resistance||University of Texas Southwestern Medical Center|Yes|Completed|January 2005|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|176|||Both|18 Years|65 Years|No|||December 2014|December 16, 2014|July 18, 2006|No|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00353652||180432|
NCT00354744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST0431|High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma|Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma||Children's Oncology Group|Yes|Active, not recruiting|July 2006|||January 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|N/A|49 Years|No|||September 2015|September 10, 2015|July 19, 2006|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT00354744||180351|
NCT00354757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940711|CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing|The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease||National Taiwan University Hospital||Completed|June 2005|December 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Both|20 Years|80 Years|No|||November 2012|November 30, 2012|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00354757||180350|
NCT00359788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.325|A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.|A Randomized, Double-blind, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium 18 mcg Daily to Combivent MDI 2 Actuations Qid in COPD Patients Previously Prescribed Combivent MDI||Boehringer Ingelheim||Completed|July 2006|||April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|349|||Both|40 Years|N/A|No|||September 2013|May 7, 2014|August 1, 2006||||No|April 17, 2009|https://clinicaltrials.gov/show/NCT00359788||179973|
NCT00360035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM007|Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia|A Multi-Center, Open-Label, Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Myelofibrosis With Myeloid Metaplasia (MF)||Teva Pharmaceutical Industries|No|Completed|July 2006|February 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|August 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360035||179955|
NCT00360048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-000246-39|Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers|Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers||Medical University of Vienna||Completed|August 2006|||||N/A|Observational|Time Perspective: Prospective||||10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 10, 2007|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00360048||179954|
NCT00350896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020916|Safety Study of Thumb Orthoses in Osteoarthritis in the Base of the Thumb (BTOA)|Comparative Study of the Efficacy of Thumb Orthoses in the Base of the Thumb (BTOA)||Assistance Publique - Hôpitaux de Paris||Completed|December 2003|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|45 Years|75 Years|No|||January 2006|July 10, 2006|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00350896||180640|
NCT00350922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|452639|A Clinical Trial of a Self-Management Education Program for People With Chronic Stable Angina|A Psychoeducation Trial for People With Chronic Stable Angina||University of Toronto||Active, not recruiting|September 2003|November 2005||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||130|||Both|N/A|N/A|No|||November 2005|July 8, 2006|July 8, 2006||||No||https://clinicaltrials.gov/show/NCT00350922||180638|
NCT00350935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3456|Attention and Visual Perception in Schizophrenia: A Functional Magnetic Resonance Imaging (fMRI) Study|Attention and Grouping of Visual Information: What is Disturbed in Patients With Schizophrenia?||University Hospital, Strasbourg, France||Completed|September 2006|April 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|52|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic, residents of Strasbourg|June 2010|June 25, 2010|July 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00350935||180637|
NCT00351403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDIV-2|Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection|Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA||FGK Clinical Research GmbH|No|Completed|July 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|70 Years|No|||February 2010|February 5, 2010|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351403||180601|
NCT00351689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030740|Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation|Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation||L'Oreal|Yes|Completed|January 2004|July 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351689||180579|
NCT00352001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE17Z05|Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes|A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS)||Case Comprehensive Cancer Center|Yes|Completed|May 2006|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352001||180555|
NCT00351377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ADE08|Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate|Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate (MPA)||Novartis||Completed|June 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|July 10, 2006||No||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00351377||180603|
NCT00351988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0404|Effects of Cancer Symptoms on Caregivers|Effects of Cancer Symptoms on Minority Caregivers||M.D. Anderson Cancer Center|No|Recruiting|January 2006|||January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of caregivers: African American, Latinos, and white non-Latinos.|February 2016|February 19, 2016|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351988||180556|
NCT00352235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN7000 HCV|Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection|Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection||Foundation for Liver Research||Completed|August 2003|May 2005||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|70 Years|No|||July 2006|July 13, 2006|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352235||180538|
NCT00352833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-REM-GC-02|Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma|Multicenter, Open-Label and Randomized Phase II Study to Evaluate Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients After Curative Resection of a Confirmed Gastric Adenocarcinoma Compared With Surgery Alone||Neovii Biotech||Completed|July 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||June 2007|October 25, 2007|July 14, 2006||||No||https://clinicaltrials.gov/show/NCT00352833||180493|
NCT00352846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0698|Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss|Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy||M.D. Anderson Cancer Center|Yes|Completed|January 2006|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|July 13, 2006||No||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00352846||180492|
NCT00352508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diet2006|The Dietary Intervention in e-Shopping Trial|The Dietary Intervention in e-Shopping Trial||The George Institute||Completed|September 2004|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|July 13, 2006|March 19, 2006||||No||https://clinicaltrials.gov/show/NCT00352508||180518|
NCT00352794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0206|Lenalidomide for Patients With Myelofibrosis (MF)|Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)||M.D. Anderson Cancer Center|No|Recruiting|July 2006|||September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352794||180496|
NCT00352807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-45|Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients|Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients.||Indiana University||Completed|February 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||22|||Both|18 Years|N/A|No|||October 2007|October 16, 2007|July 14, 2006||||||https://clinicaltrials.gov/show/NCT00352807||180495|
NCT00352820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0019|Experience of Brain Tumor Caregivers|The Experience of Informal Caregivers of Patients With Brain Tumors||M.D. Anderson Cancer Center|No|Completed|April 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary informal caregiver of individual with a primary brain glioma.|July 2012|July 31, 2012|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352820||180494|
NCT00353665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-04|Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)|Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis||University of Lisbon|Yes|Completed|July 2005|January 2009|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|20 Years|75 Years|No|||March 2009|March 30, 2009|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353665||180431|
NCT00349427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD102209|A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients|A Randomized, Double-Blind, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin||GlaxoSmithKline||Completed|October 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|70 Years|No|||February 2011|May 31, 2012|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349427||180749|
NCT00349440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1121|Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy|Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy||Innovative Medical||Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||September 2008|September 23, 2008|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349440||180748|
NCT00355134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2309|Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|FREEDOMS II|Novartis|Yes|Completed|June 2006|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1083|||Both|18 Years|55 Years|No|||August 2012|August 2, 2012|July 19, 2006|Yes|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00355134||180322|
NCT00353925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000003|Genetic Analysis of African-Americans With High Blood Pressure|Genetic Analysis of African-American Hypertensives||National Institutes of Health Clinical Center (CC)||Completed|October 1999|December 2007||||N/A|Observational|N/A||||1000|||Both|21 Years|N/A|No|||December 2007|September 26, 2015|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00353925||180411|
NCT00353938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-P2|Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder|Phase II Pilot Randomized Double-Blind Placebo-Controlled Study of 3,4-methylenedioxymethamphetamine (MDMA)Assisted Psychotherapy in Posttraumatic Stress Disorder (PTSD)- Switzerland||Multidisciplinary Association for Psychedelic Studies|No|Completed|October 2006|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|July 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00353938||180410|
NCT00359554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 05050|Influenza Vaccination of Nursing Home Workers.|VAXICOL: Effectiveness of Influenza Vaccination of Nursing Home Workers on Mortality of Nursing Home Residents. A Cluster Randomized Trial.||Assistance Publique - Hôpitaux de Paris||Terminated|September 2006|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||4000|||Both|60 Years|N/A|No|||February 2007|February 6, 2007|July 31, 2006||||No||https://clinicaltrials.gov/show/NCT00359554||179990|
NCT00359801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171069|Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety|An International, Multicenter, Large Simple Trial To Evaluate The Long-Term Pulmonary And Cardiovascular Safety Of Exubera In Patients With Diabetes Mellitus|VOLUME|Pfizer|Yes|Completed|July 2006|April 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1976|||Both|18 Years|N/A|No|||September 2009|January 29, 2010|July 31, 2006|Yes|Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00359801||179972|Pursuant to Pfizer’s announcement that it would exit marketing of Exubera®, study enrollment was halted on 26-October-2007.
NCT00350311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95/05|Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study|Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study||The University of New South Wales||Completed|February 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|18 Years|40 Years|No|||September 2008|September 25, 2008|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00350311||180682|
NCT00351169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00004|Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel Group, Placebo- Controlled and Active Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono- Therapy in the Treatment of Adult Patients With Major Depressive Disorder|AMBER|AstraZeneca||Completed|May 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|450|||Both|18 Years|65 Years|No|||December 2007|December 18, 2008|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351169||180619|
NCT00353171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903045|Organochlorine Exposure in Relation to Timing of Natural Menopause|Organochlorine Exposure in Relation to Timing of Natural Menopause||National Institutes of Health Clinical Center (CC)||Completed|November 2002|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|N/A|N/A|No|||June 2015|July 16, 2015|July 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00353171||180468|
NCT00353470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070918|Comparison of Psychotherapy Programs to Treat Panic Disorder|Dynamic Treatment vs. CBT for Panic Disorder||Weill Medical College of Cornell University|Yes|Completed|September 2006|September 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|70 Years|No|||December 2015|December 3, 2015|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00353470||180446|
NCT00351676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICORE-2006-001|Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment|Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)||University of Alberta|No|Completed|February 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|452|||Both|18 Years|N/A|No|||February 2006|December 7, 2007|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351676||180580|
NCT00349466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-201KCS|Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca|A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Keratoconjunctivitis Sicca||Can-Fite BioPharma|No|Completed|January 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||August 2011|February 12, 2015|July 6, 2006|Yes|Yes||No|June 20, 2011|https://clinicaltrials.gov/show/NCT00349466||180746|
NCT00349479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS050372-02|Increasing Stroke Treatment Through Interventional Change Tactics Study|Clinical Trial to Increase t-PA Use in Stroke Treatment|INSTINCT|University of Michigan|Yes|Completed|May 2005|March 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|24|||Both|N/A|N/A|No|||February 2013|February 22, 2013|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349479||180745|
NCT00353145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0946|Gemox as First and Second Line Therapy in Unknown Primary Cancer|A Phase II Study to Evaluate the Efficacy and Toxicity of Oxaliplatin in Combination With Gemcitabine as First and Second Line Therapy in Unknown Primary Cancer||M.D. Anderson Cancer Center|No|Completed|February 2004|January 2010|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00353145||180470|
NCT00353158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060198|A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity|A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity||National Institutes of Health Clinical Center (CC)||Completed|July 2006|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|62|||Both|8 Years|N/A|No|||August 2015|September 18, 2015|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00353158||180469|
NCT00353457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803437|Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma|Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma||University of Pennsylvania|Yes|Terminated|February 2006|||February 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|July 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00353457||180447|
NCT00353119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.3|A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis|Phase 3 Study With a Placebo-Controlled, Double-blind, on the Safety and Efficacy of Etanercept in Palmo-Plantar Pustulosis||Innovaderm Research Inc.|No|Completed|April 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|July 14, 2006||No||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00353119||180471|
NCT00353431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB13/06|Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia|Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia||University Hospital, Basel, Switzerland|No|Completed|December 2006|October 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|July 17, 2006||No||No|October 31, 2011|https://clinicaltrials.gov/show/NCT00353431||180449|Small sample size
NCT00353444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-07TCDHI|Transcranial Doppler Measurement and Prognosis in Moderate Head Injury|Transcranial Doppler Measurement and Prognosis in Moderate Head Injury||Universidad Autonoma de San Luis Potosí||Suspended|December 2006|March 2007||||Phase 2/Phase 3|Observational|Time Perspective: Prospective||||70|||Both|16 Years|50 Years|No|||November 2008|November 5, 2008|July 17, 2006|||Technical Conflicts|No||https://clinicaltrials.gov/show/NCT00353444||180448|
NCT00349752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87059|Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease|A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.|COSPAR1|UCB Pharma|No|Terminated|November 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|N/A|No|||October 2010|August 26, 2014|June 30, 2006|Yes|Yes|Recruitment was stopped early due to slow enrolment of this population. With no safety    concerns, the study continued normally for subjects already recruited|No|July 1, 2010|https://clinicaltrials.gov/show/NCT00349752||180725|Recruitment was stopped early due to slow enrolment of this population. With no safety concerns, the study continued normally for the 174 subjects already recruited. Results should be treated with caution due to the early termination of this study.
NCT00350038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8759|Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions|Investigations of the Effects of Aprovel, Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry.||Sanofi||Completed|February 2005|August 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|45 Years|70 Years|No|||January 2008|January 18, 2008|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00350038||180703|
NCT00354770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604M85110|N-Acetyl Cysteine in Trichotillomania|A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania||University of Chicago|Yes|Completed|July 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|July 18, 2006|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00354770||180349|
NCT00354783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701209|Continuity of Leg Movements in VLBW Premature Infants: From Spontaneous Kicking and Supported Stepping to Independent Walking|||National Taiwan University Hospital||Not yet recruiting|January 2007|December 2007||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||15|||Both|N/A|2 Months|No|||July 2006|July 18, 2006|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00354783||180348|
NCT00360100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661170|Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media|A Randomized, Multicenter, Comparative Study To Assess Tolerability Of A Single Oral 60 Mg/Kg Dose Of Zmax (Pediatric Concentration) Vs. Zmax (Adult Concentration) In Pediatric Patients With Acute Otitis Media||Pfizer||Completed|August 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|120|||Both|3 Months|48 Months|No|||May 2011|May 16, 2011|August 2, 2006||||||https://clinicaltrials.gov/show/NCT00360100||179950|
NCT00360126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA104753|An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder|An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode.||GlaxoSmithKline|No|Completed|October 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||February 2011|May 31, 2012|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00360126||179949|
NCT00349713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-031|FMP2.1 Trial in Bandiagara, Mali|Double Blind Randomized, Controlled Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the WRAIR AMA1 Malaria Antigen (FMP2.1) Adjuvanted in GSK's AS02A Versus Rabies Vaccine in Malaria-experienced Adults in Bandiagara, Mali||U.S. Army Medical Research and Materiel Command|No|Completed|November 2004|December 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|July 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00349713||180728|
NCT00349700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Stucker|Wound Dressings Adapted to Wound Exudate and Bacterial Load in Therapy Resistant Large Sized Leg Ulcers|An Open Prospective Controlled Trial: Efficiency of Wound Dressings Adapted to Wound Exudate and Bacterial Load in Therapy Resistant Large Sized Leg Ulcers||Ruhr University of Bochum||Completed|January 2003|May 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||139|||Both|18 Years|N/A|No|||July 2006|July 7, 2006|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00349700||180729|
NCT00349999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0103|Protective Immunity to Human Cholera in Bangladesh|Protective Immunity to Human Cholera in Bangladesh-EGD Substudy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2008|December 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|Samples With DNA|Duodenal biopsy samples and blood.|Both|18 Years|45 Years|No|Non-Probability Sample|18 males and nonpregnant females, without comorbid conditions, ranging from 18 to 45 years        of age, inclusive, who are admitted to the International Centre for Diarrhoeal Research,        Bangladesh (ICDDR,B) with acute cholera.|October 2009|September 5, 2013|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349999||180706|
NCT00350623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V520-027|Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)|A Phase IIa Dose-Refinement Study of the Safety and Immunogenicity of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy Adults||Merck Sharp & Dohme Corp.||Terminated|October 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|210|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|July 7, 2006|Yes|Yes||No|October 20, 2010|https://clinicaltrials.gov/show/NCT00350623||180660|An interim analysis of a related study, V520-023 (NCT00095576), showed that the vaccine used in V520-027 (NCT00350623) was not efficacious; therefore, vaccinations in V520-027 were stopped and only a high level summary of safety data was performed.
NCT00350636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG05009|A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo|Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension||Watson Pharmaceuticals|No|Completed|June 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|789|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|July 10, 2006|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT00350636||180659|
NCT00352872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-37|Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer|A Pilot Study of Cytochrome P450 Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer||Indiana University||Active, not recruiting|February 2005|February 2010|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Whole blood Plasma|Female|18 Years|45 Years|No|Non-Probability Sample|Oncology clinics.|May 2010|May 25, 2010|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352872||180490|
NCT00352885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024759|Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment|IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention||Emory University|Yes|Completed|January 2006|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|75 Years|No|||October 2014|October 2, 2014|July 13, 2006|Yes|Yes||No|March 8, 2014|https://clinicaltrials.gov/show/NCT00352885||180489|
NCT00352248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9608944339555027|Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder|Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder||The University of Hong Kong||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|3 Years|11 Years|No|||July 1999|July 13, 2006|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352248||180537|
NCT00352261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00082|An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients|An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients||AstraZeneca||Completed|January 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|70 Years|No|||March 2009|March 25, 2009|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00352261||180536|
NCT00353483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0648 / 201101961|Effect of Chemotherapy Administered Before Surgery on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells|Effect of Neoadjuvant Chemotherapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells||Washington University School of Medicine|No|Recruiting|September 2005|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00353483||180445|
NCT00352521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012387|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma|Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas||Duke University|Yes|Completed|April 2006|July 2009|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2013|July 18, 2014|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352521||180517|
NCT00352534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN0532|Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor|Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor||Children's Oncology Group|Yes|Active, not recruiting|October 2006|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|808|||Both|N/A|29 Years|No|||April 2015|April 23, 2015|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352534||180516|
NCT00352859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12178|Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib|A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma||Bayer||Terminated|August 2006|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||December 2014|December 26, 2014|July 14, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00352859||180491|
NCT00350064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVAHIC11145|Impact of Exercise Training Intensity on Abdominal Visceral Fat and Risk Factors Associated With the Metabolic Syndrome|Impact of Exercise Training Intensity on Abdominal Visceral Fat and Risk Factors Associated With the Metabolic Syndrome||University of Virginia|No|Active, not recruiting|April 2004|December 2008|Anticipated|June 2006|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2008|August 7, 2008|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00350064||180701|
NCT00353678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-008|Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)|Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin||Astellas Pharma Inc||Completed|June 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|1141|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|July 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00353678||180430|
NCT00353691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE490_4038|Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus|Glimepiride Versus Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus: A Single Blind Comparison Study||Sanofi||Completed|October 2002|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|8 Years|17 Years|No|||January 2011|January 10, 2011|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353691||180429|
NCT00349453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-2/CH|Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients|Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients||Lipomed|No|Completed|March 2005|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|4 Years|N/A|No|||December 2011|December 9, 2011|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349453||180747|
NCT00359047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUL 61.05.05|Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme|Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|June 2003|March 2013|Anticipated|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|2830|||Female|50 Years|N/A|No|||October 2011|October 20, 2011|July 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00359047||180027|
NCT00360139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCLA-SCULP-0305|Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy|A Phase IV, Prospective, Non-Blinded, Non-Randomized, Single-Center Clinical Trial to Determine the Longevity, Duration, and Volume-Correcting Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy||Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.||Withdrawn||December 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||August 2007|August 20, 2007|August 2, 2006||||||https://clinicaltrials.gov/show/NCT00360139||179948|
NCT00350025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-GU-004|Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer|Randomized Phase II Trial of Cetuximab With and Without Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer||Fox Chase Cancer Center|Yes|Completed|August 2006|September 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350025||180704|
NCT00350012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K02NS047009|Spatial Neglect and Bias in Near and Far Space|Spatial Neglect and Bias in Near and Far Space||Kessler Foundation|Yes|Recruiting|May 2004|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|950|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Persons who have had a stroke. Also, healthy volunteers.|February 2016|February 22, 2016|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00350012||180705|
NCT00350337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1151|A Phase II Trial of a WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults|Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule, to Healthy Adults||Walter Reed Army Institute of Research (WRAIR)||Completed|January 2006|||July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||88|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2008|July 16, 2008|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00350337||180681|
NCT00350350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARILENE LABORATORY|OGT Spray in the Management of Xerostomia in the Elderly|Multicenter, Controlled Parallel Groups Trial to Evaluate the Efficacy, Safety and Acceptability of OGT Oromucosal Spray Versus a Saliva Substitute in the Treatment of Xerostomia in Geriatrics||Laboratoires CARILENE|Yes|Completed|October 2003|December 2004|Actual|November 2004|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|74|||Both|70 Years|N/A|No|Probability Sample|elderly population at least 70 years old residents of old's people homes|July 2006|April 20, 2012|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00350350||180680|
NCT00350948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.3025|Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer|Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)|ASSIST-5|Telik|Yes|Terminated|May 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Female|18 Years|N/A|No|||November 2013|November 26, 2013|July 6, 2006|Yes|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT00350948||180636|
NCT00352547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040184|Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation|Influence of MDR-1 CYP3A4 and CYP3A5 Genotypes/Haplotypes on Sirolimus Pharmacokinetics and Pharmacodynamics in Patients With Renal Transplantation||National Institutes of Health Clinical Center (CC)||Completed|May 2004|December 2013||||N/A|Observational|N/A|||Actual|93|||Both|N/A|N/A|No|||December 2013|December 3, 2013|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352547||180515|
NCT00352560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV131-235|Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)|Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)||Bristol-Myers Squibb||Completed|July 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||June 2008|February 15, 2010|July 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352560||180514|
NCT00352573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020247|Ethical Dilemmas in Clinical Practice: A Survey of European Physicians|Values at the Bedside: A Survey of European Physicians Regarding Ethical Dilemmas in Clinical Practice||National Institutes of Health Clinical Center (CC)||Completed|August 2002|||||N/A|Observational|N/A|||Anticipated|3850|||Both|22 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 9, 2015|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352573||180513|
NCT00352586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020157|Effect of D-Cycloserine on Extinction of Fear Conditioning|Psychopharmacology Investigations of Fear Conditioning in Humans||National Institutes of Health Clinical Center (CC)||Completed|April 2002|February 2008||||N/A|Observational|N/A||||160|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2008|March 7, 2008|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352586||180512|
NCT00352898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105909|Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™|Comparative Study Evaluating the Immunogenicity & Safety of MeMuRu-OKA Vaccine & Measles-mumps-rubella Vaccine (Priorix™) Co-adm. With Varicella Vaccine (Varilrix™) in Children Primed With Both Measles-mumps-rubella & Varicella Vaccines||GlaxoSmithKline||Completed|April 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|15 Months|6 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|July 14, 2006||||No||https://clinicaltrials.gov/show/NCT00352898||180488|
NCT00353704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-003229-20|Analgetic and Anxiolytic Effect of Preoperative Pregabalin|Analgetic and Anxiolytic Effect of Preoperative Pregabalin in Patients Undergoing Surgery of the Vertebral Columna||Asker & Baerum Hospital||Completed|November 2005|June 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|July 17, 2006||No||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00353704||180428|
NCT00353496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-55-52030-726|Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours|Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour|CLARINET|Ipsen||Completed|June 2006|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|July 17, 2006|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT00353496||180444|
NCT00353509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.1621|Safety and Effectiveness Study of the Solysafe Septal Occluder|Prospective Mono-center Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device in Patients With Atrial Septum Defect (ASD)||Carag AG||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Years|N/A|No|||October 2013|October 8, 2013|July 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00353509||180443|
NCT00349765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X041217008|Effects of Various Higher Fat and Lower Fat Snacks on Cardiovascular Risk Factors in Men and Women.|Cardiovascular Health Effects of Isocaloric Substitution of Polyunsaturated Fat Rich Snacks for Saturated and Trans Fat or Refined Carbohydrate Snacks in Moderately Hypercholesterolemic Individuals.||University of Alabama at Birmingham||Completed|March 2005|February 2006||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||42|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||September 2007|September 12, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00349765||180724|
NCT00349492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCST-L-0001|A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer|Randomized, Phase III Trial Comparing Etoposide/Cisplatin (EP) With Irinotecan/Cisplatin (IP) in Patients With Previously Untreated, Extensive Disease (ED) Small Cell Lung Cancer (SCLC)||Clinical Research Center for Solid Tumor, Korea||Completed|June 2006|October 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|372|||Both|18 Years|N/A|No|||March 2012|December 3, 2013|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349492||180744|
NCT00350688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005407-01H|Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy|Phase II Trial To Evaluate The Potential For Helical Tomotherapy IMRT To Improve Bladder Cancer Chemoradiation||Ottawa Hospital Research Institute|No|Terminated|November 2005|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2007|July 11, 2012|July 7, 2006||No|More advanced treatments superceded study design|No||https://clinicaltrials.gov/show/NCT00350688||180655|
NCT00350077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-05-045|The Effect of High Dose Vitamin C in Burn Patients|The Effect of High Dose Versus Low Dose Intravenous Vitamin C (Ascorbic Acid)on Burn Injury Resuscitation|Vitamin C|United States Army Institute of Surgical Research|No|Withdrawn|July 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|72 Years|No|||December 2011|December 19, 2011|July 6, 2006||No|Inadequate resources to submit for approval|No||https://clinicaltrials.gov/show/NCT00350077||180700|
NCT00350961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMOXEL cholangiocarcinoma|Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma|Phase I-II Study of bi-Weekly Fixed Dose Rate Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma||Rigshospitalet, Denmark||Completed|June 2004|February 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|75 Years|No|||August 2008|August 25, 2008|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00350961||180635|
NCT00350974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 0000 4194|ADMA Levels in End-Stage Renal Disease|Determination of Asymmetrical Dimethylarginine (ADMA) Accumulation in End Stage Renal Disease||University of Michigan||Recruiting|July 2006|June 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2006|December 1, 2006|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00350974||180634|
NCT00359866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0977 / 201104019|Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients|Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients||Washington University School of Medicine|No|Active, not recruiting|February 2006|July 2016|Anticipated|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||August 2015|August 14, 2015|August 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00359866||179968|
NCT00360152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0530 / 201109077|Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes|Minimally Invasive Staging of the Axilla in Breast Cancer: A Pilot Study to Assess the Feasibility of Axillary Ultrasound, Fine Needle Aspiration Biopsy and Molecular Analysis||Washington University School of Medicine|No|Completed|August 2006|April 2013|Actual|January 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Female|18 Years|N/A|No|||July 2013|July 2, 2013|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360152||179947|
NCT00350662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-1|Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients|Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients||Lipomed|No|Completed|January 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|95|||Both|4 Years|N/A|No|||November 2012|November 16, 2012|July 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00350662||180657|
NCT00350675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4194-RG-CTIL|Medical Utilization in Israel During Second Intifada|Medical Utilization, Psychotropic Prescriptions, and Somatic Complaints in Israel During the Second Intifada: An Ecological Study of the Impact of Stress.||Sheba Medical Center||Not yet recruiting|July 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||July 2006|July 9, 2006|July 9, 2006||||No||https://clinicaltrials.gov/show/NCT00350675||180656|
NCT00350363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5004|One Hour Preoperative Gatifloxacin|One Hour Preoperative Gatifloxacin||Stanford University||Completed|January 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|July 5, 2006||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT00350363||180679|
NCT00350376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1467|Impact of Asthma Treatments on Daily Activities|Study on Asthma Treatments on Daily Activities as Reported by Patients (STAR)||Ovation Research Group||Recruiting|June 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||1500|||Both|18 Years|55 Years||||July 2006|July 5, 2006|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00350376||180678|
NCT00350649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0407026913|Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management|Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management||Yale University|Yes|Completed|December 2004|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|205|||Both|18 Years|65 Years|No|||September 2011|September 26, 2011|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350649||180658|
NCT00352287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78235|Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults|Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT||Stanford University||Completed|March 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||July 2006|July 12, 2006|July 12, 2006||||||https://clinicaltrials.gov/show/NCT00352287||180535|
NCT00352300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9919|Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer|A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined With Paclitaxel and Pegfilgrastim (Neulasta): A Feasibility Study in Patients With Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer||Gynecologic Oncology Group||Completed|June 2006|||July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352300||180534|
NCT00352313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060170|ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma|A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent Intracranial Malignant Glioma||National Institutes of Health Clinical Center (CC)||Completed|May 2006|January 2008|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|July 13, 2006||||||https://clinicaltrials.gov/show/NCT00352313||180533|
NCT00352326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FITTS PILOT|Optimizing Assisted Communication Devices for Children With Motor Impairments Using a Model of Information Rate and Channel Capacity|Optimizing Assisted Communication Devices for Children With Motor Impairments Using a Model of Information Rate and Channel Capacity||University of Southern California||Completed|January 2006|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|5 Years|25 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00352326||180532|
NCT00352599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-08-069-01|Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)|Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)|NF1|University of California, Los Angeles|Yes|Completed|September 2009|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|10 Years|50 Years|No|||July 2015|July 14, 2015|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352599||180511|
NCT00352339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aripiprazole study 2006|The New Strategy for Pharmacological Treatment in People With Schizophrenia|Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia||Inje University|Yes|Recruiting|August 2006|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|45 Years|No|||August 2009|August 3, 2009|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352339||180531|
NCT00352612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00003301|Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections|Comparison of Cephalexin Versus Clindamycin in the Empiric, Outpatient Treatment of Suspected Staphylococcal Cutaneous Infections in the Era of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA)||Johns Hopkins University|Yes|Completed|September 2006|August 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|200|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||April 2013|April 1, 2013|July 13, 2006||No||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00352612||180510|
NCT00353184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUSM HSC #01-0464|Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years|Randomized Controlled Trial of Oral Montelukast Added to Standard Therapy for Acute Asthma Exacerbations in Children Age 6 to 14 Years||Washington University School of Medicine||Terminated|September 2001|February 2005|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|27|||Both|6 Years|14 Years|No|||February 2010|February 23, 2010|July 17, 2006|||Results of the interim analysis suggested no significant diff between study groups.|No||https://clinicaltrials.gov/show/NCT00353184||180467|
NCT00353210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-23.04.04-HMO-CTIL|The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos|The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos||Hadassah Medical Organization|No|Recruiting|April 2004|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|N/A||1|Anticipated|30|Samples With DNA|Retain serum samples of embryo donors.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Embryo donors of embryos that have undergone PGD analysis after IVF which the donors have        no intention of using for family-building purposes.|February 2016|February 28, 2016|July 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00353210||180465|
NCT00353223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH073566|Interpersonal Psychotherapy for Depression in People With Heart Failure|Interpersonal Psychotherapy for Depression in Patients With Heart Failure||University of Iowa|No|Completed|July 2006|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|55 Years|N/A|No|||May 2013|May 30, 2013|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00353223||180464|
NCT00353717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cpblb1-HMO-CTIL|Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma|Phase II of Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma||Hadassah Medical Organization|No|Recruiting|November 2006|September 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||February 2009|January 12, 2009|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353717||180427|
NCT00349505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIPOVAC1|Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma|Phase II Study of Intra-Peritoneal Hyper-Thermic Chemotherapy as Consolidation Therapy for Advanced Epithelial Ovarian Carcinoma||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|September 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||67|||Female|18 Years|65 Years|No|||September 2006|October 5, 2006|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349505||180743|
NCT00349518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-083|Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL|A Phase II Study of Dasatinib (BMS-354825) in Subjects With Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib||Bristol-Myers Squibb||Withdrawn|December 2006|||January 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A||||April 2011|February 16, 2016|July 6, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00349518||180742|
NCT00349531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.615|A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS|A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome||Boehringer Ingelheim||Completed|July 2006|||May 2007|Actual|Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|369|||Both|18 Years|80 Years|No|||May 2012|May 18, 2012|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349531||180741|
NCT00349778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT183|High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma|High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma||Stanford University||Completed|August 2006|April 2010|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|75 Years|No|||October 2010|October 7, 2010|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349778||180723|
NCT00350090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005113|A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.|A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin Alfa) at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy||Ortho Biotech Products, L.P.|No|Terminated|September 2002|March 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|98|||Both|18 Years|N/A|No|||March 2010|May 17, 2011|July 7, 2006|||This study was stopped early due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT00350090||180699|
NCT00350428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R221/13/2001|Laser Iridotomy Versus Phacoemulsification in Acute Angle Closure|Angle Closure: Laser Iridotomy Versus Phacoemulsification Study (ACLIPS)- A Study of Acute Primary Angle Closure Glaucoma Comparing Two Treatment Modalities: Laser Peripheral vs Phacoemulsification With Posterior Intraocular Lens Implant||Singapore National Eye Centre||Completed|October 2001|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||October 2004|October 23, 2006|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00350428||180674|
NCT00359879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-CR-GWBH|Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes|Safety and Efficacy of Exenatide Taken Before Lunch and Before Dinner Compared With Before Breakfast and Before Dinner in Patients With Type 2 Diabetes Using Oral Antidiabetic Therapy||AstraZeneca|No|Completed|September 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|377|||Both|18 Years|75 Years|No|||January 2015|February 20, 2015|August 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00359879||179967|
NCT00360763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH-01|Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody|||Huazhong University of Science and Technology||Recruiting||December 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|80 Years|No|||August 2006|August 4, 2006|August 4, 2006||||No||https://clinicaltrials.gov/show/NCT00360763||179903|
NCT00360776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00086|Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia|A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia||National Cancer Institute (NCI)||Terminated|June 2006|||April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2013|June 11, 2013|August 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360776||179902|
NCT00351182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telit_L_00276|Controlled Trial: 5-Day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus|Phase 3 Study of Controlled Trial: 5-Day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus||Chosun University Hospital||Recruiting|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||June 2006|July 11, 2006|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351182||180618|
NCT00352014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-05.13|Evaluation and Comparison of Several Point-of-Care Platelet Function Tests in Predicting Clinical Outcomes in Clopidogrel Pre-Treated Patients Undergoing Elective PCI.|Do Point-of-Care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-Treated Patients Undergoing Elective PCI. (The POPular Study)||R&D Cardiologie||Recruiting|January 2006|May 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1000|||Both|21 Years|N/A|No|||July 2006|July 13, 2006|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352014||180554|
NCT00352027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOD05|Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma|Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma||St. Jude Children's Research Hospital|Yes|Active, not recruiting|July 2006|November 2022|Anticipated|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|N/A|21 Years|No|||June 2015|June 11, 2015|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352027||180553|
NCT00352079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL11|BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer|A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder||Canadian Cancer Trials Group|Yes|Terminated|April 2006|January 2012|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|July 13, 2006||No|terminated due to poor accrual|No||https://clinicaltrials.gov/show/NCT00352079||180550|
NCT00352092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL313|Pilot Study for HLA Identical Living Donor Renal Transplant Recipients|A Pilot Study of Corticosteroid-Free, Calcineurin-Sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipient||University of Cincinnati|No|Completed|June 2002|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||November 2014|November 12, 2014|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352092||180549|
NCT00352352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3469296479554546|Use of Acupuncture In Children With Autistic Spectrum Disorder|Randomized Control Trial of Using Acupuncture In Children With Autistic Spectrum Disorder||The University of Hong Kong||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|3 Years|15 Years|No|||July 1999|July 13, 2006|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352352||180530|
NCT00352937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1124528|Comparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear Stress Test|Comparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear Stress Test||Providence VA Medical Center|Yes|Completed|March 2006|December 2009|Actual|December 2009|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|All patients without prior CAD referred for nuclear stress testing|May 2014|May 14, 2014|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00352937||180485|
NCT00353236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4170-JK-CTIL|The Contribution of Internal Maternal Resources to Creation of Motherhood. Comparison Among Mothers to Twins and Singleton|||Sheba Medical Center||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||July 2006|July 17, 2006|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353236||180463|
NCT00353197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33-26.07.02-HMO-CTIL|Derivation of New Human Embryonic Stem Cell Lines Lines for Clinical Use|The Derivation of New Human Embryonic Stem Cell Lines for Clinical Use||Hadassah Medical Organization|Yes|Recruiting|July 2002|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|N/A||1|Anticipated|40|Samples With DNA|Blood serum samples of donor couple.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Embryo donors who have derived embryos via IVF and have surplus embryos that they will not        use for family-building.|February 2016|February 28, 2016|July 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00353197||180466|
NCT00353548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5046/#6158R|Determining the Response to Sipping Beverages Without Swallowing in People With Eating Disorders|Study of Response to the Taste of Beverages That Are Not Swallowed (Sipping and Spitting in Eating Disorders)||New York State Psychiatric Institute|No|Completed|April 2005|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|80|||Female|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with anorexia nervosa, bulimia nervosa, and binge eating disorder as well as gender,        age, and weight-matched control participants.|July 2012|July 20, 2012|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00353548||180440|
NCT00353730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020265|Identification of Genes Expressed in Atherosclerotic Plaque|Identification of Genes Expressed in Atherosclerotic Plaques||National Institutes of Health Clinical Center (CC)||Completed|August 2002|||||N/A|Observational|N/A|||Actual|69|||Both|21 Years|N/A|No|||October 2015|November 3, 2015|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353730||180426|
NCT00353743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-452|The Use of Antibiotics After Hospital Discharge in Septic Abortion|A Randomized Clinical Trial on the Use or Not of Antibiotics After Hospital Discharge in Septic Abortion.|APA|Hospital de Clinicas de Porto Alegre|Yes|Terminated|May 2006|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|50 Years|No|||March 2007|December 18, 2008|July 13, 2006||No|Rate of cure was higher than expected, IRB suspended for no additional benefit|No||https://clinicaltrials.gov/show/NCT00353743||180425|
NCT00353756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV14-C001|Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease|A Placebo-Controlled, Phase 1, Single and Multiple IV Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of C326 in Adults With Crohn’s Disease||Avidia||Recruiting|September 2006|September 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||52|||Both|18 Years|65 Years|No|||September 2006|October 10, 2006|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353756||180424|
NCT00349791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002006|Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido|A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 24 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.||Warner Chilcott|No|Completed|June 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|549|||Female|40 Years|70 Years|No|||April 2013|April 15, 2013|July 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00349791||180722|
NCT00349804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111-2006|Intermittent Cold and Dry Air Underneath Football Shoulder Pads|Intermittent Cold and Dry Air Underneath Football Shoulder Pads as a Method to Assist in Temperature Homeostasis: Evaluation of Efficacy||University of Florida||Completed|June 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349804||180721|
NCT00349544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-10|Validation of the Spanish Version of the Neck Disability Index|Validation of the Transcultural Adaptation of the Neck Disability Index in the Spanish Population||Kovacs Foundation|Yes|Completed|October 2005|November 2007|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|221|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who visit their physician for cervicalgia, with or without referred pain|May 2008|May 7, 2008|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349544||180740|
NCT00350103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0874|A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy|A Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy Using Two Different Titration Schemes||UCB Pharma||Completed|June 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|537|||Both|18 Years|N/A|No|||September 2009|September 19, 2014|July 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00350103||180698|
NCT00350116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Stucker|Topical Vitamin B12 in Chronic Plaque Psoriasis|Topical Vitamin B12 in Chronic Plaque Psoriasis||Ruhr University of Bochum||Completed|January 2001|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||July 2006|July 6, 2006|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00350116||180697|
NCT00350441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/CA/01|Does Sildenafil Protect Against Pulmonary Related Complications Following Cardiopulmonary Bypass?|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study of the Pre-Operative Effect of Sildenafil Citrate on Pulmonary Related Complications Following Cardiopulmonary Bypass in Children Undergoing Cardiac Surgical Repair.||NHS Greater Glasgow Yorkhill Division||Recruiting|June 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|3 Months|5 Years|No|||July 2006|October 10, 2006|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00350441||180673|
NCT00359892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM011|Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma|A Multi-Center, Open-Label Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Relapsed or Refractory Hodgkin's Lymphoma||Teva Pharmaceutical Industries|No|Completed|July 2006|November 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|August 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00359892||179966|
NCT00361322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLSA-HMO-CTIL|Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris|Topical Clindamycin Salicylic Acid Preparation for the Treatment of Acne Vulgaris||Hadassah Medical Organization||Completed|April 2005|January 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|45 Years||||August 2006|August 6, 2006|August 6, 2006||||No||https://clinicaltrials.gov/show/NCT00361322||179861|
NCT00351416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001895|Letrozole Treatment in Normal and GnRH Deficient Women|Letrozole Treatment in Normal and GnRH Deficient Women||Massachusetts General Hospital|Yes|Active, not recruiting|July 2004|December 2018|Anticipated|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|70|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|July 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351416||180600|
NCT00351429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PN1010510|Study of PGA Suture in Ophthalmology|Evaluating the Safety and Efficacy of Polyglycolic Acid Suture in Ophthalmic Surgical Procedures||Aurolab|No|Completed|October 2005|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||February 2009|February 10, 2009|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351429||180599|
NCT00351715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20144|Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients|Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients: a Phase II Multicenter, Open Label, Feasibility Study||AHS Cancer Control Alberta||Terminated|July 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||October 2008|January 24, 2013|July 11, 2006||No|Study stopped due to low accrual|No||https://clinicaltrials.gov/show/NCT00351715||180577|
NCT00351728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB #05-04-016|Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone|||University of California, Los Angeles||Recruiting|June 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|choroidal melanoma patients|February 2009|June 17, 2010|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351728||180576|
NCT00351741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-06-005|BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-|BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study: A Prospective Randomized Controlled Trial||United States Army Institute of Surgical Research|No|Terminated|July 2006|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|July 11, 2006||No||No|July 16, 2010|https://clinicaltrials.gov/show/NCT00351741||180575|After 3 yrs of enrollment, interim analysis revealed a significant number of subjects in the Conventional arm required rescue, which served as the trigger to close the study to further enrollment.
NCT00352365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00785|Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy||National Cancer Institute (NCI)||Completed|June 2006|July 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|60 Years|N/A|No|||January 2014|July 25, 2014|July 13, 2006|Yes|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00352365||180529|
NCT00352625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3269-302|Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee||Endo Pharmaceuticals||Completed|June 2006|March 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||330|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00352625||180509|
NCT00353275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-209|Hyperglycemia in Surgical Infections|Studies on Hyperglycemia in Surgical Infections||The University of Texas Health Science Center, Houston|Yes|Terminated|August 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|July 17, 2006||No|Difficulty in enrolling eligible patients|No|February 19, 2014|https://clinicaltrials.gov/show/NCT00353275||180460|
NCT00352911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT004|Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects|A Randomized, Placebo-controlled, Dose Escalating, Phase II Trial of the Anti -HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects||VGX Pharmaceuticals, LLC||Completed|July 2006|November 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|No|||March 2010|March 4, 2010|July 13, 2006||Yes|||April 15, 2009|https://clinicaltrials.gov/show/NCT00352911||180487|
NCT00352924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999993013|Agriculture Health Study|The Main Agricultural Health Study - A Prospective Study of Cancer and Other Diseases Among Men and Women in Agriculture||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 1993|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|90500|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||January 2016|February 2, 2016|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00352924||180486|
NCT00353249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH076099|Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Homeless Women|Cognitive Behavioral Therapy for Homeless Women With Post-Traumatic Stress Disorder (PTSD)||RAND||Completed|June 2008|November 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|N/A|No|||May 2014|May 6, 2014|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00353249||180462|
NCT00353795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-05-23-01|Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)|Coronary Atherosclerosis Evaluation by Arterial Wall MRI||Johns Hopkins University||Completed|July 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|179|||Both|45 Years|N/A|No|||September 2009|May 25, 2010|July 18, 2006||||No|August 4, 2009|https://clinicaltrials.gov/show/NCT00353795||180421|Cross sectional study
NCT00353808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061029|A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.|An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN).||Pfizer||Terminated|July 2006|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||April 2011|April 6, 2011|July 17, 2006||Yes|This study has been terminated early as the esreboxetine development program is being    discontinued. There are no safety or efficacy concerns.|No||https://clinicaltrials.gov/show/NCT00353808||180420|
NCT00353522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC19453|A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.|A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent||Hoffmann-La Roche||Completed|July 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00353522||180442|
NCT00353535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLIFSGSusp|Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal Graft|Phase 1 Study of TLI Pretransplant to Prevent Recurrence of FSGS in the Graft||University of Sao Paulo||Completed|January 2000|December 2002||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||September 2005|July 17, 2006|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353535||180441|
NCT00349557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI 3031500|Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer|Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer||Benaroya Research Institute||Completed|April 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Male|18 Years|N/A|No|||July 2014|July 15, 2014|July 5, 2006||||||https://clinicaltrials.gov/show/NCT00349557||180739|
NCT00349817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Toronto|Genetics Education: Preparing Physicians for the Future|||University of Toronto||Recruiting|October 2005|January 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||64|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2006|July 6, 2006|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349817||180720|
NCT00350129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-ZAC-2004-002|Effect of Glucose on Ocular Blood Flow|Influence of Plasma Glucose Levels on Retinal Vascular Diameter and Choroidal Blood Flow in Vasospastic Subjects||University Hospital, Basel, Switzerland|No|Completed|December 2002|February 2003|Actual|February 2003|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|healthy vasospastic subjects, healthy non-vasospastic subjects|September 2008|September 25, 2008|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350129||180696|
NCT00350454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02306|Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3)|Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)||Deutsches Herzzentrum Muenchen|Yes|Completed|June 2006|October 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|605|||Both|18 Years|N/A|No|||January 2008|January 10, 2008|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350454||180672|
NCT00360438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0298|Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS|Pharmacokinetic Evaluation of Rasburicase Dosed for 5 Consecutive Days as Uricolytic Therapy in Adult Patients With Leukemia and/or Lymphoma at High or Potential Risk of Tumor Lysis Syndrome (TLS)||M.D. Anderson Cancer Center|No|Completed|July 2006|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 31, 2012|August 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00360438||179926|
NCT00360451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH0522070|Effectiveness of School-Based Cognitive Behavioral Therapy in Preventing Depression in Young Adolescents|Preventing Depression in School Children||University of Pennsylvania||Completed|September 2002|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2008|September 9, 2015|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360451||179925|
NCT00360464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661175|A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases|A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases In Japan Adults||Pfizer||Completed|October 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|64|||Both|16 Years|80 Years|No|||April 2011|April 20, 2011|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360464||179924|
NCT00360815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-DK-6-2204-A (completed)|Diabetes Control and Complications Trial (DCCT)|Diabetes Control and Complications Trial (DCCT)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 1983|April 1993||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1441|||Both|13 Years|39 Years||||March 2010|March 1, 2010|August 2, 2006||||No||https://clinicaltrials.gov/show/NCT00360815||179899|
NCT00360828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14633|Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas|A Phase II Study of Irinotecan HCI in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|February 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|August 3, 2006|No|Yes|Principal Investigator left Moffitt and study had low accrual.|No|October 3, 2011|https://clinicaltrials.gov/show/NCT00360828||179898|Low accrual prevented us from completing the planned analysis. The initial Principal Investigator (PI) left Moffitt and there were only 10 participants.
NCT00351442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAVI 002|Examining Factors That May Influence Resistance to HIV-1 Infection|Prospective Study of the Determinants of Host Resistance to HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2007|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|522|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample, including HIV infected individuals and their uninfected partners.|April 2014|April 8, 2014|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351442||180598|
NCT00351455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18609|Watchful Waiting of Incisional Hernias|Watchful Waiting of Incisional Hernias: A Prospective Trial||Baylor College of Medicine|No|Completed|May 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||December 2010|December 2, 2010|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00351455||180597|
NCT00351702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|trc20B|Preventive Therapy for Tuberculosis in HIV Infected Persons|Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons||Tuberculosis Research Centre, India|No|Active, not recruiting|February 2001|June 2011|Anticipated|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|650|||Both|15 Years|60 Years|No|||June 2011|June 19, 2011|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351702||180578|
NCT00352053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-104-0321|Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents||Gilead Sciences|Yes|Completed|June 2006|December 2013|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|12 Years|17 Years|No|||June 2015|June 15, 2015|July 13, 2006|Yes|Yes||No|March 5, 2010|https://clinicaltrials.gov/show/NCT00352053||180552|Participants left the study for a number of reasons (eg, turned 18 years old, switched to a different HIV treatment regimen), which led to small numbers of participants analyzed at later time points, and the study was concluded earlier than planned.
NCT00352105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF5842|Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer|A Phase I/II Trial of Concurrent Chemotherapy and ZD1839 (IRESSA) With Hyperfractionated Radiation Therapy, Followed by Maintenance ZD1839 (IRESSA) for Patients With Locally Advanced Squamous Cell Head and Neck Cancer||Case Comprehensive Cancer Center|Yes|Completed|April 2006|May 2010|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|July 13, 2006|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT00352105||180548|
NCT00352638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-FCRB-04-004-P|Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer|Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients||Fox Chase Cancer Center|No|Completed|August 2005|November 2013|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized|||Anticipated|660|||Both|40 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 15, 2014|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352638||180508|
NCT00352391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0424|Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients|Vanguard Study Characterizing Occurrence of Recurrent or Second Primary Tumors in Patients With Prior History of Definitively Treated Stage I/II Head and Neck or Non-Small Cell Lung Cancer Who Are Current or Former Smokers||M.D. Anderson Cancer Center|Yes|Completed|August 2004|January 2016|Actual|January 2016|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|54|Samples With DNA|Samples of lung tissue, saliva, blood, and scrapings from inside of cheek. Fluid and mucous      collected during bronchoscopies.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a prior history of a definitively treated stage I/II head and neck or        non-small cell lung cancer who are current or former smokers.|February 2016|February 2, 2016|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00352391||180527|
NCT00352950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040145|Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer|An Open-Label Clinical Trial Evaluating the Safety and Pharmacodynamics of Sirolimus and Panitumumab in Subjects With Advanced Non-Small Cell Lung Cancer||Amgen||Withdrawn|March 2006|February 2008||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|April 6, 2006||||||https://clinicaltrials.gov/show/NCT00352950||180484|
NCT00352963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/097|Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).|Immunogenicity & Safety Study of GSK Biologicals' Hib-MenC+Infanrix Penta™ Vaccines and NeisVac-C (Meningitis C Vaccine;Baxter)+GSK's Infanrix Hexa™ vs. Meningitec™ (Men. C Vaccine;Wyeth)+Infanrix Hexa™ in Healthy Infants (2,4,6 M).||GlaxoSmithKline||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||480|||Both|N/A|7 Days|Accepts Healthy Volunteers|||July 2009|July 22, 2009|July 14, 2006||||No||https://clinicaltrials.gov/show/NCT00352963||180483|
NCT00353262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP18587|A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.|An Open-label Study to Assess the Pharmacokinetic Interaction Between Xeloda and Oxaliplatin in Patients With Metastatic Colorectal Cancer.||Hoffmann-La Roche||Completed|July 2005|April 2008|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 17, 2006|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT00353262||180461|
NCT00353574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAR-311-E|DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension|DORADO-EX - A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311-E)|Darusentan|Gilead Sciences|Yes|Terminated|September 2006|April 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|282|||Both|35 Years|80 Years|No|||February 2014|February 19, 2014|July 17, 2006|Yes|Yes|Study DAR-312 did not meet primary co-endpoints|No||https://clinicaltrials.gov/show/NCT00353574||180438|
NCT00349635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF23-0121 04 01|A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.|A Double-Blind, 3-Arm Study on Weight Loss With a Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Per Day Compared to Metformin 1,700 mg and to Placebo, at 6 Months, in Obese Patients, Followed by: A Double-Blind, 2-Arm Investigation of Weight-Loss Maintenance With the Same Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Compared to Placebo, at 6 Months, in the Responders.||Solvay Pharmaceuticals||Completed|October 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||148|||Both|30 Years|50 Years|No|||August 2007|August 31, 2007|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349635||180734|
NCT00353769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCR/P15/2003|Comparison Study on Hair Apposition Technique Performed Between Nurses and Doctors in Emergency Department.|A Single-Blinded Comparative Study on Hair Apposition Technique Performed Between Nurses and Doctors in Emergency Department.(HAT2 Study)||Singapore General Hospital||Completed|November 2002|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||360|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2006|November 29, 2006|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353769||180423|
NCT00353782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030280|Causes and Natural History of Dyslipidemias|Disease Pathogenesis and Natural History of Lipid Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|September 2003|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|2 Years|N/A|No|||March 2016|March 15, 2016|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353782||180422|
NCT00349856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/209/04/O|Dispensing Overnight Study in Lenses|Dispensing Overnight Study in Lenses||University of Waterloo|No|Completed|January 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|July 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00349856||180717|
NCT00349830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0006|Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy|Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy||Stanford University||Recruiting|January 2002|||January 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|cancer patients|August 2014|August 28, 2014|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349830||180719|
NCT00349843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/211/04/L|Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort|Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort With Daily Wear FDA Group IV Hydrogel Lenses||University of Waterloo||Completed|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349843||180718|
NCT00350467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010861|A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia|A Randomized, 6-week Double-blind, Parallel Study to Evaluate the Efficacy and the Safety of Flexible Doses of Extended Release OROS Paliperidone Compared With Olanzapine in the Treatment of Patients With Schizophrenia||Xian-Janssen Pharmaceutical Ltd.||Completed|June 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|288|||Both|18 Years|65 Years|No|||May 2010|May 18, 2011|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00350467||180671|
NCT00350792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9941|Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients|A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients||Eli Lilly and Company|No|Completed|August 2006|November 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|70 Years|N/A|No|||October 2010|October 11, 2010|July 10, 2006|Yes|Yes||No|November 5, 2009|https://clinicaltrials.gov/show/NCT00350792||180648|
NCT00351039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14659|Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer|Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in the First-Line Treatment of Elderly Patients With Advanced (Stage IIIB(With Malignant Pleural Effusion) or IV) Non-Squamous Non-Small Cell Lung Cancer (NSCLC)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|July 2006|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|70 Years|N/A|No|||August 2010|August 9, 2010|July 11, 2006|Yes|Yes|slow accrual|No|October 9, 2009|https://clinicaltrials.gov/show/NCT00351039||180629|This study was closed early due to poor accrual. The recommended Phase II dose was determined after the brief Phase I run-in, but the Phase II component of this study was never initiated.
NCT00361062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hae064910706ctil|Aggressive Behavior Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) During the First Month of Treatment|Aggressive Behavior Induced by SSRIs During the First Month of Treatment||HaEmek Medical Center, Israel||Recruiting|September 2006|||July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 3, 2010|August 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00361062||179881|
NCT00351234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000003020|Carnitine Levels and Carnitine Supplementation in Type I Diabetes|Correlation Between Carnitine Deficiency and Hypoglycemic Events in Type I Diabetes; Effects of Carnitine Supplementation on Hypoglycemic Events in Type I Diabetes||Children's Mercy Hospital Kansas City|No|Completed|October 2004|April 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|7 Years|21 Years|No|Probability Sample|1. Children (male or female), between the ages of 7 and 21,          2. who have had a diagnosis of Type 1 diabetes mellitus for at least two years and          3. are currently on insulin replacement therapy.|February 2012|February 24, 2012|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351234||180614|
NCT00351208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-20-|Spinal Cord Stimulation Efficacy Measures|The Efficacy of Spinal Cord Stimulation at Varying Stimulation Frequencies and Pulse-Widths||New York Neurosurgery & Neuroscience Associates, PLLC||Recruiting|May 2006|August 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||June 2006|July 11, 2006|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351208||180616|
NCT00351221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INMS-110-801|Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome|A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome||Insmed Incorporated||Terminated||||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|2 Years|16 Years||||February 2007|March 29, 2007|July 11, 2006|||Terminated due to a patent legal settlement|||https://clinicaltrials.gov/show/NCT00351221||180615|
NCT00352066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-102|Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together|A Phase I, Open Label, Controlled, Intra-subject Comparison Study to Investigate the Effect of Co-administration Upon the Pharmacokinetics of Tipranavir (Ritonavir Boosted) and Apricitabine.||Avexa|No|Completed|July 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|July 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352066||180551|
NCT00351468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA105325|EXTEND (Eltrombopag Extended Dosing Study)|EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.|EXTEND|Novartis|No|Completed|June 2006|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|302|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00351468||180596|
NCT00352378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-02-034|Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer|A Phase III Randomized Study of Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer||National Cancer Center, Korea|No|Completed|June 2002|January 2006|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|209|||Female|18 Years|N/A|No|||September 2007|June 23, 2011|July 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00352378||180528|
NCT00352404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE 000043385|Chromoscopic Guided Endomicroscpy to Diagnose Colitis Associated Dysplasia|Diagnosis of Intraepithelial Neoplasia in Patients With Long Standing Ulcerative Colitis With Chromoscopic Guided Endomicroscopy||Johannes Gutenberg University Mainz||Completed|August 2003|November 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||114|||Both|18 Years|80 Years|No|||August 2003|July 13, 2006|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352404||180526|
NCT00352664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0425|The Effect of Donepezil on Sedation and Other Symptoms|Donepezil for Cancer Patients With Sedation Related to Opioid Treatment: A Double-blind Placebo Controlled Randomized Study||M.D. Anderson Cancer Center|No|Terminated|November 2003|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||December 2009|December 28, 2009|July 12, 2006||No|Low patient accrual|No|May 21, 2009|https://clinicaltrials.gov/show/NCT00352664||180506|Insufficient drug supply and low patient accrual closed study early.
NCT00352651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11609-27650|Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo|Placebo-Controlled Study of Pregabalin for the Pain of Acute Herpes Zoster||University of California, San Francisco||Terminated|June 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|34|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||March 2011|April 12, 2011|July 12, 2006|No|Yes|This study should be terminated as the study has been closed for years and the investigator    has since retired. No records are available.    Thank you, Marlene|No||https://clinicaltrials.gov/show/NCT00352651||180507|
NCT00353587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M102-20509|Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin|Phase 2/3, Randomized, Double-blind, Placebo- and Active Comparator-controlled, Parallel, Multicenter Study to Determine Safety and Efficacy of Metaglidasen in Treatment of Type 2 Diabetes Suboptimally Controlled on Insulin||CymaBay Therapeutics, Inc.|No|Completed|May 2006|November 2007|Actual|November 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|396|||Both|18 Years|75 Years|No|||April 2015|April 29, 2015|July 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00353587||180437|
NCT00353834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS #05-45|The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes|The Effect of Exenatide Compared to Lantus Insulin on Vascular Function Before and After a Meal Tolerance Test in Patients With Type 2 Diabetes||Joslin Diabetes Center|No|Completed|August 2006|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||March 2014|March 28, 2014|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353834||180418|
NCT00353561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHN/Adhoc/23/2003-2004|Diabetes Mellitus and Vulvovaginal Candidiasis|Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management||Indian Council of Medical Research||Completed|June 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|66 Years|No|||May 2008|May 21, 2008|July 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00353561||180439|
NCT00349895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALING IIb|Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth|Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth. A Clinical, Multi-center, Prospective, Non-Randomized Study||OrbusNeich|Yes|Completed|August 2006|January 2012|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|85 Years|No|||April 2014|April 7, 2014|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349895||180714|
NCT00349570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-1027|Xtract™ Aspiration Catheter Registry Study|Xtract™ Aspiration Catheter Registry Study||Lumen Biomedical|No|Completed|August 2006|March 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2008|October 20, 2008|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349570||180738|
NCT00349583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1683|Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation|Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|50 Years|N/A||||May 2007|May 30, 2007|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349583||180737|
NCT00349596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0895|A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)|Phase I Study of Low Dose 5-Aza-2'-Deoxycytidine Administered Daily for 5 Days Every Other Week for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|July 2006|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||October 2014|October 13, 2014|July 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00349596||180736|
NCT00350142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0005|Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer|Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer||Stanford University|Yes|Completed|April 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|90 Years|No|||August 2014|August 6, 2014|July 5, 2006||No||No|December 6, 2013|https://clinicaltrials.gov/show/NCT00350142||180695|
NCT00350155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2425|Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel|A 16-Day, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Trial Comparing Lumiracoxib 100mg o.d. With Naproxen 500 mg b.i.d. Plus Omeprazole 20mg o.d. and Placebo in Healthy Volunteers to Investigate on the Safety and Tolerability of Lumiracoxib in the Small Bowel.||Novartis||Completed|May 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A||||December 2007|December 12, 2007|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00350155||180694|
NCT00350168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2403|Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension|An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension||Novartis||Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|647|||Both|18 Years|N/A||||November 2011|November 7, 2011|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00350168||180693|
NCT00350181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT184|Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant|Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplantation||Stanford University||Completed|August 2006|April 2010|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|38|||Both|2 Years|60 Years|No|||October 2010|October 7, 2010|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00350181||180692|
NCT00350480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uterine Bleeding|Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial|Treatment of Non-Gestational Acute Uterine BleedingComparing Oral Medroxyprogesterone Acetate and Monophasic Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol||Kaiser Permanente||Completed|April 2003|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Female|18 Years|65 Years|No|||March 2015|March 10, 2015|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00350480||180670|
NCT00350493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3Yr FollowUp|Three Year Follow up of a Randomised Controlled Trial (RCT) of an Intervention for Tobacco Dependence Among Those With a Psychotic Illness|Three Year Follow up of a Randomised Controlled Trial of an Intervention for Tobacco Dependence Among Those With a Psychotic Illness||The University of New South Wales||Completed|January 2005|February 2006|Actual|February 2006|Actual|Phase 4|Observational|N/A||||298|||Both|18 Years|67 Years|No|||September 2008|September 25, 2008|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00350493||180669|
NCT00360503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BURNS04A0|Antimicrobial Resistance in Cystic Fibrosis (CF)|Antimicrobial Resistance in Sputum Obtained From Patients With Cystic Fibrosis (CF)||Seattle Children's Hospital|No|Completed|March 2006|June 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|304|Samples With DNA|Bacterial isolates|Both|6 Years|N/A|No|Non-Probability Sample|Children and young adults with cystic fibrosis|February 2009|February 6, 2009|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360503||179921|
NCT00361335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012781|A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Centocor, Inc.|Yes|Completed|September 2006|September 2009|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|643|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|August 4, 2006|Yes|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00361335||179860|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients.
NCT00361348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050137|Palifermin DDI (Drug Drug Interaction)|An Open-label, Randomized, 2-part, Parallel Design Study to Characterize the Effect of Heparin on Palifermin Pharmacokinetics and the Effect of Palifermin on Heparin Pharmacodynamics in Healthy Subjects||Swedish Orphan Biovitrum|No|Completed|December 2005|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|August 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361348||179859|
NCT00351520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGS05/97|Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica|Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis||Tehran University of Medical Sciences||Completed|May 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Both|12 Years|60 Years|No|||September 2011|September 19, 2011|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351520||180592|
NCT00351494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP06-HM/FIBROME|Myoma Microvascularization Analysis Using Sonovue Before and After Uterine Artery Embolization|Myoma Microvascularization Analysis Using Sonovue Before and After Uterine Artery Embolization||University Hospital, Tours|No|Recruiting|July 2006|June 2009|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|N/A|No|Non-Probability Sample|Women candidate for embolization of myomas|November 2007|November 21, 2007|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351494||180594|
NCT00351507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2343|A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes|A Double-blind, Crossover, Placebo-Controlled, Multiple-dose Study to Evaluate the Effects of Vildagliptin on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes||Novartis||Completed|May 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|10|||Both|35 Years|65 Years|No|||May 2012|May 4, 2012|July 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351507||180593|
NCT00351481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRE-study|Failure of Implantation After Recurrent Embryo Transfers|Recurrent Embryo Implantation Failure in Women Undergoing IVF/ ICSI; an Investigation of the Intra-Uterine Environment During the Window of Implantation||UMC Utrecht||Completed|July 2006|May 2008|Actual|May 2008|Actual|N/A|Observational|N/A|||Anticipated|80|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||April 2007|May 28, 2008|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351481||180595|
NCT00351754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP 106|Detection of Pulmonary Embolism With CECT|Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography||Bracco Diagnostics, Inc|No|Completed|July 2006|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||120|||Both|18 Years|N/A|No|||January 2008|January 3, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00351754||180574|
NCT00351767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGF3554g|A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers||Genentech, Inc.||Completed|January 2006|||January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|170|||Both|18 Years|80 Years|No|||January 2013|January 16, 2013|July 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351767||180573|
NCT00352131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491224|Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors|A Phase I Study to Assess the Safety and Pharmacokinetics of huC242-DM4 Administered as a Single Intravenous Infusion Once Every Three Weeks to Subjects With Solid Tumors||ImmunoGen, Inc.||Completed|February 2005|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2010|March 16, 2010|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352131||180546|
NCT00352677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-406|Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INNO-406 in Adult Patients With Imatinib-Resistant or Intolerant Philadelphia Chromosome-Positive (Ph+) Leukemias||CytRx|No|Completed|July 2006|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2009|May 29, 2009|July 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352677||180505|
NCT00352690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1195|A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer|A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer||Washington University School of Medicine|Yes|Terminated|April 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|July 14, 2006|Yes|Yes|Safety of patients|No|April 13, 2015|https://clinicaltrials.gov/show/NCT00352690||180504|(3) grade 5 serious adverse events occurred and led to the study closing early for the safety of participants.
NCT00352976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2006-05|TBI Dose De-escalation for Fanconi Anemia|Total Body Irradiation Dose De-escalation Study in Patients With Fanconi Anemia Undergoing Alternate Donor Hematopoietic Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|May 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||January 2016|January 21, 2016|July 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352976||180482|
NCT00353873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM104926|Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids|A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100µg Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200µg Twice Daily, Both Delivered Via a Dry Powder Inhaler (DiskusTM) for 12 Weeks in Asthma in Children Aged 4-11 Years Not Controlled by Inhaled Corticosteroids Alone at Medium Dose||GlaxoSmithKline|No|Completed|November 2005|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|506|||Both|4 Years|11 Years|No|||January 2015|September 24, 2015|July 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00353873||180415|
NCT00353288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105908|Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™|Comparative Study Evaluating the Immunogenicity and Safety of MeMuRu-OKA Vaccine and Measles-Mumps-Rubella Vaccine (Priorix™) co-Administered With Varicella Vaccine (Varilrix™) in Children Primed With Measles-Mumps-Rubella Vaccine||GlaxoSmithKline||Completed|March 2006|||November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||446|||Both|15 Months|6 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353288||180459|
NCT00349921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01NS041386_TRIAL1|Clonidine Versus Adenosine to Treat Neuropathic Pain|Clonidine Versus Adenosine to Treat Neuropathic Pain||Wake Forest School of Medicine|Yes|Completed|August 2004|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|N/A|N/A|No|||January 2014|January 8, 2014|July 5, 2006|Yes|Yes||No|May 12, 2009|https://clinicaltrials.gov/show/NCT00349921||180712|
NCT00353821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030201|Investigating Cytokine Genes of Stem Cell Donors|Cytokine Gene Polymorphisms in Allotransplant Donors||National Institutes of Health Clinical Center (CC)||Completed|June 2003|||||N/A|Observational|N/A|||Actual|24|||Both|2 Years|80 Years|No|||September 2015|September 18, 2015|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353821||180419|
NCT00350194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28791-D|The Effects of Omega-3 Fatty Acids on Metabolic Syndrome|Pilot Study: The Effects of Omega-3 Fatty Acids on Metabolic Syndrome and Vascular Structure in Metabolic Syndrome as Assessed by Carotid IMT||University of Washington|Yes|Active, not recruiting|October 2006|June 2012|Anticipated|October 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00350194||180691|
NCT00349869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31AT003362-01A1|Yoga for Rheumatoid Arthritis|Yoga for Persons With Rheumatoid Arthritis||Johns Hopkins University|Yes|Completed|August 2006|August 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349869||180716|
NCT00349882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/216/05/L|Effects of Contact Lens Care Regimens on the Corneal Epithelium|Effects of Contact Lens Care Regimens on the Corneal Epithelium||University of Waterloo||Completed|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|N/A||||July 2006|July 5, 2006|July 5, 2006||||No||https://clinicaltrials.gov/show/NCT00349882||180715|
NCT00350818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0417|Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)|Azacitidine Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for AML and MDS||M.D. Anderson Cancer Center|No|Completed|October 2005|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350818||180646|
NCT00351078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-005e-CF|PTC124 for the Treatment of Cystic Fibrosis|A Phase 2b Extension Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis||PTC Therapeutics||Completed|December 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|N/A|No|||October 2007|October 16, 2007|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351078||180626|
NCT00360867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050130|An Open Label Treatment Extension Study of AMG 706|An Open Label Treatment Extension Study of AMG 706||Amgen||Terminated|December 2005|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|August 3, 2006|Yes|Yes|Amgen decision|No||https://clinicaltrials.gov/show/NCT00360867||179895|
NCT00360893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-DK-6-2204|Epidemiology of Diabetes Interventions and Complications (EDIC)|Epidemiology of Diabetes Interventions and Complications (EDIC)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Active, not recruiting|April 1994|February 2016||||N/A|Observational|Time Perspective: Prospective|||||||Both|19 Years|45 Years||||October 2013|October 31, 2013|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360893||179894|
NCT00361101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD11070-1001|A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus|Multicenter, Dose-finding Safety and Activity Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus.||Sanofi|No|Completed|October 2005|April 2010|Actual|August 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|August 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00361101||179878|
NCT00361361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-ost-1360|The Efficacy of 308nm Excimer Laser in White Striae|The Efficacy of 308nm Excimer Laser in White Striae||hahid Beheshti University of Medical Sciences||Completed|July 2006|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2006|February 19, 2008|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00361361||179858|
NCT00351780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0602-027-167|Fractional Flow Reserve-guided Provisional Side Branch Intervention|Physiologic Evaluation of the Provisional Side Branch Intervention Strategy for Bifurcation Lesions Using Fractional Flow Reserve||Seoul National University Hospital||Completed|June 2004|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||July 2011|July 15, 2011|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351780||180572|
NCT00352118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS012|Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer|Phase II Pilot Study of TPF (Docetaxel, Cisplatin, and 5-FU) Induction Chemotherapy Followed by Concurrent Cisplatin and Reduced Dose Radiation in Locally Advanced Head and Neck Cancer||Masonic Cancer Center, University of Minnesota|No|Terminated|March 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|July 13, 2006|Yes|Yes|Low dose radiation treatment was not appropriate for these patients.|No|June 2, 2009|https://clinicaltrials.gov/show/NCT00352118||180547|All 4 patients received high dose radiation (66-70 Gy). The radiation oncologist on this study deemed low dose radiation treatment was not appropriate for these patients. Therefore, the study participants are not evaluable.
NCT00351806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA721A02|AISTCM-Outcome Measurement of Acute Ischemic Stroke With Traditional Chinese Medicine|AISTCM-The Pathological Pattern Differentiation and Outcome Measurement of Acute Ischemic Stroke Treated With Traditional Chinese Medicine||Guangzhou University of Traditional Chinese Medicine||Completed|July 2005|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2|||500|||Both|40 Years|85 Years|No|||August 2013|August 5, 2013|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351806||180570|
NCT00352417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIA-2291-02|Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy|A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-Lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients With Carotid Stenosis Undergoing Elective Carotid Endarterectomy||Tallikut Pharmaceuticals, Inc.|Yes|Completed|July 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|80 Years|No|||July 2012|July 19, 2012|July 12, 2006||No||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00352417||180525|The small number, less than optimal quality, and diversity of types of plaque samples posed a significant limitation to the interpretation of the plaque data in this study.
NCT00359762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-EW-GWBE|Exenatide Versus Glimepiride in Patients With Type 2 Diabetes|Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)||AstraZeneca|No|Completed|September 2006|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1029|||Both|18 Years|85 Years|No|||August 2015|August 17, 2015|July 31, 2006|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT00359762||179975|Only patients who reached primary endpoint 12 months or more before the projected end of the study could enter period III.
NCT00353847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYD-06|Acupuncture for Treatment of Chronic LBP, RCT, Single Blinded|A Randomized, Single Blind, Controlled Clinical Trial to Evaluate the Pain Relief Efficacy, Functional Improvement and Safety of Acupuncture in Patients With Chronic Low Back Pain||Korea Institute of Oriental Medicine||Active, not recruiting|July 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|20 Years|N/A|No|||June 2006|November 15, 2006|July 18, 2006||||No||https://clinicaltrials.gov/show/NCT00353847||180417|
NCT00353860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020111|Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Role of Preparative Regimen and T Cell Dose in Graft Rejection and GVHD||National Institutes of Health Clinical Center (CC)||Completed|January 2002|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|10 Years|80 Years|No|||June 2015|July 16, 2015|July 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00353860||180416|
NCT00349622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS049640-02|Clinical Trial Ceftriaxone in Subjects With ALS|Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)||Massachusetts General Hospital|Yes|Completed|July 2006|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|513|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|July 5, 2006|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00349622||180735|
NCT00360945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000482280|Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma|Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse||National Cancer Institute (NCI)||Active, not recruiting|April 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|87|||Both|4 Years|20 Years|No|||November 2006|September 16, 2013|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360945||179890|
NCT00349908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNV:ARG:P-01|A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries|A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries||Codman & Shurtleff|No|Completed|September 2006|March 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||May 2014|May 28, 2014|July 6, 2006||No||No|February 2, 2011|https://clinicaltrials.gov/show/NCT00349908||180713|
NCT00350207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.342|Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg|A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype||Boehringer Ingelheim||Completed|July 2006|||September 2008|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|388|||Both|18 Years|65 Years|No|||September 2013|November 27, 2013|July 7, 2006||||No|August 24, 2009|https://clinicaltrials.gov/show/NCT00350207||180690|
NCT00350519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012460|The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery|An Open Label, Multicenter, Randomized, Controlled Study to Evaluate Efficacy and Safety of PROCRIT in Subjects Undergoing Elective Major Abdominal and/or Pelvic Surgery||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|August 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|July 7, 2006|Yes|Yes|The study was stopped due to slow enrollment|No|February 20, 2009|https://clinicaltrials.gov/show/NCT00350519||180667|No formal analysis was conducted due to early termination.
NCT00350506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCT-001|A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT|An Open-Label, Non-Randomized, Multi-Center Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT||GE Healthcare||Completed|October 2005|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||144|||Both|18 Years|75 Years|No|||August 2007|August 15, 2007|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00350506||180668|
NCT00351091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_2501|Risedronate in Postmenopausal Women With Low Bone Density|a Six Month, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Followed by 150mg Monthly Dose for 5 Months in Postmenopausal Women With Low Bone Density.||Sanofi||Completed|November 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|150|||Female|65 Years|80 Years|No|||February 2012|February 15, 2012|July 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00351091||180625|
NCT00351299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001786, BWH|Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium|Study of Dexmedetomidine as an Effective Sedative to Treat Acute ICU Delirium||Brigham and Women's Hospital|Yes|Active, not recruiting|January 2006|September 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|July 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00351299||180609|
NCT00351312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4163-UG-CTIL|Creation of a Pressure Reducing Areas in Socks|Evaluation of Foot Pressure in Volunteers Wearing Socks Weaved With Pressure Reducing Soles||Sheba Medical Center||Active, not recruiting|June 2006|June 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||4|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2006|July 11, 2006|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351312||180608|
NCT00361647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|719P|Screening for Occult Malignancy in Idiopathic Venous Thromboembolism|||University of Padova||Completed|January 2006|||May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A||||June 2008|June 10, 2008|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00361647||179836|
NCT00361907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-04|Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes|Effect of Pulsatile IV Insulin Delivery on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes||Florida Atlantic University|Yes|Terminated|February 2005|December 2010|Anticipated|June 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|21 Years|85 Years|No|||August 2009|August 25, 2009|April 13, 2006||No|Administrative|No||https://clinicaltrials.gov/show/NCT00361907||179817|
NCT00362141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-013|Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus|Safety and Tolerability of Add-on Levetiracetam in Status Epilepticus||Medical Center Haaglanden|No|Recruiting|October 2006|April 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||March 2007|March 30, 2007|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362141||179799|
NCT00351247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4066-VG-CTIL|Postconditioning in Primary PCI and Direct Stenting|Clinical and MRI Evaluation of 2 Vs 4 Cycles of Postconditioning During Primary PCI With Direct Stenting||Sheba Medical Center||Not yet recruiting|July 2006|May 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|21 Years|80 Years|No|||July 2006|July 11, 2006|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351247||180613|
NCT00351260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COREC2006|BBC ONE - British Bifurcation Coronary Study|British Bifurcation Coronary Study - Old, New and Evolving Strategies.|BBC ONE|Royal Sussex County Hospital|Yes|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|500|||Both|18 Years|N/A|No|||March 2008|April 15, 2008|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351260||180612|
NCT00351533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28503-A|A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)|A Randomized, Double-blind Study of the Effect of Fish Oil (Eicosapentaenoic Acid and Docosahexanoic Acid) on Lung and Systemic Inflammation in Patients With Acute Lung Injury (ALI)||University of Washington|Yes|Completed|July 2006|August 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|July 11, 2006||No||No|February 16, 2011|https://clinicaltrials.gov/show/NCT00351533||180591|
NCT00351546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2352|A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes|A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes||Novartis||Completed|February 2005|December 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Both|21 Years|65 Years|No|||May 2012|May 4, 2012|July 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351546||180590|
NCT00351793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RL-004|A Clinical Trial Follow-up Study of the Genesis II Posterior Stabilized Total Knee Replacement|A Clinical Trial Follow-up Study of the Genesis II Posterior Stabilized Total Knee Replacement||Nova Scotia Health Authority|No|Active, not recruiting|January 2003|December 2015|Anticipated|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|186|||Both|N/A|N/A|No|Non-Probability Sample|Total knee replacement candidates|March 2014|May 14, 2015|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351793||180571|
NCT00352144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-050|6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia|A Six-Month, Chronic Efficacy and Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia: A Randomized Double-Blind, Placebo-Controlled Study||Sunovion|No|Completed|October 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|830|||Both|21 Years|64 Years|No|||February 2012|February 21, 2012|July 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352144||180545|
NCT00352157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCS-61-06|Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women|Effect of Revival Soy on Weight Loss and Appearance of Skin, Hair, and Nails in High BMI Premenopausal Women||Physicians Pharmaceuticals, Inc.||Completed|July 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 20, 2009|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352157||180544|
NCT00352703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050100|PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation|An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation||Swedish Orphan Biovitrum|No|Completed|April 2006|May 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|145|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352703||180503|
NCT00353002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB11730|A Comparison of Amethocaine Cream vs. Liposomal Lidocaine Cream for Venipuncture in Children.|A Comparison of Amethocaine Creams Versus Liposomal Lidocaine Cream as Pain Reliever Prior to Venipuncture in Children at the Paediatric Emergency Department.||Lawson Health Research Institute|Yes|Recruiting|July 2006|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|5 Years|12 Years|No|||August 2006|April 12, 2007|July 14, 2006||||No||https://clinicaltrials.gov/show/NCT00353002||180480|
NCT00360022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060580|Transition Study of Inflammatory Bowel Disease (IBD) Patients From Pediatric Gastroenterologist to Adult Gastroenterologist|Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model||Vanderbilt University|No|Recruiting|August 2006|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|16 Years|N/A|No|||July 2011|July 14, 2011|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360022||179956|
NCT00353301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1135.cc|Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma|A Phase II Single Arm Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Tarceva™ (Erlotinib Hydrochloride) and Rapamune™ (Sirolimus) in the Treatment of Metastatic Renal Cell Carcinoma.||University of Colorado, Denver|Yes|Completed|July 2006|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|July 14, 2006|Yes|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT00353301||180458|One limitation of this study was the lack of von Hippel–Lindau (VHL) mutational status assessment.
NCT00353327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIT-01|Study of the Effectiveness of Passive Immunotherapy in HIV-Infected Patients Who Are in Virologic Failure|Passive Immunotherapy in HIV-Infected Patients Who Fail to Respond to Multiple Highly Active Antiretroviral Treatment. Randomized Study in Two Phases.||Hospital Clinic of Barcelona||Suspended|October 2006|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|July 17, 2006|||low recruitment|No||https://clinicaltrials.gov/show/NCT00353327||180457|
NCT00360009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303-2002|Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease|Cognition and Mood in Parkinson's Disease (PD) in Subthalamic Nucleus (STN) Versus Globus Pallidus Interna (GPi) Deep Brain Stimulation (DBS)||University of Florida|Yes|Completed|January 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|62|||Both|30 Years|75 Years|No|||October 2012|October 25, 2012|August 2, 2006||No||No|August 5, 2009|https://clinicaltrials.gov/show/NCT00360009||179957|
NCT00349648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP-E9/2001-140|Conservative or Operative Treatment for the Shoulder Impingement Syndrome?|Conservative or Operative Treatment for the Shoulder Impingement Syndrome? A Randomized Controlled Trial of 140 Patients Followed Up for Two Years.||Central Hospital of Kanta-Hame||Active, not recruiting|March 2001|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Both|18 Years|60 Years|No|||July 2006|July 6, 2006|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349648||180733|
NCT00361452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|epinephrine_albuterol_rsv.ctil|Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study|Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study||Rambam Health Care Campus||Terminated|December 2000|May 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|N/A|1 Year|No|||November 2000|August 6, 2006|August 6, 2006||||No||https://clinicaltrials.gov/show/NCT00361452||179851|
NCT00350220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12408|Transfusion Strategies in Pediatric Cardiothoracic Surgery|A Prospective, Randomized, Controlled Clinical Trial Comparing Two Transfusion Strategies in Pediatric Patients Undergoing Cavopulmonary Connection.||University of Rochester||Completed|July 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|4 Months|7 Years|No|||May 2015|May 29, 2015|July 5, 2006||No||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00350220||180689|There were no limitations to this study. There was 100% compliance with study procedures. There were no adverse events.
NCT00361153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-202|Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus|Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|No|Completed|May 2006|March 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|75 Years|No|||June 2008|June 24, 2008|August 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361153||179874|
NCT00361686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3820|Comparison of Tramadol vs Remifentanyl Patient Controlled Analgesia for Second Trimester Abortions|Randomized Double Blind Study Comparing Patient Controlled Analgesia With Tramadol vs. Remifentanyl for Women Undergoing 2nd Trimester Abortions||Rabin Medical Center||Completed|January 2006|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2006|November 23, 2015|August 6, 2006||||No||https://clinicaltrials.gov/show/NCT00361686||179833|
NCT00350831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL820-002|Study of XL820 Given Orally Daily to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the KIT Inhibitor XL820 Administered Orally Daily to Subjects With Solid Tumors||Exelixis||Completed|July 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||August 2008|August 14, 2008|July 7, 2006||||||https://clinicaltrials.gov/show/NCT00350831||180645|
NCT00362206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF0242780-01 05 04|Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin|A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Pravastatin Alone||Solvay Pharmaceuticals|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|423|||Both|18 Years|75 Years|No|||July 2009|July 7, 2009|August 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00362206||179795|
NCT00362843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060214|Protein Synthesis in the Brain of Patients With Fragile X Syndrome|PET Measurement of Regional Rates of Cerebral Protein Synthesis in Subjects With Fragile X Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|August 2006|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|150|||Male|18 Years|24 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|August 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00362843||179746|
NCT00362453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002161|Tai Chi Mind-Body Therapy for Knee Osteoarthritis|Tai Chi Mind-Body Therapy for Knee Osteoarthritis: a Pilot Single-blind Randomized Controlled Trial||Tufts Medical Center|Yes|Completed|August 2005|June 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|N/A|No|||February 2010|February 10, 2010|August 9, 2006||No||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00362453||179776|small sample size
NCT00361920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2034|Cell Biology of Steroid Resistant Asthma|Investigating Biomarkers of Steroid Resistant Asthma||National Jewish Health||Completed|August 2006|March 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|40|||Both|12 Years|65 Years|No|||September 2014|September 24, 2014|August 7, 2006||||No||https://clinicaltrials.gov/show/NCT00361920||179816|
NCT00362167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010092|Pain Evaluation and Treatment|Evaluation and Treatment of Pain (Training Protocol)||National Institutes of Health Clinical Center (CC)||Completed|February 2001|December 2006||||N/A|Observational|N/A||||50|||Both|4 Years|N/A|No|||December 2006|September 26, 2015|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362167||179798|
NCT00351559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0004|IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection|Invasive Monitoring Attenuation Through Gene Expression (IMAGE) Trial||XDx||Completed|January 2005|October 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|629|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351559||180589|
NCT00351572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-5-0055|Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients|Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients||AHS Cancer Control Alberta||Completed|July 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic and any other interested parties|April 2011|April 15, 2011|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351572||180588|
NCT00351819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27995|Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception|Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome|TAP|Boston University|No|Completed|April 2006|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|84|||Male|18 Years|N/A|No|||July 2014|July 18, 2014|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00351819||180569|
NCT00351832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1303|A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin (50mg qd, 50mg Bid, 100mg qd) to Placebo in Patients With Type 2 Diabetes||Novartis||Completed|June 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||236|||Both|20 Years|N/A||||May 2007|May 7, 2007|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351832||180568|
NCT00352716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-31-00250-100|Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children|Efficacy of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children||Ipsen||Completed|June 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Male|1 Month|36 Months|No|||September 2007|September 26, 2007|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352716||180502|
NCT00352989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-31-00250-101|Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children|Efficacy of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children||Ipsen||Completed|July 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Male|1 Month|36 Months|No|||September 2007|September 26, 2007|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352989||180481|
NCT00353340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70202|Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine|Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine in Patients Undergoing Cardiac Catheterization||Shaare Zedek Medical Center||Completed|January 2005|May 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2010|February 24, 2010|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353340||180456|
NCT00360971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0435|Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer|A Randomized, Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Palifermin (NSC# 740548; IND # 6370) for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Radiation Therapy With Concurrent Chemotherapy (Followed by Surgery for Selected Patients)||Radiation Therapy Oncology Group|Yes|Terminated|July 2006|February 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|21|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|August 3, 2006|Yes|Yes|Due to positive preliminary results from other palifermin studies.|No|April 16, 2014|https://clinicaltrials.gov/show/NCT00360971||179888|This study terminated early with 21 subjects accrued out of 298 planned, therefore no statistical testing was performed. The termination was decided due to positive preliminary results from other palifermin studies.
NCT00360321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 06/5-M|Descriptive Study of a French Sample of “at Risk” and Pathological Gamblers Followed in a French Structure Specialised in Addictive Disorders.|Descriptive Study of a French Sample of “at Risk” and Pathological Gamblers Followed in a French Structure Specialised in Addictive Disorders.||Nantes University Hospital||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||July 2006|August 3, 2006|August 3, 2006||||No||https://clinicaltrials.gov/show/NCT00360321||179935|
NCT00360659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2004.02.PHH|Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP.|||Regional Hospital Holstebro||Completed|February 2004|February 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||50|||Both|20 Years|65 Years|No|||April 2008|April 17, 2008|August 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00360659||179911|
NCT00360308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-309|Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations||Eisai Inc.||Terminated|November 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|723|||Both|30 Years|N/A|No|||August 2013|June 26, 2014|August 2, 2006||No|Study stopped due to lack of efficacy.|No|October 23, 2012|https://clinicaltrials.gov/show/NCT00360308||179936|
NCT00360672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0293|Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome|Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities||M.D. Anderson Cancer Center|No|Completed|January 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|August 4, 2006|Yes|Yes||No|May 31, 2013|https://clinicaltrials.gov/show/NCT00360672||179910|
NCT00360646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017208|Drug-Induced Liver Injury (DILN)Network Retrospective|Idiosyncratic Liver Injury Associated With Drugs (ILIAD): A Retrospective Study|ILIAD|Duke University|Yes|Recruiting|September 2004|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|Samples With DNA|Samples with DNA|Both|2 Years|N/A|No|Non-Probability Sample|Patients with liver injury ascribed to any drug or HDS/CAM agent which the DILI onset date        occurred beyond six months from enrollment.|August 2015|August 3, 2015|August 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00360646||179912|
NCT00361972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15444|Elucidation of Acid-Induced Pulmonary Inflammation|Elucidation of Acid-Induced Pulmonary Inflammation||University of Utah|No|Completed|August 2006|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||April 2009|April 22, 2009|August 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00361972||179812|
NCT00361439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14757A (P04908)|Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis|Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis||University of Chicago|No|Terminated|August 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|August 4, 2006|Yes|Yes|Study stopped early due to slow accrual.|No|July 20, 2012|https://clinicaltrials.gov/show/NCT00361439||179852|Early termination due to slow accrual
NCT00361959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO40036|SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease|A Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104 Week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/500mcg With Tiotropium Bromide 18 Mcg on the Rate of Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|September 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1270|||Both|40 Years|80 Years|No|||August 2006|August 7, 2006|August 7, 2006||||No||https://clinicaltrials.gov/show/NCT00361959||179813|
NCT00361946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 1K126K63691|The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).|The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).||Baylor College of Medicine||Recruiting|August 2006|||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Cross-Sectional||||60|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||August 2006|August 8, 2006|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00361946||179814|
NCT00362856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1001-004|Safety and Tolerability Study of AT1001 in Celiac Disease Subjects|A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of AT-1001 in Celiac Disease Subjects During Gluten Challenge.||Alba Therapeutics||Completed|August 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|79|||Both|18 Years|65 Years|No|||February 2007|November 12, 2007|August 8, 2006||||No||https://clinicaltrials.gov/show/NCT00362856||179745|
NCT00362492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-Prothege|Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement|9-10 Days Versus Prolonged Thromboprophylaxis in Patients Without Evidence of Ultrasound Proximal Thromboembolism After Total Knee Joint Replacement: a Randomized Controlled Trial||University Hospital, Caen||Completed|June 2004|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|850|||Both|46 Years|N/A|No|||October 2010|October 27, 2010|August 9, 2006||||No||https://clinicaltrials.gov/show/NCT00362492||179773|
NCT00358774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-089|Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral Colds|A Double-blind, Placebo-controlled Trial to Test the Efficacy of Homeopathic Nasal Formulation for the Management of Experimental Rhinoviral Colds in an Outpatient Setting||University of Wisconsin, Madison||Completed|March 2001|March 2002|Actual|March 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|July 28, 2006||||No||https://clinicaltrials.gov/show/NCT00358774||180048|
NCT00362180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012-CS10|Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia||Sanofi|Yes|Completed|July 2006|September 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|August 7, 2006|Yes|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT00362180||179797|The limitations to this study are 1) post-hoc amendments that caused early termination of cohorts and limited the accomplishment of study objectives and 2) post-hoc amendments which added cohorts into the study that were not previously specified.
NCT00362193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK62258 (completed)|Glycemic Relapse Prevention: Maintenance Dose Assessment|Longitudinal Diabetes Care: A Randomized Controlled Trial to Prevent Glycemic Relapse||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|June 2002|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||165|||Both|18 Years|80 Years|No|||February 2010|February 12, 2010|August 7, 2006||||No||https://clinicaltrials.gov/show/NCT00362193||179796|
NCT00362440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000159|Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome|A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial||Beth Israel Deaconess Medical Center|No|Completed|August 2006|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 18, 2013|August 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00362440||179777|
NCT00358475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR100688|Study Of Perennial Allergic Rhinitis|Study of Perennial Allergic Rhinitis -Long Term Treatment Study-||GlaxoSmithKline||Completed|June 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|65|||Both|16 Years|N/A|No|||May 2012|April 11, 2013|July 27, 2006||||No||https://clinicaltrials.gov/show/NCT00358475||180071|
NCT00352170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ag14683|Calcium and Vitamin D Malnutrition in Elderly Women|Calcium and Vitamin D Malnutrition in Elderly Women||Creighton University|Yes|Completed|May 2000|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1180|||Female|55 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 8, 2008|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00352170||180543|
NCT00352430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060202|Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension|Cardiopulmonary Function Assessment and NO Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension||National Institutes of Health Clinical Center (CC)||Completed|July 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00352430||180524|
NCT00352443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0528|S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989) and Everolimus (RAD001) in Patients With Advanced Solid Tumors||Southwest Oncology Group|Yes|Completed|September 2006|September 2013|Actual|August 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352443||180523|
NCT00353015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-523|Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract|A Phase II Study of Irinotecan and Cisplatin for Metastatic or Unresectable High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract||M.D. Anderson Cancer Center|No|Completed|March 2003|July 2009|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||August 2012|August 1, 2012|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00353015||180479|
NCT00353028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S114.3.117|Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents|SME3110 (Fluvoxamine Maleate) in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placeb-controlled Study||Solvay Pharmaceuticals|Yes|Completed|October 2006|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|8 Years|18 Years|No|||March 2010|March 3, 2010|July 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00353028||180478|
NCT00359775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/32,GC 95|Coping Skills Training (CST) for Children With Chronic Health Conditions|Coping Skills Training (CST) for Children With Chronic Health Conditions: An Extension From Children With Diabetes to Children With Rheumatologic Conditions, Epilepsy, Spina Bifida, and Asthma||Children's Hospital and Health System Foundation, Wisconsin||Completed|July 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|38|||Both|8 Years|12 Years|No|||February 2012|February 16, 2012|July 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00359775||179974|
NCT00351364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18169|Does Montelukast Have an Affect on the Function of the Artery in Patients With Heart Disease|The Effect of Leukotriene Receptor Blockade on Endothelial Function in Acute Coronary Syndrome Patients||University of Calgary|Yes|Terminated|July 2006|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||December 2014|December 1, 2014|July 10, 2006||No|Diffic;ulty recruiting|No||https://clinicaltrials.gov/show/NCT00351364||180604|
NCT00361179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561706020|Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C|An Extension, Observational Protocol to Evaluate the Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C in the Original Study ML17862||National Taiwan University Hospital||Completed|May 2006|December 2011||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||320|||Both|18 Years|N/A|No|||August 2006|August 4, 2006|August 4, 2006||||No||https://clinicaltrials.gov/show/NCT00361179||179872|
NCT00361192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEMP ARTERITIS 001A|Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis|||Shaare Zedek Medical Center||Recruiting|August 2006|January 2007||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|90 Years|No|||August 2006|December 5, 2006|August 6, 2006||||||https://clinicaltrials.gov/show/NCT00361192||179871|
NCT00361205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/03|Electronic Compliance Monitoring in Parkinson's Disease|Electronic Compliance Monitoring in Parkinson's Disease||South Glasgow University Hospitals NHS Trust||Completed|November 2003|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||120|||Both|18 Years|85 Years|No|||December 2005|October 16, 2006|August 7, 2006||||No||https://clinicaltrials.gov/show/NCT00361205||179870|
NCT00349674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97.129|WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides|Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial||Hospices Civils de Lyon||Active, not recruiting|January 1999|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||126|||Both|18 Years|80 Years|No|||October 2007|October 9, 2007|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349674||180731|
NCT00349973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043347|Clinical Trial of Dipyridamole in Schizophrenia|Clinical Trial of Dipyridamole in Schizophrenia||University of Maryland|Yes|Completed|May 2001|September 2011|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||January 2013|January 11, 2013|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00349973||180708|
NCT00383175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060328003|Reading Fluency and Accommodative Lag|Reading Fluency and Accommodative Lag||University of Alabama at Birmingham|No|Completed|August 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|72|||Both|5 Years|9 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383175||178211|
NCT00383188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631007|An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis|A 12-Week, Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Safety, Pharmacokinetics, And Efficacy Of PH-797804, Administered Orally Once Daily In Subjects With Active Rheumatoid Arthritis||Pfizer|No|Completed|December 2006|July 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|305|||Both|18 Years|N/A|No|||October 2009|October 7, 2009|September 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383188||178210|
NCT00383487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0021|A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer|A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer||Stanford University|Yes|Terminated|March 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|90 Years|No|||January 2013|January 25, 2013|September 29, 2006||No|Extreme toxicity|No||https://clinicaltrials.gov/show/NCT00383487||178187|
NCT00383747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04T574|The Effects of Nicotine on Cognition in Schizophrenia|A Double Blind Placebo Controlled Trial of the Effects of Transdermal Nicotine on Cognitive Function in Non-Smokers With and Without Schizophrenia||Massachusetts General Hospital|No|Completed|April 2004|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383747||178167|
NCT00384072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3068A1-303|Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women|A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|500|||Female|45 Years|N/A|No|||May 2007|December 19, 2007|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00384072||178142|
NCT00384085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3515|Insulin Glargine "All to Target" Trial|All to Target Trial Lantus® (Insulin Glargine) With Stepwise Addition of APIDRA® (Insulin Glulisine) or Lantus With One Injection of Apidra vs a Twice-Daily Premixed Insulin Regimen (Novolog® Mix 70/30) in Adult Subjects With Type 2 Diabetes Failing Dual or Triple Therapy With Oral Agents: a 64-week, Multi-center, Randomized, Parallel, Open-label Clinical Study.||Sanofi||Completed|May 2006|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|588|||Both|30 Years|80 Years|No|||May 2011|May 4, 2011|October 3, 2006|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00384085||178141|
NCT00384033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-335|Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder||Pfizer||Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|638|||Both|18 Years|N/A||||February 2012|February 9, 2012|October 2, 2006|Yes|Yes|||February 9, 2012|https://clinicaltrials.gov/show/NCT00384033||178145|
NCT00384332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051235|Medication, Weight Gain and GI Hormones|Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones||Vanderbilt University|Yes|Completed|January 2007|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00384332||178122|
NCT00384319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRS-01-06-01|Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients|Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients||Life Recovery Systems|No|Completed|October 2006|December 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2007|January 3, 2008|October 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384319||178123|
NCT00384930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9797|Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|August 2006|October 2008|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1058|||Male|45 Years|N/A|No|||August 2009|August 26, 2009|October 3, 2006|Yes|Yes||No|October 17, 2008|https://clinicaltrials.gov/show/NCT00384930||178076|
NCT00385177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SON-2310-06-101|Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors|A Multicenter Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors||OncoGenex Technologies|No|Completed|September 2006|May 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|October 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00385177||178058|
NCT00385190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-108|Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese Men|An Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Study Drug Administred Orally to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|December 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 17, 2009|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00385190||178057|
NCT00385151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0920-2004|To Compare the Ischemic Pre-conditioning and Post-conditioning on Reperfusion Injury in Humans.|The Mechanism of Ischemic Post Conditioning in Humans, Minimizing Reperfusion Injury.||Emory University||Completed|May 2006|August 2006||||N/A|Observational|Time Perspective: Prospective||||20|||Both|15 Years|35 Years|Accepts Healthy Volunteers|||November 2013|November 15, 2013|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00385151||178060|
NCT00385164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20328|The Utility of FDG-PET for Radiation Treatment in NSCLC|The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)||AHS Cancer Control Alberta||Recruiting|October 2006|||||Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Non-small cell lung cancer|August 2011|January 18, 2012|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00385164||178059|
NCT00381836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005658-37|Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer|A Randomized, Multi-center Study to Assess the Effect of Darbepoetin Alfa (Aranesp®) for the Treatment of Anemia in Patients With Advanced Hormone Independent Prostate Cancer and Anaemia||University of Aarhus|No|Terminated|October 2006|February 2007|Actual|February 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|140|||Male|18 Years|N/A|No|||February 2008|December 3, 2015|September 27, 2006||No|Terminated by sponsor due to general risk that aranesp caused tumor progression|No||https://clinicaltrials.gov/show/NCT00381836||178313|
NCT00381849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2115-05|Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones|Cystone for Treatment of Nephrolithiasis||Mayo Clinic|No|Completed|April 2006|June 2010|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|100 Years|No|||January 2016|January 4, 2016|September 27, 2006|Yes|Yes||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00381849||178312|There were no serious adverse events and no adverse events. Power of the study was diminished by failure of patients to return all required 24 hour urine samples. The botanical authenticity of Cystone was not documented.
NCT00382083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSTMRI - 001|Premedication to Reduce Discomfort With Screening Mammography|||Mountain States Tumor and Medical Research Institute||Completed|March 2006|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|30 Years|N/A|No|||September 2006|September 27, 2006|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00382083||178295|
NCT00382057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 K23 DK02858-1526|Testosterone Effects on Men With the Metabolic Syndrome|Effect of Increasing Testosterone Levels on Insulin Sensitivity in Men With the Metabolic Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Withdrawn|May 2006|March 2011|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Male|50 Years|75 Years|No|||November 2008|December 4, 2008|September 26, 2006||||||https://clinicaltrials.gov/show/NCT00382057||178297|
NCT00382317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-44-009|A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal Angiography|A Clinical Study of Iobitridol in Multislice CT Abdominal Angiography Indications||Guerbet|No|Completed|August 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|85 Years|No|||November 2008|November 25, 2008|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382317||178277|
NCT00382590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0177|Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients|A Randomized Phase II Study of the Combination of 5-Azacytidine With Valproic Acid (VPA) Versus Low-Dose Ara-C in Patients With AML/MDS Not Eligible for Other Studies||M.D. Anderson Cancer Center|Yes|Completed|August 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|60 Years|N/A|No|||August 2012|August 1, 2012|September 27, 2006||No||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00382590||178256|
NCT00382928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216-2004|Automatic External Defibrillation Monitoring in Cardiac Arrest|Automatic External Defibrillation Monitoring in Cardiac Arrest||Atlanta Research and Education Foundation|Yes|Completed|October 2006|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|September 29, 2006|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00382928||178230|
NCT00382941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-01-05-05|Study of LED Phototherapy for Musculoligamentous Lesions|||Hermano Miguel Foundation||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||December 2008|December 5, 2008|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00382941||178229|
NCT00382889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/1401/001/01|As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma|Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.||Chiesi Farmaceutici S.p.A.||Completed|August 2002|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|18 Years|65 Years|No|||September 2006|September 29, 2006|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00382889||178233|
NCT00382902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-13|Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Silicone Hydrogel Soft Contact Lenses|Clinical Evaluation of the Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution Compared to Two Marketed Multi-Purpose Solutions for Care of Silicone Hydrogel Soft Contact Lenses||Alcon Research||Completed|August 2004|February 2005|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||233|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2006|August 15, 2012|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382902||178232|
NCT00382915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH076672|Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder|Nicotine Intake in Smokers With Schizophrenia||Rutgers, The State University of New Jersey|No|Completed|October 2006|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|276|Samples With DNA|Whole blood for DNA extraction|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be 100 smokers with schizophrenia, 100 smokers with bipolar disorder and 100        smokers without mental illness. This will include smokers within the New Jersey        metropolitan area, who receive treatment at the UMDNJ-University Behavioral Health Care        System (UBHC) or at another outpatient behavioral health care agency. A community sample        of healthy volunteer smokers without mental illness will be recruited through        advertisements to participate in the study.|May 2013|May 24, 2013|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00382915||178231|
NCT00383500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0007|Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status|To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status||Stanford University|Yes|Recruiting|May 2005|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|200|||Female|18 Years|N/A|No|||October 2011|October 25, 2011|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383500||178186|
NCT00383513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0006|Study of Epratuzumab in Systemic Lupus Erythematosus|An Open-Label Re-treatment Trial for Patients Previously Randomized Into the SL0003 and SL0004, Randomized, Double-blind, Placebo-controlled, Multi-center Studies of Epratuzumab in Patients With Systemic Lupus Erythematosus||UCB Pharma|Yes|Completed|June 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383513||178185|
NCT00383773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1yumbo-HMO-CTIL|Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion|||Hadassah Medical Organization||Not yet recruiting|October 2006|October 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|October 3, 2006|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383773||178165|
NCT00383786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060253|Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder|Evaluation of the Efficacy of the NK1 Antagonist GR205171 in Posttraumatic Stress Disorder||Baylor College of Medicine|Yes|Completed|September 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||December 2013|December 27, 2013|October 3, 2006|No|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00383786||178164|Limitations include the small sample size and brief duration of the trial, as 8 weeks might have been insufficient to test the efficacy of GR205171 for chronic PTSD. Sample size was also a limitation.
NCT00384592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00104|PPI Sequencing Study|A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI)||AstraZeneca||Completed|September 2006|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00384592||178102|
NCT00384605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-037|An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Obese Patients and in Overweight Patients With Obesity-Related Co-Morbidities, Followed by a 1-Year Extension||Merck Sharp & Dohme Corp.||Terminated|October 2006|December 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1000|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|October 3, 2006|Yes|Yes|The overall profile does not support development for obesity|No||https://clinicaltrials.gov/show/NCT00384605||178101|
NCT00384917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-111|Study to Determine the Impact of Multiple Doses of Ketoconazole on Single-Dose Pharmacokinetics of HCV-796|An Open Label, 2-Period, Sequential Study to Determine the Impact of Multiple Doses of Ketoconazole on Single-Dose Pharmacokinetics of HCV-796||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|September 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|October 3, 2006||||||https://clinicaltrials.gov/show/NCT00384917||178077|
NCT00385203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00046|The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).|An Open-Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by [F 18] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate||AstraZeneca||Completed|September 2006|December 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||June 2012|June 11, 2012|October 5, 2006|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00385203||178056|
NCT00385216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6273|Nicotine as an Adjuvant Analgesic for Third Molar Surgery|Effect of Nicotine on Pain After Third Molar Extraction.||Columbia University|No|Completed|July 2004|June 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||December 2010|December 1, 2010|October 5, 2006|Yes|Yes||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00385216||178055|This was a small study under typical clinical conditions.
NCT00381212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB#06-003|A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.|A Pilot Study (Phase I/II) Testing the Immunologic Activity and Safety of AGS-004, an Autologous HIV Immunotherapeutic, in HIV-Infected Adults on HAART||McGill University Health Center|Yes|Completed|September 2006|November 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00381212||178358|
NCT00385450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004052 00|Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor|Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor in the Perioperative Period||Mayo Clinic|Yes|Terminated|October 2006|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|41|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|October 5, 2006|No|Yes|Study closed at Mayo prior to completion|No||https://clinicaltrials.gov/show/NCT00385450||178038|
NCT00385463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK ADA103575|Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray Versus Montelukast in Adolescents/Adults With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus(R) or Placebo||Creighton University||Completed|April 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|600|||Both|15 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 20, 2008|October 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00385463||178037|
NCT00381563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR047785|Knee Bracing for People With Patellofemoral Osteoarthritis|Bracing in Patellofemoral Osteoarthritis: A Clinical Trial||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Active, not recruiting|December 2006|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2009|May 21, 2009|September 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381563||178333|
NCT00382096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237A2302|Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes|A Randomized, Double-blind, Active-controlled, Multicenter Study to Compare the Effect of 24 Weeks Treatment With a Fixed Combination Therapy of Vildagliptin and Metformin to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|September 2006|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1179|||Both|18 Years|78 Years|No|||January 2013|January 2, 2013|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382096||178294|
NCT00382395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLX53|SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma|Randomized, Controlled, Multicenter Comparative Trial to Evaluate the SOLX Gold Shunt for the Reduction of Intraocular Pressure (IOP) in Glaucomatous Eyes Following Failed Medical and Conventional Surgical Treatments||SOLX, Inc.|No|Suspended|November 2005|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|21 Years|N/A|No|||September 2015|September 17, 2015|September 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382395||178271|
NCT00382629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHT-3009-03|BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis|BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis||Bayhill Therapeutics||Completed|February 2006|June 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||252|||Both|18 Years|55 Years|No|||February 2008|February 7, 2008|September 27, 2006||||||https://clinicaltrials.gov/show/NCT00382629||178253|
NCT00382642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA010522-11|Pharmacological Treatment for Alcoholism|Pharmacological Treatment for Alcoholism||University of Virginia|Yes|Completed|June 2006|December 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|N/A|No|||February 2012|February 3, 2012|September 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382642||178252|
NCT00382330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120050348|Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.|Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.||Rutgers, The State University of New Jersey||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Female|18 Years|75 Years||||April 2013|September 5, 2013|September 27, 2006||||No||https://clinicaltrials.gov/show/NCT00382330||178276|
NCT00382343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 35/00|A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux|Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux.||IRCCS Burlo Garofolo|No|Completed|November 1999|March 2007|Actual|March 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|96|||Both|N/A|30 Months|No|||April 2015|April 27, 2015|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382343||178275|
NCT00382603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-09|Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Soft Contact Lenses in Symptomatic Patients|Clinical Evaluation of the Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution Compared to a Marketed Multi-Purpose Solution for Care of Soft Contact Lenses in Symptomatic Patients||Alcon Research||Completed|August 2004|February 2005|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||362|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|August 15, 2012|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382603||178255|
NCT00382967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT409|A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms|A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting.||GE Healthcare|Yes|Completed|October 2006|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|September 29, 2006||No||No|May 14, 2012|https://clinicaltrials.gov/show/NCT00382967||178227|
NCT00383201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-01|Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles|Long-Term Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles of Soft Contact Lenses||Alcon Research||Completed|March 2005|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2006|August 15, 2012|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00383201||178209|
NCT00383214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0004(IMMU-103-04)|Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)|A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.||UCB Pharma|No|Terminated|May 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383214||178208|
NCT00383526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID17|Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly|||Sanofi|No|Completed|September 2006|September 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3707|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383526||178184|
NCT00384358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100N7-211|Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures|A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-Of-Care Controlled, Feasibility And Safety Study Of rhBMP-2/CPM As An Adjuvant Therapy For Fractures Of The Proximal Femur||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2006|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|108|||Both|55 Years|N/A|No|||February 2013|February 21, 2013|October 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384358||178120|
NCT00383799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001505-25|Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia|Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study||Hospital General Universitario Gregorio Marañon||Recruiting|September 2005|April 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||302|||Both|18 Years|N/A|No|||October 2006|October 3, 2006|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383799||178163|
NCT00384618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C97-1707|Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study|Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease||VU University Medical Center||Terminated|May 2001|August 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|80 Years|No|||October 2006|October 4, 2006|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384618||178100|
NCT00384631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8414|Intravitreal Bevacizumab for Neovascular Glaucoma|Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial|IVB NVG|hahid Beheshti University of Medical Sciences|Yes|Completed|April 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|10 Years|80 Years|No|||February 2008|February 14, 2008|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384631||178099|
NCT00384345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0184-BE|Exercise and Bright Light Treatment: Effects on Body Weight and Composition|Moderate Exercise and Bright Light Treatment in Overweight Individuals||University Health Network, Toronto||Completed|September 2003|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|55 Years|No|||July 2006|October 4, 2006|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384345||178121|
NCT00384943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRSQ 024018|Study of Home-Based Exercise to Alleviate Postpartum Depression|Decreasing Health Care Utilization With Alternative Approaches for the Treatment of Depression: A Randomized Trial of Exercise for Postpartum Depression||McGill University||Completed|November 2001|November 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 4, 2006|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384943||178075|
NCT00381251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713E1-134|Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.|An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Two New Formulations of 0.45 mg/1.5 mg Premarin / Medroxyprogesterone Acetate (MPA) Compared With a Reference Formulation of 0.45mg/1.5mg Premarin / MPA (Prempro™) in Healthy Postmenopausal Women.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|January 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Female|35 Years|70 Years|Accepts Healthy Volunteers|||June 2007|June 8, 2007|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381251||178355|
NCT00381550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00209|3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia|Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)||National Cancer Institute (NCI)|No|Completed|August 2006|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||June 2014|December 16, 2014|September 26, 2006|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT00381550||178334|
NCT00382109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCT0431|Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission|A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia||Children's Oncology Group|Yes|Active, not recruiting|March 2007|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|1 Year|21 Years|No|||January 2014|January 23, 2014|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382109||178293|
NCT00382122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMS-06-06|Prevalence of Ocular Surface Disease in Glaucoma Patients|Prevalence of Ocular Surface Disease in Glaucoma Patients||Alcon Research||Completed|September 2006|February 2007|Actual|February 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|101|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years or older with open-angle glaucoma or ocular hypertension were        consecutively recruited for the study.|September 2007|May 25, 2012|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00382122||178292|
NCT00382408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-ADV-301|A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001||Teva Pharmaceutical Industries|Yes|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|4041|||Both|17 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 24, 2012|September 27, 2006|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00382408||178270|In the past 6 years, Type-7 ADV has only rarely been recovered from recruits with ARD (Russell 2007). Therefore, it may not be possible to directly measure the protective effect of the vaccine against Type-7 ADV in the proposed study.
NCT00382707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3540|Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.|Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.||University Hospital, Strasbourg, France||Completed|May 2006|August 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|12 Years|N/A|No|||August 2011|August 29, 2011|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382707||178247|
NCT00382382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03HD051656|Diffusion Tensor Imaging in Autism|Diffusion Tensor Imaging in Autism||University of Florida|No|Withdrawn|July 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|0|||Male|8 Years|12 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|September 28, 2006||No|Study was completed but there were no participants. It was completed as a theoretical study.    Requests for final progress report can be sent to Dr. Liu.|No||https://clinicaltrials.gov/show/NCT00382382||178272|
NCT00382655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10019|Prehospital Screening to Prevent Injury and Illness|Prehospital Screening to Prevent Injury and Illness||University of Rochester||Completed|February 2003|August 2005||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||700|||Both|65 Years|N/A|No|||September 2006|September 27, 2006|September 27, 2006||||No||https://clinicaltrials.gov/show/NCT00382655||178251|
NCT00382668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-051|A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug|Single-Dose Pharmacokinetics of Dasatinib in Subjects With Hepatic Impairment Compared to Healthy Adult Subjects||Bristol-Myers Squibb|No|Completed|October 2006|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|Samples With DNA|Whole Blood|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Male and Female Subjects with hepatic insufficiency conforming to Child-Pugh        classification B        Male and Female Subjects with hepatic insufficiency conforming to Child-Pugh        classification C        Healthy Control subjects in good health|April 2011|April 13, 2011|September 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00382668||178250|
NCT00382980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0052|Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Trial of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Immunization With Inactivated, Vero Cell-Culture Derived Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Young Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|308|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2008|August 26, 2010|September 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00382980||178226|
NCT00383253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001342|Methods Study to Characterize Early Indicators of Weight Loss in People|A Randomized, Open-Label, Parallel Group, Fixed Energy Deficit Methodology Trial to Characterize Early Efficacy Biomarkers During Treatment of Obesity in Adult, Obese, Male Subjects.||Pfizer|No|Completed|October 2006|March 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|57|||Male|18 Years|55 Years|No|||March 2009|March 20, 2009|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383253||178205|
NCT00383266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0541 / 201103198|A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer|A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer||Washington University School of Medicine|Yes|Terminated|October 2006|June 2010|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|October 2, 2006|Yes|Yes|Low accrual|No|October 20, 2015|https://clinicaltrials.gov/show/NCT00383266||178204|The study was terminated due to lack of participant accrual.
NCT00382616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-03-NV-220-CTIL|Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD|Studying the Effects of Phosphatidylserine Enriched With Omega-3 Fatty Acids on Symptoms of Attention-Deficit/Hyperactivity Disorder in Children||Tel-Aviv Sourasky Medical Center||Completed|July 2004|January 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|8 Years|13 Years|No|||September 2006|November 6, 2006|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382616||178254|
NCT00382954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-BMT-145|Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML|A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute Myelogenous Leukemia||University of Kentucky|Yes|Completed|February 2004|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||September 2010|September 28, 2010|September 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00382954||178228|
NCT00383812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bevacizumab for PCV|Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy|Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy||Asan Medical Center||Recruiting|May 2006|May 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|20 Years|80 Years|No|||October 2006|October 3, 2006|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383812||178162|
NCT00383227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/032|Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years|A Phase III, Clinical Trial Comparing the Immunogenicity and Safety of SmithKline Beecham Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B, in Pre-haemodialysis/Haemodialysis Patients (>=15 Years of Age)||GlaxoSmithKline||Completed|December 1999|November 2000|Actual|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|165|||Both|15 Years|N/A|No|||October 2015|October 29, 2015|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383227||178207|
NCT00383240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04334|Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)|A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids||Merck Sharp & Dohme Corp.|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|781|||Both|12 Years|N/A|No|||October 2015|October 9, 2015|September 29, 2006|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00383240||178206|
NCT00384124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2005.087|Topical Imiquimod for Bowen's Disease of the Head and Neck|Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks.||Brooke Army Medical Center|Yes|Enrolling by invitation|November 2006|||November 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2008|March 25, 2008|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00384124||178138|
NCT00384371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI P05-71030|Pilot Study to Assess the Efficacy of Botulinum Toxin A Treatments on Pain and Disability in Sub-Acute Low Back Pain|Pilot Study to Assess the Efficacy of Botulinum Toxin A (BOTOX®) Treatment of Paravertebral Muscles on Pain and Disability in Subjects Suffering From Sub-Acute Low Back Pain.||Walter Reed Army Medical Center|Yes|Terminated|June 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 4, 2009|October 4, 2006||No|Funding was unable to be secured for this study|No||https://clinicaltrials.gov/show/NCT00384371||178119|
NCT00384644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS-1|Skeletal Muscle Oxygenation in Critically Ill|Skeletal Muscle Oxygenation in Critically Ill||University Medical Centre Ljubljana|Yes|Recruiting|April 2004|December 2010|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Intensive care patients|June 2008|June 4, 2008|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00384644||178098|
NCT00384657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWG_06_01|Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease|The Effects of Intravenous Iron Therapy for Anemia Correction in Patients With Severe Chronic Heart Failure and Concomitant Moderate Chronic Kidney Disease||Anemia Working Group Romania|No|Recruiting|January 2008|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00384657||178097|
NCT00384956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0585|A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes|A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes||Washington University School of Medicine|Yes|Completed|August 2006|March 2010|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|October 4, 2006|Yes|Yes||No|August 11, 2014|https://clinicaltrials.gov/show/NCT00384956||178074|
NCT00384969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF06523|Sorafenib and RAD001 Renal Cell Carcinoma|A Phase I Study of Sorafenib and RAD001 in Patients With Metastatic Renal Cell Carcinoma||University of California, San Francisco|Yes|Completed|October 2006|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|21 Years|N/A|No|||August 2014|August 15, 2014|October 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00384969||178073|
NCT00385229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 106-01|Post Term Pregnancy - Induction of Labor or Monitoring of Pregnancy|Post Term Pregnancy - Induction of Labor or Monitoring of Pregnancy||St. Olavs Hospital|No|Completed|September 2002|July 2004|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|508|||Female|N/A|N/A||||November 2011|November 3, 2011|October 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00385229||178054|
NCT00385242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-37412|PET and Recovery Following Revascularization (PARR 2)|PET and Recovery Following Revascularization: Outcome and Cost-effectiveness of FDG PET in Left Ventricular Dysfunction (PARR 2)||Ottawa Heart Institute Research Corporation|Yes|Completed|June 2000|June 2011|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|430|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00385242||178053|
NCT00381277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG-1|The Effects of Sports Drinks on Urinary Lithogenicity|The Effects of Sports Drinks on Urinary Lithogenicity||VA New York Harbor Healthcare System|No|Completed|March 2006|September 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2011|February 18, 2011|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381277||178353|
NCT00381290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR052528|Intensive Diet and Exercise for Improving Knee Osteoarthritis in Obese and Overweight Older Adults|Intensive Diet and Exercise for Arthritis||Wake Forest School of Medicine|No|Completed|October 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|454|||Both|55 Years|N/A|No|||September 2011|September 14, 2011|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00381290||178352|
NCT00385476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0526|Cancer Patients' Medication Knowledge in the Emergency Center|Cancer Patients' Medication Knowledge in the Emergency Center||M.D. Anderson Cancer Center|No|Completed|August 2005|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|308|||Both|16 Years|N/A|No|Non-Probability Sample|Study participants admitted to the UT MD Anderson Cancer Center Emergency Center.|July 2012|July 31, 2012|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00385476||178036|
NCT00385489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3201A1-102|Study Evaluating LXR-623 in Healthy Japanese Adults|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Japanese Male Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 6, 2009|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00385489||178035|
NCT00385502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCHM EC-200|A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail|A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail||MacroChem Corporation|No|Active, not recruiting|September 2006|June 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||November 2007|February 5, 2009|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00385502||178034|
NCT00385515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-1012-CLN2-006|Efficacy of SNX-1012 in the Treatment of Oral Mucositis|A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer||Mucosal Therapeutics|No|Completed|June 2006|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||April 2009|April 8, 2009|October 5, 2006|Yes|Yes||No|January 19, 2009|https://clinicaltrials.gov/show/NCT00385515||178033|
NCT00381225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00002641|Feasibility of Radiofrequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance.|Feasibility of Radio-Frequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance||Johns Hopkins University||Not yet recruiting|November 2006|November 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|90 Years|No|||September 2006|September 26, 2006|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381225||178357|
NCT00381238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA104617|Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease|An Open-label Extension to Study 49653/461, to Assess the Long-term Safety of Rosiglitazone (Extended Release Tablets) in Subjects With Mild to Moderate Alzheimer's Disease||GlaxoSmithKline||Completed|June 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|50 Years|85 Years|No|||November 2013|November 21, 2013|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381238||178356|
NCT00382135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7011|A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg|An Evaluation of Semen Characteristics After 40 Weeks Daily Dosing With 20 mg Tadalafil||Eli Lilly and Company|Yes|Completed|November 2003|December 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|282|||Male|45 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 23, 2007|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00382135||178291|
NCT00383071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-I-0235|Development of Immune Globulin Treatment for Avian Flu|A Phase II Vaccine Dose Finding Pilot Study for Development of an Anti-Influenza A (H5N1) Intravenous Hyper-Immune Globulin||National Institutes of Health Clinical Center (CC)|Yes|Active, not recruiting|August 2006|May 2013|Anticipated|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|126|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|September 29, 2006|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00383071||178219|
NCT00382694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG#13/03|Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients|Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients: A Randomised, Placebo Controlled, Double Blind Phase II Trial: NMSG #13/03||Nordic Myeloma Study Group||Active, not recruiting|May 2005|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|64 Years|No|||September 2006|September 28, 2006|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382694||178248|
NCT00382681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-03-41|Evaluation of an Investigational Multi-Purpose Disinfecting Solution for Care of Soft Contact Lenses|Clinical Evaluation of the Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution Compared to a Marketed Multi-Purpose Solution for Care of Soft Contact Lenses||Alcon Research|No|Completed|July 2004|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|252|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 1, 2012|September 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382681||178249|
NCT00383019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641050|A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).|A 8-Week, Randomized, Double-Masked, Parallel Group, Phase III Study Comparing The Efficacy And Safety Of Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).||Pfizer||Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|289|||Both|20 Years|N/A|No|||August 2009|August 3, 2009|September 29, 2006||No||No|October 1, 2008|https://clinicaltrials.gov/show/NCT00383019||178223|
NCT00382993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX106573|A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)|A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)||GlaxoSmithKline||Completed|December 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|65 Years|No|||April 2011|May 31, 2012|September 29, 2006|Yes|Yes||No|November 14, 2008|https://clinicaltrials.gov/show/NCT00382993||178225|
NCT00383539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID23|Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults|||Sanofi|No|Completed|September 2006|December 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2256|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383539||178183|
NCT00383552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04073|Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)|A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids||Merck Sharp & Dohme Corp.|No|Completed|September 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|746|||Both|12 Years|N/A|No|||February 2015|February 6, 2015|September 29, 2006|Yes|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00383552||178182|
NCT00383565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00240|FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study of Depsipeptide, a Histone Deacetylase Inhibitor, in Relapsed or Refractory Mantle Cell or Diffuse Large Cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Terminated|September 2006|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||April 2013|May 2, 2014|September 29, 2006|Yes|Yes||No|July 19, 2012|https://clinicaltrials.gov/show/NCT00383565||178181|
NCT00383578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2398|Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd or Metformin 1500 mg Daily in Elderly Drug Naive Patients With Type 2 Diabetes||Novartis||Completed|September 2006|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|335|||Both|65 Years|N/A|No|||January 2013|January 2, 2013|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383578||178180|
NCT00384098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA018-CL-2001|Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis|A Randomized, Double-blind, Parallel-group, 4-arm, 12-week Study to Evaluate the Safety and Efficacy of Topically Applied CTA018 vs Vehicle for the Treatment of Adult Subjects With Chronic Plaque Psoriasis||OPKO Health, Inc.|No|Completed|September 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|18 Years|75 Years|No|||June 2007|September 26, 2014|October 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00384098||178140|
NCT00384111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106NH301|Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL|A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma||Spectrum Pharmaceuticals, Inc|No|Terminated|October 2006|March 2010|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||March 2011|March 7, 2011|October 3, 2006|Yes|Yes|A pending new protocol will replace this study.|No||https://clinicaltrials.gov/show/NCT00384111||178139|
NCT00384384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51/05|Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients|Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients||University Hospital Inselspital, Berne||Completed|August 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|N/A|N/A|No|||January 2011|January 12, 2011|October 5, 2006||||||https://clinicaltrials.gov/show/NCT00384384||178118|
NCT00384397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA44|A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers|An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age||Sanofi|No|Completed|September 2006|February 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1128|||Both|249 Days|305 Days|Accepts Healthy Volunteers|||January 2014|January 20, 2014|October 5, 2006|Yes|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00384397||178117|
NCT00384670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1048|A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children|A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children||U.S. Army Medical Research and Materiel Command|Yes|Completed|August 2003|May 2004|Actual|May 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|October 4, 2006|Yes|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00384670||178096|
NCT00384995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR021676|Bicarbonate v Saline to Prevent Contrast Nephropathy|Phase 4 Study of Bicarbonate Versus Saline Infusion Therapy to Prevent Contrast Induced Nephropathy (CAN-IT PREVENT Protocol)||Italian Society of Nephrology|Yes|Terminated|December 2006|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|October 5, 2006|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00384995||178071|
NCT00384982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medical University of Vienna|Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study|Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: A Multicenter, Randomized Trial Comparing Early and Late Intracoronary or Combined (Intramyocardial and Intracoronary) Administration of Stem Cells|MYSTAR|Medical University of Vienna|Yes|Completed|January 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||August 2008|January 21, 2010|October 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384982||178072|
NCT00385255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106323|Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults|A Study to Evaluate Immunogenicity and Safety of Boostrix When Co-administered With Fluarix in Subjects 19 Years of Age and Older||GlaxoSmithKline||Completed|October 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|1726|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2012|March 1, 2012|October 6, 2006||||No||https://clinicaltrials.gov/show/NCT00385255||178052|
NCT00385268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803895|Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence|A Phase II, Double-Blind, Placebo-controlled, Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence|CAMPRAL|University of Pennsylvania|Yes|Completed|November 2006|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|October 6, 2006|Yes|Yes||No|August 28, 2013|https://clinicaltrials.gov/show/NCT00385268||178051|
NCT00385528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS-3200-066718|Effects of a Multi-Faceted Psychiatric Intervention Targeted at the Complex Medically Ill: a Randomized Controlled Trial|Effects of a Multi-Faceted Psychiatric Intervention Targeted at the Complex Medically Ill: a Randomized Controlled Trial||University of Lausanne Hospitals||Completed|November 2002|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Both|19 Years|65 Years|No|||October 2006|October 16, 2008|October 6, 2006||||No||https://clinicaltrials.gov/show/NCT00385528||178032|
NCT00367913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTS Opportunist Mycobacteria|Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease|Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae||British Thoracic Society||Completed|March 1995|September 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|16 Years|N/A|No|||July 2006|August 21, 2006|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367913||179365|
NCT00368264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAL V|TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )|A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V Glomerulonephritis||Medical University of Vienna||Terminated|September 2006|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||October 2009|October 2, 2009|August 23, 2006||No|Failure to recruit patients with membranous lupus nephritis not previously treated with    azathioprine .|No||https://clinicaltrials.gov/show/NCT00368264||179338|
NCT00381576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300976|Multiple Sclerosis and Heavy Progressive Resistance Training|Multiple Sclerosis and Muscle Function - Effects of Heavy Progressive Resistance Training||University of Aarhus|No|Completed|November 2006|June 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2008|August 11, 2008|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00381576||178332|
NCT00381862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000503649|Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting|A Multi-Center, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aprepitant and Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Colorectal Cancer (CRC) Patients Receiving FOLFOX or FOLFIRI Chemotherapy||OHSU Knight Cancer Institute|Yes|Completed|June 2006|July 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|54|||Both|18 Years|120 Years|No|||February 2016|February 9, 2016|September 26, 2006|Yes|Yes||No|June 10, 2011|https://clinicaltrials.gov/show/NCT00381862||178311|
NCT00382148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q3623g|A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g|A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)||Genentech, Inc.||Completed|November 2006|||June 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Years|75 Years|No|||November 2009|November 12, 2009|September 26, 2006|Yes|Yes||No|November 5, 2009|https://clinicaltrials.gov/show/NCT00382148||178290|
NCT00383084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR053168|Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia|Lifestyle Physical Activity for Fibromyalgia||Johns Hopkins University|Yes|Completed|September 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|65 Years|No|||June 2013|June 28, 2013|September 29, 2006||No||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00383084||178218|
NCT00383045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014718-04|HIV Risk Reduction and Drug Abuse Treatment in Malaysia|HIV Risk Reduction and Drug Abuse Treatment in Malaysia||Yale University||Completed|April 2003|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Male|18 Years|65 Years|No|||February 2009|February 23, 2009|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00383045||178221|
NCT00383058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-Greentea-06-01|The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial|The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial||Taipei City Hospital|Yes|Completed|September 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|16 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00383058||178220|
NCT00383032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS # 16429|Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction|Randomized Controlled Trial of Mifepristone Versus Laminaria for Cervical Ripening In Midtrimester Induction||Dartmouth-Hitchcock Medical Center||Completed|January 2004|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Female|16 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 27, 2007|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00383032||178222|
NCT00383006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSYUNIZH26092006|Affect Management Group for Adult Survivors of Childhood Trauma|||University of Zurich|No|Withdrawn|May 2006|May 2008|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|70 Years|No|||June 2009|June 2, 2009|September 29, 2006|||Difficulties in finding enough study participants.|No||https://clinicaltrials.gov/show/NCT00383006||178224|
NCT00383279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-99106|Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer|Improving Employment Among Gynecologic Cancer Survivors||Comprehensive Cancer Center of Wake Forest University||Completed|February 2006|||February 2007|Actual|N/A|Interventional|N/A|||Anticipated|70|||Female|18 Years|N/A|No|||June 2013|June 4, 2013|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00383279||178203|
NCT00383591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/047|Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years|A Phase III, Clinical Trial Comparing the Persistence of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B at Months 24, 30, 36, in Pre-haemodialysis/Haemodialysis Patients (≥15 Years of Age)||GlaxoSmithKline||Completed|March 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|15 Years|N/A|No|||September 2011|September 29, 2011|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383591||178179|
NCT00383838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AA13284-01|Self-Selected Brief Alcohol Intervention for Adolescents|Self-Selected Brief Alcohol Intervention for Adolescents||RAND||Completed|September 2002|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||1200|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||October 2006|October 2, 2006|March 20, 2006||||No||https://clinicaltrials.gov/show/NCT00383838||178160|
NCT00383825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B02-123456-2|ICG Angiography in Amniotic Membrane Graft and Conjunctival Autograft After Pterygium Excision|Interventional Study of Vascularization Detected by ICG Angiography in Amniotic Membrane Graft and Conjunctival Autograft After Pterygium Excision||Baskent University||Completed|January 2003|December 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Screening||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2006|October 2, 2006|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383825||178161|
NCT00384410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAB-20051|Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients|Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients: A Placebo-Controlled, Randomized, Crossover Insomnia Pilot Study||University Health Network, Toronto||Recruiting|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|65 Years|No|||November 2005|October 4, 2006|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384410||178116|
NCT00384683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0434|Endothelial Dysfunction As A Predictor Of Perioperative Outcome|Endothelial Dysfunction As A Predictor Of Perioperative Outcome In Major Thoracic Surgery - An Observational Study||M.D. Anderson Cancer Center|No|Completed|March 2006|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|90|Samples With DNA|Blood samples collected to measure number of circulating blood cells that become endothelial      cells. During surgery a small sample of lung tissue collected, if available.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants is scheduled to have major chest (lung or esophagus) surgery or is a        healthy volunteer.|May 2013|May 31, 2013|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00384683||178095|
NCT00385008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX105848|TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine|An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.||GlaxoSmithKline|No|Completed|September 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|No|||February 2011|May 31, 2012|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00385008||178070|
NCT00385281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0041|Proteomic Profiling for Influenza Vaccination - FluMist|Proteomic Profiling for Influenza Vaccination, 2nd Study: FluMist||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|21 Years|49 Years|Accepts Healthy Volunteers|||March 2010|August 26, 2010|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00385281||178050|
NCT00385294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB3535|Role of B2 Adrenergic Receptors in Labor Pain|Role of B2 Adrenergic Receptors in Labor Pain||Columbia University|No|Completed|September 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples With DNA|DNA identified by subject number will be retained for analysis.|Female|18 Years|40 Years|No|Non-Probability Sample|Nuliparous women anticipating NSVD|October 2010|October 1, 2010|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00385294||178049|
NCT00385541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA2949|Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)|The Comparison of Morphine and Hydromorphone Patient-Controlled Analgesia||Columbia University|No|Completed|November 2003|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||March 2015|March 3, 2015|October 5, 2006||No||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00385541||178031|This was a small study under typical clinical conditions.
NCT00381264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB1 Study 002|Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis|A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis||NEMA Research, Inc.||Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|75 Years|No|||February 2008|February 14, 2008|September 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381264||178354|
NCT00368277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2344|A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly|A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension||Novartis||Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|901|||Both|65 Years|N/A|No|||February 2011|February 28, 2011|August 22, 2006|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00368277||179337|
NCT00381589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/2006|Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide|Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide||Centre for Addiction and Mental Health|No|Completed|October 2006|||June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381589||178331|
NCT00381875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060211|Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV|A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance||National Institutes of Health Clinical Center (CC)||Completed|July 2006|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|September 26, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00381875||178310|
NCT00382421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia|Swiss Interventional Study on Silent Ischemia (SWISSI 1)||Luzerner Kantonsspital||Completed|February 1992|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|40 Years|N/A|No|||October 2006|October 10, 2006|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382421||178269|
NCT00382434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U18HS015818|Emergency Pharmacist Safety Study|The ED Pharmacist as a Safety Measure in Emergency Medicine||University of Rochester|No|Completed|August 2005|December 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|10224|||Both|N/A|N/A||Probability Sample|emergency department patients|January 2010|January 13, 2010|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00382434||178268|
NCT00383370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0603|Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD|A Trial to Assess the Safety and Tolerability of Repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects With Neovascular Age Related Macular Degeneration||Regeneron Pharmaceuticals|No|Completed|October 2006|July 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|50 Years|N/A|No|||April 2011|April 20, 2011|October 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383370||178196|
NCT00383331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9431|Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer|A Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Terminated|February 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|September 29, 2006|Yes|Yes|Trial was stopped early due to low enrollment|No|January 6, 2009|https://clinicaltrials.gov/show/NCT00383331||178199|Trial was stopped early due to low enrollment. Some secondary outcomes were not analyzed due to the low numbers.
NCT00383318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX 06-001|Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia|Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia||Mednax Center for Research, Education and Quality||Completed|September 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|450|||Both|N/A|6 Days|Accepts Healthy Volunteers|||January 2008|January 24, 2008|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383318||178200|
NCT00383305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE G990037|CoolCap Trial, Treatment of Perinatal Hypoxic-Ischemic Encephalopathy|Brain-Cooling for the Treatment of Perinatal Hypoxic-Ischemic Encephalopathy||Olympic Medical||Completed|July 1999|September 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||235|||Both|N/A|6 Hours|No|||September 2006|September 29, 2006|September 29, 2006||||||https://clinicaltrials.gov/show/NCT00383305||178201|
NCT00383292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10409|A Study of LY573636 in Treating Patients With Malignant Melanoma|A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle as Second-Line Treatment in Patients With Unresectable or Metastatic Melanoma||Eli Lilly and Company|No|Completed|November 2006|July 2015|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383292||178202|
NCT00383851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN-224-008|Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma|A Randomized Phase II Trial of ATN-224 in Combination With Temozolomide or Temozolomide Followed by ATN-224 in Patients With Advanced Melanoma||Attenuon||Active, not recruiting|September 2006|September 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 4, 2007|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383851||178159|
NCT00384137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1205|A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients|A Multicenter, Open, Single Sequence Crossover Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, FK506E (MR4), Based Immunosuppressive Regimen in Stable Kidney Transplant Patients Converted From a Prograf® Based Immunosuppressive Regimen||Astellas Pharma Inc|Yes|Completed|October 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|October 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00384137||178137|
NCT00384696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0806|Risk Perception Among Quitting Smokers|Health Communications and Risk Processing Among Smokers||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2006|||December 2017|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Current smoker, age 18 to 65 years, with history of 5 cigarettes/day for last year wishing        to quit|September 2015|September 10, 2015|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00384696||178094|
NCT00385034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-777601096-01|Computer-assisted Screening for Intimate Partner Violence in Family Practice|Computer-assisted Screening for Intimate Partner Violence in Family Practice - a Randomized Controlled Trial||St. Michael's Hospital, Toronto||Completed|March 2005|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening||||280|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00385034||178068|
NCT00385021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCT 06-06|ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer|ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer||Southwestern Regional Medical Center|No|Terminated|October 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|86 Years|No|||October 2007|October 31, 2007|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00385021||178069|
NCT00385320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/006|Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months|To Assess the Efficacy, Immuno & Safety of 2 Doses of GSK HRV Vaccine at Different Virus Concentrations in Healthy Infants Aged 2 Months & Previously Uninfected With HRV, Concurrently Given With DTPw-HBV, Hib.||GlaxoSmithKline||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2640|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||October 2006|October 6, 2006|October 6, 2006||||No||https://clinicaltrials.gov/show/NCT00385320||178047|
NCT00385307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6607|Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)|An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of Two Fixed Doses of SR58611A (175 mg q12/ 350 mg q12) in Outpatients With MDD||Sanofi||Completed|September 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|680|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|October 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00385307||178048|
NCT00385567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRG2|A Trial of PEHRG214 in HIV-Infected Patients|A Phase 2 Randomized, Controlled Trial of PEHRG214 in HIV-Infected Patients||Virionyx Corporation Limited|Yes|Terminated|January 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||August 2010|August 24, 2010|October 1, 2006||Yes|Difficulty recruiting eligible patients in timely fashion|||https://clinicaltrials.gov/show/NCT00385567||178029|
NCT00385554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP 4885|Botswana Study of UC-781 Vaginal Microbicide|Phase I Trial of the Safety, Toxicity, and Acceptability of the Microbicide UC-781 When Topically Applied by HIV-uninfected Women and Men in Botswana||Centers for Disease Control and Prevention||Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|0|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 15, 2012|October 5, 2006||Yes|Study product is no longer being considered for further development.|||https://clinicaltrials.gov/show/NCT00385554||178030|
NCT00368303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR103124|A Local Register Study For Major Depression Of Paroxetine Controlled Release|A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression||GlaxoSmithKline|No|Completed|December 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||362|||Both|18 Years|65 Years|No|||March 2011|May 31, 2012|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00368303||179335|
NCT00368316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999900003|Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel|Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2003|February 2009|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2799|||Both|1 Year|4 Years|No|||June 2012|June 21, 2012|August 22, 2006|No|Yes||No|May 9, 2012|https://clinicaltrials.gov/show/NCT00368316||179334|No efficacy could be assessed after 2nd injection of S. sonnei conjugate due to the small number of positive isolates at that time. There were too few cases of S. flexneri 2a infection for evaluation of vaccine B efficacy.
NCT00381602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHRP ESRD 01|A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis|||QLT Inc.||Terminated|September 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|3|||Both|18 Years|70 Years|No|||March 2011|March 25, 2011|September 26, 2006|||Lack of enrolment|||https://clinicaltrials.gov/show/NCT00381602||178330|
NCT00381888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000503985|Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer|Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial||Masonic Cancer Center, University of Minnesota|Yes|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|September 26, 2006|Yes|Yes||No|October 29, 2009|https://clinicaltrials.gov/show/NCT00381888||178309|
NCT00384488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-04PEsta-02|Automated Diabetes Prevention Program|Effectiveness of Automated Telephone Intervention on Behavioral and Weight Outcomes for Patients With Pre-Diabetes.||Kaiser Permanente||Completed|May 2004|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||84|||Both|18 Years|N/A|No|||October 2006|October 5, 2006|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00384488||178110|
NCT00383344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-086|Use of FDG PET/CT to Evaluate Crohn Disease|Phase II Study on the Role of the Positron Emission Tomography Combined With CT Scan for the Evaluation on Crohn Disease||Université de Sherbrooke||Recruiting|September 2006|May 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||30|||Both|18 Years|N/A|No|||October 2006|April 5, 2007|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383344||178198|
NCT00383357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0070|Sleepiness and the Risk of Falling|Aging, Hypnotics, Sleep Inertia and the Risk of Falling||National Institute on Aging (NIA)||Completed|August 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2007|September 19, 2007|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00383357||178197|
NCT00383630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC2128|Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure|The Effect of Intramyocardial Injection of Immunoselected Bone Marrow Cells on Myocardial Function in LVAD Bridge to Transplant Patients||Columbia University|Yes|Terminated|August 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|September 29, 2006|Yes|Yes|Study has been terminated due to logistical barriers to cell processing and poor enrollment|No||https://clinicaltrials.gov/show/NCT00383630||178176|
NCT00383617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antragsnummer : EA4/058/05|Referral Recommendations for Axial Spondyloarthritis|Performance of Referral Recommendations in Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis||Charite University, Berlin, Germany||Completed|July 2004|||April 2007|Actual|N/A|Observational|N/A|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 12, 2013|October 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00383617||178177|
NCT00383604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0009|Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2|Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2||Stanford University|Yes|Completed|July 2005|April 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples With DNA|blood|Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer survivors|May 2013|May 28, 2013|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383604||178178|
NCT00384163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0453-2006|Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique|Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique||Emory University||Terminated|August 2007|August 2007|Actual|August 2007|Actual|N/A|Observational|Time Perspective: Retrospective||||50|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|October 3, 2006|||sufficient data collected|No||https://clinicaltrials.gov/show/NCT00384163||178135|
NCT00384150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-NH-302|Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)|A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination With Rituximab for Subjects With Relapsed, Follicular Non-Hodgkin's Lymphoma Who Previously Responded on Study 114-NH-301||Biogen|No|Terminated|November 2007|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 4, 2006|Yes|Yes|Enrollment challenges due to changes in standards of care resulted in premature termination.    No safety or efficacy events factored into this action.|No||https://clinicaltrials.gov/show/NCT00384150||178136|
NCT00385333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060252|Metabolic Mapping to Measure Retinal Metabolism|A Novel Non-Invasive In Vivo Imaging System to Measure Retinal Metabolism||National Institutes of Health Clinical Center (CC)||Completed|September 2006|September 2010|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|28|||Both|18 Years|N/A|No|||September 2010|September 26, 2015|October 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00385333||178046|
NCT00385593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00010|Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults|A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 Micrograms, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week, Randomised, Open-label, Parallel-group, Multicentre Study. Study SPAIN||AstraZeneca||Terminated|September 2006|October 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|654|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|October 6, 2006||||No|October 14, 2009|https://clinicaltrials.gov/show/NCT00385593||178027|The study was prematurely stopped, because it was not possible to recruit the sample size required in the period of time established.
NCT00381329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP#4100027295_2|Pennsylvania Adolescent Smoking Study (PASStudy)|Pennsylvania Adolescent Smoking Study (PASS) - Randomized Controlled Trial Comparing Motivational Interviewing and Structured Brief Advice for the Reduction of Adolescent Cigarette Smoking||Pennsylvania Department of Health|Yes|Active, not recruiting|September 2007|May 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|14 Years|18 Years|No|||January 2009|January 29, 2009|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381329||178349|
NCT00381342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWBJ|Safety and Efficacy of Exenatide as Monotherapy|Safety and Efficacy of Exenatide as Monotherapy in Drug Naive Patients With Type 2 Diabetes||AstraZeneca|No|Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|233|||Both|18 Years|N/A|No|||January 2015|February 20, 2015|September 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381342||178348|
NCT00385580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-085|Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer|Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer||Bristol-Myers Squibb|No|Completed|January 2007|October 2010|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Male|18 Years|N/A|No|||October 2012|April 24, 2013|October 4, 2006|Yes|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00385580||178028|
NCT00381303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011869|GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.|GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.||Tibotec, Inc|Yes|Completed|November 2006|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|429|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|September 26, 2006|Yes|Yes||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00381303||178351|
NCT00381316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143-002|Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches|Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches||GE Healthcare||Completed|July 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|291|||Both|18 Years|N/A|No|||November 2007|December 3, 2007|September 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381316||178350|
NCT00368875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03012|Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer|Phase I/II Study of a Combination of Suberoylanilide Hydroxamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer||National Cancer Institute (NCI)|Yes|Completed|July 2006|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||March 2014|October 6, 2015|August 24, 2006|Yes|Yes||No|June 18, 2015|https://clinicaltrials.gov/show/NCT00368875||179291|
NCT00368888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVI4099|Clinical Study of New Urine Collection Bag for Infants.|||Bergaliden Barnavårdscentral||Completed|March 2004|September 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|3 Years|Accepts Healthy Volunteers|||September 2006|September 11, 2006|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00368888||179290|
NCT00381901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000509793|Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery|Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE]||National Cancer Institute (NCI)||Completed|May 2006|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|3400|||Female|18 Years|N/A|No|||July 2009|May 12, 2011|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381901||178308|
NCT00382161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/05|Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors|Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction||University Hospital, Saarland|Yes|Withdrawn|October 2006|December 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Male|18 Years|N/A|No|||February 2009|February 12, 2009|September 27, 2006|||not enough patients meeting inclusion criteria|No||https://clinicaltrials.gov/show/NCT00382161||178289|
NCT00382720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCOX_C_00082|Docetaxel and Oxaliplatin in Gastric Cancer|A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease||Sanofi||Completed|September 2006|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|275|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|September 27, 2006|Yes|Yes||No|April 29, 2011|https://clinicaltrials.gov/show/NCT00382720||178246|
NCT00382733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN ATDTROC0501|Oral Topotecan to Treat Recurrent or Persistent Solid Tumors|Oral Topotecan, Utilization for a Metronomic Dosing Schedule to Treat Recurrent or Persistent Solid Tumors||Accelerated Community Oncology Research Network|No|Completed|November 2006|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|September 27, 2006|Yes|Yes||No|May 10, 2013|https://clinicaltrials.gov/show/NCT00382733||178245|
NCT00382746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES- CI 02|EarlySense Monitoring Device Evaluation on CHF Patients|EarlySense Monitoring Device Evaluation on CHF Patients||EarlySense Ltd.||Completed|October 2006|March 2008|Actual|November 2007||N/A|Observational|Time Perspective: Prospective|||Anticipated|25|||Both|45 Years|N/A|No|||April 2008|April 22, 2008|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382746||178244|
NCT00383669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD32257-01|A Trial of Vitamins and HAART in HIV Disease Progression|Trial of Vitamins in HIV Progression and Transmission (A Trial of Vitamins and HAART in HIV Disease Progression)||Harvard School of Public Health|Yes|Completed|November 2006|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4012|||Both|18 Years|N/A|No|||September 2011|September 2, 2011|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383669||178173|
NCT00383929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2456C00001|Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg|A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate BP Control on Monotherapy With CC 32mg||AstraZeneca||Completed|September 2006|October 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1979|||Both|20 Years|80 Years|No|||March 2008|March 19, 2008|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383929||178153|
NCT00383643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95900|Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.|Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study.||Stanford University||Completed|May 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|No|||July 2011|July 6, 2011|September 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00383643||178175|
NCT00383656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-004396|Pulsatile GnRH in Anovulatory Infertility|Pulsatile GnRH in Anovulatory Infertility||Massachusetts General Hospital|Yes|Recruiting|January 1989|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|270|||Female|16 Years|45 Years|No|||July 2014|July 31, 2014|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383656||178174|
NCT00383890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-006|A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine Used for Sedation During Elective Awake Fiberoptic Intubation||Hospira, Inc.||Completed|August 2006|March 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|October 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383890||178156|
NCT00383864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG/RBV POST-TOH|Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.|Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation||Hospital Clinic of Barcelona||Completed|July 2001|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||55|||Both|18 Years|70 Years|No|||October 2006|October 5, 2006|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383864||178158|
NCT00383877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1684|Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|September 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|263|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383877||178157|
NCT00384436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT-MD-39|Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients|Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients||Forest Laboratories||Completed|October 2006|||October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|580|||Both|18 Years|65 Years|No|||January 2008|January 3, 2008|October 3, 2006||||||https://clinicaltrials.gov/show/NCT00384436||178114|
NCT00384449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3849s|Lucentis (Ranibizumab) for Eales' Disease|The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease||Oregon Health and Science University||Completed|October 2006|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|21 Years|N/A|No|||April 2009|April 2, 2009|October 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384449||178113|
NCT00384423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX-CP-018|Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept|A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.||Epix Pharmaceuticals, Inc.|No|Completed|October 2006|||October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|80|||Both|60 Years|N/A|No|||January 2008|January 29, 2008|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384423||178115|
NCT00385047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1280|A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults|Phase I/IIa Study of the Safety, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge of FMP2.1/AS01B and FMP2.1/AS02A Candidate Malaria Vaccines Administered Intramuscularly at Months 0, 1, and 2 in Malaria-naive Adults Living in the United States||U.S. Army Medical Research and Materiel Command|No|Completed|September 2006|September 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|October 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00385047||178067|
NCT00385346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lfd.Nr.068/06|Expressive Writing in Male Infertility|Expressive Writing as a Therapeutic Intervention in Male Infertility||University Hospital, Bonn||Completed|November 2006|February 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|56|||Male|18 Years|55 Years|No|||September 2009|June 29, 2010|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00385346||178045|
NCT00381355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051703|RCT of a Written Action Plan vs. Usual Care in Children With Acute Asthma|Does the Use of a New Written Action Plan Increase Short-term Adherence to Prescribed Medication and Asthma Control in Children Treated for an Asthma Attack in the Emergency Department: A Randomized Controlled Trial.||McGill University Health Center||Completed|October 2006|||April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Actual|218|||Both|1 Year|17 Years|No|||March 2014|March 25, 2014|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00381355||178347|
NCT00381641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00213|Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery|Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers||National Cancer Institute (NCI)|No|Active, not recruiting|August 2006|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|March 24, 2016|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381641||178327|
NCT00381914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-06-01|Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants|Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants||McGill University|No|Completed|March 2007|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|132|||Both|N/A|5 Weeks|Accepts Healthy Volunteers|||March 2012|March 1, 2012|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00381914||178307|
NCT00368641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25885|Heart Failure and Peritoneal Ultrafiltration|Treatment-Resistant Heart Failure (HF) and Peritoneal Ultrafiltration (PUF): A Randomized Prospective Trial of Standard Care Versus Standard Care With Peritoneal Ultrafiltration in Patients With Treatment-Resistant Severe Heart Failure||Baxter Healthcare Corporation|No|Terminated|August 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2009|April 30, 2009|August 23, 2006|Yes|Yes|Enrollment|No|April 30, 2009|https://clinicaltrials.gov/show/NCT00368641||179309|The number of subjects enrolled & duration of therapy were insufficient to complete the planned efficacy analyses & to draw any conclusion regarding all-cause hospitalization rates in both intervention and standard therapy arms.
NCT00368901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010215|STAAR-2 Clinical Study|A Multicenter Study Using Once Every Other Week Subcutaneous Administration of Aranesp™ (Darbepoetin Alfa) and Iron Guided Algorithms to Treat Subjects With Anemia of Chronic Renal Insufficiency (CRI)||Amgen||Completed|January 2002|May 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|618|||Both|18 Years|N/A|No|||March 2010|March 4, 2010|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00368901||179289|
NCT00368914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0402, CDR0000491204|Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors|Pharmacodynamic-Guided Dose Finding Study of Rapamycin (Rapamune®, Sirolimus) in Adult Patients With Solid Tumors||Sidney Kimmel Comprehensive Cancer Center||Completed|December 2004|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00368914||179288|
NCT00382447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC# 26168|Breath Actuated Nebulizer Study Protocol|Breath Actuated Nebulizer Study Protocol||Christiana Care Health Services|Yes|Withdrawn|October 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|September 27, 2006||No|Unable to put forth the human resources for patient enrollment|No||https://clinicaltrials.gov/show/NCT00382447||178267|
NCT00382460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV123-229|Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)|Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)||Bristol-Myers Squibb||Completed|November 2000|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||4000|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|September 27, 2006||||||https://clinicaltrials.gov/show/NCT00382460||178266|
NCT00382772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107876|A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).|Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-dose Primary Vaccination.||GlaxoSmithKline||Completed|November 2006|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||1200|||Both|11 Weeks|17 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00382772||178242|
NCT00383396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1963|Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|N/A|N/A||||February 2007|February 12, 2007|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00383396||178194|
NCT00383097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19275|Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma|Administration of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma or Chronic Active EBV Infection (ALDI)|ALDI|Baylor College of Medicine|Yes|Terminated|September 2006|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||May 2012|May 22, 2012|September 28, 2006|Yes|Yes|The trial was terminated in 2010 due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00383097||178217|
NCT00384267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0119|Congenital and Neonatal Malaria in Mali|Congenital and Neonatal Malaria in Mali||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|44|Samples Without DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|A cross-sectional analysis of 300 inpatient neonates of both sexes who weigh at least        2000g, are 0 - 28 days old and are referred to the Unit of Reanimation and Neonatology of        Hopital Gabriel Toure, Bamako, Mali|September 2008|November 10, 2011|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00384267||178127|
NCT00384280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-110|Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796|An Open Label, 2-period, Sequential Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2009|October 3, 2006||||||https://clinicaltrials.gov/show/NCT00384280||178126|
NCT00384540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3660|Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling|Allograft Vasculopathy After Heart Transplantation : Diagnostic Interest of Dobutamine Stress Echocardiography and Brain Natriuretic Peptide Coupling||University Hospital, Strasbourg, France||Active, not recruiting|September 2006|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00384540||178106|
NCT00384761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024767a|Predictive Medicine Research|Predictive Medicine Research: Investigation of Predictors of Health, Sub-clinical and Clinical Organ System Disease||Emory University||Completed|March 2006|October 2010|Actual|October 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|223|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Individuals between ages 20-90|November 2013|November 15, 2013|October 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00384761||178089|
NCT00383942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109040|Cervical Ripening Interventions|Ripening Interventions: Prostaglandins vs. EASI Catheter||Loyola University||Terminated|July 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|N/A|No|||November 2011|November 30, 2011|October 2, 2006||No|Change in treatment plan for this population halted enrollment and project was terminated.|No||https://clinicaltrials.gov/show/NCT00383942||178152|
NCT00383903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/013|Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa|A Phase II, Randomized, Double-blind, Placebo-controlled Study of Safety, Reactogenicity and Immunogenicity of 2 or 3 Doses of GSK Bios' Oral Live Attenuated Human Rotavirus Vaccine at 106.5 CCID50 Viral Concentration in Healthy Infants (Approximately 5-10 Weeks Old) in the Republic of South Africa||GlaxoSmithKline||Completed|September 2003|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|472|||Both|5 Weeks|10 Weeks|Accepts Healthy Volunteers|||January 2013|January 30, 2013|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383903||178155|
NCT00383916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B1-119|Study Comparing 2 Different Formulations of Pantoprazole in Healthy Adults.|An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between the Altana Formulation of Pantoprazole Delayed-Release Granules and the Wyeth Formulation of Pantoprazole Delayed-Release Granules in Healthy Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2006|October 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2007|March 7, 2007|October 2, 2006||||||https://clinicaltrials.gov/show/NCT00383916||178154|
NCT00384176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00013|First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX|A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer|HORIZON III|AstraZeneca||Active, not recruiting|August 2006|December 2015|Anticipated|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1814|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|October 3, 2006|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00384176||178134|
NCT00384189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-209|A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma (6-11 y) (BY9010/M1-209)|A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma||Takeda|No|Completed|October 2006|June 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|1050|||Both|6 Years|11 Years|No|||July 2008|May 4, 2012|October 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384189||178133|
NCT00384462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA140|Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants|A Prospective, Non-Interventional Study to Evaluate the Incidence of Hospitalizations and Medically-Attended Lower Respiratory Tract Infection (MALRI) in Premature Infants 32 to 35 Weeks Gestational Age Who Are Not Recommended to Receive Prophylaxis for RSV||MedImmune LLC|No|Completed|October 2006|January 2008|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|346|||Both|1 Month|6 Months|No|Non-Probability Sample|2 cohorts of premature infants and premature newborns 32-35 weeks|February 2009|February 3, 2009|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00384462||178112|
NCT00384722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0011|EASYTRAK 3 Downsize Lead|EASYTRAK® 3 Downsize Lead Clinical Investigation||Boston Scientific Corporation||Completed|March 2006|May 2008|Actual|July 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||June 2009|June 23, 2009|October 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384722||178092|
NCT00384709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gerivsnot|Geriatric Education and Its Effect on Certain Aspects of Hospital Care of Nursing Home Patients|Geriatric Education and Its Effect on Certain Aspects of Hospital Care of the Nursing Home Patients||Maimonides Medical Center||Completed|September 2006|October 2007|Actual|||N/A|Observational|N/A||1|||||Both|N/A|N/A||Non-Probability Sample|- All patients admitted to Maimonides Medical Center (MMC) from affiliated Metropolitan        Jewish Geriatric Nursing Home (MJGNH) for a 3 month period.|August 2011|August 17, 2011|October 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00384709||178093|
NCT00381368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20115|Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients|Phase II Open Label Study to Establish the Safety and Efficacy of Intravenous Loading Dose of Ibandronate 6 mg in 3 Consecutive Days in Breast Cancer Patients With Skeletal Metastases||University of Turku||Recruiting|October 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||November 2006|December 1, 2006|September 25, 2006||||No||https://clinicaltrials.gov/show/NCT00381368||178346|
NCT00381680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL0433|Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia|Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies||Children's Oncology Group|Yes|Active, not recruiting|March 2007|||March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|275|||Both|1 Year|29 Years|No|||March 2016|March 18, 2016|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381680||178324|
NCT00381693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000503972|Azacitidine in Treating Patients With Myelofibrosis|Phase II Study of Azacitidine in Myelofibrosis||Mayo Clinic|Yes|Terminated|August 2006|April 2009|Actual|March 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|September 26, 2006|Yes|Yes|Due to lack of accrual and trial has demonstrated too little clinical benefit|No|November 9, 2010|https://clinicaltrials.gov/show/NCT00381693||178323|
NCT00381654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-412-06-101|Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies|A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies||AVEO Pharmaceuticals, Inc.|No|Terminated|October 2006|February 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||September 2011|September 30, 2011|September 27, 2006|No|Yes|Study did not meet pre-specified objectives.|No||https://clinicaltrials.gov/show/NCT00381654||178326|
NCT00381667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C104604|Study to Assess GW642444 in Asthma Patients|A Randomised, Double-blind, Placebo-controlled, Dose Ascending, Five-way Crossover Study, to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of a Single Administration of Three Inhaled Doses (25, 100 and 400 Âµg) of GW642444M||GlaxoSmithKline||Completed|August 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|14|||Both|18 Years|70 Years|No|||February 2011|May 31, 2012|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381667||178325|
NCT00381927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-159|Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development|Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development||Baystate Medical Center||Completed|August 2003|April 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||80|||Female|18 Years|N/A|No|||September 2006|September 19, 2007|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381927||178306|
NCT00382187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P2|Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults|A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two Surface Antigen Adjuvanted With MF59C.1 Influenza Vaccines Containing 7.5 Micrograms or 15 Micrograms of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 Micrograms of A/H5N1 Influenza Antigen, in Adults||Novartis||Completed|November 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 12, 2012|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00382187||178287|
NCT00369239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002263|Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis|Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?||Janssen Pharmaceutica N.V., Belgium||Completed|March 2006|November 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|303|||Both|18 Years|N/A|No|||April 2010|May 16, 2011|August 25, 2006||||No||https://clinicaltrials.gov/show/NCT00369239||179263|
NCT00369252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB1000-007|Phase I Study of Nimotuzumab in Solid Tumours|A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours||YM BioSciences||Completed|June 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||February 2007|February 27, 2007|August 25, 2006||||No||https://clinicaltrials.gov/show/NCT00369252||179262|
NCT00382486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311041|Low Dose Irradiation for Small Bowel Transplant|Low Dose Ex-Vivo X-Irradiation of the Allograft and Simultaneous Bone Marrow Cell Infusion to Enhance Intestinal/Multivisceral Allograft Survival||University of Pittsburgh||Completed|July 2001|September 2003|Actual|||N/A|Observational|Time Perspective: Prospective||||100|||Both|17 Years|70 Years|No|||December 2007|December 13, 2007|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382486||178264|
NCT00382759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012000|Nonmyeloablative Stem Cell Transplant in Elderly|Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial||Azienda Ospedaliera San Giovanni Battista|No|Completed|March 2000|March 2007|Actual|March 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|60 Years|N/A|No|||July 2009|July 31, 2009|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00382759||178243|
NCT00383682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01HD033990|Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain|Randomized, Placebo-Controlled, Double-Blind Cross-Over Trial of Opioids Versus Mexiletine in the Treatment of Postamputation Pain||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 1997|April 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|85 Years|No|||September 2006|September 29, 2006|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00383682||178172|
NCT00384501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPAGNI-6175|Management of Patients With Keratoconus With Intacs|Intacs for the Treatment of Keratoconus||University Hospital of Crete||Terminated|January 2000|July 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 5, 2006|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00384501||178109|
NCT00383955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078440/Z/05/Z|Comparison of Screening Tools for Coronary Artery Disease|Comparison of Screening Tools for Coronary Artery Disease With Thallium Scintigraphy in Adult Population in Karachi.||Aga Khan University||Recruiting|October 2006|||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||450|||Both|40 Years|80 Years|No|||October 2006|October 3, 2006|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383955||178151|
NCT00384254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA 17972|Tobacco Quitlines:Adjunct to Dental Office Tobacco Intervention|Tobacco Quitlines as an Adjunct to Dental Office Tobacco Intervention||Oregon Research Institute|Yes|Completed|January 2004|January 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2177|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|October 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00384254||178128|
NCT00384826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0504|Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma|Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.||Intergroupe Francophone de Cancerologie Thoracique|No|Completed|September 2006|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00384826||178084|
NCT00384839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05015|Vidaza to Restore Hormone Thx Prostate|Phase II Study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy||US Oncology Research|No|Completed|April 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Male|18 Years|N/A|No|||June 2012|June 13, 2012|October 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00384839||178083|
NCT00385372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBU_PAD_CU_1|Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria|Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria||University Hospital Muenster||Completed|January 2005|April 2007|Actual|January 2007|Actual|N/A|Interventional|N/A||||150|||Both|7 Years|80 Years|No|||February 2007|January 27, 2009|October 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00385372||178043|
NCT00384241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1359|Evaluating the Relationship Between Inflammation, Genetics, and Stress in the Development of High Blood Pressure|Inflammatory Factors, Genes and Stress Induced Pressure Natriuresis in Youth||Georgia Regents University|Yes|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1099|Samples With DNA|Blood samples of 500 subjects have been collected and stored in previous funded studies.      Buccal swabs from 599 biological parents have been collected from the current study.|Both|15 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|15-19 years old African American and European American school children.|May 2015|May 13, 2015|October 4, 2006||No||No|June 21, 2013|https://clinicaltrials.gov/show/NCT00384241||178129|No treatment was given.
NCT00384202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1105|A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients|A Multicenter, Open, Single Sequence Crossover Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, FK506E (MR4), Based Immunosuppressive Regimen in Stable Liver Transplant Patients Converted From a Prograf® Based Immunosuppressive Regimen||Astellas Pharma Inc|Yes|Completed|October 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|October 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00384202||178132|
NCT00384215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4020|Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin|Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin: a Randomized, Open, Parallel Study||Sanofi||Completed|December 2001|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||352|||Both|18 Years|79 Years|No|||January 2011|January 10, 2011|October 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384215||178131|
NCT00384228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A1101|A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL|A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant CML, or Relapse/Refractory Ph+ALL||Novartis||Completed|May 2005|||January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|N/A|No|||April 2012|April 11, 2012|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00384228||178130|
NCT00384748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4492-R|Home-based Telehealth Stroke Care: A Randomized Trial for Veterans|Home-Based Tele-Health Stroke Care: A Randomized Trial for Veterans||VA Office of Research and Development|No|Completed|November 2008|June 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|45 Years|90 Years|No|||November 2014|November 12, 2014|October 3, 2006||No||No|October 22, 2014|https://clinicaltrials.gov/show/NCT00384748||178090|
NCT00385073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126/05|Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson’s Disease|Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson’s Disease||Austin Health||Recruiting|April 2005|December 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||30|||Both|N/A|N/A|No|||October 2006|October 5, 2006|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00385073||178066|
NCT00384735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOSS|An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial|An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial|TOSS|Terry Fox Foundation|Yes|Active, not recruiting|January 2006|June 2015|Anticipated|June 2010|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|500|||Both|1 Year|65 Years|No|Non-Probability Sample|Patients operated for primary or recurrent extremity bone & soft tissue sarcomas|November 2014|November 13, 2014|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00384735||178091|
NCT00385606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECO|GECO: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced Non-Small Cell Lung Cancer|Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polychemotherapy With Cisplatin and Gemcitabine and the Fixed Dose Rate Infusion of Gemcitabine in Association With Cisplatin in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer||National Cancer Institute, Naples||Completed|January 2003|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||400|||Both|18 Years|70 Years|No|||August 2007|August 22, 2007|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00385606||178026|
NCT00385632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 065A|Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants|Quality of Life and Healthcare Utilization Substudy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2002|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1224|||Both|13 Years|N/A|No|Non-Probability Sample|Participants using conservation and viral suppression ART treatment regimens|April 2014|April 16, 2014|October 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00385632||178025|
NCT00382226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-05-10|IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy|IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy||Alcon Research||Completed|September 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|195|||Both|18 Years|N/A|No|||April 2008|April 7, 2012|September 27, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00382226||178284|
NCT00382525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1 April 25th, 2005|PANORAMA Observational Study|Phase IV Long Term Observational Study of Patients Implanted With Medtronic CRDM Implantable Cardiac Devices||Medtronic Bakken Research Center|No|Completed|January 2005|March 2013|Actual|October 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8586|||Both|N/A|N/A|No|Non-Probability Sample|Patients receiving market released Medtronic Cardiac Rhythm device, worldwide|April 2013|April 8, 2013|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382525||178261|
NCT00382837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0005|Study of Epratuzumab in Systemic Lupus Erythematosus|A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems||UCB Pharma||Withdrawn|January 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2007|May 20, 2014|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00382837||178237|
NCT00381940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01063|Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy|A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease||National Cancer Institute (NCI)||Completed|January 2007|||June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|29 Years|No|||June 2014|June 18, 2014|September 26, 2006|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00381940||178305|
NCT00382213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-422 AIMS|A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis|A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis||Daiichi Sankyo Inc.||Completed|June 2000|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|18 Years|N/A|No|||September 2006|September 27, 2006|September 27, 2006||||||https://clinicaltrials.gov/show/NCT00382213||178285|
NCT00370058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECT and Homocysteine|Study on the Influence of Electroconvulsive Therapy (ECT) on Homocysteine Levels|Modulation of Homocysteine-Plasma Levels by ECT - Association With Clinical Response. A Pilot Study in Patients With Major Depression||University of Erlangen-Nürnberg Medical School||Completed|August 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|80 Years|No|||December 2007|July 9, 2008|August 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00370058||179202|
NCT00383110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP 82-001|Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes|Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes||VA Office of Research and Development|No|Completed|November 2004|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|equal number of White and Black Americans over the age of 18 with Type II diabetes|June 2014|April 6, 2015|September 28, 2006||No||No|August 4, 2014|https://clinicaltrials.gov/show/NCT00383110||178216|
NCT00383383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/042|Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years|To Compare the Immunogenicity & Safety of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B, in Pre-Haemodialysis/Haemodialysis Patients (≥15 Years of Age)||GlaxoSmithKline||Completed|December 1999|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||141|||Both|15 Years|N/A|No|||October 2006|October 2, 2006|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383383||178195|
NCT00384514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-001|EPC by Intracoronary Injection in Patients With Chronic Stable Angina|A Study for Testing Safety and Efficacy of the Administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients With Severe Anginal Syndrome||TheraVitae Ltd.||Active, not recruiting|July 2004|September 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|80 Years|No|||October 2006|October 19, 2006|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00384514||178108|
NCT00384527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-3032|Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease|Multicenter, Double-blind Study of Nitazoxanide Compared to Vancomycin in the Treatment of Clostridium Difficile-associated Disease||Romark Laboratories L.C.|No|Terminated|December 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||October 2008|May 4, 2015|October 5, 2006|Yes|Yes|Study was terminated early due to slow recruitment.|No||https://clinicaltrials.gov/show/NCT00384527||178107|
NCT00383994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0234|Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation|Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2006|||September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||March 2016|March 2, 2016|October 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00383994||178148|
NCT00384774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL MIG-201|A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine|A Placebo-Controlled, Group Sequential, Adaptive Treatment Assignment Study of Intravenous COL-144 (LY573144) in the Acute Treatment of Migraine||CoLucid Pharmaceuticals||Completed|October 2006|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|65 Years|No|||December 2008|December 4, 2008|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384774||178088|
NCT00384787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 069|Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults|A Phase Ib Clinical Trial to Compare the Safety, Tolerability, and Immunogenicity of an HIV-1 Adenoviral Vector Boost Administered Intramuscularly, Intradermally, or Subcutaneously After an HIV-1 DNA Plasmid Vaccine Prime Administered Intramuscularly to Healthy Adenovirus Type 5 Seropositive HIV-1-Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2006|December 2012|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|October 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00384787||178087|
NCT00353353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/02|The Bread Trial: Effects of Bread Fortified With Folic Acid and Vitamin B12|The Bread Trial: a Demonstration Trial to Show Effects of Fortification of Food With Both Folic Acid and Vitamin B12||Wageningen University|No|Completed|July 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|150|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||July 2007|July 6, 2007|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353353||180455|
NCT00385086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050312|Lumbar Spinal Fibrosis and TNF Alpha Inhibition|Efficacy of TNF-alpha Inhibition in Sciatica With Post-operative Lumbar Spinal Fibrosis||Assistance Publique - Hôpitaux de Paris|No|Completed|February 2007|December 2014|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00385086||178065|
NCT00385099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI103143|Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome|A Phase IIa, Single-centre, Randomised, Placebo-controlled, Double-blind, Three-period Crossover Study Investigating the Effects on Gut Autonomic Responses of Single Administrations of Either 20 mg or 200 mg GW876008, a CRF1 Antagonist, to Adult Patients With Irritable Bowel Syndrome||GlaxoSmithKline||Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|10|||Both|18 Years|65 Years|No|||July 2009|July 22, 2009|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00385099||178064|
NCT00384800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-94037|A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)|||Far Eastern Memorial Hospital||Recruiting|September 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||March 2006|February 6, 2009|October 4, 2006||||No||https://clinicaltrials.gov/show/NCT00384800||178086|
NCT00385112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000124|Follow Up on Freestyle Valves in Children|Follow Up on Freestyle Valves for Right Ventricular Outflow Tract Reconstruction in Children||Emory University|No|Active, not recruiting|November 2006|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|8 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients that have received the Medtronic Freestyle® porcine aortic root for right        ventricular outflow tract reconstruction that have not had a standard of care        echocardiogram performed in the last 12 months.|March 2016|March 3, 2016|October 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00385112||178063|
NCT00384475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-413|A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older||Takeda||Completed|October 2006|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||June 2011|May 4, 2012|October 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00384475||178111|
NCT00381706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-80403|Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer|Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|September 2006|||December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|245|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381706||178322|
NCT00381719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203818-004|Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy|||Allergan||Completed|October 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|330|||Both|18 Years|N/A|No|||December 2007|January 3, 2008|September 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00381719||178321|
NCT00381732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7019|A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction|A Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5mg and 5mg) Administered Once Daily to Men With Erectile Dysfunction||Eli Lilly and Company|No|Completed|October 2003|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|280|||Male|18 Years|N/A|No|||November 2007|November 6, 2007|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381732||178320|
NCT00381953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV02-01|High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV|A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV||Foundation for Liver Research|No|Completed|February 2003|July 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|70 Years|No|||March 2015|March 12, 2015|September 27, 2006||||No||https://clinicaltrials.gov/show/NCT00381953||178304|
NCT00381966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0511|Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy|A Pilot Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy|J0511|Sidney Kimmel Comprehensive Cancer Center||Completed|June 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5|||Male|18 Years|N/A|No|||November 2012|November 15, 2012|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00381966||178303|
NCT00382239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-JE-GWAV|A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes|A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled||AstraZeneca|No|Completed|September 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|153|||Both|20 Years|75 Years|No|||January 2015|February 20, 2015|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382239||178283|
NCT00382265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71603 (completed)|Tamsulosin for Urolithiasis in the Emergency Dept|Study of Tamsulosin for Urolithiasis in the Emergency Department|STONE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|January 2008|||August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382265||178281|
NCT00382278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELTHEP-01|Safety Study of Autologous Stem Cell in Liver Cirrhosis|Phase 1/2 Study of Autologous Bone Marrow Derived Mononuclear Cells in Liver Cirrhosis||Universidade Federal do Rio de Janeiro|Yes|Terminated|November 2005|February 2008|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||February 2008|April 2, 2008|September 28, 2006||No|Other authors showed the same metabolic effect may be obtained when BMMC are delivered    peripherally, with lower risk and cost than through hepatic artery.|No||https://clinicaltrials.gov/show/NCT00382278||178280|
NCT00382499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2006512-01H|Intraoperative Lidocaine Infusion for Analgesia (ILIA)|A Prospective Evaluation of the Addition of Intraoperative Intravenous Lidocaine Infusion to General Anesthetic in Total Abdominal Hysterectomy.||University of Ottawa|No|Completed|November 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|93|||Female|30 Years|70 Years|No|||September 2009|September 9, 2009|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382499||178263|
NCT00382512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD2244g|A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis|A Randomized, Placebo-Controlled, Single-Blind, Parallel-Group Study to Evaluate the Effects of 12 Weekly Subcutaneous Doses of 1.0 mg/kg Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis||Genentech, Inc.||Completed|May 2003|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years|No|||September 2006|September 27, 2006|September 27, 2006||||||https://clinicaltrials.gov/show/NCT00382512||178262|
NCT00382811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV06-0039|OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer|Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy|OVATURE|MEI Pharma, Inc.||Completed|October 2006|April 2011|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Female|18 Years|N/A|No|||February 2012|February 23, 2012|September 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382811||178239|
NCT00382824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LaheyC|Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)|Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study||Lahey Clinic|No|Completed|September 2006|January 2015|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|62|||Both|30 Years|N/A|No|||August 2015|August 4, 2015|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382824||178238|
NCT00383123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104858|Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children|A Phase III, Single-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix® (GSK Biologicals) Compared With Fluzone® (Aventis Pasteur/Sanofi) Administered Intramuscularly in Children (6 Months and Older)||GlaxoSmithKline||Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|3327|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||December 2011|December 15, 2011|September 29, 2006|Yes|Yes||No|October 15, 2008|https://clinicaltrials.gov/show/NCT00383123||178215|
NCT00369590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00677|VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide|Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas||National Cancer Institute (NCI)|Yes|Completed|August 2006|October 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 24, 2006|Yes|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT00369590||179238|
NCT00383968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06GS009CHS|Prevalence of Chronic KIdney Disease in Hypertensive Patients|Prevalence of Chronic KIdney Disease in Hypertensive Patients||Aga Khan University||Recruiting|October 2006|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||248|||Both|40 Years|80 Years|No|||October 2006|October 3, 2006|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383968||178150|
NCT00383981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-950067|Lipid Peroxidation in Workers Exposed to Al,Ga,In,As,and Sb in Optoelectronic Industry|||Kaohsiung Medical University Chung-Ho Memorial Hospital||Completed|March 2003|December 2003||||Phase 1|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional||||170|||Both|22 Years|45 Years|Accepts Healthy Volunteers|||April 2006|October 3, 2006|October 3, 2006||||No||https://clinicaltrials.gov/show/NCT00383981||178149|
NCT00384293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-041|Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)|A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK0524A 2g Coadministered With Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Media Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (heFH)|ACHIEVE|Merck Sharp & Dohme Corp.||Terminated|September 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|937|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|October 3, 2006|Yes|Yes||No|July 23, 2009|https://clinicaltrials.gov/show/NCT00384293||178125|After a detailed review of pooled carotid IMT data from contemporary studies, the Steering Committee recommended that Merck prematurely stop the study; as designed, the study was significantly underpowered. Efficacy analyses were not performed.
NCT00384553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSHO #071|Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma|Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma||University of Magdeburg||Recruiting|June 2004|June 2010||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||October 2006|October 5, 2006|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00384553||178105|
NCT00350298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-GCDX-06-02|Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease|A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease||University of Massachusetts, Worcester|Yes|Completed|July 2006|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||October 2010|October 26, 2010|July 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00350298||180683|
NCT00384813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-2006|Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma|Project ASPIRE: Improving Pediatric Asthma Management for Urban Families|ASPIRE|Emory University|Yes|Completed|January 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|8 Years|13 Years|No|||July 2014|July 3, 2014|October 3, 2006||No||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00384813||178085|
NCT00385359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA-01|A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control|A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma||University Health Network, Toronto||Recruiting|October 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|60 Years|No|||October 2006|October 6, 2006|October 6, 2006||||No||https://clinicaltrials.gov/show/NCT00385359||178044|
NCT00385645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATEM-PEP|Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis|Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study||Hospital Clinic of Barcelona||Completed|May 2006|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|255|||Both|18 Years|N/A|No|||March 2010|March 30, 2010|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00385645||178024|
NCT00385658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BDE35|Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome|A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome||Novartis||Completed|August 2006|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|75|||Both|18 Years|75 Years||||November 2011|November 7, 2011|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00385658||178023|
NCT00381381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKI-6-004|The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease|A Multi-center Study for the Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease||Eisai Inc.||Completed|May 2006|December 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|199|||Both|60 Years|90 Years|No|||July 2010|August 23, 2012|September 25, 2006||No||No|August 3, 2010|https://clinicaltrials.gov/show/NCT00381381||178345|
NCT00381394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STQ105938|A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.|A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas.||GlaxoSmithKline|No|Completed|August 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|16 Years|50 Years|No|||February 2011|May 31, 2012|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381394||178344|
NCT00381758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD00600|The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting|A Randomized, Double-Blind Comparison of the Time Course of Response to Two Extended-Release Oral Delivery Systems for Methylphenidate in Pediatric Patients With Attention Deficit Hyperactivity Disorder in an Analog Classroom Setting: The CoMACS Study||UCB Pharma||Completed|May 2002|August 2002|Actual|August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||184|||Both|6 Years|12 Years|No|||March 2008|March 7, 2008|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381758||178319|
NCT00381979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169/2003|Supportive Expressive Therapy for Depressed and Anxious Adolescents|Supportive Expressive Therapy for Depressed and Anxious Adolescents||Centre for Addiction and Mental Health|No|Completed|January 2004|October 2007|Actual|October 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|15 Years|24 Years|No|||September 2015|October 21, 2015|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381979||178302|
NCT00382252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510046|PET Scan and CT Scan in Evaluating Response in Patients Undergoing Radiofrequency Ablation for Lung Metastases|Study of Positron Emission Tomography/CT Scan for Response Evaluation After Radiofrequency Ablation in Patients With Lung Metastases||National Cancer Institute (NCI)||Completed|September 2005|||May 2011|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|80|||Both|18 Years|N/A|No|||July 2009|May 12, 2011|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00382252||178282|
NCT00350844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12735|Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension|A Pilot Study of Hydroxyurea for the Treatment of Pulmonary Hypertension in Children and Young Adults With Sickle Cell Disease||Ann & Robert H Lurie Children's Hospital of Chicago|No|Terminated|July 2006|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|10 Years|25 Years|No|||March 2013|March 28, 2013|July 10, 2006|Yes|Yes|Low subject accrual|No|February 18, 2013|https://clinicaltrials.gov/show/NCT00350844||180644|Early termination leading to no data analysis completed.
NCT00350857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD417-311|The Young Adult and Pediatric Bipolar Study|A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder.||Validus Pharmaceuticals||Completed|July 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|10 Years|17 Years|No|||November 2009|February 19, 2014|July 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00350857||180643|
NCT00382850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-08-01-01|Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children|Randomized Controlled Trial of Laparoscopic Compared to Open Nissen Fundoplication in Children Younger Than 2 Years of Age||Johns Hopkins University|Yes|Recruiting|November 2005|November 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||68|||Both|N/A|24 Months|No|||April 2007|April 4, 2007|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00382850||178236|
NCT00382863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200|Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial|Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial|PEERLESS-HF|Paracor Medical, Inc|Yes|Terminated|October 2006|May 2012|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|74 Years|No|||June 2012|June 7, 2012|September 28, 2006|No|Yes|Resources unavailable to continue study follow-up.|No|May 13, 2011|https://clinicaltrials.gov/show/NCT00382863||178235|An interim analysis indicated trial futility based on a primary endpoint. Enrollment was suspended in July, 2009. Study was terminated as of April, 2011 due to insufficient resources.
NCT00383136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FATA|FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab|FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study|FATA|University of Bologna|Yes|Completed|June 2003|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|692|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383136||178214|
NCT00383149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-116|A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer|A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer||R-Pharm|No|Completed|January 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 28, 2006|Yes|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00383149||178213|Study CA163-116 was completed; however, the combination tested in this trial failed to meet the primary objective to demonstrate a 6-month survival rate greater than 50% in participants with metastatic pancreatic cancer.
NCT00383435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04229|Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)|A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD||Merck Sharp & Dohme Corp.|Yes|Completed|October 2006|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1055|||Both|40 Years|N/A|No|||September 2015|September 2, 2015|September 29, 2006|Yes|Yes||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00383435||178191|
NCT00401570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M200-1205|A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer|Phase 2 Open-Label Study of Volociximab (M200) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer Not Previously Treated With Chemotherapy||AbbVie||Completed|March 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|November 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401570||176829|
NCT00401869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012205|The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)|The Effect of PROCRIT on Hemoglobin and Hematocrit and the Relationship to Postoperative Function, Vigor and Strength in Patients Undergoing Primary Total Joint Arthroplasty: A Randomized, Parallel Group, Open-Label Trial||Ortho Biotech Clinical Affairs, L.L.C.||Completed|February 1999|December 2001|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|289|||Both|18 Years|N/A|No|||April 2010|April 5, 2010|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401869||176806|
NCT00383708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-55-52030-727|Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients|Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone||Ipsen|No|Completed|October 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|75 Years|No|||June 2012|June 18, 2012|October 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00383708||178170|
NCT00352742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN-224-007|A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma|A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib||Attenuon||Terminated|June 2006|December 2008|Anticipated|September 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||October 2008|October 27, 2008|July 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352742||180500|
NCT00352755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0312|A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis|A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis||Washington University School of Medicine||Terminated|May 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|July 14, 2006|Yes|Yes|after interim analysis it was determined that the risks were too great in comparision to the    results|No||https://clinicaltrials.gov/show/NCT00352755||180499|
NCT00353041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UToronto|A Study of the Effect of Time on Topical Anesthetic Efficacy.|A Study of the Effect of Time on Topical Anesthetic Efficacy.||University of Toronto||Recruiting|July 2006|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training||||90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2006|July 13, 2006|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00353041||180477|
NCT00349986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4059|LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus|The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients||Sanofi||Terminated|September 2006|||June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|40 Years|65 Years|No|||December 2009|December 4, 2009|July 7, 2006||No|prematurely terminated due to loss of interest|No||https://clinicaltrials.gov/show/NCT00349986||180707|
NCT00381485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04431|Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)|A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously Treated With High-Dose Inhaled Glucocorticosteroids||Merck Sharp & Dohme Corp.|No|Completed|July 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|834|||Both|12 Years|N/A|No|||August 2015|August 20, 2015|September 26, 2006|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00381485||178338|
NCT00381511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A-101657|Deferment of Imaging for Pulmonary Embolism|Objective Assessment of Pulmonary Embolism Can be Deferred Without Increased Risk||Azienda Ospedaliera Universitaria Policlinico||Completed|January 1999|April 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Both|18 Years|N/A|No|||September 2006|October 16, 2006|September 27, 2006||||No||https://clinicaltrials.gov/show/NCT00381511||178337|
NCT00353613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-050570|Prevention of Surgical Site Infections|Prevention of Surgical Site Infections||The University of Texas Health Science Center, Houston||Completed|March 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|900|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|July 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00353613||180435|
NCT00353600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999994034|Delaying the Progression of Diabetic Nephropathy in Pima Indians|Delaying the Progression of Diabetic Nephropathy in Pima Indians||National Institutes of Health Clinical Center (CC)||Completed|August 1994|August 2011||||N/A|Observational|N/A|||Anticipated|25|||Both|18 Years|65 Years|No|||August 2011|August 17, 2011|July 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00353600||180436|
NCT00385671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10822|An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain|An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain||Eli Lilly and Company|No|Completed|September 2006|November 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|407|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|October 6, 2006|Yes|Yes||No|August 23, 2010|https://clinicaltrials.gov/show/NCT00385671||178022|
NCT00385684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4483-I|Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)|Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)|LDOT|VA Office of Research and Development|Yes|Completed|October 2007|June 2014|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|11|||Both|55 Years|N/A|No|||November 2015|November 18, 2015|October 6, 2006||No||No|June 2, 2014|https://clinicaltrials.gov/show/NCT00385684||178021|
NCT00381407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074013|Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder|Organizational Skills Treatment for ADHD Children||New York University School of Medicine|No|Completed|September 2006|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|157|||Both|8 Years|11 Years|No|||April 2013|April 17, 2013|September 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00381407||178343|
NCT00381420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-6307|The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.|A Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Coated BX Velocity Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions.|C-SIRIUS|Cordis Corporation|Yes|Completed|March 2001|June 2008|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2008|October 30, 2008|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00381420||178342|
NCT00381771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2006-01-028|Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus|Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus||Samsung Medical Center|No|Completed|February 2006|December 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|340|||Both|20 Years|75 Years|No|Non-Probability Sample|Globus phryngeus patients (complaining foreign body sensation in the throat, but not        having true mass lesions)|July 2010|July 27, 2010|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00381771||178318|
NCT00381992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060815005|Risk Assessment of Long-Haul Truck Drivers|Risk Assessment of Long-Haul Truck Drivers||Wake Forest School of Medicine|No|Completed|September 2005|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|294|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|American long-haul truck drivers affiliated with participating companies or presenting as        clients at participating truck stops.|December 2014|December 8, 2014|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381992||178301|
NCT00351117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-355|St. John's Wort in the Treatment of Raynaud's Phenomenon|A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon||Lawson Health Research Institute|No|Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|70 Years|No|||July 2009|July 10, 2009|July 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00351117||180623|
NCT00382538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24597|Mifepristone and Mid-Trimester Termination of Pregnancy|A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy||Boston University||Completed|March 2005|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 3, 2008|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382538||178260|
NCT00382551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN-20060043|The Effect of Beer, Red Wine and Fruit Juice on Blood Vessel Function in Persons With Cardiovascular Disease|The Effect of Alcohol and Polyphenolic Compounds on Endothelial Function||Aalborg Universitetshospital||Completed|October 2006|||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|49|||Both|30 Years|80 Years|No|||January 2009|January 29, 2009|September 28, 2006||||No||https://clinicaltrials.gov/show/NCT00382551||178259|
NCT00382876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LKC-01061958|Identifying the Relative Change in Ventilation in Newborns With Placement in Car Bed or Car Seat|Identifying the Relative Change in Ventilation With Changes in Infant Sleeping Position||University Medical Centre Ljubljana||Recruiting|September 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|N/A|2 Days|No|||September 2006|October 16, 2006|September 29, 2006||||No||https://clinicaltrials.gov/show/NCT00382876||178234|
NCT00351611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081096|Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo|Prospective Randomized 12-week Controlled Study Of Visual Field Change In Subjects With Partial Seizures Receiving Pregabalin Or Placebo||Pfizer|No|Recruiting|July 2006|November 2019|Anticipated|November 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|284|||Both|18 Years|65 Years|No|||March 2016|March 7, 2016|July 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00351611||180585|
NCT00351910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00007|Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment|ONYX|AstraZeneca||Completed|May 2006|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|494|||Both|18 Years|65 Years|No|||January 2011|January 25, 2011|July 12, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00351910||180562|
NCT00372216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPAMI|CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction|CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction||Stiftung Institut fuer Herzinfarktforschung|Yes|Completed|October 2006|January 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|337|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|September 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00372216||179040|
NCT00384007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-SJ-1001|A Randomized Trial Comparing SpineJet® Hydrodiscectomy to Open Lumbar Microdiscectomy for Treatment of Lumbar Radiculopathy Due to Disc Herniation|A Randomized Trial Comparing SpineJet® Hydrodiscectomy to Open Lumbar Microdiscectomy for Treatment of Lumbar Radiculopathy Due to Disc Herniation||Pinnacle Pain Medicine||Completed|October 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|58|||Both|18 Years|75 Years|No|||June 2009|June 4, 2009|October 2, 2006||||||https://clinicaltrials.gov/show/NCT00384007||178147|
NCT00353626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4211-UG-CTIL|Gait Evaluation of Experienced Below Knee Amputees|Gait Evaluation of Experienced Post Traumatic Below Knee Amputees||Sheba Medical Center|No|Completed|June 2006|September 2007|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|9|||Both|20 Years|75 Years|No|Non-Probability Sample|Trans tibial amputees without pain or complaints about stump or prosthesis,using their        prosthesis more than 3 months.|March 2008|March 19, 2008|July 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00353626||180434|
NCT00349687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA016131|Practicing Self-Control Lowers the Risk of Smoking Lapse|Practicing Self-Control Lowers the Risk of Smoking Lapse||University at Albany|No|Completed|May 2004|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349687||180730|
NCT00385762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605008515|SSRI Effects on Semen Parameters in Men|Effect of Selective Serotonin Reuptake Inhibitor Antidepressants on Semen Parameters||Weill Medical College of Cornell University||Active, not recruiting|January 2007|September 2007|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|Samples With DNA|Serum samples Semen samples|Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|November 2010|November 4, 2010|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00385762||178015|
NCT00381823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE Study|Healthy Outcomes of Pregnancy Education|Intervention for Risk Factors in Pregnant Women in Washington, D.C. (DC-HOPE)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|July 2001|August 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||1750|||Female|18 Years|N/A|No|||September 2006|September 28, 2006|September 26, 2006||||No||https://clinicaltrials.gov/show/NCT00381823||178314|
NCT00350597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-CSF 040906|GM-CSF as Adjuvant Therapy of Melanoma|Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma.||Northern California Melanoma Center||Completed|September 2004|July 2010||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|14 Years|N/A|No|||July 2006|July 10, 2006|July 10, 2006||||No||https://clinicaltrials.gov/show/NCT00350597||180662|
NCT00353899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060208|Cardiovascular Magnetic Resonance Imaging of Pediatric Normal Volunteers|Cardiovascular Magnetic Resonance Imaging of Pediatric Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|July 2006|||||N/A|Observational|N/A|||Actual|41|||Both|8 Years|21 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|July 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00353899||180413|
NCT00353912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2402|Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension|A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension||Novartis||Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|571|||Both|18 Years|N/A||||November 2011|November 7, 2011|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353912||180412|
NCT00385385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-1648-026|RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease|Randomized Evaluation of Short-Term Rifalazil Treatment on Carotid Atherosclerosis and Intima Media Thickness||ActivBiotics||Recruiting|October 2006|September 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|72|||Both|50 Years|85 Years|No|||April 2007|April 27, 2007|October 6, 2006||||||https://clinicaltrials.gov/show/NCT00385385||178042|
NCT00385697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA031-01|The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus|A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of MGA031, a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus||MacroGenics|Yes|Completed|October 2006|August 2011|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|554|||Both|8 Years|35 Years|No|||August 2012|August 21, 2012|October 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00385697||178020|
NCT00385710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/10-H|Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)|Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy||Nantes University Hospital||Completed|November 2006|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|45 Years|75 Years|No|||May 2011|November 2, 2012|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00385710||178019|
NCT00349934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P005|IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma|IMP321 Phase I Study in Metastatic Breast Carcinoma Patients Receiving First-line Paclitaxel||Immutep S.A.|No|Completed|July 2006|January 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00349934||180711|
NCT00349947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391|Exercise Therapy to Treat Adults With Abdominal Aortic Aneurysms|Abdominal Aortic Aneurysms: Simple Treatment or Prevention (AAA: STOP)|AAA:STOP|Stanford University|Yes|Completed|November 2006|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2400|||Both|50 Years|N/A|No|||June 2013|June 5, 2013|July 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00349947||180710|
NCT00349960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3025|Epoetin Dosing Regimens in Haemodialysis|Once-Weekly Versus Once-Fortnightly Subcutaneous Epoetin Beta Administration in the Maintenance Phase of Anaemia Treatment in Haemodialyzed Patients||Romanian Society of Nephrology||Completed|March 2004|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|90 Years|No|||February 2006|July 6, 2006|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349960||180709|
NCT00350233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM002|MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors|MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors||InSightec||Completed|May 2006|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|July 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00350233||180688|
NCT00350246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66-04|Long-term Effects of Laser Refractive Surgery|Long-term Effects of Laser Refractive Surgery||Mayo Clinic||Completed|July 2004|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|62|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 27, 2010|July 7, 2006||||No||https://clinicaltrials.gov/show/NCT00350246||180687|
NCT00350259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-001-US-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2006|||||N/A|N/A|N/A||||||||||||||April 29, 2008|July 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00350259||180686|
NCT00350272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-015|Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects|A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.||Achillion Pharmaceuticals|Yes|Completed|May 2006|April 2009|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|60 Years|No|||February 2016|February 22, 2016|July 6, 2006|Yes|Yes||No|February 22, 2016|https://clinicaltrials.gov/show/NCT00350272||180685|
NCT00350532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01NS041386_TRIAL2|Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain|Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain||Wake Forest School of Medicine|Yes|Completed|September 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 5, 2014|July 5, 2006|Yes|Yes||No|March 23, 2009|https://clinicaltrials.gov/show/NCT00350532||180666|
NCT00350545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT177|A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease|A Phase II Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease||Stanford University|Yes|Active, not recruiting|August 2006|June 2014|Anticipated|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|1 Year|75 Years|No|||December 2013|December 12, 2013|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00350545||180665|
NCT00350571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101010101|Brief Interventions for Drop-out Re-engagement|Adaptive Brief Interventions for Drop-out Re-engagement||Yale University|Yes|Completed|November 2004|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|299|||Both|18 Years|65 Years|No|||September 2014|September 16, 2014|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350571||180664|
NCT00383760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00173|Eribulin Mesylate as Second-Line Therapy in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer|A Phase II Study of the Halichondrin B Analog E7389 as Second Line Therapy for Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer||National Cancer Institute (NCI)||Completed|August 2006|||July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383760||178166|
NCT00351104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3269-301|Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Ankle Sprain or Strain|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Grade 1 or Grade 2 Ankle Sprain or Strain||Endo Pharmaceuticals||Completed|June 2006|March 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00351104||180624|
NCT00351325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-004|A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies|A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies||Bristol-Myers Squibb|No|Terminated|September 2007|March 2009|Anticipated|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||September 2009|September 3, 2009|July 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00351325||180607|
NCT00351338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chayas-HMO-CTIL|Nutritional Deficiencies in the Bariatric Patients|Preoperative Nutritional Deficiencies in the Bariatric Surgery Patients||Hadassah Medical Organization||Recruiting|July 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||July 2006|April 10, 2007|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351338||180606|
NCT00351923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106670|Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes|Open, Multicenter, Randomised, Controlled Phase IIIb Study Evaluating the Immunogenicity and Safety of Subcutaneous Versus Alternative Administration Route of Combined MeMuRu-OKA Vaccine to Healthy Children Aged 11 to 21 Months.||GlaxoSmithKline||Completed|March 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||330|||Both|11 Months|22 Months|Accepts Healthy Volunteers|||October 2008|October 9, 2008|July 12, 2006||||No||https://clinicaltrials.gov/show/NCT00351923||180561|
NCT00352768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S114.3.118|Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents|SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study||Solvay Pharmaceuticals|Yes|Terminated|August 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|18 Years|No|||March 2010|March 3, 2010|July 14, 2006||No|This study was prematurely terminated (26 June 2009) due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00352768||180498|
NCT00353054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-02-01|Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.|A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Calcium/Vitamin D Supplementation (Caltrate 600+ D) on Body Weight and Fat Loss in Overweight and Obese Individuals on a Weight-Reducing Program.||Laval University||Completed|January 2003|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||November 2002|July 14, 2006|July 14, 2006||||No||https://clinicaltrials.gov/show/NCT00353054||180476|
NCT00352469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET408|Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety|12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety||Creighton University|Yes|Completed|February 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|65 Years|No|||December 2008|December 5, 2008|July 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00352469||180521|
NCT00385437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-03-0255-A|Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder|Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder||University Health Network, Toronto||Completed|April 2003|June 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|25 Years|50 Years|No|||February 2006|October 5, 2006|October 5, 2006||||No||https://clinicaltrials.gov/show/NCT00385437||178039|
NCT00381524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040223020|HIV Prevention in the Primary Care Setting|Special Projects of National Significance||University of Alabama at Birmingham||Completed|June 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|234|||Male|18 Years|N/A|No|||November 2009|November 12, 2009|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00381524||178336|
NCT00381537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99NR58|Prediction of Childhood Epilepsy Outcome in Bangladesh|||Institute of Child Health||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||92|||Both|2 Years|16 Years|No|||December 2006|December 22, 2006|September 27, 2006||||No||https://clinicaltrials.gov/show/NCT00381537||178335|
NCT00382356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVODART-550-04|Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)|A Pilot Investigation of Dutasteride (Avodart) After Failure of Finasteride (Proscar) In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)||North Florida/South Georgia Veterans Health System|Yes|Completed|November 2004|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|50 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 18, 2012|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382356||178274|
NCT00382369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOCALCORD-HMO-CTIL|Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis|Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis||Hadassah Medical Organization|No|Recruiting|May 2005|December 2007|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|DNA prepared from blood|Both|10 Years|N/A|No|Probability Sample|Families suffering of familial vocal cord paralysis|November 2007|May 12, 2008|September 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00382369||178273|
NCT00381797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01090|Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma|Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2006|||December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|N/A|21 Years|No|||December 2015|January 11, 2016|September 26, 2006|Yes|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT00381797||178316|Neuroimaging data capturing Volume Enhancing and Perfusion Ratio was so limited to run any statistical model. Similarly, due to limited data, some PK and Biology objectives were not able to be addressed.
NCT00381810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3389g|A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus|An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g|VOYAGER|Genentech, Inc.||Terminated|June 2006|February 2012|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|16 Years|75 Years|No|||March 2015|March 24, 2015|September 26, 2006|Yes|Yes|During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended    that enrollment in this extension trial be terminated.|No|November 11, 2009|https://clinicaltrials.gov/show/NCT00381810||178315|Since study U2971g did not demonstrate efficacy, a decision was made not to evaluate efficacy in this study and only safety results were evaluated.
NCT00382044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-06-10|Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients|Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience||Sir Charles Gairdner Hospital|No|Completed|September 2006|April 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|N/A|N/A|No|||May 2008|May 22, 2008|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00382044||178298|
NCT00350883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804915|Cognitive Therapy for Negative Symptoms and Functioning|Cognitive Therapy for Negative Symptoms and Functioning||University of Pennsylvania|Yes|Completed|July 2006|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||May 2012|May 2, 2012|July 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00350883||180641|
NCT00382577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITOLES06-01|Efficacy and Safety of Itopride vs Placebo in Heartburn|A Randomized, Double-Blind, Two Period, Crossover Study to Evaluate the Effects of a Single Dose of Itopride 200 mg on Esophageal and Gastric pH and Reflux in Patients With Heartburn||Axcan Pharma|No|Completed|October 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|70 Years|No|||May 2007|May 2, 2007|September 27, 2006||||No||https://clinicaltrials.gov/show/NCT00382577||178257|
NCT00353886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNEAD|Study of Antiepileptic Drug Effects on Child Development|Retrospective Study of In Utero Antiepileptic Drug Effects in Neurodevelopment||Georgia Regents University||Completed|September 2002|June 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|81|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||July 2007|July 19, 2007|July 17, 2006||||No||https://clinicaltrials.gov/show/NCT00353886||180414|
NCT00349661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCLA|Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel|Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel Associated To Aspirin: Double-Blind Randomized Trial Against Placebo||University Hospital, Brest||Completed|June 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|85 Years|No|||August 2008|August 22, 2008|July 6, 2006||||No||https://clinicaltrials.gov/show/NCT00349661||180732|
NCT00350285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-8666-G-05|The Teen Marijuana Check-Up|Reaching and Motivating Change in Teen Marijuana Smokers|TMCU3|University of Washington|No|Completed|September 2004|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|310|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||October 2008|October 21, 2008|July 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00350285||180684|
NCT00350584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telehealth for PTSD Symptoms|Evaluation of Telehealth Interventions for Post-Trauma Stress|Evaluation of Two Telehealth Interventions Targeting Post-Trauma Stress in Combat Veterans: Comparing Mindfulness and Psychoeducation||VA Boston Healthcare System|No|Completed|February 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||January 2009|July 28, 2011|July 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00350584||180663|
NCT00350870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408026992|CBT With Disulfiram and Contingency Management|Maximizing the Efficacy of Cognitive Behavioral Therapy With Medication and Contingency Management||Yale University|Yes|Completed|April 2005|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|181|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|July 7, 2006|Yes|Yes||No|November 12, 2014|https://clinicaltrials.gov/show/NCT00350870||180642|
NCT00384046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005108|Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen|24-Week Study to Evaluate the Efficacy/Safety of Transdermal Testosterone in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen Therapy.||Warner Chilcott|No|Completed|November 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|272|||Female|40 Years|70 Years|No|||April 2013|April 15, 2013|October 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384046||178144|
NCT00384059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-007|Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|286|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||January 2013|January 22, 2013|October 2, 2006|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00384059||178143|
NCT00351351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-035|Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy|Randomized Control Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy||Indiana Kidney Stone Institute|No|Completed|July 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|July 11, 2006||No||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00351351||180605|Multiple surgeons were involved,thus subtle differences in PCNL technique existed between sites. Some surgeons may have defined the stone removal time differently.
NCT00351624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Martek #2006-1008|Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in Preschool Children||DSM Nutritional Products, Inc.||Completed|May 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|216|||Both|4 Years|4 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|July 11, 2006||||No||https://clinicaltrials.gov/show/NCT00351624||180584|
NCT00384579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI P05-71031|Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain|Pilot Study to Assess the Efficacy of Botulinum Toxin B (Myobloc®) Treatment of Paravertebral Muscles on Pain and Disability in Subjects Suffering From Acute Low Back Pain||Walter Reed Army Medical Center|Yes|Terminated|February 2008|August 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2010|March 1, 2010|October 4, 2006||No|No eligible candidates in 2 years of recruiting|No||https://clinicaltrials.gov/show/NCT00384579||178103|
NCT00384891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102.1|Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer|A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)||Medical Enterprises Europe B.V.||Terminated|February 2002|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|N/A|No|||October 2014|October 5, 2014|October 5, 2006||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00384891||178079|
NCT00384904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-328|Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients|Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine With or Without Tenofovir on the Pharmacokinetics of Atazanavir When Given With Ritonavir in HIV-Infected Subjects||Bristol-Myers Squibb|No|Completed|December 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|40|||Both|18 Years|65 Years|No|||November 2008|February 3, 2010|October 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00384904||178078|
NCT00353067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG-031-CV-301|Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study).||deCODE genetics||Suspended|May 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||3450|||Both|35 Years|N/A|No|||November 2006|November 28, 2006|July 14, 2006||||No||https://clinicaltrials.gov/show/NCT00353067||180475|
NCT00353366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103366|To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination|Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First Vaccination||GlaxoSmithKline||Completed|November 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1432|||Both|6 Weeks|24 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Filipino subjects aged at least 6 weeks at the time of first vaccination|November 2012|November 21, 2012|July 17, 2006|No|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00353366||180454|
NCT00385775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-104|Study of XIAP Antisense for Advanced Cancers|A Phase I Trial of AEG35156 Administered by 2-Hour Intravenous Infusion in Patients With Advanced Cancers||Aegera Therapeutics|No|Terminated|June 2006|November 2008|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|October 6, 2006||No|Dosing cohort (650mg) exceeded current 350mg dosing in other trials.|No||https://clinicaltrials.gov/show/NCT00385775||178014|
NCT00382070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-42|Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer|A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer||NSABP Foundation Inc|Yes|Active, not recruiting|August 2006|October 2018|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3966|||Female|18 Years|120 Years|No|||February 2016|February 5, 2016|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382070||178296|
NCT00391794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29920-J|Efficacy of Early Stage Alzheimer's Support Groups|Efficacy of Early Stage Alzheimer's Support Groups||University of Washington|Yes|Completed|September 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 9, 2014|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00391794||177560|
NCT00392873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15353|Increased Calorie Intake to Reverse Energy Deficiency in Exercising Women: Impact on Bone and Menstrual Cyclicity|"REFUEL" Active Women's Study II: Increased Caloric Intake to Reverse Energy Deficiency in Exercising Women: Impact on Bone and Menstrual Cyclicity||Penn State University|Yes|Completed|September 2006|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|233|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00392873||177479|
NCT00393159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC06YO3567CTIL|The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children|The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children||Tel-Aviv Sourasky Medical Center||Recruiting|October 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||October 2006|October 24, 2006|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00393159||177460|
NCT00394693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1042.06|Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma|Phase II Clinical Trial of Intra-lesional Administration of TG1042 (Adenovirus-Interferon-gamma) in Patients With Relapsing Primary Cutaneous B-Cell Lymphomas.||Transgene||Completed|November 2006|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|80 Years|No|||July 2014|July 15, 2014|October 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00394693||177344|
NCT00393432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070010|Enhancing Motor Task Training by Action Observation Watching Others Perform the Task|Enhancing Motor Memory Encoding by Action Observation||National Institutes of Health Clinical Center (CC)||Completed|October 2006|July 2008||||N/A|Observational|N/A||||40|||Both|18 Years|55 Years|No|||July 2008|July 19, 2008|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393432||177440|
NCT00393445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOF-Ex|Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans|Effect of GLP-1 on Glucose Metabolism in Healthy Subjects and Patients With T2DM. Part 1: A Pilot Study to Assess the Efficacy of Exendin(9-39)Amide as a GLP-1 Receptor Antagonist in Healthy Subjects||Ludwig-Maximilians - University of Munich|No|Completed|November 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 2, 2011|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393445||177439|
NCT00393757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0124|Malaria Transmission and Immunity in Highland Kenya|Malaria Transmission and Immunity in Highland Kenya||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|October 2006|January 2010||||N/A|Observational|Time Perspective: Prospective||||6400|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2007|August 26, 2010|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393757||177415|
NCT00394043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT002303-01A2|Treatment Efficacy of OMT for Carpal Tunnel Syndrome|Treatment Efficacy of OMT for Carpal Tunnel Syndrome||University of North Texas Health Science Center||Recruiting|October 2006|October 2009||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||138|||Both|21 Years|65 Years|No|||October 2006|October 27, 2006|October 27, 2006||||No||https://clinicaltrials.gov/show/NCT00394043||177393|
NCT00394394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04002|Antihypertensive Effectiveness of the Associations of Hydrochlorothiazide and Amiloride and Hydrochlorothiazide and Enalapril|Hydrochlorothiazide and Amiloride vs Hydrochlorothiazide and Enalapril: a Randomized Clinical Trial of Antihypertensive Effectiveness.||Hospital de Clinicas de Porto Alegre||Completed|February 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years||||October 2006|October 30, 2006|October 30, 2006||||No||https://clinicaltrials.gov/show/NCT00394394||177367|
NCT00391586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0601C|Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung|INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung||New Mexico Cancer Care Alliance|Yes|Terminated|July 2006|May 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|80 Years|No|||August 2015|August 14, 2015|October 23, 2006|Yes|Yes|PI left institution.|No|June 15, 2015|https://clinicaltrials.gov/show/NCT00391586||177576|
NCT00391599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-SL-002|Enemas Before Elective Cesarean Section|Are Enemas Given Before Elective Cesarean Section Useful?||Wolfson Medical Center||Not yet recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||||||Female|18 Years|50 Years|No|||June 2006|August 6, 2007|October 22, 2006||||No||https://clinicaltrials.gov/show/NCT00391599||177575|
NCT00391625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKT025EXT|Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)|An Open-Label Extension of Study TKT025 Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A Enzyme Replacement Therapy||Shire Human Genetic Therapies, Inc.|No|Completed|February 2005|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|October 20, 2006|Yes|Yes||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00391625||177573|Imputation was applied to missing data.
NCT00393679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4 ABC|Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children|Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children||Institute of Tropical Medicine, Belgium|Yes|Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|4112|||Both|6 Months|59 Months|No|||January 2014|January 31, 2014|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00393679||177421|
NCT00393939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181064|Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer|A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients|SUN 1064|Pfizer|Yes|Completed|February 2007|July 2011|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|594|||Female|18 Years|N/A|No|||July 2012|July 13, 2012|October 30, 2006|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00393939||177401|
NCT00394277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV18210|A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C|Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater Than or Equal to 85 kg||Hoffmann-La Roche||Completed|February 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1175|||Both|18 Years|N/A|No|||July 2010|July 30, 2010|October 30, 2006|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00394277||177375|
NCT00394602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0529|Chemoradiation-Induced Nausea and Emesis: Quality of Life|Chemoradiation-Induced Nausea and Emesis: A Prospective Study to Assess Patient Preferences and Quality of Life||M.D. Anderson Cancer Center|No|Recruiting|April 2004|||April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients receiving chemoradiation for abdominal-pelvic tumors and healthy controls.|January 2016|January 4, 2016|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00394602||177351|
NCT00394615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC0001|Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA|Metabolic Imaging: Predicting Histopathologic Response to Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer||Stanford University||Terminated|October 2003|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2010|March 25, 2010|July 5, 2006||No|Protocol approval expired|No||https://clinicaltrials.gov/show/NCT00394615||177350|
NCT00394628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-003|AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme|A Phase 1b/2a, Multicenter, Open-Label Study of AQ4N in Combination With Radiation Therapy and Temozolomide, to Evaluate the Safety, Tolerability, and Efficacy in Subjects With Newly Diagnosed Glioblastoma Multiforme||Novacea||Recruiting|October 2006|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||May 2007|May 29, 2007|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394628||177349|
NCT00390299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0671|Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM)||Mayo Clinic|No|Recruiting|October 2006|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390299||177675|
NCT00390884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC29|Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.|Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) Among Healthy Children Immunized in Fall 2005 With Fluzone Vaccine or Placebo||Sanofi|No|Completed|October 2006|September 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|173|||Both|11 Months|14 Months|Accepts Healthy Volunteers|||January 2014|January 16, 2014|October 20, 2006|Yes|Yes||No|September 21, 2009|https://clinicaltrials.gov/show/NCT00390884||177630|
NCT00390897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMC/PETHEMA|Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia|Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia||PETHEMA Foundation||Completed|July 2003|December 2007|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||360|||Both|18 Years|72 Years|No|||November 2008|November 26, 2008|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00390897||177629|
NCT00391170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070005|Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease|Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease||National Institutes of Health Clinical Center (CC)||Recruiting|October 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|106|||Both|12 Years|N/A|No|||April 2015|September 25, 2015|October 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391170||177608|
NCT00391183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-CAGB/2005|Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.|Effect of Palliative Biliary Stenting Versus Conservative Treatment on the Quality of Life (QOL) of Patients With Unresectable Carcinoma of the Gallbladder With Hiliar Block: A Randomised Controlled Trial||All India Institute of Medical Sciences, New Delhi||Completed|January 2006|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|90 Years|No|||July 2013|July 10, 2013|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00391183||177607|
NCT00391443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-321|BUILD 3: Bosentan Use in Interstitial Lung Disease|Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.|BUILD 3|Actelion||Completed|February 2007|July 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|616|||Both|18 Years|N/A|No|||August 2015|September 9, 2015|October 20, 2006|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00391443||177587|
NCT00390910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107737|Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants|Assess Safety/Immunogenicity of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine When Co-administered With DTPa-HBV-IPV/Hib Vaccine in Preterm Infants as a 3-dose Primary Immunization Course During the First 6 Months of Life||GlaxoSmithKline||Completed|October 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|286|||Both|8 Weeks|16 Weeks|Accepts Healthy Volunteers|||September 2009|September 25, 2009|October 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390910||177628|
NCT00391469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29121-B|Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest|Study of the Use of Mild Hypothermia in Out-of-hospital Cardiac Arrest Using a Rapid Infusion of 2 Liters of Cold Normal Saline||University of Washington|Yes|Completed|December 2007|August 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1359|||Both|18 Years|N/A|No|||November 2014|November 23, 2014|October 20, 2006|Yes|Yes||No|November 23, 2014|https://clinicaltrials.gov/show/NCT00391469||177585|
NCT00392574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT-099-001|Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea|A Multicenter, Double-Blind, Randomized Study to Compare The Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers||Merck Sharp & Dohme Corp.|No|Completed|August 2006|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|N/A|No|||August 2010|April 27, 2015|October 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392574||177500|
NCT00392587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKI106209|A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)|A Randomised, Double-blind, Placebo-controlled Parallel Study to Assess the Safety, Tolerability,Pharmacodynamics and Steady State Pharmacokinetics of Repeated Doses of GW856553 in Patients With COPD||GlaxoSmithKline|No|Completed|August 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|30|||Both|40 Years|75 Years|No|||March 2011|May 31, 2012|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00392587||177499|
NCT00393770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC01|Acetylcarnitine and Insulin Sensitivity|A Pilot Study to Evaluate the Short-term Effects of Acetyl-carnitine on Insulin Resistance and the Metabolic Syndrome in Patients at Increased Risk of Type 2 Diabetes: Acetyl-carnitine in Insulin Resistance||Mario Negri Institute for Pharmacological Research|No|Completed|February 2004|September 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|40 Years|65 Years|No|||June 2011|June 9, 2011|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00393770||177414|
NCT00390364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05107 CDR0000508071|Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy|Phase II Study of Single Agent RAD001 in Patients With Colon Cancer and Activating Mutations in the PI3KCA Gene||Sidney Kimmel Comprehensive Cancer Center||Terminated|October 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2014|October 7, 2014|October 18, 2006||Yes|Withdrawn due to low accrual||September 15, 2014|https://clinicaltrials.gov/show/NCT00390364||177670|Out of 28 subjects pre-screened/screened, only one was enrolled and treated, and she progressed after 1 cycle. Study terminated by investigator because of low enrollment.
NCT00390663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/EN/03|A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children|A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children: Antiseptic Cream Alone v's Antiseptic Cream With Nasal Cautery||NHS Greater Glasgow Yorkhill Division||Recruiting|October 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||216|||Both|1 Year|14 Years|No|||October 2006|October 19, 2006|October 19, 2006||||No||https://clinicaltrials.gov/show/NCT00390663||177647|
NCT00390377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT240-2006|Use of Hair to Diagnose Breast Cancer|A Study to Evaluate a Test for the Diagnosis of Breast Cancer Using X-Ray Diffraction of Hair Fibres.||Fermiscan Ltd||Recruiting|October 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||240|||Female|20 Years|N/A||||October 2006|October 18, 2006|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00390377||177669|
NCT00390988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD FME 45/06|Capillary and Venous Blood Count Parameters|Comparison of Capillary and Venous Blood Count Parameters||University of Magdeburg||Completed||||||N/A|Observational|Time Perspective: Prospective||||250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 19, 2009|October 20, 2006||||No||https://clinicaltrials.gov/show/NCT00390988||177622|
NCT00391261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0143/12/05|An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.|A Prospective Open-label Trial of Metformin for Weight Control of Pediatric Patients on Atypical Antipsychotic Medications.||Cambridge Health Alliance|No|Completed|July 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|10 Years|18 Years|No|||June 2008|March 24, 2010|October 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00391261||177601|
NCT00391274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10717|Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy||Eli Lilly and Company|No|Completed|October 2006|June 2010|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|October 19, 2006|Yes|Yes||No|December 21, 2009|https://clinicaltrials.gov/show/NCT00391274||177600|The primary outcome measure of this trial was designed to include pooled data. In addition, the results for the outcome on Duration of Response could not be presented due to the low number of patients being analyzed in the docetaxel group.
NCT00391612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 30|EASE Trial: Exhale Airway Stents for Emphysema|A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects With Severe Hyperinflation|EASE|Broncus Technologies||Active, not recruiting|May 2006|December 2013|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|35 Years|N/A|No|||January 2011|January 10, 2011|October 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391612||177574|
NCT00391300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616117|Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions|Development of an Electrical Diagnostic for Melanoma and Other Cutaneous Malignancies||National Cancer Institute (NCI)|No|Active, not recruiting|October 2006|April 2007|Anticipated|April 2007|Anticipated|Phase 1|Interventional|Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2008|December 17, 2013|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00391300||177598|
NCT00391313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002624-42|CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease|CuraChik : Double Blind Placebo-controlled Randomized Trial : Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease.||Assistance Publique Hopitaux De Marseille||Terminated|May 2006|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|66 Years|No|||August 2015|August 27, 2015|October 20, 2006|||Terminated Chikungunya diseases has regressed and no more patients was suffering|No||https://clinicaltrials.gov/show/NCT00391313||177597|
NCT00391859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-70373|Pharmacist-initiated Intervention Trial in OsteoArthritis (PhIT-OA)|Pharmacist-initiated Intervention Trial in OsteoArthritis (PhIT-OA)||University of British Columbia|No|Completed|September 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|135|||Both|50 Years|95 Years|No|||March 2014|March 14, 2014|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00391859||177555|
NCT00393692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAM-Study|Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy|Prospective Natural History Study of Fundus Autofluorescence Imaging in Age-related Macular Degeneration (FAM-Study) Using Confocal Scanning Laser Ophthalmoscopy||University Hospital, Bonn||Recruiting|August 2000|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with unilateral or bilateral geographic atrophy due to AMD, aged 50 years and        older. German population|December 2014|December 2, 2014|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393692||177420|
NCT00393978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA|Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania|Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents||University of Cincinnati|No|Completed|November 2006|March 2014|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|12 Years|21 Years|No|||October 2014|October 1, 2014|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00393978||177398|
NCT00394641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30/10/2006.CTIL|Impact of Listening to Low Tones on Motor Function in Children With CP|Impact of Listening to Low Tones Via Sterephonic Headphones on Hypertonia and Motor Function in Children With Cerebral Palsy- Randomized Controlled Study||Shaare Zedek Medical Center||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||30|||Both|3 Years|12 Years|No|||October 2006|October 31, 2006|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394641||177348|
NCT00390312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-001|Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction|Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Single Dose Comparison of Analgesic Efficacy and Safety of Intranasal Morphine, Immediate Release Oral Morphine, Intravenous Morphine and Placebo in Postsurgical Dental Pain||Javelin Pharmaceuticals|No|Completed|September 2001|November 2001|Actual|November 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|225|||Both|18 Years|40 Years|No|||December 2007|December 28, 2007|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390312||177674|
NCT00390325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00196|Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer|Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|October 2006|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390325||177673|
NCT00390598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARE-05-073M|PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy|A Single Blind, Single Centre, Parallel Group, Randomized Controlled Trial Comparing PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy|TARE-05-073M|Umeå University||Completed|September 2005|December 2006|Actual|December 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2|||490|||Both|18 Years|N/A|No|||December 2008|March 23, 2011|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00390598||177652|
NCT00390611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GYN 19|Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer|A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer||SCRI Development Innovations, LLC|No|Completed|October 2006|April 2014|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Female|18 Years|N/A|No|||December 2014|December 12, 2014|October 19, 2006|No|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00390611||177651|
NCT00390585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. E00605|Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)|Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI||Deutsches Herzzentrum Muenchen|Yes|Completed|July 2006|December 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|324|||Both|18 Years|N/A|No|||February 2008|March 12, 2010|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00390585||177653|
NCT00390923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170/2006|Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence|Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence||Centre for Addiction and Mental Health|No|Terminated|July 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2013|August 27, 2013|October 19, 2006||No|Preliminary results did not support the utility of combining selegeline + NRT.|No||https://clinicaltrials.gov/show/NCT00390923||177627|
NCT00391495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-06-NV-246-CTIL|Inflammation in Children With Attention-Deficit/Hyperactivity Disorder|Inflammation in Children With Attention-Deficit/Hyperactivity Disorder|ADHD_CYTO|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|September 2007|December 2007|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Anticipated|45|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||August 2006|June 18, 2007|October 22, 2006||||No||https://clinicaltrials.gov/show/NCT00391495||177583|
NCT00391508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sept-HN-2003|Skin Problems in Ostomy Patients: An Epidemiological Study|An Epidemiological Study of Peristomal Skin Problems in Patient With an Ostomy in Roskilde County||Roskilde County Hospital||Active, not recruiting|September 2003|August 2005||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 23, 2006|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391508||177582|
NCT00393458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2334|Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control|A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control||Novartis||Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1732|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|October 25, 2006||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00393458||177438|
NCT00393471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-308|Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.|A Double-Blind Study Evaluating the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Comparison to Etanercept Alone or Methotrexate Alone in Rheumatoid Arthritis Patients.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2000|October 2001||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||615|||Male|18 Years|N/A|No|||October 2006|October 26, 2006|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393471||177437|
NCT00394706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29919-A|Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve|Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve and Early Versus Delayed Analysis||University of Washington|Yes|Terminated|June 2007|July 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|11738|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|October 30, 2006|Yes|Yes|Terminated because preliminary data suggested no difference in the strategies.|No|March 23, 2012|https://clinicaltrials.gov/show/NCT00394706||177343|
NCT00390390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRSW-GN-302|Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn|A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of 14 Day Treatment With Lansoprazole 15 mg Once a Day in Frequent Heartburn||Novartis||Completed|June 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||576|||Both|18 Years|N/A|No|||April 2007|May 24, 2010|October 18, 2006||||||https://clinicaltrials.gov/show/NCT00390390||177668|
NCT00394745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ADE25|Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome|A 12 Week Treatment, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome||Novartis||Completed|November 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394745||177341|
NCT00390676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHX-01-006|A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine|A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006)||Adherex Technologies, Inc.||Completed|November 2006|November 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||December 2010|December 27, 2010|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390676||177646|
NCT00390689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.627|A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.|A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Pramipexole at Fixed Doses of 0.25 mg, 0.5 mg, and 0.75 mg in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by a 46-week Open-label Long-term Study||Boehringer Ingelheim||Completed|October 2006|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|154|||Both|20 Years|80 Years|No|||April 2014|June 23, 2014|October 19, 2006|Yes|Yes||No|March 5, 2009|https://clinicaltrials.gov/show/NCT00390689||177645|
NCT00391001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0131/09/05|Taurine in Adolescents With Bipolar Disorder|Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study in Adolescents With Bipolar Disorder||Cambridge Health Alliance|No|Terminated|February 2006|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|13 Years|18 Years|No|||June 2008|February 2, 2010|October 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00391001||177621|
NCT00391287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011587|Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure|A Prospective, Immunogenicity Surveillance Registry (PRIMS) to Estimate the Incidence of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia Among Subjects With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products|PRIMS|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2006|December 2010|Actual|December 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15334|||Both|18 Years|N/A|No|Probability Sample|All patients should have documented chronic renal failure (CRF) and be receiving or about        to receive (within 1 month) a marketed erythropoietin product by the subcutaneous route of        administration at the time of enrollment. Patients may be at any stage of CRF (Stages 1 to        5) or be receiving any treatment for CRF, including predialysis, peritoneal dialysis, or        hemodialysis, but should not be receiving immunosuppressive treatment following an organ        transplant.        Patients will be enrolled at sites located in the E.U. and Australia.|October 2014|October 2, 2014|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00391287||177599|
NCT00396604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2212|Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Double-dummy, Active (Formoterol 12 µg b.i.d) and Placebo Controlled, Multi-center, 5 Period Crossover Study to Assess the Bronchodilatory Efficacy and Safety of Single Doses of Indacaterol 150 µg, 300 µg and 600 µg Delivered Via Single Dose Dry Powder Inhaler vs. Placebo in Patients With Moderate to Severe COPD.||Novartis||Completed|October 2006|January 2007|Actual|January 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|51|||Both|40 Years|75 Years|No|||October 2011|October 24, 2011|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396604||177200|
NCT00396916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hybridCTIL|Hybrid PET/CT in Cancer Patients|The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin||Rambam Health Care Campus||Completed|December 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||45|||Both|N/A|N/A|No|||April 2007|April 10, 2007|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00396916||177176|
NCT00391872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C05262|A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome|A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]|PLATO|AstraZeneca||Completed|October 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18624|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|October 23, 2006|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00391872||177554|
NCT00394303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4214|Tight Intra-Operative Glucose Control During Coronary Artery Bypass Surgery|Tight Intra-Operative Glucose Control Using Continuous Insulin Infusion During Coronary Artery Bypass Surgery: Randomized Controlled Trial||Rabin Medical Center|Yes|Terminated|February 2007|August 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|N/A|No|||June 2007|March 31, 2009|October 31, 2006||No|Trial suspended on 26 February, following the publication of a trial with negative results    (Ann Intern Med 146(4), 2007). Pending ethics committee re-approval.|No||https://clinicaltrials.gov/show/NCT00394303||177373|
NCT00394316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070017|Gene Therapy for Chronic Granulomatous Disease|Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Terminated|October 2006|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|3 Years|55 Years|No|||April 2014|April 9, 2014|October 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00394316||177372|
NCT00394329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|445|Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)|Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)|TREXA|Milton S. Hershey Medical Center|Yes|Completed|November 2006|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|288|||Both|6 Years|18 Years|No|||April 2013|April 5, 2013|October 30, 2006|Yes|Yes||No|February 24, 2013|https://clinicaltrials.gov/show/NCT00394329||177371|
NCT00390962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 157/06|The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)|Copeptin as a Novel Diagnostic and Prognostic Marker in the Management of Neurological and Neurosurgical Patients With Sodium Imbalance The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment)||University Hospital, Basel, Switzerland||Completed|November 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|469|Samples Without DNA|bood sampling|Both|N/A|N/A|No|Probability Sample|All consecutive patients who are admitted to the emergency department with an ischemic or        hemorrhagic stroke or transient ischemic attach (TIA) according to the World Health        organization criteria [37] with symptom onset within the last 3 days.|September 2008|September 22, 2008|October 20, 2006||||No||https://clinicaltrials.gov/show/NCT00390962||177624|
NCT00391222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012145|A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder||Janssen Pharmaceutica N.V., Belgium|No|Completed|November 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|585|||Both|18 Years|65 Years|No|||April 2014|April 24, 2014|October 20, 2006|Yes|Yes||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00391222||177604|
NCT00391235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0132/09/05|White Matter in Pediatric Bipolar Disorder: A DTI Study|White Matter Connectivity in Pediatric Bipolar Disorder: A Diffusion Tensor Imaging Study||Cambridge Health Alliance|No|Completed|September 2005|October 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|28|||Both|6 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|Bipolar Disorder|December 2010|December 2, 2010|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00391235||177603|
NCT00391521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26865|AS703569 Phase I in Patients With Solid Tumours|A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours||EMD Serono||Completed|August 2006|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|October 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00391521||177581|
NCT00391534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC-039/K|EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy|Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy||Desitin Arzneimittel GmbH|No|Terminated|October 2006|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2009|April 14, 2010|October 23, 2006||No|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT00391534||177580|
NCT00391547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609059R44NR009015-02|Pilot Efficacy Study to Treat Gingivitis|Phase II Pilot Efficacy Study to Treat Gingivitis||Biomedical Development Corporation||Completed|October 2006|January 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||14|||Both|18 Years|N/A|No|||October 2007|October 18, 2007|October 20, 2006||||||https://clinicaltrials.gov/show/NCT00391547||177579|
NCT00390936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-012|A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors|Phase I Multiple Ascending Dose Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|October 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|N/A|No|||March 2010|January 24, 2011|October 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390936||177626|
NCT00390949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC3239_DFID|Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe|Impact and Process Evaluation of Integrated Community and Clinic-based HIV-1 Control: a Cluster-randomised Trial in Eastern Zimbabwe||Imperial College London||Completed|July 1998|February 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2006|May 27, 2015|October 20, 2006||||No||https://clinicaltrials.gov/show/NCT00390949||177625|
NCT00391807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-05806|Study of Safety and Efficacy of an Oral Contraceptive|Open-Label Study of the Safety and Efficacy of a Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol||Warner Chilcott|No|Completed|November 2006|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1683|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|October 20, 2006|Yes|Yes||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00391807||177559|
NCT00391209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9630|Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus|A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naive Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company||Completed|October 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|379|||Both|18 Years|N/A|No|||January 2010|January 21, 2010|October 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391209||177605|
NCT00392340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000508641|Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma|An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)]||National Cancer Institute (NCI)||Active, not recruiting|March 2008|||January 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|63|||Both|1 Year|20 Years|No|||June 2009|September 16, 2013|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392340||177518|
NCT00393809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-05-02.CTIL|Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer|Phase 1/2a, Dose-Escalation, Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer||Hebrew University of Jerusalem||Completed|January 2006|December 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2007|December 25, 2007|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393809||177411|
NCT00394082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA043|ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer|A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer||Celgene|No|Completed|June 2006|February 2011|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||October 2012|April 3, 2013|October 30, 2006|Yes|Yes||No|April 3, 2013|https://clinicaltrials.gov/show/NCT00394082||177390|Interpretation of results is limited since the cell receptor subtype status of patients is not known.
NCT00394407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|419-2005|Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes|Comparative Trial Between Insulin Glargine Plus Supplemental Glulisine (Apidra) Versus Sliding Scale Regular Insulin In Hospitalized Patients With Type 2 Diabetes||Emory University|Yes|Completed|September 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Female|18 Years|70 Years|No|||November 2013|November 20, 2013|October 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00394407||177366|
NCT00394420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1321-03|Emergency Department Telephone Quitline|A Telephone Quitline Intervention for Smoking Cessation Through the Emergency Department||Mayo Clinic||Completed|September 2003|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 19, 2010|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394420||177365|
NCT00394446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC6827-04-001|Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors|Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.||Myrexis Inc.|No|Completed|March 2005|February 2008|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||February 2008|February 11, 2008|October 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00394446||177363|
NCT00394732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006|Disc Prosthesis Versus Multidisciplinary Rehabilitation|Effect of Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation Program in Patients With Chronic Low Back Pain and Degenerative Disc. A Prospective Randomized Clinical Multicentre Trial.||Oslo University Hospital||Completed|April 2004|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|179|||Both|25 Years|55 Years|No|||October 2012|October 11, 2012|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00394732||177342|
NCT00390403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0602 CDR0000507451|Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I, Open Label Study of AT-101 Plus Radiotherapy and Temozolomide and of AT-101 Plus Adjuvant Temozolomide for Patients With Newly-Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center||Completed|February 2007|||June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390403||177667|
NCT00390442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM03073, P030428, ENR20040504|Out-of-Hospital CPAP for Severe Cardiogenic Pulmonary Edema|Effect of Continuous Positive Airway Pressure as a First Line Therapy in Out-of-Hospital Management of Severe Cardiogenic Pulmonary Edema||Hopital Lariboisière||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2006|October 17, 2006|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00390442||177664|
NCT00390416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-096|Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma|A Phase II Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Completed|October 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 17, 2006|No|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00390416||177666|
NCT00390702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pfm 01/2005|Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System|International Multicentre Clinical Device Investigation on Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System for VSD Occlusion Developed by Pfm AG, Cologne|pfm-01/2005|pfm medical ag|Yes|Suspended|October 2006|August 2016|Anticipated|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|338|||Both|2 Years|N/A|No|||August 2012|August 22, 2012|October 19, 2006||No|further recruitment terminated after CE mark attained; enclosed patients will be followed up    to 5 years|No||https://clinicaltrials.gov/show/NCT00390702||177644|
NCT00390715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML99<=65 años|Treatment of Acute Myeloblastic Leukemia in Younger Patients|Prospective Study of the Value of the Cytogenetic and of the Monitoring of the Minimal Residual Disease||PETHEMA Foundation||Completed|January 1999|January 2010|Actual|December 2007|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|65 Years|No|Non-Probability Sample|AML of new diagnose, no treated previously|March 2010|March 11, 2010|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00390715||177643|
NCT00399438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN148-013|A Study of BMS-562086 in Patients With Irritable Bowel Syndrome|A Dose-Ranging Study of the Pharmacodynamic Effects of BMS-562086 on Gastrointestinal Transit in Women With Diarrhea-Predominant Irritable Bowel Syndrome||Bristol-Myers Squibb|No|Completed|December 2006|January 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|39|||Female|18 Years|65 Years|No|||September 2008|September 25, 2008|November 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399438||176989|
NCT00397228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTROPANE dosing|ALTROPANE® SPECT Imaging in Patients With Parkinson Disease|Optimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson Disease||Molecular NeuroImaging|No|Completed|November 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|27|||Both|30 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 21, 2014|November 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397228||177153|
NCT00391638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004137-15|Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients|Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG.|HB01EMVIPEG|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|January 2007|October 2012|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|October 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00391638||177572|
NCT00394368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/033011/001/03|EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI|DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®) IN THE 12-WEEK TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA||Chiesi Farmaceutici S.p.A.||Completed|November 2004|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|65 Years|No|||October 2006|October 30, 2006|October 30, 2006||||No||https://clinicaltrials.gov/show/NCT00394368||177369|
NCT00391560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 217|Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia|Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia||AEterna Zentaris|No|Completed|October 2006|October 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2012|March 4, 2013|October 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391560||177578|
NCT00391573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE-05-0008|Polyglactin Sutures Versus Nylon Sutures for Suturing of Conjunctival Autograft in Pterygium Surgery: a Randomised Controlled Trial|Polyglactin Sutures Versus Nylon Sutures for Suturing of Conjunctival Autograft in Pterygium Surgery: a Randomised Controlled Trial||Hospital Authority, Hong Kong||Completed|March 2005|June 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||June 2011|June 14, 2011|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391573||177577|
NCT00391833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ginseng-AD|Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease|||Seoul National University Hospital||Completed|April 2004|October 2005||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|40 Years|83 Years||||October 2006|October 22, 2006|October 22, 2006||||No||https://clinicaltrials.gov/show/NCT00391833||177557|
NCT00391846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00010|Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone|A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Systolic Dysfunction||AstraZeneca|No|Completed|October 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|October 19, 2006|Yes|Yes||No|May 10, 2010|https://clinicaltrials.gov/show/NCT00391846||177556|
NCT00392093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSG1957|Effect of Hormone Replacement Therapy on Lupus Activity|Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||Completed|November 1997|December 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Female|18 Years|65 Years|No|||October 2006|October 23, 2006|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00392093||177537|
NCT00393484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-105|A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection|A Phase IV Study of the Antiviral Activity and Safety of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen in Korea||Bristol-Myers Squibb||Completed|February 2007|September 2013|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|16 Years|N/A|No|||November 2014|November 6, 2014|October 26, 2006|Yes|Yes||No|October 21, 2010|https://clinicaltrials.gov/show/NCT00393484||177436|
NCT00391820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0038|Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of TD-5108 for the Treatment of Chronic Constipation||Theravance Biopharma R & D, Inc.|No|Completed|October 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|360|||Both|18 Years|64 Years|No|||December 2014|December 1, 2014|October 20, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00391820||177558|
NCT00392080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5231018|A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers|A Multicenter, Randomized, Placebo And Active-Controlled Study Of The Effect Of CJ-023,423 On The Incidence Gastroduodenal Endoscopic Ulcers In Healthy Subjects||Pfizer|No|Completed|November 2006|February 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|340|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2008|March 18, 2008|October 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392080||177538|
NCT00392886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000503990|Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors|Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]||National Cancer Institute (NCI)||Active, not recruiting|March 2004|||December 2010|Anticipated|Phase 3|Interventional|Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|10 Years|No|||October 2010|December 17, 2013|October 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392886||177478|
NCT00394108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997/098|Changes in Cerebrovascular Reactivity During Cognitive Activation After Cardiopulmonary Bypass: Relation With Intraoperative Embolic Load and Postoperative Neuropsychological Dysfunctions|Changes in Cerebrovascular Reactivity During Cognitive Activation After Cardiopulmonary Bypass: Relation With Intraoperative Embolic Load and Postoperative Neuropsychological Dysfunctions||University Ghent|No|Completed|August 1999|July 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|18 Years|69 Years|No|||December 2007|December 19, 2007|October 30, 2006||||No||https://clinicaltrials.gov/show/NCT00394108||177388|
NCT00394121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-3-003|New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma|Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma||SkyePharma AG||Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|12 Years|N/A|No|||August 2010|August 24, 2010|October 27, 2006||||No||https://clinicaltrials.gov/show/NCT00394121||177387|
NCT00394095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1D-MC-X304|Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine|A Double-Blind, Randomized, Placebo-Controlled, Pilot Study of Topiramate vs. Placebo in Combination With Olanzapine for the Prevention of Weight Gain in Manic or Mixed Youth With Bipolar Disorder||University of Cincinnati|Yes|Completed|December 2006|September 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|10 Years|18 Years|No|||April 2013|April 3, 2013|October 27, 2006|Yes|Yes||No|March 23, 2011|https://clinicaltrials.gov/show/NCT00394095||177389|One subject experienced hyperthermia and was admitted to hospital. Subject was discontinued from study.
NCT00394433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-100|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer|A Phase II Trial of Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer||Dana-Farber Cancer Institute||Active, not recruiting|September 2006|December 2014|Anticipated|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|October 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00394433||177364|
NCT00394758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE 4804|A Randomized Trial of Surgical Treatments for Vulvar and Vaginal Dysplasia|Comparison of Surgical Procedures in Vulvar and Vaginal Dysplasias||University Hospital Case Medical Center||Completed|January 2000|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Female|18 Years|N/A|No|||October 2006|October 30, 2006|October 30, 2006||||No||https://clinicaltrials.gov/show/NCT00394758||177340|
NCT00390429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505821|Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|Phase I/II Study of Docetaxel and OSI-774 (Erlotinib) in Solid Tumor Patients With an Emphasis on NSCLC Using Molecular Correlates as Potential Markers of Response||University of California, Davis|Yes|Completed|July 2002|August 2012|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|October 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390429||177665|
NCT00390728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_3505|Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)|A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ "HALT" Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes|AT-LANTUS|Sanofi||Completed|April 2002|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2346|||Both|18 Years|N/A|No|||August 2010|August 30, 2010|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390728||177642|
NCT00390741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20834|BHS4 - Bone/Muscle Changes Following Hip Fracture in Older White Women|Bone/Muscle Changes Following Hip Fracture in Older White Women|Hip4|University of Maryland|Yes|Completed|October 1998|September 2005|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|170|||Female|65 Years|N/A|No|||May 2008|May 27, 2008|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00390741||177641|
NCT00398671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreCoCa-1|PreCoCa - "Prehospital Cooling With Cool-Caps"|||Charite University, Berlin, Germany||Completed|January 2006|||June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|50|||Both|18 Years|N/A|No|||December 2008|February 26, 2015|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00398671||177046|
NCT00399451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYZXYY06002|Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)|Preliminary Study on Submucous Sclerosis of Pharynges With 1% Polidocanol to Treat Obstructive Sleep Apnea (OSA) & Snoring Subjects (SS)||Liaoyang Central Hospital||Not yet recruiting|December 2006|June 2009||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||November 2006|November 20, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399451||176988|
NCT00395369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR439106CTIL|Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.|||Soroka University Medical Center||Not yet recruiting|December 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||30|||Both|N/A|N/A|No|||November 2006|November 2, 2006|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395369||177294|
NCT00391014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000703-34|Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis|AMBINEB: Clinical Trial to Evaluate Tolerance and Safety of Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis in Patients With Acute Myeloid Leukemia and Allogeneic Haematopoietic Progenitor Cell Transplant (Alo-HPCT)|AMBINEB|PETHEMA Foundation|Yes|Completed|January 2006|April 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|18 Years|N/A|No|||May 2009|May 11, 2009|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00391014||177620|
NCT00391027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171084|A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®|A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents||Pfizer|No|Completed|December 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|30 Years|N/A|No|||June 2015|June 30, 2015|October 19, 2006|No|Yes||No|August 5, 2009|https://clinicaltrials.gov/show/NCT00391027||177619|Enrollment period concluded earlier than planned due to cancellation of Exubera® program by sponsor; enrollment was undersized to meet requirements of its inferential objectives. Revised analysis approach was descriptive with no inferential analyses.
NCT00391040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201-10/03|SGS: a Structured Treatment and Teaching Programme for Elderly Patients With Diabetes Mellitus|SGS: a Structured Treatment and Teaching Programme for Elderly Patients With Diabetes Mellitus - a Prospective Randomized Controlled Multicenter Trial||German Diabetes Association||Completed|November 2003|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||200|||Both|65 Years|N/A|No|||October 2006|October 20, 2006|October 20, 2006||||No||https://clinicaltrials.gov/show/NCT00391040||177618|
NCT00398437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJB-HER2-NEU-CE-1384|Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer|Role of Gadolinium Enhanced Brain Magnetic Resonance in the Follow Up of Metastatic Breast Cancer Patients Overexpressing HER2 Neu. A Randomized Prospective Study||National Cancer Institute (NCI)||Recruiting|September 2006|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|||Anticipated|96|||Female|18 Years|N/A|No|||March 2007|August 9, 2013|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398437||177064|
NCT00393276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5232|Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals|Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by Identifying Determinants of Responsiveness: A Pilot Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|29|||Both|18 Years|65 Years|No|||December 2014|December 8, 2014|October 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00393276||177452|
NCT00381615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P6|Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study|A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine±OMV, When Administered to Healthy Infants at 2, 4, 6 and/or 12 Months of Age||Novartis|No|Completed|September 2006|August 2008|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|147|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 27, 2006||No||No|February 4, 2015|https://clinicaltrials.gov/show/NCT00381615||178329|
NCT00381628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 08-06-23|Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations|Use of Nasal Epithelial Cells and Blood Lymphocytes to Identify Markers for Cystic Fibrosis and Cystic Fibrosis Pulmonary Exacerbations||University Hospital Case Medical Center|No|Completed|September 2006|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|59|||Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nasal epithelial cells and blood will be obtained from four groups of subjects age 15        years and older: Stable subjects with CF at baseline, Subjects with CF at the beginning        and end of treatment for a pulmonary exacerbation, stable subjects with asthma, and        healthy voulnteers|May 2015|May 28, 2015|September 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00381628||178328|
NCT00390624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMBMT-123|Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol|Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.||Rocky Mountain Cancer Centers|Yes|Completed|July 2003|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|20|||Both|18 Years|65 Years|No|||May 2008|May 30, 2008|October 19, 2006||Yes||||https://clinicaltrials.gov/show/NCT00390624||177650|
NCT00390637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiOGenes FP6-2005-513946|Diet, Obesity and Genes (DiOGenes)|Diet, Obesity and Genes|DIOGENES|University of Copenhagen|Yes|Active, not recruiting|January 2006|December 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|1020|||Both|5 Years|65 Years|Accepts Healthy Volunteers|||November 2007|January 20, 2009|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00390637||177649|
NCT00392379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003091|Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction|Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction||Mayo Clinic|Yes|Completed|January 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|October 24, 2006|Yes|Yes||No|June 2, 2010|https://clinicaltrials.gov/show/NCT00392379||177515|
NCT00393497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606-24|A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment|A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment||Indiana University|Yes|Completed|April 2007|January 2011|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||September 2014|September 19, 2014|October 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393497||177435|
NCT00392353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01050|Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia|A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS)||National Cancer Institute (NCI)||Active, not recruiting|November 2006|||May 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|October 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392353||177517|
NCT00392613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003B118|RAte Control Efficacy in Permanent Atrial Fibrillation|RAte Control Efficacy in Permanent Atrial Fibrillation, a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure.||University Medical Center Groningen||Completed|January 2005|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|500|||Both|18 Years|80 Years|No|||July 2007|January 6, 2010|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392613||177498|
NCT00394056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP106254|Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.|Randomised, Double-blind, Placebo Controlled, Cross-over Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 14 Days of Vestipitant or Vestipitant / Paroxetine Combination in an Enriched Population of Subjects With Tinnitus & Hearing Loss||GlaxoSmithKline|No|Completed|December 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|65 Years|No|||March 2012|March 29, 2012|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00394056||177392|
NCT00394069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-268|PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)|A Randomized, 3-Period, Multiple-Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Plasma Concentration Profile of Montelukast Administered Once Daily as Oral Granules in Children Aged 3 to 6 Months||Merck Sharp & Dohme Corp.|No|Completed|July 2003|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|14|||Both|3 Months|6 Months|No|||May 2015|May 5, 2015|October 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00394069||177391|
NCT00390468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02865|Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases|A Phase II Study of Tandutinib (MLN518) in Androgen-Independent Prostate Cancer With Bone Metastases||National Cancer Institute (NCI)|No|Completed|October 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|N/A|No|||January 2013|May 13, 2014|October 18, 2006|Yes|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00390468||177662|The study was closed to further accrual per design specifications.
NCT00394459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 04-1-83|Safety of Two Epidural Catheters in Thoracic Epidural Anaesthesia (TEA)|Randomised, Prospective, Single-blind, Controlled Multicenter Study on the Safety of Two Epidural Catheters in Patients Undergoing Surgery Under Thoracic Epidural Anaesthesia||Maastricht University Medical Center|No|Completed|April 2005|May 2009|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|75 Years|No|||May 2011|May 12, 2011|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00394459||177362|
NCT00396903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-H-0403|Evaluation of a Standard Epidural Catheter During Clinical Practice|Evaluation of a Standard Epidural Catheter During Clinical Practice||Maastricht University Medical Center|No|Completed|April 2003|November 2005|Actual|||N/A|Observational|Time Perspective: Prospective||||100|||Both|18 Years|75 Years|No|||April 2015|April 7, 2015|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00396903||177177|
NCT00397813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2056.00|Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders|Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Recruiting|January 2006|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|144|||Both|N/A|N/A|No|||December 2015|December 2, 2015|November 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00397813||177110|
NCT00398684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT-2; R01-HD39615; ANRS 1208|Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand|||Institut de Recherche pour le Developpement||Completed|January 2001|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3|||1792|||Female|N/A|N/A|No|||May 2008|May 2, 2008|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00398684||177045|
NCT00395382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 06099C|Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease|Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study||Monash University|Yes|Completed|January 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|85 Years|No|||February 2010|February 8, 2010|November 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395382||177293|
NCT00395746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1701|Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|October 2006|May 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|264|||Both|20 Years|N/A|No|||November 2014|November 17, 2014|November 2, 2006|Yes|Yes||No|February 23, 2010|https://clinicaltrials.gov/show/NCT00395746||177266|
NCT00396331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD31002112|AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts|A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Poor Mobilizing Adult Patients Who Have Previously Failed Stem Cell Collection/Attempts||Sanofi|No|Completed|October 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|78 Years|No|||February 2014|February 10, 2014|November 2, 2006|Yes|Yes||No|November 2, 2010|https://clinicaltrials.gov/show/NCT00396331||177221|
NCT00393289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01270319|Calcium Absorption and Retention From Marine Products|Calcium Absorption and Retention From Marine Products||University of Copenhagen||Active, not recruiting|November 2005|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2005|November 10, 2010|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393289||177451|
NCT00393627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24091-G|Behavioral Sleep Intervention in Adult Family Homes|Efficacy of Behavioral Interventions to Improve Sleep in Adult Family Homes||University of Washington|Yes|Completed|June 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|N/A|N/A|No|||June 2012|June 12, 2012|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393627||177425|
NCT00382174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSPU|Study of Thymosin Beta 4 in Patients With Pressure Ulcers|A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Pressure Ulcers||RegeneRx Biopharmaceuticals, Inc.|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|85 Years|No|||January 2010|January 6, 2010|September 26, 2006|Yes|Yes||No|December 29, 2009|https://clinicaltrials.gov/show/NCT00382174||178288|
NCT00390975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919GUS62|Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis|An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms||Novartis||Terminated|January 2007|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|75 Years|No|||May 2012|May 3, 2012|October 20, 2006|||This study was terminated early as a result of regulatory action suspending tegaserod use in    2007|||https://clinicaltrials.gov/show/NCT00390975||177623|
NCT00391248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-105472|Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)|A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial)||Ontario Clinical Oncology Group (OCOG)|Yes|Completed|November 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2011|January 28, 2013|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00391248||177602|
NCT00392392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 83|Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer|Phase II Study of Preoperative Bevacizumab and Trastuzumab Administered With ABI-007 and Carboplatin in HER2 Overexpressing Breast Cancer||SCRI Development Innovations, LLC|No|Completed|October 2006|December 2011|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||September 2013|September 17, 2013|October 25, 2006||No||No|January 11, 2013|https://clinicaltrials.gov/show/NCT00392392||177514|
NCT00393172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000511819|Women in Steady Exercise Research [Formerly Women, Oxidative Stress, Exercise and Estrogens (WOSEE)]|Women in Steady Exercise Research (WISER)|WISER|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|May 2006|March 2010|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00393172||177459|
NCT00393783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-101|Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity|Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2006|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|October 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00393783||177413|
NCT00393796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005.145|Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma|Randomized Blinded Phase II Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma||University of Michigan Cancer Center|Yes|Terminated|May 2006|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|October 27, 2006||No|Low accrual|No|June 19, 2014|https://clinicaltrials.gov/show/NCT00393796||177412|This multicenter study was limited by premature closure and a small sample size.
NCT00393185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBC|Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis|Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis: A Phase I Study||Northwestern University|Yes|Withdrawn|January 2006|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|No|||October 2012|October 4, 2012|October 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393185||177458|
NCT00393510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-8342|Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers|An Evidence Base Study on the Clinical Effects of Integrated Western Medicine and Traditional Chinese Medicine for Diabetic Foot Ulcer Treatment||Chinese University of Hong Kong|No|Completed|November 2000|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|No|||July 2010|July 6, 2010|October 26, 2006||No||No|November 23, 2009|https://clinicaltrials.gov/show/NCT00393510||177434|
NCT00391053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM05|Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly|Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.||Sanofi|Yes|Completed|October 2006|February 2008|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3851|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|October 20, 2006|Yes|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00391053||177617|
NCT00391066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152CL201|Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)|A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia|LUCID|Biogen|Yes|Terminated|November 2006|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|627|||Both|18 Years|N/A|No|||April 2011|September 17, 2015|October 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391066||177616|
NCT00391326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J.nr. 2006-41-6849|Efficacy and Safety of Prehospital Administration of Bivalirudin in STEMI Patients|Efficacy and Safety of Prehospital Administration of Bivalirudin in STEMI Patients Redirected for Primary PCI Based on Tele-Transmitted 12-Lead ECGs||Rigshospitalet, Denmark|No|Completed|November 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|102|||Both|N/A|N/A|No|Probability Sample|Patients with STEMI transferred directly to primary PCI based og transmission of a        prehospital ECG|May 2008|May 20, 2008|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00391326||177596|
NCT00391339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-C-64-Wel-06|Bryophyllum vs. Nifedipine|Bryophyllum p. Versus Nifedipine for the Treatment of Premature Contractions||Weleda AG||Not yet recruiting|November 2006|October 2008||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2006|October 19, 2006|October 19, 2006||||No||https://clinicaltrials.gov/show/NCT00391339||177595|
NCT00397514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-70642|Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery|Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery||University of British Columbia|No|Completed|October 2006|November 2009|Actual|November 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|34|||Both|N/A|18 Years|No|Non-Probability Sample|The study cohort will consist of infants, children, and adolescents (<18 years) who are        scheduled to undergo open-heart surgery for CHD. Each year approximately 150-200 patients        undergo surgery to repair their CHD (see Section 6.4 for sample size estimates).|September 2013|September 6, 2013|November 7, 2006||No||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00397514||177132|The study was limited by a small sample.Our study patients underwent BiV pacing just prior to extubation, by which time myocardial dysfunction may have recovered, so they represented a potentially healthier subset in comparison to adults.
NCT00398411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05001|Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells|Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells|MoxiProph|University of Cologne|Yes|Completed|October 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|66|||Both|18 Years|75 Years|No|||June 2015|June 1, 2015|November 8, 2006||No||No|August 5, 2013|https://clinicaltrials.gov/show/NCT00398411||177066|
NCT00398424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1112|Evaluating Patients With Impaired Hepatic Function|A Phase I, Open-Label Study Evaluating The Pharmacokinetics of Components of S-1 Patients With Impaired Hepatic Function||Taiho Oncology, Inc.||Completed|February 2006|March 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2009|August 6, 2009|November 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00398424||177065|
NCT00399217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-05290|Further Acute Research of a Subcutaneous Implantable Defibrillator (S-ICD) System|Acute Intra-operative Testing of Subcutaneous Implantable Defibrillator Emulator and Parasternal Electrode, Acutely Implanted, for Comparison With Transvenous System||Boston Scientific Corporation||Completed|November 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|patients requiring ICD therapy|May 2010|May 18, 2010|November 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00399217||177006|
NCT00396045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-026|Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma|A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients||University of Turin, Italy||Completed|January 2005|January 2008||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|65 Years|N/A|No|||November 2006|November 29, 2006|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00396045||177243|
NCT00396929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX-001|Efficiency of a New Therapy to Treat Stenosis of Coronary Vessels in Comparison With Two Already Admitted Therapies|Local-Tax Trial: Local Intracoronary Administration of Paclitaxel After Stent Implantation for Prevention of Restenosis in Comparison With Stent Implantation Alone and With Implantation of a Paclitaxel-Eluting Stent||University Hospital Tuebingen|Yes|Active, not recruiting|August 2005|July 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Anticipated|204|||Both|18 Years|80 Years|No|||May 2007|May 15, 2007|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00396929||177175|
NCT00396942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070020|Motor Skill Learning in People With Parkinson's Disease|Evaluation of the Plasticity of the Primary Motor Cortex and Motor Learning in Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2006|October 2008||||N/A|Observational|N/A||||24|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||October 2008|October 4, 2008|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00396942||177174|
NCT00392990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 06H2|Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma|A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma||Northwestern University|Yes|Active, not recruiting|October 2006|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|October 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392990||177470|
NCT00382200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-054|Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes|Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2006|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|120 Years|No|||October 2015|October 5, 2015|September 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00382200||178286|
NCT00382473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605115|Mitochondrial Dysfunction in Type 2 Diabetes Mellitus and Capacity for Fat Oxidation During Exercise|Mitochondrial Dysfunction in Type 2 Diabetes Mellitus and Capacity for Fat Oxidation During Exercise||University of Pittsburgh|No|Terminated|September 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|29|||Both|28 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|September 28, 2006||No|lack of funding|No||https://clinicaltrials.gov/show/NCT00382473||178265|
NCT00392899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000512573|Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery|Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer||National Cancer Institute (NCI)||Completed|October 2006|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Both|20 Years|80 Years|No|||July 2009|December 17, 2013|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392899||177477|
NCT00398151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-366|To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)|An Open-Label Study to Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy||Merck Sharp & Dohme Corp.||Completed|August 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|58|||Both|20 Years|N/A|No|||October 2015|October 1, 2015|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398151||177084|
NCT00398177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYM0001|Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease|Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease||Stanford University|Yes|Recruiting|June 1999|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9999|Samples Without DNA|tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|Any type of NHL or Hodgkin's disease.|February 2015|February 19, 2015|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00398177||177083|
NCT00392678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 06-20, NIH U01 DK74556|Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)|Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate|TINSAL-T2D|Joslin Diabetes Center|Yes|Completed|October 2006|December 2010|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|277|||Both|18 Years|75 Years|No|||July 2013|July 25, 2013|October 25, 2006|Yes|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT00392678||177494|
NCT00392639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051038|Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study)|Clinical Interest of Endovascular Cooling in the Management of Cardiac Arrest: Impact on Mortality in a Randomized Medico-economical Trial (the ICEREA Study)||Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2006|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Actual|389|||Both|18 Years|79 Years|No|||July 2007|November 30, 2009|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00392639||177497|
NCT00392652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00867|Diindolylmethane in Healthy Volunteers|Phase 1 Multiple-Dose Safety, Pharmacokinetic, and Drug Interaction Clinical Study of Nutritional-Grade, Absorption-Enhanced DIM (BR-DIM)||National Cancer Institute (NCI)||Completed|November 2006|October 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|14|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2014|September 12, 2014|October 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00392652||177496|
NCT00392665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-111|Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck|Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck||Massachusetts General Hospital||Active, not recruiting|October 2006|December 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|October 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392665||177495|
NCT00392912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-294|Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone|A Pilot Study of the Effect of Testosterone on Cerebral Glucose Metabolism in Hypogonadal Males With Alzheimer's Disease||VA Medical Center, Houston|No|Completed|April 2007|July 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|55 Years|N/A|No|||August 2010|August 18, 2010|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00392912||177476|
NCT00393523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V232-058|Hepatitis B Vaccine Booster Study (V232-058)|A Study to Assess the Anamnestic Immune Response 4 to 8 Years After a Primary Vaccination Series With HBVAXPRO||Merck Sharp & Dohme Corp.|No|Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|1478|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|October 25, 2006|Yes|Yes||No|May 27, 2009|https://clinicaltrials.gov/show/NCT00393523||177433|
NCT00393536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEOVPAPHC-01|Study of Whether Educational Visits to Primary Care Professionals Improves the Quality of Care They Provide.|A Pragmatic Randomized Controlled Trial of Untargeted Educational Outreach Visiting Delivered by Pharmaceutical Advisers in Primary Care.||Newcastle University||Completed|July 1999|December 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||73|||Both|N/A|N/A|No|||October 2006|October 26, 2006|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393536||177432|
NCT00393822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040122|A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer|A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer Receiving 5-FU and Leucovorin as Adjuvant Therapy||Amgen|No|Completed|August 2005|March 2014|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393822||177410|
NCT00396305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0070|Th1 Response to Influenza: Aging and Vaccine Efficacy|Th1 Response to Influenza: Aging and Vaccine Efficacy||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|November 2006|January 2008|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|41|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2010|August 26, 2010|November 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00396305||177223|
NCT00396318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N3699g|A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|TROPICS 2|Genentech, Inc.||Completed|December 2006|||June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|251|||Both|N/A|N/A|No|||March 2011|March 29, 2011|November 2, 2006|Yes|Yes||No|September 19, 2010|https://clinicaltrials.gov/show/NCT00396318||177222|
NCT00396591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD6772|AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites|A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites||Sanofi|No|Completed|October 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|N/A|No|||July 2011|January 9, 2013|November 6, 2006|Yes|Yes||No|August 17, 2012|https://clinicaltrials.gov/show/NCT00396591||177201|
NCT00398138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-085|Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma|Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Thoracic and Myeloid Neoplasms||Memorial Sloan Kettering Cancer Center||Completed|October 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|120 Years|No|||February 2016|February 2, 2016|November 9, 2006|No|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00398138||177085|
NCT00398944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFTG1968A|Impact of a Computerized Guidelines on the Management of Hypertension and Diabetes|Impact of a Computerized Decision Support System, Based on EBM French Guidelines, on the Management of Hypertension and Diabetes: a Randomised Controlled Trial in Primary Care|ASTI|Société de Formation Thérapeutique du Généraliste|No|Completed|November 2006|May 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|2715|||Both|25 Years|N/A|No|||November 2006|July 26, 2010|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00398944||177026|
NCT00395109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-370|PET/CT to Image Hypoxia in Head and Neck Tumours|PET/CT to Image Hypoxia in Head and Neck Tumours||Lawson Health Research Institute|No|Recruiting|January 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|17|||Both|18 Years|80 Years|No|||February 2009|February 10, 2009|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00395109||177314|
NCT00392431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000B133|Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation|Continuous Versus Episodic Prophylactic Treatment With Oral Amiodarone for the Prevention of Permanent Atrial Fibrillation: a Randomized Study on Morbidity and Quality of Life||University Medical Center Groningen||Completed|January 2003|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||220|||Both|18 Years|N/A|No|||March 2007|March 21, 2007|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392431||177511|
NCT00392444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00693|Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma|A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Completed|February 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||April 2013|May 5, 2014|October 25, 2006|Yes|Yes||No|October 21, 2013|https://clinicaltrials.gov/show/NCT00392444||177510|
NCT00393003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foch-1|Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index|Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index: Comparison Between Manual Perfusion and Automated Perfusion||Hopital Foch|No|Completed|September 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|N/A|No|||August 2009|August 28, 2009|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00393003||177469|
NCT00392730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gerber07-01-06JLA|Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children|Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children||Vanderbilt University|Yes|Completed|August 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|122|Samples Without DNA|Blood|Both|N/A|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Term and preterm infants on prolonged PN in the NICU and post-discharge and young children        on home PN and age-matched controls|December 2013|December 18, 2013|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00392730||177490|
NCT00392743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT108154|A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients|An Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders||GlaxoSmithKline|No|Completed|December 2006|May 2007|Actual|May 2007|Actual|N/A|Observational|N/A||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a methodology study.|October 2012|November 1, 2012|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00392743||177489|
NCT00393029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070003|Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes|Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)|No|Completed|October 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||August 2011|August 10, 2011|October 25, 2006||No||No|June 1, 2011|https://clinicaltrials.gov/show/NCT00393029||177468|
NCT00382785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDD#504604|Psychosocial Outcomes in Online Cancer Support Groups|Psychosocial Outcomes in Online Cancer Support Groups||Christiana Care Health Services|No|Completed|September 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|51|||Female|21 Years|N/A|No|||November 2010|November 23, 2010|September 28, 2006||No||No|September 29, 2010|https://clinicaltrials.gov/show/NCT00382785||178241|One limitation was the lack of a control group of women who did not take part in an online or face-to-face support group. The reasons for this are explained above.
NCT00382798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7081-5101|Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin|A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, & Food Effect of RO5024048 in Healthy Volunteers & in Patients With Chronic HCV Infection|R7128|Pharmasset|Yes|Completed|October 2006|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|13||Anticipated|75|||Both|18 Years|65 Years|No|||April 2009|April 23, 2009|September 28, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00382798||178240|
NCT00392119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUROLITT|MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors|The Clinical Evaluation of the Stereotactic, MR Guided, Laser Interstitial Thermal Therapy (LITT ) for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors - a Phase I Study With Direct Patient Benefice||BioTex, Inc.||Completed|October 2006|December 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||December 2009|December 30, 2009|October 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00392119||177535|
NCT00398957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011611|An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg|An Open Label Evaluation of the Dose Proportionality of Dilaudid SR (OROS� Hydromorphone HCL) Tablets 8mg, 16mg, 32mg, and 64mg||Alza Corporation, DE, USA||Completed||September 1998|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00398957||177025|
NCT00399230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5279|A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||August 2007|August 17, 2007|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00399230||177005|
NCT00399464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5791|Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia|Efficacy and Safety of SL77.0499-10 10mg Once Daily in Comparison With Placebo and Tamsulosin Hydrochloride 0.2mg in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH).||Sanofi||Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1177|||Male|50 Years|N/A|No|||October 2009|October 1, 2009|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399464||176987|
NCT00395122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT in band atrophy|Optical Coherence Tomography Measurements in Eyes With Band Atrophy|Evaluation of the Diagnostic Ability of Optical Coherence Tomography With a Normative Database to Detect Band Atrophy of the Optic Nerve||University of Sao Paulo||Completed|April 2005|October 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2006|November 1, 2006|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395122||177313|
NCT00392925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA101|A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects|A Phase 2A, Randomized, Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Effect on Body Weight of Recombinant-Methionyl Human Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects||AstraZeneca|No|Completed|October 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|177|||Both|18 Years|55 Years|No|||March 2015|March 26, 2015|October 24, 2006|Yes|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT00392925||177475|
NCT00393198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91473|Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia|Multicenter Study to Investigate the Bleeding Profile and the Insertion Easiness in Women Inserted With a Second Consecutive MIRENA for Contraception or Menorrhagia||Bayer|No|Completed|October 2006|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|204|||Female|23 Years|45 Years|No|||October 2014|October 31, 2014|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393198||177457|
NCT00392938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6129|Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone|Positron Emission Tomography Imaging of Bone in Patients With Metastatic Prostate Cancer - A Pilot Study Evaluating Treatment Response||University of Washington||Completed|December 2005|||May 2010|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|40|||Male|18 Years|N/A|No|||May 2013|May 15, 2013|October 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00392938||177474|
NCT00393835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661176|A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis|A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin Sustained Release (SR) For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis In Japan Adults||Pfizer||Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|99|||Both|16 Years|80 Years|No|||May 2008|May 15, 2008|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393835||177409|
NCT00394134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0901|Targeted Intervention for Melanoma Prevention|A Targeted, Family-Focused Intervention for Melanoma Prevention||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2005|||April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|570|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00394134||177386|
NCT00391092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20231|A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.|A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer.||Hoffmann-La Roche||Completed|September 2006|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|424|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|October 20, 2006||No||No|July 21, 2015|https://clinicaltrials.gov/show/NCT00391092||177614|
NCT00397215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108251|Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age|Evaluate Immunogenicity & Safety of a Single or Double-dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-administration Schedule (21 Days Apart) in Adults Over 60 Yrs||GlaxoSmithKline||Completed|November 2006|September 2009|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|437|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 28, 2013|November 7, 2006|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00397215||177154|
NCT00391365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4513-R|Treatment Outcomes for Ankle Arthritis|Treatment Outcomes for Ankle Arthritis||VA Office of Research and Development|No|Active, not recruiting|October 2006|July 2022|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|358|None Retained|No biospecimens are used in this project|Both|18 Years|89 Years|No|Non-Probability Sample|Subjects with ankle osteoarthritis who will undergo either ankle arthrodesis (fusion) or        ankle arthroplasty (replacement)|January 2016|January 22, 2016|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00391365||177593|
NCT00391703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC05/31|Assessment of Quadriceps Muscle Electrostimulation Used in Patients Suffering From Cystic Fibrosis|Assessment of Quadriceps Muscle Electrostimulation Used as an Additional Procedure for Effort Retraining in Patients Suffering From Cystic Fibrosis Associated With Severe Pulmonary Dysfunction|STIMUCO|University Hospital, Grenoble|No|Terminated|October 2006|September 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2010|November 10, 2010|October 23, 2006||No|enrolment difficulties|No||https://clinicaltrials.gov/show/NCT00391703||177567|
NCT00391924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR 98-2-301|Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome|Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration||UMC Utrecht||Completed|May 2000|January 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Female|18 Years|N/A|No|||October 2006|October 24, 2006|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00391924||177550|
NCT00392210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15107|Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery|Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery||University of Rochester|No|Completed|October 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|135|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 15, 2009|October 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00392210||177528|
NCT00392457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 HD15788 - 234|Investigating the Regulation of Reproductive Hormones in Adult Men|Feedback Control of FSH Secretion in the Human Male||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|July 1995|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|175|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2010|February 12, 2015|October 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00392457||177509|
NCT00393042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124E US15|Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR|Sleep and Tolerability of Extended Release Dexmethylphenidate vs. Mixed Amphetamine Salts: A Double Blind, Placebo Controlled Study (SAT STUDY)||University of Illinois at Chicago|Yes|Completed|January 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|77|||Both|9 Years|17 Years|No|||September 2010|September 27, 2010|October 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393042||177467|
NCT00393315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBM-VS-53|P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses|P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses: A Comparison to the Paclitaxel-Eluting Taxus™ Stent. A Pilot Study||University Hospital, Saarland||Completed|November 2005|December 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393315||177449|
NCT00393328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-282|Bioequivalence Study of Atazanavir 300 mg Capsule|Bioequivalence Study of Atazanavir Single 300 mg Capsule Relative to Two Atazanavir 150 mg Capsules in Healthy Subjects||Bristol-Myers Squibb||Completed|November 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2|||46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|April 7, 2011|October 23, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00393328||177448|
NCT00383695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000503948|Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer|A Multicentre Randomised Phase II Clinical Trial Comparing Oxaliplatin (Eloxatin), Capecitabine (Xeloda) and Pre-Operative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision for the Treatment of Patients With Magnetic Resonance Imaging (MRI) Defined High Risk Rectal Cancer|EXPERT-C|Royal Marsden NHS Foundation Trust|Yes|Active, not recruiting|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|164|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383695||178171|
NCT00392132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMMC - HIV and CKD|Impact of Screening Patients With HIV for Kidney Disease|Impact of Screening Patients With HIV for Kidney Disease||University of Mississippi Medical Center||Withdrawn|October 2005|October 2006|Anticipated|October 2006|Anticipated|N/A|Observational|N/A||||1400|||Both|18 Years|N/A|No|||November 2008|November 24, 2008|October 23, 2006||No|Sufficient study funding was not obtained.|No||https://clinicaltrials.gov/show/NCT00392132||177534|
NCT00395408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-097|Linear Growth Study (0476-097)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Effect on Linear Growth of Montelukast With Placebo and Inhaled Beclomethasone in Pediatric Patients (Prepubertal, Tanner Stage I) With Mild Asthma||Merck Sharp & Dohme Corp.||Completed|June 2000|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|360|||Both|6 Years|8 Years|No|||September 2015|September 22, 2015|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395408||177291|
NCT00395421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-08A-008|Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin|A Partially-blinded, Randomized, Parallel-group Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between Valopicitabine and Ribavirin When Administered in Combination With Pegylated Interferon Alfa-2a in Treatment-naive Patients With Chronic Hepatitis C||Merck Sharp & Dohme Corp.|No|Completed|October 2006|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|65 Years||||June 2010|June 9, 2010|November 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00395421||177290|
NCT00397241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A733|24-hour Intraocular Pressure (IOP) Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-angle Glaucoma|24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy.||Aristotle University Of Thessaloniki|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|33|||Both|29 Years|80 Years|No|||May 2014|May 9, 2014|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00397241||177152|
NCT00397254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078-00|Two Rizatriptan Prescribing Portions for Treatment of Migraine|An Observer-Blind, Randomized, Parallel-Group Study to Compare the Efficacy of Two Rizatriptan Prescribing Portions for the Treatment of Migraine||Clinvest|No|Completed|December 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|June 7, 2010|November 7, 2006|Yes|Yes||No|March 6, 2009|https://clinicaltrials.gov/show/NCT00397254||177151|
NCT00396344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS#20361|Cortisol Control of Human Inflammatory Responses to Endotoxin|The Effect of Glucocorticoid Pre-Treatment on the Systemic Cytokine Response to Endotoxin in Human Volunteers||Dartmouth-Hitchcock Medical Center||Completed|October 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2008|May 6, 2008|November 3, 2006||||No||https://clinicaltrials.gov/show/NCT00396344||177220|
NCT00396955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3175A1-202|A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee|A Multicenter, Randomized, Double-Blind Comparison of 4 Dose Regimens of Pla-695, Naproxen, and Placebo Administered Daily for 6 Weeks in Subjects With Active Osteoarthritis of the Knee||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|November 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||560|||Both|50 Years|75 Years|No|||December 2007|December 19, 2007|November 7, 2006|||imbalance of gastrointestinal and the lipase events|||https://clinicaltrials.gov/show/NCT00396955||177173|
NCT00396968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-2201|AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS|AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes||Sanofi||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|60 Years|No|||February 2014|February 10, 2014|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00396968||177172|
NCT00393848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR052293|Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery|Restoration of Muscle Following Hip Surgery||University of Arkansas|Yes|Completed|October 2006|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|40|||Both|30 Years|80 Years|No|||May 2014|May 30, 2014|October 27, 2006|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00393848||177408|
NCT00394771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-ASC-201|A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale|A Prospective, Multicenter, Double-Blinded, Randomized Study to Evaluate Bleeding Patterns in Women Using One of Three Different Doses of DR-1031 Oral Contraceptive Compared to Seasonale Oral Contraceptive Regimen||Teva Pharmaceutical Industries|No|Completed|October 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|567|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|October 30, 2006|Yes|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT00394771||177339|
NCT00390455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00475|Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive|Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 2006|||July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|295|||Female|18 Years|N/A|No|||January 2015|June 1, 2015|October 18, 2006|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT00390455||177663|
NCT00391105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIC 287/04|Remifentanil Versus Morphine for Sedation of Premature Neonates With Respiratory Distress Syndrome|Comparative Study of the Use of Remifentanil Versus Morphine for Sedation and Analgesia of Premature Neonates During Mechanical Ventilation in the Treatment of Respiratory Distress Syndrome (RDS)||Federal University of Minas Gerais||Completed|April 2004|November 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|||||||Both|N/A|28 Days|No|||October 2006|October 19, 2006|October 19, 2006||||No||https://clinicaltrials.gov/show/NCT00391105||177613|
NCT00391378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906245|Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)|Cerebral Lesions and Outcomes After Cardiac Surgery (CLOCS)||National Institutes of Health Clinical Center (CC)||Completed|September 2006|January 2011||||N/A|Observational|N/A|||Anticipated|363|||Both|18 Years|N/A|No|||January 2011|September 26, 2015|October 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00391378||177592|
NCT00391716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMAS014028|Gabapentin Treatment of Alcohol Dependence|Gabapentin Treatment of Alcohol Dependence||The Scripps Research Institute|No|Completed|February 2004|February 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|October 20, 2006|Yes|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT00391716||177566|
NCT00391937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-DP-001|Efficacy of a New Resurfacing Hip Prosthesis|Efficacy of a New Resurfacing Hip Prosthesis. A Multicenter, Prospective, Randomized, Controlled Study||Erasmus Medical Center||Completed|October 2006|January 2013|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|60 Years|No|||February 2013|February 28, 2013|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00391937||177549|
NCT00392223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661150|Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne|A Phase III, Multicenter, Randomized, Double Blind-Double Dummy Study, To Evaluate Efficacy And Safety Of Treatment With Azithromycin, Microspheres, Oral Powder For Suspension, 2 G, In One Administration A Week, For 8 Weeks, Compared With Treatment With Minocycline Capsules, 100 Mg Die For 8 Weeks, In Outpatients With Moderate To Severe Inflammatory Acne.||Pfizer||Terminated|October 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|118|||Both|16 Years|N/A|No|||January 2010|January 5, 2010|October 23, 2006|Yes|Yes|See Detailed Description|No|June 11, 2009|https://clinicaltrials.gov/show/NCT00392223||177527|
NCT00392236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH074844|Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers|2-Way Pagers to Improve Schizophrenia Medication Adherence||Northwell Health|Yes|Completed|April 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|October 23, 2006||No||No|March 10, 2014|https://clinicaltrials.gov/show/NCT00392236||177526|
NCT00392756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HD028138-024|Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)|Role of Gonadotropin Pulsations in the Reversal of Hypogonadotropic Hypogonadism||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|April 1989|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|800|||Both|16 Years|N/A|No|||March 2016|March 15, 2016|October 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00392756||177488|
NCT00392769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0211|Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer|Phase II Study of Cetuximab (Erbitux) in Patients With Progressive or Recurrent Endometrial Cancer||M.D. Anderson Cancer Center|No|Completed|October 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|N/A|N/A|No|||August 2012|August 3, 2012|October 25, 2006||No||No|August 3, 2012|https://clinicaltrials.gov/show/NCT00392769||177487|
NCT00393055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-18038|Xylitol Adult Caries Trial (X-ACT)|Xylitol Adult Caries Trial (X-ACT)||University of North Carolina, Chapel Hill|Yes|Completed|January 2007|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|709|||Both|25 Years|80 Years|No|||September 2011|September 9, 2011|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00393055||177466|
NCT00393341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609-21|Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer|Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer|EPC|Indiana University||Completed|October 2006|August 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|68|Samples With DNA|Blood sample|Female|18 Years|N/A|No|Non-Probability Sample|Women 18 or older with breast cancer recieving treatment at IUSCC and willing to donate a        blood sample and complete consent form.|August 2015|August 27, 2015|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00393341||177447|
NCT00391885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foch-4|Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy|Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy of the Electroencephalogram: Comparison Between Manual Perfusion and Automated Perfusion||Hopital Foch||Completed|September 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||April 2007|April 21, 2007|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00391885||177553|
NCT00395759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCO2-2233|The Visual Effect of an Investigational Artificial Tear in the Tear Layer.|The Visual Effect of an Investigational Artificial Tear in the Tear Layer.||Southern California College of Optometry||Completed|September 2005|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Supportive Care||||30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2007|October 21, 2007|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395759||177265|
NCT00396058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002554-29|The Effect of Methylphenidate on Motor Learning in Stroke Patients|Methylphenidats Betydning for motoriskindlæring Hos Patienter Med Apopleksi||University of Aarhus|No|Terminated|November 2006|March 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|13|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|November 3, 2006|||Recruitment of patients proved much too difficult based on the chosen criteria.|No||https://clinicaltrials.gov/show/NCT00396058||177242|
NCT00396617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3736|Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy|Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy||University Hospital, Strasbourg, France|No|Recruiting|December 2007|March 2014|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00396617||177199|
NCT00396630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106260|A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family|A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family||GlaxoSmithKline||Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|6 Weeks|14 Weeks|Accepts Healthy Volunteers|||March 2009|April 1, 2009|November 6, 2006|Yes|Yes||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00396630||177198|
NCT00392691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 37/05|Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment|Ibritumomab Tiuxetan and High-Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation for Elderly Patients With Lymphoma in Relapse or Resistant to Chemotherapy. A Multicenter Phase I Trial||Swiss Group for Clinical Cancer Research|No|Completed|October 2006|May 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|65 Years|N/A|No|||July 2013|July 9, 2013|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00392691||177493|
NCT00394472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00011|Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients|A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an Incomplete Response to PPI.||AstraZeneca||Completed|November 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|244|||Both|17 Years|70 Years|No|||February 2013|February 14, 2013|October 31, 2006||||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00394472||177361|
NCT00394485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPPI-MPTA-COPD-1|Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients|A Randomized Crossover Trial Comparing the Efficacy and Safety of Tiotropium + Procaterol vs. Tiotropium + Placebo in Moderate COPD Patients||Otsuka Pharmaceutical, Inc., Philippines||Terminated|May 2006|April 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|40 Years|75 Years|No|||December 2009|December 15, 2009|October 31, 2006||No|Difficulty in recruting patients|No||https://clinicaltrials.gov/show/NCT00394485||177360|
NCT00390754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95530-00|Usefulness of Home Pregnancy Testing|Utility of Home Pregnancy Testing in Medicaid Women at Risk for Unintended Pregnancy||Michigan State University|Yes|Completed|October 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|198|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||July 2008|July 25, 2008|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00390754||177640|
NCT00390780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA/2004/01/04|Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients|A Comparative Randomized, Double-blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (Clotrimazole 10mg) Administered Five Times a Day in the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients||Onxeo|Yes|Completed|July 2006|January 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|578|||Both|18 Years|N/A|No|||February 2013|September 5, 2013|October 19, 2006|Yes|Yes||No|September 7, 2012|https://clinicaltrials.gov/show/NCT00390780||177638|
NCT00391118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10708|Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")|A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer||Eli Lilly and Company|Yes|Completed|November 2006|July 2012|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|149|||Female|18 Years|N/A|No|||July 2012|July 19, 2012|October 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391118||177612|
NCT00391391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID07|Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children|Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.||Sanofi|Yes|Completed|October 2006|October 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|520|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||November 2011|November 21, 2011|October 23, 2006|Yes|Yes||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00391391||177591|
NCT00391729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-855|A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)||Abbott||Completed|October 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|60 Years|No|||October 2011|October 14, 2011|October 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391729||177565|
NCT00391950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GGB12|Maintaining Bone Strength in Men With Prostate Cancer|An Open-Label, Randomized, Multicentre Study to Evaluate the Efficacy of Two Zoledronic Acid Schedules on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy||Novartis||Terminated|October 2006|||May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Male|18 Years|N/A|No|||November 2009|November 20, 2009|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391950||177548|
NCT00392249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGMILRH 01|Supervised Treatment of Schizophrenia, a Randomized Controlled Trial.|Supervised Treatment in Outpatients for Schizophrenia (STOPS)Versus Treatment as Usual in Outpatients, a Randomized Controlled Trial.||Lady Reading Hospital, Pakistan||Active, not recruiting|November 2006|September 2008|Anticipated|September 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|110|||Both|17 Years|60 Years|No|||February 2008|February 25, 2008|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00392249||177525|
NCT00392470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000512816|Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer|Neoadjuvant Conformal Radiotherapy and Concomitant CPT-11 and EGFR Inhibition With Cetuximab in Patients With Rectal Cancer Phase I Study||National Cancer Institute (NCI)||Recruiting|August 2006|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|74 Years|No|||April 2008|May 24, 2011|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392470||177508|
NCT00392782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004UC035|Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease|A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies||Masonic Cancer Center, University of Minnesota|Yes|Completed|July 2005|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|60 Years|No|||November 2012|November 6, 2012|October 25, 2006|Yes|Yes||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00392782||177486|
NCT00393068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 91|Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer|A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer||SCRI Development Innovations, LLC|No|Completed|February 2007|August 2011|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|October 25, 2006|No|Yes||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00393068||177465|
NCT00393354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-041|Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)|A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain||Merck Sharp & Dohme Corp.||Completed|April 2000|November 2000|Actual|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|325|||Both|18 Years|75 Years|No|||November 2015|November 27, 2015|October 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393354||177446|
NCT00383409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/2005|Multivitamins do Not Improve Radiation Therapy Related Fatigue|Multivitamins do Not Improve Radiation Therapy Related Fatigue: Results of a Double-Blind Randomized Cross-Over Trial||Faculdade de Medicina do ABC||Completed|March 2006|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Female|18 Years|75 Years|No|||October 2006|October 2, 2006|October 2, 2006||||No||https://clinicaltrials.gov/show/NCT00383409||178193|
NCT00383422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8580|Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis|The Comparison of the Efficacy and Safety of Arzoxifene Versus Raloxifene in Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|320|||Female|50 Years|75 Years|No|||January 2010|January 26, 2010|September 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00383422||178192|
NCT00383448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2006-14|HSCT for High Risk Inherited Inborn Errors|Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation||Masonic Cancer Center, University of Minnesota|No|Completed|September 2006|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|N/A|70 Years|No|||April 2015|April 22, 2015|September 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00383448||178190|
NCT00397826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0733-265|Evaluation of the Effects of Simvastatin 40mg|Evaluation of the Effects of Simvastatin 40 Mg on Lipid Profiles and Specified Circulatory Parameters in Normotensive Hypercholesterolemia Patients(MK-0733-265)||Cardinal Tien Hospital|No|Completed|January 2005|December 2015|Actual|January 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00397826||177109|
NCT00397839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BON105960|The Effect Of Oral Ibandronate In Male Osteoporosis|A Parallel, Placebo-controlled, Randomized (2:1) Double-blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-monthly Versus Placebo on LS BMD in Men With Osteoporosis|STRONG|Hoffmann-La Roche||Completed|January 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Male|30 Years|N/A|No|||November 2009|November 17, 2009|November 9, 2006|Yes|Yes||No|November 17, 2009|https://clinicaltrials.gov/show/NCT00397839||177108|
NCT00393900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0605013|Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion|Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion||Children's Hospital of Pittsburgh|No|Completed|August 2006|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|Samples With DNA|Buccal cells obtained for DNA|Both|3 Years|6 Years|No|Probability Sample|Children 3-6 years old who underwent tympanostomy tube insertion for chronic otitis media        with effusion within the 6 weeks prior to study enrollment|December 2013|December 19, 2013|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00393900||177404|
NCT00392145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008579|Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis|Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis: A Randomized Controlled Trial||The Hospital for Sick Children|Yes|Completed|November 2006|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|90 Days|18 Years|No|||December 2013|December 10, 2013|June 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00392145||177533|
NCT00392405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1|Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate|Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate||Norton Community Hospital||Not yet recruiting|November 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||656|||Both|18 Years|N/A|No|||October 2006|October 25, 2006|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392405||177513|
NCT00393562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADRECC 01|Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease|Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease||VA Office of Research and Development|No|Withdrawn|March 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|50 Years|80 Years|No|||June 2015|June 25, 2015|October 26, 2006|||Unable to recruit any subjects for this study|No||https://clinicaltrials.gov/show/NCT00393562||177430|
NCT00390494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-44020|Questionnaire Study to Assess Quality of Life After Treatment of Fibroids|Outcome From Fibroid Therapies: A Comparison With Normal Controls||Walter Reed Army Medical Center||Active, not recruiting|December 2005|December 2010||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 26, 2008|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00390494||177660|
NCT00390793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0478|Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL|Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2006|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390793||177637|
NCT00390806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYT105962|Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer|A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer||GlaxoSmithKline|Yes|Completed|December 2006|September 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|472|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|October 19, 2006|Yes|Yes||No|March 8, 2013|https://clinicaltrials.gov/show/NCT00390806||177636|
NCT00391404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK-CCFGrants2005.TFL|Fosamax for Childhood Cancer Survivors|Randomized Controlled Study on the Benefits and Safety of Bisphosphonate Treatment in Childhood Cancer Survivors||Chinese University of Hong Kong|No|Recruiting|May 2006|October 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|N/A|No|||May 2008|May 22, 2008|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391404||177590|
NCT00391742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIP|Stepped Interventions for Problem Drinkers|A Stepped-Care Approach for General Practice Patients With Alcohol Use Disorders||University of Luebeck||Completed|October 2001|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||450|||Both|18 Years|64 Years|No|||October 2006|October 23, 2006|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391742||177564|
NCT00391963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foch-2|Comparison of the Bispectral Index and the Entropy of the Electroencephalogram During Total Intravenous Anesthesia|Comparison of the Bispectral Index and the Entropy of the Electroencephalogram During Total Intravenous Anesthesia||Hopital Foch||Completed|June 2006|April 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||84|||Both|18 Years|N/A|No|||January 2009|January 14, 2009|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00391963||177547|
NCT00392262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489ADE03|A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients|An Multicenter Study to Evaluate the Efficacy and Tolerability of a 4-week Therapy With the Combination of Valsartan 160mg + Amlodipine 5mg in Hypertensive Patients Not Adequately Responding to 4-week Treatment With Amlo 5mg or Felodipine 5mg in Monotherapy||Novartis||Completed|August 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|224|||Both|18 Years|N/A||||November 2011|November 7, 2011|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00392262||177524|
NCT00392275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0208-29|Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs|Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs||Indiana University||Completed|November 2002|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||48|||Both|N/A|N/A|No|||December 2007|April 8, 2013|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00392275||177523|
NCT00392483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHP-06-02-FEAP|Reuptake of an E-Learning Programme in General Practice|The Use and Diffusion of an E-learning Programme in Diagnostic Evaluation of Dementia Among General Practitioners in Denmark||Research Unit Of General Practice, Copenhagen||Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3632|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All GPs in Denmark|November 2006|June 24, 2010|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392483||177507|
NCT00392496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00692|Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma|A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma||National Cancer Institute (NCI)||Completed|February 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2013|April 28, 2014|October 25, 2006|Yes|Yes||No|October 21, 2013|https://clinicaltrials.gov/show/NCT00392496||177506|
NCT00392795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG072472 01A1|The BRAIN Intensive Care Unit (ICU) Study: Bringing to Light the Risk Factors|The BRAIN ICU Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors|BRAIN-ICU|Vanderbilt University|No|Active, not recruiting|January 2007|December 2016|Anticipated|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|826|Samples With DNA|blood|Both|18 Years|N/A|No|Probability Sample|Medical and Surgical ICUs|November 2015|November 4, 2015|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00392795||177485|
NCT00392808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSISP-VAC-MENC1|Immunogenicity of the Booster Dose of Two MenC Vaccines|Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life.|CSISP-MENC1|Centro Superior de Investigación en Salud Publica|No|Completed|January 2007|May 2009|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|389|||Both|14 Months|19 Months|Accepts Healthy Volunteers|||August 2013|August 6, 2013|October 25, 2006||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT00392808||177484|
NCT00393705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10916|Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)|A Comparison of Insulin Lispro MM Intensive Mixture Therapy With Progressive Dose-Titration of Insulin Lispro LM or Biphasic Insulin Aspart 30/70|S019|Eli Lilly and Company|No|Completed|October 2006|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|30 Years|75 Years|No|||July 2010|July 15, 2010|October 26, 2006|Yes|Yes||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00393705||177419|
NCT00394004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070015|Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials|Exploring Decision Making of Hispanics and African Americans With HIV/AIDS Participating in Clinical Trials||National Institutes of Health Clinical Center (CC)||Completed|October 2006|April 2011||||N/A|Observational|N/A|||Actual|35|||Both|18 Years|N/A|No|||April 2011|September 26, 2015|October 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00394004||177396|
NCT00383461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2004-P-001029/2|Computer-Based Stop Smoking Program in Assisting Doctors in Helping Adults Stop Smoking|Computerized EMR-Assisted Smoking Cessation (CEASCE)||Brigham and Women's Hospital|No|Completed|April 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label|||Anticipated|4314|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|September 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00383461||178189|
NCT00383721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04230|Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)|A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD||Merck Sharp & Dohme Corp.|Yes|Completed|September 2006|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1196|||Both|40 Years|N/A|No|||September 2015|September 2, 2015|September 29, 2006|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00383721||178169|
NCT00398697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 102|Phase I Perifosine and Gemcitabine Study|Phase 1 Trial of the Combination of Perifosine and Gemcitabine||AEterna Zentaris||Completed|August 2004|January 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||19|||Both|18 Years|N/A|No|||January 2007|February 12, 2014|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00398697||177044|
NCT00395135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-009|BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management|BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management; A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients||Arena Pharmaceuticals|Yes|Completed|November 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3182|||Both|18 Years|65 Years|No|||January 2013|January 4, 2013|October 31, 2006|Yes|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00395135||177312|
NCT00393913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1357|Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness|Relating Sleep Disordered Breathing to Daytime Function||New York University School of Medicine|Yes|Completed|October 2006|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects coming to the NYU sleep center with complaints of sleep disordered breathing and        normal controls.|January 2015|January 12, 2015|October 30, 2006||No||No|February 18, 2014|https://clinicaltrials.gov/show/NCT00393913||177403|
NCT00394212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-EC-002|Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass|Randomized Evaluation of Endoscopic Suturing Transorally for Anastomotic Outlet Reduction (RESTORe) for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass Surgery||C. R. Bard|Yes|Terminated|November 2006|May 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|October 27, 2006|Yes|Yes|For business reasons|No|August 3, 2011|https://clinicaltrials.gov/show/NCT00394212||177380|Limitations of this study are that study enrollment was prematurely discontinued; therefore the study was underpowered for the analysis of both the primary and secondary effectiveness endpoints.
NCT00393211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-042|Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)|A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain||Merck Sharp & Dohme Corp.||Completed|April 2000|November 2000|Actual|November 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|319|||Both|18 Years|75 Years|No|||November 2015|November 27, 2015|October 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393211||177456|
NCT00393549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALP-000986|NeuroPath Comparative Validation Study Plan|||Excel-Tech Ltd.||Terminated|August 2006|December 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2007|June 5, 2007|October 27, 2006|||Sponsor decision to terminate.|No||https://clinicaltrials.gov/show/NCT00393549||177431|
NCT00394823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ADE24|VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients|A Randomized, Open-label, Multicentric Parallel Group Study to Assess the Impact of Supportive Measures on the Drug Adherence of Patients With Essential Hypertension Treated With Valsartan or Valsartan Plus HCTZ for 34 Weeks With or Without Respective Measures||Novartis||Completed|November 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|206|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394823||177335|
NCT00390221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205-MS-201|Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis|Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis|SELECT|Biogen|Yes|Completed|February 2008|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|626|||Both|18 Years|55 Years|No|||October 2014|October 13, 2014|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390221||177681|
NCT00390520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2386|Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes|A Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Assess the Effect of Vildagliptin on Glucagon Counterregulatory Response During Hypoglycemia in Patients With Type 2 Diabetes.||Novartis||Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A||||July 2009|July 13, 2009|October 19, 2006||||No||https://clinicaltrials.gov/show/NCT00390520||177658|
NCT00390819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131074|Epidemiology of Community Acquired Pneumonia in North Israel|Epidemiology of Community Acquired Pneumonia in North Israel||HaEmek Medical Center, Israel||Not yet recruiting|November 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|100|||Both|18 Years|N/A|No|||October 2006|October 19, 2006|October 19, 2006||||No||https://clinicaltrials.gov/show/NCT00390819||177635|
NCT00391131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-SCIG-05-23|Subcutaneous Ig NextGen 16% in PID Patients|A Multi-centre, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Subcutaneous Infusions of Ig NextGen 16% in Patients With Primary Immunodeficiency (PID).||CSL Limited||Completed|April 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|3 Years|N/A|No|||June 2012|June 5, 2012|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00391131||177611|
NCT00391417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EST005|Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms|Phase III, Multicenter, Double-Blind Study of the Safety and Efficacy of Bio-E-Gel (Topical Estradiol Gel) Versus Placebo for Treatment of Vasomotor Symptoms and Vulvovaginal Atrophy in Postmenopausal Females||BioSante Pharmaceuticals||Completed|September 2003|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||431|||Female|18 Years|N/A|No|||October 2006|October 20, 2006|October 20, 2006||||||https://clinicaltrials.gov/show/NCT00391417||177589|
NCT00391430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH058911|Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder|Cognitive Behavioral Therapy vs. Sertraline in the Treatment of Post Traumatic Stress Disorder||New York University School of Medicine||Completed|May 2005|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 3, 2013|October 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391430||177588|
NCT00391755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-013R|A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches|A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches||Charlottesville Neuroscience|Yes|Terminated|October 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|October 22, 2006|Yes|Yes|Failure to recruit necessary number of patients.|No||https://clinicaltrials.gov/show/NCT00391755||177563|
NCT00391976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100B2301|Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis|The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis|ELITE|Novartis|No|Completed|November 2003|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|6 Months|N/A|No|||July 2011|July 29, 2011|October 19, 2006||No||No|May 18, 2011|https://clinicaltrials.gov/show/NCT00391976||177546|
NCT00391989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1205|Treatment of Adult Ph+ LAL With BMS-354825|A Phase II Multicenter Study on the Treatment of Adult de Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) With the Protein Tyrosine Kinase Inhibitor BMS-354825. EudraCT Number 2005-005107-42.||Gruppo Italiano Malattie EMatologiche dell'Adulto||Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|October 24, 2006||No||No|January 23, 2014|https://clinicaltrials.gov/show/NCT00391989||177545|
NCT00392288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6695|Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.|A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 μg BID or 40 μg BID for 12 Weeks in Patients Aged 4 to <12 Years With Persistent Asthma.||Nycomed||Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|528|||Both|4 Years|11 Years|No|||May 2012|May 4, 2012|October 24, 2006|Yes|Yes||No|July 1, 2009|https://clinicaltrials.gov/show/NCT00392288||177522|
NCT00392509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB IND 12875|ALD-301 for Critical Limb Ischemia, Randomized Trial|A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease|CLI-001|Aldagen|Yes|Completed|October 2006|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|October 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392509||177505|
NCT00393367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-8-4875|Budesonide Inhalation Suspension for Acute Asthma in Children|Budesonide Inhalation Suspension for Acute Asthma in Children||Children's Hospital of Philadelphia|No|Completed|December 2006|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|2 Years|18 Years|No|||August 2012|August 6, 2012|October 25, 2006||No||No|April 9, 2010|https://clinicaltrials.gov/show/NCT00393367||177445|
NCT00393718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1700|Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|November 2006|May 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|20 Years|N/A|No|||November 2014|November 17, 2014|October 27, 2006|Yes|Yes||No|February 23, 2010|https://clinicaltrials.gov/show/NCT00393718||177418|
NCT00393731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-008|A Randomized, Control Trial for Preinduction Cervical Ripening|A Randomized, Control Trial for Preinduction Cervical Ripening||The University of Texas Health Science Center, Houston||Completed|January 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|540|||Female|N/A|N/A||||January 2008|January 11, 2008|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393731||177417|
NCT00394017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPH-06-01-FEAP|The Use of Reminders in Implementing an E-learning Program in General Practice|Implementation of an E-learning Program in Diagnostic Evaluation of Dementia by Reminders: A RCT Among General Practitioners in Copenhagen||Research Unit Of General Practice, Copenhagen||Completed|November 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|339|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||October 2009|October 23, 2009|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00394017||177395|
NCT00394355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03418|Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)|Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Density in Adults With Asthma||Merck Sharp & Dohme Corp.|No|Completed|September 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|566|||Both|18 Years|50 Years|No|||June 2015|June 23, 2015|October 31, 2006||No||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00394355||177370|
NCT00352196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-EMR-4026|Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study|A Biological Basis of Therapy for Negative Symptom Spectrum Disorders: Risperdal Effect on Frontal Metabolism in Asperger's Disorder||Georgia Regents University|No|Completed|November 2001|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|6 Years|N/A|No|||January 2015|January 13, 2015|July 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00352196||180541|
NCT00395395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC021A2112|Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women|A Partially-Blind, Randomized, Single-Dose, Placebo-Controlled Crossover Phase I Study Assessing the Effect of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of SMC021 0.8 mg in Healthy Postmenopausal Women||Novartis||Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|56|||Female|40 Years|70 Years||||May 2007|May 25, 2007|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00395395||177292|
NCT00393640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG RPR 04027|Early and Regular Breast Milk Expression to Help Establish Lactation After Delivery: a Randomized Controlled Trial|Early and Regular Breast Milk Expression to Help Establish Lactation After Delivery: a Randomized Controlled Trial|Pumping|National University Hospital, Singapore|Yes|Completed|February 2005|March 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Female|N/A|55 Years|No|||September 2009|September 18, 2009|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00393640||177424|
NCT00394238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20174CTIL|Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis|||Shaare Zedek Medical Center||Not yet recruiting|November 2006|October 2008||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||50|||Both|18 Years|N/A|No|||July 2006|October 30, 2006|October 29, 2006||||No||https://clinicaltrials.gov/show/NCT00394238||177378|
NCT00394251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA045|Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer|An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer||Celgene|Yes|Completed|August 2006|February 2008|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Female|18 Years|70 Years|No|||August 2013|August 8, 2013|October 30, 2006|Yes|Yes||No|November 2, 2010|https://clinicaltrials.gov/show/NCT00394251||177377|
NCT00394225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB 05-186|Helium-Hyperoxia and 6MWT Distance in COPD|The Effects of Helium-Hyperoxia on 6-Minute Walking Distance in Chronic Obstructive Pulmonary Disease – A Randomized, Controlled Trial||University of Saskatchewan||Completed|July 2005|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||16|||Both|N/A|N/A|No|||October 2006|October 30, 2006|October 30, 2006||||No||https://clinicaltrials.gov/show/NCT00394225||177379|
NCT00394537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3997|Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy|||Rabin Medical Center||Completed||May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|N/A|No|||May 2007|June 4, 2007|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394537||177356|
NCT00394524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021877|Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU|Comparative Trial Between a Computer-Guided Intravenous Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU||Emory University|Yes|Completed|June 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Female|18 Years|70 Years|No|||November 2013|November 12, 2013|October 31, 2006||No||No|December 8, 2008|https://clinicaltrials.gov/show/NCT00394524||177357|
NCT00390507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC-II|Modification of Posttetanic Count (PTC) for Monitoring Deep Neuromuscular Block II|||Rigshospitalet, Denmark|Yes|Completed|October 2006|||April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|65 Years|No|||September 2010|September 2, 2010|October 19, 2006||||No||https://clinicaltrials.gov/show/NCT00390507||177659|
NCT00390533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5582|An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder|An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Efficacy, Safety and Tolerability of Two Fixed Doses (100 and 30 mg Once Daily) of Saredutant in Patients With Generalized Anxiety Disorder||Sanofi||Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|428|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|October 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390533||177657|
NCT00391144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2006|Avastin for CNV Secondary to Pattern Dystrophy|Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy||University of Trieste||Recruiting|July 2006|October 2006||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||5|||Both|20 Years|80 Years|No|||October 2006|October 20, 2006|October 20, 2006||||No||https://clinicaltrials.gov/show/NCT00391144||177610|
NCT00392002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00096|Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response|A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].||AstraZeneca||Completed|October 2005|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Both|18 Years|N/A|No|||January 2008|January 24, 2008|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00392002||177544|
NCT00392015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC.2006.0001|NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1|A Two Part Clinical Trial Assessing the Safety, Tolerability, Immunogenicity and Protective Efficacy of NMRC-M3V-Ad-PfCA, a Multivalent, Adenovirus-Vectored Plasmodium Falciparum Malaria Vaccine, in Healthy, Malaria-Naïve Adults||U.S. Army Medical Research and Materiel Command|No|Active, not recruiting|October 2006|June 2016|Anticipated|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|October 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392015||177543|
NCT00392301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0094|Split-Thickness Skin Graft Donor Site Wound Healing Study|Split-Thickness Skin Graft Donor Site Wound Healing Study||University of Mississippi Medical Center|No|Suspended|October 2009|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with split thickness skin graft donor sites|June 2009|June 17, 2009|October 23, 2006||No|Temporary loss of personnel|No||https://clinicaltrials.gov/show/NCT00392301||177521|
NCT00392522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.417|50% Nitrous Oxide and 50% Oxygen (MEOPA) Conscious Sedation Versus Placebo in Fiberoptic Bronchoscopy|50% Nitrous Oxide and 50% Oxygen (MEOPA) Conscious Sedation Versus Placebo in Fiberoptic Bronchoscopy : Randomized, Double Blind, Placebo-Controlled Study||Hospices Civils de Lyon||Active, not recruiting|November 2006|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|90 Years|No|||October 2007|October 4, 2007|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392522||177504|
NCT00392821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 44|Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer|Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma||SCRI Development Innovations, LLC|No|Completed|December 2006|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|October 25, 2006|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT00392821||177483|
NCT00393094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060250|Bevacizumab and Irinotecan to Treat Brain Tumors|A Phase II Trial of Bevacizumab and Irinotecan for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (NCT00271609)(Bevacizumab Alone for Recurrent Gliomas)||National Institutes of Health Clinical Center (CC)|No|Terminated|September 2006|March 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|October 25, 2006|Yes|Yes|Terminated due to the limitations of accrual.|No|March 27, 2012|https://clinicaltrials.gov/show/NCT00393094||177464|Evaluating combination therapy, 19 GBM patients were enrolled. Accrual was terminated after it became clear that we could not reach our efficacy rule of 3 or more of 29 patients responding. The AG arm never fully accrued before the study was closed.
NCT00393380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|435|Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor|A Phase II Study of Parathyroid Hormone Following Myeloablative Sequential Unrelated Cord Blood Transplantation||The EMMES Corporation|Yes|Terminated|September 2006|March 2012|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|45 Years|No|||April 2013|April 22, 2013|October 25, 2006|Yes|Yes|Study stopped because of toxicity concerns.|No|November 6, 2012|https://clinicaltrials.gov/show/NCT00393380||177444|The study was closed prematurely due to early mortality and lack of efficacy.
NCT00393393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11-07-05|Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee|A Single-Blind Prospective Parallel Control Group Pilot Study to Assess the Effect of Hylan G-F 20 (Synvisc) Supplementation on Cartilage Preservation in Osteoarthritis of the Knee||Cabrini Medical Centre||Recruiting|January 2006|January 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|80 Years|No|||October 2006|October 26, 2006|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393393||177443|
NCT00394381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIK#1/2006|Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome|Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome||Singapore General Hospital|Yes|Completed|October 2006|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|12 Years|75 Years|No|||May 2012|May 14, 2012|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00394381||177368|
NCT00394654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP138|A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma||MedImmune LLC|No|Completed|November 2006|January 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||October 2013|October 18, 2013|October 31, 2006|Yes|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT00394654||177347|
NCT00394667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPO-1|Effect of Tesofensine on Weight Reduction in Patients With Obesity.|Effect of Tesofensine on Weight Reduction in Patients With Obesity. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study.||NeuroSearch A/S||Completed|September 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|65 Years|No|||April 2013|April 19, 2013|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394667||177346|
NCT00390338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-118|Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma||University of Pittsburgh|Yes|Completed|October 2006|January 2015|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390338||177672|
NCT00352482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|414|Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension|Sildenafil Treatment in Patients With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - a Pilot Cross-Over Study||National Heart, Lung, and Blood Institute (NHLBI)||Completed|November 2004|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|19 Years|N/A|No|||December 2007|August 4, 2008|July 13, 2006||||No||https://clinicaltrials.gov/show/NCT00352482||180520|
NCT00393653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-016|Prescription Methods Assessment Project (PMAP)|Prescription Methods Assessment Project (PMAP)||American Academy of Family Physicians||Terminated|October 2006|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 9, 2011|October 26, 2006|||Funding ended early|No||https://clinicaltrials.gov/show/NCT00393653||177423|
NCT00394264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 EA-0000048|How Does Manual Therapy Improve Low Back Pain for Soldiers?|Manual Manipulative Therapy for Back Pain in Active Duty Military Personnel||University of North Texas Health Science Center||Recruiting|October 2006|October 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|17 Years|35 Years|No|||October 2006|October 27, 2006|October 27, 2006||||No||https://clinicaltrials.gov/show/NCT00394264||177376|
NCT00394563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091008|A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain|A Randomized, Parallel Arm, Placebo-Controlled, Double-Blind, Multiple-Dose Study of the Safety and Efficacy of RN624 in Adults With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee||Pfizer|Yes|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|450|||Both|40 Years|75 Years|No|||October 2009|October 7, 2009|October 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00394563||177354|
NCT00394576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0186-1|Assessing Novel Methods of Improving Patient Education of Nutrition|Assessing Novel Methods of Improving Patient Education of Nutrition: eHealth, Health Literacy and Chronic Kidney Disease||University of Wisconsin, Madison|No|Recruiting|November 2006|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|180|||Both|18 Years|90 Years|No|||February 2009|February 13, 2009|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00394576||177353|
NCT00394550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011003593|Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty|Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty||Indiana University|Yes|Recruiting|January 2002|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|757|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00394550||177355|
NCT00390247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.291|Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients|Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients: A Randomized Control Trial||Chinese University of Hong Kong||Withdrawn|January 2007|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|80 Years|No|||April 2007|February 8, 2016|October 18, 2006|||Fail of applying funding|No||https://clinicaltrials.gov/show/NCT00390247||177679|
NCT00390234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00177|Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma|A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas||National Cancer Institute (NCI)|Yes|Completed|September 2006|August 2013|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Female|18 Years|N/A|No|||May 2013|December 3, 2015|October 18, 2006|Yes|Yes||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00390234||177680|
NCT00390832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. I01106|Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3)|REVIVAL-3|Deutsches Herzzentrum Muenchen|Yes|Completed|December 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|80 Years|No|||March 2009|December 16, 2010|October 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00390832||177634|
NCT00391157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000186-19|VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma|VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients.||PETHEMA Foundation||Completed|August 2005|January 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|64 Years|No|||September 2009|September 17, 2009|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00391157||177609|
NCT00392028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p1101v1|Penetration of Ertapenem Into Bone|Penetration of Ertapenem Into Bone in Patients With Diabetes Mellitus or Peripheral Vascular Diseases Who Underwent Bellow Knee Amputation||HaEmek Medical Center, Israel|No|Withdrawn|November 2006|July 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||July 2007|July 12, 2007|October 24, 2006|||no recruitment|No||https://clinicaltrials.gov/show/NCT00392028||177542|
NCT00392314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRA2432_CTIL|Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.|Phase 2 Study.Tailored Therapy for Hodgkin Lymphoma Based on Predefined Risk Factors and Early Interim PET/CT for Response Assessment and Further Therapy Decisions.||Rambam Health Care Campus|No|Completed|October 2006|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|365|||Both|18 Years|60 Years|No|||May 2014|May 8, 2014|October 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392314||177520|
NCT00392535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510112|Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer|Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP||National Cancer Institute (NCI)||Recruiting|October 2002|||September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2163|||Male|N/A|N/A|No|||July 2009|May 19, 2011|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392535||177503|
NCT00392834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-048|Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma|Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma||AIDS Malignancy Consortium|No|Completed|September 2006|July 2013|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|October 25, 2006|Yes|Yes||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00392834||177482|
NCT00392847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051045|Promoting Parental Skills and Enhancing Attachment in Early Childhood|Promoting Parental Skills and Enhancing Attachment in Early Childhood|CAPEDP|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2006|January 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|440|||Female|N/A|26 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00392847||177481|
NCT00393107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR2|Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab|Phase II Study of Rituximab in Combination With Fludarabine and Cyclophosphamide for the Treatment of Relapsed Follicular Lymphoma||Gruppo Italiano Studio Linfomi||Completed|March 2000|August 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|18 Years|70 Years|No|||October 2006|October 25, 2006|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00393107||177463|
NCT00394030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP107724|Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers|See Detailed Description||GlaxoSmithKline||Completed|October 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|63|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|October 27, 2006||||||https://clinicaltrials.gov/show/NCT00394030||177394|
NCT00390351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oct-MM-2005|Investigate the Diagnostic Value and Possibilities of OCT in Non-Melanoma Skin Cancer.|Diagnosis of Non-Melanoma Skin Cancer With Optical Coherence Tomography||Roskilde County Hospital||Recruiting|February 2006|July 2008||||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 18, 2006|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00390351||177671|
NCT00390650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5581|A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder|An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder||Sanofi||Completed|October 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|366|||Both|18 Years|N/A|No|||April 2011|April 5, 2011|October 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390650||177648|
NCT00393302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 03-326C|HIV Testing in Pregnant Women: Evaluating an Opt-Out Testing Strategy|HIV Testing in Pregnant Women: An Evaluation of an Opt-Out Strategy in an Ambulatory Care Clinic Setting||St. Michael's Hospital, Toronto|No|Completed|September 2003|February 2006|Actual|January 2006|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|1074|||Female|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women attending antenatal intake appointments at the Women's Health Care        Centre at St. Michael's Hospital in Toronto, Canada between September 2003 and February        2006.|July 2008|July 16, 2008|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393302||177450|
NCT00393926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0635450Z|Robot-Assisted Motivating Rehabilitation|Robot-Assisted Motivating Rehabilitation to Increase Upper Limb Function After Stroke||Medical College of Wisconsin||Completed|July 2006|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|85 Years|No|||February 2014|February 3, 2014|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00393926||177402|
NCT00393952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-3-004|New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg or 250/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Placebo or Fluticasone (250 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Moderate to Severe Asthma||SkyePharma AG||Completed|June 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|557|||Both|12 Years|N/A|No|||June 2011|June 8, 2011|October 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393952||177400|
NCT00394290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJL-PPC-EP02|Down Syndrome and Continuous Positive Pressure Therapy|Follow-up of the Therapeutic Coverage by Continuous Positive Pressure of the Obstructive Sleep Apnea Syndrome for Down Syndrome Patients|Morphee|Institut Jerome Lejeune|No|Recruiting|November 2006|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00394290||177374|
NCT00390286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051010|Telemedicine's Utility for Augmenting Clinical Trials and Informed Consent TACTIC|Telemedicine's Utility for Augmenting Clinical Trials and Informed Consent TACTIC||University of California, San Diego|No|Not yet recruiting|November 2015|March 2020|Anticipated|December 2019|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Both|18 Years|N/A|No|Non-Probability Sample|Acute stroke patients|November 2015|November 30, 2015|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00390286||177676|
NCT00394589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04249|Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)|Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.|Re³|Merck Sharp & Dohme Corp.|No|Terminated|March 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 31, 2006||No|Study enrollment was stopped due to insufficient subject accrual.|No|October 28, 2009|https://clinicaltrials.gov/show/NCT00394589||177352|
NCT00390260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0966-179|Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)|Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Rofecoxib 50 mg and Hydrocodone 7.5 mg With Acetaminophen 750 mg in Patients With Postoperative Arthroscopic Pain||Merck Sharp & Dohme Corp.||Completed|February 2002|February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||420|||Both|18 Years|60 Years|No|||July 2015|July 3, 2015|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00390260||177678|
NCT00390546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-70156|Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia|Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia||University of British Columbia||Completed|October 2006|August 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|N/A|4 Months|No|||September 2013|September 6, 2013|October 18, 2006||No||No|March 11, 2013|https://clinicaltrials.gov/show/NCT00390546||177656|Besides issues of recruitment, potential limitations of this study include the selected dosing for propranol, as a higher dosage is sometimes used, and the lack of dose titration before the 2-month visit, both of which could influence drug efficacy.
NCT00390845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKN106762|P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain|A Double-blind Placebo-controlled Study of the Efficacy and Safety of the P38 Map Kinase Inhibitor SB681323 in Patients With Neuropathic Pain Following Nerve Trauma||GlaxoSmithKline|No|Completed|August 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|80 Years|No|||November 2010|November 4, 2010|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00390845||177633|
NCT00390858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0106E1|A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.|A 4-year Extension to a Phase II a Multicenter Study Evaluating Long-term Safety, Tolerability, Pharmacokinetics and Effects on Liver Iron Concentration of Repeated Doses of 10 mg/kg/Day of Deferasirox in Pediatric Patients With Transfusion Dependent β-thalassemia Major.||Novartis||Completed|September 2003|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|1 Year|18 Years|No|||July 2011|July 20, 2011|October 18, 2006|Yes|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT00390858||177632|
NCT00391768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0059|Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza|A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) for the Treatment of Children Less Than 24 Months of Age With Confirmed Influenza Infection (CASG 114)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2007|April 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|N/A|23 Months|No|||February 2010|April 25, 2013|October 20, 2006|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00391768||177562|
NCT00392041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220060122|Eszopiclone in the Treatment of Insomnia and Fibromyalgia|Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia||Rutgers, The State University of New Jersey|No|Completed|August 2006|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|64 Years|No|||February 2014|February 19, 2014|October 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392041||177541|
NCT00392054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USJan13/09CANAug1/06EUJan1/07|First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)|First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment: A Multi-center Randomized Trial|RAAFT|Population Health Research Institute|Yes|Active, not recruiting|August 2006|January 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|19 Years|75 Years|No|||July 2011|July 20, 2011|October 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00392054||177540|
NCT00392067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO19123-C21|LEO19123 Cream in the Treatment of Atopic Dermatitis|LEO19123 Cream in the Treatment of Atopic Dermatitis||LEO Pharma||Completed|October 2006|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|75|||Male|18 Years|50 Years|No|||August 2007|April 29, 2008|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00392067||177539|
NCT00392327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0332|Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma|Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients||Children's Oncology Group|Yes|Suspended|March 2007|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|3 Years|21 Years|No|||March 2015|March 17, 2015|October 25, 2006|Yes|Yes|Temporarily stopped for assessment|No||https://clinicaltrials.gov/show/NCT00392327||177519|
NCT00392548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG0611|URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol|Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence||Tel-Aviv Sourasky Medical Center||Not yet recruiting|October 2006|October 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||130|||Both|18 Years|N/A|No|||September 2006|October 25, 2006|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392548||177502|
NCT00392561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15091A (R01-CA10743-1)|Bangladesh Vitamin E and Selenium Trial|Bangladesh Vitamin E and Selenium Trial|BEST|University of Chicago|Yes|Active, not recruiting|April 2006|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|7000|||Both|25 Years|65 Years|No|||December 2012|September 4, 2013|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00392561||177501|
NCT00392860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02484, 0511136|Development of an Ergonomic Wheelchair Pushrim|Development of an Ergonomic Manual Wheelchair Pushrim- Phase II||VA Pittsburgh Healthcare System|No|Completed|August 2008|September 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|4|||Both|18 Years|55 Years|No|||January 2014|January 4, 2014|October 24, 2006||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00392860||177480|
NCT00393120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 9471-201|Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients|A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.||Incyte Corporation|No|Completed|October 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|No|||January 2012|January 20, 2012|October 24, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00393120||177462|
NCT00393146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA3103718|A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis|A Randomized, Double Blind, Placebo Controlled Study to Investigate the Safety and Tolerability and Clinical Activity of 28 Days of Oral Repeat Dosing With GW856553 at 7.5mg BID in Subjects With Active Rheumatoid Arthritis on Stable Anti-rheumatic Therapy.||GlaxoSmithKline|No|Completed|October 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|57|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393146||177461|
NCT00393406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907013|The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach|The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach||National Institutes of Health Clinical Center (CC)||Completed|October 2006|October 2008||||N/A|Observational|Time Perspective: Prospective||||40|||Female|35 Years|74 Years|Accepts Healthy Volunteers|||October 2008|October 29, 2008|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393406||177442|
NCT00393419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-36002|Federal Study of Adherence to Medications in the Elderly (FAME)|Federal Study of Adherence to Medications in the Elderly (FAME)||Walter Reed Army Medical Center||Completed|June 2004|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||200|||Both|65 Years|N/A|No|||October 2006|October 26, 2006|October 26, 2006||||No||https://clinicaltrials.gov/show/NCT00393419||177441|
NCT00393744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIST_L_01683|Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children|A Phase III, Open, Randomised, Multicentre Study Comparing the Efficacy and Safety of Pristinamycin, at Dosages of 50 mg/kg/d in 2 Doses for Children, and 1g Twice Daily in Adults for 4 Days Versus Amoxicillin at a Dosage of 50 mg/kg/d in 2 Doses in Children and 1 g Twice Daily in Adults for 6 Days, Consumed Orally, in the Treatment of Tonsillitis Induced by Group-A Beta-Haemolytic Streptococcus in Patients Aged Between 6 and 25 Years.|PRI-angine|Sanofi|No|Completed|October 2006|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|395|||Both|6 Years|25 Years|No|||March 2009|March 16, 2009|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00393744||177416|
NCT00394680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABGvsStent-Jerusalem|Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.|Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.||Shaare Zedek Medical Center||Completed|November 2006|May 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|700|||Both|N/A|N/A|No|Probability Sample|Patients which are insured in the relevant HMO's and suffer from a multi-vessel coronary        disease and were treated during 2000-2004|May 2011|May 26, 2011|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394680||177345|
NCT00392106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-003|High Intensity Focused Ultrasound (HIFU) Ablation System Study|Study of Focused Circumferential UltraSound for the Treatment of Atrial Fibrillation||ProRhythm, Inc.||Suspended|April 2006|June 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||June 2008|June 16, 2008|October 24, 2006|Yes|Yes|voluntarily by Sponsor to investigate an anticipated SAE|No||https://clinicaltrials.gov/show/NCT00392106||177536|
NCT00392366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITT / METASTASE HEPATIQUES|Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis|The Clinical Evaluation of the Laser Interstitial Thermal Therapy (LITT ), Under "Real Time" MRI Guidance, for the "Minimal Invasive" Treatment of Liver Metastasis - a Phase IIa Mono-centric Study, Without Direct Benefice to the Patient||BioTex, Inc.||Completed|July 2006|July 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2009|December 30, 2009|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00392366||177516|
NCT00393666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01 NS055829|Why Are Patients With Absence Seizures Absent? A Brain Imaging Study|Functional Neuroimaging in Childhood Absence Epilepsy||Yale University||Completed|September 2006|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|180|Samples With DNA|Saliva samples|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric patients diagnosed with absence epilepsy|January 2016|January 25, 2016|October 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00393666||177422|
NCT00393965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-6827-04-002|Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases|Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases||Myrexis Inc.|No|Completed|December 2005|February 2008|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2008|February 11, 2008|October 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00393965||177399|
NCT00393991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-3-001|Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma||SkyePharma AG||Completed|July 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|475|||Both|12 Years|N/A|No|||June 2011|June 8, 2011|October 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393991||177397|
NCT00390572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-213|Sleep Specialty Consultation: Improving Management of Sleep Disorders|Sleep Specialty Consultation: Improving Management of Sleep Disorders||VA Office of Research and Development|No|Completed|January 2007|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|October 18, 2006||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT00390572||177654|
NCT00390871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANIST|Acute Neurological ICU Sedation Trial (ANIST)|Acute Neurological ICU Sedation Trial (ANIST)|ANIST|Johns Hopkins University||Completed|April 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||April 2013|April 11, 2013|October 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390871||177631|
NCT00390273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRNHRA-06-001|Effect of Metformin on Lactate Metabolism|Effect of Metformin on Lactate Metabolism in Healthy Subjects||Centre de Recherche en Nutrition Humaine Rhone-Alpe|Yes|Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2008|October 6, 2008|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00390273||177677|
NCT00390559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-11082-3|Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3|Effects of Transdermal Nicotine on Tobacco Withdrawal and the Effects of Smoking-related Stimuli in Men and Women||Virginia Commonwealth University|No|Completed|October 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|October 18, 2006|No|Yes||No|November 10, 2011|https://clinicaltrials.gov/show/NCT00390559||177655|
NCT00391456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#01061809|Animal-Assisted Therapy for Hospitalized Heart Failure Patients|Use of Animal-Assisted Therapy to Decrease Cardiopulmonary Pressures, Neurohormone Levels, and State Anxiety in Patients Hospitalized With Heart Failure||University of California, Los Angeles||Active, not recruiting|November 2001|July 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||76|||Both|18 Years|80 Years|No|||October 2006|October 23, 2006|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391456||177586|
NCT00391196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351022|A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients|A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus||Pfizer|Yes|Terminated|November 2006|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|975|||Both|18 Years|70 Years|No|||November 2012|November 5, 2012|October 19, 2006|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00391196||177606|
NCT00391482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA014499|Study to Reduce Intravenous Exposures (STRIVE)|Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-Infected Injection Drug Users||National Institute on Drug Abuse (NIDA)||Completed|June 2002|February 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||750|||Both|18 Years|35 Years|No|||November 2008|November 13, 2008|October 20, 2006||||No||https://clinicaltrials.gov/show/NCT00391482||177584|
NCT00391781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WARMHSG.CTIL|Warm Contrast Media for Pain Reduction During Hystersalpingography|Prospective Randomised Controlled Trian of Warmed vs. Room Temperature Contrast Media for Hystersalpingography||Shaare Zedek Medical Center||Recruiting|December 2006|December 2008||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Female|18 Years|45 Years|No|||August 2007|September 24, 2007|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391781||177561|
NCT00398983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0358|Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)|Randomized Study of Decitabine Versus Observation or Continued Standard Chemotherapy as Maintenance Therapy for Adults With Unfavorable Risk AML in First Complete Remission (CR) or Adults With Relapsed AML in Second or Greater CR||M.D. Anderson Cancer Center|Yes|Completed|August 2006|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|November 9, 2006||No||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00398983||177023|
NCT00398710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 221|A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia|A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia||AEterna Zentaris|No|Completed|October 2006|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||November 2011|March 4, 2013|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398710||177043|
NCT00394862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205-2004|Efficacy of Weekly Versus Daily Folic Acid Supplementation|||Emory University||Completed|January 2006|July 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||460|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394862||177332|
NCT00399243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC08|Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache|4mg StatDose Imitrex for Acute Treatment of Cluster Headache||Diamond Headache Clinic|No|Recruiting|November 2006|August 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 29, 2009|November 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399243||177004|
NCT00389129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060142|Danish Aspirin Resistance Trial - Pilot Study|Comparative Evaluation of Aspirin Resistance With Point-of-Care Testing - Danish Aspirin Resistance Trial (DANART) - Pilot Study||University of Aarhus|No|Completed|November 2006|March 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 10, 2007|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389129||177762|
NCT00396084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-553|Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis|Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2004|December 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|70|||Both|18 Years|65 Years|No|||March 2010|June 9, 2011|November 3, 2006|Yes|Yes||No|November 19, 2008|https://clinicaltrials.gov/show/NCT00396084||177240|The small sample size had limited power to detect small differences in EBA between study arms even though we enrolled patients with smear-positive TB and high sputum bacillary burden to improve chances of detecting differences between treatment arms.
NCT00396097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281280|Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature|A Four-Year Open-Label Multi-Center Randomized Two-Arm Study Of Genotropin In Idiopathic Short Stature Patients: Comparing An Individualized, Target-Driven Treatment Regimen To Standard Dosing Of Genotropin||Pfizer|No|Completed|December 2006|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|316|||Both|3 Years|10 Years|No|||December 2013|December 20, 2013|November 2, 2006|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00396097||177239|
NCT00389688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08051|Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery|Randomized Phase II Study of Pemetrexed and Cisplatin as Either Induction or Adjuvant Chemotherapy in Stage IB-II Non-Small Cell Lung Cancer (NSCLC)||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|August 2006|||July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|October 18, 2006|||low accrual|No||https://clinicaltrials.gov/show/NCT00389688||177721|
NCT00396071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2387|Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin|A Single-Center, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study to Assess the Effect of Vildagliptin on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin||Novartis||Completed|October 2006|||November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|22|||Both|30 Years|78 Years||||October 2008|October 6, 2008|November 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00396071||177241|
NCT00396357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23104|Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone|A Multicenter, Double-blind, Randomized Parallel-group, Study to Demonstrate the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd as add-on to Metformin 500 mg Bid Compared to Metformin 1000 mg Bid in Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy||Novartis||Completed|October 2006|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|914|||Both|18 Years|78 Years|No|||December 2012|December 28, 2012|November 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00396357||177219|
NCT00396370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-351|BCG Vaccination Delivered Intradermally, Orally and by Combined Routes|Phase I Studies of the Safety and Immunogenicity of Primary and Secondary BCG Vaccination Delivered Intradermally, Orally and by Combined Routes of Administration in Healthy and Previously Immunologically Naïve Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2008|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|69|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|September 12, 2013|November 3, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00396370||177218|
NCT00396643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI 03T-315|Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis|Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial||Medical University of Vienna|Yes|Completed|May 2004|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|81|||Both|13 Years|25 Years|No|||December 2007|December 20, 2007|November 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00396643||177197|
NCT00386243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4437-I|Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)|Evaluation of Stepped Care for Chronic Pain in Iraqi/Afghanistan Veterans|ESCAPE|VA Office of Research and Development|Yes|Completed|December 2007|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|October 6, 2006||No||No|September 25, 2013|https://clinicaltrials.gov/show/NCT00386243||177979|Single VA Center; May not generalize to non-VA samples
NCT00386503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAMF_L_01570|Bioavailability of the Fixed Combination of Amodiaquine and Artesunate Under Fed & Fasted Conditions|A Randomized, Open-Label, Cross-Over Study, to Compare the Bioavailability of the Fixed Combination of Amodiaquine and Artesunate (COARSUCAM™) After Single Oral Administration Under Fed and Fasted Conditions in Healthy Subjects||Sanofi||Completed|June 2006|||December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2008|December 8, 2008|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386503||177960|
NCT00386516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAVFU-007|Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer|Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer||Galectin Therapeutics Inc.|No|Terminated|September 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|October 10, 2006|No|Yes|Financing and re-organization|No||https://clinicaltrials.gov/show/NCT00386516||177959|
NCT00386529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST-HT-01|Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-controlled Hypertensive Patients|A Multi-center, Double-Blind Randomized, Cross-over, Active-control, Comparative Clinical Study to Evaluate the Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-Controlled Hypertensive Patients (Phase IV)||Boryung Pharmaceutical Co., Ltd|Yes|Completed|September 2006|August 2008|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|191|||Both|30 Years|70 Years|No|||December 2010|December 14, 2010|October 9, 2006||||No||https://clinicaltrials.gov/show/NCT00386529||177958|
NCT00386555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5301010|A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.|Phase 2 Study of CP-868,596 + Docetaxel, AG-013736 + Docetaxel, or CP-868,596 + AG-013736 + Docetaxel and of Docetaxel Alone in Patients With Stage IIIb or IV Non-Small Cell Lung Cancer.||Arog Pharmaceuticals, Inc.||Withdrawn|May 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||May 2007|August 7, 2012|October 6, 2006|||Study was cancelled before patient enrollment|||https://clinicaltrials.gov/show/NCT00386555||177956|
NCT00386789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907004|Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age|Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age||National Institutes of Health Clinical Center (CC)||Completed|October 2006|June 2008||||N/A|Observational|N/A||||0|||Both|10 Years|13 Years|No|||June 2008|June 18, 2008|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00386789||177939|
NCT00386802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004973-55|Antifungal Use in Oncohematological Neutropenic Patients|ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.||PETHEMA Foundation|Yes|Completed|August 2006|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|2 Years|N/A|No|||September 2009|September 17, 2009|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00386802||177938|
NCT00386815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10512|Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma|Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma||Eli Lilly and Company||Completed|October 2006|February 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|20 Years|75 Years|No|||April 2007|April 10, 2007|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386815||177937|
NCT00387179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|406|Effectiveness of Combining Light and Non-Light Treatments for Jet Lag and Sleep Disorders|Circadian Integration of Photic and Non-photic Stimuli||National Heart, Lung, and Blood Institute (NHLBI)||Recruiting|October 2006|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|October 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387179||177910|
NCT00387192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWF01|A Study With OPTIVATE® in People With Von Willebrand Disease|An Open Multi-centre Study in Patients With Von Willebrand Disease to Investigate the Pharmacokinetics, Efficacy and Safety of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate||Bio Products Laboratory|No|Terminated|November 2006|September 2008|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|12 Years|N/A|No|||March 2010|March 2, 2010|October 11, 2006|||Due to slow recruitment and a significant delay in reaching the recruitment target.|No||https://clinicaltrials.gov/show/NCT00387192||177909|
NCT00387478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TreeMATAMPL204|Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis|A Double Blind Study to Investigate the Clinical Efficacy and Safety of TreeMATAMPL (Allergy Therapeutics, (UK) Ltd.), TreeMATA (Allergy Therapeutics, (UK) Ltd.) and Placebo in Patients With Seasonal Allergic Rhinitis Due to Birch Pollen Allergy, in an Environmental Exposure Chamber (EEC) Model When Exposed to Birch Pollen and Oak Pollen||Allergy Therapeutics||Suspended|October 2006|June 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|50 Years|No|||June 2010|June 16, 2010|October 12, 2006|Yes|Yes|Enrollement target could not be achieved, study will potentially be resumed|No||https://clinicaltrials.gov/show/NCT00387478||177887|
NCT00387491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-102|Dose Ranging Study in Healthy Methadone Maintenance Subjects|A Randomized, Double-blind, 4-period Crossover, Dose-ranging Study to Determine the Effects on the Oral-cecal Transit Time of Single Doses of MOA-728 and the Safety and Tolerability of Multiple Doses of MOA-728 in Stable Methadone Maintenance Subjects||Valeant Pharmaceuticals International, Inc.||Completed|June 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|October 11, 2006||||||https://clinicaltrials.gov/show/NCT00387491||177886|
NCT00387452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO4-0001|Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes|Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes||University of British Columbia|No|Recruiting|February 2006|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 12, 2011|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00387452||177889|
NCT00387465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00220|Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer|A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|August 2006|November 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|N/A|No|||March 2014|April 30, 2015|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00387465||177888|
NCT00395174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC03|Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults|Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine, to a Licensed Egg-Grown Influenza Vaccine In Ambulatory Elderly Adults||Protein Sciences Corporation|Yes|Completed|October 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|870|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 16, 2009|October 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395174||177309|
NCT00399256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKP201|Improved Estimation of GFR by Cystatin C in Preventing Contrast Induced Nephropathy by NAC or Zn|Improved Estimation of Glomerular Filtration Rate by Serum Cystatin C in Preventing Contrast Induced Nephropathy by N-Acetylcysteine or Zinc||Robert Bosch Gesellschaft für Medizinische Forschung mbH||Terminated|March 2004|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|January 31, 2007|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399256||177003|
NCT00395161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HD049934|The CRISIS Prevention Study|The Critical Illness Stress-induced Immune Suppression Prevention Trial|CRISIS|University of Utah|Yes|Terminated|April 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|293|||Both|12 Months|17 Years|No|||April 2013|April 16, 2013|October 31, 2006|Yes|Yes|Terminated for futility on 11/30/09 based on the recommendation of the DSMB|No|November 14, 2012|https://clinicaltrials.gov/show/NCT00395161||177310|The Data Safety Monitoring Board met on November 30, 2009. Interim analysis of the first 273 patients was presented. Per the Board's recommendations, the study was terminated based on futility.
NCT00394836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111772|HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab|A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy||GlaxoSmithKline|Yes|Completed|May 2007|September 2013|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Actual|116|||Both|18 Years|N/A|No|||November 2013|December 12, 2013|October 31, 2006|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00394836||177334|
NCT00394849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0006-26|Effect of Tonsillar Pillar Closure on Postoperative Pain and Bleeding Risk After Tonsillectomy|Effect of Tonsillar Pillar Closure on Postoperative Pain and Bleeding Risk After Tonsillectomy||Indiana University|No|Completed|July 2000|March 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|763|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00394849||177333|
NCT00395772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11528|Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis|Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.||Bayer||Completed|December 2004|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|543|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|November 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00395772||177264|
NCT00396994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0071|"VIBES"--Low Magnitude Mechanical Stimulation to Improve Bone Mineral Density|Low Magnitude Mechanical Stimulation (LMMS) to Improve Bone Mineral Density (BMD)||Hebrew Rehabilitation Center, Boston|Yes|Completed|February 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|174|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 18, 2013|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00396994||177170|
NCT00397293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-101|Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer|An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer After Prior Platinum Containing First Line Chemotherapy||Ascenta Therapeutics|No|Completed|November 2006|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||August 2010|August 20, 2010|November 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397293||177148|
NCT00386048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD pain management protocol|Pain Management Protocol for Pediatric Sickle Cell Disease|Home-based Pain Management Protocol for Children With Sickle Cell Disease||University of South Carolina|Yes|Completed|November 2006|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|8 Years|18 Years|No|Non-Probability Sample|The study population are youths with sickle cell disease who are experiencing intermittent        pain episodes that interfere with quality of life.|September 2012|September 17, 2012|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386048||177994|
NCT00386256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E4204-R|Home Telerehabilitation for Deconditioned Older Adults|Home Based Telerehabilitation for Deconditioned Older Adults||VA Office of Research and Development|No|Completed|October 2006|June 2008|Actual|May 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|38|||Both|60 Years|N/A|No|||August 2014|August 12, 2014|October 6, 2006||No||No|September 11, 2013|https://clinicaltrials.gov/show/NCT00386256||177978|Intervention was developed on a male Veteran population, direct comparisons between groups were formed based on the participant’s preference, exercise adherence was based on participants’ self reports, small convenience sample.
NCT00386581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9081|Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder|Phase III Multicenter, Randomized, Double-Blind Placebo-Controlled Outpatient Study of Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|July 2004|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|105|||Both|6 Years|16 Years|No|||June 2007|June 11, 2007|October 6, 2006||||No||https://clinicaltrials.gov/show/NCT00386581||177955|
NCT00386828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL NUMBER: OZM-004|Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial|Phase II Study of Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial||British Columbia Cancer Agency|Yes|Completed|October 2006|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||November 2010|November 24, 2010|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00386828||177936|
NCT00397553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3517|Insulin Glulisine, Diabetes Mellitus Type 1|Multicenter, Open, Non-randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine||Sanofi||Completed|January 2005|||December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||May 2009|September 17, 2009|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00397553||177129|
NCT00397566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI441-008|A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects|Randomized, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-707035 in HIV-1 Infected Subjects||Bristol-Myers Squibb||Withdrawn|February 2007|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|60 Years|No|||April 2012|April 26, 2012|November 8, 2006||||||https://clinicaltrials.gov/show/NCT00397566||177128|
NCT00397852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colaris05|Dislocated Stable Distal Both-Bone Forearm Fractures in Children|Treatment of Stable Dislocated Both-Bone Distal Forearm Fractures in Children: A Randomized Trial Between Treatment With en Without Kirschner-Wires||Colaris, Joost, M.D.||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||110|||Both|N/A|15 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397852||177107|
NCT00397865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2006-1259|A Primary Care Educational Intervention for Families of Overweight Children|A Primary Care Educational Intervention for Families of Overweight Children||University of Wisconsin, Madison|No|Completed|October 2006|August 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||July 2010|October 1, 2015|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00397865||177106|
NCT00387777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|631766|Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations|Multiple Dose Bioequivalence Trial Comparing a New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch.||Grünenthal GmbH||Terminated|October 2006|December 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|October 12, 2006||||No||https://clinicaltrials.gov/show/NCT00387777||177864|
NCT00388076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG105427|Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)|A Phase I, Open-Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Paclitaxel on a Weekly Schedule for 3 Consecutive Wks, Paclitaxel & Carboplatin on an Every 21 Days Schedule and Lapatinib & Paclitaxel on a Weekly Schedule for 3 Consecutive Weeks||GlaxoSmithKline||Completed|April 2006|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|86|||Both|18 Years|N/A|No|||February 2011|March 15, 2012|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00388076||177842|
NCT00395824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pe2006-01|Citrate Anticoagulation vs. Heparin-Coated Dialyzers|Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: a Prospective Randomised Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding||Universitaire Ziekenhuizen Leuven||Completed|January 2005|September 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||33|||Both|18 Years|N/A|No|||November 2006|November 2, 2006|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395824||177260|
NCT00395447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPLACE|REPLACE: Implantable Cardiac Pulse Generator Replacement Registry|Prospective Assessment of the Complication Rate After Device Replacement Due to ERI, Advisory or Upgrade|REPLACE|Biotronik, Inc.|Yes|Completed|July 2007|June 2009|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1744|||Both|18 Years|N/A|No|Probability Sample|Subjects with device replacement procedures at study sites|March 2015|March 24, 2015|November 1, 2006||No||No|August 24, 2010|https://clinicaltrials.gov/show/NCT00395447||177288|
NCT00395460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91536|Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients|A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients||Bayer|No|Completed|September 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|147|||Both|18 Years|65 Years|No|||May 2015|May 13, 2015|November 2, 2006||No||No|July 4, 2011|https://clinicaltrials.gov/show/NCT00395460||177287|
NCT00395798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVisi|Effect of Cervical Collar in Cervical Radicular Pain.|Effect of Conservative Treatment With Cervical Collar in Patients With Cervical Radiculopathy and Radicular Pain. A Randomized Controlled Study||Oslo University Hospital||Completed|January 2004|August 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||May 2006|July 3, 2011|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395798||177262|
NCT00396110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25V06|Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)|Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)||AstraZeneca||Completed|February 2003|||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||3889|||Both|18 Years|75 Years|No|||February 2003|November 3, 2006|November 3, 2006||||No||https://clinicaltrials.gov/show/NCT00396110||177238|
NCT00396396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVMS 06-03-FB-0044|Role of Acetylcysteine in Creatinine Clearance|||Eastern Virginia Medical School||Recruiting|October 2006|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label||||35|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||November 2006|November 3, 2006|November 3, 2006||||No||https://clinicaltrials.gov/show/NCT00396396||177216|
NCT00395785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGUARD|Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting|Protection During Carotid Stenting in High Risk Patients With the TriActiv ProGuard System||Kensey Nash Corporation||Terminated|November 2006|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||July 2007|July 20, 2007|November 1, 2006|||Sponsor elected to not pursue this indication for the study device.|No||https://clinicaltrials.gov/show/NCT00395785||177263|
NCT00396669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291006 HMO-CTIL|A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.|A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers, Using 11 C Raclopride in Positron Emission Tomography (PET)||Hadassah Medical Organization|Yes|Recruiting|July 2007|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00396669||177195|
NCT00396682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAN-HCC-002|Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma|Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide||Hannover Medical School||Completed|February 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00396682||177194|
NCT00397306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95/06|Evaluation of a Bioimpedance Method for Determination of Dry Weight in Dialysis Patients|Study for the Evaluation of a Bioimpedance Method for Determination of Dry Weight in Dialysis Patients||University Hospital, Saarland|No|Completed|November 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2009|April 7, 2009|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00397306||177147|
NCT00396383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-2108|Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation|Treatment With AMD3100 in Multiple Myeloma Patients to Mobilize Peripheral Blood Progenitor Cells For Collection and for Transplantation||Sanofi|Yes|Terminated|November 2004|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||February 2014|February 10, 2014|November 2, 2006|No|Yes|Insufficient cell mobilization for tandem transplants|No|February 11, 2009|https://clinicaltrials.gov/show/NCT00396383||177217|Study had limited enrollment prior to termination.
NCT00397917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-17958|Oral Cleft Prevention Program|Oral Cleft Prevention Program||University of Iowa|Yes|Active, not recruiting|November 2006|September 2011|Anticipated|May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|6000|||Female|16 Years|45 Years|No|||December 2009|December 2, 2009|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00397917||177102|
NCT00386867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1.3|A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP|||Gynuity Health Projects|Yes|Completed|October 2006|March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|June 1, 2007|October 10, 2006||||||https://clinicaltrials.gov/show/NCT00386867||177933|
NCT00386880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-Phono-CA|Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs|Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs||Thomas Jefferson University|No|Completed|August 2006|September 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|38|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult women and men with a diagnosis of episodic migraine|August 2014|August 4, 2014|October 11, 2006||No||No|August 5, 2012|https://clinicaltrials.gov/show/NCT00386880||177932|
NCT00386061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4733|Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe)||Sanofi||Completed|October 2001|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1507|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|October 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00386061||177993|
NCT00386269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02AR53|Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants|Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants||Institute of Child Health||Completed|January 2004|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|44|||Both|4 Months|8 Months|Accepts Healthy Volunteers|||November 2007|November 28, 2007|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386269||177977|
NCT00386282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1.4|Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol|Acceptability and Feasibility of Medical Abortion in Mexico, Puerto Rico, Armenia and Azerbaijan: A Study of Buccal Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days' Gestation||Gynuity Health Projects|No|Completed|September 2006|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1250|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00386282||177976|
NCT00386542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-ISO-4785|Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children|Clinical Trial of Safety (Reactogenicity) and Immunogenicity of Needle-free Jet Injection of Reduced-dose, Intradermal Influenza Vaccine (INF) Administered to >= 6 to < 24 Month-old Infants and Toddlers in the Dominican Republic||Centers for Disease Control and Prevention|Yes|Completed|October 2006|May 2010|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|450|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||June 2010|June 8, 2010|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386542||177957|
NCT00397579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012013-061|DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND# 11314): a Phase I/II Clinical Trial||University of Texas Southwestern Medical Center|Yes|Completed|May 2013|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|November 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397579||177127|
NCT00386841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGENDA|Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression|Associations Between Gene-Polymorphisms, Endo-Phenotypes for Depression and Antidepressive Treatment (AGENDA)||University of Copenhagen|Yes|Completed|April 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00386841||177935|
NCT00398203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-10111|Safety and Efficacy of Using NaviAid™ BGE Device (Balloon Guided Endoscopy) For Endoscopic Diagnosis and Treatment|Safety and Efficacy of Using NaviAid™ BGE Device (Balloon Guided Endoscopy) For Endoscopic Diagnosis and Treatment||Smart Medical Systems Ltd.|No|Completed|February 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|No|||June 2012|June 11, 2012|November 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398203||177081|
NCT00398463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCA-01-III|Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance|Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel|3T/2R|Università degli Studi di Ferrara|Yes|Completed|May 2006|May 2011|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||June 2008|June 29, 2011|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00398463||177062|
NCT00398476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFU108556|Fluticasone Nasal Spray Patient Preference Study|A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subject With Allergic Rhinitis||GlaxoSmithKline|No|Completed|December 2006|||December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||125|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|November 9, 2006||||||https://clinicaltrials.gov/show/NCT00398476||177061|
NCT00398190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57407|Media Literacy to Prevent Adolescent Smoking|Media Literacy to Prevent Adolescent Smoking||University of Pittsburgh||Recruiting|October 2006|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1200|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00398190||177082|
NCT00398723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUH IRB # JCO 0590|Narrowband UVB Treatment in Patients With Vitiligo|Effects of Narrowband UVB Phototherapy on Melanocyte Proliferation in Patients With Vitiligo||Rockefeller University|No|Completed|November 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2011|October 11, 2011|November 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398723||177042|
NCT00396149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO49.06 DK|Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1|A Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Higher Multi Dose Regimens to Subjects Sensitised to Birch Pollen||Stallergenes|No|Completed|November 2006|June 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|60 Years|No|||April 2009|June 26, 2013|November 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00396149||177235|
NCT00396474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281279|Safety Study In Patients Who Were Born Small And Short And Were Treated With Growth Hormone To Achieve Normal Height|Long-Term Metabolic Risk In Small for Gestational Age (SGA) Patients After Growth Hormone Treatment Compared To Matched, Untreated Controls||Pfizer|No|Withdrawn|January 2009|January 2012|Anticipated|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|whole blood, serum|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|SGA Subjects treated or untreated with growth hormone|April 2015|April 21, 2015|November 6, 2006|Yes|Yes|Study design no longer relevant and no patients were recruited.|No||https://clinicaltrials.gov/show/NCT00396474||177210|
NCT00395811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCD200601|Stem Cell Therapy to Improve Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|||China National Center for Cardiovascular Diseases|Yes|Active, not recruiting|January 2007|June 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||October 2008|October 28, 2008|November 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395811||177261|
NCT00396409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025ADE03|Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis|A Randomized, 20 Week, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Combination With Depigoid, Versus Depigoid Only, in Adult and Adolescent Patients With Seasonal Allergic Asthma and Comorbid Seasonal Allergic Rhinoconjunctivitis - Open-label Depigoid Monotherapy Extension Periods 2007 and 2008-||Novartis||Completed|February 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|12 Years|45 Years|No|||May 2011|May 5, 2011|November 6, 2006||No||No|November 22, 2010|https://clinicaltrials.gov/show/NCT00396409||177215|Study Start Date: February 2006 (core study)
NCT00396422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012367|Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis|A Phase IIa Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multi-Center, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RWJ-445380 Administered to Patients With Plaque Psoriasis||Alza Corporation, DE, USA||Completed|September 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||February 2011|February 17, 2011|November 3, 2006||||No||https://clinicaltrials.gov/show/NCT00396422||177214|
NCT00396695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 6-198 R|Neuroimmunological Model of Traumatic Memory|Neuroimmunological Model of Traumatic Memory||Ziv Hospital||Recruiting|October 2006|December 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2006|November 6, 2006|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396695||177193|
NCT00396435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRIT|Correction of Anaemia and Progression of Renal Failure on Transplanted Patients|Multicenter, Prospective, Randomised, Open-label Study, Evaluating the Effect of Two Levels of Haemoglobin on Quality of Life and Speed of Progression of Renal Insufficiency on Renal Transplanted Patients With Chronic Graft Dysfunction (CGD)||Centre Hospitalier Universitaire, Amiens|No|Completed|April 2004|May 2010|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|70 Years|No|||May 2010|May 26, 2010|November 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00396435||177213|
NCT00396708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Wearable Robotic Functional Assistance for Stroke Rehabilitation|Wearable Robotic Functional Assistance for Stroke Rehabilitation||Myomo||Completed|August 2006|||December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||February 2010|February 2, 2010|November 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00396708||177192|
NCT00396721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIREPNA/05|Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy|Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus.|SIREPNA|Hospital Universitari de Bellvitge|Yes|Completed|January 2006|February 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||September 2011|September 14, 2011|November 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00396721||177191|
NCT00397605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-00239|Cannabinoids in Bipolar Affective Disorder|Cannabinoids in Bipolar Affective Disorder: A Controlled Pilot Study||University of British Columbia||Withdrawn|November 2006|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|60 Years|No|||September 2014|September 16, 2014|November 7, 2006||No|study was never started and no patients were ever enrolled|No||https://clinicaltrials.gov/show/NCT00397605||177125|
NCT00397631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-064|Initial Combination With Pioglitazone Study (0431-064)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|December 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|520|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|November 8, 2006|No|Yes||No|May 19, 2009|https://clinicaltrials.gov/show/NCT00397631||177124|
NCT00397644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060351|Assisting Low-Income Families at Pediatric Well-Child Care Visits|Enhancing a Medical Home for Vulnerable Children by Addressing Family Psychosocial Problems at Well-Child Care Visits: THE WE CARE Project||Johns Hopkins University||Completed|March 2006|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||200|||Both|N/A|N/A|No|||November 2006|April 4, 2007|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00397644||177123|
NCT00387283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4020-21b|Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020|Pharmacokinetic Study of AVI-4020 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration||Sarepta Therapeutics||Completed|October 2006|June 2009|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||July 2009|July 6, 2009|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00387283||177902|
NCT00387296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST Lidocaine|Study of Functional Microarray-Facilitated Lidocaine Liposomal Cream Absorption for Cutaneous Anesthesia in Volunteers|FAST Lidocaine, "Study of Functional Microarray-Facilitated Lidocaine Liposomal Cream Absorption for Cutaneous Anesthesia in Volunteers"||Massachusetts General Hospital|Yes|Withdrawn|January 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 25, 2009|October 11, 2006||No|Funding nonavailability and principal investigator move|No||https://clinicaltrials.gov/show/NCT00387296||177901|
NCT00396656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BDE06|Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients|A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients||Novartis||Completed|December 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|65 Years|No|||May 2011|May 5, 2011|November 6, 2006||Yes||No|January 7, 2011|https://clinicaltrials.gov/show/NCT00396656||177196|
NCT00396981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4902|MAPS Trial: Matrix And Platinum Science|A Prospective, Randomized, Multicenter Trial Investigating Matrix 2® and GDC® Detachable Coils for the Treatment of Intracranial Saccular Aneurysms|MAPS|Stryker Neurovascular|Yes|Completed|March 2007|March 2015|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|626|||Both|18 Years|80 Years|No|||January 2016|January 19, 2016|November 6, 2006|No|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT00396981||177171|
NCT00397267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR440906CTIL|Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids|||Soroka University Medical Center||Not yet recruiting|January 2007|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|18 Years|60 Years|No|||October 2006|November 26, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397267||177150|
NCT00397280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070023|Immune Cell Response to Stimuli|Innate Immunity Signal Transduction in Human Leukocytes||National Institutes of Health Clinical Center (CC)||Recruiting|November 2006|||||N/A|Observational|N/A|||Anticipated|2040|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|February 12, 2016|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00397280||177149|
NCT00398489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000516034|Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery|Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON]||National Cancer Institute (NCI)||Active, not recruiting|October 2006|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|94|||Female|18 Years|N/A|No|||September 2008|November 6, 2010|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398489||177060|
NCT00399022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4360-JZ-CTIL|Treatment With Duloxetine for OCD Patients|||Sheba Medical Center||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||January 2008|January 28, 2008|November 13, 2006||No|Funding was not recieved|No||https://clinicaltrials.gov/show/NCT00399022||177020|
NCT00397878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00067|AZD0530 in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer|Phase II Study of AZD0530 (NSC 735464) in Patients With Previously Treated Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Terminated|November 2006|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2013|May 7, 2014|November 9, 2006|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00397878||177105|
NCT00397891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133K1-102|Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|October 2006|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|80|||Both|50 Years|85 Years|No|||August 2014|August 20, 2014|November 8, 2006||No||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00397891||177104|
NCT00398996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA 003|A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients|Study to Compare Three Existing Starting Points of ART Initiation in HIV/TB Co-infected Patients|SAPIT|Centre for the AIDS Programme of Research in South Africa|Yes|Completed|June 2005|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|642|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00398996||177022|
NCT00399009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ups03-130|Comparative Study of Circular Stapling Instruments|Comparative Study of Circular Stapling Instruments Concerning the Risk of Anastomotic Dehiscence After Anterior Resection for Rectal Cancer.||Uppsala University Hospital||Terminated|January 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|880|||Both|18 Years|N/A|No|||June 2008|June 5, 2008|November 13, 2006|||One of the instruments in the study was withdrawn from the market before the calculated number    of persons were included.|No||https://clinicaltrials.gov/show/NCT00399009||177021|
NCT00399269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR - 50/9180|Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure|Assessment of Efficacy & Safety of Recombinant Human Erythropoietin -Alpha, (rHu-EPO-Alpha) in Patients With Anemia of Chronic Renal Failure.||Cadila Pharnmaceuticals||Completed|December 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|18 Years|70 Years|No|||June 2009|June 10, 2009|November 12, 2006||||No||https://clinicaltrials.gov/show/NCT00399269||177002|
NCT00398736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Caval vein sonography|A Non-invasive Approach to the Assessment of Volume Status in Mechanically Ventilated Septic Patients.|||Charite University, Berlin, Germany||Completed||||||Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|90 Years||Probability Sample|Critically ill patients with sepsis|July 2009|July 14, 2009|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00398736||177041|
NCT00394875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-06-03-SL|The Diabetes Specialist Nurse as Delegated Main Care Provider for Patients With Type 2 Diabetes|The Diabetes Specialist Nurse as Delegated Main Care Provider for Patients With Type 2 Diabetes in a Secondary Care Setting: a Randomized Controlled Trial.||Medical Research Foundation, The Netherlands||Completed|March 2002|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||81|||Both|N/A|N/A|No|||October 2006|October 31, 2006|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00394875||177331|
NCT00396487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-2006-002957-56|Tailored Treatment in Metastatic Colorectal Cancer|Tailored Treatment of Metastatic Colorectal Cancer Based on Genetic Markers||Vejle Hospital||Terminated|November 2006|February 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Both|60 Years|N/A|No|||June 2015|June 10, 2015|November 6, 2006||No|Only one patient included as per Feb. 4, 2008.|No||https://clinicaltrials.gov/show/NCT00396487||177209|
NCT00396734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281006-HMO-CTIL|The Effects of Pharmacotherapy on Brain Mechanisms Underlying Cocaine Dependence.|The Effects of Modafinil and Topiramate on Brain Mechanisms Underlying Cue-induced Cocaine Craving and Dependence in Methadone Maintained Cocaine Dependent Patients.||Hadassah Medical Organization|Yes|Suspended|April 2007|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|50 Years|No|||June 2010|June 9, 2010|November 6, 2006||No|Grant was not renewed|No||https://clinicaltrials.gov/show/NCT00396734||177190|
NCT00396448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351019|Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.|A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects||Pfizer|Yes|Terminated|February 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1253|||Both|18 Years|70 Years|No|||November 2012|November 5, 2012|November 6, 2006|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00396448||177212|
NCT00396461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0510|ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients|Phase IV-IV. ICULIP,a Prospective,Multi-centre,Randomised,Comparative,Double-blind Study to Evaluate Two Different Types of Lipid Emulsions Used for Total Parenteral Nutrition in Critical Patients and Their Influence on Nosocomial Infection.|ICULIP|B. Braun Medical SA||Terminated|November 2006|February 2011|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||July 2013|July 18, 2013|November 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00396461||177211|
NCT00397683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-011|A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)|Proprietary Information - Exploratory (Non-Confirmatory) Trial||Merck Sharp & Dohme Corp.||Terminated|October 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|2|||Both|40 Years|N/A|No|||October 2015|October 30, 2015|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397683||177120|
NCT00397007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI 574/12-1|Psychophysiological Treatment of Chronic Tinnitus|Evaluation of Psychological and Psychophysiological Effects of a Biofeedback-Based Cognitive-Behavioral Psychotherapy for Chronic Tinnitus-Sufferers||Philipps University Marburg Medical Center||Completed|May 2005|May 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|130|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||May 2008|May 8, 2008|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00397007||177169|
NCT00397020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bipolar Mania|Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes|A Single-Blind, Randomized, Naturalistic Pilot Study, Comparison of Divalproex ER and Quetiapine for Adults With Acute Mania or Mixed Episodes||University of California, San Diego|No|Completed|December 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00397020||177168|
NCT00397319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050045|Growth Hormone's Effect on the Cardiovascular System|The Role of Growth Hormone in Cardiovascular Health||Vanderbilt University||Terminated|August 2005|December 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2007|July 2, 2007|November 8, 2006|||Inadequate retention of GHD adults to maintain power to study the effect of GH on    fibrinolysis. A comparison between GHD adults and controls was completed.|No||https://clinicaltrials.gov/show/NCT00397319||177146|
NCT00397332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-05-HMO-CTIL|Alefacept for Chronic Graft Versus Host Disease|An Investigator Initiated Open-label and Explorative Study of Alefacept Treatment for Chronic Extensive Graft Versus Host Disease||Hadassah Medical Organization|No|Completed|October 2006|July 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|70 Years|No|||February 2011|April 19, 2015|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00397332||177145|
NCT00397657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-12027|Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis|ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)||Walter Reed Army Medical Center||Terminated|November 2006|October 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|30 Years|N/A|No|||June 2009|June 16, 2009|November 8, 2006||No|Independent steering committee has stopped the trial based on results of a prespecified,    blinded interim analysis. It was not stopped due to safety concerns.|No||https://clinicaltrials.gov/show/NCT00397657||177122|
NCT00397670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN 003OL|Open Label Study of the Safety and Contraceptive Efficacy of BufferGel® With Diaphragm|A Multicenter Open-Label Study of the Safety and Contraceptive Efficacy of BufferGel® Spermicide Used With Diaphragm||ReProtect Inc||Completed|January 2004|May 2006||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397670||177121|
NCT00397527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO_L_01810|Acceptability Dermacyd Wipes - Lactoserum - Hygiene|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up of Dermacyd Wipes||Sanofi||Completed|July 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2008|May 15, 2008|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397527||177131|
NCT00397540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2006-001|The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)|Prospective Cohort Study of the Effect of Serum HBV DNA Level on Intrahepatic Recurrence in Locally Treatable, HBV-related HCC Patients||Seoul National University Hospital|Yes|Completed|October 2006|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|19 Years|80 Years|No|||May 2015|May 18, 2015|November 7, 2006|Yes|Yes||No|September 22, 2009|https://clinicaltrials.gov/show/NCT00397540||177130|
NCT00397904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-095|Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin|Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Irinotecan and Cisplatin-Refractory Metastatic Esophageal and Gastric Cancer||Memorial Sloan Kettering Cancer Center||Completed|October 2006|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|120 Years|No|||October 2015|October 22, 2015|November 9, 2006|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00397904||177103|
NCT00398216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-PRT011|A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery|A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement||Daiichi Sankyo Inc.||Completed|May 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|903|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|November 9, 2006|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00398216||177080|
NCT00398229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|freezehcg-HMO-CTIL|hCG Supplementation in Frozen-Thawed Embryo Transfer Cycle|The Benefit of Human Chorionic Gonadotropin (hCG) Supplementation Throughout the Secretory Phase of Frozen-Thawed Embryo Transfer Cycles||Hadassah Medical Organization||Completed|November 2006|May 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|45 Years|No|||November 2007|December 31, 2008|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00398229||177079|
NCT00399035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00051|Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer|A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer.|HORIZON II|AstraZeneca||Active, not recruiting|November 2006|January 2017|Anticipated|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1254|||Both|18 Years|130 Years|No|||December 2015|January 11, 2016|November 13, 2006|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT00399035||177019|
NCT00398801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND - DK74008|Gastroparesis Registry|Gastroparesis Registry|GpR|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|December 2006|March 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|591|Samples With DNA|Plasma and serum|Both|18 Years|N/A|No|Non-Probability Sample|Tertiary care centers for patients with symptoms of gastroparesis|June 2014|June 16, 2014|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00398801||177037|
NCT00398749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005596|Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)|Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2||Janssen-Cilag B.V.||Completed|October 2005|November 2009|Actual|November 2009|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|1927|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients receiving epoetin alfa as anemia treatment during chemotherapy, as part of        the common practice of participating physicians. Patients may enter the study as soon as        their epoetin alfa treatment starts.|November 2012|November 5, 2012|November 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00398749||177040|
NCT00394888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|High Risk Hemangioma|Hemangioma Associated With High Rates of Morbidity|Hemangioma Associated With High Rates of Morbidity:A Prospective Study||Medical College of Wisconsin|No|Completed|November 2005|January 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|433|||Both|N/A|18 Years|No|||September 2013|September 17, 2013|November 1, 2006||No||No|May 4, 2011|https://clinicaltrials.gov/show/NCT00394888||177330|
NCT00394901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081120|A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia|A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia||Pfizer||Completed|September 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|372|||Both|18 Years|N/A|No|||February 2010|February 26, 2010|October 31, 2006||Yes||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00394901||177329|
NCT00395187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10514|A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa|A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa||University of Kansas Medical Center|No|Completed|October 2006|September 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|55 Years|No|||October 2007|October 4, 2007|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395187||177308|
NCT00395473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-087|Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)|Ezetimibe Added to Statin Therapy||Merck Sharp & Dohme Corp.||Completed|March 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|141|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395473||177286|
NCT00396760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1172/04|Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery|The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization||German Heart Center||Active, not recruiting|January 2005|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||220|||Both|18 Years|N/A|No|||November 2006|November 6, 2006|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396760||177188|
NCT00396747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIERA|A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study|Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone||Université Catholique de Louvain|Yes|Completed|June 2003|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||October 2007|October 18, 2007|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396747||177189|
NCT00396123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 7825|Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study|Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study||University of Michigan|No|Active, not recruiting|November 2006|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Nephrology clinic|April 2011|April 15, 2011|November 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00396123||177237|
NCT00396136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061550|COSMO Post Approval Registry: Corox OTW Steroid LV Lead Monitoring|Corox OTW Steroid LV Lead Monitoring||Biotronik, Inc.||Completed|October 2006|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|November 1, 2006|Yes|Yes||No|February 22, 2012|https://clinicaltrials.gov/show/NCT00396136||177236|
NCT00397358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31656|Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients|Open-Label Study to Evaluate the Effects of Once Daily Extraneal (7.5% Icodextrin) Peritoneal Dialysis Solution on Triglyceride Levels in Peritoneal Dialysis Patients||Baxter Healthcare Corporation|No|Terminated|November 2006|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||June 2007|June 29, 2007|November 7, 2006|||Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00397358||177143|
NCT00397696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-IA02|Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease|Evaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease Subjects||Institute for Neurodegenerative Disorders|Yes|Completed|November 2006|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|21 Years|N/A|No|||April 2014|April 16, 2014|November 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397696||177119|
NCT00397033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010498|Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|November 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|316|||Both|18 Years|65 Years|No|||July 2013|July 23, 2013|November 7, 2006|Yes|Yes||No|March 16, 2009|https://clinicaltrials.gov/show/NCT00397033||177167|
NCT00397345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV3/001/06|TroVax Renal Immunotherapy Survival Trial|An International, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate Whether TroVax, Added to First-line Standard of Care Therapy, Prolongs the Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.||Oxford BioMedica|Yes|Completed|September 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||June 2010|June 4, 2010|November 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397345||177144|
NCT00398541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-322|Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)|Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients||Merck Sharp & Dohme Corp.||Completed|March 2005|June 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|50 Years|N/A|No|||September 2015|September 23, 2015|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398541||177056|
NCT00397592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051212|Growth Hormone's Effect on Endothelial Progenitor Cells|The Effect of Exogenous Growth Hormone on the Mobilization of Endothelial Progenitor Cells||Vanderbilt University|No|Completed|August 2006|January 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2007|July 2, 2007|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397592||177126|
NCT00398502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-105|Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone|A Randomized, Open-label, 3-period Crossover Study to Determine the Relative Bioavailability of Two Oral Formulations of MOA-728 and to Compare the Pharmacodynamics of the Two Oral Formulations of MOA-728 and the Subcutaneous Formulation in Subjects on Stable Methadone Maintenance||Valeant Pharmaceuticals International, Inc.||Completed|October 2006|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 2011|July 22, 2011|November 9, 2006||||||https://clinicaltrials.gov/show/NCT00398502||177059|
NCT00398775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/36|Procalcitonin in Fever of Unknown Etiology|Procalcitonin Guided Antimicrobial Discontinuation in Hospitalised Patients With Fever of Unknown Etiology||Changi General Hospital||Terminated|January 2007|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|90|||Both|21 Years|N/A|No|||November 2007|November 19, 2007|November 13, 2006|||Very low recruitment|No||https://clinicaltrials.gov/show/NCT00398775||177039|
NCT00398788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013255|A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain|An Open-Label, Repeated-Dose Trial to Characterize the Efficacy and Safety, and Impact on Quality of Life Measures of Dilaudid CR (Hydromorphone HCI) in Patients With Chronic Low Back Pain||Alza Corporation, DE, USA||Completed||November 2001|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|207|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00398788||177038|
NCT00399048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013270|An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)|A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in Patients With Chronic Osteoarthritis||Alza Corporation, DE, USA||Completed||May 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|140|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00399048||177018|
NCT00399282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNFTRI-2484|Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis|Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis||hahid Beheshti University of Medical Sciences|Yes|Completed|October 2006|April 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|16 Years|75 Years|No|||April 2007|April 17, 2007|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399282||177001|
NCT00394914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04295|Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)|A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure||Merck Sharp & Dohme Corp.|No|Completed|August 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|311|||Both|6 Years|65 Years|No|||June 2015|June 23, 2015|October 31, 2006|Yes|Yes||No|August 27, 2013|https://clinicaltrials.gov/show/NCT00394914||177328|
NCT00394927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01228|Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients|A Multicenter, Non-interventional Surveillance Study to Evaluate the Adverse Effects of Antiepileptic Drug Treatment in Patients With Epilepsy||UCB Pharma||Completed|April 2007|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|1000|||Both|4 Years|N/A|No|Non-Probability Sample|Patients with confirmed diagnosis of epilepsy requiring anti-epileptic treatment and which        are already receiving daily anti-epileptic treatment|July 2012|July 18, 2012|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00394927||177327|
NCT00395200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRCRG44871|Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)|Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis|MSCIMS|University of Cambridge|Yes|Completed|July 2008|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||October 2011|October 22, 2011|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00395200||177307|
NCT00395486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00061|ROMEO (Rosuvastatin in Metabolic syndrOme)|A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C||AstraZeneca||Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|November 1, 2006|Yes|Yes||No|June 9, 2009|https://clinicaltrials.gov/show/NCT00395486||177285|
NCT00395499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000H0115|Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva|Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva||Ohio State University||Completed|May 2001|April 2003||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||19|||Both|4 Years|14 Years|No|||March 2002|November 2, 2006|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395499||177284|
NCT00397124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vagusCTIL|The Role of the Vagus Nerve in Tumor-to-Brain Communication in Lung Cancer Patients|Does the Vagus Nerve Play a Role in Tumor-to-Brain Communication? a Preliminary Study in Patients With Newly Diagnosed Lung Cancer||Rambam Health Care Campus||Recruiting|April 2002|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||40|||Both|35 Years|70 Years|No|||November 2006|November 7, 2006|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00397124||177161|
NCT00397423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-123456-1|G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response|Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response||Peking University||Completed|December 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||November 2007|November 27, 2007|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397423||177139|
NCT00397098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTE5894|Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder|A Double-Blind Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A Versus Placebo in the Prevention of Relapse of Anxiety up to 1 Year in Patients With GAD Improved After 12 Weeks of Open Label Treatment With SR58611A.|VEGA|Sanofi||Terminated|November 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|257|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|November 7, 2006|No|Yes|reprioritization of indications|No||https://clinicaltrials.gov/show/NCT00397098||177163|
NCT00397111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070021|Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders|Development of Functional and Structural Magnetic Resonance Imaging Techniques for the Study of Mood and Anxiety Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|November 2006|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|280|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00397111||177162|
NCT00397046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-104|A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors|An Ascending and Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of HKI-272 Administered Orally to Japanese Subjects With Advanced Solid Tumors||Puma Biotechnology, Inc.||Completed|November 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|N/A|No|||May 2012|May 10, 2012|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00397046||177166|
NCT00397384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00107|Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer|A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer||National Cancer Institute (NCI)||Completed|January 2007|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2014|September 28, 2015|November 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00397384||177142|
NCT00398008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014718-02S1|HIV Risk Reduction and Drug Abuse Treatment in Iran|HIV Risk Reduction and Drug Abuse Treatment in Iran||Yale University||Withdrawn|October 2004|December 2008|Anticipated|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|65 Years|No|||July 2013|July 25, 2013|November 9, 2006||No|Study was never able to start in IRAN|No||https://clinicaltrials.gov/show/NCT00398008||177095|
NCT00398021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2006-1168|Predictors of Constipation in Healthy Children|Predictors of Constipation in Healthy Children||University of Wisconsin, Madison|No|Completed|June 2006|March 2010|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|1430|||Both|5 Years|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children ages 5 through 8 who present for a health maintenance visit at eleven general        pediatric offices.|June 2010|October 1, 2015|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00398021||177094|
NCT00397969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000492752|Improving the Frequency of Colonoscopy in Patients With a Previous Colorectal Polyp|Improving Surveillance for Colorectal Polyps||National Cancer Institute (NCI)||Completed|February 2005|June 2008|Actual|||N/A|Interventional|Allocation: Randomized|||Anticipated|800|||Both|21 Years|N/A|No|||December 2006|December 18, 2013|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00397969||177098|
NCT00398281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000513051|Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer|Detection of Prostate Cancer With Contrast-Enhanced Ultrasound After Treatment With Dutasteride||National Cancer Institute (NCI)||Completed|November 2006|September 2012|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Diagnostic|2||Anticipated|450|||Male|18 Years|80 Years|No|||June 2009|January 9, 2014|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398281||177075|
NCT00398554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000514344|Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma|Pilot Study for Therapy Optimising for Hodgkin's Lymphoma in Childhood and Adolescence; Optimising Therapy for Boys With Hodgkin's Lymphoma in Intermediate and Advanced Stages. Safety and Efficacy Study for Drug Combination VECOPA||Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|June 2005|March 2013|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|N/A|18 Years|No|||November 2015|November 17, 2015|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00398554||177055|
NCT00398242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colaris03|Treatment of Stable Both-Bone Midshaft Forearm Fractures in Children|Treatment of Stable Both-Bone Midshaft Forearm Fractures in Children: A Randomized Trial Between Treatment With Above Elbow Cast and a Combination of Above- and Below Elbow Armcast.||Colaris, Joost, M.D.||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|N/A|15 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00398242||177078|
NCT00398255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-AR43538|Healthier Living With Arthritis Online Program|Internet Arthritis Self-Management Study||Stanford University||Completed|February 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||900|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398255||177077|
NCT00398515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00151|Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma|A Phase I Trial of CC-5013 (Lenalidomide) and CCI-779 in Patients With Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|March 2007|||February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00398515||177058|
NCT00399061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5278|Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms|Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms||Innovative Medical||Completed|November 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|N/A|No|||September 2008|September 23, 2008|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00399061||177017|
NCT00399308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P001-001-B|Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers|An Initial Evaluation Of The Safety And Activity Of Celaderm(TM) Treatment Regimens In Healing Venous Leg Ulcers||Shire Regenerative Medicine, Inc.|No|Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|80 Years|No|||August 2013|August 9, 2013|November 10, 2006|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00399308||176999|Limitations of the trial include the potential for outcome assessment bias as the study was not blinded.
NCT00399295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011608|An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg|An Open-Label Evaluation of the Independent Effect of Coadministration of a High Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCL) 16 mg||Alza Corporation, DE, USA||Completed||June 1997|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00399295||177000|
NCT00395213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013655|Antidepressant Safety in Kids Study|Antidepressant Safety in Kids (ASK) Study: An Open-label, Prospective, Cohort Study of Antidepressants in Children and Adolescents With Anxiety Disorders, Depressive Disorders, Eating Disorders, or Obsessive-Compulsive Disorder|ASK|Duke University|Yes|Completed|May 2007|July 2009|Actual|July 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|569|||Both|7 Years|17 Years|No|Non-Probability Sample|Children and adolescents age 7 to 17 years old.|April 2015|April 16, 2015|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00395213||177306|
NCT00395512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-322OPI-002|Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes||Takeda|No|Completed|November 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|655|||Both|18 Years|80 Years|No|||February 2013|February 19, 2013|November 1, 2006|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00395512||177283|
NCT00395538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070016|Effects of PTH Replacement on Bone in Hypoparathyroidism|Effects of PTH Replacement on Bone in Hypoparathyroidism||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2006|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|70 Years|No|||March 2016|March 22, 2016|November 2, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395538||177282|
NCT00395551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF 3688 Non-AMD|Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.|A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.||Ophthalmic Consultants of Boston|No|Completed|December 2005|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 7, 2010|November 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395551||177281|
NCT00395564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6613|Chart Review of Those Who Have Had Open, Laparoscopic, Ureteroscopic, or Percutaneous Surgery|Retrospective Chart Review of Patients Who Have Had an Open, Laparoscopic, Ureteroscopic or Percutaneous Surgery||University of California, Irvine|No|Enrolling by invitation|November 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Those who have urologic conditions that need to be treated with open, laparoscopic,        ureteroscopic, or percutaneous urologic surgery.|June 2013|June 24, 2013|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00395564||177280|
NCT00395837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#S2004.004|Efficacy of Lifestyle Changes in Modifying Practical Markers of Wellness and Aging.|Efficacy of Lifestyle Changes in Modifying Practical Markers of Wellness and Aging||St. Anthony's Health Care||Completed|September 2004|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||56|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2006|November 1, 2006|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395837||177259|
NCT00397137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202/99|Stapled Anopexy Versus Closed Haemorrhoidectomy for Haemorrhoids|Prospective Randomized Multi-Centre Trial Comparing the Clinical Efficacy, Safety and Patient Acceptability of Circular Stapled Anopexy With Closed Diathermy Haemorrhoidectomy for Haemorrhoids||University of Dundee||Completed|September 2000|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||182|||Both|16 Years|N/A|No|||November 2006|November 7, 2006|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00397137||177160|
NCT00397150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCO-CT-2004-003660|PROMISE EBF: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV in Sub-Saharan Africa|PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV||Centre For International Health|No|Completed|November 2006|April 2011|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2579|||Both|15 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|November 7, 2006||No||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00397150||177159|Trial not entirely blinded.
NCT00397722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH103390|Treatment Of Patients With Social Anxiety Disorder|Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)||GlaxoSmithKline||Completed|November 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||280|||Both|18 Years|64 Years|No|||October 2010|October 1, 2010|November 8, 2006||||||https://clinicaltrials.gov/show/NCT00397722||177117|
NCT00397735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603001228|N-acetylcysteine in Intra-amniotic Infection/Inflammation|Effect of N-acetylcysteine in Preventing Adverse Neonatal Outcomes in Women With Intra-amniotic Infection/Inflammation||Yale University|No|Recruiting|October 2006|April 2015|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||July 2012|July 18, 2012|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00397735||177116|
NCT00397059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-371|Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism|Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism||University of Southern Denmark||Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00397059||177165|
NCT00397072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZK219477IV|Epothilone in Recurrent Glioblastoma Patients|Phase II Study: Systemic Treatment With iv ZK219477-Epothilone in Recurrent Glioblastoma Patients||Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||Completed|June 2006|December 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|70 Years|No|||April 2014|April 16, 2014|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00397072||177164|
NCT00397709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBQXCU2|Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection|Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection: A Randomized Clinical Trial.||Hospital Virgen de la Luz||Terminated|March 1996|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||228|||Both|16 Years|89 Years|No|||November 2006|December 30, 2008|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00397709||177118|
NCT00398580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDC106220|28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men|A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism||GlaxoSmithKline|No|Completed|October 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Male|18 Years|70 Years|No|||March 2013|March 29, 2013|November 8, 2006||||||https://clinicaltrials.gov/show/NCT00398580||177053|
NCT00397982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00133|Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma|A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma||National Cancer Institute (NCI)||Active, not recruiting|May 2007|||December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397982||177097|
NCT00397995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colaris04|Undislocated Distal Both-Bone Forearm Fractures in Children|Treatment of Undislocated Both-Bone Distal Forearm Fractures in Children: A Randomized Trial Between Treatment With Above- and Under Elbow Cast.||Colaris, Joost, M.D.||Recruiting|January 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|15 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397995||177096|
NCT00398294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0733-264|To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)|An Open-Label, Single-Arm, Prospective Study to Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet in Patients With Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|May 2005|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398294||177074|
NCT00398307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1111|Evaluating Patients With Varying Degrees of Renal Function|A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function||Taiho Oncology, Inc.||Completed|February 2006|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|November 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00398307||177073|
NCT00398866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR050607|A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb|A Study of Hyaluronan (Synvisc) for the Treatment of Osteoarthritis in the Thumb: Randomized Control Trial||Hospital for Special Surgery, New York|Yes|Completed|August 2006|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|213|||Both|45 Years|95 Years|No|||August 2015|August 17, 2015|November 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398866||177032|
NCT00397930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515123|Yoga in Treating Sleep Disturbance in Cancer Survivors|Yoga for Persistent Sleep Disturbance in Cancer Survivors|YOCAS|University of Rochester|Yes|Completed|October 2006|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|410|||Both|21 Years|120 Years|No|||October 2015|October 13, 2015|November 9, 2006||No||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00397930||177101|The study did not account for components such as time or attention, as this would have required the use of a placebo yoga intervention for the YOCAS program. The results are not generalizable for all yoga types, nor for all socioeconomic backgrounds.
NCT00398268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colaris06|Dislocated Unstable Distal Both-Bone Forearm Fractures in Children|Treatment of Unstable Dislocated Both-Bone Distal Forearm Fractures in Children: A Follow-up Study||Colaris, Joost, M.D.||Recruiting|January 2006|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|15 Years|Accepts Healthy Volunteers|||November 2006|November 8, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00398268||177076|
NCT00398528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSAV1-2006|An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis|An fMRI Study of Treatment Optimization Recommendations Comparing Patients Changing Treatment From Glatiramer Acetate 20 mg qd SC (Copaxone®) to IFN-β-1a 30 Mcg qw IM (Avonex®) to Those Changing From to IFN-β-1a 30 Mcg qw IM (Avonex®) to Glatiramer Acetate 20 mg qd SC (Copaxone®) in a Multicenter Study of Patients With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy.||Neurognostics||Terminated|September 2006|November 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective|||Anticipated|48|||Both|18 Years|65 Years|No|||November 2007|November 30, 2007|November 9, 2006|||rate of enrollment|No||https://clinicaltrials.gov/show/NCT00398528||177057|
NCT00398814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 124|Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers|An Open-Label Phase I Study of the Safety of Perifosine in Combination With Sorafenib for Patients With Advanced Cancers||AEterna Zentaris|No|Completed|October 2006|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2011|February 14, 2014|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398814||177036|
NCT00394953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH17847|A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.|A Randomized, Open Label Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis.||Hoffmann-La Roche||Completed|January 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|490|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00394953||177325|
NCT00394966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04351|A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)|A Phase 2, MultiCenter, Randomized, Placebo-Controlled, Double-Blind, Dose Finding Study to Determine the Safety and Efficacy of SCH 619734 for the Treatment of Chemotherapy Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)||Schering-Plough|No|Completed|September 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|450|||Both|18 Years|N/A|No|||October 2009|October 22, 2009|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00394966||177324|
NCT00394940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1349|Identifying Inflammatory Biomarkers of Chronic Obstructive Pulmonary Disease|Serum Inflammatory Biomarkers as Predictors of COPD Morbidity and Mortality||University of Arizona||Active, not recruiting|July 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|DNA, serum, supernatants|Both|N/A|N/A|No|Probability Sample|Sample of the general population that was enrolled in 1972|August 2012|August 7, 2012|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00394940||177326|
NCT00395590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5594ctil|Polymorphisms in Inflammatory Cytokines Genes in Subjects With Obstructive Sleep Apnea|A Cross Sectional Study of Patients With Obstructive Sleep Apnea for Polymorphisms in Genes of Inflammatory Cytokines.||Shaare Zedek Medical Center||Not yet recruiting|November 2006|November 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|18 Years|75 Years|No|||February 2005|November 2, 2006|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395590||177278|
NCT00395850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-13441|Disulfiram for Cocaine Abuse|Disulfiram for Cocaine Abuse||University of Arkansas|Yes|Completed|April 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|118|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 6, 2013|November 2, 2006|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00395850||177258|
NCT00395863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 126|Multihance at 3 Tesla in Brain Tumors|A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T||Bracco Diagnostics, Inc|No|Completed|November 2006|March 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|46|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|September 12, 2006||No||No|March 30, 2009|https://clinicaltrials.gov/show/NCT00395863||177257|
NCT00395889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3782|Physical Activities in Daily Life After Lung Transplantation|Effects of a 6-month Outpatient Rehabilitation Program Including Structured Exercise Training on Participation in Physical Activities in Daily Life in Lung Transplant Recipients||Katholieke Universiteit Leuven|No|Completed|November 2006|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||February 2011|February 18, 2011|November 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00395889||177255|
NCT00396162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00006212|Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis|||University of Michigan||Completed|November 2006|February 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|15 Years|70 Years|No|||June 2012|June 12, 2012|November 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00396162||177234|
NCT00397163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/0128|Effect of Remote Ischemic Preconditioning in Patient Undergoing Cardiac Bypass Surgery|A Clinical Study Investigating Ischemic Preconditioning in Type II Diabetic Patients Undergoing Coronary Artery Bypass Graft Surgery.||University College London Hospitals|Yes|Recruiting|December 2010|November 2016|Anticipated|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00397163||177158|
NCT00397176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-1200|Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women|Ascending, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of DVS SR Administered Orally to Healthy Japanese Female Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2006|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||32|||Female|20 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00397176||177157|
NCT00397436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506M70827|Pilot Study of Protein Profiling of the Human Epidermal Cells After Ultraviolet Irradiation|Pilot Study of Protein Profiling of the Human Epidermal Cells After Ultraviolet Irradiation||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|February 2007|December 2015|Anticipated|November 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00397436||177138|
NCT00397397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/2006CTIL|Comparative Treatment Study in Patients With Lower Ureteral Stones|Comparative Study in Patients With Lower Ureteral Stones Treated With 10 MG Alfuzosin,10 MG Alfuzosin With Rowatinex, and Rowatinex Alone||Hillel Yaffe Medical Center||Not yet recruiting|January 2007|March 2007||||Phase 0|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|18 Years|N/A|No|||November 2006|November 8, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397397||177141|
NCT00397410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-2-0284|Prevention of Hip Fractures With Soft and Hard Hip Protectors|Compliance With and Effect of Soft and Hard Hip Protectors in Norwegian Nursing Homes||Norwegian Institute of Public Health||Completed|May 2005|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label|1||Actual|1236|||Both|N/A|N/A|No|||May 2012|May 10, 2012|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00397410||177140|
NCT00398333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA-05|Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients|Randomized Controlled, Open-label, Pilot Study to Assess the Effectiveness of a Nutritional Supplementation Enriched With Eicosapentaenoic Acid on Chemotherapy Tolerance in Patients With Advanced Colorectal Cancer||Hospital Clinic of Barcelona||Terminated|June 2005|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|November 9, 2006||No|Impossibility to accomplish the sample size in assigned time.|No||https://clinicaltrials.gov/show/NCT00398333||177071|
NCT00398359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2006-1018|Treatment of Childhood Obesity in Primary Care|Treatment of Childhood Obesity in Primary Care||University of Wisconsin, Madison|No|Completed|May 2006|December 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||December 2011|September 30, 2015|November 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00398359||177070|
NCT00398372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0031|Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment|Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment||Stanford University||Completed|November 2000|September 2009|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|18 Years|N/A|No|||July 2010|May 31, 2011|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00398372||177069|
NCT00398320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|END0002|Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors|A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors||Stanford University||Completed|November 2006|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2013|October 15, 2013|October 31, 2006|No|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00398320||177072|
NCT00398567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-202|A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer|A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer||Puma Biotechnology, Inc.|No|Active, not recruiting|April 2007|December 2017|Anticipated|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398567||177054|
NCT00399373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001352|Structuring the Integration of Care Management Services For Medicaid Enrollees Recipients With Chronic Illness, Substance Abuse Problems and Possible Psychiatric Disorders|Structuring the Integration of Services For Medicaid Recipients With Chronic Illness, Substance Abuse Problems and Possible Psychiatric Disorders||Johns Hopkins University||Active, not recruiting|November 2005|January 2007||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||258|||Both|21 Years|65 Years|No|||November 2006|November 13, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399373||176994|
NCT00397943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106227|Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults|Safety, Reactogenicity & Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Administered Intramuscularly According to a Schedule of 0, 1 Month, to Healthy Adults Aged 18 to 50 Years||GlaxoSmithKline||Completed|November 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|110|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397943||177100|
NCT00397956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-053|To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)|An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability & Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults||Merck Sharp & Dohme Corp.||Completed|September 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00397956||177099|
NCT00399074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/HD11/1353U|Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia|Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia||Makerere University||Completed|October 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Both|6 Months|12 Years|No|||July 2009|July 1, 2009|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399074||177016|
NCT00399321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.016|A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer|A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|April 2006|April 2016|Anticipated|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|refer to protocol|Female|18 Years|N/A|No|Non-Probability Sample|Women with breast cancer|May 2015|May 18, 2015|November 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00399321||176998|
NCT00394992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPATICA|Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer|Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone||Dutch Colorectal Cancer Group|Yes|Terminated|December 2006|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|November 1, 2006||No|Data from the C08 study and Avant study|No||https://clinicaltrials.gov/show/NCT00394992||177323|
NCT00395239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asthma/Steroid Withdrawal|Asthma/Steroid Withdrawal Study|The Temporal Sequence of Inflammatory Mediators During a Controlled Exacerbation of Asthma by Steroid Withdrawal.||University of Alberta|Yes|Active, not recruiting|October 2006|October 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 30, 2010|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00395239||177304|
NCT00395226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-05-03|Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial|"Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial." Prospective, Double Blind, Randomized, Controlled Trial Comparing the Effects of Supplemental Zinc Sulfate and Placebo on the Severity of Rosacea.||Essentia Health|No|Terminated|July 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 3, 2011|October 31, 2006||No|Difficulty recruiting subjects|No|June 3, 2011|https://clinicaltrials.gov/show/NCT00395226||177305|
NCT00395577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX06-702-304|A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702|A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate||Vertex Pharmaceuticals Incorporated||Completed|November 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|75 Years|No|||December 2007|December 5, 2007|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395577||177279|
NCT00395616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e120537192|Comparison Between Type A Botulinum Toxin Injection and Corticosteroid Injection in the Treatment of Tennis Elbow|||E-DA Hospital||Recruiting|November 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|20 Years|80 Years|No|||November 2006|November 2, 2006|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395616||177276|
NCT00395876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N3698g|A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|TROPICS 1|Genentech, Inc.||Completed|November 2006|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||July 2010|July 14, 2010|November 2, 2006|Yes|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00395876||177256|
NCT00395902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040261|Post Transplant Study|A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients||Amgen||Completed|August 2005|||||N/A|Observational|Time Perspective: Retrospective||||50|||Both|18 Years|N/A||||December 2007|December 20, 2007|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395902||177254|
NCT00396175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-111|Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)|A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia||Merck Sharp & Dohme Corp.||Completed|March 1998|||January 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||355|||Male|40 Years|60 Years|No|||September 2014|September 25, 2014|November 2, 2006||||||https://clinicaltrials.gov/show/NCT00396175||177233|
NCT00396500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Deworming and Vitamin A (DEVTA) Prepilot Study|To Assess the Effectiveness of Six-Monthly Deworming With Vitamin A Administration on Growth in 1-5 Year Old Children in the Urban Slums of Lucknow||King George's Medical University||Completed|April 1994|December 1996||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||4000|||Both|1 Year|5 Years|No|||November 2006|November 6, 2006|November 4, 2006||||No||https://clinicaltrials.gov/show/NCT00396500||177208|
NCT00397787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02823|Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine|A Phase II Study of Sunitinib Malate (SU11248, NSC #736511, IND #74,019) in Patients With Previously Treated Pancreatic Adenocarcinoma With Measurable Metastatic Disease Following Progression on Front-Line Gemcitabine-Based Therapy||National Cancer Institute (NCI)||Completed|November 2006|||September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|November 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00397787||177112|
NCT00398086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA040|Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer|A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer||Celgene|No|Completed|November 2006|December 2010|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|November 8, 2006|Yes|Yes||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00398086||177089|
NCT00397449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2005-004568-22|GMZ2-Aluminum Hydroxide Phase I, Tübingen|Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial||European Malaria Vaccine Initiative|No|Active, not recruiting|October 2006|December 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 9, 2007|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397449||177137|
NCT00398034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2192-06-049|Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-Treated Chronic Pain Patients: A Pilot Study.|Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-Treated Chronic Pain Patients: A Pilot Study.||James J. Peters Veterans Affairs Medical Center||Recruiting|November 2006|October 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||62|||Male|18 Years|60 Years|No|||November 2006|November 8, 2006|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00398034||177093|
NCT00398047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515108|Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes|Combination of Azacitadine and Hematopoietic Growth Factors for Myelodysplastic Syndrome||Comprehensive Cancer Center of Wake Forest University|No|Terminated|September 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||March 2012|March 23, 2012|November 9, 2006|No|Yes|Slow accrual|No|January 21, 2011|https://clinicaltrials.gov/show/NCT00398047||177092|
NCT00398060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL223-3|GOAL Life-Style Change Intervention to Prevent Type 2 Diabetes|GOAL Life-Style Change Implementation Intervention to Prevent Type 2 Diabetes in Primary Health Care||National Institute for Health and Welfare, Finland|No|Completed|January 2003|March 2007|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|389|||Both|50 Years|65 Years|No|||February 2008|February 13, 2008|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00398060||177091|
NCT00398606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_546|A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)|A Triple-Blind, Randomized, Active-Controlled, Parallel-Group, Multicenter Study to Evaluate and Compare the Efficacy and Tolerability of Alendronate Sodium With Calcium Supplementation in the Treatment of Osteoporosis in Postmenopausal Women||Merck Sharp & Dohme Corp.||Completed|April 1995|||February 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||650|||Female|45 Years|N/A|No|||May 2013|May 28, 2013|November 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398606||177051|
NCT00398619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB13739-103|A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes|A Double-blind, Placebo Controlled Pharmacodynamic Study of the Effect of INCB013739 on Systemic and Adipose Tissue 11βHSD1 Activity in Obese, Insulin Resistant Subjects.||Incyte Corporation||Completed|November 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||January 2012|January 20, 2012|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00398619||177050|
NCT00398879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 211|Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients|A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients||AEterna Zentaris|No|Completed|August 2005|October 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|381|||Both|18 Years|N/A|No|||February 2012|March 4, 2013|November 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398879||177031|
NCT00399126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 104|Phase I Trial of Paclitaxel With Perifosine|A Phase 1 Trial of the Combination of Perifosine and Paclitaxel Given Either Weekly or Every 3 Weeks||AEterna Zentaris|No|Completed|November 2004|October 2011|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2011|February 12, 2014|November 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00399126||177012|
NCT00399152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 125|Perifosine + Sunitinib Malate for Patients With Advanced Cancers|An Open-Label Phase I Study of the Safety of Perifosine in Combination With Sunitinib Malate for Patients With Advanced Cancers||AEterna Zentaris|No|Completed|October 2006|October 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2011|February 14, 2014|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399152||177011|
NCT00398827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005|A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Dexmedetomidine for Sedation During Monitored Anesthesia Care||Hospira, Inc.||Completed|December 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|326|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|November 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398827||177035|
NCT00399087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 105|Phase I Trial of Docetaxel With Perifosine|A Phase 1 Trial of the Combination of Perifosine and Docetaxel With or Without Prednisone||AEterna Zentaris|No|Completed|November 2004|January 2011|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|No|||February 2013|February 12, 2014|November 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00399087||177015|
NCT00399334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010609|PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders|Study PROFILe3: Clinic Observations Profile of Relapse and Readmission in Emergency/Acute Settings: Epidemiologic Survey in Schizophrenic Patients||Janssen-Cilag, S.A.||Completed|June 2005|December 2005|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1607|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Schizophrenia or Schizoaffective disorder with a diagnosis over 2 years that        are hospitalized in a Short-Term Psychiatric Hospitalization Unit or Acute Unit.|April 2010|May 18, 2011|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00399334||176997|
NCT00395265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1342|Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome|Association of Thrombophilia and Inflammation With Post-Thrombotic Syndrome||University of Vermont|No|Completed|June 2006|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2211|||Both|40 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will examine previously collected data from participants in the San Diego        Population Study.|January 2012|January 26, 2012|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00395265||177302|
NCT00395252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT-No. 2005-005168-94|Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer|Multicenter Phase II-trial to Investigate Safety and Efficacy of an Adjuvant Therapy With Gemcitabine and Erbitux® in Patients With R0 or R1 Resected Pancreatic Cancer|ATIP|Philipps University Marburg Medical Center|Yes|Completed|October 2006|January 2012|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00395252||177303|
NCT00395603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-122|Vytorin Treating Uncontrolled Lipids (VyTUL) Study (TERMINATED)|Compare Ezetimibe 10mg and Simvastatin 40mg vs Atorvastatin 80mg Daily in Subjects With Cardiovascular Heart Disease and/or Diabetes Mellitus With Uncontrolled Lipids on Statin Therapy||Merck Sharp & Dohme Corp.||Terminated|September 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|550|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|November 2, 2006|||This study was terminated early due to poor recruitment.|No||https://clinicaltrials.gov/show/NCT00395603||177277|
NCT00395915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004708-38|Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia|Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial.|CHAT|Universita di Verona|Yes|Active, not recruiting|September 2006|December 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|106|||Both|18 Years|N/A|No|||February 2009|February 17, 2009|November 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00395915||177253|
NCT00396513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1142/05|Simvastatin and Metformin Therapy in PCOS Women. Prospective Randomised Trial.|Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial||Poznan University of Medical Sciences||Recruiting|September 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|40 Years|No|||November 2006|November 3, 2006|November 3, 2006||||No||https://clinicaltrials.gov/show/NCT00396513||177207|
NCT00396526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999|ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia|Effectiveness of 3 Day Amoxycillin Versus 5 Day co-Trimoxazole in the Treatment of Non-Severe Pneumonia in Children Aged 2- 59 Months of Age: - A Multi-Centric Open Labeled Trial||King George's Medical University||Completed|April 2004|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Both|2 Months|59 Months|No|||December 2006|December 5, 2006|November 4, 2006||||No||https://clinicaltrials.gov/show/NCT00396526||177206|
NCT00396773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elactrobrainwaves-HMO-CTIL|Neonatal Brain Waves After Electrocoagulation|Neonatal Brain Waves After Electrocoagulation||Hadassah Medical Organization||Not yet recruiting|February 2007|January 2008|Anticipated|||Phase 0|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|60|||Both|N/A|30 Days|Accepts Healthy Volunteers|||November 2006|November 8, 2006|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396773||177187|
NCT00396786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11527|Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement|Controlled, Double-Blind, Randomized, Dose-ranging Study of Once-daily Regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXaHIP-OD|ODIXaHIP-OD|Bayer|Yes|Completed|November 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|877|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|November 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00396786||177186|
NCT00398099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-052|To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)|Clinical Evaluation for the Efficacy, Safety, Tolerability & Medical Resource Utilization of Invanz (Ertapenem Sodium) Therapy||Merck Sharp & Dohme Corp.||Completed|July 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|20 Years|N/A|No|||October 2015|October 29, 2015|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398099||177088|
NCT00397488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-081|Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium|Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium||Memorial Sloan Kettering Cancer Center||Completed|September 2006|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|120 Years|No|||December 2015|December 17, 2015|November 8, 2006|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00397488||177134|
NCT00397748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060246|PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)|PET Scanning of Brain Dopaminergic Signal Transduction Involving Arachidonic Acid in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||National Institutes of Health Clinical Center (CC)||Completed|September 2006|November 2012||||N/A|Observational|N/A|||Actual|16|||Male|18 Years|55 Years|No|||November 2012|February 19, 2014|November 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00397748||177115|
NCT00398073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-113|Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma|Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse gp100 DNA: A Pilot Study to Compare Intramuscular Jet Injection With Particle Mediated Delivery||Memorial Sloan Kettering Cancer Center||Completed|October 2006|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|1 Year|N/A|No|||March 2013|March 12, 2013|November 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00398073||177090|
NCT00398632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97143|Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction|Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction||Stanford University|No|Terminated|November 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||May 2015|May 30, 2015|November 10, 2006|No|Yes|Unable to recruit subjects|No|April 19, 2015|https://clinicaltrials.gov/show/NCT00398632||177049|Open label trial, only six subjects enrolled, only 4 completed the trial
NCT00398593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL 09788|Methods of Improvement Adherence With Therapy in Ulcerative Colitis.|Patient Adherence to Prescribed Therapy in Ulcerative Colitis: an Investigation of Barriers & Methods of Improvement.||University Hospitals, Leicester||Active, not recruiting|December 2007|April 2009|Anticipated|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|18 Years|80 Years|No|||February 2009|February 13, 2009|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00398593||177052|
NCT00398892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001543-36|The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes|The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes||University of Edinburgh||Recruiting|December 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||October 2010|November 5, 2010|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00398892||177030|
NCT00399399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95.067|CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors|CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients.||Hospices Civils de Lyon||Active, not recruiting|July 1996|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Both|15 Years|90 Years|No|||November 2006|November 13, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399399||176992|
NCT00398840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 171-101|A Study of ARQ 171 in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors||ArQule|No|Suspended|November 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||January 2009|January 8, 2009|November 9, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00398840||177034|
NCT00398853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK060126|Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes|Chromium and Insulin Action||Pennington Biomedical Research Center||Completed|October 2003|June 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|25 Years|N/A|No|||April 2009|January 25, 2010|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00398853||177033|
NCT00399347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4940706|Prevalence of Type 2 Diabetes Mellitus in Ethiopian Community in Israel: an Update|Prevalence of Diabetes Mellitus in Ethiopian Community in Israel: an Update||HaEmek Medical Center, Israel||Active, not recruiting|January 2005|December 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||500|||Both|33 Years|N/A|No|||November 2006|November 12, 2006|November 12, 2006||||No||https://clinicaltrials.gov/show/NCT00399347||176996|
NCT00399360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-49302-10AR|Lifestyle Modification and Metformin Use in the Treatment of HIV|Strategies for the Treatment of HIV Associated Metabolic Syndrome||Massachusetts General Hospital|Yes|Completed|December 2006|June 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|50|||Both|18 Years|65 Years|No|||September 2012|September 13, 2012|November 13, 2006|Yes|Yes||No|May 18, 2012|https://clinicaltrials.gov/show/NCT00399360||176995|The study was relatively small and may have been underpowered to assess effect on secondary endpoints and to assess the effects of lifestyle modification. The sample size may have limited our ability to determine differences in dropout rates.
NCT00395005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709146|Correlation of Urinary Kallikrein With Cytokines, Proteinuria and Renal Function in Chronic Renal Disease Patients|The Correlation of Urine Tissue Kallikrein Protein Level With Cytokines, Degree of Proteinuria and Renal Function Deterioration in Chronic Renal Disease Patients After Angiotensin II Receptor Blocking||National Taiwan University Hospital||Completed|October 2006|October 2006||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||50|||Both|20 Years|70 Years|No|||October 2006|March 22, 2007|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00395005||177322|
NCT00395928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/126/2001|Chronic and Acute Effects of Smoking on the Left and Right Ventricular Relaxation in Young Healthy Smokers|Chronic and Acute Effect of Smoking on the Left and Right Ventricular Systolic and Diastolic Function in Young Healthy Smokers||Medical University of Warsaw||Completed|November 2001|November 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||33|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2006|November 3, 2006|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395928||177252|
NCT00395629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2202|Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis|A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis.||Novartis|No|Completed|August 2006|March 2009|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|November 1, 2006|Yes|Yes||No|December 6, 2010|https://clinicaltrials.gov/show/NCT00395629||177275|
NCT00396539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29.12.06-19-HMO-CTIL|Hydrogen Sulfide Production by Oral Microflora|Detection of Hydrogen Sulfide Production by Oral Microflora Samples||Hadassah Medical Organization||Completed|January 2007|September 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|45 Years|No|||November 2006|February 1, 2009|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396539||177205|
NCT00396799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-114|Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women|An Open-Label, Single-Dose, Randomized-to-Sequence, 2-Period, Crossover, Pivotal Bioequivalence Study Between Bazedoxifene Acetate/Conjugated Estrogens (Premarin Current Process) and Bazedoxifene Acetate/Conjugated Estrogens (Premarin New Process) Tablets Administered to Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2006|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|35 Years|70 Years|Accepts Healthy Volunteers|||March 2007|March 12, 2007|November 7, 2006||||||https://clinicaltrials.gov/show/NCT00396799||177185|
NCT00396812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ARA04|Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)|An Open Label, Single Arm, Single Center, Phase I/II Trial of Rituximab (a Monoclonal Antibody to CD20) for the Treatment of Early Rheumatoid Arthritis||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|November 2006|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|November 6, 2006|No|Yes|The perceived risk-benefit ratio for individuals with early active RA|No|October 11, 2012|https://clinicaltrials.gov/show/NCT00396812||177184|The trial terminated early due to rituximab’s risk-benefit ratio for individuals with early active Rheumatoid Arthritis. Mechanistic samples were not processed and corresponding endpoints were not assessed. Only descriptive statistics are presented.
NCT00396825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44AG025593-04A;|Video-Based Coping Skills Training for Caregivers|Phase II Trial of a Video That Presents Training in Stress Coping Skills for Caregivers of a Relative With Alzheimer's Disease or Other Dementia||Williams LifeSkills|Yes|Completed|January 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|116|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2012|August 10, 2012|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00396825||177183|
NCT00397189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU 112006|Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients|A Double-blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of Circadin® 2 mg in the Treatment of Insomnia Patients With Low Endogenous Melatonin||Neurim Pharmaceuticals Ltd.||Completed|October 2006|April 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|930|||Both|18 Years|80 Years|No|||December 2010|April 21, 2015|November 7, 2006|Yes|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00397189||177156|
NCT00397202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-70478|FLOW-Finding Lasting Options for Women|FLOW-Finding Lasting Options for Women: A Prospective, Randomized, Multicenter Trial Comparing Tampons to a Menstrual Cup||University of British Columbia|No|Completed|November 2006|June 2011|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|110|||Female|19 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00397202||177155|
NCT00397501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-2188|BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain|A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients||OHSU Knight Cancer Institute|Yes|Withdrawn|October 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|75 Years|No|||October 2013|October 25, 2013|November 8, 2006|Yes|Yes|after original approval, IRB closed enrollment; major revisions required to re-open.|No||https://clinicaltrials.gov/show/NCT00397501||177133|
NCT00397761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000513169|Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer|Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer||National Cancer Institute (NCI)||Recruiting|July 2006|||||Phase 2/Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Female|18 Years|N/A|No|||November 2006|February 6, 2009|November 8, 2006||||No||https://clinicaltrials.gov/show/NCT00397761||177114|
NCT00398398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0603|Study of XELOX With Cetuximab in Advanced Gastric Cancer|A Prospective Phase II Study of Cetuximab (Erbitux®) in Combination With XELOX [XELoda® (Capecitabine) and OXaliplatin] in Patients With Advanced Gastric Cancer||Asan Medical Center|No|Completed|November 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|70 Years|No|||October 2015|October 6, 2015|November 9, 2006||No||No|December 15, 2013|https://clinicaltrials.gov/show/NCT00398398||177067|
NCT00398645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFA106783|A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.|See Detailed Description||GlaxoSmithKline||Completed|November 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||648|||Both|12 Years|N/A|No|||December 2009|December 10, 2009|November 9, 2006||||||https://clinicaltrials.gov/show/NCT00398645||177048|
NCT00398905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10944|Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement|Controlled, Double-Blind, Randomised, Dose-Ranging Study on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939|ODIXa-HIP2|Bayer||Completed|January 2004|September 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|726|||Both|18 Years|N/A|No|||May 2009|May 7, 2009|November 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00398905||177029|
NCT00399165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2962-A|Oral Androgens in Man-4: (Short Title: Oral T-4)|Oral Androgens in Man-4: Gonadotropin Suppression Medicated by Oral Testosterone Enanthate in Oil Plus Dutasteride (Short Title: Oral T-4)||University of Washington|No|Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399165||177010|
NCT00399412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-05291|ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients|Further Research on Human Feasibility of a Subcutaneous Implantable Defibrillator (S-ICD)- ECG Signal Collections From Various Patient Groups Whilst Attending Outpatient Follow-up||Boston Scientific Corporation|No|Completed|November 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|86|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with long QT syndrome, heart failure, cardiac resynchronization therapy or wide        QRS.|October 2009|October 8, 2009|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00399412||176991|
NCT00399100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-277/99|Is it Possible to Treat Cyanide Poisoning With HBO?|||Rigshospitalet, Denmark||Recruiting|November 2006|November 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A||||November 2006|November 13, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399100||177014|
NCT00399113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-6D2-A|Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma|An Open-Label Phase I Safety, Pharmacokinetic & Dosimetry Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma||Pain Therapeutics|No|Completed|May 2007|||June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399113||177013|
NCT00395278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907018|Development of Serologic Assays for Human Herpes Virus-8|Development of Serologic Assays for Human Herpes Virus-8||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2006|||||N/A|Observational|N/A|||Anticipated|429|||Both|N/A|N/A|No|||April 2015|November 6, 2015|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00395278||177301|
NCT00395642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061653|TRIAGE-CRT Telemonitoring in Patients With CHF and Indication of CRT-D|TRIAGE-CRT Telemonitoring in Patients With Congestive Heart Failure and Indication of ICD-Cardiac Resynchronization Therapy||Biotronik, Inc.|No|Completed|November 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||January 2010|January 15, 2010|November 1, 2006||No||No|December 14, 2009|https://clinicaltrials.gov/show/NCT00395642||177274|
NCT00395655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/012/ICI|Hydralazine and Valproate Added to Chemotherapy for Breast Cancer|A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma||National Institute of Cancerología||Terminated|June 2005|August 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||43|||Female|18 Years|N/A|No|||November 2006|November 1, 2006|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395655||177273|
NCT00395941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharma 6/699|Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis|||Postgraduate Institute of Medical Education and Research||Not yet recruiting|December 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|65 Years||||November 2006|November 3, 2006|November 3, 2006||||No||https://clinicaltrials.gov/show/NCT00395941||177251|
NCT00395954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL 10217|Amount of Lactose Causing Symptoms in Lactose Intolerant People|A Study to Determine the Threshold of Lactose Ingestion That Provokes Symptoms in Lactose Intolerant People.||University Hospitals, Leicester||Completed|November 2006|June 2007|Actual|June 2007|Actual|Phase 0|Observational|Time Perspective: Prospective|||Anticipated|48|||Both|18 Years|N/A|No|||February 2009|February 13, 2009|November 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00395954||177250|
NCT00396188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atlas II-2006-1-v1|Screening Aid to Identify Corneas That May Have Pathologies or Other Conditions|Corneal Analysis - Pathology Detection Aid||Carl Zeiss Meditec, Inc.|Yes|Completed|February 2007|February 2008|Actual|February 2008|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Actual|769|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will consist of patients seeking consult in the Principal Investigator's (PI)        clinical practice and volunteers responding to the study's advertisements.|August 2015|August 13, 2015|November 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00396188||177232|
NCT00396201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-2106|AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease|Treatment With AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells in Patients With Hodgkin's Disease||Sanofi|No|Completed|November 2004|January 2008|Actual|October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|November 2, 2006|Yes|Yes||No|February 10, 2009|https://clinicaltrials.gov/show/NCT00396201||177231|
NCT00396214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S154.3.021|Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients|A Randomized, Multicenter, Double-Blind, Parallel Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients||Solvay Pharmaceuticals|No|Terminated|April 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|83|||Both|18 Years|65 Years|No|||May 2008|May 30, 2008|November 3, 2006|Yes|Yes|This trial discontinued on 2 May 2008 due to lack of enrolment|No||https://clinicaltrials.gov/show/NCT00396214||177230|
NCT00396552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100/2006|Treating Refractory Obsessive Compulsive Disorder With rTMS|Treating Refractory Obsessive Compulsive Disorder With Repetitive Transcranial Magnetic Stimulation: A Double-blind Sham Controlled Longitudinal Study||Centre for Addiction and Mental Health|No|Completed|June 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|No|||February 2013|February 14, 2013|November 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00396552||177204|
NCT00396838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1909CTIL|Cardiac Autonomic Reactivity and Behavioral Response to Pain in Full-Term Neonates|Cardiac Autonomic Reactivity and Behavioral Response to Pain in Full-Term Neonates||Rambam Health Care Campus||Completed|November 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||March 2008|October 11, 2008|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00396838||177182|
NCT00388869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HILLER-HMO-CTIL|Renal Artery Calcium and Hypertension|Calcifications of the Renal Arteries and Renal Artery Stenosis in Patients With and Without Hypertension?||Hadassah Medical Organization||Not yet recruiting|November 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|300|||Both|30 Years|N/A|No|||October 2006|October 16, 2006|October 15, 2006||||No||https://clinicaltrials.gov/show/NCT00388869||177782|
NCT00397800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515982|Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma|Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells||Technische Universität München||Active, not recruiting|June 2005|May 2013|Anticipated|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|50 Years|75 Years|No|||August 2012|August 27, 2012|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00397800||177111|
NCT00398385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-NCCCTS-05-122|Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|May 2005|||April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|170|||Both|18 Years|N/A|No|||April 2008|August 9, 2013|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398385||177068|
NCT00389636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-0601|TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers|TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers||Soluble Systems, LLC|No|Active, not recruiting|September 2006|July 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2008|May 5, 2008|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00389636||177725|
NCT00389649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20887|Effect of Chronic Changes in Heart Rate on Congestive Heart Failure|Effect of Chronic Changes in Heart Rate on Congestive Heart Failure||University of Maryland||Completed|November 2001|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||April 2008|April 16, 2008|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389649||177724|
NCT00398918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25360|Alcohol Self Administration Laboratory|Alcohol Self Administration Laboratory||Boston University|No|Completed|November 2006|March 2009|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|10|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 27, 2010|November 13, 2006||No||No|February 8, 2010|https://clinicaltrials.gov/show/NCT00398918||177028|
NCT00399178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003233-32|A Randomised Open Controlled Parallel Group Study Comparing Norspan and Tramadol|A Randomised Open Controlled Parallel Group Multicenter Study to Evaluate the Efficacy and Safety of Norspan Versus Tiparol Retard in Subjects With Chronic Moderate to Severe OA Pain of the Hip and/or Knee.||Mundipharma AB||Completed|November 2006|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|N/A||||November 2006|August 16, 2007|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00399178||177009|
NCT00399191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43 DK64495 (completed)|A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|August 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|15|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|November 13, 2006||||||https://clinicaltrials.gov/show/NCT00399191||177008|
NCT00399425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APM/00/PD1|Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients|Triple-Blind Clinical Trial With Placebo Control to Evaluate the Efficacy of a Heparin of Low Molecular Weight (Bemiparin) for Treating Slow-Responding Ulcers in Diabetic Foot in Primary Care||Spanish National Health System||Terminated|June 2001|April 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|18 Years|N/A|No|||November 2006|November 13, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399425||176990|
NCT00395018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-109|Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection|Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection||Bristol-Myers Squibb|No|Completed|April 2007|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|109|||Both|16 Years|N/A|No|||April 2012|April 30, 2012|November 1, 2006|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT00395018||177321|
NCT00399386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-05039|Electrocardiogram (ECG) Recordings in Paediatric Population|ECG Recordings From EP Study, Defibrillator Implantation or Ablation Procedure in Paediatric Population||Boston Scientific Corporation||Completed|November 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric patients at the Bristol Royal Hospital for Children|October 2009|October 8, 2009|November 10, 2006||||No||https://clinicaltrials.gov/show/NCT00399386||176993|
NCT00395031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03I/C24|Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder|The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder||Manhattan Psychiatric Center|Yes|Completed|September 2003|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|65 Years|No|||July 2011|July 28, 2011|November 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395031||177320|
NCT00395291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12569|Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients|Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients||University of Virginia|Yes|Completed|August 2006|May 2010|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|November 1, 2006|Yes|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00395291||177300|We completed the appropriate number of subjects to get the statistical data needed. We had several screen fails (subjects that did not meet the inclusion/exclusion criteria.)
NCT00395681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13980|Population PK/PD of Propofol in the Morbidly Obese Patient|Population Pharmacokinetics and Pharmacodynamics of Propofol in the Morbidly Obese Patient||St. Antonius Hospital||Completed|September 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2006|October 21, 2010|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395681||177271|
NCT00395967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-2109|AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone|Effect of AMD3100 (240µg/kg) on the Apheresis Yield of CD34+ Cells When Given To Multiple Myeloma or Non-Hodgkin's Lymphoma Patients Predicted to be Unable to Mobilize ≥2 x 10^6 CD34+ Cells in Three Apheresis Days When Given G-CSF Alone||Sanofi|No|Terminated|April 2005|August 2006|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|75 Years|No|||April 2015|April 10, 2015|November 2, 2006|No|Yes|Enrollment terminated in 2005 to focus on Phase 3 study enrollment.|No|January 27, 2009|https://clinicaltrials.gov/show/NCT00395967||177249|Limited enrollment due to early termination of the study.
NCT00395980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5106|Muscle Pressure in the Flank Position|Muscle Pressure in the Flank Position||University of California, Irvine||Completed|October 2006|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 11, 2008|November 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00395980||177248|
NCT00396253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N3701g|A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters|A Phase III, Open-Label Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters|TROPICS 4|Genentech, Inc.||Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|223|||Both|N/A|N/A|No|||September 2011|September 21, 2011|November 2, 2006|Yes|Yes||No|March 25, 2010|https://clinicaltrials.gov/show/NCT00396253||177227|
NCT00396227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23119|Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as Add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone|A Multi-Center, Randomized, Open-Label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment With Vildagliptin 100 mg, qd to Thiazolidinedione (TZD) as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in a Community-Based Practice Setting.||Novartis||Completed|October 2006|||October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2665|||Both|18 Years|80 Years||||October 2008|October 10, 2008|November 2, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00396227||177229|
NCT00396240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00008|ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals|ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals||AstraZeneca||Withdrawn|February 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1294|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|November 3, 2006|||study cancelled prior to FSI|No||https://clinicaltrials.gov/show/NCT00396240||177228|
NCT00396851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharma 6/700|Double Blind Randomized Trial to Compare Gurmar (Gymnema Sylvestre) With Metformin in Type 2 Diabetes|||Postgraduate Institute of Medical Education and Research||Not yet recruiting|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|25 Years|70 Years|No|||November 2006|November 6, 2006|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396851||177181|
NCT00396864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI-0052-100|Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma|Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma||Triphase Research and Development I Corporation|No|Completed|May 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|November 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00396864||177180|
NCT00397462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSERC-005|Blood Flow and Bone Density in Healthy Adult Women|||Binghamton University||Completed|October 2006|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||April 2008|April 28, 2008|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00397462||177136|
NCT00397475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142/06|Evaluation of Colecalciferol Substitution in Dialysis Patients|Evaluation of Colecalciferol Substitution in Dialysis Patients||University Hospital, Saarland||Completed|November 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 7, 2006||||No||https://clinicaltrials.gov/show/NCT00397475||177135|
NCT00397774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.2179|Physical Activity and Functioning in Palliative Cancer Patients - a Clinical Randomised Trial|Phase 3 Physical Activity and Functioning in Palliative Cancer Patients - a Clinical Randomised Trial||Norwegian University of Science and Technology|No|Completed|October 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|231|||Both|N/A|N/A|No|||March 2015|March 28, 2015|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00397774||177113|
NCT00388336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004594|PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy|A Pilot Study to Evaluate the Response Rate of PROCRIT� (Epoetin Alfa) at 60,000 Units Every Two Weeks in Anemic Cancer Patients Not Receiving Chemotherapy Or Radiation Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2004|March 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|57|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|October 13, 2006||||||https://clinicaltrials.gov/show/NCT00388336||177823|
NCT00388349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT135|Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease|Gemcitabine and High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease||Stanford University||Completed|September 2001|September 2010|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|146|||Both|18 Years|70 Years|No|||August 2013|August 27, 2013|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00388349||177822|
NCT00388596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9108985|A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.|An Open-Label, Partially Randomized, Interaction Study to Evaluate the Effects of SB-751689 on the Pharmacokinetics of Rosuvastatin and Atorvastatin or the Effects of Ketoconazole on the Pharmacokinetics of SB-751689 in Healthy Postmenopausal Female Subjects||GlaxoSmithKline||Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Female|N/A|65 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|October 13, 2006||||||https://clinicaltrials.gov/show/NCT00388596||177803|
NCT00388362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT175|Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease|A Phase II Trial of Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease||Stanford University||Completed|November 2005|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|13 Years|N/A|No|||March 2013|March 29, 2013|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00388362||177821|
NCT00389103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-249-005|Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)|A Phase 1, Placebo-Controlled, Double-Blind Study of the Safety and Immunogenicity of Two Injections of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia Naive Adult Subjects With a History of Atopic Dermatitis (AD)||Sanofi|Yes|Withdrawn|October 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|October 16, 2006|Yes|Yes|Senior management decision|No||https://clinicaltrials.gov/show/NCT00389103||177764|
NCT00398112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01830|Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of Sunitinib Malate for Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||National Cancer Institute (NCI)||Completed|August 2007|January 2011|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2012|April 28, 2014|November 9, 2006|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT00398112||177087|
NCT00398125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRZ107460|Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults|A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults.||GlaxoSmithKline|No|Completed|November 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|65 Years|No|||July 2012|July 26, 2012|November 8, 2006||||||https://clinicaltrials.gov/show/NCT00398125||177086|
NCT00389324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060001|A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency|An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics and Safety of Subcutaneous Gamunex® 10% (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) in Subjects With Primary Immunodeficiency||Grifols Therapeutics Inc.|No|Completed|November 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|13 Years|75 Years|No|||March 2015|March 31, 2015|October 17, 2006|Yes|Yes||No|July 30, 2009|https://clinicaltrials.gov/show/NCT00389324||177747|
NCT00389337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01-108/04|Sepsis: Prognosis and Evaluation of Early Diagnosis and Intervention (SPEEDI Study)|Sepsis: Prognosis and Evaluation of Early Diagnosis and Intervention (SPEEDI Study)||Hvidovre University Hospital||Active, not recruiting|January 2005|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||300|||Both|18 Years|N/A|No|||October 2006|October 17, 2006|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389337||177746|
NCT00398658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8019|Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis|||hahid Beheshti University of Medical Sciences||Completed|March 2002|December 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|3 Years|N/A|No|||November 2006|October 17, 2008|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00398658||177047|
NCT00389948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRSW-GN-301|Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Lansoprazole 15 mg Once a Day in Frequent Heartburn||Novartis||Completed|June 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||576|||Both|18 Years|N/A|No|||April 2007|April 13, 2007|October 18, 2006||||||https://clinicaltrials.gov/show/NCT00389948||177701|
NCT00398931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-051|FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)|A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial||Merck Sharp & Dohme Corp.||Completed|February 1998|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1099|||Female|60 Years|86 Years|No|||February 2015|February 16, 2015|November 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00398931||177027|
NCT00399204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharma6/701|Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients|A Randomised Pilot Study to Compare the Effect of Pioglitazone and Metformin on Cardiovascular Morbidity and Mortality in Patients With Type 2 Diabetes||Postgraduate Institute of Medical Education and Research||Recruiting|January 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||100|||Both|25 Years|60 Years|No|||November 2006|November 13, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399204||177007|
NCT00386035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 065B|Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants|HIV Transmission Risk Behavior Substudy||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2002|September 2008|Actual|January 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|883|||Both|13 Years|N/A|No|Non-Probability Sample|HIV infected participants with a CD4+ cell count greater than 350 cells/mm3 currently        receiving or not receiving ART.|April 2014|April 15, 2014|October 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00386035||177995|
NCT00395044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA020766-01|Gabapentin Treatment of Cannabis Dependence|Gabapentin for Cannabis Withdrawal and Use||National Institute on Drug Abuse (NIDA)|No|Completed|August 2006|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|65 Years|No|||February 2009|February 6, 2009|November 1, 2006||||||https://clinicaltrials.gov/show/NCT00395044||177319|
NCT00395057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211745-001|A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration|||Allergan||Terminated|January 2007|February 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|138|||Both|50 Years|N/A|No|||August 2015|August 25, 2015|October 31, 2006|Yes|Yes|The study was terminated early due to company decision (non-safety related).|No|November 9, 2011|https://clinicaltrials.gov/show/NCT00395057||177318|The study was terminated early due to a company decision (non-safety related). Because the study was terminated early, data for certain outcome measures (ie, "Visual Functioning Questionnaire [VFQ] at Month 3") were not analyzed.
NCT00395304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444|Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)|Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)|BADGER|Milton S. Hershey Medical Center|Yes|Completed|March 2007|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|182|||Both|6 Years|18 Years|No|||February 2013|February 24, 2013|October 31, 2006|Yes|Yes||No|May 17, 2010|https://clinicaltrials.gov/show/NCT00395304||177299|The study was not designed or powered to evaluate the long-term safety of long-acting beta-agonists in children. The duration of the trial and its sample size preclude statements regarding long-term risks.
NCT00395317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4M105038|Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)|Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects With Relapsing-Remitting Multiple Sclerosis||GlaxoSmithKline|No|Completed|December 2006|August 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|343|||Both|18 Years|65 Years|No|||April 2012|April 5, 2012|November 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395317||177298|
NCT00395668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2103-05-0005|TETRA (Terrestrial Trunked Radio)|Assessment of Acute Changes in Cognitive Performance Arising From Exposure to TETRA Handset.||University of Aarhus||Completed|November 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|56|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||September 2007|September 6, 2007|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00395668||177272|
NCT00395694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM107844|Clinical Evaluation of BW430C in Epilepsy|Clinical Evaluation of BW430C in Epilepsy<Phase III Study>||GlaxoSmithKline||Completed|August 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|2 Years|65 Years|No|||September 2012|April 11, 2013|November 2, 2006|Yes|Yes||No|August 16, 2012|https://clinicaltrials.gov/show/NCT00395694||177270|
NCT00395993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT04002/003|Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding|Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding||Luitpold Pharmaceuticals||Completed|May 2005|June 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|456|||Female|18 Years|N/A|No|||September 2013|September 16, 2013|November 2, 2006|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00395993||177247|
NCT00396006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460502|Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)|The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)||Baxalta US Inc.||Completed|October 2006|||December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|21|||Both|18 Years|N/A|No|||March 2011|June 26, 2015|November 3, 2006|No|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00396006||177246|Isoelectric focusing (IEF) analyses that were intended to compare the profile of plasma α1-PI & ELF α1-PI were not carried out due to fact that ELF samples were either missing, insufficient or too dilute for such assays.
NCT00396266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-C201|AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF|Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF||Sanofi|Yes|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||February 2014|February 4, 2014|November 2, 2006|No|Yes||No|October 30, 2010|https://clinicaltrials.gov/show/NCT00396266||177226|
NCT00396565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012625|A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia|A Placebo-Controlled Double Blind Comparative Study of JNS007ER in Patients With Schizophrenia||Janssen Pharmaceutical K.K.||Completed|July 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|394|||Both|20 Years|N/A|No|||April 2014|April 10, 2014|November 3, 2006||No||No|March 27, 2012|https://clinicaltrials.gov/show/NCT00396565||177203|
NCT00396877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5314|Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation|International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt|CLARINET|Sanofi|Yes|Completed|November 2006|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|906|||Both|N/A|92 Days|No|||October 2014|October 14, 2014|November 7, 2006|Yes|Yes||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00396877||177179|
NCT00396890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070022|Enhancing Brain Activity With Magnetic Stimulation|Enhancing Interhemispheric Disinhibition Between Motor Cortices Using Bilateral Brain Stimulation||National Institutes of Health Clinical Center (CC)||Completed|November 2006|December 2008||||N/A|Observational|N/A||||72|||Both|18 Years|55 Years|No|||December 2008|December 16, 2008|November 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00396890||177178|
NCT00387751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00134|Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma|A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma||National Cancer Institute (NCI)||Completed|August 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2013|June 3, 2015|October 12, 2006|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00387751||177866|
NCT00387764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG107769|Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer|An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192||GlaxoSmithKline||Completed|September 2006|October 2012|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||October 2013|December 12, 2013|October 12, 2006|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00387764||177865|
NCT00388063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-106|Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma|A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma||Callisto Pharmaceuticals|No|Completed|October 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||December 2007|December 17, 2007|October 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388063||177843|
NCT00388635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-VEL-2004-01|Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.|A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.||PETHEMA Foundation||Completed|April 2004|December 2008|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|65 Years|N/A|No|||January 2011|January 8, 2011|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00388635||177800|
NCT00388609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB109-007|Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects|A Randomized, Double-blind, Placebo-Controlled, Parallel Arm, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BMS-646256 in Obese and High Risk Overweight Subjects||Bristol-Myers Squibb|No|Terminated|November 2006|April 2009|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|705|||Both|18 Years|70 Years|No|||May 2009|September 15, 2010|October 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388609||177802|
NCT00388622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG019105|Improving Drug Use for Elderly Heart Failure Patients|Improving Drug Use for Elderly Heart Failure Patients||University of North Carolina, Chapel Hill||Completed|February 2001|November 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||314|||Both|50 Years|N/A|No|||October 2006|October 16, 2006|October 8, 2006||||No||https://clinicaltrials.gov/show/NCT00388622||177801|
NCT00389311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC 200-2001-08015-02|A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides|A Pilot Protocol to Determine the Effects of Chemical and Mechanical Stress on Rectal Permeability as a Surrogate for Toxicity Evaluation of Rectally Applied Microbicides||Johns Hopkins University||Completed|April 2007|June 2009|Actual|February 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|12|||Male|21 Years|N/A|Accepts Healthy Volunteers|||January 2009|March 30, 2015|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00389311||177748|
NCT00389350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hitchcock Tea 1|Effect of an Extract of Green Tea on Adults With Type 2 Diabetes|The Effect of an Extract of Green Tea on Glucose Control in Adults With Type 2 Diabetes||Dartmouth-Hitchcock Medical Center||Completed|August 2005|June 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||October 2006|October 17, 2006|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00389350||177745|
NCT00389363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-02|Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects|A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients||ALK-Abelló A/S||Completed|August 2006|April 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|800|||Both|14 Years|N/A|No|||August 2010|August 16, 2010|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389363||177744|
NCT00389974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00648|Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery|A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma||National Cancer Institute (NCI)||Completed|January 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||March 2014|February 4, 2015|October 18, 2006|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT00389974||177700|
NCT00390195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2453|Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)|Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma - With a Pharmacokinetic Study of RAD001||National Health Research Institutes, Taiwan||Recruiting|October 2006|June 2011|Anticipated|June 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|20 Years|75 Years|No|||June 2009|June 29, 2009|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00390195||177683|
NCT00389987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-037|Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)|A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults||Merck Sharp & Dohme Corp.||Completed|September 2001|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389987||177699|
NCT00390208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDEX|Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration|A Prospective Masked Pilot Study Comparing Group 1 Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Group 2 Monotherapy - Intravitreal Ranibizumab Alone.|PDEX|Bay Area Retina Associates|Yes|Completed|August 2006|December 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|N/A|No|||May 2010|May 25, 2010|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390208||177682|
NCT00395070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX01-315|A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma|A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment With 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects With Recurrent Metastatic Melanoma||Vical|Yes|Completed|October 2006|July 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|390|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|October 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395070||177317|
NCT00395083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|560|Bronchitis and Emphysema Advice and Training to Reduce Hospitalization|CSP #560 - Bronchitis and Emphysema Advice and Training to Reduce Hospitalization (BREATH)|BREATH|VA Office of Research and Development|Yes|Terminated|July 2006|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|426|||Both|40 Years|N/A|No|||September 2014|September 4, 2014|November 1, 2006||No|The DMC detected an imbalance in safety outcomes between the two groups.|No|August 4, 2014|https://clinicaltrials.gov/show/NCT00395083||177316|
NCT00395330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-714|Airways Dysfunction Following WTC Dust Exposure|Airways Dysfunction Following WTC Dust Exposure||New York University School of Medicine||Completed|April 2003|October 2006|Actual|October 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1||500|||Both|18 Years|80 Years|No|Non-Probability Sample|study will retrospectively review the charts of all patients referred to the pulmonary        function laboratory for evaluation of symptoms following exposure to WTC dust.|August 2015|August 19, 2015|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00395330||177297|
NCT00395343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-051|Sitagliptin Added-on to Insulin Study (0431-051)|A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)||Merck Sharp & Dohme Corp.||Completed|December 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|641|||Both|21 Years|N/A|No|||April 2015|April 24, 2015|November 1, 2006|Yes|Yes||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00395343||177296|
NCT00395707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3423s|Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration|Phase I Study Of Intravitreal Ranibizumab (Lucentis) For The Treatment Of Stage 1 And 2 Retinal Angiomatous Proliferations||The National Retina Institute||Completed|August 2005|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 6, 2009|November 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00395707||177269|
NCT00396019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 06-116|Study of PEG-Intron for Plexiform Neurofibromas|A Phase II Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas||University of Pittsburgh|Yes|Active, not recruiting|November 2006|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Months|21 Years|No|||February 2016|February 24, 2016|November 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00396019||177245|
NCT00396032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N3700g|A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters|TROPICS 3|Genentech, Inc.||Completed|October 2006|||December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|16 Years|N/A|No|||May 2010|May 1, 2010|November 2, 2006|Yes|Yes||No|March 24, 2010|https://clinicaltrials.gov/show/NCT00396032||177244|
NCT00396279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040215|Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone|An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone||Amgen||Completed|July 2006|February 2011|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|November 2, 2006|Yes|Yes||No|January 23, 2014|https://clinicaltrials.gov/show/NCT00396279||177225|
NCT00396292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT03001|Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia|Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in Subjects Who Display Postpartum Anemia||Luitpold Pharmaceuticals|No|Completed|February 2005|February 2006|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|361|||Female|N/A|N/A|No|||October 2013|October 15, 2013|November 2, 2006|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00396292||177224|
NCT00387140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2295-005|A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005)|A Randomized Double-blind, Placebo-and Active Comparator-Controlled 2-Part Study to Evaluate the Efficacy of MK2295 in Patients With Postoperative Dental Pain||Merck Sharp & Dohme Corp.||Completed|October 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|89|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|October 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00387140||177913|
NCT00396578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORIHS # 2004-3799|Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation|Aerosolized Antibiotics in Mechanically Ventilated Patients||Stony Brook University||Completed|August 2003|September 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||November 2006|November 6, 2006|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00396578||177202|
NCT00387153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-2130-04-002|Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer|Phase 1 OL, Dose Escalating, Multiple Dose Study To Determine The Safety, Tolerability, MTD, And Pharmacokinetics Of MPC-2130 Administered As Daily IV Infusions For 5 Days, Repeated Every 21 Days, In Patients With Refractory Cancer||Myriad Therapeutics, Inc.|No|Terminated|August 2005|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2009|October 27, 2009|October 10, 2006|No|Yes|Last subject enrolled experienced bradycardia; study was terminated by Sponsor.|No|June 23, 2009|https://clinicaltrials.gov/show/NCT00387153||177912|
NCT00388037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00647|Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)|No|Completed|January 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||April 2014|January 15, 2015|October 12, 2006|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00388037||177845|
NCT00388050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003513|Diabetes Medication Choice|Wiser Choices for Patients With Type II Diabetes: Diabetes Medication Choice||Mayo Clinic||Completed|July 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00388050||177844|
NCT00388089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505990|Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors|Phase I Study of Weekly Bortezomib (VELCADE, PS-341) and Weekly Topotecan (HYCAMTIN) in Solid Tumor Patients With an Emphasis on Small Cell Lung Cancer (SCLC)||University of California, Davis|Yes|Completed|December 2004|June 2008|Actual|November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2007|June 25, 2010|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388089||177841|
NCT00388375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25185|Can Ultrasound be Used to Verify CVC Position and to Exclude Pneumothorax?|Can Ultrasound be Used as an Alternative to Chest Radiography After Central Venous Catheter Insertion to Confirm Proper Catheter Position and to Exclude Pneumothorax?||Christiana Care Health Services||Terminated|October 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|N/A|No|||November 2012|October 17, 2014|October 12, 2006||No|Not feasible, did not have the study population.|No||https://clinicaltrials.gov/show/NCT00388375||177820|
NCT00398970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12562|Utility of Endobronchial Ultrasound in the Investigation of Suspected Lung Cancer.|Diagnostic Utility of Endobronchial Ultrasound in the Investigation of Suspected Malignant Lung Lesions Where the Lesions Are Not Visible During Bronchoscopy.||Haukeland University Hospital||Completed|June 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|240|||Both|N/A|N/A|No|||February 2008|February 25, 2008|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00398970||177024|
NCT00388895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BES02|Glivec in Ph Positive Lymphoblastic Leukemia|Positive Ph Acute Lymphoblastic Leucemia With Intensive Induction Chemotherapy and Glivec, Before and After the Hematopoetic Progenitor Transplant||PETHEMA Foundation||Completed|June 2002|October 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|N/A|65 Years|No|||November 2008|November 17, 2008|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00388895||177780|
NCT00388882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.346|Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.|A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 Mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI||Boehringer Ingelheim||Completed|October 2006|||October 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Actual|327|||Both|40 Years|N/A|No|||October 2013|October 31, 2013|October 16, 2006||||||https://clinicaltrials.gov/show/NCT00388882||177781|
NCT00389116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/069/HP|Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction|Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction||University Hospital, Rouen|Yes|Completed|November 2006|August 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00389116||177763|
NCT00395148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175/04|Improving Metabolism With HDL Cholesterol|A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol||Bayside Health|No|Completed|March 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|13|||Male|18 Years|65 Years|No|||October 2006|May 9, 2011|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00395148||177311|
NCT00395434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC4P1-105|Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors|OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors||OXiGENE||Completed|September 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|November 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00395434||177289|
NCT00389662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/345|The Effect of Wearing the 'Nike Free'Shoe on Isokinetic Muscle Strength of Foot and Ankle and on Proprioception.|The Effect of Wearing the 'Nike Free'Shoe on Isokinetic Muscle Strength of Foot and Ankle and on Proprioception.||University Ghent|No|Completed|November 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389662||177723|
NCT00389675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol DAR-312-E|DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension|A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)|Darusentan|Gilead Sciences|Yes|Terminated|May 2007|May 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|661|||Both|35 Years|80 Years|No|||January 2014|January 3, 2014|October 17, 2006|Yes|Yes|Study DAR-312 did not meet its primary co-endpoints.|No||https://clinicaltrials.gov/show/NCT00389675||177722|
NCT00390000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0515|Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors|Phase I Study of PTK/ZK in Combination With Pemetrexed Disodium (ALIMTA)||Mayo Clinic|Yes|Active, not recruiting|January 2007|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390000||177698|
NCT00385788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0015|Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease|Allogeneic Stem Cell Transplantation Followed By Adoptive Immunotherapy for Patients With Relapsed and Refractory Hodgkin's Disease||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2005|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|65 Years|No|||June 2015|June 29, 2015|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00385788||178013|
NCT00385801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-EMR-4021|Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence|A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence||Massachusetts General Hospital||Completed|September 2005|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|October 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00385801||178012|
NCT00385827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012346|A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)|A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)||Centocor, Inc.|Yes|Terminated|November 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|106|||Male|18 Years|N/A|No|||August 2014|August 18, 2014|October 6, 2006|Yes|Yes|Prematurely stopped after Independent Data Monitoring Committee (IDMC) evaluation for lack of    efficacy.|No|May 13, 2014|https://clinicaltrials.gov/show/NCT00385827||178011|Results of few secondary endpoints were not reported as the study was terminated early due to the premature suspension and subsequent halting of study enrollment.
NCT00395096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1354|Environmental Exposures, Genetics, and Exhaled Nitric Oxide in Pediatric Asthma|Environmental Exposures, NOS Genes, and Exhaled Nitric Oxide in Pediatric Asthma||National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|July 2006|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|225|Samples With DNA|Blood and urine|Both|6 Years|12 Years|No|Non-Probability Sample|Cincinnati area children with asthma|February 2009|February 17, 2009|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00395096||177315|
NCT00395356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRSQ-5574|Efficacy and Feasibility of an Intermittent Weight Loss Program.|Efficacy and Feasibility of an Intermittent Weight Loss Program: A Pilot Study.||Université de Sherbrooke||Completed|September 2005|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|51 Years|75 Years|Accepts Healthy Volunteers|||November 2006|November 1, 2006|November 1, 2006||||No||https://clinicaltrials.gov/show/NCT00395356||177295|
NCT00395720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB010|The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV||University of Oxford|Yes|Completed|November 2006|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|November 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00395720||177268|
NCT00395733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91537|Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients|A Single-blind, Intra-individual, Crossover, Multicenter Study of the Efficacy, Safety and Tolerability of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent in the Enhanced Magnetic Resonance Angiography (MRA) in Chinese Patients||Bayer|No|Completed|October 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|83|||Both|18 Years|65 Years|No|||November 2013|November 25, 2013|November 2, 2006|No|Yes||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00395733||177267|
NCT00387166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1339|Socioeconomic Status, Psychosocial Factors, and CVD Risk in Mexican-American Women|Cardiovascular Risk Disparities: Socio-Emotional Pathways||San Diego State University|Yes|Completed|October 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|304|Samples Without DNA|Blood and urine specimens were collected to identify stress hormones and inflammatory      markers. Whole blood, plasma, and serum are stored for possible future assays based on new      discoveries.|Female|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include healthy Mexican-American women from the South San Diego        community.|January 2012|January 4, 2012|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00387166||177911|
NCT00387738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV1-SAR-09|Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults|A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Dose-Regimen Study of the Efficacy and Safety of TOLAMBA™ in Ragweed-Allergic Rhinitis Adults||Dynavax Technologies Corporation|Yes|Terminated|April 2006|March 2008|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|738|||Both|18 Years|55 Years|No|||February 2016|February 26, 2016|October 11, 2006|Yes|Yes|Interim data indicated that subjects exhibited no meaningful allergic disease during the first    ragweed season, making it impossible to measure treatment effect.|No||https://clinicaltrials.gov/show/NCT00387738||177867|
NCT00398450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000511743|Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma|A Phase I Study of 5-Azacytidine (Vidaza) With Interferon α2b in Metastatic Melanoma Patients||National Cancer Institute (NCI)||Active, not recruiting|February 2006|||May 2007|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||January 2007|February 6, 2009|November 9, 2006||||No||https://clinicaltrials.gov/show/NCT00398450||177063|
NCT00369863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8126|A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema|||hahid Beheshti University of Medical Sciences||Completed|June 2002|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||76|||Both|44 Years|79 Years|No|||February 2007|February 27, 2007|August 29, 2006||||No||https://clinicaltrials.gov/show/NCT00369863||179217|
NCT00369837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-06-02|Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)|Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)|VELOCITY|The Medicines Company|No|Completed|September 2006|February 2007|Actual|January 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|August 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00369837||179219|
NCT00369850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000482381|Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98|Investigating Bone Density and Bone Loss Without Baseline Information||International Breast Cancer Study Group|Yes|Completed|May 2004|January 2012|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|458|||Female|30 Years|N/A|No|||July 2012|July 26, 2012|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00369850||179218|
NCT00370409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8525|Cryotherapy of Sclerotomy Sites for Prevention of Late Postvitrectomy Diabetic Hemorrhage|||hahid Beheshti University of Medical Sciences||Completed|January 2006|June 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|112|||Both|N/A|N/A|No|||July 2008|July 31, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370409||179176|
NCT00370435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104916|Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)|An Open-label, Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of 90mg of GW274150 in Adult and Elderly RA Subjects.||GlaxoSmithKline||Completed|August 2005|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Both|50 Years|N/A|No|||January 2012|January 19, 2012|August 17, 2006||||No||https://clinicaltrials.gov/show/NCT00370435||179174|
NCT00370448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMB-57|Evaluation of Interventions to Prevent Suicide of Medical Students Through the School-Based Social Support System|Evaluation of Interventions to Prevent Suicide of Medical Students Through the School-Based Social Support System||Anhui Medical University||Recruiting|September 2007|October 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|12000|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2008|November 13, 2008|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370448||179173|
NCT00370812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8528|The Role of Amniotic Membrane Transplantation in Ocular Chemical Burns|||hahid Beheshti University of Medical Sciences||Recruiting|July 2006|January 2009|Anticipated|December 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|N/A|No|||September 2008|September 23, 2008|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00370812||179145|
NCT00371449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4352-R|Predicting Success With Hearing Aids|Speech-in-Noise Measures as a Predictor of Hearing Aid Outcomes||VA Office of Research and Development|No|Completed|November 2006|June 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|adults with sensorineural hearing loss|April 2015|April 8, 2015|September 1, 2006||No||No|February 18, 2015|https://clinicaltrials.gov/show/NCT00371449||179097|
NCT00371696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMD LREC 108/01|Feasibility of n-of-1 Trials - a Pilot Study|Pilot Study of the Feasibility of n-of-1 Trials: the Individualisation of Treatments for Osteoarthritis||University of Bristol||Completed|December 2001|December 2003||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research||||10|||Both|N/A|N/A|No|||January 2003|September 1, 2006|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371696||179079|
NCT00371709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2013|TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions|TAXUS ATLAS: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions||Boston Scientific Corporation|Yes|Completed|August 2004|March 2010|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|871|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|August 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371709||179078|
NCT00371995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEI PDE 06 03|Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar|The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India||Banaras Hindu University||Completed|October 2007|February 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|2 Years|65 Years|No|||September 2008|June 21, 2011|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00371995||179057|
NCT00372008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTE05|Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males|A Phase II Randomised, Two-Way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered-Dose (MD) Lotion Doses in Hypogonadal Male Subjects||Acrux DDS Pty Ltd||Completed|October 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|40|||Male|18 Years|70 Years|No|||June 2008|June 18, 2008|September 5, 2006||||||https://clinicaltrials.gov/show/NCT00372008||179056|
NCT00367549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-SØR: S-05308|Nutrition as a Determinant of Labor Outcome|Nutrition as Determinant of Labor Outcome||Oslo University Hospital||Completed|September 2006|December 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|200|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2010|July 3, 2011|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367549||179393|
NCT00367562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEREKOWA33|Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy|Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy||Hospital Britanico||Completed|January 1996|December 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|21 Years|70 Years|No|||January 1996|October 31, 2006|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367562||179392|
NCT00373581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5096|Effects of Vigabatrin on Cocaine Self-Administration|Effects of Vigabatrin on Cocaine Self-Administration||New York State Psychiatric Institute||Terminated|April 2006|||December 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|September 7, 2006|||Funding ran out|||https://clinicaltrials.gov/show/NCT00373581||178938|
NCT00373594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911238|Therapy for Chronic Cold Agglutinin Disease|Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine.||University of Bergen||Completed|June 2005|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|90 Years|No|||June 2010|June 18, 2010|September 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00373594||178937|
NCT00370071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91386|Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis|Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis||Bayer|No|Completed|November 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|16 Years|55 Years|No|||September 2015|September 29, 2015|August 29, 2006|No|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00370071||179201|
NCT00370994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 11|Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Neurolysis on Low Back Pain|A Randomized, Prospective, Double-blind Controlled Evaluation of the Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Hypertonic Saline Neurolysis||Pain Management Center of Paducah|Yes|Completed|January 2006|April 2013|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|August 30, 2006||No||No|March 21, 2012|https://clinicaltrials.gov/show/NCT00370994||179131|The results of this study are limited by potentially inadequate double blinding, by the lack of a placebo group.
NCT00403013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-AnIt-06|Plexus Anesthesia in Lateral, Head-Down Position for Elective Surgery of the Shoulder|Axillary Plexus Block for Perioperative Analgesia in Patients Scheduled for Elective Surgery of the Shoulder: Influence of Lateral, Head-Down Position||University Hospital Muenster||Completed|April 2007|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||July 2009|July 3, 2009|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403013||176718|
NCT00368459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0096|Raloxifene for Women With Alzheimer's Disease|Raloxifene in Women With AD: Randomized Controlled Trial||Stanford University|Yes|Completed|August 2006|January 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|60 Years|N/A|No|||March 2015|March 20, 2015|August 22, 2006||No||No|March 1, 2015|https://clinicaltrials.gov/show/NCT00368459||179323|
NCT00368719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614402-1|Evaluation to Assess the Long Term Safety of Tacrolimus Ointment for Atopic Dermatitis|APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long Term Safety Of Tacrolimus Ointment For The Treatment Of Atopic Dermatitis||University of California, Davis|No|Withdrawn|September 2007|July 2016||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|16 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|August 24, 2006||No|withdrawn due to contractual issues|No||https://clinicaltrials.gov/show/NCT00368719||179303|
NCT00371371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUVENTAS|Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)|Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial|JUVENTAS|UMC Utrecht|Yes|Completed|September 2006|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|September 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00371371||179103|
NCT00370110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITODG04-02|Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Single Center, Parallel Group Study to Evaluate the Effects of Itopride(100 mg and 200 mg t.i.d.) on Gastric Motor and Sensory Functions in Healthy Volunteers||Axcan Pharma|No|Completed|August 2005|November 2005|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 18, 2008|August 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00370110||179198|
NCT00370461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP67110|Basic Life Support Termination of Resuscitation Implementation Study|Basic Life Support Termination of Resuscitation in the Prehospital Environment for Primary Care Paramedics - A Prospective Observational Study of the Implementation of a Clinical Prediction Rule||Sunnybrook Health Sciences Centre|No|Completed|January 2006|June 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|350|||Both|18 Years|N/A|No|Probability Sample|This is a multi centre prospective observational study of the implementatiaon of a Basic        Life Support Termination of Resuscitation(BLS TOR)guideline.The study will accrue all out        of hospital cardiac arrest cases from 9 regions across the province of Ontario(Cornwall,        Hamilton,Peel, Peterborough, Grey Bruce Huron, Timmins, Sault Ste Marie, Simcoe/Muskoka,        Cambridge). There are 22 participating EMS systems over the 9 regions.|November 2015|November 16, 2015|August 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00370461||179172|
NCT00370123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4251-RM-CTIL|The Immune Base of Endometriosis|In This Study we Aim to Explore the Immune Nature of Endometriosis as Manifested in the Peripheral Blood, Endometriosis Lesions, Normal Peritoneum and Normal Endometrium of Patients Suffering From Documented Endometriosis.||Sheba Medical Center||Withdrawn|September 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|women of childbrearing age suffering from endometriosis and undergoing laparoscopy|June 2011|June 26, 2011|August 29, 2006||No|The study was withrawn do to logistic difficulties|No||https://clinicaltrials.gov/show/NCT00370123||179197|
NCT00371124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R359/17/2004|Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children|A Randomised, Double-Masked Study to Compare The Safety and Efficacy of Bilateral 0.5%, 0.1% & 0.01% Atropine Treatment In Controlling Progression of Myopia In Children||Singapore National Eye Centre||Active, not recruiting|March 2006|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|400|||Both|6 Years|12 Years|No|||May 2010|August 30, 2010|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00371124||179121|
NCT00371137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-008|A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia||Jazz Pharmaceuticals|No|Completed|August 2006|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|548|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|August 30, 2006|Yes|Yes||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00371137||179120|
NCT00371150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-085|Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection|A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive||Bristol-Myers Squibb|No|Completed|November 2006|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|16 Years|N/A|No|||March 2012|March 22, 2012|August 29, 2006|Yes|Yes||No|March 22, 2012|https://clinicaltrials.gov/show/NCT00371150||179119|
NCT00371462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4429-I|PDA+: A Personal Digital Assistant for Obesity Treatment|PDA+: A Personal Digital Assistant for Obesity Treatment|PDA+|VA Office of Research and Development||Terminated|October 2007|September 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|August 31, 2006||No|PI no longer has an appointment and has seperated from Hines VAH and project was not    transferred to another PI?|No||https://clinicaltrials.gov/show/NCT00371462||179096|
NCT00371735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA 714703/006|Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria|A Multi-Centre, Randomised, Double-Blind Study to Compare the Efficacy and Safety of Chlorproguanil-Dapsone-Artesunate Versus Chlorproguanil-Dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults in Africa.||GlaxoSmithKline||Completed|April 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||900|||Both|12 Months|N/A|No|||May 2009|May 15, 2009|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371735||179076|
NCT00372047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1845-08/06|Evaluation of Excessive UV Irradiation on Skin Aging by Multiphoton Laser Imaging and Biophysical Methods|||University of Jena||Not yet recruiting||||||Phase 1/Phase 2|Observational|Time Perspective: Retrospective|||||||Female|20 Years|25 Years|Accepts Healthy Volunteers|||June 2008|June 2, 2008|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372047||179053|
NCT00371722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-052|Appendectomy Versus no Appendectomy With Cesarean Section|A Randomized Controlled Trial Evaluating Appendectomy at the Time of Cesarean Section||Regional Obstetrical Consultants|No|Completed|July 2002|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371722||179077|
NCT00372021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8136|Neurotomy of Optic Nerve in Non-Arthritic Anterior Ischemic Optic Neuropathy|||hahid Beheshti University of Medical Sciences||Completed|January 2003|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||November 2002|October 11, 2006|September 5, 2006||||No||https://clinicaltrials.gov/show/NCT00372021||179055|
NCT00372034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRRP2005-018|The Effect of Punctal Plugs on Tear Volume and Osmolality|||The University of New South Wales||Completed|July 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2009|April 6, 2009|September 3, 2006||||No||https://clinicaltrials.gov/show/NCT00372034||179054|
NCT00367575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053/2005|An Internet-based Intervention for Problem Drinking|An Internet-based Intervention for Problem Drinking||Centre for Addiction and Mental Health||Completed|September 2006|September 2009||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|359|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367575||179391|
NCT00367848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM001- HMO-CTIL|Efficacy of Ultrasound in Evaluating Occult Fractures|The Efficacy of Ultrasound in Evaluating Fractures in the Ankle and Foot in Children When the X-Ray Does Not Demonstrate Fractures.||Hadassah Medical Organization||Completed|November 2006|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|N/A|15 Years|No|||May 2008|May 19, 2008|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367848||179370|
NCT00377689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 04-022|Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke|Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke - a Randomized Controlled Study||Umeå University||Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Actual|34|||Both|55 Years|N/A|No|||October 2008|October 27, 2008|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00377689||178626|
NCT00377702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1350|Lifetime Risk for Cardiovascular Disease Among Non-White Ethnic Groups|Epidemiologic Study of Ethnicity and Lifetime Risks for Cardiovascular Disease||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2006|July 2006|Actual|||N/A|Observational|Time Perspective: Retrospective||||500000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|February 17, 2016|September 14, 2006||||No||https://clinicaltrials.gov/show/NCT00377702||178625|
NCT00377715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM02|Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease|Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease||Medivation, Inc.||Completed|September 2005|||August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|50 Years|N/A|No|||November 2015|November 9, 2015|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00377715||178624|
NCT00371943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVL|EVL Plus Drug to Prevent Variceal Rebleeding|A Controlled Trial of Ligation Plus Drug Vs. Drug Alone in the Prevention of Variceal Rebleeding||National Science Council, Taiwan||Terminated|July 2001|March 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|20 Years|75 Years|No|||September 2006|September 14, 2006|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371943||179061|
NCT00371956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HARECCTR0500058|Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy|Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study||Tuen Mun Hospital|Yes|Completed|September 2006|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Female|18 Years|N/A|No|||September 2010|September 15, 2010|September 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00371956||179060|
NCT00402415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510000723|Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy|A Phase I Trial of the Combination of Sirolimus and SU11248 (Sutent(R)) in Patients With Advanced Solid Tumors That Are Non-Curable With Standard Therapy||Yale University|No|Terminated|February 2006|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|November 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00402415||176764|
NCT00402428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1008-C1060|Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients|Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 1. ACHIEVE-1||Human Genome Sciences Inc.||Completed|December 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1331|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|November 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402428||176763|
NCT00370357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-002|SPL7013 Gel - Male Tolerance Study|A Phase 1, Placebo Controlled Study of the Safety of 3% w/w SPL7013 Gel, Administered to the Penis of Healthy Male Volunteers Once Daily for Seven Days||Starpharma Pty Ltd||Completed|August 2006|June 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||36|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 10, 2008|August 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00370357||179180|
NCT00370370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8533|Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD|||hahid Beheshti University of Medical Sciences||Active, not recruiting|November 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||||||Both|50 Years|N/A|No|||June 2008|June 25, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370370||179179|
NCT00368732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1352|Genetic and Nutritional Causes of Heart Birth Defects|Gene and Nutrient Etiologies of Human Heart Defects||National Heart, Lung, and Blood Institute (NHLBI)||Completed|July 2006|December 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1610|Samples With DNA|Buccal cell collection|Both|N/A|12 Months|Accepts Healthy Volunteers|Probability Sample|Mothers of babies with heart defects and mothers of babies without any malformation.|December 2007|December 17, 2007|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00368732||179302|
NCT00369044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200608A|Prednisone for Decompensated Congestive Heart Failure|Chronic Administration of Prednisone in Management of Patients With Decompensated Congestive Heart Failure||Hebei Medical University||Suspended|October 2006|July 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|90 Years|No|||June 2007|April 7, 2009|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369044||179278|
NCT00369005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IowaBell001|Liberal Versus Restrictive Transfusion Guidelines for Preterm Infants|Randomized Trial of Liberal Versus Restrictive Guidelines for Red Blood Cell Transfusion in Preterm Infants||University of Iowa||Completed|December 1992|June 1999||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|2 Weeks|No|||August 2006|August 28, 2006|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369005||179281|
NCT00369629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05H8|Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome|Phase I/II Trial of Gemcitabine/Pemetrexed Combination in Patients With Advanced Cutaneous T-Cell Lymphoma||Northwestern University|Yes|Terminated|June 2006|September 2016|Anticipated|May 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|August 24, 2006|No|Yes|This was planned as a phase I/II study originally, but due to a lack of funding, the phase II    portion was never conducted.|No||https://clinicaltrials.gov/show/NCT00369629||179235|
NCT00369642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF212-2004|A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder||University of South Florida||Completed|October 2004|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||April 2008|August 5, 2010|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00369642||179234|
NCT00369876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3392-OB-CTIL|Anorexia in Children With Burn Injury and the Reactions of the Immune and Endocrine Systems|The Association Between Anorexia and the Level of Hormones, Cytokines and Neuroendocrine Peptides in Children After Burn Injury||Sheba Medical Center||Active, not recruiting|August 2004|July 2006||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||10|||Both|6 Months|16 Years|Accepts Healthy Volunteers|||January 2007|January 23, 2007|August 29, 2006||||No||https://clinicaltrials.gov/show/NCT00369876||179216|
NCT00370136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF)01288200|Sentinel Node With Ultrasound Contrast in Melanoma|Sentinel Node Diagnostics With Ultrasound Contrast in Melanoma||Rigshospitalet, Denmark||Completed|August 2006|April 2008||March 2008||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|20|||Both|18 Years|N/A|No|||June 2008|June 17, 2008|August 29, 2006||||No||https://clinicaltrials.gov/show/NCT00370136||179196|
NCT00371475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2039|A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions|TAXUS ATLAS LONG LESION: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With Long de Novo Coronary Artery Lesions||Boston Scientific Corporation|Yes|Completed|March 2005|May 2011|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|September 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371475||179095|
NCT00371488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF105635|GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer|Phase I/II Clinical Study of GW572016 (Lapatinib Ditosylate Monohydrate) in Combination With Trastuzumab in Patients With Breast Cancer Previously Treated With Trastuzumab||GlaxoSmithKline|No|Completed|April 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|20 Years|74 Years|No|||November 2012|April 11, 2013|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00371488||179094|
NCT00371748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2033|A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels|TAXUS ATLAS SMALL VESSEL: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions in Small Vessels||Boston Scientific Corporation|Yes|Completed|February 2005|April 2011|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|261|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|September 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371748||179075|
NCT00372073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC202-06-14 (A1)|Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer|A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer||Cyclacel Pharmaceuticals, Inc.|Yes|Terminated|July 2006|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|September 3, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372073||179051|
NCT00372060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-055|MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)|MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone add-on Study for Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|August 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|September 5, 2006|Yes|Yes||No|January 27, 2009|https://clinicaltrials.gov/show/NCT00372060||179052|Period II (Weeks 12-52) was open-label and uncontrolled, with all patients receiving sitagliptin. Results are pooled data from both treatment groups and should be considered in the context of the Type 2 Diabetes Mellitus (T2DM) population studied.
NCT00367588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TN3 / CvZ nr.01111|Low Bacterial Diet in Patients With Cytopenia|Low Bacterial Diet in Patients With Cytopenia After Intensive Chemotherapy for Hematological Malignancy: a Study of Efficacy||Maastricht University Medical Center||Completed||June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||20|||Both|18 Years|N/A|No|||June 2004|October 19, 2006|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367588||179390|
NCT00367874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF_ARA_001|Treatment of Polydrug-Using Opiate Dependents During Withdrawal|Treatment of Polydrug-Using Opiate Dependents During Withdrawal||Sorlandet Hospital HF||Completed|February 2003|November 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|20 Years|50 Years|No|||August 2006|August 22, 2006|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367874||179368|
NCT00367887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-200|A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects|A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|246|||Both|18 Years|65 Years|No|||February 2013|February 7, 2013|August 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367887||179367|
NCT00367809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC Protocol 942|Wellness Interventions After Transplant Study|Impact of Mind-Body Interventions Post Organ Transplant|WIAT|National Institute of Nursing Research (NINR)|No|Completed|August 2003|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 12, 2008|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367809||179373|
NCT00372203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0085-A|Endobronchial Ultrasound vs Mediastinoscopy in NSCLC|Prospective Controlled Trial of Mediastinoscopy Compared With Endobronchial Ultrasound Guided Transbronchial Needle Aspiration for Assessment of the Mediastinum in Lung Cancer.||University Health Network, Toronto|No|Completed|July 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|September 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00372203||179041|
NCT00402701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-3850-E/A|Pedestrian Behavior Following Implementation of a Walking School Bus|Pedestrian Behavior Following Implementation of a Walking School Bus||University of Washington|No|Completed|November 2004|April 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|735|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2007|October 30, 2007|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402701||176742|
NCT00369057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510008190|Intra Ocular Pressure During Robotic Prostatectomy|Intra Ocular Pressure During Robotic Prostatectomy||Weill Medical College of Cornell University|No|Completed|February 2006|February 2008|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Male|18 Years|N/A|No|Non-Probability Sample|Adult males aged 18 or older, undergoing robotic prostatectomy at NewYork Presbyterian        Hospital with no pre-existing eye conditions.|March 2012|March 7, 2012|August 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00369057||179277|
NCT00369070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060136|A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC|A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer||Amgen|Yes|Terminated|July 2007|August 2011|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|186|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369070||179276|
NCT00369343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-403|Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women|A Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2006|July 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|381|||Female|40 Years|70 Years|No|||April 2012|April 9, 2012|August 25, 2006|Yes|Yes||No|November 26, 2008|https://clinicaltrials.gov/show/NCT00369343||179255|
NCT00369018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC CE101/06|A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.|Methyl Aminolevulinate (MAL) and Hexaminolevulinate (HAL) Photodynamic Therapy (PDT)of Cervical Intraepithelial Lesions (SIL) - a Double-blind Dose-finding Study||Photocure|No|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|96|||Female|18 Years|N/A|No|||November 2010|November 26, 2010|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369018||179280|
NCT00369031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005983-10|Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63|A Phase I, Open Label, Parallel Group Trial To Evaluate Safety And Immunogenicity Of Three Nasal Immunisations Using A Fixed Dose-Level Of HIV gp140 V2 Loop Deleted Protein Adjuvanted With LTK63 Followed By Intramuscular Boosting With HIV gp140 V2 Loop Deleted Protein Adjuvanted With MF59 When Administered To Healthy Adults||St George's, University of London|No|Terminated|September 2006|March 2008|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|August 24, 2006||No|Safety issues|No||https://clinicaltrials.gov/show/NCT00369031||179279|
NCT00369889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0148 / 0606-20|A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer|A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma||Indiana University|No|Completed|August 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|August 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369889||179215|
NCT00370149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512-37|Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children|A Randomized, Controlled Trial of Catheter Related Infectious Event Rates Using Antibiotic-impregnated Catheters vs. Conventional Catheters in Pediatric Cardiovascular Surgery Patients||Indiana University|Yes|Terminated|September 2006|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|326|||Both|N/A|17 Years|No|||January 2016|January 27, 2016|August 28, 2006|Yes|Yes|Blinded interim analysis resulted in early termination of the study.|No|October 19, 2015|https://clinicaltrials.gov/show/NCT00370149||179195|A blinded interim analysis by an independent Data Safety Monitoring Board resulted in early termination of the study: of 288 evaluable patients, the rates of CRBSI and line-related complications were similar between the 2 groups.
NCT00370162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO_L_01839|Acceptability Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata New Fragrance||Sanofi||Completed|June 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2008|May 15, 2008|August 29, 2006||||No||https://clinicaltrials.gov/show/NCT00370162||179194|
NCT00370838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSkepclon|Comparison of Keppra and Clonidine in the Treatment of Tics|Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome||Johns Hopkins University|Yes|Completed|February 2007|June 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|7 Years|19 Years|No|||September 2011|September 1, 2011|August 30, 2006||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00370838||179143|
NCT00371501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HARECCTR0500059|Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus|Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial||Tuen Mun Hospital|Yes|Completed|June 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|72|||Both|18 Years|N/A|No|||September 2010|September 15, 2010|September 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00371501||179093|
NCT00371761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04498|PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)|An Open-Label, Randomized, Comparative Study With PegIntron vs. Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan||Merck Sharp & Dohme Corp.|No|Completed|September 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|70 Years|No|||October 2015|October 7, 2015|August 31, 2006|No|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00371761||179074|
NCT00371774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-08|Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program|Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program||Astellas Pharma Inc|No|Completed|June 2005|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|426|||Both|16 Years|N/A|No|Non-Probability Sample|Dermatologic patients in Canada|November 2011|November 15, 2011|August 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00371774||179073|
NCT00367601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LUN04-77|Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer|A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer||Hoosier Cancer Research Network|Yes|Completed|August 2006|December 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|August 21, 2006||No||No|January 13, 2016|https://clinicaltrials.gov/show/NCT00367601||179389|
NCT00367900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906093|Parkinson's Genes and Environment Study|The Parkinson's, Genes and Environment (PAGE) Study||National Institutes of Health Clinical Center (CC)||Completed|February 2006|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|9000|||Both|50 Years|80 Years|No|||May 2015|November 3, 2015|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367900||179366|
NCT00368238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506000139|Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects|Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects||Yale University||Completed|October 2005|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||96|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||August 2006|August 23, 2006|August 23, 2006||||No||https://clinicaltrials.gov/show/NCT00368238||179340|
NCT00368251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01236|Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease||UCB Pharma|No|Completed|November 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|56|||Both|16 Years|N/A|No|||April 2015|April 9, 2015|August 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368251||179339|
NCT00367822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tulir 03/01|Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)|Transdermal Lisuride: a Double-blind, Randomized, Active- and Placebo-controlled Multi-centre Phase III Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)||Axxonis Pharma AG||Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|80 Years|No|||January 2010|March 6, 2012|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367822||179372|
NCT00367835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-307|SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms|A Double-Blind, Randomized, Multi-Center, Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 (Guanfacine Hydrochloride) in Children Aged 6-12 With Symptoms of Oppositionality and a Diagnosis of Attention Deficit/Hyperactivity Disorder||Shire||Completed|September 2006|January 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Both|6 Years|12 Years|No|||October 2010|October 7, 2010|August 22, 2006|Yes|Yes||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00367835||179371|
NCT00367796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905072|Genetic Analysis of Craniosynostosis, Philadelphia Type|Genetic Analysis of Craniosynostosis, Philadelphia Type (OMIM 601222)||National Institutes of Health Clinical Center (CC)||Completed|January 2005|December 2008||||N/A|Observational|N/A||||25|||Both|N/A|N/A|No|||December 2008|September 26, 2015|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367796||179374|
NCT00368108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-302|Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations||Eisai Inc.||Completed|August 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|752|||Both|30 Years|N/A|No|||January 2013|May 13, 2013|August 22, 2006|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00368108||179350|
NCT00368121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMMA-1|EMMA-1 (Erbitux for Multiple Myeloma)|Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma)|EMMA-1|University of Cologne|No|Terminated|August 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|August 23, 2006||No|Lack of recruitable patients|No||https://clinicaltrials.gov/show/NCT00368121||179349|
NCT00368134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1301|To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Compare the Effects of 12 Weeks Treatment With Vildagliptin 50 mg Bid to Voglibose 0.2 mg Tid in Patients With Type 2 Diabetes||Novartis||Completed|August 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||370|||Both|20 Years|N/A||||June 2007|June 27, 2007|August 23, 2006||||No||https://clinicaltrials.gov/show/NCT00368134||179348|
NCT00368069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01235|A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR|A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra® Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.||UCB Pharma|No|Completed|August 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|12 Years|70 Years|No|||August 2015|August 13, 2015|August 11, 2006|No|Yes||No|April 1, 2009|https://clinicaltrials.gov/show/NCT00368069||179353|
NCT00368082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17946-TGFBeta|Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)|Administration of TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma|TGF-beta|Baylor College of Medicine|Yes|Active, not recruiting|April 2006|July 2031|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||December 2015|December 30, 2015|August 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00368082||179352|
NCT00368095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH_CER_004|Rajavithi Health Promotion Project (Population Base Cohort)|The Rajavithi Prospective Cohort Study on Community's Member Health (HPH-Cohort Study)||Rajavithi Hospital||Recruiting|August 2006|August 2016|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Human Genetic Bank will be storaged in Biomolecular center Rajavithi Hospital for determine      the gene that influence the specific disease in the population|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General population in Dindang destrict Bangkok|August 2008|August 2, 2008|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368095||179351|
NCT00369096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRIAT-BEM-2005-01|Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)|Randomized, Controlled and Open Study to Assess the Efficacy (Peritoneal Biocompatibility) of the Addition of Bemiparin to Icodextrin Solution in Patients in Peritoneal Dialysis With Peritoneal Transport Disorders||Fundación Renal Iñigo Alvarez De Toledo|Yes|Completed|September 2006|May 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||May 2010|May 13, 2010|August 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00369096||179274|
NCT00369382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E7-408|Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients|A Randomized Open-Label Study To Compare The Safety And Efficacy Of Conversion From A Calcineurin Inhibitor To Sirolimus Vs Continued Use Of A Calcineurin Inhibitor In Heart Transplant Recipients With Mild-Moderate Impaired Renal Function||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|September 2006|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|N/A|No|||May 2011|May 25, 2011|August 25, 2006||No||No|April 26, 2011|https://clinicaltrials.gov/show/NCT00369382||179253|
NCT00369356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEREA-DES|Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis|Clinical and Angiographic Outcome of Patients Treated With Bare Metal Stent (BMS) Implantation Compared With Drug Eluting Stents or BMS Plus Systemic Prednisone Therapy. A Randomized, Multicentre Study.||Universita di Verona|Yes|Completed|October 2006|January 2011|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|375|||Both|18 Years|80 Years|No|||January 2013|January 20, 2013|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00369356||179254|
NCT00369330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET-B03|KONVERT-AF - Relevance of Point in Time for Conversion of Acute Atrial Fibrillation|Prospective, Randomized Parallel-group Study for Evaluation of Impact of Early Versus Delayed Cardioversion of Acute Atrial Fibrillation on Further Clinical Course||German Atrial Fibrillation Network||Withdrawn|September 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||August 2006|August 31, 2012|August 28, 2006|||withdrawn because of insufficient financial capacities|No||https://clinicaltrials.gov/show/NCT00369330||179256|
NCT00370500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449L00029|Quetiapine and the Dopaminergic Epigenetic Control|Quetiapine and the Dopaminergic Epigenetic Control - a Pilot Study||University of Erlangen-Nürnberg Medical School|No|Completed|April 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2008|July 9, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370500||179169|
NCT00370513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG107200|A Phase I Study of Pazopanib in Adult Patients With Liver Cancer|A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034)in Adult Patients With Hepatocellular Cancer||GlaxoSmithKline||Completed|December 2006|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|21 Years|N/A|No|||February 2011|March 15, 2012|August 29, 2006||||No||https://clinicaltrials.gov/show/NCT00370513||179168|
NCT00370825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAMRC0601|Combination Chemotherapy for the Treatment of Indian Kala-Azar|Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study||Banaras Hindu University||Completed|September 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|12 Years|65 Years||||September 2008|September 11, 2008|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00370825||179144|
NCT00370539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8542|Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD|||hahid Beheshti University of Medical Sciences||Recruiting|September 2006|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A|No|||November 2006|November 13, 2006|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370539||179166|
NCT00371202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8390|Comparison of Penetrating Keratoplasty and Deep Lamellar Keratoplasty With the Big Bubble Technique for Keratoconus|||hahid Beheshti University of Medical Sciences||Active, not recruiting|July 2006|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|15 Years|50 Years|No|||January 2007|January 12, 2007|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371202||179115|
NCT00371215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499E02|Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting|A Phase 2 Study of Recombinant Human Thrombin (rThrombin) Administered Using a Spray Applicator in Subjects Undergoing Autologous Skin Grafting Following Burn or Traumatic Skin Injury||ZymoGenetics|Yes|Completed|August 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|2 Years|75 Years|No|||March 2009|March 6, 2009|August 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371215||179114|
NCT00371163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614530|Molecular and Cellular Characterization of Spongiotic Dermatitis|Molecular and Cellular Characterization of Spongiotic Dermatitis|Spongiotic|University of California, Davis|No|Completed|September 2006|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Males or females aged 18-55 with either contact dermatitis, psoriasis, atopic dermatitis,        or no skin disease.|April 2015|April 20, 2015|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00371163||179118|
NCT00371176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORD-NIMH-20061|A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD|A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD||VA Office of Research and Development|Yes|Completed|October 2006|July 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|August 31, 2006|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00371176||179117|The study experienced sustained recruitment difficulties, ultimately recruiting a smaller number of participants (N=26) than originally projected (N=68).
NCT00371189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0050|Adenovirus Vaccine for Malaria|A Phase I Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2007|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|75|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|September 18, 2014|August 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00371189||179116|
NCT00371787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/240/06/CV|Evaluation of the Performance of Non-molded Soft Contact Lenses|Evaluation of the Performance of Non-molded Soft Contact Lenses||University of Waterloo|No|Completed|August 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|17 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 5, 2011|September 1, 2006|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT00371787||179072|
NCT00371800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17648|The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes|The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes||Dartmouth-Hitchcock Medical Center||Completed|October 2005|May 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|13 Years|18 Years|No|||August 2006|August 31, 2006|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371800||179071|
NCT00372099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-262/Psy 05-038|Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women|Evaluation of the Effects of Salmon Calcitonin Nasal Spray Compared to Placebo on Bone Microarchitecture Measured by High Resolution Peripheral Micro- Computed-tomography Over 2 Years in Postmenopausal Women (a Pilot Study)||University Hospital, Geneva||Completed|January 2007|November 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|90|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||December 2011|December 22, 2011|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372099||179049|
NCT00372086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/315|Rosiglitazone and Insulin in T1DM Adolescents|The Addition of Rosiglitazone to Insulin in Adolescents With Type 1 Diabetes and Poor Glycaemic Control: a Randomized, Placebo Controlled Trial||The University of New South Wales||Completed|August 2003|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Both|10 Years|18 Years||||September 2006|September 3, 2006|September 3, 2006||||No||https://clinicaltrials.gov/show/NCT00372086||179050|
NCT00367614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001A3-337|Study Evaluating Pantoprazole in Adolescents With GERD|A Multicenter, Randomized, Open-Label, Single And Multiple Dose Study Of The Pharmacokinetics And Safety of Two Dose Levels of Pantoprazole Sodium Tablets In Adolescents Aged 12 Through 16 Years With A Clinical Daignosis Of GERD.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2007|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|12 Years|16 Years|No|||December 2007|December 7, 2007|August 21, 2006||||||https://clinicaltrials.gov/show/NCT00367614||179388|
NCT00367627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-026|Relative Efficacy of Two Regimens of Ante-helminthic Treatment|||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|December 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|2 Years|5 Years|No|||August 2006|July 11, 2011|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367627||179387|
NCT00367640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO34.04|Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis|Randomised,Double-blind,Placebo-controlled,Multinational,Multi-centre,Phase IIb/III Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy (SLIT) Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis||Stallergenes||Completed|November 2004|August 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||600|||Both|18 Years|45 Years||||October 2009|October 8, 2009|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367640||179386|
NCT00367861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST1571BFR14|Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance|A Prospective Multicentric Randomized Study of Glivec® in Patients With Advanced Gastrointestinal Stromal Tumors Expressing C-kit Comparing Treatment Interruption After 5 Years vs Treatment Maintenance||Centre Leon Berard|Yes|Completed|May 2002|May 2013|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|564|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|August 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00367861||179369|
NCT00368199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Vlaar|Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes|Diagnostic Value Transcranial Duplex Scanning and Single Photon Emission Tomography in Patients Suspected of Having Idiopathic Parkinson Disease or Atypical Parkinson Syndromes||Maastricht University Medical Center|Yes|Active, not recruiting|September 2006|September 2010|Anticipated|||Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|None Retained|no biocpsicmens|Both|18 Years|N/A|No|Probability Sample|250 Patients with unclear parkinsonism at the outpatient clinic|January 2009|January 12, 2009|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00368199||179343|
NCT00368147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002027-01H|Access Creation for Hemodialysis: Association With Structural Changes of the Heart|Access Creation for Hemodialysis: Potential Contribution to Left Ventricular Remodelling||Ottawa Hospital Research Institute|No|Completed|April 2002|February 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|N/A|No|||February 2009|February 19, 2009|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368147||179347|
NCT00368160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-059|Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers|The Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Healthy Volunteers Compared to Placebo||Sunovion|No|Completed|March 2004|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|August 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368160||179346|
NCT00368485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD045047|Neural Control of Non-invasive Ventilation in the Preterm|Neural Control of Non-invasive Ventilation in the Preterm||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|August 2006|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|6 Months|No|||September 2011|September 19, 2011|August 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368485||179321|
NCT00368472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-207|4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures|An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures||Eisai Inc.|No|Completed|October 2006|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|18 Years|70 Years|No|||November 2015|November 5, 2015|August 22, 2006|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT00368472||179322|
NCT00369395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206-MM-201|A Study of Volociximab in Metastatic Melanoma|A Phase 2, Open-Label, Two-Stage Study of Volociximab (M200) for the Treatment of Subjects With Metastatic Melanoma||Abbott|No|Terminated|December 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|August 24, 2006|Yes|Yes|Insufficient clinical activity|No||https://clinicaltrials.gov/show/NCT00369395||179252|
NCT00369408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-107-2|Targeted Naltrexone for Problem Drinkers|Targeted Naltrexone for Problem Drinkers||University of Connecticut Health Center|Yes|Completed|June 2003|March 2008|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|70 Years|No|||June 2011|June 17, 2011|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369408||179251|
NCT00369902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3817-OG-CTIL|The Effect of Acupuncture Treatment on the Perception of Pain and Coping With Pain|Pilot Study on the Effect of Acupuncture Treatment on Pain Perception and on the Ability to Cope With Pain||Sheba Medical Center|No|Completed|May 2006|May 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|41 consequtive patients with chronic musculosckeletal pain|July 2009|July 19, 2009|August 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00369902||179214|
NCT00369915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060234|The Antidepressant Efficacy of the Anticholinergic Scopolamine|The Antidepressant Efficacy of the Anticholinergic Scopolamine||National Institutes of Health Clinical Center (CC)||Terminated|August 2006|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|55 Years|No|||January 2013|August 20, 2013|August 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369915||179213|
NCT00369655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01827|VEGF Trap in Treating Patients With Metastatic Breast Cancer|Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane||National Cancer Institute (NCI)||Completed|January 2007|January 2011|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2013|April 2, 2014|August 24, 2006|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00369655||179233|
NCT00370851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8532|Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial|Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial||hahid Beheshti University of Medical Sciences||Completed|August 2006|June 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|40 Years|N/A|No|||November 2009|November 23, 2009|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00370851||179142|
NCT00370864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-PAN-05-17|Study of a Pandemic Influenza Vaccine in Children|Phase II Study of a Pandemic Influenza Vaccine in Children||CSL Limited||Completed|September 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|220|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||November 2008|November 6, 2008|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370864||179141|
NCT00371228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005010|Timing of Cord Clamping and Neonatal Hemoglobin|Delayed Versus Immediate Cord Clamping and Changes in Neonatal Hemoglobin||Oklahoma State University Center for Health Sciences|No|Withdrawn|September 2006|||June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||May 2008|May 16, 2008|August 30, 2006||No|PI left university|No||https://clinicaltrials.gov/show/NCT00371228||179113|
NCT00371527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN 01TMcIl 01 B|Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease|Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease||Kaiser Permanente||Completed|October 2002|January 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2006|October 16, 2008|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371527||179092|
NCT00371826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2421|SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus|A Prospective, Open-label, Controlled Multicenter Trial to Assess the Efficacy and Safety of an Induction Regimen of Cyclosporine Micro Emulsion, Enteric-coated Mycophenolate Sodium (EC-MPS) and Corticosteroids, Followed by Administration of Everolimus and Enteric-coated Mycophenolate Sodium (EC-MPS), With Either the Withdrawal of Cyclosporine Micro Emulsion or Corticosteroids in de Novo Kidney Transplant Recipients||Novartis|Yes|Completed|March 2006|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|65 Years|No|||June 2013|June 13, 2013|September 1, 2006||No||No|June 13, 2013|https://clinicaltrials.gov/show/NCT00371826||179069|
NCT00372112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C108562|A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 2-wk Study to Evaluate the Safety, Tolerability,Pharmacodynamics and Pharmacokinetics of GW642444H(100 Administered Once Daily in the Morning Via DISKUS™ Dry-powder Inhaler)Compared With SEREVENT(Salmeterol)(50mcg Administered Twice Daily Via DISKUS Dry-powder Inhaler)and Placebo in Subject w/COPD||GlaxoSmithKline|No|Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|71|||Both|40 Years|80 Years|No|||October 2012|October 17, 2012|September 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372112||179048|
NCT00372125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH1234|Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome|Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome||Karolinska University Hospital|Yes|Completed|April 2005|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|50 Years|No|||April 2015|April 6, 2015|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372125||179047|
NCT00367653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661155|Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.|A Phase 3, Randomized, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa||Pfizer||Completed|November 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|N/A|No|||September 2008|September 15, 2008|August 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367653||179385|
NCT00367666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 414500|Using Diagnostic Tools to Stage Breast Cancer|Evaluation of Multimodality Breast Imaging: Lesion Staging||University of Pennsylvania||Active, not recruiting|March 2002|July 2007||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|400|||Female|18 Years|80 Years||||May 2007|May 8, 2007|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367666||179384|
NCT00367679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG105290|Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer|A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects With Stage IA, IB, IIA or IIB (to T2) Resectable Non-Small Cell Lung Cancer (NSCLC)||GlaxoSmithKline|No|Completed|November 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|21 Years|N/A|No|||May 2012|June 7, 2012|August 22, 2006||||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00367679||179383|
NCT00367926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFMC-0001-103|The Effect of American Ginseng Root and Its Components on Glycemia in Healthy Individuals|Effect of American Ginseng Root and Derived Polysaccharides on Postprandial Glycemia in Healthy Individuals||Risk Factor Modification Centre||Completed|June 2005|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||September 2005|August 22, 2006|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367926||179364|
NCT00378300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-08-007-01|The Effects of Probiotics in Atopic Dermatitis|Probiotics Ameliorate Atopic Dermatitis by Induction of T Regulatory Cells||University of California, Los Angeles|No|Withdrawn|July 2007|June 2008|Anticipated|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|6 Months|3 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 18, 2006||No|Inadequate funding to support this fellow-in-training initiated study.|No||https://clinicaltrials.gov/show/NCT00378300||178579|
NCT00378313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP-FB-GE-001|A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer|A Phase 2 Study of Neoadjuvant Chemotherapy With Gemcitabine, Epirubicin and Paclitaxel (Taxol)[GET] in Locally Advanced Breast Cancer||NSABP Foundation Inc||Completed|November 2001|November 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||76|||Female|18 Years|N/A|No|||November 2008|November 24, 2008|September 7, 2006||||No||https://clinicaltrials.gov/show/NCT00378313||178578|
NCT00368225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060193|Transplant-Related Accelerated Progression of Hepatitis C|Transplant-Related Accelerated Progression of Hepatitis C (TRAP-C)||National Institutes of Health Clinical Center (CC)||Completed|June 2006|January 2009||||N/A|Observational|Time Perspective: Prospective||||100|||Both|18 Years|N/A|No|||January 2009|September 26, 2015|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368225||179341|
NCT00368173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSM-110-303|IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome|||Insmed Incorporated||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Years|18 Years||||September 2012|September 11, 2012|August 23, 2006||||||https://clinicaltrials.gov/show/NCT00368173||179345|
NCT00368186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0877X-100722|Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.|An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants.||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|May 2001|November 2002||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||51|||Both|57 Days|112 Days|No|||August 2006|August 23, 2006|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00368186||179344|
NCT00368498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950115|A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely|A Randomized Single Blind Parallel Control Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely||National Taiwan University Hospital||Recruiting|June 2006|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|16 Years|N/A|No|||August 2006|August 23, 2006|August 23, 2006||||No||https://clinicaltrials.gov/show/NCT00368498||179320|
NCT00368745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081092|Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Pregabalin in Subjects With Generalized Anxiety Disorder (GAD) Switching From Benzodiazepine Therapy.|GAD|Pfizer|No|Completed|September 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||November 2009|November 9, 2009|August 23, 2006|Yes|Yes||No|August 10, 2009|https://clinicaltrials.gov/show/NCT00368745||179301|
NCT00369122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00722|Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer|A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA||National Cancer Institute (NCI)||Completed|August 2006|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|N/A|N/A|No|||October 2013|September 22, 2014|August 24, 2006|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00369122||179272|Ineligible patients are included in the adverse event reporting on ClinicalTrials.gov, but not in endpoint results, nor in any publications, per the protocol.
NCT00369421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760238|Diagnosis and Treatment of Patients With Inborn Errors of Metabolism|Diagnosis and Treatment of Patients With Inborn Errors of Metabolism or Other Genetic Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|November 1976|||||N/A|Observational|N/A|||Anticipated|4000|||Both|1 Month|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00369421||179250|
NCT00370188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96/2006|Topiramate on Gambling-Related Behaviours|Clinical Assessment of Topiramate on Gambling-Related Behaviours in Problem Gamblers: Effects of Gender and Negative Emotionality||Centre for Addiction and Mental Health||Withdrawn|September 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|19 Years|65 Years|No|||July 2015|July 20, 2015|August 29, 2006|||Change to investigator's research affiliation and other employment.|No||https://clinicaltrials.gov/show/NCT00370188||179193|
NCT00369668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00061194|Post Stroke Hand Functions: Bilateral Movements and Electrical Stimulation Treatments|Subacute Stroke Recovery (Upper Extremity Motor Function): Bimanual Coordination Training||University of Florida|No|Completed|August 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|44 Years|86 Years|No|||April 2012|June 12, 2012|August 24, 2006||No||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00369668||179232|
NCT00370201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8259|Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment|||hahid Beheshti University of Medical Sciences||Active, not recruiting|March 2004|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 2004|October 6, 2006|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370201||179192|
NCT00370526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-CLIN 008|HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study|HEmodynamic Assessment of Optimal Left Heart Lead Placement for Heart Failure Enabled by Magnetic Navigation||Stereotaxis|Yes|Terminated|February 2007|December 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||January 2008|January 2, 2008|August 29, 2006||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00370526||179167|
NCT00370877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2005/GL-01|rhuFVIIa in Post-partum Hemorrhage|Recombinant Human Activated Factor VII as Salvage Therapy in Women With Severe Postpartum Hemorrhage||Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2007|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|18 Years|45 Years|No|||March 2015|March 26, 2015|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370877||179140|
NCT00370890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKNPCSG 0502|A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy|A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin||Chinese University of Hong Kong|Yes|Active, not recruiting|September 2006|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370890||179139|
NCT00371241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0122|Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO|Antibody Secreting Cell (ASC) and Immunoactive Protein Profiles in Neonates on Extracorporeal Membrane Oxygenation (ECMO)||The University of Texas Health Science Center, Houston|Yes|Completed|September 2006|November 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Plasma and whole blood|Both|N/A|30 Days|No|Probability Sample|Infants requiring ECMO|December 2007|December 3, 2007|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00371241||179112|
NCT00371254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-059|A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer|Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer||Bristol-Myers Squibb|No|Completed|December 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Female|18 Years|N/A|No|||February 2011|February 18, 2011|September 1, 2006|Yes|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00371254||179111|
NCT00371540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDCF 2005043|Extending HIV Care Beyond the Rural Health Center|Extending HIV Care Beyond the Rural Health Center||Indiana University|Yes|Completed|February 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|N/A|No|||August 2008|August 26, 2008|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00371540||179091|
NCT00371813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051055|An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Multinational Study Of Efficacy And Safety Of Varenicline Tartrate For Smoking Cessation||Pfizer||Completed|September 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|334|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371813||179070|
NCT00371839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4338-R|Clinical Applications for Time-Compressed Speech Tests|Clinical Applications for Time-Compressed Speech Tests||VA Office of Research and Development|No|Completed|September 2006|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|August 31, 2006||No||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00371839||179068|
NCT00371852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO_L_01811|Topic Compatibility Dermacyd Wipes - Lactoserum - Hygiene|Safety Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensibility) of Dermacyd Wipes||Sanofi||Completed|May 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2008|May 15, 2008|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371852||179067|
NCT00367965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-055|Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis|The Effect of Eszopiclone 3 mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis||Sunovion|No|Completed|February 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|153|||Both|25 Years|64 Years|No|||February 2012|February 21, 2012|August 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367965||179361|
NCT00367978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIB002FUS06|Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus|A Randomized, Multicenter, Study to Determine the Efficacy and Safety of Amlodipine/Benazepril Hydrochloride Versus Enalapril in the Treatment of Hypertension in an African-American Population With Type 2 Diabetes||Novartis||Completed|December 2001|September 2003|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|275|||Both|18 Years|80 Years||||August 2006|November 7, 2011|August 23, 2006||||||https://clinicaltrials.gov/show/NCT00367978||179360|
NCT00367692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3165A1-106|Study Evaluating PSI-697 in Patients With Scleritis|An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|September 2006|April 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|12|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|August 21, 2006||||||https://clinicaltrials.gov/show/NCT00367692||179382|
NCT00367939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489ADE01|Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine|An Multicenter Study to Evaluate the Efficacy and Safety of a 5 Week Therapy With the Combination of Valsartan 160 mg Plus Amlodipine 10 mg in Hypertensive Patients Not Adequately Responding to a 5 Week Therapy With Ramipril 5 mg and Felodipine 5 mg||Novartis||Completed|December 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|132|||Both|18 Years|N/A||||November 2011|November 7, 2011|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367939||179363|
NCT00367952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-201E|A Long Term, Safety Study of Apricitabine in HIV-infected Subjects|An Open Label Long Term Safety Extension Study of Apricitabine in Treatment-experienced HIV-1 Infected Subjects||Avexa|Yes|Completed|August 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|65 Years|No|||June 2011|June 22, 2011|August 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367952||179362|
NCT00378651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETINA-2|Use of the Stethoscope to Confirm Breathing Tube Placement|Differentiation Between Esophageal and Tracheal Intubation Utilizing Neck Auscultation||University of Manitoba||Completed|September 2006|January 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 14, 2007|September 19, 2006||||No||https://clinicaltrials.gov/show/NCT00378651||178552|
NCT00368550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-225-2|Sertraline Pharmacotherapy for Alcoholism Subtypes|Sertraline Pharmacotherapy for Alcoholism Subtypes||University of Connecticut Health Center|Yes|Completed|February 2004|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|65 Years|No|||June 2011|June 17, 2011|August 22, 2006|Yes|Yes||No|June 4, 2010|https://clinicaltrials.gov/show/NCT00368550||179316|
NCT00368563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN.1010.02|A Capacitance and Transepidermal Water Loss Test to Determine the Ability of Sunscreen to Moisturize Skin|||Loreal USA||Completed|August 2006|October 2006|Actual|October 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind|||||||Both|18 Years|55 Years||||February 2009|February 10, 2009|August 23, 2006||Yes||||https://clinicaltrials.gov/show/NCT00368563||179315|
NCT00368576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPL107629|A Study To Determine The Effect Of SB-480848 On Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Repeat Dose Study to Assess the Effect of SB-480848 on Overall Asthma Control in Adult Subjects With Persistent Asthma Controlled on Stable, Low-dose, Inhaled Corticosteroids||GlaxoSmithKline|No|Completed|August 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|67|||Both|18 Years|65 Years|No|||June 2011|March 15, 2012|August 22, 2006||||||https://clinicaltrials.gov/show/NCT00368576||179314|
NCT00368212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH040487|Integrated Treatment Program for Hypochondriasis in Primary Care Settings|Treating Refractory Symptoms in Primary Care (Hypochondriasis: Diagnosis, Description and Medical Care)||Brigham and Women's Hospital|No|Completed|May 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|70 Years|No|||March 2013|March 15, 2013|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368212||179342|
NCT00368511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-09-06-01|Fall Prevention Strategies Including Music and Posturography|The Nolwenn Effect in Geriatric Nursing Homes in the Netherlands||Carrick Institute for Graduate Studies|Yes|Completed|August 2006|April 2007|Actual|March 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 5, 2008|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368511||179319|
NCT00368771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR007768|A Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome|A Six-Month Study to Compare Outcome Differences and Visceral Response in Subjects Randomized to a Psychological Intervention for Irritable Bowel Syndrome||University of California, Los Angeles||Completed|July 2002|May 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|163|||Both|18 Years|65 Years|No|||May 2012|May 21, 2012|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00368771||179299|
NCT00368758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JRA1|The Effect of Probioticson Bloating in IBS|The Effect of Probioticson Bloating in IBS||Royal Veterinary and Agricultural University, Denmark||Recruiting|August 2006|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|18 Years|N/A|No|||August 2006|August 24, 2006|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00368758||179300|
NCT00369083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|515|Hospitalization at Home of Elderly Patients With Exacerbated COPD|Home Hospitalizationfor Elderly Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: a Randomized Controlled Trial.||Azienda Ospedaliera San Giovanni Battista||Completed|April 2004|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|75 Years|N/A|No|||January 2004|August 28, 2006|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369083||179275|
NCT00370214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR001|REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management|REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management||Actelion|Yes|Completed|March 2006|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3515|||Both|3 Months|N/A|No|Probability Sample|Patients with WHO Group I Pulmonary Arterial Hypertension from US based PAH centers.|May 2013|May 16, 2013|August 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00370214||179191|
NCT00370552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-115|A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer|A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer||R-Pharm|No|Completed|March 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|August 30, 2006|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00370552||179165|
NCT00370565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-109|Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.|Efficacy And Safety Of Exubera (Inhaled Insulin) Therapy In Subjects With Type 2 Diabetes Mellitus Not Well Controlled With Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial.||Pfizer||Completed|June 1999|September 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||345|||Both|35 Years|80 Years|No|||February 2007|February 9, 2007|August 29, 2006||||||https://clinicaltrials.gov/show/NCT00370565||179164|
NCT00370903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005009|Postpartum Depression and Cesarean Section|Retrospective Study of Relationship of Postpartum Depression to Planned Versus Emergent Cesarean Section||Oklahoma State University Center for Health Sciences||Completed|August 2006|November 2007|Actual|November 2007|Actual|N/A|Observational|Time Perspective: Retrospective||||200|||Female|15 Years|43 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370903||179138|
NCT00371878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAL0601|Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection|Open Label Study of Lung and Serum Immunoglobulin Responses to 7-Valent Pneumococcal Conjugate Vaccine in HIV Infected and Non-HIV Infected Malawian Adults||Royal Liverpool University Hospital||Completed|February 2003|October 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|17 Years|N/A|Accepts Healthy Volunteers|||September 2006|August 7, 2008|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371878||179065|
NCT00372164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 14|Retrospective Evaluation of ASIPP Guidelines Implementation|Evaluation of the Effectiveness of Implementation of American Society of Interventional Pain Physician Guidelines for Interventional Techniques: A Retrospective Evaluation||Pain Management Center of Paducah||Withdrawn|January 1998|July 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|current patients|October 2015|October 20, 2015|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00372164||179044|
NCT00371553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Testis protocol Version 003|Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer|Prospective Open-Labeled Non Randomised Phase-II Study of SU011248 (Sunitinib) in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer - A CUOG / GTCSG Cooperative Phase II Study -||British Columbia Cancer Agency|Yes|Completed|November 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Male|18 Years|N/A|No|||July 2009|July 7, 2009|September 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00371553||179090|
NCT00371566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF104334|A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer|A Randomized, Single Blinded, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)||GlaxoSmithKline||Completed|March 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|August 31, 2006|||||December 26, 2008|https://clinicaltrials.gov/show/NCT00371566||179089|
NCT00368004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060230|Family Studies of Uveal Coloboma|Family Studies of Uveal Coloboma||National Institutes of Health Clinical Center (CC)||Terminated|July 2006|April 2013||||N/A|Observational|N/A|||Actual|100|||Both|N/A|N/A|No|||April 2013|February 26, 2014|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368004||179358|
NCT00368329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESOPH0001|Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer|Phase I Study of Dose Escalation Using Image-guided Radiotherapy to Deliver a Stereotactic Radiosurgical Boost After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer||Stanford University|Yes|Terminated|June 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|August 22, 2006||No|low accrual|No||https://clinicaltrials.gov/show/NCT00368329||179333|
NCT00368628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405026711|Continuous Positive Airway Pressure for the Treatment of Stroke|Continuous Positive Airway Pressure for the Treatment of Acute Ischemic Stroke: A Feasibility Pilot Study||Yale University||Completed|November 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|50 Years|N/A|No|||March 2009|March 2, 2009|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00368628||179310|
NCT00378664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-124|Lumbar to Sacral Ventral Nerve Re-Routing|Lumbar to Sacral Ventral Nerve Re-Routing||William Beaumont Hospitals|Yes|Completed|September 2006|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|6 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00378664||178551|
NCT00368589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT106468|Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging|A 12 Week, Randomised, Double Blind Study Evaluating the Effects of Low Dose (10mg) and High Dose (80mg) Atorvastatin on Macrophage Activity and Carotid Plaque Inflammation as Determined by Ultra Small Super-Paramagnetic Iron Oxide (USPIO) Enhanced Carotid Magnetic Resonance Imaging (MRI)||GlaxoSmithKline|No|Completed|July 2006|August 2007|Actual|August 2007|Actual|N/A|Observational|N/A||1|Actual|47|||Both|18 Years|80 Years|No|||April 2015|April 15, 2015|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00368589||179313|
NCT00368524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F920822004|Cost Effective Treatment for Dually Diagnosed Homeless|Cost Effective Treatment for Dually Diagnosed Homeless||University of Alabama at Birmingham||Completed|November 2001|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||August 2006|August 23, 2006|August 23, 2006||||No||https://clinicaltrials.gov/show/NCT00368524||179318|
NCT00368537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-900|Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections|A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|550|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|August 21, 2006|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00368537||179317|
NCT00368784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513098|T Cell Repertoire Analysis of Immune Mediated Skin Diseases|T Cell Repertoire Analysis of Immune Mediated Skin Diseases||University of California, Davis|No|Recruiting|January 2007|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Fifteen tablespoons of blood will be collected prior to the initiation of a treatment and      again after the patient shows a clinical response to a treatment. The time between blood      draws will be no less than 3 months. There will be no more than two blood draws per patient.      Blood samples will be used to determine the patient's HLA haplotype via PCR and DNA      sequencing. After the patient's haplotype has been established the activated T cell      repertoire will be analyzed for clonal expansions. Clonal expansions in the T cell      repertoire will be determined by immunoscope analysis, which is a PCR based technique.|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects aged 18 years to 55 years who have an immune mediated skin disease, such as        psoriasis or mycosis fungoides, and age-matched controls (subjects who do not have an        immunce midiated skin disease).|April 2015|April 20, 2015|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00368784||179298|
NCT00369109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000479118|Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors|Collection of Skin Biopsy With Hair Follicles as Surrogate to Develop Biomarker Assays From Patients With Advanced Solid Tumor Malignancies Receiving Either Single Agent Weekly Irinotecan or Gemcitabine||Barbara Ann Karmanos Cancer Institute|No|Completed|February 2006|June 2007|Actual|November 2006|Actual|N/A|Observational|N/A|||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00369109||179273|
NCT00368797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI6143|Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.|TALISMAN 201|Sanofi||Completed|March 2002|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|125|||Both|40 Years|N/A|No|||November 2008|November 14, 2008|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00368797||179297|
NCT00369681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0615 CDR0000492792|Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma|Phase II Trial of Rituximab -ABVD for Classical Hodgkin's Disease||Sidney Kimmel Comprehensive Cancer Center||Completed|May 2006|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 24, 2006|Yes|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT00369681||179231|
NCT00369694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|446-Med/ERC-05|Short Course Terlipressin for Control of Acute Variceal Bleeding|Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed||Aga Khan University|Yes|Completed|August 2006|August 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|85 Years|No|||September 2008|September 24, 2008|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00369694||179230|
NCT00369928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006012|Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate|A Multicenter, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG-760564 in Adult Patients With RA Receiving Methotrexate||Procter and Gamble|No|Completed|August 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|254|||Both|18 Years|70 Years|No|||August 2011|August 4, 2011|August 29, 2006|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00369928||179212|
NCT00369941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-021|A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™||Merck Sharp & Dohme Corp.|No|Completed|August 2006|February 2012|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|566|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 29, 2006|Yes|Yes||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00369941||179211|
NCT00370227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107706|Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine|To Assess Safety, Reactogenicity & Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine, Co-admin With GSK Biologicals' MMRV Vaccine in Children (2nd yr of Life) Primed With the Pneumococcal Conjugate Vaccine in Study 105553.||GlaxoSmithKline||Completed|October 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||390|||Both|12 Months|14 Months|Accepts Healthy Volunteers|||September 2012|September 20, 2012|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370227||179190|
NCT00370578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HaE064990ctil|Aspiration Device in Myocardial Infarction Trial|Aspiration Device Myocardial Infarction Trial||HaEmek Medical Center, Israel|Yes|Recruiting|September 2006|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2006|August 27, 2007|August 9, 2006||||No||https://clinicaltrials.gov/show/NCT00370578||179163|
NCT00370591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM40104|Study Of Airway Physiology In Adults.|Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of Seretide Diskus 50/100 Mcg Bid vs Flixotide 200 Mcg Bid||GlaxoSmithKline||Completed|December 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|65 Years|No|||August 2013|September 5, 2013|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370591||179162|
NCT00370916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAB 05-204|Reducing Transition Drug Risk|Reducing Transition Drug Risks After Patient Transfer||VA Office of Research and Development|No|Completed|October 2005|September 2010|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|612|||Both|18 Years|N/A|No|||December 2010|April 6, 2015|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370916||179137|
NCT00367757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF06002AF|STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial|Open, Prospective, Randomized Trial Comparing Trigger vs Substrate vs Hybrid Approaches for AF Ablation||St. Jude Medical|No|Completed|August 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|107|||Both|18 Years|75 Years|No|||July 2009|July 30, 2009|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367757||179377|
NCT00368667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 02749 (completed)|Energy Homeostasis in Anorexia Nervosa|Energy Homeostasis in Anorexia Nervosa||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|April 2000|December 2004||||N/A|Observational|Time Perspective: Prospective||||120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00368667||179307|
NCT00367705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL-HMO-CTIL|VSL#3 Treatment in Children With Crohn's Disease|Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease||Hadassah Medical Organization|No|Not yet recruiting|August 2009|December 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|6 Years|18 Years|No|||August 2006|August 16, 2009|August 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00367705||179381|
NCT00367718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRG-NP04/23/06|Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma|A Phase II Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma||Johns Hopkins University||Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|75 Years|No|||August 2006|August 21, 2006|August 21, 2006||||No||https://clinicaltrials.gov/show/NCT00367718||179380|
NCT00367991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506000140|Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction|Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction||Yale University|Yes|Completed|November 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|21 Years|75 Years|No|||September 2011|September 14, 2011|August 23, 2006||No||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00367991||179359|
NCT00368342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-340-14-6-1-PU-79|Chronic Bronchiolitis or Resistant Asthma?|||Baqiyatallah Medical Sciences University||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A||||January 2006|February 17, 2009|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00368342||179332|
NCT00368355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-8701-MOHEL|T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts|CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning|MOHEL|Baylor College of Medicine|Yes|Recruiting|April 2000|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|87|||Both|N/A|55 Years|No|||December 2015|December 1, 2015|September 21, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368355||179331|
NCT00368368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP19470|A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.|An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.||Hoffmann-La Roche||Completed|January 2006|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|August 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00368368||179330|
NCT00378677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA-DPI|Dry Powder Inhalation of Cyclosporine A in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome|Pilot Study of Cyclosporine A Dry Powder Inhalation in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome||University Medical Center Groningen||Recruiting|February 2007|||||Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||7|||Both|18 Years|N/A|No|||February 2007|February 6, 2007|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00378677||178550|
NCT00368290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804537|Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior|Modafinil Treatment for Cocaine Dependence and HIV-High Risk Behavior|MOD6|University of Pennsylvania|Yes|Completed|September 2006|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|60 Years|No|||December 2013|December 12, 2013|August 22, 2006|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00368290||179336|
NCT00368602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-06-00351|Beta Blocker for Chronic Wound Healing|Beta Adrenergic Receptor Modulation of Burn Wound Healing||University of California, Davis|No|Terminated|June 2005|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|August 24, 2006||No|Lack of funding.|No||https://clinicaltrials.gov/show/NCT00368602||179312|
NCT00368810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906104|Study of Factors Involved in Resistance to Severe Malaria|Response to Plasmodium Falciparum-Derived TLR Ligands in Severe and Uncomplicated Malaria in Mali||National Institutes of Health Clinical Center (CC)||Completed|February 2006|November 2006||||N/A|Observational|N/A||||120|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||November 2006|March 5, 2008|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00368810||179296|
NCT00368823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS10516-03|A Trial of Point of Care Information in Ambulatory Pediatrics|A Randomized Clinical Trial to Improve Prescribing Patterns in Ambulatory Pediatrics||University of Washington||Completed|November 1999|December 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||44|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2006|August 24, 2006|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00368823||179295|
NCT00369135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFP-111-111|Cross-Disciplinary Workplace Intervention Strategy for Chronic Musculoskeletal Disorders|Cross-Disciplinary Workplace Intervention Strategy for Chronic Musculoskeletal Disorders||Institut Universitaire Romand de Sante au Travail|Yes|Recruiting|March 2006|February 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|58 Years|No|||November 2008|November 20, 2008|August 25, 2006||||No||https://clinicaltrials.gov/show/NCT00369135||179271|
NCT00369434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-337|Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women|A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of DVS SR for Treatment of Vasomotor Symptoms Associated With Menopause||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2006|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|450|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2007|May 31, 2007|August 25, 2006||||||https://clinicaltrials.gov/show/NCT00369434||179249|
NCT00369707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 06H1|Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL|A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin's Lymphoma||Northwestern University|Yes|Active, not recruiting|August 2006|August 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369707||179229|
NCT00369954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000496764|Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin|A Phase II Trial of Intravenous Gemcitabine (NSC #613327) and Intraperitoneal Carboplatin (NSC # 241240) in the Treatment of Patients With Platinum-Sensitive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma With Non-Measurable Disease||Gynecologic Oncology Group||Withdrawn|April 2006|||||Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||October 2007|June 7, 2013|August 29, 2006|Yes|Yes|Trial was never activated|No||https://clinicaltrials.gov/show/NCT00369954||179210|
NCT00370240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(CRH 05353A)|Chlorhydrate of Ropivacaine and Breast Cancer Surgery|Efficacy of Infiltration of Chlorhydrate of Ropivacaine in the Prevention of Chronic Breast Pain After Surgery for Breast Cancer.||Centre Rene Huguenin||Completed|September 2006|November 2008|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|260|||Female|18 Years|85 Years|No|||July 2007|May 14, 2012|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370240||179189|
NCT00370253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-TER|Noradrenalin vs Terlipressin in Hepatorenal Syndrome|Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study||University of Turin, Italy|Yes|Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||April 2008|April 9, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370253||179188|
NCT00370604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-PAngle|Effect of Small Versus Large Epidural Needles on Postdural Puncture Headache Study|Randomized Controlled Trial Examining the Effect of Small Versus Large Tuohy-type Epidural Needles on the Incidence and Severity of Postdural Puncture Headache||Sunnybrook Health Sciences Centre|Yes|Completed|June 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1081|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|August 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00370604||179161|
NCT00371865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4306-I|Behavioral Treatments for Chronic Pain|Acceptance-Based Treatment for Chronic Pain||VA Office of Research and Development|Yes|Completed|October 2006|September 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|August 31, 2006||No||No|February 2, 2015|https://clinicaltrials.gov/show/NCT00371865||179066|
NCT00367770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-409|BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology|A Multi-Center, Open-Label Extension Study to Protocol AC-052-405 to Evaluate the Safety and Efficacy of Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology||Actelion||Completed|January 2004|December 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|12 Years|N/A|No|||November 2006|February 11, 2010|August 21, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00367770||179376|
NCT00372138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS TC211|Prevention of Endoleaks Using Autologous Platelet Gel on Unruptured Abdominal Aortic Aneurysms|Prevention of Endoleaks Using Autologous Platelet Gel During Endovascular Procedures on Unruptured Abdominal Aortic Aneurysms: Pilot Study||Rennes University Hospital||Terminated|September 2006|July 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372138||179046|
NCT00372151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Theanine 10/2006.ctil|L-Theanine in the Management of Schizophrenia|The Value of Augmenting L-Theanine in the Management of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial||Sha’ar Menashe Mental Health Center|Yes|Completed|October 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||December 2008|December 15, 2008|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372151||179045|
NCT00368381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-05-1813|Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis|A Blinded, Placebo Controlled Trial of Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis||CAMC Health System|No|Withdrawn|September 2006|September 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|August 23, 2006||No|Study closed for PI failure to submit renewal paperwork|No||https://clinicaltrials.gov/show/NCT00368381||179329|
NCT00368394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964/1019|Dose-Exposure-Response in Type 1 Diabetes Mellitus|Dose-Exposure-Response Relationship of Insulin Glulisine (HMR1964) in Subjects With Type 1 Diabetes Mellitus Assessed With the Euglycemic Clamp Technique Using the Biostator (TM)||Sanofi||Completed|January 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||18|||Male|18 Years|55 Years|No|||August 2006|August 23, 2006|August 23, 2006||||No||https://clinicaltrials.gov/show/NCT00368394||179328|
NCT00368654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513613-1|Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy|An Open-Label Study to Evaluate Whether a Short-Term Course of Methotrexate in Psoriasis Patients Treated With Efalizumab is Safe and Increases Efficacy||University of California, Davis|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 20, 2012|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368654||179308|
NCT00368940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH074659|Problem Adaptation Therapy (PATH) vs. Supportive Therapy in Treating Depressed, Cognitively Impaired Older Adults|A Treatment for Depressed, Cognitively Impaired Elders||Weill Medical College of Cornell University|No|Active, not recruiting|April 2006|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|65 Years|N/A|No|||March 2014|March 6, 2014|August 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00368940||179286|
NCT00379249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00001|Rosuvastatin ORBITAL Germany|Effects of a Twelve Months ROSUVASTATIN Treatment Plus Additional Care (Drug Intake Adherence and Lifestyle Enhancing Initiatives ) Compared to ROSUVASTATIN Treatment Alone on Long-Term Disease-Related Costs in Patients With an Indication for Statin Treatment According to the Joint European Guidelines||AstraZeneca||Completed|February 2002|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||8000|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379249||178508|
NCT00379795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3426g (Cohort 1)|An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO|An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study||Genentech, Inc.||Completed|April 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|853|||Both|50 Years|N/A|No|||January 2013|January 30, 2013|September 21, 2006|Yes|Yes||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00379795||178466|
NCT00368615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513097|Characterization of the Melanoma-Specific Immune Response|Characterization of the Melanoma-Specific Immune Response|Melanoma|University of California, Davis|No|Recruiting|August 2007|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Peripheral blood will be collected prior to initiation of chemotherapy. There will be no      more than two blood draws per subject. Most subjects will receive a single blood draw;      however, some may be asked to return for an additional blood draw if investigators were      unable to isolate melanoma-specific immune cells after the first blood draw. Two separate      blood draws will be the maximum.|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects aged 18 years to 85 years who have a biopsy diagnosis of melanoma, and        age-matched controls (subjects who do not have a diagnosis of melanoma).|April 2015|April 20, 2015|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00368615||179311|
NCT00368836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|433|Breath Analysis Technique to Diagnose Pulmonary Embolism|Expired CO2/O2 Analysis to Diagnose Pulmonary Embolism||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|March 2006|June 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|475|||Both|18 Years|N/A|No|||September 2008|September 29, 2008|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368836||179294|
NCT00369148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-NHK2|Combination of Glinides With Premixed Insulin|Evaluation of Usefulness of Combination Therapy of Rapid Acting Insulin Secretagogue (Glinide) With Premixed Insulin in Type 2 Diabetes||Keio University||Completed|July 2004|March 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||August 2009|August 25, 2009|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369148||179270|
NCT00369161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2426|A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients|A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients||Novartis||Completed|June 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|228|||Both|18 Years|65 Years|No|||March 2011|March 25, 2011|August 25, 2006||Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00369161||179269|
NCT00369447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB1000-010|A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer|A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination With External Radiotherapy in Stage IIB, III and IV NSCLC||YM BioSciences|No|Terminated|March 2009|July 2011|Anticipated|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|August 24, 2006|Yes|Yes|The study was closed due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00369447||179248|
NCT00369460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8205|Changes in Muscle Tissue in Patients With Pancreatic Cancer|Pilot Study of Changes in Fat-Free Mass in Pancreatic Carcinoma Patients||Case Comprehensive Cancer Center|Yes|Completed|January 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|N/A|N/A|No|Probability Sample|Primary care clinic|October 2015|October 8, 2015|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00369460||179247|
NCT00369720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051169|Use of Blended Oxygen for Delivery Room Resuscitation of Very Low Birth Weight Infants|Use of Blended Oxygen for Delivery Room Resuscitation of VLBW Infants||University of California, San Diego||Active, not recruiting|January 2005|January 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|23 Weeks|32 Weeks|No|||April 2007|April 18, 2007|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369720||179228|
NCT00369967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120008FN|Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents|"Quick Start" Initiation of the Contraceptive Vaginal Ring in Adolescents: A Randomized Controlled Trial||Virginia Commonwealth University||Terminated|February 2007|July 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|42|||Female|15 Years|21 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|August 29, 2006||No|difficulty in subject recruitment|No||https://clinicaltrials.gov/show/NCT00369967||179209|
NCT00370266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8247|Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion|||hahid Beheshti University of Medical Sciences||Completed|February 2003|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|N/A|No|||June 2008|June 16, 2008|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370266||179187|
NCT00370279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8405|Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial|||hahid Beheshti University of Medical Sciences||Recruiting|September 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||||||Both|40 Years|N/A|No|||June 2008|June 25, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370279||179186|
NCT00370617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METVIRAL|Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance|An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance||University of Turin, Italy||Recruiting|September 2006|January 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|65 Years|No|||November 2006|November 13, 2006|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370617||179160|
NCT00370630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8544|Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)|||hahid Beheshti University of Medical Sciences||Recruiting|August 2006|February 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||15|||Both|40 Years|N/A|No|||February 2007|February 20, 2007|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00370630||179159|
NCT00371592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA PE 003|Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)|A Phase II, Randomized, Double-blind, Placebo-controlled Trial of Acyclovir for the Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load and Mucosal Shedding in HIV-1, Herpes Simplex Virus, Type 2 (HSV-2) Co-Infected Women||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||September 2013|September 20, 2013|September 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00371592||179087|
NCT00368056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-060|Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability|Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Patients With Primary Insomnia Compared to Placebo||Sunovion|No|Completed|April 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|No|||February 2012|February 21, 2012|August 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368056||179354|
NCT00368433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060232|Hypersensitivity in Tourette Syndrome|Hypersensitivity in Tourette Syndrome: An Evaluation of Perceived Intensity Versus Threshold||National Institutes of Health Clinical Center (CC)||Completed|August 2006|May 2011||||N/A|Observational|N/A|||Actual|46|||Both|18 Years|65 Years|No|||May 2011|May 25, 2011|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368433||179325|
NCT00367731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH_CER_003|NOW Thai HAART Study|Neurological Outcomes With in THAI National HAART Program.||Rajavithi Hospital||Completed|January 2005|September 2006||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||500|||Both|15 Years|N/A|No|||August 2006|August 22, 2006|August 22, 2006||||No||https://clinicaltrials.gov/show/NCT00367731||179379|
NCT00367744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI060484-02-C|Rosiglitazone Effect on Mitochondria and Lipoatrophy|Placebo Controlled Study of Rosiglitazone in HIV Lipoatrophy||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||August 2006|February 22, 2010|August 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00367744||179378|
NCT00368017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060042|Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease|Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease||Vanderbilt University|No|Terminated|April 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|75 Years|No|||November 2010|November 1, 2010|August 23, 2006||No|unable to replace Fellow conducting the study who left institution in 2007|No||https://clinicaltrials.gov/show/NCT00368017||179357|
NCT00368030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-052|A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder|Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Related to MDD Acronym: DREAMDD||Sunovion|No|Completed|January 2004|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|545|||Both|21 Years|64 Years|No|||February 2012|February 21, 2012|August 23, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368030||179356|
NCT00368953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipsia-Yukon-DM|YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus|A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus||University of Leipzig||Completed|September 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2010|February 1, 2010|August 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368953||179285|
NCT00369265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10166|Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux|A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis||American Institute for Voice and Ear Research||Terminated|August 2006|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|89 Years|No|||August 2012|August 23, 2012|August 24, 2006||No|Pharmaceutical company purchased by another company and funding was terminated.|No|July 11, 2012|https://clinicaltrials.gov/show/NCT00369265||179261|The study was terminated due to inadequate subject recruitment.
NCT00369564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0402|Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer|Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer||University of South Florida|Yes|Completed|May 2007|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|250|||Both|3 Years|20 Years|No|||December 2013|January 30, 2014|August 24, 2006|Yes|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00369564||179240|
NCT00369577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-201|StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.||Alexza Pharmaceuticals, Inc.||Completed|August 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|65 Years|No|||January 2007|January 18, 2007|August 25, 2006||||No||https://clinicaltrials.gov/show/NCT00369577||179239|
NCT00369772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000256|STAAR-1 Clinical Study|A Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (Darbepoetin Alfa) in Subjects With Anemia of Chronic Renal Insufficiency (CRI)||Amgen||Completed|February 2002|May 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||2000|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00369772||179224|
NCT00368979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI105326|Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects|Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (Dutasteride) in Subjects With Benign Prostatic Hyperplasia.||GlaxoSmithKline|No|Completed|February 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|378|||Male|50 Years|N/A|No|||February 2014|April 17, 2014|August 24, 2006||||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00368979||179283|
NCT00379821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0022|Chloroquine Alone or in Combination for Malaria in Children in Malawi|A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2007|September 2012|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|640|||Both|6 Months|5 Years|No|||July 2014|August 7, 2014|September 21, 2006|Yes|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00379821||178464|
NCT00379834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31861|12-Month Stability of Diurnal IOP Control on Cosopt|12-Month Stability of Diurnal IOP Control on Cosopt||West Virginia University|No|Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|September 21, 2006||No||No|July 25, 2013|https://clinicaltrials.gov/show/NCT00379834||178463|
NCT00369512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060106002|A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma|A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas|RAD0503|University of Alabama at Birmingham|Yes|Completed|August 2006|September 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|19 Years|N/A|No|||August 2013|August 6, 2013|August 24, 2006||No||No|June 3, 2013|https://clinicaltrials.gov/show/NCT00369512||179243|
NCT00368849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200508775|Atomoxetine and Huntington's Disease|Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study||University of Iowa|Yes|Completed|November 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||December 2012|December 18, 2012|August 24, 2006|Yes|Yes||No|May 9, 2011|https://clinicaltrials.gov/show/NCT00368849||179293|We cannot rule out carryover effects. Additionally, the sample size may be too low to detect small treatment changes, the treatment duration may have been too brief, and our participants had only early-stage HD which may have limited the drug effect.
NCT00369174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02968|Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia|Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia||National Cancer Institute (NCI)||Completed|June 2006|||August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|N/A|No|||January 2013|February 12, 2013|August 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00369174||179268|
NCT00369187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-06-02|Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase|||Halozyme Therapeutics||Completed|July 2006|October 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||January 2008|January 7, 2008|August 25, 2006||||||https://clinicaltrials.gov/show/NCT00369187||179267|
NCT00369473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060119|Long-Term Assessment of Safety and Physical Function With AMG 108 in RA|A Long-Term Assessment of Safety and Physical Function With AMG 108 Subcutaneous Monthly Treatment in Subjects With Rheumatoid Arthritis||Amgen||Completed|September 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|690|||Both|18 Years|N/A|No|||April 2009|April 9, 2009|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00369473||179246|
NCT00369486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-104|A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema|A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema|Peribulbar|Diabetic Retinopathy Clinical Research Network|Yes|Completed|December 2004|October 2007|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|113|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|August 25, 2006|Yes|Yes||No|October 14, 2009|https://clinicaltrials.gov/show/NCT00369486||179245|
NCT00369499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV05003PC|STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?|STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?||St. Jude Medical||Terminated|March 2007|June 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|656|||Both|18 Years|50 Years|No|||February 2008|February 22, 2008|August 28, 2006||No|Not enough patients/ ethical concerns|No||https://clinicaltrials.gov/show/NCT00369499||179244|
NCT00370643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|number: 637-02|Glucose Control in Open Heart Surgery|Intensive Glucose Control Versus Conventional:Tendency Of Better Clinical Outcome In Open Heart Surgery||University of Sao Paulo||Completed|October 2002|November 2004||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||98|||Both|21 Years|N/A|No|||February 2009|February 18, 2009|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370643||179158|
NCT00370929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSPC-06-03-001|A Study of Meditation as a Treatment for Epilepsy|Treatment of Epilepsy by Meditation and Cultivation of Emotional Balance||University of California, Los Angeles||Active, not recruiting|May 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|18 Years|N/A|No|||March 2006|August 30, 2006|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370929||179136|
NCT00369980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GunmaU|Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient|||Gunma University||Completed|September 1998|August 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||August 2005|November 6, 2006|August 29, 2006||||No||https://clinicaltrials.gov/show/NCT00369980||179208|
NCT00369993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS104449|Spacer Comparison In Adult Asthmatics|A Randomised, Open Label, Five-way Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate and Salmeterol From SERETIDE/ADVAIR 250HFA MDI Alone and With AeroChamber-Max Spacer and VOLUMATIC Both in Their Washed and Unwashed States in Adult Subjects With Mild or Intermittent Asthma||GlaxoSmithKline||Completed|March 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|65 Years|No|||August 2013|September 5, 2013|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369993||179207|
NCT00371280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8422|Prosthetic Motility and Complications in Pegged Versus Unpegged Hydroxyapatite Orbital Implants|||hahid Beheshti University of Medical Sciences|Yes|Active, not recruiting|November 2005|November 2006|Anticipated|October 2006|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||June 2008|May 10, 2010|September 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00371280||179109|
NCT00370955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8527|The Effect of Hydrodynamic Parameters on Corneal Endothelial Cell Loss After Phacoemulsification|The Effect of Hydrodynamic Parameters on Corneal Endothelial Cell Loss After Phacoemulsification||hahid Beheshti University of Medical Sciences|No|Completed|March 2007|December 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|70 Years|No|||October 2008|December 24, 2009|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00370955||179134|
NCT00371579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-125|Rosuvastatin for Hepatitis C|Treatment With Rosuvastatin in Patients With Hepatitis C||UMC Utrecht||Withdrawn|October 2006|October 2007|Anticipated|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||February 2009|June 2, 2015|September 1, 2006|||no actual patients recruited within year 1 after ethical committee approval|No||https://clinicaltrials.gov/show/NCT00371579||179088|
NCT00371891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA007-0603-01|Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)|The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS)||St. Joseph's Healthcare Hamilton|Yes|Completed|September 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|168|||Both|18 Years|N/A|No|||November 2010|November 24, 2010|September 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00371891||179064|
NCT00370084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITODG04-01|Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia|Effects of Itopride Hydrochloride on Gastric Emptying, Glycaemia and "Meal-Related" Symptoms in Patients With Type 1 and Type 2 Diabetes Mellitus||Axcan Pharma|No|Completed|March 2005|July 2006|Actual|May 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||December 2008|December 19, 2008|August 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00370084||179200|
NCT00370383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT2-05-07|A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)|A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy||Agennix||Completed|July 2006|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|70 Years|N/A|No|||July 2012|July 31, 2012|August 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00370383||179178|
NCT00368407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fmmu200504|Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck|Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck||Fourth Military Medical University||Completed|April 2005|July 2006||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|2 Years|60 Years|No|||April 2005|August 23, 2006|August 23, 2006||||No||https://clinicaltrials.gov/show/NCT00368407||179327|
NCT00368446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060217|Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease|Genetic Disorders of Mucociliary Clearance||National Institutes of Health Clinical Center (CC)||Completed|July 2006|||||N/A|Observational|Time Perspective: Prospective|||Actual|87|||Both|2 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 15, 2015|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368446||179324|
NCT00368992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02903|S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|August 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||February 2013|August 11, 2015|August 24, 2006|No|Yes||No|October 30, 2012|https://clinicaltrials.gov/show/NCT00368992||179282|
NCT00368420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR OP.2|Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer|Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer||AGO Study Group|No|Completed|September 2006|October 2009|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|122|||Female|18 Years|N/A|No|Probability Sample|Patients with recurrence of invasive epithelial ovarian-, fallopian tube- or primary        peritoneal cancer of any initial stage who have relapsed after a tumor-free interval of at        least 6 months after completion of first-line therapy.|February 2011|February 11, 2011|August 23, 2006||||No||https://clinicaltrials.gov/show/NCT00368420||179326|
NCT00368680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO032006|Early CPAP in Respiratory Distress Syndrome|Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI)||Pontificia Universidad Catolica de Chile||Recruiting|January 2007|September 2009||April 2008||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|256|||Both|N/A|30 Minutes|No|||April 2007|December 23, 2010|August 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00368680||179306|
NCT00368966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-501|Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|619|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||July 2012|July 6, 2012|August 25, 2006|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00368966||179284|
NCT00369278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ADE12|Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating an Intensified Enteric-coated Mycophenolate Sodium (EC-MPS) Dosing Regimen in Comparison to a Standard Dosing Regimen of EC-MPS in Combination With Cyclosporin Microemulsion and Corticosteroids in de Novo Renal Transplant Patients||Novartis||Completed|June 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|70 Years||||March 2011|March 25, 2011|August 25, 2006||||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00369278||179260|
NCT00379275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060239|Eye and Immunogenetic Features of Sarcoidosis|Ocular and Immuno-Genetic Manifestations of Sarcoidosis||National Institutes of Health Clinical Center (CC)||Completed|September 2006|December 2007||||N/A|Observational|N/A||||100|||Both|6 Years|N/A|No|||December 2007|September 26, 2015|September 20, 2006||||No||https://clinicaltrials.gov/show/NCT00379275||178506|
NCT00368927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00836|Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia|Randomized, Phase IIb Trial of Sulindac in Smokers With Bronchial Dysplasia||National Cancer Institute (NCI)||Completed|August 2006|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|61|||Both|40 Years|79 Years|No|||October 2011|May 7, 2014|August 24, 2006|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00368927||179287|
NCT00368862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL172-9|Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism.|Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism||National Institute for Health and Welfare, Finland||Completed|December 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||August 2006|August 28, 2006|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00368862||179292|
NCT00369200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00163|AFP464 in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Terminated|June 2006|||January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|August 24, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00369200||179266|
NCT00369213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDO/18/67|Randomised Controlled Trial of Condoms Plus Additional Lubrication|Randomised Controlled Trial of the Effect of Additional Spermicidal Lubrication on Condom Failure||University of Manchester||Completed|April 1998|April 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2004|August 24, 2006|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00369213||179265|
NCT00370292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10940|Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer. A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial||Eli Lilly and Company|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|August 29, 2006|Yes|Yes||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00370292||179185|
NCT00370305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ek. 211-02d|11ß-HSD1 and Metabolic Syndrome|The Pathogenic Role of 11ß-Hydroxysteroid Dehydrogenase in the Metabolic Syndrome - the Effect of Rosiglitazone||Charite University, Berlin, Germany||Recruiting|May 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|7|||Both|20 Years|65 Years|No|||May 2007|May 11, 2007|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370305||179184|
NCT00370318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107017|Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines|Multicentre Study to Assess the Effect of Prophylactic Antipyretic Treatment on the Rate of Febrile Reactions Following Concomitant Administration of GSK Biologicals' 10-valent Pneumococcal Conjugate, Infanrix Hexa and Rotarix Vaccines||GlaxoSmithKline||Completed|September 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|9 Weeks|16 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|June 2, 2006||||No||https://clinicaltrials.gov/show/NCT00370318||179183|
NCT00370942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPB106652|GW823093C For The Treatment Of Type 2 Diabetes Mellitus|Clinical Evaluation of GW823093C in Patients With Type 2 Diabetes Mellitus -Double-Blind Dose Finding and the Extension Study- <Phase 2 Study>||GlaxoSmithKline||Terminated|April 2006|October 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|200|||Both|20 Years|74 Years|No|||July 2012|April 11, 2013|August 30, 2006|||Safety issue|No||https://clinicaltrials.gov/show/NCT00370942||179135|
NCT00371267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4281-I|Telephone-Delivered Cognitive Behavior Therapy for Chronic Pain|Telephone-Delivered Cognitive Behavior Therapy for Chronic Pain||VA Office of Research and Development|Yes|Completed|October 2006|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|55 Years|N/A|No|||October 2014|October 29, 2014|August 31, 2006||No||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00371267||179110|The fact that the study was conducted in California may have posed some threat to external validity when applying these findings to the nationwide VA system.
NCT00371293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|442|The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease|Inflammatory Response to Sleep Apnea in Obese Subjects: The Cardiovascular Effects of Obstructive Sleep Apnea (COSA) Study||University of Pennsylvania|Yes|Active, not recruiting|September 2006|August 2012|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|181|||Both|18 Years|80 Years|No|||June 2012|June 13, 2012|September 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371293||179108|
NCT00370968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND-040 ICP (2001)/13|Zinc-ORS in Severe and Complicated Acute Diarrhea|Extended Studies on Safety and Efficacy of Zinc-ORS Compared to ORS Alone in Hospitalized Children With Severe and Complicated Acute Diarrhea||Centre For International Health|No|Completed|September 2003|December 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||352|||Male|1 Month|36 Months|No|||May 2010|May 12, 2010|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00370968||179133|
NCT00371306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-078|Comparison of Glucovance to Insulin for Diabetes During Pregnancy|A Comparison of Glucovance (Glyburide and Metformin) to Insulin Therapy for the Treatment of Gestational Diabetes and Adult Onset Diabetes in Pregnancy||Regional Obstetrical Consultants|No|Recruiting|September 2002|September 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||200|||Female|18 Years|45 Years|No|||April 2007|April 19, 2007|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371306||179107|
NCT00371319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HARECCTR0500018|Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis|To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis||Tuen Mun Hospital|Yes|Completed|September 2005|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|September 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00371319||179106|
NCT00370422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8412|Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial|||hahid Beheshti University of Medical Sciences||Active, not recruiting|November 2005|September 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2005|March 12, 2007|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370422||179175|
NCT00370786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8543|Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)|||hahid Beheshti University of Medical Sciences||Completed|November 2005|February 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|N/A|No|||July 2008|July 9, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370786||179147|
NCT00368693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apopharma RS03-2004|Efficacy and Safety Study of Dermal-Living Skin Replacement to Treat Diabetic Foot Ulcers|Pivotal Study to Evaluate the Efficacy and Safety of Dermal - Living Skin Replacement (Dermal - LSR) in the Treatment of Chronic Diabetic Foot Ulcers||University of California, Davis|No|Terminated|August 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|August 24, 2006|No|Yes|Study terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00368693||179305|
NCT00368706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90506/CHoTD01|A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients|A Randomized, Double-Blind, Paralleled, Active Controlled, Multi-Center Study of the Efficacy and Safety of 5mg Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder||Astellas Pharma Inc|No|Completed|September 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|246|||Both|18 Years|75 Years|No|||April 2008|April 9, 2008|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00368706||179304|
NCT00370747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-ECBT-CS02|Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome|Efficacy and Safety of Ecabet Ophthalmic Solution for the Treatment of Dry Eye Syndrome||Bausch & Lomb Incorporated|No|Completed|September 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||162|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|August 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00370747||179150|
NCT00370760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8404|Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)|||hahid Beheshti University of Medical Sciences||Recruiting|September 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||||||Male|18 Years|65 Years|No|||June 2008|June 25, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370760||179149|
NCT00371072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8370|Trabeculectomy With MMC Versus Ahmed Glaucoma Implant for Treatment of Pediatric Aphakic Glaucoma|||hahid Beheshti University of Medical Sciences||Completed|March 2004|November 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|N/A|16 Years|No|||July 2003|October 6, 2006|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371072||179125|
NCT00400738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 019|The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients|Pharmacokinetics of and Rate of HIV-1 RNA Decline in ARV-naive HIV-1 Infected Patients Treated With Low- or Standard-dose Saquinavir HGC (Invirase®) and Lopinavir/Ritonavir (Kaletra®||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|March 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|November 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00400738||176891|
NCT00401024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510133|Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma|Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration||National Cancer Institute (NCI)||Completed|July 2006|||June 2009|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|N/A|No|||July 2009|July 24, 2010|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00401024||176870|
NCT00401297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0010|Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes|Intervenable Host- Leishmania (Vianna) Interactions Project 3: Immune and Inflammatory Responses in L. (Viannia) Infection Aim 1: To Determine if Th1/Th2 Polarization Occurs and is Linked to the Outcome of Infection by L. Viannia||Yale University|Yes|Completed|December 2006|April 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|122|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Age between 18-70 years               1. Historical and confirmed cases of chronic leishmaniais disease with no current                  leishmaniasis               2. Historical cases of confirmed recurrent leishmaniasis disease 3 Asymptomatic                  infection cases: (Resident of endemic area, PBMCs responsive to leishmanial                  antigen)             4. Healthy donors:          -  No history or evidence of exposure to transmission of leishmaniasis|August 2011|August 3, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401297||176850|
NCT00401310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0724-018|The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)|A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke||Merck Sharp & Dohme Corp.||Terminated|July 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||July 2015|July 21, 2015|November 17, 2006|Yes|Yes|Termination date was 20-Oct-2008. Subjects were monitored during the post treatment 90 day    follow-up period (per protocol) resulting in LPLV 19-Jan-2009.|No||https://clinicaltrials.gov/show/NCT00401310||176849|
NCT00379574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2006-276|Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL|A Phase I/II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients With Advanced Stage Diffuse Large B-cell Lymphomas||Asan Medical Center|Yes|Completed|September 2006|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|15 Years|70 Years|No|||March 2013|March 13, 2013|September 21, 2006||No||No|February 4, 2011|https://clinicaltrials.gov/show/NCT00379574||178483|
NCT00369551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02718|Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer|A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer||National Cancer Institute (NCI)||Terminated|June 2006|||February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||January 2013|March 5, 2014|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369551||179241|
NCT00369733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010243|STAAR-3 Clinical Study|Disease/Case Management of Patients Receiving ARANESP™ (Darbepoetin Alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI)||Amgen||Completed|May 2002|May 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|443|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|August 24, 2006||||No||https://clinicaltrials.gov/show/NCT00369733||179227|
NCT00370006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jacobson VCL CT-02 IDTC|Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM|A Phase 1 Clinical Trial to Evaluate the Safety of, and Kinetics and Magnitude of the CMV-Specific Immune Response to, Challenge With a Live Attenuated Strain of CMV (Towne) in Healthy, CMV- Seronegative, Adult Subjects Who Previously Received a CMV Immunotherapeutic Trivalent pDNA Vaccine (VCL CT02) Administered Intradermally or Intramuscularly||University of California, San Francisco||Completed|September 2006|August 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2006|January 10, 2007|August 28, 2006||||||https://clinicaltrials.gov/show/NCT00370006||179206|
NCT00370019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060201|Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure|Effect of Transdermal Estradiol Replacement Therapy on Ovulation Rate in Women With Premature Ovarian Failure: A Randomized, Placebo-Controlled Trial||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|40 Years|No|||December 2011|December 30, 2011|August 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00370019||179205|
NCT00370331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA102537|RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag|A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP.|RAISE|GlaxoSmithKline||Completed|November 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|August 29, 2006|Yes|Yes||No|July 17, 2009|https://clinicaltrials.gov/show/NCT00370331||179182|
NCT00371007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-043|MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)|MK0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|June 2004|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||126|||Both|20 Years|69 Years|No|||February 2016|February 3, 2016|August 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371007||179130|
NCT00370656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 235|Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep|A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy||University of Surrey||Completed|February 2007|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||November 2009|November 16, 2009|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00370656||179157|
NCT00370981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP456-040|Exploratory Study of Pagoclone in Men With Premature Ejaculation.|A Four-arm, Randomized, Double-blind, Parallel, Placebo-controlled Exploratory Study of Pagoclone 0.15mg, 0.30mg, and 0.60mg in Men With Primary Premature Ejaculation.||Endo Pharmaceuticals|No|Completed|July 2006|October 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4|||100|||Male|18 Years|55 Years|No|||February 2007|December 3, 2013|August 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00370981||179132|
NCT00371904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPTURE|Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients|A Prospective Open Label Randomised Multicentre Study Evaluating the Efficacy & Safety of Rituximab Given Pre-Transplant to Sensitised Renal Allograft Recipients in Addition to a "Standard" Desensitisation Regimen Consisting of PE/IVIG & MMF|RAPTURE|Hunter and New England Health||Recruiting|April 2006|January 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|192|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371904||179063|
NCT00371332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI-145`|Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis|||OraPharma||Completed|January 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||128|||Both|30 Years|65 Years||||September 2006|September 22, 2006|September 1, 2006||||||https://clinicaltrials.gov/show/NCT00371332||179105|
NCT00372177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biotectid POC EP 1645|The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis|The Use of Anti-CD4 mAb-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis (an Open Proof of Concept Study)||Biotectid GmbH|Yes|Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|50 Years|80 Years|No|||May 2008|May 26, 2008|September 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00372177||179043|
NCT00367783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7081004|Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity|A 12-Week, Phase 2A, Randomized, Subject And Investigator Blind, Placebo-Controlled Trial To Evaluate The Effect Of CP-741,952 On Weight Loss In Otherwise Healthy Overweight And Obese Adult Subjects||Pfizer|No|Terminated|June 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 29, 2011|May 30, 2006|||See Detailed Description for termination reason.|||https://clinicaltrials.gov/show/NCT00367783||179375|
NCT00370799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 10|Effectiveness of Caudal Epidural Injections in Treatment of Chronic Low Back and Lower Extremity Pain|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Caudal Epidural Injections in Lumbar Disc Herniations, Spinal Stenosis, Discogenic Pain, and Post-Lumbar Laminectomy Syndrome||Pain Management Center of Paducah|Yes|Completed|January 2007|March 2010|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|240|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370799||179146|
NCT00370396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107046|Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.|To Assess the Safety, Reactogenicity & Immunogenicity of a 4th Dose of GSK Biologicals' Pneumococcal Vaccine or Prevenar™ in Children (12-18 mo) Previously Vaccinated in the Primary Study 105553 With Either Pneumococcal Vaccine or Prevenar™||GlaxoSmithKline||Completed|September 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|1200|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||June 2012|June 12, 2014|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370396||179177|
NCT00371085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICORE 2006-003|Congestive Heart Failure Outreach Program|Congestive Heart Failure Outreach Program (The COPE Study)|COPE|University of Alberta|No|Completed|October 2004|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|539|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00371085||179124|
NCT00371046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O4U.289|Does Fetal Fibronectin and Ultrasound Cervical Length Help in the Evaluation of Women With Suspected Preterm Labor?|The Use of Fetal Fibronectin and Transvaginal Ultrasound Cervical Length in Women With Threatened Preterm Labor:A Randomized Trial||Thomas Jefferson University|Yes|Completed|October 2003|December 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Female|N/A|N/A|No|||March 2007|March 1, 2007|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371046||179127|
NCT00371059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005087-93|Memantine for Agitation in Dementia|Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia|MAGD|East Kent Hospitals University NHS Foundation Trust|Yes|Recruiting|September 2007|September 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|164|||Both|55 Years|N/A|No|||May 2008|May 7, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00371059||179126|
NCT00371384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001927|Effect of Massage on Chronic Low Back Pain|Effect of Massage on Chronic Low Back Pain||Group Health Cooperative|Yes|Completed|August 2006|September 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|399|||Both|20 Years|64 Years|No|||November 2011|November 7, 2011|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00371384||179102|
NCT00371644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4445-R|Treatment for Veterans With Military Sexual Trauma|Manualized Treatment for Veterans With Military Sexual Trauma||VA Office of Research and Development|Yes|Completed|February 2007|June 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|August 31, 2006||No||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00371644||179083|
NCT00380185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1361|Understanding the Genetic Basis of Atherosclerosis and Peripheral Arterial Disease|The Genetic Determinants of Peripheral Arterial Disease|GenePAD|Stanford University|Yes|Completed|April 2004|||July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1789|Samples With DNA|Serum, Plasma, White Cells|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from individuals undergoing elective coronary angiography for        suspected CAD at Stanford University or Mount Sinai Medical Centers.|May 2015|May 27, 2015|September 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00380185||178436|
NCT00370344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GANO-05-147M|Small-incision Open Cholecystectomy or Laparoscopic Cholecystectomy for Gallbladder Disease|An Expertise-based Randomized Controlled Trial Comparing Minilaparotomy Cholecystectomy and Laparoscopic Cholecystectomy||Umeå University|No|Completed|September 2006|November 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370344||179181|
NCT00369538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3742|Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria|Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria||University Hospital, Strasbourg, France||Suspended|August 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||February 2009|February 16, 2009|August 28, 2006||No|principle investigator moved, new investigators will join, insurance expired - project needs    to be re-examined by an ethic committee|No||https://clinicaltrials.gov/show/NCT00369538||179242|
NCT00370032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S3B40042|Study to Assess the Effect Of Alosetron On Mucosal Blood Flow|A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects||GlaxoSmithKline|No|Completed|December 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|49|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|August 28, 2006|||||December 19, 2008|https://clinicaltrials.gov/show/NCT00370032||179204|
NCT00370045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04745|Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin|Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study||LifeBridge Health||Recruiting|March 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||August 2006|August 29, 2006|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00370045||179203|
NCT00371020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8373|The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR|||hahid Beheshti University of Medical Sciences||Active, not recruiting|February 2005|July 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||July 2007|July 11, 2007|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371020||179129|
NCT00371033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK65209-CPCRN-2 (IND)|Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|CPCRN RCT#2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Active, not recruiting|March 2006|April 2008|Anticipated|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|318|||Male|18 Years|N/A|No|||March 2011|March 15, 2011|August 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371033||179128|
NCT00370669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8411|Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema|||hahid Beheshti University of Medical Sciences||Recruiting|November 2005|February 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|N/A|N/A|No|||February 2007|February 21, 2007|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370669||179156|
NCT00370682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1281|A Phase II Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand|Phase II, Randomized, Double-blind, Single Center, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults||U.S. Army Medical Research and Materiel Command|No|Completed|April 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|120|||Both|20 Years|25 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|August 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00370682||179155|
NCT00371930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1742-03/06|Photodynamic Therapy for Permanent Hair Removal|||University of Jena||Not yet recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|60 Years||||June 2008|June 2, 2008|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371930||179062|
NCT00371631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4444-P|Colonizing Neurogenic Bladders With Benign Flora|Colonizing Neurogenic Bladders With Benign Flora||VA Office of Research and Development|No|Completed|October 2006|April 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|N/A|N/A|No|||November 2014|November 20, 2014|August 31, 2006|Yes|Yes||No|November 13, 2014|https://clinicaltrials.gov/show/NCT00371631||179084|Lack of placebo control.
NCT00372190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0609|Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse.|A Prospective and Comparative Study of the Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse||Radboud University||Recruiting|August 2006|||October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|194|||Female|N/A|N/A|No|||June 2008|June 6, 2008|September 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00372190||179042|
NCT00368043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060223|Endocrine and Psychological Evaluation of Adopted Children|Biobehavioral Study of Recently Adopted Children||National Institutes of Health Clinical Center (CC)||Terminated|August 2006|March 2015||||N/A|Observational|N/A|||Actual|38|||Both|10 Months|4 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|August 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00368043||179355|
NCT00369811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXFEN2006|Oxycodone vs Fentanyl for Pain Treatment After Laparoscopic Cholecystectomy|Comparative Study of Oxycodone and Fentanyl Given Intravenously in the Treatment of Early Postoperative Pain After Laparoscopic Cholecystectomy||Danish Pain Research Center|Yes|Completed|August 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Female|18 Years|N/A|No|||November 2007|November 16, 2007|August 28, 2006||||No||https://clinicaltrials.gov/show/NCT00369811||179221|
NCT00370773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0705|Comparison of Intraspinal Nerve Root Stimulation With Dorsal Column Stimulation|Treatment of Chronic Low Back Pain With Spinal Cord Stimulation: Comparison of Subthreshold Intraspinal Nerve Root Stimulation With Subthreshold and Suprathreshold Dorsal Column Stimulation and a Secondary Study of the Effect of Pulse Width||Boston Scientific Corporation|No|Terminated|January 2006|February 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|N/A|No|||August 2008|September 4, 2008|August 30, 2006||No|Slow Enrolling|No||https://clinicaltrials.gov/show/NCT00370773||179148|
NCT00371410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-05-029|Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema|The Safety and the Efficacy of Combined Vitrectomy, Intravitreal Triamcinolone Acetonide and Macular Focal Laser Photocoagulation for the Treatment of Intractable Diffuse Diabetic Macular Edema||Samsung Medical Center||Completed|April 2005|October 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|80 Years||||August 2006|August 31, 2006|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371410||179100|
NCT00371397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0068|Yoga, Immune Function, and Health|Psychoneuroimmunology and Mind-Body Interventions||Ohio State University|Yes|Completed|September 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|52|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|August 31, 2006||No||No|September 16, 2009|https://clinicaltrials.gov/show/NCT00371397||179101|
NCT00371657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006017|Maternal Obesity and Small for Gestational Age Infants|Obesity as a Risk Factor for Small for Gestational Age and Intrauterine Growth Restriction Infants||Oklahoma State University Center for Health Sciences||Completed|July 2006|November 2006|Actual|November 2006|Actual|N/A|Observational|Time Perspective: Retrospective||||420|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00371657||179082|
NCT00371969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-HAS-14323|Reducing Unsafe Alcohol Use in HIV-Positive Individuals|Reducing Unsafe Drinking in HIV Primary Care||Research Foundation for Mental Hygiene, Inc.||Completed|October 2006|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00371969||179059|
NCT00376896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI103147|Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers|A Phase IIa Experimental Medicine Study Assessing Alterations in Regional Cerebral Blood Flow by Functional Magnetic Resonance Imaging (fMRI) in Female IBS Patients and Healthy Controls Following Single Doses of GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)||GlaxoSmithKline||Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|September 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00376896||178686|
NCT00369785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU91105|Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors|Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain||Wake Forest School of Medicine|Yes|Completed|January 2008|June 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|198|||Both|18 Years|N/A|No|||December 2011|June 28, 2012|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369785||179223|
NCT00369798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060215|Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients|Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE 4) in Depressed Patients||National Institutes of Health Clinical Center (CC)||Recruiting|August 2006|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|February 11, 2016|August 25, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00369798||179222|
NCT00369226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-065|Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation|Phase I/II Trial of Bortezomib (Velcade) in Addition to Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Completed|August 2006|September 2011|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|45|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|August 24, 2006|Yes|Yes||No|August 8, 2012|https://clinicaltrials.gov/show/NCT00369226||179264|
NCT00371345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-088|Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer|Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer||Bristol-Myers Squibb|No|Completed|December 2006|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Female|18 Years|N/A|No|||April 2011|April 21, 2011|September 1, 2006|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00371345||179104|
NCT00370708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1383FK|Early Oral Intake Following Cesarean Surgery|Early Oral Intake Following Elective Cesarean Surgery in Iranian Women; the Economic Burdens and Patient Satisfaction||Tehran University of Medical Sciences||Completed|April 2003|February 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|||||||Female|20 Years|35 Years|Accepts Healthy Volunteers|||April 2004|September 6, 2006|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00370708||179153|
NCT00377988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012022|A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control|The Risk of Venous Thromboembolism, Myocardial Infarction, and Ischemic Stroke Among Women Using the Transdermal Contraceptive System Compared With Women Using Norgestimate-containing Oral Contraceptives With 35 Mcg Ethinyl Estradiol||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Active, not recruiting|April 2002|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|423|||Female|15 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women using a transdermal contraceptive system or NGM-OCs containing 35 mcg EE between        April 1, 2002 and December 31, 2006 whose medical records are accessable through research        databases in the United States.|June 2010|May 18, 2011|September 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00377988||178603|
NCT00369291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003LS014|CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant|CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution||Masonic Cancer Center, University of Minnesota|Yes|Terminated|September 2003|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|August 24, 2006|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00369291||179259|
NCT00369603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011149|Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients|Functional Neuroimaging (fMRI) Biomarker of Allosteric Nicotinic Receptor Modulation in Mild Alzheimer's Disease Patients: A Razadyne vs. Aricept Dose Escalation Trial||Duke University|Yes|Terminated|October 2006|November 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|40 Years|90 Years|No|||June 2008|April 9, 2013|August 28, 2006|No|Yes|Reduced access to AchEI medication-naive mild AD patients.|No||https://clinicaltrials.gov/show/NCT00369603||179237|
NCT00369824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107682|Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects|A Randomized, Open Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine Co-administered Intramuscularly With Boostrix® and/or Menactra™ in Healthy Female Subjects Aged 11-18 Years||GlaxoSmithKline||Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|1330|||Female|11 Years|18 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|August 28, 2006|Yes|Yes||No|September 3, 2009|https://clinicaltrials.gov/show/NCT00369824||179220|
NCT00370097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS106533|FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects|See Detailed Description||GlaxoSmithKline||Completed|August 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|6 Months|12 Months|No|||May 2009|May 15, 2009|August 28, 2006||||||https://clinicaltrials.gov/show/NCT00370097||179199|
NCT00370474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-CLIN 001|MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance|Multi-Center Assessment of Gain in Navigation Efficiency To Cardiac Resynchronization Therapy||Stereotaxis|No|Terminated|June 2006|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||June 2007|June 14, 2007|August 29, 2006|||Procedure protocol improved - study protocol became obsolete|No||https://clinicaltrials.gov/show/NCT00370474||179171|
NCT00370487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A15324;A15325|Comparison of the Safety of First Trimester Abortions Performed by Physicians and Non-Physicians in South Africa and Viet Nam.|Complication Rates of First-Trimester Manual Vacuum Aspiration Abortion Performed by Physicians and Midlevel Providers (MLP) in South Africa and Viet Nam: a Randomised, Controlled, Equivalence Trial.||World Health Organization||Completed|September 2003|June 2004||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||2860|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2005|September 5, 2006|August 30, 2006||||No||https://clinicaltrials.gov/show/NCT00370487||179170|
NCT00371098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-NP-0021-2/812/04|Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study|Prospective, Randomized, Double-Blind Placebo Controlled Study on Influenza Vaccination in Prevention From Coronary Events in Patients With Coronary Artery Disease Confirmed by Angiography||Institute of Cardiology, Warsaw, Poland|No|Completed|October 2004|December 2005|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|658|||Both|30 Years|80 Years|No|||October 2007|October 21, 2007|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00371098||179123|
NCT00371111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8524|To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema|||hahid Beheshti University of Medical Sciences||Active, not recruiting|August 2006|September 2008|Anticipated|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||July 2008|July 28, 2008|August 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00371111||179122|
NCT00371423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2032|Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions|A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Direct Stenting Treatment of Patients With de Novo Coronary Artery Lesions||Boston Scientific Corporation|Yes|Completed|March 2005|September 2010|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|August 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371423||179099|
NCT00371436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4488-R|Progressive Intervention Program for Tinnitus Management|Progressive Intervention Program for Tinnitus Management||VA Office of Research and Development|No|Completed|September 2008|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|181|||Both|N/A|N/A|No|||March 2015|March 24, 2015|August 31, 2006||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT00371436||179098|
NCT00371670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE581C2201|Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee|A Phase II, 12-Month, Double-Blind, Placebo-Controlled, Dose-Finding, Multicenter Study to Evaluate the Safety, Tolerability, and Disease Modifying Efficacy of Daily Oral AAE581 (10, 25 and 50 mg Tablets) in Patients With Painful Knee Osteoarthritis, Kellgren-Lawrence Grade 3 by X-Ray||Novartis||Completed|December 2004|||July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|223|||Both|40 Years|80 Years||||May 2009|May 18, 2009|August 31, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00371670||179081|
NCT00371683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-034|Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery|A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery||Bristol-Myers Squibb|Yes|Completed|November 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3608|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|August 30, 2006|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT00371683||179080|
NCT00371982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSERM-237-6900, Paris 6-069|Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women|||Assistance Publique - Hôpitaux de Paris||Terminated|December 2002|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Female|40 Years|60 Years|No|||November 2002|September 1, 2006|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371982||179058|
NCT00367536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-115|Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution|An Open-label, Single-dose, Randomized-to-sequence, 4-period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|August 2006||||Phase 1|Interventional|N/A||||24|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||July 2009|April 30, 2015|August 21, 2006||Yes||||https://clinicaltrials.gov/show/NCT00367536||179394|
NCT00402116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9815|Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients|Phase 1/2 Study of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma||Eli Lilly and Company|No|Completed|September 2006|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402116||176787|
NCT00370695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS-03-05|Spinal Cord Stimulation for Chronic and Intractable Back Pain|Spinal Cord Stimulation for Chronic and Intractable Back Pain in Patients Who Are Not Surgical Candidates||Boston Scientific Corporation|No|Terminated|February 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|August 30, 2006||No|Insufficient Data Collected|No||https://clinicaltrials.gov/show/NCT00370695||179154|
NCT00369746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5173|STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse|Treatment of Depression Concurrent With Alcohol Abuse, an Extension of Alcohol Use Disorder in Patients Treated for Depression||New York State Psychiatric Institute|No|Completed|September 2006|February 2009|Actual|February 2009|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|674|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants in the Sequenced Treatment Alternatives to Relieve Depression|December 2011|April 9, 2014|August 24, 2006||No||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00369746||179226|
NCT00369759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA133|An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants|An Epidemiological Study to Evaluate the Seasonality of Respiratory Syncytial Virus-Associated-Lower Respiratory Tract Infections (LRI) or Apnea in Infants in the Emergency Department||MedImmune LLC|No|Completed|September 2006|September 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2048|Samples Without DNA|Nasal wash specimen (RSV)|Both|N/A|12 Months|No|Non-Probability Sample|Eligible subjects with RSV results.|March 2009|March 16, 2009|August 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00369759||179225|
NCT00370721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8538|Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)|||hahid Beheshti University of Medical Sciences||Recruiting|March 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||June 2008|June 25, 2008|August 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00370721||179152|
NCT00370734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8375|Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease|||hahid Beheshti University of Medical Sciences|Yes|Recruiting|May 2005|February 2007||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|N/A|N/A|No|||February 2007|February 26, 2007|August 31, 2006||||No||https://clinicaltrials.gov/show/NCT00370734||179151|
NCT00403000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000514492|Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy|Phase II Study of Dutasteride in Prostate Cancer Recurrent During Androgen Deprivation Therapy||Roswell Park Cancer Institute|Yes|Completed|December 2004|April 2013|Actual|March 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|N/A|No|||April 2013|April 30, 2013|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403000||176719|
NCT00378001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03CHUS/FSH03|Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF|A Prospective, Multicenter, Investigator Blinded, Randomized, Concurrent Control Study of Efficacy and Tolerability of Two FSH Preparations (Fostimon® Versus Gonal-F®) in Women Undergoing IVF||IBSA Institut Biochimique SA||Completed|March 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||152|||Female|18 Years|40 Years|No|||February 2015|February 12, 2015|September 15, 2006||||||https://clinicaltrials.gov/show/NCT00378001||178602|
NCT00371605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0607030|An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study|An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study||University of Pittsburgh||Terminated|December 2006|April 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|liver transplant patients getting voriconazole clinically|December 2007|December 14, 2007|August 31, 2006|||Enrolled requested number of patients and completed study. In analysis|No||https://clinicaltrials.gov/show/NCT00371605||179086|
NCT00371618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 13|IPM Procedures With or Without Fluoroscopy: Outcome Comparison|Comparison of Outcomes of Interventional Pain Management Procedures Performed With or Without Fluoroscopy: A Retrospective Analysis||Pain Management Center of Paducah||Withdrawn|January 1998|May 2004||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|currently enrolled patients|October 2015|October 20, 2015|September 1, 2006||||No||https://clinicaltrials.gov/show/NCT00371618||179085|
NCT00369304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3189A1-103|Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate|A Randomized, Open Label, 2-Period Crossover Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 6, 2009|August 25, 2006||||||https://clinicaltrials.gov/show/NCT00369304||179258|
NCT00369317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML0431|Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes|The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years||Children's Oncology Group|Yes|Active, not recruiting|March 2007|||December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|205|||Both|N/A|4 Years|No|||March 2016|March 16, 2016|August 24, 2006|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT00369317||179257|
NCT00369616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT002-NicQb 02|Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers|Evaluation of Efficacy and Safety of Nicotine-Qbeta (NicQb) Vaccine Versus Placebo in Healthy Smokers||Cytos Biotechnology AG||Completed|December 2003|October 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|341|||Both|18 Years|70 Years||||March 2008|November 11, 2010|August 25, 2006||||No||https://clinicaltrials.gov/show/NCT00369616||179236|
NCT00401765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005275|A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined With Docetaxel in Subjects With Metastatic Hormone-Refractory Prostate Cancer||Centocor, Inc.|No|Completed|September 2005|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Male|18 Years|N/A|No|||May 2014|May 23, 2014|November 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00401765||176814|
NCT00400855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIG103337|Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate|See Detailed Description||GlaxoSmithKline||Completed|January 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||49|||Both|18 Years|55 Years|No|||February 2011|May 31, 2012|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400855||176882|
NCT00401115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-001|Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy|A Phase 1, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy||Santen Inc.|No|Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||July 2010|July 22, 2010|November 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00401115||176864|
NCT00401726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B1-416|Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program|Patient Outcomes With Education, Drug Therapy, and Support (POETS): A Multicenter, Open-label, Randomized Study to Evaluate Depressed Subjects Treated With Venlafaxine Extended-release vs. Venlafaxine Extended-release Plus the Dialogues Time to Talk Program in a Primary Care Setting||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2006|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|537|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|November 17, 2006||||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00401726||176817|
NCT00401739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-AML-06-26|Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia|Phase I Study of CSL360 in Patients With Relapsed, Refractory or High-Risk Acute Myeloid Leukemia||CSL Limited|No|Completed|December 2006|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2009|September 14, 2009|November 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00401739||176816|
NCT00402584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB237|A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder||Abbott|No|Completed|August 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|65 Years|No|||August 2007|August 30, 2007|November 20, 2006||||No||https://clinicaltrials.gov/show/NCT00402584||176751|
NCT00402831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F05-MMRV-304|ProQuad® Intramuscular vs Subcutaneous|An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months||Sanofi Pasteur MSD|No|Completed|October 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|405|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||April 2009|April 3, 2009|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00402831||176732|
NCT00403156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3989S|Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration||Vitreous -Retina- Macula Consultants of New York||Withdrawn|November 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|51 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|November 22, 2006|||Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00403156||176707|
NCT00403390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11-146|Generic vs. Name-Brand Levothyroxine|Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism||Children's Hospital Boston|No|Completed|November 2006|March 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00403390||176689|
NCT00403403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3995g|A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)|A Placebo-Controlled, Double-Blind, Multicenter, Randomized, Phase II Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer||Genentech, Inc.||Completed|March 2007|June 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||April 2011|April 27, 2011|November 21, 2006|Yes|Yes||No|January 28, 2010|https://clinicaltrials.gov/show/NCT00403403||176688|
NCT00403130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13761|Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer|Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer||Stanford University|Yes|Completed|February 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||February 2014|February 28, 2014|November 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00403130||176709|
NCT00403143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Opa/23|Do Blue-Blocking Lenses Block Blue Colour From Our Lives?|Do Blue-Blocking Lenses Block Colour From Our Lives? A Randomised Controlled Study Measuring Colour Vision Using the Gold Standard Colour Vision Test (an Anomaloscope)in Patients With Blue Light Filtering Intraocular Lenses (Tinted Yellow) and Comparing This With Patients Inserted With Clear, Non Blue Light Filtering Intraocular Lenses During Cataract Surgery||London North West Healthcare NHS Trust||Recruiting|October 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||May 2007|May 11, 2007|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403143||176708|
NCT00408642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP 058|An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)|An Enhanced Adherence Support Programme for HAART|eASP|Centre for the AIDS Programme of Research in South Africa|No|Completed|August 2007|March 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|297|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00408642||176293|
NCT00399841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0306|Spinal Cord Stimulation (SCS) for Neuropathic Pain of Back or Lower Extremity|Spinal Cord Stimulation (SCS) for Neuropathic Pain of Back or Lower Extremity: A Comparison of Electrode Placement at T7 and T8||Boston Scientific Corporation|No|Terminated|November 2006|November 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|November 13, 2006||No|Investigator Resigned|No||https://clinicaltrials.gov/show/NCT00399841||176958|
NCT00400127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA015|The Effect of Silicone Suspension on Standing Balance for Transfemoral Amputees|The Effect of Silicone Suspension on Standing Balance for Transfemoral Amputees||Nova Scotia Health Authority||Terminated|September 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|6|||Both|45 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 3, 2009|November 15, 2006||No|poor recruitment, pilot outcome measures inappropriate|No||https://clinicaltrials.gov/show/NCT00400127||176938|
NCT00400413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2865|Neuroanatomy of Reading in Congenital Deafness.|Phonological Perception and Learning to Read : the Neuroanatomy of Reading in Congenitally Deaf Persons||University Hospital, Strasbourg, France||Completed|November 2003|August 2011|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 29, 2011|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400413||176916|
NCT00400400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AUS51|Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance|A 4-week, Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of EC-MPS & MMF When Administered in Combination With Calcineurin Inhibitors in Renal Transplant Recipients Experiencing Gastrointestinal Intolerance||Novartis||Completed|October 2006|||June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|75 Years|No|||July 2011|July 14, 2011|November 15, 2006|Yes|Yes||No|December 3, 2010|https://clinicaltrials.gov/show/NCT00400400||176917|
NCT00400933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4,2006.2005|Evaluation of a Six-session Psycho-education Group Program|Evaluation of a Six-session Psycho-education Group Program Delivered to Family Members and Close Friends of Patients Suffering From Eating Disorders and Co-morbid Personality Disorders||Norwegian University of Science and Technology|No|Terminated|November 2006|December 2009|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|10|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||February 2012|February 9, 2012|November 16, 2006||No|shortage of experienced health care personnel after reorganisation of units|No||https://clinicaltrials.gov/show/NCT00400933||176877|
NCT00400946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-001 / CDR0000513019|Treatment of Acute Lymphoblastic Leukemia in Children|Treatment of Acute Lymphoblastic Leukemia in Children||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2005|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|1 Year|17 Years|No|||March 2015|March 17, 2015|November 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400946||176876|
NCT00401479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3I106248|A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers|An Exploratory Phase I Study in Healthy Volunteers of GI Transit Following Administration of the ß3-Adrenergic Receptor Agonist, Solabegron (Study B3I106248)||GlaxoSmithKline||Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|November 16, 2006||||||https://clinicaltrials.gov/show/NCT00401479||176836|
NCT00400894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA 4/033/06|Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma|Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma||ProteoSys AG||Active, not recruiting|September 2005|September 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||750|||Male|N/A|N/A|No|||February 2007|February 2, 2007|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00400894||176879|
NCT00401440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-Chaudhuri|Comparison of Two Regimens of Misoprostol for Second Trimester Medical Termination of Pregnancy|Comparison of Twq Different Regimen of Vaginal Misoprostol for Nid Trimester MTP||Nilratan Sircar Medical College|Yes|Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|185|||Female|14 Years|45 Years|No|||December 2008|March 11, 2010|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401440||176839|
NCT00402311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-02-055|The Effects and Cost-Effectiveness of an Integrated Multidisciplinary Approach for Psychogeriatric Patients|A Prospective Randomized Trial on the Effects of a Psychogeriatric Diagnostic Day Hospital||Maastricht University Medical Center||Completed|April 2002|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||216|||Both|55 Years|N/A|No|||November 2006|January 19, 2007|November 20, 2006||||No||https://clinicaltrials.gov/show/NCT00402311||176772|
NCT00401427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERVIN|HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer|A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2||National Cancer Institute, Naples||Completed|November 2002|December 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|N/A|No|||July 2012|July 12, 2012|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401427||176840|
NCT00402272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-369|SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe|SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions|SPIRIT V|Abbott Vascular|Yes|Completed|November 2006|June 2010|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2700|||Both|18 Years|N/A|No|||October 2010|October 13, 2010|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402272||176775|
NCT00402597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013417|Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3490|||Both|18 Years|75 Years|No|||September 2012|September 28, 2012|November 21, 2006|Yes|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00402597||176750|
NCT00402844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVM-II-2006|Safety Study of Pelvic Organ Prolapse Repair Using Transvaginal Mesh|A Multicenter Clinical Safety Assessment of Polypropylene Transvaginal Mesh in Pelvic Reconstructive Surgery||Karolinska Institutet|No|Completed|August 2006|March 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Female|18 Years|N/A|No|||November 2007|November 13, 2007|November 20, 2006||||No||https://clinicaltrials.gov/show/NCT00402844||176731|
NCT00402857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH076244|Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders|Advanced Parenting Education in Pediatrics: The APEP Project||Tufts Medical Center|No|Completed|November 2006|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|345|||Both|22 Months|38 Months|Accepts Healthy Volunteers|||February 2013|February 11, 2013|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402857||176730|
NCT00403169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-7165|Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer|Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)||The Cleveland Clinic||Active, not recruiting|August 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|26|||Both|18 Years|N/A|No|||January 2007|May 12, 2010|November 21, 2006||||||https://clinicaltrials.gov/show/NCT00403169||176706|
NCT00403416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2203|Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients|12-Month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients||Novartis||Completed|October 2006|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|215|||Both|18 Years|N/A|No|||February 2009|February 26, 2009|November 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403416||176687|
NCT00403728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.353|Ciclosporin A and Acute Myocardial Infarction|Protection by Ciclosporine A During Reperfused Acute Myocardial Infarction.||Hospices Civils de Lyon||Active, not recruiting|September 2004|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|18 Years|90 Years|No|||April 2007|April 26, 2007|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00403728||176664|
NCT00403741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0621|Consultations in Adapted Physical Activity on Behaviours in Physical Exercise by Type 2 Diabetics|Effects of Individuals Consultations in Adapted Physical Activity on Behaviours in Physical Exercise by Type 2 Diabetics||University Hospital, Grenoble|No|Completed|January 2007|July 2009|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|120|||Both|18 Years|80 Years|No|||February 2010|February 26, 2010|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403741||176663|
NCT00400153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.56|Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)|Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|November 2006|||April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|1480|||Both|40 Years|N/A|No|||June 2014|June 9, 2014|November 15, 2006||||No|April 3, 2009|https://clinicaltrials.gov/show/NCT00400153||176936|The FEV1 and FVC measurements at each observation time point were used to derive the primary and secondary efficacy endpoints and are not reported here. All statistical analyses for secondary endpoints are exploratory and the p-values are nominal.
NCT00403702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0021|Comparison High-Density Silicone Oils in Retinal Detachment|Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment||Asociación para Evitar la Ceguera en México||Recruiting|August 2006|August 2007|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||November 2006|June 28, 2009|November 2, 2006||||No||https://clinicaltrials.gov/show/NCT00403702||176666|
NCT00403715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-104|Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease||Merck Sharp & Dohme Corp.||Completed|February 2001|||September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403715||176665|
NCT00408668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC030|Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen|Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Virosomal Vaccine PEV3A and FP9-MVA ME-TRAP. A Phase I / IIa Controlled Challenge Trial||University of Oxford||Completed|August 2005|February 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2006|December 5, 2006|December 5, 2006||||No||https://clinicaltrials.gov/show/NCT00408668||176291|
NCT00408967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62206-016|Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.|An Open-label Phase II Study of Two Dose Levels of EMD 273066 Administered With Low-dose Cyclophosphamide Following Objective Response to Second-line Chemotherapy in Women With Recurrent Ovarian Carcinoma||EMD Serono||Terminated|December 2006|June 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||140|||Female|18 Years|N/A|No|||October 2013|June 27, 2014|December 6, 2006|||Poor recruitment; study design not appropriate any longer.|||https://clinicaltrials.gov/show/NCT00408967||176270|
NCT00400140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R473/22/2006|Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children|Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children||Singapore National Eye Centre||Completed|November 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||May 2010|May 11, 2010|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400140||176937|
NCT00400426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 20|DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer|DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer||University of Aarhus||Completed|November 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400426||176915|
NCT00400439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC20716|A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381|A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381||Hoffmann-La Roche||Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|November 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400439||176914|
NCT00400647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AES06|Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil|A 12-week Multicenter, Randomized, Open Study to Evaluate the Effects of Enteric-coated Mycophenolate Sodium (EC-MPS) in Terms of Quality of Life in Patients With Gastrointestinal (GI) Symptoms Treated With MMF (Mycophenolate Mofetil) After Kidney Transplant.||Novartis||Completed|July 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|136|||Both|18 Years|65 Years|No|||December 2013|December 24, 2013|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400647||176898|
NCT00401791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 26029|ACTIV- Exercise Intervention in Healthy Young Men|"ACTIV"Validation of a Paradigm for the Evaluation of Compounds That Activate Mitochondrial Biogenesis in Skeletal Muscle||Pennington Biomedical Research Center|Yes|Active, not recruiting|November 2006|October 2016|Anticipated|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|78|||Male|25 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401791||176812|
NCT00401804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract Number: 2005-003001-85|Bortezomib-Dexamethasone-Doxorubicin-Study|Bortezomib-Doxorubicin-Dexamethasone as Treatment for Patients With Multiple Myeloma Presenting With Acute Renal Failure||Austrian Forum Against Cancer||Completed|February 2006|November 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||July 2010|January 23, 2013|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00401804||176811|
NCT00402025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OncoVEX GM-CSF 005/04|OncoVEX GM-CSF in Patients With Unresectable Pancreatic Cancer|Targeted Delivery of OncoVEX GM-CSF by Endoscopic Ultrasound (EUS)-Guided Fine Needle Injection (FNI) in Patients With Irresectable Pancreatic Cancer: A Pilot Multinational Experiment on Safety and Proof of Concept||BioVex Limited||Completed|November 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2011|August 10, 2011|November 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00402025||176794|
NCT00401167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lundbeck-11267|Memantine for Agitation and Aggression in Severe Alzheimer's Disease|Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia||Sunnybrook Health Sciences Centre||Completed|November 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|65 Years|N/A|No|||January 2010|May 24, 2012|November 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401167||176860|
NCT00401180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-4737|Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer|Phase I Trial of Weekly Docetaxel and Daily Temozolomide in Patients With Metastatic Disease||The Cleveland Clinic||Completed|June 2002|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2007|July 6, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401180||176859|
NCT00401466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS024|Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy|Remote Follow-up for ICD-Therapy in Patients Meeting MADIT II Criteria (REFORM)|REFORM|Biotronik SE & Co. KG|No|Completed|January 2004|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|155|||Both|18 Years|80 Years|No|||July 2008|January 14, 2011|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401466||176837|
NCT00401973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10768|Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine|The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia||Eli Lilly and Company||Completed|November 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|199|||Both|18 Years|65 Years|No|||September 2009|September 30, 2009|November 17, 2006|Yes|Yes||No|August 27, 2009|https://clinicaltrials.gov/show/NCT00401973||176798|
NCT00402285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505501|Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer|The Molecular Effects of Nutrition Supplements (MENS) Prostate Study||University of California, San Francisco||Completed|April 2003|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|84|||Male|N/A|N/A|No|||December 2015|December 2, 2015|November 20, 2006||No||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00402285||176774|
NCT00402298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-P3|Randomized Placebo-controlled Study of MDMA-assisted Psychotherapy in People With PTSD - Israel|MDMA-assisted Psychotherapy in Twelve People With War and Terrorism-related Posttraumatic Stress Disorder (PTSD)||Multidisciplinary Association for Psychedelic Studies|No|Terminated|January 2008|February 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||March 2011|April 1, 2011|November 20, 2006|Yes|Yes|This study was terminated after enrolling five subjects due to staff turnover and its effects    on quality of data collection.|No||https://clinicaltrials.gov/show/NCT00402298||176773|
NCT00403429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-6|MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer|Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer.||National Cancer Institute, Naples||Completed|March 2006|July 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|N/A|75 Years|No|||January 2016|January 13, 2016|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403429||176686|
NCT00403754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149A1202|Dose Ranging Study for Indacaterol in Japanese Asthma Patients|A Randomized, Double-blind, Placebo-controlled, 4-period 4-treatment Crossover, Multicenter, Single-dose, Dose-ranging Study Followed by a Single Day's Treatment With Open Label Salmeterol Bid (100 µg/Day), to Assess the Efficacy and Safety of 3 Doses of Indacaterol (150, 300, & 600 µg) Delivered Via Single Dose Dry Powder Inhaler (SDDPI) in Japanese Asthma Patients||Novartis|No|Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|75 Years|No|||July 2011|July 22, 2011|November 23, 2006||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00403754||176662|
NCT00399880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000116|Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes|Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes|IMAGE-ACS|Vanderbilt University|No|Completed|November 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399880||176955|
NCT00399581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|471|Comparison of Two Methods of High Frequency Oscillatory Ventilation in Individuals With Acute Respiratory Distress Syndrome|Phase II Clinical Trial of Two Approaches to High Frequency Oscillatory Ventilation in Acute Respiratory Distress Syndrome||Johns Hopkins University|Yes|Completed|November 2006|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||July 2009|February 26, 2013|November 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00399581||176978|
NCT00408681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2080.00|Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease After Donor Stem Cell Transplant|A Pilot Study to Evaluate the Potential Efficacy of Lithium Carbonate for Stimulation of Intestinal Recovery In Patients With Acute GVHD||Fred Hutchinson Cancer Research Center|No|Completed|June 2006|||November 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|75 Years|No|||January 2011|January 4, 2011|December 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408681||176290|
NCT00400959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFT92002|CD133+ Autologous Cells After Myocardial Infarction|Intracoronary Injection of CD133+ Autologous Hematopoietic Cells After Myocardial Infarction||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||Completed|June 2004|October 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||November 2006|November 15, 2006|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00400959||176875|
NCT00401206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-06078|Use of Dexmedetomidine for Sedation During Flexible Bronchoscopy in Patients With COPD: A Descriptive Study|Use of Dexmedetomidine for Sedation During Flexible Bronchoscopy in Patients With COPD: A Descriptive Study||The Cooper Health System||Completed|November 2006|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2007|November 2, 2007|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401206||176857|
NCT00401492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILES-02|MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer|Phase II Study of Chemotherapy With Gemcitabine in Prolonged Infusion or With Schedules With Cisplatin in Non-small Cell Lung Cancer Elderly Patients||National Cancer Institute, Naples||Completed|June 2002|April 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|159|||Both|70 Years|N/A|No|||July 2012|July 12, 2012|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401492||176835|
NCT00401232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-800|Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development|Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development||Pfizer|No|Active, not recruiting|August 2006|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|900|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401232||176855|
NCT00401505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rubellain pregnancy|Rubella Susceptibility in Multiparous Women|Rubella Susceptibility in Multiparous Women||St. Michael's Hospital, Toronto||Active, not recruiting|September 2006|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All rubella susceptible women who delivered during the study period.|December 2009|September 2, 2011|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401505||176834|
NCT00401817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604008463|Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma|Phase II Study of Bevacizumab Plus CHOP-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL)||Weill Medical College of Cornell University||Active, not recruiting|November 2007|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|November 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401817||176810|
NCT00402038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 302|Study of Methylnaltrexone (MNTX) for the Relief of Constipation|A Double-Blind, Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone(MNTX) for the Relief of Constipation Due to Opioid Therapy in Advance Medical Illness.||Valeant Pharmaceuticals International, Inc.|Yes|Completed|February 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402038||176793|
NCT00401778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024810|Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)|Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)||Emory University|Yes|Completed|November 2006|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|November 17, 2006|Yes|Yes||No|January 23, 2015|https://clinicaltrials.gov/show/NCT00401778||176813|
NCT00401999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070026|OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine|OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine||National Institutes of Health Clinical Center (CC)||Completed|November 2006|January 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|35|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 29, 2011|November 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00401999||176796|
NCT00402012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 26027|"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM|Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM||Pennington Biomedical Research Center|Yes|Completed|November 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||December 2015|December 17, 2015|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402012||176795|
NCT00402610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAEI 94/0071a|A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy|A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy||Sociedad Andaluza de Enfermedades Infecciosas||Completed|January 1994|December 1998||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||332|||Both|18 Years|65 Years|No|||November 2006|October 23, 2008|November 18, 2006||||No||https://clinicaltrials.gov/show/NCT00402610||176749|
NCT00402623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 05.142.5|The Effect of Quercetin in Sarcoidosis|The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis||Maastricht University Medical Center|No|Completed|January 2006|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|N/A|N/A|No|||February 2008|February 21, 2008|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402623||176748|
NCT00401986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01|RISA Extension Study - Long Term Safety|Long Term Safety Evaluation of Bronchial Thermoplasty With the Alair® System in Patients With Severe Asthma||Asthmatx, Inc.|Yes|Active, not recruiting|December 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with severe asthma, previously treated with the Alair System in the PREDECESSOR        STUDY|May 2012|May 25, 2012|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401986||176797|
NCT00403182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515936|Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer|The CORE Study (Chemotherapy OR Endocrine Treatment First?) A Randomized Study by the Scandinavian Breast Group [CORE]||Technische Universität München||Withdrawn|May 2006|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|N/A|74 Years|No|||May 2012|May 31, 2012|November 21, 2006|||study halted prematurely, prior to enrollment of first participant|No||https://clinicaltrials.gov/show/NCT00403182||176705|
NCT00403442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2303|Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD|Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD||Vitreous -Retina- Macula Consultants of New York||Terminated|September 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|10|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 29, 2008|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403442||176685|
NCT00403767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012157|An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation|A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|December 2006|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|14269|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|November 23, 2006|Yes|Yes||No|December 2, 2011|https://clinicaltrials.gov/show/NCT00403767||176661|
NCT00399919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST 04-302|Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)|Safety and Efficacy pf Propionyl-L-Carnitine in Combination With Monitored Exercise Training in Peripheral Arterial Disease (Intermittent Claudication).||Sigma-Tau Research, Inc.|Yes|Completed|April 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|40 Years|80 Years|No|||June 2009|August 23, 2011|November 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399919||176952|
NCT00399594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAH 70-3402|Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.|Investigating Non-response to Cardiac Resynchronization: Evaluation of Methods to Eliminate Non-response & Target Appropriate Lead Location (INCREMENTAL).|INCREMENTAL|University of Calgary|Yes|Completed|March 2011|November 2015|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399594||176977|
NCT00399607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000357|Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention|Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention|PPS4B|Emory University|Yes|Active, not recruiting|June 2006|August 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|264|Samples Without DNA|Biopsies of normal-appearing rectal mucosa will be collected from participants in an      associated parent study.|Both|45 Years|75 Years|No|Non-Probability Sample|Participants in the parent study examining the impact of calcium and vitamin D        supplementation on the reoccurrence of colon polyps will be provided the opportunity to        also participate in this adjunct biomarker study.|February 2016|February 29, 2016|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399607||176976|
NCT00400452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA014|Manual Wheelchair Skills Training for Long-term-care Residents|Manual Wheelchair Skills Training for Long-term-care Residents: A Pilot Randomized Controlled Trial of Efficacy||Nova Scotia Health Authority|No|Terminated|May 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|8|||Both|17 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 4, 2011|November 15, 2006||No|poor enrollment|No||https://clinicaltrials.gov/show/NCT00400452||176913|
NCT00400660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLA103920|A First Time In Human Study To Assess The Compound GSK615915|A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK615915 in Healthy Volunteers and Mild Asthmatics.||GlaxoSmithKline||Completed|November 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400660||176897|
NCT00413348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|probiotics.sa.cim.rh.dk|Type 2 Diabetes and the Effect of Probiotics|Effect of Probiotics on Systemic Inflammation and Insulin Resistance in Type 2 Diabetics and Healthy Controls||Rigshospitalet, Denmark||Recruiting|November 2006|December 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||48|||Male|25 Years|80 Years|Accepts Healthy Volunteers|||December 2006|December 18, 2006|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00413348||175946|
NCT00400465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE49-1009|Is the Routine Pressure Dressing After Thyroidectomy Necessary?|Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study||Khon Kaen University|No|Completed|December 2006|September 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|N/A|N/A|No|||March 2015|March 31, 2015|November 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00400465||176912|
NCT00400686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-5497|Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma|A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life||The Cleveland Clinic||Active, not recruiting|March 2005|||January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2010|December 29, 2010|November 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00400686||176895|
NCT00400972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-467|Comparison of GlideScope Videolaryngoscopy to Direct Laryngoscopy for Nasal Intubation|Comparison of GlideScope Videolaryngoscopy to Direct Laryngoscopy for Nasal Intubation||Lawson Health Research Institute||Completed|November 2006|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 27, 2007|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400972||176874|
NCT00401219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713E1-136|Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioavailability Study Among 3 New Formulations of Premarin 0.625 mg/Medroxyprogesterone Acetate (Mpa) 2.5 mg Compared With a Reference Formulation of Premarin/Mpa (Prempro) 0.625 mg/2.5 mg in Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2006|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|35 Years|70 Years|Accepts Healthy Volunteers|||December 2007|December 4, 2007|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401219||176856|
NCT00402051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11077|Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC||Eli Lilly and Company|No|Completed|November 2006|May 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|November 17, 2006|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00402051||176792|
NCT00402064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|st1975-HMO-CTIL|The Influence of Bisphosphonates in the Oral Cavity in Children|The Influence of Bisphosphonates in the Oral Cavity in Children||Hadassah Medical Organization||Completed|March 2007|December 2008||||N/A|Observational|N/A||1|Anticipated|60|||Both|2 Years|20 Years|No|Non-Probability Sample|children treated with bisphosphonate who attend at the pediatric department of hadassah        hospital and or to alyn hospital|January 2009|January 28, 2009|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402064||176791|
NCT00402363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM8 Afib|Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation||GlaxoSmithKline|No|Completed|November 2006|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|663|||Both|18 Years|N/A|No|||February 2012|February 7, 2013|November 20, 2006|Yes|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00402363||176768|
NCT00402649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0072|Open-Label Study of H5 Vaccine in Participants of Protocol 04-077|Open-Label Study of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years to 10 Years||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2007|December 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||May 2008|June 9, 2011|November 21, 2006|Yes|Yes||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00402649||176746|
NCT00402324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10825|A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients|A Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode||Eli Lilly and Company||Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|60 Years|No|||May 2009|May 28, 2009|November 17, 2006|Yes|Yes||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00402324||176771|
NCT00402636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02505|Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE)|Prospective, Randomized Trial of Rapamycin Plus Estradiol-Eluting Stents Versus Rapamycin-Eluting Stents For The Reduction of Coronary Restenosis (ISAR-PEACE)||Deutsches Herzzentrum Muenchen|Yes|Completed|March 2005|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|502|||Both|18 Years|N/A|No|||November 2007|November 27, 2007|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402636||176747|
NCT00402922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1358|Evaluating the Association Between Pericardial Fat and Coronary Heart Disease - Ancillary to MESA|Pericardial Fat and Subclinical and Clinical Measures of Coronary Heart Disease - Ancillary to MESA||Wake Forest School of Medicine|No|Completed|August 2006|May 2012|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|6814|||Both|45 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participant in the MESA study|January 2013|January 15, 2013|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00402922||176725|
NCT00402870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-95|Postoperative Analgesic Requirements for the ProSeal Laryngeal Mask Airway Versus the Tracheal Tube in Females Undergoing Gynecological Laparoscopic Surgery|Postoperative Analgesic Requirements for the ProSeal Laryngeal Mask Airway Versus the Tracheal Tube in Females Undergoing Gynecological Laparoscopic Surgery||Medical University Innsbruck||Completed|August 2007|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402870||176729|
NCT00402883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 134|Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer|A Phase II Study of Pemetrexed/Carboplatin/Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer||SCRI Development Innovations, LLC|No|Terminated|November 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|November 21, 2006|No|Yes|Terminated due to bevacizumab and chemoradiotherapy toxicity|No|August 15, 2013|https://clinicaltrials.gov/show/NCT00402883||176728|
NCT00403195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OIS|Clinical and Pathophysiological Description of Ocular Ischemic Syndrome|Pathophysiological Analysis of Ocular Ischemic Syndrome and the Response to Vascular Surgery||Glostrup University Hospital, Copenhagen|Yes|Completed|November 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with the disease ocular ishemic syndrome. Patients will be screened through        vascular surgery departments.|September 2012|September 7, 2012|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00403195||176704|
NCT00403780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPARED_00|Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia|Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study||Karolinska Institutet|No|Recruiting|June 2006|July 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||May 2015|May 6, 2015|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403780||176660|
NCT00399633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuropeptide2007|Neuropeptides in the Humane Intra- og Extracerebral Circulation.|Neuropeptides in the Humane Intra- og Extracerebral Circulation - in Relation to Sumatriptan in Healthy Volunteers.||Danish Headache Center||Completed|January 2007|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind|||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 13, 2008|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399633||176974|
NCT00399906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM119-013|A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis||Bristol-Myers Squibb|Yes|Completed|August 2007|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|75 Years|No|||November 2015|November 6, 2015|November 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399906||176953|
NCT00400218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-323|Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)(COMPLETED)|Evaluate the Safety and Tolerability of Hyzaar(R) (Losartan 50 Mg/ Hydrochlorothiazide 12.5 Mg) In the Treatment of Hypertension||Merck Sharp & Dohme Corp.||Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|62|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400218||176931|
NCT00399620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3739|Chromogranin-A-Derived Peptides and Periodontitis in Diabetic Patients|Chromogranin-A-Derived Peptides in the Gingival Crevicular Fluid and the Saliva of Diabetic Patients With or Without Periodontitis||University Hospital, Strasbourg, France|No|Recruiting|March 2008|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|90|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2009|January 9, 2009|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399620||176975|
NCT00399893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005426|Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)|Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children and Young Adults With Prader-Willi Syndrome (PWS): Octreotide Intervention Sub-study||Duke University|No|Terminated|December 2006|September 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|5 Years|21 Years|No|||June 2014|June 25, 2014|November 14, 2006|Yes|Yes|Inadequate recruitment|No|January 28, 2013|https://clinicaltrials.gov/show/NCT00399893||176954|
NCT00400985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENSE-HF, V.1, Dec.8, 2004|Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure|Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure|SENSE-HF|Medtronic Bakken Research Center|No|Completed|January 2005|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|501|||Both|18 Years|N/A|No|||April 2010|April 6, 2010|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00400985||176873|
NCT00401245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-405|The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms|The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study||Pfizer|No|Completed|December 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|500|||Female|18 Years|N/A|No|||October 2011|October 24, 2011|November 17, 2006|Yes|Yes||No|September 6, 2011|https://clinicaltrials.gov/show/NCT00401245||176854|
NCT00401518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020-9052|A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis|The Investigational Plan for the Evaluation of the ACADIA® Facet Replacement System||Globus Medical Inc|Yes|Active, not recruiting|October 2006|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|390|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401518||176833|
NCT00401830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0887|Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.|A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/Day Lacosamide Tablets in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome||UCB Pharma|No|Completed|October 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|65 Years|No|||December 2009|September 19, 2014|November 9, 2006|Yes|Yes||No|September 22, 2009|https://clinicaltrials.gov/show/NCT00401830||176809|
NCT00402090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/007/ICI|DHPLC Determination of TPMT Polymorphisms.|Prevention of Thiopurines Related Toxicity Through the Determination by DHPLC TPMT Polymorphisms in Patients With ALL.||National Institute of Cancerología||Recruiting|April 2005|November 2006||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 17, 2006|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00402090||176789|
NCT00402376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3212|Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy|Effects of Combined Ventricular Unloading and Pharmacological Therapy on Left Ventricular Metabolic Dysfunction in Heart Failure||University Hospital, Strasbourg, France||Terminated|April 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402376||176767|
NCT00402337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-201|Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation|A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-group, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation||Ironwood Pharmaceuticals, Inc.|No|Completed|November 2006|February 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|310|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|November 18, 2006|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00402337||176770|
NCT00402350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-003-101|Staccato® Fentanyl Pharmacokinetics in Healthy Volunteers|Safety, Tolerability, and Pharmacokinetics of Staccato® Fentanyl for Inhalation in Normal, Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|April 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|51|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2008|February 3, 2008|November 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00402350||176769|
NCT00402935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU3803|Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer|Effects of Cytotoxic Chemotherapy on Ovarian Structure and Function||Case Comprehensive Cancer Center|Yes|Withdrawn|February 2004|May 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood collection at the same time points for follicle-stimulating hormone, estradiol, and      inhibin B levels.|Female|14 Years|35 Years|No|Non-Probability Sample|premenopausal women undergoing chemotherapy for cancer|March 2012|March 16, 2012|November 21, 2006||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00402935||176724|
NCT00403221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11112|Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer|A Phase I Study of In-Situ, Neoadjuvant, Pre-Radical Prostatectomy RTVP-1 Gene Therapy in Patients With Locally Advanced Adenocarcinoma of the Prostate (SPORE)||Baylor College of Medicine||Completed|August 2006|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||February 2012|February 9, 2012|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403221||176702|
NCT00402896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0929|Malignant Pleural Effusion With ZD6474|Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor||M.D. Anderson Cancer Center|No|Terminated|October 2006|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 20, 2006|Yes|Yes|Slow Accrual|No|September 2, 2015|https://clinicaltrials.gov/show/NCT00402896||176727|
NCT00402909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDJN608AUS13|Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone|A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Compare the Safety and Efficacy of Nateglinide vs. Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Basal Insulin Glargine in Combination With Metformin and/or Thiazolidinedione (Pioglitazone or Rosiglitazone)||Novartis||Completed|November 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|78 Years||||April 2012|April 25, 2012|November 20, 2006||||||https://clinicaltrials.gov/show/NCT00402909||176726|
NCT00403455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-009-05F|Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities|Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities|MTG|VA Office of Research and Development|No|Completed|October 2006|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|November 22, 2006||No||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00403455||176684|
NCT00403481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-449|An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes|A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension||Daiichi Sankyo Inc.||Completed|November 2006|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|18 Years|N/A|No|||November 2009|November 9, 2009|November 22, 2006|Yes|Yes||No|November 21, 2008|https://clinicaltrials.gov/show/NCT00403481||176683|
NCT00399646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|revJ060707|Evaluation of the Metricath Gemini System, a Device Intended to Make Arterial Measurements and Perform Angioplasty Dilations.|Gemini Angioplasty and Arterial Measurement Evaluation (GAAME) An Evaluation of the Metricath Gemini System, a Percutaneous Interventional Device Intended to Make Arterial Lumen Measurements and Perform Percutaneous Transluminal Angioplasty Dilations.|GAAME|Neovasc Inc.|Yes|Completed|November 2005|March 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|145|||Both|N/A|N/A|No|||May 2009|May 11, 2009|November 14, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00399646||176973|
NCT00399932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELASTO1|Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|March 2006|May 2010|Anticipated|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|Samples Without DNA|liver biopsy serum|Both|30 Years|75 Years|No|Probability Sample|patients with type 2 diabetes|September 2009|September 17, 2009|November 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00399932||176951|
NCT00399945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100B2202|Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study|A Phase 1, Single-Dose, Open-Label, Two-Way Crossover, Pharmacoscintigraphy Study of Aerosol Delivery Characteristics (Measured by In Vivo Lung Deposition, Nebulization Time, Serum Tobramycin Concentrations, and Pharmacokinetic Parameters) and Safety of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (No Compressor) vs. PARI LC PLUS (TM) Jet Nebulizer (With Compressor) in Healthy Subjects and in Subjects With Cystic Fibrosis||Novartis||Completed|May 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|May 4, 2007|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399945||176950|
NCT00400205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0414-2006|Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil|Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints||Emory University|Yes|Terminated|August 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||September 2010|March 30, 2011|November 15, 2006|Yes|Yes|Safety reasons|No|December 6, 2010|https://clinicaltrials.gov/show/NCT00400205||176932|
NCT00400504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEG-Onkologi|Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)|Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)||Rigshospitalet, Denmark||Recruiting|November 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||500|||Both|18 Years|N/A|No|||November 2006|November 16, 2006|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00400504||176909|
NCT00400192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1362|Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury|Prospective Study of the Kinetics and Mechanisms of Transfusion-associated Microchimerism in Injured Patients||Blood Systems Research Institute|No|Completed|November 2006|July 2012|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|451|Samples With DNA|Whole blood, plasma, peripheral blood mononuclear cells|Both|12 Years|N/A|No|Probability Sample|Emergency Department|April 2013|April 11, 2013|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400192||176933|
NCT00400478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL-13 (ML18223)|A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-Cell Lymphoma: NHL-13|A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-Cell Lymphoma: NHL-13||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Active, not recruiting|January 2006|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2009|January 19, 2009|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400478||176911|
NCT00400699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-0408108|Radiation Therapy Outreach Program for Minority or Low-Income Patients With Newly Diagnosed Cancer|UPMC McKeesport/ROCOG Radiation Oncology Minorities Outreach Program||University of Pittsburgh||Completed|October 2004|||November 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3150|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400699||176894|
NCT00400998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH3104994|Investigate Two Trial Models; Vienna Challenge Chamber (in and Out of Season) and Park Study (in Season) Using a Drug for Seasonal Allergic Rhinitis|A Randomised, Double Blind, Placebo Controlled, 2-way Crossover, 3 Phase Study, to Investigate the Trial Models, Vienna Challenge Chamber, in and Out of Season, and Park Study in Season and the Clinical Efficacy of Rpt Doses of Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis||GlaxoSmithKline|No|Completed|March 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|50 Years|No|||February 2011|May 31, 2012|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400998||176872|
NCT00401258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001723|An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome|An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder||Mclean Hospital|No|Completed|November 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||August 2010|August 6, 2010|November 16, 2006|No|Yes||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00401258||176853|
NCT00401531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L12|Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants|Immunogenicity Study of a DTaP IPV Hep B PRP T Combined Vaccine in Comparison to Infanrix Hexa™, Both Concomitantly Administered With Prevnar™ at 2, 4, and 6 Months of Age in Thai Infants||Sanofi|Yes|Completed|October 2006|August 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|412|||Both|50 Days|71 Days|Accepts Healthy Volunteers|||February 2014|February 14, 2014|November 16, 2006||No||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00401531||176832|
NCT00401544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060103|Darbepoetin Alfa With or Without Intravenous (IV) Iron|Once Per Cycle Treatment of Anemia With Darbepoetin Alfa With Iron in Subjects With Non Myeloid Malignancies||Amgen||Completed|December 2006|March 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|243|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|November 16, 2006||||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00401544||176831|
NCT00401843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012784|A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade Versus Velcade Alone in Subjects With Relapsed or Refractory Multiple Myeloma||Janssen Research & Development, LLC||Active, not recruiting|November 2006|September 2020|Anticipated|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|307|||Both|18 Years|99 Years|No|||January 2016|January 25, 2016|November 17, 2006|Yes|Yes||No|July 7, 2015|https://clinicaltrials.gov/show/NCT00401843||176808|
NCT00402077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFA203|A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects|A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects||AstraZeneca|No|Completed|November 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|258|||Both|18 Years|65 Years|No|||February 2015|March 5, 2015|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402077||176790|
NCT00402402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0648-AE|Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease|Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation||University Health Network, Toronto||Completed|October 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|300|||Both|18 Years|N/A|No|||November 2006|April 15, 2008|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402402||176765|
NCT00402688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012103|An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis|A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|November 2006|September 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|242|||Male|40 Years|N/A|No|||September 2013|September 2, 2013|November 21, 2006|Yes|Yes||No|March 20, 2009|https://clinicaltrials.gov/show/NCT00402688||176743|
NCT00402662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508000541|A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma|A Phase II Study of Everolimus in Combination With Imatinib in Metastatic Melanoma||Yale University||Terminated|February 2006|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|3|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|November 20, 2006|||unexpected level of toxicity|No||https://clinicaltrials.gov/show/NCT00402662||176745|
NCT00402948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI ASM8 -204|Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, To Evaluate And Compare The Safety, Tolerability And Efficacy Of Two Dosages Of Inhaled TPI ASM8 Administered For 14 Days In Patients With Mild to Moderate Asthma.||Pharmaxis|No|Terminated|February 2007|December 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||November 2012|November 30, 2012|November 21, 2006||No|Lack of substantial enrollment|No||https://clinicaltrials.gov/show/NCT00402948||176723|
NCT00402961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-145|Trial of Acupuncture for Reduction of Post-Colectomy Ileus|A Phase II Randomized Controlled Trial of Acupuncture for Reduction of Post-Colectomy Ileus||Memorial Sloan Kettering Cancer Center||Completed|October 2006|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00402961||176722|
NCT00402974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL14210.000.06|The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children|The VITAKIDS-Study: The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children||UMC Utrecht||Completed|January 2007|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|55|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||June 2008|June 5, 2008|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402974||176721|
NCT00403234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP2003|Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study to Evaluate the Analgesic Efficacy of BTDS on Postoperative Pain During Rehabilitation Following Total Knee Arthroplasty||Purdue Pharma LP||Terminated|November 2006|August 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|10|||Both|18 Years|80 Years|No|||August 2012|August 27, 2012|November 21, 2006|Yes|Yes|due to administrative reasons not related to efficacy or safety.|No|July 28, 2010|https://clinicaltrials.gov/show/NCT00403234||176701|This trial was terminated early due to administrative reasons not related to efficacy or safety. The efficacy data are not presented since the objective of this study was changed prior to study unblinding, identifying it as a safety study.
NCT00403208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA05I20091|Analgesia-Based Sedation During Mechanical Ventilation|Clinical and Economical Impact of an Analgesia-Based, Goal-Directed, Nurse-Driven Sedation Protocol on Patients on Mechanical Ventilation. A Multicenter Study||Pontificia Universidad Catolica de Chile||Recruiting|March 2006|November 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||280|||Both|18 Years|N/A|No|||November 2006|November 24, 2006|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403208||176703|
NCT00403793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06057|Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)|A Phase II -b, Placebo-Controlled Trial Investigating the Efficacy, Safety and Pharmacokinetics of a Subcutaneous Etonogestrel Implant Combined With i.m. Testosterone Undecanoate for Male Contraception||Merck Sharp & Dohme Corp.|No|Completed|October 2003|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|350|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403793||176659|
NCT00403806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 04-005|Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study|Antiemetic and Analgesic Efficacy and Safety of Dexamethasone for Paediatric Adeno-tonsillectomy - A Randomised, Placebo-controlled, Double-blind, Dose-finding Study||University Hospital, Geneva|No|Terminated|February 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|215|||Both|3 Years|16 Years|Accepts Healthy Volunteers|||January 2009|August 13, 2010|November 24, 2006||No|drug-related harm|No||https://clinicaltrials.gov/show/NCT00403806||176658|
NCT00399971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAFocus|Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia|Phase I/II Study of An Ex Vivo Immunotherapy for Treatment of Idiopathic Aplastic Anemia||Shenzhen Zhongxing Yangfan Biotech Co. Ltd.|Yes|Recruiting|November 2002|December 2009|Anticipated|June 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|10 Years|80 Years|No|||November 2008|November 7, 2008|November 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00399971||176949|
NCT00400231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800860|The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study|The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study||University of Pennsylvania||Active, not recruiting|August 2005|November 2008|Anticipated|March 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Anticipated|124|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2008|January 8, 2008|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400231||176930|
NCT00400244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA009|French-Canadian Version of the Wheelchair Skills Program (WSP)|Translation, Validation and Evaluation of the Efficacy of the French-Canadian Version of the Wheelchair Skills Program (WSP)||Nova Scotia Health Authority|No|Completed|January 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A||||January 2009|September 28, 2009|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400244||176929|
NCT00391898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200AES03|Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off|A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa||Novartis||Completed|October 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|30 Years|80 Years|No|||February 2011|February 16, 2011|October 24, 2006||||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00391898||177552|
NCT00392704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI HN 08|Treatment of Head & Neck Cancer With Chemotherapy and Radiation|A Phase II Trial of Neoadjuvant Chemotherapy Plus Bevacizumab Followed By Concurrent Chemotherapy/Bevacizumab/Erlotinib/Radiation Therapy in the Treatment of Locally Advanced Squamous Carcinoma of the Head and Neck||SCRI Development Innovations, LLC|No|Completed|December 2006|May 2012|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|October 25, 2006||No||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00392704||177492|
NCT00400491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT-2006-000177-30|Vitamin D Supplementation to Patients With Type 2 Diabetes|Vitamin D Supplementation to Patients With Type 2 Diabetes||University of Tromso|No|Completed|June 2006|September 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||May 2008|May 22, 2008|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400491||176910|
NCT00400712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS SRA 5974|Client Centred 'Tune-ups': do They Enhance Community Reintegration After Stroke?|Client Centred 'Tune-ups': do They Enhance Community Reintegration and Mobility in Stroke Survivors?||Queen's University|Yes|Active, not recruiting|December 2006|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400712||176893|
NCT00401271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-06-101|Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis|A Phase II Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Four Oral Doses of OPC-67683 in Patients With Uncomplicated, Smear-Positive, Pulmonary Tuberculosis||Otsuka Frankfurt Research Institute GmbH||Completed|November 2006|March 2007||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||54|||Both|18 Years|64 Years|No|||March 2007|March 6, 2007|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401271||176852|
NCT00401284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005|Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Hypnotic Efficacy of EVT 201 in Elderly Patient With Daytime Sleepiness||Evotec Neurosciences GmbH||Completed|November 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|135|||Both|65 Years|N/A|No|||January 2008|January 2, 2008|November 17, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00401284||176851|
NCT00401557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0139|Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection|Intervenable Host - Leishmania (Viannia) Interactions - Project 3: Immune and Inflammatory Responses in L. (Viannia) Infection - Aim 3: Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection||Yale University||Completed|December 2006|April 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|34|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Historical cases of chronic disease:          -  Age between 18-70 years          -  Historic parasitologically confirmed, skin test positive cutaneous leishmaniasis (CL)             patients who presented chronic CL lesions of > 6 months duration at the time of             diagnosis          -  No active lesions        Historical cases of recurrent disease:          -  Age between 18-70 years          -  Historic CL patients who have developed new parasitologically confirmed lesions after             resolution of prior disease          -  No active lesions        Asymptomatic infection:          -  Age between 18-70 years          -  Resident of endemic area          -  No history or evidence of active or prior dermal leishmaniasis        Healthy donors:          -  Age between 18-70 years          -  No history or evidence of exposure to transmission of leishmaniasis|August 2011|August 3, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401557||176830|
NCT00401856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004CD006B|CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone|A Randomised, Double-Blinded, Placebo-Controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy With Eplerenone||Royal Brompton & Harefield NHS Foundation Trust||Recruiting|December 2007|July 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|16 Years|N/A|No|||December 2008|December 10, 2008|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00401856||176807|
NCT00402103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A2301|An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure|A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg / Amlodipine 10 mg in Patients With Essential Hypertension||Novartis||Completed|November 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|556|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|November 18, 2006|Yes|Yes||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00402103||176788|
NCT00402389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH066265|Use of Omega-3 Fatty Acids for Perinatal Depression|Randomized Controlled Trial of Omega-3 Fatty Acids for Perinatal Depression||University of Arizona||Completed|June 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|45 Years|No|||March 2013|March 27, 2013|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402389||176766|
NCT00394784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0608120|Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates|Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates||University of Pittsburgh|Yes|Active, not recruiting|December 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|positive gram negative bacteria isolates|December 2015|December 16, 2015|October 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00394784||177338|
NCT00390481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA8456|Study of Carotid Occlusion and Neurocognition|Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON)||Columbia University|Yes|Completed|November 2004|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|294|||Both|18 Years|85 Years|No|||July 2013|July 29, 2013|October 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390481||177661|
NCT00402675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leipzig-4|Randomized Trial of Immediate Versus Early and Selective Invasive Percutaneous Coronary Intervention in NSTEMI|Leipzig Immediate Versus Early and Late PercutaneouS Coronary Intervention triAl in NSTEMI - LIPSIA-NSTEMI TRIAL|LIPSIA-NSTEMI|University of Leipzig|Yes|Completed|July 2006|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|89 Years|No|||November 2006|January 4, 2010|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402675||176744|
NCT00403247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04T-536|Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia|Double-Blind Vitamin Intervention to Lower Blood Homocysteine Levels: Amino Acid and Clinical Responses in Individuals With Schizophrenia.||Nathan Kline Institute for Psychiatric Research|No|Completed|July 2004|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||August 2007|August 21, 2007|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403247||176700|
NCT00403533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000138/1|Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus|Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus||Massachusetts General Hospital||Completed|February 2006|July 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|30 Years|80 Years|No|||November 2006|November 22, 2006|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00403533||176679|
NCT00403494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD-001|A Phase 2 Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease|A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease||BioMarin Pharmaceutical|Yes|Completed|December 2006|January 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|190|||Both|40 Years|80 Years|No|||September 2014|September 4, 2014|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403494||176682|
NCT00403507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kelly Garrett|Exercise Treatment of Mild-Stage Probable Alzheimer's Disease|Physical Activity as a Treatment of Mild-Stage Probable Alzheimer's Disease||Intermountain Health Care, Inc.|No|Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|79|||Both|65 Years|89 Years|No|||November 2006|May 9, 2011|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00403507||176681|
NCT00403832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2911|Acrylate Intraocular Lenses in Cataract Surgery of Uveitis Patients|Comparison of Two Different Acrylate Intraocular Lenses in Cataract Surgery in Patients With Non-infectious Uveitis||St. Franziskus Hospital||Completed|August 2005|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||August 2009|July 26, 2010|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00403832||176656|
NCT00399659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919N2201E1|Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.|A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain||Novartis||Terminated|November 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|360|||Both|18 Years|N/A||||April 2012|April 30, 2012|November 14, 2006|||This study was terminated early as a result of regulatory action suspending tegaserod use in    2007|||https://clinicaltrials.gov/show/NCT00399659||176972|
NCT00392158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foch-3|Manual Administration of Propofol-Remifentanil Versus Dual Closed-Loop Using Bispectral Index as the Control Variable|Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison Between Manual Perfusion and Automated Perfusion||Hopital Foch||Completed|February 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||April 2007|April 21, 2007|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00392158||177532|
NCT00400725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29060|Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis|Comparison of the Maintenance Effect of Clobex® Shampoo 0.05% Used Twice Weekly vs. Vehicle on Scalp Psoriasis in Subjects Who Successfully Responded to a 4-Week Daily Course of Clobex® Shampoo 0.05%||Galderma||Completed|September 2006|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|288|||Both|18 Years|N/A|No|||May 2008|May 28, 2008|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00400725||176892|
NCT00401011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 218|Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients|An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib||Keryx / AOI Pharmaceuticals, Inc.|No|Completed|August 2006|July 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|November 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401011||176871|
NCT00393588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070014|Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis|The Use of Magnetic Resonance Imaging to Investigate Cortical Damage in Patients With Multiple Sclerosis and Correlation With Cognitive Dysfunction||National Institutes of Health Clinical Center (CC)||Completed|October 2006|September 2011||||N/A|Observational|N/A|||Actual|50|||Both|18 Years|60 Years|No|||September 2011|September 30, 2011|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00393588||177428|
NCT00393861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609-11; IUCRO-0166|Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients|Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors||Indiana University|Yes|Completed|October 2006|November 2014|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|October 26, 2006||No||No|January 21, 2015|https://clinicaltrials.gov/show/NCT00393861||177407|
NCT00393874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR054093|Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)|Efficacy of Adjunct Sleep Interventions for PTSD|EASI-P|University of Pittsburgh|Yes|Completed|October 2006|June 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|55 Years|No|||June 2012|June 15, 2012|October 26, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00393874||177406|
NCT00394147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-HN-003|Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer|Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN)||Fox Chase Cancer Center|Yes|Terminated|October 2006|December 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|October 27, 2006||No|stopped for lack of efficacy|No||https://clinicaltrials.gov/show/NCT00394147||177385|
NCT00394160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-297|Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)|A Randomized, 3-Period, Multiple-Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Plasma Concentration Profile of Montelukast Administered Once Daily as Oral Granules in Children Aged 1 to 3 Months||Merck Sharp & Dohme Corp.||Completed|December 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|12|||Both|1 Month|3 Months|No|||June 2015|June 22, 2015|October 27, 2006||||No||https://clinicaltrials.gov/show/NCT00394160||177384|
NCT00394173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDNK333B2202|Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg b.i.d. Given Orally for 4 Weeks in Female Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)||Novartis||Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|180|||Female|18 Years|65 Years||||October 2008|October 1, 2008|October 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00394173||177383|
NCT00393887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28044|Inguinal Hernia Study Using Biodesign IHM|Inguinal Hernia Study: A Double Blinded Randomized Prospective Study||Cook|No|Completed|March 2007|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 26, 2006|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT00393887||177405|
NCT00394498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135287|Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair|Stem Cell Mobilization by G-CSF by Granulocyte Colony Stimulating Factor Post Myocardial Infarction to Promote Myocyte Repair||University of Ottawa||Recruiting|September 2005|October 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||86|||Both|40 Years|75 Years|No|||October 2006|October 30, 2006|October 30, 2006||||No||https://clinicaltrials.gov/show/NCT00394498||177359|
NCT00403260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-004-06|Pyronaridine Artesunate (3:1) Versus Mefloquine Artesunate in P Falciparum Malaria Patients|A Phase III Comparative, Open-Label, Randomised, Multi-Centre, Clinical Study to Assess the Safety and Efficacy of Fixed Dose Formulation Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Mefloquine (250 mg Tablet) Plus Artesunate (100 mg Tablet) in Children and Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria||Medicines for Malaria Venture||Completed|January 2007|December 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1269|||Both|3 Years|60 Years|No|||January 2009|January 21, 2009|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403260||176699|
NCT00403546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001372|High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms|High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms|HDZ|Massachusetts General Hospital|Yes|Completed|January 2006|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|No|||July 2011|July 5, 2011|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403546||176678|
NCT00403559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CUS37|A 4 Week Study of Elidel for the Treatment of Seborrheic Dermatitis|A 4 Week Randomized Double-Blind Parallel Group Active Comparator Controlled Study of Elidel for the Treatment of Seborrheic Dermatitis||Dermatology Specialists Research||Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|March 31, 2009|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00403559||176677|
NCT00402987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191334|Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat|A Double Blind, Randomized, Placebo-Controlled Comparison of the Efficacy, Safety, and Tolerability of Celecoxib 100-150 mg, Including Initial Doses of 50 and 100 mg, and Placebo in the Symptomatic Treatment of Patients With Painful Pharyngitis||Pfizer|No|Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|269|||Both|18 Years|N/A|No|||June 2009|June 8, 2009|November 21, 2006|No|Yes||No|November 14, 2008|https://clinicaltrials.gov/show/NCT00402987||176720|
NCT00391079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS0501|Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS|A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis||GW Pharmaceuticals Ltd.|No|Completed|September 2006|September 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|339|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|October 20, 2006||No||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00391079||177615|
NCT00391352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSR12006|fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls|A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-β-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.||Waukesha Memorial Hospital|No|Completed|February 2008|August 2012|Actual|August 2012|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|ProHealth Care, Waukesha Memorial Hospital Neuroscience Center|May 2008|June 3, 2014|October 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00391352||177594|
NCT00391677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074650|Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia|Effectiveness Trial of Attention Shaping for Schizophrenia||Rutgers, The State University of New Jersey|Yes|Completed|January 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|55 Years|No|||September 2012|September 27, 2012|October 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00391677||177569|
NCT00403520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-E033-415|Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers|Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders||Eisai Inc.||Completed|November 2006|August 2010|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|50 Years|N/A|No|||July 2014|July 11, 2014|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403520||176680|
NCT00403819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/01|Study to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children|A Phase III Multi-Centre Placebo-Controlled Crossover Study Followed by an Open Label Post-Study Follow-up to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children||Norgine||Completed|April 2002|April 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|24 Months|11 Years|No|||November 2006|November 27, 2006|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00403819||176657|
NCT00391911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHABDO 2006|Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis|A Randomized Factorial Trial of N-Acetylcysteine and Continuous Veno-Venous Hemo(Dia)Filtration for Rhabdomyolysis||Royal Alexandra Hospital|No|Completed|November 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00391911||177551|
NCT00391651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20580-A|Short Course Nitrofurantoin for Acute Cystitis|Short Course Nitrofurantoin For Acute Cystitis||University of Washington|No|Completed|January 2002|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|338|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|October 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00391651||177571|
NCT00391664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-44025|Questionnaire Study for Gynecological Cancer Survivors|Gynecologic Cancer Survivorship Survey||Walter Reed Army Medical Center||Recruiting|February 2006|February 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Female|20 Years|75 Years|No|||June 2008|June 26, 2008|October 23, 2006||||No||https://clinicaltrials.gov/show/NCT00391664||177570|
NCT00401583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG10007|A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes|A Multi-center, Open-Label, Multiple-probe Drug Interaction Study to Determine the Effects of GW786034 on the Metabolism of Cytochrome P450 Probe Drugs in Patients With Solid Tumors||GlaxoSmithKline|No|Completed|July 2006|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|21 Years|N/A|No|||April 2011|April 21, 2011|November 17, 2006||||||https://clinicaltrials.gov/show/NCT00401583||176828|
NCT00401596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q2143g|A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)|A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO)||Genentech, Inc.||Completed|July 2000|July 2002|Actual|||Phase 3|Interventional|Primary Purpose: Treatment||||1899|||Both|6 Years|75 Years|No|||March 2014|March 18, 2014|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401596||176827|
NCT00392418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000005427|Flexible Administration of Sprinkles® in Infants and Young Children in Rural Bangladesh.|The Effectiveness of Flexible Administration of Sprinkles® in a Mixed Population of Anemic and Non-anemic Infants and Young Children in Rural Bangladesh.||The Hospital for Sick Children||Completed|May 2004|March 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||360|||Both|6 Months|24 Months|No|||January 2008|March 11, 2010|October 24, 2006||||No||https://clinicaltrials.gov/show/NCT00392418||177512|
NCT00392951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-7-4873|Sirolimus for Autoimmune Disease of Blood Cells|Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series||Children's Hospital of Philadelphia|No|Recruiting|December 2006|October 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|30 Years|No|||October 2015|October 20, 2015|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00392951||177473|
NCT00393224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905187|Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families|Defining Markers of Susceptibility to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families||National Institutes of Health Clinical Center (CC)||Completed|June 2005|||||N/A|Observational|N/A|||Anticipated|2400|||Both|21 Years|N/A|No|||August 2015|September 16, 2015|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393224||177455|
NCT00393575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 040|C2P Mobilization Intervention (Pilot)|Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|January 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2011|September 5, 2011|December 28, 2005||No||No||https://clinicaltrials.gov/show/NCT00393575||177429|
NCT00393250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070011|Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease|Hypnosis as a Pain and Symptom Management Strategy in Patients With Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2006|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||March 2015|April 4, 2015|October 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00393250||177454|
NCT00393263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C US40|Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus|A Double-Blind, Parallel-group Trial of Topical Pimecrolimus Cream 1% (Elidel®) Versus Clobetasol 0.05% Cream for the Treatment of Vulvar Lichen Sclerosus||Center for Vulvovaginal Disorders||Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 8, 2014|October 25, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00393263||177453|
NCT00393601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4596|Chart Review of Laparoscopic Radical Cystectomy|Retrospective Chart Review of Laparoscopic Radical Cystectomy||University of California, Irvine|No|Completed|December 2005|October 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Those who have undergone a laparoscopic radical cystectomy performed by Dr. David        Ornstein.|January 2010|January 4, 2010|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00393601||177427|
NCT00393614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S06080|Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA)|Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) - a Placebo Controlled Double-blind Cross-over-study||Oslo University Hospital||Active, not recruiting|May 2007|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|5 Years|10 Years|No|||February 2008|September 22, 2009|October 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00393614||177426|
NCT00394186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3I105940|A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)|A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the Beta-3-Adrenergic Receptor Agonist Solabegron in Subjects With Irritable Bowel Syndrome||GlaxoSmithKline||Completed|August 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|65 Years|No|||May 2009|May 15, 2009|October 27, 2006||||No||https://clinicaltrials.gov/show/NCT00394186||177382|
NCT00394199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-3-002|Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma|A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent & Adult Patients With Mild to Moderate Asthma||SkyePharma AG||Completed|June 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|357|||Both|12 Years|N/A|No|||June 2011|June 8, 2011|October 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00394199||177381|
NCT00403273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-singh|Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Joint|Botulinum Toxin A for Painful Prosthetic Knee: Randomized, Controlled, Triple-blind Study||Minneapolis Veterans Affairs Medical Center|No|Completed|July 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|No|||April 2009|August 16, 2011|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403273||176698|
NCT00394511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02483|Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer|Phase III Randomized Evaluation of Adjuvant Radiotherapy vs No Adjuvant Therapy Following Radical Prostatectomy and Pelvic Lymphadenectomy in Surgical Stage C Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Completed|August 1988|||December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|408|||Male|18 Years|N/A||||October 2006|February 8, 2013|October 31, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00394511||177358|
NCT00394797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMR001|Surgical Correction of Moderate Ischemic Mitral Regurgitation|||Shaare Zedek Medical Center||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|18 Years|N/A||Probability Sample|Patients undergoing coronary bypass surgery who have moderate degree of ischemic MR|May 2011|May 31, 2011|October 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00394797||177337|
NCT00394810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CLN-006|Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer|Phase 2 Efficacy and Pharmacodynamic Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion(Panzem® NCD) in Patients With Taxane-Refractory, Metastatic,Hormone-Refractory Prostate Cancer||CASI Pharmaceuticals, Inc.||Completed|November 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||November 2008|November 24, 2008|October 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00394810||177336|
NCT00403871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-05|Anaesthetic Management of Women With Heart Disease For Labor and Delivery|Anaesthetic Management of Women With Heart Disease For Labor and Delivery||Samuel Lunenfeld Research Institute, Mount Sinai Hospital||Completed|November 2002|June 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||700|||Female|N/A|N/A|No|||February 2007|February 28, 2007|November 23, 2006||||No||https://clinicaltrials.gov/show/NCT00403871||176653|
NCT00399698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998H0298|Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.|Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children||Ohio State University||Completed|May 1999|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||30|||Both|4 Years|14 Years|No|||March 2006|November 13, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399698||176969|
NCT00390767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGVS-MGA 001|Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)|A Phase I Safety, Dose Escalating Study of MultiGeneAngio in Patients With Peripheral Arterial Disease||MultiGene Vascular Systems Ltd.|Yes|Active, not recruiting|October 2006|December 2024|Anticipated|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|50 Years|80 Years|No|||March 2015|March 4, 2015|October 19, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390767||177639|
NCT00400023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1108|A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors|A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of the Dihydropyrimidine Dehydrogenase (Dpd) Inhibitory Action of 5-Chloro-2,4-Dihydroxypyridine (Cdhp) as an S-1 Component||Taiho Oncology, Inc.||Completed|September 2006|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|November 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400023||176945|
NCT00400036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-64443|Dietary Fish Protein in Subjects With Insulin Resistance|Assessment of Insulin Sensitivity in Insulin-Resistant Subjects Fed Fish Protein||Laval University||Completed|February 2004|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention||||24|||Both|35 Years|65 Years|No|||November 2006|November 14, 2006|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00400036||176944|
NCT00403845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B1202|Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, 4-period 4-treatment Crossover, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of 3 Doses of Indacaterol (150, 300, and 600 µg) Delivered Via a Single Dose Dry Powder Inhaler in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)||Novartis|No|Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|50|||Both|40 Years|75 Years|No|||July 2011|July 22, 2011|November 24, 2006||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00403845||176655|
NCT00391690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446GDE22|Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer|Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer||Novartis||Completed|February 2006|||December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Male|18 Years|N/A|No|||April 2015|April 13, 2015|October 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00391690||177568|
NCT00400517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-4643|GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer|Phase II Trial of Neoadjuvant GM-CSF + Thalidomide in High-Risk Patients With Prostate Cancer Undergoing Prostatectomy||The Cleveland Clinic||Completed|March 2003|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|29|||Male|N/A|N/A|No|||January 2007|May 13, 2011|November 16, 2006||Yes||||https://clinicaltrials.gov/show/NCT00400517||176908|
NCT00392171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04601|The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601AM1)(COMPLETED)|The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma||Schering-Plough||Completed|June 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|19 Years|70 Years|No|||June 2010|June 3, 2010|October 24, 2006||Yes||No|April 21, 2010|https://clinicaltrials.gov/show/NCT00392171||177531|
NCT00392184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|German-Austrian APBI Trial|Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery|Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery||University of Erlangen-Nürnberg Medical School|No|Completed|November 2000|October 2010|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|274|||Female|35 Years|80 Years|No|||May 2015|May 29, 2015|October 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00392184||177530|
NCT00392197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-05-002-C|Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-|Post Marketing Clinical Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism-||Otsuka Pharmaceutical Co., Ltd.||Completed|November 2006|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|16 Years|N/A|No|||December 2013|December 19, 2013|October 24, 2006|No|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00392197||177529|
NCT00401882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-008|Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial|Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial|Shock n Block|William Beaumont Hospitals||Terminated|January 2007|March 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|November 17, 2006|Yes|Yes|Difficult accrual|No||https://clinicaltrials.gov/show/NCT00401882||176805|
NCT00402129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP#S-05-121|Low Fluence 1064nm Laser Hair Reduction for Pseudofolliculitis Barbae in Skin Types IV, V, VI|Clinical Safety and Efficacy of Prototype Devices for Hair Growth Control: Task 2.4||United States Naval Medical Center, San Diego||Completed|January 2006|May 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 20, 2006|November 20, 2006||||No||https://clinicaltrials.gov/show/NCT00402129||176786|
NCT00392717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-576|Regulation of Lipoprotein Metabolism in Obese Men|Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity||The University of Western Australia||Completed|February 1998|March 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Male|20 Years|70 Years|Accepts Healthy Volunteers|||October 2006|October 25, 2006|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392717||177491|
NCT00392964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSA2438CTIL|Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine|Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine||Rambam Health Care Campus|No|Completed|January 2006|November 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||1200|||Both|18 Years|N/A|No|||April 2007|April 10, 2007|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00392964||177472|
NCT00392977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES013730|Brain Manganese Deposition in High Risk Neonates|Brain Manganese Deposition in High Risk Neonates||Vanderbilt University|Yes|Completed|August 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|43|Samples Without DNA|Blood|Both|N/A|12 Months|No|Non-Probability Sample|Neonates in the NICU on prolonged PN|December 2013|December 17, 2013|October 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00392977||177471|
NCT00402714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508000433|A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies|A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies||Yale University|No|Completed|July 2006|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||January 2015|January 28, 2015|November 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00402714||176741|
NCT00402727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11974|Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection|A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections||Bayer|No|Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|813|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|November 21, 2006||No||No|October 13, 2009|https://clinicaltrials.gov/show/NCT00402727||176740|Ten patients (six from the moxifloxacin group and 4 from the comparator group) did not receive study medication. They were excluded from the safety analyses. No adverse events were reported in these patients.
NCT00403026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN-002/2006|Intravitreal Bevacizumab for Retinal Disorders|Off-Label,Intravitreal Use of Bevacizumab for Retinal Disorders||Narayana Nethralaya||Recruiting|August 2006|November 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||November 2006|November 22, 2006|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403026||176717|
NCT00403039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3851S|Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema|Phase I Study of Intravitreally Administered Ranibizumab in 20 Subjects With Macular Edema Associated With CRVO.||Vitreous -Retina- Macula Consultants of New York||Completed|November 2006|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|November 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00403039||176716|
NCT00403286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-076|A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Safety and Efficacy of Fluticasone Propionate Combined With Formoterol Fumarate in Patients With Chronic Obstructive Pulmonary Disease||Dey||Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|457|||Both|40 Years|N/A|No|||June 2009|June 26, 2009|November 21, 2006||Yes||||https://clinicaltrials.gov/show/NCT00403286||176697|
NCT00403572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ElangeTCD-2006|A Study of Cerebral-circulatory Response to Intravenous Antihypertensive Treatment in Women With Serious Preeclampsia|A Study of Cerebral-circulatory Response to Intravenous Antihypertensive Treatment in Women With Serious Preeclampsia||Oslo University Hospital||Recruiting|November 2006|May 2009|Anticipated|January 2009|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant women with moderate-to-severe pre-eclapmsia|September 2009|September 15, 2009|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403572||176676|
NCT00403585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF108005|Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814|A Phase IV, Open Label, Single Arm, Multicenter, Extension Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814||GlaxoSmithKline|No|Completed|July 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Both|18 Years|N/A|No|||November 2010|November 24, 2010|November 23, 2006||No||No|April 24, 2009|https://clinicaltrials.gov/show/NCT00403585||176675|
NCT00403598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4372-IV-CTIL|Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders|||Sheba Medical Center||Not yet recruiting||||||N/A|Observational|Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|No|||November 2006|November 23, 2006|November 23, 2006||||No||https://clinicaltrials.gov/show/NCT00403598||176674|
NCT00403611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A20764|Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil|Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil||Oswaldo Cruz Foundation|No|Completed|March 2006|May 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|10 Years|19 Years|No|||June 2015|June 16, 2015|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403611||176673|
NCT00399477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/PM101|A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease|Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)||Teva Pharmaceutical Industries|No|Completed|October 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|30 Years|N/A|No|||April 2011|April 8, 2011|November 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399477||176986|
NCT00399490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091009|Open-label Extension Study Of RN624|Open-Label, Multiple-Dose Study Of The Safety And Efficacy Of RN624 In Adults With Pain Due To Osteoarthritis Of The Knee||Pfizer|No|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|281|||Both|40 Years|75 Years|No|||October 2009|October 8, 2013|November 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399490||176985|
NCT00403858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/05 (Part I)|Movicol in Childhood Constipation (ProMotion Study)|A Single Centre Study to Assess the Safety and Efficacy of Movicol in the Treatment of Faecal Impaction in Children Followed by a Double Blind, Randomised Phase to Compare the Safety and Efficacy of Movicol and Lactulose for Maintenance Therapy||Norgine||Completed|October 2000|April 2002||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|2 Years|11 Years|No|||January 2007|January 3, 2007|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00403858||176654|
NCT00399672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-0192|Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)|Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)||University of British Columbia|No|Active, not recruiting|June 2007|December 2012|Anticipated|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|370|||Both|19 Years|N/A|No|||July 2012|July 9, 2012|November 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00399672||176971|
NCT00399685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI266-145|Drug Interaction - Oral Contraceptive|Study to Evaluate the Effect of Efavirenz Coadministration on the Pharmacokinetics of the Active Moieties of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects||Bristol-Myers Squibb||Completed|December 2006|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2011|April 13, 2011|November 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00399685||176970|
NCT00399984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437|Evaluating a Pediatric Asthma Management Education Program for Physicians|Enhancing Pediatric Asthma Management||University of California, San Francisco||Completed|April 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 11, 2013|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399984||176948|
NCT00400764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APO3585g|A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas|A Phase Ib/II, Open-Label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Dulanermin Administered Intravenously in Combination With Rituximab to Subjects With Follicular and Other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas That Have Progressed Following Previous Rituximab Therapy||Genentech, Inc.||Terminated|June 2006|||May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|72|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|November 15, 2006|Yes|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00400764||176889|The Sponsor terminated the study on 5 May 2010, prior to the completion of the 36-month follow-up (FU) period, based on the primary analysis results. All patients were off-study or in survival FU (the treatment period was completed).
NCT00400777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVEA489ABR01|Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension|An Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy of the Combination of Valsartan and Hydrochlorothiazide and Amlodipine in Hypertensive Patients Not Controlled With Valsartan and Hydrochlorothiazide||Novartis||Completed|August 2006|June 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|460|||Both|18 Years|N/A|No|||June 2008|June 17, 2008|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400777||176888|
NCT00400790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608121|Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane|A Randomised Controlled Study of Organ Protection Comparing Desflurane and Propofol in Adult Patients Undergoing Coronary Artery Surgery With Cardiopulmonary Bypass||University of Melbourne|No|Completed|September 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|182|||Both|18 Years|N/A|No|||January 2010|June 28, 2010|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400790||176887|
NCT00400751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA013121|Family Consultation for Health-Compromised Smokers|Phase 1 Study of Family Consultation for Change-Resistant Smokers||University of Arizona||Completed|September 1999|May 2003||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|30 Years|N/A|No|||September 1999|November 16, 2006|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400751||176890|
NCT00401323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6051|Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma|A Randomized Phase II-III Multicenter Trial of Docetaxel Plus Cisplatin and Docetaxel Plus 5-FU Versus Cisplatin Plus 5-FU in 1st Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.||Sanofi||Completed|January 1998|June 2003|Actual|June 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|568|||Both|18 Years|75 Years|No|||January 2011|January 19, 2011|November 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00401323||176848|
NCT00401050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-15-06|Comparison Study of Two Chiropractic Treatment Protocols for Knee Pain Due to Patellofemoral Pain Syndrome|A Randomized Clinical Trial Comparing Two Chiropractic Protocols for Patellofemoral Pain Syndrome: a Pilot Study||Cleveland Chiropractic College|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|45 Years|No|||April 2010|April 16, 2010|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401050||176869|
NCT00401336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2006/0197|Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging|Quantification of Liver Iron Overload and Steatosis Using a New Magnetic Resonance Imaging Multiecho Gradient-echo Sequence|SURFER|Rennes University Hospital|No|Completed|November 2006|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||July 2012|March 7, 2013|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401336||176847|
NCT00402142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCV-02/MANON07|Dendritic Cell Vaccine in HIV-1 Infection|Phase II Study of Autologous Myeloid Dendritic Cells as a "Cellular Adjuvant" for a Therapeutic HIV-1 Vaccine in Early Stage HIV-1+ Patients (DCV-2).||Hospital Clinic of Barcelona|Yes|Completed|November 2006|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00402142||176785|
NCT00402441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003F/4001|Risedronate in the Prevention of Osteoporosis in Postmenopausal Women|A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women||Sanofi||Completed|September 2002|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|260|||Female|45 Years|N/A|No|||April 2009|April 28, 2009|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402441||176762|
NCT00402454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAEI 94/0071B|Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis|Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis||Sociedad Andaluza de Enfermedades Infecciosas||Completed|January 1994|December 1998||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|18 Years|65 Years|No|||November 2006|January 9, 2007|November 18, 2006||||No||https://clinicaltrials.gov/show/NCT00402454||176761|
NCT00402740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|640-0071|Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)|Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)|PROTECT|Abbott Vascular|Yes|Completed|November 2006|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|322|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|November 20, 2006|Yes|Yes||No|May 7, 2012|https://clinicaltrials.gov/show/NCT00402740||176739|
NCT00402753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-519|Ambulatory Physical Exercise Program in Hematopoietic Stem Cell Transplantation Recipients|Physical Exercise to Improve Physical Performance and Health Related Quality of Life in Hematopoietic Stem Cell Transplantation Recipients||University of Zurich|Yes|Completed|January 2005|December 2009|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|70 Years|No|||January 2010|January 6, 2010|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402753||176738|
NCT00403052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-ONC-01|A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer|Phase 1 Study of the Combination of 1018 ISS, Irinotecan and Cetuximab in Patients With Metastatic Colorectal Cancer Previously Treated With a Fluoropyrimidine, Oxaliplatin or Irinotecan With or Without Bevacizumab||Dynavax Technologies Corporation|Yes|Terminated|November 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|February 26, 2016|November 21, 2006|No|Yes|Administrative reasons|No||https://clinicaltrials.gov/show/NCT00403052||176715|
NCT00403299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05203|MDCT of the Coronary Arteries in Heart Transplanted Patients|Multidetector Computer Tomography of the Coronary Arteries in Heart Transplanted Patients||Oslo University Hospital||Completed|March 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|50|||Both|18 Years|N/A|No|||April 2008|July 3, 2011|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403299||176696|
NCT00400062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The MIND ICU Study|MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care|MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care||Vanderbilt University|No|Active, not recruiting|July 2007|December 2016|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|blood|Both|18 Years|N/A|No|Probability Sample|Medical and Surgical ICUs|November 2015|November 4, 2015|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400062||176943|
NCT00400296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP18378|A Study of R547 in Patients With Advanced Solid Tumors.|A Multiple Ascending Dose (MAD) Study of R547 Administered as an Intravenous Infusion on a Weekly Schedule in Patients With Advanced Solid Tumors||Hoffmann-La Roche||Completed|May 2005|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400296||176925|
NCT00399997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-04-0084 JBS|Evaluation of Effect of Exercise on Prescription|Effect of Exercise on Prescription on Physical Activity, Physical Fitness, and Health in Patients With Lifestyle Diseases||University of Southern Denmark||Active, not recruiting|January 2005|August 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||November 2006|December 20, 2006|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00399997||176947|
NCT00400010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EB0421-1|Alcohol Expert System Intervention for Problematic Alcohol Use|Randomized Controlled Trial of a Expert System for Patients With At-risk Drinking, Alcohol Abuse and Alcohol Dependence in General Hospital||University of Luebeck|No|Completed|October 2004|November 2006|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|347|||Both|18 Years|64 Years|No|||April 2014|April 1, 2014|November 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00400010||176946|
NCT00400556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/24|ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells|A Phase I Study of Haematopoietic Stem Cell Mobilization Using G-CSF With ATRA in Patients With Cutaneous Lymphoma and Multiple Myeloma||Peter MacCallum Cancer Centre, Australia||Completed|March 2005|May 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|70 Years|No|||November 2006|November 15, 2006|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400556||176905|
NCT00400569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14902|Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma|Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|November 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|November 15, 2006||No||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00400569||176904|The trial was amended to exclude fibrosarcoma after only one patient was accrued while the other cohorts had completed 75% or more of their planned accrual. Only patients with liposarcoma, leiomyosarcoma, or MFH were enrolled after this amendment.
NCT00400530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_050|Upper GI Handling of Branded vs. Generic Alendronate|A Randomized, Single-Blind Study to Evaluate Upper Gastrointestinal Handling of Branded Versus Generic Alendronate Tablets||Merck Sharp & Dohme Corp.||Completed|December 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||25|||Female|55 Years|75 Years|No|||November 2006|November 16, 2006|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00400530||176907|
NCT00400543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 2431/04/051|Early Signs of Atherosclerosis in Obstructive Sleep Apnea: Effects of Treatment|Effects of Continuous Positive Airway Pressure (CPAP) on Early Signs of Atherosclerosis in Patients With Obstructive Sleep Apnea: a Randomized Study||University of Sao Paulo||Completed|January 2004|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||24|||Male|30 Years|60 Years|No|||November 2006|November 16, 2006|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00400543||176906|
NCT00401349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0009|Expression of Mif Alleles in Individuals With Leishmaniasis|Immune and Inflammatory Responses in L. (Viannia) Infection Aim 2: Expression of Mif Alleles in Individuals With Recurrent Leishmaniasis, Chronic Leishmaniasis and Asymptomatic Infection||Yale University|Yes|Completed|December 2006|April 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|438|Samples With DNA|DNA samples from bucal swabs are being retained for genetic analyses of MIF alleles and      possibly other genes associated with disease (leishmaniasis) resistance/susceptibility.|Both|7 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Active or historical cases of recurrent cutaneous leishmaniasis          2. Active or historical cases of chronic or recurrent cutaneous leishmaniasis          3. Endemic area controls - Resident of endemic area with no history or evidence of             active or prior dermal leishmaniasis          4. Healthy donors (non-exposed to leishmaniasis)|August 2011|August 3, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401349||176846|
NCT00401622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1039797|Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes|||LifeScan|No|Completed|October 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|320|||Both|18 Years|N/A|No|||August 2010|August 20, 2010|November 16, 2006|Yes|Yes||No|May 29, 2010|https://clinicaltrials.gov/show/NCT00401622||176825|
NCT00401635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|END-1|END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin|Phase II Multicentered Study of First-Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With the Combination of Carboplatin and Liposomal Doxorubicin||National Cancer Institute, Naples||Completed|November 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Female|18 Years|75 Years|No|||September 2007|September 4, 2007|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401635||176824|
NCT00401908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-09-VA02|Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding|Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding||Maimonides Medical Center||Withdrawn|November 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|General population.|September 2015|September 25, 2015|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401908||176803|
NCT00402181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012631|An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma|A Phase 2 Multicenter Study of CNTO 328 (Anti IL-6 Monoclonal Antibody) in Subjects With Relapsed or Refractory Multiple Myeloma||Centocor, Inc.|Yes|Completed|October 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|November 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00402181||176782|
NCT00402467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10945|An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study|||Bayer|Yes|Completed|February 2004|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|6||Actual|613|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402467||176760|
NCT00402480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4744|Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity|Effects of Hydroxyurea on the Prevention of Primary Stroke in Children With Sickle Cell Anemia and Elevated Transcranial Doppler (TCD) Flow Velocity||Duke University||Completed|April 2003|March 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|3 Years|18 Years|No|||November 2006|June 17, 2013|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402480||176759|
NCT00401609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-Step|G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients|Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer|G-Step|National Cancer Institute, Naples||Completed|November 2000|February 2009|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||85|||Both|70 Years|N/A|No|||January 2016|January 13, 2016|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401609||176826|
NCT00401895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMTIPSRCT|Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents|Clinical Efficacy of Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents in Cirrhotic Patients: A Randomized Controlled Study||University of Roma La Sapienza||Terminated|January 2006|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|75 Years|No|||January 2009|January 8, 2009|November 17, 2006||No|An interim analysis revealed a significantly higher persistence/recurrence of complications of    portal hypertension in the 8 mm-stent group.|No||https://clinicaltrials.gov/show/NCT00401895||176804|
NCT00403312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381|Increasing Physical Activity as Part of a Smoking Cessation Program|Increasing Physical Activity to Aid Smoking Cessation||National Heart, Lung, and Blood Institute (NHLBI)||Completed|January 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|June 30, 2008|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403312||176695|
NCT00403624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8128|Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer|Clinical Study to Evaluate a Protocol of Oxaliplatin -UFT- Radiotherapy for the Neoadjuvant Treatment Rectal Cancer||Sanofi||Completed|July 2001|November 2005|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Both|18 Years|75 Years|No|||April 2008|August 26, 2010|November 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00403624||176672|
NCT00403637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149A2228|Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Active (Formoterol 12 µg b.i.d) and Placebo Controlled, Multi-center, 5 Period Crossover Study to Assess the Bronchodilatory Efficacy and Safety of Single Doses of Indacaterol 150 µg, 300 µg and 600 µg Delivered Via Single Dose Dry Powder Inhaler (SDDPI) vs. Placebo in Patients With Persistent Asthma||Novartis||Completed|November 2006|February 2007||February 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Both|12 Years|75 Years|No|||October 2011|October 24, 2011|November 6, 2006||||No||https://clinicaltrials.gov/show/NCT00403637||176671|
NCT00399503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 73-1518|Assessment of Noninvasive Methods to Identify Patients at Risk of Serious Arrhythmias After a Heart Attack|Risk Estimation Following Infarction Noninvasive Evaluation (REFINE)||University of Calgary||Completed|September 2001|October 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||350|||Both|18 Years|N/A|No|||November 2006|November 13, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399503||176984|
NCT00399737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU167|Effects of Peptides Derived From Fermented Milk on Blood Pressure Regulation System in Healthy Volunteers.|||Assistance Publique - Hôpitaux de Paris||Terminated|October 2005|November 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2006|November 14, 2006|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399737||176966|
NCT00399750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8851|TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer|A Randomized Prospective Study Comparing Three Regimens of Oxaliplatin Plus Fluoropyrimidine and Avastin for Evaluation of Safety and Tolerability in First-line Treatment of Patients With Advanced Colorectal Cancer.||Sanofi||Completed|November 2002|June 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||373|||Both|18 Years|N/A|No|||October 2009|October 14, 2009|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00399750||176965|
NCT00399516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0706|Effect of Pulse Width With Spinal Cord Stimulation|The Effect of Pulse Width on the Treatment of Chronic Low Back Pain With Spinal Cord Stimulation||Boston Scientific Corporation|No|Completed|November 2006|November 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|November 13, 2006||No||No|February 13, 2012|https://clinicaltrials.gov/show/NCT00399516||176983|
NCT00399763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0563|Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder|A Randomized, Placebo-controlled Trial of Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder (SUD)||Denver Health and Hospital Authority|No|Completed|September 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|12 Years|19 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|November 13, 2006|Yes|Yes||No|August 3, 2012|https://clinicaltrials.gov/show/NCT00399763||176964|The study was not powered to assess safety.Participants received individual motivational interviewing/cognitive behavioral therapy for substance treatment. The results may not generalize to samples receiving different behavioral treatment.
NCT00400075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95.067/2|CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors|CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients||Hospices Civils de Lyon||Active, not recruiting|July 1996|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||124|||Both|15 Years|90 Years|No|||November 2006|November 15, 2006|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00400075||176942|
NCT00399711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN4440-1794|Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes|Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and Safety||Novo Nordisk A/S|No|Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|560|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399711||176968|
NCT00399724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_3504|A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus|A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus.|AT-LANTUS|Sanofi||Completed|March 2002|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||7376|||Both|18 Years|N/A|No|||August 2010|August 30, 2010|November 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00399724||176967|
NCT00400582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHI 06-890|A Pharmacogenomic Study of Candesartan in Heart Failure|Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms||Montreal Heart Institute|No|Completed|November 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|November 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400582||176903|
NCT00400257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-04/06|Screening Evaluation of the Evolution of New Heart Failure (SCREEN-HF)|SCREEN-HF (Screening Evaluation of the Evolution of New Heart Failure)||The Alfred|No|Active, not recruiting|May 2007|December 2015|Anticipated|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|Samples Without DNA|Blood samples|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People at high risk of heart failure.|January 2015|January 20, 2015|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400257||176928|
NCT00400270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC03660|Breathing and Relaxation Exercises for Asthma: a Randomised Controlled Trial|A Physical Therapy Treatment for Adults Diagnosed With Asthma in Primary Care: a Randomised Controlled Trial||University College London Hospitals||Completed|October 2004|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||56|||Both|16 Years|70 Years|No|||November 2006|May 27, 2015|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400270||176927|
NCT00401063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCU-06-VINJ001|Usefulness of Acupuncture in Cancer Pain and Quality of Life|Acupuncture Case Series: Cancer Pain and Quality of Life||Southern California University of Health Sciences|No|Completed|September 2006|October 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00401063||176868|
NCT00401076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.3.123|A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency|A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy||Abbott|No|Completed|July 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|20 Years|N/A|No|||July 2011|July 28, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401076||176867|
NCT00401362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 301|A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients|A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness||Valeant Pharmaceuticals International, Inc.|Yes|Completed|February 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|November 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401362||176845|
NCT00401375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 3301|Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI).|A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)||Valeant Pharmaceuticals International, Inc.||Completed|October 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|515|||Both|18 Years|N/A|No|||July 2011|July 17, 2011|November 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401375||176844|
NCT00401648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01069|Effect of Brivaracetam in Photosensitive Epileptic Subjects|A Placebo-controlled, Single-blind, Multi-center Study to Explore the Photoparoxysmal Response in Photosensitive Epileptic Subjects After One Single Oral Dose of Brivaracetam in Capsules.||UCB Pharma||Completed|September 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||November 2009|November 30, 2009|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401648||176823|
NCT00401661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFUS_L_01241|Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin|Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study.|SAMBA-Thailand|Sanofi||Completed|June 2006|||December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Male|50 Years|N/A|No|||September 2009|September 14, 2009|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401661||176822|
NCT00401921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001225|A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy|A Randomized, Placebo-Controlled Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy||Brigham and Women's Hospital|Yes|Terminated|October 2006|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|4|||Both|18 Years|90 Years|No|||June 2011|June 22, 2011|November 17, 2006||No|PI moved to a new facility|No||https://clinicaltrials.gov/show/NCT00401921||176802|
NCT00402194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU-IRB-0301-08|Treating the Endothelium to Restore Insulin Sensitivity|Treating the Endothelium to Restore Insulin Sensitivity||Indiana University|Yes|Completed|June 2005|March 2012|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 20, 2013|November 20, 2006|Yes|Yes||No|May 6, 2013|https://clinicaltrials.gov/show/NCT00402194||176781|
NCT00402766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0288|Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma|Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma||M.D. Anderson Cancer Center|No|Completed|August 2006|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00402766||176737|
NCT00412529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2407|Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B|A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Adults With HBeAg-positive, Compensated Chronic Hepatitis B (CHB)||Novartis||Completed|December 2006|||February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||February 2015|February 23, 2015|December 15, 2006|Yes|Yes||No|December 2, 2010|https://clinicaltrials.gov/show/NCT00412529||176007|
NCT00403078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-3603|SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy|Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy (SAPPHIRE Worldwide)||Cordis Corporation|Yes|Recruiting|October 2006|November 2014|Anticipated|July 2014|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|21000|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will consist of high-surgical risk patients with atherosclerotic disease        of the carotid artery(ies) from up to 350 clinical sites in the US and Canada.|February 2014|February 7, 2014|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00403078||176713|
NCT00403091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X050111012|Internet Intervention to Improve Rural Diabetes Care|Internet Intervention to Improve Rural Diabetes Care||University of Alabama at Birmingham|No|Completed|April 2005|April 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|205|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2010|August 10, 2010|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00403091||176712|
NCT00403325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3850S|Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy|Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.||Vitreous -Retina- Macula Consultants of New York||Completed|August 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|October 31, 2008|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403325||176694|
NCT00403338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03-6323|The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)|Prospective Evaluation of the Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent, The e-CYPHER(SM)S.T.L.L.R., Registry [Study of Deployment Technique on Clinical Results]||Cordis Corporation|No|Completed|December 2004|April 2006|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients needing an intervention and receiving a CYPHER stent.|October 2009|October 5, 2009|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403338||176693|
NCT00403650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sarcoid 6|Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension|Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension||University of Cincinnati|No|Completed|November 2006|September 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|90 Years|No|||April 2013|April 10, 2013|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403650||176670|
NCT00399529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J05118|Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer|A Feasibility Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for HER-2/Neu-Overexpressing Metastatic Breast Cancer.||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|September 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|November 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399529||176982|
NCT00399802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-016|A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)|A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women With Breast Cancer and Established Bone Metastases (MBD)||Merck Sharp & Dohme Corp.||Completed|November 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|45|||Female|18 Years|N/A|No|||February 2015|February 12, 2015|November 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399802||176961|
NCT00399776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-14216|Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy|Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy||Creighton University|No|Completed|October 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|60|||Both|10 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from within the clinic as well as community psychiatrists|August 2011|August 3, 2011|November 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399776||176963|
NCT00399789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 201|A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer|A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer||AEterna Zentaris|No|Completed|September 2004|December 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A|No|||February 2012|February 11, 2014|November 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00399789||176962|
NCT00400088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA012|Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide|A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study||Nova Scotia Health Authority|No|Terminated|June 2007|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|November 15, 2006||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00400088||176941|
NCT00400309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F06-Td5I-301|Safety of REPEVAX® Given One Month After REVAXIS®|A Double Blind, Controlled, Randomised, Clinical Study to Assess the Safety of Repevax® Administered One Month After Revaxis® or Placebo to Healthy Adults||Sanofi Pasteur MSD||Completed|June 2006|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2009|April 3, 2009|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400309||176924|
NCT00400595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0850-AE|Use of Ointments in Prevention of Catheter Related Infections in PD|A Randomized Controlled Double Blind Study Using Mupirocin Versus Polysporin Triple for the Prevention of Catheter-related Infections in Patients Treated With Peritoneal Dialysis||University Health Network, Toronto|Yes|Completed|February 2006|June 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400595||176902|
NCT00400283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN414-1384|A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Multiple Oral Dose, Dose Escalation Trial, Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 55-0414 in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|January 2001|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|23|||Both|40 Years|74 Years|No|||September 2011|June 28, 2012|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400283||176926|
NCT00400803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007UC021|Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer|Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC||Masonic Cancer Center, University of Minnesota|Yes|Completed|March 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|November 15, 2006|Yes|Yes||No|November 10, 2011|https://clinicaltrials.gov/show/NCT00400803||176886|Outcome data is available for 35 (of 38) patients only.
NCT00401089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-02-285|Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia|A Placebo-controlled Cross Study of Panax Ginseng in Augmentation of Antipsychotics in 60 Partially Treatment Responsive Patients With Schizophrenia||Lawson Health Research Institute|Yes|Completed|December 2002|October 2007|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||December 2012|December 11, 2012|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00401089||176866|
NCT00401388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 214|A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas|Sarcoma Alliance for Research Through Collaboration (SARC) Multicenter Trial: A Phase II Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas||AEterna Zentaris|Yes|Completed|November 2006|October 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|13 Years|N/A|No|||February 2012|March 4, 2013|November 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401388||176843|
NCT00401674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-5|MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer|Phase II Multicenter Study of the Combination of Weekly Carboplatin and Paclitaxel as First-line Chemotherapy for Elderly Patients With Ovarian Cancer.|MITO-5|National Cancer Institute, Naples||Completed|June 2003|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|70 Years|N/A|No|||January 2016|January 13, 2016|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401674||176821|
NCT00401687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMP 115-412|DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function|A Multicenter, Phase IV Study to Evaluate the Ability of Definity® Enhanced Versus Unenhanced Echocardiography to Improve the Accuracy and Reproducibility of Left Ventricular Ejection Fraction When Compared to Cardiac Magnetic Resonance Imaging||Lantheus Medical Imaging|No|Completed|July 2006|April 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|131|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|November 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00401687||176820|
NCT00401934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0045|Immunity to Human Cholera in Bangladesh|Protective Immunity to Human Cholera in Bangladesh||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|November 2006|||||N/A|Observational|Time Perspective: Prospective||||325|||Both|2 Years|60 Years|Accepts Healthy Volunteers|||July 2007|August 26, 2010|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00401934||176801|
NCT00402207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 05-005|The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry|The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Exhaled Nitric Oxide, Inflammatory Markers in Exhaled Breath Condensate and Conventional Parameters||Maastricht University Medical Center||Completed|August 2005|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||33|||Both|78 Months|12 Years|No|||September 2005|November 20, 2006|November 20, 2006||||No||https://clinicaltrials.gov/show/NCT00402207||176780|
NCT00402493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA6110HV|Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops|A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.||Philadelphia Eye Associates|No|Completed|December 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|51|||Both|21 Years|N/A|No|||December 2012|December 4, 2012|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402493||176758|
NCT00412542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM02-595|Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas|A Phase II Trial of Combination Therapy With Thalidomide and CPT-11 in Patients With Recurrent Anaplastic Gliomas or Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Completed|October 2003|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|N/A|N/A|No|||February 2012|February 8, 2012|December 15, 2006||No||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00412542||176006|
NCT00403104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2506POE014|Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Multi-centre, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Investigate Efficacy and Safety of ONO-2506PO Compared to Placebo, in the Presence of Riluzole, to Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS), Who Have Had Onset of Muscle Weakness Within 14 Months of Randomization||Ono Pharmaceutical Co. Ltd||Completed|November 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|74 Years|No|||June 2012|June 12, 2012|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403104||176711|
NCT00403351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-02/04|Alternative Risk Markers in Coronary Artery Disease (ARMCAD)|Correlation of Multiple Risk Factors With Presence and Severity of Coronary Artery Disease.||Monash University|Yes|Active, not recruiting|October 2006|November 2015|Anticipated|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|750|Samples Without DNA|Serum specifically for future cardiac biomarkers|Both|18 Years|N/A|No|Non-Probability Sample|ARM-CAD 1: Patients attending elective coronary angiography ARM-CAD 2: Participants in        ARM-CAD 1 plus volunteers with cardiac risk factors|June 2015|June 2, 2015|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403351||176692|
NCT00403663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02|Effect of Body Mass Index on the Dose of Intrathecal Hyperbaric Bupivacaine for Elective Cesarean Section|Effect of Body Mass Index on the ED95 of Intrathecal Hyperbaric Bupivacaine for Elective Cesarean Section||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2009|July 29, 2009|November 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00403663||176669|
NCT00399815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELASTO2|Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|June 2006|May 2010|Anticipated|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|liver biopsy serum|Both|18 Years|75 Years|No|Probability Sample|Chronic hepatitis C|September 2009|September 17, 2009|November 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00399815||176960|
NCT00400101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEV001|Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides|A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers||Swiss Tropical & Public Health Institute||Terminated|November 2003|October 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||46|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2006|November 15, 2006|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400101||176940|
NCT00400348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CLN-004|Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer|A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer||CASI Pharmaceuticals, Inc.||Completed|October 2006|November 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||November 2008|November 24, 2008|November 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400348||176921|
NCT00400361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO19373|A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.|A Dose-escalation Study of R1507 in Patients With Advanced Solid Tumors.||Hoffmann-La Roche||Completed|April 2006|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400361||176920|
NCT00400608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS105519|A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS|A Repeat-dose, Open-label, Randomized, Incomplete Block Design in Pediatric Subjects With Asthma, Ages 4 - 11 Years, to Compare Systemic Exposure and Pharmacodynamics of Fluticasone Propionate and Salmeterol Following Advair HFA 45/21mcg (2 Inhalations), ADVAIR® HFA 45/21mcg (2 Inhalations) With Aerochamber Plus Spacer and Advair Diskus 100/50 Twice Daily||GlaxoSmithKline|No|Completed|October 2006|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|4 Years|11 Years|No|||August 2013|September 5, 2013|November 15, 2006||||||https://clinicaltrials.gov/show/NCT00400608||176901|
NCT00400322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV20145|Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection|A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.||Karolinska University Hospital||Active, not recruiting|August 2006|March 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2009|January 21, 2009|November 15, 2006||||No||https://clinicaltrials.gov/show/NCT00400322||176923|
NCT00400335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDC106222|Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride|An Open Label Study to Evaluate the Impact of Novel Fixed-dose Testosterone/Dutasteride Combinations on the Relative Bioavailability of the Individual Dutasteride and Testosterone Components||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 14, 2006||||||https://clinicaltrials.gov/show/NCT00400335||176922|
NCT00401141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3156|Abnormalities of B Lymphocytes During Systemic Lupus|Phenotypic Characteristics and Transcriptomas of B Lymphocytes During Non Active Systemic Lupus Erythematosus||University Hospital, Strasbourg, France||Completed|April 2004|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 7, 2008|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00401141||176862|
NCT00401154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-025023-CR001|Study of a Stationary Cycling Intervention for Children With Spastic Diplegic Cerebral Palsy|Pediatric Endurance and Limb Strengthening (PEDALS)|PEDALS|University of Southern California|Yes|Completed|September 2003|March 2006|Actual|March 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|64|||Both|7 Years|18 Years|No|||December 2014|December 4, 2014|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00401154||176861|
NCT00401453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-119N-MA|OatMeal and Insulin Resistance: OMA-IR|Carbohydrate Days as Simple and Efficient Therapy for Patients With Type 2 Diabetes Mellitus and Insulin Resistance: Oatmeal and Insulin Resistance (OMA-IR).||Universitätsmedizin Mannheim||Completed|January 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||February 2010|February 16, 2010|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401453||176838|
NCT00400816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-4204|Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma|Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma||The Cleveland Clinic|Yes|Active, not recruiting|August 2005|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|October 31, 2015|November 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00400816||176885|
NCT00401102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5332|Interpersonal Psychotherapy for Depressed Adolescents Engaging in Non-suicidal Self-injury|An Open-clinical Trial of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) for Depressed Adolescents Engaged in Non-suicidal Self-injury|IPT-ASI|New York State Psychiatric Institute|No|Completed|November 2006|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|12 Years|18 Years|No|||December 2012|December 20, 2012|November 15, 2006||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00401102||176865|
NCT00401414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001896|Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information|CReating an Optimal Warfarin Nomogram (CROWN) Trial||Brigham and Women's Hospital|Yes|Completed|January 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|344|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|November 16, 2006||No||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00401414||176841|
NCT00401700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fluvaccinesmh|Influenza Vaccine Postpartum Questionnaire|Acceptability and Feasibility of Influenza Vaccine Administration on the Post-partum Floor Prior to Discharge Home During Flu Season||St. Michael's Hospital, Toronto|No|Completed|October 2006|July 2009|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|pregnant women|May 2011|May 25, 2011|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401700||176819|
NCT00401713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-01-CI-2006|Transplantation of Autologous RPE Versus Translocation of Autologous RPE and Choroid in AMD|Transplantation of Autologous RPE Versus Translocation of Autologous RPE and Choroid in AMD||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||Completed|February 2004|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|50 Years|N/A|No|||September 2008|September 21, 2008|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00401713||176818|
NCT00402246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|605|CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision|CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision|CONNECT|Medtronic Cardiac Rhythm Disease Management|No|Completed|November 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2009|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|November 17, 2006||No||No|September 29, 2010|https://clinicaltrials.gov/show/NCT00402246||176777|
NCT00401947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH171-002|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ACH-0137171 in Subjects With Chronic Hepatitis C Infection|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects With Chronic Hepatitis C Infection||Achillion Pharmaceuticals||Terminated|November 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|60 Years|No|||December 2015|December 29, 2015|November 17, 2006|||Nephrotoxicity|No||https://clinicaltrials.gov/show/NCT00401947||176800|
NCT00402220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fitzgeraldp|A Double-Blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression|A Double-Blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression||Bayside Health||Recruiting|January 2007|January 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||October 2007|October 30, 2007|November 18, 2006||||No||https://clinicaltrials.gov/show/NCT00402220||176779|
NCT00402233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.622|A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients|A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID)||Boehringer Ingelheim||Completed|November 2006|||September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|312|||Both|31 Years|N/A|No|||May 2014|May 7, 2014|November 19, 2006|Yes|Yes||No|September 22, 2009|https://clinicaltrials.gov/show/NCT00402233||176778|
NCT00402506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06004|A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG|MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery||Medicure|Yes|Completed|November 2006|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|3000|||Both|18 Years|N/A|No|||November 2007|November 15, 2007|November 20, 2006||||No||https://clinicaltrials.gov/show/NCT00402506||176757|
NCT00412555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV20236|A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.|An Open-label Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Children.||Hoffmann-La Roche||Completed|December 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Both|1 Year|12 Years|No|||March 2016|March 1, 2016|December 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00412555||176005|
NCT00412568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU # 04-2335-99d|Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel|Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel||Walter Reed Army Medical Center||Completed|May 2004|March 2008||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2007|March 31, 2008|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00412568||176004|
NCT00412581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0487|Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma|Phase I Safety Study of the Combination of Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy (CC-5013-MEL-003)||M.D. Anderson Cancer Center|No|Completed|September 2005|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|December 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00412581||176003|
NCT00403117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5360|Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana|||New York State Psychiatric Institute||Completed|December 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 26, 2008|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00403117||176710|
NCT00403364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112/2006|Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-Controlled Trial|Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-Controlled Trial||St. Orsola Hospital||Completed|July 2003|February 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||300|||Both|18 Years|70 Years|No|||November 2006|November 22, 2006|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403364||176691|
NCT00403676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiakonhjemmetS|Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease|Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease||Diakonhjemmet Hospital|No|Completed|September 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403676||176668|
NCT00399542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0211SIB-0432|Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation|Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation||Sucampo Pharma Americas, LLC||Completed|May 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|581|||Both|18 Years|N/A||||September 2013|September 25, 2013|November 13, 2006|No|Yes||No|October 7, 2008|https://clinicaltrials.gov/show/NCT00399542||176981|
NCT00400114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0407-C|Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer|Adjuvant Sutent Following Chemotherapy, Radiation and Surgery For Esophageal Cancer, A Phase II Trial (ASSET)||University Health Network, Toronto|No|Active, not recruiting|November 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|70 Years|No|||March 2016|March 7, 2016|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400114||176939|
NCT00400374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021851|Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2|Phase I Study of Secondary Primary Tumor Prevention With Epidermal Growth Factor Receptor (EGFR), Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva™), and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Early Stage (Stage I/II) Squamous Cell Carcinoma of Head and Neck||Emory University|Yes|Active, not recruiting|August 2007|February 2017|Anticipated|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|November 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00400374||176919|
NCT00401193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP12B-MR-301|Efficacy and Safety of XP12B in Women With Menorrhagia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia||Ferring Pharmaceuticals|Yes|Completed|November 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|304|||Female|18 Years|49 Years|No|||April 2015|April 23, 2015|November 9, 2006|Yes|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00401193||176858|
NCT00400621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 02-999|Effects of Therapeutic Doses of Acetaminophen in Moderate Drinkers|Assessment of Hepatic Injury in Subjects Who Consume Moderate Amounts of Alcohol While Being Administered Therapeutic Doses of Acetaminophen:||Denver Health and Hospital Authority||Completed|April 2003|September 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind||||150|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 16, 2006|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00400621||176900|
NCT00400868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|niedk_EK444_|Effectiveness of Occupational Therapy in Patients With Rheumatoid Arthritis(RCT)|A Randomized Controlled Study to Evaluate the Short- and Long-term Effectiveness of an Individualized Resource Oriented Occupational Therapy for Patients With Rheumatoid Arthritis||University of Zurich||Completed|July 2006|September 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|85 Years|No|||February 2010|February 23, 2010|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400868||176881|
NCT00400881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E06040|Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)|Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)||Texas Tech University Health Sciences Center, El Paso|No|Completed|January 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|122|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|November 16, 2006||No||No|August 18, 2011|https://clinicaltrials.gov/show/NCT00400881||176880|General ICU population.Two subjects in each group were randomized and data collected but were not included in analysis per protocol due to needing re-intubation for upper airway obstruction.
NCT00401752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9617L00001|Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer|A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Daily NSAID is Continued||AstraZeneca||Completed|March 2006|November 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|70 Years|No|||June 2010|June 10, 2010|November 17, 2006||||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00401752||176815|According to the protocol, the sample size was 320 patients which could achieve 80% power of superiority. Since the patient recruitment is very difficult, total 219 patients were randomized in present study, the power decreased to 60%
NCT00400829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01159|E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase 2 Study of the Halichondrin B Analog E7389 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a Taxane||National Cancer Institute (NCI)||Completed|November 2006|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||October 2013|December 23, 2014|November 16, 2006|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT00400829||176884|
NCT00400842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.3.122|A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency|A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy||Abbott|No|Completed|May 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|274|||Both|20 Years|N/A|No|||July 2011|July 27, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400842||176883|
NCT00401128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-6695|Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer|Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma||The Cleveland Clinic||Completed|May 2004|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||May 2007|May 13, 2011|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00401128||176863|
NCT00401401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-EGFr-203|Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer|An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled||Genmab|Yes|Terminated|December 2006|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|November 17, 2006|Yes|Yes|MTD was established and patients completed 16 months safety f-up and response assessments. It    is considered of limited value to follow patients for 3 years.|No|October 7, 2011|https://clinicaltrials.gov/show/NCT00401401||176842|All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years.The planned parallell group of the study was cancelled.
NCT00401960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507008023|Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.|Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis||Weill Medical College of Cornell University||Terminated|September 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|November 20, 2006|Yes|Yes|inadequate enrollment|No||https://clinicaltrials.gov/show/NCT00401960||176799|
NCT00402259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961DL00004|Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding|A Randomised, Double-Blind, Double-Dummy, Active-Controlled, Multicenter Study to Assess the Efficacy and Safety of Esomeprazole or Omeprazole for 5 Days in Subjects With Acute Non-Variceal Upper Gastrointestinal Bleeding||AstraZeneca||Completed|August 2006|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|440|||Both|18 Years|65 Years|No|||March 2009|March 11, 2009|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00402259||176776|
NCT00402558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0508|Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Alloreactive NK Cells With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for AML and MDS||M.D. Anderson Cancer Center|No|Completed|May 2006|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|70 Years|No|||May 2015|May 6, 2015|November 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00402558||176753|
NCT00402571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB #00-715|Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics|Assessment of Hepatic Function in Alcoholic Patients Administered Therapeutic Dosing of Acetaminophen- a Multicenter Study||Denver Health and Hospital Authority||Completed|January 2002|July 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind||||420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 6, 2009|November 20, 2006||||No||https://clinicaltrials.gov/show/NCT00402571||176752|
NCT00402818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26768|RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization|RESTORE (Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-label, Multi-centre, Phase IV Study of Subcutaneously Administered Raptiva® (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva®|RESTORE|Merck KGaA||Terminated|May 2006|July 2009|Actual|July 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|294|||Both|18 Years|70 Years|No|Non-Probability Sample|Consenting Raptiva® (efalizumab) treated patients with moderate to severe chronic plaque        psoriasis and meeting the inclusion/exclusion criteria specified will be eligible for        participation in this study. Subjects will be enrolled from the Raptiva®-treated clinical        patient pool at the participating Canadian investigator site.|August 2014|August 28, 2014|November 20, 2006||No|The study was terminated after the EMEA recommended to suspend the marketing authorisation of    Raptiva in the EU|No||https://clinicaltrials.gov/show/NCT00402818||176733|
NCT00402532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ever-Lung-DE01/RAD-LungDE01|Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation|Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation||Hannover Medical School||Completed|March 2005|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|65 Years|No|||December 2011|December 7, 2011|November 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00402532||176755|
NCT00402545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-128|C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase I Study of Cetuximab/Docetaxel(Taxotere)/Cisplatin/5-Fluorouracil (C-TPF) in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Dana-Farber Cancer Institute||Completed|January 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402545||176754|
NCT00412906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM2.sa.cim.rh.dk|Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls|Study of Gene Expression in Fat and Muscle Tissue in Type 2 Diabetics and Healthy Controls During Experimental Endotoxemia||Rigshospitalet, Denmark|Yes|Completed|November 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|48|||Male|25 Years|80 Years|Accepts Healthy Volunteers|||May 2008|May 20, 2008|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00412906||175979|
NCT00412919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH213/06|Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma|A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma.||Bayside Health||Terminated|December 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|7|||Both|17 Years|N/A|No|||December 2006|December 12, 2013|December 17, 2006|No|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00412919||175978|
NCT00412932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-450|An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension|A Prospective, Open Label, Single Arm Study to Evaluation the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Elderly Patients With Hypertension||Daiichi Sankyo Inc.||Completed|December 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|65 Years|N/A|No|||September 2009|September 15, 2009|December 14, 2006|Yes|Yes||No|April 28, 2009|https://clinicaltrials.gov/show/NCT00412932||175977|
NCT00403689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOW_bGlucan|Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome|Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome||German Institute of Human Nutrition||Completed|November 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403689||176667|
NCT00399555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000275|Neurodevelopmental Outcomes in Hypoplastic Left Heart Syndrome|Neurodevelopmental Outcomes in Hypoplastic Left Heart Syndrome—Correlation With Cerebral Non-invasive Infrared Spectroscopy (NIRS)||Emory University|No|Completed|November 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|28|||Both|29 Months|6 Years|No|Probability Sample|Children ages 2.5 to 6 years old who have hypoplastic left heart syndrome with surgical        palliation and near infrared spectrometry monitoring during the Stage I Norwood procedure.|November 2013|November 25, 2013|November 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00399555||176980|
NCT00399828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02CBED0602|Evaluation Of The Efficacy and Safety Of Tri-ActiveTM In Treatment Of Cellulite|Clinical Study For Evaluation Of The Efficacy and Safety Of Tri-ActiveTM (Deka M.E.L.A., Itália) In Treatment Of Cellulite||Brazilan Center for Studies in Dermatology||Terminated|August 2006|November 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2008|March 11, 2008|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399828||176959|
NCT00400387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2006-001984-53|Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss|Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss||University of Jena||Completed|November 2006|April 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|449|||Female|18 Years|N/A|No|||September 2014|September 16, 2014|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400387||176918|
NCT00400634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERE-120-02|Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease|Multicenter, Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects With Idiopathic Parkinson's Disease||Ceregene|Yes|Completed|November 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|35 Years|75 Years|No|||July 2012|July 6, 2012|November 15, 2006|Yes|Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00400634||176899|
NCT00400907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000514350|Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9|Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]||National Cancer Institute (NCI)||Active, not recruiting|January 2006|||||N/A|Observational|N/A|||Anticipated|667|||Both|18 Years|60 Years|No|||January 2007|December 17, 2011|November 16, 2006||||No||https://clinicaltrials.gov/show/NCT00400907||176878|
NCT00410722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 06-274|Effect of Nuts vs. a Wheat Bran Muffin in Type 2 Diabetes|Effect of Nuts on Glycemic Control and Cardiovascular Disease Risk in Type 2 Diabetes||University of Toronto||Active, not recruiting|December 2006|||December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|21 Years|N/A|No|||January 2013|January 8, 2013|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00410722||176138|
NCT00411021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3674-MB-CTIL|Endometrial Sampling (Pipelle)in IVF Patients|Endometrial Sampling (Pipelle)in IVF Patients||Sheba Medical Center||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||December 2006|December 12, 2006|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00411021||176117|
NCT00411697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106789|Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge|Assess Long-term Persistence of Hepatitis B Antibodies & Immune Response to a Hepatitis B Vaccine (Engerix-B Kinder) Challenge in Children Aged 4-5 Yrs (Previously Primed & Boosted in the 1st 2 Yrs of Life With DTPa-HBV-IPV/Hib Vaccine)||GlaxoSmithKline||Completed|December 2006|May 2007||May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|301|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|December 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411697||176067|
NCT00412035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9142|Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery|Safety and Efficacy of Botox Injection in Alleviating Post-Operative Pain and Improving Quality of Life in Lower Extremity Limb Lengthening and Deformity Correction|BOLLD|Shriners Hospitals for Children|Yes|Completed|January 2007|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|5 Years|21 Years|No|||December 2014|December 22, 2014|December 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00412035||176044|
NCT00412321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR008566|A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease|A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease||Centocor, Inc.|No|Completed|May 2005|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|67|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|December 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00412321||176023|
NCT00412646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006754|TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients|A Randomized, Placebo-controlled Phase II Trial in HIV-1-infected, NRTI-, PI and NNRTI-experienced Subjects to Evaluate the Safety, Tolerability and Efficacy of Different Doses of TMC125 b.i.d. on Top of an Individually Optimized Antiretroviral Therapy by Means of a 2-stage Dose-escalating Design||Tibotec Pharmaceuticals, Ireland||Completed|June 2002|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|260|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00412646||175998|
NCT00412971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC B304/04|A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer|A Randomized, Comparative Phase III, 2-center Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer||Photocure||Completed|April 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|233|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|December 18, 2006||No||No|August 5, 2013|https://clinicaltrials.gov/show/NCT00412971||175975|
NCT00413335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508000532|Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth|Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth||Yale University|No|Completed|November 2005|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|21|||Both|10 Years|18 Years|No|||July 2013|July 15, 2013|December 15, 2006||No||No|November 7, 2012|https://clinicaltrials.gov/show/NCT00413335||175947|
NCT00405522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009427|Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children|Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children: Evaluation of Two Dose Combinations||The Hospital for Sick Children|No|Completed|November 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|3 Years|12 Years|No|||August 2013|August 19, 2013|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405522||176529|
NCT00405808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIMON_R_00961|Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose|A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities|PRADO|Sanofi||Terminated|December 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2666|||Both|18 Years|75 Years|No|||January 2011|January 25, 2011|November 28, 2006||No|EMEA recommendation to suspend Acomplia marketing authorisation|No||https://clinicaltrials.gov/show/NCT00405808||176507|
NCT00413270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ACA01|Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant|A Canadian Open-label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase||Novartis||No longer available|December 2006|||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||July 2011|July 12, 2011|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413270||175952|
NCT00413283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050154|Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)|Phase 2, Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 For Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Advanced Non-Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum.||Amgen||Completed|December 2006|February 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|63|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|December 15, 2006||||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00413283||175951|
NCT00409214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSO-OL007|Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma|A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma||Light Sciences Oncology||Completed|November 2006|||February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409214||176251|
NCT00409500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAQW051A1101|Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects|A Randomized, Double-Blind, Placebo-Controlled, Interleaved, Ascending Dose Study, to Evaluate Safety, Tolerability and Pharmacokinetics of Single Oral Doses of AQW051; to Evaluate the Effect of Food on the Pharmacokinetics of AQW051, in Japanese Healthy Male Subjects||Novartis||Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||54|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 8, 2006||||No||https://clinicaltrials.gov/show/NCT00409500||176230|
NCT00409526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14479B|Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.|Pilot Study: The Effect of Inhaled Iloprost on Oxygenation in Term and Near Term Infants With Pulmonary Hypertension. Testing Two Doses.||University of Chicago||Terminated|December 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|7 Days|No|||May 2014|May 30, 2014|December 7, 2006|No|Yes|Sub-Investigator left U of C|No||https://clinicaltrials.gov/show/NCT00409526||176229|
NCT00410124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2240|RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor|RECORD-1|Novartis||Completed|November 2006|October 2011|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|416|||Both|18 Years|85 Years|No|||December 2012|December 7, 2012|December 11, 2006|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00410124||176184|
NCT00410137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43/06|Influence of Nutritional and Inflammational Status on Survival of Hemodialysis Patients|||Assaf-Harofeh Medical Center||Recruiting|March 2006|April 2008||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|18 Years|N/A|No|||December 2006|December 11, 2006|December 10, 2006||||No||https://clinicaltrials.gov/show/NCT00410137||176183|
NCT00410488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0664|Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)|Dose/Schedule Finding Study of Palonosetron in Sarcoma Patients Receiving Multi-Day Chemotherapy With Adriamycin and Ifosfamide (AI)||M.D. Anderson Cancer Center|No|Completed|December 2006|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|51|||Both|18 Years|65 Years|No|||February 2013|February 19, 2013|December 11, 2006||No||No|June 28, 2012|https://clinicaltrials.gov/show/NCT00410488||176156|
NCT00410501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149A2311|Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects|An Open Label, Single Dose, Two Period, Single Sequence Crossover Study to Assess the Pharmacokinetic Interaction of QAB149 (300 Mcg Via Inhalation) With Ketoconazole (200 mg Tablet b.i.d.) in Healthy Adult Subjects||Novartis|No|Completed|December 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 18, 2007|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410501||176155|
NCT00409435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002442|A Study of Pyridostigmine in Postural Tachycardia Syndrome|Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome||Mayo Clinic|Yes|Recruiting|October 2006|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|55 Years|No|||March 2016|March 14, 2016|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00409435||176234|
NCT00409448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073764|Internet-Based Treatment for Children With Traumatic Brain Injuries & Their Families: Counselor Assisted Problem Solving|Improving Mental Health Outcomes of Child Brain Injury|CAPS|Children's Hospital Medical Center, Cincinnati|Yes|Completed|March 2007|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|12 Years|18 Years|No|||September 2014|September 18, 2014|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409448||176233|
NCT00409734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/09/VA03|Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis|Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis||Maimonides Medical Center||Recruiting|October 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||100|||Both|N/A|9 Weeks|Accepts Healthy Volunteers|||November 2006|December 8, 2006|December 8, 2006||||No||https://clinicaltrials.gov/show/NCT00409734||176213|
NCT00410033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1676|Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin|Safety/Efficacy Trial Using Stored Serum Samples to Investigate the Immunogenicity of Insulin Aspart and Soluble Human Insulin in Children and Adolescents From Onset of Type 1 Diabetes||Novo Nordisk A/S|No|Completed|December 1989|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|74|||Both|2 Years|17 Years|No|||February 2015|February 18, 2015|December 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00410033||176191|
NCT00410046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-405|Extension Study Evaluating Etanercept in Ankylosing Spondylitis|An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|December 8, 2006||No||No|October 30, 2009|https://clinicaltrials.gov/show/NCT00410046||176190|
NCT00411333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 EY017528-0|Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy|Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy||National Eye Institute (NEI)||Completed|July 2006|July 2009|Actual|July 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2010|November 9, 2010|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00411333||176093|
NCT00411723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTL1000-1.0001|Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis|Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis||Artielle ImmunoTherapeutics||Active, not recruiting|December 2006|May 2009|Anticipated|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|No|||February 2009|February 19, 2009|December 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00411723||176066|
NCT00412048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3659|Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease|Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.||University Hospital, Strasbourg, France|No|Withdrawn|April 2012|February 2018|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|0|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 12, 2012|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412048||176043|
NCT00412061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2325|Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor|A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo|RADIANT-2|Novartis||Completed|December 2006|June 2013|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|429|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|December 13, 2006|Yes|Yes||No|October 25, 2011|https://clinicaltrials.gov/show/NCT00412061||176042|
NCT00412334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20399|SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.|Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy||Hoffmann-La Roche||Completed|January 2007|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|104|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412334||176022|
NCT00412659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIN-05-178M|Mid-line Excision Versus Karydakis Operation for Pilonidal Sinus|An Expertise-based Randomized Controlled Trial Comparing Midline Excision Versus Karydakis Operation at Surgery for Pilonidal Sinus||Umeå University||Recruiting|March 2006|||December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412659||175997|
NCT00412984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-030|Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation|A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation|ARISTOTLE|Bristol-Myers Squibb|Yes|Completed|December 2006|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|18201|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|December 18, 2006|Yes|Yes||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00412984||175974|
NCT00412997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B1101|LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma|A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma||Novartis||Completed|November 2006|||May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|N/A|No|||November 2012|November 26, 2012|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00412997||175973|
NCT00413010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081103|Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).|An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD)||Pfizer|Yes|Completed|December 2006|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|N/A|No|||December 2009|December 3, 2009|December 15, 2006|Yes|Yes||No|February 27, 2009|https://clinicaltrials.gov/show/NCT00413010||175972|Further enrollment in this study was stopped based on the recommendation of an independent Data Monitoring Committee (DMC). An interim data analysis did not suggest the potential for robust efficacy. The study was not stopped for any safety findings.
NCT00405821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907032|Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda|A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda||National Institutes of Health Clinical Center (CC)|Yes|Completed|November 2006|November 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|65 Years|No|||August 2012|August 28, 2012|November 29, 2006||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT00405821||176506|
NCT00408941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1505/06|EEG and Auditory Evoked Potentials During Local Anesthesia|EEG and Auditory Evoked Potentials During Local Anesthesia||Technische Universität München||Not yet recruiting|December 2006|December 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2006|December 7, 2006|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00408941||176272|
NCT00408954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3711045|Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms|A Multi Center Randomized Cross Over Double Blind Third Party Open Placebo Controlled Pilot Study to Assess the Urodynamic Effects of Modified Release UK-369,003 in Men With Lower Urinary Tract Symptoms.||Pfizer|No|Completed|March 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Male|40 Years|N/A|No|||November 2010|November 12, 2010|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408954||176271|
NCT00409227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165/05|Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy|Prospective Randomized Placebo Controlled Blinded Study to Evaluate the Efficacy of Alfuzosin (Alpha Blocker) on the Success Rates Following SWL.||Assaf-Harofeh Medical Center|No|Recruiting|December 2006|||July 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2008|June 17, 2008|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409227||176250|
NCT00409539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3601113|SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)|A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome||Sunovion|No|Completed|December 2006|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|550|||Both|20 Years|80 Years|No|||December 2014|December 5, 2014|December 8, 2006|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00409539||176228|
NCT00409552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N44DA-5-7744|Human Factors Analysis in VR for Burn Treatment|Phase 1 and 2 Study of Human Factors Analysis in VR for Burn Treatment||National Institute on Drug Abuse (NIDA)||Not yet recruiting|December 2009|||December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Anticipated|500|||Both|18 Years|65 Years|No|||September 2009|September 2, 2009|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409552||176227|
NCT00409812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/MRE05/16|A Study of the Effects of Sodium Citrate on Olfactory Thresholds|A Double Blinded Randomised Controlled Trial of the Effects of Sodium Citrate on Olfactory Thresholds||University Hospitals, Leicester||Not yet recruiting|February 2007|||||Phase 0|Observational|Allocation: Random Sample, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|January 18, 2007|December 8, 2006||||No||https://clinicaltrials.gov/show/NCT00409812||176207|
NCT00410085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2004.03.PHH|Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls|||Regional Hospital Holstebro||Completed|January 2005|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Basic Science||||40|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 17, 2008|December 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00410085||176187|
NCT00410436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005301-01H|Resistance Exercise in Already-active Diabetic Individuals (READI) Trial|Resistance Exercise in Already-active Diabetic Individuals (READI) Trial||Ottawa Hospital Research Institute|Yes|Completed|October 2006|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|16 Years|N/A|No|||February 2013|February 25, 2013|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00410436||176160|
NCT00410449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11461-CP-001|Oxidative Stress and Hemodialysis Access Failure|Study of the Effect of Oral Supplementation With Vitamin E on Circulating Oxidative Markers, Hemodialysis Vascular Access Occlusion, and Clinical Events in Patients With End Stage Renal Failure Treated by Hemodialysis||National Institute of Environmental Health Sciences (NIEHS)||Completed|May 2001|May 2004||||Phase 4|Observational|Time Perspective: Prospective||||35|||Both|21 Years|N/A|No|||December 2006|October 5, 2015|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410449||176159|
NCT00411034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011614|A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain|A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR( Hydromorphone HCI) in Patients With Chronic Cancer Pain||Alza Corporation, DE, USA||Completed||September 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|463|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00411034||176116|
NCT00411047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-291|Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor||Massachusetts General Hospital|Yes|Completed|September 2005|December 2012|Actual|January 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||May 2013|May 12, 2013|December 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00411047||176115|
NCT00411346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-157.1|Patient Research In Self-Management of Asthma (PRISMA)|Nurse-Led Telemonitoring Programme in Asthmatic Outpatients: a Randomized Controlled Trial||Maastricht University Medical Center||Completed|January 2003|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||112|||Both|7 Years|N/A|No|||December 2006|December 13, 2006|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00411346||176092|
NCT00411060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117-2006|Clinical Orthopaedic Data Bank (Acute and Chronic)|Orthopaedic Data Bank; Collection and Storage of Data Relating to Orthopaedic Disorders||University of Florida|No|Recruiting|January 2007|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Orthopaedic clinic|December 2015|December 8, 2015|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411060||176114|
NCT00411359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0404/77|Cardiac Rehabilitation for the Treatment of Refractory Angina|Cardiac Rehabilitation for the Treatment of Refractory Angina||National Heart and Lung Institute|No|Completed|December 2006|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|30 Years|80 Years|No|||April 2015|April 21, 2015|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411359||176091|
NCT00411372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO105782|Shortness Of Breath Questionnaire Validation Study|A Randomized, Double-blind, Parallel-group Study of Fluticasone Propionate/Salmeterol Combination (FSC 250/50mcg) Twice Daily and Salmeterol (SAL 50mcg) Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Withdrawn|November 2006|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||February 2015|February 19, 2015|December 13, 2006|||No subjects enrolled. Study was canceled before active|||https://clinicaltrials.gov/show/NCT00411372||176090|
NCT00411385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1008-C1067|Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3|Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.||Human Genome Sciences Inc.||Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|933|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|December 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411385||176089|
NCT00411736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZI/SCAND/01|Scandinavian Cystic Fibrosis Azithromycin Study|Supplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double-blinded, Placebo-controlled Scandinavian Multi-centre Study.||Rigshospitalet, Denmark|Yes|Completed|May 2008|March 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|45|||Both|1 Year|N/A|No|||March 2014|March 13, 2014|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00411736||176065|
NCT00411749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-028|V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)|V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years||Merck Sharp & Dohme Corp.||Completed|December 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|107|||Female|9 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|December 14, 2006|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00411749||176064|
NCT00412074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD047511|Establishing the Vitamin D Requirements During Lactation|Establishing the Vitamin D Requirements During Lactation||Medical University of South Carolina|Yes|Active, not recruiting|August 2006|January 2013|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|556|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|December 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00412074||176041|
NCT00412347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203-2005|Insulin Infusion in the Hospital Wards|Insulin Infusion and Outcomes for Non-Critical Wards||Emory University||Completed|August 2006|December 2006||||N/A|Observational|Time Perspective: Retrospective||1|Actual|200|||Both|19 Years|N/A|No|Non-Probability Sample|Cohort of hospitalized adult subjects in a teaching institution.|February 2014|February 7, 2014|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412347||176021|
NCT00412360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0501|Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)|Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501)||Medical College of Wisconsin|Yes|Active, not recruiting|December 2006|May 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|1 Year|21 Years|No|||November 2015|November 17, 2015|December 14, 2006|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT00412360||176020|
NCT00412672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/01|Protective Effect of Coronary Collaterals on Infarct Size in Patients With Acute Myocardial Infarction|Protective Effect of Coronary Collaterals on Infarct Size in Patients With Acute Myocardial Infarction||University Hospital Inselspital, Berne|No|Withdrawn|July 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Probability Sample|Patients with acute myocardial infarction undergoing primary PCI as reperfusion therapy of        a totally occluded coronary artery.|June 2015|June 15, 2015|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412672||175996|
NCT00413361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051070|The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS|Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study||Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|543|||Both|18 Years|N/A|No|||May 2007|January 26, 2011|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413361||175945|
NCT00406718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074047|Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia|Interventions for Adherence to Oral Antipsychotic Medications in Schizophrenia||The University of Texas Health Science Center at San Antonio|No|Completed|November 2006|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|197|||Both|18 Years|60 Years|No|||July 2015|September 1, 2015|November 30, 2006||No||No|May 1, 2015|https://clinicaltrials.gov/show/NCT00406718||176439|Patients had long-standing illness and results may not apply to patients with a more recent onset of schizophrenia/schizoaffective disorder
NCT00408980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|breastmilk.ctil|is Dietary Manipulation of Human Milk Total Fat and Caloric Content Feasible?|is Dietary Manipulation of Human Milk Total Fat and Caloric Content Feasible?||Shaare Zedek Medical Center||Not yet recruiting|January 2007|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Screening||||20|||Female|18 Years|46 Years|Accepts Healthy Volunteers|||November 2006|December 7, 2006|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00408980||176269|
NCT00408993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10599|Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China|Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China||Eli Lilly and Company||Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|December 6, 2006|Yes|Yes||No|February 5, 2009|https://clinicaltrials.gov/show/NCT00408993||176268|
NCT00409006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10918|Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers|A Phase 2 Trial of Pemetrexed and Cisplatin Followed Sequentially by Gefitinib Versus Pemetrexed and Cisplatin in Asian "Never Smoker" Patients With Advanced Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|February 2007|May 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|December 6, 2006|Yes|Yes||No|August 13, 2010|https://clinicaltrials.gov/show/NCT00409006||176267|Median overall survival cannot be estimated due to the high censor rate (25 participants per treatment group were censored). Most participants were still living at the end of the study.
NCT00409240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1127912|Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes|Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes||Providence VA Medical Center|Yes|Completed|October 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|85 Years|No|||March 2014|March 6, 2014|December 7, 2006||No||No|January 14, 2014|https://clinicaltrials.gov/show/NCT00409240||176249|Only 1 in 5 patients responded to the invitation to join the study and was willing to participate, participants were mostly male veterans, and pharmacists had prescribing privileges in the VA and in this study.
NCT00414830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023|Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.|||Odense University Hospital||Active, not recruiting|January 2005|September 2009|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|45 Years|N/A|No|||April 2008|April 29, 2008|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00414830||175835|
NCT00414843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611-55|Storage of Bile From Routine Procedures to Study Risk Factors|A Prospective Study of Human Bile and Molecular Predictors of Biliary Malignancy Risk||Indiana University||Terminated|December 2006|August 2015|Actual|August 2015|Actual|N/A|Observational|N/A||1|Actual|390|Samples Without DNA|Bile, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects presenting to Indiana University for treatment of biliary tract disease.|February 2016|February 22, 2016|December 21, 2006||No|Decreasing interest in using samples; department infrastructure waned|No||https://clinicaltrials.gov/show/NCT00414843||175834|
NCT00414856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2108|Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux|A Multi-Center, Randomized, Double-Blind, Placebo- and Positive-Control, Double-Dummy, 3 Parallel Cohort, Two-Way Crossover Single Oral Dose Study in GERD (Gastro Esophageal Reflux Disease) Patients to Evaluate the Effects of AFQ056 and Baclofen (Positive Control) on the Incidence of Meal-Induced Gastro Esophageal Reflux Events||Novartis||Completed|August 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|34|||Both|18 Years|60 Years|No|||June 2007|June 21, 2007|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00414856||175833|
NCT00409786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606089|Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal|Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal||University of Pittsburgh||Completed|November 2006|March 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|18 Years|80 Years|No|||March 2011|March 23, 2011|December 7, 2006||No||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00409786||176209|
NCT00409799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS I-040101/02|Safety and Efficacy of I 0401 in the Treatment of Tibial Plateau Fractures Requiring Grafting|A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting.||Kuros Biosurgery AG|No|Completed|November 2006|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|208|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409799||176208|
NCT00410098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bikramasthma-HMO-CTIL|Bikram Yoga and Asthma|The Influence of Bikram Yoga (39 Degree Celsius Heat and 60% Humidity) on Basic Lung Function Tests,Bronchial Challenges and Pulmonary-Heart Endurance in Young Asthmatic Adults.||Hadassah Medical Organization||Not yet recruiting|June 2007|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2006|December 11, 2006|December 10, 2006||||No||https://clinicaltrials.gov/show/NCT00410098||176186|
NCT00410111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 226/06|Pathogenesis and Cerebrovascular Manifestations of Septic Encephalopathy|A Pilotstudy on Pathogenesis and Cerebrovascular Manifestations of Septic Encephalopathy||University Hospital, Basel, Switzerland||Completed|January 2007|July 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with sepsis, severe sepsis or septic shock admitted to an intensive care unit|October 2008|October 15, 2008|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410111||176185|
NCT00410462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62061|Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma|Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|October 2006|||September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|118|||Both|18 Years|N/A|No|||July 2010|August 7, 2014|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410462||176158|
NCT00410475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999997053|Cancer Risk in X-Ray Technologists: Second Survey|Cancer Risk in X-Ray Technologists||National Institutes of Health Clinical Center (CC)||Completed|September 1997|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|146022|||Both|18 Years|110 Years|No|||April 2015|February 17, 2016|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00410475||176157|
NCT00410514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-060|A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)|A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)||Astellas Pharma Inc|No|Completed|December 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|200|||Male|45 Years|N/A|No|||September 2012|March 7, 2014|December 12, 2006|Yes|Yes||No|August 2, 2012|https://clinicaltrials.gov/show/NCT00410514||176154|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00410748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011623|Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)|Safety and Tolerability of Long-term Administration of Dilaudid CR (Hydromorphone HCI)||Alza Corporation, DE, USA||Completed||June 2000|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|388|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410748||176136|
NCT00411073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB 480848/035|Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart|A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin||GlaxoSmithKline||Completed|December 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|December 12, 2006||||||https://clinicaltrials.gov/show/NCT00411073||176113|
NCT00411398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-46|A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder|A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD), Who Are Only Partial Responders to Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's) or Selective Serotonin Reuptake Inhibitors (SSRI's).||State University of New York - Upstate Medical University||Completed|December 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 12, 2006|Yes|Yes||No|September 6, 2012|https://clinicaltrials.gov/show/NCT00411398||176088|
NCT00411762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512000905|A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma|A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma||Yale University|No|Completed|December 2006|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|December 13, 2006|Yes|Yes||No|March 10, 2015|https://clinicaltrials.gov/show/NCT00411762||176063|
NCT00412087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-16476|Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina|Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina: A Prevalence and Supplementation Model for Community Health Care Centers in the U.S.||Medical University of South Carolina|Yes|Completed|January 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|559|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|December 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00412087||176040|
NCT00412373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013099|Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.|A Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|307|||Both|18 Years|65 Years|No|||April 2014|April 24, 2014|December 15, 2006|Yes|Yes||No|July 1, 2009|https://clinicaltrials.gov/show/NCT00412373||176019|
NCT00412386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000134|Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve|Abnormal 3-dimensional MRI Flow Patterns and Plasma Matrix Metalloproteinase Levels Predict Dilatation of Ascending Aorta in Adolescent Patients With Bicuspid Aortic Valve||Emory University|No|Completed|December 2006|March 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|45|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with bicuspid Aortic valve, normal healthy volunteers, and congential heart        disease without bicuspid aortic valve|December 2013|December 2, 2013|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412386||176018|
NCT00412685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70/06|Myocardial Contrast Echocardiography in Congenital Heart Disease|Quantification of the Myocardial Microcirculation by Contrast Echocardiography In Adult Patients With Congenital Heart Disease||University Hospital Inselspital, Berne||Completed|August 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The study population is divided in three groups, which are all age- and gender-matched.        The TGA group consists of 15 patients treated withMustard or Senning procedures for        surgical repaired of D-TGA atrial switch operation. The TOF group consists of 15 patients        with surgically corrected TOF. The control group C consists of 15 control subjects (AH)        with normal Doppler Echocardiographic echocardiographic examinations.|June 2015|June 15, 2015|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412685||175995|
NCT00412698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIMON_R_00962|European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia|A European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Dyslipidemia With or Without Other Comorbidities|ETERNAL|Sanofi||Terminated|December 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|645|||Both|18 Years|75 Years|No|||December 2010|December 9, 2010|December 15, 2006||No|Company decision has been taken in light of recent demands by certain national health    authorities|No||https://clinicaltrials.gov/show/NCT00412698||175994|
NCT00413023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKF100096|Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)|A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Major Depressive Disorder (MDD)||GlaxoSmithKline|No|Completed|June 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||348|||Both|18 Years|64 Years|No|||July 2012|November 21, 2012|August 24, 2005||||No||https://clinicaltrials.gov/show/NCT00413023||175971|
NCT00413634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-203|The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)|A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia.||Shire||Completed|August 2006|March 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2010|June 6, 2014|December 19, 2006|Yes|Yes||No|March 5, 2009|https://clinicaltrials.gov/show/NCT00413634||175924|
NCT00413647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CardioPET P-01|A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease|A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of CardioPET™ as a PET Tracer for Detection of Coronary Artery Disease||Fluoropharma, Inc.|No|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413647||175923|
NCT00406380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0024|Effect of Avastin in Juxtafoveal Telangiectasias|Does Avastin Change Evolution in Juxtafoveal Telangiectasias?||Asociación para Evitar la Ceguera en México||Recruiting|September 2006|November 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|40 Years|70 Years||||November 2006|December 1, 2006|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406380||176464|
NCT00406744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0012|Efficacy of Retreatments With Intravitreal Bevacizumab|Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments||Asociación para Evitar la Ceguera en México||Recruiting|May 2006|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|60 Years|95 Years|No|||November 2006|November 30, 2006|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406744||176437|
NCT00408694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00736|Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer|A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer||National Cancer Institute (NCI)||Completed|December 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||October 2011|April 21, 2014|December 6, 2006|Yes|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00408694||176289|
NCT00409253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3738|Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine|Treatment of Severe Hypertension During Pre-Eclampsia.A Preliminary Equivalence Study Between URAPIDIL and NICARDIPINE||University Hospital, Strasbourg, France|No|Recruiting|June 2007|August 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|51 Years|No|||February 2009|February 24, 2009|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409253||176248|
NCT00409266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV06-01US|CT Assessment of Minimally Invasive Surgery and Computer Assisted Navigation in Total Knee Arthroplasty|||Stryker Instruments||Not yet recruiting||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|60 Years||||December 2006|December 7, 2006|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00409266||176247|
NCT00409565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-087|A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer||University of Pittsburgh|No|Completed|September 2006|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|December 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00409565||176226|
NCT00409851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2201E1|One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension|A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.||Novartis||Completed|April 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1293|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409851||176204|
NCT00415701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DINA-KEK7406-IBAN-2006-1|Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery|Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery||University Hospital Inselspital, Berne|No|Completed|November 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|80 Years|No|||March 2010|March 3, 2010|December 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415701||175770|
NCT00409825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #0603056|Study of Pharmacology of 17-OHPC in Pregnancy|A Study of the Pharmacology of 17-Hydroxyprogesterone Caproate in Pregnancy||University of Pittsburgh|Yes|Completed|March 2006|February 2014|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|61|||Female|18 Years|45 Years|No|||February 2015|February 9, 2015|December 8, 2006|Yes|Yes||No|January 13, 2015|https://clinicaltrials.gov/show/NCT00409825||176206|
NCT00409838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-124|A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept Administered Intravenously in Korean Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate||Bristol-Myers Squibb|No|Completed|April 2007|December 2011|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|113|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|December 8, 2006|Yes|Yes||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00409838||176205|
NCT00410735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-1078-37|Study of ONO-1078 in Patients With Chronic Sinusitis|Study of ONO-1078 in Patients With Chronic Sinusitis, a Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-center Study||Ono Pharmaceutical Co. Ltd||Completed|December 2006|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|495|||Both|15 Years|74 Years|No|||June 2012|June 12, 2012|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00410735||176137|
NCT00410527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906231|Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients|Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU)||National Institutes of Health Clinical Center (CC)||Completed|August 2006|May 2007||||Phase 4|Interventional|Primary Purpose: Treatment||||0|||Both|18 Years|N/A|No|||May 2007|September 26, 2015|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410527||176153|
NCT00410761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00058|An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer|An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer||AstraZeneca||Active, not recruiting|November 2006|December 2016|Anticipated|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|130 Years|No|||January 2016|January 6, 2016|December 6, 2006|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00410761||176135|
NCT00411086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA-2006-0260|Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma|Single-Arm, Open-Label, Phase II Trial of Rituximab Plus Sargramostim for the Treatment of Newly Diagnosed Follicular B-Cell Lymphoma in Adults||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2006|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|December 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411086||176112|
NCT00416832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000514355|Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma|Optimising Therapy for Boys With Hodgkin's Lymphoma and Quality Assurance of Therapy for Girls With Hodgkin's Lymphoma Until Start of a New Prospective Trial for Hodgkin's Lymphoma in Childhood and Adolescence||Martin-Luther-Universität Halle-Wittenberg||Completed|November 2002|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|648|||Both|N/A|17 Years|No|||November 2015|November 17, 2015|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416832||175685|
NCT00416845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2105|Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers|A Randomized, Parallel Group, Double-blind, Placebo Controlled, 14 Days Multiple-dose Treatment to Assess the Pulmonary and Cardiac Pharmacodynamics of FTY720 (0.5 and 1.25 mg) in Healthy Volunteers||Novartis||Completed|October 2006|||March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|39|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 3, 2010|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416845||175684|
NCT00417079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6193|XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer|A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen|TROPIC|Sanofi||Completed|January 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|755|||Male|18 Years|N/A|No|||March 2011|March 4, 2011|December 28, 2006|Yes|Yes||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00417079||175666|
NCT00417378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Impella M22|Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK)|Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes||Deutsches Herzzentrum Muenchen|Yes|Completed|August 2004|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||November 2007|November 27, 2007|December 29, 2006||||No||https://clinicaltrials.gov/show/NCT00417378||175643|
NCT00417391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101-01|Phase II Study of RR110 in Patients With Active Crohn's Disease|Phase II Study of RR110 in Patients With Active Crohn's Disease||R&R Inc.||Completed|December 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|N/A|No|||May 2008|May 25, 2008|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417391||175642|
NCT00417664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77815|Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients|ICU Delirium: Can Dexmedetomidine Reduce Its Incidence?||Stanford University||Active, not recruiting|April 2002|December 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||90|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||January 2007|January 3, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00417664||175621|
NCT00417989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP179/Z25|Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy|The STAR 3 Study - A Prospective, Randomized, Two-Arm Study to Compare the Efficacy of the MiniMed Paradigm REAL-Time System Versus Multiple Daily Injections (MDI) in Subjects Naïve to Insulin Pump Therapy|STAR3|Medtronic Diabetes|Yes|Completed|January 2007|June 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|485|||Both|7 Years|70 Years|No|||April 2015|April 6, 2015|January 2, 2007|Yes|Yes||No|December 24, 2010|https://clinicaltrials.gov/show/NCT00417989||175596|
NCT00418002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAQW051A2102|Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.|A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051||Novartis||Completed|May 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418002||175595|
NCT00414245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor434306ctil|Metformin for the Treatment of Diabetes in Pregnancy|Metformin for the Treatment of Diabetes in Pregnancy||Soroka University Medical Center||Not yet recruiting|January 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Female|18 Years|45 Years|No|||December 2006|December 20, 2006|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00414245||175878|
NCT00414258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06 - 0347|The Holding Study: Feeding Analgesia in Preterm Infants|The Holding Pilot Study: Feeding Analgesia in Preterm Infants||University of British Columbia|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2011|April 12, 2011|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414258||175877|
NCT00414271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS 0420|Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer|A Phase II Study of Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|January 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00414271||175876|
NCT00408707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01320120|Local Infiltration Analgesia With Ropivacaine Versus Placebo in Bilateral Knee Arthroplasty|Local Infiltration Analgesia With Ropivacaine Versus Placebo in Bilateral Knee Arthroplasty: a Placebo Controlled, Randomized, Double-Blinded Study.||Hvidovre University Hospital||Completed|September 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Both|N/A|N/A|No|||February 2008|February 28, 2008|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408707||176288|
NCT00408720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYEE06-001|Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies|Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies||The New York Eye & Ear Infirmary||Completed|October 2006|December 2006||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||25|||Both|18 Years|95 Years|No|||December 2006|December 6, 2006|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00408720||176287|
NCT00409019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AUS05|Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy|A Prospective, Randomized, Trial to Investigate the Effect of Continued Adefovir Versus Combination Regimens of Telbivudine Plus Adefovir, and Telbivudine Plus Tenofovir in Patients With Chronic Hepatitis B and Suboptimal Viral Suppression (PROACTIV Study)||Novartis||Withdrawn||||March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|70 Years||||March 2015|March 5, 2015|December 7, 2006|||Study cancelled: Withdrawn before enrollment of any participants|No||https://clinicaltrials.gov/show/NCT00409019||176266|
NCT00409032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBS-C03-OP|A Dose-response Study With Strontium Malonate in Postmenopausal Women|A Dose-response Study With Strontium Malonate in Postmenopausal Women. A 12 Week, Multi National, Double Blind, Randomized, 5 Arms, Parallel Group Placebo Controlled Open Label Active Controlled, Phase II Study With 3 Dose Levels of Strontium Malonate and Protelos Within Post Menopausal Women With a BMDT-score Below -1||Osteologix||Completed|December 2006|September 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||275|||Female|50 Years|N/A|No|||October 2009|October 22, 2009|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409032||176265|
NCT00415142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5574|An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder|An Eight-week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients With Major Depressive Disorder||Sanofi||Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|393|||Both|60 Years|64 Years|No|||July 2011|July 25, 2011|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415142||175812|
NCT00415441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|299890|Effectiveness of Physiotherapy for Chronic Shoulder Pain|Efficacy and Cost-effectiveness of Physiotherapy for Chronic Rotator Cuff Pathology||University of Melbourne|No|Completed|March 2004|September 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415441||175789|
NCT00410150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11-34-74-067|Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation|A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus||Children's Hospital Medical Center, Cincinnati|Yes|Terminated|April 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|24 Months|18 Years|No|||October 2010|October 22, 2010|December 11, 2006|Yes|Yes|Study was stopped after interim analysis and slow enrollment.|No|September 15, 2010|https://clinicaltrials.gov/show/NCT00410150||176182|
NCT00415675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0962|Respiratory Tumor and Normal Tissue Motion|Assessing the Magnitude and Potential Impact of Respiration-Induced Three-Dimensional Motion of Tumors and Normal Tissues Using Four-Dimensional CT Technology||M.D. Anderson Cancer Center|No|Completed|November 2004|||October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|||Both|N/A|N/A|No|Non-Probability Sample|Study participants with Abdominal or Lung Cancer.|October 2012|October 22, 2012|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00415675||175772|
NCT00415974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA121300-01|PACE-PC: Primary Care Management of Adolescent Obesity|PACE-PC: Primary Care Management of Adolescent Obesity||University of California, San Diego|Yes|Completed|February 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|106|||Both|11 Years|13 Years|No|||August 2012|August 15, 2012|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00415974||175749|
NCT00416247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rambam2409_CTIL|Effect of Hypnosis on Motor Cortex Excitability|Effect of Hypnosis on Motor Cortex Excitability||Rambam Health Care Campus||Completed|December 2006|June 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2006|August 4, 2010|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00416247||175728|
NCT00416533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-85302|Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of Taxotere (Docetaxel) Plus Adriamycin (Doxorubicin) and Prednisone (TAP) in Hormone-Refractory Prostate Cancer||Comprehensive Cancer Center of Wake Forest University||Completed|August 2004|||October 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|47|||Male|18 Years|N/A|No|||June 2013|June 4, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416533||175707|
NCT00416546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2113|Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects|A Double Blind, Randomized, Placebo-Controlled Study of AEB071 in Healthy Volunteers to Evaluate the Safety/Tolerability of 14 Day Multiple-Dose AEB071 and Measure the Effect of Ethnicity on Pharmacokinetics, Pharmacodynamics and Safety/Tolerability in Caucasian and Japanese Subjects Receiving Single and Multiple Doses of AEB071||Novartis||Completed|October 2006|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|August 8, 2008|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416546||175706|
NCT00416858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453783|Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery|Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer||Federation Francophone de Cancerologie Digestive||Completed||April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|40|||Both|N/A|N/A|No|||April 2007|March 3, 2014|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416858||175683|
NCT00417092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL 04-156|Biventricular Pacing After Coronary Artery Bypass Grafting (BIVAC)|||University of Schleswig-Holstein||Completed|December 2006|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|December 28, 2006||||No||https://clinicaltrials.gov/show/NCT00417092||175665|
NCT00417105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHD001|Protein-Bound Uremic Retention Solutes in Long Nocturnal Hemodialysis|A Multicentric Observational Study on the Removal of Protein-Bound Uremic Retention Solutes in Nocturnal Hemodialysis: A Cross-Sectional Analysis||Universitaire Ziekenhuizen Leuven|Yes|Completed|December 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|120|Samples Without DNA|serum, urine, dialysate|Both|18 Years|N/A|No|Probability Sample|Maintenance hemodialysis patients|March 2009|March 4, 2009|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417105||175664|
NCT00417404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNO50BO17|Vitamin A and Very Low Birthweight Babies (VitAL)|Does Additional Vitamin A Supplementation Improve Retinal Function and Conjunctival Health in Very Low Birthweight Infants?||Glasgow Royal Infirmary|Yes|Completed|January 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|94|||Both|N/A|72 Hours|No|||June 2010|June 24, 2010|December 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00417404||175641|
NCT00417417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070055|Rilonacept to Improve Artery Function in Patients With Atherosclerosis|Effects of Interleukin-1 Inhibition on C-Reactive Protein Levels, Endothelial Progenitor Cell Mobilization and Endothelial Function in Patients With Coronary Artery Disease||National Institutes of Health Clinical Center (CC)|Yes|Completed|December 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|December 29, 2006|Yes|Yes||No|September 14, 2009|https://clinicaltrials.gov/show/NCT00417417||175640|
NCT00417677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-402|A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma|A Phase I/II Study of Temsirolimus and Sunitinib in Subjects With Advanced Renal Cell Carcinoma||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|March 2007|May 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||124|||Male|18 Years|N/A|No|||October 2007|December 19, 2007|January 2, 2007|||Decision was made not to attempt a lower dose|No||https://clinicaltrials.gov/show/NCT00417677||175620|
NCT00417690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASER-AFC.001|High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease|A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease||Jacobus Pharmaceutical||Terminated|January 2007|October 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||October 2008|October 14, 2008|January 2, 2007|Yes|Yes|Efforts at recruitment have halted as recruitment was poor.|No||https://clinicaltrials.gov/show/NCT00417690||175619|
NCT00413660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921025|Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis|A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone||Pfizer|No|Completed|January 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|509|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|December 18, 2006|Yes|Yes||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00413660||175922|
NCT00413673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU # 2335-99|Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel|Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel||Walter Reed Army Medical Center||Completed|August 2001|March 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2007|March 31, 2008|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413673||175921|
NCT00413998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006HS020B|Randomised Ischaemic Mitral Evaluation (RIME) Trial|Randomized Evaluation of Mitral Annuloplasty During Coronary Artery Bypass Grafting for Moderate Functional Ischaemic Mitral Regurgitation.|RIME|Imperial College London|Yes|Completed|January 2007|August 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|N/A|N/A|No|||August 2013|June 3, 2015|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413998||175897|
NCT00414882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0017|A Cluster-Randomized Trial of DOTS vs DOTS Plus Active Case Finding|A Cluster-Randomized Trial of DOTS Versus DOTS Plus Active Case Finding to Reduce Tuberculosis Incidence in Rio de Janeiro, Brazil||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|June 2007|June 2012||||N/A|Observational|Time Perspective: Prospective||||200000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|August 26, 2010|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00414882||175831|
NCT00413985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000003971|Post Discharge Human Milk Fortifier in Preterm Infants|Growth and Development in Preterm Infants Fed Human Milk Containing a Powdered Human Milk Fortifier (HMF) Post Hospital Discharge||The Hospital for Sick Children||Completed|January 2004|||November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|4 Months|No|||December 2013|December 30, 2013|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413985||175898|
NCT00414232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-06109|Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy|Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy||Sidney Kimmel Comprehensive Cancer Center|No|Completed|November 2006|||October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Males or females greater than or equal to 18 years of age with a working diagnosis of        rectal cancer.|January 2013|January 7, 2013|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414232||175879|
NCT00413751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU #03-23004|Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes|||Walter Reed Army Medical Center||Completed||||||N/A|Observational|Time Perspective: Longitudinal||||20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2006|December 19, 2006|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413751||175915|
NCT00413764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06089|Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)|A Multicenter, Randomized, Double-Blind, Double Dummy Trial to Compare the Effects Tibolone and Transdermal Continuous Combined Estradiol/Norethisterone on Sexual Desire and Arousal in Postmenopausal Women With Sexual Dysfunction||Merck Sharp & Dohme Corp.|No|Completed|June 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|358|||Female|48 Years|68 Years|No|||May 2014|May 23, 2014|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413764||175914|
NCT00414518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0757|Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection|An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States||University of Colorado, Denver|Yes|Completed|January 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|December 19, 2006|Yes|Yes||No|September 6, 2012|https://clinicaltrials.gov/show/NCT00414518||175857|
NCT00414531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVALIP05|Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity|Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity||University of Oslo School of Pharmacy||Completed|May 2005|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|53|||Both|18 Years|N/A|No|||August 2009|December 2, 2014|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414531||175856|
NCT00416026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-HS10531|Translating Research: Patient Decision Support/Coaching|||Michigan State University||Completed|January 2002|October 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||304|||Both|19 Years|N/A|No|||December 2006|December 26, 2006|December 26, 2006||||No||https://clinicaltrials.gov/show/NCT00416026||175745|
NCT00414804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0805|Spinal Cord Stimulation Versus Nerve Blocks and Physical Therapy|Spinal Cord Stimulation (SCS) Versus Nerve Blocks and Physical Therapy for Complex Regional Pain Syndrome||Boston Scientific Corporation|No|Withdrawn|December 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|December 20, 2006||No|Investigator decided to withdraw participation in the study|No||https://clinicaltrials.gov/show/NCT00414804||175837|
NCT00410163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111774|Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients|An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With Fludarabine and Cyclophosphamide, in Patients With Previously Untreated B-cell CLL|BIFROST|GlaxoSmithKline|Yes|Completed|January 2007|May 2013|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||November 2013|December 19, 2013|December 11, 2006|No|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00410163||176181|
NCT00410176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4335CTIL|A Randomized, Controlled, Unblinded, Clinical Trial of the Acceptability and Efficacy of Non-Pharmaceutical Methods in Preventing Spread of Influenza Within the Family|||Ministry of Health, Israel||Not yet recruiting|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|N/A|N/A||||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410176||176180|
NCT00415987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|572|Hematopoietic Stem Cell Transplantation in Myeloma|||Azienda Ospedaliera San Giovanni Battista||Active, not recruiting||September 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||June 2008|June 19, 2008|December 26, 2006||||No||https://clinicaltrials.gov/show/NCT00415987||175748|
NCT00416260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10532-HFO-TGI|Combined High Frequency Oscillation and Tracheal Gas Insufflation for Severe Acute Respiratory Distress Syndrome|Phase 1/Phase 2, Single-Center, Controlled Study of the Effectiveness of Combined High Frequency Oscillation and Tracheal Gas Insufflation in Improving the Clinical Course of Patients With Severe Acute Respiratory Distress Syndrome||University of Athens|Yes|Completed|July 2006|September 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|75 Years|No|||June 2014|June 21, 2014|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00416260||175727|
NCT00416871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000468028|Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer|Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO]||Centre Leon Berard||Completed||February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|220|||Both|18 Years|70 Years|No|||September 2012|September 25, 2012|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416871||175682|
NCT00416559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454574|Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only|Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma||National Cancer Institute (NCI)||Active, not recruiting|December 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Supportive Care|||Anticipated|140|||Both|N/A|20 Years|No|||May 2007|September 19, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416559||175705|
NCT00417703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006032|Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab|A Prospective Investigation of the Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab||Oklahoma State University Center for Health Sciences||Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 4|Observational|Time Perspective: Prospective|||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 22, 2008|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00417703||175618|
NCT00416624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000522677|Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy|RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa||Mayo Clinic|Yes|Completed|May 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|320|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|December 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00416624||175700|
NCT00413400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001060|Study of TNF-Antagonism in the Metabolic Syndrome (II)|Effects of Etanercept in Patients With the Metabolic Syndrome (II)||Massachusetts General Hospital|Yes|Completed|December 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||November 2010|November 3, 2010|December 7, 2006|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00413400||175942|
NCT00413413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2316|Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension|A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy.||Novartis||Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1134|||Both|18 Years|85 Years|No|||April 2011|April 26, 2011|December 18, 2006||No||No|August 6, 2009|https://clinicaltrials.gov/show/NCT00413413||175941|
NCT00413686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1040C00002|Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies|A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies||AstraZeneca||Completed|December 2006|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||December 2010|December 3, 2010|December 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413686||175920|
NCT00414011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU # 04-2335-99e|Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)|||Walter Reed Army Medical Center||Completed||February 2005|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|December 19, 2006||||No|April 1, 2013|https://clinicaltrials.gov/show/NCT00414011||175896|
NCT00414284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-124|BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)|Evaluation of the Pharmacokinetics and Tolerability of Increased Dosage of Lopinavir/Ritonavir(LPV/r) in Individuals Experiencing Viremia on Standard Dose LPV/r Using LPV/r Tablet Formulation||Community Research Initiative of New England||Terminated|June 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||December 2010|December 6, 2010|December 20, 2006|||One subject's HIV RNA rebounded at week 12. A repeat PhenoSense GT combination resistance    assay at week 12 revealed evolution in protease inhibitor resistance.|No||https://clinicaltrials.gov/show/NCT00414284||175875|
NCT00414557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040850|Knee Malalignment and Thigh Muscle Strengthening in Individuals With Medial Knee Arthritis|The Effects of Knee Malalignment and Quadriceps Strengthening on the Adduction Moment in Individuals With Medial Knee Osteoarthritis||University of Melbourne||Completed|May 2004|December 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||107|||Both|50 Years|N/A|No|||December 2006|December 21, 2006|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00414557||175854|
NCT00416910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCLLSG-CLL6|Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia|Treatment of Advanced Chronic Lymphocytic Leukemia (CLL) Fludarabine, Mitoxantrone and Cyclophosphamide With or Without G-CSF||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||January 2006|August 1, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416910||175679|
NCT00414544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CosmetaLife 1|Evaluation of the Safety and Efficacy of CosmetaLife™ for the Correction of Nasolabial Folds|A Randomized, Double-Blind, Multicenter Comparison of the Safety and Efficacy of CosmetaLife™ Versus Control for the Correction of Nasolabial Folds||Cosmeta|Yes|Completed|October 2006|March 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 22, 2011|December 20, 2006|Yes|Yes||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00414544||175855|
NCT00415155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10460|A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma|An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma||Eli Lilly and Company||Withdrawn|August 2008|January 2011|Anticipated|January 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2008|August 27, 2008|December 20, 2006|Yes|Yes|Trial cancelled|No||https://clinicaltrials.gov/show/NCT00415155||175811|
NCT00414869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCXDE05-02|Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure|Preliminary Efficacy And Tolerability Of Oral NCX-1000 After Repeated Administrations In Patients With Portal Hypertension: A Double-Blind Dose Escalating Study||Axcan Pharma|No|Terminated|November 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||May 2010|October 31, 2011|December 21, 2006||No|Preliminary analysis of 11 patients did not demonstrate the efficacy required.|No||https://clinicaltrials.gov/show/NCT00414869||175832|
NCT00415129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPA02|Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly|||Sanofi|No|Completed|June 2006|March 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415129||175813|
NCT00415779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZANTE|ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer|Phase I Study of the Combination of Zoledronic Acid and Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer|ZANTE|National Cancer Institute, Naples|No|Completed|July 2006|July 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Male|18 Years|N/A|No|||February 2010|February 23, 2010|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00415779||175764|
NCT00415376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000520380|Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases|A Pilot Study of the Efficacy of Levetiracetam in Patients With Seizures From Brain Metastases||Northwestern University||Withdrawn|February 2007|July 2007||July 2007|Actual|N/A|Interventional|Primary Purpose: Supportive Care|||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|December 20, 2006|No|Yes|Unable to accrue subjects|No||https://clinicaltrials.gov/show/NCT00415376||175794|
NCT00415389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA9948|The Stroke Warning Information and Faster Treatment Study (SWIFT)|The Stroke Warning Information and Faster Treatment Study (SWIFT)||Columbia University|No|Terminated|February 2005|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|1635|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|December 21, 2006||No|Approval lapse|No||https://clinicaltrials.gov/show/NCT00415389||175793|
NCT00416884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449649|Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML|Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571)||OHSU Knight Cancer Institute|Yes|Terminated|May 2003|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|4 Years|75 Years|No|||July 2011|July 6, 2011|December 27, 2006|Yes|Yes|Low enrollment|No|May 31, 2011|https://clinicaltrials.gov/show/NCT00416884||175681|Study was terminated early due to low enrollment, hence the study did not have any treatment-related mortalities to report.
NCT00414817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443|Telephone-Based Program to Promote Inhaled Corticosteroid Adherence Among Individuals With Asthma|Phone Calls to Promote Adherence With Inhaled Corticosteroids||National Heart, Lung, and Blood Institute (NHLBI)|No|Active, not recruiting|June 2007|June 2011|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|14064|||Both|18 Years|N/A|No|||April 2009|June 3, 2010|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414817||175836|
NCT00415103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-00055-18|AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors|AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors|AMENO-2|PETHEMA Foundation|Yes|Completed|November 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415103||175815|
NCT00415350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAT-2006-MCA1|Bronchiectasis and Long Term Azithromycin Treatment|Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment|BAT|Medical Center Alkmaar|No|Active, not recruiting|April 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|March 16, 2010|December 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00415350||175796|
NCT00416572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU-00000603|Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer|Adjustment to Breast Cancer Among Younger Women||National Cancer Institute (NCI)||Completed||April 2006|Actual|||N/A|Interventional|Allocation: Randomized|||Anticipated|264|||Female|N/A|49 Years|No|||October 2007|May 29, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416572||175704|
NCT00416585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-hmnm-1385|Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne|Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment||hahid Beheshti University of Medical Sciences||Completed|October 2005|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2008|January 22, 2008|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416585||175703|
NCT00417118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5583|An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder|An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder||Sanofi||Completed|December 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|365|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|December 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00417118||175663|
NCT00417430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-082|Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies|Phase II Study of Efficacy of ICI 182,780 (Faslodex) in the Treatment of Systemic Lupus Erythematosus: Clinical, Serologic, Molecular||The Center for Rheumatic Disease, Allergy, & Immunology||Completed|September 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|December 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00417430||175639|
NCT00417144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ag vs antag PCOS|Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients|Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients||Eugonia||Recruiting|November 2003|May 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2006|December 28, 2006|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00417144||175661|
NCT00417456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000289|The Development and Evaluation of an "E-Visit" Program for the Management of Acne|The Development and Evaluation of an "E-Visit" Program for the Management of Acne||Massachusetts General Hospital|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|151|||Both|12 Years|N/A|No|||March 2012|March 14, 2012|December 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00417456||175637|
NCT00414037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060881|How do Sleeping Pills Affect Pain in the Brain?|Subchronic Effects of Eszopiclone (Lunesta) on Pain Behavior and Circuitry in Primary Insomnia||University of California, San Diego|No|Terminated|December 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|December 19, 2006||No|Funding terminated by sponsor, insufficient data collection|No||https://clinicaltrials.gov/show/NCT00414037||175894|
NCT00415194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8431|A Study for Patients With Head and Neck Cancer|A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer||Eli Lilly and Company|Yes|Completed|December 2006|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|795|||Both|18 Years|N/A|No|||June 2011|June 23, 2011|December 20, 2006|Yes|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00415194||175808|
NCT00416065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|plaqueCTIL|PET/CT to Identify "Vulnerable" Arterial Plaque|PET/CT to Identify "Vulnerable" Arterial Plaque||Rambam Health Care Campus||Recruiting|April 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||800|||Both|50 Years|N/A|No|||November 2006|December 26, 2006|December 26, 2006||||No||https://clinicaltrials.gov/show/NCT00416065||175742|
NCT00415818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG4010.09|Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer|A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer||Transgene||Completed|December 2005|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|December 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415818||175761|
NCT00415831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200A2102|Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 12.5 mg Carbidopa, 50 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 12.5 mg Carbidopa and 50 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fed Conditions||Novartis||Completed|June 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415831||175760|
NCT00415844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200A2103|Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 25 mg Carbidopa, 100 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 25 mg Carbidopa and 100 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions||Novartis||Completed|June 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415844||175759|
NCT00415168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10874|Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer|Phase 2 Study of ALIMTA® (Pemetrexed) Plus Cisplatin as First-Line Treatment of Gastric Cancer||Eli Lilly and Company|No|Completed|December 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|70 Years|No|||August 2010|August 11, 2010|December 20, 2006|Yes|Yes||No|July 13, 2010|https://clinicaltrials.gov/show/NCT00415168||175810|
NCT00417157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNC|Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH|Successful Application of Modified Natural Cycle in Poor Responders With High Basal FSH Prior to Oocyte Donation||Eugonia||Completed|January 2007|December 2012|Actual|December 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing IVF treatment|December 2013|December 13, 2013|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00417157||175660|
NCT00417469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NADGL00106|A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)|A Single-Blind, Randomized, Single-Center Evaluation of Procedural and Post Procedural Pain Experienced With Injections of NADG With Lidocaine Injectable Gel as Compared to Captique® Injectable Gel in Subjects Undergoing Cutaneous Correction of Nasolabial Folds||Sanofi||Completed|January 2007|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment||||45|||Both|18 Years|N/A||||March 2015|March 4, 2015|December 28, 2006||||||https://clinicaltrials.gov/show/NCT00417469||175636|
NCT00413452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060104|Etanercept SFP in RA Patients|Open-Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis.||Amgen||Completed|December 2006|October 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00413452||175938|
NCT00414921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS39087_kiddie-CAT|Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)|Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)|kiddie-CAT|University of Cincinnati|Yes|Completed|September 2003|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|4 Years|6 Years|No|||December 2007|May 20, 2009|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414921||175828|
NCT00408460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6137|Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-Small Cell Lung Cancer||University of Washington|No|Completed|February 2006|||August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|70 Years|N/A|No|||May 2013|May 7, 2013|December 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408460||176306|
NCT00408473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1556-FLEC|Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.|A Randomised Double-Blind Pilot Study Comparing Flecainide CR and Placebo in the Early Treatment of Patients With a Documented First Episode of Atrial Fibrillation.||MEDA Pharma GmbH & Co. KG||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||256|||Both|18 Years|65 Years|No|||February 2007|February 21, 2007|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408473||176305|
NCT00415116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-CCF-7216|Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors|Phase I Trial of Three-Weekly Docetaxel, Carboplatin and Oral CC-5013 in Patients With Advanced Solid Tumors||The Cleveland Clinic||Completed|August 2004|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||November 2006|July 6, 2011|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415116||175814|
NCT00415363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10710|Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy|A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer||Eli Lilly and Company|No|Completed|December 2006|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||January 2011|April 5, 2011|December 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415363||175795|
NCT00415688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF001|Lifestyle Modification for Obesity-Related Type 2 Diabetes|A Randomized, Controlled Trial of a Low-Carbohydrate, Ketogenic Diet Versus a Low-Glycemic Index Diet for Obesity-Related Type 2 Diabetes||Robert C. Atkins Foundation||Completed|July 2004|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|18 Years|65 Years|No|||December 2006|December 21, 2006|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00415688||175771|
NCT00414024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919N2302|Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.|An Open Label 52-week Study to Evaluate the Safety and Efficacy of Tegaserod Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain||Novartis||Terminated|February 2007|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A||||April 2012|April 19, 2012|December 19, 2006||No|This study was terminated early as a result of regulatory action suspending tegaserod use in    2007|||https://clinicaltrials.gov/show/NCT00414024||175895|
NCT00414895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216/06|Absolute Myocardial Perfusion Measurement in the Transplanted Heart|Absolute Myocardial Perfusion Measurement in the Transplanted Heart: a New Method for Accurate Detection of Allograft Rejection. A Pilot Study||University Hospital Inselspital, Berne||Completed|December 2006|June 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|80 Years|No|Probability Sample|Prospective study with consecutive inclusion of transplanted patients undergoing follow-up        exams. Examinations comprise endomyocardial biopsy (EMB) and, partly, coronary angiography        on the subsequent day. Group A patients (i.e. those without coronary angiography) undergo        MCE and pharmacologic stress with adenosine, the results of which are compared with the        EMB done at the same day. If they have an acute rejection, they are reexamined during a        histologically proven rejection free period, and the results are compared with those        obtained during acute rejection. Group B patients (i.e. with EMB and coronary angiography)        undergo the same procedure as in group A. Additionally, coronary collateral flow index        (CFI) is obtained and an IVUS exam is performed during coronary angiography.|October 2010|October 25, 2010|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00414895||175830|
NCT00415753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-05-0765|Procalcitonin as a Marker of Bacterial Pneumonia|||Aarhus University Hospital Skejby|No|Completed|June 2006|August 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|223|||Both|18 Years|N/A|No|||May 2008|May 22, 2008|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00415753||175766|
NCT00416325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-2000-0931|Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer|Phase I Multiple Dose Pharmacokinetic Study of Lycopene Delivered in a Well-Defined Food-Based Lycopene Delivery System (Tomato Paste-Oil Mixture) in Patients at Increased Risk for Developing Prostate Cancer||National Cancer Institute (NCI)||Completed||September 2006|Actual|||Phase 1|Interventional|Primary Purpose: Prevention|||Anticipated|18|||Male|35 Years|75 Years|No|||September 2006|June 25, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416325||175722|
NCT00413439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSA-CS-002|Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy|Open Label, Multi-center, Sequential Group Clinical Study to Determine the Safety and Efficacy of Escalating Dosing Regimens of Intravenous BAL8557 in the Prophylaxis of Patients Undergoing Chemotherapy for Acute Myeloid Leukemia||Astellas Pharma Inc|No|Completed|May 2006|June 2007|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413439||175939|
NCT00413725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 503 (Phambili)|Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults|A Multicenter Double-Blind Randomized Placebo-Controlled Phase IIB Test-of-Concept Study to Evaluate the Safety and Efficacy of a Three-Dose Regimen of the Clade B-based Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in HIV-1 Uninfected Adults in South Africa||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2007|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|801|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413725||175917|
NCT00413738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Catheters04|Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease|Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease.A Randomized Controlled Trial:Heparin-Coated Central Venous Catheters Versus Antiseptic-Coated Central Venous Catheters||Centre National de Greffe de Moelle Osseuse||Completed|December 2006|January 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|4 Years|65 Years|No|||January 2009|January 26, 2009|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413738||175916|
NCT00414323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9547|Evaluation of the Effects of Duloxetine on Norepinephrine|Evaluation of the Effects of Duloxetine on Norepinephrine Transporter Inhibition in Healthy Subjects||Eli Lilly and Company||Completed|November 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2007|June 11, 2007|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00414323||175872|
NCT00414908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.3.124|A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy|A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy||Solvay Pharmaceuticals||Completed|October 2007|December 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|December 21, 2006|Yes|Yes||No|August 7, 2009|https://clinicaltrials.gov/show/NCT00414908||175829|Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and includes events started prior to the 1st administration but which worsened after the 1st intake.
NCT00415766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ovitrelle vs pregnyl|Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders|Recombinant hCG (Ovitrelle) Vesrus Urinary hCG (Pregnyl) for Triggering Final Oocyte Maturation in High Responders||Eugonia|No|Active, not recruiting|June 2013|July 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|December 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00415766||175765|
NCT00416052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE001|Relation Between Bone Density and the Regulation of Mineral Metabolism in Renal Stone Formers|Relation Between Bone Mineral Density and the Regulation of Mineral Metabolism in Renal Stone Formers||University Hospital Inselspital, Berne||Completed|March 2004|June 2006||||N/A|Observational|Observational Model: Case-Only||1||90|||Both|18 Years|N/A|No|Non-Probability Sample|Recurrent renal calcium stone formers|May 2011|May 18, 2011|December 26, 2006||||No||https://clinicaltrials.gov/show/NCT00416052||175743|
NCT00416637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008011|Bevacizumab in Treating Patients With Advanced Solid Tumors|Biomarker and Clinical Evaluation of Bevacizumab (Avastin) to Determine the Role of Nitric Oxide in Anti-VEGF Therapy||Duke University||Completed|January 2004|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|December 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00416637||175699|
NCT00416130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR05/24/06|Clinical Trial of SAHA in Patients With Breast Cancer|Phase I/II Clinical Trial of Vorinostat in Patients With Recurrent and/or Metastatic Breast Cancer||National University Hospital, Singapore|No|Active, not recruiting|January 2007|January 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Female|18 Years|N/A|No|||December 2013|December 8, 2013|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00416130||175737|
NCT00417170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2239|Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome|A Double-blind, Double Dummy, Randomized Parallel Design Trial to Study the Effects of 12 Weeks of Treatment With 300mg Aliskiren vs. 5mg Amlodipine on Insulin Resistance and Endothelial Dysfunction in Hypertensive Patients With Metabolic Syndrome||Novartis|No|Completed|October 2007|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||September 2011|September 22, 2011|December 28, 2006|Yes|Yes||No|July 15, 2011|https://clinicaltrials.gov/show/NCT00417170||175659|
NCT00413465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPF.sa.cim.rh.dk|Study of Renal Blood Flow During Human Endotoxemia|Renal Plasma Flow During Experimental Human Endotoxemia||Rigshospitalet, Denmark||Recruiting|November 2006|December 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||32|||Male|25 Years|80 Years|Accepts Healthy Volunteers|||December 2006|December 18, 2006|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00413465||175937|
NCT00414583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II PV03/2006|Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke Patients|Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in an Unselected Group of Young Stroke Patients: an International, Multicentre Prevalence Study|sifap1|University of Rostock|Yes|Completed|January 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5000|Samples With DNA|Fabry diagnostic will be done centrally: blood samples will be retained for analysis of      a-galactosidase in blood to diagnose an a-galactosidase deficit; in females direct analysis      of the gene has to be done since due to the Lyonisation effect a-galactosidase activity      might be normal in blood although the patient might suffer from Fabry disease.|Both|18 Years|55 Years|No|Probability Sample|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology        defined as patients having an acute ischemic stroke or transient ischemic attack less than        3 months before enrollment into the study|February 2010|October 10, 2012|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414583||175852|
NCT00414596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-AXW01|Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System|Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System For Treatment of Low Back Pain||NEMA Research, Inc.||Completed|December 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2009|February 12, 2009|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00414596||175851|
NCT00414609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2340|Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)|A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized Standard Therapy||Novartis|Yes|Completed|December 2006|July 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|820|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|December 19, 2006|Yes|Yes||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00414609||175850|
NCT00415207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU# 04-23009|Pharmacogenomics of Paclitaxel in Ovarian Cancer|Pharmacogenomics of Paclitaxel in Ovarian Cancer: Predictors of Toxicity and Response||University of Southern Denmark||Completed|December 2006|December 2010|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|Samples With DNA|paraffin embedded biopsies|Female|18 Years|N/A|No|Non-Probability Sample|Patients with ovarian cancer|December 2006|August 4, 2011|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415207||175807|
NCT00408499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000517090|Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer|Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC)||University of California, Davis|Yes|Active, not recruiting|August 2006|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|December 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00408499||176304|
NCT00408512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM5STRH9 AIFA|Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study|Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.|stayondiur|Federico II University||Completed|December 2006|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2500|||Both|18 Years|75 Years|No|||November 2009|June 24, 2011|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00408512||176303|
NCT00409136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002527|Multi-Center Human Alert Trial to Prevent DVT and PE|Physician Alerts to Prevent DVT and Pulmonary Embolism in Hospitalized Patients||Brigham and Women's Hospital|Yes|Completed|March 2006|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2496|||Both|18 Years|N/A|No|Probability Sample|Hospitalized patients that have a cumulative VTE risk score of 4 or more with no orders        for prophylactic measures.|January 2009|January 29, 2009|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409136||176257|
NCT00416000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0671B|Mechanism and Prevention of Remote Organ Injury Following Ruptured Aortic Aneurysm|Phase 1 Study of Complement Activation Following Ruptured Abdominal Aortic Aneurysm: Combining Human Observation With Animal Experimentation to Establish a Framework for Human Therapy||University Health Network, Toronto|No|Completed|January 2006|December 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|Samples Without DNA|plasma|Both|30 Years|80 Years|No|Non-Probability Sample|Those undergoing AAA repair for elevtive and ruptured AAA by both EVAR and open methods.|May 2014|May 20, 2014|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00416000||175747|
NCT00416013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVMS 05-08-EX-0246|Correlations Between BNP & Dry Weight, and Between Troponin & Mortality, in Hemodialysis Patients|Correlations Between BNP and Dry Weight, and Between Troponin and Mortality, in Hemodialysis Patients||Eastern Virginia Medical School|No|Active, not recruiting|December 2005|December 2010|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|151|||Both|18 Years|85 Years|No|Non-Probability Sample|End Stage Renal Disease (ESRD) patients on hemodialysis.|October 2010|October 6, 2010|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00416013||175746|
NCT00416273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006124|A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma|Consolidation Therapy With Bortezomib <= 60 Year Old Patients With Multiple Myeloma||Janssen-Cilag G.m.b.H|No|Completed|December 2006|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|60 Years|No|||March 2015|March 5, 2015|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00416273||175726|
NCT00416286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-23.12.05-HMO-CTIL|Effect of Sustained-Release Cetylpyridinium Chloride Varnish on Streptococcus Mutans and Lactobacillus in Orthodontic Patients|Phase 1: To Evaluate the Antibacterial Efficacy of Sustained Release Cetylpyridinium Chloride Varnish in Orthodontic Patients||Hadassah Medical Organization||Not yet recruiting||||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|30|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||December 2006|December 26, 2006|December 25, 2006||||No||https://clinicaltrials.gov/show/NCT00416286||175725|
NCT00414570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-14-0054 / 23061|An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine|An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine||AHS Cancer Control Alberta|Yes|Recruiting|November 2006|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414570||175853|
NCT00415415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1346|Factors Associated With Coronary Heart Disease in African Americans in the Jackson Heart Study|Disparities in CHD in the Jackson Heart Study||National Heart, Lung, and Blood Institute (NHLBI)||Completed|September 2000|March 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||5302|||Both|35 Years|84 Years|No|||December 2006|December 20, 2006|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00415415||175791|
NCT00415740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200A2101|Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 12.5 mg Carbidopa, 50 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 12.5 mg Carbidopa and 50 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions||Novartis||Completed|May 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415740||175767|
NCT00416611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAS-02-231206|IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study|IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study|IMPULSION|Hellenic Atherosclerosis Society|Yes|Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|75 Years|No|||January 2009|January 28, 2009|December 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00416611||175701|
NCT00410631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPOH-NB2004|Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma|NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma||National Cancer Institute (NCI)||Recruiting|October 2004|||December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|642|||Both|N/A|21 Years|No|||January 2008|August 6, 2013|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410631||176145|
NCT00414336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907051|Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria|Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults||National Institutes of Health Clinical Center (CC)||Completed|December 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1|||150|||Both|18 Years|45 Years|No|||August 2009|August 27, 2009|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414336||175871|
NCT00414349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|796838|Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain|Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain.||Grünenthal GmbH||Completed|December 2006|March 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|N/A|No|||June 2009|June 15, 2009|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414349||175870|
NCT00415428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581154|A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.|Patient And Physician Alliance -Guideline Education Treatment Optimization||Pfizer||Completed|January 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2776|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic patients|April 2015|April 21, 2015|December 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415428||175790|
NCT00416338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.401-T|Method of Exit Site Care in Chronic Peritoneal Dialysis Patients|Comparison of Two Exit-Site Care Methods, Film Dressing (F) Method and Simple Gauze Dressing (G) Method, in Chronic Peritoneal Dialysis (CPD) Patients||Chinese University of Hong Kong||Terminated|January 2007|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|80 Years|No|||April 2007|May 9, 2007|December 27, 2006|||We encounter technical problems to continue with the study. (Notably difficulty in teaching    the patients to use the dressing set involved in the study.)|No||https://clinicaltrials.gov/show/NCT00416338||175721|
NCT00411944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TacLTPK|Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients|Prospective Study of the Influence of CYP3A4/CYP3A5 and MDR1 Gene Single Nucleotide Polymorphisms on Long-Term Tacrolimus Disposition in Renal Allograft Recipients: a Five Year Follow-up Study Using Abbreviated Concentration-Time Measurements.||Katholieke Universiteit Leuven||Completed|August 1999|September 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|18 Years|75 Years|No|||December 2006|December 13, 2006|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00411944||176051|
NCT00412217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20294|A Study of Tarceva (Erlotinib) in Patients With Resected Head and Neck Squamous Cell Cancer.|A Randomized, Open Label, Study of the Effect of Tarceva on Progression Free Survival When Given as Maintenance Treatment Following Concurrent Chemo-radiotherapy or Radiotherapy Alone in Patients With Resected Head and Neck Squamous Cell Cancer||Hoffmann-La Roche||Terminated|November 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 15, 2006||No|The study was terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00412217||176030|
NCT00416403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000522934|Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer|Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer||University of California, San Francisco|Yes|Completed|July 2006|June 2011|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Female|N/A|N/A|No|||December 2012|December 12, 2012|December 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00416403||175716|
NCT00417742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0728|Project CHEER (Comprehensive Headache Evaluation, Education, Relief)|A Randomized Trial of Headache Management Programs||Duke University||Completed|June 2002|December 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||828|||Both|21 Years|N/A|No|||January 2007|August 20, 2014|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00417742||175615|
NCT00417755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4108|Effect of Invasive and Non Invasive Mechanical Ventilation on Feeding Delivery in COPD Elderly Patients|Effect of Invasive and Non Invasive Mechanical Ventilation on the Nutritional Status of COPD Elderly Patients||Rabin Medical Center||Not yet recruiting|January 2007|December 2007||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||40|||Both|50 Years|95 Years|No|||December 2006|January 3, 2007|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00417755||175614|
NCT00414362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0611103|Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin|Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin||University of Pittsburgh|Yes|Active, not recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|postive gram negative culture|December 2015|December 16, 2015|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414362||175869|
NCT00415402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT/PR 7489/PID/20/285/2006|Effect of Vitamin D Supplementation on Health of Low Birth Weight Infants|Randomised Controlled Trial to Evaluate the Preventive Effect on Mortality and Serious Morbidity/ Hospitalisations of Daily Vitamin D Supplements in Small for Gestational Age Term Infants|DIVIDS|Delhi University|Yes|Completed|March 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2000|||Both|N/A|2 Days|Accepts Healthy Volunteers|||August 2012|August 21, 2012|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415402||175792|
NCT00415714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H300|Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia|A Randomized Controlled Pilot Trial Testing the Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia||Helicor||Recruiting|September 2006|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||132|||Both|18 Years|55 Years|No|||December 2006|January 26, 2007|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00415714||175769|
NCT00415727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99NR31|Prevention Of Morbidity In Sickle Cell Disease Pilot Phase|||Institute of Child Health||Recruiting|November 2006|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind||||22|||Both|4 Years|16 Years||||December 2006|December 23, 2006|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415727||175768|
NCT00409149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140/06|The Effect of a Complementary Multi Disciplinary Program on Blood Pressure in Hypertensive Patients|Comprehensive Approach to Lower Measured Blood Pressure (CALM-BP) - Results From a Randomized Controlled Trial||Assaf-Harofeh Medical Center|No|Completed|December 2006|November 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|N/A|No|||April 2007|January 16, 2011|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409149||176256|
NCT00416299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KliLuNTproBNP|Prognostic Value of New Cardiac Biomarkers in Elderly Patients Undergoing Cardiac Surgery|Observational Cohort Study on the Prognostic Value of New Cardiac Biomarkers in Elderly Patients Undergoing Cardiac Surgery||Klinikum Ludwigshafen|No|Completed|May 2007|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|100|||Both|75 Years|N/A|No|||January 2009|January 29, 2009|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00416299||175724|
NCT00416312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0636|Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma|Dose-Response in Radioimmunotherapy of Lymphoma||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416312||175723|
NCT00417443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICLO2006|Epidural Clonidine for Postoperative Hyperalgesia|A Study of Effect of Epidural Clonidine on Postoperative Pain Relief, Hyperalgesia and Chronic Pain in Patients Undergoing Colorectal Surgery||Cambridge University Hospitals NHS Foundation Trust||Withdrawn|December 2007|December 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|80 Years|No|||December 2006|January 7, 2014|December 28, 2006||||No||https://clinicaltrials.gov/show/NCT00417443||175638|
NCT00415181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-319pro|Pharmacogenomics of Paclitaxel in Ovarian Cancer|The Pharmacogenomics of Paclitaxel in Patients With Ovarian Cancer: Predictors of Toxicity and Response||University of Southern Denmark||Completed|September 2006|March 2013|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|93|Samples With DNA|blood|Female|18 Years|N/A|No|Non-Probability Sample|patients diagnosed with ovarian cancer|December 2006|January 12, 2015|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415181||175809|
NCT00416039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051033|Efficacy of Sublingual Midazolam in Association With Oral Morphine in Children Analgesia After Bone Fracture|Clinical Randomized Study of Sublingual Midazolam in Association With Morphine by Oral Route in Arm Fracture in Children at the Emergency Children Care|MIDAZODOL|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2007|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|16 Years|No|||August 2013|August 27, 2013|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00416039||175744|
NCT00416897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000523378|Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure|A Randomised Controlled Trial of Adjunctive Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Renal Failure [MERIT] MyEloma Renal Impairment Trial||National Cancer Institute (NCI)||Completed|March 2003|December 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|280|||Both|18 Years|N/A|No|||June 2007|August 23, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416897||175680|
NCT00410878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011620|A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain|A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain||Alza Corporation, DE, USA||Completed||August 1999|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410878||176126|
NCT00410891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96803 (eProtocol 4384|Topical Antibiotics and Intravitreous Injections|||Stanford University||Completed|July 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|129|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|October 2, 2006||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT00410891||176125|
NCT00410852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2005/50557-5|Efficacy and Safety of Three Insulin Protocols in Medical Intensive Care Unit Patients|Randomized Study to Evaluate the Efficacy and Safety of Two Endovenous Insulin Protocols and a Subcutaneous Insulin Protocol in Critically Ill Patients||Hospital Israelita Albert Einstein|No|Completed|May 2005|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|168|||Both|21 Years|N/A|No|||October 2007|October 31, 2007|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410852||176128|
NCT00410865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-193|Wild Type p53 Adenovirus for Oral Premalignancies|Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]||M.D. Anderson Cancer Center|Yes|Terminated|June 2003|November 2010|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|December 11, 2006|Yes|Yes|Sponsor withdrawl prior to study completion.|No||https://clinicaltrials.gov/show/NCT00410865||176127|
NCT00411216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000336|Recovery of Visual Acuity in People With Vestibular Deficits|Recovery of Visual Acuity in Vestibular Deficits||Emory University|No|Completed|August 2000|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|December 12, 2006||No||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00411216||176102|
NCT00411229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9570|Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer|A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma|CLASSIC|Sanofi||Completed|June 2006|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1035|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|December 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00411229||176101|
NCT00411541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-BFM-SG IR ALL|Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia|Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia||International BFM Study Group||Completed|April 1995|January 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2600|||Both|N/A|17 Years|No|||December 2006|December 13, 2006|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00411541||176079|
NCT00411554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-054|A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)|Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -||Merck Sharp & Dohme Corp.||Completed|January 2007|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|319|||Both|20 Years|N/A|No|||February 2016|February 3, 2016|December 13, 2006|Yes|Yes||No|August 19, 2009|https://clinicaltrials.gov/show/NCT00411554||176078|
NCT00411567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAE397A2202|A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma|An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma||Novartis|No|Completed|July 2006|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||26|||Both|18 Years|75 Years|No|||June 2007|June 21, 2007|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00411567||176077|
NCT00412230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120254|Insulin Resistance and Hypertensive Disorders in Pregnancy|The Role of Insulin Resistance in Gestational Hypertension and in Preeclampsia.||University of Messina|No|Completed|October 2006|June 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant outpatients|February 2009|February 17, 2009|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412230||176029|
NCT00411970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23 versus 20 gauge|20- Versus 23- Gauge System for Pars Plana Vitrectomy|20- Versus 23- Gauge System for Pars Plana Vitrectomy: A Prospective Randomized Clinical Study||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||Completed|September 2004|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||October 2007|October 24, 2007|December 14, 2006||||No||https://clinicaltrials.gov/show/NCT00411970||176049|
NCT00416741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAS-01-231206|Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)|Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)|ATTEMPT|Hellenic Atherosclerosis Society|Yes|Completed|February 2005|February 2011|Actual|January 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2000|||Both|18 Years|75 Years|No|Probability Sample|Metabolic Syndrome (NCEP ATP III Definition modified to AHA/NHLBI definition)|June 2011|June 23, 2011|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416741||175691|
NCT00417300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074505|Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse|Treating Adolescents With CSA Related PTSD||University of Pennsylvania|Yes|Completed|February 2006|March 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|13 Years|18 Years|No|||June 2013|June 26, 2013|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417300||175649|
NCT00417768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0238-E|Safety and Effectiveness of tPA in Intra-abdominal Abscesses|Safety and Effectiveness of Local Instillation of tPA in the Management of Complex Intra-abdominal Fluid Collections: a Randomized, Double Blinded Controlled Clinical Trial||University Health Network, Toronto|No|Terminated|July 2005|November 2013|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|80 Years|No|||January 2014|January 13, 2014|January 2, 2007||No|Change in patient population no longer fit study criteria.|No||https://clinicaltrials.gov/show/NCT00417768||175613|
NCT00414050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_053|A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants|A Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age||Merck Sharp & Dohme Corp.||Completed|September 2006|December 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1718|||Both|2 Months|2 Months|Accepts Healthy Volunteers|||May 2009|May 19, 2009|December 20, 2006|Yes|Yes||No|October 15, 2008|https://clinicaltrials.gov/show/NCT00414050||175893|
NCT00412516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEV02|Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine|Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone||PATH|No|Completed|December 2006|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|519|||Both|20 Months|36 Months|Accepts Healthy Volunteers|||October 2014|October 3, 2014|December 14, 2006||No||No|September 30, 2014|https://clinicaltrials.gov/show/NCT00412516||176008|
NCT00412828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011-CLN-11|A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma|A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma||Celldex Therapeutics|Yes|Completed|June 2006|May 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00412828||175985|
NCT00416598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00444|Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia|Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML &lt; 60 Years||National Cancer Institute (NCI)||Active, not recruiting|November 2006|||January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|546|||Both|15 Years|59 Years|No|||January 2016|February 5, 2016|December 27, 2006|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00416598||175702|
NCT00413166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0706|All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab|Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Gemtuzumab||M.D. Anderson Cancer Center|No|Completed|December 2006|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|N/A|N/A|No|||February 2016|February 15, 2016|December 15, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413166||175960|
NCT00409162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 3722; 91/06|Safety and Efficacy Study of a New Device for Tattoo Removal|A Prospective, Open Label, Non Randomized, First-In-Man (Feasibility) Study to Evaluate the Safety and Effectiveness of the Eraser Tattoo Removal Device||Assaf-Harofeh Medical Center||Not yet recruiting|December 2006|October 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2006|December 7, 2006|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409162||176255|
NCT00417131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Studieprotokoll 2006-05-12|Imaging of Islet Transplantation With PET and MRT|Imaging of Islet Transplantation With PET and MRT||Uppsala University Hospital|No|Completed|October 2006|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients referred to islet transplantation in the Nordic countries (Scandinavia)|July 2008|August 3, 2011|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417131||175662|
NCT00413699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921024|Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis|A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis||Pfizer|Yes|Recruiting|February 2007|November 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4385|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413699||175919|
NCT00413712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB18/1997|Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT|Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.||Singapore General Hospital||Completed|January 1997|March 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||206|||Both|10 Years|N/A|No|||December 2006|December 19, 2006|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413712||175918|
NCT00409656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-2003-12-2005-12|Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients|Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients||University Hospital Freiburg||Completed|December 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|N/A|No|||December 2006|December 12, 2006|December 8, 2006||||No||https://clinicaltrials.gov/show/NCT00409656||176219|
NCT00409669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI 06-0987|Intraocular Pressure Accuracy and Variability of the Barraquer Tonometer|Study to Compare the Accuracy and Variability of the Barraquer Tonometer With Other Methods of Tonometry||Barnes Retina Institute||Recruiting|November 2006|November 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 6, 2008|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409669||176218|
NCT00409981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT - Pac 2|Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II)|Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II)||University Hospital, Saarland||Completed|July 2004|June 2006||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|N/A|No|||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00409981||176195|
NCT00410345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mifepristoneoxytocin-HMO-CTIL|Cervical Rippening With Antiprogesterone in Midtrimester Abortions|Cervical Rippening With Antiprogesterone in Midtrimester Abortions||Hadassah Medical Organization||Completed|August 2004|May 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|45 Years|No|||May 2008|November 2, 2008|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410345||176167|
NCT00410618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCB0213|Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer|Neurological Effects of Chemotherapy and Radiation Treatment: Colon Cancer||University of Arizona||Completed|April 2003|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|42|||Both|N/A|N/A|No|Probability Sample|Colon cancer|August 2012|December 2, 2015|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410618||176146|
NCT00411242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178A2302|Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder|An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-label Extension (CAGO178A2302E)||Novartis||Completed|December 2006|||January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|503|||Both|18 Years|70 Years|No|||May 2012|May 2, 2012|December 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411242||176100|
NCT00411580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAD106A2101|Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)|A 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Time-lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Aß-specific Antibody Response Following Three Subcutaneous Injections of CAD106||Novartis||Completed|June 2005|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|50 Years|80 Years|No|||March 2013|March 27, 2013|December 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00411580||176076|
NCT00411593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0045|Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)|Phase I-II Study of Avastin®+ Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC||M.D. Anderson Cancer Center|No|Withdrawn|November 2006|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|December 12, 2006|Yes|Yes|Lack of Patient Accrual|No||https://clinicaltrials.gov/show/NCT00411593||176075|
NCT00411957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 073|Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients|The Pharmacokinetics of Atazanavir / Ritonavir 200/100 OD Versus 300/100 mg OD in Combination With 2 NRTIs in HIV Pre-treated Patients||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|60 Years|No|||June 2010|June 4, 2010|December 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00411957||176050|
NCT00412243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0552|Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients|Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)||M.D. Anderson Cancer Center|No|Completed|March 2006|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|21 Years|N/A|No|||March 2013|March 8, 2013|December 14, 2006||No||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00412243||176028|
NCT00413595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II PV04/2006|Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation|Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study|sifap2|University of Rostock|Yes|Recruiting|April 2007|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|EDTA-blood and urine sample for central laboratory analysis of agalsidase antibodies and Gb3      for safety issues.      There will be a proteomic analysis in blood to check whether there will be the possibility      to characterize a biomarker for Fabry disease.|Both|18 Years|55 Years|No|Probability Sample|Adult patients (18 - 55 years of age) with an acute cerebrovascular event (CVE) of any        etiology defined as patients having an ischemic stroke or transient ischemic attack and        genetic diagnosis (a-galactosidase defect) of Fabry disease.|October 2015|October 6, 2015|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413595||175927|
NCT00414063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907048|Energy Metabolism and Nutrient Absorption in Lean and Obese Individuals|Investigation of Differences in Energy Metabolism and Nutrient Absorption Between Lean and Obese Individuals||National Institutes of Health Clinical Center (CC)||Completed|December 2006|March 2013||||N/A|Observational|N/A|||Anticipated|70|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|February 19, 2014|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414063||175892|
NCT00414076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0453|Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma|A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|December 2006|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|N/A|No|||November 2015|November 3, 2015|December 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414076||175891|
NCT00413205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB19751|TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)|A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.||Hoffmann-La Roche||Completed|January 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|491|||Both|44 Years|N/A|No|||March 2016|March 1, 2016|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413205||175957|
NCT00408525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040686|Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease|Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease||Vanderbilt University|No|Recruiting|December 2006|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408525||176302|
NCT00413179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH19970383H|The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women|The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial||Wilford Hall Medical Center||Completed|December 1997|April 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2006|December 18, 2006|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00413179||175959|
NCT00408863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05885|Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Investigate Safety and Efficacy of Tibolone (Org OD14) in Women With Climacteric Symptoms and a History of Breast Cancer||Merck Sharp & Dohme Corp.|Yes|Completed|May 2002|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3148|||Female|N/A|75 Years|No|||July 2015|July 13, 2015|December 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00408863||176278|
NCT00409175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX-005|Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis|Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study||Pfizer|Yes|Completed|January 2007|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|75 Years|No|||November 2012|November 16, 2012|December 6, 2006|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00409175||176254|Instead of the intended endpoint 'heat pain and cooling threshold', results of 'summated 3 score for small nerve fiber function' were reported.
NCT00417716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0011|Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema|The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema||Asociación para Evitar la Ceguera en México||Active, not recruiting|September 2005|May 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|45 Years|N/A|No|||June 2006|January 3, 2007|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00417716||175617|
NCT00417729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB951004/C06211|Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM|Phase 4 Study Evaluation of the Effects of Acarbose Versus Glibenclamide on Mean Amplitude of Glycemic Excursions and Oxidative Stress in Patients With Type 2 Diabetes Insufficiently Controlled by Metformin||Taichung Veterans General Hospital|No|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|51|||Both|30 Years|70 Years|No|||May 2010|May 11, 2010|January 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00417729||175616|
NCT00413426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328B2101|Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects|An Open-Labeled, Randomized, Single Dose, Three Period, 2-Sequence Crossover Study to Investigate the Pharmacokinetics of Darifenacin When Given as 7.5 mg Oral Doses of a Modified Release Suspension, as Compared to the Commercial Modified Release Tablet in Healthy Adult||Novartis||Completed|June 2006|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2007|November 29, 2007|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00413426||175940|
NCT00414297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61/06|External Counterpulsation (ECP) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease|External Counterpulsation (ECP) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease||University Hospital Inselspital, Berne|Yes|Completed|August 2006|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||October 2010|October 25, 2010|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414297||175874|
NCT00414310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0686|Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)|Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -"SPORE"||M.D. Anderson Cancer Center|Yes|Completed|December 2006|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|N/A|N/A|No|||July 2015|July 15, 2015|December 19, 2006|Yes|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT00414310||175873|
NCT00409396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Urinary PGE-M UC|A Study to Determine Whether Urinary PGE-M Levels Correlate With Ulcerative Colitis Disease|Urinary PGE-M, A Metabolite of PGE2: A Novel Biomarker of Ulcerative Colitis Disease||Vanderbilt University|No|Completed|November 2006|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|35|||Both|18 Years|N/A|No|||November 2014|June 5, 2015|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00409396||176237|
NCT00409682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-806|Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease|A Multi-Center, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease||Abbott|Yes|Completed|April 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|6 Years|17 Years|No|||July 2011|July 11, 2011|December 8, 2006|Yes|Yes||No|May 18, 2011|https://clinicaltrials.gov/show/NCT00409682||176217|Absence of placebo group comparative data.
NCT00409994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-16|Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer|A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study||Maastricht Radiation Oncology|Yes|Active, not recruiting|September 2006|August 2019|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|N/A|N/A|No|||January 2016|January 27, 2016|December 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00409994||176194|
NCT00410358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBQ707A1101|A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.|A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor.||Novartis||Completed|June 2006|||February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|20 Years|N/A|No|||October 2012|October 15, 2012|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410358||176166|
NCT00410371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBI108614|Study to Compare Two Formulations of Lamotrigine in Healthy Subjects|An Open-label, Randomised, Single-dose, Parallel-group Study to Compare the Pharmacokinetic Characteristics, Safety and Tolerability of Two Formulations of Lamotrigine in Healthy Subjects||GlaxoSmithKline||Completed|December 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410371||176165|
NCT00410644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011617|A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain|A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR (Hydromorphone HCI) in Patients With Chronic Non-Malignant Pain||Alza Corporation, DE, USA||Completed||February 1999|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|463|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410644||176144|
NCT00410657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2096.00|Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant|A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease||Fred Hutchinson Cancer Research Center||Completed|July 2006|||November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|53|||Both|N/A|N/A|No|||May 2010|May 12, 2010|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410657||176143|
NCT00410670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903244|Chordoma Family Study|The Chordoma Family Study: A Pilot Collaboration Between NCI and Massachusetts General Hospital (MGH) to Identify Chordoma Families||National Institutes of Health Clinical Center (CC)||Completed|June 2003|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|80|||Both|4 Years|75 Years|No|||December 2015|December 19, 2015|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00410670||176142|
NCT00410904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00165|AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer|Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)||National Cancer Institute (NCI)||Completed|October 2006|March 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||April 2014|September 19, 2014|December 11, 2006|Yes|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT00410904||176124|Pemetrexed was approved for front line therapy based on the results of a phase III study; it became known that pemetrexed is ineffective in pts.with squamous cell lung ca. It was also challenging to combine VEGF-TKIS with chemo this pt. population.
NCT00410930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV08.01|Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients|Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients||Stallergenes||Terminated|November 2002|November 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|50 Years|No|||December 2006|December 15, 2006|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410930||176123|
NCT00411255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060192|Brain Stimulation to Treat Blepharospasm or Meige Syndrome|Blepharospasm and the Experimental Modulation of Cortical Excitability in Primary and Secondary Motor Areas. A Pilot Study.||National Institutes of Health Clinical Center (CC)||Completed|June 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|22|||Both|18 Years|N/A|No|||February 2010|September 26, 2015|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411255||176099|
NCT00411606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC - 4220|Normal Values of Facial Thermography|Normal Values of Facial Thermography||West Penn Allegheny Health System||Completed|December 2006|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|7 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|outpatient subjects at Allegheny General Hospital|April 2009|April 3, 2009|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411606||176074|
NCT00412256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS4-EK-KAG/374|Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)|Clinical Trial to Evaluate the Effect of Parenteral Supplementation With Omega-3-Fatty Acids in Patients With Rheumatoid Arthritis||Humanis Klinikum Niederosterreich||Completed|September 2004|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||December 2006|December 15, 2006|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00412256||176027|
NCT00413608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060309|Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects|Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects||Assistance Publique - Hôpitaux de Paris|No|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2007|May 4, 2011|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413608||175926|
NCT00413933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor444506ctil|Comprehensive Intervention for Falls Prevention in the Elderly|||Soroka University Medical Center||Recruiting|April 2008|||August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|65 Years|N/A|No|||December 2006|April 12, 2010|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413933||175902|
NCT00412191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM105379|Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR|A Pivotal Single-dose Randomised, Parallel-group, Open-label Study to Demonstrate Bioequivalence of 300mg Lamotrigine XR Relative to 100mg + 200mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 300mg Lamotrigine XR in Healthy Male and Female Volunteers||GlaxoSmithKline|No|Completed|February 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|180|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|December 14, 2006||||||https://clinicaltrials.gov/show/NCT00412191||176032|
NCT00412204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.371|Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise|A Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Tiotropium Bromide on Gas Exchange in Subjects With COPD During Exercise||McMaster University|No|Completed|June 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|N/A|No|||October 2009|October 20, 2009|December 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00412204||176031|
NCT00413218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0105|Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections|A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections||Astellas Pharma Inc|Yes|Completed|December 2006|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|N/A|No|||August 2015|September 2, 2015|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413218||175956|
NCT00413231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigational Plan #078|Valor II: The Valiant Thoracic Stent Graft System Clinical Study|The Valiant Thoracic Stent Graft System. The Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System in the Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in Subjects Who Are Candidates for Endovascular Repair.||Medtronic Endovascular|Yes|Completed|December 2006|October 2014|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|85 Years|No|||October 2015|November 25, 2015|December 15, 2006|Yes|Yes||No|December 23, 2011|https://clinicaltrials.gov/show/NCT00413231||175955|Adverse Events and Serious Adverse Events listed in ClinicalTrials.gov were re-coded, using MedDRA 13.1. To do so, events were reclassified. As a result, data in listings may not match those in Clinical Update reports, SSEDs, or Instructions for Use.
NCT00408538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19-AI060614:P4 Aim 1|Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally|A Phase 1 Randomized, Blinded, Placebo-Controlled Safety and Acceptability Study of the UC-781 Vaginal Microbicide Gel Formulation Applied Rectally in HIV-1 Seronegative Adults||University of California, Los Angeles||Completed|December 2006|April 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 1, 2009|December 6, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00408538||176301|
NCT00408551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515900|Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver|A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis||National Cancer Institute (NCI)||Recruiting|November 2005|||June 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|No|||June 2009|December 18, 2013|December 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00408551||176300|
NCT00408889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|post OLT|Prospective Evaluation of Predictors for Organ Failure Following Liver Transplantation|Prospective Evaluation of Predictors for Organ Failure Following Liver Transplantation||Heidelberg University||Completed|December 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing liver transplantation|December 2008|April 8, 2010|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408889||176276|
NCT00408876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10545|Duloxetine Versus Placebo in Chronic Low Back Pain|Protocol F1J-MC-HMEO Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain||Eli Lilly and Company|No|Completed|December 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|404|||Both|18 Years|N/A|No|||November 2009|November 19, 2009|December 6, 2006|Yes|Yes||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00408876||176277|
NCT00409461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2001-434|Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts|Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts||AZ-VUB||Terminated||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|||||||Both|18 Years|65 Years||||December 2006|December 8, 2006|December 8, 2006||||No||https://clinicaltrials.gov/show/NCT00409461||176232|
NCT00410072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-110|Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B|A Comparative Study of Chronic Hepatitis B Subjects Treated With Entecavir Plus Tenofovir Combination Therapy vs. Entecavir Monotherapy in Adults Who Are Treatment-Naive to Nucleosides and Nucleotides: The BE-LOW Study||Bristol-Myers Squibb|No|Completed|April 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|669|||Both|16 Years|N/A|No|||March 2013|March 13, 2013|December 11, 2006|Yes|Yes||No|November 4, 2011|https://clinicaltrials.gov/show/NCT00410072||176188|
NCT00408824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIEM-G-3|Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)|Assessment of Genetic Risk of Metabolic Syndrome in Company Employee and Making New Health Guidance Program (NGK Study)||Nagoya University||Recruiting|September 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||Anticipated|4000|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2007|September 19, 2007|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408824||176280|
NCT00409097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK0506|Effect of Rosiglitazone on ADMA in Critical Illness|||VU University Medical Center||Recruiting|April 2006|December 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|75 Years|No|||December 2006|December 7, 2006|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409097||176260|
NCT00409383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM108|Abraxane and Temodar Plus Genasense in Advanced Melanoma|A Pilot Study of Abraxane® (Albumin-bound Paclitaxel) and Temodar® (Temozolomide) Plus Genasense® (Oblimersen Sodium) in Subjects With Advanced Melanoma ("The ATG Study").||Genta Incorporated|No|Active, not recruiting|November 2006|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||July 2010|November 4, 2011|December 7, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00409383||176238|
NCT00410007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|med.res.hos.2006.cc.03|The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease|The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease, During Basal Conditions and After Hypertonic Saline Infusion.||Regional Hospital Holstebro|No|Completed|October 2006|November 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|29|||Both|18 Years|65 Years|No|||December 2011|December 4, 2011|December 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00410007||176193|
NCT00410384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1006-C1056|A Study of Belimumab in Subjects With Systemic Lupus Erythematosus|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)|BLISS-76|Human Genome Sciences Inc.|Yes|Completed|December 2006|March 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|819|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|December 8, 2006|Yes|Yes||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00410384||176164|
NCT00410683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000523568|Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery|Phase III Study Comparing Post-Operative Conformal Radiotherapy to No Post-Operative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement [Lung ART]|LUNG ART|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|February 2007|February 2022|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410683||176141|
NCT00410943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013276|Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain|A Randomized, Double-Blind, Repeated Dose, Parallel-Group Comparison of the Efficacy & Tolerability of Dilaudid SR Tablets and Immediate Release Dilaudid Tablets (Hydromorphone HCI) in Patients With Chronic Pain||Alza Corporation, DE, USA||Completed||June 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|169|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410943||176122|
NCT00410956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-114|Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery|A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2007|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|120 Years|No|||November 2015|November 25, 2015|December 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00410956||176121|
NCT00411268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013258|Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain|Safety, Efficacy and Impact on Quality of Life of Long-Term Administration of Dilaudid CR (Hydromorphone HCI) in Patients With Chronic Low Back Pain||Alza Corporation, DE, USA||Completed||June 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|207|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00411268||176098|
NCT00411619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB# 06-07-50|Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex|Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex||Children's Hospital Medical Center, Cincinnati|Yes|Completed|January 2007|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|3 Years|N/A|No|||October 2014|October 17, 2014|December 12, 2006|No|Yes||No|September 18, 2014|https://clinicaltrials.gov/show/NCT00411619||176073|
NCT00411983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 006|A Long-term Follow-up of the HIV-NAT Cohort|A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Recruiting|November 2002|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|PBMC collection once a year|Both|18 Years|N/A|No|Non-Probability Sample|All HIV infected adult patients from HIV-NAT.|February 2016|February 18, 2016|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00411983||176048|
NCT00412594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0223|2CDA With Rituximab in Hairy Cell Leukemia|Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed By Rituximab in Hairy Cell Leukemia||M.D. Anderson Cancer Center|No|Recruiting|September 2004|||September 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00412594||176002|
NCT00412607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWI40036|Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia|NaviStar ThermoCool Catheter for Endocardial RF Ablation in Patients With Ventricular Tachycardia|VT-CoA|Biosense Webster, Inc.||Completed|January 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|249|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|December 14, 2006|Yes|Yes||No|September 23, 2014|https://clinicaltrials.gov/show/NCT00412607||176001|
NCT00413959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606|VELCADE®,Rituximab,Cyclophosphamide and Decadron (VRCD Regimen)|Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma|VRCD|Oncology Specialists, S.C.|No|Terminated|August 2006|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|90 Years|No|||October 2013|October 17, 2013|December 19, 2006||No||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00413959||175900|
NCT00413972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04420|Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)|A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Groups Study Comparing the Efficacy and Safety of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|April 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|392|||Both|18 Years|75 Years|No|||June 2015|June 16, 2015|December 19, 2006||No||No|April 28, 2010|https://clinicaltrials.gov/show/NCT00413972||175899|
NCT00412841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-8795|Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus|AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial||New York University School of Medicine|Yes|Terminated|November 2002|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|43|||Female|18 Years|75 Years|No|||February 2016|February 3, 2016|December 18, 2006|Yes|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT00412841||175984|
NCT00413192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-E044-207|E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma|Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma||Eisai Inc.||Completed|January 2007|February 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||April 2014|June 30, 2014|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00413192||175958|
NCT00413257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7813|Effects of Nefopam on Hyperalgesia After Cardiac Surgery|Study of the Effects of Nefopam on Hyperalgesia Following Sternotomy in Cardiac Surgery|NefalCard|University Hospital, Bordeaux|Yes|Completed|December 2006|November 2008|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|55 Years|75 Years|No|||May 2010|May 27, 2010|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413257||175953|
NCT00408590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515008|Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer||Mayo Clinic|Yes|Active, not recruiting|April 2004|||December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|N/A|No|||March 2015|March 23, 2015|December 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408590||176297|
NCT00408564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000518313|Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Phase II Study of Neoadjuvant Gemcitabine/Oxaliplatin and Cetuximab Followed by Surgery or Concurrent External Beam Radiation With Capecitabine for Patients With Locally Advanced Unresectable Nonmetastatic Pancreatic Cancer||Medical University of South Carolina|Yes|Completed|January 2006|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|December 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00408564||176299|
NCT00408577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSRAFFA_III_2004_003|Prevention of Cardiac and Vascular Events in Patients With NGT/IGT.|Prevention of Cardiovascular Relapses by L-Arginine Oral Administration in Patients With CAD and IGT and/or Insulin Resistance.||IRCCS San Raffaele||Completed|November 2004|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|30 Years|N/A|No|||December 2006|December 11, 2006|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408577||176298|
NCT00408902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03014|Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer|Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|November 2006|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2014|January 26, 2015|December 6, 2006|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00408902||176275|Principal Investigator closed this study due to lack of response and toxicities of drug, therefore overall survival analysis was not done.
NCT00408850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G 06M 2610|Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity|Mechanisms of Sympathetic Overactivity in the Metabolic Syndrome: Effects of Reversing Insulin Resistance by Drug Treatment||Baker Heart Research Institute|No|Recruiting|November 2008|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|45 Years|65 Years|No|||January 2013|January 16, 2013|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00408850||176279|
NCT00409110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082-KAR-2006-001|Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry|Relationship Between Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry In Healthy Subjects||University Hospital, Basel, Switzerland|No|Terminated|January 2006|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|45 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|August 2011|August 8, 2011|December 7, 2006||No|methodological problems|No||https://clinicaltrials.gov/show/NCT00409110||176259|
NCT00409123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-KRK-2004-001|Effect of Systemic Cooling in Vasospasms|Effect of Systemic Cooling in Vasospasms (Kühleffekte Beim Vasospastischen Syndrom)||University Hospital, Basel, Switzerland|No|Completed|September 2004|June 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|||Female|19 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|vasospastic women|September 2008|September 25, 2008|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409123||176258|
NCT00410020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 990321|Arrhythmia Prevention With an Alpha-Linolenic Enriched Diet|Secondary Prevention of Atrial Fibrillation With an Alpha-Linolenic Enriched Diet : a Randomized Study||Assistance Publique - Hôpitaux de Paris||Completed|June 1999|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||130|||Both|18 Years|77 Years|No|||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410020||176192|
NCT00410397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006028|The Use of Manual Therapy to Treat Low-Back and Hip Pain|The Use of Myofascial Release in Lumbopelvic Pain||Oklahoma State University Center for Health Sciences|No|Completed|December 2006|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|60 Years|No|||January 2008|January 8, 2008|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410397||176163|
NCT00410423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.70|Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias|Phase I/II Trial of VELCADE® (Bortezomib) in Combination With Mitoxantrone and Etoposide for Relapsed or Refractory Acute Leukemias||Thomas Jefferson University|Yes|Completed|January 2006|September 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410423||176161|
NCT00410969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRS-01-05-02|Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients|Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients||Life Recovery Systems|Yes|Completed|December 2006|September 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|December 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00410969||176120|
NCT00410982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0803|Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies|Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|December 2006|||September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|18 Years|69 Years|No|||September 2012|September 24, 2012|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410982||176119|
NCT00411307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013267|A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain|A Randomized, Open-Label, Single-Dose, Pilot Study to Evaluate the Safety and Efficacy of OROS Hydromorphone in Patients With Acute, Moderate-to-Severe Postoperative Pain||Alza Corporation, DE, USA||Completed||October 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00411307||176095|
NCT00411281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML0532|Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder|Treatment of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)||Children's Oncology Group|Yes|Withdrawn|March 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||August 2013|September 28, 2015|December 11, 2006|No|Yes|Per Group Chair: This study will not move forward.|No||https://clinicaltrials.gov/show/NCT00411281||176097|
NCT00411294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-01|Ergocalciferol in Chronic Kidney Disease|The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4||Saint Louis VA Medical Center||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|80 Years|No|||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00411294||176096|
NCT00411632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0826|BATTLE Program: Tarceva and Targretin in Patients With NSCLC|A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2006|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411632||176072|
NCT00411645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1263-300|Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients|A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.||Shire|Yes|Completed|December 2006|May 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|681|||Both|18 Years|N/A|No|||March 2014|June 3, 2015|December 12, 2006|Yes|Yes||No|May 15, 2015|https://clinicaltrials.gov/show/NCT00411645||176071|
NCT00411658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR06-002|Devitalized Non-valved Pulmonary Artery Allograft Implant for the Repair of Congenital Cardiac Abnormalities|||LifeNet Health||Withdrawn||||||N/A|Interventional|N/A|2||Actual|0|||||||||April 2015|April 3, 2015|December 13, 2006|||Submission converted to 510(k)|No||https://clinicaltrials.gov/show/NCT00411658||176070|
NCT00411996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 044|The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin|The Pharmacokinetics and Safety of Ritonavir-boosted Indinavir 600/100mg Bid Combined With NRTIs in ARV naïve HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|December 2006|December 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|No|||June 2010|June 4, 2010|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00411996||176047|
NCT00412269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 97022|Healthy Transitions: Menopause Effect on Obesity, Energy Balance, and Insulin|Healthy Transitions: Menopause Effect on Obesity, Energy Balance, and Insulin||Pennington Biomedical Research Center|Yes|Completed|February 1998|March 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Female|47 Years|52 Years|Accepts Healthy Volunteers|Probability Sample|Pennington Biomedical Research Center is located in Baton Rouge, Louisiana, adjacent to        the medical services district of the Regional Medical Center. The city of Baton Rouge is        the home of state government, the 27,000-student Louisiana State University, the        9,000-student Southern University and a large petrochemical industry. Lacking the        traditional active urban "downtown", the region is characterized by the suburban pattern        of single family subdivisions and small apartment complexes. The population within a 7        parish (i.e. county) area is 635,202. The population of East Baton Rouge Parish is 380,105        with an ethnic distribution of 62% Caucasian, 35% African-American, 1% Asian, and <1%        Native American and Hispanic. There are 34,885 people over age 65 and 251,586 between ages        16-65 yr.|January 2016|January 22, 2016|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412269||176026|
NCT00413296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007843|Levetiracetam in Post-Traumatic Stress Disorder|A Double-Blind Discontinuation Study of Levetiracetam in Post- Traumatic Stress Disorder|PTSD|Duke University|Yes|Completed|November 2005|March 2008|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||June 2010|July 18, 2014|December 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00413296||175950|
NCT00408629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-827|Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis||Abbott|Yes|Completed|November 2006|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|518|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|December 5, 2006|Yes|Yes||No|March 3, 2011|https://clinicaltrials.gov/show/NCT00408629||176294|
NCT00405496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJE2079/2-02-PC|Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis|Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Inluding Iritis, Cyclitis, Iridocyclitis, and Panuveitis).||Sirion Therapeutics, Inc.||Completed|March 2000|April 2001||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|20 Years|75 Years|No|||November 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405496||176531|
NCT00412854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104567|Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.|Phase IIIb, Multicentre Study to Assess Safety & Immunogenicity of GSK Biologicals' Combined DTPa/Hib (Infanrix/Hib) Vaccine vs Separate Administration of DTPa (Infanrix) & Hib (Hiberix) Vaccines in Healthy Infants 3,4,&5 Months of Age||GlaxoSmithKline||Completed|January 2007|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|660|||Both|90 Days|120 Days|Accepts Healthy Volunteers|||November 2012|November 21, 2012|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00412854||175983|
NCT00412867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527-0611|Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）|Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Phase 4)||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|20 Years|N/A|No|||September 2012|September 11, 2012|December 17, 2006||No||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00412867||175982|
NCT00412880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.11|BI 2536 Second Line Monotherapy in SCLC|An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer||Boehringer Ingelheim||Completed|January 2007|||June 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00412880||175981|
NCT00408603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0010|Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer|A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer||Sunesis Pharmaceuticals|Yes|Completed|November 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|143|||Female|18 Years|N/A|No|||November 2009|June 5, 2012|December 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408603||176296|
NCT00408616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-12|Efficacy and Safety of Grazax in Children|A Phase III Trial Investigating the Efficacy and Safety of Grazax in Children Aged 5-16 Years With Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma||ALK-Abelló A/S|Yes|Completed|November 2006|November 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|5 Years|16 Years|No|||March 2009|March 6, 2009|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408616||176295|
NCT00408928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04U.177|Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease|Phase II Trial of VELCADE® (Bortezomib) for Steroid Refractory Acute GVHD||Thomas Jefferson University|Yes|Completed|November 2005|September 2009|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|December 6, 2006||No||No|July 18, 2013|https://clinicaltrials.gov/show/NCT00408928||176273|
NCT00408915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIPSO|Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion|Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy||Axxonis Pharma AG||Completed|July 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|75 Years|No|||March 2012|March 6, 2012|December 5, 2006||||No||https://clinicaltrials.gov/show/NCT00408915||176274|
NCT00409747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070024|Minocycline to Treat Childhood Regressive Autism|Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS||National Institutes of Health Clinical Center (CC)|No|Completed|November 2006|April 2011|Actual|June 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|3 Years|12 Years|No|||November 2015|November 5, 2015|December 8, 2006|No|Yes||No|October 22, 2012|https://clinicaltrials.gov/show/NCT00409747||176212|Small, uncontrolled pilot.
NCT00409760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2201|Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.|A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.||Novartis||Completed|January 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1930|||Both|18 Years|N/A|No|||November 2011|November 22, 2011|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409760||176211|
NCT00409409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO52.06|Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis|A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis||Stallergenes||Completed|December 2006|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|280|||Both|5 Years|17 Years|No|||September 2011|September 28, 2011|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409409||176236|
NCT00409695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0370|Thymoglobulin (ATG) Dose Finding Study|Dose Finding Study of Thymoglobulin (ATG) in Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)||M.D. Anderson Cancer Center|Yes|Terminated|December 2006|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|N/A|N/A|No|||January 2012|January 19, 2012|December 7, 2006|Yes|Yes|Lack of Accrual|No||https://clinicaltrials.gov/show/NCT00409695||176216|
NCT00410059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0824|BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC|A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2006|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|December 8, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00410059||176189|
NCT00410410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-108|A Study of Abatacept in Patients With Active Ulcerative Colitis|A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy||Bristol-Myers Squibb|Yes|Completed|December 2006|November 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|591|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|December 11, 2006|Yes|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00410410||176162|This study was terminated after review of the IP1C results due to lack of efficacy. Enrollment for the MP and for IP2C was not completed. Participants in MP, IP2C, and OL were early terminated at the time of study termination.
NCT00410696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2006-001|Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy|Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy With Peripheral Autologous Stem Cell Reinfusion in Patients With Hematological Neoplasms and Solid Tumors: Phase II Randomised Trial||Istituto Clinico Humanitas|Yes|Completed|September 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00410696||176140|
NCT00410995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11186|Effects of Naproxen on Physical Performance|Effects of Naproxen on Physical Performance||University of Oklahoma||Terminated|May 2004|August 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2007|October 10, 2007|December 12, 2006|||Study never initiated.|No||https://clinicaltrials.gov/show/NCT00410995||176118|
NCT00411320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR002|Determinants of Corticosteroid Insensitivity in Smokers With Asthma|Determinants of Corticosteroid Insensitivity in Smokers With Asthma||University of Glasgow|Yes|Completed|January 2007|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|53|||Both|18 Years|60 Years|No|||September 2008|August 3, 2011|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411320||176094|
NCT00411671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0827|BATTLE Program: Sorafenib in Patients With NSCLC|A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|Yes|Completed|November 2006|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 12, 2006||No||No|November 5, 2015|https://clinicaltrials.gov/show/NCT00411671||176069|
NCT00411684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914-005|Safety and Efficacy of CDB-2914 for Emergency Contraception|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Sex||HRA Pharma||Completed|November 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1320|||Female|18 Years|N/A|No|||June 2010|June 16, 2010|December 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411684||176068|
NCT00412009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL+ 2671|Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal|Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal||Institut de Recherche pour le Developpement||Completed|May 2003|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1500|||Both|15 Years|65 Years|No|||December 2006|December 14, 2006|December 14, 2006||||No||https://clinicaltrials.gov/show/NCT00412009||176046|
NCT00412022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOBOE|HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.|Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.|HOBOE|National Cancer Institute, Naples|No|Active, not recruiting|March 2004|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1050|||Female|18 Years|N/A|No|||November 2015|November 27, 2015|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412022||176045|
NCT00412295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU#04-23006|Evaluation of Alcon Ladarvision Wavefront-Guided PRK|Evaluation of Alcon Ladarvision Wavefront-Guided PRK||Walter Reed Army Medical Center||Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|January 12, 2015|December 15, 2006|||Lack of resources and not because of any concern with the safety or effectiveness of the    procedures studied.|No||https://clinicaltrials.gov/show/NCT00412295||176025|
NCT00412308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133N060005|A Comparison of High vs. Low Tidal Volumes in Ventilator Weaning for Individuals With Cervical Spinal Cord Injuries|A Comparison of High vs. Low Tidal Volumes in Ventilator Weaning for Individuals With Sub-Acute Cervical Spinal Cord Injuries||Craig Hospital||Completed|December 2006|August 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|55 Years|No|||June 2011|June 27, 2011|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412308||176024|
NCT00412620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-816|An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia|Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia||Abbott|Yes|Terminated|December 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|156|||Both|18 Years|65 Years|No|||September 2010|April 25, 2011|December 14, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00412620||176000|
NCT00412633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA098861|Clinical & Web-based Diet & Activity Counseling for Men|Clinical & Web-based Diet & Activity Counseling for Men||University of California, San Diego||Completed|February 2004|October 2010|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|442|||Male|25 Years|55 Years|No|||June 2012|June 8, 2012|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412633||175999|
NCT00412958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-003|A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)|A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial||ThromboGenics|Yes|Completed|December 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|125|||Both|18 Years|N/A|No|||April 2014|December 2, 2014|December 18, 2006|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00412958||175976|
NCT00413309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000376|Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention|Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention||Brigham and Women's Hospital|Yes|Completed|April 2006|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2009|February 2, 2009|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00413309||175949|
NCT00413322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-4|Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors|A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors||Onxeo|No|Completed|September 2005|June 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|December 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00413322||175948|
NCT00408655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00691|Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors|Phase I Study of CCI-779 (NSC 683864) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumours||National Cancer Institute (NCI)||Completed|February 2007|||January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|December 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408655||176292|
NCT00405262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008719|A Comparison of Bupivacaine and Ketorolac for Postoperative Analgesia After Iliac Crest Bone Harvesting|The Effectiveness of Bupivicaine Infusion Versus Intravenous Ketorolac for Postoperative Analgesia After Iliac Crest Bone Harvesting for Lefort I Osteotomy or Alveolar Cleft Repair.||The Hospital for Sick Children|No|Completed|May 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Both|10 Years|20 Years|No|||August 2013|August 19, 2013|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405262||176549|
NCT00412893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0104|Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis|A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.||Astellas Pharma Inc|Yes|Completed|March 2007|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|527|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|December 18, 2006|Yes|Yes||No|March 19, 2015|https://clinicaltrials.gov/show/NCT00412893||175980|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00413244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-1081|The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery|The Cardiac Benefit of Androgen Replacement in Hypogonadal Males With Coronary Artery Disease Following Successful Percutaneous Coronary Intervention (PCI).||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2007|November 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|139|||Male|40 Years|75 Years|No|||November 2015|November 24, 2015|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413244||175954|
NCT00409201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|284|Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia|Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures||Abarbanel Mental Health Center||Recruiting|March 2006|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|65 Years|No|||March 2006|December 7, 2006|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409201||176252|
NCT00409487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0617|Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients|Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.|VALSAS|University Hospital, Grenoble|Yes|Completed|December 2006|May 2009|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|September 7, 2010|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409487||176231|
NCT00409188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 63325-001|Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)|A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.|START|EMD Serono|Yes|Completed|January 2007|April 2015|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1513|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|December 7, 2006|Yes|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT00409188||176253|
NCT00409773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-107|Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease||Merck Sharp & Dohme Corp.||Completed|January 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1143|||Both|18 Years|79 Years|No|||September 2015|September 2, 2015|December 8, 2006|Yes|Yes||No|June 16, 2009|https://clinicaltrials.gov/show/NCT00409773||176210|15 patients were randomized but not treated. Since these patients were not treated no Adverse Event Data was collected.
NCT00409422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 15994|Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children|Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children||Yale University|No|Completed|May 2002|February 2007|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|8 Years|16 Years|No|||June 2008|June 20, 2008|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00409422||176235|
NCT00409708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124D2201|Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-label, Behavioral-treatment-controlled Evaluation of the Effects of Extended Release Methylphenidate on the Frequency of Cytogenetic Abnormalities in Children 6 - 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD)||Novartis||Completed|November 2006|||March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|6 Years|12 Years|No|||April 2011|April 19, 2011|December 8, 2006|Yes|Yes||No|December 6, 2010|https://clinicaltrials.gov/show/NCT00409708||176215|Since no cytogenetic effects were observed, blood samples were not analyzed for pharmacokinetics/pharmacodynamics.
NCT00409721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204|The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)|A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS||University of Alberta|Yes|Completed|March 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|80 Years|No|||March 2011|March 1, 2011|December 8, 2006||||No||https://clinicaltrials.gov/show/NCT00409721||176214|
NCT00410709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-106-06|A Pharmacokinetic (PK) Study of NatrOVA Topical Creme (1%) in Pediatric Subjects 6 to 24 Months of Age|A Phase 1B Single Treatment, Pharmacokinetic and Tolerance Study of NatroVA Topical Creme (1%) i Pediatric Subjects 6 to 24 Months of Age||ParaPRO LLC|No|Completed|December 2006|January 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||July 2008|July 31, 2008|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410709||176139|
NCT00408122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-20060109|Evaluation of Preoperative Investigations in Patients With Liver Cancer|Evaluation of Positron Emission Tomography/ CT Scan, Endoscopic Ultrasono¬Graphy, and Laparoscopic Ultrasonography in the Preoperative Assess¬Ment of Resectability in Patients With Primary and Secondary Liver Cancer||Odense University Hospital||Completed|January 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|||Both|18 Years|N/A|No|Probability Sample|PAtients with liver tumors|October 2014|October 15, 2014|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408122||176331|
NCT00403910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17|Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study|Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure||Heart Care Foundation||Completed|September 2002|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||500|||Both|18 Years|80 Years|No|||April 2009|April 16, 2009|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00403910||176650|
NCT00404729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86216880|Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases|Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases||Fondazione G.B. Bietti, IRCCS||Completed|February 2005|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2006|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404729||176587|
NCT00404170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Precept|Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease|Assessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT Cohort||Institute for Neurodegenerative Disorders|No|Completed|November 2006|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|396|||Both|30 Years|N/A|No|||May 2015|May 13, 2015|November 22, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404170||176630|
NCT00404430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0627|Protocol Chronic Obstructive Pulmonary Disease|Predictive Factors of Endothelial Function in Chronic Obstructive Disease Patients at the End of a Acute Exacerbation.||University Hospital, Grenoble|Yes|Recruiting|January 2007|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Serum samples for analysis of inflammatory and oxidative biological markers|Both|18 Years|N/A|No|Probability Sample|Patients with exacerbated (50) or stable (50) COPD|August 2015|August 19, 2015|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404430||176610|
NCT00404976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 03-228|Inflammatory Markers in Exhaled Breath (Condensate) in Childhood Asthma|Biomarkers in Exhaled Breath (Condensate) Indicate Presence, Severity and Control of Asthma||Maastricht University Medical Center||Completed|June 2004|April 2005||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||November 2003|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404976||176568|
NCT00405574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN-224-005|Study of ATN-224 in Patients With Prostate Cancer|A Randomized, Phase II Study of Two Dose Levels of ATN-224 in Patients With Biochemically Relapsed, Early Stage Prostate Cancer Not on Hormone Therapy||Attenuon||Active, not recruiting|November 2006|September 2008|Anticipated|June 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 28, 2008|November 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405574||176525|
NCT00406120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0042-A|Validation of a Molecular Prognostic Test for Eye Melanoma|Validation of a Molecular Test for Predicting Metastasis in Patients With Uveal Melanoma||Washington University School of Medicine||Withdrawn|January 2007|December 2017|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|2000|||Both|N/A|N/A|No|||May 2007|May 16, 2007|November 29, 2006|||It has come to our attention that the site was not necessary for our research project.|No||https://clinicaltrials.gov/show/NCT00406120||176483|
NCT00406393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0402|Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)|A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus With Tacrolimus/Methotrexate as Graft-versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation (BMT CTN #0402)||Medical College of Wisconsin|Yes|Completed|November 2006|October 2015|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Both|2 Years|60 Years|No|||February 2016|February 8, 2016|November 30, 2006|Yes|Yes||No|January 6, 2016|https://clinicaltrials.gov/show/NCT00406393||176463|
NCT00406406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A1-103|Study Evaluating SKI-606 Administered to Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKI-606 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2006|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406406||176462|
NCT00438048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAVK-130108245-1|A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment|Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva||Pontificia Universidad Catolica de Chile|Yes|Completed|November 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||May 2008|May 21, 2008|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438048||174085|
NCT00406055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-717|CHOICE: Carotid Stenting For High Surgical-Risk Patients|Carotid Stenting For High Surgical-Risk Patients; Evaluating Outcomes Through The Collection Of Clinical Evidence||Abbott Vascular||Completed|October 2006|June 2012|Actual|June 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|18855|||Both|N/A|N/A|No|Non-Probability Sample|Patients enrolled into this registry will be male and female patients derived from the        general population who satisfy the inclusion and exclusion criteria.|July 2013|July 24, 2013|November 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00406055||176488|
NCT00406068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIS-0611-0602|Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer|Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG||Bioniche Life Sciences Inc.|Yes|Completed|November 2006|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|December 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406068||176487|
NCT00406354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11149|Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany|A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder||Eli Lilly and Company||Completed|November 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|181|||Both|6 Years|17 Years|No|||February 2010|February 19, 2010|November 29, 2006|Yes|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00406354||176466|
NCT00406692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25544|The Effects of Zonisamide on Alcohol Dependence|The Effects of Zonisamide on Alcohol Dependence||Boston University|Yes|Completed|November 2006|November 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|21 Years|64 Years|No|||May 2010|May 6, 2010|November 30, 2006||No||No|February 8, 2010|https://clinicaltrials.gov/show/NCT00406692||176441|Limitations of this trial include lack of a placebo controlled arm and small sample size.
NCT00406939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#H-6836|Vector Delivery of the IL-12 Gene in Men With Prostate Cancer|Phase I Study of Adenoviral Vector Delivery of The IL-12 Gene in Men With Recurrence or Persistent Cancer of the Prostate After Primary Therapy With or Without Metastatic Disease (SPORE)||Baylor College of Medicine||Completed|June 1998|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Male|18 Years|N/A|No|||July 2008|July 8, 2008|December 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406939||176422|
NCT00408135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6371|Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections|Evaluation of the Safety, Efficacy and Acceptability of HMR 3647 (20％ Fine Granules 1 g Sachet) in Children With Infections||Sanofi||Completed|August 2004|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|111|||Both|6 Months|16 Years|No|||April 2009|April 2, 2009|December 5, 2006||||No||https://clinicaltrials.gov/show/NCT00408135||176330|
NCT00408148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIMON_C_01346|High Density Lipoprotein Turnover|A Randomized, Double-blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in Patients With Abdominal Obesity and Additional Cardiometabolic Risk Factors||Sanofi||Terminated|October 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|35 Years|65 Years|No|||December 2010|December 9, 2010|December 5, 2006||No|Company decision has been taken in light of recent demands by certain national health    authorities|No||https://clinicaltrials.gov/show/NCT00408148||176329|
NCT00407576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070036|PET Imaging of Brain Amyloid Using [11C]MeS-IMPY|PET Imaging of Brain Amyloid Using [11C]MeS-IMPY||National Institutes of Health Clinical Center (CC)||Completed|December 2006|||November 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1|||30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|December 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00407576||176373|
NCT00407810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00171|Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer||National Cancer Institute (NCI)||Completed|October 2006|||February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|December 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407810||176355|
NCT00404456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSCAP|The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients|The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients||Meander Medical Center||Completed|April 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|85 Years|No|||January 2008|January 28, 2008|November 27, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00404456||176608|
NCT00404469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patellar tendinopathy|Effects of Peritendinous Corticosteroid Injections, Eccentric Training and Heavy Slow Resistance Training in Patellar Tendinopathy|Effects of Peritendinous Corticosteroid Injections, Eccentric Training and Heavy Slow Resistance Training in Patellar Tendinopathy||Bispebjerg Hospital||Completed|March 2006|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|39|||Male|18 Years|55 Years|No|||May 2008|May 21, 2008|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404469||176607|
NCT00404482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-1106|Cyclosporine A in the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Chronic Anterior Uveitis|Efficacy and Adverse Effects of Cyclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis||St. Franziskus Hospital||Completed|January 1991|August 2006||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1||60|||Both|N/A|16 Years|No|Probability Sample|patients with JIA and cyclosporin A therapy|June 2009|June 2, 2009|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404482||176606|
NCT00404443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM04001|Acupuncture for the Treatment of Rheumatoid Arthritis|Efficacy of Traditional Chinese Acupuncture in the Treatment of Rheumatoid Arthritis: a Double-Blind Controlled Pilot Study||Chinese University of Hong Kong|No|Completed|December 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|November 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404443||176609|
NCT00404716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-2006-A006|Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation|Effects of Triple Versus Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Coronary Stent Implantation||Shenyang Northern Hospital||Completed|December 2004|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||November 2006|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404716||176588|
NCT00405327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005.050|A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation|A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation||University of Michigan Cancer Center|Yes|Active, not recruiting|June 2006|December 2015|Anticipated|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|30 Years|No|||September 2015|September 11, 2015|November 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405327||176544|
NCT00414635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-156|FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment|A Randomized Controlled Trial of a Weekly Schedule of Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment (5/2 Intermittent Treatment Schedule) Versus Continuous Treatment in Individuals With Virologic Suppression on This Combination||Community Research Initiative of New England||Completed|August 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||February 2012|February 9, 2012|December 20, 2006||No||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00414635||175848|Conclusions are limited by the small "n" studied. The results are only applicable to the specific drug regimen studied and thus can not be generalized to all ART. We only studied individuals already virologically undetectable.
NCT00415506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e1529|Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation|A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation||Oregon Health and Science University||Completed|January 2007|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|December 21, 2006|No|Yes||No|May 20, 2013|https://clinicaltrials.gov/show/NCT00415506||175785|
NCT00414934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941220|18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer.|The Effectiveness of Whole-body 18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer: A Comparison Study With 99mTc-MDP Bone Scintigraphy.||National Taiwan University Hospital|No|Recruiting|October 2006|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|metastatic bone lesion for patients with cancer|August 2009|August 13, 2009|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00414934||175827|
NCT00414947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2111|Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers|A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects||Novartis||Completed|December 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00414947||175826|
NCT00415454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panc4242|Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma|Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma||Henry Ford Health System|Yes|Terminated|November 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||June 2011|June 21, 2011|December 21, 2006|No|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00415454||175788|
NCT00415467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0942|Treatment of Resectable Malignant Brain Tumors|Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors||M.D. Anderson Cancer Center|No|Terminated|January 2005|July 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|December 22, 2006||No|Sponsor decision to terminate study.|No||https://clinicaltrials.gov/show/NCT00415467||175787|
NCT00406770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|We-Light|Bright Light Therapy for Weight Loss|||Russian Academy of Medical Sciences|No|Completed|December 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|41|||Both|20 Years|65 Years|No|||October 2009|October 18, 2009|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406770||176435|
NCT00406081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN VAR 05|Immune Response to Varicella Vaccination in Children With Atopic Dermatitis|Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|December 2005|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|69|None Retained|Blood collected for endpoint measurements.|Both|12 Months|36 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children with or without AD who received the chicken pox vaccine including a group of AD        subjects with eczema herpeticum (ADEH+)|April 2014|April 1, 2014|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406081||176486|
NCT00407277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63/2005|Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia|Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia||Centre for Addiction and Mental Health|No|Completed|February 2007|||August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 17, 2009|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00407277||176396|
NCT00406705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI 824|The Effect of Breathing Helium-Hyperoxia During Pulmonary Rehabilitation in Patients With COPD|A Randomized Controlled Trial to Study the Effect of Exercise Training Breathing Helium-Hyperoxia on The Exercise Tolerance and Quality of Life of Patients With Chronic Obstructive Pulmonary Disease||University of Alberta||Completed|March 2005|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||38|||Both|N/A|N/A|No|||March 2007|May 3, 2007|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406705||176440|
NCT00406952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001337|Study for Evaluating Different Methods of Measuring Depression Treatment Response|A Phase 4 Randomized, Double-Blind, Placebo Controlled Methodology Study to Evaluate the Time of Onset of AntiDepressant Response in Subjects With Major Depressive Disorder||Pfizer||Completed|November 2006|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|165|||Both|18 Years|65 Years|No|||August 2008|August 20, 2008|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406952||176421|
NCT00406965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAE3973g|A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of HAE1 (PRO98498) in Subjects With Moderate to Severe Allergic Asthma||Genentech, Inc.||Completed|December 2006|September 2007|Actual|||Phase 2|Interventional|Primary Purpose: Treatment||||50|||Both|12 Years|75 Years|No|||December 2007|December 31, 2007|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406965||176420|
NCT00407849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETAAC001|Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema|Phase I/II Study of Intravitreal Triamcinolone Acetonide Microspheres for Treatment of Diffuse Diabetic Macular Edema Unresponsive to Conventional Laser Photocoagulation Treatment.||Federal University of São Paulo||Active, not recruiting|October 2006|August 2008|Anticipated|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00407849||176352|
NCT00407589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|478-PK|Systemic Pharmacokinetics of BOL-303224-A|Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis||Bausch & Lomb Incorporated|No|Completed|October 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|December 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00407589||176372|
NCT00407602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-003-001|Argus® II Retinal Stimulation System Feasibility Protocol|Argus® II Retinal Stimulation System Feasibility Protocol||Second Sight Medical Products|Yes|Active, not recruiting|September 2006|August 2019|Anticipated|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|December 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00407602||176371|
NCT00407823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/07949-7|Comparison of Pediatric Septic Shock Treatment With and Without Central Venous Oxygen Saturation Monitoring|An Outcomes Comparison of ACCM/PALS Guidelines For Pediatric Septic Shock With and Without Central Venous Oxygen Saturation Monitoring||University of Sao Paulo||Completed|January 2004|August 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||268|||Both|1 Month|19 Years|No|||December 2006|December 4, 2006|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407823||176354|
NCT00404235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N057E|Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase II Trial of Carboplatin (CBDCA) and ABI-007(ABX) in Patients With Unresectable Stage IV Melanoma||Alliance for Clinical Trials in Oncology|Yes|Completed|October 2006|March 2010|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404235||176625|
NCT00417781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361700470|A Follow-up, Family Study on Attention-deficit Hyperactivity Disorder|A Follow-up, Family Study on Attention-deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Completed|January 2005|December 2009|Actual|||N/A|Observational|Observational Model: Case Control||1|Actual|1800|||Both|10 Years|18 Years|No|Non-Probability Sample|Community-based sample & children with ADHD and their families|April 2012|November 12, 2012|December 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00417781||175612|
NCT00404989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR|Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.|Antiretroviral Pregnancy Registry|APR|INC Research|Yes|Recruiting|January 1989|January 2099|Anticipated|January 2099|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|||Female|12 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women exposed to antiviral medications during pregnancy.|December 2015|December 14, 2015|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404989||176567|
NCT00405314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL06-04|Prehospital CPAP vs. Usual Care for Acute Respiratory Failure|Prehospital CPAP Versus Usual Care for Acute Respiratory Failure: a Randomized Controlled Trial||Dalhousie University||Completed|July 2002|March 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|16 Years|N/A|No|||November 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405314||176545|
NCT00405002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101020|A Validation Study of a New System for Measuring the End Expiratory Lung Volume During Mechanical Ventilation|A Validation Study of a New System for Measuring the End Expiratory Lung Volume During Mechanical Ventilation Acute in Intubated Patients||Policlinico Hospital|No|Completed|November 2006|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|85 Years|No|Non-Probability Sample|ALI/ARDS patients|November 2011|November 30, 2011|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00405002||176566|
NCT00414375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 11 164|Early Versus Delayed Operation for Perforated Appendicitis|Early Versus Delayed Operation for Perforated Appendicitis With Abscess, a Pilot Study||Children's Mercy Hospital Kansas City||Completed|December 2006|March 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|18 Years|No|||March 2009|March 2, 2009|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414375||175868|
NCT00414622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTS21-201|GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease|A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease||CoMentis||Completed|November 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|50 Years|80 Years|No|||December 2006|April 18, 2007|December 19, 2006||||Yes||https://clinicaltrials.gov/show/NCT00414622||175849|
NCT00415519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI186-18|Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III|An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|75 Years|No|||September 2014|September 16, 2014|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00415519||175784|
NCT00415493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-005 NAR|Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation|Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation||Associated Scientists to Help Minimize Allergies|No|Completed|December 2006|May 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|December 21, 2006||No||No|July 20, 2012|https://clinicaltrials.gov/show/NCT00415493||175786|
NCT00406978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM2005|Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients|A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients|MPTD|University of Turin, Italy|No|Terminated|February 2006|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||September 2010|October 18, 2010|November 30, 2006||No|difficulties in enrolling patients|No||https://clinicaltrials.gov/show/NCT00406978||176419|
NCT00406991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-015|Retinal Blood Flow and Microthrombi in Type 1 Diabetes|Retinal Blood Flow and Microthrombi in Type 1 Diabetes||Massachusetts Eye and Ear Infirmary||Completed|June 2003|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2006|October 28, 2015|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406991||176418|
NCT00407615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12106|Double-Blind Placebo Study on Magnetic Field Therapy in Chronic Lumbar Pain|A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ON MAGNETIC FIELD THERAPY TO IMPROVE CHRONIC LUMBAR PAIN||Weintraub, Michael I., MD, FACP, FAAN||Recruiting|December 2006|October 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2007|September 20, 2007|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00407615||176370|
NCT00407290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 2005/13mai/87|The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor.|The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor, on Either Immediate Postpartum Perineal Pain or Development of Chronic Perineal Pain After Vaginal Delivery.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|March 2006|October 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2006|December 4, 2006|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00407290||176395|
NCT00407836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor444006ctil|Efficacy Study of T Cell Vaccination in HIV Infection|Phase II Study of Efficacy, Tolerability and Safety of CD4-Specific T-cell Vaccine in HIV Infection||Soroka University Medical Center|No|Completed|November 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|60 Years|No|||November 2006|December 1, 2009|December 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00407836||176353|
NCT00416351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-065|Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment|A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2006|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|2 Years|N/A|No|||March 2015|March 24, 2015|December 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00416351||175720|
NCT00403923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL 10253|Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative Colitis|A Study to Determine the Threshold of Lactose Ingestion That Provokes Symptoms in Lactose Intolerant People Who Also Have Ulcerative Colitis||University Hospitals, Leicester|Yes|Completed|April 2007|June 2007|Actual|June 2007|Actual|Phase 0|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|48|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lactose intolerance|February 2009|February 13, 2009|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403923||176649|
NCT00404209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-008|Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment|Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment||Asociación para Evitar la Ceguera en México||Recruiting|March 2007|February 2008|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||November 2007|November 29, 2007|June 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00404209||176627|
NCT00404222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-772|A Study Comparing Vicodin® CR and NORCO® to Placebo in Subjects With Acute Pain Following Bunionectomy|A Randomized, Multicenter, Single-blind Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Immediate Release Hydrocodone/Acetaminophen (NORCO®) to Placebo in Subjects With Acute Pain Following Bunionectomy||Abbott|No|Completed|November 2005|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|65 Years|No|||July 2011|July 22, 2011|November 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404222||176626|
NCT00417482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5598R|Antipsychotic Discontinuation in Alzheimer's Disease|Antipsychotic Discontinuation in Alzheimer's Disease|ADAD|New York State Psychiatric Institute|Yes|Completed|August 2004|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|50 Years|95 Years|No|||March 2013|March 14, 2013|December 28, 2006||No||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00417482||175635|Comparisons of adverse events in Phase B were limited by the small sample & the truncated observation period for relapsed subjects. Identification of predictors of relapse after discontinuation of treatment was limited by the small sample.
NCT00413790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328A2413|Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects|A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older||Novartis||Completed|November 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|162|||Both|50 Years|N/A||||January 2008|January 14, 2008|December 19, 2006||||||https://clinicaltrials.gov/show/NCT00413790||175912|
NCT00414102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-375-069|Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of Ramelteon on Sleep Using a Post Sleep Questionnaire - Interactive Voice Response System (PSQ-IVRS) in an "At-Home Setting" in an Adult Population With Chronic Insomnia||Takeda|No|Completed|October 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|552|||Both|18 Years|64 Years|No|||May 2010|May 31, 2010|December 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414102||175889|
NCT00404742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX211-02-UV|A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis|A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis|LUMINATE|Lux Biosciences, Inc.|Yes|Completed|January 2007|May 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|232|||Both|13 Years|N/A|No|||June 2012|June 21, 2012|November 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404742||176586|
NCT00405015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR49653-4|The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.|The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. A Double Blind Placebo- Controlled Cross-over Study in Subjects With the Metabolic Syndrome||Radboud University|No|Completed|April 2007|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|13|||Both|20 Years|70 Years|No|||October 2008|August 23, 2010|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405015||176565|
NCT00414960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10723|A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers|Phase IIB Randomized, Placebo-Controlled, Double-Blind Study of Enzastaurin HCL (LY317615) for Lung Cancer Prevention in Former Smokers||Eli Lilly and Company|Yes|Completed|November 2006|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|39|||Both|45 Years|N/A|No|||October 2010|February 25, 2011|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414960||175825|
NCT00414973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10591|A Study for Patients With Osteoporosis|Comparison of Teriparatide and Calcitonin in the Treatment of Men and Postmenopausal Women With Osteoporosis||Eli Lilly and Company|Yes|Completed|December 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|40 Years|85 Years|No|||October 2009|October 22, 2009|December 20, 2006|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00414973||175824|
NCT00415870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21CA115615-01A1|mDiet - Ecological Momentary Intervention of Diet Via Mobile Technology|Ecological Momentary Intervention of Diet Via Mobile Technology||University of California, San Diego|No|Completed|June 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|55 Years|No|||June 2013|June 20, 2013|December 22, 2006||No||No|June 20, 2013|https://clinicaltrials.gov/show/NCT00415870||175757|
NCT00415220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCER-99-10-04[99-03-03r]|Manipulation or Microdiscectomy For Sciatica? A Prospective Randomized Controlled Trial.|Comparison of Treatment Outcomes Between Chiropractic and Back Surgery for the Treatment of Sciatica Secondary to Lumbar Herniated Disc: A Prospective Randomized Controlled Trial.||McMorland, Gordon, D.C.||Completed|January 2000|May 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2006|December 21, 2006|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00415220||175806|
NCT00415233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000522490|Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer|Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO]|HiLo|University College, London|Yes|Active, not recruiting|November 2006|July 2020|Anticipated|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|438|||Both|16 Years|80 Years|No|||December 2015|December 3, 2015|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00415233||175805|
NCT00415246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-55-52014-145|Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer|A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin, a Gonadotrophin Releasing Hormone Analogue in Patients With Prostate Cancer||Ipsen||Terminated|November 2006|October 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|N/A|No|||November 2007|November 15, 2007|December 21, 2006|||The preliminary data do not support the expected sustainable blood levels of triptorelin for a    duration of 4 months in all patients.|No||https://clinicaltrials.gov/show/NCT00415246||175804|
NCT00407069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN AMP 01|Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus|Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus (ADVN AMP01)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2005|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|286|Samples With DNA|Blood and skin samples will be retained|Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People of good general health|April 2014|April 1, 2014|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00407069||176412|
NCT00407342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-075ex03/04|Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.|Prospective, Randomized Half-side Comparison of Alefacept (Amevive) With or Without UVB-311nm Phototherapy in Patients With Psoriasis (Translated From German)||Medical University of Graz|No|Completed|February 2004|September 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||September 2009|September 29, 2009|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00407342||176391|
NCT00407355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-06-09-05|Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions|A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects With Macular Edema Secondary to Vein Occlusions.|LVO|Johns Hopkins University|No|Completed|January 2006|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|December 1, 2006|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00407355||176390|
NCT00406731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-080206|Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure|Role of endothelin-and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure||Medical University of Vienna|Yes|Withdrawn|January 2008|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406731||176438|
NCT00407316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-A-6803|Quality of Life and Visual Function in Uveitis Patients|||The New York Eye & Ear Infirmary||Recruiting|June 2006|November 2006||||Phase 0|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||50|||Both|18 Years|95 Years|No|||December 2006|December 4, 2006|December 2, 2006||||No||https://clinicaltrials.gov/show/NCT00407316||176393|
NCT00407329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uPAR|Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia|Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy||Queen's University|No|Completed|November 2006|January 2012|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Male|18 Years|N/A|No|Probability Sample|Men needing TURP|November 2013|November 5, 2013|December 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00407329||176392|
NCT00407641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06_06|Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis|Effects of Tinzaparin Sodium on Cardio-vascular OUtcomes and on Blood Lipids in Diabetic Patients on Chronic HEmodialysis: A Long-term, Prospective Study (The "Tinzaparin COULD HELP" Study).||Anemia Working Group Romania||Suspended|March 2009|December 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|80 Years|No|||January 2013|January 26, 2013|December 4, 2006||No|Financial and administrative matters did not allow collaboration among centers.|No||https://clinicaltrials.gov/show/NCT00407641||176368|
NCT00407303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM012|Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)|A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)||Teva Pharmaceutical Industries|No|Completed|October 2006|November 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|December 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407303||176394|
NCT00407628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561703031|Neural Correlates of Lower Extremity Motor Recovery in Stroke Patients: Longitudinal Diffusion Spectrum Imaging Studies|Neural Correlates of Lower Extremity Motor Recovery in Stroke Patients: Longitudinal Diffusion Spectrum Imaging Studies||National Taiwan University Hospital||Completed|August 2006|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|24|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|stroke patients|January 2013|July 4, 2013|December 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00407628||176369|
NCT00408161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-PET03510|Contingency Management for Chronic Recidivist Alcohol-Dependent Patients|Contingency Management for Chronic Recidivist Alcohol-Dependent Patients||University of Connecticut Health Center|Yes|Completed|August 2003|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||March 2012|March 26, 2012|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00408161||176328|
NCT00408174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZUC3003|Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Actively-Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3 g Bid Versus Mesalamine (5-ASA) as Asacol® 0.8 g Tid in Mildly to Moderately Active Ulcerative Colitis||Valeant Pharmaceuticals International, Inc.||Completed|May 2006|November 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|December 4, 2006||||||https://clinicaltrials.gov/show/NCT00408174||176327|
NCT00403936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAdecompress1|Effects of OA Decompression on the Autonomic Nervous System|Effects of OA Decompression on Activity of the Autonomic Nervous System||Nova Southeastern University||Completed|April 2005|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 24, 2010|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00403936||176648|
NCT00414115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-70358|National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children|Canadian Pharmacogenomics Network for Drug Safety||University of British Columbia|No|Recruiting|August 2005|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|7000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Children under 19 years who have taken drugs and adults to replicate findings in children|July 2015|July 16, 2015|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414115||175888|
NCT00413777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-04-250|Tolvaptan Open-Label Pilot Efficacy, Tolerability and Safety Study in ADPKD|A Phase 2, Multi-center, Open-label Study to Determine Long-term Safety, Tolerability and Efficacy of Split-dose Oral Regimens of Tolvaptan Tablets in a Range of 30 to 120 mg/d in Patients With Autosomal Dominant Polycystic Kidney Disease|TEMPO 2/4|Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|December 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413777||175913|
NCT00414089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-10-0100|Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL|Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma||AHS Cancer Control Alberta||Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2007|February 12, 2016|December 19, 2006|||Funding will not be provided for the drug|No||https://clinicaltrials.gov/show/NCT00414089||175890|
NCT00414999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH-TG100801-001|A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers|A Phase 1, Double-Masked, Placebo-Controlled, Dose-Escalation Study (in Two Parts) of TG100801 and a Colored Vehicle in Adult Healthy Volunteers||TargeGen||Completed|November 2006|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 27, 2007|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00414999||175822|
NCT00415259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350297|Effects of Shoes Insoles on Symptoms and Disease Progression in Knee Osteoarthritis|Effects of Shoes Insoles on Symptoms and Disease Progression in Knee Osteoarthritis||University of Melbourne|Yes|Completed|May 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|50 Years|N/A|No|||January 2013|January 15, 2013|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415259||175803|
NCT00416169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003106|A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia|An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2003|July 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|41|||Both|30 Years|80 Years|No|||January 2011|June 6, 2011|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00416169||175734|
NCT00416429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000468571|Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer|Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO]||Centre Leon Berard||Completed||February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|456|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416429||175715|
NCT00416442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRSV604A2101|Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.|A Randomized, Double-blind Placebo-controlled Single- to Multiple-dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of RSV604 Intravenous Formulation in Healthy Subjects||Novartis|No|Completed|October 2006|||November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 1, 2011|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416442||175714|
NCT00415857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0360|Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)|Potential of Immunotherapy to Convert a Complete Cytogenetic Remission in Chronic Myelogenous Leukemia to a Molecular Complete Remission: Randomized Phase II Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and Peginterferon Alfa-2b [PEG-INTRON(R), Schering Corporation]||M.D. Anderson Cancer Center|Yes|Terminated|December 2006|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|December 22, 2006|Yes|Yes|Vaccine sponsor ceased operations.|No|March 28, 2014|https://clinicaltrials.gov/show/NCT00415857||175758|
NCT00416143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4065-EC-CTIL|Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss|Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss||Sheba Medical Center||Recruiting|June 2006|December 2008||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|16 Years|N/A|No|||December 2006|December 24, 2006|December 24, 2006||||No||https://clinicaltrials.gov/show/NCT00416143||175736|
NCT00416156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCVGH 05082|Effect of Weight Reduction on Inflammatory Markers and Genes Expression in Obese Individuals|||Taichung Veterans General Hospital||Completed|May 2005|November 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||25|||Both|20 Years|70 Years|No|||December 2006|December 26, 2006|December 25, 2006||||No||https://clinicaltrials.gov/show/NCT00416156||175735|
NCT00407940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007A|ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion|ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion. A Prospective Randomized Trial Comparing Silverhawk™ Atherectomy to CryoPlasty® Therapy for Lower Extremity Claudication||University of California, San Diego||Recruiting|December 2006|December 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||December 2006|December 4, 2006|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407940||176345|
NCT00407953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U8070|PROLIEVE® Post-Marketing Study TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)|Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)||Boston Scientific Corporation|No|Active, not recruiting|September 2005|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Male|50 Years|N/A|No|||February 2013|February 4, 2013|December 1, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00407953||176344|
NCT00406757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGA105446|Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma|Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.||GlaxoSmithKline||Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|13|||Both|N/A|64 Years|No|||May 2011|May 31, 2012|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406757||176436|
NCT00415792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arvekap vs pregnyl|Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs|Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients||Eugonia||Active, not recruiting|November 2003|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2007|January 4, 2007|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415792||175763|
NCT00407004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAT|Elimination of Albumin-Bound Substances by MARS and Prometheus|Effect of Extracorporeal Liver Support by MARS and Prometheus on Albumin-Bound Substances in Acute-on-Chronic Liver Failure||Medical University of Graz||Completed|March 2003|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||November 2006|December 1, 2006|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00407004||176417|
NCT00407017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5264-T|Therapeutic Variables in Cataract Surgery|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|N/A|N/A||||August 2007|August 17, 2007|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00407017||176416|
NCT00407030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0408|IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With a Double-blind Parallel-group Extension Period to Investigate the Efficacy and Safety of Different Doses of IncobotulinumtoxinA (Xeomin) in the Treatment of Cervical Dystonia||Merz Pharmaceuticals GmbH|Yes|Completed|July 2006|June 2009|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|233|||Both|18 Years|75 Years|No|||July 2013|July 12, 2013|November 30, 2006|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00407030||176415|
NCT00416364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-020|The Economic Impact of Four Varieties of Mesh Inguinal Hernia Repair- a Double-Blinded, Prospective, Randomized Trial|The Economic Impact of Four Varieties of Mesh Inguinal Hernia Repair- a Double-Blinded, Prospective, Randomized Trial||United States Naval Medical Center, Portsmouth|No|Terminated|March 2006|October 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|23|||Male|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|AD males with primary hernia|December 2007|December 4, 2007|December 27, 2006||No|Inadequate accrural rates|No||https://clinicaltrials.gov/show/NCT00416364||175719|
NCT00407654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00176|VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer|Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer||National Cancer Institute (NCI)|Yes|Completed|October 2006|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||May 2013|July 22, 2015|December 4, 2006|Yes|Yes||No|March 27, 2015|https://clinicaltrials.gov/show/NCT00407654||176367|
NCT00416078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-107|Online Caregiver Psychoeducation and Support for Alzheimer's|Caregiver Psychoeducation and Support: Improving Outcomes in AD/ADRD||VA Office of Research and Development|No|Completed|August 2007|December 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|95 Years|No|||April 2015|April 7, 2015|December 22, 2006||No||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00416078||175741|
NCT00416923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454842|Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma|Phase I Study of Intrathecal Rituximab in Patients With Recurrent CNS Lymphoma||University of California, San Francisco||Completed|August 2002|April 2007|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|17 Years|N/A|No|||February 2015|February 12, 2015|December 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00416923||175678|
NCT00416936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB_12_12_2006|Bacterial Contamination of Anaesthetists' Hands by Personal Mobile Phones Used in the Operating Theatre|||Medical University Innsbruck||Completed|January 2007|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 9, 2009|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416936||175677|
NCT00417209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6596|Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen|A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen|PAPRIKA|Sanofi|Yes|Completed|December 2006|November 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|408|||Both|18 Years|N/A|No|||August 2011|August 9, 2011|December 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00417209||175656|
NCT00416650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC THO 0214|Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer|Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) in Patients With Advanced Bronchioalveolar Cell Lung Cancer.||Vanderbilt-Ingram Cancer Center|Yes|Completed|July 2002|March 2013|Actual|October 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2013|April 2, 2013|December 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00416650||175698|
NCT00416663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-013|Vescell(TM) for the Treatment of Patients With Severe Anginal Syndrome With or Without Heart Failure|A Study for Testing Efficacy and Safety of the Administration of Vescell(TM) (Blood-Borne Autologous Angiogenic Cell Precursors) to Alleviate Anginal Symptoms and Myocardial Ischemia in Severe Anginal Syndrome +/- Heart Failure||TheraVitae Ltd.|Yes|Not yet recruiting|August 2007|August 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||December 2006|August 30, 2007|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416663||175697|
NCT00417183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|long vs flexible|Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation|Randomized Controlled Trial Comparing the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation in Normal Responders||Eugonia||Recruiting|September 2005|June 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Female|21 Years|39 Years|Accepts Healthy Volunteers|||December 2006|December 28, 2006|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00417183||175658|
NCT00417196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2101|Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of Intravenous QAX576||Novartis|No|Completed|December 2006|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 30, 2010|December 28, 2006||||No||https://clinicaltrials.gov/show/NCT00417196||175657|
NCT00413478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0428|5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia|Phase II Study of 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Terminated|September 2006|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|December 15, 2006||No|Slow accrual.|No|June 3, 2015|https://clinicaltrials.gov/show/NCT00413478||175936|Early termination led to small numbers of subjects analyzed.
NCT00414687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90427|Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension|An Explorative, Open-Label, Multicenter, Randomized, Parallel-Group Comparative Study of Safety, Tolerability, and the Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension Over 2 Years||Bayer||Completed|July 1998|May 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|70 Years|No|||May 2009|May 14, 2009|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414687||175845|
NCT00414388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603|Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer|Phase I/II Study to Evaluate the Ability of Sorafenib in Overcoming Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer (AIPC)||Oncology Specialists, S.C.|No|Completed|December 2006|March 2012|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|90 Years|No|||February 2014|February 28, 2014|December 19, 2006||No||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00414388||175867|
NCT00414401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 01-108|Clinical Reminders in Test Reports to Improve Guideline Compliance|Clinical Reminders in Test Reports to Improve Guideline Compliance||VA Office of Research and Development|No|Completed|May 2001|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|1500|||Both|18 Years|N/A|No|||December 2006|April 6, 2015|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00414401||175866|
NCT00414648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5702|Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)|Lymphangioleiomyomatosis Efficacy and Safety Trial||Office of Rare Diseases (ORD)|Yes|Active, not recruiting|December 2006|September 2011|Anticipated|September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||August 2009|August 27, 2009|December 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414648||175847|
NCT00415545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|423|Educational Program to Improve Heart Failure Outcomes in Adults Living in Rural Areas|Improving Self Care Behavior and Outcomes in Rural Patients With Heart Failure|REMOTE-HF|University of California, San Francisco|Yes|Completed|January 2007|January 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|614|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415545||175782|
NCT00415896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKKG3|Impact of Respiratory Muscle Unloading on Respiratory Muscle Endurance|Impact of Respiratory Muscle Unloading on Respiratory Muscle Endurance||Krankenhaus Kloster Grafschaft||Recruiting|December 2006|June 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||December 2006|December 22, 2006|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415896||175755|
NCT00416754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450754|Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations|Improving the Long-Term Outcomes of BRCA1/BRCA2 Mutation Testing||Georgetown University|No|Active, not recruiting|December 2000|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1109|||Female|25 Years|75 Years|No|||August 2014|March 12, 2015|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416754||175690|
NCT00416455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00600|Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer|Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage||National Cancer Institute (NCI)||Active, not recruiting|September 2007|||September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|384|||Female|18 Years|N/A|No|||July 2014|November 9, 2015|December 27, 2006|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT00416455||175713|Relatively small number of patients with abdominal metastasis in both cervical and endometrial cancer cohorts
NCT00416728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPV100A2102|Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.|An Open-Label, Randomized, Two-Treatment, Two Period Crossover, Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image (FMI) Aliskiren/Valsartan 150/80 mg Tablets and the Free Combination of Aliskiren 150 mg and Valsartan 80 mg in Healthy Subjects||Novartis||Completed|November 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416728||175692|
NCT00415805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 128|Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent|A Pilot, Open-Label, Multicenter Intra-Individual Comparison of Multihance and Vasovist for Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) of Renal Arteries||Bracco Diagnostics, Inc|No|Completed|December 2006|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|39|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00415805||175762|
NCT00416104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zimmerctil|Postcesarean Section Pain: Possible Demographic and Medical Predictors|Postcesarean Section Pain: Possible Demographic and Medical Predictors||Rambam Health Care Campus||Not yet recruiting|December 2006|February 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||600|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2006|December 26, 2006|December 26, 2006||||No||https://clinicaltrials.gov/show/NCT00416104||175739|
NCT00416091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561706006|Neuropsychological Functioning Among Children With Tourret's Disorder and ADHD|Neuropsychological Functioning, Symptomatology, and Social Adjustment Among Children With Tourret's Disorder, Attention-Deficit/Hyperactivity Disorder, and Comorbid Conditions.||National Taiwan University Hospital|Yes|Completed|January 2007|December 2007|Actual|||N/A|Observational|Observational Model: Case Control||1|Actual|120|||Both|8 Years|16 Years|No|Non-Probability Sample|Children with ADHD, children with ADHD and Tourette's disorder, normal control|September 2008|November 12, 2012|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00416091||175740|
NCT00416689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000460041|Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer|Determination of Utilities for Control of Chemotherapy-Induced Nausea or Vomiting||Alliance for Clinical Trials in Oncology|No|Completed|April 2000|January 2006|Actual|March 2003|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|99|||Both|18 Years|N/A|No|Probability Sample|Breast or lung cancer patients undergoing chemotherapy|September 2013|September 29, 2013|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416689||175695|
NCT00416676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-NB-1993-01|Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma|UKCCSG Stage IIB/3 (INSS) Neuroblastoma Pilot Study [ENSG VI (Pilot 2B/3)]||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|1 Year|N/A|No|||December 2006|August 1, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416676||175696|
NCT00417222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-179|Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan|Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)|SUPPORT|Tohoku University|Yes|Completed|November 2006|December 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1145|||Both|20 Years|79 Years|No|||May 2014|May 16, 2014|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417222||175655|
NCT00417833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0017|Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment|||Asociación para Evitar la Ceguera en México||Completed|December 2005|July 2006||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|N/A|N/A||||October 2008|October 17, 2008|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00417833||175608|
NCT00417508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P REK NORD 64/2003|Nutritional Intervention in Malnourished Elderly Patients|Effectiveness of Nutritional Intervention in Malnourished Elderly Patients||University Hospital of North Norway|No|Completed|December 2006|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|65 Years|N/A|No|||June 2012|June 13, 2012|December 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00417508||175633|
NCT00417521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975R|Open Trial of Family-Based Treatment for Anorexia Nervosa|Pilot Study of Manualized Family Therapy for Adolescents With Anorexia Nervosa||New York State Psychiatric Institute|No|Completed|July 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|17 Years|No|||December 2006|September 25, 2013|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417521||175632|
NCT00417495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGASSU 0502|Sentinel Lymph Node Technique in Multifocal Breast Cancer|Interest of Sentinel Lymph Node Technique in Women With a Multifocal Breast Cancer - IGASSU-0502||Centre Oscar Lambret||Completed|March 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|216|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|December 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00417495||175634|
NCT00417794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2115|Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD|A Study of the Efficacy of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal Alcohol Syndrome or Effects|B4Z-MC-X017|University of Oklahoma|Yes|Active, not recruiting|August 2005|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|11 Years|No|||December 2014|December 2, 2014|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00417794||175611|
NCT00413491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBCG07MRBRCA|National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations|National Screening i Danmark Med MR-scanning af Brystet Kontra Klinisk Mammografi Hos Kvinder Der er bærere af Risikogivende BRCA1 Eller BRCA2 Mutationer|MR BRCA|Danish Breast Cancer Cooperative Group||Recruiting|January 2007|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|300|||Female|25 Years|70 Years|No|||January 2009|May 19, 2014|December 14, 2006||||No||https://clinicaltrials.gov/show/NCT00413491||175935|
NCT00413803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-5.1/8|Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis|Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis: Long Dialysis Study||Ege University|Yes|Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|N/A|No|||August 2009|August 3, 2009|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413803||175911|
NCT00415038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PST2238-DM-03-010|Efficacy of Rostafuroxin in the Treatment of Essential Hypertension|A Double Blind, Dose Range, Placebo Controlled Study of the Effects of Rostafuroxin vs Placebo in Patients With Stable, Uncomplicated, Essential Hypertension.||sigma-tau i.f.r. S.p.A.|Yes|Completed|February 2005|August 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|438|||Both|30 Years|59 Years|No|||June 2011|June 16, 2011|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415038||175820|
NCT00414414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006301-01H|A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection|A Randomized, Prospective Double Blind Placebo Control Clinical Trial of Prednisone as Adjunctive Therapy for the Treatment of Hospitalized Patients With Pulmonary TB and HIV Co-infection||Ottawa Hospital Research Institute||Completed|February 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|412|||Both|17 Years|N/A|No|||August 2010|August 19, 2010|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414414||175865|
NCT00414661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921029|Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550|A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550||Pfizer|No|Completed|April 2007|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have received at least one dose of study drug and ceased participation in any        Phase 2B or 3 randomized, controlled or open-label (qualifying) study of CP-690,550 for        the treatment of RA, but are no longer receiving CP-690,550.|November 2012|November 28, 2012|December 19, 2006|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT00414661||175846|
NCT00414986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0457|Using Learning Teams for Reflective Adaptation for Diabetes and Depression|Using Learning Teams for Reflective Adaptation|ULTRA-DM/MDD|University of Colorado, Denver|No|Completed|September 2005|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1565|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00414986||175823|
NCT00416468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPV100A2101|Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.|An Open-Label, Randomized, Two-Treatment, Two Period Crossover, Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image (FMI) Aliskiren/Valsartan 75/160 mg Tablets and the Free Combination of Aliskiren 75 mg and Valsartan 160 mg in Healthy Subjects||Novartis||Completed|November 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416468||175712|
NCT00416481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-360401|Assessing Older Patients With Cancer|Development of a Geriatric Assessment Measure for Older Patients With Cancer||Alliance for Clinical Trials in Oncology|No|Completed|December 2006|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|93|||Both|65 Years|N/A|No|Non-Probability Sample|Patients aged 65 years and older with a histologically confirmed malignancy enrolled on        any cooperative group-sponsored cancer treatment trial.|July 2015|July 7, 2015|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416481||175711|
NCT00417313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0073|Osteopuncture for Osteoarthritis-Associated Knee Pain & Disability|Osteopuncture for Osteoarthritis-Associated Knee Pain & Disability||National Institute on Aging (NIA)||Completed|October 2004|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||88|||Both|65 Years|N/A|No|||December 2006|December 28, 2006|December 28, 2006||||No||https://clinicaltrials.gov/show/NCT00417313||175648|
NCT00417014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-HD-8201|Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma|Hodgkins Disease Study||National Cancer Institute (NCI)||Active, not recruiting||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|358|||Both|N/A|14 Years|No|||December 2006|August 1, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00417014||175671|
NCT00408278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPA 2005|Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)|Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients. Maintenance Therapy With ATRA + Low Dose Chemotherapy (Methotrexate + Mercaptopurine).||PETHEMA Foundation||Completed|July 2005|December 2013|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|75 Years|No|||October 2014|October 27, 2014|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408278||176319|
NCT00408291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060166|Evaluation of Treatment of Fractures of the Humerus With a Plate.|Evaluation of the Winsta PH Osteosynthesis Device in the Treatment of Three- and Four-Part Fractures of the Proximal Humerus A Prospective Migration and Bone Density Study||University of Aarhus|No|Recruiting|December 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|50 Years|85 Years|No|Probability Sample|The study population will be included at 2 orthopaedic departments at 2 hospitals|July 2013|May 19, 2015|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408291||176318|
NCT00416117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2001.123|Manual Physical Therapy and Exercise for Mechanical Neck Disorders|The Effectiveness of Manual Physical Therapy and Exercise for Mechanical Neck Disorders: A Randomized Controlled Trial||Brooke Army Medical Center||Completed|July 2001|June 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||December 2006|December 26, 2006|December 26, 2006||||No||https://clinicaltrials.gov/show/NCT00416117||175738|
NCT00416377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-HD-9201|Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma|Hodgkin's Disease Study||National Cancer Institute (NCI)||Active, not recruiting||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|353|||Both|N/A|N/A|No|||December 2006|August 1, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416377||175718|
NCT00416962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSYO380A2101|Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine|An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.||Novartis||Completed|August 2006|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2007|November 29, 2007|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416962||175675|
NCT00417235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05PHN01|Dressing: Frequency of Change and Evaluation of an Antiseptic-Impregnated Catheter Dressing in ICU Patients|Dressing: Comparison of 3-Day and 7-Day Catheter Dressing Frequency and Efficacy of Antiseptic Impregnated Dressing in Preventing Catheter-Related Infection in ICU|DRESSING|University Hospital, Grenoble|Yes|Completed|January 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1600|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417235||175654|
NCT00416949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0628|Iodine I 131 in Treating Patients With Thyroid Cancer|Dose-Response in Radionuclide Therapy of Thyroid Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|April 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|N/A|No|||May 2013|August 6, 2014|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416949||175676|
NCT00417846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00006147|Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)|Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)||Johns Hopkins University|Yes|Completed|January 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|||Both|50 Years|N/A|No|Non-Probability Sample|Participants will have neovascular AMD in the fellow eye and non-neovascular AMD in the        candidate study eye to be eligible for this study. Additional inclusion and exclusion        criteria are listed below.|October 2009|October 2, 2009|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00417846||175607|
NCT00417859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO 218/01|Total Knee Arthroplasty: Comparison of Fixed and Mobile Bearings|Total Knee Arthroplasty: Comparison of Fixed and Mobile Bearings||University of Lausanne Hospitals||Completed|February 2004|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|N/A|N/A|No|||December 2015|December 1, 2015|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00417859||175606|
NCT00417872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-2015|Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis|Multicenter, Double Blind, Metronidazole Controlled, Dose Range Finding Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis||Romark Laboratories L.C.||Completed|January 2004|September 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||114|||Both|18 Years|N/A|No|||October 2005|January 3, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00417872||175605|
NCT00413504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000599|Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism|Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study)||Brigham and Women's Hospital|Yes|Completed|April 2006|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2009|February 2, 2009|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00413504||175934|
NCT00413517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU # 06-23020|Evaluation of Epi-lasik in U.S. Army Personnel|Evaluation of Epi-lasik in U.S. Army Personnel||Walter Reed Army Medical Center||Completed|November 2006|September 2009|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 15, 2010|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413517||175933|
NCT00413816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004152|The Israeli Trigger for Blood Transfusions in the ICU|A Multicenter Study of Anemia in the ICU Patient: Determination of the Israeli Trigger and Post ICU Course||Rabin Medical Center||Recruiting|October 2006|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||500|||Both|18 Years|80 Years|No|||October 2006|December 19, 2006|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413816||175910|
NCT00417807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BIT06|Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors|Open-label Trial of Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors (DSRCT) Expressing PDGF-R||Novartis||Completed|August 2005|||June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|16 Years|N/A|No|||December 2010|December 23, 2010|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00417807||175610|
NCT00417820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCT194A2101|Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.|A Multicenter, Double-Blind, Placebo Controlled Exploratory Study to Evaluate the Safety, Tolerability and Pharmacodynamics of a Single Administration of BCT194 in Healthy Volunteers and Multiple Administrations in Patients With Psoriasis.||Novartis||Completed|November 2006|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|75 Years|No|||November 2007|November 28, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00417820||175609|
NCT00414128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCYC|Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis|A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis.|MYCYC|Cambridge University Hospitals NHS Foundation Trust|Yes|Completed|March 2007|February 2013|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|N/A|N/A|No|||December 2013|December 5, 2013|December 19, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414128||175887|
NCT00414427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051420|Using Ultrasonography to Predict Clinical Response to Intraarticular Corticosteroids in Knee Osteoarthritis|Using Ultrasonography to Predict Clinical Response to Intraarticular Corticosteroids in Knee Osteoarthritis||University of California, San Diego||Completed|December 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||December 2006|July 7, 2010|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414427||175864|
NCT00415584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-09-244|Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients|Cinacalcet for Treatment of Persistent Secondary Hyperparathyroidism in Renal Transplant Recipients: Effect on Renal Function, Serum Calcium and Bone Histomorphometry||Montefiore Medical Center||Withdrawn|January 2007|November 2009||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||November 2009|November 3, 2009|December 21, 2006|Yes|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT00415584||175779|
NCT00415597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-KNT-302|Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain|A Long-Term, Open-Label Safety Study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Chronic Moderate to Severe Nonmalignant Pain||Pfizer||Completed|December 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|467|||Both|18 Years|70 Years|No|||September 2013|September 13, 2013|December 21, 2006|Yes|Yes||No|September 11, 2009|https://clinicaltrials.gov/show/NCT00415597||175778|
NCT00415025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0168|Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer|Evaluation of Normal Tissue Toxicities in Head and Neck Cancer Patients Receiving Intensity Modulated Radiotherapy (IMRT)||University of Wisconsin, Madison||Completed|June 2004|July 2007|Actual|||N/A|Observational|N/A|||Anticipated|20|||Both|18 Years|120 Years|No|||October 2015|October 15, 2015|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00415025||175821|
NCT00415272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H52476-29802-01|Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease|||University of California, San Francisco||Terminated||July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A||||January 2008|January 11, 2008|December 20, 2006|||Inadequate enrollment.|No||https://clinicaltrials.gov/show/NCT00415272||175802|
NCT00415532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060131|Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura|A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura||Amgen||Completed|December 2006|July 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|December 21, 2006||||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00415532||175783|
NCT00417027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-027|Programmed Intermittent Epidural Bolus Time Interval and Injection Volume|Effect of Manipulation of the Programmed Intermittent Bolus Time Interval and Injection Volume on Total Drug Use for Labor Epidural Analgesia: a Randomized Controlled Trial||Northwestern University|No|Completed|August 2006|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|190|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|December 27, 2006||No||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00417027||175670|No group that received a continuous infusion or PCEA without a background infusion was included. Conclusions are limited to our patient population, drug concentrations, and mode of initiation of labor analgesia.
NCT00417937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14428|A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily|A Multicenter, Double-Blind Clinical Trial to Assess the Efficacy and Tolerability of Topical Azelaic Acid 15% Gel Once Daily Compared to Topical Azelaic Acid 15% gelTwice Daily in Subjects With Papulopustular Rosacea||Bayer|No|Completed|January 2007|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|January 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00417937||175600|
NCT00417950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950801/C06138|Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes|||Taichung Veterans General Hospital||Recruiting|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|25 Years|75 Years|No|||January 2007|January 3, 2007|January 1, 2007||||No||https://clinicaltrials.gov/show/NCT00417950||175599|
NCT00408304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schiff1|Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.|Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.||Bnai Zion Medical Center||Recruiting|December 2006|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|N/A|N/A|No|||December 2006|December 5, 2006|December 5, 2006||||No||https://clinicaltrials.gov/show/NCT00408304||176317|
NCT00408317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT20CF05-01|Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)|A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF)||Forest Laboratories|Yes|Completed|November 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|7 Years|N/A|No|||January 2014|January 27, 2014|December 4, 2006|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT00408317||176316|
NCT00416390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000492778|Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia|The Effect of Lycopene on DNA Damage in Human Prostate||National Cancer Institute (NCI)||Completed||March 2011|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Male|N/A|N/A|No|||October 2007|September 19, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416390||175717|
NCT00416702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149A2307|Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics of 600 µg Indacaterol in Subjects With Impaired Hepatic Function in Comparison With Healthy Control Subjects||Novartis||Completed|November 2006|March 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|70 Years|No|||June 2008|June 9, 2008|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416702||175694|
NCT00416975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-00036|Individualized Risk-Based Education in Promoting Breast Cancer Screening in Healthy Women|Breast Cancer Risk-Tailored Messages for More Women||Virginia Commonwealth University|No|Completed|May 2000|February 2013|Actual|December 2005|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|899|||Female|40 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 23, 2013|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00416975||175674|
NCT00417248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LUN06-107|Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer|A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107||Hoosier Cancer Research Network|Yes|Terminated|June 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|December 28, 2006||No|Negative sorafenib results from ESCAPE trial and safety concerns of regimen|No||https://clinicaltrials.gov/show/NCT00417248||175653|
NCT00417261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATF936A2201|Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.|A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Ascending Single and Multiple Dose, Seamless Design Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Orally Administered Compounds, ATF936 and AXT914, in Healthy Male and Female Subjects||Novartis|No|Completed|November 2006|April 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|65|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||June 2008|June 20, 2008|December 28, 2006||||No||https://clinicaltrials.gov/show/NCT00417261||175652|
NCT00417534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214841|Genetic Predisposition of Coronary Artery Disease -- The COROGENE-Study|Genetic Predisposition of Coronary Artery Disease in Patients Verified With Coronary Angiogram The COROGENE-Study||Helsinki University||Recruiting|June 2006|December 2009|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|5000|||Both|N/A|N/A|No|||December 2006|July 2, 2007|December 29, 2006||||No||https://clinicaltrials.gov/show/NCT00417534||175631|
NCT00417885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181108|A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer|Phase 1/2 Open-Label Trial Of Sutent (Sunitinib Malate) And Aromasin(Exemestane) In The First-Line Treatment Of Hormone Receptor-Positive Metastatic Breast Cancer||Pfizer|No|Terminated|June 2007|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||September 2010|September 16, 2010|January 2, 2007|No|Yes|See Detailed Description for Termination Reason|No|July 9, 2010|https://clinicaltrials.gov/show/NCT00417885||175604|
NCT00417898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATPA-HMO-CTIL|Study of Aspirin and TPA in Acute Ischemic Stroke|Phase 1 Study to Assess the Safety of 500mg of Aspirin Added to IV TPA at Standard Doses to Prevent re-Occlusion of Cerebral Vessels After Successful Reperfusion.||Hadassah Medical Organization||Not yet recruiting|March 2007|December 2012|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|85 Years|No|||January 2007|January 3, 2007|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00417898||175603|
NCT00413530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0220|Effects of Pomegranate Juice or Extract on Rising PSA Levels in Men Following Primary Therapy for Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Pomegranate Juice or Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer||M.D. Anderson Cancer Center|Yes|Completed|December 2006|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|N/A|No|||June 2015|June 17, 2015|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00413530||175932|
NCT00413543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL11494.075.06|Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|Early Pulmonary Rehabilitation After Hospitalisation for Acute Exacerbation COPD||Isala|Yes|Terminated|October 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|40 Years|80 Years|No|||September 2015|September 17, 2015|December 18, 2006||No|enrollment insufficient: lack of motivated patients|No||https://clinicaltrials.gov/show/NCT00413543||175931|
NCT00413829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aug1202|Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)|Open-label, Phase II Study Assessing Immediate Effects of Lucentis®(Ranibizumab) Administered in Conjunction With Photodynamic Therapy With Visudyne® in Patients With Choroidal Neovascularization Secondary to AMD||University Hospital Inselspital, Berne|No|Completed|October 2006|March 2008|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|N/A|No|||January 2010|January 13, 2010|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413829||175909|
NCT00414440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE12|Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease|A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)||Novartis||Completed|December 2006|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|431|||Both|18 Years|50 Years|No|||January 2015|January 13, 2015|December 20, 2006|Yes|Yes||No|October 7, 2014|https://clinicaltrials.gov/show/NCT00414440||175863|
NCT00414700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIG/ACT/01/2000&Extension|RCT of ChondroCelect® (in an ACI Procedure) vs Microfracture in the Repair of Cartilage Defects of the Knee|Prospective Multicenter Randomized Controlled Trial of ChondroCelect® (Via Autologous Chondrocyte Implantation) vs Microfracture (as Procedure) in the Repair of Symptomatic Cartilaginous Defects of the Femoral Condyles|TIGACT01|TiGenix n.v.|No|Completed|February 2002|January 2010|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|50 Years|No|||September 2011|September 22, 2011|December 21, 2006|Yes|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00414700||175844|
NCT00416208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006127|Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma|Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75||Janssen-Cilag G.m.b.H|No|Completed|October 2006|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|61 Years|75 Years|No|||March 2015|March 4, 2015|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00416208||175731|
NCT00416780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMBC-HS05-182|Psychosocial Support in Treating Women With Recurrent Breast Cancer or Stage I, Stage II, or Stage IV Breast Cancer|Psychobiological Pathways: Breast Cancer Interventions||National Cancer Institute (NCI)||Completed||March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|350|||Female|25 Years|N/A|No|||March 2006|May 29, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416780||175688|
NCT00415285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU822-03|Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer|Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer||Georgia Center for Oncology Research & Education||Recruiting|December 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|18 Years|N/A|No|||February 2007|February 12, 2007|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00415285||175801|
NCT00415558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR2049541|Prospective Clinical Study of the Guidant Microwave Ablation System for the Treatment of PAF in the MIS Procedure|Prospective, Multicenter, Un-Blinded, Single Arm, Clinical Study Using the Guidant Microwave Ablation System Comprised of the Flex 10 Ablation Probe and Microwave Generator for Patients With Symptomatic Paroxysmal Atrial Fibrillation||Maquet Cardiovascular||Terminated|May 2007|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A||||June 2009|June 5, 2009|December 20, 2006||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT00415558||175781|
NCT00415571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-50608|Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors|Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study||QuatRx Pharmaceuticals Company||Completed|December 2006|August 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|72|||Male|20 Years|N/A|No|||February 2010|February 2, 2010|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415571||175780|
NCT00415883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVNP489A2106|To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers|An Open-Label, Randomized, Single Dose, Two Period, Crossover Study to Determine the Relative Bioavailability of Valsartan 160 mg Japanese Formulation and Valsartan 160 mg Global Formulation in Healthy Adult Volunteers||Novartis|No|Completed|July 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415883||175756|
NCT00417365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG105B|Efficacy of (WaterWorks®)Douching Device for Elimination of Perceived Vaginal Odor Not Caused by BV or Vaginitis|"A Comparison Study of the WaterWorks® Douching Device vs. Commercial OTC Douching Device for the Reduction or Abatement of Perceived Vaginal Odor With or Without Complaints of Discharge in Women With no Infectious Causes of Vaginitis"||Abbott Research Group||Recruiting|August 2006|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|N/A|No|||August 2007|August 13, 2007|December 28, 2006||||No||https://clinicaltrials.gov/show/NCT00417365||175644|
NCT00417612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AR054086|Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets|The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH)||Yale University|Yes|Completed|January 2007|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|9 Years|N/A|No|||October 2014|October 22, 2014|December 28, 2006|Yes|Yes||No|August 2, 2014|https://clinicaltrials.gov/show/NCT00417612||175625|
NCT00417625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070056|Validation of MRI Measurement of Cardiac Blood Flow|Validation of Cardiac MR Perfusion With Cardiac Catheterization Physiological Assessment||National Institutes of Health Clinical Center (CC)||Completed|December 2006|July 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|34|||Both|21 Years|N/A|No|||July 2010|September 26, 2015|December 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00417625||175624|
NCT00417638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rapid MI-ICE-Pilot|Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention|A Randomized, Controlled Study of the Use of Central Venous Catheter Core Cooling Combined With Cold Saline, and Rewarming as an Adjunct to Percutaneous Coronary Intervention For the Treatment of Acute Myocardial Infarction||Philips Healthcare|No|Completed|January 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||January 2010|January 14, 2010|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00417638||175623|
NCT00417963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-VX-1502|ViVEXX Carotid Revascularization Trial (VIVA)|The ViVEXX Carotid Revascularization Trial (VIVA) for High Surgical Risk Patients With Extracranial Carotid Artery Stenosis Using the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System||C. R. Bard|Yes|Completed|October 2005|March 2010|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|407|||Both|18 Years|85 Years|No|||June 2011|June 21, 2011|January 2, 2007|Yes|Yes||No|April 16, 2011|https://clinicaltrials.gov/show/NCT00417963||175598|
NCT00404066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0002|Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer|Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab||Stanford University|Yes|Completed|October 2006|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|70 Years|No|||March 2011|November 6, 2012|November 22, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00404066||176638|
NCT00416715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6346|Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer|A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness Associated With Letrozole (Femara® )||University of Washington|No|Completed|October 2006|||May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Female|18 Years|N/A|No|||May 2013|May 7, 2013|December 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00416715||175693|
NCT00416988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000454855|Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants|Skin Self-Examination for Early Detection of Melanoma: Intervention and Consequence||Rhode Island Hospital||Completed||||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|1135|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|June 19, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416988||175673|
NCT00417586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|468|Cost-Effectiveness of a Specialized Ultrasound Instrument to Diagnose Carotid Stenosis as a Way to Reduce the Risk of Stroke|New Ultrasound Instrument for Carotid Screening||DVX, LLC|Yes|Completed|June 2007|November 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|984|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care patients who fit inclusion criteria|December 2013|December 9, 2013|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417586||175627|
NCT00413556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-16|Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets|Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study Investigating Changes in Immunological Parameters and Cutaneous Reactivity Induced by a Short Course Immunotherapy With ALK Grass Tablets||ALK-Abelló A/S|No|Completed|January 2007|December 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|65 Years|No|||March 2008|March 4, 2008|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413556||175930|
NCT00413569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610008805|The Effect of Intubation Method on Outcome of Cervical Spine Surgery|||Weill Medical College of Cornell University||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|85 Years||||December 2006|December 18, 2006|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00413569||175929|
NCT00417547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNFTRI|Comparison of Body Dissatisfaction Among Islamic Veil Practicing (IVP), Non-Complete IVP, and Inconsiderate to IVP Women|Comparison of Body Dissatisfaction Among Islamic Veil Practicing (IVP), Non-Complete IVP, and Inconsiderate to IVP Women||hahid Beheshti University of Medical Sciences||Completed|February 2006|September 2006||||N/A|Observational|N/A||||3000|||Female|12 Years|59 Years|Accepts Healthy Volunteers|||February 2009|February 4, 2009|December 29, 2006||||No||https://clinicaltrials.gov/show/NCT00417547||175630|
NCT00417560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIRD-5000|Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses|A Single Center, Open-label, Phase I/II Study of Two 90 Microgram Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses||Centers for Disease Control and Prevention||Active, not recruiting|January 2007|January 2013|Anticipated|December 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 6, 2012|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417560||175629|
NCT00414154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026|The Importance of Patient Education - A Randomised Controlled Trial|The Effect of a Group Based Multidisciplinary Patient Education Programme for Patients With Osteoporosis - a Controlled Randomised Trial||Odense University Hospital||Completed|May 2002|May 2007||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||300|||Both|45 Years|80 Years|No|||March 2007|February 23, 2011|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00414154||175885|
NCT00413881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU # 04-23011|A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures|A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures||Walter Reed Army Medical Center||Completed|July 2004|March 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2008|January 13, 2010|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413881||175905|
NCT00414453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TALENT-MS|Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis|Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (TALENT-MS)||University of Rochester|No|Terminated|January 2007|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|December 19, 2006||No|Did not reach enrollment goals|No|March 11, 2015|https://clinicaltrials.gov/show/NCT00414453||175862|
NCT00414466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1622|A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain|A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.||MedtronicNeuro|Yes|Terminated|December 2006|August 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|254|||Both|18 Years|70 Years|No|||August 2013|August 19, 2013|December 20, 2006|Yes|Yes|Study closed and subject follow-up completed following analysis of blinded study data.|No|December 22, 2010|https://clinicaltrials.gov/show/NCT00414466||175861|
NCT00413842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070049|Effects of tDCS Over the Cerebellum on Motor Function|Effects of tDCS Over the Cerebellum on Motor Function||National Institutes of Health Clinical Center (CC)||Completed|December 2006|August 2008||||N/A|Observational|N/A||||40|||Both|18 Years|40 Years|No|||August 2008|August 21, 2008|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413842||175908|
NCT00414141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrassMATAMPL301|Efficacy and Safety/Tolerability of Grass MATA MPL|Efficacy and Safety/Tolerability of Grass MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study||Allergy Therapeutics||Completed|November 2006|November 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1028|||Both|18 Years|59 Years|No|||September 2009|June 16, 2010|December 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414141||175886|
NCT00415051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FY04-33, Log A-13698|Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine|Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study|MP-12|U.S. Army Medical Research and Materiel Command|No|Completed|September 2006|December 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|June 8, 2015|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415051||175819|
NCT00415298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000520463|AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer|AP5346 for Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck: A Pilot Study With Clinical and Biological Endpoints||National Cancer Institute (NCI)||Active, not recruiting|May 2006|||||N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||May 2007|January 9, 2014|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00415298||175800|
NCT00416793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02894|Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer||National Cancer Institute (NCI)||Completed|December 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2013|May 12, 2014|December 27, 2006|Yes|Yes||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00416793||175687|Given the toxicity and lack of objective responses observed with this regimen, the protocol met prospective criteria for early stopping and was terminated.
NCT00415909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0837|TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients|Phase II "Proof of Concept" Study of TALL-104 (MHC Non-Restricted Cytotoxic T-Cell Line) and Imatinib Mesylate (Gleevec) in Chronic Myelogenous Leukemia in Chronic Phase||M.D. Anderson Cancer Center|No|Terminated|December 2006|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|December 22, 2006|Yes|Yes|Slow Accrual|No|May 29, 2014|https://clinicaltrials.gov/show/NCT00415909||175754|
NCT00415922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200A2104|Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 37.5 mg Carbidopa, 150 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 37.5 mg Carbidopa and 150 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions||Novartis||Completed|July 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415922||175753|
NCT00416182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z3297S|Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis|The Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot Study||University of Vermont|Yes|Completed|December 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|5 Years|N/A|No|||November 2014|November 12, 2014|December 26, 2006|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT00416182||175733|recruitment for a long trial was difficult so enrollment was truncated.
NCT00416195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-208|Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures||Eisai Inc.||Completed|December 2006|March 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|70 Years|No|||August 2013|June 26, 2014|December 26, 2006|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00416195||175732|
NCT00404664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 7370|Improving Influenza Vaccination Rates Among Health Care Professionals|A Novel Approach To Improve Influenza Vaccination Rates Among Health Care Professionals: A Prospective Randomized Controlled Trial||The Cleveland Clinic||Completed|September 2004|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||800|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2006|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404664||176592|
NCT00417651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H0078|Testing for Bacterial Contamination During Gastric Surgeries|Transgastric Bacterial Contamination of the Abdomen||Ohio State University|No|Completed|July 2006|October 2007|Actual|October 2007|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|70 Years|No|Probability Sample|observational studies patients morbidly obese.|December 2011|December 13, 2011|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00417651||175622|
NCT00417976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-05110|Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer|A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|December 2006|February 2011|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|January 2, 2007|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00417976||175597|42 patients enrolled, 39 were evaluable for the primary end point.
NCT00413621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070050|MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems|MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems||National Institutes of Health Clinical Center (CC)||Completed|December 2006|||October 2009|Actual|N/A|Observational|N/A||||40|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||October 2009|October 22, 2009|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00413621||175925|
NCT00404365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mskcc 06-038|Depression Screening in Patients With Lung Cancer|Maximizing Utilization of Depression Screening in Lung Cancer Patients: A Randomized Trial||Memorial Sloan Kettering Cancer Center||Completed|April 2006|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|241|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404365||176615|
NCT00404378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV105093|Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]|An Open-label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of [GW679769]||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 27, 2006||||||https://clinicaltrials.gov/show/NCT00404378||176614|
NCT00417001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05-075|Reduction of Conscious Sedation Requirements by Olfactory Stimulation|Reduction of Conscious Sedation Requirements by Olfactory Stimulation||United States Naval Medical Center, Portsmouth|No|Completed|October 2006|October 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|284|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 20, 2009|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00417001||175672|
NCT00417274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBL-DD-05-C-H-2003|Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer|An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer||Cleveland BioLabs|No|Completed|December 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Male|18 Years|N/A|No|||September 2012|March 6, 2013|December 27, 2006|Yes|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00417274||175651|
NCT00417287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-12-II-01|Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer|A Randomized Phase II Open-Label Study of Two Different Dose Levels of PX-12 in Patients With Advanced Carcinoma of the Pancreas Whose Tumors Have Progressed on Gemcitabine or on a Gemcitabine-Containing Combination||Oncothyreon Inc.|Yes|Terminated|December 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|December 29, 2006|Yes|Yes|Investigator decision|No||https://clinicaltrials.gov/show/NCT00417287||175650|
NCT00417573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-489|Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections|Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections||The Center for Rheumatic Disease, Allergy, & Immunology||Completed|December 2004|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||December 2006|December 29, 2006|December 28, 2006||||No||https://clinicaltrials.gov/show/NCT00417573||175628|
NCT00413855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9335|Laparoscopic Appendectomy for Chronic Right Lower Abdominal Pain|Elective Laparoscopic Appendectomy for Chronic Right Lower Abdominal Pain; Outcome of a Prospective Randomized Double-Blind Controlled Surgical Trial||Maxima Medical Center||Completed|September 1994|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|15 Years|45 Years|No|||December 2006|December 19, 2006|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413855||175907|
NCT00414167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DK071646|Craving, Binge Eating and Obesity|Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder||Yale University||Completed|December 2005|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|65 Years|No|||February 2014|February 12, 2014|December 20, 2006||No||No|October 22, 2012|https://clinicaltrials.gov/show/NCT00414167||175884|
NCT00415077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU# 04-23009|A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia|A Prospective Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia||Walter Reed Army Medical Center||Terminated|June 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|960|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 15, 2010|December 21, 2006|||Change in excimer laser systems prior to completion of study|No||https://clinicaltrials.gov/show/NCT00415077||175817|
NCT00414479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-KY-DK-06|Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment|Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment||DBL -Institute for Health Research and Development||Completed|July 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|9 Years|12 Years|No|Non-Probability Sample|children 9-12 years of age|January 2010|January 13, 2010|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414479||175860|
NCT00414713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/02/102/1729 HCSCSP|Transfusion Requirements in Gastrointestinal (GI) Bleeding|Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|October 2002|December 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|860|||Both|18 Years|N/A|No|||December 2010|December 28, 2010|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00414713||175843|
NCT00415064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 127|Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma|An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma||AEterna Zentaris|No|Completed|December 2006|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||November 2011|July 3, 2012|December 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415064||175818|
NCT00415610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609M93128|Antihypertensive Treatment in Acute Cerebral Hemorrhage|Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)|ATACH|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2005|March 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|December 21, 2006|No|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT00415610||175777|Limited by small sample size and likelihood of imbalances in subject characteristics among the three tiers. Clinical measures may be insensitive. Not designed to provide comparative event rates and not powered toward prediction of clinical outcomes.
NCT00415935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04RU01|PRINTO (the Paediatric Rheumatology International Trials Organisation)|||Institute of Child Health||Recruiting||December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|16 Years|No|||December 2006|December 23, 2006|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415935||175752|
NCT00416494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008646|Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer|Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Colorectal Cancer||Duke University||Completed|September 2003|August 2014|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|December 27, 2006|Yes|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT00416494||175710|
NCT00416767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453858|Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery|Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|80 Years|No|||June 2007|July 23, 2008|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416767||175689|
NCT00417326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5046Na-14|Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia|ONO-5046Na Phase II Study - A Pilot Study for Patients With Acute Respiratory Failure||Ono Pharmaceutical Co. Ltd||Completed|December 2006|||August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|174|||Both|20 Years|79 Years|No|||June 2012|June 12, 2012|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417326||175647|
NCT00404404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515534|ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer|Phase II Trial of Abraxane Administered on a Weekly Schedule in Combination With Bevacizumab in Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2006|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||April 2007|December 17, 2013|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404404||176612|
NCT00404898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01|NYU/Bellevue WTC Health Impacts Research Registry|NYU/Bellevue Red Cross WTC Health Impacts Research Registry||New York University School of Medicine||Recruiting|December 2007|||June 2019|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|7000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The populations to be served will consist predominantly of a) local residents who were        impacted by the dispersion of the WTC dusts and fumes, b) individuals involved in cleaning        and debris removal of local commercial spaces, and c) responders to the WTC collapse.        These populations will be recruited from past and ongoing programs that we have developed        as well as from ongoing collaborations with community organizations that include: the        Beyond Ground Zero Network, 9/11 Environmental Action committee, and the WTC Residents        Coalition.|November 2015|November 25, 2015|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00404898||176574|
NCT00405236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.270|Effect of Tiotropium on Inflammation and Exacerbations in COPD|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Changes in Inflammatory Markers in Induced Sputum Following Treatment With Tiotropium Inhalation Capsules 18mcg Once Daily in Patients With Chronic Obstructive Pulmonary Disease||Royal Free and University College Medical School||Completed|October 2002|January 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|N/A|N/A|No|||November 2006|November 27, 2006|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00405236||176551|
NCT00405249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-443-014A|Safety Study of Elvucitabine in HIV-1 Subjects|14-Day Randomized Double-Blind Comparative Viral Kinetic Study of Elvucitabine Versus Lamivudine Once Daily to HIv-1 Subjects With M184V||Thomas Jefferson University||Completed|September 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|5|||Both|18 Years|65 Years|No|||February 2009|February 3, 2009|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405249||176550|
NCT00436787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART108029|Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers|Pharmacokinetic Properties of Fondaparinux Sodium in Morbidly Obese Volunteers||University of Pittsburgh||Completed|February 2007|December 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|21|||Both|18 Years|65 Years|No|||May 2008|May 15, 2008|February 16, 2007||||Yes||https://clinicaltrials.gov/show/NCT00436787||174178|
NCT00417599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-10880|Preventing Overweight in USAF Personnel: Minimal Contact Program|Preventing Overweight in USAF Personnel: Minimal Contact Program||Baylor College of Medicine||Active, not recruiting|December 2001|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417599||175626|
NCT00414180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007293|Bupropion SR for Treating Smokeless Tobacco Use|Bupropion SR for Treating Smokeless Tobacco Use||Mayo Clinic||Completed|August 2003|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||225|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 10, 2011|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00414180||175883|
NCT00417911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG 15/05|Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients|Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05)||Nordic Myeloma Study Group||Completed|December 2005|May 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00417911||175602|
NCT00417924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT06170409X|Eye on Diabetes: A Multidisciplinary Patient Education Intervention|Eye Health and Vision Care for Patients With Diabetes: Comparing Usual Care to a Targeted Intervention in a Randomized Controlled Trial||Nova Southeastern University||Completed|October 2004|October 2005||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||90|||Both|18 Years|N/A|No|||December 2006|January 2, 2007|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00417924||175601|
NCT00413582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 08 128|Pain Management for Pectus Excavatum Repair|Prospective Randomized Trial: Pain Management Strategy After Pectus Excavatum Repair||Children's Mercy Hospital Kansas City||Completed|October 2006|October 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|8 Years|18 Years|No|||December 2011|December 12, 2011|December 18, 2006||No||No|December 12, 2011|https://clinicaltrials.gov/show/NCT00413582||175928|
NCT00413868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU 3 04-2335-99f|A Prospective Evaluation of Contrast Sensitivity and Disability Glare in Refractive Surgery, a Sub-Study of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)|||Walter Reed Army Medical Center||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label||||50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|December 19, 2006||||No||https://clinicaltrials.gov/show/NCT00413868||175906|
NCT00415324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00168|Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of Halichondrin B Analog (E7389) in Combination With Cisplatin in Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|December 2006|||May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||April 2014|May 19, 2014|December 20, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00415324||175798|
NCT00415337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ebus101101|Endobronchial Ultrasound Guided Transbronchial Lung Biopsy With or Without Guide Sheath in Lung Tumors and the Analysis of Echoic Patterns of Lung Tumors and Mediastinal Lymph Nodes, and the Association Between Diagnostic Yield of Transbronchial Lung Biopsy and EBUS Echoic Features.|||Chang Gung Memorial Hospital||Active, not recruiting|April 2007|||||N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patient with radiologically confirmed peripheral lung mass|December 2011|December 13, 2011|December 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00415337||175797|
NCT00414726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS051412|Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial|Clinical Trial of Normobaric Oxygen Therapy in Acute Ischemic Stroke||Massachusetts General Hospital|Yes|Terminated|January 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|December 21, 2006|Yes|Yes|Imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded    external medical monitor.|No|July 1, 2010|https://clinicaltrials.gov/show/NCT00414726||175842|Early termination leading to small numbers of subjects analyzed.
NCT00415948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0101|Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement|Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement||Biosite||Completed|December 2006|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Plasma Specimens|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting the to the ED within 6 hours with symptoms consistent with ACS.|December 2009|December 17, 2009|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00415948||175751|
NCT00416221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD-106|PACEPro - Mood Management Pilot|Development and a Pilot Study of the PACEPRO Exercise and Mood Management Program in Depressed Patients on Escitalopram Oxalate (Lexapro)||University of California, San Diego||Completed|April 2006|January 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|25 Years|65 Years|No|||August 2011|August 17, 2011|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00416221||175730|
NCT00416507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000453847|Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|190|||Both|N/A|N/A|No|||May 2008|January 22, 2011|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00416507||175709|
NCT00416520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E07|A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia|A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia||Mitsubishi Tanabe Pharma Corporation|No|Completed|June 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|336|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|December 27, 2006||No||No|August 22, 2014|https://clinicaltrials.gov/show/NCT00416520||175708|
NCT00417040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-70501|Using the Internet to Collect Symptoms and the Ability to Carry Out Daily Activities From Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Collection of Patient-Reported Symptoms and Performance Status Via the Internet||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|December 2006|||March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Male|18 Years|N/A|No|Non-Probability Sample|Patients enrolled on CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603,        CALGB-40502, CALGB-40503, CALGB-70604, or CALGB-80405|July 2015|July 23, 2015|December 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00417040||175669|
NCT00417339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHD002|Protein-bound Uremic Retention Solutes and Long Nocturnal Hemodialysis: a Longitudinal Analysis|A Multicentric Observational Trial on Protein Bound Uremic Toxins in Nocturnal Hemodialysis||Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|December 2006|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|20|Samples Without DNA|serum, urine, dialysate|Both|18 Years|N/A|No|Probability Sample|maintenance dialysis patients|December 2013|December 16, 2013|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417339||175646|
NCT00417352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Compensatory motion|Study of Compensatory Motion While Using an Upper Limb Prosthesis|Kinematic and Kinetic Profile of Common Tasks for the Development of Design Parameters of an Upper Limb Prosthesis||University of South Florida||Completed|December 2006|May 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2006|August 5, 2010|December 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00417352||175645|
NCT00417053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-NB-1999-03|Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant|European Infant Neuroblastoma Study Final Protocol||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 3|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|1 Year|No|||December 2006|August 1, 2013|December 27, 2006||||No||https://clinicaltrials.gov/show/NCT00417053||175668|
NCT00404417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI P06-71038|Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain|Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain: A Prospective Randomized Double-blind Placebo-controlled Crossover Study||Walter Reed Army Medical Center|Yes|Active, not recruiting|March 2007|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2010|March 1, 2010|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404417||176611|
NCT00404677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB 06-92|The Correlation Between Airway Inflammation and Loss of Deep Inhalation Bronchoprotection in Asthmatics|The Correlation Between Airway Inflammation and Loss of Deep Inhalation Bronchoprotection in Asthmatics||University of Saskatchewan||Completed|June 2006|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|18|||Both|18 Years|N/A|No|||January 2008|January 18, 2008|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404677||176591|
NCT00404911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 04-0063|Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth|Family Groups to Reduce Youth Behavioral Difficulties||Icahn School of Medicine at Mount Sinai|No|Completed|October 2006|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|416|||Both|7 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 21, 2013|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00404911||176573|
NCT00437112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9631|Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared With Once-Daily Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Mellitus on Oral Agents||Eli Lilly and Company||Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||July 2008|July 15, 2008|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00437112||174155|
NCT00413894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20572|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.|An Open Label Study of the Effect of Intravenous Mircera on Hemoglobin Levels in Anemic Patients With Chronic Kidney Disease Who Are on Dialysis, and Who Have Previously Received Epoetin Alfa or Beta or Darbepoetin Alfa Treatment.||Hoffmann-La Roche||Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|424|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|December 19, 2006||No||No|January 17, 2016|https://clinicaltrials.gov/show/NCT00413894||175904|
NCT00413920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AFR05|Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients|A Multicenter Randomized Open Label Study to Assess Efficacy and Safety of a Steroid Avoidance Regimen in Comparison to a Treatment With Steroids, in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS) 2.16 g/d for 6 Weeks and Cyclosporine Microemulsion, in de Novo Adult Renal Transplant Recipients||Novartis||Completed|April 2007|||March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|70 Years|No|||April 2011|April 19, 2011|December 19, 2006||No||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00413920||175903|
NCT00414193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0611104|Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase|Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase||University of Pittsburgh|Yes|Active, not recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|positive cultures|December 2015|December 16, 2015|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00414193||175882|
NCT00414492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06106|Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer|Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|December 2006|June 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|liver tissue from surgical specimen|Both|18 Years|N/A|No|Non-Probability Sample|Patients with colon cancer metastases to the liver|September 2010|September 15, 2010|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414492||175859|
NCT00414739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAC-2006-1|Testing of Innocuousness of Benzalkonium Chloride on the Eye Concerning Possible Growth of Langerhans Cells|||University of Rostock||Recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2006|December 21, 2006|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00414739||175841|
NCT00414752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2109|Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking|A Randomized, Double Blind, Multiple Dose, Cross-Over, Placebo- and Active-Controlled Proof of Concept Study to Explore the Effects of AFQ056 and Nicotine (Active Comparator) on Craving and Withdrawal During Voluntary Smoking Abstinence in Healthy Smokers||Novartis||Completed|September 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00414752||175840|
NCT00406263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1016|Comparison of Scheimpflug Photos of the Crystalline Lens in Patients Who Have Undergone Vitrectomy Surgery and Controls|Comparison of Scheimpflug Photos of the Crystalline Lens in Patients Who Have Undergone Vitrectony Surgery and Controls||Barnes Retina Institute|No|Recruiting|November 2006|January 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing vitrectony surgery and controls|May 2008|May 6, 2008|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406263||176472|
NCT00406601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2006-002|BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas|Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy||Istituto Clinico Humanitas|No|Completed|November 2006|September 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00406601||176447|
NCT00415311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2232-02|A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.|A Multicenter, Open-Label, Randomized, Phase 1B Study Evaluating the Safety and Tolerability of Intravenous Recombinant Human Mannose‑Binding Lectin (rhMBL) in Liver Transplant Recipients||Enzon Pharmaceuticals, Inc.|Yes|Terminated|December 2006|December 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|December 20, 2006|No|Yes|Sponsor decision to terminate the study|No||https://clinicaltrials.gov/show/NCT00415311||175799|
NCT00415623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531085|A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient|A Double-Blind, Comparative Study Between Amlodipine 5mg And 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective||Pfizer|No|Completed|January 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|305|||Both|20 Years|79 Years|No|||December 2008|December 5, 2008|December 21, 2006||No||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00415623||175776|
NCT00415636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11911|Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer|A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer||Eli Lilly and Company|No|Completed|December 2006|July 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||August 2010|August 30, 2010|December 21, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00415636||175775|
NCT00416234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Larissa CBD stones trial|Laparoendoscopic Rendez Vous Versus Standard Two Stage Approach for the Management of Cholelithiasis/Choledocholithiasis|Laparoendoscopic Rendez Vous (Intraoperative ERCP) vs Two Stage Approach (Preoperative ERCP Followed by Laparoscopic Cholecystectomy) for the Management of Cholelithiasis/Choledocholithiasis||University of Thessaly|Yes|Recruiting|September 2006|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2008|January 13, 2010|December 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00416234||175729|
NCT00407771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-alhaddad|The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention|A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention||Jordan Hospital||Not yet recruiting|November 2007|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00407771||176358|
NCT00408395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P2|Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children|A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children||Novartis||Completed|November 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|281|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||December 2011|December 1, 2011|December 5, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00408395||176311|
NCT00416819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000458052|Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma|Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: A Pilot Study||University of California, San Francisco|Yes|Completed|September 2003|February 2012|Actual|December 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||August 2015|August 18, 2015|December 27, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00416819||175686|
NCT00417066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|poor responders|Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders|The Flexible GnRH Antagonist Protocol Provides Better Results (IVF Outcomes) Than Flare up GnRH Agonist Protocol in Poor Responders||Eugonia||Completed|September 2003|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|December 13, 2013|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00417066||175667|
NCT00404391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-609|A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery|A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Analgesic Activity of Hydrocodone/Acetaminophen Extended Release and Placebo in Subjects With Pain Following Bunionectomy Surgery||Abbott|No|Completed|October 2003|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|65 Years|No|||January 2011|January 14, 2011|November 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404391||176613|
NCT00404950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408007400|Effects of Hyperglycemia During Cardiopulmonary Bypass on Renal Function|Effects of Hyperglycemia During Cardiopulmonary Bypass on Renal Function||Weill Medical College of Cornell University|No|Active, not recruiting|July 2005|July 2012|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|At the following times when plasma glucose will be measured, an additional 6 mL of blood      will be drawn (from indwelling routine arterial line catheter) into EDTA tubes and      immediately centrifuged: baseline following induction, once during cardiopulmonary bypass,      at arrival in the intensive care unit, and the morning after surgery- totaling 24 mls of      blood. The platelet rich plasma will be withdrawn and one half of the volume immediately      frozen for subsequent HPLC measurement of BH2 and BH4. The remaining plasma will be      subjected to progressive centrifugation steps in order to concentrate the platelet fraction      that will then be suspended in buffer and frozen. VASP expression and phosphorylation will      be determined by Western blot.|Both|50 Years|N/A|No|Non-Probability Sample|Patients undergoing on pump cardiopulmonary bypass for either myocardial revascularization        (coronary artery bypass graft) or valvular surgery (valve repair or replacement)|March 2012|March 7, 2012|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00404950||176570|
NCT00404963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIX109177|A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects|See Detailed Description||GlaxoSmithKline||Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|November 27, 2006||||||https://clinicaltrials.gov/show/NCT00404963||176569|
NCT00404690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 09 141|Bedside Silo Versus Operative Closure for Gastroschisis|Bedside Silo Versus Attempted Operative Closure for Gastroschisis: A Pilot Study||Children's Mercy Hospital Kansas City|No|Terminated|October 2006|October 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|1 Day|No|||January 2016|January 27, 2016|November 27, 2006||No|Change in referral pattern changed the population we were studying|No||https://clinicaltrials.gov/show/NCT00404690||176590|
NCT00404924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00044|ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures|A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)||AstraZeneca||Completed|November 2006|November 2014|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1140|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|November 28, 2006|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00404924||176572|
NCT00404937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-60|Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle|Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle||Alcon Research||Withdrawn|December 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||September 2007|March 3, 2012|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404937||176571|
NCT00405275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|551|Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy|CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy|RACAT|VA Office of Research and Development|Yes|Completed|July 2007|May 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|353|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|November 29, 2006|Yes|Yes||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00405275||176548|
NCT00437723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20200|A Study of NeoRecormon in Patients With Chronic Kidney Disease.|An Open-Label Study to Investigate the Effect of NeoRecormon on Hemoglobin Level and Renal Function in Patients With Chronic Kidney Disease, Stage 2-4||Hoffmann-La Roche||Completed||April 2008|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||May 2009|May 13, 2009|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00437723||174109|
NCT00437970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DART-MSHR-06-29|Medication in Early Diabetes (MED) Study|Drug naïve Indigenous Australians With Type 2 Diabetes, Enrolled in a Randomised Controlled Trial of Rosiglitazone Versus Metformin Monotherapy to Assess the Effects on Metabolic and Cardiovascular Parameters||Menzies School of Health Research|Yes|Withdrawn|April 2008|February 2009|Anticipated|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2009|April 26, 2009|February 18, 2007||No|Unable to secure supply of the study medication|No||https://clinicaltrials.gov/show/NCT00437970||174091|
NCT00413946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B0-108176|Does Erythropoietin Improve Outcome in Very Preterm Infants?|Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants||Swiss Neonatal Network|Yes|Completed|January 2006|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|420|||Both|N/A|3 Hours|No|||February 2015|February 23, 2015|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413946||175901|
NCT00414206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG003-201|Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)|A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (NV-AMD)||CoMentis|Yes|Terminated|March 2007|September 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|343|||Both|50 Years|N/A|No|||October 2010|October 26, 2010|December 19, 2006|Yes|Yes|Sponsor decision|No|August 16, 2010|https://clinicaltrials.gov/show/NCT00414206||175881|
NCT00405210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 06-003|Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer|Open-label, Multicenter,PhaseI Trial in Order To Determine the Safety and Pharmacokinetics of BAY43-9006 in Combination With Docetaxel as First-line Treatment in Metastatic Hormone Refractory Prostate Cancer Patients||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|September 2006|December 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||May 2011|May 20, 2011|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405210||176552|
NCT00405483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL06-03|RSA for a Comparison of MIS vs. Standard Exposure in Total Hip Arthroplasty|A Randomized Controlled Trial Utilizing RSA for a Comparison of Minimally Invasive Surgery (MIS) vs. Standard Exposure in Primary Total Hip Arthroplasty With the ProfemurZ Modular Femoral Stem||Dalhousie University|No|Active, not recruiting|October 2005|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|65 Years|No|||September 2015|September 29, 2015|November 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405483||176532|
NCT00414505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K06070|A Randomized Controlled Double Blinding Study of Intradermal Acupuncture Treatment on Obesity|Korea Institute of Oriental Medicine||Wonkwang University||Recruiting|August 2006|December 2014|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|180|||Female|20 Years|50 Years|No|||May 2014|May 29, 2014|December 20, 2006||No||No||https://clinicaltrials.gov/show/NCT00414505||175858|
NCT00414765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPRL002A2201|Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma|Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies||Novartis||Completed|January 2006|||March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2013|February 9, 2013|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00414765||175839|
NCT00414778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLHT344A2101|Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects|A Single-center, Open-label, Single and Multiple Oral Dose Study to Assess Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects||Novartis||Completed|October 2006|||October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 12, 2011|December 21, 2006||||No||https://clinicaltrials.gov/show/NCT00414778||175838|
NCT00415090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMUNE|Study to Evaluate the Replacement of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors by Nevirapine in Patients on Triple Treatment With Analogues Only|Substitution by Nevirapine in HIV-1 Infected Patients on Triple Treatment of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors||Hospital de Calella|No|Completed|August 2004|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||October 2008|October 30, 2008|December 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00415090||175816|
NCT00406913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14208B|Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery|Assessment of Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery Using Intranasal Mupirocin Ointment||University of Chicago||Completed|October 2005|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|November 30, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00406913||176424|
NCT00415649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI V002|Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults|A Phase II, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine in Healthy Adult Volunteers at Risk for HIV Infection||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|December 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00415649||175774|
NCT00415662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO 07/02|Effect of Biomagnetic Therapy on Gonarthrosis|||University of Lausanne Hospitals||Terminated|June 2002|June 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind|||||||Both|35 Years|N/A||||December 2006|December 22, 2006|December 22, 2006||||No||https://clinicaltrials.gov/show/NCT00415662||175773|
NCT00415961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-CMS-005|Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety|Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety||Conor Medsystems||Terminated|November 2006|May 2012|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|95 Years|No|||January 2009|January 8, 2009|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00415961||175750|
NCT00407511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081097|Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP|A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain||Pfizer|No|Completed|January 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||October 2009|October 8, 2009|December 1, 2006|Yes|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00407511||176378|
NCT00407524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03GP013|AKL 1 Asthma Study|AKL1 Asthma Study - Randomised, Double-Blind, Placebo Controlled, Cross Over Study to Determine Safety and Efficacy of Oral AKL1 in Treating Patients With Asthma||University of Aberdeen||Completed|October 2003|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||40|||Both|18 Years|70 Years||||December 2006|December 4, 2006|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407524||176377|
NCT00407797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081090|Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial|Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin|PREPS MEXICO|Pfizer|No|Terminated|March 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|18 Years|N/A|No|||February 2011|February 4, 2011|December 1, 2006|Yes|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00407797||176356|
NCT00404092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-687|Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis|A Phase II Dose Escalation Study of Caspofungin in Patients With Invasive Aspergillosis||University of Cologne|Yes|Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|46|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|November 24, 2006||No||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00404092||176636|
NCT00404651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L11|Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants|Lot to Lot Consistency Study of DTaP-IPV-Hep B-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Mexican Infants||Sanofi|Yes|Completed|November 2006|July 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1189|||Both|2 Months|N/A|Accepts Healthy Volunteers|||April 2014|April 11, 2014|November 28, 2006||No||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00404651||176593|
NCT00404105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-Ophthalmology-1999-01|A Comparison of PRK and LASIK for Correction of Myopia|A Prospective, Randomised Trial of Photo-Refractive Keratectomy (PRK) and Laser-in-Situ-Keratomileusis (LASIK) for Correction of Myopia||University of Aarhus||Completed|June 2000|May 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|49 Years|No|||November 2006|November 24, 2006|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00404105||176635|
NCT00405301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIIMS/MED/2006/10|Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage|Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity||All India Institute of Medical Sciences, New Delhi|No|Completed|December 2006|December 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|175|||Both|16 Years|65 Years|No|||February 2012|February 14, 2012|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00405301||176546|
NCT00405834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0065|A Pilot Study of the Envision® Surface|A Pilot Study of the Envision® Surface in a Patient Population at High Risk for or Who Have Pressure Ulcers: Evaluation of Pressure Ulcer Incidence, Changes in Existing Pressure Ulcers, Clinical Staff Satisfaction and Patient Comfort||Hill-Rom|No|Completed|June 2007|October 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|30|||Both|N/A|N/A|No|||June 2007|July 1, 2008|November 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00405834||176505|
NCT00405288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008482|The Safety of Proctofoam-HC in the Third Trimester of Pregnancy|The Safety of Proctofoam-HC in the Third Trimester of Pregnancy||The Hospital for Sick Children|Yes|Completed|November 2006|June 2010|Actual|November 2009|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|408|||Female|18 Years|N/A|No|Probability Sample|Pregnant woman with a primary anorectal condition during the third trimester of pregnancy        and pregnant women in the third trimester of pregnancy without anorectal condition|January 2014|January 3, 2014|November 28, 2006||No||No|August 16, 2013|https://clinicaltrials.gov/show/NCT00405288||176547|
NCT00405535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04I/C06|Adjunctive Glycine for Obsessive Compulsive Disorder|Adjunctive Glycine for Obsessive Compulsive Disorder||Nathan Kline Institute for Psychiatric Research|No|Completed|June 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||August 2007|August 21, 2007|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00405535||176528|
NCT00437411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-HUM00008669|Healing Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial|Healing Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial||University of Michigan|No|Active, not recruiting|April 2007|April 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||May 2007|December 11, 2008|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437411||174132|
NCT00414219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU# 04-23010|Visual Prognosis in Non-Penetrating Corneal Blast Injuries|Visual Prognosis in Non-Penetrating Corneal Blast Injuries||Walter Reed Army Medical Center||Completed|November 2004|May 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|US Army patients age 18 years and older prsenting with corneal foreign bodies from        non-penetrating ocular blast injuries|December 2010|December 29, 2010|December 20, 2006||||No||https://clinicaltrials.gov/show/NCT00414219||175880|
NCT00406003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR104074|Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects|A Randomized, Open, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Dosing of Each Enteric-coated Geomatrix Control Release Tablet Strength (12.5, 25, 37.5mg) in Healthy Chinese Subjects||GlaxoSmithKline||Completed|March 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406003||176492|
NCT00406016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATI355A2102|Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI|A Multi-center, Open-label, Cohort Study to Assess Feasibility, Acute Safety, Tolerability and Pharmacokinetics of 4 Dose Regimens of Continuous Intrathecal ATI355 Infusion and Two Regimen of Repeated Intrathecal Bolus Injections in Acute Spinal Cord Injury Paraplegic and Tetraplegic Patients||Novartis||Completed|May 2006|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|65 Years|No|||November 2011|November 2, 2011|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406016||176491|
NCT00406029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04501|Dyskinesia in Parkinson's Disease (Study P04501)|A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias||Merck Sharp & Dohme Corp.|Yes|Completed|November 2006|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|253|||Both|30 Years|N/A|No|||April 2015|April 8, 2015|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406029||176490|
NCT00405743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-106|A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies|A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies||Clavis Pharma|No|Completed|May 2006|May 2010|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|November 29, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405743||176512|
NCT00405756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-015|A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.|A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID¿) IN COMBINATION WITH MELPHALAN AND PREDNISONE VERSUS PLACEBO PLUS MELPHALAN AND PREDNISONE IN SUBJECTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE 65 YEARS OF AGE OR OLDER||Celgene|Yes|Active, not recruiting|January 2007|December 2015|Anticipated|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|459|||Both|65 Years|N/A|No|||October 2015|October 26, 2015|November 29, 2006|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00405756||176511|
NCT00405990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro625|Male Partner Involvement in the Prevention of MTCT of HIV|Optimizing the Impact of Prevention of Mother to Child Transmission of HIV in South Africa: the Forgotten Half of the Equation.||Imperial College London|Yes|Completed|November 2006|May 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2008|May 28, 2015|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00405990||176493|
NCT00406640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-402|Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women|A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2006|October 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|595|||Female|40 Years|70 Years|No|||May 2010|May 26, 2010|November 29, 2006|Yes|Yes||No|February 27, 2009|https://clinicaltrials.gov/show/NCT00406640||176444|
NCT00406653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-084|A Study of Abatacept in Patients With Active Crohn's Disease|A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Crohn's Disease (CD) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy||Bristol-Myers Squibb|Yes|Terminated|December 2006|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|451|||Both|18 Years|N/A|No|||September 2010|September 10, 2010|December 1, 2006|Yes|Yes|Sponsor Decision|No|July 30, 2010|https://clinicaltrials.gov/show/NCT00406653||176443|
NCT00406614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|446|Health Literacy-Focused Program to Improve Blood Pressure Control in Korean Americans|Health Literacy Intervention for Korean Americans With High Blood Pressure (HBP)||Johns Hopkins University|Yes|Completed|September 2007|July 2011|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|360|||Both|60 Years|N/A|No|||November 2011|November 28, 2011|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406614||176446|
NCT00406887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJE2079/3-01-PC|Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis|Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis).||Sirion Therapeutics, Inc.||Completed|August 2002|November 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||140|||Both|12 Years|N/A|No|||November 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406887||176426|
NCT00406900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIA|Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma|||Ludwig-Maximilians - University of Munich||Recruiting|January 1999|September 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||560|||Both|N/A|N/A|No|||November 2006|December 5, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406900||176425|
NCT00407186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRITICS|Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)|A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study)||Dutch Colorectal Cancer Group|Yes|Recruiting|December 2006|December 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|788|||Both|18 Years|N/A|No|||August 2011|August 27, 2011|December 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00407186||176403|
NCT00407784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2006-103|Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.|Aldosterone-Renin Ratio to Diagnose Primary Aldosteronism in a Population of Patients With Therapy-Resistant Hypertension: Test Characteristics, Diagnostic Value and Predictive Value for Antihypertensive Treatment. The Dutch ARRAT Study.||Erasmus Medical Center||Recruiting|January 2007|November 2009||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||500|||Both|18 Years|65 Years|No|||March 2007|March 6, 2007|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407784||176357|
NCT00403897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/04|An Open Single Centre Study To Assess Treatment of Chronic Constipation in Children|An Open Single Centre Study To Assess the Safety and Efficacy of Movicol in the Treatment of Chronic Constipation in Children||Norgine|No|Completed|August 2001|January 2003||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|24 Months|11 Years|No|||April 2008|April 15, 2008|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403897||176651|
NCT00408057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRC 020|Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE )|Quality Enhancement Research Initiative (QERI) in the Dyslipidemia Management Strategy Involving Ezetimibe With Statin in High Risk Patients Who Have Not Achieved Recommended LDL Targets|GUIDE|Canadian Heart Research Centre|No|Completed|December 2005|November 2007|Actual|November 2007|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients considered at high risk for cardiovascular events|May 2008|May 12, 2008|December 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00408057||176336|
NCT00408070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF 3696s|Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Phase 2 Study of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||University of Connecticut Health Center|Yes|Terminated|October 2006|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|19 Years|N/A|No|||November 2010|November 16, 2010|December 5, 2006|Yes|Yes|Did not meet accrual goals.|No|October 14, 2010|https://clinicaltrials.gov/show/NCT00408070||176335|This trial ended early after enrolling only 5 of 100 patients. Due to the small enrollment number and incomplete data set, no data analyses were performed.
NCT00408083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 127|Crossover Study With MultiHance vs a Comparator for Peripheral MRA|A Phase IIIB, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.1 Mmol/kg of Multihance With 0.1 Mmol/kg of Magnevist for Contrast-Enhanced Magnetic Resonance Angiography(CE-MRA) of Peripheral Arteries||Bracco Diagnostics, Inc|No|Completed|December 2006|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00408083||176334|
NCT00408408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-40|Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery|A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens||NSABP Foundation Inc|Yes|Active, not recruiting|November 2006|March 2016|Anticipated|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|1206|||Female|18 Years|120 Years|No|||February 2016|February 5, 2016|December 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00408408||176310|
NCT00408421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10546|Duloxetine Versus Placebo for Osteoarthritis Knee Pain|Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain||Eli Lilly and Company|Yes|Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|231|||Both|40 Years|N/A|No|||July 2009|July 7, 2009|December 6, 2006|Yes|Yes||No|October 2, 2008|https://clinicaltrials.gov/show/NCT00408421||176309|
NCT00404118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAD 06-036|Senior Coordinated Referral Study|Senior Coordinated Referral (SCORE) Study|SCORE|VA Office of Research and Development|No|Completed|September 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|543|||Both|N/A|N/A|No|Non-Probability Sample|Patients for whom a Geriatric and Extended Long-Term Care referral form was completed. For        each of these patient's his/her family caregiver, provider making the referral, and        long-term care program coordinator is also included.|August 2014|April 6, 2015|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00404118||176634|
NCT00404144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID: BBM-VS-52|PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel|PEPCAD I, The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel Coronary Artery Disease. A Pilot Study||Heart Centre Rotenburg||Completed|January 2006|September 2012|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00404144||176632|
NCT00406094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARES|Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)|The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES)||Bernstein, Jonathan A., M.D.||Recruiting|November 2006|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|65 Years|No|||January 2009|January 15, 2009|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406094||176485|
NCT00406367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0433|IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Blepharospasm||Merz Pharmaceuticals GmbH||Completed|October 2006|July 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|80 Years|No|||March 2013|March 13, 2013|November 30, 2006|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00406367||176465|
NCT00438022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN ADEH 06|Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis|Risk Factors in Atopic Dermatitis for the Development of Eczema Herpeticum||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|240|Samples With DNA|Blood and skin samples will be retained|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|People of good general health, living in Germany|April 2014|April 1, 2014|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438022||174087|
NCT00405769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00005390|Lipid Lowering in Patients With Statin Intolerance|Alternative Lipid Lowering in Patients With Statin Intolerance: Use of Red Yeast Rice and Therapeutic Lifestyle Changes in a Randomized, Placebo-Controlled Trial||Chestnut Hill Health System||Completed|January 2007|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|80 Years|No|||October 2007|October 30, 2007|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405769||176510|
NCT00405782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-212|Exercise Intervention in Women With Metastatic Breast Cancer|Pilot Study of a Moderate-Intensity Exercise Intervention in Women With Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2006|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|N/A|N/A|No|||April 2014|April 28, 2014|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405782||176509|
NCT00405795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-2005-083|Envision® Surface Evaluation|Envision® Surface Evaluation for Patients With Stage II, Stage III, or Stage IV Pressure Ulcers||Hill-Rom|No|Completed|June 2007|March 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|No|||July 2008|July 1, 2008|November 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00405795||176508|
NCT00406276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1342-2004|Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer|Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer||Emory University|Yes|Terminated|November 2006|February 2013|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|November 17, 2006|Yes|Yes|data analysis showed insufficient drug efficacy|No|March 30, 2012|https://clinicaltrials.gov/show/NCT00406276||176471|
NCT00406289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/391|Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) in Patients With Head and Neck Tumor|Phase I Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) With Patients With Head and Neck Tumor||University Hospital, Ghent|No|Completed|November 2006|February 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||September 2010|September 3, 2010|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406289||176470|
NCT00406627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0137|Research for Elimination of Lymphatic Filariasis (ICIDR)|Research for Elimination of Lymphatic Filariasis (ICIDR)||Washington University School of Medicine||Completed|December 2006|December 2011||||N/A|Observational|Time Perspective: Prospective||||117500|||Both|6 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 8, 2008|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406627||176445|
NCT00407238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-08|Corneal Barrier Function With Multi-Purpose Solutions|Comparison of Human Corneal Barrier Function With Three Marketed Multi-Purpose Solutions||Southern California College of Optometry||Completed|November 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 21, 2007|November 17, 2006||||No||https://clinicaltrials.gov/show/NCT00407238||176399|
NCT00407251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-005/CEPO906A2402|Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy|A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer||British Columbia Cancer Agency||Completed|February 2007|||June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|73|||Male|18 Years|N/A|No|||November 2010|November 3, 2010|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00407251||176398|
NCT00407199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608M91257|The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment|The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment||University of Minnesota - Clinical and Translational Science Institute||Completed|December 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|25 Years|No|||October 2011|October 26, 2011|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407199||176402|
NCT00407537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841047|Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors|A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice|CRUCIAL|Pfizer|No|Completed|March 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1531|||Both|35 Years|79 Years|No|||June 2015|June 30, 2015|December 1, 2006|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00407537||176376|
NCT00407212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCH346B103|A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's Disease||Novartis||Completed|January 2002|November 2003|Actual|November 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|301|||Both|30 Years|80 Years||||November 2011|November 22, 2011|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407212||176401|
NCT00407550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000516012|Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer||Mayo Clinic|Yes|Active, not recruiting|November 2006|December 2015|Anticipated|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|December 4, 2006|Yes|Yes||No|February 17, 2012|https://clinicaltrials.gov/show/NCT00407550||176375|
NCT00407563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN ALSSOPR0501|Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer|A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma||Accelerated Community Oncology Research Network|No|Completed|January 2007|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||March 2012|March 8, 2012|December 4, 2006|Yes|Yes||No|September 28, 2011|https://clinicaltrials.gov/show/NCT00407563||176374|
NCT00404183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-643|A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis|A Randomized, Multi-center, Double-blind Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen and Placebo in Subjects With Osteoarthritis||Abbott|No|Completed|August 2004|||March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|21 Years|75 Years|No|||January 2011|January 14, 2011|November 26, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404183||176629|
NCT00404196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO19123-C22|LEO19123 Cream in the Treatment of Hand Eczema|LEO19123 Cream in the Treatment of Hand Eczema||LEO Pharma||Completed|October 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|75|||Male|18 Years|N/A|No|||August 2007|August 2, 2007|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404196||176628|
NCT00408096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060165|Comparison of Two Resurfacing Prostheses in the Treatment of Osteoarthritis of the Shoulder|Comparison of Two Resurfacing Prostheses in the Treatment of Osteoarthritis of the Shoulder A Prospective, Randomized Migration and Bone Density Study||University of Aarhus|Yes|Active, not recruiting|December 2006|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||October 2014|October 21, 2014|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408096||176333|
NCT00403884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Eye Hospital SRT|Selective RPE Laser Treatment (SRT) for Various Macular Diseases|Selective RPE Laser Treatment (SRT) for Various Macular Diseases||University of Regensburg|No|Active, not recruiting|October 2004|August 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2006|January 11, 2010|November 24, 2006||No||No||https://clinicaltrials.gov/show/NCT00403884||176652|
NCT00404131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-105|Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease||Merck Sharp & Dohme Corp.||Completed|March 2001|||December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00404131||176633|
NCT00404157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3388g|A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g|A Phase III, Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g||Genentech, Inc.||Withdrawn||||||Phase 3|Interventional|Primary Purpose: Treatment||||140|||Both|16 Years|75 Years|No|||January 2008|January 28, 2008|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00404157||176631|
NCT00404703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO19734|A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer|An Open Label Study of the Safety of First-Line Treatment With Avastin in Combination With Cisplatin-Gemcitabine or Carboplatin-Paclitaxel in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer, Who Are Considered to be at High Risk of Pulmonary Haemorrhage||Hoffmann-La Roche||Terminated||March 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||August 2008|August 26, 2008|November 28, 2006||No|Primary (safety) endpoint reached|No||https://clinicaltrials.gov/show/NCT00404703||176589|
NCT00405548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004190|Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.|To Define in Human Preclinical Diastolic Dysfunction (PDD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal and Humoral Function and on the Integrated Response to Acute Sodium Loading||Mayo Clinic|Yes|Completed|March 2008|August 2012|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|41|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|November 29, 2006|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT00405548||176527|
NCT00405561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMT/P2GI/001 Part III|Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003|A Prospective, Open, Single-Arm, Multicenter Phase II Clinical Trial to Evaluate the Progression Free Survival and Safety in Patients With Advanced Colorectal Carcinoma Treated With AMT2003||Auron Healthcare GmbH||Terminated|October 2006|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|79 Years|No|||March 2013|March 19, 2013|November 29, 2006||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00405561||176526|
NCT00405847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC #06-107|A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients|A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients||University of Arizona||Recruiting|July 2006|May 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|21 Years|85 Years|No|||November 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405847||176504|
NCT00406107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC-001|Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion|Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion||Palmetto Retina Center, LLC|Yes|Completed|January 2006|April 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|November 30, 2006|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT00406107||176484|
NCT00437775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/06|ACEIs and ARBs Treatment in Diabetic Patients -Drug Interactions and Adverse Drug Effects|Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.||Assaf-Harofeh Medical Center||Recruiting|January 2007|March 2007||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|40 Years|90 Years|No|||January 2007|February 20, 2007|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437775||174105|
NCT00437788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1907CTIL|The Effect of a Digital Photograph of the Patient in a CT Scan Examination on the Quality of Diagnosis by the Radiologist|||Shaare Zedek Medical Center||Not yet recruiting||||||Phase 0|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal||||10000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2007|February 20, 2007|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437788||174104|
NCT00405509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC#4065|The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years|The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to <14 Years||West Penn Allegheny Health System||Completed|October 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|33|Samples With DNA|Buccal brushing for genotyping|Both|6 Years|13 Years|No|Non-Probability Sample|Male and Female subjects ages 6 to under 14 years with common cold symptoms of less than        24 hours in duration.|September 2014|September 24, 2014|November 28, 2006||No||No|May 8, 2009|https://clinicaltrials.gov/show/NCT00405509||176530|Respiratory viruses were not detected in approximately 2/3 of the enrolled subjects. Future studies will need to apply more stringent inclusion/exclusion criteria to circumvent this problem.
NCT00406315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281148|Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone|A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder||Pfizer|No|Completed|November 2006|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|255|||Both|18 Years|55 Years|No|||February 2010|February 2, 2010|November 29, 2006|Yes|Yes||No|December 1, 2009|https://clinicaltrials.gov/show/NCT00406315||176468|
NCT00406341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJE2079/3-03|Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation|Phase 3 Confimatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treament of Postoperative Inflammation||Sirion Therapeutics, Inc.||Completed|April 2004|March 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|20 Years|N/A|No|||November 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406341||176467|
NCT00406042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16678|The Role of Steroids Following Selective Laser Trabeculoplasty|The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty||West Virginia University|No|Completed|September 2005|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||25|||Both|18 Years|N/A|No|||March 2007|March 28, 2007|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406042||176489|
NCT00406679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-01270-A015|Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-containing Solutions in Post-Surgical Dental Pain|Single-Dose Comparison of the Analgesic Efficacy, Safety and Tolerability of Two Paracetamol 1%-Containing Solutions and Placebo in a Post-Surgical Dental Pain Model||Baxter Healthcare Corporation|No|Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|65 Years|No|||August 2011|August 10, 2011|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00406679||176442|
NCT00406302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004639-31|Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)|Multicenter Phase II Study Evaluating Docetaxel, CDDP, and Cetuximab as Induction Regimen Prior to Surgery in Chemo-naive Patients With NSCLC Stage IB, II and IIIA||Medical University of Vienna|No|Completed|January 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|December 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00406302||176469|
NCT00407264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPD2001|Randomized Trial of Fluticasone in Bronchial Premalignancy|The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study||VU University Medical Center||Completed|February 2002|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|November 29, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00407264||176397|
NCT00406926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2878|The Effect of Growth Hormone in Very Young Girls With Turner Syndrome|The Effect of Recombinant Human Growth Hormone Treatment on the Growth of Infants and Toddlers With Turner Syndrome||Eli Lilly and Company||Completed|August 1999|August 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|9 Months|4 Years|No|||November 2006|November 29, 2006|November 29, 2006||||||https://clinicaltrials.gov/show/NCT00406926||176423|
NCT00407225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJE2079/2-01-PC|Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation|Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation After Cataract Surgery||Sirion Therapeutics, Inc.||Completed|December 1999|October 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|12 Years|75 Years|No|||November 2006|December 5, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00407225||176400|
NCT00408109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070042|Safety Study of Avian Flu Vaccine|VRC 304: A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP), Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|December 2006|August 2008||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1|||45|||Both|18 Years|60 Years|No|||August 2008|August 29, 2008|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408109||176332|
NCT00389168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV131-052|Irbesartan and Atenolol in Hypertensive Heart Disease|Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy|SILVHIA|Karolinska Institutet|No|Completed|April 1995|April 1997|Actual|April 1997|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 3, 2015|October 17, 2006|No|Yes||No|August 19, 2012|https://clinicaltrials.gov/show/NCT00389168||177759|
NCT00389441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061027|Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer|A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer||Pfizer|No|Completed|December 2006|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|October 16, 2006|Yes|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00389441||177738|
NCT00389727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-01avr-074|Simultaneous Integrated Boost (SIB)- IMRT|A Dose Escalation Study With Intensity Modulated Radiation Therapy (IMRT) in Moderately Advanced (T2N0, T2N1, T3N0) Squamous Cell Carcinomas (SCC) of the Oropharynx, Larynx and Hypopharynx Using a Simultaneous Integrated Boost (SIB) Approach.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|September 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2004|October 18, 2006|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389727||177718|
NCT00390052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00139|3-AP in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone(3-AP,Triapine) in the Treatment of Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|December 2006|||February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00390052||177694|
NCT00385866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120060236|Addressing Disparities in Cancer Care for Latino Medicare Beneficiaries|Addressing Disparities in Cancer Care for Latino Medicare Beneficiaries||Rutgers, The State University of New Jersey||Completed|October 2006|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1272|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 12, 2012|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00385866||178008|
NCT00386100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVT105913|A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin|A Randomized, Parallel Group, Double-blind, Multi-center Study Comparing the Efficacy and Safety of AVANDAMET and Metformin After 80 Weeks of Treatment.||GlaxoSmithKline|No|Completed|October 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|688|||Both|18 Years|75 Years|No|||July 2013|June 17, 2015|October 9, 2006|Yes|Yes||No|July 8, 2010|https://clinicaltrials.gov/show/NCT00386100||177990|Ten participants who started the study and were randomized did not receive any study medication (6 participants in the metformin arm and 4 participants in the avandamet arm). These participants are not included in any of the analysis populations.
NCT00387608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060172|ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer|A Phase 0 Pharmacokinetic, Pharmacodynamic Study of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), in Refractory Solid Tumors and Lymphoid Malignancies||National Institutes of Health Clinical Center (CC)||Completed|June 2006|April 2009|Actual|February 2008|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|October 12, 2006|No|Yes||||https://clinicaltrials.gov/show/NCT00387608||177877|
NCT00389051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006001|A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma|A Multicenter, Open Study to Assess the Tolerability, Pharmacokinetics and Antitumor Effect of Bendamustine Hydrochloride (SyB L-0501: 90 or 120 mg/m2/Day) Administered Intravenously for Two Days in Patients With Indolent Lymphoma||SymBio Pharmaceuticals||Completed|October 2006|September 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|20 Years|75 Years|No|||May 2007|August 20, 2007|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00389051||177768|
NCT00402805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0380-AE|Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy|Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy||University Health Network, Toronto||Completed|October 2006|July 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|50|||Both|16 Years|N/A|No|||November 2006|April 15, 2008|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00402805||176734|
NCT00403377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000499830|Investigation of a Behavioral Substitute for Sunbathing|Investigation of a Behavioral Substitute for Sunbathing||University of Massachusetts, Worcester|No|Completed|April 2006|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|307|||Both|18 Years|120 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00403377||176690|
NCT00386854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01-2003-1|Metabolic Study of Concentric and Eccentric Muscle Training|||Vorarlberg Institute for Vascular Investigation and Treatment||Completed|April 2003|August 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|30 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386854||177934|
NCT00418314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD378|FREEDOM - A Frequent Optimization Study Using the QuickOpt Method|FREEDOM - A Frequent Optimization Study Using the QuickOpt Method||St. Jude Medical|No|Completed|October 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1647|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 3, 2007||No||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00418314||175571|
NCT00387517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2333|Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension|An Eight-Week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy||Novartis||Completed|October 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|726|||Both|18 Years|N/A|No|||July 2008|July 16, 2008|October 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387517||177884|
NCT00419133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-8IR|Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine|Immune Responses Following One Versus Two Doses of Killed Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India||International Vaccine Institute|Yes|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|1 Year|40 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00419133||175508|
NCT00388934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORT-OUT II|Comparison of Cypher Select and Taxus Express Coronary Stents|Randomized Clinical Comparison of Cypher Select and Taxus Express Stent Implantation in Unselected Patients With Coronary Artery Disease.|SORT-OUTII|Aarhus University Hospital Skejby|Yes|Completed|August 2004|January 2009|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2095|||Both|18 Years|N/A|No|||May 2007|July 29, 2013|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00388934||177777|
NCT00389181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB6286|A Randomized Trial of Unruptured Brain AVMs|A Randomized Trial of Unruptured Brain Arteriovenous Malformations|ARUBA|Columbia University|Yes|Completed|October 2006|May 2015|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00389181||177758|
NCT00389194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-0095_01|PREventing Progression of Adipose Tissue Redistribution|A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.||International Antiviral Therapy Evaluation Center|No|Completed|April 2006|October 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389194||177757|
NCT00389454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93/03|Acetaminophen Concentration in Cerebrospinal Fluid in Infants|Acetaminophen Concentration in Cerebrospinal Fluid in Infants||Assaf-Harofeh Medical Center||Completed|January 2004|June 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|N/A|2 Years|No|||August 2006|October 30, 2007|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389454||177737|
NCT00386646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152/2004|Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye|A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial||Chulalongkorn University||Completed|February 2004|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||October 2006|June 2, 2015|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386646||177950|
NCT00385879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Health Plus at Home|The Effects of Case Management in a Medicaid Managed Care Plan|The Effects of Case Management in a Medicaid Managed Care Plan||Metropolitan Jewish Health System||Recruiting|May 2006|January 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||500|||Both|18 Years|N/A|No|||October 2006|October 10, 2006|October 9, 2006||||No||https://clinicaltrials.gov/show/NCT00385879||178007|
NCT00386113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107973|Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly|A Phase II, Open, Controlled Study to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With Either Fluarix™ or the Adjuvanted Vaccine.||GlaxoSmithKline||Completed|October 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||83|||Both|67 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|October 9, 2006||||No||https://clinicaltrials.gov/show/NCT00386113||177989|
NCT00387322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505895|Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|Phase I/II Study of Two Different Schedules of Pemetrexed (ALIMTA) and Erlotinib (TARCEVA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC)||University of California, Davis|Yes|Completed|March 2005|May 2009|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2010|March 25, 2010|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00387322||177899|
NCT00387634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V48P7E1|Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults|A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization||Novartis||Completed|September 2006|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|323|||Both|15 Years|68 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00387634||177875|
NCT00387894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000492762|Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Phase-2 Study of Tarceva in Patients With Recurrent EGFR Positive and Phosphatase and Tensin Homolog (PTEN) Wild Type Glioblastoma Multiforme and Gliosarcoma||University of California, San Francisco|Yes|Terminated|January 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2013|May 25, 2013|October 12, 2006|Yes|Yes|Insufficient accrual of population likely to benefit; progression in 6 patients|No|April 12, 2013|https://clinicaltrials.gov/show/NCT00387894||177856|The study was terminated early for 2 reasons: 1. ongoing literature at the time confirming that the selection process was not likely to enrich for a patient population expected to benefit, and 2. Rapid disease progression in the first 6 patients.
NCT00389064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00015|Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Generalised Anxiety Disorder||AstraZeneca||Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|450|||Both|66 Years|N/A|No|||March 2012|March 30, 2012|October 17, 2006|Yes|Yes||No|April 15, 2009|https://clinicaltrials.gov/show/NCT00389064||177767|
NCT00389896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0733-216|A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C||Merck Sharp & Dohme Corp.||Completed|July 2001|October 2002|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389896||177705|
NCT00388765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0240|Normal Control Cohort Sample Bank|Protocol to Establish a Research Sample Bank of Lung Biopsy and BAL Samples for a Non-Atopic, Non-Asthmatic Subject Cohort||University of Wisconsin, Madison||Completed|September 2006|November 2006|Actual|November 2006|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 1, 2015|October 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00388765||177790|
NCT00388778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-pts-964|The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne|The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne||hahid Beheshti University of Medical Sciences||Recruiting|October 2005|October 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2008|January 22, 2008|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00388778||177789|
NCT00388791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-S4507|Comparison of Systane Free vs. Saline in the Treatment of Dry Eye|Comparison of Systane Free vs. Saline in the Treatment of Dry Eye||Southern California College of Optometry||Completed|October 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00388791||177788|
NCT00389025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-30|Mast-Cell Stabilizing Effects of Olopatadine|Mast-Cell Stabilizing Effects of Olopatadine||Alcon Research||Completed|October 2006|||April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 4, 2010|October 13, 2006||||||https://clinicaltrials.gov/show/NCT00389025||177770|
NCT00399568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APA-301|Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery|Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel, Multiple-Dose Study of the Analgesic Efficacy and Safety of IV Acetaminophen (APAP) Versus Placebo Over 48 Hours(Hrs) for the Treatment of Postoperative Pain After Gynecologic Surgery||Mallinckrodt|No|Completed|November 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Female|18 Years|75 Years|No|||May 2015|May 14, 2015|November 14, 2006|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00399568||176979|
NCT00399854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02CBED0501|Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring|Clinical Study for Evaluation of the Efficacy of Mechanical Massage by Endermologie (Dhermia® – Industra Mecânica Fina Ltda) in Treatment of Cellulite and Body Contouring||Brazilan Center for Studies in Dermatology||Completed|March 2006|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||November 2006|November 14, 2006|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399854||176957|
NCT00387530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000504022|Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer|A Phase II Study of Phenylbutyrate and Valganciclovir in Epstein-Barr Virus Positive Tumors||National Cancer Institute (NCI)||Active, not recruiting|May 2006|||January 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||March 2008|February 6, 2009|October 12, 2006||||No||https://clinicaltrials.gov/show/NCT00387530||177883|
NCT00387543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002344|Alpha Lipoic Acid for Burning Mouth|Review of Mayo Clinic Experience With Burning Mouth Syndrome - Use of Alpha Lipoic Acid||Mayo Clinic||Completed|January 2000|July 2007|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|200|||Both|1 Year|N/A|No|Non-Probability Sample|records of patients diagnosed with BMS in the Department of Dermatology between 1995 and        2005|April 2011|April 4, 2011|October 12, 2006||||No||https://clinicaltrials.gov/show/NCT00387543||177882|
NCT00418847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000004763|Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis|Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis: Single and Multiple Oral Doses||The Hospital for Sick Children|No|Active, not recruiting|July 2004|October 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|6 Years|20 Years|No|||January 2008|March 11, 2010|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00418847||175530|
NCT00388141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005 0149|Nursing and Nurturing Premature Infants|Nursing and Nurturing Premature Infants. An Intervention Study Investigating Systematic Use of Newborn Individualized Developmental Care Assessment Program NIDCAP® Improves Development of Infants and the Mothers' Parental Competence||University of Aarhus|No|Completed|March 2005|June 2007|Actual|||Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|90|||Both|N/A|32 Weeks|No|||November 2007|November 30, 2007|October 12, 2006||||No||https://clinicaltrials.gov/show/NCT00388141||177838|
NCT00388154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0823|Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer|A Phase II Study of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer||M.D. Anderson Cancer Center|No|Completed|August 2004|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|N/A|N/A|No|||November 2014|November 12, 2014|October 12, 2006||No||No|November 5, 2014|https://clinicaltrials.gov/show/NCT00388154||177837|
NCT00419146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA.01.07.0001|Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants|A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders||Oslo University Hospital|No|Completed|September 2001|April 2004|Actual|April 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2010|January 3, 2011|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419146||175507|
NCT00387790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01829|Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma|A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood||National Cancer Institute (NCI)||Completed|June 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|N/A|21 Years|No|||December 2012|May 7, 2014|October 12, 2006|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00387790||177863|
NCT00387803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinicals0010|Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation|VENTAK CHF/CONTAK CD Biventricular Pacing Study||Boston Scientific Corporation||Completed|February 1998|August 2001||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||581|||Both|N/A|N/A||||January 2007|January 23, 2007|October 11, 2006||||||https://clinicaltrials.gov/show/NCT00387803||177862|
NCT00387829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DURA-US-2006-1|DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery|Randomized Controlled Trial of DuraGen Plus® Adhesion Barrier Matrix to Minimize Adhesions Following Lumbar Discectomy||Integra LifeSciences Corporation|No|Terminated|October 2006|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|347|||Both|18 Years|70 Years|No|||September 2013|September 17, 2013|October 12, 2006|Yes|Yes|Sponsor voluntarily terminated study|No|June 7, 2013|https://clinicaltrials.gov/show/NCT00387829||177861|
NCT00388661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06.31 M / Melody|Melatonin and Quality of Life in Dialysis Patients|Double Blind Placebo-controlled Study on the Efficacy of Melatonin on Sleep, Resulting in an Improved Quality of Life in Hemodialysis Patients||Meander Medical Center|No|Completed|April 2007|December 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|85 Years|No|||July 2011|July 19, 2011|October 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388661||177798|
NCT00388674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-080|Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection|Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated With Nucleoside/Nucleotide Monotherapy for Patients With Chronic HBV Infection: The REALM Study||Bristol-Myers Squibb|Yes|Active, not recruiting|December 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|12500|Samples With DNA|buccal|Both|16 Years|N/A|No|Non-Probability Sample|Chronic hepatitis B patients receiving nucleoside therapy|July 2015|March 11, 2016|October 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388674||177797|
NCT00388687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr: 241/2006|Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer|Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer||Medical University of Vienna||Recruiting|July 2006|July 2007||||Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||25|||Female|18 Years|80 Years|No|||October 2006|October 16, 2006|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00388687||177796|
NCT00388947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012|Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS Products|The Prolapse Registry: An Observational Collection of Short- and Long-Term Patient Outcomes Following Use of AMS Surgical Devices for the Repair of Female Genital Prolapse|POWER1012|American Medical Systems|No|Completed|September 2006|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1543|||Female|21 Years|N/A|No|Non-Probability Sample|Female subjects greater than or equal to 21 years of age with genital prolapse who undergo        surgical reconstruction of the pelvic floor using an AMS Prolapse Repair device.|August 2012|October 16, 2012|October 16, 2006|No|Yes||No|August 3, 2012|https://clinicaltrials.gov/show/NCT00388947||177776|
NCT00386126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA 06-115|Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study|Randomized Trial to Assess the Effects of Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study||Hospital de Clinicas de Porto Alegre||Recruiting|August 2006|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||117|||Both|18 Years|N/A|No|||August 2006|October 6, 2006|October 6, 2006||||No||https://clinicaltrials.gov/show/NCT00386126||177988|
NCT00386360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005040|Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method|A Non-Invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D-Peripheral Quantitative Computed Tomography (3D-pQCT)||Warner Chilcott|No|Completed|April 2006|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|161|||Female|40 Years|55 Years|No|||October 2011|December 6, 2011|October 9, 2006|Yes|Yes||No|August 12, 2011|https://clinicaltrials.gov/show/NCT00386360||177971|
NCT00386139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2332|A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients|An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy||Novartis||Completed|September 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|881|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|October 9, 2006||||No||https://clinicaltrials.gov/show/NCT00386139||177987|
NCT00386659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVAN-Z-2|Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.|A Randomized, Pilot Study on the Antiviral Activity and Immunological Effects of Lopinavir/Ritonavir vs. Efavirenz in Treatment-naïve HIV-Infected Patients With CD4 Cell Counts Below 100 Cells/mm3||Hospital Clinic of Barcelona||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386659||177949|
NCT00386958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010274-01-00R|A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers|A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers||University of California, Los Angeles||Completed|November 2002|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||172|||Both|1 Month|N/A|No|||October 2006|January 12, 2010|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00386958||177927|
NCT00387309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200L2-300|Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus.||Valeant Pharmaceuticals International, Inc.||Completed|December 2006|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||495|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|October 11, 2006||||||https://clinicaltrials.gov/show/NCT00387309||177900|
NCT00387335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00214|Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma||National Cancer Institute (NCI)||Completed|August 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2012|July 21, 2014|October 12, 2006|Yes|Yes||No|December 4, 2013|https://clinicaltrials.gov/show/NCT00387335||177898|
NCT00387621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004027|Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction|To Define in Normal Controls, Human Preclinical Systolic Dysfunction (PSD) and Preclinical Diastolic Dysfunction (PDD) the Actions of Acute Subcutaneous Nesiritide (BNP) on the Cardiorenal and Humoral Function and the Integrated Response to Acute Sodium Loading|PPG1|Mayo Clinic|Yes|Completed|February 2006|August 2009|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 18, 2012|October 12, 2006|Yes|Yes||No|October 26, 2011|https://clinicaltrials.gov/show/NCT00387621||177876|Different baseline characteristics of the three groups of subjectsDid not define a mechanism for the impaired renal cGMP activationFuture studies needed to determine effects of chronic nesiritide therapy in preclinical HF.
NCT00388479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14CL308|Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus|A Multicenter Phase III, Double-Blind, Placebo-Controlled, Parallel Study of ADL-8-2698 in Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus||Cubist Pharmaceuticals LLC|No|Completed|December 2001|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||666|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|October 12, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00388479||177812|
NCT00388505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2302|Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis|A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects|EAGER|Novartis||Completed|February 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|517|||Both|6 Years|N/A|No|||June 2012|June 19, 2012|October 16, 2006|Yes|Yes||No|June 19, 2012|https://clinicaltrials.gov/show/NCT00388505||177810|
NCT00389909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRAP060309|Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants|Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants||Maternite Regionale Universitaire|No|Completed|November 2006|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|N/A|3 Months|No|||April 2010|February 18, 2011|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00389909||177704|
NCT00389272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53/05|Adding a Second Drug for Febrile Children Treated With Acetaminophen|Adding a Second Drug for Febrile Children Treated With Acetaminophen||Assaf-Harofeh Medical Center||Recruiting|September 2005|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Months|4 Years|No|||October 2006|October 30, 2007|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389272||177751|
NCT00399867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMVA-272/04|Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.|Determination of the Efficacy and Feasibility of Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma – a Phase II Clinical Trial.||Ludwig-Maximilians - University of Munich||Completed|April 2005|April 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||November 2006|December 19, 2006|November 14, 2006||||No||https://clinicaltrials.gov/show/NCT00399867||176956|
NCT00400673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILG-AML 01/00|A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia|Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia||Northern Italy Leukemia Group|No|Completed|May 2000|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|581|||Both|15 Years|65 Years|No|||March 2011|March 31, 2011|November 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00400673||176896|
NCT00418340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.IBS.1|Manipulation of Visceral Sensitivity and Immune System in IBS|Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity||London North West Healthcare NHS Trust||Not yet recruiting|December 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 15, 2007|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00418340||175569|
NCT00418587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSC-GAC734-HR16356|Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)|Phase 1 Study of Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)||Medical University of South Carolina|Yes|Active, not recruiting|December 2006|September 2008|Anticipated|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|85 Years|No|||September 2008|September 18, 2008|January 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00418587||175550|
NCT00387855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMHS1255|An Evaluation of the SOS (Suicide Prevention) Program|An Outcome Evaluation of the SOS Suicide Prevention Program||University of Connecticut Health Center|No|Active, not recruiting|September 2001|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|6000|||Both|N/A|N/A|No|||July 2012|July 23, 2012|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00387855||177859|
NCT00388167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-CAS-2003-01|Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection|PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection||PETHEMA Foundation||Completed|March 2004|February 2008|Actual|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|320|||Both|18 Years|N/A|No|Non-Probability Sample|Diagnosis of AI or CI|May 2009|May 11, 2009|October 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00388167||177836|
NCT00388414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1J-MC-I006|Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication|Functional MRI Neural Correlates of Medication Efficacy in Patients With Chronic Low Back Pain||Stanford University||Completed|September 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Male|18 Years|60 Years|No|||June 2012|June 21, 2012|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388414||177817|
NCT00388180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD100958|An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation|A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects||GlaxoSmithKline||Completed|December 2004|||||N/A|Observational|N/A||1|Actual|71|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388180||177835|
NCT00388427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-038|Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies|Phase I Study of Cetuximab Plus Dasatinib (BMS-354825) in Advanced Solid Malignancies||University of Pittsburgh|Yes|Completed|June 2007|February 2013|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||January 2014|May 27, 2015|October 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00388427||177816|
NCT00388700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAVFU006|A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer|Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy||Galectin Therapeutics Inc.|No|Terminated|October 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|October 13, 2006|No|Yes|Financing and re-organization|No||https://clinicaltrials.gov/show/NCT00388700||177795|
NCT00385892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK150OS|Safety Study of Textile Binder for Abdominal Compression|Feasibility Study DK150OS. Testing of Compression Textile. A Safety Study Among Healthy Volonteers||Coloplast A/S||Terminated|August 2005|October 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 10, 2006|October 9, 2006||||No||https://clinicaltrials.gov/show/NCT00385892||178006|
NCT00390078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-POL-002|Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection|Single-Blind, Randomized, Controlled, Phase I/II Vaccination Study on Safety and Immunogenicity of a Recombinant MVA-HIV Polytope Vaccine (MVA-mBN32) in HIV-1 Infected Patients With CD4 Counts > 250/µl||Bavarian Nordic||Completed|January 2007|January 2009|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|No|||July 2009|July 9, 2009|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00390078||177692|
NCT00390091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJP 394-90-16|Study of LJP 394 (Abetimus Sodium) in Lupus Patients|A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE)||La Jolla Pharmaceutical Company||Withdrawn|September 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|0|||Both|12 Years|70 Years|No|||February 2007|August 31, 2015|October 17, 2006||||||https://clinicaltrials.gov/show/NCT00390091||177691|
NCT00385905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-2|Excel Drug-Eluting Stent Pilot Clinical Registry|Excel Drug-Eluting Stent Pilot Clinical Registry||JW Medical Systems Ltd||Completed|February 2006|January 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00385905||178005|
NCT00385918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4027|Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI)|Cardiovascular Parameters for Lokomat Training in Chronic Incomplete SCI||VA Office of Research and Development|Yes|Completed|October 2006|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|80 Years|No|||April 2014|April 11, 2014|October 6, 2006||No||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00385918||178004|Skin irritation caused missed sessions.Attendance rates were lower than desired given medical and transportation factors.No clearly defined exclusion criteria for bone density in individuals with SCI using this type intervention.
NCT00386984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S 980916|Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma|Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma||University Hospital Freiburg||Completed|October 1999|February 2003||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|18 Years|N/A|No|||October 2006|October 11, 2006|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00386984||177925|
NCT00386672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000505|Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)|Calcium Supplementation for a Healthy Weight- LITE||Massachusetts General Hospital||Active, not recruiting|May 2006|April 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2006|November 16, 2006|October 6, 2006||||No||https://clinicaltrials.gov/show/NCT00386672||177948|
NCT00386971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614280|Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART|Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART||University of California, Davis|No|Completed|October 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|70 Years|No|||April 2013|April 4, 2013|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386971||177926|
NCT00387920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00361|Sunitinib in Treating Young Patients With Refractory Solid Tumors|A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|October 2006|||September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|2 Years|21 Years|No|||January 2014|January 27, 2014|October 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387920||177854|
NCT00388258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14CL302|Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus|A Multicenter Phase III, Double-Blind, Placebo-Controlled, Parallel Study of ADL-8-2698 in Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus||Cubist Pharmaceuticals LLC|No|Completed|March 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||451|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|October 13, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00388258||177829|
NCT00388518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM17864|A Study of Aleglitazar in Patients With Type 2 Diabetes|A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.||Hoffmann-La Roche||Completed|November 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|332|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|October 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388518||177809|
NCT00388804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0819|External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer|Randomized Trial of External Beam Radiation With or Without Short-Course Hormonal Therapy in Intermediate Risk Prostate Cancer Patients||M.D. Anderson Cancer Center|Yes|Terminated|February 2005|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Male|N/A|N/A|No|||June 2012|June 29, 2012|October 15, 2006||No|Slow accrual.|No|June 29, 2012|https://clinicaltrials.gov/show/NCT00388804||177787|
NCT00389610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0619, CDR0000508892|Vaccine Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery|A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2006|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389610||177726|
NCT00390169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20444|Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients|Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients||AHS Cancer Control Alberta||Active, not recruiting|October 2006|July 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|300|||Female|18 Years|N/A|No|||August 2011|January 18, 2012|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00390169||177685|
NCT00389922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505878|Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors|Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination With Vinorelbine in Advanced Solid Tumors||University of California, Davis|Yes|Completed|December 2005|December 2011|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||April 2012|April 17, 2012|October 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00389922||177703|
NCT00400166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607001641|Recovery Guide Intervention for Recurrent Psychiatric Hospitalization|Recovery Guide Intervention for Recurrent Psychiatric Hospitalization||Yale University|No|Completed|December 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|71|||Both|18 Years|80 Years|No|||June 2009|June 10, 2009|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00400166||176935|
NCT00400179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU S-1301|A Safety and Efficacy Study in Patients With Gastric Cancer|An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease||Taiho Oncology, Inc.|No|Completed|May 2005|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1053|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|June 30, 2005|Yes|Yes||No|January 6, 2012|https://clinicaltrials.gov/show/NCT00400179||176934|
NCT00387244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0506|Efficacy of the Spinal Cord Stimulation System as Salvage Therapy|Efficacy of the Precision Spinal Cord Stimulation System as Salvage Therapy for Patients With Chronic Intractable Pain of the Trunk and or Limbs Who Have Failed Treatment With an Intraspinal Infusion Pump or Other Spinal Cord Stimulation Device||Boston Scientific Corporation|No|Terminated|August 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|October 10, 2006||No|Insufficient Data Collected|No||https://clinicaltrials.gov/show/NCT00387244||177905|
NCT00387257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP2108364|Effect Of Rilapladib (SB-659032) On Platelet Aggregation|A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers||GlaxoSmithKline|No|Completed|October 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|58|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00387257||177904|
NCT00387270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM03|Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease|A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease||Medivation, Inc.||Completed|October 2006|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||September 2007|January 3, 2008|October 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387270||177903|
NCT00387231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Comparison of Anti-Ischemic Drug Therapy and Percutaneous Transluminal Angioplasty After Myocardial Infarction|Swiss Interventional Study on Silent Ischemia (SWISSI 2)||Luzerner Kantonsspital||Completed|June 1991|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00387231||177906|
NCT00388440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209762/147|Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.|A Study to Assess the Safety and Immunogenicity of GSK Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.||GlaxoSmithKline||Completed|November 2000|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||150|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||October 2006|October 13, 2006|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388440||177815|
NCT00388713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBCO5- HMO-CTIL|Radiation Induced Atherosclerosis in Breast Cancer Patients|Radiation Induced Atherosclerosis in Breast Cancer Patients||Hadassah Medical Organization||Recruiting|October 2006|January 2010|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|350|||Female|18 Years|85 Years|No|||December 2005|May 15, 2007|October 15, 2006||||No||https://clinicaltrials.gov/show/NCT00388713||177794|
NCT00388726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-305|E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer|The "EMBRACE" Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus "Treatment of Physician's Choice" in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane||Eisai Inc.||Completed|October 2006|March 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|762|||Female|18 Years|N/A|No|||July 2014|July 25, 2014|October 13, 2006|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00388726||177793|
NCT00388960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC Protocol 08062|Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer|Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)||Celgene|Yes|Completed|November 2006|December 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|N/A|No|||April 2011|March 27, 2013|October 13, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388960||177775|
NCT00388973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1448C00014|Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Major Depressive Disorder||AstraZeneca||Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|338|||Both|66 Years|N/A|No|||March 2010|March 22, 2010|October 16, 2006|Yes|Yes||No|December 29, 2008|https://clinicaltrials.gov/show/NCT00388973||177774|
NCT00389207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1470|Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults|Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.||Boehringer Ingelheim||Completed|October 2006|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|576|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|October 17, 2006||||No|January 13, 2012|https://clinicaltrials.gov/show/NCT00389207||177756|
NCT00389467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS044378|Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy|Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy|MR RESCUE|University of California, Los Angeles|Yes|Completed|May 2004|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|85 Years|No|||February 2014|February 26, 2014|October 16, 2006|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00389467||177736|
NCT00390065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRAP060308|Follow-Up at 6 Years of a Cohort of Children Born Very Prematurely|Follow-Up at 6 Years of a Cohort of Children Born Very Prematurely With Respiratory and Neurodevelopmental Impact of Early Treatment With Inhaled Nitric Oxide||Maternite Regionale Universitaire|Yes|Completed|October 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|108|||Both|6 Years|8 Years|No|||September 2009|September 18, 2009|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00390065||177693|
NCT00386685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD6595|XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer|Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)||Sanofi||Completed|July 2006|January 2011|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|18 Years|N/A|No|||April 2011|April 11, 2011|October 10, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00386685||177947|
NCT00386698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104887|Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults|Evaluate Reactogenicity & Immunogenicity of Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Administered in Young & Elderly Adults Will be Used as Reference||GlaxoSmithKline||Completed|October 2006|December 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|October 9, 2006||||No||https://clinicaltrials.gov/show/NCT00386698||177946|
NCT00387660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505840|Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer|Phase II Study of Irinotecan and Carboplatin in Metastatic or Relapsed Small-Cell Lung Cancer||University of California, Davis|No|Completed|October 2001|January 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2011|December 16, 2011|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00387660||177873|
NCT00387647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14496|Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy|A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction Chemotherapy||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|August 2006|August 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|60 Years|N/A|No|||August 2014|August 19, 2014|October 12, 2006|Yes|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT00387647||177874|Only five participants completed study and defined follow-up period and one participant remained on follow-up at time of analysis.
NCT00387907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD10037|Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer|Open Label, Uncontrolled, Study of XRP9881 (Larotaxel) in Combination With Weekly Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)||Sanofi||Completed|October 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||August 2011|August 9, 2011|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00387907||177855|
NCT00388271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGH/URO/XTR001|Use of Alfuzosin in Stone Treatment With ESWL|To Investigate if Alpha-Blocker Therapy (Alfuzosin) Increases Stone Free Rates and Improves Pain Control After ESWL (Extra-Corporeal Shock Wave Lithotripsy) for Renal and Ureteric Stones.||Singapore General Hospital|No|Recruiting|October 2006|December 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|N/A|No|||October 2007|October 3, 2007|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388271||177828|
NCT00388492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70-1002-075|BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects|BLADE: "A Comparison of Once Daily LPV/r to LPV/r BID in HIV-Infected Virologically Controlled Antiretroviral Experienced Subjects"||Bellos, Nicholaos C., M.D.||Not yet recruiting||||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||45|||Both|18 Years|N/A||||October 2006|January 10, 2007|October 12, 2006||||No||https://clinicaltrials.gov/show/NCT00388492||177811|
NCT00388817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL069399|Improving Medication Use in Patients With Hypertension|Improving Medication Use in Patients With Hypertension||University of North Carolina, Chapel Hill||Completed|January 2002|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||492|||Both|18 Years|N/A|No|||October 2006|October 16, 2006|October 8, 2006||||No||https://clinicaltrials.gov/show/NCT00388817||177786|
NCT00388557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA183-009|Effect of Ketoconazole on the Pharmacokinetics of Vinflunine|Effect of Ketoconazole on the Pharmacokinetics of Intravenous (IV) Vinflunine in Patients With Advanced Cancer||Bristol-Myers Squibb|No|Completed|October 2005|September 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2008|June 27, 2008|October 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00388557||177806|
NCT00421954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 5239|Open-label Ziprasidone Study for Psychosis Treatment in Adolescents|Open-label Feasibility Study for the Treatment of Psychotic Adolescents With Ziprasidone in the Inpatient and Day Hospital Settings||New York State Psychiatric Institute||Completed|May 2006|May 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|13 Years|17 Years|No|||January 2007|July 21, 2011|January 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421954||175295|
NCT00389935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00198|Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding|Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding|TAG|Northport Veterans Affairs Medical Center|Yes|Completed|October 2006|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2011|August 1, 2011|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389935||177702|
NCT00388206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3991n|A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)|An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology)|ARIES|Genentech, Inc.||Completed|May 2006|March 2012|Actual|March 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3998|Samples With DNA|blood and tumor|Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic|December 2012|December 14, 2012|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388206||177833|
NCT00388219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|964711|Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations|Single Dose Bioequivalence Trial Comparing a New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch||Grünenthal GmbH||Terminated|October 2006|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2007|July 5, 2007|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388219||177832|
NCT00387595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02-0103|Family Atherosclerosis Counseling and Testing Project|Family Atherosclerosis Counseling and Testing Project (FACT)||University of British Columbia|No|Completed|February 2003|October 2006|Actual|October 2006|Actual|Phase 1/Phase 2|Observational|N/A|||||||Both|16 Years|N/A||||August 2008|August 6, 2008|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00387595||177878|
NCT00387842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLOR I|COlon Cancer Laparoscopic or Open Resection|A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Colon Cancer||Erasmus Medical Center||Active, not recruiting|March 1997|March 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||1200|||Both|18 Years|N/A||||October 2006|October 12, 2006|October 12, 2006||||No||https://clinicaltrials.gov/show/NCT00387842||177860|
NCT00388986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP20194|A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.|An Open-label, Crossover Study to Investigate the Potential Pharmacodynamic and Potential Pharmacokinetic Interaction Between Glyburide and GK Activator(2) in Type 2 Diabetes Patients Inadequately Controlled With Glyburide as Standard Prescribed Therapy.||Hoffmann-La Roche||Completed|October 2006|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|October 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00388986||177773|
NCT00389493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5188/#6258R|Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder|Maximizing Treatment Outcome in OCD||New York State Psychiatric Institute|Yes|Completed|October 2006|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|70 Years|No|||October 2013|March 20, 2014|October 16, 2006|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00389493||177734|
NCT00389220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05EU01|Limus Eluted From A Durable Versus ERodable Stent Coating|A Randomized Comparison of a Biolimus-Eluting Stent With a Sirolimus-Eluting Stent for Percutaneous Coronary Intervention|LEADERS|Biosensors Europe SA|Yes|Completed|November 2006|June 2012|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1707|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|October 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00389220||177755|
NCT00389480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARN-AR67-CT101|Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies|A Phase I Study of DB-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) in Adult Patients With Refractory or Metastatic Solid Malignancies||Arno Therapeutics|Yes|Completed|October 2006|May 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|October 17, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00389480||177735|
NCT00386152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012985|A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy|A Randomized, Open-Label, Comparative Study of Epoetin Alfa (PROCRIT) 80,000 Units or 120,000 Units Q3W (Every 3 Weeks) Versus Darbepoetin Alfa (ARANESP) 500 Mcg Q3W in Anemic Cancer Subjects Receiving Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|November 2006|May 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|235|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|October 6, 2006|Yes|Yes|No safety signals were noted. The study was stopped because it was no longer consistent with    the company's scientific and strategic focus.|No|April 1, 2009|https://clinicaltrials.gov/show/NCT00386152||177986|Due to the significantly reduced power (stopped prematurely when 235 patients enrolled), all protocol-specified hypothesis tests were not performed. Instead, desriptive statistics were presented for each of the endpoints by treatment group.
NCT00389766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-NB-2006-08|High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma|International Phase II Studies of I-mIBG in Combination With Topotecan and Peripheral Blood Stem Cell Rescue for (A) Primary Resistant High Risk Neuroblastoma and (B) Relapsed Stage 4 Neuroblastoma||National Cancer Institute (NCI)||Withdrawn|July 2008|||July 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|1 Year|17 Years|No|||June 2007|July 9, 2013|October 18, 2006|||Withdrawn because protocol has been discontinued. It was never opened.|No||https://clinicaltrials.gov/show/NCT00389766||177715|
NCT00389779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol DAR-312|DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension|A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo (Protocol DAR-312)|Darusentan|Gilead Sciences|Yes|Completed|September 2006|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|849|||Both|35 Years|80 Years|No|||February 2014|February 19, 2014|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389779||177714|
NCT00386373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0433|Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients|Use and Tolerability of Imatinib Mesylate (Gleevec®) in Patients With Philadelphia-Positive Chronic Myeloid or Acute Leukemia During the First 100 Days Following Bone Marrow or Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Completed|August 2003|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|16 Years|N/A|No|||July 2012|July 31, 2012|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00386373||177970|
NCT00386386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hylenex1|Recombinant Hyaluronidase in Out-of-Hospital Setting: The EASI Access Trial|Enzymatically Augmented Subcutaneous Infusion (EASI) In Out-Of-Hospital Care||Massachusetts General Hospital|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 12, 2008|October 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00386386||177969|
NCT00387673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4439-R|Effect of Prolonged Electrical Stimulation on Neural Plasticity in Spinal Cord Injury|Effect of Prolonged Electrical Stimulation on Neural Plasticity in SCI||VA Office of Research and Development|Yes|Completed|October 2006|June 2011|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|60 Years|No|||September 2014|September 15, 2014|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00387673||177872|
NCT00387972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPB107246|Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)|A Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline||Withdrawn|May 2006|October 2007|Anticipated|October 2007|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|October 12, 2006|||Study cancelled before enrollment|No||https://clinicaltrials.gov/show/NCT00387972||177850|
NCT00387933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006014|Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma|Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea||Duke University||Completed|July 2005|||January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||November 2012|October 11, 2015|October 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387933||177853|
NCT00387946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5514|Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)|An International, Seven-week, Double-blind, Placebo-controlled, Two Parallel Group Study to Assess the Efficacy of Dianicline 40 mg Bid as an Aid to Smoking Cessation in Cigarette Smokers||Sanofi||Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|630|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|October 12, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387946||177852|
NCT00387959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-066|Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With B Cell Lymphoid Malignancies||Memorial Sloan Kettering Cancer Center|Yes|Completed|July 2006|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|October 12, 2006|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00387959||177851|
NCT00388531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004414-17|Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma|Multicenter, Prospective, Open Label Trial, Uncontrolled to Determine the Efficacy and Safety of Depocyt ® for the Treatment of CNS Relapse in Adult Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma||PETHEMA Foundation||Completed|March 2006|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00388531||177808|
NCT00388544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19150|Enhancing Quality of Life for Nursing Home Residents|A Prescription for Enhancing Resident Quality of Life||Penn State University|Yes|Completed|May 2005|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|128|||Both|65 Years|N/A|No|||May 2012|May 8, 2012|October 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00388544||177807|
NCT00388830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26046|Emergency Ultrasound of the Gallbladder|"Emergency Bedside Ultrasonography of the Gallbladder: Does Fasting Matter?"||Christiana Care Health Services||Completed|May 2006|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388830||177785|
NCT00388752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#06-20011A|Acupuncture for the Treatment of Phantom Limb and Residual Limb Pain After Amputation|Acupuncture for Post Amputation Limb Pain: A Pilot Study||Walter Reed Army Medical Center||Recruiting|September 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|21|||Both|18 Years|N/A|No|||October 2006|June 5, 2007|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00388752||177791|
NCT00388453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060860|Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease|ADHERE Study: Application of Dx-pH Catheter for Extra-esophageal Reflux Evaluation|ADHERE|Vanderbilt University|No|Completed|October 2006|July 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|102|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|April 29, 2014|October 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00388453||177814|
NCT00387556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0528|Ondansetron Reduce Vomiting Associated With Ketamine PSA|Does Ondansetron Reduce the Incidence of Vomiting When Used in Conjunction With Ketamine During Procedural Sedation in the Pediatric Emergency Department||University of Colorado, Denver|No|Completed|December 2002|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|268|||Both|1 Year|21 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|October 12, 2006||||No||https://clinicaltrials.gov/show/NCT00387556||177881|
NCT00387569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-502|Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers|A Randomized, Observer-Blinded, Parallel-Group, Active-Control, Phase 1/2 Trial of the Safety, Immunogenicity, and Tolerability of 20 µg, 60 µg, and 200 µg of Meningococcal Group B rLP2086 Vaccine in Healthy Adolescents Aged 10 to 12 Years||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|October 2006|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|99|||Both|18 Months|36 Months|Accepts Healthy Volunteers|||May 2008|May 6, 2008|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00387569||177880|
NCT00387582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3799S|Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema|Lucentis in the Treatment of Macular Edema - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab Versus Focal Laser Treatment in Subjects With Diabetic Macular Edema||Rocky Mountain Retina Consultants|Yes|Completed|July 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|October 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387582||177879|
NCT00390104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-12-205|Molecular Analysis of Patients With Neuromuscular Disease|Molecular Analysis of Nucleic Acids Derived From Patients With Neuromuscular Disease and Their Family Members||Children's Hospital Boston|Yes|Recruiting|January 2002|January 2015|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|DNA from blood or saliva and muscle samples from proband/ DNA from blood or saliva from      family members|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Families will be ascertained world-wide as the muscular dystrophies are a pan-ethinic        group of diseases.|July 2011|July 21, 2011|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00390104||177690|
NCT00389792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI 2042-CLN 205|Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers|A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients With Paroxysmal Atrial Fibrillation and Pacemakers With Atrial Fibrillation Data Logging Capabilities||ARYx Therapeutics|No|Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389792||177713|
NCT00389805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505966|Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|Phase I/II Study of Two Different Schedules of Bortezomib (VELCADE, PS-341) and Pemetrexed (ALIMTA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|March 2005|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|86|||Both|18 Years|N/A|No|||July 2007|February 6, 2009|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389805||177712|
NCT00385931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAS489A2301|Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin|A Multi-centre Study to Evaluate the Effects of Valsartan and the Combination of Valsartan and Simvastatin on Blood Pressure (Ambulatory and Std Cuff) and on Biochemical Markers of Endothelial Function (hsCRP, MCP-1, Serum F2 Isoprostanes, PAI-1, tPA, PICP, PIIINP, MMP9, MMP1, TIMP 1), Safety and Tolerability||Novartis||Completed|January 2002|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|412|||Both|50 Years|N/A|No|||October 2006|November 7, 2011|October 9, 2006||||||https://clinicaltrials.gov/show/NCT00385931||178003|
NCT00386399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0626|Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene|Phase II Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene||Sidney Kimmel Comprehensive Cancer Center||Withdrawn|October 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|100 Years|No|||October 2015|October 6, 2015|October 10, 2006||No|All 29 consented subjects tested negative for the BRCA2 mutation. None started study, so PI    decided to close the study.|No||https://clinicaltrials.gov/show/NCT00386399||177968|
NCT00386711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBH038|A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care|A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care||Nanjing Medical University||Not yet recruiting|October 2006|January 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||2160|||Both|18 Years|80 Years|No|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386711||177945|
NCT00386997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-MC-131-0165|ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia|ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol||Gilead Sciences||Terminated|November 2006|September 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|20|||Both|55 Years|N/A|No|||August 2007|August 20, 2007|October 10, 2006|||Study closed due to recruitment challenges.|No||https://clinicaltrials.gov/show/NCT00386997||177924|
NCT00387010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3054/BP/US|Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain|A 4-week Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Pain||Teva Pharmaceutical Industries|No|Terminated|December 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|218|||Both|18 Years|80 Years|No|||September 2012|September 19, 2012|October 10, 2006|Yes|Yes|The sponsor felt enough information was available for the exploratory assessment of the effect    of treatment with FBT on pain anxiety|No|August 17, 2012|https://clinicaltrials.gov/show/NCT00387010||177923|This study was terminated early. Additional research is recommended to develop a valid measure of anxiety, specifically related to breakthrough pain.
NCT00387023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0696|Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma|Pilot Trial of Radioimmunotherapy With Yttrium 90-Labeled (90Y) Zevalin for Low-Grade Follicular Non-Hodgkin's Lymphoma or MALT of the Orbit/Conjunctiva||M.D. Anderson Cancer Center|No|Completed|February 2004|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|October 10, 2006||No||No|September 4, 2013|https://clinicaltrials.gov/show/NCT00387023||177922|
NCT00387036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-036|Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)|A Multicenter, Double-Blind Placebo-Controlled Crossover Study to Investigate the Effects of an Inhaled Corticosteroid on Cardiopulmonary Exercise Parameters in Patients With Chronic Obstructive Pulmonary Disease||Merck Sharp & Dohme Corp.||Terminated|December 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|N/A|No|||December 2015|December 17, 2015|October 5, 2006|Yes|Yes|Termininated for business reasons|No|April 8, 2010|https://clinicaltrials.gov/show/NCT00387036||177921|
NCT00387049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018734|Anxiety Sensitivity Program for Smoking Cessation|Anxiety Sensitivity Program for Smoking Cessation||University of Vermont|Yes|Completed|January 2005|April 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||October 2006|October 21, 2010|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00387049||177920|
NCT00387348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505774|Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer|Symptom Management Trial in Cancer Survivors||Massachusetts General Hospital|Yes|Terminated|March 2006|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|24|||Both|35 Years|85 Years|No|||November 2012|November 2, 2012|October 12, 2006||No|DSMB stopped study because placebo arm had more adverse events|No|July 12, 2012|https://clinicaltrials.gov/show/NCT00387348||177897|After an interim analaysis, the DSMB decided to terminate the trial early because of the rate of adverse events (HAM-D scores increasing by at least 25%) and deaths were higher in participants receiving placebo.
NCT00387361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-56|Osteopathic Manipulative Treatment for Post-Operative Nausea and Vomiting|Osteopathic Manipulative Treatment (OMT) as Possible Prophylaxis Against Post-Operative Nausea and Vomiting (PONV) in Patients Receiving Inhalational Anesthesia||University of North Texas Health Science Center|No|Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|75 Years|No|||January 2011|January 11, 2011|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00387361||177896|
NCT00387686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100N7-210|A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures|A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study Of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) In Closed Diaphyseal Tibial Fracture||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|November 2006|March 2010|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|367|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|October 11, 2006|Yes|Yes|Decision was taken by Wyeth Sr. Management to early terminate the 3100N7-210 study (terminate    enrollment but complete follow-up).|No||https://clinicaltrials.gov/show/NCT00387686||177871|
NCT00387985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200K1-103|Bioequivalence Study in Healthy Volunteers|An Open-label, Single-dose, Randomized, 2-period Crossover, Bioequivalence Study Between the Current Formulation and the New Formulation of MOA-728 Administered Subcutaneously in Healthy Subjects||Valeant Pharmaceuticals International, Inc.||Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|October 11, 2006||||||https://clinicaltrials.gov/show/NCT00387985||177849|
NCT00388284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0106|Safety and Efficacy Study Comparing Thrombin for Arterial Sealing|Comparative Analysis of Thrombin Utilized in Endovascular Procedures of the Femoral Artery - CEASE Study||Vascular Solutions, Inc||Completed|August 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||270|||Both|18 Years|N/A|No|||February 2008|December 7, 2015|October 11, 2006||||||https://clinicaltrials.gov/show/NCT00388284||177827|
NCT00388297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-TSH|Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy|A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy|TSH|The George Washington University Biostatistics Center|Yes|Completed|October 2006|October 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1203|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388297||177826|
NCT00388310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26018|Effective Antibiotic Treatment of MRSA|Effective Duration of Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA)||Christiana Care Health Services||Completed|February 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 7, 2012|October 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00388310||177825|
NCT00389597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDR-001|LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE|LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE||LDR Spine USA|Yes|Active, not recruiting|April 2006|March 2015|Anticipated|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|599|||Both|18 Years|69 Years|No|||April 2014|April 1, 2014|October 18, 2006|Yes|Yes||No|January 3, 2014|https://clinicaltrials.gov/show/NCT00389597||177727|
NCT00418015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-025|Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia|Mu-Opioid Receptor Genetic Polymorphism and the Duration of Intrathecal Fentanyl Labor Analgesia. Mu-Opioid Receptor Genetic Polymorphism and the Efficacy of Postoperative Intrathecal Morphine Analgesia||Northwestern University|No|Completed|October 2005|June 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|293|Samples With DNA|Blood Samples|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|March 2014|March 17, 2014|December 31, 2006||No||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00418015||175594|A limitation to the finding of this study was the relatively low number of OPRM1 heterozygous subjects.
NCT00418028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/237|Standard Versus Continuous Capecitabine in Advanced Breast Cancer|Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.||Hospital San Carlos, Madrid|No|Active, not recruiting|September 2005|December 2011|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Female|18 Years|75 Years|No|||March 2011|August 8, 2011|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418028||175593|
NCT00421928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013402|Tapentadol (CG5503)|A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2007|December 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1030|||Both|40 Years|N/A|No|||April 2012|April 16, 2012|January 12, 2007|Yes|Yes||No|July 8, 2009|https://clinicaltrials.gov/show/NCT00421928||175297|
NCT00421941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.06.US.HCN|Enteral Feeding Study of Formula Containing Fish Oil in Critical Care Setting|Use of a High-protein Enteral Formula Containing Prebiotics and Fish Oil in Critical Care||Nestlé||Terminated|January 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|70 Years|No|||October 2013|October 31, 2013|January 12, 2007||No|Unable to meet enrollment goal|No||https://clinicaltrials.gov/show/NCT00421941||175296|
NCT00389506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060240|Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma|A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2006|May 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|October 18, 2006||||||https://clinicaltrials.gov/show/NCT00389506||177733|
NCT00389038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS050536|Pediatric Chronic Headache Trial|Drug and Non-Drug Treatment of Pediatric Chronic Headache||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|October 2006|September 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|10 Years|17 Years|No|||April 2011|April 21, 2011|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00389038||177769|
NCT00388999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2232-01|Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant|Multi-Center,Open-Label,Randomized,Phase 1B Study Evaluating Safety & Tolerability of Intravenous rhMBL in Pts With Multiple Myeloma Receiving Melphalan-Based High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant||Enzon Pharmaceuticals, Inc.|Yes|Completed|September 2006|May 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|October 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00388999||177772|
NCT00388193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001067-64|Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma|Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)||PETHEMA Foundation||Completed|August 2006|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|N/A|No|||February 2013|October 27, 2014|October 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00388193||177834|
NCT00390117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I177|AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma|A Phase I Study of AT7519M Given Twice Weekly in Patients With Advanced Incurable Malignancy||Canadian Cancer Trials Group|No|Completed|August 2006|January 2013|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||August 2012|October 19, 2015|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00390117||177689|
NCT00385944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10632|The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)|A Randomized Double-Blind Cross-Over Study Comparing the Pharmacodynamic (PD)Response in Subjects With ACS Receiving 14 Days 10-mg Maintenance Dose (MD) Prasugrel vs 14 Days 150-mg MD Clopidogrel After Using a 900-mg Loading Dose (LD) of Clopidogrel to Reduce Ongoing Platelet Activation||Eli Lilly and Company|Yes|Completed|March 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|85 Years|No|||August 2010|August 25, 2010|October 6, 2006|No|Yes||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00385944||178002|
NCT00385957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVAN-Z|Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100|Comparison of Antiretroviral Activity and Immunological Effect of Two Triple Treatments With and Without Protease Inhibitors in naïve HIV-1-infected Patients With CD4 < 100/mm3||Hospital Clinic of Barcelona||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||October 2006|December 14, 2010|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00385957||178001|
NCT00386165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1001-002|Safety Study of AT1001 to Treat Celiac Disease.|A Phase Ib, Randomized, Double-Blind, Placebo Controlled Study to Determine the Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Effects of Single Doses of AT-1001 in Celiac Disease Subjects.||Alba Therapeutics||Completed|January 2006|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|59 Years|No|||October 2006|October 10, 2006|October 9, 2006||||||https://clinicaltrials.gov/show/NCT00386165||177985|
NCT00386425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10553|Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)|A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients With Severe Sepsis and Multiple Organ Dysfunction||Eli Lilly and Company|Yes|Completed|November 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|486|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|October 6, 2006|No|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00386425||177966|Fewer patients than planned had severe PC deficiency so only 2 higher doses were tested & fewer required longer infusions so a large proportion of alternative therapy patients in effect received standard therapy making treatment comparisons difficult
NCT00386438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391/47|Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification|||Chulalongkorn University||Completed|December 2005|July 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386438||177965|
NCT00386724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0406|Effectiveness of Precision Spinal Cord Stimulation With Artisan Paddle Electrode|Effectiveness of the Precision Spinal Cord Stimulation System With the Artisan Paddle Electrode in Patients With Back or Lower Extremity Pain||Boston Scientific Corporation|No|Terminated|October 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|October 10, 2006||No|Insufficient Data Collected|No||https://clinicaltrials.gov/show/NCT00386724||177944|
NCT00387062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUT-113-2005; 06140-01|Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment|Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment, A Pilot Study||Posit Science Corporation||Completed|October 2006|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|50|||Both|21 Years|N/A|No|||June 2008|June 23, 2008|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00387062||177919|
NCT00387374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02704|Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab|A Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non Small Cell Lung Cancer in Combination With Bevacizumab, Paclitaxel, and Carboplatin in Patients at High Risk for Bevacizumab-Associated Hemoptysis||National Cancer Institute (NCI)||Completed|October 2006|||June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00387374||177895|
NCT00388843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00002285|Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI)|Short Term Carotid Plaque Regression in Patients With Atherosclerotic Disease Taking Statins Assessed by High Field MRI||Medical College of Wisconsin|No|Withdrawn|August 2006|February 2009|Actual|February 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|21 Years|N/A|No|Non-Probability Sample|Patients diagnosed with coronary artery disease or suspected cerebrovascular accident who        have carotid plaque (> 1.1 mm) and whose statin dose has been increased to moderate or        high dose (increased statin dose) or maintained (maintained statin dose).|August 2015|August 21, 2015|October 16, 2006||No|PI has left institution|No||https://clinicaltrials.gov/show/NCT00388843||177784|
NCT00387998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510867|Health Education in Improving the Understanding of Medical Information|Randomized Trial of a Primer to Help Patients Understand Risk||Dartmouth-Hitchcock Medical Center|No|Completed|October 2004|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|555|||Both|35 Years|79 Years|Accepts Healthy Volunteers|||January 2008|August 28, 2013|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00387998||177848|
NCT00389285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|494F01|Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma|A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly With Sorafenib (Nexavar) in Subjects With Metastatic Renal Cell Carcinoma||ZymoGenetics||Completed|October 2006|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||May 2009|May 26, 2009|October 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389285||177750|
NCT00389298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCH759-201|A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.|A Phase 2, Multicenter, Randomized, Double-blinded, and Placebo-controlled Study of the Antiviral Activity, Safety and Pharmacokinetics of VCH-759 in Subjects With Chronic Hepatitis C-infection.||Vertex Pharmaceuticals Incorporated|Yes|Completed|October 2006|June 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Male|18 Years|60 Years|No|||September 2009|September 23, 2009|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00389298||177749|
NCT00421980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-312|An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis|An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2002|July 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||January 2007|January 12, 2007|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00421980||175293|
NCT00386308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP12B-MR-303|Efficacy and Safety Study of XP12B in Women With Menorrhagia|A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia||Ferring Pharmaceuticals|Yes|Completed|October 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Female|18 Years|49 Years|No|||June 2010|May 3, 2011|October 6, 2006|Yes|Yes||No|December 11, 2009|https://clinicaltrials.gov/show/NCT00386308||177975|
NCT00422279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR06:3393|A Study of Dental Implants Coated With Bone Morphogenetic Protein|Evaluation of Implant Stability and Local Bone Formation at Endosseous Dental Implants With a Titanium Porous Oxide Surface Adsorbed With rhBMP-2||Nobel Biocare|Yes|Completed|November 2006|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|4|||Both|18 Years|N/A|No|||October 2015|December 8, 2015|January 11, 2007|No|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT00422279||175270|
NCT00389519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K726-06-4003|A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study Assessing the Efficacy, Safety, and Dose-Response of Ramipril for the Treatment of Hypertension in Children and Adolescents||Pfizer||Terminated|October 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|422|||Both|6 Years|16 Years|No|||June 2012|June 6, 2012|October 17, 2006|||A planned interim analysis was performed after approx. 240 subjects completed the trial. The    study was stopped, as permitted by protocol, after the analysis.||January 21, 2010|https://clinicaltrials.gov/show/NCT00389519||177732|
NCT00389818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-047|Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma|A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma||AIDS Malignancy Consortium|No|Completed|January 2007|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|October 18, 2006|Yes|Yes||No|May 29, 2012|https://clinicaltrials.gov/show/NCT00389818||177711|
NCT00389831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0879|Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms|A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Trial to Assess the Efficacy, Safety and Tolerability of Ascending Doses of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms in Subjects With Idiopathic Restless Legs Syndrome||UCB Pharma|No|Completed|August 2006|December 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||February 2011|September 24, 2014|October 17, 2006|No|Yes||No|July 28, 2009|https://clinicaltrials.gov/show/NCT00389831||177710|
NCT00388739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSBUPR0045|Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department|Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department||Baylor College of Medicine||Not yet recruiting|November 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment||||251|||Both|1 Year|18 Years|No|||October 2006|October 13, 2006|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388739||177792|
NCT00385970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCSGO-CCTG-0501|A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer|A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer||Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group|Yes|Active, not recruiting|March 2006|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|20 Years|80 Years|No|||October 2012|October 25, 2012|October 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00385970||178000|
NCT00386178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2833|Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma|Comparison of Gamma-tocopherol Supplementation in Allergic Asthmatics and Normal Volunteers||University of North Carolina, Chapel Hill|No|Completed|October 2006|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 20, 2010|October 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00386178||177984|
NCT00386412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002813-19.|TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant|Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant||PETHEMA Foundation||Completed|November 2005|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|2 Years|N/A|No|||September 2009|September 17, 2009|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00386412||177967|
NCT00386191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY6913|Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment|Evaluation of the Safety and Efficacy of Clopidogrel sulfate50mg and Clopidogrel Sulfate 75mg for the Treatment of Cerebral Infarction||Sanofi||Completed|September 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1110|||Both|20 Years|74 Years|No|||February 2010|February 23, 2010|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386191||177983|
NCT00386451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/331|Comparing a Closing System Without a Needle With Positive Pressure to a Heparin Lock With Positive Pressure|Prospective Study Which Compares the Use of a Closing System Without a Needle and With Positive Pressure to a Heparin Lock With Positive Pressure for Patients With a Catheter for Chemotherapy||University Hospital, Ghent|No|Completed|November 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||April 2009|April 24, 2009|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386451||177964|
NCT00386737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-2-R44-HL070344-02|Development of a Breath Analyzer for Asthma Screening|Development of a Breath Analyzer for Asthma Screening||Ekips Technologies||Recruiting|September 2004|February 2007||||Phase 0|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||2000|||Both|4 Years|65 Years|Accepts Healthy Volunteers|||October 2006|October 11, 2006|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00386737||177943|
NCT00386750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566A2412|Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function|An Open-label, Single-center Study of the Effects of Co-artemether, Atovaquone-proguanil, and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older.||Novartis||Terminated|June 2005|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||265|||Both|12 Years|N/A|No|||April 2012|April 25, 2012|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00386750||177942|
NCT00388011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-002|Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery|Randomized, Double-Blind, Placebo and Comparator-Controlled, Dose-Response Trial of the Efficacy and Safety of Intranasal Morphine, Intravenous Morphine and Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery||Javelin Pharmaceuticals|No|Completed|January 2005|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|187|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388011||177847|
NCT00387725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-501|Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents|A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years||Pfizer|Yes|Completed|November 2006|February 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|127|||Both|8 Years|14 Years|No|||November 2014|November 14, 2014|October 11, 2006||No||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00387725||177868|
NCT00387387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG105424|Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)|An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination With FOLFOX 6 orCapeOx in Subjects With Colorectal Cancer||GlaxoSmithKline|No|Completed|October 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|70|||Both|21 Years|N/A|No|||April 2011|May 31, 2012|October 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387387||177894|
NCT00387400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I162|Temozolomide and Everolimus in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme|A Phase I Study of Temozolomide and RAD001C in Patients With Malignant Glioblastoma Multiforme||Canadian Cancer Trials Group|Yes|Completed|July 2006|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00387400||177893|
NCT00389077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 207|Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas|A Phase IIA Trial of Two Schedules of Perifosine||AEterna Zentaris|Yes|Completed|January 2005|September 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|558|||Both|18 Years|N/A|No|||November 2011|February 12, 2014|October 16, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389077||177766|
NCT00389090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O6BG 202|A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma|A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma||Keryx / AOI Pharmaceuticals, Inc.|No|Terminated|October 2006|February 2009|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|October 16, 2006|Yes|Yes|AOI Pharma terminated the license agreement. IND Transferred to NCI|No||https://clinicaltrials.gov/show/NCT00389090||177765|
NCT00421343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0074|Secondary Prevention of Osteoporosis|Secondary Prevention of Osteoporosis: A Window of Opportunity in the Acute Rehabilitation Setting||Hebrew Rehabilitation Center, Boston|No|Completed|February 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|65 Years|N/A|No|||May 2011|May 11, 2011|January 10, 2007||No||No|July 8, 2010|https://clinicaltrials.gov/show/NCT00421343||175341|
NCT00421655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-14|A Trial of Grazax in Subjects With Hayfever|A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma||ALK-Abelló A/S|Yes|Completed|December 2006|October 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|329|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|January 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421655||175318|
NCT00421668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD048969|A Trial of Zinc and Micronutrients in Tanzanian Children|A Trial of Zinc and Micronutrients in Tanzanian Children||Harvard School of Public Health|Yes|Completed|September 2000|October 2002|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|2400|||Both|6 Weeks|18 Months|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421668||175317|
NCT00386321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH011103|Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma|Yt90Zevalin Plus CHOP, Z-CHOP||Chulalongkorn University|No|Terminated|April 2006|January 2010|Anticipated|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||November 2010|November 17, 2010|October 10, 2006|||Participants are no longer being examined or treated.|No||https://clinicaltrials.gov/show/NCT00386321||177974|
NCT00418327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 1120|Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma|Phase I Studies of TarcevaTM (Erlotinib Hydrochloride, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma||Gustave Roussy, Cancer Campus, Grand Paris||Completed|June 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|1 Year|21 Years|No|||August 2009|August 6, 2009|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418327||175570|
NCT00389532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC35|Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)||Sanofi|No|Completed|October 2006|September 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 17, 2014|October 18, 2006|Yes|Yes||No|February 24, 2009|https://clinicaltrials.gov/show/NCT00389532||177731|
NCT00389844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22361|BHS5 - Testing the Effectiveness of the Exercise Plus Program|Testing the Effectiveness of the Exercise Plus Program on Efficacy Expectations, Exercise Behavior & Activity of Older Adults Following a Hip Fracture|Hip5|University of Maryland|Yes|Completed|July 2000|September 2005|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|240|||Female|65 Years|N/A|No|||May 2008|May 27, 2008|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00389844||177709|
NCT00389857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC34|Trial to Collect Safety Data and Sera for Immunogenicity Testing|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)||Sanofi|No|Completed|October 2006|July 2008|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|31|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||January 2014|January 17, 2014|October 18, 2006|No|Yes||No|February 24, 2009|https://clinicaltrials.gov/show/NCT00389857||177708|
NCT00389233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL994-01/2001|A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution|A Randomised, Multi-Centre, Single-Blinded, Pivotal Phase III Trial to Assess the Efficacy, Acceptability and Safety of a New 2 Litre Gut Cleansing Solution NRL994 Versus a Standard Colon Preparation With 4L PEG+E.||Norgine|No|Completed|June 2002|December 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|85 Years|No|||April 2008|April 15, 2008|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00389233||177754|
NCT00390143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108595 Mth18|Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612|Assess Long Term Persistence of a Primary Dose of GSK Biologicals' Meningococcal Vaccine 134612 Versus One Dose of Mencevax™ ACWY in Healthy Adolescents/Young Adults (15 to 19 Years at Vaccination)||GlaxoSmithKline||Completed|February 2007|May 2009|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390143||177687|
NCT00385983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP005|Total Thyroidectomy With Harmonic Scalpel®|Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial||Brazilian Society of Head and Neck Surgery||Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||280|||Both|18 Years|N/A|No|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00385983||177999|
NCT00386204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-pts-11073|Side Effects of Q-Switched Ruby Laser for the Treatment of Lentigines in Light and Dark Skin Types|Efficacy and Side Effects of Q-Switched Ruby Laser Treatment of Solar Lentigines in Two Different Fitzpatrick Skin Types II and IV||hahid Beheshti University of Medical Sciences||Completed|November 2005|September 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||90|||Both|N/A|80 Years|Accepts Healthy Volunteers|||June 2008|June 2, 2008|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386204||177982|
NCT00387413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3A106308|A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers|A Double-blind, Double-dummy, Placebo-controlled, Incomplete Block, Two Period Crossover Study of the Histamine H3 Antagonist GSK189254 and Duloxetine in the Electrical Hyperalgesia Model of Central Sensitisation in Healthy Volunteers||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00387413||177892|
NCT00387426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00207|Sunitinib in Treating Patients With Idiopathic Myelofibrosis|A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis||National Cancer Institute (NCI)||Terminated|September 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||October 2013|May 12, 2014|October 12, 2006|Yes|Yes||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00387426||177891|
NCT00387699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000508653|Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase II Trial of Bevacizumab in Combination With Cisplatin/Etoposide and Twice Daily Radiation for Patients With Limited-Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|October 2006|April 2014|Actual|October 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|79|||Both|18 Years|N/A|No|||October 2008|April 27, 2015|October 12, 2006|Yes|Yes||||https://clinicaltrials.gov/show/NCT00387699||177870|
NCT00388024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000504047|PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|A Pilot Feasibility Study of PET-CT Imaging in Patients With Cancer of the Head and Neck Treated With Definitive Chemoradiation||Comprehensive Cancer Center of Wake Forest University|No|Completed|February 2006|January 2015|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|January 2015|January 14, 2015|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00388024||177846|
NCT00388323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 051041|Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human|Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human : Study of Pro- and Anti-inflammatory Cytokines and ADIPOKINES..|RIHTA|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2006|January 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|47|||Both|18 Years|75 Years|No|||November 2012|December 10, 2012|October 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00388323||177824|
NCT00388570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AER-036|Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment|A Multicenter, Device Randomized, Open-label Prospective Single-cohort Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment|eNOugh|Aerocrine AB|No|Completed|October 2006|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|151|||Both|4 Years|65 Years|No|||November 2011|November 3, 2011|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00388570||177805|
NCT00388583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID04|Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects|Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects||Sanofi||Completed|September 2006|September 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|817|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 13, 2012|October 16, 2006|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00388583||177804|
NCT00420758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-109796-b|Effectiveness Trial on Alleviation of Infant Malnutrition With Fortified Spread or Maize-Soy Flour Food Supplements|LCNI-7. A Three-centre Intervention Trial in Rural Malawi, Testing the Effectiveness of Fortified Spread or Maize-Soy Flour Supplementation to Alleviate Moderate Malnutrition Among 6-18 Month Old Children||University of Tampere|Yes|Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|299|||Both|6 Months|15 Months|No|||December 2015|December 3, 2015|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00420758||175385|
NCT00388856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17791137|Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status|Vitamin C and E Supplementation in Pregnant Women With Low Antioxidant Status||Showa University|Yes|Completed|October 2006|February 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|400|||Female|17 Years|45 Years|Accepts Healthy Volunteers|||March 2007|February 16, 2010|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00388856||177783|
NCT00421356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104850|Comparison of Prosthetic Knee Performance During Sitting and Standing|Kinetic and Kinematic Comparison of Power Assisted Versus Stance Control Artificial Knees During Sit To Stand||University of South Florida||Completed|January 2007|February 2009|Actual|||Phase 0|Observational|Time Perspective: Prospective||6|Anticipated|35|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons with Transfemoral Amputation|April 2007|August 5, 2010|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421356||175340|
NCT00421642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002167|Open-Label Adalimumab for Ulcerative Colitis Patients|An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Ulcerative Colitis Patients||Mayo Clinic|No|Completed|October 2006|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421642||175319|
NCT00386893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC_03082005|Somatosensory Processing in Depression|Influence of Escitalopram on Somatosensory Processing in Patients With Major Depression||Ludwig-Maximilians - University of Munich||Withdrawn|October 2006|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|60 Years|No|||April 2015|April 13, 2015|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386893||177931|
NCT00386906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSP00-106|Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma|Sentinel Lymph Node Localization and Biopsy for Conjunctival and Eyelid Melanoma||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2000|||May 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|38|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00386906||177930|
NCT00386919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P-000110/3|Short Course of Radiation for Gliomas in Elderly Patients|A Phase II Study of Hypofractionated Radiation With CyberKnife Stereotactic Radiosurgery Boost for High Grade Gliomas in Elderly Patients With Good Performance Status||Beth Israel Deaconess Medical Center||Completed|April 2006|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|65 Years|N/A|No|||January 2014|January 9, 2014|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00386919||177929|
NCT00422305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603-15|Assessment of Lung Structure and Function of Infants Born Prematurely|Assessment of Lung Structure and Function of Infants Born Prematurely||Indiana University|Yes|Recruiting|January 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|129|||Both|2 Months|36 Months|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be selected from Infant Lung Disease Clinics at Riley Hospital,        flyer in the community, and the neonatal intensive care unit (NICU) at Riley Hospial for        Children, Indiana University and Methodist Hospital.|November 2015|November 12, 2015|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00422305||175268|
NCT00389259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70/04*1|Scopolamine Treatment for Patients With Organophosphate Poisoning|Scopolamine Treatment for Patients With Organophosphate Poisoning - a Randomized, Double Blind, Placebo-Controlled Study.||Assaf-Harofeh Medical Center||Withdrawn|October 2007|December 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|60 Years|No|||March 2010|April 4, 2011|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389259||177752|
NCT00389558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRAP190406|Antiseptic Use and Dressing Application|Comparison of Amukin Versus Biseptine Use for Dressing Application of Epicutaneocavous Catheters for Nosocomial Infection Prevention||Maternite Regionale Universitaire|No|Completed|September 2006|October 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|453|||Both|N/A|3 Months|No|||September 2009|September 18, 2009|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00389558||177729|
NCT00389545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA 8225|Intracoronary Stem Cells in Large Myocardial Infarction|Intracoronary Stem Cells in Large Myocardial Infarction||Charles University, Czech Republic||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|79 Years||||October 2006|October 18, 2006|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389545||177730|
NCT00390130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009089|Does the Order in Which Vaccines Are Administered Affect Pain Response?|Does the Order in Which Vaccines Are Administered Affect Pain Response? A Randomized, Double-blind, Clinical Trial of Pentacel vs. Prevnar||The Hospital for Sick Children|No|Completed|July 2006|July 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||November 2013|November 10, 2013|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00390130||177688|
NCT00386464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 67887-03|Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement|Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement||Johns Hopkins University|No|Completed|April 2002|September 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|60|||Both|18 Years|N/A|No|||April 2007|November 8, 2007|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386464||177963|
NCT00386763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566B2303|Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.|A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants and Children.||Novartis||Completed|August 2006|March 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||890|||Both|N/A|12 Years|No|||March 2009|March 11, 2009|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00386763||177941|
NCT00387075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARS|A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease|Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease||Institute for Neurodegenerative Disorders|No|Active, not recruiting|November 2006|November 2013|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|3000|||Both|50 Years|N/A|No|||February 2012|February 9, 2012|October 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387075||177918|
NCT00387088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.372|Tiotropium / Respimat One Year Study in COPD.|Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD||Boehringer Ingelheim||Completed|September 2006|||January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|3991|||Both|40 Years|N/A|No|||September 2013|May 7, 2014|October 11, 2006||||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00387088||177917|
NCT00387101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS03-2004|Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers|Pivotal Study to Evaluate the Efficacy and Safety of Dermal-Living Skin Replacement (Dermal-LSR) in the Treatment of Chronic Diabetic Foot Ulcers||ApoPharma||Terminated|February 2006|April 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|288|||Both|18 Years|84 Years|No|||April 2008|April 30, 2008|October 10, 2006|||Low recruitment rate|No||https://clinicaltrials.gov/show/NCT00387101||177916|
NCT00387439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.429|ORALIA Trial Medical Treatment vs Anoperineal Physiotherapy for Adult Anal Incontinence.|ORALIA Trial Randomized Controlled Trial of Medical Treatment Alone vs Medical Treatment Associated With Anoperineal Physiotherapy for Adult Anal Incontinence. Assessment of Incontinence Symptoms and Quality of Life.||Hospices Civils de Lyon||Terminated|October 2006|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|173|||Both|18 Years|75 Years|No|||September 2013|September 18, 2013|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00387439||177890|
NCT00387712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3834-R|Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise|Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise||VA Office of Research and Development|Yes|Completed|October 2006|August 2014|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|80 Years|No|||October 2014|October 20, 2014|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00387712||177869|
NCT00420147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20RR16458-3|Wedged Orthoses and Knee Osteoarthritis|Effect of in-Shoe Wedges on Knee Osteoarthritis||University of Delaware||Completed|February 2002|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||January 2009|January 26, 2009|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00420147||175431|
NCT00420433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0999|Bone Response in Metastatic Breast Cancer Involving Bones|Prospective Study of Tumor Response Assessment in Metastatic Breast Cancer Involving Bones||M.D. Anderson Cancer Center|No|Completed|September 2004|May 2012|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|37|||Both|N/A|N/A|No|Non-Probability Sample|Study participants with breast cancer that has spread to the bones.|May 2012|February 17, 2016|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00420433||175410|
NCT00420459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609-22|Aripiprazole in Fragile X Syndrome|Aripiprazole in Fragile X Syndrome||Indiana University|Yes|Completed|April 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|5 Years|35 Years|No|||April 2012|April 25, 2012|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00420459||175408|
NCT00420472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20240|A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.|An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept||Hoffmann-La Roche||Terminated|March 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2007|November 19, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00420472||175407|
NCT00421031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-315|Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause|A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR For Relief of Vasomotor Symptoms Associated With Menopause||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2003|April 2004||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||540|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2007|January 10, 2007|January 10, 2007||||||https://clinicaltrials.gov/show/NCT00421031||175365|
NCT00421044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2121E1|A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function|An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function||Novartis||Completed|May 2006|||February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421044||175364|
NCT00421681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0075|Exercise Adherence Among Older Adults With Osteoarthritis|Exercise Adherence Among Older Adults With Osteoarthritis||National Institute on Aging (NIA)|No|Active, not recruiting|October 2003|September 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|60 Years|N/A|No|||January 2008|December 10, 2009|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421681||175316|
NCT00421694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMBC142|Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide|||University of L'Aquila||Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||119|||Male|18 Years|75 Years|No|||October 2007|October 5, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00421694||175315|
NCT00421707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI105626|Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome|A Randomised, Double-blind, Placebo-controlled, Crossover Study to Evaluate Efficacy and Safety of the CRF1 Receptor Antagonist GW876008 in Patients With Irritable Bowel Syndrome||GlaxoSmithKline|No|Completed|November 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|64 Years|No|||September 2015|September 17, 2015|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421707||175314|
NCT00386945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA021349|Tobacco Cessation Via Doctors of Chiropractic|||Oregon Research Institute|No|Completed|May 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|September 19, 2006||No||No||https://clinicaltrials.gov/show/NCT00386945||177928|
NCT00386594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100606|Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus|||Rogers, B.H. Gerald, M.D.||Terminated|October 2006|October 2012|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2006|January 20, 2009|October 8, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00386594||177954|
NCT00389584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000506074|Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors|Phase I/II Study of Irinotecan and Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors||University of California, Davis|Yes|Completed|December 2002|November 2006|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|30|||Both|1 Year|N/A|No|||March 2010|March 15, 2010|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389584||177728|
NCT00389883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050320|Anaesthesia for Supratentorial Tumor Resection|Anaesthesia for Supratentorial Tumor Resection : a Double-blind Comparison of Target Plasma Concentration of Propofol-remifentanil and Sevoflurane-sufentanil||Assistance Publique - Hôpitaux de Paris|No|Completed|November 2006|November 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|75 Years|No|||July 2012|July 6, 2012|October 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00389883||177706|
NCT00389870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510284|Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil|A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)]||National Cancer Institute (NCI)||Recruiting|December 2006|||March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1269|||Both|18 Years|N/A|No|||July 2007|August 23, 2013|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389870||177707|
NCT00386477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509-55 (Study #)|Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial|Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial||Indiana University|Yes|Terminated|September 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|300|||Female|18 Years|N/A|No|||December 2010|January 14, 2010|October 9, 2006||No|Difficulty recruiting|No|November 11, 2009|https://clinicaltrials.gov/show/NCT00386477||177962|The study was stopped before the planned enrollment of 1000 due to difficulty recruiting. Results are of a planned safety analysis at 300 subjects.
NCT00386776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P-000420|Patient Computer Dialog in Primary Care|Cybermedicine for the Patient and Physician||Beth Israel Deaconess Medical Center|No|Completed|January 2005|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 11, 2013|October 11, 2006||No||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00386776||177940|
NCT00419640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR04032AF|SAFE Study - Septal Pacing for Atrial Fibrillation Suppression Evaluation|Septal Pacing for Atrial Fibrillation Suppression Evaluation|SAFE|St. Jude Medical|Yes|Completed|May 2005|November 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|385|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00419640||175470|
NCT00419900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER2k|Use of Hair to Diagnose the Presence of Breast Cancer|||Fermiscan Ltd||Recruiting|December 2006|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Screening||||2000|||Female|20 Years|N/A|Accepts Healthy Volunteers|||January 2007|January 7, 2007|January 7, 2007||||No||https://clinicaltrials.gov/show/NCT00419900||175450|
NCT00419913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR2006 1.0|A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)|A Randomized Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) Treatment for Two Months Before Starting Ovulation Induction for in Vitro Fertilization (IVF)||Center for Human Reproduction||Terminated|January 2007|January 2008|Actual|July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Female|40 Years|45 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|January 7, 2007||No|Failure to recruit sufficient participants.|No||https://clinicaltrials.gov/show/NCT00419913||175449|
NCT00420160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03CA119747|Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?|Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?||The Miriam Hospital||Completed|February 2007|December 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|59|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00420160||175430|
NCT00420446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA20060149|The Effect of Daily Intakes of Dairy Products on Blood Pressure in Human Beings|||Glostrup University Hospital, Copenhagen||Completed|January 2007|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2007|July 25, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00420446||175409|
NCT00420771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4906/#5998R|Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients|A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients||New York State Psychiatric Institute|No|Completed|January 2007|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|No|||December 2012|December 11, 2012|January 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420771||175384|
NCT00422292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA37|Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers|An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers||Sanofi|Yes|Completed|December 2006|April 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|1664|||Both|9 Months|12 Months|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 12, 2007|Yes|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00422292||175269|
NCT00386074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6107050200|Iron-fortified Whole Maize Flour Trial|The Efficacy of Iron Fortified Whole Maize Flour on the Iron Status of School Children in Kenya||Wageningen University||Completed|May 2004|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||412|||Both|3 Years|8 Years|No|||April 2010|April 20, 2010|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386074||177992|
NCT00386607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPV100A2301|A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.|A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg /Valsartan 320 mg in Patients With Essential Hypertension Followed by a 26 Week Open-label Extension to Assess the Long-term Safety and Tolerability of the Triple Combination of Aliskiren/Valsartan/Hydrochlorothiazide(HCTZ)||Novartis||Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|601|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|October 10, 2006|No|Yes||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00386607||177953|Open label study with no comparator treatment/arm.
NCT00390182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042314|Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)|GCC 0319: Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)|GCC0319|University of Maryland|Yes|Completed|October 2003|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|October 17, 2006|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00390182||177684|
NCT00390156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06991|Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors|A Phase I Trial of Imatinib, Bevacizumab, & Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors||University of California, San Francisco|Yes|Completed|August 2006|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|October 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390156||177686|
NCT00386217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0568|Psychosocial Impact of Cancer-Related Female Infertility|Psychosocial Impact of Cancer-Related Female Infertility||M.D. Anderson Cancer Center|No|Completed|December 2004|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|239|||Female|14 Years|N/A|No|Non-Probability Sample|Female survivors of breast cancer, cervical cancer, Hodgkin's Disease, or non-Hodgkin's        lymphoma, age 14 years and older, who were diagnosed before the age of 41 during the        period of 1993-1998.|July 2012|July 31, 2012|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00386217||177981|
NCT00387114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002368-27|Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study|Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study||University of Turin, Italy||Terminated|June 2005|November 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||80|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2006|October 10, 2006|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00387114||177915|
NCT00387127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF105884|Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer|A Randomized, Double-blind, Placebo Controlled, Multicentre, Phase II Study of Oral Lapatinib in Combination With Concurrent Radiotherapy and Cisplatin Versus Radiotherapy and Cisplatin Alone, in Subjects With Stage III, IVA, B Squamous Cell Carcinoma of the Head and Neck (SCCHN)||GlaxoSmithKline|Yes|Completed|November 2006|January 2014|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||February 2015|May 28, 2015|October 10, 2006|Yes|Yes||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00387127||177914|
NCT00419367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-042|Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)|Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma||Merck Sharp & Dohme Corp.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||May 2015|May 29, 2015|January 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00419367||175490|
NCT00419120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL003|Augmentation Cystoplasty Using an Autologous Neo-Bladder|An Open-Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Spina Bifida||Tengion|Yes|Terminated|December 2006|April 2011|Actual|October 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|3 Years|21 Years|No|||November 2015|November 2, 2015|January 4, 2007|No|Yes|36 months follow up without change to profile. No further studies planned.|No|December 8, 2009|https://clinicaltrials.gov/show/NCT00419120||175509|
NCT00419380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0556|Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)|Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)||University of Colorado, Denver|No|Completed|January 2007|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|January 4, 2007|Yes|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT00419380||175489|
NCT00419653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy|Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy With Amisulpride, Olanzapine or Haloperidol. A Study With Functional Magnetic Resonance Imaging (fMRI) and Diffusion Tensor Imaging (DTI)||University of Jena|No|Terminated|January 2003|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|65 Years|No|||September 2008|September 15, 2008|January 8, 2007||No|Recruitment issues|No||https://clinicaltrials.gov/show/NCT00419653||175469|
NCT00421057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0309|Combined Strength Training and Functional Endurance Exercise Regimen on Cancer -Related Fatigue and Physical Performance|The Effects of Combined Strength Training and Functional Endurance Exercise Regimen on Cancer-Related Fatigue and Physical Performance||M.D. Anderson Cancer Center|Yes|Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|25|||Female|21 Years|60 Years|No|Non-Probability Sample|Participants with breast cancer that will be receiving chemotherapy.|July 2012|July 27, 2012|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00421057||175363|
NCT00420797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/PFI/01|A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Topical 10% Phenylephrine Gel in the Management of Ileal Pouch Anal Anastomosis (IPAA)-Related Faecal Incontinence||S.L.A. Pharma AG|No|Withdrawn|February 2007|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2007|May 18, 2015|January 9, 2007|||Terminated, new protocol to be developed|No||https://clinicaltrials.gov/show/NCT00420797||175382|
NCT00420810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0928-049|Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)|A Double-Blind, Placebo Controlled, Randomized, Cross-Over Polysomnographic Study of MK0928 15 mg in Adult Patients With Primary Insomnia||H. Lundbeck A/S||Terminated|September 2006|||March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||138|||Both|18 Years|64 Years|No|||January 2015|January 13, 2015|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00420810||175381|
NCT00421369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|t3rbx-HMO-CTIL|Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.|Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.||Hadassah Medical Organization|No|Completed|September 2007|August 2011|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2007|March 21, 2013|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421369||175339|
NCT00421395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hLL2-06EU|Safety Study of NHL With 90Y-hLL2 IgG|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG||Immunomedics, Inc.|No|Completed|August 2002|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||January 2008|January 16, 2008|January 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421395||175338|
NCT00421070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC2005.060|Effect of Massage Therapy on Aggression in a Psychiatric Inpatient Unit|The Evaluation of Relaxation Massage Therapy as an Intervention Treatment for Reducing the Level of Arousal and Aggression on a Young Adult Psychiatric Inpatient Unit||Melbourne Health|No|Completed|May 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|15 Years|25 Years|No|||April 2015|April 26, 2015|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421070||175362|
NCT00421967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004638-33.|Postoperative Analgesia After Total Knee Arthroplasty|Postoperative Analgesia After Total Knee Arthroplasty. A Comparison of Continuous Epidural Infusion and Wound Infiltration With Continuous Intraarticular Infusion||University of Aarhus|Yes|Terminated|January 2007|April 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|January 12, 2007||No|Interim analysis|No||https://clinicaltrials.gov/show/NCT00421967||175294|
NCT00390013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-3225-53540306 Kennedy GCRC|To Evaluate if the Medication Gabapentin Lessens Vulvar Pain|Vulvar Pain: Treatment Trial Using Gabapentin-Placebo in a Cross-Over Design, Pilot Study.||University of Iowa|Yes|Completed|January 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||March 2009|March 12, 2009|October 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390013||177697|
NCT00385840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108708|Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate|A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years and Above.||GlaxoSmithKline||Completed|October 2006|||February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|678|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|April 25, 2013|October 10, 2006|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00385840||178010|
NCT00386087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10517|Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy|A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen||Eli Lilly and Company||Completed|November 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|41|||Female|18 Years|N/A|No|||April 2008|June 5, 2008|October 6, 2006||||||https://clinicaltrials.gov/show/NCT00386087||177991|
NCT00387868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHS07.0006a|Preoperative Treatment of Patients With High Risk Thymoma|Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence||Valley Health System|Yes|Completed|October 2006|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|October 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00387868||177858|
NCT00387881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA107563|TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET)||GlaxoSmithKline|No|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|679|||Both|18 Years|65 Years|No|||May 2012|July 26, 2012|October 11, 2006|Yes|Yes||No|February 19, 2009|https://clinicaltrials.gov/show/NCT00387881||177857|
NCT00402155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCO2-2218|Visual Discomfort and Reading|Visual Discomfort and Reading||Southern California College of Optometry||Completed|July 2004|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|17 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be chosen from the student population and Claremont McKenna College.|January 2009|November 11, 2009|November 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00402155||176784|
NCT00402168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-010|A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids|Belatacept Conversion Trial in Renal Transplantation||Bristol-Myers Squibb|Yes|Completed|January 2007|June 2013|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|November 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402168||176783|
NCT00422266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCDC-6980|Effect of Omega -3 Fatty Acids Supplements and Plant Sterol Enriched Food in Dyslipidemic Adults|Effect of Omega -3 Fatty Acids Supplements and Plant Sterol Enriched Drink/Food on the Composite Risk Profile of Dyslipidemic Adults||Centre for Chronic Disease Control, India|Yes|Completed|December 2006|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|178|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||September 2007|September 24, 2007|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00422266||175271|
NCT00385996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI TAR 728|Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer|A Pilot Study of Preoperative Tarceva (Erlotinib) Monotherapy in Patients With Early Stage (I/II) Non-Small Cell Lung Cancer||Weill Medical College of Cornell University|No|Completed|October 2006|August 2011|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|85 Years|No|||December 2012|December 13, 2012|October 9, 2006||No||No|October 12, 2012|https://clinicaltrials.gov/show/NCT00385996||177998|
NCT00386230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT-1|Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1|Short ZDV Course to Prevent Perinatal HIV in Thailand||Institut de Recherche pour le Developpement||Completed|June 1997|August 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4|||1554|||Female|N/A|N/A|No|||May 2008|May 1, 2008|October 10, 2006||||No||https://clinicaltrials.gov/show/NCT00386230||177980|
NCT00386490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1001-003|Safety of AT-1001 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-Dose Study to Determine the Safety, Tolerance and Pharmacokinetics of 3 Dose Levels of AT-1001 in Healthy Volunteers||Alba Therapeutics||Completed|January 2006|February 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2006|October 10, 2006|October 9, 2006||||||https://clinicaltrials.gov/show/NCT00386490||177961|
NCT00418821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID01803|A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants|A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme (Laronidase) Treatment on Lactation in Women With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants||Sanofi|No|Recruiting|October 2010|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|N/A|N/A|No|||October 2015|October 26, 2015|January 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00418821||175532|
NCT00420173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2742-1|Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)|Interdisciplinary Study Group of Lupus Erythematosus||European Society of Cutaneous Lupus Erythematosus e.V.|No|Completed|September 2004|June 2008|Actual|July 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cutaneous lupus erythematosus|December 2013|December 11, 2013|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00420173||175429|
NCT00420485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBQ707A2101|Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors|A Phase I Open-label, Multi-center Dose-escalation Study to Determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors||Novartis||Completed|March 2006|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|January 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00420485||175406|
NCT00420498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27678|Effects of Atomoxetine on Cognitive Function in Schizophrenia|Effects of Atomoxetine on Cognitive Function in Schizophrenia||Yale University|No|Completed|August 2005|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|59 Years|No|||December 2007|December 11, 2007|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00420498||175405|
NCT00420784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX06-950-106|A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)|A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy||Vertex Pharmaceuticals Incorporated|Yes|Completed|February 2007|April 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|465|||Both|18 Years|70 Years|No|||July 2014|July 9, 2014|January 8, 2007|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00420784||175383|
NCT00420511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065-00|Beta-Cell Function and Sitagliptin Trial (BEST)|A Randomized Controlled Pilot Study Assessing the Effect of Sitagliptin on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes|BEST|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|January 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|30 Years|75 Years|No|||December 2011|December 28, 2011|January 10, 2007||No||No|June 24, 2011|https://clinicaltrials.gov/show/NCT00420511||175404|The modest sample size of this pilot study may have lacked sufficient statistical power to detect an effect on preservation of beta-cell function.
NCT00389142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-11-160|Genetic Studies in Interstitial Cystitis|Genetic Studies in Interstitial Cystitis/Painful Bladder Syndrome/Chronic Pelvic Pain Syndrome||Children's Hospital Boston|Yes|Recruiting|January 2006|June 2012|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|We will collect and store DNA (via saliva) and urine on all participants.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are collecting patients throughout North America (including the United States and        Canada)|July 2011|July 21, 2011|October 17, 2006||No||No||https://clinicaltrials.gov/show/NCT00389142||177761|
NCT00389376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT003566-01|Phase I Trial of Silymarin for Chronic Liver Diseases|Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease|SyNCH|National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|November 2006|February 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Actual|56|||Both|18 Years|N/A|No|||February 2008|February 15, 2008|October 16, 2006|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00389376||177743|
NCT00421083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9108|Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess Efficacy and Safety of Tadalafil (LY450190) in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury||Eli Lilly and Company||Completed|September 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Male|18 Years|N/A|No|||October 2007|October 23, 2007|January 9, 2007||||No||https://clinicaltrials.gov/show/NCT00421083||175361|
NCT00389389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2782C00001|Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly or Every Two Weeks in Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|September 2006|October 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||April 2009|April 30, 2009|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389389||177742|
NCT00421408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR053701|The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women|Impact of a Protein Supplement on Bone Mass in Older Men and Women||Yale University|Yes|Completed|February 2007|September 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|208|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|January 11, 2007||No||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00421408||175337|The limitations of this study include the large attrition rate due to the length of the intervention and the difficulty in adhering to 40 grams of protein or placebo powder as a daily supplement.
NCT00421421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI106807|Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter|A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 Weeks to Reduce The Risk of Acute Urinary Retention Relapse Following Successful Trial Without Catheter.||GlaxoSmithKline||Terminated|March 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||276|||Male|50 Years|N/A|No|||November 2007|November 26, 2007|January 11, 2007|||Incomplete information|No||https://clinicaltrials.gov/show/NCT00421421||175336|
NCT00385853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-013|PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs|A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma||Massachusetts General Hospital|Yes|Completed|September 2006|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|October 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00385853||178009|
NCT00386620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0595|Spousal Relationships and Pain in Metastatic Breast Cancer|Spousal Relationships and Pain in Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Completed|October 2004|||July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|548|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women diagnosed with metastatic breast cancer and their male spouse or significant other|July 2015|July 6, 2015|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00386620||177952|
NCT00388466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-005|Whole Body Vibration - a New Therapeutic Approach to Improve Muscle Function in CF|Cystic Fibrosis: Improvement of Muscle Force and Function by Whole Body Vibration Exercise||University of Cologne||Completed|June 2005|August 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 13, 2006|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388466||177813|
NCT00403065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000517194|Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery|Quality of Life After Radiotherapy & Steroids. A Phase III Multi-Centre Randomised Controlled Trial to Assess Whether Optimal Supportive Care Alone (Including Dexamathasone) is As Effective as Optimal Supportive Care (Including Dexamethasone ) Plus Whole Brain Radiotherapy in the Treatment of Patients With Inoperable Brain Metastases From Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|October 2006|March 2013|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Both|18 Years|N/A|No|||January 2007|August 23, 2013|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00403065||176714|
NCT00422578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9113|Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction|Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy||Eli Lilly and Company||Completed|October 2004|September 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Male|18 Years|N/A|No|||October 2007|October 23, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00422578||175247|
NCT00386009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11233|Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|October 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Male|40 Years|N/A|No|||July 2009|July 1, 2009|October 9, 2006|Yes|Yes||No|May 4, 2009|https://clinicaltrials.gov/show/NCT00386009||177997|
NCT00418301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0305|Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain|Changes in Regional Cerebral Blood Flow as an Indicator of Neuronal Activity in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain||Boston Scientific Corporation|No|Completed|January 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00418301||175572|
NCT00418535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-10-08|Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma|A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma||Samsung Medical Center||Completed|April 2006|July 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||January 2007|October 20, 2009|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418535||175554|
NCT00419666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18102|A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis|PK and PD of Calcitriol Following Twice Daily Application of Calcitriol 3 µg/g Ointment Under Conditions of Maximal Use in Adolescents With Plaque Psoriasis||Galderma||Completed|August 2006|November 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|12 Years|17 Years|No|||April 2011|March 8, 2012|January 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00419666||175468|
NCT00419926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2419|Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients|A Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Therapeutic Benefit of an Initially Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Dosing Regimen, in Combination With Cyclosporine and Corticosteroids in de Novo Renal Transplant Patients||Novartis||Completed|December 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|313|||Both|18 Years|65 Years||||February 2011|February 25, 2011|January 8, 2007||Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00419926||175448|
NCT00419679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT3.6k-2006|Use of Hair to Diagnose Breast Cancer|A Prospective Blinded Study to Evaluate and Characterise an Assay for the Diagnosis of Breast Cancer Using Synchrotron-Derived X-Ray Diffraction of Hair Fibres.||Fermiscan Ltd||Recruiting|December 2006|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||3600|||Female|20 Years|N/A|No|||January 2007|January 7, 2007|January 7, 2007||||No||https://clinicaltrials.gov/show/NCT00419679||175467|
NCT00419939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-RHN-01|Intensive Rehabilitation of Patients With Severe Traumatic Brain Injury - Development of a Didactic Model|Improvement of the Interaction Between Motivation, Involvement and Re-learning of Daily Life Competences During the Intensive Neurorehabilitation of Patients With Severe TBI. Development of a Research-based Didactic Model.||University of Aarhus|No|Completed|February 2007|June 2011|Actual|June 2011|Actual|Phase 0|Observational|Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), >18 år, PTA phase at the        end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing|June 2011|June 20, 2011|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00419939||175447|
NCT00420186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-004|A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-690514 in Combination With Paclitaxel and Carboplatin for Patients With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|October 2007|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|January 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00420186||175428|
NCT00388908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-MOP-79325|Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures|Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures: The AVOID FRACTURE Study|AVOID Fracture|University of Alberta|No|Completed|November 2006|July 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|60 Years|N/A|No|||July 2015|July 25, 2015|October 16, 2006||No||No||https://clinicaltrials.gov/show/NCT00388908||177779|
NCT00389428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTR0305-101|Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.|Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies.||Celator Pharmaceuticals||Completed|September 2006|December 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|October 16, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00389428||177739|
NCT00389740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-189|A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)|A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women With Osteoporosis||Merck Sharp & Dohme Corp.||Completed|April 2001|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|400|||Female|40 Years|N/A|No|||October 2015|October 30, 2015|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389740||177717|
NCT00389402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-IAT-0110|BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes|A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen.||International Antiviral Therapy Evaluation Center|No|Completed|July 2006|July 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389402||177741|
NCT00389701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000509044|Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment|Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy||National Cancer Institute (NCI)||Recruiting|March 2006|||December 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2009|January 9, 2014|October 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389701||177720|
NCT00386334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-904|A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia|A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia||Sunovion|No|Completed|October 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|388|||Both|65 Years|85 Years|No|||February 2016|February 12, 2016|October 9, 2006|Yes|Yes||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00386334||177973|The data gathered was subjective (except for actigraphy endpoints) and relied either on self reporting or patient assessments derived from standardized questionnaires.
NCT00386633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-POL-001|Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection|Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of Two Different Doses of a Recombinant MVA HIV Polytope Vaccine (MVA-mBN32) in HIV-negative 18-50 Year Old Healthy Volunteers||Bavarian Nordic|No|Completed|October 2006|November 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|October 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00386633||177951|
NCT00388232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Gunen|Prevalence of COPD: First Epidemiological Data From a Large Region of Turkey|Inonu University, The Department of Pulmonary Medicine||Inonu University||Completed||||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||1200|||Both|18 Years|N/A||||October 2006|October 13, 2006|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388232||177831|
NCT00389012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025024|Strength Training Effectiveness Post-Stroke (STEPS)|Strength Training Effectiveness Post-Stroke (STEPS)||University of Southern California||Active, not recruiting|May 2004|January 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||October 2006|October 16, 2006|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00389012||177771|
NCT00402779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0824|Erlotinib Prevention of Oral Cancer (EPOC)|Erlotinib Prevention of Oral Cancer (EPOC)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2006|||November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402779||176736|
NCT00402519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEC-ESTRO APBI Trial|APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer|Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast||University of Erlangen-Nürnberg Medical School||Active, not recruiting|November 2004|November 2019|Anticipated|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1300|||Female|40 Years|N/A|No|||December 2014|December 2, 2014|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00402519||176756|
NCT00418561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhASA-01|Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)|A Single Center, Open-label, Non-randomized, Uncontrolled, Multiple-dose, Dose Escalation Study of the Safety, Pharmacokinetics and Efficacy of Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)||Shire|Yes|Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|1 Year|5 Years|No|||February 2014|July 16, 2015|January 4, 2007||No||No|July 16, 2015|https://clinicaltrials.gov/show/NCT00418561||175552|ASA activity in leukocytes could not be included in basic results format as the results were presented graphically. Due to quick disappearance of rhASA from plasma, rhASA levels were not possible to report.
NCT00418574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABA-01|Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients|A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy|MIMOSA|Menarini Group|Yes|Terminated|December 2006|June 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|888|||Female|18 Years|N/A|No|||November 2011|November 17, 2011|January 4, 2007|Yes|Yes|No benefit on primary end point (RFS); no rationale to collect survival data|No|July 1, 2011|https://clinicaltrials.gov/show/NCT00418574||175551|
NCT00386022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-P-002498|The Effects of Aging and Estrogen on the Brain|Pituitary Contribution to the Decline in Gonadotropin Secretion With Age||Massachusetts General Hospital|Yes|Active, not recruiting|January 2002|January 2018|Anticipated|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|60|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|October 6, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00386022||177996|
NCT00418548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-314|Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis|A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly Compared With 25 mg Twice Weekly in Subjects With Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2004|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||350|||Both|18 Years|70 Years|No|||January 2007|January 4, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00418548||175553|
NCT00418834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-112|Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)|A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHD||Merck Sharp & Dohme Corp.||Completed|January 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1053|||Both|65 Years|N/A|No|||October 2015|October 30, 2015|January 3, 2007|Yes|Yes||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00418834||175531|
NCT00419393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01281|Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures|An Open-label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-onset Seizures||UCB Pharma|No|Completed|December 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|12 Years|75 Years|No|||June 2011|August 26, 2014|January 4, 2007|Yes|Yes||No|March 25, 2011|https://clinicaltrials.gov/show/NCT00419393||175488|
NCT00419406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2466|Medium-Dose UVA1 Versus Narrow-Band UVB in Atopic Dermatitis|Medium-Dose UVA1 Versus Narrow-Band UVB Phototherapy: A Randomized Double-Blind Controlled Cross-Over-Study||Ruhr University of Bochum|No|Completed|March 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||January 2009|January 21, 2009|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00419406||175487|
NCT00387504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000508770|Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors|Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors||California Cancer Consortium||Completed|November 2006|||July 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00387504||177885|
NCT00388115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000505536|Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ|A Pilot Study of Radiofrequency Ablation of Early Invasive and In Situ Breast Cancer||University of California, Davis|Yes|Completed|October 2001|May 2007|Actual|May 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2010|March 25, 2010|October 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00388115||177840|
NCT00388388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPC030|Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects|Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects||Sir Mortimer B. Davis - Jewish General Hospital|Yes|Terminated|March 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|25 Years|70 Years|No|||May 2015|May 18, 2015|October 13, 2006||No|Few subjects recruited, sponsor withdrew support.|No||https://clinicaltrials.gov/show/NCT00388388||177819|
NCT00388648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBs2000|Very Low Protein Diet or Dialysis in Uremic Elderly?|Efficacy and Safety of a Very Low Protein Diet in Postponing Dialysis in Elderly: a Prospective Randomized Multicenter Controlled Study||Università degli Studi di Brescia||Completed|January 2000|July 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||160|||Both|70 Years|95 Years|No|||October 2006|October 16, 2006|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00388648||177799|
NCT00389155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA183-002|First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy|A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy||Bristol-Myers Squibb|Yes|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00389155||177760|
NCT00389415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1303E1|Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes|A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin (100 mg qd) In Patients With Type 2 Diabetes (Extension Study of Study CLAF237A1303)||Novartis||Completed|October 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|20 Years|N/A||||November 2008|November 26, 2008|October 16, 2006||||No||https://clinicaltrials.gov/show/NCT00389415||177740|
NCT00390039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-003|Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery|Randomized, Double-Blind, Active- and Placebo-Controlled Study of Analgesic Efficacy and Safety of Repeated Dosing of MNS075 (Intranasal Morphine), IV Morphine, and Placebo in Acute Post-Operative Pain After Elective Orthopedic Surgery||Javelin Pharmaceuticals|No|Completed|May 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|256|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|October 17, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00390039||177695|
NCT00389753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/326|Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure|A Prospective, Randomized, Double Blinded Controlled Clinical Trial of the Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure||University Hospital, Ghent|No|Suspended||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|25|||Both|3 Years|75 Years|No|||September 2010|September 28, 2010|October 18, 2006||No|study never started|No||https://clinicaltrials.gov/show/NCT00389753||177716|
NCT00389714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191055nano HMO-CTIL|Clinical Evaluation of Esthetic Restorations Placed in Primary Molars With Composite Resin Enriched With Insoluble Anti Bacterial Nano Particles|Phase 2 Clinical Study :Evaluation of the Efficacy of Insoluble Antibacterial Nanoparticles Incorporated Into Commercialy Used Composit Resins as an Esthetic Restoration Material in Children|IABN|Hadassah Medical Organization||Not yet recruiting|February 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|60|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||December 2007|December 10, 2007|October 18, 2006||||No||https://clinicaltrials.gov/show/NCT00389714||177719|
NCT00390026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA001|The Avastin vs Visudyne for Neovascular AMD Study|A Prospective, Randomized, Double-Masked, Controlled Study on Intravitreal Bevacizumab (Avastin) Versus Verteporfin (Visudyne) Photodynamic Therapy (PDT) for Patients With Neovascular Age-Related Macular Degeneration (AMD)||St. Erik Eye Hospital||Withdrawn|November 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|50 Years|N/A|No|||May 2007|May 24, 2007|October 17, 2006|||Lucentis, a treatment superior to PDT, has become available i Sweden.|No||https://clinicaltrials.gov/show/NCT00390026||177696|
NCT00386347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRZ108532|A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.|A Single Dose, Randomized, 5-Period, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK364735 and Pharmacokinetics Following a Double Blind, Placebo Controlled, Repeat Dose Administration to Healthy Subjects.||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 6, 2006||||||https://clinicaltrials.gov/show/NCT00386347||177972|
NCT00388245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0213/P01/2006/31|Revascularization in Heart Failure Trial – REHEAT 2|Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery||Ministry of Science and Higher Education, Poland||Not yet recruiting|January 2007|December 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|19 Years|90 Years|No|||October 2006|October 13, 2006|October 13, 2006||||No||https://clinicaltrials.gov/show/NCT00388245||177830|
NCT00389246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WR001|Evaluation of Consultation Including Genetic Aspects of Obesity|Evaluation of Consultation Including Genetic Aspects of Obesity||Philipps University Marburg Medical Center||Completed|September 2002|June 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2006|October 17, 2006|October 17, 2006||||No||https://clinicaltrials.gov/show/NCT00389246||177753|
NCT00402792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-765|A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy|A Randomized, Multicenter, Double-blind Study Comparing the Analgesic Efficacy and Safety of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) to Placebo in Subjects With Acute Pain Following Bunionectomy||Abbott|No|Completed|December 2006|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|65 Years|No|||January 2011|January 24, 2011|November 20, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00402792||176735|
NCT00418041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-115|Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)|Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)||Tohoku University|Yes|Active, not recruiting|October 2006|December 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|20 Years|N/A|No|Probability Sample|Patients in teaching hospitals|May 2015|May 11, 2015|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418041||175592|
NCT00422552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2211|Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol|An Exploratory, Double-Blind Comparison of Inspiratory Capacity (IC) and FEV1 in COPD Patients Following Single Dose Administration of Indacaterol and Placebo and Open Label b.i.d. Administration of Formoterol||Novartis||Completed|September 2006|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|40 Years|80 Years|No|||June 2007|June 21, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00422552||175249|
NCT00422565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0137|Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients|Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients|ZEST-AMI|CardioVascular Research Foundation, Korea|Yes|Terminated|October 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|328|||Both|18 Years|N/A|No|||January 2009|January 30, 2009|January 16, 2007||No|The recruitment rate was much slower than expected.|No||https://clinicaltrials.gov/show/NCT00422565||175248|
NCT00418860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-09-025|The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent|The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease (DATE Registry)|DATE|Samsung Medical Center|Yes|Completed|September 2006|April 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Both|N/A|N/A|No|||August 2011|August 10, 2011|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418860||175529|
NCT00387205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG105430|Study To Assess Long Term Safety Of Pazopanib|An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients||Novartis|No|Active, not recruiting|June 2006|December 2016|Anticipated|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|October 10, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00387205||177908|
NCT00387218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD043770|Exercise Study For People With Parkinson's Disease|Exercise, Physical Function, and Parkinson's Disease||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|December 2002|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|170|||Both|30 Years|N/A|No|||May 2008|May 21, 2008|October 11, 2006||||No||https://clinicaltrials.gov/show/NCT00387218||177907|
NCT00388128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001902-10|Caffeine and Intermittent Claudication|Effects of Caffeine in Patients With Intermittent Claudication.||University of Aarhus|Yes|Completed|September 2006|September 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|40 Years|N/A|No|||June 2011|June 8, 2011|October 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00388128||177839|
NCT00388401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14CL313|Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus|A Multicenter Phase III, Double-Blind, Placebo-Controlled, Parallel Study of ADL-8-2698 in Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus||Cubist Pharmaceuticals LLC|No|Completed|January 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||510|||Both|18 Years|N/A|No|||October 2008|July 16, 2015|October 13, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00388401||177818|
NCT00388921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005033|High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM|||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed|October 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||260|||Both|6 Months|59 Months|No|||November 2005|October 16, 2006|October 15, 2006||||No||https://clinicaltrials.gov/show/NCT00388921||177778|
NCT00422058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-1807|The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes|Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period||Novo Nordisk A/S|No|Completed|January 2007|April 2009|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|564|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|January 12, 2007|Yes|Yes||No|April 27, 2010|https://clinicaltrials.gov/show/NCT00422058||175287|
NCT00418145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 01-0781|Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks|Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)||Icahn School of Medicine at Mount Sinai|No|Terminated|September 2003|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|50 Years|No|||October 2013|October 25, 2013|January 2, 2007|Yes|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT00418145||175584|
NCT00418158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|poho studie|Pulmonary Complications After Heart Surgery.|Pulmonary Complications After Heart Surgery||Catharina Ziekenhuis Eindhoven||Completed|December 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|No|||November 2009|November 9, 2009|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418158||175583|
NCT00418431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0016|Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy|||Asociación para Evitar la Ceguera en México||Recruiting|April 2006|August 2006||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|50 Years||||June 2006|January 3, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418431||175562|
NCT00418717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-321|Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA|An Open-label, Multicenter, Dose-regimen Study Evaluating the Efficacy and Safety of Etanercept 50 mg Once-weekly Dose in Japanese Subjects With Rheumatoid Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|75 Years|No|||March 2012|March 1, 2012|January 2, 2007||No||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00418717||175540|
NCT00418691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0925|Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning|Assessing the Efficacy of Immediate Release Methylphenidate, Sustained Release Methylphenidate and Modafinil for Patients With Brain Tumors||M.D. Anderson Cancer Center|No|Terminated|February 2004|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|January 3, 2007||No|Closed early due to slow accrual.|No|January 10, 2011|https://clinicaltrials.gov/show/NCT00418691||175542|Early termination lead to limited analysis.
NCT00418704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC 05-04|Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression.||Groupe Francais De Pneumo-Cancerologie|No|Completed|May 2006|June 2009|Actual|June 2006|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|65 Years|N/A|No|Non-Probability Sample|Patients with non small-cell lung cancer stage IV and IIIB (T4 with pleural effusion) in        elderly independent patients évaluant|September 2013|September 29, 2013|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00418704||175541|
NCT00418977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 04-0978|Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents|Early Identification and Treatment of Anorexia Nervosa||Icahn School of Medicine at Mount Sinai|No|Completed|September 2005|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|10 Years|17 Years|No|||November 2015|November 19, 2015|January 3, 2007||No||No|March 10, 2014|https://clinicaltrials.gov/show/NCT00418977||175520|Limitations include a small sample size and attrition leading to missing end-of-intervention data. In addition, participation with follow-up evaluations was poor.
NCT00418964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK00001|Clinical Trial Comparing Three Anterior Cruciate Ligament Reconstructive Procedures|Functional, Clinical & Radiological Outcome of Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Control Clinical Trial Studies Comparing Bone Patella Bone, Single Bundle and Double Bundle Method.||Chinese University of Hong Kong|No|Completed|December 2006|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|62|||Male|18 Years|40 Years|No|||March 2012|March 22, 2012|January 4, 2007||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00418964||175521|
NCT00419211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A06-B25-06A|An Intervention Study to Increase Physical Activity and Maternal Well-being During Pregnancy|"Fit Pregnancy": A Transtheoretical-Model Based Intervention Designed To Increase Physical Activity and Maternal Well-Being During Pregnancy||McGill University||Completed|January 2007|||December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|76|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00419211||175502|
NCT00419536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589A2105|Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone|A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC)||Novartis||Terminated|May 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||108|||Male|18 Years|N/A|No|||April 2010|April 7, 2010|January 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00419536||175478|
NCT00419783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459-09|A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine|A Phase 1, Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic Effects of Bilastine in Healthy Adult Subjects||Faes Farma, S.A.|No|Completed|August 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|January 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00419783||175459|
NCT00430287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-775|Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?|Correlation of DDLS Grading to OCT, HRT, and HVF||Wills Eye|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|101|||Both|45 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|glaucoma service|November 2008|January 25, 2010|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00430287||174671|
NCT00430586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0527/1|Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Determine the Optimal Dose of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines||Merz Pharmaceuticals GmbH||Completed|November 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|191|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|February 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00430586||174649|
NCT00430599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3384|The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis|||Newcastle-upon-Tyne Hospitals NHS Trust||Completed|February 2007|September 2009|Actual|||Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|60 Years|No|Probability Sample|Patients with multiple sclerosis and clinical evidence of cerebellar tremor.|October 2015|October 7, 2015|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00430599||174648|
NCT00420641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SND 103288|MDD POC Study GSK372475 Subjects Depressive Disease|A Ten-week, Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled, Paralleled-Group, Flexible-Dose Study Evaluating the Efficacy, Safety and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed With Major Depressive Disorder||GlaxoSmithKline|No|Completed|December 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|492|||Both|18 Years|64 Years|No|||June 2014|October 2, 2014|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00420641||175394|
NCT00421824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0098|Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer|Phase II Randomized Trial of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer||Sanofi||Completed|May 2006|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|75 Years|No|||January 2011|January 3, 2011|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421824||175305|
NCT00422136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC005630|Genetics of Middle Ear Disease|Genetic Epidemiology of Otitis Media||Children's Hospital of Pittsburgh|No|Completed|July 2002|July 2009|Actual|July 2007|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|2121|Samples With DNA|Blood samples, DNA|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Families with 2 or more full sibs who had tympanostomy tubes inserted|November 2011|November 11, 2011|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422136||175281|
NCT00418184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-Omega3-2|The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder||Enzymotec||Completed|March 2007|November 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|6 Years|13 Years|No|||January 2010|February 12, 2014|December 31, 2006||No||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00418184||175581|
NCT00418197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0051|Total Facet Arthroplasty System®(TFAS®) Clinical Trial|A Prospective and Randomized Controlled Trial to Evaluate the Safety and Effectiveness of Total Facet Arthroplasty in the Treatment of Degenerative Spinal Stenosis||Archus Orthopedics, Inc.||Active, not recruiting|August 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|450|||Both|50 Years|85 Years|No|||February 2009|February 4, 2009|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00418197||175580|
NCT00421798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0042 transfer from DMID|Rapid Characterization of Paucibacillary TB Along Tex/Mex Border|Rapid Characterization of Mycobacteria and Drug Resistance In Paucibacillary TB||The University of Texas Health Science Center, Houston|No|Completed|January 2007|May 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|780|Samples With DNA|Blood from participants will be collected, and DNA extracted from white blood cells. These      are expected to also contain DNA from M. tuberculosis- that will be the research question|Both|18 Years|85 Years|No|Non-Probability Sample|Studies will be conducted in the population from the TExas-Mexico border, and in Colombia.        Participants are TB suspects, or controls.|July 2009|July 8, 2009|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421798||175307|
NCT00421772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-05-03|Prospective Follow-up of a Multicentric Cohort of Children With Prenatal Discovery of Mild Isolated Cerebral Ventriculomegaly. Evaluation at 2 and 5 Years.|Prospective Follow-up of a Multicentric Cohort of Children With Prenatal Discovery of Mild Isolated Cerebral Ventriculomegaly. Evaluation at 2 and 5 Years.||University Hospital, Angers||Recruiting|January 2007|January 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||245|||Both|22 Months|26 Months|Accepts Healthy Volunteers|||January 2007|January 11, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421772||175309|
NCT00421785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346147CTIL|Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients|Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients.||Assaf-Harofeh Medical Center||Recruiting|February 2007|January 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|85 Years|No|||July 2007|July 6, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421785||175308|
NCT00422396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|877-017|Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis|Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis||University of Michigan||Completed|January 2001|April 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|January 12, 2007|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00422396||175261|
NCT00419003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0850|Research Study for Major Depressive Disorder: Investigation of Glutamate Medications|Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression||Baylor College of Medicine|No|Completed|December 2006|September 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|70 Years|No|||February 2016|February 19, 2016|January 4, 2007|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00419003||175518|The open-label administration of ketamine limits interpretation of phase 1 results. The sample size was too small to detect moderators and mediators of response. Third,lack of placebo-controlled efficacy data supporting riluzole's use in depression.
NCT00419016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4489-RG-CTIL|Association Between Schizophrenia and Cancer|||Sheba Medical Center||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|No|||January 2007|January 4, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00419016||175517|
NCT00419250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CLL-001|A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia|A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia||Celgene|Yes|Completed|December 2006|June 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|52|||Both|18 Years|N/A|No|||August 2013|August 26, 2013|January 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00419250||175499|
NCT00418990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-681|Effect of Vitamins on Academic Performance of School Children|Effect of a Randomized Trial of Multivitamin-Mineral Supplementation on Standardized Assessment of Academic Performance in Elementary School Children||Rutgers, The State University of New Jersey||Completed|August 2003|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1600|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||January 2007|January 4, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418990||175519|
NCT00419224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4675|Influenza Vaccination in Bone Marrow Transplantation|Immunogenicity of Influenza Vaccination (Flu Vac) in Patients Receiving Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NM Allo PBSCT) Compared to Healthy Controls||The Cleveland Clinic||Completed|October 2002|April 2003||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2007|January 9, 2007|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419224||175501|
NCT00419237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFA10013|Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function|A Study to Investigate the Pharmacokinetics of a Single Inhaled Dose (400mcg) of GW685698X and Its Effect on Serum Cortisol in Patients With Impaired Liver Function and Matched Control Subjects.||GlaxoSmithKline||Completed|January 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419237||175500|
NCT00419549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-ERCP-AP/2006|Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)|Effect of Transdermal Glyceryl-Trinitrate and Parecoxib (Valdecoxib) for the Prevention of Post -ERCP Pancreatitis||All India Institute of Medical Sciences, New Delhi|No|Terminated|October 2003|September 2005|Actual|September 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|371|||Both|18 Years|N/A|No|||January 2009|January 28, 2009|January 5, 2007||No|Because one of the drugs Valdecoxib was withdrawn due to safety concerns.|No||https://clinicaltrials.gov/show/NCT00419549||175477|
NCT00419809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA1101607|SB-681323-Methotrexate Interaction Study|A Placebo Controlled Study to Evaluate the Safety and Tolerability of Repeat Doses of SB-681323 in Patients Receiving Methotrexate for Rheumatoid Arthritis.||GlaxoSmithKline||Completed|May 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|18|||Both|18 Years|75 Years|No|||January 2012|May 31, 2012|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419809||175457|
NCT00431704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VinCaT|VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer|Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study|VinCaT|National Cancer Institute, Naples|No|Active, not recruiting|October 2007|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|18 Years|75 Years|No|||November 2015|November 27, 2015|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431704||174564|
NCT00431717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0609/037-019|Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes|Study Comparing Coronary Computed Tomography Angiography and SPECT to Detect Subclinical Coronary Atherosclerosis in Asymptomatic Diabetes||Seoul National University Bundang Hospital|Yes|Completed|November 2006|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Asymptomtaic type 2 diabetes mellitus with multiple risk factors|August 2008|August 22, 2008|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431717||174563|
NCT00427635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9614C00004|Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients|A Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of Esomeprazole Once Daily for the Treatment of Gastroesophageal Reflux Disease (GERD) in Neonatal Patients, Including Premature and up to 1 Month Corrected Age||AstraZeneca||Completed|October 2006|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|32|||Both|N/A|1 Month|No|||December 2010|December 2, 2010|January 25, 2007||||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00427635||174868|
NCT00421538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B0-105991|Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)|Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography|CACTUS-PTS|University Hospital, Geneva|Yes|Recruiting|January 2008|September 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421538||175327|
NCT00421213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL2003|Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers|Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers||Ziopharm||Completed|December 2006|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421213||175351|
NCT00421226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A1101|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Demonstrate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered as Intravenous Infusion and Subcutaneous Injection in Japanese Healthy Volunteers||Novartis||Completed|December 2006|December 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 27, 2012|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421226||175350|
NCT00422149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG/0021|Twin SUBLIVAC® Grasses Clinical Efficacy Study|Twin SUBLIVAC® Grasses Clinical Efficacy Study||HAL Allergy|Yes|Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|12 Years|N/A|No|||February 2012|February 6, 2012|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422149||175280|
NCT00422162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10614|A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression|An Eight-Week, Randomized, Double Blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 Per Day in Patients Hospitalized for Severe Depression||Eli Lilly and Company||Completed|February 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|339|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|January 11, 2007|Yes|Yes||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00422162||175279|
NCT00422175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312A2101|Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312|A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers||Novartis||Completed|October 2006|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||63|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|November 28, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00422175||175278|
NCT00422448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V9-B05 (FWF)|Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.|BRAF and Nevi.Nevi Are Common Benign Pigmented Tumors of the Skin. Mutations in So-called BRAF and NRAS Genes Genes Appear to be Initiating Events Responsible for the Formation of Nevi.||Medical University of Graz|Yes|Completed|September 2006|April 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|43|||Both|9 Years|80 Years|Accepts Healthy Volunteers|||December 2010|December 14, 2010|January 15, 2007||No||No|April 25, 2010|https://clinicaltrials.gov/show/NCT00422448||175257|During first year of enrollment too few patients agreed to participate. Therefore a sample of 21 nevi were additionally retrospectively included.
NCT00422461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7331007|A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure|A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study Of PF-00489791 In Subjects With Stage 1 And 2 Essential Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)||Pfizer|No|Completed|February 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|140|||Both|18 Years|70 Years|No|||October 2009|October 7, 2009|January 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00422461||175256|
NCT00418210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 06.02|Accelerated Partial Breast Irradiation for Early Breast Cancer|A Multicentre Feasibility Study of Accelerated Partial Breast Irradiation Using Three-dimensional Conformal Radiation Therapy for Early Breast Cancer.||Trans-Tasman Radiation Oncology Group (TROG)|Yes|Active, not recruiting|August 2007|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Female|50 Years|N/A|No|||January 2016|January 18, 2016|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00418210||175579|
NCT00418223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lukasse-2006|Detecting Urinary Retention After Child Birth With a Ultrasound Scanner|Detecting Urinary Retention After Child Birth With a Ultrasound Scanner||Oslo University Hospital||Completed|November 2005|February 2007||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|50 Years|No|Non-Probability Sample|Women after childbirth|April 2011|April 18, 2011|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00418223||175578|
NCT00421811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHX-01-007|A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan|An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).||Adherex Technologies, Inc.||Completed|April 2007|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||December 2010|December 27, 2010|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421811||175306|
NCT00422097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-111|A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer|A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer||R-Pharm||Completed|January 2007|April 2011|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 12, 2007|No|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00422097||175284|
NCT00422071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070063|Detecting a Reward Signal in the Motor Cortex|Detecting a Reward Signal in the Motor Cortex||National Institutes of Health Clinical Center (CC)||Completed|January 2007|March 2014||||N/A|Observational|N/A|||Actual|168|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422071||175286|
NCT00422084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-005-06|Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients|A Phase III Comparative, (Double-Blind, Double-Dummy), Randomised, Multi-Centre, Clinical Study to Assess the Safety and Efficacy of Fixed Dose Formulation of Oral Pyronaridine Artesunate Tablet (180:60 mg) Versus Coartem® (Artemether Lumefantrine) in Children and Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria||Medicines for Malaria Venture||Completed|January 2007|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1269|||Both|3 Years|60 Years|No|||May 2008|May 19, 2008|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422084||175285|
NCT00422409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|672|Endoscopic Stenting of Gastrointestinal Cancer|Palliative Endoscopic Treatment of Malignant GI-strictures With Self Expanding Metal Stents(SEMS)-a Prospective Multicenter Study||Oslo University Hospital||Completed|October 2006|April 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|270|||Both|18 Years|N/A|No|||April 2007|July 3, 2011|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00422409||175260|
NCT00419263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-211|Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.|A Phase II, Multicenter, Randomized, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza.||BioCryst Pharmaceuticals|Yes|Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|344|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|January 4, 2007|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00419263||175498|
NCT00419575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0867|Renal Transplantation With Immune Monitoring|Renal Transplantation With Immune Monitoring||Washington University School of Medicine||Completed|October 2006|May 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Kidney transplant recipients.|June 2008|June 4, 2008|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419575||175475|
NCT00419562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral Insulin (IND)|Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus|Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|February 2007|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|3 Years|45 Years|No|||January 2016|January 15, 2016|January 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00419562||175476|
NCT00419822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA-TCM-001|Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients|A Randomized, Intent to Treat, Controlled Study of the Efficacy of Verum Acupuncture Compared to Sham Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Subjects That Have Undergone Axillary Surgery||Legacy Health System||Completed|September 2006|||March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Female|21 Years|N/A|No|||May 2010|June 30, 2011|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00419822||175456|
NCT00420056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481002|An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.|A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma||Pfizer|No|Completed|May 2007|March 2012|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|99 Years|No|||October 2015|October 6, 2015|January 5, 2007|No|Yes||No|March 4, 2015|https://clinicaltrials.gov/show/NCT00420056||175438|Results are reported for change from baseline in maximum standard uptake value (SUVmax) instead of percent change from baseline in SUVmax.
NCT00420069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|di123HMO-CTIL|Biphasic Extrathoracic Cuirass Ventilation During Dental Treatment|Biphasic Extrathoracic Cuirass Ventilation During Dental Treatment Under Deep Sedation||Hadassah Medical Organization||Withdrawn|July 2008|December 2009|Anticipated|||N/A|Observational|N/A|||Anticipated|20|||Both|12 Months|6 Years|Accepts Healthy Volunteers|||January 2007|May 19, 2008|January 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00420069||175437|
NCT00420342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91507|Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension|A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension||Bayer|No|Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|92|||Female|45 Years|65 Years|No|||May 2015|May 11, 2015|January 9, 2007|Yes|Yes||No|October 28, 2009|https://clinicaltrials.gov/show/NCT00420342||175417|Small sample size, as this was a pilot study.
NCT00420667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery|Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery||G. d'Annunzio University||Completed|November 2004|May 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|35 Years|75 Years|No|||January 2007|January 8, 2007|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00420667||175392|
NCT00420680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05934|Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)(COMPLETED)|A Multi -Center, Randomized, Parallel-Group, Placebo-Controlled, Safety Assessor-Blinded Trial, Evaluating the Safety and Efficacy of Sugammadex in Cardiac Patients||Merck Sharp & Dohme Corp.|No|Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420680||175391|
NCT00431483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AW2007|Clinical and Economic Impact of Interventions by a Clinical Pharmacist on Antibiotic Use on Surgical Wards|Clinical and Economic Impact of Interventions by a Clinical Pharmacist on Antibiotic Use on Surgical Wards||Ludwig-Maximilians - University of Munich|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|779|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00431483||174580|
NCT00431496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040196|A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)|A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management||Amgen||Completed|September 2006|October 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|February 1, 2007||||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00431496||174579|
NCT00431730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-121203|Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?|Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?||Medical University of Vienna|Yes|Completed|December 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2008|July 1, 2008|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431730||174562|
NCT00421265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138/06|Active Surveillance for Prostate Cancer With Indolent Features|Prospective Cohort Study of Active Surveillance for Prostate Cancer With Indolent Linical Features||Assaf-Harofeh Medical Center||Not yet recruiting||||||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Male|65 Years|80 Years|No|||January 2007|January 10, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00421265||175347|
NCT00421278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0633-008|The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)|A Clinical Study to Evaluate the Efficacy and Safety of MK0633 in Patients With Atherosclerosis||Merck Sharp & Dohme Corp.||Completed|November 2006|January 2007|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|180|||Male|40 Years|85 Years|No|||January 2016|January 21, 2016|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421278||175346|
NCT00421837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0092|Pilot Study of Genotypic Analysis|Pilot Study of the Genotypic Analysis of Patients Infected With Influenza Virus Compared With Uninfected Spouse/Close Contact Controls||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|6|Samples With DNA|Sera and saliva|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects > 55 yo hospitalized with Influenza vs healthy household members and close        contacts|April 2011|August 15, 2013|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421837||175304|
NCT00421850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1938-00|Using Networks, Informatics, Technology, and Education in Care for People With Diabetes|UNITED Planned Care for People With Diabetes||Mayo Clinic||Completed|July 2001|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||3491|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 20, 2011|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421850||175303|
NCT00422188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-06-04|Deoxycholic Acid Injection for the Treatment of Superficial Lipomas|Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of the Pharmacokinetics, Safety, and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas||Kythera Biopharmaceuticals|No|Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|16|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|January 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00422188||175277|
NCT00422201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070008|Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion|Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion||HRA Pharma||Terminated|December 2006|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|85 Years|No|||August 2013|October 14, 2013|January 12, 2007|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00422201||175276|As a consequence of the premature study end, analyses performed were primarily descriptive due to the reduced number of enrolled and completed patients.
NCT00422474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-95-C-012|Prognostic Significance of the Baroreflex Sensitivity Changes After Acute Ischemic Stroke|Noninvasive Study of the Time Course of Baroreflex Sensitivity 6-Month After Acute Ischemic Stroke and the Relation of Its Changes With Post Stroke Prognosis||Far Eastern Memorial Hospital||Recruiting|January 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|50 Years|80 Years|No|||July 2008|July 8, 2008|January 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00422474||175255|
NCT00418236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3068A1-400|Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density|Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2006|April 2010|Actual|||Phase 4|Observational|Time Perspective: Retrospective||||400|||Female|18 Years|63 Years|No|||December 2007|August 17, 2010|January 2, 2007||||||https://clinicaltrials.gov/show/NCT00418236||175577|
NCT00418249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#69 REV 00|Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women|Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women||Rabin Medical Center||Not yet recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Female|50 Years|N/A|No|||December 2006|January 3, 2007|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00418249||175576|
NCT00418171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281062|Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)|An International, Multicenter, Large Simple Trial (LST) To Compare The Cardiovascular Safety Of Ziprasidone And Olanzapine||Pfizer||Completed|February 2002|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18239|||Both|18 Years|N/A|No|||October 2009|October 23, 2009|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418171||175582|
NCT00422110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01272|A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures|A Phase IIb/III, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Seletracetam as Adjunctive Treatment in Subjects (≥16 to 70 Years Old) With Refractory Partial Onset Seizures.||UCB Pharma||Withdrawn|May 2008|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|16 Years|70 Years|No|||May 2012|May 25, 2012|January 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00422110||175283|
NCT00422123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D144CC00004|Phase 3 /Seroquel SR Acute Mania Monotherapy - US|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Mania||AstraZeneca||Completed|January 2007|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|447|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00422123||175282|
NCT00418730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOSH101-CLIN-AGA003|Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss|A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men||Neosil, Inc.||Completed|January 2007|April 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||May 2008|May 16, 2008|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418730||175539|
NCT00418743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC 05-01|Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)|A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC), Comparing Oral Combination Chemotherapy (CCNU, Cyclophosphamide, Etoposide) With Intravenous Association Chemotherapy.||Groupe Francais De Pneumo-Cancerologie|Yes|Recruiting|December 2005|May 2010|Anticipated|||Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|138|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Small-cell lung cancer who, after (at least) a first line of chemotherapy        based on platinum, had a partial response and then progressed, or who had a complete        response and then relapsed within three months following the last course of this        first-line therapy.|March 2010|March 8, 2010|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00418743||175538|
NCT00419276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAINfRE TKA Investigation|Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement|Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Arthroplasty: A Multicenter, Randomized, Triple-Masked, Placebo-Controlled Investigation||National Institute of General Medical Sciences (NIGMS)|Yes|Completed|April 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|75 Years|No|||September 2010|September 23, 2010|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00419276||175497|
NCT00419289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA20060179|Optimizing the Effect of COPD Rehabilitation|Rehabilitation of COPD Patients: Can the Effect be Prolonged by Follow-up and Continued Rehabilitation||Glostrup University Hospital, Copenhagen||Not yet recruiting|January 2007|June 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|N/A|N/A|No|||January 2007|January 4, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00419289||175496|
NCT00419302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-03B|To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.|||Mannkind Corporation||Completed|October 2003|April 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|70 Years|No|||October 2009|October 12, 2009|January 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00419302||175495|
NCT00419588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL054062-09A1|Growth of Airways and Lung Tissues in Premature and Healthy Infants|Growth of Airways and Lung Parenchyma||Indiana University|Yes|Recruiting|September 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|215|Samples With DNA|Buccal Cells are being obtained.|Both|2 Months|24 Months|No|Non-Probability Sample|We are recruiting premature infants from Riley Hospial for Children, Methodist Hospital        and IU NICu's. We also recruit from the Infant Lung Disease clinic at Riley Hospital for        Children. Healhy full term infant are recruited through advertisements.|November 2015|November 12, 2015|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419588||175474|
NCT00419848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|src-hmj-1385|the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris|the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris||hahid Beheshti University of Medical Sciences||Recruiting|August 2006|February 2008|Anticipated|January 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2008|January 28, 2008|January 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00419848||175454|
NCT00419835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST01|Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus|Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus||University of Sao Paulo||Completed|May 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|80|||Both|30 Years|N/A|No|||January 2007|August 3, 2011|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00419835||175455|
NCT00420082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA-2306/ACC|A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber|A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber||Faes Farma, S.A.|No|Completed|October 2006|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|55 Years|No|||April 2012|April 4, 2012|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00420082||175436|
NCT00420095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11423|A Study for Patients With Diabetes Mellitus (IOPA)|Comparison of HbA1c in Type 1 or Type 2 Diabetic Patients Using Insulin Treated Twice Daily With Either Insulin Lispro Low Mixture or Human Insulin Mix 30/70|IOPA|Eli Lilly and Company|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|70 Years|No|||June 2009|June 9, 2009|January 5, 2007|Yes|Yes||No|January 7, 2009|https://clinicaltrials.gov/show/NCT00420095||175435|
NCT00420355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12637|Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients|The Pharmacokinetics of Lopinavir/Ritonavir in Combination With Atazanavir in HIV-Infected Subjects||University of Oklahoma|No|Terminated|April 2007|September 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|60 Years|No|||February 2009|February 5, 2009|January 9, 2007||No|Unexpected adverse event|No||https://clinicaltrials.gov/show/NCT00420355||175416|
NCT00420693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/15|Interest of Using the Sevoflurane in the Prevention of Newborns Pain|Interest of Using the Sevoflurane in the Prevention of Newborns Pain||Assistance Publique Hopitaux De Marseille||Completed|August 2006|||May 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||January 2009|January 14, 2009|November 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00420693||175390|
NCT00420706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153A1-105|Study Evaluating SCA-136 Tolerability With Dose Titration and Food|A Multi-Dose, Double-Blind, Parallel-Group Study of the Effects of Dose Titration and Administration With Food on the Tolerability of SCA-136 in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|December 2006|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 6, 2007|January 8, 2007||||||https://clinicaltrials.gov/show/NCT00420706||175389|
NCT00435643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12383|Influence of nCPAP on Metabolic Consequences Associated With OSAS|Improvement in Hypothalamic-Pituitary-Adrenal Axis Function After Continuous Positive Airway Pressure Therapy in Obstructive Sleep Apnea Syndrome||Federal University of São Paulo|Yes|Completed|October 2004|March 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2007|November 19, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435643||174266|
NCT00435890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-091105|Triage Liaison Physician - Evaluation of a Novel Approach to Address Emergency Department Overcrowding|Randomized Controlled Trial of a Liaison Physician at the Triage Desk to Reduce Emergency Department Overcrowding and Improve Patient Flow.||University of Alberta|No|Completed|December 2005|June 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5718|||Both|17 Years|N/A|No|||September 2008|September 11, 2008|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00435890||174247|
NCT00435903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC #21-04|Pilot Study of the Feasibility of Palm Pilots in Monitoring Smoking Behavior in Individuals With Chronic Mental Illness|Pilot Study of the Feasibility of Palm Pilots in Monitoring Smoking Behavior in Individuals With Chronic Mental Illness||North Suffolk Mental Health Association||Active, not recruiting|June 2005|October 2005||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||11|||Both|18 Years|50 Years|No|||February 2007|May 14, 2009|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435903||174246|
NCT00421863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C 33|Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study|Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study||Heart Care Foundation|No|Completed|February 2005|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1111|||Both|55 Years|N/A|No|||March 2013|August 14, 2013|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00421863||175302|
NCT00422214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D144CC00002|Phase III/Seroquel SR Bipolar Depression Monotherapy - US|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression||AstraZeneca||Completed|December 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00422214||175275|
NCT00422227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-408|Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region|A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|70 Years|No|||July 2010|July 28, 2010|January 11, 2007||No||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00422227||175274|
NCT00422487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2044-20610|Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes|Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of MBX-2044 to Evaluate the Multiple-dose Pharmacokinetics, Safety and Tolerability When Administered Orally in Patients With Type 2 Diabetes||CymaBay Therapeutics, Inc.||Completed|October 2006|September 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|60|||Both|18 Years|70 Years|No|||April 2015|April 29, 2015|January 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00422487||175254|
NCT00422500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0701|Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer|Longitudinal Study of the Prevalence, Severity, and Interference of Multiple Symptoms in Advanced Lung Cancer||M.D. Anderson Cancer Center|No|Completed|November 2003|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|204|Samples With DNA|Study participants enrolled at M. D. Anderson will have additional serum drawn for cytokine      analysis and DNA repair capacity. This blood will be drawn at the routine blood draws before      treatment begins, and at the beginning of each treatment cycle.|Both|18 Years|N/A|No|Probability Sample|Study participants with advanced-stage lung cancer and disease- or treatment-related        symptoms.|August 2012|August 1, 2012|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422500||175253|
NCT00418457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-692|Regional Anesthesia and Breast Cancer Recurrence|Regional Anesthesia and Breast Cancer Recurrence||The Cleveland Clinic|Yes|Recruiting|January 2007|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1100|||Female|18 Years|85 Years|No|||February 2016|February 27, 2016|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418457||175560|
NCT00418444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCRA#017731|Body Image and Psychosocial Functioning in Women With Breast Cancer: Can We Fix What We've Broken?|Randomized Control Trial of a Group Therapy Intervention Addressing Body Image and Psychosocial Functioning for Women With Breast Cancer||University Health Network, Toronto||Completed|January 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|180|||Female|18 Years|65 Years|No|||January 2007|June 30, 2015|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00418444||175561|
NCT00419029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 06-004|Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment|Motivational Interviewing to Engage OEF/OIF Veterans in Mental Health Treatment||San Francisco Veterans Administration Medical Center|No|Completed|September 2007|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 25, 2014|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00419029||175516|
NCT00419042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC 05-05|Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase II Trial in NSCLC Stage IV et IIIB in Elderly Dependent Patients With Evaluation of the Sequence Gemcitabine First Line Followed by Erlotinib When Progression Versus Erlotinib First Line Followed by Gemcitabine When Progression.||Groupe Francais De Pneumo-Cancerologie|Yes|Completed|July 2006|March 2010|Actual|September 2006|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|65 Years|N/A|No|Non-Probability Sample|Patients with non small-cell lung cancer stage IV et IIIB (T4 with pleural effusion) in        elderly dependent patients|March 2010|September 29, 2013|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00419042||175515|
NCT00419601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKSK 251|Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants|Prospective Randomized, Double-blinded Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants||University of Cologne|No|Completed|November 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|N/A|60 Days|No|||May 2010|June 24, 2010|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419601||175473|
NCT00419861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0051|Inpatient Influenza Surveillance|Inpatient Surveillance for Influenza Infections in Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Nasal and throat swabs will be obtained and combined for viral culture, rapid antigen      testing, and PCR. Specimens obtained from hospitalized subjects will be tested for influenza      A & B viruses by viral culture, rapid antigen testing and Real-Time Reverse-Transcriptase      PCR (RTrtPCR) analysis.|Both|50 Years|N/A|No|Non-Probability Sample|Inclusion Criteria:          1. Adults >/= 50 years of age          2. Resident of Davidson County          3. Admitted to hospital during defined 24 hour periods          4. Patients with one or more of the following admission diagnoses (International             Classification of Diseases, 9th Revision Number): pneumonia (480-486), upper             respiratory infection (465), bronchitis (466), influenza (487), chronic obstructive             pulmonary disease (490 to 492;496), asthma (493), viral illness (079.9)[13], dyspnea             (786), acute respiratory failure (518.81), pneumonitis due to solids/liquids (507),             or fever (780.6) without localizing symptoms.        Exclusion Criteria:          1. Adults >/= 50 years residing outside the surveillance areas          2. Adults >/= 50 years not admitted on a surveillance day          3. Adults < 50 years of age          4. Anyone without the above admitting criteria.|January 2012|August 22, 2013|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419861||175453|
NCT00420108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.232|Optivol Diagnostic Data for Discharge in Heart Failure|Comparing ICD Device Diagnostics to Hospitalized Heart Failure Patient Symptoms and Physician Opinion on Discharge Readiness|3DHF|Thomas Jefferson University|No|Completed|December 2006|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|None Retained|No biospecimens to be retained|Both|18 Years|N/A|No|Probability Sample|The study population is hospitalized patients who have an implanted Medtronic device with        Optivol capability.|August 2010|August 18, 2010|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00420108||175434|
NCT00420368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-109796-a|Efficacy Trial on Alleviation of Infant Malnutrition With Fortified Spread or Maize-soy Flour Food Supplements|LCNI-6. A Single-centre Intervention Trial in Rural Malawi, Testing the Efficacy of Fortified Spread or Maize-soy Flour Supplementation to Alleviate Moderate Malnutrition Among 6-18 Month Old Children||University of Tampere|Yes|Completed|February 2007|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||189|||Both|6 Months|15 Months|No|||June 2012|June 17, 2012|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00420368||175415|
NCT00420381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10738|Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer|A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma||Eli Lilly and Company|Yes|Completed|January 2007|December 2014|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||March 2015|March 10, 2015|January 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420381||175414|
NCT00420394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR446006ctil|Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer|Phase II Study of Preoperative Chemotherapy and Postoperative Chemo-Radiation for Newly Diagnosed, Potentially Resectable Gastric Cancer||Soroka University Medical Center|Yes|Recruiting|April 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|75 Years|No|||January 2007|June 19, 2007|January 9, 2007||||No||https://clinicaltrials.gov/show/NCT00420394||175413|
NCT00420719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN 20-0009-0005|Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)|Multi-Center Pivotal Study of Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)||Synapse Biomedical||Active, not recruiting|October 2004|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 16, 2009|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420719||175388|
NCT00420953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101|Relative Bioavailability of PM101 IV and Cordarone IV|A Randomized, Double-Blind, 2-Period Crossover Trial to Determine the Relative Bioavailability of PM101 I.V. (Amiodarone HCl) and Cordarone I.V. in Healthy Adult Volunteers||Prism Pharmaceuticals||Completed|December 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||January 2008|January 14, 2008|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00420953||175370|
NCT00420966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|456-2005|Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy|Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers||Sunnybrook Health Sciences Centre|No|Recruiting|October 2005|||September 2016|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Children who have received at least one dose of palivizumab.|June 2015|June 16, 2015|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420966||175369|
NCT00421291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001063|Effect of Information on Service Delivery in Rural India|||Johns Hopkins University||Completed|April 2004|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|||||||Both|N/A|N/A||||January 2007|January 9, 2007|January 9, 2007||||No||https://clinicaltrials.gov/show/NCT00421291||175345|
NCT00432133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK70553|Individual and Environmental Mechanisms of PA Change|Behavioral 2X2 Randomized Controlled Trial to Determine Individual and Environmental Mechanisms of Physical Activity Behavior Change||Kaiser Permanente|Yes|Completed|February 2006|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|452|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 26, 2012|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00432133||174532|
NCT00435942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-0004-06|Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft|Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies||Bolton Medical|Yes|Active, not recruiting|January 2007|May 2015|Anticipated|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|February 14, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00435942||174243|
NCT00421902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYM # 325|Acupuncture Treatment for Hot Flashes Study|Acupuncture Treatment for Hot Flashes in Men With Prostate Cancer, A Phase I/II Study||New York Methodist Hospital||Recruiting|January 2006|July 2010||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Male|18 Years|N/A|No|||November 2006|January 12, 2007|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00421902||175299|
NCT00421915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-311|Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis|Multicenter, Double-Blind, Parallel, Placebo-Controlled, Randomised Phase 3 Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis: 12-Week Final Data||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2002|August 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||84|||Both|18 Years|70 Years|No|||January 2007|January 12, 2007|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00421915||175298|
NCT00421551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005962-38|Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136|A Randomized Multicenter Study With Non-inferiority Hypothesis, Comparing the Availability to Maintain a Complete Viral Suppression by a Monotherapy of Darunavir/r to a NRTI Containing Regimen Including Darunavir/r, in HIV-1 Infected Patients With Previous Prolonged Complete Viral Suppression. ANRS 136 MONOI||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|March 2007|February 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421551||175326|
NCT00421564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM/CTS/004|Study the Effect of Danggui Buxue Tang on Menopausal Symptoms|A Randomized, Double-Blind, Placebo Controlled Study of the Effect of Danggui Buxue Tang on Menopausal Symptoms and Quality of Life in Hong Kong Chinese Women||Chinese University of Hong Kong||Completed|February 2003|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Female|18 Years|N/A|No|||January 2007|January 11, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421564||175325|
NCT00421577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gum-HMO-CTIL|Technique for Localization of Caries Associated Bacteria on Tooth Surfaces.|Usage of Laboratory Technique for Localization of Caries Associated Bacteria on Tooth Surfaces as Clinical Measurement to Caries Diagnosis and Treatment Efficiency.||Hadassah Medical Organization||Not yet recruiting||||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|January 11, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421577||175324|
NCT00421876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60|GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study|GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study||Heart Care Foundation||Completed|December 2000|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||3200|||Both|18 Years|75 Years|No|||January 2007|January 12, 2007|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00421876||175301|
NCT00421889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-8|A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment|A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours||Onxeo|No|Completed|August 2005|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Female|18 Years|N/A|No|||July 2015|July 7, 2015|January 12, 2007|Yes|Yes||No|July 1, 2014|https://clinicaltrials.gov/show/NCT00421889||175300|
NCT00418522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171095|This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus|A Six Month, Open Label, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents||Pfizer|No|Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|413|||Both|30 Years|75 Years|No|||July 2009|September 8, 2009|January 3, 2007|Yes|Yes||No|July 30, 2009|https://clinicaltrials.gov/show/NCT00418522||175555|Due to cancellation of the EXUBERA program, the collected Patient Reported Outcome (PRO) data were not summarized, and no statistical analyses were performed.
NCT00410774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000517330|Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery|A Phase I/II Study of Fixed-Dose Rate Gemcitabine and Bevacizumab for Postoperative Adjuvant Treatment of Patients With Resected Pancreatic Cancer||University of California, San Francisco|Yes|Terminated|July 2006|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|December 11, 2006|Yes|Yes|low accrual-no data available|No||https://clinicaltrials.gov/show/NCT00410774||176134|
NCT00411125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC021A2111|Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women|A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Crossover Phase I Study Assessing Pharmacokinetics and Pharmacodynamics of Two Different SMC021 0.8 mg Variants and the Effect of Timing of Drug Intake in Healthy Postmenopausal Women||Novartis||Completed|August 2006|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||86|||Female|40 Years|70 Years||||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00411125||176109|
NCT00418795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhPBGD-02|Porphozym in the Treatment of Acute Attacks in AIP|A Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym(Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP||Zymenex A/S||Completed|February 2003|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2007|January 4, 2007|January 4, 2007||||Yes||https://clinicaltrials.gov/show/NCT00418795||175534|
NCT00418808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4067-OB-CTIL|Early Movements as a Predictor of Future Developmental Delay|Analysis of Movements of Singletons and Infants of Multiple Fetus Pregnancy as a Predictor of Developmental Delay||Sheba Medical Center||Recruiting|August 2006|August 2009||||Phase 1|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||50|||Both|N/A|4 Months|No|||January 2007|January 22, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00418808||175533|
NCT00418470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFC #19/2006|Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People|Prolonging the Duration on Site of Short Peripheral Venous Catheters Used to Administer Intravenous Antibiotics in Cystic Fibrosis Adults. Randomized Controlled Trial on the Effect of Different Concentrations of Antibiotic in Normal Saline||University of Florence|No|Terminated|March 2007|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|January 3, 2007||No|impossibility to find volunteers|No||https://clinicaltrials.gov/show/NCT00418470||175559|
NCT00418483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050003|A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion|A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion|PRIORITY|Grifols Therapeutics Inc.|Yes|Completed|March 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|83|||Both|18 Years|N/A|No|||July 2010|July 8, 2010|January 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00418483||175558|
NCT00418756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2115|Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects|A Phase I Open-label, Two Period, Single Center Study to Assess the Effect of 600 mg Daily Oral Dose of Rifampin (CYP3A4 Inducer) on the Pharmacokinetics of a Single 400 mg Oral Dose of Nilotinib in Healthy Subjects||Novartis||Completed|October 2006|||November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 18, 2010|January 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00418756||175537|
NCT00418769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2117|Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers|A Randomized, Open Label, Two-arm, Three Period Crossover Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers||Novartis||Completed|June 2006|||August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|January 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00418769||175536|
NCT00419055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801441|Outpatient Percutaneous Coronary Intervention|Outpatient Percutaneous Coronary Intervention in a Selected, Stable Patient Population||University of Pennsylvania|Yes|Terminated|August 2004|August 2006|Actual|||Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients less than 75 years who have undergone PCI|March 2012|March 29, 2012|January 4, 2007||No|Stopped early due to inability to recruit full 100 subjects over 2 years|No||https://clinicaltrials.gov/show/NCT00419055||175514|
NCT00419315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-058|A Randomized Clinical Trial of Alcohol Care Management|Primary Care Based Disease Management for Alcohol Dependence||VA Office of Research and Development|Yes|Completed|August 2007|July 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|January 4, 2007||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00419315||175494|The data presented in the results does not provide a true measure of the longitudinal effects done with GEE modeling.
NCT00420134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|348|Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial|A Phase One/Two Clinical Trial on the Use of Autograft Mesenchymal Stem Cells Differentiated Into Progenitor of Hepatocytes for the Salvage Treatment of Patients With End-stage Liver Disease||hahid Beheshti University of Medical Sciences||Completed|February 2006|June 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 15, 2009|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00420134||175432|
NCT00420420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0249-011|MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease||Merck Sharp & Dohme Corp.||Completed|November 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|144|||Both|55 Years|N/A|No|||January 2015|January 28, 2015|January 9, 2007|Yes|Yes||No|October 25, 2010|https://clinicaltrials.gov/show/NCT00420420||175411|
NCT00420745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106481|To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants|Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants||GlaxoSmithKline||Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1009|||Both|6 Weeks|14 Weeks|Accepts Healthy Volunteers|||March 2011|June 12, 2014|January 9, 2007|Yes|Yes||No|March 13, 2009|https://clinicaltrials.gov/show/NCT00420745||175386|
NCT00420121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2742-2|European Society of Cutaneous Lupus Erythematosus (EUSCLE)|European Society of Cutaneous Lupus Erythematosus||European Society of Cutaneous Lupus Erythematosus e.V.|No|Enrolling by invitation|January 2007|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with systemic or cutaneous lupus erythematosus|February 2016|February 11, 2016|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00420121||175433|
NCT00420407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056-1502-090|Low Dose Vasopressin in Traumatic Shock|Prospective, Randomized, Double-Blind, Multi-Center Trial of Low Dose Vasopressin Versus Placebo in Traumatic Shock Resuscitation||The University of Texas Health Science Center at San Antonio|Yes|Terminated|February 2007|February 2011|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|January 9, 2007|Yes|Yes|accrual rate|No|September 11, 2012|https://clinicaltrials.gov/show/NCT00420407||175412|
NCT00420732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0201|Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer|A Phase II Study of Tergenpumatucel-L (HyperAcute Lung) Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment||NewLink Genetics Corporation|Yes|Terminated|January 2007|December 2014|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|January 8, 2007|Yes|Yes|Enrollment goals unable to be reached.|No||https://clinicaltrials.gov/show/NCT00420732||175387|
NCT00420992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-KNT-301|A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee||Pfizer||Completed|December 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|547|||Both|21 Years|N/A|No|||September 2013|September 13, 2013|January 10, 2007|Yes|Yes||No|September 11, 2009|https://clinicaltrials.gov/show/NCT00420992||175368|
NCT00421317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-Mel-Inib 0508|Imatinib in Adult Patients With Metastatic Ocular Melanoma|A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma|O-Mel-Inib|Centre Oscar Lambret|No|Terminated|December 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|January 9, 2007||No|Study stopped at the end of the first step|No||https://clinicaltrials.gov/show/NCT00421317||175343|
NCT00421590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC021C2208|Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).|A Randomized, Partially Blind, Placebo Controlled, Crossover, Single Oral Dose Study to Assess the Effect of Concomitant Antacid (Calcium Carbonate / Magnesium Hydroxide) on the Pharmacokinetics and Pharmacodynamics of SMC021 (0.8 mg Salmon Calcitonin/200 mg 5-CNAC) in Healthy Postmenopausal Women||Novartis||Completed|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||38|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421590||175323|
NCT00435955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3320|Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma|MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA||Azienda Ospedaliera San Giovanni Battista||Active, not recruiting|March 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|60 Years|No|||February 2007|February 15, 2007|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00435955||174242|
NCT00436280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9819|Chemotherapy for Patients With Lymphoma|An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine and Oxaliplatin Plus Enzastaurin as Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma||Eli Lilly and Company|Yes|Completed|February 2007|November 2012|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|60 Years|N/A|No|||November 2012|November 28, 2012|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00436280||174217|
NCT00418288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0089|The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia|The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Subjects During Hypoglycemia Assessed by Positron Emission Tomography||University of Aarhus|No|Completed|January 2007|February 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 9, 2008|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418288||175573|
NCT00422240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18087|Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris||Galderma||Completed|June 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1656|||Both|12 Years|N/A|No|||September 2007|September 10, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00422240||175273|
NCT00422513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20336|A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.|A Randomized, Open-label Study Comparing the Pharmacoeconomic (Time and Motion) Benefit of Mircera and Epoetin Alfa in Patients With Chronic Kidney Disease (Stage V) on Dialysis.||Hoffmann-La Roche||Terminated|March 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||November 2011|November 9, 2011|January 15, 2007|Yes|Yes|Strategic decision unrelated to safety or efficacy|No|March 29, 2011|https://clinicaltrials.gov/show/NCT00422513||175252|
NCT00418262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4Z-MC-X050|Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD|An Open-label Study of the Long Term Tolerability and Safety of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal-Alcohol Syndrome or Effects.||University of Oklahoma|Yes|Recruiting|June 2006|June 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|4 Years|11 Years|No|||December 2010|December 6, 2010|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00418262||175575|
NCT00418275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB-001-P02|Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.|A Dose Finding, Pharmacokinetic and Safety Study of a Recombinant Human Plasminogen Activator (HTU-PA) in Patients With Acute Ischemic Stroke||Global Biotech||Completed|April 2001|June 2004||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||December 2006|January 3, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418275||175574|
NCT00410189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0825|BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC|A Phase II, Open Label Study of ZD6474 in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|Yes|Completed|November 2006|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|December 8, 2006|No|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT00410189||176179|
NCT00410540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013261|A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.|A Randomized, Double-Blind, Controlled Trial of Hydromorphone (Immediate and Sustained- Release) vs Morphine (Immediate and Sustained-release) in Cancer Pain||Alza Corporation, DE, USA||Completed||May 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|202|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410540||176152|
NCT00411424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8007-CL-0001|Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis|Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Initial Efficacy of ASK8007 in Comparison With Placebo in Patients With Active Rheumatoid Arthritis - a Randomized, Double Blind, Placebo-controlled, Combined Single Dose Escalation and Multiple Dose Study||Astellas Pharma Inc|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411424||176086|
NCT00411099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178A2301|Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder|An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-label Extension (CAGO178A2301E)||Novartis||Completed|December 2006|||January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|508|||Both|18 Years|70 Years|No|||May 2012|May 2, 2012|December 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411099||176111|
NCT00411112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3737|Sentinel Node in Colon Cancer|Sentinel Node Study in Colon Cancer Surgery||University Hospital, Strasbourg, France||Recruiting|March 2007|||March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411112||176110|
NCT00418496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06006|Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma|A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|December 2006|||December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|January 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00418496||175557|
NCT00418509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOR258H2104|Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers|A Randomized, Single Dose, 3-Period Crossover Study to Evaluate the Dosage Form Proportionality, Dose Proportionality and Pharmacokinetics of Mometasone Furoate and Formoterol Fumarate From Three Combination MDI Formulations||Novartis||Completed|November 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00418509||175556|
NCT00418782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6341008|A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain|A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicenter Study Of CE-224,535 In Subjects With Osteoarthritic Pain Of The Knee||Pfizer|Yes|Terminated|January 2007|August 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|212|||Both|18 Years|75 Years|No|||February 2008|February 29, 2008|January 4, 2007|No|Yes|Results of interim analysis indicate lack of efficacy when compared to placebo.|No||https://clinicaltrials.gov/show/NCT00418782||175535|
NCT00419328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR002|A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors|NGR002: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors: Definition of an Optimal Biological Dose||MolMed S.p.A.|No|Completed|March 2005|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419328||175493|
NCT00419341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB04_009CR|Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy|A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)||CSL Behring||Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|2 Years|75 Years|No|||December 2012|December 16, 2012|December 22, 2006|Yes|Yes||No|December 16, 2012|https://clinicaltrials.gov/show/NCT00419341||175492|
NCT00419627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProtHYMC|Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas|Proteomic Analysis of Serology and Peptides Presented on the HLA Complex of Breast, Ovarian, Colon, Rectal, Gastric and Pancreatic Adenocarcinoma.||Hillel Yaffe Medical Center||Not yet recruiting|February 2007|||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||160|||Both|N/A|N/A||||January 2007|January 5, 2007|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419627||175471|
NCT00412399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97068|Job Adaptation in Patients With Rheumatoid Arthritis|Job Adaptation in Patients With Rheumatoid Arthritis||Hospital for Special Surgery, New York||Completed|June 1999|October 2001||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||244|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2006|December 15, 2006|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00412399||176017|
NCT00412412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120BC101|CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study|A Ph1 Open-Label,Dose-Escalation,Safety,PK & PD Study of CNF2024 as a Single-Agent Treatment in Subjects w/HER2- Adv Breast Cancer or in Combo w/Trastuzumab in Subjects w/HER2+ Advanced Breast Cancer||Biogen|No|Completed|December 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||December 2011|June 7, 2012|December 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00412412||176016|
NCT00412724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAQ|Development and Validation of the Food Acceptability Questionnaire|Development and Validation of the Food Acceptability Questionnaire||Physicians Committee for Responsible Medicine|Yes|Completed|November 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|189|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women following a theraputic diet for at least 1 month|August 2012|August 6, 2012|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412724||175993|
NCT00412737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV20235|A Study of Tamiflu (Oseltamivir) for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.|A Double-blind, Randomized, Placebo Controlled, Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.||Hoffmann-La Roche||Completed||November 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|477|||Both|1 Year|N/A|No|||July 2010|July 30, 2010|December 15, 2006|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00412737||175992|There were no overall limitations and caveats.
NCT00421005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126/2004/U/Sper|Fluvastatin After Heart Transplantation|Safety and Efficacy of Fluvastatin in Heart Transplant Recipients||University of Bologna||Active, not recruiting|November 2004|November 2008|Anticipated|November 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421005||175367|
NCT00421018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050166|Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)|Optimization of the Anti-Inflammatory Treatment of Asthma Patients Through Exhaled NO Measurements for Increased Asthma-Related Quality of Life in Primary Health Care (NOAK)||Karolinska Institutet||Completed|November 2006|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|64 Years|No|||August 2012|August 14, 2012|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421018||175366|
NCT00421330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00/144|Dutch Randomised Endovascular Aneurysm Management (DREAM-) Trial|Endovascular Versus Transabdominal Treatment of the Abdominal Aortic Aneurysm: the Dutch Randomised Endovascular Aneurysm Management (DREAM-) Trial||UMC Utrecht|Yes|Active, not recruiting|November 2000|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|392|||Both|N/A|N/A|No|||June 2008|June 3, 2008|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00421330||175342|
NCT00421616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE06/332|Effectiveness of High Protein Diets in Promoting Weight Loss in Overweight and Obese Subjects.|A Diet Higher in Animal-Based Protein is More Effective in Promoting Weight Loss in Overweight and Obese Individuals Than Other Protein Based Diets.||University of Wollongong||Not yet recruiting|February 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2007|February 16, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421616||175321|
NCT00421629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHHPBD25|Experimental Study to Assess Interventions Aimed at Improving the Equity Impact of Community-Based Health Insurance|Experimental Study to Assess Interventions Aimed at Improving the Equity Impact of Community-Based Health Insurance||London School of Hygiene and Tropical Medicine||Completed|October 2003|April 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||688|||Both|18 Years|N/A||||January 2007|January 11, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00421629||175320|
NCT00422253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/06|Dietary Advanced Glycation End-products and Insulin Resistance in Overweight and Obese Humans|Will Reduction in Dietary Advanced Glycation End- Products Reduce Chronic Low Grade Inflammation and Improve Insulin Sensitivity in Overweight and Obese Humans||Bayside Health|No|Completed|November 2006|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|27|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2007|December 12, 2013|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00422253||175272|
NCT00436293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976F_6002|Taxotere + Cisplatin in Nasopharyngeal Carcinoma|A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC)||Sanofi||Completed|December 2002|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||November 2010|November 16, 2010|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436293||174216|
NCT00409890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP 109,2004/2005|The Effect of Hyoscine Butyl Bromide on the First Stage of Labor in Term Pregnancies|The Effect of Hyoscine Butyl Bromide on the First Stage of Labor in Term Pregnancies||University Hospital of the West Indies||Completed|June 2005|October 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00409890||176202|
NCT00411437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121154|Effects Of Detrol LA On Memory And Cognition In Elderly Population|A Randomized, Double-Blind, Placebo-Controlled, Three Arm Study To Evaluate The Effects Of Tolterodine ER 4 mg Vs. Placebo Vs. Oxybutynin ER On Memory And Other Cognitive Abilities In Elderly Subjects||Pfizer||Completed|December 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||June 2008|June 10, 2008|December 13, 2006||||||https://clinicaltrials.gov/show/NCT00411437||176085|
NCT00409864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIS/1/2003|Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer|Endoscopic Versus Percutaneous Biliary Drainage For Hilar Block Due to Carcinoma Gall Bladder: A Randomized Prospective Trial and Quality Of Life Assessment||All India Institute of Medical Sciences, New Delhi||Completed|October 2003|December 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|80 Years|No|||December 2006|May 25, 2010|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409864||176203|
NCT00410202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-111|Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus|A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-resistant Chronic Hepatitis B Subjects: The DEFINE Study|DEFINE|Bristol-Myers Squibb|No|Completed|March 2008|July 2012|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|629|||Both|16 Years|N/A|No|||October 2013|October 29, 2013|December 11, 2006|Yes|Yes||No|April 24, 2012|https://clinicaltrials.gov/show/NCT00410202||176178|
NCT00410553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00172|Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery|A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|November 2006|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2015|February 15, 2016|December 11, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00410553||176151|
NCT00410787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013264|Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain|Safety and Tolerability of Long-Term Administration of Dilaudid SR (Hydromorphone HCI) in Cancer Pain||Alza Corporation, DE, USA||Completed||April 2002|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|68|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410787||176133|
NCT00412763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21829|Efficacy of Silymarin for Acute Hepatitis|Efficacy of Silymarin for Treatment of Acute Hepatitis In Egypt: A Randomized, Double-Blinded, Controlled Trial||University of Maryland||Completed|July 2003|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|13 Years|70 Years|No|||December 2006|December 15, 2006|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00412763||175990|
NCT00411814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I13105054|A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers|A Dose-escalating Study of the Safety and Pharmacokinetics of GSK679586A in Healthy Volunteers and Mild Asthmatics.||GlaxoSmithKline|No|Completed|November 2006|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|March 15, 2012|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00411814||176060|
NCT00411827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU#06-23014|Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK|Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK||Walter Reed National Military Medical Center||Active, not recruiting|January 2008|December 2014|Anticipated|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|December 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00411827||176059|
NCT00411840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAM-PAD|Novel Therapy of PAD by Combined Transplantation of BMCs|Transplantation of Autologous Mononuclear Bone Marrow Stem Cells in Patients With Peripheral Arterial Disease (TAM-PAD Study)||Heinrich-Heine University, Duesseldorf||Recruiting|July 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|N/A|N/A|No|||December 2006|December 13, 2006|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00411840||176058|
NCT00419094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01280|Conversion to Monotherapy Study With Keppra XR for Partial Seizures|A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures||UCB Pharma|No|Completed|August 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|228|||Both|12 Years|75 Years|No|||January 2011|August 26, 2014|January 4, 2007|Yes|Yes||No|September 13, 2010|https://clinicaltrials.gov/show/NCT00419094||175511|
NCT00419107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040108|Beta Cell Function in Women With Turner Syndrome|Beta Cell Function in Women With Turner Syndrome||University of Aarhus||Terminated|November 2004|January 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|25|Samples With DNA|Blood samples.|Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|13 women with TS and 12 control women|November 2011|November 7, 2011|January 5, 2007||No|Completed|No||https://clinicaltrials.gov/show/NCT00419107||175510|
NCT00419068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005−003562−42|Trial of Adjunctive Vitamin D in Tuberculosis Treatment|Trial of Adjunctive Vitamin D in Tuberculosis Treatment||Barts & The London NHS Trust||Completed|January 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|146|||Both|18 Years|N/A|No|||September 2009|September 29, 2009|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419068||175513|
NCT00419081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-Tio-05-202|Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens|A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.||BioCryst Pharmaceuticals||Terminated|July 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|January 5, 2007|Yes|Yes|Issues with Manufacturing|No||https://clinicaltrials.gov/show/NCT00419081||175512|
NCT00419874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR444206CTIL|Characteristics of Blood- Brain Barrier Permeability in Neurological Patients|Blood- Brain Barrier Permeability in Neurological Patients: Anatomical, Neurophysiological, and Clinical Characteristics||Soroka University Medical Center||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||November 2006|January 7, 2007|January 7, 2007||||No||https://clinicaltrials.gov/show/NCT00419874||175452|
NCT00419887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2109|Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel-Group, Ascending Single and Multiple Oral Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LAF237 in Chinese Healthy Subjects||Novartis||Completed|September 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00419887||175451|
NCT00413387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/033011/002/03|Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)|Double Blind, Double Dummy, Multinational, Multicentre, Parallel-Group Design Clinical Trial of the Efficacy and Tolerability of CHF 1535 (Beclomethasone Dipropionate 100 µg + Formoterol 6 µg) pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler® (Symbicort®) in the 12-Week Treatment of Adult Patients With Moderate to Severe Persistent Asthma||Chiesi Farmaceutici S.p.A.|No|Completed|September 2004|October 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|65 Years|No|||April 2008|April 21, 2008|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413387||175943|
NCT00408746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFO-MAPA-1/2006|Orofacial Development of Preterm and Low Birthweight Infants Versus Term Infants|Prospective (Multicentre) Epidemiologic Longitudinal Study of Orofacial Development of Preterm and Low Birthweight Infants Compared to Term Infants in Consideration of Perinatal, Biometrical, Nutritional, Functional and Parental Parameters||University Hospital Muenster|No|Recruiting|January 2003|August 2013|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Caucasian preterm and term babies|February 2007|March 23, 2009|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00408746||176285|
NCT00409305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BET201|The Effect of Betahistine on Body Weight in Obese Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Subjects||OBEcure Ltd.||Completed|January 2007|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2007|April 20, 2015|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00409305||176244|
NCT00413036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NHL-003|A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma||Celgene|Yes|Completed|June 2006|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|217|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|December 18, 2006|Yes|Yes||No|January 9, 2013|https://clinicaltrials.gov/show/NCT00413036||175970|
NCT00413049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2315|Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension|A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Monotherapy||Novartis||Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|698|||Both|18 Years|85 Years|No|||April 2011|April 26, 2011|December 18, 2006||No||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00413049||175969|
NCT00413374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000082|Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism|Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism||Brigham and Women's Hospital|Yes|Completed|May 2006|December 2008|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|December 15, 2006|No|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00413374||175944|
NCT00408733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G06-09-104-01|Evaluating a Low-Literacy Discharge Medication Education Tool|Evaluating a Low-Literacy Discharge Medication Education Tool||University of California, Los Angeles|No|Completed|January 2007|August 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|287|||Both|18 Years|N/A|No|||December 2007|January 24, 2008|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00408733||176286|
NCT00409045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-08-002|Evaluation of Obstructive Sleep Apnea as a Risk Factor for Pulmonary Embolism|Evaluation of Obstructive Sleep Apnea as a Risk Factor for Pulmonary Embolism||Atlantic Health System||Completed|November 2005|September 2007|Actual|||Phase 1/Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|male and female patients age 18 years and older|October 2007|November 2, 2007|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00409045||176264|
NCT00409279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0097|An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease|An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease||National Institute on Aging (NIA)|Yes|Recruiting|September 2003|April 2008|Anticipated|April 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|100|||Both|21 Years|90 Years|No|||February 2008|February 28, 2008|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409279||176246|
NCT00409292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-197|RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer|Phase II Study of RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer||Dana-Farber Cancer Institute||Completed|January 2007|May 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|December 6, 2006|Yes|Yes||No|April 30, 2014|https://clinicaltrials.gov/show/NCT00409292||176245|
NCT00431795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/03.12|Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer|A Multicenter Randomized Phase II Study of Second Line Chemotherapy With Epirubicin( Farmorubicin) Versus the Pegylated Liposomal Doxorubicin in Advanced Breast Cancer Patients||Hellenic Oncology Research Group||Terminated|June 2003|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|75 Years|No|||February 2013|February 12, 2013|February 5, 2007||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00431795||174557|
NCT00411450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060277|Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment|Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer|PRECEPT|Amgen|No|Completed|November 2006|October 2010|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 12, 2006|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT00411450||176084|
NCT00411866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAA105416|Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812|Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg.||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00411866||176056|
NCT00410215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hookey picosalax|A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy|A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy||Queen's University|No|Completed|February 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|315|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00410215||176177|
NCT00410228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAHT956A2101|Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects|A Single Center, Randomized, Double-Blind, Placebo-and Positive-Controlled, Interleaved, Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHTT956 in Healthy Subjects||Novartis||Completed|June 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410228||176176|
NCT00410241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070002|ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study|ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study||National Institutes of Health Clinical Center (CC)||Recruiting|December 2006|||||N/A|Observational|N/A|||Anticipated|2000|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||January 2014|March 14, 2014|December 9, 2006||No||No||https://clinicaltrials.gov/show/NCT00410241||176175|
NCT00412126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-223|Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI|Does Reduction of Hyperglycemia With Insulin Impact Restenosis and Improve Clinical Outcomes Following PCI?||McMaster University||Completed|July 2002|September 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|90 Years|No|||December 2006|December 13, 2006|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00412126||176037|
NCT00412451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-002|A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)|A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME.|MIVI-II|ThromboGenics|Yes|Completed|December 2006|March 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|N/A|No|||April 2014|December 2, 2014|December 14, 2006||No||No|July 4, 2013|https://clinicaltrials.gov/show/NCT00412451||176013|
NCT00412464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3091|Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis|A Pilot Dose-finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-induced Thrombocytopenia||FDA Office of Orphan Products Development|Yes|Completed|September 2006|December 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|1 Year|18 Years|No|||October 2011|April 14, 2015|December 15, 2006|No|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00412464||176012|
NCT00413127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-AnIt-06|Perioperative Protective Effects of Lidocaine|Perioperative Protective Effects of Lidocaine - Clinical Study on the Route and Timing of Administration||University Hospital Muenster|No|Terminated|September 2007|March 2015|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|78|||Both|18 Years|85 Years|No|||June 2015|June 25, 2015|December 18, 2006||No|Less patients than expected for inclusion, therefore patient recruitment is to low|No||https://clinicaltrials.gov/show/NCT00413127||175963|
NCT00419692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROR106470|Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food|An Open Label, Repeat Dose, Dose Escalation Study Conducted in RLS Patients to Characterize Pharmacokinetics and Food Effect of Ropinirole Controlled Release for RLS||GlaxoSmithKline|No|Completed|August 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|65 Years|No|||February 2011|March 15, 2012|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419692||175466|
NCT00413101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20201|A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.|An Open-Label Study to Investigate Improvement in Heart Function After Complete Anemia Correction With NeoRecormon in Patients With End-Stage Renal Disease Already Receiving Sub-Optimal Doses of NeoRecormon||Hoffmann-La Roche||Completed||March 2008|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||May 2009|May 13, 2009|December 18, 2006||No||No||https://clinicaltrials.gov/show/NCT00413101||175965|
NCT00411411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1502|Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes|Phase 3, Double Blinded, Placebo Controlled Study of the Effects of 12 Weeks DPP-IV Inhibitor Treatment on Secretion and Action of the Incretin Hormones in Patients With Type 2 Diabetes||University Hospital, Gentofte, Copenhagen|Yes|Completed|February 2007|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|80 Years|No|||July 2014|July 21, 2014|December 13, 2006||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00411411||176087|
NCT00419354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4134|The Impact of Right Ventricular Pacing on Tricuspid Regurgitation|||Rabin Medical Center|No|Recruiting|March 2007|March 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Outpatients, clinically stable, with a permanent pacemaker and who are not pacemaker        dependent.|July 2006|April 20, 2009|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00419354||175491|
NCT00419614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PancStumpHYMC|Outcome of Pancreatic Stump Closure Following Resection of Tumors of the Head of the Pancreas.|Retrospective Chart Review on the Association of Pancreaticoduodenectomy Without Pancreatic-Gastrointestinal Anastomosis to Perioperative Morbidity and Mortality||Hillel Yaffe Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||January 2007|January 5, 2007|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419614||175472|
NCT00412100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3006|Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation|A Randomsied, Double-blind, Double-dummy, Parallel-group Multicentre Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Non-malignant Pain Taking Oxycodone Equivalent of 60-80 mg/Day as Oxycodone/Naloxone Prolonged Release Compared to Subjects Taking Oxycodone Prolonged Release Tablets Alone||Mundipharma Research GmbH & Co KG||Completed|April 2006|September 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||August 2012|August 9, 2012|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412100||176039|
NCT00413075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-9|Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma|Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors||Onxeo|No|Completed|June 2006|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|December 18, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00413075||175967|
NCT00409344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001827|Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms|Phase 4 Study of Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms||Massachusetts General Hospital|Yes|Terminated|January 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 16, 2009|December 7, 2006|Yes|Yes|Surgical approach changed therefore subject enrollment not possible.|No|February 26, 2009|https://clinicaltrials.gov/show/NCT00409344||176241|Unable to enroll participants into the study
NCT00409604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1017-001|PROTECT : Pacing to Protect Heart for Damage From Blocked Heart Vessel and From Re-opening Blocked Vessel(s)|Clinical Evaluation of Pacing During the Onset of Revascularization / Feasibility Study||Guidant Corporation||Completed|December 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||August 2010|August 30, 2010|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409604||176223|
NCT00409318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001699|Study of TNF-Antagonism in Metabolic Syndrome|Effects of TNF-Alpha Antagonism in Patients With the Metabolic Syndrome (I)||Massachusetts General Hospital|Yes|Completed|April 2004|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|No|||May 2008|May 23, 2008|December 7, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00409318||176243|
NCT00409591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT-5 First Phase|Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand|Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.|PHPT-5|Institut de Recherche pour le Developpement|Yes|Terminated|July 2008|June 2015|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|435|||Both|N/A|N/A|No|||January 2016|January 26, 2016|December 8, 2006||No|Change in National PMTCT guidelines in Thailand|No||https://clinicaltrials.gov/show/NCT00409591||176224|
NCT00409903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2006.02.HV|The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.|The Effect of Eprosartan on Vasoactive Hormones and Renal Tubular Function in Healthy Humans.||Regional Hospital Holstebro||Completed|November 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2007|September 13, 2007|December 10, 2006||||No||https://clinicaltrials.gov/show/NCT00409903||176201|
NCT00409916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06001-M2-124-1-3|PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing|Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF)||CardioDynamics|Yes|Recruiting|January 2007|December 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2009|June 1, 2009|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409916||176200|
NCT00410254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-109|HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects|An Open Label, Single-Dose Midazolam, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Midazolam||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|December 8, 2006||||||https://clinicaltrials.gov/show/NCT00410254||176174|
NCT00410566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHINGO00605|Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)|A Phase I, Single-Center, Single Dose, Dose Escalation Study of Recombinant Human Acid Sphingomyelinase (rhASM) in Adults With Acid Sphingomyelinase Deficiency (ASMD)||Sanofi|Yes|Terminated|December 2006|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|11|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|December 11, 2006|No|Yes|Terminated by sponsor - Single dose safety objective achieved.|No||https://clinicaltrials.gov/show/NCT00410566||176150|
NCT00410800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999996032|Insulin Secretory Defects in Pima Indians at High Risk for NIDDM|Insulin Secretory Defects in Pima Indians at High Risk for NIDDM||National Institutes of Health Clinical Center (CC)||Completed|August 1996|August 2011||||N/A|Observational|N/A|||Anticipated|310|||Both|18 Years|65 Years|No|||August 2011|August 17, 2011|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00410800||176132|
NCT00432185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-009|To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC|An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.||Peplin|No|Completed|February 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432185||174528|
NCT00411879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10531-VMA|Combined Vasopressin, Methylprednisolone, and Epinephrine for Inhospital Cardiac Arrest|Phase 2, Single-Center, Placebo-Controlled Study of the Effects of Combined Administration of Vasopressin, Methylprednisolone, and Epinephrine During Cardiopulmonary Resuscitation on Survival After Cardiac Arrest||University of Athens|Yes|Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00411879||176055|
NCT00412165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R18DK064321|PACE-iDP: An Intervention for Youth at Risk for Diabetes|PACE-iDP: An Intervention for Youth at Risk for Diabetes||University of California, San Diego||Completed|February 2006|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|101|||Both|12 Years|16 Years|No|||August 2012|August 15, 2012|December 13, 2006||No||No||https://clinicaltrials.gov/show/NCT00412165||176034|
NCT00411853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4232-RW-CTIL|Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients|An Open Phase II Clinical Trial of Fermented Wheat Germ Extract in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients||Sheba Medical Center|No|Recruiting|June 2007|June 2012|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||July 2009|July 30, 2009|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00411853||176057|
NCT00412477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 984|A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults|RV 151: A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults, WRAIR #984, HSRRB Log # A-11905.||U.S. Army Medical Research and Materiel Command|No|Completed|August 2004|November 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|December 15, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00412477||176011|
NCT00412776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB4-845-01-IIIA|Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer|A Randomized, Multicentre Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Proxinium Plus Best Supportive Care Versus Best Supportive Care Alone in Patients With Advanced SCCHN Who Have Received at Least One Anti-cancer Treatment Regimen for Advanced Disease||Viventia Bio|Yes|Terminated|December 2005|April 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 14, 2006||No|Corporate reasons unrelated to safety and efficacy|No||https://clinicaltrials.gov/show/NCT00412776||175989|
NCT00412789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A1103|Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan|A Phase IA, Open-label, Dose Escalation Study of Patupilone Administered Intravenously Every 3 Weeks in Adult Patients With Advanced Solid Tumors||Novartis||Completed|August 2006|||January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||May 2010|May 28, 2010|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412789||175988|
NCT00413114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM013|Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)|A Phase II Study of Obatoclax Mesylate (GX15-070MS) in Patients With Previously-Untreated Myelodysplastic Syndromes (MDS) With Anemia and/or Thrombocytopenia||Teva Pharmaceutical Industries|No|Completed|December 2006|November 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|December 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00413114||175964|
NCT00419952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5896C00022|A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.|A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (≥12 Years) African American Subjects With Asthma||AstraZeneca||Completed|February 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|742|||Both|12 Years|N/A|No|||September 2012|September 28, 2012|January 5, 2007|No|Yes||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00419952||175446|
NCT00408772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000517440|Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery|Efficacy of Neoadjuvant XELOX/AVASTIN Therapy for Nonresectable Colorectal Liver Metastases With Secondary Hepatic Resection/Radiofrequency||National Cancer Institute (NCI)||Recruiting|June 2007|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2010|January 27, 2010|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408772||176283|
NCT00412113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841045|A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk|A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.|TOGETHER|Pfizer|No|Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|245|||Both|21 Years|N/A|No|||March 2009|November 12, 2009|December 13, 2006|Yes|Yes||No|April 13, 2009|https://clinicaltrials.gov/show/NCT00412113||176038|
NCT00412425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0506|Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting|Evaluation of Two Different Schedules of Palonosetron for the Prevention of Nausea and Vomiting in Patients With Metastatic Melanoma Receiving Concurrent Biochemotherapy||M.D. Anderson Cancer Center|No|Completed|November 2006|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||April 2012|April 9, 2012|December 14, 2006||No||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00412425||176015|
NCT00411788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605001396|A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer|A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer||Yale University|No|Recruiting|December 2006|May 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||June 2009|June 5, 2009|December 14, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411788||176062|
NCT00411801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNI-108|Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)|A Blinded Non-inferiority Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)||Octapharma|Yes|Terminated|May 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|December 13, 2006|Yes|Yes|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00411801||176061|
NCT00413088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-BEM-2005-01|Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly|Clinical Trial to Assess Bemiparin Pharmacokinetics at Therapeutic (115 IU/kg) and Prophylactic Doses (3500 IU) Administered Subcutaneously in Single or Multiple Doses in Renal Insufficiency and in the Elderly||Rovi Pharmaceuticals Laboratories||Completed|March 2006|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 17, 2011|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00413088||175966|
NCT00409617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-829|Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease|A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease||Abbott|No|Completed|December 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|945|||Both|18 Years|75 Years|No|||October 2011|October 6, 2011|December 8, 2006|Yes|Yes||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00409617||176222|
NCT00409058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-10-36|Teen Online Problem Solving (TOPS) - An Online Intervention Following TBI|An Online Intervention for Families Following Adolescent TBI - Teen Online Problem Solving (TOPS)|TOPS|Children's Hospital Medical Center, Cincinnati|No|Completed|October 2005|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|11 Years|18 Years|No|||September 2014|October 27, 2014|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409058||176263|
NCT00409331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0234|Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment|A Phase II Study To Assess The Efficacy of Amifostine for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment With Intensity- Modulated Radiation Therapy (IMRT) for Parotid Salivary Sparing||M.D. Anderson Cancer Center|No|Terminated|December 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|December 7, 2006||No|Study terminated by Principal Investigator; no patients completed study.|No|December 11, 2009|https://clinicaltrials.gov/show/NCT00409331||176242|
NCT00410280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3174K1-200|Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma|Allergen Challenge||Pfizer|No|Completed|March 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||November 2014|November 7, 2014|December 8, 2006|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT00410280||176172|The study was stopped early due to futility of the interim efficacy analysis results. Hence, only safety results and key efficacy results were presented for this study.
NCT00410293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2004-201|NT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs|NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs||Erasmus Medical Center||Completed|December 2004|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic||||500|||Both|18 Years|N/A|No|||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410293||176171|
NCT00409929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2114|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071|A Randomized, Double-blind, Placebo-controlled, Time Lagged, Parallel Group, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AEB071 Doses Greater Than 500 mg in Healthy Subjects||Novartis||Completed|June 2006|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 18, 2010|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00409929||176199|
NCT00410267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511006|Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-Selective Laser Trabeculoplasty Anterior Chamber Flare and Cells|A Randomized Prospective Double - Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-Selective Laser Trabeculoplasty Anterior Chamber Flare and Cells||University of Pittsburgh|No|Terminated|February 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A|||Actual|1|||Both|18 Years|95 Years|No|||January 2008|January 24, 2008|December 11, 2006||No|low recruitment|No||https://clinicaltrials.gov/show/NCT00410267||176173|
NCT00410579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP LTS-01|Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers|Patient Reported Outcomes in Long Term Survivors With Colon and Rectal Cancer||NSABP Foundation Inc|No|Completed|November 2006|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|744|||Both|N/A|N/A|No|Non-Probability Sample|Study population to be interviewed comprises patients who were treated at least 5 years        ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07|December 2010|December 15, 2010|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410579||176149|
NCT00410813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000520348|S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone|Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|March 2007|September 2013|Anticipated|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|December 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00410813||176131|
NCT00411164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013273|A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis|A Phase 3, Randomized, Double-Blind, Fixed-Dose, Parallel Group Comparison of Controlled-Release Hydromorphone HCI vs Placebo in Subjects With Osteoarthritis||Alza Corporation, DE, USA||Completed|November 2003|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|990|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 4, 2013|December 12, 2006||||||https://clinicaltrials.gov/show/NCT00411164||176106|
NCT00433407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000449959|T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors|A Study to Assess HER2-Specific T Cell Responses in Patients Receiving Trastuzumab for Solid Tumor Treatment||Jonsson Comprehensive Cancer Center|No|Completed|August 2005|||February 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||October 2012|October 3, 2012|February 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00433407||174437|
NCT00412178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC|Effect of Mobile Communication With a Cellular Phone With a Glucometer on Glucose Control in Type 2 Diabetic Patients|||The Catholic University of Korea||Terminated|December 2004|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||80|||Both|30 Years|70 Years|No|||December 2006|December 14, 2006|December 13, 2006||||No||https://clinicaltrials.gov/show/NCT00412178||176033|
NCT00412503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 1197|Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents|Phase 1 Study of Temozolomide Associated With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents||Gustave Roussy, Cancer Campus, Grand Paris||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|6 Months|21 Years||||August 2009|August 6, 2009|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00412503||176009|
NCT00412139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-1001/2-05|Serum Uremic Toxins and Histological Findings of the Blood Vessels in Dialysis Patients|A Correlation Between Histological Findings of the Blood Vessels in Patients With Chronic Renal Failure and Serum Uremic Toxins and Its Diagnostic Performance in the Assessment of the Cardiovascular Morbidity and Mortality||University of Skopje|Yes|Completed|December 2006|January 2010|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|100|None Retained|3 aliquots of 2-3 ml sera are retained for various uremic markers determination|Both|18 Years|65 Years|No|Non-Probability Sample|CKD patients with a need for dialysis within a few months CKD patients on dialysis with        thormbosis of AV fistula CKD patients on dialysis scheduled for kidney transplantation|December 2008|February 8, 2010|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00412139||176036|
NCT00412802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-01|Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome|Validation of Enoxaparin Dose Adaptation in Patients With Moderate Renal Failure Hospitalized for an Acute Coronary Syndrome, the VALIDE Study||French Cardiology Society|Yes|Completed|December 2006|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412802||175987|
NCT00413140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 03-228-CF|Non-Invasive Biomarkers in Cystic Fibrosis|Biomarkers in Exhaled Breath Indicate Presence, Control and Severity of Cystic Fibrosis||Maastricht University Medical Center||Completed|June 2004|May 2005||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|5 Years|25 Years|Accepts Healthy Volunteers|||November 2003|December 18, 2006|December 18, 2006||||No||https://clinicaltrials.gov/show/NCT00413140||175962|
NCT00419965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06C.358|Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure|Measuring GRK2 in the Blood to Diagnose and Treat Patients With Heart Failure||Thomas Jefferson University|Yes|Completed|October 2006|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|582|Samples With DNA|Frozen serum/plasma - coded samples|Both|18 Years|N/A|No|Probability Sample|The study population subjects includes individuals in a range of age groups with a        diagnosis of heart failure or at least one cardiovascular risk factor along with a subset        of normal control subjects.|August 2010|August 18, 2010|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00419965||175445|
NCT00408434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-U102|Study of an Experimental New Drug, PPAR Agonist Taken by Mouth by Patients With Advanced or Metastatic Cancer|A Phase I Dose Finding Study of an Experimental New Drug, PPAR Agonist Taken by Mouth by Patients With Advanced or Metastatic Cancer||Daiichi Sankyo Inc.|No|Completed|November 2006|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|December 6, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408434||176308|
NCT00412438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIEM-G-1|Investigation of Genetic Risk of Atrial Fibrillation|Investigation of Genetic Risk of Atrial Fibrillation||Nagoya University||Recruiting|October 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2006|December 15, 2006|December 15, 2006||||No||https://clinicaltrials.gov/show/NCT00412438||176014|
NCT00412750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2406|Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)|A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq 180 µg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Treatment naïve Patients With HBeAg-positive CHB.||Novartis||Terminated|December 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|70 Years|No|||June 2011|June 14, 2011|December 15, 2006|Yes|Yes|Enrollment stopped for safety issues|No|December 2, 2010|https://clinicaltrials.gov/show/NCT00412750||175991|
NCT00413062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05722|Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)|A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE)||Merck Sharp & Dohme Corp.|No|Completed|June 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2281|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|December 18, 2006|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00413062||175968|
NCT00409630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10384|Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma|Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma||University of Kansas Medical Center||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|20 Years|45 Years|No|||April 2012|April 11, 2012|December 8, 2006|||Sponsor decided against going forward with the study.|No||https://clinicaltrials.gov/show/NCT00409630||176221|
NCT00409643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2307|Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients|A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients||Novartis||Completed|January 2004|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1259|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409643||176220|
NCT00409942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N/GF-TORAFIC-06|Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.|Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure|TORAFIC|Ferrer Internacional S.A.|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||June 2009|July 14, 2009|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00409942||176198|
NCT00410306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14203|Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice|International, Multi-center Post Authorization Surveillance Study on the Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido)|IPASS Nebido|Bayer|No|Completed|October 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1493|||Male|18 Years|N/A|No|Non-Probability Sample|Patients from routine practice|September 2010|September 23, 2010|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410306||176170|
NCT00410319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF 20040016|Information or Physical Activity for Chronic LBP|||University of Southern Denmark||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years||||April 2007|April 25, 2007|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00410319||176169|
NCT00410332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32/6|Traumeel for Post-Tonsillectomy Pain|A Randomized, Double-Blind, Placebo-Controlled Pilot Study for Evaluating the Efficacy of the Homeopathic Remedy Traumeel S on Pain Reduction Following Tonsillectomy in Adult Patients.||Shaare Zedek Medical Center||Recruiting|March 2011|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2012|February 19, 2012|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00410332||176168|
NCT00410592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00106|Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD|A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD||AstraZeneca||Completed|October 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|69 Years|No|||March 2009|March 10, 2009|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410592||176148|
NCT00410826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6106|Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck||University of Washington|Yes|Completed|June 2006|||May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|December 11, 2006|Yes|Yes||No|December 14, 2012|https://clinicaltrials.gov/show/NCT00410826||176130|
NCT00411177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ege0683|Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis|Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis (TURKISH HDF STUDY)||Ege University|Yes|Completed|January 2007|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|782|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411177||176105|
NCT00411489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0165|Endoscopic Stomach and Pouch Reduction in Patients With Weight Regain Following Roux-En-Y Bypass Surgery|Use of a New Endosurgical Operating System for Endoscopic Stoma and Pouch Reduction in Patients With Weight Regain Following Roux-En-Y Bypass Surgery||USGI Medical||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|64 Years|No|||June 2007|March 17, 2008|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00411489||176082|
NCT00411515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-2000-05-2006-06|A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty|||University Hospital Freiburg||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|N/A||||December 2006|December 14, 2006|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00411515||176081|
NCT00434343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK65209B (IND)|Physical Therapy Trial for Pelvic Pain|A Pilot Feasibility Study of Physical Therapy for the Treatment of Urologic Pelvic Pain Syndromes|UPPCRN-RCT#1|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|November 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00434343||174365|
NCT00434356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4057g|A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)|A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer||Genentech, Inc.||Terminated|March 2007|||May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||November 2009|November 17, 2009|February 9, 2007|Yes|Yes|Based on data collected, the combination appeared to be poorly tolearated.|No|September 1, 2009|https://clinicaltrials.gov/show/NCT00434356||174364|Based on the early safety results from this study, further recruitment and treatment was halted. Insufficient efficacy data were available to perform all protocol-specified analyses and limited the interpretation of the analyses performed.
NCT00434369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510-08|5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients|A Multi-Center, Open-Label, Single-Arm Phase II Trial Assessing the Efficacy and Safety of Weekly Bolus Infusions of 5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Advanced Breast Cancer Patients Who Failed Anthracycline and Taxane Chemotherapy Regimens||Mast Therapeutics, Inc.||Active, not recruiting|February 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|31|||Female|18 Years|N/A|No|||April 2008|April 18, 2008|February 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00434369||174363|
NCT00418873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPRIS-0601-TW|Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward|A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward||Astellas Pharma Inc|No|Terminated|March 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|65 Years|No|||April 2010|April 15, 2010|January 3, 2007||No|Study was stopped due to difficulty in patient enrollment|No||https://clinicaltrials.gov/show/NCT00418873||175528|
NCT00418886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00036|Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients|A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC|ZEAL|AstraZeneca||Active, not recruiting|January 2007|March 2016|Anticipated|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|698|||Both|18 Years|130 Years|No|||December 2015|December 2, 2015|January 4, 2007|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00418886||175527|
NCT00412490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0126|Smoking Status and Body Image in Oral Cancer Patients|A Prospective Examination of Smoking Status and Body Image in Surgical Patients With Cancer of the Oral Cavity||M.D. Anderson Cancer Center|No|Completed|December 2005|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals, age 18 years or older, diagnosed with head and neck malignancy involving an        oral cavity site without previous treatment, and current treatment plan includes surgical        intervention.|January 2016|January 27, 2016|December 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00412490||176010|
NCT00413153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002239|Metabolic Effects of Switching Kaletra to Boosted Reyataz|Metabolic Effects of Switching Kaletra to Boosted Reyataz||Massachusetts General Hospital|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||March 2010|March 5, 2010|December 15, 2006|Yes|Yes||No|November 4, 2009|https://clinicaltrials.gov/show/NCT00413153||175961|
NCT00419419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005|Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon|Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon||MediQuest Therapeutics||Completed|December 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2007|May 29, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00419419||175486|
NCT00420563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-ANGI 0601|Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer|A Phase II Randomized Study to Assess the Benefit of a Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer|PALANGI-0601|Centre Oscar Lambret|Yes|Completed|September 2006|July 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00420563||175400|
NCT00420576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM/CTS/05/336|Dose Finding Study of Danggui Buxue Tang (Herbal Formula)on the Treatment of Menopausal Symptoms|A Randomized, Double-Blind, Multiple-Dose Escalation Study of the Effect of Danggui Buxue Tang on Symptomatic Postmenopausal Hong Kong Chinese Women (Continuation of a Completed Study Using the Same Formula)||Chinese University of Hong Kong|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|N/A|No|||January 2007|December 17, 2008|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00420576||175399|
NCT00408447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA7701|Stem Cell Transplant in Sickle Cell Disease and Thalassemia|Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia||Columbia University|Yes|Recruiting|September 2004|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|1 Month|30 Years|No|||January 2016|January 5, 2016|December 6, 2006||No||No||https://clinicaltrials.gov/show/NCT00408447||176307|
NCT00408785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107457|A Study Of BOTOX For The Treatment Of Glabellar Lines|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of BOTOX? (Botulinum Toxin Type A) in Subjects With Glabellar Lines||GlaxoSmithKline|No|Completed|November 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2|||256|||Both|18 Years|65 Years|No|||November 2011|November 10, 2011|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408785||176282|
NCT00409071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCCULINE|Placebo-controlled Evaluation of Cocculine® Efficacy in the Management of Nausea After Chemotherapy in Breast Cancer.|Placebo-controlled Evaluation of Homeopathic Remedy (Cocculine®) Efficacy in the Management of Nausea After Adjuvant Chemotherapy in Non Metastatic Breast Cancer.||Centre Leon Berard|No|Completed|September 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|431|||Female|18 Years|N/A|No|||February 2010|February 4, 2010|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409071||176262|
NCT00408759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eschiff|Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients|Phase 2 Study of Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients||Bnai Zion Medical Center||Recruiting|November 2006|December 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||December 2006|December 6, 2006|December 6, 2006||||No||https://clinicaltrials.gov/show/NCT00408759||176284|
NCT00409357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5234|Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of SL77.0499-10 Once Daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH)||Sanofi||Completed|November 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|473|||Male|50 Years|N/A|No|||October 2009|October 1, 2009|December 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00409357||176240|
NCT00421096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCOL 0401|Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer|Stage IB2 to IVA Uterine Cervical Cancer: Phase 2 Study to Assess a New Therapeutic Sequence Associating a Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine|GEMCOL|Centre Oscar Lambret|No|Terminated|May 2005|December 2011|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|70 Years|No|||July 2012|July 23, 2012|January 10, 2007||No|Problems of recruitment|No||https://clinicaltrials.gov/show/NCT00421096||175360|
NCT00409955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1536/05|Lamellar Transplant With Lyophilized Corneas|Randomized Clinical Trial for Lamellar Transplants Using Lyophilized and Optisol Corneas||Federal University of São Paulo||Completed|December 2005|December 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||December 2006|December 11, 2006|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00409955||176197|
NCT00409968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0823|BATTLE Program: Umbrella Protocol for Patients With NSCLC|A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2006|||November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|A sample of your tumor tissue will be collected for biomarker analysis, and based on the      results, you will be assigned to one of four phase II studies.|Both|18 Years|N/A|No|Probability Sample|Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the        body.|May 2015|May 11, 2015|December 8, 2006||No||No||https://clinicaltrials.gov/show/NCT00409968||176196|
NCT00421720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USA107212|A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus Sufentanil/Propofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.|A Randomized, Open-Label, Multicenter, Parallel-Group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days||GlaxoSmithKline||Terminated|January 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||164|||Both|18 Years|N/A|No|||July 2007|July 24, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421720||175313|
NCT00421733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-741|The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors|VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With Renin-angiotensin System Inhibitors|VITAL|Abbott|No|Completed|December 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|281|||Both|20 Years|N/A|No|||January 2012|January 18, 2012|January 10, 2007|Yes|Yes||No|June 9, 2010|https://clinicaltrials.gov/show/NCT00421733||175312|
NCT00410605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00150|Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma|Phase II Trial of Bevacizumab Combined With Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Active, not recruiting|November 2006|||December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|December 11, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00410605||176147|
NCT00410839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-04 (CPPRB Bordeaux B)|Studies of the Prevention of Atrial Fibrillation by ALA|Prevention of Atrial Fibrillation Recurrence By An Alpha-Linolenic Enriched Diet - A Pilot Study||University of Toronto||Active, not recruiting|June 1999|June 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||130|||Both|18 Years|77 Years|No|||August 2004|December 12, 2006|December 12, 2006||||No||https://clinicaltrials.gov/show/NCT00410839||176129|
NCT00411190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-462795/008|Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin|An Open-Label, Two-Period, Fixed Sequence, Randomized, Parallel Group, Interaction Study to Determine the Effects of Repeat Doses of Relacatib on the Metabolism of Acetaminophen, Ibuprofen and Atorvastatin in Healthy Postmenopausal Female Subjects||GlaxoSmithKline||Completed|October 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|32|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|December 11, 2006||||No||https://clinicaltrials.gov/show/NCT00411190||176104|
NCT00411203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02T-162|Tamoxifen in Treatment of Acute Mania|Double Blind Placebo Controlled Trial of a Protein Kinase C Inhibitor: Tamoxifen Citrate in Treatment of Acute Mania||Stanley Medical Research Institute||Completed|April 2003|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||July 2014|July 30, 2014|December 12, 2006||No||No||https://clinicaltrials.gov/show/NCT00411203||176103|
NCT00411528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2229|Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer|A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer||Novartis||Completed|September 2006|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|185|||Male|18 Years|N/A|No|||March 2013|March 7, 2013|December 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411528||176080|
NCT00435227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP146|A Study to Evaluate a Single IM Dose of Motavizumab Treatment of Children With RSV (Respiratory Syncytial Virus) Illness|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children With RSV Illness||MedImmune LLC||Completed|March 2007|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|N/A|12 Months|Accepts Healthy Volunteers|||July 2012|July 2, 2012|February 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00435227||174298|
NCT00419172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2127|Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers|A Phase I, Single Center, Open-label, One-sequence Cross-over Study to Investigate the Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers||Novartis||Completed|January 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|January 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00419172||175505|
NCT00412815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-99-004|Exercise Training, Insulin Resistance and Coronary Artery Disease|The Effects of Exercise Training on Insulin Resistance in Patients With Coronary Artery Disease and Insulin Resistance, the Exercise, Coronary Artery Disease and Insulin Resistance (EXCADIR) Randomized Controlled Trial||Lawson Health Research Institute||Completed|July 1997|January 2001||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||60|||Both|18 Years|N/A|No|||December 2006|December 14, 2006|December 14, 2006||||No||https://clinicaltrials.gov/show/NCT00412815||175986|
NCT00419159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2241|Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy|A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens||Novartis||Completed|December 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|199|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|January 4, 2007|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00419159||175506|
NCT00419445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTS21-202|Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder|A Double-Blind, Randomized, Proof-of-Concept Crossover Trial to Assess the Effects of GTS21 on Cognitive Function, Clinical Symptoms, and Adverse Events in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder||CoMentis|No|Completed|February 2007|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|55 Years|No|||August 2010|August 16, 2010|January 4, 2007|Yes|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT00419445||175484|
NCT00419978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|750040399|The Significance of Sentinel Node Analysis in Colon Cancer|The Significance of Sentinel Node Analysis in Colon Cancer||Legacy Health System||Terminated|June 2004|May 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|85 Years|No|||June 2008|June 27, 2008|January 5, 2007|||Slow accrural to study.|No||https://clinicaltrials.gov/show/NCT00419978||175444|
NCT00419705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTS-INT06-007|Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)|NeuroThera® Effectiveness and Safety Trial - 2 (NEST-2) A Double Blind, Randomized, Controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Effectiveness of the Treatment of Acute Ischemic Stroke With the NeuroThera® Laser System Within 24 Hours From Stroke Onset||PhotoThera, Inc|Yes|Completed|December 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|660|||Both|40 Years|90 Years|No|||June 2011|June 7, 2011|January 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00419705||175465|
NCT00420862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANTE|The DANTE Trial. A Randomized Study on Lung Cancer Screening With Low-Dose Spiral Computed Tomography|||Istituto Clinico Humanitas||Terminated|June 2001|February 2010||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening||||2400|||Male|60 Years|74 Years|Accepts Healthy Volunteers|||January 2007|January 10, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00420862||175377|
NCT00421161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Refael Segal|Olive Oil With Omega 3 to Treat Stasis Dermatitis|Phase 1 and 2 Study on the Efficacy and Side Effects of Olive Oil and Omega 3 Local Treatment in Stasis Dermatitis||Assaf-Harofeh Medical Center||Not yet recruiting|January 2007|March 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|80 Years|No|||January 2007|January 10, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00421161||175355|
NCT00420199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-119|A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate||Bristol-Myers Squibb|No|Completed|May 2007|May 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|January 8, 2007|Yes|Yes||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00420199||175427|
NCT00408798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-00278|Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin|Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin||University of British Columbia|No|Not yet recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|65 Years|No|||September 2010|September 23, 2010|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408798||176281|
NCT00409084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM10546|Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding|Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding||Virginia Commonwealth University|Yes|Terminated|December 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Both|18 Years|75 Years|No|||July 2010|July 2, 2010|December 6, 2006||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00409084||176261|
NCT00409370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-25|Trial of Safety Nets In Hospitalized Patients|A Randomized Clinical Trial to Compare The Use Of Safety Net Enclosures With Standard Restraints in Agitated Hospitalized Patients||Griffin Hospital||Completed|April 2003|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||60|||Both|18 Years|N/A|No|||December 2006|December 7, 2006|December 7, 2006||||No||https://clinicaltrials.gov/show/NCT00409370||176239|
NCT00421109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 2006/UCI|Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria|Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria||Faes Farma, S.A.|No|Completed|July 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|522|||Both|18 Years|70 Years|No|||April 2012|April 4, 2012|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00421109||175359|
NCT00421122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5892C00013|Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD|A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD||AstraZeneca||Completed|September 2006|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|315|||Both|40 Years|N/A|No|||March 2009|March 26, 2009|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421122||175358|
NCT00421434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-3036|Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C|Randomized Study of Nitazoxanide-Peginterferon, Nitazoxanide-Peginterferon-Ribavirin and Peginterferon-Ribavirin in the Treatment of Chronic Hepatitis C|STEALTHC-1|Romark Laboratories L.C.|No|Completed|June 2006|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A|No|||September 2008|September 23, 2008|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421434||175335|
NCT00421746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMI 001 / SMR-1389|A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure|A Proof of Biological Efficacy Study Assessing the Potential of Piboserod, a Specific 5-HT4 Antagonist, for the Treatment of Symptomatic Congestive Heart Failure on Top of Usual Evidence Based Pharmacological Treatment||Bio-Medisinsk Innovasjon|Yes|Completed|January 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|80 Years|No|||August 2007|August 2, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421746||175311|
NCT00421993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18088|A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris||Galderma||Completed|October 2006|December 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1670|||Both|12 Years|N/A|No|||October 2009|October 19, 2009|January 11, 2007|Yes|Yes||No|January 15, 2009|https://clinicaltrials.gov/show/NCT00421993||175292|
NCT00422318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#345|Treatment of Hyperuricemia in Patients With Heart Failure|Hyperuricemia and the Effects of the Uricosuric Agents Benzbromarone in Patients With Chronic Heart Failure||Tottori University Hospital||Completed|January 2004|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|N/A|N/A||||January 2007|January 12, 2007|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00422318||175267|
NCT00422331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDS04004|Safety and Efficacy Study of Lithium in Bipolar Disorder|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder||JDS Pharmaceuticals||Active, not recruiting|January 2007|December 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|206|||Both|18 Years|65 Years|No|||August 2007|August 13, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00422331||175266|
NCT00418054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-2022|Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C|Phase II, Multi-Center, Randomized, Double-Blind Study of Nitazoxanide Tablets Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Chronic Hepatitis C||Romark Laboratories L.C.||Completed|December 2005|July 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2007|January 3, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418054||175591|
NCT00418067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0136|Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions|Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions|ZEST|CardioVascular Research Foundation, Korea|Yes|Completed|October 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|2645|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418067||175590|
NCT00418353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20024615|Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"|||University of Oklahoma||Completed|August 2002|April 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|18 Years|45 Years|No|||January 2007|January 2, 2007|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00418353||175568|
NCT00436085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3346C0-100907|Randomized Controlled Trial of Stress Management Training in HIV|Randomized Controlled Trial of Stress Management Training in Individuals With HIV Infection|SWISSIT|University of Zurich||Completed|December 2003|December 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||February 2007|February 15, 2007|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436085||174232|
NCT00436098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. H00107|Pediatric Exercise With Congenital Heart Defects (Kinderturnen Mit Angeborenem Herzfehler)|Pediatric Exercise With Congenital Heart Defects (Kinderturnen Mit Angeborenem Herzfehler)||Deutsches Herzzentrum Muenchen|Yes|Recruiting|February 2007|May 2010|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|4 Years|7 Years|No|||August 2008|August 26, 2008|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436098||174231|
NCT00419731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01DA019446-01|Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation|Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|November 2006|July 2010|Anticipated|February 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 2, 2009|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00419731||175463|
NCT00419432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009387|Outcomes of Orthopaedic Surgery Using Gait Laboratory Versus Observational Gait Analysis in Children With Cerebral Palsy|Functional Outcomes Following Orthopaedic Surgery Based on Gait Laboratory Versus Observational Gait Analysis in Ambulatory Children With Cerebral Palsy: A Multi-center Randomized Controlled Trial.||The Hospital for Sick Children|Yes|Recruiting|January 2007|March 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|15 Years|No|||December 2014|December 23, 2014|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419432||175485|
NCT00419991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPLA-6625|Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection|An Open-Label Noncomparative, Multicenter, Clinical Trail Measuring Time Related Clinical Response Factors in Relation to Time to Bacterial Eradication With Tigecycline Treatment in Patients With Catheter Infection||CPL Associates||Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|85 Years|No|||June 2011|June 21, 2011|January 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00419991||175443|
NCT00420225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tampere University Hospital|Mesh Repair of Anterior Vaginal Wall Prolapse|Low-Weight Polypropylene Mesh for Anterior Vaginal Wall Prolapse: A Prospective Randomized Study||University of Tampere||Completed|April 2003|May 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||202|||Female|50 Years|N/A|No|||January 2007|January 9, 2007|January 9, 2007||||No||https://clinicaltrials.gov/show/NCT00420225||175425|
NCT00420238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-403|Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis|A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2007|May 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|70 Years|No|||June 2010|June 24, 2010|January 8, 2007||No||No|May 13, 2010|https://clinicaltrials.gov/show/NCT00420238||175424|
NCT00421499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECA-02-005|Effects of Cocoa Intake on Blood Pressure in Elderly Individuals With Mild Hypertension|Randomized Controlled, Parallel Group, Single Blinded, Phase 1 Study That Investigates the Effects of Regular Daily Intake of Small Amounts of Dark or White Chocolate on Blood Pressure in Elderly Individuals With Mild Hypertension||University of Cologne||Completed|January 2005|May 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||44|||Both|55 Years|75 Years|No|||January 2007|January 11, 2007|January 11, 2007||||No||https://clinicaltrials.gov/show/NCT00421499||175330|
NCT00420212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS301|Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis|DEFINE|Biogen|Yes|Completed|January 2007|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1234|||Both|18 Years|55 Years|No|||January 2015|January 13, 2015|January 8, 2007|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00420212||175426|
NCT00420524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2121|A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function|An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function||Novartis||Completed|January 2006|||July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420524||175403|
NCT00420537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003035-78|Shift to Everolimus (RAD) Kidney Sparing Study|Safety and Efficacy of Low-dose Cyclosporine in Association With Everolimus to Minimize Renal Dysfunction in Heart Transplant Recipients||University of Bologna||Terminated|September 2006|March 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|N/A|No|||May 2009|January 11, 2010|January 9, 2007||No|A cluster of adverse events in everolimus arm was noted.|No||https://clinicaltrials.gov/show/NCT00420537||175402|
NCT00420823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHREC 2006/040|A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment|A 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.||Melbourne Health||Completed|January 2007|December 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|25 Years|No|||November 2015|November 18, 2015|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00420823||175380|
NCT00421759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0072|Noise-Enhanced Sensory Function in Elders at Risk for Falls|Noise-Enhanced Sensory Function in Elders at Risk for Falls||National Institute on Aging (NIA)|Yes|Recruiting|April 2006|January 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|70 Years|N/A|No|||August 2008|December 10, 2009|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421759||175310|
NCT00421447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-375|Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole|Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole||McMaster University|Yes|Completed|January 2007|August 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|||Female|N/A|N/A|No|Non-Probability Sample|Post-menopausal Women|September 2015|September 22, 2015|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421447||175334|
NCT00422357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNFTRI-1385|Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus|Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2007|April 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|30 Years|N/A|No|||April 2007|April 17, 2007|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00422357||175264|
NCT00422006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 06/8-I|Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance|Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance||Nantes University Hospital|Yes|Completed|February 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|111|||Both|18 Years|65 Years|No|||April 2014|April 2, 2014|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422006||175291|
NCT00422019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060100|A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma|A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma||Amgen||Completed|January 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|January 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00422019||175290|
NCT00422344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-105|A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma|A Phase I Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma Patients||Memorial Sloan Kettering Cancer Center||Completed|October 2006|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2010|February 25, 2010|January 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00422344||175265|
NCT00418080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCLT-1236|Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy|The Role of HER Receptor Family as Indicator of Prognosis and Drug Responsiveness in Locally Advanced Prostate Cancer||University of L'Aquila||Completed|April 2002|December 2006||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||86|||Male|18 Years|75 Years|No|||October 2007|October 5, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418080||175589|
NCT00418093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-356|Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma|A Phase II Evaluation of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma||Dana-Farber Cancer Institute||Terminated|September 2006|October 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|January 2, 2007|Yes|Yes|THe study was terminated early due to a lack of accural|No|April 27, 2012|https://clinicaltrials.gov/show/NCT00418093||175588|The trial was closed after enrolling 19 of the 53 projected patient accrual.
NCT00418366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-008|A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)|An Open- Label, 2 Part Study to Investigate the Pharmacokinetics, Safety, and Tolerability of MK0431(Sitagliptin Phosphate) in Patients With Varying Degrees of Renal Insufficiency||Merck Sharp & Dohme Corp.||Completed|January 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|January 3, 2007||||||https://clinicaltrials.gov/show/NCT00418366||175567|
NCT00418379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO53.06|Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets|A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of Two Dosing Regimens of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis||Stallergenes||Completed|December 2006|September 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|633|||Both|18 Years|50 Years|No|||June 2012|June 4, 2012|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418379||175566|
NCT00430248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-GT06-153|Efficacy and Safety of Oral Febuxostat in Participants With Gout|A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.|CONFIRMS|Takeda|Yes|Completed|February 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2269|||Both|18 Years|85 Years|No|||January 2012|January 31, 2012|January 25, 2007|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00430248||174674|
NCT00420017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510-23|Prevention of Atrial Fibrillation Following Esophagectomy|Prevention of Atrial Fibrillation Following Thoracoabdominal Esophagectomy Surgery||Indiana University|Yes|Completed|September 2005|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|40 Years|N/A|No|||September 2013|September 6, 2013|January 8, 2007|Yes|Yes||No|July 27, 2010|https://clinicaltrials.gov/show/NCT00420017||175441|Design not double-blind placebo-control Atrial fibrillation was left to discretion of treating MD Larger study necessary to determine differences in length of hospital stay and cost and identify infrequently occurring amiodarone adverse effects
NCT00419458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD 5R01HD42705|Inspiratory Muscle Training in Ventilator Dependent Patients|Respiratory Muscle Training in Ventilator Dependent Patients||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|February 2004|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|16 Years|N/A|No|||November 2009|November 6, 2009|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00419458||175483|
NCT00419718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1562|Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes|Effect of Exercise on the Pharmacokinetics and Pharmacodynamics of Inhaled Human Insulin in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|October 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|65 Years|No|||July 2012|July 9, 2012|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00419718||175464|
NCT00420251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13042004|Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis|Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development||Ludwig-Maximilians - University of Munich||Completed|March 1996|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|4 Years|14 Years|No|||January 2007|January 9, 2007|January 9, 2007||||No||https://clinicaltrials.gov/show/NCT00420251||175423|
NCT00420589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-012|A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED)|A Study to Assess the Efficacy and Tolerability of Taranabant in Maintaining Weight Loss Induced by Diet in Obese Patients Followed by a 1-Year Extension||Merck Sharp & Dohme Corp.||Terminated|October 2006|November 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1000|||Both|18 Years|65 Years|No|||February 2015|February 4, 2015|January 5, 2007|Yes|Yes|The overall profile does not support development for obesity|No||https://clinicaltrials.gov/show/NCT00420589||175398|
NCT00420602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHA STGD3|DHA Supplementation in Patients With STGD3|Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3||University of Utah|No|Active, not recruiting|August 2006|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|105 Years|No|||October 2015|October 7, 2015|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00420602||175397|
NCT00421512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-016|A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients|A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients||Memorial Sloan Kettering Cancer Center||Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||November 2008|November 10, 2008|January 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00421512||175329|
NCT00421525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL: IMMU-115-01|Phase I/II Study of hLL1 in Multiple Myeloma|A Phase I/II Study of Immunotherapy With hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients With Multiple Myeloma||Immunomedics, Inc.|No|Completed|January 2007|||August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|January 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421525||175328|
NCT00420849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-018|A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma|A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma||Celgene||Completed|November 2006|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|587|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|January 9, 2007||No||No|February 10, 2012|https://clinicaltrials.gov/show/NCT00420849||175378|This study was defined primarily as an expanded access program in the selected countries. Treatment was to continue until disease progression, study drug was discontinued for any reason, or lenalidomide became commercially available for indication.
NCT00421135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM1001|A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer|A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer||Ziopharm||Completed|February 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 16, 2009|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421135||175357|
NCT00421174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465|Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation|A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Cell Transplantation (BMT CTN #0403)|BMT CTN 0403|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|August 2007|July 2013|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421174||175354|
NCT00420550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-188|Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC|Pilot Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With Interstitial Cystitis||William Beaumont Hospitals||Completed|January 2007|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|10|||Female|18 Years|N/A|No|||March 2012|March 19, 2012|January 9, 2007||||No||https://clinicaltrials.gov/show/NCT00420550||175401|
NCT00420836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100B2201|Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study|Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (no Compressor) vs. PARI LC PLUSTM Jet Nebulizer (With Compressor) in Cystic Fibrosis Subjects||Novartis||Completed|April 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|6 Years|N/A||||January 2007|January 10, 2007|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00420836||175379|
NCT00421460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH 023101|The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction|Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction||Chulalongkorn University|No|Completed|January 2007|May 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||May 2012|May 14, 2012|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421460||175333|
NCT00422370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-29.12.06|Lipid Based Food Additives for Treating Patients With Dry Mouth|Lipid Based Food Additives for Treating Patients With Dry Mouth||Hadassah Medical Organization||Not yet recruiting|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|20|||Both|18 Years|90 Years|No|||December 2006|January 16, 2007|December 14, 2006||||No||https://clinicaltrials.gov/show/NCT00422370||175263|
NCT00422383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA17044|A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)|A Randomized, Double-blind Study to Evaluate the Effect of Various Re-treatment Regimens of MabThera in Combination With Methotrexate on Treatment Response in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.||Hoffmann-La Roche||Completed|February 2006|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|378|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|January 15, 2007||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT00422383||175262|
NCT00418119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4273|Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function|Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function||Rabin Medical Center||Not yet recruiting|January 2007|January 2008||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||December 2006|January 3, 2007|January 2, 2007||||No||https://clinicaltrials.gov/show/NCT00418119||175586|
NCT00422032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0535|2 Arm Study of Clofarabine IV in MDS Patients|Phase II Randomized Study of Two Different Schedules of Intravenous Clofarabine in Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Completed|January 2006|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||June 2012|June 22, 2012|January 11, 2007||No||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00422032||175289|
NCT00418106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24211|Kangaroo Holding Effects on Breast Milk|Early Kangaroo Holding Effects on Breast Milk Composition||Christiana Care Health Services|No|Completed|November 2005|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|14 Days|Accepts Healthy Volunteers|Non-Probability Sample|Mothers of preterm infants|January 2008|January 16, 2008|January 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00418106||175587|
NCT00418639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-3027|Study of Nitazoxanide in the Treatment of Chronic Hepatitis C|Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in the Treatment of Chronic Hepatitis C||Romark Laboratories L.C.||Completed|February 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||January 2007|January 3, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418639||175546|
NCT00418652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4252-RA-CTIL|Interruption of Dorsal Visual Stream Using TMS|Interruption of Dorsal Visual Stream Using TMS in Normal Controls||Sheba Medical Center||Completed|January 2006|||July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 3, 2011|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00418652||175545|
NCT00418925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDC DRO 2006|Efficacy of Dronabinol for the Treatment of Cervical Dystonia|Phase II, Double Blind, Randomized, Placebo Controlled Trial of Dronabinol for the Treatment of Cervical Dystonia||University Health Network, Toronto|No|Recruiting|September 2006|December 2009|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|75 Years|No|||August 2007|September 8, 2008|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00418925||175524|
NCT00429403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0464|Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer|Phase III Randomized Study of a Goserelin Acetate for Preservation of Ovarian Function in Patients With Primary Breast Cancer (PBC)||M.D. Anderson Cancer Center|Yes|Terminated|August 2006|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Female|15 Years|46 Years|No|||July 2011|July 27, 2011|January 29, 2007||No|Study stopped due to low accrual.|No|June 27, 2011|https://clinicaltrials.gov/show/NCT00429403||174736|
NCT00429663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25934|A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Distal Femur Fractures|Study of Locked Plates Versus Intramedullary Nails in Distal Femur Fractures: A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation (S.O.L.V.E.D)||Boston Medical Center|Yes|Active, not recruiting|February 2007|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|N/A|N/A|No|||January 2015|January 26, 2015|January 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00429663||174717|
NCT00420277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6090|Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty|A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of an Oxygen-Carrying Plasma Expander, Hemospan®, Compared With Voluven® toTreat Hypotension in Patients Undergoing Primary Hip Arthroplasty With Spinal Anesthesia||Sangart|Yes|Completed|February 2007|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|462|||Both|50 Years|N/A|No|||August 2013|August 15, 2013|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00420277||175421|
NCT00420290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060661|Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients|Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients||Vanderbilt University|Yes|Completed|January 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||October 2011|October 10, 2011|January 10, 2007|Yes|Yes||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00420290||175420|The sample size is small and the intervention is of short duration. Also, the results cannot be generalized to all CHD patients because our inclusion criteria were stringent.
NCT00420004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11174|A Study for Patients With Major Depression|A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression||Eli Lilly and Company|No|Completed|December 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|470|||Both|18 Years|65 Years|No|||October 2009|October 5, 2009|January 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420004||175442|
NCT00420628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459|Pediatric Zylet Safety and Efficacy Study|A Safety and Efficacy Study of Zylet® (Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension) Compared to Vehicle in the Management of Lid Inflammation (Chalazion/Hordeolum) in Pediatric Subjects||Bausch & Lomb Incorporated|No|Completed|November 2006|June 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|N/A|6 Years|No|||September 2011|September 30, 2011|January 8, 2007|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00420628||175395|
NCT00420875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-706WW|Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis|"Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis"|TOPAZ Registry|ArthroCare Corporation||Withdrawn|June 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|January 9, 2007||No|Did not meet enrollment goals|No||https://clinicaltrials.gov/show/NCT00420875||175376|
NCT00421187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-MM-131-0162|Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics|Phase III Study of 3 Sequential Doses (10 mg/kg, 5 mg/kg, and 5 mg/kg) vs 3 mg/kg/Day of AmBisome® in the Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics||Gilead Sciences|No|Terminated|March 2007|May 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2008|March 9, 2011|January 8, 2007||No|Unable to recruit subjects in the Turkey site.|No||https://clinicaltrials.gov/show/NCT00421187||175353|
NCT00422422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01263|Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.|Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From ≥1 Month to <16 Years Old With Epilepsy||UCB Pharma|Yes|Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|1 Month|16 Years|No|||August 2015|August 28, 2015|January 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00422422||175259|
NCT00422435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The PreCiSE Trial: CP-03|CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation|The PreCiSE Trial: CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation||Conor Medsystems|No|Completed|January 2007|May 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||October 2008|October 23, 2008|January 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00422435||175258|
NCT00421486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 KI 0501|Oral Human Papillomavirus Infection in HIV-infected Men|Incidence, Prevalence, Spectrum of HPV-types, and Viral Load Determination of High-risk Human Papillomavirus Infection of the Oral Cavity in HIV-infected Men Who Have Sex With Men||Deutsche Luft und Raumfahrt||Recruiting|March 2006|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|HIV-infected men who have sex with men|January 2016|January 20, 2016|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00421486||175331|
NCT00421148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05961|Dose-Finding Pediatric Trial With Sugammadex (19.4.306)(P05961)(COMPLETED)|A Multi -Center, Randomized, Parallel Dose-Finding, Safety Assessor-Blinded Trial to Explore the Efficacy, Safety and Pharmacokinetics of Four Doses of Sugammadex and Placebo in Pediatric and Adult Subjects.||Merck Sharp & Dohme Corp.|No|Completed|May 2005|June 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|120|||Both|N/A|65 Years|No|||June 2015|June 5, 2015|January 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421148||175356|
NCT00421473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 06.02|Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients|Drug Interactions Between ATOvaquone Used in MAlaria Prophylaxis and Antiretroviral Agents in HIV-1 Infected Patients (ATOMA)||Radboud University||Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|79|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 24, 2009|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00421473||175332|
NCT00422045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xMUO-05|Assessment of Low Level Laser Therapy for Late Postoperative Pain After Lumbar Fusion Surgery|Assessment of Low Level Laser Therapy for Late Postoperative Pain After Lumbar Fusion Surgery||University of Toledo Health Science Campus|No|Withdrawn|December 2006|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||December 2014|December 9, 2014|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00422045||175288|
NCT00418132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR002187|Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis|T Cell Immunity in Collagen Biosynthesis of Scleroderma||New York University School of Medicine|Yes|Terminated|August 2000|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|January 3, 2007|No|Yes|Study terminated early due to difficulties in subject recruitment|No||https://clinicaltrials.gov/show/NCT00418132||175585|
NCT00418418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH 6220|Combined CABG and Stem-Cell Transplantation for Heart Failure|Combined CABG and Stem-Cell Transplantation for Heart Failure||Helsinki University|Yes|Recruiting|October 2006|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2008|August 18, 2008|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418418||175563|
NCT00418678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-05-017|A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting|A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting||Veeda Oncology|No|Terminated|August 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||August 2008|November 30, 2010|January 3, 2007||No|Enrollment was too slow|No||https://clinicaltrials.gov/show/NCT00418678||175543|
NCT00418392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950510|Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax|Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax: A Randomized Trial||National Taiwan University Hospital||Recruiting|November 2006|December 2012|Anticipated|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|15 Years|40 Years|No|||November 2012|December 13, 2012|December 31, 2006||No||No||https://clinicaltrials.gov/show/NCT00418392||175565|
NCT00418405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUMAN|Hanyang University Medical Center Arthritis Network|Hanyang University Medical Center Arthritis Network||Hanyang University||Not yet recruiting|January 2007|January 2012||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1500|||Both|18 Years|N/A|No|||January 2007|January 3, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00418405||175564|
NCT00418665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060102|A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.||Amgen||Completed|December 2006|October 2010|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|5||Actual|39|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|January 4, 2007||||No|November 24, 2010|https://clinicaltrials.gov/show/NCT00418665||175544|
NCT00418938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060141|SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial|A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors||Amgen|Yes|Completed|November 2006|May 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|January 4, 2007|Yes|Yes||No|October 4, 2013|https://clinicaltrials.gov/show/NCT00418938||175523|
NCT00418951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0536|Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections|Open, Randomized Comparative Trial of Two Different Schedules of Liposomal Amphotericin B Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections||M.D. Anderson Cancer Center|Yes|Completed|November 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|120|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|January 3, 2007||No||No|April 15, 2011|https://clinicaltrials.gov/show/NCT00418951||175522|
NCT00419198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.364|Clinical Outcomes of Angioplasty Postconditioning|Postconditioning and Functional Recovery After Acute Myocardial Infarction||Hospices Civils de Lyon||Completed|September 2005|December 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|91|||Both|18 Years|90 Years|No|||March 2010|March 8, 2010|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419198||175503|
NCT00429975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS G03/103|Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia|Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia||Hospital Mutua de Terrassa||Terminated|August 2004|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||45|||Both|18 Years|N/A|No|||January 2007|January 31, 2007|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00429975||174694|
NCT00430274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|073-GRM-2006-001|Photographic Imaging of the Retina and Optic Nerve Head of Glaucoma Patients and Normal Controls|Photographic Imaging of the Retina and Optic Nerve Head of Glaucoma Patients and Normal Controls||University Hospital, Basel, Switzerland|No|Active, not recruiting|January 2006|September 2016|Anticipated|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|45 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with vascular dysregulation|October 2015|October 1, 2015|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430274||174672|
NCT00420914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SToP Study|Strategies for Transfusion of Platelets (SToP)|Strategies for Transfusion of Platelets (SToP) [Formerly Titled "Evaluation of the Hemostatic Efficacy and Platelet Utilization Rates of Low Versus Standard Dose Platelet Therapy"]||McMaster University||Terminated|October 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research|||Actual|130|||Both|17 Years|N/A|No|||May 2008|May 27, 2008|January 8, 2007|||Stopped at the request of the Data Safety Monitoring Board for safety reasons.|No||https://clinicaltrials.gov/show/NCT00420914||175373|
NCT00420264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThermaChoice III|ThermaChoice III Under Local Sedation in the Office Setting|Feasibility of Using Gynecare Thermachoice III in the Office Setting Without Conscious Sedation||Female Pelvic Medicine & Urogynecology Institute of Michigan||Completed|November 2005|May 2009|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00420264||175422|
NCT00420615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2123|Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies||Novartis||Completed|December 2006|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|January 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00420615||175396|
NCT00420888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06762004|ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma|A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.||Active Biotech AB|No|Completed|January 2007|January 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|526|||Both|18 Years|N/A|No|||June 2014|June 30, 2015|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00420888||175375|
NCT00420901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSRRM1999/4|Effect of Chronic PDE5-Inhibition on Endothelial Function in Diabetics|Effect of Chronic Administration of Sildenafil on Endothelial Function in Men With Diabetes||IRCCS San Raffaele||Completed|January 1999|February 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Male|35 Years|75 Years|No|||January 2007|January 9, 2007|January 9, 2007||||No||https://clinicaltrials.gov/show/NCT00420901||175374|
NCT00421200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6084|Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty|A Randomized, Double-blind, Phase III Study of the Efficacy and Safety of an Oxygen-carrying Plasma Expander, Hemospan®, Compared With Voluven® to Prevent Hypotension in Patients Undergoing Primary Hip Arthroplasty With Spinal Anesthesia||Sangart|Yes|Completed|February 2007|June 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|375|||Both|50 Years|N/A|No|||August 2013|August 15, 2013|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00421200||175352|
NCT00434174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2112|Safety of Everolimus and Pemetrexed in Lung Cancer Patients|A Phase I Study Investigating the Combination of Everolimus With Pemetrexed in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy||Novartis||Completed|December 2006|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|February 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00434174||174378|
NCT00434187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142A2-115|Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects|An Ascending Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics of ERB-041 Administered Orally to Healthy, Female Japanese Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|October 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|February 9, 2007||||No||https://clinicaltrials.gov/show/NCT00434187||174377|
NCT00433862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070090|Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders|Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders||National Institutes of Health Clinical Center (CC)||Completed|February 2007|May 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|8|||Both|18 Years|N/A|No|||May 2010|September 26, 2015|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433862||174402|
NCT00433875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030210|Phase 2 AMG 714 in Rheumatoid Arthritis|A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs||Amgen||Completed|December 2002|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|18 Years|N/A||||December 2007|December 20, 2007|February 8, 2007||||||https://clinicaltrials.gov/show/NCT00433875||174401|
NCT00433888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH20563|Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)|Clinical Study of Switching From rHuEPO to R744 and Maintenance Treatment With R744 in Renal Anemia Patients on Hemodialysis (Phase Ⅲ Study)||Chugai Pharmaceutical|No|Completed|January 2007|October 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|20 Years|N/A|No|||January 2009|January 29, 2009|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433888||174400|
NCT00435656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/11OCT/AC/189|Pharmacogenetics of Antiretroviral Drugs|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|September 2007|||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|HIV infected patients|August 2011|August 24, 2011|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435656||174265|
NCT00435708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ref 200651|Effect of Increased Fruit and Vegetable Intake on Chronic Obstructive Pulmonary Disease (COPD)|Effect of Increased Fruit and Vegetable Intake on Airway Inflammation and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD)|DISCO|Queen's University, Belfast|No|Completed|February 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|N/A|N/A|No|||September 2015|September 28, 2015|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435708||174261|
NCT00436514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 06/12-L|Colonoscopy by Videocapsuls Versus Standard Colonoscopy. Intra-individual Comparison for the Subject With a Medium or High Risk of Colorectal Cancer.|Colonoscopy by Videocapsuls Versus Standard Colonoscopy. Intra-individual Comparison for the Subject With a Medium or High Risk of Colorectal Cancer.||Nantes University Hospital||Completed|April 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|550|||Both|18 Years|80 Years|No|||July 2009|July 21, 2009|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436514||174199|
NCT00425672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6308|ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment|Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients With Advanced Refractory Breast Cancer||University of Washington|No|Active, not recruiting|September 2005|||April 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|January 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00425672||175014|
NCT00425685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Use of ECM in acute MI|Use of ECMO in Acute MI|Use of Extracorporeal Membrane Oxygenation in Treatment of Acute Myocardial Infarction Following Cardiac Surgery Procedures||Johann Wolfgang Goethe University Hospitals||Active, not recruiting|January 2003|December 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||60|||Both|17 Years|90 Years|No|||January 2007|January 22, 2007|January 22, 2007||||No||https://clinicaltrials.gov/show/NCT00425685||175013|
NCT00426270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAM10-02|Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults|Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults||Octapharma|Yes|Completed|June 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|January 22, 2007|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00426270||174970|
NCT00426283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-10-07|A Study of Flovent in Patients With Eosinophilic Esophagitis|A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis||Children's Hospital Medical Center, Cincinnati|Yes|Completed|January 2007|October 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|3 Years|30 Years|No|||September 2014|September 10, 2014|January 22, 2007|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00426283||174969|
NCT00427921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W06-405|Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)|A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)|ACCESS|Abbott|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|304|||Both|18 Years|N/A|No|||November 2009|November 12, 2009|January 26, 2007||No||No|January 9, 2009|https://clinicaltrials.gov/show/NCT00427921||174847|Subjects who failed prior infliximab therapy were eligible to enter study after minimum 8 week wash-out since last dose. Includes subjects who previously used infliximab & never responded or responded & developed intolerance/lost efficacy.
NCT00431158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001878|ARDSnet Protocol vs. Open Lung Approach in ARDS|ARDSnet Protocol vs. the Open Lung Approach for the Ventilatory Management of Severe, Established ARDS: A Global Randomized Controlled Trial||Massachusetts General Hospital|Yes|Completed|January 2007|March 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|80 Years|No|||September 2014|September 17, 2014|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00431158||174605|
NCT00431171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN101|Safety and Pharmacokinetics Study of Oral Lithium in Patients With Chronic Spinal Cord Injury|A Three Month, Open-label, Single-arm Trial Evaluating the Safety and Pharmacokinetics of Oral Lithium in Patients Diagnosed With Chronic Spinal Cord Injury||The University of Hong Kong||Completed|September 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|60 Years|No|||January 2012|January 13, 2012|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00431171||174604|
NCT00431444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HUS121|Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density|A Multi-center, Randomized, Double-blind, Double-dummy Study in Postmenopausal Women With Low Bone Mineral Density to Compare the Effects of a Single Dose of i.v. Zoledronic Acid 5 mg, With Daily Oral Raloxifene 60 mg OD on Bone Turnover Markers||Novartis||Completed|January 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|45 Years|80 Years|No|||March 2011|March 25, 2011|February 1, 2007|Yes|Yes||No|November 12, 2010|https://clinicaltrials.gov/show/NCT00431444||174583|
NCT00431457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/005|Controlled Randomized Stimulation Versus Resection (CoRaStiR)|Prospective Randomized Controlled Study of Neurostimulation in the Medial Temporal Lobe for Patients With Medically Refractory Medial Temporal Lobe Epilepsy; Controlled Randomized Stimulation Versus Resection (CoRaStiR)||University Hospital, Ghent|No|Recruiting|June 2007|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431457||174582|
NCT00432744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01FD003032-01A1|Phase III Trial of Coenzyme Q10 in Mitochondrial Disease|Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease||University of Florida|Yes|Completed|January 2007|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|12 Months|17 Years|No|||April 2014|April 30, 2014|February 6, 2007|Yes|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT00432744||174486|The trial intended to accrual 40 subjects, but accrual was below expectations and the granting agency turned down a request for extended accrual.
NCT00428961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-102|Diabetes Genome Project: A Prospective Registry to Identify Genetic Variation Among Diabetic Patients|Diabetic Genome Project: A Multi-Phase Prospective Registry to Identify Genetic Variation Among Diabetic Patients Undergoing Coronary Revascularization|DGP|Saint Luke's Health System|Yes|Completed|July 2002|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1607|Samples With DNA|Whole blood separated into 12 x1000µL, 10x500µL EDTA plasma, 2x1,000 µL and 20x200 µL of      buffy coat (baseline only) and 2x1,000 µL of RBCs (baseline only)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Regional population attending a single-center specialty care clinic|January 2013|January 8, 2013|January 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00428961||174769|
NCT00429208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yakir@hmo|Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers|Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers: A Double-Blind, Within-Subjects, Placebo-Controlled Study||Hadassah Medical Organization||Not yet recruiting|February 2007|April 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|40|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||January 2007|January 30, 2007|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429208||174751|
NCT00429221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5327|Parent-Provider Intervention for Improving Medication Adherence in Children With Attention Deficit Hyperactivity Disorder|ADHD Medication Adherence: A Parent-Provider Intervention Modeled From HIV||New York State Psychiatric Institute||Withdrawn|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Both|6 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 22, 2013|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429221||174750|
NCT00433277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMolnar|Autoimmunity in Retinitis Pigmentosa|||Semmelweis University||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|N/A|N/A||||February 2007|February 8, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00433277||174447|
NCT00433953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-06-44|Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients|Pharmacogenetics of Mycophenolic Acid in Kidney Transplant Patients||Children's Hospital Medical Center, Cincinnati||Terminated|February 2007|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|2 Years|18 Years|No|||February 2013|February 18, 2013|February 8, 2007||No|No longer following patient and no plans to publish.|No||https://clinicaltrials.gov/show/NCT00433953||174395|
NCT00434200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG-97-024|Rheumatoid Arthritis Patients in Training|Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA|RAPIT|Leiden University Medical Center||Active, not recruiting|January 1998|June 2000||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|17 Years|70 Years|No|||February 2007|February 9, 2007|February 9, 2007||||No||https://clinicaltrials.gov/show/NCT00434200||174376|
NCT00434213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-411|Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA|A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).||Noven Therapeutics|No|Completed|January 2007|July 2008|Actual|August 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|309|||Both|6 Years|12 Years|No|||June 2015|June 23, 2015|February 12, 2007|No|Yes||No|February 4, 2009|https://clinicaltrials.gov/show/NCT00434213||174375|
NCT00434863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-015-LK/2005|Comparative Study of the Effect of Dysport and Botox|A Comparative Randomized Double-Blinded Study of the Effect of Dysport and Botox on Forehead Wrinkles and EMG Activity||Laserklinik Karlsruhe||Completed|October 2005|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||February 2007|February 12, 2007|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434863||174325|
NCT00435344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA080254-01A1|Provider and Peer Delivered Youth Smoking Intervention|Provider and Peer Delivered Youth Smoking Intervention||University of Massachusetts, Worcester||Completed|February 1999|January 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||2711|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||February 2007|February 12, 2007|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00435344||174289|
NCT00434538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO-CIP01-P|BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers|A Multicenter, Prospective, Randomized Comparison Study of BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers||BioSyntech Canada Inc.|No|Terminated|February 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|80 Years|No|||February 2009|February 3, 2009|February 9, 2007||No|Due to Sponsor's financial reasons|No||https://clinicaltrials.gov/show/NCT00434538||174350|
NCT00434551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-36|MACCS: Multicenter Australian CE in Patients With Suspected Crohn's Disease Study|Evaluation of Capsule Endoscopy in Patients With Suspected Small Bowel Crohn's Disease|MACCS|Given Imaging Ltd.|No|Completed|February 2005|February 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|119|||Both|10 Years|N/A|No|Probability Sample|clinics|February 2007|March 25, 2009|February 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00434551||174349|
NCT00434564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/0517/2001|Acute Chest Pain Treatment and Evaluation (ACTION) Study|A Randomised Trial on Early Stress Nuclear Scan for Patients Presented to the Emergency Department (ED) With Chest Pain But Non-Diagnostic Electrocardiography-Acute Chest Pain Treatment and Evaluation (ACTION) Study||Singapore General Hospital||Completed|August 2000|May 2002||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||1690|||Both|25 Years|N/A|No|||January 2007|February 12, 2007|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434564||174348|
NCT00434876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101206|The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence|The Effects of Quetiapine on Sleep During Alcohol Abstinence||Philadelphia Veterans Affairs Medical Center|Yes|Completed|August 2007|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||July 2013|July 9, 2013|February 12, 2007|No|Yes||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00434876||174324|The limitations of this study include the small sample size, and assessment of PSQI, PHQ-9, BAI, and SF-12 at week 9 (immediately after washout from the study drug). The corruption of stored online actigraphic sleep data prevented its interpretation.
NCT00435370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH079639|Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia|Tropisetron With Risperidone for Schizophrenia||Baylor College of Medicine|No|Completed|November 2006|August 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|64 Years|No|||August 2014|August 12, 2014|February 13, 2007||No||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00435370||174287|Since all participants were the first episode and drug naive patients, some participants quit before the completion of the entire clinical trial
NCT00435383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-02-220|Comparing Oxygen Saturation in Post Anesthesia Care Unit After Different Methods of Pain Relief|Oxygen Saturation During Transfer From Operating Room to Post Anesthesia Care Unit After Current Anesthesia Care||The University of Texas Health Science Center, Houston||Completed|March 2003|October 2008|Actual|February 2007|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Male|1 Year|6 Years|Accepts Healthy Volunteers|Probability Sample|Children scheduled for elective uni or bilateral orchidopexy.|December 2015|December 11, 2015|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435383||174286|
NCT00435396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108890|Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects|A Phase I, Open-label, Vaccination Study to Evaluate the Safety and Immunogenicity of the GSK Biologicals Recombinant CMV gB Sub-unit Vaccine GSK1492903A in CMV-seronegative Healthy Male Adult Subjects||GlaxoSmithKline||Completed|February 2007|September 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|February 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00435396||174285|
NCT00435721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC 03-2003|Families Coping With Mental Illness Program|The Families Coping With Mental Illness Program||North Suffolk Mental Health Association||Active, not recruiting|June 2002|August 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||50|||Both|18 Years|N/A|No|||January 2007|February 14, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435721||174260|
NCT00435669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-008|A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)|Mass Balance, Pharmacokinetics and Metabolism of [14C]BMS-582664 Prodrug of BMS-540215, in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2008|January 21, 2009|February 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00435669||174264|
NCT00435682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001251-35|To Study the Peripheral Effect of Botulinum Toxin-A (Botox-A) on Experimentally Induced Cutaneous Pain in Healthy Subjects|||Aalborg University||Completed|March 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research|||||||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2008|February 5, 2008|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435682||174263|
NCT00435695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTP103265|Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males|An Open Label, Non-randomized Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain 5-HT1A Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK163090, Using the Ligand [11C]-WAY100635.||GlaxoSmithKline|No|Completed|November 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2012|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435695||174262|
NCT00425971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITRI-BEL1217B-CP002|Safety Study of Anti-Asthma Agent BMEC-1217B|A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Safety Study of BMEC-1217B, in Healthy Volunteers||Medigreen Biotechnology Corp.||Recruiting|July 2008|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|32|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||September 2008|September 3, 2008|January 23, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00425971||174992|
NCT00425984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1AI171-1-02|Male Circumcision for HIV Prevention in Rakai, Uganda|Randomized Trial of Male Circumcision for HIV Prevention, Rakai, Uganda||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2002|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||5000|||Male|15 Years|49 Years|Accepts Healthy Volunteers|||August 2007|August 23, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00425984||174991|
NCT00426322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shapiral-HMO-CTIL|Efficacy of Sinus Floor Augmentation Using Large or Small Bovine Bone Mineral.|Efficacy of Sinus Floor Augmentation Using Large (1-2mm) or Small (0.25-1mm) Bovine Bone Mineral Particles (Bio-Oss®): A Comparative Histomorphometric Clinical Study||Hadassah Medical Organization||Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 9, 2013|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426322||174967|
NCT00427648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH 06-092|Local Anesthetic Treatments for Overactive Bladder|Intravesical Alkalized Lidocaine for the Treatment of Overactive Bladder (OAB), a Randomized, Double-blinded Controlled Trial||NorthShore University HealthSystem Research Institute|No|Terminated|March 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|N/A|No|||March 2014|March 14, 2014|January 26, 2007|Yes|Yes|Data collection complete; analysis to take place|No||https://clinicaltrials.gov/show/NCT00427648||174867|
NCT00427661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #0504048|A Pilot Study of HSCT for Patients With High-Risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen|A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism||University of Pittsburgh|Yes|Recruiting|June 2002|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|35 Years|No|||October 2008|October 16, 2008|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00427661||174866|
NCT00428142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY13|Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma|A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (BCVP-R) for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment||Canadian Cancer Trials Group|Yes|Completed|December 2006|January 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428142||174830|
NCT00428389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DUS38|Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease|A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease||Novartis||Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|262|||Both|50 Years|N/A|No|||June 2014|June 5, 2014|January 26, 2007|Yes|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00428389||174813|
NCT00433030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT-Cohort|Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand|Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand||Institut de Recherche pour le Developpement|No|Active, not recruiting|January 2007|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2816|Samples With DNA|Blood samples|Both|N/A|N/A|No|Non-Probability Sample|HIV-infected Adults and Children|December 2015|December 22, 2015|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433030||174465|
NCT00428675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G118160539|A New Tool for Assessing Fatigue in Individuals With Advanced Cancer|Development of a Rapid Assessment Tool for Fatigue in Palliative Care||University of Alberta|No|Completed|October 2005|October 2010|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|221|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with advanced cancer|November 2011|November 29, 2011|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428675||174791|
NCT00433290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11198|Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain|Protocol F1J-MC-HMFG Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain||Eli Lilly and Company|Yes|Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|256|||Both|40 Years|N/A|No|||August 2009|August 26, 2009|February 7, 2007|Yes|Yes||No|April 30, 2009|https://clinicaltrials.gov/show/NCT00433290||174446|
NCT00433303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intercourse-Prostanoid DP|Correlation Between Coital Activity During Pregnancy and Premature Delivery Related to Prostanoid Receptor Polymorphisms|Correlation Between Coital Activity During Pregnancy and Premature Delivery Related to Prostanoid Receptor Polymorphisms||Shaare Zedek Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Female|20 Years|40 Years||||February 2007|February 8, 2007|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433303||174445|
NCT00433563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000531709|Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer|A 2-Arm Randomized Controlled Trial of Concurrent Chemo-Radiotherapy Comparing Twice-Daily and Once-Daily Radiotherapy Schedules in Patients With Limited Stage Small Cell Lung Cancer (SCLC) and Good Performance Status [CONVERT]|CONVERT|Christie Hospital NHS Foundation Trust|Yes|Active, not recruiting|April 2008|November 2015|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|547|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433563||174425|
NCT00433966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORIZONS AMI|Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction|Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™)||Cardiovascular Research Foundation, New York|Yes|Completed|March 2005|November 2010|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3604|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|February 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00433966||174394|
NCT00434226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3996g|A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)|A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer||Genentech, Inc.||Terminated|March 2007|||April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2009|July 9, 2009|February 11, 2007|Yes|Yes|Based on data collected, the combination appeared to be poorly tolearated.|No|July 9, 2009|https://clinicaltrials.gov/show/NCT00434226||174374|Based on the early safety results from this study, Genentech halted further recruitment and discontinued treatment. Insufficient efficacy data was available to perform additional analyses and limited the interpretation of the analyses performed.
NCT00434239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/49|Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia|A Pilot Study of the Combination of Lenalidomide (Revlimid®) With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor (rhSCF; Ancestim) for Myelodysplasia.||Peter MacCallum Cancer Centre, Australia|Yes|Active, not recruiting|February 2007|May 2014|Anticipated|May 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|February 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00434239||174373|
NCT00434252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4096g|A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma|BEAM|Genentech, Inc.||Completed|February 2007|||April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|N/A|No|||August 2011|August 22, 2011|February 11, 2007|Yes|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00434252||174372|
NCT00434577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108494|Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects|A Vaccination Study to Evaluate the Safety and Immune Response of the GSK Biologicals Zoster Vaccine, GSK1437173A, and to Compare 3 Dosages of GSK1437173A in Healthy Elderly Subjects, Aged 60 Years and Above||GlaxoSmithKline||Completed|February 2007|July 2010|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|715|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 22, 2012|February 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00434577||174347|
NCT00434590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AIT09|Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients|Controlled, Randomized, Parallel Group Study to Assess Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients||Novartis||Terminated|March 2007|May 2008||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A||||March 2011|March 8, 2011|February 12, 2007|||The study has been stopped because of the lack of enrollment|No|December 13, 2010|https://clinicaltrials.gov/show/NCT00434590||174346|
NCT00434889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB 06-181|A Study of Why People With Early Memory Problems Fall or Almost Fall|Factors Associated With Falls and Near-Falls in Community Dwelling Older Adults With Early-Stage Dementia||University of Saskatchewan|No|Recruiting|August 2007|December 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|January 2010|January 8, 2010|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00434889||174323|
NCT00435149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060974|Post-operative Mobilization for Carpal Tunnel Syndrome|Post-operative Mobilization for Carpal Tunnel||Vanderbilt University|No|Completed|December 2006|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2011|February 17, 2011|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00435149||174304|
NCT00435162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489K2303|Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure|A Randomized, Multicenter, Double-blind, 6 Week Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 6 Months - 5 Years Old With Hypertension, Followed by a 2 Week Placebo Withdrawal Period.||Novartis||Completed|March 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|74|||Both|6 Months|5 Years|No|||April 2011|April 15, 2011|February 13, 2007|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00435162||174303|
NCT00435409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181099|A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer|A Randomized, Phase 3 Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Previously Treated Breast Cancer||Pfizer|Yes|Completed|February 2007|June 2011|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|442|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|February 13, 2007|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00435409||174284|
NCT00435422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuroaxial blokade and BP|Neuroaxial Blokade and Blood Pressure|Neuroaxial Blokade and the Effect of Fluid Optimization||Rigshospitalet, Denmark||Recruiting|January 2010|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|80 Years|No|||February 2009|March 24, 2010|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435422||174283|
NCT00435968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-E002-2006-1|Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults|Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults||Afexa Life Sciences Inc||Completed|March 2007|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2007|July 16, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435968||174241|
NCT00425997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BUS07|Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension|A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hypertension||Novartis||Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|480|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|January 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00425997||174990|
NCT00426296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL102060|SHARE: Simple HAART With Abacavir, Reyataz, and Epivir|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks||Clinical Alliance for Research & Education - Infectious Diseases, LLC.||Recruiting|August 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||October 2007|October 30, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426296||174968|
NCT00426959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-04100|Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy|Feasibility Study of Image-guided, Dynamic Dosimetry for Permanent Interstitial Prostate Brachytherapy||Sidney Kimmel Comprehensive Cancer Center||Completed|February 2005|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|6|||Male|18 Years|N/A|No|||November 2012|November 13, 2012|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00426959||174919|
NCT00426972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1002-0066|Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites|A Double Blind, Placebo Controlled Trial to Investigate the Efficacy of Zesteem (Estradiol) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites.||Renovo|No|Completed|January 2007|October 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|148|||Both|18 Years|85 Years|No|||August 2009|August 27, 2009|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00426972||174918|
NCT00436241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20734|A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.|A Open Label Study of the Effect of First-line Therapy With Xeloda in Combination With Oxaliplatin on Overall Response Rate in Patients With Locally Advanced and/or Metastatic Gastric Cancer||Hoffmann-La Roche||Completed|March 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436241||174220|
NCT00436488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12C501|Frequency of ICAM-1 Polymorphisms in Obese Subjects|Study of the Association Between ICAM-1 Polymorphisms and Severe Obesity||Istituto Auxologico Italiano||Completed|January 2005|July 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2007|February 16, 2007|February 16, 2007||||No||https://clinicaltrials.gov/show/NCT00436488||174201|
NCT00427934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001056|Maraviroc in Rheumatoid Arthritis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate||Pfizer|No|Terminated|February 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|January 25, 2007|Yes|Yes|See Detailed Description.|No|October 6, 2009|https://clinicaltrials.gov/show/NCT00427934||174846|
NCT00436501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00218|VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer||National Cancer Institute (NCI)|No|Completed|January 2007|November 2012|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|N/A|No|||March 2013|March 11, 2015|February 15, 2007|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT00436501||174200|
NCT00428155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH#06-140|Arterial Closure Device Comparison Trial II – ACDC Trial II|A Randomized Trial of Angioseal and Starclose for Hemostasis After PCI||St. Michael's Hospital, Toronto||Recruiting|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||448|||Both|25 Years|N/A|No|||January 2007|January 26, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00428155||174829|
NCT00433043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-107|BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)|Beta-blocker Uptitration in Heart Failure Patients Receiving Cardiac Resynchronization Therapy With Optivol Fluid Status Monitoring System||St. Luke's-Roosevelt Hospital Center|No|Terminated|January 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|99 Years|No|||January 2014|October 28, 2015|February 8, 2007||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00433043||174464|
NCT00433316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC064113CTIL|Pain Relief by Intra-Peritoneal Ropivacaine During Gynecological Laparoscopy|Pain Relief by Continuous Intra-Peritoneal Nebulization of Ropivacaine During Gynecological Laparoscopic Surgery||Carmel Medical Center|No|Completed|February 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||February 2007|June 19, 2008|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433316||174444|
NCT00433329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-419|Combination Therapy in Pulmonary Arterial Hypertension|COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling|COMPASS 3|Actelion||Completed|March 2007|August 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|12 Years|N/A|No|||May 2013|May 30, 2013|February 7, 2007|No|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT00433329||174443|
NCT00433576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00864|Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery|Phase I Repeat-Dose Study of Resveratrol in Colorectal Cancer Patients: Tolerability, Target Tissue Levels and Pharmacodynamics||National Cancer Institute (NCI)||Completed|December 2006|March 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2011|September 12, 2014|February 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00433576||174424|
NCT00433589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10041|Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes|MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes|MINDACT|European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|December 2006|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6600|||Female|18 Years|120 Years|No|||October 2015|October 2, 2015|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433589||174423|
NCT00434915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02|Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?|Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?||Mayo Clinic||Completed|April 2003|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434915||174321|
NCT00434928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70464|Dietary Intake and Nutrient Status of Children With ADHD|Dietary Intake and Nutrient Status of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)||University of British Columbia||Completed|January 2006|January 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||60|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||February 2007|February 13, 2007|February 13, 2007||||No||https://clinicaltrials.gov/show/NCT00434928||174320|
NCT00435175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0242|Acute Metabolic Effects of Estradiol|Acute Effects of Estradiol on Lipolysis in Subcutaneous Adipose Tissue and Muscle Assessed by Microdialysis and Tissue Biopsies||University of Aarhus||Completed|June 2005|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||8|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||February 2007|February 13, 2007|February 13, 2007||||No||https://clinicaltrials.gov/show/NCT00435175||174302|
NCT00434603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Expressive Arts as a Social and Community Integration Tool for Youth Recovering From Brain Injury|Expressive Arts as a Social and Community Integration Tool for Adolescents With Acquired Brain Injury: "I Want to Thrive, Not Just Survive!"||University of Toronto|No|Active, not recruiting|July 2007|July 2009|Anticipated|July 2009|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|8|||Both|13 Years|16 Years|No|Non-Probability Sample|Youth recovering from acquired brain injury|February 2009|February 26, 2009|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00434603||174345|
NCT00434902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO51082|Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease|Evaluation of the Characteristics, Prevalence and Prognosis of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease: Study ETENDARD.|ETENDARD|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|February 2007|December 2012|Anticipated|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Patients With Sickle Cell Disease|November 2012|December 18, 2012|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00434902||174322|
NCT00436007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106369|Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen|Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants||GlaxoSmithKline||Completed|April 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|511|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||May 2013|May 23, 2013|February 15, 2007|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00436007||174238|
NCT00431834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURE-AF/Permanent|Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study|Medtronic Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF)/Permanent Study||Medtronic Cardiovascular|Yes|Completed|May 2007|August 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||August 2013|November 3, 2013|February 2, 2007|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00431834||174554|Slow/delayed enrollmentMedical management of subjects by non-investigators leading to medication washout protocol deviationsMissing endpoint data (attrition) due to cohort demographics (old age, dementia, relocation, etc.)
NCT00436306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD036663|Stage Matched Intervention to Increase Dual Method Use|Stage Matched Intervention to Increase Dual Method Use|PROTECT|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|October 1999|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|550|||Female|13 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436306||174215|
NCT00436319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-2|Duration of GnRH-analogue Downregulation and Pregnancy Rates|Effect of the Duration of GnRH-analogue Downregulation on Pregnancy Rates in IVF||Aristotle University Of Thessaloniki||Terminated|May 2006|||June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Female|19 Years|38 Years|No|||February 2016|February 11, 2016|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436319||174214|
NCT00435981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/P2/04/3|Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes|A Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus||Diamyd Therapeutics AB||Completed|January 2005|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|10 Years|18 Years|No|||January 2008|January 29, 2008|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00435981||174240|
NCT00431808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA1_02_07|Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])|Randomized Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Pichia Pastoris-Expressed P. Falciparum Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) Versus Tetanus Toxoid, in Healthy Malian Adult in Bandiagara||African Malaria Network Trust|Yes|Recruiting|May 2007|June 2008|Anticipated|June 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2008|April 1, 2008|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431808||174556|
NCT00426595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/013|Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation|Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation||University Hospital, Ghent||Completed|April 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|14|||Both|N/A|18 Years|No|||April 2009|April 9, 2009|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426595||174947|
NCT00426608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS105511|To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.|Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover Study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone With a Single Dose of GSK561679 or Alprazolam in Healthy Volunteers||GlaxoSmithKline||Completed|October 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|1||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426608||174946|
NCT00426985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3269-304|Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee||Endo Pharmaceuticals||Terminated|January 2007|October 2008|Anticipated|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|330|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|January 24, 2007|||Sufficient number of subjects accrued to conduct analysis|No||https://clinicaltrials.gov/show/NCT00426985||174917|
NCT00432107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP3003|A Study to Assess APO866 for the Treatment of Advanced Melanoma|A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.||Onxeo|No|Completed|July 2006|March 2009|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2013|September 28, 2015|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432107||174534|
NCT00432757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003-15|Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens Wearers||Vistakon Pharmaceuticals||Completed|January 2007|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|8 Years|N/A|No|||April 2009|April 8, 2009|February 4, 2007||||||https://clinicaltrials.gov/show/NCT00432757||174485|
NCT00432120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAGUE 8|Clopidogrel Only Before Percutaneous Coronary Intervention or Before Every Coronarography?|Clopidogrel Loading Dose for ad-Hoc Percutaneous Coronary Intervention Immediately Following Elective Coronary Angiography: Randomized Multicenter Trial Comparing Pre-Treatment > 6 Hours Before Every Angiography vs. Cath-Lab Administration After Angiography (Just Before Intervention): the PRAGUE-8 Trial.||Charles University, Czech Republic||Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|18 Years|N/A||||August 2007|January 28, 2008|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432120||174533|
NCT00432471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0493|Optical Imaging of Skin Cancers for Margin Delineation of Non-melanoma Skin Cancers|Evaluation of Optical Imaging for Margin Delineation of Non-melanoma Skin Cancers||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2007|||January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00432471||174506|
NCT00432783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01-023E|A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor|A Comparison of Adherence Rates to Ritonavir (Soft-gel Capsules) and Its Accompanying Protease Inhibitor (PI) in Patients Receiving Ritonavir Boosted PI Regimens||Montefiore Medical Center||Active, not recruiting|June 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the Montefiore Medical Center Infectious Diseases Clinic        who meet eligibility criteria described below.|November 2009|November 4, 2009|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432783||174483|
NCT00433056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOTTI|Long Term Treatment Interruptions|Strategic, Long Term, Immunologically Driven Treatment Interruptions in Patients on Effective HAART: A Controlled, Randomized Study||A.O. Ospedale Papa Giovanni XXIII||Completed|January 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||April 2008|April 24, 2008|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00433056||174463|
NCT00433342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3532|The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients|Study on the Effect of Flucloxacillin on the Serum Level of P-cresol in Peritoneal Dialysis Patients||Universitaire Ziekenhuizen Leuven|No|Suspended|March 2006|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00433342||174442|
NCT00433602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-90051|Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors|TEACH Survey (Thrombo-Embolism And Chemotherapy) A Prospective Survey on the Incidence of Venous Thromboembolic Events During Chemotherapy for Solid Tumors||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 2006|||March 2007|Actual|N/A|Observational|N/A|||Actual|64|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433602||174422|
NCT00434941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2005-01|Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours|Multicenter Phase IV.II Trial, for the Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours||Spanish Breast Cancer Research Group||Terminated|September 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|70 Years|No|||June 2009|June 25, 2009|February 13, 2007||No|Due to the slow rate of recruitment the study was stopped.|No||https://clinicaltrials.gov/show/NCT00434941||174319|
NCT00435188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3386-R|Life 2: Improving Fitness and Function in Elders|Life 2: Improving Fitness and Function in Elders|Project LIFE|VA Office of Research and Development|No|Completed|November 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|70 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 8, 2015|February 12, 2007||No||No|October 7, 2014|https://clinicaltrials.gov/show/NCT00435188||174301|
NCT00435461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFU109045|Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine|A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis||GlaxoSmithKline|No|Completed|December 2006|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1000|||Both|12 Years|N/A|No|||January 2016|January 28, 2016|February 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00435461||174280|
NCT00435435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL-175-1|Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence|Phase Four Randomized, Multicentre, Open-Label, Comparative Trial Of Disulfiram, Nalterexone And Acamprosate In The Treatment Of Alcohol Dependence|DNA|National Institute for Health and Welfare, Finland||Completed|September 2000|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||243|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2000|February 15, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435435||174282|
NCT00435448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-202|Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia|A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia||Threshold Pharmaceuticals||Terminated|June 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Male|50 Years|80 Years|No|||April 2009|April 28, 2009|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00435448||174281|
NCT00435734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFEL011174506|Obesity Intervention "Obeldicks" for Obese Children, Adolescents and Their Parents|Evaluation of the Intervention Program "Obeldicks" for Obese Children and Adolescents|Obeldicks|University of Witten/Herdecke||Recruiting|July 1999|December 2035|Anticipated|December 2034|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|clinic based study of obese children|December 2015|December 3, 2015|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435734||174259|
NCT00435994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311-21|Assessment of Airway Obstruction in Infants With Lower Respiratory Infections|Assessment of Airway Obstruction in Infants With Lower Respiratory Infections||Indiana University|Yes|Completed|December 2003|December 2012|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|2 Months|2 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00435994||174239|
NCT00436332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529756|S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma|A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC)||Southwest Oncology Group|No|Active, not recruiting|July 2007|||June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|February 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00436332||174213|
NCT00432263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281274|Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.|Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain Injury||Pfizer||Withdrawn|April 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|55 Years|No|||April 2015|April 21, 2015|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432263||174522|
NCT00432276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-322OPI-004|Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg Versus Dose Titration From 30 mg to 45 mg of Pioglitazone HCl (ACTOS®) in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Control on a Combination of Metformin and 30 mg of Pioglitazone HCl Therapy||Takeda|No|Completed|January 2007|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|803|||Both|18 Years|80 Years|No|||April 2013|April 1, 2013|February 5, 2007|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00432276||174521|
NCT00432198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6199-JC-0001|Zolpidem Postmarketing Study in Adolescent Patients With Insomnia|Zolpidem Postmarketing Clinical Study: A Double Blind, Placebo Controlled Group Comparative Trial in the Adolescent Patients With Insomnia||Astellas Pharma Inc|No|Completed|February 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|122|||Both|12 Years|18 Years|No|||March 2010|March 3, 2010|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432198||174527|
NCT00432211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1009|Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.|A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.||Renovo||Active, not recruiting|May 2006|September 2012|Anticipated|July 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||February 2009|February 3, 2009|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432211||174526|
NCT00432224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-272867|Treatment of Actinic Keratoses With Photodynamic Therapy Using Sunlight Versus Red Light|||Bispebjerg Hospital||Completed|May 2006|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||28|||Both|18 Years|N/A|No|||February 2007|February 6, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432224||174525|
NCT00431821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H24242|Reshaping Exercise Habits and Beliefs (REHAB)|Reshaping Exercise Habits and Beliefs (REHAB): Pilot Testing of a Behavioral Intervention to Improve Mobility After Stroke|REHAB|VA Office of Research and Development|Yes|Completed|October 2006|October 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|40 Years|85 Years|No|||July 2013|July 18, 2013|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431821||174555|
NCT00426621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-PN-316|Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis|A 12-Week, Randomized, Double-Blind, Multi-Center, Vehicle-Controlled, Parallel Group Study to Assess the Efficacy and Safety of the Diclofenac Sodium Gel 1% for the Relief of Signs and Symptoms in Patients With Osteoarthritis of the Knee.||Novartis|No|Completed|November 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|420|||Both|35 Years|N/A|No|||December 2007|December 13, 2007|January 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426621||174945|
NCT00426634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907068|Children With Asthma in New Orleans After Hurricane Katrina|Head-Off Environmental Asthma in Louisiana||National Institutes of Health Clinical Center (CC)||Completed|January 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1950|||Both|4 Years|12 Years|No|||May 2015|May 20, 2015|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00426634||174944|
NCT00426647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP4006|Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine|A Randomised Double-blind Multicentre Equivalence Study With Active Parallel Comparator Group to Evaluate the Efficacy and Safety of Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip, Knee &/or Lumbar Spine.||Norpharma A/S|No|Completed|February 2007|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2010|January 29, 2010|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426647||174943|
NCT00436267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000530018|Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery|Phase II Study of SIRT and SERT With Chemotherapy in Patients With Recurrent /Metastatic Pancreatic Cancer||National Cancer Institute (NCI)||Active, not recruiting|November 2006|||October 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2009|December 18, 2013|February 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00436267||174218|
NCT00432419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS131|Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy.|Therapeutic Intensification for HIV-associated Non-Hodgkin's Lymphoma by Autologous Transplantation of Either Unselected or CD34+-Selected Peripheral Blood Stem Cells, in Patients in First or Second Complete Remission. ANRS 131||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Terminated|February 2007|October 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|55 Years|No|||December 2011|December 21, 2011|February 5, 2007||No|only one patient enrolled|No||https://clinicaltrials.gov/show/NCT00432419||174510|
NCT00432432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-2005-003|Combination Methotrexate and Infliximab|The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation||Chinese University of Hong Kong|No|Completed|February 2005|October 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|70 Years|No|||February 2012|February 10, 2012|February 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432432||174509|
NCT00432445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0883|Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma|A Phase II Trial of Proton Beam Radiation Therapy for Intra- and Periocular Retinoblastoma||M.D. Anderson Cancer Center|No|Terminated|January 2007|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||February 2015|February 12, 2015|February 5, 2007||No|Low accrual.|No|February 12, 2015|https://clinicaltrials.gov/show/NCT00432445||174508|
NCT00432770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1779-06-001|Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers|A Phase 1, Single-Site, Double-Blind,Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779 Compared to Placebo in Healthy Volunteers||Archemix Corp.||Completed|December 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432770||174484|
NCT00432796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-267|PERIOP 2 - A Safety and Effectiveness Study of LMWH Bridging Therapy Versus Placebo Bridging Therapy for Patients on Long Term Warfarin and Require Temporary Interruption of Their Warfarin.|A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)||Lawson Health Research Institute|Yes|Active, not recruiting|December 2006|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1473|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00432796||174482|
NCT00433069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-DMI-05-116|Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone|A Pilot Study of Treatment With Pegylated Interferon-Alpha2a, Ribavirin and Insulin Sensitizer Pioglitazone of Insulin Resistance (With the Exception of Diabetes) in Hepatitis C Virus Infection (The INSPIRED HCV Study)||University Hospital, Geneva|No|Completed|January 2007|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433069||174462|
NCT00433355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0265|Epstein-Barr Virus as a Possible Cause for Chronic Fatigue Syndrome|Studies on Epstein-Barr Virus as a Possible Etiological Agent for Chronic Fatigue Syndrome||University of Mississippi Medical Center|Yes|Completed|January 2007|October 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|18 y/o and above with history of CFS matched those without as to age and gender.|March 2009|March 18, 2009|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00433355||174441|
NCT00433615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH20566|Clinical Study of R744 to Predialysis Patients|Switch and Maintenance Study of Subcutaneous or Intravenous Injections of R744 to Predialysis Patients ( Phase Ⅲ Study ).||Chugai Pharmaceutical|No|Completed|February 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|20 Years|N/A|No|||January 2009|January 29, 2009|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433615||174421|
NCT00433628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070094|Accuracy of Hemoglobin A1C to Predict Glycemia in HIV|Accuracy of Hemoglobin A1C to Predict Glycemia in HIV||National Institutes of Health Clinical Center (CC)||Completed|February 2007|||November 2008|Actual|N/A|Observational|Time Perspective: Prospective||||175|||Both|18 Years|N/A|No|||August 2009|September 26, 2015|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433628||174420|
NCT00433121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101|Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD|Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - an Open Study.||Sykehuset Innlandet HF|No|Completed|September 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|N/A|No|||August 2007|August 23, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00433121||174458|
NCT00435747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3481100|Efficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo Following Sub Muscular Breast Augmentation|A Double-Blind Comparative Multicenter Study Of The Efficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo On Reducing Opioids Consumption Following Sub Muscular Breast Augmentation Surgery||Pfizer||Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|February 13, 2007||||No||https://clinicaltrials.gov/show/NCT00435747||174258|
NCT00436020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|paulfitzgerald|rTMS in the Treatment of Bipolar Depression|A Double-Blind Sham Controlled Trial of rTMS in the Treatment of Bipolar Depression||Bayside Health||Recruiting|April 2007|December 2009|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||May 2008|May 5, 2008|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00436020||174237|
NCT00434967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2456C00002|Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo|A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults||AstraZeneca||Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|2207|||Both|20 Years|80 Years|No|||November 2010|November 30, 2010|February 13, 2007|Yes|Yes||No|January 9, 2009|https://clinicaltrials.gov/show/NCT00434967||174317|
NCT00436059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/175|The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)|The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)||Vejle Hospital||Completed|February 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436059||174234|
NCT00436072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-177|ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer|Phase I Study of ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer||Dana-Farber Cancer Institute||Completed|February 2007|August 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|February 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00436072||174233|
NCT00432887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK67486 (completed)|Experimental Studies of the Effects of Caffeine on Glucose Regulation|Caffeine and Glucose Regulation||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 2004|February 2007||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||March 2010|March 1, 2010|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432887||174476|
NCT00433134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-093|Survey of Adherence to Immunosuppression and Other Medications in Kidney Transplant Patients|Survey Investigation of Adherence to Immunosuppression and Other Medications Among Kidney Transplant Recipients at SUNY Downstate||State University of New York - Downstate Medical Center|No|Completed|June 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|||April 2009|April 23, 2009|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00433134||174457|
NCT00433108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTQ-HC-001|Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C|A Double-Blind, Parallel, Randomized Comparison of Two Doses of MitoQ and Placebo for the Treatment of Patients With Raised Liver Enzymes Due to Hepatitis C||Antipodean Pharmaceuticals, Inc.|No|Completed|March 2007|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||August 2008|August 12, 2008|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00433108||174459|
NCT00426998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ComB-V001|Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD|A 24 Month Randomized, Double-Masked, Single Center, Phase II Study Comparing Photodynamic Therapy With Verteporfin (Visudyne)Plus Two Different Timing Regimens of Intravitreal Bevacizumab (Avastin) Given 1 Week Prior to or 1 Week Following Photodynamic Therapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.||Retinal Consultants Medical Group||Completed|April 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|55 Years|N/A|No|||January 2007|January 25, 2007|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00426998||174916|
NCT00427011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-220|A Study of E2007 In Patients With Parkinson's Disease|A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 In Patients With Parkinson's Disease Who Experience End-of-Dose "Wearing-Off" Motor Fluctuations||Eisai Inc.||Terminated|February 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2013|February 5, 2013|January 24, 2007|Yes|Yes|Study stopped due to lack of efficacy.|No|November 20, 2012|https://clinicaltrials.gov/show/NCT00427011||174915|Due to early termination, a limited number of subjects (n=26) were screened for inclusion in the study and only 25 subjects were analyzed. The majority of subjects did not reach the scheduled Week 56 assessment.
NCT00431782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-5923-CLN-504|Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation|An Open-Label Multi-Center Study of ATI-5923 for Anticoagulation in Patients With Atrial Fibrillation||ARYx Therapeutics||Completed|December 2006|October 2007|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||May 2007|November 7, 2007|February 2, 2007||||No||https://clinicaltrials.gov/show/NCT00431782||174558|
NCT00431769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010519|An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma|A Phase II, Open-Label Trial Using Velcade for ReTreatment of Multiple Myeloma Subjects Following an Initial Response to Velcade||Janssen-Cilag International NV|No|Completed|June 2006|January 2010|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431769||174559|
NCT00432146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/117|Effect of Lugol's Solution in the Patients With Graves' Disease|Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease||Istanbul University||Completed|September 2005|September 2006||||N/A|Observational|Time Perspective: Prospective||||36|||Both|14 Years|61 Years|No|||February 2007|October 17, 2008|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432146||174531|
NCT00432458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000530050|Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma|A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma||Mayo Clinic|Yes|Completed|July 2003|April 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|February 5, 2007|Yes|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00432458||174507|
NCT00433654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212|EMRI SureScan™ Clinical Study|EnRhythm MRI™ SureScan™ Pacing System Clinical Investigation||Medtronic Cardiac Rhythm Disease Management|Yes|Completed|February 2007|August 2010|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|484|||Both|N/A|N/A|No|||July 2011|October 17, 2011|February 2, 2007|Yes|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00433654||174418|Comparisons with a historical control (5076 Lead) were performed for secondary objectives #11-#16, however the results database is currently only designed to allow for reporting of participants specifically enrolled as part of this protocol.
NCT00433667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010357|A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.|Epilepsy Phase III Trial||SK Life Science||Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|563|||Both|16 Years|N/A|No|||June 2012|June 15, 2012|February 9, 2007||||||https://clinicaltrials.gov/show/NCT00433667||174417|
NCT00433979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHP-79215|Study of Pharmacokinetics in HIV-infected Women|Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression on Combination Antiretroviral Therapy||Women's College Hospital|No|Completed|February 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|88|Samples Without DNA|Blood samples will be drawn before and after antiretroviral drugs are taken for visits 1-3.|Female|18 Years|65 Years|No|Non-Probability Sample|The patient population will consist of 80 HIV-infected women (who are on their first cART        regimen containing either a PI or an NNRTI for at least three months and who have evidence        of full virologic suppression (HIV RNA VL < 50 copies/mL) on at least two occasions at        least one month apart. The first cART regimen can include ARV switches as long as these        switches are not due to virologic failure. The patient population is being limited to        women who have full virologic suppression to avoid inclusion of women with difficulty with        drug adherence.|July 2012|July 27, 2012|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433979||174393|
NCT00433693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH20562|Correction Study of R744 in Renal Anemia Patients on Hemodialysis|Correction Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase Ⅲ Study ).||Chugai Pharmaceutical|No|Completed|February 2007|October 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|N/A|No|||January 2009|January 29, 2009|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433693||174415|
NCT00433368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA001|Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy|Efficacy of a Three Days’ Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study||Aga Khan University||Completed|October 2003|September 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||108|||Both|14 Years|65 Years|No|||February 2007|February 8, 2007|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433368||174440|
NCT00433641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003371|Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes|Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients||Mayo Clinic|No|Completed|July 2006|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|181|||Both|18 Years|65 Years|No|||March 2011|March 10, 2011|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433641||174419|
NCT00432536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20307|Redesigning Cardiac Surgery to Reduce Neurologic Injury|Redesigning Cardiac Surgery to Reduce Neurologic Injury||Dartmouth-Hitchcock Medical Center|No|Completed|October 2002|February 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|469|Samples Without DNA|Serum to study neurologic biomarker, Sb100.|Both|40 Years|89 Years|No|Non-Probability Sample|Patients undergoing cardiac surgery.|May 2013|May 14, 2013|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00432536||174502|
NCT00432549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSS-328|Detoxification and Treatment of Subjects With Medication Overuse Headache|Evaluation of Almotriptan and Topiramate in the Detoxification and Treatment of Subjects With Medication Overuse Headache||The New England Center for Headache, P.C.||Recruiting|January 2007|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Both|18 Years|N/A|No|||February 2007|February 7, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432549||174501|
NCT00432562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|530-01|A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.|A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.||Mast Therapeutics, Inc.|No|Completed|February 2007|December 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|February 6, 2007|Yes|Yes||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00432562||174500|
NCT00433758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA-A2-2007-01-CTIL|Evaluation of the GlucoTrack, Non-Invasive Glucose Monitoring Device|Evaluation of the Performance and Use of the GlucoTrack(TM), Non-Invasive Glucose Monitoring Device||Integrity Applications Ltd.|Yes|Active, not recruiting|December 2006|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|142|||Both|10 Years|N/A|No|||September 2007|March 17, 2008|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433758||174410|
NCT00434018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-274|Enhancing Indoor, Community, and Advanced Wheelchair Skills in Spinal Cord Injury (SCI)|Enhancing Indoor, Community, and Advanced Wheelchair Skills in SCI||VA Office of Research and Development|No|Completed|April 2008|December 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|138|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|February 8, 2007||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT00434018||174390|
NCT00434980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000383|Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia|Pilot Study of the Feasibility of a Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia||Beth Israel Deaconess Medical Center||Completed|February 2005|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00434980||174316|
NCT00431886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0603/031-009|Usefulness of 64 Slice Multi-Detector Computed Tomography as a First Diagnostic Approach in Acute Chest Pain Patients|Usefulness of 64 Slice Multi-Detector Computed Tomography as a First Diagnostic Approach in Acute Chest Pain Patients||Seoul National University Bundang Hospital|No|Completed|April 2006|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|400|||Both|19 Years|N/A|No|||February 2007|June 20, 2011|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431886||174550|
NCT00431899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDW3|Effects of Omega 3 in Hemodialysis Patients|Effets of Fish Oil on Metabolic Fate of an Oral Glucose Load in Patients With End Stage Renal Disease Undergoing Hemodialysis||Laboratoire Régional de Nutrition Humaine||Completed|May 2003|November 2003||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening||||8|||Both|18 Years|75 Years|No|||February 2007|March 2, 2016|February 3, 2007||||No||https://clinicaltrials.gov/show/NCT00431899||174549|
NCT00433446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526555|S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients With Hormone Refractory Prostate Cancer||Southwest Oncology Group|No|Completed|April 2007|July 2011|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Male|18 Years|N/A|No|||January 2013|January 2, 2013|February 8, 2007|Yes|Yes||No|November 9, 2012|https://clinicaltrials.gov/show/NCT00433446||174434|
NCT00433771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-WALLFLEX-BIL-PALL-001U|A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction|A Multi-Center, Single Arm, Prospective Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction||Boston Scientific Corporation|No|Completed|March 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||June 2010|June 21, 2010|February 8, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00433771||174409|
NCT00434031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETRA|CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer|Neoadjuvant Therapy With Trastuzumab and Docetaxel Followed by Trastuzumab, Caelyx (Liposomal Doxorubicin) and Cyclophosphamide in Operable or Locally Advanced Her-2 Positive Breast Cancer|CETRA|National Cancer Institute, Naples||Withdrawn|September 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||July 2012|July 27, 2012|February 9, 2007||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00434031||174389|
NCT00432627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2125|Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.|An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of 20 mg/kg Oral Deferasirox in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function||Novartis||Completed|December 2006|||August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 2, 2011|February 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432627||174495|
NCT00432926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA021115|Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users|Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users||University of California, San Diego|Yes|Completed|February 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|429|||Male|18 Years|N/A|No|||September 2012|September 27, 2012|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432926||174473|
NCT00432172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2006-03|Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients|"A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients"||Spanish Breast Cancer Research Group||Active, not recruiting|September 2007|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|189|||Female|18 Years|70 Years|No|||November 2012|November 21, 2012|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432172||174529|
NCT00432510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVP2006-5|Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects|Protocol LEVP2006-5: Pharmacokinetics of C1INH-nf in Hereditary Angioedema Subjects||Shire|No|Completed|October 2006|June 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|27|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|February 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00432510||174504|
NCT00432159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-DISCOVER|Comparison of DISCOVER™ Artificial Cervical Disc and ACDF for Treatment of Cervical DDD (IDE Study)|A Multi-Center, Prospective, Randomized Controlled Trial Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion for the Treatment of Cervical Degenerative Disc Disease||DePuy Spine|Yes|Active, not recruiting|July 2006|May 2016|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|500|||Both|21 Years|70 Years|No|||August 2015|August 4, 2015|February 5, 2007|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00432159||174530|Enrollment terminated early, and beginning in March 2013, follow-up visits beyond 24 months were limited to Discover subjects only.
NCT00432484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2005-001|Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis|Lingzhi (Ganoderma Lucidum) and Sen Miao San Supplementation in Rheumatoid Arthritis(RA): An Animal Model and A Phase I Study||Chinese University of Hong Kong|No|Completed|May 2005|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|February 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432484||174505|
NCT00433394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AADM01P1|Registration and Informed Consent Study for the Childhood Cancer Research Network|Protocol for Registration and Consent to the Childhood Cancer Research Network - A Limited Institution Pilot||Children's Oncology Group|No|Completed|May 2001|January 2011|Actual|January 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|2242|||Both|N/A|20 Years|No|||June 2013|June 26, 2013|February 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00433394||174438|
NCT00433680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72932|Targeted Obesity Prevention Program for Adolescent Females|Targeted Obesity Prevention Program for Adolescent Females||Oregon Research Institute|Yes|Completed|March 2007|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|405|||Female|17 Years|19 Years|No|||April 2014|April 7, 2014|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433680||174416|
NCT00433706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 1248|Image Guided Radiation Therapy For Prostate Cancer|Economic Evaluation of Image Guided Radiation Therapy For Prostate Cancer||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|June 2007|September 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|520|||Male|N/A|N/A|No|||September 2007|September 11, 2007|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433706||174414|
NCT00434265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3493|Obesity, Physical Inactivity or Dietary Fat ?|OBESITY, PHYSICAL INACTIVITY OR DIETARY FAT ? Role of Physical Activity in the Trafficking of Dietary Fatty Acids Varying in Length and Saturation Degree.||University Hospital, Strasbourg, France||Completed|March 2007|August 2011|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|55 Years|No|||January 2009|August 29, 2011|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434265||174371|
NCT00434616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001825-24|Autologous Bone Marrow Stem Cell Transplantation for Critical, Limb-threatening Ischemia|Security and Effectiveness of Autologous Bone Marrow Stem Cell Transplantation to Avoid Amputations in Patients With Limb-threatening Ischemia: A Multicentric Randomized Placebo-controlled Double-blind Study|BONMOT|Franziskus-Krankenhaus|No|Active, not recruiting|April 2007|July 2011|Anticipated|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|95 Years|No|||April 2011|April 5, 2011|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434616||174344|
NCT00434278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z3877g|A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease||Genentech, Inc.||Terminated|March 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|14 Years|N/A|No|||October 2010|October 18, 2010|February 11, 2007|Yes|Yes|This study was terminated for administrative reasons. There were no safety concerns.|No|October 18, 2010|https://clinicaltrials.gov/show/NCT00434278||174370|Because the study was terminated (for administrative reasons and infeasibility of enrollment), no conclusions can be made about the effect of Pulmozyme on exercise tolerance in this population.
NCT00434330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-07|Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis|A Phase 2, Open-Label, Multi-Center, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin||Affymax|No|Completed|December 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|91|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|February 12, 2007|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00434330||174366|Notable issues with some documentation occurred at some of the study sites. In general, overall results excluding the sites with issues were comparable to results based on the full population.
NCT00434655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-010|Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy|Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy: A Prospective Trial||North Texas Veterans Healthcare System||Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2009|December 14, 2009|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434655||174341|
NCT00434668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOGA 0501|Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer|Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial|TOLEDO|University Hospital, Antwerp||Completed|December 2005|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|99|||Both|18 Years|75 Years|No|||November 2010|November 29, 2010|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434668||174340|
NCT00434681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARAC_L_00859|Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.|Multicentre, Open, Non-Comparative Study of the Acceptability and Safety of Paracetamol Oral Paediatric Suspension at 4.8%.||Sanofi|No|Completed|October 2006|April 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||48|||Both|N/A|8 Years|No|||July 2008|July 18, 2008|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00434681||174339|
NCT00435487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301079|Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome|Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy||Pfizer|No|Terminated|June 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|February 13, 2007||No|See termination reason in detailed description.|No|December 22, 2009|https://clinicaltrials.gov/show/NCT00435487||174278|This study was terminated due to insufficient recruitment of subjects.
NCT00435786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J.nr. 01 199/02|Diabetic Patients With End-Stage Renal Disease|||Rigshospitalet, Denmark||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A||||February 2007|February 14, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435786||174255|
NCT00432575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6938|Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Fixed-Dose, 8-Week Treatment, Multi-Center Trial Evaluating the Efficacy and the Safety of 3 Oral Doses of Surinabant as an Aid to Smoking Cessation in Cigarette Smokers||Sanofi||Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|810|||Both|18 Years|N/A|No|||April 2009|April 14, 2009|February 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432575||174499|
NCT00432588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Misoprostol vs Dinoprostone|Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies|||Hormozgan University of Medical Sciences||Not yet recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A||||February 2007|May 31, 2007|February 6, 2007||||||https://clinicaltrials.gov/show/NCT00432588||174498|
NCT00429637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11618|Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients|Phase 2 Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients||University of Virginia||Recruiting|December 2004|January 2009|Anticipated|||Phase 2|Observational|N/A|||Anticipated|120|||Both|N/A|N/A|No|||August 2008|August 6, 2008|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429637||174719|
NCT00429650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0369|Using the Energy Gap to Prevent Weight Regain|Using the Energy Gap to Prevent Weight Regain|Lose-It|University of Colorado, Denver|Yes|Active, not recruiting|July 2007|December 2017|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429650||174718|
NCT00434993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|474|Drug Study of Albuterol to Treat Acute Lung Injury|Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury|ALTA|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|August 2007|November 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|282|||Both|13 Years|N/A|No|||December 2012|June 7, 2013|January 29, 2007||No|Stopped for futility by DSMB|No|December 4, 2012|https://clinicaltrials.gov/show/NCT00434993||174315|
NCT00432939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1955|Primary Hyperparathyroidism: Non-classical Manifestations|Primary Hyperparathyroidism: Non-classical Manifestations||Columbia University|Yes|Completed|October 2005|December 2012|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|Samples Without DNA|Specimens of frozen serum will be retained for possible future analyses.|Both|50 Years|75 Years|No|Non-Probability Sample|Adults age 50 to 75 with Primary Hyperparathyroidism|March 2015|March 6, 2015|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432939||174472|
NCT00433186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25973|Mycophenolate Mofetil in Systemic Sclerosis|Phase I, Open-label Study of Mycophenolate Mofetil In Systemic Sclerosis||Boston University||Completed|March 2006|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 29, 2011|February 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00433186||174453|
NCT00432523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X04-MMRr-301|Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route|An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of M-M-R™II Manufactured With Recombinant Human Albumin (rHA) and VARIVAX® When Administered Concomitantly by Intramuscular (IM) Route or Subcutaneous (SC) Route at Two Separate Injection Sites in Healthy Subjects 12 to 18 Months of Age||Sanofi Pasteur MSD||Completed|January 2005|July 2006||July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||752|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||April 2009|April 3, 2009|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00432523||174503|
NCT00432809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EES IIS 19900|Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes|STAMPEDE: Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently||The Cleveland Clinic|Yes|Active, not recruiting|February 2007|January 2016|Anticipated|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|20 Years|60 Years|No|||December 2013|December 20, 2013|February 6, 2007||No||No|November 9, 2012|https://clinicaltrials.gov/show/NCT00432809||174481|Important limitations in the primary endpoint and 1 year outcomes are the short duration of follow-up (12 months), the study occurred at a single-center and the open-label nature of the study (subjects were not blinded to treatment).
NCT00433082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1345104|Metabolic Syndrome and Inflammatory Markers|Effect of Fasting With Two Meals on Inflammatory Markers of Metabolic Syndrome||Free Islamic University of Medical Sciences||Completed|August 2006|November 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|N/A|N/A|No|||February 2007|February 8, 2007|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433082||174461|
NCT00433381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00743|Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma|A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma||National Cancer Institute (NCI)||Completed|March 2007|February 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||November 2012|May 7, 2014|February 8, 2007|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00433381||174439|
NCT00433147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAU-CL-201|Safety Study of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy|A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving ERT||Amicus Therapeutics|No|Completed|February 2007|March 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|65 Years|No|||August 2010|August 17, 2010|February 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00433147||174456|
NCT00433992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI065348-01A2|Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications|Effects of Thymidine Sparing Regimens on Mitochondrial Metabolism and Adipocyte Apoptosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|December 2009|Actual|October 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood collection|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients who are enrolled in ACTG A5202, starting their first nucleoside        reverse transcriptase inhibitor (NRTI)-containing regimen|August 2007|February 22, 2010|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433992||174392|
NCT00434291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-02|Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia|A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)||TaiGen Biotechnology Co., Ltd.||Completed|December 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|264|||Both|18 Years|N/A|No|||November 2009|November 23, 2009|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434291||174369|
NCT00434304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROP106064|Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)|Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study -||GlaxoSmithKline||Completed|April 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|20 Years|N/A|No|||March 2012|April 11, 2013|February 9, 2007||||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00434304||174368|
NCT00431847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4506-I|Regional Anesthesia Military Battlefield Pain Outcomes Study|Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes|RAMBPOS|VA Office of Research and Development|No|Active, not recruiting|October 2007|November 2014|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|670|||Both|N/A|N/A|No|Probability Sample|Military service members with one or more severely injured, mangled or amputated limbs        from Iraq/Afghanistan war.|October 2014|October 24, 2014|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431847||174553|
NCT00432835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0185|Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis|Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis||University of Mississippi Medical Center|Yes|Completed|August 2005|November 2007|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|70 Years|No|||November 2012|November 1, 2012|February 7, 2007|Yes|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00432835||174479|New lead implantation techniques now minimize dislodgment (only adverse effect); Parallel, non-crossover protocol will address any carry-over effect after tGES activation OFF; stratification for baseline mucosal EGG and medications may be useful.
NCT00432861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancrecarb|Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis||Digestive Care, Inc.|Yes|Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|7 Years|N/A|No|||February 2012|February 21, 2012|February 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432861||174478|
NCT00432874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT16122|Prospective Evaluation of Safety and Efficacy of Two Forms of Corneal Stromal Hydration|A Prospective Evaluation of the Safety and Efficacy of Two Forms of Corneal Stromal Hydration||University of Utah|No|Completed|February 2007|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Both|N/A|N/A|No|||October 2010|October 15, 2010|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432874||174477|
NCT00428285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-216|Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men|A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Active, not recruiting|February 2007|December 2015|Anticipated|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|65 Years|No|||August 2015|August 10, 2015|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428285||174820|
NCT00428571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-001|Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients|Laparoscopic Bariatric Surgery for Treatment of Type 2 Diabetes in Obese Patients With End Organ Damage: A Prospective Randomized Controlled Pilot Study||McMaster University||Completed|May 2007|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|65 Years|No|||March 2014|April 7, 2015|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428571||174799|
NCT00435214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907079|Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer|The HPV Persistence and Progression (PaP) Cohort at Kaiser Permanente Northern California||National Institutes of Health Clinical Center (CC)||Completed|January 2007|||||N/A|Observational|N/A|||Anticipated|135600|||Female|21 Years|100 Years|No|||March 2016|March 22, 2016|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435214||174299|
NCT00428584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27133|RNF and Betaseron® Tolerability Study|A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension|REFORMS|EMD Serono||Completed|December 2006|September 2009|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|60 Years|No|||August 2013|August 1, 2013|January 29, 2007|No|Yes||No|November 26, 2008|https://clinicaltrials.gov/show/NCT00428584||174798|
NCT00436358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106175|Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals in Mexico|Implementation of Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals With Pediatric Medical Care in Mexico||GlaxoSmithKline||Completed|April 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Prospective||5|Actual|134|||Both|N/A|1 Year|No|Probability Sample|IMSS hospitals with pediatric medical care in Mexico|January 2011|January 27, 2011|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436358||174211|
NCT00436371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9517|Amisulpride in Schizophrenic Acute Phase Patients|The Use of Amisulpride in Schizophrenic Acute Phase Patients.|ASAP|Sanofi||Completed|May 2005|||November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||50|||Both|18 Years|75 Years|No|||September 2008|September 4, 2008|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436371||174210|
NCT00429390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1345103|Effect of Fasting With Two Meals on Insulin Resistance Indices of Metabolic Syndrome|||Free Islamic University of Medical Sciences||Completed|August 2006|November 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||55|||Male|N/A|N/A|No|||January 2007|January 30, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00429390||174737|
NCT00429416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04U.115|Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation|A Phase I/II Study of Llme Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies||Thomas Jefferson University|Yes|Completed|March 2004|May 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|January 29, 2007|Yes|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT00429416||174735|
NCT00429936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRFR-001|Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration|A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration||Sirion Therapeutics, Inc.|Yes|Completed|December 2006|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|245|||Both|50 Years|89 Years|No|||June 2010|June 21, 2010|January 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00429936||174697|
NCT00429949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1159|A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma|A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma||Washington University School of Medicine||Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|January 31, 2007|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00429949||174696|
NCT00432952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M186|Acute Single Meal Effects of Trout on Cardiovascular Risk Markers and Plasma Proteome|||University of Copenhagen||Active, not recruiting|January 2007|January 2009|Anticipated|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention||||6|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||August 2008|August 12, 2008|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00432952||174471|
NCT00433199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S176.3.104|Testosterone Treatment for Hypogonadal Men|A Multi-Center, Randomized, Double-Blind,Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men||Abbott||Completed|February 2007|April 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|274|||Male|18 Years|80 Years|No|||November 2011|January 15, 2015|February 8, 2007|Yes|Yes||No|May 27, 2011|https://clinicaltrials.gov/show/NCT00433199||174452|
NCT00433498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000531141|Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer|A Multicentre Phase III Randomized Double Blind Placebo Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Patients With Small Lung Cancer||University College, London|Yes|Completed|January 2007|November 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|846|||Both|18 Years|N/A|No|||January 2013|December 1, 2014|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433498||174430|
NCT00433511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00561|Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer|A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2009|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|4950|||Both|18 Years|N/A|No|||January 2016|March 24, 2016|February 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00433511||174429|
NCT00434694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Penn:PVI Strategies|A Study of Strategies for Electrical Isolation of Pulmonic Veins for Curative Treatment of Atrial Fibrillation|Electrical Isolation of Pulmonic Veins for Curative Treatment of Atrial Fibrillation: Efficacy of Isolating All Veins Vs Arrhythmogenic Veins Only Using Standard 4-mm or 8-mm Ablation Catheter Vs Saline Irrigated Cooled Tip Catheter||University of Pennsylvania|Yes|Completed|July 2003|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|300|||Both|40 Years|N/A|No|||November 2015|November 24, 2015|February 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00434694||174338|
NCT00432822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH4/III/05/001|Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety|Double-Blind, Placebo Controlled, Multicentre Study With an Open Label Extension to Evaluate the Efficacy and Safety of Tetrahydrobiopterin (BH4) in Children and Adolescents With Hyperphenylalaninemia Caused by Phenylalanine Hydroxylase Deficiency||Orphanetics Pharma Entwicklungs GmbH||Terminated||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|18 Years|No|||September 2007|September 19, 2007|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00432822||174480|
NCT00433095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mamma-2-2004|Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer|||Ludwig-Maximilians - University of Munich||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|75 Years||||February 2007|March 11, 2011|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00433095||174460|
NCT00435201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECH-0596|Characterization of Clonal B Cell Populations in HCV Infection|Characterization of Clonal B Cell Populations in HCV Infection||Rockefeller University|Yes|Completed|January 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|Samples With DNA|white blood cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|NYC area|August 2013|August 6, 2013|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435201||174300|
NCT00434629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 18406|Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant|A Phase I Study of Bexxar® (Tositumomab and 131I-Tositumomab) Radioimmunotherapy in Patients With Relapsed or Residual CD20 Antigen-Expressing B-Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation||University of Pennsylvania|Yes|Recruiting|February 2007|||August 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||November 2008|November 4, 2008|February 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00434629||174343|
NCT00434642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4095g|A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma|A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma|OCEANS|Genentech, Inc.||Completed|April 2007|July 2013|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|484|||Female|18 Years|N/A|No|||September 2014|September 26, 2014|February 9, 2007|Yes|Yes||No|September 26, 2011|https://clinicaltrials.gov/show/NCT00434642||174342|
NCT00435760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT000860|Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients|||Almirall, S.A.||Completed|February 2007|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|115|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435760||174257|
NCT00435773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 102/03|Leeches for the Treatment of Knee Osteoarthritis|Single and Repeated Leech Therapy for the Treatment of Late Stage Knee Osteoarthritis. A Randomized, Placebo Controlled Comparative Trial||RWTH Aachen University||Completed|February 2004|December 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||118|||Both|N/A|N/A|No|||April 2007|April 6, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435773||174256|
NCT00431860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0606/034-019|Subclinical COronary Atheroscleorosis Updated With Coronary cT Angiography (SCOUT Study)|Subclinical COronary Atheroscleorosis Updated With Coronary cT Angiography (SCOUT Study)||Seoul National University Bundang Hospital|Yes|Recruiting|December 2005|November 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||Anticipated|3000|||Both|20 Years|75 Years|No|||May 2007|May 2, 2007|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431860||174552|
NCT00431873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-009|A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia|A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia||Mirati Therapeutics Inc.|No|Completed|January 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|February 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00431873||174551|
NCT00427544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3208A1-1000|Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Women of Nonchildbearing Potential||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|January 25, 2007||||||https://clinicaltrials.gov/show/NCT00427544||174875|
NCT00427557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0553|Cellular Therapy With Cord Blood Cells|Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Completed|October 2006|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|80 Years|No|||May 2012|May 23, 2012|January 25, 2007||No||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00427557||174874|
NCT00433420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM-2|Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer|A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients||National Cancer Institute (NCI)||Active, not recruiting|April 2003|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Female|18 Years|70 Years|No|||May 2007|August 1, 2013|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433420||174436|
NCT00433433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20051|Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma|The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma|H10|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Completed|October 2006|||December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|1952|||Both|15 Years|70 Years|No|||June 2014|June 13, 2014|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433433||174435|
NCT00433745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070091|Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy|Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|85 Years|No|||June 2014|June 5, 2014|February 9, 2007|No|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00433745||174411|Although there was one partial response at 7 weeks, this patient went on to relapse as well.Consequently, all 4 patients had rapid relapses despite vaccination. Accrual was stopped at 4.
NCT00428090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105640|Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease|A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease. (REFLECT-1)||GlaxoSmithKline|No|Completed|February 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|862|||Both|50 Years|90 Years|No|||February 2014|February 13, 2014|January 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00428090||174834|
NCT00428298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06TGF-981|Research Study of Bipolar Mood Symptoms and Cognitive Problems|A Double Blind Placebo Controlled Study of Valacyclovir in Cognitive Impairment and Mood Symptoms of Bipolar Disorder||Johns Hopkins University|No|Active, not recruiting|March 2007|October 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2011|May 18, 2012|January 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00428298||174819|
NCT00428870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04200|Operative or Conservative Treatment for Subacromial Impingement Syndrome?|Arthroscopic Decompression Versus Diagnostic Arthroscopy Without Subacromial Decompression Versus Supervised Exercise Therapy in Treatment of Subacromial Impingement Syndrome. A Blinded Randomized Controlled Trail.||Helsinki University||Active, not recruiting|October 2005|December 2023|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|210|||Both|35 Years|65 Years|No|||September 2013|September 18, 2013|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00428870||174776|
NCT00428883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM5X8AWM|High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis|Rare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis||Università Politecnica delle Marche||Recruiting|January 2007|February 2009||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|80 Years|No|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428883||174775|
NCT00429429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R21-AT-002557-02|Immunotherapy for Peanut Allergy|Immunotherapy for Peanut Allergy||University of North Carolina, Chapel Hill|Yes|Completed|April 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|6 Years|35 Years|No|||September 2012|September 14, 2012|January 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00429429||174734|
NCT00433836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489K2302|Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure|A Multicenter, Randomized, Double-blind, Parallel-group, Evaluation of 12 Weeks of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children 6 to 17 Years of Age With Hypertension||Novartis||Completed|January 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|300|||Both|6 Years|17 Years|No|||April 2011|April 19, 2011|February 8, 2007|Yes|Yes||No|December 8, 2010|https://clinicaltrials.gov/show/NCT00433836||174404|
NCT00433849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH20564|Clinical Study of R744 to Peritoneal Dialysis Patients|Switch and Maintenance Study of Subcutaneous or Intravenous Injections of R744 to Peritoneal Dialysis Patients (Phase Ⅲ Study)||Chugai Pharmaceutical|No|Completed|February 2007|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|20 Years|N/A|No|||January 2009|January 29, 2009|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433849||174403|
NCT00434109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14888|Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization|Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|November 2006|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||July 2012|September 7, 2012|February 9, 2007||No||No|August 8, 2012|https://clinicaltrials.gov/show/NCT00434109||174383|
NCT00434512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108706|Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers|A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate HIV Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.||GlaxoSmithKline||Completed|February 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|180|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434512||174352|
NCT00435500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-64215|Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children|Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children||University of Toronto||Active, not recruiting|June 2003|January 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||1320|||Both|6 Months|71 Months|Accepts Healthy Volunteers|||August 2009|August 21, 2009|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435500||174277|
NCT00435799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNN-UUS-CCL07|Evaluating Collagen Cross-Linking (CCL) Treatment in Norway|Treatment of Keratectasia With Collagen Cross-Linking (CCL) at the Eye Departments of the University Hospital, North Norway in Tromsø and Ullevål University Hospital in Oslo||Ullevaal University Hospital||Recruiting|February 2007|January 2010|Anticipated|January 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|45 Years|No|||January 2007|June 9, 2008|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435799||174254|
NCT00432601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-283|Testing the Helpfulness of 2 Decision Aids for Prostate Cancer|Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making||VA Office of Research and Development|Yes|Completed|August 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1028|||Male|N/A|N/A|No|||March 2016|March 7, 2016|February 6, 2007||No||No|March 19, 2015|https://clinicaltrials.gov/show/NCT00432601||174497|
NCT00432614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6224|Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder|A Multi-National, Multi-Center, DB, Placebo-Controlled, Parallel Group, Fixed Dose Efficacy & Safety Study of SR58611A 350 mg Twice Daily vs. Placebo in Adults With Major Depressive Disorder on Concomitant Treatment With Escitalopram 10mg/d|ALBERIO|Sanofi||Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|510|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|February 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432614||174496|
NCT00431093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06673|Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)|A Multicenter, Randomized, Double-Blind, Double Dummy, Group-Comparative Trial to Compare the Effects of Livial® and Activelle ® on the Vaginal Bleeding Pattern, Vasomotor Complaints, Vaginal Atrophy, QoL and Sexual Function|TOTAL|Merck Sharp & Dohme Corp.|No|Completed|November 2002|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|570|||Female|45 Years|64 Years|No|||June 2015|June 3, 2015|February 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00431093||174610|
NCT00431106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/02.11|Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer|A Multicenter Randomized Phase III Study of Combination Treatment With Vinorelbine and Gemcitabine Versus Capecitabine Monotherapy in Metastatic Breast Cancer Patients Following Treatment Failure With the Combination of a Taxane and an Anthracycline||Hellenic Oncology Research Group||Completed|April 2002|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Female|19 Years|75 Years|No|||September 2009|September 25, 2009|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431106||174609|
NCT00435474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kf 0102006-5491|Malignant Wounds, Wound Treatment, Psycho-Social Support and Relaxation Therapy|Malignant Wounds: A Randomized Clinical Trial Investigating a Complementary Multidimensional Intervention||Rigshospitalet, Denmark|Yes|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2009|June 8, 2009|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435474||174279|
NCT00436345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108701|Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)|A Randomized, Open Label, Multicentre Study to Compare the Pharmaco-economic Implications of an Analgesia Based Regimen With Remifentanil and a Conventional Sedation Based Regimen Using Propofol in Medical and Post-surgical ICU Subjects Requiring Mechanical Ventilation for at Least 2 Days.||GlaxoSmithKline||Terminated|November 2007|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|February 15, 2007||No|recruitment issues|No|August 7, 2009|https://clinicaltrials.gov/show/NCT00436345||174212|
NCT00427882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFUS_L_01778|Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study|An Open, Non-Comparative, Multicenter Study on the Sexual Function Improvement Following Treatment With Alfuzosin in Patients With Benign Prostate Hyperplasia||Handok Pharmaceuticals Co., Ltd.||Completed|September 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|125|||Male|40 Years|N/A|No|||November 2007|November 28, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427882||174850|
NCT00428077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526322|Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|A Multi-Center Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease||OHSU Knight Cancer Institute|Yes|Terminated|October 2005|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|January 25, 2007|Yes|Yes|Withdrawn because there were no dramatic changes in the main endpoint, as well as low    enrollment numbers. The data are not interpretable in terms of efficacy.|No|May 26, 2011|https://clinicaltrials.gov/show/NCT00428077||174835|
NCT00428311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOPCOS 01/2003|Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS|The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives||Hospital Universitario Ramon y Cajal||Completed|April 2004|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|12 Years|45 Years|Accepts Healthy Volunteers|||January 2007|January 30, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428311||174818|
NCT00428337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 067|Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 and Recombinant MVA-HIV Polytope Vaccine MVA-mBN32, Separately and in a Combined Prime-boost Regimen, When Given to Healthy, Vaccinia-naive, HIV-1-uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2007|August 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|January 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00428337||174817|
NCT00428610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10410|A Study of Chemotherapy Treatment for Patients With Ovarian Cancer|A Phase 2 Study of LY573636 as Treatment for Patients With Platinum-Resistant Ovarian Cancer||Eli Lilly and Company||Completed|February 2007|January 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||January 2012|January 31, 2012|January 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00428610||174796|
NCT00428623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Torben V Schroeder|Aquacel Compared to Traditional Post Surgical Wound Dressing in Vascular Surgery Patients|||Rigshospitalet, Denmark||Completed|January 2004|January 2006||||Phase 3|Observational|Allocation: Random Sample, Time Perspective: Longitudinal||||160|||Both|18 Years|N/A|No|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428623||174795|
NCT00428896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO|A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer|A Pilot Feasibility Study to Evaluate the Efficacy of ZD1839 (IRESSA) in Eliminating Chemo- and Hormone- Resistant Cytokeratin-Positive Tumour Cells Circulating in the Blood of Women With Breast Cancer||University Hospital of Crete||Completed|April 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|75 Years|No|||July 2008|July 18, 2008|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00428896||174774|
NCT00428597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181111|A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors|A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors||Pfizer|Yes|Terminated|June 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||September 2010|September 16, 2010|January 29, 2007|Yes|Yes|Refer to Detailed Description.|No|April 15, 2010|https://clinicaltrials.gov/show/NCT00428597||174797|
NCT00429156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE 06-0147/FR-1|Non-invasive Ventilation Versus Sham Ventilation in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Controlled Trial of Continuation of Home Non-invasive Ventilation vs Sham Ventilation in Survivors of Acute Hypercapnic Respiratory Failure in Chronic Obstructive Pulmonary Disease||United Christian Hospital|Yes|Completed|January 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||October 2009|October 22, 2009|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429156||174755|
NCT00431184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-002344|Effects of Pentazocine Versus Lorazepam on Manic Symptoms|Effects of Pentazocine Versus Lorazepam on Manic Symptoms||Mclean Hospital|No|Completed|January 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|No|||August 2014|August 5, 2014|February 1, 2007|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00431184||174603|
NCT00429143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.20|A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative|A Two Step Approach To Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies From HLA Partially-Matched Related Donors||Thomas Jefferson University|Yes|Completed|January 2006|June 2010|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|January 29, 2007||No||No|June 4, 2012|https://clinicaltrials.gov/show/NCT00429143||174756|Limitations of the trial include small sample size and single institution
NCT00434122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS24|Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix|A Randomised, Assessor-blind, Parallel Groups, Multi-centre, Exploratory Study Assessing the Impact of Subcutaneous Administration of Degarelix 2.5 mg on Synchronisation of Follicle Cohort Compared to Placebo and Evaluating the Effects of Degarelix 2.5 mg Started in the Mid-luteal or Early Follicular Phase on Endometrial Receptivity Compared to a Fixed Gonadotrophin Releasing Hormone Antagonist Protocol in Oocyte Donors Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproductive Technologies||Ferring Pharmaceuticals|No|Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|85|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2011|May 18, 2011|February 9, 2007||No||No|January 19, 2009|https://clinicaltrials.gov/show/NCT00434122||174382|
NCT00434499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00048859|Effect of EGCG on the Body's Response to Insulin|An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects||University of Maryland|Yes|Withdrawn|February 2007|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|February 10, 2007|Yes|Yes|Not funded|No||https://clinicaltrials.gov/show/NCT00434499||174353|
NCT00425269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFR 166998/166977|Lifestyle Intervention for Pakistani Women in Oslo|Evaluation of a Lifestyle Intervention to Prevent Type 2 Diabetes/Metabolic Syndrome Among Pakistani Immigrants - Focusing on Changes in Diet and Physical Activity|InnvaDiab|University of Oslo|No|Completed|April 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|198|||Female|25 Years|N/A|Accepts Healthy Volunteers|||April 2014|June 24, 2014|January 19, 2007||No||No|April 11, 2014|https://clinicaltrials.gov/show/NCT00425269||175044|
NCT00424957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060120|Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System|Brain Energy Metabolism in Patients With Acute Hepatic Encephalopathy Measured With PET||University of Aarhus|Yes|Completed|November 2006|October 2008|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|18|||Both|45 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|6 patients with liver cirrhosis with an acute episode of hepatic encephalopathy, 6        patients with liver cirrhosis without an acute episode of hepatic encephalopathy, 6        healthy subjects age and sex matched|February 2009|February 4, 2009|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00424957||175067|
NCT00436384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0265-AE|Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients|Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients||University Health Network, Toronto||Completed|November 2005|March 2008|Actual|March 2008|Actual|Phase 4|Observational|N/A||||150|||Both|18 Years|N/A|No|||February 2007|April 15, 2008|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436384||174209|
NCT00431912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP3001|A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma|A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma||Onxeo|No|Completed|February 2007|September 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431912||174548|
NCT00433459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000531687|Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma|First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents||Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|January 2007|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2134|||Both|N/A|17 Years|No|||November 2015|November 17, 2015|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433459||174433|
NCT00432900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070092|Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [(11)C]PBR28 in Patients With Multiple Sclerosis (MS)||National Institutes of Health Clinical Center (CC)||Completed|February 2007|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|May 3, 2014|February 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00432900||174475|
NCT00432913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA/POL/02|Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa|The Effect of Two Dose Levels of Eicosapentaenoic Acid (EPA) on Apoptosis and Cell Proliferation in the Colonic Mucosa of Patients With a History of Colonic Polyps.||S.L.A. Pharma AG|No|Completed|October 2006|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||October 2008|October 16, 2008|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00432913||174474|
NCT00431366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070088|Sequence Effect in Parkinson's Disease|The Characteristics of Sequence Effect in de Novo and Advanced Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|February 2007|December 2008||||N/A|Observational|N/A||||24|||Both|18 Years|N/A|No|||December 2008|September 26, 2015|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431366||174589|
NCT00431379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0605329|Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study|Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study: Phase I||Medical Center of Central Georgia||Withdrawn|February 2007|December 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||November 2013|November 4, 2013|February 2, 2007|Yes|Yes|drug has expired, no enrollments in study. Company pulled funding|No||https://clinicaltrials.gov/show/NCT00431379||174588|
NCT00436033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F02207GE302|A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome|A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome||Pierre Fabre Medicament||Completed|February 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1429|||Both|18 Years|70 Years|No|||July 2013|July 10, 2013|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436033||174236|
NCT00436046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0074|Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally|Type 1 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2007|October 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|95|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2009|June 9, 2011|February 15, 2007|No|Yes||No|October 9, 2008|https://clinicaltrials.gov/show/NCT00436046||174235|
NCT00432237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-016|Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)|A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 in the Acute Treatment of Migraine With or Without Aura||Merck Sharp & Dohme Corp.||Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1703|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|February 5, 2007|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00432237||174524|
NCT00432250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLHSPTL|The Use of Cervical Length to Reduce Hospital Stay in Women Admitted Because of Preterm Labor.|||Hospital Clinic of Barcelona||Completed|January 2002|April 2005||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research||||150|||Female|18 Years|N/A||||February 2007|February 6, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432250||174523|
NCT00427895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-004|Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults|A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS||Pfizer|No|Completed|March 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|2141|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|January 25, 2007|Yes|Yes||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00427895||174849|
NCT00428350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00004|Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic|A 24-Week, Multi-Centre, Open-Label, Single-Arm, Phase IV Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) With Daily Dose 600mg-750mg as Mono-Therapy in the Treatment of Acute Schizophrenic Patients||AstraZeneca||Completed|December 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|60 Years|No|||March 2009|March 24, 2009|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428350||174816|
NCT00428363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK2512001|Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification|||Medical University of Vienna||Completed|June 2001|March 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||52|||Both|40 Years|N/A|No|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428363||174815|
NCT00428636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 00154|Early Temporary Stoma Closure After Proctectomy|Study of Early Closure of Temporary Loop Ileostomy After Elective Rectal Resection With Low Pelvic Anastomoses||Assistance Publique - Hôpitaux de Paris||Completed|May 2001|July 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||270|||Both|18 Years|N/A|No|||January 2007|January 26, 2007|January 26, 2007||||No||https://clinicaltrials.gov/show/NCT00428636||174794|
NCT00428909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A2107|Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)|A Non-randomized, Open-label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)||Novartis||Completed|November 2006|||August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||November 2009|November 20, 2009|January 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00428909||174773|
NCT00428922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06027|Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients|Phase II Trial of Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|June 2007|||November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 29, 2007|Yes|Yes||No|November 10, 2015|https://clinicaltrials.gov/show/NCT00428922||174772|
NCT00429169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5933R|Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression|Paroxetine Versus Bupropion for Suicide Ideators or Attempters With Major Depressive Disorder||New York State Psychiatric Institute|No|Terminated|June 2004|January 2013|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|65 Years|No|||December 2012|March 25, 2015|January 29, 2007|Yes|Yes|Interim analysis showed differential treatment effects.|No|December 11, 2012|https://clinicaltrials.gov/show/NCT00429169||174754|Significant dropout meant the number of subjects with analyzable data was smaller than the number enrolled.An interim analysis of this pilot study showed differential treatment effects so a decision was made to stop enrollment early.
NCT00429182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0280|Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer|Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients||M.D. Anderson Cancer Center|No|Completed|June 2007|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|55 Years|No|||February 2013|February 28, 2013|January 29, 2007|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT00429182||174753|
NCT00430898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSX-001|Basiliximab in Moderate to Severe Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, With Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis||Cerimon Pharmaceuticals|Yes|Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|181|||Both|18 Years|75 Years|No|||December 2008|December 17, 2008|January 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00430898||174625|
NCT00430911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC, P000502 AOM 98071|Radiotherapy for Malignant Astrocytomas in the Elderly|||Assistance Publique - Hôpitaux de Paris||Completed|February 2001|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|70 Years|N/A|No|||January 2007|January 31, 2007|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00430911||174624|
NCT00429676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0362|Pilot Study of Haloperidol to Treat Critical Illness Delirium|A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium||University of Colorado, Denver||Completed|December 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||November 2009|November 13, 2012|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429676||174716|
NCT00424944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMZ2_2_07|Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine|A Single Centre, Randomised Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Lactococcus Lactis Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine Versus Rabies Vaccine in Healthy Gabonese Adult Volunteers||African Malaria Network Trust|Yes|Recruiting|June 2007|August 2008|Anticipated|July 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 1, 2008|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00424944||175068|
NCT00425256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-141-2005-53|Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)|||Palatin Technologies||Completed|February 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Female|21 Years|70 Years||||February 2011|February 22, 2011|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00425256||175045|
NCT00425282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013012|A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.||SK Life Science||Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|566|||Both|16 Years|N/A|No|||June 2012|June 19, 2012|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425282||175043|
NCT00431925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MucoCyt- HMO-CTIL|Can Cytokines Predict the Severity of Acute Mucositis and the Need for Gastrostomy Tubes (PEG)?|Can Cytokines Predict the Severity of Acute Mucositis and the Need for PEG During Chemo-Radiation Treatment to Head and Neck Cancer?||Hadassah Medical Organization||Not yet recruiting||May 2011|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|35|||Both|18 Years|85 Years|No|||February 2007|August 9, 2007|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431925||174547|
NCT00430521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107495|Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)|Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules||GlaxoSmithKline||Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|512|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2012|February 9, 2012|February 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00430521||174654|
NCT00432289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002763|Acupuncture for Treatment of Acute Spinal Cord Injury: an Exploratory/Developmental Study|Acupuncture for Treatment of Acute Spinal Cord Injury||Craig Hospital|Yes|Completed|November 2006|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|N/A|No|||June 2010|June 10, 2010|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00432289||174520|
NCT00434005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22969-D|Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans|Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans - the Role of Oxidative Stress||University of Washington|No|Completed|July 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|August 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00434005||174391|
NCT00434317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EHU03|Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases|A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer||Novartis||Completed|August 2005|||April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434317||174367|
NCT00431392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-180601|Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions|Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions||Medical University of Vienna||Completed|September 2001|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||January 2007|February 2, 2007|February 2, 2007||||No||https://clinicaltrials.gov/show/NCT00431392||174587|
NCT00431353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV17973|VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients|A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients||Hoffmann-La Roche||Completed|April 2004|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|325|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431353||174590|
NCT00431613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/04.26|Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)|Sequential Administration of Docetaxel/Gemcitabine Followed by Concurrent Chemo-radiotherapy, With or Without Consolidation Chemotherapy, as First Line Treatment in Patients With Unresectable Stage IIIA/IIIB NSCLC. A Randomized Phase II Study||Hellenic Oncology Research Group||Terminated|March 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|19 Years|75 Years|No|||May 2015|May 28, 2015|February 5, 2007||No|Due to Poor Accrual|No||https://clinicaltrials.gov/show/NCT00431613||174570|
NCT00431626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0348-040|A Clinical Trial Comparing Laser TURP With and Without Dutasteride.|A Randomized, Placebo-Controlled, Double-Masked Clinical Trial Comparing Laser TURP With and Without Neo-Adjuvant Dutasteride||Northwestern University|Yes|Terminated|October 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Male|50 Years|N/A|No|||October 2015|October 6, 2015|February 2, 2007|Yes|Yes|Low enrollment|No|December 19, 2014|https://clinicaltrials.gov/show/NCT00431626||174569|Difficulty in recruitment forced the closing of this trial.
NCT00428649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK58763-opt|Optimization of Selenoprotein P in Chinese Subjects|Optimization of Selenoprotein P in Chinese Subjects||Vanderbilt University||Completed|March 2007|October 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|98|||Both|17 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 6, 2012|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428649||174793|
NCT00427843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REH-324-06|The Influence of Hip Strengthening Exercises on Walking Patterns and Muscle Strength in Persons With Knee Osteoarthritis|The Influence of a Home Program of Hip Abductor Exercises on Gait Parameters and Muscle Strength in Persons With Knee Osteoarthritis||Queen's University|Yes|Completed|January 2007|September 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|40 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 14, 2008|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427843||174852|
NCT00427856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM014|Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)|A Multi-Center, Open-Label, Phase II Study of Sequential, Single-Agent Obatoclax Mesylate (GX15-070MS)Followed by a Combination With Rituximab to Patients With Previously-Untreated Follicular Lymphoma (FL)||Teva Pharmaceutical Industries|No|Completed|March 2007|July 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|January 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00427856||174851|
NCT00429195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPGENE Dietary Intervention|The Effect of Dietary Fat Modification on Risk Factors Associated With the Metabolic Syndrome|LIPGENE Dietary Intervention Study||University College Dublin||Completed|February 2004|January 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||480|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||January 2007|January 18, 2013|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429195||174752|
NCT00429442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoSim-01|Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis|A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in Patients Treated With Copaxone for at Least 3 Months||Glostrup University Hospital, Copenhagen||Withdrawn|March 2008|March 2011|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||February 2014|February 19, 2014|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429442||174733|
NCT00430001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERNATA|Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer|A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer||Danish Breast Cancer Cooperative Group||Recruiting|May 2005|December 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|74 Years|No|||May 2008|May 6, 2008|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00430001||174692|
NCT00430014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0913|Study of Atiprimod Treatment for Patients With Advanced Cancer|An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer||M.D. Anderson Cancer Center|No|Terminated|March 2005|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|13 Years|N/A|No|||February 2012|February 14, 2012|January 31, 2007|No|Yes|Sponsor Withdrew|No||https://clinicaltrials.gov/show/NCT00430014||174691|
NCT00428935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRI IRB05-00118|Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy|Phase 1 Clinical Trial of rAAV2.5-CMV-mini-Dystrophin Gene Vector in Duchenne Muscular Dystrophy||Nationwide Children's Hospital||Completed|March 2006|July 2010|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Male|5 Years|15 Years|No|||February 2013|February 4, 2013|January 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00428935||174771|
NCT00430885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175464/V50|Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction|Phase III Study of Intravenous Immunglobulin (IVIG) in Patients With Heart Failure After Myocardial Infarction||Oslo University Hospital|No|Completed|February 2007|May 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|18 Years|No|||January 2014|January 24, 2014|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430885||174626|
NCT00435110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22|Effects of PEEP and FIO2 in ALI and ARDS|Effects of PEEP and FiO2 in the Evaluation of Severity of ALI and ARDS|HELP|Instituto Canario de Investigacion Biomedica||Completed|May 2004|October 2005||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||170|||Both|14 Years|N/A|No|||February 2006|February 13, 2007|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00435110||174306|
NCT00429689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4480-RA-CTIL|Hormonal Levels in Men With Major Depressive Disorder|Hormonal Levels in Men With Major Depressive Disorder||Sheba Medical Center||Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Male|18 Years|65 Years|No|Non-Probability Sample|Men diagnosed with Major depression disorder|August 2011|August 28, 2011|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429689||174715|
NCT00429988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378088|Study of Ductal Lavage in Women at High Risk for Breast Cancer|Ductal Lavage to Monitor and Treat High Risk Women||University of California, San Francisco||Completed|August 2002|June 2004|Actual|June 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|N/A|No|Non-Probability Sample|Women at increased risk for breast cancer|September 2012|September 25, 2012|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429988||174693|
NCT00424645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0119|Voraxaze for Delayed Methotrexate Clearance|Randomized, Double-Blind, Placebo Controlled Trial of Voraxaze™ in Patients With a Delayed MTX Clearance||M.D. Anderson Cancer Center|Yes|Terminated|January 2007|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|3|||Both|N/A|N/A|No|||December 2012|December 4, 2012|January 17, 2007|No|Yes|Sponsor terminated due to low accrual.|No|November 9, 2010|https://clinicaltrials.gov/show/NCT00424645||175090|
NCT00424970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCA06|Treatment of High Altitude Polycythemia by Acetazolamide|Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment||Association pour la Recherche en Physiologie de l'Environnement||Completed|January 2007|November 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|55|||Male|18 Years|65 Years|No|||January 2013|January 23, 2013|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00424970||175066|
NCT00424697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH104150|A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.|A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.||GlaxoSmithKline||Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|January 17, 2007||||||https://clinicaltrials.gov/show/NCT00424697||175086|
NCT00430534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN/P001-EBV-003|Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals’ EBV (Epstein Barr Virus) Vaccine (268664).|To Evaluate the Safety, Immunogenicity and Efficacy of GSK Biologicals’ EBV Vaccine (268664) in Healthy Seronegative Adolescents/Adults When Injected Intramuscularly According to a 0-1-5 Month Schedule in Belgium.||Henogen||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||200|||Both|16 Years|25 Years|Accepts Healthy Volunteers|||February 2007|February 1, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00430534||174653|
NCT00433719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXTREC 023-04|Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis|Randomised Controlled Trial of Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis||University of Oxford|Yes|Active, not recruiting|September 2005|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|15 Years|N/A|No|||June 2008|August 6, 2008|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00433719||174413|
NCT00433732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT400-302|To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches|A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches||POZEN||Completed|August 2004|April 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1400|||Both|18 Years|65 Years|No|||April 2005|February 9, 2007|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433732||174412|
NCT00434954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-SB-GWBN|Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes|Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment||AstraZeneca|No|Completed|February 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|494|||Both|18 Years|90 Years|No|||March 2015|March 19, 2015|February 12, 2007|Yes|Yes||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00434954||174318|
NCT00431405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVARA|Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population|Assessing Risk of Cardiovascular Events in RA Patients Using a Retrospective Cohort From the VARA Registry||Dallas VA Medical Center||Active, not recruiting|August 2006|January 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||450|||Both|18 Years|N/A|No|||February 2007|February 1, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00431405||174586|
NCT00431418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R 06/34|The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease|The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease (SPICE Trial): a Pilot Study||Mercy Hospital for Women, Australia||Completed|January 2007|June 2012|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|7 Days|No|||September 2015|September 21, 2015|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431418||174585|
NCT00431639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050093|Effects of Pet Therapy on Pain in Cancer Patients|The Effect of Animal-Assisted Therapy on Distress in Oncology Patients Being Treated for Pain||National Institutes of Health Clinical Center (CC)||Completed|February 2005|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|36|||Both|18 Years|N/A|No|||July 2015|August 5, 2015|February 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00431639||174568|
NCT00427570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000071312|Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery|A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer||National Cancer Institute (NCI)||Completed|September 1977|May 2006|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|N/A|79 Years|No|||August 2010|June 21, 2013|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00427570||174873|
NCT00429455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0997|Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among HSCT Patients|Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among Young Women Who Underwent Hematopoietic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Completed|March 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|196|||Female|16 Years|50 Years|No|Probability Sample|Female patients who had a hematopoietic stem cell transplantation between January 1987 and        September 2004 at M. D. Anderson Cancer Center.|July 2012|July 31, 2012|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00429455||174732|
NCT00428103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H0138|Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy|Destiny Trial: Effects of Mitral Valve Annuloplasty With the Geoform Ring on Left Ventricular Geometry and Function in Patients With Cardiomyopathy||Ohio State University|No|Withdrawn|October 2006|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428103||174833|
NCT00430027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0011.cc|Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma|Pilot Feasibility Trial of Preoperative Capecitabine, Oxaliplatin, Cetuximab and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma||University of Colorado, Denver|Yes|Terminated|November 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|January 30, 2007|Yes|Yes|This study was terminated due slow accrual.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT00430027||174690|This study was terminated due slow accrual.
NCT00430040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1918|Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.|Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation.||Kaleida Health|No|Active, not recruiting|February 2007|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2012|December 17, 2012|January 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00430040||174689|
NCT00430300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3971013|Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.|A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Evaluate the Efficacy And Safety of UK-432,097 Dry Powder For Inhalation In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease.||Pfizer|Yes|Terminated|January 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|40 Years|80 Years|No|||May 2013|May 17, 2013|January 30, 2007|Yes|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT00430300||174670|Study was terminated prematurely due to futility based on results of interim analysis.
NCT00430612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|469|The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)|The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)|OBTAIN|Northwestern University|Yes|Active, not recruiting|May 2009|June 2016|Anticipated|December 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|6830|||Both|30 Years|N/A|No|Non-Probability Sample|non-voluntary registry of consecutive patients diagnosed as having a MI at each study site|April 2015|April 30, 2015|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430612|2 Years|174647|
NCT00430625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKT032|A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease|A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease||Shire|No|Completed|January 2007|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|2 Years|N/A|No|||February 2014|February 19, 2014|February 1, 2007|Yes|Yes||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00430625||174646|Due to small sample sizes no conclusions could be drawn on Quality of life (QOL).
NCT00436254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6532|Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer|A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors||University of Washington|Yes|Active, not recruiting|October 2001|||March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Female|18 Years|N/A|No|||May 2015|May 1, 2015|February 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00436254||174219|
NCT00431470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/09/VA01|Are Character Building Lessons Effective in Decreasing Bullying Behaviors?|Is the Classroom Education Program Intervention Effective in Increasing Positive Self Esteem, Enhancing Leadership Behaviors, While Decreasing the Prevalence of Bullying Behaviors in Fifth Grade Elementary Students?||Maimonides Medical Center||Completed|February 2007|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|175|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||October 2006|February 4, 2009|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431470||174581|
NCT00424658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleep concordance|Sleep Apnea. Concordance Between Non-reference and Reference Centres|||Hospital Clinic of Barcelona||Completed|January 2000|April 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||90|||Both|18 Years|70 Years|No|||January 2007|March 31, 2015|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00424658||175089|
NCT00424671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2310|Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine|An Open-Label Study in Healthy Subjects and in Subjects With Stable Impaired Hepatic Function to Assess the Effect of Moderate Hepatic Impairment on Licarbazepine Pharmacokinetics and Metabolism After a Single Dose of 1000 mg Licarbazepine IR Tablets||Novartis||Completed|November 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00424671||175088|
NCT00424983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446E2105|Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year|A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)||Novartis||Completed|November 2006|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|75 Years|No|||September 2014|September 8, 2014|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00424983||175065|
NCT00425334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6012|Safety Study of Hemospan® in Prostatectomy Patients|A Clinical Safety (Phase II) Increasing Dose Study of MP4 (Hemospan®) in Total Prostatectomy Surgical Patients||Sangart|Yes|Completed|July 2005|November 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|N/A|No|||August 2013|August 15, 2013|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425334||175039|
NCT00425373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A1301|Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients||Novartis||Completed|November 2006|March 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|1474|||Both|20 Years|80 Years|No|||April 2011|April 20, 2011|January 22, 2007||||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00425373||175036|
NCT00429962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081-PRC-2006-005|Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV|Randomized, Phase IIIb Study Comparing Safety, Tolerability and Efficacy Between Lucentis® Administered in Conjunction With PDT With Visudyne® and Lucentis® in Patients With Subfoveal CNV Secondary to Age-Related Macular Degeneration||University Hospital, Basel, Switzerland|No|Completed|July 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|95 Years|No|||April 2009|April 6, 2009|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429962||174695|
NCT00430261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 05160|Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma|Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma||Swedish Medical Center|No|Completed|January 2007|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2010|October 5, 2010|January 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00430261||174673|
NCT00430833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9164|CHANCE - Candesartan in Hypertrophic Cardiomyopathy|Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study||Charles University, Czech Republic||Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||January 2007|January 31, 2007|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00430833||174630|
NCT00431119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beissert-BP#1|Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid|A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid||University Hospital Muenster||Completed|October 1997|October 2000||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|90 Years|No|||February 2007|February 2, 2007|February 2, 2007||||No||https://clinicaltrials.gov/show/NCT00431119||174608|
NCT00431691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-110106|Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.|Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.||Medical University of Vienna||Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2008|July 1, 2008|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431691||174565|
NCT00431665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-070699|Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters|Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters||Medical University of Vienna||Completed|July 1999|June 2000||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||9|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||February 2007|February 5, 2007|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431665||174567|
NCT00427583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BDE57|Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors|An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors||Novartis||Terminated|May 2006|||April 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|January 25, 2007||No|stopped due to slow recruitment and no effect|No||https://clinicaltrials.gov/show/NCT00427583||174872|
NCT00427596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3A106044|A Two-Part Study to Determine: Best Medication Formulation and Food Effect|A Two-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Four MR Formulations and Food Effect of GW427353 (Solabegron) in Healthy Adult Subjects||GlaxoSmithKline||Completed|January 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2008|October 6, 2008|January 25, 2007||||||https://clinicaltrials.gov/show/NCT00427596||174871|
NCT00433550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0543|Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer|A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|May 2007|||December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|33|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|February 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00433550||174426|
NCT00428116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30201-D|Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya|Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (0-4.5 Month Randomized Controlled Trial)||University of Washington|Yes|Terminated|September 2007|December 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|N/A|54 Months|No|||July 2015|July 24, 2015|January 22, 2007||No|DSMB recommended termination because TI was safe but not durable.|No|June 8, 2015|https://clinicaltrials.gov/show/NCT00428116||174832|
NCT00429702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0503|Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy|Phase II Randomized, Double-Blinded Study of an Antiemetic Pump, Using Benadryl®, Avitan® and Decadron® (BAD), for Children Receiving Moderately or Highly Emetogenic Chemotherapy||University of South Florida|Yes|Terminated|October 2007|November 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|7|||Both|8 Years|18 Years|No|||June 2014|June 26, 2014|January 31, 2007|Yes|Yes|Closed due to poor accrual and lack of feasibility to finish study per DSMB|No|March 24, 2014|https://clinicaltrials.gov/show/NCT00429702||174714|The study was closed prior to completing enrollment based on the recommendation by the SunCoast CCOP Research Base Data Safety Monitoring Board for a lack of feasibility and poor enrollment.
NCT00429715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT110-1384|Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin|A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin||Tehran University of Medical Sciences||Completed|January 2007|December 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|150|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 16, 2011|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429715||174713|
NCT00429728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH103004|A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.|An Open-Label, Parallel Group, Single Session Study Comparing the Pharmacokinetics of a Single Oral Dose of GW876008 Administered to Healthy Volunteer Smokers and Healthy Volunteer Non-Smokers.||GlaxoSmithKline||Completed|November 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|January 30, 2007||||||https://clinicaltrials.gov/show/NCT00429728||174712|
NCT00434135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SICOG trial 0506|Alimta and Gemcitabine in Non-Small Cell Lung Cancer|A Phase II Randomized Trial Assessing the Combination of Gemcitabine and Pemetrexed in the First Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer|ANGEL|Southern Italy Cooperative Oncology Group|No|Completed|May 2006|October 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|85 Years|No|||February 2009|February 4, 2009|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434135||174381|
NCT00434148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2305|Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease|A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease||Novartis|No|Completed|December 2006|May 2014|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|February 9, 2007|Yes|Yes||No|January 3, 2013|https://clinicaltrials.gov/show/NCT00434148||174380|
NCT00430313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0735|Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin|Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2007|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|75 Years|No|||September 2015|September 11, 2015|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00430313||174669|
NCT00434837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR047910|Initial Graft Tension and ACL Surgery|Effects of Initial Graft Tension on Anterior Cruciate Ligament Reconstruction||Rhode Island Hospital|Yes|Active, not recruiting|February 2004|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 3, 2014|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434837||174327|
NCT00434850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-03|Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes|Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2006|November 2013|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|February 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00434850||174326|
NCT00431197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|344-03|Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men|Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men||Mayo Clinic||Completed|February 2004|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|||Anticipated|40|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||January 2010|January 26, 2010|February 2, 2007||||||https://clinicaltrials.gov/show/NCT00431197||174602|
NCT00424684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#0611163|Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation|Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation||University of Pittsburgh||Withdrawn|January 2007|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 18, 2007|||unable to obtain contract with sponsor|No||https://clinicaltrials.gov/show/NCT00424684||175087|
NCT00425659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.404-T|Evaluation of New Diagnostic and Treatment Algorithm for Obstructive Sleep Apnea|Evaluation of New Diagnostic and Treatment Algorithm for Obstructive Sleep Apnea in High Risk Population in Hong Kong||Chinese University of Hong Kong|No|Completed|January 2007|June 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|150|||Both|18 Years|65 Years|No|||July 2009|July 9, 2009|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425659||175015|
NCT00430573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DA017904-S1|Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use|Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use||Boston University|Yes|Completed|February 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|No|||April 2013|May 23, 2013|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430573||174650|
NCT00430547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/53|Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies|Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies||Barwon Health||Completed|August 2003|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||August 2003|February 1, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00430547||174652|
NCT00430560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDB0003|Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia|Work Activity Augmented by Cognitive Rehabilitation: Continuation and Follow-up||VA Connecticut Healthcare System|No|Active, not recruiting|October 2000|October 2015|Anticipated|October 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430560||174651|
NCT00430846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG035-0001|Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies|A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.||Seattle Genetics, Inc.|No|Completed|November 2006|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|February 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00430846||174629|
NCT00431132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG-1748|Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis|A 12 Month, Open-label, Multi-center Trial to Investigate the Endometrial Safety of Vagifem Low Dose (10ug 17beta-estradiol Vaginal Tablet) in Postmenopausal Women With Atrophic Vaginitis Symptoms||Novo Nordisk A/S|No|Completed|January 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|336|||Female|45 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 19, 2012|February 2, 2007|Yes|Yes||No|February 7, 2011|https://clinicaltrials.gov/show/NCT00431132||174607|This was a single-arm, 12-month, open label, multicentre trial; therefore there were no comparator results available.
NCT00428662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101|Evaluation of a New Nanotechnology Based Drug-Eluting Stent for Opening of Narrowed Arteries of the Heart|Clinical and Angiographic Evaluation of Paclitaxel Eluting, Non-Polymeric, Nanoporous Carbon-Carbon Coated, Cobalt-Chromium Stent||All India Institute of Medical Sciences, New Delhi||Recruiting|January 2007|October 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|70 Years|No|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428662||174792|
NCT00431678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11215|Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia|A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Treatment of Patients With Severe Community-acquired Pneumonia||Bayer|No|Completed|January 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|738|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|February 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00431678||174566|
NCT00427609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8389|Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications|Efficacy of Bicillin LA for the Treatment of Chronic, Plaque-type Psoriasis Unresponsive to Topical Medications.||University of Tennessee|No|Terminated|January 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|January 25, 2007||No|Not enough enrollees to obtain a valid conclusion|No||https://clinicaltrials.gov/show/NCT00427609||174870|
NCT00433901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-04Esta-05|Family Connections Weight Management|Managing Weight in Overweight and At-Risk Children||Kaiser Permanente||Completed|November 2004|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||220|||Both|8 Years|12 Years|No|||July 2010|July 16, 2010|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433901||174399|
NCT00433914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P9|Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants|A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old||Novartis|No|Completed|February 2007|July 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Both|6 Months|8 Months|Accepts Healthy Volunteers|||March 2015|March 5, 2015|February 9, 2007||No||No|February 18, 2015|https://clinicaltrials.gov/show/NCT00433914||174398|
NCT00428948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-04-251|Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD|A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease|TEMPO3/4|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|January 2007|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1445|||Both|18 Years|50 Years|No|||February 2013|February 1, 2013|January 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00428948||174770|
NCT00435357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.407|Comparison Between Fixed- Versus Mobile-bearing TKA|Comparison Between Fixed- Versus Mobile-bearing TKA : a Randomized Prospective Study||Hospices Civils de Lyon||Completed|February 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|160|||Both|50 Years|90 Years|No|||June 2013|June 20, 2013|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435357||174288|
NCT00434525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-011|Laparoscopic Sleeve Gastrectomy With and Without Omentectomy|Metabolic Effects of Laparoscopic Sleeve Gastrectomy With or Without Omentectomy: Prospective Randomized Trial||North Texas Veterans Healthcare System|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||August 2009|December 14, 2009|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434525||174351|
NCT00435916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG040-0004|Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma|A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)||Seattle Genetics, Inc.|No|Completed|December 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|February 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00435916||174245|
NCT00435929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP17921|A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.|Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients||Hoffmann-La Roche||Completed|September 2006|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|February 15, 2007|Yes|Yes||No|December 2, 2015|https://clinicaltrials.gov/show/NCT00435929||174244|
NCT00435123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006002|ProStat Supplementation in Dialysis Patients|A Randomized, Placebo Controlled, Double Blind Study of the Use of a Nutritional Supplement, ProStat-64, in Chronic Hemodialysis Patients With Poor Nutritional Status.||Fresenius Medical Care North America|No|Terminated|July 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||February 2008|February 12, 2008|February 12, 2007||No|Increased use of commercial product; less eligible patients & poor enrollment.|No||https://clinicaltrials.gov/show/NCT00435123||174305|
NCT00435331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WILK1|6R-BH4 Pulmonary Arterial Hypertension Study|A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of 6R-BH4 in Subjects With Pulmonary Arterial Hypertension||Vanderbilt University|Yes|Completed|March 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|February 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00435331||174290|
NCT00424996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNToronto|Utility of Heidelberg Retina Tomograph in Monitoring Glaucoma Progression|Utility of Heidelberg Retina Tomograph in Monitoring Glaucoma Progression||University Health Network, Toronto||Completed|August 2006|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|74|||Both|20 Years|80 Years|No|Non-Probability Sample|University glaucoma unit|May 2014|May 20, 2014|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00424996||175064|
NCT00425945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37698|Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study|Cardiovascular Effects of Pine Bark Extract||Stanford University|Yes|Completed|October 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 19, 2014|January 23, 2007||No||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00425945||174994|
NCT00425958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3856-AB-CTIL|Examination of Virtual Supermarket (Vmall) as an Assessment of Executive Functions in Children and Adolescents With Acquired Brain Injury|||Sheba Medical Center|No|Completed|April 2006|September 2006|Actual|||Phase 2|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|40|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||September 2007|September 23, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00425958||174993|
NCT00430872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0809|Development of the MDASI-Spine Tumor Module|Validation of the M.D. Anderson Symptom Inventory-Spine Tumor Module||M.D. Anderson Cancer Center|No|Completed|January 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|128|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a tumor on the spine or spinal cord.|July 2012|July 31, 2012|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430872||174627|
NCT00430859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP SEP 02-01|Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis|A Pilot, Double-blind, Randomised, Placebo-controlled, Exploratory Study to Investigate the Safety and Effect of Bovine Intestinal Alkaline Phosphatase in Patients With Sepsis||AM-Pharma|Yes|Completed|September 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|80 Years|No|||March 2012|March 30, 2012|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430859||174628|
NCT00431145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091977|Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)|Influence of Combined Therapy of Niacin and Statins on Stem Cell Mobilization and Inflammatory Parameters in Patients Suffering From Coronary Artery Disease – Randomized Clinical Study -||Ludwig-Maximilians - University of Munich||Recruiting|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||February 2007|February 1, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00431145||174606|
NCT00431431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06090|Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)|A Multinational, Randomized, Double-Blind, Parallel Group Comparative Trial on the Effects of 2 Years Treatment With Tibolone (1.25 mg Org OD 14) and Raloxifene (60 mg) on Bone Mineral Density in Osteopenic Postmenopausal Women|STEP|Merck Sharp & Dohme Corp.|No|Completed|October 2000|February 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|324|||Female|60 Years|79 Years|No|||May 2014|May 23, 2014|February 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00431431||174584|
NCT00428402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0125|Using Focus Groups to Assess the Impact of Environmental Health Science Programs for K-12 Educational Community|Using Focus Groups to Assess the Impact of Environmental Health Science Programs for K-12 Educational Community||M.D. Anderson Cancer Center|No|Completed|January 2007|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participant is a 4th-8th grade student in select schools from Bastrop Independent School        District (BISD).|February 2012|February 27, 2012|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428402||174812|
NCT00428415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPO-2|Effect of Tesofensine on Energy Balance in Humans.|The Effect of Tesofensine on Energy Balance in Humans. A Randomised, Double-Blind, Placebo-Controlled, Parallel- Group, Single Centre Study.||NeuroSearch A/S||Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 3, 2008|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428415||174811|
NCT00427622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC05CC|Skin Conduction Device for Measuring Hot Flashes in Postmenopausal Women With Hot Flashes|A Trial to Examine the Accuracy of an Ambulatory Sternal Skin Conductance Recording Tool to Measure Hot Flashes||Mayo Clinic|Yes|Completed|May 2006|||June 2007|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|25|||Female|18 Years|N/A|No|||June 2007|April 7, 2014|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427622||174869|
NCT00427908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108658|Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612|Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age)||GlaxoSmithKline||Completed|February 2007|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|612|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||August 2012|March 28, 2013|January 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00427908||174848|
NCT00428129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-M-005|Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT|An Open Label Clinical Trial of Microplasmin Administered Via the Trellis-8 Infusion System for the Treatment of Acute Iliofemoral Deep Vein Thrombosis|MAX-DVT|ThromboGenics|Yes|Terminated|March 2007|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|January 26, 2007||No|Sponsor's decision to not pursue uPLi for vascular conditions including DVT.|No||https://clinicaltrials.gov/show/NCT00428129||174831|
NCT00428376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0636-01|Does Block Play Improve Language Acquisition: A Randomized Trial|Clinical Trial of Building Block Distribution in Children||University of Washington||Completed|September 2005|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind||||200|||Both|18 Months|30 Months|Accepts Healthy Volunteers|||September 2008|September 25, 2008|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428376||174814|
NCT00433927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRE-3|5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)|Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.||Ludwig-Maximilians - University of Munich||Active, not recruiting|January 2007|December 2016|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|568|||Both|18 Years|75 Years|No|||March 2014|March 13, 2014|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433927||174397|
NCT00433940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immune Suppression of Infants|Immune Suppression Of Infants Treated With Steroids|Immune Suppression of Infants Treated With Oral Corticosteroids for Infantile Hemangiomas: A Pilot Study||Medical College of Wisconsin|No|Completed|October 2006|July 2010|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|None Retained|Collection of blood samples at each visit. Following laboratory testing, no samples were      retained.|Both|N/A|6 Months|No|Non-Probability Sample|Subjects were recruited from a hospital based pediatric dermatology clinic.|January 2013|January 23, 2013|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433940||174396|
NCT00434161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050219|A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma|A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation||Swedish Orphan Biovitrum|No|Completed|December 2006|May 2012|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|281|||Both|18 Years|70 Years|No|||March 2015|March 10, 2015|February 8, 2007|Yes|Yes||No|March 2, 2010|https://clinicaltrials.gov/show/NCT00434161||174379|
NCT00424125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT DC CPIT|Involving Community Pharmacies in Improving Asthma Outcomes in an Urban Pediatric Population|Improving Pediatric Asthma Care in the District of Columbia (IMPACT DC)-Community Pharmacy Intervention||Children's Research Institute||Completed|July 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|125|||Both|12 Months|12 Years|No|||August 2015|August 21, 2015|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00424125||175130|
NCT00424138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000527084|FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy|[18F]FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer|ACRIN 6678|American College of Radiology Imaging Network|Yes|Terminated|March 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|96|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|January 16, 2007||No|Recruitment obstacles; data to be combined with other resources for analysis|No||https://clinicaltrials.gov/show/NCT00424138||175129|
NCT00424788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS001|A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)|A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)||Biogen||Completed|January 2007|October 2007|Actual|October 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|50 Years|No|||September 2009|September 3, 2009|January 18, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00424788||175079|
NCT00425048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A_B_19_01_2007|Does Gloved Medical Personnel Scratch Less Often?|||Medical University Innsbruck||Completed|January 2007|December 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2009|February 9, 2009|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425048||175060|
NCT00425061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3174K1-201|Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma|Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study Conducted Sequentially With 3 Doses Of Ima-638 Administered Sc.||Pfizer|No|Completed|February 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|80 Years|No|||January 2015|January 12, 2015|January 18, 2007|Yes|Yes||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00425061||175059|The study was stopped early due to futility of the interim efficacy analysis results. Hence, only safety results and key efficacy results were presented for this study.
NCT00425438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19978|A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.|A Randomized, Open-label Study to Compare the Effect of CellCept Plus Corticosteroids, and Cyclophosphamide Plus Corticosteroids Followed by Azathioprine, on Remission Rate in Patients With Lupus Nephritis||Hoffmann-La Roche||Terminated|March 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||September 2014|September 22, 2014|January 22, 2007||No|Study was terminated early for administrative reasons.|No|August 14, 2014|https://clinicaltrials.gov/show/NCT00425438||175032|The study was terminated early due to administrative reasons.
NCT00424775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-066|A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)|A Phase I Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)||Merck Sharp & Dohme Corp.||Terminated|January 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|20 Years|N/A|No|||March 2015|March 31, 2015|January 19, 2007|No|Yes||No|April 3, 2009|https://clinicaltrials.gov/show/NCT00424775||175080|
NCT00425451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI/006P|The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis|The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis||Dexcel Pharma Technologies Ltd.||Completed|August 2008|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|25 Years|N/A|No|||June 2011|June 13, 2011|January 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00425451||175031|
NCT00425737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/004|Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants|A Study to Assess the Efficacy, Immunogenicity and Safety of Two Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in Healthy Infants.||GlaxoSmithKline||Completed|August 2000|December 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||405|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||January 2007|January 22, 2007|January 22, 2007||||No||https://clinicaltrials.gov/show/NCT00425737||175009|
NCT00425425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000516821|Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer|Neoadjuvant Radiochemotherapy in Local Advanced Squamous Cell Carcinoma of the Esophagus With Weekly Cetuximab Plus Oxaliplatin Plus Continuous IV. 5-FU and Conventional Fractionated External Multi-Field Irradiation up to 45 Gray. A Phase I/II Study||Technische Universität München|No|Active, not recruiting|July 2006|May 2015|Anticipated|May 2010|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|43|||Both|18 Years|70 Years|No|||April 2014|April 30, 2014|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00425425||175033|
NCT00426335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2839|Evaluation of Group CBT Programme With Breast Cancer Patients|An Evaluation of a Group CBT Programme for Women With Primary Breast Cancer.||Royal Marsden NHS Foundation Trust||Recruiting|January 2007|||||Phase 0|Observational|Time Perspective: Prospective||1|Anticipated|78|||Female|18 Years|N/A|No|Non-Probability Sample|78 participants in total including 39 female RMH patients with primary breast cancer and        are post adjuvant treatment.|January 2010|January 12, 2010|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426335||174966|
NCT00457340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581020|Atorvastatin For The Reduction Of Ventricular Arrhythmias|Cholesterol Lowering and Arrhythmia Recurrences After Internal Defibrillator Implantation (CLARIDI)|CLARIDI|Pfizer||Completed|February 2000|September 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||220|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457340||172622|
NCT00457626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489K2303E1|An Open Label Extension Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension|An Open Label Extension Study to Evaluate Safety, Tolerability, and Efficacy of 18 Weeks of Valsartan Treatment in Children 6 Months-5 Years Old With Hypertension||Novartis|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|6 Months|5 Years|No|||November 2012|November 30, 2012|April 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00457626||172600|
NCT00457639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3085|Cholic Acid for Hepatic Steatosis in Lipodystrophy|Phase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy Patients||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|April 2006|October 2013|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|6 Years|70 Years|No|||August 2011|August 2, 2011|April 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00457639||172599|
NCT00426556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001J2101|Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer|A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer||Novartis||Completed|July 2007|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|88|||Female|18 Years|N/A|No|||November 2015|November 24, 2015|January 23, 2007|Yes|Yes||No|March 20, 2015|https://clinicaltrials.gov/show/NCT00426556||174950|
NCT00426569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4534-AY-CTIL|Normal Paranasal Sinuses Microflora Study|||Sheba Medical Center|No|Completed|February 2007|May 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|N/A|No|Probability Sample|Healthy adults undergoing orthognatic procedure|May 2015|May 22, 2015|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426569||174949|
NCT00426920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOV/QD001|Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler|Evaluation of the Pharmacokinetics and Pharmacodynamics of Spray-Dried Recombinant Human Insulin Powder for Inhalation Administered Via a Dry Powder Inhalation Device Relative to SC Recombinant Human Insulin in Healthy Male Volunteers||QDose Limited||Not yet recruiting|February 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2007|January 24, 2007|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00426920||174922|
NCT00423241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-06-004|SEMPERFLO* Pain Management System in Inguinal Hernia Repair|A Prospective, Randomized, Exploratory Comparison of the SEMPERFLO* Pain Management System to a Commercially Available Pain Relief System in Subjects Undergoing Open Inguinal Hernia Repair||Ethicon, Inc.|No|Terminated|January 2007|January 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||August 2010|August 20, 2010|January 16, 2007||No|Market dynamics including other technologies made the project not viable.|No||https://clinicaltrials.gov/show/NCT00423241||175196|
NCT00423553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070057|Collection of Heart Tissue Sample During Open Heart Surgery|Modifying Tolerance to Ischemic Injury in Human Atrial Tissue||National Institutes of Health Clinical Center (CC)||Completed|January 2007|December 2007||||N/A|Observational|N/A||||0|||Both|18 Years|80 Years|No|||December 2007|March 5, 2008|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00423553||175173|
NCT00422929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0605009|Eustachian Tube Growth and Development|Eustachian Tube Growth and Development: Anatomy/Function||University of Pittsburgh|No|Active, not recruiting|August 2006|June 2020|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|cells obtained from buccal brushing|Both|3 Years|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric otolaryngology clinic|January 2016|January 15, 2016|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422929||175220|
NCT00423228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEB-ZTSR-201|Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease|A Randomised, Double-blind, Double-dummy, Oral Donepezil Controlled Study on the Safety and Efficacy of Repeated Monthly Subcutaneous Injections of a Sustained-release Implant of ZT 1 in Patients With Moderate Alzheimer's Disease|BRAINz|Debiopharm International SA|Yes|Completed|February 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|228|||Both|50 Years|N/A|No|||January 2015|January 13, 2015|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423228||175197|
NCT00435019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1689|Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes|An Efficacy and Safety Comparison of Insulin Detemir vs. NPH Insulin in Children and Adolescents Diagnosed With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|February 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|348|||Both|2 Years|16 Years|No|||November 2014|November 20, 2014|February 13, 2007|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00435019||174313|
NCT00424801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasointense|Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris|Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris||University of Aarhus|Yes|Terminated|January 2007|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 5, 2009|January 19, 2007||No|Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis|No||https://clinicaltrials.gov/show/NCT00424801||175078|
NCT00425074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROM-EC-ECC-FIb|Pharmacodynamic-pharmacokinetic Trial, of Slow Release ASA, in the Platelet Functionalism.|Pharmacodynamic- Pharmacokinetic Trial, Comparative Double Blind, of the Chronic Administration of 150 mg of Slow Release ASA Versus 150 mg of Normal Release ASA, in the Platelet Functionalism.||Rottapharm Spain||Completed|January 2007|July 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00425074||175058|
NCT00425464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNC-601-IOL|A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Synchrony Dual Optic Intraocular Lens in Patients Undergoing Cataract Extraction|A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Synchrony Dual Optic Intraocular Lens in Patients Undergoing Cataract Extraction||Abbott Medical Optics||Terminated|November 2005|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|50 Years|N/A|No|||September 2013|September 16, 2013|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425464||175030|
NCT00425477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0675 CDR0000525989|Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|November 2006|||July 2016|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|120 Years|No|||October 2015|October 30, 2015|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425477||175029|
NCT00425750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0501|Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Trial of Combination Weekly Bortezomib (VELCADE) and Docetaxel (TAXOTERE) in Patients With Recurrent and/ or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)||Vanderbilt-Ingram Cancer Center|Yes|Completed|August 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|January 19, 2007|Yes|Yes||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00425750||175008|
NCT00426010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2051072|Measuring Placebo Effect by Elimination and Investigating Mechanism of Action|Measuring Placebo Effect by Elimination and Investigating Its Mechanism of Action||King Faisal Specialist Hospital & Research Center||Completed|January 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 11, 2011|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426010||174989|
NCT00426348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPH200603|A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy|A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy||Guangdong General Hospital|Yes|Completed|May 2007|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|60 Years|No|||August 2013|August 27, 2013|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426348||174965|
NCT00458120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 227|Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus|Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 13, 2010|April 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00458120||172562|
NCT00458367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003373|RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice|Risperdal Safety Protocol Evaluation Consta Treatment; A Post Authorization Safety Survey With RISPERDAL CONSTA TM||Janssen Pharmaceutica N.V., Belgium||Completed|June 2002|October 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|5296|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with long-acting injectable risperidone as decided after agreement        between the physician and the patient, in accordance with the local SmPC, are eligible for        inclusion in this survey. According to the global SmPC, long-acting injectable risperidone        is indicated for the treatment of schizophrenia and schizoaffective disorder.|October 2010|October 15, 2010|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00458367||172543|
NCT00426582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2105|Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors|A Phase Ib, Multicenter, Open-label, Dose-finding Study of Patupilone Administered Intravenously Every 3 Weeks in Combination With Carboplatin AUC 6 in Adult Patients With Advanced Solid Tumors||Novartis||Completed|August 2006|||August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|January 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426582||174948|
NCT00426933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-HDSD-06-01|Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections|Phase 2 Multicenter Randomized Semi-Single Blind Study to Compare Efficacy and Safety of High-dose Short Duration Daptomycin With Conventional Therapy in Complicated Skin and Skin Structure Infections Due to Gram-positive Bacteria||Cubist Pharmaceuticals LLC|No|Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|18 Years|85 Years|No|||September 2010|September 13, 2010|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426933||174921|
NCT00426946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACMHC1|Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study|Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study||Geha Mental Health Center||Recruiting|January 2005|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|6 Years|18 Years|No|||September 2004|January 24, 2007|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00426946||174920|
NCT00422968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0012|Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease|PREmier of Randomized COMparison of Bypass Surgery Versus AngioplasTy Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease|PRECOMBAT|CardioVascular Research Foundation, Korea|Yes|Completed|March 2005|December 2013|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1454|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00422968||175217|
NCT00423254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC1106-PP-001|Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.|A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies||Mannkind Corporation|No|Completed|February 2007|November 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||August 2010|August 2, 2010|January 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00423254||175195|
NCT00423267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04558|POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)|A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis||Merck Sharp & Dohme Corp.|No|Completed|May 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|13 Years|N/A|No|||September 2015|September 18, 2015|January 17, 2007|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00423267||175194|
NCT00423852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-077|Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin|Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients||Memorial Sloan Kettering Cancer Center||Completed|August 2006|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423852||175150|
NCT00424151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U4126s|Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy|Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II||Silkiss, Rona Z., M.D., FACS||Completed|December 2006|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2010|October 4, 2010|January 17, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00424151||175128|
NCT00423865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSKCC 06-129|Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors|A Phase I Study of Weekly Low-Dose Cisplatin Plus Escalating Doses of Oral RAD001(Everolimus) for Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Completed|November 2006|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2012|May 22, 2015|January 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00423865||175149|
NCT00435253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-C06-003|US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study|Phase 2 Study of the Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema||Aeris Therapeutics|Yes|Completed|February 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|N/A|No|||October 2011|October 21, 2011|February 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00435253||174296|
NCT00424450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C01-2006|Assessment of Bypass Surgery and Balloon Angioplasty Effects in Peripheral Arterial Disease Using Contrast Ultrasound|Assessment of Revascularization Effects in Peripheral Arterial Disease Using Contrast Ultrasound Tissue Perfusion Imaging (REVASC-PI)||University Hospital Freiburg|No|Active, not recruiting|October 2006|July 2008|Anticipated|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|PAD patients|June 2008|June 5, 2008|January 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00424450||175105|
NCT00424463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI186-17|Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)|An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3)||Mitsubishi Tanabe Pharma Corporation|No|Completed|January 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|20 Years|N/A|No|||February 2013|February 27, 2013|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00424463||175104|
NCT00424814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006200-11|Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva|Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. A Multicenter Randomised Phase II/III Open Label Study With a Group of 100 Pregnant Women Receiving Lopinavir/Ritonavir and a Group of 50 Receiving Lopinavir/Ritonavir Plus Zidovudine and Lamivudine. ANRS 135 Primeva||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|March 2007|November 2012|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Female|18 Years|N/A|No|||July 2013|July 17, 2013|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00424814||175077|
NCT00425100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221007|A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients|A 12-Week, Multicenter, Open-Label, Single-Arm Study To Evaluate The Effects Of Fesoterodine On Treatment Satisfaction And Symptom Relief In Overactive Bladder Patients.||Pfizer|No|Completed|January 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|516|||Both|18 Years|N/A|No|||February 2009|February 24, 2009|January 19, 2007|Yes|Yes||No|October 10, 2008|https://clinicaltrials.gov/show/NCT00425100||175057|
NCT00425113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907041|Metronidazole for Pulmonary Tuberculosis (South Korea)|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Metronidazole Combined With Antituberculous Chemotherapy vs. Antituberculous Chemotherapy With Placebo in Subjects With Multi-Drug Resistant Pulmonary Tuberculosis||National Institutes of Health Clinical Center (CC)|Yes|Completed|December 2006|February 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|20 Years|N/A|No|||May 2013|May 10, 2013|January 19, 2007|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT00425113||175056|Major limitation of our study was the small sample size. Planned enrollment was 80 subjects but DSMB recommended closing the study to new enrollment after 35 subjects due to increased peripheral neuropathy in the metronidazole arm.
NCT00425490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4373-OC-CTIL|Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus|Phase III Study on the Effect of Sitagliptin on Maximal Beta Cell Stimulation||Sheba Medical Center|No|Completed|January 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|65 Years|No|||September 2009|September 22, 2009|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425490||175028|
NCT00436397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304713|A New Radiation Therapy Planning System in Patients Undergoing Radiation Therapy for Cancer|Evaluation of the Radionics Body Localizer System and XPLAN/IMRT for Extra-Cranial Sites: A Pilot Study||Fox Chase Cancer Center||Completed|June 2002|August 2005|Actual|||N/A|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|N/A|No|||February 2010|February 11, 2010|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436397||174208|
NCT00426023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eudract 2006-003689-32|Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis|Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Cyclosporine Eye Drop Treatment in Preventing Vernal Keratoconjunctivitis (VKC) Relapses and in Treating the Acute Phase.||Campus Bio-Medico University||Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|5 Years|50 Years|No|||January 2009|January 27, 2009|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426023||174988|
NCT00426673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01172|An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.|A Multi-Center, Open-Label, Unilateral Interaction Study of Ucb 34714 on Stable Phenytoin Monotherapy During a 45 Day b.i.d. Administration Period in 15 Adult Subjects Suffering From Epilepsy||UCB Pharma||Completed|April 2005|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||March 2008|March 7, 2008|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426673||174941|
NCT00432302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91490|Investigation of Mass Balance of the Test Drug and Major Metabolites|Investigation of Mass Balance and Major Metabolites After Administration of 28 mg Radiolabeled ZK 219477 in Patients With Solid Tumor in an Open-label, Non Randomized Design||Bayer|No|Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432302||174519|
NCT00422721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 06/8-F|Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy|Genetical, Multi-center, Prospective Study of Phenotyping and Genotyping of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy in the Aim of the Realisation of a Clinical Trial of Gene Therapy||Nantes University Hospital|No|Completed|April 2007|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|360|||Both|N/A|N/A|No|||November 2011|November 23, 2011|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422721||175236|
NCT00423007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-BR-CS03|Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis|Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With a History of Allergic Conjunctivitis||Bausch & Lomb Incorporated|No|Completed|November 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||90|||Both|10 Years|N/A|No|||March 2013|March 13, 2013|January 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423007||175214|
NCT00427219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-153-06-1|The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate|A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS)Due to Benign Prostatic Hypertrophy (BPH)||Spectrum Pharmaceuticals, Inc||Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Male|50 Years|N/A|No|||June 2012|June 6, 2012|January 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00427219||174899|
NCT00422682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11484|A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors|A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors||Sanofi||Completed|January 2007|September 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|136|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|January 12, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00422682||175239|
NCT00422942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA19078|A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)|An Open-label, Exploratory Study of the Pharmacokinetic and Pharmacodynamic Activity of MabThera in Combination With Methotrexate in Synovial Tissue and in Peripheral Blood of Patients With Active Rheumatoid Arthritis.||Hoffmann-La Roche||Terminated|January 2006|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|80 Years|No|||July 2014|July 14, 2014|January 15, 2007||No|Study was terminated after enrollment of 3 participants due to recruitment difficulties.|No|May 7, 2014|https://clinicaltrials.gov/show/NCT00422942||175219|Study terminated after enrollment of 3 participants due to recruitment difficulties and since the objectives and data under study had been published from other, independent sources it was not appropriate to expose further participants to study drug.
NCT00433784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.E.2004-06-24|H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel|Evaluation of the Effect of the H2 Haplotype and CYP3As Polymorphisms on the Antiplatelet Response to Clopidogrel Given Before Elective Percutaneous Coronary Intervention||Hopital du Sacre-Coeur de Montreal||Completed|September 2004|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||120|||Both|18 Years|N/A|No|||June 2008|August 20, 2012|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433784||174408|
NCT00434044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-322|Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis|Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase III Study of Etanercept in the Treatment of Subjects With Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2007|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||December 2007|December 11, 2007|February 9, 2007||||No||https://clinicaltrials.gov/show/NCT00434044||174388|
NCT00423566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB002|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.||University of Oxford||Completed|September 2002|July 2003||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2006|January 17, 2007|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00423566||175172|
NCT00423579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04039|The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)|A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of Administration of Ezetimibe/Simvastatin Tablet 10/20 mg Versus Doubling the Dose of Simvastatin 20 mg [Simvastatin 40 mg] in Subjects With Primary Hypercholesterolemia and Coronary Heart Disease||Merck Sharp & Dohme Corp.|No|Completed|July 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||April 2015|April 1, 2015|January 17, 2007||No||No|March 19, 2009|https://clinicaltrials.gov/show/NCT00423579||175171|
NCT00423878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STROUP06STN0|Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder|Clinical Management of Metabolic Problems in Patients With Schizophrenia|CAMP|National Institute of Mental Health (NIMH)|Yes|Completed|January 2007|March 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|65 Years|No|||November 2010|December 7, 2015|January 16, 2007|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00423878||175148|Open-label treatment is a limitation of this study, particularly for outcomes not measured in the laboratory but instead subject to clinical judgment.
NCT00435552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2007.001|Ease-it Spray for the Treatment of Fire Ant Stings|||C.R.Darnall Army Medical Center||Completed|February 2007|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|60 Years||||January 2007|February 14, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435552||174273|
NCT00435565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ringholm|Severe Hypoglycemia in Pregnant Women With Type 1 Diabetes|Severe Hypoglycemia in Pregnant Women With Type 1 Diabetes. Incidence, Risk Markers and Possibilities for Prevention||Rigshospitalet, Denmark||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Female|N/A|N/A||||February 2007|February 14, 2007|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00435565||174272|
NCT00435578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-304|Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma|An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma||Threshold Pharmaceuticals||Terminated|February 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|February 13, 2007||||||https://clinicaltrials.gov/show/NCT00435578||174271|
NCT00424476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1006-C1057|A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)|BLISS-52|Human Genome Sciences Inc.|Yes|Completed|May 2007|March 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|865|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|January 17, 2007|Yes|Yes||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00424476||175103|
NCT00424489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myasthenia Gravis Auto 2002|Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis|Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis||Northwestern University|No|Active, not recruiting|February 2002|February 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|15 Years|65 Years|No|||March 2016|March 21, 2016|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00424489||175102|
NCT00435513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000001|A Common Polymorphism of the SRD5A2 Gene is Not Associated With Male-to-Female and Female-to-Male Transsexualism|Association Study of a SRD5A2 SNP and Transsexualism.||Medical University of Vienna|No|Completed|March 2007|July 2008|Actual|May 2008|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1770|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Female-to-male transsexuals and male-to-female transsexuals|May 2015|May 3, 2015|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435513||174276|
NCT00435812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-10|Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine|A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®||Dynavax Technologies Corporation|Yes|Completed|December 2006|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2428|||Both|11 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|February 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00435812||174253|
NCT00436111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KK-2007-1|Characterization of Macroprolactinemia|||Kansai Medical University||Completed|January 2005|December 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||February 2007|February 15, 2007|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436111||174230|
NCT00436124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20910|A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.|A Randomized, Open Label Study to Evaluate the Effect of Tamiflu on Viral Shedding and on Serum and Cytoplasmic Inflammatory Cytokine Concentrations in Patients With Laboratory-Confirmed Influenza||Hoffmann-La Roche||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|64 Years|No|||December 2007|December 18, 2007|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436124||174229|
NCT00431977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0610/038-002|Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes|DEtection of Subclinical Coronary AtheRosclerosis in diabeTES Using Coronary CT Angiography (DESCARTES Trial)||Seoul National University Bundang Hospital||Completed|November 2006|December 2012||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|||Anticipated|1000|||Both|50 Years|75 Years|No|||October 2006|June 20, 2011|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431977||174544|
NCT00431990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/34|A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma|A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma||Peter MacCallum Cancer Centre, Australia|Yes|Recruiting|November 2006|January 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2011|August 11, 2011|February 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00431990||174543|
NCT00432003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPCRA 065F|Effects of Anti-HIV Therapy on Nervous System Function|Neurology: A Substudy of a Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (SMART) to Determine the Impact of the Strategies Upon Central and Peripheral Nervous System Function||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2005|July 2007|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|297|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432003||174542|
NCT00426036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC477D2311|Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine|An Open-Label Study in Healthy Subjects and in Patients With Stable Impaired Renal Function to Assess the Effect of Severe Renal Impairment on Licarbazepine Pharmacokinetics and Metabolism After the Single Administration of a 500 mg Licarbazepine Immediate Release (IR) Tablet||Novartis||Completed|June 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2007|June 21, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426036||174987|
NCT00426361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108464|Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects|A Multicentre Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) Co-administered With Boostrix Polio (dTpa-IPV) in Healthy Female Subjects Aged 10-18 Years||GlaxoSmithKline||Completed|February 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|751|||Female|10 Years|18 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|January 23, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00426361||174964|
NCT00426660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001050|Expanded Access Program for Maraviroc At Multiple Centers|A Multi-Center, Open Label, Expanded Access Trial Of Maraviroc||ViiV Healthcare|Yes|Completed|February 2007|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1047|||Both|16 Years|N/A|No|||September 2011|September 12, 2011|January 22, 2007|Yes|Yes||No|June 2, 2011|https://clinicaltrials.gov/show/NCT00426660||174942|Viral loads were not available for subjects uniformly as this expanded access study followed local country guidelines and practices that could vary significantly between countries, and testing frequency may have been affected by insurance status.
NCT00432315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_AT1_203|Docetaxel in Non Small Cell Lung Cancer (NSCLC)|Multicenter Phase II Study Evaluating Docetaxel and CDDP as Induction Regimen Prior to Surgery or Radiochemotherapy With Docetaxel, Followed by Adjuvant Docetaxel Therapy in Chemonaive Patients With NSCLC Stage II, IIIa and IIIb||Sanofi||Completed|May 2001|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|19 Years|75 Years|No|||September 2010|September 13, 2010|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432315||174518|
NCT00432640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/461|Assessment of Surgical sTaging vs Endoscopic Ultrasound in Lung Cancer: a Randomized Clinical Trial (ASTER Study)|Complete Echo-Endoscopic Staging of Lung Cancer vs Surgical Staging: a Randomized Clinical Trial||University Hospital, Ghent|No|Completed|January 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|240|||Both|18 Years|N/A|No|||December 2010|December 15, 2010|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00432640||174494|
NCT00432653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ritux-AS-01|Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis|Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis||Charite University, Berlin, Germany||Not yet recruiting|March 2007|November 2009||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||February 2007|February 7, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432653||174493|
NCT00427245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-OPTION|Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer|Ovarian Protection Trial In Premenopausal Breast Cancer Patients [OPTION]||National Cancer Institute (NCI)||Completed|August 2004|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|400|||Female|N/A|N/A|No|||May 2007|August 6, 2013|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427245||174897|
NCT00427258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-1106|Study Evaluating MOA-728 Administered in Healthy Men|An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]MOA-728 in Healthy Men||Valeant Pharmaceuticals International, Inc.||Withdrawn|January 2010|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|January 25, 2007||||||https://clinicaltrials.gov/show/NCT00427258||174896|
NCT00423033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-95-c-046|Qualitative Analysis on the Experiences of Employment Among Schizophrenic Patients|||Far Eastern Memorial Hospital||Completed|March 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|December 25, 2008|January 14, 2007||||No||https://clinicaltrials.gov/show/NCT00423033||175212|
NCT00423319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-035|Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)|A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)||Bristol-Myers Squibb|Yes|Completed|March 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|5407|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|January 17, 2007|Yes|Yes||No|April 14, 2014|https://clinicaltrials.gov/show/NCT00423319||175190|
NCT00423644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL2001b|A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b|A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b||Ziopharm||Active, not recruiting|January 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|January 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00423644||175166|
NCT00427232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 242/2002|Endothelin-Receptor Blockade in Coronary Heart Disease|Selective and Non-Selective Endothelin-Receptor Blockade in Coronary Artey Disease||Medical University of Vienna||Completed|May 2003|August 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||26|||Both|19 Years|N/A|No|||January 2007|January 25, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427232||174898|
NCT00422695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120060172|Pain and Sensory Changes Assessment in HIV+ Patients|Pain and Sensory Changes Assessment in HIV+ Patients, A Model for Pain and Sensory Changes Related Compromised Immune System.||Rutgers, The State University of New Jersey||Completed|January 2007|May 2008|Actual|May 2008||N/A|Observational|Time Perspective: Prospective|||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 25, 2008|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00422695||175238|
NCT00434057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061|Evaluation of Pigmented Skin Lesions With MelaFind(R) System|Evaluation of Pigmented Skin Lesions With MelaFind(R) System||MELA Sciences, Inc.|No|Completed|January 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1383|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 10, 2012|February 8, 2007|Yes|Yes||No|May 26, 2009|https://clinicaltrials.gov/show/NCT00434057||174387|
NCT00434395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200L2-104|Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects|A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)-Controlled, 4-Period Crossover Study of the Effects of a Single Dose of MOA-728 Infused Intravenously on Cardiac Repolarization in Healthy Subjects||Valeant Pharmaceuticals International, Inc.||Completed|March 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|February 9, 2007||||||https://clinicaltrials.gov/show/NCT00434395||174361|
NCT00434408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000146|Impact of Umbilical Cord Cleansing With 4.0% Chlorhexidine on Neonatal Mortality|Impact of Umbilical Cord Cleansing With Chlorhexidine on Neonatal Mortality and Omphalitis in Rural Sylhet District of Bangladesh|CHX|Johns Hopkins Bloomberg School of Public Health|No|Completed|May 2007|November 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|28797|||Both|N/A|7 Days|No|||July 2007|August 9, 2011|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434408||174360|
NCT00434421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-10|Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma|A Safety and Pilot Dosing Study for Sublingual-Oral Administration of Glycerinated German Cockroach Allergenic Extract in Pediatric and Adult Subjects With Cockroach Allergy and Perennial Allergic Rhinitis With or Without Asthma|SCSS|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|5 Years|55 Years|No|||June 2015|June 5, 2015|February 12, 2007|Yes|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT00434421||174359|
NCT00434382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF 0311537|Neuronal Mechanisms of Sensory Processing During General Anesthesia|Neuronale Mechanismen Der Sensorischen Reizverarbeitung in Der Narkose|BEO|Ludwig-Maximilians - University of Munich||Active, not recruiting|October 2002|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Supportive Care||||768|||Both|18 Years|65 Years|No|||February 2007|July 29, 2010|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434382||174362|
NCT00434707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPTRIPLE0001|Outcome of Small Pupil Phacotrabeculectomy in Persons With Glaucoma and Cataract|||Aravind Medical Research Foundation||Not yet recruiting|March 2007|December 2007||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||70|||Both|40 Years|70 Years|No|||February 2007|February 12, 2007|February 10, 2007||||No||https://clinicaltrials.gov/show/NCT00434707||174337|
NCT00435006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-107/03|Hypopituitarism Following Traumatic Brain Injury or Spontaneous Subarachnoidal Haemorrhages|||Rigshospitalet, Denmark||Completed|August 2003|June 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|65 Years||||February 2007|February 13, 2007|February 13, 2007||||No||https://clinicaltrials.gov/show/NCT00435006||174314|
NCT00435851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Estimabl|Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients|Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl|Estimabl|Gustave Roussy, Cancer Campus, Grand Paris||Not yet recruiting|February 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment||||950|||Both|18 Years|N/A|No|||February 2007|February 16, 2007|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00435851||174250|
NCT00435240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4 726/2004|Paleolithic Diet in the Treatment of Diabetes Type 2 in Primary Health Care|||Lund University Hospital||Completed|January 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||May 2008|May 13, 2008|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435240||174297|
NCT00435825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV19432|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).|A Randomized, Double-blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.||Hoffmann-La Roche||Completed|March 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|551|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|February 15, 2007|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00435825||174252|
NCT00436137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sequist Colorectal Cancer|Improving Followup of Abnormal Colon Cancer Screening Tests|Improving Followup of Positive Fecal Occult Blood Tests||Harvard Vanguard Medical Associates|No|Completed|June 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|70|||Both|18 Years|80 Years|No|||November 2008|November 5, 2008|February 14, 2007||||No||https://clinicaltrials.gov/show/NCT00436137||174228|
NCT00436410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070043|Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer|An Evaluation of the Tissue Distribution and the Selective Tumor Trafficking of TNF-Bound Colloidal Gold (CYT-6091) Following Intravenous Administration in Subjects With Primary and Metastatic Cancer Undergoing Surgical Resection||National Institutes of Health Clinical Center (CC)||Completed|December 2006|August 2009|Actual|||Phase 0|Interventional|Primary Purpose: Treatment|||Anticipated|108|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436410||174207|
NCT00432354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTCRD 96-03|An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus|||Buddhist Tzu Chi General Hospital||Recruiting|March 2007|March 2009|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|16 Years|80 Years|No|||March 2007|March 19, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432354||174515|
NCT00431951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-246 RD PHS 1|Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers|Double-blind, Randomized, Placebo-controlled, Escalating, Multiple-dose, Phase I Trial to Assess Safety, Tolerability and Pharmacokinetics of ST-246 Administered as a Single Daily Dose for 21 Days in Healthy, Non-fasted Volunteers|SIGA-246-002|SIGA Technologies|Yes|Completed|February 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 15, 2010|February 2, 2007|No|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00431951||174546|
NCT00431964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ0004|Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa|Multi-center, Multi-national, Randomized, Placebo-Controlled Trial of Azithromycin in Subjects With Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa||CF Therapeutics Development Network Coordinating Center|Yes|Completed|February 2007|November 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|6 Years|18 Years|No|||July 2015|July 24, 2015|February 2, 2007|Yes|Yes||No|July 24, 2015|https://clinicaltrials.gov/show/NCT00431964||174545|
NCT00422734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9501|Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life|Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life||Eli Lilly and Company|No|Completed|November 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|342|||Male|18 Years|N/A|No|||June 2009|June 8, 2009|January 16, 2007|Yes|Yes||No|December 23, 2008|https://clinicaltrials.gov/show/NCT00422734||175235|
NCT00422747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL17407.000.07/2007-001817-40|Early Diagnosis of Asthma in Young Children|Early Diagnosis of Asthma in Young Children||Maastricht University Medical Center|No|Completed|April 2007|August 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|202|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|January 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00422747||175234|
NCT00423046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108933|Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age|Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]||GlaxoSmithKline||Completed|January 2007|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1106|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|November 14, 2013|January 16, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00423046||175211|
NCT00422708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1608-05|Local Anesthesia for Prostate Biopsy|Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention||Mayo Clinic||Completed|June 2006|June 2008|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|243|||Male|18 Years|90 Years|No|||January 2010|January 19, 2010|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00422708||175237|
NCT00422981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-108-211|Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment|A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment||Allon Therapeutics|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|144|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00422981||175216|
NCT00422994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRL103628|A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole|An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)||GlaxoSmithKline||Completed|April 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||48|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|January 12, 2007||||||https://clinicaltrials.gov/show/NCT00422994||175215|
NCT00423280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q1604/114|Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)|A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects With Coronary Artery Disease||University of Oxford|Yes|Recruiting|November 2006|February 2009|Anticipated|February 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||June 2008|August 6, 2008|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423280||175193|
NCT00434434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4160g|A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lyophilized and Aged Liquid Omalizumab in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|AQUA|Genentech, Inc.||Completed|October 2007|June 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|65 Years|No|||April 2010|April 30, 2010|February 11, 2007|Yes|Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00434434||174358|
NCT00434733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P4|Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects|A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects||Novartis||Completed|January 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|4400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 23, 2008|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00434733||174335|
NCT00434746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3199K1-1102|Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects|Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-094 Administered IV and One Dose of SC Administered to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|56|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434746||174334|
NCT00434720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-490|Comparison of GlideScope Specific Stylet to Malleable Stylet for GlideScope Intubation|Comparison of GlideScope Specific Stylet to Malleable Stylet for GlideScope Intubation||Lawson Health Research Institute|No|Completed|January 2007|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434720||174336|
NCT00435032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R073223335|Early Versus Interval Appendectomy for Ruptured Appendicitis in Children|Early Versus Interval Appendectomy for Ruptured Appendicitis in Children. Ruptured Appendicitis Pilot Trial (RAPTOR)|RAPTOR|University of Tennessee||Completed|October 2006|||September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|N/A|18 Years|No|||January 2010|January 11, 2010|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00435032||174312|
NCT00432055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20624503|Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy|A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy||Sunnaas Rehabilitation Hospital|No|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||February 2009|February 23, 2009|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00432055||174538|
NCT00435526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 218|Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I|Protective Efficacy of Orally Delivered Bovine Milk Immunoglobulin (BIgG) Specific for the Minor CFA/I Fimbrial Adhesin CfaE Against Challenge With H10407 Enterotoxigenic E. Coli (ETEC) Strain Expressing CFA/I|BIgGI|Johns Hopkins Bloomberg School of Public Health||Completed|March 2006|October 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2007|February 14, 2007|February 13, 2007||||No||https://clinicaltrials.gov/show/NCT00435526||174275|
NCT00435539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-004|A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)|A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of Vitreomacular Traction (VMT).||ThromboGenics|Yes|Completed|February 2007|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|N/A|No|||April 2014|December 2, 2014|February 14, 2007||No||No|July 4, 2013|https://clinicaltrials.gov/show/NCT00435539||174274|
NCT00436150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077588|Interpersonal Therapy-Based Treatment to Prevent Postpartum Depression in Adolescent Mothers|Preventing Postpartum Depression in Adolescent Mothers||Women and Infants Hospital of Rhode Island|Yes|Completed|February 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|106|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||March 2013|March 8, 2013|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00436150||174227|
NCT00436423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN0561-008|A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer|||Korea University Anam Hospital||Completed|March 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||October 2007|October 31, 2007|February 16, 2007||||No||https://clinicaltrials.gov/show/NCT00436423||174206|
NCT00432016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFS-AMDX-203|Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV|A Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerance, Pharmacokinetics and Antiviral Activity of Amdoxovir and Zidovudine in Untreated HIV-1 Infected Subjects Currently Untreated||RFS Pharma, LLC|No|Completed|February 2007|May 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|N/A|No|||May 2007|May 10, 2007|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432016||174541|
NCT00432029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-180506|Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers.|Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers||Medical University of Vienna||Completed|December 2006|January 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|July 1, 2008|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00432029||174540|
NCT00432978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00534|Effect of Bosentan on Exercise Capacity at High Altitude|Effect of Bosentan on Exercise Capacity at High Altitude||VA Loma Linda Health Care System|No|Completed|July 2006|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2007|April 17, 2007|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432978||174469|
NCT00432328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0041|Juvista (Avotermin) in Breast Reduction Surgery Scars|A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Improvement of Scar Appearance in Patients Undergoing Bilateral Reduction Mammaplasty.||Renovo||Terminated|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|39|||Female|18 Years|65 Years|No|||January 2009|January 12, 2009|February 6, 2007||No|Futility analysis undertaken, determined that study was underpowered.|No||https://clinicaltrials.gov/show/NCT00432328||174517|
NCT00432341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedAff-BTX-0615|Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia|||Allergan||Terminated|June 2007|June 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|75 Years|No|||November 2011|November 14, 2011|February 5, 2007|Yes|Yes|Study was terminated early due to difficulties with patient recruitment|No|November 14, 2011|https://clinicaltrials.gov/show/NCT00432341||174516|The study was terminated early due to difficulties with patient recruitment.
NCT00422760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boerhaave|A 75 Year Old With Dyspnea a Case Report.Observational Study|||Stanley Medical College||Completed|January 2007|February 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1|||Male|N/A|N/A|No|||January 2007|January 13, 2007|January 13, 2007||||No||https://clinicaltrials.gov/show/NCT00422760||175233|
NCT00422773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-COFI-014|Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer|Open Labeled, Multicenter Phase I/II Study Evaluating the Dose Escalation/Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan as First-Line Treatment of Metastatic Colorectal Cancer||Technische Universität Dresden||Completed|January 2007|||June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||February 2009|February 26, 2009|January 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00422773||175232|
NCT00423059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|koh01|Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy|Histologic Changes of Fibrovascular Membrane Associated With Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab (Avastin®)||Yonsei University||Completed|December 2006|March 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|N/A|N/A|No|||January 2007|March 12, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00423059||175210|
NCT00423332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00030|Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma|A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy.||AstraZeneca||Active, not recruiting|January 2007|January 2017|Anticipated|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|99 Years|No|||December 2015|January 11, 2016|January 16, 2007|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT00423332||175189|
NCT00433160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10494|Phase 3 Clinical Trial of Teriparatide in Japan|Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis||Eli Lilly and Company||Completed|January 2007|September 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|55 Years|N/A|No|||September 2010|September 14, 2010|February 7, 2007|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00433160||174455|Original data presented were for the 52-week double-blinded treatment phase; results of the open label phases at 76 weeks and 104 weeks have now been added
NCT00433173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71168 (suspended)|Insulin Sensitivity in Men With the Metabolic Syndrome|Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Suspended|May 2006|March 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|72|||Male|50 Years|75 Years|No|||March 2010|March 1, 2010|February 8, 2007|No|Yes|Primary investigator is taking a leave of absence|No||https://clinicaltrials.gov/show/NCT00433173||174454|
NCT00433472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-2002 CDR0000274785|MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806|Effect of RSR13 on T2 and T2* Cranial MRI Images: An Imaging Companion Study to NABTT 9806||Sidney Kimmel Comprehensive Cancer Center||Withdrawn||||||N/A|Interventional|Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 8, 2007|Yes|Yes|not enough interest|No||https://clinicaltrials.gov/show/NCT00433472||174432|
NCT00433797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFPI|Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients|Prostate Phytochemical & PUFA Intervention - a Phase I/II Study||University of Oslo|No|Completed|June 2007|December 2013|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Male|N/A|N/A|No|||December 2013|December 18, 2013|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433797||174407|
NCT00434759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-32000|Social Phobia Intervention Study of Mannheim|Evaluation of the Efficacy, Mechanisms of Change and Efficiency of a Stepped-care Program With a Computer-based Self-help Module and Minimal Therapist Contact in Comparison to a Standard Cognitive Therapy for Patients With Social Phobia||Central Institute of Mental Health, Mannheim|Yes|Completed|September 2006|December 2011|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|60 Years|No|||October 2012|October 28, 2012|February 9, 2007||No||No|November 29, 2011|https://clinicaltrials.gov/show/NCT00434759||174333|
NCT00434772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bisseliches-glucagon-ctil|Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers|Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers||Shaare Zedek Medical Center||Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|48 Hours||||May 2009|May 27, 2009|February 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00434772||174332|
NCT00435058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1021/05|Visual Function Changes After Intraocular Pressure Reduction|Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial||University of Sao Paulo||Completed|September 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||54|||Both|18 Years|80 Years|No|||February 2007|February 16, 2007|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00435058||174310|
NCT00435071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061043|The Effect of Surgical Incision Size on Carpal Tunnel Surgery|The Effect of Surgical Incision Size on Carpal Tunnel Surgery||Vanderbilt University|No|Terminated|December 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2011|February 17, 2011|February 12, 2007||No|Investigator initiated suspension to focus on other studies.|No||https://clinicaltrials.gov/show/NCT00435071||174309|
NCT00435045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM9L|Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered With Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects||GlaxoSmithKline||Completed|February 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|79 Years|No|||September 2010|September 3, 2010|February 13, 2007|Yes|Yes||No|October 22, 2008|https://clinicaltrials.gov/show/NCT00435045||174311|
NCT00435266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95093546-1|Remote Ischemic Preconditioning in Primary PCI|The Effect of Remote Preconditioning in Primary Percutaneous Intervention of Acute ST Elevation Myocardial Infarction||University of Aarhus|No|Completed|February 2007|February 2009|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2009|February 16, 2009|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435266||174295|
NCT00432068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995K2101|Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers|A Phase I , Open Label, Single Center, Dose Escalation Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of a New Extended Long-acting Formulation of Octreotide Pamoate Administered i.m. in Healthy Cholecystectomized Volunteers||Novartis|No|Completed|January 2007|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00432068||174537|
NCT00432081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2001-15-DDJ|Effect of Indomethacin on the Progression of Alzheimer's Disease|Effect of Indomethacin on the Progression of Alzheimer's Disease||Radboud University||Completed|May 2000|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|40 Years|90 Years|No|||February 2007|February 5, 2007|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432081||174536|
NCT00432094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006LS032|Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors|Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|December 2006|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|10 Years|69 Years|No|||January 2016|January 21, 2016|February 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432094||174535|
NCT00435838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNA108223|A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701|A Retrospective, Multi-Centre Observational Study to Evaluate Disease Management and Adverse Events in Adult Subjects With HIV-1 Infection Who Were Withdrawn From CNA106030 Due to a Positive HLA-B*5701 Test Result||GlaxoSmithKline||Completed|March 2007|||||N/A|Observational|Time Perspective: Retrospective||||35|||Both|18 Years|N/A|No|||October 2008|October 13, 2008|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00435838||174251|
NCT00436163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20601|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).|An Open Label Study Evaluating Safety and the Effect of PEGASYS® on HBV DNA Levels in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B||Hoffmann-La Roche||Completed|March 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436163||174226|
NCT00436436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529875|O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy|A Phase 2 Study of O-Benzylguanine (O-BG) and Temozolomide in Patients With Glioblastoma Progressing at Least 3 Months After Completion of Primary Treatment With Radiation Therapy and Temozolomide||National Cancer Institute (NCI)||Active, not recruiting|December 2006|||December 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2008|December 13, 2008|February 15, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00436436||174205|
NCT00436449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1010|RN1001(Avotermin) in Scar Improvement Following Breast Augmentation|A Double Blind, Within Subject, Placebo Controlled Randomised Trial to Investigate the Scar Improvement Efficacy of a Single Intradermal Application of RN1001 (Avotermin) in Female Subjects Undergoing Bilateral Breast Augmentation||Renovo|No|Completed|December 2004|January 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|63|||Female|18 Years|60 Years|No|||August 2008|August 13, 2008|February 16, 2007||||No||https://clinicaltrials.gov/show/NCT00436449||174204|
NCT00432042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X06-MMRV-302|Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly|An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age||Sanofi Pasteur MSD||Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|960|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||April 2009|April 3, 2009|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00432042||174539|
NCT00432367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMP_REG04|Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy|The Effectiveness, Cost and Cost Effectiveness of Intermittent Preventive Treatment or Screening and Treatment of Malaria in Pregnancy Among Women Using Long Lasting Insecticide Treated Bed Net: a Randomised Controlled Trial.||Gates Malaria Partnership|Yes|Completed|February 2007|September 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3333|||Female|N/A|N/A|No|||February 2014|February 21, 2014|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00432367||174514|
NCT00432692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMK001|Falls Prevention in Osteoporosis|Falls Prevention for People With Increased Risk of Fractures as a Result of Osteoporosis: a Randomized Controlled Study on the Effects of a Modified Program||Sint Maartenskliniek||Completed|December 2005|December 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|96|||Both|65 Years|N/A|No|||April 2007|February 24, 2010|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00432692||174490|
NCT00432965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC2001-08|Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in Diabetic Foot Ulcers|KCI VAC Protocol VAC2001-08, "A Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in the Treatment and Blinded Evaluation of Diabetic Foot Ulcers"||KCI USA, Inc.||Completed|May 2002|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|338|||Both|18 Years|N/A|No|||September 2011|September 8, 2011|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432965||174470|
NCT00432666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0410|IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Post-stroke Spasticity of the Upper Limb||Merz Pharmaceuticals GmbH||Completed|June 2006|May 2008|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||November 2010|November 25, 2010|February 7, 2007|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00432666||174492|
NCT00432679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD105248|A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study|Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Combination Therapy With SU) - A Placebo-Controlled Double-Blind Study -||GlaxoSmithKline||Completed|May 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|140|||Both|20 Years|N/A|No|||October 2010|October 1, 2010|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432679||174491|
NCT00423072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607009|Middle Ear Pressure Disregulation in Cleft Palate Patients|Middle Ear Pressure Disregulation in Cleft Palate Patients: Form-Function Correlates||University of Pittsburgh|No|Active, not recruiting|August 2006|June 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Both|N/A|24 Months|No|Non-Probability Sample|Children with cleft palate <2 years of age|January 2016|January 15, 2016|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00423072||175209|
NCT00423358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0011|Treatment of Hypovitaminosis D in Rheumatoid Arthritis|Treatment of Hypovitaminosis D in Rheumatoid Arthritis||University of Wisconsin, Madison|Yes|Completed|February 2005|February 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|90 Years|No|||July 2015|July 27, 2015|January 17, 2007||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00423358||175187|
NCT00423371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-02|Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Osteoarthritis (OA) of the First Carpometacarpal (CMC) Joint||Ferring Pharmaceuticals|No|Completed|December 2006|September 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|40 Years|N/A|No|||May 2011|May 18, 2011|January 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00423371||175186|
NCT00433485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000522464|Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants|In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome||National Cancer Institute (NCI)||Active, not recruiting||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Prevention|||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|February 14, 2009|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433485||174431|
NCT00433810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66557 (completed)|Longitudinal Assessment of Bariatric Surgery|Longitudinal Assessment of Bariatric Surgery (LABS-1)|LABS-1|University of Pittsburgh|Yes|Completed|March 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5102|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All eligible bariatric surgery candidates at the participating LABS clinical sites.|December 2010|December 23, 2010|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00433810||174406|
NCT00434083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT400-301|To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches|A Double-Blind Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches||POZEN||Completed|July 2004|January 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1200|||Both|18 Years|65 Years|No|||February 2007|February 9, 2007|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00434083||174385|
NCT00434070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907093|Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load Monitoring|Comparison of the Development of Thymidine Analogue Mutations With CD4 Monitoring Alone Versus CD4 Monitoring Plus Viral Load Monitoring in Naive HIV-1 Individuals on First-Line Antiretroviral Therapy in Africa||National Institutes of Health Clinical Center (CC)||Completed|February 2007|February 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1500|||Both|18 Years|N/A|No|||February 2013|February 19, 2014|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434070||174386|
NCT00435617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44HD041805|Study of Hand Therapy 3 to 24 Months After Stroke|Clinical Assessment of a Massed Practice Therapy Device||Kinetic Muscles|No|Completed|May 2005|May 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|80 Years|No|||July 2012|July 18, 2012|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435617||174268|
NCT00435864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 06/6-N|Natural Killer Index From Hematopoietic Stem Cell Graft|Pilot, Multicenter and Prospective Study of the Natural Killer Index From Hematopoietic Stem Cell Graft at a Genotypic, Phenotypic and Functional Level||Nantes University Hospital|No|Completed|April 2007|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|92|||Both|1 Year|N/A|Accepts Healthy Volunteers|||April 2014|April 29, 2014|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00435864||174249|
NCT00435279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-062|A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia|A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia||Sunovion|No|Completed|June 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|678|||Both|18 Years|64 Years|No|||February 2012|February 21, 2012|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00435279||174294|
NCT00435591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-084|A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase 4, Randomized, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia||Cumberland Pharmaceuticals|No|Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|121|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|February 14, 2007|Yes|Yes||No|April 28, 2010|https://clinicaltrials.gov/show/NCT00435591||174270|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.
NCT00435604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-07-01|A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase|Phase I Dose-Ranging Randomized Double-Blinded Controlled Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase||Halozyme Therapeutics||Completed|February 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research|||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2007|October 13, 2011|February 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00435604||174269|
NCT00436176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59751|Improving Diabetes Care for African Americans|The Expanded Chronic Care Model: Targeting Disparities in Diabetes Care||Harvard Vanguard Medical Associates|No|Completed|June 2007|November 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|6000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 20, 2009|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00436176||174225|
NCT00432705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11-34-CAI-B|Changes in Unstable Ankles After Balance Training|Modulation of Sensorimotor Measures in Chronically Unstable Ankles||University of North Carolina, Charlotte|No|Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2009|July 21, 2009|February 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00432705||174489|
NCT00432718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|342/01|Saline Instillation Before Tracheal Suctioning and the Incidence of Ventilator Associated Pneumonia|||Hospital do Cancer, Sao Paulo||Completed|August 2001|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention||||260|||Both|18 Years|N/A|No|||February 2007|February 7, 2007|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00432718||174488|
NCT00432991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609008727|Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section|A Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Intramuscular Ephedrine on the Incidence of Perioperative Nausea and Vomiting During Elective Cesarean Section||Weill Medical College of Cornell University|No|Completed|February 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|53|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00432991||174468|
NCT00433238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCMSH|Screening for Mental Health Concerns for at-Risk Community Living Chinese Seniors|Screening for Mental Health Concerns for at-Risk Community Living Chinese Seniors - a Feasibility Study||Mount Sinai Hospital, Canada||Not yet recruiting|March 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Screening||||100|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||February 2007|February 7, 2007|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00433238||174449|
NCT00433264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3645|The Interrelation of the Vasculature, Endothelium, Bone Metabolism and Uremic Toxins in Peritoneal Dialysis|The Interrelation of the Vasculature, Endothelium, Bone Metabolism and Uremic Toxins in Peritoneal Dialysis|INVEST-PD|Universitaire Ziekenhuizen Leuven|Yes|Completed|February 2007|December 2008|Actual|December 2008|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|Samples With DNA|serum, plasma, DNA|Both|18 Years|N/A|No|Non-Probability Sample|Tertiary referral center university hospital|March 2009|March 4, 2009|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00433264||174448|
NCT00433212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTG-2007-NIPPV|Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV)|Efficacy and Safety of NIPPV to Increase Survival Without Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants|NIPPV|McMaster University|Yes|Completed|April 2007|December 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1011|||Both|N/A|28 Days|No|||December 2014|December 3, 2014|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00433212||174451|
NCT00433225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5293|Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|50 Years|N/A||||September 2007|September 5, 2007|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00433225||174450|
NCT00433524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304723|Computed Tomography in Detecting Movement of the Esophagus in Patients Undergoing Radiation Therapy to the Chest|Evaluation of Esophageal Motion by Computed Tomography (CT) During the Course of Thoracic Radiotherapy||Fox Chase Cancer Center||Completed|April 2003|September 2007|Actual|||N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|30|||Both|N/A|N/A|No|||February 2010|February 11, 2010|February 8, 2007||||No||https://clinicaltrials.gov/show/NCT00433524||174428|
NCT00423696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000523435|Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Metastatic Colorectal Cancer [ACCORD]||National Cancer Institute (NCI)||Active, not recruiting|January 2006|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|144|||Both|18 Years|75 Years|No|||September 2011|September 28, 2011|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00423696||175162|
NCT00423956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6203|Repair of Orthodontically-induced Tooth Root Resorption by Ultrasound|Repair of Orthodontically-induced Tooth Root Resorption by Ultrasound in Human Subjects||University of Alberta, Graduate Orthodontic Program|Yes|Recruiting|January 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|72|||Both|12 Years|28 Years|Accepts Healthy Volunteers|||January 2013|January 20, 2013|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423956||175142|
NCT00433823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-19|A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis|A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis||Abant Izzet Baysal University||Recruiting|January 2007|January 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Both|18 Years|70 Years||||February 2007|February 9, 2007|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00433823||174405|
NCT00434096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5749|Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)|A Randomized Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen (SR141716 20 mg), Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Patients With Dyslipidemia.||Sanofi||Terminated|February 2007|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|915|||Both|20 Years|N/A|No|||July 2009|July 17, 2009|February 9, 2007||No|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00434096||174384|
NCT00434785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3189A1-105|A Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 in Healthy Japanese Males|An Ascending, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Healthy Male Japanese Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2007|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Male|20 Years|40 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|February 9, 2007||||No||https://clinicaltrials.gov/show/NCT00434785||174331|
NCT00434447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EAU22|Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases|A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety||Novartis||Completed|December 2006|||September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|73|||Both|18 Years|N/A|No|||October 2010|October 21, 2010|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00434447||174357|
NCT00434460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABATE VAP|Study of Knowledge Translation of Clinical Practice Guidelines for Ventilator Associated Pneumonia|Active Observational Study of the Adoption and Transfer of Clinical Practice Guidelines Through Education, for Ventilator Associated Pneumonia (ABATE VAP Study)|ABATEVAP|Canadian Critical Care Trials Group|No|Completed|April 2007|July 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1320|||Both|17 Years|N/A|No|Probability Sample|Patients invasively mechanically ventilated > 48 hours in the critical care setting.|August 2010|August 31, 2010|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00434460||174356|
NCT00435630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA7372|Documenting a Learning Curve and Test-retest Reliability of a Virtual Reality Training Simulator in Laparoscopic Surgery|Documenting a Learning Curve and Test-retest Reliability of a Virtual Reality Training Simulator in Laparoscopic Surgery||Columbia University|No|Completed|July 2004|August 2008|Actual|January 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00435630||174267|
NCT00426803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7ICH-1371|Recombinant Factor VIIa in Acute Intracerebral Haemorrhage|Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Parallel Groups, Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage||Novo Nordisk A/S|No|Completed|August 2002|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|400|||Both|18 Years|N/A|No|||September 2011|June 26, 2012|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00426803||174931|
NCT00435877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907044|Procurement of Tissue Samples for Cell Cultures and Analyses|Procurement of Normal Bone, Dermis, Spleen, Thymus and Adipose Tissue for Establishment of Cell Cultures and Tissue Analyses||National Institutes of Health Clinical Center (CC)||Terminated|January 2007|November 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|August 20, 2013|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00435877||174248|
NCT00436215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070058|Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer|A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|December 2006|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|February 15, 2007|Yes|Yes||No|March 16, 2015|https://clinicaltrials.gov/show/NCT00436215||174222|
NCT00436189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVA-001-C01|Assess Cancer in Ovarian Tumors With Biomarkers.|Whole Blood Collection Protocol For Ovarian Assay Clinical Trial In Women With Ovarian Tumors||Ciphergen Biosystems||Completed|February 2007|April 2008|Actual|April 2008||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|1000|||Female|18 Years|N/A|No|||April 2008|April 25, 2008|February 13, 2007||||No||https://clinicaltrials.gov/show/NCT00436189||174224|
NCT00436202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anemia|Evaluation of an Intervention Program for the Prevention of Anemia|||Wolfson Medical Center||Active, not recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|4 Months|N/A|Accepts Healthy Volunteers|||September 2010|September 12, 2010|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436202||174223|
NCT00436462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-4|Expression of Steroid Receptors in Endometrium|Expression of Steroid Receptors in Endometrium During the Early Follicular Phase in Stimulated Cycles||Aristotle University Of Thessaloniki|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|endometrial tissue|Female|20 Years|39 Years|No|Probability Sample|infertile women|November 2009|November 6, 2009|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436462||174203|
NCT00422799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-008|Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2006|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|January 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00422799||175230|
NCT00422812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-001-202|Staccato® Prochlorperazine for Inhalation in Migraine|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy and Safety Outpatient Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache||Alexza Pharmaceuticals, Inc.||Completed|April 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||400|||Both|18 Years|70 Years|No|||June 2008|June 2, 2008|January 12, 2007||||No||https://clinicaltrials.gov/show/NCT00422812||175229|
NCT00423111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4487-AA-CTIL|Correlation Between Cognitive Functions and MRI in Multiple Sclerosis|||Sheba Medical Center||Recruiting|February 2007|February 2009|Anticipated|||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal|||Anticipated|100|||Both|18 Years|65 Years|No|||September 2007|September 20, 2007|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00423111||175206|
NCT00432380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109216|A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.|Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine (GSK 357941A) in Healthy Infants.||GlaxoSmithKline||Completed|March 2007|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|375|||Both|5 Weeks|10 Weeks|Accepts Healthy Volunteers|||September 2011|September 29, 2011|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432380||174513|
NCT00432731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X04-VAR-402|Safety Study of a Refrigerator-Stable Formulation of VARIVAX®|A Double-Blind, Randomised, Controlled, Multi-Centre Safety Study of a Refrigerator-Stable Formulation of VARIVAX® in Healthy 12 to 15 Month-Old Infants.||Sanofi Pasteur MSD||Completed|December 2004|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind||||500|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||April 2009|April 3, 2009|February 7, 2007||||No||https://clinicaltrials.gov/show/NCT00432731||174487|
NCT00433004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805358|Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens|A Pilot Randomized Control Trial of Advanced Supply of Levonorgestrel Emergency Contraception vs. Routine Postpartum Contraceptive Care in the Teenage Population||University of Pennsylvania||Completed|February 2007|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Female|14 Years|19 Years|Accepts Healthy Volunteers|||August 2011|August 8, 2011|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00433004||174467|
NCT00433017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952A2309|Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)|24-month Randomized, Double-masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.||Novartis||Terminated|May 2007|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|50 Years|N/A|No|||April 2011|April 18, 2011|February 8, 2007|Yes|Yes|Study was terminated based on the results of analyses performed as planned at Month 12.|No|January 12, 2011|https://clinicaltrials.gov/show/NCT00433017||174466|
NCT00423722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0494|Parenteral Hydration in Advanced Cancer Patients|Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial||M.D. Anderson Cancer Center|Yes|Completed|January 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|262|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|January 16, 2007||No||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00423722||175160|Study had a planned sample size of 150 participants but due to funding issues recruitment was halted after 129 patients; additionally, participants with delirium or severe dehydration were excluded for logistic purposes.
NCT00423735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00744|Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)|No|Active, not recruiting|January 2007|||March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|January 16, 2007|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00423735||175159|Designed as a 2-stage study. The protocol was amended after Stage 1 to add Stage 1B allowing intra-patient escalation. Per protocol criteria, the study did not continue to Stage 2.
NCT00424255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF102988|Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery|A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)||GlaxoSmithKline||Completed|December 2006|November 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|688|||Both|18 Years|70 Years|No|||June 2014|July 10, 2014|January 17, 2007|No|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00424255||175120|
NCT00424268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-128|Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)|Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study|HELIOS|Takeda|No|Completed|January 2007|July 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|743|||Both|40 Years|N/A|No|||August 2011|May 4, 2012|January 18, 2007|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00424268||175119|
NCT00433537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02966|Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma|A Phase II Study of VcR-CVAD With Rituximab Maintenance for Untreated Mantle Cell Lymphoma||National Cancer Institute (NCI)|No|Completed|May 2007|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||January 2014|October 24, 2014|February 8, 2007|Yes|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00433537||174427|
NCT00424619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-449|A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients|A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients||McMaster University|No|Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|64|||Both|50 Years|N/A|No|||May 2012|May 11, 2012|January 17, 2007||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00424619||175092|
NCT00455052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MER-001|A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors|A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors||Mersana Therapeutics|No|Active, not recruiting|March 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|April 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00455052||172796|
NCT00455338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24-HD0147-6|Effect of Meal Composition on Postprandial Testosterone Concentration in Women With Polycystic Ovary Syndrome|The Effect of Meals of Varying Fat and Fiber Content on Postprandial Testosterone Concentration in Women With Polycystic Ovary Syndrome||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|May 2005|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Female|19 Years|40 Years|Accepts Healthy Volunteers|||April 2007|April 2, 2007|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00455338||172774|
NCT00434473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-SCD1121|IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome|IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients With Sickle Cell Disease and Vaso-occlusive Crisis)||Anthera Pharmaceuticals|Yes|Completed|December 2006|December 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|5 Years|N/A|No|||January 2014|January 30, 2014|February 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00434473||174355|
NCT00434486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-104|Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606|An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2007|March 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2007|September 10, 2007|February 9, 2007||||||https://clinicaltrials.gov/show/NCT00434486||174354|
NCT00434798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC.2006.0009|Campylobacter Jejuni Challenge Model Development: Dose Ranging Study|Campylobacter Jejuni Challenge Model Development: Dose Ranging Study||University of Vermont||Active, not recruiting|February 2007|October 2008|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 4, 2008|February 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00434798||174330|
NCT00434811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-07|Islet Transplantation in Type 1 Diabetes|Islet Transplantation in Type 1 Diabetes||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2006|May 2014|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|65 Years|No|||January 2015|January 2, 2015|February 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00434811||174329|
NCT00435084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP3005|A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL|An Open Phase I/II Clinical Study Assessing the Safety and Tolerability of APO866 in Patients With Refractory B-cell Lymphocytic Leukaemia Not Amenable to Allogeneic Hemopoietic Stem Cell Transplantation||Onxeo|No|Completed|February 2007|April 2009|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2013|September 22, 2015|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00435084||174308|
NCT00435292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOA-03P|Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi Center Study of Flavocoxid ( Limbrel) vs Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee||Primus Pharmaceuticals|No|Completed|April 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|350|||Both|35 Years|85 Years|No|||November 2008|October 19, 2015|February 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00435292||174293|
NCT00427102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-0657|MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck|A Phase 1 Study of Oral MRX-1024 in Combination With Standard Fractionation Radiation Therapy and High-Dose Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Following Surgical Resection||Sidney Kimmel Comprehensive Cancer Center||Terminated|January 2007|July 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2012|November 13, 2012|January 24, 2007|||No subjects enrolled and PI went to another facility|No||https://clinicaltrials.gov/show/NCT00427102||174908|
NCT00427115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-173/04|Multimodal Intervention in Allogeneic Stem Cell Transplantation|Pilot Study of an Exercise an Psycho-Educational Intervention During Allogeneic Stem Cell Transplantation||Rigshospitalet, Denmark||Completed|August 2005|April 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Actual|42|||Both|18 Years|65 Years|No|||May 2008|May 20, 2008|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427115||174907|
NCT00427336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDP00-266|Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia|Purine Analog-Based Conditioning for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia||M.D. Anderson Cancer Center|No|Completed|December 2000|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|70 Years|No|||September 2011|September 20, 2011|January 25, 2007||No||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00427336||174890|
NCT00427349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526256|AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors|A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors||Eastern Cooperative Oncology Group|Yes|Completed|September 2008|April 2015|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|January 25, 2007|Yes|Yes||No|May 19, 2015|https://clinicaltrials.gov/show/NCT00427349||174889|
NCT00436228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPB107935|To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug|An Open-Label, Randomized, Crossover Study to Estimate the Formulation Effect on the Relative Bioavailability of Single Dose Oral SB-742510 in Healthy Subjects||GlaxoSmithKline||Completed|November 2006|February 2007|Actual|February 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|February 15, 2007||||||https://clinicaltrials.gov/show/NCT00436228||174221|
NCT00436475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK76092 (completed)|Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes|Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes|CaDDM|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|September 2007|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|112|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 15, 2011|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436475||174202|
NCT00427128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4099R|Prozac Treatment of Major Depression: Discontinuation Study|Prozac Treatment of Major Depression: Discontinuation Study||New York State Psychiatric Institute||Completed|November 1995|March 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|627|||Both|18 Years|65 Years|No|||December 2011|December 14, 2011|January 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00427128||174906|
NCT00432393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8125|Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy|Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy||hahid Beheshti University of Medical Sciences||Completed|June 2002|April 2003||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|50 Years|N/A||||February 2007|October 17, 2008|February 6, 2007||||No||https://clinicaltrials.gov/show/NCT00432393||174512|
NCT00432406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSA-2006-002|Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis|TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile||Chinese University of Hong Kong|No|Completed|May 2006|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||March 2009|March 10, 2009|February 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00432406||174511|
NCT00423709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-259|Allogeneic Blood Stem Cell Transplantation|A Study of Allogeneic Blood Stem Cell Transplantation With Purine Analog-Based Conditioning For Patients With Advanced Hodgkin's Disease||M.D. Anderson Cancer Center|No|Completed|January 1998|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|46|||Both|N/A|65 Years|No|||January 2012|January 20, 2012|January 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00423709||175161|
NCT00423748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB-320|Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.|Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension||Gilead Sciences||Completed|December 2003|February 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||186|||Both|18 Years|N/A|No|||April 2009|April 15, 2009|January 17, 2007||||||https://clinicaltrials.gov/show/NCT00423748||175158|
NCT00423761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH103152|An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam.|An Open-Label, Single-Sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of GW876008 in Healthy Subjects||GlaxoSmithKline||Completed|December 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|January 17, 2007||||||https://clinicaltrials.gov/show/NCT00423761||175157|
NCT00424632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9491001|Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors|A Phase 1, Open Label, Multi-Center, Accelerated Dose-Escalation, Pharmacokinetic And Pharmacodynamic Trial Of The Oral Single Agent Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors For Whom No Standard Therapy Is Available||Pfizer|No|Completed|November 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|January 18, 2007|No|Yes||No|March 21, 2012|https://clinicaltrials.gov/show/NCT00424632||175091|
NCT00424294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7701005|A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CP-195543 And Celecoxib Dual Therapy In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate||Pfizer|Yes|Terminated|June 2006|February 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|January 18, 2007|Yes|Yes|See Detailed Description field|No|September 10, 2014|https://clinicaltrials.gov/show/NCT00424294||175117|The study was terminated early because it was determined that the dual therapy with CP-195543 and celecoxib had poor tolerability and a high discontinuation rate.
NCT00455858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1762|Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea|A 20-week, Multi-centre, Open-labelled, Non-comparative Evaluation of the Safety and Efficacy of Insulin Detemir in Combination With Oral Anti-diabetic Drug(s), in Subjects With Type 2 Diabetes Mellitus Who Were Inadequately Controlled on Current Therapy in Korea||Novo Nordisk A/S|No|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|April 3, 2007|Yes|Yes||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00455858||172735|
NCT00455637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-97-52120-727|Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?|A Phase II, Randomised, Double-Blind, Dose-Ranging Study in Children and Young People to Determine the Optimal Dose of Botulinum Toxin Type-A (Dysport®) in Managing the Symptoms of Hip Muscle Spasticity Due to Cerebral Palsy||Ipsen|No|Terminated|March 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|4 Years|16 Years|No|||June 2008|June 18, 2008|April 3, 2007|||Low levels of recruitment|No||https://clinicaltrials.gov/show/NCT00455637||172752|
NCT00456118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I06014|Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies|Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies||University Hospital, Limoges||Recruiting|September 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||150|||Female|18 Years|45 Years|No|||April 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456118||172716|
NCT00434824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43203|Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency||Merck Sharp & Dohme Corp.|No|Completed|November 2001|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|322|||Male|50 Years|N/A|No|||April 2015|April 15, 2015|February 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00434824||174328|
NCT00435097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colmri-HMO-CTIL|Computer Assisted Early Detection of Liver Metastases From fMRI Maps|Computer Assisted Early Detection of Liver Metastases From fMRI Maps||Hadassah Medical Organization||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2007|February 13, 2007|February 13, 2007||||No||https://clinicaltrials.gov/show/NCT00435097||174307|
NCT00425854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.10|An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer|An Open Label Phase II Trial to Assess the Efficacy and Safety of a Once Daily Oral Dose of 50 mg BIBW 2992 in Two Cohorts of Patients With HER2-negative Metastatic Breast Cancer After Failure of no More Than Two Chemotherapy Regimen||Boehringer Ingelheim||Completed|November 2006|||May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Female|18 Years|N/A|No|||August 2013|December 5, 2013|January 22, 2007||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00425854||175001|
NCT00435305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002128-32|Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion|Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion||University Hospital Tuebingen|Yes|Terminated|November 2006|November 2007|Anticipated|||Phase 4|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|N/A|No|||June 2008|June 6, 2008|February 13, 2007|||difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to    continue enrolling patients,|No||https://clinicaltrials.gov/show/NCT00435305||174292|
NCT00435318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060984|Lateral Epicondylitis Iontophoresis Randomized Control Trial (LERCT)|Lateral Epicondylitis Iontophoresis Randomized Control Trial (LERCT)||Vanderbilt University||Withdrawn|February 2007|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|February 12, 2007|||Study approval deferred by the IRB.|No||https://clinicaltrials.gov/show/NCT00435318||174291|
NCT00426192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-01|Effects of Hemofiltration and Mannitol Treatment on Cardiopulmonary-Bypass Induced Immunosuppression|Mechanisms of Endotoxin-Tolerance of Human Monocytes After CABG-Sugery - Effects of Hemofiltration and Mannitol Treatment||University Hospital, Saarland||Active, not recruiting|October 2003|November 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||52|||Male|35 Years|80 Years|No|||January 2007|January 23, 2007|January 3, 2007||||No||https://clinicaltrials.gov/show/NCT00426192||174976|
NCT00427362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W05-399|A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)|A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)||Abbott|No|Completed|May 2006|||May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|18 Years|N/A|No|||April 2008|April 30, 2008|January 26, 2007||||No||https://clinicaltrials.gov/show/NCT00427362||174888|
NCT00426816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXS107714|To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of SB-649868 (10, 30 mg and 60 mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia||GlaxoSmithKline|No|Completed|December 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|48|||Male|18 Years|64 Years|No|||August 2012|August 9, 2012|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426816||174930|
NCT00426829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0881|Proton Therapy and Bevacizumab for Primary Liver Tumors|Phase I Study of Proton Radiotherapy and Bevacizumab for Primary Liver Tumors||M.D. Anderson Cancer Center|No|Terminated|May 2007|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||July 2012|July 31, 2012|January 23, 2007||No|Low Accural|No||https://clinicaltrials.gov/show/NCT00426829||174929|
NCT00422591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0813|Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)|Prospective Evaluation of Standard Chemotherapy Regimen of Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2006|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|15 Years|75 Years|No|||November 2015|November 9, 2015|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00422591||175246|
NCT00427375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2006/03|Local Excision in Downstaged Rectal Cancer|Phase III Randomized Trial of Local Excision Versus Total Mesorectal Excision in Downstaged T2T3 Low Rectal Cancer After Radiochemotherapy|GRECCAR 2|University Hospital, Bordeaux|Yes|Active, not recruiting|March 2007|December 2017|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|148|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00427375||174887|
NCT00423384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-1471|Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.|Ibandronate Versus Placebo as add-on to Active Vitamin D and Calcium in the Prevention of Bone Loss After Renal Transplantation.||Smerud Medical Research International AS|No|Active, not recruiting|January 2007|December 2010|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423384||175185|
NCT00423397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000521454|Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer|A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin||National Cancer Institute (NCI)||Active, not recruiting|September 2006|||January 2008|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||March 2008|December 18, 2013|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00423397||175184|
NCT00423410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC2006-04|A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer|A First In Man Phase I Study Of EPC2407, A Microtubule Inhibitor Anti-Cancer Drug With Tumor Vascular Endothelial Disrupting Activity: Intravenous Administration Daily For Three Days In Patients With Advanced Solid Tumors And Lymphomas||EpiCept Corporation|No|Completed|December 2006|September 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423410||175183|
NCT00423436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-243|Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients|Using an Interactive Voice Response Telephone System in the Assessment and Management of Symptoms in Advanced Lung Cancer Patients Receiving Chemotherapy||M.D. Anderson Cancer Center|No|Completed|April 2003|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|84|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|January 16, 2007||No||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00423436||175182|
NCT00424021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB-220-E|Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension|An Open-Label, Long-Term Study of Ambrisentan in Pulmonary Hypertension Subjects Having Completed Myogen Study AMB-220||Gilead Sciences||Completed|April 2003|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|January 17, 2007|Yes|Yes||No|July 12, 2011|https://clinicaltrials.gov/show/NCT00424021||175137|The small sample size, nonrandomized dose group assignments, and the potential for dose adjustments precluded meaningful comparisons between the dose groups. Therefore, efficacy results are only presented for the combined ambrisentan group.
NCT00424034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB107623|A Study of GSK1325760A in Healthy Japanese Subjects|See Detailed Description||GlaxoSmithKline||Completed|January 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|32|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||October 2008|March 28, 2011|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00424034||175136|
NCT00423969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0301-35|Galantamine Augmentation of Escitalopram for Treatment of Depression|Galantamine Augmentation of Escitalopram for Treatment of Depression Associated Cognitive Impairment in Outpatients - A Randomized Single Blind Clinical Trial||Indiana University||Terminated|November 2003|September 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Both|18 Years|60 Years|No|||January 2007|January 17, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00423969||175141|
NCT00424281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU protocol ID= 066706MP4F|Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication|Pharmacokinetics of Fondaparinux (Arixtra) to Critically Ill Patients on Vasopressor Therapy||Wayne State University||Not yet recruiting|February 2007|January 2010||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||40|||Both|18 Years|80 Years|No|||January 2007|January 17, 2007|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00424281||175118|
NCT00424307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACR0906|Bilateral Cochlear Implant Benefit in Young Children|Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants||Advanced Bionics|No|Active, not recruiting|January 2007|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|12 Months|36 Months|No|||June 2011|June 24, 2011|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00424307||175116|
NCT00424320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-001|Clinical Trial of Sodium Bicarbonate to Prevent Contrast-Induced Nephropathy|Clinical Controlled Trial to Determinate the Role of Sodium Bicarbonate in the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing to Diagnostic Coronariography and/or Percutaneous Coronary Intervention||Instituto Nacional de Cardiologia Ignacio Chavez||Recruiting|October 2006|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||100|||Both|18 Years|N/A|No|||January 2007|January 18, 2007|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00424320||175115|
NCT00456144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-086|Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer|Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone (GnRH) Agonist Therapy for Prostate Cancer||Massachusetts General Hospital||Completed|August 2006|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|36|Samples With DNA|Whole blood Urine|Male|18 Years|N/A|No|Non-Probability Sample|Men with prostate cancer scheduled to undergo GnRH agonist therapy with intended treatment        duration of 6 or 24 months.|July 2013|July 9, 2013|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456144||172714|
NCT00455871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0769|Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD|An Open-Label, Single-Site, Comparative, Pilot Study of the Treatment Effects of Combination Therapy of Lucentis (Ranibizumab) Plus Reduced Fluence Photodynamic Therapy With Visudyne in Patients With Exudative Age-Related Macular Degeneration (AMD)||Barnes Retina Institute|Yes|Recruiting|April 2007|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||May 2008|May 6, 2008|April 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455871||172734|
NCT00425581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4255-IM-CTIL|N-Terminal Pro-B-Type Natriuretic Peptide and Troponin Levels as Markers of Hemodynamic Stability in Very Low Birth Weight Infants During the First Days of Life|N-Terminal Pro-B-Type and Cardiac Troponin T Levels for Monitoring Effectiveness of Treatment in Very Low Birth Weight Infants With Hemodynamic Instability||Sheba Medical Center|No|Withdrawn|February 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|N/A|3 Days|No|||January 2008|January 22, 2008|January 22, 2007||No|Did not receive budget needed.|No||https://clinicaltrials.gov/show/NCT00425581||175021|
NCT00425594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F38-25|A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population|A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population||Braintree Laboratories|No|Completed|January 2007|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||150|||Both|6 Years|16 Years|No|||December 2007|December 20, 2007|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425594||175020|
NCT00425867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR1 polymorphisms|PAR Family Polymorphisms and Placental Invasion Disorders|||Shaare Zedek Medical Center||Not yet recruiting|March 2007|November 2007||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||January 2007|January 25, 2007|January 22, 2007||||No||https://clinicaltrials.gov/show/NCT00425867||175000|
NCT00426439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSB-2006-Coartem|Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau|Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau.||Bandim Health Project|Yes|Completed|December 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|6 Months|15 Years|No|||January 2011|January 2, 2011|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426439||174959|
NCT00425620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC-05-01|Amphotericin B Suspension in Refractory Chronic Sinusitis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Intranasal Amphotericin B Suspension in Patients With Refractory, Postsurgical Chronic Sinusitis (CS)||Accentia Biopharmaceuticals|No|Completed|December 2006|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|85 Years|No|||November 2007|November 29, 2007|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425620||175018|
NCT00426452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787A2121|A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers|A Phase IB, Open Label, Single Center, Drug-drug Interaction Study of Oral 1250 mg of PTK787/ZK 222584 Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor (Omeprazole) in Healthy Sterile or Postmenopausal Female Volunteers||Novartis||Completed|July 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Female|35 Years|70 Years||||November 2009|November 18, 2009|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426452||174958|
NCT00426790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1400|Open Lung Approach During General Anaesthesia to Prevent Post-Operative Pulmonary Complications|||Università degli Studi dell'Insubria||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||January 2007|January 24, 2007|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00426790||174932|
NCT00426205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-023|GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies|GM-CSF Secreting Leukemia Cell Vaccinations After Allogeneic Non-myeloablative Peripheral Blood Stem Cell Transplantation in Patients With Advanced Myelodysplastic Syndrome or Refractory Acute or Advanced Chronic Myeloid Leukemia||Dana-Farber Cancer Institute|Yes|Completed|June 2004|September 2009|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426205||174975|
NCT00426218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2203|Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)|Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)||Novartis||Completed|December 2006|||March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|4 Years|20 Years|No|||August 2011|August 8, 2011|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426218||174974|
NCT00426153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004128|Octreotide in Severe Polycystic Liver Disease|Pilot Study Of Long-Acting Octreotide (Octreotide LAR® Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease||Mayo Clinic|No|Completed|January 2007|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|No|||October 2012|October 22, 2012|January 22, 2007|Yes|Yes||No|October 22, 2012|https://clinicaltrials.gov/show/NCT00426153||174979|
NCT00426166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUO-06|Assessment Of Infrared Photobiotherapy for Improved Wound Healing|||University of Toledo Health Science Campus||Completed|January 2007|May 2011|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||March 2010|May 9, 2011|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00426166||174978|
NCT00426179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571E2204|Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen|An Exploratory Study of the Effects of Imatinib on Allergic Inflammation Following Out of Allergy Season Repeated Nasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis Sensitive to Timothy Grass Pollen - an Exploratory Study of c-Kit Inhibition in Allergic Respiratory Diseases||Novartis||Completed|December 2006|August 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Male|18 Years|55 Years|No|||November 2007|November 16, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426179||174977|
NCT00426465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070072|Spaced Versus Massed Skill Learning|Neural Substrates of Lasting Motor Skill Learning by Spacing Effect||National Institutes of Health Clinical Center (CC)||Completed|January 2007|December 2013||||N/A|Observational|N/A|||Actual|213|||Both|18 Years|80 Years|No|||December 2013|May 21, 2014|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426465||174957|
NCT00426478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BTW02|Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients|The Comparison of the Antihypertensive Efficacy and Tolerability Between Valsartan Plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5mg in the Essential Hypertensive Patients||Novartis||Completed|November 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426478||174956|
NCT00427141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPS106400|A Three-Part Study Of GSK580416 In Healthy Subjects|A Three-part First Time in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Food Effect of Single Oral Doses of GSK580416 in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00427141||174905|
NCT00422851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609093|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3c|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3c||Children's Hospital of Pittsburgh|No|Completed|June 2007|February 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3||45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Adults 18-50 years old with at least one intact and effusion-free middle ear|September 2010|September 8, 2010|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422851||175226|
NCT00422838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRES|Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.|Impact of Immune Responses in Chronic Hepatitis C Genotype 1,2,3 Virus Infected Patients During Treatment With Pegylated Interferon-alpha-2b and Ribavirin (CIRES).|CIRES|Foundation for Liver Research|No|Completed|January 2007|November 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|27|Samples With DNA|PBMC Serum RNA Liver infiltrating lymphocytes|Both|18 Years|70 Years|No|Non-Probability Sample|Patients chronically infected with HCV-genotype 1,2 or 3|September 2011|September 6, 2011|January 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00422838||175227|
NCT00422825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571O2102|Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib|A Phase I, Open-label, Randomized, Crossover Study to Investigate the Effect of Food on the Bioavailability of a Single 800 mg Imatinib Dose in a Modified Release Formulation (MR2) and Compare the Bioavailability Between MR2 and Imatinib 400 mg Twice Daily Immediate Release Tablet (IR) in Healthy Subjects||Novartis|No|Completed|June 2006|September 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00422825||175228|
NCT00424723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-309|Pemetrexed in Patients With Advanced Neuroendocrine Tumors|A Phase II Study of Pemetrexed in Patients With Advanced Neuroendocrine Tumors||Dana-Farber Cancer Institute||Completed|December 2005|March 2010|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||August 2010|August 10, 2010|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00424723||175084|
NCT00423982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1603|Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty|Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty||Oslo University Hospital|Yes|Active, not recruiting|April 2006|December 2014|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||June 2013|June 26, 2013|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423982||175140|
NCT00424333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-107|Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes|Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial||Pfizer||Completed|May 1999|October 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||320|||Both|12 Years|65 Years|No|||February 2007|February 9, 2007|January 17, 2007||||||https://clinicaltrials.gov/show/NCT00424333||175114|
NCT00424346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2201|Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis|A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) With Three Different Dose Regimens in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate Including 76-week and 96-week Extensions||Novartis||Completed|November 2006|October 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|274|||Both|18 Years|N/A|No|||June 2013|January 14, 2014|January 17, 2007|Yes|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT00424346||175113|
NCT00456755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM/CTS/03/333|Herbal Treatment for Perennial Allergic Rhinitis|A Herbal Formula (SBL) for the Treatment of Perennial Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Clinical Trial||Chinese University of Hong Kong|No|Completed|March 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|65 Years|No|||November 2009|November 23, 2009|April 4, 2007||No||No|November 23, 2009|https://clinicaltrials.gov/show/NCT00456755||172667|
NCT00457002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-036|Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness|A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.|ADOPT|Bristol-Myers Squibb|Yes|Completed|June 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|6758|||Both|40 Years|N/A|No|||May 2014|December 7, 2015|April 4, 2007|Yes|Yes||No|April 14, 2014|https://clinicaltrials.gov/show/NCT00457002||172648|
NCT00457249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD515|A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older|Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age||Sanofi|No|Completed|March 2007|November 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1564|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 17, 2012|April 5, 2007|Yes|Yes||No|September 17, 2012|https://clinicaltrials.gov/show/NCT00457249||172629|
NCT00425295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501050|Effectiveness of Human Simulation Training for Medical Crisis Management Skills|Effectiveness of Human Simulation Training for Medical Crisis Management Skills||University of Pittsburgh|Yes|Withdrawn|October 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|January 19, 2007||No|too much cross over bias between small numbers of participants|No||https://clinicaltrials.gov/show/NCT00425295||175042|
NCT00425607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01-007|Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria|An Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies||Children's Hospital Boston|Yes|Active, not recruiting|May 2007|October 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|1 Year|N/A|No|||December 2007|December 24, 2007|January 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425607||175019|
NCT00425880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0578-F2L|Monitoring and Outcome Measures in Asthmatics and Smokers During Pregnancy|GCRC: Monitoring and Outcome Measures in Asthmatics and Smokers (MOMAS) During Pregnancy||University of Kentucky||Withdrawn|January 2007|October 2010|Actual|October 2010|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from clinics at the University of Kentucky and from the        surrounding community.|August 2013|August 7, 2013|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425880||174999|
NCT00425893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCID-UCI000439A|A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households|A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households||Centers for Disease Control and Prevention|No|Completed|February 2007|November 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|6069|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2012|April 12, 2012|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00425893||174998|
NCT00425906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526182|Nicotine in Treating "Hunger Pain" in Patients With Malignant Bowel Obstruction Caused By Cancer|A Pilot Study of Nicotine for "Hunger Pain" in Patients With Bowel Obstruction From Incurable Cancer||Mayo Clinic|Yes|Withdrawn|December 2003|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|120 Years|No|||July 2011|January 11, 2016|January 19, 2007|No|Yes|No patient enrollment occurred.|No||https://clinicaltrials.gov/show/NCT00425906||174997|
NCT00426881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03216|Brain Power: Resistance Training and Cognitive Function|The Effect of Resistance Training on Cognitive Performance, Cortical Plasticity, and Fall Risk in Women Aged 65-75 Years Old: A 12-Month RCT||University of British Columbia|No|Completed|January 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|155|||Female|65 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426881||174925|
NCT00426894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yael01-HMO-CTIL|Microbial Surveillance in Children Hospitalized for Cardiovascular Surgery|Longitudinal Microbial Surveillance in Children Hospitalized for Cardiac Surgery Before the Operation and During Hospitalization||Hadassah Medical Organization||Not yet recruiting|January 2007|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|||||||Both|N/A|N/A|No|||January 2007|January 24, 2007|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00426894||174924|
NCT00426491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99077|Misoprostol for Non-Viable Pregnancies|Misoprostol for the Medical Management of Non-Viable First Trimester Pregnancies||Madigan Army Medical Center|No|Completed|March 1999|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2008|February 1, 2008|January 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426491||174955|
NCT00426842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00893|A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride|A Dose Response Trial Using 5 and 10 mg. of Midodrine Hydrochloride to Treat Orthostatic Hypotension in Persons With SCI||James J. Peters Veterans Affairs Medical Center|No|Completed|January 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||May 2015|May 8, 2015|January 24, 2007|No|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00426842||174928|A matching placebo tablet was not used and the order of testing was not randomized. The total number of subjects recruited was relatively small and extrapolation to a broader group of individuals with chronic SCI may not be appropriate.
NCT00426855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOHT-01/07|Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)|Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study||Kantonsspital Aarau|No|Completed|January 2007|June 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|January 24, 2007||No||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00426855||174927|
NCT00427154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1540|Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes|Effect of Inhaled Pre-Prandial Human Insulin Plus Metformin & Glimepiride Versus Rosiglitazone Plus Metformin & Glimepiride on HbA1c in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Terminated|January 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|January 25, 2007|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00427154||174904|
NCT00422604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2106956|Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|See Detailed Description||GlaxoSmithKline|No|Completed|October 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|60|||Both|40 Years|75 Years|No|||March 2011|May 31, 2012|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00422604||175245|
NCT00423163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-05-002|A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis|A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis||Astellas Pharma Inc|Yes|Withdrawn|February 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|2 Years|N/A|No|||August 2015|August 31, 2015|January 17, 2007|||An alternative joint industry effort will provide information on combination versus single    agent therapy for treatment of aspergillosis|No||https://clinicaltrials.gov/show/NCT00423163||175202|
NCT00423176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04824|The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)|Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis||Merck Sharp & Dohme Corp.|No|Terminated|December 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|237|||Both|12 Years|N/A|No|||June 2015|June 29, 2015|January 17, 2007|Yes|Yes|Based on business priorities. Not related to any safety or efficacy issue & took place before    data were unblinded or analyzed|No|July 29, 2009|https://clinicaltrials.gov/show/NCT00423176||175201|The study was terminated early due to a very high screening failure rate (mainly caused by the necessity to demonstrate CT changes at baseline indicative of acute sinusitis), which limits any conclusions.
NCT00423150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04273|Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)|A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter||Merck Sharp & Dohme Corp.|No|Terminated|January 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|November 30, 2006|No|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00423150||175203|Due to low response rate for colorectal cancer in interim analyses, low enrollment in head & neck and non-small cell lung cancer groups due to low methylation rates, and low overall response rate in esophageal cancer group, the study was terminated.
NCT00423462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEST307/95|First Experimental Study of Transference-Interpretations (FEST)|First Experimental Study of Transference Interpretations (FEST)||University of Oslo||Completed|January 1993|December 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||100|||Both|20 Years|60 Years|No|||August 2007|August 24, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00423462||175180|
NCT00423124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK007|Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies|A Phase I-II Study: Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK, After Transplantation of Allogeneic T-depleted Stem Cells From a Haploidentical Donor in Patients With Haematological Malignancies||MolMed S.p.A.|No|Completed|July 2002|November 2013|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00423124||175205|
NCT00423137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1219.5|Effect of BIBW 2948 BS in COPD|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of a 4-week Treatment of 15 and 30 mg b.i.d BIBW2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) on Epithelial Mucin Stores and the Safety and Efficacy in COPD Patients With Symptoms Associated With Chronic Bronchitis||Boehringer Ingelheim||Completed|January 2007|||July 2008|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|48|||Both|40 Years|70 Years|No|||April 2014|April 30, 2014|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00423137||175204|
NCT00423449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-058|Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)|A Phase I Clinical Trial of Vorinostat in Combination With Gemcitabine Plus Platinum in Patients With Advanced Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.||Completed|March 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 17, 2007|No|Yes||No|July 6, 2011|https://clinicaltrials.gov/show/NCT00423449||175181|
NCT00424736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|igorjer1|the Role of Total Body Imaging in Asymptomatic Pediatric Trauma Patients|Role of Whole Body Imaging in Asymptomatic Pediatric Trauma Patients||Assaf-Harofeh Medical Center||Not yet recruiting|January 2007|January 2008||||Phase 0|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||100|||Both|1 Month|15 Years|No|||January 2007|January 18, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00424736||175083|
NCT00424749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004767|Rituxan in Churg Strauss Syndrome With Renal Involvement|A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement||Mayo Clinic|Yes|Terminated|June 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2011|November 3, 2011|January 19, 2007|Yes|Yes|Company providing study drug terminated study due to lack of funds|No|September 12, 2011|https://clinicaltrials.gov/show/NCT00424749||175082|The limited number of individuals enrolled into the study makes it difficult to draw firm conclusions that are more than hypothesis generating. The company providing study drug terminated study due to lack of funds.
NCT00423995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04822|Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)|Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit||Merck Sharp & Dohme Corp.||Completed|November 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|379|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00423995||175139|
NCT00424008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04705|Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)|A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumarate 200/10mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated With Medium Doses of Inhaled Glucocorticosteroids||Merck Sharp & Dohme Corp.|No|Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|722|||Both|12 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 27, 2015|January 17, 2007|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00424008||175138|The sponsor closed the study early, at 12 weeks treatment, for reasons that were not safety related. No efficacy analysis of data collected beyond 12 weeks of treatment was performed. All safety data were examined regardless of treatment duration.
NCT00424710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3934s|Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)|Phase I Study of Ranibizumab Injection for Polypoidal Choroidal Vasculopathy (PEARL)|PEARL|Hawaii Pacific Health|No|Completed|January 2007|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|25 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 3, 2014|January 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00424710||175085|
NCT00456768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-80265|Efficacy of Treatment for Panic Disorder|Efficacy of Treatment for Panic Disorder||University of British Columbia|No|Completed|May 2003|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|250|||Both|19 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients referred to the Anxiety Disorders Clinic, Vancouver, who receive a primary        diagnosis of Panic Disorder, and are accepted for treatment at the clinic.|April 2011|April 28, 2011|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456768||172666|
NCT00457015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDEMA4 (DX-88/20)|Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)|EDEMA4: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema||Dyax Corp.|Yes|Completed|April 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|10 Years|N/A|No|||August 2015|August 17, 2015|April 4, 2007|Yes|Yes||No|December 30, 2009|https://clinicaltrials.gov/show/NCT00457015||172647|
NCT00457275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-070|Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)|A Multicentre, Open-Label, Observational Local Study to Evaluate the LDL-C Lowering Effect of Ezetimibe as Prescribed in Daily Routine Practice in the South African Population||Merck Sharp & Dohme Corp.||Completed|April 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||440|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457275||172627|
NCT00425308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AFR06|Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.|A Prospective Multicenter Open-label Randomized Study to Assess Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus Without Calcineurine Inhibitor in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.||Novartis||Completed|October 2006|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A||||March 2011|March 23, 2011|January 19, 2007||||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00425308||175041|
NCT00425321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012511|Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|December 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|259|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425321||175040|
NCT00425633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|418-2006|Efficacy Study of Homeopathic Potassium Dichromate to Treat Tracheal Secretions in Critically Ill Patients|A Study To Evaluate The Effect Of Homeopathic Concentrations Of Potassium Dichromate On Tracheal Secretions In Critically Ill Patients.||Sunnybrook Health Sciences Centre|No|Terminated|January 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|January 22, 2007||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00425633||175017|
NCT00425919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3180A1-200|Study Evaluating PPM-204 In Subjects With Type 2 Diabetes|A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of PPM-204 In Subjects With Type 2 Diabetes||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|January 2007|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|70 Years|No|||December 2007|December 18, 2007|January 19, 2007|||Study terminated as a result of interim analysis not meeting predetermined criteria.|No||https://clinicaltrials.gov/show/NCT00425919||174996|
NCT00426517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070075|Donor Stem Cell Transplantation for Congenital Immunodeficiencies|Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients With Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning With Campath- 1H or h-ATG, Radiation, and Sirolimus||National Institutes of Health Clinical Center (CC)||Recruiting|January 2007|December 2023|Anticipated|December 2020|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|2 Years|65 Years|No|||December 2015|December 24, 2015|January 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00426517||174953|
NCT00422630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNE 595-0107|The Metabolic Effects of Different Weight Loss Diets|Dietary Interventions for Insulin Resistance and the Metabolic Syndrome||Rockefeller University|Yes|Completed|October 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422630||175243|
NCT00422643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBICTIL|The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator|The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator||Assaf-Harofeh Medical Center||Not yet recruiting|March 2007|October 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||60|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||January 2007|January 17, 2007|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00422643||175242|
NCT00426504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005781-01H|Radiation Therapy Using Helical Tomotherapy IMRT for Head and Neck Cancer|Helical Tomotherapy Intensity Modulated Radiotherapy:A Phase I/II Pilot Study to Determine the Toxicity Profile, Pattern of Failures and Quality of Life of Patients With Squamous Cell Carcinoma of the Head and Neck||Ottawa Hospital Research Institute||Completed|November 2006|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426504||174954|
NCT00426868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECISE-01|A Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium|A Randomized Clinical Trial of adiPose-deRived stEm & Regenerative Cells In the Treatment of Patients With Non revaScularizable ischEmic Myocardium - The PRECISE Trial||Cytori Therapeutics|Yes|Completed|January 2007|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|75 Years|No|||August 2013|August 27, 2013|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426868||174926|
NCT00422864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/35|A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer|A Single-Arm Prospective Trial Evaluating The Local And Systemic Benefits Of Oxaliplatin And 5FU With Concurrent Radiation In Patients With Metastatic Rectal Cancer||Peter MacCallum Cancer Centre, Australia||Completed|October 2006|January 2011|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||September 2011|December 14, 2011|January 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00422864||175225|
NCT00423787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RagweedMATAMPL301|Efficacy and Safety/Tolerability of Ragweed MATA MPL|Efficacy and Safety/Tolerability of Ragweed MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study||Allergy Therapeutics|Yes|Completed|March 2007|March 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|993|||Both|18 Years|59 Years|No|||June 2010|June 16, 2010|January 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423787||175155|
NCT00423800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05016|Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)|Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) Therapy (1.5 mcg/kg/Week + 800-1200 mg/Day) in Naïve Genotype 1 Hepatitis C Patients With High Baseline Viral Load Who Are HCV-RNA Negative at Week 4 and Week 12||Merck Sharp & Dohme Corp.|No|Terminated|December 2006|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|January 17, 2007|No|Yes|The study was terminated due to difficulty in recruiting participants.|No|January 27, 2011|https://clinicaltrials.gov/show/NCT00423800||175154|Due to the small sample size (n=5), no conclusions should be drawn.
NCT00424047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-010|A Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Patients With Multiple Myeloma|A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.||Celgene|Yes|Completed|September 2003|November 2013|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|January 17, 2007|No|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT00424047||175135|
NCT00423774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070067|Education Program to Manage Emotional Stress of Stem Cell Transplant Recipients and Their Caregivers|A Feasibility Study to Test an Individualized Dyadic Problem-Solving Education Intervention to Improve Problem-Solving Skills of Patients and Family Caregivers During Allogeneic HSCT||National Institutes of Health Clinical Center (CC)||Completed|January 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||September 2010|September 26, 2015|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423774||175156|
NCT00424359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20050607|Ambulation Study in Multiple Sclerosis|A Prospective Study of Clinical Indices as Predictors of Ambulatory Effectiveness in Multiple Sclerosis||Brown, Theodore R., M.D., MPH|No|Completed|April 2005|January 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|70 Years|No|Probability Sample|Subjects with Multiple Sclerosis|May 2011|May 12, 2011|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00424359||175112|
NCT00424372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081121|A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia|A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In The Treatment Of Postherpetic Neuralgia||Pfizer|No|Completed|January 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||October 2009|October 30, 2009|January 18, 2007||Yes||No|August 19, 2009|https://clinicaltrials.gov/show/NCT00424372||175111|
NCT00425386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526204|Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Dose Escalation Phase II Study of Sunitinib Plus Erlotinib in Advanced Renal Carcinoma||OHSU Knight Cancer Institute|Yes|Completed|August 2006|March 2014|Actual|August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|January 19, 2007|Yes|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT00425386||175035|
NCT00457028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-80266|Efficacy of Treatment for Obsessive Compulsive Disorder|Efficacy of Treatment for Obsessive Compulsive Disorder||University of British Columbia|No|Completed|May 2003|June 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|19 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in the study will be recruited from individuals receiving treatment at the        Anxiety Disorders Clinic of UBC Hospital.|June 2011|June 7, 2011|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00457028||172646|
NCT00457288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICUMA|Efficacy and Safety of TF002 in Cutaneous Mastocytosis|Efficacy and Safety of TF002 in Cutaneous Mastocytosis||JADO Technologies GmbH|Yes|Completed|April 2007|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||November 2007|November 9, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457288||172626|
NCT00425347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuLuc63-1701|Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma|Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma||Facet Biotech|Yes|Completed|December 2006|July 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2009|September 21, 2009|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425347||175038|
NCT00425360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000528021|Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC]||National Cancer Institute (NCI)||Completed|September 2006|March 2013|Actual|||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1110|||Both|18 Years|N/A|No|||May 2009|August 23, 2013|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425360||175037|
NCT00425646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6351|Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study Evaluating a Maintenance Strategy of Gleevce® (Imatinib Mesylate) and Bevacizumab in Patients With Advanced, Non-squamous, Non-small Cell Lung Cancer, Following Completion of First-line Chemotherapy With Bevacizumab||University of Washington||Completed|November 2006|July 2009|Actual|October 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425646||175016|
NCT00426530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001J2102|Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer|A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer||Novartis||Completed|February 2007|||June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426530||174952|
NCT00427167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070083|Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine|Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria||National Institutes of Health Clinical Center (CC)||Completed|January 2007|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1|||300|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427167||174903|
NCT00422617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASIA-7002|Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients|||Uni-Pharma||Completed|January 2005|November 2005||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||40|||Both|16 Years|N/A|No|||September 2004|January 16, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00422617||175244|
NCT00423514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-125|Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease|A Phase I/II Dose Escalation Trial of Clofarabine, in Addition to Melphalan and Thiotepa as Myeloablative Regimen Followed by an Allogeneic Unmodified Hematopoietic Stem Cell Transplant From HLA-Compatible Related or Unrelated Donors for the Treatment of High Risk and/or Advanced Hematologic Malignancies||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2006|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|N/A|54 Years|No|||August 2015|August 14, 2015|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423514||175176|
NCT00423527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|keppra3|Levetiracetam in Central Pain in Multiple Sclerosis(MS)|Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis||Odense University Hospital||Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2007|December 17, 2009|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423527||175175|
NCT00423475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000523446|Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer|Phase III Randomized Study of Adjuvant Radiotherapy With Versus Without Concurrent Goserelin in Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer||UNICANCER|Yes|Completed|October 2006|||January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|743|||Male|18 Years|N/A|No|||February 2015|February 2, 2015|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00423475||175179|
NCT00423488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04037|Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)|A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing the Efficacy, Safety, and Tolerability of Co-administration of Ezetimibe 10 mg With Ongoing Treatment With Simvastatin 20 mg Versus Doubling the Dose of Simvastatin in Subjects With Primary Hypercholesterolemia Diabetes Mellitus Type 2 and Coronary Heart Disease||Merck Sharp & Dohme Corp.|No|Completed|July 2005|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|75 Years|No|||September 2015|September 18, 2015|January 17, 2007||Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00423488||175178|
NCT00423813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009|A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.|A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.||Jazz Pharmaceuticals|No|Completed|December 2006|June 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|573|||Both|18 Years|N/A|No|||December 2011|January 20, 2012|January 16, 2007|Yes|Yes||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00423813||175153|
NCT00424099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0613|Methylphenidate and a Nursing Telephone Intervention for Fatigue|A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2007|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|212|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00424099||175132|
NCT00424060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26061|Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma|Phase II Study of ZK 219477 in Patients With Recurrent Glioblastoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 2006|||August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|38|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00424060||175134|
NCT00424086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|720601|Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)|Single Blind, Randomized, Actively Controlled Phase 1/2 Study to Compare the Safety and Immunogenicity of a Split Virus, Vero Cell Derived, Seasonal Influenza Vaccine (VCIC) With a Licensed, Egg Derived, Split Virus, Seasonal Influenza Vaccine (EIV)||Nanotherapeutics, Inc.|Yes|Completed|January 2007|September 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|October 7, 2015|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00424086||175133|
NCT00424385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST1571BUS260 (0617)|Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)|Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-Independent Chemotherapy-Failure Prostate Cancer.||Oncology Specialists, S.C.|No|Completed|January 2007|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|18 Years|90 Years|No|||June 2014|June 19, 2014|January 17, 2007||No||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00424385||175110|
NCT00424398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTA-BEPO-CS01|Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis|A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis||Bausch & Lomb Incorporated||Completed|February 2007|||July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|107|||Both|10 Years|N/A|No|||February 2013|February 13, 2013|January 17, 2007|Yes|Yes||No|October 8, 2009|https://clinicaltrials.gov/show/NCT00424398||175109|
NCT00425022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-223|VATS Lobectomy for Clinical Stage IB or II Lung Cancer|Feasibility of VATS(Video-Assisted Thoracoscopic Surgery) Lobectomy for Clinical Stage IB or II Non-Small Cell Lung Cancer||National Cancer Center, Korea||Recruiting|January 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|80 Years|No|||January 2007|January 29, 2007|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425022||175062|
NCT00425035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020374|Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2|A Two-part, Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of ABX-EGF in Patients With Renal Carcinoma||Amgen||Completed|February 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||115|||Both|N/A|N/A||||May 2013|May 10, 2013|January 18, 2007||||||https://clinicaltrials.gov/show/NCT00425035||175061|
NCT00425009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XH-2002-Clin4|Therapeutic Effects of Berberine in Patients With Type 2 Diabetes|Effects of Berberine on Improvement of Glucose and Lipid Metabolism in Patients With Type 2 Diabetes||Shanghai Jiao Tong University School of Medicine||Completed|January 2004|December 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|25 Years|75 Years|No|||January 2007|January 18, 2007|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00425009||175063|
NCT00425698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH - EPONTX - 01/06|Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation|Effect of Erythropoietin on Renal Function After Kidney Transplantation||Hannover Medical School|Yes|Completed|February 2007|November 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|88|||Both|18 Years|70 Years|No|||September 2010|September 23, 2010|January 22, 2007||No||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00425698||175012|
NCT00457301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHE-188|Using Health-related Quality of Life (HRQL) in Routine Clinical Care|An Assessment of the Effects of the Use of Measures of Health-related Quality of Life in Routine Clinical Care:an Application to Lung Transplantation.||University of Alberta|Yes|Completed|July 2005|May 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|213|||Both|18 Years|N/A|No|||August 2009|September 21, 2009|April 4, 2007||No||No|April 15, 2009|https://clinicaltrials.gov/show/NCT00457301||172625|Randomizing patients instead of clinicians lead to sensitizing effects. EQ-5D is a generic preference-based measure, a specific measure should have been used to maximize responsiveness.
NCT00457314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR050597|The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease|Exercise Training and Deconditions: Implications for Therapy in Mitochondrial Myopathy||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Recruiting|June 2007|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||May 2009|May 18, 2009|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457314||172624|
NCT00457600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB-R01HS014947|ParentLink: Better and Safer Emergency Care for Children|ParentLink: Better and Safer Emergency Care for Children||Children's Hospital Boston||Completed|June 2005|July 2006||||Phase 2/Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||3000|||Both|N/A|12 Years|No|||January 2007|April 5, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457600||172602|
NCT00425932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3900s|Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis|Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis||Gaylis, Norman B., M.D.||Completed|February 2007|November 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||August 2013|August 21, 2013|January 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425932||174995|
NCT00426231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001948|Culturally-Tailored Approach to Improve Medication Use in Patients With Heart Attacks|Culturally-Tailored Hospital-based Model to Improve Statin Use and Outcomes in Patients With Coronary Disease||Johns Hopkins University|No|Completed|March 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|140|||Both|21 Years|N/A|No|||January 2014|January 13, 2014|January 23, 2007||No||No|January 13, 2014|https://clinicaltrials.gov/show/NCT00426231||174973|
NCT00426907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-016-TLH|Weightbearing After High Tibial Osteotomy|Weightbearing After Proximal Open-wedge Tibial Osteotomy - a Clinical, Randomized RSA-study.||Northern Orthopaedic Division, Denmark|No|Completed|January 2007|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||April 2015|April 9, 2015|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426907||174923|
NCT00427180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-80-00-00-00-01-V01|IRIS PILOT - Extended Pilot Study With a Retinal Implant System|Extended Pilot Study to Evaluate Pattern Recognition With a Chronic Retinal Implant System||Intelligent Medical Implants GmbH|No|Active, not recruiting|December 2006|December 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|79 Years|No|||March 2010|March 2, 2010|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427180||174902|
NCT00427193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016876|CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy|Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy (CALERIE)||Duke University|Yes|Completed|May 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|238|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00427193||174901|
NCT00422877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-05-23|Taxoprexin® Treatment for Advanced Primary Cancers of the Liver|Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Second Line Therapy for Patients With Advanced Primary Cancers of the Liver, Including Hepatocellular Carcinoma and Carcinoma of the Gallbladder or Biliary Tract||Luitpold Pharmaceuticals||Completed|January 2007|December 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||January 2010|January 8, 2010|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00422877||175224|
NCT00422890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-RELAZA-008|Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)|||Technische Universität Dresden||Completed|January 2007|||December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2011|July 8, 2011|January 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00422890||175223|
NCT00422903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF107692|Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer|Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation.||GlaxoSmithKline|No|Completed|April 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Female|18 Years|80 Years|No|||July 2012|June 4, 2015|January 16, 2007|Yes|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT00422903||175222|
NCT00423189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUV|Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration|Lucentis Utilizing Visudyne (LUV Trial)-- Reduced Fluence Photodynamic Therapy With Visudyne Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration||Greater Houston Retina Research|Yes|Terminated|January 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Both|55 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|January 16, 2007|Yes|Yes|Lack of efficacy|No|October 17, 2012|https://clinicaltrials.gov/show/NCT00423189||175200|The trial was discontinued due to a lack of efficacy.
NCT00423202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB-321|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.|Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.||Gilead Sciences||Completed|December 2003|October 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||186|||Both|18 Years|N/A|No|||April 2009|April 15, 2009|January 17, 2007||||||https://clinicaltrials.gov/show/NCT00423202||175199|
NCT00423540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03345|Exploring the Role of Magnesium in Rest Cramps|Magnesium Status & Effect of Magnesium Infusions on Rest Cramps||University of British Columbia|No|Completed|January 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|54|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 9, 2008|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00423540||175174|
NCT00423839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFTBVAC|A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers|A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers||University of Oxford||Completed|March 2003|July 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2006|January 17, 2007|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00423839||175151|
NCT00423501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20688|A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.|A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.||Hoffmann-La Roche||Completed|February 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|306|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|January 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423501||175177|
NCT00424112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2_P1|Motivation in Alcohol Treatment Facilities|Stages an Processes of Change in Help-Seeking and Drinking Behavior||University Medicine Greifswald||Completed|October 2004|September 2006||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||450|||Both|18 Years|64 Years||||January 2007|January 17, 2007|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00424112||175131|
NCT00424437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-106|Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.|Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial||Pfizer||Completed|September 1999|September 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||320|||Both|12 Years|65 Years|No|||February 2007|February 9, 2007|January 17, 2007||||||https://clinicaltrials.gov/show/NCT00424437||175106|
NCT00424762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK 102610|Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride|Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride||University of Texas Southwestern Medical Center|No|Completed|February 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|January 18, 2007|Yes|Yes||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00424762||175081|Larger than anticipated study discontinuation-72% with complete primary data analysis with lower numbers analyzed for imaging endpoints
NCT00424411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-108|Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes|Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial||Pfizer||Completed|September 1999|December 2000||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|35 Years|80 Years|No|||February 2007|February 9, 2007|January 17, 2007||||||https://clinicaltrials.gov/show/NCT00424411||175108|
NCT00424424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0719-002|A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)|Proprietary Information - Exploratory (Non-Confirmatory) Trial||Merck Sharp & Dohme Corp.||Terminated|August 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|81|||Male|18 Years|45 Years|No|||October 2015|October 30, 2015|January 18, 2007||||||https://clinicaltrials.gov/show/NCT00424424||175107|
NCT00425724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25600|HSP-glomerulonephritis Trial: MP vs CyA|||Oulu University Hospital||Completed|January 2000|February 2011|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|18 Years|No|||August 2011|August 5, 2011|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425724||175010|
NCT00425399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lichtenbergCTIL2|Shiatsu Adjuvant Therapy For Schizophrenia|Shiatsu Adjuvant Therapy for Hospitalized Psychiatric Patients: an Open Pilot Study||Herzog Hospital||Completed|January 2007|June 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2009|May 21, 2014|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425399||175034|
NCT00425711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Warnock_Acamprosate|Study of Acamprosate in Driving Under the Influence (DUI) Court Participants|An Open-Label Study of Acamprosate in DUI Court Participants||University of Oklahoma|No|Terminated|February 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|64 Years|No|||July 2012|July 26, 2012|January 22, 2007||No|Recruitment barriers.|No||https://clinicaltrials.gov/show/NCT00425711||175011|
NCT00457860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-8015-1002|Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)||Cambridge Antibody Technology|No|Recruiting|March 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||April 2007|April 16, 2007|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457860||172582|
NCT00458094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078613|Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses|Activating Consumers to Exercise in Community Psychiatry Through Peer Support||Johns Hopkins University|Yes|Completed|March 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00458094||172564|
NCT00426244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT003304-01A1|Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects|Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects||University of North Texas Health Science Center|Yes|Completed|April 2006|September 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|400|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 19, 2015|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00426244||174972|
NCT00426257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06OVH-OVHIPEC|Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer|Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy||The Netherlands Cancer Institute|Yes|Recruiting|February 2007|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Female|18 Years|76 Years|No|||June 2014|June 5, 2014|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426257||174971|
NCT00426543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 02 282294|Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome|Phase 1 Study of B-cell Depletion With Rituximab on Oral, Ocular and General Disease Manifestations in Patients With Primary Sjögren's Syndrome||University of Copenhagen|Yes|Completed|January 2007|August 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||August 2010|January 13, 2011|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426543||174951|
NCT00427206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB #04-0486|Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing|Hepatic Function Following Five Days of Therapeutic Dosing of Acetaminophen in Alcoholics||Denver Health and Hospital Authority|Yes|Completed|November 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|181|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 6, 2009|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00427206||174900|
NCT00422955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/376|Fluid Retention in AVANDIA Treated Subjects With Autonomic Neuropathy|A 16-Week, Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Investigate Fluid Retention in Insulin-Treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4 mg bd||GlaxoSmithKline||Completed|November 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|30 Years|75 Years|No|||October 2008|October 15, 2008|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00422955||175218|
NCT00422669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|604|Optimize RV Selective Site Pacing Clinical Trial|Optimize RV Selective Site Pacing Clinical Trial||Medtronic Cardiac Rhythm Disease Management|No|Terminated|January 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|January 12, 2007||No|Study enrollment significantly below protocol expectations|No|June 9, 2011|https://clinicaltrials.gov/show/NCT00422669||175240|Early study termination due to enrollment rates significantly below protocol expectations.
NCT00422656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-077|Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia|A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Completed|September 2006|November 2012|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|January 12, 2007|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00422656||175241|
NCT00422916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFEL011174505|Treatment of Overweight Children and Adolescents|Evaluation of the Intervention Program "Obeldicks Light" for Overweight Children and Adolescents||University of Witten/Herdecke||Completed|January 2007|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|66|||Both|8 Years|16 Years|No|||February 2009|January 10, 2012|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00422916||175221|
NCT00423215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_5062|LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus|An Open Therapeutic Observational Evaluation of the Efficacy and Safety Profile of Lantus in Everyday Medical Practice in Type 2 Diabetes Mellitus Patients, Who Start Receiving Lantus - Treated With Any Other Insulin, With A1c>7%||Sanofi|No|Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1007|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Type II Diabetes|June 2009|June 12, 2009|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423215||175198|
NCT00424164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10053|Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer|Pharmacokinetics Study of Combined Treatment Lapatinib and Tamoxifen in Advanced/Metastatic Breast Cancer|LAPATAM|European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|November 2006|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00424164||175127|
NCT00423826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000518230|Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease|A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies||Barbara Ann Karmanos Cancer Institute||No longer available|January 2007|January 2015|Actual|January 2015|Actual|N/A|Expanded Access|N/A|||||||Both|N/A|69 Years|No|||February 2016|February 26, 2016|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423826||175152|
NCT00405366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0603|Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer|A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate for Patients With Stage II or Greater Renal Cell Carcinoma|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|November 2006|July 2015|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00405366||176541|
NCT00440284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1b|Flexible, Intensive vs. Conventional Insulin Therapy in Insulin-Naive Adults With Type 2 Diabetes|Flexible, Intensive vs. Conventional Insulin Therapy in Insulin-Naive Adults With Type 2 Diabetes - a Non-Blinded, Randomized Controlled Cross-Over Clinical Trial of Metabolic Control and Patient Preference||University of Jena|No|Active, not recruiting|January 2004|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Both|40 Years|65 Years|No|||February 2007|February 23, 2007|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00440284||173915|
NCT00440557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010411|An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease|A Randomized, Open Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens, Once-Weekly and Every-Two-Weeks, With the Three-Times-Weekly Dosing Regimen for Initiation and Maintenance Treatment in Anemic Subjects With Chronic Kidney Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|375|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|February 26, 2007|Yes|Yes||No|February 23, 2009|https://clinicaltrials.gov/show/NCT00440557||173894|
NCT00406159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.10.0004|Effects of Hyperbaric Oxygen Therapy on Children With Autism|Effects of Hyperbaric Oxygen Therapy on Behavioral Measures of Short Term Memory, Learning, and Behavior in Children With Autism||Thoughtful House||Completed|November 2006|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||August 2009|August 6, 2009|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406159||176480|
NCT00405886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579-0508/1|Neramexane for Tinnitus|A Randomised, Double-Blind, Placebo-Controlled, Clinical Dose-Ranging Trial to Evaluate Efficacy and Safety of a NMDA Antagonist for Oral Administration in Patients With Subjective Tinnitus||Merz Pharmaceuticals GmbH|No|Completed|October 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|431|||Both|18 Years|65 Years|No|||March 2011|March 10, 2011|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00405886||176501|
NCT00406172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC 0016|Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)|Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)||Asociación para Evitar la Ceguera en México||Recruiting||||||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|N/A|N/A||||November 2006|December 4, 2006|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406172||176479|
NCT00407082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415-001|Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants|A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye||Bausch & Lomb Incorporated|No|Completed|December 2000|September 2005|Actual|September 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|278|||Both|6 Years|N/A|No|||December 2011|December 7, 2011|December 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407082||176411|
NCT00406458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-509-0601|Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy|A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy||Sangamo Biosciences|No|Completed|November 2006|May 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|70 Years|No|||October 2012|October 30, 2012|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406458||176458|
NCT00406471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAVE|Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion|Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion||Greater Houston Retina Research||Completed|May 2005|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 12, 2013|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406471||176457|
NCT00408356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-017|Immunological and Clinical Responses to Zinc in Children With Diarrhoea|Immunological and Clinical Responses to Zinc: A Randomized, Double-Blind Trial of Zinc Treatment vs. Zinc Treatment Plus Daily Supplementation for 3 Months Among Children Under 2 Years of Age With an Acute Diarrheal Illness.||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|November 2004|November 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|338|||Both|6 Months|24 Months|No|||February 2009|February 19, 2009|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408356||176314|
NCT00408382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481/HOP1|Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque|||Astellas Pharma Inc||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|20 Years|74 Years|No|||December 2006|November 15, 2011|December 5, 2006||||No||https://clinicaltrials.gov/show/NCT00408382||176312|
NCT00419497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU 665-02|Paleolithic Diet in the Treatment of Glucose Intolerance|Paleolithic Diet in the Treatment of Glucose Intolerance||Lund University Hospital||Completed|January 2003|September 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Male|N/A|N/A|No|||January 2007|January 4, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00419497||175480|
NCT00419510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704355|Genetic Counseling in African American Women|Genetic Counseling for Breast Cancer Susceptibility in African American Women||University of Pennsylvania||Recruiting|February 2003|August 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||360|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||March 2007|March 21, 2007|January 4, 2007||||No||https://clinicaltrials.gov/show/NCT00419510||175479|
NCT00420316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109810|Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.|To Assess Long-term Efficacy & Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in the Primary Vaccination Study (102247).||GlaxoSmithKline||Completed|February 2007|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||2601|||Both|32 Months|3 Years|Accepts Healthy Volunteers|||September 2012|October 4, 2012|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00420316||175418|
NCT00420654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-BH-GH|Growth Hormone Treatment of Women With Turner Syndrome|Growth Hormone Treatment of Women With Turner Syndrome: Body Composition and Heart Function.||University of Aarhus|Yes|Completed|August 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Female|20 Years|40 Years|No|||November 2011|November 6, 2011|January 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00420654||175393|
NCT00407680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8417|Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension|Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension||Kitasato University||Recruiting|October 2006|March 2009|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|20 Years|N/A|No|||October 2007|October 21, 2007|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407680||176365|
NCT00438295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.2007.03.EBP|Temperature Control During Dialysis Treatment|Effect of Temperature Control During Dialysis Treatment With Glucose in Dialysis Water in Patients With Chronic Renal Failure||Regional Hospital Holstebro|No|Completed|August 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2007|September 14, 2015|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438295||174066|
NCT00438308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002118|Comparison of Early and Late Therapy for Adults With Operatively Treated Distal Radius Fractures|Prospective Randomized Comparison of Early and Late Wrist Mobilization After Volar Plate Fixation of a Fracture of the Distal Radius||Massachusetts General Hospital||Completed|December 2004|May 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the MGH Hand and Upper Extremith Service|August 2010|August 11, 2010|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438308||174065|
NCT00438568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30579-B|SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)|Therapeutic Effects of Intranasal Insulin Administration in AD|SNIFF 120|University of Washington|Yes|Completed|June 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|173|||Both|55 Years|N/A|No|||September 2012|September 12, 2012|February 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00438568||174046|
NCT00407862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCW-02-04|Telmisartan and Losartan in Hypertensive IGT|Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects||Medical University of Graz||Completed|January 2005|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|40 Years|75 Years|No|||December 2006|December 4, 2006|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407862||176351|
NCT00407875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMVI-RT|Intensity Modulated Versus Interstitial - Radiation Therapy|A Randomized Phase II Study Comparing Intensity Modulated External Beam Radiation Therapy (IMRT) Versus Permanent Interstitial Prostate Brachytherapy (PIPB) for Low Risk and Low-tier Intermediate Risk Prostate Cancer||British Columbia Cancer Agency||Suspended|March 2007|November 2016||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|N/A|N/A|No|||October 2009|October 14, 2009|December 1, 2006||No|Accrual has been very slow. We are currently determining whether or not to keep the trial    going as is or to close the trial and write a new protocol.|No||https://clinicaltrials.gov/show/NCT00407875||176350|
NCT00404807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 01009|Cardiac Function After CPAP Therapy in Patients With Chronic Heart Failure and Sleep Apnea. A Multicenter Study|Cardiac Function After CPAP Therapy in Patients With Chronic Heart Failure and Sleep Apnea. A Multicenter Study||Sociedad Española de Neumología y Cirugía Torácica||Terminated|January 2001|June 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||245|||Both|30 Years|85 Years|No|||November 2006|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404807||176581|
NCT00403949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1400418|A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis|A 6-week, Vehicle-controlled, Randomized, Double-blind, Parallel-group Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Perioral Dermatitis||Bayer|No|Completed|November 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||February 2015|February 15, 2015|November 23, 2006||No||No||https://clinicaltrials.gov/show/NCT00403949||176647|
NCT00404248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0503 CDR0000515952|Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma|Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|January 2007|February 2012|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|November 27, 2006|Yes|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT00404248||176624|We were not able to complete the phase 2 portion of this study as the company had internal issues and no longer had funds to support the project. We did complete the phase I and determined the (Maxium Tolerated Dose) MTD, 1700mg/day x 5 days
NCT00405054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-008|A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)|A Phase II Study of MK0457 in Patients With T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia||Merck Sharp & Dohme Corp.||Terminated|December 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|November 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00405054||176563|
NCT00404781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-2006-C001|Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention|Pilot Study of Personal Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes||Shenyang Northern Hospital|Yes|Completed|June 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|305|||Both|35 Years|75 Years|No|||October 2009|October 13, 2009|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00404781||176583|
NCT00404794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW05-205 T/868|A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis|A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis||Hospital Authority, Hong Kong||Completed|November 2005|October 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|65 Years||||October 2013|October 22, 2013|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404794||176582|
NCT00405041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-06-OK-06-203-CTIL|Randomized Controlled Study to Assess the Efficacy of a Dietary Ingredient in Patients With Herniated Lumbar Disc Compression|A Two-Center, Phase II/III, Randomized, Double-Blind, Placebo-Controlled, Study, to Assess the Therapeutic Efficacy of a Dietary Ingredient in Patients With Herniated Lumbar Disc Causing Nerve Root Compression||Tel-Aviv Sourasky Medical Center||Completed|November 2006|April 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|75 Years|No|||April 2008|April 8, 2008|November 21, 2006||||No||https://clinicaltrials.gov/show/NCT00405041||176564|
NCT00405340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004833|Rituximab in the Treatment of Idiopathic Membranous Nephropathy|Rituximab in the Treatment of Idiopathic Membranous Nephropathy||Mayo Clinic||Completed|October 2006|April 2012|Actual|July 2010|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00405340||176543|
NCT00405353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 3239|Testosterone Treatment for Multiple Sclerosis|Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial||University of California, Los Angeles||Completed|April 2002|March 2004||||Phase 1/Phase 2|Observational|Time Perspective: Prospective||||10|||Male|18 Years|65 Years|No|||November 2006|July 11, 2013|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00405353||176542|
NCT00405639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004186|Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function|To Define in Human Preclinical Systolic Dysfunction (PSD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal, and Humoral Function and on the Integrated Response to Acute Sodium Loading||Mayo Clinic|Yes|Completed|June 2006|May 2013|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 4, 2014|November 29, 2006|Yes|Yes||No|February 4, 2014|https://clinicaltrials.gov/show/NCT00405639||176520|
NCT00407095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.3.007|An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.|An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.||Solvay Pharmaceuticals|Yes|Completed|August 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|30 Years|N/A|No|||September 2010|September 10, 2010|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407095||176410|
NCT00407108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-005|Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy|||Asociación para Evitar la Ceguera en México||Recruiting|March 2006|June 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||November 2006|December 5, 2006|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00407108||176409|
NCT00407394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9998|Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze|Randomized Double Blind Placebo Controlled Trial of Amoxycillin in the Treatment of Non-Severe Pneumonia With Wheeze in Children Aged 2- 59 Months of Age: A Multi-Centric Study||King George's Medical University||Completed|April 2004|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||2000|||Both|2 Months|59 Months|No|||December 2006|December 2, 2006|December 2, 2006||||No||https://clinicaltrials.gov/show/NCT00407394||176387|
NCT00407407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA034|ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma|A Phase I Dose Escalation Study of ABI-007 With Carboplatin TM as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma||Celgene|No|Terminated|November 2006|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||August 2008|April 6, 2012|December 1, 2006|Yes|Yes|MTD not determined|No||https://clinicaltrials.gov/show/NCT00407407||176386|
NCT00404079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28130805|The Glucosamine-study: The Effect of Glucosamine in Treatment of Chronic Low Back Pain|Phase 4 Study of Glucosamine Sulphate in the Treatment for Chronic Low Back Pain Patients With Degenerative Lumbar MRI Findings||Oslo University Hospital|Yes|Completed|December 2006|November 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|25 Years|N/A|Accepts Healthy Volunteers|||February 2011|April 4, 2011|November 23, 2006||No||No|February 21, 2011|https://clinicaltrials.gov/show/NCT00404079||176637|Free participation and the focus on glucosamine may attract a certain type of patients with specific personality traits. Adjunctive management was permitted, which may influence outcome. Compliance was assessed by capsule counts.
NCT00419796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2475|Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension|A 4-Week, Multicentre, Randomized, Double-Blind, Placebo Controlled, Double Dummy, Parallel Group Study, to Assess the Effect of Lumiracoxib 100 mg o.d. and Ibuprofen 600 mg t.i.d on 24-Hour Blood Pressure Profile and on Urinary Excretions of Eicosanoids, in Osteoarthritis Patients With Controlled Hypertension||Novartis||Completed|November 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|78|||Both|50 Years|N/A|No|||November 2007|November 28, 2007|January 8, 2007||||No||https://clinicaltrials.gov/show/NCT00419796||175458|
NCT00420043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571O 2103|Effect of Food on Bioavailability of Modified Release Formulations of Imatinib|A Phase I, Two Arm, Open-label, Randomized, Study to Investigate the Effect of Food on the Bioavailability of a Single 800 mg Imatinib Dose in Modified Release Formulations (MR3 and MR4) and Compare the Bioavailability Between MR3, MR4 and Imatinib 400 mg Twice Daily Immediate Release Tablet (IR) in Healthy Subjects||Novartis|No|Completed|September 2006|November 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00420043||175439|
NCT00407693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070035|PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28|PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28||National Institutes of Health Clinical Center (CC)||Recruiting|November 2006|September 2017|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|December 2, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00407693||176364|
NCT00407914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONAQ-US01|Safety and Effectiveness of Aquamid as Compared to Restylane for the Aesthetic Treatment of Nasolabial Folds|A Double-Masked, Randomized, Multi-Center, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Aquamid and Restylane for the Aesthetic Treatment of Nasolabial Folds||Contura||Completed|December 2006|July 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 6, 2009|December 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407914||176347|
NCT00438581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMA-05-017-ZEV|Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma|Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma|Zevalin|McGill University||Not yet recruiting|March 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2007|February 26, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438581||174045|
NCT00438828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-14-0055|Dexamethasone for the Prophylaxis of Pain Flare Study|Dexamethasone for the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases||Sunnybrook Health Sciences Centre|Yes|Completed|February 2007|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438828||174026|
NCT00403962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP103401|A Combination Therapy In Patients With Social Anxiety Disorder|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD)||GlaxoSmithKline||Completed|November 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||204|||Both|18 Years|64 Years|No|||October 2008|October 15, 2008|August 29, 2005||||No||https://clinicaltrials.gov/show/NCT00403962||176646|
NCT00403975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-109|Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease|A Multi-Center, Parallel Group, Double-Masked, Randomized, Placebo-Controlled Study of Multiple Ocular Instillations of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease||Merck Sharp & Dohme Corp.||Completed|June 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|640|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00403975||176645|
NCT00405665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009282|The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis|Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis||The Hospital for Sick Children|No|Completed|November 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|14 Years|N/A|No|||August 2013|August 30, 2013|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405665||176518|
NCT00404768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTA105256|The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor|A Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK221149A Administered Intravenously and to Investigate the Pharmacokinetics of GSK221149A Administered Orally to Healthy, Pregnant Females With Uncomplicated Pre-term Labor Between 300/7 and 356/7 Weeks' Gestation||GlaxoSmithKline||Completed|October 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|45 Years|No|||June 2013|August 6, 2015|November 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404768||176584|
NCT00405899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC - 4064|Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections|Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections||West Penn Allegheny Health System||Completed|October 2006|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|6 Years|18 Years|No|Non-Probability Sample|Male and Female patients aged 6 to 18 years being treated for allergies.|May 2010|May 28, 2010|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405899||176500|
NCT00405600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA016|Spine Fusion Instrumented With BMP-2 vs Uninstrumented With Infuse BMP-2 Alone|A Prospective Randomized Clinical Investigation of Posterolateral Lumbosacral Spinal Fusions With BMP-2 and Titanium Pedicle Screw Instrumentation Versus BMP-2 Alone.||Nova Scotia Health Authority|No|Completed|November 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|N/A|No|||February 2013|February 13, 2013|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405600||176523|
NCT00405613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSF-201090|Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population|Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population||Carolinas Healthcare System||Completed|May 2003|December 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2006|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00405613||176522|
NCT00405873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMT/P2GI/001 Part I|Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003|A Prospective, Open, Single-arm, Multicenter Phase II Clinical Trial to Evaluate the Tumour Response and Safety in Patients With Advanced Primary Hepatocellular Carcinoma Treated With AMT2003||Auron Healthcare GmbH||Terminated|March 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|79 Years|No|||March 2013|March 19, 2013|November 29, 2006||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00405873||176502|
NCT00406822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking 0502|OculusGen-Glaucoma Historical Control Study in Taiwan|Study of the Safety and Effectiveness of the OculusGen Collagen Matrix Implant as an Aid in Glaucoma Surgery||Pro Top & Mediking Company Limited||Terminated|December 2006|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||June 2007|April 25, 2008|October 10, 2006|||Terminated due to the change of supplier and sponsor|No||https://clinicaltrials.gov/show/NCT00406822||176431|
NCT00407719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF 3687|Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)|An Open-Label, Pilot Study of Bevacizumab in Subjects With Choroidal Neovascularization Secondary to Diseases Other Than Age-Related Macular Degeneration||Johns Hopkins University||Completed|June 2005|May 2008|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|65 Years|No|||January 2009|February 2, 2009|December 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407719||176362|
NCT00407966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02986|Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias||National Cancer Institute (NCI)||Completed|October 2006|November 2009|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2012|July 14, 2015|December 4, 2006|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00407966||176343|
NCT00420303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-404|Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy|A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||July 2010|July 15, 2010|January 8, 2007||No||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00420303||175419|
NCT00421239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00421239|Risk Factors of Hypertensive Urgencies|Retrospective Study of Hypertensive Urgencies in Patients With Arterial Hypertension|OSADA|Russian Cardiology Research and Production Center|No|Completed|January 2007|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1200|||Both|18 Years|79 Years|No|Probability Sample|Participants will be selected from hospital/policlinic database by random telephone        dialing to every third patient who are diagnosed with arterial hypertension        (SBP/DBP>140/90 Hg or taking antihypertensive drugs)|December 2008|December 8, 2008|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00421239||175349|
NCT00421252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P-000416|Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.|Impact of Pre-Treatment With 600mg of Clopidogrel (Plavix) on the Incidence of Ischemic and Hemorrhagic Complications in Patients Undergoing Elective Percutaneous Coronary Revascularization.--Prospective Randomized Trial.||Beth Israel Deaconess Medical Center||Not yet recruiting|January 2007|September 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|85 Years|No|||March 2008|March 10, 2008|January 10, 2007||||No||https://clinicaltrials.gov/show/NCT00421252||175348|
NCT00420927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-810|Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis|A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)|OPTIMA|Abbott|No|Completed|December 2006|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1032|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|January 9, 2007||No||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00420927||175372|
NCT00407888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6141|Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery|Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II||University of Washington|No|Completed|May 2006|||May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||May 2013|May 7, 2013|December 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00407888||176349|
NCT00408213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX18411|A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.|A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone||Hoffmann-La Roche||Completed|June 2004|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|80 Years|No|||May 2008|May 22, 2008|December 5, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00408213||176324|
NCT00408226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-102|Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer|Phase 1/2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 3 Weeks in Combination With Pemetrexed||CASI Pharmaceuticals, Inc.||Completed|October 2006|January 2012|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|December 5, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408226||176323|
NCT00403988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9116|Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma|A Clinical Phase II Study of Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma||American University of Beirut Medical Center||Terminated|June 2004|December 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|75 Years|No|||August 2008|November 3, 2008|November 23, 2006|Yes|Yes|The results of a same study design have shown low response with important side effects.    Accordingly & ethicly, the study has been stopped.|No||https://clinicaltrials.gov/show/NCT00403988||176644|
NCT00404001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-104-201|Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia|A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Safety and Efficacy of Orally Administered MD-0727 in Patients With Primary Hypercholesterolemia||Ironwood Pharmaceuticals, Inc.|No|Completed|November 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|150|||Both|18 Years|N/A|No|||September 2007|September 28, 2007|November 22, 2006||||No||https://clinicaltrials.gov/show/NCT00404001||176643|
NCT00404014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL 208-201|Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery|A Phase II Study Designed to Evaluate the Safety, Tolerability, and Effect of a Single, Rising Dose of Intravenous AL-208, Followed by a Placebo-Controlled, Double-Blind, Parallel-Group Evaluation of a Single Dose of AL-208, on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery.||Allon Therapeutics|No|Completed|August 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|234|||Both|50 Years|79 Years|No|||October 2012|October 18, 2012|November 24, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404014||176642|
NCT00404313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0633-007|The Effect of MK0633 in Patients With Chronic Asthma (0633-007)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK0633 in Adult Patients With Chronic Asthma||Merck Sharp & Dohme Corp.||Terminated|January 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|688|||Both|18 Years|70 Years|No|||October 2015|October 19, 2015|November 21, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404313||176619|
NCT00405418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_C_00579|Lantus Versus Levemir Treat-To-Target|Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.|L2T3|Sanofi||Completed|November 2006|||June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|973|||Both|40 Years|75 Years|No|||September 2009|September 14, 2009|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00405418||176537|
NCT00405080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV105091|A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).|An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]||GlaxoSmithKline||Completed|November 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 27, 2006||||||https://clinicaltrials.gov/show/NCT00405080||176561|
NCT00405093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607008636|Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.|Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta. A Retrospective Study.||Weill Medical College of Cornell University|No|Recruiting|July 2006|September 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Adult male and female patients having surgery of ascending and aortic arch with the use of        Antifibrinolytic agents (Aprotinin and Aminocaproic Acid)|September 2010|March 7, 2012|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405093||176560|
NCT00404508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/32/DII|A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors|A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors||National Institute of Cancerología||Completed|September 2005|October 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||November 2006|November 27, 2006|November 25, 2006||||No||https://clinicaltrials.gov/show/NCT00404508||176604|
NCT00404521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM2734-A-001-05|A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors|A Phase I Single-institution, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.||PharmaMar|No|Terminated|August 2005|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|November 27, 2006|Yes|Yes|Low rate recruitment|No||https://clinicaltrials.gov/show/NCT00404521||176603|
NCT00406523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-2006-B003|A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease|||Shenyang Northern Hospital||Completed|February 2006|September 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||November 2006|November 30, 2006|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406523||176453|
NCT00405067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR-733-001|The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia|A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia||Aegerion Pharmaceuticals, Inc.||Completed|May 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|70 Years|No|||January 2014|January 15, 2014|November 28, 2006||||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00405067||176562|
NCT00405379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL06-02|Trabecular Metal Mesh Tibial Monoblock RSA|A Prospective Randomized Controlled Trial Using Roentgen Stereophotogrammetric Analysis of Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty Component "TMM".||Dalhousie University|No|Completed|July 2002|February 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|67|||Both|55 Years|80 Years|No|||April 2008|April 8, 2008|November 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405379||176540|
NCT00405626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hompostpartum-HMO-CTIL|Double Blind Placebo Controlled Bellis Perenis and Arnica Montana as a Drug for PPH|Phase 2 Study of the Effect of Bellis Perenis and Arnica Montana on Post Partum Hemmorhage||Hadassah Medical Organization||Not yet recruiting|April 2007|September 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|210|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405626||176521|
NCT00407420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ4316|Can a Novel Treatment Using "Mandometer®" Technology Improve Weight Loss in a Childhood Obesity Clinic?|||University of Bristol||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||90|||Both|10 Years|18 Years|No|||December 2006|December 4, 2006|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00407420||176385|
NCT00407433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGR 1205|Clinical Studies of Gemcitabine-Oxaliplatin|Phase 2 Single-Arm Studies of Gemcitabine in Combination With Oxaliplatin Refractory and Relapsed Pediatric Solid Tumors||Gustave Roussy, Cancer Campus, Grand Paris||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|156|||Both|6 Months|20 Years|No|||August 2009|August 6, 2009|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407433||176384|
NCT00407446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124-04|PDE5-Inhibition With Sildenafil in Chronic Heart Failure|Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure||University of Milan||Completed|January 2004|February 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Male|30 Years|80 Years|No|||December 2006|December 12, 2006|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00407446||176383|
NCT00407732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2944 PEG228|Overcoming Psychiatric Barriers to the Treatment of Hepatitis C|Overcoming Neuropsychiatric Barriers to the Treatment of Hepatitis C||University of North Carolina, Chapel Hill|No|Completed|January 2007|October 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|101|||Both|18 Years|70 Years|No|||January 2012|January 24, 2012|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00407732||176361|
NCT00436761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529361|Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors|A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|May 2004|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|N/A|21 Years|No|||June 2007|December 17, 2013|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436761||174180|
NCT00436774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-GC-2006-06|Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01|Cross-Sectional Evaluation of Outcome Following Extra-Cranial Germ Cell Tumors Treated According to UKCCSG GC 7901 (GC I) and GC 8901 (GC II) Protocols||National Cancer Institute (NCI)||Recruiting|June 2006|||September 2010|Anticipated|N/A|Observational|N/A|||Anticipated|60|||Both|5 Years|N/A|No|||June 2009|August 9, 2013|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436774||174179|
NCT00421304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP141|A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Treatment of Children Hospitalized With RSV Illness||MedImmune LLC|Yes|Completed|January 2007|January 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|118|||Both|N/A|12 Months|No|||June 2012|June 27, 2012|January 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00421304||175344|
NCT00420940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0332-AE|The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause|The Effect of Daily Whole-Body Vibration on Tibial Trabecular Bone Mineral Density in Osteopenic Postmenopausal Women||University Health Network, Toronto|No|Completed|November 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|202|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2008|April 7, 2010|January 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00420940||175371|
NCT00404027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-201|Patient and Provider Attitudes in the Healthcare Context|Patient and Provider Attitudes in the Healthcare Context||VA Office of Research and Development|No|Completed|June 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|Veteran primary care patients|May 2015|May 12, 2015|November 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00404027||176641|
NCT00404547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/CA-102|Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)|An Open-Label Randomized, Multicenter Study in Patients With Asthma to Evaluate the Effectiveness of Alvesco® (Ciclesonide) Compared to Asthma Usual Care in a Primary Practice Setting||Takeda|No|Completed|November 2006|December 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1121|||Both|18 Years|N/A|No|||March 2010|May 4, 2012|November 27, 2006|Yes|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00404547||176601|
NCT00407901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWUIRB#120526|Functional Assessment Questionnaire for the Visually Challenged|Functional Assessment Questionnaire for the Visually Challenged: Proposed Model to Quantitatively Measure the Functional Level of Individuals Who Are Legally Blind||George Washington University|No|Completed|April 2006|August 2006|Actual|August 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|31|||Both|18 Years|80 Years|No|Non-Probability Sample|Approximately 30 legally blind individuals. Between 12-15 individuals will be categorized        as poor or low-functioning, and the same number of subjects that are categorized as        high-functioning.        The factors that will establish high-functioning abilities will be outward skills in        adapting to vision loss, such as:          1. Employment in mainstream job market          2. Extensive vision rehabilitation          3. Inclusion into mainstream society          4. Success in real world          5. Demonstrated ability to live independently, shop, cook, clean, pay bills, and move             around safely without assistance.|January 2008|January 16, 2008|December 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00407901||176348|
NCT00407927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033-101|A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Safety, Efficacy, and Tolerability Study of Two Doses of Epinastine Nasal Spray (0.05% and 0.1%) vs. Placebo in Subjects With Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|December 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|571|||Both|12 Years|N/A||||October 2015|October 9, 2015|December 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407927||176346|
NCT00408239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-029|Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement|Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement: A Randomized, Enoxaparin-controlled, Open Label, Dose-escalation Study|PEARL-1|Astellas Pharma Inc||Completed|December 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|367|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|December 4, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00408239||176322|
NCT00408252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2006-01|Efficacy of SU 011248 in Head And Neck Carcinoma|A Phase II Study Of Su011248 In Patients With Recurrent And/Or Metastatic Squamous Head And Neck Carcinoma.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Terminated|February 2007|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|December 4, 2006||No|Too frequent grade 3-4 toxicities|No||https://clinicaltrials.gov/show/NCT00408252||176321|
NCT00404534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-422|Helicobacter Eradication Relief of Dyspeptic Symptoms|Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up|HEROES-12|Hospital de Clinicas de Porto Alegre|Yes|Completed|November 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|407|||Both|18 Years|N/A|No|||March 2010|March 29, 2010|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404534||176602|
NCT00405405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06C.46|Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer|A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer||Thomas Jefferson University|Yes|Completed|December 2006|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|November 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00405405||176538|
NCT00405704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK074059 (IND)|Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)|Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)|RIVUR|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|May 2007|May 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|607|||Both|2 Months|71 Months|No|||April 2015|April 15, 2015|November 29, 2006|Yes|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00405704||176515|Results may not apply to children with different demographic or clinical characteristics or in locales where choice of TMP-SMZ may be limited by susceptibility patterns or clinical acceptability. Some subgroup analyses had limited statistical power.
NCT00405912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002296|St. John's Wort for Tobacco Cessation|St. John's Wort for Tobacco Cessation||Mayo Clinic||Completed|September 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|118|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 15, 2011|November 29, 2006|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00405912||176499|
NCT00405392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109393|Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis|An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study||Hoffmann-La Roche||Completed|March 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|364|||Female|N/A|N/A|No|||October 2010|January 17, 2012|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405392||176539|
NCT00405652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ADE09|Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients|Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients (MyLiver)||Novartis||Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||February 2011|February 8, 2011|November 27, 2006||No||No|December 1, 2010|https://clinicaltrials.gov/show/NCT00405652||176519|
NCT00406211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208136/039|Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine|Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®.||GlaxoSmithKline||Completed|July 2004|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|398|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||November 2012|November 8, 2012|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00406211||176476|
NCT00406549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I2MS 05-010077|Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus|Multi-Center Clinical Performance Evaluation of a Rapid In Vitro Diagnostic Device for Direct Detection of Staphylococcus Aureus Nasal Colonization: Comparative Analysis to Culture Screening Methods||3M||Completed|December 2006|March 2007||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||2000|||Both|18 Years|N/A|No|||March 2007|March 7, 2007|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406549||176451|
NCT00406185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-db1|Database Registry of the Intermountain Heart Collaborative Study|Database Registry of the Intermountain Heart Collaborative Study||Intermountain Health Care, Inc.|No|Active, not recruiting|October 1994|January 2024|Anticipated|January 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|Samples With DNA|whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing a procedure within the catheterization laboratory|September 2015|September 25, 2015|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406185||176478|
NCT00406497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJE2079/2-03-PC|Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation|Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation||Sirion Therapeutics, Inc.||Completed|April 2003|July 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|20 Years|N/A|No|||November 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00406497||176455|
NCT00406510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5283|Comparison of Frequency of Use of Optive and Systane|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||May 2007|May 30, 2007|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406510||176454|
NCT00407134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/382|Acute Haemodynamic Effects of Peritoneal Dialysis as Evaluated by Sphygmocor Technology|Acute Haemodynamic Effects of Peritoneal Dialysis as Evaluated by Sphygmocor Technology||University Hospital, Ghent|No|Completed|December 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||December 2007|December 19, 2007|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00407134||176407|
NCT00407147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProBac|Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection|ProBac - Use of Procalcitonin Level as Part of a Decision Tree to Discontinue Antibiotics When Started Empirically in the ICU in Hemodynamically Stable Patients With no Site of Infection Identified||Brahms AG|Yes|Terminated|July 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|November 29, 2006||No|termination due to futility (very slow patient enrollment)|No||https://clinicaltrials.gov/show/NCT00407147||176406|
NCT00407745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081107|A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury|A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury||Pfizer|Yes|Completed|January 2007|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|December 1, 2006|Yes|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00407745||176360|
NCT00408005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00307|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|January 2007|||September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|16||Anticipated|1900|||Both|1 Year|30 Years|No|||January 2016|March 24, 2016|December 4, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00408005||176340|
NCT00408018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/02/05|Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms|An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms||Piramal Enterprises Limited|No|Terminated|March 2006|October 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||December 2008|December 31, 2008|December 4, 2006||No|The decision to terminate this study after 202 mg/m2 cohort was taken as MTD achieved in other    study at 185 mg/m2|No||https://clinicaltrials.gov/show/NCT00408018||176339|
NCT00408031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heresco 4 CTIL|D-cycloserine for Major Depressive Disorder|N-methyl-D-aspartate Receptor (NMDAR)-Based Pharmacotherapy With D-cycloserine for Treatment-resistant Major Depressive Disorder||Herzog Hospital||Completed|January 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|75 Years|No|||August 2012|August 2, 2012|December 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00408031||176338|
NCT00408330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401201|A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face|A Double-Blind, Randomized, Vehicle-Controlled, Six-Week Exploratory Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Seborrheic Dermatitis of the Face||Bayer|No|Completed|December 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|December 5, 2006||No||No||https://clinicaltrials.gov/show/NCT00408330||176315|
NCT00440973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC IRB #03-0194-05|Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer|Phase II Study of Interleukin- 2 and Bevacizumab in Patients With Progressive Metastatic Renal Cell Carcinoma||The Methodist Hospital System|No|Terminated|October 2006|November 2007|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 23, 2007|Yes|Yes|contract issues|No||https://clinicaltrials.gov/show/NCT00440973||173862|
NCT00440986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMHHPE|Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis|Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis||San Filippo Neri General Hospital|No|Completed|April 2003|December 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2007|February 28, 2007|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00440986||173861|
NCT00421603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5368|A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence|A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) and Topiramate for the Treatment of Cocaine Dependence|TACT|New York State Psychiatric Institute|Yes|Completed|February 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|January 10, 2007|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00421603||175322|The two-arm placebo controlled design does not allow us to address whether both medications are necessary for efficacy. Potential limited treatment masking that occurred when giving two medications with distinctive adverse effect profiles.
NCT00407368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75/06|Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease|||Assaf-Harofeh Medical Center||Recruiting|September 2006|December 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|18 Years|N/A|No|||November 2006|December 4, 2006|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407368||176389|
NCT00407381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00005254|The READ-2 Study: Ranibizumab for Edema of the mAcula in Diabetes|Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)||Johns Hopkins University|Yes|Active, not recruiting|December 2006|December 2009|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|126|||Both|18 Years|N/A|No|||January 2009|January 30, 2009|December 1, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00407381||176388|
NCT00404586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGS105049|Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber|See Detailed Description||GlaxoSmithKline||Completed|September 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Male|18 Years|65 Years|No|||October 2008|October 15, 2008|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404586||176598|
NCT00404820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HDE31|Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis|A Multi-center, Randomized, Open-label, Controlled, One-year Trial to Measure the Effect of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteopenia and Osteoporosis|ROSE|Novartis||Completed|October 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|604|||Female|55 Years|90 Years|No|||June 2011|June 6, 2011|November 28, 2006|Yes|Yes||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00404820||176580|
NCT00404833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1838-02|Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental|A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)||Hospital Authority, Hong Kong||Completed|January 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|16|||Both|18 Years|65 Years||||October 2013|October 22, 2013|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404833||176579|
NCT00405106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-4|The Effect of Final Exam Preparation on Anxiety Level, Self-Perception, Ocular Symptoms, Accommodation and Vergence in Myopia|||Southern California College of Optometry||Completed|December 2005|May 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||25|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||May 2004|November 28, 2006|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00405106||176559|
NCT00408265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-ALE-03510|Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study|Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study||University of Connecticut Health Center|Yes|Completed|January 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Male|18 Years|N/A|No|||November 2011|November 17, 2011|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00408265||176320|
NCT00404300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8VWF03|Optivate in People With Von Willebrand Disease Undergoing Surgery|An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate, in Patients With Von Willebrand Disease Who Are Undergoing Surgery||Bio Products Laboratory||Terminated|February 2007|September 2008|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|12 Years|N/A|No|||March 2010|March 2, 2010|November 27, 2006|||Due to slow recruitment and a delay in reaching the recruitment target.|No||https://clinicaltrials.gov/show/NCT00404300||176620|
NCT00405158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84839|Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding|A RCT in Sweden of Acupuncture and Care Interventions for the Relief of Inflammatory Symptoms of the Breast During Lactation||Karlstad University||Completed|January 2002|March 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||210|||Female|N/A|N/A|No|||November 2006|November 30, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00405158||176556|
NCT00405470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL06-01|A Prospective Randomized Trial Using Roentgen Stereophotogrammetric Analysis of the Advance Medial Pivot Knee|A Prospective Randomized Trial Using Roentgen Stereophotogrammetric Analysis of the Advance Medial Pivot Knee||Dalhousie University|No|Completed|July 2001|June 2006|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|45 Years|80 Years|No|||August 2010|August 11, 2010|November 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405470||176533|
NCT00405678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007112|Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.|The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study||Duke University||Completed|September 2006|September 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Female|18 Years|N/A|No|||July 2013|July 9, 2014|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00405678||176517|
NCT00405691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPS-US-IDE-002|Safety and Effectiveness Study of the TOPS System, a Total Posterior Arthroplasty Implant Designed to Alleviate Pain Resulting From Moderate to Severe Lumbar Stenosis|A Prospective, Multi-Center Clinical Study to Assess the Saftey and Effectiveness of the Impliant TOPS System||Impliant, Ltd.|Yes|Completed|September 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Anticipated|450|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||January 2010|May 17, 2011|November 29, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00405691||176516|
NCT00406198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP 97 02 06|Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis|Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis||Hopital Lariboisière||Completed|March 1997|December 1999||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||400|||Both|18 Years|N/A|No|||November 2006|December 1, 2006|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406198||176477|
NCT00406562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107924|Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.|Open, Booster Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Administered to Healthy Chinese Children 6-8 Years of Age.||GlaxoSmithKline||Completed|January 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||30|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00406562||176450|
NCT00406250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81612|Intravitreal Bevacizumab in Agioid Streaks|Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Angioid Streaks: 24 Months Follow-up||Second University of Naples|Yes|Completed|November 2006|May 2009|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|44 Years|67 Years|No|||February 2016|February 5, 2016|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406250||176473|
NCT00406835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROSG99-1|Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases|Phase 3 Study of Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for 1-4 Brain Metastases||Hokkaido University Hospital||Completed|October 1999|April 2005||||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||180|||Both|18 Years|N/A|No|||November 2006|November 30, 2006|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406835||176430|
NCT00407121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0025|Intravitreal Bevacizumab for Inflammatory Neovascular Membranes|Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation||Asociación para Evitar la Ceguera en México||Completed|August 2006|November 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|25 Years|60 Years|No|||December 2006|December 1, 2006|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00407121||176408|
NCT00406848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10815|A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients|Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression||Eli Lilly and Company|No|Completed|November 2006|November 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|370|||Both|65 Years|N/A|No|||September 2010|September 13, 2010|November 29, 2006|Yes|Yes||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00406848||176429|
NCT00407459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2006-003|Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma|Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Malignant Pleural Mesothelioma||Istituto Clinico Humanitas|No|Completed|September 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00407459||176382|
NCT00407472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25821|ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency|||EMD Serono||Completed|September 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00407472||176381|
NCT00407173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-112|Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects|An Open-Label, Single-Dose, Parallel Group Study to Evaluate the Effects of Age and Gender on the Pharmacokinetics, Safety, and Tolerability of HCV-796 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2006|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 10, 2008|November 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00407173||176404|
NCT00407498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/01/04|Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms|An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms||Piramal Enterprises Limited|No|Completed|May 2005|September 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2008|December 31, 2008|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00407498||176379|
NCT00407758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000517318|Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Enzastaurin (Lilly IND # 60, 933) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|November 2006|||January 2013|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Female|18 Years|N/A|No|||May 2007|July 18, 2012|December 4, 2006||||||https://clinicaltrials.gov/show/NCT00407758||176359|
NCT00408044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 2005/05SEPT/134|Dysesthesia Study After Sternotomy|Pain After Sternotomy||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|December 2006|March 2007|Actual|February 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|85 Years|No|||May 2008|May 19, 2008|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00408044||176337|
NCT00408369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-015|Prophylactic Antimalarial Activity of DB289 in Volunteers|Prophylactic Antimalarial Activity of DB289 in Volunteers Challenged With Plasmodium Falciparum||Immtech Pharmaceuticals, Inc||Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|19|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 25, 2008|December 4, 2006||Yes||No||https://clinicaltrials.gov/show/NCT00408369||176313|
NCT00436826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26593|A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)|A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-β) Treatment in Multiple Sclerosis Subjects With Active Disease|ONWARD|EMD Serono||Completed|November 2006|March 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|65 Years|No|||August 2013|August 4, 2013|February 15, 2007|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00436826||174176|The 96-week DB treatment period of study was completed as planned, and safety and exploratory efficacy results are presented here. The duration of OL Ext. period was reduced for some participants, following termination of the development program.
NCT00422526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03WH13|Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial|Randomised Study to Examine the Effectiveness of Progesterone in Preventing Severe Preterm Delivery||King's College Hospital NHS Trust||Completed|September 2003|November 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||250|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2007|January 16, 2007|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00422526||175251|
NCT00422539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC-BBA-1385-6-1|Efficacy of TCA Effect on Varicella Atrophic Scars|Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars||hahid Beheshti University of Medical Sciences||Recruiting|March 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|15 Years|45 Years|Accepts Healthy Volunteers|||January 2007|January 16, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00422539||175250|
NCT00404040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/05 (Part II)|Movicol in Childhood Constipation (ProMotion Study)|A Single Centre Study to Assess the Safety and Efficacy of Movicol in the Treatment of Faecal Impaction in Children Followed by a Double Blind, Randomised Phase to Compare the Safety and Efficacy of Movicol and Lactulose for Maintenance Therapy||Norgine||Completed|October 2000|July 2002||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|2 Years|11 Years|No|||November 2006|November 27, 2006|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00404040||176640|
NCT00405119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAV104616|A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.|See Detailed Description||GlaxoSmithKline|No|Completed|May 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|92|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00405119||176558|
NCT00405145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0618|Mapping of the Epileptic Brain|Mapping of the Eloquent Cortex and of Epileptic Networks Using Functional Magnetic Resonance Imaging and Electroencephalography in Epileptic Patients||University Hospital, Grenoble||Recruiting|July 2006|July 2011||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal||||400|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2006|November 28, 2006|August 7, 2006||||No||https://clinicaltrials.gov/show/NCT00405145||176557|
NCT00405431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #03-598|Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?|Influence of Post-Operative Cyclosporine 0.05% (Restasis) on the Success of Glaucoma Filtering Surgery||Wills Eye|No|Completed|March 2004|November 2007|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||January 2008|January 25, 2010|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405431||176536|
NCT00405444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009018|Intranasal Fentanyl Versus Placebo for Catheterization During a Voiding Cystourethrogram in Children|Intranasal Fentanyl Versus Placebo for Catheterization During a Voiding Cystourethrogram in Children||The Hospital for Sick Children|Yes|Completed|November 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|4 Years|8 Years|No|||December 2010|December 10, 2010|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405444||176535|
NCT00438698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 04-021|Low Glycemic Index Diets vs. High Cereal Fibre Diets in Type 2 Diabetes|Effect of Low Glycemic Index Diets on Glucose Control in Non-Insulin Dependent Diabetics||University of Toronto|No|Completed|September 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|21 Years|100 Years|No|||December 2015|December 15, 2015|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438698||174036|
NCT00405951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM010|Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer|A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered Every 3 Weeks in Combination With Docetaxel to Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)||Teva Pharmaceutical Industries|No|Completed|October 2006|September 2009|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405951||176496|
NCT00405964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04684|Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)||Merck Sharp & Dohme Corp.|No|Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|716|||Both|12 Years|N/A|No|||April 2015|April 9, 2015|November 30, 2006||No||No|March 25, 2009|https://clinicaltrials.gov/show/NCT00405964||176495|
NCT00405925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-184-010403|FREE Study: Efficacy and Toxicity of Trizivir|Free Study: a Randomised, Open Label, Multicentre Strategic Study to Evaluate the Efficacy and Toxicity of an Early Switch From a PI-containing Regimen to Trizivir ® on Guidance of Viral Load in HIV-1 Infected , Antiretroviral naïve Adults||Rijnstate Hospital||Completed|March 2003|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||May 2010|May 31, 2010|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00405925||176498|
NCT00405938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 86|Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer|A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients)||SCRI Development Innovations, LLC|No|Completed|November 2006|June 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Female|18 Years|N/A|No|||December 2013|December 5, 2013|November 28, 2006|No|Yes||No|January 11, 2013|https://clinicaltrials.gov/show/NCT00405938||176497|
NCT00406575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLX.CHF.002|Recombinant Human Relaxin for the Treatment of Decompensated CHF|A Phase II Randomized, Double Blind, Placebo-Controlled Study of Recombinant Human Relaxin in Patients With Decompensated Congestive Heart Failure||Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies||Terminated|November 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|11|||Both|19 Years|N/A|No|||May 2014|May 6, 2014|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406575||176449|
NCT00406536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK60302|Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI|Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF||Avanti Polar Lipids, Inc.||Completed|January 2007|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|110|||Both|6 Years|17 Years|No|||January 2013|January 11, 2013|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00406536||176452|
NCT00407160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-245|A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients|Comparison of Two Different Immunosuppression Protocols in Highly Sensitized Renal Transplant Recipients: Campath Induction With Tacrolimus Monotherapy vs Thymoglobulin Induction With Triple Drug Protocol.||The University of Texas Medical Branch, Galveston|Yes|Completed|August 2004|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|75 Years|No|Probability Sample|Patients with end stage renal disease , on dialysis, who are regarded as "high        immunological risk" becuase they have lost previous transplants to rejection, or have a        high panel reactive antibody (PRA).|September 2011|September 6, 2011|November 21, 2006||No||No||https://clinicaltrials.gov/show/NCT00407160||176405|
NCT00407485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02840|VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium|A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium||National Cancer Institute (NCI)||Completed|November 2006|April 2014|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2013|October 10, 2014|December 4, 2006|Yes|Yes||No|August 27, 2014|https://clinicaltrials.gov/show/NCT00407485||176380|
NCT00440947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPZ108859|Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection|See Detailed Description||ViiV Healthcare|No|Completed|March 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|515|||Both|18 Years|N/A|No|||July 2011|March 15, 2012|February 23, 2007|Yes|Yes||No|May 19, 2011|https://clinicaltrials.gov/show/NCT00440947||173864|
NCT00440960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002.0.297.000-06|Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic|||Hospital Pompeia|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||February 2007|February 26, 2007|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00440960||173863|
NCT00440739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SiEc 161/2548|Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)|Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy: A Factorial Randomized Controlled Trial||Mahidol University|No|Completed|September 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|128|||Male|18 Years|N/A|No|||February 2007|February 4, 2009|February 2, 2006||No||No||https://clinicaltrials.gov/show/NCT00440739||173880|
NCT00437398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003564|Islet Transplantation for Type 1 Diabetes Mellitus|Islet Transplantation for Type 1 Diabetes Mellitus||Mayo Clinic|Yes|Terminated|July 2006|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||March 2013|April 18, 2013|February 20, 2007|Yes|Yes|The study was terminated early due to difficulty in recruiting subjects, and ran short of    funds.|No|March 5, 2013|https://clinicaltrials.gov/show/NCT00437398||174133|The study was terminated early due to difficulty in recruiting subjects, and ran short of funds. The sample size (n=2) was too small to perform a meaningful analysis.
NCT00437710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2007|Safety and Efficacy of Bone Marrow Cell Transplantation in Humans Myocardial Infarction|Cardiac Study. Cellular Cardiomyoplasty of Infarcted Failed Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans|CARDIAC|Azienda Unità Sanitaria Locale di Piacenza||Recruiting|July 2005|February 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|80 Years|No|||February 2007|March 23, 2010|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00437710||174110|
NCT00409578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2347|Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational Clinical Trial to Evaluate the Efficacy of Aliskiren and Valsartan Versus Placebo in Lowering Levels on NT-proBNP in Stabilized Patients Post Acute Coronary Syndromes||Novartis||Completed|February 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1101|||Both|18 Years|N/A|No|||April 2011|April 15, 2011|December 7, 2006|No|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00409578||176225|
NCT00404053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-2004-A003|Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation|One Year Effects of Different Clopidogrel Maintaining Dosage on Patients With Acute Coronary Syndrome Undergoing Coronary Drug Eluting Stent Implantation||Shenyang Northern Hospital||Completed|December 2004|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2006|November 28, 2006|November 24, 2006||||No||https://clinicaltrials.gov/show/NCT00404053||176639|
NCT00404573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-03|Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia||Forest Laboratories||Completed|November 2006|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|375|||Both|18 Years|65 Years|No|||January 2008|January 3, 2008|November 27, 2006||||||https://clinicaltrials.gov/show/NCT00404573||176599|
NCT00404339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515081|Vaccine Therapy in Treating Patients With Head and Neck Cancer|Adjuvant p53 Peptide Loaded DC-Based Therapy for Subjects With Squamous Cell Cancer of the Head and Neck (A Phase I Safety and Immunogenicity Trial)||National Cancer Institute (NCI)||Recruiting|September 2005|||||Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||October 2007|February 26, 2011|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404339||176617|
NCT00404352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP27025|REbif FLEXible Dosing in Early Multiple Sclerosis (MS)|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)|REFLEX|Merck KGaA|Yes|Completed|November 2006|July 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|517|||Both|18 Years|50 Years|No|||December 2013|December 18, 2013|November 27, 2006|No|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT00404352||176616|
NCT00404599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR 15330|Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.|A Randomised, Double Blind, Parallel-Group Study of the Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.|SOS|VU University Medical Center|Yes|Recruiting|February 2007|July 2009|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||June 2008|June 9, 2008|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404599||176597|
NCT00404326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/013/ICI|Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer|A Phase II Study of Transcriptional Therapy With the DNA Demethylating Hydralazine and the HDAC Inhibitor Valproate Associated to Concomitant Cisplatin Chemoradiation in FIGO Stage III Cervical Cancer.||National Institute of Cancerología||Completed|May 2005|November 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Female|18 Years|70 Years|No|||November 2006|November 27, 2006|November 25, 2006||||No||https://clinicaltrials.gov/show/NCT00404326||176618|
NCT00404846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|906001|Effects of Hyperbaric Oxygenation Therapy on Adaptive, Aberrant and Stereotyped Behaviors in Children With Autism|||The Center for Autism and Related Disorders||Active, not recruiting|November 2006|December 2007|Anticipated|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|2 Years|14 Years|No|||May 2009|May 1, 2009|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404846||176578|
NCT00405184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-PID-05-22|Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)|A Multi-centre, Open-label, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of Ig NextGen 10% With Intragam P in Patients With Primary Immune Deficiency (PID)||CSL Limited|No|Completed|May 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00405184||176554|
NCT00405457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5261|Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms|Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms||Innovative Medical||Completed|November 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2010|February 19, 2010|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405457||176534|
NCT00405717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-2006-C002|Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel|Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention||Shenyang Northern Hospital||Completed|February 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1300|||Both|18 Years|85 Years|No|||November 2008|November 6, 2008|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00405717||176514|
NCT00405730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-65|Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo|Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (Nepafenac Vehicle) for the Prevention and Treatment of Ocular Inflammation and Ocular Pain Associated With Cataract Surgery: European Study||Alcon Research|No|Completed|November 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|227|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00405730||176513|
NCT00406224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FliOxyGen|Effect of Oxygen Breathing on Flicker Induced Blood Flow Changes in the Optic Nerve Head|||Medical University of Vienna||Completed|December 2002|December 2003||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Male|19 Years|N/A|Accepts Healthy Volunteers|||November 2006|December 1, 2006|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406224||176475|
NCT00439842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1 HL085397-05|Self-Management and Care of Heart Failure With Group Clinics (SMAC-HF)|HF Group Clinic Appointments: Rehospitalization Prevention||University of Kansas Medical Center|Yes|Completed|March 2007|November 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|198|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00439842||173949|
NCT00406861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMRCERC2004-2007627|Montelukast in ENL Reaction|Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy||The Leprosy Mission Bangladesh||Not yet recruiting|December 2006|June 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|15 Years|65 Years|No|||November 2006|December 1, 2006|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00406861||176428|
NCT00406874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPMG-1|Effect of Omega 3 Fats on Sperm Quality and Sexual Function|Effect of Omega 3 Fats on Sperm Quality and Sexual Function in Infertile Men Age 35-55||Reproductive Partners Medical Group|No|Terminated|January 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|6|||Male|35 Years|55 Years|No|||June 2013|June 3, 2013|November 30, 2006||No|reports indicating that increased folic acid intake may increase colin cancer|No||https://clinicaltrials.gov/show/NCT00406874||176427|
NCT00440726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2005-003|Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)|A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Completed|June 2006|||February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|1 Year|21 Years|No|||June 2012|June 29, 2012|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440726||173881|
NCT00440466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010414|PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients|A Randomized, Open-label, Multicenter Study of Epoetin Alfa Comparing Two Extended Dosing Regimens, Once-every-two-weeks and Once-every-four-weeks, With the Once-weekly Dosing Regimen for Maintenance Treatment in Anemic Subjects With Chronic Kidney Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|July 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|430|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|February 26, 2007|Yes|Yes||No|May 13, 2010|https://clinicaltrials.gov/show/NCT00440466||173901|
NCT00436527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10041|Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application|MetroGel 1% Hydration Study: A Kinetic Regression Study||Galderma Laboratories, L.P.|No|Completed|August 2006|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|65 Years|No|||April 2008|April 11, 2008|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436527||174198|
NCT00436540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10013|A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam|A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis||Galderma Laboratories, L.P.|No|Completed|March 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|80 Years|No|||March 2008|March 27, 2008|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436540||174197|
NCT00436800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9281|Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma|Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC)||Sanofi||Completed|March 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2009|September 17, 2009|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436800||174177|
NCT00437138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG/05/003 DISARM 2|Controlled Exposures to Air Pollution in Patients With Coronary Heart Disease|The Effects of Air Pollution on Vascular and Endogenous Fibrinolytic Function in Patients With Coronary Heart Disease||University of Edinburgh||Completed|April 2006|June 2006||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||20|||Both|18 Years|70 Years|No|||February 2007|February 16, 2007|February 16, 2007||||No||https://clinicaltrials.gov/show/NCT00437138||174153|
NCT00411138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000521447; P06.031|Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer|Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3|PORTEC-3|Leiden University Medical Center|Yes|Active, not recruiting|October 2006|December 2018|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|670|||Female|18 Years|90 Years|No|||August 2014|August 28, 2014|December 11, 2006||No||No||https://clinicaltrials.gov/show/NCT00411138||176108|
NCT00411151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-SU-2006|Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer|An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer||Johannes Gutenberg University Mainz|Yes|Completed|December 2006|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||January 2011|January 19, 2011|December 11, 2006||No||No|November 29, 2010|https://clinicaltrials.gov/show/NCT00411151||176107|
NCT00404625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1908|Infections Caused by ESbL-Producing Enterobacteriaceae in Italy|Infections Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases in Italy: Molecular Epidemiology, Clinical Impact, Treatment Outcome and Risk Factors||University of Siena||Recruiting|October 2006|November 2006||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||813|||Both|16 Years|N/A|No|||November 2006|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404625||176595|
NCT00404638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004192|Treatment of Enuresis Nocturna by Circular Muscle Exercise (Paula Method)|Treatment of Enuresis Nocturna by Circular Muscle Exercise (Paula Method)||Rabin Medical Center||Not yet recruiting|December 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|5 Years|15 Years|No|||November 2006|November 28, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404638||176594|
NCT00404885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX211-03-UV|A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis|A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis|LUMINATE|Lux Biosciences, Inc.|Yes|Completed|January 2007|May 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|108|||Both|13 Years|N/A|No|||June 2012|June 21, 2012|November 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404885||176575|
NCT00404560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070033|Detection and Characterization of Infections and Infection Susceptibility|Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility||National Institutes of Health Clinical Center (CC)||Recruiting|November 2006|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1500|||Both|2 Years|N/A|No|||April 2015|September 24, 2015|November 28, 2006||No||No||https://clinicaltrials.gov/show/NCT00404560||176600|
NCT00405171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIROCCO|Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia|Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study||University Hospital, Caen||Completed|June 2003|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00405171||176555|
NCT00438204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000531832|Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients With Stages IIIB/IV Non- Squamous, Non-Small Cell Lung Cancer (NSCLC)||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|May 2006|June 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|February 20, 2007|Yes|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00438204||174073|There were no significant limitations of the trial.
NCT00438464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00856|Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery|A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride Versus Placebo for Patients With Clinically Organ-Confined Prostate Cancer||National Cancer Institute (NCI)|No|Completed|February 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|204|||Male|18 Years|N/A|No|||June 2015|February 10, 2016|February 20, 2007|Yes|Yes||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00438464||174053|Predefined molecular signature could not easily distinguish GG 4 from GG 3 tumor areas in the placebo arm.
NCT00438711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI K07 CA104701|Surgical Decision Making Among People With Inflammatory Bowel Disease|Surgical Decision Making Among People With Inflammatory Bowel Disease||University of North Carolina, Chapel Hill|No|Completed|September 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|91|||Both|18 Years|N/A|No|Non-Probability Sample|People with inflammatory bowel disease who respond to advertisements and study        announcements or who were treatment at the recruitment site and referred by their        physician.|July 2011|July 19, 2011|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438711||174035|
NCT00438945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2006.03.HV|The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension|The Effect of Eprosartan in Patients With Essential Hypertension on Renal Tubular Function and Vasoactive Hormones During Baseline Conditions and After Activation of the Sympathetic Nervous System.||Regional Hospital Holstebro||Completed|January 2007|January 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|18|||Both|18 Years|65 Years|No|||May 2008|May 5, 2008|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438945||174017|
NCT00439517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200025-001|Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.|A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer.|FUTURE|Merck KGaA|Yes|Completed|February 2007|May 2012|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|February 22, 2007||No||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00439517||173974|Dosing of UFT/ folinic acid in the experimental arm were not directly recorded, so dosing data is not fully available in the UFOX plus cetuximab arm (36/151). Comparative conclusions on drug exposure might be impacted by a bias due to missing data.
NCT00405977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 05-055|The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block|The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block - A Randomised Electrophysiology Study|MagRoc|University Hospital, Geneva|No|Completed|May 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 15, 2011|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00405977||176494|
NCT00406237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-120|Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis|Open Label, Single Dose Study Of The Pharmacokinetics Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|November 29, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00406237||176474|
NCT00406588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.3.002|SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.||Solvay Pharmaceuticals|Yes|Completed|March 2007|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|295|||Both|30 Years|N/A|No|||July 2008|February 9, 2015|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406588||176448|
NCT00440154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6589|A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Ezetimibe-Calibrated, Multicenter Study Evaluating the Safety and Efficacy of Four Doses and Two Dose-Regimens of AVE5530 Over 4 Weeks in Patients With Mild to Moderate Primary Hypercholesterolemia||Sanofi||Completed|February 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|206|||Both|18 Years|N/A|No|||December 2008|December 15, 2008|February 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00440154||173925|
NCT00440440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-940|Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes|Effect of Androgel on Total and Regional Adipose Tissue and Lean Body Mass in Type 2 Diabetic Patients With Hypogonadism||Diabetes Center of the Southwest|No|Withdrawn|August 2009|July 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Male|35 Years|75 Years|No|||August 2015|August 6, 2015|February 23, 2007|Yes|Yes|study merged with another study|No||https://clinicaltrials.gov/show/NCT00440440||173903|
NCT00440453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS_CH_2007|Feeding the Patient at Nutritional Risk: Does the Clinical Outcome Improve?|Feeding the Patient at Nutritional Risk: Does the Clinical Outcome Improve?|EMS|University Hospital Inselspital, Berne|No|Completed|February 2007|August 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440453||173902|
NCT00440180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00016246|Aromatase Inhibitors in the Treatment of Male Infertility|The Role of Aromatase Inhibitors in the Treatment of Infertility in Obese Male||University of Utah|Yes|Terminated|March 2007|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|16 Years|80 Years|No|||May 2014|February 5, 2016|February 22, 2007|Yes|Yes|Not able meet target enrollment.|No|February 5, 2016|https://clinicaltrials.gov/show/NCT00440180||173923|
NCT00440752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL Oct-Dec/06-07|The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance|The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance in an Area of Seasonal Transmission||Tropical Medicine Research Institute|No|Completed|October 2006|December 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|Blood spots on glass fibre membranes. 0.5ml of whole blood preserved in TRI reagent.|Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample||October 2007|March 25, 2008|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00440752||173879|
NCT00437125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11127|Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease|An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease||Eli Lilly and Company||Completed|March 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|30 Years|75 Years|No|||September 2010|September 1, 2010|February 16, 2007|Yes|Yes||No|July 16, 2010|https://clinicaltrials.gov/show/NCT00437125||174154|
NCT00436865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD049454-01A2|Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study|Insulin and the Polycystic Ovary Syndrome||Virginia Commonwealth University||Active, not recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436865||174173|
NCT00437762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2005/08|Effectiveness of Botulinum Toxin Injection in the Tennis Elbow Treatment|Effectiveness of Botulinum Toxin A Injection for the Treatment of Lateral Epicondylitis Unrelieved by Usual Medical Cares : A Double Blind Randomized Controlled Trial Versus Placebo|TBA|University Hospital, Bordeaux|Yes|Completed|April 2007|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00437762||174106|
NCT00411463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608080|Psychotherapy for Bipolar II Depression, Pilot Study, Phase II|Psychotherapy for Bipolar II Depression, Pilot Study, Phase II||University of Pittsburgh|No|Completed|December 2006|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||January 2013|January 20, 2013|December 12, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00411463||176083|
NCT00437346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15312|Functional Dyspepsia - Effect of Acid-Reducing Treatment and Information.|Study of Gastroscopy Negative Dyspepsia - Effect of Acid-reducing Treatment and Information on Various Types of Dysmotility.||Helse Fonna||Active, not recruiting|January 2007|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|60 Years|No|||January 2015|January 22, 2015|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00437346||174137|
NCT00404859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 05-114|FLAME: Airway Inflammation Monitoring in Asthma and Cystic Fibrosis|Monitoring Chronic Airway Inflammation in Children With Asthma and Cystic Fibrosis||Maastricht University Medical Center||Completed|January 2006|June 2007||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal||||70|||Both|5 Years|46 Years|No|||December 2005|November 30, 2006|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00404859||176577|
NCT00404872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1363|Evaluating the Relationship Between Fatty Acids and Heart Disease|n-3 and Trans Fatty Acids and Major Cardiovascular Outcomes||Brigham and Women's Hospital||Completed|January 1989|June 2006|Actual|June 2006|Actual|N/A|Observational|N/A||||4766|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|November 27, 2006||||No||https://clinicaltrials.gov/show/NCT00404872||176576|
NCT00437931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-07-EMC|Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction|||HaEmek Medical Center, Israel||Not yet recruiting|February 2007|February 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|60|||Both|18 Years|75 Years|No|||February 2007|February 19, 2007|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437931||174094|
NCT00437944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/06|Relation Between Polymorphism in Genes Related to Kidney Disease and Renal Manifistations in Fabry Disease|||Shaare Zedek Medical Center||Completed|May 2006|July 2006||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2007|February 19, 2007|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437944||174093|
NCT00438477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-538|Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer|A Preliminary Study To Explore Subareolar Injection As The Site For Lymphatic Mapping And Sentinel Lymph Node Biopsy In Patients With Breast Cancer||M.D. Anderson Cancer Center|No|Completed|June 2005|April 2008|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|74|||Both|N/A|N/A|No|||July 2012|July 27, 2012|February 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00438477||174052|
NCT00438958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000528289|Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases|A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies||National Cancer Institute (NCI)||Completed|March 2007|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|230|||Both|16 Years|65 Years|No|||July 2009|March 4, 2014|February 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00438958||174016|
NCT00438971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000263|The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder|The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder||Massachusetts General Hospital|No|Completed|August 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||October 2013|October 29, 2013|February 20, 2007||No||No|July 19, 2013|https://clinicaltrials.gov/show/NCT00438971||174015|
NCT00439530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA Trial 0002|Pharmacologic Study of Oseltamivir in Healthy Volunteers|Pharmacologic Study of Oseltamivir in Healthy Volunteers|SEA002|Mahidol University|Yes|Completed|November 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2006|July 24, 2009|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439530||173973|
NCT00439231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070104|Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase II Study of Lenalidomide Revlimid(Registered Trademark) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2007|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|21 Years|N/A|No|||November 2013|November 14, 2013|February 22, 2007||No||No|September 19, 2011|https://clinicaltrials.gov/show/NCT00439231||173996|
NCT00440167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-57 crossover|Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine|Randomized Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer||Ludwig-Maximilians - University of Munich||Active, not recruiting|June 2006|December 2012|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|75 Years|No|||July 2012|July 5, 2012|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00440167||173924|
NCT00439855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEUS|Enoxaparin Versus Unfractionated Heparin in PCI|Enoxaparin Versus Unfractionated Heparin in PCI||Triemli Hospital||Completed|September 2003|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2100|||Both|N/A|N/A|No|||February 2007|February 23, 2007|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00439855||173948|
NCT00439868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WXL108709|A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure|A Cross-over Study to Evaluate the Effect of WELLBUTRIN XL on Intraocular Pressure in Healthy Volunteers||GlaxoSmithKline|No|Completed|February 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|February 22, 2007||||||https://clinicaltrials.gov/show/NCT00439868||173947|
NCT00440479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012361|ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.|An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)||Janssen-Cilag B.V.|No|Completed|September 2006|January 2011|Actual|January 2011|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Multiple Myeloma patients treated with bortezomib at first relapse after participation in        first line HOVON 49 or 50 clinical studies|April 2015|April 15, 2015|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440479||173900|
NCT00436839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_01833|Taxotere Prostate Cancer New Indication Registration Trial in China|An Multicenter, Randomized Study of Comparison of Docetaxel Plus Prednisone With Mitoxantrone Plus Prednisone in the Patients With Hormone-refractory (Androgen-independent) Metastatic Prostate Cancer||Sanofi||Completed|January 2007|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Male|N/A|N/A|No|||July 2012|July 5, 2012|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436839||174175|
NCT00436852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL0621|ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment|A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma||Children's Oncology Group|Yes|Active, not recruiting|January 2007|||September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|N/A|21 Years|No|||January 2016|January 29, 2016|February 15, 2007|Yes|Yes||No|November 19, 2013|https://clinicaltrials.gov/show/NCT00436852||174174|
NCT00436579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00221|Sorafenib in Treating Patients With Advanced Solid Tumors|A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Nomotensive Patients With Advanced Malignancies||National Cancer Institute (NCI)||Terminated|January 2007|||September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|110|||Both|14 Years|N/A|No|||October 2011|February 21, 2014|February 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00436579||174194|
NCT00437424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-015|A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction|A Pharmacokinetic Study of Brivanib (BMS-582664) in Subjects With Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma With Impaired Hepatic Function||Bristol-Myers Squibb|No|Completed|July 2007|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2011|May 3, 2011|February 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00437424||174131|
NCT00437437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-022|A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)|Phase I Study to Determine the Effect of a High Fat Meal on the Pharmacokinetics of BMS-540215, the Active Metabolite of Brivanib Alaninate in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|May 2000|February 2013|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|February 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00437437||174130|
NCT00437450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040759|Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid|Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid||Groupe Francophone des Myelodysplasies|Yes|Active, not recruiting|October 2004|September 2005||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||99|||Both|18 Years|N/A|No|||February 2007|November 17, 2009|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437450||174129|
NCT00437463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE498_6015|Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor|Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial||Sanofi||Completed|July 2004|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||November 2010|November 17, 2010|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437463||174128|
NCT00411892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1683|Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes|Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Terminated|November 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|December 14, 2006|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00411892||176054|
NCT00412152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3001|Oxycodone-naloxone in Relieving Opioid-related Constipation|A Randomised, Double-blind, Parallel-group, Multicentre Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Non-malignant Pain Taking Oxycodone Equivalent of >20 mg/Day and <50 mg/Day as Oxycodone/Naloxone Prolonged Release Compared to Subjects Taking Oxycodone Prolonged Release Tablets Alone.||Mundipharma Research GmbH & Co KG|No|Completed|January 2006|June 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||August 2012|August 9, 2012|December 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00412152||176035|
NCT00437060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL06N1|Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia|A Study of Neurocognitive Function in Children Treated for ALL||Children's Oncology Group|Yes|Active, not recruiting|January 2007|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|249|Samples With DNA|blood and cerebrospinal fluid|Both|1 Year|17 Years|No|Non-Probability Sample|Patients with a diagnosis of acute lymphoblastic leukemia meeting other criteria.|August 2014|August 20, 2014|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00437060||174159|
NCT00437073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107671|Brain Metastases In ErbB2-Positive Breast Cancer|Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy||GlaxoSmithKline||Terminated|May 2007|February 2010|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||October 2012|September 24, 2015|February 15, 2007|Yes|Yes|Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into    remaining arm terminated due to operational issues.|No|September 13, 2012|https://clinicaltrials.gov/show/NCT00437073||174158|
NCT00437086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529906|Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders|A Prospective Open-Label Pilot Trial of PS-341 (Bortezomib; VELCADE) for the Therapy of Symptomatic Advanced Myeloproliferative Disorders||Mayo Clinic|Yes|Completed|September 2005|November 2008|Actual|November 2008|Actual|Phase 0|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|February 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00437086||174157|
NCT00437359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBCRN-06|Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer|Antiestrogen vs Aromatase Inhibitor After Chemotherapy for Adjuvant Setting: Efficacy of Endocrine Therapy After Chemotherapy in Postoperative Adjuvant Therapy for Breast Cancer||Japan Breast Cancer Research Network|Yes|Terminated|May 2007|May 2020|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|N/A|N/A|No|||March 2012|March 28, 2012|February 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00437359||174136|
NCT00437372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06C.549|Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients|A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer||Thomas Jefferson University|Yes|Completed|March 2007|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437372||174135|
NCT00404612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX211-01-UV|A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis|A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis|LUMINATE|Lux Biosciences, Inc.|Yes|Completed|January 2007|May 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|218|||Both|13 Years|N/A|No|||October 2012|October 9, 2012|November 27, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00404612||176596|
NCT00437905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.0-12/2003|Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial|Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial||Medical University of Vienna||Terminated|June 2003|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||February 2007|February 20, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00437905||174096|
NCT00438737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000530116|Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer|Randomized Phase II Trial Evaluating the Feasibility and Tolerance of the Combination of FOLFOX With Cetuximab and the Combination of FOLFOX With Cetuximab and Bevacizumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2007|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|80 Years|No|||September 2007|September 1, 2011|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438737||174033|
NCT00438724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0103|Couples Coping With Alzheimer's Disease|A Randomized Control Trial of an Intervention for Couples Coping With Alzheimer's Disease||National Institute on Aging (NIA)||Recruiting|November 2004|November 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|200|||Both|21 Years|90 Years|No|||September 2007|September 19, 2007|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00438724||174034|
NCT00438984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2140.00|Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma|Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center|Yes|Completed|December 2006|February 2012|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||March 2012|March 14, 2012|February 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00438984||174014|
NCT00439244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2409|Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis|A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis||Novartis||Completed|December 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|412|||Female|45 Years|89 Years|No|||March 2011|March 23, 2011|February 22, 2007||||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00439244||173995|No teriparatide placebo available, Short study duration, Only bone mineral data, No bone strength or bone stucture assessment, No bone turnover markers data between 8 and 26 weeks, Study not powered for fracture outcomes.
NCT00439543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TILOPF|Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis|Inhaled Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis||Interstitial Lung Disease Study Group, Korea||Not yet recruiting|March 2007|August 2007||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|N/A|No|||February 2007|February 22, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439543||173972|
NCT00440193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11702a|Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study|Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism||Bayer|Yes|Completed|March 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3449|||Both|18 Years|N/A|No|||January 2014|January 26, 2014|February 23, 2007|Yes|Yes||No|November 22, 2012|https://clinicaltrials.gov/show/NCT00440193||173922|
NCT00436553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952A2308|Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization|A 24-month Randomized, Double-masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration||Novartis||Completed|February 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|321|||Both|50 Years|N/A|No|||March 2011|March 23, 2011|February 16, 2007|Yes|Yes||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00436553||174196|Shorten the study duration from 24 months to 12 months based on results of the European combination study MONT BLANC (CBPD952A2309).
NCT00436566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000533793|Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery|Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer||Mayo Clinic|Yes|Completed|March 2007|||April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|1||Actual|122|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|February 15, 2007|Yes|Yes||No|October 22, 2012|https://clinicaltrials.gov/show/NCT00436566||174195|
NCT00436592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-0240|Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients|Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients|Flo 24|CoAxia|Yes|Completed|February 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|85 Years|No|||February 2009|February 3, 2009|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00436592||174193|
NCT00437151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10022|Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%|An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris.||Galderma Laboratories, L.P.|No|Completed|June 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|61|||Both|13 Years|18 Years|No|||March 2008|March 27, 2008|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00437151||174152|
NCT00437177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH SPECT APO|Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)|Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence: Predictive Value for Relapse|ALC-DRD2-APO|Hospital Universitari Vall d'Hebron Research Institute||Recruiting|January 2007|June 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Male|25 Years|60 Years|No|||April 2009|April 28, 2009|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00437177||174150|
NCT00437190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRYAN(R) Cervical Disc IDE|Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF|Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease||Medtronic Spinal and Biologics|Yes|Active, not recruiting|June 2003|April 2016|Anticipated|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|494|||Both|21 Years|N/A|No|||September 2015|September 23, 2015|February 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00437190||174149|
NCT00437814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETICP.CTIL|Effect of Ketamine (Ketalar) on Intracranial Pressure|Effect of Ketamine (Ketalar) on Intracranial Pressure||Rambam Health Care Campus||Recruiting|September 2005|February 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|N/A|N/A|No|||February 2007|February 20, 2007|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437814||174103|
NCT00411905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM BAR-C-2005|Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes|Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes||Groupe Francophone des Myelodysplasies|No|Recruiting|June 2006|June 2006||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||39|||Both|18 Years|N/A|No|||December 2006|March 9, 2007|December 14, 2006||||No||https://clinicaltrials.gov/show/NCT00411905||176053|
NCT00411931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 119|A Pharmacokinetics Study of MultiHance in Pediatric Patients|A Clinical Investigation of the Pharmacokinetics and Safety of MultiHance in Patients From 2-5 Years of Age Undergoing A Clinical Indicated MRI of the CNS||Bracco Diagnostics, Inc||Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|2 Years|5 Years|No|||January 2008|January 10, 2008|December 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00411931||176052|
NCT00437099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLP-OMEGA 3|Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder|Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial.||Hospital Universitari Vall d'Hebron Research Institute||Recruiting|February 2009|September 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|102|||Both|18 Years|65 Years|No|||May 2010|May 26, 2010|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00437099||174156|
NCT00437697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008/2003|Thromboprophylaxis in Critically Ill Patients|Thromboprophylaxis in Critically Ill Patients: a Prospective, Randomized Study Comparing Anti-Xa Activities Following Subcutaneous Administration of 5000 IU and 7500 IU Dalteparin||Medical University of Vienna||Terminated|April 2003|April 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||90|||Both|19 Years|N/A|No|||February 2007|February 20, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00437697||174111|
NCT00405197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHS 2003B068|MARIS Study; Mediterranean Approach to Reduce Insulin-Resistance Study|Study on the Effect of Mono-Unsaturated Fatty Acids (MUFA) and the Mediterranean Diet on Hyperinsulinemia and Other Components of the Metabolic Syndrome||Wageningen University||Completed|November 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|60|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 10, 2007|November 28, 2006||||No||https://clinicaltrials.gov/show/NCT00405197||176553|
NCT00438230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000743|Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants|Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs|DACUS|Azienda Ospedaliera Universitaria Policlinico||Completed|November 2003|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Years|N/A|No|||February 2007|February 21, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438230||174071|
NCT00438243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8377|Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-Operative Cystoid Macular Edema.|Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-Operative Cystoid Macular Edema.||Johns Hopkins University||Active, not recruiting|May 2008|September 2010|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 14, 2008|February 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00438243||174070|
NCT00438490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001057|The Safety and Efficacy of Recombinant Human Prolactin|Phase 2 Study of Recombinant Human Prolactin Efficacy and Safety||Massachusetts General Hospital||Completed|April 2002|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|February 20, 2007|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT00438490||174051|
NCT00439283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A R C R 2003 - 01 / PO 3353|Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis|Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis: Comparison of Infusion Every 6 Weeks Versus Infusion on Demand||Association de Recherche Clinique en Rhumatologie|No|Completed|April 2003|December 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|18 Years|N/A|No|||February 2007|February 26, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439283||173992|
NCT00439582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU599|Trans Fatty Acids and Cardiovascular Risk Factors|Comparative Effect of 2 Different Sources of Trans Fatty Acid (Milk Fat vs Hydrogenated Oil)on Cardiovascular Risk Factors in Healthy Humans|TRANSFACT1|Institut National de la Recherche Agronomique||Completed|August 2005|December 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2|||46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 13, 2009|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00439582||173969|
NCT00439257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 94-001|Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)|Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)||VA Office of Research and Development|No|Completed||June 2000|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|124|||Both|N/A|N/A|No|||February 2007|April 6, 2015|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00439257||173994|
NCT00439270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-086|Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer|Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer||Bristol-Myers Squibb|No|Completed|July 2007|January 2013|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|49|||Male|18 Years|N/A|No|||February 2014|February 28, 2014|February 22, 2007|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT00439270||173993|
NCT00439556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0066|Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies|Bortezomib (Velcade) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2007|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|N/A|70 Years|No|||July 2015|July 13, 2015|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00439556||173971|
NCT00439569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01NS42361_NPTUNE01|Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III|Phase I/IIa Clinical Trial of Sodium Phenylbutyrate in Pediatric Subjects With Type II/III Spinal Muscular Atrophy|NPTUNE01|Westat|Yes|Terminated|January 2008|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|2 Years|11 Years|No|||August 2009|August 30, 2010|February 21, 2007|Yes|Yes|Due to poor compliance with study drug administration.|No|January 19, 2010|https://clinicaltrials.gov/show/NCT00439569||173970|The study was closed early due to poor study drug compliance. The sample size is therefore extremely limited.
NCT00439881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA1107570|A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose|A Study to Assess the Safety and Tolerability of SB-681323 Administered Via the Intravenous Route||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||16|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00439881||173946|
NCT00439894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060364|Ancillary Study to Protocol 20060104|Protein Phosphorylation Ancillary Study to Amgen Protocol 20060104: Open Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis||Amgen||Completed|December 2006|October 2007|Actual|August 2007|Actual|N/A|Observational|N/A||1|Actual|50|None Retained|no biospecimens will be retained.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who enrolled in to Etanercept SFP 20060104 study and signed the 20060364 informed        consent.|March 2008|March 20, 2008|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439894||173945|
NCT00440505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA4808|Effect of Nicotine on Chronic Pelvic Pain|Effect of Nicotine on Chronic Pelvic Pain||Columbia University|No|Completed|February 2004|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Female|18 Years|60 Years|No|||January 2011|January 12, 2011|February 26, 2007||No||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00440505||173898|
NCT00440765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003469|VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands|A Post Authorization Study, Designed to Learn More About the Safety and Efficacy of the Use of VELCADE (Bortezomib) in the Netherlands||Janssen-Cilag B.V.|No|Completed|November 2004|January 2012|Actual|January 2012|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|331|||Both|18 Years|N/A|No|Non-Probability Sample|Multiple Myeloma patients treated with bortezomib in second or later line of therapy|January 2014|January 13, 2014|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440765||173878|
NCT00440778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASY-MI|A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI|A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute Myocardial Infarction: The EASY-MI Pilot Study.|EASY-MI|Laval University|Yes|Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|105|||Both|18 Years|N/A|No|||November 2011|November 23, 2011|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440778||173877|
NCT00437164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADG106149|A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus|A Randomized, Double-blind, Parallel, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of Oral GW677954 Capsules (15 mg) in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Terminated|September 2006|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1|||Both|30 Years|65 Years|No|||May 2011|May 31, 2012|February 16, 2007||Yes|Company decision not related to safety.|||https://clinicaltrials.gov/show/NCT00437164||174151|
NCT00436891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0081|Streptococcal Infections in Fiji - Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 4 -The Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2007|April 2007||||N/A|Observational|Time Perspective: Prospective||||550|||Both|N/A|12 Months|Accepts Healthy Volunteers|||October 2007|May 1, 2008|February 16, 2007||||No||https://clinicaltrials.gov/show/NCT00436891||174171|
NCT00437476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamon 1|Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy|Pilot, Multicenter, Randomized Study on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV ARV-Naive Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin and Pegylated Interferon||IRCCS San Raffaele||Recruiting|February 2007|December 2010|Anticipated|July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2009|February 5, 2009|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437476||174127|
NCT00406419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT3985g|A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)|A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment|STAGE|Genentech, Inc.||Terminated|December 2006|April 2015|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1015|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 30, 2006|Yes|Yes|Based on analysis of results and consideration of available treatments, the overall benefit to    risk profile of ocrelizumab was not favorable in RA.|No||https://clinicaltrials.gov/show/NCT00406419||176461|
NCT00406432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR104075|A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects|A Steady-state Study to Assess the Pharmacokinetic Profile of Paroxetine After 14 Day Repeated Daily Dosing of the Controlled Release Paroxetine Tablet (25 mg) in Healthy Chinese Subjects||GlaxoSmithKline||Completed|May 2006|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 30, 2006||||No||https://clinicaltrials.gov/show/NCT00406432||176460|
NCT00418600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECT00406|A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis|A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® Capsules When Converting From Hectorol® Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis||Sanofi||Completed|November 2006|August 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|January 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00418600||175549|
NCT00437385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ek224-05b|Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients|Phase 1 Study: Evaluation of Three Continuation Therapies After Acute Electroconvusive Therapy (ECT) Concerning Efficacy and Cognition in Severly Depressed Patients|EffECT|Charite University, Berlin, Germany|Yes|Completed|March 2005|March 2011|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|90 Years|No|||November 2011|November 8, 2011|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437385||174134|
NCT00437918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDC-07-01|The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients|Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy||Inje University|Yes|Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|40 Years|80 Years|No|||March 2008|March 21, 2008|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437918||174095|
NCT00438217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-EDG 01|Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children|Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children|CPP-EDG 01|University of Pisa||Recruiting||||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||February 2007|February 21, 2007|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00438217||174072|
NCT00439309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAS-06-001|Study to Evaluate Safety & Effectiveness of Vascular Sealant System|Randomized Study to Evaluate Safety & Effectiveness of Vascular Sealant to Control Suture Line Bleeding||Integra LifeSciences Corporation|Yes|Terminated|April 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|February 21, 2007|No|Yes|Business Decision|No|November 7, 2013|https://clinicaltrials.gov/show/NCT00439309||173990|
NCT00439010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-39 001|Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects|Evaluation of [123I] AV39 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Molecular NeuroImaging|No|Completed|February 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 22, 2008|February 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00439010||174013|
NCT00439023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.2007.01.EBP|Glucose in Dialysis Water in Non-diabetics|Effect of Glucose in Dialysis Water on Blood Pressure and Vasoactive Hormones in Dialysis Patients||Regional Hospital Holstebro|No|Completed|May 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2007|September 14, 2015|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00439023||174012|
NCT00439296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2005-001|ABT-751 With Chemotherapy for Relapsed Pediatric ALL|A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL)||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|May 2006|September 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|21 Years|No|||November 2012|November 28, 2012|February 21, 2007|Yes|Yes|The study was stopped due to poor accrual and lack of funding.|No||https://clinicaltrials.gov/show/NCT00439296||173991|
NCT00439595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARS-Handeni|A Trial of 2 'Point of Care' Diagnostic Methods to Improve Detection and Treatment of Anaemia in African Children|A Cluster Randomised Trial of Different Methods of Haemoglobin Measurement to Improve Recognition and Treatment of Childhood and Pregnancy-related Anaemia in a Malaria Endemic Area of North East Tanzania.|EARS|London School of Hygiene and Tropical Medicine|No|Completed|February 2007|May 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|450|||Both|N/A|5 Years|No|||May 2010|May 26, 2010|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439595||173968|
NCT00439608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-EG-203|BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer|BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091||Brown University|Yes|Completed|October 2004|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|February 22, 2007|Yes|Yes||No|May 9, 2013|https://clinicaltrials.gov/show/NCT00439608||173967|
NCT00439907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2005-07|Comparison of Overlap and End-to-end Repair in Anal Sphincter Rupture During Delivery|A Prospective, Randomized Study Comparing the Outcome of Overlap and End-to-end Repair in Anal Sphincter Rupture During Delivery||Helse Stavanger HF|No|Completed|February 2005|April 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|N/A|No|||August 2010|July 27, 2015|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00439907||173944|
NCT00440206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002060-01H|Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes|Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes||Ottawa Hospital Research Institute||Completed|September 2001|December 2001||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||50|||Both|18 Years|N/A|No|||February 2007|February 26, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00440206||173921|
NCT00440492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3175A3-104|Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis|An Open-Label Study To Evaluate The Potential Pharmacokinetic Interaction Between PLA-695 And Methotrexate When Coadministered Orally To Adult Subjects With Rheumatoid Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2006|November 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||December 2007|December 11, 2007|February 23, 2007||||||https://clinicaltrials.gov/show/NCT00440492||173899|
NCT00440518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0906|A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.|SP906|UCB Pharma|No|Completed|February 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|218|||Both|18 Years|65 Years|No|||September 2011|September 19, 2014|February 23, 2007|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00440518||173897|
NCT00436878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71095|Intake Promoting Effects of Large Portions in Children|||Temple University||Recruiting|October 2005|||July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||June 2010|February 4, 2011|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436878||174172|
NCT00436904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529809|Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia|Antibody Therapy With Alemtuzumab and Rituximab for Initial Treatment of High Risk Chronic Lymphocytic Leukemia||Mayo Clinic|Yes|Completed|December 2004|November 2011|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|February 15, 2007|Yes|Yes||No|September 16, 2011|https://clinicaltrials.gov/show/NCT00436904||174170|
NCT00437203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8211001|PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine|Phase I Study of PF-00477736 With Gemcitabine In Patients With Advanced Solid Malignancies||Pfizer|No|Terminated|December 2006|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|February 16, 2007|No|Yes|See termination reason in detailed description.|No|March 6, 2012|https://clinicaltrials.gov/show/NCT00437203||174148|The study was prematurely terminated due to business reasons.
NCT00406133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-2402|Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes|A Randomized Clinical Trial to Assess the Efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) in the Management of Type 1 Diabetes||JDRF Artificial Pancreas Project|Yes|Completed|December 2006|February 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|451|||Both|8 Years|N/A|No|||September 2010|September 30, 2010|November 30, 2006||No||No|May 11, 2009|https://clinicaltrials.gov/show/NCT00406133||176482|
NCT00406146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91199 / 104. DAN.8-864|Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children|||University of Ghana Medical School||Active, not recruiting|October 2004|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|6 Months|14 Years||||November 2006|November 30, 2006|November 13, 2006||||No||https://clinicaltrials.gov/show/NCT00406146||176481|
NCT00418912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4329-RG-CTIL|Family Study in Schizophrenia|||Sheba Medical Center||Recruiting|March 2007|January 2009|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|schizophrenia|February 2008|February 13, 2008|January 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00418912||175525|
NCT00419471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIIS-11592A|Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome|Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial||Chonnam National University Hospital|Yes|Completed|May 2007|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|85 Years|No|||June 2013|June 11, 2013|January 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00419471||175482|
NCT00437983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Memory_PS 001|The Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment||Enzymotec||Completed|April 2007|September 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|157|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||January 2010|January 3, 2010|February 20, 2007||No||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00437983||174090|
NCT00437736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP1001|A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors|Phase I Dose Finding and Pharmacokinetic Study of Intravenous APO010, a Recombinant Form of Human Fas Ligand, in Patients With Solid Tumors|AP1001|Onxeo|Yes|Completed|February 2007|May 2009|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437736||174108|
NCT00437749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBA-TP0301|A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer|Phase 3, Randomized, Double-Blind, Placebo-controlled Study of CBT-1 and Paclitaxel/Carboplatin in Patients With Inoperable Non-Small Cell Lung Cancer||CBA Research||Terminated|August 2001|November 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|N/A|No|||September 2011|September 8, 2011|February 19, 2007|Yes|Yes|slow accrual rate; interim accrual objective met|No||https://clinicaltrials.gov/show/NCT00437749||174107|
NCT00438256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-248|Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer|Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|49|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438256||174069|
NCT00437957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14886|Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases|Phase I Trial Of Temozolomide Combined With The Histone Deacetylase Inhibitor Valproic Acid (VPA) And Whole Brain Radiation Therapy (WBR) For Brain Metastases From Solid Tumors In Adults||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|December 2006|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2011|November 21, 2013|February 19, 2007||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00437957||174092|
NCT00437671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060002|Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels|Pharmacokinetics Of Active And Passive Tetanus Immunization Given Concurrently In Subjects With No Known Primary Immunization History Or In Subjects With Tetanus Antibody Levels Below Protective Levels||Grifols Therapeutics Inc.|No|Terminated|March 2007|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|February 20, 2007|No|Yes|Study terminated for cGCP non-compliance. Analyses could not be performed.|No||https://clinicaltrials.gov/show/NCT00437671||174113|
NCT00437684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamon 2|Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy|A Pilot, Open Label, Multicenter, Randomized Clinical Trial on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin and Pegylated Interferon||IRCCS San Raffaele||Recruiting|February 2007|December 2010|Anticipated|July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2009|February 5, 2009|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437684||174112|
NCT00439062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-89861966|Treatment of Rheumatoid Arthritis With Roxithromycin|Treatment of Rheumatoid Arthritis With Roxithromycin||Nazilli State Hospital||Completed|June 2006|June 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||February 2007|February 20, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00439062||174009|
NCT00439075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508703|OUT-OF-HOSPITAL CPAP STUDY|Randomised Controlled Comparison of Continuous Positive Airway Pressure (CPAP) With Standard Treatment in Out-of-Hospital Patients With Acute Cardiogenic Pulmonary Edema.||University Hospital, Toulouse|No|Completed|October 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|124|||Both|18 Years|N/A|No|||July 2007|July 25, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439075||174008|
NCT00439621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-24|Safety Study of Anti-IgE Immunotherapy in Allergic Patients|A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients||Resistentia Pharmaceuticals AB|Yes|Completed|February 2007|August 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|42|||Male|18 Years|50 Years|No|||August 2008|August 13, 2008|February 22, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00439621||173966|
NCT00439946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-PH-410|Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH|Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) Using the Crono Five Ambulatory Infusion Pump in Patients With Stable Pulmonary Arterial Hypertension (PAH): Safety, Efficacy and Treatment Satisfaction||United Therapeutics|No|Terminated|February 2007|March 2011|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||June 2013|June 12, 2013|February 22, 2007|Yes|Yes|Study closed due to limited availability of eligible subjects and competition by for    enrollment by other studies|No|March 26, 2013|https://clinicaltrials.gov/show/NCT00439946||173941|The main limitations of this study are the modest sample size and relatively short duration of follow-up.
NCT00439959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSP108233|Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK625433 in Healthy Subjects and in Subjects Who Are Chronically Infected With Hepatitis C.||GlaxoSmithKline|No|Terminated|October 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|February 22, 2007||||||https://clinicaltrials.gov/show/NCT00439959||173940|
NCT00440232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/FHA-FRV/ 01|A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting|A Pilot Trial Examining the Safety and Efficacy of Frovatriptan as a Preemptive Treatment for Fasting-Induced Migraine Headache||Thomas Jefferson University||Completed|July 2007|September 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|No|||May 2011|May 23, 2011|February 22, 2007|Yes|Yes||No|October 26, 2010|https://clinicaltrials.gov/show/NCT00440232||173919|
NCT00440245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-REB 06-231|Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease|Bronchoprotection of Salbutamol in Asthma and COPD||University of Saskatchewan|No|Recruiting|February 2007|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00440245||173918|
NCT00439920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL0496|GIMEMA LAL 0496: High-Dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.|GIMEMA LAL 0496: High-Dose Anthracycline in the Induction Regimen for the Treatment of Adult Acute Lymphoblastic Leukemia. A Prospective Multicentric GIMEMA Trial.||Gruppo Italiano Malattie EMatologiche dell'Adulto||Completed|October 1996|May 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|16 Years|60 Years|No|||September 2000|February 23, 2007|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00439920||173943|
NCT00439933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Tafel|Weight Loss in Obese Children and Adolescents and Its Effect on Improvement of Destructive Changes in Blood Vessels|Weight Loss in Obese Children and Adolescents and Its Effect on Improvement of Endothelial Dysfunction||Heidelberg University||Recruiting|April 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|180|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||March 2007|May 8, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439933||173942|
NCT00440219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0001-A|The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy.|The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy.||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|Yes|Completed|November 2010|June 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|February 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00440219||173920|
NCT00436605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00219|Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma|A Phase 2 Study of Dasatinib in Advanced Melanoma||National Cancer Institute (NCI)||Completed|December 2006|November 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||October 2011|April 29, 2014|February 15, 2007|Yes|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00436605||174192|
NCT00440804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCR-00-01/CB88|Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA|Randomized, Double-Blind Study of Ibuprofen L-Lysine Intravenous Solution in Premature Infants for the Early Treatment of Patent Ductus Arteriosus||Farmacon|Yes|Completed|December 2002|August 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|28 Weeks|34 Weeks||||February 2007|February 23, 2007|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00440804||173875|
NCT00436618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC048G|Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment|Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma||Mayo Clinic|Yes|Completed|August 2005|||December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|277|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|February 15, 2007|Yes|Yes||No|May 1, 2013|https://clinicaltrials.gov/show/NCT00436618||174191|
NCT00406484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DA013108-04|Brief Introductory Therapy for Opioid Dependence|Brief Introductory Therapy for Opioid Dependence||Yale University|No|Completed|September 2004|September 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00406484||176456|
NCT00406809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-814|A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies|A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies||AbbVie|No|Active, not recruiting|November 2006|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|110|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|November 30, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00406809||176432|
NCT00407043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donnenfeld Review 1|Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis|A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine||Ophthalmic Consultants of Long Island|Yes|Completed|November 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|5|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 20, 2011|November 30, 2006||No||No||https://clinicaltrials.gov/show/NCT00407043||176414|
NCT00407056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJE2079/3-02-PC|Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis|Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis).||Sirion Therapeutics, Inc.||Completed|August 2002|June 2003||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|12 Years|N/A|No|||November 2006|November 29, 2006|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00407056||176413|
NCT00418613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0633-009|A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MK0633 in Patients With COPD||Merck Sharp & Dohme Corp.||Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|40 Years|75 Years|No|||September 2015|September 2, 2015|January 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00418613||175548|
NCT00419484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309|Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes|||Dokkyo Medical University||Completed|March 2004|July 2008||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||1000|||Both|20 Years|70 Years|No|||January 2007|January 5, 2007|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419484||175481|
NCT00419744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589CC00003|A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD|A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects||AstraZeneca||Completed|January 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1200|||Both|40 Years|N/A|No|||August 2010|August 18, 2010|January 5, 2007||||No|August 18, 2010|https://clinicaltrials.gov/show/NCT00419744||175462|
NCT00438035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI 2002|Heart Rate Variability and Postoperative Pain|Evaluation of Postoperative Pain by Spectral Analysis of ECG R-R Intervals|ECG-Spectral|University Hospital, Bordeaux|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|106|||Both|18 Years|N/A|No|||February 2007|August 11, 2008|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00438035||174086|
NCT00437996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.424|Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial|Epidural Analgesia During Labour. Impact of Clonidine Addition to Levobupivacaine and Sufentanil||Hospices Civils de Lyon||Completed|February 2007|January 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|85|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 26, 2009|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437996||174089|
NCT00438009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSX-X-03|A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients|A Phase I, Open Label, Cohort Study of Two Doses of Cavatak (Coxsackievirus Type A21) Given Intratumourally in Stage IV Melanoma Patients.||Viralytics|Yes|Completed|February 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00438009||174088|
NCT00438503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.2007.02.EBP|Glucose in Dialysis Water in Diabetics With Chronic Renal Failure|Effect of Glucose in Dialysis Water in Diabetics With Chronic Renal Failure on Blood Pressure, Pulse Rate, Plasma Glucose, Plasma Concentrations of Insulin, Growth Hormone, Renin, Angiotensin II, Endothelin and Body Temperature||Regional Hospital Holstebro|No|Completed|May 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2007|September 14, 2015|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438503||174050|
NCT00438750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001157|Comparison of Occupational Therapy and Home Exercises for Adults With Operatively Treated Distal Radius Fractures|Prospective Randomized Comparison of Occupational Therapy vs Home Exercises After Volar Plate Fixation of a Fracture of the Distal Radius||Massachusetts General Hospital||Completed|January 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|February 20, 2007||No||No|March 27, 2012|https://clinicaltrials.gov/show/NCT00438750||174032|
NCT00408187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISA05-25|Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients|A Phase III, Randomized, Multicentre, Double-Blind, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients|ESSENCE|Aurinia Pharmaceuticals Inc.|Yes|Completed|December 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|642|||Both|18 Years|N/A|No|||July 2009|July 29, 2009|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00408187||176326|
NCT00408200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805346HUP|A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation|A Randomized Trial to Assess the Utility of Empirical Anti-Arrhythmic Drug Therapy to Prevent Atrial Arrhythmia During the 6 Weeks Following Pulmonary Vein Isolation to Treat Paroxysmal Atrial Fibrillation||University of Pennsylvania||Completed|November 2006|June 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||June 2012|January 31, 2013|December 1, 2006||No||No|September 12, 2012|https://clinicaltrials.gov/show/NCT00408200||176325|
NCT00439322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 96-030|Post Traumatic Stress Disorder Among VA Ambulatory Care Patients|Post Traumatic Stress Disorder Among VA Ambulatory Care Patients||VA Office of Research and Development|No|Completed||September 2000|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|473|||Both|N/A|N/A|No|||February 2007|April 6, 2015|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00439322||173989|
NCT00439335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0089|Higher Dose Intradermal H5 Vaccine|A Phase I/II Randomized, Double-Blinded Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Immunization With Inactivated Subvirion Influenza A/H5N1 Vaccine Administered by the Intradermal or the Intramuscular Route Among Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2007|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|227|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2009|March 28, 2013|February 22, 2007|Yes|Yes||No|March 24, 2009|https://clinicaltrials.gov/show/NCT00439335||173988|
NCT00439634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6726|Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia|A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia.|CONNECT|Sanofi||Terminated|February 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|873|||Both|18 Years|65 Years|No|||May 2010|May 11, 2010|February 22, 2007|Yes|Yes|Following a pre-specified interim analysis and Data Monitoring Committee recommendation due to    insufficient level of efficacy|No||https://clinicaltrials.gov/show/NCT00439634||173965|
NCT00439972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28565-D|Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity|Comparison of Oral and Patch Forms of Hormonal Contraception on Plasma Lipoproteins, Glycemia, Clotting Factors, Indices of Inflammation and Vascular Reactivity||University of Washington|Yes|Active, not recruiting|February 2007|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|36|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|February 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00439972||173939|
NCT00440531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V232-059|Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)|A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process||Merck Sharp & Dohme Corp.||Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|540|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|February 26, 2007|Yes|Yes||No|November 11, 2008|https://clinicaltrials.gov/show/NCT00440531||173896|
NCT00440791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-54|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon||Given Imaging Ltd.|No|Terminated|June 2006|July 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|40|||Both|18 Years|N/A|No|||August 2007|August 1, 2007|February 26, 2007|||Interim analysis|No||https://clinicaltrials.gov/show/NCT00440791||173876|
NCT00440817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011239|An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.|A Review of Reports of Lymphoma Occurring in Patients With Rheumatoid Arthritis or Crohn's Disease in Centocor-Sponsored and Centocor-Supported Disease Registries||Centocor Ortho Biotech Services, L.L.C.|No|Completed|February 2006|August 2006|Actual|August 2006|Actual|Phase 4|Observational|Time Perspective: Retrospective||1|Actual|120|||Both|N/A|N/A|No|||April 2014|April 9, 2014|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440817||173874|
NCT00436917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC05C8|Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer|Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy||Mayo Clinic|Yes|Active, not recruiting|April 2006|December 2015|Anticipated|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|60|||Female|18 Years|N/A|No|||March 2015|March 23, 2015|February 15, 2007|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00436917||174169|
NCT00405860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1679-02|CellCept in p-ANCA Vasculitis|A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction.||Mayo Clinic||Completed|December 2002|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|N/A|No|||March 2011|March 21, 2011|November 29, 2006||||No||https://clinicaltrials.gov/show/NCT00405860||176503|
NCT00406783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04683|Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)||Merck Sharp & Dohme Corp.|No|Completed|August 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|547|||Both|12 Years|N/A|No|||May 2015|May 15, 2015|November 29, 2006||No||No|November 21, 2008|https://clinicaltrials.gov/show/NCT00406783||176434|
NCT00407706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 6-218 S|Using Test of SCM for Detection Breast Cancer|Breast Cancer- Early Detection of Cancer Disease and Pre-Cancer Disease, and in Women That Are at High Risk for Developing Breast Cancer by Identifying Lymphocytes Previously Exposed to Specific Cancer Antigen.||Ziv Hospital||Recruiting|December 2006|December 2010||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||180|||Female|18 Years|50 Years|No|||December 2006|December 4, 2006|December 4, 2006||||No||https://clinicaltrials.gov/show/NCT00407706||176363|
NCT00418626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2116|Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function|A Phase I, Single Center, Open-label, Single Oral Dose, Study to Assess the Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function||Novartis||Completed|November 2006|||September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|January 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00418626||175547|
NCT00418899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0974|Gliogene: Brain Tumor Linkage Study|Gliogene: Brain Tumor Linkage Study||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2004|||February 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|17080|Samples With DNA|About 3 tablespoons of blood will be drawn and if unable to donate blood, researchers will      collect a saliva sample.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants with a glioma or a family member of someone with a glioma.|March 2016|March 17, 2016|January 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00418899||175526|
NCT00419757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5896C00021|An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma|A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma||AstraZeneca||Completed|January 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|558|||Both|12 Years|N/A|No|||August 2012|August 24, 2012|January 5, 2007|No|Yes||No|May 20, 2009|https://clinicaltrials.gov/show/NCT00419757||175461|
NCT00419770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12842|The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study|The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study||Los Angeles Biomedical Research Institute|Yes|Completed|October 2007|December 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|2 Years|N/A|No|||August 2011|September 2, 2011|January 5, 2007|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00419770||175460|
NCT00438321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001526|Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome|Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome||Massachusetts General Hospital||Recruiting|September 2006|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Male|50 Years|75 Years|No|||May 2010|May 3, 2010|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438321||174064|
NCT00438516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1HD043492|Follow-up of Families in Early Preventive Intervention|Follow-up of Families in Early Preventive Intervention|MemphisYear9|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|June 2000|March 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|627|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2007|January 9, 2008|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438516||174049|
NCT00438542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMWadpkcb|HMW-Adiponectin is Raised in Newborns|||University of Oslo||Completed|July 2003|July 2006||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|N/A|30 Minutes|No|||February 2007|February 21, 2007|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00438542||174048|
NCT00438763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002327|CMC Arthritis - Neoprene Vs. Thermoplast Short Opponens Splinting|Prospective Randomized Comparison: Neoprene Vs. Thermoplast Short Opponens Splinting. Outcomes After a Five-week to Sixteen-week Treatment Trial.||Massachusetts General Hospital||Completed|December 2005|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the MGH Hand and Upper Extremity service.|September 2013|September 25, 2013|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438763||174031|
NCT00404274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV105097|A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers|An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin When Co-administered With Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects.||GlaxoSmithKline|No|Completed|November 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 27, 2006||||||https://clinicaltrials.gov/show/NCT00404274||176622|
NCT00439036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA019436-01|Acceptance Therapy During Methadone Detoxification|Acceptance Therapy During Methadone Detoxification||The University of Texas Health Science Center, Houston|Yes|Completed|July 2006|December 2012|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439036||174011|
NCT00439049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09262-13|Substance Abuse Pre-Treatment Screening Study|General Evaluation of Eligibility for Substance Abuse/Dependence Research||The University of Texas Health Science Center, Houston|Yes|Recruiting|October 2005|September 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|7500|Samples With DNA|whole blood, serum, white cells|Both|18 Years|60 Years|No|Non-Probability Sample|Cocaine Dependent Subjects|December 2015|December 28, 2015|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439049||174010|
NCT00439647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446M2309|Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis|A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men||Novartis||Completed|December 2006|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1199|||Male|50 Years|85 Years|No|||October 2011|October 10, 2011|February 22, 2007||No||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00439647||173964|
NCT00439660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIL/ROTA/014|Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old|Double-Blind Randomized Placebo-Controlled Dose Escalating Phase Ib/IIa Study to Evaluate the Safety and Immunogenicity of Live Attenuated Oral Rotavirus Vaccine 116E in Healthy Non-Malnourished Infants 8 to 20 Weeks of Age||Bharat Biotech International Limited||Active, not recruiting|December 2006|November 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||540|||Both|8 Weeks|20 Weeks|Accepts Healthy Volunteers|||February 2007|March 21, 2007|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00439660||173963|
NCT00439998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-03|Ultrasound Imaging For Facilitating Labour Epidurals in Obese Parturients|Ultrasound Imaging For Facilitating Labour Epidurals in Obese Parturients||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|54|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2009|July 29, 2009|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00439998||173937|
NCT00440011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-LUM01|Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%|||Allergan||Completed|August 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|February 22, 2007|Yes|Yes||No|September 25, 2008|https://clinicaltrials.gov/show/NCT00440011||173936|
NCT00439985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK074580|Improving Metabolic Control in Diabetic Young Children|Improving Metabolic Control in Diabetic Young Children||Icahn School of Medicine at Mount Sinai|No|Terminated|September 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|7 Years|11 Years|No|||June 2011|June 6, 2011|February 23, 2007||No|decreased enrollment. (there are no data results for this study)|No||https://clinicaltrials.gov/show/NCT00439985||173938|
NCT00440258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-AP-404-207-1|Cabergoline Reduces OHSS|Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|April 2004|July 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2007|February 26, 2007|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00440258||173917|
NCT00440271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.98|SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC|SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care||Boehringer Ingelheim||Terminated|February 2007|||October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||January 2014|June 17, 2014|February 26, 2007|Yes|Yes||No|October 20, 2009|https://clinicaltrials.gov/show/NCT00440271||173916|The study was terminated early due to low patient enrollment, and, therefore, no analysis was performed on the primary and secondary endpoints
NCT00440544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMUVA-01|A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)|A Phase I Trial of the Safety and Immunogenicity of an Adjuvated TB Subunit Vaccine (Ag85B-ESAT6 + LTK63) Administered at 0 and 2 Months|TMUVA-01|St George's, University of London|Yes|Terminated|January 2007|February 2008|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 31, 2008|February 26, 2007||No|Safety Issues|No||https://clinicaltrials.gov/show/NCT00440544||173895|
NCT00405587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX06-02|Safety Study of PLX4032 in Patients With Solid Tumors|A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX4032 in Patients With Solid Tumors||Plexxikon|No|Active, not recruiting|November 2006|September 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|November 28, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00405587||176524|
NCT00406445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070030|Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome|Metabolic Regulation by Tumor Suppressor p53 in Li-Fraumeni Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|November 2006|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|246|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|November 25, 2006||No||No||https://clinicaltrials.gov/show/NCT00406445||176459|
NCT00406796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3565s|Lucentis for Central Retinal Vein Occlusion (CRVO)|FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease||California Retina Consultants|Yes|Completed|January 2006|October 2010|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|November 29, 2006||No||No||https://clinicaltrials.gov/show/NCT00406796||176433|
NCT00407979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN CATH 02|Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis|Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2005|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|80|Samples With DNA|Blood, skin, and saliva samples will be retained|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Generally healthy individuals|April 2014|April 1, 2014|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00407979||176342|
NCT00407992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFGGL113006|An Italian Randomized Open-label Study of Occipital Nerve Stimulation in the Treatment of Chronic Migraine Headache|An Italian, Randomized, Single-centre, Open-label Study of Occipital Nerve Stimulation in the Treatment of Chronic Migraine Headache|Migraine|Ospedale Sacro Cuore - Don Calabria||Completed|December 2006|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|December 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00407992||176341|
NCT00419185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH|Indocyanine Green or Trypan Blue for Delamination of the Internal Limiting Membrane in Macular Hole Surgery|Internal Limiting Membrane (ILM)- Peeling With Indocyanine Green or Trypan Blue in Macular Hole Surgery: A Prospective Randomized Trial||University of Luebeck||Completed|April 2003|January 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||January 2007|January 5, 2007|January 5, 2007||||No||https://clinicaltrials.gov/show/NCT00419185||175504|
NCT00420030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charles University, Prague|Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock|Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial.||Charles University, Czech Republic|Yes|Completed|September 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2009|June 22, 2009|January 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00420030||175440|
NCT00407667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TraGAT|Transcranial Galvanic Stimulation After Stroke|Transcranial Direct Current Stimulation (tDCS) of the Lesioned or Non-lesioned Hemisphere Plus Computer-assisted Arm Trainer: a Randomized, Placebo-controlled Double-blind Multi-centre Study in Patients With Severe Arm Paresis Early After Stroke|TraGAT|Charite University, Berlin, Germany||Completed|December 2006|December 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|80 Years|No|||November 2006|March 18, 2011|December 1, 2006||No||No||https://clinicaltrials.gov/show/NCT00407667||176366|
NCT00438269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AATICC Pilot Study|Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection|Appropriate Antimicrobial Therapy in Critical Care: A Pilot Randomized Controlled Trial||Canadian Critical Care Trials Group||Completed|February 2003|March 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||February 2007|February 21, 2007|February 17, 2007||||No||https://clinicaltrials.gov/show/NCT00438269||174068|
NCT00438282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0036|Age 6 Test of Home Visits by Nurses vs Paraprofessionals|Age 6 Test of Home Visits by Nurses vs Paraprofessionals|DenverY06|University of Colorado, Denver|Yes|Completed|March 2001|December 2007|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|604|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2013|April 30, 2013|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438282||174067|
NCT00438555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc004055ctil|Randomized, Controlled, Open, Comparative Intervention Study for Obesity Prevention in Children|Randomized, Controlled, Open, Comparative Intervention Study for Obesity Prevention in Children|4055obesityprv|Rabin Medical Center||Completed|October 2006|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|248|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||July 2014|March 18, 2015|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438555||174047|
NCT00438776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1D-US-X165|Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling|||Lindner Center of HOPE||Completed|February 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|75 Years|No|||December 2011|December 12, 2011|February 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00438776||174030|
NCT00438789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-002|The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol||EMBRACE|Alexion Pharmaceuticals||Approved for marketing||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A||||September 2011|May 5, 2014|February 20, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00438789||174029|
NCT00438802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000530071|Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma|A Phase I Study of Alefacept (AmeviveTM) in the Treatment of Cutaneous T-cell Lymphoma and Peripheral T-cell NHL||Mayo Clinic|Yes|Active, not recruiting|March 2006|May 2018|Anticipated|July 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|February 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00438802||174028|
NCT00438815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVP2006-1|Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks|LEVP2006-1 CHANGE 2 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Safety/Efficacy Repeat Exposure Study of C1INH-nf (Human) in the Treatment of Acute HAE Attacks|CHANGE 2|Shire||Completed|September 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|1 Year|N/A|No|||March 2014|March 19, 2014|February 21, 2007|Yes|Yes||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00438815||174027|
NCT00404287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BES04|Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.|Double Blind Randomized Phase IV Clinical Trial to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in the Haemodynamic Progression of Degenerative Aortic Stenosis. The AORTICA 1 Study.||AORTICA Group|Yes|Suspended|October 2006|November 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|164|||Both|18 Years|N/A|No|||October 2014|October 13, 2014|November 27, 2006||No|Funding not enough to complete the study|No||https://clinicaltrials.gov/show/NCT00404287||176621|
NCT00439348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.02.01|Over-the-Counter Medication Usage|Improving Over-the-counter Medication Compliance.||Florida Hospital||Completed|February 2007|February 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|246|||Female|19 Years|50 Years|Accepts Healthy Volunteers|||November 2009|November 20, 2009|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439348||173987|
NCT00439361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0527|Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma|Phase-I Study of Bortezomib (VELCADE) Plus ICE (Ifosfamide, Carboplatin, Etoposide) for Patients With Relapsed Classical Hodgkin Lymphoma||M.D. Anderson Cancer Center|No|Completed|February 2007|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|16 Years|N/A|No|||July 2012|July 5, 2012|February 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00439361||173986|
NCT00404261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108835|Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).|An Open Label, Multicentre Study to Evaluate Patient Satisfaction With Fluticasone/Salmeterol HFA MDI With Counter in Adult Subjects (18 Years of Age and Older) With Asthma or COPD.||GlaxoSmithKline|No|Completed|January 2007|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|November 27, 2006||No||No||https://clinicaltrials.gov/show/NCT00404261||176623|
NCT00404495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5961166|Combination of Irinotecan and Temozolomide in Children With Brain Tumors.|Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.||Pfizer|No|Completed|April 2007|December 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|6 Months|18 Years|No|||April 2012|April 16, 2012|November 27, 2006|Yes|Yes||No|January 13, 2012|https://clinicaltrials.gov/show/NCT00404495||176605|This study had one treatment arm but two distinct cohorts with different diagnostics and treatment durations.
NCT00404755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5294R|Dichotic Listening as a Predictor of Medication Response in Depression|Dichotic Listening as a Predictor of Medication Response in Depression||New York State Psychiatric Institute|No|Completed|July 2006|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|65 Years|No|||April 2012|April 26, 2012|November 28, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT00404755||176585|
NCT00428051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-900|Colombia Epidemiologic Surveillance Study|Multinational Latin American Epidemiologic Surveillance For Invasive Pneumococcal Disease|LEAP II|Pfizer|No|Terminated|September 2006|October 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|32867|Samples With DNA|Cerebral Spinal Fluid Pleural Fluid S. pneumoniae isolates|Both|N/A|36 Months|No|Probability Sample|Epidemiologic study that will include children 28 days to 36 months of age that meet        entrance criteria|October 2011|October 26, 2011|January 25, 2007||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00428051||174837|
NCT00436930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000530026|Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma|Randomized Phase II Trial of Autologous Vaccines Consisting of Adjuvant GM-CSF Plus Proliferating Tumor Cells Versus GM-CSF Plus Dendritic Cells Loaded With Proliferating Tumor Cells in Patients With Metastatic Melanoma (MAC-VAC)||National Cancer Institute (NCI)||Completed|December 2006|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|N/A|No|||June 2009|January 9, 2014|February 15, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00436930||174168|
NCT00436943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-12-021|Smoking Cessation Program: A Quality Improvement Trial in a Resident-Based Outpatient Clinic|Smoking Cessation Program: A Quality Improvement Trial in a Resident Based Outpatient Clinic||Atlantic Health System||Terminated|January 2007|January 2008|Anticipated|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|900|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient clinic|July 2010|July 9, 2010|February 16, 2007||||No||https://clinicaltrials.gov/show/NCT00436943||174167|
NCT00436956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070059|AZD2171 to Treat Prostate Cancer|A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|January 2007|March 2013|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Male|18 Years|N/A|No|||July 2014|July 7, 2014|February 15, 2007|Yes|Yes||No|March 7, 2014|https://clinicaltrials.gov/show/NCT00436956||174166|
NCT00437554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIME_L_01019|Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)|A 16-Week Controlled, Double Blind, Double Dummy, Randomized, Two Arm Parallel-Group Study to Compare the Efficacy and Safety of Amaryl M 1/250 mg b.i.d vs. Amaryl M SR 2/500 mg od. in Patients With Type 2 Diabetes Mellitus||Handok Pharmaceuticals Co., Ltd.|No|Completed|August 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|188|||Both|30 Years|75 Years|No|||November 2007|November 28, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00437554||174122|
NCT00437528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2456_CTIL|Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity|Phase I Study for Evaluating the Safety and Applicability of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity||Rambam Health Care Campus|No|Recruiting|November 2006|December 2007||||Phase 1|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2007|May 16, 2007|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437528||174124|
NCT00437541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Insulation study|Housing, Insulation and Health Study|The Impact of Insulating Domestic Houses on the Health of Occupants: an Intervention Study|HIHS|University of Otago||Completed|July 2001|December 2002||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||4000|||Both|N/A|N/A|No|||February 2007|February 20, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00437541||174123|
NCT00437866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0, 25.11.2006|Hepcidin in Anemic Chronic Heart Failure (CHF) Patients|Hepcidin in the Pathogenesis of Anemia in Patients With Chronic Heart Failure||Medical University of Vienna||Completed|January 2007|July 2010|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Heart failure outpatients|December 2012|December 5, 2012|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437866||174099|
NCT00438165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0683|Age 12 Follow-up of Early Preventive Intervention (Memphis)|Age 12 Follow-up of Early Preventive Intervention|MemphisY12|University of Colorado, Denver|Yes|Completed|September 2003|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|609|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438165||174076|
NCT00438633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002235|Comparison of Early and Late Therapy for Adults With Non-Operatively Treated Proximal Humerus Fractures|Early vs Delayed Physical Therapy (Exercises) for Non-Operatively-Treated Proximal Humerus Fractures: A Prospective Randomized Trial||Massachusetts General Hospital||Active, not recruiting|February 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the MGH Hand and Upper Extremity or Trauma service|August 2015|August 28, 2015|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438633||174041|
NCT00449566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 05/208-K|Magnetic Resonance Imaging of Brain Development in Autism|Magnetic Resonance Imaging of Brain Development in Autism||UMC Utrecht|No|Recruiting|January 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||300|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||March 2007|March 18, 2007|March 18, 2007||||No||https://clinicaltrials.gov/show/NCT00449566||173209|
NCT00454337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000162-20|Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load|Randomized Non-inferiority Study Comparing a Strategy Maintaining Current Enfuvirtide-based Antiretroviral Therapy to a Strategy Replacing Enfuvirtide by an Integrase Inhibitor (Raltegravir) in HIV-1 Infected Subjects With Plasma Hiv-1 RNA Levels Below 400 Copies Per ml.ANRS 138 EASIER|EASIER|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454337||172849|
NCT00450099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-03|Minimum Local Anesthetic Volume of Bupivacaine in Labour Epidurals|Determination of the Minimum Local Anesthetic Volume of 0.125% Bupivacaine in Labour Epidurals||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2005|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 12, 2007|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00450099||173168|
NCT00450112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gel/1132|Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee|A Multi-Center Extension and Open-Label Study of a Single or Repeat Intra-Articular Injection of Gel-200 in Osteoarthritis of the Knee.||Seikagaku Corporation|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|40 Years|80 Years|No|||July 2011|July 25, 2011|March 20, 2007|Yes|Yes||No|April 15, 2011|https://clinicaltrials.gov/show/NCT00450112||173167|
NCT00439400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600419|A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period|A Double-Masked, Randomized, Placebo-Controlled Study of ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution) for the Treatment of Dry Eye Administered QID for a 56 Day Period Utilizing the Controlled Adverse Environment Model||Alacrity Biosciences, Inc.||Completed|February 2007|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|160|||Both|18 Years|N/A||||October 2007|October 1, 2007|February 22, 2007||||||https://clinicaltrials.gov/show/NCT00439400||173983|
NCT00439738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BUS06|Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults|A 16-Week Double-Blind, Randomized, Multicenter, Force-Titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients||Novartis||Completed|December 2006|||November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|412|||Both|40 Years|N/A|No|||January 2009|February 9, 2009|February 23, 2007|Yes|Yes||No|November 5, 2008|https://clinicaltrials.gov/show/NCT00439738||173957|
NCT00440089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F31AT003021|Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors|Effects of Hands-on-Healing vs. Touch for Fatigue and Inflammation in Breast Cancer Survivors||University of California, San Diego||Completed|October 2005|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|76|||Female|18 Years|70 Years|No|||November 2009|May 24, 2010|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440089||173930|
NCT00440024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 570|The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance|A Single-Blind Study to Assess Benefits of a Controlled Daily Skin Care Regimen on Retinoid Intolerant Patients (Derm 570)||University of Michigan||Completed|February 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||January 2011|January 7, 2011|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00440024||173935|
NCT00440323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXS104094|Disturbed Sleep Model Study.|A Double-blind, Double-dummy, Randomised, Placebo-controlled,Four-way Crossover Study to Investigate the Effect of Single Oral Doses of SB-649868 and of Zolpidem in a Model of Noise Induced Situational Insomnia in Healthy Male Volunteers.||GlaxoSmithKline|No|Completed|January 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|52|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00440323||173912|
NCT00440596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002698-01A2|Mindfulness Based Stress Reduction for High Blood Pressure|Mindfulness Based Stress Reduction for High Blood Pressure||National Center for Complementary and Integrative Health (NCCIH)|Yes|Recruiting|September 2006|||May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||May 2009|May 18, 2009|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440596||173891|
NCT00440609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3802s|Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema|A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) With 0.5mg Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab||Long Island Vitreoretinal Consultants|Yes|Completed|March 2007|December 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|February 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00440609||173890|
NCT00440843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JC0002|Zyprexa and Task Engagement in Schizophrenia|Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia||VA Connecticut Healthcare System|No|Withdrawn|February 2007|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||December 2013|December 19, 2013|February 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00440843||173872|
NCT00440310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSO-OL006|Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases|A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Treating Colorectal Cancer Patients With Recurrent Liver Metastases Using the Litx™ System Plus Chemotherapy as Compared to Chemotherapy Only||Light Sciences Oncology|Yes|Completed|February 2007|October 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|483|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|February 23, 2007|Yes|Yes||No|July 28, 2015|https://clinicaltrials.gov/show/NCT00440310||173913|
NCT00428246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510-04|Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation|Anti-Inflammatory and Endothelial Protectant Effects of Paricalcitol||Indiana University|No|Completed|November 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|January 25, 2007||No||No|April 6, 2009|https://clinicaltrials.gov/show/NCT00428246||174822|
NCT00428272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070040|HGS-ETR2 to Treat Children With Solid Tumors|A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients With Refractory Pediatric Solid Tumors||National Institutes of Health Clinical Center (CC)||Terminated|December 2006|October 2015|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|1 Year|30 Years|No|||October 2015|October 10, 2015|January 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00428272||174821|
NCT00437255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10034|Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis|An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis||Galderma Laboratories, L.P.|No|Completed|August 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|80 Years|No|||April 2008|April 3, 2008|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00437255||174144|
NCT00437268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10538|A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer|A Randomized Phase 2 Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Recurrent Colorectal Cancer||Eli Lilly and Company|Yes|Completed|March 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||April 2010|April 16, 2010|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00437268||174143|
NCT00437281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081074|Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures|A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures||Pfizer|No|Completed|April 2007|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|1 Month|16 Years|No|||January 2014|January 29, 2014|February 16, 2007|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00437281||174142|Results are reported for AUCtau for multiple-dose PK analysis and AUC (0-∞) for single-dose PK analysis, instead of AUC (0-24), as per change in planned analysis.
NCT00437853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033MX/0001|Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer|||Instituto Nacional de Cancerologia de Mexico||Completed|June 2003|February 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Female|66 Years|N/A|No|||February 2007|February 20, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00437853||174100|
NCT00437567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZMC/CH/32007|Prebiotics in the Prevention of Necrotizing Enterocolitis|Prebiotics vs. Placebo in the Prevention of Necrotizing Enterocolitis in Premature Neonates||Shaare Zedek Medical Center|Yes|Recruiting|July 2009|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|260|||Both|N/A|7 Days|No|||January 2014|January 2, 2014|February 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00437567||174121|
NCT00438178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX006|Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies|A Phase I Study of Obatoclax Mesylate (GX15-070MS) in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myeloid Leukemia (CML)in Myeloid Blast Phase, Myelofibrosis, Previously-Treated Chronic Lymphocytic Leukemia (CLL), or Aplastic Anemia||Teva Pharmaceutical Industries|No|Completed|October 2005|||October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|February 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00438178||174075|
NCT00438139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0011-1|Ph1 Marinol Interaction Study - Part 1 - 1|Phase 1, Pilot Study to Examine the Cardiovascular Effects of Smoked Marijuana, Interactions With Oral Dronabinol, and Effects of Dronabinol on Withdrawal in Marijuana Dependent Volunteers||National Institute on Drug Abuse (NIDA)||Active, not recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2007|October 25, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438139||174078|
NCT00438152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV20507|Lopinavir Capsules to Kaletra or Invirase Tablets|A 24-week, Randomized, Open-label, 2-arm Study to Compare the Safety, Efficacy and Tolerability of Invirase® Tablets With Ritonavir Versus Kaletra® Tablets in HIV 1 Infected Adults on a Kaletra® Based Regimen With 2 Nucleosides/Nucleotides|LoCKIT|Royal Free Hampstead NHS Trust|Yes|Completed|September 2006|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||February 2007|July 15, 2011|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00438152||174077|
NCT00449839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS 265 PK IAsp 2006/199|Changes of the Infusion Rate in Insulin Pump Treatment|Changes of the Infusion Rate in Insulin Pump Treatment. A Randomized, Unblinded Cross-Over Study.||University of Aarhus|Yes|Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 30, 2009|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00449839||173188|
NCT00450762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gem/Carbo MUC01|Gemcitabine + Carboplatin in Breast Cancer|Gemcitabine Plus Carboplatin in Patients With Pretreated Metastatic Breast Cancer||Ludwig-Maximilians - University of Munich||Completed|March 2004|October 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|75 Years||||March 2007|March 21, 2007|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450762||173118|
NCT00454571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00202|Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer|A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy||National Cancer Institute (NCI)|Yes|Completed|June 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Male|18 Years|N/A|No|||September 2012|January 8, 2016|March 27, 2007|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00454571||172831|
NCT00439140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-082|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder|||Allergan|Yes|Terminated|June 2007|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|80 Years|No|||December 2013|December 9, 2013|February 21, 2007|No|Yes|In agreement with FDA the study was terminated based on data available.|No|December 9, 2013|https://clinicaltrials.gov/show/NCT00439140||174003|
NCT00439413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CSP-1022-1|Selegiline for Smoking Cessation - 1|Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation.||National Institute on Drug Abuse (NIDA)|Yes|Completed|June 2007|January 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|246|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 24, 2011|February 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00439413||173982|
NCT00439790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602508|Sympathetic Nerve Activity and an Implantable Cardioverter Defibrillator in Heart Failure Patients|Validation of a Prognostic Score to Identify Heart Failure Patients Who Might Need an Implantable Cardioverter Defibrillator Using Muscle Sympathetic Nerve Activity and Autonomic Testing||University Hospital, Toulouse|No|Completed|January 2007|December 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|109|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patient|June 2012|June 12, 2012|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00439790||173953|
NCT00440336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31663|Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.|Comparison of Efficacy of Prostaglandin Analogues (Xalatan) and Aqueous Suppressants (Cosopt) in Reducing Intraocular Pressure Following Selective Laser Trabeculoplasty in the Management of Open-Angle Glaucoma.||Advanced Glaucoma Specialists|No|Recruiting|October 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||30|||Both|18 Years|N/A|No|||February 2007|February 28, 2007|February 24, 2007||||No||https://clinicaltrials.gov/show/NCT00440336||173911|
NCT00440622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/03.09|Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients|A Multicenter Randomized Phase III Study of Gemcitabine Plus Herceptin Combination Versus the Capecitabine Plus Herceptin Combination in Pretreated Patients With HER-2 Positive Metastatic Breast Cancer||Hellenic Oncology Research Group|No|Terminated|April 2003|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|75 Years|No|||February 2013|February 12, 2013|February 26, 2007||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00440622||173889|
NCT00440856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DT2656|Presentation of Lumbar Disc and Reduction of Symptoms|Reduction in Leg and Back Pain Following Lumbar Microdiscetomy in Those Shown the Removed Disc Fragments After the Operation: a Double Blind Randomized Control Trial.|POLDAROS|St George's, University of London|No|Completed|February 2007|May 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|June 8, 2015|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440856||173871|
NCT00436644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC0661|Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin|A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma||Mayo Clinic|Yes|Completed|March 2007|November 2012|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||March 2014|March 20, 2014|February 15, 2007|Yes|Yes||No|February 17, 2012|https://clinicaltrials.gov/show/NCT00436644||174189|
NCT00440570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors|Treatment of Advanced Cancer With Amplitude-modulated Electromagnetic Fields of Low Intensity by Means of an Intrabuccal Probe|THBC001|Pasche, Boris, M.D.|No|Completed|October 2004|December 2007|Actual|September 2006|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1|||2|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|February 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00440570||173893|
NCT00440583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH011101|The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP|Yt90 Zevalin & Combination Chemotherapy in Treating Patients With Stage II,Stage III,or Stage IV Diffuse Large B-cell Lymphoma||Mahidol University|No|Completed|September 2006|May 2012|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||January 2015|January 28, 2015|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440583||173892|
NCT00437593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-2-CI-2007|UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue|UHR-OCT and HD-OCT for Preretinal Membranes: Is There a Difference Between ICG and Membrane Blue? A Randomized Clinical Trial||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|September 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2007|September 21, 2008|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00437593||174119|
NCT00437307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3104000|Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse|Topotecan Plus Carboplatin im Vergleich Zur Standardtherapie (Paclitaxel Plus Carboplatin Oder Gemcitabin Plus Carboplatin) in Der Therapie Von Patientinnen Mit Platin-sensitivem Rezidivierten Epithelialen Ovarialkarzinom, Peritonealkarzinom Oder Tubenkarzinom|HECTOR|North Eastern Germany Society of Gynaecologic Oncology||Active, not recruiting|March 2007|June 2016|Anticipated|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00437307||174140|
NCT00438113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-001|Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF|Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF|SMAC AF|Nova Scotia Health Authority|No|Active, not recruiting|December 2009|November 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|184|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00438113||174080|
NCT00438126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK47096 (completed)|Family-Centered Diabetes Project - Sharing Wisdom|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2002|May 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438126||174079|
NCT00438438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2200-100792|Interaction of Chronic Sleep Restriction and Circadian Misalignment on Sleep and Neuro-cognitive Performance|"Interaction of Chronic Sleep Restriction and Circadian Misalignment on Sleep and Neuro-cognitive Performance"||Brigham and Women's Hospital|No|Completed|April 2006|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|9|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2011|August 31, 2011|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438438||174055|
NCT00438451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEPONE05|Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs|A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.|STEP-ONE|Johannes Gutenberg University Mainz|No|Completed|January 2007|August 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|361|||Both|60 Years|N/A|No|||January 2013|January 24, 2013|February 21, 2007||No||No|September 24, 2012|https://clinicaltrials.gov/show/NCT00438451||174054|
NCT00438412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2006.01.PHH|Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea|||Regional Hospital Holstebro||Suspended|October 2006|||||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Adults, males and females,age 30 -65|April 2008|April 17, 2008|February 20, 2007||No|It was not possible to recruit enough patients with obstructive sleep apnea.|No||https://clinicaltrials.gov/show/NCT00438412||174057|
NCT00438425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 04-056c|Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia|Assessment of the Practical Application, Acceptability and Effectiveness of a Portfolio Diet in Reducing Serum Cholesterol||University of Toronto|No|Active, not recruiting|January 2007|January 2016|Anticipated|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|351|||Both|21 Years|100 Years|No|||December 2015|December 3, 2015|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438425||174056|
NCT00454038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ae-01.CTIL|Study of Collagen Membrane in Guided Bone Regeneration|Preliminary Study of Hypro-Sorb® F Bilayer Bioabsorbable Membrane for Guided Tissue and Bone Regeneration|GBR|The Baruch Padeh Medical Center, Poriya||Recruiting|June 2007|May 2009|Anticipated|January 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||January 2009|July 9, 2009|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00454038||172872|
NCT00454051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AFR02|Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma|Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment.||Novartis|Yes|Completed|December 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|March 28, 2007||No||No|December 3, 2010|https://clinicaltrials.gov/show/NCT00454051||172871|
NCT00450788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907120|Esophageal Cancer in Northeastern Iran|The Golestan Cohort Study of Esophageal Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50000|||Both|30 Years|99 Years|Accepts Healthy Volunteers|||February 2016|March 10, 2016|March 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00450788||173116|
NCT00451022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040274|Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies|Follow-Up of Study Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents||National Institutes of Health Clinical Center (CC)||Recruiting|September 2004|||||N/A|Observational|N/A|||Anticipated|750|||Both|18 Years|120 Years|No|||November 2015|February 2, 2016|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00451022||173098|
NCT00451009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRH-01|Safety and Efficacy of Freezing and Thawing of Human Eggs in Assisted Reproductive Technology|Safety and Effectiveness of Freeze and Thaw Media Kits for the Manufacturing of Oocytes for Future Use in Assisted Reproductive Technology||ViaCell|Yes|Withdrawn|March 2007|April 2009|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|21 Years|35 Years|No|||May 2014|May 28, 2014|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00451009||173099|
NCT00451035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2202|Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase|A Phase II, Multicentre Study of Oral LBH589 in Patients With Chronic Phase Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors||Novartis||Completed|January 2007|||September 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00451035||173097|
NCT00438854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-211|Dasatinib in Relapsed Chronic Lymphocytic Leukemia|Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia||Massachusetts General Hospital||Completed|December 2006|March 2013|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|February 20, 2007|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00438854||174024|
NCT00438867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-3-001|Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Female Patients With Stable Angina Pectoris Who Are Not Candidates for Revascularization|AWARE|Cardium Therapeutics|Yes|Active, not recruiting|May 2007|||November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Female|18 Years|75 Years|No|||November 2008|February 11, 2013|February 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00438867||174023|
NCT00438880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS0382|Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma|A Phase I/II Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy for Patients With Previously Treated CD20+ Non-Hodgkin Lymphoma||Mayo Clinic|No|Completed|October 2004|November 2014|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||September 2015|January 4, 2016|February 20, 2007|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00438880||174022|
NCT00440115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA101963|Disease Management for Smoking Cessation|Disease Management for Smokers in Rural Primary Care||University of Kansas Medical Center|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|750|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 29, 2012|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440115||173928|
NCT00440063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20828|A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.|A Randomized Study to Compare the Safety and Effectiveness of Two Monitoring Schedules to Maintain Hemoglobin Levels and Iron Parameters in Patients With Renal Anemia Receiving NeoRecormon||Hoffmann-La Roche||Terminated||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||December 2007|December 18, 2007|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00440063||173932|
NCT00440076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS0104|Velcade in Myelodysplastic Syndrome - Pilot Study|Phase II Study of PS341 (VELCADE) in Myelodysplastic Syndromes (MDS). EudraCT Number 2004-002935-23||Gruppo Italiano Malattie EMatologiche dell'Adulto||Terminated|August 2006|March 2008|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|February 23, 2007||No|Low accrual|No||https://clinicaltrials.gov/show/NCT00440076||173931|
NCT00440349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR09|Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis|A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis||University of Parma|No|Active, not recruiting|October 2000|April 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Both|N/A|N/A|No|||February 2007|February 23, 2007|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00440349||173910|
NCT00440869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21-DK077350 (completed)|Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis|Effects of N-acetylcysteine on Muscle Fatigue in ESRD|NAC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|March 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 2, 2010|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440869||173870|
NCT00436657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0917|Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer|A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease||M.D. Anderson Cancer Center|No|Completed|February 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|3 Years|18 Years|No|||March 2012|March 29, 2012|February 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00436657||174188|
NCT00436670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060161|Phase II Study to Evaluate the Efficacy of AMG 317|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma||Amgen||Completed|March 2007|February 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|294|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|February 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00436670||174187|
NCT00436969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-OV-01|ORTHOVISC Shoulder RCT|A Comparison of Orthovisc® to Corticosteroid Injection in Shoulder Osteoarthritis: Orthovisc Randomized Clinical Trial|OV Shoulder|DePuy Mitek|Yes|Completed|December 2006|August 2011|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|275|||Both|25 Years|75 Years|No|||May 2014|May 9, 2014|February 16, 2007|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00436969||174165|
NCT00436982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-S-015 Triathlon RSA_1|Evaluation of Triathlon - a New Total Knee Prosthesis System - Triathlon vs. Duracon|Evaluation of Triathlon - a New Total Knee Prosthesis System. Prospective, Comparative, Randomised, Roentgen Stereophotogrammetric Analysis (RSA) Series||Stryker European Operations BV|No|Active, not recruiting|February 2006|November 2016|Anticipated|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|85 Years|No|||September 2015|November 3, 2015|February 16, 2007|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT00436982||174164|
NCT00437008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benfo-1-2005|Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes|Acute Effects of a Low-AGE vs. High-AGE Meal on Postprandial Endothelial Function in People With Type 2 Diabetes Mellitus. Protective Effects of Benfotiamine|AGE-Benfo|Ruhr University of Bochum||Completed|November 2004|January 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention||||21|||Both|35 Years|70 Years|No|||February 2007|February 15, 2007|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00437008||174162|
NCT00437320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29057|Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin|Comparison of Metvix PDT With Its Vehicle in the Treatment of Photoaged Skin||Galderma|No|Completed|March 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|30 Years|N/A|No|||January 2009|January 6, 2009|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00437320||174139|
NCT00437632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN106587|Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809|A Placebo Controlled, Single Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses of GSK598809 in Healthy Male and Female Volunteers for 28 Days.||GlaxoSmithKline|No|Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|104|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|February 19, 2007||||No||https://clinicaltrials.gov/show/NCT00437632||174116|
NCT00437606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP20131|A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.|A Nonrandomized, Open Label Study to Examine the Effect of Hepatic Impairment on the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.'||Hoffmann-La Roche||Terminated||February 2009|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|75 Years|No|||April 2008|April 16, 2008|February 19, 2007||No|poor recruitment|No||https://clinicaltrials.gov/show/NCT00437606||174118|
NCT00437619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19876|A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.|An Open Label Study to Evaluate the Clinical Response to Sequential Treatment With Daivobet and Daivonex in Patients With Mild to Moderate Psoriasis||Hoffmann-La Roche||Completed|February 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00437619||174117|
NCT00430924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B109LB1|Inhibition of Aldosterone in Patients With Chronic Renal Disease|The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease||Herlev Hospital|Yes|Completed|March 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|February 1, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00430924||174623|
NCT00430937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBC134A2402|Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections|A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)||Novartis||Terminated|April 2006|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|February 1, 2007||No||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00430937||174622|
NCT00438672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000322|Corticosteroid Injection for Common Upper Extremity Problems|Corticosteroid Injection for Common Upper Extremity Problems||Massachusetts General Hospital||Completed|April 2003|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|February 20, 2007||No||No|March 22, 2012|https://clinicaltrials.gov/show/NCT00438672||174038|
NCT00438685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA017118-01|Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders|Development of Outpatient MST for Dually Diagnosed Youth||Medical University of South Carolina||Completed|October 2004|September 2010|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|40|||Both|12 Years|17 Years|No|||July 2010|April 10, 2015|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438685||174037|
NCT00450450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCT0631|Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases|A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation||Children's Oncology Group|Yes|Active, not recruiting|December 2007|||June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|N/A|21 Years|No|||March 2015|March 4, 2015|March 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00450450||173142|
NCT00450463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070107|Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer|A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2007|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Male|18 Years|110 Years|No|||July 2015|January 8, 2016|March 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00450463||173141|
NCT00450476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30/3/25-01-2007|Aspiration of Subglottic Secretions Using Hi-Lo Evac Endotracheal Tube: Tube Size and Incidence of Suction Lumen Dysfunction|Aspiration of Subglottic Secretions in Intubated Critically Ill Patients Using Hi-Lo Evac Endotracheal Tube: Correlation Between Tube Size and Incidence of Suction Lumen Dysfunction||University Hospital, Alexandroupolis|No|Recruiting|January 2007|||||Phase 4|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||60|||Both|18 Years|90 Years|No|||March 2007|March 21, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00450476||173140|
NCT00450515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0632|Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer|Phase II Trial of Vinfluinine and Capecitabine in Previously Treated Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|March 2007|||January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450515||173137|
NCT00451295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E09|A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia|A Phase III, Double-Blind, Multi-Centre, Randomised, Parallel Group Design, Placebo-Controlled, Flexible Dose Study of MCI-196 in Combination With a Ca-Based Phosphate Binder in CKD Stage V Subjects on Dialysis With Hyperphosphatemia.||Mitsubishi Tanabe Pharma Corporation|No|Terminated|May 2007|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|80 Years|No|||November 2011|November 13, 2011|March 22, 2007||No|This study was stopped because of insufficient enrollment.|No||https://clinicaltrials.gov/show/NCT00451295||173077|
NCT00439166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI 06-47|Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid|Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid||McMaster University|No|Active, not recruiting|February 2007|December 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|50 Years|N/A|No|||September 2009|July 27, 2010|February 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00439166||174001|
NCT00439751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-P1|Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy|A Randomized Comparison of Immediate Versus Deferred Androgen Deprivation Therapy Using Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy.|ELAAT|Ontario Clinical Oncology Group (OCOG)|Yes|Active, not recruiting|April 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Male|18 Years|N/A|No|||June 2015|October 14, 2015|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00439751||173956|
NCT00439764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-JCL-14|Health Education vs. Health Education Plus Physical Therapy for Low Back Pain Patients|Health Education vs. Health Education Plus Physical Therapy for Low Back Pain Patients||Kovacs Foundation|Yes|Completed|March 2007|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|680|||Both|18 Years|N/A|No|||November 2008|May 27, 2009|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00439764||173955|
NCT00439777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11702b|Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study|Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism||Bayer|Yes|Completed|March 2007|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4833|||Both|18 Years|N/A|No|||January 2014|January 25, 2014|February 23, 2007|Yes|Yes||No|November 22, 2012|https://clinicaltrials.gov/show/NCT00439777||173954|
NCT00440700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601M79066|Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation|Reducing Sedative Exposure in Ventilated ICU Patients||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|364|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|February 23, 2007||No||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00440700||173883|Overall limitations of the trial include the challenges of obtaining informed consent from patients' themselves. Many times patients were too sedated or not alert enough to participate in the consent process.
NCT00440713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms|Phase 3 Study of Aripriprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms|AripipPTSD|Federal University of São Paulo|Yes|Completed|January 2004|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|18 Years|60 Years|No|||February 2007|February 23, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00440713||173882|
NCT00440362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX502-002|A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza|A Single-Site, Phase 1/2, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Healthy Volunteers||AlphaVax, Inc.|Yes|Completed|April 2007|September 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|12||Actual|216|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2008|November 7, 2008|February 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00440362||173909|
NCT00440375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 05/74|Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women|||Baskent University|Yes|Completed|June 2005|March 2006||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||82|||Female|45 Years|N/A|Accepts Healthy Volunteers|||February 2007|February 26, 2007|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00440375||173908|
NCT00436683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IH 003 (ACT3)|Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia|An Open Label, Dose-Ranging Study to Establish the Tolerability of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia.|ACT3|Ineos Healthcare Limited|Yes|Completed|February 2007|April 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00436683||174186|
NCT00436995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050210|Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis|A Multicentre, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis.||Amgen||Completed|April 2006|December 2008|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436995||174163|
NCT00437294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10536|Enzastaurin in Combination of Capecitabine to Treat Breast Cancer|A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane||Eli Lilly and Company|Yes|Terminated|March 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|N/A|No|||February 2010|February 16, 2010|February 16, 2007|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00437294||174141|
NCT00437580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0015|Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus Intestinal Carriage|Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus (VRE) Intestinal Carriage : a Double Blind Randomized Pilot Study||University Hospital, Clermont-Ferrand||Recruiting|February 2007|August 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|February 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00437580||174120|
NCT00437021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0012|MVA Post-Event: Administration Timing and Boost Study|Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2007|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|206|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||March 2010|October 24, 2013|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00437021||174161|
NCT00437034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00181|Aflibercept for Relapsed Multiple Myeloma|A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)|Yes|Terminated|January 2007|April 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2012|July 28, 2015|February 15, 2007|Yes|Yes|Poor accrual|No|May 7, 2015|https://clinicaltrials.gov/show/NCT00437034||174160|
NCT00437892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7948|Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis|The Effect of Statins on D-dimer Levels in Patients With a Previous Venous Thromboembolic Event||Università degli Studi dell'Insubria|No|Terminated|May 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|February 20, 2007||No|Competitive trials and slow recruitment rate|No||https://clinicaltrials.gov/show/NCT00437892||174097|
NCT00437645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2404|Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension|A Double-blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of Treatment With the Combination of Valsartan/Amlodipine 160/5 mg Compared to Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Alone||Novartis||Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1183|||Both|55 Years|N/A|No|||November 2014|November 3, 2014|February 16, 2007|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00437645||174115|
NCT00437879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185-2006|Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment|Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment||Sunnybrook Health Sciences Centre|Yes|Recruiting|January 2007|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|Women who are receiving neoadjuvant chemotherapy or neoadjuvant chemo-radiotherapy for        locally-advanced breast cancer.|April 2012|April 25, 2012|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00437879||174098|
NCT00431210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-179|Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma|A Pilot Feasibility Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2007|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00431210||174601|
NCT00450489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 02-030E|Assessment of Quality of Life and Satisfaction With Medical Care of Pediatric Type 1 Diabetes Mellitus Patients|Assessment of Quality of Life and Satisfaction With Medical Care of Pediatric Type 1 Diabetes Mellitus Patients||Children's Mercy Hospital Kansas City|No|Withdrawn|June 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|120|||Both|6 Years|17 Years|No|Probability Sample|Children cared for Type 1 Diabetes Mellitus, in Children's Mercy Hospital and Clinics,        Endocrine Clinic.|March 2010|March 3, 2010|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450489||173139|
NCT00450502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070097|Safety of Batracylin in Patients With Solid Tumors and Lymphomas|A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|February 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||August 2013|October 23, 2014|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450502||173138|
NCT00450775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5299|Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars|Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars||Innovative Medical||Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 23, 2008|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450775||173117|
NCT00439205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0673|Oral Margin Spectroscopy Detection Using Optical Spectroscopy|Oral Tumor Margin Detection Using Optical Spectroscopy||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2007|||February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Tissue removal and study biopsies to be done so that researchers can better compare the      appearance and diagnosis at these sites to the images that were taken.|Both|18 Years|N/A|No|Non-Probability Sample|Participants with precancerous or cancerous oral lesions.|March 2016|March 15, 2016|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439205||173998|
NCT00439465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0717|Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma|Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|January 2007|December 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||September 2015|September 16, 2015|February 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00439465||173978|
NCT00439816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP 82-003|Veteran Preference For Group Visits and Its Effect on Hypertension Outcomes|Veteran Preference For Group Visits and Its Effect on Hypertension Outcomes||VA Office of Research and Development|No|Completed|February 2005|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|21 Years|N/A|No|||November 2007|April 6, 2015|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439816||173951|
NCT00439478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171074|Dental Safety Profile of High-Dose Radioiodine Therapy|The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer||University Hospital, Basel, Switzerland||Completed|September 2004|September 2006|Actual|||Phase 4|Observational|N/A||||202|||Both|N/A|N/A|No|||October 2007|November 13, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439478||173977|
NCT00440128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV100781|The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer|A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer||GlaxoSmithKline|No|Completed|May 2007|July 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||August 2011|March 15, 2012|February 22, 2007||No||||https://clinicaltrials.gov/show/NCT00440128||173927|
NCT00439452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61251|Telemedicine-Based Collaborative Care to Reduce Rural Disparities|Telemedicine-Based Collaborative Care to Reduce Rural Disparities||University of Arkansas|No|Completed|May 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 31, 2011|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00439452||173979|
NCT00429247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/01.60|Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients|A Pilot Randomized Phase II Study of Adjuvant Administration of Trastuzumab (HERCEPTIN) Versus Observation After the Completion of Adjuvant Chemotherapy and Radiotherapy in Patients With Stage I-III Breast Cancer Who Have Detectable Disseminated and/or Circulating Tumor Cells (DTCs and/or CTCs) in the Bone Marrow or/and the Peripheral Blood Before or/and After the Completion of Adjuvant Treatment||University Hospital of Crete|No|Completed|February 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|75 Years|No|||January 2008|July 20, 2011|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429247||174748|
NCT00440102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060213|Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity|Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity|KETASED|Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|655|||Both|18 Years|N/A|No|||May 2007|September 21, 2011|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440102||173929|
NCT00440388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-203|Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma|An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma||Ascenta Therapeutics||Completed|October 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||August 2010|August 24, 2010|February 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00440388||173907|
NCT00440401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-023-IM|TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)|A Randomised, Open Label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety of TachoSil® Versus Standard Haemostatic Treatment in Cardiovascular Surgery||Nycomed|Yes|Completed|February 2007|November 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||July 2010|May 4, 2012|February 26, 2007|No|Yes||No|May 7, 2010|https://clinicaltrials.gov/show/NCT00440401||173906|
NCT00440687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMUL - WISP 01|Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care|Phase 4 Withdrawal of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease in Primary Care: a Randomised Controlled Trial||Queen Mary University of London|Yes|Completed|January 2001|March 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||256|||Both|40 Years|N/A|No|||February 2007|February 26, 2007|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00440687||173884|
NCT00440635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002185|Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma|International Single-Arm Protocol to Provide Expanded Access to Bortezomib for Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma||Janssen-Cilag International NV||Completed|January 2004|October 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|641|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00440635||173888|
NCT00440648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD3-163-201|Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate|A Double-Blind, Cross-Over Design Study of Sevelamer Hydrochloride (Renagel®) and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis||Sanofi||Completed|March 2005|July 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|February 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00440648||173887|
NCT00440882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/16|Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome|Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome||Assistance Publique Hopitaux De Marseille|Yes|Completed|September 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|90 Years|No|Non-Probability Sample|patients whom suffered ARDS with a PaO2/FIO2 < 200 mmHg at a positive end-expiratory        pressure (PEEP) ³ 5 cm H2O and for which ARDS criteria from less than 24 hours|October 2008|October 8, 2008|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440882||173869|
NCT00436696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL06B1|Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions|Genetic Basis of Neuroblastoma Tumorigenesis||Children's Oncology Group|No|Active, not recruiting|December 2006|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|9350|Samples With DNA|Blood, Bone Marrow|Both|N/A|120 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants With Neuroblastoma or Noncancerous Conditions|May 2015|September 30, 2015|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00436696||174185|
NCT00437658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-56418-0603|Safety and Efficacy Study of NBI-56418 in Endometriosis|A Phase II, Randomized, Double Blind, Active-controlled Study to Access the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis||AbbVie|No|Completed|November 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|252|||Female|18 Years|49 Years|No|||January 2013|January 2, 2013|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00437658||174114|
NCT00430326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0042|Juvista (Avotermin) in Scars Following Varicose Vein Removal|A Dose Response Trial to Investigate the Efficacy of Juvista (Avotermin) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins Following Bilateral Varicose Vein Removal.||Renovo|No|Completed|November 2006|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|156|||Both|18 Years|85 Years|No|||March 2010|March 8, 2010|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430326||174668|
NCT00438191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002319|A Clinical Trial of Splinting for DeQuervain's Tenosynovitis|A Clinical Trial of Full Time vs. As Needed Splint Wear for DeQuervain's Tenosynovitis||Massachusetts General Hospital||Active, not recruiting|December 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the MGH Hand and Upper Extremity Service.|April 2015|April 6, 2015|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438191||174074|
NCT00431509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTTKR1|Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery|A Randomized Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery. Influence on Operative Result, Health-Related Quality of Life, and Coordinative Abilities.||University of Schleswig-Holstein||Recruiting|January 2007|June 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||477|||Both|18 Years|N/A|No|||April 2007|April 23, 2007|February 2, 2007||||No||https://clinicaltrials.gov/show/NCT00431509||174578|
NCT00431756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DK068149|Predicting Risk of Cancer in Barrett's Esophagus|Methylation in Cancer Progression of Barrett's Esophagus|BE|Johns Hopkins University|No|Recruiting|January 2002|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|540|Samples With DNA|approx. 24 ml blood, 1-8 esophageal mucosal pinch specimens and or esophageal brushings|Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|People who have esophageal cancer, Barrett's esophagus or gastro-esophageal reflux disease|February 2016|February 25, 2016|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431756||174560|
NCT00427700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RACLO|Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome|Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|August 2008|August 2009|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||July 2010|July 7, 2010|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00427700||174863|
NCT00450203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000536013|Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer|A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies|ST03|Medical Research Council|Yes|Recruiting|October 2007|December 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1103|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450203||173160|
NCT00450801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030165|R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma|Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma||University of Miami|Yes|Completed|April 2004|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|March 20, 2007|Yes|Yes||No|August 7, 2015|https://clinicaltrials.gov/show/NCT00450801||173115|
NCT00439829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB 06-03|Synchronization of Follicle Wave Emergence and Ovarian Stimulation|Synchronization of Follicle Wave Emergence and Ovarian Stimulation in Women With a History of Poor Ovarian Response to Treatment||University of Saskatchewan||Completed|February 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|43 Years|No|||May 2010|May 21, 2010|February 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00439829||173950|
NCT00427687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3189A1-104|Study Evaluating AGG-523 in Subjects With Osteoarthritis|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2007|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|N/A|No|||August 2008|August 1, 2008|January 25, 2007||||||https://clinicaltrials.gov/show/NCT00427687||174864|
NCT00440141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-AP01|Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%|||Allergan||Completed|July 2006|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|February 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00440141||173926|
NCT00428168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BET202|Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment||OBEcure Ltd.|No|Terminated|March 2007|December 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|16 Years|45 Years|No|||October 2008|October 13, 2015|January 25, 2007||No|Interim Analysis result indicated the study will not show a significant benefit of the study    medication on the primary endpoint.|No||https://clinicaltrials.gov/show/NCT00428168||174828|
NCT00439803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX601-001|A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)|A Single-Site, Phase 1, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Cytomegalovirus Genes (AVX601) in Healthy Volunteers|CMV|AlphaVax, Inc.|Yes|Completed|April 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 7, 2008|February 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00439803||173952|
NCT00429494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-710|GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients|Phase II Study of GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients||M.D. Anderson Cancer Center|No|Completed|November 2002|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|N/A|40 Years|No|||May 2013|May 20, 2013|January 29, 2007||No||No|May 20, 2013|https://clinicaltrials.gov/show/NCT00429494||174729|
NCT00429507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0349|Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases|Phase 2 Study of 153 Sm-EDTMP Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases||M.D. Anderson Cancer Center|No|Completed|March 2007|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||October 2015|October 22, 2015|January 29, 2007|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00429507||174728|
NCT00440934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THBC 002|A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma|Étude de Phase II Pour déterminer l'efficacité Des Ondes électromagnétiques de Basse intensité administrées Par Voie Buccale Dans le Traitement du Cancer du Foie avancé|THBC002|Pasche, Boris, M.D.|No|Terminated|February 2007|December 2007|Actual|December 2007|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||May 2008|May 2, 2008|February 24, 2007||No|Poor patient accrual|No||https://clinicaltrials.gov/show/NCT00440934||173865|
NCT00428688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4359-DM-CTIL|Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma|Assessment of Endothelial Function and IMT in Survivors Hodgkin's Lymphoma Patients||Sheba Medical Center|No|Enrolling by invitation|July 2009|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|50 Years|No|Non-Probability Sample|Young-adult survivors of Hodgkin's disease|December 2012|December 12, 2012|January 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00428688||174790|
NCT00428701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00107|An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium|An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours||AstraZeneca||Completed|October 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428701||174789|
NCT00440661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC/ART06572N|Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis|Exploratory Study of Some Synovial Fluid Inflammation Mediatorsunder Diacerhein in Knee Osteoarthritis Patients. Phase IV Study.||Laboratoires NEGMA|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|96|||Both|45 Years|80 Years|No|||October 2007|March 3, 2010|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440661||173886|
NCT00440674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The DECIDE Trial: CP-05|Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)|The DECIDE Trial: Prospective, Multi-center, Randomized Study to Evaluate the CoStar Paclitaxel-Eluting Coronary Stent System Using a Direct Stenting Technique Compared to Conventional Stenting With Pre-dilatation Strategy|DECIDE|Conor Medsystems|No|Terminated|February 2007|July 2009|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|90 Years|No|||October 2009|October 29, 2009|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440674||173885|
NCT00440895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASY-RESCUE|A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI|A Randomized Trial of Early Discharge After Trans-Radial Stenting of Coronary Arteries in Acute Myocardial Infarction and RESCUE-PCI: The EASY-RESCUE Pilot Study|EASY-RESCUE|Laval University|Yes|Completed|February 2007|May 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|75 Years|No|||May 2013|May 7, 2013|February 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00440895||173868|
NCT00436709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529855|Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer|A Pilot Study of Bevacizumab With Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Dose Dense Nanoparticle Albumin Bound Paclitaxel for the Treatment of Early Stage Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2006|||||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||June 2007|January 3, 2014|February 15, 2007||||No||https://clinicaltrials.gov/show/NCT00436709||174184|
NCT00436722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-005635-10|Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial|Study of ATEGE-Fresenius Induction in Liver Transplantation Followed by Tacrolimus Weaning.|ATEGE-LIVER|Hospital Clinic of Barcelona|No|Terminated|June 2006|||July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||May 2009|May 19, 2009|February 16, 2007||No|Experimental arm (induction + low dose tacrolimus) not effective.|No||https://clinicaltrials.gov/show/NCT00436722||174183|
NCT00430053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040081|Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma|Pathogenesis And Course Of Cutaneous T-Cell Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|January 2004|June 2010|Actual|||N/A|Observational|N/A|||Anticipated|100|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00430053||174688|
NCT00431223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05I/C52|Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training|Does Computerized Cognitive Skills Training Change Brain Activation Patterns in Schizophrenia?|fMRI|Manhattan Psychiatric Center|Yes|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Male|18 Years|55 Years|No|||April 2015|April 14, 2015|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431223||174600|
NCT00430638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-451|A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension|A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension||Daiichi Sankyo Inc.||Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|N/A|No|||January 2010|January 27, 2010|February 1, 2007|Yes|Yes||No|October 3, 2008|https://clinicaltrials.gov/show/NCT00430638||174645|
NCT00451334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-01|Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement|Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement|GS|Assaf-Harofeh Medical Center|No|Not yet recruiting||||||Phase 2/Phase 3|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2006|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451334||173074|
NCT00451607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNA STRESS 07|Environmental Stress and Individualized Sensorimotor Care on Autonomic Nervous System Activity in Premature Population|Evaluation of Environmental Stress and Individualized Sensorimotor Care on Autonomic Nervous System Activity in a Premature Population : a Prospective Study||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2007|September 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|||Both|N/A|6 Weeks|No|Non-Probability Sample|Premature Birth|June 2009|June 10, 2009|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451607||173054|
NCT00427947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9440-05|Leg Amputation and Continuous Sciatic Nerve Block|Continuous Popliteal Sciatic Nerve Block Interest in Postoperative Pain Management for Patients With Leg Amputation|CAPDAF|University Hospital, Bordeaux|Yes|Terminated|December 2006|December 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||December 2009|December 28, 2009|January 26, 2007||No|lack of patients|No||https://clinicaltrials.gov/show/NCT00427947||174845|
NCT00428428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJ2|Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract|Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract||Fredericia Hosptial|Yes|Completed|February 2007|November 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2007|November 15, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428428||174810|
NCT00440414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.05|Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)||Hellenic Oncology Research Group|No|Completed|April 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|80 Years|No|||August 2010|August 18, 2010|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440414||173905|
NCT00440427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-1201|Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)|A Randomized, Open-Label, Single-Dose Parallel Group Study of the Pharmacokinetic Profile, Safety, and Tolerability of 25- and 50-mg Desvenlafaxine Sustained Release (DVS SR) in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2007|February 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|February 23, 2007||||||https://clinicaltrials.gov/show/NCT00440427||173904|
NCT00429481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/007|Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants|A Study to Assess the Efficacy, Immunogenicity and Safety of 2 Doses of Oral Live Attenuated Human Rotavirus Vaccine (Rotarix) at Different Viral Concentrations in Healthy Infants.||GlaxoSmithKline||Completed|December 2000|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||2460|||Both|11 Weeks|17 Weeks|Accepts Healthy Volunteers|||January 2007|January 30, 2007|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429481||174730|
NCT00429767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA - 022243|Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals|Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine: Study 1||Wayne State University|Yes|Completed|January 2007|January 2010|Actual|January 2010|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|55 Years|No|Non-Probability Sample|Heroin dependent and Cocaine abuse or dependent research volunteers.|June 2012|June 1, 2012|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429767||174710|
NCT00429780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J/423/1058, 30/05/1385|Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)|A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0)||Tehran University of Medical Sciences||Completed|January 2007|December 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429780||174709|
NCT00440908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-032|Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers|A Prospective Observational Cohort Study Tracking Laboratory Markers for Changes Over Time, After Converting Dialyzer Practice From Reuse to Single Use in Outpatient Dialysis Units||Fresenius Medical Care North America|No|Completed|March 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2500|||Both|18 Years|N/A|No|Non-Probability Sample|patients receiving dialysis in facilities where re-use of dialyzers processed with Renalin        is practiced|May 2008|May 6, 2008|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00440908||173867|
NCT00440921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP06.008|Clinical Trial for Fibrin Sealant in Knee Surgery|Randomized Clinical Trial for Fibrin Sealant in Knee Surgery||Sanquin Research & Blood Bank Divisions|Yes|Withdrawn|December 2008|June 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|February 26, 2007||No|No agreement between investigator and sponsor|No||https://clinicaltrials.gov/show/NCT00440921||173866|
NCT00436735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070047, CDR0000529905|Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors|A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2006|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|February 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00436735||174182|
NCT00436748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050256|Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease|A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis||Amgen|No|Terminated|September 2008|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|116|||Both|1 Year|18 Years|No|||March 2015|March 26, 2015|February 15, 2007|Yes|Yes|Study Terminated; Commitment met per Regulatory Authorities.|No|March 4, 2015|https://clinicaltrials.gov/show/NCT00436748||174181|
NCT00437333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-187-2004|Metformin Suspension and Insulin Sensitivity|Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome||University Magna Graecia||Completed|December 2003|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Female|20 Years|30 Years|No|||February 2007|February 20, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00437333||174138|
NCT00430963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0520/1|IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines||Merz Pharmaceuticals GmbH|No|Completed|October 2006|November 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||October 2011|October 25, 2011|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430963||174620|
NCT00427713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526299|Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer|Chemotherapy or No Chemotherapy in Clear Margins After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. A Randomised Phase III Trial of Control Vs Capecitabine Plus Oxaliplatin [CHRONICLE]||National Cancer Institute (NCI)||Completed|November 2004|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|800|||Both|18 Years|N/A|No|||June 2007|August 23, 2013|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427713||174862|
NCT00427986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dorte Nellemann, galactose|Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema|Diabetic Macular Oedema: Quantification of the Effect of Rising the Intracapillary Osmotic Pressure With Intravenous Galactose on the Retinal Thickness||Glostrup University Hospital, Copenhagen||Terminated|January 2007|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2007|June 25, 2007|January 25, 2007|||No sufficient increase in plasma osmolarity by galactose (one patient included)|No||https://clinicaltrials.gov/show/NCT00427986||174842|
NCT00428779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601095|Neuromuscular and Cognitive Fatigue During a 24 Hour Treadmill Running Exercise|Neuromuscular and Cognitive Fatigue During a 24h Treadmill Running Exercise.||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2009|June 10, 2009|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00428779||174783|
NCT00428454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2006-02|Sirolimus-eluting vs Zotarolimus-eluting Stents for Chronic Total Coronary Occlusions|A Randomized Comparison of Sirolimus-eluting Stent Implantation With Zotarolimus-eluting Stent Implantation for the Treatment of Chronic Total Coronary Occlusions. The PRISON III Trial.||R&D Cardiologie||Completed|January 2007|June 2015|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00428454||174808|
NCT00428467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apex-stitch|Apical Compression Stitch - a New Option for LV Remodelling|Pronounced Apical Dilatation in Failing Left Ventricles – a New Option for Surgical Remodelling Techniques||Johann Wolfgang Goethe University Hospitals||Active, not recruiting|May 2004|April 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428467||174807|
NCT00428181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA_FIE_015439|Multidisciplinary Approach to Reduce Injury and Alcohol|Multidisciplinary Approach to Reduce Injury and Alcohol||University of Texas at Austin|Yes|Completed|September 2007|October 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|605|||Both|18 Years|N/A|No|||April 2012|April 5, 2012|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428181||174827|
NCT00428740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2006-0388|Long-Term IOP Fluctuation and VF Progression After Triple Procedure|Long-Term Intraocular Pressure Fluctuation and Visual Field Progression in Glaucoma Patients With Low Intraocular Pressure After Triple Procedure||Yonsei University||Completed|October 2005|December 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||300|||Both|N/A|N/A|No|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428740||174786|
NCT00429026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0364|Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Adaptive Randomization of Fludarabine-Melphalan Versus Fludarabine-Cyclophosphamide Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor for Metastatic Renal Cell Carcinoma||M.D. Anderson Cancer Center|Yes|Terminated|January 2004|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|65 Years|No|||February 2013|February 26, 2013|January 29, 2007||No|Slow accrual, study terminated.|No|February 26, 2009|https://clinicaltrials.gov/show/NCT00429026||174764|Primary outcome measure was not assessed due to early study termination, e.g. patients did not receive assigned treatment.
NCT00451347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200611006R|Comparison of The Clinical Effects Between Different Physical Therapy Tools in Patellofemoral Pain Patients|||National Taiwan University Hospital||Recruiting|November 2006|August 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||90|||Both|16 Years|50 Years|No|||November 2006|March 21, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00451347||173073|
NCT00451867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK765209-Cellcept (IND)|A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .|A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Mycophenolate Mofetil (CellCept) for the Treatment of Refractory Interstitial Cystitis (IC)|ICCRN RCT2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Terminated|March 2007|April 2008|Anticipated|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|March 23, 2007|Yes|Yes|The major and primary reason for the study termination is the observed reduced efficacy of    CellCept compared to placebo.|No||https://clinicaltrials.gov/show/NCT00451867||173035|
NCT00428727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fcv075|Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON|Double Blind, Randomized, Placebo Controlled Clinical Trial for the Treatment of Diabetic Foot Ulcers, Using a Nitric Oxide Releasing Patch: PATHON||Fundación Cardiovascular de Colombia|Yes|Completed|January 2005|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428727||174787|
NCT00429013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC-05-44|Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue.|A Prospective, Randomised, Controlled, Open Study. Phase II Treatment Equivalent.||University Hospital, Grenoble|Yes|Terminated|September 2006|March 2009|Actual|January 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|N/A|No|||May 2009|May 25, 2009|January 29, 2007||No|principal criteria was achieved with the intermediate statistical analysis|No||https://clinicaltrials.gov/show/NCT00429013||174765|
NCT00428714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10737|Phase 2 Trial of Enzastaurin in Prostate Cancer in Patients Who Have Had Hormonal and Chemotherapy|Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy||Eli Lilly and Company|No|Completed|January 2007|January 2011|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Male|18 Years|N/A|No|||August 2011|August 1, 2011|January 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00428714||174788|
NCT00429000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007HT|Perinatal Hypothermia, Risk Factors and Long-Term Consequences in Guinea-Bissau, Westafrica|Reducing the Prevalence of Hypothermia Among Newborns by Means of Continuous Temperature Monitoring Using Thermospot.||Bandim Health Project||Not yet recruiting|January 2007|October 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||788|||Both|N/A|6 Hours|Accepts Healthy Volunteers|||January 2007|January 29, 2007|January 26, 2007||||No||https://clinicaltrials.gov/show/NCT00429000||174766|
NCT00430079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02419|Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma|Assessment of Hypoxia in Malignant Gliomas Using EF5||National Cancer Institute (NCI)||Terminated|July 2001|||September 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 30, 2007|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00430079||174686|
NCT00430092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-601A-002b|Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)|A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery||Sirion Therapeutics, Inc.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|219|||Both|2 Years|N/A||||May 2009|May 12, 2009|January 30, 2007||||No|May 12, 2009|https://clinicaltrials.gov/show/NCT00430092||174685|
NCT00430105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC20-CT97-0019|Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides|Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides||Cambridge University Hospitals NHS Foundation Trust||Completed|February 1998|April 2004||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|18 Years|80 Years|No|||January 2007|January 31, 2007|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00430105||174684|
NCT00429793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02707|Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)||Completed|February 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||December 2012|April 30, 2014|January 30, 2007|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00429793||174708|
NCT00430378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0763|Acupuncture for Prevention of Radiation-Induced Xerostomia|Acupuncture for Prevention of Radiation-Induced Xerostomia||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2007|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00430378||174665|
NCT00430391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH067902|Comparison of Video Consent Versus Routine Consent for Participation in Research Studies|Comparison of Video Consent and Routine Consent for Research||University of California, San Diego|Yes|Completed|December 2003|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|8||Actual|382|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2011|June 18, 2013|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430391||174664|
NCT00428974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-201PS|Safety and Efficacy Study of CF101 to Treat Psoriasis|A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis||Can-Fite BioPharma|No|Completed|June 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|70 Years|No|||August 2011|February 25, 2015|January 29, 2007|Yes|Yes||No|June 20, 2011|https://clinicaltrials.gov/show/NCT00428974||174768|
NCT00428987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070077|Physical and Behavioral Traits of Overweight and Obese Adults|Study of the Phenotype of Overweight and Obese Adults||National Institutes of Health Clinical Center (CC)||Recruiting|January 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 4, 2015|January 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00428987||174767|
NCT00429234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0574|Gemcitabine and Dasatinib in Advanced Solid Tumors|Phase I Open-Labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors||M.D. Anderson Cancer Center|No|Completed|January 2007|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00429234||174749|
NCT00429468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-835|A Study to Evaluate the Interaction Between Vicodin® CR and Ethanol in Healthy Male and Female Moderate Alcohol Drinkers|A Single-Centre, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Interaction Between Vicodin® CR and Ethanol in Healthy Male and Female Moderate Alcohol Drinkers||Abbott||Completed|January 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||25|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||October 2007|October 24, 2007|January 29, 2007||||||https://clinicaltrials.gov/show/NCT00429468||174731|
NCT00429754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 06.01|Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)|A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Bleomycin -Etoposide - Cisplatin (BEP) Treatment of Patients With Testis Carcinoma (A-BEP)||Radboud University|No|Withdrawn||September 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|75 Years|No|||January 2016|January 25, 2016|January 31, 2007|||change of study population and chemotherapeutic regimen|No||https://clinicaltrials.gov/show/NCT00429754||174711|
NCT00427388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRS 2007|Steroids In caRdiac Surgery Trial (SIRS Trial)|Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass||McMaster University|Yes|Active, not recruiting|June 2007|August 2014|Anticipated|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7507|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00427388||174886|
NCT00427999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BDE59|Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer|A Single Stage Phase II, Multi-centre, Open Label Study of Imatinib in Combination With Pioglitazone, Etoricoxib, Dexamethasone and Low-dose Treosulfane for Anti-inflammatory and Angiostatic Treatment in Patients With Hormone-refractory Prostate Cancer|INV342|Novartis||Completed|February 2007|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Male|18 Years|N/A|No|||March 2016|March 5, 2016|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427999||174841|
NCT00428792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124DDE04|Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)|An Open-label, Randomized, Rater-blinded, Cross-over, Multicenter Study Comparing the Clinical Efficacy of Methylphenidate (Immediate Release/Extended Release) Treatment (20 or 40 mg Orally od) in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Under Different Breakfast Conditions Over Two Weeks||Novartis||Completed|April 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|6 Years|12 Years|No|||April 2011|April 11, 2011|January 29, 2007||||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00428792||174782|
NCT00429065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemato INCAN 01/2007|Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.|Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.||Instituto Nacional de Cancerologia de Mexico||Recruiting|January 2007|January 2007||||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||30|||Both|15 Years|60 Years|No|||January 2007|January 30, 2007|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429065||174761|
NCT00428753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0070|China Case Control Avian Influenza|Matched Case-Control Study of Risk Factors for Human Infection With Avian Influenza A (H5N1) Virus, China||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2007|January 2008||||N/A|Observational|N/A||||100|||Both|1 Year|N/A|Accepts Healthy Volunteers|||May 2008|May 29, 2008|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00428753||174785|
NCT00428766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-003-001|Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer|A Study of the Safety, Tolerability, and Pharamcokinetics of MORAb-003, a Humanized Monoclonal Antibody, in Subjects With Advanced Ovarian Cancer||Morphotek||Completed|June 2005|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Female|18 Years|N/A|No|||November 2013|November 5, 2013|January 28, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00428766||174784|
NCT00452192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB 423-TP B5 Niere MRT|Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome|Detailed Analysis of the Effects of Telmisartan on Renal Perfusion in Patients With Metabolic Syndrome||University of Erlangen-Nürnberg Medical School|No|Completed|November 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Male|18 Years|65 Years|No|||July 2012|July 6, 2012|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452192||173010|
NCT00452205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICK-07521|Bone Marrow-derived Cells' Contribution to Tumor Formation and Inflammation|Bone Marrow-derived Cells' Contribution to Tumor Formation and Epithelial Cells Regeneration in the Gastrointestinal Tract||Komagome Hospital|No|Recruiting|April 2007|March 2017|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|tissue|Both|20 Years|70 Years|No|Non-Probability Sample|patients received bone marrow transplantation in Tokyo Metropolitan Komagome Hospital|August 2009|August 3, 2009|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452205||173009|
NCT00429533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51,988|Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris|A Prospective Randomized Placebo-Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance Phase Pemphigus Vulgaris||Jacobus Pharmaceutical||Terminated|November 1996|February 2004||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Both|18 Years|80 Years|No|||February 2007|February 1, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00429533||174726|
NCT00429806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-213|DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy|DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy-Phase I Randomized,Placebo-Controlled, Double-Blind Study.||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|November 2006|July 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Female|40 Years|75 Years|No|||March 2016|March 19, 2016|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429806||174707|
NCT00429260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY6577|A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression|A 1-week, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Outpatients With Depression Who Completed 8 Weeks of Treatment With Saredutant 100 mg Once Daily||Sanofi||Completed|January 2007|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|125|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|January 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00429260||174747|
NCT00430690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002489|Acoustic Startle Reduction In Cocaine Dependence|Acoustic Startle Reduction In Cocaine Dependence||Emory University|No|Active, not recruiting|September 2006|December 2016|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|135|Samples With DNA|Blood and extracted DNA|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with cocaine dependence who are entering substance abuse treatment; siblings of        these subjects; and healthy controls|January 2016|January 14, 2016|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430690||174641|
NCT00430703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNRC-AAU-06-1|Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Traumatic Brain Injury.|Effect of Massive Proprioceptive Stimulation With Passive Gait Training on the Cortical Activity in Patients With Impaired States of Consciousness After Severe Traumatic Brain Injury.||University of Aarhus|No|Completed|August 2006|August 2008|Actual|August 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2008|November 5, 2008|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430703||174640|
NCT00430989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6/07|The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial|Large, Randomised, Parallel-group, Controlled Trial, With Patients Randomly Allocated to Either N2O-containing (70% N2O in Oxygen [FiO2 0.3]) or N2O-free (70% Nitrogen in Oxygen [FiO2 0.3]).||Bayside Health|Yes|Completed|April 2007|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|7103|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|January 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00430989||174618|
NCT00431002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70624|Provincial Roll-Out Bone Health Strategy|||University of British Columbia|No|Withdrawn||September 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|0|||Female|65 Years|75 Years|No|||March 2013|March 26, 2013|January 31, 2007||No|Withdrawn|No||https://clinicaltrials.gov/show/NCT00431002||174617|
NCT00430066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571POLIVERA|Effects of Imatinib Mesylate in Polycythemia Vera|Glivec (Imatinib Mesylate) in the Treatment of Polycythemia Vera||Niguarda Hospital|Yes|Completed|February 2007|September 2012|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2014|October 7, 2014|January 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00430066||174687|
NCT00430352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO19872|MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.|A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.||Hoffmann-La Roche||Completed|September 2006|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|545|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 31, 2007||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT00430352||174667|
NCT00430365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0400401|Maintenance Therapy Using Lenalidomide in Myeloma|Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).|IFM2005-02|University Hospital, Toulouse|Yes|Active, not recruiting|June 2006|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|614|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430365||174666|
NCT00430651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/04.14|Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)|Multicenter Randomized Phase III Study Comparing Docetaxel With Carboplatin Versus Docetaxel Single Agent as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (NSCLC).||Hellenic Oncology Research Group||Completed|July 2004|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|75 Years|No|||January 2009|January 27, 2009|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430651||174644|
NCT00430664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7134-PG-1Tg-05/5469-71|A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis|A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis||Postgraduate Institute of Medical Education and Research||Recruiting|January 2006|December 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|12 Years|N/A|No|||February 2007|February 1, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00430664||174643|
NCT00430950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS866CM-B-E302|Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension|Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy||Daiichi Sankyo Inc.||Completed|February 2007|October 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1011|||Both|18 Years|N/A|No|||April 2009|April 29, 2009|February 1, 2007|Yes|Yes||No|February 9, 2009|https://clinicaltrials.gov/show/NCT00430950||174621|
NCT00427726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030124|Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies|Follow-Up Study of Breast Cancer and Multiple Myeloma Subjects Previously Enrolled in Retroviral Gene Transfer Studies||National Institutes of Health Clinical Center (CC)||Completed|March 2003|May 2014||||N/A|Observational|N/A|||Actual|12|||Both|N/A|N/A|No|||May 2014|May 21, 2014|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427726||174861|
NCT00428818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072005-011|Trimethoprim-Sulfamethoxazole or Doxycycline for Skin and Soft Tissue Infections|Empiric Therapy With Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High MRSA Prevalence: A Prospective Randomized Trial||University of Texas Southwestern Medical Center||Completed|August 2005|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||75|||Both|18 Years|N/A|No|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00428818||174780|
NCT00429078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3020-01A1|Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer|Phase I Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer||Roger Williams Medical Center|Yes|Withdrawn|July 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|January 30, 2007|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00429078||174760|
NCT00429325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUH-2|Fecal Calprotectin: Cheap Marker for Diagnosing Acute Infectious Diarrhea|Comparative Evaluation of Accuracy of Fecal Calprotectin, Lactoferrin and Occult Blood Testing (FOBT) in Predicting Microbiological Diagnosis for Acute Infectious Diarrhea: A Prospective Multicentre Double Blind Randomized Controlled Trial.||Johann Wolfgang Goethe University Hospitals||Completed|January 2004|January 2007||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal||||400|||Both|18 Months|N/A|No|||February 2007|July 16, 2007|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429325||174742|
NCT00451399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jzhao|Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain|Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison||Central South University|Yes|Completed|October 2004|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||128|||Both|18 Years|45 Years|No|||October 2007|October 30, 2007|March 22, 2007||||Yes||https://clinicaltrials.gov/show/NCT00451399||173069|
NCT00451620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H02-70584|Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes|Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes||University of British Columbia|No|Completed|November 2003|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|65 Years|N/A|No|||February 2014|February 17, 2014|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451620||173053|
NCT00451633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-E044-213|The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations|A Randomized, Double Blind, Placebo-Controlled Study To Investigate The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations||Eisai Inc.||Withdrawn|March 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|30 Years|80 Years|No|||October 2013|October 30, 2013|March 21, 2007|Yes|Yes|The study group changed from patients to a healthy volunteers. A healthy-volunteer study is    being planned to replace 213.|No||https://clinicaltrials.gov/show/NCT00451633||173052|
NCT00429819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084-GUK-2006-002|Neurovascular Coupling in Eyes of Glaucoma Patients|Neurovascular Coupling in Eyes of Glaucoma Patients||University Hospital, Basel, Switzerland|No|Completed|December 2006|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|||Both|40 Years|79 Years|No|Non-Probability Sample|glaucoma patients ocular hypertension|December 2014|December 15, 2014|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429819||174706|
NCT00430118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000528029|Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia|ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia||University of Schleswig-Holstein||Completed|July 2000|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|4559|||Both|1 Year|18 Years|No|||May 2013|May 28, 2013|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00430118||174683|
NCT00430131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKR-06-055|Investigating Best Practices for Children With Cerebral Palsy: A Pilot Study of Two Approaches|Investigating Best Practices for Children With Cerebral Palsy: A Pilot Study of Two Approaches||University of Toronto|No|Active, not recruiting|December 2006|September 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|7 Years|12 Years||||August 2009|August 12, 2009|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00430131||174682|
NCT00430729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-112|Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)|Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52 Weeks Double Blind Study With 500mcg Roflumilast Once Daily Versus Placebo. Ratio-Study.||Takeda||Completed|January 2003|October 2004||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||1100|||Both|40 Years|N/A|No|||February 2007|May 4, 2012|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00430729||174638|
NCT00430742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0364-011|An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) Followed by a 1-Year Extension||Merck Sharp & Dohme Corp.||Terminated|November 2006|November 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|600|||Both|18 Years|75 Years|No|||February 2015|February 12, 2015|February 1, 2007|Yes|Yes|The overall profile does not support development for obesity|No||https://clinicaltrials.gov/show/NCT00430742||174637|
NCT00430404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/0846/2004|Screening and Treatment of Depression in the Community|Randomized Controlled Trial of a Community-based Early Psychiatric Intervention Strategy to Screen and Manage Depression in the Elderly||National University Hospital, Singapore|No|Completed|August 2004|September 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|60 Years|N/A|No|||January 2014|January 2, 2014|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430404||174663|
NCT00430417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610073|Bone Metabolism and Parathyroid Hormone-related Protein (PTHrP) Lactation Study|A Prospective Cohort Pilot Study of Bone Metabolism in Lactating and Non-lactating Postpartum Women and Healthy Non-pregnant Women||University of Pittsburgh|Yes|Completed|January 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|49|Samples Without DNA|archival blood serum and plasma|Female|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|New mothers who are either almost exclusively breast feeding or bottle feeding; normal        controls to match those new mothers.|October 2013|October 30, 2013|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430417||174662|
NCT00430716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481244|To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.|A Multinational, Multicentre, Randomized, Parallel Group, Double-Blind Study To Assess The Efficacy and Safety Of 1 mg, 5 mg and 20 mg TID of Oral Sildenafil in the Treatment of Subjects Aged 18 Years and Over With Pulmonary Arterial Hypertension (PAH)||Pfizer|Yes|Terminated|April 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|130|||Both|18 Years|N/A|No|||May 2011|May 25, 2011|January 31, 2007|Yes|Yes|This study was terminated at the recommendation of an independent Data Monitoring Committee.    The decision was not based on any safety concerns.|No|April 22, 2011|https://clinicaltrials.gov/show/NCT00430716||174639|The trial was not designed to demonstrate the equivalence of doses and due to premature study termination, the resulting sample size was not adequately powered to show superiority.
NCT00431015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-03|Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)|A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients||Infinity Pharmaceuticals, Inc.|No|Completed|January 2007|December 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|January 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00431015||174616|
NCT00431262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT no. 2006-004921-27|Antabuse in Severe Alcoholism: an Open Controlled Study|Antabuse in Severe Alcoholism: an Open Controlled Study||Psykiatrisk Center Gentofte||Recruiting|February 2007|June 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|70 Years|No|||March 2007|March 2, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00431262||174597|
NCT00430677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-075|Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis|A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)||Bristol-Myers Squibb|Yes|Terminated|June 2007|August 2011|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|423|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 1, 2007|Yes|Yes|Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period|No|February 13, 2012|https://clinicaltrials.gov/show/NCT00430677||174642|
NCT00430976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0101|Exercise, Executive Processes and the Aging Brain|Exercise, Executive Processes and the Aging Brain||National Institute on Aging (NIA)||Completed|December 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|60 Years|74 Years|Accepts Healthy Volunteers|||August 2008|December 10, 2009|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00430976||174619|
NCT00431236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV102551|A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy|See Detailed Description||GlaxoSmithKline||Completed|November 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1|||810|||Both|18 Years|N/A|No|||October 2010|October 13, 2010|February 2, 2007||||||https://clinicaltrials.gov/show/NCT00431236||174599|
NCT00431522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9387|Valproic Acid Sodium Salt in Bipolar Disorder|Protective Effect of Valproate on Brain Cells:A Magnetic Resonance Imaging and Spectroscopy Study in Patients With Bipolar Disorder Diagnosis||Sanofi||Completed|December 2004|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|58|||Both|18 Years|65 Years|No|||May 2009|May 28, 2009|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431522||174577|
NCT00428025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diclofenac trial hookey|Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients|Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients: A Prospective, Randomized, Double Blind, Placebo Controlled Trial.||Queen's University|No|Terminated|October 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|23|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|January 25, 2007||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00428025||174839|
NCT00428194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006LS019|Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer|Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|January 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|January 25, 2007|Yes|Yes|Withdrawn due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00428194||174826|
NCT00428480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-06-07-104-01|Walking Study for Stroke Rehabilitation|Stroke Inpatient Rehabilitation Reinforcement of Walking Speed|SIRROWS|University of California, Los Angeles|No|Completed|May 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|35 Years|85 Years|No|||July 2009|November 10, 2011|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00428480||174806|
NCT00428831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0096|Clinical IGSP-CHOP Boston|Clinical Correlates to Influenza Genomic Data||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Will recruit patients of both genders and of any health status. Will be recruited at        Children's Hospital Boston and at Beth Israel Deaconess Medical Center. At Children's        Hospital, patients 30 days to 5 years of age will be recruited; at Beth Israel Deaconess        Medical Center patients of any age will be eligible.|September 2008|December 19, 2013|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428831||174779|
NCT00429091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-818|A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)||Abbott||Completed|January 2007|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|243|||Both|18 Years|60 Years|No|||September 2010|November 1, 2010|January 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00429091||174759|
NCT00429338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0333|3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate|Feasibility Study of 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate||M.D. Anderson Cancer Center|No|Terminated|January 2007|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|8|||Male|18 Years|N/A|No|||January 2015|January 7, 2015|January 29, 2007||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00429338||174741|
NCT00453128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGR1|Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients|Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease||Sociedade Galega de Reumatoloxía|No|Completed|January 1997|December 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||240|||Both|N/A|N/A|No|||March 2007|March 27, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00453128||172941|
NCT00453440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNA109479|Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701|Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected UK Patients||GlaxoSmithKline|No|Completed|March 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|1569|||Both|18 Years|N/A|No|||August 2010|August 31, 2010|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00453440||172918|
NCT00452465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200603MOP-158331-SDA-CJAA|Primary Healthcare for Community Living Old Elderly|The ElderCare Project: Primary Healthcare for Community Living Old Elderly||Memorial University of Newfoundland|No|Completed|February 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|236|||Both|80 Years|N/A|No|||March 2016|March 14, 2016|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452465||172989|
NCT00430144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-214|Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix|A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix||National Cancer Center, Korea|No|Completed|January 2007|October 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|N/A|No|||April 2012|April 25, 2012|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430144||174681|
NCT00430157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPR107498|Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber|An 8 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)||GlaxoSmithKline|No|Completed|January 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|50 Years|No|||February 2011|May 31, 2012|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00430157||174680|
NCT00430430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 05-120|Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets|Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets||University of Toronto||Active, not recruiting|April 2007|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00430430||174661|
NCT00430443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-105|Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML|Phase I Study of Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed Acute Lymphocytic Leukemia and Acute Myelogeneous Leukemia||Callisto Pharmaceuticals|No|Terminated|February 2007|January 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|12 Months|21 Years|No|||August 2011|August 30, 2011|January 30, 2007|Yes|Yes|Participants are no longer being examined or treated.|No||https://clinicaltrials.gov/show/NCT00430443||174660|
NCT00431041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VES-001|Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)|VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients|VECTOR|Astellas Pharma Inc|No|Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||June 2010|June 1, 2010|February 1, 2007|Yes|Yes||No|October 5, 2009|https://clinicaltrials.gov/show/NCT00431041||174614|The relatively high incidence of AEs, specifically dry mouth, in both groups may be a result of the direct questioning methodology used. Subjects were also informed the primary objectives were the relative frequency and severity of dry mouth.
NCT00431054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0970|Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer|Pharmacodynamic Trial: Molecular Marker & Imaging Studies as Primary Endpoints to Determine Optimal Biological Dosage of Perifosine, Orally Avail AKT PH Domain Inhibitor Combined w/ Docetaxel in Patients w/Relapsed Epithelial Ovarian Cancer||M.D. Anderson Cancer Center|No|Completed|February 2007|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||June 2012|February 17, 2016|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431054||174613|
NCT00431028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duocat 001|Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery|Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery||Federal University of São Paulo|Yes|Terminated|September 2005|March 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|140|||Both|50 Years|N/A|No|||March 2008|March 6, 2008|February 1, 2007||No|Terminated|No||https://clinicaltrials.gov/show/NCT00431028||174615|
NCT00431288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA 0355332B|A Nutrition Intervention to Lower Blood Pressure in Adolescents|Efficacy of a Nutrition Intervention Emphasizing Fruits, Vegetables and Dairy to Lower Blood Pressure in Adolescents||University of Cincinnati||Completed|August 2003|June 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||54|||Both|11 Years|18 Years|No|||February 2007|February 1, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00431288||174595|
NCT00431561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP 12009-G004|Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma|Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week||Isarna Therapeutics GmbH|Yes|Completed|April 2003|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|141|||Both|18 Years|75 Years|No|||December 2013|December 2, 2013|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431561||174574|
NCT00431249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960126|Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease|Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease.||Tungs’ Taichung Metroharbour Hospital|No|Completed|February 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|40|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|February 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00431249||174598|
NCT00431535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SvO2|Study Concerning Relationship Between Mixed Venous Saturation (SvO2) and Balance|Descriptive Study Concerning the Connection Between SvO2 and Orthostatic Function Post Operatively||Rigshospitalet, Denmark||Completed|February 2007|May 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|17|||Male|18 Years|80 Years|No|||October 2007|June 14, 2013|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431535||174576|
NCT00427401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8441003|A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks|A Double Blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-00915275 After Oral Administration To Subjects With Type 2 Diabetes Mellitus For 4-Weeks||Pfizer||Terminated|February 2007|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|70 Years|No|||September 2008|September 25, 2008|January 25, 2007|||This study was terminated May 7, 2007. The study stopped due to tablet formulation issues. No    safety issues were involved in the termination decision.|No||https://clinicaltrials.gov/show/NCT00427401||174885|
NCT00428012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 DK77322 (completed)|Quality of Life Therapy for Adults With ESRD Awaiting Renal Transplantation|Quality of Life Therapy for Adults With ESRD Awaiting Renal Transplantation||Beth Israel Deaconess Medical Center|Yes|Completed|January 2007|April 2011|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|65|||Both|21 Years|70 Years|No|||January 2012|January 5, 2012|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428012||174840|
NCT00428493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0055|Prospective Study of AI H5N1 in China|Prospective Study of Individuals Exposed to Confirmed Cases of Human Influenza A (H5N1) Infection in China||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2007|January 2008||||N/A|Observational|Time Perspective: Prospective||||4000|||Both|12 Months|N/A|Accepts Healthy Volunteers|||May 2008|May 29, 2008|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00428493||174805|
NCT00428805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72958|Child Health Initiative for Lifelong Eating and Exercise (CHILE)|Site Specific Approaches to Prevention or Management of Pediatric Obesity: Child Health Initiative for Lifelong Eating and Exercise--CHILE|CHILE|University of New Mexico|Yes|Completed|March 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|980|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||July 2009|November 30, 2015|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428805||174781|
NCT00429364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461|Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network|Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)||New England Research Institutes|Yes|Completed|January 2007|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|608|||Both|6 Months|25 Years|No|||January 2014|March 17, 2015|January 29, 2007|Yes|Yes||No|February 25, 2015|https://clinicaltrials.gov/show/NCT00429364||174739|The effect of losartan on TGF-β was not assessed. The study results do not apply to Marfan subjects whose BSA–adj. aortic-root z score is ≤3.Subjects may find their treatment based on the appearance of the drug.
NCT00429611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQCA02|High Low Biphasic Energy Defibrillation (HiLoBED)|A Multicentre Prospective Randomised Study Comparing the Efficacy of High Versus Low Biphasic Energy Defibrillation in Patients With Cardiac Arrest||Singapore General Hospital|Yes|Active, not recruiting|November 2004|December 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|600|||Both|21 Years|N/A|No|||June 2009|June 30, 2009|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429611||174721|
NCT00429377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506-LN02|Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study|Phase 3 Study of Tacrolimus(FK506)for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study||Astellas Pharma Inc||Completed|June 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||64|||Both|16 Years|64 Years|No|||January 2007|January 29, 2007|January 29, 2007||||No||https://clinicaltrials.gov/show/NCT00429377||174738|
NCT00429351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK75018|Aromatic Amino Acid Metabolism in the Pathogenesis of Kwashiorkor|||Baylor College of Medicine||Completed|September 2006|June 2010|Actual|||Phase 0|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|82|Samples Without DNA|plasma, expired breath|Both|6 Months|18 Months|No|Non-Probability Sample|82 children aged 6 to 18 months and diagnosed with severe protein-energy malnutrition. By        the Wellcome Classification patients will have marasmus (< 60 % weight/age and no edema),        marasmic-kwashiorkor (< 60 % weight/age plus edema) or kwashiorkor (< 80 % weight/age plus        edema)|December 2010|December 21, 2010|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429351||174740|
NCT00454506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26131|Hospital for Special Surgery Hip Arthroplasty Cohort|Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: HSS Hip Arthroplasty Cohort||Hospital for Special Surgery, New York|Yes|Active, not recruiting|April 2007|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|We will be asking all patients undergoing a total hip arthroplasty to participate.|August 2015|August 17, 2015|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454506||172836|
NCT00453700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06H-561004|Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram|Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram||University of California, Los Angeles|No|Recruiting|February 2007|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening||||300|||Both|18 Years|60 Years|No|||March 2007|March 28, 2007|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00453700||172898|
NCT00430456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H26843|Treadmill Exercise Prescriptions to Improve Fitness Versus Ambulatory Function After Stroke.|Treadmill Exercise Prescriptions to Improve Fitness Versus Ambulatory Function After Stroke|STEPs|VA Office of Research and Development|Yes|Completed|August 2006|June 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|85 Years|No|||June 2012|June 11, 2012|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430456||174659|
NCT00430755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBK080|Improving the Quality of Patient Care by Using a Clinical Expert System.|Quality Assessment for History Taking With or Without an Knowledge Based Interview System.|CLEOS|Robert Bosch Gesellschaft für Medizinische Forschung mbH|No|Completed|August 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|98|||Both|18 Years|N/A|No|||November 2015|November 15, 2015|January 31, 2007||No||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00430755||174636|
NCT00430768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|438|Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency|Preclinical & Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV1-CB-hAAT) Gene Vector to AAT-Deficient Adults||University of Massachusetts, Worcester|Yes|Completed|February 2006|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|January 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00430768||174635|
NCT00431067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.11|Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy|Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy||Boehringer Ingelheim||Completed|September 2006|||August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||November 2013|June 3, 2014|February 2, 2007||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00431067||174612|
NCT00431301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG024040-01A2|Risk Factors for Progressive Supranuclear Palsy (PSP)|Genetic and Environmental Risk Factors for PSP||University of Louisville||Completed|August 2006|June 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|942|Samples With DNA|DNA will be used for genotyping specific genes of interest related to the disease.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with clinically diagnosed Progressive Supranuclear Palsy and healthy controls|July 2013|July 3, 2013|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00431301||174594|
NCT00431574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234/2003|Antipsychotic Medication Extended Dosing Study|Antipsychotic Medication Extended Dosing Study||Centre for Addiction and Mental Health||Completed|August 2002|October 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|75 Years|No|||February 2008|February 25, 2008|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431574||174573|
NCT00427453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB004|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously||University of Oxford||Completed|June 2003|March 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2006|January 26, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427453||174881|
NCT00427466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jth_006|Pemetrexed in Patients With Soft Tissue Sarcoma|Multicenter Phase II Study With Pemetrexed in Patients With Pre-Treated Metastatic Soft Tissue Sarcomas||University Hospital Tuebingen||Completed|January 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Both|18 Years|90 Years|No|||February 2009|February 13, 2009|January 26, 2007||||No||https://clinicaltrials.gov/show/NCT00427466||174880|
NCT00431275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671011|Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody|An Open Label, Randomized Clinical Comparability Study Of The Current Liquid And Commercial Liquid Formulations||AstraZeneca|No|Completed|June 2006|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|February 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00431275||174596|
NCT00431548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-180198|Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV)|Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV).||Medical University of Vienna||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|19 Years|70 Years||||February 2007|February 5, 2007|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431548||174575|
NCT00427739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0200|Data Collection During CT for Axial Flow VADs|Pilot Study of Data Collection During Computerized Tomography (CT) to Determine Accurate Flow Rates for Axial Flow Ventricular Assist Device (VAD) Patients||Ohio State University|No|Completed|June 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||April 2010|April 9, 2010|January 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00427739||174860|
NCT00427752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H0120|Abdominal Exploration Without Incisions|Diagnostic Transluminal Endoscopic Peritoneoscopy||Ohio State University|No|Completed|October 2006|January 2012|Actual|January 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|80 Years|No|||May 2012|May 3, 2012|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427752||174859|
NCT00427765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0190|Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma|A Phase II Study of High-Dose Intravenous Busulfan Plus Melphalan With Allogeneic or Autologous Marrow or Peripheral Blood Progenitor Cell Transplantation for Lymphoid Malignancies or Multiple Myeloma||M.D. Anderson Cancer Center|No|Completed|December 2004|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|18 Years|65 Years|No|||December 2011|December 15, 2011|January 25, 2007||No||No|November 14, 2011|https://clinicaltrials.gov/show/NCT00427765||174858|
NCT00428207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-18|Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy|Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy||Joslin Diabetes Center|No|Terminated|February 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|75 Years|No|||December 2012|December 27, 2012|January 25, 2007|Yes|Yes|The differences in treatment could be better observed and monitored by using a continuous    glucose monitoring system instead of the 7 point fingerstick.|No||https://clinicaltrials.gov/show/NCT00428207||174825|
NCT00428220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181114|A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.|An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment||Pfizer|No|Completed|July 2007|September 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|226|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|January 26, 2007|No|Yes||No|July 26, 2015|https://clinicaltrials.gov/show/NCT00428220||174824|
NCT00428519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75558|Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals|A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals||University of Pennsylvania|Yes|Completed|January 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|N/A|No|||April 2010|April 23, 2010|January 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00428519||174803|
NCT00428506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALB-PPCD|Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction|Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction in Cirrhotic Patients With Ascites||University of Turin, Italy|Yes|Recruiting|February 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|70|||Both|18 Years|75 Years|No|||April 2008|April 9, 2008|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428506||174804|
NCT00438061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-256|Effect of Abdominal Obesity on Lipoprotein Metabolism|Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity||The University of Western Australia||Completed|January 1995|December 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2007|February 23, 2007|February 20, 2007||||No||https://clinicaltrials.gov/show/NCT00438061||174084|
NCT00429897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|Double Blind Crossover Comparison of Diuretics in the Young|Double Blind Crossover Comparison od Diuretics in Young Patients With Low Renin Hypertension||University of Cambridge||Recruiting|August 2006|July 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Both|18 Years|45 Years|No|||January 2007|January 31, 2007|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00429897||174700|
NCT00450931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000513888|Drug Facts Page or a Short Drug Summary in Helping Patients and Doctors Understand Medical Information|Helping Patients and Physicians Make Sense of Medical Data||National Cancer Institute (NCI)||Active, not recruiting||||||N/A|Interventional|Allocation: Randomized|||Anticipated|200|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||September 2008|January 3, 2014|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450931||173105|
NCT00450359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABROIN-06-MRE01-14|Computer-Aided Breast Cancer Detection in Women Undergoing Screening Mammography|A Prospective Evaluation of Computer Aided Detection (CAD) in the NHS Breast Screening Programme [CADET II]||National Cancer Institute (NCI)||Completed|September 2006|October 2008|Actual|||N/A|Interventional|Allocation: Randomized, Primary Purpose: Screening|||Anticipated|30000|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||October 2008|August 1, 2013|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450359||173149|
NCT00430183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB 90203|Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer|A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer||Alliance for Clinical Trials in Oncology|Yes|Recruiting|December 2006|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Male|18 Years|N/A|No|||March 2015|March 13, 2015|January 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00430183||174678|
NCT00430781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG105281|Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer|A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen||GlaxoSmithKline||Completed|November 2006|July 2011|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|228|||Female|18 Years|N/A|No|||April 2015|April 15, 2015|January 31, 2007|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00430781||174634|
NCT00430469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP 02-02; SC13|Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients|Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients||AM-Pharma|Yes|Withdrawn|November 2008|June 2009|Anticipated|March 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|February 1, 2007||No|Strategic company decision|No||https://clinicaltrials.gov/show/NCT00430469||174658|
NCT00431327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|705823|Facilitators to Keeping Colonoscopy Appointments|Peer Coach Intervention to Improve Attendance to Scheduled Colonoscopy||University of Pennsylvania||Completed|February 2005|October 2006||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||140|||Both|50 Years|N/A|No|||February 2007|February 2, 2007|February 1, 2007||||No||https://clinicaltrials.gov/show/NCT00431327||174592|
NCT00431340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-16|A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma|A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma||Onxeo||Terminated|March 2007|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|February 2, 2007|||Terminated due to dose limiting toxicity|||https://clinicaltrials.gov/show/NCT00431340||174591|
NCT00431314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD|Effect of Hemodialysis on Toe Pressure- and Finger Pressure and Skin Autofluorescence in Hemodialysis Patients|The Effect of Hemodialysis on Toe Pressure- and Finger Pressure Measurements and Measurement of Skin Autofluorescence; a Pilot Study in the Assessment of Critical Limb Ischemia in Hemodialysis Patients.||Isala|No|Completed|January 2007|March 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|hemodialysis patients in one hemodialysis centre|January 2007|July 8, 2008|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431314||174593|
NCT00431587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|metabo-HMO-CTIL|Changes in Different Fat Compartments and Their Effect on Particular Manifestations of Metabolic Syndrome After Bariatric Procedures.|Changes in Different Fat Compartments During Weight Loss and Their Effect on Particular Manifestations of Metabolic Syndrome After Bariatric Procedures.||Hadassah Medical Organization||Recruiting|June 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|65 Years|No|||January 2007|April 16, 2008|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431587||174572|
NCT00427505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2126|Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam|An Open-label, One-sequence Cross-over Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam in Healthy Volunteers||Novartis||Completed|July 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427505||174877|
NCT00427479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002UR005B|Oral Allergy Syndrome (OAS): a Pilot Study to Evaluate a Clinical Questionnaire as a Diagnostic Tool|The Prevalence of Oral Allergy Syndrome and Types of Food Commonly Causing Reactions in Birch Pollen Sensitive Patients Who Have Springtime Hayfever||Royal Brompton & Harefield NHS Foundation Trust||Completed|July 2002|December 2003||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2007|January 26, 2007|January 26, 2007||||No||https://clinicaltrials.gov/show/NCT00427479||174879|
NCT00427492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02 290964|Effect of Postoperative Laxative on Bowel Function After Colonic Surgery|Effect of Postoperative Laxative on Bowel Function After Colonic Surgery||Hvidovre University Hospital|Yes|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|56|||Both|18 Years|N/A||||February 2009|February 10, 2009|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00427492||174878|
NCT00427778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|obgy-160-06|Incontinence Ring on Stress Urinary Incontinence|Effect of the Incontinence Ring on Urodynamic Stress Urinary Incontinence: A Randomized Trial.||Queen's University|No|Terminated|January 2007|May 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 30, 2008|January 25, 2007|Yes|Yes|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00427778||174857|
NCT00428233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-200|Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation|Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation||Dana-Farber Cancer Institute|Yes|Completed|November 2006|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428233||174823|
NCT00428532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-07-EMC|The Effect of Licorice Root Extract and Pomegranate Juice on Atherosclerotic Parameters in Diabetic Patients|||HaEmek Medical Center, Israel||Recruiting|March 2007|August 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Male|18 Years|N/A|No|||January 2007|May 7, 2007|January 27, 2007||||No||https://clinicaltrials.gov/show/NCT00428532||174802|
NCT00428545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0764|Bevacizumab and Bortezomib in Patients With Advanced Malignancy|A Phase I Trial of Bevacizumab and Bortezomib in Patients With Advanced Malignancy||M.D. Anderson Cancer Center|No|Completed|January 2007|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|N/A|N/A|No|||February 2013|February 11, 2013|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00428545||174801|
NCT00428844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-016|Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci|A Phase 2 Randomized Study Investigating the Safety, Efficacy and Pharmacokinetics of Daptomycin 6 mg/kg and 8 mg/kg Versus Comparator in the Treatment of Subjects Undergoing Surgical Standard of Care for Osteomyelitis Associated With an Infected Prosthetic Hip or Knee Joint Caused by Staphylococci||Cubist Pharmaceuticals LLC|Yes|Completed|January 2007|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|January 26, 2007|Yes|Yes||No|March 16, 2011|https://clinicaltrials.gov/show/NCT00428844||174778|
NCT00429104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM01-0100|Herceptin and GM-CSF for Metastatic Breast Cancer|Phase II Study of GM-CSF to Overcome Herceptin-Resistant HER-2/Neu-Overexpressing Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Completed|August 2002|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|N/A|N/A|No|||December 2012|December 4, 2012|January 29, 2007||No||No|March 25, 2011|https://clinicaltrials.gov/show/NCT00429104||174758|
NCT00429117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0724|Interest in Spirituality and Oncology: Is It An International Phenomenon?|Interest in Spirituality and Oncology: Is It An International Phenomenon?||M.D. Anderson Cancer Center|No|Withdrawn|January 2007|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physician members of the International Gynecologic Oncologists Society or the Society of        Gynecologic Oncologists.|November 2011|November 17, 2011|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429117||174757|
NCT00429624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-0085|Randomized Controlled Trial of Chiropractic Manipulation Versus Medical Therapy for Chronic Neck Pain|Randomized Controlled Trial of Chiropractic Manipulation Versus Medical Therapy for Chronic Neck Pain||University of Colorado, Denver||Completed|September 1994|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Both|18 Years|70 Years|No|||January 2007|February 4, 2013|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429624||174720|
NCT00449553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6E-CP-GLAR|Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.|A Prospective Study of Associations of Changes in HbA1C and Fasting Blood Lipids Due to Treatment With Pioglitazone for 6 Months and Genetic Polymorphism's in PPAR-gamma||Takeda|No|Completed|June 2001|September 2003|Actual|September 2003|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|326|Samples With DNA|Whole blood for DNA-analyses|Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving pioglitazone therapy.|February 2012|February 27, 2012|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00449553||173210|
NCT00451204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-NS051591|A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)|A Combination Trial of Copaxone Plus Estriol in RRMS|Estriol in MS|University of California, Los Angeles|Yes|Completed|March 2007|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|158|||Female|18 Years|50 Years|No|||December 2014|December 18, 2014|March 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451204||173084|
NCT00430794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14399|The Efficacy of Spironolactone in Patients With Resistant Hypertension|A Randomised, Placebo Controlled Trial of the Efficacy of the Addition of Spironolactone to Modern Antihypertensive Treatment Regimens in Patients With Resistant Hypertension||Sheffield Teaching Hospitals NHS Foundation Trust||Terminated|March 2007|December 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||February 2007|December 3, 2010|February 1, 2007|||Difficulties with recruitment.|No||https://clinicaltrials.gov/show/NCT00430794||174633|
NCT00430495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27298|A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)|A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy|AUGUST I|EMD Serono|No|Completed|December 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|256|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 30, 2007|Yes|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT00430495||174656|
NCT00431080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/04.22|Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer|A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-Supported Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Women With Axillary Lymph Node Positive Breast Cancer||Hellenic Oncology Research Group||Completed|August 2004|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|478|||Female|18 Years|75 Years|No|||January 2008|January 18, 2008|February 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00431080||174611|
NCT00439088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRC-0020-02|Try Walking a Mile in These Shoes: Activity Level of Lower Extremity Amputees|Comparison of the Patient Activity Monitor to a Pedometer During Ambulation Monitoring of Transtibial Amputees|PamPed|University of Ottawa||Completed|July 2005|August 2005||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2007|March 7, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439088||174007|
NCT00431600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-121103|The Validity of Retinal Blood Flow Measurements During Hyperoxia in Humans Using Fourier Domain Color Doppler Optical Coherence Tomography (CDOCT)|The Validity of Retinal Blood Flow Measurements During Hyperoxia in Humans Using Fourier Domain CDOCT||Medical University of Vienna|Yes|Completed|September 2010|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||July 2008|September 20, 2012|February 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00431600||174571|
NCT00427531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000525737|Skin Conduction Device and Patient Diary for Measuring Hot Flashes in Postmenopausal Women With Hot Flashes|An Exploratory Trial to Examine the Accuracy of Various Hot Flash Variables With an Ambulatory Sternal Skin Conductance Recording Tool||Mayo Clinic|Yes|Completed|June 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|3|||Both|18 Years|N/A|No|||March 2011|March 16, 2011|January 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00427531||174876|
NCT00439673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS0205|PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS|A Open Label, Phase II, Non Randomized, Clinical Trial of Chemotherapy Treatment With 5-Azacytidine Plus Valproic Acid and Eventually Atra for Patients Diagnosed With Intermediate II and High Risk Myelodysplastic Syndrome (MDS). EudraCT Number 2005-004811-31. GIMEMA Protocol MDS0205||Gruppo Italiano Malattie EMatologiche dell'Adulto||Completed|May 2007|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|N/A|No|||November 2010|November 24, 2010|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00439673||173962|
NCT00427817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 06 11|PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma|PRO-STATE: Prognostic Interest of Serum Protein Profiles of Patients Undergoing a Prostate Biopsy: Search for a Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins.||University Hospital, Grenoble||Completed|August 2006|January 2011|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Male|18 Years|N/A|No|Non-Probability Sample|Patient undergoing a prostate biopsy or a prostatectomy(according to common criteria).|October 2011|October 5, 2011|January 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00427817||174854|
NCT00427830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB005|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG||University of Oxford||Completed|May 2003|January 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2006|January 26, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427830||174853|
NCT00427791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0989|Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia|Phase II Randomized Study Evaluating the Addition of Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia||M.D. Anderson Cancer Center|Yes|Completed|July 2005|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|N/A|60 Years|No|||April 2012|April 10, 2012|January 25, 2007||No||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00427791||174856|
NCT00427804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D-2007|Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption|Tumor Necrosis Factor-α Induces Vitamin D Resistance in Small Intestinal Calcium Absorption||Atlanta VA Medical Center|No|Completed|January 2007|November 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|January 25, 2007||No||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00427804||174855|
NCT00427414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-050|Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma|Pilot Study of Viral Load and Transcription in Kaposi's Sarcoma Patients Treated With Liposomal Anthracyclines||AIDS Malignancy Consortium|No|Terminated|September 2008|November 2011|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|January 25, 2007||No|Terminated due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00427414||174884|
NCT00427427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 06-05-104|Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer|A Phase II Trial of Delayed Adjuvant Herceptin® in Patients With HER-2 Positive Breast Cancer||University of California, Los Angeles||Terminated|January 2007|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Female|18 Years|N/A|No|||October 2007|October 25, 2007|January 25, 2007|||lack of accrual|No||https://clinicaltrials.gov/show/NCT00427427||174883|
NCT00427440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050253|A Phase II Study to Treat Advanced Malignant Glioma|A Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Malignant Glioma||Amgen||Completed|November 2006|April 2013|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|January 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00427440||174882|
NCT00428558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060504|Timed-Sequential Induction in CBF-AML|A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)||Assistance Publique - Hôpitaux de Paris|No|Completed|July 2007|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|60 Years|No|||July 2007|December 19, 2013|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00428558||174800|
NCT00440830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB5945|Nicotine Patch as an Analgesic Adjuvant After Surgery|Study to Determine Whether the Use of a Nicotine Patch During the Day of Surgery Improves Postoperative Pain and Reduces Opioid Requirement.||Columbia University|No|Completed|December 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|68|||Both|18 Years|60 Years|No|||October 2010|October 29, 2010|February 26, 2007|Yes|Yes||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00440830||173873|
NCT00428857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070501|Noninvasive Ventilatory Support After Lung Surgery in COPD Patients|Noninvasive Ventilatory Support After Lung Surgery to Prevent Pulmonary Complications in COPD Patients|POPVNI|Assistance Publique - Hôpitaux de Paris||Completed|June 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|360|||Both|18 Years|N/A|No|||January 2007|February 23, 2011|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00428857||174777|
NCT00437489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171086|A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.|A 16 Week Open-Label Outpatient, Randomized, Parallel Study Assessing The Impact Of Two Different Initial Dose Prescriptions For Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents.||Pfizer|No|Terminated|June 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||February 2009|April 13, 2009|February 20, 2007|Yes|Yes|This protocol was terminated not for safety reasons, but because Pfizer decided to return the    worldwide rights for Exubera to Nektar, on 18 October 2007.|No|December 11, 2008|https://clinicaltrials.gov/show/NCT00437489||174126|As a result of Pfizer's decision (18Oct2007) to return the worldwide rights for Exubera (insulin human [rDNA origin]) Inhalation Powder) to Nektar, from which Pfizer licensed inhaled insulin technology, it was decided to terminate this study.
NCT00437502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013247|A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer|A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA-51) as Consolidation Following Optimal Debulking and Systemic Chemotherapy for Women With Advanced Stage Ovarian, Tubal, or Peritoneal Cancer||Duke University|Yes|Completed|March 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||November 2012|November 15, 2012|February 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00437502||174125|
NCT00437827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rEEGTRD010|rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure|A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure||CNS Response|No|Completed|August 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2009|October 23, 2009|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00437827||174102|
NCT00438334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000170|Real-World Benefit From Directional Hearing Aids|Real-World Benefit From Directional Microphone Hearing Aids||Vanderbilt University||Completed|April 2001|March 2004||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||105|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2007|February 21, 2007|December 5, 2006||||No||https://clinicaltrials.gov/show/NCT00438334||174063|
NCT00438594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0776|Age 9 Follow-up of Preventive Intervention (Denver)|Age 9 Follow-up of Preventive Intervention|DenverY09|University of Colorado, Denver|Yes|Completed|February 2004|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|584|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 29, 2013|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438594||174044|
NCT00449826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI 2006361-01H|Risk Stratification of Non ST Elevation ACS With Computed Tomographic Angiography (REACT)|Risk Stratification of Non ST Elevation ACS With Computed Tomographic Angiography (REACT)||Ottawa Heart Institute Research Corporation||Completed|September 2006|December 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|107|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00449826||173189|
NCT00451451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS302|Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis|A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis|CONFIRM|Biogen|Yes|Completed|June 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1417|||Both|18 Years|55 Years|No|||January 2015|January 13, 2015|March 21, 2007|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00451451||173065|
NCT00451711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-AU-131-0176|Intermittent Liposomal Amphotericin B Primary Prophylaxis|A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisome® in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia||Bayside Health|Yes|Recruiting|May 2007|October 2014|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|60|||Both|18 Years|80 Years|No|||March 2007|December 12, 2013|March 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00451711||173047|
NCT00430508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS866CM-B-E301|Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension|Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy||Daiichi Sankyo Inc.|No|Completed|February 2007|May 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|972|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|February 1, 2007|Yes|Yes||No|February 9, 2009|https://clinicaltrials.gov/show/NCT00430508||174655|
NCT00430807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102808|Hydroxychloroquine in Giant Cell Arteritis|Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis.||University Hospital, Toulouse|No|Completed|January 2002|December 2006|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|85 Years|No|||October 2015|October 4, 2015|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430807||174632|
NCT00430820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060201|Discovery of New Circulating Biomarkers of Coronary Atherosclerosis|Discovery of New Circulating Biomarkers of Coronary Atherosclerosis Using Differential Proteomics: the BIOmarkers of CORonary Events (BIOCORE) Study||Assistance Publique - Hôpitaux de Paris|No|Completed|March 2007|November 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|124|Samples With DNA|biomarqueurs|Both|18 Years|80 Years|No|Probability Sample|Identification de nouveaux marqueurs circulants de l'athérosclérose coronarienne et de ses        complications par une nouvelle technique de protéomique différentielle.        Identification of new parqueurs circulated in coronary artheriosclerosis and complications        of the new differentiel technicology|April 2009|December 2, 2010|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00430820||174631|
NCT00440037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060113|Open Label Extension Study of AMG 531 in Japanese Subjects With ITP|An Open Label Extension Study Evaluating the Safety and Efficacy of Long Term Dosing of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura||Kyowa Hakko Kirin Company, Limited|No|Completed|November 2006|September 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|20 Years|N/A|No|||September 2014|September 11, 2014|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00440037||173934|
NCT00439374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801 SCAN|RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix|A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Nulliparous Women With a Short Cervix|SCAN|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Terminated|April 2007|December 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|657|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|October 26, 2012|February 21, 2007|Yes|Yes|Halted by NICHD after recommendation by DSMC to stop for futility|No||https://clinicaltrials.gov/show/NCT00439374||173985|
NCT00439686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM2001|Study of ZIO-201 in Advanced Sarcoma|A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma||Ziopharm||Completed|February 2006|December 2013|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|February 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00439686||173961|
NCT00439699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033|A Pilot Clinical Trial Of Memantine for Essential Tremor|A Pilot Clinical Trial of Memantine for Essential Tremor||VA Greater Los Angeles Healthcare System||Completed|February 2007|December 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 20, 2012|February 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00439699||173960|
NCT00439712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levo-6-06|Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis|Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis||Institut für Atemwegsforschung GmbH|No|Completed|February 2007|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2008|January 12, 2008|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00439712||173959|
NCT00440297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V232-060|Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)|A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process||Merck Sharp & Dohme Corp.||Completed|December 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|277|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|February 26, 2007|Yes|Yes||No|March 24, 2009|https://clinicaltrials.gov/show/NCT00440297||173914|
NCT00428064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-310|Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients|A Randomized, Open-Label Study of Continuous Therapy With Cyclosporine and Sirolimus Versus Induction With Cyclosporine and Sirolimus Followed by Continuous Therapy With Sirolimus in Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 1998|June 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||408|||Both|13 Years|N/A|No|||January 2007|January 26, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00428064||174836|
NCT00428038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309-15|Assessment of the Pulmonary Diffusion Capacity in Healthy Infants and Infants With Chronic Lung Disease|Assessment of the Pulmonary Diffusion Capacity in Healthy Infants and Infants With Chronic Lung Disease||Indiana University|Yes|Completed|February 2004|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|68|||Both|2 Months|2 Years|No|Non-Probability Sample|Recruitment for premature infants were through Infant Lung Disease clinic at Riley        Hospital for Children and IU NICU. Healthy full term infants were recruited through        advertisements in local newspapers.|March 2012|March 29, 2012|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00428038||174838|
NCT00437229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV100787|A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults|An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant [GW679769] and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|February 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|37|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|February 16, 2007||||||https://clinicaltrials.gov/show/NCT00437229||174146|
NCT00437242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI103221|Odiparcil QT Definitive Study|A Study to Evaluate the Effect of Repeat Oral Doses of Odiparcil on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin.||GlaxoSmithKline||Terminated|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|February 16, 2007||||||https://clinicaltrials.gov/show/NCT00437242||174145|
NCT00436631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00008471|Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy|Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy||Johns Hopkins University|No|Completed|February 2007|December 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00436631||174190|
NCT00437216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10029|Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis|Phase 4 Open-Label Multicenter Community-Based 4-Wk Trial to Assess Efficacy, Tolerance to Tx & Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis||Galderma Laboratories, L.P.|No|Completed|February 2006|July 2006|Actual|July 2006|Actual|Phase 4|Observational|Observational Model: Case-Only||2|Actual|2488|||Both|18 Years|80 Years|No|Non-Probability Sample|Community Sample|March 2008|March 27, 2008|February 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00437216||174147|
NCT00437840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN107606|A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809|A Placebo-Controlled, Single-Blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers||GlaxoSmithKline||Completed|March 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|February 20, 2007||||||https://clinicaltrials.gov/show/NCT00437840||174101|
NCT00438373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-1|LH/HCG Receptor Expression and Retrieval Rates|Association of LH/HCG Receptor Expression and Retrieval Rates at Oocyte Pick up.||Aristotle University Of Thessaloniki||Suspended|January 2007|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|39 Years|No|Probability Sample|infertile patients undergoing assisted reproduction tratment|February 2015|February 25, 2015|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438373||174060|
NCT00438386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000935|Aripiprazole for the Treatment of Refractory Anxiety|Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters||Massachusetts General Hospital||Completed|April 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||August 2009|August 7, 2009|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438386||174059|
NCT00438100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBCRN-05|Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer|Randomized Control Study of Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer Patients||Japan Breast Cancer Research Network|Yes|Completed|April 2008|May 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Female|25 Years|74 Years|No|||May 2015|May 14, 2015|February 18, 2007||No||No|May 14, 2015|https://clinicaltrials.gov/show/NCT00438100||174081|
NCT00438074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186-2006|A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer|A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer||Sunnybrook Health Sciences Centre||Recruiting|February 2007|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Female|20 Years|80 Years|No|Non-Probability Sample|Women who are receiving neoadjuvant chemotherapy or neoadjuvant chemo-radiotherapy for        locally-advanced breast cancer.|April 2012|April 25, 2012|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438074||174083|
NCT00438087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051072|Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery|Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-pontine Angle Surgery||Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2007|January 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|313|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|February 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00438087||174082|
NCT00450125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1061|Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection|Six-Minute Walk Test in the Evaluation of Patients at High Risk for Complications From Lung Resection||M.D. Anderson Cancer Center|No|Recruiting|February 2007|||December 2017|Anticipated|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|101|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients at high risk for complications from lung resection.|September 2015|September 30, 2015|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00450125||173166|
NCT00450138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00062|Open Label, Phase I ZD6474 Head and Neck Cancer Study|An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma||AstraZeneca||Completed|December 2006|November 2011|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|March 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00450138||173165|
NCT00449813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY1023/NL511|The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)|The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms||Takeda|No|Terminated|March 2007|November 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2008|May 4, 2012|March 2, 2007|Yes|Yes|Inclusion-rate does not seem feasible anymore to obtain te required number of patients before    the end of the trial.|No||https://clinicaltrials.gov/show/NCT00449813||173190|
NCT00439387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070103|The Role of Serotonin in Seizures|Imaging Serotoninergic Neurotransmission in Epilepsy||National Institutes of Health Clinical Center (CC)||Terminated|February 2007|June 2015||||N/A|Observational|N/A|||Actual|46|||Both|18 Years|60 Years|No|||June 2015|November 3, 2015|February 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00439387||173984|
NCT00439725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11899|Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study|Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study||Bayer|No|Completed|February 2007|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1197|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|February 23, 2007|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT00439725||173958|
NCT00439426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20508|A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.|An Open Label Study of First Line Chemotherapy With Xeloda in Combination With Cisplatin on Treatment Response in Patients With Metastatic Nasopharyngeal Cancer||Hoffmann-La Roche||Completed|April 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00439426||173981|
NCT00440050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0099|DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease|A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease|DHA|Alzheimer's Disease Cooperative Study (ADCS)|Yes|Completed|February 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|402|||Both|50 Years|N/A|No|||September 2014|September 15, 2014|February 22, 2007|Yes|Yes||No|May 28, 2010|https://clinicaltrials.gov/show/NCT00440050||173933|
NCT00452348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA109057|A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma|A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 Mcg BID and Fluticasone Propionate (FP) DISKUS 250 Mcg BID in Treatment of Subjects With Asthma||GlaxoSmithKline||Completed|May 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|628|||Both|12 Years|N/A|No|||May 2012|November 14, 2013|March 26, 2007|Yes|Yes||No|January 20, 2010|https://clinicaltrials.gov/show/NCT00452348||172998|
NCT00453531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070124|Model System for Transient Forearm Blood Vessel Dysfunction|Pilot Study for the Development of Transient Forearm Endothelial Dysfunction||National Institutes of Health Clinical Center (CC)||Completed|March 2007|||February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1|||20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|June 17, 2010|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453531||172911|
NCT00453843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD045343|Shoulder, or Elbow, or Wrist: What Should we Train First After a Stroke?|The Effect of Proximal and Distal Training on Stroke Recovery||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|June 2004|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|190|||Both|21 Years|N/A|No|||March 2007|October 28, 2012|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453843||172887|
NCT00454389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVI-114|A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration|A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration|CABERNET|NeoVista|Yes|Active, not recruiting|April 2007|August 2012|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|494|||Both|50 Years|N/A|No|||July 2011|July 26, 2011|March 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454389||172845|
NCT00454077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIRC 1185|rhTSH-Thyroid Ablation With 1850 MBq of 131I|Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities||University of Siena|No|Completed|December 2004|September 2006|Actual|||Phase 3|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||72|||Both|18 Years|90 Years|No|||October 2006|March 28, 2007|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00454077||172869|
NCT00454090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1536C00001|AZD8330 First Time in Man in Patients With Advanced Malignancies|A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies||AstraZeneca||Completed|March 2007|March 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|March 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454090||172868|
NCT00454103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wue_123IMTO_100/05|Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy|||University of Wuerzburg|Yes|Completed|March 2007|February 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|30 Years|N/A|No|||October 2007|August 17, 2010|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00454103||172867|
NCT00454376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000537344|Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors|Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients With G.I.-Related Neuroendocrine Tumours||National Cancer Institute (NCI)||Active, not recruiting|October 2006|||||Phase 4|Observational|N/A|||Anticipated|408|||Both|18 Years|N/A|No|||November 2008|October 28, 2013|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00454376||172846|
NCT00445133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00781440|Study on Magnetic Field Therapy to Improve Quality of Sleep and Reduction of Chronic Spine Pain|A Double-Blind, Randomized, Placebo-Controlled Study on Magnetic Field Therapy to Improve Quality of Sleep and Reduction of Chronic Spine Pain (Sleep/Mag)|SLEEP/MAG|Weintraub, Michael I., MD, FACP, FAAN|No|Recruiting|February 2007|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|85 Years|No|||September 2007|September 26, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00445133||173543|
NCT00442676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB HM10590|Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia|Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia||Virginia Commonwealth University|Yes|Withdrawn|June 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|February 28, 2007|Yes|Yes|No patients were recruited. Treatment drug expired.|No||https://clinicaltrials.gov/show/NCT00442676||173731|
NCT00442702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH20051|A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.|An Open-label, Randomized, Multi-center, Parallel Group Non-inferiority Study of Subcutaneous Injections of RO0503821 Given Once Monthly vs. Darbepoetin Alfa Given According to Local Label in Patients With Chronic Kidney Disease Who Are Not on Dialysis.||Hoffmann-La Roche||Completed|September 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Both|18 Years|N/A|No|||December 2011|December 13, 2011|March 1, 2007|Yes|Yes||No|August 29, 2011|https://clinicaltrials.gov/show/NCT00442702||173729|
NCT00445822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-CML-paed 016|Registration of Children With CML and Treatment With Imatinib|Protocol for Standardized Diagnostic Procedures, Registration, and Treatment Recommendations in Children and Adolescents With Philadelphia Chromosome-positive Chronic Myeloid Leukemia (CML)|CML-paed II|Technische Universität Dresden|Yes|Recruiting|March 2007|December 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Bone Marrow and blood smears|Both|N/A|18 Years|No|Non-Probability Sample|Pts younger than 19 years with PH+ CML are recruited from primary care clinics|February 2012|February 28, 2012|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00445822||173493|
NCT00445835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060902|Active Detection of the Extension of Atherothrombosis in High Risk Coronary Patients|Active Detection and Management of the Extension of Atherothrombosis in High Risk Coronary Patients In Comparison With Standard of Care for Coronary Atherosclerosis: The AMERICA Study|AMERICA|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|September 2007|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|526|||Both|18 Years|N/A|No|||September 2010|September 30, 2010|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00445835||173492|
NCT00446706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Estimation PEEPi|Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)|Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)||Texas Tech University Health Sciences Center, El Paso|No|Completed|January 2004|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with Acute Respiratory Distress Syndrome|November 2015|November 10, 2015|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446706||173426|
NCT00446719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH 06-0307-A|Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder|An Open-Label Pilot Study Evaluating the Safety and Antidepressant Effects of Rellidep (BI= Biological Isolate) in Major Depressive Disorder||Mount Sinai Hospital, Canada|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|64 Years|No|||January 2011|January 4, 2011|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446719||173425|
NCT00450983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1965.00|Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases|Transplantation of Haploidentical CD34+ Purified Peripheral Blood Stem Cells With NK-Cell Add-Back Following Conditioning With Total Body Irradiation, Thiotepa, Fludarabine and OKT3||Fred Hutchinson Cancer Research Center|No|Completed|December 2006|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|45 Years|No|||August 2010|August 24, 2010|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450983||173101|
NCT00450996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PostkeratoplastySteroids|Analysis of a Beneficial Effect of Prolonges Topical Steroid Treatment After Low-risk Penetrating Keratoplasty|Phase 3: Analysis of a Beneficial Effect of Prolonges Topical Steroid Treatment After Low-risk Penetrating Keratoplasty||University of Erlangen-Nürnberg Medical School|No|Completed|January 1999|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450996||173100|
NCT00446966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1733860001|Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery|Fish Oil to Inhibit Supraventricular Arrhythmias After Cardiac Surgery: The Fish Trial|FISH|University of Iowa|Yes|Completed|February 2007|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|260|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2007|May 10, 2010|March 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00446966||173406|
NCT00446979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-4744|Safety Study of UC-781 Vaginal Microbicide|Phase I Study of the Safety and Acceptability of UC-781 Topical Vaginal Microbicide in Women and Acceptability in Their Male Partners,Chiang Rai, Thailand||Centers for Disease Control and Prevention|No|Completed|June 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 18, 2013|March 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00446979||173405|
NCT00446992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK69265|Diabetes in Neuropsychiatric Disorders|Metabolic Effects of Olanzapine in Patients With Newly Diagnosed Psychosis||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|April 2006|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|64 Years|No|||November 2014|November 6, 2014|March 12, 2007||No||No|October 22, 2014|https://clinicaltrials.gov/show/NCT00446992||173404|The most important limitations in our study were sample size and duration. With a larger sample, some of these measures may have a significant change within this time frame.
NCT00447005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061022|Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors|A Phase 1 Study Of AG-013736 (Axitinib) In Japanese Patients With Advanced Solid Tumors||Pfizer|Yes|Completed|February 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|75 Years|No|||May 2012|May 17, 2012|March 12, 2007|No|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00447005||173403|
NCT00447018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0224|Mannitol Versus Hypertonic Saline Solution in the Treatment of Elevated Intracranial Pressure|Equimolar Doses of Mannitol and Hypertonic Saline in the Treatment of Elevated Intracranial Pressure||University Hospital, Grenoble|No|Completed|October 2002|June 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||March 2007|March 12, 2007|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00447018||173402|
NCT00451516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006000925|St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety|St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety||The University of Queensland|No|Completed|March 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|65 Years|No|||May 2008|May 16, 2008|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451516||173061|
NCT00451750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007DR3069|Cortisol in the Treatment of Phobias|The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias||University of Zurich||Completed|May 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|55 Years|No|||January 2010|January 11, 2010|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451750||173044|
NCT00451763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165/07|Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia|Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia||University of Sao Paulo|Yes|Completed|January 2006|December 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|40 Years|N/A|No|||March 2007|July 21, 2008|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00451763||173043|
NCT00452920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20020358|Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer|A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026)||University of Miami Sylvester Comprehensive Cancer Center|Yes|Withdrawn|September 2003|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||August 2013|July 25, 2014|March 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00452920||172954|
NCT00453856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPTi-DRWG- SP Lambaréné|Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children|Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné||Albert Schweitzer Hospital||Terminated|March 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|139|||Both|6 Months|59 Months|No|||August 2007|August 8, 2007|March 28, 2007|||The study was terminated because of Early Treatment Failure in child.The justification for    this decision are concerns about safety of children.|No||https://clinicaltrials.gov/show/NCT00453856||172886|
NCT00454116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00048|A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients|A Phase II, Double Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With Anoxaliplatin and Fluoropyrimidine Containing Regimen||AstraZeneca|No|Completed|March 2007|November 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|N/A|No|||April 2011|April 27, 2011|March 28, 2007|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00454116||172866|
NCT00454129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBE ERC|ERC Via Double-Balloon-Enteroscopy in Patients With Biliodigestive Anastomosis|ERC Via Double-Balloon-Enteroscopy in Patients With Biliodigestive Anastomosis|DBE ERC|Heidelberg University|No|Recruiting|March 2007|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||March 2007|January 25, 2013|March 29, 2007||||No||https://clinicaltrials.gov/show/NCT00454129||172865|
NCT00450541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0004|Fatigue Experience in Cancer Patients|The Experience of Fatigue for Patients With Cancer||M.D. Anderson Cancer Center|No|Completed|March 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|73|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with cancer that may be experiencing fatigue.|July 2012|July 26, 2012|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450541||173135|
NCT00450554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/004/HP|Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac|EVALUATION DE LA REPONSE IMMUNITAIRE CONTRE LA SOUCHE DE NEISSERIA MENINGITIDIS B:14,P1.7,16||University Hospital, Rouen|Yes|Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 3|Observational|Time Perspective: Prospective||1|Actual|236|||Both|2 Years|7 Years|Accepts Healthy Volunteers|Probability Sample|children born between 01/01/2000 and 06/23/2005, living in Dieppe-Est, Dieppe-Ouest and        Offranville|March 2012|March 26, 2012|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00450554||173134|
NCT00450216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-CA-303|Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment|A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|March 2007|October 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|906|||Both|40 Years|80 Years|No|||April 2013|April 22, 2013|March 19, 2007|Yes|Yes||No|May 17, 2011|https://clinicaltrials.gov/show/NCT00450216||173159|
NCT00450528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 31-2006|Kinetics of D-Dimers After Abdominal Surgery|The Kinetics of D-Dimers After Abdominal Surgery as a Function of the Invasiveness of Surgery||University of Zurich|No|Completed|February 2007|October 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|90|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2007|October 23, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00450528||173136|
NCT00441714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPost|Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise|Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise||Radboud University|No|Withdrawn|October 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|0|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|February 28, 2007|||new insights have let us to expect marginal annexin targeting with a 10 minutes delay between    reperfusion and administration of Annexin A5|No||https://clinicaltrials.gov/show/NCT00441714||173805|
NCT00442351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04654|Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)|A Comparative Study of The Efficacy and Tolerability of Maintenance Treatment of Patients With Mild/Moderate Persistent Asthma With Asmanex Twisthaler 220 mcg QD PM Versus "Asmanex" Placebo QD PM||Merck Sharp & Dohme Corp.|No|Terminated|September 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|75 Years|No|||September 2015|September 28, 2015|February 28, 2007|Yes|Yes|Slow Enrollment|No|March 26, 2010|https://clinicaltrials.gov/show/NCT00442351||173756|This study was terminated early due to a high screening failure rate and poor enrollment that resulted from stringent inclusion and exclusion criteria. Efficacy data were not evaluated.
NCT00442377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHMI-8|Study to Investigate the Induction of an Protective Immune Response to Malaria|Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis||Radboud University||Completed|January 2007|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 15, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442377||173754|
NCT00442390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998/4375|Metabolic Effects of Acute Cortisol Withdrawal in Adrenal Failure|Effects of Cortisol on Carbohydrate, Lipid, and Protein Metabolism; Studies of Acute Cortisol Withdrawal in Adrenocortical Failure.||University of Aarhus|No|Completed|January 2002|January 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Female|18 Years|50 Years|No|||February 2007|February 28, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442390||173753|
NCT00442715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4400-YY-CTIL|Exercise Challenge Test in 3-6 Years Old Asthmatic Children|Exercise Challenge Test in 3-6 Years Old Asthmatic Children||Sheba Medical Center|No|Completed|October 2006|December 2006||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|3 Years|6 Years|No|||March 2007|March 5, 2007|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00442715||173728|
NCT00450424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000443988|Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer|Facilitating Informed Decisions for MSI Testing||Fox Chase Cancer Center|No|Completed|June 2007|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|239|||Both|21 Years|N/A|No|||September 2014|September 4, 2014|March 20, 2007|Yes|Yes||No|August 5, 2014|https://clinicaltrials.gov/show/NCT00450424||173144|
NCT00450437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P13|A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults|A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine||Novartis|Yes|Completed|March 2007|January 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3539|||Both|11 Years|55 Years|No|||January 2015|January 15, 2015|March 21, 2007|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00450437||173143|
NCT00446147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0403|Study of Pyridoxine for Hand-Foot Syndrome|Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome||Asan Medical Center|No|Completed|June 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|389|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|March 9, 2007||No||No|January 13, 2014|https://clinicaltrials.gov/show/NCT00446147||173469|
NCT00451789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW1|Risk Factors of Minor Head Injury|Risk Factors of Minor Head Injury in Traumatological Patients||Medical University of Vienna|No|Completed|December 2004|April 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||12500|||Both|N/A|N/A|No|||March 2007|March 23, 2007|March 23, 2007||||No||https://clinicaltrials.gov/show/NCT00451789||173041|
NCT00452062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-106|Dexamethasone and the Prevention of Post-Extubation Airway Obstruction in Adults|Mackay Memorial Hospital||Mackay Memorial Hospital|Yes|Recruiting|October 2004|July 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||70|||Both|18 Years|95 Years|No|||March 2007|March 23, 2007|March 23, 2007||||No||https://clinicaltrials.gov/show/NCT00452062||173020|
NCT00446732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-71-003|The Use of the UroShield Device in Patients With Indwelling Urinary Catheters|Catheter Associated Urinary Tract Infections|CAUTI|Nanovibronix|Yes|Recruiting|March 2007|June 2009|Anticipated|April 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|March 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00446732||173424|
NCT00451529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006 B0|Predictive Value for Stroke|Predictive Value of Magnetic Resonance Imaging (MRI), 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), and Microemboli Detection for Stroke||Dutch Heart Foundation|Yes|Recruiting|August 2007|September 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a history of transient ischemic attack or minor stroke within three months        of enrollment and an ipsilateral 30-69% carotid stenosis.|April 2011|April 18, 2011|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451529||173060|
NCT00451776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608119|Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC|Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC. A Prospective, Monocentric, Randomised Double Blind Study||Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2008|October 29, 2008|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451776||173042|
NCT00452036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW2|Diagnostic Algorithm in Patients With Minor Head Injury|Prospective Study to Find a Diagnostic Algorithm for Diagnosis of Minor Head Injury||Medical University of Vienna|No|Completed|December 2004|July 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|12500|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients seen in the trauma outpatient area|July 2010|July 26, 2010|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452036||173022|
NCT00452049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3052|The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure|Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure||Universitaire Ziekenhuizen Leuven|No|Recruiting|April 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|Renal transplant recipients|May 2012|May 28, 2012|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452049||173021|
NCT00453544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0110|Enhancing Consent for Alzheimer's Research|Enhancing Consent for Alzheimer's Research|BWP-AD|National Institute on Aging (NIA)|Yes|Recruiting|April 2006|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|272|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 23, 2009|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453544||172910|
NCT00454142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00197|Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer|A Phase 2 Study of GW786034 (Pazopanib) in Asian Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma||National Cancer Institute (NCI)|No|Completed|August 2007|August 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||January 2012|November 16, 2015|March 27, 2007|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00454142||172864|
NCT00454402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9795|ALF-STONE: Alfuzosin in Uretheric Stones|Alfuzosin in Uretheric Stones||Sanofi|No|Terminated|August 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Male|18 Years|N/A|No|||September 2007|September 21, 2007|March 29, 2007|||Discontinued due to incomplete recruitment|No||https://clinicaltrials.gov/show/NCT00454402||172844|
NCT00450229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00905|Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer|Phase Ib Placebo-Controlled Trial of Diindolylmethane (BR-DIM) in the Study of the Modulation of Intermediate Endpoint Markers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy||National Cancer Institute (NCI)||Completed|February 2007|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Male|18 Years|N/A|No|||May 2013|December 3, 2015|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450229||173158|
NCT00450242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2332|5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis|Use of 5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis||University of North Carolina, Chapel Hill|No|Terminated|December 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|March 21, 2007|Yes|Yes|lack of funding|No|February 27, 2012|https://clinicaltrials.gov/show/NCT00450242||173157|The study terminated due to lack of funding and difficulties with recruitment. More extensive data analysis to include secondary outcome measures was not performed due to inability to fund statistical programming and analysis efforts.
NCT00450567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000423222|Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy|Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT||Jonsson Comprehensive Cancer Center|No|Completed|December 2004|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with non-small cell lung cancer (stage III B or stage IV) and will be        treated with an experiemntal drug or a combination of chemotherapy and new drugs, as part        of standarad of care or because of enrollment in a study protocol.|August 2012|October 28, 2015|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450567||173133|
NCT00450814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC038C|Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma|Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma||Mayo Clinic|Yes|Recruiting|January 2007|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450814||173114|
NCT00451074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS043186|Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons|A Six Month Randomized, Clinical Trial of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon Mutations||Nationwide Children's Hospital|Yes|Completed|March 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|5 Years|20 Years|No|||March 2012|March 22, 2012|March 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00451074||173094|
NCT00442364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV012|Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt|An Open Label Multicenter Safety Study of the Varisolve® Procedure for the Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt|MRI|BTG International Inc.|Yes|Completed|March 2007|August 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|60 Years|No|||February 2015|February 19, 2015|February 27, 2007|Yes|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT00442364||173755|
NCT00442013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|454|Lansoprazole to Treat Children With Asthma|Phase III: The Study of Acid Reflux in Children With Asthma|SARCA|Johns Hopkins University|Yes|Completed|March 2007|August 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|306|||Both|6 Years|17 Years|No|||December 2012|December 5, 2012|February 28, 2007|Yes|Yes||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00442013||173782|Results limited to patients without overt Gastroesophageal reflux disease(GERD). Did not conduct on-treatment potential hydrogen(pH) probe studies to confirm treatment effect. Protein-pump inhibitors(PPI) dose may not induce maximal acid suppression.
NCT00442403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSP 97008500|Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria|Etude de l’Activite (Efficacite et Tolerance) de l’Association de la Chloroquine Avec la Dehydroepiandrosterone-Sulfate (Dheas) Dans le Traitement de l’Acces Palustre Simple A Plasmodium Falciparum||Université Victor Segalen Bordeaux 2|No|Suspended|April 2002|September 2002||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|15 Years|N/A|No|||February 2007|February 28, 2007|February 28, 2007|||At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line    therapy for of uncomplicated malaria.|No||https://clinicaltrials.gov/show/NCT00442403||173752|
NCT00451282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-9-4974|Stepped Preventive Care to Reduce the Impact of Acute Pediatric Injury|Stepped Preventive Care to Reduce the Impact of Acute Pediatric Injury||Children's Hospital of Philadelphia|Yes|Completed|April 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|290|||Both|8 Years|17 Years|No|||April 2015|April 2, 2015|March 22, 2007||No||No|December 23, 2010|https://clinicaltrials.gov/show/NCT00451282||173078|
NCT00450736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20030283|Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery|A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity||University of Miami Sylvester Comprehensive Cancer Center||Completed|March 2004|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450736||173120|
NCT00450749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00857|Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer|Phase II Placebo Controlled Trial of Preoperative Lycopene Supplementation in Prostate Cancer Patients||National Cancer Institute (NCI)|No|Completed|February 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|10|||Male|18 Years|N/A|No|||April 2013|April 23, 2014|March 20, 2007|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00450749||173119|
NCT00452088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSP3_BF_0302|A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso|Randomized, Controlled, Dose Escalation Phase Ib Trial of MSP 3 LSP Adjuvanted in Aluminium Hydroxide Versus Hepatitis Bin 12 to 24 Month Old Children in Burkina Faso.|MSP3LSP|African Malaria Network Trust|Yes|Recruiting|April 2007|May 2008|Anticipated|May 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|45|||Both|1 Year|2 Years|Accepts Healthy Volunteers|||November 2007|May 6, 2008|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452088||173018|
NCT00452101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARC005-065|Effects of Aquamin F on Osteoarthritis of the Knee|Randomized, Placebo Controlled Trial: Effects of Aquamin F Alone or in Combination With Glucosamine Sulfate on Joint Mobility and Pain in Osteoarthritis of the Knee||Marigot Ltd.|No|Completed|January 2006|December 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||March 2007|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00452101||173017|
NCT00451269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 06066|Evaluation of Rapid Diagnosis Tests in Imported Malaria|Multicentric Evaluation of Rapid Diagnosis Tests for the Diagnosis of Imported Malaria.|TDR-PALU|Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1297|||Both|N/A|N/A|No|Non-Probability Sample|Suspected malaria|March 2007|February 18, 2011|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451269||173079|
NCT00452075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 20539|Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy|A Phase II Study of Erlotinib and Predictive Markers as First-line Treatment of Advanced Non-small Cell Lung Cancer for Patients Unfit for Chemotherapy||Rigshospitalet, Denmark|Yes|Terminated|March 2007|August 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|March 23, 2007||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00452075||173019|
NCT00452361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H-101864|Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient|A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipient||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|April 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|March 23, 2007||No||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00452361||172997|Study terminated early due to difficulties in enrolling qualified patients. No patients completed 104 weeks (primary outcome); a few completed 60 weeks. Insufficient data were available for efficacy analyses.
NCT00452647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16807|Comparison of Blood Pressure Throughout Pregnancy|Comparison of Blood Pressure Throughout Pregnancy||Drexel University||Terminated|February 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Female|18 Years|40 Years|No|Non-Probability Sample|Population defined as parturients who present for delivery. See Eligibility Criteria.|September 2013|September 5, 2013|March 26, 2007||No|data did not indicate any meaningful information|No||https://clinicaltrials.gov/show/NCT00452647||172975|
NCT00452660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2412-HMO-CTIL|Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load|A Phase IV , Multicenter ,Open Label ,Non Comparative ,Investigator Initiated Study , Evaluating the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load||Wolfson Medical Center|Yes|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452660||172974|
NCT00453271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-002-002|Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail|A Randomized, Double-Blind, Parallel-Group,Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of NB-002 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail||NanoBio Corporation|No|Completed|January 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|443|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|March 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00453271||172930|
NCT00453869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2006-05|Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail|Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail|SNIFF11|University Hospital, Angers|No|Terminated|April 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|||Male|18 Years|N/A|No|Non-Probability Sample|All subjects in jail who have a medical evaluation.|December 2014|December 11, 2014|March 28, 2007||No|Few prevalence of liver fibrosis in subjects|No||https://clinicaltrials.gov/show/NCT00453869||172885|
NCT00454415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1376|Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children|Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children||Brigham and Women's Hospital|No|Completed|January 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16000|||Both|9 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|U.S. children|December 2012|December 24, 2012|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00454415||172843|
NCT00450255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00182|VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma||National Cancer Institute (NCI)||Completed|June 2007|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||April 2013|February 2, 2015|March 20, 2007|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00450255||173156|
NCT00450593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-LCC-99/3/45|Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma|Studies of Familial Melanoma||National Cancer Institute (NCI)||Recruiting|January 1989|||December 2020|Anticipated|N/A|Observational|N/A|||Anticipated|5000|||Both|N/A|N/A|No|||April 2008|August 9, 2013|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450593||173131|
NCT00450840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3732006|Simvastatin in Patients With Septic Shock|||Medical University of Vienna||Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||September 2007|September 14, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00450840||173112|
NCT00450827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-072|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma|Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study||Memorial Sloan Kettering Cancer Center||Completed|August 2006|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|1 Year|N/A|No|||September 2015|September 25, 2015|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450827||173113|
NCT00451087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561703048|Comparisons of Mechanical Properties of Tendon Structures|Phase 1 Study: Comparison of Electromechanical Delay Phase 2 Study: Research in Viscoelasticity of Tendon Structures Phase 3 Study: Effects of Exercise Training in the Mechanical Properties||National Taiwan University Hospital|No|Recruiting|December 2006|September 2009|Anticipated|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|49 Years|Accepts Healthy Volunteers|||December 2006|January 28, 2008|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451087||173093|
NCT00451360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC / CHO 90040N|Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip|Evaluation of the CHOndromodulating Effect of DIAcerein in Osteoarthritis of the Hip. ECHODIAH.|ECHODIAH|Laboratoires NEGMA|No|Completed|March 1993|April 1997|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|50 Years|75 Years|No|||March 2007|July 24, 2008|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451360||173072|
NCT00442026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.11|Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC|A Multicenter Randomized Phase III Study of the Docetaxel and Gemcitabine Combination Versus Monotherapy With Gemcitabine as First-line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)||Hellenic Oncology Research Group|No|Terminated|December 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|70 Years|85 Years|No|||June 2012|June 26, 2012|February 28, 2007||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00442026||173781|
NCT00442416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20338|A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.|A Randomized, Open Label Study to Compare the Effect of Monthly Injections of Mircera Versus Epoetin Alfa on Hemoglobin Levels in Peritoneal Dialysis Patients Who Self-inject or Receive In-center Injections||Hoffmann-La Roche||Terminated|February 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|March 1, 2007|Yes|Yes|Strategic decision unrelated to safety or efficacy|No||https://clinicaltrials.gov/show/NCT00442416||173751|
NCT00442429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00898|Morbidity and Mortality Among Dialysis Patients After Treatment for Depression|Morbidity and Mortality Among Dialysis Patients After Treatment for Depression||Portland VA Medical Center||Recruiting|July 2004|June 2010||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||350|||Both|18 Years|N/A|No|||March 2007|March 1, 2007|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00442429||173750|
NCT00452868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000537049|Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain|A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|June 2006|||February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|8 Years|17 Years|No|||February 2015|February 2, 2015|March 27, 2007|Yes|Yes||No|August 31, 2012|https://clinicaltrials.gov/show/NCT00452868||172958|small number (11) analyzed
NCT00453167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-05-155|Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer|A Phase II Study of Weekly Paclitaxel and Gemcitabine as Second-line Therapy in Patients With Metastatic or Recurrence Small Cell Lung Cancer||National Cancer Center, Korea|No|Completed|December 2005|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2010|July 9, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453167||172938|
NCT00453180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611-10|A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders|A Pilot Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders||Indiana University|Yes|Completed|March 2007|November 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|4 Years|12 Years|No|||June 2014|June 3, 2014|March 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00453180||172937|
NCT00451568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|027|Metformin and Oral Contraceptives in PCOS|Metformin and Oral Contraceptives in PCOS||Odense University Hospital|Yes|Completed|March 2007|April 2013|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Female|18 Years|40 Years|No|||April 2015|April 10, 2015|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451568||173057|
NCT00451542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0063|Divalproex vs. Lamotrigine for Bipolar Disorder|Time to Relapse During Treatment With Divalproex vs. Lamotrigine for Bipolar Disorder||Tuscaloosa Research & Education Advancement Corporation|No|Completed|February 2006|February 2008|Actual|May 2007|Actual|Phase 3|Observational|Time Perspective: Retrospective||1|Actual|1000|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with Bipolar Disorder I or II who had a prescription of divalproex or        lamotrigine.|August 2012|August 30, 2012|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451542||173059|
NCT00451555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10736|Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer|A Randomized, Double-Blind, Phase II Trial of Fulvestrant Plus Enzastaurin Versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer||Eli Lilly and Company|Yes|Active, not recruiting|March 2007|December 2015|Anticipated|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|N/A|No|||June 2015|June 4, 2015|March 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451555||173058|
NCT00451828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM2277|Cholesterol and Pharmacogenetic Study|Cholesterol and Pharmacogenetic Study|CAP|Children's Hospital & Research Center Oakland|Yes|Completed|March 2002|||October 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|30 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|March 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451828||173038|
NCT00452374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0373|Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL|A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|November 2004|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||October 2011|October 25, 2011|March 23, 2007||No||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00452374||172996|
NCT00452673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-004|Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer|Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer||Bristol-Myers Squibb|No|Completed|June 2007|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Female|18 Years|N/A|No|||March 2015|March 4, 2015|March 26, 2007|No|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00452673||172973|
NCT00452686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108638|Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix (dTpa) Vaccine and the Chinese DT Vaccine, When Administered as Booster Vaccination in Healthy Children Aged 6-8 Years||GlaxoSmithKline|No|Completed|March 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||660|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||October 2012|October 25, 2012|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452686||172972|
NCT00452387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN AVAHRPC0607|Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)|Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)||Accelerated Community Oncology Research Network|No|Terminated|May 2007|January 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|N/A|No|||September 2011|September 13, 2011|March 26, 2007|Yes|Yes|Early stopping rule|No|August 17, 2009|https://clinicaltrials.gov/show/NCT00452387||172995|Early termination, according to the stopping rule included in the protocol, leading to a small number of subjects analyzed
NCT00452972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-04|Exteriorized Versus In Situ Uterine Repair at Cesarean Delivery|Complications of Exteriorized Versus In Situ Uterine Repair at Cesarean Delivery Under Spinal Anesthesia||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|April 2004|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2007|March 26, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00452972||172953|
NCT00453297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-101-003|Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components|A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women.||Bionovo||Terminated|October 2006|April 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|32|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 27, 2008|March 26, 2007||||Yes||https://clinicaltrials.gov/show/NCT00453297||172929|
NCT00453310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004|Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment|A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors||Memorial Sloan Kettering Cancer Center||Completed|March 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|120 Years|No|||September 2015|September 24, 2015|March 27, 2007|Yes|Yes||No|September 24, 2015|https://clinicaltrials.gov/show/NCT00453310||172928|
NCT00454155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPSC030|Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|A Phase I/II Study of the Safety and Pharmacokinetics of Opebacan (rBPI21) in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|HSCT|XOMA (US) LLC|Yes|Terminated|February 2007|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|N/A|60 Years|No|||May 2011|July 27, 2012|March 28, 2007|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00454155||172863|
NCT00454428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27579|Randomized Trial of Pulsatile vs Non Pulsatile Perfusion on Short Term Changes in Kidney Function Using an Intra-Aortic Ballooon Pump During Cardioplegic Arrest in Patients Undergoing Myocardial Reperfusion|||University of Cantanzaro|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|75 Years||||March 2006|March 29, 2007|March 29, 2007||||No||https://clinicaltrials.gov/show/NCT00454428||172842|
NCT00450268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK208122001|Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation|Analysis of Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation|DCalloTX|Technische Universität Dresden|Yes|Recruiting|January 2005|January 2010|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||50|||Both|18 Years|N/A|No|||March 2007|March 21, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00450268||173155|
NCT00450580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APV109141|HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults|Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.||ViiV Healthcare||Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|N/A|No|||April 2012|May 31, 2012|March 21, 2007|Yes|Yes||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00450580||173132|
NCT00451113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03067|Sitagliptin in the Elderly|Sitagliptin in the Elderly||University of British Columbia|No|Completed|November 2006|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|65 Years|N/A|No|||March 2014|March 14, 2014|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451113||173091|
NCT00451386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-036|Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)|A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Local Tolerability, and Clinical Outcome of Ertapenem Versus Ceftriaxone in Pediatric Patients With Complicated Urinary Tract Infection, Skin and Soft Tissue Infection, or Community-Acquired Pneumonia||Merck Sharp & Dohme Corp.||Completed|January 2002|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||400|||Both|3 Months|17 Years|No|||October 2015|October 16, 2015|March 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451386||173070|
NCT00450632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/031/HP|Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection|CONSTITUTION D'UNE BIOTHEQUE DE PATIENTS DE SEINE-MARITIME AUX ANTECEDENTS D'INFECTION INVASIVE A MENINGOCOQUES||University Hospital, Rouen|Yes|Completed|September 2005|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|101|||Both|N/A|N/A|No|Non-Probability Sample|Subjects of Seine-Maritime with a meningococcal disease|March 2012|March 26, 2012|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00450632||173128|
NCT00451100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05931|Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)(COMPLETED)|Comparison of Rocuronium and Org25969 With Cisatracurium and Neostigmine When Neuromuscular Block is Reversed at Reappearance of T2||Merck Sharp & Dohme Corp.|No|Completed|November 2005|August 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|March 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451100||173092|
NCT00451373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709099|Acute Renal Failure in the Surgical Intense Care Units - NTUH-SICU-ARF (NSARF) Study|||National Taiwan University Hospital|Yes|Recruiting|July 2006|December 2012|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|18 Years|80 Years|No|||January 2007|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451373||173071|
NCT00451893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJUNO 05-109M|The Significance of the Mesh Thickness in the Operation of Inguinal Hernia|An Expertise-based Multicentre Randomized Controlled Trial Comparing a Heavy-weight and a Light-weight Mesh in the Operation of Inguinal Hernia|LJUNO|Umeå University|No|Active, not recruiting|December 2006|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Male|25 Years|N/A|No|||April 2015|April 22, 2015|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00451893||173033|
NCT00442039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-2005-07-01|Lithium for the Treatment of Pediatric Mania|Pediatric Pharmacokinetic and Tolerability Study of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long Term Safety Period, Discontinuation Phase, and Restabilization Period.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|December 2006|September 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|61|||Both|7 Years|17 Years|No|||February 2012|February 24, 2012|February 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00442039||173780|
NCT00442052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA325-101|To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin|An Open-Label, Investigator-Blinded, Randomized, Parellel Group Study to Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA 325 Versus Enteric-Coated Aspirin.||POZEN|Yes|Completed|November 2006|January 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2007|February 28, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00442052||173779|
NCT00453492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_4036|Risedronate Sodium in Post Menopausal Osteoporosis|A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily||Sanofi||Completed|January 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||246|||Female|55 Years|80 Years|No|||March 2008|March 10, 2008|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00453492||172914|
NCT00451048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00211|Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia|A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia||National Cancer Institute (NCI)|Yes|Completed|February 2007|October 2012|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2013|December 3, 2015|March 20, 2007|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00451048||173096|
NCT00451308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4114729401-01|Induction of Labor With a Foley Balloon Catheter: Inflation With 30ml Compared to 60ml|Induction of Labor With a Foley Catheter Balloon: A Randomized Trial Comparing Inflation With 30ml and 60ml||University of California, San Francisco|No|Completed|November 2006|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Female|N/A|N/A|No|||July 2013|July 31, 2013|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451308||173076|
NCT00451802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701410|A Pilot Scheme - Specimen Collection of Health Management Center|A Pilot Scheme - Specimen Collection of Health Management Center||National Taiwan University Hospital||Completed|January 2003|December 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||7000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2005|March 23, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451802||173040|
NCT00452140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-ERT-BC-03|Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment|Phase II Study for Repeated Dosing of the Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab in Patients With HER-2/Neu 1+ or 2+/FISH Negative Expressing Advanced or Metastatic Breast Cancer (Stage IIIb/IV) Progressing After Endocrine Treatment||Neovii Biotech|Yes|Terminated|March 2007|February 2009|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||May 2009|May 18, 2009|March 26, 2007||No|company focus on other projects|No||https://clinicaltrials.gov/show/NCT00452140||173014|
NCT00452114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11138|In-exsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis|A Randomized, Controlled Study Evaluating the Effectiveness of the Inexsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis||University of Massachusetts, Worcester|No|Terminated|April 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|March 22, 2007||No|interim analysis indicates statistical futility for primary outcomes|No|January 30, 2013|https://clinicaltrials.gov/show/NCT00452114||173016|
NCT00452127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO3967g|A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Have Been Treated With a Prior Rituximab-Containing Regimen||Genentech, Inc.||Terminated|May 2007|||May 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|March 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00452127||173015|
NCT00452400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.5|Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.|Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (3 - 4 Doses) Delivered by the Respimat® Inhaler in Patients With COPD||Boehringer Ingelheim||Completed|March 2007|||January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|409|||Both|40 Years|N/A|No|||May 2014|June 17, 2014|March 26, 2007||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00452400||172994|
NCT00452699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA109055|A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma|A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma||GlaxoSmithKline|No|Completed|May 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|621|||Both|12 Years|N/A|No|||June 2012|June 12, 2014|March 26, 2007|Yes|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00452699||172971|
NCT00452985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_BD1_601|Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer|Randomised Study With Docetaxel, Cisplatin and Cyclophosphamide vs Docetaxel and Carboplatin as First Line Chemotherapy With Advanced or Metastatic Ovarian Cancer|OCSTUD|Sanofi||Completed|February 2002|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Female|15 Years|75 Years|No|Non-Probability Sample|Patients with advanced or metastatic ovarian cancer|August 2012|August 13, 2012|March 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00452985||172952|
NCT00453557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 99009|Mechanism of Growth Hormone Effects on Adipose Tissue||GH|Pennington Biomedical Research Center|Yes|Completed|April 1999|December 2000|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||30|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453557||172909|
NCT00453570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I42|Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months|||Sanofi|No|Completed|March 2007|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|792|||Both|60 Days|74 Days|Accepts Healthy Volunteers|||April 2012|April 13, 2012|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453570||172908|
NCT00454441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF101 Ancillary Study|Sleep Quality in CHIMES (MF101)|Sleep Quality in CHIMES (MF101)||Bionovo||Completed|February 2006|February 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||March 2007|March 29, 2007|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00454441||172841|
NCT00450853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRA / SC-IV|Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients|Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated With Platinum Based Chemotherapy||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|April 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00450853||173111|
NCT00450294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2006:180|Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair|The Effect of Aortic Infrarenal Clamping and Unclamping On Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair||University of Manitoba|Yes|Completed|March 2007|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients with known infrarenal abdominal aortic aneurysm for open repair will be        screened through the preadmission anesthetic clinic. If they do not meet exclusion        criteria and have signed informed consent for the the study, they will be enrolled to        assess for changes in intraocular pressure during open abdominal aortic aneurysm repair.|February 2014|February 12, 2014|March 21, 2007||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00450294||173153|There were no limitations to trial during course of study.
NCT00450619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070106|153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer|A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Male|18 Years|N/A|No|||January 2016|January 27, 2016|March 20, 2007|Yes|Yes||No|May 10, 2013|https://clinicaltrials.gov/show/NCT00450619||173129|This study was stopped before full accrual(after about two-thirds of the subjects were enrolled) due to a significant decrease in enrollment despite making this a multicenter study.
NCT00450645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/05|Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis|Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs|Cancer-DACUS|Azienda Ospedaliera Universitaria Policlinico|Yes|Recruiting|March 2005|March 2011|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||March 2009|March 3, 2009|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450645||173127|
NCT00451178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9824|An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only|An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma||Eli Lilly and Company|Yes|Completed|May 2007|January 2013|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|March 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451178||173086|
NCT00451646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-SMOF-006|Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition|A Double-blind, Randomised Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition||Fresenius Kabi||Completed|October 2007|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|85 Years|No|||October 2008|August 26, 2010|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451646||173051|
NCT00451126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|personalityandcortisol|Moderating Impact of Various Emotion Personality Factors on Salivary Cortisol Response to a TSST|Moderating Impact of Various Emotion Personality Factors on Salivary Cortisol|cortpersonal|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|October 2005|January 2006|Actual|||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||||58|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2007|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451126||173090|
NCT00451139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AITM0107|Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials|||Faculty of Medical Sciences Jimma University||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|5 Years|N/A||||March 2007|March 22, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00451139||173089|
NCT00452543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001592/1|Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism|A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence||Massachusetts General Hospital|No|Completed|March 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|64 Years|No|||June 2012|June 4, 2012|March 26, 2007||No||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00452543||172983|
NCT00452556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET-L-01892|The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study|The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study: A Phase II Study of Chemo - Hormonal Therapy and Radiation in High Risk Prostate Cancer||Nova Scotia Cancer Centre|Yes|Active, not recruiting|May 2007|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Male|N/A|N/A|No|||March 2014|March 18, 2014|March 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00452556||172982|
NCT00444106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566A2417|Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function|An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older||Novartis||Completed|May 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|265|||Both|12 Years|N/A||||April 2011|April 1, 2011|March 6, 2007|Yes|Yes||No|December 8, 2010|https://clinicaltrials.gov/show/NCT00444106||173621|
NCT00444119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wü_NNRIS_45/04|Survey in Patients With Chronic Adrenal Insufficiency in Germany|||University of Wuerzburg||Completed|May 2004|April 2005||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A|No|||March 2007|March 5, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444119||173620|
NCT00451061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor449907ctil|The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones|||Soroka University Medical Center|No|Not yet recruiting|April 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|65 Years|No|||February 2007|July 11, 2012|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00451061||173095|
NCT00451321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115493|TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)|TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD)|TTEDD|GlaxoSmithKline|No|Completed|July 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|12 Years|45 Years|No|||July 2012|November 15, 2012|March 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451321||173075|
NCT00451594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-009|High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP|A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic Purpura||Cooperative Study Group A for Hematology|Yes|Completed|September 2005|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Both|16 Years|N/A|No|||January 2011|January 12, 2011|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451594||173055|
NCT00451581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709036|A Prospective Randomized Study Comparing Different Dilation Durations for Endoscopic Papillary Balloon Dilatation|A Prospective Randomized Multicenter Study Comparing Different Dilation Durations During Endoscopic Papillary Balloon Dilatation for Bile Duct Stones.||National Taiwan University Hospital||Recruiting|January 2007|January 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Both|18 Years|N/A|No|||October 2006|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451581||173056|
NCT00451815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204-PD-201|BIIB014 Phase 2a Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson’s Disease||Biogen||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|78 Years|No|||March 2007|March 23, 2007|January 31, 2006||||No||https://clinicaltrials.gov/show/NCT00451815||173039|
NCT00452738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006036|The Effect of Pre Surgery Dog Visits on Post Surgery Consumption of Pain Medication|The Effect of Pre Surgery Dog Visits on Post Surgery Consumption of Pain Medication|Dog|Oklahoma State University Center for Health Sciences|No|Withdrawn|April 2007|February 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|4 Years|7 Years|No|||January 2008|April 20, 2015|March 23, 2007|||PI left university. Did not start study|No||https://clinicaltrials.gov/show/NCT00452738||172968|
NCT00453024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB A/06/375|Imaging Ahmed Glaucoma Tubes With a Pericardial Graft and Tissue Glue or Partial-Thickness Scleral Flap and Sutures|Anterior Segment Optical Coherence Tomography Findings in Patients With Ahmed Glaucoma Drainage Implants With Either a Pericardial Patch Graft and Fibrin Tissue Glue or a Partial-Thickness Scleral Flap and Conventional Sutures||National University Hospital, Singapore|Yes|Recruiting|February 2007|March 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|41 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 12, 2008|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453024||172949|
NCT00452413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11183|A Study of Enzastaurin and Erlotinib in Patients With Solid Tumors and Lung Cancer|A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy||Eli Lilly and Company|No|Active, not recruiting|May 2007|April 2014|Anticipated|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|March 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00452413||172993|
NCT00452712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156/06|Orthostatic Hypotension in Children With Acute Febrile Illness|||Assaf-Harofeh Medical Center||Recruiting|November 2006|||||Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|100|||Both|4 Years|18 Years||||May 2007|May 2, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452712||172970|
NCT00452998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB A/06/293|Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study|Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study||National University Hospital, Singapore|Yes|Completed|November 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|22 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 12, 2008|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00452998||172951|
NCT00453323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-05-156|Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer|A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer||National Cancer Center, Korea|No|Active, not recruiting|June 2006|December 2010|Anticipated|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||July 2010|July 9, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453323||172927|
NCT00453895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRAC-1|Sunitinib in Refractory Adrenocortical Carcinoma|Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy|SIRAC|University of Wuerzburg|No|Active, not recruiting|July 2007|June 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||July 2010|July 6, 2010|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00453895||172883|
NCT00450606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR450007CTIL|The Effects of Ambulatory Treatment at the Dead Sea on Osteoarthritis of the Knees|||Soroka University Medical Center|No|Completed|March 2007|||December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|N/A|N/A||||May 2008|May 20, 2008|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00450606||173130|
NCT00454467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26132|Hospital for Special Surgery Knee Arthroplasty Cohort|Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: The HSS Knee Arthroplasty Cohort||Hospital for Special Surgery, New York|Yes|Active, not recruiting|April 2007|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|We will be asking all patients undergoing total knee arthroplasty to participate.|August 2015|August 17, 2015|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454467||172839|
NCT00450333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD490-301|Dynepo Infrequent Dosing Study|An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease Who Are Pre-Dialysis or Require Peritoneal Dialysis or Haemodialysis||Shire|No|Terminated|October 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|407|||Both|18 Years|N/A|No|||November 2009|June 6, 2014|March 21, 2007||No|The termination of the study is not linked to a product recall or result of any safety signal.    Rather it was sponsor's commercial decision to withdraw the MA|No|August 18, 2009|https://clinicaltrials.gov/show/NCT00450333||173150|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.
NCT00451191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIST2|Botulinum Toxin Injection for the Management of BPH|Intraprostatic Injection of Botulinum Toxin for the Management of Benign Prostatic Hyperplasia: A Randomized Phase II Trial|MIST2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2006|December 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Male|50 Years|N/A|No|||June 2013|June 20, 2013|March 21, 2007|Yes|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT00451191||173085|First, this study was not designed to compare the effect of onabotulinum toxin A to placebo. Second, we assessed our primary outcome, treatment efficacy, at 3 months post-injection. The long-term safety of this product should also be evaluated.
NCT00450866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5106|Epothilone B in Treating Patients With CNS Metastases From Breast Cancer|Phase II Trial of Patupilone in Patients With Brain Metastases From Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|January 2007|May 2012|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|March 20, 2007|Yes|Yes||No|July 26, 2013|https://clinicaltrials.gov/show/NCT00450866||173110|
NCT00450879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00183|Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery|Pilot Study of GW786034 (Pazopanib), a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Operable Breast Cancer||National Cancer Institute (NCI)||Terminated|January 2007|September 2011|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2013|March 24, 2015|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450879||173109|
NCT00452855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PropSevoRemi|Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea|Postoperative Nausea and Vomiting Are Similar When Propofol or Sevoflurane Are Used as Adjuvant to Remifentanil During Anaesthesia for Gynaecological Surgery||Central Jutland Regional Hospital|No|Completed|January 2002|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||160|||Female|18 Years|50 Years|No|||March 2007|March 28, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452855||172959|
NCT00453115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-05-157|Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|A Phase II Study of Gemcitabine Plus Oxaliplatin for Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer||National Cancer Center, Korea|No|Active, not recruiting|January 2006|May 2011|Anticipated|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||July 2010|October 22, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453115||172942|
NCT00453193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0408|Alemtuzumab and Pentostatin In T-cell Neoplasms|A Phase II Study of Alemtuzumab and Pentostatin In T-Cell Neoplasms||M.D. Anderson Cancer Center|No|Terminated|September 2004|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|March 26, 2007||No|Slow accrual.|No|March 1, 2011|https://clinicaltrials.gov/show/NCT00453193||172936|
NCT00444132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3621-SM-CTIL|Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS|Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS||Sheba Medical Center||Completed|March 2005|June 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|80 Years|No|||September 2007|September 19, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444132||173619|
NCT00451854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-12018|Student Athlete Testing Using Random Notification|Student Athlete Drug Surveillance Trail|SATURN|National Institute on Drug Abuse (NIDA)|No|Completed|September 1999|October 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||14000|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||March 2007|March 23, 2007|March 23, 2007||||No||https://clinicaltrials.gov/show/NCT00451854||173036|
NCT00452153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601072|Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis|Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis||Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|March 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|March 26, 2007||No|Too much difficulties to includ patient|No||https://clinicaltrials.gov/show/NCT00452153||173013|
NCT00451841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-12073|Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux|Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux||University of Massachusetts, Worcester|No|Suspended|March 2007|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|frozen sputum supernatant and exhaled breath condensate fixed sputum cell preparations|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients evaluated for cough in the Lung and Allergy Center of Umass Memorial        Medical Center|July 2010|March 13, 2015|March 22, 2007||No|insufficient enrollment; study suspended pending analysis|No||https://clinicaltrials.gov/show/NCT00451841||173037|
NCT00453037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17019ex05-06|Effects of a Structured Education Program on Blood Pressure in Essential Hypertensive Patients|Effects of a Structured Education Program on Blood Pressure in Essential Hypertensive Patients and Effects of a Reminder Program for Physicians to Guide Optimal Therapy|herzleben|Medical University of Graz|No|Completed|March 2007|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|256|||Both|18 Years|85 Years|No|||January 2011|January 14, 2011|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453037||172948|
NCT00453011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|338|Comparison of AC and PC Lenses After Vitreous Loss During ECCE|CSP #338 - Comparison of Anterior and Posterior Chamber Lens Implants After Vitreous Loss in Attempted Extracapsular Cataract Extraction||VA Office of Research and Development||Completed|February 1992|February 1998||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||1202|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00453011||172950|
NCT00453336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20020618|Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract|A Phase II Clinical Trial on the Efficacy of Photodynamic Therapy With Porfimer Sodium (Photofrin®) for Malignant and Pre-Malignant Lesions and Condemned Mucosa Syndrome in the Upper Aerodigestive Tract||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|June 2003|May 2010|Actual|August 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2013|July 25, 2014|March 27, 2007|No|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00453336||172926|
NCT00453583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00420|Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine|Evaluation of the Treatment Satisfaction in Children Suffering From an Allergy and Who Received an Antihistamine Treatment||UCB Pharma||Completed|March 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|4581|||Both|2 Years|12 Years|No|Non-Probability Sample|Primary Care|May 2012|December 13, 2013|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453583||172907|
NCT00453596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16520|Analysis of Implantation Failure and Establishment of Therapy for Implantation Failure|||Yamaguchi University Hospital||Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||||||Female|N/A|N/A||||March 2007|March 28, 2007|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453596||172906|
NCT00453882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-06-003|Uretal Flow Assessment During Gynecological Procedures|An Evaluation of Ureteral Flow After Temporary Bilateral Uterine Artery Occlusion During Conservative Gynecological Procedures||Ethicon, Inc.|No|Completed|November 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Female|25 Years|N/A|No|||January 2012|January 26, 2012|March 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00453882||172884|
NCT00454168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000510853|Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission|A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study||National Cancer Institute (NCI)||Active, not recruiting|May 2005|||April 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|244|||Both|18 Years|N/A|No|||February 2009|January 3, 2014|March 27, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00454168||172862|
NCT00454207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481252|Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension|A Phase 3, Multi-Center, Open-Label Study to Assess Safety and Efficacy of Sildenafil Citrate 20 mg TID in Subjects With Pulmonary Arterial Hypertension||Pfizer|No|Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|16 Years|N/A|No|||August 2010|August 19, 2013|March 28, 2007||No||No|February 18, 2010|https://clinicaltrials.gov/show/NCT00454207||172859|
NCT00452829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05ND07|Prevention of Neural Tube Defects by Inositol in Conjunction With Folic Acid (PONTI Study)|Prevention of Neural Tube Defects by Inositol in Conjunction With Folic Acid (PONTI Study)||Institute of Child Health|No|Completed|September 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00452829||172961|
NCT00453687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2108380|A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.|See Detailed Description||GlaxoSmithKline||Completed|March 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|March 27, 2007||||||https://clinicaltrials.gov/show/NCT00453687||172899|
NCT00453960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roberta Granese, MD, PhD|Genistein and Endometrial Hyperplasia|Effect of Genistein on Endometrial Hyperplasia||University of Messina|Yes|Completed|January 2007|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|59|||Female|44 Years|55 Years|No|||December 2008|December 18, 2008|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453960||172878|
NCT00450918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5901|Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and Adolescents|Longitudinal Study of Primary Ciliary Dyskinesia: Participants 5-18 Years of Age||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|August 2006|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Blood samples|Both|5 Years|18 Years|No|Non-Probability Sample|Children and adolescents with primary ciliary dyskinesia|March 2016|March 4, 2016|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450918||173106|
NCT00451698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 04/161|Erythropoietin and Pediatric Cardiac Surgery|Erythropoietin and Pediatric Cardiac Surgery|EPO|Medical College of Wisconsin|Yes|Terminated|October 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|9|||Both|6 Weeks|18 Years|No|||July 2013|July 25, 2013|March 22, 2007|Yes|Yes|Inadequate patient enrollment|No|March 21, 2013|https://clinicaltrials.gov/show/NCT00451698||173048|Data for all recruited patients was included with available results. The number of participants fell far short of study goals and the study was terminated prematurely due to inadequate enrollment.
NCT00451932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-778-01-100|A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients|A Multicentre, Randomised, Double-Blind, Tacrolimus Dual Therapy-Controlled, Parallel Group, Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of FK778 in Liver Transplant Patients Receiving Standard Tacrolimus (FK506) and Steroids Therapy||Astellas Pharma Inc|Yes|Completed|October 2002|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|303|||Both|18 Years|65 Years|No|||April 2008|April 15, 2008|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00451932||173030|
NCT00451945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF 2007-004|New Indications for Ultrasound in the Staging of Cervical Cancer|New Indications for Ultrasound in the Staging of Cervical Cancer||Rigshospitalet, Denmark|No|Withdrawn|March 2007|March 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||||||Female|18 Years|N/A||||June 2008|June 17, 2008|March 23, 2007||||No||https://clinicaltrials.gov/show/NCT00451945||173029|
NCT00452881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-05-158|Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC|A Randomized Phase II Study Adjuvant Gemcitabine And Oxaliplatin Versus Gemcitabine and Cisplatin for Completely Resected Stage IB, II or IIIA Non-Small Cell Lung Cancer||National Cancer Center, Korea|No|Active, not recruiting|May 2006|December 2014|Anticipated|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||July 2010|October 22, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00452881||172957|
NCT00443859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC 27004|N-Terminal Pro-Brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension|Clinical Significance of N-Terminal Pro-Brain Natriuretic Peptide Levels in Persistent Pulmonary Hypertension||Christiana Care Health Services|No|Terminated|February 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Whole blood|Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|All infants who are admitted to the NICU with a diagnoses of PPHN.|May 2009|May 1, 2009|March 2, 2007||No|Interim analysis showed greater variablility in NT-proBNP findings than anticipated.|No||https://clinicaltrials.gov/show/NCT00443859||173640|
NCT00444704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3208A1-1002|Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Japanese Females||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2007|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|20 Years|64 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00444704||173576|
NCT00452166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p06-108a|Rosiglitazone and Insulin Resistance in Renally Impaired Patients|Rosiglitazone and Insulin Resistance in Renally Impaired Patients||Leiden University Medical Center|Yes|Terminated|April 2007|May 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2008|September 30, 2008|March 26, 2007|||it was not possible to recruit new patients anymore|No||https://clinicaltrials.gov/show/NCT00452166||173012|
NCT00451880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL281-001|Study of XL281 in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors||Exelixis||Completed|February 2007|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||October 2011|October 11, 2011|March 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00451880||173034|
NCT00452439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0124|A Study of Actonel for the Prevention of Bone Loss|A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)||M.D. Anderson Cancer Center|Yes|Completed|February 2004|||August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452439||172991|
NCT00452426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-06-0004|Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy|Multi-center Pivotal Clinical Trial to Compare the Safety and Effectiveness of Procedural Sedation in GI Endoscopy: A Computer-Assisted Personalized Sedation (CAPS) Device Versus Current Standard of Care||Ethicon Endo-Surgery|Yes|Completed|March 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1000|||Both|18 Years|N/A|No|||December 2010|December 30, 2010|March 26, 2007|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00452426||172992|
NCT00452725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAX08|Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome|Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome||Sanofi|No|Completed|October 1997|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|3 Years|15 Years|No|||October 2010|October 4, 2010|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452725||172969|
NCT00453622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD303|RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D|RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D|RISK|St. Jude Medical|Yes|Completed|November 2005|August 2012|Actual|August 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|222|Samples Without DNA|Blood samples will be collected|Both|18 Years|90 Years|No|Probability Sample|heart failure patients indicated for the CRT-D therapy|July 2013|July 17, 2013|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453622||172904|
NCT00453349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11981|A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease|A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 Days in Subjects With an Uncomplicated Pelvic Inflammatory Disease (PID). Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study)||Bayer|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|460|||Female|18 Years|N/A|No|||September 2014|September 2, 2014|March 27, 2007||No||No|September 1, 2009|https://clinicaltrials.gov/show/NCT00453349||172925|Out of the 460 randomized subjects, 5 subjects (3 moxifloxacin subjects, 2 placebo subjects) did not receive any study medication. Only one of these patients had an adverse event (stomachache, randomized to Moxifloxacin).
NCT00453362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI3926g|A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib|Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib||Genentech, Inc.||Completed|December 2006|||April 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|March 26, 2007|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00453362||172924|
NCT00453609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY Upstate MU IRB # 5463|Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)|Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI): An Open Prospective Pilot Trial|vivitrol|State University of New York - Upstate Medical University|Yes|Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|69 Years|No|||December 2008|December 10, 2008|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453609||172905|
NCT00453908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9397|Alfuzosin Versus Placebo in Acute Urinary Retention|Does Alfuzosin OD vs. Placebo in Male Patients Facilitate Spontaneous Voiding During Clean Intermittent Self-Catheterization Following Acute Urinary Retention?|ALF-RIK|Sanofi|No|Terminated|May 2004|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||160|||Male|50 Years|N/A|No|||August 2007|August 17, 2007|March 28, 2007|||The study was early terminated due to slow and difficult recruitment|No||https://clinicaltrials.gov/show/NCT00453908||172882|
NCT00450281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000446084|S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men||Southwest Oncology Group|Yes|Completed|October 2005|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|981|||Both|18 Years|120 Years|No|Non-Probability Sample|Cancer center|December 2013|October 23, 2015|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450281||173154|
NCT00453427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-Control-103662|Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas|Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study|ACCAPELA|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|September 2006|May 2015|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453427||172919|
NCT00454493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05H-561610|The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease|The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease||University of California, Los Angeles||Recruiting|August 2006|July 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|75 Years|No|||March 2007|March 29, 2007|March 29, 2007||||No||https://clinicaltrials.gov/show/NCT00454493||172837|
NCT00450320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-051|Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma|A Pilot Study of Rapamycin in Patients With HIV-Related Kaposi's Sarcoma||AIDS Malignancy Consortium|No|Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450320||173151|
NCT00451438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701003R|Investigation of Muscle Activity Pattern of Gluteus Medius and Tensor Fascia Lata in Patients With PFPS|||National Taiwan University Hospital|No|Completed|January 2007|March 2007||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||30|||Female|20 Years|50 Years|No|||January 2007|March 21, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00451438||173066|
NCT00452257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10724|A Study of Enzastaurin in Patients With Leukemia|A Phase 1b Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL)||Eli Lilly and Company|No|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2009|March 18, 2009|March 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00452257||173005|
NCT00452270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTCS-CE-301|Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold|A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study, Evaluating the Decongestant Effect, Time to Onset, Duration of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold||Novartis|No|Completed|March 2007|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||May 2007|May 2, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452270||173004|
NCT00452517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG-SIR-BM-07|Comparison of Stent Graft, Sirolimus Stent, and Bare Metal Stent Implanted in Patients With Acute Coronary Syndrome|Comparison of Stent Graft, Sirolimus Stent, and Bare Metal Stent Implanted in Patients With Acute Coronary Syndrome: Clinical and Angiographic Follow-up||University of Zagreb|No|Completed|March 2004|November 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|20 Years|80 Years|No|||March 2007|March 26, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452517||172985|
NCT00452842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5091075|Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies|An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials.||Pfizer||Terminated|October 2007|||||N/A|Observational|N/A||||26784|||Both|10 Years|N/A|No|||December 2007|February 21, 2008|March 26, 2007|||See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00452842||172960|
NCT00443599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512|SPECS: Safe Pediatric Euglycemia in Cardiac Surgery|Maintaining Normal Blood Sugar Levels in Children Undergoing Heart Surgery to Reduce the Risk of Infections and Improve Recovery (The SPECS Study)|SPECS|Children's Hospital Boston|Yes|Completed|November 2006|January 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|989|||Both|N/A|36 Months|No|||March 2014|March 13, 2014|March 5, 2007||No||No|January 28, 2014|https://clinicaltrials.gov/show/NCT00443599||173660|
NCT00443872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-1.0-IV|Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists|Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications|AtoZ|Parkinson's Disease and Movement Disorder Center of Boca Raton|No|Completed|March 2007|December 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|30 Years|90 Years|No|||October 2014|October 30, 2014|March 3, 2007|No|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00443872||173639|
NCT00443885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07020078|Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC|Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC to Problematic Gram-negative Organisms||University of Pittsburgh|Yes|Active, not recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|gram negative bacteria|December 2015|December 16, 2015|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443885||173638|
NCT00444730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-031|Urology Database for Outcomes Research|Urology Database for Outcomes Research||William Beaumont Hospitals|No|Completed|January 2007|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|860|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing radical prostatectomy or InterStim implantation at William Beaumont        Hospital.|August 2014|August 26, 2014|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444730||173574|
NCT00445029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.435|Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation|Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation||Hospices Civils de Lyon||Recruiting|March 2007|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 3, 2007|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445029||173551|
NCT00452179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD125-004|Safety and Efficacy Study of APD125 in Patient With Insomnia|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Effects of APD125 in Patients With Chronic Primary Insomnia||Arena Pharmaceuticals||Completed|February 2007|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|173|||Both|18 Years|64 Years||||September 2007|September 6, 2007|March 23, 2007||||||https://clinicaltrials.gov/show/NCT00452179||173011|
NCT00452452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3002|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children|A Phase 3 Open-label Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Older Infants and Children Who Are Naive to Previous Vaccination With Pneumococcal Conjugate Vaccine.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|355|||Both|7 Months|5 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|March 23, 2007|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00452452||172990|
NCT00452751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0520310-2|Comparison of Laparoscopic Versus Open Gastrectomy for Gastric Cancer: A Prospective Randomized Trial|Multi-institutional Prospective Randomized Trial on the Assessment of Laparoscopic Surgery for Gastric Cancer|KLASS|National Cancer Center, Korea|Yes|Recruiting|February 2006|May 2014|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1400|||Both|20 Years|80 Years|No|||September 2010|September 20, 2010|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452751||172967|
NCT00453921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17363|Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)|Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)||Dartmouth-Hitchcock Medical Center|Yes|Completed|February 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|18 Years|65 Years|No|||June 2013|June 19, 2013|March 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00453921||172881|
NCT00454181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03HUHI19|Treatment of Oral Warts in HIV+ Patients|Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial||Amarillo Biosciences, Inc.|No|Completed|February 2007|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|March 29, 2007|Yes|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00454181||172861|Only 59 of 80 planned subjects were randomized, so statistical power of the study was limited.
NCT00454454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|797-2002|Virtual Reality Helmet to Test for Problems With Memory|Display Enhanced TEsting for Cognitive Impairment and Traumatic Brain Injury|DETECT|Emory University|No|Completed|March 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|425|||Both|65 Years|N/A|No|Non-Probability Sample|geriatric clinic, retirement facilities|July 2013|July 27, 2013|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00454454||172840|
NCT00453635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/03.08|Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients|A Multicenter Randomized Phase II Study of First Line Treatment With Sequential Administration of Docetaxel, Carboplatin and Herceptin Versus the Administration of Vinorelbine and Herceptin Combination in HER-2 Positive Patients With Metastatic Breast Cancer||Hellenic Oncology Research Group|No|Terminated|December 2003|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Female|18 Years|75 Years|No|||March 2012|March 12, 2012|March 28, 2007||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00453635||172903|
NCT00453934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V4001|Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device|h-Patch vs. Pen or Needle and Syringe as Insulin Administration Device in Type 1 or 2 Diabetes Patients Using MDI: Patient Preference and Glycemic Control After Switch in an Open-Label, Randomized Cross-Over Study||Valeritas, Inc.|No|Terminated|May 2007|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|75 Years|No|||March 2007|December 5, 2007|March 27, 2007|||Endpoint no longer deemed meaningful|No||https://clinicaltrials.gov/show/NCT00453934||172880|
NCT00454194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0626|Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Completed|September 2007|May 2013|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|March 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454194||172860|
NCT00454246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20337|A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.|A Randomized, Open Label Study of the Effect of Intravenous Mircera on Hemoglobin Control in Patients Transitioning From Chronic Kidney Disease Stage 4 Through Dialysis||Hoffmann-La Roche||Terminated|April 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|111|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|March 29, 2007|Yes|Yes|Strategic decision unrelated to safety or efficacy|No|March 29, 2011|https://clinicaltrials.gov/show/NCT00454246||172856|
NCT00450671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seton vs. Surgisis|Treatment of Perirectal Fistula With Cutting Seton vs. Collagen Plug|Seton Placement vs. Surgisis Anal Fistula Plug Insertion for Perirectal Fistula: A Prospective Randomized Study||University of Southern California|Yes|Recruiting|February 2007|February 2012|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||March 2007|November 25, 2008|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450671||173125|
NCT00449007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-OQU-015630-02|Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism|A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence)||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Active, not recruiting|February 2006|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|65 Years|No|||September 2008|September 26, 2008|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449007||173250|
NCT00454259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2006/08|Fentanyl Ultra Low Doses Effects on the Nociceptive Threshold|Fentanyl Ultra Low Doses Effects on Human Volunteer's Nociceptive Threshold. Towards a Simple Pharmacological Test Able to Predict Pain Vulnerability, Post Operative Hyperalgesia Development Risk?|FENTANULD|University Hospital, Bordeaux|Yes|Completed|March 2007|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|48|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2007|June 2, 2015|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454259||172855|
NCT00454272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M000507_6004|Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients|Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients||Sanofi|No|Completed|January 2005|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Both|2 Years|N/A|No|||March 2009|March 5, 2009|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454272||172854|
NCT00443612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBEH_L_00702|Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing|A Randomized, Open Label, Cross-over Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension||Sanofi||Completed|September 2006|||October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|70 Years|No|||September 2009|September 30, 2009|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443612||173659|
NCT00444418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAMOR_015553-01A1S1|Medication and Counseling for Controlled Drinking (Project SMART)|Naltrexone and CBT for Problem-drinking MSM||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Completed|April 2006|June 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Male|18 Years|65 Years|No|||April 2013|April 30, 2013|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444418||173598|
NCT00445055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2006/02|Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea|Study of Evaluation of the Profile of Efficiency / Tolerance of 2 Doses of Intravenous Droperidol in the Prevention of the Postoperative Nausea and Vomits Related to the Surgery of the Thyroid|DIPAVO|University Hospital, Bordeaux|No|Terminated|April 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|71|||Female|18 Years|N/A|No|||December 2011|December 12, 2011|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00445055||173549|
NCT00445068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2203|Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma|A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy||Novartis||Terminated|April 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|March 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00445068||173548|
NCT00445094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0787B-092|A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)(COMPLETED)|A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit||Merck Sharp & Dohme Corp.||Completed|November 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00445094||173546|
NCT00450684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE-CHD|Cardiac Resynchronization Therapy in Congenital Heart Defects|Cardiac Resynchronization Therapy in Heart Failure Patients With Congenital Heart Defects|CARE-CHD|Competence Network for Congenital Heart Defects||Completed|May 2007|September 2013|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|N/A|N/A|No|||October 2014|October 9, 2014|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00450684||173124|
NCT00453375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHT-3021-01|Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus|A Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic Study of BHT-3021 With Open Label Cross-Over in Subjects With Type I Diabetes Mellitus||Bayhill Therapeutics|Yes|Completed|October 2006|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2011|June 27, 2011|March 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00453375||172923|
NCT00453050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000536471|Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin|Laser and TLR-Agonist Immunotherapy: A Novel Autologous Melanoma Vaccine Study||National Cancer Institute (NCI)||Completed|March 2006|||March 2009|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||November 2008|May 5, 2015|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453050||172947|
NCT00453063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05067|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|March 2007|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|426|||Both|12 Years|N/A|No|||March 2015|March 17, 2015|March 26, 2007|Yes|Yes||No|February 3, 2010|https://clinicaltrials.gov/show/NCT00453063||172946|
NCT00453076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-11|Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction|Randomized Trial of Conventional Covered Self Expandable Metallic Stent Versus Paclitaxel Eluting Covered Self Expandable Metallic Stent in Unresectable Malignant Bile Duct Obstruction||Asan Medical Center|Yes|Completed|November 2006|June 2009|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||November 2006|June 10, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453076||172945|
NCT00453388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2064.00|Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia|Nonmyeloablative Hematopoietic Cell Transplantation for Patients With Fanconi Anemia Using Alternative Marrow Donors: A Phase II Dose-Finding Study||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|February 2007|||June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1|||Both|N/A|N/A|No|||August 2015|August 28, 2015|March 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00453388||172922|
NCT00453648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Harvest Plus 8025|Impact of Consumption of Orange-fleshed Sweet Potatoes on the Vitamin A Status of Bangladeshi Women of Reproductive Age|Efficacy of Daily Consumption of Sweet Potatoes for Increasing Total Body Vitamin A Pool Size, and the Effect of Consumption of Sweet Potatoes on Iron and Zinc Absorption in Bangladeshi Women of Reproductive Age||University of California, Davis|No|Completed|March 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|130|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453648||172902|
NCT00450892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10054|Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer|A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Completed|February 2007|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|129|||Female|18 Years|70 Years|No|||October 2015|October 2, 2015|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450892||173108|
NCT00451672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950912|The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism|||National Taiwan University Hospital|No|Recruiting|January 2007|December 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|20 Years|60 Years|No|||December 2006|March 22, 2007|March 22, 2007||||Yes||https://clinicaltrials.gov/show/NCT00451672||173049|
NCT00451919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|375|The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease|Sickle-Cell Disease: Neuroimaging and Cognitive Decline||National Heart, Lung, and Blood Institute (NHLBI)||Recruiting|July 2006|||||N/A|Observational|N/A|||Anticipated|120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 29, 2013|March 23, 2007||||No||https://clinicaltrials.gov/show/NCT00451919||173031|
NCT00448149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC IRB#1006-0152|Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer|Phase I/II Trial of RAD001 Plus Nexavar® For Patients With Metastatic Renal Cell Carcinoma||The Methodist Hospital System|No|Completed|December 2006|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448149||173316|
NCT00448487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL-2007|Haptoglobin Phenotype and Cardiovascular Complications in Diabetic Patients|Prospective Observational Study to Asses the Incidence of CVD Complications in Diabetic Patients Pre-stratified by Haptoglobin Phenotype From the I CARE Registry|ICARER|Technion, Israel Institute of Technology|No|Completed|April 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3054|||Both|55 Years|N/A|No|Probability Sample|patients recruited from primary care clinics. all are diabetic patients 55 years old or        older.|June 2015|June 10, 2015|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00448487||173290|
NCT00448461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arcard2007/001|Antithrombotic Regimens and Outcome|Comparison of Bivalirudin and Unfractioned Heparin in Elective Percutaneous Coronary Interventions|ARNO|Careggi Hospital|Yes|Completed|March 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|850|||Both|18 Years|N/A|No|||February 2009|February 9, 2009|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00448461||173292|
NCT00448474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1163-1-3|Development and Evaluation of A Mailed Arthritis Self-Management Program|Mail-Delivered Arthritis Self-Management Education -- Years 1, 2, Carryover||University of North Carolina, Chapel Hill|Yes|Completed|November 2005|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 15, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00448474||173291|
NCT00448734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502|A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer|A Phase 1/2 Study of Picoplatin and Docetaxel (With Prednisone) in Subjects With Chemotherapy-Naive Metastatic Hormone-Refractory Prostate Cancer||Poniard Pharmaceuticals|Yes|Active, not recruiting|June 2006|July 2010|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|95|||Male|18 Years|N/A|No|||January 2009|January 20, 2009|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448734||173271|
NCT00449020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20030244|Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer|Carboplatin and Irinotecan Concomitantly With Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel for Locally Advanced Non-Small Cell Lung Cancer (GIA 12177).||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|January 2004|January 2008|Actual|May 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449020||173249|
NCT00449228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051040|Efficacy of Preoperative Education and Mini-invasive Surgery for Total Hip Replacement|Evaluation of Preoperative Education and Mini-invasive Total Hip Replacement in Regard to the Attainment of Functional Independency and Reduction of Hospital Stay|ANRACT|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|April 2007|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|||Anticipated|215|||Both|40 Years|N/A|No|||March 2007|June 4, 2012|March 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00449228||173233|
NCT00444145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061244|Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?|Do Laryngeal Biopsy Findings Predict Treatment Response in Suspected Laryngopharyngeal Reflux|biopsy II|Vanderbilt University|No|Completed|March 2007|December 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2010|November 12, 2010|March 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00444145||173618|
NCT00444431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004090-13|Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance. A Prospective, Randomized, Controlled Multi-Center Study|Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance in Children With Scintigraphically Prooved Obstruction. A Prospective, Randomized, Controlled Multi-Center Study|TOKU|University Hospital, Essen|Yes|Not yet recruiting|March 2007|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||240|||Both|4 Months|6 Months|No|||March 2007|March 5, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444431||173597|
NCT00444717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGU-64|Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome|Multicenter Study for Anti-oxidative and Anti-inflammatory Effects of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome||Aichi Gakuin University|Yes|Completed|April 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|20 Years|N/A|No|||October 2008|July 12, 2011|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444717||173575|
NCT00445367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-001|Biobank For MS And Other Demyelinating Diseases|Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases||Accelerated Cure Project for Multiple Sclerosis|No|Active, not recruiting|May 2006|||||N/A|Observational|Observational Model: Case Control||2|||||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM),        Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and        Optic Neuritis (ON)), and related and unrelated unaffected controls.|May 2015|May 1, 2015|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00445367||173525|
NCT00453453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00038961|BNP Therapy Observation Unit Outcomes STudy (BOOST)|BNP Therapy Observation Unit Outcomes STudy|BOOST|Emory University|Yes|Terminated|March 2007|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453453||172917|
NCT00452764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2006-135|Regulatory T Cells in COPD|Phenotype and Number of Regulatory T Cells Present in Peripheral Blood of COPD Patients Versus Healthy Controls||Groningen Research Institute for Asthma and COPD|Yes|Completed|January 2007|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Male|40 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 7, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452764||172966|
NCT00452777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVT.115959-005|Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study Evaluating the Efficacy and Tolerability of Oral BVT.115959, a Novel A2A Agonist, Versus Placebo in the Treatment of Diabetic Neuropathic Pain||Swedish Orphan Biovitrum|Yes|Completed|May 2007|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|193|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452777||172965|
NCT00453141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06030|Betamethasone Dosing Interval - 12 or 24 Hours?|Betamethasone Dosing Interval - 12 or 24 Hours?||The Cooper Health System|No|Completed|April 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||March 2009|November 7, 2009|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00453141||172940|
NCT00453154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00465|Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) For Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|March 2007|||June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|March 27, 2007|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00453154||172939|
NCT00452478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-403|Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5|A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion From Standard Phosphate Binder Therapy to Fosrenol® in Chronic Kidney Disease Stage 5 Patients on Haemodialysis||Shire||Terminated|May 2007|December 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||December 2007|June 6, 2014|March 23, 2007|No|Yes|This study was stopped by the sponsor based on a non-safety related corporate decision|No||https://clinicaltrials.gov/show/NCT00452478||172988|
NCT00453661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0419|Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities|Cancer Prevention and Treatment Demonstration for Hispanic Medicare Eligible Beneficiaries - CMS||M.D. Anderson Cancer Center|Yes|Active, not recruiting|March 2007|||March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2812|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hispanic American 40 Years + treated for cancer and Medicare eligible.|September 2015|September 30, 2015|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453661||172901|
NCT00453674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wue-ACC-R-86-03|German Adrenocortical Carcinoma Registry|Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry||University of Wuerzburg|No|Recruiting|January 2003|December 2025|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Adrenocortical carcinoma patients in Germany (or treated in Germany)|September 2015|September 6, 2015|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453674||172900|
NCT00454480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526121|Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome||National Cancer Institute (NCI)||Completed|August 2006|||August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2000|||Both|N/A|N/A|No|||August 2008|August 23, 2013|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00454480||172838|
NCT00450905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F06001|Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population|Randomized Evaluation of a Low-Frequency Investigational Device Employing Neuromodulation Therapy in Patients With Fibromyalgia||Fralex Therapeutics|Yes|Terminated|March 2007|December 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||February 2008|October 3, 2008|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00450905||173107|
NCT00451152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-19|Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma|A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma||Alcon Research|No|Completed|March 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||May 2012|November 27, 2012|March 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451152||173088|
NCT00452504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3197A1-100|Single Ascending Dose Study of SRA-444 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRA-444 Administered Orally to Healthy Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2007|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|64|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|March 23, 2007||||||https://clinicaltrials.gov/show/NCT00452504||172986|
NCT00452816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-4829-E/G 01|Marketing Workplace Chronic Disease Prevention|Marketing Workplace Chronic Disease Prevention||University of Washington|Yes|Completed|April 2007|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Both|N/A|N/A|No|||November 2009|November 18, 2009|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452816||172962|
NCT00448162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL-032-01|The Chinese Mutation Hotspot of ENaC Causing Liddle's Syndrome and the Association of ENaC Variations and Hypertension|||Peking Union Medical College|Yes|Suspended|May 2005|December 2009||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|8 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients were defined as being hypertensive if they had systolic and/or diastolic BP        levels >=140/90mm Hg on three occasions within 2 months and if they were without any        antihypertensive treatment, and/or if they had been diagnosed as being hypertensive in the        past and were currently receiving antihypertensive medications. The normotensive controls        were defined as having systolic and/or diastolic BP levels <130/85mm Hg and with no family        history of hypertension. Patients were excluded when they had any known renal diseases or        secondary hypertension.|May 2009|March 30, 2011|March 15, 2007||No|no enough fund|No||https://clinicaltrials.gov/show/NCT00448162||173315|
NCT00448175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPC032006|Overactive Bladder Innovative Therapy Trial (OrBIT)|Overactive Bladder Innovative Therapy Trial|OrBIT|Uroplasty, Inc||Completed|June 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|March 15, 2007||No||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00448175||173314|
NCT00448760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20040006|Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery|A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma||University of Miami Sylvester Comprehensive Cancer Center||Completed|October 2004|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 15, 2007|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00448760||173269|
NCT00448773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-20061243|REDucing Influenza Among University Students, University of California at Berkeley|Effectiveness of Selected Non-pharmaceutical Interventions in Reducing Influenza-like Illness Among University Students|REDI-US|Centers for Disease Control and Prevention||Completed|February 2007|May 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|3000|||Both|17 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 6, 2010|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00448773||173268|
NCT00448747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS 130 047|Investigation of a New, Oral Growth Hormone Secretagogue, Macimorelin (AEZS-130) as a Growth Hormone Stimulation Test.|A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy||AEterna Zentaris|No|Completed|June 2007|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|February 19, 2014|March 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448747||173270|
NCT00449254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAN-OE-US-04|Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults|A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults.||Manhattan Pharmaceuticals|No|Active, not recruiting|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Male|18 Years|60 Years|No|||June 2007|June 4, 2007|March 16, 2007||||Yes||https://clinicaltrials.gov/show/NCT00449254||173231|
NCT00449241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.227-T|Acupuncture Treatment in Adults Undergoing Diagnostic OGD : A Double-Blind Placebo Controlled Randomized Trial|Acupuncture Treatment in Adults Undergoing Diagnostic Upper Gastrintestinal Endoscopy: A Double-Blind Placebo Controlled Randomized Trial||Chinese University of Hong Kong|Yes|Recruiting|November 2006|July 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2007|March 19, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449241||173232|
NCT00444158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200L2-1108|Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects|A Randomized, Double-Blind, Double-Dummy, 2-Period Crossover Study to Characterize the PK/PD Relationship of a 20-Minute Versus a 4-hour Intravenous Infusion of MOA-728 in Subjects on Stable Methadone Maintenance||Valeant Pharmaceuticals International, Inc.||Completed|March 2007|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|March 5, 2007||||||https://clinicaltrials.gov/show/NCT00444158||173617|
NCT00444743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-093-03-200|Phase 2 Study of MM-093 to Treat Patients With Uveitis|A Phase 2, Double - Blind, Placebo - Controlled, Randomized Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Uveitis||Merrimack Pharmaceuticals|No|Completed|February 2007|||November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00444743||173573|
NCT00444756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|622.04|Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Intravenous (IV) Catheterization in Children|Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Peripheral Intravenous Catheterization in Children||Norton Healthcare|Yes|Completed|April 2005|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||70|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||March 2007|March 7, 2007|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00444756||173572|
NCT00441077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907102|Interventions to Educate An Underserved Population About Inherited Disease Risks|Using a Communication Intervention to Provide Information About Inherited Risk to Underserved Latino Communities||National Institutes of Health Clinical Center (CC)||Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1|||550|||Both|18 Years|N/A|No|||August 2009|September 26, 2015|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00441077||173854|
NCT00451958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS21A|A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy|An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients With Prostate Cancer Requiring Androgen Ablation Therapy||Ferring Pharmaceuticals|Yes|Completed|March 2007|December 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|386|||Male|18 Years|N/A|No|||March 2013|March 20, 2013|March 23, 2007|No|Yes||No|October 10, 2012|https://clinicaltrials.gov/show/NCT00451958||173028|
NCT00451971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWA486_4020|Objective Study in Rheumatoid Arthritis|Objective Study in Rheumatoid Arthritis|OSRA|Sanofi||Completed|March 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|249|||Both|18 Years|75 Years|No|||September 2008|September 4, 2008|March 23, 2007||||No||https://clinicaltrials.gov/show/NCT00451971||173027|
NCT00452283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0792|Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy|The Effect of a Systemic Non-selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.||University of Colorado, Denver|No|Completed|March 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with pulmonary hypertension|January 2013|January 29, 2013|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452283||173003|
NCT00452231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFS2045|RCT of CBT Combined With D-Cycloserine for Treating PTSD|Comparative Study of the Efficacy of a Cognitive-Behavioral Therapy for Post-Traumatic Stress Disorder With or Without D-Cycloserine||Université de Montréal|Yes|Recruiting|February 2007|July 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|65 Years|No|||March 2007|March 26, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452231||173007|
NCT00453401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-001-003|Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis|The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis||NanoBio Corporation|No|Completed|February 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|1000|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2008|May 28, 2008|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00453401||172921|
NCT00453414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C200-007|Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension|Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension||Actelion||Withdrawn|July 2006|October 2006|Anticipated|October 2006|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|3 Years|18 Years|No|||February 2010|February 12, 2010|March 27, 2007||Yes|Withdrawn due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT00453414||172920|
NCT00454220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRTSH01505|Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter|Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction With Radioiodine for the Treatment of Multinodular Goiter.||Sanofi|No|Completed|July 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|96|||Both|35 Years|80 Years|No|||October 2014|October 27, 2014|March 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454220||172858|
NCT00454233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543-CL-003|A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects|A Randomized, Double Blind, Placebo and Active Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Potential Efficacy of a 12-Week Treatment With YM543 in Subjects With Type 2 Diabetes Mellitus||Astellas Pharma Inc|Yes|Completed|February 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|97|||Both|18 Years|65 Years|No|||October 2008|October 14, 2008|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454233||172857|
NCT00450658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-CA-301|Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers|A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|March 2007|October 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|627|||Both|40 Years|80 Years|No|||April 2013|April 22, 2013|March 19, 2007|Yes|Yes||No|May 17, 2011|https://clinicaltrials.gov/show/NCT00450658||173126|
NCT00451412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEX839BDE03|A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients|A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients||Novartis|No|Completed|January 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3254|||Both|70 Years|N/A|No|||July 2012|July 24, 2012|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451412||173068|
NCT00451425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2007/031|Weight Gain During Pregnancy - a Randomized Controlled Trial of Intervention to Prevent Excessive Gestational Weight Gain|Weight Gain During Pregnancy - a Randomized Controlled Trial of Intervention to Prevent Excessive Gestational Weight Gain.|VIGA|University Hospital Orebro|No|Recruiting|May 2007|October 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|430|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 28, 2009|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451425||173067|
NCT00453102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060078|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma|Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma||University of Miami|Yes|Completed|February 2006|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|120 Years|No|||November 2015|November 30, 2015|March 27, 2007|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT00453102||172943|Data reported for only 16 of 18 enrolled participants due to 2 participants withdrawing consent.
NCT00448500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/ko/2006/004|Exhaled Breath Condensate (EBC) Assessment in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Measurement of Biomarkers in the Exhaled Breath Condensate in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease||Chinese University of Hong Kong|No|Completed|February 2006|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|80|None Retained|Exhaled breath condensate|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|COPD patients with exacerbations Stable COPD patients Normal subjects|May 2008|May 6, 2008|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00448500||173289|
NCT00452621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V48P4E3|Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years|A Phase IV, Uncontrolled, Open-Label, Multi-Center Study in Children and Adolescents: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New Pediatric TBE Vaccine (Free of Protein-Derived Stabilizer) in Study V48P4E1, Five Years After First Booster Immunization||Novartis||Completed|February 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|235|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452621||172977|
NCT00452894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051076|Phase 1 Clinical Trial of Varenicline in Chinese Healthy Smoking Volunteers|A Pharmacokinetic, Toleration And Safety Study Of Single And Multiple Oral Doses Of Varenicline In Chinese Healthy Volunteers||Pfizer||Completed|March 2007|March 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||14|||Both|18 Years|45 Years|No|||March 2008|March 28, 2008|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452894||172956|
NCT00449033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12006|A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)|A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)|NEXUS|Bayer|Yes|Completed|February 2007|June 2011|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|904|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|March 16, 2007||No||No|April 20, 2011|https://clinicaltrials.gov/show/NCT00449033||173248|Inclusion of squamous patients stopped in FEB 2008, as 11961 (NCT00558636) trial reported higher mortality for this subgroup. Squamous patients in 12006 (NCT00449033) trial discontinued drug as a precaution endorsed by Data Monitoring Committee.
NCT00449046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110101|Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-|Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-||GlaxoSmithKline||Completed|March 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|5 Years|14 Years|No|||April 2015|April 16, 2015|March 16, 2007||||No|November 21, 2008|https://clinicaltrials.gov/show/NCT00449046||173247|
NCT00452907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTEN_L_00848|ACT MALI: Treatment of Malaria Based on Combination Therapies|Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali||Sanofi||Completed|July 2005|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|780|||Both|6 Months|N/A|No|||February 2010|February 16, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00452907||172955|
NCT00453219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024918|FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity|Functional Hypothalamic Amenorrhea: Characterization of Metabolic Status, Brain Circuitry, and Stress-reactivity||Emory University|Yes|Withdrawn|July 2011|||||N/A|Observational|Time Perspective: Prospective||3|Actual|0|Samples With DNA|Blood samples will be collected, processed, and stored for the evaluation of genetic markers      assocaited with stress vulnerability. Serum and plasma specimens will be collected and      stored for the evaluation of factors associated with the regulation of reproduction.|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women ages 18-35|October 2013|October 29, 2013|March 26, 2007||No|prior to participant recruitment, PI left Emory, study stopped|No||https://clinicaltrials.gov/show/NCT00453219||172934|
NCT00453505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070122|Modulation of Motor Function by Stimulation of the Central and Peripheral Nervous System|Modulation of Motor Function by Stimulation of the Central and Peripheral Nervous System||National Institutes of Health Clinical Center (CC)||Recruiting|March 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|N/A|No|||June 2015|January 14, 2016|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453505||172913|
NCT00449579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC_01|The Diagnostic Benefits of the HyperQTM System in ECG Stress Testing|The Diagnostic Benefits of the HyperQTM System in ECG Stress Testing||Assuta Hospital Systems||Recruiting|August 2006|October 2007||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|||Anticipated|1200|||Both|45 Years|N/A|Accepts Healthy Volunteers|||October 2006|April 16, 2015|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449579||173208|
NCT00444444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0038|Genetic Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP)|Clinical Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP) in Korean Population Based on the HLA Analysis by Using a High Resolution (Sequence Based) Techniques||Asan Medical Center|No|Completed|February 2002|June 2007|Actual|||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|40|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||March 2007|June 25, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444444||173596|
NCT00444782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX115.1.1-201|A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.|"Heptovax" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma.||Pharmexa A/S||Completed|November 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||December 2008|December 17, 2008|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444782||173570|
NCT00445081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD_PROVE_001|Prednisolone vs. Ciclosporine in Severe Atopic Eczema|Prednisolone vs. Ciclosporine in Severe Atopic Eczema|PROVE|Technische Universität Dresden|Yes|Completed|March 2007|January 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|55 Years|No|||October 2010|October 28, 2010|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445081||173547|
NCT00441103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27178|A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis|A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis|IMPROVE|Merck KGaA||Completed|December 2006|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|60 Years|No|||June 2014|June 6, 2014|February 26, 2007||No||No|May 20, 2010|https://clinicaltrials.gov/show/NCT00441103||173852|
NCT00441116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106377|A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia|An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)||GlaxoSmithKline||Completed|December 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|150|||Male|18 Years|49 Years|No|||August 2011|August 11, 2011|February 27, 2007|Yes|Yes||No|January 20, 2009|https://clinicaltrials.gov/show/NCT00441116||173851|
NCT00451659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0053|Characterization of Recently Deployed Veterans|Characterization of Recently Deployed Veterans||Tuscaloosa Research & Education Advancement Corporation|No|Completed|February 2005|February 2007|Actual|||Phase 3|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||500|||Both|19 Years|N/A|No|||March 2007|March 21, 2007|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00451659||173050|
NCT00452530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-047|Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery|A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)|ADVANCE-2|Bristol-Myers Squibb|Yes|Completed|June 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3221|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|March 23, 2007|Yes|Yes||No|April 14, 2014|https://clinicaltrials.gov/show/NCT00452530||172984|
NCT00453089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VG-101-001|VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women|A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women||Bionovo||Not yet recruiting|June 2012|August 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|40|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|March 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00453089||172944|
NCT00453947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbosco2|Non-Invasive Ventilation in Pulmonary Edema|Non Invasive Positive Airway Pressure And Risk Of Myocardial Infarction In Acute Cardiogenic Pulmonary Edema: Continuous Positive Airway Pressure Vs Non Invasive Positive Pressure Ventilation||Ospedale S. Giovanni Bosco|Yes|Completed|July 2002|May 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||March 2007|March 28, 2007|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00453947||172879|
NCT00450307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-015|Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma|3F8 Antibody Dose Escalation Plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma: A Phase I Trial||Memorial Sloan Kettering Cancer Center||Completed|June 2005|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|21 Years|No|||October 2013|October 14, 2013|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450307||173152|
NCT00451165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-282|Bowel, Urinary and Sexual Function After Laparoscopic Colorectal Surgery|Outcome Study of Bowel, Urinary and Sexual Function After Laparoscopic Colorectal Surgery, Using Questionnaire and Function Tests||Kyoto University|No|Completed|May 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Male|20 Years|80 Years|No|Probability Sample|Male patients who will receive laparoscopic colorectal surgery|January 2009|April 14, 2010|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451165||173087|
NCT00446953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3740|Caesarean and Corticotherapy|Interest in Programming Caesarean Section at 38 Weeks of Pregnancy With Antenatal Betamethasone to Prevent Neonatal Respiratory Distress and to Avoid Emergency Caesarean Section Before Planned Date.||University Hospital, Strasbourg, France|No|Completed|February 2007|November 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|N/A|N/A|No|||September 2013|October 13, 2015|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446953||173407|
NCT00452244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-177|Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)|Randomized Phase II Trail Comparing Gefitinib Plus Simvastatin and Gefitinib Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)||National Cancer Center, Korea|No|Completed|May 2006|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||September 2011|September 15, 2011|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452244||173006|
NCT00452491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH5126A|MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children|A Cohort of Pre-pubertal Children for the Study of Optimization of Methods of Administration of the Biosynthetic Growth Hormone MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation||Sanofi|No|Completed|May 1993|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|306|||Both|3 Years|11 Years|No|||October 2010|October 4, 2010|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452491||172987|
NCT00447928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orthoderm-1-001-06|Phase II Dose-Ranging Study of OrthoDerm Patch for Patients With Tennis Elbow|A Randomized, Double-Blind, Placebo-Controlled Phase II Dose-Ranging Study of the OrthoDerm Transdermal Nitroglycerin Patch for Patients With Chronic Lateral Epicondylitis||Cure Therapeutics|No|Not yet recruiting|April 2007|November 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||164|||Both|18 Years|70 Years|No|||March 2007|March 13, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447928||173333|
NCT00452322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRM 96/17|Safety of Testosterone Undecanoate i.m. in Hypogonadal Men|Long-Term Intervention Phase 2 Study of Safety Aspects of Testosterone Undecanoate i.m. in Hypogonadal Men||University Hospital Muenster|Yes|Completed|April 1997|January 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Male|17 Years|70 Years|No|||March 2007|March 26, 2007|March 26, 2007||||No||https://clinicaltrials.gov/show/NCT00452322||173000|
NCT00452608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05589|Statin for Immunomudulation in Sepsis|Use of Statins in Modulation of Inflammatory Answer in Septic Patients||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|December 2006|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|15 Years|N/A|No|||June 2009|June 25, 2009|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452608||172978|
NCT00453518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-1004|The RETRIEVE Study: Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts|Evaluating the Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts: The RETRIEVE Study|RETRIEVE|Lumen Biomedical|Yes|Completed|March 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||August 2009|August 17, 2009|March 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00453518||172912|
NCT00453206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000538185|Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases|Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients With Hematological Diseases||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|February 2007|August 2014|Actual|February 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|N/A|70 Years|No|||September 2014|September 11, 2014|March 27, 2007|Yes|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT00453206||172935|By the time the primary objective of this trial was completed, the treatment approach of the trial had become standard of care. Analysis was therefore limited.
NCT00453804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRB # 5371|Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)|Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study|vivitrol|State University of New York - Upstate Medical University|Yes|Completed|July 2006|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|69 Years|No|||March 2008|March 17, 2008|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453804||172890|
NCT00454064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGT090774|Cognitive-Behavioural Treatment of Chronic Back Pain|Study to Compare a Cognitive-Behavioral Treatment With a Cognitive-Behavioral Treatment With Biofeedback Elements to Patients With Chronic (Low) Back Pain||Philipps University Marburg Medical Center|Yes|Completed|September 2004|February 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|80 Years|No|||May 2008|May 27, 2008|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00454064||172870|
NCT00454350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECT00106|A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis|A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis||Sanofi||Completed|February 2007|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|March 28, 2007||||||https://clinicaltrials.gov/show/NCT00454350||172848|
NCT00453778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMS40273|A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients|A Study to Investigate the Effect of Inhaled Fluticasone Propionate on the Bronchial Responsiveness to Leukotriene D4 in Asthmatics Patients||GlaxoSmithKline|No|Completed|November 2002|May 2004|Actual|May 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||14|||Both|18 Years|50 Years|No|||February 2013|February 11, 2013|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453778||172892|
NCT00453791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF2105450|The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics|A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics||GlaxoSmithKline|No|Terminated|February 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453791||172891|
NCT00444457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3005|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1712|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||October 2012|October 10, 2012|March 5, 2007|Yes|Yes||No|June 11, 2010|https://clinicaltrials.gov/show/NCT00444457||173595|Commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella) was not available as planned; the alternate of a commercially available MMR and a commercially available varicella vaccine was administered in separate injections.
NCT00444769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBA106809|Dental Pain 3rd Molar Tooth Extraction GW842166|A Multi-Centre, Randomised, Single-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy of Single Pre-Emptive Doses of GW842166X, a Non-Cannabinoid CB2 Receptor Agonist, on Pain Following Third Molar Tooth Extraction.||GlaxoSmithKline||Completed|October 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|50 Years|No|||May 2009|May 15, 2009|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444769||173571|
NCT00445393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70606|Adolescent Idiopathic Scoliosis and Mental Health|Prevalence of Psychiatric Disorders in Adolescents With Idiopathic Scoliosis: A Pilot Study of a Validated Screening Tool||University of British Columbia|Yes|Completed|October 2006|October 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|11 Years|16 Years|No|Probability Sample|Aadolescents undergoing spinal surgery for scoliosis.|January 2009|January 5, 2009|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445393||173524|
NCT00442312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM 003|Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy|An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension.||Genovate Biotechnology Co., Ltd.,|No|Active, not recruiting|May 2006|November 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||43|||Both|20 Years|N/A|No|||February 2007|February 28, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00442312||173759|
NCT00442325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581095|Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets|ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg.|ACTFAST 2|Pfizer||Completed|January 2003|February 2004||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||595|||Both|18 Years|N/A|No|||April 2007|October 24, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442325||173758|
NCT00450086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-60/COC|Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis|Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules vs. Mesalazine Granules vs. Placebo for Patients With Collagenous Colitis.||Dr. Falk Pharma GmbH|Yes|Completed|March 2007|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|80 Years|No|||May 2014|May 16, 2014|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450086||173169|
NCT00451906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO19390|A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.|Open Label Study of Avastin in Combination With Platinum-containing Chemotherapy as 1st Line Treatment in Patients With Stage IIIb/IV Non-squamous NSCLC||Hoffmann-La Roche||Completed|October 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2118|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451906||173032|
NCT00452218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14636A|Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)|Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)||University of Chicago|Yes|Completed|March 2007|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|March 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00452218||173008|
NCT00446095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00023|Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma|A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of Fostamatinib in Patients With Relapsed/Refractory B-Cell Lymphoma||AstraZeneca|Yes|Completed|April 2007|October 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|80 Years|No|||December 2014|December 17, 2014|March 8, 2007|Yes|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00446095||173473|This is a small, non-randomized study. Comparisons between the 3 groups cannot be reliably made and should be interpreted with caution.
NCT00446394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30692-J|Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI)|Exercise & Health Promotion for MCI: A Controlled Trial||University of Washington|Yes|Completed|June 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|70 Years|N/A|No|||October 2012|October 18, 2012|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446394||173450|
NCT00446680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-CF-301|Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study|Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study||Pharmaxis|Yes|Completed|March 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|340|||Both|6 Years|N/A|No|||June 2010|June 23, 2010|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446680||173428|
NCT00447291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.02.001|Safety & Efficacy of Omega-3 Fish Oil in Overweight Children & Adolescents|Evaluation of the Safety and Efficacy of Omega-3 Fish Oil Dietary Supplementation in Biometric Measurement, Lipid Profile, Serum Markers for Inflammation, and Insulin Resistance in Overweight Children and Adolescents||Children's Heart Center|No|Terminated|December 2006|July 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|1||Actual|60|||Both|8 Years|18 Years|No|||September 2006|January 26, 2011|March 12, 2007||No|Zone Labs, Inc discontinue utilizing their fish oil supplement and frozen foods|No||https://clinicaltrials.gov/show/NCT00447291||173381|
NCT00447538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rpat1CTIL|Posttraumatic Symptoms Among Toddlers and Their Parents Following Exposure to Terrorism|Identifying Distress, Developmental and Behavioral Problems Among Toddlers, and Posttraumatic Distress Among Their Parents Following Continuous Exposure to Terrorism||Herzog Hospital|Yes|Completed|November 2005|January 2007||||Phase 4|Observational|Time Perspective: Retrospective||||300|||Both|24 Months|48 Months|Accepts Healthy Volunteers|||April 2013|April 29, 2013|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447538||173363|
NCT00447551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLYL_L_01777|Canadian Aesthetic Experience With Sculptra Therapy|Canadian Study of the Use of Injectable POLY-L-LACTIC Acid (Sculptra Therapy) in Aesthetic Medicine||Sanofi||Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|75 Years|No|||November 2009|November 12, 2009|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447551||173362|
NCT00447564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-805|Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence||Titan Pharmaceuticals|Yes|Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|65 Years|No|||October 2012|October 18, 2012|March 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00447564||173361|
NCT00447941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153A1-103|Safety, PK and PD Study in Healthy Male Japanese Subjects|Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sca-136 Administered Orally to Healthy Male Japanese Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 6, 2009|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447941||173332|
NCT00448188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bleeding risk in CVCs|Bleeding Risk in CVCs|Thrombocytes and International Normalized Ratio Are no Predictors for Bleeding in Application of Central Veneous Catheters||Heidelberg University|Yes|Completed|November 2005|March 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||September 2007|January 25, 2013|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00448188||173313|
NCT00452634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-176|Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)|A Phase II Study of Irinotecan/Cisplatin Plus Simvastatin in Chemo-naive Patients With Extensive Disease-Small Cell Lung Cancer||National Cancer Center, Korea|No|Completed|April 2006|May 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|March 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00452634||172976|
NCT00453817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-019|Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging|Suivi Par résonance magnétique après Transplantation d'îlots de Langerhans||University Hospital, Geneva|No|Terminated|June 2005|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|October 4, 2006||No|Feasibility issues|No||https://clinicaltrials.gov/show/NCT00453817||172889|
NCT00454363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00201|Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer|A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma||National Cancer Institute (NCI)|No|Completed|March 2007|December 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|21 Years|N/A|No|||May 2015|October 15, 2015|March 27, 2007|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT00454363||172847|
NCT00454584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013015|An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis|A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis||Centocor, Inc.|Yes|Completed|March 2007|January 2009|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|903|||Both|18 Years|N/A|No|||October 2012|October 19, 2012|March 28, 2007|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00454584||172830|
NCT00444795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181146|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene||Pfizer|No|Completed|December 2007|March 2015|Actual|March 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|620|||Both|18 Years|N/A|No|Non-Probability Sample|patients diagnosed as GIST after disease progression on or intolerance to imatinib        mesylate or patients diagnosed as advanced RCC or patients diagnosed as unresectable,        well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma|October 2015|October 6, 2015|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444795||173569|
NCT00445107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-363|SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)|An Open Label, Observational Study to Assess The Efficacy, Safety and Tolerability of Added Singulair in Persistent Asthma Patients With or Without Allergic Rhinitis and Long Acting B-Agonist|STAR|Merck Sharp & Dohme Corp.||Completed|November 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|198|||Both|15 Years|80 Years|No|||October 2015|October 9, 2015|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00445107||173545|
NCT00441402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK65995 (completed)|Exercise Amenorrhea Stress and Bone Health in Adolescents|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed||||||N/A|Observational|Time Perspective: Prospective|||||||Female|14 Years|21 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00441402||173829|
NCT00445419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHEPC001|Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides|A Phase I Single-blind Randomised Placebo Controlled Dose Escalating Study of One Virosome Formulated CD4 and Two Virosomes Formulated CD8 Hepatitis C Virus (HCV) Vaccine Components (PEV2A and PEV2B) Administered to Healthy Adult Volunteers||Pevion Biotech Ltd|Yes|Completed|December 2006|June 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 5, 2010|March 8, 2007||||No||https://clinicaltrials.gov/show/NCT00445419||173522|
NCT00442936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-011|Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura||Merck Sharp & Dohme Corp.|No|Completed|February 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1380|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|February 28, 2007|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT00442936||173711|
NCT00446134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA003142-204|Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)|Phase 2 Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection||Valeant Pharmaceuticals International, Inc.|Yes|Completed|March 2007|April 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|278|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|March 8, 2007|Yes|Yes||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00446134||173470|
NCT00446433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CD-001|A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease||Celgene||Completed|March 2002|December 2003||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|12 Years|75 Years|No|||April 2007|April 3, 2007|March 7, 2007||||||https://clinicaltrials.gov/show/NCT00446433||173447|
NCT00446446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062088|PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)|Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck||Amgen|No|Active, not recruiting|October 2007|April 2016|Anticipated|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|March 8, 2007|Yes|Yes||No|February 1, 2016|https://clinicaltrials.gov/show/NCT00446446||173446|
NCT00452790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-011|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India|A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2007|February 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|708|||Both|42 Days|72 Days|Accepts Healthy Volunteers|||March 2011|March 22, 2011|March 23, 2007|Yes|Yes||No|October 13, 2010|https://clinicaltrials.gov/show/NCT00452790||172964|Geometric Mean Concentration Outcome Measures were identified as secondary analysis in the study protocol, but are included to maintain consistency with other postings for this program.
NCT00452803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-164|Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study Preoperative Chemotherapy Versus Preoperative Concurrent Chemoradiotherapy for Patients With Biopsy-Proven N2 Stage IIIA Non-Small Cell Lung Cancer||National Cancer Center, Korea|No|Recruiting|April 2006|December 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||July 2010|July 9, 2010|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00452803||172963|
NCT00446108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002765|Retrospective Pulmonary Valve Replacement Imaging|Proposal for Retrospective Review of Imaging Pre- and Post - Pulmonary Valve Replacement||Emory University|No|Completed|February 2007|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|153|||Both|1 Year|65 Years|No|Non-Probability Sample|This is a retrospective chart review examining children and adults with history of        Tetralogy of Fallot or pulmonary stenosis who have undergone subsequent pulmonary valve        replacement. The primary interest of the study is to analyze the routine pre- and        post-operative imaging studies. All charts reviewed will be of patients who had their        surgery at Children's Healthcare of Atlanta or Emory University Hospital between January        1, 1994 and May 1, 2008. We will review approximately 200 patients' charts for patients        between the ages of 1 and 65 years of age who have required pulmonary valve replacement.|November 2013|November 25, 2013|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446108||173472|
NCT00446121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0410/55|Inhaled Mannitol and Ciliary Beat Frequency in COPD Patients|The Effect of Inhaled Mannitol on Ciliary Beat Frequency in COPD Patients||Imperial College London||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|38 Years|80 Years|No|||March 2007|March 9, 2007|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446121||173471|
NCT00446407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANAS|Evaluating the Benefits and Affordability of a Program to Improve the Care of Common Mental Disorders in Primary Care|The Effectiveness and Cost-effectiveness of a Collaborative Stepped Care Intervention for the Treatment of Common Mental Disorders in Primary Care Settings in Goa, India|MANAS|London School of Hygiene and Tropical Medicine|Yes|Completed|April 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2796|||Both|18 Years|N/A|No|||July 2009|March 31, 2015|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446407||173449|
NCT00446420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.228|Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations|Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations||Melbourne Health|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446420||173448|
NCT00446693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFPS01|Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement|A Single Arm, Multi-center, Prospective Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement||Endogun Medical Systems Ltd.|Yes|Completed|February 2007|June 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|40 Years|80 Years|No|||November 2009|November 18, 2009|March 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00446693||173427|
NCT00447304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002056-14|Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy|Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy = ACDC-study|ACDC|Heidelberg University|Yes|Completed|October 2006|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|644|||Both|18 Years|N/A|No|||March 2007|July 20, 2012|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447304||173380|
NCT00447577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512|Zylet vs TobraDex in Blepharokeratoconjunctivitis|A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis||Bausch & Lomb Incorporated|No|Completed|January 2007|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|March 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00447577||173360|
NCT00447590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBA-001|Effectiveness and Safety Study of LAP-BAND Treatment for Obese Adolescents|||Apollo Endosurgery, Inc.||Completed|March 2007|June 2013|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Both|14 Years|17 Years|No|||September 2014|September 22, 2014|March 14, 2007|Yes|Yes||No|September 16, 2014|https://clinicaltrials.gov/show/NCT00447590||173359|
NCT00448201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0306|Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease|Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen|LCCC 0306|UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|November 2003|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|70|||Both|10 Years|N/A|No|||November 2015|November 23, 2015|March 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448201||173312|
NCT00452010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601001|Pain Reducing Effect of Transcutaneous Electrical Nerve Stimulation in Patients With Chronic Low Back Pain or Lumbo-radiculalgia|Pain Reducing Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Chronic Low Back Pain or Chronic Lumbo-radiculalgia and Followed in Pain Treatment Centers|LOBOTENS|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||September 2008|July 3, 2012|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452010||173024|
NCT00453232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCA-CCTC-ACCELERATED-BEP|Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors|Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor||National Cancer Institute (NCI)||Completed|August 2004|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|20|||Male|18 Years|40 Years|No|||August 2007|August 6, 2013|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453232||172933|
NCT00453245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920040018|Molecular Basis of the Growth Axis in Short Stature|Study of the Molecular Basis of the Growth Axis Among Short Stature Children||HaEmek Medical Center, Israel|Yes|Completed|January 2004|January 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|1 Year|81 Years|No|||January 2004|March 27, 2007|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453245||172932|
NCT00453258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0862|Pilot Study of Human Tear Proteins|Analysis of Human Tear Proteins: A Pilot Study to Describe the Tear Film Proteome of Patients Undergoing Ophthalmic Examination.||University of Colorado, Denver|No|Terminated|February 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects receiving eye examination|October 2012|January 15, 2013|March 26, 2007||No|Stopped due to low enrollment|No||https://clinicaltrials.gov/show/NCT00453258||172931|
NCT00453830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 04-179|Laparoscopic Versus Open Sigmoid Colectomy for Diverticular Disease|Laparoscopic Versus Open Sigmoid Colectomy for Diverticular Disease: A Prospective Randomized Single-Blind Trial||University Hospital, Geneva|No|Completed|January 2005|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2009|February 17, 2009|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453830||172888|
NCT00450177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052007738|Efficacy of Enteral Iron Supplementation in Critical Illness|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Enteral Iron Supplementation on Anemia and Risk of Infection in Critical Illness||Weill Medical College of Cornell University|No|Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450177||173162|
NCT00450190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26443|Saizen® E-Device User Trial|User Trial on the Use in Common Practice of a New Electronic Auto-injector of Saizen®, the E-Device (Electronic Device), in Children Treated by Recombinant Human Growth Hormone Over a Period of 2 Months||Merck KGaA||Completed|February 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A||||February 2014|February 17, 2014|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00450190||173161|
NCT00441090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKR-501-CL-003|Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).||Eisai Inc.|No|Completed|February 2007|June 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|February 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00441090||173853|
NCT00441389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/ko/2006/003|Infectious Etiology of Acute Exacerbations of COPD|Infectious Etiology of Acute Exacerbations of COPD in Hong Kong||Chinese University of Hong Kong|No|Completed|May 2004|December 2007||||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal||||500|||Both|40 Years|N/A|No|||February 2007|February 27, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441389||173830|
NCT00445432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-837|A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease|A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease||Abbott||Completed|March 2007|November 2010|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|82|||Both|15 Years|75 Years|No|||February 2012|February 1, 2012|March 7, 2007||No||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00445432||173521|
NCT00441961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mtx in eosinophilic fasciitis|Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis|Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis||Radboud University|No|Completed|October 2006|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2010|August 10, 2011|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441961||173786|
NCT00442689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK73411|Metabolic Syndrome in PCOS: Precursors and Interventions|Metabolic Syndrome in PCOS: Precursors and Interventions||Northwestern University|Yes|Completed|July 2006|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|97|||Female|18 Years|35 Years|No|||May 2014|May 9, 2014|February 5, 2007|Yes|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00442689||173730|Please note there were 2 additional arms at the start of the study: Metformin alone (n=8) and Metformin+Flutamide (n=6), which were discontinued. These arms are therefore not included in these results data.
NCT00445809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0401|Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury|EValuation Of NGAL in Early and eVolving Acute kidnEy Injury|EVOLVE|Biosite|Yes|Completed|February 2007|April 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|355|Samples Without DNA|Blood Samples (3 10ml, 7 5ml) at ten timepoints over 5 days.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing CABG Surgery that are thought to have a risk of developing AKI        during/after surgery.|August 2009|August 3, 2009|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00445809||173494|
NCT00446459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24223-A|Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.|The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant||University of Washington|Yes|Completed|April 2006|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|No|||April 2010|April 5, 2010|March 9, 2007|Yes|Yes||No|December 29, 2009|https://clinicaltrials.gov/show/NCT00446459||173445|The treatment of highly sensitized patients on dialysis with single agent therapy of mycophenolate was hampered by gastrointestinal side effects that reduced anticipated maximum tolerated doses and duration of treatment.
NCT00447317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DK067181|Dietary Adherence Enhancement in Peritoneal Dialysis: BalanceWise-PD|Dietary Adherence Enhancement in Peritoneal Dialysis|BalanceWise-PD|University of Pittsburgh|Yes|Completed|November 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00447317||173379|
NCT00447603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-327|A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)|A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Essential Hypertension||Merck Sharp & Dohme Corp.|No|Terminated|May 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|6 Years|17 Years|No|||March 2015|March 25, 2015|March 14, 2007|Yes|Yes|Achieving site readiness and enrolling the trial within a reasonable time|No|January 23, 2014|https://clinicaltrials.gov/show/NCT00447603||173358|The study was discontinued early (during screening) due to limited availability of sites and readiness of sites to enroll participants within the predefined time.
NCT00447954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTF 2|A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration|A Phase II Study of Implants of Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Participants With Visual Acuity Impairment Associated With Atrophic Macular Degeneration||Neurotech Pharmaceuticals|Yes|Completed|January 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|50 Years|N/A|No|||April 2011|April 12, 2011|March 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00447954||173331|
NCT00452023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM03-0109|Pegasys® in Patients With Myeloproliferative Diseases|PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2005|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|280|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00452023||173023|
NCT00452335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0211SC-0641|Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation|A Multi-center, Open-labeled Study of the Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients With Constipation||Sucampo Pharma Americas, LLC|No|Completed|January 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|127|||Both|2 Years|17 Years|No|||October 2009|October 21, 2009|March 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00452335||172999|
NCT00450697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608008682|Feeding Tolerance in Preterm Infants|Feeding Tolerance in Preterm Infants: Randomized Trial of Bolus Feeding Every 4 Hours Versus Every 3 Hours||Weill Medical College of Cornell University|No|Recruiting|February 2007|November 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|N/A|2 Months|No|Non-Probability Sample|very low birth weight premature infants with birth weight <= 1250g|November 2010|November 4, 2010|February 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00450697||173123|
NCT00445224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0138-F2L|Comparing Rehabilitation Programs for Patellofemoral Pain Syndrome|Comparison of Early Hip Strengthening to Early Quadriceps Strengthening in the Treatment of Females With Patellofemoral Pain||University of Kentucky|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|33|||Female|15 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|March 6, 2007||No||No|January 28, 2010|https://clinicaltrials.gov/show/NCT00445224||173536|Early termination leading to small number of subjects analyzed. Intention to treat analysis, last score carried forward, was used to analyze all outcome data.
NCT00451737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461712111|Correlation of 6-Minute Walk Test and Neuromuscular Parameters in the Elderly|Correlation of 6-Minute Walk Test and Neuromuscular Parameters in the Elderly: Knee Proprioception, Standing Balance, Quadriceps Muscle Strength, Endurance, and Torque Acceleration Energy||National Taiwan University Hospital||Recruiting|November 2006|March 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||January 2006|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451737||173045|
NCT00443001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 347|Noninvasive Blood Pressure Monitor Evaluation Including Performance During Dysrhythmias|Noninvasive Blood Pressure Monitor Evaluation Including Performance During Dysrhythmias||GE Healthcare|Yes|Recruiting|November 2001|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2008|July 23, 2008|March 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443001||173706|
NCT00452309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 06-1007|Validation of a Correction Factor for Measurement of an Accurate Ankle-Brachial Index in the Seated Position|Validation of a Correction Factor for Measurement of an Accurate Ankle-Brachial Index in the Seated Position||The Cleveland Clinic||Completed|March 2007|August 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|50|||Both|60 Years|N/A||||September 2007|September 25, 2007|March 25, 2007||||No||https://clinicaltrials.gov/show/NCT00452309||173001|
NCT00452569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA PH INT 2005 CL001|Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma|Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma|OPTIMUM|Celgene|Yes|Completed|February 2006|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|499|||Both|18 Years|N/A|No|||September 2009|March 27, 2013|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00452569||172981|
NCT00452582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF-N-1|Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke|Phase 1 Study of Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke||Henry Ford Health System|Yes|Terminated|April 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||March 2011|March 15, 2011|March 26, 2007|Yes|Yes|Failure to recruit in expected time period.|No||https://clinicaltrials.gov/show/NCT00452582||172980|
NCT00452595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-318|Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder|A 12-Month Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2004|May 2005||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2007|March 23, 2007|March 23, 2007||||||https://clinicaltrials.gov/show/NCT00452595||172979|
NCT00473460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11229|Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis|A Double-blind, Randomized, Placebo-controlled Study to Investigate Chronic Intermittent-pulse-therapy of Moxifloxacin as a Prevention of Acute in Exacerbation Out-patients With Chronic Bronchitis.||Bayer|No|Completed|October 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1404|||Both|45 Years|90 Years|No|||October 2014|October 27, 2014|May 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00473460||171412|
NCT00442728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVAL300107|The Effect of Neuromuscular Electrical Stimulation|on Muscle Wasting in Artificially Ventilated and Sedated Patients at the Intensive Care Unit: a Pilot Study||Provinciale Hogeschool Limburg||Completed|January 2003|June 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||21|||Both|50 Years|75 Years|No|||March 2007|March 1, 2007|February 11, 2007||||No||https://clinicaltrials.gov/show/NCT00442728||173727|
NCT00474045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1687|Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes|A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir®) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Women With Type 1 Diabetes||Novo Nordisk A/S|Yes|Completed|May 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|470|||Female|18 Years|N/A|No|||August 2014|August 12, 2014|May 15, 2007|Yes|Yes||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00474045||171369|
NCT00443183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AA012417-03|Emergency Physician Brief Interventions for Alcohol|Emergency Physician Brief Interventions for Alcohol||Yale University||Completed|May 2002|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00443183||173692|
NCT00443196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20060042|Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas|Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas||DiaTech Oncology||Completed|March 2006|September 2010|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|N/A|N/A|No|||March 2011|March 23, 2011|June 14, 2006||No||No||https://clinicaltrials.gov/show/NCT00443196||173691|
NCT00443521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310/05|Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy||University of Sao Paulo|Yes|Completed|March 2005|July 2006||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|40 Years|N/A|No|||March 2007|March 2, 2007|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00443521||173666|
NCT00443794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rx-Medical-CVS-06-01|The Indian POLYCAP Study (TIPS)|A Randomized Double Blind Controlled Trial of the Efficacy and Safety of POLYCAP (Quintapill)Versus Its Components in Subjects With at Least One Additional Cardiovascular Risk Factor||St. John's Research Institute|Yes|Completed|March 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|9||Actual|2050|||Both|45 Years|80 Years|No|||September 2010|September 22, 2010|February 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00443794||173645|
NCT00444067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS3-06-002|Study to Evaluate Safety & Effectiveness of Spinal Sealant|A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery||Integra LifeSciences Corporation|Yes|Completed|May 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|75 Years|No|||September 2014|September 4, 2014|March 6, 2007|Yes|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT00444067||173624|
NCT00454519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUCC-0701|Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis|Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial|IPHC|Wuhan University|Yes|Recruiting|March 2007|||December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|70 Years|No|||February 2009|February 12, 2009|March 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454519||172835|
NCT00450710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS06005|Neuroendocrine Brake for Type 2 Diabetes Mellitus|Phase IV Study of Neuroendocrine Brake Surgical Procedure for Type 2 Diabetes Mellitus||Medtronic - MITG||Completed|March 2006|September 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||40|||Both|18 Years|65 Years||||August 2014|August 21, 2014|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00450710||173122|
NCT00451243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701244|Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment|Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatmen||National Taiwan University Hospital||Completed|January 2005|June 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||20|||Both|N/A|N/A|No|||December 2004|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451243||173081|
NCT00450944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000495296|Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia|A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Recruiting|November 2005|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|17 Years|N/A|No|||June 2007|February 6, 2009|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450944||173104|
NCT00442741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2123E1|Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)||Novartis||Withdrawn|July 2007|||July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|March 1, 2007||No|pts. will be captured in core|No||https://clinicaltrials.gov/show/NCT00442741||173726|
NCT00443014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200201054-12/12BMA2/400|The Dementia Study in Northern Norway|Phase 4 Study of Cognitive Therapy and Donepezil in Alzheimers Disease.||University Hospital of North Norway|Yes|Completed|June 2003|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|187|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 9, 2011|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443014||173705|
NCT00443326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060349|AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of AMG 714 After Multiple Dose Administration in Subjects With Moderate to Severe Psoriasis||Amgen||Completed|March 2007|May 2010|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|March 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443326||173681|
NCT00443300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0696|Effectiveness of Protected Environment Rooms for AML and MDS|Effectiveness of HEPA-filtered Rooms ("Protected Environment") to Prevent Morbidity and Mortality in Patients Age >/ = 60 Receiving Lower Intensity ("Targeted") Therapy for Untreated AML and High-risk Myelodysplasia (MDS)||M.D. Anderson Cancer Center|Yes|Terminated|January 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|3|||Both|60 Years|N/A|No|Probability Sample|Patients with AML or high-risk MDS Age >/= 60 years with a Zubrod performance status of        0,1, or 2|August 2012|August 1, 2012|March 1, 2007||No|Terminated due to low accrual.|No||https://clinicaltrials.gov/show/NCT00443300||173683|
NCT00443313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907080|Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta|HPV Testing to Improve Cervical Cancer Screening in the Mississippi Delta (Mississippi Delta Project)||National Institutes of Health Clinical Center (CC)||Completed|January 2007|June 2015||||N/A|Observational|N/A|||Anticipated|1000|||Female|26 Years|65 Years|No|||June 2015|October 17, 2015|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443313||173682|
NCT00442481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4205-JL-CTIL|Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder|Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder||Sheba Medical Center|No|Recruiting|February 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|No|||March 2007|March 1, 2007|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00442481||173746|
NCT00473772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBM-VS-54|DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery Disease|Paclitaxel-Eluting PTCA-Balloon in Combination With the CoroflexTM Blue Stent vs the Sirolimus Coated CypherTM Stent in the Treatment of Advanced Coronary Artery Disease|PEPCADIII|University Hospital, Saarland|Yes|Completed|July 2007|January 2011|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|643|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473772||171390|
NCT00474071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03467|Optimum Dose of Remifentanil for Intubation in Small Children|Investigation to Determine the Optimum Dose of Remifentanil for Tracheal Intubation in Children Using the Up/Down Method||University of British Columbia|No|Completed|March 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|3 Weeks|No|||May 2007|September 24, 2008|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00474071||171367|
NCT00473746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016969|Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer|Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer||Janssen Research & Development, LLC|No|Completed|June 2006|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Male|18 Years|N/A|No|||March 2014|March 27, 2014|May 11, 2007|No|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00473746||171391|
NCT00474032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01-70210|Using Botox to Treat Patients With Idiopathic Clubfoot|Efficacy of Botox in Patients With Idiopathic Clubfoot||University of British Columbia|Yes|Recruiting|March 2003|March 2023|Anticipated|March 2023|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|N/A|12 Years|No|||November 2015|November 30, 2015|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00474032||171370|
NCT00474331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-70223|Gene Mutations and Orthopaedic Symptoms Correlation of Multiple Hereditary Exostoses: Multicentre Project|Genotype-Phenotype Correlation of Multiple Hereditary Exostoses: Multicentre Project||University of British Columbia|No|Suspended|June 2004|June 2023|Anticipated|June 2023|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|New patients presenting with HME will be identified through the offices and clinics of        British Columbia Children's Hospital Orthopaedic Department.|December 2014|December 12, 2014|May 14, 2007||No|Due to unavailability of testing for gene mutation|No||https://clinicaltrials.gov/show/NCT00474331||171348|
NCT00474344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-70319|Genetic Linkage Study of Idiopathic Talipes Equinovarus (ITEV) (Clubfoot)|Genetic Linkage Study of Idiopathic Talipes Equinovarus (ITEV) (Clubfoot)||University of British Columbia|No|Completed|August 2004|August 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|370|||Both|N/A|N/A|No|Probability Sample|One family member, usually child, must have clubfoot.|March 2014|March 27, 2014|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00474344||171347|
NCT00442949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050705|Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndrome (ACS)|Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention (The ABOARD Study)|ABOARD|Assistance Publique - Hôpitaux de Paris|Yes|Completed|August 2006|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||April 2008|February 11, 2009|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00442949||173710|
NCT00443209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-012|Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)|A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura||Merck Sharp & Dohme Corp.|Yes|Completed|February 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1068|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|February 28, 2007|Yes|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT00443209||173690|
NCT00443222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Remicade myositis|Treatment With TNF Blockade, Infliximab, in Patients With Myositis|An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies||Karolinska Institutet|No|Completed||||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2007|March 2, 2007|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00443222||173689|
NCT00443534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181078|A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.|A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.||Pfizer|No|Completed|May 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|March 2, 2007|No|Yes||No|December 15, 2012|https://clinicaltrials.gov/show/NCT00443534||173665|The reason for not completed ‘Study Terminated by Sponsor’ in participant flow table indicates the termination of study at few sites as captured in case report forms at those sites and does not reflect overall status of study.
NCT00453973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-10|Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)|An Open-Label, Multi-Center, Extension Study to Evaluate the Safety and Tolerability of Peginesatide for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease||Affymax|No|Terminated|November 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|March 27, 2007|Yes|Yes|Due to more robust long-term data generated in other active-controlled studies|No|April 26, 2012|https://clinicaltrials.gov/show/NCT00453973||172877|Early termination of study due to generation of controlled long-term data in Phase 3 studies. Amended dosing guidelines during the trial to reflect label changes for ESAs; the primary outcome was assessed after the dosing guideline change.
NCT00453986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109067|Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults|Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the Co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age||GlaxoSmithKline||Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|1352|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|April 9, 2015|March 28, 2007|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00453986||172876|
NCT00453999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-201|Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza|Phase II, Multicenter, Randomized, Double-Mask, Double-Dummy Study Comparing Efficacy and Safety of Intravenous Peramivir Once Daily Versus Oral Oseltamivir Twice Daily in Adults With Acute Serious or Potentially Life-Threatening Influenza||BioCryst Pharmaceuticals|Yes|Completed|July 2007|August 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|137|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|March 27, 2007|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00453999||172875|
NCT00454285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13559|Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing|Bacteremia From Dental Extractions vs. Oral Hygiene||Carolinas Healthcare System|Yes|Completed|January 2003|June 2006|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|290|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 2, 2009|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454285||172853|
NCT00450385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061138|Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)|Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP|R-CHOP|University of Miami|Yes|Recruiting|February 2007|||December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|213|||Both|18 Years|120 Years|No|||February 2016|February 1, 2016|March 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00450385||173147|
NCT00450398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSPSL-0002-PF|YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation|A Controlled, Prospective, Blinded, Randomized, Single-Center, Study of YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation||Y's Therapeutics, Inc.|Yes|Active, not recruiting|March 2007|February 2008|Anticipated|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2008|January 24, 2008|March 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00450398||173146|
NCT00451256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-5126-25|Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)|Clinical Study to Assess the Safety and Efficacy of ex-Vivo Vein Graft Exposure to AVI-5126 in Coronary Artery By-Pass Grafting to Reduce Clinical Graft Failure||Sarepta Therapeutics|Yes|Terminated|March 2007|March 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|600|||Both|18 Years|N/A|No|||July 2009|July 6, 2009|March 21, 2007|||Protocol-defined outcome in terms of efficacy would not be achieved.|No||https://clinicaltrials.gov/show/NCT00451256||173080|
NCT00451503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051023|Evaluation of Middle Ear Implantation|Evaluation of Middle Ear Implants in the Therapeutic Strategy of Auditory Rehabilitation in Case of Failure of Conventional Hearing Aid||Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2007|June 2012|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|March 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00451503||173062|
NCT00451490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200610027R|The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder|The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder||National Taiwan University Hospital|Yes|Withdrawn|October 2006|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research|||Anticipated|24|||Both|18 Years|65 Years|No|||January 2007|December 24, 2007|March 21, 2007|||This study not get the approval by the drug company|No||https://clinicaltrials.gov/show/NCT00451490||173063|
NCT00442494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5204515|Corticosteroids for the Prevention of Atrial Fibrillation After Cardiac Surgery|Feasibility of Corticosteroid in the Prevention of Atrial Fibrillation After Cardiac Surgery: A Prospective, Double-Blind Randomized Multicenter Trial||Kuopio University Hospital|No|Terminated|October 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|1|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2012|November 15, 2012|March 1, 2007||No|Study has been completed as planned|No||https://clinicaltrials.gov/show/NCT00442494||173745|
NCT00442754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dendric cells in lungcancer|Dendritic Cells in Lung Cancer|Vaccination With Autologous Dendritic Cells Pulsed With Allogeneic Tumour Lysate (MelCancerVac) for the Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. A Phase II Study||Herlev Hospital|No|Completed|December 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2009|March 19, 2012|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00442754||173725|
NCT00443625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK3530_FE|Phase 1 Study of SK3530 to Investigate of the Effect of Food|Clinical Trials to Investigate the Influence of Food on Pharmacokinetics of SK3530 in Healthy Male Volunteers.||SK Chemicals Co.,Ltd.||Completed|December 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00443625||173658|
NCT00443638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0568|Longitudinal Follow Up of Subjects Enrolled in Randomized Trial of Prenatal and Infancy Home Visitation|Longitudinal Follow Up of Subjects Enrolled in Randomized Trials of Prenatal and Infancy Home Visitation|ElmiraY19|University of Colorado, Denver|Yes|Completed|May 1998|April 2000|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|320|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 29, 2013|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443638||173657|
NCT00443365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6/252/35/3747|Should we Repair Ischemic Mitral Regurgitation?|||Medical University of Silesia||Recruiting|March 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||May 2008|May 27, 2008|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00443365||173678|
NCT00443339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-DAR500-2006-01|Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)|A Phase II Study of Darbepoetin Alpha in Myelodysplastic Syndromes (MSD)||Groupe Francophone des Myelodysplasies|Yes|Recruiting|December 2006|July 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|99|||Both|18 Years|N/A|No|||March 2007|May 15, 2007|March 4, 2007||||No||https://clinicaltrials.gov/show/NCT00443339||173680|
NCT00473473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaliBic.ICU.07|Effect of the Homeopathic Remedy Kalium Bichromicum (Potassium Dichromate) on Viscosity and Amount of Sputum and Time to Extubation in Mechanically Ventilated ICU Patients.|A Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Investigate the Efficacy and Safety of the Homeopathic Remedy Kalium Bichromicum (Potassium Dichromate) to Decrease Viscosity and Amount of Sputum as Well as Time to Extubation, in Intubated Mechanically Ventilated ICU Patients.||Shaare Zedek Medical Center|No|Recruiting|July 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||February 2012|February 19, 2012|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473473||171411|
NCT00473486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005970-26|Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib|A Randomized (PhaseII), Double-blind, Multicenter Phase I/II Trial of Pemetrexed, Carboplatin Plus or Minus Sorafenib in the First-line Treatment of Patients With Stage IIIb or IV Non-Small Cell Lung Cancer|PECASO|University Hospital Muenster|Yes|Terminated|May 2007|January 2010|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||June 2007|January 26, 2010|May 14, 2007|||Sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance    thrombocytopenia compared to historical data.|No||https://clinicaltrials.gov/show/NCT00473486||171410|
NCT00474084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAP/CT/01|Hydroxyapatite Active Pro Healing Clinical Trial Program|First In Man Evaluation of the Vesta™ & VestaCOR™ (Hydroxy-Apetite Coated genX™) Stent for Treatment of de Novo Native Coronary Artery Lesion(s)|HApFIM|BioSync Scientific Pvt. Ltd.|Yes|Not yet recruiting|July 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||May 2007|May 15, 2007|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474084||171366|
NCT00474643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-06-043|Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome|||Samsung Medical Center|Yes|Completed|August 2006|December 2006|Actual|||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|51|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||May 2007|May 15, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00474643||171325|
NCT00474058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0889|Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine|Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease|RECOVER|UCB Pharma|No|Completed|May 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|287|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 14, 2007|Yes|Yes||No|February 25, 2010|https://clinicaltrials.gov/show/NCT00474058||171368|During the course of the trial, the manufacturing process for rotigotine was changed. At that time, the expiry date for trial medication was Apr 2009, recruitment for SP889 had to be stopped effective on 17 Nov 2008.
NCT00474617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05950|Comparison of Org 25969 in Elderly Subjects With Adult Subjects (19.4.305)(P05950)(COMPLETED)|A Multicenter, Parallel Group, Comparative, Phase IIIa Trial to Compare the Efficacy, Safety, and Pharmacokinetics of Org 25969 in Elderly Subjects With Adult Subjects||Merck Sharp & Dohme Corp.|No|Completed|December 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|May 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00474617||171327|
NCT00474864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1108357|Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.|A Double-Blind, Placebo-Controlled, Parallel Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.||GlaxoSmithKline|No|Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|66|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474864||171308|
NCT00442962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5227|HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV|The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-"Nearly Naive" Participants|Nearly Naive|AIDS Clinical Trials Group|Yes|Completed|May 2007|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|16 Years|N/A|No|||June 2015|June 1, 2015|March 2, 2007|No|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00442962||173709|
NCT00443235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001111-21|GEM05 for Patients With Multiple Myeloma More Than 65 Years Old|A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old.||PETHEMA Foundation|Yes|Completed|March 2005|December 2009|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|66 Years|N/A|No|||September 2011|September 16, 2011|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443235||173688|
NCT00443547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VECTR 1492|Outcome Study of Patients Treated With Translational Cervical Plate Used to Treat Degenerative Disc Disease|Prospective Multi-Center Clinical Study of Patients With Degenerative Disc Disease Treated With Anterior Cervical Decompression and Fusion Using the Vectra-T Translational Cervical Plate.||Synthes USA HQ, Inc.|No|Completed|March 2006|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|231|||Both|18 Years|N/A|No|||July 2011|July 1, 2011|March 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00443547||173664|
NCT00454298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3189A1-106|Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Regimen, Parallel-Group Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGG-523 Administered Orally to Subjects With Severe Osteoarthritis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|2|||Both|55 Years|N/A|No|||July 2009|July 28, 2009|March 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454298||172852|
NCT00454532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZL-101-002|A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer|A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer.||Bionovo|Yes|Completed|March 2007|||December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||February 2012|February 27, 2012|March 26, 2007|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00454532||172834|
NCT00454545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-02|Atorvastatin in Moderate Active Crohns Disease|||Skane University Hospital|Yes|Completed|October 2006|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|65 Years|No|||October 2007|October 18, 2007|March 29, 2007||||No||https://clinicaltrials.gov/show/NCT00454545||172833|
NCT00441831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-261|The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy|||Mackay Memorial Hospital|Yes|Recruiting|February 2007|February 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|65|||Both|15 Years|95 Years|No|Non-Probability Sample|patients with previous distal gastrectomy|February 2009|February 4, 2009|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00441831||173796|
NCT00442091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070010|Dandelion Juice in the Treatment of Dyshidrotic Hand Eczema|Dandelion Juice in the Treatment of Dyshidrotic Hand Eczema||Odense University Hospital|No|Recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00442091||173776|
NCT00442104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0501|Open-label Extension to Protocol 1042-0500|An Open-label Clinical Study to Evaluate the Safety and Antiepileptic Activity of Ganaxolone in Treatment of Patients Diagnosed With Infantile Spasms.||Marinus Pharmaceuticals|No|Terminated|January 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|4 Months|24 Months|No|||October 2009|October 28, 2009|February 27, 2007|Yes|Yes|ganaxolone did not significantly reduce spasms after an 8-day placebo control period|No||https://clinicaltrials.gov/show/NCT00442104||173775|
NCT00442507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1105|Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Trial of Erlotinib and Avastin in Previously Treated Patients With Cancer of the Esophagus or Gastroesophageal Junction|OSI3650|Washington University School of Medicine|No|Terminated|March 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|March 1, 2007|Yes|Yes|Slow accrual|No|June 10, 2015|https://clinicaltrials.gov/show/NCT00442507||173744|
NCT00442520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10270|Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy|Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy||University of Kansas Medical Center|Yes|Completed|February 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|medical center|November 2012|November 8, 2012|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00442520||173743|
NCT00443352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #: F1J-MC-I|A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache|A Single-Center, Open Label Pilot Study Examining The Use Of Duloxetine In The Prevention Of Episodic Migraine||Thomas Jefferson University|Yes|Completed|August 2007|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|27|||Both|18 Years|65 Years|No|||April 2014|April 25, 2014|March 5, 2007|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT00443352||173679|This trial was uncontrolled. Five of the 27 subjects did not complete.
NCT00443378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-3810-C 01|Computer Assisted Rx Education for HIV-Positives: CARE+|Computer Assisted Rx Education for HIV-Positives: CARE+|CARE+|University of Washington|Yes|Completed|March 2006|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|240|||Both|18 Years|N/A|No|||January 2008|January 22, 2008|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443378||173677|
NCT00443651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3924g|A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis|An Open-Label, Prospective Study of the Safety of Rituximab in Combination With Other Disease-Modifying Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis|SUNDIAL|Genentech, Inc.||Completed|January 2007|February 2013|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|578|||Both|18 Years|80 Years|No|||May 2013|May 20, 2013|March 2, 2007|Yes|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT00443651||173656|
NCT00443898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSFO327N2301|Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail|A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis||Novartis|No|Completed|December 2006|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|518|||Both|12 Years|75 Years|No|||May 2012|May 1, 2012|March 5, 2007|Yes|Yes||No|January 19, 2011|https://clinicaltrials.gov/show/NCT00443898||173637|
NCT00473785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSFO4857|CVD Risk Reduction Trial|Community Outreach Heart Health and Risk Reduction Trial|COHRT|University Health Network, Toronto|Yes|Completed|January 2002|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|827|||Both|35 Years|74 Years|No|||May 2007|May 14, 2007|May 11, 2007||||No||https://clinicaltrials.gov/show/NCT00473785||171389|
NCT00474656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164451|The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study|The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study|OSCILLATE|Canadian Critical Care Trials Group|Yes|Completed|June 2007|December 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|16 Years|N/A|No|||January 2009|January 29, 2009|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474656||171324|
NCT00474357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH55/2007.CTIL|Myths About Bipolar Affective Disorder: The Role of Structured Group Psychoeducation Therapy|Myths About Bipolar Affective Disorder: The Role of Structured Group Psychoeducation Therapy|BAD|Lev-Hasharon Mental Healtlh Center|Yes|Recruiting|May 2007|October 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|110|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2008|December 16, 2010|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474357||171346|
NCT00475202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6106|Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers|||Assaf-Harofeh Medical Center||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|90 Years|No|||May 2007|May 17, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475202||171282|
NCT00442975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMVfluvaccinees|Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status|A Phase IV, Single Group Study to Evaluate the Immune Response to Licensed Seasonal Influenza Vaccine and Relationship of This to Cytomegalovirus-Associated Immunosenescence in UK Older Adults Aged 50-80 Years|CMVflu|Public Health England|No|Completed|March 2007|September 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|100|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||February 2008|July 9, 2008|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00442975||173708|
NCT00453713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8771|Race, Ethnicity, and Diffuse Parenchymal Lung Disease|Determinants of Outcome in Diffuse Parenchymal Lung Disease||Columbia University|No|Completed|July 2006|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|565|Samples With DNA|Plasma/serum, DNA, and circulating cells and endothelial microparticles will be collected      and processed.|Both|18 Years|N/A|No|Non-Probability Sample|Diffuse parenchymal lung disease|April 2015|April 20, 2015|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00453713||172897|
NCT00454012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05046|Use of Intrapartum Biophysical Profile When Fetal Heart Rate Monitoring is Non-reassuring in Labor|Use of Intrapartum Biophysical Profile When Fetal Heart Rate Monitoring is Non-reassuring in Labor||The Cooper Health System|No|Terminated|April 2005|December 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||March 2009|November 7, 2009|March 27, 2007|||poor enrolment|No||https://clinicaltrials.gov/show/NCT00454012||172874|
NCT00450723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20040015|Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer|Thoracoscopic Internal Mammary Sentinel Node Biopsy||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|May 2004|March 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 20, 2007|No|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00450723||173121|A total of 39 subjects were enrolled however; only 34 of the subjects had identifiable internal mammary sentinel lymph nodes. As a result, the data of 34 subjects were analyzed.
NCT00441259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-040-004|Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age|Randomised, Double Blind, Controlled, Safety, Tolerability and Immunogenicity Phase II Trial of ChimeriVax™-JE and Japanese Encephalitis Inactivated Mouse Brain Vaccine in Children of Descending Age.||Sanofi|Yes|Completed|January 2007|December 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|96|||Both|9 Months|10 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|February 27, 2007|Yes|Yes||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00441259||173840|
NCT00441272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070105|Pioglitazone to Treat Fatty Liver in People With HIV Infection|Pioglitazone for Hepatic Steatosis in HIV||National Institutes of Health Clinical Center (CC)||Completed|February 2007|||October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||October 2008|January 29, 2010|February 27, 2007||No||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00441272||173839|Early termination prior to enrollment leading to no analysis of enrolled participants receiving Pioglitazone or placebo.
NCT00441285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS054805|Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)|Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole||Universidad Peruana Cayetano Heredia|Yes|Completed|January 2010|September 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|156|||Both|16 Years|65 Years|No|||May 2015|May 15, 2015|February 27, 2007|Yes|Yes||No|January 28, 2010|https://clinicaltrials.gov/show/NCT00441285||173838|
NCT00450957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02709|Lycopene in Healthy Male Participants|Phase I Multiple Dose Pharmacokinetic Study of the Dietary Supplement Lycopene Delivered in Capsule Form to Healthy Male Volunteers Between 18 and 55 Years of Age||National Cancer Institute (NCI)||Completed|October 2006|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 14, 2015|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00450957||173103|
NCT00450970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT3-06-04|Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)|Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA)|SPERA|Agennix|No|Terminated|February 2007|December 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|344|||Male|18 Years|N/A|No|||August 2012|August 9, 2012|March 20, 2007|Yes|Yes|Sponsor decided to discontinue study drug development.|No||https://clinicaltrials.gov/show/NCT00450970||173102|
NCT00442533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2247|Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors|High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.||Radio Isotope Therapy of America|Yes|Active, not recruiting|August 2005|||August 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|March 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00442533||173742|
NCT00442767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18629|Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus|Reducing Postprandial Hyperglycemia With Adjuvant Premeal Pramlintide and Postmeal Insulin in Children With Type 1 Diabetes Mellitus.||Baylor College of Medicine|Yes|Completed|February 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|12 Years|21 Years|No|||November 2010|November 30, 2010|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00442767||173724|
NCT00442780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204PD203|Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease|MOBILE|Biogen|Yes|Completed|August 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|30 Years|N/A|No|||January 2009|January 8, 2009|March 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00442780||173723|
NCT00443027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001303|Effect Of Menstrual Cycle On Vaginal Blood Flow In Pre-Menopausal Healthy Women.|Effect Of Menstrual Cycle On Vaginal Blood Flow (As Determined By The Heat Wash-Out Technique) Before, During And After Visual Sexual Stimulation In Pre-Menopausal Healthy Women.|HWO VBF|Pfizer|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 6, 2009|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443027||173704|
NCT00442793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20680|A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.|A Randomized, Open Label Study Comparing the Effect of Mircera and Epoetin Beta on Hemoglobin Response in Patients With Chronic Kidney Disease Who Are on Dialysis||Hoffmann-La Roche||Completed|May 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00442793||173722|
NCT00443040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMP2004|Asimadoline for the Treatment of Post-Operative Ileus|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Asimadoline on the Duration of POI in Subjects Undergoing Laparoscopic/Hand-Assisted Lap Segmental Colonic Resection Secondary to Colon Cancer, Polypectomy or Diverticulitis||Tioga Pharmaceuticals|No|Terminated|January 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|80 Years|No|||November 2011|November 30, 2011|February 27, 2007|Yes|Yes|poor enrollment (31 of a planned 114 subjects were randomized and evaluable)|No|October 14, 2011|https://clinicaltrials.gov/show/NCT00443040||173703|Early termination leading to small numbers of subjects analyzed; no efficacy analysis was completed.
NCT00443664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-A/06/165|External Micropulse Diode Laser Transscleral Trabeculoplasty (EMDLT) for Severe Open Angle Glaucoma|External Micropulse Diode Laser Transscleral Trabeculoplasty(EMDLT) For Severe Open Angle Glaucoma|EMDLT|National University Hospital, Singapore|No|Recruiting|June 2006|December 2008|Anticipated|||Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|21 Years|N/A|No|||May 2008|May 13, 2008|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443664||173655|
NCT00474097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-03|Follow-Up Phone Calls After Colorectal Surgery|Follow-Up Phone Calls After Colorectal Surgery to Assess Patient Satisfaction and Post-Operative Outcomes||University Hospital Case Medical Center|No|Completed|February 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Colorectal Surgery clinic patients|December 2014|December 12, 2014|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474097||171365|
NCT00474630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-304|A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus||Orexigen Therapeutics, Inc|Yes|Completed|May 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|505|||Both|18 Years|70 Years|No|||November 2014|November 18, 2014|May 15, 2007|Yes|Yes||No|October 10, 2014|https://clinicaltrials.gov/show/NCT00474630||171326|
NCT00474916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTCL100|Neuropathic Pain in Patients With Cancer|A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer||DARA Therapeutics|Yes|Completed|June 2006|April 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|May 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474916||171304|
NCT00474877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC/01/6/43|The Clinical Effectiveness of Static Resting Splints in Early Rheumatoid Arthritis|The Clinical Effectiveness of Static Resting Splints in Early Rheumatoid Arthritis: a Randomized Controlled Trial||University of Southampton|No|Completed|October 2001|April 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|2||Actual|120|||Both|18 Years|N/A|No|||May 2007|May 16, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00474877||171307|
NCT00453752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/66/2006|Non-Invasive Diagnostic and Functional Evaluation of Cardiac Involvement in Patients With Systemic Sclerosis|||Medical University of Warsaw|Yes|Recruiting|April 2006|April 2010|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2006|March 28, 2007|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00453752||172894|
NCT00453765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL14828.075.06|The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity|Prospective Single-centre, Double Blind Randomised Trial of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity|montelukast|Isala|Yes|Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|90 Years|No|||April 2013|April 5, 2013|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453765||172893|
NCT00453466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWHSP-03-2001|Group Empowerment of Battered Women as a Tool for Violence Prevention||EBW|Ben-Gurion University of the Negev|Yes|Completed|December 2001|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Female|20 Years|70 Years|No|||March 2007|March 28, 2007|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00453466||172916|
NCT00453479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2108378|A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.|A Randomised, Double-blind, Placebo-controlled, Dose Ascending,2-cohort, Parallel Group Study to Examine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Twice-daily Inhaled Doses of GSK233705B Formulated With the Excipient Magnesium Stearate in COPD Subjects for 7-days.||GlaxoSmithKline||Completed|March 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|1||Actual|24|||Both|40 Years|75 Years|No|||July 2009|July 22, 2009|March 27, 2007||||No||https://clinicaltrials.gov/show/NCT00453479||172915|
NCT00453726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbosco3|Brain Natriuretic Peptide (BNP) Levels in Patients in Non Invasive Mechanical Ventilation|Evaluation of BNP in Patients With Severe Acute Respiratory Failure Requiring Non Invasive Mechanical Ventilation||Ospedale S. Giovanni Bosco|Yes|Completed|May 2006|July 2009|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|90 Years|No|Probability Sample|Patients of the city of Torino, admitted to the emergency department for acute respiratory        failure.|October 2009|October 2, 2009|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00453726||172896|
NCT00453739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-06-006|TVT Worldwide Registry|TVT-World Wide Observational Registry for Long-Term Data||Ethicon, Inc.|No|Completed|February 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1407|||Female|18 Years|N/A|No|Non-Probability Sample|Women diagnosed with SUI who are suitable candidates for a TVT system, according the        relevant Instructions for Use (IFU).|May 2014|May 5, 2014|March 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00453739||172895|
NCT00454558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12166|An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension|A Multicenter, Non-randomized, Non-blinded, Noncontrolled Study to Investigate the Impact of Multiple Doses of BAY 63-2521 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Pulmonary Hypertension in a 12-week 3 Times a Day Individual Dose Titration Scheme||Bayer|No|Completed|January 2007|September 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|65 Years|No|||September 2015|October 14, 2015|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00454558||172832|
NCT00450411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0526|Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy|A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy||Radiation Therapy Oncology Group|Yes|Active, not recruiting|May 2007|||June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Male|18 Years|120 Years|No|||March 2016|March 3, 2016|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450411||173145|
NCT00445588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03018|Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|January 2007|||August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445588||173510|
NCT00441571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500Lu01|Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer|A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer|CYT-500|Cytogen Corporation|No|Recruiting|February 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Male|18 Years|N/A|No|||September 2007|September 6, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441571||173816|
NCT00441584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03833|The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)|Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys||Merck Sharp & Dohme Corp.|No|Terminated|July 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|70 Years|No|||October 2015|October 7, 2015|February 28, 2007||No|Subject accrual was prematurely terminated due slow enrollment.|No|June 18, 2009|https://clinicaltrials.gov/show/NCT00441584||173815|Due to slow enrollment, an unplanned interim analysis was conducted: 75 of 93 (80.6%) subjects who had reached treatment Week 12 did not achieve early virologic response. Given the low likelihood of response, a decision was made to stop enrollment.
NCT00441558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.84|A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).|Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD||Sprout Pharmaceuticals, Inc|Yes|Terminated|February 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1723|||Female|18 Years|55 Years|No|||May 2014|May 14, 2014|February 28, 2007|Yes|Yes|terminated for administrative reasons|No|May 14, 2014|https://clinicaltrials.gov/show/NCT00441558||173817|
NCT00442546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081133|Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement|A Multicenter, Double-Blind Randomized, Placebo-Controlled Study Of The Efficacy And Safety Of Pregabalin In The Treatment Of Subjects With Post-Operative Pain Following Total Knee Arthroplasty (TKA)||Pfizer|Yes|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|307|||Both|18 Years|80 Years|No|||February 2011|February 15, 2011|March 1, 2007|Yes|Yes||No|December 15, 2009|https://clinicaltrials.gov/show/NCT00442546||173741|
NCT00442559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-367|Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)|Korean Study of "Real-World" Montelukast Use in Mild Asthmatic Children With Concomitant Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|January 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|191|||Both|2 Years|14 Years|No|||July 2015|July 31, 2015|February 28, 2007|Yes|Yes||No|October 12, 2008|https://clinicaltrials.gov/show/NCT00442559||173740|This was an open-label study. Only 53 patients had diary information with daytime asthma symptom score - thus, 138 cases were dropped from analysis due to lack of daytime asthma symptom score.
NCT00443677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD2000|Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)|Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)|HD2000|Gruppo Italiano Studio Linfomi|No|Completed|April 2000|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|307|||Both|18 Years|65 Years|No|||March 2009|March 19, 2009|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443677||173654|
NCT00443690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKI-303|Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms, Diuresis, Renal Function, and Clinical Outcomes in Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring Intravenous Therapy|REACH UP|NovaCardia, Inc.|Yes|Completed|August 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||February 2009|February 19, 2009|March 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443690||173653|
NCT00443911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBI-06-053-0406|Rheohemapheresis and Lutein Supplementation in the Non-Exsudative Form of Age-Related Macular Degeneration|Rheohemapheresis and Lutein Supplementation (Xantophyll Carotenoid) in the Non-Exsudative Form of Age-Related Macular Degeneration|ReLux-AMD|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Active, not recruiting|March 2007|May 2012|Anticipated|||Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Serum|Both|50 Years|N/A|No|Non-Probability Sample|Patients with non-exudative AMD|June 2011|June 23, 2011|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443911||173636|
NCT00443924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08645|Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Ascending Dose Study of INS115644 Ophthalmic Solution in Subjects With Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma||Merck Sharp & Dohme Corp.||Completed|March 2007|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|56|||Both|18 Years|75 Years|No|||January 2015|January 19, 2015|March 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443924||173635|
NCT00444171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eMPC_CUP1|Glucose Control by eMPC Algorithm in Peri- and Postoperative Period in Cardiac Surgery Patients|Randomized Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm With Variable Sampling Rate (eMPC) vs. Routine Glucose Management Protocol in Peri- and Postoperative Period in Cardiac Surgery Patients||Charles University, Czech Republic|No|Completed|September 2006|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|N/A|N/A|No|||March 2007|March 5, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444171||173616|
NCT00475748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28962|Surgical Management of Spinal Cord Injuries In Neck|ASIA Motor, Functional and Health Related Quality of Life Outcome in Traumatic Central Cord Syndrome, a Prospective Randomized Study|CCSS|Maryland Department of Health and Mental Hygiene|No|Active, not recruiting|May 2007|May 2010|Anticipated|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2009|June 23, 2009|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475748||171240|
NCT00474890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/03 Inopec ITEM|Study to Compare the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Placebo on Symptoms in Patients With Allergic Rhinitis Within/Out of Season|A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy's Reproducibility of a Combination of Pseudoephedrine and Cetirizine on Symptom Scores and Rhinomanometry in Patients With Allergic Rhinitis Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC) in- and Outside the Grass Pollen Season||Fraunhofer-Institute of Toxicology and Experimental Medicine|Yes|Completed|June 2007|February 2008||December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|55 Years|No|||February 2008|February 12, 2008|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474890||171306|
NCT00474903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00838|Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus|Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients||National Cancer Institute (NCI)||Completed|April 2007|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|122|||Both|18 Years|N/A|No|||January 2014|June 2, 2014|May 16, 2007|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00474903||171305|
NCT00444392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061003|Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus|Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus||Vanderbilt University|Yes|Active, not recruiting|March 2007|August 2010|Anticipated|June 2008|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|No|||February 2008|February 7, 2008|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444392||173600|
NCT00454025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1015|Intraocular Pressure (IOP) Changes Associated With Muslim Prayer Postural Changes|Intraocular Pressure Changes Associated With Muslim Prayer Postural Changes||University of Colorado, Denver|No|Terminated|January 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients 18 and up, diagnosed with primary open angle glaucoma, and are able to assume the        standing, bowing, and prostrate positions.|January 2013|January 29, 2013|March 27, 2007||No|Stopped due to low enrollment|No||https://clinicaltrials.gov/show/NCT00454025||172873|
NCT00454311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-CR-1106-307-5|The Impact of the Biopsy of 1-2 Cells in a PGD Program for Anueploidy Screening|Prospective and Randomized Study of the Impact of the Biopsy of 1-2 Cells in a PGD Program for Aneuploidy Screening||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||||||Both|25 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 3, 2011|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454311||172851|
NCT00454324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0519|Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer|Phase II Clinical Trial of Carboplatin and Abraxane in Patients With Extensive Stage Small Cell Lung Cancer|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|April 2006|December 2014|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 28, 2007|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00454324||172850|
NCT00445276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC / ART 05 566 N|Symptomatic Efficacy of Diacerein in Knee Osteoarthritis|Efficacy Study of Diacerein in the Symptomatic Treatment of Knee Osteoarthritis||Laboratoires NEGMA|No|Completed|November 2005|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||500|||Both|18 Years|N/A|No|||March 2010|March 3, 2010|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00445276||173532|
NCT00445289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASOPI|Automatic Control of Pressure Support Ventilation in Surgical Intensive Care Units|Automatic Control of Pressure Support Ventilation in Surgical Intensive Care Units - a Bicentric, Prospective, Randomized, Controlled Trial|ASOPI|University of Schleswig-Holstein|Yes|Completed|March 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|N/A|No|||August 2008|August 15, 2008|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445289||173531|
NCT00445601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000534235|S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer|A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer||Southwest Oncology Group|Yes|Active, not recruiting|September 2007|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|371|||Both|18 Years|120 Years|No|||January 2016|January 26, 2016|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445601||173509|
NCT00441298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA 004|Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV|Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa||Centre for the AIDS Programme of Research in South Africa|Yes|Completed|May 2007|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|889|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00441298||173837|
NCT00441610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBQ707A1101E1|An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor|An Extension Trial to a Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor||Novartis||Completed|January 2007|||September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|20 Years|N/A|No|||April 2012|April 27, 2012|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441610||173813|
NCT00442169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-244-003|Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults|Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults||Sanofi|Yes|Completed|December 2005|April 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|208|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 17, 2014|February 27, 2007|Yes|Yes||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00442169||173770|
NCT00442117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04880|A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)|A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Mild Persistent and Moderate Persistent Asthmatic Patients||Merck Sharp & Dohme Corp.|No|Completed|June 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|12 Years|N/A|No|||February 2016|February 19, 2016|February 28, 2007|Yes|Yes||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00442117||173774|
NCT00442130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-196|Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination|Reduced Intensity Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia Followed by Vaccination With Lethally Irradiated Autologous Tumor Cells Admixed With Granulocyte Macrophage-colony Stimulating Factor Secreting K562 Cells||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2007|July 2021|Anticipated|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00442130||173773|
NCT00441844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDFT1DMSIMVA|Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation|Phase 2 Study Examining the Effect of Simvastatin vs Placebo on Monocyte Function and Inflammation in Patients With Type 1 Diabetes||University of California, Davis|Yes|Completed|October 2002|July 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|20 Years|N/A|No|||February 2007|February 28, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441844||173795|
NCT00442143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|024|Treatment of Severe Limb Ischemia With Autologous Bonemarrow Derived Mononuclear Cells|Treatment of Severe Limb Ischemia With Autologous Bonemarrow Derived Mononuclear Cells|DANCELL-CLI|Odense University Hospital|No|Recruiting|January 2007|December 2007|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|20 Years|85 Years|No|||March 2007|July 22, 2010|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442143||173772|
NCT00442156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-131|The Course of Response to Focal Photocoagulation for DME|The Course of Response to Focal Photocoagulation for Diabetic Macular Edema|Laser Resp|Diabetic Retinopathy Clinical Research Network|No|Completed|January 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|122|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetics within the United States who are at least 18 years old and have DME treatable        with laser photocoagulation.|March 2011|March 18, 2011|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00442156||173771|
NCT00443053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART108053|Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)|See Detailed Description||GlaxoSmithKline||Completed|March 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3002|||Both|18 Years|N/A|No|||February 2013|February 18, 2016|March 2, 2007||||No|July 2, 2010|https://clinicaltrials.gov/show/NCT00443053||173702|
NCT00443391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-889|A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)|The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study||AbbVie||Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Both|18 Years|60 Years|No|||January 2013|January 10, 2013|March 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443391||173676|
NCT00443404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phantom pain-UPatras|Optimized Perioperative Analgesia Reduces the Prevalence and the Intensity of Phantom Pain in Lower Limb Amputation|Double Blind, Placebo Controlled Study for the Study of the Effectiveness of Perioperative Analgesia in Phantom and Stump Pain||University of Patras|Yes|Completed|December 2003|May 2009|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|60|||Both|18 Years|82 Years|No|||September 2009|November 4, 2011|March 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443404||173675|
NCT00443950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-319|Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Etanercept in Chinese Subjects With Active Rheumatoid Arthritis Receiving Methotrexate||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2006|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||December 2007|December 11, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00443950||173633|
NCT00444197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC00174-01|Community-Based Violence Prevention for High-Risk Youth|||Johns Hopkins University|No|Completed|August 2001|January 2006||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||198|||Both|9 Years|15 Years|No|||March 2007|March 5, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444197||173614|
NCT00443937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE05|Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients|Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Stable Renal Transplant Patients||Charite University, Berlin, Germany||Completed|January 2004|March 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||October 2007|October 31, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00443937||173634|
NCT00444184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3243|24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost|A Crossover, Double-Masked Comparison Investigating the 24-Hour Intraocular Pressure Control With the Travoprost/Timolol Fixed Combination Versus Travoprost, When Both Are Given in the Evening, in Subjects With Primary Open-Angle Glaucoma||Aristotle University Of Thessaloniki|No|Completed|March 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|29 Years|81 Years|No|||May 2014|May 9, 2014|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444184||173615|
NCT00474370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04889|Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)|Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4)||Merck Sharp & Dohme Corp.|Yes|Completed|May 2007|October 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|16 Years|N/A|No|||December 2015|December 18, 2015|May 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474370||171345|
NCT00475254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23EY018356|Stress and Vision Fluctuations in Retinitis Pigmentosa|Stress and Vision Fluctuations in Retinitis Pigmentosa||Johns Hopkins University|No|Completed|August 2007|April 2011|Actual|April 2011|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with a confirmed diagnosis of retinitis pigmentosa|August 2008|April 5, 2011|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475254||171278|
NCT00475228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pitt IRB PRO06040004|IUD Insertion After D&E Procedure|Immediate Versus Delayed Insertion of the Levonorgestrel-Releasing Intrauterine Device Following Dilation and Evacuation: A Randomized Controlled Trial|ILIAD|University of Pittsburgh|No|Completed|March 2007|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 25, 2011|May 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00475228||171280|
NCT00444405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCNS-01|Surgical Treatment Comparison for Recurrent Lumbar Disc Herniation|Surgical Treatment Comparison for Recurrent Lumbar Disc Herniation||St. John's Health System, Missouri|Yes|Withdrawn|March 2007|April 2009|Actual|||Phase 4|Observational|Time Perspective: Prospective||1|Actual|4|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients with recurrent lumbar disc herniation.|October 2011|October 12, 2011|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444405||173599|
NCT00444678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU# 04-10 H11817|Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer|A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With EGFR-Expressing Metastatic Colorectal Cancer||New York University School of Medicine|Yes|Completed|June 2004|June 2015|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00444678||173578|
NCT00444977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK3159|Enhancing Oral Health Care Use by HIV Positive Individuals|Enhancing Oral Health Care Use by HIV-Positives||Columbia University|Yes|Completed|April 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|600|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444977||173555|
NCT00445302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD31001101|Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment|A Phase I Study Of The Safety, Pharmacokinetics, And Hematological Activity Of AMD3100 (240 µg/kg) In Subjects With Renal Impairment||Sanofi|No|Completed|January 2006|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|78 Years|No|||February 2014|February 10, 2014|March 7, 2007|No|Yes||No|December 12, 2010|https://clinicaltrials.gov/show/NCT00445302||173530|
NCT00441597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atorv01|Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?|Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?||Radboud University|No|Completed|February 2007|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 16, 2009|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441597||173814|
NCT00442182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/112|The Efficacy and Safety of ITF2357 in AIS|The Effects and Side Effects of ITS2357 in Autoinflammatory Syndromes||Radboud University||Recruiting|September 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||February 2007|February 28, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442182||173769|
NCT00442572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20020|SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).|'A Randomized, Open-label Study to Investigate the Effect on Sustained Virologic Response, and the Safety, of Intermittent Long Term Treatment With PEGASYS in Patients With HBeAg Negative Chronic Hepatitis B Who Have Responded to Previous Treatment With Interferon Alfa.' (SOFIA-LTT Study)||Hoffmann-La Roche||Completed|July 2006|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|February 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00442572||173739|
NCT00442585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gebro-I-24-13|S(+)-Ibuprofen Effects on Asprin Treated Volunteers|Double Blind, Randomised, Parallel Group, Placebo Controlled Clinical Trial of S(+)-Ibuprofen Effects on TxB2 Concentrations and Platelet Aggregation in Aspirin-treated Healthy Adult Volunteers||Gebro Pharma GmbH|No|Completed|September 2006|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00442585||173738|
NCT00442806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOLLO - 01|Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction|A Randomized Clinical Trial of AdiPOse-derived Stem ceLLs in the Treatment of Patients With ST-elevation myOcardial Infarction - The APOLLO Trial||Cytori Therapeutics|Yes|Completed|November 2007|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|80 Years|No|||November 2013|November 25, 2013|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00442806||173721|
NCT00443066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1635|Clinical Study of Spinal Muscular Atrophy|Clinical Study of Spinal Muscular Atrophy||Columbia University|No|Active, not recruiting|May 2005|December 2015|Anticipated|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|Samples With DNA|blood and skin tissue|Both|N/A|N/A|No|Non-Probability Sample|People diagnosed with Spinal Muscular Atrophy types I, II, or III before the age of 17.|March 2015|March 5, 2015|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00443066||173701|
NCT00443703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-032|MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A||Merck Sharp & Dohme Corp.||Terminated|May 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|352|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 2, 2007|Yes|Yes|primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus    lopinavir (+) ritonavir|No|October 16, 2009|https://clinicaltrials.gov/show/NCT00443703||173652|The reason for early termination: Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™.
NCT00443716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004111|Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women|Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women||Mayo Clinic|Yes|Completed|April 1985|April 1989|Actual|April 1989|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|30 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 14, 2010|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00443716||173651|
NCT00444808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.E. 2004-11-77|Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs|Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs||Université de Montréal|No|Terminated|February 2007|January 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|March 7, 2007||No|Medication expired|No||https://clinicaltrials.gov/show/NCT00444808||173568|
NCT00444210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL6049-0301|DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles|A Randomized Study of the Safety and Effectiveness of DL6049 (Injectable Poly-L-Lactic Acid) Versus CosmoPlast Collagen Implant in the Treatment of Nasolabial Fold Wrinkles||Sanofi|No|Completed|June 2004|April 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||240|||Both|18 Years|75 Years|No|||April 2008|April 8, 2008|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444210||173613|
NCT00444470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P.S.I. Grant No. 02-69|Safety of Tranexamic Acid in Reducing Bleeding in Adults Undergoing Spinal Surgery|Efficacy of Tranexamic Acid in Reducing Blood Loss in Adult Patients Having Major Spine Surgery||University Health Network, Toronto|Yes|Completed|February 2003|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|85 Years|No|||November 2007|November 29, 2007|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444470||173594|
NCT00474669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-GYN-07-001|A Phase I Study of Intraperitoneal Hyperthermic Docetaxel|A Phase I Study of Intraperitoneal Hyperthermic Docetaxel at the Time of Second Look Surgery Following Front-Line Normothermic Intraperitoneal and Intravenous Cisplatin/Paclitaxel for Patients With Stage II and III Ovarian Carcinoma|IP|James Graham Brown Cancer Center|Yes|Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|19 Years|N/A|No|||January 2010|April 22, 2013|May 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00474669||171323|
NCT00475527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-HMO-CTIL|Helicobacter Pylori and Iron Deficiency: Prevalence of Association and Effect of Therapy|||Hadassah Medical Organization|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|18 Years|No|||January 2009|August 19, 2015|May 15, 2007|||problem of accrual|No||https://clinicaltrials.gov/show/NCT00475527||171257|
NCT00476021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO06070007|Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery|Randomized Trial of Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device After Vaginal Delivery|POPI|University of Pittsburgh|No|Completed|May 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|168|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 22, 2016|May 17, 2007||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT00476021||171220|
NCT00445003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-134|Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy|Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|LRTforDME+PRP|Diabetic Retinopathy Clinical Research Network|Yes|Completed|March 2007|July 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|333|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|March 6, 2007|Yes|Yes||No|April 14, 2011|https://clinicaltrials.gov/show/NCT00445003||173553|
NCT00445016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nd001|Neurologic Complications in Peripheral Regional Anesthesia - An Evaluation Based on a Standardized Protocol|Neurologic Complications in Peripheral Regional Anesthesia - A Clinical Follow Up Study to Evaluate the Incidence of Neurologic Complications Defined According to a Standardized Protocol Considering Motoric and Sensory Function and Pain||BG Unfallklinik||Active, not recruiting|May 2008|December 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients receiving peripheral regional anesthesia (routine)|May 2008|May 5, 2008|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445016||173552|
NCT00444691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCR 2007/01|Sensitivity of Echography in Arthritis|Sensitivity of Echography in Arthritis|SEA|Association de Recherche Clinique en Rhumatologie|No|Active, not recruiting|March 2007|April 2010|Anticipated|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||August 2009|August 25, 2009|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444691||173577|
NCT00444990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00781441|Study on Magnetic Field Therapy to Improve Chronic Lumbar Pain|A Double-Blind, Randomized, Placebo-Controlled Study on Magnetic Field Therapy to Improve Chronic Lumbar Pain (Lbp)|LBP|Weintraub, Michael I., MD, FACP, FAAN||Recruiting|February 2007|December 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|85 Years|No|||September 2007|September 20, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444990||173554|
NCT00441311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6315|Dissemination of Colorectal Cancer Screening to Primary Care Physicians|Dissemination of Colorectal Cancer Screening to Primary Care Physicians||Columbia University|Yes|Completed|May 2003|September 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|264|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2011|January 28, 2011|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00441311||173836|
NCT00441857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOSE|Effect of Plant Stanols on Cholesterol Absorption|The Effect of Three Different Stanol Ester Doses in Margarines on Cholesterol Absorption Efficiency|DOSE|Oy Foodfiles Ltd|No|Completed|March 2007|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3|||60|||Both|25 Years|68 Years|Accepts Healthy Volunteers|||July 2007|July 4, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00441857||173794|
NCT00442611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100 186|A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)|A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis||Stanford University||Completed|November 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|March 1, 2007|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00442611||173736|
NCT00442598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-303|Safety and Efficacy Study of Glufosfamide in Ovarian Cancer|An Open-Label Phase 2 Study of the Safety and Efficacy of Glufosfamide in Ovarian Cancer||Eleison Pharmaceuticals LLC.|No|Terminated|January 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Female|18 Years|N/A|No|||March 2015|March 6, 2015|February 28, 2007|Yes|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT00442598||173737|
NCT00442832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0041|TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection|A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections||Theravance Biopharma Antibiotics, Inc.|No|Completed|December 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|65 Years|No|||August 2009|August 15, 2009|February 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00442832||173719|
NCT00442819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR95-IRB-79|Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney|||China Medical University Hospital|Yes|Completed|July 2006|September 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|26 Years|82 Years|No|||March 2007|March 1, 2007|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00442819||173720|
NCT00443417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART_II_2006|A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease|Dose Finding Study to Assess the Efficacy and Safety of SK-PC-B70M in Patients With Mild to Moderate Alzheimer's Disease||SK Chemicals Co.,Ltd.||Completed|April 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|188|||Both|55 Years|85 Years|No|||January 2008|December 8, 2009|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443417||173674|
NCT00443430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR049762|Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis|Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA)||Seattle Children's Hospital|Yes|Completed|May 2007|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|2 Years|17 Years|No|||May 2013|May 30, 2013|March 2, 2007|No|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00443430||173673|small number of participants with recent onset poly JIA
NCT00444483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0099-9/98 (KIMII)-955|Structured Patient Education and Quality of Life of Elderly Patients With Diabetes Mellitus- a Prospective Study|Structured Treatment and Teaching of Elderly Patients With Type 2 Diabetes Mellitus||Heidelberg University|No|Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||50|||Both|54 Years|N/A||||March 2007|March 6, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444483||173593|
NCT00444236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 20135|Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression|Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression||University of Utah|Yes|Terminated|April 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|March 6, 2007|No|Yes|The sponsor decided to terminate the study due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT00444236||173611|
NCT00445120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO2|Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment|Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Lactobacillus Rhamnosus GG Treatment in Preventing Vernal Keratoconjunctivitis VKC) Relapses.||Campus Bio-Medico University|No|Completed|March 2007|January 2009|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|5 Years|16 Years|No|||January 2009|January 28, 2009|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445120||173544|
NCT00445406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 24/06|Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer|Bevacizumab and Pegylated Liposomal Doxorubicin as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. A Multicenter, Single-Arm Phase II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|December 2006|March 2009|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||June 2012|June 26, 2012|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445406||173523|
NCT00475501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-014-05F|5-Alpha Reductase and Anabolic Effects of Testosterone|5-Alpha Reductase and Anabolic Effects of Testosterone||VA Office of Research and Development|No|Completed|January 2007|October 2014|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Male|60 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 16, 2007|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT00475501||171259|
NCT00475540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-232|Efficacy Study of Vaginal Mesh for Prolapse|A Randomized Clinical Trial of Vaginal Mesh for Prolapse|VAMP|Medstar Research Institute|Yes|Completed|January 2007|August 2013|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Female|21 Years|N/A|No|||September 2015|September 21, 2015|May 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00475540||171256|
NCT00475514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VML 251-3MRM02|A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine|A Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, and Safety of Oral Frovatriptan in the Prevention on Menstrually-related Migraine (MRM) Headaches in a 'Difficult to Treat' Population||Endo Pharmaceuticals|No|Completed|October 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Actual|500|||Female|15 Years|N/A|No|||February 2014|February 14, 2014|May 16, 2007||||||https://clinicaltrials.gov/show/NCT00475514||171258|
NCT00475774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7261|Body Fat Distribution and Fat Metabolism|The Effect of Body Fat Distribution on the Physiological Response to a Dietary Fat Intervention||TNO|No|Completed|May 2007|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Anticipated|12|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||April 2008|April 4, 2008|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00475774||171238|
NCT00445042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC IRB#03-0194-05|Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer|A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma||The Methodist Hospital System|No|Completed|November 2005|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445042||173550|
NCT00445315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121002|A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients|A Phase 1, Randomized, Double Blind (3rd Party Open), Placebo-controlled, Sequential Group, Multicentre Study To Evaluate The Multiple Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics, of PF-00868554 in Hepatitis C Virus (HCV) Positive Otherwise Healthy Patient Volunteers||Pfizer|No|Completed|January 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|65 Years|No|||January 2014|January 2, 2014|March 6, 2007|No|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00445315||173529|Designation of outcomes as primary, secondary based on team’s input. Results for relationship analyses of baseline susceptibility to PF-00868554 and/or non-structural 5B genotype and change in HCV RNA was not done, as per change in planned analysis.
NCT00445328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301080|Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients|Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients.||Pfizer|No|Terminated|June 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|84|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|March 7, 2007|Yes|Yes|See Detailed Description|No|July 20, 2009|https://clinicaltrials.gov/show/NCT00445328||173528|Study terminated prematurely due to delay in overall study start-up and inability to meet predefined protocol recruitment milestones; sample size too small to permit meaningful statistical analyses. No statistical analyses for all but 2 endpoints.
NCT00440999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-006-06|Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria|A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-Dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients With Acute Plasmodium Vivax Malaria||Medicines for Malaria Venture|Yes|Completed|March 2007|September 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|456|||Both|3 Years|60 Years|No|||January 2009|January 21, 2009|February 26, 2007||||No||https://clinicaltrials.gov/show/NCT00440999||173860|
NCT00441324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN03B001|Efficacy and Safety of R-hLH (Luveris ®) Priming Prior to R-HFSH Treatment in Infertile Women Undergoing IVF-ET|Efficacy and Safety of R-hLH (Luveris ®) Priming Prior to R-HFSH Treatment in Infertile Women Undergoing IVF-ET||NHS Greater Clyde and Glasgow|No|Completed|March 2003|February 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Female|19 Years|37 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441324||173835|
NCT00441623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS001|The Role of P-cresol and Related Protein Fermentation Metabolites in Chronic Kidney Disease Patients|A Single Centre Observational Cohort Study on the Prognostic Relevance of P-cresol and Related Uremic Retention Solutes in the Development and/or Progression of Renal Failure and Cardiovascular Disease in Chronic Kidney Disease Patients||Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|October 2005|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Serum, plasma Urine (if provided by patient)|Both|16 Years|N/A|No|Probability Sample|chronic kidney disease patients KDOQI stage 1-5 not yet on dialysis|December 2013|December 16, 2013|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441623||173812|
NCT00441870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-0225-01|Study of EC0225 for the Treatment of Refractory or Metastatic Tumors|Protocol EC-0225-01: A Phase 1 Study of EC0225 Administered Weeks 1 and 3 of a 4-Week Cycle||Endocyte|No|Completed|February 2007|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|February 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00441870||173793|
NCT00443443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3839g|A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)|A Long-Term Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)|SUNSTONE|Genentech, Inc.||Completed|January 2007|September 2013|Actual|September 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1026|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with RA who have had an inadequate response to one or more anti-TNF therapies|March 2015|March 26, 2015|March 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443443||173672|
NCT00443456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531086|Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient|Long-Term Study For Amlodipine 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective||Pfizer|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|20 Years|79 Years|No|||October 2009|October 19, 2009|March 2, 2007||No||No|June 10, 2009|https://clinicaltrials.gov/show/NCT00443456||173671|
NCT00442845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581087|Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)|ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg|ACTFAST|Pfizer||Completed|January 2003|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2080|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442845||173718|
NCT00443079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051117|A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)|A Single-center, Single-blinded, Placebo-controlled Pilot Study of IdB 1016 (Siliphos) in Adult Patients With Non-alcoholic Steatohepatitis (NASH)||University of California, San Diego||Completed|March 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2008|June 24, 2010|March 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443079||173700|
NCT00444223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529363|Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants|The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study||Jonsson Comprehensive Cancer Center|No|Active, not recruiting|May 2004|||January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444223||173612|
NCT00443989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KA-20060172|Troponin-T for Detection of Perioperative Cardiovascular Events|A Pilot for the:"Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study"|VISION-pilot|Rigshospitalet, Denmark|No|Completed|March 2007|March 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Troponin-T|Both|45 Years|N/A|No|Non-Probability Sample|Patients for major surgery more than 45 years of age|March 2007|May 27, 2008|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00443989||173630|
NCT00445445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1105|Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women|Longitudinal Changes in Mammographic Density and Risk of Breast Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|January 2007|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|3000|Samples With DNA|Time perspective: Prospective and retrospective. Blood and urine samples will be processed      in our lab and stored in a -80 degree freezer until needed. Urine samples will be assessed      for levels of bisphenol-A and remaining samples of urine and blood will be stored for future      projects.|Female|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Breast cancer cases diagnosed after 1994 and equal number of frequency-matched (by age        within 2 years and ethnicity) controls. Cases and eligible controls with at least 3        screening mammograms since 1994 will be recruited through the University Hospitals Breast        Center, and primary care clinics within the University Hospitals Health System (UHHS). The        restriction of 3 or more screening mammograms will allow us to adequately model the        longitudinal change patterns.|February 2016|February 16, 2016|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445445||173520|
NCT00444496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-4566-E/G 01|SPHERE Hypertension Baseline Data Study|SPHERE Hypertension Baseline Data Study||University of Washington|Yes|Completed|February 2007|July 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|470|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|People seen by Renton, Bellevue, and Shoreline fire departments with blood pressure higher        than 160/100.|February 2008|February 12, 2008|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444496||173592|
NCT00441129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186|Obtain a Good Blood Glucose Control With the Paradigm Real Time System|To Assess Whether Type 1 Diabetic Patients Treated With M D I and in Poor Metabolic Control Can Improve Using the Paradigm® Real Time System Compared to Self-Monitoring Blood Glucose and Continuous Subcutaneous Insulin Infusion|RTD|Medtronic|No|Recruiting|June 2006|October 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|2 Years|65 Years|Accepts Healthy Volunteers|||December 2006|March 5, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441129||173850|
NCT00444821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-2005-01|The (PIVOTAL) Study|Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)||Medtronic Vascular||Terminated|March 2005|January 2010|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|728|||Both|40 Years|90 Years|No|||February 2010|February 4, 2010|March 6, 2007|No|Yes|Interim analysis of Primary Endpoint completed|No||https://clinicaltrials.gov/show/NCT00444821||173567|
NCT00444834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-EG-006|A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension|A Phase II, Multi-Center, Multiple-Dose, Double-Blind, Randomized, Crossover Study Comparing the Pharmacodynamic Effects of a Once-Daily Controlled-Release Carvedilol (CRC; Egalet® Formulation) and an Immediate-Release Carvedilol (IRC) Formulation in Patients With Primary Hypertension||Egalet Ltd|No|Terminated|April 2007|October 2007|Anticipated|October 2007|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2008|February 12, 2008|March 7, 2007||No|IMP supply|No||https://clinicaltrials.gov/show/NCT00444834||173566|
NCT00474955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20434|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.|An Open Label Study of the Effect of PEGASYS on Sustained Virological Response in Patients With Chronic Hepatitis C and Chronic Renal Failure||Hoffmann-La Roche||Completed|July 2007|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00474955||171301|
NCT00474968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e2TM Cervical cell Collector|Adequacy and Efficacy of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique.|Clinical Study Validating the Adequacy, Efficacy, and Safety of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique In Patients With Recent History of Abnormal Pap Test Returning for Colposcopy/Biopsy.||CytoCore, Inc.|Yes|Completed|April 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|737|None Retained|Cervical cells|Female|18 Years|N/A|No|Non-Probability Sample|Women > 18 years of age with an abnormal pap within 30 days to 1 year for whom a        colposcopy is scheduled.|November 2009|November 16, 2009|May 16, 2007||No||No|May 4, 2009|https://clinicaltrials.gov/show/NCT00474968||171300|
NCT00476047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 2301|Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission|A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission||Fred Hutchinson Cancer Research Center|No|Completed|February 2007|||February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|May 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00476047||171218|
NCT00445354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20060194H|Randomized Controlled Clinical Trial of Cinnamon to Lower Hemoglobin A1c|A Randomized Controlled Clinical Trial Comparing the Effect of 1g of Daily Cinnamon Plus Usual Care to Usual Cre on the Hemoglobin A1c of Uncontrolled Type 2 Diabetics||Eglin AFB Regional Hospital|Yes|Recruiting|March 2007|August 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||140|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2007|March 7, 2007|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445354||173526|
NCT00445341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070081|Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma|A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)||National Institutes of Health Clinical Center (CC)|No|Completed|January 2007|May 2012|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|March 7, 2007|Yes|Yes||No|September 5, 2012|https://clinicaltrials.gov/show/NCT00445341||173527|
NCT00441012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V121-019|Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)|A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus Influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process||Merck Sharp & Dohme Corp.||Completed|December 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|546|||Both|40 Days|80 Days|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 26, 2007|Yes|Yes||No|May 11, 2009|https://clinicaltrials.gov/show/NCT00441012||173859|
NCT00441636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-247-06|Treatment Resistant Depression and Obstructive Sleep Apnea, Effect of Continuous Positive Airway Pressure (CPAP)|Treatment Resistant Depression and Obstructive Sleep Apnea: Effect of Treatment With CPAP on Mood, Anxiety and Quality of Life||Queen's University|Yes|Recruiting|March 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00441636||173811|
NCT00442195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070113|Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers|Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|February 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|8 Years|N/A|Accepts Healthy Volunteers|||June 2015|October 27, 2015|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00442195||173768|
NCT00442884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1261|Effect of Acute Psychological Stress on Glucose Concentrations in Patients With Type 2 Diabetes|Effect of Acute Psychological Stress on Glucose Concentrations in Patients With Type 2 Diabetes||University of Zurich|No|Completed|February 2006|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training||||30|||Both|18 Years|80 Years|No|||March 2007|March 2, 2007|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00442884||173715|
NCT00442897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-126|Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)|Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery Disease||Merck Sharp & Dohme Corp.||Completed|September 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|February 28, 2007|Yes|Yes||No|October 1, 2009|https://clinicaltrials.gov/show/NCT00442897||173714|
NCT00443729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-033|MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B||Merck Sharp & Dohme Corp.||Terminated|May 2007|April 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|March 2, 2007|Yes|Yes|Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus    lopinavir (+) ritonavir|No|October 12, 2009|https://clinicaltrials.gov/show/NCT00443729||173650|Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™.
NCT00443742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-06293a|Diagnosis of Depression Among Adolescents|Diagnosis of Depression Among Adolescents - a Clinical Validation Study of Key Questions and Questionnaire||University of Oslo|No|Completed||||||N/A|Observational|N/A|||Anticipated|323|||Both|14 Years|16 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|March 3, 2007||||No||https://clinicaltrials.gov/show/NCT00443742||173649|
NCT00443963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSESOM0391|Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-Steroidal Anti-Inflammatory Drugs|Effects of Esomeprazole Magnesium on Gastric Free Radical Production and Total Antioxidant Capacity in Dyspeptic Patients Receiving Non-Steroidal Anti-Inflammatory Drugs||Medstar Research Institute|No|Terminated|December 2006|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||December 2007|December 17, 2007|March 6, 2007|||The Principal Investigator is no longer affiliated with the Study Site.|||https://clinicaltrials.gov/show/NCT00443963||173632|
NCT00443755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004002|Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance|Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance||Mayo Clinic|Yes|Completed|August 2005|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|N/A|No|||October 2013|October 7, 2013|February 26, 2007||No||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00443755||173648|
NCT00443976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I181|Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma|A Phase I Study of AT9283 Given As a 24 Hour Infusion on Days 1 and 8 Every Three Weeks in Patients With Advanced Incurable Malignancy||Canadian Cancer Trials Group|Yes|Completed|January 2007|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2012|October 5, 2015|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443976||173631|
NCT00445146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-183-0130|Safety of Ritonavir-Boosted Elvitegravir Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infection|A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects||Gilead Sciences|No|Completed|February 2007|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|N/A|N/A|No|||April 2015|April 15, 2015|February 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445146||173542|
NCT00445458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-203|A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer|A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer||Puma Biotechnology, Inc.|No|Active, not recruiting|September 2007|December 2017|Anticipated|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|115|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|March 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445458||173519|
NCT00441155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2103E1|Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib|An Extension to a Phase I Multicenter, Dose Escalation Study of Nilotinib in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST)||Novartis||Completed|November 2006|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|N/A|N/A|No|||May 2013|May 9, 2013|February 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00441155||173848|
NCT00441441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA106484|A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma|A Randomized, Double-blind, Parallel Group Study Evaluating the Safety of Fluticasone Propionate/Salmeterol 100/50mcg HFA (2 Inhalations of 50/25mcg) Twice Daily Compared With Fluticasone Propionate 100mcg HFA (2 Inhalations of 50mcg) Twice Daily in Subjects 4-11 Years of Age With Persistent Asthma||GlaxoSmithKline|No|Completed|February 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|351|||Both|4 Years|11 Years|No|||February 2015|February 26, 2015|February 28, 2007|Yes|Yes||No|January 23, 2009|https://clinicaltrials.gov/show/NCT00441441||173826|A post-hoc evaluation confirmed that no clinically relevant ECG abnormalities were present. Differences in the primary and post-hoc analyses were associated with variation in the method of ECG interpretation and are not fully interpretable.
NCT00441142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-377|Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors|Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma|Zactima|Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2007|March 2016|Anticipated|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|February 27, 2007|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00441142||173849|
NCT00441428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDASOL-1520|Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity|||University of L'Aquila|Yes|Completed|February 2006|||January 2007||Phase 2|Observational|N/A|||||||Male|40 Years|80 Years|No|||June 2008|June 2, 2008|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441428||173827|
NCT00475267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0601|Aortic Valve Replacement With Trifecta(TM)|An Observational, Prospective Evaluation of the Trifecta Valve||St. Jude Medical|Yes|Completed|May 2007|January 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|203|||Both|18 Years|N/A|No|||November 2009|March 9, 2012|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475267||171277|
NCT00476060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRC85-13|Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis|Autologous Mesenchymal Stem Cell Transplantation in Patients With Decompensated Cirrhosis: A Randomized Placebo-controlled Trial||University of Tehran|Yes|Active, not recruiting|January 2007|August 2011|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||February 2009|January 10, 2011|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00476060||171217|
NCT00476073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3501|Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma|||Mundipharma Research Limited|No|Completed|April 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|228|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00476073||171216|
NCT00475787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-011-06F|Chiropractic Management of Chronic Lower Back Pain in Older Adults|Chiropractic Management of Chronic Lower Back Pain in Older Adults||VA Office of Research and Development|Yes|Completed|April 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Both|65 Years|N/A|No|||December 2014|December 16, 2014|May 17, 2007||No||No|October 21, 2014|https://clinicaltrials.gov/show/NCT00475787||171237|Sham intervention was that it did involve some tactile stimulationOnly VA sites/predominantly maleClinicians not blinded to invention deliveredAll received educational bookletConsideration of non-specific therapeutic effects
NCT00441051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FESB-DE-310|Efficacy and Safety of Diclofenac Sodium (0.1%) Gel in Patients With UV Induced Painful Sunburn|A Randomized, Double-Blind, Vehicle-Controlled, Single Center, Intra-Individual Comparative Study of the Efficacy and Safety of Diclofenac Sodium 1 mg/g (0.1%) Gel in Subjects With Painful UV-Induced Erythema||Novartis|No|Completed|November 2006|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441051||173856|
NCT00441064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AUS02|Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren|A Randomized, Open-label, Blinded Endpoint, Multi-center, Cross-over Study to Evaluate the Effect of High and Low Sodium Diets on Reduction in Mean 24-hour Ambulatory Blood Pressure in Systolic Hypertensive Patients Treated With Aliskiren (300 mg)||Novartis|No|Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|60 Years|No|||February 2011|February 28, 2011|February 26, 2007||||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00441064||173855|
NCT00441025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH 011002|The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL|A Phase II Study of Alemtuzumab in Combination With CHOP as First-Line Treatment in Peripheral T-Cell Lymphoma||Mahidol University||Terminated|September 2006|August 2009|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|15 Years|65 Years|No|||February 2007|June 24, 2009|February 26, 2007|||a lack of a potential patient.|No||https://clinicaltrials.gov/show/NCT00441025||173858|
NCT00441038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-13|A Trial on the Effect on Low Back Pain Related Disability of Different Health Education Programs for Retired Persons|Controlled Randomized Clinical Trial on the Effect on Low Back Pain Related Disability of Different Health Education Programs for Retired Persons||Kovacs Foundation|Yes|Withdrawn|December 2006|September 2008|Anticipated|July 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|1100|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2011|August 23, 2011|February 23, 2007||No|Pilot study showed recruitment rates were lower than expected,and number of losses to    follow-up, much higher.|No||https://clinicaltrials.gov/show/NCT00441038||173857|
NCT00441337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-001 ST|A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies|A Phase 1, Open Label, Dose-escalation, Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies|MDX1106-01|Bristol-Myers Squibb|No|Completed|August 2006|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|39|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|February 27, 2007|No|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT00441337||173834|
NCT00441883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9441001|Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma|A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost||Bausch & Lomb Incorporated|Yes|Completed|March 2007|July 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|February 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00441883||173792|
NCT00441896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0500|A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms|A Double-blind, Placebo-controlled, Dose-ranging Clinical Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Treatment of Patients With Infantile Spasms||Marinus Pharmaceuticals|Yes|Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|4 Months|24 Months|No|||October 2009|October 29, 2009|February 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00441896||173791|
NCT00443092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP100M|Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee|A Double Blind Cross-over Study of the Efficacy of a Proprietary Cherry Juice Blend in Osteoarthritis of the Knee.||CherryPharm|No|Completed|March 2007|December 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|59|||Both|18 Years|90 Years|No|||August 2012|August 1, 2012|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443092||173699|
NCT00443105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050321|Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study|||Assaf-Harofeh Medical Center|No|Active, not recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|5 Years|N/A||||December 2006|March 2, 2007|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00443105||173698|
NCT00443157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNB3|Meningococcal B Vaccination in University Students|A Phase II, Open Label, Randomised, Single Centre Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three or Four Doses of Meningococcal Serogroup B Outer Membrane Vesicle (OMV) Vaccine MENZBTM When Administered to Healthy Adults (University Students)|MNB3|Public Health England||Completed|February 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2007|December 4, 2008|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00443157||173694|
NCT00443495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP/01/006|Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis|First Into Man Administration of Chitin Microparticles: a Randomised,Double Blind,Placebo Controlled Parallel Group Upward Titration Evaluation of 3 Dose Levels Given Intr-Nasally Over 24 Hours,Followed by a Placebo Controlled,Randomised Parallel Group Evaluation of Safety and Biological Activity Over 7 Days in Subjects Suffering From Allergic Rhinitis||CMP Therapeutics Ltd|No|Completed|October 2006|March 2007||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Male|18 Years|50 Years|No|||March 2007|March 2, 2007|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00443495||173668|
NCT00443118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fundasamin 102|Newborn Ventilation in the Delivery Room: Could it be Improved With a T-piece Resuscitator?|NEWBORN VENTILATION IN THE DELIVERY ROOM: CAN IT BE IMPROVED WITH A T-PIECE RESUSCITATOR? Multicenter Cross-over Cluster Randomized Controlled Trial||Fundacion para la Salud Materno Infantil|Yes|Completed|December 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1032|||Both|N/A|2 Minutes|No|||January 2015|March 30, 2015|March 2, 2007||No||No|February 22, 2014|https://clinicaltrials.gov/show/NCT00443118||173697|
NCT00443469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#64/2006|Spinal Magnetic Stimulation in Neuropathic Pain|A Randomized Placebo-controlled Trial on the Use of Repetitive Spinal Magnetic Stimulation as a Therapeutic Option in Patients With Intractable Neuropathic Pain of the Lower Limbs||Singapore General Hospital|Yes|Completed|August 2006|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|80 Years|No|||March 2010|March 30, 2010|March 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00443469||173670|
NCT00443482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOR258D2201|Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)|A Randomized, Multi-centre, Double-blind, Double Dummy Placebo Controlled Single-dose Cross-over Study to Demonstrate That 12 and 24 µg of Formoterol Delivered by Concept1 Has a Bronchodilator Efficacy Which is Equivalent to the Same Dose of Formoterol Delivered by Aerolizer in Adult Patients With Persistent Asthma||Novartis||Completed|February 2007|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A||||October 2011|October 24, 2011|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00443482||173669|
NCT00444847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANET HIV/AIDS Trial Q050021|Effect of Repeated Exposures to Compressed Air on Patients With AIDS|Effect of Repeated Exposure to Compressed Air on Patients With AIDS (Acquired Immunodeficiency Syndrome)|DANET1|Designed Altobaric Technology, Incorporated|Yes|Suspended|July 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||March 2007|April 2, 2007|March 7, 2007|||Change in institutional headquarters for the US study.|No||https://clinicaltrials.gov/show/NCT00444847||173565|
NCT00444860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-019|ZOSTAVAX(R) Local Registration Trial (V211-019)|A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX(R) in Healthy Adults in Taiwan||Merck Sharp & Dohme Corp.||Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00444860||173564|
NCT00445471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4222|A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment|||Rabin Medical Center|No|Terminated|April 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|2 Years|5 Years|No|||December 2014|December 24, 2014|March 8, 2007||No|Mifne began treating younger patients who could not be diagnosed with the ADOS used in the    study|No||https://clinicaltrials.gov/show/NCT00445471||173518|
NCT00441168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011065|Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma|A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed After Primary Therapy for Multiple Myeloma||Janssen-Cilag International NV|No|Terminated|December 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|February 27, 2007|Yes|Yes|TRIAL STOPPED due to a change in standard of care and the required patient numbers could no    longer be achieved|No|December 3, 2009|https://clinicaltrials.gov/show/NCT00441168||173847|Due to a substantial decline in the use of the VAD regimen as standard of care, recruitment of the study was halted at 30 subjects. It was not possible to statistically evaluate any long term efficacy parameter.
NCT00441727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00003|Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)|A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)|Oberon|AstraZeneca||Completed|February 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2426|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|February 27, 2007|Yes|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00441727||173804|Not enough patients had peptic ulcer, gastric ulcer, or duodenal ulcer to report the intended primary endpoint of time to peptic ulcer and two secondary endpoints, time to gastric ulcer and time to duodenal ulcer. Percentage used instead.
NCT00441974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF108356|Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients|A 48-week Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B||GlaxoSmithKline||Completed|December 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1470|||Both|16 Years|65 Years|No|||October 2009|October 15, 2009|February 28, 2007||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00441974||173785|
NCT00441987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3183A1-101|Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953|A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 Administered Orally to Healthy Japanese Male Subjects and Healthy Elderly Male Japanese Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|96|||Male|20 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 17, 2010|February 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00441987||173784|
NCT00442000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-024|Outcomes Comparison of Robotic, Retropubic, and Perineal Prostatectomy|Outcomes Comparison of Robotic, Retropubic, and Perineal Prostatectomy||William Beaumont Hospitals|No|Completed|January 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|700|||Male|18 Years|N/A|No|Non-Probability Sample|Patients undergoing prostatectomy at William Beaumont-Royal Oak.|March 2012|March 19, 2012|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00442000||173783|
NCT00442338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-334|Study of MK0476 in Adult Patients With Acute Asthma (0476-334)|MK0476 Phase III Open Label Exploratory Comparative Clinical Study -Acute Exacerbations of Asthma -||Merck Sharp & Dohme Corp.||Completed|March 2007|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|91|||Both|15 Years|75 Years|No|||May 2015|May 11, 2015|February 27, 2007|Yes|Yes||No|May 22, 2009|https://clinicaltrials.gov/show/NCT00442338||173757|
NCT00475280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1104|"Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients|"Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17|LAL1104|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|November 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|60 Years|N/A|No|||February 2015|February 23, 2015|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475280||171276|
NCT00475293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-06-04|Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC|A Phase 2 Clinical Trial of Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With Metastatic Colorectal Cancer||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|May 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||February 2013|September 12, 2013|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475293||171275|
NCT00476359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 017|A PK and Salvage Study for Children With HIV-infection|Lopinavir/r Plus Saquinavir Salvage Therapy in HIV-infected Children With NRTI and/or NNRTI Failure: PK and Two-year Treatment Follow up||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|October 2003|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|1 Year|16 Years|No|||March 2015|March 26, 2015|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476359||171194|
NCT00441363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-AD-04-03-US-2|Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin|A Randomized, Double-Blind, Parallel-Group Trial to Assess the Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin in Patients With Type 2 Diabetes Mellitus||VeroScience|No|Terminated|February 2005|March 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||326|||Both|18 Years|75 Years|No|||February 2007|February 27, 2007|February 27, 2007|||Failure to Recruit in a Timely manner|No||https://clinicaltrials.gov/show/NCT00441363||173832|
NCT00441376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-06-101-01|A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver|A Phase I Dose Escalation Tolerability Study of ThermoDox™ (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) of Primary and Metastatic Tumors of the Liver||Celsion|No|Completed|February 2007|December 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00441376||173831|
NCT00441350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS866CM-B-E303|Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension|Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension||Menarini Group|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1004|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00441350||173833|
NCT00441649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH045358|Methylphenidate for Treating Children With ADHD and Tourette Syndrome|Methylphenidate Treatment of ADHD in Children With Tourette Syndrome||Stony Brook University||Completed|February 2000|January 2007|Actual|June 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||71|||Both|6 Years|12 Years|No|||October 2013|October 29, 2013|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00441649||173810|
NCT00442858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-286-99|Incidence of Cardiovascular Diseases in Patients With Hypopituitarims|||Lund University Hospital|No|Completed|January 1999|December 2002||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||800|||Both|N/A|N/A|No|||March 2007|March 1, 2007|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00442858||173717|
NCT00442871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA104412|Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment|An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg [SB-497115] in Healthy Subjects and in Subjects With Mild, Moderate, or Severe Renal Impairment||GlaxoSmithKline|No|Completed|September 2006|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2011|May 31, 2012|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00442871||173716|
NCT00443768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R060112/SW|Medication Review in Patients on Anti-parkinson Therapy|Medication Review in Patients on Anti-parkinson Therapy|PDCom|South Glasgow University Hospitals NHS Trust|No|Completed|October 2006|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|Community sample of Parkinson's disease patients|February 2013|February 1, 2013|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443768||173647|
NCT00444509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZA108799|Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.|A Randomised, Double Blind, Two-way Crossover Study, to Examine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Inhaled Administration of GW685698X (800?g) With and Without Magnesium Stearate, in Mild/Moderate Asthmatic Patients.||GlaxoSmithKline|No|Completed|February 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|65 Years|No|||February 2011|May 31, 2012|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444509||173591|
NCT00444522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-002-101|Staccato® Alprazolam for Inhalation in Panic Disorder|Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoTM Alprazolam for Inhalation in Normal, Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|June 2005|August 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2007|March 7, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444522||173590|
NCT00444535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF103890|Lapatinib and Bevacizumab for Metastatic Breast Cancer|A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer||GlaxoSmithKline|No|Active, not recruiting|February 2007|June 2016|Anticipated|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|March 6, 2007|Yes|Yes||No|July 9, 2009|https://clinicaltrials.gov/show/NCT00444535||173589|
NCT00444561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137-160|Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects|A Phase 2, Randomized, Double‑Blind, Placebo‑Controlled, Multicenter Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects||AstraZeneca|No|Completed|August 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|184|||Both|25 Years|60 Years|No|||May 2015|June 10, 2015|March 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00444561||173587|
NCT00444873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52030-163|Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly|A Phase III, Multicentre, Open Label, Comparative, Dose-interval Titration Study Evaluating the Efficacy and Safety of Six Repeated Deep Subcutaneous Administrations of Lanreotide Autogel 120mg, in Acromegalic Patients Previously Treated With Octreotide LAR||Ipsen|No|Completed|January 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|25 Years|N/A|No|||June 2012|June 18, 2012|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444873||173563|
NCT00445484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06102 CDR0000532944|Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma|Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2007|September 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|March 7, 2007|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT00445484||173517|
NCT00441181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP 2007-02|Effects of Travoprost on Neovascular Glaucoma|Effects of Travoprost on Neovascular Glaucoma||Federal University of São Paulo|No|Withdrawn|January 2008|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||February 2007|June 21, 2011|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441181||173846|
NCT00441194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSOCT001|To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series|To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series With Respect to Reliability, Reproducibility, Test Duration, Patient Preference, Technician Preference.||Haag Streit USA|Yes|Terminated|November 2006|May 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All subjects|March 2012|March 2, 2012|February 27, 2007|||Study terminated due to resources|No||https://clinicaltrials.gov/show/NCT00441194||173845|
NCT00441467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-305|Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma|An Open-Label Phase 2 Study of the Efficacy and Safety of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma||Eleison Pharmaceuticals LLC.||Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 27, 2007|Yes|Yes||No|February 16, 2015|https://clinicaltrials.gov/show/NCT00441467||173824|
NCT00441454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVT vs. TVT-O|Retropubic vs. Transobturator Tension-free Vaginal Tape|Retropubic vs. Transobturator Tension-free Vaginal Tape (TVT vs. TVT-O): A Randomized Trial||Austrian Urogynecology Working Group (AUWG)||Completed|September 2004|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|564|||Female|18 Years|N/A|No|||December 2012|December 9, 2012|February 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00441454||173825|
NCT00441740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/04.04|Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer|Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine as First Line Treatment in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC). A Prospective , Multicenter, Randomized, Phase III Trial||Hellenic Oncology Research Group|No|Completed|April 2004|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|419|||Both|18 Years|75 Years|No|||October 2008|October 29, 2008|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441740||173803|
NCT00475852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013954|A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure|Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)||Scios, Inc.|No|Completed|May 2007|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7141|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|May 18, 2007|No|Yes||No|September 27, 2011|https://clinicaltrials.gov/show/NCT00475852||171232|Only summary counts of deaths by group are provided for other pre-specified endpoints “All-cause mortality through Day 30” and “All-cause mortality through Day 180.” Formal statistical comparisons were not planned.
NCT00475553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50403|Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®|The Frequency and Management of Breakthrough Bleeding During Extended Therapy With the Transvaginal Contraceptive Ring||Scott and White Hospital & Clinic|No|Completed|May 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 17, 2009|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475553||171255|
NCT00475839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 7616|Study Comparing Tension-free Vaginal Tape With the Monarc Procedure for Stress Urinary Incontinence|A Randomized Trial Comparing the Monarc Subfascial Hammock Procedure With Tension-free Vaginal Tape Procedure for the Surgical Treatment of Stress Urinary Incontinence||The Cleveland Clinic|No|Completed|December 2004|July 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|180|||Female|21 Years|N/A|No|||January 2013|January 9, 2013|May 17, 2007||||No||https://clinicaltrials.gov/show/NCT00475839||171233|
NCT00476086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-063|Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus|A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2006|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|N/A|No|||August 2013|August 23, 2013|May 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00476086||171215|
NCT00441909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19AI051661|Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide|Phase I Study of the Safety and Persistence of 0.1% UC-781 Vaginal Gel in HIV-1 Seronegative Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2006|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|8||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 3, 2009|February 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00441909||173790|
NCT00441922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/03.07|Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase II Study of Docetaxel Versus Vinorelbine as First-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)||Hellenic Oncology Research Group|No|Completed|January 2003|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|65 Years|80 Years|No|||October 2008|October 28, 2008|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441922||173789|
NCT00442208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN200-105|An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers|||POZEN|Yes|Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2008|April 21, 2008|February 28, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00442208||173767|
NCT00442221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT400-303|The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months|An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months||POZEN|Yes|Completed|May 2004|August 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||500|||Both|18 Years|65 Years|No|||February 2007|February 28, 2007|February 28, 2007||||Yes||https://clinicaltrials.gov/show/NCT00442221||173766|
NCT00442234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6010-J081-591|Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism|Pharmacokinetic/Pharmacodynamic Study of Monteplase ("Cleactor") in Acute Pulmonary Embolism||Eisai Inc.||Completed|May 2007|||April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||4|||Both|20 Years|75 Years|No|||January 2010|January 27, 2010|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00442234||173765|
NCT00442650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25030|Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis|||Merck KGaA||Completed||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years||||March 2009|July 30, 2014|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442650||173733|
NCT00442910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-004; SPL7013-006|Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women|Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel™) Applied Vaginally in Sexually Active Young Women||Starpharma Pty Ltd|Yes|Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|61|||Female|18 Years|24 Years|Accepts Healthy Volunteers|||June 2010|June 22, 2010|March 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00442910||173713|
NCT00442624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 196/05 SB|Effects of Chronic Insomnia on the Neuroendocrine Regulation of Glucose and Lipid Metabolism|Effects of Chronic Insomnia on the Neuroendocrine Regulation of Glucose and Lipid Metabolism||University Hospital, Basel, Switzerland|Yes|Completed|January 2007|December 2008||||Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|Samples Without DNA|plasma and serum samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|outpatient clinic, general population|March 2012|March 8, 2012|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00442624||173735|
NCT00442637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIRO3|Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma|Maintenance Treatment With Capecitabine and Bevacizumab Versus Observation After Induction Treatment With Chemotherapy and Bevacizumab as First-line Treatment in Patients With Advanced Colorectal Carcinoma|CAIRO3|Dutch Colorectal Cancer Group|Yes|Active, not recruiting|January 2007|December 2013|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|635|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00442637||173734|
NCT00443131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107731|Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines|Adjuvant Justification Study of Candidate Malaria Vaccines (257049), Administered According to a 0, 1, 2 Months Schedule .||GlaxoSmithKline||Completed|March 2007|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|March 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443131||173696|
NCT00444002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0305 AE|Oxidative Stress and Fatty Acids in Hepatitis C|Hepatitis C Infection With Liver Steatosis Compared to Hepatitis C Infection Without Liver Steatosis: Is There a Difference in Lipid Peroxidation and Indicators of Inflammation?||University Health Network, Toronto|No|Completed|July 2005|July 2010|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|105|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic Hep C infection undergoing routine pre-treatment liver biopsy|January 2014|January 9, 2014|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444002||173629|
NCT00444015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14984|Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)|Phase I Trial Evaluating the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Recurrent Non-small Cell Lung Cancer (NSCLC)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|March 2007|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||June 2011|November 21, 2013|March 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00444015||173628|
NCT00444028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-101|Staccato® Loxapine for Inhalation in Schizophrenia|Safety, Tolerability, and Pharmacokinetics of a Single Dose of Staccato™ Loxapine for Inhalation in Normal, Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|October 2005|November 2005||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2007|March 5, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444028||173627|
NCT00444886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03355|Treatment of Thoracic Outlet Syndrome (TOS) With Botox|Treatment of Thoracic Outlet Syndrome With Botulinum Toxin Injection: A Double-Blind, Randomized Controlled Trial||University of British Columbia|No|Completed|May 2007|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||February 2011|February 9, 2011|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444886||173562|
NCT00445497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-MX3006|Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia|A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE]||National Cancer Institute (NCI)||Recruiting|July 2007|||July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|400|||Both|18 Years|N/A|No|||May 2007|August 9, 2013|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445497||173516|
NCT00445510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA106620|This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge|A Double Blind, Placebo Controlled, Repeat Dose Study to Determine the Effect of GSK256066 87.5 Mcg to Protect Against AMP Challenge in the Lung in Mild Steroid-naive Asthmatics.||GlaxoSmithKline|No|Completed|June 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|18 Years|55 Years|No|||February 2011|May 31, 2012|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445510||173515|
NCT00445523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI IRB#0206-0028|Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer|A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer||The Methodist Hospital System|No|Completed|May 2006|February 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445523||173514|
NCT00441207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCA 06-04|Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors|A Phase I Study of High-Dose IV Vitamin C Treatment in Patients With Solid Tumors||Midwestern Regional Medical Center|Yes|Completed|August 2006|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|February 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00441207||173844|
NCT00441493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13035|Fluvastatin Versus Hepatitis C Virus|A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C With Special Attention to the African-American Population.||Bader, Ted, M.D.||Completed|September 2006|September 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Both|18 Years|75 Years|No|||September 2006|July 26, 2012|February 27, 2007||Yes||||https://clinicaltrials.gov/show/NCT00441493||173822|
NCT00441480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CardiaBeat_003|Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels|Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels in Healthy, Hyperlipidemic Subjects||Enzymotec|Yes|Completed|March 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|February 28, 2007||No||No|July 1, 2009|https://clinicaltrials.gov/show/NCT00441480||173823|
NCT00441753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSCH0601|Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest|Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest||Radboud University||Recruiting|September 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|95 Years|No|Probability Sample|Patients after cardiac arrest, comatose and treated with therapeutic hypothermia|February 2009|February 5, 2009|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441753||173802|
NCT00441766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203818-008|Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain|||Allergan||Terminated|March 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|213|||Female|18 Years|N/A|No|||December 2011|December 16, 2011|February 27, 2007|Yes|Yes|Study was terminated due to company decision after Part A. Part B was never conducted|No|December 16, 2011|https://clinicaltrials.gov/show/NCT00441766||173801|Only Part A results are presented; Due to termination of the study, Part B was never conducted.
NCT00476112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235-0703B|A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter|A Phase II/III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter|Scene 2|Cardiome Pharma|Yes|Completed|August 2003|September 2004|Actual|September 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|May 18, 2007||||No||https://clinicaltrials.gov/show/NCT00476112||171213|
NCT00476099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM/PR/033011/005/05|Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD|A 48-week, Double Blind, Double Dummy, Randomised, Multinational, Multicentre, 3-arm Parallel Group Clinical Study of "Fixed Combination" Beclometasone Dipropionate Plus Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant Versus "Fixed Combination" Budesonide Plus Formoterol DPI Versus Formoterol DPI in Patients With Stable Severe Chronic Obstructive Pulmonary Disease (COPD)||Chiesi Farmaceutici S.p.A.|Yes|Completed|December 2006|November 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|828|||Both|40 Years|N/A|No|||April 2008|January 29, 2013|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476099||171214|
NCT00476385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8912|Practicability and Acceptability of Stylomax® in Children|Usability and Acceptability of Stylomax® in Growth Hormone Deficient Children.||Sanofi|No|Completed|June 2003|||December 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|3 Years|18 Years|No|||February 2009|February 11, 2009|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476385||171192|
NCT00472368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2108|A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589|An Open-label, Single Center, Study to Determine the Absorption, Distribution, Metabolism, and Excretion (ADME) of LBH589 After a Single Oral Administration of 20 mg (14C) LBH589 in Advanced Cancer Patients||Novartis||Completed|May 2007|||June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|May 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00472368||171493|
NCT00441662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wills Eye Sub-Tenon Kenalog|Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema|Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema Following Plaque Radiotherapy for Uveal Melanoma||Wills Eye||Completed|November 2004|May 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||170|||Both|18 Years|N/A|No|||February 2007|February 28, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00441662||173809|
NCT00441675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS107541|A Long Term Prospective Follow Up Study For The CATO Study (SAS30018/SER9702)|A Long Term Follow up Study for a Comparison of Stepwise Treatment of Asthmatic Children With Salmeterol/Fluticasone Propionate Combination Product (SERETIDE®) and/or Fluticasone Propionate (FLIXOTIDE (TM)) Based on PD20 Methacholine and Symptoms or Based on Symptoms Only.||GlaxoSmithKline||Completed|January 2007|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case-Only||2|Actual|137|||Both|N/A|N/A|No|Probability Sample|All patients randomized in the CATO study (SAS30018) (total of 210) were asked to        participate in the follow up study.        Any subject who gave informed consent to participate in the CATO study, and met all the        criteria required for randomisation into the clinical study took part in this follow up        study.|June 2011|March 15, 2012|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00441675||173808|
NCT00441935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-073|InterStim Prospective Database|InterStim Prospective Database for Outcomes Research||William Beaumont Hospitals|No|Enrolling by invitation|April 2004|April 2029|Anticipated|April 2029|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|patients at least 18 years of age scheduled for sacral nerve stimulator implantation at        William Beaumont Hospital, Royal Oak|November 2015|November 1, 2015|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00441935||173788|
NCT00442247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feb-UH-2007|A Randomised, Controlled Study of Bimesh, Pelvicol for Vaginal Wall Prolapse|A Randomised, Controlled Study of Bimesh, Pelvicol for Vaginal Wall Prolapse||Roskilde County Hospital|Yes|Active, not recruiting|September 2004|December 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|55 Years|75 Years|No|||February 2007|February 28, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442247||173764|
NCT00442260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOXIL|Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer|Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination With Abraxane (Abraxane) in Patients With Metastatic Breast Cancer (MBC) [Phase I and II]||West Virginia University|Yes|Completed|February 2007|October 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|No|||January 2009|January 15, 2009|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442260||173763|
NCT00443508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIL01|Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion|Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study||Rabin Medical Center|No|Recruiting|February 2007|February 2010||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Male|N/A|N/A|No|||September 2005|March 5, 2007|March 4, 2007||||No||https://clinicaltrials.gov/show/NCT00443508||173667|
NCT00443781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0603|Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain|Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain|SODA|Medtronic Spine LLC|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|62|||Both|21 Years|N/A|No|||March 2012|March 19, 2012|March 2, 2007|Yes|Yes||No|June 23, 2010|https://clinicaltrials.gov/show/NCT00443781||173646|There were 12 subjects which did not undergo both PD (Provocative Discography) and F.A.D. (Functional Anesthetic Discography) and therefore could not be included in the primary endpoint analysis (analyzable population for primary endpoint = 50/62).
NCT00444041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO-ASSO-LM1|Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer|Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer (mCRC). A Multicenter, Single Arm Phase I/II Academic Trial|ASSO-LM1|Austrian Society Of Surgical Oncology|Yes|Completed|January 2007|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444041||173626|
NCT00443144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-TUE-FH1|D3-GHR Polymorphism and Turner Syndrome|D3-Growth Hormone Receptor Polymorphism and Total Effect of Recombinant Human Growth Hormone on Growth in Girls With Turner Syndrome||University Hospital Tuebingen|No|Completed|May 2005|May 2007|Actual|April 2007|Actual|N/A|Observational|N/A|||||||Female|38 Months|14 Years||||December 2015|December 2, 2015|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443144||173695|
NCT00444574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-302|Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD|A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Noven Therapeutics|No|Completed|September 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|282|||Both|6 Years|12 Years|No|||June 2015|June 23, 2015|March 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00444574||173586|
NCT00444587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19944|A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.|A Randomized, Open-label Study to Compare Time to Disease Progression in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin.||Hoffmann-La Roche||Completed|March 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444587||173585|
NCT00444600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-133|Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema|Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema|LRT for DME|Diabetic Retinopathy Clinical Research Network|Yes|Completed|March 2007|February 2014|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|691|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|March 6, 2007|Yes|Yes||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00444600||173584|
NCT00444249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBI-06-172-1006|Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin|Influence of Blue Light Filtering Intra Ocular Lenses on Daytime Levels of Melatonin in Patients With Non-Exudative Age-Related Macular Degeneration|BluMel|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Terminated|March 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|136|||Both|60 Years|N/A|No|||April 2009|April 20, 2009|March 5, 2007||No|Because only a few patients follow the inclusion and exclusion criteria.|No||https://clinicaltrials.gov/show/NCT00444249||173610|
NCT00444548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061028|Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers|Measurement Of Urethral Function In Healthy Female Volunteers - Evaluation Of The Sensitivity of Urethral Reflectometry Compared To Urethral Pressure Profilometry, Using [S,S]-Reboxetine.||Pfizer||Completed|May 2007|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444548||173588|
NCT00445159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT-15C|UT-15C SR in the Treatment of Critical Limb Ischemia|An Investigator Initiated Eight Week Two Center Open-Label Pilot Study of the Tolerability and Safety of Oral UT-15C (Treprostinil Diethanolamine)SR Tablets in Patients With Critical Limb Ischemia (CLI) and Ischemic Rest Pain||Southern Arizona Vascular Institute|Yes|Recruiting|November 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||20|||Both|45 Years|85 Years|No|||March 2007|March 7, 2007|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445159||173541|
NCT00445172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0302-J081-762|A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)||Eisai Inc.||Active, not recruiting|February 2008|December 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|20 Years|N/A|No|||February 2016|February 26, 2016|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00445172||173540|
NCT00445185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN015/HBV-EXT001|Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™|A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™||Henogen|No|Completed|March 2007|November 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|102|||Both|16 Years|N/A|No|||November 2009|November 18, 2009|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445185||173539|
NCT00445198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-822|A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies|A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies||AbbVie||Completed|April 2007|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|March 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445198||173538|
NCT00445549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070061|Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the Vascular Endothelial Growth Factor 2 (VEGFR2) Inhibitor, ZD6474 (Vandetanib) in Women With Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||National Institutes of Health Clinical Center (CC)|No|Terminated|January 2007|October 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||May 2012|May 22, 2012|March 7, 2007||No|The study closed because of inadequate early activity.|No|June 30, 2011|https://clinicaltrials.gov/show/NCT00445549||173513|The study closed after the first stage of accrual because of inadequate early activity with 32 cycles of administered treatment.
NCT00451464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100205283|Studies of Apolipoprotein Genotyping on the Drug Treatment of Hyperlipidemic Patients|Studies of Apolipoprotein Genotyping on the Drug Treatment of Hyperlipidemic Patients||National Taiwan University Hospital||Completed|January 2002|January 2005||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2005|March 22, 2007|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00451464||173064|
NCT00441506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP04|Effects of Daily Interruption of Sedatives in Critically Ill Children|Effects of Daily Interruption of Sedatives in Critically Ill Children||Radboud University|No|Completed|November 2004|July 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|12 Years|No|||February 2007|August 23, 2010|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00441506||173821|
NCT00441779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1378|Transfusion-Associated Microchimerism in Previously Injured Individuals Who Received a Blood Transfusion|Retrospective Study of the Prevalence of Transfusion-Associated Microchimerism Following Traumatic Injury, Burns, and Elective Orthopedic Procedures||National Heart, Lung, and Blood Institute (NHLBI)|No|Terminated|August 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|59|Samples With DNA|Whole blood, plasma, peripheral blood mononuclear cells|Both|8 Years|N/A|No|Probability Sample|Previously hospitalized patients|October 2014|October 23, 2014|February 28, 2007||No|A separate study (similar subjects) identified transfusion-associated microchimerism only    rarely, making this observational study impractical to conduct.|No||https://clinicaltrials.gov/show/NCT00441779||173800|
NCT00476411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 036|A Study to Test the Efficacy of the HBV Vaccine and to Look at the Prevalence of HBV Infection|The Efficacy of HBV Vaccine Response and Prevalence of Occult HBV Infection in Isolated Anti HBc Between HIV Infected and HIV Un-infected Thai Patients||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|December 2006|December 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2010|June 4, 2010|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476411||171190|
NCT00476398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P001321|Evaluation of Patients With Non-cardiac Chest Pain|Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus.||Brigham and Women's Hospital|No|Completed|January 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|80 Years|No|||September 2009|September 8, 2009|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476398||171191|
NCT00472381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060202|Efficacy and Safety of Continuous Intravenous Versus Usual Subcutaneous Insulin in Acute Ischemic Stroke|Assessment of Continuous Intravenous Insulin Protocol Versus Subcutaneous Insulin in Acute Ischemic Stroke|INSULINFARCT|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2007|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|19 Years|N/A|No|||September 2012|June 4, 2014|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472381||171492|
NCT00441415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29058|Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 0.1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris||Galderma||Completed|February 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|272|||Both|12 Years|35 Years|No|||August 2008|August 5, 2008|February 27, 2007||||||https://clinicaltrials.gov/show/NCT00441415||173828|
NCT00441688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109477|Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients|Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients||GlaxoSmithKline||Completed|March 2007|||||N/A|Observational|Time Perspective: Prospective||||2469|||Both|18 Years|N/A|No|||October 2008|October 13, 2008|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00441688||173807|
NCT00441701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04592|Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)|Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD||Merck Sharp & Dohme Corp.|Yes|Terminated|December 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|99|||Both|41 Years|75 Years|No|||July 2015|July 29, 2015|February 28, 2007|Yes|Yes||No|August 11, 2014|https://clinicaltrials.gov/show/NCT00441701||173806|
NCT00441948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peterio-05|Enhanced Safety Laser Hair Removal System|Peterio™ – an Add-on Device for Enhanced Safety of Aesthetic Laser Treatments.||Scilex Ltd.|No|Not yet recruiting|May 2007|April 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2007|February 27, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441948||173787|
NCT00442273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCS-0001|Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome|Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome||Chonnam National University Hospital||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|20 Years|61 Years||||February 2007|February 28, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442273||173762|
NCT00442286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360009|Rheos® Pivotal Trial|Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System||CVRx, Inc.|Yes|Active, not recruiting|October 2006|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|80 Years|No|||July 2015|July 8, 2015|February 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00442286||173761|
NCT00442299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3041|Albumin Dialysis in End-Stage Renal Disease: Detoxification Capacity and Impact on Vascular Endothelial Function|Phase 1 Study of Albumin Dialysis Using Prometheus in End Stage Renal Disease: Detoxification Capacity and Impact on Vascular Endothelial Function||Universitaire Ziekenhuizen Leuven|Yes|Suspended|April 2005|December 2009||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||10|||Both|18 Years|N/A|No|||February 2007|February 28, 2007|February 28, 2007|||Major side-effects|No||https://clinicaltrials.gov/show/NCT00442299||173760|
NCT00443807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:008|EEG Monitoring to Assess Emergence From Neuroanesthesia|A Comparison of the EEGo and BIS Monitors to Assess Emergence From Neuroanesthesia||University of Manitoba|No|Completed|August 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|80 Years|No|||April 2008|April 15, 2008|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443807||173644|
NCT00444262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051009-AOM 05086|Stroke Volume Optimisation in Patients With Hip Fracture|Study Multicentric, Randomised, in Duplicate Blind Person of the Impact of a Per Operatory Strategy of Optimization of the Cardiac Output on the Forecast of the Old Subjects Operated for Fracture of the Upper End of the Femur " FRACTALE "|FRACTALE|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|April 2007|March 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|215|||Both|70 Years|N/A|No|||June 2011|October 6, 2011|March 6, 2007||No|termination of the study due to difficulties to include patients|No||https://clinicaltrials.gov/show/NCT00444262||173609|
NCT00444275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00111|Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients|A Randomized, Open, Parallel-group Study to Evaluate the Efficacy of Three Different Patient Management Strategies During a 12 Weeks Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related|MAESTRO|AstraZeneca|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|3029|||Both|18 Years|50 Years|No|||November 2012|November 14, 2012|March 5, 2007|Yes|Yes||No|March 29, 2010|https://clinicaltrials.gov/show/NCT00444275||173608|Planned number of patients not reached: statistical analysis plan revised,comparisons between treatment arms performed globally (No stratified analysis).Safety pop=3032-3 incorrect enrolments (withdrawals at V2) with no information on ttmt received
NCT00444288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907112|PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2|PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2||National Institutes of Health Clinical Center (CC)||Completed|February 2007|March 2010||||N/A|Observational|N/A|||||||Female|18 Years|N/A|No|||March 2010|September 26, 2015|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444288||173607|
NCT00444613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0302-J081-761|A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)||Eisai Inc.||Completed|April 2007|July 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|373|||Both|20 Years|N/A|No|||December 2014|December 4, 2014|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444613||173583|
NCT00444626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGE00105|A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)|A Subject- and Evaluator-Blinded, Randomized, Multi-Center Study to Evaluate the Safety and Effectiveness of Injection With DGE Injectable Gel as Compared to an FDA-Approved Dermal Filler in Subjects Undergoing Cutaneous Correction of Nasolabial Folds||Sanofi|No|Completed|May 2007|July 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 7, 2007|Yes|Yes||No|April 7, 2015|https://clinicaltrials.gov/show/NCT00444626||173582|
NCT00444899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA3840020|Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients|Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Diabetic Patients|GRC|Université de Sherbrooke|No|Active, not recruiting|March 2007|June 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444899||173561|
NCT00445211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001|HEROIC (Heparin Requirement in Counterpulsation)|Heparin Requirement in Counterpulsation|HEROIC|William Beaumont Hospitals||Completed|January 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2013|January 20, 2013|March 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445211||173537|
NCT00451217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05960|Comparison of Org 25969 With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (19.4.301)(P05960)|A Multi -Center Randomized Parallel Group Comparative Active Controlled Safety Assessor Blinded Phase 3a Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agents of a Neuromuscular Block Induced by Rocuronium or Vecuronium at Reappearance of T2||Merck Sharp & Dohme Corp.|No|Completed|November 2005|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|March 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00451217||173083|
NCT00451230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000p 000323|Metabolic Effects of Cocaine|Elucidating the Role of the Hypothalamic-Pituitary-Adrenal (HPA) Axis in the Mechanisms Underlying Cocaine Dependence||National Institute on Drug Abuse (NIDA)|No|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind||||15|||Both|21 Years|49 Years|No|||October 2002|April 30, 2013|March 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00451230||173082|
NCT00451997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0935|Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes|Phase II Trial of Gleevec and Low-Dose Ara-C for Elderly Patients With C-Kit Positive Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Completed|March 2004|April 2007|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|60 Years|N/A|No|||July 2012|July 31, 2012|March 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00451997||173025|
NCT00451724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0014-07|Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair|Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair||Rhode Island Hospital|Yes|Completed|May 2007|February 2010|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|45|||Both|1 Year|7 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|March 21, 2007||||No||https://clinicaltrials.gov/show/NCT00451724||173046|
NCT00451984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN2005/32|Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2||HEPVACHIV|Aalborg Universitetshospital|No|Recruiting|March 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2007|October 31, 2007|March 23, 2007||||No||https://clinicaltrials.gov/show/NCT00451984||173026|
NCT00452296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor450807ctil|Tight Glycemic Control in Acute Exacerbations of COPD|Tight Glycemic Control in Acute Exacerbations of COPD||Soroka University Medical Center|No|Active, not recruiting|April 2007|December 2012|Anticipated|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|84|||Both|45 Years|90 Years|No|||June 2012|June 25, 2012|March 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00452296||173002|
NCT00442455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 18729|Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck|Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck||Grupo de Investigación Clínica en Oncología Radioterapia|Yes|Active, not recruiting|January 2006|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|70 Years|No|||May 2015|May 7, 2015|March 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00442455||173748|
NCT00442468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC109043|Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath|An Evaluation of the Prevalence of Airway Obstruction Consistent With Chronic Obstructive Pulmonary Disease (COPD) in Subjects With a History of Cigarette Smoking and Symptoms of Chronic Bronchitis in a Primary Care Setting||GlaxoSmithKline||Completed|April 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1283|||Both|40 Years|N/A|No|Probability Sample|Male or female, ≥40 years of age, current or previous cigarette smokers with ≥10        pack-years of smoking history and self reported symptoms of chronic bronchitis where        chronic bronchitis.|October 2012|January 4, 2013|March 1, 2007||||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00442468||173747|
NCT00472394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTP|Determining Women's Preferences for Medical Abortion Using Willingness to Pay|||University of Pittsburgh|No|Completed|October 2006|June 2007|Actual|||N/A|Observational|Time Perspective: Cross-Sectional|||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|August 17, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472394||171491|
NCT00472407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004H0161|Eye Teaming Evaluation Study|||Ohio State University||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|72|||Both|9 Years|30 Years|Accepts Healthy Volunteers|||July 2008|July 1, 2008|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00472407||171490|
NCT00442988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NODAT|Prediction of NODAT After Renal Transplantation|Early Prediction of New Onset Diabetes Mellitus After Transplantation (NODAT) in Renal Transplantation: Use of Oral Glucose Tolerance Test (OGTT) and Fasting Plasma Glucose (FPG).||Katholieke Universiteit Leuven|No|Completed|October 2000|October 2005||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||360|||Both|18 Years|75 Years|No|||March 2007|March 2, 2007|March 2, 2007||||No||https://clinicaltrials.gov/show/NCT00442988||173707|
NCT00443274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIFS001|Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms||BIFS|Allergan||Recruiting|November 2006|October 2026|Anticipated|October 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|57000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with breast implants for augmentation, reconstruction, or revision of augmentation        or reconstruction|March 2016|March 7, 2016|March 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443274||173685|
NCT00442663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F050629003|Trial of Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction|Randomized Trial of Transcervical Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction|FOLEYEASI|University of Alabama at Birmingham|No|Completed|June 2003|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||170|||Both|15 Years|45 Years|Accepts Healthy Volunteers|||April 2007|April 23, 2007|February 28, 2007||||No||https://clinicaltrials.gov/show/NCT00442663||173732|
NCT00442923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P50DA018165|"The Evaluation of Stimulant Withdrawal"|Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse|MARC|Oregon Health and Science University|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|March 2, 2007|||This study was withdrawn for lack of progress. No subjects were recruited.|No||https://clinicaltrials.gov/show/NCT00442923||173712|
NCT00443170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YAK106752|A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects|A Randomized, Blinded, Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3/DYRK3 Inhibitor GSK626616AC in Healthy Subjects||GlaxoSmithKline|No|Completed|November 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00443170||173693|
NCT00443820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSFO327N2302|Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail|A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis||Novartis|No|Completed|December 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|526|||Both|12 Years|75 Years|No|||March 2011|March 22, 2011|March 2, 2007|Yes|Yes||No|January 19, 2011|https://clinicaltrials.gov/show/NCT00443820||173643|
NCT00444054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-064|The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer|Pilot Feasibility Study Of A Low Carbohydrate Diet In Patients With Advanced Cancer|RECHARGE|Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|February 2006|May 2012|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|N/A|No|||September 2012|September 24, 2012|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444054||173625|
NCT00444301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-117PCER|Pain Assessment, Incidence & Nature in Heart Failure|Investigating Pain in Heart Failure Patients|PAIN-HF|PC-HEART|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|349|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with advanced heart failure|June 2008|June 8, 2008|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444301||173606|
NCT00450372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20030698|Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery|Clinical Protocol for Phase II Testing of ADI-PEG 20 in Patients With Metastatic Melanoma||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|June 2004|February 2012|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 20, 2007|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT00450372||173148|Of the 38 subjects enrolled, only 10 were ASS-positive and 17 were ASS-negative. The remaining 11 subjects, who declined pre-treatment biopsies, were not assessed.
NCT00444912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD31002113|The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)|A Pilot Cohort Study of AMD3100 in Combination With G-CSF and Rituximab Compared With AMD3100 in Combination With G-CSF Alone for Mobilization of BPCs in Patients With Relapsed or Refractory NHL or HD Prior to Autologous HPC Transplant||Sanofi|Yes|Completed|February 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|March 7, 2007|Yes|Yes||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00444912||173560|
NCT00444925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221008|Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)|12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)||Pfizer|No|Completed|April 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1712|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|March 6, 2007|Yes|Yes||No|July 14, 2009|https://clinicaltrials.gov/show/NCT00444925||173559|
NCT00456573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002 (14437B)|Cytokine Profiles in Children With Obstructive Sleep Apnea|Local and Systemic Cytokine Profiles in Children With Obstructive Sleep Apnea and Controls||University of Chicago|No|Recruiting|April 2006|December 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Months|12 Years|Accepts Healthy Volunteers|||June 2008|June 2, 2008|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456573||172681|
NCT00456586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-005|12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa|A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|April 2002|May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||180|||Both|30 Years|N/A|No|||April 2007|June 22, 2010|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456586||172680|
NCT00456859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-KD ver.3|Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease|Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease (CAP-KD)|CAP-KD|Institute for Health Outcomes and Process Evaluation Reseach|Yes|Completed|April 2004|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||450|||Both|20 Years|N/A|No|||October 2007|October 17, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456859||172659|
NCT00426062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4116-AD-CTIL|Free Radical Level in SCC of Tongue Patients Tumor, Serum and Saliva|||Sheba Medical Center||Recruiting||||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A||||February 2007|February 18, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426062||174985|
NCT00426075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/98|Full-Leg vs Below-Knee Elastic Stockings for Prevention of the Post-Thrombotic Syndrome|||University of Padova||Completed|January 2006|||November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|N/A|No|||June 2008|June 9, 2008|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426075||174984|
NCT00457353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTER_L_01486|ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children|Phase III Comparative Study to Assess the Efficacy and Safety of Oral Rehydration Therapy (ORT) in Combination With Spores of Bacillus Clausii (Enterogermina)Versus ORT Alone, Administered for 5 Days With the Treatment of Acute Diarrhea in Children.|ENIGMA|Sanofi|No|Completed|March 2007|||December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|264|||Both|6 Months|5 Years|No|||January 2009|January 20, 2009|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457353||172621|
NCT00457652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rosuva01|Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?|Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?||Radboud University|Yes|Completed|June 2007|November 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457652||172598|
NCT00427271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-353|Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients|Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study||Hospital de Clinicas de Porto Alegre||Recruiting|March 2003|January 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|30 Years|80 Years|No|||January 2007|January 26, 2007|January 26, 2007||||No||https://clinicaltrials.gov/show/NCT00427271||174895|
NCT00438841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000536219|Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma|A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients||National Cancer Institute (NCI)||Active, not recruiting|August 2006|||December 2008|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|February 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00438841||174025|
NCT00439101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03499|A Randomized Clinical Trial of Megestrol Acetate as an Appetite Stimulant in Malnourished Children With Cancer|A Randomized, Double Blind, Placebo-Controlled Trial of Megestrol Acetate as an Appetite Stimulant in Malnourished Children With Cancer||University of British Columbia|No|Completed|April 2007|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|N/A|18 Years|No|||July 2012|July 11, 2012|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439101||174006|
NCT00457847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1380|Identifying Genetic Characteristics That Increase the Risk of Developing Primary Graft Dysfunction Following Lung Transplantation|Genetics of Primary Graft Dysfunction||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|February 2007|February 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1150|Samples With DNA|Blood samples|Both|15 Years|65 Years|No|Probability Sample|Patients going under lung transplant or heart & lung transplants|July 2009|July 14, 2009|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457847||172583|
NCT00458562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6113|Identifying Genes That Predict Risk of Developing Cervical Intraepithelial Neoplasia or Invasive Cervical Cancer|HIV-Associated DNA Hypermethylation in Cervical Cancer||University of Washington|No|Completed|January 2006|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1680|Samples With DNA|Cervical brush in PreservCyt, cervical swab in STM, cervical swab in Roche media, whole      blood, void urine, cervical tissue biopsy.|Female|18 Years|N/A|No|Non-Probability Sample|All study participants will be African women presenting to the clinical sites in Dakar,        Senegal. Subjects will be representative of ethnic and racial groups living in Senegal.|November 2013|November 15, 2013|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458562||172528|
NCT00454714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBK091|Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm|Application of Sildenafil in Patients With Documented Coronary Vasospasm to Explore the Pathophysiology of Coronary Vasospasm and the Therapeutic Effect of Sildenafil in Patients Suffering From Coronary Vasospasm||Robert Bosch Gesellschaft für Medizinische Forschung mbH|No|Suspended|March 2007|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|50 Years|N/A|No|||October 2015|October 27, 2015|March 29, 2007||No|Patient study insurance expired|No||https://clinicaltrials.gov/show/NCT00454714||172820|
NCT00454688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMP2003|Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome|A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of Asimadoline in Subjects With Irritable Bowel Syndrome||Tioga Pharmaceuticals|No|Completed|August 2006|December 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|596|||Both|18 Years|79 Years|No|||October 2011|October 17, 2011|March 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454688||172822|
NCT00454701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0485-CL-0001|Assessment and Tracking of Long-term Alefacept Safety|Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)|ATLAS|Astellas Pharma Inc|Yes|Terminated|June 2003|February 2012|Actual|February 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1897|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with alefacept for chronic plaque psoriasis|December 2013|December 10, 2013|March 29, 2007|No|Yes|The Sponsor has made a decision, driven by business needs, to cease promotion, manufacturing,    distribution and sales of Amevive|No||https://clinicaltrials.gov/show/NCT00454701||172821|
NCT00454935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-GLIO-LEV|Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy|Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy||VU University Medical Center|No|Recruiting|April 2007|October 2008|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Blood Tumor tissue|Both|18 Years|N/A|No||Consecutive adult (> 18 years) glioma patients who suffer from partial seizures, with or        without secondary generalisation, preoperatively. Patients must have undergone surgery for        their newly diagnosed or recurrent glioma not more than 42 days previously and be treated        with levetiracetam monotherapy at the time of inclusion.|June 2008|June 6, 2008|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00454935||172805|
NCT00455533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-100|Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer|A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer||Bristol-Myers Squibb|No|Completed|October 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|384|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|April 2, 2007|Yes|Yes||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00455533||172760|
NCT00455507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-0608|A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study)||Kyowa Hakko Kirin Company, Limited|No|Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|363|||Both|20 Years|N/A|No|||August 2012|August 28, 2012|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455507||172762|
NCT00455741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000P-002496|Postmenopausal Women Estrogen and Progesterone Infusion|Effect of Age on Gonadotropin Responses to Short-Term Negative and Positive Feedback Effects of Gonadal Steroids Using PET Scanning||Massachusetts General Hospital|Yes|Active, not recruiting|November 2000|January 2018|Anticipated|February 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|April 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455741||172744|
NCT00455754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYNEX|Esomeprazole Treatment for Patients With Lymphocytic Gastritis|Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on the Efficacy of Esomeprazole Treatment for Patients With Lymphocytic Gastritis|LYNEX|Technische Universität Dresden|Yes|Recruiting|February 2007|December 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|80 Years|No|||February 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00455754||172743|
NCT00425503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11047|PS-341 Followed by Removal of Prostate for Those With Prostate Cancer|H-11047: A Study of PS-341 Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate (Spore #: 11-01-30-13)||Baylor College of Medicine||Completed|December 2001|December 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||April 2014|April 3, 2014|January 22, 2007|No|Yes||No|February 15, 2014|https://clinicaltrials.gov/show/NCT00425503||175027|
NCT00425763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-5022|Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria|Efficacy of Amodiaquine-artesunate in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children at an IPTi Site in Rural Western Kenya|IPTi DRWG|Centers for Disease Control and Prevention|No|Completed|May 2007|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Both|6 Months|59 Months|No|||April 2012|April 4, 2012|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425763||175007|
NCT00426374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yael11-HMO-CTIL|Assessment of Asymptomatic Heart Disease in Children With HIV|Evaluation of the Cardiac Complications in Congenitally HIV-1 Infected Children in Israel by the Echocardiography and Measurement of N-Terminal Pro-B-Type Natriuretic Peptide (N-BNP).||Hadassah Medical Organization||Not yet recruiting|January 2007|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||January 2007|January 31, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426374||174963|
NCT00426686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO51064|ADAMTS13 in Thrombotic Thrombocytopenic Purpura|ADAMTS13-related Prognostic Factors in Adult and Pediatric Thrombotic Thrombocytopenic Purpura|ADAMTS13|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2006|April 2011|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|153|Samples With DNA|March 2010|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult and pediatric patients with TTP related to a severe ADAMTS13 deficiency.|April 2011|December 11, 2012|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00426686||174940|
NCT00426699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE002|Urinary Excretion of Enteroviruses From Children With a Presumed Enteroviral Infection|||University Hospital Inselspital, Berne||Completed|June 2006|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|82|||Both|N/A|16 Years|No|Non-Probability Sample|children age 0-16|May 2011|May 18, 2011|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00426699||174939|
NCT00427024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTX + Transport|Renal Transporters After Renal Transplantation|Study of Renal Transporters and Their Regulators After Renal Transplantation||University Hospital Muenster||Not yet recruiting|February 2007|February 2009||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||200|||Both|18 Years|N/A|No|||February 2007|February 5, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427024||174914|
NCT00438347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0102|Influence of Fitness on Brain and Cognition|Influence of Fitness on Brain and Cognition||University of Illinois at Urbana-Champaign|Yes|Recruiting|April 2006|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|140|||Both|60 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults over 60|March 2014|March 29, 2014|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438347||174062|
NCT00438607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204PD202|Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa||Biogen|Yes|Completed|April 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|83|||Both|30 Years|N/A|No|||July 2009|July 10, 2009|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438607||174043|
NCT00439114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA05/207|Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze|Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze||Baskent University||Completed|July 2005|June 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|18 Years|71 Years|Accepts Healthy Volunteers|||February 2007|February 21, 2007|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00439114||174005|
NCT00439127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOSI-MN-1-07|OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation|Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma?||Oncology Institute of Southern Switzerland||Completed|January 2005|January 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||28|||Both|N/A|N/A|No|||February 2007|February 27, 2007|February 22, 2007||||No||https://clinicaltrials.gov/show/NCT00439127||174004|
NCT00458341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-006-CF|PTC124 for Pediatric Patients With Cystic Fibrosis|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis||PTC Therapeutics|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|6 Years|18 Years|No|||April 2009|April 1, 2009|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00458341||172545|
NCT00458354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0641|Use of Spinal Sealant System During Spinal Surgery|A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery||M.D. Anderson Cancer Center|Yes|Completed|January 2006|December 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|75 Years|No|||October 2011|October 10, 2011|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00458354||172544|
NCT00454753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-109|Korean Early Access Program|Study of Dasatinib (BMS-354825) in Subjects With Chronic Phase or Advanced Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant to or Intolerant of Imatinib Mesylate||Bristol-Myers Squibb||Approved for marketing|May 2007|||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||May 2010|May 7, 2010|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00454753||172818|
NCT00458575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013210|A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa|A Phase I Open Label Non-comparative Study Evaluating the Safety of a Single, Unilateral, Subretinal Administration of CNTO 2476 in Advanced Retinitis Pigmentosa||Centocor, Inc.|Yes|Terminated|April 2007|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|April 10, 2007|No|Yes|Internal Business Decision|No||https://clinicaltrials.gov/show/NCT00458575||172527|
NCT00454948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DK073377-01|Nutrition Intervention and Play Group Exercise for Low-Income Latinas|Home Based Nutrition Intervention Nad Play Group Exercise for Low-Income Latinas|CHICOS|Stanford University|Yes|Recruiting|March 2007|August 2009|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||250|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2007|March 30, 2007|March 29, 2007||||No||https://clinicaltrials.gov/show/NCT00454948||172804|
NCT00454961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC-2007|Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania|Effectiveness of Artemether-Lumefantrine Treatment Provided by Community Health Worker Against Uncomplicated Malaria in Children Under 5 Years of Age in Tanzania|C3|Karolinska University Hospital||Completed|April 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|N/A|5 Years|No|||October 2007|October 24, 2007|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00454961||172803|
NCT00455221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|418-A-2209|Safety Assessment of a Multipeptide-gene Vaccine in CML|Safety Assessment of a Peptide Vaccine Derived From Bcr-abl Along With Cytokine Genes in CML Patients Undergoing Imatinib Treatment||Tehran University of Medical Sciences|Yes|Completed|February 2008|November 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||May 2012|May 31, 2012|March 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00455221||172783|
NCT00455520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012466|A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy|A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects With Painful Diabetic Peripheral Neuropathy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|395|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|April 1, 2007|No|Yes||No|August 19, 2009|https://clinicaltrials.gov/show/NCT00455520||172761|
NCT00455546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-CVD-2221|PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease|PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease|PLASMA|Anthera Pharmaceuticals|No|Completed|April 2007|September 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|400|||Both|18 Years|N/A|No|||January 2008|February 1, 2010|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00455546||172759|
NCT00455767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEB-EPIV-201|Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients|Phase IIA Multicenter 1 Week Treatment, Randomised, Double-Blind, Placebo Controlled Study of Depelestat in Patients Suffering From Acute Respiratory Distress Syndrome||Debiopharm International SA|Yes|Completed|July 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||June 2008|June 23, 2008|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00455767||172742|
NCT00456001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001982|Heparin Induced Thrombocytopenia: Pharmacoeconomics|Study to Compare the Heparin Induced Thrombocytopenia Rates Associated With Heparin and Low Molecular Weight Heparin Usage as Well as Evaluate the Economic and Long-Term Clinical Burden of Heparin Induced Thrombocytopenia.||Brigham and Women's Hospital|Yes|Completed|July 2006|January 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|All patients hospitalized at BWH who have a PF4-Positive antibody test|February 2009|February 26, 2009|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456001||172724|
NCT00456274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999P-003770|Baselines in Reproductive Disorders|Baselines in Reproductive Disorders||Massachusetts General Hospital|Yes|Recruiting|September 1999|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|180|||Female|16 Years|45 Years|No|||July 2014|July 31, 2014|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456274||172704|
NCT00425516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJP AU651/Afssaps060744|Breast Cancer Treated by Neoadjuvant Chemotherapy|Clinical Trial of the Neoadjuvant Standard Chemotherapy 3 FEC 100 + 3 TAXOTERE Protocol Versus the Same Protocol Adapted as a Function of Clinical Response||Centre Jean Perrin||Completed|January 2007|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|264|||Female|18 Years|70 Years|No|||February 2007|September 30, 2014|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425516||175026|
NCT00426101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLH-2004|Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004|HLH-2004 Treatment Protocol||Karolinska University Hospital|Yes|Active, not recruiting|January 2004|December 2016|Anticipated|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|18 Years|No|||September 2015|September 14, 2015|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426101||174983|
NCT00425776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K07-01|Treatment of Hot Flushes in Breast Cancer Patients With Acupuncture|||Vejle Hospital|No|Completed|February 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|94|||Female|35 Years|N/A|No|||August 2015|August 20, 2015|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425776||175006|
NCT00426712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-09|Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients|A Phase 1, Randomized, Observer-blind, Dose-escalating Study in Adult End-stage Renal Failure Patients to Explore the Safety, Tolerability, Pharmacokinetics and Immune Response to Recombinant Hepatitis B Virus Surface Antigen (rHBsAg) Co-administered With Dynavax Immunostimulatory Phosphorothioate Oligodeoxyribonucleotide (1018 ISS)||Dynavax Technologies Corporation|Yes|Completed|January 2006|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|42|||Both|40 Years|N/A|No|||August 2015|February 26, 2016|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426712||174938|
NCT00426725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACUMT-07-KS-3811-CTIL|Testing the Efficiency of a Device Meant to Relieve Labour Pain|Protocol for Testing the Efficiency of a Device Meant to Relieve Labour Pain||ACU Medical Technologies Ltd|No|Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 30, 2008|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426725||174937|
NCT00426738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-0686|Neoadjuvant Gemcitabine, Oxaliplatin, and Radiation Therapy for Pancreatic Cancer|A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|December 2006|||March 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|January 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426738||174936|
NCT00426400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3876-HLV-CTIL|Anti-Aggregative Therapy and Laser Iridectomy|||Sheba Medical Center||Recruiting|March 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|N/A|No|||January 2007|January 23, 2007|October 25, 2006||||No||https://clinicaltrials.gov/show/NCT00426400||174962|
NCT00427050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-007|A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel|An Open-label, Multi-centre, Dose-escalation, Cohort Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel When Applied to a 25 cm2 Contiguous Actinic Keratoses Treatment Area on the Face or Face and Scalp.||Peplin||Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||December 2008|September 11, 2015|January 24, 2007||||No||https://clinicaltrials.gov/show/NCT00427050||174912|
NCT00427037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D-2006|Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects|Efficacy of Cholecalciferol (Vitamin D3) Therapy in Correcting Vitamin D Insufficiency and Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease: A Randomized, Placebo Controlled Pilot Study||Atlanta VA Medical Center|No|Completed|December 2005|March 2013|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|85 Years|No|||July 2015|July 20, 2015|January 24, 2007||No||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00427037||174913|
NCT00438360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400CIT04|Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis|A 24-week, Double-blind, Randomized, Placebo-controlled, Multicenter Study, to Evaluate the Effectiveness of Cyclosporine 2,5 mg/kg/Day Bid Twice a Week on Reducing Relapse Rate, in Maintenance Patients With Chronic Plaque Psoriasis||Novartis||Completed|May 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|65 Years||||July 2011|July 13, 2011|February 21, 2007||No||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00438360||174061|
NCT00438620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-08-0054|The Feasibility of Physical Activity in Advanced Cancer Patients|A Pilot Study to Explore the Role of Physical Activity as a Quality of Life Intervention in Advanced Cancer Patients||AHS Cancer Control Alberta||Completed|October 2006|||November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Advanced Cancer Patients|January 2012|February 24, 2016|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438620||174042|
NCT00439439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1427/05|ACHAT-STUDY, Alternative Treatment of Chronic Globus Sensations|ACHAT-STUDY: Argon-Beamer-Ablation of Cervical Heterotopic Gastral Mucosa, an Alternative Treatment of Chronic Globus Sensations - "Sham-Controlled" Multicenter Study||Technische Universität München||Completed|October 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||May 2008|May 19, 2008|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439439||173980|
NCT00457873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-06-016|Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy|Isotonic Versus Hypotonic Saline for Maintenance Intravenous Fluid Therapy: A Pilot Randomized Trial||McGill University Health Center||Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|1 Month|18 Years|No|||May 2008|May 20, 2008|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457873||172581|
NCT00458107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153A1-1115|Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SCA-136 Administered Orally to Healthy Japanese and Non-Japanese Female Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2007|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|64|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|April 5, 2007||||||https://clinicaltrials.gov/show/NCT00458107||172563|
NCT00455247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.23.CLI|Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects|||Nestlé||Completed|October 2007|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||June 2013|June 4, 2013|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00455247||172781|
NCT00455260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-VD-102|A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study, to Assess Tolerability, Safety, Pharmacokinetic and Pharmacodynamic Profiles of hGH-ViaDerm™ System in Adult Subjects With Growth Hormone Deficiency||Teva Pharmaceutical Industries|No|Completed|April 2007|||October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|20 Years|60 Years|No|||April 2009|August 30, 2013|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455260||172780|
NCT00423592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB-222|Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension|A Phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects With Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities||Gilead Sciences||Completed|May 2005|March 2009|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|12 Years|75 Years|No|||June 2013|June 7, 2013|January 17, 2007|Yes|Yes||No|May 14, 2010|https://clinicaltrials.gov/show/NCT00423592||175170|Seven subjects were excluded from the change from baseline analysis of the SF-36 Health Survey because the incorrect version of the SF-36 questionnaire was used for evaluation at baseline, which made comparisons problematic.
NCT00423605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-010|Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.|A Long-Term, Open-Label, Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.||Jazz Pharmaceuticals|No|Completed|December 2006|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|560|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|January 16, 2007|Yes|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00423605||175169|
NCT00454740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-006|Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder|An Open-Label Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients Who Wish to Switch From Detrol LA® (Tolterodine Tartrate Extended Release) for the Treatment of Overactive Bladder Symptoms Versus: VESIcare® Efficacy and Research Study US|VERSUS|Astellas Pharma Inc|No|Completed|June 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|441|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|March 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00454740||172819|
NCT00454974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD7465|Pilot Study of Wearable Artificial Kidney|Preliminary Study to Assess the Safety and Efficacy of a Wearable Artificial Kidney Device for the Treatment of Patients With Endstage Renal Failure|WAK|Royal Free Hampstead NHS Trust|Yes|Completed|March 2007|March 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8|||Both|18 Years|75 Years|No|||March 2007|March 30, 2007|March 29, 2007||||No||https://clinicaltrials.gov/show/NCT00454974||172802|
NCT00455234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22F484|Rapid Tranquillization Trial: TREC-India II|Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine.|TRECIndia-II|Christian Medical College, Vellore, India|No|Completed|September 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||March 2007|April 2, 2007|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00455234||172782|
NCT00424515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-056|Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma|A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.|BUS255|Dana-Farber Cancer Institute|Yes|Active, not recruiting|July 2006|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00424515||175100|
NCT00424827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM200602|A Trial of Chemo & Radiation Therapy for Pancreatic Cancer|A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma||University of Massachusetts, Worcester|No|Completed|June 2006|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||April 2015|April 7, 2015|January 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00424827||175076|
NCT00424840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM200601|Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy|Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer||University of Massachusetts, Worcester|No|Completed|June 2006|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|January 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00424840||175075|
NCT00425126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-4044|Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation|Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation||West Penn Allegheny Health System||Completed|February 2007|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|76|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00425126||175055|
NCT00425139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-04-001|Evaluation of a Video Game for Adolescents and Young Adults With Cancer|Multi-site Evaluation of a Video Game for Adolescents and Young Adults With Cancer||HopeLab Foundation||Completed|October 2004|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||375|||Both|13 Years|29 Years|No|||January 2007|March 19, 2015|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425139||175054|
NCT00426114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/016|Acute Haemodynamic Impact of an IV Glucose-Injection|Acute Haemodynamic Impact of an IV Glucose-Injection||University Hospital, Ghent|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 9, 2009|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426114||174982|
NCT00426764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPI-06-0002|A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma|A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)||Celgene|Yes|Active, not recruiting|June 2007|December 2016|Anticipated|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|January 23, 2007|Yes|Yes||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00426764||174934|
NCT00427063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danish Twin Registry 1998|Heredity of Retinal Vessel Tortuosity|Heredity of Retinal Vessel Tortuosity - A Twin Study||Glostrup University Hospital, Copenhagen||Completed|January 1998|December 1998||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||218|||Both|20 Years|46 Years|Accepts Healthy Volunteers|||January 2007|January 25, 2007|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00427063||174911|
NCT00427284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1033|Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease|||University of Zurich||Completed|July 2004|||||Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|42|||Both|30 Years|80 Years|No|Probability Sample|Patients with coronary heart disease|December 2011|December 22, 2011|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427284||174894|
NCT00438893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 03-043|Effects of a Long Term Dietary Portfolio and of Sequential Removal of Food Components From the Diet|The Long-Term Effect of Viscous Fibers, Soy Protein, and Plant Sterol Foods in Combination on Serum Cholesterol and Other Risk Factors for Cardiovascular Disease||University of Toronto|No|Active, not recruiting|January 2004|||April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 22, 2013|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438893||174021|
NCT00439153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03184|Minimizing Tourniquet Pressures in Paediatric Orthopaedic Knee Surgery|Quality of Surgical Field in Reconstructive Anterior Cruciate Ligament Surgery: Comparison of Tourniquet Cuff Pressure Determined by an Automated Limb Occlusion Pressure Measurement to a Standard Pressure of 300 mm Hg.||University of British Columbia||Completed|September 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|41|||Both|N/A|18 Years|No|||October 2011|October 12, 2011|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00439153||174002|
NCT00438906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3 P50CA062924-13SB|Cancer of the Pancreas Screening Study (CAPS 3)|Screening for Early Pancreatic Neoplasia|CAPS 3|Johns Hopkins University|Yes|Completed|December 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|approx 40 ml of blood, approx 10 ml pancreatic juice, pancreatic cells if fine needle      aspirate is clinically recommended|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|People at risk for developing pancreatic cancer related to a strong family history of        pancreatic cancer or carries a known genetic mutations associated with pancreatic cancer|February 2016|February 25, 2016|February 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00438906||174020|
NCT00439192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELB245201-06|ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)|A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)||elbion AG||Terminated|February 2007|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|275|||Both|18 Years|N/A|No|||August 2007|August 7, 2007|February 22, 2007|||side effect profile did not match expectations|No||https://clinicaltrials.gov/show/NCT00439192||173999|
NCT00458588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000538232|Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children|Adolescent Diet, Hormones and Breast Cancer Susceptibility||Fox Chase Cancer Center||Active, not recruiting|September 2005|||October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|301|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Adolescent females|March 2016|March 1, 2016|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458588||172526|
NCT00458601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX110-003|Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme|A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|ACT III|Celldex Therapeutics|No|Active, not recruiting|August 2007|December 2016|Anticipated|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|April 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458601||172525|
NCT00423293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0529|Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer|A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal||Radiation Therapy Oncology Group|Yes|Active, not recruiting|December 2006|||February 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|January 16, 2007|Yes|Yes||No|April 11, 2013|https://clinicaltrials.gov/show/NCT00423293||175192|
NCT00423306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL2005|A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma|A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma||Ziopharm||Active, not recruiting|January 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423306||175191|
NCT00423618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-VORTEX|Radiation Therapy in Treating Patients Who Have Undergone Surgery for Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet|Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX]||National Cancer Institute (NCI)||Completed|March 2006|July 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|400|||Both|16 Years|N/A|No|||December 2007|August 9, 2013|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00423618||175168|
NCT00423631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD 17-002-0018, A-9356.1|Web-based Education to Enhance Fibromyalgia Management|Internet-Enhanced Management of Fibromyalgia||University of Michigan|No|Completed|September 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|70 Years|No|||October 2011|October 6, 2011|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423631||175167|
NCT00423891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-028|A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection|Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive||Bristol-Myers Squibb|No|Active, not recruiting|June 2007|October 2017|Anticipated|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|2 Years|18 Years|No|||October 2015|October 7, 2015|January 16, 2007|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00423891||175147|
NCT00424177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA108057|Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)|An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP)||GlaxoSmithKline|No|Completed|March 2007|November 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||May 2012|July 25, 2013|January 17, 2007||||No|June 23, 2009|https://clinicaltrials.gov/show/NCT00424177||175126|
NCT00424190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-06|Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection|cSSSI|Forest Laboratories|No|Completed|February 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|698|||Both|18 Years|N/A|No|||November 2010|November 23, 2010|January 16, 2007|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00424190||175125|
NCT00424502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20538|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.|An Open-label Study to Evaluate the Effect of MabThera on Treatment Response in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Previous TNF Inhibition.||Hoffmann-La Roche||Completed|January 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|January 18, 2007||No||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00424502||175101|
NCT00424528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-902|Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)|A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Once Daily in Subjects With Chronic Obstructive Pulmonary Disease||Sunovion|No|Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|235|||Both|45 Years|N/A|No|||May 2012|May 29, 2012|January 17, 2007|No|Yes||No|October 24, 2008|https://clinicaltrials.gov/show/NCT00424528||175099|As of October 24, 2008, Sepracor is unaware of any limitations or caveats associated with this study.
NCT00424853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976B_2506|ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)|Randomized Phase II Trial of Two Sequential Schedules of Docetaxel and Cisplatin Followed by Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer.||Sanofi||Completed|May 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|70 Years|No|||December 2009|December 4, 2009|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00424853||175074|
NCT00424866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVBT-2006-PAD-01|FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease|A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication||CardioVascular BioTherapeutics, Inc.|No|Not yet recruiting|December 2014|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|24|||Both|50 Years|75 Years|No|||November 2014|November 7, 2014|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00424866||175073|
NCT00424892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A4-330|Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome|A 6-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Fibromyalgia Syndrome.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed||June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|N/A|No|||December 2007|December 4, 2007|January 18, 2007||||||https://clinicaltrials.gov/show/NCT00424892||175072|
NCT00425152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP C-04|Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer|A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon||NSABP Foundation Inc|Yes|Completed|July 1989|April 2004|Actual|June 1998|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||Actual|2151|||Both|N/A|70 Years|No|||February 2010|February 5, 2010|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425152||175053|
NCT00426777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-CMX-01|Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer|A Randomized, Single-blind, Placebo-controlled, Multicentre Study to Evaluate the Effect of Risedronate and Placebo on Bone Mineral Density in Men Undergoing Androgen Deprivation Therapy With Leuprolide Acetate||CMX Research|No|Completed|January 2007|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|160|||Male|18 Years|N/A|No|||February 2012|February 2, 2012|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00426777||174933|
NCT00426413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024857|Ketosis Prone Diabetes in African-Americans|Ketosis Prone Diabetes Mellitus in African-Americans: Insulin Signaling, Proteomics, and Outcomes||Emory University|Yes|Completed|May 2007|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|44|Samples With DNA|The study has IRB approval for blood sample collection for future DNA analyses and HLA      typing.|Both|19 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|36 Obese AA subjects with DKA or severe hyperglycemia and 8 obese nondiabetic subjects,        age 19-65.|November 2013|November 12, 2013|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00426413||174961|
NCT00426751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106915|Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)|Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction||GlaxoSmithKline||Completed|October 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|429|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|January 24, 2007||No||No|April 6, 2010|https://clinicaltrials.gov/show/NCT00426751||174935|
NCT00427297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30200-D|Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya|Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT)||University of Washington|Yes|Terminated|September 2007|December 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|6 Months|18 Months|No|||March 2010|March 16, 2010|January 22, 2007||No|There is no longer equipoise.|No||https://clinicaltrials.gov/show/NCT00427297||174893|
NCT00422786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP_CAP001|Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma|A Multi-Centre, Open Label, Phase II Study of the Safety, Efficacy and Pharmacokinetic (PK) Profile of CAP-232 Administered Through Continuous Intravenous Infusion in Patients With Metastatic Kidney Cancer||Thallion Pharmaceuticals|Yes|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2008|July 10, 2008|January 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00422786||175231|
NCT00438399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29064|Subject Preference for Scalp Psoriasis Treatment|Subject Preference Comparison Between Clobetasol Propionate Shampoo, 0.05% and Three Other Topical Corticosteroids in the Treatment of Moderate to Severe Scalp Psoriasis||Galderma|No|Completed|February 2007|February 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|219|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|February 21, 2007||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00438399||174058|
NCT00438646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907109|Oral Bacteria and Allergic Disease in Children|Oral Bacteria and History of Allergic Disease in Children: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|February 2007|||December 2008|Actual|N/A|Observational|Time Perspective: Prospective||||60|||Both|6 Years|11 Years|No|||November 2008|August 24, 2009|February 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00438646||174040|
NCT00423345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23504|Colon Investigation - Factors Determining Choice of Procedure|Colon Investigation With Barium Enema, CT Colonography and Colonoscopy: A Prospective Registration of Indications, Delay and Procedure Results.||Sykehuset Telemark|Yes|Active, not recruiting|October 2006|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|750|||Both|18 Years|N/A|No|Non-Probability Sample|All patients referred for colonoscopy, barium enema or CT Colonoscopy and willing to        participate|August 2012|August 24, 2012|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00423345||175188|
NCT00423020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOC-AMI 2006|Anti-Restenosis After AMI by Erythropoietin|Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI)||Kyoto Prefectural University of Medicine||Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|20 Years|79 Years|No|||January 2007|January 16, 2007|January 16, 2007||||No||https://clinicaltrials.gov/show/NCT00423020||175213|
NCT00423917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0539|Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|August 2007|||February 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423917||175145|
NCT00424216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070066|Direct Current Brain Polarization of the Frontal Lobes|Direct Current Brain Polarization of Bilateral Prefrontal Cortex||National Institutes of Health Clinical Center (CC)||Completed|January 2007|December 2008||||Phase 1|Interventional|Primary Purpose: Treatment|1|||25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|September 26, 2015|January 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00424216||175123|
NCT00423904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1_P1|Brief Alcohol Intervention in General Hospitals|Implementing Early Intervention for Alcohol Use Disorders in the General Hospital||University Medicine Greifswald||Completed|October 2001|August 2005||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||1035|||Both|18 Years|64 Years||||January 2007|January 17, 2007|January 17, 2007||||No||https://clinicaltrials.gov/show/NCT00423904||175146|
NCT00424203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000523419|Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery|Multicenter Pilot Clinical Study of Adjuvant Chemotherapy for Subjects Over 70 Years: Impact on the Independence and Quality of Life of the Administration of Anthracycline-Based Chemotherapy in Adjuvant Setting for Patients Presenting With Immediately Operable Breast Cancer, Hormone Receptor Negative (RH-), and Lymph Node Positive (pN+) or pN0 But of Scarff-Bloom-Richardson* Grade III and ≥ 2cm [GERICO]||UNICANCER|No|Completed|January 2006|November 2011|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|70 Years|N/A|No|||September 2013|September 2, 2013|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00424203||175124|
NCT00425165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-111|Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease|A Randomized, Double-Blind, Two Way Crossover Evaluation of the Effects of a Single Dose of Denufosol Tetrasodium (INS37217) Inhalation Solution Versus Placebo (0.9% Sodium Chloride Solution) on Mucociliary Clearance in Patients With Mild to Moderate Cystic Fibrosis Lung Disease||Merck Sharp & Dohme Corp.|No|Terminated|August 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|6|||Both|10 Years|N/A|No|||March 2015|March 17, 2015|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425165||175052|
NCT00425178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVBT-W2005-01|FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers|A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Patients With Diabetic or Venous Stasis Ulcers||CardioVascular BioTherapeutics, Inc.||Completed|September 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||November 2007|January 7, 2008|January 18, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00425178||175051|
NCT00425529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.04.CLI|Tolerance and Practicality of Module AOX|Tolerance and Practicality of Module AOX - a Modular Device for Supplementation of Enteral Nutrition||VU University Medical Center||Completed|February 2002|May 2003||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care||||20|||Both|18 Years|75 Years|No|||January 2007|January 22, 2007|January 22, 2007||||No||https://clinicaltrials.gov/show/NCT00425529||175025|
NCT00425789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115/05|Hyperbaric Therapy and Deep Chemical Peeling|Hyperbaric Therapy and Healing From Deep Chemical Peel||Assaf-Harofeh Medical Center||Recruiting|January 2007|July 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||December 2005|April 4, 2011|January 22, 2007||||No||https://clinicaltrials.gov/show/NCT00425789||175005|
NCT00457977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|477|Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease|Pneumococcal Vaccine Response in COPD|PNEUMO|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|181|||Both|40 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 5, 2007|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00457977||172573|
NCT00458224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150089|Prevention of Permanent Obesity in Children|Prevention of Permanent Obesity in Children||Sykehuset Innlandet HF|No|Completed|February 2007|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|48|||Both|5 Years|7 Years|No|||June 2015|June 2, 2015|April 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00458224||172554|
NCT00458445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD465-311|A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators|A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)||Shire||Withdrawn|April 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|19 Years|25 Years|No|||April 2008|March 3, 2015|April 2, 2007|Yes|Yes|This study was stopped by the sponsor before enrollment based on a non-safety related    corporate decision.|No||https://clinicaltrials.gov/show/NCT00458445||172537|
NCT00427076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol V.3, dated 01.06.09|Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections|Treatment With Cotrimoxazole vs. Vancomycin for Infections Caused by Methicillin-resistant Staphylococcus Aureus: Randomized Controlled Trial||Rabin Medical Center|Yes|Completed|June 2007|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|100 Years|No|||September 2015|September 23, 2015|January 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00427076||174910|
NCT00427089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL 994-01/2004 (HSG)|Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening|Parallel Group Comparison of the New 2 Liter Gut Cleansing Solution NRL 994 Versus Sodium Phosphate Preparation in Routine Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening.||Norgine|No|Completed|September 2004|May 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2008|April 15, 2008|January 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00427089||174909|
NCT00427310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP C-02|Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery|A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon||NSABP Foundation Inc||Completed|March 1984|February 2001|Actual|September 1989|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1158|||Both|18 Years|N/A|No|||December 2012|December 31, 2012|January 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00427310||174892|
NCT00427323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0076|Light Exposure to Treat Sleep Disruption in Older People|Disrupted Sleep in the Elderly: Light Exposure Studies||National Institute on Aging (NIA)||Suspended|June 2006|September 2007|Anticipated|September 2007|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||September 2007|December 10, 2009|January 25, 2007||No|recruitment has been put on hold until a future date|No||https://clinicaltrials.gov/show/NCT00427323||174891|
NCT00423085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713D1301|Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease|A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)||Novartis||Completed|January 2007|April 2010|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|859|||Both|50 Years|85 Years|No|||January 2014|January 14, 2014|January 11, 2007|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00423085||175208|
NCT00423098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2420|Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare|A Randomized, Multicenter, Open-label, 6-month Study to Explore the Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare||Novartis||Completed|February 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|January 16, 2007||No||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00423098||175207|
NCT00438659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N06C4|Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ|Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy||Alliance for Clinical Trials in Oncology|No|Completed|August 2007|June 2014|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|176|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|February 20, 2007|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00438659||174039|
NCT00438919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC06-01|A Multi-center Post-Market Surveillance Registry|The e-SELECT Registry a MULTICENTER POST-MARKET SURVEILLANCE|E-SELECT|Cordis Corporation|Yes|Completed|May 2006|December 2009|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15000|||Both|N/A|N/A|No|||December 2009|December 2, 2009|February 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00438919||174019|
NCT00439179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-PA-205|A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema|BrUOG-PA-205 A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema GSK Study ProtocolGSK #103556|BrUOG-PA205|Brown University|Yes|Completed|July 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|February 22, 2007|Yes|Yes||No|May 13, 2013|https://clinicaltrials.gov/show/NCT00439179||174000|
NCT00423683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 06-034|Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism|A Randomized Control Trial of Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With A Venous Thromboembolism||Northwell Health|Yes|Terminated|January 2007|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|January 17, 2007|Yes|Yes|Study accrual stopped due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00423683||175163|
NCT00423657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-07|Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroloine Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI)||Forest Laboratories|No|Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|680|||Both|18 Years|N/A|No|||November 2010|November 23, 2010|January 16, 2007|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00423657||175165|
NCT00423930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-130|Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2006|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|January 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00423930||175144|
NCT00424229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-REV-2006-02|Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]|Phase II Study of the Efficacy and Safety of Lenalidomide in Adult Subjects With Intermediate-2-or Higt Risk Myelodysplastic Syndrome(MDS) Associated With a Deletion (DEL) 5q [31]||Groupe Francophone des Myelodysplasies|No|Recruiting|October 2006|October 2008||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||49|||Both|18 Years|N/A|No|||January 2007|March 9, 2007|January 15, 2007||||No||https://clinicaltrials.gov/show/NCT00424229||175122|
NCT00424567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI 55-0503-1|Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.|TRC Autologous Bone Marrow Cells for the Treatment of Appendicular Skeletal Fracture Non-Union||Vericel Corporation||Completed|October 2003|June 2007||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||36|||Both|18 Years|N/A|No|||January 2007|January 18, 2007|January 18, 2007||||Yes||https://clinicaltrials.gov/show/NCT00424567||175096|
NCT00424541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A1104|Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension|A Multiple Center, Randomized, Double Blind, Parallel Group, Multiple Oral Doses Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profiles of 150 mg and 300 mg of SPP100 in Japanese Patients With Mild to Moderate Essential Hypertension||Novartis||Completed|January 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|34|||Both|20 Years|80 Years|No|||November 2007|November 28, 2007|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00424541||175098|
NCT00424554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04602|Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)|A Phase II Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.||Merck Sharp & Dohme Corp.|No|Completed|September 2006|February 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||June 2015|June 11, 2015|January 18, 2007|No|Yes||No|June 3, 2011|https://clinicaltrials.gov/show/NCT00424554||175097|The assay developed to measure MGMT activity had high variability.The TMZ assay was unable to detect the low levels of the drug due to the relatively low dose and short half life of TMZ.
NCT00424905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0199|DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect|Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study.||Sanofi||Completed|December 2006|||December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|1 Year|5 Years|No|||November 2008|November 28, 2008|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00424905||175071|
NCT00425542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B0-112165|Safety Study of Outpatient Treatment for Pulmonary Embolism|Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial|OTPE|University of Lausanne Hospitals|Yes|Completed|January 2007|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|343|||Both|18 Years|N/A|No|||October 2009|June 10, 2010|January 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00425542||175024|
NCT00425555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2201|Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma|A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma||Novartis||Completed|January 2007|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425555||175023|
NCT00425802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-150|Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-Compatible Related or Unrelated Donors in Patients With B Cell Lymphoid Malignancies||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2006|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|70 Years|No|||April 2015|April 28, 2015|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00425802||175004|
NCT00425815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TURNS01|Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia|A Placebo-Controlled Trial of Org 24448 (Ampakine) Added to Atypical Antipsychotics in Patients With Schizophrenia||University of California, Los Angeles|No|Withdrawn|April 2009|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||February 2016|February 5, 2016|January 22, 2007|Yes|Yes|Study terminated at Sponsor's request.|No||https://clinicaltrials.gov/show/NCT00425815||175003|
NCT00426127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIEnox001|Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer|Phase II Trial of Docetaxel and Liposomal Doxorubicin (Doxil) Chemotherapy Combined With Enoxaparin in Patients With Advanced Pancreatic Cancer||University of Iowa||Terminated|November 2006|January 2009|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|27|||Both|18 Years|N/A|No|||March 2009|March 27, 2009|January 23, 2007||No|Inadequate number of eligible patients|No||https://clinicaltrials.gov/show/NCT00426127||174981|
NCT00458237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-124|Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer|A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|April 2007|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|April 9, 2007|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT00458237||172553|
NCT00458718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4798|Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch|Single Country, Double-Blind, Randomized, 2-Arm, Parallel-Group Study, Evaluating Efficacy and Safety of Rimonabant 20 mg OD, With/Without Association of Nicotine Patch, as Aid to Smoking Cessation During 9-Week Period|CIRRUS|Sanofi||Completed|September 2004|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|755|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|April 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00458718||172518|
NCT00458731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00184|Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma|Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|May 2007|||December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|15 Years|N/A|No|||December 2013|February 14, 2014|April 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00458731||172517|
NCT00458458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HD43281|Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)|Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|August 2004|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Female|18 Years|55 Years|No|||October 2012|October 24, 2012|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458458||172536|
NCT00458705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-067|Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma|Bortezomib + Pegylated Liposomal Doxorubicin (Doxil) + Dexamethasone Followed by Thalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone for Patients With Symptomatic Untreated High-Risk or Primary Resistant Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Completed|November 2006|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|120 Years|No|||December 2015|December 16, 2015|April 9, 2007|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00458705||172519|
NCT00454818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELL-001|Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure|A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts)|CUPID|Celladon Corporation|Yes|Completed|March 2007|August 2012|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|51|||Both|18 Years|75 Years|No|||August 2014|August 19, 2014|March 30, 2007|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00454818||172813|Limitations of this study include its small sample size and the inability to conclusively prove that the delivered gene was responsible for the observed clinical effects. Larger confirmatory trials are needed.
NCT00438932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P000486|Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease|Reduced Phosphate Intake in "Normo-Phosphatemic" Chronic Kidney Disease Patients||Massachusetts General Hospital|Yes|Completed|January 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|16|||Both|18 Years|80 Years|No|||September 2011|September 23, 2011|February 20, 2007||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00438932||174018|In addition to limited power, the small sample size led to imbalances in baseline laboratory tests, which added further variability to the analyses. .
NCT00439218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01NS42361_NPTUNE02|Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I|Phase I/IIa Clinical Trial of Sodium Phenylbutyrate in Pediatric Subjects With Type I Spinal Muscular Atrophy|NPTUNE 02|Westat|Yes|Terminated|January 2008|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Months|48 Months|No|||May 2009|October 27, 2010|February 22, 2007|Yes|Yes|Extremely slow enrollment|No|April 16, 2010|https://clinicaltrials.gov/show/NCT00439218||173997|This study was closed early due to slow accrual. The sample size is therefore extremely limited.
NCT00439491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303040158|Role of Adipose Tissue in Pathogenesis of Insulin Resistance|Role of Adipose Tissue in Pathogenesis of Insulin Resistance||Charles University, Czech Republic||Completed|January 2004|December 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||35|||Female|18 Years|60 Years|No|||February 2007|February 21, 2007|February 21, 2007||||No||https://clinicaltrials.gov/show/NCT00439491||173976|
NCT00439504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0012-1|Ph1 Lobeline Interaction Study - 1|Double-Blind, Placebo-Controlled, Cross-Over Assessment of Intravenous Methamphetamine and Sublingual Lobeline Interactions||National Institute on Drug Abuse (NIDA)||Recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2007|October 23, 2007|February 22, 2007||||||https://clinicaltrials.gov/show/NCT00439504||173975|
NCT00455832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS Study|Influence of Ribavirin and Interferon on Semen Quality, IRIS Study|Influence of Ribavirin and Interferon on Semen Quality, IRIS Study|IRIS|Foundation for Liver Research|No|Completed|November 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Male|18 Years|70 Years|No|Probability Sample|primary care clinic|February 2012|February 28, 2012|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455832||172737|
NCT00423670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03523|Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)|A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1||Merck Sharp & Dohme Corp.|Yes|Completed|January 2007|November 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|765|||Both|18 Years|60 Years|No|||February 2015|February 16, 2015|January 17, 2007|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00423670||175164|
NCT00424242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 06C2|Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases|A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases||Northwestern University|Yes|Active, not recruiting|January 2007|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00424242||175121|
NCT00424593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10544|Duloxetine Versus Placebo in Chronic Low Back Pain|Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain||Eli Lilly and Company|No|Completed|January 2007|October 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|January 17, 2007|Yes|Yes||No|October 16, 2009|https://clinicaltrials.gov/show/NCT00424593||175094|
NCT00424606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/01.04|Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients|A Multicenter Randomized Phase III Study of Adjuvant Treatment With Epirubicin Followed by Docetaxel (E/T) Versus Epirubicin and Docetaxel Combination (ET) in High Risk Lymph Node Negative Breast Cancer Patients||Hellenic Oncology Research Group||Completed|June 2001|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|658|||Female|18 Years|75 Years|No|||May 2015|May 19, 2015|January 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00424606||175093|
NCT00424580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-REB# 06-232|Airway Responses to Montelukast and Desloratadine.|Airway Responses to Montelukast and Desloratadine.||University of Saskatchewan||Completed|January 2007|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|N/A|No|||January 2008|January 18, 2008|January 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00424580||175095|
NCT00424918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMCRI-3000|"Generation Fit and Exerlearning With In the Groove"|Generation-Fit, a Pilot Study of Youth in Maine Middle Schools Using an "Exerlearning" Dance Video Game to Promote Physical Activity During School||Maine Medical Center||Recruiting|September 2006|September 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention||||85|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||January 2007|January 18, 2007|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00424918||175070|
NCT00425191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976B_2501|Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.|A Multicenter, Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.||Sanofi||Completed|July 2002|||April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|70 Years|No|||December 2009|December 4, 2009|January 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00425191||175050|
NCT00425204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020375|Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment|A Multi-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment||Amgen||Completed|March 2004|March 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||September 2008|September 11, 2008|January 18, 2007||||No||https://clinicaltrials.gov/show/NCT00425204||175049|
NCT00425217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 627-04|Rituximab in Membranous Nephropathy|The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy||Mayo Clinic||Completed|August 2004|April 2007|Actual|April 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425217||175048|
NCT00425841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000515934|Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer|Lokal Fortgeschrittenes Pankreas-Karzinom: Stereotaktische Radiotherapie Gefolfgt Von Gemox-Chemotherapie||Technische Universität München||Completed|May 2006|December 2009|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|29|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425841||175002|
NCT00426140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2122|Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.|An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.||Novartis||Completed|August 2006|||November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|January 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00426140||174980|
NCT00426426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.2369|Comparing Cognitive Behaviour Therapy (CBT) With Metacognitive Therapy (MCT) in the Treatment of GAD|A Randomised Controlled Trial Comparing the Effectiveness of Cognitive Behaviour Therapy (CBT) With Metacognitive Therapy (MCT) in the Treatment of Patients With Generalised Anxiety Disorder (GAD)||Norwegian University of Science and Technology|No|Completed|January 2007|March 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|January 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00426426||174960|
NCT00454597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910-0459|Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity|PHASE 1 The Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity|omentectomy|Universidad de Guanajuato|Yes|Completed|February 2007|December 2007|Actual|March 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|21|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2008|May 30, 2008|March 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00454597||172829|
NCT00454831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153-PTL-001|Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol|A 16 Week With 12 Week Active Treatment Multi-Center, Placebo-Controlled, Randomized Study Evaluating the Efficacy of HEP-40 Chitosan in Managing Moderate Hypercholesterolemia|HEP-40|DNP Canada|No|Completed|February 2006|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|207|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2007|November 14, 2007|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00454831||172812|
NCT00455065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB20474|Weight Loss and Cardiovascular Disease (CVD) Prevention Via a Whole Grain Diet in Men and Women With Metabolic Syndrome|Weight Loss and Cardiovascular Disease (CVD) Prevention Via a Whole Grain Diet in Men and Women With Metabolic Syndrome||Penn State University|No|Active, not recruiting|August 2005|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2007|March 30, 2007|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00455065||172795|
NCT00455351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCTnumber 2006-003631-76|Vorinostat and Palliative Radiotherapy|Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.|PRAVO|Oslo University Hospital|No|Completed|February 2007|August 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455351||172773|
NCT00455364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14559A|Voriconazole as Prophylactic Therapy in Lung Transplant Recipients|Assessment of Safety and Efficacy of Voriconazole as Prophylactic Antifungal Therapy for Lung Transplant Recipients|VORI|University of Chicago|No|Terminated|April 2007|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|20|||Both|18 Years|65 Years|No|||February 2013|February 5, 2013|April 2, 2007||No|Protocol never received funding.|No||https://clinicaltrials.gov/show/NCT00455364||172772|
NCT00455624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-256|Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer|Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer||Massachusetts General Hospital|No|Completed|November 2002|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|Samples With DNA|Whole blood|Male|18 Years|N/A|No|Non-Probability Sample|Men identified with prostate cancer.|July 2013|July 9, 2013|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455624||172753|
NCT00431743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mastectomy opti.|Fluid Infusion During Breast Surgery|Phase 4 Study of Fluid Infusion During Breast Surgery.||Rigshospitalet, Denmark||Not yet recruiting|April 2009|September 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|70 Years|No|||February 2009|February 27, 2009|February 5, 2007||||No||https://clinicaltrials.gov/show/NCT00431743||174561|
NCT00427674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|_mZINT_001/002|Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients|Phase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human Subjects||Institute for Neurodegenerative Disorders|Yes|Terminated|January 2007|October 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|28|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2010|October 5, 2010|January 25, 2007|No|Yes|Scan results to date did not show reason to continue with study|No||https://clinicaltrials.gov/show/NCT00427674||174865|
NCT00455611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbosco4|Effects of CPAP on Ventricular Function Modifications|Evaluation of the Effects of Intra-thoracic Positive Pressure Applicated With CPAP (Continuous Positive Airway Pressure) on Ventricular Function in Patients With Chronic Heart Failure: Modification Induced on Baroreflex Sensitivity||Ospedale S. Giovanni Bosco|Yes|Withdrawn|May 2006|||December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Actual|0|||Both|18 Years|90 Years|No|||April 2007|March 7, 2013|April 2, 2007|||No patients enrolled in the study|No||https://clinicaltrials.gov/show/NCT00455611||172754|
NCT00423943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513585-1|Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia|Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia||University of California, Davis||Completed|September 2005|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|January 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00423943||175143|
NCT00456365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0704|Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease||University of Colorado, Denver|Yes|Completed|November 2006|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|8 Years|21 Years|No|||December 2012|December 12, 2012|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00456365||172697|
NCT00456651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB570/05|Sleep Apnea-Hypopnea Syndrome and the Pathogenesis of Obesity|Sleep Apnea-Hypopnea Syndrome and the Pathogenesis of Obesity||Sociedad Española de Neumología y Cirugía Torácica|Yes|Recruiting|February 2007|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Male|25 Years|65 Years|No|||April 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456651||172675|
NCT00456378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAM™ Device vs. Cons. Care|Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care|A Prospective, Randomized, Controlled Pivotal Clinical Investigation of DIAM™ Spinal Stabilization System in Patients With Lumbar Degenerative Disc Disease.||Medtronic Spinal and Biologics|Yes|Active, not recruiting|December 2006|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|311|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|March 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00456378||172696|
NCT00424931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013390|A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy|A Phase II Randomized, Double-blind, Double-dummy, Placebo and Comparator-controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of a Single Dose of JNJ-17216498 Administered to Subjects With Narcolepsy.||Alza Corporation, DE, USA||Completed|January 2007|December 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|55 Years|No|||May 2014|May 21, 2014|January 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00424931||175069|
NCT00425230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06J02H|Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain|Pilot Study of Use of Duloxetine for the Treatment of Phantom Limb Pain||Baylor College of Medicine||Terminated|January 2007|June 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 21, 2010|January 19, 2007|||No patients were enrolled in this study. The study onset was delayed due to problems with drug    acquisition.|No||https://clinicaltrials.gov/show/NCT00425230||175047|
NCT00425243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTE5407|Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)|Evaluation of the Long-Term Efficacy and Safety of Zolpidem-MR 12.5 mg Compared to Placebo, When Both Are Administered Over a Long-Term Period "as Needed", in Patients With Chronic Primary Insomnia||Sanofi||Completed|August 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|1025|||Both|18 Years|64 Years|No|||April 2009|April 3, 2009|January 19, 2007||||No||https://clinicaltrials.gov/show/NCT00425243||175046|
NCT00425568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIR1-SLGSC|Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR|Phase I Study of Transdermal Testosterone Gel and Its Effect on Erection Quality as Measured by a Digital Inflection Rigidometer (DIR)||Lamm, Steven, M.D.||Recruiting|December 2005|||||Phase 1|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||30|||Male|21 Years|59 Years|Accepts Healthy Volunteers|||January 2007|January 22, 2007|January 20, 2007||||No||https://clinicaltrials.gov/show/NCT00425568||175022|
NCT00457444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-SkinSIT-001|Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration|ZU-SkinSIT-001 Single Center Phase I/IIa, Placebo Controlled, Randomized, Double Blind Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration||University of Zurich|No|Completed|December 2005|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||35|||Both|18 Years|65 Years|No|||April 2007|April 5, 2007|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457444||172614|
NCT00457743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181045|A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)|A Phase I/II Study of Sunitinib Malate (SU011248) In The Treatment of Patients With Malignant Gastrointestinal Stromal Tumor (GIST) Previously Treated by Imatinib Mesylate.||Pfizer|Yes|Completed|January 2005|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|20 Years|75 Years|No|||October 2009|October 2, 2009|April 4, 2007||No||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00457743||172591|
NCT00457990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL-NEO-IRON-2|Neurodevelopment After Early Iron Supplementation|Early Versus Late Enteral Iron Supplementation in Infants With a Birth Weight of Less Than 1301g – Neurocognitive Development at 5.3 Years Corrected Age||University of Ulm|No|Completed|April 2002|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||204|||Both|4 Years|7 Years|No|||April 2007|April 6, 2007|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00457990||172572|
NCT00458471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11717|E. Coli for Prevention of Catheter UTI in SCI Patients|Evaluate the Safety in Human Subjects of Using Bladder Catheters That Are Pre-Coated With a Biofilm That Contains Living Bacteria Escherichia Coli 83972.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|November 2003|July 2005||||Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Prevention||||12|||Both|18 Years|64 Years|No|||April 2007|April 9, 2007|April 9, 2007||||No||https://clinicaltrials.gov/show/NCT00458471||172535|
NCT00455091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1206|A Phase III Study in Post-Operative HBV-Related Hepatocellular Carcinoma|A Randomization Trial of Adjuvant Lamivudine/ Adefovir Dipivoxil Against Recurrence in Post-Operative HBV-Related Hepatocellular Carcinoma||National Health Research Institutes, Taiwan|Yes|Active, not recruiting|May 2007|April 2018|Anticipated|April 2012|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|309|Samples With DNA|HBVDNA|Both|18 Years|70 Years|No|Probability Sample|Post-operative HBV-related Hepatocellular Carcinoma|June 2009|June 29, 2009|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455091||172793|
NCT00455104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFDI 001|Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study|Enzyme Replacement Therapy for Fabry Disease: A Model for the Integration of Rare Disease Therapeutics Into the Canadian Health Care System|CFDI|Canadian Fabry Research Consortium|Yes|Recruiting|January 2007|March 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|5 Years|85 Years|No|||February 2016|February 2, 2016|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00455104||172792|
NCT00454857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050237|Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|A Prospective Observational Descriptive Study and Retrospective Chart Review of Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)||Amgen||Completed|May 2006|August 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|326|None Retained|None retained.|Both|18 Years|N/A|No|Probability Sample|Patients s diagnosed with ITP and currently treated for ITP by a hematologist or        hematologist-oncologist recruited from community based clinics and adademic/referral        centers.|October 2013|October 23, 2013|March 29, 2007||||No|October 16, 2009|https://clinicaltrials.gov/show/NCT00454857||172811|
NCT00455078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15272A|GI Reflux in Lung Transplant and Its Relationship to Chronic Rejection|The Role of Reflux in Innate Immunity Activation After Lung Transplantation.|LTXGERD|University of Chicago|No|Completed|June 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects who have undergone pretransplant evaluation and are on the waiting list or        subjects transplanted < 18mos.|September 2013|September 4, 2013|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455078||172794|
NCT00455377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHF 5690.11, REK S-00166|Lung Function and Airway Inflammation in Portland Cement Workers|Airway Inflammation in Cement Dust Exposed Workers|SPUTUM|Sykehuset Telemark|No|Completed|March 2007|December 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|72|Samples Without DNA|Induced sputum samples and blood samples|Both|18 Years|67 Years|Accepts Healthy Volunteers|Non-Probability Sample|Workers from Norways largest cement plant|June 2013|June 12, 2013|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00455377||172771|
NCT00455884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-79-58035-006|A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency|International Cooperative Metabolic Study (iNCMS) of NutropinAq® [Somatropin (rDNA Origin) Injection] Replacement Therapy in Adults With Growth Hormone Deficiency||Ipsen|No|Completed|June 2006|December 2011|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|546|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients treated with NutropinAq in the specialised adult endocrinology centres in        Germany, Italy, and UK.|April 2012|April 3, 2012|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00455884||172733|
NCT00427960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00060|Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg|A Phase IV, 6-week, Randomised, Double-blind, Multicentre, Parallel Group, Comparative Study to Evaluate the Efficacy of Rosuvastatin 5mg and Atorvastatin 10mg in UK Asian Subjects With Primary Hypercholesterolaemia||AstraZeneca||Terminated|December 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|January 25, 2007|||Due to inadequate recruitment|No|March 25, 2009|https://clinicaltrials.gov/show/NCT00427960||174844|The study achieved only 8% of the randomised target number of patients and for this reason alone was terminated early. Planned statistical analyses could not be performed. No scientifically valid conclusions can be drawn from the limited study data.
NCT00427973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00130|AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer|A Phase II Study of AZD2171 in Hepatocellular Carcinoma||National Cancer Institute (NCI)||Terminated|May 2009|||April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|January 25, 2007|Yes|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00427973||174843|
NCT00428441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2175|D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism|The Negative Predictive Value of D-dimer on the Risk of Recurrent Venous Thromboembolism in Patients With Multiple Previous Events: a Prospective Cohort Study||Università degli Studi dell'Insubria|No|Terminated|May 2007|May 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|January 26, 2007||No|Enrolment was halted prematurely because of the observed excess in recurrences|No|August 18, 2011|https://clinicaltrials.gov/show/NCT00428441||174809|
NCT00456404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-2|Effect of Peppermint Water on Breast Crack|Effect of Peppermint Water on Prevention of Nipple Crack in Lactating Primiparous Women: a Randomized Controlled Trial||Tabriz University|Yes|Completed|February 2005|June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||196|||Female|14 Years|40 Years|Accepts Healthy Volunteers|||March 2004|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456404||172694|
NCT00456131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72982|Prevention of Obesity at Universities: A Randomized Trial||Healthy Start|Drexel University|Yes|Completed|September 2006|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|330|||Female|18 Years|19 Years|No|||August 2012|August 16, 2012|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456131||172715|
NCT00456092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSA-001|Phase II Study With CC-10004 in Psoriatic Arthritis|A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of CC-10004 in Subjects With Active Psoriatic Arthritis||Celgene|Yes|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|204|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|April 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00456092||172718|
NCT00456105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70482|The Effect of a Diabetes Action Team in Patients Post Infrainguinal Bypass Surgery With and Without Diabetes|Early Post-Operative Dysglycemia in Patients With and Without Diabetes Post-Infrainguinal Bypass Surgery and the Effectiveness of a Diabetes Action Team in the Management of Diabetes Post Infrainguinal Bypass Surgery on Glycemic Control, Length of Stay, and Infection Rates: A Pilot Study||University of British Columbia|No|Terminated|July 2006|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|10|||Both|30 Years|N/A|No|||March 2014|March 14, 2014|April 2, 2007||No|The study was stopped due to lack of resources of the study coordinator's time|No||https://clinicaltrials.gov/show/NCT00456105||172717|
NCT00456391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5200906.EMC|The Utility of Performing Brain CT Scan in Non Trauma Patients at the Pediatric Emergency Unit|The Utility of Performing Brain CT Scan in Non Trauma Patients at the Pediatric Emergency Unit. A Retrospective Observational Study.||HaEmek Medical Center, Israel|No|Completed|October 2006|March 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|18 Years|No|||April 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456391||172695|
NCT00456924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914-002|Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914|Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium||HRA Pharma|No|Completed|January 2004|December 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||48|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||June 2010|June 16, 2010|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456924||172654|
NCT00456937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Escitalopram-173CTIL|Escitalopram in Schizophrenia in OCD- Open Label Study|Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study||BeerYaakov Mental Health Center|No|Completed|July 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|15|||Both|18 Years|65 Years|No|||January 2009|January 26, 2009|December 3, 2006||No||No||https://clinicaltrials.gov/show/NCT00456937||172653|
NCT00456950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 04-272|Magnetic Resonance Imaging of the Coronary Vessel Wall|Detection of Vulnerable Plaque With Coronary Vessel Wall Magnetic Resonance Imaging||Maastricht University Medical Center|No|Completed|October 2005|||June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|75|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|-  Patients with (un)stable angina or non-st-elevated myocardial infarction: sample from             dept. of cardiology          -  healthy volunteers: community sample|September 2009|September 23, 2009|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00456950||172652|
NCT00457158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501105|PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption|PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study|PREPIC2|Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|July 2006|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|399|||Both|18 Years|N/A|No|||November 2012|November 22, 2012|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457158||172636|
NCT00457171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBD100729|GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis|A Double-Blind, Placebo-Controlled Phase I/II Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X, an Oral ICAM-1 and E-Selectin Inhibitor||GlaxoSmithKline||Terminated|December 2004|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||16|||Both|18 Years|55 Years|No|||May 2009|May 15, 2009|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457171||172635|
NCT00457184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1700802.EMC|Thrombophilia and Migraine, Are They Related?|Thrombophilia and Migraine, Are They Related? - A Clinical Study||HaEmek Medical Center, Israel|No|Completed|January 2004|June 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|50|||Both|5 Years|20 Years|No|||January 2004|August 27, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457184||172634|
NCT00457470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4991010|A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)|A Phase 2, Multi-Stage, Multi-Center Trial Exploring The Safety And Efficacy Of AG-014699 In Subjects With Diffuse Diabetic Macular Edema (DME) Involving The Center Of The Retina||Pfizer||Withdrawn|June 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|April 4, 2007|||Cancelled before first patient enrolled|No||https://clinicaltrials.gov/show/NCT00457470||172612|
NCT00457756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiosLife 2005-4|The Effect of BiosLife on Serum Lipids|The Effect of an Integrative Dietary Supplement on the Lipid Profile of Subjects With Hypercholesterolemia||University of Utah|No|Completed|January 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2008|May 5, 2008|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457756||172590|
NCT00458003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-31|Phenylephrine in Spinal Anesthesia in Preeclamptic Patients|Phenylephrine Versus Ephedrine to Treat Spinal Anesthesia-Induced Hypotension in Preeclamptic Patients During Cesarean Delivery||Northwestern University|No|Recruiting|July 2006|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00458003||172571|
NCT00454610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15671|Family Lifestyle Overweight Prevention Program|Family Lifestyle Overweight Prevention Program: Evaluation of a Weight Management Program for Mexican American Youth|FLOW|Baylor College of Medicine|No|Active, not recruiting|January 2005|March 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||100|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||March 2007|March 30, 2007|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00454610||172828|
NCT00454870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM 3454-003|Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease||Memory Pharmaceuticals|No|Completed|February 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|50 Years|80 Years|No|||May 2008|May 5, 2008|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00454870||172810|
NCT00455689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-001512|Understanding Experimentally Induced Hot Flushes|Understanding Experimentally Induced Hot Flushes||Massachusetts General Hospital|Yes|Active, not recruiting|November 2005|October 2012|Anticipated|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|April 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455689||172748|
NCT00455390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPPI A|Evaluation of the Effects of Post-Immediate Psychotherapeutic Interventions in Secondary Prevention of Psychotraumatic Disorders|Evaluation of the Effects of Post-Immediate Psychotherapeutic Interventions in Secondary Prevention of Psychotraumatic Disorders|IPPI A|Groupe Francais d'Epidemiologie Psychiatrique|No|Recruiting|January 2007|April 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||330|||Both|18 Years|65 Years|No|||April 2007|April 2, 2007|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00455390||172770|
NCT00455650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC #2006-P-001361|Study of the Effects of Mecamylamine and Varenicline in Schizophrenia|Cognitive Effects of Mecamylamine and Varenicline in Schizophrenia||Massachusetts General Hospital|No|Completed|March 2007|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455650||172751|
NCT00455663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062850|Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia|Medication Adherence and Outcomes in Schizophrenia||The University of Texas Health Science Center at San Antonio|Yes|Completed|November 2000|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|60 Years|No|||May 2015|May 29, 2015|April 2, 2007||No||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00455663||172750|Subjects were ill for a long-period of time
NCT00456443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4140905.EMC|Invasive Infections in Children With Hemoglobinopathies|Invasive Infections in Children With Hemoglobinopathies. A Clinical Descriptive Retrospective Study.||HaEmek Medical Center, Israel|No|Completed|January 2006|June 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||200|||Both|N/A|40 Years|No|||April 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456443||172691|
NCT00456456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 013|The Daily Habits Survey|The Daily Habits Survey||American University||Recruiting|October 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||300|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||April 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456456||172690|
NCT00429039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.0082|A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation|LLME Treated Cellular Immunotherapy Following T-cell Depleted Allogeneic Heamtopoietic Stem Cell Transplantation for Acceleration of Immune Reconstitution||Thomas Jefferson University|Yes|Terminated|September 2000|August 2009|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|16 Years|N/A|No|||December 2014|December 3, 2014|January 29, 2007||No|Low accrual.|No||https://clinicaltrials.gov/show/NCT00429039||174763|
NCT00429273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH077248-01|Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder|An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years|Project1|University of California, Los Angeles|Yes|Completed|January 2007|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|7 Years|14 Years|No|||January 2016|January 11, 2016|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00429273||174746|
NCT00429286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03CA124200-01|Preserving Function in Breast Cancer Patients|Preserving Function in Rural Breast Cancer Patients Undergoing Chemotherapy||Dartmouth-Hitchcock Medical Center|Yes|Completed|May 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients undergoing chemotherapy at the Norris Cotton Cancer Center in        Lebanon, NH.|October 2011|October 24, 2011|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00429286||174745|
NCT00429520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90026-0423/1|Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds|Prospective, Multicentre, Not Controlled Clinical Study to Investigate Efficacy and Tolerability of the Hyaluronic Acid Filler IMD1 Basic After Single Bilateral Injection for Correction of Nasolabial Folds (NLF)||Merz Pharmaceuticals GmbH||Completed|December 2005|December 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||114|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429520||174727|
NCT00456703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000144|Restricted Fluid Regimen in Open Abdominal Bowel Surgery|Safety and Efficacy of Restricted Fluid Regimen in Open Abdominal Bowel Surgery||Beth Israel Deaconess Medical Center|No|Withdrawn|July 2008|December 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|April 4, 2007||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00456703||172671|
NCT00456716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 0639|Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma|A Phase II Trial of Sorafenib in BAC or Never-Smokers With Any Lung Adenocarcinoma||Swedish Medical Center|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|April 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00456716||172670|
NCT00455845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15/2007|The Effectiveness of Lng IUD for Treatment of the Patient Undergone Conservative Surgery for Pelvic Endometriosis|A Double Blind Randomized Controlled Trial to Study the Effectiveness of a Levonorgestrel Releasing Intrauterine Device for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis||Mahidol University|No|Completed|April 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|54|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2007|March 1, 2011|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00455845||172736|
NCT00456963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM5JYE9K|Prevention of Diabetes and Hypertension|Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.|PHIDIAS|Istituto Auxologico Italiano|Yes|Terminated|September 2007|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|3000|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 4, 2011|April 4, 2007||No|Because of delay in approval of the protocol by a number of Ethics Commitees the trial was    terminated on March 4, 2010. No patient had received any study drug.|No||https://clinicaltrials.gov/show/NCT00456963||172651|
NCT00457210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-BC-040-CTIL|The Influence of Radiotherapy on Cognitive Function|The Influence of the Radiotherapy or Stereotactic Radiosurgery on the Cognitive Function of the Patients With the Neurotrax Assessment System and a Cognitive Questionnaire.||Tel-Aviv Sourasky Medical Center||Not yet recruiting|April 2007|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||150|||Both|20 Years|80 Years|No|||April 2007|April 5, 2007|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457210||172632|
NCT00456664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QM094007|CMV Disease and IRIS in HIV-1 Infected Persons|Molecular Diagnostics for CMV Disease and IRIS in HIV-1 Infected Persons, and the Mechanism Study for CMV Alternative Gene Splicing in Immediate Early Protein||Kaohsiung Medical University Chung-Ho Memorial Hospital||Completed|November 2006|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A|||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2008|February 1, 2009|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456664||172674|
NCT00457769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBarrett2|Aricept to Improve Functional Tasks in Vascular Dementia|Phase 1 Study of Aricept Plus a Behavioral Strategy to Improve Functional Tasks in Vascular Dementia||Kessler Foundation|Yes|Active, not recruiting|May 2007|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|April 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00457769||172589|
NCT00457197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112006-046|Quetiapine for Bipolar Disorder and Alcohol Dependence|Quetiapine for Bipolar Disorder and Alcohol Dependence||University of Texas Southwestern Medical Center|Yes|Completed|March 2007|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|No|||December 2015|December 21, 2015|April 4, 2007|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT00457197||172633|Larger sample size possibly needed for between-group differences in outcome measures. Pill counts not an optimum measure of medication adherence.
NCT00457457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3711044|Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.|A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)||Pfizer|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|609|||Male|40 Years|N/A|No|||October 2010|October 27, 2010|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457457||172613|
NCT00458250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|418-A-1954|Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H|Haploidentical Hematopoietic Stem Cell Transplantation in the Treatment of Hematological Malignancies Using CAMPATH-1H||Tehran University of Medical Sciences|Yes|Completed|September 2006|February 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|50 Years|No|||November 2008|November 15, 2008|April 7, 2007||||No||https://clinicaltrials.gov/show/NCT00458250||172552|
NCT00455130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-CF-201|A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis|||Pharmaxis||Completed|March 2004|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|8 Years|N/A|No|||January 2010|January 31, 2010|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00455130||172790|
NCT00455403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|482|Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)|Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3|ARCH-MS|Washington University School of Medicine|Yes|Active, not recruiting|April 2006|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|70 Years|No|||December 2015|December 7, 2015|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00455403||172769|
NCT00455416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dietary intervention FL|Dietary Intervention in Follicular Lymphoma|Dietary Intervention in Stage III/IV Follicular Lymphoma. Impact on Markers of Cell Proliferation, Apoptosis, Host Immune Cell Infiltrate and Oxidative Stress.|KLYMF|Oslo University Hospital|No|Recruiting|April 2007|December 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||April 2007|May 20, 2008|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455416||172768|
NCT00455676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I06020|Chevron Osteotomy Versus SCARF Osteotomy in the Treatment of Hallux Valgus|Chevron Osteotomy Versus SCARF Osteotomy in the Treatment of Hallux Valgus||University Hospital, Limoges|No|Completed|June 2006|November 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||74|||Both|18 Years|N/A|No|||December 2008|December 29, 2008|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00455676||172749|
NCT00455702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001040|Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia|Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals||Massachusetts General Hospital|No|Completed|July 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||July 2014|July 14, 2014|April 2, 2007|Yes|Yes||No|June 11, 2014|https://clinicaltrials.gov/show/NCT00455702||172747|As the first study of once-weekly dosing in Schizophrenia, this study was exploratory and so results must be considered preliminary. Additional studies are needed to replicate these findings.
NCT00455897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-342|CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma|Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma||Massachusetts General Hospital||Terminated|December 2006|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|April 2, 2007|Yes|Yes|Accrual was too slow. Trial terminated|No||https://clinicaltrials.gov/show/NCT00455897||172732|
NCT00456157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-OA-001|A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee|A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular Osteogenic Protein-1 OP-1 in Subjects With Osteoarthritis of the Knee|Knee OA|Stryker Biotech|No|Completed|March 2007|November 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|33|||Both|40 Years|N/A|No|||June 2010|June 16, 2010|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456157||172713|
NCT00456469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.49 TF Cuevas|Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children|Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children|ALTAC|Liverpool School of Tropical Medicine|Yes|Not yet recruiting|May 2007|October 2009|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||500|||Both|1 Year|14 Years|No|||April 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456469||172689|
NCT00456482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415-004|Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant|A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye||Bausch & Lomb Incorporated|Yes|Terminated|May 2002|April 2006|Actual|April 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|239|||Both|6 Years|N/A|No|||December 2011|December 7, 2011|April 3, 2007|Yes|Yes|SARS epidemic in Asia and Canada|No||https://clinicaltrials.gov/show/NCT00456482||172688|
NCT00429052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-C-001|Mechanism of Percutaneous Revascularization for Coronary Bifurcation Disease|Insights Into the Mechanism of Percutaneous Revascularization of Coronary Bifurcation Disease in the Drug-eluting Stent Era. An Angiographic and Intravascular Ultrasound Study. The INSIGHT Trial||University of Florida|No|Terminated|November 2006|September 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|80 Years|No|Non-Probability Sample|from cathet labs|January 2007|March 6, 2012|January 30, 2007||No|PI left institution,inability to enroll and analyze data due to software/technical    limitations, pt enrollment terminated early with no data generated|No||https://clinicaltrials.gov/show/NCT00429052||174762|
NCT00429299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF106988|Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer|Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation.|CHERLOB|GlaxoSmithKline|No|Completed|August 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Female|18 Years|65 Years|No|||January 2016|February 22, 2016|January 29, 2007|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT00429299||174744|
NCT00429312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-IT-MEL005|A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma|A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma||Jennerex Biotherapeutics|Yes|Completed|March 2007|December 2009|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2010|January 13, 2015|January 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00429312||174743|
NCT00429546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077493|Assisting HIV-infected Mothers in Disclosing Their Serostatus to Their Children|Maternal HIV: Intervention to Assist Disclosure to Children|TRACK|University of California, Los Angeles|No|Completed|September 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|160|||Both|6 Years|65 Years|No|||June 2013|June 24, 2013|January 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00429546||174725|
NCT00456677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heikki31|Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma|Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma|Mino|State University of New York - Downstate Medical Center|No|Active, not recruiting|June 1996|October 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|75 Years|No|||April 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456677||172673|
NCT00456690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5190906/2.EMC|Endocrine and Nutritional Assessment in B Thalassemia Major|Endocrine and Nutritional Assessment in B Thalassemia Major - A Clinical Trial||HaEmek Medical Center, Israel|No|Completed|May 2007|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|133|||Both|5 Years|40 Years|No|||August 2015|August 30, 2015|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00456690||172672|
NCT00457223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401/49|To Compare Fibrin Glue and Suture in Primary Pterygium Excision With Amniotic Membrane Transplantation|Randomized Controlled Trial to Compare Fibrin Glue and Suture in Primary Pterygium Excision With Amniotic Membrane Transplantation||Chulalongkorn University|Yes|Completed|April 2007|August 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|No|||February 2008|February 12, 2008|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457223||172631|
NCT00457496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5147SD2003.0271|Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in Working Communities|Effectiveness of a Cognitive and Physical Program in Reducing Headache, Neck and Shoulder Pain: a Workplace Controlled Trial||University of Turin, Italy|No|Completed|March 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 11, 2008|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457496||172610|
NCT00457509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF01|Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults|||Sanofi|No|Completed|January 2007|September 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|251|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457509||172609|
NCT00457483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAMIS|Nijmegen Antihypertensive Management Improvement Study|A Cross-over Trial to Identify Patient Characteristics That Predict Blood Pressure Response to Antihypertensive Therapy in General Practice|NAMIS|Radboud University|No|Completed|August 2007|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|18 Years|65 Years|No|||April 2011|February 13, 2012|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457483||172611|
NCT00458029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND - DK61230-HEALTHY|Middle-School Based Primary Prevention Trial of Type 2 Diabetes|Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)|HEALTHY|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|August 2006|February 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4603|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00458029||172569|
NCT00458016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB07803-202|Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus|A Phase 2, 28-day, Multicenter, Double-Blind,Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of MB07803 in Patients With Type 2 Diabetes Mellitus||Ligand Pharmaceuticals|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|105|||Both|18 Years|70 Years|No|||September 2011|September 29, 2011|April 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00458016||172570|
NCT00458484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE12806|Radiosurgery in Treating Patients With Kidney Tumors|Evaluation of a Radio-Surgical Approach for the Treatment of Kidney Tumors in Poor Surgical Candidates||Case Comprehensive Cancer Center|Yes|Recruiting|February 2007|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00458484||172534|
NCT00455143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-0453|Cognitive Protection - Dexmedetomidine and Cognitive Reserve|Cognitive Protection - Dexmedetomidine and Cognitive Reserve||Icahn School of Medicine at Mount Sinai|No|Terminated|September 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|27|||Both|65 Years|N/A|No|||March 2016|March 16, 2016|April 2, 2007|Yes|Yes|Pilot study initiated to provide support data for main grant GCO 06-0217 funded before this    pilot collected significant data. no results for this study.|No||https://clinicaltrials.gov/show/NCT00455143||172789|
NCT00455156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN275200403366I|Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring|A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150µg of Nestorone® and 15µg of Ethinyl Estradiol (150/15 NES/EE CVR)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|December 2006|September 2009|Actual|January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1143|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||April 2012|October 26, 2012|April 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455156||172788|
NCT00455429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012946|An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis|A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis That is Moderate in Severity||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|April 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|84|||Both|18 Years|65 Years|No|||February 2014|February 11, 2014|April 1, 2007|Yes|Yes|The study was stopped due to a non-clinical safety finding.|No|February 28, 2013|https://clinicaltrials.gov/show/NCT00455429||172767|Participants were not enrolled into JNJ-26113100(250 mg) twice daily dose because the study was stopped during 100mg twice daily dose due to preclinical finding of retinal atrophy in high dose group(150 mg/kg) of 6-month, albino rat toxicology study.
NCT00455923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM103976|SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)|SERETIDE vs FLIXOTIDE in Mild Persistent Asthma (GINAII)||GlaxoSmithKline|No|Completed|May 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|70 Years|No|||January 2012|May 31, 2012|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00455923||172730|
NCT00456196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000820|Epidemiology of Venous Thromboembolism|Epidemiology of Venous Thromboembolism: Analyses and Publications From the DVT FREE Database||Brigham and Women's Hospital|No|Completed|April 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5451|||Both|N/A|N/A|No|Non-Probability Sample|Patients from the DVT FREE study with ultrasound-confirmed deep vein thrombosis|July 2009|July 9, 2009|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456196||172710|
NCT00455910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020895|Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200|Thalidomide for the Treatment of Cytopenias of Patients With Low Risk Myelodysplastic Syndromes||Groupe Francophone des Myelodysplasies|Yes|Completed|January 2003|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||112|||Both|18 Years|N/A|No|||April 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00455910||172731|
NCT00456170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Harmonic Vag Hyst|Are Sutures Required for Vaginal Hysterectomy: A Randomized Controlled Trial|Randomized Controlled Trial Comparing Traditional Vaginal Hysterectomy to Harmonic Scalpel Hysterectomy|HAVE|Southern Health|Yes|Not yet recruiting|April 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456170||172712|
NCT00456183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB007|Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis.||University of Oxford|Yes|Completed|August 2005|April 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2007|May 30, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456183||172711|
NCT00456781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wright1|Use of Graft Jacket for Rotator Cuff Repair|GraftJacket® Rotator Cuff Tendon Reinforcement Scaffold: A Randomized Prospective Clinical Evaluation||Wright Medical Technology|No|Completed|April 2007|March 2011|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|February 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00456781||172665|
NCT00456794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-006|12-Week, Double-Blind, Placeob-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa|A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|March 2002|October 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||325|||Both|30 Years|N/A|No|||April 2007|June 22, 2010|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456794||172664|
NCT00429559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.14|Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma|Weekly Administration of Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer||Hellenic Oncology Research Group||Completed|June 2006|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|75 Years|No|||July 2011|July 21, 2011|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00429559||174724|
NCT00429832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-006|A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department|A Randomized Controlled Trial of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department||University of New Mexico||Completed|October 2003|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|18 Years|N/A|No|||January 2007|January 31, 2007|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00429832||174705|
NCT00429858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000525724|Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer|Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial||University of California, San Francisco|Yes|Terminated|January 2007|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|January 30, 2007|Yes|Yes|Study accrual rate is very slow, it was mandated by NCI to be terminated.|No||https://clinicaltrials.gov/show/NCT00429858||174703|
NCT00456417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-187-01|Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects|Evaluation of [123I] MNI-187 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Institute for Neurodegenerative Disorders|No|Completed|April 2007|||December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 17, 2008|April 3, 2007||||Yes||https://clinicaltrials.gov/show/NCT00456417||172693|
NCT00456729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4150905.EMC|Malabsorption as a Cause of Iron Treatment Failure in Infants|Malabsorption as a Cause of Iron Treatment Failure in Infants - A Clinical Observational Study||HaEmek Medical Center, Israel|No|Completed|May 2006|July 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||100|||Both|6 Months|4 Years|No|||January 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456729||172669|
NCT00456976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8514|Efficacy of Selegiline in Negative Symptoms of Schizophrenia|Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia||Tabriz University|Yes|Completed|April 2007|September 2007||||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||70|||Both|20 Years|65 Years|No|||July 2008|July 22, 2008|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456976||172650|
NCT00456989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 575-03|Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer|Phase I/II Study of Docetaxel (Taxotere) in Combination With Doxorubicin HCI Liposome Injection (Doxil) in Advanced Androgen-Independent Prostate Cancer (AIPC)||James Graham Brown Cancer Center|No|Completed|January 2004|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Male|18 Years|N/A|No|||October 2014|October 6, 2014|April 4, 2007|No|Yes||No|October 6, 2014|https://clinicaltrials.gov/show/NCT00456989||172649|
NCT00457236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-BK-2003-1|Effect of Clopidogrel Loading and Risk of PCI|Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement|EXCELSIOR|Heart Center Bad Krozingen||Active, not recruiting|March 2003|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||800|||Both|18 Years|N/A|No|||April 2007|April 5, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457236||172630|
NCT00457782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2478-EU-001|A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma|A Phase I, Open-Label, Dose-escalation, Multicentre Study of KW-2478 Administered as a Single Agent Intravenously in a Consecutive Dosing Schedule in Patients With Relapsed/Refractory Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma||Kyowa Hakko Kirin Pharma, Inc.|Yes|Completed|April 2007|January 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||January 2011|January 31, 2011|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457782||172588|
NCT00457795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-080806-2|24-hour IOP-lowering Effect of Brimonidine 0.1%|||Allergan||Completed|December 2006|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|40 Years|80 Years|No|||October 2011|October 18, 2011|April 6, 2007|Yes|Yes||No|October 18, 2011|https://clinicaltrials.gov/show/NCT00457795||172587|
NCT00458276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-051-350|Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery|Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Cardiac Surgery||Actelion|Yes|Terminated|April 2007|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|April 6, 2007|Yes|Yes|6 month vital status report not collected after 28 day follow up analysis indicated no    difference between placebo & tezosentan|No||https://clinicaltrials.gov/show/NCT00458276||172550|
NCT00458263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc003515ctil|Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature|One Arm, Open Study to Assess Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature|ISS|Rabin Medical Center|No|Completed|April 2006|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|3 Years|9 Years|No|||October 2011|January 1, 2013|April 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00458263||172551|
NCT00458497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#788|Effect of Holofiber Socks and Bedding on Pain and Quality of Sleep in Subjects With Chronic Foot Pain|Effect of Holofiber Socks and Bedding on Pain and Quality of Sleep in Subjects With Chronic Foot Pain||Southern California Institute for Research and Education|No|Terminated|April 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|21 Years|N/A|No|||June 2010|June 2, 2010|April 9, 2007||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT00458497||172533|
NCT00454883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281159|Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.|Treatment Of Manic Or Mixed Episodes Of Up To Moderate Severity In Patients With Bipolar Disorder And Schizoaffective Disorder||Pfizer|No|Completed|April 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|379|||Both|18 Years|N/A|No|Probability Sample|The patients were identified in in- and outpatients settings (university departments,        hospital wards, outpatients clinics, daily psychiatric hospitals)|June 2015|June 30, 2015|March 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00454883||172809|
NCT00455117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parecoxib_HREC2006.133|Effect of Parecoxib on Post-craniotomy Pain|Phase Four Study of Intravenous Parecoxib on Post-craniotomy Pain||Melbourne Health|No|Completed|September 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|65 Years|No|||May 2013|May 28, 2013|April 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00455117||172791|
NCT00455442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-200|A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain|A Two-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain in Healthy Male Volunteers||Corcept Therapeutics|Yes|Completed|March 2007|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Actual|57|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|March 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00455442||172766|
NCT00455455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/245/06/L|Corneal and Conjunctival Sensitivity and Staining Study|Corneal and Conjunctival Sensitivity and Staining Study||University of Waterloo|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|17 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 9, 2010|March 23, 2007|Yes|Yes||No|January 5, 2010|https://clinicaltrials.gov/show/NCT00455455||172765|Sample size completed as anticipated.
NCT00455715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000529|A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia|A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia||Massachusetts General Hospital|No|Completed|February 2006|September 2008|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||June 2011|June 27, 2011|April 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455715||172746|
NCT00455949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-MM-0106-307-14|Effect of Premature Luteinization on the Oocyte Quality in Oocyte Donation Program.|||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Female|18 Years|34 Years|Accepts Healthy Volunteers|||April 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00455949||172728|
NCT00456222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD040291|Impact of Sleep Disruption on the Menstrual Cycle|Impact of Sleep Disruption on the Menstrual Cycle||Brigham and Women's Hospital|No|Completed|June 2003|August 2009|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|18|Samples Without DNA|Blood/plasma|Female|18 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|Healthy women with regular menstrual cycles|August 2009|August 20, 2009|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456222||172708|
NCT00456508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-88/19|Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)|Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks||Dyax Corp.|No|Completed|April 2007|September 2010|Actual|June 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|10 Years|N/A|No|||November 2012|November 27, 2012|April 4, 2007|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00456508||172686|
NCT00456209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.02.112|Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact on Occupations|Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact of Occupations||Hackensack University Medical Center|No|Completed|December 2006|June 2011|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|13 Years|19 Years|No|Non-Probability Sample|Adolescents being treating for cancer and the impact of their lived experience on        engagement in occupations and social participation.|February 2014|February 1, 2014|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456209||172709|
NCT00456521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-302|A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program||Orexigen Therapeutics, Inc|Yes|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|793|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|April 3, 2007|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT00456521||172685|
NCT00456495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4192s|Effect of Ranibizumab on Malignant Conjunctival Neoplasia|Effect of Ranibizumab on Malignant Conjunctival Neoplasia||The New York Eye Cancer Center|No|Completed|March 2007|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|N/A|No|||May 2013|May 3, 2013|April 3, 2007|Yes|Yes||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00456495||172687|This was a small case series involving a small number of subjects. Further investigations for dose, drug delivery and case selection are warranted.
NCT00457041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907073|Research Participants' Views on the Ethics of Clinical Research|Pilot Study Investigating Research Participants' Views on the Ethics of Clinical Research||National Institutes of Health Clinical Center (CC)||Completed|January 2007|September 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|11|||Both|18 Years|N/A|No|||September 2010|September 26, 2015|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457041||172645|
NCT00429572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-268|Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer|Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Completed|January 1998|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|60 Years|No|||August 2012|August 1, 2012|January 29, 2007||No||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00429572||174723|
NCT00429845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA2004-012|Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial|Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start on Highly Active Antiretroviral Therapy: a Randomized Trial||Hospital de Clinicas de Porto Alegre||Completed|March 2004|February 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||80|||Both|18 Years|N/A|No|||January 2007|January 31, 2007|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429845||174704|
NCT00430170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dipy001|Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?|Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?||Radboud University|No|Completed|January 2007|April 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2008|July 28, 2008|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430170||174679|
NCT00456430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408-34|Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response|Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response||Indiana University|No|Completed|July 2003|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2010|November 11, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00456430||172692|
NCT00456742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-80375|Efficacy of Treatment for Generalized Anxiety Disorder|Efficacy of Treatment for Generalized Anxiety Disorder||University of British Columbia|No|Completed|June 2006|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|250|||Both|19 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in the study will be recruited from individuals receiving treatment for        generalized anxiety disorder (GAD) at the Anxiety Disorders Clinic of UBC Hospital|April 2012|April 30, 2012|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456742||172668|
NCT00457522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30NR008995|Telephone Intervention to Increase Safety in Abused Women|Phone Intervention to Increase Safety in Abused Women: Pilot||Johns Hopkins University||Completed|April 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Female|18 Years|N/A|No|||September 2006|April 5, 2007|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457522||172608|
NCT00457808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB # 02-10-16|Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM|Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis||Children's Hospital Medical Center, Cincinnati|Yes|Completed|December 2002|March 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|No|||April 2007|April 6, 2007|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00457808||172586|
NCT00458510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPO45/06/FCNS|Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain|An Open-Label Study Investigating Long-Term Safety and Tolerability of Fentanyl Citrate Nasal Spray in the Treatment of BTCP in Subjects Taking Regular Opioid Therapy||Archimedes Development Ltd|No|Completed|January 2007|July 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|403|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|April 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458510||172532|
NCT00454623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06041EX|Normal Serum Adiponectin Levels in Females|Normal Serum Adiponectin Levels in Females During the Childbearing Ages and Normal Serum Adiponectin Levels in Pregnancy||The Cooper Health System|No|Active, not recruiting|March 2006|June 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||300|||Female|15 Years|40 Years|Accepts Healthy Volunteers|||March 2007|March 30, 2007|March 29, 2007||||No||https://clinicaltrials.gov/show/NCT00454623||172827|
NCT00454896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-005|A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder|VENUS|Astellas Pharma Inc|No|Completed|May 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|739|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|March 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00454896||172808|
NCT00455468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-037|Randomized Controlled Trial (RCT) in Children With Severe Pneumonia|||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|December 2005|April 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|368|||Both|2 Months|59 Months|No|||March 2007|July 11, 2011|April 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00455468||172764|
NCT00455494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K0154-2|Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial|Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial||Tulane University Health Sciences Center|Yes|Recruiting|March 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||14|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||April 2007|April 2, 2007|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00455494||172763|
NCT00455728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-79-58035-005|A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders|International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program for NutropinAq® [Somatropin (rDNA Origin) Injection]|iNCGS|Ipsen|No|Recruiting|June 2006|December 2099|Anticipated|December 2099|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5250|||Both|N/A|18 Years|No|Non-Probability Sample|Children treated with NutropinAq in the specialised paediatric endocrinology centres|December 2015|December 21, 2015|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00455728||172745|
NCT00455936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-05-126|First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker|A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung||National Cancer Center, Korea|No|Completed|October 2005|March 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|75 Years|No|||March 2010|October 22, 2010|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00455936||172729|
NCT00456820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406-27|Wellbutrin XL Effects on SSRIs Induced Changes|Wellbutrin XL Effects on SSRIs Induced Changes in the Reactivity of the Frontal Cortex and Limbic System to Emotional Stimuli: An fMRI Study||Indiana University||Completed|July 2004|November 2007||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|60 Years|No|||April 2007|October 15, 2007|September 14, 2005||||No||https://clinicaltrials.gov/show/NCT00456820||172662|
NCT00457054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0303-28|Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania|Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania Before and After Lithium Treatment: An Brain fMRI Study||Indiana University|No|Completed|July 2003|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 27, 2011|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT00457054||172644|
NCT00457067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070095|Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization||National Institutes of Health Clinical Center (CC)||Completed|March 2007|October 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|80 Years|No|||October 2007|October 25, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457067||172643|
NCT00456807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109801|Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years|Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820.||GlaxoSmithKline||Completed|April 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Female|26 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 17, 2011|April 4, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00456807||172663|No safety data were collected in the framework of this ancillary study.
NCT00457613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP05|Effects of Alkaline Phosphatase on Renal Function in Septic Patients|Effects of Alkaline Phosphatase on Renal Function in Patients With Severe Sepsis or Septic Shock.||Radboud University||Completed|November 2004|March 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||15|||Both|18 Years|80 Years|No|||March 2006|April 5, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457613||172601|
NCT00429585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25923|A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Proximal Tibial Fractures|Intramedullary Nail Versus Plate Fixation Re-Evaluation Study in Proximal Tibial Fractures: A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation (IMPRESS)||Boston Medical Center|Yes|Recruiting|February 2007|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00429585||174722|
NCT00429871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/02.09|Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer|A Multicenter Randomized Comparative Study of Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine Combinations as First Line Treatment of Metastatic Breast Cancer||Hellenic Oncology Research Group||Completed|May 2002|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|272|||Female|19 Years|75 Years|No|||May 2009|May 28, 2009|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00429871||174702|
NCT00429884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-027M|Studies of Disorders and Mechanisms Related to Atrial Fibrillation Before and After DC-Conversion.|Studies of Disorders and Mechanisms Related to Atrial Fibrillation Before and After DC-Conversion: Polysomnography, Heart Rate Variability and 24h Holter.||Umeå University||Recruiting|January 2007|||||N/A|Observational|Time Perspective: Prospective|||||||Both|N/A|N/A|No|||June 2008|July 1, 2008|January 31, 2007||||No||https://clinicaltrials.gov/show/NCT00429884||174701|
NCT00457262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1344|Effects of Soy Protein on Serum paraoxonase1 Activity and Lipoproteins in Postmenopausal Women|Effects of Soy Protein on Serum paraoxonase1 Activity and Lipoproteins in Postmenopausal Women||Iran University of Medical Sciences|Yes|Completed|January 2006|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||42|||Female|51 Years|57 Years|Accepts Healthy Volunteers|||March 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457262||172628|
NCT00457535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|710808|Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning HD|Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis||Hamamatsu University||Terminated|August 2000|July 2004||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||April 2007|April 5, 2007|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457535||172607|
NCT00457821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX06-770-101|Safety Study of Ivacaftor in Subjects With Cystic Fibrosis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D||Vertex Pharmaceuticals Incorporated|Yes|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|39|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|April 5, 2007|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00457821||172585|
NCT00458042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-PH-412|Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction|Transitioning To Intravenous Remodulin® (Treprostinil Sodium) From Inhaled Iloprost (Ventavis®) in Patients With Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction||United Therapeutics|No|Terminated|March 2007|November 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|65 Years|No|||November 2007|November 9, 2007|April 5, 2007|||Low Enrollment|No||https://clinicaltrials.gov/show/NCT00458042||172568|
NCT00458289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0530|Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate|||University of Illinois at Chicago|No|Completed|January 2007|August 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 11, 2009|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00458289||172549|
NCT00454662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-JAN-2007|Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)|Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)||COLM Study Research Organization|Yes|Completed|April 2007|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5141|||Both|65 Years|84 Years|No|||January 2013|January 22, 2013|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00454662||172824|
NCT00454636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20777|A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.|An Open-label Study of the Effect of First Line Treatment With Xeloda in Combination With Chemotherapy on Safety and Treatment Response in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-based Regimen.||Hoffmann-La Roche||Completed|February 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|159|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00454636||172826|
NCT00454649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061019|Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor|A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors||Pfizer|No|Completed|December 2005|April 2011|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|March 29, 2007|No|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00454649||172825|
NCT00455182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 06 10 007|Acupuncture for Pain Management After Hip or Knee Arthroplasty|Acupuncture for Pain Management After Hip or Knee Arthroplasty||HealthEast Care System|No|Withdrawn|March 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|March 29, 2007||No|Inability to enroll subjects who were willing to be randomized to control group|No||https://clinicaltrials.gov/show/NCT00455182||172786|
NCT00456235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I06024|Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors|Interruption of the Calcineurine Inhibitors (ICN) and Introduction of Mycophenolate Mofetil (MMF) in Liver Transplant Patients With Side Effects Due to ICN: Study of the Reduction of the Risks of Rejection by Mycophenolate Mofetil Therapeutic Drug Monitoring|MONOCEPT|University Hospital, Limoges||Completed|September 2006|September 2011|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|80 Years|No|||April 2007|April 16, 2013|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456235||172707|
NCT00456534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 014|The Effect of Smoking on Perception|||American University|No|Recruiting|November 2006|June 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||||130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456534||172684|
NCT00457093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-07|A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes|A Double Blind, Randomized, Parallel, Cross-Over Comparision of Glycemic Control Achieved With Once a Day Insulin Glargine Versus Detemir in Type 2 Diabetes||Diabetes Care Center|No|Completed|October 2006|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||April 2007|November 17, 2010|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00457093||172641|
NCT00457327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|433/2005|Pilot Study for Evaluation of the Need for Protective Ileostomy After Low Anterior Resection Due to Rectal Cancer|Pilot Study for Evaluation of the Need for Protective Ileostomy After Low Anterior Resection Due to Rectal Cancer||Heidelberg University|No|Terminated|July 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|April 4, 2007||No|RCT with same hypothesis ended and showed a superiority for protective ileostomy after lower    anterior rectum resection.|No||https://clinicaltrials.gov/show/NCT00457327||172623|
NCT00457080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPNO-P806|Application of Capnography Monitoring on the General Care Nursing Unit|Application of Capnography Monitoring on the General Care Nursing Unit|ETCO2|Texas Health Resources|Yes|Completed|October 2006|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 8, 2008|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00457080||172642|
NCT00430196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 02-0510|BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity|Placebo-Controlled Trial of BOTOX® Versus Zanaflex® for the Treatment of Subjects With Post Stroke Upper Limb Spasticity||Icahn School of Medicine at Mount Sinai||Completed|December 2003|September 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||135|||Both|18 Years|85 Years|No|||January 2007|January 31, 2007|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00430196||174677|
NCT00430482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017904|Stress, Distress Intolerance, and Drug Dependence|Stress, Distress Intolerance, and Drug Dependence||Boston University|Yes|Completed|June 2005|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|70 Years|No|||April 2013|May 23, 2013|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430482||174657|
NCT00457548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R49/CCR123228-03|Phone Intervention for Alcohol (ETOH) Use in Emergency Department Motor Vehicle Crash (ED MVC) Patients|Study of Effectiveness of BI Given to Injured MVC ED Patients Who Use Alcohol Harmfully and Hazardously|DIAL|Rhode Island Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||February 2009|March 29, 2011|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00457548||172606|
NCT00457561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19710808|Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis|||Hamamatsu University||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||April 2007|April 5, 2007|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457561||172605|
NCT00457834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Um dnr 03-032|Bi-Ventricular Pacing in Patients With Atrial Fibrillation and Heart Failure (BIFF-Study)|Study on the Efficacy of bi-Ventricular Pacing of Patients With Severe Heart Failure and Chronic Atrial Fibrillation|BIFF|Umeå University||Active, not recruiting|November 2003|June 2008|Anticipated|June 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||January 2008|January 8, 2008|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457834||172584|
NCT00458068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL-NEO-IRON-1|Early Versus Late Enteral Iron in Infants Less Than 1301 Grams|Prospective Randomized Trial of Early Versus Late Enteral Iron Supplementation in Infants With a Birth Weight of Less Than 1301 Grams||University of Ulm|No|Completed|June 1996|September 1999|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention||||126|||Both|N/A|7 Days|No|||April 2007|April 6, 2007|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00458068||172566|
NCT00458055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHC-RI 0906|High-Density Lipoprotein (HDL) Treatment Study|Treatment Study for Severe High-Density Lipoprotein Deficiency||McGill University Health Center|Yes|Completed|November 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|April 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458055||172567|
NCT00458302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013159|Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir|A Randomised, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg O.D. vs a Triple Combination Therapy With DRV/r in HIV-1 Infected Patients With Undetectable Plasma HIV-RNA on Their Current Treatments.|MONET|Janssen-Cilag International NV|Yes|Completed|June 2007|January 2011|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||December 2012|December 14, 2012|April 6, 2007|Yes|Yes||No|February 4, 2010|https://clinicaltrials.gov/show/NCT00458302||172548|This study was not blinded and not designed to demonstrate a safety benefit to stopping nucleoside analogues.
NCT00458523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-CTRU-CLL207|Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission|Eradication of Minimal Residual Disease (MRD) in Patients With Chronic Lymphocytic Leukaemia (CLL) With Alemtuzumab: A Phase II Study||National Cancer Institute (NCI)||Completed|December 2006|February 2008|Actual|||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|54|||Both|18 Years|N/A|No|||April 2007|August 9, 2013|April 9, 2007||||No||https://clinicaltrials.gov/show/NCT00458523||172531|
NCT00454675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-2006-01|Pulmonary Function Changes in 10 Pack Year Smokers With Chronic Bronchitis|Pulmonary Function Changes in 10 Pack Year Smokers With Chronic Bronchitis||Westside Family Medical Center, P.C.||Completed|March 2007|August 2008|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|80 Years|No|Probability Sample|Primary care|June 2008|August 13, 2008|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00454675||172823|
NCT00454909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109377|Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.|Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.||GlaxoSmithKline||Completed|April 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|873|||Both|10 Years|25 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|March 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00454909||172807|
NCT00455169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URRSRB15397A|Influenza Vaccine in Premature Infants|Influenza Vaccine Immunogenicity in Extremely Premature Infants||University of Rochester|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|66|None Retained|No retention|Both|6 Months|17 Months|No|Probability Sample|Premature infants < 30 week's gestation, < 1001 grams' birth weight or full-term infants        37-42 week's gestation >2500 grams' birth weight|September 2015|September 15, 2015|March 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00455169||172787|
NCT00455195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03206|Late-Onset Treatment Study Extension Protocol|An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704||Sanofi|Yes|Completed|March 2007|November 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|8 Years|N/A|No|||February 2014|February 4, 2014|March 30, 2007|Yes|Yes||Yes|November 23, 2011|https://clinicaltrials.gov/show/NCT00455195||172785|
NCT00455975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 43|High-dose Bevacizumab in Advanced Renal Carcinoma Patients|Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma||SCRI Development Innovations, LLC|No|Completed|February 2007|September 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|April 3, 2007|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00455975||172726|
NCT00455988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Questionnaire06-27-1|Developement of Questionnaire to Evaluate a Regularity of Lifestyle in Type 2 Diabetic Patients|||Eulji University Hospital|No|Recruiting|September 2006|December 2007|Anticipated|||Phase 4|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional||||360|||Both|30 Years|80 Years|No|||April 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00455988||172725|
NCT00456248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX-CIFN-402|Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin|Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy|ENHANCE|Kadmon Pharmaceuticals|Yes|Terminated|February 2007|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|65 Years|No|||October 2012|October 11, 2012|April 2, 2007|Yes|Yes|slow enrollment|No||https://clinicaltrials.gov/show/NCT00456248||172706|
NCT00456261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 139|First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC|A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|March 2007|September 2012|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|70 Years|N/A|No|||January 2013|January 23, 2013|April 3, 2007|No|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00456261||172705|
NCT00426049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE07|Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation|Monocenter, Double Blinded, Prospective, Randomized Placebo Controlled Study Investigating Prevention of Major Adverse Cardiac Events (MACEs) Within 6 Months by Systemic Treatment With Everolimus After Coronary Intervention With Bare Metal Stents in Patients With Significant Coronary Artery Disease||German Heart Institute||Recruiting|October 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||484|||Both|18 Years|N/A|No|||January 2007|January 23, 2007|January 23, 2007||||No||https://clinicaltrials.gov/show/NCT00426049||174986|
NCT00456547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-020|Coagulation Factor Changes Associated With Postpartum Hysterectomies|Coagulation Factor Changes Associated With Postpartum Hysterectomies||Northwestern University|No|Completed|December 2003|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women|March 2014|March 17, 2014|April 3, 2007||No||No|November 6, 2011|https://clinicaltrials.gov/show/NCT00456547||172683|
NCT00456560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV650-019|AV650 Drug-Drug Interaction Study|A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects||Avigen|No|Completed|April 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2007|September 13, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456560||172682|
NCT00456833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2111|Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy|A Combined Phase 1 and 2 Study Investigating the Combination of RAD001 and Erlotinib in Patients With Advanced NSCLC Previously Treated Only With Chemotherapy||Novartis|No|Completed|June 2005|||March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|80 Years|No|||April 2012|April 12, 2012|April 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00456833||172661|
NCT00456846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA042|First Line Therapy for Patients With Metastatic Breast Cancer|An Open-Label, Phase II Study of Weekly ABI-0007 as First Line Therapy for Patients With Metastatic Breast Cancer||Celgene|No|Terminated|February 2008|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Female|18 Years|N/A|No|||September 2015|September 25, 2015|April 3, 2007|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00456846||172660|
NCT00457886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2005-142|Measurement of Hormone Levels in Patients Receiving 17-HPC for Preterm Delivery|Serum Levels of Hormones Known to Affect Parturition in Patients Receiving 17 Alpha-Hydroxyprogesterone Caproate (17-P) for the Prevention of Preterm Delivery||Georgetown University||Completed|July 2005|June 2007||||Phase 4|Observational|Time Perspective: Prospective||1||20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|April 2007|June 30, 2009|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00457886||172580|
NCT00429910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000352370|Natural History Study of Patients With Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia (CML) Cohort||National Cancer Institute (NCI)||Completed|February 2003|||March 2009|Actual|N/A|Observational|N/A|||Anticipated|2000|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|January 30, 2007||||No||https://clinicaltrials.gov/show/NCT00429910||174699|
NCT00429923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-601A-002a|Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)|A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery||Sirion Therapeutics, Inc.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|219|||Both|2 Years|N/A||||May 2009|May 12, 2009|January 31, 2007||||No|May 12, 2009|https://clinicaltrials.gov/show/NCT00429923||174698|
NCT00430209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|083-GUK-2006-001|Neurovascular Coupling in Eyes of Glaucoma Patients|Neurovascular Coupling in Eyes of Glaucoma Patients||University Hospital, Basel, Switzerland|No|Completed|December 2006|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|150|||Both|40 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|glaucoma patients ocular hypertensives normal controls|December 2013|December 10, 2013|January 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00430209||174676|
NCT00430235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-001|A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer|A Phase II Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer||British Columbia Cancer Agency||Completed|March 2007|||August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Male|18 Years|N/A|No|||August 2010|August 4, 2010|January 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00430235||174675|
NCT00457574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM301|Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas|A Single-Center, Open-Label, Phase I Study of Single-Agent GMX1777 Administered as a 24-Hour Infusion Every 3 Weeks to Patients With Refractory Solid Tumors or Lymphomas||Teva Pharmaceutical Industries|No|Withdrawn|March 2007|August 2010|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|April 5, 2007|No|Yes|Study terminated prematurely due to financial constraints.|No||https://clinicaltrials.gov/show/NCT00457574||172604|
NCT00457587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wue-Immuno-ACC-83/05|Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma|Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma||University of Wuerzburg|No|Active, not recruiting|September 2005|December 2016|Anticipated|December 2011|Actual|Phase 0|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|70|Samples With DNA|whole blood for monocytes isolation serum urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adrenocortical carcinoma|September 2015|September 9, 2015|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457587|2 Years|172603|
NCT00458081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIMON_L_01031|Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors|A 12-month Multicentre, Randomised, Double-blind, Placebo-controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors.|RIALTO|Sanofi|No|Terminated|March 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|174|||Both|30 Years|75 Years|No|||December 2010|December 9, 2010|April 6, 2007||No|Company decision has been taken in light of recent demands by certain national health    authorities|No||https://clinicaltrials.gov/show/NCT00458081||172565|
NCT00458328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99010208|The Effect of Z-338 in Subjects With Functional Dyspepsia|The Effect of Z-338 in Subjects With Functional Dyspepsia, Evaluate the Function of Gastro-duodenum by Ultrasound||Zeria Pharmaceutical|Yes|Completed|April 2007|July 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|20 Years|79 Years|No|||November 2010|November 21, 2010|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458328||172546|
NCT00458549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000538993|Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery|Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids||National Cancer Institute (NCI)||Recruiting|July 2006|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|600|||Male|18 Years|N/A|No|||July 2008|February 6, 2009|April 9, 2007||||No||https://clinicaltrials.gov/show/NCT00458549||172529|
NCT00458315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cis/Gem/Tax +/- Avastin|Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor|Randomized Fase II Trial: Comparing Cisplatin, Paclitaxel and Gemcitabine Versus Cisplatin, Paclitaxel, Gemcitabine and Avastin in Patients With Unknown Primary Tumors||Rigshospitalet, Denmark|Yes|Withdrawn|May 2007|May 2012|Anticipated|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|70 Years|No|||September 2009|May 6, 2015|April 6, 2007||No|never been started|No||https://clinicaltrials.gov/show/NCT00458315||172547|
NCT00458536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-117|Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF|Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2004|December 2016|Anticipated|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 10, 2007|Yes|Yes||No|January 20, 2016|https://clinicaltrials.gov/show/NCT00458536||172530|
NCT00455208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURA-07-10|A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis|Study Evaluating Cura-100 in Rheumatoid Arthritis and Osteoarthritis||Cura Biotech LLC|Yes|Not yet recruiting|May 2007|December 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2007|February 18, 2009|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00455208||172784|
NCT00454922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0106|Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients|Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients||University of Colorado, Denver|No|Completed|October 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|N/A|No|||October 2008|December 4, 2012|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454922||172806|
NCT00455962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-001397|Effect of Race on Gonadotropin Responses|Effect of Race on Gonadotropin Responses to Short Term Negative and Positive Feedback Effects of Gonadal Steroids||Massachusetts General Hospital|Yes|Active, not recruiting|January 2005|December 2018|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|April 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455962||172727|
NCT00447057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10721|Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)|A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC||Eli Lilly and Company|No|Completed|March 2007|June 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|204|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|March 9, 2007|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00447057||173399|Baseline Characteristics are presented by histology (nonsquamous/squamous) for each arm. Per the protocol amendment of August 2008, study entry criteria were changed to exclude participants with predominantly squamous cell histology.
NCT00447070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICN 99034|Effect of Atazanavir on Endothelial Function in HIV-Infected Patients|Effect of Atazanavir on Endothelial Function in HIV-Infected Patients Compared to Standard Proteinase Inhibitors on Top of Potent Antiviral Combination Therapy|ENDOPACT|Foundation for Cardiovascular Research, Zurich|No|Completed|August 2004|May 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|18 Years|65 Years|No|||March 2007|May 26, 2009|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00447070||173398|
NCT00446771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-PK-101|A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects|||Pharmaxis||Completed|October 2006|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 12, 2007|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00446771||173421|
NCT00446784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6341006|Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis|A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate||Pfizer||Completed|April 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446784||173420|
NCT00446797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191332|Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain|An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain||Pfizer|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|N/A|No|||June 2009|June 12, 2009|March 9, 2007|Yes|Yes||No|April 21, 2009|https://clinicaltrials.gov/show/NCT00446797||173419|
NCT00447109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122/02|Time Interval for Changing Closed System Suction Catheters, Effect on Ventilator Associated Pneumonia|Endotracheal Suction With or Without Daily Changes of Closed System Suction. Effect on Ventilator Associated Pneumonia and Cost||Bayside Health|No|Completed|September 2003|April 2004||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||344|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 13, 2007|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00447109||173395|
NCT00447122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-PA-209|BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer|BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer: A Phase II Study #108181||Brown University|Yes|Terminated|March 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|March 12, 2007|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00447122||173394|
NCT00447135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04104|Immunologic Function in the Elderly After Injury|Immunologic Function in the Elderly After Injury: the Polymorphonuclear Leukocyte (PMN) and Innate Immunity||Summa Health System|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|55|||Both|66 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Elderly after injury|January 2008|January 28, 2008|August 7, 2006||No||No||https://clinicaltrials.gov/show/NCT00447135||173393|
NCT00447707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA015016|Positive Choice: Prevention for Positive Health|Positive Choice: Prevention for Positive Health||National Institute on Drug Abuse (NIDA)|No|Completed|December 2003|September 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||497|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2007|April 2, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447707||173350|
NCT00447720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704260|HIV Prevention Among Substance Abusing SMI|Translation of CDC and NIDA Programs to Prevent HIV/AIDS Among Persons With Serious Mental Illness||University of Pennsylvania|Yes|Completed|June 2004|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|238|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447720||173349|
NCT00468741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-193|Component and Couple Analysis of Cancer Communications|Component and Couple Analysis of Cancer Communications||University of Wisconsin, Madison|No|Completed|September 2003|June 2014|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|338|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|May 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00468741||171767|
NCT00468988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-06-21|Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers|Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers||Alcon Research||Completed|May 2007|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 23, 2012|May 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468988||171748|
NCT00468949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2713|Health-Related Quality of Life in Patients With Dupuytren's Disease|Health-Related Quality of Life in Patients With Dupuytren's Disease: A Prospective Cohort Study.||McMaster University|No|Completed|May 2007|July 2011|Actual|July 2011|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with dupuytren's contracture|July 2011|July 27, 2011|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00468949||171751|
NCT00468923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE-3|Heart Outcomes Prevention Evaluation-3|Heart Outcomes Prevention Evaluation-3|HOPE-3|Population Health Research Institute|Yes|Active, not recruiting|May 2007|March 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12705|||Both|55 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|May 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468923||171753|
NCT00468936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB 06-006|Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms|Open-Label, Randomized Study Comparing the Patient Reported Severity of GI Side Effects of MMF Versus EC-MPS in Maintenance Heart Transplant Patients.||McGill University Health Center|No|Recruiting|May 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2008|October 16, 2008|May 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468936||171752|
NCT00469261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP-TOP|Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling|Tetracycline (Doxycycline) In Patients With Large Acute Myocardial Infarction TO Prevent Left Ventricular Remodeling. TIPTOP Study|TIPTOP|Careggi Hospital|Yes|Completed|May 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469261||171727|
NCT00469508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA018185-03|Modafinil vs Placebo for the Treatment of Methamphetamine Dependence|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Modafinil vs Placebo for the Treatment of Methamphetamine Dependence|Modafinil|University of California, Los Angeles|Yes|Completed|April 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|May 3, 2007|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00469508||171708|study is powered to detect at least a moderate effect for modafinil (d = 0.50) in the overall sample; subgroups may be more meaningful
NCT00448838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20057548|Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Pilot Study of Gemcitabine, Oxaliplatin, and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|May 2006|March 2011|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00448838||173263|
NCT00448851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0528|Study of Dust Mite Inhalation in Humans|Phase 1 Study of Dermatophagoides Farinae Inhalation in Humans||University of North Carolina, Chapel Hill|No|Completed|February 2007|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Both|18 Years|50 Years|No|||December 2013|December 9, 2013|March 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00448851||173262|
NCT00449124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0061|TG4040 in Patients With Chronic HCV|A Phase I, Randomized, Double-Blind, Dose-Ranging, Crossover Trial of HCV Vaccine (TG4040) in Patients With Chronic Hepatitis C to be Conducted in Two Parts||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||September 2007|Anticipated|September 2007|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|85|||Both|18 Years|65 Years|No|||June 2008|August 26, 2010|March 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00449124||173241|
NCT00449631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multidrug Resistance|Multidrug Resistance After Trabeculectomy With Mitomycin C|Multidrug Resistance After Trabeculectomy With Mitomycin C||University of Cologne|No|Completed||||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Both|8 Years|85 Years|No|||March 2007|March 23, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449631||173204|
NCT00449878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14293|Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|DIGEST|Anthera Pharmaceuticals|Yes|Completed|May 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|7 Years|N/A|No|||October 2014|October 15, 2014|March 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449878||173185|
NCT00445614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M187|The Effects of Trout Fed With a Vegetable Based Feed on Cardiovascular Risk Markers and Plasma Proteome|Healthy, Nutritious and Tasty Fish for the Future||University of Copenhagen|No|Completed|March 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|3||Anticipated|72|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||August 2008|August 12, 2008|March 8, 2007||||No||https://clinicaltrials.gov/show/NCT00445614||173508|
NCT00445627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070115|Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus|Natural History of Type 2 Diabetes Mellitus in Children and Young Adults||National Institutes of Health Clinical Center (CC)||Recruiting|March 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|430|||Both|8 Years|25 Years|Accepts Healthy Volunteers|||August 2015|September 12, 2015|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00445627||173507|
NCT00445653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450146|Risk Factors for Barrett's Esophagus in Patients With BE, Gastroesophageal Reflux, or Gastrointestinal Bleeding|Molecular Epidemiology of Barrett's Esophagus||Massachusetts General Hospital|No|Completed|August 2005|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|170|Samples With DNA|Blood samples only were collected|Both|18 Years|90 Years|No|Non-Probability Sample|Patients coming in for EGD|September 2015|September 30, 2015|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445653||173506|
NCT00445666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070064, CDR0000532130|Tumor-Infiltrating Lymphocytes in Treating Patients With Persistent or Recurrent B-Cell Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma After a Previous Donor Stem Cell Transplant|Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 2007|||||Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|75 Years|No|||September 2011|September 29, 2011|March 7, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00445666||173505|
NCT00446745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU628|Abdominal Adiposity and Muscle Mitochondrial Functions|Study of Interaction Between Adipose and Muscle Tissues in the Control of Muscle Mitochondrial Functions|Mithycal|Institut National de la Recherche Agronomique|No|Completed|April 2006|January 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Male|35 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  60 Male subjects          -  Age between 35 and 50          -  waist circumference (Waist) > 75 cm             15 men with Waist between 75 and <87cm, 15 men with Waist between 87 and <94cm, 15             men with Waist between 94 and <102cm, and 15 men with Waith equal or higher than             102cm.|September 2012|September 18, 2012|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446745||173423|
NCT00446758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14511|Trial of Zinc and HIV Progression in Children|Trial of Zinc and HIV Progression in Children||Harvard School of Public Health|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|440|||Both|6 Weeks|60 Months|No|||September 2012|September 13, 2012|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446758||173422|
NCT00447083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-CDR-Fibromyalgia|Benefits of Tanning in Fibromyalgia Patients|A Pilot Study of the Effect of Ultraviolet Light on Pain in Persons With Fibromyalgia Syndrome||Wake Forest School of Medicine|No|Completed|May 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|25 Years|60 Years|No|||February 2009|February 12, 2009|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447083||173397|
NCT00446511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489K2302E1|Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension|An Extension to Study Protocol CVAL489K2302 to Evaluate the Long Term Safety, Tolerability and Efficacy of Valsartan in Children 6 to 17 Years of Age With Hypertension, Versus Enalapril Treatment for 14 Weeks, or Combined With Enalapril Versus Enalapril for 66 Weeks in Chronic Kidney Disease Patients.||Novartis|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|250|||Both|6 Years|17 Years|No|||June 2011|June 30, 2011|March 9, 2007|Yes|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00446511||173441|Study was prolonged from 14 to 66 wks for CKD patients only. Most CKD patients completed the initial 14 wk extension period prior to amendment approval and the study was terminated prematurely with 3 CKD patients progressing to a maximum of Visit 13.
NCT00447408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605006|Impact of a Personal Digital Assistant (PDA) - Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients|Impact of a PDA-Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients|BalanceWise-HD|University of Pittsburgh|Yes|Completed|January 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|22|||Both|21 Years|N/A|No|||June 2010|June 24, 2010|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00447408||173372|
NCT00447746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH 262|A Comparison Between D1 and D2 Lymphadenectomy in Gastric Cancer : A Prospective Randomized Controlled Trial|A Comparison Between D1 and D2 Lymphadenectomy in Gastric Cancer : A Prospective Randomized Controlled Trial||Tata Memorial Hospital|Yes|Not yet recruiting|March 2007|March 2014||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||600|||Both|18 Years|70 Years|No|||March 2007|March 14, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00447746||173347|
NCT00447395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-JB-1106-307-4|Genetic Abnormalities and Oxidative Stress in Sperm as Cause of Recurrent Miscarriage.|Genetic Abnormalities and Oxidative Stress in Sperm as Cause of Recurrent Miscarriage.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|February 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|90|||Male|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Couples with recurrent miscarriages|October 2015|October 21, 2015|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447395||173373|
NCT00448032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3180A1-107|Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male Subjects|A Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Ppm-204 Administered Orally to Healthy Male Japanese Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00448032||173325|
NCT00469014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0200|Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia|Busulfan-Fludarabine-Clofarabine With Allogeneic Stem Cell Transplantation for Advanced Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Advanced, Gleevec Refractory Chronic Myeloid Leukemia. A Randomized Phase II Study.||M.D. Anderson Cancer Center|Yes|Completed|September 2006|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|72|||Both|N/A|60 Years|No|||April 2013|April 1, 2013|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469014||171746|
NCT00469027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-PAH 001|Pulmonary Hypertension: Assessment of Cell Therapy|Phase I Trial to Establish Safety of Autologous Progenitor Cell-based Gene Therapy Delivery of heNOS in Patients With Severe Pulmonary Arterial Hypertension(PAH)Refractory to Conventional Treatment|PHACeT|Northern Therapeutics|Yes|Completed|May 2006|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469027||171745|
NCT00468715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-022|Bicalutamide in Treating Patients With Metastatic Breast Cancer|Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2007|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|May 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468715||171769|
NCT00469274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPES|Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure|A Randomized Open-Label Non-Inferiority Study to Examine the Impact of Pertussis Vaccination of Healthcare Workers on Post-exposure Prophylaxis|VPES|Vanderbilt University|No|Completed|May 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1102|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|May 3, 2007||No||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00469274||171726|
NCT00469287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7348|Early Diagnosis of Diabetes Mellitus Type 2 (DM2)|Exploration of Early Diagnosis of Diabetes Mellitus Type 2 Based on Traditional Chinese Medicine by MERID Diagnostics, Biophoton Measurements, Heart Rate Variability and Systems Biology|7348|TNO|No|Completed|June 2007|June 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||April 2008|April 4, 2008|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469287||171725|
NCT00469534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-9-0039|Minimized Time to Beam in Patients With High Grade Gliomas|A Pilot Study Evaluating Minimized Time to Beam Hypofractionated IMRT With PET-Assisted Target Definition in Patients With High Grade Gliomas||AHS Cancer Control Alberta|Yes|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2011|September 21, 2011|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00469534||171706|
NCT00469300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-H-221|Iontophoretic Application of Acyclovir Gel to Treat Cold Sores|A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of the Electrokinetic Transdermal System (ETS) With Acyclovir Gel for the Episodic Treatment of Herpes Labialis||Transport Pharmaceuticals|No|Completed|April 2007|October 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|810|||Both|18 Years|75 Years|No|||January 2008|January 31, 2008|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00469300||171724|
NCT00448864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501-001|Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement|KALAHARI-1: Kallikrein Antagonist (DX-88 [Ecallantide]) Effect on Blood Loss Associated With Heart Surgery Requiring Institution of Bypass||Cubist Pharmaceuticals LLC|Yes|Terminated|May 2007|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|75|||Both|18 Years|85 Years|No|||November 2015|January 5, 2016|March 16, 2007|Yes|Yes|Experience gained from this study is sufficient to design and facilitate the follow-on study.|No|April 22, 2015|https://clinicaltrials.gov/show/NCT00448864||173261|
NCT00449137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20050801|Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment|A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|June 2005|December 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449137||173240|
NCT00449644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011929|TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).|A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).||Janssen Infectious Diseases BVBA|Yes|Completed|June 2007|October 2012|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|208|||Both|18 Years|65 Years|No|||April 2014|April 10, 2014|March 16, 2007|Yes|Yes||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00449644||173203|In Participant Flow, deaths occurring during the trial are reported. In addition, 1 TMC207 and 2 placebo subjects in stage 1 and 4 TMC207 and 1 placebo subject in stage 2 died after discontinuation during long-term survival follow-up.
NCT00449657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJCC 07-01|Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC|Phase II Trial of Pulsed Paclitaxel With Concurrent Radiotherapy,and Adjuvant Chemotherapy in Stage III Non-Small Cell Lung Cancer||Leo W. Jenkins Cancer Center|No|Active, not recruiting|February 2007|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00449657||173202|
NCT00449670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109630|Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults|Assess the Consistency of the Immunogenicity of a GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults Aged Between 18 and 60 Years||GlaxoSmithKline||Completed|March 2007|June 2008|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|1206|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|March 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449670||173201|
NCT00449917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11|"Visiobiane Anti-age" Effects on Vision Parameters|Study of the Effects of "Visiobiane Anti-age" Dietary Supplement on Macular Pigment Optical Density, Contrast Sensibility and Visual Acuity||Pileje|No|Completed|September 2006|November 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||30|||Male|45 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00449917||173182|
NCT00449930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-049|Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)|A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1050|||Both|18 Years|78 Years|No|||April 2015|April 27, 2015|March 19, 2007|Yes|Yes||No|June 23, 2009|https://clinicaltrials.gov/show/NCT00449930||173181|Site 0490125 was non-compliant with Good Clinical Practice (GCP). Data from the 8 patients at this site were removed from all analyses.
NCT00449891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 97517|Neuropsychological and Neuroanatomical Studies of Young Children With and Without Type 1 Diabetes Mellitus|Neuropsychological and Neuroanatomical Studies of Young Children With and Without Type 1 Diabetes Mellitus||Stanford University|Yes|Active, not recruiting|January 2007|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|3 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|please see inclusion and exclusion criteria|September 2012|September 18, 2012|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00449891||173184|
NCT00445939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-729|A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease|A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease||Abbott||Completed|February 2007|||December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|15 Years|75 Years|No|||June 2011|June 20, 2011|March 7, 2007||No||No|December 23, 2008|https://clinicaltrials.gov/show/NCT00445939||173484|Small population, therefore no statistical tests were performed
NCT00446277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP01|Corneal Endothelial Cell Loss in Diabetes Type II During Cataract Surgery|Corneal Endothelial Cell Loss in Diabetes Type II During Cataract Surgery||Frederiksberg University Hospital|Yes|Suspended|January 2007|June 2007|Anticipated|June 2007|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|50 Years|N/A|No|||May 2008|May 9, 2008|March 9, 2007||No|The present study was joining 2005-41-4933 into one study|No||https://clinicaltrials.gov/show/NCT00446277||173459|
NCT00446212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.125|Dreaming and EEG Changes During Anaesthesia Maintained With Propofol or Desflurane|Dreaming and EEG Changes During Anaesthesia Maintained With Propofol or Desflurane||Melbourne Health|No|Completed|August 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|300|||Both|18 Years|50 Years|No|||May 2013|May 28, 2013|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446212||173464|
NCT00446225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EURTAC-SLCG // GECP06/01|Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR|Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR||Spanish Lung Cancer Group|Yes|Completed|February 2007|December 2012|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|N/A|No|||October 2008|March 8, 2013|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446225||173463|
NCT00446498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbosco1|CPAP Versus NPPV in ACPE|Continuous Positive Airway Pressure Versus Non-Invasive Positive Pressure Support Ventilation in Acute Cardiogenic Pulmonary Oedema: a Prospective Randomised Multicentre Trial.||Ospedale S. Giovanni Bosco||Completed|July 2002|May 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||April 2007|April 2, 2007|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00446498||173442|
NCT00446238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23MH064604-01A1|Treatment of Depressed Adolescents With Physical Illness|Treatment of Depressed Adolescents With Physical Illness||University of Pittsburgh|Yes|Completed|September 2002|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|11 Years|17 Years|No|||May 2014|May 19, 2014|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446238||173462|
NCT00446810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benfotiamine_ED_2007|Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus|Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System||Ruhr University of Bochum|Yes|Recruiting|September 2007|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|35 Years|70 Years|No|||September 2007|September 25, 2007|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00446810||173418|
NCT00446823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XC-0201-VU|Effectiveness of XCell on Autolytic Debridement of Venous Ulcers|A Prospective, Randomized, Controlled Clinical Study to Evaluate the Effectiveness of a Cellulose Matrix Wound Dressing for Autolytic Debridement and Healing of Chronic Venous Ulcers|XCell|Xylos Corporation|No|Completed|June 2002|December 2003||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2007|March 12, 2007|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446823||173417|
NCT00448045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133N060022|Preventing Pneumonia and Other Respiratory Problems in Persons With Spinal Cord Injury|Prevention of Long-Term Respiratory Complications of Spinal Cord Injury: a Randomized Controlled Trial||Kessler Foundation|Yes|Completed|June 2007|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|70 Years|No|||January 2013|January 14, 2013|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00448045||173324|
NCT00448344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-202|Family-supported Smoking Cessation for Chronically Ill Veterans|Family-Supported Smoking Cessation for Chronically Ill Veterans||VA Office of Research and Development|No|Completed|February 2008|July 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|471|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|March 14, 2007||No||No|August 13, 2014|https://clinicaltrials.gov/show/NCT00448344||173301|
NCT00469599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2006-005981-37|Treatment of Secondary Hyperparathyroidism in the Uremic Patient|Treatment of Secondary Hyperparathyroidism in the Uremic Patient. A Study Comparing Alfacalcidol and Paricalcitol||Roskilde County Hospital|Yes|Terminated|July 2007|October 2010|Actual|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|May 3, 2007||No|Terminated after 86 pt included, because of recruitment problems|No||https://clinicaltrials.gov/show/NCT00469599||171701|
NCT00469612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H0045|Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment|Evaluating the Efficacy of NeuroVisions's NVC Treatment for Low Myopia||Ohio State University|No|Completed|June 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||July 2008|April 9, 2010|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469612||171700|
NCT00469001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001|Evaluation of NT PRO BNP Guided Therapy on Hospitalization Rate and Mortality in Patients With Chronic HF NYHA II-IY|Phase 1 Study of Using BNP as Guided Parameter in Treatment HF||Hillel Yaffe Medical Center|No|Completed|June 2007|March 2010|Actual|January 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|108|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic heart failure. Half of the patients were treated by common medical        practice for patients with heart failure. The other half were treated according to BNP        values and common medical practice.|September 2010|September 12, 2010|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00469001||171747|
NCT00469326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC EK-361/05|Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study|Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study|TIPS|University Hospital, Motol|No|Completed|April 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|N/A|N/A|No|||January 2009|January 26, 2009|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469326||171722|
NCT00468962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-05|The Effct of Chitooligosaccharide on Immune Function in Healthy Adults|||Eulji University Hospital||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|20 Years|50 Years||||May 2007|May 2, 2007|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00468962||171750|
NCT00468975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7881004|A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.|A Phase IIA Randomised, Double-blind, Double Dummy, Placebo and Active Controlled 5-Way Cross-over Trial to Examine the Bronchodilator Effects of PF-610,355 and to Test for Superiority Versus Placebo in Reversible Asthmatic Patients||Pfizer||Completed|May 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||42|||Both|18 Years|65 Years|No|||October 2010|October 27, 2010|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00468975||171749|
NCT00469313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L1234|Efficacy of Inspiratory Muscle Training on Inspiratory Capacity in Patients With COPD|Efficacy of Inspiratory Muscle Training on Inspiratory Capacity in Patients||Hospital Hietzing|No|Enrolling by invitation|May 2007|||||N/A|Observational|Time Perspective: Prospective|||||||Both|40 Years|75 Years|No|||May 2008|May 21, 2008|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469313||171723|
NCT00469885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA13333-8|Reduction of Smoking in Cardiac Disease Patients|Harm Reduction Treatment for Smokers With Cardiovascular Disease {Reduction of Smoking in Cardiovascular Disease Patients (ROSCAP)}||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2001|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||June 2008|June 27, 2008|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00469885||171680|
NCT00449345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006055|Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis|||Assuta Hospital Systems|No|Recruiting|May 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 28, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449345||173224|
NCT00449358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Checking Wether the m-ALA Cream Could Mark Correctly the Borders of BCC's Tumors|Correlation Between Mohs Surgery and Microscopic Fluorescence Photometry in Determination of Histological Borders in Basal Cell Carcinoma .||Assuta Hospital Systems||Active, not recruiting|February 2006|April 2013|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||32|||Both|18 Years|N/A|No|||January 2006|April 14, 2013|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449358||173223|
NCT00449709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTA106004|A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects|A Two-part, Open-label, Cross-over Study to Assess the Pharmacokinetics of GSK221149 Following Single Oral Doses of Various Modified Release Formulations and a Solution in Healthy Adult Subjects||GlaxoSmithKline|No|Terminated|March 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|March 19, 2007||||||https://clinicaltrials.gov/show/NCT00449709||173198|
NCT00449943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006360-01H|Comparison of Cardiac Computed Tomographic Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)|Comparison of Cardiac Computed Tomographic Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)||Ottawa Heart Institute Research Corporation||Completed|September 2006|December 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|107|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00449943||173180|
NCT00449956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507A-149|MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)|Multicenter, Double-Blind, Active Comparator-controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers||Merck Sharp & Dohme Corp.||Completed|March 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|474|||Both|20 Years|N/A|No|||April 2015|April 7, 2015|March 19, 2007|Yes|Yes||No|January 23, 2009|https://clinicaltrials.gov/show/NCT00449956||173179|
NCT00445679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-336|Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD|A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|807|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|March 6, 2007|Yes|Yes||No|February 26, 2010|https://clinicaltrials.gov/show/NCT00445679||173504|
NCT00446290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0609|Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer|A Phase I Study of Docetaxel, Capecitabine and Oxaliplatin (DXO) in Patients With Advanced Stomach Cancer|DXO|Asan Medical Center|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|70 Years|No|||September 2015|September 2, 2015|March 9, 2007||No||No|December 15, 2013|https://clinicaltrials.gov/show/NCT00446290||173458|
NCT00446862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X070104001|The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study|Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study|FAACET|University of Alabama at Birmingham|Yes|Completed|March 2007|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|36|||Both|19 Years|85 Years|No|Non-Probability Sample|Adult patients with confirmed diagnosis of Fabry disease, who are receiving enzyme        replacement therapy with agalsidase beta|August 2013|November 17, 2013|March 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00446862||173414|
NCT00445913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509115|Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study|Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study||University of Pittsburgh|Yes|Completed|March 2007|February 2016|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445913||173486|
NCT00445926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-40206|Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in Schizophrenia|Deep TMS With the H Coils as a Novel Strategy for the Treatment of Negative Symptoms of Schizophrenia||Shalvata Mental Health Center|Yes|Completed|July 2006|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||May 2010|May 5, 2010|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00445926||173485|
NCT00446251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25668-A|Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant|The Highly Sensitized Patients: Effects of Rituximab and Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.||University of Washington|Yes|Completed|December 2006|December 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||March 2010|March 30, 2010|March 9, 2007|Yes|Yes||Yes|December 29, 2009|https://clinicaltrials.gov/show/NCT00446251||173461|
NCT00446524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A1302|Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)|A 54-week Extension to the Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of VAA489 (Valsartan and Amlodipine Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAA489 in Patients With Essential Hypertension (Extension From A1301 Study)||Novartis|No|Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|403|||Both|20 Years|N/A|No|||May 2012|May 6, 2012|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446524||173440|
NCT00447187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX201-01|Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk|A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk||Lux Biosciences, Inc.|Yes|Terminated|April 2007|November 2010|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|368|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|March 12, 2007|Yes|Yes|The primary efficacy endpoint was not met|No||https://clinicaltrials.gov/show/NCT00447187||173389|
NCT00447200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Validation of cycles|Study of the Natural Variation in Strokevolume|Study of the Natural Variation in Strokevolume, and Investigation in the Number of Cycles Necessary to Find a 10% Strokevolume Variation Using Esophageal Doppler||Rigshospitalet, Denmark|No|Completed|March 2007|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|20|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2007|October 12, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447200||173388|
NCT00447148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACIM 2006-001|Standard vs. 3-Dimensional Coronary Angiography: a Paired Comparison|Standard vs. 3-Dimensional Coronary Angiography: a Paired Comparison Using Intra-Coronary Marker Wires as Matched-Comparison "Gold Standard"|3-DCA|Antwerp Cardiovascular Institute Middelheim|No|Completed|October 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|36|||Both|18 Years|N/A|No|||October 2007|October 29, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447148||173392|
NCT00447161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTER_L_01125|Preventing Antibiotic-Associated DiarRhea Using Erceflora|Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Efficacy and Safety|PADRE|Sanofi||Completed|July 2006|||October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|6 Months|12 Years|No|||September 2008|September 4, 2008|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447161||173391|
NCT00447421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11089|A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy|Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer||Eli Lilly and Company|No|Terminated|February 2007|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2009|October 24, 2009|March 12, 2007|Yes|Yes|Interim results of another trial showed inferior activity of treatment|No|May 28, 2009|https://clinicaltrials.gov/show/NCT00447421||173371|The Study Phase 1 was stopped early based on interim results of another trial, showing inferior activity of pemetrexed/carboplatin compared to etoposide/carboplatin in extensive small cell lung cancer. The Study did not progress to Phase 2.
NCT00448058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SND 103285|A Study Of New Medicine (GSK 372475) For The Treatment Of Depression|A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/Day to 2.0 mg/Day) or Extended Release Venlafaxine XR (150 mg/Day to 225 mg/Day) Compared to Placebo in Adult s||GlaxoSmithKline||Completed|April 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|396|||Both|18 Years|64 Years|No|||November 2011|October 2, 2014|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00448058||173323|
NCT00448617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-PED-1094|Cigarette Smoke and Susceptibility to Influenza Infection|Cigarette Smoke and Susceptibility to Influenza Infection||University of North Carolina, Chapel Hill|No|Completed|July 2006|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|138|Samples With DNA|nasal lavage fluid, urine, blood, nasal epithelial tissue from subjects who consent to have      excess samples stored in our repository|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. smokers          2. nonsmokers who are NOT exposed to SHS|May 2015|May 28, 2015|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448617||173280|
NCT00469365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01HS010871|Pharmacy Interventions to Improve Chronic Disease Medication Refill|A Randomized Controlled Trial of Two Pharmacy Interventions to Improve Refill Adherence for Chronic Disease Medications||Medical University of South Carolina|Yes|Completed|January 2006|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|3048|||Both|N/A|N/A|No|||May 2007|November 25, 2008|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469365||171719|
NCT00469378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4M108119|Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis|An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast||GlaxoSmithKline|Yes|Completed|July 2007|February 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|65 Years|No|||June 2014|July 3, 2014|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469378||171718|
NCT00469339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907140|Risk Communication Within Mexican-American Families|The Role of Family History and Culture in Communal Coping Within Mexican-American Families||National Institutes of Health Clinical Center (CC)||Completed|April 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|560|||Both|18 Years|70 Years|No|||August 2015|August 28, 2015|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469339||171721|
NCT00469560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS0306|Safety, Tolerability, and Efficacy of Deferasirox in MDS|Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|June 2007|November 2013|Actual|March 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|158|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469560||171704|
NCT00469898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0321|Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase II Trial of Carboplatin and Irinotecan (CPT-11) as First-Line Therapy for Patients With Extensive Stage Small Cell Lung Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|December 2003|July 2010|Actual|July 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|May 3, 2007|Yes|Yes||No|October 11, 2010|https://clinicaltrials.gov/show/NCT00469898||171679|
NCT00445718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL00P2|Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging|Perinatal Neuroblastoma: Expectant Observation A Children's Oncology Group Pilot Study||Children's Oncology Group|No|Active, not recruiting|July 2001|||January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|97|Samples With DNA|Urine, Tumor tissue|Both|N/A|6 Months|No|Non-Probability Sample|Patients with sonographically identified adrenal mass|May 2015|May 11, 2015|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445718||173501|
NCT00445744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2130.00|Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome|Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.||Fred Hutchinson Cancer Research Center|Yes|Completed|December 2006|June 2013|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|65 Years|No|||April 2014|April 3, 2014|March 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00445744||173499|
NCT00445952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000423221|Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant|Fungemia Survey in Cancer Patients||National Cancer Institute (NCI)||Active, not recruiting|February 2005|||||N/A|Observational|N/A|||Anticipated|300|||Both|18 Years|N/A|No|||July 2009|May 14, 2011|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445952||173483|
NCT00445965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-122|Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer|Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms||Memorial Sloan Kettering Cancer Center||Recruiting|January 2006|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|131|||Both|N/A|N/A|No|||February 2016|February 8, 2016|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445965||173482|
NCT00445978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD-001|A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease|A Phase 2a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Efficacy of 6R-BH4 in Subjects With Sickle Cell Disease||BioMarin Pharmaceutical|No|Completed|April 2007|June 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|15 Years|N/A|No|||September 2014|September 4, 2014|March 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00445978||173481|
NCT00446303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM aza05|A Phase II Study of Maintenance With Azacitidine in MDS Patients|A Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission (CR or PR) After Intensive Chemotherapy||Groupe Francophone des Myelodysplasies|Yes|Terminated|July 2006|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|85 Years|No|||June 2010|January 18, 2012|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446303||173457|
NCT00445692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2135.00|Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma|Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|January 2007|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00445692||173503|
NCT00445705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203818-503|Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome|||Allergan||Terminated|March 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|211|||Female|18 Years|75 Years|No|||August 2015|August 25, 2015|March 7, 2007|Yes|Yes|This study was terminated early due to company decision. Part B was never conducted.|No|December 16, 2011|https://clinicaltrials.gov/show/NCT00445705||173502|This study was terminated early due to company decision. Only Part A results are presented; Part B was never conducted.
NCT00446316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-088|Effect of Antacids on Gleevec® in Healthy Volunteers|Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)||University of Pittsburgh|Yes|Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446316||173456|
NCT00446264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 01/48|Islet Allotransplantation With Steroid Free Immunosuppression|Sequential Islet Transplantation With Steroid Free Immunosuppression for Type 1 Diabetes||University Hospital, Lille|Yes|Completed|May 2003|February 2009|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||February 2009|April 23, 2012|March 9, 2007||No||No|May 18, 2009|https://clinicaltrials.gov/show/NCT00446264||173460|
NCT00446836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC IRB#03-0192-05|Efficacy and Safety Study of Xyotax to Treat Prostate Cancer|Phase II Study of Xyotax in Advanced Hormone Refractory Prostate Cancer||The Methodist Hospital System|No|Completed|March 2005|January 2008|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|March 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00446836||173416|
NCT00448409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI IRB#0106-0009|Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer|A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer||The Methodist Hospital System|No|Completed|May 2006|May 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|March 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448409||173296|
NCT00447798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK3156|Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users|Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users||Columbia University|Yes|Completed|June 2005|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|413|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447798||173343|
NCT00448071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTR107IL-104|Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients|A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients||Wolfson Medical Center|Yes|Recruiting|May 2006|March 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|20 Years|75 Years|No|||December 2006|March 14, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00448071||173322|
NCT00448084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070117|Brain Activity in People With Functional Movement Disorders|BOLD-fMRI of the Perception of Volition in Functional Movement Disorders||National Institutes of Health Clinical Center (CC)||Completed|March 2007|August 2008||||N/A|Observational|N/A||||65|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 6, 2008|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00448084||173321|
NCT00472173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06236|Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth|Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth|APEXMTA|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2007|May 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|6 Years|18 Years|No|||November 2011|November 9, 2011|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472173||171507|
NCT00469911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P20RR02064302|Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy|Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy|MRS|Washington University School of Medicine|No|Completed|August 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 2, 2014|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00469911||171678|
NCT00469573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5302|Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes|Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes||Innovative Medical||Completed|May 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469573||171703|
NCT00469586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1787|Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes|Efficacy and Safety of Inhaled Prandial Insulin Compared to Metformin Plus Glimepiride in Type 2 Diabetes|iINHALE 7|Novo Nordisk A/S|No|Terminated|April 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|174|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|May 3, 2007|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00469586||171702|
NCT00449722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-26/UCA|OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis|Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis||Dr. Falk Pharma GmbH|Yes|Completed|July 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||380|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00449722||173197|
NCT00449423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060810|Metabolic Modulation as Treatment in Acute Heart Failure|Metabolic Modulation as Treatment in Acute Heart Failure|MEMO|University of Aarhus|No|Terminated|March 2007|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|85 Years|No|||October 2007|October 24, 2007|March 19, 2007|||due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00449423||173219|
NCT00449696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-6606/01|Gel-200 Versus Placebo in Osteoarthritis of the Knee|A Multi-Center, Randomized, Double-Blind, Controlled, Parallel-Group Study of a Single Intra-Articular Injection of Gel-200 With a Single Intra-Articular Injection of Phosphate Buffered Saline (PBS) in Osteoarthritis of the Knee.||Seikagaku Corporation|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|379|||Both|40 Years|80 Years|No|||October 2011|October 3, 2011|March 20, 2007|Yes|Yes||No|April 15, 2011|https://clinicaltrials.gov/show/NCT00449696||173199|
NCT00446030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_00713|Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer|A Phase II, Open-Label, Multicenter, Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer||Sanofi|Yes|Completed|March 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Female|18 Years|70 Years|No|||June 2012|June 21, 2012|March 8, 2007|Yes|Yes||No|August 18, 2011|https://clinicaltrials.gov/show/NCT00446030||173478|The number of participants enrolled into the TCH with bevacizumab arm was reduced to half of the originally intended number. Therefore, all conclusions related to the safety of TCH with bevacizumab must be interpreted with caution.
NCT00446043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18089|A Long-Term Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris|A Long-Term Safety and Efficacy Study of a Fixed Combination of Adapalene 0.1% and Benzoyl Peroxide 2.5% (Adapalene and Benzoyl Peroxide Topical Gel) Gel in Subjects With Acne Vulgaris||Galderma||Completed|February 2004|May 2004||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||452|||Both|12 Years|N/A|No|||March 2007|March 8, 2007|March 8, 2007||||No||https://clinicaltrials.gov/show/NCT00446043||173477|
NCT00449995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1129/04|Confocal Laserscanning Microscopy for Detection of Barretts Esophagus|Confocal Laserscanning Microscopy for Detection of Barretts Esophagus. A Blinded Multi-Center Study.||Technische Universität München||Completed|March 2007|November 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Anticipated|73|||Both|18 Years|80 Years|No|||December 2008|December 23, 2008|February 23, 2007||||No||https://clinicaltrials.gov/show/NCT00449995||173176|
NCT00445731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002NT039|A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant|A Randomized Trial of the Effect of a Walking Regimen on the Functional Status of Adult Allogeneic Donor Bone Marrow Transplant Patients||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2002|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Actual|115|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445731||173500|
NCT00446563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489ADE02|Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy|An Open-label, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Amlodipine in Combination With Valsartan Compared to Losartan in Combination With Hydrochlorothiazide Given for 52 Weeks on the Regression of Left Ventricular Hypertrophy in Patients With Mild to Moderate Hypertension||Novartis|No|Completed|March 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|80 Years|No|||May 2011|May 6, 2011|March 12, 2007|No|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00446563||173437|
NCT00446576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005599|The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease|A Study in Early Renal Insufficiency Patients to Assess the Effect of Maintaining Three Different Hemoglobin Levels With the Use of Erythropoetin Alpha on Left Ventricular Hypertrophy and Dilation and Quality if Life; The "Cardiac Results of Early Treatment of Anaemia (CRETA)" Study||Janssen-Cilag B.V.||Completed|November 1999|April 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|176|||Both|18 Years|73 Years|No|||January 2011|January 31, 2011|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00446576||173436|
NCT00446849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-404|Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)|A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)||Shire||Completed|May 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|290|||Both|18 Years|N/A|No|||October 2011|October 19, 2011|March 12, 2007|No|Yes||No|April 9, 2010|https://clinicaltrials.gov/show/NCT00446849||173415|
NCT00447473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI IRB#0106-0010|Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer|Phase II Trial to Assess the Activity of Ketoconazole and Mitoxantrone Plus GM-CSF in Patients With Progressive Hormone Refractory Prostate Cancer||The Methodist Hospital System|No|Terminated|July 2006|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|March 12, 2007||No|PI decision|No||https://clinicaltrials.gov/show/NCT00447473||173368|
NCT00446537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240446|Procedural Learning in Participants With ADHD|||Shaare Zedek Medical Center|Yes|Not yet recruiting||||||Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|12 Years|50 Years||||January 2007|March 12, 2007|March 11, 2007||||No||https://clinicaltrials.gov/show/NCT00446537||173439|
NCT00446550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAU-CL-202|A Study of Oral AT2101 in Treatment-naive Patients With Gaucher Disease|A Randomized, Open-label Study To Assess the Safety and Tolerability of AT2101 in Treatment-naive Adult Patients With Type I Gaucher Disease||Amicus Therapeutics|Yes|Completed|December 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|74 Years|No|||May 2011|May 12, 2011|March 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00446550||173438|
NCT00447434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I050308|Efficacy and Safety of Natto Extract|An Open-Label, Parallel Comparison Study to Evaluate the Effect of Oral Administration of Nattokinase Taken by Normal Subjects, Patients Under Dialysis, and Patients of Cardiovascular High Risk Groups||Changhua Christian Hospital|No|Completed|June 2005|October 2005||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||45|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2007|March 13, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447434||173370|
NCT00447863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A2-109|Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women|An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study to Compare Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg in 2 Dosage Forms With Different Dissolution Characteristics in Healthy, Cycling Women||Wyeth is now a wholly owned subsidiary of Pfizer||Withdrawn|August 2007|August 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2010|August 21, 2010|March 13, 2007||||||https://clinicaltrials.gov/show/NCT00447863||173338|
NCT00448110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-004|Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery|Randomized, Double-Blind, Active- and Placebo-Controlled Study of the Efficacy and Safety of Repeated Dosing of DIC075V Relative To Parenteral Ketorolac and Placebo in Patients With Acute Post-Op Pain After Abdominal or Pelvic Surgery||Javelin Pharmaceuticals|No|Completed|May 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|331|||Both|18 Years|65 Years|No|||May 2009|May 21, 2009|March 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448110||173319|
NCT00447759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCOT Trial|The Standard Care Versus Celecoxib Outcome Trial|Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's|SCOTLSSS|University of Dundee|Yes|Completed|June 2007|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|7300|||Both|60 Years|N/A|No|||January 2016|January 7, 2016|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00447759||173346|
NCT00447772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52120-098|Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia|Open Multicentre Study to Demonstrate the Efficacy and Safety of Botulinum Toxin A (500 Units Dysport®) in the Treatment of Heterogeneous Forms of Cervical Dystonia||Ipsen|No|Completed|October 2004|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|516|||Both|18 Years|N/A|No|||July 2009|July 23, 2009|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447772||173345|
NCT00447785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nutrialcohol|Endocrine Regulation of Energy and Fluid Supplies in Alcoholic Patients|Etude Des déterminants Endocrinologiques Des Apports énergétiques et Fluides Des Patients Alcooliques en Cours de Sevrage||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|September 2004|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2007|March 14, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00447785||173344|
NCT00448942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01115|The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections|The Impact of the Use of Chlorhexidine-Based Bathing System in the Hospital to Reduce the Incidence of MRSA/VRE Infection or Colonization and Nosocomial Bloodstream Infections (BSI)||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Completed|November 2004|January 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||5300|||Both|18 Years|N/A|No|||March 2007|March 15, 2007|March 15, 2007||||No||https://clinicaltrials.gov/show/NCT00448942||173255|
NCT00448955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-0403-004|Open-Label Study of ARD-0403 in Testosterone Deficient Men|A Phase III Open-Label Study of the Efficacy and Safety of ARD-0403, a Testosterone Cream, in Testosterone Deficient Men||Ardana Bioscience Ltd||Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|150|||Male|18 Years|N/A|No|||April 2008|April 17, 2008|March 16, 2007||||No||https://clinicaltrials.gov/show/NCT00448955||173254|
NCT00467961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070136|Stem Cell Transplantation for Patients With Cancers of the Blood|Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies||National Institutes of Health Clinical Center (CC)|Yes|Completed|April 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|75 Years|No|||December 2014|December 22, 2014|April 28, 2007|Yes|Yes||No|December 22, 2014|https://clinicaltrials.gov/show/NCT00467961||171827|
NCT00467974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC017|Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma|A Randomized Controlled Trial of Transarterial Ethanol Ablation (TEA) With Lipiodol-Ethanol Mixture (LEM) Versus Transcatheter Arterial Chemoembolisation (TACE) for Unresectable Hepatocellular Carcinoma||Chinese University of Hong Kong|Yes|Completed|June 2007|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||December 2014|January 21, 2015|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00467974||171826|
NCT00470145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP4110001|Comparison Of Two Tablet Formulations Of SB-568859|A Randomised, Single Blind, 2 Period, Crossover Study to Compare the Single Dose Pharmacokinetics and Tolerability of Formulations Containing Unmilled and Micronised SB-568859 in Healthy Adults||GlaxoSmithKline|No|Completed|April 2007|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00470145||171660|
NCT00450021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070118|Imaging of Cannabinoid Receptors Using New Radioactive Tracer|Imaging of Cannabinoid CB(1) Receptors Using [11C] MePPEP||National Institutes of Health Clinical Center (CC)||Completed|March 2007|||February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2008|May 10, 2012|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450021||173174|
NCT00450008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI IRB#1006-0153|Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer|Phase II Study of Patients With Hormone-Naïve Prostate Cancer With a Rising Prostate Specific Antigen: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Thalidomide Plus Docetaxel||The Methodist Hospital System|No|Terminated|December 2006|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|March 19, 2007||No|PI decision|No||https://clinicaltrials.gov/show/NCT00450008||173175|
NCT00446355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07010069|Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes|Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes||University of Pittsburgh|Yes|Completed|February 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|CDAD confirmed|April 2009|April 12, 2009|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446355||173453|
NCT00446017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-ANAE-101|The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG|Phase 3 Study of Adrenaline and Milrinone in Patients With Myocardial Dysfunction|AMORI|University of Luebeck|No|Completed|June 2003|April 2007|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|85 Years|No|||April 2007|June 2, 2015|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446017||173479|
NCT00446329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/16-01-2007|Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis|||Papageorgiou General Hospital||Terminated|July 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|March 9, 2007||No|due to financial problems|No||https://clinicaltrials.gov/show/NCT00446329||173455|
NCT00446615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-168|Multifaceted Intervention to Improve Prescribing in Patients With Chronic Kidney Disease|Multifaceted Intervention to Improve Prescribing of Medications Requiring Dose Adjustment in Patients With Chronic Kidney Disease||McMaster University|No|Not yet recruiting|March 2007|March 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|||||||Both|65 Years|N/A|No|||March 2007|March 9, 2007|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446615||173433|
NCT00446004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-074|Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers|Effect of a Proton Pump Inhibitor (Omeprazole, Prilosec®) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS258)||University of Pittsburgh|Yes|Completed|April 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|March 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00446004||173480|
NCT00447174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BromD1CTIL|Parental Bereavement Study Among Couples Coping Traumatic Loss of a Child|Dyadic Therapy Assessment Among Couples Coping With Traumatic Loss of a Child|PBS|Herzog Hospital|Yes|Recruiting|January 2007|March 2007||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||March 2007|March 13, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447174||173390|
NCT00446875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeedHatfield|Analgesic Properties of Oral Sucrose During Immunizations|Efficacy of Oral Sucrose and Maternal Contact During Routine Immunizations in Postnatal Infants||Penn State University|Yes|Recruiting|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||141|||Both|3 Months|11 Months|Accepts Healthy Volunteers|||March 2007|March 9, 2007|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446875||173413|
NCT00448448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR052113|Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)|Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)|BrAIST|University of Iowa|Yes|Completed|February 2007|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|383|||Both|10 Years|15 Years|No|||June 2014|June 23, 2014|March 14, 2007||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00448448||173293|Study was terminated early due to efficacy. 119 subjects were still on protocol.
NCT00447460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/EICH2005|Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell|A Phase I/II Trial in Treating Patients With Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell||University of Salamanca|Yes|Recruiting|January 2007|August 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|65 Years|No|||March 2007|March 20, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447460||173369|
NCT00448643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20020138|Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery|A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|May 2002|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|80 Years|No|||August 2013|July 25, 2014|March 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00448643||173278|
NCT00448656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p06.0550l|Treatment of Atrial Fibrillation by Minimal Invasive Surgery|Treatment of Atrial Fibrillation by Minimal Invasive Epicardial Pulmonary Vein Isolation: The ABOLISH-AF Study|ABOLISH-AF|University Medical Center Groningen|Yes|Completed|June 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|76 Years|No|||June 2012|June 18, 2012|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448656||173277|
NCT00448968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA-0806-003|The Utility of Ischemia Modified Albumin (IMA) in Sepsis|The Utility of Ischemia Modified Albumin (IMA) in Sepsis||Inverness Medical Innovations|No|Completed|March 2007|September 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 26, 2007|March 16, 2007||||No||https://clinicaltrials.gov/show/NCT00448968||173253|
NCT00468195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-002|Optimizing Image Quality in Obese Patients Undergoing Coronary Computed Tomography (CT) Angiography|Optimizing Image Quality in Obese Patients Undergoing Coronary CT Angiography|BMI40|William Beaumont Hospitals|Yes|Completed|May 2007|September 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|175|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers greater than 18 years of age; referred from EC, inpatients, physician offices|March 2012|March 20, 2012|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468195||171809|
NCT00468208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5522|Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis|A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis||University of Pennsylvania|Yes|Completed|February 2008|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|15 Years|N/A|No|||December 2015|December 15, 2015|April 30, 2007|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT00468208||171808|The main limitation of this trial is the small sample size and the open-label, uncontrolled design.
NCT00468221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0304|The Effect of Low Level Ozone Exposure on Healthy Volunteers|The Effect of Low Level Ozone Exposure on Healthy Volunteers|Lowoz|University of North Carolina, Chapel Hill|No|Withdrawn|June 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 30, 2007|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00468221||171807|
NCT00468520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20030859|Adjuvant Oxytocin for Preinduction Ripening With a Foley catheter--a Clinical Trial|A Prospective, Randomized Trial of Transcervical Foley Catheter With or Without Oxytocin for Preinduction Cervical Ripening||Columbia University|No|Completed|November 2003|October 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Female|18 Years|55 Years|No|||February 2011|February 28, 2011|May 1, 2007||||No||https://clinicaltrials.gov/show/NCT00468520||171784|
NCT00468845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081153|Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy|A Multiple Dose, Randomized, Double-Blind Multicenter Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Treatment Of Patients With Post-Surgical Pain From Hysterectomy||Pfizer|Yes|Completed|June 2007|October 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|501|||Female|25 Years|70 Years|No|||June 2011|June 7, 2011|May 1, 2007|Yes|Yes||No|April 29, 2011|https://clinicaltrials.gov/show/NCT00468845||171759|
NCT00445770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-315|Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Multicenter, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Active Rheumatoid Arthritis||Pfizer|No|Completed|July 2006|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|550|||Both|20 Years|75 Years|No|||August 2011|August 10, 2011|March 8, 2007|Yes|Yes||No|July 12, 2011|https://clinicaltrials.gov/show/NCT00445770||173497|Total Sharp Score and modified total Sharp Score were used interchangeably in the protocol and meant the same thing. In the statistical analysis plan and study results, mTSS was used consistently.
NCT00446056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-379|Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)|Montelukast, on Pediatric Bronchial Asthma in Multicenter Comparative Double-Blind Clinical Study (Phase IV) With Ketotifen Fumarate||Merck Sharp & Dohme Corp.||Completed|September 2003|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|188|||Both|6 Years|14 Years|No|||December 2015|December 16, 2015|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446056||173476|
NCT00445757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5806|Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors|Evaluation of a Radio-Surgical Approach for the Treatment of Kidney Tumors||Case Comprehensive Cancer Center|Yes|Withdrawn|January 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|March 7, 2007|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00445757||173498|
NCT00446082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230C2110|Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease|A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease||Novartis||Completed|June 2006|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|March 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00446082||173474|
NCT00446368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC IRB#03-0183-05|Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer|Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer|RAD001|The Methodist Hospital System|No|Completed|May 2005|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|March 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00446368||173452|
NCT00446342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0009|Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies|Phase 1 Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Advanced B-Lymphoid Malignancies||Sunesis Pharmaceuticals|No|Completed|February 2007|March 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|March 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00446342||173454|
NCT00446628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCPDCID-CC-0612047|Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children|Pittsburgh Influenza Prevention Project|PIPP|Centers for Disease Control and Prevention|Yes|Completed|January 2007|September 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3360|||Both|6 Months|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446628||173432|
NCT00446901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCRF 2004/21|Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression|Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression|SePros|Wageningen University|No|Completed|June 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Male|N/A|N/A|No|||March 2011|March 11, 2011|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446901||173411|
NCT00447213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10299|A Study for Patients With Type 1 Diabetes Mellitus|A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company||Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|N/A|No|||October 2010|October 12, 2010|March 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00447213||173387|
NCT00447226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT108741|Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists|A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer||GlaxoSmithKline|No|Terminated|May 2007|September 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|March 13, 2007|||The study had failed to meet the primary objective of tumor response rate at 12 weeks from    first dose.|No|January 11, 2010|https://clinicaltrials.gov/show/NCT00447226||173386|Study terminated prematurely: preliminary assessment (prompted by low screening/enrollment rates) showed primary objective of tumor response rate not met. Also unable to test primary treatment comparison after randomization following SD at 12 wks.
NCT00446888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71303|Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients|Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients||University of Arkansas||Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|35|||Both|40 Years|N/A|No|||June 2009|June 17, 2009|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446888||173412|
NCT00446589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47b/31-1-2005|The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density|||Papageorgiou General Hospital||Terminated|July 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|March 12, 2007||No|due to financial problems|No||https://clinicaltrials.gov/show/NCT00446589||173435|
NCT00446602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013198|A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)|A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Withdrawn||August 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|March 12, 2007|||Due to company decision to focus resources on a larger, controlled study in this patient    population.|||https://clinicaltrials.gov/show/NCT00446602||173434|
NCT00447811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-1109|Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance|Two Ascending Single Doses Crossover, Placebo Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MOA-728 Administered Orally to Subjects on Stable Methadone Maintenance||Valeant Pharmaceuticals International, Inc.||Completed|March 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|March 13, 2007||||||https://clinicaltrials.gov/show/NCT00447811||173342|
NCT00448097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI IRB#0206-0027|Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy|A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate||The Methodist Hospital System|No|Terminated|February 2007|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|March 14, 2007|No|Yes|lack of patient population - slow accrual|No||https://clinicaltrials.gov/show/NCT00448097||173320|
NCT00448136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20383|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.|An Open Label Study to Evaluate the Effect of Avastin in Association With Chemotherapy on Progression-free Survival in Patients With Progressive Advanced/Metastatic Well-differentiated Digestive Endocrine Tumors of the Gastrointestinal Tract||Hoffmann-La Roche||Completed|July 2007|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|March 15, 2007||No||No|October 31, 2014|https://clinicaltrials.gov/show/NCT00448136||173317|
NCT00448708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-VWAV06|Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access|Trial to Assess the Effectiveness of Maintaining Patency and Safety of the Vascular Wrap Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® ePTFE Vascular Graft in the Upper Extremity for Hemodialysis Vascular Access||Angiotech Pharmaceuticals|Yes|Terminated|March 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||October 2011|October 13, 2011|March 15, 2007|Yes|Yes|Due to an imbalance in graft infections between groups.|No|June 8, 2011|https://clinicaltrials.gov/show/NCT00448708||173273|Due to an observed imbalance in the number of graft infections, enrollment in the 1-year study 012-VWAV06 was suspended at the recommendation of the DSMC. Many of the planned efficacy analyses did not occur as a result of this suspension.
NCT00448422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT-099-002|Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers|A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers||Optimer Pharmaceuticals LLC|No|Completed|December 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|268|||Both|18 Years|N/A|No|||September 2010|September 22, 2010|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448422||173295|
NCT00448435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110099|Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma|A Study to Compare GW815SF HFA MDI With Concomitant Treatment With Salmeterol Xinafoate DPI Plus Fluticasone Propionate DPI and to Assess Long-term Safety of GW815SF HFA MDI||GlaxoSmithKline||Completed|April 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|5 Years|14 Years|No|||June 2010|June 3, 2010|March 14, 2007||||No|January 19, 2009|https://clinicaltrials.gov/show/NCT00448435||173294|
NCT00448669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-4940|Botswana TDF/FTC Oral HIV Prophylaxis Trial|Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana|TDF2|Centers for Disease Control and Prevention|Yes|Completed|March 2007|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1219|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00448669||173276|
NCT00449215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-88-H-0010|The Genetic and Life Style Determinants of Bone Mass of Young Greek Males|||University of Athens|No|Completed|October 2004|December 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||301|||Male|16 Years|35 Years|Accepts Healthy Volunteers|||March 2007|March 18, 2007|March 18, 2007||||No||https://clinicaltrials.gov/show/NCT00449215||173234|
NCT00449527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5896C00023|A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects|A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Daily Versus Weekly in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Actuations Twice Daily||AstraZeneca||Completed|March 2007|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|March 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449527||173212|
NCT00469105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-04-NN-16 (ADA)|Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills|Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills||Vanderbilt University|No|Completed|December 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|110|||Both|18 Years|85 Years|No|||April 2010|April 22, 2010|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469105||171739|
NCT00460070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M52332|Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine or Lamotrigine for Epilepsy|Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females.||Rikshospitalet University Hospital|No|Completed|January 2007|March 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|240|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Patients from the outpatients clinic|October 2009|July 26, 2011|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460070||172420|
NCT00460317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050201|MONET1-MOtesanib NSCLC Efficacy and Tolerability Study|A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.||Amgen|Yes|Terminated|July 2007|August 2013|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1450|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|April 12, 2007|Yes|Yes|Amgen discontinued the development of AMG706 because 20050201 did not meet its primary    objective.|No||https://clinicaltrials.gov/show/NCT00460317||172401|
NCT00462176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2818 - 20/02/2006 a|Laparoscopic Segmental Bowel Resection for Deep Infiltrating Colorectal Endometriosis|A Retrospective Follow-up of Patients After Laparoscopic Segmental Bowel Resection for Deep Infiltrating Colorectal Endometriosis||University Hospital, Gasthuisberg|No|Completed|September 2004|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|45|Samples Without DNA|The diagnosis of endometriosis was confirmed by histologic examination of resected lesions.|Female|19 Years|43 Years|No|Non-Probability Sample|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep        infiltrating endometriosis with active involvement of the colorectal surgeon performing a        bowel resection were selected retrospectively from the list of all patients (n=more than        400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and        July 2006.|February 2009|February 19, 2009|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00462176||172262|
NCT00450047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0662|Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia|Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia: a Randomized Controlled Trial||Hiroshima University|No|Completed|September 2005|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||120|||Both|65 Years|N/A|No|||March 2007|March 20, 2007|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450047||173172|
NCT00446069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-EG-002|A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients|A Double-Blind, Randomized, 2-Way Cross-Over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment||Egalet Ltd|No|Completed|August 2007|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|N/A|No|||September 2008|September 3, 2008|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446069||173475|
NCT00456014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6351R (formerly 5206)|Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment|Biological Predictors of Response to Antidepressants||New York State Psychiatric Institute|No|Completed|September 2006|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|65 Years|No|||May 2013|May 10, 2013|April 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00456014||172723|
NCT00446641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCC|Overcome Biochemical Aspirin Resistance Through Cilostazol Combination|Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients|ARCC|Asan Medical Center|No|Completed|March 2007|July 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|244|||Both|35 Years|N/A|No|||November 2009|December 10, 2009|March 12, 2007||No||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00446641||173431|
NCT00446914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|474-2006|High Blood Pressure Strategy (HBPS)|High Blood Pressure Strategy: Hypertension Management Initiative Study||Heart and Stroke Foundation of Ontario||Recruiting|January 2007|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|5000|||Both|18 Years|N/A|No|||August 2008|August 18, 2008|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446914||173410|
NCT00447265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ALN01|Etanercept for the Treatment of Lupus Nephritis|A Randomized, Double-Blind, Placebo-Controlled, Phase II, Multi-Center Study for Treatment of Lupus Nephritis by Inhibition of Tumor Necrosis Factor-alpha Using Etanercept||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|February 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|75 Years|No|||February 2013|February 6, 2013|March 12, 2007|Yes|Yes|The perceived risk-benefit ratio for individuals with early active RA|No|October 7, 2011|https://clinicaltrials.gov/show/NCT00447265||173383|The study terminated early with 1 subject enrolled. Based on safety info from other trials, the protocol chairs decided possible risks to patients outweighed the potential benefits. Analysis of groups is not possible. Study objectives cannot be met.
NCT00447499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS315|Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel|A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel|SALSA|Ipsen||Completed|April 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|March 12, 2007|Yes|Yes||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00447499||173366|
NCT00447824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-06471a|Pain Detection and Interception in Neonates|Pain Detection and Interception in Neonates During Blood Sampling||Sorlandet Hospital HF|Yes|Recruiting|March 2007|November 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||160|||Both|31 Weeks|36 Weeks|Accepts Healthy Volunteers|||March 2007|March 13, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447824||173341|
NCT00447837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRC-AB01-003|Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis|A Phase 2, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating the Safety and Efficacy of SPRC-AB01, Tobramycin Solution for Nasal Inhalation, in Post-Surgical Subjects With Chronic Sinusitis||Naryx Pharma|No|Completed|October 2006|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|16 Years|N/A|No|||December 2007|March 13, 2008|March 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00447837||173340|
NCT00447239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gluco study|The Effect of Intensive Insulin Therapy|The Effect of Intensive Insulin Therapy on the Incidence of Ventilator-Associated Pneumonia in Surgical Critically Ill Patients||University Medical Centre Ljubljana|Yes|Completed|September 2004|July 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||117|||Both|18 Years|N/A|No|||March 2007|October 23, 2008|March 13, 2007||||Yes||https://clinicaltrials.gov/show/NCT00447239||173385|
NCT00447486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBA109389|A Study of GW842166 in Adults With Osteoarthritis Pain|A Multicentre, Randomised, Double-Blind, Placebo and Naproxen (500mg) BID Controlled, Phase II Proof of Concept, Parallel Group Study to Assess the Efficacy and Safety of Oral GW842166 at Two Dose Levels Administered for 4 Weeks in Adults With Osteoarthritis of the Knee||GlaxoSmithKline||Completed|April 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|308|||Both|40 Years|N/A|No|||May 2009|May 15, 2009|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00447486||173367|
NCT00447850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-EL-1006- 307-2|Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization|Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization||Instituto Valenciano de Infertilidad, IVI VALENCIA||Completed|April 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|N/A|||||||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447850||173339|
NCT00457899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00003|Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder|RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)|RAPID|AstraZeneca||Terminated|July 2007|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|234|||Both|18 Years|65 Years|No|||November 2007|November 26, 2007|April 5, 2007|||Study terminated due to poor recruitment|No||https://clinicaltrials.gov/show/NCT00457899||172579|
NCT00457912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB05-00101|Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy|Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy||Nationwide Children's Hospital|No|Active, not recruiting|June 2005|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|whole blood, muscle tissue|Both|N/A|N/A|No|Non-Probability Sample|any subject with clinical diagnosis of LGMD|February 2015|February 2, 2015|April 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00457912||172578|
NCT00448682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20040005|Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery|A Phase II Study of Weekly 24-hour Infusion 5-fluoro-deoxyuridine (FUdR)/Leucovorin With Oxaliplatin and Docetaxel (Taxotere) as First-line Treatment in Patients With Metastatic Gastric Adenocarcinoma (IIT# 14065)||University of Miami Sylvester Comprehensive Cancer Center|Yes|Terminated|June 2005|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 15, 2007|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT00448682||173275|The study was terminated prematurely by the University of Miami Institutional Review Board. The results have not been analyzed.
NCT00448695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRTA06-1|MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer|Phase 1 Study of MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer||University Health Network, Toronto|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||June 2012|June 14, 2012|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00448695||173274|
NCT00448981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEZID-5033|Stopping Upper Respiratory Infections and Flu in the Family: The Stuffy Trial|Stopping URIs and Flu in the Family: The Stuffy Trial|STUFFY|Centers for Disease Control and Prevention|Yes|Completed|November 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|2788|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2012|October 1, 2012|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00448981||173252|
NCT00458614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU-10840|Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis|Lansoprazole Disposition in Young Children With Cystic Fibrosis||Arkansas Children's Hospital Research Institute||Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2011|April 9, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00458614||172524|
NCT00472186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-11-0513|The Effects of Reducing Stomach Acid on Post-Tonsillectomy Pain|The Effects of Gastro-Esophageal Acid Suppression on Post-Tonsillectomy Pain||Children's Hospital Boston|Yes|Recruiting|December 2007|May 2009|Anticipated|May 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||December 2007|December 26, 2007|May 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00472186||171506|
NCT00460330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HXJ-DFI-001|Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT|The Value of Real-Time Polymerase Chain Reaction (RT-PCR) Assay, Galactomannan and β-D-Glucan Detection (GM/G-Test) for Diagnosis of Invasive Fungal Infection (IFI) in Chinese Patients After Hematopoietic Stem Cell Transplantation (HSCT)||Peking University|Yes|Recruiting|April 2007|December 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||120|||Both|N/A|N/A|No|||April 2007|April 12, 2007|April 11, 2007||||No||https://clinicaltrials.gov/show/NCT00460330||172400|
NCT00460629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK126092000|Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation|Specific Cellular Immunotherapy in Patients With Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation||University Hospital Carl Gustav Carus|No|Completed|March 2005|||December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||June 2013|June 19, 2013|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460629||172377|
NCT00460967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHEO-AMD 01-06|Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis|Safety and Effectiveness, in a Multi-Center, Randomized, Sham Controlled Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD)Using Rheopheresis|RHEO-AMD|OccuLogix|No|Suspended|January 2007|December 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|325|||Both|50 Years|85 Years|No|||April 2007|November 6, 2007|April 16, 2007|||In light of the company's current financial position we have indefinately suspended the    Rheo-AMD trial.|No||https://clinicaltrials.gov/show/NCT00460967||172352|
NCT00460980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB9401|Effect of Virtual Reality Training by Novices on Laparoscopic Cholecystectomy in a Porcine Model|Effect of Virtual Reality Training by Novices on Laparoscopic Cholecystectomy in a Porcine Model||Columbia University|No|Withdrawn|May 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|April 13, 2007||No|Principal investigator left institution.|No||https://clinicaltrials.gov/show/NCT00460980||172351|
NCT00445796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM_L_0163|Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance|Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack|ATOL|Sanofi||Completed|June 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|N/A|N/A|No|||April 2008|April 8, 2008|March 8, 2007||||No||https://clinicaltrials.gov/show/NCT00445796||173495|
NCT00455273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237-2006|Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer|Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer||Sunnybrook Health Sciences Centre|Yes|Recruiting|November 2006|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Female|N/A|N/A|No|Non-Probability Sample|Women who are receiving neoadjuvant chemotherapy or neoadjuvant chemo-radiotherapy for        locally-advanced breast cancer.|April 2012|April 25, 2012|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00455273||172779|
NCT00455286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1406|a Phase II Study in Primary Central Nervous System Lymphoma|High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma – a Phase II Study||National Health Research Institutes, Taiwan|Yes|Recruiting|November 2006|November 2011|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|75 Years|No|||April 2007|April 3, 2007|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00455286||172778|
NCT00445783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-LCC-1/3/57|Study of Families With Melanoma|Melanoma Family Case-Control Study Protocol||National Cancer Institute (NCI)||Recruiting|July 2000|||December 2020|Anticipated|N/A|Observational|N/A|||Anticipated|3700|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|August 9, 2013|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445783||173496|
NCT00455793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000238|Subclinical Atherosclerosis in HIV-infected Patients|Subclinical Atherosclerosis in HIV-infected Patients||Massachusetts General Hospital|No|Completed|June 2006|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|263|Samples With DNA|DNA|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV infected men and women and non-HIV infected control men and women|November 2013|November 27, 2013|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455793||172740|
NCT00446381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-821|Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)|Effect of Macugen (Pegaptanib) on Surgical Outcomes and Growth Factors Including Vascular Endothelial Growth Factor (VEGF) Levels in Patients With Proliferative Diabetic Retinopathy (PDR) and Clinically Significant Diabetic Macular Edema (CSDME)|PEGAP001|Lawson Health Research Institute|No|Completed|October 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|28|||Both|18 Years|N/A|No|||April 2012|April 17, 2012|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446381||173451|
NCT00446654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47-MD-002|Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD|A Phase Ib Randomized Open Label Study Between Once-every-two-weeks and Once-every-four-weeks Treatment of CGC-11047 in Patients With CNV Due to Age Related Macular Degeneration||Progen Pharmaceuticals|No|Completed|April 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|50 Years|N/A|No|||June 2012|June 28, 2012|March 9, 2007|Yes|Yes||No|May 29, 2012|https://clinicaltrials.gov/show/NCT00446654||173430|Early termination leading to small numbers of subjects analyzed: 100 patients were planned; 43 patients were recruited.
NCT00446667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-COPD-HIP-101b|A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD|A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD||Pharmaxis|No|Completed|October 2006|June 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|35 Years|75 Years|No|||August 2008|August 27, 2008|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00446667||173429|
NCT00446927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001298|SPY Imaging System: Its Role in Pediatric Cardiac Surgery|SPY Imaging System: Its Role in Pediatric Cardiac Surgery||Emory University|No|Completed|April 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|N/A|18 Years|No|Non-Probability Sample|The study patients will be consented in the pre-operative clinic, Cardiac Intesive Care        unit or from the Cardiac Step-down Unit.|May 2012|May 22, 2012|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446927||173409|
NCT00446940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13133|Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C|Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C||Bader, Ted, M.D.|No|Completed|December 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|16|||Both|18 Years|75 Years|No|||September 2008|September 8, 2008|March 11, 2007||||No||https://clinicaltrials.gov/show/NCT00446940||173408|
NCT00447278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11576|A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents|A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naïve Children and Adolescents|ADHD LIFE|Eli Lilly and Company||Completed|March 2007|July 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|399|||Both|6 Years|16 Years|No|||April 2010|April 22, 2010|March 12, 2007|Yes|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00447278||173382|
NCT00447252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brom2CTIL|Needs Assessment for Bereaved Families|Needs Assessment for Bereaved Families|NABF|Herzog Hospital|Yes|Recruiting|January 2007|||||Phase 1|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|2 Years|N/A|Accepts Healthy Volunteers|||March 2007|March 13, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447252||173384|
NCT00447876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52120-100|Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis|Double-blind, Placebo-controlled, Randomised, Multicentre Study on the Efficacy and Safety of a Single Injection of Botulinum Toxin A (200 Units Dysport®) in the Treatment of Chronic Plantar Fasciitis||Ipsen|No|Completed|July 2005|April 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2009|October 20, 2009|March 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00447876||173337|
NCT00448123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-107|The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients|The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients||William Beaumont Hospitals|No|Completed|February 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|378|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 1, 2012|March 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448123||173318|
NCT00457678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAPER|Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself|A Multicenter, Randomized, Single-Masked Comparison of Lucentis™ Monotherapy With Triple Therapy of Reduced Fluence Visudyne-Lucentis-Dexamethasone (V-L-D) in Patients With CNV Secondary to AMD as Second Line Therapy After Lucentis Monotherapy||Vitreous -Retina- Macula Consultants of New York||Available||||||N/A|Expanded Access|N/A|||||||Both|50 Years|N/A||||December 2015|December 30, 2015|April 4, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00457678||172596|
NCT00448721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosne 228|A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer|A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma||AEterna Zentaris|Yes|Completed|March 2007|October 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2012|February 11, 2014|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448721||173272|
NCT00458133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK068298|Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes|Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes|HART-D|Pennington Biomedical Research Center|Yes|Completed|April 2007|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|262|||Both|30 Years|75 Years|No|||November 2012|November 2, 2012|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00458133||172561|
NCT00458146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-093-01-201|A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis|A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate||Merrimack Pharmaceuticals|No|Completed|February 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||March 2008|March 24, 2008|April 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458146||172560|
NCT00448994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0101|Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients|Serial Monitoring of Adenovirus and Fungal Load by Real-Time, Quantitative Polymerase Chain Reaction (PCR) Assay and Correlation With Outcomes in Pediatric Hematopoietic Stem Cell Transplant Patients||ViraCor Laboratories|No|Withdrawn|March 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|0|||Both|2 Years|17 Years|No|Non-Probability Sample|Pediatric|December 2014|December 8, 2014|March 15, 2007||No|Method development/validation|No||https://clinicaltrials.gov/show/NCT00448994||173251|
NCT00458406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-1-5190|Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA|Evaluation of Adherence and Therapeutic Effectiveness of BiPAP With Bi-Flex Versus CPAP in Children With Obstructive Sleep Apnea||Children's Hospital of Philadelphia|No|Completed|May 2007|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|2 Years|16 Years|No|||March 2014|March 31, 2014|April 6, 2007||No||No|January 10, 2013|https://clinicaltrials.gov/show/NCT00458406||172540|Limitations of the study include the relatively small sample size in the CPAP arm.
NCT00468247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP2006-01|Registration Enabling Study of the Safety and Efficacy of the Use of the Navigator Circulatory Management System|A Prospective,Open,Multicentre,RCT to Assess the Safety & Efficacy of Navigator v Conventional Care in Post-op Cardiac Surgery Patients Undergoing CABG &/or Heart Valve Repair/Replacement Utilising Heart Lung Perfusion Pump(The NAV-1 Study)|NAV-1|Applied Physiology Pty Ltd|No|Completed|March 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||April 2008|April 24, 2008|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468247||171805|
NCT00467987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Androgel 1920|Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism|Effect of Androgel on Atherogenesis, Inflammation, Cardiovascular Risk Factors And Adiposity in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism.: a Prospective, Randomized and Controlled-Study||University at Buffalo|No|Recruiting|June 2007|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|80|||Male|31 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|April 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467987||171825|
NCT00469625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z # 13178|A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease|A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease||Winthrop University Hospital|No|Withdrawn|July 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|85 Years|No|||December 2015|December 24, 2015|May 3, 2007||No|Investigator left the Institution.|No||https://clinicaltrials.gov/show/NCT00469625||171699|
NCT00455299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-06466b|LVHR Multicenter Study|Randomized Controlled National Multicenter Study for Evaluation of Two Different Ways of Fixation of Mesh-implants and Differences With or Without Approximation of Herniadefects at Laparoscopic Operation for Incisional and Ventral Hernia||Oslo University Hospital|No|Completed|March 2007|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|156|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455299||172777|
NCT00455559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 210|Ph II Study of Perifosine Plus Gleevec for Patients With GIST|A Phase II Study of Perifosine Plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor||AEterna Zentaris|No|Completed|August 2006|October 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2011|February 14, 2014|March 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455559||172758|
NCT00455780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66759 (completed)|Weight Loss Maintenance in Primary Care|Weight Loss Maintenance in Primary Care|PrimaryCare|Drexel University|No|Completed|January 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|238|||Both|18 Years|70 Years|No|||May 2011|May 24, 2011|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00455780||172741|
NCT00456313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM109352|No Resistance After Long Term Treatment SERETIDE|Rationale for Therapy With Low Dose Steroids Combined With Long-acting beta2-agonists in Patients With Allergic Asthma: Redirecting Innate Immune Responses by Long-term Treatment With High Doses of Inhaled Steroids||GlaxoSmithKline||Withdrawn|December 2007|December 2007|Anticipated|December 2007|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|50 Years|No|||April 2015|April 15, 2015|April 3, 2007||No|lack of data|No||https://clinicaltrials.gov/show/NCT00456313||172701|
NCT00456326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001941|Heparin-Induced Thrombocytopenia Registry|A 3 Year Retrospective Heparin Induced Thrombocytopenia Registry (HIT) at Brigham and Women's Hospital.|HIT|Brigham and Women's Hospital|Yes|Completed|October 2005|August 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|242|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with Heparin Induced Thrombocytopenia|February 2008|February 12, 2008|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456326||172700|
NCT00456287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-109|Platelet Activation and Circadian Rhythms of Clotting-Fibrinolysis Factors in Patients With Sleep Apnea Syndrome|Platelet Activation and Circadian Rhythms of Clotting-Fibrinolysis Factors in Patients With Sleep Apnea Syndrome. Implications in the Precipitation of Cardiovascular Events||Sociedad Española de Neumología y Cirugía Torácica|Yes|Recruiting|February 2007|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||40|||Male|25 Years|65 Years|No|||April 2007|April 2, 2007|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00456287||172703|
NCT00456599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.025|Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer|A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer||University of Michigan Cancer Center|Yes|Completed|April 2007|January 2013|Actual|May 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|April 4, 2007|Yes|Yes||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00456599||172679|
NCT00456872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0457|Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies|A Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies||Ohio State University Comprehensive Cancer Center|Yes|Completed|December 2004|May 2007|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|49|||Both|18 Years|N/A|No|Probability Sample|Oncology clinic|April 2012|April 13, 2012|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456872||172658|
NCT00457106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: 082-02|A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks|A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks||Beth Israel Medical Center||Completed|June 2002|June 2003|Actual|June 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|65 Years||||November 2010|November 30, 2010|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00457106||172640|
NCT00447889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-042|A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography|A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR)||Guerbet|No|Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||November 2008|November 25, 2008|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00447889||173336|
NCT00447902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.99|Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation|Safety and Antiviral Activity of TPV in Hepatitis C or Hepatitis B HIV Coinfected Patients - TDM Randomised Pilot Evaluation||Boehringer Ingelheim||Terminated|March 2007|||October 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|March 14, 2007||||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00447902||173335|Due to an early termination of the trial no analysis has been performed for primary and secondary endpoints
NCT00447915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JA19761|Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis|Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index -||Chugai Pharmaceutical|No|Completed|March 2007|December 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1265|||Both|60 Years|N/A|No|||July 2012|July 31, 2012|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00447915||173334|
NCT00458198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH070938|Integrated Behavioral Therapy for Treating Children With Selective Mutism|Integrated Behavioral Treatment for Selective Mutism||University of California, Los Angeles||Completed|January 2006|June 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|4 Years|8 Years|No|||May 2013|May 30, 2013|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00458198||172556|
NCT00458159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-11006-MDS-001|A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes|A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes||Celgene|No|Terminated|May 2007|December 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||August 2009|August 28, 2009|April 5, 2007|No|Yes|The compound has a benign safety profile with short-term use, clinically sig efficacy    responses have not been demonstrated, or if so, have not been sustained.|No||https://clinicaltrials.gov/show/NCT00458159||172559|
NCT00458172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00011805|Lay Theories of Health in Young and Middle Aged American Adults|Study 1 of Lay Theories of Health: Conceptualizations of Physical, Mental, and Social Health in Young and Middle-Aged Adults||University of Michigan|No|Recruiting|April 2007|July 2007|Anticipated|||Phase 2|Observational|Time Perspective: Cross-Sectional||||400|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2007|April 6, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00458172||172558|
NCT00457925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTA105101|Absorption, Distribution, Metabolism And Excretion Study For GSK221149A|An Open-label, Two Period Study to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK221149A, Administered as Single Doses of an Oral Solution and an Intravenous Infusion to Healthy Female Volunteers||GlaxoSmithKline||Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Female|30 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|April 6, 2007||||||https://clinicaltrials.gov/show/NCT00457925||172577|
NCT00458380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/2004|Perifollicular Vascularity Assessment in in-Vitro Fertilization|Clinical Use of the Perifollicular Vascularity Assessment in in-Vitro Fertilization Cycles: a Pilot Study||University Magna Graecia|No|Completed|September 2004|February 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||116|||Female|18 Years|N/A|No|||April 2007|April 9, 2007|April 6, 2007||||No||https://clinicaltrials.gov/show/NCT00458380||172542|
NCT00458393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iPrEx|Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men|Chemoprophylaxis for HIV Prevention in Men||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2007|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2653|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|April 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458393||172541|
NCT00472199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.629|Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)|A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period||Boehringer Ingelheim||Completed|May 2007|||July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|85 Years|No|||May 2012|June 17, 2014|May 10, 2007|Yes|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00472199||171505|
NCT00468559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9614C00096|Phase 3/Safety & Efficacy of Esomeprazole in Infants|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux (GERD) in Infants Aged 1 to 11 Months, Inclusive||AstraZeneca||Completed|April 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|98|||Both|1 Month|11 Months|No|||April 2014|May 6, 2014|April 30, 2007|Yes|Yes||No|June 3, 2009|https://clinicaltrials.gov/show/NCT00468559||171781|
NCT00468572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH075757|Using Affectionate Communication as a Response to Acute Stress|Affectionate Communication as a Mechanism for Responding to Acute Stress||Arizona State University|No|Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2012|January 6, 2012|May 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00468572||171780|
NCT00468234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-05|Validation of Biomarkers of Exposure and Host Response|Validation of Biomarkers of Exposure and Host Response||University of Nebraska|No|Completed|December 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||60|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 31, 2009|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00468234||171806|
NCT00468533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YLH-IRB-9506|The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial|The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial||Yu-Li Hospital|Yes|Recruiting|May 2006|July 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|16 Years|65 Years|No|||April 2007|April 30, 2007|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00468533||171783|
NCT00455806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESAMOX_01_2007|Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection|Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection|ESAMOX|Technische Universität Dresden|Yes|Recruiting|January 2007|February 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||132|||Both|18 Years|N/A|No|||March 2007|April 3, 2007|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00455806||172739|
NCT00455572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107240|Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer|Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer||GlaxoSmithKline||Terminated|May 2007|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|71|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|April 2, 2007|Yes|Yes|Study early termination was due to slow recruitment and difficulties at achieving the required    enrolment for the study.|No||https://clinicaltrials.gov/show/NCT00455572||172757|
NCT00456352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS07004|Duodenal Exclusion for the Treatment of T2DM|Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes Mellitus (T2DM)||Medtronic - MITG||Completed|April 2007|October 2010|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00456352||172698|
NCT00456638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16402|Clinical Study of Depodur Efficacy in Decreasing Post Operative Pain After Off Pump Coronary Artery Bypass Grafting (OP-CABG)|Clinical Study of Depodur Efficacy in Decreasing Post Operative Pain After Off Pump Coronary Artery Bypass Grafting (OP-CABG)||Drexel University|No|Withdrawn|April 2008|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|80 Years|No|||April 2008|August 13, 2014|April 4, 2007||No|Difficulty aquiring investigational drug|No||https://clinicaltrials.gov/show/NCT00456638||172676|
NCT00456027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/P2/04/2|Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)|A Placebo-Controlled Study to Investigate the Impact of Diamyd® on the Diabetes Status of Patients With LADA (Latent Autoimmune Diabetes in Adult)||Diamyd Therapeutics AB|Yes|Completed|December 2004|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|30 Years|70 Years|No|||April 2007|June 9, 2011|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456027||172722|
NCT00456300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16488|Role of Exenatide in Type 1 Diabetes|The Role of Exenatide in Type 1 Mellitus||Baylor College of Medicine|Yes|Completed|March 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|17|||Both|12 Years|21 Years|No|||November 2010|November 30, 2010|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456300||172702|
NCT00456612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P-000464|Radiosurgery for Glioblastoma Multiforme|Phase I/II Study of Fractionated CyberKnife Stereotactic Radiosurgery for High Grade Gliomas in Elderly Patients With Poor Performance Status||Beth Israel Deaconess Medical Center|No|Terminated|February 2007|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|66 Years|N/A|No|||December 2015|December 18, 2015|April 4, 2007||No|Poor accrual|No|June 22, 2011|https://clinicaltrials.gov/show/NCT00456612||172678|Early termination due to difficulty in recruitment and retaining due to extremely bad prognosis of disease
NCT00456885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-p-000361|The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women|The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus||Beth Israel Deaconess Medical Center|No|Completed|April 2007|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|42|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 24, 2012|April 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00456885||172657|
NCT00447512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L2/2003|Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones|Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones||Max-Planck-Institute of Psychiatry|No|Completed|March 2004|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2007|October 29, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00447512||173365|
NCT00447525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F05-TdI-301|REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-Old Children|Comparison of the Immunogenicity and Safety of a Combined Adsorbed Low Dose Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (REVAXIS®) With a Combined Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (DT Polio®) When Given as a Booster Dose at 6 Years of Age||Sanofi Pasteur MSD||Completed|February 2007|January 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|734|||Both|6 Years|6 Years|Accepts Healthy Volunteers|||April 2009|April 3, 2009|March 12, 2007||||No||https://clinicaltrials.gov/show/NCT00447525||173364|
NCT00457665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-56583|Mechanisms of Lipodystrophy in HIV-Infected Pateints|Mecahnisms of Lipodystrophy in HIV-Infected Patients||University of Texas Southwestern Medical Center|Yes|Completed|February 2002|October 2014|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||200|||Both|18 Years|70 Years|No|||August 2014|May 29, 2015|April 4, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00457665||172597|
NCT00458666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoagulationAmnioticFluid_CTIL|Coagulation Parameters During Pregnancy in Amniotic Fluid|Coagulation Parameters During Pregnancy in Amniotic Fluid||Rambam Health Care Campus|Yes|Recruiting|June 2006|||||N/A|Observational|Time Perspective: Longitudinal||||170|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2007|April 10, 2007|April 10, 2007||||No||https://clinicaltrials.gov/show/NCT00458666||172521|
NCT00458679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19747-PRIMAL|Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells|Prolonged Immunization With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells for Treatment of B-Chronic Lymphocytic Leukemia (B-CLL)|PRIMAL|Baylor College of Medicine|Yes|Completed|December 2006|August 2013|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|April 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00458679||172520|
NCT00454805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00007|AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer|A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients||AstraZeneca||Active, not recruiting|March 2007|December 2016|Anticipated|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|130 Years|No|||December 2015|January 11, 2016|March 29, 2007|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00454805||172814|
NCT00457938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1-074959|Novel Therapies for Metabolic Complications of Lipodystrophies|Novel Therapies for Metabolic Complications in Patients With Lipodystrophies||University of Texas Southwestern Medical Center|Yes|Recruiting|April 2006|December 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|72|||Both|14 Years|70 Years|No|||June 2013|June 19, 2013|April 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00457938||172576|
NCT00458419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17355|Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease|Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease||Dartmouth-Hitchcock Medical Center|No|Completed|September 2005|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|17|||Both|50 Years|90 Years|No|||October 2007|October 31, 2007|April 8, 2007||||No||https://clinicaltrials.gov/show/NCT00458419||172539|
NCT00458185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101871|Study Evaluating Etanercept in Patients With Ankylosing Spondylitis|Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||March 2008|March 11, 2008|April 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00458185||172557|
NCT00467766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0114|Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease|Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease||National Institute on Aging (NIA)|Yes|Completed|July 1999|June 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|300|||Both|21 Years|N/A|No|||May 2007|May 3, 2007|April 27, 2007||||No||https://clinicaltrials.gov/show/NCT00467766||171842|
NCT00467779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEK4592g|Study of GDC-0973/XL518 in Patients With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors||Genentech, Inc.||Active, not recruiting|April 2009|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00467779||171841|
NCT00468000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-55-0610-1|Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia|Use of Ixmyelocel-T (Formerly TRC Autologous Bone Marrow Cells) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia|RESTORE-CLI|Vericel Corporation|Yes|Completed|April 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|90 Years|No|||October 2012|October 1, 2012|April 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468000||171824|
NCT00468013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15-MUPS-8484|A Computer-Based Intervention for Medically Unexplained Physical Symptoms|||Rutgers, The State University of New Jersey|No|Completed|March 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||February 2015|February 6, 2015|April 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00468013||171823|
NCT00468260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2120E1|The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies-extension Study||Novartis||Terminated|May 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|May 1, 2007|Yes|Yes|pts. will be captured in core|No||https://clinicaltrials.gov/show/NCT00468260||171804|
NCT00468273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAM-PID-03-US|A Clinical Study of Intravenous Immunoglobulin|A Clinical Study of Immune Globulin Intravenous (Human) Omr-IgG-am IGIV in Subjects With Primary Immune Deficiency Diseases|IGIV|FFF Enterprises|Yes|Completed|November 2006|August 2009|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|57|||Both|3 Years|75 Years|No|||August 2014|August 7, 2014|May 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468273||171803|
NCT00468871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415-002|Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy|A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye||Bausch & Lomb Incorporated|Yes|Completed|April 2002|June 2006|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|6 Years|N/A|No|||December 2011|December 7, 2011|May 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468871||171757|
NCT00455819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTME/VL-06.12|Home Treatment of Patients With Pulmonary Embolism Based on Pro-Brain Natriuretic Peptide (BNP) Levels|Home Treatment of Patients With Pulmonary Embolism Based on Pro-BNP Levels||St. Antonius Hospital|Yes|Completed|December 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|150|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00455819||172738|
NCT00456040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-p-000302|Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant|Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation||Massachusetts General Hospital|No|Completed|March 2007|March 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||25|||Both|18 Years|N/A|No|||April 2007|April 3, 2007|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00456040||172721|
NCT00456053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-SM2216-019|A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin|A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin||FibroGen|No|Completed|December 2005|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|145|||Both|18 Years|N/A|No|||November 2007|November 2, 2007|April 2, 2007||||No||https://clinicaltrials.gov/show/NCT00456053||172720|
NCT00449592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4196-MKM-CTIL|Oral Zinc Therapy for the Prevention of Mucositis|A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support||Sheba Medical Center|No|Completed|April 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2008|October 2, 2008|March 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00449592||173207|
NCT00456625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108984|Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.|To Evaluate Immune Response to a Hepatitis B Vaccine (Engerix™-B ) Challenge Dose in Healthy Subjects Who Received GSK Biologicals' Hepatitis B Vaccine (Engerix™-B ) Approximately 20 Years Ago as Primary Vaccination at 0, 1, 2 and 12 Months.||GlaxoSmithKline||Completed|April 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|76|||Both|20 Years|21 Years|Accepts Healthy Volunteers|||May 2009|May 21, 2009|April 4, 2007|Yes|Yes||No|January 15, 2009|https://clinicaltrials.gov/show/NCT00456625||172677|
NCT00456898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-1203|Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway|A Randomized, Open-Label, 3-Period Crossover Study to Evaluate the Effect of Multiple Doses of DVS SR and Paroxetine on the CYP2D6 Biotransformation of Codeine to Morphine in Healthy Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2007|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00456898||172656|
NCT00457132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44/05|The Effect of Neuromuscular Training on Osteoarthritis: A Comparative Prospective Randomized Study|Dynamic Wedging: A Novel Treatment for Knee Osteoarthritis||Assaf-Harofeh Medical Center|No|Completed|September 2005|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|45 Years|85 Years|No|||April 2007|June 26, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457132||172638|
NCT00457145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070096|Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization||National Institutes of Health Clinical Center (CC)||Completed|March 2007|October 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|80 Years|No|||October 2007|October 25, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457145||172637|
NCT00457405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dipy003|Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?|Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?||Radboud University|No|Completed|June 2007|March 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457405||172617|
NCT00457418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04831|High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)|A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma||Merck Sharp & Dohme Corp.||Completed|February 2007|July 2012|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|April 5, 2007|No|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT00457418||172616|
NCT00457366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-05-00331|A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room|A Comparison Study of the Efficacy of a Rapid Titration of Quetiapine and Haloperidol in Agitated Adults in an Emergency Setting.||University of Southern California|Yes|Completed|May 2006|May 2009|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|60 Years|No|||January 2014|January 29, 2014|April 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00457366||172620|
NCT00457379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4031214|Effect of Exercise Training on the Function of HDL-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Coronary Artery Disease (HERCET-Study)|Randomized, Clinical Trial to Study the Effect of Exercise Training on the Function of HDL-Cholesterol, Endothelial Function, Oxidative Stress and Regenerative Capacity of Endothelial Progenitor Cells in Patients With Coronary Artery Disease|HERCET|Hannover Medical School||Recruiting|April 2007|April 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|30|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||April 2007|August 14, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457379||172619|
NCT00457392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181087|A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone|A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib||Pfizer|Yes|Completed|July 2007|December 2012|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|960|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|April 4, 2007|Yes|Yes||No|July 6, 2011|https://clinicaltrials.gov/show/NCT00457392||172618|
NCT00447980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTF 4|A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa|A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome||Neurotech Pharmaceuticals|Yes|Completed|January 2007|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|No|||April 2011|April 12, 2011|March 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00447980||173329|
NCT00447031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|koh02|Combination Therapy for Neovascular Age Related Macular Degeneration|Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone Acetonide Injection Versus Intravitreal Bevacizumab for Age Related Macular Degeneration||Yonsei University|No|Withdrawn|March 2007|November 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|N/A|No|||March 2009|February 5, 2010|March 12, 2007|||Insufficient patients who met inclusion criteria|No||https://clinicaltrials.gov/show/NCT00447031||173401|
NCT00447044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72779|Combined Effects of Nutritional and Exercise Countermeasures|Combined Effects of Nutritional and Exercise Countermeasures||University of Arkansas||Completed|January 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|31|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 17, 2009|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00447044||173400|
NCT00458653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-098|Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma|Vaccination With Dendritic Cell/Tumor Fusions in Conjunction With Autologous Stem Cell Transplant in Patients With Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2005|December 2016|Anticipated|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|April 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458653||172522|
NCT00468637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/04|Association of Multiple CardiOvascular Risk Factors and Erectile Function Across Europe|Association of Multiple CardiOvascular Risk Factors and Erectile Function Across Europe|AMORE-Eur|University Hospital, Saarland|No|Recruiting|May 2007|September 2011|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|1200|||Male|18 Years|N/A|No|Non-Probability Sample|primary care clinic, outpatient department, general practitioner|February 2009|February 13, 2009|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00468637||171775|
NCT00468026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Human Ex-Vivo - V001-3.2007|Evaluation of the ProstaPlant Prostate Stent Insertion in Ex Vivo Human Prostate|||ProstaPlant Urology System Ltd.||Not yet recruiting||||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Male|18 Years|N/A||||March 2007|April 30, 2007|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00468026||171822|
NCT00468039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237A2302S1|A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin|A Multicenter, Open-label Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin 100mg qd Plus Metformin 1000mg Bid in Drug Naive Patients With Type 2 Diabetes With Very Poor Glycemic Control||Novartis||Completed|March 2007|||June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|78 Years|No|||January 2013|January 2, 2013|April 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00468039||171821|
NCT00468286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS18|Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy|An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy||Ferring Pharmaceuticals|Yes|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Male|18 Years|N/A|No|||March 2011|March 21, 2011|April 13, 2007||Yes||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00468286||171802|
NCT00468611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBP8298-SP-03|Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis|A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis|MAESTRO-03|BioMS Technology Corp.|Yes|Terminated|June 2007|September 2009|Anticipated|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|510|||Both|18 Years|65 Years|No|||August 2009|August 12, 2009|May 1, 2007|Yes|Yes|Negative efficacy results of the MAESTRO-01 study|No||https://clinicaltrials.gov/show/NCT00468611||171777|
NCT00468585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-030|Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model|A Multicenter, Phase I/II Study of Every Other Week Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model||Memorial Sloan Kettering Cancer Center|Yes|Completed|June 2005|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|May 2, 2007|No|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00468585||171779|
NCT00468598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/07|The Prognostic Value of Troponin T for Long-term Outcome After Cardiac Surgery|The Prognostic Value of Troponin T for Long-term Outcome After Cardiac Surgery||University Hospital, Basel, Switzerland|No|Completed|January 2007|March 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3000|||Both|16 Years|N/A|No|Probability Sample|adults patients undergoing on-pump cardiac surgery at University Hospital Basel|March 2015|March 9, 2015|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00468598||171778|
NCT00449059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nitrate_USZ04|Nitrate and Hypertension in Heart Transplanted Patients|Acute Effect of Nitroglycerin on Cyclosporine-Induced Hypertension After Cardiac Transplantation||University of Zurich|No|Completed|January 2003|December 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|80 Years|No|||March 2007|March 15, 2007|March 15, 2007||||No||https://clinicaltrials.gov/show/NCT00449059||173246|
NCT00456066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0018|Coronary Thromboaspiration and Infarct Size|Assessment of Efficacity of Coronary Thromboaspiration (Export System) Performed Before Angioplasty on Infarct Size in Patients Treated by Coronary Percutaneous Interventions During Acute Phase.||University Hospital, Clermont-Ferrand||Terminated|June 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 7, 2008|April 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00456066||172719|
NCT00456339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001 (14397A)|Systemic Steroids Plus Antibiotics in Sleep Apnea Syndrome in Children|The Effect of a Combination of Systemic Steroids and Antibiotics on Obstructive Sleep Apnea Syndrome in Children||University of Chicago|No|Terminated|July 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Months|12 Years|No|||September 2013|September 4, 2013|April 3, 2007||No|Problems recruiting; patient relapse following treatment|No||https://clinicaltrials.gov/show/NCT00456339||172699|
NCT00445861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 75/06|Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery|Cetuximab in Combination With Radiation Therapy and Chemotherapy Prior to Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma. A Multicenter Phase IB-II Trial||Swiss Group for Clinical Cancer Research|Yes|Completed|January 2007|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|70 Years|No|||June 2012|June 8, 2012|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445861||173490|
NCT00445874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003-23|Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens Wearers||Vistakon Pharmaceuticals|No|Completed|February 2007|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|120|||Both|8 Years|N/A|No|||April 2009|April 8, 2009|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445874||173489|
NCT00456911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELPAS 2002-RN31|Family Dietary Coaching to Improve Nutritional Intakes and Body Weight Control|Prospective Longitudinal Study on Health and Diet (Etude Longitudinale Prospective Alimentation et Santé)|ELPAS|Centre d'Etudes et de Documentation du Sucre|Yes|Completed|March 2005|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||2020|||Both|6 Years|65 Years|Accepts Healthy Volunteers|||April 2007|February 12, 2008|April 3, 2007||||No||https://clinicaltrials.gov/show/NCT00456911||172655|
NCT00457431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HACA in-hospital|Hypothermia After In-hospital Cardiac Arrest|Hypothermia After In-hospital Cardiac Arrest|HACAinhospital|University of Schleswig-Holstein|Yes|Recruiting|April 2007|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00457431||172615|
NCT00457717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR94-IRB-49|Myopia Control by Combining Auricular Acupoint and Atropine Eyedrops|||China Medical University, China|Yes|Completed|July 2005|July 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Both|6 Years|15 Years|No|||April 2007|April 5, 2007|April 5, 2007||||No||https://clinicaltrials.gov/show/NCT00457717||172593|
NCT00457730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1083575|A Study to Test the Use of Duloxetine for Pain in MS|A Randomized Placebo Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis||Brown, Theodore R., M.D., MPH|No|Completed|January 2007|August 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 4, 2007|Yes|Yes||No|August 27, 2014|https://clinicaltrials.gov/show/NCT00457730||172592|
NCT00457964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB #2008-0812(04-07-22)|RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM|RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis||Children's Hospital Medical Center, Cincinnati|Yes|Completed|August 2005|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|No|||September 2013|September 23, 2013|April 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00457964||172574|
NCT00457119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2114|Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients|A Two-step Phase 1 Study Investigating the Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy||Novartis|Yes|Completed|February 2007|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|69|||Both|23 Years|76 Years|No|||February 2013|February 9, 2013|April 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00457119||172639|
NCT00457951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX-ODSH-2006|A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD|An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Subjects With Exacerbations of Chronic Obstructive Pulmonary Disease|COPD|Cantex Pharmaceticals|Yes|Terminated|April 2007|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|40 Years|N/A|No|||December 2012|December 13, 2012|April 6, 2007|No|Yes|Interim analysis results showed evidence of safety without efficacy of ODSH in patients with    acute COPD.|No||https://clinicaltrials.gov/show/NCT00457951||172575|
NCT00448240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS 05-03|Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer|Erlotinib (Tarceva) Given Intermittently During First Line Standard Platinum Containing Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck||Henry Ford Health System|No|Terminated|February 2007|January 2015|Anticipated|January 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2009|February 1, 2010|March 14, 2007|Yes|Yes|Low Accrual, Funding|No||https://clinicaltrials.gov/show/NCT00448240||173309|
NCT00447330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008710|Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma|A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas|XAGastric|Duke University|Yes|Completed|February 2007|July 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2014|January 28, 2015|March 13, 2007|Yes|Yes||No|January 20, 2015|https://clinicaltrials.gov/show/NCT00447330||173378|
NCT00447616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-214|Prostatectomy Prospective Database|Prostatectomy Database||William Beaumont Hospitals|No|Active, not recruiting|October 2003|October 2029|Anticipated|October 2029|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|896|||Male|18 Years|N/A|No|Non-Probability Sample|Patients having prostatectomy or cryosurgery for the treatment of prostate cancer at        William Beaumont Hospital.|November 2015|November 1, 2015|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447616||173357|
NCT00468676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH041739|Nurse-led Case Management for Diabetes and Cardiovascular Disease Patients With Depression|Randomized Trial of Liaison Psychiatry in Primary Care||University of Washington|Yes|Completed|May 2007|August 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|80 Years|No|||May 2014|May 1, 2014|May 1, 2007||No||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00468676||171772|Limitations include the study being completed in one health care system in one geographic area, inadequate power to determine cardiovascular events or rates of hospitalization, potential "spill-over of intervention to usual care patients.
NCT00468689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9107262|Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.|A Two-Part Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-751689 When Administered as an Oral Formulation at Supratherapeutic Dose Levels in Healthy Adult Subjects.||GlaxoSmithKline||Completed|April 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|May 1, 2007||||||https://clinicaltrials.gov/show/NCT00468689||171771|
NCT00468910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00841|Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer|Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia||National Cancer Institute (NCI)||Active, not recruiting|March 2007|||December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|115|||Both|N/A|75 Years|No|||December 2013|December 6, 2013|May 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468910||171754|
NCT00469222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-11-0072 / 23117|Hypofractionated Radiotherapy for Small Cell Lung Cancer|Phase I Dose Escalation Trial of Hypofractionated Limited-field External Beam Thoracic Radiotherapy for Limited Stage Small Cell Carcinoma of the Lung||AHS Cancer Control Alberta|Yes|Completed|March 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2012|February 24, 2016|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469222||171730|
NCT00468624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04_ENDO_41|Effect of Pegvisomant on GH/IGF-I Relationship in GHD|A Study of the Relationship Between Serum Growth Hormone (GH) and Insulin-Like Growth Factor One (IGF-I) in Patients With Severe Adult Growth Hormone Deficiency (AGHD)||Christie Hospital NHS Foundation Trust|No|Terminated|December 2004|July 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|2||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2007|May 2, 2007|May 2, 2007|||recruitment completed|No||https://clinicaltrials.gov/show/NCT00468624||171776|
NCT00468897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXR107453|A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.|An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions||GlaxoSmithKline||Completed|March 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|May 1, 2007||||||https://clinicaltrials.gov/show/NCT00468897||171755|
NCT00449267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PN1010614|Aurolab Hydrophobic Foldable Intraocular Lens Study|Clinical Evaluation of Hydrophobic Foldable Intraocular Lenses||Aurolab|Yes|Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|40 Years|65 Years|No|||February 2009|February 10, 2009|March 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00449267||173230|
NCT00449280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14908B|Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies|A Drug Interaction Study of Sorafenib (BAY 43-9006 Tosylate) and Rapamycin in Patients With Advanced Malignancies||University of Chicago|Yes|Completed|November 2006|September 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|March 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00449280||173229|
NCT00449618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASA100-2004/2|Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension|A Prospective, Randomized, Multi-Center, Double-Blind Crossover Study to Compare Awakening Versus Bedtime Administration of 100 mg Aspirin or Placebo in Subjects With High-Normal Blood Pressure or Mild Essential Hypertension||University of Vigo|Yes|Terminated|January 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 31, 2008|March 19, 2007||No|Not enough recruitment during the proposed period.|No||https://clinicaltrials.gov/show/NCT00449618||173205|
NCT00450151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612008895|Platelet Activation Markers in Pediatric Cardiac Surgery|Effect of Cardiopulmonary Bypass on Platelet Activation Markers Such as Platelet Factor 4 and Transforming Growth Factor B, in Pediatric Cardiac Surgery||Weill Medical College of Cornell University|No|Completed|February 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|For all patients, after obtaining written consent, 3.15ml of blood will be collected in CTAD      tubes, from arterial line pre cardiopulmonary bypass and post cardiopulmonary bypass. Blood      sample will be cooled in ice bath, centrifuged at 2500 rpm for 30 minutes, and supernatant      plasma sample will be collected. This plasma will be stored at -20 degrees celcius or below.      Enzyme-linked immunosorbent assay (ELISA) will be performed using the plasma to make      quantitative assessment of platelet factor 4 and transforming growth factor beta.|Both|N/A|7 Years|No|Non-Probability Sample|The targeted population will be pediatric patients with congenital heart defects who will        be needing cardiopulmonary bypass (CPB) while undergoing cardiac surgery. The age range        will be newborn to 7 years of age.|February 2012|February 29, 2012|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00450151||173164|
NCT00445848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000531056|S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer|A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas||Southwest Oncology Group|No|Active, not recruiting|July 2007|July 2013|Anticipated|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445848||173491|
NCT00446160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002790|Adult Congenital Heart Disease Surgery|Proposal for Retrospective Review of an Adult Congenital Heart Surgery Program||Emory University|No|Active, not recruiting|January 2000|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|350|||Both|19 Years|65 Years|No|Non-Probability Sample|This is a retrospective chart review examining patients over the age of 18 years who have        undergone operations for congenital heart disease. The primary interest of the study is to        look at the breakdown of our adult congenital program in regards to location, personnel,        and case type. All charts reviewed will be of patients who had their surgery at Children's        Healthcare of Atlanta or Emory University between January 1, 2000 and December 31, 2007.        We will review approximately 350 charts for this study.        Some of the patients have been cared for in the system for many years, first at Egleston        and then at Emory. We are only interested in the congenital operations performed on        patients after the age of 18 years old up until approximately 65 years of age. Initially        these were done at Egleston, although more recently they are being done at Emory.|December 2015|December 11, 2015|March 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00446160||173468|
NCT00446173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0710|Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia|Autologous Purged Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)||M.D. Anderson Cancer Center|Yes|Withdrawn|March 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|65 Years|No|||August 2015|August 21, 2015|March 9, 2007|No|Yes|Terminated due to low accrual.|No||https://clinicaltrials.gov/show/NCT00446173||173467|
NCT00446472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#778|Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers|Evaluation of Windowed Casts With and Without Regranex® Gel for Healing||Southern California Institute for Research and Education|No|Recruiting|April 2007|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|85 Years|No|||June 2010|June 2, 2010|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00446472||173444|
NCT00457691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181122|Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer|A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment||Pfizer|Yes|Completed|June 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|768|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|April 4, 2007|Yes|Yes||No|March 9, 2011|https://clinicaltrials.gov/show/NCT00457691||172595|
NCT00457704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APHP-SARM-HAD-2003|Carriage and Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Patients Admitted to Home Care.|||Assistance Publique - Hôpitaux de Paris||Terminated||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|90 Years||||April 2007|April 4, 2007|April 4, 2007||||No||https://clinicaltrials.gov/show/NCT00457704||172594|
NCT00458432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070127|Functional Neuroanatomy of Emotion Perception, Recognition, Learning, and Memory|Functional Neuroanatomy of Emotion Perception, Recognition, Learning, and Memory||National Institutes of Health Clinical Center (CC)||Completed|April 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||||180|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2009|March 15, 2011|April 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00458432||172538|
NCT00447343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-022|Reorganization of Brain Functions in Patients With Cervical Myelopathy Using fMRI and MRS|Mapping of the Sensorimotor Cortex in Cervical Myelopathy Using Functional Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy||Lawson Health Research Institute|No|Recruiting|September 2008|August 2012|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Twenty-five patients and ten controls will be recruited from the Clinical Neurological        Sciences outpatient clinic at the London Health Sciences Centre, University Campus|June 2010|June 2, 2010|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447343||173377|
NCT00447356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1697|High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma|Phase III Randomized Study of Four Weeks High Dose IFN-2b in StageT3-T4 or N1 (Microscopic) Melanoma||Hackensack University Medical Center|Yes|Withdrawn|January 2000|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A||||May 2013|May 9, 2013|March 12, 2007|||There were no patient enrolled in this study at this site|No||https://clinicaltrials.gov/show/NCT00447356||173376|
NCT00447369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-PN-001|Efficacy of Pregabalin in Migraine Prevention|||Hospital Militar del General Luis Felipe Brieba Aran|Yes|Withdrawn|May 2007|March 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|65 Years|No|||May 2008|May 6, 2008|March 13, 2007|||Because we did not find funds to do it|No||https://clinicaltrials.gov/show/NCT00447369||173375|
NCT00447668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT003208|Effect of Yoga Vs. Stretching on Chronic Back Pain|Effect of Yoga Vs. Stretching on Chronic Back Pain|YES|Group Health Cooperative|Yes|Completed|March 2007|August 2011|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|20 Years|64 Years|No|||November 2011|November 7, 2011|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00447668||173353|
NCT00447681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3199K1-100|Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetiks, and Pharmacodynamics of ILV-094 Administered Intravenously and One Dose of ILV-094 Administered Subcutaneously to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2006|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 11, 2007|March 13, 2007||||||https://clinicaltrials.gov/show/NCT00447681||173352|
NCT00447694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS04|Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment|An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months||Novartis||Completed|February 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|10 Years|N/A|No|||April 2012|April 25, 2012|March 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00447694||173351|
NCT00448526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8-H-077|Effect of Low Protein Diet in Preventing the Progression of Diabetic Nephropathy||LPD|Kanazawa Medical University|Yes|Terminated|December 1997|August 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|20 Years|65 Years||||March 2007|March 16, 2007|March 16, 2007|||Terminated: recruiting or enrolling participants has halted and will not resume because low    protein diet is not feasible nor efficious.|No||https://clinicaltrials.gov/show/NCT00448526||173287|
NCT00448539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2080-A001-302|Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures||Eisai Inc.|No|Completed|March 2007|December 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Both|12 Years|80 Years|No|||November 2012|November 12, 2012|March 15, 2007|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00448539||173286|This study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.
NCT00468702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-0014|Postoperative Canadian Oral Anticoagulation Self-Management (Post-COAGS) Trial|Postoperative Canadian Oral Anticoagulation Self-Management (Post-COAGS) Trial||Hoffmann-La Roche||Withdrawn|September 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|70 Years|No|||November 2007|November 20, 2007|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00468702||171770|
NCT00468650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481251|A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.|A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico.||Pfizer|No|Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Male|18 Years|N/A|No|||April 2015|April 21, 2015|May 1, 2007||No||No|February 12, 2009|https://clinicaltrials.gov/show/NCT00468650||171774|
NCT00468663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14716-CP-001|Ambient Air Pollution, Preeclampsia, and Preterm Delivery|Ambient Air Pollution, Preeclampsia, and Preterm Delivery||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|July 2006|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective|||Actual|4200|||Both|18 Years|N/A||||April 2015|April 13, 2015|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00468663||171773|
NCT00469482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061218|The SOMNUS Study: Sedative Optimization Via Monitoring Neurological Status|A Randomized Control Trial Using the BIS Monitor to Avoid Over Sedation and Prolonged Neuropsychological Deficits in Mechanically Ventilated ICU Patients|SOMNUS|Vanderbilt University|Yes|Active, not recruiting|June 2007|December 2016|Anticipated|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469482||171710|
NCT00469235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0064|Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars|A Single-centre, Double Blind, Randomised, Rising Dose Tolerance Study to Investigate the Safety of Juvista When Administered Following Excision of Ear Lobe Keloids.||Renovo|No|Completed|June 2007|May 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||September 2009|September 15, 2009|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00469235||171729|
NCT00449852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 5845|Interactive Voice Response Telephone Technology for the Treatment of Smoking in Patients With Heart Disease|An Interactive, Voice Response-Mediated, Follow-up and Triage System for Smoking Cessation in Smokers With Coronary Heart Disease|IVR|Ottawa Heart Institute Research Corporation|No|Completed|July 2006|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|442|||Both|18 Years|90 Years|No|||April 2011|April 27, 2011|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00449852||173187|
NCT00450164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KT-2000|Secondary Prophylaxis After Variceal Bleeding in Non-Responders|Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response.|KT-2000|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|November 2000|June 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||50|||Both|18 Years|80 Years|No|||March 2007|March 20, 2007|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00450164||173163|
NCT00449319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM99P|AML Treatment in Untreated Adult Patients|AML Treatment in Untreated Adult Patients According to EORTC-GIMEMA Protocols AML8 and AML10|LAM99P|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|November 1998|December 2002|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|15 Years|61 Years|No|||March 2007|March 22, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449319||173226|
NCT00446186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-378|MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)|Mk0476 Phase II Dose Finding Study -Allergic Rhinitis-||Merck Sharp & Dohme Corp.||Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|945|||Both|15 Years|65 Years|No|||June 2015|June 23, 2015|March 9, 2007||||No||https://clinicaltrials.gov/show/NCT00446186||173466|
NCT00446199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91493|Low-dose Hormone Therapy for Relief of Vasomotor Symptoms|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Lowest Effective Dose of Combinations of Oral Drospirenone and 17 Beta-Estradiol for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Over a Treatment Period of 12 Weeks||Bayer|No|Completed|March 2007|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|735|||Female|40 Years|N/A|No|||April 2015|April 16, 2015|March 9, 2007|Yes|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT00446199||173465|
NCT00446485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL-001|Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency|Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment||Milsing d.o.o.|Yes|Completed|May 2007|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|50 Years|N/A|No|||September 2015|September 24, 2015|March 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00446485||173443|
NCT00445887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0214|Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer|Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610)||Gynecologic Oncology Group||Active, not recruiting|March 2008|||December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|60|||Female|30 Years|N/A|No|||September 2013|September 19, 2013|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445887||173488|
NCT00445900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000530973|Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia|Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide ("TPC") in the Therapy of Myelofibrosis With Myeloid Metaplasia (MMM)||Mayo Clinic||Completed|October 2004|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|22|||Both|18 Years|N/A|No|||March 2011|March 16, 2011|March 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00445900||173487|
NCT00458211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPCIRB 03-02|Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics|Evaluation of Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotic Medications||Bronx Psychiatric Center|No|Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|April 6, 2007|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00458211||172555|
NCT00447642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX201-02|Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty|A Multi-center, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 Implantation for the Prevention of Corneal Allograft Rejection Episodes or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty||Lux Biosciences, Inc.|Yes|Terminated|April 2007|January 2010|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|122|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|March 13, 2007|Yes|Yes|The primary efficacy endpoint was not met|No||https://clinicaltrials.gov/show/NCT00447642||173355|
NCT00447655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC R01DD000153|Improving Outcomes Following Limb Loss: PALS Plus|Improving Outcomes Following Limb Loss: PALS Plus|PALS-PLUS|Johns Hopkins University|Yes|Not yet recruiting|March 2007|August 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|85 Years|No|||February 2009|February 3, 2009|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00447655||173354|
NCT00447096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102006-040|rTMS for Treatment of Depressed Phase of Bipolar Disorder Type II|rTMS (Repetitive Transcranial Magnetic Stimulation) for Acute Treatment of Depressed Phase of Bipolar Disorder Type II|rTMS|University of Texas Southwestern Medical Center|No|Suspended|February 2007|February 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|65 Years|No|||June 2008|June 4, 2008|March 12, 2007|||Suspended due to lack of funding|No||https://clinicaltrials.gov/show/NCT00447096||173396|
NCT00447382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX1729-1778|Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes|A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bolus Regimen With Insulin Aspart as the Bolus Insulin||Novo Nordisk A/S|No|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|March 13, 2007|Yes|Yes||No|November 24, 2010|https://clinicaltrials.gov/show/NCT00447382||173374|
NCT00447993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTF 3|A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa|A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome||Neurotech Pharmaceuticals|Yes|Completed|January 2007|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|68 Years|No|||April 2011|April 12, 2011|March 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00447993||173328|
NCT00468364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clamp EC 48/2003|Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes|Comparison of Carbohydrate Metabolism During the Night and at Hypoglycemia in Type-2 Diabetic Patients Either on Glargine or NPH Insulin|ClampHOE901|University of Giessen|No|Completed|July 2003|March 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|12|||Both|N/A|N/A|No|||August 2007|August 29, 2007|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00468364||171796|
NCT00468299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25999|MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure|Treatment of Early Pregnancy Failure|MiMi|Boston University|Yes|Terminated|April 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|May 1, 2007|Yes|Yes|poor enrollment|No|April 12, 2011|https://clinicaltrials.gov/show/NCT00468299||171801|The study was terminated because of poor enrollment. Few eligible women were referred.
NCT00468312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05106|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|March 2007|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|429|||Both|12 Years|N/A|No|||February 2015|February 24, 2015|April 30, 2007||||No|May 21, 2010|https://clinicaltrials.gov/show/NCT00468312||171800|
NCT00468325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-016|Coronary Computed Tomography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT)|Coronary Computed Tomography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT)|CTSTAT|William Beaumont Hospitals|Yes|Completed|May 2007|May 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|750|||Both|25 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 13, 2009|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468325||171799|
NCT00469248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLU-IABPSHOCK|Aortic Balloon Counterpulastion in Myocardial Infarction Related Shock|Intra-Aortic Balloon Counterpulsation in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock - The Prospective, Randomised IABP SHOCK Trial for Attenuation of Multi-Organ Dysfunction Syndrome|IABPSHOCK|Martin-Luther-Universität Halle-Wittenberg|No|Completed|March 2003|June 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|N/A|N/A|No|||April 2007|May 3, 2007|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469248||171728|
NCT00449098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking 0701|Ologen (OculusGen)-Glaucoma MMC Control Trial in India|Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery||Pro Top & Mediking Company Limited||Recruiting|January 2007|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00449098||173243|
NCT00449306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-01-2354-JS-CTIL|Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques|Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques||Sheba Medical Center|No|Active, not recruiting|March 2001|July 2016|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|120|Samples Without DNA|Tissue for RNA extraction (frozen); Tissue for histological analysis (formalin fixation);      Plasma for CV biomarkers (frozen)|Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic patients|December 2015|December 15, 2015|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00449306||173227|
NCT00449111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-325|An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)|An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension||Merck Sharp & Dohme Corp.||Terminated|March 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|March 16, 2007||||No||https://clinicaltrials.gov/show/NCT00449111||173242|
NCT00449332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14516A|Early Indicators of Chronic Rejection in Lung Transplant|Role of Inflammatory and Fibroproliferative Cytokines in the Pathogenesis of Bronchiolitis Obliterans Syndrome-OP in Lung Transplant Recipients.|BOS|University of Chicago|No|Recruiting|March 2006|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|lung tissues, bal, blood|Both|18 Years|65 Years|No|Non-Probability Sample|Post lung transplant patients|December 2012|September 4, 2013|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00449332||173225|
NCT00449904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14298|Open-Label Phase III Long-Term Safety Trial of Liprotamase|An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|DIGEST|Anthera Pharmaceuticals|Yes|Completed|June 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|214|||Both|7 Years|N/A|No|||October 2014|October 15, 2014|March 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449904||173183|
NCT00449865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS43128 NET-PD|NET-PD LS-1 Creatine in Parkinson's Disease|A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)||University of Rochester|Yes|Terminated|March 2007|May 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1741|||Both|N/A|N/A|No|||March 2015|March 23, 2015|March 20, 2007|Yes|Yes|Futility|No|February 19, 2015|https://clinicaltrials.gov/show/NCT00449865||173186|
NCT00471783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70513|Flossing With Chlorhexidine|The Effects of Flossing With a Chlorhexidine Solution on Interproximal Gingivitis: a Randomized Controlled Trial||University of British Columbia|No|Completed|April 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 13, 2008|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471783||171537|
NCT00471796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCP-2|A Comparison of Factors of Symptoms Generation and Evaluation of Role of Biofeedback in Patients With Different Types of Functional Esophageal Disorders (Functional Heartburn and Functional Chest Pain)|||Assaf-Harofeh Medical Center|No|Not yet recruiting||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years||||April 2007|May 9, 2007|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00471796||171536|
NCT00471770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101894|Pneumoniae Epidemiology Study in China|Epidemiological Study of Hospitalized Pediatric Pneumonia in China||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|1000|Samples Without DNA|deep respiratory aspirate,pleural fluid,cerebrospinal fluid,serum|Both|N/A|60 Months|No|Non-Probability Sample|Hospitalized children with pneumoniae less than 5 years,located in Tianjin Children's        Hospital|March 2008|March 12, 2008|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471770||171538|
NCT00467857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS 100-06-0001|Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination|A Randomized, Controlled, Parallel Group, Multi-center, Open Label Study Comparing Common Surgical Skin Preparation Solutions in Combination With InteguSeal Versus Common Surgical Skin Preparation Solutions to Reduce Skin Flora Contamination.||Kimberly-Clark Corporation|No|Completed|April 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|293|||Both|18 Years|N/A|No|||January 2011|September 13, 2012|April 27, 2007|Yes|Yes||No|November 3, 2010|https://clinicaltrials.gov/show/NCT00467857||171835|
NCT00467870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP157-001|Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men|A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men|TU|Endo Pharmaceuticals|No|Completed|March 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Male|18 Years|N/A|No|||September 2012|September 13, 2012|April 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467870||171834|
NCT00468780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|724180022|Standardized Comparison of Triage in EMS|Study to Evaluate the Safety and Efficacy of Redirecting Ambulance Patients to Destinations Based on Acuity||St. Michael's Hospital, Toronto|No|Completed|February 2003|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|928|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|This study is taking place in 7 EMS systems in Ontario: Peterborough, Thunder Bay,        Hamilton, Simcoe/Muskoka, Durham, Peel, and Toronto.        The participants(Both Primary care paramedics and Advance Care Parmaeidcs)are riding as        civilian observers under contract to the Sunnybrook and Women's College Health Sciences        Centre Research Institute and have signed liability release forms.        The main focus of the SCORE study is to determine how well paramedics in the field can        correctly assign CTAS scores. By showing that it can be done reliably, decisions can be        made on suitable destinations, especially for the low acuity patient.|May 2014|May 23, 2014|May 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00468780||171764|
NCT00468793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16312|Traditional Versus ScvO2 Guided Perioperative Fluid Therapy|Randomized Clinical Study of Traditional Versus ScvO2 Guided Perioperative Fluid Therapy||Haukeland University Hospital|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||May 2009|June 5, 2009|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00468793||171763|
NCT00469352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003335|A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD|The Effect of Genotype and Environmental Risk Factors on Treatment Response to Intravitreal Lucentis (Ranibizumab) for Neovascular AMD||Oregon Health and Science University|No|Completed|May 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|50 Years|N/A|No|||July 2011|July 20, 2011|May 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00469352||171720|
NCT00491335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907173|HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers|HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, MD: A Pilot Study of Biomarkers||National Institutes of Health Clinical Center (CC)||Completed|June 2007|February 2010||||N/A|Observational|Time Perspective: Prospective|||||||Both|17 Years|N/A|No|||February 2010|September 26, 2015|June 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00491335||170064|
NCT00491595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-N01-CN-75035|Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women|Phase I Multiple-Dose Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women||University of North Carolina, Chapel Hill|Yes|Completed|March 2004|July 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|36|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2007|June 25, 2007|June 22, 2007||||Yes||https://clinicaltrials.gov/show/NCT00491595||170044|
NCT00462202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX 101-302|Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong|An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients With Persistent Microalbuminuria in Australia, New Zealand, and Hong Kong||Keryx Biopharmaceuticals|Yes|Terminated|April 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 16, 2007|Yes|Yes|Interim analysis of efficacy trial showed no drug efficacy.|No||https://clinicaltrials.gov/show/NCT00462202||172260|
NCT00462436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB06-179C|Innovative Strategies For Risk Reduction Following CABG|Do Innovative Strategies Complement Medical Management to Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?||St. Michael's Hospital, Toronto|No|Completed|February 2007|May 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2009|July 21, 2010|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00462436||172243|
NCT00469547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30225-D|62% & 15% Ethanol in Emollient Gel as Topical Male Microbicides|Safety & Acceptance of 62% & 15% Ethanol in Emollient Gel as Topical Male Microbicides||University of Washington|Yes|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 28, 2009|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469547||171705|
NCT00469859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML06P1|Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia||Children's Oncology Group|Yes|Active, not recruiting|June 2007|||March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|1 Year|30 Years|No|||September 2015|September 11, 2015|May 3, 2007|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT00469859||171682|
NCT00469872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD044444|Focus on Function Study for Children With Cerebral Palsy|Family Centred Functional Therapy for Children With Cerebral Palsy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|June 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|12 Months|5 Years|No|||September 2014|September 23, 2014|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469872||171681|
NCT00470340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051062|Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients|Arterial LIPIODOLISED Chemotherapy Versus Systemic Chemotherapy With Gemcitabine Plus Oxaliplatin (GEMOX) Versus no Treatment Following Surgical Resection or Local Ablation of Hepatocellular Carcinoma in Cirrhotic Patients|GEMOXIAL|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|June 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|263|||Both|18 Years|75 Years|No|||May 2007|May 4, 2011|May 4, 2007||No|during the study|No||https://clinicaltrials.gov/show/NCT00470340||171645|
NCT00470093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0620 CDR0000543428|Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma|A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a||Sidney Kimmel Comprehensive Cancer Center||Completed|August 2007|||January 2010|Actual|N/A|Interventional|Primary Purpose: Treatment|||Actual|4|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470093||171664|
NCT00471588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT106512|Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors|Dopamine D2/D3 Receptor Agonist and Antagonist Drug Effects on Fronto-striatal Systems Related to Compulsive Behaviour in Healthy Volunteers and Patients With Addictive and Compulsive Disorders||GlaxoSmithKline|No|Completed|August 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471588||171552|
NCT00471601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-024|Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions|Measuring Patient Expectations for Breast Reconstruction: Development and Validation of a Patient-Reported Outcomes Instrument||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2007|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|357|||Female|18 Years|75 Years|No|||March 2016|March 7, 2016|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471601||171551|
NCT00471614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003374-01A1|Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine|Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|April 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|65 Years|No|||May 2012|May 15, 2012|May 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00471614||171550|
NCT00471809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|447|Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)|Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)|MARS|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|March 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|6 Years|17 Years|No|||April 2012|April 30, 2012|May 8, 2007|||The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a    futility analysis with 55 randomized children.|No||https://clinicaltrials.gov/show/NCT00471809||171535|
NCT00471822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101849|Nasopharyngeal Streptococcus Pneumoniae Carriage|An Evaluation of Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Taiwanese Children Attending Pediatric Clinics in Hospitals, Day Care Centers, or Kindergartens||Pfizer|No|Completed|July 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9707|||Both|2 Months|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects aged between 2 months and 5 years attending pediatric clinics in hospitals,        daycare centers, and kindergartens|September 2013|September 18, 2013|May 8, 2007|No|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00471822||171534|
NCT00471575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38/07|Fatty Liver in Pregnancy|Prospective Observational Study||Assaf-Harofeh Medical Center|No|Not yet recruiting|June 2007|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Female|18 Years|N/A||||April 2007|May 13, 2007|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00471575||171553|
NCT00471263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7365|The Effects of Milk Proteins on Blood Pressure|The Effects of Casigold and Casimax on Blood Pressure in Subjects With Highnormal Blood Pressure or Mild Hypertension||TNO|No|Completed|May 2007|February 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|84|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||April 2008|April 4, 2008|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471263||171577|
NCT00468156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00004225|The Fruit and Vegetable Study|Implementation Intentions for Improving Fruit and Vegetable Intakes||University of Michigan|Yes|Completed|September 2006|June 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|97|||Both|40 Years|N/A|Accepts Healthy Volunteers|||November 2008|December 19, 2012|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468156||171812|
NCT00472069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060505|A New Therapeutic Strategy for Urethral Sphincter Insufficiency|EVALUATION Of A NEW THERAPEUTIC STRATEGY FOR URETHRAL SPHINCTER INSUFFICIENCY BASED ON THE INTRA-URETHRAL IMPLANTATION OF AUTOLOGOUS MYOFIBERS WITH THEIR SATELLITE CELLS||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|40 Years|75 Years|No|||September 2007|May 4, 2011|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472069||171515|
NCT00467883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060603|Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment|AMBIZYGO: Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial|AMBIZYGO|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2007|March 2013|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||July 2014|July 17, 2014|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00467883||171833|
NCT00470756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM03-HMO-CTILL|Forefoot Adduction (FFA) in Infants and Toddlers. Differences of Neuromuscular Activity.|Difference of Neuromuscular Activity in Infants and Toddlers With Foot Dorsiflexion Compare to Infants and Toddlers With Foot Plantarflexion||Hadassah Medical Organization||Suspended|March 2008|||March 2012|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|2 Months|1 Year|No|Probability Sample|infants and toddlers with Forefoot adduction|April 2011|May 11, 2011|May 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00470756||171615|
NCT00469053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|855509|Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)|Multiple Dose Bioequivalence Trial Comparing a Down-Scaled New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch (Protocol ID: 855509)||Grünenthal GmbH||Terminated|May 2007|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|November 15, 2007|April 18, 2007|||The trail end was achived according to the definition in the trial protocol|No||https://clinicaltrials.gov/show/NCT00469053||171743|
NCT00469066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-11-0073|Cone Beam CT Scanning in Lung and Bladder Cancer.|Improving the Accuracy of Radiotherapy Planning and Delivery Using Kilovoltage Cone Beam CT Imaging||AHS Cancer Control Alberta|Yes|Completed|May 2007|April 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clniic|December 2011|February 23, 2016|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469066||171742|
NCT00491348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950508|Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study|Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study||National Taiwan University Hospital|Yes|Terminated|April 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2008|December 21, 2008|June 23, 2007||No|Change of MRI mode|No||https://clinicaltrials.gov/show/NCT00491348||170063|
NCT00491361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700519|Chinese Versions of the Swanson, Nolan, and Pelham, Version IV (SNAP-IV) Scale and Strengths Difficulties Questionnaire.|Psychometric Study of the Chinese Versions of the Swanson, Nolan, and Pelham, Version IV (SNAP-IV) Scale and Strengths Difficulties Questionnaire.||National Taiwan University Hospital|No|Completed|January 2005|July 2006|Actual|||N/A|Observational|N/A||1|Actual|3600|||Both|6 Years|16 Years|No|Non-Probability Sample|School-based subjects & Clinical subjects with ADHD|August 2008|November 12, 2012|June 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00491361||170062|
NCT00491608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499F04|Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis|A Phase 3b, Open-Label, Single-Group Immunogenicity and Safety Study of Topical Recombinant Thrombin (rThrombin) in Surgical Hemostasis||ZymoGenetics|No|Completed|June 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|234|||Both|18 Years|N/A|No|||January 2012|January 11, 2012|June 22, 2007|Yes|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00491608||170043|
NCT00462761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0001|A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status|Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia||Daiichi Sankyo Inc.|No|Completed|January 2007|December 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|April 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00462761||172219|
NCT00463008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000346432|Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma|A Pharmacokinetic Study of Methotrexate Using an Intratumoral Microdialysis Catheter||National Cancer Institute (NCI)||Completed|May 2004|April 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||January 2008|June 21, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463008||172202|
NCT00462449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611012|Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity|Single Blind, Randomized Study to Determine the Safety and the Efficacy of Using Functional Electrical Stimulation (FES) and Repetitive Task Practice vs. Repetitive Task Practice Alone in Persons Receiving Botulinum Neurotoxin Type A Injections for Upper Extremity Spasticity|Botox + FES|University of Pittsburgh|Yes|Completed|November 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||June 2014|June 19, 2014|April 17, 2007|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00462449||172242|
NCT00470106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-026-06S|Improving Basic and Social Cognition in Veterans With Schizophrenia|Improving Basic and Social Cognition in Veterans With Schizophrenia|IBASC|VA Office of Research and Development|Yes|Completed|September 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|60 Years|No|||June 2015|June 26, 2015|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470106||171663|
NCT00470366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-044|Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors|Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|March 2007|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|120 Years|No|||September 2015|September 25, 2015|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470366||171643|
NCT00470665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H1-903|Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients|An Open-Label, Concentration-Controlled, Randomized, 12-Month Study of Prograf + Rapamune + Corticosteroids Compared to Cyclosporine,USP (Modified) + Rapamune + Corticosteroids in High Risk Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2002|July 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||460|||Both|13 Years|N/A|No|||May 2007|May 7, 2007|May 7, 2007||||||https://clinicaltrials.gov/show/NCT00470665||171621|
NCT00470678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2304|EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months||Novartis||Completed|June 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|50 Years|N/A|No|||April 2012|April 27, 2012|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00470678||171620|
NCT00468468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-192|Mentor Integration Study|Mentor Integration Study||University of Wisconsin, Madison||Completed|September 2003|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|126|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468468||171788|
NCT00468481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91523|Efficacy and Safety Study for an Oral Contraceptive Containing Folate|Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone||Bayer|No|Completed|April 2007|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|385|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|April 30, 2007|Yes|Yes||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00468481||171787|
NCT00468806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN106589|Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Occupancy Kinetics, Pharmacokinetics and Safety of Single Oral Doses of GSK598809, Using [11C]-(+)-PHNO as PET Ligand.||GlaxoSmithKline||Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|May 1, 2007||||No||https://clinicaltrials.gov/show/NCT00468806||171762|
NCT00472095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC 2007-34|Fotonovela for Type 2 Diabetes Mellitus|Utility of a Diabetes Themed Fotonovela to Encourage Glycemic Control: a Culturally Appropriate Tool for Education in Latinos||University of California, San Francisco|No|Recruiting|June 2007|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|260|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00472095||171513|
NCT00467896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C200-008|The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting|A Comparison of Safety and Inhalation Times of Ventavis (Iloprost) Inhalation Solution Delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"||Actelion||Terminated|September 2006|June 2011|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|85 Years|No|||March 2013|March 27, 2013|April 27, 2007|No|Yes|Sponsor's decision|No|September 27, 2012|https://clinicaltrials.gov/show/NCT00467896||171832|Study was terminated early due to the discontinuation of the I-neb Power Disc-15 development program.
NCT00468143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR v XR|A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall|A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall||New York University School of Medicine|No|Completed|August 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|55 Years|No|||March 2013|March 11, 2013|April 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468143||171813|
NCT00467909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04B9-P|Nutrition and Cognition in Indian Children|Efficacy of Fortified Products on Improving Long Term Cognitive Performance in School Children in India|CHAMPION|St. John's Research Institute|No|Completed|November 2005|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind|4||Actual|600|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||April 2007|April 30, 2007|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00467909||171831|
NCT00472082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003005|Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients|An Open Label, Single-Center Pilot Study of Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Primary Renal Transplant Recipients||Emory University|Yes|Terminated|May 2007|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||December 2013|December 19, 2013|May 10, 2007|Yes|Yes|This study was terminated at the request of the drug manufacturer.|No|November 9, 2012|https://clinicaltrials.gov/show/NCT00472082||171514|
NCT00468767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235-0703|Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation|A Phase III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation|ACT I|Cardiome Pharma|Yes|Completed|August 2003|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|May 1, 2007||||No||https://clinicaltrials.gov/show/NCT00468767||171765|
NCT00471354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11098|A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine|Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride||Eli Lilly and Company|No|Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|8 Years|11 Years|No|||January 2010|January 4, 2010|May 7, 2007|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00471354||171570|
NCT00471913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03242|Functional Outcome and MRI of Muscle Damage Following Nailing Procedure in Femur (Thigh) Fractures Using Different Entry Points|Functional Outcome and MR Imaging of Abductor Damage Following Antegrade Femoral Nailing With Different Entry Points: A Prospective Randomized Trial||University of British Columbia|No|Completed|April 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|19 Years|60 Years|No|||April 2011|April 13, 2011|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471913||171527|
NCT00471926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR96-IRB-41|Diabetes Quality Improvement Program on Diabetes Case Management Program 2001|Diabetes Quality Improvement Program on Diabetes Case Management Program 2001|DQIP-DCMP|China Medical University Hospital|Yes|Recruiting|April 2007|April 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|20000|||Both|N/A|N/A|No|||May 2007|May 9, 2007|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471926||171526|
NCT00471939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS I-020502/01|Safety and Efficacy of I-020502 in Meshed Skin Autografting|A Phase II, Multi-Centre, Controlled Study of the Safety and Efficacy of Wound Healing Gel I-020502 (KUR-212) in Patients Undergoing Autologous Meshed Skin Grafting.||Kuros Biosurgery AG|No|Completed|April 2007|January 2009|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2009|March 2, 2009|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00471939||171525|
NCT00461630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSUTHRIVE1|Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE|A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant|HPS2-THRIVE|University of Oxford|Yes|Completed|January 2007|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25673|||Both|50 Years|80 Years|No|||January 2014|January 27, 2014|April 17, 2007|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00461630||172302|Participants may have SAEs reported in >1 category hence total participants affected across reported categories is less than total given.
NCT00461903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC4-9490-123-CAN|Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension|A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension|CTAF-2|Montreal Heart Institute|Yes|Completed|December 2007|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461903||172281|
NCT00458757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090767-amputy-HMO-CTIL|The Effect of Amputation on Spatial Visual Representation in Peripersonal Space|The Effect of Upper Arm Amputation and the Use of Prosthetics on Spatial Visual Representation in Peripersonal Space - a Behavioural Study||Hadassah Medical Organization||Not yet recruiting|November 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In this experiment we plan to employ a paradigm which is inspired by the affordance        effect, originally introduced by Tucker and Elice (1998): we will present subjects with        brief images of either manipulable or non manipulable objects in either the left or right        visual field. The subjects will be required to determine whether the object contains a        metal or not, by moving either their left or their right shoulder. We predict that while        the control group of normal subjects would show a congruency effect (that is superior        performance (faster and more accurate responses) when the responding shoulder is congruent        with the position of the objects, the amputees will show spatial biases towards the        non-amputated side. This effect should be more prominent for the manipulable objects.|March 2007|May 12, 2008|April 10, 2007||||No||https://clinicaltrials.gov/show/NCT00458757||172515|
NCT00459030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC-05016|Traditional Print Communication Methods, Simple Electronic Communication Methods, or Usual Care in Increasing How Often Older Women Undergo Colorectal Cancer Screening|Two Delivery Channels to Improve CRC Screening||Fox Chase Cancer Center|No|Completed|October 2005|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|904|||Female|50 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 16, 2013|April 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00459030||172496|
NCT00470119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS 1960.00|Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women|Exercise Diet and Sex Hormones in Postmenopausal Women (NEW)||Fred Hutchinson Cancer Research Center|Yes|Completed|December 2004|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|439|||Female|50 Years|75 Years|No|||September 2012|September 7, 2012|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00470119||171662|
NCT00470132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040262|Ventricular Shunt and Drain Infections - Timing of Reimplantation|Ventricular Shunt and Drain Infections - Timing of Reimplantation||University of Pittsburgh|No|Completed|May 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|400|||Both|18 Years|N/A|No|Probability Sample|infected ventricular shunt|August 2012|August 23, 2012|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00470132||171661|
NCT00470691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StOlavsH-ort-radius|Dorsal Splint or Circular Cast for Colles' Fracture?|Comparison of Dorsal Plaster Splint and Circular Plaster Cast for Colles' Fractures||St. Olavs Hospital|No|Completed|June 2004|June 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Female|50 Years|N/A|No|||April 2015|April 7, 2015|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00470691||171619|
NCT00470977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol: FVF4140S|Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy|Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)|FVF4140S|Manhattan Eye, Ear & Throat Hospital|No|Completed|May 2007|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|May 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470977||171598|
NCT00469404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297307|Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID 297307)|Single Dose Bioequivalence Trial Comparing a Down-Scaled New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch.||Grünenthal GmbH||Terminated|May 2007|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|November 15, 2007|April 18, 2007|||The trial end was achieved according to the definition in the trial protocol|No||https://clinicaltrials.gov/show/NCT00469404||171716|
NCT00469638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A07|Efficacy and Safety Study on Agilis NxT Introducer in AF Patients|Ablation Success With the Use of Steerable AGILIS NxT Introducer Compared With Conventionally Used Swartz SL0.|AGILIS|St. Jude Medical|No|Completed|May 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|75 Years|No|||April 2010|April 21, 2010|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469638||171698|
NCT00471302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907141|Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali|Establishment of Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali||National Institutes of Health Clinical Center (CC)||Recruiting|May 2007|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|280|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|November 17, 2015|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471302||171574|
NCT00471315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR16489|Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)|Pilot Study of the Efficacy and Tolerability of Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction).|SOD|Medical University of South Carolina|No|Completed|July 2006|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||February 2009|December 18, 2013|May 8, 2007||No||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00471315||171573|Most frequently reported adverse events included fatigue, nausea, headaches, constipation, decreased appetite and insomnia at primarily mild to moderate severity.
NCT00471627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06088|New Type of a Pancreaticojejunostomy|New Type of a Pancreaticojejunostomy - a Pilot Study||University of Tampere|No|Recruiting|December 2006|||December 2008|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2008|June 9, 2008|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00471627||171549|
NCT00471835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-62206|Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Phase I/II Study of Hypofractionated Stereotactic Body Radiotherapy for Stage I/II Non-small Cell Lung Cancer Within the Central Lung Region and the Prognostic Impact of FDG Positron Emission Tomography||Comprehensive Cancer Center of Wake Forest University||Withdrawn|January 2007|||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471835||171533|
NCT00471848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2007-000902-55|Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia|Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia and Comparison With Matched Historical Patients Treated With Horse ATG and Ciclosporin|RATGAA07|European Group for Blood and Marrow Transplantation|Yes|Active, not recruiting|August 2008|December 2012|Anticipated|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|16 Years|N/A|No|||August 2012|August 23, 2012|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00471848||171532|
NCT00472108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC T307/00|Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma|A Multicenter, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma||Galderma|No|Completed|December 2000|April 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472108||171512|
NCT00467948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS_200306|Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients|Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery||Tehran University of Medical Sciences|Yes|Completed|June 2004|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|90|||Both|N/A|N/A|No|||June 2003|April 30, 2007|April 29, 2007||||No||https://clinicaltrials.gov/show/NCT00467948||171828|
NCT00468429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEI-00001|Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery|Comparative Study of the Safety and Effectiveness Between Off-Label Subconjunctival Bevacizumab and Mitomycin C in Glaucoma Filtering Surgery.||Grewal Eye Institute|No|Recruiting|May 2007|December 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|No|||June 2007|June 1, 2007|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00468429||171791|
NCT00468442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-05|B-Lymphocyte Immunotherapy in Islet Transplantation|B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression (CIT-05)||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|November 2006|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||February 2016|February 21, 2016|May 1, 2007|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00468442||171790|
NCT00468455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05-17|Post-Op Quality of Life After Colorectal Surgery|Postoperative Quality of Life: Development and Assessment of a Novel Tool to Assess Quality of Life Following Colorectal Surgery||University Hospital Case Medical Center|No|Completed|October 2005|May 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients scheduled to undergo laparscopic or open procedures from the Deopartment of        Surgery at University Hospitals of Cleveland.|December 2014|December 12, 2014|May 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00468455||171789|
NCT00461305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91616|Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea|A Multicenter, Single-blind, Randomized Study, to Investigate Efficacy of Ethinylestradiol for Intracyclic Bleeding Profile During 24 Weeks (6 Cycles) by Oral Administration of Drospirenone 3 mg/Ethinylestradiol 20 µg and Drospirenone 3 mg/ Ethinylestradiol 30 µg in Patients With Dysmenorrheal and to Investigate the Long Term Safety Oral Administration of Drospirenone 3 mg/Ethinylestradiol 20 µg Administered for 52 Weeks (13 Cycles)||Bayer|No|Completed|February 2007|August 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|420|||Female|20 Years|N/A|No|||January 2013|January 22, 2013|April 17, 2007||No||No|September 10, 2010|https://clinicaltrials.gov/show/NCT00461305||172326|
NCT00461643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2007|Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS|Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial||University Magna Graecia|No|Recruiting|January 2007|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|552|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 5, 2013|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00461643||172301|
NCT00461916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5152|Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin|Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin in a Long Protocol of Controlled Ovarian Stimulation for ICSI/ET||Tehran University of Medical Sciences|No|Completed|May 2005|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||182|||Female|N/A|35 Years|No|||April 2007|April 17, 2007|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461916||172280|
NCT00458770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/22|Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks|Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks||Assistance Publique Hopitaux De Marseille|No|Terminated|May 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1|||Both|18 Years|65 Years|No|||February 2014|February 24, 2014|April 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00458770||172514|
NCT00458783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-140|Red Cell Storage Duration and Outcomes in Cardiac Surgery|Red Cell Storage Duration and Outcomes in Cardiac Surgery||The Cleveland Clinic|Yes|Recruiting|April 2007|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|2800|||Both|18 Years|N/A|No|||February 2016|February 27, 2016|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458783||172513|
NCT00459043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-283|Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck|Randomized Phase II Study of Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Dana-Farber Cancer Institute|Yes|Completed|March 2007|February 2012|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|April 10, 2007|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT00459043||172495|
NCT00470704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-213|Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer|A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2007|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|May 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470704||171618|
NCT00470990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001445 (completed)|Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men|Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2002|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|40|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|May 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470990||171597|
NCT00470171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URSONASH05-01|Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis|Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis|URSONASH|Axcan Pharma|No|Completed|October 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||February 2009|February 2, 2009|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00470171||171658|
NCT00469937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC RAD 0521|Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases|A Phase I Study of Lithium During Whole Brain Radiotherapy for Patients With Brain Metastases||Vanderbilt-Ingram Cancer Center|Yes|Terminated|February 2006|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|No|||February 2012|February 26, 2012|May 3, 2007|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00469937||171676|
NCT00470743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQPDA02|Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies|A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants||KK Women's and Children's Hospital|No|Withdrawn|May 2007|June 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|29 Weeks|No|||June 2009|September 1, 2015|May 7, 2007|||Funding withdrawn|No||https://clinicaltrials.gov/show/NCT00470743||171616|
NCT00471029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC-2005-110|Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer|Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial|NPH|Pamela Youde Nethersole Eastern Hospital|Yes|Recruiting|September 2005|September 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||May 2007|May 8, 2007|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471029||171594|
NCT00471653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543866|Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy|A Pharmacokinetic and Pharmacogenomic Study of Patients With High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide||National Cancer Institute (NCI)||Active, not recruiting|November 2006|||December 2008|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||July 2009|November 6, 2009|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471653||171547|
NCT00468832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD0305|Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)|Longitudinal Study of the Relationship Between Impairment, Activity Limitation, Participation and Quality of Life in Persons With Confirmed Duchenne Muscular Dystrophy (DMD)||Cooperative International Neuromuscular Research Group|Yes|Recruiting|December 2005|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|810|Samples With DNA|Blood samples are being collected for single-nucleotide polymorphism, Genome-wide      Association Study, and biomarker analyses.|Male|2 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|The incidence of DMD is considered equal across racial and ethnic groups. At the start of        the CINRG program, it was assumed by investigators that the aggregate subject populations        of the participating US sites should closely mirror the racial and ethnic distribution of        the US population.        DMD is an X-linked recessive disease affecting only males. However, female carriers of the        disease can be symptomatic due to skewed X-inactivation, a secondary genetic event. We        have opted to study the most commonly affected population, males, to ensure subject        homogeneity. As such, there are no outreach programs planned for women in this study.|February 2016|February 22, 2016|May 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00468832||171760|
NCT00468169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14401A|Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer|A Randomized Phase II Trial of Concurrent Chemoradiation With Cetuximab (ERBITUX®), 5 Fluorouracil, Hydroxyurea, and Twice-daily Radiation (CetuxFHX) Versus Cetuximab (ERBITUX®), Cisplatin, and Accelerated Radiation With Concomitant Boost (CetuxPX) After Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer|EPIC|University of Chicago|Yes|Active, not recruiting|July 2006|November 2012|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|April 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468169||171811|
NCT00469950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.2005.1437|The Effect of Training on Endothelial Function, Progression of Disease,Inflammation, Heart Rate Variability and Mental Health After Percutaneous Coronary Intervention|Effect of Exercise Training After Percutaneous Coronary Intervention|EFECTOR|Helse Stavanger HF|No|Completed|January 2006|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|85 Years|No|||February 2009|April 13, 2015|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00469950||171675|
NCT00469963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0364|Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery|Clinical Trial of Sir Spheres® in Patients With Primary Hepatocellular Carcinoma||Vanderbilt-Ingram Cancer Center|Yes|Terminated|December 2003|April 2007|Actual|October 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|85 Years|No|||August 2012|August 31, 2012|May 3, 2007|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00469963||171674|
NCT00471666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907148|Medical Implications of Coinfection With Malaria and Filariasis Parasites|Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications||National Institutes of Health Clinical Center (CC)||Completed|May 2007|January 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1039|||Both|1 Year|20 Years|No|||January 2012|February 1, 2012|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00471666||171546|
NCT00461656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR 14357|Povidone-iodine Antisepsis for Strabismus Surgery|Prospective, Randomized, Double-blind Comparison of 5 % Against 1.25 % Povidone-iodine Solution as Preoperative Antisepsis for Strabismus Surgery in Young Children|PASS|Erasmus Medical Center|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|70|||Both|N/A|5 Years|No|||July 2011|March 4, 2013|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461656||172300|
NCT00461669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPUS-2|Hip Fracture Characterization With Ultrasound Exam|||Rabin Medical Center|No|Not yet recruiting|April 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||100|||Both|50 Years|N/A|No|||March 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461669||172299|
NCT00461929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST1571ACA10 GIST|Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib|Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.|GIST|University Health Network, Toronto|No|Terminated|February 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|68|||Both|18 Years|N/A|No|||April 2007|February 12, 2009|April 16, 2007||No|study terminated 12Feb09 due to low recruitment|No||https://clinicaltrials.gov/show/NCT00461929||172279|
NCT00461942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA702B02-2|Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease Patients||Xuanwu Hospital, Beijing|Yes|Completed|April 2006|March 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|480|||Both|30 Years|N/A|No|||August 2011|August 15, 2011|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461942||172278|
NCT00462215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810601|Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)|An Open Label Phase III Study of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine to Assess the Immunogenicity and Safety and to Investigate the Need for and Timing of a Booster Vaccination||Nanotherapeutics, Inc.|Yes|Completed|April 2007|February 2010|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|October 7, 2015|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00462215||172259|
NCT00462228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-44|Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury|Double-blind Cross-over Study of the Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury, Protocol NAM-MD-44||University of Missouri-Columbia|No|Terminated|April 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|50 Years|No|||October 2013|October 24, 2013|April 10, 2007|Yes|Yes|The study was stopped due to a lack of additional subjects.|No|May 18, 2012|https://clinicaltrials.gov/show/NCT00462228||172258|The enrollment goal for the study was 20 subjects. The study included 11 subjects but was terminated due to a lack of additional subjects.
NCT00462462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00122 GI 201 (ORF)|Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.|Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.||Orfagen|No|Completed|May 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Both|12 Years|N/A|No|||January 2015|January 6, 2015|April 16, 2007|Yes|Yes||No|December 5, 2014|https://clinicaltrials.gov/show/NCT00462462||172241|
NCT00463034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540737|Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer|Genetic Factors Affecting Breast Cancer Progression||National Cancer Institute (NCI)||Active, not recruiting|April 2005|||March 2008|Anticipated|N/A|Observational|N/A|||Anticipated|1800|||Female|N/A|N/A|No|||November 2008|December 17, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463034||172200|
NCT00463047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3055/BP/MN|Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain|A Randomized, Double-Blind, Active-Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Compared With Immediate-release Oxycodone for the Management of Breakthrough Pain in Opioid-Tolerant Patient With Chronic Pain||Teva Pharmaceutical Industries||Completed|July 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|80 Years|No|||May 2012|May 22, 2012|February 8, 2007|Yes|Yes||No|February 26, 2010|https://clinicaltrials.gov/show/NCT00463047||172199|
NCT00461266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19355|ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.|A Randomized, Open Label Study to Determine the Immunological Benefits of Adding Fuzeon to an Antiretroviral Regimen in HIV-Infected Fuzeon-naïve Patients With Sustained HIV Viral Suppression||Hoffmann-La Roche||Terminated||May 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2008|March 19, 2008|April 16, 2007||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00461266||172329|
NCT00461604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1690/07|High Dosage Esomeprazole and Baclofen for Therapy of Gastroesophageal Reflux Disease||NEXBAC|Technische Universität München|Yes|Completed|October 2006|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|70 Years|No|||May 2008|May 19, 2008|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461604||172304|
NCT00470379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0578|Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery|Transcutaneous (Topical) Peptide Immunization With NY-ESO-1b (SLLMWITQC) Peptide Using Resiquimod as an Immune Adjuvant: A Pilot Study||Mayo Clinic|Yes|Completed|April 2006|October 2011|Actual|October 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2012|October 30, 2014|May 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470379||171642|
NCT00470392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMB-004-06S|Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis|Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis||VA Office of Research and Development|Yes|Terminated|May 2007|July 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Actual|9|||Both|18 Years|80 Years|No|||February 2014|February 12, 2014|May 4, 2007|Yes|Yes|Recruiting complete and administrative termination|No|September 26, 2013|https://clinicaltrials.gov/show/NCT00470392||171641|No synchronized T cell reactivation was observed upon immunohistochemical analysis, nor upon analysis of T cell death associated gene (TDAG) mRNA by PCR, with Clobetasol treatment, so this arm was terminated.
NCT00470717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-UH-1001|Feeding and Wellness Among Late Preterm Infants|Early Feeding and Wellness Among Late Preterm Infants Born at MacDonald Women's Hospital: A Feasibility Study for a Breastfeeding Intervention||University Hospital Case Medical Center|No|Completed|November 2008|January 2010|Actual|February 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Female|18 Years|N/A|No|||December 2010|December 27, 2010|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00470717||171617|
NCT00472121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMG-MMG|The Precision and Arm-to-Arm Variation of Mechanomyography and Acceleromyography for Monitoring of Neuromuscular Block|The Precision and Arm-to-Arm Variation og Mechanomyography and Acceleromyography for Monitoring the Neuromuscular Block During Anesthesia, A Randomized Controlled Study||Rigshospitalet, Denmark|Yes|Completed|May 2007|October 2007|Actual|October 2007|Actual|Phase 4|Observational|N/A||2|||||Both|18 Years|65 Years||||April 2008|April 17, 2008|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472121||171511|
NCT00472134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-05-22|Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump|Prospective, Randomized, Double-blind Trial of Continuous Infusion of 0.5% Bupivacaine be Elastomeric Pump for Prospective Pain Management After Laparoscopic Ventral Hernia Repair.||University Hospital Case Medical Center|Yes|Completed|December 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||January 2012|June 4, 2015|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472134||171510|
NCT00469976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000542546|Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Enzastaurin Plus Carboplatin and Gemcitabine (ECoG) in Bevacizumab-Ineligible Patients and Enzastaurin Plus Carboplatin, Gemcitabine and Bevacizumab (B-ECoG) in Bevacizumab-Eligible Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Eastern Cooperative Oncology Group|No|Withdrawn|June 2007|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|120 Years|No|||October 2015|October 6, 2015|May 3, 2007|Yes|Yes|ECOG will not proceed with activation|No||https://clinicaltrials.gov/show/NCT00469976||171673|
NCT00470444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 06-185|Transfusion Triggers in Cardiac Surgery|Transfusion Triggers in Cardiac Surgery|TTRICS|St. Michael's Hospital, Toronto|Yes|Completed|December 2006|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2008|July 30, 2015|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00470444||171638|
NCT00472147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBF-2007002|Selection of Shock Energy in Out-Of-Hospital Cardiac Arrest|||Charite University, Berlin, Germany|No|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||May 2007|May 10, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472147||171509|
NCT00472160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060230|Preoxygenation Using NIV in Hypoxemic Patients|Preoxygenation Using Noninvasive Ventilation Prior Intubation in Hypoxemic Patients|PREOXY|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2007|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|18 Years|N/A|No|||May 2007|March 25, 2011|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472160||171508|
NCT00469651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSP3_TN_0303|Phase Ib Trial of MSP3 LSP in Children in Tanzania|A Double Blind, Randomized, Controlled Phase Ib Field Trial in 12 to 24 Month Old Children in Tanzania to Evaluate the Safety and Immunogenicity of Candidate Malaria Vaccine MSP 3 Versus Hepatitis B Vaccine|MSP3TN|African Malaria Network Trust|Yes|Recruiting|October 2007|August 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|45|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||December 2007|December 13, 2007|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469651||171697|
NCT00469664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00110|Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia|A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia|Guanfacine|Research Foundation for Mental Hygiene, Inc.|No|Active, not recruiting|February 2000|December 2008|Anticipated|August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||May 2008|May 20, 2008|May 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00469664||171696|
NCT00470457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-GTP-001|A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy|A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration||University of Zurich|No|Completed|June 2001|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00470457||171637|
NCT00470470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00216|Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT||National Cancer Institute (NCI)||Completed|April 2007|October 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2014|December 15, 2014|May 3, 2007|Yes|Yes||No|March 19, 2014|https://clinicaltrials.gov/show/NCT00470470||171636|
NCT00462774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHZB/CARDIO133/2007/1|Bypass Surgery and CD133 Marrow Cell Injection for Treatment of Ischemic Heart Failure|Evaluierung Eines Therapiemodells Der Autologen Knochenmark-Transplantation Bei Herzerkrankungen Mit Besonderem Schwerpunkt Der Prüfung Verschiedener Progenitorzellen|Cardio133|German Heart Institute|Yes|Completed|April 2007|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462774||172218|
NCT00463021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECT00306|A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection|A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis.||Sanofi||Completed|April 2007|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|April 18, 2007||||||https://clinicaltrials.gov/show/NCT00463021||172201|
NCT00462813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-CRISP-1|Diindolylmethane in Treating Patients With Abnormal Cervical Cells|An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1]||National Cancer Institute (NCI)||Completed|October 2004|January 2010|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|3000|||Female|N/A|N/A|No|||September 2008|August 6, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462813||172216|
NCT00459342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00225|Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Phase II Study of Dasatinib in Non Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|March 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2012|April 29, 2014|April 9, 2007|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00459342||172475|
NCT00459901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022-03|Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer|Phase II Trial of OSI-774 (Erlotinib, Tarceva™,) and Capecitabine for Patients With Previously Untreated Metastatic Colorectal Cancer||Beth Israel Medical Center||Terminated|June 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 11, 2007|No|Yes|Study halted by drug manufacturer|No||https://clinicaltrials.gov/show/NCT00459901||172433|
NCT00461617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAD1301|Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients|Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes||Kissei Pharmaceutical Co., Ltd.|No|Completed|August 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|291|||Both|25 Years|70 Years|No|||April 2007|October 20, 2008|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461617||172303|
NCT00469924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etchells1|Effect of an Automated Paging System on Response to Critical Laboratory Values|Effect of an Automated Paging System on Response to Critical Laboratory Values||Sunnybrook Health Sciences Centre|No|Recruiting|February 2006|September 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|2||Anticipated|400|||Both|N/A|N/A|No|||May 2007|May 4, 2007|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469924||171677|
NCT00461890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syracuse VA IRB #00364|Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial|Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial||State University of New York - Upstate Medical University||Terminated|October 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||October 2011|October 21, 2011|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00461890||172282|
NCT00471861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109944|Inflammatory Markers in Patients With Active Migraine Headaches|Does Migraine As A Partly Inflammatory Disease Increase The Inflammatory Markers Of The Patient When Actively Having a Migraine?||Westside Family Medical Center, P.C.|No|Completed|May 2007|February 2009|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Migraine|February 2009|August 5, 2011|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471861||171531|
NCT00468182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220060228|Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis|Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis||Rutgers, The State University of New Jersey|No|Completed|April 2007|December 2011|Actual|December 2011|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|24|||Both|18 Years|60 Years|No|Non-Probability Sample|Multiple Sclerosis Clinic patient|May 2015|May 5, 2015|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468182||171810|
NCT00468819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91552|A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children|Open-label Multi-center Study of Magnetic Resonance Imaging (MRI) With 0.1 mmol/kg Body Weight (BW) Gadavist (1.0 M) to Assess Pharmacokinetics, Safety and Tolerability in Children.||Bayer|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|140|||Both|2 Years|17 Years|No|||June 2015|June 29, 2015|May 2, 2007||No||No|June 10, 2011|https://clinicaltrials.gov/show/NCT00468819||171761|Originally, urine was collected up to 6 hours post injection in patients > 9 years. This was amended to patients of all age groups. As a result, urine was collected in 102 of 138 patients with gadobutrol injection (lowest rate in patients 2-6 years).
NCT00470210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORE|Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens|Efficacy and Safety of High-dose Ribavirin (1600 mg/d) Boosted With Epoetin β (450 IU/kg/wk) in HIV/HCV Coinfected Patients Not Responding to Previous Treatment Regimens||Germans Trias i Pujol Hospital|No|Completed|May 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||April 2010|April 15, 2010|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470210||171655|
NCT00470197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00243|Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia|Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias||National Cancer Institute (NCI)||Completed|April 2007|||January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|May 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470197||171656|
NCT00471341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219-2001|Effect of Celecoxib on Markers of Vascular Inflammation|A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease||University of Florida|No|Completed|July 2002|December 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||75|||Both|50 Years|N/A|No|||May 2007|September 16, 2011|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00471341||171571|
NCT00468494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120060208|Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?|Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia||Rutgers, The State University of New Jersey|No|Completed|September 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|308|||Both|18 Years|80 Years|No|Non-Probability Sample|non-diabetic adults undergoing surgery|January 2013|January 24, 2013|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468494||171786|
NCT00468507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067030|The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application|The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application||Maastricht University Medical Center|Yes|Completed|March 2007|March 2010|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|45 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 30, 2010|May 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00468507||171785|
NCT00469079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA013333|Health Effects of SLT, Cigarette Smoking, and New Tobacco Products|Comparing the Health Effects of Smokeless Tobacco, Cigarette Smoking, and New Tobacco Products Advertised as Safer Alternatives Part of Tobacco Exposure Reduction|ANTS3|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|130|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|May 3, 2007||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00469079||171741|Smokeless tobacco products commercially available have been introduced, withdrawn, or changed at a relatively rapid rate resulting in products that are no longer available and changes that occurred during the time period that the study occurred.
NCT00469092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1731|Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes|A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin naïve Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|May 3, 2007|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00469092||171740|
NCT00470184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543376|Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer|Phase II Study of Capecitabine in Combination With Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer||Roswell Park Cancer Institute|Yes|Completed|November 2006|||October 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|May 3, 2007|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT00470184||171657|
NCT00471042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5258|Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care|Buprenorphine for Treatment of Opioid Dependence in Primary Care||New York State Psychiatric Institute|No|Completed|June 2006|August 2012|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Adults aged 18-65 who are seeking buprenorphine maintenance treatment for opioid        dependence|May 2015|May 19, 2015|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00471042||171593|
NCT00471952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC 09|Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache|Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache||Diamond Headache Clinic|No|Completed|April 2007|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|May 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00471952||171524|
NCT00471965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALI_L_00858|Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients|Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment|EACH|Sanofi|No|Completed|March 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|371|||Both|18 Years|75 Years|No|||September 2010|September 17, 2010|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00471965||171523|
NCT00467740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.6|Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma|Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (4 Doses) Delivered by the Respimat® Inhaler in Patients With Asthma||Boehringer Ingelheim||Completed|May 2007|||October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|296|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|April 30, 2007||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00467740||171844|
NCT00462254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#789|Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease|Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease||Southern California Institute for Research and Education|No|Terminated|June 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|4|||Both|45 Years|85 Years|No|||November 2010|November 10, 2010|April 16, 2007|No|Yes|Study discontinued.|No||https://clinicaltrials.gov/show/NCT00462254||172256|
NCT00462488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB4-845-02-IIA|Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ|Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG)||Viventia Bio|No|Completed|March 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00462488||172239|
NCT00462787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-012|Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia|A Phase I Dose Escalation Trial of Clofarabine in Addition to Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients With Relapsed or Refractory Acute Leukemia||Memorial Sloan Kettering Cancer Center||Completed|April 2007|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|28 Years|No|||November 2013|November 13, 2013|April 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00462787||172217|
NCT00459602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA7985|Incisional Hernia Outcomes Study Using Parietex Composite Mesh|A Multi-Center, Laparoscopic Abdominal-Wall Hernia Repair Outcomes Study Using Parietex Composite Mesh||Columbia University|No|Terminated|August 2004|September 2008|Actual|September 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Surgical clinic|March 2015|March 25, 2015|April 10, 2007||No|Principal Investigator left institution.|No||https://clinicaltrials.gov/show/NCT00459602||172456|
NCT00459914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUCAP2004|Sleep Apnea and Refractory Hypertension: Prevalence and Effect of CPAP Treatment|Sleep Apnea in Patients With Refractory Hypertension: Study of the Prevalence and the Effect of CPAP Treatment on Blood Pressure Control, Endothelial Dysfunction and Angiogenesis.||Fundacio Catalana de Pneumologia|No|Completed|January 2005|December 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|130|||Both|18 Years|75 Years|No|||January 2009|January 27, 2009|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459914||172432|
NCT00470158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.05.03.11.C2|Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes|Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|1000|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||December 2009|August 10, 2011|May 3, 2007||No||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00470158||171659|
NCT00471003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12729|The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension|A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients|METABOLIC|Bayer|No|Completed|September 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5448|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2010|January 19, 2010|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00471003||171596|
NCT00470405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC PHI0367|Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma|A Phase I Study of ALIMTA Plus Oxaliplatin Administered Every Other Week in the Treatment of Patients With Metastatic Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|May 2004|November 2007|Actual|May 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||April 2011|April 14, 2011|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470405||171640|
NCT00470418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-009-06S|Development of NIC5-15 in the Treatment of Alzheimer's Disease|Development of NIC5-15 in the Treatment of Alzheimer's Disease||VA Office of Research and Development|Yes|Completed|January 2007|March 2010|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|N/A|N/A|No|||October 2013|November 1, 2013|May 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470418||171639|
NCT00467922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-109|An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy|A Randomized Prospective Double Blind Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care Versus Either Colloid and Crystalloid||Spectrum Health Hospitals|No|Completed|May 2007|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|80 Years|No|||October 2009|October 20, 2009|April 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00467922||171830|
NCT00467935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3933|Scotoma Reduction in AMD Patients Treated With Ranibizumab|A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis|SALVAGE|Retina Research Foundation|Yes|Completed|March 2007|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|90 Years|No|||July 2011|July 28, 2011|April 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467935||171829|
NCT00469391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-3|Multi-Center Pre-Bariatric Weight Loss Study|A Multi-Center, Pilot Efficacy Study of the GI Sleeve for Pre-Surgical Weight Loss||GI Dynamics|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|55 Years|No|||August 2010|August 5, 2010|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00469391||171717|
NCT00470509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASAS|Adalimumab in Severe and Acute Sciatica|Adalimumab in Severe and Acute Sciatica|ASAS|University Hospital, Geneva|No|Completed|May 2005|June 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||June 2008|June 6, 2008|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00470509||171633|
NCT00470522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS Grant 95072|Study of Methotrexate in Lupus Erythematosus|A Canadian Multicenter, Randomized, Double-Blind Placebo-Controlled Study of Methotrexate and Folic Acid in Systemic Lupus Erythematosus: A Phase III Trial.|SMILE|University Health Network, Toronto|Yes|Completed|June 1995|December 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||May 2007|May 4, 2007|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00470522||171632|
NCT00471874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4427|Study Evaluating Health Related Utility in Rheumatoid Arthritis|An Observational Study to Examine the Relationship Between Rheumatoid Arthritis Disease Severity and Health Related Utility||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2007|December 2007|Actual|||N/A|Observational|Time Perspective: Retrospective|||Anticipated|250|||Both|18 Years|N/A|No|||December 2007|December 11, 2007|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471874||171530|
NCT00471887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543416|Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma|A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients With In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies||Jonsson Comprehensive Cancer Center|Yes|Completed|January 2007|March 2015|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00471887||171529|
NCT00471900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200110130|Six Months DHEA Treatment in Female Adrenal Failure|Physiolocal Effects of 6 Months DHEA Substitutional Therapy in Female Adrenal Failure in a Randomised, Placebo Controlled and Overcrossed Study.||University of Aarhus|No|Completed|October 2001|February 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|60 Years|No|||May 2007|May 9, 2007|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00471900||171528|
NCT00470769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-UR-00001|The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR|Color-Doppler Ultrasonography vs 99mTc-DTPA Scintigraphy to Assess the Renal Blood Flow||University of Roma La Sapienza|No|Recruiting|September 2006|May 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|2006|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||May 2007|May 7, 2007|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00470769||171614|
NCT00471055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Khonkaen-ortho 1|Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo|Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo|OAknee|Khon Kaen University|Yes|Completed|June 2007|December 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||April 2008|July 8, 2008|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471055||171592|
NCT00471068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD-05-03|Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension|Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Terminated|March 2007|||August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||February 2010|April 7, 2012|May 8, 2007|Yes|Yes|Question raised by Ethics Committee|No|October 21, 2009|https://clinicaltrials.gov/show/NCT00471068||171591|Sample size smaller than the one defined by the protocol
NCT00471081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109375|Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.|Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age||GlaxoSmithKline||Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|385|||Both|9 Months|9 Months|Accepts Healthy Volunteers|||January 2012|May 24, 2012|May 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00471081||171590|
NCT00471367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2782C00006|Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877|A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma||AstraZeneca||Terminated|April 2007|December 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|May 7, 2007|Yes|Yes|Part B of the study was terminated early due to a lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00471367||171569|
NCT00471380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-04-04|A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension|A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|March 2007|||October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|46|||Both|40 Years|N/A|No|||March 2010|March 10, 2010|May 8, 2007||||No|November 4, 2009|https://clinicaltrials.gov/show/NCT00471380||171568|
NCT00471978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450128|DNA Analysis of Blood and Tissue From Patients With Lung Cancer|Molecular and Genetic Analysis of Lung Cancer||National Cancer Institute (NCI)||Recruiting|September 2005|||June 2011|Anticipated|N/A|Observational|N/A|||Anticipated|6800|||Both|N/A|N/A|No|||June 2009|June 14, 2011|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471978||171522|
NCT00467753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220055339|Oxcarbazepine Versus Placebo in Childhood Autism|Oxcarbazepine Versus Placebo in Childhood Autism||Rutgers, The State University of New Jersey|Yes|Completed|April 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|5 Years|17 Years|No|||March 2013|October 25, 2013|April 27, 2007|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00467753||171843|Patients became more irritable coming off of previous medication and were unable to tolerate monotherapy with the medication.
NCT00458809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540283|Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer|A Phase I Evaluation of Intraperitoneal Hyperthermic Chemoperfusion With Oxaliplatin for Peritoneal Surface Disemmination of Appendiceal and Colorectal Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|March 2007|||November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458809||172511|
NCT00459069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-240|The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma|The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Completed|July 2004|November 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|April 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00459069||172493|
NCT00459615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1263|Phase II Dose Ranging Study of Artesunate|A Phase II, Randomized, Open-Label, Dose-Ranging Study of Intravenous Artesunate Therapy for the Treatment of Acute, Uncomplicated Plasmodium Falciparum Malaria.||Walter Reed Army Institute of Research (WRAIR)||Completed|April 2007|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|120|||Both|12 Years|65 Years|No|||September 2008|September 23, 2008|April 10, 2007||||||https://clinicaltrials.gov/show/NCT00459615||172455|
NCT00459927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-06JGott-01-B|Comparison of Floseal Hemostasis Tonsillectomy With Coblation Tonsillectomy and Cautery Hemostasis Tonsillectomy|Prospective, Controlled Clinical Trial of a Novel Hemostatic Sealant Versus Electrocautery Hemostasis and Coblation Dissection in Patients Undergoing Tonsillectomy||Kaiser Permanente|No|Withdrawn|July 2009|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||March 2014|March 18, 2014|April 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00459927||172431|
NCT00471016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0210S34223|An Intervention to Improve End of Life Decision Making Among Homeless Persons|An Intervention to Improve End of Life Decision Making Among Homeless Persons||University of Minnesota - Clinical and Translational Science Institute|No|Completed|June 2006|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|May 4, 2007|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00471016||171595|
NCT00471328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2201|Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib|A Randomized, Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib Versus Best Supportive Care With or Without a Tyrosine Kinase Inhibitor (Investigator's Choice) in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Both Imatinib and Sunitinib|ENEST|Novartis|Yes|Completed|March 2007|June 2011|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|April 26, 2007|Yes|Yes||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00471328||171572|
NCT00468546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA17042|A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy|A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies||Hoffmann-La Roche||Completed|July 2003|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|522|||Both|18 Years|80 Years|No|||September 2015|September 1, 2015|April 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468546||171782|
NCT00471640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|versie 1|Dexamethasone Infusion in Community-acquired Pneumonia|Dexamethasone Infusion in Community-acquired Pneumonia|Ovidius|St. Antonius Hospital|Yes|Completed|November 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2010|September 24, 2010|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471640||171548|
NCT00469690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5305|Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects|Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects||Innovative Medical||Completed|May 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 19, 2008|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469690||171695|
NCT00469989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB08A3|Randomised Placebo Controlled Study of Effects of Therapeutic Hookworm Infection in Asthma|Randomised Placebo Controlled Study of Effects of Therapeutic Hookworm Infection in Asthma||University of Nottingham|Yes|Completed|January 2007|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2008|January 2, 2008|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00469989||171672|
NCT00470223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sarcome 09/0603|Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma|OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant|OS2006|UNICANCER|Yes|Terminated|March 2007|April 2025|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|318|||Both|5 Years|50 Years|No|||January 2016|January 3, 2016|May 3, 2007||No|IDMC decision upon interim efficacy analysis|No||https://clinicaltrials.gov/show/NCT00470223||171654|
NCT00470535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543406|Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer|Phase II Study of Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma||Roswell Park Cancer Institute|Yes|Terminated|January 2007|September 2010|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 3, 2007|Yes|Yes|This study was terminated earlier due to a phase III study that showed this drug inferior to    sorafenib|No|December 3, 2014|https://clinicaltrials.gov/show/NCT00470535||171631|This study was terminated earlier due to a phase III study that showed this drug was not better than sorafenib
NCT00470483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMT106386|A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder||GlaxoSmithKline||Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00470483||171635|
NCT00470496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 74606|Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer|A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer||Roswell Park Cancer Institute|Yes|Active, not recruiting|October 2006|||October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470496||171634|
NCT00471094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-EE05-123|Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis|A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.||Takeda|No|Completed|May 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|831|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|May 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00471094||171589|
NCT00471393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMW 5936|Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease|Double-Blind Randomized Clinical Study on Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease in Women.||University of Alberta, Graduate Orthodontic Program|Yes|Completed|May 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2007|May 7, 2007|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00471393||171567|
NCT00471406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDT-0001|Photodynamic Therapy With Verteporfin for Corneal Neovascularization|||Chonnam National University Hospital||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|35 Years|70 Years||||October 2008|October 16, 2008|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471406||171566|
NCT00471419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-31|Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye|Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye||Alcon Research||Completed|July 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|750|||Both|18 Years|N/A|No|||March 2008|June 3, 2012|May 7, 2007||||||https://clinicaltrials.gov/show/NCT00471419||171565|
NCT00471679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-047|Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma|Phase I Study of an Ethanol-Lock Strategy to Prevent Central Venous Catheter Infections Among Patients With High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Completed|April 2007|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|N/A|N/A|No|||March 2013|March 4, 2013|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471679||171545|
NCT00471705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECET-001|Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.|Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.||Universidad de Antioquia|No|Completed|June 2006|December 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|437|||Male|18 Years|40 Years|No|||June 2009|July 15, 2010|May 7, 2007||No||No|June 14, 2010|https://clinicaltrials.gov/show/NCT00471705||171543|
NCT00471991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91539|Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition|Monocenter, Open-label, Randomized Study to Determine the Ovulation Inhibitory Effect of the Combined Oral Contraceptive SH T04769G and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), Applied for Two Treatment Cycles to 60 Healthy Female Volunteers||Bayer|No|Completed|April 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00471991||171521|
NCT00472004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0753T-101800|Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women|A Prospective, Randomized, Open Label Study To Compare The Efficacy, Safety And Tolerability Of 17-B Estradiol/Trimegestone CC 1 Mg (Totelle) And Tibolone (Livial) In Postmenopausal Women.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 28, 2010|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00472004||171520|
NCT00459082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10760|A Pharmacokinetic Study of Dexmedetomine in Infants|A Pharmacokinetic Study of Dexmedetomine in Infants||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|May 2004|November 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||36|||Both|1 Month|24 Months|No|||April 2007|April 10, 2007|April 9, 2007||||No||https://clinicaltrials.gov/show/NCT00459082||172492|
NCT00459355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRH 05-056|Home Safety Clinical Trial for Alzheimer's Disease|Clinical Trial of a Home Safety Intervention for Alzheimer's Disease||VA Office of Research and Development|No|Completed|July 2007|December 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|254|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|April 6, 2007||No||No|August 21, 2014|https://clinicaltrials.gov/show/NCT00459355||172474|
NCT00459368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL079055|Using Information Technology to Improve Asthma Adherence|Adherence Feedback for Improving Respiratory Medication Use|AFFIRM|Henry Ford Health System|No|Completed|May 2007|November 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2698|||Both|5 Years|56 Years|No|||June 2010|August 10, 2010|April 9, 2007||No||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00459368||172473|
NCT00459628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/009|Trial of Tomotherapy in Breast Cancer|Randomized Trial Comparing Conventional vs Short-course Reduced Volume Conformal Post-surgery Radiation Treatment in Women With Stage I or II Breast Cancer|TomoBreast|Vrije Universiteit Brussel|Yes|Active, not recruiting|May 2007|December 2016|Anticipated|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Female|18 Years|N/A|No|||September 2014|September 8, 2014|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459628||172454|
NCT00460850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20135|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.|An Open Label Study to Evaluate the Effect of PEGASYS on ALT and HBV DNA Levels in Patients With Lamivudine-Resistant HbeAg-Negative Chronic Hepatitis B||Hoffmann-La Roche||Terminated|September 2007|June 2008|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||June 2008|June 27, 2008|April 16, 2007||No|Low recruitment rate due to treatment regimen change|No||https://clinicaltrials.gov/show/NCT00460850||172361|
NCT00460863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602-2002|Effects of Hemodialysis on the Sleep/Wake Cycle|Effects of Hemodialysis on the Slee/Wake Cycle of Patients on Chronic Hemodialysis||Emory University|Yes|Completed|April 2003|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|58|||Both|21 Years|75 Years|No|||May 2008|April 22, 2014|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00460863||172360|
NCT00468858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14040|A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children|Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children||U.S. Army Medical Research and Materiel Command|No|Completed|July 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|636|||Both|12 Months|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|May 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468858||171758|
NCT00469144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0366|IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome|A Randomized Study of Once Daily IV Busulfan With Fludarabine With Hemopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Completed|June 2005|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|233|||Both|N/A|65 Years|No|||November 2015|November 23, 2015|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469144||171736|
NCT00469157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5303|Refractive Surgery and Optive Compatibility Study|Refractive Surgery and Optive Compatibility Study||Innovative Medical||Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|92|||Both|18 Years|N/A|No|||April 2008|April 16, 2008|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469157||171735|
NCT00469417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC T304/99|Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma|A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma||Galderma||Completed|October 1999|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469417||171715|
NCT00469703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic Pancreatitis|Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis|A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis.||Winthrop University Hospital||Terminated|August 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|75 Years|No|||January 2008|January 10, 2008|May 3, 2007|||Terminated|No||https://clinicaltrials.gov/show/NCT00469703||171694|
NCT00470002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MES 03069|Effects of Growth Hormone on the Nitric Oxide Pathway|Effects of Growth Hormone (GH) on Parameters of the Nitric Oxide (NO) Pathway||Hannover Medical School|No|Completed|May 2004|January 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Male|50 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 4, 2007|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00470002||171671|
NCT00470236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 07.01|Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast|A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast|DCIS|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Active, not recruiting|June 2007|June 2024|Anticipated|June 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1608|||Female|18 Years|N/A|No|||January 2016|January 24, 2016|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00470236||171653|
NCT00470782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-5-0064 / ethics 23429|Aerobic Capacity and Body Composition in Colon Cancer Patients|Changes in Aerobic Capacity and Body Composition in Colon Cancer Patients Receiving Chemotherapy||AHS Cancer Control Alberta|Yes|Completed|October 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|April 2012|February 24, 2016|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00470782||171613|
NCT00470808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0051-07-EMC|The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients||POMX|HaEmek Medical Center, Israel|No|Not yet recruiting|May 2007|August 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||April 2007|May 7, 2007|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00470808||171611|
NCT00470821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mela-UniMi-0001|Oral Melatonin in Critically Ill High-risk Patients|Randomized, Controlled, Double Blind Trial to Evaluate Sedation and Quality of Life in High-risk, Critically Ill Patients Treated With Oral Melatonin||University of Milan|No|Completed|May 2007|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|85 Years|No|||January 2010|July 26, 2010|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470821||171610|
NCT00470834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVO108943|Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy|A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase||GlaxoSmithKline|No|Completed|May 2007|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|127|||Male|40 Years|90 Years|No|||July 2013|August 29, 2013|May 7, 2007|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT00470834||171609|
NCT00471107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070147|Effect of Electrical Stimulation (DC Polarization) to the Brain on Memory|Effect of Direct Current Brain Polarization on Verbal Memory||National Institutes of Health Clinical Center (CC)|No|Completed|May 2007|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 23, 2016|May 8, 2007||No||No|January 17, 2012|https://clinicaltrials.gov/show/NCT00471107||171588|
NCT00471432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I154|OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors|A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel||Canadian Cancer Trials Group||Completed|March 2003|December 2009|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2010|November 7, 2010|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471432||171564|
NCT00471445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543103|Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients|Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN)||University of Rochester|Yes|Completed|October 2007|November 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|462|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|May 8, 2007|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00471445||171563|Since ketamine and amitriptyline are both analgesics, it is possible that the effects of the ketamine plus amitriptyline-containing creams may have been diluted when all three neuropathy symptoms were assessed together.
NCT00471692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0008762|Local Anaesthetic Following Hernia Repair|A Randomised, Double Blind, Placebo Controlled Study to Compare Ilio Inguinal Nerve Block and Local Wound Irrigation||Royal Hobart Hospital|No|Terminated|October 2006|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|May 8, 2007||No|Due to high incidence of neurological complication in those with ilioinguinal block|No||https://clinicaltrials.gov/show/NCT00471692||171544|
NCT00467792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP|Natural History of Urticaria Pigmentosa in Children|Natural History of Urticaria Pigmentosa in Children|UP|Medical College of Wisconsin|No|Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Both|N/A|18 Years|No|Non-Probability Sample|This study involves children, of age 0-18 years old who are diagnosed with urticaria        pigmentosa during their visit at the Pediatric Dermatology Clinic.|December 2008|December 5, 2008|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00467792||171840|
NCT00468052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120060313|Pain Relief for Children Undergoing Tonsillectomy & Adenoidectomy|Use of Dexmedetomidine Infusion for Analgesia and Emergence Agitation for Children Undergoing Tonsillectomy and Adenotonsillectomy||Rutgers, The State University of New Jersey|No|Completed|March 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|122|||Both|2 Years|10 Years|No|||November 2010|November 30, 2010|April 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00468052||171820|
NCT00458835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-422|Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)|A Randomized, Open-label, Single-dose, 3-period Crossover, Pharmacokinetic Study Designed to Compare the Systemic Des-ciclesonide Exposure of OMNARIS™ (Ciclesonide) Nasal Spray, Ciclesonide HFA Nasal Aerosol, and Orally Inhaled Ciclesonide||Takeda|No|Completed|April 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||January 2012|May 4, 2012|April 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00458835||172509|
NCT00459108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00224|Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery|A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma||National Cancer Institute (NCI)||Terminated|April 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2014|March 19, 2015|April 9, 2007|Yes|Yes|Halted early for futility.|No|June 19, 2014|https://clinicaltrials.gov/show/NCT00459108||172491|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.
NCT00459381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02710|Pazopanib in Treating Patients With Recurrent Glioblastoma|A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma||National Cancer Institute (NCI)||Completed|May 2007|||December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|February 1, 2013|April 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00459381||172472|
NCT00460512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012949|An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia|PERFlexS|Janssen-Cilag International NV|No|Active, not recruiting|April 2007|December 2016|Anticipated|January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1812|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00460512||172386|
NCT00460525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0003|Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali|Randomized, Controlled Phase II Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali||U.S. Army Medical Research and Materiel Command|Yes|Completed|May 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|400|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||August 2012|May 18, 2015|April 12, 2007|Yes|Yes||No|July 2, 2010|https://clinicaltrials.gov/show/NCT00460525||172385|
NCT00460538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL-002|Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms|Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms||Milsing d.o.o.|Yes|Completed|April 2007|November 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2010|April 2, 2010|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460538||172384|
NCT00469170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 011|A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method|A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method for the Prevention of HIV Infection in Women||International Partnership for Microbicides, Inc.|Yes|Completed|March 2007|February 2010|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2010|November 10, 2010|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469170||171734|
NCT00469443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/05.16|Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC|A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer||Hellenic Oncology Research Group|No|Completed|December 2006|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|72 Years|No|||August 2010|August 18, 2010|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469443||171713|
NCT00469430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Hansson|Study of Conservative Versus Surgical Treatment of Appendicitis|Randomized Study of Conservative Versus Surgical Treatment of Appendicitis; Analyses of Result and Economics||Göteborg University|No|Completed|May 2006|October 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|No|||April 2009|April 20, 2009|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469430||171714|
NCT00469729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC P#02.01.001|Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy|A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy|ExCell|Gamida Cell -Teva Joint Venture Ltd.|Yes|Completed|October 2007|June 2015|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|12 Years|55 Years|No|||March 2013|July 9, 2015|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00469729||171692|
NCT00470249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000542627|Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes||National Cancer Institute (NCI)||Recruiting|February 2007|||April 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||July 2009|August 1, 2009|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00470249||171652|
NCT00470860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G04-07-038-02|Educational Technology to Enhance Diabetes Care - Retention Study|||University of California, Los Angeles|No|Completed|December 2004|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|105|||Both|N/A|N/A|No|||May 2007|May 7, 2007|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00470860||171607|
NCT00470873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12842|Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive Men|A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Obtain Data on Safety and Efficacy of Levitra® in Routine Treatment of Erectile Dysfunction in Depressive and Non-Depressive Men.||Bayer|No|Completed|January 2007|February 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2471|||Male|18 Years|N/A|No|Non-Probability Sample|Primary care erectile dysfunction patients for whom physician decided to start the        treatment with vardenafil|November 2014|November 26, 2014|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00470873||171606|
NCT00471146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061028|Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.|A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.||Pfizer|Yes|Completed|July 2007|November 2010|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|630|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|May 7, 2007|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00471146||171585|
NCT00470548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000542904|Abraxane and Alimta in Advanced Solid Tumors|Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer|UCDCC#185|University of California, Davis|Yes|Completed|April 2007|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|May 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470548||171630|
NCT00470795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP.GP.07|Acupuncture for Diabetic Gastroparesis|A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis.||Shaare Zedek Medical Center|No|Suspended|June 2009|September 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2008|December 14, 2008|May 7, 2007||No|Protocol to be re-designed (primary outome still GCSI)|No||https://clinicaltrials.gov/show/NCT00470795||171612|
NCT00470847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-356|Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer|A Phase I Study of Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|April 2007|June 2012|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|May 7, 2007||No||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00470847||171608|
NCT00471120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13806-CC113|Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer|Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women||CytoCore, Inc.|Yes|Terminated|November 2006|February 2008|Actual|April 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Female|18 Years|N/A|No|||August 2015|August 3, 2015|May 7, 2007||No|Study terminated due to protocol deficiencies.|No||https://clinicaltrials.gov/show/NCT00471120||171587|
NCT00471133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003|Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation|A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma||Ichor Medical Systems Incorporated|No|Completed|April 2007|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||June 2011|June 3, 2011|May 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00471133||171586|
NCT00471458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02134|Follow-up Study of the RAI-Treated Hyperthyroid Patients|Follow-up Study of Hyperthyroid Patients Treated With RAI in 1965-2002: Morbidity in Long-Term Follow-up||University of Tampere|No|Completed|January 1969|December 2003|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|5222|||Both|N/A|N/A|No|||May 2007|May 9, 2007|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00471458||171562|
NCT00467805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-s4c|Immediate Effect of Light on Reproductive Hormones in Women: a Role of the Spectrum|||Russian Academy of Medical Sciences|No|Completed|March 2009|October 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|April 8, 2010|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00467805||171839|
NCT00468065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0037-07|VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department|VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department||Lifespan|Yes|Recruiting|April 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|17 Years|No|||April 2007|May 5, 2008|April 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00468065||171819|
NCT00459953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA118035|Extended Cessation Treatment for Teen Smokers|Extended Cessation Treatment for Teen Smokers|Nicoteens|Stanford University|Yes|Completed|September 2006|July 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|April 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00459953||172429|
NCT00460213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIT-061003-1|Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study|Study on Optimal Anti-hypertensive Therapy With Valsartan by Using Home Blood Pressure Measurement||Kitakyushu-Tsuyazaki Hospital|Yes|Completed|July 2006|November 2013|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|103|||Both|20 Years|80 Years|No|||December 2013|December 5, 2013|March 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00460213||172409|
NCT00460226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBI108245|Lamictal Bipolar Observational Study|A Multi-centre, Observational Study to Evaluate the Incidence of Non-serious Rash in Korean Bipolar I Patients With Lamotrigine Therapy in Real World Setting||GlaxoSmithKline||Completed|March 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|238|||Both|18 Years|N/A|No|Probability Sample|Patient setting and reflecting usual clinical practice in general hospital|January 2011|March 15, 2012|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460226||172408|
NCT00460902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|395/3.11.06(HMO)|Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication|Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression||Hadassah Medical Organization|No|Completed|April 2007|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|70 Years|No|||March 2015|March 18, 2015|April 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00460902||172357|
NCT00461175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2006_01|European Active Surveillance Study for Intrauterine Devices|European Active Surveillance Study for Intrauterine Devices|EURAS-IUD|Center for Epidemiology and Health Research, Germany|Yes|Completed|November 2006|December 2013|Actual|May 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|63194|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment of cohort members will be conducted via a network of approximately 2000        gynecologists.|June 2015|June 24, 2015|April 16, 2007||No||No|October 16, 2014|https://clinicaltrials.gov/show/NCT00461175||172336|In observational studies like EURAS-IUD, the possibility of bias and residual confounding can never be entirely eliminated. Thus, for risk estimates smaller than 2-fold, causality cannot be inferred confidently in view of alternative explanations.
NCT00461188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004842|Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA|Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA||Barts & The London NHS Trust|No|Recruiting|March 2007|April 2099|Anticipated|April 2099|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|DNA sample, tissue sample|Both|6 Years|N/A|No|Non-Probability Sample|pituitary disease patients|July 2015|July 15, 2015|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461188||172335|
NCT00461201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI060715|Nurse vs General Practitioner Care for Patients Requesting Same Day Consultations in Primary Care|Effectiveness of an Intervention in Primary Care: Randomized Controlled Trial Comparing Care for Patients Requesting Same Day Consultations by Nurse Practitioner vs General Practitioners||Catalan Institute of Health|No|Not yet recruiting|January 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||1640|||Both|15 Years|N/A|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461201||172334|
NCT00468884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral GLP-1 and PYY|Oral Administration of Peptides; Absorption From Gastrointestinal Tract|Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: a Proof of Concept Study in Healthy Subjects||University Hospital, Basel, Switzerland|No|Completed|October 2006|February 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00468884||171756|
NCT00469183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10010|Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma|An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma||Galderma Laboratories, L.P.|No|Completed|May 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|65 Years|No|||March 2008|March 28, 2008|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469183||171733|
NCT00469716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15789|Hypertonic Saline-Hetastarch in Cardiac Surgery|Infusion of Hypertonic Saline-Hetastarch in Cardiac Surgery|HH|Haukeland University Hospital|Yes|Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2008|December 15, 2008|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469716||171693|
NCT00470015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000542631|Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma|Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study||Mayo Clinic|Yes|Active, not recruiting|March 2007|December 2015|Anticipated|April 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|May 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470015||171670|
NCT00470886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12827|Assessment of Compliance With Antihypertensive Telmisartan Therapy|A Non-Interventional, Post-Marketing Surveillance, Phase IV Study to Assess Compliance With Antihypertensive Telmisartan Therapy|COAST|Bayer|No|Completed|April 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3400|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic hypertensive patients for whom physician decided to start the        treatment with telmisartan|November 2012|November 14, 2012|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00470886||171605|
NCT00470899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH20041201|Effect of Placental Drainage of Fetal Blood at Cesarean Section on the Incidence of Feto-Maternal Transfusion|Effect of Placental Drainage of Fetal Blood at Cesarean Section on the Incidence of Feto-Maternal Transfusion: A Randomized Controlled Trial||Lester E. Cox Medical Centers|Yes|Completed|January 2005|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|86|||Female|N/A|N/A|No|||May 2007|April 6, 2015|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00470899||171604|
NCT00470561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS 1908.00|Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density|The Effect of Aspirin on Mammogram Density (TEAM)||Fred Hutchinson Cancer Research Center|Yes|Completed|November 2005|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|144|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||November 2010|November 10, 2010|May 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470561||171629|
NCT00471471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-173|Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma||University of Pittsburgh|Yes|Completed|October 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|May 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00471471||171561|
NCT00471718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC URO 0426|ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase1/2 Trial of ABT-751 in Patients With Advanced, Androgen-Independent Prostate Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|January 2004|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|N/A|No|||June 2012|June 27, 2012|May 8, 2007|Yes|Yes|pharmaceutical company closed study because the treatment was not effective|No|October 26, 2011|https://clinicaltrials.gov/show/NCT00471718||171542|
NCT00472017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJBG07-SJ|Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma|Phase I Trial of Vandetanib (ZD6474, ZACTIMA) With Concurrent Radiation in Treatment of Newly Diagnosed Brainstem Glioma||St. Jude Children's Research Hospital|No|Completed|April 2007|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|2 Years|21 Years|No|||October 2012|October 11, 2012|May 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00472017||171519|
NCT00468078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPCITKR001|Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients|The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients|FPCIT|Asan Medical Center|Yes|Completed|November 2006|October 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|78|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468078||171818|
NCT00468338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120060266|Correlation BIS Scores Mentally Retarded Patients|Correlation Between the Severity of Mental Retardation and BIS in Mentally Retarded Patients Undergoing Dental Rehabilitation||Rutgers, The State University of New Jersey|No|Completed|December 2006|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|12 Years|65 Years|No|Non-Probability Sample|mentally retarded persons ages 12 to 65 ubdergoing dental rehabilitation|April 2015|April 23, 2015|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00468338||171798|
NCT00459667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91656|BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose|International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg|Beyond|Bayer|No|Completed|May 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|1420|||Both|18 Years|55 Years|No|||April 2015|April 3, 2015|April 11, 2007|Yes|Yes||No|March 16, 2009|https://clinicaltrials.gov/show/NCT00459667||172451|Due to the termination of the study before start of Phase B according to protocol defined stopping rules, functional assessments of multiple sclerosis (FAMS) and EuroQoL (EQ-5D) were not performed.
NCT00459966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-041/03|Preoperative Prevention and Early Rehabilitation for Patients Undergoing Elective Spine Surgery|||Rigshospitalet, Denmark|No|Completed|February 2005|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||60|||Both|18 Years|N/A|No|||April 2007|April 12, 2007|April 11, 2007||||No||https://clinicaltrials.gov/show/NCT00459966||172428|
NCT00460915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL109776|Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years|Korea University Guro Hospital|ELDER|Korea University Guro Hospital||Completed|January 2007|February 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|204|||Both|55 Years|80 Years|No|||November 2009|March 1, 2010|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00460915||172356|
NCT00460577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOR258DVE02|Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction|Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-<12 Years) With Acute Bronchial Obstruction Attending Emergency Services||Novartis||Completed|March 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|12 Years|No|||March 2011|March 23, 2011|April 13, 2007||||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00460577||172381|Secondary Outcome Measure 2: Safety Assessed by Pulse Oxymetry, Clinical Assessments, Adverse Events has not been posted. Analysis of Pulse Oxymetry and Clinical Assessment was not performed. Adverse events are reported in the Adverse Event section.
NCT00461214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1896|General Surgery Training Outcomes Project|General Surgery Training Outcomes Project: Evaluating the Impact of the Curriculum on General Surgery Resident Training and Evaluation||Columbia University|No|Terminated|October 2006|||August 2008|Actual|N/A|Observational|N/A||1|Actual|35|||Both|18 Years|65 Years|No|Non-Probability Sample|Surgery interns and PGY2-5's|November 2012|November 19, 2012|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00461214||172333|
NCT00469196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-11-0077 / 22933|Tomotherapy Treatment for Mesothelioma|Tomotherapy Treatment for Mesothelioma||AHS Cancer Control Alberta|Yes|Active, not recruiting|October 2006|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469196||171732|
NCT00469209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0893|Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients|Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Completed|June 2006|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|N/A|75 Years|No|||August 2012|August 1, 2012|May 3, 2007||No||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00469209||171731|
NCT00469469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS 0510|Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma|A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex.||Dartmouth-Hitchcock Medical Center|Yes|Withdrawn|May 2007|September 2009|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2008|April 21, 2015|May 2, 2007|||unable to enroll subjects into the study|No||https://clinicaltrials.gov/show/NCT00469469||171711|
NCT00469742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-020|Aprotinin in Neonates Undergoing Cardiopulmonary Bypass|Safety Profile of Aprotinin in Neonates Undergoing Cardiopulmonary Bypass: A Retrospective Chart Review||Children's Healthcare of Atlanta|No|Completed|April 2007|December 2008|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|290|||Both|N/A|1 Month|No|Non-Probability Sample|neonates who underwent Cardiopulmonary Bypass (CPB) at Chldren's Healthcare of Atlanta        between March 2004 and March 2007.|May 2010|March 14, 2012|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469742||171691|
NCT00469456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-71|Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD)||Forest Laboratories||Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|265|||Both|50 Years|N/A|No|||December 2009|December 21, 2009|May 2, 2007|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00469456||171712|
NCT00469755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10026|Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne|A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-Week Treatment Switched to Tazorac® Cream, 0.1% 6-Week Treatment in Patients With Acne Vulgaris||Galderma Laboratories, L.P.|No|Completed|February 2006|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|302|||Both|12 Years|35 Years|No|||March 2008|March 28, 2008|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469755||171690|
NCT00470275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS0621|Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma|Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma||Children's Oncology Group|Yes|Completed|May 2007|December 2013|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|30 Years|No|||October 2014|October 9, 2014|May 3, 2007|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT00470275||171650|
NCT00470288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-10-477|Randomized Controlled Trial of Bladder Flap vs.None|Randomized Controlled Trial of Bladder Flap vs.None||Mountain Area Health Organization Center|No|Recruiting|October 2005|June 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|123|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2007|May 4, 2007|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00470288||171649|
NCT00470574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-156|Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer|Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2007|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|May 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470574||171628|
NCT00470587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APACE|Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study|Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study|APACE|University Hospital, Basel, Switzerland|Yes|Recruiting|April 2006|June 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|Samples Without DNA|EDTA plasma, Heparin, Serum, Citrate|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department with typical angina pectoris or other        thoracic sensations at rest or minor exertion that are suspected to be caused by        myocardial ischemia. Onset of symptoms within the last 12 hours prior to presentation.|March 2016|March 3, 2016|May 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00470587||171627|
NCT00470600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-008C|Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients|A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF IBUPROFEN INJECTION (IVIb) FOR TREATMENT OF PAIN IN POST-OPERATIVE ORTHOPEDIC ADULT PATIENTS||Cumberland Pharmaceuticals|Yes|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|80 Years|No|||August 2015|August 3, 2015|May 7, 2007|Yes|Yes||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00470600||171626|
NCT00470912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG 003|Sunscreen RV 2457C in Photoinduced CLE|Photoprotective Effects of the RV 2457C Sunscreen Milk in Photoinduced Cutaneous Lupus Erythematosus||Heinrich-Heine University, Duesseldorf|No|Completed|May 2001|February 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|25|||Both|18 Years|70 Years|No|||May 2007|May 7, 2007|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00470912||171603|
NCT00471237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9108963|A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.|Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis||GlaxoSmithKline|Yes|Terminated|May 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|569|||Female|18 Years|79 Years|No|||March 2014|March 27, 2014|May 7, 2007|Yes|Yes|Terminated for futility by sponsor after a pre-planned interim review of data|No||https://clinicaltrials.gov/show/NCT00471237||171579|
NCT00471159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8501007|A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.|A Randomized Phase 2 Clinical Trial Of Docetaxel With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Breast Cancer||Pfizer||Withdrawn|August 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|N/A|No|||April 2015|April 30, 2015|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00471159||171584|
NCT00471172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001187|Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss|A 6-Month, Randomized Study To Evaluate The Efficacy Of Various Non-Pharmacologic, Disease Management Programs For The Treatment Of Obesity||Pfizer||Completed|August 2004|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label||||350|||Both|25 Years|60 Years|No|||September 2008|September 12, 2008|May 7, 2007||||No||https://clinicaltrials.gov/show/NCT00471172||171583|
NCT00471497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2303|A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|ENESTnd|Novartis||Active, not recruiting|July 2007|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|846|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|May 7, 2007|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00471497||171559|
NCT00471731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070145|Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure|Ocular Impact of X Chromosome Karyotype and Sex Hormones in Turner Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 2007|November 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|72|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00471731||171541|
NCT00472030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100569|Efficacy and Safety of Omalizumab in Bullous Pemphigoid|An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid||University of Iowa|No|Completed|August 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|May 8, 2007|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00472030||171518|Limitations of this trial include low enrollment of research subjects and the need to withdraw a subject from the trial.
NCT00468091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATEX|Effects of Exendin(9-39) on Gastroduodenal Motility|Regulation of Antro-pyloro-duodenal and Proximal Gastric Motility by GLP-1: Involvement of Cholinergic Pathways||Ludwig-Maximilians - University of Munich||Completed|February 1999|September 2000|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|4||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2007|March 31, 2015|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00468091||171817|
NCT00467844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200502|Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.|Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in Patients With Cancer||GTx|No|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|159|||Both|N/A|N/A|No|||June 2014|June 26, 2014|April 30, 2007|No|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00467844||171836|
NCT00468351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154342005|Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)|Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema|IBEME|University of Sao Paulo|Yes|Active, not recruiting|April 2006|April 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||April 2007|May 1, 2007|May 1, 2007||||No||https://clinicaltrials.gov/show/NCT00468351||171797|
NCT00460239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-8|Buprenorphine's Dose Response Curve|Evaluation of Opioid Antagonist Activity in Humans||National Institute on Drug Abuse (NIDA)|No|Active, not recruiting|January 2007|December 2012|Anticipated|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|12|||Both|21 Years|55 Years|No|||April 2012|April 21, 2012|April 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00460239||172407|
NCT00460551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN204|Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer|A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients||Genmab|Yes|Terminated|April 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|April 12, 2007|Yes|Yes|Due to considerations regarding the appropriate therapeutic regimen for these patients.|No|September 12, 2011|https://clinicaltrials.gov/show/NCT00460551||172383|The trial was prematurely closed. The original protocol contained Part 1A, followed by Part 1B and Part 2. The trial was terminated when 13 patients were enrolled in Part 1A. Scans for efficacy were planned for Part 1B and Part 2.
NCT00460564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX108509|Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity|A Multicenter Study to Evaluate the Efficacy and Safety in Patients With Post-Stroke Upper Limb Spasticity Receiving a Double-Blind, Placebo-Controlled GSK1358820 Treatment Followed by an Open-Label GSK1358820 Treatment||GlaxoSmithKline|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|109|||Both|20 Years|80 Years|No|||March 2011|March 17, 2011|April 13, 2007||No||No|September 2, 2009|https://clinicaltrials.gov/show/NCT00460564||172382|The frequency threshold (5%) for reporting other adverse events is based on the result of the double-blind phase for the first four arms listed in the table and on the open-label phase for the last four arms listed in the table.
NCT00460590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB008|Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine MVA85A, in Healthy Volunteers With no Evidence of Infection With Mycobacterium Tuberculosis, in Cape Town||University of Oxford|Yes|Completed|October 2005|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|36|||Both|12 Years|50 Years|Accepts Healthy Volunteers|||June 2008|August 6, 2008|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460590||172380|
NCT00460941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20728|A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.|A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.||Hoffmann-La Roche||Completed|April 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|133|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|April 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00460941||172354|
NCT00460928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-07-045|Preventive IVIG Therapy for Congenital Heart Block|Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)|PITCH|New York University School of Medicine|No|Completed|April 2007|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|54|||Female|18 Years|50 Years|No|||March 2016|March 17, 2016|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460928||172355|
NCT00469781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5306|Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening|||Center For Excellence In Eye Care||Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|95|||Both|18 Years|N/A|No|||September 2008|September 23, 2008|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00469781||171688|
NCT00470028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04263|Transcranial Magnetic Stimulation: Treatment Trial for Depressed Adolescents|A Study of Transcranial Magnetic Stimulation (TMS) Treatment in Depressed Adolescents||The University of New South Wales|No|Terminated|April 2005|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|13 Years|18 Years|No|||November 2009|January 19, 2010|May 3, 2007|||Low recruitment.|No||https://clinicaltrials.gov/show/NCT00470028||171669|
NCT00469768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 018|A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium|A Double-blind, Randomized, Placebo-controlled Safety and Pharmacokinetic Study in Healthy HIV-negative Women to Assess the Delivery of Dapivirine From Matrix and Reservoir Intravaginal Rings Each Containing 25 mg of Dapivirine||International Partnership for Microbicides, Inc.|No|Completed|May 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|24|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469768||171689|
NCT00470301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00239|Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer|A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer||National Cancer Institute (NCI)|Yes|Completed|April 2007|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2014|May 6, 2015|May 3, 2007|Yes|Yes||No|May 6, 2015|https://clinicaltrials.gov/show/NCT00470301||171648|
NCT00470314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-LOLA/2005|Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure|Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure: A Double- Blind, Randomized, Placebo- Controlled Study||All India Institute of Medical Sciences, New Delhi|No|Active, not recruiting|January 2005|May 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|150|||Both|N/A|N/A|No|||April 2007|January 4, 2008|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00470314||171647|
NCT00470613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGT53-01|Safety Study of Infusion of SGT-53 to Treat Solid Tumors|A Phase I Open-Label Safety and Pharmacokinetic Study of Escalating Doses of SGT-53 for Infusion in Subjects With Advanced Solid Tumors||SynerGene Therapeutics, Inc.|Yes|Active, not recruiting|February 2008|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|May 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00470613||171625|
NCT00471523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2006|Treatment of Anovulatory Infertility in PCOS Patients|Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome||University Magna Graecia|No|Completed|May 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|41 Years|No|||May 2007|May 8, 2007|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471523||171557|
NCT00471484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543536|Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery|A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma||National Cancer Institute (NCI)||Recruiting|March 2007|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|54|||Both|16 Years|75 Years|No|||November 2008|June 21, 2011|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471484||171560|
NCT00471185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31511-W|ACY-6 Oral Administration of Acyline|Oral Administration of the GnRH Antagonist Acyline in Normal Men|ACY-6|University of Washington|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|May 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00471185||171582|
NCT00471510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOSH101-CLIN-AGA004|Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss|A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men||Neosil, Inc.|No|Active, not recruiting|May 2007|||February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|140|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||May 2008|May 16, 2008|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471510||171558|
NCT00471744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004468-22|HEAD-Study Optimizing the Treatment of Children With BECTS|HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes|HEAD|Ludwig-Maximilians - University of Munich|Yes|Terminated|June 2006|July 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|44|||Both|6 Years|12 Years|No|||January 2009|January 28, 2009|May 8, 2007|||low patient number after 2 years recruiting|No||https://clinicaltrials.gov/show/NCT00471744||171540|
NCT00467818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220060238|Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders|Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders||Rutgers, The State University of New Jersey|Yes|Recruiting|January 2007|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|17 Years|No|||November 2010|November 23, 2010|April 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467818||171838|
NCT00468117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-06|Efficacy of Islet After Kidney Transplantation|Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation (CIT-06)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|January 2007|July 2017|Anticipated|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|68 Years|No|||February 2016|February 21, 2016|May 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468117||171815|
NCT00468377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-21|Safety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNFα Therapies|An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFα Therapies||Hoffmann-La Roche|No|Active, not recruiting|March 2004|October 2014|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|341|||Both|18 Years|80 Years|No|||November 2011|November 23, 2011|April 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468377||171795|
NCT00468390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capsaicin in CRPS|Capsaicin-Evoked Pain in Patients With CRPS|Capsaicin-Evoked Pain in Patients With Complex Regional Pain Syndrome||Danish Pain Research Center|No|Completed|April 2007|January 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|October 2008|October 10, 2008|May 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00468390||171794|
NCT00468104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11415|Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas|Response to Instillation of Activase in the Pleural Cavity vs Placebo in the Management of Complicated Pleural Effusion/Empyema|CPE|Midwest Pulmonary and Critical Care|Yes|Completed|April 2004|August 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|April 29, 2007|Yes|Yes||No|December 18, 2011|https://clinicaltrials.gov/show/NCT00468104||171816|The sample size for secondary outcomes in the Placebo group is small
NCT00459992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070126|Effects of Betahistine Hydrochloride in Overweight Women|Pilot Study of the Metabolic Effects of Betahistine Hydrochloride in Overweight Women||National Institutes of Health Clinical Center (CC)||Completed|April 2007|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|150|||Female|18 Years|70 Years|No|||December 2014|December 12, 2014|April 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459992||172426|
NCT00460252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM4|Tight Glycemic Control by eMPC Algorithm in Medical ICU Patients.|An Open, Mono-Centre Randomised Controlled Trial to Investigate the Feasibility of Blood Glucose Control With the Software-Algorithm eMPC (Enhanced Model Predictive Control) Via the Arterial-Intravenous Route in Patients at the Medical Intensive Care Unit.||Medical University of Graz|No|Completed|May 2006|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|90 Years|No|||April 2007|April 12, 2007|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00460252||172406|
NCT00460265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050251|Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|SPECTRUM|Amgen|Yes|Completed|May 2007|May 2012|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|658|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|April 12, 2007|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00460265||172405|
NCT00460278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL418-001|Study of XL418 in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL418 Administered Orally Daily to Subjects With Solid Tumors||Exelixis|Yes|Suspended|April 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|63|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|April 11, 2007|||Enrollment suspended due to low drug exposure.|||https://clinicaltrials.gov/show/NCT00460278||172404|
NCT00460954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN158-001|A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects|An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects||Bristol-Myers Squibb||Completed|June 2007|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||August 2008|August 13, 2008|April 16, 2007||||||https://clinicaltrials.gov/show/NCT00460954||172353|
NCT00461240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004604|Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States|Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States||Barts & The London NHS Trust|No|Completed|June 2007|December 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|Samples With DNA|blood samples will be retained|Both|18 Years|75 Years|No|Non-Probability Sample|Patients with growth hormone excess (acromegaly) or growth hormone deficiency|July 2012|July 24, 2012|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461240||172331|
NCT00491894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sc-GLYCO-06-01|Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions|A Six-Month, Multi-Center, Open-Label Study to Assess the Safety and Efficacy of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions||Shionogi Inc.|No|Completed|March 2007|June 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|3 Years|18 Years|No|||April 2012|June 5, 2012|June 22, 2007|Yes|Yes||No|August 2, 2010|https://clinicaltrials.gov/show/NCT00491894||170021|There were no limitations of the trial
NCT00461253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2006_02|Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs|Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs||Center for Epidemiology and Health Research, Germany|Yes|Completed|October 2006|March 2014|Actual|March 2014|Actual|Phase 4|Observational|Observational Model: Case Control||2|Actual|25565|||Female|N/A|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases will be identified from population-based cancer registries, tumor centers and breast        centers. Matched controls will be accrued from the same region as the case came from.|December 2015|December 17, 2015|April 16, 2007||No||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00461253||172330|Limitations include information-bias, which cannot be entirely eliminated in retrospective studies. However, in this study recall is likely not to be differential between cases and controls.
NCT00469495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701008939|Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis|Empiric Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Trial in Subjects Co-Infected With Helminths and Leishmania Brasiliensis||Hospital Universitário Professor Edgard Santos|Yes|Completed|February 2007|November 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|90|||Both|13 Years|50 Years|No|||August 2009|August 25, 2009|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00469495||171709|
NCT00469794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/06|The Significance of Arrhythmias in Athletes|The Long Term Significance of Exercise Induced Ventricular Arrhythmias in Trained Athletes|Athlete|Assaf-Harofeh Medical Center|No|Recruiting|May 2006|May 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||Anticipated|300|||Both|10 Years|35 Years|No|||May 2007|May 4, 2007|May 4, 2007||||No||https://clinicaltrials.gov/show/NCT00469794||171687|
NCT00469807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-CV-0604-507-22|Ghrelin Levels in Early IVF Pregnancies|Maternal Serum Ghrelin Levels in Early IVF Pregnancies: Lack of Prognostic Value for Gestational Outcome and Altered Post-Prandial Responses||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|June 2004|May 2007|Actual|||N/A|Observational|Time Perspective: Longitudinal|||||||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2007|May 4, 2007|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469807||171686|
NCT00470262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-020-06S|Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation|Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation in Subjects With Impaired Glucose Tolerance||VA Office of Research and Development|No|Active, not recruiting|January 2007|December 2014|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470262||171651|
NCT00470639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07103|Transcranial Magnetic Stimulation for Bipolar Depression|A Comparison of Left vs. Right Prefrontal Cortex Transcranial Magnetic Stimulation as a Treatment for Bipolar Depression||The University of New South Wales|No|Suspended|April 2007|April 2010|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|80 Years|No|||September 2008|September 25, 2008|May 7, 2007|||Poor recruitment|No||https://clinicaltrials.gov/show/NCT00470639||171623|
NCT00470626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-507|Celect Vena Cava Filter Clinical Trial|Prospective Study of the Cook Celect Filter, Including Permanent and Retrievable Use||Cook|Yes|Completed|November 2005|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|September 14, 2005|Yes|Yes||No|February 3, 2010|https://clinicaltrials.gov/show/NCT00470626||171624|
NCT00471224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4321004|A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product|A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Formulated Drug Product (LOT 8716-098).||Pfizer|No|Completed|June 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|55 Years|90 Years|No|Non-Probability Sample|A subset of subjects enrolled in study A4321001 and who have received formulated drug        product.|February 2011|February 16, 2011|May 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00471224||171580|
NCT00471211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBT2-201|Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease|A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease||Prana Biotechnology Limited|Yes|Completed|December 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|80|||Both|56 Years|N/A|No|||January 2008|January 13, 2008|May 8, 2007||||No||https://clinicaltrials.gov/show/NCT00471211||171581|
NCT00471536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00203|Pazopanib in Treating Patients With Metastatic Urothelial Cancer|A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer||National Cancer Institute (NCI)||Completed|August 2008|December 2013|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2013|May 22, 2014|May 8, 2007|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00471536||171556|
NCT00471549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1991/2128|Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes|Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria||University of Aarhus|Yes|Completed|June 1991|December 1993|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|18|||Both|N/A|N/A|No|||May 2007|May 9, 2007|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00471549||171555|
NCT00467831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070132|Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome|Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome||National Institutes of Health Clinical Center (CC)|No|Terminated|April 2007|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||June 2013|June 3, 2013|April 28, 2007|No|Yes|insufficient enrollment|No|June 3, 2013|https://clinicaltrials.gov/show/NCT00467831||171837|The study was terminated because enrollment was too low. The results shown are not statistically significant.
NCT00468130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220055441|Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children|Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children|Abilify|Rutgers, The State University of New Jersey|No|Completed|May 2006|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|5 Years|17 Years|No|||September 2014|September 23, 2014|April 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468130||171814|
NCT00468403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-04|LEA29Y (Belatacept) Emory Edmonton Protocol|Islet Transplantation in Type I Diabetes With LEA29Y (Belatacept) Maintenance Therapy (CIT-04)|LEEP|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2008|April 2013|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||May 2014|May 30, 2014|May 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00468403||171793|
NCT00468728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101.1.C.004|PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)|A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)||Optimer Pharmaceuticals LLC|No|Completed|April 2007|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|535|||Both|16 Years|N/A|No|||August 2011|August 8, 2011|May 1, 2007|Yes|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00468728||171768|
NCT00460291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProVena|Pilot Study to Asses the Function and Patency of Polyester-Coated Composite Bypasses From Autologous Varicose Veins|Pilot Study to Asses the Function and Patency of Polyester-Coated Composite Bypasses From Autologous Varicose Veins|PROVENA|Johann Wolfgang Goethe University Hospitals|No|Recruiting|June 2005|December 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||October 2007|October 2, 2007|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00460291||172403|
NCT00460603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061020|Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer|A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion||Pfizer|No|Completed|January 2006|November 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|187|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|April 13, 2007|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00460603||172379|Time to Treatment Failure (TTF) was included as a secondary endpoint of the study after change in analysis plan.
NCT00491907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FolicAcid881|Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure|Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure||University of Zurich|No|Terminated|October 2004|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|18 Years|80 Years|No|||October 2007|October 1, 2007|June 25, 2007|||recruitment is finished|No||https://clinicaltrials.gov/show/NCT00491907||170020|
NCT00491920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003186-14|High Dosage Vitamin D and Osteoporosis|High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women||University Hospital of North Norway|No|Completed|February 2007|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|297|||Female|50 Years|80 Years|Accepts Healthy Volunteers|||November 2011|November 2, 2011|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491920||170019|
NCT00492232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-375-071|Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia|Randomized, Double Blind, Placebo-Controlled Study to Assess Whether the Administration of Ramelteon Could Facilitate the Discontinuation of Zolpidem (Ambien®) ≥10 mg Therapy in Subjects With Chronic Insomnia||Takeda|No|Completed|April 2007|May 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||July 2010|July 13, 2010|June 25, 2007|Yes|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00492232||169997|
NCT00469521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5304|Pilot Study Evaluation of 2 Artificial Tears. Evaluation of TBUT, Tear Meniscus Height and Tear Thickness|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||September 2007|September 5, 2007|May 2, 2007||||No||https://clinicaltrials.gov/show/NCT00469521||171707|
NCT00469833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-010-06S|Insulin Secretion in Diabetes Before and After Glycemic Control|Pathogenesis of the Impaired Incretin Effect in Type 2 Diabetes||VA Office of Research and Development|No|Completed|April 2008|September 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|May 4, 2007||No||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00469833||171684|Two subjects could not complete the initial assessment due to poor IV access. All 15 subjects who completed the initial assessment and were started on insulin completed the study. There were no significant adverse events.
NCT00469820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06118 CDR0000543531|Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant|Posttransplant Immunotherapy With Donor Lymphocyte Infusions and Autologous Tumor Vaccines After HLA-Matched Transplant||Sidney Kimmel Comprehensive Cancer Center||Terminated|April 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|70 Years|No|||March 2014|March 20, 2014|May 3, 2007|||low accrual|No||https://clinicaltrials.gov/show/NCT00469820||171685|
NCT00470041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/155|Bioavailability Study of a New Pediatric Formulation of Zidovudine/Lamivudine in Adult Volunteers|Bioavailability Study of a New Pediatric Formulation of Zidovudine/Lamivudine in Adult Volunteers||University Ghent|No|Completed|June 2007|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 15, 2010|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470041||171668|
NCT00470353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 78706|Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery|A Pilot Study of Low and High Dose Vitamin Cholecalciferol (D3) With Pharmacokinetic and Pharmacodynamic Correlates in Patients With Resected Colon Cancer||Roswell Park Cancer Institute||Terminated|September 2006|September 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Actual|8|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|May 3, 2007||No|Withdrawn due to poor accrual/lack of funding|No||https://clinicaltrials.gov/show/NCT00470353||171644|
NCT00470652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIU-1|Management of Acute Pain in the Emergency Department|Management of Acute Pain in the Emergency Department:Impact of a Computer-Assisted Support||Centre Hospitalier Universitaire Vaudois|No|Completed|May 2007|September 2008|Actual|||N/A|Observational|Time Perspective: Prospective||3|Actual|631|||Both|16 Years|N/A|No|Non-Probability Sample|Consecutive patients discharged from our ED who either had pain on admission or suffered        of a new pain while in our ED|January 2009|January 26, 2009|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470652||171622|
NCT00470925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mZINT_003|Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects|Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects|mZINT|Institute for Neurodegenerative Disorders|No|Terminated|May 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2010|December 28, 2010|May 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470925||171602|
NCT00470938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0202070062|A Randomized Controlled Trial of the Effects of Reactive Neuromuscular Training on Balance|||Logan College of Chiropractic||Completed|March 2007|March 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|20 Years|30 Years|Accepts Healthy Volunteers|||February 2008|February 19, 2008|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470938||171601|
NCT00471757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040291|Etiology of Community Acquired Pneumonia|Etiology of Community Acquired Pneumonia|CAP|University of Pittsburgh|Yes|Active, not recruiting|May 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|streptococcus pneumoniae positive|December 2015|December 16, 2015|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00471757||171539|
NCT00471562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543744|Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors|Phase I Clinical Trial of Angiotensin 1-7 for Advanced Solid Tumors||Comprehensive Cancer Center of Wake Forest University|No|Completed|March 2007|||October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2012|February 27, 2013|May 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00471562||171554|
NCT00472043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC T308/00|PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma|A Multicentre, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma.||Galderma|No|Completed|October 2000|September 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472043||171517|
NCT00472056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0271|Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies|Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas||M.D. Anderson Cancer Center|Yes|Completed|March 2005|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|N/A|80 Years|No|||June 2012|February 17, 2016|May 9, 2007||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00472056||171516|
NCT00469040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C108784|Safety, Blood Levels and Effects of GW642444|A Randomised, Double-blind, Placebo-controlled, Parallel-group, 14 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Extra-pulmonary Pharmacodynamics of Inhaled Doses of GW642444M Formulated With Magnesium Stearate in Healthy Subjects||GlaxoSmithKline||Completed|February 2007|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|May 3, 2007||||No||https://clinicaltrials.gov/show/NCT00469040||171744|
NCT00468416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-43-01-2|Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection|Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|February 2007|February 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|18 Years|N/A|No|||May 2007|May 3, 2007|May 1, 2007||||No||https://clinicaltrials.gov/show/NCT00468416||171792|
NCT00468754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000275|A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine|A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine||Hoffmann-La Roche||Completed|July 2003|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|60 Years||||June 2010|March 1, 2016|May 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00468754||171766|
NCT00460304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01|The Effect of Pramlintide on Meal Time Insulin Bolus|The Effect of Pramlintide on Meal Time Insulin Bolus||Diabetes Care Center|No|Completed|September 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||April 2009|April 2, 2009|April 11, 2007||||No||https://clinicaltrials.gov/show/NCT00460304||172402|
NCT00460616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-2|Cardiac Valve Complications in Prolactinomas Treated With Cabergoline|Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline|ValveCab|Federico II University|No|Completed|January 2007|September 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Three different study populations will be studied.          -  Group 1) Patients already receiving treatment with cabergoline for at least 12 months          -  Group 2) Newly diagnosed patients with hyperprolactinemia who never received             treatment with dopamine-agonists          -  Group 3) Non hyperprolactinemic subjects matched with the patients for sex and age to             be used as controls.|October 2007|April 14, 2008|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460616||172378|
NCT00492245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP0075/06|Phototherapeutic Keratectomy (PTK) With Mitomycin in Adenoviral Opacities|Phototherapeutic Keratectomy With Mitomycin C in Adenoviral Infiltrates||Federal University of São Paulo|No|Active, not recruiting|April 2006|December 2008|Anticipated|May 2008||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||July 2008|August 1, 2008|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00492245||169996|
NCT00462189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-8015-1001|Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patient With Relapsed or Refractory Hairy Cell Leukemia (HCL)||Cambridge Antibody Technology|No|Recruiting|April 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00462189||172261|
NCT00492505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551556|Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma|A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma||National Cancer Institute (NCI)||Recruiting|April 2007|||December 2011|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2009|January 9, 2014|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00492505||169977|
NCT00469846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212250-02071|L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia|Supplementation With L-Arginine and Antioxidant Vitamins During Pregnancy in a Medical Food to Reduce the Risk of Preeclampsia in a High Risk Population|L-Arg|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes|Yes|Terminated|January 2001|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|585|||Female|19 Years|32 Years|No|||April 2007|May 7, 2007|May 4, 2007|||Recruitment and follow-up has been completed.|No||https://clinicaltrials.gov/show/NCT00469846||171683|
NCT00470080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060501|Randomised Trial of Eutectic Mixture of Local Anaesthetics Cream and Oral Sucrose Solution for Venepuncture|Randomised Trial of Eutectic Mixture of Local Anaesthetics Cream and Oral Sucrose Solution for Venepuncture in Preterm Infants|VIEP|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|80|||Both|26 Weeks|37 Weeks|No|||May 2007|May 3, 2011|May 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00470080||171665|
NCT00470327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14163A|A Study of the Natural Progression of Interstitial Lung Disease (ILD)|A Study of the Natural Progression of Interstitial Lung Disease (ILD)||University of Chicago|No|Recruiting|September 2005|December 2025|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Subjects cared for in the ILD (Interstitial Lung Disease)clinic|September 2012|September 13, 2012|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00470327||171646|
NCT00470054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00467|Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of Dasatinib (NSC #732517) in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|April 2007|April 2013|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||June 2014|April 14, 2015|May 3, 2007|Yes|Yes||No|January 2, 2013|https://clinicaltrials.gov/show/NCT00470054||171667|
NCT00470067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543389|Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer|A Multi-center Phase II Study of Doxil®/Carboplatin in Patients With Advanced or Recurrent Endometrial Carcinoma||Roswell Park Cancer Institute|Yes|Terminated|February 2007|December 2009|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||August 2014|August 8, 2014|May 3, 2007|Yes|Yes|Due to low accrual|No|January 27, 2014|https://clinicaltrials.gov/show/NCT00470067||171666|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.
NCT00470964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-0011-001|Titanium-Sapphire Laser Trabeculoplasty in Glaucoma: A Randomized Study Comparing Titanium-Sapphire With Argon Laser Trabeculoplasty in Open-Angle Glaucoma Patients|||Goldschleger Eye Institute|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|40 Years|91 Years|No|||May 2007|May 7, 2007|May 6, 2007||||Yes||https://clinicaltrials.gov/show/NCT00470964||171599|
NCT00471276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181068|Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer|A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer||Pfizer|Yes|Completed|August 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Female|18 Years|N/A|No|||July 2011|July 21, 2011|May 7, 2007|No|Yes||No|June 23, 2011|https://clinicaltrials.gov/show/NCT00471276||171576|
NCT00471289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADI/200601|PTA and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia|Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia|PADI|Netherlands Society for Interventional Radiology|No|Active, not recruiting|August 2007|March 2023|Anticipated|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|May 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00471289||171575|
NCT00470951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-179|Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer|A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial|CTS-179|National Cancer Center, Korea|Yes|Active, not recruiting|April 2006|August 2014|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|80 Years|No|||August 2012|August 16, 2012|May 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00470951||171600|
NCT00471250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070142|Collection of Lung Fluid and Tissue Samples for Research|Research Respiratory Tract Procedures||National Institutes of Health Clinical Center (CC)||Recruiting|May 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|550|||Both|10 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 20, 2015|May 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00471250||171578|
NCT00460369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Malariallada|Treatment of Uncomplicated Malaria in Benin|Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study||Institut de Recherche pour le Developpement|Yes|Completed|April 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|240|||Both|6 Months|119 Months|No|||April 2008|April 11, 2008|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460369||172397|
NCT00460382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000670-23|Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses|Prospective Clinical Trial to Assess Safety and Efficacy of DRV/r(TMC 114/r), ETV(TMC 125) and MK-0518 in Addition to OBT in HIV-1 Infected Patients With Limited to No Treatment Options ANRS 139 TRIO|ANRS139 TRIO|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|May 2007|September 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||September 2010|September 16, 2010|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460382||172396|
NCT00460356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0221|Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes|Glycoprotein and Glycan Profiling in Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA &gt; 4 CM, IIB to IVA) Undergoing Pelvic and Para-aortic (Abdominal) Lymphadenectomy||Gynecologic Oncology Group||Active, not recruiting|April 2007|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|286|||Female|18 Years|N/A|No|Probability Sample|Patients with Stage IB-IVA cervical cancer undergoing surgery to remove pelvic and        abdominal lymph nodes|February 2016|February 19, 2016|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00460356||172398|
NCT00460668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL14089.075.06|The Effect of Post-thoracotomy Pulmonary Rehabilitation on Quality of Life|A Prospective Single Centre Open Randomized Trial on the Effect of Post-thoracotomy Pulmonary Rehabilitation on Quality of Life||Isala|Yes|Completed|April 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|57|||Both|18 Years|80 Years|No|||April 2013|April 5, 2013|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460668||172374|
NCT00460681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSH-LCI-FJ-0001|Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma|Phase III Study of Thymopentin in Patients After Curative Resection of Small||Fudan University|Yes|Recruiting|February 2007|February 2012|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|220|||Both|18 Years|75 Years|No|||October 2007|October 30, 2007|April 13, 2007||||No||https://clinicaltrials.gov/show/NCT00460681||172373|
NCT00461006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20653|A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.|A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.||Hoffmann-La Roche||Completed|June 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|April 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461006||172349|
NCT00492791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2006-2|Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy|Development and Validation of an Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy|CAPSCDEIS|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|March 2007|December 2011|Actual|December 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|||Both|18 Years|N/A|No|Probability Sample|Active or quiescent Crohn's Disease|August 2011|April 16, 2012|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492791||169955|
NCT00492804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/015/2B|Elective Neurectomy During Inguinal Hernia Repair|Effect of Elective Intraoperative Neurectomy on Chronic Pain After Lichtenstein Hernia Repair. A Prospective, Single-blind, Randomized, Controlled Clinical Trial||Cantonal Hospital of St. Gallen|No|Completed|July 2005|September 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|200|||Male|18 Years|N/A|No|||January 2013|January 25, 2013|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492804||169954|
NCT00491933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-RHEU-2007-001|Quantiferon-TB Gold in the Assessment of Latent TB in Patients Candidate to Treatment or Treated With TNFα Antagonists|Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in the Assessment of Latent Mycobacterium Tuberculosis Infection in Patients Candidate to Treatment or Treated With TNFα Antagonists|TNFTB|Ospedale L. Sacco – Polo Universitario|No|Recruiting|June 2007|October 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||June 2007|June 25, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491933||170018|
NCT00493324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0485-CL-0003|Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis|An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept||Astellas Pharma Inc|No|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|43|||Both|18 Years|N/A|No|||January 2012|February 1, 2012|June 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493324||169915|
NCT00493337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL18496.041.07|A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment|A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment||Utrecht Institute for Pharmaceutical Sciences|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|373|||Both|65 Years|90 Years|No|||June 2007|June 24, 2010|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493337||169914|
NCT00493909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL-2007-06|Prospective, Randomised, Single-Blinded, Monocentric Clinical Study to Compare Postoperative Analgesia and Outcome After Combined Paravertebral and Intrathecal Versus Thoracic Epidural Analgesia for Thoracotomy|Prospective, Randomised, Single-Blinded, Monocentric Clinical Study to Compare Postoperative Analgesia and Outcome After Combined Paravertebral and Intrathecal Versus Thoracic Epidural Analgesia for Thoracotomy||University Hospital Freiburg|Yes|Completed|June 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||February 2009|February 12, 2009|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00493909||169870|
NCT00462735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-1155|Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer|Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer||Icahn School of Medicine at Mount Sinai|Yes|Completed|February 2007|||October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2008|October 12, 2010|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462735||172221|
NCT00462748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-121|A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)|A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C <2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/l||Merck Sharp & Dohme Corp.||Completed|March 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|786|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|April 18, 2007|Yes|Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00462748||172220|
NCT00462995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB#: 06-0052-C|Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)|Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial|SELECT|University Health Network, Toronto|Yes|Completed|May 2006|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|95 Years|No|||May 2015|May 26, 2015|April 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00462995||172203|
NCT00463294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI-065|Coronary Artery Bypass Surgery (CABG) Off or On Pump Revascularization Study|CABG Off or On Pump Revascularization Study (CORONARY)|CORONARY|Population Health Research Institute|Yes|Active, not recruiting|October 2007|April 2016|Anticipated|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4752|||Both|21 Years|N/A|No|||March 2016|March 15, 2016|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463294||172180|
NCT00458991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10734|rhGH Therapy on Hepatic Drug Metabolism|Recombinant Human Growth Hormone Therapy and Drug Metabolism||University of Louisville|No|Completed|June 2001|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|4 Years|14 Years|No|Non-Probability Sample|Children recently diagnosed with idiopathic GH deficiency who were candidates for rhGH        therapy were eligible for enrollment. All subjects were recruited via informed parental        consent and patient assent (for children > 7 years). The anticipated sample size was 12        children.|April 2007|August 4, 2011|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458991||172499|
NCT00459277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPO43/06/FCNS|Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids|A Multicenter, Placebo-Controlled, Double-Blind, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy||Archimedes Development Ltd|No|Completed|December 2006|August 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|73|||Both|18 Years|N/A|No|||January 2010|January 20, 2012|April 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00459277||172480|
NCT00459524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0060|Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)|Longitudinal Assessment of Neurocognitive Function and Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Treatment||M.D. Anderson Cancer Center|No|Completed|April 2004|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with acute myelogenous leukemia or myelodysplastic syndrome.|July 2012|July 31, 2012|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459524||172462|
NCT00459511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMUSP/ cappesq 675/05|The Importance of Adrenomedullin (AM) on ACTH-Cortisol-Glucose Axis|The Importance of Adrenomedullin (AM) on Pituitary-Adrenal Axis and Glucose Kinetics in Pediatric Patients With Systemic Inflammatory Response Syndrome|AM|University of Sao Paulo|Yes|Completed|January 2006|October 2006|Actual|||Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||20|||Both|2 Years|16 Years|No|||April 2007|April 11, 2007|April 11, 2007||||No||https://clinicaltrials.gov/show/NCT00459511||172463|
NCT00459745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sc-PRAVA-06-02|A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia|A Multi-Center, Prospective, Longitudinal, Randomized, Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of Daily Administration of Pravastatin 40 mg or Fenofibrate 160 mg or Pravafen (the Combination of Pravastatin and Fenofibrate 40/160 mg) for 12 Weeks Followed by a 52-Week Open-Label Safety Phase of the Pravafen Alone in the Treatment of Combined Hyperlipidemia.||Shionogi Inc.||Completed|April 2007|July 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|481|||Both|18 Years|75 Years|No|||July 2009|July 2, 2009|April 9, 2007||||||https://clinicaltrials.gov/show/NCT00459745||172445|
NCT00461344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976D_2504|Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer|A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed ≥ 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®- Based Chemotherapy||Sanofi|No|Terminated|July 2004|August 2007|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Female|18 Years|70 Years|No|||April 2008|April 1, 2008|April 17, 2007|||due to slow recruitment of patients|No||https://clinicaltrials.gov/show/NCT00461344||172323|
NCT00461682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRA107438|Sb-705498 Rectal Pain Study|A Double-blind, Randomised, Placebo Controlled, Single Dose, Two-period Crossover Study to Investigate the Therapeutic Potential of the TRPV1 Antagonist SB-705498 in Treatment of Subjects With Rectal Hypersensitivity Including Irritable Bowel Syndrome.||GlaxoSmithKline|No|Terminated|January 2007|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|65 Years|No|||February 2011|May 31, 2012|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461682||172298|
NCT00460083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGXP - 060674/ IRB00002569|Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis|A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis||Ceragenix Pharmaceuticals|No|Completed|April 2007|February 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|2 Years|12 Years|No|||February 2008|February 5, 2008|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00460083||172419|
NCT00460096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamada API-002|Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency|Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency|Kamada API|Kamada, Ltd.|Yes|Completed|March 2007|September 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||October 2007|October 16, 2007|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00460096||172418|
NCT00461019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-MS-01|CardioFit™ for the Treatment of Heart Failure|CardioFiT™ for Heart Failure - Safety and Efficacy Study Protocol||BioControl Medical|No|Completed|February 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|No|||March 2011|March 4, 2011|April 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00461019||172348|
NCT00461318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLRT-2001-00683|The Effectiveness of Supported Employment for People With Severe Mental Illness: an RCT in Six European Countries|Enhancing the Quality of Life and Independence of Persons Disabled by Severe Mental Illness Through Supported Employment|EQOLISE|University of Oxford|No|Completed|April 2003|November 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|55 Years|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461318||172325|
NCT00492271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNB-001|First Time in Man Trial for Friulimicin B|A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single (Part A) and Multiple (Part B) Intravenous Doses of Friulimicin B in Healthy Subjects||MerLion Pharmaceuticals GmbH|No|Terminated|June 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 22, 2008|June 25, 2007|||Unfavourable Pharmakokinetics|No||https://clinicaltrials.gov/show/NCT00492271||169994|
NCT00492297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11538|A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma|A Phase II, Multi-center, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of BAY 43-9006 Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma.||Bayer|No|Completed|April 2005|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|June 26, 2007||No||No|October 28, 2009|https://clinicaltrials.gov/show/NCT00492297||169992|Due to the small number of patients, no conclusions can be drawn from these data in terms of BRAF mutations.
NCT00492583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-273|Study to Investigate the Potential of Probiotics in Yogurt|Study to Investigate the Potential of Probiotics in Yogurt|SIPPY|Georgetown University|Yes|Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|182|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||June 2011|July 21, 2011|June 25, 2007||No||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00492583||169971|
NCT00493077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFE|Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy|A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy|SAFE|Biogen|Yes|Completed|May 2004|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|55 Years|No|||January 2008|January 28, 2008|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493077||169933|
NCT00493610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0031|Mucomyst for Hepatitis C|Use of Mucomyst (NAC) to Ameliorate Oxidant Stress as Measured by Surrogate Serum in Patients With Hepatitis C||VA Office of Research and Development|No|Suspended|November 2006|June 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|80 Years|No|||June 2008|January 7, 2010|June 26, 2007||No|Collaborator no longer interested, short of funds|No||https://clinicaltrials.gov/show/NCT00493610||169893|
NCT00493623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19360|BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.|A Randomized, Double-blind Study of the Efficacy of Intravenous Bonviva in the Relief of Pain After Recent Vertebral Osteoporotic Fracture in Osteoporotic Patients.||Hoffmann-La Roche||Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|30 Years|N/A|No|||March 2016|March 1, 2016|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493623||169892|
NCT00493636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN AC01B07|1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy|A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy||Accelerated Community Oncology Research Network|Yes|Completed|June 2007|November 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|June 26, 2007|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT00493636||169891|
NCT00493363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Dondorp|Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia|Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia||University of Oxford|Yes|Completed|June 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|N/A|No|||January 2010|January 21, 2010|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493363||169912|
NCT00493688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0303|A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes|A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2005|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Individuals scheduled for elective major intrabdominal surgery or pelvic surgeries        surgeries (e.g. gastrectomy, esophagectomy, pancreatectomy, radical cystectomy, radical        transabdominal debulking with or without intrabdominal hyperthermic perfusion, pelvic        exenteration, retroperitoneal lymph node dissections, and low anterior resection).|July 2015|July 2, 2015|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493688||169887|
NCT00459290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0170K|Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase II Evaluation of Mifepristone in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma||Gynecologic Oncology Group|Yes|Completed|May 2007|||July 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||June 2014|June 16, 2014|April 9, 2007|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00459290||172479|
NCT00459303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05012006|Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof|Intraidivisual Comparison of Functional Vision Provided by AMO Tecnis Z9000 and ALcon SA60AT Acrysof Posterior Chamber Intraocular Lenses||National Taiwan University Hospital|Yes|Completed|October 2005|December 2007|Actual|September 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 29, 2013|April 10, 2007||No||No|October 5, 2009|https://clinicaltrials.gov/show/NCT00459303||172478|small sample size
NCT00459563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|648-2006|Vitamin D and Blood Pressure|A Randomized Placebo-controlled Double Blinded Trial to Evaluate Cholecalciferol (Vitamin D3) and Calcitriol Treatment on Reducing Blood Pressure in Middle Aged Adults With Stage I Hypertension and Vitamin D Deficiency||Atlanta VA Medical Center|No|Withdrawn|March 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|April 10, 2007||No|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT00459563||172459|
NCT00459836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-1003|PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors|A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors||Proacta, Incorporated||Completed|February 2007|||October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||February 2011|February 28, 2011|April 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459836||172438|
NCT00458744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0613|Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment|A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias||Children's Oncology Group|No|Withdrawn|February 2007|||July 2008|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|1 Year|21 Years|No|||August 2014|August 7, 2014|April 9, 2007|No|Yes|Study withdrawn because of toxicity reported on the adult phase 1 trial.|||https://clinicaltrials.gov/show/NCT00458744||172516|
NCT00459004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI5747|Japanese Dose-Response Study of Rimonabant in Obese Patients|A Dose-Response Relationship Study of SR141716 in Obese Patients||Sanofi||Completed|October 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|527|||Both|20 Years|70 Years|No|||April 2009|April 6, 2009|April 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459004||172498|
NCT00459017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA -02-2773-YM-CTIL|The Effect of Frequent Self Measurements of Blood Pressure on the Control of Hypertension|The Effect of Frequent Self Measurements of Blood Pressure on the Control of Hypertension||Sheba Medical Center|No|Completed|December 2002|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||April 2007|April 10, 2007|April 10, 2007||||No||https://clinicaltrials.gov/show/NCT00459017||172497|
NCT00459537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSFO327N2303|Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis|A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis||Novartis||Completed|March 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1029|||Both|12 Years|75 Years|No|||May 2011|May 3, 2011|April 10, 2007||No||No|January 19, 2011|https://clinicaltrials.gov/show/NCT00459537||172461|
NCT00459550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106006|A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease|A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients With Alzheimer's Disease.||GlaxoSmithKline|Yes|Completed|March 2007|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|55 Years|80 Years|No|||December 2011|December 15, 2011|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459550||172460|
NCT00460733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISED_L_01930|SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.|Local (Brazil) Study, Multicenter, Opened, Comparative, Randomized, With Parallel Groups, Phase IV, in Post Menopausal Woman With Colles' Fracture of the Risedronate Sodium Usage in the Consolidation and in the Callus of the Colles'Fracture.|SOLID|Sanofi||Completed|March 2007|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Female|N/A|N/A|No|||October 2011|October 3, 2011|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460733||172369|
NCT00459784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASYcareGIDS study|Implementation Study of Dementia Guidelines in Primary Care|How to Reach Evidence Based Practice in Diagnostic Assessment and Management of Dementia by General Practitioners and Primary Care Nurses? The Effectiveness of an EASYcare Based Educational Program.||Radboud University|No|Recruiting|November 2006|March 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Educational/Counseling/Training||||200|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2007|April 12, 2007|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00459784||172442|
NCT00459797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-040|Comparison of Conventional GlideScope to Single-Use GlideScope Cobalt for Orotracheal Intubation|Comparison of Conventional GlideScope to Single-Use GlideScope Cobalt for Orotracheal Intubation||Lawson Health Research Institute|No|Completed|April 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 20, 2009|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00459797||172441|
NCT00461058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20265|A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.|A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos in Patients With Type 2 Diabetes and NYHA Class II Heart Failure.||Hoffmann-La Roche||Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461058||172345|
NCT00461357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTX-OFO-01|Sirolimus Based Immunosuppression for Patients Undergoing Kidney Transplantation in the Eurotransplant Senior Program|Outcome After Renal Transplantation of a Randomized Prospective Trial in the Eurotransplant Senior Program|ESP|Medical University of Vienna|No|Active, not recruiting|January 2003|December 2007|Anticipated|||Phase 4|Observational|Allocation: Random Sample, Time Perspective: Longitudinal||||48|||Both|65 Years|N/A|No|||April 2007|April 17, 2007|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461357||172322|
NCT00460694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIK#2/2007|Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies|A Phase II Trial on Allogeneic Cytokine-induced Killer Cell Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies|alloCIK|Singapore General Hospital|Yes|Completed|August 2006|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|12 Years|60 Years|No|||May 2015|May 18, 2015|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460694||172372|
NCT00460707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV109990|A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults|A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant [GW679769] in Healthy Subjects||GlaxoSmithKline|No|Completed|April 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|April 12, 2007||||||https://clinicaltrials.gov/show/NCT00460707||172371|
NCT00462241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 73 - RCT (NMA)|Treatment Study Comparing Manual Treatment or Advice in Acute, Musculoskeletal Chest Pain|Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 2: Treatment Study|CARPA|Clinical Locomotion Science|Yes|Completed|August 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00462241||172257|
NCT00462475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-3|Effect of 5 Years of GH Replacement on Atherosclerosis|Phase 4 Study of Recombinant GH on Intima-Media Thickness at Common Carotids and on Cardiovascular Risk Factors in Hypopituitary Patients|5yrGH|Federico II University|No|Completed|January 1996|December 2006|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Three groups are studied: 1) Males with severe GHD undergoing GH replacement; 2) Males        with severe GHD who did not undergo GH replacement because of either refusal or presence        of risk factors for this treatment; 2) control men, age-matched with the patients.|October 2007|October 15, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462475||172240|
NCT00492570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-009-06-AVX|GER-009-06-AVX Early Therapy in Multiple Sclerosis|GER-009-06-AVX Early Therapy in Multiple Sclerosis|FIT|Biogen|No|Completed|April 2006|December 2008|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|230|||Both|N/A|N/A|No|Non-Probability Sample|multi-center using 150-200 neurologists and their patient populations.|June 2009|June 15, 2009|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00492570||169972|
NCT00492596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOL2004-001|The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence|An Evaluation of the AttenueX IntraVesical System in the Management of Female Subjects With Stress Urinary Incontinence||Solace Therapeutics, Inc.|No|Completed|June 2006|June 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|166|||Female|18 Years|N/A|No|||August 2014|August 7, 2014|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492596||169970|
NCT00493090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/015|Evaluating the Impact of GP and Practice Nurse Training in Self Regulations Skills on Patient Outcomes|Effects of Patient-centred Asthma Education for GPs and Practice Nurses:Evaluating the Impact of Training in Self Regulation Skills on Patient Outcomes:a Randomised Controlled Trial||University of Aberdeen|Yes|Completed|October 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|360|||Both|18 Years|55 Years|No|||November 2015|January 20, 2016|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493090||169932|
NCT00493103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN989/03|TG Gene Mutations and Congenital Hypothyroidism|Congenital Hypothyroidism Due to Thyroglobulin Mutations in an Inbred Brazilian Family: A Novel Compound Heterozygous Constellation and Intronic Mutation Related to Fetal Goiter.||University of Sao Paulo|No|Completed|July 2003|June 2007|Actual|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2007|June 25, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00493103||169931|
NCT00493974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|476|Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)|Antileukotriene Therapy for COPD Exacerbations|LEUKO|University of Minnesota - Clinical and Translational Science Institute|Yes|Terminated|March 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|45 Years|N/A|No|||April 2013|April 12, 2013|June 28, 2007||No|Lack of feasibility due to low recruitment|No|December 18, 2009|https://clinicaltrials.gov/show/NCT00493974||169865|Early termination leading to small numbers of subjects recruited
NCT00459316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1065|Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth|Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in HIV-Infected Children and Youth And Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2007|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|384|||Both|2 Years|24 Years|No|||January 2016|January 12, 2016|April 10, 2007|Yes|Yes||No|March 3, 2014|https://clinicaltrials.gov/show/NCT00459316||172477|
NCT00459576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0211-15|Risk of Asthma in Infants With Atopic Dermatitis|Risk of Asthma in Infants With Atopic Dermatitis||Indiana University|Yes|Completed|May 2005|December 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|We have retained nasal cell samples, whole blood cells, and serum.|Both|2 Months|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Our population was recruited through primary physician, pediatric practices, and        dermatology groups through out Indianapolis Indiana and the surrounding counties. We also        ran ads in local newspapers.|April 2013|April 16, 2013|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459576||172458|
NCT00459849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO# 07-0092|Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma|Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma||Barnes Retina Institute|No|Active, not recruiting|July 2000|July 2007|Anticipated|July 2007|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|175|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459849||172437|
NCT00460122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070125|Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients|Pilot Study of the Incidence of HLA Class I and Class II Antibodies in Platelet Donors and Their Effects on the Transfusion Recipient||National Institutes of Health Clinical Center (CC)||Completed|April 2007|August 2012||||N/A|Observational|N/A|||Actual|135|||Both|18 Years|N/A|No|||August 2012|January 14, 2014|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460122||172416|
NCT00460109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0682|Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma|A Phase II Clinical Trial of Denileukin Diftitox in Combination With Rituximab in Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2008|March 2011|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2015|July 4, 2015|April 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00460109||172417|
NCT00461032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-340|Montelukast Back to School Asthma Study (0476-340)|A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School Year in Pediatric Patients With Chronic Asthma||Merck Sharp & Dohme Corp.|No|Completed|June 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1162|||Both|6 Years|14 Years|No|||June 2015|June 23, 2015|April 13, 2007|Yes|Yes||No|January 12, 2010|https://clinicaltrials.gov/show/NCT00461032||172347|
NCT00459810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540438|Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer|A Phase II Study of Paclitaxel Poliglumex (PPX) in Combination With Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer After Docetaxel Chemotherapy||OHSU Knight Cancer Institute|Yes|Terminated|February 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||March 2012|March 28, 2012|April 11, 2007|Yes|Yes||No|May 25, 2010|https://clinicaltrials.gov/show/NCT00459810||172440|
NCT00459823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7107-E044-102|A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours|A Phase I Open-Label, Single-Arm, Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours||Eisai Inc.||Suspended|May 2007|||June 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2009|March 23, 2009|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459823||172439|
NCT00461994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc003189CTil|The Role of Exercise and Diet in Weight Loss in Obese Children|The Role of Exercise and/or Diet in Weight Loss, and Weight Maintenance in Obese Preadolescent Children||Rabin Medical Center|No|Completed|April 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||April 2007|April 17, 2007|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461994||172274|
NCT00461955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2000/04|Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation|Pilot Clinical Trial of Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation in Adult Patients With Multiple Myeloma in First Response|Expansion|University Hospital, Bordeaux|No|Completed|August 2007|August 2009|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|65 Years|No|||November 2010|November 3, 2010|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461955||172277|
NCT00461695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYTEL-Protocol V1.A1|Influence of Persistent CMV-infection on Immune Senescence|Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study)||University of Zurich|No|Completed|May 2007|December 2010|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|183|||Both|70 Years|N/A|No|||August 2013|August 26, 2013|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461695||172297|
NCT00461968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072004-28|Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both|Genetic Determinanats of Cardiovascular Risk Factors: Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both||University of Texas Southwestern Medical Center|Yes|Completed|February 2005|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||240|||Male|20 Years|70 Years|Accepts Healthy Volunteers|||April 2007|April 17, 2007|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461968||172276|
NCT00461981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP128|A Phase 2 Study to Evaluate Immune Responses of FluMist®|A Phase 2, Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of FluMist® Compared With Trivalent Inactivated Vaccine (TIV) in Children 12 to <36 Months of Age||MedImmune LLC|Yes|Completed|May 2007|February 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|12 Months|35 Months|Accepts Healthy Volunteers|||January 2010|January 12, 2010|April 16, 2007|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00461981||172275|
NCT00463060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-0906|Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer|Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2007|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|65|||Both|18 Years|N/A|No|||June 2008|June 17, 2008|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463060||172198|
NCT00492310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003669-01|Yoga for Women Attempting Smoking Cessation|Yoga for Women Attempting Smoking Cessation: an Initial Investigation||The Miriam Hospital|No|Active, not recruiting|August 2007|March 2011|Anticipated|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 19, 2010|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00492310||169991|
NCT00492843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLC0701|Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis|A Randomized Study to Evaluate the Safety and Efficacy of Loading Dose of Bondronat Versus Standard Dose of Bondronat in Patients With Lung Cancer and Skeletal Metastasis Experiencing Moderate to Severe Pain||Chinese Society of Lung Cancer|Yes|Terminated|July 2007|July 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 14, 2016|June 25, 2007||No|It is too difficult to recruit suitable patients.|No||https://clinicaltrials.gov/show/NCT00492843||169951|
NCT00492817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0445|Evaluation of Single Session Stereotactic Body Radiotherapy|Phase I/II Evaluation of Single Session Stereotactic Body Radiotherapy for Spinal or Paraspinal Metastases||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2005|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||January 2016|January 19, 2016|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492817||169953|
NCT00493116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-8001|Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta|A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability|RENeu|Biogen|No|Completed|October 2003|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|No|||July 2011|September 12, 2013|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493116||169930|
NCT00459329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-4237-C 01|PEARL Intervention to Reduce Depression Among Adults With Epilepsy|PEARL Intervention to Reduce Depression Among Adults With Epilepsy|PEARL|University of Washington|No|Active, not recruiting|March 2007|March 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00459329||172476|
NCT00459589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2006/11|Nutritional Intervention in Geriatric Oncology|Nutritional Intervention in Geriatric Oncology in Patients at Risk of Undernutrition|INOGAD|University Hospital, Bordeaux|Yes|Completed|April 2007|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|341|||Both|70 Years|N/A|No|||June 2012|June 19, 2012|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459589||172457|
NCT00459862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00656|Pazopanib in Treating Patients With Malignant Pleural Mesothelioma|Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Completed|March 2007|May 2013|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||October 2013|January 28, 2015|April 11, 2007|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00459862||172436|
NCT00459875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-019|Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer|Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|March 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|120 Years|No|||October 2015|October 26, 2015|April 11, 2007|Yes|Yes||No|September 24, 2015|https://clinicaltrials.gov/show/NCT00459875||172435|
NCT00460148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROP109087|Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole|An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets.||GlaxoSmithKline|No|Completed|April 2007|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|30 Years|85 Years|No|||February 2011|May 31, 2012|April 11, 2007||||No||https://clinicaltrials.gov/show/NCT00460148||172414|
NCT00460759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0050|Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine|Pharmacokinetic Issues in the Use of Moxifloxacin Plus Rifapentine||Johns Hopkins University||Active, not recruiting|June 2007|December 2007||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|July 17, 2009|April 12, 2007||||||https://clinicaltrials.gov/show/NCT00460759||172367|
NCT00460785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|544506|Bioequivalence Trial of a New Opioid Combination Compared to Reference|Phase 1 Single Center Trial to Demonstrate the Bioequivalence of a New Combination Analgesic Formulation as Compared to an Equimolar Marketed Formulation||Grünenthal GmbH||Completed|February 2007|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2007|July 5, 2007|March 28, 2007||||No||https://clinicaltrials.gov/show/NCT00460785||172366|
NCT00460720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013384|Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)|Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)||Johnson & Johnson Taiwan Ltd||Completed||February 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|591|||Both|6 Years|16 Years|No|Probability Sample|Patients aged 6-16 years old with clinical diagnosis of DSM-IV ADHD|April 2010|April 26, 2010|April 13, 2007||||No||https://clinicaltrials.gov/show/NCT00460720||172370|
NCT00461045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI-0052-101|Phase 1/2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Phase 1/2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma||Triphase Research and Development I Corporation|No|Active, not recruiting|March 2007|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|December 20, 2014|April 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00461045||172346|
NCT00461331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-0215|Comparison of Insulins Aspart and Lispro in Insulin Pumps|A Comparison of the Efficacy Beyond 48 Hours of Insulin Aspart (Novolog) and Lispro (Humalog) in Insulin Pumps||Tulane University Health Sciences Center|Yes|Completed|October 2004|August 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||September 2010|April 19, 2011|April 16, 2007|No|Yes||No|May 12, 2009|https://clinicaltrials.gov/show/NCT00461331||172324|
NCT00462280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00896|Lovastatin in Treating Patients At High Risk of Melanoma|A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology||National Cancer Institute (NCI)|Yes|Completed|May 2007|February 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|N/A|No|||February 2014|October 24, 2014|April 18, 2007|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT00462280||172254|
NCT00462540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-081|A Crossover Study in the Treatment of Patients With COPD|||Dey||Completed|May 2007|October 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|40 Years|N/A|No|||March 2009|March 3, 2009|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00462540||172236|
NCT00461370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN001|Safety Study of SRX251 Capsules in Healthy Female Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX251 Capsules in Healthy Female Volunteers|AVN001|Azevan Pharmaceuticals|Yes|Completed|April 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|77|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2007|March 11, 2008|April 16, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00461370||172321|
NCT00462501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-021|Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer|A Pilot Study of Neoadjuvant Chemotherapy With Selective Use of Radiation for Locally Advanced Rectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2007|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 18, 2007|No|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00462501||172238|
NCT00462826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00597|VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)||Completed|November 2007|||January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|April 18, 2007|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00462826||172215|
NCT00463073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBI-GBM-01|Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas|A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide||Rigshospitalet, Denmark|No|Completed|August 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|32|||Both|18 Years|N/A|No|||December 2008|December 10, 2008|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463073||172197|
NCT00458822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006|Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis|Risk-Adapted Intravenous Melphalan With Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients With Systemic Light-Chain (AL) Amyloidosis||Memorial Sloan Kettering Cancer Center||Completed|February 2007|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|70 Years|No|||March 2015|March 11, 2015|April 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458822||172510|
NCT00492609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 05 47|Medical and Economical Evaluation of Computer-assisted Reconstruction of the Anterior Cruciate Ligament (ACL)|Medical and Economical Evaluation of Computer-assisted Reconstruction of the ACL||University Hospital, Grenoble|Yes|Completed|May 2006|April 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|285|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with first knee surgery, available to control's visits at 6 months and one year|November 2009|November 10, 2009|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492609||169969|
NCT00492830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093ST101|Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase 1, Open-label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors||Tracon Pharmaceuticals Inc.|No|Completed|June 2007|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2010|February 3, 2010|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492830||169952|
NCT00493129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0142|Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)|ONTAK (Denileukin Diftitox) in Patients With Systemic Mastocytosis||M.D. Anderson Cancer Center|No|Completed|July 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||February 2012|February 7, 2012|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00493129||169929|
NCT00493376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPZ Targeting Cervix Study|Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer|Prospective Study of Tirapazamine Targeting in Cervical Cancer||British Columbia Cancer Agency|No|Terminated|August 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Female|18 Years|N/A|No|Non-Probability Sample|primary care clinic|February 2012|February 1, 2012|June 26, 2007||No|This study was a companion study to another one. The other study closed early so this one did    as well.|No||https://clinicaltrials.gov/show/NCT00493376||169911|
NCT00458796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000538879|Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone|Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule||National Cancer Institute (NCI)||Recruiting|March 2006|||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|1500|||Both|18 Years|N/A|No|||November 2007|August 23, 2013|April 9, 2007||||No||https://clinicaltrials.gov/show/NCT00458796||172512|
NCT00459056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHC 2007-01|The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients|The Vascular Effects of Carvedilol Controlle Release (CR) + Lisinopril Versus Lisinopril + Hydrochlorothiazide (HCTZ) in Abdominally Obese Hypertensive Patients||St. Paul Heart Clinic|No|Completed|April 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|April 10, 2007|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00459056||172494|crossover study design
NCT00460460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2782C00002|Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies|A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN||AstraZeneca||Terminated|March 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|April 12, 2007||Yes|Study was terminated due to low enrollment|No||https://clinicaltrials.gov/show/NCT00460460||172390|
NCT00460473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-06-09|A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery|A Phase III,Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel, Multicenter Study Evaluating the Efficacy and Safety of Dexmedetomidine in the Prevention of Postoperative Delirium in Subjects Undergoing Surgery for Fractured Hip With General Anesthesia||Hospira, Inc.|No|Terminated|April 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|April 13, 2007|Yes|Yes|The incidence of post-operative delirium observed from interim blinded data was significantly    lower than the current literature in this population.|No||https://clinicaltrials.gov/show/NCT00460473||172389|
NCT00459888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-001|Cryoplasty CLIMB-registry|CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5).|CLIMB|Flanders Medical Research Program|No|Completed|May 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||July 2010|July 2, 2010|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00459888||172434|
NCT00460135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-06-004|The Impact of Resistance Exercise Training On Metabolic Dysregulation in Obese Children.|The Impact of Resistance Exercise Training On Metabolic Dysregulation in Obese Children.||McGill University Health Center|No|Completed|April 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||March 2009|March 3, 2009|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00460135||172415|
NCT00461084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-038|Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma|Biaxin(Clarithromycin)Based Antibiotic Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma||Memorial Sloan Kettering Cancer Center|Yes|Completed|April 2007|September 2014|Actual|September 2014|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|36|Samples Without DNA|tissue and whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Previously Untreated follicular lymphoma or non-follicular lymphoma will be recrited at        MSKCC|September 2014|September 17, 2014|April 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461084||172343|
NCT00461071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP11957ONB|Randomised Controlled Study on the Use of Psychoeducation for Bulimia Nervosa in Young Women|RCT on the Use of Psychoeducation for Bulimia Nervosa in Young Women||Medical University of Vienna|Yes|Active, not recruiting|April 2007|April 2010|Anticipated|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Female|16 Years|30 Years|No|||September 2009|September 17, 2009|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461071||172344|
NCT00460395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS97-199|Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial|Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial||M.D. Anderson Cancer Center|Yes|Completed|January 1998|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|64|||Both|16 Years|N/A|No|||February 2012|February 22, 2012|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00460395||172395|
NCT00460408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751019|Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration|European Epidemiologic COHORT Study: A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration (AMD) In Europe||Pfizer|No|Completed|August 2006|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|501|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with age-related macular degeneration|November 2012|November 14, 2012|April 13, 2007||No||No|September 24, 2012|https://clinicaltrials.gov/show/NCT00460408||172394|
NCT00460421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010133|A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT|A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects With Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplant (HSCT)||Swedish Orphan Biovitrum|Yes|Completed|August 2006|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|27|||Both|1 Year|16 Years|No|||November 2014|November 4, 2014|April 12, 2007|Yes|Yes||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00460421||172393|The original protocol included a long term follow-up (LTFU) phase up to 10 years. This was reduced in a protocol amendment to up to the time when the last enrolled subject had completed the day +100 follow-up.
NCT00460746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011866|Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.|Open Label Phase 3b, 48 wk Pilot Study of the Antiviral Efficacy and Tolerability of Combination of PREZISTA/r and TMC125 When Substituted for Enfuvirtide, Current Protease Inhibitor(s) and NNRTI(s) in Antiretroviral Resistant Patients With Viral Suppression But Who Are Intolerant of Enfuvirtide.||Tibotec, Inc|No|Completed|May 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|April 13, 2007|Yes|Yes||No|October 2, 2009|https://clinicaltrials.gov/show/NCT00460746||172368|Conclusions on efficacy and safety are limited as the target enrollment of 40 subjects was not reached due to a shortage of eligible subjects.
NCT00462553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00212|Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors|A Phase I Study of Sunitinib Malate and Standard Infusion Gemcitabine in Solid Tumors||National Cancer Institute (NCI)||Completed|March 2007|||June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||April 2013|February 21, 2014|April 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00462553||172235|
NCT00462267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-9295|Examining the Feasibility of Collaborative Care Treatment for Overweight Adolescents|Examining the Feasibility of Collaborative Care Treatment for Overweight Adolescents|SHINE-Garfield|Kaiser Permanente|No|Completed|January 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Female|13 Years|15 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00462267||172255|
NCT00463086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAARTIPT07|Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons|A Randomized-controlled Trial of Isoniazid Plus Highly Active Antiretroviral Therapy Against Placebo to Prevent Tuberculosis in HIV-infected Persons|HAART-IPT|University of Cape Town|Yes|Completed|November 2007|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1368|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463086||172196|
NCT00463099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990426|Multicenter Orthopaedics Outcomes Network for ACL Reconstructions|Prognosis and Predictors of ACL Reconstruction - A Multicenter Cohort Study||Vanderbilt University|No|Active, not recruiting|January 2007|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|10 Years|33 Years|No|Non-Probability Sample|All eligible ACL-deficient candidates scheduled for a unilateral ACL reconstruction at one        of the participating MOON sites.|December 2015|December 7, 2015|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463099||172195|
NCT00463112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511/8-1-04|Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS|Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS: a Randomized, 24-Week Study||Hippocration General Hospital|No|Completed|March 2004|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2003|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463112||172194|
NCT00493402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hcc-001|Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma|The Efficacy, Safety, and Patient Reported Outcomes of Different Regimens of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma|TACEforHCC|Sun Yat-sen University|Yes|Completed|July 2007|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|365|||Both|18 Years|75 Years|No|||December 2012|December 12, 2012|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493402||169909|
NCT00493701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 21041|"ADAPT" The Adaptation to High Fat Diets Extention|ADAPT-The Adaptation to High Fat Diets||Pennington Biomedical Research Center|Yes|Active, not recruiting|October 2010|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|65|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493701||169886|
NCT00493714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0341|Delirium Recall in Advanced Cancer Patients|The Impact of Acute Delirium On the Level of Distress In Patients With Advanced Cancer and Their Caregivers||M.D. Anderson Cancer Center|No|Completed|July 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Advanced cancer patient having had an episode of delirium with complete recover; and their        caregivers, age 18 years or older.|July 2012|July 27, 2012|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493714||169885|
NCT00493987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD043348|The Role of 5-alpha Reductase in Mediating Testosterone Actions|The Role of 5-alpha Reductase in Mediating Testosterone Actions|5aR|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|November 2002|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|184|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|May 12, 2010|June 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00493987||169864|
NCT00494286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074737|Abuse-Focused Cognitive Behavioral Therapy for Children Who Have Been Physically Abused|Treatment of Child Physical Abuse: An Effectiveness Trial (PFF)|PFF|University of Pittsburgh|Yes|Completed|September 2006|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|5 Years|15 Years|No|||February 2013|February 15, 2013|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00494286||169843|
NCT00494299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11721|Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)|Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)||Bayer|Yes|Completed|April 2006|November 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|458|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|June 28, 2007||No||No|December 21, 2010|https://clinicaltrials.gov/show/NCT00494299||169842|
NCT00460161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP.PLP.10.06|Acupuncture for Phantom Limb Pain|Acupuncture for Phantom Limb Pain: A Randomized, Double-Blind, Placebo/Sham - Controlled Study||Shaare Zedek Medical Center|No|Suspended|February 2009|||August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2008|February 17, 2009|April 12, 2007||No|Lack of patients|No||https://clinicaltrials.gov/show/NCT00460161||172413|
NCT00460837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.senna.SMH|Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience|Virtual Colonoscopy: Comparison of Reduced Laxative Virtual Colonoscopy Regimens With Standard Preparation on Patient Experience and Compliance - a Questionnaire Based Study||London North West Healthcare NHS Trust|Yes|Withdrawn|November 2007|March 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2010|July 23, 2010|March 23, 2007||No|Supply of adequate label was not provided to the MHRA|No||https://clinicaltrials.gov/show/NCT00460837||172362|
NCT00461110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-005|A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)|A Phase 1 Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)||Bristol-Myers Squibb|No|Terminated|January 2008|April 2009|Anticipated|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||September 2009|September 3, 2009|April 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00461110||172341|
NCT00460434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15P01|Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial|Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling (OPUS) Trial|OPUS|NICHD Pelvic Floor Disorders Network|Yes|Completed|May 2007|March 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|517|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 27, 2013|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460434||172392|
NCT00460447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 92062003|Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation|Gentuzumab Ozogamicin Berfore Allogeneic Stem Cell Transplantation in Patients With Relapsed CD33+ Acute Myeloid Leukemia||University Hospital Carl Gustav Carus|No|Recruiting|October 2004|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|70 Years|No|||April 2007|April 12, 2007|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00460447||172391|
NCT00460798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181115|SUTENT® In The First Line Treatment Of Renal Cell Carcinoma|A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Cancer|SUNIKA|Pfizer|No|Completed|February 2007|September 2009|Actual|September 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|356|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated by office-based oncologists, office-based urologists specialized in        oncology or hospital-based oncologist/urologists|November 2010|November 3, 2010|April 13, 2007|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00460798||172365|Owing to extent of missing data, the planned TTP analyses derived from standardized lesion measurement was not reported. An additional TTP analysis using Investigator Disease Status and Overall Objective Tumor Assessments at 12 months was reported.
NCT00460811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-202|Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-design, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Irritable Bowel Syndrome With Constipation||Ironwood Pharmaceuticals, Inc.||Completed|April 2007|April 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|420|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|April 13, 2007|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00460811||172364|
NCT00461448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNFTRI-B2484|A Pilot Study of Potassium Supplementation for Adult Patients With Rheumatoid Arthritis|Pilot Study of Potassium Supplementation in the Treatment of Rheumatoid Arthritis: a 4-Week, Randomized, Double-Blind, Placebo-Controlled Trial||hahid Beheshti University of Medical Sciences|Yes|Completed|February 2007|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|60 Years|No|||February 2009|February 4, 2009|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461448||172316|
NCT00461461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM04-108|a Multifaceted Program for Improving Quality of Care in ICU|IATROREF III: a Multifaceted Program for Improving Quality of Care in Critically Ill Patients||Groupe Hospitalier Paris Saint Joseph|Yes|Completed|January 2007|June 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Actual|2117|||Both|18 Years|N/A|No|||June 2009|June 24, 2009|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461461||172315|
NCT00461422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|soltsman2004.CTIL|Early Follicular Supplementation of Ganirelix in IVF 2004|Early Follicular GnRH Antagonist Supplementation Improves Fertilization and Embryo Cleavage Rates in IVF-ET GnRH Antagonist Cycles||The Baruch Padeh Medical Center, Poriya|No|Completed|January 2004|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|N/A|N/A|No|||June 2008|June 26, 2008|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461422||172318|
NCT00461435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS01|Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa|Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa||Azienda Policlinico Umberto I||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|20 Years|70 Years||||April 2007|April 17, 2007|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461435||172317|
NCT00461396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14465|Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron|Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 Months|START|Bayer|No|Completed|May 2007|November 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|50 Years|No|Non-Probability Sample|Community sample|April 2011|April 7, 2011|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461396||172320|
NCT00461409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoLev 1|IV Levetiracetam for the Treatment of Neonatal Seizures: a Pharmacokinetic and Preliminary Efficacy and Safety Study|Phase I/II Study of IV Levetiracetam as an add-on Drug for Seizures in Term Neonates Assessing Pharmacokinetics, Safety and Efficacy.||University of California, San Diego|Yes|Completed|April 2007|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|37 Weeks|42 Weeks|No|||October 2015|October 7, 2015|April 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461409||172319|
NCT00461708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20296|A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival|An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas : Relationship Between Skin Rash and Survival||Hoffmann-La Roche||Completed|May 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|April 17, 2007||No||No|November 10, 2014|https://clinicaltrials.gov/show/NCT00461708||172296|
NCT00461721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-AgNT-003|Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis|Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis Due to Grass Pollen During Immunotherapy||University of Zurich|No|Completed|December 2006|December 2008|Actual|January 2007|Actual|Phase 1|Observational|Observational Model: Case Control||2|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|x|December 2015|December 2, 2015|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00461721||172295|
NCT00463125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPM13746IC|Platelet Gel in Systemic Sclerosis|Platelet Gel for Digital Ulcers in Patients With SSc: a Randomized Controlled Trial||Università Politecnica delle Marche|No|Recruiting|March 2007|March 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|80 Years|No|||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463125||172193|
NCT00462527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI 06-49|Cystatin C as a Marker for Detecting Early Renal Dysfunction in a Pediatric Emergency Department|Cystatin C as a Marker for Detecting Early Renal Dysfunction in a Pediatric Emergency Department|CARING|Children's Hospital of Eastern Ontario|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|464|||Both|1 Year|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children less than 18 years old who visit the treating pediatric emergency department.        Gastro cohort: children suffer acute gastroenteritis with signs of dehydration and require        intravenous fluid rehydration Injury cohort: children suffer musculoskeletal injury that        require intravenous sedation for the repair|September 2007|June 27, 2011|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00462527||172237|
NCT00459654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15280|A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer|A Phase II Randomised, Placebo-controlled, Multicentre Study in Prostate Cancer Patients With Painful Bone Metastases to Evaluate the Efficacy of Repeated Radium-223 Injections||Bayer|No|Completed|February 2004|May 2007|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Male|40 Years|N/A|No|||June 2014|June 24, 2014|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459654||172452|
NCT00459940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030288|The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients|"Can Growth Hormone's Lipolytic and Insulin-Antagonistic Effects be Modified by Peroxisome Proliferator-Activated Gamma Agonists?"||University of Aarhus|Yes|Completed|September 2004|March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Male|19 Years|71 Years|No|||April 2007|April 12, 2007|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00459940||172430|
NCT00494338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976J_2504|Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer|A Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer||Sanofi||Terminated|November 2004|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Male|18 Years|N/A|No|||September 2009|September 30, 2009|June 28, 2007||No|due to celecoxib safety issues|No||https://clinicaltrials.gov/show/NCT00494338||169839|
NCT00493727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0030|Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria|Use of Mucomyst (NAC) to Ameliorate Oxidant Stress in Diabetic Patients as Measurable by Surrogate Serum Markers||VA Office of Research and Development|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||May 2008|May 16, 2008|June 27, 2007||||No||https://clinicaltrials.gov/show/NCT00493727||169884|
NCT00494013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10935|Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)|Treat-to-Target Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Comparator) in Basal Therapy for Patients With Type 2 Diabetes Mellitus|IOOY|Eli Lilly and Company|No|Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|442|||Both|18 Years|N/A|No|||November 2009|November 4, 2009|June 27, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00494013||169863|
NCT00494026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10015|Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)|Phase II Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage of Small Cell Lung Cancer||Eli Lilly and Company|Yes|Terminated|September 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2009|November 17, 2009|June 27, 2007|Yes|Yes|Study stopped early based on interim results of another trial, showing inferior activity of    pemetrexed/carboplatin compared to etoposide/carboplatin in SCLC.|No|October 14, 2009|https://clinicaltrials.gov/show/NCT00494026||169862|
NCT00494325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 73/05|The Role of Macular Pigment in Patients With Age-related Macular Degeneration|The Role of Macular Pigment in Patients With Age-related Macular Degeneration||University Hospital Inselspital, Berne|No|Active, not recruiting|October 2005|December 2015|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with early ARM|June 2015|June 10, 2015|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00494325||169840|
NCT00460174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04I6|Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer|A Phase II Trial of Weekly Gemcitabine Hydrochloride and Bevacizumab in Combination With Abdominal Radiation Therapy in Patients With Localized Pancreatic Cancer||Northwestern University|Yes|Active, not recruiting|October 2005|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|120 Years|No|||September 2015|September 24, 2015|April 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00460174||172412|
NCT00460187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-1145|EPIC US Pivotal Study|Evaluating the Use of the FiberNet Embolic Protection System in Carotid Artery Stenting: The EPIC US Pivotal Study.|EPIC|Lumen Biomedical|Yes|Completed|March 2007|June 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|237|||Both|18 Years|N/A|No|||October 2008|October 20, 2008|April 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00460187||172411|
NCT00461500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM108037|SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults|See Detailed Description||GlaxoSmithKline||Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|81|||Both|18 Years|40 Years|No|||March 2012|March 22, 2012|April 17, 2007||||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00461500||172312|
NCT00461513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-068|Patient-Centered Heart Failure Trial|Patient-Centered Disease Management for Heart Failure Trial|PCDM|VA Office of Research and Development|Yes|Completed|May 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|392|||Both|18 Years|N/A|No|Non-Probability Sample|VA Patients in Denver, Palo Alto, Richmond and Seattle who have a diagnosis of Chronic        Heart Failure and have low health status.|September 2014|April 6, 2015|April 17, 2007||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT00461513||172311|
NCT00460824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003541|A Retrospective Review - Anti-HLA Antibodies|A Retrospective Review of Anti-HLA Antibodies and Donor Crossmatch Results as a Predictor of Pediatric Heart Transplant Outcomes||Emory University|No|Withdrawn|July 1988|||||N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|N/A|18 Years|No|Non-Probability Sample|-  heart transplants at Childrens Healthcare of Atlanta, Egleston Hospital          -  transplants between July 1, 1988 through and including January 31, 2007          -  complete HLA data          -  survived more than 30 days after transplant|December 2013|December 29, 2013|April 16, 2007||No|Not a Clinical trial. Retrospective Data review only.|No||https://clinicaltrials.gov/show/NCT00460824||172363|
NCT00461097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CoFAR3|Oral Immunotherapy for Childhood Egg Allergy|Oral Desensitization to Egg With Subsequent Induction of Tolerance for Egg-Allergic Children (CoFAR 3)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2007|December 2013|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|5 Years|18 Years|No|||December 2013|December 24, 2013|April 16, 2007|Yes|Yes||No|December 29, 2011|https://clinicaltrials.gov/show/NCT00461097||172342|
NCT00461760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-04032|HPV Testing for Cervical Cancer Screening Study|A Randomized Controlled Evaluation of HPV Testing for Cervical Cancer Screening|HPVFOCAL|University of British Columbia|No|Active, not recruiting|March 2007|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|28000|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|April 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00461760||172292|
NCT00461773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609001793|Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer|Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer||Yale University|No|Recruiting|March 2007|May 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||June 2009|June 5, 2009|April 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461773||172291|
NCT00461747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001110-41|GEM05 for Patients With Multiple Myeloma Under 65 Years|A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autologous Hemopoietic Stem Cell Support and Maintenance Treatment With Interferon-a Versus Thalidomide Versus Thalidomide / Velcade in Untreated Patients With Multiple Myeloma Less Than 65 Yrs Old|GEM05MENOS65|PETHEMA Foundation|Yes|Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|390|||Both|N/A|65 Years|No|||September 2009|September 17, 2009|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461747||172293|
NCT00461734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTECT-PACE Version 4|PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing|PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing. Does Right Ventricular High-septal Pacing Improve Outcome Compared With Right Ventricular Apical Pacing?|PROTECT-PACE|Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|May 2007|August 2015|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461734||172294|
NCT00462007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939117|Study to Evaluate Initiation of Stalevo in Early Wearing-off|Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients|SENSE|Orion Corporation, Orion Pharma|No|Completed|September 2006|December 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|35 Years|N/A|No|||April 2015|April 20, 2015|April 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00462007||172273|
NCT00458861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104RA203|BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF||Biogen|Yes|Terminated|March 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|March 22, 2007|Yes|Yes|Interim analysis of data failed to meet primary endpoint.|No||https://clinicaltrials.gov/show/NCT00458861||172507|
NCT00458848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL0904|Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia|Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring.|LAL0904|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|October 2004|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|470|||Both|15 Years|60 Years|No|||May 2015|May 26, 2015|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458848||172508|
NCT00462839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-029|Accuracy of Blood Loss Estimation After Vaginal Delivery|The Accuracy of Blood Loss Estimation After Simulated Vaginal Delivery||Northwestern University|No|Completed|July 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|106|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|April 17, 2007||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00462839||172214|A limitation to our study is that we asked participants to estimate blood loss based on inspection of the conical drape only. We did not ask them to estimate blood loss in hidden places. In addition, this was not an actual delivery but a simulation.
NCT00490178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF23-0121 06 02|Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia|An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia||Solvay Pharmaceuticals|No|Completed|March 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|20 Years|80 Years|No|||August 2007|August 31, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490178||170152|
NCT00494039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP|I-125 Versus Pd-103 for Low Risk Prostate Cancer|I-125 Versus Pd-103 for Low Risk Prostate Cancer||VA Puget Sound Health Care System|Yes|Active, not recruiting|January 1998|January 2010|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|602|||Male|40 Years|80 Years|No|||June 2007|June 28, 2007|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00494039||169861|
NCT00494312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-00-TL-OPI-506|Safety Study of Pioglitazone Compared To Glyburide on Liver Function|A Randomized, Comparator Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl vs Glyburide With Metformin and Insulin as Part of Step Therapy in Subjects With Type 2 (Non-Insulin Dependent) Diabetes||Takeda|Yes|Completed|October 2000|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2120|||Both|18 Years|80 Years|No|||February 2012|February 27, 2012|June 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00494312||169841|
NCT00490659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8191|Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes|A Phase II Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (-With Weekly Low-Dose Gemcitabine) in the Treatment of Nodes Positive NSCLC Patients||Eli Lilly and Company|No|Completed|September 2003|December 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|75 Years|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490659||170115|
NCT00460200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000385692|Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer|Depression and IL-6 in Epithelial Ovarian Cancer: Genetic Diathesis and Psychological Stress||Jonsson Comprehensive Cancer Center|No|Withdrawn|December 2003|||||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Female|18 Years|55 Years|No|Non-Probability Sample|diagnosis of ovarian epithelial cancer|October 2012|October 3, 2012|April 11, 2007||No|no patient accrual|No||https://clinicaltrials.gov/show/NCT00460200||172410|
NCT00460486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|690601|Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule|Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older||Pfizer|Yes|Completed|September 2006|||November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||330|||Both|16 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460486||172388|
NCT00460499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23735|Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control|||American Heart Association|Yes|Completed|July 2004|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|90 Years|No|||June 2015|June 22, 2015|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460499||172387|
NCT00461162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 43-09|Dyspnea Self-Management: Internet or Face-to-Face|Dyspnea Self-Management: Internet or Face-to-Face||University of California, San Francisco||Completed|January 2007|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|125|||Both|40 Years|N/A|No|||August 2014|August 14, 2014|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00461162||172337|
NCT00461123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12496|Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy|A Randomized, Double-blind, Parallel Group Prospective Pilot Study to Assess the Effect of Vardenafil on Clinical Outcome and on Procedure Duration After Green Light Laser-ablation of the Prostate Gland for Therapy of Benign Prostate Hypertrophy (BPH)||Bayer|No|Completed|March 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|80 Years|No|||December 2014|December 4, 2014|April 16, 2007||No||No|September 29, 2009|https://clinicaltrials.gov/show/NCT00461123||172340|
NCT00461136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2242|Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes|An Open-Label, One-Period, One-Treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy||Novartis|No|Completed|August 2005|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|30 Years|80 Years|No|||June 2007|June 21, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461136||172339|
NCT00461474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-025022|Study of Strengthening Exercises and Improving Movement for Painful Shoulders in Adults With Spinal Cord Injury|Strengthening and Optimal Movements for Painful Shoulders in Chronic Spinal Cord Injury (STOMPS)||University of Southern California|Yes|Completed|March 2004|March 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||80|||Both|19 Years|75 Years|No|||April 2007|April 18, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461474||172314|
NCT00461487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1456|A Parent-Based Intervention to Reduce Sexual Risk Behavior in Adolescents|Reducing Teen Sexual Behavior: A Clinic-Based Approach||Columbia University|No|Completed|April 2007|August 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|530|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461487||172313|
NCT00462332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC0405|Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia|Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features|LLC0405|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|May 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|N/A|60 Years|No|||August 2013|August 20, 2013|April 18, 2007||No||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00462332||172251|
NCT00462046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD001|Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia|The Efficacy and Safety of Berberine in the Treatment of Type 2 Diabetes With Dyslipidemia||Shanghai Jiao Tong University School of Medicine|Yes|Completed|April 2005|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|25 Years|70 Years|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00462046||172271|
NCT00462020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 02 031|Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis|Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis||Children's Mercy Hospital Kansas City|No|Completed|March 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|N/A|18 Years|No|||December 2011|December 12, 2011|April 16, 2007||No||No|December 12, 2011|https://clinicaltrials.gov/show/NCT00462020||172272|
NCT00462319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/07|ARTIST: ARThrose Intervention STandardisée|Evaluation of Standardized Management of Knee Arthritis Patients|ARTIST|Almirall, SAS|No|Completed|May 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training|||||||Both|45 Years|75 Years|No|||April 2007|April 18, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462319||172252|
NCT00462306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-026|Incidence of Obstructive Sleep Apnea in Pregnancy|Incidence of Obstructive Sleep Apnea in Pregnancy|OSA|Northwestern University|No|Completed|September 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4577|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant females spontaneously laboring, scheduled for induction of labor or scheduled for        a cesarean delivery, and non-pregnant females presenting for outpatient surgery between        the ages of 18-45.|March 2014|March 17, 2014|April 17, 2007||No||No|March 28, 2011|https://clinicaltrials.gov/show/NCT00462306||172253|The Berlin questionnaire has not been validated as a screening tool in pregnancy.
NCT00458874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU#06-12025|Better Adherence to Therapeutic Lifestyle Change Efforts Trial|Better Adherence to Therapeutic Lifestyle Change Efforts (BATTLE) Trial|BATTLE|Walter Reed National Military Medical Center|No|Completed|November 2007|April 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 16, 2013|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458874||172506|
NCT00459134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97106|L-Arginine Supplements in Treating Women Who Are Cancer Survivors|A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors||Wake Forest NCORP Research Base|Yes|Completed|May 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|186|||Female|18 Years|N/A|No|||July 2015|July 15, 2015|April 9, 2007||No||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00459134||172489|
NCT00459121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539273|Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery|Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC)||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|July 2007|October 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2013|April 3, 2013|April 9, 2007|Yes|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00459121||172490|This was a single center study. We did not accrue enough particpants in a timely fashion and a joint decision was made with AstraZeneca to terminate the study.
NCT00459641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS I-040302/01|Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts|A Phase 2 Randomised, Open-label, Multi-centre Ascending Dose Study of the Efficacy, Safety and Tolerability of I-040302 Versus Control Injection (Bone Marrow Aspirate or Steroids) in Children and Young Adults With Solitary Bone Cysts||Kuros Biosurgery AG|Yes|Withdrawn|December 2012|July 2019|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|16 Years|No|||July 2012|July 16, 2012|April 11, 2007||No|Stopped before any site initiation or any recruitment due to change in overall product    development plan|No||https://clinicaltrials.gov/show/NCT00459641||172453|
NCT00459407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00894|Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate|Phase Ib Study of Polyphenon E in a Pre-prostatectomy Prostate Cancer Cohort||National Cancer Institute (NCI)||Completed|March 2007|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Male|18 Years|N/A|No|||February 2013|October 7, 2014|April 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459407||172471|
NCT00459420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-06-68|Caffeine for Excessive Daytime Somnolence in Parkinson's Disease|Caffeine for Excessive Daytime Somnolence in Parkinson's Disease||McGill University Health Center|Yes|Completed|April 2007|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459420||172470|
NCT00490191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2073|Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency|Comparison of an Incremental Weight-Based Dose Regimen With an Individualized Dosage Adjusted According to the IGF-I Response in Adults With Growth Hormone Deficiency||Eli Lilly and Company|No|Completed|January 1999|July 2001|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|387|||Both|20 Years|N/A|No|||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490191||170151|
NCT00490204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110458|Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis|A Randomized, Double Blind, Placebo Controlled Study for Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup (CTZ DS) (2.5 mg or 5 mg Twice a Day) in Children (2 Years of Age or Older But Under 15 Years Old) Suffering From Perennial Allergic Rhinitis.||GlaxoSmithKline||Completed|July 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||236|||Both|2 Years|14 Years|No|||May 2009|May 21, 2009|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00490204||170150|
NCT00493389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007255-01H|Cortisol Response to Adrenocorticotrophin (ACTH) in Acute Stress|Improving The Assessment of Hypothalamic Pituitary Adrenal Function In Acute Stress|CRAAS|University of Ottawa|Yes|Recruiting|July 2007|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|40 Years|80 Years|No|||July 2008|August 1, 2008|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493389||169910|
NCT00493740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-NV-218-CTIL|Cephalic Phase of Oncology Patients Before and After Chemotherapy as Compared to Healthy Controls|Cephalic Phase of Oncology Patients Before and After Chemotherapy as Compared to Healthy Controls|Cephalic chemo|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|July 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|July 5, 2007|June 27, 2007||||No||https://clinicaltrials.gov/show/NCT00493740||169883|
NCT00493753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCD-ACU-SLE|Feasibility and Safety of Acupuncture for Systemic Lupus|Feasibility and Safety of Acupuncture for Systemic Lupus Erythematosus||University of Pittsburgh|Yes|Completed|November 2004|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind|3||Actual|24|||Both|18 Years|N/A|No|||June 2007|June 26, 2007|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00493753||169882|
NCT00490412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 063|Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection|Randomized, Placebo-controlled Trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease Bone Turnover in Adolescents and Young Adults With HIV Infection Being Treated With Antiretroviral Therapy Containing Tenofovir Compared to Those Being Treated With Antiretroviral Therapy Not Containing Tenofovir||Westat|Yes|Completed|December 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|207|||Both|18 Years|24 Years|No|||February 2016|February 29, 2016|June 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00490412||170134|
NCT00490971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010825|A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder|A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|May 2006|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|768|||Both|18 Years|65 Years|No|||March 2015|March 25, 2015|June 18, 2007|Yes|Yes||No|April 26, 2011|https://clinicaltrials.gov/show/NCT00490971||170091|The study employed a randomized withdrawal design, and as such, was enriched for responders to the study drug. Thus, the long-term efficacy demonstrated cannot be extrapolated to a population of patients without prior exposure to paliperidone ER.
NCT00461149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-1|Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly|Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly|HDacro|Federico II University|No|Completed|January 1995|December 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||April 2007|April 13, 2007|April 13, 2007||||No||https://clinicaltrials.gov/show/NCT00461149||172338|
NCT00461786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8364|A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer|A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma||Eli Lilly and Company|Yes|Completed|September 2004|May 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|N/A|N/A|No|||December 2009|December 1, 2009|April 16, 2007|Yes|Yes||No|October 13, 2008|https://clinicaltrials.gov/show/NCT00461786||172290|
NCT00462059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-05TDela-02|Assessment of a Medication Reconciliation Program on Transitional Care|Impact of a Medication Reconciliation Program on Patients Transitioning From an Inpatient Hospitalization to Primary Care||Kaiser Permanente|No|Completed|June 2005|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00462059||172270|
NCT00462072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-01|Centocor Microarray Study of Patients|Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases||University of Rochester|No|Completed|March 2007|August 2010|Actual|June 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|12 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 17, 2007||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00462072||172269|
NCT00462085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94/04|Muscle Activity With the Use of Ankle Foot Orthoses in Cerebral Palsy|Muscle Activity With the Use of Ankle Foot Orthoses in Cerebral Palsy||University Children's Hospital Basel|Yes|Completed|September 2004|April 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||24|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||April 2007|April 17, 2007|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00462085||172268|
NCT00462345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20934|A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.|An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Treatment Response in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies||Hoffmann-La Roche||Completed|June 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|No|||October 2014|October 30, 2014|April 18, 2007||No||No|May 8, 2014|https://clinicaltrials.gov/show/NCT00462345||172250|
NCT00462579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040057|Risk Factors for Carbapenem-resistant Acinetobacter Baumannii|Risk Factors for Carbapenem-resistant Acinetobacter Baumannii||University of Pittsburgh|Yes|Active, not recruiting|April 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|carbapenem-resistant acinetobacter baumannii positive cultures|December 2015|December 16, 2015|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00462579||172233|
NCT00462566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA004|The Efficacy of Motor Cortex Stimulation for Pain Control|The Efficacy of Motor Cortex Stimulation for Pain Control||Nova Scotia Health Authority|No|Completed|October 2005|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|N/A|N/A|No|||September 2010|September 8, 2010|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00462566||172234|
NCT00462852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRH-HCTU-FRAGEM|Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]||National Cancer Institute (NCI)||Completed|April 2003|November 2011|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|N/A|No|||April 2007|August 9, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462852||172213|
NCT00458887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL05C1|Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin|A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy||Children's Oncology Group|No|Completed|May 2007|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|1 Year|18 Years|No|Non-Probability Sample|Patients planning to undergo treatment with any cisplatin-containing therapeutic regimen        for cancer or planning to enroll on clinical trial ACCL0431|February 2016|February 19, 2016|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458887||172505|
NCT00459160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(ER) H-19631|A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients|A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients Undergoing Laparotomy or Thoracotomy for Trauma: A Prospective Randomized Controlled Clinical Trial||Baylor College of Medicine|Yes|Recruiting|July 2007|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|271|||Both|12 Years|45 Years|No|||November 2010|November 30, 2010|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00459160||172488|
NCT00459433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258|The Right Intervention for the Right Patient|The Right Intervention for the Right Patient||The Back Research Center, Denmark|No|Completed|October 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||May 2009|May 28, 2009|April 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00459433||172469|
NCT00459680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-05-06|Acupuncture and Laser Acupoint Treatment on Hypertension|Acupuncture and Laser Acupoint Treatment on Hypertension||Logan College of Chiropractic|No|Recruiting|February 2008|June 2009|Anticipated|January 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||October 2008|January 20, 2010|April 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00459680||172450|
NCT00459979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE17806|Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery|A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors||Case Comprehensive Cancer Center|Yes|Completed|March 2007|September 2013|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|April 11, 2007|Yes|Yes||No|November 19, 2013|https://clinicaltrials.gov/show/NCT00459979||172427|
NCT00494390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kek-98/07|Evaluation Study for a Non-Contact Biometer|Neuartige Kontaktlose Biometrische Messungen||University Hospital Inselspital, Berne|Yes|Completed|July 2007|||March 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample||July 2007|March 18, 2008|June 27, 2007||||No||https://clinicaltrials.gov/show/NCT00494390||169835|
NCT00490217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R065585-1|Spontaneous Bacterial Peritonitis: Incidence, Risk Factors and Outcome|Spontaani Bakterielli Peritoniitti: Esiintyvyys, riskitekijät ja Vaikutus Ennusteeseen||University of Tampere|No|Completed|December 1993|March 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|240|||Both|N/A|N/A|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490217||170149|
NCT00493766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2105|Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone|A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC)||Novartis||Terminated|May 2006|||July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|June 26, 2007|No|Yes|Because of a strategic decision by Novartis|No||https://clinicaltrials.gov/show/NCT00493766||169881|
NCT00490165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0198|Periodontal and Periapical Inflammation and Pregnancy|Associations Between Periodontal and Periapical Inflammation and Pregnancy Outcomes||University of Mississippi Medical Center|No|Completed|March 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|30|||Female|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are looking at charts of patients (former patients) at the University of Mississippi        School of Dentistry. Since this is a pregnancy study we are looking only at the charts of        female patients. The youngest record we review is 10 and there is no upper limit to the        age.|April 2012|April 5, 2012|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00490165||170153|
NCT00490672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT07-02|Community Based Multiple Risk Factors Intervention Strategy|Community Based Multiple Risk Factors Intervention Strategy to Prevent Cardiovascular and Chronic Kidney Diseases [CORFIS]|CORFIS|Ministry of Health, Malaysia|Yes|Completed|August 2007|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|770|||Both|18 Years|80 Years|No|||April 2010|April 6, 2015|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490672||170114|
NCT00490997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-017|Ketamine/Propofol vs Ketamine Alone for Pediatric Fracture Reduction|A Prospective Randomized Double Blind Evaluation of Ketamine/Propofol vs Ketamine Alone for Pediatric Extremity Fracture Reduction||Lawson Health Research Institute|Yes|Completed|June 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|2 Years|16 Years|No|||August 2008|August 14, 2008|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490997||170089|
NCT00460876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14711603062|Phase I Trial of Periocular Topotecan in Retinoblastoma|Toxicity and Activity of Periocular Topotecan in Children With Retinoblastoma||Hospital JP Garrahan|Yes|Completed|March 2007|April 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|18 Years|No|||April 2008|April 30, 2008|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00460876||172359|
NCT00460889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB9478|Renal Donor Comparison of Outcomes: Hand Assist Versus Laparoscopic Nephrectomy|Renal Donor Comparison of Outcomes: Hand Assist Versus Laparoscopic Nephrectomy||Columbia University|No|Withdrawn|October 2006|August 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Surgical clinic|April 2015|April 2, 2015|April 13, 2007||No|Principal Investigator left institution|No||https://clinicaltrials.gov/show/NCT00460889||172358|
NCT00461526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRN-002-202|Diarrhea Predominant Irritable Bowel Syndrome in Females|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN-002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS) in Females||Valeant Pharmaceuticals International, Inc.|Yes|Completed|October 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Female|18 Years|N/A|No|||November 2010|November 19, 2010|November 9, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461526||172310|
NCT00461539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078596|Reducing Health Risk Behavior and Improving Health in Adolescents With Depression|Reducing Health Risk Behavior and Improving Health in Adolescent Depression||University of California, Los Angeles|Yes|Completed|October 2007|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Both|13 Years|18 Years|No|||June 2013|June 5, 2013|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461539||172309|
NCT00461799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-01|Orlistat Treatment of Crigler-Najjar Disease|Orlistat Treatment of Unconjugated Hyperbilirubinemia in Crigler-Najjar Disease; A Randomized Controlled Trial||University Medical Center Groningen|No|Completed|September 2003|January 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Both|8 Years|N/A|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461799||172289|
NCT00462098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007527|Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates|Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates||Duke University|Yes|Completed|August 2006|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|N/A|N/A|No|||February 2013|February 19, 2013|April 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00462098||172267|
NCT00462358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-520-101|A Study of ARRY-520 in Patients With Advanced Cancer|||Array BioPharma||Completed|April 2007|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|April 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00462358||172249|
NCT00462618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-19343|Group Cognitive Behavioral Therapy (CBT I) Vs. Quetiapine for Residual Insomnia Impairing Recovery Among Elderly With Stable Major Affective Disorders|||Michael Debakey Veterans Affairs Medical Center|No|Completed|April 2007|March 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|60 Years|N/A|No|||April 2013|April 22, 2013|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00462618||172230|
NCT00462592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|monbud8035|Comparison of Combination Therapy: Montelukast and Inhaled Steroid on Exercise Induced Bronchoconstriction|A Randomised Double Blind, Placebo Controlled 4-way Cross Over Study Comparing Montelukast, Inhaled Budesonide and Their Combination on Exercise-induced Bronchoconstriction||McMaster University|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Both|8 Years|35 Years|No|||October 2009|October 20, 2009|April 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00462592||172232|
NCT00462605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00195|MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia|A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies||National Cancer Institute (NCI)|Yes|Completed|April 2007|||March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|April 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00462605||172231|
NCT00462865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG BR-213|Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse|A Phase II Study of Adjuvant Gemcitabine/Capecitabine and Bevacizumab for Patients Treated Neoadjuvantly Chemotherapy for Early Stage Breast Cancer With High Risk for Relapse||Brown University|Yes|Terminated|November 2007|January 2014|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|80 Years|No|||April 2015|April 7, 2015|April 18, 2007|No|Yes|DSMB determined toxicity of regimen more than originally thought. Slow accrual.|No|November 14, 2013|https://clinicaltrials.gov/show/NCT00462865||172212|
NCT00463138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brom3CTIL|Follow-up Study on Recipients of Treatment at the Jerusalem Center for the Treatment of Psychotrauma|Follow-up Study on Recipients of Treatment at the Jerusalem Center for the Treatment of Psychotrauma||Herzog Hospital|Yes|Completed|April 2007|March 2008|Actual|March 2008|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|100|||Both|12 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All clients who were exposed to a traumatic event within the last 2 years and completed        treatment at the Trauma Center within the last year|September 2013|September 3, 2013|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463138||172192|
NCT00463151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-06-001|An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis|An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis||Otsuka Pharmaceutical Co., Ltd.|No|Completed|June 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|16 Years|N/A|No|||February 2011|February 9, 2011|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463151||172191|
NCT00459186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-184|The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer|A Phase I/II Study of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer||Dana-Farber Cancer Institute|No|Completed|November 2005|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||January 2014|January 20, 2014|January 23, 2006|Yes|Yes||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00459186||172486|
NCT00459173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4796|Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation|Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Maintenance of Smoking Cessation (1-Year Treatment, 1-Year Follow-up)|STRATUS-WW|Sanofi||Completed|November 2002|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|4850|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|April 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459173||172487|
NCT00459459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704016R|Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma|||National Taiwan University Hospital|Yes|Completed|January 2006|December 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||100|||Both|10 Years|90 Years|No|||April 2007|April 11, 2007|April 11, 2007||||No||https://clinicaltrials.gov/show/NCT00459459||172467|
NCT00459446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070128|Imaging of Totally Blocked Arteries|Gadofosveset Imaging of Chronic Total Peripheral Artery Occlusion (CTO)||National Institutes of Health Clinical Center (CC)||Completed|April 2007|||November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1|||20|||Both|18 Years|N/A|No|||November 2008|September 26, 2015|April 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459446||172468|
NCT00459693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070129|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using (11C)PBR28 in HIV-Seropositive Patients With (MCMD)||National Institutes of Health Clinical Center (CC)||Terminated|April 2007|April 2014|Actual|April 2014|Actual|N/A|Interventional|Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|October 9, 2014|April 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459693||172449|
NCT00482495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546757|Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Trial of Bevacizumab in Patients With Relapsed or Refractory Multiple Myeloma||Mayo Clinic||Completed|April 2006|November 2009|Actual|December 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|June 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00482495||170737|
NCT00490425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHGU-195/02|Prevention of Asthma and Allergy by Probiotic Lactobacillus GG|Efficacy of Lactbacillus GG on Wheeze and Allergic Sensitization in Infants at Risk|FRALAC|Johann Wolfgang Goethe University Hospitals|Yes|Completed|October 2002|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|131|||Both|6 Months|24 Months|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490425||170133|
NCT00490438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-123|Measurement of Vaginal Squeeze Pressure in Incontinent Patients|||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|January 2007|July 2007|Anticipated|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Female|30 Years|70 Years|No|||September 2006|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490438||170132|
NCT00490685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2006-004|Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|Randomized Continuation, Dose Escalation Trial of Sorafenib in Patients With Advanced HCC With Radiological Progression on Prior Sorafenib Treatment (Phase II Study)||Istituto Clinico Humanitas|Yes|Completed|April 2007|||June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|142|||Both|18 Years|N/A|No|||August 2009|September 1, 2010|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00490685||170113|
NCT00490984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS 001|Tongue Advancement for Obstructive Sleep Apnea|Tongue Advancement for Obstructive Sleep Apnea. An Evaluation fo the Aspire Medical Advance System.||Aspire Medical|Yes|Completed|February 2006|July 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|65 Years|No|||April 2009|December 22, 2009|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490984||170090|
NCT00490698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0652|Zoledronate With Atorvastatin in Renal Cell Carcinoma|Bone-Targeted Therapy Combining Zoledronate With Atorvastatin in Renal Cell Carcinoma: A Phase II Study||M.D. Anderson Cancer Center|No|Completed|October 2006|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|N/A|No|||February 2013|February 13, 2013|June 21, 2007||No||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00490698||170112|
NCT00461552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063656|Therapeutic Approaches to HAART-Induced Lipodystrophy|Therapeutic Approaches to HAART-Induced Lipodystrophy||University of Texas Southwestern Medical Center|Yes|Completed|January 2003|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|14 Years|65 Years|No|||June 2015|June 22, 2015|April 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461552||172308|
NCT00461825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Afssaps-980654|Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation|Efficacy and Safety of Maintenance Neoral Compared to Bitherapy Neoral-Imurel or Neoral-CellCept in Renal Transplantation||Poitiers University Hospital|No|Completed|July 1998|February 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||207|||Both|25 Years|N/A|No|||April 2007|April 17, 2007|March 30, 2007||||No||https://clinicaltrials.gov/show/NCT00461825||172287|
NCT00461812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001154|A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma|A Single-Blind, Randomized, Positive-Controlled Study to Compare Monotherapy With an Inhaled Corticosteroid (Mometasone) to Combination Therapy With an Inhaled Corticosteroid + a Long-Acting Bronchodilator (Advair) in Patients With Milder Persistent Asthma||Johns Hopkins University|Yes|Recruiting|April 2007|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||45|||Both|18 Years|65 Years|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461812||172288|
NCT00462111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKM002|Indomethacin and Mechanisms Underlying Risk of Falling|Effect of Indomethacin on Reaction Time, Postural Balance and the Ability to Avoid Suddenly Appearing Obstacles During Gait in Healthy Middle-aged Individuals.||Sint Maartenskliniek||Completed|April 2007|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|20|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00462111||172266|
NCT00462644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-050|Evaluation of Etomidate on Adrenal Function in Trauma Patients|A Single Dose of Etomidate During Rapid Sequence Induction in Trauma Patients Causes Significant Adrenocortical Insufficiency: A Prospective Randomized Study||University of Tennessee|No|Completed|February 2006|September 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||February 2010|February 17, 2010|April 17, 2007||No||No|March 4, 2009|https://clinicaltrials.gov/show/NCT00462644||172228|Small trial most likely underpowered; large number of exclusions; other limitations discussed in published paper (PMID: 18784570).
NCT00462631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBM-VS-55|Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients|Paclitaxel-Eluting Balloon Angioplasty and Cobalt-Chromium Stents Versus Conventional Angioplasty and Paclitaxel-Eluting Stents in the Treatment of Native Coronary Artery Stenoses of Diabetic Patients|PEPCAD IV|Heart Centre Rotenburg|Yes|Completed|May 2007|February 2016|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00462631||172229|
NCT00462878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2002-GTA|Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation|MERONEM: Observational Study About Efficacy of Meropenem in Comparison of Meropenem and Glycopeptide in Treatment of Neutropenia Febrile in Allogenic Blood Stem Cell Transplantation Patients|MERONEM|PETHEMA Foundation|Yes|Completed|November 2002|April 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|392|||Both|18 Years|N/A|No|Non-Probability Sample|Patients submitted to allogenic transplant with neutropenia (neutrophils account < 500/mm3        or neutrophils account < 1000/mm3 with prevision to decrease until 500/mm3 at the next        24-48 h); Signs and symptoms to infection; Fever (Temperature> 38,3 ºC registered one        time, or 38 ºC en two times separated 60 minutes in a period of 12 h)|May 2009|May 11, 2009|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00462878||172211|
NCT00463164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-179|Functional MRI of Cognitive Control in Autism|Functional MRI of Cognitive Control in Autism||UMC Utrecht|No|Not yet recruiting|December 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||||90|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463164||172190|
NCT00463177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFGV5503-02|Augmented Cerebral Pain Processing in Chronic, Unexplained Pain: a fMRI Study|Augmented Cerebral Pain Processing in Chronic, Unexplained Pain: a 3T Event-Related Functional MRI Study||UMC Utrecht|No|Completed|March 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic unexplained pain patients|September 2008|September 3, 2008|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463177||172189|
NCT00459212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00206|GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia|Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias||National Cancer Institute (NCI)||Completed|March 2007|||December 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2013|December 3, 2015|April 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459212||172485|
NCT00459472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA9177|Operating Room Outcomes After Resident Training on a Virtual Reality Simulator|Operating Room Outcomes After Resident Training on a Virtual Reality Simulator||Columbia University|No|Terminated|January 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 3, 2015|April 10, 2007||No|Principal investigator left institution.|No||https://clinicaltrials.gov/show/NCT00459472||172466|
NCT00459706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881K1-6000|Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept|A 3-Month, Randomised, Open-Label, Parallel-Group, Descriptive Study To Explore And Compare Perceptions and Satisfaction For Two Different Delivery Mechanisms For Etanercept (Etanercept Autoinjector And The Etanercept Prefilled Syringe) In Patients With Rheumatoid Arthritis||Pfizer||Completed|September 2007|September 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|640|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|April 11, 2007||No||No|September 7, 2011|https://clinicaltrials.gov/show/NCT00459706||172448|
NCT00460005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2W106188|Clinical Study Of Migraine Evolution|A Multicenter Study to Determine the Clinical Characteristics of the Temporal Aspects of Migraine in a Canadian Population: Clinical Study Of Migraine Evolution (C-SOME)||GlaxoSmithKline||Completed|January 2006|||||Phase 4|Observational|Time Perspective: Prospective||||250|||Both|18 Years|N/A|No|||April 2008|April 14, 2008|April 12, 2007||||No||https://clinicaltrials.gov/show/NCT00460005||172425|
NCT00460018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-04AFerr-04-H|Diet, Exercise, and Breastfeeding Intervention Program for Women With Gestational Diabetes (DEBI Trial)|Diet, Exercise and Breastfeeding Intervention (DEBI) Program for Women With Gestational Diabetes|DEBI|Kaiser Permanente|No|Completed|September 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Female|20 Years|45 Years|No|||January 2009|June 18, 2009|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00460018||172424|
NCT00483288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-30104B|Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap Smears|Wake Forest University Cervical Screening and Follow Up System for Hispanic Women - A Pilot Study||Comprehensive Cancer Center of Wake Forest University||Completed|May 2005|||September 2006|Actual|N/A|Interventional|Primary Purpose: Health Services Research|||Anticipated|238|||Female|18 Years|70 Years|No|||June 2013|June 4, 2013|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483288||170677|
NCT00490451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10408|A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma|A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma||Eli Lilly and Company|No|Completed|August 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00490451||170131|
NCT00490464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0233|Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH|||University of Illinois at Chicago|No|Completed|June 2004|February 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|163|||Both|18 Years|70 Years|No|||June 2007|June 21, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490464||170130|
NCT00490477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-257|The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial|Polymyxin-B Hemoperfusion Inactivates Circulating Proapoptotic Factors||University of Turin, Italy|Yes|Completed|May 2006|December 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|N/A|No|||June 2007|June 4, 2010|June 20, 2007||No||No|March 9, 2010|https://clinicaltrials.gov/show/NCT00490477||170129|
NCT00483275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-001-SP|Fall Prevention by Alfacalcidol and Training|Effects of a Multi-modal 12-month-intervention With Alfacalcidol Plus Calcium, Patient Education and a Mobility Program on the Number of Fallers Among Patients With an Impaired Kidney Function Aged 65 and Older.|SPALT|Ruhr University of Bochum|No|Withdrawn|June 2007|September 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|484|||Both|65 Years|N/A|No|||July 2011|July 20, 2011|June 6, 2007|||No final agreement with sponsor|No||https://clinicaltrials.gov/show/NCT00483275||170678|
NCT00461227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1353|Effect of Heredity and Environment on Asthma Development and Severity in Puerto Rican Children|Genes, Home Allergens, and Asthma in Puerto Rican Children||University of Pittsburgh|No|Completed|August 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1127|Samples With DNA|Serum|Both|6 Years|14 Years|No|Probability Sample|Children of Puerto Rican descent (having four Puerto Rican grandparents) living in        Hartford (Connecticut) and in the metropolitan areas of San Juan and Caguas in the island        of Puerto Rico.|December 2012|December 18, 2012|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00461227||172332|
NCT00461565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11337|FDA Phase IV - Commitment - Retinal Function Study|A Double Blind, Randomized, Placebo Controlled, Two Part, Two Session Balanced, Crossover Study to Evaluate Visual Changes in Healthy Male Subjects Aged 18 - 55 Years After Receiving: 1. at Least 15 Doses of 20 mg Vardenafil, Compared to Placebo and 2. Two Doses of Sildenafil, 200 mg Compared to Placebo||Bayer|No|Completed|February 2005|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|63|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|April 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00461565||172307|
NCT00462124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-01|Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy|One-Arm, Multi-Center, Prospective Study to Assess the Safety and Efficacy of BioProtect Biodegradable Implantable Balloon in Prostate Cancer Subjects Undergoing Radiotherapy||BioProtect|No|Recruiting|June 2007|February 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Male|N/A|80 Years|No|||June 2009|June 9, 2009|April 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00462124||172265|
NCT00462371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB21004821|Comparison Between Insulin Pump Treatment and Multiple Daily Insulin Injections in Diabetic Type 1 Children|Open-Label, Randomised Trial Comparing Efficacy of Continuous Subcutaneous Insulin Infusion(CSII) and Multiple Daily Insulin Injections (MDII) in Improving Glycemic Control and Quality of Life in Poorly Regulated Type 1 Diabetic Children.||Erasmus Medical Center|Yes|Completed|January 2002|February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||38|||Both|4 Years|16 Years|No|||April 2007|April 18, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462371||172248|
NCT00462657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000539539|Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease|Early Diagnosis of Invasive Aspergillosis in a High Risk Group of Patients Using Serum and Bronchoalveolar Lavage Fluid Real Time PCR and Galactomannan ELISA||National Cancer Institute (NCI)||Recruiting|July 2005|||||N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|200|||Both|18 Years|N/A|No|||September 2007|August 23, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462657||172227|
NCT00462670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-06-002|A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)|A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)||Otsuka Pharmaceutical Co., Ltd.|No|Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|20 Years|85 Years|No|||December 2013|December 24, 2013|April 17, 2007||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT00462670||172226|
NCT00462904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XO-400761|Pharmacokinetic Response to BPI in Burns|Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-Increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury.||University of Texas Southwestern Medical Center|No|Completed|April 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|13 Years|60 Years|No|||April 2007|June 2, 2008|April 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00462904||172209|
NCT00462891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-114|A Mammography FastTrack Program in Increasing the Number of Women Undergoing Breast Cancer Screening|Breast Cancer Screening and Follow-Up in a PBRN: The Mammography FastTrack Trial||Massachusetts General Hospital|No|Completed|March 2007|||March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|6730|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 18, 2013|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00462891||172210|
NCT00463190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-BIO-440021|Effect of Probiotics (Bio-Three) in Children's Enterocolitis|Postmarketing Study of Probiotics Medication in Childhood Diarrhea||Chang Gung Memorial Hospital|Yes|Completed|February 2006|November 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Anticipated|300|||Both|3 Months|12 Years|No|||April 2007|September 18, 2008|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463190||172188|
NCT00463203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI-Brain-01|Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy|||Rigshospitalet, Denmark|No|Completed|March 2007|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|April 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00463203||172187|
NCT00458900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/071|Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients|Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients||University Hospital, Ghent|No|Completed|July 2007|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|April 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00458900||172504|
NCT00459225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002287|Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease|Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease: An Open Label Trial||Emory University|No|Withdrawn|April 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|N/A|2 Months|No|||December 2014|December 8, 2014|April 10, 2007|Yes|Yes|Difficulty recruiting subjects|No||https://clinicaltrials.gov/show/NCT00459225||172484|
NCT00459485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200714985|Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on Plasma Zinc Concentration|Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on the Magnitude and Velocity of Change in Plasma Zinc Concentration||University of California, Davis|No|Completed|April 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|58|||Male|19 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 18, 2010|April 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00459485||172465|
NCT00459719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR4LTxCN01|A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With Steroids in Patients Undergoing Liver Transplantation and a Pharmacokinetics Study.||Astellas Pharma Inc|No|Completed|March 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|April 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00459719||172447|
NCT00460031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE12805|Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation||Case Comprehensive Cancer Center|Yes|Active, not recruiting|September 2006|April 2016|Anticipated|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Male|18 Years|N/A|No|||November 2015|November 5, 2015|April 11, 2007|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT00460031||172423|
NCT00483054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210041000824904203|Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin|Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin|N2R|Bamrasnaradura Infectious Diseases Institute|Yes|Completed|January 2007|December 2010|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|60 Years|No|||June 2009|November 21, 2011|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483054||170695|
NCT00490230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1303|Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application|Assessment of Cutaneous Leishmaniasis Scar (Caused by Leishmania Major) for Cosmetic Outcome After Treatment With WR279396 (Paromomycin/Gentamicin Cream in Vehicle) Versus a No Treatment Control Group (Natural Healing)|SCAR|U.S. Army Medical Research and Materiel Command|No|Completed|April 2007|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|108|||Both|5 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00490230||170148|
NCT00483015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0707|Differences in the Presentation Outcome and Response to Treatment Between Never- Smokers and Smokers With NSCLC|Differences in the Presentation, Outcome and Response to Treatment Between Never- Smokers and Smokers With Non- Small Cell Lung Cancer.||Washington University School of Medicine|No|Completed|March 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Time Perspective: Retrospective|||Actual|280|||Both|18 Years|88 Years|No||Age Range 18-88, diagnosed with non- small cell lung cancer between Jan 1 1996 and Dec 31        2002.|August 2013|August 9, 2013|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00483015||170698|
NCT00484159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00007158|Efficacy and Cost: Benefit Ratio of 0, 1, and 2 Medial Branch Blocks for Lumbar Facet Joint Radiofrequency Denervation|Prospective Randomized Study Comparing 0, 1, and 2 Diagnostic Lumbar Medial Branch (Facet Joint) Blocks Before Radiofrequency Denervation in Patients With Chronic Low Back Pain: A Cost: Benefit Analysis.||Johns Hopkins University|Yes|Completed|February 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|N/A|No|||January 2009|July 25, 2011|June 6, 2007|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00484159||170611|This study only followed patients for 3 months, so we don't know if proceeding straight to radiofrequency is associated with the same duration of pain relief as when diagnostic facet blocks are performed.
NCT00461578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA/RWD/2006|Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children|Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children||London School of Hygiene and Tropical Medicine|No|Completed|April 2005|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||800|||Both|12 Months|59 Months|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461578||172306|
NCT00461591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-611|Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing TUR-BT|A Multicenter,Randomized,Placebo-Controlled,Double-Blind,Phase3 Trial of Single Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in Early Post Operative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer||Spectrum Pharmaceuticals, Inc|No|Completed|April 2007|April 2012|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|802|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|April 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461591||172305|
NCT00461864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPUS-1|Diagnosis of Occult Hip Fractures With Ultrasound|||Rabin Medical Center|No|Not yet recruiting|April 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||40|||Both|50 Years|N/A|No|||March 2007|April 17, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00461864||172284|
NCT00461877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31286|High-Risk HPV Infections in Women Aged 25 to 65|High-Risk HPV Infections in Women Aged 25 to 65||University of Washington|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|303|Samples With DNA|Vaginal swab samples for HPV DNA testing|Female|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|25 to 65 year old women who date online|November 2013|November 15, 2013|April 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00461877||172283|
NCT00461838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2818 - 22/10/2004|Outcome After Multidisciplinary CO2 Laser Laparoscopic Excision of Deep Infiltrating Colorectal Endometriosis|Outcome After Multidisciplinary CO2 Laser Laparoscopic Excision of Deep Infiltrating Colorectal Endometriosis||University Hospital, Gasthuisberg|No|Completed|September 1996|July 2004|Actual|July 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|56|Samples Without DNA|Endometriosis was proven by histologic examination of excised lesions.|Female|18 Years|45 Years|No|Non-Probability Sample|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep        infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist        were selected retrospectively from the list of all patients (n=more than 2000) operated at        the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.|February 2009|February 19, 2009|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00461838||172286|
NCT00461851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609001823|Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma|A Phase II, Multicenter Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma||Yale University|No|Active, not recruiting|March 2007|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2014|June 22, 2014|April 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00461851||172285|
NCT00462137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.101|The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux|The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux||Thomas Jefferson University|No|Completed|March 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|subjects who have esophageal reflux|October 2008|October 8, 2008|February 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00462137||172264|
NCT00462384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20659|A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients With Chronic Kidney Disease.|An Open-label, Multi-center Study to Demonstrate Correction of Anemia and to Assess the Maintenance of Hemoglobin Levels Using Subcutaneous Once Monthly Injections of Mircera in Pre-dialysis Patients With Chronic Kidney Disease||Hoffmann-La Roche||Completed|February 2008|April 2011|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00462384||172247|
NCT00462683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURIC0445100|Bone Loss, Fractures, and Management of Bone Health in People With Stroke in Managed Rehabilitation Settings|Bone Loss, Fractures, and Management of Bone Health in People With Stroke in Managed Rehabilitation Settings||Northwestern University|No|Completed|July 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|87|Samples Without DNA|Two 10ml tubes of blood will be obtained from each participant. Serum will be separated and      frozen to be saved for possible measurement of vitamin D levels and/or bone markers.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have experienced brain injury.|January 2012|January 4, 2012|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00462683||172225|
NCT00462917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0113|REVEAL III: Risk Evaluation and Education for Alzheimer's Disease|Risk Evaluation and Education for Alzheimer's Disease|REVEAL|Brigham and Women's Hospital|Yes|Completed|March 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|290|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|April 17, 2007||No||No|August 21, 2014|https://clinicaltrials.gov/show/NCT00462917||172208|
NCT00463216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F03-05|A Coordinated Return to Work Program|A Coordinated Return to Work Program for Workers on Long-term Sickness Absence Due to Musculoskeletal Disorders: a Prospective Controlled Intervention Study||Vejle Hospital|No|Completed|April 2004|April 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||120|||Both|18 Years|65 Years|No|||March 2007|February 5, 2010|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463216||172186|
NCT00458913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08052|Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma|Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|February 2007|March 2012|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458913||172503|
NCT00459498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN736/02|Expression of NIS Protein and mRNA in Thyroid Tumors|Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors||University of Sao Paulo|No|Completed|April 2002|October 2006|Actual|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||||30|||Both|18 Years|80 Years|No|||April 2007|April 10, 2007|April 10, 2007||||No||https://clinicaltrials.gov/show/NCT00459498||172464|
NCT00459732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-106|Zinc & Bone Health in Thalassemia: The Think Zinc Study|Zinc and Bone Metabolism in Thalassemia|ThinkZn|Children's Hospital & Research Center Oakland|Yes|Completed|April 2006|February 2011|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|6 Years|30 Years|No|||October 2011|October 4, 2011|April 11, 2007||No||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00459732||172446|
NCT00460044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK0607|ADMA and Mechanical Ventilation in Preterm Infants|Plasma ADMA Concentrations at Birth and Mechanical Ventilation in Preterm Infants||VU University Medical Center|No|Completed|January 2002|July 2003|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||35|||Both|N/A|32 Weeks|No|||April 2007|April 12, 2007|April 11, 2007||||No||https://clinicaltrials.gov/show/NCT00460044||172422|
NCT00460057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EJRG-06-001-11E32|The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss|The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women||Eulji University Hospital|No|Completed|March 2006|February 2007|Actual|December 2006|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|63|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 2, 2014|April 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00460057||172421|
NCT00491621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501106|Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer|Study Evaluating the Interest of Cytology-molecular Tumor Markers Association for the Diagnostic Strategy in Adult Kidney Tumors|CMM|Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|April 2007|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|74|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 25, 2007||No|No enough inclusion. The aim is no longer relevant. The sponsor decided to stop this study.|No||https://clinicaltrials.gov/show/NCT00491621||170042|
NCT00491634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-3116-AN-CTIL|Treosulfan-based Conditioning for Transplantation in AML/MDS|Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.||Sheba Medical Center|No|Completed|June 2007|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|68 Years|No|||November 2015|November 30, 2015|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491634||170041|
NCT00482742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVC-P01-00.CTIL|Safety & Performance Randomized Study of the CiTop™ Guidewire for Peripheral CTO|A Feasibility, Multi Center Multinational Randomized Open Label Study, to Evaluate the Safety and Performance of the CiTop™ Guidewire for Crossing Total Occlusion in Peripheral Arteries.||Ovalum|Yes|Terminated|October 2006|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||July 2013|July 6, 2013|June 3, 2007||No|product development was cancelled|No||https://clinicaltrials.gov/show/NCT00482742||170719|
NCT00483587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTR-ECG-1|Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?|A Safety and Efficacy Study to Evaluate Intravenous Heme Arginate Infusion in Patients With an Acute Coronary Syndrome Without ST-elevation (NSTEMI)|HAEM|University Medical Center Groningen|No|Completed|July 2007|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|No|||September 2010|September 17, 2010|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483587||170655|
NCT00483899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIG102335|Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects|Double-blind, Placebo-controlled, 3-way Crossover Study to Investigate the Effect of 7-days Repeat Once Daily Inhaled Doses of GW870086X Administered Via DISKHALER on Airway Responsiveness to AMP in Mild Steroid-naive Male Asthmatics||GlaxoSmithKline|No|Completed|October 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Male|18 Years|55 Years|No|||February 2011|May 31, 2012|June 5, 2007||||No||https://clinicaltrials.gov/show/NCT00483899||170631|
NCT00484172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 03-045E|Genomic Search for Childhood Obesity Genes-A Pilot Study|Genomic Search for Childhood Obesity Genes-A Pilot Study||Children's Mercy Hospital Kansas City|No|Not yet recruiting|June 2007|June 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|500|||Both|2 Years|8 Years|Accepts Healthy Volunteers|||May 2007|June 7, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484172||170610|
NCT00484185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090X1-4403|Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B|Post Marketing Surveillance To Observe Safety And Efficacy Of BeneFIX In Patients With Hemophilia B||Pfizer|No|Completed|August 2007|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|183|||Both|N/A|N/A|No|Non-Probability Sample|Hemophilia B (congenital factor IX deficiency or Christmas disease).|May 2013|May 15, 2013|June 7, 2007|No|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00484185||170609|
NCT00492492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I06029|Treatement of Extension Fractures of the Distal Radius|Treatement of Extension Fractures of the Distal Radius : Prospective Randomized Postoperative Comparison Between Trans-Styloid and Intrafical Pinning on the One Side and Volar Fixed-Angle Plating on the Other Side.|fradius|University Hospital, Limoges|Yes|Completed|May 2007|July 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|50 Years|N/A|No|||December 2008|December 29, 2008|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492492||169978|
NCT00462410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540528|Effect of Advertisements on Treatment Compliance in Women With Breast Cancer|Socio-anthropological Study Evaluating the Impact of Observance or Treatment in Patients With Breast Cancer||National Cancer Institute (NCI)||Completed|March 2006|||May 2011|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Health Services Research|||Anticipated|65|||Female|N/A|N/A|No|||May 2011|January 20, 2012|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462410||172245|
NCT00492739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VZVinOLTx|Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients|Induction and Maintenance of Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients: a Retrospective and Prospective Nationwide Study in Switzerland|VZVinOLTx|University Hospital, Geneva|Yes|Recruiting|June 2007|December 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|18 Years|No|||May 2015|May 26, 2015|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00492739||169959|
NCT00462150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR 99-1-401|Effects of Home-Based Emotional Disclosure in Rheumatoid Arthritis|Psychological, Physiological, and Clinical Consequences of Emotional Disclosure in Rheumatoid Arthritis (RA)||UMC Utrecht|No|Completed|September 2002|June 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||April 2007|April 16, 2007|April 16, 2007||||No||https://clinicaltrials.gov/show/NCT00462150||172263|
NCT00462397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540233|Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer|Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer||National Cancer Institute (NCI)||Recruiting|June 2005|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|N/A|No|||April 2007|August 23, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462397||172246|
NCT00493857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB 1000-015|Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer|A Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly Plus Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks Plus Irinotecan (Cohort 2) in Patients With Irinotecan-Refractory Metastatic Colorectal Cancer||YM BioSciences|Yes|Terminated|June 2007|December 2008|Anticipated|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2008|November 14, 2008|June 27, 2007||No|Cohort 2 not going forward. Manadate changes in Company|No||https://clinicaltrials.gov/show/NCT00493857||169874|
NCT00462943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGX-635-CML-203|Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML|A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy||Teva Pharmaceutical Industries|Yes|Completed|March 2007|September 2013|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|April 17, 2007|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00462943||172207|
NCT00463229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHE-78692|Interdisciplinary Team Approach to Stroke Rehabilitation in Home Care|The Comparative Acceptability, Safety, Effects and Expense of Specialized, Integrated, and Interdisciplinary Community Rehabilitation for Stroke Survivors and Their Caregivers||McMaster University|No|Completed|February 2006|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|N/A|N/A|No|||August 2010|September 28, 2010|April 18, 2007||No||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00463229||172185|
NCT00458926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6742|Enhancing Utilization of Non-Invasive Positive Pressure Ventilation in Critical Care|Enhancing Utilization of Non-Invasive Positive Pressure Ventilation in Critical Care||Tufts Medical Center|No|Active, not recruiting|November 2003|December 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years of age or older who require mechanical ventilation.|May 2012|May 30, 2012|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00458926||172502|
NCT00490243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/135/03/KE|Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma|A Randomized, Double-Blind Trial of the Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma||Medical Universtity of Lodz|Yes|Completed|July 2003|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|150|||Both|6 Years|18 Years|No|||June 2007|June 27, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490243||170147|
NCT00490256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002654|Modified Perfusion for Neonatal Aortic Arch Reconstruction|Evaluation of a Modified Perfusion Strategy for Neonatal Aortic Arch Reconstruction: Does Perfusing the Lower Body During Arch Repair Help?||Emory University|No|Completed|June 2007|June 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|N/A|1 Year|No|||May 2014|May 21, 2014|June 20, 2007||No||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00490256||170146|Early termination leading to small numbers for analysis
NCT00490490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0046|Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma|Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma||Stanford University|Yes|Terminated|January 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|19 Years|N/A|No|||June 2014|June 19, 2014|June 20, 2007||No|Low Accrual|No||https://clinicaltrials.gov/show/NCT00490490||170128|
NCT00490503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0501|Non-Invasive Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy Techniques (MRS) for Assessing Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer|Non-Invasive MRI and MRS Techniques for Assessing Therapeutic Response to Pre-surgical Chemotherapy in Breast Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2006|||October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|28|Samples Without DNA|The tissues removed during surgery (mastectomy) will be collected as part of this study.|Both|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to        start systemic chemotherapy.|April 2015|April 16, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00490503||170127|
NCT00490711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4720|Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer|Phase II Study of Sequential Therapy With Paclitaxel Plus Carboplatin Followed by Gemzar Plus Carboplatin in the Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages III-IV||Eli Lilly and Company|No|Completed|July 2003|April 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|75 Years|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490711||170111|
NCT00490724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013903|An Exploratory Study of Nesiritide in Participants With Acute Heart Failure|An Exploratory Study of JNS004 (Nesiritide) in Patients With Acute Heart Failure (J2)||Janssen Pharmaceutical K.K.|No|Completed|March 2007|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|67|||Both|20 Years|N/A|No|||December 2013|December 31, 2013|June 21, 2007|Yes|Yes||No|June 7, 2013|https://clinicaltrials.gov/show/NCT00490724||170110|
NCT00491036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|342|Intraaortic Balloon Pump in Cardiogenic Shock II|Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction|IABP-SHOCK II|University of Leipzig|Yes|Completed|June 2009|June 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|90 Years|No|||June 2013|June 17, 2013|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00491036||170086|
NCT00492531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070177|Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease|Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|June 2007|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|12 Years|70 Years|No|||December 2015|December 7, 2015|June 26, 2007|Yes|Yes|Subjects on drug were more likely to have severe pain crises requiring hospitalization.|No|April 28, 2011|https://clinicaltrials.gov/show/NCT00492531||169975|As a result of early termination due to safety findings, the study was underpowered to assess the effects of sildenafil therapy on the predetermined efficacy endpoints.
NCT00483600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001571|Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction|Studies of Fondaparinux in Patients With Renal Dysfunction: PK Study of Fondaparinux in Outpatients With Renal Dysfunction||Duke University|No|Withdrawn|August 2007|August 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||February 2011|July 25, 2014|June 5, 2007|||unable to enroll|No||https://clinicaltrials.gov/show/NCT00483600||170654|
NCT00483912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04005|Albumindialysis in Acute Pancreatitis|Molecular Adsorbent Recirculating System (MARS) in Severe Acute Pancreatitis|pancreatitis|University of Tampere|No|Suspended||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|18 Years|80 Years||||June 2007|June 7, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00483912||170630|
NCT00492518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC-Theo-1.3|Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy|Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy: A Placebo Controlled Randomized Study|ATHENS|Technische Universität München|Yes|Completed|February 2002|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|254|||Both|18 Years|N/A|No|||June 2007|June 26, 2007|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00492518||169976|
NCT00492778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0238|Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer|A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus||Gynecologic Oncology Group|Yes|Recruiting|February 2008|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Female|N/A|N/A|No|||February 2016|February 9, 2016|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492778||169956|
NCT00462423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070223|Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study|Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study|AbraxAvast|Northern California Melanoma Center|Yes|Completed|April 2007|January 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|April 18, 2007||No||No|July 6, 2013|https://clinicaltrials.gov/show/NCT00462423||172244|This was a single arm study. Follow-up trials to further explore this regimen are warranted.
NCT00462696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540537|MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer|Study Evaluating the Contribution of MRI for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Patients With Infiltrative Breast Cancer||National Cancer Institute (NCI)||Completed|February 2006|||May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Diagnostic|||Anticipated|30|||Female|18 Years|70 Years|No|||December 2008|May 12, 2011|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00462696||172224|
NCT00493012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Vitamin D Effects in Overweight Patients|Effects of a Vitamin D (Cholecalciferol) Supplement on Body Composition, Blood Pressure, and Lipid and Diabetes Parameters in Overweight Patients Attending a Telemedically Guided Weight Loss Program|SMART|Heart and Diabetes Center North-Rhine Westfalia|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2011|February 7, 2012|June 26, 2007||||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00493012||169938|
NCT00493519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-NV-219-CTIL|Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters|Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters|Cephalic 1|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|July 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|July 4, 2007|June 27, 2007||||No||https://clinicaltrials.gov/show/NCT00493519||169900|
NCT00493532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20882|A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.|An Open Label Study to Evaluate the Effect on Bone Mineral Density, and the Safety, of Quarterly Intravenous Bonviva in Patients With Post-menopausal Osteoporosis.||Hoffmann-La Roche||Completed|June 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|N/A|80 Years|No|||February 2016|February 1, 2016|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493532||169899|
NCT00458978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00148|Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer|Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients||National Cancer Institute (NCI)||Completed|February 2007|July 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2014|April 14, 2015|April 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00458978||172500|
NCT00459251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-304|Pharmacogenetics Study in Taiwan's Ethnic Groups|The Pharmacogenetics Study of Drug-Metabolising Enzyme Genetic Polymorphisms in Aboriginal and Minnan/Hakka Ethnic Groups in Taiwan||Mackay Memorial Hospital|No|Completed|December 2006|April 2007|Actual|||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||350|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2007|April 10, 2007|April 10, 2007||||No||https://clinicaltrials.gov/show/NCT00459251||172482|
NCT00494156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 00-508|Anticoagulation in Blunt Cerebrovascular Injuries|Anticoagulation in the Management of Grade I-III Blunt Cerebrovascular Injuries||Denver Health and Hospital Authority||Withdrawn|July 2003|July 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|June 25, 2007|||Study halted prematurely prior to enrollment of first participant.|No||https://clinicaltrials.gov/show/NCT00494156||169853|
NCT00463242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178A2303|A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)|An 8-week, Multicenter, Randomized, Double-blind, Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine 25 or 50 mg Given Once Daily in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week Open-label Treatment With Agomelatine 25 or 50 mg||Novartis||Completed|March 2007|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|501|||Both|18 Years|70 Years|No|||May 2012|May 2, 2012|April 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00463242||172184|
NCT00463255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ernaehrung-Neuromod 01|Diet and the Aging Brain|Phase IV Interventional Study: Effect of Diet on Brain Function in Elderly Healthy People||University Hospital Muenster|Yes|Completed|August 2006|October 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|120|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463255||172183|
NCT00458952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-IB12|Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma|A Phase I-II Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma||Molecular Insight Pharmaceuticals, Inc.|No|Active, not recruiting|April 2007|May 2013|Anticipated|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|April 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00458952||172501|
NCT00460343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOK/WINAp/CZ-03|Pharmacy Implementation Trial: Adherence to Antihypertensive Therapy|Implementation of a Pharmacy-Intervention to Establish and if Necessary Improve Adherence to Antihypertensive Therapy. A Cluster Randomized Trial.||Radboud University|No|Completed|April 2007|June 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|57|||Both|18 Years|N/A|No|||July 2008|July 9, 2008|April 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00460343||172399|
NCT00460642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 74,817|GnRH Antagonist to Prepare Recipients for Embryo Transfer|Use of GnRH Antagonist (Cetrotide) Protocol, Instead of Agonist, to Prepare Recipients for Embryo Transfer||Institute for Human Reproduction (IHR)|Yes|Completed|January 2007|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|130|||Female|20 Years|50 Years|No|||May 2010|May 24, 2010|April 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00460642||172376|
NCT00460655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX108512|Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity|A Multicenter Study to Evaluate the Efficacy and Safety in Patients With Post-Stroke Lower Limb Spasticity Receiving a Double-Blind, Placebo-Controlled GSK1358820 Treatment Followed by an Open-Label GSK1358820 Treatment||GlaxoSmithKline|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|20 Years|80 Years|No|||August 2010|August 30, 2010|April 13, 2007||No||No|September 2, 2009|https://clinicaltrials.gov/show/NCT00460655||172375|
NCT00460993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|057-2006|Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients|Efficacy and Safety of Eszopiclone (Lunesta) in Nursing Home Patients||Emory University|Yes|Completed|June 2005|December 2010|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|65 Years|N/A|No|||June 2014|June 16, 2014|April 16, 2007|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT00460993||172350|Low power to detect statistically significant effects of the interventions on outcomes; Inability to examine predictors of responsiveness because of the small sample size and the large number of predictors of response.
NCT00461279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165/2006|Attachment Security as Mediator and Moderator of Outcome in Major Depression|Attachment Security as Mediator and Moderator of Outcome in Major Depression Following Interpersonal Therapy and Cognitive Behavior Therapy||Centre for Addiction and Mental Health|No|Completed|August 2006|March 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|April 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00461279||172328|
NCT00461292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-516|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder|||Allergan||Completed|May 2007|April 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|275|||Both|18 Years|80 Years|No|||September 2015|September 17, 2015|April 13, 2007|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT00461292||172327|
NCT00483301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL0205|A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma|A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma||Mt. Sinai Medical Center, Miami|Yes|Completed|May 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 2, 2012|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00483301||170676|
NCT00492258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-RE05-SORCE|Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer|SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse||National Cancer Institute (NCI)||Completed|June 2007|December 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1656|||Both|18 Years|N/A|No|||April 2008|August 9, 2013|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00492258||169995|
NCT00493584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thorsted 1|Acute Balloon Angioplasty vs. Traditional Early Invasive Treatment of Non-ST-Elevation Myocardial Infarction|Acute Angioplasty (Primary PCI) Versus Traditional Early Invasive Treatment of Patients Presenting With NSTEMI (The Second Danish Non-ST-Elevation MI Trial - DaNSTEMI-2)|DaNSTEMI2|University of Aarhus|Yes|Terminated|March 2008|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|N/A|No|||May 2009|May 19, 2009|June 27, 2007||No|Due to insufficient patient inclusion the study has been stopped prematurely.|No||https://clinicaltrials.gov/show/NCT00493584||169895|
NCT00493597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 7/5/36|Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of in-Stent Restenosis|Blood Endothelium Progenitor Cells and Dendritic Cells as Novel Predictive Biomarkers of in-Stent Restenosis After Percutaneous Coronary Intervention.||University Hospital, Antwerp|No|Recruiting|October 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|90 Years|No|Non-Probability Sample|Non-diabetic patients scheduled for PCI with a single bare metal stent in a significant de        novo coronary lesion|October 2007|January 30, 2009|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493597||169894|
NCT00462709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVP2006-4|Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks|LEVP2006-4 CHANGE 3 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Use of C1INH-nf (Human) for the Prophylactic Treatment to Prevent HAE Attacks and as Treatment in Acute HAE Attacks|CHANGE 3|Shire||Completed|June 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|146|||Both|1 Year|N/A|No|||March 2014|March 19, 2014|April 17, 2007|Yes|Yes||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00462709||172223|
NCT00462722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0769|Myogenic and Osteogenic Responses to eXercise and Ibuprofen|COX Inhibition & Musculoskeletal Responses to Exercise|MOXI|University of Colorado, Denver|Yes|Completed|July 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|159|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|April 17, 2007||No||No|June 11, 2015|https://clinicaltrials.gov/show/NCT00462722||172222|The study did not include a no-exercise control group. The variability in the BMD responses was greater than expected.The results may be specific to ibuprofen and not to other NSAIDs.
NCT00462982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-009|Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma|A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain||Memorial Sloan Kettering Cancer Center||Completed|March 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|120 Years|No|||November 2015|November 24, 2015|April 18, 2007|Yes|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT00462982||172204|
NCT00462956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF100642|GW572016 In Patients With Advanced Or Metastatic Breast Cancer|Phase II Clinical Study of GW572016 in Patients With Advanced or Metastatic Breast Cancer||GlaxoSmithKline|No|Completed|June 2004|December 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Female|20 Years|40 Years|No|||April 2012|April 11, 2013|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00462956||172206|
NCT00462969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC06701|Cytologic Analysis of Distention Media as a Screening Test for Endometrial Cancer|Cytologic Analysis of Distention Media as a Screening Test for Endometrial Cancer||University of Wisconsin, Madison|Yes|Completed|April 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|40|||Female|18 Years|N/A|No|||January 2015|January 30, 2015|April 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00462969||172205|
NCT00463268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG/OP 001|Osteoporosis Prevention With Low Dose Alendronate|Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.||University Hospital of Mont-Godinne|No|Completed|September 2007|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|83|||Female|45 Years|60 Years|No|||May 2013|May 28, 2013|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463268||172182|
NCT00463281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23211204|CT Based Definition of a Tissue Window for Acute Stroke Thrombolysis|Observational Study of Multimodal CT in Acute Ischemic Stroke to Define a Tissue Window for Thrombolysis|CT-DEFINE|Technische Universität Dresden|No|Completed|January 2007|January 2009|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Ischemic stroke patients presenting within 12 hrs from symptom onset|January 2009|May 13, 2009|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463281||172181|
NCT00459264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q1604/110|Prevention of Mood Disorders by Folic Acid Supplementation|Prevention of Mood Disorders by Folic Acid Supplementation|PRE-EMPT|University of Oxford|Yes|Recruiting|December 2005|December 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|14 Years|24 Years|Accepts Healthy Volunteers|||June 2010|February 2, 2011|April 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00459264||172481|
NCT00459238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000538178|Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants|A Telephone-Based Education and Prevention Intervention for Teens and Young Adults||Georgetown University|No|Active, not recruiting|October 2006|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|April 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00459238||172483|
NCT00494429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU-10750|Optimizing the Use of Morphine in Pre-Term Neonates|Optimizing Pain Treatment in Pre-Term Neonates||Children's Research Institute|No|Completed|May 2005|November 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|22 Weeks|32 Weeks|No|||January 2016|January 11, 2016|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494429||169832|
NCT00459758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0922060043|Effect of Electrical Stimulation at Acupoints on Blood Pressure|Pilot Study Using Electrical Stimulation on Hypertension||Logan College of Chiropractic|Yes|Completed|January 2007|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|70 Years|No|||July 2007|July 31, 2007|April 10, 2007||||No||https://clinicaltrials.gov/show/NCT00459758||172444|
NCT00459771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06HER|Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity|Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab||The Netherlands Cancer Institute|Yes|Completed|June 2007|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Female|18 Years|79 Years|No|||December 2014|December 1, 2014|April 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00459771||172443|
NCT00473239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton2|The Pharmacokinetics of a Single Large Dose of Vitamin D3|The Pharmacokinetics of a Single Large Dose of Vitamin D3|Stoss|Creighton University|No|Completed|October 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 30, 2015|May 11, 2007||||No||https://clinicaltrials.gov/show/NCT00473239||171428|
NCT00473538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2004|Structured Exercise Training Program Versus Hypocaloric Hyperproteic Diet in Obese Anovulatory Infertile Patients With PCOS|Effects of Structured Exercise Program Versus Hypocaloric Hyperproteic Diet on the Reproductive Function in Obese Anovulatory Infertile Patients With Polycystic Ovary Syndrome: a 24-Week Prospective Study.||University Magna Graecia|No|Completed|January 2004|August 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|35 Years|No|||November 2007|November 13, 2007|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473538||171406|
NCT00474136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-PK-006|Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium|Open-Label, Randomized, Single Center Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses) Versus Oral Diclofenac Potassium in Healthy Adult Volunteers Following Single- and Multiple-Dose Administration||Javelin Pharmaceuticals|No|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 27, 2007|May 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00474136||171362|
NCT00474162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03374|The Clotting Effects of Pentastarch and Normal Saline in Obstetric Patients|Observational Pilot Study of the Effect of Intravenous Saline or Pentastarch on Coagulation in Women Having an Elective Cesarean Section||University of British Columbia|No|Completed|May 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|30|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2008|February 20, 2008|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00474162||171361|
NCT00447733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78i068|Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders|Effects of Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders|ROP|University of Oslo|Yes|Completed|March 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||March 2012|March 23, 2012|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00447733||173348|
NCT00448292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPX-CP-020|A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of PRX-00023 in Patients With Major Depressive Disorder.||Epix Pharmaceuticals, Inc.|No|Completed|March 2007|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|65 Years|No|||November 2007|November 9, 2007|March 13, 2007||||No||https://clinicaltrials.gov/show/NCT00448292||173305|
NCT00448331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-9-27|Facilitated Referral for Children Screening Positive for Mental Illness|Facilitated Referral for Children Screening Positive for Mental Illness in the Pediatric Emergency Department and Readiness to Seek Care|MI|Children's Hospital Medical Center, Cincinnati|No|Completed|June 2004|August 2007|Actual|||Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|551|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Emergency Department patients ages 6-18 who present without any history of mental health        issues.|October 2007|October 31, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00448331||173302|
NCT00448877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16618|Deployment of Functional Optical Brain Monitor [fNIR] in Clinical Anesthesia|Deployment of Functional Optical Brain Monitor [fNIR] in Clinical Anesthesia||Drexel University||Completed|December 2006|||July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|80 Years|No|||April 2008|April 6, 2009|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448877||173260|
NCT00449150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z033|Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)|Cetrorelix Pamoate Intermittent IM Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment||AEterna Zentaris|No|Terminated|March 2007|December 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|667|||Male|50 Years|N/A|No|||June 2011|June 6, 2011|March 15, 2007|Yes|Yes|Trial did not meet primary efficacy endpoint for double blind phase.|No|October 5, 2010|https://clinicaltrials.gov/show/NCT00449150||173239|
NCT00449969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-AnIt-07|Out-of-hospital Cardiopulmonary Resuscitation and AED Feedback|Quality of Out-of-hospital Cardiopulmonary Resuscitation (CPR) With Real Time Automated Feedback: a Prospective Randomized Study||University Hospital Muenster|No|Completed|April 2007|December 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|March 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00449969||173178|
NCT00474604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0588|Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants|MRI Evaluation of Breast Tumor Growth and Treatment Response||Vanderbilt-Ingram Cancer Center|No|Recruiting|March 2006|December 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Female|18 Years|N/A|No|||August 2015|August 25, 2015|May 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474604||171328|
NCT00475176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070143|S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C|Effects of S-Adenosyl Methionine (SAMe) on Viral and Cell Signaling Response to Combination Therapy for Chronic Hepatitis C||National Institutes of Health Clinical Center (CC)|No|Completed|May 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|May 17, 2007||No||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00475176||171284|
NCT00475189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60783|Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)|Prospective Comparison of Hormone Withdrawal Symptoms of a 24/4 Regimen With a 21/7 Regimen of OC||Scott and White Hospital & Clinic|No|Completed|June 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475189||171283|
NCT00474838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIIT-KMC-0701|Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy|The Effect of Intensive and Short-term Insulin Treatment on Long-term Pancreatic β-cell Function in Newly Diagnosed People With Type 2 Diabetes in Korea|KIIT|Kyunghee University Medical Center|Yes|Completed|April 2007|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|25 Years|70 Years|No|||September 2013|September 25, 2013|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00474838||171310|
NCT00475670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO17299|A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer|An Open-label Study of the Effect of First-line Herceptin Alone or in Combination With a Taxane on Tumor Response and Disease Progression in Patients With Metastatic Breast Cancer Who Relapsed After Receiving Adjuvant Herceptin for HER2-positive Early Breast Cancer||Hoffmann-La Roche||Completed|October 2005|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|N/A|No|||September 2014|September 9, 2014|May 17, 2007||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00475670||171246|Cohort A (trastuzumab monotherapy) was closed prematurely due to enrollment difficulties. Therefore, Cohort A included only 3 participants.
NCT00475943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070156|Movement of Epiglottis During Swallowing|Biomechanics of Human Epiglottal Movement and Inversion||National Institutes of Health Clinical Center (CC)||Completed|May 2007|||September 2009|Actual|N/A|Observational|Time Perspective: Prospective||||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 2, 2009|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00475943||171225|
NCT00476203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS - 6434|Yoga Study in Breast Cancer Patients|Effect of Yoga on Weight and Fatigue in Breast Cancer Patients Study|Yoga|Fred Hutchinson Cancer Research Center|No|Completed|May 2007|May 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|63|||Female|21 Years|75 Years|No|||November 2012|November 27, 2012|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00476203||171206|
NCT00476450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070153|Effects of Stem Cell Transplantation on Bacteria in the Mouth|Effects of Peripheral Blood Stem Cell Transplantation on the Microbial Flora of the Oral Cavity||National Institutes of Health Clinical Center (CC)||Completed|May 2007|March 2016||||N/A|Observational|Time Perspective: Prospective|||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00476450||171187|
NCT00473018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH061180|Behavioral, Clinical and Basic Science Studies of Non-occupational Post-exposure Prophylaxis ("PEP-2")||PEP-2|University of California, San Francisco|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|||||||Both|14 Years|N/A|Accepts Healthy Volunteers|||May 2007|June 1, 2015|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00473018||171444|
NCT00473252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE003|Surveillance of Fungal Infections During Construction Activity|||University Hospital Inselspital, Berne|No|Completed|May 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|340|||Both|16 Years|N/A|No|Probability Sample|Prevalent hemodialysis patients and incident renal transplant recipients in the Department        of Nephrology and Hypertension, University Hospital Bern, Switzerland|May 2011|May 19, 2011|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473252||171427|
NCT00473551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0682|Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies|Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Treatment of Indolent Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Terminated|May 2007|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|70 Years|No|||December 2011|December 16, 2011|May 11, 2007|Yes|Yes|Terminated due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00473551||171405|
NCT00474396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1094|Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules|Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules|dietUAT|Icahn School of Medicine at Mount Sinai|Yes|Completed|April 2005|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Actual|59|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2007|May 15, 2007|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00474396||171343|
NCT00474409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRS-CHN-001|A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation|A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation||Eisai Inc.||Terminated|May 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|360|||Both|18 Years|80 Years|No|||December 2008|December 5, 2008|May 3, 2007||No|Due to poor enrollment, this study was terminated.|No||https://clinicaltrials.gov/show/NCT00474409||171342|
NCT00474422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-0723|Hospital-Based Paraprofessional Lactation Clinic|Hospital-Based Paraprofessional Lactation Clinic||Baylor College of Medicine|No|Completed|December 2003|February 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|522|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2007|May 14, 2007|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00474422||171341|
NCT00474175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZ-03-07|Benzocaine Gel Toothache Dose-Response Study|Benzocaine Gel Toothache Dose-Response Study||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|577|||Both|12 Years|N/A|No|||February 2013|February 22, 2013|May 14, 2007|Yes|Yes||No|December 9, 2011|https://clinicaltrials.gov/show/NCT00474175||171360|
NCT00474929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS0689|Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma|A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|August 2007|||November 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|May 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474929||171303|
NCT00474942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 04-0474|Natural History of Apparent Mineralocorticoid Excess Syndrome|Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol||Icahn School of Medicine at Mount Sinai|Yes|Completed|April 2007|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|Samples With DNA|Peripheral blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with apparent mineralocorticoid excess plus their family members|December 2015|December 10, 2015|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00474942||171302|
NCT00474682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR04/2006|Relative Bioavailability of Ferric Pyrophosphate From an Apple Juice Drink|Relative Bioavailability of Ferric Pyrophosphate From an Apple Juice Drink||Institute of Food Research|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Basic Science|||Anticipated|16|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|December 2, 2008|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00474682||171322|
NCT00474695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21441|Study Evaluating Genotypes Using Lucentis|VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis|SEAGUL|University of Utah|No|Terminated|May 2007|December 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|65|||Both|50 Years|N/A|No|Probability Sample|Moran Eye Center Clinic|February 2015|February 10, 2015|May 15, 2007|No|Yes|IND holder relocated from the University of Utah|No||https://clinicaltrials.gov/show/NCT00474695||171321|
NCT00448357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0510|Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases|Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen|LCCC 0510|UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|October 2005|August 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|No|||November 2015|November 23, 2015|March 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00448357||173300|
NCT00448019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDACC-2005-0992|FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)|Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|February 2007|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|N/A|N/A|No|||October 2015|October 5, 2015|March 13, 2007||No||No|July 13, 2015|https://clinicaltrials.gov/show/NCT00448019||173326|
NCT00448318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WKG_07_BB|Evaluating the Effects of Music Interventions on Hospitalised People With Dementia|Evaluating the Effects of Music Interventions on Hospitalised People With Dementia||National Ageing Research Institute, Australia|No|Not yet recruiting|March 2007|October 2008||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||180|||Both|60 Years|N/A|No|||February 2007|March 14, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00448318||173303|
NCT00449683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06F.275|Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin|Antidepressant Induced Excessive Sweating: Measurement and Treatment With Terazosin|ADIES|Thomas Jefferson University|No|Completed|March 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449683||173200|
NCT00449982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 1018|Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts|A Randomized, Double-Blind, Three-Arm Parallel-Group, Placebo-Controlled Phase 3 Trial to Investigate the Clinical Efficacy and Safety of Polyphenon E in the Treatment of External Genital Warts||MediGene|No|Completed|July 2003|August 2004||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|18 Years|N/A|No|||March 2007|March 20, 2007|March 20, 2007||||No||https://clinicaltrials.gov/show/NCT00449982||173177|
NCT00475475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28740-A|Sweetened Beverages and Food Intake|Sweetened Beverages and Food Intake||University of Washington|No|Completed|May 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|10|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2012|April 30, 2012|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475475||171261|
NCT00475709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0501|Aortic Valve Replacement With Trifecta(TM)|An Observational, Prospective Evaluation of the Trifecta Valve||St. Jude Medical|Yes|Completed|June 2007|January 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1022|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|May 16, 2007|No|Yes||No|September 19, 2012|https://clinicaltrials.gov/show/NCT00475709||171243|The SAEs reported are based on the Edmunds criteria noted in Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller CM, Weisel RD. Guidelines for reporting Morbidity and Mortality after Cardiac Valvular Operations. Ann Thorac Surg 1996;62:932-5.
NCT00475956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00014|Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours|Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours||AstraZeneca||Completed|May 2007|October 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2010|April 14, 2010|May 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00475956||171224|
NCT00475449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC/98/2/123|The Stent or Surgery (SoS) Trial|A Randomised Controlled Trial to Compare Coronary Artery Bypass Grafting With Percutaneous Transluminal Coronary Angioplasty and Primary Stent Implantation in Patients With Multi-Vessel Coronary Artery Disease||Royal Brompton & Harefield NHS Foundation Trust|Yes|Completed|November 1996|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|988|||Both|N/A|N/A|No|||May 2007|May 17, 2007|May 17, 2007||||No||https://clinicaltrials.gov/show/NCT00475449||171263|
NCT00475683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curcumin-HMO-CTIL|Curcumin for Prevention of Oral Mucositis in Children Chemotherapy|Randomized Cross-over Study of Curcumin for Prevention of Oral Mucositis in Children Receiving Doxorubicin Based Chemotherapy.||Hadassah Medical Organization|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|5 Years|30 Years|No|||June 2011|August 17, 2015|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475683||171245|
NCT00475696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6984|Urge Incontinence Bladder Overactivity Study|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Bladder Overactivity||Eli Lilly and Company||Completed|November 2002|March 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 16, 2007|May 16, 2007||||||https://clinicaltrials.gov/show/NCT00475696||171244|
NCT00472212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001H0401|Correction of Farsightedness in Children Study|Correction of Hyperopia in Children Study|CHICS|Ohio State University|No|Completed|November 2003|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00472212||171504|
NCT00472719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 072|Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults|A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Serotype 35 (rAd35) and Serotype 5 (rAd5) HIV-1 Vaccines When Given in Heterologous Prime-Boost Regimens or as a Boost to a Recombinant DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants With Pre-Existing Immunity to Adenovirus Serotype 5 Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2007|January 2013|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|May 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00472719||171466|
NCT00473265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5457|Bone Properties in Hypoparathyroidism: Effects of PTH|Bone Properties in Hypoparathyroidism: Effects of PTH||Columbia University|No|Completed|May 2004|June 2014|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|May 14, 2007|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00473265||171426|Only 16 subjects received a bone biopsy, which is why many of the measurements were only analyzed in 16 subjects. In total, data was only analyzed for the first 30 subjects analyzed for data.
NCT00473863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00742|Coronary Computed Tomographic Angiography in Emergency Department Chest Pain Patients at Intermediate Risk of Acute Coronary Syndrome|Coronary Computed Tomographic Angiography in Emergency Department Chest Pain Patients at Intermediate Risk of Acute Coronary Syndrome|CCTA|Vancouver General Hospital|No|Recruiting|November 2007|July 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|19 Years|N/A|No|||November 2007|November 19, 2007|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00473863||171383|
NCT00474201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070149|Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil|The Influence of Lopinavir/Ritonavir on Gemfibrozil Pharmacokinetics in Healthy Volunteers|GEM-PK|National Institutes of Health Clinical Center (CC)|No|Completed|May 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|May 15, 2007||No||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00474201||171358|
NCT00474214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-387|Safety And Feasibility of Early DischargE - a Prospective And Randomized Trial of Low-risk Primary Percutaneous Coronary Intervention (PCI) Patients|Safety And Feasibility of Early DischargE - a Prospective And Randomized Trial of Low-risk Primary PCI Patients (The SAFE-DEPART Trial)|SAFE-DEPART|McMaster University|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|54|||Both|N/A|N/A|No|||February 2010|February 22, 2010|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474214||171357|
NCT00474708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B2-4418|Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients|The Efficacy of Venlafaxine XR (Efexor XR®) Versus SSRIs & Conventional Antidepressants in Depressed Patients Switched From Prior Antidepressants in Psychiatric Outpatient Care Settings in China||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|April 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1151|||Both|18 Years|65 Years|No|||March 2012|March 2, 2012|May 10, 2007||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00474708||171320|365 participants were assessed for safety. Certain demographic data (gender and age) is missing for one participant. Thereby resulting in the participant flow reflecting 364 participants.
NCT00474981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6-181-505|Impact of the Integrated Management of Neonatal and Childhood Illness Strategy on Neonatal and Infant Mortality|Impact of the Integrated Management of Neonatal and Childhood Illness Strategy on Neonatal and Infant Mortality in Haryana, India|IMNCI-India|Society for Applied Studies|No|Completed|June 2006|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|66600|||Both|N/A|12 Months|Accepts Healthy Volunteers|||April 2012|April 2, 2012|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00474981||171299|
NCT00474994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-054|Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas|A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas||Memorial Sloan Kettering Cancer Center||Completed|April 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|120 Years|No|||December 2015|December 15, 2015|May 16, 2007|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00474994||171298|
NCT00448890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM1107296|Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers|Single-Blind, Randomised, Placebo-Controlled Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Escalating Doses and Repeat Doses of GSK729327 in Healthy Volunteers||GlaxoSmithKline||Completed|November 2006|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|March 15, 2007||||No||https://clinicaltrials.gov/show/NCT00448890||173259|
NCT00448903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-BEM-2006-01|Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers|Multicentric, Randomized, Double-blind, Controlled Clinical Trial to Assess the Efficacy and Safety of Bemiparin Sodium as Treatment of Diabetic Foot Ulcers||Rovi Pharmaceuticals Laboratories|Yes|Completed|March 2007|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|329|||Both|18 Years|N/A|No|||May 2010|March 16, 2011|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448903||173258|
NCT00448604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-257|Viral Infections in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Impact of Viral Infections in Patients With Chronic Obstructive Pulmonary Diseases: Virological Work-up During Exacerbations and 1-year Follow-up|VICE|University Hospital, Geneva|No|Completed|May 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|86|Samples Without DNA|Naso-pharyngeal swaps|Both|18 Years|N/A|No|Non-Probability Sample|Patients with COPD admitted with acute exacerbation|February 2009|November 3, 2010|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00448604||173281|
NCT00449436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101957|Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults|A Randomized, Open Label Study to Compare the Safety and Efficacy of a Long Term Maintenance With TRIZIVIR After a Switch From a Boosted PI or a NNRTI as First Line Therapy for 96 Weeks.||GlaxoSmithKline||Completed|October 2004|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|152|||Both|18 Years|N/A|No|||February 2008|February 26, 2008|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449436||173218|
NCT00449449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISI-03-1|A Phase II Clinical Study of Lidocain Pertubation as Treatment for Couples With Unexplained Infertility|A Randomised, Open, Controlled, Parallel Group, Multi-Centre Phase II Clinical Study of Lidocain Pertubation as Treatment for Couples With Unexplained Infertility||Isifer AB|Yes|Completed|September 2003|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||330|||Female|20 Years|40 Years|No|||March 2007|March 19, 2007|March 17, 2007||||No||https://clinicaltrials.gov/show/NCT00449449||173217|
NCT00475722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00007622|Healthy Eating for Colon Cancer Prevention|A Mediterranean Diet in Colon Cancer Prevention||University of Michigan|Yes|Completed|May 2007|December 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|May 17, 2007||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT00475722||171242|
NCT00475982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-012-06F|Effect of Weight Loss on Prostate Cancer Pathology|Effect of Weight Loss on Prostate Cancer Pathology||VA Office of Research and Development||Completed|January 2009|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|44|||Male|N/A|N/A|No|||March 2016|March 22, 2016|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475982||171222|
NCT00475462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA720A10|The Effectiveness of Metoprolol in the Prevention of Syncope Recurrence in Children and Adolescents|||Peking University First Hospital|Yes|Completed|July 2001|December 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|6 Years|18 Years|No|||May 2007|May 18, 2007|May 17, 2007||||No||https://clinicaltrials.gov/show/NCT00475462||171262|
NCT00475969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6089|Duloxetine vs Placebo in the Treatment of General Anxiety|Duloxetine Hydrochloride Once Daily Compared With Placebo in the Treatment of Generalized Anxiety Disorder||Eli Lilly and Company|No|Completed|August 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||327|||Both|18 Years|N/A|No|||May 2007|May 17, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475969||171223|
NCT00476229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0892|Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies|Total Lymphoid Irradiation, Thymoglobulin, and Rituximab for Allogeneic Transplantation in Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|June 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|70 Years|No|||August 2012|August 1, 2012|May 17, 2007||No||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00476229||171204|Early termination due to financial support.
NCT00476255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0080-06|Evaluating Models for Dissemination of Injury Prevention Information in the Pediatric Emergency Department Setting|Evaluating Models for Dissemination of Injury Prevention Information in the PED||Rhode Island Hospital|Yes|Withdrawn|December 2011|||November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|November 5, 2014|May 18, 2007||No|Unfunded|No||https://clinicaltrials.gov/show/NCT00476255||171202|
NCT00472225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSCT-01-2007|Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease|Open-Labelled, Multicenter Phase II Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease||The Korean Society of Hematopoietic Stem Cell Transplantation|Yes|Active, not recruiting|May 2007|May 2009|Anticipated|May 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|3 Years|74 Years|No|||February 2009|February 20, 2009|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472225||171503|
NCT00472238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBF-2007001|Effects of Endurance Training on Patients With Reduced Left Ventricular Ejection Fraction (LVEF) and Cardiac Resynchronisation Therapy Especially for Cardiac Arrhythmias|Effects of Endurance Training on Patients With Reduced LVEF and Cardiac Resynchronisation Therapy Especially for Cardiac Arrhythmias||Charite University, Berlin, Germany|Yes|Recruiting|August 2007|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||May 2007|November 19, 2008|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472238||171502|
NCT00472459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC T313/03|PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer|A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer||Galderma|No|Completed|July 2003|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|81|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472459||171486|
NCT00472693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02106|Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer|A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer||University of Pennsylvania|Yes|Completed|May 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||January 2012|January 31, 2013|May 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00472693||171468|
NCT00472706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-16107|Trial of Excision Versus Photodynamic Therapy in the Treatment of Bowen's Disease|A Randomized Clinical Trial of Excision Versus Photodynamic Therapy in Bowen's Disease||Catharina Ziekenhuis Eindhoven|Yes|Terminated|May 2007|February 2010|Actual|February 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||May 2010|May 12, 2010|May 10, 2007|Yes|Yes|Study stopped because of disappointing inclusion rates|No||https://clinicaltrials.gov/show/NCT00472706||171467|
NCT00473005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSMTS0010|Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast|A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer||Stanford University|Yes|Terminated|August 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||May 2012|May 24, 2012|May 11, 2007|No|Yes|Principal Investigator (Dr. Guardino) left Stanford|No||https://clinicaltrials.gov/show/NCT00473005||171445|
NCT00472732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5104|Neurologic Injuries in Adults With Urea Cycle Disorders|Assessing Neural Mechanisms of Injury in Inborn Errors of Urea Metabolism Using Structural MRI, Functional MRI, and Magnetic Resonance Spectroscopy||Children's Research Institute|Yes|Completed|March 2007|July 2010|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|46|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset        presentation of OTCD|May 2015|May 28, 2015|May 11, 2007||No||No|April 22, 2015|https://clinicaltrials.gov/show/NCT00472732||171465|This study examined the neurobiological differences between OTCD patients and controls. This was, however, not a clinical trial, since participants received no form of drug therapy or treatment as part of this study.
NCT00474188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-NHL-005|A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid ®) in Combination With Dexamethasone in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma||Celgene|Yes|Terminated|May 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||August 2009|August 27, 2009|May 14, 2007|Yes|Yes|Business decision|No|June 30, 2009|https://clinicaltrials.gov/show/NCT00474188||171359|Study terminated prematurely as a business decision. Analyses of efficacy not conducted.
NCT00474747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0513|Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia|Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From HLA-Compatible Unrelated Donors in Severe Aplastic Anemia||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2006|||February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|N/A|65 Years|No|||January 2016|January 6, 2016|May 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474747||171317|
NCT00474760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021010|Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors|Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors||Pfizer|No|Completed|August 2005|October 2012|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|9 Years|N/A|No|||October 2013|October 25, 2013|May 16, 2007|No|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00474760||171316|The study was completed and 2 participants in figitumumab 20 mg/kg RP2D ESFT group were transitioned to compassionate figitumumab treatment as investigators judged they were receiving benefit from the protocol therapy.
NCT00474721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCHSD10926|Comparison of Acetaminophen With Codeine and Ibuprofen for Children With Injuries|A Randomized Blinded Comparison of Acetaminophen With Codeine and Ibuprofen for Treatment of Acute Pain in Children With Extremity Injuries||University of California, San Diego|Yes|Completed|November 2002|February 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|68|||Both|5 Years|18 Years|No|||May 2007|May 16, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00474721||171319|
NCT00475007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-01377|Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema|A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema|IBV®Valve|Spiration, Inc.|Yes|Active, not recruiting|September 2007|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|74 Years|No|||February 2013|February 26, 2013|May 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00475007||171297|
NCT00475800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2360E1|Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)|A 39-week, Open-label Extension to CCOX189A2360, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator||Novartis||Completed|January 2004|||December 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|833|||Both|18 Years|N/A||||May 2012|May 18, 2012|May 18, 2007||||No||https://clinicaltrials.gov/show/NCT00475800||171236|
NCT00449384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F06002|SIB-Norwegian Version, Validation and Reliability Study|Severe Impairment Study - Norwegian Version. A Validation and Reliability Study.||Sykehuset Innlandet HF|No|Completed|February 2007|May 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|59|||Both|N/A|N/A|No|||July 2007|July 2, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449384||173222|
NCT00449397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-SEA-0003|Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis|A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years.||AstraZeneca|No|Completed|July 2003|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|15 Years|25 Years|No|||January 2011|January 25, 2011|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449397||173221|
NCT00449735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030003|Quinolone Resistance in Bloodstream Isolates of Escherichia Coli|Quinolone Resistance in Bloodstream Isolates of Escherichia Coli||University of Pittsburgh|Yes|Recruiting|March 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|E coli positive cultures|December 2015|December 16, 2015|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00449735||173196|
NCT00449748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0759|Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis|Evaluation of RAD001 as Therapy for Patients With Systemic Mastocytosis||M.D. Anderson Cancer Center|Yes|Completed|April 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|March 19, 2007|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00449748||173195|
NCT00449163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20060042|Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer|Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer||University of Miami Sylvester Comprehensive Cancer Center|Yes|Terminated|March 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 15, 2007|Yes|Yes|Study terminated by University of Miami Institutional Review Board|No|January 23, 2013|https://clinicaltrials.gov/show/NCT00449163||173238|A total of 25 subjects were enrolled however; data were analyzed for 22 subjects only. Study was terminated early by the University of Miami Institutional Review Board.
NCT00449410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPACE1|Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients|Silent Cerebrovascular Lesion and Cognitive Decline Prevention in Atrial Fibrillation by Intensive Cholesterol Lowering in Elderly Patients|SPACE|Radboud University|No|Completed|May 2005|October 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||35|||Both|68 Years|82 Years|No|||March 2007|March 19, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449410||173220|
NCT00475735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0249-018|A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Incomplete Block, Two-period, Crossover Clinical Trial to Study the Safety and Efficacy of MK0249, 10 mg, for Adult Patients, Ages 18 to 55, With Attention Deficit Hyperactivity Disorder (ADHD)||Merck Sharp & Dohme Corp.||Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|55 Years|No|||July 2015|July 21, 2015|May 17, 2007|Yes|Yes||No|October 13, 2010|https://clinicaltrials.gov/show/NCT00475735||171241|
NCT00476216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070309006|Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer|Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer||University of Alabama at Birmingham|Yes|Completed|September 2007|December 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|79 Years|No|||March 2014|March 3, 2014|May 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00476216||171205|
NCT00476268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM/PR/033011/003/03|Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma|A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma||Chiesi Farmaceutici S.p.A.|No|Completed|February 2004|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|824|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476268||171201|
NCT00472784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-6079|Quantitative and Qualitative Changes in Neural Efferent Receptors|Quantitative and Qualitative Changes in Neural Efferent Receptors, Collagen and Smooth Muscle Content in the Bladder, Following Spinal Cord Injury (SCI) in Humans||Baylor College of Medicine|Yes|Withdrawn|October 1998|December 2010|Anticipated|December 2010|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Male|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Spinal cord injury Bladder dysfunction|April 2011|April 1, 2011|May 11, 2007||No|Study no longer being conducted.|No||https://clinicaltrials.gov/show/NCT00472784||171461|
NCT00472498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206-2000|Comparison on the Efficacy of a Monophasic|Comparison on the Efficacy of a Monophasic, Manually Operated Defibrillator to That of a Biphasic Automatic External Defibrillator in the Hospital Setting.|AED|Emory University|No|Terminated|June 2005|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|95|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who are hospitalized at the Atlanta VAMC hospital.|September 2013|September 26, 2013|April 16, 2007||No|Terminated: No longer recruiting.|No||https://clinicaltrials.gov/show/NCT00472498||171483|
NCT00472511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001H0269|Study of Eyes and Attention Deficit (SEAD)|||Ohio State University||Completed||||||N/A|Observational|Time Perspective: Prospective||||75|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||July 2008|July 1, 2008|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00472511||171482|
NCT00472472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACCOCATH - FEM I|Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries|Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries (PACCOCATH - FEM I)|PACCOCATH_F|University Hospital, Saarland|Yes|Completed|April 2004|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|95 Years|No|||May 2007|June 29, 2010|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472472||171485|
NCT00472485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00H0185|Study of Eye Movement Testing and Therapy|||Ohio State University||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||July 2008|July 1, 2008|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00472485||171484|
NCT00473031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0079|The Effect of Weight Loss and Dietary Protein Intake on Bone|Nutritional Regulation of Bone - Aim 1||Rutgers University|Yes|Completed|March 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00473031||171443|
NCT00473603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-05|Effect of Free Fatty Acids (FFA) on Androgen Precursors in Women|Effect of Free Fatty Acids on Androgen Precursors in Vivo in Healthy Young Women||Charite University, Berlin, Germany|No|Completed|December 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||May 2007|July 23, 2008|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473603||171401|
NCT00474227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH33/2007.CTIL|Proper Nutrition, Physical Exercise and Appropriate Weight in Individuals With Long Term Mental Illness|Proper Nutrition, Physical Exercise and Appropriate Weight in Individuals With Long Term Mental Illness||Lev-Hasharon Mental Healtlh Center|Yes|Completed|April 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|70 Years|No|||May 2008|May 1, 2008|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474227||171356|
NCT00474474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-02-001|Study of the Impact of Virtual Patient Designs on the Reasoning Pattern and Therapeutic Decision Making|Study of the Impact of How the Virtual Patient's Anamnesis is Designed on the Reasoning Pattern and Therapeutic Decision Making|VPtdl-rct1|Karolinska Institutet|No|Completed|February 2007|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|1||Actual|58|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2007|May 16, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00474474||171337|
NCT00474435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 04.03|Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis|The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania|PETE|African Poverty Related Infection Oriented Research Initiative|Yes|Recruiting|November 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2008|December 16, 2010|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00474435||171340|
NCT00474448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00457|The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses|The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses||University of British Columbia|No|Completed|May 2007|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients or parents of child patients in British Columbia.|July 2015|July 30, 2015|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474448||171339|
NCT00475306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01-005|The Montefiore Metoclopramide Study|A Randomized, Facorial Design Study to Optimize the Dose of Parenteral Metoclopramide||Montefiore Medical Center|No|Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|289|||Both|21 Years|65 Years|No|||November 2012|November 28, 2012|May 16, 2007|Yes|Yes||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00475306||171274|
NCT00475813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3502|Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma|||Mundipharma Research Limited|No|Completed|March 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|211|||Both|4 Years|12 Years|No|||March 2016|March 15, 2016|May 18, 2007||||No||https://clinicaltrials.gov/show/NCT00475813||171235|
NCT00475826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1067/06|Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe|Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe||University of Sao Paulo|Yes|Recruiting|April 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind|2||||||Both|18 Years|70 Years|No|||May 2007|March 20, 2008|May 18, 2007||||No||https://clinicaltrials.gov/show/NCT00475826||171234|
NCT00448370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC 06-09-57|Role of Placenta Growth Factor in Sickle Acute Chest Syndrome|Role of Placenta Growth Factor in Sickle Acute Chest Syndrome||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|March 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|175|||Both|66 Months|30 Years|No|Non-Probability Sample|Participants will have sickle cell disease (HbSS, HbSC, or Hb Sbeta-thalassemia) and will        be equal to or greater than 5.5 years old.|January 2016|January 26, 2016|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00448370||173299|
NCT00448383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-497|A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis|An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis|ReAct|Abbott||Completed|September 2002|||November 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6610|||Both|18 Years|N/A|No|||July 2008|July 31, 2008|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00448383||173298|
NCT00448630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281160|An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics|A Multi-Center, Non-Interventional, Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics|MESSAGE|Pfizer|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|328|Samples With DNA|Whole blood (fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol,      triglyceride levels)|Both|18 Years|45 Years|No|Non-Probability Sample|Female and male patients diagnosed as schizophrenia by DSM-IV (Diagnostic and Statistical        Manual of Mental Disorders, Fourth Edition) criteria; Age between 18-45 years; Patients        who started atypical antipsychotic drug treatment or patients who switched from the        previous conventional or atypical antipsychotic treatment to another atypical        antipsychotic drug treatment by the decision of their physicians in psychiatry clinics in        state and university hospitals.|June 2010|June 4, 2010|March 16, 2007||No||No|July 27, 2009|https://clinicaltrials.gov/show/NCT00448630||173279|
NCT00448916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081075|Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures|A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures||Pfizer|No|Completed|May 2007|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|1 Month|16 Years|No|||November 2014|November 24, 2014|March 15, 2007|Yes|Yes||No|October 6, 2014|https://clinicaltrials.gov/show/NCT00448916||173257|
NCT00450034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060247|Optimization of Drug Treatment in Hospitalized Elderly (OMAGE)|Impact of Optimization of Drug Treatment of Elderly Admitted in 4 Acute Geriatric Wards : Randomized Trial|OMAGE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|665|||Both|70 Years|N/A|No|||March 2007|November 30, 2011|March 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00450034||173173|
NCT00475215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05932|Evaluation of Safety and Efficacy of Org 25969 in Subjects With or Having a Past History of Pulmonary Disease (19.4.308)(P05932)(COMPLETED)|A Multicenter, Randomized, Parallel Group, Comparative, Safety-Assessor Blinded, Phase IIIa Trial in Adult Surgical Subjects Under General Anesthesia at Increased Risk for Pulmonary Complications||Merck Sharp & Dohme Corp.|No|Completed|October 2005|September 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00475215||171281|
NCT00475488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2006/02690|Radial Artery Graft Patency Study|The Department of Cardiac Surgery at Austin Health is Conducting a Prospective Randomised Trial, Comparing the Performance of the Radial Artery With the Currently Used Grafts in Patients Requiring Coronary Artery Bypass Grafts.|RAS|Austin Health|Yes|Active, not recruiting|June 1996|March 2015|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|619|||Both|36 Years|83 Years|No|||May 2007|May 17, 2007|May 17, 2007||||No||https://clinicaltrials.gov/show/NCT00475488||171260|
NCT00476034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2361E1|Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)|A 39-week, Double-blind, Active-controlled Extension to CCOX189A2361, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator||Novartis||Completed|December 2003|||November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1312|||Both|18 Years|N/A||||May 2012|May 18, 2012|May 18, 2007||||No||https://clinicaltrials.gov/show/NCT00476034||171219|
NCT00476242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5936R R01 DA015822-01|Memantine as a Supplement to Naltrexone in Treating Heroin Dependence|Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence|NAMHS|New York State Psychiatric Institute|No|Completed|June 2008|August 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|60 Years|No|||April 2014|June 4, 2014|May 17, 2007|Yes|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00476242||171203|
NCT00473044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0085|An Intervention to Increase Physical Activity Among African American Women|An Intervention to Increase Physical Activity Among African American Women||National Institute on Aging (NIA)|No|Completed|April 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|104|||Female|60 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 29, 2008|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00473044||171442|
NCT00473278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1067|Analysis of Human Tear Proteins in Children|Analysis of Human Tear Proteins in Children: A Pilot Study to Describe the Tear Film Proteome of Pediatric Patients Undergoing Ophthalmic Examination.||University of Colorado, Denver|No|Completed|January 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|children less than 18 years of age|January 2013|January 29, 2013|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00473278||171425|
NCT00473291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB029|Vibration Response Imaging (VRI) in Management and Evaluation in Patients With Pleural Effusion|Vibration Response Imaging (VRI) in Management and Evaluation in Patients With Pleural Effusion||Deep Breeze|No|Completed|November 2006|December 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients diagnosed with pleural effusion|June 2009|June 15, 2009|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473291||171424|
NCT00472745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0084|The Effect of Weight Loss on Bone in Men|Nutritional Regulation of Bone - Pilot Study||Rutgers University|Yes|Completed|March 2007|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Male|50 Years|72 Years|Accepts Healthy Volunteers|||December 2012|July 12, 2014|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472745||171464|
NCT00473850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H98-70441|Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC|Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC||University of British Columbia||Terminated|December 1998|March 2023|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Benetic profile of families in British Columbia with HME.|April 2011|April 13, 2011|May 14, 2007||No|This study is recruiting under a different title - "Genotype-Phenotype Correlation of Multiple    Hereditary Exostoses: Multicentre Project" NCT00474331|No||https://clinicaltrials.gov/show/NCT00473850||171384|
NCT00474461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOIC070833|Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)|Myocardial Regeneration Using Cardiac Stem Cells Harvested From Right Atrial Appendages in Patients With Ischemic Cardiomyopathy.|SCIPIO|University of Louisville|Yes|Completed|February 2009|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|75 Years|No|||October 2014|October 15, 2014|May 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00474461||171338|
NCT00474734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-063|Intravascular Ultrasound for Hepatocellular Carcinoma Staging|Intravascular Ultrasound for the Staging of Hepatocellular Carcinoma: a Pilot Study||University Hospital, Geneva|Yes|Recruiting|May 2007|September 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|18 Years|65 Years|No|||May 2007|May 16, 2007|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474734||171318|
NCT00474786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-404|Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib|A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy|INTORSECT|Pfizer|Yes|Completed|September 2007|January 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|512|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|May 15, 2007|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00474786||171314|
NCT00475020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0726|Allogeneic Stem Cell Transplantation for Myelofibrosis|Allogeneic Stem Cell Transplantation for Myelofibrosis Using Reduced Intensity Busulfan and Fludarabine Conditioning||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2006|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|N/A|75 Years|No|||September 2015|September 8, 2015|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00475020||171296|
NCT00475033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3008|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|603|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||April 2011|April 18, 2011|May 15, 2007|Yes|Yes||No|May 4, 2010|https://clinicaltrials.gov/show/NCT00475033||171295|
NCT00475046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EB0120-TP3|Smoking Cessation and Relapse Prevention in Women Postpartum|Smoking Cessation and Relapse Prevention in Women Postpartum|EARLINT-EP3|University Medicine Greifswald|No|Completed|October 2001|May 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2790|||Female|1 Year|N/A|No|||May 2007|May 18, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475046||171294|
NCT00475319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037E-06-001|Late Phase 2 Study of OPC-12759 Ophthalmic Suspension|Late Phase 2 Study of OPC-12759 Ophthalmic Suspension||Otsuka Pharmaceutical Co., Ltd.|No|Completed|May 2007|June 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|308|||Both|20 Years|N/A|No|||May 2013|June 4, 2013|May 16, 2007||No||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00475319||171273|
NCT00475332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK Protocol #109407|Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar|Feasibility Study of External Beam Radiotherapy and Iodine-131 Tositumomab (Bexxar) for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma||University of Florida|No|Terminated|September 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|May 16, 2007|Yes|Yes|PI left our institution|No|November 28, 2011|https://clinicaltrials.gov/show/NCT00475332||171272|The PI left our institution and the study was closed. There were only 2 patients enrolled on the study so no conclusions can be drawn regarding the objectives of the study.
NCT00448396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2120|Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies||Novartis||Completed|March 2007|||February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448396||173297|
NCT00448929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking 0702|Ologen (OculusGen)-Glaucoma Case Control Trial in India|Comparative Study of the Safety and Effectiveness Between Trabeculectomy and Trabeculectomy With Ologen (OculusGen) Collagen Matrix Implant||Pro Top & Mediking Company Limited||Recruiting|January 2007|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|N/A|No|||October 2011|October 6, 2011|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448929||173256|
NCT00449787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEDNet2|Comparing Naproxen to Sumatriptan for Emergency Headache Patients|A Randomized Clinical Trial to Compare Naproxen and Sumatriptan for Headache Patients Discharged From the Emergency Department (ED)|HEDNet2|Montefiore Medical Center|No|Completed|March 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|65 Years|No|||October 2012|October 29, 2012|March 19, 2007|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00449787||173192|
NCT00476281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3887|Nutritional, Metabolic and Respiratory Status in Cystic Fibrosis|Multicenter Prospective Study of Abnormalies Tolerance Glucose by the Continuous Measurement of Glucose of Nutritional Status and Breathing in the Patient With Cystic Fibrosis||University Hospital, Strasbourg, France||Recruiting|April 2008|October 2023|Anticipated|October 2023|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|10 Years|N/A|No|||March 2016|March 16, 2016|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476281||171200|
NCT00476294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0665|Long-Term Follow Up Study for AMD3100 Patients|Long-Term Observational Follow-Up Study of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 MCG/KG) Plus G-CSF (10 MCG/KG) Versus G-CSF (10 MCG/KG) Plus Placebo to Mobilize and Collect >/= 6 x 10^6 CD34+ Cells/KG in Multiple Myeloma Patients for Autologous Transplantation||M.D. Anderson Cancer Center|Yes|Completed|October 2006|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|7|||Both|18 Years|78 Years|No|Probability Sample|Patients who were randomized in a double-blind study and received a stem cell transplant        after treatment with AMD3100 and G-CSF OR treatment with Placebo and G-CSF.|July 2012|July 10, 2012|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00476294||171199|
NCT00472251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT110446|One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reductase Inhibitor in Korean BPH Patients|One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reductase Inhibitor in Korean BPH Patients||Seoul National University Hospital|Yes|Completed|May 2006|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Male|45 Years|75 Years|No|Non-Probability Sample|We recruited men aged 45-75 years with moderate to severe symptomatic BPH (IPSS > 7 and a        peak urinary flow rate of < 15 mL/s),an enlarged prostate (≥30 mL on TRUS), a PSA level of        <10 ng/mL, and no evidence of prostate cancer (on a DRE or TRUS) among patients who        visited our clinic.|July 2011|July 20, 2011|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472251||171501|
NCT00472264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011012|A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients|An Exploratory Study To Investigate The Reproducibility Of Lung 18Fluoro-Deoxyglucose Positron Emission Tomography In Patients With Chronic Obstructive Airways Disease (COPD) In The Absence Of Anti-Inflammatory Treatments||Pfizer|No|Terminated|May 2007|November 2008|Actual|October 2008|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 Moderate to Severe COPD patients and 8 age- and gender-matched Healthy Volunteer        Subjects.|July 2009|July 1, 2009|May 9, 2007||No|Study terminated on Nov 7, 2008 as a result of poor recruitment and changes in business    priorities. The decision was not based on safety concerns.|No||https://clinicaltrials.gov/show/NCT00472264||171500|
NCT00472290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060197|Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)|An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)||Amgen||Completed|April 2007|December 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|May 10, 2007||||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00472290||171499|Early termination leading to small number of subjects analyzed;
NCT00476008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-49|Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease|Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease||Florida Atlantic University|No|Completed|July 2007|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|N/A|No|||August 2014|August 7, 2014|May 17, 2007|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT00476008||171221|
NCT00472524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003H0072|Cycloplegic Delivery Investigation|||Ohio State University||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||50|||Both|8 Years|30 Years|Accepts Healthy Volunteers|||July 2008|July 1, 2008|May 9, 2007||||No||https://clinicaltrials.gov/show/NCT00472524||171481|
NCT00472758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP145|A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545|A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation, Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose, Intravenously Administered MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Chronic Plaque Psoriasis|CP145|MedImmune LLC|Yes|Completed|February 2007|March 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||November 2011|November 16, 2011|May 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00472758||171463|
NCT00472537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU030123PR|ProLOVE - Prospective Randomized Study of Midline Incisional Hernia Treatment|Prospective Randomized Evaluation of Open vs. Laparoscopic Operation of Ventral Incisional Eventrations. A Swedish Multicenter Study|ProLOVE|Skane University Hospital|No|Completed|November 2005|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|157|||Both|18 Years|N/A|No|Probability Sample|Patients referred to specialist centers for treatment of midline incisional hernias.|April 2013|April 22, 2013|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472537||171480|
NCT00472797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27955|Rebif New Formulation (RNF) Quality of Life (QOL) Study|A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF)|RebiQoL|EMD Serono||Completed|April 2007|November 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|232|||Both|18 Years|60 Years|No|||August 2013|August 2, 2013|May 10, 2007|No|Yes||No|February 18, 2009|https://clinicaltrials.gov/show/NCT00472797||171460|
NCT00472810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking 0703|Ologen (OculusGen)-Glaucoma MMC Control in Pakistan|Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery||Pro Top & Mediking Company Limited|No|Completed|March 2007|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00472810||171459|
NCT00473564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061228004|Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery|Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery||University of Alabama at Birmingham|Yes|Completed|February 2007|December 2015|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|20 Years|N/A|No|||February 2016|February 5, 2016|May 14, 2007||No||No|April 14, 2015|https://clinicaltrials.gov/show/NCT00473564||171404|
NCT00473577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC 0401|Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients|Two Phase, Open-Label, Sequential, Ascending Dose Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients||Pharmacyclics|Yes|Completed|August 2005|December 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A||||August 2010|August 24, 2010|May 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00473577||171403|
NCT00473304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R501/50/2006|Contact Lens in Pediatrics (CLIP) in an Asian Population Study||CLIP|Singapore National Eye Centre|No|Completed|December 2006|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||May 2010|May 10, 2010|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473304||171423|
NCT00473590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4064g|A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)|A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma|AMBER|Genentech, Inc.||Completed|May 2007|||November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||December 2011|December 13, 2011|May 14, 2007|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00473590||171402|
NCT00474253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05946|Comparison of Recovery From Rocuronium 1.2 mg/kg Followed By Org 25969 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(COMPLETED)|A Multicenter, Randomized, Parallel Group, Comparative, Active-Controlled, Safety-Assessor Blinded, Phase IIIa, Trial, in Adult Subjects Comparing Recovery From 1.2 mg.Kg-1 Rocuronium Followed by 16 mg.Kg-1 Org 25969 at 3 Minutes With Recovery From 1.0 mg.Kg-1 Succinylcholine||Merck Sharp & Dohme Corp.|No|Completed|February 2006|September 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|65 Years|No|||June 2015|June 5, 2015|May 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474253||171354|
NCT00475085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000544841|Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial|Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial||University of Rochester|Yes|Completed|December 2006|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|1021|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|May 16, 2007|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00475085||171291|
NCT00475358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6231|Efficacy and Safety Stress Urinary Incontinence Study|Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence||Eli Lilly and Company||Completed|April 2003|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Female|20 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 16, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475358||171270|
NCT00474773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA3190YM|Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery|Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery: A Randomized Controlled Study||St. Louis Joint Replacement Institute|No|Active, not recruiting|June 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Both|N/A|N/A||||April 2009|April 9, 2009|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474773||171315|
NCT00475345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A05-M27-00|Impact of Optimized Titration and Delivery of Bedtime Insulin on Prevention of Nocturnal Hypoglycemia|Impact of Optimized Titration and Delivery of Bedtime Insulin on Prevention of Nocturnal Hypoglycemia in Adults With Type 1 Diabetes Undergoing Intensive Management||McGill University|No|Completed|August 2000|September 2001|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|29|||Both|18 Years|65 Years|No|||May 2007|May 17, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475345||171271|
NCT00475566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-103|A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System|A Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions|STRIDES|Abbott Vascular|Yes|Completed|May 2007|February 2010|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475566||171254|
NCT00449488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B213|Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction|A Prospective, Randomised, Clinical Study to Examine the Effects of a Single Bolus Erythropoietin on Left Ventricular Function in Patients With an Acute Myocardial Infarction|HEBEIII|University Medical Center Groningen|Yes|Completed|January 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|529|||Both|18 Years|N/A|No|||December 2009|December 14, 2009|March 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00449488||173215|
NCT00450060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLPH-01/07|Juvenile Postlumbar Puncture Headache After Puncture With Needles With Quincke Tip or With Sprotte Tip|Postlumbar Puncture Complaints After Lumbar Punctures in Children and Adolescents: Frequency and Impact by Compariosn of Two Needle Designs||Heidelberg University|No|Recruiting|January 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||150|||Both|4 Years|18 Years|No|||March 2007|March 19, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00450060||173171|
NCT00450073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cystic Fibrosis Vitamin D|Improving Vitamin D Status In Cystic Fibrosis|Desktop Tanning Unit to Improve Vitamin D Status in Patients With Cystic Fibrosis and Short Bowel Syndrome: A Pilot Study||Atlanta VA Medical Center|No|Completed|November 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|60 Years|No|||January 2014|January 7, 2014|March 19, 2007||No||No|January 28, 2013|https://clinicaltrials.gov/show/NCT00450073||173170|
NCT00475761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907150|Breast Mammogram and Tissue Study|Breast Radiology Evaluation and Study of Tissues (Breast) Stamp Project||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Female|40 Years|65 Years|No|||July 2015|July 25, 2015|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00475761||171239|
NCT00472316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2U19AI045432-06|Innovative Approaches to Tuberculosis Control|A Cluster Randomized Trial of DOTS vs DOTS Plus Active Case Finding||Johns Hopkins University|Yes|Active, not recruiting|May 2007|May 2011|Anticipated|October 2009|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Residents of AP3.1 and AP 5.3 in Rio de Janeiro Brazil|August 2009|August 7, 2009|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472316||171497|
NCT00476307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110221|Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People Aged 18 Years or Above||GlaxoSmithKline|No|Completed|June 2007|July 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 29, 2011|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00476307||171198|
NCT00472771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-206-P2|INNO-206 in Patients With Small Cell Lung Cancer (SCLC)|A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy||CytRx|No|Withdrawn|May 2008|November 2008|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|May 11, 2007|Yes|Yes|Terminated due to clinical trial material production delays|No||https://clinicaltrials.gov/show/NCT00472771||171462|
NCT00473083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21016|Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer|A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer|LUTRAERL|British Columbia Cancer Agency|No|Completed|January 2009|August 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00473083||171439|
NCT00473317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton3|Sunlight Exposures Effect on Serum Vitamin D Levels|Sunlight Exposures Effect on Serum Vitamin D Levels||Creighton University|No|Completed|July 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 30, 2008|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00473317||171422|
NCT00473057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP-10385|Study of Autologous Stem Cell Transplantation for Patients With Ischemic Stroke|Phase I Study of Autologous Bone Marrow Cell Transplantation in Patient With Ischemic Stroke||Universidade Federal do Rio de Janeiro|Yes|Completed|December 2005|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||May 2011|May 18, 2011|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00473057||171441|
NCT00473876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WON001|Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)|Metformin in Insulin Resistant LV Dysfunction, a Double-blind, Placebo-controlled Trial (TAYSIDE Trial)|TAYSIDE|University of Dundee|Yes|Completed|August 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|25 Years|80 Years|No|||May 2013|May 28, 2013|May 15, 2007||No||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00473876||171382|
NCT00474266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109670|Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children|Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children||GlaxoSmithKline||Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1000|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||February 2011|June 7, 2012|May 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474266||171353|
NCT00474487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P17|A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults|A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age.||Novartis|Yes|Completed|May 2007|February 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|2831|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|May 16, 2007|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00474487||171336|
NCT00475384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0695|Haploidentical Transplantation in Patients With Acute Leukemia and Myelodysplasia|Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplant From A Haploidentical Donor For Patients With Acute Leukemia and Myelodysplasia||M.D. Anderson Cancer Center|No|Completed|June 2006|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|N/A|50 Years|No|||November 2014|November 7, 2014|May 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00475384||171268|
NCT00475397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6232|Duloxetine Stress Urinary Incontinence Efficacy and Safety Study|Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence||Eli Lilly and Company||Completed|December 2003|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Female|20 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 16, 2007|May 16, 2007||||||https://clinicaltrials.gov/show/NCT00475397||171267|
NCT00475059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608090|Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients|Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|59|||Both|18 Years|N/A|No|||January 2010|January 5, 2010|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475059||171293|
NCT00475072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16814|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.|An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C||Hoffmann-La Roche||Completed|June 2003|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|N/A|No|||November 2015|November 2, 2015|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475072||171292|
NCT00475579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/03/2006|Endotracheal Tube With Polyurethane Cuff and Subglottic Secretion Drainage|Influence of an Endotracheal Tube With Polyurethane Cuff and Subglottic Secretion Drainage on Ventilator-Associated Pneumonia|A/N|Hospital Universitario de Canarias|Yes|Completed|March 2006|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|280|||Both|18 Years|90 Years|No|||May 2007|May 17, 2007|May 17, 2007||||No||https://clinicaltrials.gov/show/NCT00475579||171253|
NCT00475878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA022207|SSRI and Buprenorphine|Antidepressants During Office-Based Buprenorphine||Butler Hospital|Yes|Completed|December 2006|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|May 18, 2007||No||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00475878||171230|
NCT00475865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY6046|Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis|A Randomized, Multinational, Double-blind, Placebo-controlled, Parallel-group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Glatiramer Acetate in Subjects With Multiple Sclerosis||Sanofi|Yes|Completed|April 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|123|||Both|18 Years|55 Years|No|||November 2012|November 5, 2012|May 18, 2007|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00475865||171231|
NCT00449176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013399|A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain|A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Subjects With Moderate to Severe Chronic Low Back Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|981|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|March 16, 2007|Yes|Yes||No|April 17, 2009|https://clinicaltrials.gov/show/NCT00449176||173237|
NCT00449462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL15420.081.06|Effect of Conjugated Linoleic Acid Intake on Liver and Kidney Function|The Effect of Conjugated Linoleic Acid Intake on Liver and Kidney Function in Healthy Volunteers (CLAxon-Study)||Wageningen University|No|Completed|March 2007|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2007|July 5, 2007|March 19, 2007||||No||https://clinicaltrials.gov/show/NCT00449462||173216|
NCT00449761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2211|Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)|A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors||Novartis||Completed|February 2007|||August 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|March 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00449761||173194|
NCT00476320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Becker-LE-FU-2007|The Use of Myocardial Deformation Imaging|The Use of Myocardial Deformation Imaging Based on Ultrasonic Pixel Tracking to Identify Reversible Myocardial Dysfunction||RWTH Aachen University|No|Completed|August 2004|April 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|18 Years|80 Years|No|||May 2007|May 21, 2007|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00476320||171197|
NCT00476333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70/07|The Effect of Custom-Made Biomechanical Perturbation Platform on Kinetics, Kinematics and Electromyography in Healthy Subjects|||Assaf-Harofeh Medical Center|No|Recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||||||Male|20 Years|30 Years|Accepts Healthy Volunteers|||April 2007|May 21, 2007|May 19, 2007||||No||https://clinicaltrials.gov/show/NCT00476333||171196|
NCT00472329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMBMT-166-A|Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant|Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant||Colorado Blood Cancer Institute|No|Recruiting|March 2007|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|74 Years|No|||June 2014|June 26, 2014|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472329||171496|
NCT00472550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mannheim-Eso-001|Esomeprazole and Gastric Emptying of Beer|Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers||Heidelberg University|Yes|Completed|January 2006|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|May 10, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472550||171479|
NCT00472303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|761101|A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine|A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain||Grünenthal GmbH|No|Completed|July 2007|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|622|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|May 10, 2007|Yes|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT00472303||171498|
NCT00473330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4170g|A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)|A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus|RISE|Genentech, Inc.||Completed|June 2007|November 2012|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|377|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|May 13, 2007|Yes|Yes||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00473330||171421|
NCT00473343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC T310/00|Metvix PDT in Patients With "High Risk" Basal Cell Carcinoma|An Open Multicenter, Phase III Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Patients With "High Risk" Basal Cell Carcinoma||Galderma|No|Completed|September 2000|June 2006|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473343||171420|
NCT00473642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007002|Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration|A Prospective Pilot Study of Reduced Fluence Photodynamic Therapy With Visudyne® (Verteporfin) in Combination With Lucentis™ (Ranibizumab) for the Treatment of Age-Related Macular Degeneration||Oklahoma State University Center for Health Sciences|No|Completed|May 2007|April 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|50 Years|N/A|No|||October 2012|October 9, 2012|May 14, 2007|Yes|Yes||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00473642||171399|This study was limited by a small number of subjects. Additionally, several subjects did not meet the 12 month study endpoint. These subjects were included in the final analysis if their last visit was within 2 months of the final endpoint.
NCT00473616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1040C00004|Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan|A Phase I Open-label, Multi-center, Dose-escalation and Safety Expansion Study to Assess Safety, Tolerability, and Pharmacokinectics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose of Irinotecan in Patients With Advanced Solid Malignancies.||AstraZeneca|No|Terminated|May 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2011|February 10, 2011|May 14, 2007|Yes|Yes|Termination of the study was made after a full review of program data and assessment of the    current risk-benefit profile.|No||https://clinicaltrials.gov/show/NCT00473616||171400|
NCT00474240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|733-003|AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia||Aegerion Pharmaceuticals, Inc.|No|Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|157|||Both|18 Years|70 Years|No|||January 2013|January 15, 2014|May 14, 2007|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00474240||171355|Study AEGR-733-003, initiated in May 2007, was halted, and restarted under an amended Protocol in November 2007.
NCT00474799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-PK-006|Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine)|An Open Label, Randomized, Single Center, Repeat Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine) in Opioid naïve, Healthy Adult Volunteers||Javelin Pharmaceuticals|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 11, 2008|May 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00474799||171313|
NCT00441220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHB3557|Cyclophosphamide in Lupus Nephritis|Failure of Cyclophosphamide Therapy in Lupus Nephritis Patients: the Role of Bioactivation Phenotype and Genotype||University of Auckland, New Zealand|No|Recruiting|October 2006|October 2010|Anticipated|||N/A|Observational|Observational Model: Case-Only||2|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|Patients with lupus nephritis who are receiving or have previously received intravenous        cyclophosphamide.|February 2009|March 4, 2009|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00441220||173843|
NCT00475371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-253-001|A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males|A Phase 1a, Single-Dose, Open-Label, Parallel, Ascending Dose, Controlled Safety and Tolerability Trial of Inhaled MKC253 in Healthy Adult Male Subjects||Mannkind Corporation||Completed|April 2007|||June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475371||171269|
NCT00476125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000017|Effects of Dietary Manipulation on Metabolism in Healthy Adults|Effects of Dietary Manipulation on Metabolism in Healthy Adults||Beth Israel Deaconess Medical Center|No|Active, not recruiting|March 2008|February 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|November 13, 2015|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00476125||171212|
NCT00476138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISIONERVE-01|Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma|Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma||Catholic University of the Sacred Heart|Yes|Recruiting|November 2006|July 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|35 Years|60 Years|No|||May 2007|May 18, 2007|May 18, 2007||||No||https://clinicaltrials.gov/show/NCT00476138||171211|
NCT00442065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-001P2|ARBITER-II: Aorfix™ Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels|A Study to Assess the Acute Technical Success of Aorfix™ Stent Grafts in the Treatment of Abdominal Aortic and Aorto-Iliac Aneurysm Where a Significant Degree of Vessel Angulation Exists at the Neck of the Aneurysm|ARBITER-II|Lombard Medical|No|Completed|October 2006|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|19 Years|N/A|No|||October 2012|October 15, 2012|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00442065||173778|
NCT00449189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0065|A Placebo-Controlled Study of Mirtazapine for PTSD|A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans and Veterans From All Other Southwest Asia Conditions|Mirtazapine|Tuscaloosa Research & Education Advancement Corporation|Yes|Completed|October 2006|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|19 Years|N/A|No|||August 2012|August 30, 2012|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00449189||173236|
NCT00449202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAN-OE-OS-03|Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)|A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects||Manhattan Pharmaceuticals|No|Active, not recruiting|June 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||March 2007|March 16, 2007|March 16, 2007||||Yes||https://clinicaltrials.gov/show/NCT00449202||173235|
NCT00449774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBI108617|Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers|An Open-label, Randomised, Single-dose, Parallel-group Study to Demonstrate Bioequivalence of Two Formulations and the Effect of Food and Water on One Formulation of Lamotrigine in Healthy Male and Female Volunteers||GlaxoSmithKline|No|Completed|May 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|220|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|March 19, 2007||||||https://clinicaltrials.gov/show/NCT00449774||173193|
NCT00449501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5896C00025|A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects|A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Act. Twice Daily||AstraZeneca||Completed|March 2007|November 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|134|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|March 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00449501||173214|
NCT00454987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109664|Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine|Assessment of Long-term Antibody Persistence After a Booster Dose of GSK Biologicals' Hib & Meningococcal C Vaccine (Menitorix™) 811936 Given at 12-15 Months of Age to Subjects Primed With 3 Doses of Menitorix™ at 2, 3, 4 Months of Age||GlaxoSmithKline||Completed|May 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|288|||Both|24 Months|64 Months|Accepts Healthy Volunteers|||October 2015|November 12, 2015|March 30, 2007|Yes|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT00454987||172801|
NCT00455000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951001|A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease|A Phase I, Randomized, Placebo Controlled, Double Blind Dose Escalation Study Of The Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|March 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|50 Years|85 Years|No|||October 2009|October 12, 2009|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00455000||172800|
NCT00476346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD-17-01-1-0807|Calcium and Vitamin D Supplementation Decreases Incidence of Stress Fractures in Female Navy Recruits|Calcium and Vitamin D Supplementation Decreases Incidence of Stress Fractures in Female Navy Recruits||Creighton University|No|Completed|May 2002|March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5201|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2008|March 24, 2015|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476346||171195|
NCT00472355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS021062|Low Dose Apomorphine and Parkinsonism|Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism?||Oregon Health and Science University||Completed|October 2005|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|14|||Both|35 Years|85 Years|No|||September 2009|September 3, 2009|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472355||171494|
NCT00472836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351038|Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug|A Phase 1, Open-Label, Parallel Group, Multiple-Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of CP-945,598 Administered To Subjects With Severely Impaired And Normal Renal Function||Pfizer|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2008|August 11, 2009|May 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00472836||171457|
NCT00472849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1026|Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias|A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Completed|May 2007|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|May 11, 2007||No||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00472849||171456|
NCT00472823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0081|Vitamin D Supplementation in Older Women|Determination of RDA for Vitamin D in Caucasian and African American Women|VIDOS|Creighton University|Yes|Completed|April 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|273|||Female|57 Years|N/A|No|||March 2016|March 11, 2016|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472823||171458|
NCT00473070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-37|A Clinical Study of Tobradex AF|A Clinical Study of Tobradex AF||Alcon Research||Completed|November 2006|||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|900|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|May 10, 2007||||||https://clinicaltrials.gov/show/NCT00473070||171440|
NCT00473109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050311|Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study|Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study|HDSH|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2007|May 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||May 2007|May 22, 2009|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00473109||171437|
NCT00473356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061211001|Nutritional Effect of an Amino Acid Mixture on Lean Body Mass (LBM) in Post-bariatric Surgery Patients|Nutritional Effect of an Amino Acid Mixture on Lean Body Mass (LBM) in Post-bariatric Surgery Patients||University of Alabama at Birmingham|No|Completed|June 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 17, 2013|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00473356||171419|
NCT00473889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-056|A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)|A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)||Merck Sharp & Dohme Corp.|No|Terminated|May 2007|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|May 14, 2007|Yes|Yes|The study was terminated based on the recommendation by the DSMB following a pre-planned    protocol interim analysis because the endpoint was not achieved.|No|September 3, 2009|https://clinicaltrials.gov/show/NCT00473889||171381|The study was stopped following a pre-planned interim analysis because the goal for this study to continue was not met, based on 100 events, a reduction in the hazard ratio for progression-free survival by > 23% with a one-sided p-value < 0.1
NCT00473902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Older Adult Training Study|Older Adult Training Study With Creatine and CLA|Creatine Monohydrate and Conjugated Linoleic Acid Improve Strength and Body Composition Following Resistance Exercise in Older Adults|OTR|McMaster University|No|Completed|August 2003|September 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|39|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||May 2007|May 15, 2007|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00473902||171380|
NCT00473915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15061B|Intranasal Steroids and the Nasal Ocular Response|Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response||University of Chicago|No|Completed|April 2007|February 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|May 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00473915||171379|
NCT00475098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051084|Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)|Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.|TILT|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|June 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|553|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475098||171290|
NCT00475111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR041687|Cognitive Behavioral Therapy Treatments for Adults With Rheumatoid Arthritis (The SARA Study)|Stress and Adaptation in Rheumatoid Arthritis (SARA)||Arizona State University|No|Completed|March 2001|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|136|||Both|21 Years|75 Years|No|||May 2013|May 16, 2013|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475111||171289|
NCT00441233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07 001|Clinical Performance of Extended Wear Silicone Hydrogel Lenses|||University of Melbourne||Completed|March 2007|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|45 Years||||December 2007|December 27, 2007|February 27, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00441233||173842|
NCT00441246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-MUCD-001|Phase 4 Study - Mucinex D as Adjunct Therapy|A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Mucinex D as Adjunct Therapy to Antibiotic Treatment of Acute Respiratory Infection||Adams Respiratory Therapeutics|Yes|Completed|February 2007|July 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|75 Years|No|||February 2008|February 5, 2008|February 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00441246||173841|
NCT00475592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VaricealGrading_EsoCapsule|Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy|Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy||Johns Hopkins University|Yes|Recruiting|January 2007|May 2008|Anticipated|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2007|December 15, 2010|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475592||171252|
NCT00441792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4257|The Effect of Etomidate on Patient Outcomes After Single Bolus Doses|A Randomized Trial of Etomidate Versus Midazolam for Intubation of Patients With Sepsis.||Advocate Hospital System|No|Completed|October 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||April 2012|April 8, 2012|February 27, 2007|No|Yes||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00441792||173799|Because of limitations in the availability of study investigators and pharmacists, we were unable to enroll all potentially eligible patients, raising the possibility that our study sample was not representative of our entire patient population.
NCT00442442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCVNHIL01|Clinical Evaluation of Mosquito Coils to Control Malaria in China|Clinical Evaluation of Mosquito Coils to Control Malaria in China||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|April 2007|December 2007|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|8000|||Both|6 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 30, 2007|March 1, 2007||||No||https://clinicaltrials.gov/show/NCT00442442||173749|
NCT00442078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020402|I-STOP TOMS - Trans Obturator Male Sling|Evaluation of the Efficacy on Urinary Continence and Quality of Life of the Sub-urethral Tape I-STOP® Using the Transobturator and Perineal Route on Male Incontinent After Radical Prostatectomy.||CL Medical|No|Completed|May 2006|June 2009|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|N/A|N/A|No|||September 2012|September 8, 2012|February 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00442078||173777|
NCT00449540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL-2006-001|Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura|Phase III Randomized Double-Blind Parallel Group Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive Non-repetitive Transcranial Magnetic Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache||Neuralieve|No|Completed|August 2006|March 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|201|||Both|18 Years|65 Years|No|||July 2011|August 9, 2011|March 18, 2007||No||No|January 7, 2009|https://clinicaltrials.gov/show/NCT00449540||173211|
NCT00449514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tamoxi vs clomiphene.CTIL|Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle|Prospective Randomized Study of Ovulation Induction Using Either Tamoxifen or Clomiphene Citrate for Women Who Had Thin Endometrium During Previous Treatment With Clomiphene Citrate||Shaare Zedek Medical Center|No|Recruiting|May 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|35 Years|No|||May 2007|September 19, 2007|March 18, 2007||||No||https://clinicaltrials.gov/show/NCT00449514||173213|
NCT00455312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2006-06|SCT for Dyskeratosis Congenita or SAA|Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|August 2007|November 2016|Anticipated|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|N/A|70 Years|No|||January 2016|January 21, 2016|March 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455312||172776|
NCT00455585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR001|Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products|Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products.||Makerere University|No|Completed|January 2007|November 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Both|18 Years|N/A|No|||February 2008|February 7, 2008|April 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00455585||172756|
NCT00472342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kenshin46|The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients|The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients||Yonsei University|Yes|Recruiting|March 2007|December 2007|Anticipated|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|182|||Both|30 Years|70 Years|No|||May 2007|May 10, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472342||171495|
NCT00472888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 05/244|Clinical Factors Associated Floppy Iris|Clinical Factors Associated With Floppy Iris Signs: a Prospective Study From Two Centers||Baskent University|Yes|Completed|November 2005|November 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|500|||Both|28 Years|90 Years|Accepts Healthy Volunteers|||May 2007|May 10, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472888||171453|
NCT00473148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051018|B-type Natriuretic Peptide for the Management of Weaning|Weaning of Mechanical Ventilation Guided by the Natriuretic Peptide of Type B|BMW|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||November 2008|April 29, 2010|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00473148||171434|
NCT00473096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-98-1-8022|Efficacy Study of an Educational Program for Decision Support for Breast Cancer|Assessing the Efficacy of a CDSS for Breast Cancer|H-6019|Baylor College of Medicine|No|Completed|October 2000|October 2006|Actual|October 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Female|N/A|N/A|No|||September 2015|September 18, 2015|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00473096||171438|
NCT00472862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333077|Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual|NEUROCOM: Cognitive Training for Patients With First Episode Schizophrenia|NEUROCOM|Neurocom|No|Completed|January 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|35 Years|No|||April 2015|April 14, 2015|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00472862||171455|
NCT00473122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0955|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Breast Reconstruction||M.D. Anderson Cancer Center|No|Completed|April 2005|||August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Female|N/A|N/A|No|||September 2015|September 1, 2015|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00473122||171436|
NCT00473369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2007.nsg.med.tohoku|Prognosis of Atypical Pituitary Adenomas|||Tohoku University|Yes|Active, not recruiting|January 2001|May 2007|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|12 Years|74 Years||||May 2007|May 14, 2007|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473369||171418|
NCT00473382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4168g|A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)|A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus|RIDE|Genentech, Inc.||Completed|June 2007|September 2012|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|382|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|May 13, 2007|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00473382||171417|
NCT00473655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-CRESTOR-0002|Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients|A Double-blind, Double Dummy, Phase IV, Randomized, Multicenter, Parallel Group, Placebo Controlled Trial to Evaluate the Effect of Rosuvastatin on Triglycerides Levels in Mexican Hypertriglyceridemic Patients||AstraZeneca||Completed|January 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|334|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|May 14, 2007||||No|May 10, 2010|https://clinicaltrials.gov/show/NCT00473655||171398|
NCT00473668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104977|Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib|Non-inferiority of One Formulation of GSK Biologicals' DTPw-HBV/Hib to 2 Formulations of GSK Biologicals' DTPw-HBV/Hib With Respect to the Immune Response to the PRP Antigen, When Administered to Healthy Infants at 6, 10, 14 Weeks of Age||GlaxoSmithKline||Completed|June 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|300|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||June 2012|June 14, 2012|May 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00473668||171397|
NCT00473928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POT-CP1006|Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)|Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)|ASaP|Potentia Pharmaceuticals, Inc.|Yes|Completed|May 2007|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|27|||Both|50 Years|N/A|No|||March 2010|March 16, 2010|May 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00473928||171378|
NCT00473941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21CA107428-01A2|Life After Cancer Treatment Study|Expressive Writing and Adjustment to Colorectal Cancer||Temple University|Yes|Completed|September 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2010|August 24, 2011|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00473941||171377|
NCT00445562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENBASIX-00127|Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters|Breast Cancer Siblings Database||National Cancer Institute (NCI)||Recruiting|January 2001|||December 2004|Actual|N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 9, 2013|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445562||173512|
NCT00472641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96972|Geodon in Weight Loss Study for Bipolar Disorders|Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder||Stanford University|No|Completed|January 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|No|||December 2012|December 11, 2012|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00472641||171472|
NCT00472654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0083|The Effect of Vitamin D Supplementation During Caloric Restriction on Intestinal Calcium Absorption|Nutritional Regulation of Bone - Aim 3||Rutgers University|Yes|Completed|March 2007|March 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|83|||Female|50 Years|N/A|Accepts Healthy Volunteers|||July 2012|October 11, 2014|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472654||171471|
NCT00441519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA325-102|A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin|An Open-Label, Investigator-Blinded, Stratified, Randomized, Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin||POZEN|Yes|Completed|February 2007|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 9, 2009|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441519||173820|
NCT00441532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-117|Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy|A Double-Blind Randomized Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy||William Beaumont Hospitals|No|Completed|August 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Male|18 Years|N/A|No|||October 2010|November 22, 2011|February 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00441532||173819|
NCT00441818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-650.101|Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma|A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma||Tanox|No|Recruiting|May 2006|June 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|59|||Both|18 Years|N/A|No|||February 2007|May 8, 2008|May 17, 2006||||No||https://clinicaltrials.gov/show/NCT00441818||173797|
NCT00458627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2044-CTIL|Body Plethysmograph Measurements Before and After Methacholine Challenge in Early Childhood|Body Plethysmograph Measurements Before and After Methacholine Challenge in Early Childhood||Rambam Health Care Campus|Yes|Completed|February 2006|September 2006||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||50|||Both|3 Years|7 Years|No|||April 2007|April 10, 2007|April 10, 2007||||No||https://clinicaltrials.gov/show/NCT00458627||172523|
NCT00454766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1014|Evaluating Materials to Educate Patients About Cervical Dysplasia|Evaluating Materials to Educate Patients About Cervical Dysplasia||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2007|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women, over 18 years of age, with an abnormal Papanicolaou (Pap) smear are referred for a        colposcopy and biopsy.|September 2015|September 11, 2015|March 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00454766||172817|
NCT00449800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTRM 2006-02|Pharmacokinetic of Ceftriaxone in Septic ICU Patients|Pharmacokinetics Variability of Ceftriaxone in Septic ICU Patients|PORTHOS|Association Pour La Promotion A Tours De La Reanimation Medicale|No|Recruiting|July 2006|March 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||March 2007|March 20, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00449800||173191|
NCT00455598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113715-CS14|Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea|A Phase 2, Multi Center, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, PK, & Activity of ISIS 113715 Administered Weekly in Subjects With Type 2 DM Treated w/ Sulfonylurea||Ionis Pharmaceuticals, Inc.|No|Completed|February 2007|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|70 Years|No|||August 2009|August 26, 2009|April 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00455598||172755|
NCT00476372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAarhus|Cognitive Impairment in Parkinson's Disease Categorised in Accordance to Motor Symptoms|Cognitive Impairment in Parkinson's Disease Categorised in Accordance to Motor Symptoms -the Relation Between Cognitive Deficits and Comorbid Psychiatric Disorders, Medication, and Age at Disease Onset||University of Aarhus|No|Completed|August 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|107|||Both|50 Years|N/A|No|Non-Probability Sample|77 patients with PD and 30 healthy control participants|January 2013|January 11, 2013|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476372||171193|
NCT00473161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMG biofeedback|Use of Surface Electromyography Biofeedback to Improve Reaching in Children With Cerebral Palsy|||University of Southern California|No|Completed|May 2007|||January 2009|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|1 Month|21 Years|No|Non-Probability Sample|Children with movement disorders, cerebral palsy.|May 2014|May 21, 2014|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00473161||171433|
NCT00443248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001302|Vaginal Heat Wash-Out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)).|A 2-Way Repeatability Study To Investigate Vaginal Blood Flow Before, During And After Visual Sexual Stimulation In Pre- And Post-Menopausal Women With And Without Female Sexual Arousal Disorder, Using The Heat Wash-Out Technique.|FSAD HWO VBF|Pfizer|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|64|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 6, 2009|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443248||173687|
NCT00472563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065-120606|Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate|Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate|PROMEC|Universidad de Antioquia|Yes|Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|212|||Both|18 Years|N/A||||April 2008|May 5, 2008|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472563||171478|
NCT00472576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070152|Antidepressant Effects of NR2B in Major Depression|An Investigation of the Antidepressant Effects of the Selective NR2B Antagonist MK-0657 in Major Depression||National Institutes of Health Clinical Center (CC)|No|Completed|May 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|55 Years|No|||July 2012|July 19, 2012|May 10, 2007|Yes|Yes||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00472576||171477|The study was ended early due to recruitment problems.
NCT00472875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q0703/18|Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?|||King's College Hospital NHS Trust|No|Recruiting|May 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|75 Years|No|||May 2007|May 10, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472875||171454|
NCT00473694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05945|Comparison of Sugammadex With Neostigmine Administered at 1-2 PTCs After Administration of Rocuronium or Vecuronium (19.4.302)(P05945)(COMPLETED)|A Multicenter Randomized Parallel Group Comparative Active-Controlled Safety-Assessor Blinded Phase 3a, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a NMB Induced by Maintenance Dosing of Rocuronium or Vecuronium at 1-2 PTCs||Merck Sharp & Dohme Corp.|Yes|Completed|November 2005|January 2007|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|May 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00473694||171395|
NCT00473980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kl4501122|Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients|Preoperative Treatment With NSAID in Colorectal Cancer Patients in Relationship to Tumor Host Reactions||Göteborg University|No|Completed|December 1998|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|80 Years|No|||March 2012|March 30, 2012|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00473980||171374|
NCT00473954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGEN-001-201|Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer|A Phase 1, Open-Label, Dose Escalation Study of the Safety and Preliminary Efficacy of EGEN-001 in Combination With Carboplatin and Docetaxel in Women With Recurrent, Platinum-Sensitive, Epithelial Ovarian Cancer||EGEN, Inc.|Yes|Completed|April 2007|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||March 2013|March 25, 2013|May 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00473954||171376|
NCT00473967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-06-02|Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults|Double-blind, Randomized, Controlled Phase 1 Study of the Safety and Immunogenicity of Na-ASP-2 Hookworm Vaccine in Previously-Infected Brazilian Adults||Albert B. Sabin Vaccine Institute|Yes|Terminated|May 2007|March 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|May 14, 2007|No|Yes|Occurrence of unacceptable adverse events.|No||https://clinicaltrials.gov/show/NCT00473967||171375|
NCT00473681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS013160|Intervention Study to Control High Blood Pressure for Korean American|High Blood Pressure Care for Korean Americans|HBP|Johns Hopkins University|Yes|Completed|September 2003|August 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|445|||Both|40 Years|65 Years|No|||May 2008|May 5, 2008|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473681||171396|
NCT00474500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR13/2006|Effect of Coca-Cola on Iron Absorption|Effect of Coca-Cola on Iron Absorption||Institute of Food Research|Yes|Completed|May 2007|May 2010|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|16|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 16, 2011|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00474500||171335|
NCT00445575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM 03-54|Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone|Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone|PROFIDYS|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|July 2007|July 2014|Anticipated|July 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|156|||Both|8 Years|N/A|No|||March 2010|December 29, 2011|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00445575||173511|
NCT00472953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1617|Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)|Inhaled Pre-prandial Human Insulin Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Chronic Obstructive Pulmonary Disease: A 52-week Open Label, Multicentre, Randomized, Parallel Trial to Investigate Long-term Safety|iINHALE 8|Novo Nordisk A/S|No|Terminated|May 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|30 Years|N/A|No|||May 2012|May 22, 2012|May 11, 2007|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00472953||171448|
NCT00472966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10031|Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma|Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma||Galderma Laboratories, L.P.|No|Completed|November 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472966||171447|
NCT00441545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-319|Head to Head Study Against Sevelamer Hydrochloride|A Prospective, Multicenter, Open-label, Randomized, Cross-over Study to Compare the Efficacy and Safety of Fosrenol® and Sevelamer Hydrochloride in Patients Receiving Hemodialysis for End Stage Renal Disease||Shire||Completed|February 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||August 2011|June 6, 2014|February 27, 2007|Yes|Yes||No|June 29, 2009|https://clinicaltrials.gov/show/NCT00441545||173818|
NCT00441805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-RF/ACN02/06IL CTIL|The Treatment of Acne Vulgaris With Radiofrequency Device|The Treatment of Acne Vulgaris With Radiofrequency Device||Alma Lasers|No|Withdrawn|November 2006|September 2007||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 22, 2007|February 27, 2007||||No||https://clinicaltrials.gov/show/NCT00441805||173798|
NCT00473187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKJ-Haffner-XLHR-08-2004|Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets|Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children With X-Linked Hypophosphatemic Rickets||University of Rostock||Active, not recruiting|August 2004|August 2009|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|3 Years|10 Years|No|||May 2007|May 11, 2007|May 11, 2007||||No||https://clinicaltrials.gov/show/NCT00473187||171431|
NCT00454792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-20060111|Rehabilitation of Patients With Modic Changes in the Lumbar Spine|Rehabilitation of Patients With Modic Changes in the Lumbar Spine - a Randomized Controlled Trial||The Back Research Center, Denmark|No|Completed|March 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||September 2011|September 23, 2011|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00454792||172815|
NCT00454779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050236|PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response|A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy…||Amgen|Yes|Completed|January 2007|May 2014|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|70 Years|No|||October 2014|November 11, 2014|March 29, 2007|Yes|Yes||No|October 11, 2013|https://clinicaltrials.gov/show/NCT00454779||172816|
NCT00455013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-034|A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation|A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept (BMS-224818)-Based Corticosteroid-Free Regimens in Renal Transplant||Bristol-Myers Squibb|Yes|Completed|July 2007|August 2012|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|70 Years|No|||May 2014|May 27, 2014|March 30, 2007|Yes|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT00455013||172799|Main limitations of this study include: small size (small number of participants in each treatment arm), the open-label nature of the trial, its exploratory nature, and the high rate of switches from sirolimus to MMF in one of the belatacept groups.
NCT00448513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2006005|Effects of Tea Catechin Extracts on Oxidative Damage|Effects of Tea Catechin Extracts on the Frequency Changes of Micronuclei in Peripheral Lymphocytes in Late Middle Aged Healthy Volunteers||University of Shizuoka|No|Completed|June 2007|April 2012|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|40|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||April 2009|July 14, 2013|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00448513||173288|
NCT00448786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060443|Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors|An Open-Label, Randomized, Phase 1b Study Evaluating the Effect of Different Doses of AMG 706 on the Gallbladder in Subjects With Advanced Solid Tumors||Amgen||Completed|February 2007|March 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|March 15, 2007||||No||https://clinicaltrials.gov/show/NCT00448786||173267|
NCT00472602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0001|Pathogenesis of Liver Fluke Induced Cancer in Thailand|Pathogenesis of Liver Fluke Induced Cancer in Thailand||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|August 2007|||||N/A|Observational|Time Perspective: Prospective||||6000|||Both|20 Years|60 Years|No|||May 2007|August 26, 2010|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472602||171475|
NCT00443261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10498|Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase I Study of Azacitidine in Combination With Cisplatin Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||University of Kansas Medical Center|Yes|Terminated|February 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|March 2, 2007|Yes|Yes|Accrual problems|No||https://clinicaltrials.gov/show/NCT00443261||173686|
NCT00472589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE06-120|A Biological Sample Collection Protocol of Women With and Without Breast Cancer|A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team||Hoosier Cancer Research Network|Yes|Completed|May 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|400|Samples With DNA|plasma, serum, whole blood and tissue samples|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women and women with breast cancer|August 2013|August 26, 2013|May 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00472589||171476|
NCT00473408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15437|The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas|The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas|Gliomstudien|Haukeland University Hospital|No|Terminated|March 2007|November 2011|Actual|May 2007||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Tumor samples and blood samples are collected and frozen for future analysis for tumor      vascularization and tumor stem cells.|Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years or older diagnosed and operated for high-grade astrocytoma.|November 2011|November 18, 2011|May 14, 2007||No|Moved to another country, not possible to recruit from abroad.|No||https://clinicaltrials.gov/show/NCT00473408||171416|
NCT00473421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Human sementstudie|"How do Contrast Medias in Bone Cement Affect DXA Measurements After THR"|||Ullevaal University Hospital|No|Recruiting|May 2007|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||||||Both|50 Years|80 Years||||May 2007|May 14, 2007|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473421||171415|
NCT00473993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepCOP Zurich|Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland|Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung|HepCOP|Seidenberg, Arztpraxis A., M.D.|Yes|Completed|July 2007|December 2007|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|||Patients in opioid maintenance treatment in the kanton of Zurich, Switzerland|May 2007|February 13, 2009|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00473993||171373|
NCT00474292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070154|Influence of Area of Brain Damage on Brain Reorganization After Chronic Stroke|Influence of Lesion Location on Cortical Reorganization After Chronic Stroke||National Institutes of Health Clinical Center (CC)||Completed|May 2007|April 2011||||N/A|Observational|N/A|||Actual|4|||Both|18 Years|80 Years|No|||April 2011|April 9, 2011|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474292||171351|
NCT00474513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3B106026|An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.|A PET Study Using [11C] GSK189254 to Establish the Dose, Plasma Concentration and Brain Receptor Occupancy Relationship of GSK239512, a Histamine H3 Antagonist, in Healthy Subjects||GlaxoSmithKline|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Male|35 Years|49 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474513||171334|
NCT00474279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC #7444|Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults|Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults|MOT089|University of Virginia|Yes|Completed|July 1998|June 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 15, 2007|May 15, 2007||||No||https://clinicaltrials.gov/show/NCT00474279||171352|
NCT00474812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00228|Dasatinib in Treating Patients With Metastatic Pancreatic Cancer|Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas||National Cancer Institute (NCI)|Yes|Completed|May 2007|February 2014|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||November 2013|April 14, 2015|May 16, 2007|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT00474812||171312|
NCT00444951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA40|Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia|Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia.||Sanofi|No|Completed|February 2007|February 2009|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|450|||Both|16 Years|19 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|March 7, 2007|Yes|Yes||No|February 9, 2011|https://clinicaltrials.gov/show/NCT00444951||173557|
NCT00472433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH011003|The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias|A Phase II Study of Alemtuzumab in Autoimmune Cytopenias||Phramongkutklao College of Medicine and Hospital|No|Terminated|March 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||June 2009|June 18, 2009|April 25, 2007|||no eligible patient|No||https://clinicaltrials.gov/show/NCT00472433||171488|
NCT00473213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN1B/99|Optimizing IFN Beta - 1B Dose|Optimizing IFN Beta - 1B Dose|Optims|University of Turin, Italy|Yes|Completed|September 1999|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|50 Years|No|||May 2007|May 11, 2007|May 11, 2007||||No||https://clinicaltrials.gov/show/NCT00473213||171429|
NCT00472940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-19709|Prevalence of Hypogonadism in Male Cancer Patients|Prevalence of Hypogonadism in Male Cancer Patients||Baylor College of Medicine|Yes|Completed|November 2006|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|135|Samples Without DNA|Plasma|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male subjects with cancer and non-cancer controls|June 2011|June 23, 2011|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00472940||171449|
NCT00473499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBM-VS54-HOM|PEPCAD III Substudy: Stem Cell Mobilization|Paclitaxel-Eluting PTCA-Balloon in Combination With the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease - Substudy Homburg/Saar|PEPCADIIIsub|University Hospital, Saarland|Yes|Completed|July 2007|November 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473499||171409|
NCT00447629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3180A1-1109|Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart|A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)- Controlled, 4-Period Crossover Study of the Effects of Single Oral Doses of PPM 204 on Cardiac Repolarization in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2007|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|March 14, 2007||||||https://clinicaltrials.gov/show/NCT00447629||173356|
NCT00449072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRG5029C_3503|Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR)||Sanofi||Completed|March 2007|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|299|||Both|3 Years|9 Years|No|||October 2011|August 7, 2012|March 15, 2007|Yes|Yes||No|June 29, 2012|https://clinicaltrials.gov/show/NCT00449072||173245|Two study sites with significant GCP noncompliance were reported to the U.S. Food and Drug Administration (FDA) by the Sponsor. A total of 5 treated participants (1 placebo and 4 TAA-AQ) from these 2 study sites were excluded from the analysis.
NCT00455026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.236|Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia|Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia||Melbourne Health|No|Completed|March 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|45|||Both|18 Years|60 Years|No|||March 2007|May 28, 2013|April 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00455026||172798|
NCT00455039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0514C|INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients|INST 0514C- A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study||University of New Mexico|Yes|Completed|July 2005|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Female|N/A|N/A|No|||October 2009|June 23, 2010|March 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00455039||172797|
NCT00455325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|395|Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)|Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2|ARCH-MS|Washington University School of Medicine|Yes|Active, not recruiting|March 2007|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|March 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00455325||172775|
NCT00472901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV015|Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)|A Phase III, Randomised, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of CUV1647 in Patients Suffering From Polymorphic Light Eruption (PLE).||Clinuvel Pharmaceuticals Limited|No|Completed|May 2007|September 2010|Actual|December 2009|Actual|Phase 3|Observational|Time Perspective: Prospective||1|Actual|18|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with moderate/severe polymorphic light eruption (PLE)|October 2011|October 4, 2011|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472901||171452|
NCT00443573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAP-0601|Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer|Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2||ARCA Biopharma, Inc.|Yes|Suspended|December 2006|||August 2007|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||May 2008|May 5, 2008|March 2, 2007|Yes|Yes|Company suspended development of product.|No||https://clinicaltrials.gov/show/NCT00443573||173662|
NCT00443586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0002|Follow-up Evaluation of Home Nurse Visitation Program for Socially Disadvantaged Women and Their Children|Age-27 Follow-up of Early Preventive Intervention||University of Colorado, Denver|Yes|Active, not recruiting|September 2004|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|345|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00443586||173661|
NCT00473135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 229|Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine|Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2007|||January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 11, 2010|May 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00473135||171435|
NCT00473707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26008|Active Versus Expectant Management of the Third Stage of Labor|A Randomized Trial of Active Versus Expectant Management of the Third Stage of Labor||Christiana Care Health Services|No|Completed|August 2002|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|218|||Female|16 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 14, 2008|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473707||171394|
NCT00473720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606001535|Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers|Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers||Yale University|No|Completed|May 2007|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2013|January 21, 2013|May 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00473720||171393|
NCT00444080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14967|Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma|A Multi Center Study Comparing the Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma||University of Virginia|No|Completed|October 2006|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00444080||173623|
NCT00444314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CLN-008|Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma|Phase II Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion Alone and in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma Progressing on Sunitinib Malate||CASI Pharmaceuticals, Inc.||Completed|February 2007|October 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|March 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00444314||173605|
NCT00444327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007005|Use Cord Blood Single Nucleotide Polymorphism to Predict the Later Development of Atopy and Allergy|Observational Study of Cord Blood Single Nucleotide Polymorphisms of Genes Related to Atopy and Allergic Diseases||Min-Sheng General Hospital|Yes|Recruiting|March 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|N/A|1 Minute|Accepts Healthy Volunteers|Non-Probability Sample|hospital and primary care clinic based study|May 2009|May 13, 2009|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444327||173604|
NCT00444340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-101615|An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis|An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2004|July 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||70|||Both|18 Years|N/A|No|||December 2007|December 5, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444340||173603|
NCT00474526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P14|A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants|A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants||Novartis||Completed|March 2007|November 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|17||Actual|4545|||Both|2 Months|2 Months|Accepts Healthy Volunteers|||February 2014|February 24, 2014|May 16, 2007|Yes|Yes||No|May 27, 2013|https://clinicaltrials.gov/show/NCT00474526||171333|
NCT00445237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-505|Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression|Evaluation of the H1 Coil and H2 Coil TMS Device - Safety and Feasibility in Major Depression Episode||Shalvata Mental Health Center|No|Completed|May 2006|March 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 2007|February 4, 2009|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00445237||173535|
NCT00445250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004253|The Role of Calcipotriol as Radioprotector of Skin|Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.||Rabin Medical Center|Yes|Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Female|18 Years|75 Years|No|||January 2007|March 7, 2007|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00445250||173534|
NCT00472667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060204|PROcalcitonin Reduce Antibiotic Treatments in Acute-Ill Patients (PRORATA)|Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients|PRORATA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|630|||Both|18 Years|N/A|No|||May 2007|November 24, 2008|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00472667||171470|
NCT00473811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P30DK032520-24|Diabetic Educational Eating Plan|Applicability of a Low Glycemic Index Diet in Diabetes|DEEP|University of Massachusetts, Worcester|No|Completed|August 2005|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|No|||August 2012|August 28, 2012|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473811||171387|
NCT00473200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #005-210|Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine|Effect of Oral S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine in Human Subjects||Baylor Research Institute|Yes|Completed|August 2009|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00473200||171430|
NCT00473798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS98-269|Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer|Patient Satisfaction and Psychological Distress Related to Emerging Technologies for Cervical Cancer Screening and Diagnosis||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 1999|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||5|Anticipated|5885|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Women who are eligible to participate in a study of the technical feasibility of optical        spectroscopy. Total Accrual for Study A: 3510; Study A': 350; pilot tests for Study A':        120; Study B: 360; and Study C: 645. Health care providers will participate in Study D        with a total accrual of 900.|March 2016|March 7, 2016|May 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00473798||171388|
NCT00449085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAH061225|Clinical Evaluation of the CARTO™ XP EP Navigation System v9 and Biosense Webster SOUNDSTAR 3D Diagnostic Ultrasound. A Feasibility Study|Clinical Evaluation of the CARTO™ XP EP Navigation System v9 and Biosense Webster SOUNDSTAR 3D Diagnostic Ultrasound. A Feasibility Study||Biosense Webster, Inc.|No|Withdrawn|April 2007|||July 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00449085||173244|
NCT00448253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX001|Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum|Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers.||Cangene Corporation|Yes|Completed|July 2007|September 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|March 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00448253||173308|
NCT00448266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N06IAA|Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD|Randomized Phase II/III Study of Intensified Alkylating Agent Chemotherapy With Peripheral Blood Progenitor Cell Support in the Preoperative Chemotherapy of Breast Tumors That Are Deficient for Homologous Recombination.||The Netherlands Cancer Institute|No|Terminated|May 2007|||February 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|237|||Female|18 Years|59 Years|No|||October 2010|October 25, 2010|March 14, 2007||No|Activation of a similar multicenter study for same population|No||https://clinicaltrials.gov/show/NCT00448266||173307|
NCT00447967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/04.18|Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients|A Randomized Phase II Study of Irinotecan and Oxaliplatin Versus the Combination of 5-FU/LV and Oxaliplatin, as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer||Hellenic Oncology Research Group|No|Completed|July 2004|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|75 Years|No|||September 2009|September 25, 2009|March 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00447967||173330|
NCT00448214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-030|Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation|Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin||Astellas Pharma Inc|Yes|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|448|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|March 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00448214||173311|
NCT00448227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810B2301|Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection|A Multicenter, Open-label, Single-arm Study to Evaluate the Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections||Novartis|No|Completed|October 2007|||November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|1 Month|1 Year|No|||February 2011|February 9, 2011|March 15, 2007|Yes|Yes||No|November 12, 2010|https://clinicaltrials.gov/show/NCT00448227||173310|
NCT00448799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-83 001|Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls|Evaluation of [123I] AV83 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Molecular NeuroImaging|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 9, 2008|March 16, 2007||||No||https://clinicaltrials.gov/show/NCT00448799||173266|
NCT00448812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2005|||||N/A|N/A|N/A||||||||||||||February 11, 2010|March 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448812||173265|
NCT00448825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11620|Novel Pharmacotherapy for Dual Dependence|Novel Pharmacotherapy for Dual Dependence||University of Virginia|Yes|Recruiting|March 2007|June 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|March 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00448825||173264|
NCT00472615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01RR000056|Menstrual Effects On Mood Symptoms in Bipolar Disorder|Menstrual Effects On Mood Symptoms in Bipolar Disorder||University of Pittsburgh|No|Completed|August 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples Without DNA|whole blood|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample and outpatient psychiatric offices|February 2009|February 25, 2009|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472615||171474|
NCT00474565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-156|Coronary Artery and Coronary Artery Bypass Graft Imaging Using a Specialized Catheter and Computed Tomography|Contrast-Enhanced Coronary Artery and Coronary Artery Bypass Graft Imaging Using Aortic Root Catheter Injection With Computed Tomographic Angiography (CTA)||William Beaumont Hospitals|Yes|Withdrawn|February 2007|December 2008|Anticipated|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|0|||Both|20 Years|N/A|No|||September 2012|September 19, 2012|May 16, 2007||No|Suspended failure to follow Conflict of Interest Management Plan|No||https://clinicaltrials.gov/show/NCT00474565||171330|
NCT00474591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-361|Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study|Fondaparinux Compared With Heparin to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery|Fonda CABG|McMaster University|No|Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2007|May 25, 2007|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00474591||171329|
NCT00473434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013213|An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia|An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia||Janssen-Cilag Pty Ltd|No|Completed|April 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|65 Years|No|||December 2012|December 4, 2012|May 11, 2007||No||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00473434||171414|
NCT00443833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-46-21|Genetic Analysis of Thyrotoxic Periodic Paralysis|Genetic Analysis of Thai Patients With Thyrotoxic Periodic Paralysis||Ramathibodi Hospital|No|Completed|January 2004|December 2005||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||||80|||Male|15 Years|N/A|No|||March 2007|March 5, 2007|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00443833||173642|
NCT00444353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL6049-0301LT|DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up|A Randomized Study of the Safety and Effectiveness of DL6049 (Injectable Poly-l-Lactic Acid) Versus Cosmoplast Collagen Implant in the Treatment of Nasolabial Fold Wrinkles (Long Term Follow-up)||Sanofi|No|Completed|August 2004|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||240|||Both|18 Years|75 Years|No|||April 2008|April 22, 2008|March 5, 2007||||No||https://clinicaltrials.gov/show/NCT00444353||173602|
NCT00444379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NCI Grant #: R01 CA119903|Anti-Retrovirals for Kaposi's Sarcoma|A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa|ARKS|University of California, San Francisco|Yes|Completed|April 2007|July 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|March 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00444379||173601|
NCT00444652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3779|Thromboprophylaxis and Bariatric Surgery|Thromboprophylaxis During Bariatric Surgery||University Hospital, Strasbourg, France|No|Recruiting|November 2006|December 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|18 Years|60 Years|No|||June 2012|June 28, 2012|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444652||173580|
NCT00444665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-06-24|Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy|Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy||Alcon Research|No|Completed|May 2007|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|750|||Both|18 Years|N/A|No|||April 2008|April 7, 2012|March 7, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00444665||173579|
NCT00475657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11473|Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer|Phase II Study of Pemetrexed Plus Cisplatin in the Treatment of Patients With Extensive Small Cell Lung Cancer||Eli Lilly and Company|No|Terminated|October 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2009|May 22, 2009|May 16, 2007|Yes|Yes|Terminated due to lack of efficacy|No|March 31, 2009|https://clinicaltrials.gov/show/NCT00475657||171247|On the advice of an independent monitoring board, this trial was stopped early due to lack of efficacy of the combination pemetrexed/carboplatin for small cell lung cancer.
NCT00444639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-48-52014-142|Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)|Phase II Multi-Centric, Randomised, Open-label, Parallel-Group Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer||Ipsen||Terminated|February 2007|June 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Male|18 Years|N/A|No|||December 2009|December 10, 2009|March 7, 2007||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT00444639||173581|
NCT00444938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-50506|Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device in the Treatment of Bipolar Depression|Evaluation of the H-Coil (TMS) Device - Safety and Feasibility in Bipolar Depression||Shalvata Mental Health Center|Yes|Completed|June 2006|March 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||March 2007|February 4, 2009|March 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00444938||173558|
NCT00445263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC/AP 39-2005|Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation|Treatment by Anti GP IIb/IIIa in the Setting of a Strategy of Early Coronarography to Patients With an Acute Coronary Syndrome Without ST Elevation|SISCA|Hospital Avicenne|Yes|Terminated|March 2007|July 2013|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|March 7, 2007||No|Because of inclusion delay|No|January 26, 2015|https://clinicaltrials.gov/show/NCT00445263||173533|
NCT00472992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS401|Pregnancy Exposure Registry for Tysabri®|TYSABRI® Pregnancy Exposure Registry||Biogen|No|Completed|January 2007|July 2012|Actual|July 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|376|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women with MS or CD who were exposed to Tysabri® in the US, Canada, and the Rest        of World within 90 days prior to their last menstrual period.|August 2014|August 7, 2014|May 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00472992|52 Weeks|171446|
NCT00473824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-3104|Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation|A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients||Biotest Pharmaceuticals Corporation|No|Terminated|May 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|75 Years|No|||May 2012|May 7, 2012|May 14, 2007|Yes|Yes|New sponsor's decision to pursue a redesigned clinical study|No|January 5, 2012|https://clinicaltrials.gov/show/NCT00473824||171386|Early termination by sponsor due to data from the initial 7 patients of 36 planned for this study. Therefore, statistical analysis was not performed and no conclusion were reached regarding efficacy or drug safety.
NCT00473512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016909|A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy|A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy||Cougar Biotechnology, Inc.|Yes|Completed|November 2005|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Male|18 Years|N/A|No|||February 2014|February 27, 2014|May 11, 2007|No|Yes||No|June 7, 2013|https://clinicaltrials.gov/show/NCT00473512||171408|
NCT00474383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016915|An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy|A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy||Cougar Biotechnology, Inc.|No|Completed|November 2006|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Male|18 Years|N/A|No|||April 2014|April 10, 2014|May 14, 2007|Yes|Yes||No|May 13, 2013|https://clinicaltrials.gov/show/NCT00474383||171344|
NCT00448279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18742|THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.|A Randomized, Open-label Study to Compare Progression-free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin||Hoffmann-La Roche||Completed|April 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|N/A|No|||October 2014|October 21, 2014|March 15, 2007||No||No|October 21, 2014|https://clinicaltrials.gov/show/NCT00448279||173306|
NCT00449293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606054|Behavioral Therapy for Reduction in Smoking Craving|Behavioral Therapy for Reduction in Smoking Craving||University of Pittsburgh|No|Active, not recruiting|October 2006|June 2009|Anticipated|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 4, 2008|March 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00449293||173228|
NCT00449605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10007|A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes|A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control With Rimonabant in Comparison With Glimepiride Over 1 Year in Overweight/Obese Type2 Diabetic Patients Not Adequately Controlled With Metformin|ALLEGRO|Sanofi||Terminated|March 2007|March 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|508|||Both|18 Years|N/A|No|||June 2009|June 12, 2009|March 19, 2007|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00449605||173206|
NCT00448578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1440L00006|Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients|A Double Dummy & Double Blind, Multicenter, Randomized Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania in Patients With Bipolar Disorder|STAR|AstraZeneca||Completed|August 2005|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||150|||Both|18 Years|65 Years|No|||December 2010|December 7, 2010|March 16, 2007||||No||https://clinicaltrials.gov/show/NCT00448578||173283|
NCT00472628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0501 - CLOSED|Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET)|Multi-marker Index for the Risk Assessment of Sepsis in the Emergency Department|MINDSET|Biosite|No|Withdrawn|May 2007|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 10, 2007|||Change in company strategy|No||https://clinicaltrials.gov/show/NCT00472628||171473|
NCT00474851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01-0004|The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial|The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial||Children's Hospital Boston|Yes|Completed|August 2007|January 2015|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Female|13 Years|22 Years|No|||March 2015|March 17, 2015|May 15, 2007|No|Yes||No|March 4, 2015|https://clinicaltrials.gov/show/NCT00474851||171309|Sample of skeletally mature young women; Measurements of aBMD are two-dimensional and do not yield information regarding skeletal strength or microarchitecture
NCT00443560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-028|The Association Between Decreasing Labor Analgesia Epidural Infusion and Forceps Delivery|A Retrospective Case-controlled Study of the Association Between Request to Discontinue Second Stage Labor Epidural Analgesia and Risk of Instrumental Vaginal Delivery||Northwestern University|No|Completed|January 2006|March 2006|Actual|March 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2162|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant Women|March 2014|March 17, 2014|March 2, 2007||No||No|May 9, 2011|https://clinicaltrials.gov/show/NCT00443560||173663|The retrospective design incurs the risk of unrecorded or unobserved data. The sample selected included all patients with neuraxial analgesia who underwent IVD, but a limited sample of SVD.
NCT00444093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002948-28|Prospective Randomized Open Label Study of the Treatment of Therapy-Associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium -|Prospective Randomized Open Label Study of the Treatment of Therapy-Associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium|Loop|Philipps University Marburg Medical Center|Yes|Not yet recruiting|September 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|200|||Both|18 Years|N/A||||August 2007|August 31, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444093||173622|
NCT00475436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC4106889|A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers|See Detailed Description||GlaxoSmithKline||Completed|May 2007|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|May 16, 2007||||No||https://clinicaltrials.gov/show/NCT00475436||171264|
NCT00475631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-70532|Economic Evaluation of Clubfoot Treatment: One Centre's Experience|Economic Evaluation of Clubfoot Treatment: One Centre's Experience||University of British Columbia|No|Withdrawn|October 2003|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|14 Years|No|Non-Probability Sample|All patients who were diagnosed and treated for idiopathic clubfoot at BCCH between        January 1984 and present are eligible for the study. Patients whose clubfoot is a        secondary diagnosis to another disorder (mal-position, neuromuscular disorder and        chromosomal abnormality) are excluded from this study.|March 2012|March 8, 2012|May 16, 2007||No|The person who started the study joined medical school|No||https://clinicaltrials.gov/show/NCT00475631||171249|
NCT00475644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8671|A Study of Enzastaurin in Patients With Follicular Lymphoma|A Phase 2 Study of Enzastaurin in Patients With Follicular Lymphoma||Eli Lilly and Company|No|Completed|May 2007|December 2014|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|May 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00475644||171248|
NCT00475904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC2007-02|A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)|A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)||EpiCept Corporation|No|Completed|July 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|May 17, 2007|Yes|Yes||No|April 20, 2011|https://clinicaltrials.gov/show/NCT00475904||171228|
NCT00475917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL844-002|A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies||Exelixis||Terminated|May 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|May 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00475917||171227|
NCT00444964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303-C02R|Growth Hormone Use in Adults With Prader-Willi Syndrome|Growth Hormone Use in Adults With Prader-Willi Syndrome||Children's Mercy Hospital Kansas City|Yes|Recruiting|April 2005|February 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||10|||Both|16 Years|60 Years|No|||March 2007|March 7, 2007|March 6, 2007||||No||https://clinicaltrials.gov/show/NCT00444964||173556|
NCT00476437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1864|Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.|Safety and Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Human Insulin 50 in Patients With Type 2 Diabetes Mellitus.||Novo Nordisk A/S|No|Completed|April 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|81|||Both|20 Years|N/A|No|||November 2014|November 3, 2014|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00476437||171188|
NCT00472446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 06/010/1B|Cervical Block in Thyroid Surgery|Impact and Cost Efficiency of Bilateral, Superficial Cervical Block in Thyroid Surgery Under General Anesthesia||Cantonal Hospital of St. Gallen|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|4||Anticipated|200|||Both|N/A|N/A|No|||December 2008|December 17, 2008|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472446||171487|
NCT00473525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7941005|12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin|A Phase 2a, Randomized, Placebo-Controlled, Parallel Group, Multiple-Dose Study To Evaluate The Efficacy, Safety, And Tolerability Of 12-Week Oral Administration Of PF-00734200 Tablets To Subjects With Type 2 Diabetes Mellitus On Stable Treatment With Metformin||Pfizer|No|Completed|July 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|303|||Both|18 Years|70 Years|No|||June 2010|June 22, 2010|May 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00473525||171407|
NCT00473837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC1076|Chloroquine and Post Malaria Anaemia Study|Chloroquine as a Therapeutic Option for Mild Post Malaria Anaemia|CQ-PMA|Medical Research Council Unit, The Gambia|No|Completed|July 2007|December 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|12 Months|72 Months|Accepts Healthy Volunteers|||October 2014|October 9, 2014|May 15, 2007||No||No|October 9, 2014|https://clinicaltrials.gov/show/NCT00473837||171385|
NCT00474110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03799|Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's Mucositis|Ketamine and Hydromorphone PCA Analgesia for Antineoplastic-Induced Pediatric Mucositis||University of British Columbia|No|Withdrawn|August 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|5 Years|19 Years|No|||October 2010|October 29, 2010|May 14, 2007||No|Clinical practice had changed between time of initial protocol development and subject    recruitment. We were not able to find eligible patients.|No||https://clinicaltrials.gov/show/NCT00474110||171364|
NCT00474123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|893/05|Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe|Comparison of Antiplatelet and Anti-inflammatory Effects of High Dose Statin Monotherapy Versus Moderate Dose Statin Plus Ezetimibe||University of Sao Paulo|No|Completed|January 2006|August 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|80 Years|No|||February 2010|June 18, 2010|May 15, 2007|Yes|Yes||No|January 8, 2010|https://clinicaltrials.gov/show/NCT00474123||171363|Adverse Events were assessed, but none were observed.
NCT00475241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-010-06F|Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms|Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms||VA Office of Research and Development|No|Completed|January 2008|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|May 17, 2007||No||No|October 27, 2014|https://clinicaltrials.gov/show/NCT00475241||171279|
NCT00448006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIS-CL-001|Clinical Feasibility Study of Allium's Biliary Stent|A Clinical Feasibility Study to Evaluate the New Allium Biliary Stent, in Patients Suffering From “Malignant Biliary Duct Obstruction” (Endoscopic Insertion)||Allium, Ltd.|No|Not yet recruiting|April 2007|December 2008||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||30|||Both|18 Years|N/A|No|||March 2007|March 14, 2007|March 14, 2007||||No||https://clinicaltrials.gov/show/NCT00448006||173327|
NCT00448552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20030243|Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer|Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|February 2004|June 2008|Actual|April 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|March 15, 2007||||No||https://clinicaltrials.gov/show/NCT00448552||173285|
NCT00448565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEC-06-2807|Prediction of Extubation Success by the Patient|||Ospedale Regionale Bellinzona e Valli||Completed|January 2007|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|16 Years|N/A|No|Probability Sample|Patients in interdisciplinary ICU|January 2009|January 30, 2009|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448565||173284|
NCT00448305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 4002|EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients|An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients||MediGene|Yes|Completed|January 2007|March 2011|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|143|||Female|18 Years|N/A|No|||January 2012|January 3, 2012|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00448305||173304|
NCT00448591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO19391|A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.|An Open-label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-based Chemotherapy in Patients With Locally Recurrent or Metastatic Breast Cancer||Hoffmann-La Roche||Completed|September 2006|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2296|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|March 16, 2007||No||No|December 22, 2014|https://clinicaltrials.gov/show/NCT00448591||173282|
NCT00443287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI6174|Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease|A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of HMR1766 Assessing the Efficacy and Safety of 3 Doses of HMR1766 Versus Placebo With Cilostazol as a Calibrator, Administered for 26 Weeks in Patients With Peripheral Arterial Disease (PAD) Fontaine Stage II|ACCELA|Sanofi||Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|553|||Both|40 Years|N/A|No|||March 2011|March 31, 2011|March 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00443287||173684|
NCT00474318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB# 2008-1634|Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Adolescent Bariatrics: Assessing Health Benefits and Risk|Adolescent Bariatrics: Assessing Health Benefits and Risks|Teen-LABS|Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|March 2007|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Serum, plasma and urine, as well as liver samples (if agreed upon as part of the study; may      participate in the study without giving samples per Informed Consent)|Both|12 Years|18 Years|No|Non-Probability Sample|Adolescents who are approved to undergo bariatriac surgery, at a participating study site,        by a Teen-LABS approved surgeon, that have signed Informed Consent to participate in the        study|June 2012|February 3, 2015|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474318||171349|
NCT00443846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S06-ROT-304|RotaTeq® and Meningococcus C Vaccine in Healthy Infants|An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants||Sanofi Pasteur MSD||Completed|February 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|246|||Both|42 Days|56 Days|Accepts Healthy Volunteers|||April 2009|November 27, 2015|March 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00443846||173641|
NCT00475150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00129|Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase II Study of AZD2171 in the Treatment of Patients With Acute Leukemia and Myelodysplastic Syndrome.||National Cancer Institute (NCI)||Completed|May 2008|March 2012|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||November 2011|September 18, 2014|May 16, 2007|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00475150||171286|
NCT00475163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-04-018|Mentors in Motion: A Physical Activity Intervention for Obese Adolescents|Mentors in Motion: A Physical Activity Intervention for Obese Adolescents|MIM|McGill University Health Center|No|Completed|November 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||March 2009|March 3, 2009|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475163||171285|
NCT00475930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU87F7|Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates|Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates: A Randomized, Double-Blind, Placebo-Controlled Trial||Uniformed Services University of the Health Sciences|Yes|Completed|May 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1563|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00475930||171226|
NCT00476190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-254|ALL Adult Consortium Trial: Adult ALL Trial|ALL Adult Consortium Trial: Adult ALL Trial||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2007|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|50 Years|No|||February 2016|February 11, 2016|May 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00476190||171207|
NCT00476177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-003|Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant|Infusion of Donor Dendritic Cells and Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogenic Transplant||Dana-Farber Cancer Institute|Yes|Completed|July 2003|July 2009|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|May 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00476177||171208|
NCT00472680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0082|The Effect of Severe Weight Loss and Protein Intake on Bone|Nutritional Regulation of Bone - Aim 2||Rutgers University|Yes|Recruiting|March 2008|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Female|18 Years|70 Years|No|||July 2012|July 12, 2014|May 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00472680||171469|
NCT00465426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK49302-10AR|HIV and Cardiovascular Risk|Assessment of Cardiovascular Risk in HIV Patients||Massachusetts General Hospital|No|Completed|April 2007|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|129|Samples Without DNA|blood will be frozen for end of study analysis for insulin, CRP, adiponectin, TNF-α, sTNFR2,      IL-6, PAI-1, MCP-1|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Flyers and advertisements regarding this study will be posted in community centers and        newspapers|October 2012|October 30, 2012|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465426||172020|
NCT00465699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001369|Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis|Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis||Spartanburg Regional Family Medicine|Yes|Recruiting|April 2007|April 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||50|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||April 2007|April 23, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465699||171999|
NCT00465972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8899|The Treatment of Insomnia in Patients With HIV Disease|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Doxepin and Temazepam in HIV Seropositive Patients With Insomnia.||Duke University|Yes|Completed|March 2007|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|69 Years|No|||May 2013|July 26, 2013|April 25, 2007|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00465972||171978|
NCT00487149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1233R0203|Respiratory Muscle Strength in Bronchiectasis: Repeatability and Reliability|||University of Ulster|Yes|Completed|October 2005|July 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 13, 2009|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00487149||170382|
NCT00487357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0294|MATCh Parents' Supplemental Survey|MATCh Parents' Supplemental Survey: Predictors of Smoking in Mexican American Youth||M.D. Anderson Cancer Center|No|Completed|June 2006|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1215|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Parents/guardians of participants in the MATCh study (accompany UT MDACC Protocol        2004-0616, "Predictors of Smoking in Mexican American Youth," also known as the MATCh        study).|June 2012|February 17, 2016|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487357||170366|
NCT00487968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA110087|Eltrombopag Taste Testing in Healthy Adult Volunteers|Eltrombopag Pediatric Formulation Taste Testing in Healthy Adult Volunteers||GlaxoSmithKline|No|Completed|May 2007|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|June 15, 2007||||||https://clinicaltrials.gov/show/NCT00487968||170319|
NCT00487929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP051937|Oxidative Stress and Cardiovascular Morbidity in Sleep Apnea-Hypopnea Syndrome (SAHS)|Phase 4 Study of the Relationship Between the Oxidative Stress and the Development of Cardiovascular Complications in the Sleep Apnea-hypopnea Syndrome (SAHS). Effect of the Treatment With CPAP|OSCAMSA|Hospital Universitario La Paz|No|Completed|June 2007|October 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2008|April 1, 2013|June 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487929||170322|
NCT00488540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291/06|Is Paracetamol an Effective Treatment for Chronic Moderate Pain in the Newborn After Operative Vaginal Delivery?|Is Paracetamol an Effective Treatment for Chronic Moderate Pain in the Newborn After Operative Vaginal Delivery?||Basel Women’s University Hospital|No|Completed|June 2007|May 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|280|||Both|N/A|1 Hour|Accepts Healthy Volunteers|||July 2012|July 19, 2012|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00488540||170276|
NCT00467571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID11-48-20|Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura|Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura||Mahidol University|Yes|Completed|March 2006|December 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|2 Years|18 Years|No|||September 2008|May 1, 2013|April 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00467571||171857|
NCT00467584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004850|Aspirin for Treatment of Multiple Sclerosis-Related Fatigue|Aspirin for Treatment of Multiple Sclerosis-Related Fatigue||Mayo Clinic|No|Terminated|July 2007|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|65 Years|No|||May 2014|May 15, 2014|April 26, 2007|No|Yes|Interim analysis indicated treatment unlikely effective;slow recruitment|No|April 17, 2014|https://clinicaltrials.gov/show/NCT00467584||171856|Early termination leading to smaller number of subjects analyzed.
NCT00463398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2818 - 20/02/2006 b|Fertility Surgery, Prospective Analysis|Quality Control in Surgical Diagnosis and Treatment of Endometriosis.||University Hospital, Gasthuisberg|No|Recruiting|September 2006|August 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Endometriosis is confirmed by histologic examination of excised lesions|Female|19 Years|45 Years|No|Non-Probability Sample|All patients operated at the Leuven University Fertility Centre (LUFc) between september        2006 and August 2008.|August 2010|August 31, 2010|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463398||172172|
NCT00463411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025|Study of Male Osteoporosis and Aging|Study on Male Osteoporosis and Aging||Odense University Hospital||Recruiting|December 2006|December 2017|Anticipated|||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal||||30000|||Male|60 Years|70 Years|Accepts Healthy Volunteers|||December 2006|April 19, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463411||172171|
NCT00463697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C106996|A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients|A Randomized, Single-dose, Dose-ascending, Double Blind, Placebo-controlled, 5-way Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With Magnesium Stearate in Asthmatic Patients||GlaxoSmithKline||Completed|April 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|70 Years|No|||February 2011|May 31, 2012|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463697||172149|
NCT00463983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-32|Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide|Phase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary Fibrosis|FIBROSAND|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|October 2006|January 2012|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|40 Years|N/A|No|||September 2012|September 20, 2012|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463983||172127|
NCT00463996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-Center-001|MRI in Staging Ovarian Cancer Using MRI Contrast Agent|Værdien af MRI Til Staging af c.Ovarii-et Prospektivt Studie||University of Aarhus|No|Not yet recruiting|April 2007|April 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal||||50|||Female|N/A|N/A|No|||April 2007|April 18, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463996||172126|
NCT00464308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006397|A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg|The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)||Janssen-Cilag Pty Ltd|No|Completed|November 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1392|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|April 20, 2007||No||No|June 9, 2009|https://clinicaltrials.gov/show/NCT00464308||172103|The MCID of 7.5% was amended to 9% to maintain power with smaller sample size.The proportion of patients without heartburn symptoms at baseline was not evenly distributed between treatment arms. This was a significant predictor of symptom resolution.
NCT00463970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINS2007|Cognitive Interventions and Nutritional Supplementation for Patients With Long-lasting Back Pain|A Randomized Controlled Multicentre Trial of a Brief Intervention (BI) Versus a BI Plus Cognitive Behavioural Treatment (CBT) Versus Nutritional Supplementation for Patients With Long-lasting Back Pain.|CINS|Uni Research|Yes|Completed|February 2008|August 2012|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|414|||Both|20 Years|60 Years|No|||June 2015|June 25, 2015|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463970||172128|
NCT00464269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01253|Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures|An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures||UCB Pharma|No|Completed|September 2007|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|400|||Both|16 Years|70 Years|No|||March 2015|March 9, 2015|April 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464269||172106|
NCT00464282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gunma 444|Fluorine-18-α–Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer|||Gunma University||Completed||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|8 Months|2 Years|No|||April 2007|April 20, 2007|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00464282||172105|
NCT00464854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-2323|Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward|Feasiblity, Safety And Efficacy Of Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward||Assaf-Harofeh Medical Center|No|Terminated|July 2005|September 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||April 2007|April 23, 2007|April 22, 2007|||The study was started before the official request for protocol registration|No||https://clinicaltrials.gov/show/NCT00464854||172062|
NCT00464867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-032|Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine|||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|January 2006|December 2008|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|128|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||June 2012|June 9, 2012|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464867||172061|
NCT00464880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2243|Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy|A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipient/Overt Diabetic Nephropathy||Novartis|No|Completed|September 2005|November 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|30 Years|80 Years|No|||November 2007|November 28, 2007|April 21, 2007||||No||https://clinicaltrials.gov/show/NCT00464880||172060|
NCT00465192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG/PD/009/USA|Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of 17-Beta Estradiol 10 Micrograms and 25 Micrograms (Vagifem) Doses in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis||Novo Nordisk A/S|No|Completed|August 1994|November 1995|Actual|November 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|230|||Female|45 Years|80 Years|No|||March 2012|March 19, 2012|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465192||172038|
NCT00465439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27071995|Safety/Efficacy Study of Local Anesthetic Prior to Femoral Artery Sheath Removal|Randomized Controlled Trial Examining the Effect of Subcutaneous Xylocaine 2% on the Incidence of Vasovagal Reactions and Pain Intensity During Femoral Artery Sheath Removal.||McMaster University|No|Completed|May 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 21, 2008|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465439||172019|
NCT00465712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN05-FP/AMNIO2006|Effect of Amnioinfusion on External Cephalic Version Successful Rate|Effect of Amnioinfusion on External Cephalic Version After Initial Failure a Prospective Multicentric Randomized Study|AMNIO|University Hospital, Tours|Yes|Terminated|July 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|N/A|No|||May 2011|May 31, 2011|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465712||171998|
NCT00465985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2304|Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome|A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome|REMITTER|Novartis||Completed|April 2007|||October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|4 Years|75 Years|No|||July 2012|July 31, 2012|April 25, 2007|Yes|Yes||No|November 16, 2010|https://clinicaltrials.gov/show/NCT00465985||171977|The outcomes for this study were reported in separate tables for each period. The SAE and AEs were reported in all in one table.
NCT00487162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120070093|The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality|The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality||Rutgers, The State University of New Jersey|No|Terminated|June 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|95 Years|No|||February 2014|February 20, 2014|June 13, 2007||No|potential harm of insulin infusion outweights the benefit.|No|December 3, 2010|https://clinicaltrials.gov/show/NCT00487162||170381|Study was terminated. No final conclusion drawn. A sentinel article was published in Feb 2009 issue of Anesthesiology which questioned the safety of intense insulin therapy/strict glycemic control.
NCT00487630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM-01-076|Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease|A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease|HEART|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2005|June 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Female|15 Years|N/A|No|||June 2007|June 15, 2007|June 15, 2007||||No||https://clinicaltrials.gov/show/NCT00487630||170345|
NCT00487942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/2033/SZ/US|Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits|A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia||Teva Pharmaceutical Industries||Completed|July 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|60 Years|No|||July 2013|July 12, 2013|June 15, 2007|Yes|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00487942||170321|
NCT00488241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401663|Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema|A Multicenter, Open Uncontrolled Clinical Study to Examine the Efficacy and Safety of Zarzenda in the Management of Hand Eczema||Bayer|No|Completed|June 2007|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488241||170299|
NCT00488527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_01890|DOMME Dose Optimization Multicentric Mexican Evaluation|Multicentric, Open Label Clinical Trial. Use of Optimal Method to Initiate and Maintain Lantus Therapy (Insulin Glargine) in Combination With Hypoglycemic Agents, Assessing the Resulting Metabolic Control and the Safety in T2 Diabetes Mellitus Patients.|DOMME|Sanofi||Completed|April 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|371|||Both|18 Years|N/A|No|||September 2010|September 10, 2010|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488527||170277|
NCT00488553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0281|Molecular Epidemiology of Lymphoma Patients|Molecular Epidemiology of Lymphoma Patients||M.D. Anderson Cancer Center|No|Withdrawn|August 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Subjects will also provide 30 cc of blood. The blood will be genotyped, and the genotype and      epidemiological data will be used to evaluate the role of genomic instability (baseline and      induced) in the development of lymphomas.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants in this study will include 400 with newly diagnosed lymphoma and 400 matched        controls.|February 2012|February 23, 2012|June 19, 2007||No|No participants recruited, study discontinued.|No||https://clinicaltrials.gov/show/NCT00488553||170275|
NCT00467597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCD-003-05F|Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)|Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One)||VA Office of Research and Development|Yes|Completed|April 2006|October 2013|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|36|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson's disease patients on Levodopa with or without dyskinesia (abnormal involuntary        movements caused by levodopa usage).|November 2014|November 19, 2014|April 27, 2007|No|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT00467597||171855|
NCT00467610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS 2005-01|Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS|A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome||Rush University Medical Center|Yes|Terminated|May 2007|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|April 26, 2007|Yes|Yes|lack of efficacy.|No|August 21, 2012|https://clinicaltrials.gov/show/NCT00467610||171854|
NCT00463424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#2K-049C|Comparison of NeuFlex and Swanson Metacarpophalangeal Implants for Rheumatoid Arthritis|NeuFlex and Swanson Metacarpophalangeal Implants for Rheumatoid Arthritis: a Prospective Randomized Controlled Clinical Trial||St. Michael's Hospital, Toronto|No|Completed|October 2000|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463424||172170|
NCT00463710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-05-AVX|Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS|Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis||State University of New York at Buffalo|No|Completed|June 2005|September 2006|Actual|||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||150|||Both|18 Years|65 Years|No|||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463710||172148|
NCT00464035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01-144/02|The Effect of Calcium on Postprandial Lipid Profile and Appetite|||University of Copenhagen||Completed|February 2005|October 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2004|January 20, 2009|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00464035||172123|
NCT00464009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-P-91251/4-02|Development and Evaluation of a Medical Intervention for Early Childhood Caries|Development and Evaluation of a Medical Intervention for Early Childhood Caries|IMB-RCT|University of North Carolina, Chapel Hill|No|Completed|February 2001|November 2007|Actual|April 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2009|January 28, 2010|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00464009||172125|
NCT00464022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-3277|CO2 Insufflation During Double Balloon Enteroscopy|Carbon Dioxide Versus Air Insufflation in Double-Balloon Endoscopy -a Randomised Controlled Multicentre Trial||Rikshospitalet University Hospital|No|Completed|November 2006|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|100|||Both|16 Years|90 Years|No|||October 2007|October 16, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00464022||172124|
NCT00464321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1008FSGS00505|Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS|A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)||Sanofi|Yes|Completed|May 2007|February 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|April 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00464321||172102|
NCT00464334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V950-001|A Study of V950 in People With Alzheimer Disease (V950-001 AM7)|A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease||Merck Sharp & Dohme Corp.|No|Completed|March 2007|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|11||Actual|86|||Both|55 Years|N/A|No|||September 2015|September 24, 2015|April 20, 2007|No|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00464334||172101|
NCT00464581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF-4153s|Lucentis for Treatment of Macular Edema|A Single-center Phase 2 Trial of Intravitreous Injections of Lucentis (Ranibizumab) in Subjects With Cystoid Macular Edema Secondary to Non-ischemic Retinopathy|FVF4153s|Retina Institute of Hawaii|No|Completed|May 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|N/A|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Macular Edema|May 2012|May 24, 2012|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00464581||172083|
NCT00464893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-CAT-GC-03|Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection|Multicenter, Open-label Phase II Study to Evaluate the Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients With Gastric Adenocarcinoma After Neoadjuvant Chemotherapy and Intended Curative Resection||Neovii Biotech|Yes|Completed|April 2007|April 2013|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464893||172059|
NCT00465205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21760-A (2)|HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons|A Randomized,Double-Blind , Placebo-Controlled Crossover Trial of Antivirals for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Co-infected Persons||University of Washington|No|Completed|January 2005|December 2007|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|20|||Female|18 Years|N/A|No|||August 2013|August 21, 2013|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465205||172037|
NCT00465452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUO-04|Impact of Switching to Continuous Release Dopamine Agonists|The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects||University of Toledo Health Science Campus|No|Completed|January 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|55 Years|N/A|No|||March 2009|March 18, 2009|April 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465452||172018|
NCT00465725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602 Oral Picoplatin|A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors|A Randomized Crossover Oral Bioavailability Study Comparing the Pharmacokinetics and Pharmacodynamics of Picoplatin Administered Orally With Picoplatin Administered Intravenously in Subjects With Advanced Non-Hematological Malignancies||Poniard Pharmaceuticals|Yes|Completed|April 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|April 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465725||171997|
NCT00466830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540539|Psychological and Social Factors That May Increase the Risk of Developing Chronic Pain After Surgery in Women With Breast Cancer|Study of Psychological and Sociological Predisposing the Development of Chronic Pain After Surgery in Women With Resectable Breast Cancer||National Cancer Institute (NCI)||Completed|September 2005|||May 2011|Actual|N/A|Observational|N/A|||Anticipated|150|||Female|18 Years|N/A|No|||May 2011|May 12, 2011|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466830||171913|
NCT00487409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-06-33|Random Comparison of LigaSure and Disposable Staples for Laparoscopic Surgery|A Randomized Trial Comparing Outcomes for the LigaSure and Disposable Stapling Instruments for Laparoscopic Surgery||University Hospital Case Medical Center|No|Completed|December 2006|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||December 2014|December 12, 2014|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487409||170362|
NCT00487643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU# 07-23021|Normal Lacritin Levels in Human Tears- Development of a New Clinical Assay|Normal Lacritin Levels in Human Tears- Development of a New Clinical Assay||Walter Reed Army Medical Center||Completed|May 2008|March 2014|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Military health care beneficiary between the ages of 21-55.|July 2014|July 10, 2014|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487643||170344|
NCT00487656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-001|Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation|A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation||Artisan Pharma, Inc.|Yes|Completed|July 2007|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|750|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|June 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487656||170343|
NCT00487383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070165|Brain Changes in Blepharospasm|Suppression and Facilitation of the Motor Cortex by Stimulation of the Cerebellum in Patients With Dystonia and Healthy Controls||National Institutes of Health Clinical Center (CC)||Terminated|June 2007|June 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|47|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2012|February 19, 2014|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487383||170364|
NCT00487396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-51|Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease|Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease|MA-51|Given Imaging Ltd.|No|Completed|September 2007|November 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|98|||Both|10 Years|65 Years|No|||March 2012|April 17, 2012|June 14, 2007||No||No|March 20, 2012|https://clinicaltrials.gov/show/NCT00487396||170363|
NCT00487994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-475-002|Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia|A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of Lapaquistat Acetate Alone or Coadministered With Atorvastatin in Subjects With Primary Dyslipidemia||Takeda|Yes|Completed|November 2004|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2130|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|June 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487994||170317|
NCT00488254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03385|The Long QT Syndrome in Pregnancy|The Long QT Syndrome in Pregnancy||University of British Columbia|No|Completed|June 2007|April 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|12|||Female|N/A|N/A|No|Probability Sample|Women managed at St. Paul's or BC Women's, Vancouver, who have been pregnant in the last 5        years|April 2011|April 12, 2011|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488254||170298|
NCT00487981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS0206|Spinal Cord Stimulation for Painful Diabetic Neuropathy|Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy|DPN|Boston Scientific Corporation|No|Terminated|February 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|June 15, 2007||No|Insufficient Data Collected|No|February 13, 2012|https://clinicaltrials.gov/show/NCT00487981||170318|One subject enrolled.
NCT00464620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC009|Trial of Dasatinib in Advanced Sarcomas|A Phase II Trial of Dasatinib in Advanced Sarcomas||Sarcoma Alliance for Research through Collaboration|Yes|Active, not recruiting|May 2007|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|386|||Both|13 Years|N/A|No|||June 2014|December 17, 2014|April 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00464620||172080|
NCT00463437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109507|Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines|Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines||GlaxoSmithKline||Completed|April 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1437|||Both|11 Months|18 Months|Accepts Healthy Volunteers|||August 2012|June 12, 2014|April 19, 2007|Yes|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00463437||172169|
NCT00463450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90651|Efficacy of Gynodian® Depot in Women With Impaired Well-being|A Multicenter, Double-blind, Randomized, Cross-over Study to Investigate the Efficacy of Gynodian® Depot i.m. Compared to 4 mg Estradiol Valerate i.m. Both Given Every Four Weeks for Five Months Combined With 5 mg Medroxyprogesterone Acetate Orally in Postmeno-pausal Women With Impaired Well-being, Mood and Sexuality||Bayer|No|Completed|May 2002|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Female|45 Years|65 Years|No|||December 2014|December 28, 2014|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463450||172168|
NCT00465231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01|Preventive Analgesia in Multiparas Undergoing Induction of Labour|Preventive Analgesia in Labour:A Randomised, Placebo-Controlled Study in Multiparas Undergoing Induction of Labour||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|January 2007|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 12, 2007|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465231||172035|
NCT00464347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-EI-0064|TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration|Multi-Center, Randomized, Phase II Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide and Avastin® in Combination With Photodynamic Therapy in Participants With Neovascular Age Related Macular Degeneration|VERTACL|National Eye Institute (NEI)|Yes|Terminated|January 2007|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||October 2007|March 23, 2010|April 19, 2007|||Study was terminated because of poor enrollment.|No||https://clinicaltrials.gov/show/NCT00464347||172100|
NCT00464607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00IF/HMG06|Prospective, Randomized, Controlled, Clinical Study on Tolerability and Efficacy of hMG-IBSA|A Prospective, Randomized, Controlled Clinical Study on the Assessment of Tolerability and of Clinical Efficacy of MERIONAL® (hMG-IBSA) Administered Subcutaneously Versus MERIONALâ Administered Intramuscularly in Women Undergoing Controlled Ovarian Hyperstimulation (COH) in an ART Programme (IVF)||IBSA Institut Biochimique SA|No|Completed|December 2001|April 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||160|||Female|20 Years|40 Years|No|||April 2007|April 20, 2007|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00464607||172081|
NCT00464594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEDIS ver.4.0|Japan Early Diabetes Intervention Study|A Randomized Comparative Clinical Study on Suppression of Progression From Early Diabetes, Diet/Exercise Standard Intervention vs. Concurrent Pharmacological Standard Intervention|JEDIS|Japan Early Diabetes Intervention Study Group||Recruiting|April 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||2560|||Both|30 Years|69 Years|No|||April 2007|April 22, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00464594||172082|
NCT00465465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB009|A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG|A Dose Selection Study Evaluating the Safety and Immunogenicity of 2 Different Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Have Previously Been Vaccinated With BCG||University of Oxford|No|Completed|October 2005|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|April 2, 2008|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465465||172017|
NCT00465738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201 - 0607 / 1|IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity|Prospective, Randomized, Observer-blind, Parallel-group, Multi-center Trial to Assess Efficacy and Safety of Two Different Dilutions of incobotulinumtoxinA (Xeomin) in Patients With Upper Limb Spasticity|NT-Spin|Merz Pharmaceuticals GmbH|No|Completed|February 2007|May 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||December 2010|December 21, 2010|April 24, 2007|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00465738||171996|
NCT00465998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StaHF483201|Study of Ultrasound Imaging to Predict Time and Outcome in Pregnancies With Induced Labor|Prediction of Labor and Delivery With the Use of Ultrasound in Pregnancies With Induced Labor||Helse Stavanger HF|No|Completed|January 2006|March 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|250|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant females with indication for induced labor|August 2010|July 27, 2015|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00465998||171976|
NCT00466011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0099/07|Validation of the Stardust Cardio-Respiratory Recorder|Validation of the Stardust Cardio-Respiratory Recorder|Stardust|Associação Fundo de Incentivo à Pesquisa|Yes|Completed|April 2007|May 2008|Actual|November 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ambulatory patients with complains of OSA|July 2012|July 11, 2012|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466011||171975|
NCT00466310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008577|Metabolic Signatures and Biomarkers in Schizophrenia|Metabolic Signatures and Biomarkers in First Episode and Recurrent Patients With Schizophrenia in Comparison to Healthy Controls||Duke University|No|Completed|February 2007|January 2011|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|July 11, 2014|April 25, 2007|No|Yes||No|April 5, 2011|https://clinicaltrials.gov/show/NCT00466310||171952|Limited to patients admitted to Psychiatric facility
NCT00466596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0768|Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements|Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements|MiteE|University of North Carolina, Chapel Hill|No|Completed|March 2007|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|April 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00466596||171931|
NCT00466609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/55628-8|Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment|Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study|EPMTOC|University of Sao Paulo|Yes|Completed|May 2007|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|65 Years|No|||May 2010|May 12, 2010|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466609||171930|
NCT00467350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-07-117|Comparison Trial of Enema vs. PEG 3350 for Constipation|Randomized Clinical Trial of Milk and Molasses Enema vs. PEG 3350 for Fecal Impaction in Childhood Constipation||Children's Mercy Hospital Kansas City|No|Terminated|December 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|1 Year|17 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|April 26, 2007||No|concern patients in oral cleaout arm had worse outcome|No||https://clinicaltrials.gov/show/NCT00467350||171873|
NCT00487188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV18406|A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience|Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients|INTENSE|Hoffmann-La Roche||Completed|November 2005|April 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|June 14, 2007||No||No|March 22, 2011|https://clinicaltrials.gov/show/NCT00487188||170379|
NCT00487695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA0002805|Confocal Endomicroscopy for Barrett's Esophagus|Confocal Laser Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Associated Neoplasia|CEBE|Johns Hopkins University|Yes|Completed|April 2007|September 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|46|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|June 18, 2007||No||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00487695||170340|Relatively small study (39 patients) and performed at a tertiary care, referral center, which can reduce generalizability.
NCT00487708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2102|Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms|An Open-Label, Phase II Dose Titration Study of ACZ885 (Human Anti-IL-1β Monoclonal Antibody) to Assess the Clinical Efficacy, Safety, Pharmacokinetics and Pharmacodynamics in Patients With NALP3 Mutations||Novartis|Yes|Completed|January 2005|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|4 Years|75 Years|No|||February 2009|February 16, 2009|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00487708||170339|
NCT00488007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.414|Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids|Clinical Trial on Cognitive, Behavioural, Quality of Life and Medico-Economic Benefits of Hearing Aids in Alzheimer Disease Patients Suffering From Presbycusis||Hospices Civils de Lyon|No|Recruiting|May 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||30|||Both|65 Years|N/A|No|||June 2007|June 18, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00488007||170316|
NCT00487669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0433|Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)|Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-small Cell Lung Cancer.||Dartmouth-Hitchcock Medical Center|Yes|Completed|October 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|June 14, 2007|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT00487669||170342|
NCT00487682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15L-CL-221|Dose-finding Study of ASP2151 in Subjects With Herpes Zoster|Dose-finding Study of ASP2151 in Subjects With Herpes Zoster- A Multicenter, Randomized, Double-blind, Valacyclovir Hydrochloride-controlled, Parallel-group, Comparative Study||Astellas Pharma Inc|No|Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|403|||Both|20 Years|79 Years|No|||December 2011|December 19, 2011|June 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00487682||170341|
NCT00488280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|313-2006|Restoring Walking in Non-ambulatory Children With Severe Chronic Spinal Cord Injury (SCI) (Kids STEP Study)|Restoring Walking in Non-ambulatory Children With Severe Chronic SCI (Kids STEP Study)||University of Florida|No|Completed|February 2007|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|3 Years|13 Years|No|||January 2010|January 7, 2013|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488280||170296|
NCT00464932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 168/2003|Vasoactive Intestinal Peptide in COPD||VIPCOPD|Medical University of Vienna|Yes|Completed|June 2003|July 2006|Actual|||Phase 2|Observational|Allocation: Random Sample, Time Perspective: Longitudinal||||34|||Both|18 Years|75 Years|No|||April 2007|April 23, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00464932||172057|
NCT00464945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3000|Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomised,Active-Controlled ,Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|269|||Both|41 Days|99 Days|Accepts Healthy Volunteers|||July 2012|July 6, 2012|April 23, 2007|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00464945||172056|
NCT00464958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol C2/5/TZ:MS-05 EXT|One Year Extension Study To Protocol C2/5/TZ:MS-05|Long Term Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in Patients With Multiple Sclerosis - Open Label Extension Study||Teva GTC|No|Terminated|January 2008|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|65 Years|No|||January 2009|February 17, 2009|April 22, 2007|||Study was stopped as the sponsor is no longer funding this project|No||https://clinicaltrials.gov/show/NCT00464958||172055|
NCT00465478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QL060308|Autologous Bone Marrow Mononuclear Cells Transplantation in Treating Diabetes Patients|Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Patients With Type 1 or 2 Diabetes Mellitus－a Phase 1/2 Study||Shandong University|Yes|Recruiting|March 2006|March 2014|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|16 Years|65 Years|No|||April 2007|April 24, 2007|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465478||172016|
NCT00465751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 211/04 SB|Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism|Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia||University Hospital, Basel, Switzerland|Yes|Completed|October 2004|||||Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465751||171995|
NCT00465764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK44|Tolerance and Development of Healthy, Term Infants|Pilot Tolerance and Bone Status of Healthy, Term Infants Fed Infant Formulas||Abbott Nutrition|Yes|Completed|April 2007|June 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|N/A|8 Days|Accepts Healthy Volunteers|||June 2008|April 24, 2009|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465764||171994|
NCT00464919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950914|Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)|A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma||National Taiwan University Hospital|Yes|Completed|April 2007|March 2009|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2009|July 6, 2009|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464919||172058|
NCT00465218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006785-01H|Transcranial Doppler (TCD) Assessment During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement|"Transcranial Doppler Assessment of Cerebral Embolization During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement: Comparison of High-dose Aspirin Versus Warfarin Plus Low-dose Aspirin"|Tissue-Valve|Ottawa Heart Institute Research Corporation|No|Completed|March 2007|March 2011|Actual|December 2007|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with aortic valve stenosis and/or insuficiency undergoing aortic valve        replacement with a bioprosthetic valve (tissue valve).|June 2012|June 20, 2012|April 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00465218||172036|
NCT00466323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-255|The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.|The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness||VA Office of Research and Development|No|Completed|September 2007|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|70 Years|No|||August 2014|April 6, 2015|April 24, 2007||No||No|October 9, 2014|https://clinicaltrials.gov/show/NCT00466323||171951|
NCT00466622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-000792-33|Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin|Uterine Artery Blood Flow in Pregnant Women With Polycystic Ovary Syndrome(PCOS)Treated With Metformin - a Substudy to The PregMet Study|FlowMet|Norwegian University of Science and Technology|No|Completed|April 2007|February 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Female|18 Years|45 Years|No|||November 2011|November 16, 2011|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466622||171929|
NCT00466635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOL26700706|A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea|An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea||Sanofi||Terminated|April 2007|August 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|65|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|April 25, 2007||||||https://clinicaltrials.gov/show/NCT00466635||171928|
NCT00466843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5406|Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome|Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)||Office of Rare Diseases (ORD)|Yes|Recruiting|April 2007|February 2010|Anticipated|February 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||June 2009|June 1, 2009|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466843||171912|
NCT00467103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-006-06S|Neural Networks and Language Recovery in Aphasia From Stroke: fMRI Studies|Neural Networks and Language Recovery in Aphasia From Stroke: fMRI Studies||VA Office of Research and Development|No|Recruiting|October 1999|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|45 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chronic stroke patients with nonfluent aphasia|February 2016|February 29, 2016|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00467103||171892|
NCT00467376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_00348|Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus|12-week, Multicenter, Controlled, Open, 3:1 Randomized, Parallel Clinical Trial Comparing Insulin Glulisine With Regular Human Insulin (Insulin Lispro) Injected Subcutaneously in Subjects With Type 1 or 2 Diabetes Mellitus Also Using Lantus (Insulin Glargine)||Sanofi|No|Completed|January 2007|||June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|485|||Both|18 Years|70 Years|No|||September 2009|September 14, 2009|April 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00467376||171871|
NCT00467649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA401|A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes|A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes||AstraZeneca|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|75 Years|No|||March 2015|March 26, 2015|April 27, 2007|Yes|Yes||No|April 10, 2009|https://clinicaltrials.gov/show/NCT00467649||171851|
NCT00478400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0256|Awareness of Deficit After Combat-related Brain Injury|Awareness of Deficit After Combat-related Brain Injury||University of Wisconsin, Madison|Yes|Recruiting|October 2007|October 2016|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Veterans will be recruited through the Middleton VA Hospital in Madison, WI. Civilian        participants will be recruited from a previous study led by Dr. Johnson.|September 2010|October 6, 2015|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00478400||171043|
NCT00487422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-INT-12|Efficacy and Safety Study of Prucalopride for the Treatment of Elderly Patients With Chronic Constipation|A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Quality-of-Life of R108512 Tablets in Elderly Subjects With Chronic Constipation||Movetis|No|Completed|October 1998|September 1999|Actual|September 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|303|||Both|65 Years|N/A|No|||June 2007|May 28, 2008|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487422||170361|
NCT00487721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1076.cc|The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer|A Pilot Biomarker Study of Oral Silybin-Phytosome Followed by Prostatectomy in Patients With Localized Prostate Cancer||University of Colorado, Denver|No|Completed|August 2006|November 2010|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|N/A|No|||March 2014|March 3, 2014|June 16, 2007|Yes|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT00487721||170338|Some end of study blood samples were not obtained due to the timing of surgery, tissue was successfully obtained in all participants.
NCT00488020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|imc1|Stem Cells for Treating Critical Ischemia|the Use of Autogenous Adult Stem Cells in the Treatment of Critical Ischemia||Instituto de Molestias Cardiovasculares|Yes|Recruiting|April 2006|June 2007|Anticipated|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|80 Years|No|||June 2007|June 12, 2008|June 15, 2007||||No||https://clinicaltrials.gov/show/NCT00488020||170315|
NCT00488033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-026|Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64|Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64: A Randomized Control Study (The faCTor-64 Study)|faCTor-64|Intermountain Health Care, Inc.|Yes|Completed|June 2007|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|900|||Both|18 Years|N/A|No|||September 2014|October 3, 2014|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00488033||170314|
NCT00464646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-5|Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer|A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer||NSABP Foundation Inc|No|Completed|May 2007|May 2014|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Female|18 Years|N/A|No|||July 2014|July 17, 2014|April 19, 2007|Yes|Yes||No|August 24, 2012|https://clinicaltrials.gov/show/NCT00464646||172078|
NCT00464971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG/PD/012/USA|Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial|Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis||Novo Nordisk A/S|No|Completed|January 1995|November 1996|Actual|November 1996|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|102|||Female|45 Years|80 Years|No|||March 2012|March 19, 2012|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00464971||172054|
NCT00464373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX-URO-01|Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome|Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial|BTX-URO-01|Cantonal Hospital of St. Gallen|Yes|Terminated|April 2007|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Male|18 Years|70 Years|No|||January 2014|January 31, 2014|April 20, 2007||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00464373||172099|
NCT00464984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05175.1|Lifestyle Intervention in Morbidly Obese Patients|Lifestyle Intervention in Morbidly Obese Patients||The Hospital of Vestfold|No|Active, not recruiting|August 2006|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2015|February 17, 2015|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464984||172053|
NCT00464633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6663|Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)|A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL||Sanofi|Yes|Completed|March 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|April 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464633||172079|
NCT00465816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109063|Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612|Non-inferiority of GSK Biologicals' Meningococcal Vaccine 134612 Given Concomitantly With GSK Biologicals' Twinrix™ Versus 134612 Alone and Twinrix™ Alone in Healthy Subjects Aged 11 Through 17 Years.||GlaxoSmithKline||Completed|April 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|611|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|April 24, 2007|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00465816||171990|
NCT00466050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-7-234-S|Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS|Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS|IVUS|Ziv Hospital|Yes|Completed|April 2007|May 2009|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled to coronary angiography and IVUS|April 2007|August 23, 2009|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466050||171972|
NCT00465244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STILL|Seizure Therapy With Intravenous Levetiracetam and Lorazepam|Seizure Therapy With Intravenous Levetiracetam and Lorazepam|STILL|Massachusetts General Hospital|Yes|Withdrawn|January 2008|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|April 23, 2007|No|Yes|Inability to recruit subjects|No||https://clinicaltrials.gov/show/NCT00465244||172034|
NCT00466063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2411|ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox|A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox||Novartis|Yes|Completed|May 2007|July 2015|Actual|July 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|||Both|2 Years|5 Years|No|Non-Probability Sample|200 unselected children aged from 2 to <6 years at enrolment with chronic iron overload        due to repeated blood transfusions. The participating countries were selected on the basis        of both a high incidence of young children with thalassemia or other transfusion dependent        anemias and on the basis that the drug is approved and 'on the market' in the country        selected.|December 2015|December 26, 2015|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466063||171971|
NCT00465491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601|Study of Picoplatin Efficacy After Relapse|A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.|SPEAR|Poniard Pharmaceuticals|Yes|Active, not recruiting|April 2007|||May 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|399|||Both|18 Years|N/A|No|||April 2009|April 13, 2009|April 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465491||172015|
NCT00465777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-MTV-2004|Improved Management and in-Hospital Mortality|Reduced in-Hospital Mortality After Improved Management of Patients Hospitalised With Malaria. A Randomised Trial|MTV|Bandim Health Project|No|Completed|December 2004|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||950|||Both|3 Months|5 Years|No|||April 2007|April 23, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465777||171993|
NCT00466024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001673|Particulate Reduction Education in City Homes|Particulate Reduction Education in City Homes (PREACH)|PREACH|Johns Hopkins University|Yes|Completed|October 2006|June 2010|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|125|||Both|6 Years|12 Years|No|||March 2009|August 31, 2015|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466024||171974|
NCT00465790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-56|Research of Biomarkers in Parkinson Disease|GENomic Biomarkers for PARKinson's Disease|Genepark|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|October 2007|June 2012|Actual|June 2012|Actual|Phase 0|Observational|N/A||1|Actual|219|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Parkinson's disease and related|December 2011|September 26, 2012|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465790||171992|
NCT00466037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-05-OE-204-CTIL|The Effect of Rituximab on the Humoral Response to Influenza Vaccine|Vaccination Against Influenza in Rheumatoid Arthritis Patients: The Effect of Rituximab on the Humoral Response||Tel-Aviv Sourasky Medical Center|No|Terminated|September 2005|February 2006||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||64|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2007|April 25, 2007|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00466037||171973|
NCT00466336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612012R|Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices|Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices||National Taiwan University Hospital|Yes|Completed|January 2003|January 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|503|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic hepatitis C patients with abnormal ALT levels (> 2X ULN) with percutaneous liver        biopsy|March 2008|March 5, 2008|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466336||171950|
NCT00466349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0202-03|International SMA Patient Registry|International Spinal Muscular Atrophy Patient Registry||Indiana University|Yes|Recruiting|May 1986|||December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|Individuals or family members of individuals who have been diagnosed with SMA.|February 2016|February 22, 2016|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00466349|50 Years|171949|
NCT00466648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV-2007|Randomized Controlled Trial Comparing Different Closure Methods for Laparoscopic Port Sites|Randomized Controlled Trial Comparing Two Different Methods of Laparoscopy Port Closure||New York Downtown Hospital|Yes|Completed|March 2007|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||20|||Female|16 Years|70 Years|Accepts Healthy Volunteers|||April 2007|April 25, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466648||171927|
NCT00466856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0365|Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors|Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors||Vanderbilt-Ingram Cancer Center|Yes|Terminated|December 2003|October 2007|Actual|October 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|April 25, 2007|Yes|Yes|due to slow accrual|No||https://clinicaltrials.gov/show/NCT00466856||171911|
NCT00467116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0466|PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca|A Phase I Study of Erbitux and Gemcitabine With Radiation Therapy for Locally Advanced Pancreas Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|October 2005|October 2007|Actual|August 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467116||171891|
NCT00467363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGeR|The Effects of Aspirin in Gestation and Reproduction|The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.|EAGeR|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|June 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1228|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|April 27, 2007||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT00467363||171872|
NCT00463788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200027-051|Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer|Randomized Phase II Trial With Cetuximab and Cisplatin in the Treatment of ER-negative, PgR-negative, HER2-negative Metastatic Breast Carcinoma ("Basal Like")|BALI-1|Merck KGaA|No|Completed|June 2007|February 2011|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|181|||Female|18 Years|N/A|No|||January 2014|January 20, 2014|April 19, 2007||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00463788||172142|Participants were randomized to 2 groups in a 2:1 ratio.
NCT00463801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBC134AIT01|Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections|A Multicentre, Open Label, Uncontrolled Clinical Trial to Evaluate Efficacy and Safety of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections (cSSTI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)||Novartis||Terminated|January 2007|||November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2011|March 22, 2011|April 19, 2007|No|Yes|Because of inadequate accrual.|No|December 9, 2010|https://clinicaltrials.gov/show/NCT00463801||172141|Inadequate accrual caused the premature study termination and the insufficient sample size, therefore none of the planned study analyses were performed; nor were any tabulations with descriptive statistics were provided.
NCT00480181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:051|Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis|A Comparative, Single Center, Randomized, Double-blinded, Parallel, Placebo-controlled Study to Evaluate the Efficacy of Nabilone (Cesamet) as Adjunctive Therapy to Gabapentin (Neurontin) in the Management of Neuropathic Pain (NPP) Symptoms in Subjects With Multiple Sclerosis (MS)||University of Manitoba|No|Completed|June 2007|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||March 2011|July 26, 2012|May 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00480181||170910|
NCT00480480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-261 ASB|Randomized Controlled Trial of the Effectiveness of Group Treatment With War-Exposed Bosnian Adolescents|Long-Term Post- War Adjustment in Bosnian Adolescents, Their Parents and Teachers||Brigham Young University|No|Completed|September 2000|October 2001|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||May 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00480480||170888|
NCT00477230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENABLE 25-2064|Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs|Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic Atrial Fibrillation (AF)|ENABLE|CardioFocus|Yes|Terminated|March 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|80 Years|No|||June 2012|June 26, 2012|May 21, 2007|Yes|Yes|Study terminated based on decision of Sponsor.|No|June 26, 2012|https://clinicaltrials.gov/show/NCT00477230||171130|This study was terminated early due to Sponsor decision. Therefore, full patient assignement to treatments post-randomziation did not occur. Results and other measures cannot be determined because most patients exited the study before completion.
NCT00477529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA301|ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer|A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer||Celgene|No|Completed|April 2007|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Male|18 Years|N/A|No|||September 2015|September 9, 2015|May 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477529||171108|
NCT00480194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XY-005-IM|Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)|A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting||Nycomed|Yes|Completed|December 2006|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|For inclusion the patient must buy ZyComb® nasal spray with the intention to start using        it either the same or the next day. Male or female patients over 18 years of age, visiting        any of the participating pharmacies are eligible for inclusion.|February 2008|May 4, 2012|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00480194||170909|
NCT00488293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 05-278|Impact of Teledermatology on Health Services Outcomes in the Department of Veterans Affairs|Impact of Teledermatology on Health Services Outcomes in the VA||VA Office of Research and Development|Yes|Completed|November 2008|June 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|392|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|June 18, 2007||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT00488293||170295|
NCT00479011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|marcelrlopes|Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery|Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery||Santa Casa de Passos|Yes|Terminated|September 2005|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|2||Actual|33|||Both|18 Years|N/A|No|||May 2007|May 24, 2007|May 24, 2007|||significant reduction in length of hospital stay (primary endpoint)|No||https://clinicaltrials.gov/show/NCT00479011||170998|
NCT00465270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-006|RESPECT PFO Clinical Trial|Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment||St. Jude Medical|Yes|Active, not recruiting|August 2003|June 2016|Anticipated|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|980|||Both|18 Years|60 Years|No|||January 2016|January 7, 2016|April 23, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00465270||172032|
NCT00465257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOIII|Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar|Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction as New Treatment Policy for Uncomplicated Plasmodium Falciparum Malaria in Zanzibar||Karolinska University Hospital||Suspended|May 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|110|||Both|6 Months|59 Months|No|||May 2008|May 16, 2008|April 23, 2007|||Due to lack of malaria patients in Zanzibar the study has been suspended.|No||https://clinicaltrials.gov/show/NCT00465257||172033|
NCT00465283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donepezil-180CTIL|Donepezil Double Blind Trial for ECT Memory Disfunction|Donepezil Double Blind Trial for ECT Memory Disfunction||BeerYaakov Mental Health Center||Recruiting|May 2007|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||January 2009|January 26, 2009|April 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465283||172031|
NCT00465504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-70290|Comparison of Two Different Methods of Delivering Local Analgesia During Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis|Comparison of Iontophoresis of Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA®) Cream Versus Subcutaneous Injections of Lidocaine and EMLA® for Pain Relief in Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis: A Randomized Clinical Trial||University of British Columbia|No|Completed|July 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|4 Years|18 Years|No|||May 2011|May 13, 2011|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465504||172014|
NCT00465829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK6657_2|Long-term Effects of Bariatric Surgery|Longitudinal Assessment of Bariatric Surgery (LABS-2)|LABS-2|University of Pittsburgh|Yes|Active, not recruiting|March 2006|June 2016|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2400|Samples With DNA|Whole blood, serum, plasma, urine.|Both|18 Years|N/A|No|Non-Probability Sample|All bariatric surgical candidates at participating LABS centers who are 18 years or older        and have not had prior bariatric surgery.|January 2016|January 7, 2016|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465829||171989|
NCT00466362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK0702|Lifestyle Intervention in Obesity, Effect on Diabetes|One Year Observational Study on Effects of Lifestyle Intervention in Morbidly Obese Persons With Type 2 Diabetes.||Evjeklinikken|Yes|Recruiting|April 2007|December 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|50|||Both|18 Years|67 Years|No|||May 2007|May 22, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466362||171948|
NCT00466076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kmc060033|Copaxone in Age Related Macular Degeneration|Subcutaneous Copaxone as Treatment for Dry Age Related Macular Degeneration||Kaplan Medical Center|No|Recruiting|August 2006|April 2007|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||30|||Both|50 Years|N/A|No|||April 2007|April 25, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466076||171970|
NCT00466661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#16928|Acamprosate vs. Placebo in Bipolar Alcoholics|A Double-Blind, Randomized, Placebo-Controlled Trial of Acamprosate in Alcohol-Dependent Individuals With Comorbid Bipolar Disorder||Medical University of South Carolina|No|Active, not recruiting|April 2007|March 2010|Anticipated|February 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||March 2010|March 25, 2010|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466661||171926|
NCT00465803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-21|A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension|Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid||Alcon Research|No|Completed|March 2007|||January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||May 2012|July 22, 2014|April 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465803||171991|
NCT00466869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BET203|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin||OBEcure Ltd.|No|Terminated|May 2007|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|30 Years|75 Years|No|||August 2007|September 24, 2007|April 25, 2007|||Sponsor decision|No||https://clinicaltrials.gov/show/NCT00466869||171910|
NCT00467129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540670|Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer|The Role of Genetic Factors in Clinical Outcome for Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2002|||||N/A|Observational|N/A|||Anticipated|800|||Both|N/A|N/A|No|||May 2007|December 17, 2013|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00467129||171890|
NCT00467389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-014-05S|Use of Donepezil for Treatment of Cocaine Dependence|Donepezil Effects on Cocaine Craving and Pharmacokinetics||VA Office of Research and Development|Yes|Completed|February 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|50 Years|No|||May 2014|May 21, 2014|April 27, 2007||No||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00467389||171870|
NCT00467662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|376.hmo-ctil|Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)|The Safety, Efficacy and Convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.||Hadassah Medical Organization|Yes|Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|70 Years|No|||April 2007|April 30, 2007|April 17, 2007||||No||https://clinicaltrials.gov/show/NCT00467662||171850|
NCT00463528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-BF-JNP-05|Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso|Women and Childres at the Focal Point for the Schistosomiasis Control and Sustainability and Effectiveness in the Hydro Agricultural Zone of Sourou, Burkina Faso||DBL -Institute for Health Research and Development||Completed|December 2006|February 2007|Actual|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|360|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2007|July 2, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463528||172162|
NCT00463541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-007|Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms|An Open-label Study of the Efficacy and Safety of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients With Overactive Bladder Symptoms VOLT: VESIcare® Open-Label Trial|VOLT|Astellas Pharma Inc|No|Completed|June 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2225|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|April 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00463541||172161|
NCT00463554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-05-002|TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence|An Evaluation of the GYNECARE TVT-SECUR* System (Tension-Free Support for Incontinence) for the Treatment of Stress Urinary Incontinence *Trademark||Ethicon, Inc.|No|Completed|April 2006|December 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Female|21 Years|N/A|No|Non-Probability Sample|Women with stress urinary incontinence|January 2009|January 26, 2009|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463554||172160|
NCT00476463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 023|Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection|Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naive Patients With HIV/HBV Co-infection||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|April 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476463||171186|
NCT00476983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 041|Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg|Pharmacokinetic and Efficacy of Saquinavir Mesylate Film Coated Tablet / Ritonavir 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg Once Daily in HIV Pretreated Patients||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Withdrawn||||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|May 20, 2007||No|No funding|No||https://clinicaltrials.gov/show/NCT00476983||171149|
NCT00477217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HAU21|Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee|A Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of Zoledronic Acid in Spontaneous Osteonecrosis of the Knee (SONK)||Novartis||Terminated|January 2008|May 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|85 Years||||November 2008|November 10, 2008|May 22, 2007||||No||https://clinicaltrials.gov/show/NCT00477217||171131|
NCT00480207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICHN-4413|Folic Acid and Omega -3 Fatty Acid Supplementation in Depressed Older Adults|Randomized Double-blind Controlled Clinical Trial to Assess the Impact of Folic Acid and Omega-3 Fatty Acids Supplementation on the Severity of Depressive Symptoms in Older Adults With Identified Depression||Beersheva Mental Health Center|Yes|Completed|May 2007|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|15|||Both|65 Years|N/A|No|||November 2012|November 5, 2012|May 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00480207||170908|
NCT00478738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB104958|A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients|See Detailed Description||GlaxoSmithKline|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|40 Years|75 Years|No|||March 2011|March 10, 2011|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00478738||171018|
NCT00479297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-101|Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||72|||Male|20 Years|45 Years|No|||August 2009|August 6, 2009|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00479297||170976|
NCT00479622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3206K3-103|Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus|A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|August 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||May 2008|May 7, 2008|May 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479622||170952|
NCT00465023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-084|Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases|Phase I Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases||Massachusetts General Hospital|Yes|Active, not recruiting|June 2003|April 2019|Anticipated|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465023||172050|
NCT00465517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0600|A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as add-on Therapy in Adult Subjects With Epilepsy Consisting of Uncontrolled Partial-onset Seizures.||Marinus Pharmaceuticals|No|Completed|February 2007|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|69 Years|No|||October 2009|October 28, 2009|April 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465517||172013|
NCT00465296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEARLS|Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS|Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS||Medstar Research Institute|Yes|Terminated|January 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||April 2007|May 21, 2008|April 23, 2007|||Funding Discontinued|No||https://clinicaltrials.gov/show/NCT00465296||172030|
NCT00465530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10553|Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children|Safety and Efficacy of Once Daily Intranasal Gentamycin Irrigation Versus Saline in the Treatment of Pediatric Chronic Sinusitis||University of Kansas Medical Center|Yes|Completed|March 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|4 Years|17 Years|No|||April 2013|April 22, 2013|April 23, 2007|Yes|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00465530||172012|
NCT00465842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS0541|Protein Biomarker in Hepatocellular Carcinoma|Protein Biomarkers for Early Detection and Prognostication in Hepatocellular Carcinoma (HCC)||Sidney Kimmel Comprehensive Cancer Center||Suspended|June 2006|December 2010|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|1050|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 19, 2008|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465842||171988|
NCT00466089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO19182|Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer|Phase II Randomized Trial of 3D Radiotherapy Versus the Combination of 3D Radiotherapy and Erlotinib (Tarceva®) in Patients With Localized-Unresectable Non-Small Cell Lung Cancer Non Susceptible for Chemotherapy Treatment.||Hospital of Navarra|No|Recruiting|March 2006|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2007|January 9, 2008|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466089||171969|
NCT00466102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 41|Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases|RADAR: A Randomized Discontinuation Phase II Study to Determine the Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases|RADAR|German Breast Group|Yes|Active, not recruiting|December 2006|December 2012|Anticipated|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Female|18 Years|N/A|No|||August 2012|August 29, 2012|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466102||171968|
NCT00466375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genetics of Hemangioma|Genetic Basis of Hemangiomas|Genetic Basis of Hemangiomas||Medical College of Wisconsin|No|Active, not recruiting|April 2007|May 2017|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Family-Based||2|Anticipated|3000|Samples With DNA|Buccal smear (cheek cells)or small blood sample (4 mL or one teaspoon)|Both|N/A|N/A|No|Probability Sample|Clinics from Children's Hospital of Wisconsin.|March 2016|March 16, 2016|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466375||171947|
NCT00466882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAMED|Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients|Issues Related to the Use of the INAMED LAPBAND SYSTEM to Reduce BMI's in Obese Renal Failure Patients Needing Renal Transplantation: A Pilot Study||Summa Health System|Yes|Completed|October 2005|January 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|April 26, 2007||No||No|May 30, 2013|https://clinicaltrials.gov/show/NCT00466882||171909|There were no SAEs, the study had a small sample size and was not able to enroll enough participants to get quality data.
NCT00466674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.385|Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning|Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning (IFM 2005-03)|IFM 2005-03|Hospices Civils de Lyon|Yes|Completed|January 2007|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||January 2014|January 14, 2014|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466674||171925|
NCT00466895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06003|Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.|Phase I Study of Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|April 2007|||December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||October 2014|October 19, 2014|April 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466895||171908|
NCT00467142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540522|Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery|Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|January 2007|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|61|||Both|18 Years|N/A|No|||July 2009|May 13, 2011|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00467142||171889|
NCT00467402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178A2304|Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder|A 52-week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of the Long-term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-label Treatment of 16-24 Weeks||Novartis||Completed|April 2007|||September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|644|||Both|18 Years|70 Years|No|||May 2012|May 2, 2012|April 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467402||171869|
NCT00467675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03403-06-C|Establishing Ambulatory Glucose Profiles for People Without Diabetes Using CGM Data|Observational Study of Interstitial Glucose Monitoring With the FreeStyle Navigator CGM System to Develop Novel Methods for Displaying, Reporting and Analyzing CGM Data for Clinical Decision-Making: Phase 2-Establishing Ambulatory Glucose Profiles for Individuals Without Diabetes||HealthPartners Institute|No|Completed|April 2006|January 2007|Actual|||Phase 2|Observational|Time Perspective: Prospective|||Actual|35|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||September 2007|December 2, 2015|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00467675||171849|
NCT00463567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2335S|26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d.) and Open Label Tiotropium (18 µg o.d.) as Active Controls||Novartis||Completed|April 2007|August 2008|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|2059|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|April 19, 2007|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00463567||172159|
NCT00463580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011734|A Study of Infliximab for Treatment Resistant Major Depression|An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators|Infliximab|Emory University|Yes|Completed|November 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|60 Years|No|||October 2014|October 2, 2014|April 19, 2007||No||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00463580||172158|Our study was underpowered to adequately test placebo response typically reported for TRD. Also, no direct measures of the effect of either infliximab or placebo on the CNS were obtained.
NCT00477542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704-30 IUCRO-0186|A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT|A Phase I Trial of Myeloablative Conditioning Using Clofarabine and High-Dose Busulfan for Patients With Refractory Hematological Malignancies Undergoing Allogeneic HSCT||Indiana University|Yes|Completed|May 2007|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|60 Years|No|||September 2014|September 17, 2014|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00477542||171107|
NCT00477854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 24040|Effects of Chromium Picolinate on Food Intake|Effects of Chromium Picolinate on Food Intake, Satiety, and Eating Attitudes in Overweight Women With Food Cravings||Pennington Biomedical Research Center|No|Completed|April 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|42|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|May 23, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00477854||171084|
NCT00478166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-174|Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease|Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease|PC|University of Wisconsin, Madison|Yes|Completed|July 2005|October 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|206|||Both|55 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|People who are enrolled in the Wisconsin Registry for AD Prevention (WRAP), recruited from        Memory clinics and the community.|April 2011|October 1, 2015|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00478166||171061|
NCT00478179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN005-0009|Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia|A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients With Post-Herpetic Neuralgia||Durect||Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|21 Years|N/A|No|||September 2009|September 9, 2009|May 22, 2007||||No||https://clinicaltrials.gov/show/NCT00478179||171060|
NCT00478998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890pal- HMO-CTIL|Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin|Phase II Study Comparing Two Groups of Patients Undergoing ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin||Hadassah Medical Organization|No|Not yet recruiting||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||||||Both|18 Years|80 Years||||May 2007|May 24, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00478998||170999|
NCT00478946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501|A Study of Picoplatin in Colorectal Cancer|A Phase I Open-Label Study of Picoplatin in Combination With 5-Fluorouracil and Leucovorin as Initial Therapy in Subjects With Metastatic Colorectal Cancer||Poniard Pharmaceuticals|No|Active, not recruiting|April 2006|June 2010|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|43|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478946||171003|
NCT00478959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-HL|Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma|Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma||University Health Network, Toronto|Yes|Completed|December 2006|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478959||171002|
NCT00472914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMG auditory|Use of EMG to Assess Clinical Hypertonia|Initial Assessment of the Use of Surface Electromyography as a Tool for Clinical Evaluation of Hypertonia in Children||University of Southern California|No|Completed|January 2007|March 2007|Actual|||Phase 1/Phase 2|Observational|Time Perspective: Prospective||||14|||Both|6 Years|18 Years|No|||May 2014|May 21, 2014|May 11, 2007||||No||https://clinicaltrials.gov/show/NCT00472914||171451|
NCT00472927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713E1-1142|Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Three New Formulations of Premarin 0.45mg/Medroxyprogesterone Acetate (MPA) 1.5mg Compared With a Reference Formulation of Premarin/MPA (PremproTM) 0.45mg/1.5mg in Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|35 Years|70 Years|Accepts Healthy Volunteers|||December 2007|December 4, 2007|May 10, 2007||||No||https://clinicaltrials.gov/show/NCT00472927||171450|
NCT00465309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR60ANMA06|Protective Ventilation With Carbon Dioxide (CO2) -Removal Technique in Patients With Adult Respiratory Distress Syndrome (ARDS)|||University of Turin, Italy||Completed|April 2007|November 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|85 Years|No|||January 2009|January 9, 2009|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465309||172029|
NCT00465543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-010|Mint Tea for the Treatment of Nasal Polyps|A Double-blind,Placebo-controlled, Randomized, Crossover Trial of Mint Tea High in Rosmarinic Acid in Adults With Nasal Polyposis||McMaster University|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 8, 2011|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465543||172011|
NCT00473733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65/07|Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2||GLP|Assaf-Harofeh Medical Center||Not yet recruiting||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||||||Both|18 Years|70 Years|No|||April 2007|May 14, 2007|May 13, 2007||||No||https://clinicaltrials.gov/show/NCT00473733||171392|
NCT00474006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-006|High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML|A RANDOMIZED COMPARISON OF TWO DIFFERENT DOSAGES OF DAUNORUBICIN IN INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA|ADcomparison|Cooperative Study Group A for Hematology|No|Completed|August 2001|April 2010|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|398|||Both|15 Years|60 Years|No|||June 2011|June 8, 2011|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474006||171372|
NCT00466115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI Protocol : #7605|A Phase II Study of MS-275, in Combination With GM-CSF Treating Relapsed and Refractory Myeloid Malignancies|A Phase II Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies||Johns Hopkins University|Yes|Not yet recruiting|April 2007|April 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||18|||Female|18 Years|N/A|No|||April 2007|April 25, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466115||171967|
NCT00474019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9615C00021|Phase 1 Pharmacokinetics of Intravenous Nexium in Children|A Phase I, Randomised, Open-label, Multi-National Study to Evaluate the Pharmacokinetics of Repeated Once-Daily Intravenous Doses of Esomeprazole in Paediatric Patients 0 to 17 Years Old, Inclusive.||AstraZeneca|No|Completed|October 2007|October 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|N/A|17 Years|No|||December 2010|December 2, 2010|May 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00474019||171371|
NCT00466388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAO-101|Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia|An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma|SMILE|American Academy of Otolaryngology-Head and Neck Surgery Foundation|No|Completed|May 2007|August 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|April 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466388||171946|
NCT00466401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-5-155-S|Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation|Phase 4 Study on Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation In Hypercholesterolemic Patients on Simvastatin||Ziv Hospital||Completed|February 2005|August 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 19, 2013|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466401||171945|
NCT00466687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL 0418|Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma|A Phase II Trial of Tarceva (Erlotinib) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Melanoma||Vanderbilt-Ingram Cancer Center|Yes|Completed|September 2004|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|April 25, 2007|Yes|Yes||No|June 2, 2011|https://clinicaltrials.gov/show/NCT00466687||171924|
NCT00466908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-07-001|Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery|Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery||Medical University of South Carolina|No|Completed|March 2007|August 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|40 Years|80 Years|No|Probability Sample|Subject must have undergone corneal refractive surgery (RK, PRK or LASIK) prior to        cataract extraction.        Age: 40 to 80 years old.|October 2010|October 1, 2010|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466908||171907|
NCT00467155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0004|Helicobacter in The Gambia (Part 2)|Genotypes of Helicobacter Pylori in West African Children and Adults: Part 2: The Application of a Minimally Invasive Technique for H. Pylori Isolation in a Population Study||Medical Research Council Unit, The Gambia|No|Withdrawn|June 2007|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|3 Months|23 Months|No|Non-Probability Sample|The study population will consist of rural subsistence farmers and semi-urban dwellers        attending the clinic at the MRC research laboratories in Fajara, The Gambia. Subjects will        comprise; i) children who have a nasogastric tube inserted for nutritional rehabilitation        on the ward at Fajara; ii) mothers of children who are found to be H. pylori positive.|April 2015|September 23, 2015|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00467155||171888|
NCT00467415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC_COSAB9147|Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy|Multi-Center Project: Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy|SSTTEP|Shriners Hospitals for Children|No|Active, not recruiting|May 2007|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|66|||Both|6 Years|13 Years|No|||August 2008|June 26, 2009|April 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00467415||171868|
NCT00467688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIDAM 049-06|Effect of Continuous Glucose Monitoring on Course of Glucose in Type 1 Diabetes|The Effect of Continuous Glucose Monitoring With and Without Real Time Access to Glucose Values and Glucose Alerts on Course of Glucose and Satisfaction With CGMS in Type 1 Diabetic Patients||Forschungsinstitut der Diabetes Akademie Mergentheim|Yes|Completed|February 2007|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||October 2007|October 30, 2007|April 30, 2007||||No||https://clinicaltrials.gov/show/NCT00467688||171848|
NCT00475891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07050007|Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures|Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures||University of Pittsburgh|Yes|Completed|April 2007|December 2014|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|isolates for rectal surveillance|December 2014|December 5, 2014|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475891||171229|
NCT00485602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAFENALIGN-HMO-CTIL|Orthodontic Treatment With a Part-Time Wearing Esthetic Removable Appliance|||Hadassah Medical Organization|No|Not yet recruiting|December 2007|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|8 Years|68 Years|Accepts Healthy Volunteers|||June 2007|June 12, 2007|June 12, 2007||||No||https://clinicaltrials.gov/show/NCT00485602||170501|
NCT00485615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHOMEGA3SP|An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia|An Open-label, Pilot Study Evaluating the Efficacy of Enteric-coated Eicosapentaenoic Acid (o3mega+Joy) in the Treatment of Social Phobia|OMEGA3SP|START Clinic for Mood and Anxiety Disorders|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||June 2010|October 29, 2013|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485615||170500|
NCT00478465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV21103 Version 3.0|Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV)||Stanford University||Active, not recruiting|May 2007|August 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|0|||Both|18 Years|N/A|No|||August 2007|August 29, 2007|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00478465||171039|
NCT00478478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-REG-001|Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke|Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke||Stryker Neurovascular|No|Completed|June 2007|September 2010|Actual|May 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|N/A|N/A|No|Probability Sample|All patients with ischemic stroke treated with a Merci Retriever either alone or in        combination with adjunctive therapies such as lytics will be included in the Registry.|November 2014|November 6, 2014|May 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00478478||171038|
NCT00478686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1003|Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine|A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2007|||May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|210|Samples With DNA|5 to 7.5 milliliter (mL) sample of blood. Alternatively, DNA will be extracted from 10um      slices of formalin-fixed paraffin-embedded tissue from previously collected tumor tissue      (from the time of the breast cancer diagnosis).|Both|N/A|N/A|No|Probability Sample|Patients with breast cancer who experienced toxicity/side effects related to capecitabine        chemotherapy.|February 2016|February 29, 2016|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478686||171022|
NCT00479895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-0002|Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization|Phase II, Open-Label Study in the Catheterization Laboratory Setting to Challenge the Concept That HBOC-201 Administration Might Improve Myocardial 'Oxygenation' and Myocardial Function at the Moment of (Brief) Coronary Occlusion||Biopure Corporation|No|Completed|April 2007|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|80 Years|No|||May 2008|May 29, 2008|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479895||170932|
NCT00479908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC/2003/8/35|Blood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina|Investigation of the Time Course of the Interaction of the Hypotensive Effects of Sildenafil Citrate and Sublingual Glyceryl Trinitrate (GTN) in Men With Stable Angina Pectoris||University of Edinburgh|No|Completed|January 2004|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|20|||Male|30 Years|80 Years|No|||May 2007|May 29, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00479908||170931|
NCT00465322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101|Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation|Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation|EFA-1|University Hospital Inselspital, Berne|No|Completed||||||Phase 4|Observational|Time Perspective: Longitudinal||||100|||Both|18 Years|95 Years|No|||April 2007|April 23, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465322||172028|
NCT00473174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYCCRA-2006/01|Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension|A Prospective, Randomized, Open Label, Blinded-endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM in Subjects With Mild-to-moderate Essential|HYCCRA|University of Vigo|Yes|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||September 2009|September 1, 2009|May 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00473174||171432|
NCT00473447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|800|A Modified Constraint-Induced Movement Therapy Program in Rehabilitation of Arm Paresis in Children With Cerebral Palsy|Phase1 Effectiveness of a Modified Constraint-Induced Movement Therapy Program in Rehabilitation of Arm Paresis in Children With Cerebral Palsy: a Cross-Over Study|mCIT|Universita di Verona|No|Completed|January 2004|April 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|10|||Both|1 Year|10 Years|No|||May 2007|May 14, 2007|May 14, 2007||||No||https://clinicaltrials.gov/show/NCT00473447||171413|
NCT00465556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR009093|Domestic Violence Enhanced Home Visitation Program (DOVE)|Domestic Violence Enhanced Home Visitation Program - DOVE||Johns Hopkins University|Yes|Completed|February 2006|November 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|239|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465556||172010|
NCT00465855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002700|One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning|Randomized Trial of One Versus Three Hyperbaric Oxygen Treatments for Acute CO Poisoning|1V3CORCT|Intermountain Health Care, Inc.|Yes|Recruiting|April 2007|May 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|79 Years|No|||August 2015|August 24, 2015|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465855||171987|
NCT00466453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004123|Adapting Web-based Instruction to Baseline Knowledge of Physicians-in-training|Adapting Web-based Instruction to Learner Baseline Knowledge: A Randomized Controlled Trial||Mayo Clinic||Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label||||144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 14, 2010|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466453||171942|
NCT00466128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.528|Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)|A Double-blinded Randomized Controlled Trial With Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Between 24 and 32 Weeks Gestation||Thomas Jefferson University|Yes|Recruiting|April 2007|April 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|116|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466128||171966|
NCT00474305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR-PTSD-HMO-CTIL|Virtual Reality Prolonged Exposure (PE) for Bus Bomb Survivors|Effectiveness of Virtual Reality for Persons With PTSD Following a Bus Bombing||Hadassah Medical Organization|Yes|Recruiting|December 2007|December 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||May 2010|December 15, 2010|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00474305||171350|
NCT00474539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3007|Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|449|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||January 2013|January 22, 2013|May 15, 2007|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00474539||171332|
NCT00474552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3182A1-101|Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315|An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 Administered Orally to Healthy Young Adult and Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|June 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 13, 2008|May 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00474552||171331|
NCT00474825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRF 06-01|Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck|Phase I Clinical Trial of Hyperbaric Oxygen Combined With Radiation and Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|HBO-XRT|Baromedical Research Foundation|Yes|Completed|July 2007|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|70 Years|No|||February 2012|February 3, 2012|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00474825||171311|
NCT00475124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS036|Virtual Clinic Pacemaker Follow-up|VIRTUE: Virtual Clinic Pacemaker Follow-up|VIRTUE|Biotronik SE & Co. KG|No|Terminated|May 2007|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|123|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|May 16, 2007||No|Redundant in-clinic visits increased the workload in virtual follow-up group. An interim    analysis showed that the study would not support the primary hypothesis|No||https://clinicaltrials.gov/show/NCT00475124||171288|
NCT00475137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03732|Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression|A Randomized, Single-Blind Comparison of Lamotrigine Add-on Versus Switch to Lamotrigine Monotherapy in the Treatment of Bipolar II Depression Unresponsive to Antidepressant Treatment||University of British Columbia|No|Completed|December 2007|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|15|||Both|17 Years|70 Years|No|||June 2015|June 2, 2015|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00475137||171287|
NCT00475410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cx401/FATT1|Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease|A Phase III Multicenter, Single Blind, Randomized, Comparative and add-on Clinical Trial, in Three Parallel Groups, to Evaluate Efficacy and Safety of a New Therapy With Adipose-derived Autologous Stem Cells for the Treatment of Complex Perianal Fistulas in Patients Without Inflammatory Bowel Disease|FATT1|Cellerix|No|Completed|February 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|214|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475410||171266|
NCT00475423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20948|A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.|An Open Label Study of a Fixed Dose Regimen of MabThera on Overall Response Rate in Patients With Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura.||Hoffmann-La Roche||Completed|May 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|May 17, 2007||No||No|October 6, 2014|https://clinicaltrials.gov/show/NCT00475423||171265|
NCT00475605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-5801|A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis|APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis|APPLES|Astellas Pharma Inc|Yes|Active, not recruiting|May 2005|August 2022|Anticipated|August 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8037|||Both|N/A|16 Years|No|Non-Probability Sample|Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus ointment        exposure|July 2015|July 9, 2015|May 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00475605||171251|
NCT00475618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Mejia|Effect of Therapeutic Measures in Dental Caries Reduction in Children With Primary Dentition From Medellín City|Effect of Therapeutic Measures in Dental Caries Reduction in Children With Primary Dentition From Metropolitan Area Sorrounded Medellín City. A Clinical Trial||CES University|No|Completed|May 2007|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|180|||Both|29 Months|41 Months|Accepts Healthy Volunteers|||May 2012|May 29, 2012|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00475618||171250|
NCT00463840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-64|Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer|A Phase I/II Study of Chemoradiation With Oxaliplatin and 5FU for Locally Advanced Pancreatic Cancer||New York University School of Medicine|Yes|Terminated|June 2004|October 2015|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|April 18, 2007|Yes|Yes|Due to slow accrual|No|March 5, 2012|https://clinicaltrials.gov/show/NCT00463840||172138|This study did not reach its target accrual due to slow accrual. Small number of patients were analyzed.
NCT00485927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-10|The Effects of Stress on the Clinical Performance of Residents in Simulated Trauma Scenarios|The Effects of Stress on the Clinical Performance of Residents in Simulated Trauma Scenarios||University of Toronto|No|Recruiting|April 2007|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research|||Anticipated|20|||Both|21 Years|50 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485927||170476|
NCT00485940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-13|Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic Constipation|A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of R108512 Tablets in Subjects With Chronic Constipation||Movetis|No|Completed|March 1998|May 1999|Actual|May 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|641|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|June 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00485940||170475|
NCT00486460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-NA-132-CTIL|Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer|||Tel-Aviv Sourasky Medical Center||Recruiting|June 2005|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||June 2007|June 13, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486460||170435|
NCT00486473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH 131|Multihance Versus Magnevist in Breast MRI|Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast|DETECT|Bracco Diagnostics, Inc|No|Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|130|||Female|18 Years|N/A|No|||July 2010|July 14, 2010|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00486473||170434|
NCT00486746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5551811|Lifestyle Intervention Treatment for Patients With Mild Obstructive Sleep Apnea|Lifestyle Intervention Treatment for Patients With Mild Obstructive Sleep Apnea||Kuopio University Hospital|No|Active, not recruiting|October 2004|||December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00486746||170413|
NCT00465595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0647|Psychopharmacology of Psilocybin in Cancer Patients|Psychopharmacology of Psilocybin in Cancer Patients||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|April 2007|March 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|44|||Both|21 Years|80 Years|No|||February 2015|February 12, 2015|April 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465595||172007|
NCT00465335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-135 IMPACCT|Usefulness of Coronary CT Angiography in Patients With Inconclusive Stress Test Results|Multi-Detector Computer Tomography(MDCT)in Patients With Equivocal/Intermediate Post Test Probability of Coronary Artery Disease|IMPACCT|William Beaumont Hospitals|Yes|Completed|March 2006|February 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|200|||Both|18 Years|90 Years|No|Probability Sample|Patients with chest pain over the age of 18 years old with symptoms of Coronary Artery        Disease|September 2012|September 19, 2012|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465335||172027|
NCT00465569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00002102|A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy|A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy||Johns Hopkins University|Yes|Completed|August 2006|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|6 Years|21 Years|No|||April 2012|April 27, 2012|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465569||172009|
NCT00466466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2116|Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients|A Phase Ib Study Investigating the Combination of RAD001 With Cisplatin and Etoposide in Patients With Extensive-stage Small-cell Lung Cancer Not Previously Treated With Chemotherapy||Novartis||Completed|April 2007|||November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|April 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466466||171941|
NCT00466713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5367|Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy|Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy||Stanford University|No|Terminated|March 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||May 2014|May 12, 2014|April 25, 2007||No|concern over safety of rosiglitazone in heart failure|No||https://clinicaltrials.gov/show/NCT00466713||171922|
NCT00466414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-222-000-024-112|Alveolar Ridge Preservation With Polycaprolactone Scaffold for Implant Site Development|Alveolar Ridge Preservation With Polycaprolactone Scaffold for Implant Site Development||National University Hospital, Singapore|Yes|Recruiting|March 2007|April 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 14, 2008|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466414||171944|
NCT00466440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11311|A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients|A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study With and Without Enzastaurin in Combination With Docetaxel and Prednisone, Followed By Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients||Eli Lilly and Company|Yes|Completed|June 2007|June 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Male|18 Years|N/A|No|||November 2010|November 23, 2010|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466440||171943|
NCT00466700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0053|Helicobacter in The Gambia (Part 1)|Genotypes of Helicobacter Pylori in West African Children and Adults: Part 1: The Development and Evaluation of Minimally Invasive Techniques for Obtaining H. Pylori Isolates From Adults and Children in The Gambia||Medical Research Council Unit, The Gambia|No|Completed|July 2007|March 2009|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|||Both|6 Months|N/A|No|Non-Probability Sample|The study population will consist of rural subsistence farmers and semi-urban dwellers        attending the clinic at the MRC research laboratories in Fajara, The Gambia. The study        will be comprised of subjects who are undergoing endoscopy for diagnostic purposes within        the endoscopy unit at Fajara.|May 2015|May 7, 2015|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466700||171923|
NCT00466921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04H5|Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome|Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma||Northwestern University|Yes|Active, not recruiting|February 2005|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466921||171906|
NCT00467168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522301118|Optimal Dietary Fat Pattern to Prevent Cardiovascular Disease Among Type 2 Diabetes|Effects of Fatty Acid Composition Ratios of Oral Fatty Loads on the Dynamic Metabolism of Postprandial Lipid and Triglyceride-Rich Lipoproteins in Chinese NIDDM Out-Patients||Sun Yat-sen University|Yes|Completed|January 1998|May 1998|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||30|||Both|N/A|N/A|No|||April 2007|April 26, 2007|April 26, 2007||||No||https://clinicaltrials.gov/show/NCT00467168||171887|
NCT00467428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2359-001|Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder|Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder. A Randomised, Double-Blind, Placebo-Controlled Study||NeuroSearch A/S||Completed|August 2003|September 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|55 Years|No|||April 2007|April 27, 2007|April 27, 2007||||No||https://clinicaltrials.gov/show/NCT00467428||171867|
NCT00467441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VSF-173-2001|VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VSF-173 and Matching Placebo in Healthy Male and Female Subjects With Induced Excessive Sleepiness||Vanda Pharmaceuticals||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2007|October 31, 2007|April 26, 2007||||No||https://clinicaltrials.gov/show/NCT00467441||171866|
NCT00467701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHF 5690.10|Community Acquired Pneumonia in Telemark and Ostfold|Prevalence of Legionella Infections, Bacterial Etiology in Pneumonia Among Patients Admitted to Hospital,- and Risk Factors/Characteristics for These Patients.(Translated From Norwegian)|CAPITO|Sykehuset Telemark|No|Completed|May 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|380|Samples Without DNA|sputum|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to hospital with community acquired pneumonia.|January 2009|January 16, 2009|April 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00467701||171847|
NCT00467714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-181351|Evaluation Of Cloumella Strut Effect In Tip Rotation|Evaluation of Cloumella Strut in Maintenance of Tip Rotation||Tehran University of Medical Sciences|Yes|Completed|February 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2008|November 17, 2008|April 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467714||171846|
NCT00463593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-UG-NK-06|Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes|Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control||DBL -Institute for Health Research and Development|No|Completed|December 2006|June 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1293|None Retained|faeces blood|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|children enrolled in formal schools and children not enrolled in formal school identified        by household survey|January 2008|January 23, 2008|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463593||172157|
NCT00485979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10073|Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients|A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized Breast Cancer.|SATIN|Sanofi||Completed|June 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|330|||Female|18 Years|75 Years|No|||June 2011|June 27, 2011|June 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00485979||170472|
NCT00486798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00009|FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis||FAST|AstraZeneca||Terminated|May 2007|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|65 Years|No|||April 2009|December 8, 2010|June 14, 2007|||study was not ethically acceptable to continue and therefore it was finally stopped|No||https://clinicaltrials.gov/show/NCT00486798||170409|
NCT00486213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551757|Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer|Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS)||National Cancer Centre, Singapore|Yes|Terminated|June 2007|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|210|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|June 13, 2007||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00486213||170454|
NCT00486486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3241|24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination|A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma|BTFC|Aristotle University Of Thessaloniki|Yes|Completed|March 2007|July 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|39 Years|81 Years|No|||May 2014|May 9, 2014|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00486486||170433|
NCT00486759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20603|A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)||Hoffmann-La Roche||Terminated|July 2007|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|787|||Both|18 Years|79 Years|No|||November 2012|November 28, 2012|June 14, 2007|Yes|Yes|Due to an unfavorable benefit/risk ratio.|No|November 28, 2012|https://clinicaltrials.gov/show/NCT00486759||170412|Due to premature termination of the study, the efficacy results should be interpreted with caution.
NCT00486772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Yilmaz|Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD|||Gulhane School of Medicine|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|18 Years|65 Years|No|||June 2007|June 18, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486772||170411|
NCT00487019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|038FAR042005|Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment|Comparative Study of Two Antibiotic Regimen - Penicillin G/Gentamicin Versus Ampicillin/Gentamicin in Empirical Treatment of Early Onset Neonatal Septicaemia||University of Tartu|No|Completed|August 2006|December 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|281|||Both|N/A|72 Hours|No|Probability Sample|Neonates hospitalised within 72h of life and requiring empirical antibacterial treatment        for early onset neonatal sepsis.|May 2008|May 27, 2008|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487019||170392|
NCT00465608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604603|Propranolol in Post Traumatic Stress Disorder|Reduction of the Traumatic Memory by Reconsolidation Blockade: A Pilot Study|Reductrauma|University Hospital, Toulouse|No|Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||January 2009|January 6, 2009|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465608||172006|
NCT00465621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-10|Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research||Completed|March 2007|||July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|April 23, 2007||||||https://clinicaltrials.gov/show/NCT00465621||172005|
NCT00465868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StaHF461301|MR, Myocardial Infarct and Heart Failure|Magnetic Resonance Imaging, Myocardial Infarction and Development of Heart Failure.|KoMPiS|Helse Stavanger HF|No|Completed|December 2004|May 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|44|Samples Without DNA|collagen markers, inflammatory markers and heart failure markers|Both|18 Years|N/A|No|Probability Sample|Patients admited with AMi and rescue PCI.|June 2008|July 27, 2015|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465868||171986|
NCT00466141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2097-07|Weight Maintenance Study for 2007 Shape UP RI Participants|Evaluation of the 2007 Shape Up RI Campaign: Study 3 Maintenance|STOPRegain|The Miriam Hospital|Yes|Completed|June 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2007|January 21, 2008|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00466141||171965|
NCT00466479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARMANP001|Brimonidine vs ALTP in Progressing Human Glaucoma|Topical Brimonidine vs Argon Laser Trabeculoplasty in Progressing Human Glaucoma. A Prospective Randomized Clinical Trial.||University of Parma|No|Completed|August 1999|October 2002|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||50|||Both|50 Years|70 Years|No|||April 2007|April 26, 2007|April 26, 2007||||No||https://clinicaltrials.gov/show/NCT00466479||171940|
NCT00466947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109563|COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine|COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media||GlaxoSmithKline||Completed|June 2007|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|23802|||Both|6 Weeks|16 Weeks|Accepts Healthy Volunteers|||June 2013|June 20, 2013|April 26, 2007|Yes|Yes||No|August 25, 2011|https://clinicaltrials.gov/show/NCT00466947||171904|
NCT00467207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/1553|Intensive Strength Training in Children With Cerebral Palsy - Effect on Hand Function|||St. Olavs Hospital|No|Completed|September 2006|March 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|10 Years|17 Years|No|||April 2007|June 2, 2008|April 27, 2007||||No||https://clinicaltrials.gov/show/NCT00467207||171884|
NCT00466934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070139|Measuring Blood Flow in the Brain|Cross-Validating NIRS With fMRI||National Institutes of Health Clinical Center (CC)||Completed|April 2007|December 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|31|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 30, 2011|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466934||171905|
NCT00467181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP05009|A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery|||Summa Health System|Yes|Completed|January 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||April 2007|January 28, 2008|April 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00467181||171886|
NCT00467194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540163|Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Phase I Study of Rapamycin in Combination With Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma||National Cancer Centre, Singapore||Completed|December 2006|||May 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 14, 2013|April 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00467194||171885|
NCT00467454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703M04084|Naltrexone in the Treatment of Pyromania|A Double-Blind, Placebo-Controlled Study of Naltrexone in Pyromania||University of Minnesota - Clinical and Translational Science Institute|Yes|Withdrawn|June 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|75 Years|No|||December 2011|December 13, 2011|April 27, 2007|Yes|Yes|Funding allocation to different clinical trials.|No||https://clinicaltrials.gov/show/NCT00467454||171865|
NCT00467727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0702|Visibility of Lesion Characteristics With Phase Contrast Mammography|Lesion Characteristics' Visibility With Phase Contrast Mammography in Comparison to X-Ray Mammography for Women Undergoing X-Ray Diagnostic Mammography||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|April 2007|September 2008|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|53|||Female|40 Years|N/A|No|||April 2012|April 27, 2012|April 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00467727||171845|
NCT00463606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-844|A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia|A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia||AstraZeneca|No|Completed|April 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|760|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|April 19, 2007|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00463606||172156|
NCT00463853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-017-04S|Stem Cell Therapy as Adjunct to Revascularization|Stem Cell Therapy as Adjunct to Revascularization: STAR|STAR|VA Office of Research and Development|Yes|Withdrawn|August 2007|October 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|April 17, 2007|No|Yes|inability to recruit due to administrative difficulties at the site|No||https://clinicaltrials.gov/show/NCT00463853||172137|
NCT00486005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7932|Weight Gain Management in Patients With Schizophrenia|Weight Gain Management in Patients With Schizophrenia During Treatment With Olanzapine in Association With Nizatidine||Eli Lilly and Company||Completed|February 2003|October 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00486005||170470|
NCT00486018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4165g|A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)|A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion|BRAVO|Genentech, Inc.||Completed|July 2007|November 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|397|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|June 11, 2007|Yes|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT00486018||170469|
NCT00486226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN07-01|The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System|The SUNRISE Registry - A Multicenter Post-Market Surveillance With the CORDIS ENTERPRISE™ Vascular Reconstruction Device and Delivery System|SUNRISE|Codman & Shurtleff|Yes|Completed|June 2007|December 2013|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|18 Years|80 Years|No|||March 2014|March 19, 2014|June 13, 2007|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00486226||170453|This study was powered to have a total of 250 subjects, but was stopped early due to slow enrollment. Hence, this study ended up having only 105 total subjects, making it underpowered.
NCT00486499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-4407-V04|I-125 Versus Pd-103 for Medium Risk Prostate Cancer|||VA Puget Sound Health Care System||Recruiting|March 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|660|||Male|40 Years|90 Years|No|||June 2007|June 12, 2007|June 12, 2007||||No||https://clinicaltrials.gov/show/NCT00486499||170432|
NCT00486785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFUS_L_01667|SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin|Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study||Sanofi||Completed|April 2006|March 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|431|||Male|50 Years|90 Years|No|||September 2009|September 29, 2009|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00486785||170410|
NCT00487032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAI03|Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation|A Proof of Concept Study to Evaluate Differential Tachyphylaxis of Alpha 1 and Alpha 2 Adrenoreceptor Mediated Decongestant Response to Oxymetazoline and Its Acute Reversal by Corticosteroid in Healthy Volunteers||University of Dundee|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 28, 2009|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487032||170391|
NCT00466180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSOVIR|Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients||POSOVIR|University Hospital, Caen|No|Completed|June 2004|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466180||171962|
NCT00466193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZI-12|A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of the Zolpidem Tartrate Sublingual Tablet in Adult Subjects With Insomnia Characterized by Difficulty Returning to Sleep After Awakening in the Middle-of-the-Night (MOTN)||Transcept Pharmaceuticals|No|Completed|May 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|295|||Both|18 Years|64 Years|No|||February 2012|February 10, 2012|April 24, 2007|Yes|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT00466193||171961|
NCT00465881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01929-05-C|Develop Novel Methods to Display, Report and Analyze CGM Data for Clinical Decision-Making in People With Diabetes|Observational Study of Interstitial Glucose Monitoring With the FreeStyle Navigator Continuous Glucose Monitoring (CGM) System to Develop Novel Methods for Displaying, Reporting and Analyzing CGM Data for Clinical Decision-Making||HealthPartners Institute|No|Completed|January 2006|April 2006|Actual|||Phase 1|Observational|Time Perspective: Prospective||||30|||Both|21 Years|N/A|No|||September 2007|December 2, 2015|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465881||171985|
NCT00466154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 5-173 S|The Effect of Serum LDL Lowering on Aspirin Resistance|The Effect of Serum LDL Lowering on Aspirin Resistance||Ziv Hospital|Yes|Completed|July 2005|January 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 19, 2013|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466154||171964|
NCT00466167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.525|Pivotal Study in Advanced Parkinsons Disease Patients|A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).||Boehringer Ingelheim||Completed|April 2007|||November 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|3||Actual|517|||Both|32 Years|N/A|No|||May 2014|June 24, 2014|April 25, 2007|Yes|Yes||No|November 17, 2009|https://clinicaltrials.gov/show/NCT00466167||171963|
NCT00466960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6168|Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy|A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer||University of Washington|No|Completed|May 2006|||July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|April 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00466960||171903|
NCT00467233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU679|Study of Acid Peel and Laser for the Treatment of Melasma|A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of 30 % Salicylic Acid Peel vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.||Northwestern University|No|Completed|May 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||September 2012|September 14, 2012|April 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467233||171882|
NCT00467467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512M78807|Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort|Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|June 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|||Anticipated|60|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|April 27, 2007||||No||https://clinicaltrials.gov/show/NCT00467467||171864|
NCT00463307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-KY-JK-06|Evaluation of the Use of a Urin Test Strip to Determine the Spread of Schistosoma Infections in Areas Where Schistosomiasis Infections Are Low in Kenya|Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya||DBL -Institute for Health Research and Development|No|Completed|April 2006|November 2006|Actual|||N/A|Observational|N/A|||Actual|1100|||Both|10 Years|18 Years|No|||October 2007|October 30, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463307||172179|
NCT00463320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD7108238|A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.|A Placebo-controlled, Randomized, Dose Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Ocular Doses of Pazopanib in Healthy Adult and Elderly Subjects.||GlaxoSmithKline|No|Completed|March 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|29|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|April 18, 2007||||||https://clinicaltrials.gov/show/NCT00463320||172178|
NCT00463619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVT123|Follow-up Study With Retarded Release Phosphatidylcholine in Ulcerative Colitis|||Heidelberg University|No|Completed|April 2000|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|132|||Both|16 Years|N/A|No|Non-Probability Sample|Patients from previous studies with retarded release phosphatidylcholine|April 2010|August 15, 2011|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463619||172155|
NCT00463866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00022|Local Phase 4 Pan-European SMART Study|||AstraZeneca||Completed|March 2007|December 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8424|||Both|18 Years|N/A|No|||March 2010|March 8, 2010|April 19, 2007|Yes|Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00463866||172136|
NCT00463879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508000458|Galantamine for Cognitive Deficits in Schizophrenia|Galantamine for Cognitive Deficits in Schizophrenia||Yale University|No|Completed|September 2005|September 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|21|||Both|18 Years|65 Years|No|||December 2007|December 11, 2007|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463879||172135|
NCT00463892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRMG #07-001|High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes|A Phase II Study of High-resolution Contrast-enhanced MRI of Regional Lymph Nodes in Patients With Clinically Localized Invasive Melanoma||Redwood Regional Medical Group|No|Completed|June 2007|June 2013|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2014|November 8, 2014|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463892||172134|
NCT00464217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETHEMA/LAM-99|Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years|PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years||PETHEMA Foundation|Yes|Completed|October 1998|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|65 Years|N/A|No|||January 2010|January 3, 2010|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00464217||172110|
NCT00464490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703054|Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts|A Prospective, Randomized, Controlled Study on the Use of Dexmedetomidine to Facilitate Extubation in Surgical Intensive-Care-Unit Patients Who Failed Previous Weaning Attempts||University of California, San Francisco|No|Terminated|November 2007|December 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|69 Years|No|||October 2014|October 29, 2014|April 19, 2007||No|Lack of eligible participants|No|October 25, 2014|https://clinicaltrials.gov/show/NCT00464490||172090|Lower than anticipated enrollment due to unwillingness of providers to assign patients to the control group led to smaller-than-planned samples for analysis
NCT00486239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-06-06|Emotional Processing and Memory Evaluation in Epilepsy Patients|Emotional Processing and Memory Evaluation in Epilepsy Patients||University Hospital Case Medical Center|No|Recruiting|October 2006|||||Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|36|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2007|June 13, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486239||170452|
NCT00486525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06137|Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors|Breast Cancer Survivors: Physical Activity, Inflammation, Fatigue, and Distress||Ohio State University Comprehensive Cancer Center|Yes|Completed|August 2007|March 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|200|||Female|21 Years|N/A|No|||April 2014|April 17, 2014|June 13, 2007||No||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00486525||170430|We did not compare yoga to an active control group; Fatigue and depressive symptoms were not used as part of the inclusion criteria. Accordingly, our data may underestimate yoga's potential benefit.
NCT00486538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-882|Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib|An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib||AbbVie|No|Completed|June 2007|June 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|June 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486538||170429|
NCT00487539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014176|An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis||Janssen Research & Development, LLC|Yes|Completed|August 2007|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1065|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|June 14, 2007|Yes|Yes||No|April 29, 2013|https://clinicaltrials.gov/show/NCT00487539||170352|
NCT00466219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASL17|Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant|||University Hospital, Geneva|No|Completed|May 2002|December 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||25|||Both|18 Years|65 Years|No|||April 2007|April 25, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466219||171959|
NCT00466492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-6-06|Advantages and Disadvantages of Long Term Sedation in Intensive Care Unit Patients|Advantages and Disadvantages of Long Term Sedation in ICU Patients||Odense University Hospital|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|N/A|No|||June 2009|March 18, 2010|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466492||171939|
NCT00466752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6307|Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer|A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer||University of Washington|No|Completed|December 2006|||April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||May 2013|May 7, 2013|April 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00466752||171919|
NCT00466986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB#20051730|Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer|A Phase II, Non-Randomized Study of Abraxane Plus Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer||Southeastern Gynecologic Oncology|No|Completed|November 2005|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|N/A|N/A|No|||October 2011|October 7, 2011|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466986||171901|
NCT00466726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML 0206|Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia|Phase II Multicenter Study of P210-B3A2 Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Response With Persistent Molecular Residual Disease During Imatinib Treatment|CML 0206|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|March 2007|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466726||171921|
NCT00466739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/S0709/95|European Compliance Study in Parkinson's Disease|European Study of Therapeutic Compliance in Parkinson's Disease||South Glasgow University Hospitals NHS Trust||Completed|January 2006|September 2007|Actual|||Phase 3|Observational|N/A|||Anticipated|144|||Both|18 Years|80 Years|No|Non-Probability Sample||May 2008|May 22, 2008|April 26, 2007||||No||https://clinicaltrials.gov/show/NCT00466739||171920|
NCT00467506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 03/2-U|Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma|Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma|RIT in MTC|Nantes University Hospital|Yes|Completed|May 2004|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2011|November 10, 2011|April 27, 2007||||No||https://clinicaltrials.gov/show/NCT00467506||171862|
NCT00467220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3049-30095-01|Effect of Daily Calorie or Alternate-day Calorie Reductions on Risk for Cardiovascular Disease and Cancer|Effect of Daily Calorie Restriction or Alternate-day Reductions in Calorie Intake on Risk for Cardiovascular Disease and Cancer|1072|University of California, San Francisco|Yes|Active, not recruiting|April 2007|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|40|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00467220||171883|
NCT00467493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-001|Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers|A Partial Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Anastrozole, an Aromatase Inhibitor, on Endometrial Thickness in Healthy Premenopausal Women When Dosed at Various Times During the Menstrual Cycle (Protocol M-001)||Meditrina Pharmaceuticals|No|Completed|March 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|64|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 2, 2009|April 27, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00467493||171863|
NCT00463333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196/2004|Postoperative Delirium at Heidelberg's Intensive Care Unit -New Diagnostic Markers|||Heidelberg University|No|Completed|May 2005|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|No|||April 2007|April 19, 2007|September 10, 2005||||No||https://clinicaltrials.gov/show/NCT00463333||172177|
NCT00463645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM3_adipose|Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients|An Open, Mono-Centre Trial to Investigate the Correlation Between the Interstitial and Arterial Blood Concentrations of Glucose During Subcutaneous Glucose Monitoring in Patients With Severe Sepsis at the Medical Intensive Care Unit||Medical University of Graz|No|Completed|September 2005|January 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||10|||Both|18 Years|90 Years|No|||April 2007|June 5, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463645||172153|
NCT00463632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-BF-ST-06|Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control|Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control||DBL -Institute for Health Research and Development|No|Completed|January 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|None Retained|urine faeces blood|Female|15 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|antenatal care clinics child immunization program|January 2010|January 11, 2010|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463632||172154|
NCT00463905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMED RJ4783|Evaluation of the Impact of a Case-finding Strategy for Vertebral Fractures|Evaluation of the Impact of a Case-finding Strategy for Vertebral Fractures on Bisphosphonate and Other Drug Prescribing in Primary Care, Using the Cohort for Skeletal Health in Bristol and Avon (COSHIBA)|COSHIBA|University of Bristol|Yes|Completed|October 2007|August 2011|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|3200|||Female|65 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463905||172133|
NCT00463918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051070|A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers|Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers||Pfizer||Completed|May 2007|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|73|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||November 2008|November 18, 2008|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463918||172132|
NCT00464230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2005-OS|Hemiarthroplasty or Internal Fixation for Displaced Femoral Neck Fractures|The Management of Intracapsular Fractures of the Proximal Femur. A Prospective, Randomized Trial of Two Parallel Screws and Hemiarthroplasty||Oslo University Hospital|No|Completed|September 2002|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||220|||Both|60 Years|N/A|No|||April 2007|June 30, 2011|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00464230||172109|
NCT00486811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|335862|A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|A Randomized Double-blind, Placebo- and Active-control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.||Grünenthal GmbH|No|Completed|June 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|990|||Both|40 Years|N/A|No|||April 2012|April 16, 2012|June 14, 2007|Yes|Yes||No|October 25, 2010|https://clinicaltrials.gov/show/NCT00486811||170408|
NCT00487097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4428|The Effect of Antioxidants on the Immune Response and Wound Healing in Critically Ill Patients|Effect of EPA, GLA and Antioxidants on the Immune Response - Cellular and Molecular Mechanisms of Wound Healing in Critically Ill Patients.||Rabin Medical Center|No|Completed|September 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||February 2013|February 15, 2013|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487097||170386|
NCT00487045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB_001|Prevention and/or Reduction of Hemorrhoids and/or Thrombosed External Hemorrhoids Using the HEM-AVERT Perianal Stabilizer Instrument|Prevention and/or Reduction of Hemorrhoids and/or Thrombosed External Hemorrhoids (TEH) Using the HEM-AVERT Perianal Stabilizer Instrument|HEM-AVERT|Plexus Biomedical, Inc.|Yes|Completed|December 2007|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Female|18 Years|40 Years|No|||July 2009|July 23, 2009|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00487045||170390|
NCT00487344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-01-D-0001|Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations|Comparison of Body Fat Reduction in Overweight and Obese Subjects Utilizing Personalized Low-Fat Meal Plans vs. Non-Personalized Low-Fat Meal Plans.||Central FITT, Inc|No|Recruiting|June 2007|November 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|2||Anticipated|32|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||May 2007|July 2, 2007|June 15, 2007||||No||https://clinicaltrials.gov/show/NCT00487344||170367|
NCT00487305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-275|Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma|A Phase I Trial of Vaccination With Lethally Irradiated Lymphoma Cells Admixed With Granulocyte-Macrophage Colony Stimulating Factor Secreting K562 Cells for the Treatment of Previously Untreated or Relapses Follicular Lymphoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|June 2007|October 2024|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|35 Years|N/A|No|||October 2015|October 29, 2015|June 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487305||170370|
NCT00487318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13358|Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin|A Randomized Controlled Trial of Adding Fluvastatin to Standard Medical Treatment (SMT) and a Pilot Trial of Rosuvastatin and Other Statins With SMT, for Patients Infected With Chronic Hepatitis C Who Are Naive to Therapy.||Bader, Ted, M.D.|No|Completed|June 2007|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||August 2012|August 20, 2012|June 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00487318||170369|
NCT00487331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1113|Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study|Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study||M.D. Anderson Cancer Center|No|Completed|June 2007|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|52|||Both|N/A|N/A|No|||October 2013|January 7, 2015|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487331||170368|
NCT00466518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|475-06-FB|Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant|Sitagliptin Treatment in Patients With Type 2 Diabetes Mellitus After Kidney Transplant||University of Nebraska|No|Active, not recruiting|April 2007|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||January 2010|January 11, 2010|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00466518||171937|
NCT00466505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0410|Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery|A Phase 2 Study of Cetuximab in Combination With Celecoxib in Colorectal Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|May 2005|November 2008|Actual|July 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2012|December 14, 2012|April 25, 2007|Yes|Yes||No|August 15, 2011|https://clinicaltrials.gov/show/NCT00466505||171938|
NCT00467246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPI2|Sub-Cutaneous Insulin in Hyperglycaemic Emergencies|The Use of a Long-Acting Sub-Cutaneous Insulin Analogue in the Management of Hyperglycaemic Emergencies||The Royal Bournemouth Hospital|Yes|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||April 2007|April 27, 2007|April 27, 2007|||Ethics approval denied|No||https://clinicaltrials.gov/show/NCT00467246||171881|
NCT00466973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/11/VA07|Atrial Fibrillation Ablation Device Comparison Study|Randomized Comparison of Ablation Devices Used During Surgery for the Treatment of Atrial Fibrillation||Maimonides Medical Center|Yes|Recruiting|April 2007|May 2009|Anticipated|||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|19 Years|75 Years|No|||April 2007|April 26, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466973||171902|
NCT00463359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN07DE002|A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base|A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base||University of Glasgow|Yes|Not yet recruiting||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|49 Years|89 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463359||172175|
NCT00467519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD517|Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age|Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine as Fifth Dose Booster in Children 4 to 6 Years of Age||Sanofi|No|Completed|April 2007|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1045|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|April 27, 2007|Yes|Yes||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00467519||171861|
NCT00463346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-MD-13|Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism|Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism||Yale University|Yes|Completed|September 2006|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|21 Years|65 Years|No|||December 2015|December 11, 2015|April 18, 2007||No||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00463346||172176|
NCT00464256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5794|Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation|Comparison of the Efficacy and Safety of a 20 mg/Day Oral Dose of Rimonabant Versus Placebo as an Aid to Smoking Cessation - a US, Randomized, Double-blind, 2 Arm, Placebo-controlled, Parallel-group, Fixed Dose, 12-week Study|STRATUS-META|Sanofi||Completed|April 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|533|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|April 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00464256||172107|
NCT00464568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPR109764|A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis|A Randomised, Open, Placebo-controlled 5-way Crossover Trial of Single Doses of Intranasal GSK256066 in Subjects With Seasonal Allergic Rhinitis (SAR).||GlaxoSmithKline|No|Completed|March 2007|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|50 Years|No|||February 2011|May 31, 2012|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00464568||172084|
NCT00463931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-GH-FA-06|Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana|Using Community-Based Volunteers to Reach Non-Enrolled School-Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana||DBL -Institute for Health Research and Development|No|Completed|September 2006|January 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||||916|||Both|6 Years|15 Years||||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463931||172131|
NCT00464243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6072|Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study|Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study|NOCTURNE907|Sanofi||Completed|April 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|604|||Both|18 Years|N/A|No|||February 2009|February 16, 2009|April 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464243||172108|
NCT00464516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR3076|Preoperative Estetrol in Breast Cancer|Preoperative Hormone Therapy for Pre- and Postmenopausal Women With ER Positive Breast Cancer: A Double Blind Randomized Parallel Group Phase II Trial, Comparing the Effect of 2 Weeks of Preoperative Estetrol With Placebo||Pantarhei Bioscience|No|Completed|April 2007|March 2010|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|70 Years|No|||June 2012|June 28, 2012|April 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464516||172088|
NCT00464529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.0741|Accuracy and Safety of Real Time Continuous Glucose Monitoring Before, During and After Surgery|Peri-Operative Accuracy and Safety of Real Time Continuous Glucose Monitoring System in Cardiac Surgical Patients. A Pilot Study|GluContinu|Medical Research Foundation, The Netherlands|No|Completed|May 2007|October 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|30|||Both|18 Years|N/A|No|||May 2007|November 6, 2007|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00464529||172087|
NCT00487110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0021|Clinical Confirmation of a Pharmacodynamic Interaction Between Tropisetron and Paracetamol||Tropisétron|University Hospital, Clermont-Ferrand||Completed|June 2008|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2010|March 26, 2010|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487110||170385|
NCT00486265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2782C00007|Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)|A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML) Excluding Promyelocytic Leukemia||AstraZeneca||Terminated|July 2007|July 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||July 2010|December 7, 2010|June 13, 2007|Yes|Yes|AML assess. of response in Part B patients find treatment failure in all 8 evaluable for    marrow response following a maximum of 2 induction courses of therapy|No|July 20, 2010|https://clinicaltrials.gov/show/NCT00486265||170450|On 16 June 2009, the study was terminated for a lack of efficacy. None of the 8 patients had experienced CR or CRi. The secondary efficacy outcome measures were not evaluated due to early termination and small number of participants.
NCT00487591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-06009|An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia|An Evaluation of Simvastatin 20 mg Plus Omacor 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia||Provident Clinical Research|No|Completed|November 2006|August 2007|Actual|August 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|serum and plasma|Both|18 Years|79 Years|No|||April 2008|April 28, 2008|June 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487591||170348|
NCT00487604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMRC1371|Retrospective Study of the Impact of Drug Eluting Stents|Retrospective Study of the Impact of Drug Eluting Stents on Intermediate Term Survival, Cardiovascular Outcomes Including Revascularization, Bleeding Rates and Economic Costs||Providence Health & Services|No|Recruiting|May 2007|May 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|9800|||Both|18 Years|N/A|No|||April 2007|August 1, 2007|June 14, 2007||||No||https://clinicaltrials.gov/show/NCT00487604||170347|
NCT00487058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBQ707A1103|A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors.||Novartis||Completed|May 2007|||June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|28|||Both|20 Years|N/A|No|||November 2009|November 18, 2009|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487058||170389|
NCT00487071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.274|Anal Fistula Plug for High-type Anal Fistulae|Efficacy of Anal Fistula Plug in the Management of High-type Anal Fistulae: a Pilot Study||Chinese University of Hong Kong|Yes|Terminated|August 2006|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|June 13, 2007||No|No financial support|No||https://clinicaltrials.gov/show/NCT00487071||170388|
NCT00487916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907170|Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum|Phase 1 Study of the Safety, Reactogenicity and Immunogenicity of AMA1-C1/ISA 720: A Blood Stage Vaccine for Plasmodium Falciparum||National Institutes of Health Clinical Center (CC)||Completed|June 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||150|||Both|18 Years|45 Years|No|||September 2009|September 23, 2009|June 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00487916||170323|
NCT00466999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2.2|Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion|Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion||Gynuity Health Projects|No|Completed|February 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 28, 2012|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466999||171900|
NCT00467012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JO19901|Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer|Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer||Chugai Pharmaceutical|No|Completed|April 2007|September 2011|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Female|20 Years|N/A|No|||April 2012|April 25, 2012|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00467012||171899|
NCT00466765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol no. 2004-03|Breast Reconstruction and Augmentation With Brava Enhanced Autologous Fat Micro Grafting|Breast Reconstruction and Augmentation With Brava Enhanced Autologous Fat Micro Grafting||Brava|No|Completed|January 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|589|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 1, 2015|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466765||171918|
NCT00467545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AKR02|An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B|An Extension to A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Adults With HBeAg-positive, Compensated Chronic Hepatitis B (CHB) (An Open-label Multicenter, follow-on Trial of the Safety of Oral Administration of Telbivudine (LDT600) 600 mg Over 21 Months in Adults With HBeAg-positive Ompensated Chronic Hepatitis B (CHB))||Novartis||Completed|April 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|70 Years|No|||May 2012|May 7, 2012|April 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00467545||171859|
NCT00467532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV Reactivation in Burns|Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients|A Prospective Longitudinal Study of the Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Patients Sustaining Significant Burn Injury||University of North Carolina, Chapel Hill|No|Completed|March 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the North Carolina Jaycee Burn Center within 72 hours of burn injury        with at least a 10% Total Body Surface (TBSA)burn and expected length of stay at least two        weeks.|January 2013|January 16, 2013|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00467532||171860|
NCT00463671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBO2/03|Hyperbaric Oxygen, Oxidative Stress, NO Bioavailability and Tissue Oxygenation|The Relation Between Hyperbaric Oxygen, Oxidative Stress, NO Bioavailability and Tissue Oxygenation in Diabetic Patients Suffering From Foot Ulcers||Assaf-Harofeh Medical Center|No|Completed|December 2003|September 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|N/A|No|||May 2007|October 16, 2008|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463671||172151|
NCT00464295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|449-Med/ERC-05|Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)|Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)|HCC-CAP|Aga Khan University|No|Completed|August 2006|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2007|December 13, 2007|April 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00464295||172104|
NCT00463658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFAAA0506164|Interdisciplinary Falls Prevention for Seniors|The Comparative Effects and Expenses of a Proactive Nurse-Led, Multifactorial and Interdisciplinary Team Approach to Falls Prevention for Older At-Risk Home Care Clients||McMaster University|No|Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|109|||Both|75 Years|N/A|No|||May 2008|May 5, 2008|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463658||172152|
NCT00463944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Assessment of an Electronic Voting System Within the Tutorial Setting. A Randomised Controlled Trial|Assessment of an Electronic Voting System Within the Tutorial Setting. A Randomised Controlled Trial||University of Adelaide||Completed|January 2001|December 2001||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||130|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2005|April 19, 2007|June 30, 2005||||No||https://clinicaltrials.gov/show/NCT00463944||172130|
NCT00463957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 06/Q0108/200|The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil|The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil||University of Cambridge|No|Active, not recruiting|August 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic||||12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2007|January 11, 2010|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463957||172129|
NCT00465166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-05|Lumbar Spine Ultrasound of Patients With Previous Accidental Dural Puncture During Labour Epidural|Lumbar Spine Ultrasound of Patients With Previous Accidental Dural Puncture During Labour Epidural||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|February 2007|July 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|56|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who had a documented, accidental dural puncture during placement of their labor        epidural.|December 2007|December 12, 2007|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465166||172040|
NCT00465179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0437|Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer|Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma||M.D. Anderson Cancer Center|No|Completed|March 2007|||March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|N/A|N/A|No|||March 2015|March 18, 2015|April 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00465179||172039|
NCT00464542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030124|Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study|Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding|MASH|University of Pittsburgh|No|Completed|December 2007|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||August 2011|August 31, 2011|April 19, 2007||No||No|March 22, 2011|https://clinicaltrials.gov/show/NCT00464542||172086|Inadequate controls (study would have been improved by inclusion of women without herpes simplex virus type 2 infection) to better determine the strength of the association between recalcitrance of BV and HSV-2 infection.
NCT00464555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-02|Strategies to Improve Islet Survival|Strategies to Improve Long Term Islet Graft Survival||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2006|February 2014|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||June 2014|June 10, 2014|April 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464555||172085|
NCT00464828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-04|Ultrasound Imaging of Neck Blood Vessels in Pregnant and Non-Pregnant Women|Internal Jugular Vein and Carotid Artery Anatomic Relation as Determined by Ultrasonography in Obstetric Patients||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2006|June 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|156|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2007|November 13, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00464828||172064|
NCT00464841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-02|Usefulness of the Tsui Test in Combined Spinal-Epidural Analgesia in Labour|Can the Tsui Test be Used to Test the Placement of Epidural Catheters Following the Intrathecal Component of a Combined Spinal-epidural Technique Used for Labor Analgesia?||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|February 2007|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|14|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 2, 2011|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464841||172063|
NCT00465153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-REB 06-211|The Combined Effects of Resistance Training and Flax Oil Supplementation Upon Inflammation in Older Adults|The Combined Effects of Resistance Training and Flax Oil Supplementation Upon Inflammation in Older Adults||University of Saskatchewan|No|Completed|April 2007|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 1, 2007|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00465153||172041|
NCT00465959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP631-024|Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease|Safety, Tolerability, Pharmacokinetics, and Efficacy of Single Inhaled Administrations of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease||Endo Pharmaceuticals||Completed|April 2007|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|40 Years|80 Years||||July 2011|December 3, 2013|April 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00465959||171979|
NCT00487370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KN1996|Implantation of Gold Beads to Relieve Discomfort From Knee Osteoarthritis|Extraarticular Gold Implantation for Treatment of Knee Osteoarthritis.||Research Unit Of General Practice, Copenhagen|No|Completed|March 1997|December 1998|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||June 2007|June 15, 2007|June 15, 2007||||No||https://clinicaltrials.gov/show/NCT00487370||170365|
NCT00487617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3801|Arteriopathy and Endothelial Function|Endothelial Dysfunction Reversibility in Patients With Peripheral Arterial Disease||University Hospital, Strasbourg, France|No|Recruiting|July 2007|April 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||February 2009|February 24, 2009|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487617||170346|
NCT00487084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-021|Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia|Interaction Between Epidural 2-chloroprocaine and Epidural Morphine: Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia||Northwestern University|No|Completed|August 2004|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|136|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|June 13, 2007||No||No|February 9, 2011|https://clinicaltrials.gov/show/NCT00487084||170387|We used a single 30-minute interval between morphine and 2-chloroprocaine administration and additional investigation is warranted to determine the optimum interval for administration.
NCT00487955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-AH-176-CTIL|The Metabolic Contribution of the Human Microbiota to Resting Energy Expenditure|The Metabolic Contribution of the Human Microbiota to Resting Energy Expenditure|A-P-REE|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|June 2007|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|40|||Both|20 Years|60 Years|No|||March 2007|June 18, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00487955||170320|
NCT00488228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMTT# 2096-07|Behavioral Self-Regulation|Behavioral Self-Regulation for Weight Loss in Young Adults||The Miriam Hospital||Completed|April 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|41|||Both|18 Years|35 Years|No|||January 2008|April 12, 2012|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488228||170300|
NCT00487565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06005|Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System|LCS® PS: A Prospective, Multi-center Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System||DePuy Orthopaedics|No|Completed|September 2006|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|80 Years|No|||August 2013|August 6, 2013|June 14, 2007|No|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00487565||170350|
NCT00487578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106542|Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction|Evaluation of the Efficacy of Naratriptan for the Treatment and Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction||Cady, Roger, M.D.|Yes|Terminated|October 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|June 14, 2007|Yes|Yes|Terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration    November 2009.|No|November 16, 2009|https://clinicaltrials.gov/show/NCT00487578||170349|Study terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration November 2009 (study drug had previously been re-supplied at expiration of 1st batch November 2007).No analysis performed.
NCT00488215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-GBR-10|A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of Prucalopride|A Double-Blind, Placebo-Controlled, 2-Way Cross-Over Trial in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Oral Prucalopride at Steady State, After up-Titration to a Maximum of 20 mg.||Movetis|No|Completed|January 2000|March 2000|Actual|March 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|May 28, 2008|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488215||170301|
NCT00467558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701M00804|Double-Blind Naltrexone in Compulsive Sexual Behavior|A Double-Blind, Placebo-Controlled Study of Naltrexone in Compulsive Sexual Behavior||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|May 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|21 Years|75 Years|No|||April 2012|April 18, 2012|April 27, 2007|Yes|Yes||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00467558||171858|
NCT00467259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007004|Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women|A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.||Warner Chilcott|Yes|Completed|April 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1271|||Female|45 Years|70 Years|No|||November 2011|November 10, 2011|April 27, 2007|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00467259||171880|
NCT00467272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0958|Catheter Related - Gram Positive Bloodstream Infections|Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections||M.D. Anderson Cancer Center|No|Completed|March 2007|||September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00467272||171879|
NCT00463684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEV03|Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age|Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka|JEV03|PATH|No|Completed|July 2007|April 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|277|||Both|9 Months|9 Months|Accepts Healthy Volunteers|||April 2009|May 4, 2009|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463684||172150|
NCT00463372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241002|Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia|A Phase I, Investigator And Subject-Blind (Sponsor Unblinded), Placebo-Controlled Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-02545920 After Multiple Oral Dose Administration In Subjects With Stable Schizophrenia||Pfizer||Completed|October 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|55 Years|No|||September 2007|September 17, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463372||172174|
NCT00463385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MMM-001|A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia|A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia||Celgene|Yes|Completed|April 2007|December 2013|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|88|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|April 19, 2007|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00463385||172173|
NCT00477204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1036|Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes|Clinical Trial of Zocor and Vytorin in Adolescents With Type 1 Diabetes||University of Colorado, Denver|Yes|Completed|May 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|12 Years|18 Years|No|||August 2013|August 19, 2013|May 21, 2007|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00477204||171132|Recruitment for this study failed to meet target and therefore it is difficult to make conclusions on the data obtained in these 9 subjects.
NCT00477828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1AG008415|Effect of Treating Sleep Apnea on Cognition in Patients With Dementia|Cognitive Benefits of Treating Apnea in Dementia||University of California, San Diego|No|Completed|April 2000|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|2||Actual|61|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||May 2007|May 22, 2007|May 22, 2007||||No||https://clinicaltrials.gov/show/NCT00477828||171086|
NCT00478140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00217|Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery|A Phase II Study Trastuzumab (NSC 688097) in Her2/Neu Positive Cancer of the Gallbladder or Biliary Tract (NCI 7756)||National Cancer Institute (NCI)|Yes|Completed|May 2007|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2013|May 15, 2014|May 23, 2007|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00478140||171062|
NCT00489762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heating Study|Does Improving Insulation and Heating Improve Health?|Housing, Heating and Health Study:a Randomised Community Trial||University of Otago|No|Completed|June 2005|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|1||Actual|409|||Both|6 Years|12 Years|No|||June 2007|June 19, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489762||170184|
NCT00479661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005012|Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU)|A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Propofol for Continuous Sedation of Ventilated Patients in Intensive Care Unit|Prodex|Orion Corporation, Orion Pharma|Yes|Completed|May 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|May 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479661||170949|
NCT00479635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI 287-04|A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer|A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Taxane Regimen||Cortice Biosciences, Inc.|No|Terminated|January 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|N/A|No|||January 2014|January 9, 2014|May 24, 2007|Yes|Yes|Sponsor could no longer support; enrollment stopped August 2008.|No||https://clinicaltrials.gov/show/NCT00479635||170951|
NCT00480246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL- 1020.02|A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer|||BioLineRx, Ltd.||Completed|May 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Male|21 Years|35 Years|Accepts Healthy Volunteers|||May 2007|July 20, 2009|May 28, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00480246||170905|
NCT00480272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURE|Prospective Study on Intensive Early Rheumatoid Arthritis Treatment|A Phase IV Multicenter, Randomized, Double-blind Study. prospeCtive Study on Intensive Early Rheumatoid Arthritis Treatment With adalimUmab: Induction of REmission and Maintenance|CURE|IRCCS Policlinico S. Matteo|Yes|Recruiting|May 2007|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|70 Years|No|||August 2009|August 3, 2009|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00480272||170903|
NCT00480220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0200601|Specific Care and Assistance Plan for Alzheimer's Disease|Specific Care and Assistance Plan for Alzheimer's Disease: Impact Study on Disease Progression and Management Modalities|PLASA|University Hospital, Toulouse|No|Completed|August 2003|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1200|||Both|65 Years|N/A|No|||August 2015|August 18, 2015|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00480220||170907|
NCT00480233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4420-RG-CTRL|Screening Questionnaire for Depression|Validation of a Hebrew Version of a Brief Screening Questionnaire for Depression in General Medicine||Sheba Medical Center|No|Recruiting|January 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care and general medical patients|February 2008|February 4, 2008|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00480233||170906|
NCT00480857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.066|Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy|Salvage Radiation Therapy and Docetaxel (Taxotere) for Biochemical Failure After Radical Prostatectomy||University of Michigan Cancer Center|Yes|Terminated|March 2007|July 2014|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||January 2015|January 9, 2015|May 29, 2007|No|Yes|Lack of funding.|No|January 9, 2015|https://clinicaltrials.gov/show/NCT00480857||170859|
NCT00488787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-003|Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the Treatment of Postoperative Dental Pain||Javelin Pharmaceuticals|No|Completed|March 2001|April 2001|Actual|April 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|16 Years|N/A|No|||February 2008|February 5, 2008|June 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488787||170257|
NCT00488800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-102324|Safety and Local Tolerability of Prevenar in Indian Children|A Postmarketing Surveillance Study Evaluating the Safety and Local Tolerance of PREVENAR in Indian Children||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|January 2007|Actual|January 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||||1000|||Both|6 Weeks|24 Months|No|||December 2007|December 20, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00488800||170256|
NCT00481000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASA-0230|Dialectical Cognitive Traumatherapy (DCT) on Patients With Severe PTSD Following Sexual Abuse|Dialectical Cognitive Traumatherapy (DCT) on Patients With Severe Posttraumatic Stress Disorder Following Sexual Abuse - A Randomised Controlled Trial|PASA|Central Institute of Mental Health, Mannheim|No|Active, not recruiting|April 2007|October 2010|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Female|17 Years|N/A|No|||April 2010|April 20, 2010|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481000||170849|
NCT00481013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H0249|Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy|Prospective Controlled Trial of Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA) Study|VALIANTSMA|University of Utah|Yes|Completed|July 2007|November 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|60 Years|No|||January 2015|January 13, 2015|May 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00481013||170848|
NCT00489385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070001|An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals|An Open Label Non-Randomized Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals||National Institutes of Health Clinical Center (CC)||Completed|June 2007|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2012|September 26, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489385||170213|
NCT00489398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5316|Comparison of CL Wear Between Two Allergy Drops|Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride||Hom, Milton M., OD, FAAO|Yes|Withdrawn|July 2007|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 5, 2010|June 19, 2007||No|Protocol changes|No||https://clinicaltrials.gov/show/NCT00489398||170212|
NCT00478426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00210|Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer|A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma||National Cancer Institute (NCI)|No|Active, not recruiting|April 2007|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||December 2015|March 23, 2016|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478426||171042|
NCT00488397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-102091|Tigecycline In-Vitro Surveillance Study In Taiwan|Tigecycline In-Vitro Surveillance Study In Taiwan||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2006|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7902|||Both|N/A|N/A|No|Non-Probability Sample|hospital or community acquired infection|March 2011|March 21, 2011|June 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00488397||170287|
NCT00480740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 3908|The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease|The Pharmacology of Dexmedetomidine in Children With Congenital Heart Disease||Children's Research Institute|No|Completed|December 2006|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|N/A|18 Years|No|||June 2015|June 17, 2015|May 29, 2007|No|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT00480740||170868|
NCT00481039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5311006.EMC|Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel|Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel- An Observational Study||HaEmek Medical Center, Israel|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|All the patients diagnosed with abnormal hemoglobin in the bedouin arab village|September 2009|September 3, 2009|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481039||170846|
NCT00481052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML0307|Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase|The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+ Chronic Myeloid Leucemia (CML) in Early Chronic Phase: a Phase II Exploratory, Multicenter Study. GIMEMA Protocol CML 0307. EUDRACT 2007-000597-22.|CML0307|Gruppo Italiano Malattie EMatologiche dell'Adulto|Yes|Active, not recruiting|June 2007|November 2018|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481052||170845|
NCT00477841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320106196208052017|Self-Expandable Esophageal Radiation Stent:a Randomized Controlled Trial in Patients With Advanced Esophageal Cancer|||Southeast University, China|No|Completed|April 2004|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|80 Years|No|||May 2007|April 17, 2008|May 22, 2007||||No||https://clinicaltrials.gov/show/NCT00477841||171085|
NCT00478712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD028088|Hirschsprung Disease Genetic Study|Genetic Analysis of Hirschsprung Disease||Johns Hopkins University|No|Recruiting|January 2001|March 2025|Anticipated|March 2025|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Study volunteers are asked to provide blood or cheek swab/saliva samples. DNA is extracted      from the samples for use in the study.|Both|N/A|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population includes individuals with Hirschsprung disease and their family        members.|October 2015|October 22, 2015|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478712||171020|
NCT00478725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG10004|Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034|An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects With Solid Tumor Malignancies||GlaxoSmithKline|No|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|May 24, 2007||||||https://clinicaltrials.gov/show/NCT00478725||171019|
NCT00485953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO06080002 (REBBeCA II)|Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy|The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy|REBBeCA II|University of Pittsburgh|Yes|Completed|September 2007|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|109|||Female|55 Years|N/A|No|||July 2014|July 8, 2014|June 11, 2007|Yes|Yes||No|June 2, 2014|https://clinicaltrials.gov/show/NCT00485953||170474|
NCT00485966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3-07-001|Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase 2, Multi-Center, Open Label Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of Quarfloxacin (CX-3543) in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)||Cylene Pharmaceuticals|No|Withdrawn|June 2007|June 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2008|November 3, 2008|June 11, 2007|Yes|Yes|This study was withdrawn prior to patient enrollment|No||https://clinicaltrials.gov/show/NCT00485966||170473|
NCT00480012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3437-RA-CTIL|The Effects of TMS on Memory-consolidation in Human Primary Visual Cortex|The Effects of Transcranial Magnetic Stimulation of the Brain on Memory-consolidation in Human Primary Visual Cortex||Sheba Medical Center||Withdrawn|May 2005|||June 2007|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 28, 2011|May 29, 2007||No|Due to administrative issues, the study was withdrawn.|No||https://clinicaltrials.gov/show/NCT00480012||170923|
NCT00480025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109493|GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer|GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer||GlaxoSmithKline||Terminated|October 2007|September 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2278|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|May 29, 2007|Yes|Yes|The study was terminated following assessment of the lack of efficacy of the study product by    the Independent Data monitoring Committee for the study.|No||https://clinicaltrials.gov/show/NCT00480025||170922|
NCT00480259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25351|Hyperproteic Nutrition:Correlation of BUN to Nitrogen Balance|Hyperproteic Nutrition; Correlation of BUN to Nitrogen Balance and Associated Infection Rates With Bimodal Protein Administration||Penn State University|No|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|2||||||Both|18 Years|N/A|No|||May 2007|May 29, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00480259||170904|
NCT00480584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14624|A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer|A Phase I Trial of GemCap-T, Capecitabine in Combination With Gemcitabine and Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|April 2007|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|May 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00480584||170880|
NCT00480831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APM4074g|A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)|A Randomized, Double-Blind, Phase II Trial of Paclitaxel + Carboplatin + Bevacizumab With or Without PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer||Genentech, Inc.||Completed|June 2007|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00480831||170861|
NCT00480844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4639-JL-CTIL|Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone|Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone||Sheba Medical Center|No|Recruiting|October 2008|||October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480844||170860|
NCT00476541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO-AML 2004|NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia|NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia||University of Aarhus|Yes|Active, not recruiting|January 2004|January 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|N/A|18 Years|No|||March 2012|March 21, 2012|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476541||171180|
NCT00477672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-012|A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis|A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease||ACADIA Pharmaceuticals Inc.||Completed|June 2007|||June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|298|||Both|40 Years|N/A|No|||February 2014|February 6, 2014|May 22, 2007|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT00477672||171097|
NCT00476788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X060928006|Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM|Fast Track Continuous Subcutaneous Insulin Infusion (CSII) in Children With Newly Diagnosed Type 1 Diabetes Mellitus: An Evaluation of a Novel CSII Device in the Immediate Period Following Diagnosis of Type 1 Diabetes (T1DM)||University of Alabama at Birmingham|No|Completed|April 2007|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|1 Year|8 Years|Accepts Healthy Volunteers|||December 2010|December 20, 2010|May 18, 2007||No||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00476788||171163|
NCT00477997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-GH-20070052|Effect of Growth Hormone on Insulin Signaling in Muscle Tissue|The Effect of a Physiological Bolus of Growth Hormone (GH) on Insulin Signaling Pathways in Muscle Tissue From Healthy Adults||University of Aarhus|No|Completed|May 2007|August 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|8|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2009|April 20, 2009|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00477997||171073|
NCT00488267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMK-301|Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee|A Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy of ThermoProfen™ in the Treatment of Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee (ZMK-301)||ZARS Pharma Inc.|No|Completed|June 2007|September 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|679|||Both|18 Years|75 Years|No|||May 2012|May 17, 2012|June 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488267||170297|
NCT00477191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000494|Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis|Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis||Massachusetts General Hospital|No|Terminated|May 2007|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|May 18, 2007||No|Difficulty in recruitment.|No||https://clinicaltrials.gov/show/NCT00477191||171133|
NCT00477490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS29|Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study With a Double Blind Extension Investigating the Efficacy and Safety of a Fast- Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults||Ferring Pharmaceuticals|Yes|Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|799|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|May 22, 2007|Yes|Yes||No|June 16, 2015|https://clinicaltrials.gov/show/NCT00477490||171111|
NCT00477503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0623|Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA|Phase 1 Study Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA||M.D. Anderson Cancer Center|No|Terminated|May 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1|||Both|2 Years|N/A|No|||July 2012|July 31, 2012|May 21, 2007|No|Yes|One participant enrolled, study terminated .|No||https://clinicaltrials.gov/show/NCT00477503||171110|
NCT00478972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6648|Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients Inadequately Controlled With Diet and Exercise Alone|SOLO|Sanofi||Terminated|May 2007|January 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|321|||Both|20 Years|N/A|No|||July 2009|July 17, 2009|May 24, 2007|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00478972||171001|
NCT00488657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RushUMC|Improve Speech Using an In-the-ear Device in Parkinson's Disease|Treating Speech Disorders in Patients With Parkinson's Disease Using Altered Auditory Feedback|MJFFSpeech|Rush University Medical Center|No|Completed|June 2006|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|25 Years|90 Years|No|||January 2013|January 17, 2013|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488657||170267|
NCT00488670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00050|Escitalopram and Depression in Elderly Alzheimer's Patients|An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease||University of British Columbia|No|Terminated|December 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|N/A|No|||June 2011|June 2, 2011|June 18, 2007||No|Dr. Rabheru left VCH last year and the study was cancelled according to his research    coordinator.|No||https://clinicaltrials.gov/show/NCT00488670||170266|
NCT00476671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 040|Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1|Prevalence and Risk Factors of HIV-Associated Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1 Infected Thai Individuals With Undetectable Viral Load in the HAART Era.||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|March 2007|June 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|PBMC and plasma|Both|18 Years|N/A|No|Non-Probability Sample|HIV infected adults with viral < 50 copies/ml on NNRTI based HAART|October 2008|October 19, 2008|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476671||171170|
NCT00476684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023-04REK|The Effect of Radiofrequency-treatment on Patients With Facet-joint Pain in Cervical- and Lumbar-columna|The Effect of Radiofrequency-treatment on Patients With Facet-joint Pain in Cervical- and Lumbar-columna||Norwegian University of Science and Technology|No|Completed|August 2004|May 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|75 Years|No|||March 2012|March 6, 2012|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476684||171169|
NCT00476970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P 002254|Colorectal Cancer Screening Navigator Program for Low Income and Non-English Speaking Populations|Improving Colorectal Cancer Screening Rates by Lowering Barriers in Low Income and Non-English Speaking Populations: The Chelsea Colorectal Cancer Screening Project||Massachusetts General Hospital|No|Recruiting|September 2007|September 2010|Anticipated|September 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1400|||Both|52 Years|79 Years|Accepts Healthy Volunteers|||April 2010|April 30, 2010|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476970||171150|
NCT00478439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070410002|Investigation of Macular Pigment Augmentation on Dark Adaptation|Investigation of Macular Pigment Augmentation on Dark Adaptation||University of Alabama at Birmingham|No|Terminated|December 2007|October 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|13|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||October 2010|October 26, 2010|May 22, 2007||No|Study terminated: Recruitment delay due to equipment malfunction|No||https://clinicaltrials.gov/show/NCT00478439||171041|
NCT00478452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|707800|Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients|Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Carcinoma|DC-Ova|University of Pennsylvania|Yes|Completed|August 2005|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|N/A|No|||August 2011|August 25, 2011|May 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00478452||171040|
NCT00479284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 06-094|Efficacy of Average Volume Assured Pressure Support With Bi-Level Pressure Support Nocturnal Ventilation|Contribution of Average Volume Assured Pressure Support (AVAPS) to Efficacy of bi-Level Pressure Support Nocturnal Ventilation and Impact on Sleep Structure||University Hospital, Geneva|No|Completed|June 2006|May 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|2||Actual|14|||Both|18 Years|75 Years|No|||May 2007|May 25, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479284||170977|
NCT00485641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-516-05|Saeboflex Dynamic Hand Orthosis for Inpatient Rehabilitation Stroke Patients|Screening of Inpatient Rehabilitation Stroke Patients for Their Potential to Qualify to Use the Saeboflex Dynamic Hand Orthosis||Kessler Foundation|No|Completed|August 2005|January 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|222|||Both|N/A|N/A|No|||June 2007|June 12, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485641||170498|
NCT00480311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-19|World Health Organization Disability Assessment Schedule II (WHODAS-II) for Patients With Symptomatic Lumbar Spinal Stenosis|WHODAS-II for Patients With Symptomatic Lumbar Spinal Stenosis||Kovacs Foundation|Yes|Terminated|April 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients seen at Hospital Universitario Marqués de Valdecilla in Santander, Spain - for        symptomatic lumbar spinal stenosis.|June 2011|June 26, 2011|May 28, 2007||No|Recruitment was so slow, that it made the study impossible. Organizational changes made it    impossible for recruiting centers to continue recruitment|No||https://clinicaltrials.gov/show/NCT00480311||170900|
NCT00480324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107625|Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants|Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants||GlaxoSmithKline||Completed|June 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|765|||Both|6 Weeks|14 Weeks|Accepts Healthy Volunteers|||February 2011|April 11, 2013|May 29, 2007|Yes|Yes||No|March 30, 2010|https://clinicaltrials.gov/show/NCT00480324||170899|
NCT00479986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS-K-016|Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease|Effects of Pioglitazone in Patients With Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Vascular Complications : A Placebo-Controlled Study|PIOcard|IKFE Institute for Clinical Research and Development|Yes|Completed|June 2005|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|92|||Both|20 Years|80 Years|No|||May 2007|March 31, 2015|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00479986||170925|
NCT00479999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070167|Phase 1 Safety Study of Two Experimental HIV Vaccines|VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults||National Institutes of Health Clinical Center (CC)||Completed|May 2007|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|18 Years|50 Years|No|||May 2014|January 29, 2015|May 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479999||170924|
NCT00480883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol|Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate 20 Mg/Kg/Day Versus Meglumine Antimoniate 10 Mg/Kg/Day And Tablet Allopurinol 20 Mg/Kg/Day||Combined Military Hospital, Pakistan|No|Completed|January 2008|December 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|50 Years|No|||May 2008|June 1, 2010|May 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00480883||170857|
NCT00480571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-1020 II|Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder|An Open-label, Multi-center, 6-week, Sequential Cohort Study Designed to Determine the Safety and Tolerability of Two Dose Ranges of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-affective Disorder||BioLineRx, Ltd.|Yes|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||August 2007|July 20, 2009|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480571||170881|
NCT00477984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-221/O|Effects of Alcohol on Simulated Driving|The Effects of Five Dosages of Ethanol on Simulated Driving Performance and Event-Related Potentials||Utrecht Institute for Pharmaceutical Sciences|No|Completed|May 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 11, 2008|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00477984||171074|
NCT00478010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0666, CDR0000530879|Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer|Research Participation: Decision Making and Outcomes in Cancer Clinical Trials||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|January 2007|||December 2008|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Health Services Research|||Anticipated|200|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00478010||171072|
NCT00488579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFEG|Routine Iron Prophylaxis During Pregnancy|Routine Iron Prophylaxis During Pregnancy - Effects on Maternal and Child Health in Maputo City and Province (Mozambique)|PROFEG|National Istitute For Health and Welfare, Finland|No|Active, not recruiting|May 2007|December 2012|Anticipated|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|4326|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 16, 2012|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488579||170273|
NCT00488605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-9926-LCH III|H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis|H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis||University of New Mexico|Yes|Active, not recruiting|February 2004|February 2010|Anticipated|February 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|476|||Both|N/A|18 Years|No|||May 2009|June 23, 2010|June 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488605||170271|
NCT00477815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546732|Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma|A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|May 2005|||May 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|120 Years|No|||January 2016|January 11, 2016|May 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477815||171087|
NCT00478101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-SC-61|Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain|||Gachon University Gil Medical Center|No|Completed|February 2006|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2006|||Both|19 Years|N/A|No|||March 2008|March 12, 2008|May 22, 2007||||No||https://clinicaltrials.gov/show/NCT00478101||171065|
NCT00478114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12750|Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)|An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma||Mahidol University|No|Completed|May 2007|March 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478114||171064|
NCT00478127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO-272|Hepatocyte Growth Factor and Cardiovascular Autonomic Function|||Oita Red Cross Hospital||Completed||||||N/A|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A||||May 2007|May 23, 2007|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00478127||171063|
NCT00479921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201.3.126|Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe|Immunogenicity and Reactogenicity of Trivalent Influenza Subunit Vaccine Influvac® for the Season 2007/2008. An Open, Baseline-Controlled Multi-Center Study in Two Groups of Healthy Subjects: Adults and Elderly||Solvay Pharmaceuticals||Completed|June 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 29, 2009|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00479921||170930|
NCT00488098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SND110117|GSK372475 Bioequivalence Study|An Open Label, Randomized, Parallel Groups, Bioequivalence Study to Compare a Single Oral Dose of GSK372475B or GSK372475C in Male and Female Healthy Volunteers.||GlaxoSmithKline|No|Completed|July 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|June 15, 2007||||No||https://clinicaltrials.gov/show/NCT00488098||170309|
NCT00488423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8585|Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery|Glucose Metabolism in the Immediate and Short Term Follow up From Bariatric Surgery|MIDAS|The Cleveland Clinic|No|Completed|November 2006|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|21|||Both|19 Years|65 Years|No|||June 2011|June 21, 2011|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488423||170285|
NCT00488683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P16|B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants|A Phase II, Single Center, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants||Novartis|No|Completed|July 2007|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|216|||Both|56 Days|83 Days|Accepts Healthy Volunteers|||September 2014|September 18, 2014|June 19, 2007|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT00488683||170265|
NCT00488644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0804|Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors|Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors||M.D. Anderson Cancer Center|No|Terminated|February 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|June 19, 2007||No|Slow accrual.|No|March 22, 2012|https://clinicaltrials.gov/show/NCT00488644||170268|
NCT00477516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10571|Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients|Determination of FDF-23 Levels in Non-suppressible PTH Secretion and the Influence of Inflammation on Fetuin A Levels During Hemodialysis Treatment||University of Kansas Medical Center|No|Completed|January 2007|August 2007|Actual|August 2007|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00477516||171109|
NCT00489203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2079.00|Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens||Fred Hutchinson Cancer Research Center|No|Completed|April 2007|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|140|||Both|N/A|N/A|No|||March 2015|March 5, 2015|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489203||170227|
NCT00489476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-104-201|Staccato® Loxapine for Inhalation in Patients With Migraine Headache|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Migraine Headache||Alexza Pharmaceuticals, Inc.|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 9, 2008|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489476||170206|
NCT00489775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6937|Duloxetine Versus Paroxetine for Major Depression|Duloxetine Versus Paroxetine in the Acute Treatment of Major Depression||Eli Lilly and Company|No|Completed|January 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||480|||Both|18 Years|N/A|No|||June 2007|June 19, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489775||170183|
NCT00486512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO CP-01-US|Chemoprevention of Colorectal Adenomas|A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas||Colotech A/S|No|Terminated|June 2007|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|40 Years|75 Years|No|||February 2011|February 4, 2011|June 12, 2007|Yes|Yes|Planned Interim Analysis failed to show difference between the active and placebo groups|No||https://clinicaltrials.gov/show/NCT00486512||170431|
NCT00479713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-809|A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)|A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients With Primary High Cholesterol and High Cardiovascular Risk Not Controlled With a Prior Statin Treatment||Merck Sharp & Dohme Corp.||Completed|February 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|618|||Both|18 Years|79 Years|No|||September 2015|September 1, 2015|May 24, 2007|Yes|Yes||No|February 11, 2009|https://clinicaltrials.gov/show/NCT00479713||170945|
NCT00479726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8300|Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)|Lilly's Emotional and Physical Symptoms of Depression Study|LEAPS|Eli Lilly and Company|No|Completed|August 2004|January 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8000|||Both|18 Years|N/A|No|||May 2007|May 25, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479726||170944|
NCT00480285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE2006.287-T|A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients|A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients||Chinese University of Hong Kong|Yes|Recruiting|November 2006|November 2011|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|70 Years|No|||May 2007|May 29, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00480285||170902|
NCT00480298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/067|Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis|Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis||University Hospital, Ghent|No|Completed|November 2002|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||48|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00480298||170901|
NCT00480610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-40|Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment|Clinical Study on Tacrolimus Ointment Over the Long-term. "CONTROL Study - Adults"||Astellas Pharma Inc|No|Completed|April 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|16 Years|N/A|No|||September 2014|September 17, 2014|May 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00480610||170878|
NCT00480896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-41|Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment|Clinical Study on Tacrolimus Ointment Over the Long-term. "CONTROL Study - Children"||Astellas Pharma Inc|No|Completed|June 2004|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|2 Years|15 Years|No|||September 2014|September 17, 2014|May 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00480896||170856|
NCT00480870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP nº051/99|The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients|The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients|ACHALZSLEEP|Associacao Fundo de Incentivo a Psicofarmcologia|No|Completed|April 1999|January 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|50 Years|90 Years|No|||December 2007|December 3, 2007|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480870||170858|
NCT00477685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking 0704|Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India|Study of the Safety and Effectiveness of the OculusGenTM Collagen Matrix Implant as an Aid in Phacotrabeculectomy Surgery||Pro Top & Mediking Company Limited||Completed|May 2007|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|May 23, 2007||No||No|October 24, 2011|https://clinicaltrials.gov/show/NCT00477685||171096|Limited sample size.
NCT00477711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-769|A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer||EXTRA|Peking University|Yes|Completed|March 2007|February 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|75 Years|No|||May 2015|May 17, 2015|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477711||171095|
NCT00488878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0137|Data Collection for Patients With Low Grade Ovarian Carcinoma|Data Collection for Patients With Low Grade Ovarian Carcinoma||M.D. Anderson Cancer Center|No|Recruiting|May 2006|||May 2034|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|Samples With DNA|If patient gives consent, tumor tissue left over from earlier surgery or surgeries that is      preserved in wax or on glass slides will be stored in a research tissue bank.|Female|N/A|N/A|No|Non-Probability Sample|Department of Gynecologic Oncology or the Department of Gynecologic Medical Oncology at UT        MD Anderson Cancer Center in Houston, Texas|December 2015|December 14, 2015|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488878||170251|
NCT00479557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134K1-200|Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease|A Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|May 2007|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|86|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|May 24, 2007||No||No|May 6, 2014|https://clinicaltrials.gov/show/NCT00479557||170957|
NCT00487487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USUHS-G192EI|Study of Mental Fatigue in Polio Survivors|||Uniformed Services University of the Health Sciences|No|Recruiting||||||N/A|Observational|Allocation: Random Sample, Time Perspective: Cross-Sectional|||||||Both|18 Years|N/A|No|||March 2007|June 15, 2007|June 14, 2007||||No||https://clinicaltrials.gov/show/NCT00487487||170356|
NCT00478699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECP-SCAT|Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)|Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients|GECP-SCAT|Spanish Lung Cancer Group|Yes|Completed|June 2007|July 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478699||171021|
NCT00488111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2579FW|Fluid Management for Cesarean Section|Fluid Management With Ringer's and 6% Starch for Cesarean Section After Epidural or Spinal Anesthesia|FMCS|Nanjing Medical University|No|Completed|May 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|850|||Female|21 Years|40 Years|No|||August 2008|August 12, 2008|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488111||170308|
NCT00489242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4S-MC-X022|Prediction of CK-MB Release During Otherwise Successful Stenting Procedure|PREDICT Trial: Prediction of CK-MB Release During Otherwise Successful Stenting Procedure Correlating With Indicators of Microvascular Obstruction|PREDICT|Icahn School of Medicine at Mount Sinai||Completed|August 2003|September 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||June 2007|June 20, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489242||170224|
NCT00488943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H53537-26003|Follow-up After Endovascular Repair of Abdominal Aortic Aneurysm|Follow-up After Endovascular Repair of Abdominal Aortic Aneurysm||University of California, San Francisco|Yes|Completed|January 2005|||December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Abdominal Aortic Aneurysms treated with Zenith Stent-Graft|June 2012|June 28, 2012|June 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00488943||170246|
NCT00488930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070685|Characteristics of Dendritic Cells Before and After Gastric Banding|Characteristics of Dendritic Cells Before and After Gastric Banding||University of California, San Diego|No|Terminated|June 2007|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects being treated for obesity at this institution|July 2011|July 14, 2011|June 11, 2007||No|Terminated due to a lack of recruitment and decision by the PI not to continue.|No||https://clinicaltrials.gov/show/NCT00488930||170247|
NCT00489489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY6045|Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis|A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Interferon-beta in Subjects With Multiple Sclerosis.||Sanofi|Yes|Completed|May 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|118|||Both|18 Years|55 Years|No|||November 2012|November 5, 2012|June 20, 2007|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00489489||170205|
NCT00485628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5286|Safety Study in Outpatient Japanese Children With ADHD|An Open-Label, Dose Titration Safety Study of Atomoxetine Hydrochloride in Outpatient Japanese Children With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|April 2003|October 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|6 Years|17 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485628||170499|
NCT00489788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000990|Predictors for Pulmonary Valve Replacement - Anatomic and Hemodynamic Using MRI|MRI Assessment of Right and Left Ventricular Strain, Associated Function, Volume and ECG Parameters as Predictors of Optimal Timing for Pulmonary Valve Replacement in Patients Post Repair for Tetralogy of Fallot||Emory University|No|Completed|September 2008|March 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|||Both|3 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatrics and young adults aged 3-30 years following surgical repair of Tetralogy of        Fallot. Also looking at normal control subjects.|December 2013|December 10, 2013|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00489788||170182|
NCT00485654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-198|Racial Distribution of Heterotaxy Syndrome|Racial Distribution of Heterotaxy Syndrome and Effects on Clinical Outcomes Protocol||Children's Healthcare of Atlanta|No|Terminated|January 1990|February 2008|Actual|January 2005|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|65|||Both|N/A|21 Years|No|Non-Probability Sample|This study will be a retrospective chart review of approximately 90 - 100 medical charts,        conducted on the Egleston campus of Children's Healthcare of Atlanta. Charts reviewed will        cover a period between January 1, 1990 and December 31, 2005. Data to be collected        includes: DOB, diagnosis, surgical procedure, surgical outcome, survival, length of        hospitalization, repeat surgical intervention, incidence of hospitalization, length of        inotropic support, ventilator time, infection rate, insurance provider, list of        antibiotics and zip code of residence at initial admission. In addition to the above        information, data to be extracted from the medical chart of a decedent will include age at        death, cause of death, laboratory data at time of death and autopsy results.|February 2008|March 14, 2012|June 12, 2007||No|study was terminated because study conclusions varied.|No||https://clinicaltrials.gov/show/NCT00485654||170497|
NCT00480597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gemcitabin 02 MC|Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer|Randomised, Multicenter Phase II Study in Patients With Metastatic Breast Cancer With Gemcitabine Plus Vinorelbine Versus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Capecitabine||Ludwig-Maximilians - University of Munich|Yes|Completed|October 2002|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|141|||Female|18 Years|70 Years|No|||May 2007|October 27, 2010|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00480597||170879|
NCT00476554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC682-06-05|A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma|||Cyclacel Pharmaceuticals, Inc.||Terminated|April 2007|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|May 19, 2007|Yes|Yes|slow accrual and financial resource limitation|No||https://clinicaltrials.gov/show/NCT00476554||171179|
NCT00477360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15052007|Humeral Resurfacing Hemiarthroplasty|Humeral Resurfacing Hemiarthroplasty. Phase 2: Prospective Cohort Study|CAP|University of Calgary|No|Active, not recruiting|January 2007|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||August 2011|August 10, 2011|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477360||171120|
NCT00477373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPKOT_L_01567|Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study|Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study|GEVANS|Sanofi|No|Completed|December 2006|||December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|75 Years|No|||December 2008|December 18, 2008|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477373||171119|
NCT00488306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-101994|Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI|A Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Tigecycline to Treat Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Patients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A|No|||July 2009|July 6, 2009|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00488306||170294|
NCT00488592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070159|Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers|Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies||National Institutes of Health Clinical Center (CC)|Yes|Completed|June 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|85 Years|No|||June 2014|June 5, 2014|June 19, 2007|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00488592||170272|Although not tested or described formally, no clinically meaningful hematological responses were seen.Despite boosting, cellular immune responses were only transient.
NCT00479570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8361015|Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.|Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).||Pfizer|No|Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Female|45 Years|65 Years|No|||April 2009|April 7, 2009|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00479570||170956|
NCT00480727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135/07|Determining Optimal Halo Pin Management Practises to Decrease Pin Complications|Determining Optimal Halo Pin Management Practises to Decrease Pin Complications||Bayside Health|No|Completed|April 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|80 Years|No|||May 2010|February 10, 2013|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00480727||170869|
NCT00487500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3482|Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression|Affective and Cognitive Consequences of ECT||New York State Psychiatric Institute|Yes|Completed|December 1998|May 2005|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|180|||Both|18 Years|90 Years|No|||June 2007|August 15, 2014|June 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487500||170355|
NCT00487812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0017|Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT to Predict Left Ventricular Remodelling in Patients Reperfused in the Acute Phase of MI|Prediction of Left Ventricular Remodelling in Patients Treated by Angioplasty in the Acute of Phase of a First Myocardial Infarction by Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT||University Hospital, Clermont-Ferrand||Completed|December 2004|September 2008|Actual|August 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2008|October 6, 2008|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00487812||170331|
NCT00487825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2204|Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis|A 26-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR50) and to Determine a Biomarker Profile in Responders to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) Plus MTX as Compared to MTX Alone in Early Rheumatoid Arthritis Patients||Novartis|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|75 Years|No|||July 2012|July 24, 2012|June 18, 2007|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00487825||170330|
NCT00488410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0016|SYNCHRO. Evaluation of the Forecasts Parameters of Real Time-three-dimensional Doppler Echocardiography in Selecting Patients With Chronic Heart Failure for Cardiac Resynchronisation Therapy|Evaluation of the Forecasts Parameters of Real Time Three-dimensional Doppler Echocardiography in Selecting Patients With Chronic Heart Failure for Cardiac Resynchronisation Therapy||University Hospital, Clermont-Ferrand||Completed|November 2006|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind|1||||||Both|18 Years|N/A|No|||September 2010|September 6, 2010|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488410||170286|
NCT00488982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF055511|Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC|A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer||University of California, San Francisco|Yes|Completed|April 2007|May 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Male|18 Years|N/A|No|||January 2015|January 9, 2015|June 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488982||170243|
NCT00488995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671029|Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients|A Phase 2 Study To Evaluate The Safety, Tolerability, Virologic And Immunologic Effect Of Single-Dose CP-675,206 In Patients Infected With Human Immunodeficiency Virus||Pfizer||Withdrawn|July 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|June 19, 2007||||||https://clinicaltrials.gov/show/NCT00488995||170242|
NCT00488696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03930|Branched Aortic Arch Study|Branched Stent-Graft Repair for Endo Repair of Aneurysms Involving the Proximal Aortic Arch||University of California, San Francisco|Yes|Recruiting|October 2006|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488696||170264|
NCT00489216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0605|Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids|Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Versus-Host Disease of the Skin and Liver|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|December 2006|October 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|June 20, 2007|No|Yes|insufficient accrual|No||https://clinicaltrials.gov/show/NCT00489216||170226|
NCT00489229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID: 305/PPSP/6112215|To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients|Studies on Diabetic and Pre Diabetic Vascular Disease and the Effect of Selected Therapeutic Modalities on Associated Vasculopathy||University of Science Malaysia|Yes|Completed|October 2002|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|66|||Both|30 Years|65 Years|No|||March 2007|July 15, 2009|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489229||170225|
NCT00489502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML002|Clinical Observation of Implementing the MedGem Into a Medical Specialty Practice|Phase I: Clinical Observation of Implementing the MedGem Into a Medical Specialty (i.e. Cardiology) Practice||Microlife|No|Recruiting|June 2007|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|30|||Both|18 Years|N/A||||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489502||170204|
NCT00486252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111138|Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®|Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN® (Latanoprost) as First-Line Monotherapy and as Second-Line Monotherapy After Beta-Blockers Therapy Failure||Pfizer|No|Completed|June 2007|January 2008|Actual|January 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|996|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients with unilateral or bilateral open angle glaucoma or ocular hypertension|November 2009|November 4, 2009|June 12, 2007||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00486252||170451|
NCT00485667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C105|Phase 1 Thorough QT Study in Young Healthy Volunteers|Evaluation of the Effects of Therapeutic and Supra-therapeutic Single Doses of SKY0402 Given as Subcutaneous Injection on the QT/QTc Interval in Young Healthy Volunteers. A Prospective, Randomized, Placebo- and Positive-controlled, Double Blind, Single-centre, Crossover Phase 1 Study.|TQT|Pacira Pharmaceuticals, Inc|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2010|September 7, 2010|June 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00485667||170496|
NCT00476801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 438|UVA1 Light for Treatment of Scleroderma and Similar Conditions|The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study||University of Michigan|No|Completed|July 2001|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|10 Years|80 Years|No|||July 2015|July 8, 2015|May 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00476801||171162|
NCT00476814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|will002-HMO-CTIL|NPD Measurements in PSC Patients|Cystic Fibrosis Transmembrane Conductance Regulator Function as Measured by Nasal Potential Difference Measurements in Patients With Primary Sclerosing Cholangitis||Hadassah Medical Organization|No|Not yet recruiting||||||N/A|Observational|Time Perspective: Prospective|||||||Both|10 Years|N/A||||October 2007|October 30, 2007|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00476814||171161|
NCT00480051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007CD002.GH|Birmingham Biventricular Pacing in Patients With Heart Failure Unselected for Dyssynchrony|Birmingham Biventricular Pacing in Patients With Heart Failure Unselected for Dyssynchrony (QRS < 120ms)- a Randomised Controlled Trial|BIPIDS|Heart of England NHS Trust|Yes|Recruiting|July 2007|June 2010|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2007|July 9, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00480051||170920|
NCT00480337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4317-AH-CTIL|In Vitro Maturation of Immature Oocytes|||Sheba Medical Center|No|Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|20 Years|45 Years|Accepts Healthy Volunteers|||December 2008|December 16, 2008|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00480337||170898|
NCT00477087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0017|Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer|Phase II Study of Granulocyte-Macrophage Colony Stimulating Factor Plus Mitoxantrone for the Treatment of Hormone Refractory Prostate Cancer||Stanford University|Yes|Completed|July 2006|July 2010|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|75 Years|No|||July 2012|July 3, 2012|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00477087||171141|
NCT00477334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810A2310|Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients|A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients||Novartis||Completed|June 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|May 22, 2007|Yes|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00477334||171122|
NCT00477659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2501055|Neural Correlates In Mild Alzheimer's Disease|A Single Center Study To Examine Neural Correlates Of Cognition In Subjects With Mild Alzheimer's Disease After Three Months Of Open Label Donepezil HCl (Aricept® ) Treatment||Eisai Inc.|No|Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|50 Years|N/A|No|||May 2009|May 6, 2009|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00477659||171098|
NCT00477126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 037|Bioequivalence Study of Generic GPO Ritonavir Versus Norvir®|Bioequivalence Study of Generic GPO Ritonavir Versus Norvir® in Thai Healthy Volunteers||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 3, 2012|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00477126||171138|
NCT00479947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UB-CHr-N|Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis|A Double-Blind,Randomized Placebo-Controlled Study Using Probiotic Lactobacillus GR-1 and RC-14 as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis||Faith Mediplex|No|Recruiting|May 2007|December 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|50 Years|No|||May 2007|May 29, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00479947||170928|
NCT00476658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050318|Macrophage Infiltration in Human Adipose Tissue|Characterisation of Macrophage Infiltration in Obesity and Its Complications||Assistance Publique - Hôpitaux de Paris|No|Completed|January 2007|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|adipose tissue, visceral adipose tissue, muscle, liver, bowel and stomach|Both|18 Years|60 Years|No|Non-Probability Sample|Inclusion Criteria:          -  Obese subjects group :               -  Obesity with BMI> 40 kg/m² or obesity with BMI between 35 and 40 kg/M² with                  comorbidities (OAS, diabetes, hypertension etc…)               -  Age: 18-60          -  Non obese subjects group               -  Abdominal surgery planned               -  Age: 18-60        Exclusion Criteria:          -  Inflammatory disease          -  cancer          -  stroke          -  Drugs (AINS)|May 2007|December 6, 2011|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476658||171171|
NCT00476957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0 - 12 April 2007|Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)|PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial|PROTECT|Medtronic Vascular|Yes|Completed|June 2007|July 2014|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|8709|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|May 21, 2007||No||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00476957||171151|
NCT00488436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMD/ATG-CSA/2002|Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome|SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome||PETHEMA Foundation|Yes|Completed|May 2002|December 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||November 2008|November 17, 2008|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488436||170284|
NCT00488449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMA110015|Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers|A Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK256073A, in a Randomized, Single-Blind, Dose Escalation Study in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|June 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|June 18, 2007||||||https://clinicaltrials.gov/show/NCT00488449||170283|
NCT00488124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA6280030|Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin|Evaluation of Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin: A Prospective, Longitudinal Non-randomised, Open, Phase II Study|ISS|University of Erlangen-Nürnberg Medical School|No|Completed|November 2005|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|4 Years|10 Years|No|||March 2011|March 29, 2011|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488124||170307|
NCT00488137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-INT-6|Efficacy and Safety Study of Prucalopride to Treat Chronic Constipation|A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation||Movetis|No|Completed|March 1998|July 1999|Actual|July 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|716|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00488137||170306|
NCT00489567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109551|Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden|A Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE, Its Complications and Diversity of Co-circulating Rotavirus Strains in Children < 5 Years of Age in Sweden||GlaxoSmithKline||Completed|October 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|642|Samples With DNA|Stool sample, Blood sample|Both|N/A|5 Years|No|Probability Sample|Children < 5 years of age in Sweden|January 2011|January 27, 2011|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489567||170199|
NCT00489827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151:2003/70403|Glutamate for Metabolic Intervention in Coronary Surgery|Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease|GLUTAMICS|University Hospital, Linkoeping|Yes|Active, not recruiting|October 2005|December 2014|Anticipated|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Both|N/A|85 Years|No|||January 2013|January 16, 2013|June 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00489827||170179|
NCT00489515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000550095|Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder|Visceral Lymphatic Mapping Project: A Pilot Study||Comprehensive Cancer Center of Wake Forest University|No|Completed|February 1999|August 2010|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|120 Years|No|Non-Probability Sample|patients with gastrointestinal cancer|October 2015|October 22, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489515||170203|
NCT00488956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00540|Foot and Ankle Edema Post-Cesarean Delivery|Foot and Ankle Edema Post-Cesarean Delivery||University of British Columbia|No|Completed|June 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|35|||Female|N/A|N/A|No|Probability Sample|Pregnant women booked for an elective Cesarean delivery will be recruited into the study.|March 2014|March 14, 2014|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488956||170245|
NCT00485992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-201|Chlorhexidine Swabs Effectiveness in Reducing Blood Stream Infections|Effectiveness of Utilizing Chlorhexidine Swabs for Accessing Lines and Results Impact on Catheter Related Blood Stream Infections in the Cardiac Intensive Care Unit||Children's Healthcare of Atlanta|Yes|Terminated|August 2006|December 2007|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|352|||Both|N/A|18 Years|No|Non-Probability Sample|This study will observe from all children admitted to Children's CICU between 8.1.06 to        12.31.06; including both medical and surgical service patients.|January 2008|November 18, 2011|June 12, 2007||No|sufficient data has been collected for significant conclusion|No||https://clinicaltrials.gov/show/NCT00485992||170471|
NCT00486551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03MH067845|Anger Control Training for Youth With Tourette Syndrome|Anger Control Training for Youth With Tourette Syndrome||Yale University|Yes|Completed|August 2001|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|26|||Both|11 Years|16 Years|No|||June 2007|June 13, 2007|June 12, 2007||||No||https://clinicaltrials.gov/show/NCT00486551||170428|
NCT00486824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97873|Indomethacin Versus Nifedipine for Preterm Labor Tocolysis|Indocin Versus Nifedipine for Preterm Labor Tocolysis - A Randomized Double-Blinded Clinical Trial||Stanford University|No|Recruiting|April 2007|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||November 2014|November 18, 2014|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00486824||170407|
NCT00480935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0017-C|A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma|A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma||University Health Network, Toronto|Yes|Terminated|October 2007|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 29, 2007||No|poor recruitment|No||https://clinicaltrials.gov/show/NCT00480935||170854|
NCT00476827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014926|A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain|A Phase II Safety and Tolerability Study of Avastin When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain||Duke University|No|Terminated|May 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|16|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|May 18, 2007|Yes|Yes|Slow accrual|No|December 10, 2012|https://clinicaltrials.gov/show/NCT00476827||171160|
NCT00476853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 033|Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy|A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Antituberculous Therapy||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|October 2005|December 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|60 Years|No|||June 2010|June 4, 2010|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476853||171159|
NCT00477100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1072|Inflammatory Breast Cancer (IBC) Registry|Inflammatory Breast Cancer (IBC) Registry||M.D. Anderson Cancer Center|No|Recruiting|April 2007|||April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|The collection of serum and plasma from patients with inflammatory breast cancer.|Both|18 Years|N/A|No|Probability Sample|Patients with recently diagnosed inflammatory breast cancer (IBC).|March 2016|March 17, 2016|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00477100||171140|
NCT00477347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/37|Closed-Loop Anesthesia, Using Bispectral Index as the Control Variable, During Liver Transplantation|Comparison of Manual Propofol and Remifentanil Administration and Dual Closed-Loop, Using Bispectral Index as the Control Variable, During Liver Transplantation|Drone-TH|Hopital Foch|No|Withdrawn|May 2007|September 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|May 21, 2007||No|lack of recrutment|No||https://clinicaltrials.gov/show/NCT00477347||171121|
NCT00477113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS402|TYSABRI Global Observational Program in Safety|TYGRIS: TYSABRI® Global Observational Program in Safety|TYGRIS|Biogen|No|Completed|January 2007|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2207|Samples With DNA|whole blood, serum|Both|N/A|N/A|No|Non-Probability Sample|MS patients treated with TYSABRI in North America|June 2015|June 18, 2015|May 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477113||171139|
NCT00477139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0009|A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer|A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer||Stanford University|Yes|Completed|January 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|4|Samples Without DNA|Blood|Female|18 Years|N/A|No|Non-Probability Sample|individuals with HER-2 positive breast cancer.|April 2011|April 11, 2011|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00477139||171137|
NCT00477399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK0701|Long Term Follow up After 1 Year Initial Lifestyle Intervention|Effect of Four Years Intensive- Versus Regular Follow up, After a One Year Weight Loss Period, in Patients With Morbid Obesity.||Evjeklinikken|Yes|Recruiting|May 2007|May 2012|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|67 Years|No|||May 2007|May 22, 2007|May 22, 2007||||No||https://clinicaltrials.gov/show/NCT00477399||171117|
NCT00479245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-17|WHODAS-II for Patients With Nonspecific Low Back Pain|WHODAS-II for Patients With Nonspecific Low Back Pain||Kovacs Foundation|Yes|Terminated|April 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|80 Years|No|||June 2011|June 26, 2011|May 25, 2007||No|Recruitment rate, lower than expected. Organizational changes made it impossible for    recruiting centers to continue|No||https://clinicaltrials.gov/show/NCT00479245||170980|
NCT00479258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171083|Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents|Safety And Efficacy Of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents Ages 6-17 Years With Type 1 Diabetes Mellitus: A 12 Month, Outpatient, Randomized, Open Label, Parallel Group Comparative Trial.||Pfizer|No|Terminated|October 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|554|||Both|6 Years|17 Years|No|||October 2008|October 31, 2008|May 24, 2007|Yes|Yes|See termination reason in detailed description.|No|October 29, 2008|https://clinicaltrials.gov/show/NCT00479258||170979|Pfizer announced Oct07 it would stop marketing Exubera; recruitment placed on hold. Nektar, from which Pfizer licensed Exubera, announced April 9, 2008 it had stopped its search for a new marketing partner. Study terminated; no further recruitment.
NCT00487253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50100119|Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia|Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia||Centro Internacional de Entrenamiento e Investigaciones Médicas|Yes|Active, not recruiting|July 2007|December 2010|Anticipated|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|2 Years|12 Years|No|||February 2010|February 13, 2010|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487253||170374|
NCT00487474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL6049-0502|A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCULPTRA Measured by Three Dimensional Digital Surface Imaging|A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of Sculptra (Poly-L-Lactic Acid) Measured by Three Dimensional Digital Surface Imaging||Sanofi|No|Completed|June 2007|February 2008|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||March 2009|March 12, 2009|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487474||170357|
NCT00488969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133N060027|Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury|Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury||Icahn School of Medicine at Mount Sinai|Yes|Completed|July 2007|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||March 2016|March 18, 2016|June 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488969||170244|
NCT00489840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSC-AA|Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate|Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate|CSC-AA|Manhattan Eye, Ear & Throat Hospital|No|Completed|May 2007|||July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489840||170178|
NCT00489853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5892C00014|Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD|A Multi-centre, Randomised, Double-blind, Cross-over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort ®(Budesonide/Formoterol) 320/9μg One Inhalation Twice Daily Compared With Placebo and Oxis® 9μg One Inhalation Twice Daily in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD).|CODEX|AstraZeneca||Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|137|||Both|40 Years|N/A|No|||July 2012|July 27, 2012|June 19, 2007||No||No|August 6, 2009|https://clinicaltrials.gov/show/NCT00489853||170177|
NCT00489255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-47-52844-003|Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment|A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent "Off" Episodes, With Phased Withdrawal of Subjects From Tigan® to Placebo||Ipsen|No|Completed|May 2007|March 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|June 20, 2007|Yes|Yes||No|December 24, 2012|https://clinicaltrials.gov/show/NCT00489255||170223|
NCT00489801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 11 2006-4305|Trial Comparing Home-based Cardiac Rehabilitation With Comprehensive Centre-based Cardiac Rehabilitation in Patients Older Than 65 Years With Coronary Heart Disease. The HOMEBASE Trial|RCT Comparing Home-based Cardiac Rehabilitation With Comprehensive Centre-based Cardiac Rehabilitation and Usual Care in Patients Older Than 65 Years With Coronary Heart Disease. The HOMEBASE Trial.|HOME-BASE|Bispebjerg Hospital|No|Active, not recruiting|January 2007|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|115|||Both|65 Years|N/A|No|||November 2009|November 9, 2009|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489801||170181|
NCT00489528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9037|Growth Hormone in the Treatment of HIV-Associated Wasting|A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting||EMD Serono||Completed|July 1997|March 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A||||October 2013|October 21, 2013|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489528||170202|
NCT00489814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0956|Study of Quality of Life for Prostate Proton Therapy|Prospective Evaluation of Quality of Life After Proton Therapy for Prostate Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2006|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1084|||Male|N/A|N/A|No|Probability Sample|Study participants who are planned to undergo local proton radiotherapy for biopsy-proven,        untreated, prostate adenocarcinoma.|September 2015|September 30, 2015|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00489814||170180|
NCT00486564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0610|Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma|A Phase I Trial of Nifurtimox for Relapsed or Refractory Neuroblastoma||University of Vermont|Yes|Completed|November 2006|June 2009|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|21 Years|No|||October 2009|October 22, 2009|June 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00486564||170427|
NCT00487136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-887|Interaction Between ABT-335, Rosuvastatin and Warfarin|Multiple-Dose Pharmacokinetic and Pharmacodynamic Interaction Between ABT-335, Rosuvastatin and Warfarin||AstraZeneca|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|45|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00487136||170383|
NCT00480623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT1-06-01|A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence|A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence Following Radical Prostatectomy||Agennix|No|Terminated|May 2007|April 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Male|18 Years|N/A|No|||March 2012|March 21, 2012|May 29, 2007|Yes|Yes|Sponsor decided to discontinue study drug development|No||https://clinicaltrials.gov/show/NCT00480623||170877|
NCT00480636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301082|Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients|Fragmin Safety And Efficacy In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism And Extended Thromboprophylaxis In Cancer Patients In Slovakia (An Open, Prospective, Non-Comparative Study)||Pfizer|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|70 Years|No|Probability Sample|The patients are identified in primary care setting.|July 2010|July 14, 2010|May 29, 2007|No|Yes||No|May 25, 2010|https://clinicaltrials.gov/show/NCT00480636||170876|
NCT00480649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100614|Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)|SUccessful Control and Clinical Effectiveness of SERETIDE Study in aSthma, a Randomised Controlled Study to Investigate the Clinical Effectiveness and Health Outcome of SERETIDE in Patients With Moderate and Severe Persistent Asthma in Korea||GlaxoSmithKline|No|Completed|January 2004|September 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|424|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480649||170875|
NCT00480662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-206|A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)|A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone||Merck Sharp & Dohme Corp.||Completed|October 2001|October 2002|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|60|||Both|18 Years|90 Years|No|||February 2015|February 12, 2015|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00480662||170874|
NCT00480961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRRB/00/2006|Congestive Heart Failure Surgical Treatmment With Autologous Stem Cell Therapy|||The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|Yes|Recruiting|May 2007|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||May 2007|May 31, 2007|May 31, 2007||||No||https://clinicaltrials.gov/show/NCT00480961||170852|
NCT00476866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIT-17|Intermittent Positive-Pressure Breathing Effects in Patients With High Spinal Cord Injury|Intermittent Positive-Pressure Breathing Effects in Patients With High Spinal Cord Injury||University of Versailles|No|Terminated|December 2002|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|16 Years|N/A|No|||May 2007|May 21, 2007|May 21, 2007|||The number of patients desired has been reached|No||https://clinicaltrials.gov/show/NCT00476866||171158|
NCT00476879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090600-deleted|Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content|Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning||University of Aarhus|No|Completed|August 2006|June 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|10|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2008|August 11, 2008|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476879||171157|
NCT00477425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4223g|A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab|Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab||Genentech, Inc.||Withdrawn|June 2007|||||Phase 4|Observational|Time Perspective: Prospective||||150|||Both|N/A|N/A|No|||December 2010|December 1, 2010|May 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477425||171115|
NCT00477451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-002-201|Staccato™ Alprazolam for Inhalation in Panic Attack|Investigation of a Single Dose of Staccato™ Alprazolam for Inhalation on Doxapram-Induced Panic Attack in Patients With Panic Disorder||Alexza Pharmaceuticals, Inc.|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||June 2008|June 2, 2008|May 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00477451||171114|
NCT00477464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109749|Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer|Clinical Evaluation of Lapatinib Administered With Capecitabine in Japanese Patients With ErbB2 Overexpressing Advanced or Metastatic Breast Cancer||GlaxoSmithKline|Yes|Completed|June 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|20 Years|N/A|No|||September 2011|September 15, 2011|May 22, 2007||No||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00477464||171113|
NCT00480441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P60DA005186-19|Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal|A Phase II Double-Blind Placebo-Controlled Trial of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal||University of Pennsylvania|Yes|Completed|August 2006|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|55 Years|No|||January 2012|January 17, 2012|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00480441||170891|
NCT00487266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT003479-01A1|Soft Tissue Biomechanical Behavior During Acupuncture in Low Back Pain|Soft Tissue Biomechanical Behavior During Acupuncture in Low Back Pain||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|September 2006|August 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|180|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 4, 2013|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487266||170373|
NCT00487279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Determine2007v12|DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation|DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation|DETERMINE|St. Jude Medical|Yes|Terminated|June 2007|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||March 2012|March 25, 2012|June 13, 2007|Yes|Yes|Study terminated early due to inability to enroll.|No|January 4, 2012|https://clinicaltrials.gov/show/NCT00487279||170372|
NCT00488163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00131-03-1284|Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia|Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia||Research Foundation for Mental Hygiene, Inc.|No|Completed|January 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||June 2007|June 18, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00488163||170305|
NCT00488176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/94/07KE|Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis|Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis||Medical Universtity of Lodz|Yes|Recruiting|April 2007|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|116|||Both|6 Years|18 Years|No|||February 2013|February 6, 2013|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488176||170304|
NCT00487838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070169|Effects of Sun Filters on Age-related Macular Degeneration in People With Lens Implants|Noninvasive Optical Imaging of the Effects of External Spectral Filters on Macular Autofluorescence in Pseudophakic Eyes||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2007|May 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|21 Years|75 Years|No|||May 2012|May 10, 2012|June 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00487838||170329|
NCT00488709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMR 2003|Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia|FLAT|PETHEMA Foundation|Yes|Completed|May 2003|April 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||November 2008|November 17, 2008|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00488709||170263|
NCT00488722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jzhang|A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer|A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer||Tianjin Medical University|Yes|Recruiting|April 2007|March 2009||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||||||Female|25 Years|50 Years|No|||April 2007|June 25, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00488722||170262|
NCT00485745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-023|Repeat Sternotomy for Pediatrics|Repeat Sternotomy for Pediatric Cardiac Surgery: Indications, Risks and Results||Children's Healthcare of Atlanta|No|Completed|January 2002|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1281|||Both|N/A|21 Years|No|Probability Sample|The study population for this retrospective chart review will be all patients, under 21        years of age who have undergone a repeat sternotomy at Children's Healthcare of Atlanta at        Egleston between January 1, 2002 and December 31, 2006. A repeat sternotomy is defined as        having been performed more than a month after the most recent previous sternotomy.|November 2014|November 25, 2014|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00485745||170490|
NCT00485680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7598|Olanzapine Versus Comparator in the Treatment of Bipolar Disorder|Olanzapine Versus Lithium Carbonate in the Treatment of Bipolar Disorder, Manic or Mixed Episodes||Eli Lilly and Company||Completed|December 2003|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||June 2007|June 11, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485680||170495|
NCT00485693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C208|Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty|A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 Via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty.|TKA|Pacira Pharmaceuticals, Inc|No|Completed|June 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|75 Years|No|||July 2013|July 3, 2013|June 11, 2007|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00485693||170494|
NCT00489541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2043|TAXUS PERSEUS Small Vessel|A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels|PERSEUS SV|Boston Scientific Corporation|Yes|Completed|July 2007|October 2013|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|June 20, 2007|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00489541||170201|There were no commercially available dedicated small vessel paclitaxel-eluting stents at the time of study enrollment, thus, the PERSEUS Small Vessel comparator group does not represent the most recently available paclitaxel-eluting stents.
NCT00489554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109661|Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix||GlaxoSmithKline||Completed|July 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|230|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2012|June 14, 2012|June 20, 2007|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00489554||170200|
NCT00486278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1731-1804|Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds|A Multi-centre, Randomised, Double-blinded, Controlled, Dose-escalation Trial on Safety and Efficacy of Activated Recombinant FVII Analogue (NN1731) in the Treatment of Joint Bleeds in Congenital Haemophilia Patients With Inhibitors||Novo Nordisk A/S|Yes|Completed|June 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|51|||Male|12 Years|N/A|No|||April 2015|April 15, 2015|June 13, 2007|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00486278||170449|
NCT00486577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Promo 2005|Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus|Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus|ACOUSCO|University Hospital, Bordeaux|Yes|Completed|June 2007|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|70 Years|No|||January 2011|January 27, 2011|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00486577||170426|
NCT00487123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BSG02|Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months|A Multi-Center, Randomized, Proof-of-Concept, Parallel Control Study With Remind Cap® in Patients With Essential Hypertension and Newly Treated With Valsartan+/-Hydrochlorothiazide (HCTZ)||Novartis||Completed||September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||June 2008|June 13, 2008|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00487123||170384|
NCT00480948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InFat™001|Effects of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants|Effects of InFat™ Product (High Sn-2 Palmitic Acid) on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants: a Triple-blind, Randomized, Placebo-controlled Trial||Enzymotec||Terminated|September 2008|August 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|N/A|8 Days|Accepts Healthy Volunteers|||August 2008|June 6, 2011|May 30, 2007||No|Study design changes were needed due to change of protocol to a multisite trial and updated    set up|No||https://clinicaltrials.gov/show/NCT00480948||170853|
NCT00476632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0112|Epidemiology Controls Using Healthy Participants|Epidemiology Controls Using Healthy Participants||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2004|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|2 ½ tablespoons of blood drawn.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals 18 years or older with no history of cancer.|October 2015|October 13, 2015|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476632||171173|
NCT00476593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47026200|Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications|Retinal Optical Coherence Tomography and Multifocal Electroretinogram; Establishing Normal Ranges Related to Age and Reproductive Factors; With the Use of Anti-inflammatory Medications;In Uncomplicated Anterior Uveitis; Anatomy and Function.||Norwegian University of Science and Technology|No|Completed|September 2005|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|218|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 9, 2011|May 21, 2007||No||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00476593||171176|
NCT00476606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 015|A Prospective Cohort of Children With HIV Infection|Treatment Outcome of Children With HIV Infection||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Recruiting|March 2003|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|PBMC|Both|N/A|20 Years|No|Non-Probability Sample|HIV-infected infants, children and adolescents (range age 1 day - 20 years old) who have        participated in HIV-NAT trials|February 2016|February 19, 2016|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476606||171175|
NCT00476892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/377|Multi-centre Randomised Controlled Trial of Pelvic Floor Muscle Training for Prolapse|A Multi-centre Randomised Controlled Trial of a Pelvic Floor Muscle Training Intervention for Women With Pelvic Organ Prolapse|POPPY|Glasgow Caledonian University|Yes|Completed|June 2007|March 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|448|||Female|N/A|N/A|No|||February 2010|March 22, 2011|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476892||171156|
NCT00477477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01-0020|Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp)|Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors||Children's Hospital Boston|No|Terminated|May 2007|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|8 Years|17 Years|No|||October 2014|October 24, 2014|May 22, 2007||No|Inadequate enrollment and lack of funds.|No||https://clinicaltrials.gov/show/NCT00477477||171112|
NCT00486993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsuRiesgo|Cardiovascular Risk Factors in an Ambulatory Urban Patient Population|Estimation of Prevalence and Assessment of the Effects of Modification of Cardiovascular Risk Factors in an Ambulatory Urban Patient Population|AsuRiesgo|Heidelberg University|Yes|Active, not recruiting|May 2006|May 2016|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|7000|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00486993||170394|
NCT00487240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10937|Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes|Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients With Type 1 Diabetes|IOOZ|Eli Lilly and Company|No|Completed|June 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|387|||Both|18 Years|N/A|No|||October 2010|October 20, 2010|June 14, 2007|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00487240||170375|
NCT00487513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-276|Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials|Procurement of Follicular B Cell Lymphoma Cells From Blood, Tissue or Malignant Effusion for the Purpose of Possible Use in Future Clinical Trials: A Minimal Risk Protocol||Dana-Farber Cancer Institute|No|Active, not recruiting|June 2007|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Whole Blood Lymph node biopsy Drainage of an effusion Bone marrow biopsy|Both|35 Years|N/A|No|Non-Probability Sample|Participants are selected because they have Non-Hodgkin's lymphoma.|December 2015|December 14, 2015|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487513||170354|
NCT00488475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-102335|Observational Trial With Enbrel|A 1 Year Observational Study of the Use of Etanercept in Routine German Clinical Practice to Treat Rheumatoid Arthritis Patients: a Health Economic, Safety and Effectiveness Evaluation||Pfizer|No|Completed|September 2006|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4945|||Both|18 Years|N/A|No|Non-Probability Sample|Only patients for whom the decision has already been made to initiate treatment with        Enbrel® can be enrolled in this observational trial. These patients must have a proven        diagnosis of Rheumatoid Arthritis|July 2014|July 25, 2014|June 18, 2007|No|Yes||No|April 16, 2014|https://clinicaltrials.gov/show/NCT00488475||170281|Prioritization of endpoints as primary or secondary was not specified in protocol and was based on study team's inputs.
NCT00488462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD053129-01A1|Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe|Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe|NASG|University of California, San Francisco|Yes|Completed|October 2007|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|887|||Female|15 Years|N/A|No|||January 2015|January 16, 2015|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488462||170282|
NCT00489008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0574|SRS Study in Patients With Non-Small Cell Lung Cancer|Phase II Stereotactic Body Radiotherapy for Stage I (T1-T2, N0, M0), Selective Stage II (Chest Wall T3, N0M0) or Isolated Peripheral Lung Recurrent Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2005|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|138|||Both|N/A|N/A|No|||March 2016|March 7, 2016|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489008||170241|
NCT00485758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-069|Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)|A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes||Merck Sharp & Dohme Corp.||Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|796|||Both|18 Years|80 Years|No|||October 2015|October 9, 2015|June 12, 2007|Yes|Yes||No|August 4, 2009|https://clinicaltrials.gov/show/NCT00485758||170489|
NCT00485771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7980|Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression|Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression||Eli Lilly and Company||Completed|November 2003|January 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|60 Years|No|||June 2007|June 11, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485771||170488|
NCT00485706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML4181|Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients|Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients||Universitaire Ziekenhuizen Leuven|No|Completed|June 2007|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|75 Years|No|||June 2007|January 15, 2010|June 12, 2007||||No||https://clinicaltrials.gov/show/NCT00485706||170493|
NCT00485719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11440|Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors||Sanofi||Completed|June 2007|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|June 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00485719||170492|
NCT00485732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107291|A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years|A Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly in Healthy Female Subjects Aged 15 - 25 Years||GlaxoSmithKline||Completed|June 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|225|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||February 2011|April 7, 2011|June 12, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00485732||170491|
NCT00486031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZUC3005|Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study|A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis||Valeant Pharmaceuticals International, Inc.|No|Completed|October 2006|December 2008|Actual|April 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00486031||170468|
NCT00486291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-202|Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics|A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults||VIVUS, Inc.|No|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|65 Years|No|||September 2012|September 5, 2012|June 12, 2007|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00486291||170448|
NCT00486304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0523|Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy|Phase I Randomized, Double-blind, Placebo-controlled Trial of the Effect of Temporary Dietary Antioxidant Depletion on Tumor Growth and Cachexia in Head and Neck Cancer Patients Receiving Chemoradiation Therapy||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|February 2006|May 2008|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|4|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00486304||170447|
NCT00486629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT 2006-021|Impact of Diet and Exercise Activity on Pregnancy Outcomes|Impact of a Community-based Obesity and Diabetes Prevention Program on Pregnant Outcomes in Pregnant Women|IDEA|University of Manitoba|Yes|Recruiting|July 2004|July 2020|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00486629||170422|
NCT00486837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100452|Deposition of Inhaled Prolastin in Cystic Fibrosis Patients|Multicenter, Randomized, Parallel Group Study to Investigate the Optimal Deposition Site for Inhaled Prolastin® in Patients With Cystic Fibrosis (CF)|CF2|Grifols Therapeutics Inc.|No|Completed|December 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|8 Years|N/A|No|||August 2014|August 5, 2014|June 13, 2007|No|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00486837||170406|
NCT00486850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMV versus NIPPV Trial|Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress|Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress||University of Southern California|Yes|Completed|October 2006|January 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|N/A|120 Minutes|No|||February 2009|July 9, 2009|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00486850||170405|
NCT00480688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB001|A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers|A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers||University of Oxford|Yes|Completed|November 2001|May 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00480688||170872|
NCT00476645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-01890|Fulvestrant in Hormone Refractory Prostate Cancer|Fulvestrant in Hormone-refractory Prostate Cancer||Stanford University|Yes|Completed|September 2006|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||August 2014|August 4, 2014|May 18, 2007|Yes|Yes||No|June 30, 2014|https://clinicaltrials.gov/show/NCT00476645||171172|
NCT00476619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P000510|Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial|Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial|ERIN|Brigham and Women's Hospital|Yes|Terminated|September 2004|June 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|17|||Both|18 Years|N/A|No|||April 2009|April 2, 2009|May 21, 2007|Yes|Yes|The exclusion criteria were stringent and enrollment was slow.|No||https://clinicaltrials.gov/show/NCT00476619||171174|
NCT00477152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1838-003|Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children|INcreased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration (INFUSE-Pediatric Rehydration Study): Phase IV Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase (HYLENEX) for Infants and Children|INFUSE-PR|Baxter Healthcare Corporation|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|2 Months|10 Years|No|||November 2011|November 22, 2011|May 18, 2007|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00477152||171136|
NCT00508560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUD-Q|Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders|Contingency Management for Smoking Cessation Among Veterans With Schizophrenia or Other Psychoses||VA Office of Research and Development|No|Terminated|July 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|July 27, 2007||No|Stopped due to low recruitment.|No||https://clinicaltrials.gov/show/NCT00508560||168765|
NCT00487006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH|Study of High Blood Sugars and Insulin in Hospitalized, Critically Ill Children|Insulin Resistance Versus Absolute Insulin Deficiency: Evaluating the Mechanism of Hyperglycemia in Pediatric Critical Illness|CIH|Children's Healthcare of Atlanta|No|Completed|October 2006|February 2015|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|209|||Both|2 Years|12 Years|No|||June 2015|June 12, 2015|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00487006||170393|
NCT00487851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/2:3|Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer|Endoscopic Strategy Versus Surgical by Pass in Nonresectable Periampullary Cancer||Karolinska Institutet|Yes|Withdrawn|March 2007|December 2012|Actual|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||April 2013|April 11, 2013|June 18, 2007||No|Withdrawn|No||https://clinicaltrials.gov/show/NCT00487851||170328|
NCT00489021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/2007-1-HY-CTIL|Feasibility and Outcomes of Older Patients Hospitalization|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|July 2007|August 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|65 Years|N/A|No|||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489021||170240|
NCT00488735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KarolinskaI|Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation vs. Traditional Primary Care|Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation Compared With Traditional Primary Care Concerning Sick-listing and Health-care Visits. A Randomized Controlled Trial, 18-month Follow-up||Karolinska Institutet|No|Completed|August 2000|July 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|59 Years|No|||June 2007|May 6, 2010|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00488735||170261|
NCT00486044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0116|Evaluating Simvastatin's Potential Role in Therapy|Effect of Statins on Pathobiology of Alzheimer's Disease|ESPRIT|University of Wisconsin, Madison|Yes|Completed|February 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|103|||Both|35 Years|69 Years|Accepts Healthy Volunteers|||March 2014|October 1, 2015|June 12, 2007||No||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00486044||170467|
NCT00486057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-199|Daclizumab Experience in Pediatric Heart Transplant|A Retrospective Review of Daclizumab Experience in Pediatric Heart Transplant||Children's Healthcare of Atlanta|No|Terminated|August 2004|November 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|30|||Both|N/A|21 Years|No|Non-Probability Sample|Status post heart transplant Age 0-21 years Received Daclizumab as induction therapy|November 2007|November 18, 2011|June 12, 2007||No|sufficient data collected for conclusion of retrospective study|No||https://clinicaltrials.gov/show/NCT00486057||170466|
NCT00486317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC021A2110|Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis|SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.||Nordic Bioscience A/S||Completed|October 2005|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|52 Years|75 Years||||June 2007|June 13, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486317||170446|
NCT00486642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00200|Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase 2 Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 2007|||August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Male|18 Years|N/A|No|||July 2015|August 3, 2015|June 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486642||170421|
NCT00486863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0039|S. Japonicum and Pregnancy Outcomes|S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|370|||Female|18 Years|99 Years|No|||July 2014|December 17, 2015|June 14, 2007|Yes|Yes||No|October 31, 2013|https://clinicaltrials.gov/show/NCT00486863||170404|
NCT00480974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5321006.EMC|Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea|Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea.Observational Retrospective Study.||HaEmek Medical Center, Israel|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|5 Years|40 Years|No|Non-Probability Sample|Patients with Sickle Cell Anemia treated at the Pediatric Hematology Unit and receiving        Hydroxyurea|September 2009|September 3, 2009|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00480974||170851|
NCT00512304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/097/HP|Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)|Feasibility Study of 2 Parallel Phases II Pre or Postgastrectomy in Patients With Gastric Cancer (FOLFIRI-radiotherapy Plus 5 Fluorouracil-surgery or Surgery-FOLFIRI-radiotherapy Plus 5 Fluorouracil)|TRACE|University Hospital, Rouen|No|Completed|August 2007|||December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512304||168479|
NCT00512317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0601|Open-label Extension to Protocol 1042-0600|An Open-label Extension Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as add-on Therapy in Adult Patients With Epilepsy Consisting of Uncontrolled Partial-onset Seizures.||Marinus Pharmaceuticals|No|Completed|June 2007|September 2013|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|69 Years|No|||October 2013|October 14, 2013|August 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00512317||168478|
NCT00512616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070201|A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder|An Investigation of the Efficacy of the Glutamate Transporter GLT 1 in the Treatment of Bipolar Depression||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2007|September 2009|Anticipated|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||September 2009|November 16, 2011|August 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00512616||168455|
NCT00476905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0856|Spectral Diagnosis of Cutaneous Malignancy|Spectral Diagnosis of Cutaneous Malignancy||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2007|||April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Probability Sample|Adult patients, at routine skin examination, found to have a lesion(s) in one of the five        categories: basal cell carcinoma, squamous cell carcinoma, pre-cancer lesions, pigmented        lesions, and benign lesions, which may also warrant biopsy.|October 2015|October 13, 2015|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476905||171155|
NCT00476918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21091968|Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema|Dosage Dependency of Intravitreal Triamcinolone Acetonide for Treatment of Diabetic Macular Edema||Heidelberg University|Yes|Recruiting|July 2006|December 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2007|May 21, 2007|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00476918||171154|
NCT00477165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10539-18502|Citalopram in Irritable Bowel Syndrome|Effect of Citalopram on Clinical Symptoms and Visceral Sensitivity in Patients With Irritable Bowel Syndrome||University of California, San Francisco|No|Completed|April 2001|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00477165||171135|
NCT00477178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133-04REK|The Effect of Codeine on Driving Abilities|The Effect of Codeine on Driving Abilities||Norwegian University of Science and Technology|No|Completed|August 2004|December 2005|Actual|May 2005|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|60|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|chronic pain patients driving more than 50,000 km/yr|May 2007|August 9, 2011|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00477178||171134|
NCT00508573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0973|Women Who Are At Risk Or May Have Lynch Syndrome|Registry for Women Who Are At Risk Or May Have Lynch Syndrome||M.D. Anderson Cancer Center|No|Recruiting|May 2007|||May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Leftover tissue samples will be collected from surgery performed. These samples will be      stored and used to perform molecular studies to characterize Lynch syndrome tumors.|Female|18 Years|N/A|No|Non-Probability Sample|Women, 18 years or older, that have or are at risk for Lynch Syndrome.|November 2015|November 10, 2015|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508573||168764|
NCT00487292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDCSRE-003|Naps and Pulses of Bright Light in Shift Workers|The Effects of a Combination of Napping and Bright Light Pulses on Shift Workers Sleepiness at the Wheel A Pilot Study||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2003|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|9|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||June 2007|June 18, 2007|June 15, 2007||||No||https://clinicaltrials.gov/show/NCT00487292||170371|
NCT00487526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS07006|Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)|Clinical Evaluation of the Effect of Duodenal Jejunal Bypass on Type Two Diabetes in Non Obese Adults|DJBD|Ferzli, George S., M.D. F.A.C.S.|Yes|Recruiting|June 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|65 Years|No|||July 2007|July 10, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00487526||170353|
NCT00487890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1021-B|Performance Evaluation and Research for Older Adults Requiring Major Surgery|Performance Evaluation and Research for Older Adults Requiring Major Surgery|PERFORM|University of Washington|No|Active, not recruiting|April 2004|September 2009|Anticipated|||N/A|Observational|N/A||1|Anticipated|400|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults, aged 65 and older, who are undergoing an abdominal or cardiothoracic surgical        procedure at the University of Washington Medical Center in Seattle, WA.|December 2008|December 31, 2008|June 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00487890||170325|
NCT00487903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-015|Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems|A Phase 2 Trial of PB127 Myocardial Perfusion Echocardiography to Evaluate and Optimize Additional Ultrasound Imaging Systems||Point Biomedical|No|Terminated|September 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 1, 2008|June 15, 2007|Yes|Yes|Discontinued PB127 development program for business reasons|No||https://clinicaltrials.gov/show/NCT00487903||170324|
NCT00488189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-102370|Study Evaluation Tazocin Intervention|Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|134|||Both|18 Years|N/A|No|||June 2010|April 14, 2011|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488189||170303|
NCT00489034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 009|Engaging Care for HIV-Infected Adolescent Females.|Drug Use and HIV-Infected Female Adolescents' Care Use||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Active, not recruiting|July 2003|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||200|||Female|18 Years|23 Years|No|||March 2005|June 19, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489034||170239|
NCT00489294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN-05-001|Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency|An Open-Label Study of the Pharmacokinetics and Pharmacodynamics of Syntropin (a Human Growth Hormone) in Growth Hormone-Suppressed Healthy Volunteers||Phage Pharmaceuticals, Inc.|Yes|Completed|August 2004|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|June 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00489294||170220|
NCT00489268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-200|Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years|Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years|AIM|Covidien, GI Solutions|No|Completed|November 2003|October 2009|Actual|February 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|102|||Both|18 Years|75 Years|No|||June 2011|June 6, 2011|June 19, 2007|No|Yes||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00489268||170222|Study had no concurrent control arm, biopsy forceps were not standardized for all cases, the original patient group comprised 70 patients, whereas 69 and 61 patients were available at 1 and 2.5 years, respectively, 60 eligible patients at 5 years.
NCT00489281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0676 CDR0000540593|Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders|A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies||Sidney Kimmel Comprehensive Cancer Center||Recruiting|May 2007|||May 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489281||170221|
NCT00489892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-437-02|Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI|Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI||Kessler Foundation|No|Recruiting|August 2003|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|No|||July 2007|July 23, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489892||170174|
NCT00489580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-519-05|A Pilot Study Investigating the Feasibility of the Saebo Arm Training Program on an Inpatient Population|A Pilot Study Investigating the Feasibility of Using a Functional Tone Management (F.T.M.) Arm Training Program With the SaeboFlex Dynamic Hand Orthosis on an Inpatient Population||Kessler Foundation|No|Completed|August 2005|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||July 2007|July 23, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489580||170198|
NCT00489593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0620|Olanzapine in Patients With Advanced Cancer and Weight Loss|Phase I Dose-Finding Pilot Study of the Safety and Tolerability of Olanzapine in Patients With Advanced Cancer and Weight Loss||M.D. Anderson Cancer Center|No|Completed|October 2006|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|N/A|N/A|No|||January 2015|January 7, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489593||170197|
NCT00489606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK3530_DI_TS|Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530|Clinical Trial to Investigate the Influence of Drug Interaction After Oral Administration of Tamsulosin and SK3530 in Healthy Male Volunteers||SK Chemicals Co.,Ltd.|Yes|Completed|April 2007|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|16|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489606||170196|
NCT00489866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA IRB#01163|Aripiprazole Augmentation of Antidepressants in PTSD|Aripiprazole Augmentation of Antidepressants in PTSD||Durham VA Medical Center||Completed|March 2007|December 2014|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|June 20, 2007||No||No|September 16, 2011|https://clinicaltrials.gov/show/NCT00489866||170176|One of the primary limitations of this pilot clinical trial is small sample size. Results of this study will clearly need to be replicated in a larger cohort.
NCT00489879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seoul R&BD Program|Management of Patients With Type 2 Diabetes and Hypertension Using Mobile Health Care System|Efficacy of Mobile Health Care System in Patients With Type 2 Diabets and Hypertension||Korea University|Yes|Completed|July 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|140|||Both|20 Years|75 Years|No|||May 2008|May 19, 2008|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489879||170175|
NCT00486590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPPF 001-2006|Evaluation of Prolact-Plus Human Milk Fortifier|The Evaluation of Prolact-Plus, Human Milk Fortifier (Human, Pasteurized) for Pre-Term Infants Receiving Human Milk||Prolacta Bioscience|No|Completed|August 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|105|||Both|N/A|30 Days|No|||February 2008|February 27, 2008|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00486590||170425|
NCT00486603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0603 CDR0000549734|Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Hydroxychloroquine in Conjunction With Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|October 2007|||January 2013|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|June 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486603||170424|
NCT00486655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS0701|NOTES-Assisted Laparoscopic Cholecystectomy Surgery|Assisted Laparoscopic Cholecystectomy Surgery||USGI Medical|No|Terminated|May 2007|June 2007|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|85 Years|No|||August 2012|August 7, 2012|June 12, 2007||No|Change of Focus for the company|No||https://clinicaltrials.gov/show/NCT00486655||170420|
NCT00486668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-41|A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer|A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response||NSABP Foundation Inc|Yes|Active, not recruiting|July 2007|March 2016|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|529|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|June 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486668||170419|
NCT00486876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPI-TOFP-203|A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome|A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients With Irritable Bowel Syndrome||Pharmos|Yes|Completed|June 2007|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|324|||Female|18 Years|65 Years|No|||August 2011|August 1, 2011|June 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486876||170403|
NCT00487175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0020|Tramadol and Pain Sensitization|Tramadol and Pain Sensitization|TRAMADOL|University Hospital, Clermont-Ferrand||Completed|September 2007|March 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2009|March 16, 2009|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00487175||170380|
NCT00480987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1089|Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)|A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse With Complete Remission Duration < 1 Year||M.D. Anderson Cancer Center|No|Terminated|July 2007|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|N/A|N/A|No|||August 2012|August 1, 2012|May 30, 2007||No|Lack of support.|No|June 6, 2011|https://clinicaltrials.gov/show/NCT00480987||170850|
NCT00512083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1411-C-201|Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia|An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia||Antisoma Research||Completed|July 2007|||April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|August 6, 2007||||||https://clinicaltrials.gov/show/NCT00512083||168496|
NCT00512330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM ELISA in childhood TB|Lipoarabinomannan (LAM) Enzyme-Linked Immunosorbent Assay (ELISA) in Diagnostics of Childhood Tuberculosis (TB)|Evaluation of Urine Lipoarabinomannan ELISA In Diagnostics of Childhood Tuberculosis||University Hospital, Bonn|No|Recruiting|August 2007|August 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|N/A|14 Years|Accepts Healthy Volunteers||Children up to 14 years of age with suspicion of TB|August 2008|August 5, 2008|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512330||168477|
NCT00476931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-509-0701|Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy|A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity||Sangamo Biosciences|No|Completed|May 2007|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|70 Years|No|||October 2012|October 30, 2012|May 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00476931||171153|
NCT00476944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P000944|Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI|Minimizing Post-Procedural Vascular Complications: Comparing Bivalirudin Versus Heparin/GP IIB/IIA in Patients Undergoing Percutaneous Coronary Intervention||Gold, Herman K., MD||Recruiting|September 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|18 Years|N/A|No|||May 2007|May 18, 2007|May 18, 2007||||||https://clinicaltrials.gov/show/NCT00476944||171152|
NCT00508287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB110-005|Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes|Randomized, Placebo-Controlled, Single-Dose, Crossover Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes||Bristol-Myers Squibb|No|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|70 Years|No|||March 2009|March 13, 2009|July 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00508287||168786|
NCT00508300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P166/07|Epidural Analgesia (EDA) Versus Patient Controlled Analgesia (PCA) in Laparoscopic Colon Surgery|Epidural Analgesia (EDA) Versus Patient Controlled Analgesia (PCA) in Laparoscopic Colon Surgery: A Monocentric Controlled Non-blinded Randomized Superiority Trial|EVA|University of Lausanne Hospitals|No|Completed|January 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508300||168785|
NCT00509691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000557037|Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy|A Phase I Trial to Examine the Safety, Clinical, Immunologic and Virologic Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistent or Therapy Refractory Infections||University of Louisville|Yes|Completed|June 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|2 Years|N/A|No|||June 2013|June 10, 2013|July 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00509691||168679|
NCT00487864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|In Vivo Confocal Scanning Laser Microscopy of Benign Nevi|In Vivo Confocal Scanning Laser Microscopy of Benign Globular, Homogeneous and Reticular Nevi; Comparison With Dermoscopy and Histopathology|CSLM-nevi|Medical University of Graz|No|Completed|September 2006|May 2007|Actual|||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2007|June 18, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00487864||170327|
NCT00487877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-06-NV-380-CTIL|Measurements of Skin Physiological Parameters as Mean of Metabolic Assessment|Measurements of Skin Physiological Parameters as Mean of Metabolic Assessment|TEMP|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|June 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2006|June 18, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00487877||170326|
NCT00488488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-102045|A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting|A Non-Interventional Study To Evaluate The Safety And Effectiveness Of Tygacil In The Treatment Of Patients With Complicated Intra-Abdominal Infections Or Complicated Skin And Skin Structure Infections||Pfizer|No|Completed|November 2006|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1028|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (i.e., at least 18 years old) with a verified diagnosis of complicated        Intra-Abdominal Infection (cIAI) or complicated Skin and Skin Structure Infection (cSSSI),        for whom the decision for Tygacil treatment had already been made.|June 2011|July 20, 2011|June 18, 2007|No|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00488488||170280|
NCT00489060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9716|A Randomized Trial of External Beam Radiotherapy Versus Cryoablation in Patients With Localized Prostate Cancer|A Randomized Trial of External Beam Radiotherapy Versus Cryoablation in Patients With Clinically Localized Prostate Cancer||University of Calgary|Yes|Completed|December 1997|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Male|N/A|N/A|No|||July 2008|July 16, 2008|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489060||170238|
NCT00488748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026868|Magnetic Seizure Therapy (MST) for Severe Mood Disorder|Magnetic Seizure Therapy (MST) for the Treatment of Severe Mood Disorder||Duke University|No|Completed|June 2007|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|90 Years|No|||January 2015|January 16, 2015|June 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488748||170260|
NCT00488761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101993|Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI|A Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Tigecycline to Treat Complicated Skin and Skin Structure Infections (cSSSI) in Hospitalized Patients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A|No|||December 2007|December 21, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00488761||170259|
NCT00489619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 02 - Pilot|Safe Pregnancy by Infectious Disease Control|Safe Pregnancy by Infectious Disease Control in the Democratic Republic of Congo - Pilot Study||NICHD Global Network for Women's and Children's Health|Yes|Completed|April 2004|March 2005|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|2008|||Female|15 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489619||170195|
NCT00489632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0628|Children's Resiliency, Adjustment, and Coping|Children's Resiliency, Adjustment, and Coping: Cancer-Related, Family Context, and Within-Child Factors||M.D. Anderson Cancer Center|No|Completed|April 2006|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children with a diagnosis of leukemia and their parent(s) or caregiver(s).|February 2012|February 17, 2012|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489632||170194|
NCT00489307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0816|Dexamethasone for Symptom Burden in Advanced Cancer Patients|The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2006|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489307||170219|
NCT00489671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000550074|Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis|Differential Diagnosis Between Pancreatic Cancer and Chronic Pancreatitis: Value of the Detection of Urinary Cadmium||Comprehensive Cancer Center of Wake Forest University|No|Completed|June 2003|August 2007|Actual|October 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|32|||Both|N/A|120 Years|No|Non-Probability Sample|chronic pancreatitis|October 2015|October 22, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489671||170191|
NCT00489905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.137-T|Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer|Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer||Hospital Authority, Hong Kong||Completed|April 2005|May 2008|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Male|50 Years|80 Years||||October 2013|October 22, 2013|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489905||170173|
NCT00489918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-2006-001|Dose Ranging Study - Macroflux PTH in Postmenopausal Women With Osteoporosis|A Dose Ranging Study of the Effects of Macroflux® PTH Compared With Macroflux® Placebo and FORTEO® in Postmenopausal Women With Osteoporosis||Zosano Pharma Inc.|No|Completed|June 2007|August 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|165|||Female|50 Years|N/A|No|||May 2009|May 7, 2009|June 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489918||170172|
NCT00486070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-197|Review of Descending Aortic Flow Reversal in Total Anomalous Pulmonary Venous Connection|Proposal for Retrospective Review of Descending Aortic Flow Reversal in Total Anomalous Pulmonary Venous Connection||Children's Healthcare of Atlanta|No|Terminated|December 2006|September 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1||40|||Both|N/A|21 Years|No|Non-Probability Sample|TAPVC patients|January 2008|March 14, 2012|June 12, 2007||No|conclusions drawn, manuscript written|No||https://clinicaltrials.gov/show/NCT00486070||170465|
NCT00486330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUTI|Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir|Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Tipranavir/Ritonavir in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone|BUTI|Yale University|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|June 12, 2007|No|Yes||No|February 25, 2010|https://clinicaltrials.gov/show/NCT00486330||170445|First, the sample size was small. Second, this study utilized a within-subject design with patients acting as their own controls and thereby resulting in less intra-patient variability in the analysis of BUP/NLX.
NCT00486343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-03-C07-401|Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS|A Randomized, Double-Blind, Placebo Controlled Study of Zileuton CR Tablets Versus Placebo in Adult Patients With Poorly Controlled Asthma Patients on Moderate Dose Inhaled Corticosteroids (ICS)||Critical Therapeutics|No|Terminated|July 2007|June 2008|Anticipated|May 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|12 Years|70 Years|No|||April 2008|April 1, 2008|June 13, 2007|Yes|Yes|Slower than anticipated enrollment|No||https://clinicaltrials.gov/show/NCT00486343||170444|
NCT00486616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117/07|Examination of Double-Lumen Tube Placement by Functional Electrical Impedance Tomography|Examination of Double-Lumen Tube Placement: Functional Electrical Impedance Tomography Versus Fibreoptic Bronchoscopy||University Hospital Freiburg|No|Completed|May 2007|August 2007|Actual|August 2007|Actual|N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|No|||August 2007|February 11, 2008|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486616||170423|
NCT00477802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06122801|Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease|Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study||University of Cincinnati|Yes|Terminated|May 2007|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|35 Years|75 Years|No|||February 2009|February 13, 2009|May 22, 2007|No|Yes|Intervention did not appear to be effective in most enrolled patients.|No||https://clinicaltrials.gov/show/NCT00477802||171088|
NCT00486889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03606|Growth and Development Study of Alglucosidase Alfa.|A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.||Sanofi|No|Active, not recruiting|August 2008|January 2026|Anticipated|December 2025|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|24 Months|No|||October 2015|October 26, 2015|June 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486889||170402|
NCT00486902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-030|Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?|Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?||Northwestern University|No|Completed|July 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Female|18 Years|60 Years|No|||March 2014|March 17, 2014|June 13, 2007||No||No|March 15, 2011|https://clinicaltrials.gov/show/NCT00486902||170401|
NCT00512070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1D-MC-X302|Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine|Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality||Seattle Institute for Biomedical and Clinical Research|Yes|Active, not recruiting|July 2007|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512070||168497|
NCT00508833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287615/005|Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)|Safety and the Efficacy of GSK Biologicals' Candidate Adjuvanted Vaccines (287615) Containing HBsAg With Various Adjuvants to Induce Cytotoxic T Lymphocytes (CTL) in Healthy Adult Volunteers||GlaxoSmithKline||Completed|March 2000|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|200|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2007|July 27, 2007|July 27, 2007||||No||https://clinicaltrials.gov/show/NCT00508833||168744|
NCT00509132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-1436C-101|A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers|A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers||Genaera Corporation||Completed|May 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2008|January 8, 2008|July 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00509132||168721|
NCT00512629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-03-0105|Cholestasis Prevention: Efficacy of IV Fish Oil|Cholestasis Prevention: Efficacy of IV Fish Oil||Children's Hospital Boston|Yes|Completed|July 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Both|N/A|3 Months|No|||December 2011|December 14, 2011|August 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512629||168454|
NCT00508313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1082|Thermal Signature of Patients Undergoing Radiation Therapy|Phase I Assessment of Thermal Signature of Patients Undergoing Radiation Therapy||M.D. Anderson Cancer Center|No|Terminated|July 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with lung cancer and healthy participants without cancer.|September 2009|October 7, 2009|July 26, 2007||No|No patients enrolled; study terminated.|No|September 4, 2009|https://clinicaltrials.gov/show/NCT00508313||168784|Early termination leading to no patients accrued.
NCT00508326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0092|Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement|Phase I Study of Paclitaxel Administered by Hepatic Artery Infusion to Patients With Advanced Cancer and Dominant Liver Involvement||M.D. Anderson Cancer Center|No|Completed|October 2005|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|13 Years|N/A|No|||July 2012|July 27, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508326||168783|
NCT00480493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15NR008391-01|STEP: Social Support To Empower Parents|STEP: Social Support To Empower Parents|STEP|University of Massachusetts, Worcester|No|Completed|June 2004|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|May 29, 2007||No||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00480493||170887|We did not have enough parents recruited to look at structural equation modeling.
NCT00480506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-078|Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major|Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major||Dana-Farber Cancer Institute|No|Completed|April 2004|October 2005|Actual|October 2005|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Thalassemia patients being treated at Shariati Hospital in Tehran.|February 2012|February 22, 2012|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00480506||170886|
NCT00487552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-014|Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction|Endoscopic Gastroenteric Anastomosis Formed by Magnetic Compression and Stent Placement for Palliation of Malignant Gastric Outlet Obstruction|MAD|Cook|No|Terminated|January 2008|April 2011|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|18 Years|N/A|No|||June 2012|December 29, 2015|June 15, 2007|Yes|Yes|Failure to achieve one of the primary endpoints.|No|January 16, 2012|https://clinicaltrials.gov/show/NCT00487552||170351|Enrollment was stopped in Feb 2009, due to the death of a patient after distal stent migration.
NCT00489073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6158|Duloxetine Versus Placebo for Fibromyalgia|Duloxetine Versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder||Eli Lilly and Company|No|Completed|November 2002|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||345|||Female|18 Years|N/A|No|||June 2007|June 19, 2007|June 19, 2007||||||https://clinicaltrials.gov/show/NCT00489073||170237|
NCT00489086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551655|Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face|A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome||Children's Hospital & Research Center Oakland|No|Completed|July 2004|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|June 20, 2007|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT00489086||170236|34 pts. were included in the analysis of the primary endpoint. 23 pts. completed 18 months (68%). Only 2 of 34 patients achieved complete resolution (CR = 5.9%). 13 pts. completed 36 month trial (first 18 months tazarotene, months 19-36 observation).
NCT00489320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESCOVER|An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).|An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).|DESCOVER|Cordis Corporation|No|Completed|December 2004|July 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|7759|||Both|N/A|N/A|No|||August 2007|August 1, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489320||170218|
NCT00489658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NECS|Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda|Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda|NECS|Epicentre|No|Terminated|October 2002|||||Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|31|||Both|N/A|N/A|No|||June 2007|June 20, 2007|June 20, 2007|||Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was    taken to terminate recruitment in March 2003.|No||https://clinicaltrials.gov/show/NCT00489658||170192|
NCT00489346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-910|A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)|A Double-Blind, Randomized, Double-Dummy, Multicenter Study to Evaluate and Compare Oral Montelukast and Inhaled Fluticasone in the Control of Asthma for 6- to 14-Year-Olds With Mild Persistent Asthma||Merck Sharp & Dohme Corp.||Completed|October 2001|June 2002|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|994|||Both|6 Years|14 Years|No|||June 2015|June 22, 2015|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489346||170216|
NCT00489684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001881-33|Effect of Opioids on Experimental Hyperalgesia in Oesophagus, Skin and Muscles|Investigation of the Effect of Opioids on Experimental Hyperalgesia in Oesophagus and Skin, and in an Ischemic Model of Musclepain. Including an Explorative Study of the Effect of Morphine on the Pain Processing in the Brain|AEO-2007-01|University of Aarhus|Yes|Completed|August 2007|March 2008|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|24|Samples With DNA|Blood samples are collected to study the pharmacokinetic of the drugs|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|June 2008|June 13, 2008|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489684||170190|
NCT00489931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070172|Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally|A Phase I Open-Label Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for the Influenza Virus H5 Hemagglutinin Protein Administered Intradermally in Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|June 2007|April 2009||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||44|||Both|18 Years|60 Years|No|||April 2009|April 16, 2009|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489931||170171|
NCT00485784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/26|Interest of Circulating Endothelial Biomarkers in Vascular Pregnancy Complications|Interest of Circulating Endothelial Biomarkers in Vascular Pregnancy Complications||Assistance Publique Hopitaux De Marseille||Completed|July 2007|||July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|280|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 27, 2014|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00485784||170487|
NCT00486083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6934|Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD|A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate Hydrochloride in Pediatric Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|December 2003|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|330|||Both|6 Years|16 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00486083||170464|
NCT00486356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|284-04|Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer|A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients||University of Nebraska|Yes|Completed|October 2004|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|June 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00486356||170443|
NCT00478985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2006/06|Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia|Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM)|STIM|University Hospital, Bordeaux|Yes|Completed|June 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478985||171000|
NCT00478088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA-ND-0501|Evaluating The Safety and Effectiveness of The NeoDisc™ Versus ACDF in Subjects With Single-Level Cervical Disc Disease|A Pivotal, Multi-Center, Randomized, Controlled Trial Evaluating The Safety and Effectiveness of The NeoDisc™ Versus Instrumented Anterior Cervical Discectomy and Fusion (ACDF) in Subjects With Single-Level Cervical Disc Disease|NeoDisc™|NuVasive|Yes|Completed|September 2006|March 2012|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|488|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|May 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478088||171066|
NCT00511810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McNamara Omega3 MDD|Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder|Evaluation of Omega-3 Fatty Acids as a Treatment-adjunct in Adolescent Patients With Major Depressive Disorder Exhibiting Partial Response to SSRI Medications: An Open-label Neuroimaging Trial||University of Cincinnati|Yes|Completed|August 2007|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|18 Years|No|||December 2014|December 3, 2014|August 3, 2007|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00511810||168517|
NCT00509158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSA3_01_06|Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine|Phase I and IIa Trial for Assessment of Safety, Immunogenicity and Efficacy Against Sporozoite Challenge of the Candidate Malaria Vaccine PfLSA-3-rec|LSA-3-rec|Radboud University|Yes|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|February 22, 2010|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509158||168719|
NCT00509444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00063|Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial|Cancer Prevention and Treatment Among African American Older Adults|CPTD|Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|October 2006|December 2012|Anticipated|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|65 Years|N/A|No|||June 2012|June 18, 2012|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00509444||168697|
NCT00512642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999999040|Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Bronchial Lesions: Novel Approaches for Early Detection of Lung Cancer in High Risk Patients|Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Bronchial Lesions: Novel Approaches for Early Detection of Lung Cancer in High Risk Patients||National Institutes of Health Clinical Center (CC)||Completed|July 1999|||||N/A|Observational|N/A|||Anticipated|200|||Both|35 Years|N/A|No|||February 2016|February 20, 2016|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512642||168453|
NCT00509431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000557423|Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma|A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus in Patients With Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics||Jonsson Comprehensive Cancer Center|Yes|Completed|August 2006|September 2012|Actual|December 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|July 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00509431||168698|
NCT00509990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CVE01|Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting|Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting||Novartis||Completed|April 2005|||September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|3 Months|12 Years|No|||November 2011|November 1, 2011|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00509990||168657|
NCT00480519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scmc4304ctil|Use of Sedation and Local Anesthesia in Meatotomy: A Prospective Comparison Study|Use of Sedation and Local Anesthesia in Meatotomy: A Prospective Comparison Study||Rabin Medical Center|No|Recruiting|May 2007|May 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Anticipated|75|||Male|3 Years|18 Years|No|||May 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00480519||170885|
NCT00480818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-102|Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 9, 2007|May 29, 2007||||||https://clinicaltrials.gov/show/NCT00480818||170862|
NCT00488202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03235|Advanced Ovarian Cancer and Sexuality Phase 1|Advanced Ovarian Cancer and Sexuality Phase 1|ANOVA1|University of British Columbia|No|Completed|May 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|26|||Female|19 Years|65 Years|No|Non-Probability Sample|women diagnosed with advanced ovarian cancer|April 2013|April 16, 2013|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488202||170302|
NCT00488566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCB107718|GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers|Double Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of GSK Drug and the Effect of Single Doses of GSK Drug or Lamotrigine on Resting Motor Threshold in Healthy Volunteers||GlaxoSmithKline|No|Completed|May 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488566||170274|
NCT00488813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101441|Study of Antibiotic Utilization Measures and Control of ESBLs in China|Association of Antibiotic Utilization Measures and Control of Extended-spectrum β-lactamases (ESBLs) in MICU1 and MICU2 at Buddhist Tzu Chi General Hospital.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00488813||170255|
NCT00489333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0001-01|ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome|The Effects of ProAlgaZyme Novel Algae Infusion vs. Placebo on Metabolic Syndrome and Markers of Cardiovascular Health||Health Enhancement Products, Inc.|No|Completed|May 2006|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|52|||Both|25 Years|60 Years|No|||June 2007|June 19, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489333||170217|
NCT00489645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAM025/04|Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide|The Influence of Ambient Glycemia on the Effect of Pramlintide on Gastric Emptying in Patients With Type 1 Diabetes and Healthy Subjects||Ludwig-Maximilians - University of Munich|Yes|Completed|January 2005|April 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 15, 2008|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00489645||170193|
NCT00489359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9516|Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer|A Phase 1 and 2 Clinical Trial of ALIMTA® (Pemetrexed) in Combination With Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer||Eli Lilly and Company|No|Completed|July 2005|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|N/A|No|||May 2011|May 17, 2011|June 19, 2007|Yes|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00489359||170215|
NCT00489944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551559|Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma|A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma||National Cancer Institute (NCI)||Recruiting|May 2007|||December 2012|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2009|January 9, 2014|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489944||170170|
NCT00479271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSG001|Evaluating the Effectiveness of a Community Based Intervention for Persons With Dementia and Their Caregivers in a Developing Country|The Dementia Home Care Project: a Randomised Controlled Trial to Evaluate the Effectiveness of a Home Care Program for Supporting Caregivers of Persons With Dementia in Developing Countries: a Randomised Controlled Trial From Goa, India||London School of Hygiene and Tropical Medicine|Yes|Completed|October 2003|February 2005|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|2||||||Both|60 Years|N/A|No|||May 2007|March 31, 2015|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479271||170978|
NCT00485849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6639|A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD|An Open Label Pilot Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behavior Problems in Children and Adolescents With Autistic Spectrum Disorders||Eli Lilly and Company||Completed|February 2004|October 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|6 Years|17 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485849||170482|
NCT00485797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR454707CTIL|Effects of Ritalin on Postural Stability of Hyper Active Children|Effects of Methylphenidate on Postural Stability of Children Suffer From Attention Deficit Hyperactivity Disorder (ADHD) Under Single and Dual Task Conditions.||Soroka University Medical Center|Yes|Completed|October 2007|June 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||May 2007|February 17, 2011|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00485797||170486|
NCT00485810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5293|Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia|A Study Examining Clinical Therapeutic Dose of Rapid Acting Intra-Muscular Olanzapine in Japanese Agitated Patients With Schizophrenia||Eli Lilly and Company||Completed|June 2004|November 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|64 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485810||170485|
NCT00486096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-012|Femoral Arterial Cannulation|Femoral Arterial Cannulation in Infants Following Complicated Sternal Re-entry||Children's Healthcare of Atlanta|No|Terminated|February 2007|August 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|N/A|3 Months|No|Non-Probability Sample|Pediatric children of successful angio-catheter use on 5 kg child|June 2007|March 14, 2012|June 12, 2007|||sufficient data collected.|No||https://clinicaltrials.gov/show/NCT00486096||170463|
NCT00486109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTN 012.1|A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port|A Study Assessing an Injection Port for Administration of Insulin||Patton Medical Devices|No|Completed|October 2006|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|74|||Both|14 Years|70 Years|No|||March 2008|March 10, 2008|June 12, 2007||||No||https://clinicaltrials.gov/show/NCT00486109||170462|
NCT00486369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC021C2102|SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study|SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.||Nordic Bioscience A/S||Completed|January 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|52 Years|75 Years||||June 2007|June 13, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486369||170442|
NCT00486382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LVVPX-104|Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India|A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India||IDRI|Yes|Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|June 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486382||170441|
NCT00479596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX0621|This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.|Safety and Efficacy Study of Intradetrusor Injections of Botox® for the Treatment of Urinary Incontinence Secondary to Benign Prostatic Obstruction (BTX0621)|BTX0621|Urological Sciences Research Foundation|No|Recruiting|January 2007|May 2007|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|40|||Male|40 Years|90 Years|No|||January 2007|May 29, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479596||170954|
NCT00479609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTinMMS|Testosterone Therapy in Men With Low Testosterone Levels and Metabolic Syndrome or Early Stages of Type 2 Diabetes|A Randomised Placebo Controlled Study of Transdermal Testosterone Therapy to Investigate the Efficacy and Safety in Men With Abdominal Obesity, Low Testosterone Levels and Early Stages of the Metabolic Cluster Syndrome.||Karolinska Institutet|Yes|Recruiting|April 2007|April 2009|Anticipated|January 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Male|30 Years|70 Years|No|||May 2008|May 6, 2008|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479609||170953|
NCT00479934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2006/05|Efficacy and Safety of Imatinib in Scleroderma|Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.|SCLEROGLIVEC|University Hospital, Bordeaux|Yes|Completed|December 2007|December 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00479934||170929|
NCT00508066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCLA-0116|Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery|Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery||Shriners Hospitals for Children|No|Completed|May 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|8 Years|18 Years|No|||January 2013|January 15, 2013|July 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00508066||168803|
NCT00508339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0111|Functional Outcomes Following Limb Sparing Surgery for Sarcoma Patients|Functional Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma and Pre-Operative Radiotherapy||M.D. Anderson Cancer Center|No|Withdrawn|September 2006|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of soft tissue sarcoma.|July 2012|July 31, 2012|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508339||168782|
NCT00479960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022006|A Preliminary Study on Effect of Omega-3 on Human Sperm|Effect of Dietary Supplementation With Omega-3 Fatty Acids on Human Sperm Characteristics, a Preliminary Study||Hadassah Medical Organization|No|Not yet recruiting|June 2007|June 2007|Anticipated|||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|20|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 2006|May 29, 2007|May 28, 2007||||No||https://clinicaltrials.gov/show/NCT00479960||170927|
NCT00509145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LAQ-301|Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|ALLEGRO|Teva Pharmaceutical Industries|Yes|Completed|December 2007|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1106|||Both|18 Years|55 Years|No|||February 2012|February 16, 2012|July 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509145||168720|
NCT00509418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIUNASH-07|Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis|Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized, Controlled and Open Label Study||Catalysis SL|Yes|Completed|February 2007|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||January 2009|January 9, 2009|July 30, 2007||||No||https://clinicaltrials.gov/show/NCT00509418||168699|
NCT00480532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 2907|A Study of Continuous Oral Contraceptives and Doxycycline|A Study of Continuous Oral Contraceptives and Doxycycline||Oregon Health and Science University|No|Completed|May 2007|May 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|131|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|May 30, 2007|Yes|Yes||No|May 21, 2012|https://clinicaltrials.gov/show/NCT00480532||170884|Treatment Arm: Subjects had difficulty understanding when to start and stop treatment.
NCT00480805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_554|HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)|HYZAAR Versus Ramipril Diabetic Patients||Merck Sharp & Dohme Corp.||Completed|October 2002|||October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||280|||Both|18 Years|N/A|No|||May 2013|May 24, 2013|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00480805||170863|
NCT00476502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 031|Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r|Study of Genetic Polymorphisms of CYP 3A and MDR-1 Genes in Thai HIV-1 Infected Patients on Saquinavir/Ritonavir||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|February 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|250|Samples With DNA|PBMC|Both|18 Years|N/A|No|Probability Sample|patients on stable SQV based HAART therapy|April 2012|April 3, 2012|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476502||171183|
NCT00476528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK8633|Early Rehabilitation of Patients With Posttraumatic Amnesia|Early Rehabilitation of Patients With Posttraumatic Amnesia. A Clinical Controlled Investigation of the Effect of a Nursing Programme in Patients With Traumatic Brain Injury in the Acute Care||University of Aarhus|Yes|Active, not recruiting|September 2007|September 2010|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|62|||Both|18 Years|70 Years|No|||August 2010|August 9, 2010|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476528||171181|
NCT00476775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK073006|Ethnic Dance and Screen Time Reduction to Prevent Weight Gain in Latina Girls|Ethnic Dance and Screen Time Reduction to Prevent Weight Gain in Latina Girls|ECHALE|Stanford University|No|Completed|May 2007|August 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|233|||Female|7 Years|9 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476775||171164|
NCT00488501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-16106|Clinical Usefulness and Efficacy of Intrathoracic Impedance Monitoring Using the OptiVol Patient Alert(TM)|Clinical Usefulness and Efficacy of Intrathoracic Impedance Monitoring Using the OptiVol Patient Alert(TM) in Medtronic(R) ICD's for Early Detection of Decompensated Heart Failure||Catharina Ziekenhuis Eindhoven|No|Completed|July 2007|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|N/A|No|Non-Probability Sample|patients who have been implanted a biventricular pacemaker ICD equipped with impedance        monitoring and who are known with chronic heart failure of any cause|November 2009|November 9, 2009|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488501||170279|
NCT00488514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA107977|Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents|Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents||GlaxoSmithKline|No|Completed|July 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|656|||Both|12 Years|17 Years|No|||March 2011|May 31, 2012|June 18, 2007|Yes|Yes||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00488514||170278|
NCT00488839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX056-B06-03|IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis|A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis||IMPAX Laboratories, Inc.|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|173|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|June 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488839||170253|
NCT00488865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REX-US-2006-001|RexMedical- Option* Vena Cava Filter IDE Study|RexMedical- Option* Vena Cava Filter IDE Study||Rex Medical|Yes|Completed|October 2006|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|N/A|No|||August 2010|August 4, 2010|June 18, 2007|Yes|Yes||No|May 3, 2010|https://clinicaltrials.gov/show/NCT00488865||170252|
NCT00488826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101518|Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants|An Open-Label Controlled Phase I/III Study to Evaluate the Safety and Immunogenicity of Pneumococcal 7-Valent Conjugate Vaccine [DIPHTHERIA CRM197 PROTEIN] (PrevenarTM) in Healthy Infants||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2005|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|800|||Both|90 Days|120 Days|Accepts Healthy Volunteers|||January 2010|January 15, 2010|June 18, 2007||||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00488826||170254|
NCT00489099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V232-054|A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)|A Study in Healthy Young Adults To Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade||Merck Sharp & Dohme Corp.|No|Completed|June 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|860|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489099||170235|
NCT00489372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00505|Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients|Phase I Study of Single Oral Dose of Se-Methyl-Seleno-L-Cysteine (MSC) in Adult Men||National Cancer Institute (NCI)|Yes|Completed|July 2007|July 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|36|||Male|18 Years|70 Years|No|||September 2014|November 13, 2014|June 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00489372||170214|
NCT00479583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-005|Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-690514 in Combination With FOLFIRI and FOLFOX in Subjects With Advanced Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|September 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||March 2011|November 29, 2011|May 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479583||170955|
NCT00480454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB012|Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines|An Open Randomized Dose Selection Study Evaluating the Safety, Immunogenicity, and Impact of a TB Vaccine, MVA85A, on the Immunogenicity of EPI Vaccines Administered Simultaneously to Healthy Infants Previously Vaccinated With BCG.||University of Oxford|Yes|Completed|October 2006|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|214|||Both|2 Months|3 Months|Accepts Healthy Volunteers|||February 2010|February 8, 2010|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480454||170890|
NCT00485823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6696|Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia|The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy||Eli Lilly and Company||Completed|December 2002|September 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485823||170484|
NCT00485836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4166g|A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)|A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion|CRUISE|Genentech, Inc.||Completed|July 2007|December 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|392|||Both|18 Years|N/A|No|||February 2011|February 1, 2011|June 11, 2007|Yes|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT00485836||170483|
NCT00486122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7972|Evaluation of Continuous Symptom Treatment of ADHD|Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera||Eli Lilly and Company||Completed|September 2003|June 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|282|||Both|6 Years|12 Years|No|||June 2007|June 11, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00486122||170461|
NCT00486135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11433|Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 Administered Orally Daily to Subjects With Solid Tumors or Lymphoma||Sanofi||Completed|June 2007|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|118|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|June 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00486135||170460|
NCT00486915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR2007-1|Impact of Left Atrial Appendage Exclusion on Short-Term Clinical Outcomes and Long-Term Stroke Incidence|Concurrent Prophylactic Left Atrial Appendage Exclusion: A Randomized Controlled Trial||London Health Sciences Centre|No|Recruiting|April 2007|December 2011|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|N/A|No|||June 2011|June 22, 2011|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00486915||170400|
NCT00480753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003|Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon|Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon||MediQuest Therapeutics||Completed|May 2007|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|75 Years|No|||December 2007|December 18, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00480753||170867|
NCT00480766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217-193|A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of Oral Alendronate Sodium Once Weekly for the Prevention and Treatment of Glucocorticoid-Induced Bone Loss||Merck Sharp & Dohme Corp.||Completed|July 2001|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|173|||Both|18 Years|80 Years|No|||February 2016|February 3, 2016|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00480766||170866|
NCT00479973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dug2006-1|The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark|The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark (Cinnamomum Verum and C. Aromaticum) (Cinnamonforce™) - Randomized Placebo-Controlled Clinical Trial||University Health Network, Toronto|Yes|Recruiting|September 2007|May 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|75 Years|No|||November 2007|November 19, 2007|May 28, 2007||||No||https://clinicaltrials.gov/show/NCT00479973||170926|
NCT00508846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0211|Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients|Screening for Gynecologic Cancers Among Women With Hereditary Non-Polyposis Colon Cancer (HNPCC)||M.D. Anderson Cancer Center|No|Completed|May 2003|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|93|||Female|25 Years|N/A|No|Non-Probability Sample|Women, age 25 years of age or older, diagnosed with Hereditary Non-Polyposis Colon Cancer        (HNPCC).|March 2016|March 10, 2016|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508846||168743|
NCT00480545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-05-0095|Changes in Bleeding and Clotting During the Menstrual Cycle|Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle||The University of Texas Health Science Center, Houston|No|Withdrawn|October 2005|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Blood samples will be discarded when the study is completed.|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 18 to 50 years with regular menstrual cycles.|December 2014|December 3, 2014|May 29, 2007||No|IRB Approval lapsed|No||https://clinicaltrials.gov/show/NCT00480545||170883|
NCT00480558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB011|A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Asymptomatic Volunteers Who Are Infected With Either Mycobacterium Tuberculosis (M.tb.), Human Immunodeficiency Virus (HIV) or Both||University of Oxford|Yes|Completed|July 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|48|||Both|21 Years|50 Years|No|||March 2011|March 25, 2011|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480558||170882|
NCT00509457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002646 11|GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)|Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC). A Phase II Study of GV 1001 Telomerase Peptide Vaccination in Patients With Locally Advanced NSCLC||Oslo University Hospital||Completed|November 2006|August 2009|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2009|June 30, 2011|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00509457||168696|
NCT00509704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO 2006/232|Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma|Pilot Study on the Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma||Radboud University|No|Completed|October 2008|May 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|Patients with a malignant abdominal tumor or metastases (minimal diameter 2 cm)|October 2010|November 8, 2010|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509704||168678|
NCT00476515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2672s|Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor|Multicenter Trial Using Multi-Dose Rituximab as Induction and Desensitization Therapy for Patients on the Waiting List for Kidney Transplant With a Positive Donor Specific Crossmatch to a Living Donor||Massachusetts General Hospital|Yes|Completed|March 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2008|February 15, 2008|May 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00476515||171182|
NCT00477061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG11|Morphine Analgesia in Patients With Acute Appendicitis|Double Blind Randomized Study of Morphine Analgesia in Patients With Acute Appendicitis||Tehran University of Medical Sciences|No|Completed|January 2004|March 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|71|||Both|13 Years|75 Years|No|||May 2007|May 20, 2007|May 20, 2007||||No||https://clinicaltrials.gov/show/NCT00477061||171143|
NCT00488774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014188|An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis|A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis||Janssen Research & Development, LLC|Yes|Terminated|August 2007|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|291|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|June 18, 2007|Yes|Yes|Protocol was cancelled by company based on overall efficacy, no safety concern|No|April 29, 2013|https://clinicaltrials.gov/show/NCT00488774||170258|Data collection was not considered complete for primary outcome measure because study was terminated prematurely.
NCT00489125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97305|Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer|Breast Clinic Strength and Range of Motion Study||Comprehensive Cancer Center of Wake Forest University|Yes|Recruiting|March 2005|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|275|||Female|N/A|120 Years|No|Non-Probability Sample|Any woman treated in the Breast Clinic of WFUBMC with a diagnosis of stage 0-IV breast        cancer and identified as a candidate by their surgeon.|February 2016|February 10, 2016|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489125||170233|
NCT00489112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0044-07-EMC|The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study|||HaEmek Medical Center, Israel|Yes|Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|80 Years||||June 2007|June 25, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489112||170234|
NCT00489697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA06-FT/STIC-AVASTIN|Evaluation of Contrast-Enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases|Medical and Economical Evaluation of Contrast-Enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases||University Hospital, Tours|No|Recruiting|January 2007|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|80 Years|No|||February 2009|February 19, 2009|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489697||170189|
NCT00480467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3182A1-102|Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 Administered Orally to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00480467||170889|
NCT00480168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-05-116|A Prospective Study to Assess Metabolic Changes in Children and Adolescents Treated With Atypical Antipsychotics|A Prospective Study to Assess Metabolic Changes in Children and Adolescents Aged 6-18 Treated With Atypical Antipsychotics||Lawson Health Research Institute|No|Recruiting|May 2007|August 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|6 Years|18 Years|No|Non-Probability Sample|Community sample of youth 6-18 where treatment with atypical antipsychotic medication is        being initiated|March 2010|March 22, 2010|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00480168||170911|
NCT00486148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA-1-GOS-05|Safety and Efficacy of an Infant Formula Supplemented With Galacto-oligosaccharides (GOS)|Randomized, Double Blind Study to Evaluate the Safety and Efficacy of an Infant Formula Supplemented With Galacto-oligosaccharides (GOS) in Healthy, Full Term Infants||Heinz Italia SpA|No|Completed|February 2006|June 2013|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|N/A|15 Days|No|||March 2015|March 17, 2015|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00486148||170459|
NCT00481026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11707|A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and Depression|A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and Depression||Bayside Health|No|Recruiting|July 2007|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2007|May 5, 2008|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00481026||170847|
NCT00486681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 05 51|Clinical Assessment of an in-Patient Glucose Monitoring System (Accu-Chek Inform Cobas IT 1000)|Evaluation of the Implementation of the Accu-Chek Inform Cobas IT 1000 System in Three Medical Hospital Departments: Impact on the Management of Diabetes|COBAS|University Hospital, Grenoble|No|Completed|January 2007|January 2008|Actual|July 2007|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|949|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring a monitoring of capillary blood glucose levels|February 2008|February 26, 2008|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00486681||170418|
NCT00486694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T26/181/33|Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria|A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan.||London School of Hygiene and Tropical Medicine|No|Completed|March 2004|August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|190|||Both|2 Years|N/A|No|||June 2007|June 13, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486694||170417|
NCT00478803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040412|Conservative Aortic Valve Surgery for Aortic Insufficiency and Aneurysms of the Aortic Root. CAVIAAR|Conservative Aortic Valve Surgery for Aortic Insufficiency and Aneurysms of the Aortic Root|CAVIAAR|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2007|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||July 2012|March 6, 2015|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478803||171013|
NCT00478816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P3|Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines|A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines||Novartis|No|Completed|May 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478816||171012|
NCT00478829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B2-4417|Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in China|Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in 5 Large Cities in China||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2007|July 2007|Actual|||N/A|Observational|Time Perspective: Prospective||||8000|||Both|18 Years|N/A|No|||December 2007|December 4, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00478829||171011|
NCT00480389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0655-C|Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal|Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy||University Health Network, Toronto|Yes|Completed|May 2007|March 2013|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00480389||170894|
NCT00511706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-016|Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)|||Allergan|No|Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|243|||Both|50 Years|N/A|No|||August 2012|August 1, 2012|August 2, 2007|Yes|Yes||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00511706||168525|
NCT00511719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-003b2|Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes|A Prospective, Controlled, Single-Center, Open-Label,Randomized, Replicated, Crossover Isoglycemic Glucose Clamp Study Evaluating Intrapatient Variability in Bioavailability of Technosphere® Insulin Compared With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes||Mannkind Corporation|No|Completed|February 2004|March 2005|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|No|||June 2011|June 28, 2011|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00511719||168524|
NCT00511732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-005|18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes|A Randomized, Double-blind, Controlled, Stepwise Titration Study to Evaluate Dose Response to Prandial Administration of Inhaled Technosphere/Insulin or Technosphere in Patients With Type 2 Diabetes Mellitus Who Are Sub-optimally Treated||Mannkind Corporation||Completed|June 2004|August 2007|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|80 Years|No|||April 2012|April 27, 2012|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00511732||168523|
NCT00512018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067/03|Neuromuscular Electrical Stimulation and Isokinetic Training|Neuromuscular Electrical Stimulation and Isokinetic Training: Effects on Strength and Neuromuscular Properties||Universidade Federal de Sao Carlos|No|Completed|January 2005|July 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|20|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|August 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00512018||168501|
NCT00512252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0227 / 201011796|AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia|A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML|AMD3100+MEC|Washington University School of Medicine|No|Completed|July 2007|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|70 Years|No|||September 2014|September 12, 2014|August 6, 2007|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00512252||168483|
NCT00512551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDP00-075|DNA Array Analysis of Patients With Cervical Cancer|A Pilot Study of Early Changes in DNA Array Expression Following Chemo-Radiation Treatment of Cervical Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2000|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18|Samples With DNA|Two biopsies of the cervix will be performed to obtain tumor cells.|Female|N/A|N/A|No|Non-Probability Sample|Patients with cervical cancer already scheduled to begin radiation therapy.|September 2015|September 30, 2015|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00512551||168460|
NCT00512564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0087-07-EMC|Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia|Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia - An Observational and Laboratory Study||HaEmek Medical Center, Israel||Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|All tha patinets suffering from Sickle cell disease trreated at the Pediatric Hematology        Unit|August 2011|August 25, 2011|August 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00512564||168459|
NCT00508235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0791|Quality of Friendships in Children With Neurofibromatosis|Quality of Friendships in Children With Neurofibromatosis: Relationship to Disease Severity||M.D. Anderson Cancer Center|No|Completed|December 2004|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|61|||Both|8 Years|18 Years|No|Non-Probability Sample|Study participants with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18        years old.|July 2012|July 31, 2012|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508235||168790|
NCT00508547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013225|Psoriasis Longitudinal Assessment and Registry (PSOLAR)|A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics||Janssen Scientific Affairs, LLC|No|Active, not recruiting|June 2007|May 2021|Anticipated|December 2020|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|12054|||Both|18 Years|99 Years|No|Non-Probability Sample|Any patients with psoriasis that meets the inclusion criteria will be eligible to        participate in this registry.|March 2016|March 15, 2016|July 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00508547||168766|
NCT00508781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100206857|Multiphoton Laser Scanning Microscopy in Cutaneous Optical Pathology|Multiphoton Laser Scanning Microscopy in Cutaneous Optical Pathology||National Taiwan University Hospital|Yes|Recruiting|November 2002|December 2012|Anticipated|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|400|||Both|1 Year|90 Years|No|||November 2002|July 26, 2007|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00508781||168748|
NCT00477074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPAR2002FG|Pulmonary and Systemic Hepatocyte Growth Factors in Patients With COPD|Pulmonary and Systemic Hepatocyte Anb Keratinocyte Growth Factors in Patients With Chronic Obstructive Pulmonary Disease||Hospital Universitari Son Dureta|No|Completed|January 2004|December 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|44|||Both|40 Years|75 Years|No|||May 2007|May 18, 2007|May 18, 2007||||No||https://clinicaltrials.gov/show/NCT00477074||171142|
NCT00478595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6647|Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-diabetic Drug|SYMPHONY|Sanofi||Terminated|May 2007|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|458|||Both|20 Years|N/A|No|||July 2009|July 17, 2009|May 24, 2007|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00478595||171029|
NCT00479141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRA CH 002B|A Cluster-Randomized Intervention Trial to Improve Quality of Life for HIV-Infected Individuals in Anhui, China|A Cluster-Randomized Trail to Evaluate the Efficacy of a Combined Individual- and Community-Based Behavioral Intervention to Improve Quality of Life (QOL) For HIV-Positive Villagers in Rural China||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2006|December 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3199|||Both|18 Years|N/A|No|||January 2009|March 26, 2009|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479141||170988|
NCT00479427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBA106191|A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis|A Double-blind, Placebo Controlled Cross-over Study of the Effects of the CB2 Compound of GW842166 in Patients With Osteoarthritis||GlaxoSmithKline||Completed|July 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|45|||Both|50 Years|80 Years|No|||July 2009|July 22, 2009|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00479427||170966|
NCT00479440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3182A1-100|Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 Administered Orally to Healthy Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|May 24, 2007||||||https://clinicaltrials.gov/show/NCT00479440||170965|
NCT00479453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8299|Lilly's Emotional and Physical Symptoms of Depression|Lilly's Emotional and Physical Symptoms of Depression|LEAPS|Eli Lilly and Company|No|Completed|August 2004|January 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8000|||Both|18 Years|N/A|No|||May 2007|May 25, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479453||170964|
NCT00479466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0893-008|Dose-Range Finding Study for MK0893 (0893-008)|A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose-Range Finding Study of MK0893 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Terminated|July 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|342|||Both|21 Years|70 Years|No|||September 2015|September 8, 2015|May 25, 2007|Yes|Yes|Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort    of the study to assess the safety and efficacy|No|October 7, 2011|https://clinicaltrials.gov/show/NCT00479466||170963|Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy, thus the study was discontinued.
NCT00478556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070208011|Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT|Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT||University of Alabama at Birmingham|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|300|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 19, 2010|May 24, 2007|Yes|Yes||No|February 9, 2010|https://clinicaltrials.gov/show/NCT00478556||171032|Study was completed.
NCT00478569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-002-IM|Adherence to PTH(1-84) Treatment (FP-002-IM)|Adherence to PTH(1-84) Treatment in Europe. A Non-interventional Cohort Study Collecting Safety Information and Examining Reasons and Predictors for Adherence to PTH(1-84) Treatment in Usual Clinical Settings||Takeda|Yes|Completed|April 2007|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1179|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women with osteoporosis and a high risk of fractures prescribed PTH(1-84)        in a normal clinical setting.|April 2014|April 29, 2014|May 23, 2007||No||No|April 29, 2014|https://clinicaltrials.gov/show/NCT00478569||171031|
NCT00480922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-03-0092 (completed)|Effects of a Low Glycemic Load Diet on Fatty Liver in Children|Randomized Controlled Trial Comparing the Effects of a Low Glycemic Load Diet With a Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescents|DELIVER|Children's Hospital Boston|No|Completed|May 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|17 Years|No|||August 2011|August 25, 2011|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00480922||170855|
NCT00480090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLAP41206|A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer|A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer|SLAP|University Health Network, Toronto|Yes|Completed|April 2007|July 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||January 2013|January 10, 2013|May 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00480090||170917|
NCT00480103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCVD1H|Intrauterine Embryo Development With ANECOVA Device|Multi-Center Evaluation Program NCVD1H Intrauterine Embryo'S Development Assisted by ANECOVA ACVd1 Device|ANECOVA|Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Terminated|August 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|||||||Both|18 Years|36 Years|Accepts Healthy Volunteers|||March 2011|March 3, 2011|May 28, 2007||No|INHERENT MODIFICATIONS NEEDED BEFORE PROCEEDING|No||https://clinicaltrials.gov/show/NCT00480103||170916|
NCT00480350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shah1HMO-CTIL|RiSolubles™, the Soluble Fraction of Rice Bran for HIV-Infected Patients|||Hadassah Medical Organization||Not yet recruiting|September 2007|January 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||March 2007|September 4, 2007|May 28, 2007||||No||https://clinicaltrials.gov/show/NCT00480350||170897|
NCT00480363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000649-36|QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression|QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression|QUIREDEX|PETHEMA Foundation|Yes|Completed|May 2007|July 2013|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|May 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00480363||170896|
NCT00480701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBVM001|Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease|Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease|IBVM001|Institute for Neurodegenerative Disorders|Yes|Completed|February 2007|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 16, 2014|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00480701||170871|
NCT00512031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070079|Characterizing PAI-1 Modulation on Monocyte Adhesion|Characterizing the Effects of PAI-1 Modulation on Human Monocyte Function - The Effect of PAI-1 Post-transcriptional Regulation on Human Monocyte Adhesion||Vanderbilt University|No|Terminated|January 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|July 2011|July 15, 2011|August 3, 2007||No|Investigator left institution|No||https://clinicaltrials.gov/show/NCT00512031||168500|
NCT00512044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07/CHV|Local Versus General Anaesthesia in Stapled Hemorrhoidectomy|Local vs General Anaesthesia in Stapled Hemorrhoidectomy: A Multicentric Controlled Randomized Trial||University of Lausanne Hospitals|No|Withdrawn|October 2007|May 2008|Anticipated|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||June 2015|June 23, 2015|August 6, 2007|No|Yes|slow recruitment, internal problems with the study protocol|No||https://clinicaltrials.gov/show/NCT00512044||168499|
NCT00512265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005DR4333|Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer|Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer. A Multicenter, Prospective, Randomised Double Blind, Placebo-controlled Study||University Hospital, Basel, Switzerland|No|Completed|January 2006|January 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|20 Years|90 Years|No|||August 2013|August 27, 2013|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512265||168482|
NCT00512278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARTNER|Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C|Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection|PARTNER|The Cleveland Clinic|Yes|Completed|July 2007|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512278||168481|
NCT00512577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS02/4/RB31|Transfusion Alternatives Pre-Operatively in Sickle Cell Disease (TAPS)|Transfusion Alternatives Pre-Operatively in Sickle Cell Disease|TAPS|NHS Blood and Transplant|Yes|Recruiting|July 2007|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|1 Year|N/A|No|||August 2007|August 13, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512577||168458|
NCT00508248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270605ver3|Omega 3 Fatty Acids and Atrial Fibrillation|Use of Omega 3 Polyunsaturated Fatty Acids Supplements to Maintain Sinus Rhythm in Persistent Atrial Fibrillation||University of Dundee|Yes|Recruiting|June 2005|November 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|180|||Both|21 Years|85 Years|No|||July 2007|July 26, 2007|July 25, 2007||||No||https://clinicaltrials.gov/show/NCT00508248||168789|
NCT00500318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-MD-CL26|A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide (LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe COPD||Forest Laboratories||Completed|July 2007|||December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|40 Years|N/A|No|||November 2012|November 16, 2012|July 10, 2007|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00500318||169389|
NCT00500331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2105255|Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)|A Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment Naïve Subjects.||GlaxoSmithKline|No|Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|336|||Both|18 Years|70 Years|No|||November 2013|November 7, 2013|January 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00500331||169388|
NCT00500578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0010|Intermittent Use of Aerosolized Ribavirin for Treatment of RSV|A Randomized Study Evaluating Two Different Schedules of Aerosolized Ribavirin For Treatment of RSV Upper Respiratory Infections in Patients With Hematological Malignancies||M.D. Anderson Cancer Center|No|Completed|February 2003|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|5 Years|N/A|No|||July 2012|July 27, 2012|July 10, 2007||No||No|June 1, 2010|https://clinicaltrials.gov/show/NCT00500578||169369|The interpretation of our data is limited by our study’s open-label design, which may bias assessments of tolerability or toxicity but would be less likely to bias assessments of therapeutic endpoints.
NCT00478296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-021|Pulmonary Hypertension in Trisomy 21 Patients|Case Report: Resolution of Pulmonary Hypertension With Sildenafil and Bosentan in Patients With Trisomy 21 and Atrial Septal Defect||Children's Healthcare of Atlanta|No|Completed|October 2004|March 2008|Actual|February 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|N/A|8 Days|No|Non-Probability Sample|This is a case report of one subject with trisomy 21 and a primum atrial septum defect        with associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days        of life.|January 2008|March 14, 2012|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00478296||171051|
NCT00478322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 13739-201|Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects|||Incyte Corporation|No|Completed|April 2007|February 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||March 2012|March 13, 2012|May 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478322||171049|
NCT00478335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0588|Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus|Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus||University of Colorado, Denver|Yes|Completed|May 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Male|5 Years|25 Years|No|||October 2008|December 19, 2012|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478335||171048|
NCT00478868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-15|Modic Changes and Associated Features in Southern European Chronic Low Back Pain Patients|Modic Changes and Associated Features in Southern European Chronic Low Back Pain Patients|MODIC|Kovacs Foundation|Yes|Completed|May 2008|January 2011|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|487|||Both|35 Years|50 Years|No|Non-Probability Sample|Patients seen for chronic low back pain at the hospitals of the Spanish National Health        Service.|June 2011|June 26, 2011|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478868||171008|
NCT00479154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070160|Botulinum Toxin to Treat Restless Legs Syndrome|Pilot Study of Botulinum Toxin Type A for the Treatment of Restless Legs Syndrome||National Institutes of Health Clinical Center (CC)|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|80 Years|No|||April 2012|April 25, 2012|May 25, 2007||No||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00479154||170987|
NCT00479180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVS-06-003/06-004|Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use|Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use||Pervasis Therapeutics, Inc|Yes|Completed|July 2006|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|65|||Both|18 Years|89 Years|No|||October 2011|October 25, 2011|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479180||170985|
NCT00480064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGMT95-V|Lomustine and Intermediate Dose Cytarabine in Older Patients With AML|Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction Chemotherapy and Adding Intermediate Dose Cytarabine to Consolidation in Older Patients With Acute Myeloid Leukaemia||French Innovative Leukemia Organisation|Yes|Completed|July 1995|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|60 Years|N/A|No|||May 2007|May 29, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00480064||170919|
NCT00480077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061016-V2|Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)|Diagnostic Outcome Trial in Heart Failure|DOT-HF|Medtronic Bakken Research Center|Yes|Terminated|March 2007|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|336|||Both|18 Years|N/A|No|||February 2010|February 5, 2010|May 29, 2007||No|Low enrollment rates|No||https://clinicaltrials.gov/show/NCT00480077||170918|
NCT00479830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0828|Health and Cancer Issues in the South Asian Community|Health and Cancer Issues in the South Asian Community||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2007|||April 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||4|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|South Asian population in the Greater Houston area.|April 2015|April 9, 2015|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479830||170936|
NCT00480129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12885|The Anti-allergic Effects of Specific Probiotics|The Anti-allergic Effects of Specific Probiotics - a Double Blind Clinical Study||Lawson Health Research Institute||Completed|May 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|1||Actual|36|||Both|18 Years|66 Years|No|||August 2015|August 10, 2015|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00480129||170914|
NCT00480376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230105|Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate|Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate||HaEmek Medical Center, Israel|No|Not yet recruiting|June 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Male|21 Years|N/A|No|||May 2007|May 29, 2007|May 29, 2007||||No||https://clinicaltrials.gov/show/NCT00480376||170895|
NCT00480714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB003|A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers|A Study of the Immunogenicity of M. Bovis BCG (SSI Strain), Delivered Intradermally in Healthy Volunteers||University of Oxford|Yes|Completed|March 2003|September 2003|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00480714||170870|
NCT00512057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|apex001 version6|APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X|APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X|APEX|University of Dundee|Yes|Completed|June 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2009|June 25, 2010|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512057||168498|
NCT00512291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0746|Subcutaneous Olanzapine for Hyperactive or Mixed Delirium|Study of Subcutaneous Olanzapine for Hyperactive or Mixed Delirium||M.D. Anderson Cancer Center|No|Completed|June 2005|August 2009|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512291||168480|
NCT00499187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-104-0353|Fanconi Syndrome Due to ARVs in HIV-Infected Persons|A Preliminary Evaluation of Fanconi Syndrome Due to Antiretroviral Therapies in HIV-Infected Persons||Gilead Sciences|No|Completed|September 2007|March 2011|Actual|March 2011|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|56|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|HIV infected subjects with protocol defined Fanconi Syndrome|March 2014|March 14, 2014|July 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499187||169473|
NCT00512590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Menzies-1|Pilot Study: Relaxation and Guided Imagery in Hispanic Persons Diagnosed With Fibromyalgia|Effects of Guided Imagery on Pain, Distress, Functional Status and Self-Efficacy in Hispanics Diagnosed With Fibromyalgia||Florida International University|No|Completed|April 2005|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2007|August 3, 2007|August 3, 2007||||No||https://clinicaltrials.gov/show/NCT00512590||168457|
NCT00512603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD-CVD-1|Association Between Levels of D-Dimer, Fibrinogen and PAI-1 in Elderly Patients With Infection and Occurrence of Cardio- and Cerebro-vascular Disease After Discharge|||Wolfson Medical Center|No|Completed|January 2007|July 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|65 Years|N/A|No|Non-Probability Sample|Elderly patients hospitalized due to infections|May 2007|January 15, 2013|August 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00512603||168456|
NCT00508261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109835|Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine|Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix Hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children||GlaxoSmithKline||Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|793|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||February 2012|November 1, 2012|July 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00508261||168788|
NCT00508274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF109491|Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China|An Open-Label Multicenter Study Administering Lapatinib and Capecitabine in Women With Advanced or MEtastatic Breast Cancer||GlaxoSmithKline|No|Active, not recruiting|July 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|N/A|No|||April 2015|April 13, 2015|July 26, 2007||No||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00508274||168787|
NCT00500006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-009|A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)|A Phase I Dose Escalation of MK0457 in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia||Merck Sharp & Dohme Corp.||Terminated|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00500006||169413|
NCT00500344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4184S|CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography|CAPTAIN: Choroidal Neovascularization Assessment by Pattern Electroretinography After Ranibizumab in Naive Age-Related Macular Degeneration Patients|CAPTAIN|Washington University School of Medicine|Yes|Active, not recruiting|July 2007|March 2009|Anticipated|March 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|N/A|No|||February 2009|February 3, 2009|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00500344||169387|
NCT00478309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000538405|Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants|Gene Environment Risk Assessment and CRC Screening||Fox Chase Cancer Center||Completed|March 2007|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|697|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478309||171050|
NCT00478036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1251|Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells|A Randomized Prospective Double Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells.||University of Colorado, Denver|No|Completed|May 2007|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478036||171070|
NCT00478608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E-102362|Study Evaluating Rapamune® Maintenance Regimen|A Clinical Study to Evaluate the Efficacy and Safety of Cyclosporine (CsA) and Sirolimus (SRL) Induction Followed by Cyclosporine Withdrawal in Korean Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|79|||Both|13 Years|N/A|No|||April 2010|April 22, 2010|May 24, 2007||No||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00478608||171028|
NCT00478881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12392|A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function|Randomized, Double-blind, Placebo-controlled, Parallel Group Study of Vardenafil 10 mg Twice Daily to Assess the Effect on Urodynamics in Patients With Overactive Bladder (Detrusor Overactivity)||Bayer|No|Completed|August 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|May 24, 2007||No||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00478881||171007|635 participants were screened; 238 were not randomized because they did not fulfill the inclusion/exclusion criteria. Cystometric bladder compliance not presented since only relevant to characterization of detrusor overactivity, not to efficacy.
NCT00479167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYM 2005-01|A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma|A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg||Rush University Medical Center|No|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2009|February 4, 2009|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479167||170986|
NCT00478894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070264|Multicenter Orthopaedic Outcomes Network (MOON) ACL Reconstruction (ACLR): Onsite Follow-up|Multicenter Orthopaedic Outcomes Network (MOON) Anterior Cruciate Ligament (ACL) Reconstruction (ACLR): Onsite Follow-up|MOON-Onsite|Vanderbilt University|Yes|Enrolling by invitation|August 2007|December 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|432|||Both|12 Years|45 Years|No|Non-Probability Sample|Participants enrolled in the Multicenter Orthopaedic Outcomes Network cohort by one of        three surgeons and meeting eligibility criteria|December 2015|December 7, 2015|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478894||171006|
NCT00479765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR016-CLN-pro002|A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma|A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma||BTG International Inc.|Yes|Terminated|March 2007|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|70 Years|No|||April 2014|April 17, 2014|May 24, 2007|Yes|Yes|Sponsor business decision, not based on safety or efficacy data|No|April 17, 2014|https://clinicaltrials.gov/show/NCT00479765||170941|
NCT00479778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1121|Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms|An Open Label, Randomized, Multicenter Study To Compare Bazedoxifene Steady-State Exposures Obtained With 2 Bazedoxifene Acetate/Conjugated Estrogen Formulations In Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2007|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||72|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479778||170940|
NCT00479791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01RR000633|Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids|Lipid, Glycemic, and Insulin Responses to Meals Rich in Saturated, Cis-Monounsaturated, and Polyunsaturated Fatty (n-3 and n-6)Acids in Subjects With Type 2 Diabetes Mellitus||University of Texas Southwestern Medical Center|No|Completed|April 1997|June 1999|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|11|||Both|N/A|N/A|No|||May 2007|May 25, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00479791||170939|
NCT00479804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-067M-MA|Non-Invasive Determination of Cardiac Output by Inertgas Rebreathing Method|Non-Invasive Determination of Cardiac Output by the Inertgas Rebreathing Method Compared With Magnetic Resonance Tomography|NICO|Universitätsmedizin Mannheim||Completed|August 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|311|||Both|14 Years|90 Years|Accepts Healthy Volunteers||Consecutive patients with indication for CMR|June 2008|June 4, 2008|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479804||170938|
NCT00480142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kmc070012CTIL|Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy|Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy : Prospective Double Blind, Randomized, Placebo-Controlled Study||Kaplan Medical Center|Yes|Not yet recruiting|July 2007|July 2008||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|80 Years|No|||May 2007|June 5, 2007|April 26, 2007||||No||https://clinicaltrials.gov/show/NCT00480142||170913|
NCT00480155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP154|A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety of A Monovalent Vaccine in Healthy Adults||MedImmune LLC|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2008|December 19, 2008|May 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00480155||170912|
NCT00480116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN016/HBV-002|Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule|Phase III, Single Centre, Double Blind, Randomised Study Evaluating the Consistency of Three Lots of Henogen's New Adjuvanted Hepatitis B Vaccine, When Given at 0, 1 Month Schedule in Healthy Volunteers Aged 18 Years to 40 Years.||Henogen|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|450|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2008|August 22, 2008|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00480116||170915|
NCT00511784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014383|Relative Risks for Non-Fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-Containing Oral Contraceptives.|Postmarketing Study of ORTHO EVRA and Levonorgestrel Oral Contraceptives in Relation to Non-Fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2006|||||Phase 4|Observational|Time Perspective: Retrospective|||||||Female|15 Years|44 Years|Accepts Healthy Volunteers|||October 2007|October 11, 2007|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511784||168519|
NCT00503425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18606|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD and/or Anti-TNF Therapy.|An Open Label Study to Assess the Safety and Effect on Disease Activity of MabThera in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With DMARDs and/or One Anti-TNF Alpha Agent||Hoffmann-La Roche||Completed|June 2005|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|215|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503425||169154|
NCT00503438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.ST01US|Ankle Joint Replacement Outcomes Study|Salto Talaris Anatomic Ankle Arthroplasty Outcomes Study||Tornier, Inc.|No|Active, not recruiting|July 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503438||169153|
NCT00499200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3197A1-1104|Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy|A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|42|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 7, 2008|July 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499200||169472|
NCT00499213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-22|Rates of Hospitalization in Home Care Assisted Peritoneal Dialysis|Home Care Assisted Peritoneal Dialysis: The Impact of Expanding Eligibility for Peritoneal Dialysis on Rates of Hospitalization||Sunnybrook Health Sciences Centre|No|Active, not recruiting|July 2007|July 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A||||July 2007|February 6, 2009|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00499213||169471|
NCT00499434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-14|Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus|Correlation Between Values of Serum Cytokines and of Those Dosed by mRNA Expression Through the Use of Real-time PCR and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus||UPECLIN HC FM Botucatu Unesp|Yes|Active, not recruiting|August 2007|February 2010|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|SAE e Hospital Dia de Aids patients|December 2009|December 3, 2009|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499434||169455|
NCT00499447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000555009|Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase II Study of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Medically Inoperable Non-Small Cell Lung Cancer (Stage Ia and Select Ib) and the Predictive Value of Positron Emission Tomography||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|May 2007|||March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|120 Years|No|||September 2015|September 22, 2015|July 10, 2007|Yes|Yes||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00499447||169454|adverse events were tracked in two cycles, one during treatment and one longer term
NCT00499733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000554417|Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer|Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer||National Cancer Institute (NCI)||Recruiting|June 2007|||July 2010|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|N/A|No|||July 2009|February 24, 2011|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499733||169433|
NCT00500877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1DA017947|Mood Management Phone Counseling in Smoking Cessation|Mood Management Phone Counseling in Smoking Cessation||Butler Hospital|No|Completed|February 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||May 2013|May 1, 2013|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500877||169347|
NCT00501189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDEAMC 07-43X|Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities|Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities||Eisenhower Army Medical Center|No|Enrolling by invitation|August 2007|July 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Female|18 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing colpo for initial low grade Pap abnormality who have elected to under        Gardasil vaccination.|July 2008|August 1, 2008|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501189||169323|
NCT00501410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0842|FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer|Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048)||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2007|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|83|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00501410||169306|
NCT00478023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|731200|A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy|A Randomized, Double-blind, Parallel-arm, Placebo- and Comparator- Controlled Trial of the Efficacy and Safety of Multiple Doses of Immediate-release (IR) CG5503 for Postoperative Pain Following Abdominal Hysterectomy||Grünenthal GmbH|No|Completed|May 2007|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|854|||Female|18 Years|80 Years|No|||December 2013|December 20, 2013|May 23, 2007|Yes|Yes||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00478023||171071|Approval to conduct the trial was obtained in Slovenia. No Slovenian subjects were exposed to study drug.
NCT00478361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0839|Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function|A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency||M.D. Anderson Cancer Center|Yes|Completed|April 2007|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||June 2015|June 19, 2015|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478361||171046|
NCT00478374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFD-12581|Sorafenib With TACE to Treat Hepatocellular Carcinoma|Transarterial Chemoembolisation With Doxorubicin in Combination With Systemic Administration of Sorafenib for Patients With Hepatocellular Carcinoma|S-TACE|University of Bern|No|Completed|May 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2010|November 1, 2010|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478374||171045|
NCT00478348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-2007-CHV-UNIL|Should Prosthetic Repair of Incisional Abdominal Hernias be Drain or Not?|Adequacy of Drainage During Prosthetic Repair of Incisional Abdominal Hernias: a Randomized Controlled Trial.||University of Lausanne Hospitals|Yes|Recruiting|May 2007|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|380|||Both|20 Years|80 Years|No|||December 2014|December 3, 2014|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00478348||171047|
NCT00478621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109836|Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)|A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.||GlaxoSmithKline||Completed|May 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|540|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||April 2011|April 21, 2011|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478621||171027|
NCT00478634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2242|A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer|An Open-label, Multicenter Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patient With Metastatic Colorectal Adenocarcinoma||Novartis||Completed|May 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|No|||November 2012|November 1, 2012|May 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00478634||171026|
NCT00479219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3183A1-103|Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients|A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 9, 2008|May 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479219||170982|
NCT00479479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16941|Cobalamin Supplementation During Infancy; Effect on B-vitamin Status, Growth and Psychomotor Development|Cobalamin Supplementation During Infancy; Effect on B-vitamin Status, Growth and Psychomotor Development||Haukeland University Hospital|No|Completed|December 2004|December 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|107|||Both|N/A|4 Months|Accepts Healthy Volunteers|||July 2015|July 20, 2015|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479479||170962|
NCT00479492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5051019|Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers|A 12-Week, Randomized, Subject And Investigator Blind, Placebo-Controlled Trial To Evaluate The Effect Of CP-866,087 On Weight Loss In Obese, Otherwise Healthy Adult Subjects||Pfizer|No|Completed|June 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|94|||Both|18 Years|65 Years|No|||October 2008|September 29, 2009|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479492||170961|
NCT00479505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3711047|Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder|A Multi-Center, Randomised, Parallel Group, Double-Blind, Placebo Controlled Estimation Study To Assess The Efficacy And Safety Of Modified Release UK-369,003 In The Treatment Of Men With Storage Lower Urinary Tract Symptoms (LUTS) With And Without Erectile Dysfunction (ED).||Pfizer|No|Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|275|||Male|18 Years|N/A|No|||March 2011|March 11, 2011|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479505||170960|
NCT00479817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060342|Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer|A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer||Amgen|No|Active, not recruiting|July 2007|March 2016|Anticipated|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|161|||Female|18 Years|99 Years|No|||January 2016|January 29, 2016|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479817||170937|
NCT00511108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-061|Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)|A Phase I Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Study the Safety, Efficacy, and Mechanism of Action of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet and Exercise||Merck Sharp & Dohme Corp.||Completed|July 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|211|||Both|30 Years|65 Years|No|||June 2015|June 8, 2015|August 2, 2007|No|Yes||No|January 8, 2010|https://clinicaltrials.gov/show/NCT00511108||168571|
NCT00511459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060341|Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients|A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer||Amgen|No|Completed|July 2007|May 2014|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|228|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|August 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511459||168544|
NCT00480402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-VS-0405-507-23|Natural Progesterone and Preterm Birth in Twins|Eficacia de Los Suplementos de Progesterona Natural en la prevención Del Parto pretérmino Gemelar||Instituto Valenciano de Infertilidad, IVI VALENCIA|Yes|Completed|January 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|290|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 3, 2013|May 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00480402||170893|
NCT00511485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-008|Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)|Protocol EC-FV-03: A Phase II Study of EC145 in Patients With Progressive Adenocarcinoma of the Lung||Endocyte|No|Completed|August 2007|November 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|August 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511485||168542|
NCT00511797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91615|SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study|A Multicenter, Double-blind, Randomized, Placebo-controlled Comparative Study to Investigate the Optimal Dose of Drospirenone for Dysmenorrhea With SH T04740A [Drospirenone 1 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)], SH T 04740E [Drospirenone 2 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] and SH T00186D [Drospirenone 3 mg/ Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] Administered Orally for 16 Weeks (4 Cycles), and to Confirm the Efficacy of SH T00186D for Dysmenorrhea.||Bayer|No|Completed|July 2007|January 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|249|||Female|20 Years|N/A|No|||December 2013|December 25, 2013|August 3, 2007||No||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00511797||168518|
NCT00499239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-193-0101|A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)|Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma||Gilead Sciences|Yes|Terminated|July 2007|October 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|July 9, 2007|Yes|Yes|Unacceptable safety profile|No||https://clinicaltrials.gov/show/NCT00499239||169470|
NCT00499746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18125-3|The Discriminative Effects of Tramadol in Humans|Medications Development for Drug Abuse Disorders||National Institute on Drug Abuse (NIDA)|No|Completed|November 2007|August 2011|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Both|21 Months|55 Years|No|||April 2012|April 21, 2012|July 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499746||169432|
NCT00500019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Bornstein|Uterine Flora During Elective and Urgent Cesarean Sections|Uterine Flora During Elective and Urgent Cesarean Sections and Its Relationship to Postpartum Complications.||Western Galilee Hospital-Nahariya|Yes|Completed|January 2005|September 2008|Actual|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|600|Samples Without DNA|Uterine bacteriological cultures|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing cesarean sections in Western galilee Hospital|March 2009|March 30, 2009|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500019||169412|
NCT00500357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3009|Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects|A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine Administered to One Group of Individuals Who Participated in Study 6115A1-500||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2007|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|105|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 15, 2011|July 10, 2007|Yes|Yes||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00500357||169386|
NCT00500604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBEH_R_02584|Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension|A Comparative Study of the Efficacy of Irbesartan/Hydrochlorothiazide 300/25 mg Versus Valsartan/Hydrochlorothiazide 160/25 mg Using Home Blood Pressure Monitoring in the Treatment of Mild to Moderate Hypertension|COSIMA2|Sanofi|No|Completed|July 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1617|||Both|18 Years|80 Years|No|||July 2010|July 16, 2010|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500604||169367|
NCT00500617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDx_000004|Personalized Risk Evaluation and Diagnosis In the Coronary Tree|Identification of Gene Expression Patterns in Circulating Cells That Predict the Presence of Coronary Artery Disease|PREDICT|CardioDx|No|Terminated|July 2007|September 2011|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|4350|Samples With DNA|whole blood, buffy coat, spun plasma, rna|Both|21 Years|N/A|No|Probability Sample|Patients undergoing clinically indicated invasive coronary artery angiogram or CT        angiogram.|November 2014|November 25, 2014|July 11, 2007||No|Primary endpoint reached. Discovery, development and validationcohorts completed and analyzed|No||https://clinicaltrials.gov/show/NCT00500617||169366|
NCT00477386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704-07 IUCRO-0185|Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer|Phase I/II Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer||Indiana University|Yes|Completed|July 2007|September 2013|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||September 2014|September 19, 2014|May 21, 2007|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00477386||171118|
NCT00477724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHA/CTEPH|Latent Pulmonary Hypertension (PH) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH )After Endarterectomy and Influence of Exercise and Respiratory Therapy|Incidence of Latent Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Hypertension After Endarterectomy and Influence of Exercise and Respiratory Therapy||Heidelberg University||Recruiting|June 2007|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|75 Years|No|||July 2014|July 1, 2014|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477724||171094|
NCT00478049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00039|Iressa as Second Line Therapy in Advanced NSCLC-Asia|A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously Received Platinum Based Chemotherapy (ISTANA)|ISTANA|AstraZeneca||Completed|September 2005|February 2009|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478049||171069|
NCT00478387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805443|Ovarian Cancer and Immune Response to Flu Vaccine|Study of the Immunogenicity of Killed Influenza Vaccine in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Remission||University of Pennsylvania|Yes|Recruiting||||||N/A|Observational|Time Perspective: Prospective|||||||Female|18 Years|N/A||||January 2008|January 15, 2008|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00478387||171044|
NCT00478647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKT034|Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase|A Multicenter Open-Label Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase||Shire|No|Completed|July 2007|August 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|2 Years|N/A|No|||February 2014|March 19, 2015|May 23, 2007|Yes|Yes||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00478647||171025|
NCT00478660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-760|An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)|Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis - An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)|RHAPSODY|Abbott||Completed|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1250|||Both|18 Years|N/A|No|||October 2007|October 4, 2007|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00478660||171024|
NCT00478907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82390|Prevention of Complications of Eye Surgery|phase2 Study of Prevention of Complications of Strabismus Surgery|ocr|Isfahan University of Medical Sciences|No|Completed|March 2004|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|300|||Both|2 Years|18 Years|No|||May 2007|May 24, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00478907||171005|
NCT00479232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-055|Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)|A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome||Merck Sharp & Dohme Corp.||Completed|June 2007|March 2012|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|May 24, 2007|No|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00479232||170981|
NCT00479193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigator Initiated Trial|Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds|Prospective Randomized Trial of Polymem vs. Bacitracin/Xeroform for Superficial Second Degree Burns||MetroHealth Medical Center|No|Recruiting|October 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2008|January 24, 2008|May 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479193||170984|
NCT00479206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR #1296|Artemisinin Resistance in Cambodia|Artemisinin Resistance in Cambodia||Medical University of Vienna|No|Completed|October 2006|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|65 Years|No|||April 2008|April 29, 2008|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479206||170983|
NCT00479843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.19.CLI|Nutritional Programme for Dementia Elderly Patient|Development of a Programme to Show the Positive Effect of a Nutritional Programme on Preventing Functional and Weight Losses in Patients With Dementia||Nestlé|No|Completed|July 2005|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|946|||Both|50 Years|N/A|No|||January 2014|January 23, 2014|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479843||170935|
NCT00510835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50GM076659|Protocolized Care for Early Septic Shock|Protocolized Care for Early Septic Shock|ProCESS|University of Pittsburgh|Yes|Active, not recruiting|March 2008|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1351|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00510835||168592|
NCT00480428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907151|Radiation Exposure and Thyroid Disease in Kazakhstan|Study to Improve Thyroid Doses From Fallout Exposure in Kazakhstan||National Institutes of Health Clinical Center (CC)||Completed|May 2007|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|128|||Both|65 Years|90 Years|No|||August 2015|September 18, 2015|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480428||170892|
NCT00512343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-12 LS|Synovial Fluid Bank From Arthritic Patients|Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.||Université de Sherbrooke|Yes|Recruiting|June 2002|September 2029|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Synovial fluids from joints with effusion Sereum samples drawn on the same day|Both|3 Years|95 Years|No|Non-Probability Sample|patients suffering from various arthritides (rheumatoid arthritis, gout and other        microcristalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic        arthritis, and various other diseases, including inflammatory polyarthritis of        recent-onset in adults|August 2015|August 12, 2015|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00512343||168476|
NCT00499759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0526|Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia|In-Hospital Individualized Prescriptive Exercise Intervention for Acute Leukemia Patients Undergoing Chemotherapy||UNC Lineberger Comprehensive Cancer Center|No|Completed|February 2006|August 2009|Actual|January 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|60 Years|No|||March 2012|March 5, 2012|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499759||169431|
NCT00500032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-1000|Blood Collection for Use in Serological Assay Development From Healthy Adult Volunteers|Blood Collection for Use in Serological Assay Development From Healthy Adult Volunteers Who Completed Study 6108A1-500||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|87|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2009|September 15, 2009|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500032||169411|
NCT00500370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWBP|A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients|A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients||AstraZeneca|No|Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|July 10, 2007|Yes|Yes||No|February 26, 2009|https://clinicaltrials.gov/show/NCT00500370||169385|
NCT00501475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2006-084|NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED|||Seoul National University Hospital|No|Recruiting|March 2007|October 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||||||Both|15 Years|N/A||||July 2010|July 23, 2010|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501475||169302|
NCT00477412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0697|Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma|Phase I Study of Bortezomib (Velcade) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2007|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|79 Years|No|||August 2015|August 13, 2015|May 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477412||171116|
NCT00477737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARPRO10|Early Cardioprotective Effect of Sevoflurane|Early Cardioprotective Effect of Sevoflurane on Left Ventricular Performance During Coronary Artery Bypass Grafting on a Beating Heart||University Hospital Dubrava|No|Completed|August 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|32|||Both|40 Years|75 Years|No|||May 2007|May 23, 2007|May 22, 2007||||No||https://clinicaltrials.gov/show/NCT00477737||171093|
NCT00478062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06143 CDR0000544408|Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma|KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma||Sidney Kimmel Comprehensive Cancer Center|No|Terminated|April 2007|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|May 23, 2007|Yes|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00478062||171068|
NCT00478075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546736|Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Study of 153 Sm EDTMP (Quadramet™) and PS-341 (Velcade®) in Patients With Relapsed or Refractory Multiple Myeloma||Mayo Clinic||Completed|September 2005|June 2009|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00478075||171067|
NCT00509366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004599|Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer|Phase II Prospective Study Evaluating the Role of Personalized Chemotherapy Regimens for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy|TOP0602|Duke University|Yes|Terminated|May 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|101|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|July 30, 2007|Yes|Yes|Study terminated due to reproducibility issues with genomics prediction model.|No|May 7, 2014|https://clinicaltrials.gov/show/NCT00509366||168703|The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.
NCT00478673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2042|Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA|The NexStent® Carotid Stent System: A Post Market Approval Evaluation Study In Conjunction With the FilterWire EZ™ Embolic Protection System|SONOMA|Boston Scientific Corporation|No|Terminated|May 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|298|||Both|18 Years|N/A|No|||July 2012|July 2, 2012|May 24, 2007|No|Yes|Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent    System.|No|December 20, 2010|https://clinicaltrials.gov/show/NCT00478673||171023|Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent System. The early termination of enrollment led to a smaller than expected number of analyzable subjects (298 actual vs. 1500 anticipated).
NCT00478933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISCOVERY|DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.|Diagnostic Data Influence on Disease Management and Relation of Genetic Polymorphisms to Tachy-arrhythmia in ICD Patients.|DISCOVERY|Medtronic Bakken Research Center|No|Completed|February 2007|December 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|1223|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478933||171004|
NCT00479518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI06-IB Cohorte ABC-AVC|Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack|Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack :Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke|ABC-AVC|University Hospital, Tours|No|Recruiting|March 2007|March 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patient with Ischemic stroke or TIA|April 2009|April 9, 2009|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479518||170959|
NCT00479856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF108916|Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer|An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.||GlaxoSmithKline||Terminated|November 2007|March 2010|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||June 2011|May 31, 2012|May 25, 2007|Yes|Yes|Study was terminated due to difficulty in identifying eligible subjects|No|May 3, 2010|https://clinicaltrials.gov/show/NCT00479856||170934|
NCT00479882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524B-063|MK0524B Lipid Study (0524B-063)|A Multicenter, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia||Merck Sharp & Dohme Corp.||Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|2370|||Both|18 Years|85 Years|No|||October 2014|October 16, 2014|May 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479882||170933|
NCT00511498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001428|Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy|Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Nerve-Sparing Laparoscopic Radical Prostatectomy||Johns Hopkins University|Yes|Completed|March 2006|October 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|100|||Male|18 Years|64 Years|No|||November 2008|November 28, 2008|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00511498||168541|
NCT00511823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV110483|The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects|An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|July 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|August 2, 2007||||||https://clinicaltrials.gov/show/NCT00511823||168516|
NCT00511472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-006|An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)|A Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK-0941 Before Each Meal (q.a.c) in Subjects With Type 2 Diabetes Being Treated With Basal Insulin||Merck Sharp & Dohme Corp.||Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|70 Years|No|||June 2015|June 19, 2015|August 2, 2007|No|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00511472||168543|
NCT00511771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHTF919A2433|A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation|A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation||Novartis||No longer available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|54 Years||||November 2010|November 16, 2010|August 3, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00511771||168520|
NCT00499460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2040.00|Effect of Garlic Supplements on Opioids in Healthy Volunteers|Modulation of Opioid Effects by Garlic Supplements||Fred Hutchinson Cancer Research Center|No|Completed|November 2006|September 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 30, 2012|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499460||169453|
NCT00499473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00215|Sunitinib in Treating Patients With Recurrent Malignant Gliomas|A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas||National Cancer Institute (NCI)||Completed|June 2007|October 2014|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 10, 2007|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT00499473||169452|
NCT00499486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0415, CDR0000549899|Sirolimus in Treating Patients With Advanced Pancreatic Cancer|Phase II Clinical, Biological and Pharmacological Study of Rapamycin (Rapamune®, Sirolimus) in Patients With Advanced Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center||Completed|January 2005|||||Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|July 10, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00499486||169451|
NCT00500630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO 22/04|Objective Evaluation of Shoulder Pathology and Surgery|||University of Lausanne Hospitals||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||July 2007|July 12, 2007|July 12, 2007||||No||https://clinicaltrials.gov/show/NCT00500630||169365|
NCT00501488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhao-Qian Liu|Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response|||Central South University|Yes|Completed|March 2006|February 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|42|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||July 2007|July 19, 2007|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501488||169301|
NCT00500903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14001|A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors|An Open-Label, Dose Escalation Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.|No|Completed|May 2007|November 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|July 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00500903||169345|
NCT00501215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0220|Effect of Parathyroidectomy on Sleep|Pilot Study on the Effect of Parathyroidectomy on Sleep||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2007|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|21 Years|N/A|No|||February 2016|February 1, 2016|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501215||169321|
NCT00501462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2105253|A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function|An Evaluation of the Pharmacokinetics of a Single Oral Dose of GSK189075 in Patients With Varying Degrees of Renal Insufficiency Compared to Volunteers With Normal Renal Function||GlaxoSmithKline|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2011|March 15, 2012|July 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00501462||169303|
NCT00510003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CES02|Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old|A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis||Novartis||Completed|December 2004|||January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|117|||Both|2 Years|12 Years||||November 2011|November 1, 2011|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00510003||168656|
NCT00477750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546642|Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma|Phase I/II Trial of Melphalan, Prednisone Plus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Stem Cell Transplant||Mayo Clinic||Active, not recruiting|June 2005|December 2016|Anticipated|April 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|May 23, 2007|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT00477750||171092|
NCT00477763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5300|Oasys vs. Extreme H20 Xtra 59|Oasys vs. Extreme H20 Xtra 59||Innovative Medical||Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|52|||Both|19 Years|N/A|No|||February 2008|February 13, 2008|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00477763||171091|
NCT00477789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802|Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients|Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients||Universita di Verona|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||May 2007|May 23, 2007|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00477789||171089|
NCT00509093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4906|Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy|A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia||Case Comprehensive Cancer Center|Yes|Active, not recruiting|December 2008|||April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509093||168724|
NCT00509392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVL-06-03|ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.|Radiofrequency Endovenous ClosureFAST vs. Laser Ablation for the Treatment of Great Saphenous Reflux: A Multicenter, Single-Blinded, Randomized Study (RECOVERY)|RECOVERY|VNUS Medical Technologies, A Covidien Company|No|Completed|March 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|80 Years|No|||December 2009|December 11, 2009|July 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509392||168701|
NCT00509652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD13903|Erythrocyte Apheresis Versus Phlebotomy in Hemochromatosis|Therapeutic Effect of Erythrocyte Apheresis as Compared to Full Blood Phlebotomy in Patients With Hereditary Hemochromatosis||University of Bergen|No|Recruiting|January 2006|December 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|67|||Both|18 Years|70 Years|No|||July 2007|July 27, 2007|July 27, 2007||||No||https://clinicaltrials.gov/show/NCT00509652||168682|
NCT00510276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10803|Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes|A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes||Eli Lilly and Company|No|Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|445|||Both|18 Years|30 Years|No|||April 2010|April 7, 2010|July 30, 2007|Yes|Yes||No|January 27, 2010|https://clinicaltrials.gov/show/NCT00510276||168635|
NCT00510289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008151|Sorafenib in Myelodysplastic Syndrome|Phase II Trial of Sorafenib in Patients With Myelodysplastic Syndrome||Duke University|Yes|Terminated|July 2006|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2013|December 20, 2013|July 30, 2007|Yes|Yes|Early closure of study due to poor response|No|October 30, 2013|https://clinicaltrials.gov/show/NCT00510289||168634|The limitations of our study include the small sample size, the poor toxicity profile and the lack of response.
NCT00510224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF055514|Sandostatin for Patients With Androgen Independent Prostate Cancer|A Phase II Study of the Somatostatin Analog Sandostatin LAR in Patients With Androgen Independent Prostate Cancer||University of California, San Francisco|Yes|Terminated|July 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|N/A|N/A|No|||October 2013|October 17, 2013|July 30, 2007|Yes|Yes|Stopped at interim analyses phase due to lack of efficacy|No|October 17, 2013|https://clinicaltrials.gov/show/NCT00510224||168639|
NCT00510237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 068|Intervention for Newly Diagnosed Youth With HIV|Intervention Development for Newly Diagnosed Youth With HIV||Westat|Yes|Completed|February 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|16 Years|24 Years|No|||February 2016|February 29, 2016|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510237||168638|
NCT00510510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2206|Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|August 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|281|||Both|40 Years|N/A|No|||May 2012|May 14, 2012|August 1, 2007|Yes|Yes||No|December 23, 2010|https://clinicaltrials.gov/show/NCT00510510||168617|
NCT00479531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-17018|Sequential Compression Devices for Treatment of Restless Legs Syndrome|Sequential Compression Devices for Treatment of Restless Legs Syndrome - a Prospective, Randomized, Sham-Controlled Study||Walter Reed Army Medical Center|Yes|Completed|September 2005|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2007|November 29, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479531||170958|
NCT00510822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX-01|Cimicoxib for the Treatment of Major Depression (SECIM)|Safety and Efficacy of Cimicoxib, a Selective COX-2 Inhibitor, in Combination With Sertraline Compared to Sertraline Combined With Placebo in Treatment of Major Depression||Affectis Pharmaceuticals AG|No|Completed|October 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|60 Years|No|||November 2013|November 12, 2013|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510822||168593|
NCT00508352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006277-01H|Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer|Post-operative Locoregional Irradiation Using Helical Tomotherapy IMRT in the Management of Stage IIb-III Breast Cancer: a Feasibility Study||Ottawa Hospital Research Institute|No|Completed|January 2007|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||May 2013|May 31, 2013|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508352||168781|
NCT00511121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML 011|Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)|An Exploratory Phase II Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) in the Treatment of Chronic Myeloid Leukemia in Chronic Phase||University of Bologna|Yes|Terminated|April 2001|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||5|||Both|18 Years|65 Years|No|||August 2007|August 2, 2007|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511121||168570|
NCT00508586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC299-ONC-003-BRC|PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer|A Phase 1b Study to Assess the Safety, Feasibility, Pharmacokinetics, and Activity of PTC299 Monotherapy or Combination Therapy With Hormonal Agents in Patients With Metastatic Breast Cancer||PTC Therapeutics|No|Completed|November 2007|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||April 2012|March 1, 2016|July 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00508586||168763|
NCT00479310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02-2005|Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice|A Multi-Center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice.||Summers Laboratories||Completed|January 2006|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||120|||Both|6 Months|N/A|No|||May 2007|May 25, 2007|May 25, 2007||||||https://clinicaltrials.gov/show/NCT00479310||170975|
NCT00500045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAMF 08-51|Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions|"Retrospective Study of Niacin (as a Vasodilator), Combined With a Topical Steroid (for Macular Edema), For CRVO, HRVO, BRVO."||Palo Alto Medical Foundation|No|Active, not recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500045||169410|
NCT00501501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5|The Association Between Delivery Method and Maternal Rehospitalization|The Association Between Delivery Method and Maternal Rehospitalization||Western Galilee Hospital-Nahariya|No|Completed|January 1999|December 2000|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|92|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2007|July 13, 2007|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501501||169300|
NCT00509470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2007008|Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine|ONgoing Evaluation of Depressor Effect And Safety of Combination Therapy With Telmisartan and Low-Dose Hydrochlorothiazide in Patients With Hypertension Uncontrolled on Amlodipine Treatment|ONEAST|Tokyo University|No|Recruiting|July 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|40 Years|80 Years|No|||July 2007|July 28, 2007|July 28, 2007||||No||https://clinicaltrials.gov/show/NCT00509470||168695|
NCT00510939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMOS AML 0106|Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia|Phase II, Open-Label, Multi-centre, 2-part Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Conventional Chemotherapy ( >18 Years) or in Patients With Acute Myeloid Leukemia in First Relapse ( >60 Years)|HEMOS AML 0106|University of Bologna|Yes|Recruiting|March 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||August 2009|August 13, 2009|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00510939||168584|
NCT00477776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG SIG 06022|Maxolon to Improve Breastmilk Supply in Diabetic Women: a Randomised Controlled Trial|Metoclopramide to Improve Lactogenesis II in Diabetic Women: a Randomized Controlled Trial|Maxalon|National University Hospital, Singapore|Yes|Completed|April 2006|March 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00477776||171090|
NCT00509379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIL06|Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma|A Phase II Multicenter Non-randomized Study to Assess Safety, Toxicity and Clinical Activity of the Association of Bortezomib(VELCADE)With Rituximab in Relapsed/Refractory Indolent Non Follicular and Mantle-cell Non-Hodgkin Lymphoma|LYM-2023|Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie|Yes|Completed|September 2006|January 2011|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||July 2009|January 27, 2011|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509379||168702|
NCT00509106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-09|Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia|CAP|Forest Laboratories|No|Completed|July 2007|June 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|622|||Both|18 Years|N/A|No|||November 2010|November 9, 2010|July 27, 2007|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00509106||168723|
NCT00509405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316/06|Effect of Neutralization of Endogenous Acid Production on BMD and Bone Microarchitectural|Effect of Neutralization of Endogenous Acid Production on Bone Mineral Density and Microarchitectural Composition of Bone in Humans||Kantonsspital Baselland Bruderholz|No|Completed|July 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|202|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509405||168700|
NCT00509665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558049|Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer|A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer||Medical University of South Carolina|Yes|Completed|June 2005|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509665||168681|
NCT00511511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2007-155|Angiogenesis Inhibitors and Hypertension: Clinical Aspects|Angiogenesis Inhibitors and Hypertension: Clinical Aspects||Erasmus Medical Center|No|Completed|August 2007|December 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Blood and urine samples|Both|18 Years|N/A|No|Probability Sample|Men and women, with either renal cell carcinoma or gastro intestinal stromal tumors (GIST)        intended to be treated solely with Sunitinib (single-agent treatment) and who are        considered fit enough by their treating physician to receive Sunitinib|July 2009|January 4, 2010|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00511511||168540|
NCT00511524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBA103679|An Imaging Study to Investigate the Distribution of GW842166X in the Brain.|An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [11C]GW842166 in Healthy Subjects||GlaxoSmithKline|No|Completed|June 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Male|50 Years|80 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511524||168539|
NCT00510523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0731060030|Whole Body Vibration Therapy in Participants With MS Related Balance Deficits|Whole Body Vibration Therapy in Participants With MS Related Balance Deficits||Logan College of Chiropractic||Completed|October 2006|November 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|25 Years|65 Years|No|||May 2013|May 2, 2013|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510523||168616|
NCT00510536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-104|Treatment of Mild to Moderate Joint Pain in Patients With Chronic Plaque Psoriasis Receiving Efalizumab|A Phase 4 Study to Assess the Practical Management of Mild to Moderate Arthritic or Arthralgic Events in Patients With Chronic Plaque Psoriasis Receiving Efalizumab||Probity Medical Research|No|Completed|July 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2009|April 8, 2009|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510536||168615|
NCT00510549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SurvivalHD/PDFinal 28/03/2007|Comparison of the Impact of Dialysis Treatment Type on Patient Survival|A Prospective, Randomized, Multicenter, Open Label, Interventional Pilot Study To Compare Mortality, Morbidity and QOL in Hemodialysis Versus Peritoneal Dialysis Subjects||Baxter Healthcare Corporation|No|Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00510549||168614|
NCT00478751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4502|Impact of Long Wavelength Ultraviolet (UVA) and Visible Light on Melanocompetent Skin|Impact of Long Wavelength UVA and Visible Light on Melanocompetent Skin||Henry Ford Health System|No|Completed|May 2007|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy volunteer with Fitzpatrick Skin phototypes IV-VI.|January 2009|January 28, 2009|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478751||171017|
NCT00512096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID99-194|Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis|A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis||M.D. Anderson Cancer Center|No|Completed|August 1999|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|14 Years|N/A|No|||July 2012|July 27, 2012|August 6, 2007||No||No|November 3, 2010|https://clinicaltrials.gov/show/NCT00512096||168495|
NCT00479648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-IIV-06-27|A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants|A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 Years) and Older Adults (≥ 60 Years)||CSL Limited||Completed|May 2007|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|612|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 6, 2008|May 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479648||170950|
NCT00509730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL14625.091.06|Value of Urodynamics Prior to Stress Incontinence Surgery|Multicentered Randomized Controlled Trail to Test the Cost Effectiveness of Urodynamics in Women With Symptoms of Stress Urinary Incontinence in Whom Surgical Treatment is Considered|VUSIS|Radboud University|Yes|Terminated|March 2007|March 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|290|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2008|October 6, 2009|July 30, 2007||||No||https://clinicaltrials.gov/show/NCT00509730||168676|
NCT00500916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UN2532|Different Techniques for Insertion of the ProSeal Laryngeal Mask Airway in Patients With Difficult Airway|Different Techniques for Insertion of the ProSeal Laryngeal Mask Airway in Patients With Difficult Airway||Medical University Innsbruck|No|Completed|March 2007|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|0|||Female|19 Years|70 Years|No|||December 2007|December 3, 2007|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500916||169344|
NCT00500929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMI X-11S-G-1|A Clinical Trial in Higher Risk Geriatric Patients Undergoing OHSP|Mini-Metrxics: A Single-Centre, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Clinical Trial of CMI X-11S in Higher Risk Geriatric Patients Undergoing Open-Heart Surgical Procedures (OHSP)|MiniMetrxics|Cardiometabolics|Yes|Completed|July 2007|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|80|||Both|70 Years|N/A|No|||March 2009|March 23, 2009|July 12, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00500929||169343|
NCT00509171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-6-30-MAR-07|Effect of a Novel Reamer-Irrigator-Aspirator on the Incidence of Fat Embolism|A Prospective Randomized Trial Investigating the Effect of a Novel Reamer-Irrigator-Aspirator on the Incidence of Fat Embolism and Respiratory Function During Intramedullary Nailing of Femoral Shaft Fractures|RIA|St. Michael's Hospital, Toronto|No|Completed|January 2005|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509171||168718|
NCT00501787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2006d|Metformin Administration in Infertile Anovulatory PCOS Patients|Tailored Versus Non-tailored Metformin Protocol for Ovulation Induction in Infertile Anovulatory PCOS Patients. A Randomized Controlled Clinical Study||University Magna Graecia||Withdrawn|January 2008|||October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|35 Years||||April 2013|April 5, 2013|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501787||169278|
NCT00510952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11813|Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)|The PERSISTENT Trial: A Prospective Randomized Trial Comparing Insulin Lispro Protamine Suspension to Insulin Glargine in Patients With Type 2 Diabetes on Anti-hyperglycemic Medications|IOPE|Eli Lilly and Company|No|Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|471|||Both|18 Years|N/A|No|||October 2010|October 12, 2010|August 1, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00510952||168583|
NCT00511290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-LF-07316-CTIL|Measurement of Soluble Factors and Particulate Matter in Induced Sputum and EBC in Inflammatory Diseases of the Lung|||Tel-Aviv Sourasky Medical Center|No|Completed||||||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|7 Years|80 Years|Accepts Healthy Volunteers|||August 2007|August 2, 2007|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511290||168557|
NCT00508807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0984|RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies|Clinical Study Protocol RTA 402-C-0501: A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDO-Me) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|April 2006|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|July 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00508807||168746|
NCT00509080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAMIR|Prognosis in Asymptomatic Mitral Regurgitation (PAMIR) Study|Prognosis in Asymptomatic Mitral Regurgitation (PAMIR) Study||University Hospital, Basel, Switzerland|Yes|Active, not recruiting|April 2006|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the participating centers|July 2015|July 8, 2015|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509080||168725|
NCT00509119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-engum|ICP Waveform Analysis in Stroke Patients|Retrospective ICP Waveform Analysis in Stroke Patients Followed Prospectively||Oslo University Hospital|No|Withdrawn|December 2006|December 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Acute ICH|October 2010|April 24, 2015|July 30, 2007||No|Change of workplace for leading investigator, not replaced|No||https://clinicaltrials.gov/show/NCT00509119||168722|
NCT00510588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0815-2007|Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease||KFO|University of Leipzig||Completed|July 2007|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|120|||Male|35 Years|75 Years|No|||December 2014|December 2, 2014|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510588||168611|
NCT00510874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110028|Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults|A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant||GlaxoSmithKline||Completed|July 2007|October 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|780|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|August 1, 2007|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00510874||168589|
NCT00510887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008487|Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma|A Phase II Study of Bortezomib in Combination With Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (VR-FND) for Relapsed or Refractory Follicular Lymphoma||Duke University|No|Terminated|January 2007|September 2013|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|August 1, 2007|Yes|Yes|Low accrual.|No|December 18, 2013|https://clinicaltrials.gov/show/NCT00510887||168588|
NCT00509678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3081n|Rituxan With or Without Methotrexate in Psoriatic Arthritis|Phase IB, Investigator-Initiated, Open-Label, Multi-Center Trial of Rituximab With or Without Methotrexate In Subjects With Psoriatic Arthritis and Psoriasis||Swedish Medical Center|Yes|Completed|December 2006|March 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|80 Years|No|||January 2012|January 16, 2012|July 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509678||168680|
NCT00509964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-GI-71|Second-Line Irinotecan vs. ILF for AGC|A Randomized Phase II Trial of Irinotecan Monotherapy Versus Irinotecan, Leucovorin and 5-FU (ILF) Combination Chemotherapy in Patients With Advanced Gastric Cancer Failing Prior Chemotherapy||Gachon University Gil Medical Center|No|Recruiting|May 2007|July 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||July 2007|July 31, 2007|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00509964||168659|
NCT00477555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-CS-14075|Hemodynamic Assessment of Mosaic Ultra Stented Heart Valve in the Aortic Position|Mosaic Ultra Porcine Bioprosthesis - Hemodynamic Study||Medtronic Cardiovascular|No|Completed|April 2006|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are eligible for an aortic valve replacement can be enrolled in the study.|October 2015|October 28, 2015|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00477555||171106|
NCT00477568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-14|Back Pain Prevalence in Wheelchair Users and Associated Risk Factors|Back Pain Prevalence in Wheelchair Users and Associated Risk Factors||Kovacs Foundation|Yes|Recruiting|November 2007|September 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Wheelchair users who do so on a constant basis (not occasional).|March 2015|March 31, 2015|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477568||171105|
NCT00509938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP 02-01|Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients|Safety and Efficacy of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients Part A: Clinical Study Protocol SC12: Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients||AM-Pharma|Yes|Completed|March 2006|November 2006|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|80 Years|No|||October 2008|October 16, 2008|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00509938||168661|
NCT00509951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074777|Parent-Augmented Cognitive Behavioral Therapy to Treat Children With Specific Phobias|Augmented Treatment of Specific Phobias in Children||Virginia Polytechnic Institute and State University|No|Completed|July 2007|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|7 Years|14 Years|No|||June 2013|June 6, 2013|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509951||168660|
NCT00510250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDPDRO-002|A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer|A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer||University Health Network, Toronto|Yes|Completed|June 2007|July 2015|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||July 2015|July 24, 2015|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510250||168637|
NCT00510263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151:1828/99|Scandinavian Bell's Palsy Study|A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy|SBPS|Uppsala University Hospital|Yes|Completed|May 2001|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|839|||Both|18 Years|75 Years|No|||June 2008|June 3, 2008|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00510263||168636|
NCT00511134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609001866|Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban|A Placebo-Controlled, Randomized Trial of Eszopiclone for the Treatment of Bupropion- and Abstinence-Related Insomnia During Smoking Cessation||Yale University|No|Terminated|April 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|August 1, 2007|Yes|Yes|Study has been terminated due low recruitment of participant population.|No|September 28, 2009|https://clinicaltrials.gov/show/NCT00511134||168569|
NCT00511147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG0601|IGIV Study for Chronic ITP Patients Ages 3-70|A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura||Grifols Biologicals Inc.|No|Completed|February 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|3 Years|70 Years|No|||February 2016|February 17, 2016|August 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511147||168568|
NCT00479050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001HCC|Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm|Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm|TACE-RFA|Shandong University|Yes|Completed|January 2001|December 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|291|||Both|45 Years|75 Years|No|||May 2007|May 24, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00479050||170995|
NCT00479024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP112|Follow-up Study to Previous CARE Trial|CARE (Visipaque 320 and Isovue 370 in Cardiac Angiography in REnally Impaired Patients); FOLLOW-UP STUDY||Bracco Diagnostics, Inc|No|Completed|June 2007|April 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|294|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|September 2009|September 29, 2009|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00479024||170997|
NCT00479037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-006-IM|Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)|A 24-week, International, Multi Centre, Randomised, Open Label, Parallel Group, Phase IV Clinical Trial Investigating Changes in Bone Formation Markers in Postmenopausal Women With Primary Osteoporosis Treated With Either PTH(1-84) or Strontium Ranelate||Nycomed|Yes|Completed|April 2007|July 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Female|50 Years|N/A|No|||May 2012|May 4, 2012|May 23, 2007||No||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00479037||170996|A limitation of the trial was the open label design, however this is not considered to affect the primary or secondary outcome of the trial.
NCT00510016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA016288-01A1|Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome|Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial|NAS|National Institute on Drug Abuse (NIDA)|Yes|Completed|July 2002|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|14 Days|No|||July 2007|July 31, 2007|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00510016||168655|
NCT00508859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0831997|Maintenance Study for Adolescent Depression||MTAD|Sunnybrook Health Sciences Centre|No|Completed|July 1997|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|93|||Both|13 Years|19 Years|No|||July 2007|July 27, 2007|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00508859||168742|
NCT00508872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0816|Folfox-B Study for Patients With Colorectal Liver Metastases|Single-Institution Phase II Trial of Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab (Folfox-B) for Initially Unresectable Colorectal Liver Metastases: Downstaging Followed By Hepatic Resection||M.D. Anderson Cancer Center|No|Terminated|November 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|July 27, 2007||No|Slow accrual, study terminated.|No|October 8, 2010|https://clinicaltrials.gov/show/NCT00508872||168741|
NCT00509756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3213A1-1002|Study Evaluating FXR-450 in Healthy Japanese Men|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of FXR-450 Administered Orally to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Terminated|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|56|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 21, 2010|July 30, 2007||No|Please see termination statement in the detailed description.|No||https://clinicaltrials.gov/show/NCT00509756||168674|
NCT00510042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2007-063|National Study of Moderate and Severe Von Willebrand Disease in the Netherlands|National Study of Moderate and Severe Von Willebrand Disease in the Netherlands|WiN|Erasmus Medical Center|No|Completed|July 2007|September 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1100|Samples With DNA|plasma, DNA|Both|N/A|N/A|No|Non-Probability Sample|Patients with moderate and devere von Willebrand disease, known in a hemophilia treatment        center|April 2010|April 23, 2010|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510042||168653|
NCT00510315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-092|Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant|Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related IllnessFollowing Total Body Irradiation and Stem Cell Transplant||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2007|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|11|Samples Without DNA|whole blood|Female|18 Years|49 Years|No|Non-Probability Sample|Potential research subjects will be identified by a member of the research team from the        SCT database and the medicine and pediatrics leukemia databases.|February 2016|February 1, 2016|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510315||168632|
NCT00510055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU752|Treatment of Acne Scarring With a Novel Procedure Combination|The Effect of Subcision and Calcium Hydroxylapatite (Radiesse) Injection on Rolling Acne Scarring Appearance||Northwestern University|No|Completed|June 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2012|September 14, 2012|July 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00510055||168652|
NCT00509717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOK/WINAp/CZ-02|Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs|Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs. A Randomized Trial.||Radboud University|No|Completed|October 2006|March 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|70|||Both|18 Years|N/A|No|||July 2008|July 9, 2008|February 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00509717||168677|
NCT00511953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0056|Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women||Depomed|No|Completed|June 2007|February 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|N/A|No|||June 2011|June 6, 2011|August 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511953||168506|
NCT00508820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040209|An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP|An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)||Amgen||Completed|February 2005|March 2011|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|407|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|July 26, 2007||||No|January 11, 2012|https://clinicaltrials.gov/show/NCT00508820||168745|
NCT00510601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10282|Treating Congestive Heart Failure Using a Device to Remove Cholesterol|LDL Apheresis for the Treatment of Congestive Heart Failure||University of Kansas Medical Center|No|Completed|July 2007|July 2011|Actual|July 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|85 Years|No|||January 2016|January 12, 2016|July 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510601||168610|
NCT00511160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBK103|Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae|Prevalence of Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae||Robert Bosch Gesellschaft für Medizinische Forschung mbH|Yes|Suspended|August 2007|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|August 2, 2007||No|Study suspended due to logistical/personnel difficulties|No||https://clinicaltrials.gov/show/NCT00511160||168567|
NCT00477880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546501|Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer|Treatment of Ménétrier's Disease With EGF Receptor Blockade||National Cancer Institute (NCI)||Active, not recruiting|April 2001|||April 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|80 Years|No|||May 2010|May 14, 2010|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00477880||171082|
NCT00510562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPD-COM 06200101|Effect of Cranial Osteopathy on Visual Function|Effect of Cranial Osteopathy on Visual Function||Nova Southeastern University|No|Completed|October 2001|February 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510562||168613|
NCT00510575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCLA-0123|Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis|Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis||Shriners Hospitals for Children|No|Completed|May 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|11 Years|18 Years|No|||January 2013|January 15, 2013|July 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00510575||168612|
NCT00510848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/154|Hamstrings Autograft Versus Tibialis Allograft for Reconstruction of Anterior Cruciate Ligament|Hamstrings Autograft Versus Tibialis Allograft for Reconstruction of Anterior Cruciate Ligament: Randomized Clinical Trial With 2 Year Follow-up||University Hospital, Ghent|No|Recruiting|August 2007|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510848||168591|
NCT00510861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-MM-0205-507-26|Influence of Paternal Age on Assisted Reproduction Outcome|Influence of Paternal Age on Assisted Reproduction Outcome|MALE AGING|Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|February 2007|May 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|80 Years|No|||August 2007|August 1, 2007|August 1, 2007||||No||https://clinicaltrials.gov/show/NCT00510861||168590|
NCT00508079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1389|Evaluating the Occurence of New and Progression of Existing Peripheral Venous Disease in Leg Veins|Incidence and Progression of Peripheral Venous Disease||University of California, San Diego|No|Completed|July 2007|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1103|Samples With DNA|Whole blood, serum, plasma|Both|N/A|N/A|No|Non-Probability Sample|Previous participants from the San Diego Population Study|July 2013|July 10, 2013|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508079||168802|
NCT00479063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-16|Association of Lumbar MODIC Changes With Chronic Low Back Pain in Southern European Subjects|Modic Changes Are Not Associated With a Higher Risk of Chronic Low Back Pain Among Southern European Subjects. A Case Control Study|MODIC 2|Kovacs Foundation|Yes|Completed|February 2010|May 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|304|||Both|35 Years|50 Years|No|Non-Probability Sample|Cases: chronic LBP patients aged 30-50 in whom a lumbar MRI had been prescribed. Controls:        subjects aged 30-50 in whom a cranial MRI had been prescribed for headache, who did not        suffer from LBP and had no history of clinically relevant LBP.|June 2011|June 26, 2011|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00479063||170994|
NCT00479323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0093|Pneumococcal Reference Standard|Stimulation of Donors for Pneumococcal Reference Serum||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|250|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2011|August 11, 2011|May 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479323||170974|
NCT00479336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-06-005|A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema|A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema||Otsuka Pharmaceutical Co., Ltd.|No|Completed|June 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|104|||Both|20 Years|80 Years|No|||January 2014|January 30, 2014|May 25, 2007||No||No|December 15, 2013|https://clinicaltrials.gov/show/NCT00479336||170973|
NCT00509197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA110717|Should Non-Eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?|Should Non-Eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?||Université de Montréal|No|Recruiting|October 2007|September 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||February 2009|February 12, 2009|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00509197||168716|
NCT00510029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3205K2-1000|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 12, 2008|July 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510029||168654|
NCT00509509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OOTR-SBR001|High Risk Breast Cancer Screening Program|High Risk Breast Cancer Screening Program||Organisation for Oncology and Translational Research||Recruiting||||||N/A|Observational|Time Perspective: Prospective||1|||||Female|41 Years|N/A||Probability Sample|Women aged over 40 with high risk of breast cancer|May 2012|May 22, 2012|July 29, 2007||||No||https://clinicaltrials.gov/show/NCT00509509||168692|
NCT00510341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405|Evaluating the Collaborative Management in Pediatrics (CMP) Training Program Among Pediatric Resident Doctors and Their Patients With Asthma or Obesity|Asthma Management Support Training in Pediatrics|CMP|University of Washington|Yes|Completed|April 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|18|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510341||168630|
NCT00510354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2454|Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate|Multicenter, Single-arm, Two Stage Phase II Trial of RAD001 (Everolimus) With Imatinib in Imatinib-resistant Patients With Progressive GIST|Radix|Novartis||Completed|October 2006|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|30 Years|80 Years|No|||June 2015|June 24, 2015|July 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510354||168629|
NCT00510328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0607060023|Vibration Therapy Effects on Muscle Firing Patterns|Vibration Therapy Effects on Muscle Firing Patterns||Logan College of Chiropractic||Completed|October 2006|December 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|60|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||July 2007|August 1, 2007|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00510328||168631|
NCT00510653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-707|Gleevec Study for Patients With Ovarian Cancer|A Phase II Study of Gleevec in Patients With Recurrent Platinum-Resistant, Taxane-Resistant Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer||M.D. Anderson Cancer Center|No|Completed|March 2002|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Female|18 Years|N/A|No|||June 2013|June 14, 2013|July 31, 2007||No||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00510653||168606|
NCT00509977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU706|Study of Light Treatment and Laser Treatment for Melasma|A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of Intense Pulse Light vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.||Northwestern University|No|Completed|April 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|75 Years|No|||September 2012|September 14, 2012|July 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509977||168658|
NCT00476697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 364|UVA1 Light for Scleroderma and Similar Conditions|The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study||University of Michigan|No|Terminated|January 1997|July 2003|Actual|July 2003|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|10 Years|80 Years|No|||July 2015|July 24, 2015|May 18, 2007|Yes|Yes|inactivity|No||https://clinicaltrials.gov/show/NCT00476697||171168|
NCT00476996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT3986g|A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)|A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy|SCRIPT|Genentech, Inc.||Active, not recruiting|May 2007|December 2015|Anticipated|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|840|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|May 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00476996||171148|
NCT00477243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1044|Locus of Control and Spirituality in Palliative Care Patients|Locus of Control and Spirituality in Palliative Care Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2004|||October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|167|||Both|18 Years|N/A|No|Non-Probability Sample|Department of Symptom Control and Palliative Care at MD Anderson Cancer Center|September 2015|September 18, 2015|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477243||171129|
NCT00477594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012-CS17|Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia|An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia||Sanofi|No|Completed|May 2007|July 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|12 Years|N/A|No|||December 2013|December 2, 2013|May 22, 2007|Yes|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT00477594||171103|
NCT00512109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISIONAUG2/2007|Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)|Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study|VISION|McMaster University|No|Active, not recruiting|August 2007|July 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40060|||Both|45 Years|N/A|No|Non-Probability Sample|All patients who undergo noncardiac surgery who are at least 45 years of age and receive a        general or regional anesthetic from University and Non-University Hospitals.|March 2016|March 15, 2016|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00512109||168494|
NCT00512356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|549902|Efficacy and Safety Study of Anti-Adhesion Product in the Prevention of Intraperitoneal Adhesions|Study to Evaluate the Efficacy and Safety of Anti-Adhesion Product in the Prevention of Intraperitoneal Adhesions||Baxter Healthcare Corporation|Yes|Completed|December 2000|April 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|N/A|No|||August 2007|August 13, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512356||168475|
NCT00512369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060286|Effects of PA-1 Transcriptional Regulation on Monocyte Function|Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function||Vanderbilt University|No|Terminated|March 2006|July 2011|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Obese men and women|July 2011|July 14, 2011|August 3, 2007||No|Investigator left institution|No||https://clinicaltrials.gov/show/NCT00512369||168474|
NCT00478192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-088|Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase IIIb, Randomized, Double-Blind, Parallel Group, Multi-Center, Study to Assess the Efficacy and Safety of Multiple 30 Minute Infusions of YM087 (Conivaptan) in Subjects With Euvolemic or Hypervolemic Hyponatremia||Cumberland Pharmaceuticals|No|Completed|April 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|May 22, 2007|Yes|Yes||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00478192||171059|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.
NCT00478491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-515|fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease|fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease|ALZ|University of Wisconsin, Madison|Yes|Active, not recruiting|January 2003|July 2016|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|390|Samples Without DNA|plasma and serum|Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons with a parent with Alzheimer's disease will be recruited from the Wisconsin        Registry for Alzheimer's Prevention (WRAP). Persons with MCI will be recruited from the UW        clinics and satellite clinics. Controls for the above study groups will be recruited from        the WRAP and the local community.|October 2015|October 1, 2015|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00478491||171037|
NCT00479362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINPAC|Anticoagulant Therapy During Pacemaker Implantation|Randomized Trial of Uninterrupted Versus Interrupted Anticoagulant Therapy in Patients Undergoing Cardiac Pacing Device Implantation|FINPAC|University of Turku|No|Completed|September 2005|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Actual|447|||Both|18 Years|N/A|No|||September 2012|September 14, 2012|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479362||170971|
NCT00479349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-1104|Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Young Male and Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|32|||Male|20 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00479349||170972|
NCT00509769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM4258g|A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer|A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy||Genentech, Inc.||Completed|July 2007|June 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|N/A|N/A|No|||February 2013|February 22, 2013|July 27, 2007|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00509769||168673|
NCT00509782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0909|Phase I Trial of ZIO-101 in Patients With Solid Tumors|Phase I Trial of ZIO-101 in Patients With Solid Tumors||M.D. Anderson Cancer Center|No|Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|N/A|N/A|No|||July 2012|July 31, 2012|July 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00509782||168672|
NCT00509743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-PK-008|Study to Assess Effects of Age, Weight, and Body Composition on the Pharmacokinetics of IV Diclofenac Sodium|An Open-Label, Single-Dose Study to Assess the Effects of Age, Weight, and Body Composition on the Pharmacokinetic Profile, Safety, and Tolerability of Intravenous Diclofenac Sodium (DIC075V) in Adult Volunteers|DFC-PK-008|Javelin Pharmaceuticals|No|Completed|September 2007|March 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 11, 2009|July 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509743||168675|
NCT00510679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCID-3279|Study of Post-Training Supports for Health Workers in Benin|A Randomized Controlled Trial of Post-Training Supports for Health Workers Trained in the Use of Integrated Management of Childhood Illness Guidelines in Ouémé Department, Benin||Centers for Disease Control and Prevention|No|Completed|July 1999|October 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1577|||Both|N/A|59 Months|No|||August 2007|August 1, 2007|August 1, 2007||||No||https://clinicaltrials.gov/show/NCT00510679||168604|
NCT00510666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2579-3FW|Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy|Butorphanol and Tramadol for Morphine PCA Pain Management After Total Hysterectomy|BATPCAH|Nanjing Medical University|Yes|Completed|January 2007|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|841|||Female|19 Years|64 Years|No|||March 2009|March 30, 2009|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510666||168605|
NCT00510692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA/POL/03|Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA|A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid||S.L.A. Pharma AG|No|Completed|November 2006|April 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|July 30, 2007||No||No|July 7, 2014|https://clinicaltrials.gov/show/NCT00510692||168603|
NCT00511615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0862|Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia|A Feasibility Study of Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia||M.D. Anderson Cancer Center|No|Completed|March 2005|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples With DNA|Tissue sample removal from the cervix using LEEP during the scheduled colposcopy.|Female|18 Years|N/A|No|Non-Probability Sample|Patients with cervical cancer scheduled to be treated with the LEEP procedure.|July 2012|July 31, 2012|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511615||168532|
NCT00511628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR009313|Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia|BMI-2002 Study: Evaluation of Functionality and Evolution of Body Weight of Psychotic Patients With a High Body Mass Index||Janssen-Cilag, S.A.|No|Terminated|July 2001|January 2003|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1717|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with Schizophrenia or Schizoaffective disorder, in which physicians considered        the use of risperidone as treatment under clinical practice with a BMI >25; Patients have        increased their body weight >7% in the last year with the previous treatment even with a        BMI< 25 ; Patients that have shown intolerance to a previous antipsychotic treatment|March 2011|May 18, 2011|August 2, 2007|||Due to the achievement of minimum required sample size and new changes in local regulations.|No||https://clinicaltrials.gov/show/NCT00511628||168531|
NCT00480779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-04-2-0030|Evaluation of Group Lifestyle Balance DVD in Primary Care Practice|Screening, Training, Education and Prevention Service of the University of Pittsburgh, Phase 2|STEP UP|University of Pittsburgh|No|Completed|June 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|23|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|May 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00480779||170865|
NCT00480792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003940-50|Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients|Open-label, Randomized, and Multicentric Phase III Clinical Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV-1-infected Patients With CD4-positive T-lymphocytes Counts Above 200 permm3 ANRS HB 03 VIHVAC-B|VIHVAC-B|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|June 2007|September 2012|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|437|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480792||170864|
NCT00476476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-174|Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar|A Phase II Trial of Tarceva (Erlotinib) in Women With Squamous Cell Carcinoma of the Vulvar||Dana-Farber Cancer Institute|Yes|Completed|December 2006|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||March 2015|April 13, 2015|May 18, 2007|Yes|Yes||No|March 8, 2015|https://clinicaltrials.gov/show/NCT00476476||171185|
NCT00476489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02307EMC|Does Topical Steroid Treatment Impair the Adrenal Function?|Low Dose (1mcg) ACTH Stimulation Test for Assessment of the Hypothalamo-Pituitary- Adrenal Axis in Patients Treated With Topical Corticosteroids||HaEmek Medical Center, Israel|No|Recruiting|May 2007|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|50|||Both|18 Years|75 Years|No|||May 2007|May 21, 2007|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00476489||171184|
NCT00477009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2007-70X-20517-01-3|Effects From a Mandibular Repositioning Appliance in Patients With Obstructive Sleep Apnea and Snoring|A Randomized Controlled Trial of Effects From a Mandibular Advancement Device in Patients With Obstructive Sleep Apnea and Snoring||Umeå University|No|Completed|May 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|20 Years|70 Years|No|||January 2013|January 17, 2013|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00477009||171147|
NCT00477581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA403|A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Crossover Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|May 2007|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|70 Years|No|||August 2015|August 25, 2015|May 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00477581||171104|
NCT00477867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078639|Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172|Assessing Economic Outcomes in Women With Stage III Ovarian Cancer Treated With Intravenous Paclitaxel and Cisplatin v. Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel on GOG #172: A Feasibility Study of Assessing Costs and Medical Resource Use||Gynecologic Oncology Group||Withdrawn||||||N/A|Interventional|Primary Purpose: Health Services Research|||Actual|0|||Female|N/A|N/A|No|||October 2007|June 7, 2013|May 23, 2007|||Trial was never activated|No||https://clinicaltrials.gov/show/NCT00477867||171083|
NCT00478205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-G000-326|Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease|Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease||Eisai Inc.||Completed|June 2007|||June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1467|||Both|45 Years|90 Years|No|||January 2013|June 26, 2014|May 22, 2007|Yes|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00478205||171058|
NCT00478764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOSS|Intraocular Steroid After Cataract Surgery Study|Intracameral Use of Triamcinolone and Gatifloxacin Versus Standard Postoperative Steroid and Antibiotic Eye Drops After Cataract Surgery||Dean Health System|No|Completed|March 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||May 2007|May 24, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00478764||171016|
NCT00479700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-100|Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2006|July 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 7, 2007|May 24, 2007||||||https://clinicaltrials.gov/show/NCT00479700||170946|
NCT00479674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014837|Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer|A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer|ABC|Duke University|No|Completed|May 2007|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||January 2015|January 29, 2015|May 25, 2007|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT00479674||170948|
NCT00510705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0816-2007|Chronic Inflammatory Activation in Fat Tissue: An Atherogenic Factor in Severe Coronary Artery Disease||KFO|University of Leipzig||Terminated|July 2007|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|29|||Male|35 Years|75 Years|No|||December 2014|December 2, 2014|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510705||168602|
NCT00510718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-3100-1-01|A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer|A Phase 1, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer||Medivation, Inc.|No|Active, not recruiting|July 2007|December 2017|Anticipated|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Male|18 Years|N/A|No|||February 2016|February 12, 2016|July 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00510718||168601|
NCT00510068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2324|Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors|A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)|RADIANT-3|Novartis|Yes|Completed|July 2007|March 2014|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|July 31, 2007|Yes|Yes||No|November 11, 2011|https://clinicaltrials.gov/show/NCT00510068||168651|
NCT00510965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ADE03|Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)|Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome)||University Hospital, Bonn|No|Completed|August 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||August 2011|June 14, 2012|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510965||168582|
NCT00510978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT900/301/1-2|Probiotics in GastroIntestinal Disorders|One Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative Colitis|PROGID|University College Cork|Yes|Active, not recruiting|January 2002|November 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|360|||Both|N/A|75 Years|No|||August 2007|June 13, 2011|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00510978||168581|
NCT00511303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML 002|Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia|Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia Who Are Resistant to or Intolerant of *-Interferon. A Phase II Study||University of Bologna|Yes|Completed|August 2000|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||August 2007|August 2, 2007|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511303||168556|
NCT00511316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003373|Trial of Montelukast in Eosinophilic Esophagitis|A Randomized Placebo-Controlled Trial of Montelukast in Maintenance Therapy of Asymptomatic Eosinophilic Esophagitis||Mayo Clinic|Yes|Completed|August 2007|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00511316||168555|
NCT00511329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA628132|Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease|Growth and the Effect of Genotropin in Chronically Ill Children With Juvenile Rheumatoid Arthritis and With Crohn's Disease||Nationwide Children's Hospital|No|Terminated|August 2007|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|5 Years|17 Years|No|||May 2015|May 14, 2015|August 2, 2007|Yes|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT00511329||168554|
NCT00511277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449L00016|Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode psychosis-a Pilot Study|Single-arm, Open-label and Multicenter Phase IV Study: Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode Psychosis - a Pilot Study||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Completed|August 2007|April 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|45 Years|No|||June 2011|June 20, 2011|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511277||168558|
NCT00511979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDC-INS-0002|Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin|Effect of Different Doses of Inhaled Technosphere Insulin on Glucose Infusion Rates During Euglycemic Clamps in Comparison to a Subcutaneous Injection of Regular Human Insulin||Mannkind Corporation||Completed|August 1999|June 2000|Actual|February 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00511979||168504|
NCT00477022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-456|The Effects of Vacuum-Compression Therapy on the Healing of Diabetic Foot Ulcers||VCT|Zahedan University of Medical Sciences|No|Completed|February 2006|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|20|||Both|45 Years|69 Years|No|||May 2007|May 22, 2007|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00477022||171146|
NCT00477035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT173|Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies|A Phase I/II Study of Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for the Treatment of High-risk Hematologic Malignancies||Stanford University|Yes|Completed|May 2006|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|75 Years|No|||May 2011|May 19, 2011|May 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477035||171145|
NCT00477906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/100/0402|M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma|Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma||AVAX Technologies|No|Not yet recruiting|July 2016|January 2021|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|387|||Both|N/A|N/A|No|||December 2015|December 2, 2015|May 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00477906||171080|
NCT00477919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 95/06|E-MOSAIC Electronic Tool to Monitor Symptoms|E-MOSAIC: A Multicenter Randomized Controlled Phase III Study of Longitudinal Electronic Monitoring of Symptoms and Syndromes Associated With Advanced Cancer in Patients Receiving Anticancer Treatment in Palliative Intention||Swiss Group for Clinical Cancer Research|Yes|Completed|February 2007|January 2012|Actual|January 2012|Actual|Phase 3|Observational|N/A||2|Actual|264|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced incurable cancer|October 2015|October 8, 2015|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00477919||171079|
NCT00477256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0007|School Reintegration Outcomes in Pediatric Cancer Patients|Psychosocial Predictors of Child Adjustment and School Reintegration Outcome in a Pediatric Cancer Population||M.D. Anderson Cancer Center|No|Completed|May 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|91|||Both|6 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer, their        parent(s) or caregiver(s), and medical staff (i.e., physicians, nurse practitioners)        involved in the children's medical decision-making.|July 2012|July 27, 2012|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477256||171128|
NCT00478244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2006-15|Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa|Allogeneic Hematopoietic Cell Transplantation to Correct the Biochemical Defect and Create Tolerance to Donor Tissue in Subjects With Epidermolysis Bullosa||Masonic Cancer Center, University of Minnesota|Yes|Terminated|April 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|25 Years|No|||January 2013|January 4, 2013|May 23, 2007|Yes|Yes|Competing studies|No|July 17, 2012|https://clinicaltrials.gov/show/NCT00478244||171055|
NCT00478257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCRP 11IB-0034|Effect of Increased Light Exposure on Fatigue in Breast Cancer|Effect of Increased Light Exposure on Fatigue in Breast Cancer||University of California, San Diego|No|Completed|November 2005|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|39|||Female|18 Years|N/A|No|||February 2012|February 26, 2012|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00478257||171054|
NCT00478218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546657|Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Trial of Revlimid, Cyclophosphamide, and Dexamethasone in Patients With > Newly Diagnosed Active Multiple Myeloma||Mayo Clinic|Yes|Completed|July 2006|April 2011|Actual|September 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|May 23, 2007|Yes|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00478218||171057|
NCT00478231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001063|Multicenter, Safety Study Of Maraviroc|A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc||ViiV Healthcare|No|Completed|July 2007|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|209|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|May 22, 2007|Yes|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00478231||171056|
NCT00478504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-5103-015-06|Letrozole Versus Clomifene Citrate for Ovulation Induction|Double Blind Cross-Over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome||Derby Hospitals NHS Foundation Trust|Yes|Recruiting|May 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|212|||Female|18 Years|39 Years|No|||May 2007|May 23, 2007|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00478504||171036|
NCT00478777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-019|A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma|A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma||Celgene|Yes|Completed|March 2007|August 2009|Actual|November 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|May 23, 2007|No|Yes||No|September 26, 2011|https://clinicaltrials.gov/show/NCT00478777||171015|
NCT00479076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10089|A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients|A Single Agent-combination Hybrid Phase I, Open-label, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous AVE0005 (VEGF Trap)Administered Every 2 Weeks in Combination With Oral S-1 in Patients With Advanced Solid Malignancies||Sanofi||Completed|March 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|20 Years|N/A|No|||January 2011|January 25, 2011|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00479076||170993|
NCT00479115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMCEH004|Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100|AMD3100 in Combination With G-CSF to Mobilize Peripheral Blood Stem Cells in Patients With Fanconi Anemia(FA): A Phase I/II Study||Children's Hospital Medical Center, Cincinnati|Yes|Completed|May 2007|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|1 Year|30 Years|No|||February 2012|February 15, 2012|May 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00479115||170990|
NCT00479128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0014|Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors|Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination With Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumors||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2006|||September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||March 2016|March 22, 2016|May 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479128||170989|
NCT00480038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-18|World Health Organization Disability Assessment Schedule (WHODAS-II) for Patients With Symptomatic Lumbar Disc Herniation|WHODAS-II for Patients With Symptomatic Lumbar Disc Herniation||Kovacs Foundation|Yes|Terminated|April 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|80 Years|No|||June 2011|June 26, 2011|May 28, 2007||No|Recruitment was so slow, that it made the study impossible. Organizational changes made it    impossible for recruiting centers to continue recruitment|No||https://clinicaltrials.gov/show/NCT00480038||170921|
NCT00479401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.524|Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients|A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).||Boehringer Ingelheim||Completed|May 2007|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|539|||Both|30 Years|N/A|No|||June 2014|June 20, 2014|May 25, 2007|Yes|Yes||No|November 20, 2009|https://clinicaltrials.gov/show/NCT00479401||170968|
NCT00510120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH076141|Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder|Mediators, Moderators, and Treatment Outcomes With ODD Youth||Virginia Polytechnic Institute and State University|No|Completed|June 2007|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|8 Years|14 Years|No|||June 2013|June 6, 2013|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00510120||168647|
NCT00510393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-002|Drug Eluting Stents In The Critically Ischemic Lower Leg|The DESTINY Trial: a Prospective Randomized Multicenter Trial Comparing the Implant of a Drug Eluting Stent (XIENCE V, Abbott Vascular) vs. a Bare Metal Stent (MULTILINK VISION, Abbott Vascular) in the Critically Ischemic Lower Leg|DESTINY|Flanders Medical Research Program|Yes|Completed|March 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||December 2010|December 1, 2010|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510393||168626|
NCT00510406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-052|A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH|A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi Center Dose Ranging Study of Solifenacin Succinate in Combination With Tamsulosin Hydrochloride Compared With Solifenacin Succinate Monotherapy and Tamsulosin Hydrochloride Monotherapy in Males With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)|SATURN|Astellas Pharma Inc|No|Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|919|||Male|45 Years|N/A|No|||August 2014|August 19, 2014|July 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510406||168625|
NCT00510731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-2003-03|The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events|Prospective, Multi-Center Study Of The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of VentrIcular TachyArrhythmic Events Such As, Sudden Cardiac Death, VentricuLar Fibrillation or Ventricular Tachycardia in High Risk Patients|VITAL|Vicor Technologies, Inc.|Yes|Withdrawn|November 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at high risk of arrhythmic event who do not have an ICD|December 2015|December 7, 2015|August 1, 2007|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00510731||168600|
NCT00510991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002|Non Invasive Ventilation in Acute Asthma|Non Invasive Ventilation in Acute Asthma||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|July 2006|February 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||February 2008|February 26, 2008|August 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510991||168580|
NCT00511342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05765|Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)|An Open-Label, Randomized, Single Center Trial in Healthy Young Women, to Evaluate the Effects of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg NOMAC and 1.5 mg E2 on Bone Mineral Density (BMD) Compared to a Monophasic COC Containing 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol||Merck Sharp & Dohme Corp.|No|Completed|September 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|August 2, 2007|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00511342||168553|
NCT00511355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05764|Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)|A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate the Effects on Hemostasis, Lipids and Carbohydrate Metabolism, and on Adrenal and Thyroid Function of a Monophasic COC Containing 2.5 mg NOMAC and 1.5 mg E2 Compared to a Monophasic COC Containing 150 ug LNG and 30 ug EE||Merck Sharp & Dohme Corp.|No|Completed|September 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|August 2, 2007|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00511355||168552|
NCT00511641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-693|Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer|Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer||M.D. Anderson Cancer Center|No|Recruiting|February 2002|||February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2400|||Female|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female UT MDACC Patients, over 50 years of age, participating in an ovarian cancer        screening program.|November 2015|November 13, 2015|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00511641||168530|
NCT00511992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2674|Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer|PHASE II STUDY OF PACLITAXEL (TAXOL), INTRAPERITONEAL CISPLATIN AND IV AVASTIN FOLLOWED BY AVASTIN CONSOLIDATION FOR ADVANCED OVARIAN AND PERITONEAL CARCINOMA OR FALLOPIAN TUBE CANCER||University of Oklahoma|Yes|Active, not recruiting|July 2007|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|August 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511992||168503|
NCT00512226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0037-07-EMC|Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia|Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia Using T2* Cardiac MRI.||HaEmek Medical Center, Israel|No|Completed|September 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|August 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00512226||168485|
NCT00476710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-11B|Effects of Colesevelam HCl On Bile Acid Kinetics|Effects of Colesevelam HCl On Bile Acid Pools And Kinetic Parameters in Normal Subjects, Subjects With Impaired Glucose Tolerance, And Subjects With Type 2 Diabetes Mellitus||KineMed|No|Completed|May 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|36|||Both|40 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|overweight and obese people with normal glucose metabolism, impaired glucose tolerance and        frank type 2 diabetes|March 2015|March 30, 2015|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476710||171167|
NCT00476723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 032|HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection|Generation of HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection Receiving HBV-active Antiretroviral Therapy||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|Samples With DNA|PBMC|Both|18 Years|60 Years|No|Non-Probability Sample|HIV/Hepatitis B coinfected patients using at least one hepatitis active medications in        HAART regimen|June 2010|June 4, 2010|November 15, 2006||No||No||https://clinicaltrials.gov/show/NCT00476723||171166|
NCT00476736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56/07|The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise|Reassessment Study of The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise|NAC|Assaf-Harofeh Medical Center|No|Recruiting|May 2007|May 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|30|||Both|45 Years|70 Years|No|||May 2007|May 21, 2007|May 21, 2007||||No||https://clinicaltrials.gov/show/NCT00476736||171165|
NCT00477282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTN32313R|Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer|A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer||BioNumerik Pharmaceuticals, Inc.|Yes|Completed|August 2007|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|509|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|May 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477282||171126|
NCT00477295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-310|A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy|A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy||Eisai Inc.||Completed|May 2007|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|583|||Both|18 Years|75 Years|No|||November 2015|December 21, 2015|May 21, 2007||No||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00477295||171125|
NCT00477269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571E2203|Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)||Novartis|Yes|Completed|April 2006|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|May 22, 2007|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00477269||171127|
NCT00478270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20247|A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.|An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Metastatic Bone Pain in Patients With Breast Cancer and Skeletal Metastases.||Hoffmann-La Roche||Terminated||January 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||March 2008|March 19, 2008|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478270||171053|
NCT00477893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 04-078|Danish Multicenter Study of Adalimumab in Spondyloarthritis|Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab|DANISH|Glostrup University Hospital, Copenhagen|Yes|Active, not recruiting|February 2006|January 2013|Anticipated|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|90 Years|No|||March 2012|March 27, 2012|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00477893||171081|
NCT00478517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.455|TETRAM 2. Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study|Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study. TETRAM2|TETRAM2|Hospices Civils de Lyon|Yes|Withdrawn|May 2007|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|15 Years|65 Years|No|||March 2009|March 10, 2009|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00478517||171035|
NCT00479089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0767|Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer|Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy||M.D. Anderson Cancer Center|Yes|Terminated|February 2004|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||September 2015|October 8, 2015|May 24, 2007||No|Study halted due to drug sponsor decision to not continue.|No|July 27, 2015|https://clinicaltrials.gov/show/NCT00479089||170992|Early termination leading to small numbers of subjects analyzed.
NCT00479388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-067|Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)|A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.||Merck Sharp & Dohme Corp.||Completed|July 2007|October 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1216|||Both|18 Years|80 Years|No|||February 2015|February 20, 2015|May 24, 2007|Yes|Yes||No|June 9, 2009|https://clinicaltrials.gov/show/NCT00479388||170969|
NCT00479414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7442|Lilly's Emotional and Physical Symptoms of Depression Study|Lilly's Emotional and Physical Symptoms of Depression Study|LEAPS|Eli Lilly and Company|No|Completed|August 2004|January 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||8000|||Both|18 Years|N/A|No|||May 2007|May 25, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479414||170967|
NCT00510419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K644-07-3001|A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack|A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection With Sumatriptan Succinate Using an Auto-injector During a Single Migraine Attack||Pfizer|Yes|Completed|July 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|73|||Both|18 Years|60 Years|No|||June 2012|June 6, 2012|August 1, 2007||||No||https://clinicaltrials.gov/show/NCT00510419||168624|
NCT00510432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16/07|Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients|Inzidenz Und Art Heparin-induzierter Hautveränderungen||Johann Wolfgang Goethe University Hospitals|No|Recruiting|April 2007|January 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Patients receiving s.c. anti-coagulation|August 2009|August 18, 2009|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510432||168623|
NCT00510744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07070305|Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients|Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients||University of Pittsburgh|Yes|Recruiting|August 2007|August 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2009|February 12, 2009|August 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510744||168599|
NCT00511680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 Ro1 MH079814|Beat the Blues: Treating Depression in African American Elders|Treating Depression in African American Elders: A Community-Academic Partnership||Thomas Jefferson University|Yes|Completed|September 2008|June 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|192|||Both|55 Years|N/A|No|||August 2012|August 7, 2012|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511680||168527|
NCT00511004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907197|Effect of Albendazole Dose on Treatment of Lymphatic Filariasis|Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study||National Institutes of Health Clinical Center (CC)|No|Completed|July 2007|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|55 Years|No|||July 2015|July 30, 2015|August 2, 2007|Yes|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT00511004||168579|Study never fully enrolled so sample size was smaller than hoped for.
NCT00511017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0423|Doxercalciferol in Recurrent Pediatric Solid Tumors|A Phase I Study of Doxercalciferol in Recurrent Pediatric Solid Tumors||M.D. Anderson Cancer Center|No|Terminated|August 2007|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|2 Years|26 Years|No|||July 2012|July 27, 2012|August 2, 2007||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00511017||168578|
NCT00511368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA103001-04 Study 203|Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*|Phase 2 Dose-escalating, P-C, D-B, Parallel Group Study in HIV Treatment-experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days *(PART B)||Myrexis Inc.|Yes|Completed|April 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|65 Years|No|||January 2010|January 15, 2010|August 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511368||168551|
NCT00511654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKG10004|28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)|A Parallel Group, Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 and Its Effect on the Pharmacokinetics of Midazolam After Once-Daily Repeated Oral Doses in Healthy Subjects||GlaxoSmithKline||Completed|June 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511654||168529|
NCT00511667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-005|A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes||Merck Sharp & Dohme Corp.||Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|70 Years|No|||February 2015|February 13, 2015|August 2, 2007|No|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00511667||168528|
NCT00508768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005155|A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid Arthritis|A Randomized, Double-Blind, Parallel-Group, Pharmacokinetic Study of Oral SCIO-469 (90 mg qd and 30 mg Tid) in Female Subjects With Active Rheumatoid Arthritis||Scios, Inc.||Completed||December 2002|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|16|||Female|18 Years|N/A|No|||April 2010|May 18, 2011|July 27, 2007||||||https://clinicaltrials.gov/show/NCT00508768||168749|
NCT00477048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 027|Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity|Efficacy and Safety of a Saquinavir Based Regimen in HIV-1 Infected Thai Patients Who Have Chronic IDV Associated Nephrotoxicity.||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|May 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00477048||171144|
NCT00477321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-06|Safety Study of IL-7 in HIV-infected Patients (Inspire)|A Ph I/IIa Rand Placebo Ctrl, S-Blind Multictr Dose-Esc Study of SC Intermittent Interleukin-7 CYT107 in Chronically HIV-Infected Pts With CD4 T Lymphocyte Counts 101-400 Cells-/mm(3) and Plasma HIV RNA Less Than 50 Copies/mL After at Least 12 M of HAART||Cytheris SA|Yes|Completed|May 2007|July 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|May 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00477321||171123|
NCT00478582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB 5/2007|Validation of a New Standardized Clinical Anemia Evaluation Score Using a Hb Visual Scale in Nephrological Patients|Validation of a New Standardized Clinical Anemia Evaluation Score Using a Hb Visual Scale in Nephrological Patients||University Hospital Inselspital, Berne|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||January 2011|January 12, 2011|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478582||171030|
NCT00477607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4697-R|Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin|Prevention of Cisplatin Ototoxicity With the Antioxidant Alpha-Lipoic Acid||VA Office of Research and Development|Yes|Completed|October 2007|June 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|39|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|May 23, 2007|No|Yes||No|October 4, 2013|https://clinicaltrials.gov/show/NCT00477607||171102|Missing data constraints have the number of subjects in the study being different for different outcomes.
NCT00477620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-2005-01-01|Study of Myopia Acquisition and Prevention|Study of Myopia Acquisition and Prevention in a Randomised Trial|SMART|University Hospital Freiburg|No|Completed|April 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||||||Both|7 Years|9 Years|Accepts Healthy Volunteers|||February 2009|February 19, 2009|May 23, 2007||||No||https://clinicaltrials.gov/show/NCT00477620||171101|
NCT00477633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-00207|Study of Safety and Efficacy of an Oral Contraceptive|An Open Label Study of the Contraceptive Efficacy of Norethindrone and Ethinyl Estradiol.||Warner Chilcott|No|Completed|June 2007|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1700|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|May 22, 2007|Yes|Yes||No|October 13, 2010|https://clinicaltrials.gov/show/NCT00477633||171100|
NCT00477932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182-2006|Genes Mutation Pentalogy of Cantrell|Human Disease With Mutation of Nonmuscle Myosin Heavy Chain Genes||Children's Healthcare of Atlanta|No|Withdrawn|March 2006|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Those patients who have Pentalogy of Cantrell (as defined under STUDY DESIGN) or other        diseases that could involve mutation of any of the nonmuscle myosin genes that will be        defined in future amendments|December 2014|December 16, 2014|May 22, 2007||No|Physician's chose to not follow through with the study.|No||https://clinicaltrials.gov/show/NCT00477932||171078|
NCT00477945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704-29 IUCRO-0187|Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL|A Phase I Trial of Clofarabine in Combination With High-Dose Etoposide and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation for Patients With High-Risk or Refractory Non-Hodgkin's Lymphoma||Indiana University|Yes|Completed|May 2007|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|70 Years|No|||September 2014|September 10, 2014|May 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00477945||171077|
NCT00478283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540280|Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer|Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Hormonal Therapy in Older and/or Frail Women: A Survey of Oncologists and Geriatricians||City of Hope Medical Center||Completed|December 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Primary Purpose: Health Services Research|||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2010|February 5, 2010|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00478283||171052|
NCT00478530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4573-YR-CTIL|The Effect of Intravitreal Avastin on the Retina Measured by Electroretinogram|The Effect of Intravitreal Avastin on the Retina Measured by Electroretinogram||Sheba Medical Center|No|Completed|May 2007|October 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|85 Years|No|||February 2009|February 4, 2009|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478530||171034|
NCT00478790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking 0705|Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital|Study of the Safety and Effectiveness of the Ologen(OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery||Pro Top & Mediking Company Limited|Yes|Recruiting|February 2007|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2008|October 6, 2011|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478790||171014|
NCT00479687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHO-0106|SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder|A Multi-center, Randomized, Double-blind, Placebo Controlled Trial of SUPARTZ (Sodium Hyaluronate) for the Treatment of Chronic Shoulder Pain||Bioventus LLC|No|Completed|May 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|256|||Both|35 Years|N/A|No|||July 2013|March 17, 2015|May 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00479687||170947|
NCT00476567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK4.2007.81|Effects of Regular Exercise During Pregnancy|Training During Pregnancy - Effects of Regular Exercise During Pregnancy in Prevention of Pregnancy-related Diseases and Complications During Labour. A Randomised Clinical Trial||Norwegian University of Science and Technology|No|Completed|May 2007|June 2015|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|855|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|May 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00476567||171178|
NCT00476580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1047|Health Habits and Cancer Risk Comparison Among Migrant Sri Lankans and Sri Lankans|Health Habits and Cancer Risk Among a US Migrant Sri Lankan Population and a Comparison With Siblings Living in Sri Lanka||M.D. Anderson Cancer Center|No|Withdrawn|April 2007|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area,        but born in Sri Lanka. Siblings or the first cousins of the study participants living in        Sri Lanka of same sex and of an age plus or minus 10 years.|August 2015|August 27, 2015|May 21, 2007||No|Study terminated.|No||https://clinicaltrials.gov/show/NCT00476580||171177|
NCT00480675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00006986|Randomized Study Comparing Fluoroscopically-Guided Versus Blinded Trochanteric Bursa Injections|||Johns Hopkins University|No|Completed|March 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00480675||170873|
NCT00511381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-001-07|Genetic Testing in Detection of Late-Onset Hearing Loss|Utility of Genetic Testing in Detection of Late-Onset Hearing Loss|SoundGene|Mednax Center for Research, Education and Quality|Yes|Completed|October 2007|September 2011|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3681|||Both|N/A|14 Days|Accepts Healthy Volunteers|Non-Probability Sample|Hospital|February 2012|February 28, 2012|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511381||168550|
NCT00511394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-PHT-01|Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis|Acute Hemodynamic Effects of Albumin Versus Normal Saline in Patients With Cirrhosis With Ascites: A Randomized Controlled Trial||Govind Ballabh Pant Hospital|No|Suspended|May 2007|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|16|||Both|12 Years|75 Years|No|||October 2008|October 14, 2008|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511394||168549|
NCT00511693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI REB 07-029|Osteoporosis Coordinator for Low Volume Community Hospitals|Regional Osteoporosis Coordinator Knowledge Exchange Trial|ROCKET|Ontario Ministry of Health and Long Term Care|No|Recruiting|June 2007|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Screening|2||Anticipated|300|||Both|40 Years|N/A|No|||July 2007|August 6, 2007|August 3, 2007||||No||https://clinicaltrials.gov/show/NCT00511693||168526|
NCT00512005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030301|VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study|Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) Feasibility Study|VIVID|Myocor|Yes|Recruiting|January 2008|December 2013|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||May 2008|June 23, 2009|August 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512005||168502|
NCT00512239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUPA97-04|Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset|Early Prediction of Patient-related and Radiological Outcomes in Patients With Recent-onset Inflammatory Polyarthritis (EPA) Using Established and Novel Independent Predictors|EUPA|Université de Sherbrooke|Yes|Recruiting|November 1999|September 2021|Anticipated|June 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Serum, genomic DNA and RNA from peripheral blood, PBMC used for in vitro osteoclastogenesis|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with recent-onset inflammatory polyarthritis with an immune cause (excluding        infection, crystal-induced) and without characteristics diagnostic for connective tissue        diseases or systemic vasculatidies|August 2015|August 12, 2015|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512239|10 Years|168484|
NCT00512538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGS0769 B304|Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers|A Randomized, Open-Label, Multi-Center Study to Compare the Safety and Efficacy of Apligraf Versus Standard Therapy (i.e., Saline Moistened Dressing Regimen) in the Treatment of Diabetic (Primarily Neuropathic) Foot Ulcers||Organogenesis|No|Terminated|October 2000|September 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|80 Years|No|||August 2007|August 3, 2007|August 3, 2007|||Interruption of business relations between Study Sponsor and Device Manufacturer|No||https://clinicaltrials.gov/show/NCT00512538||168461|
NCT00477308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 013 phase II|Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs|Clinical, Immunologic and Virological Outcomes of Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|January 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|95|||Both|1 Year|18 Years|No|||June 2010|June 4, 2010|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00477308||171124|
NCT00478842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051050|Pallidal Stimulation and Gilles de la Tourette Syndrome|Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS|STIC|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|November 2007|December 2016|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|No|||July 2015|July 13, 2015|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478842||171010|
NCT00478855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-102105|Tazocin Intervention Study|Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2006|June 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||500|||Both|18 Years|N/A|No|||December 2007|December 7, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00478855||171009|
NCT00477646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000537346|Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care|New York Prevention Care Manager Project / Medicaid Managed Care Organization Version||Dartmouth-Hitchcock Medical Center|No|Completed|July 2007|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2241|||Female|50 Years|64 Years|No|||August 2011|August 4, 2011|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00477646||171099|
NCT00477958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06170|Assessment Tool for Older Patients With Cancer|Determining the Utility of an Assessment Tool for Older Patients With Cancer||City of Hope Medical Center|Yes|Active, not recruiting|December 2006|||February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|750|||Both|65 Years|N/A|No|||August 2015|August 10, 2015|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00477958||171076|
NCT00477971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546745|Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis|Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL)||Mayo Clinic|Yes|Completed|October 2005|December 2014|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|May 23, 2007|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT00477971||171075|
NCT00479739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM40056|CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE With An Adjustable Maintenance Dose Of SYMBICORT|Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250bid Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/160 in Adult Asthmatics||GlaxoSmithKline|No|Completed|November 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|700|||Both|18 Years|70 Years|No|||August 2013|September 5, 2013|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479739||170943|
NCT00479752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG /CORE 1.2.002|Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer|A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX4 + Weekly Cetuximab Versus FOLFOX4+ Biweekly Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer.|CORE 2|Central European Cooperative Oncology Group|No|Completed|January 2008|November 2015|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00479752||170942|
NCT00478543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD1-22052007|Loop Diuretics in Chronic Kidney Disease|Effect of Loop Diuretics Treatment on Blood Pressure Control in Phase 3-4 of Chronic Kidney Disease||Second University of Naples|No|Completed|September 2005|July 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|May 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00478543||171033|
NCT00479102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor448707ctil|Prevention of Iron Deficiency in 2nd Year of Life|Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency||Soroka University Medical Center|No|Not yet recruiting|May 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|8 Months|18 Months|Accepts Healthy Volunteers|||May 2007|May 24, 2007|May 24, 2007||||No||https://clinicaltrials.gov/show/NCT00479102||170991|
NCT00479375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3824-B00-05XAC|Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening|Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Screening|SWEDESCREEN|Skane University Hospital|Yes|Completed|May 1997|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Screening|2||Actual|12527|||Female|32 Years|38 Years|Accepts Healthy Volunteers|||May 2007|May 25, 2007|May 25, 2007||||No||https://clinicaltrials.gov/show/NCT00479375||170970|
NCT00492089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00256|Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer|A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage||National Cancer Institute (NCI)||Completed|June 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|No|||April 2013|April 21, 2014|June 25, 2007|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00492089||170007|
NCT00492349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040322|Varenicline Adjunctive Treatment in Schizophrenia|Varenicline Adjunctive Treatment in Schizophrenia||University of Maryland|Yes|Active, not recruiting|May 2007|December 2012|Anticipated|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||March 2012|March 19, 2012|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492349||169988|
NCT00492908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK237_06|Randomized Trial Comparing Titan Stent With Zotarolimus-Eluting Stent|Randomized Clinical Trial Comparing A Titanium-Nitride-Oxide Coated Stent With A Zotarolimus-Eluting Stent in Patients With Coronary Artery Disease||University of Bern|No|Completed|June 2007|August 2013|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00492908||169946|
NCT00493155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO18674|A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.|"An Open-label, Multiple Ascending Dose Study to Determine the Maximum Tolerated Dose of R1530 in Patients With Advanced Solid Tumors."||Hoffmann-La Roche||Completed|October 2005|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00493155||169927|
NCT00465413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-317|Bronchodilatation Effects of a Small Volume Spacer Used With a Metered-Dose Inhaler||MDI|Mackay Memorial Hospital|Yes|Completed|September 2004|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|300|||Both|6 Years|N/A||||September 2007|November 13, 2007|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465413||172021|
NCT00466258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003750-23|LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)|LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)|LINFOTARGAM|PETHEMA Foundation|Yes|Completed|October 2006|November 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||November 2009|November 23, 2009|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466258||171956|
NCT00466245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-249-002|Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine|Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination||Sanofi|Yes|Completed|July 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|590|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466245||171957|
NCT00467025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060159|AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib|A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney||Amgen|No|Completed|May 2007|June 2014|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467025||171898|
NCT00467038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-038-06F|Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder|Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder||VA Office of Research and Development|No|Completed|November 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|April 25, 2007||No||No|November 24, 2014|https://clinicaltrials.gov/show/NCT00467038||171897|Small community sample. Additionally, our emotional task was a “passive viewing task” which means that we did not examine “active” emotion regulation, per se which might be considered a study limitation by some. No comparison treatment group.
NCT00467285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDB-019-06S|Effect of Diabetic Medications on Bone Metabolism|Effect of Thiazolidinediones on Skeletal Health||VA Office of Research and Development|No|Completed|October 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|96|Samples Without DNA|Urine and serum samples collected for the study will be spin and stored at -70 degree C and      assays run intermittently|Both|30 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|subjects with type 2 diabetes and less than 55 years with or without pioglitazone as part        of their therapy for diabetes|January 2015|January 13, 2015|April 26, 2007||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00467285||171878|
NCT00494221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00039|A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX|A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib (AZD2171) in Combination With FOLFOX||AstraZeneca|No|Completed|June 2007|August 2012|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|172|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|June 27, 2007|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00494221||169848|
NCT00494234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU36-44|Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer|A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer|ICEBERG 1|AstraZeneca|Yes|Active, not recruiting|June 2007|December 2016|Anticipated|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Female|18 Years|130 Years|No|||November 2015|December 4, 2015|June 27, 2007|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00494234||169847|
NCT00494208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HD041748|TDSM- Testosterone Dose Response in Surgically Menopausal Women|Testosterone Dose Response in Surgically Menopausal Women||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|270|||Female|21 Years|60 Years|Accepts Healthy Volunteers|||January 2009|April 30, 2013|June 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00494208||169849|
NCT00490061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0020|Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy|A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.||Stanford University|Yes|Active, not recruiting|July 2007|July 2025|Anticipated|July 2025|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|June 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00490061||170161|
NCT00494247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N40202932/0651|Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes|Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes|JACK-EPC|Silesian School of Medicine|Yes|Completed|October 2007|August 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||November 2009|June 18, 2010|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494247||169846|
NCT00490048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISUC.CTIL|Assessment of Pulmonary Involvement inUlcerative Colitis by Induced Sputum|||Hillel Yaffe Medical Center||Completed|June 2007|June 2007|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Both|18 Years|75 Years|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490048||170162|
NCT00490581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHSH2003-107|Evaluation of Housing First Initiative for Chicago Homeless With Chronic Medical Illness|Evaluation of the Housing First Initiative of Chicago Housing for Health Partnership|CHHP|John H. Stroger Hospital|No|Completed|September 2003|June 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|407|||Both|18 Years|N/A|No|||June 2008|September 9, 2008|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00490581||170121|
NCT00491478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD030615|Repetitive Behavior Disorders in People With Severe Mental Retardation|Stereotypies and Mental Retardation: Neurobiological Basis||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|September 1992|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|No|||May 2003|June 22, 2007|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00491478||170053|
NCT00491764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05082|A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)|An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail||Merck Sharp & Dohme Corp.|No|Completed|June 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|218|||Both|18 Years|75 Years|No|||September 2015|September 11, 2015|June 25, 2007|Yes|Yes||No|December 23, 2009|https://clinicaltrials.gov/show/NCT00491764||170031|
NCT00492063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P4|Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly|A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture and of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects||Novartis|No|Completed|September 2004|May 2005|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|2654|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 26, 2007||Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00492063||170009|
NCT00491777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMT-IQ2/NcIQ|Correlation Research Study: IQ2, NcIQ and IQ101|Correlation Study of NMT's IQ2, NcIQ and Its' Predicate Technology, IQ101.|NMT-CT|Noninvasive Medical Technologies, Inc.|Yes|Completed|June 2007|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|25|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2007|June 22, 2007|June 22, 2007||||||https://clinicaltrials.gov/show/NCT00491777||170030|
NCT00492362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:067|Trial of Aerobic Exercise in Patients Undergoing Outpatient Hemodialysis|A Randomized Controlled Trial of Aerobic Exercise in Patients With End Stage Renal Disease During Outpatient Hemodialysis||University of Manitoba|Yes|Completed|July 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00492362||169987|
NCT00492648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109671|Month 30 & 42 Extension Studies of CRD-004 Primary Study|An Extension Study to Evaluate the Persistence of the Immune Responses Induced by GSK Biologicals Zoster Vaccine, GSK324332A, Administered in Healthy Adult Subjects Aged 18-30 Years and 50-70 Years||GlaxoSmithKline||Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492648||169966|
NCT00493415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 436|The Effect of Nitroglycerine on Microcirculatory Abnormalities During Sepsis|The Evaluation of the Effect of Nitroglycerine Versus Placebo on the Microcirculation by Means of SDF Imaging in Septic Patients on the ICU|NISMIS|Medical Centre Leeuwarden|No|Completed|June 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|90 Years|No|||July 2008|July 15, 2008|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493415||169908|
NCT00493779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV149-208|A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients|An Exploratory, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA)|DECADES|Bristol-Myers Squibb||Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|103|||Both|18 Years|N/A|No|||June 2010|August 3, 2010|June 27, 2007|Yes|Yes||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00493779||169880|The open-label and exploratory nature of this small study and the absence of control group inherently limit the interpretability of the results.
NCT00493168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3434|Determination of the Prevalence and Prognostic Importance of Unrecognized Non-Q-wave Myocardial Infarction by MRI|Unrecognized Non-Q-wave Myocardial Infarction: Prevalence, Angiographic Correlation, and Prognostic Significance in Patients With Suspected Coronary Disease||Duke University||Completed|January 1998|November 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|185|||Both|18 Years|N/A|No|||June 2007|May 24, 2013|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00493168||169926|
NCT00466570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8924|Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application|Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour||Stanford University|No|Withdrawn|April 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|0|||Both|50 Years|N/A|No|||June 2013|June 12, 2013|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466570||171933|
NCT00466544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|036706MP4F|Randomized Controlled Study of Plasmaknife Tonsillectomy Versus Monopolar Tonsillectomy||jPK|Children's Hospital of Michigan|Yes|Not yet recruiting|May 2007|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|4 Years|16 Years||||March 2007|April 26, 2007|April 26, 2007||||No||https://clinicaltrials.gov/show/NCT00466544||171935|
NCT00467051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCT0521|Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors|Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin||Children's Oncology Group|Yes|Active, not recruiting|November 2007|||March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|21 Years|No|||April 2015|April 8, 2015|April 25, 2007|Yes|Yes||No|March 11, 2015|https://clinicaltrials.gov/show/NCT00467051||171896|
NCT00467064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0398-1-3|Arthritis Self-Management Education Program|Arthritis Self-Management Education -- Dose Response||University of North Carolina, Chapel Hill|No|Completed|October 2006|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|690|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 27, 2010|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00467064||171895|
NCT00467298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 04-242|An Intervention to Improve Function in Severe Cardiopulmonary Illness|An Intervention to Enhance Function in Severe Cardiopulmonary Illness||VA Office of Research and Development|Yes|Completed|December 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|45 Years|N/A|No|||December 2014|December 1, 2014|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00467298||171877|
NCT00490035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01252|Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures|A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.||UCB Pharma|No|Completed|September 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|399|||Both|16 Years|70 Years|No|||April 2015|April 29, 2015|June 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00490035||170163|
NCT00493662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5310|Cross-Over Evaluation of Two Lubricating Eye Drops|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||January 2008|January 11, 2008|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00493662||169889|
NCT00490594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-ACL1|SeriACL™ Device Trial for Anterior Cruciate Ligament (ACL) Reconstruction|A Multi-Center Open Study to Evaluate the SeriACL™ Device for Primary Anterior Cruciate Ligament Repair||Serica Technologies, Inc.|No|Active, not recruiting|June 2007|||October 2008|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|45 Years|No|||October 2008|October 17, 2008|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00490594||170120|
NCT00490607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemangioma Study|A Prospective Study Comparing the Incidence of Infantile Hemangiomas Following Normal Pregnancies Versus Pregnancies Complicated by Placental Abnormalities|||Rady Children's Hospital, San Diego||Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Female|N/A|N/A||||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490607||170119|
NCT00490334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-08123|Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer|Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer||Stanford University|Yes|Completed|August 2007|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|72|||Both|9 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric cancer patients 8 to 16 years of age, with age- and gender-matched control        group.|May 2015|May 19, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00490334||170140|
NCT00490841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-102|The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis|A Clinical Trial to Assess the Safety and Efficacy of the RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Suboptimal Post-procedural Percutaneous Transluminal Angioplasty (PTA) in de Novo or Restenotic Renal Artery Stenoses in Patients With Uncontrolled Hypertension.|HERCULES|Abbott Vascular|Yes|Completed|August 2007|December 2012|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|June 21, 2007|Yes|Yes||No|September 6, 2011|https://clinicaltrials.gov/show/NCT00490841||170101|
NCT00491179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200703032M|Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin|Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Who Fail Interferon Alfa or Pegylated Interferon Alfa Monotherapy - a Pilot Study||National Taiwan University Hospital|Yes|Completed|June 2006|July 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||October 2009|October 7, 2009|June 23, 2007||No||No|December 21, 2008|https://clinicaltrials.gov/show/NCT00491179||170075|
NCT00491790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10854|Montelukast With Status Asthmaticus, Ages 2-5|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|December 2006|October 2010|Anticipated|January 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|52|||Both|2 Years|5 Years|No|||November 2008|December 15, 2008|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00491790||170029|
NCT00492102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB# 05-05-22|Montelukast in Very Low Birthweight Infants|Pharmacokinetics of Montelukast in Very Low Birthweight (VLBW) Preterm Infants||Children's Hospital Medical Center, Cincinnati|Yes|Completed|March 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|N/A|N/A|No|||August 2012|August 1, 2012|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492102||170006|
NCT00492661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013702|A Pilot Trial to Evaluate the Effect of Diet and Exercise in Renal Transplant Recipients on Tacrolimus|A Pilot Trial of the Effect of Dietary and Exercise Intervention on Insulin Resistance and Metabolic Parameters in De Novo Renal Transplant Recipients on Prograf (Tacrolimus)|PRIDE|Janssen-Cilag Pty Ltd|No|Completed|July 2007|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|18 Years|N/A|No|||May 2013|May 24, 2013|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492661||169965|
NCT00492921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06116 CDR0000549900|High-Dose Cyclophosphamide in Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond to Steroid Therapy|||Sidney Kimmel Comprehensive Cancer Center||Completed|May 2007|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Primary Purpose: Supportive Care|1||Actual|12|||Both|N/A|75 Years|No|||June 2013|June 3, 2013|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492921||169945|
NCT00492934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2436 - 30/12/2003|What is the Best Preparation for Embryo Transfer in Cryo Cycles: a Natural Cycle or Light Hormonal Stimulation?|Natural Cycle Versus Stimulation With Human Menopausal Gonadotropin in Cycles With Cryopreserved Embryos||University Hospital, Gasthuisberg|No|Active, not recruiting|January 2004|October 2014|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492934||169944|
NCT00494065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP07638|Chiropractic and Self-care for Back-Related Leg Pain|Chiropractic and Self-care for Back-Related Leg Pain||Northwestern Health Sciences University||Completed|June 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|21 Years|N/A|No|||January 2014|January 30, 2014|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00494065||169859|
NCT00494052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|490|Evaluating a Web-Based Educational Program for Adults at Risk for Coronary Heart Disease (The Heart to Heart Feasibility Study)|An Intervention to Enhance CHD Risk Factor Modification: The Heart to Heart Feasibility Study||University of North Carolina, Chapel Hill|Yes|Completed|June 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|186|||Both|40 Years|79 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494052||169860|
NCT00465933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pethema LPA-99 protocol|Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)|Treatment of Acute Promyelocytic Leukemia: Remission Induction With ATRA + Idarubicin (AIDA) Risk Adapted Intensity of Consolidation and Addition of ATRA Maintenance With ATRA + Methotrexate + Mercaptopurine Salvage Therapy for Molecular and Haematological Relapses||PETHEMA Foundation||Completed|March 1999|November 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|75 Years|No|||March 2008|March 27, 2008|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00465933||171981|
NCT00465946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA04-071|Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial|Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|June 2004|June 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2007|April 25, 2007|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465946||171980|
NCT00466583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2968-01|Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma|A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia-Inducible Factor-1α, Administered as a Weekly 2-Hour Intravenous Infusion in Adult Patients With Advanced Solid Tumors or Lymphoma||Enzon Pharmaceuticals, Inc.|No|Completed|March 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|April 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00466583||171932|
NCT00466804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-05|Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients|Observational Study of Alloimmunity in Cardiac Transplant Recipients||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|263|Samples With DNA|Blood samples may be retained|Both|10 Years|N/A|No|Non-Probability Sample|People who are on the waiting list for a heart transplant at one of the participating        study sites (listed below)|December 2015|December 31, 2015|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466804||171915|
NCT00467077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000540598|Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer|Phase II Trial of ZD1839 (IRESSA®) and Pegylated Interferon Alfa 2b (PEG-Intron™) in Unresectable or Metastatic Renal Cell Carcinoma||California Cancer Consortium||Completed|September 2004|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467077||171894|
NCT00467311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07552|Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients|Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization||National Heart Institute, Mexico|No|Completed|December 2006|April 2008|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|66|||Both|20 Years|85 Years|No|Non-Probability Sample|Patients over 20 years old with an indication for coronariography and/or percutaneous        coronary intervention, and with a MEHRAN contrast-induced nephropathy score from six to        fifteen.|May 2008|May 6, 2008|April 27, 2007||||No||https://clinicaltrials.gov/show/NCT00467311||171876|
NCT00493350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0278|Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer|International Stage IV Stratification Study (ISSS): Prospective Validation Trial of Circulating Tumor Cells (CTCs) as Prognostic and Predictive Markers in Women With Metastatic Breast Cancer About to Start First-Line Treatment||M.D. Anderson Cancer Center|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|660|Samples With DNA|Blood collected prior to the initiation of chemotherapy as follows: 1 x 4 ml (serum tube),      2x10 ml (CellSave Tube), and 1x10 ml EDTA (selected centers); To perform global gene      profiling on selected specimens and correlate the profiles with clinical outcomes.|Female|N/A|N/A|No|Probability Sample|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.|July 2012|July 27, 2012|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493350||169913|
NCT00493649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-038|Adj TC + Herceptin Early Stage Breast Cancer|Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients||US Oncology Research|No|Completed|June 2007|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|493|||Female|18 Years|70 Years|No|||May 2014|May 19, 2014|June 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493649||169890|
NCT00493675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06089|Biodegradable Biliary Stent for Post Operative Cystic Duct Leakage|Biodegradable Biliary Stent for Post Operative Cystic Duct Leakage. Pilot Study||University of Tampere|No|Withdrawn|June 2006|June 2010|Anticipated|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||February 2009|June 24, 2010|June 27, 2007|||Difficulties in getting suitable applicators for biodegradable stents.|No||https://clinicaltrials.gov/show/NCT00493675||169888|
NCT00493922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG-8|Trial of Rapid Diagnostic Tests in Rural Ghana|An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana|RDT|Gates Malaria Partnership|No|Completed|July 2007|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|7263|||Both|N/A|N/A|No|||June 2007|July 2, 2009|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00493922||169869|
NCT00490620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Col40296|Study of Combivir for Patients With Primary Biliary Cirrhosis|Randomized Controlled Pilot Study of Combivir for Patients With Primary Biliary Cirrhosis||University of Alberta|No|Completed|January 2004|April 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|No|||October 2007|October 31, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490620||170118|
NCT00490893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-003940-79|Hypoglycemia Counterregulation and Symptom Perception With Insulin Detemir|Effects of Insulin Detemir Versus Regular Insulin (Actrapid) on Hormonal Counterregulation, Cognitive Function and Symptom Perception During Hypoglycemia||University Hospital Tuebingen|No|Terminated|March 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2007|June 22, 2007|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00490893||170097|
NCT00490867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LipoicacidFBFV1.0|Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes|Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes||Medical University of Vienna|No|Active, not recruiting|July 2004|August 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|65 Years|No|||June 2007|June 22, 2007|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00490867||170099|
NCT00490880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8193|Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer|The Evaluation of Efficacy and Toxicity of Combined Treatment: Neoadjuvant Chemotherapy (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer Stage T2b-T3 NO/Nx M0||Eli Lilly and Company|No|Completed|November 2003|August 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490880||170098|
NCT00491192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1575|Normothermia in Patients With Acute Cerebral Damage|Normothermia in Patients With Acute Cerebral Damage||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Recruiting|June 2007|June 2009||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|16 Years|N/A|No|||June 2007|September 19, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491192||170074|
NCT00491218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-12030|The Addition of Cardiac CT to Exercise Treadmill Testing in the Evaluation of Angina|The Addition of Cardiac Computed Tomography to Exercise Treadmill Testing in the Evaluation of Angina|CT-EXTRA|Walter Reed Army Medical Center|No|Recruiting|June 2007|||||N/A|Observational|Allocation: Random Sample, Observational Model: Natural History, Time Perspective: Longitudinal|||||||Both|18 Years|70 Years||||June 2007|June 22, 2007|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00491218||170073|
NCT00492115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG08415|Cognitive Benefits of Treating Sleep Apnea in Parkinson's Disease|Cognitive Benefits of Treating Sleep Apnea in Dementia|TAP|University of California, San Diego|No|Completed|July 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|50 Years|N/A|No|||June 2013|June 17, 2013|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492115||170005|
NCT00492388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-016|Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Comparing the Efficacy and Safety of PMI-150 (Intranasal Ketamine) to Placebo as an Analgesic for the Treatment of Breakthrough Pain in Cancer Patients||Hospira, Inc.|No|Terminated|June 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|June 26, 2007|Yes|Yes|Business decision not to continue development|No||https://clinicaltrials.gov/show/NCT00492388||169986|
NCT00492401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00246|Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia|Phase II Study of Decitabine in Acute Myeloid Leukemia||National Cancer Institute (NCI)||Active, not recruiting|May 2007|||December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492401||169985|
NCT00493441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN944-006|AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer|A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer||Vertex Pharmaceuticals Incorporated|Yes|Terminated|June 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||September 2013|August 5, 2014|June 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493441||169906|
NCT00494078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|488/2005|Efficiency of Continuous Glucose Monitoring in Critically Ill Patients|Efficiency of Real Time Continuous Glucose Monitoring to Achieve Normoglycemia in Critically Ill Patients - a Prospective, Randomized Study||Medical University of Vienna|Yes|Completed|June 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||January 2009|November 29, 2010|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00494078||169858|
NCT00493831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-05|Analysis of Lipid Biomarkers of Exposure and Host Response|||University of Nebraska|No|Active, not recruiting|May 2006|July 2007|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|19 Years|N/A|No|||June 2007|June 27, 2007|June 5, 2007||||No||https://clinicaltrials.gov/show/NCT00493831||169876|
NCT00494351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4309|Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa|Prospective Controlled Study of the Efficacy of NdYag for Hidradenitis Suppurativa||Henry Ford Health System|No|Completed|June 2007|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||May 2010|May 20, 2010|June 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00494351||169838|
NCT00466271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200611011R|Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study|Prediction of Significant Hepatic Fibrosis in HCV Carriers With Persistently Normal Alanine Aminotransferase Levels by Splenic Arterial Pulsatility Index- A Validation Study||National Taiwan University Hospital|Yes|Completed|April 2007|December 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|102|||Both|18 Years|70 Years|No|Non-Probability Sample|HCV carriers with persistently normal ALT levels who will receive percutaneous liver        biopsy|December 2008|December 21, 2008|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00466271||171955|
NCT00466557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0084|Plasmodium Resistance in A. Gambiae|Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|June 2007|||||N/A|Observational|Time Perspective: Prospective||||40|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||April 2008|August 26, 2010|April 26, 2007||||No||https://clinicaltrials.gov/show/NCT00466557||171934|
NCT00467324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS 002|The Advance Trial. Tongue Advancement for Obstructive Sleep Apnea: An Evaluation of the Aspire Medical Advance System|The Advance Trial. Tongue Advancement for Obstructive Sleep Apnea: An Evaluation of the Aspire Medical Advance System||Aspire Medical|Yes|Active, not recruiting|April 2007|December 2008|Anticipated|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|65 Years|No|||October 2008|October 13, 2008|April 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00467324||171875|
NCT00467337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPESP#130/04|Medial-Wedge Insole is Highly Effective in the Treatment of Valgus Knee Osteoarthritis|Medial-Wedge Insole is Highly Effective in the Treatment of Valgus Knee Osteoarthritis||University of Sao Paulo|Yes|Terminated|June 2004|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Female|45 Years|N/A|Accepts Healthy Volunteers|||April 2007|April 27, 2007|April 27, 2007|||Terminated|No||https://clinicaltrials.gov/show/NCT00467337||171874|
NCT00466817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0046|Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections|A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2008|June 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|N/A|30 Days|No|||July 2015|August 13, 2015|April 26, 2007|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT00466817||171914|
NCT00463476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEV04|Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine|Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka||PATH|No|Completed|July 2007|April 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|306|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||April 2009|May 4, 2009|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463476||172166|
NCT00463723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-2000-2003|Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty|||University Hospital Freiburg|No|Terminated||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Both|18 Years|N/A|No|||August 1999|April 18, 2007|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463723||172147|
NCT00464048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bhmi55-hmo-ctil|A Controlled Study to Assess the Effectiveness of Aerobic Exercise as an Augmentation Therapy for Inpatients With Major Depressive Disorder|A Controlled Study to Assess the Effectiveness of Aerobic Exercise as an Augmentation Therapy for Inpatients With Major Depressive Disorder||Hadassah Medical Organization|No|Not yet recruiting|May 2007|May 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|80 Years|No|||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00464048||172122|
NCT00493961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HD028138-447|Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism|The Effects of 7 Days of Exogenous Pulsatile GnRH Treatment on the Pituitary-Gonadal Axis in Hypogonadotropic Hypogonadal Subjects||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|January 1999|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|65 Years|No|||October 2015|October 9, 2015|June 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493961||169866|
NCT00494260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD036069-07|Managing Recurrent Abdominal Pain|Intergenerational Transmission of Illness Behavior||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|November 2003|October 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|7 Years|17 Years|No|||July 2007|July 2, 2007|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00494260||169845|
NCT00490347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP070012|VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial|Evaluation of the VentrAssistTM Left Ventricular Assist Device as a Bridge to Cardiac Transplantation - Feasibility Trial||Ventracor|Yes|Completed|July 2005|October 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2008|January 15, 2008|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490347||170139|
NCT00490919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3024|Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain|Multi-center, Randomized, Double-blind, Placebo-controlled With Open Label run-in Study Assessing Efficacy, Tolerability, Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects With Moderate to Severe, Chronic Low Back Pain||Purdue Pharma LP|No|Completed|June 2007|October 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|539|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|June 21, 2007|Yes|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00490919||170095|
NCT00490906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCALSI-06-01|Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis|Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study||University of Kansas Medical Center|Yes|Completed|June 2007|December 2012|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|60|||Female|18 Years|N/A|No|Non-Probability Sample|The participants must be female with clinical diagnosis of multiple sclerosis and have        been using either Copaxone or interferon injections for the past 1 or more years.|January 2014|January 17, 2014|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490906||170096|
NCT00491231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4663-EG-CTIL|Is Orthostatic Hypotension Associated With Nondipping Hypertension|||Sheba Medical Center|No|Recruiting|July 2007|December 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|400 subjects who are referred for 24hABPM|November 2007|November 15, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491231||170072|
NCT00491491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4466-AN-CTIL|Zevalin-beam for Aggressive Lymphoma|SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma||Sheba Medical Center|No|Completed|June 2007|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491491||170052|
NCT00491504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05073|This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Using Subjective and Objective Measures to Evaluate the Clinical Efficacy of Mometasone Furoate Nasal Spray (MFNS) Following Initial and Maintenance Dosing in Subjects With Allergen-Induced Seasonal Allergic Rhinitis (SAR) in an Environmental Exposure Chamber (EEC)||Merck Sharp & Dohme Corp.||Completed|February 2007|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|65 Years|No|||February 2015|February 24, 2015|June 25, 2007||||No|March 11, 2010|https://clinicaltrials.gov/show/NCT00491504||170051|
NCT00491530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-884|A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia|A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia||Abbott|No|Completed|June 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|310|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|June 22, 2007|Yes|Yes||No|November 3, 2009|https://clinicaltrials.gov/show/NCT00491530||170049|This was an open-label study designed to assess the long-term safety of the combination therapies. Evaluation of efficacy outcomes was a secondary objective.
NCT00492674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/07|The Effect of Perioperative Neuromuscular Training on the Outcome of Total Knee Arthroplasty|The Effect of Perioperative Neuromuscular Training on the Outcome of Total Knee Arthroplasty: A Double Blind Randomized Prospective Study||Assaf-Harofeh Medical Center|No|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|55 Years|75 Years|No|||April 2007|June 26, 2007|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00492674||169964|
NCT00492947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040999|Dendritic Cell Vaccine for Head and Neck Cancer|0608 GCC:Phase I Study of Intra-tumoral Injection of Dendritic Cells for the Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Dendritic|University of Maryland|Yes|Withdrawn|June 2007|June 2012|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2010|January 10, 2013|June 26, 2007|No|Yes|major amendments in progress|No||https://clinicaltrials.gov/show/NCT00492947||169943|
NCT00493454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0571|Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas|Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma||M.D. Anderson Cancer Center|No|Terminated|April 2006|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|June 27, 2007|No|Yes|Slow accrual.|No|September 28, 2012|https://clinicaltrials.gov/show/NCT00493454||169905|
NCT00493467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0512|Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas|Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas||M.D. Anderson Cancer Center|No|Completed|June 2006|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493467||169904|
NCT00493480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-02-049/03|Danish Carvedilol Study in Portal Hypertension|Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices|DACAPO|Hvidovre University Hospital|Yes|Completed|September 2003|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2009|August 7, 2009|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493480||169903|
NCT00493181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0113|Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients|The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Completed|October 2005|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||February 2012|February 17, 2012|June 26, 2007||No||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00493181||169925|
NCT00493428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2006:156|Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study|Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study||University of Manitoba|No|Withdrawn|July 2007|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||May 2014|May 15, 2014|June 27, 2007||No|The study have been stoped because the protocol is going to be modify.|No||https://clinicaltrials.gov/show/NCT00493428||169907|
NCT00494091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-2217|Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma|Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC)||Pfizer|No|Completed|February 2007|March 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|20 Years|N/A|No|||March 2013|March 15, 2013|June 28, 2007|Yes|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT00494091||169857|
NCT00493844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-27-06|N-terminal Pro B-type Natriuretic Peptide (Nt-proBNP) Versus Exercise Test for Evaluation of Acute Chest Pain|Clinical History and NT-proBNP Versus Exercise Testing for Evaluation of Patients With Acute Chest Pain Without Ischemic Changes in the Electrocardiogram or Troponin Elevation||University of Valencia|No|Completed|January 2007|January 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|320|||Both|N/A|N/A|No|||February 2013|February 8, 2013|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493844||169875|
NCT00494364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040059|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3a Part ii|Gas Supply, Demand and Middle Ear Gas Balance: Sp Aim 3a Pt ii||Children's Hospital of Pittsburgh|No|Completed|June 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers|November 2011|November 7, 2011|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494364||169837|
NCT00466284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGCP023/05-ML19497|Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer|Phase II Trial of Tarceva Following Concurrent Chemo-Radiotherapy as First Line Therapy in Patients With Unresectable Non-Small Cell Lung Cancer||Grupo Gallego de Cancer de Pulmon|Yes|Recruiting|January 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||46|||Both|18 Years|90 Years|No|||April 2007|April 25, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466284||171954|
NCT00466297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Health Canada 102117|Interprofessional Collaborative Communication in Acute Care Hospital Teams|The SCRIPT Programme (GIM): Structuring Communication Relationships for Interprofessional Teamwork to Achieve Interprofessional Education for Collaborative Patient-Centered Practice (IECPCP)|SCRIPT|Sunnybrook Health Sciences Centre|No|Completed|April 2007|December 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1000|||Both|N/A|N/A|No|||April 2007|February 6, 2009|April 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00466297||171953|
NCT00463489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2007-LISA|Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer|Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer|LISA|Ontario Clinical Oncology Group (OCOG)|No|Active, not recruiting|August 2007|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2150|||Female|N/A|N/A|No|||February 2014|April 13, 2015|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463489||172165|
NCT00463502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-013|The Effect of Metformin Treatment on Thyroid Hormone Metabolism in Euthyroid Patients With Type 2 Diabetes Mellitus|||Haydarpasa Numune State Hospital|No|Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|35 Years|78 Years||||March 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463502||172164|
NCT00467623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-93140|Holotranscobalamin Remains Unchanged During Pregnancy|Holotranscobalamin Remains Unchanged During Pregnancy. Longitudinal Changes of Cobalamins and Its Binding Proteins During Pregnancy and Postpartum||University of Aarhus|No|Completed|January 1995|December 1997|Actual|||N/A|Observational|Time Perspective: Prospective||||150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2007|October 16, 2008|April 27, 2007||||No||https://clinicaltrials.gov/show/NCT00467623||171853|
NCT00463463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor451107ctil|Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma|Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma|Zevalin|Soroka University Medical Center|No|Recruiting|April 2007|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|65 Years|No|||February 2007|July 11, 2012|April 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00463463||172167|
NCT00464074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-06-NAT|Evaluation of Natalizumab for thE Relief of MS Associated FatiGue|Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS|ENER-G|Biogen|No|Completed|September 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|55 Years|No|Non-Probability Sample|multicenter clinic patients|July 2011|July 7, 2011|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00464074||172120|
NCT00464087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWITCH III|Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI|Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III|SWITCHIII|Medstar Research Institute|Yes|Completed|June 2007|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|April 19, 2007|No|Yes||No|April 16, 2013|https://clinicaltrials.gov/show/NCT00464087||172119|This trial included only small number of patients and is not powered to detect intergroup differences
NCT00494273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1HD38458|HIV Prevention in Haitian American Adolescents|HIV Prevention in Haitian Youths (HAP)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|December 2002|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention||||320|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||September 2014|October 28, 2014|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00494273||169844|
NCT00490074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006141-13|Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers|A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost|EV03/ANRSVAC20|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|July 2007|October 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|147|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 25, 2009|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490074||170160|
NCT00490087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 23/98|Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women|Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits||IRCCS Burlo Garofolo|No|Completed|January 1999|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Female|25 Years|50 Years|No|||June 2007|September 1, 2011|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490087||170159|
NCT00490360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-2001|Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head|Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head||University of Zurich|No|Completed|October 2001|May 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2007|||Both|18 Years|N/A|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00490360||170138|
NCT00490932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID04001|New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects|Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases – A Phase IV Surveillance Study||Society for Applied Studies|No|Completed|March 2005|April 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27966|||Both|N/A|N/A|No|||February 2007|June 22, 2007|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00490932||170094|
NCT00490945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-2101|Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers|A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects||Vanda Pharmaceuticals|No|Completed|July 2004|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|June 22, 2007||||No|February 28, 2014|https://clinicaltrials.gov/show/NCT00490945||170093|
NCT00491244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200703010M|Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C|Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Versus Pegylated Interferon Alfa-2a Alone for Treatment-naïve Hemodialysis Patients With Chronic Hepatitis C||National Taiwan University Hospital|Yes|Completed|June 2007|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|377|||Both|18 Years|65 Years|No|||January 2014|January 13, 2014|June 23, 2007||No||No|September 29, 2013|https://clinicaltrials.gov/show/NCT00491244||170071|Open-label trialResults may not be generalizable to peritoneal dialysis patientsHigher percentages of favorable IL28B genotypesSecondary endpoint may not be powered to detect the differences
NCT00491257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT82|A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)||Sanofi|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 16, 2014|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491257||170070|
NCT00491803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIL-COPD-01|Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD)|Acute Effects of a Single Dose of Sildenafil (20mg/40mg) on Pulmonary Haemodynamics and Gas Exchange at Rest and During Exercise in COPD Patients With Pulmonary Hypertension|SIL-COPD-01|Hospital Clinic of Barcelona|No|Completed|June 2007|February 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|75 Years|No|||November 2009|November 9, 2009|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00491803||170028|
NCT00493194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004115-38|Fibrosis in Renal Allografts|Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic)||University Hospital, Antwerp||Recruiting|May 2005|July 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||October 2005|November 25, 2008|June 27, 2007||||No||https://clinicaltrials.gov/show/NCT00493194||169924|
NCT00492973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCO.2006.2|Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?|Peri-articular Injections Containing a Corticosteroid During Total Knee Arthroplasty||New Lexington Clinic|No|Completed|March 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|101|||Both|18 Years|95 Years|No|||April 2013|October 29, 2013|June 25, 2007|Yes|Yes||No|October 18, 2012|https://clinicaltrials.gov/show/NCT00492973||169941|One patient died 25 days after the surgery as a result of complications associated with deep knee joint sepsis.
NCT00493220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1838-004|Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration|INcreased Flow Utilizing Subcutaneously-Enabled Ceftriaxone (INFUSE-Ceftriaxone) Study: A Phase I Study Comparing the Safety and Pharmacokinetics of Ceftriaxone Administered Subcutaneously With and Without Human Recombinant Hyaluronidase (HYLENEX Recombinant) and Intravenously in Human Volunteers|INFUSE-Cftrx|Baxter Healthcare Corporation|No|Completed|June 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 24, 2011|June 26, 2007|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00493220||169923|
NCT00493233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174/2006|Antipsychotic Polypharmacy in Schizophrenia|Antipsychotic Polypharmacy in Schizophrenia||Centre for Addiction and Mental Health|No|Completed|November 2006|||December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||May 2009|May 18, 2009|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00493233||169922|
NCT00493792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003093|X-3 Polyethylene Survival Outcomes Study|A Prospective, Randomized Study Comparing the Survival for X-3 Polyethylene to N2Vac Polyethylene When Used With the Triathlon Posterior Stabilized (PS) Total Knee System.||Mayo Clinic|No|Active, not recruiting|February 2007|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|516|||Both|21 Years|85 Years|No|||September 2015|September 8, 2015|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493792||169879|
NCT00493805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04823|Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)|Study to Evaluate Response Rates in Chronic Hepatitis C (CHC) Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders||Merck Sharp & Dohme Corp.|No|Terminated|April 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|June 25, 2007|No|Yes|Slow Enrollment|No|October 27, 2010|https://clinicaltrials.gov/show/NCT00493805||169878|
NCT00494117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X07- 0052|Investigation of Heart Failure Status Over Time Using Respiratory Parameters|Investigation of Heart Failure Status Over Time Using Respiratory Parameters||ResMed|No|Completed|June 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|The population under investigation is moderate to severe heart failure who are outpatients        of a major Sydney hospital.|July 2010|July 25, 2010|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494117||169855|
NCT00494104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD048870|Prevention of Vitamin D Deficiency|Prevention of Vitamin D Deficiency in Breastfed Infants||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|September 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|398|||Both|N/A|5 Weeks|Accepts Healthy Volunteers|||September 2006|December 14, 2012|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494104||169856|
NCT00494377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8601|Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression|Duloxetine Versus Duloxetine Plus Non-Pharmacological Intervention in the Treatment of Depression||Eli Lilly and Company|No|Completed|February 2004|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||940|||Both|18 Years|N/A|No|||June 2007|June 28, 2007|June 27, 2007||||No||https://clinicaltrials.gov/show/NCT00494377||169836|
NCT00467090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070137|Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation|Expanding the Phenotype of the LRRK-2 Mutation in Individuals With History of Parkinson s Disease and Their Relatives: a Prospective Study||National Institutes of Health Clinical Center (CC)||Terminated|April 2007|February 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 19, 2014|April 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00467090||171893|
NCT00463762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1891004|Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.|Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.||Pfizer||Withdrawn|May 2007|||||Phase 4|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|April 17, 2007||||||https://clinicaltrials.gov/show/NCT00463762||172144|
NCT00463775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702002346|Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence|Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence||Yale University|No|Withdrawn|March 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|60 Years|No|||January 2012|January 26, 2012|April 18, 2007||No|Recruitment not progressing as planned.|No||https://clinicaltrials.gov/show/NCT00463775||172143|
NCT00463736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006|Magnesium Sulfate Versus Placebo for Tocolysis in PPROM|Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes||Regional Obstetrical Consultants|Yes|Recruiting|April 2007|April 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||128|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2007|April 19, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00463736||172146|
NCT00464061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTE6673|Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus|Efficacy and Safety of 2mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-blind, Placebo-controlled Study|SAMS|Sanofi||Terminated|April 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1847|||Both|18 Years|N/A|No|||August 2009|August 27, 2009|April 19, 2007|Yes|Yes|Sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary    insomnia with predominant sleep maintenance problems|No||https://clinicaltrials.gov/show/NCT00464061||172121|
NCT00464386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-06-011|Continuous Glucose Monitoring (POC) in the ICU|Continuous Glucose Monitors (CGM) Versus Point-of-Care (POC) Glucometers in the Intensive Care Unit (ICU)|POC|United States Army Institute of Surgical Research|No|Terminated|September 2006|December 2013|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|23|||Both|18 Years|72 Years|No|||February 2015|February 2, 2015|April 20, 2007|No|Yes|The device selected for this study required modifications that were not feasible|No||https://clinicaltrials.gov/show/NCT00464386||172098|
NCT00464399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ANO01|Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients|A Pilot Study to Evaluate Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant||Novartis||Completed|September 2006|||December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|N/A||||March 2014|March 6, 2014|April 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464399||172097|
NCT00490126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0170|Data Collection of Demographics and Perioperative Care of Patients Undergoing Laparoscopic Surgery|Data Collection of Demographics and Perioperative Care of Patients Undergoing Laparoscopic Surgery in the Department of Gynecologic Oncology||M.D. Anderson Cancer Center|No|Recruiting|June 2006|||June 2027|Anticipated|N/A|Observational|N/A||1|Anticipated|5000|||Female|N/A|N/A|No|Probability Sample|All patients who had or will have laparoscopic surgery in the Department of Gynecologic        Oncology (Gynecologic Oncology and General Gynecology) since January 1, 1990 forward.|November 2015|November 9, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00490126||170156|
NCT00490139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF106708|ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D|A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer|ALTTO|GlaxoSmithKline|Yes|Active, not recruiting|May 2007|November 2022|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|8381|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|June 20, 2007|Yes|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT00490139||170155|
NCT00490100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070171|Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1|Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1)||National Institutes of Health Clinical Center (CC)|Yes|Terminated|June 2007|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|20 Years|No|||March 2014|July 2, 2015|June 21, 2007|Yes|Yes|Insufficient patient participation|No|March 18, 2014|https://clinicaltrials.gov/show/NCT00490100||170158|Due to limited subject participation, there is insufficient complete data to generate meaningful statistics for the outcome measures. Instead, this data will be reported as a case series.
NCT00490113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10417|A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria|Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria||University of Kansas Medical Center|Yes|Withdrawn|January 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 20, 2007|Yes|Yes|Drug unavailable|No||https://clinicaltrials.gov/show/NCT00490113||170157|
NCT00490633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00008566|Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza Transmission|Reducing the Transmission of Influenza by Face Masks|M-FLU|University of Michigan|Yes|Completed|October 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|August 18, 2011|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490633||170117|
NCT00491816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10864|Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer|Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer||University of Kansas Medical Center|Yes|Active, not recruiting|July 2007|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|18 Years|N/A|No|||December 2013|March 31, 2015|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00491816||170027|
NCT00491829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.77|Flibanserin Versus Placebo in Premenopausal Women With HSDD|A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder||Sprout Pharmaceuticals, Inc|Yes|Completed|June 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|945|||Female|18 Years|N/A|No|||May 2014|May 6, 2014|June 25, 2007|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT00491829||170026|
NCT00491517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRENA|Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety|Sirolimus Treatment in Patients With ADPKD|SIRENA|Mario Negri Institute for Pharmacological Research|Yes|Completed|March 2007|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|80 Years|No|||April 2013|April 23, 2013|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491517||170050|
NCT00492414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL110010|Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release|||Inje University||Recruiting||||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|||||||Both|20 Years|50 Years||||March 2007|August 7, 2007|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00492414||169984|
NCT00492427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH20565|Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)|Correction and Maintenance Study of Subcutaneous Injections of R744 to Predialysis Patients ( Phase III, Comparative Study in Comparison With Epoetin Beta)||Chugai Pharmaceutical|Yes|Completed|June 2007|November 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|187|||Both|20 Years|N/A|No|||January 2009|January 6, 2009|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492427||169983|
NCT00492986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11941|An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma|An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma||Bayer|No|Completed|October 2005|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1150|||Both|18 Years|N/A|No|||December 2014|December 26, 2014|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492986||169940|
NCT00492999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-075|Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver|A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic Chemotherapy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2007|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492999||169939|
NCT00493246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APA-102|Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients|A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (PK) and Safety in Acute Pain and Fever||Mallinckrodt|No|Completed|June 2007|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|N/A|16 Years|No|||May 2015|May 14, 2015|June 27, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00493246||169921|Median ranges were not calculated or not assessable for neonates at the following due to limited samples.:12.5 mg/kg q6h- t1/2 (h)15 mg/kg q8h -Cmax, Tmax, AUC0-t and t1/2.
NCT00493259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 02-037E|Health Related QOL, Depression and Lifestyle Changes in Insulin Resistant Adolescents|Health-Related Quality of Life, Depression and the Impact on Successful Incorporation of Lifestyle Changes in Insulin Resistant Adolescents as Evidenced by Changes in BMI, Waist Circumference and Metabolic Parameters||Children's Mercy Hospital Kansas City|No|Recruiting|June 2007|June 2008|Anticipated|June 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|11 Years|17 Years|No|Non-Probability Sample|Adoslescents treated in Children's Mercy Hospital and Clinic, Endocrine clinic.|June 2007|January 21, 2008|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493259||169920|
NCT00493493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilonidal/Cymetra|Pore Excision, Curettage, and Injection of Cymetra for Pilonidal Disease|Pore Excision, Curettage, and Injection of a Tissue Scaffold as Treatment for Pilonidal Disease||Matino, James, M.D.|No|Recruiting|January 2007|June 2008|Anticipated|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||June 2007|June 27, 2007|June 27, 2007||||No||https://clinicaltrials.gov/show/NCT00493493||169902|
NCT00493818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKT106757|Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693|An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 Given on Various Schedules in Subjects With Solid Tumors or Lymphoma||GlaxoSmithKline||Terminated|April 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|June 27, 2007||||||https://clinicaltrials.gov/show/NCT00493818||169877|
NCT00482755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA29|Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery|A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients With T1c-T3 Operable Carcinoma of the Breast||Canadian Cancer Trials Group|Yes|Completed|March 2007|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2011|June 20, 2013|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482755||170718|
NCT00494143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4372-R|Metabolic Cost Savings for Transtibial Amputees Wearing the Controlled Energy Storage and Return (CESR) Foot|Metabolic Cost Savings for Transtibial Amputees Walking With the CESR Foot||VA Office of Research and Development|No|Completed|July 2007|December 2012|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|June 28, 2007||No||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00494143||169854|Acclimatization to a prosthetic foot type can alter the measured performance. In this study, subjects were most experienced using their prescribed foot. The CESR foot was also only available in one foot size which can affect gait characteristics.
NCT00494403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0615070095|Chronic Ankle Instability and Proprioception|Effects of Ankle Instability on Cervical Proprioception||Logan College of Chiropractic|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cohort of college aged students with a history of ankle sprains.|May 2013|May 1, 2013|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00494403||169834|
NCT00494416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD 010607|Different Approaches for Delivery of IPT in Pregnancy in Burkina Faso|A Comparison of Different Approaches for Delivery of Intermittent Preventive Treatment (IPT)to Pregnant Women in Burkina Faso With Regard to Coverage and Compliance||Gates Malaria Partnership|No|Completed|June 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|11523|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494416||169833|
NCT00467636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD1|Insulin Therapy in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Influence of Insulin Therapy in Patients Admitted to Hospital With Acute Exacerbations of Chronic Obstructive Pulmonary Disease||The Royal Bournemouth Hospital|Yes|Terminated|July 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||October 2009|October 1, 2009|April 27, 2007||No|Difficulty recruiting (early discharge scheme initiated)|No||https://clinicaltrials.gov/show/NCT00467636||171852|
NCT00464412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Kasper|The Effect of a Short Educational Program on Young Women's Knowledge and Beliefs About Osteoporosis|The Effect of a Short Educational Program on Young Women's Knowledge and Beliefs About Osteoporosis||Valdosta State University|No|Completed|January 2006|February 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|135|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2007|May 8, 2007|April 19, 2007||||No||https://clinicaltrials.gov/show/NCT00464412||172096|
NCT00464100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/36|Near-infrared Spectroscopy (NIRS) Neurodevelopmental Outcomes|Neurodevelopmental Outcomes and Postoperative Hemodynamics in Children With Hypoplastic Left Heart Syndrome|NIRS ND|Medical College of Wisconsin|No|Active, not recruiting|August 2006|December 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|48|||Both|4 Years|5 Years|Accepts Healthy Volunteers|Probability Sample|Cases:          -  clinical diagnosis of hypoplastic left heart syndrome, status post Norwood procedure,             bidirectional Glenn, and completion Fontan, ages 4-5 years old, English-speaking             patient and parent, informed consent        Controls:        Healthy children 4-5 years old, English-speaking patient and parent, informed consent|September 2015|September 21, 2015|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00464100||172118|
NCT00464113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL228-001|Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL)||Exelixis|Yes|Terminated|May 2007|April 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|April 18, 2007|No|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00464113||172117|
NCT00464997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-OE-156-CTIL|The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate|The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||||30|||Both|18 Years|80 Years|No|||April 2007|April 23, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00464997||172052|
NCT00465010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061202|Effects of a Worksite Parenting Program|Talking Parents, Healthy Teens: A Worksite-Based Parenting Program for Parents of Adolescents||RAND|No|Completed|April 2002|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1252|||Both|11 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465010||172051|
NCT00490152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 062|Microbicides Acceptability Among Sexually Active Young Women|Microbicide-Use Adherence, Acceptability, and Attitudes Among Sexually Active Young Women Participating in a Phase I Microbicide Trial (MTN 004) "Tell Juliana"||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|August 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|59|||Female|18 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV-negative women ages 18 to 24 years old who are non-pregnant, sexually active and        enrolled in MTN 004 will be offered the option to enroll in ATN 062. Approximately half of        the participants will be recruited in San Juan, PR, and the other half in Tampa, FL.|August 2011|September 5, 2011|June 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00490152||170154|
NCT00490373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8621|Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic|A Phase 2 Trial of ALIMTA in Pretreated Patients With Unresectable or Metastatic Cancer of the Pancreas||Eli Lilly and Company|No|Completed|October 2003|April 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490373||170137|
NCT00490386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00126-1|Helicobacter Pylori and Acute Alcohol Induced Pancreatitis|Alkoholihaimatulehduksen Uusiminen||University of Tampere|No|Completed|June 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|100|||Both|N/A|N/A|No|||June 2007|June 21, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490386||170136|
NCT00490646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-140|A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer|Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer||R-Pharm|No|Completed|February 2008|November 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|June 21, 2007|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00490646||170116|
NCT00492154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM04-HMO-CTILL|Fracture of Distal Radius and Ulna Healed With Shortening of One Bone. Clinical Significance at Skeletal Maturity|Fracture of Distal Radius and Ulna Healed With Shortening of One Bone. Clinical Significance at Skeletal Maturity||Hadassah Medical Organization|No|Terminated|September 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|15 Years|18 Years|No|Probability Sample|Boys and girls that are at lest 12 years old at the time of the wrist fracture.|June 2009|July 20, 2009|June 26, 2007||No|the study stopped because we could not recruit enough patients.|No||https://clinicaltrials.gov/show/NCT00492154||170002|
NCT00492128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706001|Kanagawa Combination Anti-hypertensive Therapy (K-CAT)|Comparative Trial of Combination Therapy of ARB/Diuretic Versus ARB/CCB in Uncontrolled Hypertensive Patients With Monotherapy of ARB||Yokohama City University Medical Center|No|Completed|September 2007|August 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|20 Years|75 Years|No|||January 2015|January 28, 2015|June 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492128||170004|
NCT00492141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0889|Aerosol L9-NC and Temozolomide in Ewing's Sarcoma|Aerosol Liposomal 9-Nitro-20(S)-Camptothecin (L9-NC) and Temozolomide in Ewing's Sarcoma and Other Solid Tumors With Lung Involvement||M.D. Anderson Cancer Center|Yes|Completed|June 2006|September 2009|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|10 Years|N/A|No|||August 2012|August 1, 2012|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492141||170003|
NCT00492960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1001-006|Phase IIb Study to Study the Efficacy of AT1001 to Treat Celiac Disease|A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of AT-1001 in Celiac Disease Subjects During a Gluten Challenge||Alba Therapeutics|No|Completed|August 2007|March 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|184|||Both|18 Years|72 Years|No|||January 2010|January 18, 2010|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492960||169942|
NCT00492687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551555|Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas|A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas||National Cancer Institute (NCI)||Recruiting|December 2006|||July 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2009|January 9, 2014|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00492687||169963|
NCT00492700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIDO-Trials-01|A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis|A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis|FLIRT|Association pour la Recherche sur les Maladies Hépatiques Virales|No|Completed|January 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||June 2007|June 26, 2007|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00492700||169962|
NCT00481936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB6-845-01-I|Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin|A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin||Viventia Bio|No|Terminated|May 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|May 31, 2007||No|Corporate reasons unrelated to safety and efficacy|No||https://clinicaltrials.gov/show/NCT00481936||170778|
NCT00482196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0493-017|To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)|||Merck Sharp & Dohme Corp.||Completed|July 2005|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|173|||Both|21 Years|65 Years|No|||April 2015|April 27, 2015|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482196||170759|
NCT00482209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1.6|Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation|||Gynuity Health Projects||Completed|May 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|1220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 9, 2009|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482209||170758|
NCT00481962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-102184|Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)|Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2006|December 2008|Actual|December 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinical|September 2009|September 25, 2009|May 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00481962||170776|
NCT00493506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0002-01|ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency|The Effects of ProAlgaZyme Novel Algae Infusion Alone or in Combination With HAART on Markers of Immune Status, Dyslipidemia, Inflammation and Oxidative Stress in HIV or HIV/HBV Patients||Health Enhancement Products, Inc.|No|Completed|May 2006|September 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|8||Actual|59|||Both|19 Years|45 Years|No|||June 2007|June 27, 2007|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00493506||169901|
NCT00482521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4Y06|CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment|A Phase I, Open-Label Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety Profile of CC-4047 in Subjects With Advanced Solid Tumors||Case Comprehensive Cancer Center|Yes|Completed|March 2007|August 2012|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|June 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00482521||170735|
NCT00483028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001134|A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI|A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 Weeks) After Single Dose and Steady State Therapy (2 Weeks and 6 Weeks) in Subjects With Mild Cognitive Impairment||Pfizer||Completed|June 2004|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||38|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||February 2008|February 1, 2008|June 5, 2007||||No||https://clinicaltrials.gov/show/NCT00483028||170697|
NCT00483041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP139|A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528|A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma||MedImmune LLC||Terminated|July 2007|June 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|50 Years|No|||February 2014|February 4, 2014|June 4, 2007|Yes|Yes|Study is replaced by MI-CP198 per CPM.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT00483041||170696|
NCT00463515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHER@NOS|Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC|A Multicenter Phase II Study of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation in Patients With Non-resectable Stage III Non-Small-Cell-Lung Cancer|CHER@NOS|University Hospital, Antwerp||Completed|January 2003|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||77|||Both|18 Years|N/A|No|||July 2013|July 11, 2013|April 18, 2007||||No||https://clinicaltrials.gov/show/NCT00463515||172163|
NCT00463749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111/2006|Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein|Trial to Compare Infarct Size and Occurrence of Contrast Dye Induced Nephropathy in Patients With Primary Percutaneous PCI in STEMI|LIPSIA-N-ACC|University of Leipzig|Yes|Completed|December 2006|June 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|N/A|No|||July 2008|July 7, 2008|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463749||172145|
NCT00464139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC - 20/03/2007|Prevalence of Endometriosis in a Well Defined Group of Infertile Women|High Prevalence of Endometriosis in Infertile Women With Normal Ovulation and Normospermic Partners||University Hospital, Gasthuisberg|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|221|Samples Without DNA|The diagnosis of endometriosis was always confirmed by histological examination of the      lesions excised.|Female|18 Years|45 Years|No|Non-Probability Sample|The electronic files of all patients who consulted the LUFC since 2003 were searched to        select women with at least 1 year of infertility, a regular cycle (variation 21 - 35        days), whose partner had normal sperm according to World Health Organization (WHO)        criteria (n = 304).        After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of        endometriosis before referral to our centre, 221 (72,7%) infertile women were included in        our study.|February 2009|February 19, 2009|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00464139||172115|
NCT00464659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0629|Protocol Memory Deficit in Patients With Obstructive Sleep Apnea Syndrome|Comparison of the Evolution of Memory Deficit in Patients With Sleep Apnea Obstructive Syndrome (SAOS) Before and After "Effective" Versus Sham Treatment by Positive Pression Continues (PPC)||University Hospital, Grenoble|Yes|Completed|April 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|April 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00464659||172077|
NCT00464672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71P5|Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old|A Phase III, Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines in Healthy Children Aged 3 to 8 Years, in Healthy Children/Adolescents Aged 9 to 17 Years,and in Healthy Adults Aged 18 to 64 Years||Novartis|Yes|Completed|April 2007|December 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1893|||Both|3 Years|64 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|April 23, 2007|Yes|Yes||No|January 25, 2010|https://clinicaltrials.gov/show/NCT00464672||172076|
NCT00464685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-012|Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema|||Allergan|No|Completed|May 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|April 20, 2007|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00464685||172075|
NCT00490958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tchf-01-01|Telmisartan in Haemodialysis Patients With Chronic Heart Failure|Effects Of Telmisartan Added To Angiotensin Converting Enzyme Inhibitors On Mortality And Morbidity In Haemodialysed Patients With Chronic Heart Failure: A Double-Blind Placebo-Controlled Trial||Second University of Naples|No|Completed|January 1999|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|N/A|No|||November 2007|October 16, 2008|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00490958||170092|
NCT00491283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0119-08(B)|QuickVue Influenza A+B Clinical Field Trial|Comparison of Swab Types for Specimen Collection||Quidel Corporation|No|Completed|July 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||January 2008|January 23, 2008|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00491283||170068|
NCT00490399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6689|Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas|A Phase II Trial of GEMZAR Combined With Cisplatin in Patients With Inoperable Biliary Tract Carcinomas||Eli Lilly and Company|No|Completed|March 2003|September 2004|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|20 Years|70 Years|No|||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490399||170135|
NCT00491543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-2074-201|Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease||Synvista Therapeutics, Inc|No|Completed|June 2007|May 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|66|||Both|18 Years|75 Years|No|||June 2007|July 1, 2008|June 23, 2007||||No||https://clinicaltrials.gov/show/NCT00491543||170048|
NCT00492193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-07-14|Early Post-Op Recovery After Partial Large Bowel Resection|A Prospective, Observational, Multi-center Study Assessing Early Post-Operative Recovery Following Laparoscopic Partial Large Bowel Resection||University Hospital Case Medical Center|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|139|||Both|18 Years|80 Years|No|Non-Probability Sample|Colorectal Surgery clinic population|August 2008|December 12, 2014|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00492193||170000|
NCT00492440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-04|Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer|A Phase I Study of Subcutaneous "CYT 107" (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma||Cytheris SA|No|Terminated|May 2007|December 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492440||169982|
NCT00492453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UThessaly 9-04|Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy|A Controlled Randomized Trial Comparing Spinal Versus General Anesthesia for Elective Laparoscopic Cholecystectomy in Fit Patients|SALC|University of Thessaly|Yes|Recruiting|September 2004|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|January 13, 2010|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492453||169981|
NCT00492479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5314|An Evaluation of Kinerase Pro+Therapy Regimen Vs. Kinerase Vs. Control for the Treatment of Skin Aging|||Innovative Medical||Terminated|June 2007|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Female|35 Years|55 Years||||December 2007|December 18, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00492479||169979|
NCT00492713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.31.MET|Polyphenol Bioavailability From Chocolate|Comparison of the Bioavailability of Polyphenols From Milk and Dark Chocolate||Nestlé|No|Completed|June 2007|April 2012|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|18|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00492713||169961|
NCT00492726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11976|Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem|A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Complicated Intra-abdominal Infections (PROMISE Study)||Bayer|No|Completed|July 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|804|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|June 26, 2007||No||No|February 11, 2010|https://clinicaltrials.gov/show/NCT00492726||169960|
NCT00481663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-014|A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Finding Study of Once-Daily Dosing of Sitaglipin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|August 2003|May 2006|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|555|||Both|21 Years|70 Years|No|||December 2014|December 30, 2014|June 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00481663||170798|
NCT00481949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/20702/84|Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo|What is the Physiologic and Clinical Relevance of Oesophagogastric Junction Distensibility? Studies Using Endo-Flip and 96 Hour Wireless pH System||Guy's and St Thomas' NHS Foundation Trust|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Biopsies taken at the gastro-oesophageal junction will be sent to histology lab and analysed      as per routine histology specimens. These will be stored as all samples at our hospital are      stored and only results reported by the appointed histologist will be used for analysis.|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with typical reflux symptoms (heartburn, acid regurgitation)|June 2011|June 24, 2011|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481949||170777|
NCT00482222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000549541|Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer|A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy||University of Southampton|Yes|Recruiting|February 2007|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||April 2008|January 22, 2013|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482222||170757|
NCT00482508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025IA04E2|Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients|A One Year Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Poorly Controlled Moderate to Severe Allergic Asthma Patients Who Participated in the 52-week CIGE24IA04E1 Study||Novartis||Completed|May 2003|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|95|||Both|12 Years|75 Years||||October 2011|October 24, 2011|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482508||170736|
NCT00482235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0359-016|A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)|||Merck Sharp & Dohme Corp.||Completed|December 2002|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|45|||Both|40 Years|75 Years|No|||November 2015|November 30, 2015|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482235||170756|
NCT00491062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-5-I|Enteric Nervous System in Parkinson's Disease|Analysis of Dopamine Neuronal Cell Loss Within the Enteric Nervous System in Parkinson's Disease|ENTEROPARK|Nantes University Hospital|No|Completed|June 2007|November 2009|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment|4||||||Both|18 Years|N/A|No|||November 2010|November 15, 2010|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00491062||170084|
NCT00491374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04909|Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)|A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study Of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Mild-Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) Associated With Perennial Allergic Rhinitis (PAR) Using Polysomnographic Recordings of Sleep Parameters||Schering-Plough|No|Terminated|September 2006|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|45 Years|No|||January 2009|January 5, 2009|June 25, 2007|||Very poor enrollment|No|November 26, 2008|https://clinicaltrials.gov/show/NCT00491374||170061|This study was difficult to enroll subjects, and after 5 months of screening, the screen failure rate was 100%. At that time the decision was made to terminate the study. No subject was treated and no data were collected.
NCT00482768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK075692|Improving Risk Factors for Diabetes Complications in Primary Care|Improving Risk Factors for Diabetes Complications in Primary Care||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|June 2007|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2400|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|March 15, 2011|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482768||170717|
NCT00464126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: 020775|The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation|The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation||Vanderbilt University|No|Completed|August 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|N/A|36 Months|No|||March 2011|March 2, 2011|August 18, 2006|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464126||172116|
NCT00463814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00005|AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies|A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies||AstraZeneca|No|Active, not recruiting|March 2007|December 2016|Anticipated|June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|99 Years|No|||February 2016|February 1, 2016|April 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00463814||172140|
NCT00464165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4474|Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation|Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5mg/Day or 20mg/Day, Versus Placebo, as an Aid to Smoking Cessation; Multiple Country, Randomized, Double-blind, 3-arm, 10-week Treatment, 40-week Follow-up|STRATUS-EU|Sanofi||Completed|November 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|789|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|April 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00464165||172114|
NCT00464438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198782-003|A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis|||Allergan||Completed|June 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|N/A|31 Days|No|||August 2011|August 17, 2011|April 19, 2007|Yes|Yes||No|June 15, 2010|https://clinicaltrials.gov/show/NCT00464438||172094|
NCT00464425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.429-T|Electroacupuncture for Postoperative Ileus After Laparoscopic Colorectal Surgery|Electroacupuncture for Postoperative Ileus After Laparoscopic Colorectal Surgery: a Randomised Sham-controlled Pilot Study||Chinese University of Hong Kong|Yes|Completed|October 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|165|||Both|N/A|N/A|No|||April 2011|April 20, 2011|April 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00464425||172095|
NCT00469118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXW01|Clinical Efficacy and Safety of Axiom Worldwide DRX9000 Axial Decompression System for Treatment of Low Back Pain|Clinical Efficacy and Safety of Axiom Worldwide DRX9000 Axial Decompression||NEMA Research, Inc.|No|Withdrawn|February 2009|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|May 2, 2007|Yes|Yes|Financial concerns with device manufacturer.|No||https://clinicaltrials.gov/show/NCT00469118||171738|
NCT00469131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHA-LD-03-01|Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid|Randomized Comparative Study on Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparison Between Tacrolimus + MMF and Tacrolimus + Steroid||Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Completed|September 2003|August 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|69 Years|No|||September 2011|September 13, 2011|May 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00469131||171737|
NCT00491296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0034-07-EMC|Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia|||HaEmek Medical Center, Israel|Yes|Not yet recruiting|June 2007|June 2007|Anticipated|||N/A|Observational|Time Perspective: Prospective|||||||Male|30 Years|90 Years|No|||June 2007|November 5, 2008|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00491296||170067|
NCT00491270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-7-20.6-1 VER-1|Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery|Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery||Western Galilee Hospital-Nahariya|Yes|Not yet recruiting|January 2011|August 2013|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 24, 2011|June 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00491270||170069|
NCT00491842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907179|Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD|Individuals' Patterns of Disclosure About Huntington's Disease and Association With Adaptation to HD||National Institutes of Health Clinical Center (CC)||Completed|June 2007|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|315|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00491842||170025|
NCT00491855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1068|Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis|Phase I Trial of Intraperitoneal Oxaliplatin and Paclitaxel Plus Intravenous Paclitaxel and Bevacizumab in the Treatment of Advanced Peritoneal Carcinomatosis||M.D. Anderson Cancer Center|No|Completed|June 2007|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||December 2012|December 31, 2012|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491855||170024|
NCT00491881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2384|Effect of no Added Salt Diet on Urinary Sodium and Blood Pressure|Effect of "no Added Salt Diet " on Blood Pressure Control & 24 Hour Urinary Sodium Excretion in Mild to Moderate Hypertension||Shiraz University of Medical Sciences|Yes|Completed|May 2005|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2005|||Both|20 Years|70 Years|No|||June 2007|August 2, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491881||170022|
NCT00492466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOVER|Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies|A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies|RECOVER|Biogen|Yes|Completed|March 2003|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|55 Years|No|||January 2008|January 28, 2008|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492466||169980|
NCT00485550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7065|Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy|A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Not Responded to Stimulant Mono Therapy||Eli Lilly and Company||Completed|January 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|14|||Both|6 Years|12 Years|No|||June 2007|June 11, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485550||170505|
NCT00481637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA-0269|Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients|Tumor Immunity in Neurologically Normal Patients||Rockefeller University|No|Recruiting|March 1998|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with SCLC and gynecologic (breast or ovarian) tumors and patients with unrelated        cancers. Also healthy volunteers will be included as a comparison group in this study.|October 2015|October 30, 2015|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481637||170800|
NCT00481650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101742|Observational Trial With Leios/Alesse|A Prospective Observation Study (Anwendungsbeobachtung [AWB]) of the Prescribing and Administration Practices of German Gynecologists With Leios® Dragées/Alesse||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2005|March 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective|||||||Female|N/A|40 Years|Accepts Healthy Volunteers|||December 2007|December 7, 2007|May 31, 2007||||No||https://clinicaltrials.gov/show/NCT00481650||170799|
NCT00490269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0013-1|Ph1 Marinol Interaction Study - Part 2 - 1|Phase 1, Pilot Study to Examine the Cardiovascular Effects of Smoked Marijuana, Interactions With Oral Dronabinol, and Effects of Dronabinol on Withdrawal in Marijuana Dependent Volunteers||National Institute on Drug Abuse (NIDA)||Completed|October 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|June 21, 2007|No|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00490269||170145|
NCT00490516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-104-003|ACP-104 in Acutely Psychotic Subjects With Schizophrenia|A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia||ACADIA Pharmaceuticals Inc.||Completed|June 2007|||February 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|60 Years|No|||February 2008|February 22, 2008|June 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00490516||170126|
NCT00490529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0040-BMT212|Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL|Phase I/II Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma||Stanford University|Yes|Recruiting|August 2009|September 2020|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|June 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00490529||170125|
NCT00490737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-REN-07-01|Safety Study to Evaluate Daptomycin in Non-Infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis|An Evaluation of the Pharmacokinetic Profile and Safety and Tolerability of Multiple Doses of 6mg/kg Intravenous Daptomycin in Non-Infected Adult Subjects With End Stage Renal Disease on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis||Cubist Pharmaceuticals LLC|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|N/A|No|||June 2008|June 12, 2008|June 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00490737||170109|
NCT00490750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0241|Laparoscopic Dor Versus Toupet Fundoplication for the Treatment of Idiopathic Esophageal Achalasia|Randomized Prospective Trial of Laparoscopic Heller Myotomy and Partial Fundoplication for the Treatment of Idiopathic Esophageal Achalasia||Washington University School of Medicine|No|Completed|March 2003|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490750||170108|
NCT00491049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LevoProMUC03|Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery|Phase 4 Study on Effectiveness of Topical 0.5% Levofloxacin on Reduction of Preoperative Conjunctival Flora in Patients Scheduled for Intraocular Surgery||Ludwig-Maximilians - University of Munich|No|Completed|September 2004|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00491049||170085|
NCT00491647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561703011|Time Perception Deficits and Attention-Deficit/Hyperactivity Disorder|Time Perception Deficits and Behaviors of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder||National Taiwan University Hospital|Yes|Completed|May 2006|June 2007|Actual|||N/A|Observational|Observational Model: Case Control||1|Actual|258|||Both|9 Years|16 Years|No|Non-Probability Sample|Children with and without ADHD|September 2008|November 12, 2012|June 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00491647||170040|
NCT00491387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#07-01-12-01|Sympathetic Nervous System Modulation in Hypertension|Sympathetic Nervous System Modulation in Hypertension by Beta-adrenergic Blockade||University of Cincinnati|No|Terminated|August 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|80 Years|No|||July 2012|July 16, 2012|June 21, 2007|No|Yes|Publications appeared suggesting increased mortality using beta-blockers as primary therapy    for hypertension.|No|February 22, 2011|https://clinicaltrials.gov/show/NCT00491387||170060|Early termination due to a publication in the literature suggesting potential increased cardiac mortality in hypertensive patients treated primarily with beta blockers. Did not feel that continued treatment in volunteer subjects could be justified.
NCT00463827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR 003|Effect of Statins on Asthma Control in Smokers With Asthma|Effect of Statins on Asthma Control and Airway Inflammation in Smokers With Asthma: a Randomised Controlled Double-blind Parallel Group Study||NHS Greater Clyde and Glasgow|Yes|Completed|August 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||October 2007|January 15, 2010|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00463827||172139|
NCT00476424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 081|A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects|A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|June 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||June 2010|June 4, 2010|May 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00476424||171189|
NCT00464451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dex for Ped EEG|Dexmedetomidine Versus Chloral Hydrate for Pediatric Sedation During EEG|Prospective, Double Blinded,Randomized Controlled Trial of Dexmedetomidine Versus Chloral Hydrate for Pediatric Sedation During EEG||Wesley Medical Center|Yes|Withdrawn|August 2009|May 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|4 Months|18 Years|No|||January 2010|January 13, 2010|April 19, 2007|Yes|Yes|Unable to obtain approval from FDA for use of chloral hydrate|No||https://clinicaltrials.gov/show/NCT00464451||172093|
NCT00464698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002159|Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)|Duloxetine for the Treatment of Obsessive Compulsive Disorder|FIJ-MC-1003|Massachusetts General Hospital|Yes|Completed|December 2005|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||September 2014|September 15, 2014|April 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464698||172074|
NCT00465036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 309595|Effect of Flaxseed on Lipid Uptake and Appetite|Effect of Whole Flaxseeds and Flaxseed Mucilage on Lipid Absorption, Glucose and Insulin Metabolism and Appetite Regulation||University of Copenhagen|No|Completed|October 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4|||18|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2009|March 25, 2009|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465036||172049|
NCT00465049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORIHS 2007-5819|Comparison of Suturing and Packing of Drained Abscesses|Primary vs. Secondary Closure of Cutaneous Abscesses After I&D: A RCT||Stony Brook University|No|Completed|January 2007|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||October 2012|October 19, 2012|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465049||172048|
NCT00491309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reha PH Rheumatic|Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension|Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension||Heidelberg University|No|Recruiting|July 2011|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|80 Years|No|||July 2014|July 1, 2014|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491309||170066|
NCT00491010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-153|Maximum Targeted Ablation of Atrial Flutter|Maximum Targeted Ablation of Atrial Flutter||Lawson Health Research Institute|No|Recruiting|July 2006|February 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00491010||170088|
NCT00491556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 061|Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)|Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r) in Adolescents With CD4 + T Cells > 350 Cells/mm3 Initiating HAART||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|October 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|24 Years|No|||May 2014|May 15, 2014|June 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00491556||170047|
NCT00491868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH20876|Clinical Study of R744 to Hemodialysis Patients|Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase III, Double Blind Study in Comparison With Epoetin Beta).||Chugai Pharmaceutical|Yes|Completed|June 2007|August 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|134|||Both|20 Years|N/A|No|||January 2009|January 29, 2009|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491868||170023|
NCT00492167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-073|Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma|Phase I Study of Oral Yeast β-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2005|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|N/A|120 Years|No|||March 2016|March 7, 2016|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492167||170001|
NCT00484718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011030|Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.|Measures Of Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee: A Randomized, Single-Blind Washout, Double-Blind Treatment, Double Dummy Cross-Over Pilot Trial Using Placebo, Oxycodone And Celecoxib (A9011030)||Pfizer|No|Terminated|February 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|6|||Both|40 Years|75 Years|No|||January 2012|January 26, 2012|June 8, 2007||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00484718||170568|
NCT00492206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 05-106|Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC|A Phase II Study of Cetuximab in Combination With External Beam Radiation Followed By Consolidation Chemotherapy for Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)||University of Pittsburgh|Yes|Completed|June 2006|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492206||169999|
NCT00492219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCO.2006.05|Postoperative Function Following Partial and Total Knee Replacement|Postoperative Function Following Partial and Total Knee Replacement||New Lexington Clinic|No|Terminated|October 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|324|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|October 18, 2012|June 25, 2007|Yes|Yes|No longer have access to equipment used for functional data collection|No||https://clinicaltrials.gov/show/NCT00492219||169998|
NCT00494169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HD028138|Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders|Molecular Basis of Inherited Reproductive Disorders||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|January 1999|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|5000|Samples With DNA|WBC are transformed into immortalized cell lines.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who          1. fail to go through a normal, age-appropriate, spontaneous puberty, and abnormal             hormone levels.          2. have abnormally early development of puberty (Precocious Puberty) OR          3. display low gonadotropins in adulthood after having gone through normal pubertal             development.        Family members of these patients.|March 2015|March 20, 2015|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494169||169852|
NCT00494182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0940|Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer|A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2007|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00494182||169851|
NCT00490763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0619|Active Surveillance in Prostate Cancer|Active Surveillance in Prostate Cancer: A Prospective Cohort Study||M.D. Anderson Cancer Center|No|Recruiting|February 2006|||February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Male|N/A|N/A|No|Probability Sample|Study participants with low-risk prostate cancer who choose to undergo active        surveillance.|January 2016|January 8, 2016|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490763||170107|
NCT00491075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0516|Pemetrexed Plus Gemcitabine in Renal Cell Cancer|Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Advanced Non-Clear Cell Renal Cell Cancer||M.D. Anderson Cancer Center|No|Terminated|December 2005|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||April 2013|April 16, 2013|June 21, 2007||No|Closed early for poor accrual.|No|April 6, 2012|https://clinicaltrials.gov/show/NCT00491075||170083|
NCT00491088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701063R|The CPAP Effect in Severe Obstructive- Sleep- Apnea Patients Without Daytime Sleepiness: A Control Randomized Trial|The CPAP Effect in Severe Obstructive- Sleep- Apnea Patients Without Daytime Sleepiness: A Control Randomized Trial||National Taiwan University Hospital|Yes|Completed|June 2007|December 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|96|||Male|18 Years|N/A|No|||February 2010|February 25, 2010|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00491088||170082|
NCT00491400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23185|Effect of a Fibrate and a Statin on Endothelial Dysfunction|Effect of a Fibrate (Fenofibrate) and a Statin (Atorvastatin) and on Endothelial Dysfunction in Diabetes Mellitus and the Metabolic Syndrome||Boston University|No|Terminated|September 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|28|||Both|30 Years|N/A|No|||September 2012|September 24, 2012|June 22, 2007|No|Yes|Insufficient enrollment|No|May 23, 2012|https://clinicaltrials.gov/show/NCT00491400||170059|Early termination due to inadequate enrollment
NCT00492544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110168|Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age|Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 When Administered as a 3-dose Schedule in Healthy Japanese Pre-adolescent and Adolescent Female Subjects.||GlaxoSmithKline||Completed|July 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Female|10 Years|15 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|June 26, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00492544||169974|
NCT00492557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3008|Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults|A Phase 3, Randomized, Double-blind Trial to Evaluate Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine in Healthy Adults 65 Years of Age or Older, Who Are Naive to 23-Valent Pneumococcal Polysaccharide Vaccine||Pfizer|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1185|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 17, 2012|June 26, 2007|Yes|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT00492557||169973|
NCT00491946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10762|A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer|A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|June 2004|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|24|||Both|N/A|18 Years|No|||June 2007|June 25, 2007|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00491946||170017|
NCT00476151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC2006-01|A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of EpiCept™ NP-1 Topical Cream in Patients With Pain From Diabetic Peripheral Neuropathy (DPN)||EpiCept Corporation|No|Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|May 17, 2007|Yes|Yes||No|September 28, 2010|https://clinicaltrials.gov/show/NCT00476151||171210|
NCT00476164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002330-38|Study of Rituximab to Treat Chronic Renal Transplant Rejection|Randomised Trial of Anti-Cd20 in C4d+ Chronic Allograft Nephropathy|RituxiCAN-C4|King's College London|Yes|Recruiting|January 2007|January 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||April 2014|April 22, 2014|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00476164||171209|
NCT00472420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20493|A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.|An Open-label Study of the Effect of the Addition of MabThera to Standard Chemotherapy on Clinical Response in Patients With Previously Untreated Mantle Cell Lymphoma||Hoffmann-La Roche||Completed|June 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|May 10, 2007||No||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00472420||171489|
NCT00465062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070131|A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease|A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2007|March 2008||||N/A|Observational|N/A||||50|||Both|N/A|N/A|No|||March 2008|September 26, 2015|April 21, 2007||||No||https://clinicaltrials.gov/show/NCT00465062||172047|
NCT00465348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|085-Mom-2007|The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients|The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients||University Hospital, Basel, Switzerland|No|Withdrawn|June 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|None Retained|plasma|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary open-angle glaucoma patients|October 2012|October 24, 2012|April 24, 2007||No|investigator withdrew|No||https://clinicaltrials.gov/show/NCT00465348||172026|
NCT00465582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/099/HP|B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors|B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors||University Hospital, Rouen|Yes|Terminated|January 2008|April 2008|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|3296|Samples Without DNA|pharynx ecouvillonnage|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Dieppe Population 0 to 25 yaers old.|March 2012|March 26, 2012|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465582||172008|
NCT00491023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0075|Examining Macrophage Influx and Vascularization in Chronic Pancreatitis|Examining Macrophage Influx and Vascularization in Chronic Pancreatitis||University of Colorado, Denver|Yes|Completed|February 2007|August 2007|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|N/A||||February 2007|February 8, 2013|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00491023||170087|
NCT00483561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285-03|Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Study Evaluating the Efficacy of Iressa Plus Etoposide in Patients With Advanced Hormone Refractory Prostate Cancer||University of Nebraska|Yes|Active, not recruiting|January 2004|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Male|19 Years|N/A|No|||March 2011|March 8, 2011|June 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00483561||170657|
NCT00491569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC-94-2314-B-039-026|Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia|NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine||China Medical University Hospital|No|Completed|January 2005|December 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|No|||June 2007|June 24, 2007|June 24, 2007||||No||https://clinicaltrials.gov/show/NCT00491569||170046|
NCT00491582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320000-109522/1|The Effects of Growth Hormone (GH) on Lipid Depots|The Effect of Growth Hormone (GH) on Intramyocellular Lipids (IMCL), Intrahepatocellular Lipids (IHCL) and Visceral Fat Mass in Relation to Insulin Resistance||University Hospital Inselspital, Berne|No|Completed|July 2007|June 2013|Actual|July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491582||170045|
NCT00484978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-056 TASMC|Stereotactic Radiosurgery to the Resection Cavity Following Surgical Removal of Brain Metastasis|A Single Center Prospective Phase II Study: Stereotactic Radiosurgery to the Resection Cavity Following Surgical Removal of Brain Metastasis||Tel-Aviv Sourasky Medical Center|No|Recruiting|February 2007|June 2007|Anticipated|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00484978||170548|
NCT00490009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0019|Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma|Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL)||Stanford University|Yes|Completed|September 2004|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00490009||170165|
NCT00481364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-4.1/2|Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients|Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study||Ege University|Yes|Completed|November 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|80 Years|No|||September 2013|September 6, 2013|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00481364||170821|
NCT00481377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-NP-0021-42/1013/07|Ablation for ICD Intervention Reduction in Patients With CAD|Ablation for ICD Intervention Reduction in Patients With CAD - a Prospective Randomized Trial|ABLATION 4 ICD|Institute of Cardiology, Warsaw, Poland|No|Terminated|May 2007|May 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2008|July 18, 2008|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00481377||170820|
NCT00481390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNA110329|Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients|Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected Patients||GlaxoSmithKline||Completed|June 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1110|||Both|18 Years|N/A|No|Probability Sample|HIV-1 infected adults, out patients department|June 2011|June 7, 2011|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481390||170819|
NCT00491413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD042308|Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth|High Dose Erythropoietin for Neonates With Asphyxia||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Not yet recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|N/A|6 Hours|No|||August 2003|June 22, 2007|June 22, 2007||||No||https://clinicaltrials.gov/show/NCT00491413||170058|
NCT00491660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-MD-Thesis-Afaf|Effect of Gravity on Tracheal Colonization During Mechanical Ventilation in Infants|||Cairo University||Completed|January 2005|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|2||Actual|60|||Both|N/A|48 Hours|No|||June 2007|June 25, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491660||170039|
NCT00492284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPD OCR 022|Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)|A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne®-Lucentis® Combination Therapies and Lucentis® Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD.|RADICAL|QLT Inc.|Yes|Completed|July 2007|May 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|162|||Both|50 Years|N/A|No|||May 2011|May 31, 2011|June 25, 2007|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT00492284||169993|Retreatment and vision analysis limitations, sample size, lack of standard monotherapy regimen used in practice, no treatment regimen approved by regulatory authorities, potential for bias in FA assessment, no central reading center, single-masked
NCT00491686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6702C00001|AZD6765 for Treatment Resistant Depression|A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients||AstraZeneca||Completed|July 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|34|||Both|21 Years|65 Years|No|||January 2011|January 20, 2011|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00491686||170037|
NCT00464178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV3502s|A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed Refractory Multiple Myeloma||Hackensack University Medical Center|No|Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 4, 2013|April 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00464178||172113|
NCT00464464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220060139|Coping With Depression in Parkinson's Disease|Treating Depression in Parkinson's Disease: A New Method||Rutgers, The State University of New Jersey|No|Completed|April 2007|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|35 Years|85 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|April 20, 2007||No||No|March 10, 2014|https://clinicaltrials.gov/show/NCT00464464||172092|
NCT00464477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0023|Advanced Grandparental Age as a Risk Factor for Autism|Advanced Grandparental Age as a Risk Factor for Autism and Other Pervasive Developmental Disorders||University of Mississippi Medical Center|No|Completed|June 2007|October 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with any pervasive developmental disorder.|November 2007|November 6, 2007|April 20, 2007||||No||https://clinicaltrials.gov/show/NCT00464477||172091|
NCT00464711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001295|Brain GABA Levels and Treatment Response in Major Depressive Disorder|Brain GABA Levels and Treatment Response in Major Depressive Disorder||Massachusetts General Hospital|No|Active, not recruiting|September 2006|||September 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 7, 2009|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464711||172073|
NCT00464724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0516|3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate|3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate||M.D. Anderson Cancer Center|No|Recruiting|March 2007|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Male|18 Years|N/A|No|||September 2015|September 28, 2015|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464724||172072|
NCT00464737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP888|The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.|A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Doses of Rotigotine in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome|SP888|UCB Pharma|No|Completed|March 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|230|||Both|18 Years|65 Years|No|||September 2010|May 26, 2015|April 23, 2007|Yes|Yes||No|November 23, 2009|https://clinicaltrials.gov/show/NCT00464737||172071|
NCT00465075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1116|Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women|An Open-Label, Single-Dose, 3-Period, Crossover Study To Determine The Effect Of A High-Fat Meal On The Relative Bioavailability And Pharmacokinetics Of A Single Dose Of Bazedoxifene Acetate/Conjugated Estrogens (Premarin© New Process) Administered Orally To Healthy, Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2007|April 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|24|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465075||172046|
NCT00465088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019-05-06-CR|An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)|SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia|SUPREME|Abbott||Completed|April 2007|||February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|199|||Both|21 Years|N/A|No|||June 2011|June 9, 2011|April 23, 2007|Yes|Yes||No|February 10, 2009|https://clinicaltrials.gov/show/NCT00465088||172045|
NCT00465361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 02-027E|Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit|Evaluation of Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit||Children's Mercy Hospital Kansas City|No|Completed|May 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|7|||Both|N/A|N/A|No|||December 2011|February 6, 2012|April 23, 2007||No||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00465361||172025|Long-term effects of intervention are unknown.
NCT00483574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA48|Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers|Safety Study of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers||Sanofi|Yes|Completed|May 2007|April 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1378|||Both|9 Months|12 Months|Accepts Healthy Volunteers|||January 2014|January 20, 2014|June 6, 2007|Yes|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00483574||170656|
NCT00491322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000430/18|Vitamin D Deficiency, Insulin Resistance and FGF-23|Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23||Massachusetts General Hospital|Yes|Completed|May 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|June 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00491322||170065|
NCT00484146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN34508816|Alterations of Immunologic Mediators During Severe Sepsis|Alterations of Immunologic Mediators During Severe Sepsis|LAVISS_01|Klinikum St. Georg gGmbH|No|Terminated|June 2006|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Whole Blood Samples, Plasma Samples|Both|18 Years|N/A|No|Probability Sample|Patients with early stage of severe sepsis and septic shock|October 2012|October 26, 2012|June 7, 2007||No|anticipated number of patients could not be reached|No||https://clinicaltrials.gov/show/NCT00484146||170612|
NCT00484471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-OTB-0701|ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness|A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder|ABLE|Korea Otsuka International Asia Arab|No|Completed|October 2007|November 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|65 Years|No|||November 2012|November 27, 2012|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484471||170587|
NCT00485303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016921|An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy|A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy||Cougar Biotechnology, Inc.|No|Completed|June 2007|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Male|18 Years|N/A|No|||June 2013|June 25, 2013|June 8, 2007|Yes|Yes||No|April 23, 2013|https://clinicaltrials.gov/show/NCT00485303||170523|
NCT00485316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-8118|Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma|Prospective Randomized Trial Comparing Laparoscopic Assisted and Open Resection for Colonic and Rectal Carcinoma||Chinese University of Hong Kong|Yes|Completed|September 1993|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|N/A|N/A|No|||March 2009|March 30, 2009|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485316||170522|
NCT00485563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-FI-004|A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma|A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma||Endocyte|No|Terminated|June 2007|March 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|June 11, 2007|Yes|Yes|Changes in treatment paradigm resulted in a lower than expected rate of accrual.|No||https://clinicaltrials.gov/show/NCT00485563||170504|
NCT00485576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-002|Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma|A Randomized, Double Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Mild Allergic Asthma.||Alexion Pharmaceuticals|No|Completed|September 2007|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|21|||Both|18 Years|N/A|No|||January 2009|January 14, 2009|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00485576||170503|
NCT00494442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU36-58|Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer|A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer|ICEBERG 2|AstraZeneca|Yes|Active, not recruiting|June 2007|December 2016|Anticipated|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|130 Years|No|||July 2015|December 7, 2015|June 27, 2007|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT00494442||169831|
NCT00494455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108/2005|Continuous Glucose Monitoring in Critically Ill Patients|Accuracy and Reliability of Continuous Glucose Monitoring in Critically Ill Patients With Shock Requiring Norepinephrine Therapy||Medical University of Vienna|Yes|Completed|April 2005|March 2007|Actual|April 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|19 Years|N/A|No|||June 2007|February 19, 2008|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00494455||169830|
NCT00491426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015379|Antimicrobial PK in Infants With Suspected or Confirmed Infection|Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns - add-on Study)||Duke University|Yes|Completed|January 2006|November 2010|Actual|October 2010|Actual|Phase 1|Observational|Time Perspective: Retrospective||3|Actual|450|||Both|N/A|120 Days|No|Non-Probability Sample|Premature infants <32 weeks gestational age at birth at risk of infections.|November 2012|November 16, 2012|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00491426||170057|
NCT00491673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMI-SAB-UUS|A Prospective Randomized Trial of Uncemented Versus Cemented Hemiarthroplasty for Displaced Femoral Neck Fractures|A Prospective Randomized Trial of Uncemented Versus Cemented Hemiarthroplasty for Displaced Femoral Neck Fractures|HEMI04|Ullevaal University Hospital|No|Active, not recruiting|September 2004|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|70 Years|N/A|No|||September 2010|September 23, 2010|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491673||170038|
NCT00491699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-002|Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer|A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)||Symphony Evolution, Inc.|Yes|Terminated|August 2007|May 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|June 22, 2007|Yes|Yes|The study was stopped due to safety concerns|No||https://clinicaltrials.gov/show/NCT00491699||170036|
NCT00492024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11566|BAY12-8039: 5 Days for Sinusitis vs Placebo|Prospective, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg QD for 5 Days Versus Placebo in the Treatment of Acute Bacterial Sinusitis||Bayer|No|Completed|January 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|374|||Both|18 Years|N/A|No|||November 2013|October 31, 2013|June 26, 2007|Yes|Yes||No|March 19, 2009|https://clinicaltrials.gov/show/NCT00492024||170012|Confounding factors include concomitant medication for symptomatic relief not standardised, TOC visit occured earlier than for other sinusitis studies, response on placebo underestimated and short-term relief provided by the sinus tap.
NCT00492037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-043|Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia|A 5-Day, Double-Blind, Placebo-Controlled Multicenter Study of Oral YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia||Cumberland Pharmaceuticals|No|Completed|January 2000|February 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|83|||Both|18 Years|85 Years|No|||April 2014|April 30, 2014|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00492037||170011|
NCT00491959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701043D|The Application of Oral Mucosal Epithelial Cell Sheets Cultivated on Amino Membrane in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon.|Phase 1 Study of Oral Mucosal Epithelial Cell Sheets in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon||National Taiwan University Hospital|Yes|Terminated|September 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||April 2010|May 3, 2010|June 23, 2007||No|Due to unstalbe cell sheet quality. We didn't use this tech on patients.|No||https://clinicaltrials.gov/show/NCT00491959||170016|
NCT00491985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPA04|Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children|||Sanofi||Completed|June 2007|June 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|240|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00491985||170015|
NCT00464191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-004357-94|Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment|Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment||Nordfjord Psychiatric Centre||Terminated|April 2006|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||September 2009|September 19, 2009|April 20, 2007|||The study has been terminated because too few patients have been recruited|No||https://clinicaltrials.gov/show/NCT00464191||172112|
NCT00464204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-HE06-01|Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis|Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis|CRYSTMAS|Fresenius Kabi|Yes|Completed|July 2007|December 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||August 2011|January 9, 2012|April 20, 2007|Yes|Yes||No|May 30, 2011|https://clinicaltrials.gov/show/NCT00464204||172111|
NCT00465101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE0603|A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization|A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH)|PVP|American Medical Systems|No|Completed|May 2007|January 2013|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Male|45 Years|N/A|No|||June 2012|September 24, 2015|April 23, 2007||No||No|July 21, 2015|https://clinicaltrials.gov/show/NCT00465101||172044|Follow-up of subjects was discontinued in August 2012 prior to most participants completing the assessment planned at 5 years. At the time of the discontinuation, all but five of the participants remaining on study had completed 3 years of follow-up.
NCT00464750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.1012 / NSD15499|Study on the Repeatability of Cardiac Output Measurements Dependence of Temperature of Injectate|The Impact of Temperature of the Injectate on the Precision (Repeatability) of Cardiac Output Measurements Synchronized With the Respiration (the Temperature Study)||Norwegian University of Science and Technology|No|Completed|November 2006|June 2007|Actual|||Phase 0|Observational|Time Perspective: Prospective||1|Actual|40|||Both|18 Years|85 Years|No|Probability Sample|Elective patients for cardiac surgery|May 2008|May 28, 2008|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00464750||172070|
NCT00465634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRR02-FP/ARTULEP|Doppler and Biological Second Trimester Placental Insufficiency Screening|Screening for Placental Insufficiency by a Combination of Second Trimester Uterine Artery Doppler and Maternal Serum Leptin and Lipids|ARTULEP|University Hospital, Tours|No|Completed|May 2003|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|235|||Female|18 Years|45 Years|No|Non-Probability Sample|women at increased risk of pre-eclampsia (PE) and intrauterine growth restriction (IUGR)|August 2013|August 6, 2013|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465634||172004|
NCT00465894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061208008|Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms|Randomized Controlled Trial of Tolterodine in Combination With or Without Low-Dose Intra-Vaginal Estradiol Cream for the Treatment of Overactive Bladder in Post-Menopausal Women|DRIVE|University of Alabama at Birmingham|No|Completed|April 2007|December 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|40 Years|90 Years|Accepts Healthy Volunteers|||July 2015|August 15, 2015|April 23, 2007||No||No|June 1, 2012|https://clinicaltrials.gov/show/NCT00465894||171984|
NCT00484484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051048|Ketamine Associated With Opioids in Refractory Cancer Pain Treatment|Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment|KETADOL|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||June 2007|May 3, 2011|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484484||170586|
NCT00483886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-11|Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation|A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation.||Movetis|No|Completed|April 1998|May 1999|Actual|May 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|620|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|June 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00483886||170632|
NCT00493558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA018|Spine Research With Roentgen Stereophotogrammetric Analysis|A Consecutive Case Series of One-Level Lumbar Fusions With Pedicle Screw Instrumentation and the Trabecular Metal™ Intervertebral Cage Using Roentgen Stereophotogrammetric Analysis (RSA)|SpineRSA|Nova Scotia Health Authority|No|Completed|July 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|N/A|No|||February 2013|February 18, 2013|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493558||169897|
NCT00493571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0943|Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes|Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Completed|August 2007|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|June 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493571||169896|
NCT00493870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06090|TAC Versus TC for Adjuvant Breast Cancer|Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients||US Oncology Research|No|Active, not recruiting|May 2007|May 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1296|||Female|18 Years|70 Years|No|||November 2015|November 7, 2015|June 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00493870||169873|
NCT00490542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA128000|Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State|Double-blind, Placebo-controlled Trial of Ziprasidone (Geodon) for the Depressive Mixed State||Tufts Medical Center|No|Completed|December 2006|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||November 2013|November 19, 2013|June 20, 2007||No||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00490542||170124|One potential limitation in relation to secondary analyses would be sample size. The randomized study design should account for most potential confounding effects, but residual confounding cannot be completely eliminated without larger studies.
NCT00490776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2212|Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma|A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor||Novartis||Completed|June 2007|||September 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|June 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00490776||170106|
NCT00490802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0230 0001 02 PS|Intranasal Oxytocin in the Treatment of Autism|Intranasal Oxytocin in the Treatment of Autism||Anagnostou, Evdokia, M.D.|Yes|Completed|June 2006|April 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|60 Years|No|||October 2015|October 21, 2015|June 22, 2007||No||No|April 26, 2013|https://clinicaltrials.gov/show/NCT00490802||170104|Small sample size resulted in baseline differences; short duration of study; didn't examine impact of other characteristics; short-half life in the blood; inactive ingredients not identical in placebo; no participant follow-up after study
NCT00490282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0947|A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer|A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer||M.D. Anderson Cancer Center|No|Completed|June 2007|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490282||170144|
NCT00490815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-06-002|Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema|An Open Label Pharmacokinetic and Efficacy Study of 0.5 μg/Day and 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts in Subjects With Diabetic Macular Edema||Alimera Sciences||Completed|August 2007|April 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|June 21, 2007|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00490815||170103|
NCT00490828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149/00|Influence of Hydrocortisone on Immunologic Markers and Health Care Related Quality of Life in Patients After Cardiac Surgery|Influence of Hydrocortisone on Humoral and Cellular Immunologic Markers in High Risk Patients After Cardiac Surgery||Ludwig-Maximilians - University of Munich|No|Completed|June 2007|August 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|120|||Both|N/A|N/A|No|||September 2008|September 2, 2008|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490828||170102|
NCT00491140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICH n. 380|Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab|Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients||Istituto Clinico Humanitas|No|Completed|December 2006|June 2008|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|85|Samples With DNA|Paraffine embedded tumor sections|Both|18 Years|N/A|No|Non-Probability Sample|Colorectal cancer patients treated with Cetuximab|September 2008|September 30, 2008|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00491140||170078|
NCT00491153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.3606(REK)|Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist|Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist||St. Olavs Hospital|No|Terminated|September 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|16 Years|50 Years|No|Probability Sample|Patients with a tentative diagnosis of asthma or suspected asthma referred to a        pulmonologist for evaluation|December 2013|December 17, 2013|June 22, 2007||No|due to low recruitment rate secondary to very stringent inclusion criteria|No||https://clinicaltrials.gov/show/NCT00491153||170077|
NCT00492050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0733|Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia|Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2006|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|N/A|N/A|No|||December 2015|December 7, 2015|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492050||170010|
NCT00492856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0521|S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia|S0521, A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III||Southwest Oncology Group|Yes|Active, not recruiting|June 2007|November 2015|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|120 Years|No|||September 2015|September 28, 2015|June 25, 2007|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00492856||169950|
NCT00491998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1512-2PD01|PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets|Randomised, Double-blind, Double-dummy, Two-period, Cross-over Study to Determine the PK, PD and Safety of Multiple Doses of V1512 Effervescent Tablets in Parkinson's Disease Patients Compared to Sinemet® Oral Tablets||Vernalis (R&D) Ltd|No|Completed|November 2006|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|27|||Both|30 Years|N/A|No|||July 2011|July 21, 2011|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00491998||170014|
NCT00492011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-375-045|Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia Symptoms Associated With Eastward Bound Jet Lag Across 5 Time Zones in Healthy Adult Volunteers||Takeda|No|Completed|February 2007|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|110|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492011||170013|
NCT00464763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-06-06|A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel, Multicenter Study Evaluating the Efficacy and Safety of Dexmedetomidine in the Prevention of Postoperative Delirium in Subjects Undergoing Heart Surgery With Cardiopulmonary Bypass||Hospira, Inc.|No|Withdrawn|April 2007|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 23, 2007|Yes|Yes|The incidence of post-operative delirium observed from interim blinded data in DEX-06-09 was    significantly lower than the current literature in this population.|No||https://clinicaltrials.gov/show/NCT00464763||172069|
NCT00464776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2240|Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy|A Randomized, Double-blind, Cross-over, 4-period, 4 Treatment, Within-subject Placebo-controlled Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Type 2 Diabetic Patients With Incipient or Overt Nephropathy||Novartis|Yes|Completed|October 2005|||April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|26|||Both|30 Years|80 Years|No|||February 2011|February 3, 2011|April 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00464776||172068|
NCT00464789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1120|Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Bazedoxifene/Conjugated Estrogens (Premarin Current Process) And Bazedoxifene/Conjugated Estrogens (Premarin New Process) In Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|35 Years|70 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00464789||172067|
NCT00465114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-06|Minimally-invasive Assessment of Cardiac Output in Severe Preeclampsia|Minimally-invasive Assessment of Cardiac Output in Severe Preeclampsia: Radial Artery Wave Form Analysis Versus Trans-thoracic Echocardiogram||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Withdrawn|April 2007|December 2007|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Female|18 Years|N/A|No|Probability Sample|Primary Care Clinic|October 2009|October 1, 2009|April 23, 2007||No|Feasibility issues, only 1 patient recruited.|No||https://clinicaltrials.gov/show/NCT00465114||172043|
NCT00465374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN60ANRA04|A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients|||University of Turin, Italy||Recruiting|October 2002|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|85 Years|No|||April 2007|April 24, 2007|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465374||172024|
NCT00465647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP4009|An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain|A Multi-center, Open-label, Dose Titration Study Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Hydromorphone Oral Solution in Subjects From 28 Days to 16 Years of Age, Who Require Opioid Analgesics for Postoperative Pain|Palladone|Purdue Pharma LP|Yes|Completed|April 2007|April 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|116|||Both|N/A|16 Years|No|||October 2015|October 19, 2015|April 24, 2007|Yes|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00465647||172003|
NCT00465907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS 0312|Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer|Phase II Study of Weekly Paclitaxel, Carboplatin and Irinotecan in Patients With Advanced Non-Small Cell Lung Cancer Nad Malignant Plerual Effusion||Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|May 2003|December 2009|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465907||171983|
NCT00466206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD 003341|Magnetic Mini-Mover Procedure to Treat Pectus Excavatum|Phase II Magnetic Alteration of Pectus Excavatum|3MP|University of California, San Francisco|Yes|Completed|April 2007|April 2011|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 24, 2007|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00466206||171960|Technical problems with measurement of PSI. PSI is uninformative in assessing efficacy of treatment as it is a dynamic measure that varies with patient position and respiration at any given measurement.
NCT00492752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11849|A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Randomized, Double-blinded, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma||Bayer|Yes|Completed|October 2005|July 2009|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|June 26, 2007||No||No|December 8, 2010|https://clinicaltrials.gov/show/NCT00492752||169958|On review of unblinded data, up to 19 Mar. 2007, the independent Data Monitoring Committee concluded the efficacy results can be considered positive, recommended subjects under placebo to cross over to Sorafenib; study continued to extension phase.
NCT00492765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMCOMBIN|Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis|A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis|SIMCOMBIN|Biogen|Yes|Completed|February 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|55 Years|No|||October 2010|October 14, 2010|June 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492765||169957|
NCT00484731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|585|Effect of Intraoperative Infiltration With Bupivacain on the Development of Chronic Pain After Inguinal Hernia Repair|Investigating the Effect of Intra-operative Infiltration With Local Anaesthesia on the Development of Chronic Postoperative Pain After Inguinal Hernia Repair. A Randomized Placebo Controlled Triple Blinded and Group Sequential Study Design||Luzerner Kantonsspital|Yes|Recruiting|July 2006|June 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|404|||Both|18 Years|N/A|No|||May 2008|June 21, 2011|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484731||170567|
NCT00490022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31866-A|Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]|The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men|DHT-3|University of Washington|No|Completed|June 2007|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 20, 2011|June 20, 2007|Yes|Yes||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00490022||170164|
NCT00493272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070037|Dilutional Coagulopathy in Patients Undergoing Elective Surgery|Fibrinogen vs Placebo for Improvement of Clot Strength||University of Aarhus|Yes|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00493272||169919|
NCT00493285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP149|Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age|CP149|MedImmune LLC|Yes|Completed|July 2007|April 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|49|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||July 2012|July 13, 2012|June 26, 2007|Yes|Yes||No|March 12, 2012|https://clinicaltrials.gov/show/NCT00493285||169918|
NCT00493545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HspE7-00101-0601|Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia|A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects||Nventa Biopharmaceuticals Corporation|No|Active, not recruiting|May 2007|June 2008|Anticipated|June 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Female|18 Years|N/A|No|||May 2008|May 5, 2008|June 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493545||169898|
NCT00494195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U54AR050733|Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)|Phase I Gene Transfer of rAAV1.tMCK.Human-alpha-sarcoglycan for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)||Nationwide Children's Hospital|Yes|Completed|March 2008|August 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|5 Years|N/A|No|||February 2013|February 4, 2013|June 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00494195||169850|
NCT00489996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6672|Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer|A Multicenter, Randomized Trial Comparing a Combined Gemcitabine and Cisplatin 3-Week Regimen With a 4-Week Regimen in Non-Small Cell Lung Cancer Patients||Eli Lilly and Company|No|Completed|January 2003|June 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489996||170166|
NCT00491114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8192|Intravesical Chemotherapy Treatment of Superficial Bladder Cancer|Intravesical Gemcitabine Therapy in Intermediate Risk Superficial Bladder Cancer: A Phase II Study With the Marker Lesion||Eli Lilly and Company|No|Completed|July 2003|August 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00491114||170080|
NCT00490321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 12082|VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy|Evaluation of the VentrAssistTM Left Ventricular Assist Device for the Treatment of Advanced Heart Failure - Destination Therapy||Ventracor|Yes|Active, not recruiting|June 2007|June 2012|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490321||170141|
NCT00491101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-82-07-KE|Valuation of Quality of Life in Children With Asthma|Valuation of Quality of Life in Children With Asthma||Medical Universtity of Lodz|Yes|Completed|March 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|7 Years|18 Years|No|Non-Probability Sample|Children with asthma.|December 2008|September 10, 2010|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00491101||170081|
NCT00491712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glau00036|Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection|Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection||Federal University of São Paulo|No|Active, not recruiting|September 2005|June 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|80 Years|No|||March 2007|June 25, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491712||170035|
NCT00491725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1655|Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs|A Multi-centre, Single Armed, Open Labelled Trial to Study the Efficacy and Safety Profile of Repaglinide & Metformin Combination Therapy in Chinese Type 2 Diabetics||Novo Nordisk A/S|No|Completed|September 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|187|||Both|35 Years|65 Years|No|||March 2016|March 2, 2016|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491725||170034|
NCT00492869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2207|Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation|A 12-Month Open-Label, Randomized, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients||Novartis||Completed|January 2007|||May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|124|||Both|18 Years|N/A||||February 2009|February 26, 2009|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492869||169949|
NCT00492635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11336|Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED|A Randomized, Double-blind, Double-dummy, Multicenter Parallel Group Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil Versus Vardenafil PRN Versus Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving Erectile Function||Bayer||Completed|December 2004|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|628|||Male|18 Years|64 Years|No|||October 2014|October 27, 2014|June 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00492635||169967|
NCT00492323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010363|An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group With a Crossover Confirmation Period Study of RWJ-333369 for the Treatment of Postherpetic Neuralgia.||SK Life Science||Completed|March 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|85 Years|No|||January 2013|January 15, 2013|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492323||169990|
NCT00464503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAT-AZ-01|Statins and the Urinary Proteome|The Effect of Statins on the Urinary Proteome||Universiteit Antwerpen|Yes|Completed|September 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|2||Actual|7|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00464503||172089|
NCT00465140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEFEUSP-021284|Effects of Creatine Supplementation on Renal Function|Effects of Creatine Supplementation on Renal Function in Sedentary Healthy Males Urdergoing Aerobic Training: a Randomized, Double-Blind, Placebo-Controlled Trial||University of Sao Paulo|Yes|Completed|January 2004|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||18|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2007|April 23, 2007|April 23, 2007||||No||https://clinicaltrials.gov/show/NCT00465140||172042|
NCT00465387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORCE1234|FORCE (Falls, Fracture, and Osteoporosis Risk Control Evaluation) Study|Falls, Fracture, and Osteoporosis Risk Control Evaluation (FORCE) Study: A Randomized Controlled Trial With Community Partnerships in Northern Ontario||Group Health Centre|No|Completed|March 2003|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention||||400|||Both|55 Years|N/A|No|||April 2007|April 24, 2007|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465387||172023|
NCT00465660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN012605000116628|Resistive Exercise for Arthritic Cartilage Health (REACH)|The Effect of 6 Month High Intensity Progressive Resistance Training on Knee Articular Cartilage Morphology in Female Osteoarthritic Patients||University of Sydney||Active, not recruiting|April 2005|July 2009||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||60|||Female|40 Years|N/A|Accepts Healthy Volunteers|||December 2006|April 24, 2007|April 24, 2007||||No||https://clinicaltrials.gov/show/NCT00465660||172002|
NCT00465920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GV0619|Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis|Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis|mCBT|University of Cologne|Yes|Recruiting|May 2007|April 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|42|||Both|14 Years|18 Years|No|||February 2009|February 19, 2009|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00465920||171982|
NCT00466232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3557-07-C|Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer|Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer||HealthPartners Institute|No|Completed|April 2007|March 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||April 2007|December 15, 2015|April 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466232||171958|
NCT00493064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-21|To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions|Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO||Palo Alto Medical Foundation|No|Active, not recruiting|October 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|N/A|N/A|No|||October 2015|October 21, 2015|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00493064||169934|
NCT00493025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0386, CDR0000549896|Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery|Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel (Taxol®, Bristol-Myers Squibb), Cisplatin (Platinol®, Abbott Laboratories), ZD1839 (IRESSA®) and Radiotherapy Followed by Postoperative ZD1839||Sidney Kimmel Comprehensive Cancer Center||Terminated|April 2005|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|80 Years|No|||August 2011|August 15, 2011|June 25, 2007|Yes|Yes|Completed as planned|No||https://clinicaltrials.gov/show/NCT00493025||169937|
NCT00493038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11881|Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis|Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis||Bayer|No|Terminated|February 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|293|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|June 26, 2007||No|The study was prematurely terminated due to slow enrollment beyond the planned study    timelines.|No|January 20, 2009|https://clinicaltrials.gov/show/NCT00493038||169936|The study was prematurely terminated due to slow enrollment beyond the planned study timelines.
NCT00493051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHI-03|Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities|A Randomized, Double-Blind, Placebo-Controlled, Single- and Double-Dose, Comparator Arm (Standard of Care), Multicenter Phase 2b Study of Topical GAM501 (Ad5PDGF-B/Bovine Type I Collagen Gel) in the Treatment of Non-Healing Diabetic Ulcers of the Lower Extremities|MATRIX|Tissue Repair Company|Yes|Completed|November 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|124|||Both|18 Years|N/A|No|||February 2010|February 8, 2010|June 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00493051||169935|
NCT00490308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870/070|The Influence of Estradiol Supplementation During the Luteal in Patients Undergoing IVF Treatment|Blinded Randomised Trial About the Influence of Estradiol Supplementation During the Luteal in Patients Undergoing in Vitro Fertilization (IVF) Treatment||Assaf-Harofeh Medical Center|No|Not yet recruiting|August 2007|August 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2007|June 24, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00490308||170142|
NCT00493935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 008|Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia|Nocturnal Hypoglycemia Prevention Study: Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|March 2006|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|8 Years|17 Years|No|||August 2005|January 10, 2008|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00493935||169868|
NCT00493883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCT 06-11|Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors|Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors||Southwestern Regional Medical Center|No|Completed|December 2006|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00493883||169872|
NCT00490854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10513|A Study for Patients With Type 2 Diabetes Mellitus|A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Once-Daily NPH in Insulin-Naïve Patients With Type 2 Diabetes Mellitus on Oral Agents||Eli Lilly and Company|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|20 Years|N/A|No|||July 2008|July 3, 2008|June 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00490854||170100|
NCT00491166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-DME-001|Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser|A Single-Center, Investigator-Sponsored Pilot Study to Assess Safety and Biologic Activity of Bromfenac Ophthalmic Solution, 0.09%, in Subjects With Diffuse DME Refractory to Laser||Ophthalmic Consultants of Boston|No|Recruiting|June 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|June 22, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00491166||170076|
NCT00491127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6899|Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma|Phase II Study of Cisplatin With Gemcitabine in Fixed Dose Rate Infusion and Dexamethasone in Second-Line in Patients With Aggressive Non-Hodgkin’s Lymphoma||Eli Lilly and Company|Yes|Completed|April 2003|June 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2007|June 21, 2007|June 21, 2007||||No||https://clinicaltrials.gov/show/NCT00491127||170079|
NCT00491439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200702038R|Using in Vivo Confocal Microscope to Evaluate the Corneal Wound Healing After Various Ocular Surgeries|Phase 1 Study of in Vivo Confocal Microscope to Evaluate the Corneal Wound Healing After Various Ocular Surgeries||National Taiwan University Hospital|No|Completed|April 2007|September 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients receiving Epi-LASIK, penetrating keratoplasty and pars plana vitrectioy with        corneal epithelial debridement for diabetic retinopathy|November 2010|April 1, 2012|June 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00491439||170056|
NCT00491452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCH-MR1|Repair of Ischemic Mitral Regurgitation: Comparison Between Flexible and Rigid Annuloplasty Rings||IMR2|Shaare Zedek Medical Center||Completed|April 2007|July 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|||||Both|N/A|N/A||Non-Probability Sample|All patients undergoing CABG with Mitral valve repair for ischemic MR|May 2011|May 26, 2011|June 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00491452||170055|
NCT00492622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014.07|Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis|Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis||University of Louisville|No|Completed|June 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||August 2011|September 21, 2011|June 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00492622||169968|
NCT00492882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP03/102|Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome|Dynamic Changes in the Serum Anti-Müllerian Hormone Level During Low-Dose recFSH Administration Further Support Its Role in the Anovulation of Polycystic Ovary Syndrome|SOPK|University Hospital, Lille|No|Completed|November 2003|January 2007|Actual|||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|30|||Female|18 Years|40 Years|No|||September 2003|June 26, 2007|June 26, 2007||||No||https://clinicaltrials.gov/show/NCT00492882||169948|
NCT00493142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-060605|Pre-operative Rehabilitation Exercise Program for Total Knee Arthroplasty|Impact of a Pre-operative Rehabilitation Exercise Program for Patients With Severe Dysfunction Awaiting Total Knee Arthroplasty|PREP|University of Alberta|No|Active, not recruiting|July 2008|June 2015|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|240|||Both|50 Years|N/A|No|||April 2015|April 21, 2015|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00493142||169928|
NCT00492895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007DR2040|Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients|Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients||University of Zurich|No|Completed|June 2007|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 28, 2013|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00492895||169947|
NCT00464802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200L2-1107|Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects|A Double-Blind, Placebo-Controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Comparison With the Current Formulation in Healthy Subjects||Valeant Pharmaceuticals International, Inc.||Completed|April 2007|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|April 23, 2007||||||https://clinicaltrials.gov/show/NCT00464802||172066|
NCT00464815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109069|Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects|Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-Inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax™ ACWY||GlaxoSmithKline||Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1024|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|April 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00464815||172065|
NCT00465673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS 0553|Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer|A Phase II Study of Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|September 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|21 Years|N/A|No|||August 2009|August 4, 2009|April 23, 2007||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT00465673||172001|
NCT00465686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-010|Effect of Ergonomic Classroom Furniture on the Printing Legibility of Elementary Students With Cerebral Palsy|Ergonomic Classroom Furniture and the Printing Legibility of Elementary School Students With CP||Holland Bloorview Kids Rehabilitation Hospital|No|Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|30|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||May 2008|May 5, 2008|April 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00465686||172000|
NCT00465400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|086-Mom-2006-004|Oxidative Stress in Patients With Age-Related Macular Degeneration|Quantification of Oxidative Stress in Patients With Age-Related Macular Degeneration Prior to and After Photodynamic Therapy: a Comet Assay Analysis||University Hospital, Basel, Switzerland|No|Completed|November 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|None Retained|plasma|Both|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with macular degeneration|December 2008|December 8, 2008|April 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00465400||172022|
NCT00466531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-138|Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19|A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19||Memorial Sloan Kettering Cancer Center||Recruiting|March 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|April 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00466531||171936|
NCT00466791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-201|Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD|A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Optimization, Analog Classroom, Crossover Study Designed to Assess the Time Course of Treatment Effect, Tolerability and Safety of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Noven Therapeutics|No|Completed|August 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|6 Years|12 Years|No|||June 2015|June 23, 2015|April 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00466791||171916|
NCT00466778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007425|Autonomic Nervous System Dysfunction and Peripheral Neuropathy in a Cohort of Asymptomatic Juvenile Diabetic Patients (Type I): A Case-Controlled Study|Autonomic Nervous System Dysfunction and Peripheral Neuropathy in a Cohort of Asymptomatic Juvenile Diabetic Patients (Type I): A Case-Controlled Study||Weintraub, Michael I., MD, FACP, FAAN|No|Completed|April 2007|||||Phase 4|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|40|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||September 2007|September 20, 2007|April 25, 2007||||No||https://clinicaltrials.gov/show/NCT00466778||171917|
NCT00493896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107696|Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients|Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients: An Investigator Initiated Protocol||Eastern Virginia Medical School|Yes|Terminated|July 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|89 Years|No|||September 2012|January 13, 2014|June 27, 2007||No|low enrollment|No||https://clinicaltrials.gov/show/NCT00493896||169871|
NCT00493298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA-06-02|Tysabri Observational Program|TOP: Tysabri® Observational Program|TOP|Biogen|Yes|Recruiting|June 2007|December 2027|Anticipated|December 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants with RRMS who are therapy-naïve to natalizumab and who meet the criteria        defined in the indication statement for prescription in the respective country.|January 2016|January 14, 2016|June 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00493298||169917|
NCT00493311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APF-302|Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Efficacy and Safety of Intravenous Acetaminophen Versus Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males||Mallinckrodt|No|Completed|June 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|June 27, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00493311||169916|
NCT00493948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X06- 0237|Evaluation of a Portable Device for Assessing Sleep Disordered Breathing in Congestive Heart Failure|Evaluation of a Portable Device for Assessing Sleep Disordered Breathing in Congestive Heart Failure||ResMed|No|Completed|July 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|The study population under investigation are those people with moderate to severe heart        failure who are currently admitted to the Coronary Care Unit of a major Sydney hospital.|November 2009|November 9, 2009|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00493948||169867|
NCT00490295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002572|Biomarkers for Detection of Brain Ischemia|Biomarkers for the Detection of Brain Ischemia in Neonates With Congenial Heart Disease Requiring Cardiac Surgery||Emory University|No|Completed|March 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|N/A|30 Days|No|Non-Probability Sample|Ten consecutive full-term (>36 week gestation) neonates, one day to 30 days of age,        presenting for cardiac surgery for arterial switch operation or Norwood operation will be        eligible for the study|November 2013|November 25, 2013|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00490295||170143|
NCT00490555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31434-A|PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue|The Effect of Male Hormonal Contraceptive Regimens on Prostate Tissue In Normal Men|PROS-1|University of Washington|No|Completed|January 2009|March 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|June 20, 2007|Yes|Yes||No|June 19, 2013|https://clinicaltrials.gov/show/NCT00490555||170123|
NCT00490789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESSTAL|Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM|A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis|TESSTAL|Cardiff University|Yes|Active, not recruiting|October 2005|September 2009|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|65 Years|No|||April 2008|April 29, 2008|June 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00490789||170105|
NCT00491465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc074301ctil|The Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.|Randomized,Controlled,Open,Cross-Over Intervention Study for Evaluating the Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.|4301|Rabin Medical Center|No|Not yet recruiting|July 2007|July 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|2007|||Both|8 Years|16 Years|No|||June 2007|June 25, 2007|June 25, 2007||||No||https://clinicaltrials.gov/show/NCT00491465||170054|
NCT00491738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4167g|A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)|A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer||Genentech, Inc.||Terminated|August 2007|||January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||April 2009|April 9, 2009|June 25, 2007|Yes|Yes|Based on the data collected, the combination of bevacizumab and sunitinib appeared to be    poorly tolerated.|No|February 6, 2009|https://clinicaltrials.gov/show/NCT00491738||170033|Based on the early safety results from this study, Genentech terminated further recruitment and discontinued treatment. Insufficient efficacy information was available to perform additional outcome analyses.
NCT00490568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA102675|Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers|An Open-label Extension Study of the Long-term Safety and Efficacy of Rosiglitazone Extended-release (RSG XR) as Adjunctive Therapy to Acetylcholinesterase Inhibitors in Subjects With Mild-to-moderate Alzheimers Disease (REFLECT-4).||GlaxoSmithKline||Terminated|August 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1480|||Both|51 Years|91 Years|No|||May 2012|July 3, 2013|June 21, 2007|Yes|Yes|Based on preliminary parent study results|No||https://clinicaltrials.gov/show/NCT00490568||170122|
NCT00491751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23184|Clinical Utility of Endothelial Dysfunction in PAD|Clinical Utility of Endothelial Dysfunction in PAD||Boston University|Yes|Active, not recruiting|May 2004|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|June 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00491751||170032|
NCT00492076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E04/05/PP-M|Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma|A Randomised, Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract, Quantified in Mass Units, in Subjects With Perennial Mite Induced Asthma||ALK-Abelló A/S|No|Completed|October 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|45|||Both|14 Years|55 Years|No|||October 2008|October 15, 2008|June 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00492076||170008|
NCT00492336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043807|Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia|Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia||University of Maryland|Yes|Completed|January 2007|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|64 Years|No|||June 2013|June 17, 2013|June 26, 2007|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT00492336||169989|
NCT00483808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-015 & TP-038|Renal Denervation in Patients With Refractory Hypertension|Renal Denervation in Patients With Refractory Hypertension||Medtronic Vascular|Yes|Completed|June 2007|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|73|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|June 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00483808||170638|
NCT00484380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-04|The Scanner in the Coronary Evaluation|Contribution of the Scanner in the Coronary Evaluation Before Valvular Replacement||French Cardiology Society|Yes|Completed|August 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00484380||170594|
NCT00484679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609M91989|Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata|Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2007|March 2011|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 20, 2014|June 8, 2007|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00484679||170571|
NCT00484692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-Nr. 2005-006189-32|Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation|Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training®||Medical University Innsbruck|Yes|Completed|July 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|779|||Both|18 Years|65 Years|No|||June 2007|June 8, 2007|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484692||170570|
NCT00484939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO19286|A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer|A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|July 2007|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|70 Years|N/A|No|||January 2015|January 7, 2015|June 11, 2007||No||No|March 7, 2014|https://clinicaltrials.gov/show/NCT00484939||170551|
NCT00484952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/2006|Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel|Multicenter Study for Surveillance of Hospitalizations Due to Rotavirus-Associated Diarrhea and Estimation of the Economic Burden of Rotavirus Hospitalizations||Hillel Yaffe Medical Center|No|Not yet recruiting|September 2007|September 2009|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|2500|||Both|1 Month|5 Years|Accepts Healthy Volunteers|||June 2007|July 31, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00484952||170550|
NCT00495833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32168-E/G|SPHERE Hypertension Intervention Study|SPHERE Hypertension Intervention Study||University of Washington|Yes|Completed|June 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|7||Anticipated|8000|||Both|18 Years|N/A|No|||June 2010|June 25, 2010|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00495833||169727|
NCT00495846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-4|GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma|Treatment of Advanced Hepatocellular Carcinoma With Depot Somatostatin Analogues: a Pilot Prospective Study Based on Somatostatin Receptors Tumors Expression|SS-HCC|Federico II University|Yes|Completed|April 2007|December 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||August 2009|August 14, 2009|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495846||169726|
NCT00496132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO4198g|A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Have Been Treated With a Purine Nucleoside Analogue-Containing Regimen||Genentech, Inc.||Terminated|September 2007|||June 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496132||169706|
NCT00496145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76357|Spanish Diabetes Self-Management Program|Spanish Diabetes Self-Management Program|SDSMP|Stanford University|Yes|Completed|August 2002|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|567|||Both|18 Years|N/A|No|||November 2007|November 5, 2007|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00496145||169705|
NCT00496717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3914|Aorta Calcium Scoring|Measurement of an Abdominal Aorta Calcium Scoring and Its Correlation With Cardiovascular Risk Factors||University Hospital, Strasbourg, France||Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|45 Years|N/A|No|Non-Probability Sample|Patients with at least one cardiovascular risk factor in primary prevention. Mainly out        patients followed in our cardiology clinic|May 2011|July 27, 2011|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496717||169662|
NCT00496977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-02045|Danish Lung Cancer Screening Trial (DLCST)|Screening for Lung Cancer. A Randomised Controlled Trial of Low-Dose CT-Scanning.|DLCST|Danish Lung Cancer Group|Yes|Active, not recruiting|October 2004|January 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Screening|2||Actual|4104|||Both|50 Years|70 Years|No|||June 2007|July 5, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00496977||169642|
NCT00497250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDCA001|Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy|Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy||Fudan University|Yes|Recruiting|July 2007|October 2009|Anticipated|March 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|75 Years|No|||October 2008|October 20, 2008|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497250||169621|
NCT00487214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDNET2001|Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma|||Allergan||Completed|June 2002|February 2003|Actual|February 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|361|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with either open-angle glaucoma or ocular hypertension at 41 centers in the        United States|May 2011|May 31, 2011|June 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00487214||170377|
NCT00487448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMD_FLAG-IDA_98|SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia|FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia.|FLAG-IDA|PETHEMA Foundation|Yes|Completed|July 1998|June 2007|Actual|May 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|75 Years|No|||November 2008|November 17, 2008|June 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487448||170359|
NCT00488072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0916|Effects of Mirtazapine on Appetite in Advanced Cancer Patients|Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2007|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488072||170311|
NCT00488085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-ID-173-CTIL|Crohn’s Disease, Obesity and Disease Severity|Crohn’s Disease, Obesity and Disease Severity|CROHN_OBESE|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|June 2007|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|40|||Both|18 Years|N/A|No|||March 2007|June 18, 2007|June 17, 2007||||No||https://clinicaltrials.gov/show/NCT00488085||170310|
NCT00487734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01274|Effect of Testosterone Replacement on Insulin Resistance|Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome||McGuire Research Institute|No|Completed|August 2007|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Male|20 Years|65 Years|No|||October 2012|October 22, 2012|June 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00487734||170337|
NCT00488046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 239|Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults|Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine Modified H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2007|September 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|16|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2007|November 19, 2007|June 18, 2007||||No||https://clinicaltrials.gov/show/NCT00488046||170313|
NCT00484120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-2007-2|Proof-of Concept Study of Topical 3%-Diclofenac-Nano-Emulsion Cream for Knee OA Pain|Proof-of Concept Study to Evaluate the Safety and Analgesic Efficacy of Topical 3%-Diclofenac-Nano-Emulsion Cream Versus Placebo for Knee Osteoarthritis||Pharmos|Yes|Completed|June 2007|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|50 Years|N/A|No|||August 2011|August 1, 2011|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484120||170614|
NCT00484406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-05-CG-201040106|MMP Polymorphisms and Acute Coronary Syndromes|Matrix Metalloproteinase Genetic Polymorphisms and Outcome of Non-ST Elevated Acute Coronary Syndromes||University of Trieste|No|Completed|February 2005|May 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|No|||May 2007|June 7, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484406||170592|
NCT00484094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468X1-4411|Study Investigating Rapamune For Post-Marketing Surveillance|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Rapamune||Pfizer|No|Completed|July 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|209|||Both|13 Years|N/A|No|Non-Probability Sample|Patients who receive Rapamune after kidney transplantation|October 2015|October 23, 2015|June 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00484094||170616|
NCT00484107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713V-101833|Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women|A Postmarketing Surveillance Study Evaluating the Tolerability and Safety of PREMARIN VAGINAL CREAM in Indian Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|September 2005|October 2006|Actual|||Phase 4|Observational|N/A||||200|||Female|40 Years|65 Years|No|||December 2007|December 20, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484107||170615|
NCT00484393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-041|Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study|Tetracaine (Ametop®) Compared to Placebo for Reducing Pain Associated With Intramuscular Injection of Palivizumab (Synagis®) - A Pilot Study||Fraser Health|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|7|||Both|1 Month|2 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|June 6, 2007||No||No|March 5, 2015|https://clinicaltrials.gov/show/NCT00484393||170593|
NCT00484965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72/06|Erythrocyte-Mediated Drug Delivery for the Prevention of Stent Restenosis|Erythrocyte-Mediated Drug Delivery for the Prevention of Restenosis After Coronary Artery Stent Implantation:TROY-Study|TROY|University of Rome Tor Vergata|Yes|Not yet recruiting|July 2007|January 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|N/A|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00484965||170549|
NCT00485277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNIT-BR-002|A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer|A Phase I Trial of a Fixed Dose of MVA-BN-HER2 Following 1st- or 2nd-Line Chemotherapy for HER-2-Positive Metastatic Breast Cancer||Bavarian Nordic, Inc.|Yes|Completed|June 2007|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||September 2010|January 25, 2012|June 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00485277||170525|
NCT00485290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF-2007-0050|Effect of Meal on Portal and Esophagus Variceal Pressure|Effect of Meal on Portal and Esophagus Variceal Pressure|VIPE|Hvidovre University Hospital|No|Terminated|June 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|75 Years|No|||November 2007|August 6, 2008|June 11, 2007|||No eligible patients were found, the study stopped without including any patients|No||https://clinicaltrials.gov/show/NCT00485290||170524|
NCT00485537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0001|Pregnancy Outcomes With a GnRH Antagonist Protocol Versus GnRH-Agonist Protocol in ICSI Cycles|Pregnancy Outcomes With a Gonadotropin-Releasing Hormone (GnRH) Antagonist (Cetrorelix) Protocol Versus GnRH-Agonist Protocol in Ovarian Stimulation for ICSI Cycles-a Prospective Study||Clinic and Research Center in Human Reproduction Roger Abdelmassih|Yes|Completed|September 2005|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|2005|||Female|22 Years|40 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485537||170506|
NCT00481351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1068/06|Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons|Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons in Men With Stable Coronary Heart Disease.||University of Sao Paulo|No|Completed|June 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|30 Years|75 Years|No|||January 2007|January 7, 2011|May 30, 2007||No||No|January 7, 2011|https://clinicaltrials.gov/show/NCT00481351||170822|
NCT00495859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROUD|Effects of Preoperative Long-Term Immunonutrition in Patients Listed for Liver Transplantation|Randomized Controlled Double Blind Multi-Center Clinical Trial to Assess the Effects of Preoperative Long-Term Immunonutrition in Patients Listed for Liver Transplantation|PROUD|Heidelberg University|Yes|Recruiting|April 2008|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|156|||Both|18 Years|68 Years|No|||April 2008|April 2, 2008|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495859||169725|
NCT00495872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0170|Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor|A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor||M.D. Anderson Cancer Center|No|Completed|June 2007|||October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|204|||Both|N/A|N/A|No|||October 2012|October 16, 2012|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495872||169724|
NCT00505466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS99-038|Transition From Research to Disclosure in Human Genetics|Transition From Research to Disclosure in Human Genetics||M.D. Anderson Cancer Center|No|Recruiting|May 1999|||May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Optional small sample of blood (about 6 tablespoons) for genetic testing for p53 following      pre-test genetic counseling.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient diagnosed with cancer or a participant with a family member who has had cancer.|November 2015|November 24, 2015|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505466||169001|
NCT00505479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G20020584|Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy?|||Zhejiang University|Yes|Recruiting|May 2007|May 2010|Anticipated|||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Female|20 Years|40 Years|Accepts Healthy Volunteers|||July 2007|July 20, 2007|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505479||169000|
NCT00496483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro 2011|Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients|A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day||Veloxis Pharmaceuticals|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||June 2015|June 25, 2015|July 2, 2007|Yes|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT00496483||169679|
NCT00496509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00050|Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer|A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases||AstraZeneca|No|Completed|August 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00496509||169678|
NCT00496431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/07/2357/26|phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients|Phase II Study of the Histone-deacetylase Inhibitor ITF2357 in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients||Italfarmaco|Yes|Terminated|May 2007|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2009|May 23, 2013|July 3, 2007||No|ITF2357 (Givinostat) was well tollerated but had limited activity against refractory/relapsed    HL|No||https://clinicaltrials.gov/show/NCT00496431||169683|
NCT00496444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0735|Azacytidine and Valproic Acid in Patients With Advanced Cancers|Phase I Study of Low-Dose Hypomethylating Agent Azacitidine Combined With the Histone Deacetylase Inhibitor Valproic Acid in Patients With Advanced Cancers||M.D. Anderson Cancer Center|No|Completed|May 2005|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|2 Years|N/A|No|||July 2012|July 31, 2012|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00496444||169682|
NCT00496457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO19622 CLEQ 1104-1|Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy|A Double-Blind, Randomized, Multicenter Study With 500 mg QD of TRO19622 Versus Placebo in Patients With Painful Peripheral Diabetic Neuropathy||Trophos|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2009|January 26, 2009|June 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00496457||169681|
NCT00496743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-235/01|Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides|A Prospective, Open-Label Study on Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides||Bispebjerg Hospital|No|Terminated|January 2002|January 2006|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|18 Years|N/A|No|||July 2007|July 2, 2007|July 2, 2007|||The study was discontinued after the first 10 patients because of discouraging results.|No||https://clinicaltrials.gov/show/NCT00496743||169660|
NCT00496990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA013496|Treating the Partners of Drug Using Pregnant Women: Stage II|Treating the Partners of Drug Using Pregnant Women: Stage II|HOPE|Johns Hopkins University|No|Completed|October 2005|June 2010|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|60 Years|No|||March 2013|March 1, 2013|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00496990||169641|
NCT00497263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-43-01 Rev 01|End-to-End Compression Anastomosis for Left-sided Colectomy Endo-CAR Study|||Niti Medical Technologies Ltd.|Yes|Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A||||June 2011|June 28, 2011|July 4, 2007||||No||https://clinicaltrials.gov/show/NCT00497263||169620|
NCT00487786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGX-427-01|Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer|A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27||OncoGenex Technologies|Yes|Completed|June 2007|October 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||April 2014|January 14, 2016|June 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00487786||170333|
NCT00487799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ularitide-1503|A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure||Facet Biotech|Yes|Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||July 2009|July 17, 2009|June 15, 2007|||Facet no longer has ownership of ularitide.|No||https://clinicaltrials.gov/show/NCT00487799||170332|
NCT00488059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20837|A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients|A Multicenter, Open-label Study Evaluating the Antiviral Activity and Safety of Enfuvirtide (ENF) Once Daily (QD) or Twice Daily (BID) in Triple-class Experienced HIV-1 Infected Patients Changing Their Therapy to a Standard of Care (SOC) Regimen That Includes Initiating Raltegravir Plus an Optimized Background (OB) Antiviral Regimen|AMICI|Hoffmann-La Roche||Terminated|June 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|June 18, 2007|Yes|Yes|This study was terminated early due to poor enrollment.|No|November 11, 2009|https://clinicaltrials.gov/show/NCT00488059||170312|
NCT00488345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074K4-2207|Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age|A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|59|||Both|8 Years|11 Years|No|||September 2012|September 12, 2012|June 18, 2007|Yes|Yes||No|September 1, 2010|https://clinicaltrials.gov/show/NCT00488345||170291|
NCT00488358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01645|Hemodynamic Changes After Aortic Aneurysm Treatment With Stent-Graft|Hemodynamic Changes After Aortic Aneurysm Treatment With Stent-Graft||University of California, San Francisco|Yes|Completed|November 2005|August 2012|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Abdominal Aortic Aneurysm with planned treatment using Zenith Endovascular        Stent-Graft|October 2013|October 8, 2013|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488358||170290|
NCT00488904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123omega|Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery|Omega-3 Fatty Acids and Postoperative Complication After Colorectal Surgery|omega3|Aalborg Universitetshospital|No|Completed|June 2007|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|148|||Both|N/A|N/A|No|||April 2010|April 9, 2010|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488904||170249|
NCT00488631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014179|An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis||Janssen Research & Development, LLC|Yes|Completed|September 2007|February 2015|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|1228|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 18, 2007|Yes|Yes||No|May 1, 2013|https://clinicaltrials.gov/show/NCT00488631||170269|
NCT00484445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12093B|Transfer to Another Health Care Facility Following Critical Illness|Transfer to Another Health Care Facility Following Critical Illness||University of Chicago|No|Completed|January 2003|January 2003|Actual|January 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|548|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to an urban medical intensive care unit.|September 2013|September 4, 2013|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484445||170589|
NCT00484458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6000-1006-P1-R1|Wallis Stabilization System for Low Back Pain|A Prospective, Multi-center, Randomized, Active-Controlled Study of the Wallis System for the Treatment of Mild to Moderate Degenerative Disc Disease of the Lumbar Spine||Zimmer Spine|Yes|Active, not recruiting|January 2007|November 2014|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|60 Years|No|||October 2011|October 3, 2011|June 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00484458||170588|
NCT00484419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wel-409|Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin|Effects of Colesevelam HCl, Avandia® (Rosiglitazone Maleate), or JanuviaTM (Sitagliptin) on Glycemic Parameters and Lipid Profiles in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy||Daiichi Sankyo Inc.||Completed|May 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|169|||Both|18 Years|80 Years|No|||June 2009|June 17, 2009|June 7, 2007|Yes|Yes||No|April 29, 2009|https://clinicaltrials.gov/show/NCT00484419||170591|
NCT00484432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR012|Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer|NGR012: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Ovarian Cancer||MolMed S.p.A.|No|Active, not recruiting|November 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484432||170590|
NCT00485264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1066|Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents|A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|September 2007|||June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|153|||Both|N/A|18 Years|No|||August 2015|August 31, 2015|June 11, 2007|No|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT00485264||170526|
NCT00489138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/24|Prospective, Open-label Study of Pharmacokinetics of Ertapenem in the Muscle Using Microdialysis in Mechanically Ventilated Intensive Care Unit Patients, Treated or Not by Norepinephrine|||Assistance Publique Hopitaux De Marseille||Terminated|April 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489138||170232|
NCT00489411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-170601|Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer|A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2008|March 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|242|||Both|25 Years|N/A|No|||July 2015|July 6, 2015|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489411||170211|
NCT00489710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401-05|Talabostat in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Talabostat in Patients With Metastatic Renal Cell Carcinoma||University of Nebraska|Yes|Withdrawn|December 2006|May 2007|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|N/A|No|||May 2013|May 7, 2013|June 20, 2007|No|Yes|Terminated for safety reasons|No||https://clinicaltrials.gov/show/NCT00489710||170188|
NCT00489723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0056-07-EMC|Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?|||HaEmek Medical Center, Israel|Yes|Recruiting|May 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|15 Years|85 Years||||June 2007|June 20, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489723||170187|
NCT00496782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001060|Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay|Surrogate Marker For Tropism-A Multi-Center, Open Label, Pilot Study||ViiV Healthcare|No|Terminated|July 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|16|||Both|16 Years|N/A|No|||March 2010|November 10, 2010|July 3, 2007|No|Yes|See Detailed Description|No|June 23, 2009|https://clinicaltrials.gov/show/NCT00496782||169657|Study terminated prematurely due to slow enrollment. Premature termination of study was not due to any safety concerns. Efficacy data not summarized due to low sample size; only safety was summarized.
NCT00497016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTSTAT|Does Statin Therapy Reduce Sympathoexcitation in Hypertension?|Does Statin Therapy Reduce Sympathoexcitation in Hypertension?||Radboud University||Completed|May 2007|March 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||Anticipated|13|||Both|18 Years|70 Years||||September 2008|September 29, 2008|July 4, 2007||||No||https://clinicaltrials.gov/show/NCT00497016||169639|
NCT00495820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-011-06F|Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study|Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study||VA Office of Research and Development|Yes|Completed|August 2007|June 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|55 Years|N/A|No|||October 2015|October 19, 2015|July 2, 2007||No||No|January 21, 2014|https://clinicaltrials.gov/show/NCT00495820||169728|Small sample size and short duration of the study are two important limitations of the study. All male subjects in the study also make it difficult to generalize the results.
NCT00495105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL080967-01A2|Dairy Foods and Blood Pressure in Multi-Ethnic Children|Dairy Foods and Blood Pressure in Multi-Ethnic Children||University of Kansas Medical Center|Yes|Completed|August 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2115|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||February 2013|February 8, 2013|June 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00495105||169781|
NCT00496756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081-06|Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma||University of Nebraska|Yes|Active, not recruiting|March 2007|January 2015|Anticipated|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|July 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00496756||169659|
NCT00496769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-048|A Phase III Study of Apixaban in Patients With Atrial Fibrillation|Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial|AVERROES|Bristol-Myers Squibb|Yes|Active, not recruiting|August 2007|December 2015|Anticipated|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|6421|||Both|50 Years|N/A|No|||August 2015|August 11, 2015|July 2, 2007|Yes|Yes||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00496769||169658|On May 28, 2010, after a planned interim analysis for efficacy, the Data Monitoring Committee recommended early termination due to apixaban's superior efficacy over ASA, with an acceptable safety profile. The open-label phase is ongoing.
NCT00497003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 02-071/03|Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure|||Bispebjerg Hospital|No|Completed|February 2004|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|50|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||July 2007|October 12, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497003||169640|
NCT00497276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0-204-03-8/27|Comparison of Ultrasound and Nerve Stimulation Technique for Continuous Sciatic Nerve Block|A Prospective, Randomized Comparison of Ultrasound Versus Nerve Stimulation Guidance of Popliteal, Sciatic Catheter Placement After Major Foot and Ankle Surgery: Clinical Outcome and Cost Analysis||University of Aarhus|No|Completed|August 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2009|December 18, 2009|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497276||169619|
NCT00485030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070044|Diffuse Type In-Stent Restenosis After Drug-Eluting Stent|Comparison Between Drug-Eluting Stents for the Treatment of the Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation: Sirolimus-Eluting vs. Paclitaxel-Eluting Stents|DES-ISR|CardioVascular Research Foundation, Korea|Yes|Completed|March 2007|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485030||170544|
NCT00485342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-400|RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin|Multicentric, Controlled and Randomised Open Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin Using Pharmacologic Measures of Ribavirin Exposition During Combination Peginterferon Alfa-2 and Ribavirin Treatment in Naive Patients With Chronic Hepatitis C of Genotype 1 on a First Combination Therapy|RIBAJUSTE|Hospices Civils de Lyon|Yes|Recruiting|April 2006|March 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|65 Years|No|||January 2012|January 6, 2012|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00485342||170520|
NCT00485355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-150|Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy|A Prospective Randomized Trial Comparing Conventional vs. Robotic Assisted Laparoscopic Hysterectomy||The Cleveland Clinic|No|Completed|June 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|February 18, 2014|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485355||170519|
NCT00484991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEAP-001|Sapropterin Expanded Access Program|Sapropterin Expanded Access Program||BioMarin Pharmaceutical||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|9 Years|N/A||||April 2008|April 11, 2008|June 8, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00484991||170547|
NCT00485004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070041|Focal In-stent Restenosis After Drug-Eluting Stent|FOcal Type In-stent Restenosis After Drug-Eluting Stent Implantation Treated by CUtting Balloon Angioplasty Versus Sirolimus-Eluting Stent|FOCUS|CardioVascular Research Foundation, Korea|Yes|Completed|March 2007|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485004||170546|
NCT00485017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-4109-C-302|Efficacy and Safety of THR-4109 in Obese Subjects|A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of THR-4109 in Obese Subjects||Theracos|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|220|||Both|30 Years|60 Years|No|||June 2008|June 30, 2008|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00485017||170545|
NCT00488371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4410|Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®|Evaluation of Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Pneumococcal Conjugated Vaccine (Prevnar®) Under the Auspices of the Taipei City Government Vaccination Program||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2006|April 2007|Actual|||Phase 4|Observational|Time Perspective: Prospective||||250|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||December 2007|December 16, 2007|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00488371||170289|
NCT00488384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007DR2065 EK674|Acitretin Plasma Levels Under Hemodialysis|Acitretin Plasma Levels Under Hemodialysis||University of Zurich|No|Suspended|June 2007|June 2018|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2009|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 10, 2015|June 19, 2007||No|lack of subjects|No||https://clinicaltrials.gov/show/NCT00488384||170288|
NCT00481078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02841|Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Randomized Phase II Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|May 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||December 2012|October 24, 2014|May 31, 2007|Yes|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00481078||170843|
NCT00481403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-NG-0506-(1003-C-068-JH)|Study of Sperm Molecular Factors Implicated in Male Fertility|Microarray Analysis in Sperm From Fertile and Infertile Males Without Basic Sperm Analysis Abnormalities||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Active, not recruiting|May 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|After sperm washing, sperm pellet was suspended in trizol and immediately frozen by direct      immersion in liquid nitrogen and stored in a nitrogen tank until mRNA extraction.|Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infertile male undergoing assisted reproduction technique without abnormal sperm        parameters described by the OMS. Female partners are under 37 years old, IBM lower than 30        kg/m2 and do not present any obvious infertility problem as fallopian tubal obstruction,        endometriosis, ovarian failure or polycystic ovarian syndrome.|March 2015|March 9, 2015|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481403||170818|
NCT00481416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-37|“Evaluation of the PillCam™ESO Capsule in the Detection of Esophageal Varices|Evaluation of the PillCam™ Eso Capsule in the Detection of Esophageal Varices|MA-37|Given Imaging Ltd.|No|Completed|December 2004|January 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|318|||Both|18 Years|N/A|No|||June 2006|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00481416||170817|
NCT00488618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-31|Study Evaluating RGH-188 in the Treatment of Patients With Acute Mania|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in Patients With Acute Mania Associated With Bipolar I Disorder||Forest Laboratories||Completed|April 2007|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|65 Years|No|||March 2012|March 2, 2012|June 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00488618||170270|
NCT00489424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HUS136|Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass|A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study of Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an i.v. Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass||Novartis||Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|793|||Female|45 Years|79 Years|No|||February 2011|February 15, 2011|June 19, 2007|Yes|Yes||No|August 6, 2009|https://clinicaltrials.gov/show/NCT00489424||170210|
NCT00484705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG-7861|Polycystic Ovary Syndrome (PCOS) - Effect Of Physical Exercise And Electroacupuncture|Polycystic Ovary Syndrome (PCOS) - The Female Metabolic Syndrome Genes And Processes In The Aetiology And Pathogenesis Of PCOS And Identification Of New Treatment Strategies|PCOSNTS|Göteborg University|Yes|Completed|October 2005|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|84|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||November 2009|November 9, 2009|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484705||170569|
NCT00489450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK3530_AI_2006|Phase I Study to Investigate the Alcohol Interaction of SK3530|Clinical Trial to Investigate the Influence of Alcohol on the Pharmacokinetics and Safety of SK3530 in Healthy Male Volunteers||SK Chemicals Co.,Ltd.|Yes|Completed|March 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||March 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489450||170208|
NCT00489463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUD vascularization|IUD Uterine Vascularization and Side Effects|The Effect of the Levonorgestrel-Releasing Intrauterine System and the Copper-Intrauterine Device (TCu 380A) on Subendometrial Microvascularization and Uterine Artery Blood Flow.||Hospital de Clinicas de Porto Alegre|Yes|Completed|January 2004|November 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|2||Actual|63|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2006|June 20, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489463||170207|
NCT00485875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7953|Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD|An Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD)||Eli Lilly and Company||Completed|June 2004|January 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|6 Years|17 Years|No|||June 2007|June 11, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485875||170480|
NCT00485888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuCipMNSP|Flushing in Social Anxiety Disorder on Cipralex|Changes in the Vasodilatory Response to Methyl-nicotinate in Response to S-citalopram Treatment in Social Phobia Patients||START Clinic for Mood and Anxiety Disorders|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 29, 2013|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00485888||170479|
NCT00498472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOT_1|NT-proBNP in the Optimization of Treatment After Recent Acute Heart Failure Trial|NT-proBNP in the Optimization of Treatment After Recent Acute Heart Failure (BOT-AcuteHF) Trial|BOT_AcuteHF|Università degli Studi di Brescia|No|Completed|July 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||July 2007|June 14, 2010|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498472||169527|
NCT00498485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120060315|Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome|Phase IV - A Trial of Xyrem in the Treatment of Chronic Fatigue Syndrome.||Rutgers, The State University of New Jersey|No|Terminated|May 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|19|||Both|21 Years|65 Years|No|||September 2013|January 3, 2014|July 2, 2007||No|The study was terminated soon after it began because the company withdrew support.|No||https://clinicaltrials.gov/show/NCT00498485||169526|
NCT00496158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-PSI-5268-06-306|Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus|A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus|QUASH2|Pharmasset||Terminated|August 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|16 Years|N/A|No|||April 2009|April 23, 2009|July 2, 2007||Yes|The study was terminated in the interest of patient safety.|No||https://clinicaltrials.gov/show/NCT00496158||169704|
NCT00496171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC CE102/07|Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers|A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers||Photocure||Terminated||||||N/A|Observational|Time Perspective: Prospective|||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 15, 2009|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00496171||169703|
NCT00497575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no. 2002C23037|Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism||CHRO1|Zhejiang University|Yes|Completed|October 1999|September 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|N/A|5 Years||||July 2007|July 5, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497575||169596|
NCT00496821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-RSV01-105|Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus|A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus||Alnylam Pharmaceuticals|No|Completed|July 2007|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|88|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2007|November 29, 2007|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00496821||169654|
NCT00497328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQCIN01|COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT|An Open Labelled Randomized Multi-center Study of COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Incidence of Contrast Induced Nephropathy|CONTRAST|National University Hospital, Singapore|Yes|Completed|August 2007|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|477|||Both|21 Years|N/A|No|||January 2014|January 13, 2014|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497328||169615|
NCT00498134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1721-01|Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway|Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway||Hospital Authority, Hong Kong||Active, not recruiting|March 2004|April 2013|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|1200|||Both|45 Years|N/A||||July 2010|July 6, 2010|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498134||169553|
NCT00485368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/03|Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome|The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.||Bayside Health|No|Completed|January 2004|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|40 Years|No|||June 2007|June 12, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485368||170518|
NCT00481117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11719|Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes|Safety, Tolerability, PK and PD of LY2405319 After Multiple Subcutaneous Injections in Subjects With Type 2 Diabetes||Eli Lilly and Company|Yes|Completed|August 2008|December 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|37|||Both|35 Years|70 Years|No|||September 2010|September 10, 2010|May 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00481117||170840|
NCT00481091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-873|A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia||AbbVie|No|Active, not recruiting|July 2007|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00481091||170842|
NCT00481104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2330-004|Evaluation of Long Term Safety of Tesofensine in Patients With Obesity|Evaluation of Long Term Safety of Tesofensine in Patients With Obesity||NeuroSearch A/S|No|Completed|May 2007|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|65 Years|No|||March 2008|July 1, 2011|May 31, 2007||||No||https://clinicaltrials.gov/show/NCT00481104||170841|
NCT00485329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENZ-DER-002-IL|Assessment of the Safety and Efficacy of DERMASTREAM™ - ENZYSTREAM™ System for the Treatment of Chronic Venous Ulcers|A Phase I/II Randomized, Double Blind, Placebo-Controlled Dose- Escalating Study, to Assess The Safety and Efficacy of Enzystream™ Debriding Solution (Papain) Applied by Dermastream™ Device for the Treatment of Lower Extremity Chronic Venous Ulcers|ENZ-DER-002-IL|EnzySurge|Yes|Completed|July 2007|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|85 Years|No|||May 2010|May 24, 2010|June 10, 2007||||No||https://clinicaltrials.gov/show/NCT00485329||170521|
NCT00481065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P5|Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects|A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects||Novartis||Completed|April 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|405|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 31, 2013|May 31, 2007||No||No|August 26, 2011|https://clinicaltrials.gov/show/NCT00481065||170844|
NCT00481689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11490|Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens|Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens||Bayer||Completed|May 2004|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|500|||Both|18 Years|N/A|No|||June 2009|June 25, 2009|June 1, 2007||||||https://clinicaltrials.gov/show/NCT00481689||170796|
NCT00481702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-802|A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)|A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults||Merck Sharp & Dohme Corp.||Completed|December 2001|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||300|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00481702||170795|
NCT00481988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5405|Treating Depression With Transcranial Direct Current Stimulation (tDCS)|Randomized, Double Blind Crossover Study of the Treatment of Major Depressive Episode With Transcranial Direct Current Stimulation (tDCS)||New York State Psychiatric Institute|Yes|Completed|March 2007|January 2011|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||May 2013|May 17, 2013|June 1, 2007||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00481988||170774|Data for the secondary outcome measure (Beck Depression Inventory) was incompletely collected and not analyzed.
NCT00489437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS06-451|Heparin-Induced Thrombocytopenia Score Card Study|Improving the Diagnosis of Heparin-Induced Thrombocytopenia: Utility of the 4T's Score and Evaluation of New Rapid Assays||McMaster University|Yes|Completed|December 2007|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|536|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00489437||170209|
NCT00488891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014143|The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia|The Paliperidone ER Outcomes Study of Schizophrenia Patients in Typical Clinical Practice|POST|Ortho-McNeil Janssen Scientific Affairs, LLC|No|Terminated|April 2007|October 2007|Actual|October 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|43|Samples With DNA|10 mL blood sample is collected from patients who consent to the pharmacogenomic component      of the study.|Both|18 Years|N/A|No|Probability Sample|The majority of patients with schizophrenia are treated in the outpatient setting.        Therefore, this study will focus largely on the population treated in Community Mental        Health Centers (CMHCs), Veteran Affairs (VAs) Centers, as well as private practice and        other treatment settings.|August 2012|August 28, 2012|June 18, 2007||No|The study was terminated because it was not enrolling at the expected rate|No||https://clinicaltrials.gov/show/NCT00488891||170250|
NCT00482547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMD-6003|Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)|Study of a Urethral Catheter Coated With Eluting Silver Salts|SUCCESS|C. R. Bard|Yes|Terminated|June 2007|August 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1188|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|June 4, 2007||No|Terminated for futility reasons.|No|April 6, 2009|https://clinicaltrials.gov/show/NCT00482547||170734|Sample size calculations required 1244 Efficacy Evaluable 48 subjects, only 854 Efficacy Evaluable 48 subjects were enrolled, which does not allow for a fully powered study and there is the threat of a type II error (false negative result).
NCT00482560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN19341|Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening|Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening||University of Turin, Italy|No|Completed|January 2007|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|5 Days|No|||June 2007|June 28, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482560||170733|
NCT00489957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001930|Speckle Tracking in Pediatric Patients|Speckle Tracking and Function Assessment in Pediatric Patients||Emory University|No|Completed|March 2007|December 2009|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|70|||Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Newborn - 17 year old patients at Children's Healthcare of Atlanta Egleston campus with        known or suspected heart muscle dysfunction already scheduled for a routine echo. Also        looking at normal controls.|November 2013|November 25, 2013|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489957||170169|
NCT00489970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110080|Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9|Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9||GlaxoSmithKline||Active, not recruiting|June 2007|April 2016|Anticipated|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1592|||Both|28 Years|73 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|June 21, 2007|Yes|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00489970||170168|
NCT00489983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5119|Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy|A Multicenter Phase 2 Randomized Trial of Single-Agent ALIMTA or ALIMTA With Sequentially Administered GEMZAR as First-Line Chemotherapy in Elderly Patients or Patients Who Are Not Eligible for Platinum-Based Chemotherapy With Advanced NSCLC||Eli Lilly and Company|No|Completed|July 2003|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|70 Years|N/A|No|||June 2007|June 20, 2007|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489983||170167|
NCT00485589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT3984g|A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)|A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis|FILM|Genentech, Inc.||Terminated|June 2007|||April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|613|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|June 11, 2007|Yes|Yes|Based on analysis of results and consideration of available treatments, the overall benefit to    risk profile of ocrelizumab was not favorable in RA.|No||https://clinicaltrials.gov/show/NCT00485589||170502|
NCT00496184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050989|Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis|Topical Application of Nifedipine Cream for the Treatment of Vulvar Vestibulitis Syndrome||Western Galilee Hospital-Nahariya|No|Completed|April 2006|May 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|45 Years|No|||May 2008|May 2, 2008|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00496184||169702|
NCT00496470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5892C00015|Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.|A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily||AstraZeneca||Completed|May 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|660|||Both|40 Years|N/A|No|||October 2012|October 10, 2012|July 3, 2007|Yes|Yes||No|June 15, 2009|https://clinicaltrials.gov/show/NCT00496470||169680|
NCT00496561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-149-06-KE|Effect of Specific Immunotherapy to Dust Mites in Children With Asthma|Evaluation of Early Clinical and Immunological Efficacy of Specific Immunotherapy to Dust Mites in Children With Asthma||Medical Universtity of Lodz|Yes|Recruiting|August 2006|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|18 Years|No|||February 2013|February 6, 2013|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496561||169674|
NCT00497068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA012403|Tobacco Use in Opioid Agonist Treated Pregnant Women|Tobacco Use in Opioid Agonist Treated Pregnant Women|ROSE|Johns Hopkins University|No|Completed|January 2005|June 2010|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Female|18 Years|50 Years|No|||March 2013|March 1, 2013|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497068||169635|
NCT00497081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA022155-01|Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors|Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors||San Francisco Department of Public Health|Yes|Completed|May 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|July 5, 2007||No||No|October 7, 2014|https://clinicaltrials.gov/show/NCT00497081||169634|
NCT00497809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-014-P02|Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia|An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia||AviGenics|Yes|Completed|August 2007|July 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|189|||Female|18 Years|N/A|No|||May 2011|May 2, 2011|July 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00497809||169578|
NCT00484770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4389|STARBRITE: A Randomized Pilot Trial of BNP-Guided Therapy in Patients With Advanced Heart Failure|Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: Brain Natriuretic Peptide Levels Versus the Clinical Congestion Score|STARBRITE|Duke University|Yes|Completed|February 2003|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||June 2007|August 20, 2014|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484770||170564|
NCT00481130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704M05941|Alport Syndrome Treatments and Outcomes Registry|Alport Syndrome Treatments and Outcomes Registry|ASTOR|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|September 2007|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based||1|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Family and individual history of a diagnosis of Alport syndrome, confirmed by skin biopsy,        kidney biopsy, or molecular genetic analysis or diagnosis of Alport syndrome based on        presence of hematuria and confirmed diagnosis of Alport syndrome in a first-degree        relative.        Study Assessments        ASTOR central office staff will obtain informed consent form all participants along with        medical and medication histories.|November 2015|November 30, 2015|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00481130|15 Years|170839|
NCT00481442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1125|Phenylephrine Versus Norepinephrine in Septic Shock|Effects of Phenylephrine on Systemic and Regional Hemodynamics in Patients With Septic Shock: a Crossover Pilot Study||University of Roma La Sapienza|No|Completed|January 2007|March 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||March 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00481442||170815|
NCT00481455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CLN-007|Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)|A Single-Center, Open-Label, Phase II, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With Protracted Oral Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme||CASI Pharmaceuticals, Inc.|No|Completed|April 2007|October 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2008|November 24, 2008|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00481455||170814|
NCT00481429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro700|Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study|Evaluation of Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study||Imperial College London|No|Completed|May 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|65 Years|No|||May 2007|January 28, 2009|May 31, 2007||||No||https://clinicaltrials.gov/show/NCT00481429||170816|
NCT00482001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458970|Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults|The Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults: A Pilot Study||Sunnybrook Health Sciences Centre|No|Completed|June 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|22|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||February 2009|February 5, 2009|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00482001||170773|
NCT00482586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546520|Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy|Outcomes Following Image-Guided Therapy for Hepatic Malignancies||Vanderbilt University|No|Completed|October 2003|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|137|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with hepatic neoplasms who undergo Image-guided Therapy|June 2015|June 3, 2015|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482586||170731|
NCT00488917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELLIFA-01|Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)|Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)|SELLIFA|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|June 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|167|Samples Without DNA|plasma, urine, ascites fluid.|Both|18 Years|85 Years|No|Probability Sample|intensive care unit|September 2009|September 2, 2009|June 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00488917||170248|
NCT00489736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4968|Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation|Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation (AF)|DIONYSOS|Sanofi|Yes|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|504|||Both|21 Years|N/A|No|||February 2010|February 15, 2010|June 20, 2007|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00489736||170186|
NCT00482794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013845|Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome|Genetics of Antiphospholipid Antibody Syndrome|APS|Duke University|No|Recruiting|June 2006|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|2800|Samples With DNA|Serum, plasma, and DNA samples|Both|N/A|N/A|No|Non-Probability Sample|Individuals with antiphospholipid antibody syndrome and their family members|October 2015|October 23, 2015|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00482794||170715|
NCT00489749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JomhaAchillesEdm1|A Study Comparing Protected Early Weightbearing Versus Non-Weightbearing After Surgery for Achilles Tendon Rupture|The Influence of Protected Early Weightbearing Versus Nonweightbearing After Surgical Repair of the Achilles Tendon||University of Alberta|No|Completed|October 2003|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|65 Years|No|||June 2007|June 19, 2007|June 19, 2007||||No||https://clinicaltrials.gov/show/NCT00489749||170185|
NCT00483314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6-FY06-317|Homocystinuria: Treatment With N-Acetylcysteine|Homocystinuria: Treatment With N-Acetylcysteine||McGill University Health Center|No|Completed|November 2007|February 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2009|February 16, 2009|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483314||170675|
NCT00494507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS045686-02|Hyper- and Hypokalemic Periodic Paralysis Study|Dichlorphenamide vs. Placebo for Periodic Paralysis|HYP-HOP|University of Rochester|Yes|Completed|June 2007|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|71|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|June 27, 2007|Yes|Yes||No|April 30, 2014|https://clinicaltrials.gov/show/NCT00494507||169826|Sample sizes in the trial were limited by slow recruitment and the trial was concluded before attainment of the target numbers of subjects. Statistical analyses were conducted using smaller group sizes than planned, particularly for HYP subjects.
NCT00498758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tasmc-07-ng-152-ctil|The APOS System: Effects on Gait, Mobility and QOL in Patients With Parkinson's Disease|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|August 2007|August 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|80 Years|No|||July 2007|July 9, 2007|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00498758||169505|
NCT00497289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0404|Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants|Double-blind, Prospective, Randomized Comparison of a MCT/LCT/FO Containing 20% Lipid Emulsion With a MCT/LCT Emulsion (20%) for Parenteral Nutrition in Preterm Infants||B. Braun Melsungen AG|No|Completed|January 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|34|||Both|N/A|3 Days|No|||June 2011|June 8, 2011|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497289||169618|
NCT00497536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001912-21|Pharmacokinetics of IAsp Following CSII in Patients With T1DM|Pharmacokinetics of Insulin Aspart (IAsp) Following Continuous Subcutaneous Insulin Infusion (CSII) in Patients With Type 1 Diabetes Mellitus (T1DM)- Basal Rate Resolution.||University of Aarhus|Yes|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|60 Years|No|||February 2009|February 4, 2009|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497536||169599|
NCT00498719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0126|Cognitive Training in Attenuating Attention Deficits/Child Treatment for Cancer|A Pilot Study of the Effectiveness of Cognitive Training in Preventing Attention Deficits Among Children in Treatment for Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2004|||April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|||Both|6 Years|17 Years|No|Probability Sample|Participants with leukemia, lymphoma, or brain tumor that are at least 6 years old.|September 2015|September 24, 2015|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498719||169508|
NCT00485043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMC-JCarpenter dissertation-1|Effects of Modified T'ai Chi on Symptoms in Older Adults With Osteoarthritis|Effects of Modified T’ai Chi Exercise on Physical Function, Pain, and Stiffness in Older Adults With Lower Extremity Osteoarthritis||University of Kansas Medical Center|No|Completed|January 2006|April 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|60 Years|N/A|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485043||170543|
NCT00485420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-02EHunk-02-H|eCare for Moods: An Internet-based Management Program|Using the Internet to Provide Disease Management and Improve Compliance Among Bipolar and Depressed Patients||Kaiser Permanente|Yes|Completed|September 2002|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|404|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485420||170515|
NCT00481741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00018198|Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions|A Prospective Randomized Controlled Efficacy and Safety Trial of the SafeSeal Hemostasis Patch Compared to Manual Compression for Achieving Vascular Hemostasis Following Percutaneous Coronary and Peripheral Intervention.||University of Rochester|No|Completed|May 2007|December 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||July 2009|July 30, 2009|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481741||170792|
NCT00481715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|473|Comparison of Two Workplace-Sponsored Obesity Prevention Programs|Interventions to Control Obesity in Colleges||University of North Carolina, Chapel Hill|Yes|Completed|September 2008|December 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1020|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 26, 2011|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481715||170794|
NCT00481728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121189|Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.|Evaluation of Sympathetic Skin Responses and Heart Rate Variability as Objective Measures of Bladder Sensation - a Double Blind Third Party Open Placebo Controlled Randomised Study Using a Single Dose of Tolterodine in Patients With Idiopathic Overactive Bladder and Healthy Volunteers||Pfizer||Completed|June 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|28|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 27, 2009|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481728||170793|
NCT00482040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAP-I-Study|Randomized Trial Investigating Four Nasal CPAP Systems in the Management of Apnea of Prematurity|Randomized Trial Investigating Four Nasal CPAP Systems in the Management of Apnea of Prematurity||University Hospital Tuebingen|No|Terminated|March 2004|January 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|16|||Both|N/A|14 Weeks|No|||May 2007|August 23, 2007|June 1, 2007|||Recruiting took longer than expected due to a lack of eligible patients (very strong inclusion    and exclusion criterias)|No||https://clinicaltrials.gov/show/NCT00482040||170770|
NCT00481676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025ADE05|Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria|A Randomized, 24 Weeks, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Adult Patients With Chronic Urticaria Who Exhibit IgE Against Thyroperoxidase||Novartis|No|Completed|May 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|70 Years|No|||September 2011|September 14, 2011|June 1, 2007||No||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00481676||170797|
NCT00489177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73-1726|Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.|Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.|OPTIMISE-CRT|University of Calgary|No|Completed|June 2007|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|461|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00489177||170229|
NCT00489190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_00041|APIDRA Registration Study|Local, Open, Non-Randomized, Phase IV Clinical Study for the Collection of Data Regarding the Drug Portability Received During the Treatment With Subcutaneous Injection of Apidra Glulisine (HMR1964) to Patients With Diabetes Mellitus 1st Type||Sanofi||Completed|August 2005|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489190||170228|
NCT00483366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163-06|Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008)|Phase I Study of Imatinib, Gemcitabine and Capecitabine in Patients With Solid Tumors||University of Nebraska||Active, not recruiting|August 2006|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|19 Years|N/A|No|||July 2010|July 22, 2010|June 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00483366||170672|
NCT00482781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIA-09012000|DTaP and Apnea/Bradycardia in Preterm Infants|Prolonged Apnea and Prolonged Bradycardia Following DTaP Immunization in Preterm Infants: A Randomized Multicenter Study|PIA|American SIDS Institute|No|Completed|September 2000|September 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|191|||Both|56 Days|60 Days|No|||June 2007|June 4, 2007|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482781||170716|
NCT00494520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC006934-01|Cognitive Therapy to Improve Word Finding|Learning Paradigms in Aphasia Rehabilitation||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Recruiting|July 2004|June 2009|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||November 2005|March 10, 2009|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00494520||169825|
NCT00494533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-PH-402|Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension|Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension|TRUST-1|United Therapeutics|Yes|Terminated|March 2005|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|45|||Both|16 Years|75 Years|No|||January 2014|January 28, 2014|June 27, 2007||No|Safety issues related to outpatient intravenous infusion in India|No||https://clinicaltrials.gov/show/NCT00494533||169824|
NCT00494780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111775|Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients|An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).|MUNIN|GlaxoSmithKline|Yes|Completed|June 2007|September 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||May 2014|June 26, 2014|June 29, 2007|No|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00494780||169805|
NCT00494793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPNLund 564/2005|Vacuum Assisted Wound Closure (VAWC) and Mesh Mediated Fascial Traction - Prospective Study of a Novel Technique for Open Abdomen Closure|Clinical Multicenter Trial Evaluating a Combination of Mesh Mediated Fascial Traction and Vacuum for Closure of the Open Abdomen||Skane University Hospital|No|Active, not recruiting|February 2006|November 2014|Anticipated|November 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|N/A|N/A|No|||September 2010|September 24, 2010|June 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00494793||169804|
NCT00498433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2238|Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension|Part 1: An Open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin- Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity. Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity||Novartis|Yes|Terminated|June 2007|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||September 2014|September 9, 2014|July 8, 2007||No|Early termination resulted from interim analysis of the ALTITUDE trial|No|March 21, 2013|https://clinicaltrials.gov/show/NCT00498433||169530|
NCT00505609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDM-IRH|Efficacy of the Standard Days Method of Family Planning|Efficacy of the Standard Days Method of Family Planning||Georgetown University|No|Completed|November 1999|October 2001|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|478|||Female|18 Years|39 Years|No|||July 2007|July 20, 2007|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505609||168990|
NCT00505622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-318|Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations|A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations||Eisai Inc.||Terminated|July 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|328|||Both|30 Years|N/A|No|||November 2015|December 17, 2015|July 9, 2007||No|Study stopped due to lack of efficacy.|No|October 23, 2012|https://clinicaltrials.gov/show/NCT00505622||168989|Due to early termination, no subjects completed this open-label extension study.
NCT00485394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-551-C04|The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)|A Randomized, Double-Masked, Dose-Ranging, Multi-Center, Phase II Study Comparing the Safety and Efficacy of OT-551 With Placebo to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration|OMEGA|Othera Pharmaceuticals|Yes|Active, not recruiting|June 2007|||February 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|198|||Both|55 Years|N/A|No|||March 2008|March 31, 2008|June 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00485394||170517|
NCT00481507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-146|Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)|Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)|MILK|Georgetown University|Yes|Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|125|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|May 30, 2007||No||No|May 9, 2011|https://clinicaltrials.gov/show/NCT00481507||170810|
NCT00481520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-2000|Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|72|||Both|50 Years|90 Years|No|||June 2008|September 28, 2009|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00481520||170809|
NCT00482014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9031|A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer|Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)||Eli Lilly and Company|Yes|Completed|May 2007|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|May 31, 2007|Yes|Yes||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00482014||170772|
NCT00482027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A001|Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine|A Phase 1 Randomized, Placebo-controlled, Double-blind Dose-escalation Trial to Evaluate the Safety and Immunogenicity of tgAAC09, a Gag-PR-RT AAV HIV Vaccine|A001|International AIDS Vaccine Initiative|Yes|Completed|December 2003|January 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2007|January 14, 2013|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00482027||170771|
NCT00481780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004|PTA vs. CB-PTA for Treatment of Femoropopliteal Artery In-Stent Restenosis|Conventional Balloon Angioplasty vs. Cutting Balloon Angioplasty for Treatment of Femoropopliteal Artery In-Stent Restenosis - A Randomized Controlled Pilot Trial||Vienna General Hospital|No|Completed|November 2004|April 2007||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||May 2007|September 10, 2007|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00481780||170789|
NCT00482053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT186|Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT)|A Phase II Study in Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as a Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT)||Stanford University||Completed|October 2006|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2010|September 10, 2010|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00482053||170769|
NCT00482274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546975|Docetaxel in Treating Patients With Relapsed Prostate Cancer|Phase II Study of the Early Use of Docetaxel in Patients With Biochemical Relapse After Primary Therapy for Prostate Cancer and an Incomplete Response to Androgen Deprivation Therapy.||OHSU Knight Cancer Institute||Terminated|May 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|18 Years|N/A|No|||July 2011|July 5, 2011|June 4, 2007|Yes|Yes|Drug supplier stopped funding due to loss of study drug (docetaxel) patent.|No|July 27, 2010|https://clinicaltrials.gov/show/NCT00482274||170753|Due to withdrawal of sponsor support, this study was terminated after only 3 subjects were enrolled (of the planned 36 subjects). Sufficient data were not obtained to make statistically significant conclusions.
NCT00482287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTR-105-US-102|Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients|A Phase II, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study to Assess the Pharmacokinetics and Pharmacodynamics of MTR105 in Cardiac Surgery Induced Hypotension Patients During Weaning Off Cardiopulmonary Bypass||Meditor Pharmaceuticals Ltd.|No|Withdrawn|January 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|June 1, 2007|Yes|Yes|Site did not recruit any patients|No||https://clinicaltrials.gov/show/NCT00482287||170752|
NCT00482261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-PI-0103|A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression|Phase II Trial of Low Dose Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (Rev-Lite) in Patients at High Risk for Myelosuppression||Peter MacCallum Cancer Centre, Australia|Yes|Active, not recruiting|June 2007|September 2013|Anticipated|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|June 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00482261||170754|
NCT00481975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT3801|Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients|A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving||Sanofi||Completed|August 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|289|||Both|18 Years|70 Years|No|||April 2009|April 6, 2009|June 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00481975||170775|
NCT00482248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE0250011E3|Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma|An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study||Novartis||Completed|June 2003|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|132|||Both|12 Years|75 Years||||October 2011|October 24, 2011|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482248||170755|
NCT00483158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-001|First Time in Man Study of Finafloxacin Hydrochloride|A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single and Multiple Oral Doses of Finafloxacin Hydrochloride in Healthy Subjects and a Study of H. Pylori Treatment in Healthy Carriers||MerLion Pharmaceuticals GmbH|No|Completed|August 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 25, 2008|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00483158||170687|
NCT00483652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-F204|Study of Fampridine-SR Tablets in Multiple Sclerosis Patients|Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis||Acorda Therapeutics|Yes|Completed|May 2007|May 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|70 Years|No|||January 2016|January 4, 2016|June 6, 2007|Yes|Yes||No|November 22, 2010|https://clinicaltrials.gov/show/NCT00483652||170650|
NCT00483067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-232|2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)|Phase II Study: 2-Chlorodeoxyadenosine (2-CdA) and Cytarabine (Ara-C) in Idiopathic Hypereosinophilic Syndrome (HES)||M.D. Anderson Cancer Center|No|Completed|March 1998|July 2008|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|76 Years|No|||August 2012|August 1, 2012|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483067||170694|
NCT00483080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR006|Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)|NGR006: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Colorectal Cancer (CRC), Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan Based Regimens||MolMed S.p.A.|No|Completed|December 2006|April 2013|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|80 Years|No|||May 2014|May 29, 2014|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483080||170693|
NCT00483093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR004|Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor|NGR004:A Phase IB Study of NGR-hTNF in Combination With Cisplatin in Patient Affected by Advanced or Metastatic Solid Tumor||MolMed S.p.A.|No|Completed|July 2007|April 2013|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483093||170692|
NCT00483106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-22|Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)|||McGill University|No|Recruiting|November 1999|||March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|700|||Both|6 Years|12 Years|No|||December 2015|December 15, 2015|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00483106||170691|
NCT00495339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVOF_L_00972|MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis|Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB)||Sanofi||Completed|June 2007|||April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2008|March 3, 2009|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495339||169763|
NCT00495625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14733|Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)|Phase II Open-Label Study of Sunitinib Malate (SUO11248) in Adult Subjects With Metastatic and/or Surgically Unresectable Hepatocellular Cancers (HCC)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|October 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2011|March 22, 2012|June 29, 2007||No||No|January 12, 2012|https://clinicaltrials.gov/show/NCT00495625||169742|The Principal Investigator who initiated the study left Moffitt before reaching the target enrollment required to perform the planned analysis.
NCT00495950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0787|Prospective Measurement of Post-Treatment Lymphedema|Prospective Measurement of Post-Treatment Lymphedema in Patients With Melanoma||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2006|||May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Study participants with a confirmed diagnosis (M.D. Anderson pathology) of invasive        cutaneous melanoma (stages I-III).|July 2015|July 23, 2015|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495950||169720|
NCT00504400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ADE04|Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)|Ranibizumab in Idiopathic Macular Telangiectasia, Type 2. A Prospective Interventional Non-randomized Study Comparing the Efficacy and Safety of Intravitreal Ranibizumab in Type 2 Idiopathic Macular Telangiectasia.||University Hospital, Bonn|No|Completed|August 2007|September 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2009|September 21, 2009|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504400||169079|
NCT00504413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30931-A|Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone|Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects||University of Washington|Yes|Recruiting|July 2007|January 2011|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|October 11, 2010|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504413||169078|
NCT00504712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300|Testosterone for Peripheral Vascular Disease|A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus||Barnsley Hospital|No|Recruiting|February 2006|February 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|N/A|No|||July 2007|July 19, 2007|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00504712||169056|
NCT00505024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0299|Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery|A Randomized Clinical Trial of the Efficacy of an Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery||M.D. Anderson Cancer Center|Yes|Completed|July 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00505024||169033|
NCT00481143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ADE03|Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload|A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload||Novartis||Completed|May 2007|||November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481143||170838|
NCT00481468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-059|Validation of the Siemens System Somatom Definition and Operating Software for Cardiac CT Studies|Validation of the Siemens System Somatom Definition and Operating Software SYNGO CT2007 (Software Version SOMARIS/7 SYNGO® Software) for Cardiac CT Studies|SOMARIS|William Beaumont Hospitals|Yes|Completed|June 2006|March 2010|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|385|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This sutdy is taking place in a 900+ bed community setting hospital. All patients who meet        the inclusion and exclusion criteria will be asked if they would like to participate when        they arrive to the radiology department to undergo their cornary CT scan.|September 2012|September 26, 2012|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00481468||170813|
NCT00481754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906109|Benign Reproductive Tissue Analysis for Endometrial Cancer Markers|Benign Reproductive Tissue Evaluation (BRTE) Study||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 2006|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|295|||Female|18 Years|54 Years|No|||July 2015|September 19, 2015|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481754||170791|
NCT00481767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106069|Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.|Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years||GlaxoSmithKline||Completed|October 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|676|||Female|10 Years|25 Years|Accepts Healthy Volunteers|||March 2011|April 7, 2011|May 31, 2007|Yes|Yes||No|February 24, 2011|https://clinicaltrials.gov/show/NCT00481767||170790|
NCT00481481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1209|Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects|A Multicenter, Single-arm, Open, Conversion Study From a Cyclosporine (CyA) Based Immunosuppressive Regimen to a Tacrolimus Modified Release, FK506E (MR4), Based Immunosuppressive Regimen in Kidney Transplant Subjects (CONCERTO: Converting Cyclosporine to FK506E (MR4) in Renal Transplantation)|CONCERTO|Astellas Pharma Inc|No|Completed|April 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|346|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|May 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00481481||170812|
NCT00482638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0493-008|Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)|||Merck Sharp & Dohme Corp.||Completed|May 2004|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|65 Years|No|||August 2015|August 11, 2015|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482638||170727|
NCT00482300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC-CBM-15|Systematic Pelvic Lymphadenectomy Versus no Lymphadenectomy in Clinical Stage I-II Endometrial Cancer|||University of Roma La Sapienza|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|75 Years|No|||March 2007|June 4, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482300||170751|
NCT00482313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-nr 2006-002553-80|Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)|A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD||Psychiatry Karolinska|Yes|Completed|May 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|65 Years|No|||August 2009|May 7, 2010|June 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00482313||170750|
NCT00482807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195-04|Intensity-Modulated Radiation Therapy, Docetaxel, and Hormone Therapy in Treating Patients With High-Risk Locally Advanced Prostate Cancer With Pelvic Lymph Node Metastasis|Phase I Study Evaluating Extended Field Intensity Modulated Radiation Therapy and Docetaxel in Patients With Prostate Cancer Associated With Pelvic Node Metastasis||University of Nebraska|Yes|Completed|August 2004|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|19 Years|N/A|No|||February 2011|February 22, 2011|June 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00482807||170714|
NCT00482573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 009/03|Dental Anesthesia in Pregnant Women With Rheumatic Heart Disease|Maternal-Fetal Monitoring of Patients With Rheumatic Heart Disease During Dental Procedure Under Local Anesthesia||University of Sao Paulo|Yes|Completed|April 2004|January 2006|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|N/A|No|||June 2008|June 4, 2008|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482573||170732|
NCT00483171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351028|A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients|A 14-Month, Randomized, Double-Blind,Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety of CP-945,598 In Prevention Of Weight Regain In Obese Subjects||Pfizer|Yes|Terminated|January 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|699|||Both|18 Years|70 Years|No|||November 2012|November 5, 2012|June 4, 2007|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00483171||170686|
NCT00483379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03306|High Dose or High Dose Frequency Study of Alglucosidase Alfa|An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Alglucosidase Alfa Treatment in Patients With Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen||Sanofi|Yes|Completed|May 2007|July 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|6 Months|N/A|No|||February 2014|February 4, 2014|June 6, 2007|Yes|Yes||No|February 7, 2011|https://clinicaltrials.gov/show/NCT00483379||170671|This small exploratory study lacked a parallel control arm at the standard dose for a longer period; decline in respiratory or motor function prior to study was not collected systematically, thus change from baseline observations are inconclusive.
NCT00483392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J3-3545|Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients|||University Medical Centre Ljubljana|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||||||Male|18 Years|60 Years||||June 2007|June 5, 2007|June 5, 2007||||No||https://clinicaltrials.gov/show/NCT00483392||170670|
NCT00503594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060239|Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine|Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly|CNSLymphoma|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2007|July 2012|Anticipated|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|60 Years|N/A|No|||July 2007|July 27, 2012|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00503594||169141|
NCT00503607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI-800-301|BLI-800-301: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|A Safety and Efficacy Evaluation of BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy||Braintree Laboratories|No|Completed|July 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|400|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503607||169140|
NCT00504153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00223|Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer|A Phase II Study of Dasatinib (NSC 732517) in Previously-Treated Patients With Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|July 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2011|April 30, 2014|July 17, 2007|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00504153||169098|
NCT00496249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0197-CE|The Effect of Radiation on Semen Quality and Fertility in Men With Prostate Cancer|The Effect of Radiation on Semen Quality and Fertility in Men Treated With External Beam Radiation or Brachytherapy for Early Stage Prostate Cancer||University Health Network, Toronto|No|Completed|July 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Male|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Men being treated with radiation therapy for localized prostate cancer who consent to        participate and provide a semen specimen for analysis following thereapy.|December 2015|December 21, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496249||169697|
NCT00505037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0002|A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis|A Phase 2, Randomized, Double-blind-placebo-controlled and Open-label-Sevelamer Hydrochloride-controlled, Dose-ranging Study for ASP1585 in Patients With Chronic Kidney Disease(CKD) and Hyperphosphatemia on Hemodialysis||Astellas Pharma Inc|Yes|Completed|October 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|156|||Both|20 Years|75 Years|No|||March 2011|March 21, 2011|July 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505037||169032|
NCT00505349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUT-117-2005|Blood Neurotrophic Factors in Adults|Blood Neurotrophic Factors in Adults||Posit Science Corporation|No|Withdrawn|June 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 4, 2016|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505349||169010|
NCT00505362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6107|Pain Study of Rectus Muscle Closure at Cesarean Delivery|Rectus Muscle Closure vs. Non-Closure at Primary Cesarean Delivery and Post-Operative Pain||Stanford University|No|Active, not recruiting|June 2006|September 2015|Anticipated|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Female|18 Years|N/A|No|||November 2014|November 18, 2014|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505362||169009|
NCT00505661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0486|Letrozole in Patients With Ovarian Tumors|Phase II Study of Letrozole in Patients With Recurrent Advanced Borderline Tumors or Low Grade Epithelial Cancers of the Ovary, Fallopian Tube and Primary Peritoneum||M.D. Anderson Cancer Center|No|Terminated|September 2003|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|N/A|No|||April 2012|April 16, 2012|July 19, 2007||No|Terminated due to slow patient accrual.|No|September 28, 2010|https://clinicaltrials.gov/show/NCT00505661||168986|
NCT00505687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0833|An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease|A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease||UCB Pharma|No|Completed|February 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|186|||Both|31 Years|N/A|No|||September 2010|September 24, 2014|July 20, 2007|Yes|Yes||No|December 8, 2009|https://clinicaltrials.gov/show/NCT00505687||168985|
NCT00505700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-103|VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia|Phase I Dose Escalating Trial of VELCADE (PS-341) in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia||Massachusetts General Hospital|Yes|Completed|July 2003|||September 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|July 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505700||168984|
NCT00485095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2006.3407|The Effect of Plant Sterol Supplement on Blood Cholesterol|A Single Centre, Randomized Crossover Double-Blind Placebo-Controlled Study to Measure the Effect of Plant Sterol Supplement on Blood Cholesterol||Oslo University Hospital||Completed|January 2007|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2009|June 30, 2011|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485095||170539|
NCT00485108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DJ1|Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty|Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study||Queen's University|No|Completed|January 2007|December 2014|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|June 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00485108||170538|
NCT00481793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904215|Relationship of Genetic Differences to the Development of Chromosome Abnormalities|Germline Genetic Variation and Risk of Chromosome Aberrations Among Mayak Nuclear Workers||National Institutes of Health Clinical Center (CC)||Terminated|June 2004|September 2014||||N/A|Observational|N/A|||Anticipated|380|||Both|N/A|N/A|No|||September 2014|October 23, 2014|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481793||170788|
NCT00481156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0404M58647|Functional Neuroimaging Effects of Cognitive Remediation Training|||University of Minnesota - Clinical and Translational Science Institute||Completed|September 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment||||18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00481156||170837|
NCT00481169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3068A1-300|Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women|A Multicenter, Double Blind, Randomized, Placebo and Raloxifene Controlled Study to Assess Safety and Efficacy of TSE-424 (Bazedoxifene Acetate) in the Prevention of Postmenopausal Osteoporosis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2001|September 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|1742|||Female|45 Years|N/A|No|||August 2009|August 20, 2009|May 30, 2007||||||https://clinicaltrials.gov/show/NCT00481169||170836|
NCT00481494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0092|Personality Characteristics and Compliance With Antiglaucoma Medication|Personality Characteristics and Compliance With Antiglaucoma Medication|GDC|Yonsei University|No|Recruiting|May 2007|October 2007|Anticipated|||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|150|||Both|20 Years|80 Years|No|||May 2007|May 31, 2007|May 31, 2007||||No||https://clinicaltrials.gov/show/NCT00481494||170811|
NCT00482352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL03B1|Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Classification Of Acute Lymphoblastic Leukemia||Children's Oncology Group|No|Completed|December 2003|||April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11196|Samples With DNA|marrow and blood samples|Both|1 Year|30 Years|No|Non-Probability Sample|Any patient with newly diagnosed acute lymphoblastic leukemia meeting other criteria.|February 2016|February 19, 2016|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482352||170748|
NCT00482651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCT2403|Imaging of Vulnerable Plaques in Coronary Artery Disease by Multidetector Computed Tomography|Imaging of Vulnerable Plaques in Coronary Artery Disease by Multidetector Computed Tomography||University of Aarhus|Yes|Completed|November 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482651||170726|
NCT00482339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITM-Jena-935035-1|PCR-Based Detection of Bacterial Agents in Platelet Concentrates and Whole Blood|PCR-Based Detection of Bacterial Agents in Platelet Concentrates and Whole Blood (First Study)||University of Jena|No|Not yet recruiting|June 2007|July 2009|Anticipated|||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|2000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|June 4, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482339||170749|
NCT00482599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05948|Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)|A Multicenter, Parallel Group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function||Merck Sharp & Dohme Corp.|No|Completed|June 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|June 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00482599||170730|
NCT00483119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3343|Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus|Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus||New York University School of Medicine|Yes|Terminated|April 2007|February 2011|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|June 5, 2007|Yes|Yes|Study was terminated due to the death of the PI.|No|October 5, 2015|https://clinicaltrials.gov/show/NCT00483119||170690|Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.
NCT00483132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAL02|Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III|Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III||French Innovative Leukemia Organisation|Yes|Completed|September 1994|April 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|232|||Both|15 Years|65 Years|No|||June 2007|June 5, 2007|June 5, 2007||||No||https://clinicaltrials.gov/show/NCT00483132||170689|
NCT00483145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-328309|Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea|Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea||Bispebjerg Hospital||Completed|November 2006|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind|2||||||Both|18 Years|N/A||||June 2008|June 2, 2008|June 4, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00483145||170688|
NCT00483184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04HUBD01|Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease|Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease||Nobel Pharmaceuticals|No|Completed|April 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|75 Years|No|||April 2009|April 27, 2009|June 5, 2007|Yes|Yes||No|April 27, 2009|https://clinicaltrials.gov/show/NCT00483184||170685|
NCT00483730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-007-IM|Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)|A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin® in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy||Nycomed|Yes|Completed|December 2006|December 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|569|||Both|18 Years|65 Years|No|||May 2012|May 4, 2012|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483730||170644|
NCT00483405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0421|Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer|Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|October 2006|December 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|120 Years|No|||January 2016|January 20, 2016|June 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00483405||170669|
NCT00504179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIETING061855|The Effect of Osteopathic Manipulative Treatment on Recovery of Coronary Bypass Patients|The Effect of Osteopathic Manipulative Treatment on Post-Operative Medical and Functional Recovery of Coronary Artery Bypass Graft Patients|CABGOMT|Michigan State University|Yes|Completed|April 2001|October 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2007|July 17, 2007|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00504179||169096|
NCT00504166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M250|Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women|Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal||University of California, San Francisco|No|Completed|February 2006|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|53|||Female|45 Years|65 Years|No|||July 2013|July 31, 2013|July 17, 2007|No|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00504166||169097|
NCT00504426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|249-06-002OD|Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis|Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis||Otsuka Pharmaceutical Co., Ltd.|No|Completed|July 2007|May 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|101|||Female|46 Years|79 Years|No|||December 2013|December 24, 2013|July 16, 2007||No||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00504426||169077|
NCT00504439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR2100609|A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects.|See Detailed Description||GlaxoSmithKline||Completed|June 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00504439||169076|
NCT00504725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000895|Ketamine In Thoracic Surgery (KITS) Trial|Ketamine In Thoracic Surgery (KITS) Trial|KITS|Duke University|No|Completed|July 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||November 2012|July 18, 2014|July 18, 2007|No|Yes||No|September 29, 2011|https://clinicaltrials.gov/show/NCT00504725||169055|
NCT00505375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTLA (IND)|Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus|Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|February 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|6 Years|45 Years|No|||December 2013|December 17, 2013|July 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505375||169008|
NCT00505388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890C00018|A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice|A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice||AstraZeneca||Completed|July 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5137|||Both|18 Years|N/A|No|Non-Probability Sample|The patients continued with their treatment (Symbicort SMART) after enrolment. Enrolment        throug IVRS/IWRS, no randomisation. Primary care clinic.|April 2010|April 23, 2010|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505388||169007|
NCT00505713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-103|Safety and Efficacy Study Using Rexin-G for Sarcoma|Evaluation of Safety and Efficacy of Rexin-G as Intervention for Recurrent or Metastatic Sarcoma||Epeius Biotechnologies|Yes|Completed|July 2007|June 2011|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|36|||Both|10 Years|N/A|No|||June 2011|June 9, 2011|July 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505713||168983|
NCT00505947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0168X97|Treatment of Refractory Diabetic Macular Edema With Infliximab|Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study||University of Athens|Yes|Terminated|July 2007|December 2008|Actual|December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|80 Years|No|||February 2009|February 19, 2009|July 23, 2007||No|The number of the anticipated participants was not achieved|No||https://clinicaltrials.gov/show/NCT00505947||168965|
NCT00505960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DK071957|Culturally Tailored Behavioral Diabetes Care Intervention for Korean Americans|Diabetes Care for Korean Americans||Johns Hopkins University|Yes|Completed|September 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|30 Years|N/A|No|||December 2010|December 20, 2010|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505960||168964|
NCT00505973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153A1-1114|Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SCA-136 Administered Orally to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00505973||168963|
NCT00481182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102577|Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.|A Phase I, Open-Label, 2-Period, Single-Sequence, Drug Interaction Study to Assess Steady-State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD With Fosamprenavir 700mg BID + RTV 100mg BID in Opiate-Dependent, HIV Seronegative, Adult Subjects||GlaxoSmithKline||Completed|February 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2009|February 19, 2009|May 30, 2007||||||https://clinicaltrials.gov/show/NCT00481182||170835|
NCT00481195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/2032/DP/US|Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder||Teva Pharmaceutical Industries||Completed|June 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|May 30, 2007|Yes|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00481195||170834|
NCT00482105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614850-1|Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells|Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells|DermTech|University of California, Davis|No|Terminated|March 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|May 31, 2007||No|Withdrawn per sponsor and Investigator|No||https://clinicaltrials.gov/show/NCT00482105||170765|
NCT00482066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro632|Abatacept in ANCA Associated Vasculitis|A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis|ABAVAS|Imperial College London|Yes|Terminated|November 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|7|||Both|18 Years|N/A|No|||March 2015|May 28, 2015|June 1, 2007||No|Funders withdrew funding due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00482066||170768|
NCT00482079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-010|A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)|A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Completed|May 2003|June 2006|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|743|||Both|21 Years|70 Years|No|||August 2015|August 7, 2015|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482079||170767|
NCT00482365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0224|National Registry and Blood Bank of Patients With Liver Cancer|A National Registry of Patients With Hepatocellular Carcinoma||Vanderbilt-Ingram Cancer Center|Yes|Completed|April 2002|August 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|151|||Both|18 Years|N/A|No|Probability Sample|Patients identified as having Hepatocellular carcinoma (HCC).|May 2013|August 16, 2013|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482365||170747|
NCT00482911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070134|Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma|A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma||National Institutes of Health Clinical Center (CC)|No|Terminated|April 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2012|September 29, 2015|June 4, 2007|Yes|Yes|Investigator left the institute.|No|October 11, 2012|https://clinicaltrials.gov/show/NCT00482911||170706|
NCT00482885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q0702/3|Coordination Versus Pressure in Oesophageal Peristalsis|The Effect of Position on Oesophageal Peristalsis and LOS Pressures: a High Resolution Manometry Study||Guy's and St Thomas' NHS Foundation Trust|No|Completed|October 2007|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy controls and patients presenting with symptoms of reflux and endoscopy negative        dysphagia|June 2011|June 24, 2011|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00482885||170708|
NCT00482612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05706|Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)|A Two-Week, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Efficacy and Safety Out-Patient Trial With Org 50081 in Patients With Chronic Primary Insomnia|RUBY|Merck Sharp & Dohme Corp.|No|Completed|December 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|526|||Both|18 Years|65 Years|No|||May 2015|May 11, 2015|June 1, 2007|Yes|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT00482612||170729|
NCT00482820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4373|A Clinical Research Studying a Method of Intervention for Children Diagnosed With Anxiety Disorder: Attentional Bias Intervention|||Rabin Medical Center||Completed|July 2007|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|80|||Both|7 Years|12 Years|No|||February 2013|February 6, 2013|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482820||170713|
NCT00482833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL0406|Phase III Trial in Acute Promyelocytic Leukemia Patients|A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia|APL0406|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|August 2007|October 2016|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|70 Years|No|||July 2015|July 31, 2015|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482833||170712|
NCT00484042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06025|Activation of Polyamine Catabolism in Patients With Acute Pancreatitis|||University of Tampere|Yes|Completed|January 2006|June 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2007|June 7, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484042||170620|
NCT00483418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062-07|Survey of Testosterone Levels in Male Cancer Patients|Survey of Testosterone Levels in a Diverse Set of Male Patients With Hormone-Independent Cancers||Beth Israel Medical Center|No|Completed|June 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|425|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men with non-hormone dependent cancers who are having blood drawn for other purposes        before 12 noon.|March 2011|March 10, 2011|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483418||170668|
NCT00504192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-GO-BTC1|A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer|A Phase II Study of Gemcitabine in Combination With Oxaliplatin as First Line Chemotherapy in Patients With Inoperable Biliary Tract Adenocarcinoma||Soonchunhyang University Hospital|Yes|Completed|September 2006|March 2009|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2009|May 19, 2014|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504192||169095|
NCT00504205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPERGEN-SGI-0470-01|MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma|Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies||National Cancer Institute (NCI)||Terminated|May 2007|March 2010|Actual|December 2008|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||April 2008|August 1, 2013|July 17, 2007|No|Yes|Withdrawn as trial was never activated by SuperGen|||https://clinicaltrials.gov/show/NCT00504205||169094|
NCT00504452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-1461-201|Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients|An Open-Label, Multicenter, Mechanism Validation Study to Evaluate the Safety, Efficacy and Tolerability of KP-1461 as Monotherapy for 124 Days in Antiretroviral-experienced, HIV-1-infected Subjects||Koronis Pharmaceuticals.|Yes|Terminated|July 2007|June 2009|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|65 Years|No|||November 2008|November 3, 2011|July 18, 2007|Yes|Yes|Corroboration of supporting in vitro data    - Data successfully corroborated 2009|No||https://clinicaltrials.gov/show/NCT00504452||169075|
NCT00505050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|829/99|A Long-Term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients – The REMADHE Study||REMADHE|University of Sao Paulo|No|Completed|October 1999|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||||||Both|18 Years|N/A|No|||July 2007|July 18, 2007|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00505050||169031|
NCT00505063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-088|Prospective Trial of Vaccine Responses in Childhood Cancer Survivors|Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2007|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|2 Years|18 Years|No|||September 2015|September 16, 2015|July 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505063||169030|
NCT00504738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604008489|Lung Disease Collection (Qatar): Evaluation of the Lungs of Individuals With Lung Disease|Evaluation of the Lungs of Individuals With Lung Disease With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy (Qatar)|Q-LD|Weill Medical College of Cornell University|Yes|Completed|April 2006|April 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|Samples With DNA|The purpose of this protocol is to obtain biologic samples from the blood and lungs from      patients with lung diseases in order to study the causes and indications of these disorders,      learn how these lung disease manifest and progress, and how the lung disease can be treated.|Both|18 Years|N/A|No|Non-Probability Sample|Recruitment will be from the patients of the Hamad Medical Corporation and others as        relevant. The source of potential subjects will be the population of potential subjects        with lung disease, as defined by the elegibility criteria, in Qatar. Accrual will be        random with no bias as to gender or racial/ethnic group.|April 2015|April 20, 2015|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504738||169054|
NCT00505102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAREFU123|Safe Renal Function In Long Term Heart Transplanted Patients|Efficacy and Safety of Everolimus to SAve REnal Function (SAREFU) in Long Term Heart Transplanted Patients|SAREFU|A.O. Ospedale Papa Giovanni XXIII|Yes|Active, not recruiting|January 2007|July 2009|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|75 Years|No|||February 2008|February 12, 2008|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505102||169027|
NCT00505414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|672519|A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine|A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). "PR" is Synonymous With "ER" and is Interchangeable.||Grünenthal GmbH|No|Terminated|June 2007|August 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|N/A|No|||July 2010|July 5, 2010|July 19, 2007|Yes|Yes|Recall of rescue medication, alternative rescue medication availability issues.|No|May 27, 2010|https://clinicaltrials.gov/show/NCT00505414||169005|Early termination, due to a recall of the morphine rescue medication and issues regarding supply of an alternative, lead to only 93 participants out of the 573 planned (16%) being available for analysis. The data should be interpreted with caution.
NCT00505401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISST-001|Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS|A Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in HIV-1 Infected Adult Volunteers|ISST-001|Istituto Superiore di Sanità|Yes|Completed|December 2003|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|50 Years|No|||July 2007|February 28, 2011|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505401||169006|
NCT00481806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|479|Evaluating the Role of Thrombin in Saphenous Vein Graft Failure After Heart Bypass Surgery|Thrombin Dysregulation Leads to Early Saphenous Vein Graft Failure||University of Arizona||Recruiting|February 2007|December 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Whole blood and vein samples|Both|18 Years|90 Years|No|Non-Probability Sample|Male and female patients between the the age of 18-90 years belonging to all races will be        enrolled in the study|May 2013|May 8, 2013|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481806||170787|
NCT00482430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0557-027|MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia||Merck Sharp & Dohme Corp.||Completed|September 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|55 Years|No|||August 2015|August 20, 2015|May 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00482430||170742|
NCT00482092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 603|Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease|A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease||Mesoblast, Ltd.|Yes|Active, not recruiting|May 2007|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|May 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00482092||170766|
NCT00482378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546769|Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain|An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain||Mayo Clinic|Yes|Active, not recruiting|March 2005|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|120 Years|No|||January 2016|January 11, 2016|June 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00482378||170746|
NCT00483236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB-06-022|Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair|Quality of Life Measures After Mitral Valve Repair in Non-Ischaemic Cardiomyopathy||McGill University Health Center|No|Suspended|December 2007|June 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Heart Failure Clinic|September 2009|September 17, 2009|June 5, 2007||No|Lack of patient recruitment.|No||https://clinicaltrials.gov/show/NCT00483236||170681|
NCT00483496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00096 CR 205 (ORF)|Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)|Evaluation of the Protection Activity of Microfine Ti02, Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With SU: Phase II Photoprovocation Test||Orfagen||Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|16|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|June 6, 2007|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00483496||170662|
NCT00482898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0359-013|A Study of MK0359 in Patients With Chronic Asthma (0359-013)|A Multicenter, Randomized, Double-Blind, Crossover Study Comparing the Effect of MK0359 and Placebo in Adult Patients With Chronic Asthma||Merck Sharp & Dohme Corp.||Completed|September 2002|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|56|||Both|18 Years|45 Years|No|||May 2015|May 26, 2015|June 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00482898||170707|
NCT00483210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72495|Tissue Lipids and Insulin Resistance|Tissue Lipids and Insulin Resistance||University of Arkansas|Yes|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|June 4, 2007||No|The study goals were accomplished by a similar study at UAMS. (W.J. Evans)|No||https://clinicaltrials.gov/show/NCT00483210||170683|
NCT00482625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00898|Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|Phase IIA Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms||National Cancer Institute (NCI)|Yes|Terminated|June 2007|September 2013|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2014|October 7, 2014|June 4, 2007|Yes|Yes|The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug    supply, IND closure).|No|April 18, 2014|https://clinicaltrials.gov/show/NCT00482625||170728|
NCT00482846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000547155|Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma|Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma||Barbara Ann Karmanos Cancer Institute|Yes|Completed|June 2007|September 2012|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|38|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|June 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00482846||170711|
NCT00484055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFR02|Local Collagen-Gentamicin and Extra Fixation of the Sternum for Prevention of Sternal Wound Infection in Cardiac Surgery|Local Application of Collagen-Gentamicin in Addition to Fixation of the Sternum With Extra Sternal Wires for Prevention of Sternal Wound Infection in Cardiac Surgery|LOGIX|University Hospital Orebro|No|Completed|January 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1358|||Both|18 Years|N/A|No|||September 2008|October 3, 2008|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00484055||170619|
NCT00484315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2037|TAXUS PERSEUS Workhorse|A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions|PERSEUS WH|Boston Scientific Corporation|Yes|Completed|July 2007|October 2013|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1264|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|June 6, 2007|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00484315||170599|The comparator control for PERSEUS Workhorse study was chosen based on commercially available stent (TAXUS Express) at the time of study enrollment. Thus, the comparator group does not represent the most recently available paclitaxel-eluting stent.
NCT00484328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-07-3-007|Ribavirin, Its Dosing Regime|Ribavirin, Its Dosing Regime|Ribados|Maastricht University Medical Center|No|Recruiting|July 2007|February 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|June 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00484328||170598|
NCT00504218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070192|Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients|Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoitic Stem Cell Transplant Recipients||National Institutes of Health Clinical Center (CC)||Recruiting|July 2007|||||N/A|Observational|N/A|||Anticipated|500|||Both|2 Years|24 Years|No|||September 2015|September 18, 2015|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504218||169093|
NCT00504465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402-264|Combined Agent Randomized Trial of Induction of Labor|Cervical Ripening and Induction of Labor: a Randomized Controlled Trial of Combined Versus Sequential Use of Dinoprostone and Oxytocin.||Weill Medical College of Cornell University|No|Completed|May 2002|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||210|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2007|July 19, 2007|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00504465||169074|
NCT00504478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-BS-164-CTIL|Effect of HCCD Supplemented With Omega-3 Fatty-Acids on Inflammation in Healthy, Overweight Subjects||HCCD|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2008|December 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2007|July 19, 2007|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00504478||169073|
NCT00504764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAP-R2007|Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)|APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)||PETHEMA Foundation|Yes|Completed|July 2007|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504764||169052|
NCT00504777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20798|A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.|An Open Label Study to Evaluate the Safety, and Effect on Treatment Response, of MabThera in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One or More Anti-TNF Agents.||Hoffmann-La Roche||Completed|July 2007|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 19, 2007||No||No|July 9, 2014|https://clinicaltrials.gov/show/NCT00504777||169051|
NCT00504751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701008963|Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL|Phase II Trial of "VIPER" Chemotherapy in Relapsed and Refractory Diffuse Large B-cell Lymphoma (NHL)||Weill Medical College of Cornell University|No|Active, not recruiting|May 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2010|June 16, 2010|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504751||169053|
NCT00505076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TURNS02|Treatment Study for Cognitive Deficits in Schizophrenia|MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia|TURNS|University of California, Los Angeles|Yes|Completed|July 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|60 Years|No|||October 2014|October 30, 2014|July 19, 2007|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00505076||169029|
NCT00505089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2206|Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis|An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis||Novartis|No|Terminated|August 2007|||May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|11|||Both|18 Years|75 Years|No|||August 2009|August 24, 2009|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505089||169028|
NCT00505427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8476-27691-01|Alpha Lipoic Acid and Polycystic Ovary Syndrome|Alpha Lipoic Acid and Polycystic Ovary Syndrome||University of California, San Francisco|Yes|Completed|March 2006|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|50 Years|No|||June 2013|June 28, 2013|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505427||169004|
NCT00505739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-212|Mifepristone for Patients With Endometrial Cancer and LGESS|Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS)||M.D. Anderson Cancer Center|No|Completed|September 2001|May 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|N/A|N/A|No|||July 2012|July 26, 2012|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505739||168981|
NCT00482118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906092|Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China|A Hospital-Based Case-Control Study of Non-Smoking Women in Xuan Wei and Fu Yua, China: PAH Exposure, Genetic Susceptibility, and Lung Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2006|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|3750|||Female|18 Years|79 Years|No|||February 2016|February 23, 2016|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00482118||170764|
NCT00482417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0359-017|Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)|||Merck Sharp & Dohme Corp.||Completed|December 2002|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|11|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482417||170743|
NCT00482443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DID|Assessing the Effectiveness of Diabetes Interactive Diary (DID) in Diabetes Management|A Multinational, Randomised Study of the Efficacy of the Diabetes Interactive Diary (DID), a Carbohydrates/Insulin Bolus Calculator and a Telemedicine System Based on the Communication Between Physician or Dietitian and Patient by SMS|DID|The Royal Bournemouth Hospital|No|Completed|March 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||July 2008|July 8, 2008|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482443||170741|
NCT00482391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-013|Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer|Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/NEU-Overexpressed/Amplified Breast Cancer: Feasibility||Memorial Sloan Kettering Cancer Center||Completed|March 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|June 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00482391||170745|
NCT00482404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001 R03 MH075757-01A1|Effects of Romantic Affection on Blood Chemistry and Immune Parameters|Study of the Effects of Romantic Affection on Blood Lipids, Blood Glucose, C-Reactive Protein, and Antibodies to Latent Epstein-Barr Virus||Arizona State University|No|Completed|February 2007|May 2007|Actual|||Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||||||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2007|June 4, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482404||170744|
NCT00482664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5051017|The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.|A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).||Pfizer||Completed|July 2007|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|84|||Female|20 Years|45 Years|No|||October 2010|October 27, 2010|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482664||170725|
NCT00483834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XELIRI-A|A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer|A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer||University Health Network, Toronto|Yes|Completed|December 2006|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483834||170636|
NCT00483847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS403|TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World|TYGRIS - ROW: TYSABRI® Global Observational Program in Safety - Rest of World|TYGRIS - ROW|Biogen|No|Completed|September 2006|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4296|||Both|N/A|N/A|No|Non-Probability Sample|Multiple Sclerosis (MS) participants treated with TYSABRI outside of North America|April 2015|April 9, 2015|June 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00483847||170635|
NCT00483457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0561|Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients|Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on the EGFR in Skin Lesions||Vanderbilt-Ingram Cancer Center|Yes|Completed|February 2006|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Probability Sample|Patients must be ≥ 18 years of age, have the diagnosis of a malignancy for which they are        considering therapy with an inhibitor of the EGFR pathway, have no severe underlying skin        disorder, must not have a bleeding diathesis that would preclude safe biopsy and patients        on coumadin must not have an INR > 3.0 at time of biopsy.|August 2012|August 31, 2012|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483457||170665|
NCT00483197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 06005|VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial|Evaluation of the VentrAssistTM Left Ventricular Assist Device as a Bridge to Cardiac Transplantation - Pivotal Trial||Ventracor|Yes|Active, not recruiting|June 2007|June 2010|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|June 4, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00483197||170684|
NCT00482859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0188-P2G|Sleep Disturbance and Sleep Quality in Women With Fibromyalgia Syndrome|Sleep Disturbance and Sleep Quality in Women With Fibromyalgia Syndrome||University of Kentucky|No|Completed|April 2007|April 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with Fibromyalgia|January 2009|January 21, 2009|June 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00482859||170710|
NCT00482872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546713|Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer|Familial HNSCC Syndrome and p16 Germline Mutations||National Cancer Institute (NCI)||Active, not recruiting|March 2004|||December 2010|Anticipated|N/A|Observational|N/A|||Anticipated|400|||Both|18 Years|N/A|No|||February 2010|February 26, 2010|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482872||170709|
NCT00484354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002409|Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery|Reduction of Acute Renal Failure Associated With Cardiovascular Surgery: A Randomized Study Comparing Sodium Bicarbonate to Normal Saline||Wake Forest School of Medicine|Yes|Completed|May 2006|December 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|123|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00484354||170596|
NCT00484341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR016|Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.|NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS)||MolMed S.p.A.|No|Active, not recruiting|October 2010|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484341||170597|
NCT00504231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID/RD01|Intradermal Influenza Vaccine Study in Elders|Intradermal vs. Intramuscular Delivery of Influenza Vaccine in Immunocompetent Elders||PATH|Yes|Completed|September 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|257|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2011|June 8, 2012|July 12, 2007|Yes|Yes||No|January 11, 2012|https://clinicaltrials.gov/show/NCT00504231||169092|
NCT00504491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELLC-2|R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia|Rescue Treatment With Rituximab-CHOP Therapy and Alemtuzumab (R-CHOP-A) in Refractory or Recidivant Patients With Chronic Lymphocytic Leukemia After Purine-analogous Treatment|R-CHOP|CABYC|Yes|Withdrawn|July 2007|June 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||December 2011|December 28, 2011|July 19, 2007||No|IMP new owner decision|No||https://clinicaltrials.gov/show/NCT00504491||169072|
NCT00504790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPE107602|Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer|A Phase I, Open-Label, Dose-Escalation, First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics, and Pharmacodynamics of GSK923295 in Subjects With Refractory Cancers||GlaxoSmithKline|No|Completed|June 2007|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|July 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00504790||169050|
NCT00504803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJB0601|Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease|Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study||University Hospital of Liege|No|Completed|December 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|N/A|75 Years|Accepts Healthy Volunteers|||September 2011|September 1, 2011|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504803||169049|
NCT00504816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2107494|A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers|An Open Label, Single-sequence, Repeat-dose Study to Investigate the Effects of GSK189075 on the Pharmacokinetics of an Oral Contraceptive Pill When Coadministered to Healthy Female Volunteers||GlaxoSmithKline|No|Completed|April 2007|April 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00504816||169048|
NCT00505115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-CS-0707-707-30|The Human Blastocyst Secretome and Implantome|||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed||||||N/A|Observational|Time Perspective: Longitudinal|||||||Both|N/A|N/A||||July 2007|July 20, 2007|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505115||169026|
NCT00505128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051054|Impact on Outcome of Early Endoscopic Extraction of Bile Duct Stones in Biliary Pancreatitis|Impact on Outcome of Early Endoscopic Extraction of Bile Duct Stones in Biliary Pancreatitis: a Prospective Multicenter Randomized Controlled Study|EEPAB|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|900|||Both|18 Years|N/A|No|||May 2007|May 6, 2011|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505128||169025|
NCT00505440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA018943-04|Trial of Automated Risk Appraisal for Adolescents|Trial of Automated Risk Appraisal for Adolescents|TARAA|Nationwide Children's Hospital|No|Completed|June 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Screening|2||Actual|1185|||Both|11 Years|20 Years|Accepts Healthy Volunteers|||April 2013|April 22, 2013|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505440||169003|
NCT00505453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110502|A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine|A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007 - 2008 Season) in Adults Ranging in Age From 18 to 60 Years and 61 Years and Over||GlaxoSmithKline||Completed|July 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 15, 2008|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505453||169002|
NCT00505752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27591|Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)|A Phase II, Multicenter, Randomized, Assessor-blinded, Active-comparator, Dose-finding Study to Evaluate AS900672 Enriched Versus Follitropin Alfa (Gonal-f®) in Stimulating Multiple Follicular Development in Infertile Women Undergoing Assisted Reproductive Technology (ART)||Merck KGaA||Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|520|||Female|18 Years|36 Years|No|||January 2014|January 20, 2014|July 20, 2007|Yes|Yes||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00505752||168980|
NCT00505765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TURNS03|A Multicenter Study of NAP (AL-108) in Schizophrenia|A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia|AL-108|University of California, Los Angeles|Yes|Completed|July 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|63|||Both|18 Years|60 Years|No|||March 2013|March 27, 2013|July 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505765||168979|
NCT00482144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-0694|Study of the Effects of the Pulsed-dye Laser at 585nm and 595nm to Treat Post-operative Scars on Suture-removal Day|Comparison of the Effectiveness of the Pulsed Dye Laser 585nm Versus 595nm in the Treatment of New Surgical Scars||University of Miami|No|Completed|July 2003|May 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00482144||170763|
NCT00482963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1178|A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication|A Pilot Study of the Pharmacokinetic Interactions Between the Hormonal Emergency Contraception, Plan B, and Efavirenz||University of Colorado, Denver|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|June 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00482963||170702|
NCT00482976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7546|Effect of LY333531 on Vascular and Neural Functions|The Effects of a Protein Kinase C Beta Inhibitor, LY333531, on Vascular and Neural Functions in Type 2 Diabetes Mellitus - Study B7A-MC-MBDM||Eli Lilly and Company|No|Completed|December 2003|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||June 2007|June 4, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482976||170701|
NCT00482677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE6|Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme|A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients||Canadian Cancer Trials Group|Yes|Active, not recruiting|May 2007|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|562|||Both|65 Years|120 Years|No|||April 2015|March 22, 2016|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482677||170724|
NCT00482924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2720000021|Observational Study of Early Metabolic and Vascular Changes in Obesity|Study for the Investigation of New Individual Risk Profiles and Therapeutic Strategies in Obesity Related Cardiovascular and Metabolic Disorders.|STYJOBS|Medical University of Graz|No|Recruiting|January 2003|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|Collection of fasted blood samples between 9 and 12 AM.|Both|3 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Probands are residents of Graz and from the federal state of styria.|October 2015|October 5, 2015|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482924||170705|
NCT00484133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO-06.068|Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis|||Onze Lieve Vrouwe Gasthuis|No|Recruiting|June 2007|||December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2008|January 17, 2008|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00484133||170613|
NCT00483444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-9639-G|Telephone Follow-Up on Outcome After Mild Traumatic Brain Injury|The Effect of Telephone Follow-Up on Outcome After Mild TBI|TBI|University of Washington|No|Completed|October 2003|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|366|||Both|16 Years|80 Years|No|||June 2008|June 2, 2008|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483444||170666|
NCT00483431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-3-014|Dose-Finding Study for Vitamin K2 in Human Volunteers|Dose-Finding Study for Vitamin K2 in Human Volunteers||Maastricht University Medical Center|No|Completed|May 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 9, 2009|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483431||170667|
NCT00483717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX-2007-01|Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine|A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Analgesic Efficacy of Ketorolac Tromethamine Administered Intranasally for the Acute Treatment of Migraine||Luitpold Pharmaceuticals|No|Completed|July 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|65 Years|No|||June 2011|June 1, 2011|June 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00483717||170645|
NCT00484081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA9969|Microdissection Testicular Sperm Extraction (MicroTESE) and IVF-ICSI Outcome in Non-Obstructive Azoospermia (NOA)|Prospective Evaluation of Microdissection Testicular Sperm Extraction in Non-Obstructive Azoospermic Men and Their IVF-ICSI Related Outcomes at ART Treatment.||Clinic and Research Center in Human Reproduction Roger Abdelmassih|Yes|Completed|June 2005|October 2006|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|N/A|N/A|No|||June 2007|June 7, 2007|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00484081||170617|
NCT00484653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/07|Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman|Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman||Assistance Publique Hopitaux De Marseille||Completed|July 2007|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1000|||Female|18 Years|N/A|No|||August 2014|August 27, 2014|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484653||170573|
NCT00504244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ANL07|Myfortic Versus Azathioprine in Systemic Lupus Erythematosus|A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy.||Erasmus Medical Center|No|Terminated|July 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2010|November 15, 2010|July 18, 2007|Yes|Yes|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00504244||169091|
NCT00504257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14920|Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma|A Phase II Trial of Avastin in Combination With Docetaxel in Patients With Recurrence of Epithelial Carcinoma of the Ovary/Fallopian Tube/Peritoneum Within 12 Months of Platinum Therapy||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|March 2007|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||May 2013|January 7, 2014|July 17, 2007|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT00504257||169090|
NCT00504504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-218|Rituximab and ABVD for Hodgkin's Patients|A Phase II Study of Rituximab + ABVD for Patients With Hodgkin's Disease||M.D. Anderson Cancer Center|No|Completed|March 2001|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|16 Years|N/A|No|||May 2013|May 20, 2013|July 19, 2007||No||No|May 20, 2013|https://clinicaltrials.gov/show/NCT00504504||169071|
NCT00504829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-AtorFen-2001|Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia|A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia||Veloxis Pharmaceuticals|No|Completed|July 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|220|||Both|18 Years|N/A|No|||April 2008|April 11, 2008|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00504829||169047|
NCT00505141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-278|Urban Environmental Exposures and Childhood Cancer|Case-Control Study of Urban Environmental Effects on Childhood Leukemia and Brain Cancer||Georgetown University||Completed|September 2004|February 2006|Actual|||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|N/A|18 Years|Accepts Healthy Volunteers|||July 2007|July 20, 2007|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505141||169024|
NCT00506038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF01-HMO-CTIL|Efficacy Study of Fine Needle Technique on Calcific Tendinitis|Phase 2 Study of the Fine Needle Technique on Calcific Tendinitis||Hadassah Medical Organization||Terminated||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||November 2008|June 21, 2009|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00506038||168958|
NCT00506051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00041|ZD6474(Vandetanib) + Alimta Combo Study|A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.||AstraZeneca|No|Completed|July 2005|October 2011|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506051||168957|
NCT00505778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007021|A Comparison of Once a Day Dose Compared to 2 Doses/Day|A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis||Warner Chilcott|No|Completed|July 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1027|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|July 20, 2007|No|Yes||No|April 18, 2011|https://clinicaltrials.gov/show/NCT00505778||168978|
NCT00482716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000549549|Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer|Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia||National Cancer Institute (NCI)||Active, not recruiting|January 2007|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|80|||Both|16 Years|N/A|No|||August 2009|January 9, 2014|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482716||170721|
NCT00483262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-365|Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Completed|May 2007|February 2012|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|June 5, 2007|Yes|Yes||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00483262||170679|
NCT00482690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257-05|Analysis of Aldehyde Biomarkers of Exposure and Host Response|||University of Nebraska|No|Active, not recruiting|March 2006|July 2007|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|19 Years|N/A|No|||June 2007|June 4, 2007|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482690||170723|
NCT00482703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-138|A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia|A Randomized, Multicenter, Open-label Phase II Study of Dasatinib (BMS-354825) Administered Orally at a Dose of 50mg Twice Daily or 100mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Imatinib||Bristol-Myers Squibb|Yes|Completed|May 2007|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|75 Years|No|||November 2010|November 30, 2010|June 4, 2007|Yes|Yes||No|July 23, 2010|https://clinicaltrials.gov/show/NCT00482703||170722|
NCT00482937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIL-CDNP-CT001|Safety and Pharmacodynamic Study of CD-NP|A Phase I, Single Ascending Dose Trial to Examine the Safety and Pharmacodynamic Effects of CD-NP||Nile Therapeutics|No|Completed|January 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2007|June 4, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482937||170704|
NCT00482950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-Prot202|A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus||Phenomix|No|Active, not recruiting|April 2007|February 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|75 Years|No|||June 2009|June 4, 2009|June 4, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00482950||170703|
NCT00488319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012616|Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.|A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia||Janssen Research & Development, LLC|No|Completed|June 2007|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|12 Years|17 Years|No|||November 2013|November 12, 2013|June 18, 2007|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00488319||170293|
NCT00488332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0872|An Exploratory Study on Optical Assessment of Oral Mucositis|An Exploratory Study on Optical Assessment of Oral Mucositis||M.D. Anderson Cancer Center|No|Terminated|March 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|No|Probability Sample|Individuals, minimally 18 years old, undergoing radiation therapy or chemoradiotherapy for        head and neck cancer treatment.|July 2012|July 18, 2012|June 19, 2007||No|Terminated due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00488332||170292|
NCT00483223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-412|Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response|A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response||Massachusetts General Hospital|Yes|Active, not recruiting|June 2007|December 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|June 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00483223||170682|
NCT00483470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAF78|Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose|||Sanofi||Completed|June 2007|August 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|720|||Both|12 Months|15 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483470||170664|
NCT00483769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234-234-234-234-234|One Year Glargine Treatment in CFRD Children and Adolescents|One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements||Federico II University|Yes|Completed|February 2006|January 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|3 Years|20 Years|No|||February 2007|June 6, 2007|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483769||170641|
NCT00483782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC-ICON7|Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer||National Cancer Institute (NCI)||Completed|April 2006|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|1520|||Female|18 Years|N/A|No|||April 2012|August 9, 2013|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483782||170640|
NCT00483743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI 1020-203|Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients|Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.||Pharmaxis|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|62|||Both|40 Years|80 Years|No|||November 2012|November 30, 2012|May 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00483743||170643|
NCT00483756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921030|Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients|A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients||Pfizer|Yes|Completed|August 2007|April 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|338|||Both|18 Years|70 Years|No|||February 2013|February 8, 2013|June 6, 2007|Yes|Yes||No|December 3, 2012|https://clinicaltrials.gov/show/NCT00483756||170642|
NCT00484926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070186|Association of Clopidogrel Therapy and Stent Thrombosis|Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events|REAL-LATE|CardioVascular Research Foundation, Korea|Yes|Completed|March 2007|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2000|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00484926||170552|
NCT00484367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-STA12178|A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers|Family and Group Therapies for Adolescent Alcohol Abuse||The Morton Center, Inc.|No|Active, not recruiting|July 1999|August 2012|Anticipated|August 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|13 Years|17 Years|No|||November 2008|August 25, 2011|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484367||170595|
NCT00504543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2206|Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients|A 12 Month Open-label, Randomized, Multicenter, Sequential Cohort-group, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients.|AEB071|Novartis||Completed|July 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|311|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504543||169068|
NCT00504556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-PRT018|A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation|A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation||Daiichi Sankyo Inc.|Yes|Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|1146|||Both|18 Years|80 Years|No|||March 2015|March 12, 2015|July 18, 2007|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00504556||169067|
NCT00504517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27074|Preparing the Personal Physician for Practice (P4)|Preparing the Personal Physician for Practice (P4)|P4|Christiana Care Health Services|No|Completed|July 2007|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|26 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|All Family medicine residents who accept employment as a resident in the Dept of Family        Medicine will be part of the study population. These residents are interviewed prior to        acceptance. Acceptance can occur via the NRMP or osteopathic match process or outside of        the match|August 2012|August 15, 2012|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504517||169070|
NCT00504530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23079|r-hLIF for Improving Embryo Implantation in IVF|A Randomised, Double-blind, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Acceptability of r-hLIF for Improving Embryo Implantation Following in Vitro Fertilisation (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure.||Merck KGaA||Completed|September 2001|April 2002|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|50|||Female|21 Years|36 Years||||March 2009|February 17, 2014|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00504530||169069|
NCT00505167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910-0459|Memantine Versus Donepezil in Early Stages of Alzheimer's Disease|Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.||Hospital Miguel Servet|No|Completed|July 2007|December 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|N/A|N/A|No|||December 2008|December 26, 2008|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505167||169022|
NCT00505180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P000373|Accelerated Mortality on Renal Replacement|Accelerated Mortality on Renal Replacement|ArMORR|Massachusetts General Hospital|No|Completed|June 2004|June 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|10018|||Both|N/A|N/A|No|||July 2007|July 19, 2007|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00505180||169021|
NCT00505154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG012007|Effect of Rosuvastatin on Left Ventricular Remodeling|A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure||Oslo University Hospital|No|Completed|July 2007|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|80 Years|No|||January 2014|January 24, 2014|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505154||169023|
NCT00506610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K862-06-2001|A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Flexible Escalating -Dose, Pilot Analgesic Efficacy Study of T-62 in Subjects With Postherpetic Neuralgia||Pfizer|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00506610||168914|
NCT00483002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051083|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets||Pfizer|Yes|Completed|June 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3719|||Both|18 Years|N/A|No|Non-Probability Sample|Healthy smokers|April 2012|April 11, 2012|June 5, 2007|No|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00483002||170699|Planned observation time points at 4, 8 and 12 weeks were reported as from week 3 to less than week 7, from week 7 to less than week 11, at least week 11. As this is non-interventional study it is likely that adverse events had been under reported.
NCT00487435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013567|An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain|Open-Label Extension, Single-Arm, Flexible-Dosing, Phase 3 Trial With CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1166|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|June 14, 2007|Yes|Yes||No|June 24, 2010|https://clinicaltrials.gov/show/NCT00487435||170360|
NCT00483249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02810|Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm|Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm||University of California, San Francisco|Yes|Recruiting|May 2005|||December 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00483249||170680|
NCT00483522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-7055-C09|Telephone Intervention After Traumatic Brain Injury|The Effect of Scheduled Telephone Intervention on Outcomes After Traumatic Brain Injury||University of Washington|No|Completed|December 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|433|||Both|16 Years|N/A|No|||June 2012|June 19, 2012|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483522||170660|
NCT00483860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKF104864/722|A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function|A Phase I Study of Oral Topotecan in Subjects With Cancer and Impaired Renal Function||GlaxoSmithKline|No|Completed|June 2007|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||May 2012|October 25, 2012|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483860||170634|
NCT00489151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 04-315 T/637|A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy|A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy||Hospital Authority, Hong Kong||Recruiting|June 2005|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|70 Years||||July 2010|July 6, 2010|June 20, 2007||||No||https://clinicaltrials.gov/show/NCT00489151||170231|
NCT00489164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02-6316, P01-6311|Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions|A Randomized Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions (DECODE)|DECODE|Cordis Corporation|Yes|Terminated|August 2002|May 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||November 2008|November 10, 2008|June 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00489164||170230|
NCT00483509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR007|Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma|NGR007: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Small Cell Lung Carcinoma (SCLC) Previously Treated With at Least One Therapeutic Regimen|NGR007|MolMed S.p.A.|No|Active, not recruiting|December 2006|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483509||170661|
NCT00483821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0435|A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC|A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC||Vanderbilt-Ingram Cancer Center|Yes|Completed|May 2004|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|165|||Both|18 Years|80 Years|No|Non-Probability Sample|Adults with the diagnosis of primary squamous cell carcinoma of the head and neck at any        of the following sites:          -  Oral cavity          -  Oropharynx          -  Hypopharynx          -  Larynx|September 2012|September 7, 2012|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483821||170637|
NCT00483483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAASAM-016059|Project HERMITAGE: HIV Prevention in Hospitalized Russian Drinkers|Maximizing Opportunity: HIV Prevention in Hospitalized Russian Drinkers||Boston Medical Center|No|Completed|October 2007|March 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|700|||Both|18 Years|70 Years|No|||June 2012|June 18, 2012|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483483||170663|
NCT00483795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5308|Pilot Evaluation of Two Multipurpose Solutions in Regards to Corneal Staining|||Innovative Medical||Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||||||Both|18 Years|N/A||||July 2007|July 23, 2007|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00483795||170639|
NCT00484068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA-98238|Chicken-Diet vs. Enalapril to Reduce Albuminuria|Effect of Chicken-Based Diet Versus Enalapril on Albuminuria in Patients With Type 2 Diabetes and Microalbuminuria: a One-Year Randomized Controlled Study||Hospital de Clinicas de Porto Alegre|No|Completed|January 2003|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||June 2007|June 7, 2007|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00484068||170618|
NCT00485238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB A/06/177|ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function|EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES|Iridoplasty|National University Hospital, Singapore|No|Recruiting|February 2007|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|80 Years|No|||May 2008|May 13, 2008|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485238||170528|
NCT00504920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0495|Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients|Feasibility Study of the Assessment of Symptom-Related Cytokines in AML/MDS Patients Undergoing Allogeneic Blood or Marrow Transplantation||M.D. Anderson Cancer Center|No|Completed|May 2004|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples With DNA|At admission, blood sample drawn (around 2½ tablespoons) to measure levels of cytokines      before transplant procedure, then another three days postadmission, on day of transplant, 1      day after transplant, 3 days, 8 days, 15 days, 22 days, 29 days postransplant, then between      50 - 60 days postransplant and again 80 - 100 days after transplant.|Both|18 Years|N/A|No|Non-Probability Sample|Patients, over 18 years, scheduled for allogeneic translantation (bone marrow or        peripheral blook stem cell) at UT MD Anderson Cancer Center.|July 2012|July 31, 2012|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504920||169041|
NCT00504842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-06-101-CP-01-01|Transcranial Ultrasound in Clinical SONothrombolysis|A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 With Continuous Ultrasound Administration in Subjects With Acute Ischemic Stroke Receiving Treatment With Intravenous Tissue Plasminogen Activator|TUCSON|ImaRx Therapeutics|Yes|Terminated|December 2006|March 2008|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||April 2008|April 11, 2008|July 18, 2007|||Sponsor decision|No||https://clinicaltrials.gov/show/NCT00504842||169046|
NCT00504855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCH-JPB-1|Cast Sores With Waterproof Vs. Standard Cast Padding|Cast Sores With Waterproof Vs. Standard Cast Padding in a Pediatric Population||Shriners Hospitals for Children|No|Terminated|July 2007|March 2014|Anticipated|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|1 Year|18 Years|No|||April 2013|April 5, 2013|July 19, 2007||No|Staffing changes resulted in the expiration of IRB approval (2/15/12), and recruitment halted    (n=84). IRB approval is now current for retrospective analysis.|No||https://clinicaltrials.gov/show/NCT00504855||169045|
NCT00506064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM02-563|Melatonin Postoperative Sleep Study in Breast Cancer Patients|Melatonin Postoperative Sleep Study in Breast Cancer Patients||M.D. Anderson Cancer Center|No|Terminated|February 2004|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|40 Years|N/A|No|||December 2012|December 3, 2012|July 23, 2007||No|Terminated due to low accrual.|No|March 29, 2010|https://clinicaltrials.gov/show/NCT00506064||168956|Study terminated early due to low recruitment, no analysis done.
NCT00505791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120050150|Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF|Double Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction||Rutgers, The State University of New Jersey|No|Withdrawn|August 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 19, 2007|Yes|Yes|Unable to enroll patients|No||https://clinicaltrials.gov/show/NCT00505791||168977|
NCT00496730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-129|A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)|A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea||Merck Sharp & Dohme Corp.||Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|256|||Both|20 Years|79 Years|No|||November 2015|November 19, 2015|July 2, 2007|Yes|Yes||No|September 3, 2009|https://clinicaltrials.gov/show/NCT00496730||169661|
NCT00506311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS01-564|Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients|A Randomized Trial Evaluating the Use of Fibrin Tissue Adhesive Following Superficial Groin Dissection in Patients With Melanoma||M.D. Anderson Cancer Center|No|Completed|February 2003|March 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|N/A|N/A|No|||August 2012|August 1, 2012|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506311||168937|
NCT00506324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC007659-01A1|Oropharyngeal Function After Radiotherapy With IMRT|Oropharyngeal Function After Radiotherapy With IMRT||Northwestern University|Yes|Terminated|June 2006|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|21 Years|79 Years|No|Non-Probability Sample|One hundred and twenty-five patients with disease Stages III or IV squamous cell cancers        of the oral cavity, larynx or pharynx will serve as subjects. No patient will have had        prior treatment for head and neck cancer or any otolaryngologic or neurologic disorder        affecting swallow, and no preexisting swallowing disorder.|July 2015|July 10, 2015|July 20, 2007||No|Physician deceased|No||https://clinicaltrials.gov/show/NCT00506324||168936|
NCT00506623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS 04-088|Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer|A Phase Ⅱ Study of Pre-Operative Concurrent Chemoradiotherapy With Capecitabine Plus Irinotecan in Resectable Rectal Cancer.||National Cancer Center, Korea|No|Active, not recruiting|July 2004|December 2008|Anticipated|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||July 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506623||168913|
NCT00487201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-2006|Endoscopic Treatment of Biliary Strictures After LTX: Balloon Dilatation Versus Stent Placement|||University of Ulm|No|Completed|April 2006|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||May 2007|June 15, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00487201||170378|
NCT00487747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20003|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.|An Open Label Study of the Effect of PEGASYS on Treatment Response in Patients With HBeAg-positive or HBeAg-negative Chronic Hepatitis B||Hoffmann-La Roche||Completed||October 2009|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|70 Years|No|||February 2010|February 15, 2010|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00487747||170336|
NCT00487760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907161|African American Families and Lung Cancer Study|African American Families and Lung Cancer Study||National Institutes of Health Clinical Center (CC)||Completed|June 2007|August 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|18 Years|N/A|No|||August 2011|September 26, 2015|June 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00487760||170335|
NCT00487773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-87-06-KE|Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma|Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma - Randomized, Controlled Trial.||Medical Universtity of Lodz|Yes|Completed|September 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|96|||Both|5 Years|18 Years|No|||April 2010|April 12, 2010|June 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00487773||170334|
NCT00483535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEC107110|Oral Contraceptive Interaction Study for GW273225|An Open, Repeat Dose Study to Investigate the Effect of Co-administration of the Combined Oral Contraceptive Pill (COC) and GW273225 on the Pharmacokinetics of the COC and to Investigate the Effects of the COC on the Pharmacokinetics of GW273225 in Healthy Female Subjects||GlaxoSmithKline|No|Terminated|March 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483535||170659|
NCT00483548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281158|Adjunctive Ziprasidone in the Treatment of Bipolar I Depression|A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression||Pfizer|Yes|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|June 5, 2007|Yes|Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00483548||170658|
NCT00483873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44HL070129|Cardiac Arrest Recovery EEG Study|Phase IIB Study of Novel Quantitative Neurodiagnostic Technology in the Early Period After Cardiac Arrest|CARES|Infinite Biomedical Technologies|Yes|Recruiting|August 2007|December 2009|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the hospital after out-of-hospital Cardiac arrest or for an ICD        placement|January 2009|January 28, 2009|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483873||170633|
NCT00497042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-AS-030-CTIL|Safety and Efficacy of Using the Endodontic Self Adjusting File - SAF for Root Canal Treatment|Safety and Efficacy of Using the Endodontic Self Adjusting File - SAF for Root Canal Treatment||ReDent Nova|Yes|Not yet recruiting||||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 10, 2007|July 4, 2007||||No||https://clinicaltrials.gov/show/NCT00497042||169637|
NCT00497055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA022190-01|Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals|Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals||San Francisco Department of Public Health|Yes|Completed|March 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|60 Years|No|||February 2014|February 5, 2014|July 5, 2007||No||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00497055||169636|
NCT00507897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESheverdova-1|Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules|||Yaroslavl State Medical Academy|No|Terminated||December 2007|Actual|||N/A|Observational|Time Perspective: Prospective||4|Anticipated|100|||Both|N/A|N/A|No|||February 2008|February 6, 2008|July 25, 2007|||The received reliability with increase in quantity of participants of research did not vary|No||https://clinicaltrials.gov/show/NCT00507897||168816|
NCT00497926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-13947-120209|Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion|Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion||University of Louisville|Yes|Recruiting|March 2008|March 2030|Anticipated|March 2025|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|July 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00497926||169569|
NCT00497939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.310-T|The Effectiveness of Saw Palmetto and Sanmiaoshan on Benign Prostatic Hyperplasia in Chinese Patients|The Effectiveness of Saw Palmetto and Sanmiaoshan on International Prostate Symptom Score and Peak Urinary Flow Rate of Chinese Patients With Benign Prostatic Hyperplasia||Hospital Authority, Hong Kong||Recruiting|January 2006|March 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Male|50 Years|80 Years||||July 2010|July 6, 2010|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00497939||169568|
NCT00497952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-13080-122206|Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis|Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis||University of Louisville|Yes|Active, not recruiting|July 2007|December 2020|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|55 Years|No|||January 2016|January 21, 2016|July 6, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00497952||169567|
NCT00497965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-07252006|Pilot Study: Does Chiropractic Care Decrease Fall Risk in Older Adults|Pilot Study: Does Chiropractic Care Decrease Fall Risk in Older Adults?||Cleveland Chiropractic College|No|Completed|April 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|3||Anticipated|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 16, 2010|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497965||169566|
NCT00497978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAUP03.04.07/2|The Effect of Taurine on Morbidity and Mortality in the Elderly Hip Fracture Patient|The Effect of Taurine on Morbidity and Mortality in the Elderly Hip Fracture Patient|TAUP|Medical Center Alkmaar|No|Completed|March 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|236|||Both|75 Years|N/A|No|||December 2011|December 27, 2011|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00497978||169565|
NCT00497991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00007|Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia|A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia.||AstraZeneca||Completed|May 2006|April 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||December 2010|December 7, 2010|July 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00497991||169564|
NCT00498927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-064|Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma|A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma||Memorial Sloan Kettering Cancer Center||Completed|June 2007|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|120 Years|No|||February 2016|February 1, 2016|July 10, 2007|Yes|Yes||No|October 5, 2015|https://clinicaltrials.gov/show/NCT00498927||169493|
NCT00494663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIO-502|A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes|A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment With DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-502)||DiObex|No|Terminated|July 2007|December 2008|Anticipated|March 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|200|||Both|18 Years|75 Years|No|||November 2008|November 11, 2008|June 28, 2007|Yes|Yes|Program Terminated|No||https://clinicaltrials.gov/show/NCT00494663||169814|
NCT00495235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0164|Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas|Case-Control Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas||M.D. Anderson Cancer Center|No|Completed|October 2005|||May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|147|Samples With DNA|Blood sample and, if diagnosed with endometrial cancer and had surgical removal of uterus, a      piece of leftover tumor and surrounding normal tissue will be tested for markers of insulin      resistance and PCOS.|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants from Harris County who have had endometrial cancer (cases) and those who have        not (controls).|May 2014|May 20, 2014|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495235||169771|
NCT00495222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-06-0005|Endoscopic Suturing System for Tissue Apposition|Evaluation of an Endoscopic Suturing System for Tissue Apposition||Ethicon Endo-Surgery|No|Completed|February 2007|June 2008|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 8, 2009|June 29, 2007||No||No|April 21, 2009|https://clinicaltrials.gov/show/NCT00495222||169772|
NCT00495495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-D-187|Healozone Study to Evaluate the Safety and Efficacy of the Use of Ozone for Management of Dental Caries|A Multi-Center Study to Evaluate the Safety and Efficacy of the Use of Ozone for the Management of Fissure Caries||Indiana University|Yes|Completed|February 2007|December 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|394|||Both|10 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|July 1, 2007|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00495495||169751|Study length may have been too brief to permit progression of early stage caries; Low caries increment in study population; Difficult to establish that lesions were truly active at baseline.
NCT00495768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-0013-391|Reducing Depressive Symptoms During HCV Therapy: A Randomized Study|Reducing Depressive Symptoms During HCV Therapy: A Randomized Study||South Texas Veterans Health Care System|Yes|Active, not recruiting|July 2004|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|90|||Both|25 Years|68 Years|Accepts Healthy Volunteers|||December 2007|December 13, 2007|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495768||169732|
NCT00495781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFIDS-2004|Out Come Study To Define Laboratory Parameters That Are Best Suited to Diagnose Functional Iron Deficiency|Swiss Functional Iron Deficiency Study|SFIDS|Spital Zollikerberg|No|Completed|October 2004|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|2||Actual|77|||Both|18 Years|N/A|No|||July 2007|July 2, 2007|July 2, 2007||||No||https://clinicaltrials.gov/show/NCT00495781||169731|
NCT00497497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APM4187g|A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)|A Phase Ib, Dose-Escalation Study of the Safety and Pharmacokinetics of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer||Genentech, Inc.||Completed|October 2007|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2011|February 15, 2011|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00497497||169602|
NCT00497770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10733|An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed|Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study||Eli Lilly and Company|No|Completed|February 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|434|||Both|18 Years|N/A|No|Probability Sample|Patients receiving pemetrexed for second (2nd) line treatment of non-small cell lung        cancer (NSCLC): 400 Caucasians, 200 African-Americans, 200 Asian-Americans, and 200        Hispanic patients will be accrued to this study.|April 2012|April 27, 2012|July 5, 2007|No|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00497770||169581|This is an observational study, as such, the investigators followed the label recommendations and any changes to the label which occurred during the study.
NCT00497783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO_L_02949|Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)|Safety Dermatological Evaluation of the Acceptability With Gynecological Follow up for Dermacyd Femina Delicata||Sanofi|No|Completed|May 2007|||||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2008|May 19, 2008|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00497783||169580|
NCT00498108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0791|Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects|An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome||UCB Pharma||Completed|January 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|341|||Both|18 Years|75 Years|No|||September 2009|September 24, 2014|July 6, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00498108||169555|
NCT00498394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0060334B|Effects of a Ketogenic Diet on Body Weight and Cardiovascular Risk Factors|Effects of a Ketogenic Diet on Body Weight and Cardiovascular Risk Factors||University of Cincinnati|No|Completed|June 2000|October 2002|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 6, 2007|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498394||169533|
NCT00498407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-202|A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer|A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer||Clavis Pharma|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2009|June 3, 2009|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498407||169532|
NCT00498706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059708|Effectiveness of Telephone Versus Face-to-Face CBT in Treating People With Depression|Telephone Versus Face-to-Face Administration of CBT for Depression||Northwestern University|Yes|Completed|December 2007|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|325|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 8, 2007||No||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00498706||169509|
NCT00494468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU-10590|Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children|Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Zolpidem Doses in Children Ages 2 to 18 Years of Age||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|October 2002|March 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||63|||Both|2 Years|18 Years|No|||November 2005|June 28, 2007|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00494468||169829|
NCT00498745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1109|Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects|A Single Dose Bioavailability Study of 2 New Formulations of HKI-272 (240 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects||Puma Biotechnology, Inc.||Completed|July 2007|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label||||36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|July 9, 2007||||||https://clinicaltrials.gov/show/NCT00498745||169506|
NCT00495092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAF-DTX-1|Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients|Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients||Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|January 2005|October 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|60 Years|No|||February 2012|February 29, 2012|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00495092||169782|
NCT00496223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14743|A Phase I/II Study of Sunitinib and Dacarbazine|A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|September 2006|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2011|February 21, 2011|July 3, 2007|No|Yes|toxicities required dose reduction compromising effectiveness and PI left Moffitt|No||https://clinicaltrials.gov/show/NCT00496223||169699|
NCT00496236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-001.010|Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer|A Phase I/II Safety, Tolerability and "Proof of Concept" Study of Radiotherapy, Cetuximab, and Intratumoral Injections of TNFerade™ Biologic (AdGVEGR.TNF.11D) for Elderly or Frail Patients or Intermediate Stage Patients With Head and Neck Cancer||GenVec||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2011|February 22, 2012|June 28, 2007||||||https://clinicaltrials.gov/show/NCT00496236||169698|
NCT00497562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FibTek-0301|Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters)|Exploratory Study to Investigate the Efficacy and Safety of Recombinant Growth Hormone as Add-on Treatment in Patients With Severe Fibromialgia||Centro Medico Teknon|Yes|Completed|May 2004|November 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||July 2007|July 5, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497562||169597|
NCT00497666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346147Rosi|Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study|Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study||Assaf-Harofeh Medical Center|No|Not yet recruiting|August 2007|December 2007|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|18 Years|90 Years||||July 2007|July 6, 2007|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00497666||169589|
NCT00497679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00003|AZD1152 in Patients With Advanced Solid Malignancies-Study 3|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies||AstraZeneca|No|Terminated|August 2006|July 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|July 5, 2007|||Study is now terminated due to technical difficulties with administration of study drug in    this patient population with this schedule|No||https://clinicaltrials.gov/show/NCT00497679||169588|
NCT00498277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0317|Quantitative Diffusion and Fat Imaging of the Spine|Quantitative Diffusion and Fat Imaging of Vertebral Fractures||M.D. Anderson Cancer Center|No|Completed|August 2004|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Study participants with osteoporosis that have already been scheduled for MRI exams of the        spine.|July 2012|July 31, 2012|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00498277||169542|
NCT00498901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6412|Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer|Phase II Pilot of Aromatase Inhibitor Therapy With Femara® (Letrozole) and Ovarian Suppression in Premenopausal Estrogen Receptor Positive Women With Stage IV Carcinoma of the Breast||University of Washington||Terminated|February 2007|November 2008|Actual|December 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|N/A|No|||May 2013|May 7, 2013|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00498901||169495|
NCT00494676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-016|Clinical Trial of Peripheral Prism Glasses for Hemianopia|Community-based Multi-center Randomized Control Trial of Peripheral Prism Glasses for Hemianopia||Massachusetts Eye and Ear Infirmary|Yes|Completed|September 2007|April 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||September 2013|October 28, 2015|June 28, 2007||No||No|July 7, 2013|https://clinicaltrials.gov/show/NCT00494676||169813|
NCT00494962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098B1-1147|Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects|An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between Two 5-mg Tablets and a New 10-mg Tablet Formulation of Lecozotan SR in Healthy Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2007|June 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00494962||169791|
NCT00494975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704019R|The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease|The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease||National Taiwan University Hospital|No|Completed|June 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|90 Years|No|||September 2010|January 26, 2011|June 29, 2007||No||No|October 5, 2010|https://clinicaltrials.gov/show/NCT00494975||169790|small numbers of subjects analyzed
NCT00495014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIX109981|Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects|A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study With Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects||GlaxoSmithKline||Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|June 28, 2007||||||https://clinicaltrials.gov/show/NCT00495014||169788|
NCT00495508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mba/06/MIP|Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy|A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007)||Epicentre|Yes|Completed|October 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|N/A|N/A|No|||May 2010|May 12, 2010|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495508||169750|
NCT00495521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASER - AFC.002|High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children|A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease||Jacobus Pharmaceutical|No|Terminated|June 2007|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|2 Years|18 Years|No|||October 2011|October 19, 2011|June 29, 2007|Yes|Yes|Efforts at recruitment have halted as recruitment was poor|No||https://clinicaltrials.gov/show/NCT00495521||169749|
NCT00495794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 06-128|Adherence and Intensification of Medications (AIM) Implementation Study|Adherence and Intensification of Medications: A Population-Based Clinical Pharmacists Implementation Study Among Hypertensive Diabetes Patients||VA Office of Research and Development|Yes|Completed|August 2008|July 2012|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4622|||Both|18 Years|N/A|No|||July 2014|April 6, 2015|June 29, 2007||No||No|September 3, 2014|https://clinicaltrials.gov/show/NCT00495794||169730|In the intervention arm, only 53% of subjects had a pharmacist encounter. Higher rates of participation might have led to a more substantial initial improvement and a detectable longer term effect.
NCT00497510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-04052006|Feasibility Study of Short-Term Effects of Chiropractic Manipulation on Older Adults With Impaired Balance|Feasibility Study of Short-Term Effects of Chiropractic Manipulation on Older Adults With Impaired Balance||Cleveland Chiropractic College|No|Completed|October 2006|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|11|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 5, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497510||169601|
NCT00497796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1263-301|Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients|A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants||Shire|Yes|Completed|July 2007|September 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|307|||Both|18 Years|N/A|No|||March 2014|May 20, 2015|July 5, 2007|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT00497796||169579|
NCT00498121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMA-07-001 (mbasi100)|The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)|The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)||McGill University Health Center|Yes|Terminated|July 2007|May 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are intubated or more than 48 hours|December 2009|December 17, 2009|July 6, 2007||No|One of the principal investigators has moved to a different institution|No||https://clinicaltrials.gov/show/NCT00498121||169554|
NCT00498420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-01|The Natural History of Alpha-Mannosidosis|A Multicenter, Multinational Study That Will Evaluate Clinical and Surrogate Parameters Known to be Affected in Alpha-Mannosidosis Patients|HUE-MAN|Zymenex A/S|No|Completed|May 2007|November 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|45|Samples With DNA|Blood|Both|N/A|N/A|No|Probability Sample|To be eligible to proceed, each subject must meet all inclusion and exclusion criteria        during the screening periode.|February 2010|February 5, 2010|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498420||169531|
NCT00498693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561701013|Hypoxia Inducible factor1-Alpha Genetic Polymorphism of Obstructive Sleep Apnea|||National Taiwan University Hospital|Yes|Recruiting|March 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|patients referred sleep center to rule out obstructive sleep apnea|January 2009|January 12, 2009|July 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00498693||169510|
NCT00497835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biolert LTD|Study of Algorithm for Epilepsy Alert Device|Epilepsy Alert Device - Epilert Performance||Biolert|Yes|Completed|October 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15||no Biospecimen|Both|N/A|65 Years|No|Non-Probability Sample|Patients admitted to Video-LTM Unit with motor seizures.|July 2007|June 14, 2011|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00497835||169576|
NCT00498446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3938|Magnetic Resonance Imaging of Atrial Septal Defects|Imaging of Atrial Septal Defects by Velocity Encoded Cardiovascular Magnetic Resonance||Duke University|No|Completed|July 2002|July 2004|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|44|||Both|18 Years|N/A|No|||July 2007|June 18, 2013|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00498446||169529|
NCT00495612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4229n|A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma|A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma|AERO|Genentech, Inc.||Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||March 2013|March 25, 2013|June 29, 2007|Yes|Yes||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00495612||169743|
NCT00495924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3M070038|Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma|Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma||Katholieke Universiteit Leuven|Yes|Completed|October 2006|October 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Tissue, serum, blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.|July 2009|July 7, 2009|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495924||169721|
NCT00496808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0701|Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast|Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast||M.D. Anderson Cancer Center|No|Completed|March 2005|November 2010|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|N/A|N/A|No|||April 2012|April 19, 2012|July 3, 2007||No||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00496808||169655|
NCT00503568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20020225|Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy|Novel Tumor Vaccine gp96-Ig Fusion Protein in Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed First Line Chemotherapy||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|May 2007|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00503568||169143|
NCT00503581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0224|Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia|A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation||Gynecologic Oncology Group||Terminated|July 2007|||July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503581||169142|
NCT00503919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0810|Measurement of Digital Colposcopy for Fluorescence Spectroscopy of TNC Using a Second Device|A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of the Normal Cervix for Screening, Using a Second Generation Device||M.D. Anderson Cancer Center|No|Terminated|May 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|October 7, 2009|July 17, 2007||No|No patients enrolled; study terminated.|No|September 4, 2009|https://clinicaltrials.gov/show/NCT00503919||169116|Due to time and device constraints, no patients were accrued on this protocol. The type of device intended for usee to satisfy the clinical and/or scientific needs addressed in this research has changed.
NCT00503932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0657|Proton Therapy With Capecitabine for Rectal Cancer|A Phase I/II Trial of Proton Therapy With Concurrent Capecitabine for Locally Advanced and Recurrent Rectal Cancer||M.D. Anderson Cancer Center|No|Withdrawn|July 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|July 17, 2007||No|No participant enrollment.|No||https://clinicaltrials.gov/show/NCT00503932||169115|
NCT00497692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO_L_02948|Topic Compatibility Lactoserum (Dermacyd Delicata - New Fragrance)|Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensitivity) for Dermacyd Femina Delicata||Sanofi|No|Completed|May 2007|||||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2008|May 19, 2008|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00497692||169587|
NCT00498004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOL Study 2007|Quality of Life (QOL) in Female Patient With Schizophrenia|Randomized, Open Label, 8-Week Study of Quetiapine and Risperidone on Quality of Life in Female With Schizophrenia||Inje University|Yes|Terminated|August 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|60 Years|No|||November 2008|November 3, 2008|July 6, 2007||No|difficult to recruit subject|No||https://clinicaltrials.gov/show/NCT00498004||169563|
NCT00494689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02|Transcranial and Rapid Magnetic Stimulation for Gait Apraxia Due to Normal Pressure Hydrocephalus and Cerebral Ischemia|||Devathasan Neurology Practice Pte Ltd|Yes|Recruiting|January 2002|June 2007|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal|||Anticipated|30|||Both|N/A|N/A|No|||June 2007|June 28, 2007|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00494689||169812|
NCT00494988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1635|Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart|Self-control Trial to Evaluate the Remission Rate and Safety in Newly Diagnosed Type 2 Diabetes Patients After Short-term Intensive Insulin Aspart and Insulin NPH Treatment||Novo Nordisk A/S|No|Completed|December 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|33|||Both|18 Years|50 Years|No|||March 2016|March 3, 2016|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00494988||169789|
NCT00527540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC-10|Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C|Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C||Tehran Hepatitis Center|Yes|Completed|February 2007|December 2008|Actual|June 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2009|January 18, 2009|September 8, 2007||||No||https://clinicaltrials.gov/show/NCT00527540||167333|
NCT00495248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUS838|Thriving, Activity and Social Participation After Stroke|Well-being, Activity and Social Participation After Stroke/TIA. RCT-psycho Social Intervention Study.||Oslo University Hospital|No|Active, not recruiting|January 2007|September 2011|Anticipated|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|65 Years|N/A|No|||August 2011|August 8, 2011|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495248||169770|
NCT00495547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000972-18|SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome|A Multicenter, Non-Randomized, Open-Label Study to Evaluate Efficacy and Safety of Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Red Cell Transfusion Dependent With Low or Intermediate -1 Risk.|SIMIDIS|PETHEMA Foundation|Yes|Terminated|February 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495547||169748|
NCT00495807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2579-2FW|Nurses' Negative Words and Postoperative Pain Management|Influence on Pain Management of Nurses' Negative Words After Total Hysterectomy|NWPOP|Nanjing Medical University|Yes|Completed|June 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|1500|||Female|19 Years|64 Years|No|||April 2008|July 11, 2008|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495807||169729|
NCT00497523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/1404/002/05|Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms|Double Blind, Multinational, Multicentre, Parallel-group, Placebo-controlled Design Trial of the Efficacy and Safety of Nebulised Beclometahsone Dipropionate (400 μg b.i.d.) Plus as Needed Salbutamol Versus as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination, in the 12-week Treatment of Young Children With Asthma Symptoms||Chiesi Farmaceutici S.p.A.|No|Completed|March 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|283|||Both|1 Year|4 Years|No|||March 2015|March 18, 2015|July 4, 2007||||No||https://clinicaltrials.gov/show/NCT00497523||169600|
NCT00496210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907178|Predictors of Caregiver Adaptation to Pervasive Developmental Disorders|Understanding Caregiver Adaptation to Pervasive Developmental Disorders||National Institutes of Health Clinical Center (CC)||Completed|June 2007|December 2015||||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496210||169700|
NCT00497029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minah-1|Early Childhood Caries Prevention at a Pediatric Clinic|||University of Maryland Baltimore Dental School|No|Completed|June 2004|August 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|219|||Both|6 Months|27 Months|Accepts Healthy Volunteers|||July 2007|July 5, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497029||169638|
NCT00498459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_01|Intervention Centered on Adolescents' Physical Activity and Sedentary Behavior (ICAPS)|Intervention Centered on Adolescents' Physical Activity and Sedentary Behavior (ICAPS)|ICAPS|Louis Pasteur University, Strasbourg|Yes|Completed|September 2002|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|954|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498459||169528|
NCT00494754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709027|Clinical and Genetic Study of Autism Spectrum Disorder|Clinical and Genetic Study of Autism Spectrum Disorder||National Taiwan University Hospital|Yes|Recruiting|May 2007|January 2010|Anticipated|||N/A|Observational|Observational Model: Family-Based||1|Anticipated|300|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|3 Years|18 Years|No|Non-Probability Sample|The sample will consist of 300 children and adolescents with ASD, aged 3-18.|December 2009|December 14, 2009|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00494754||169807|
NCT00507598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0706-03: IUCRO-0198|Metabolomics-Based Detection of Colorectal Cancer|Metabolomics-Based Detection of Colorectal Cancer|metabolomics|Indiana University|Yes|Completed|July 2007|November 2012|Actual|March 2009|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Actual|69|Samples With DNA|serum, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|colorectal cancer patients|September 2014|September 10, 2014|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507598||168838|
NCT00507884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0875|Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors|Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2005|||March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Both|N/A|N/A|No|Non-Probability Sample|Study participants with renal tumors scheduled to have a CT scan of the kidneys and        abdomen.|September 2015|September 8, 2015|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00507884||168817|
NCT00507611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06077|Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients|Sentinel Lymph Node Mapping and Biopsy For Predicting the Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients Who Had Biopsy-Proven Axillary Lymph Node Involvement at Initial Presentation||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2006|May 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Female|18 Years|N/A|No|||September 2012|September 23, 2012|July 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507611||168837|
NCT00503945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nagasaki-SAS|Cardiac Dysfunction in Obstructive Sleep Apnea Patients: Prevalence of and Effect of nCPAP|The Clinical Significance of an Index of Cardiac Function, Tei-Index, in Obstructive Sleep Apnea Syndrome Patients.||Nagasaki University|No|Completed|November 2004|November 2006|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||July 2007|July 18, 2007|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00503945||169114|
NCT00498316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0781|Cord Blood Expansion on Mesenchymal Stem Cells|Cord Blood Expansion on Mesenchymal Stem Cells||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2007|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|1 Year|80 Years|No|||November 2015|November 2, 2015|July 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00498316||169539|
NCT00498329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070187|Brain Function in Performance of Motor Tasks|Brain Connectivity and Sensorimotor Integration During Dual/Single Motor Tasks||National Institutes of Health Clinical Center (CC)||Completed|July 2007|November 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|144|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 19, 2011|July 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00498329||169538|
NCT00498342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVM07-205|The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease|The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease||University of Vermont|No|Completed|June 2007|February 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|89 Years|No|||July 2007|February 11, 2008|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00498342||169537|
NCT00498615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00002801|A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon|Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon||Johns Hopkins University|No|Completed|April 2007|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|80 Years|No|||August 2014|November 3, 2014|July 6, 2007|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT00498615||169516|
NCT00498628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA_DTRR-2007-LITTEN-01|Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency|A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Completed|December 2007|March 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|65 Years|No|||June 2015|June 17, 2015|July 6, 2007|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00498628||169515|
NCT00498940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB5600|Biventricular Pacing After Cardiopulmonary Bypass|Biventricular Pacing After Cardiopulmonary Bypass|BIPACS|Columbia University|Yes|Terminated|October 2006|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|July 9, 2007|Yes|Yes|Accrual too slow; grant renewal unlikely; AAI as effective as BiV in Phase III|No|February 3, 2014|https://clinicaltrials.gov/show/NCT00498940||169492|
NCT00498953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-24051|Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx|Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 2007|March 2009|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00498953||169491|
NCT00527267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000183|Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects|A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis||Amgen||Completed|February 2002|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||January 2009|January 22, 2009|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527267||167354|
NCT00527280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050303|Face Reconstruction by Allotransplantation of Composite Tissues|Face Reconstruction by Allotransplantation of Composite Tissues||Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|January 2007|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||September 2007|January 10, 2014|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00527280||167353|
NCT00527553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061127|The Effect of Eggs and Egg Products on Macular Pigment|The Effect of Modified Eggs and Egg Products on the Measurable Macular Pigment in Healthy Subjects||Maastricht University Medical Center|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2008|December 30, 2008|September 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00527553||167332|
NCT00527839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26117|Hospital for Special Surgery Shoulder Arthroplasty Cohort|Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: HSS Shoulder Arthroplasty Cohort||Hospital for Special Surgery, New York|Yes|Recruiting|April 2007|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|We will be asking all patients undergoing a total shoulder arthroplasty to participate.|August 2015|August 17, 2015|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527839||167310|
NCT00527852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/59X|Assessment of Flocked Swabs for the Identification of Group A Streptococcal Pharyngitis|||Children's Hospital of Eastern Ontario|Yes|Recruiting|September 2007|December 2007|Anticipated|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|400|||Both|N/A|18 Years|No|||July 2007|September 10, 2007|September 10, 2007||||No||https://clinicaltrials.gov/show/NCT00527852||167309|
NCT00528151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123/2547|A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)|A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)||Mahidol University|Yes|Completed|May 2005|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|70|||Both|8 Years|N/A|Accepts Healthy Volunteers|||August 2004|December 20, 2012|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528151||167286|
NCT00494741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATHENA|MMF vs. AZA for Kidney Transplantation|A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients|ATHENA|Mario Negri Institute for Pharmacological Research|No|Active, not recruiting|May 2007|September 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00494741||169808|
NCT00495300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070183|Collection of Samples and Data for the National Marrow Donor Program Repository|The Collection of Research Samples and/or Data for Repository From Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program||National Institutes of Health Clinical Center (CC)||Recruiting|June 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|N/A|100 Years|No|||November 2015|November 20, 2015|June 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00495300||169766|
NCT00495313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL101-ROSE-401|Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens|Determine the Effects of COL-101 Administered Once Daily With Metronidazole Topical Gel, 1% Versus Doxycycline Hyclate 100 mg Administered Once Daily With Metronidazole Topical Gel, 1% in Patients With Moderate to Severe Rosacea||CollaGenex Pharmaceuticals|No|Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|91|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 11, 2008|June 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00495313||169765|
NCT00496795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethics committee 079.06|Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer|Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer.|MEDOBREC|University of Bergen|No|Recruiting|September 2007|December 2020|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|65 Years|No|||January 2015|January 19, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496795||169656|
NCT00497549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIS1/2004|Trial Comparing Side-to-Side Stapled and Hand-sewn Esophagogastric Anastomosis in Neck|Prospective Randomized Controlled Trial Comparing Side to Side Stapled and Hand Sewn Esophagogastric Anastomosis in the Neck||All India Institute of Medical Sciences, New Delhi||Completed|July 2004|December 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|80 Years|No|||April 2011|May 9, 2011|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497549||169598|
NCT00497822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX05-090|A Randomized Controlled Trial on the Effect of Exercise on Physical, Cognitive and Affective Function in Dementia Subjects|To Study the Effect of Exercise Training in Term of Aerobic Exercise for 3 Months, on the Physical, Cognitive and Affective Function in Dementia Subjects||Hospital Authority, Hong Kong||Recruiting|January 2006|October 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|64|||Both|60 Years|N/A||||July 2010|July 6, 2010|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00497822||169577|
NCT00494767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGW108201|Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs|An Exploratory Study to Evaluate Weight Loss, Body Composition Changes, Food Intake and Urine Glucose Excretion in Healthy Obese Subjects Over 8 Weeks of Dosing With GSK189075, GW869682 Versus Placebo||GlaxoSmithKline|No|Completed|September 2006|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|27|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|October 31, 2006||||No||https://clinicaltrials.gov/show/NCT00494767||169806|
NCT00507325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0466|Sample Collection From Melanoma Patients|Blood and Tumor Sample Collection From Patients With Malignant Melanoma for Long Term Storage||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2006|||June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Patients will provide blood and tumor samples to help researchers learn about melanoma and      other cancers.|Both|N/A|N/A|No|Non-Probability Sample|Study participants with a diagnosis of malignant melanoma.|September 2015|September 8, 2015|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507325||168859|
NCT00507039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334/06/FFM|Safety and Repeatability of Bronchial Challenge With Grass-pollen|Repeatability of a Single Concentration and Single-step Bronchial Allergen Challenge With Grass Pollen||Johann Wolfgang Goethe University Hospitals|Yes|Completed|February 2007|December 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|47|||Both|12 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In        those subjects, who develop a fall in FEV1 of more than 20%, this is followed by two        single-step challenges in an interval of at least seven days.|October 2011|October 7, 2011|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00507039||168881|
NCT00507052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346147RRF|Effect of N-Acetylcysteine on Residual Renal Function in Chronic Hemodialysis Patients|||Assaf-Harofeh Medical Center||Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|20 Years|90 Years||||July 2007|July 24, 2007|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00507052||168880|
NCT00507338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC1779-003|Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI|A Phase 2 Study of an Aptameric Von Willebrand Factor Antagonist, ARC1779, in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention|vITAL-1|Archemix Corp.|Yes|Terminated|October 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|75 Years|No|||January 2009|January 8, 2009|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507338||168858|
NCT00503633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG|Biomarkers of Insomnia and Fatigue in HIV/AIDS (Symptoms and Genetics Study)|Biomarkers of Insomnia and Fatigue in HIV/AIDS|SAG|University of California, San Francisco|No|Completed|March 2005|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Adults with HIV|June 2010|June 22, 2010|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503633||169138|
NCT00503958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULCRC-LLP|Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung Cancer|Liverpool Lung Project||National Cancer Institute (NCI)||Recruiting|August 1998|||||N/A|Observational|N/A|||Anticipated|8300|||Both|45 Years|79 Years|Accepts Healthy Volunteers|||November 2007|May 14, 2013|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503958||169113|
NCT00498654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ty800-07-0001|Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects||Avant Immunotherapeutics|Yes|Completed|July 2007|June 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|180|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2008|June 27, 2008|July 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00498654||169513|
NCT00498641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-05-0112|Anisometropia Amblyopia Improved by Perceptual Learning and Patching|||Tri-Service General Hospital|Yes|Completed|January 2005|January 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|3 Years|55 Years|Accepts Healthy Volunteers|||July 2007|July 9, 2007|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00498641||169514|
NCT00531323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 024|TMC 125 Blood Levels Study|Evaluation of the Pharmacokinetics and Safety of TMC125 Administered Once and Twice-Daily and Following a 2-Week-Treatment Period With Efavirenz in Male and Female Healthy Volunteers.||St Stephens Aids Trust|No|Completed|September 2007|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 4, 2008|September 17, 2007||||No||https://clinicaltrials.gov/show/NCT00531323||167045|
NCT00526994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-2006-15969/200-2008-28219|Randomized Controlled Trial of Routine Screening for IPV|Randomized Controlled Trial of Routine Screening for Intimate Partner Violence||Centers for Disease Control and Prevention|No|Completed|May 2008|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2700|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 29, 2013|September 6, 2007||No||No|February 12, 2013|https://clinicaltrials.gov/show/NCT00526994||167375|12% lost to follow-up differed in age, education, and insurance status from those retained. Generalizability of the findings is limited by the urban setting; exclusion of some participants.
NCT00527293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2104|Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer|Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study||Case Comprehensive Cancer Center|Yes|Completed|June 2007|February 2015|Actual|October 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|29|||Female|18 Years|N/A|No|||August 2015|August 21, 2015|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527293||167352|
NCT00527306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-022-1|Prevention of Recurrent Aphthous Stomatitis Using Vitamins|Prevention of Recurrent Aphthous Stomatitis Using Vitamins||University of Connecticut Health Center|No|Completed|December 2005|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||March 2010|March 30, 2010|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00527306||167351|
NCT00527319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT-1 CAX-001|Regimen for the Treatment of Cachexia in Subjects With NSCLC|A Pilot Open Label Randomized Controlled Study to Evaluate the Dose Tolerance Safety and Efficacy of VT-122 Regimen for the Treatment of Cachexia in Subjects With Stage IV Non-Small Cell Lung Cancer|VT-122|Vicus Therapeutics|Yes|Completed|January 2007|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|37|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|August 30, 2007|No|Yes||No|November 8, 2012|https://clinicaltrials.gov/show/NCT00527319||167350|
NCT00527865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0082|Single Dose Escalating Study of DAS181 in Adults|Study 181-1-06-01 - Phase 1A Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalating Study in Healthy Adults||Ansun Biopharma, Inc.||Completed|October 2007|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 6, 2009|September 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00527865||167308|
NCT00494494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-3115|Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery|Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery||University of North Carolina, Chapel Hill|Yes|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|82|||Both|50 Years|N/A|No|||June 2011|June 13, 2011|June 28, 2007|Yes|Yes||No|April 11, 2011|https://clinicaltrials.gov/show/NCT00494494||169827|Although the peak incidence of CME is said to be at 4–12 weeks after surgery, we may have missed the time course for detecting the maximum increased OCT measured macular thickness.
NCT00495599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051215|Adipose Secretory Function in Patients Before & After Laparoscopic Surgery|Adipose Secretory Function in Patients Before & After Laparoscopic Surgery||Vanderbilt University|No|Active, not recruiting|March 2006|December 2009|Anticipated|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2008|February 7, 2008|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495599||169744|
NCT00495898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRDDE-001|A Study of Diabetic Patients With De Novo Native Coronary Artery Lesions|A German Multicenter, Randomized, Controlled, Open-Label Study of the Cypher Sirolimus-Eluting Stent in the Treatment of Diabetic Patients With De Novo Native Coronary Artery Lesions|SCORPIUS|Cordis Corporation|Yes|Completed|November 2002|November 2009|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||December 2009|December 2, 2009|July 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00495898||169722|
NCT00497302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014979|Recovery Housing For Drug Dependent Pregnant Women|Recovery Housing For Drug Dependent Pregnant Women|HOME|Johns Hopkins University|No|Completed|November 2004|August 2009|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Female|18 Years|50 Years|No|||March 2013|March 1, 2013|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497302||169617|
NCT00498147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECIDE|Determining Rates of Cardiovascular Complications Among Patients of a Managed Diabetes Care Program|Does Managed Diabetes Care Decrease Cardiovascular Complications of Diabetes?|DECIDE|Group Health Centre|No|Active, not recruiting|July 2007|July 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|1213|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory patients of the Group Health Centre who are over the age of 18 years with a        confirmed diagnosis of diabetes mellitus and who are enrolled in the Algoma Diabetes        Education and Care (ADEC) program. ADEC is a managed diabetes care program and part of the        Group Health Centre (GHC), a multi-specialty, interdisciplinary, ambulatory care facility        located in Sault Ste. Marie, a northern Ontario community. With diagnostic services and a        comprehensive electronic medical record, GHC provides health care to most of the        community's population of approximately 75,000.|October 2009|October 5, 2009|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00498147||169552|
NCT00506766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR007618-02|Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up|Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up||University of Michigan|No|Completed|September 2000|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|360|||Female|55 Years|80 Years|Accepts Healthy Volunteers|||July 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506766||168902|
NCT00506779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN03-0177|Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma|A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC)||M.D. Anderson Cancer Center|No|Completed|December 2003|||April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Female|N/A|N/A|No|||April 2015|April 13, 2015|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506779||168901|
NCT00507910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB2006542|The Development of Flat Foot After Ankle Fractures|Pes Planus After Weber B and C Ankle Fractures||Ottawa Hospital Research Institute|No|Completed|December 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|July 2011|July 19, 2011|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507910||168815|
NCT00503620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-784-06|The Effect of Botox on Children With Cerebral Palsy|The Effect of Botulinum Toxin on Neuromuscular Function in the Child With Cerebral Palsy||Shriners Hospitals for Children|No|Completed|January 2007|June 2009|Actual|||Phase 1/Phase 2|Observational|Time Perspective: Prospective||1|Actual|11|||Both|4 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with spastic hemiplegic or diplegic CP, GMFCS Level I or II|January 2009|July 21, 2010|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00503620||169139|
NCT00503646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-069|Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their Partners|Communication and Intimacy-Enhancing Intervention for Men Diagnosed With Early Stage Prostate Cancer and Their Partners: A Pilot and Feasibility Trial||National Cancer Institute (NCI)||Recruiting|May 2007|||May 2010|Anticipated|N/A|Interventional|Allocation: Randomized|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|September 16, 2013|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503646||169137|
NCT00503984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061143|A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients|A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen.||University of Miami|Yes|Completed|May 2007|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|120 Years|No|||December 2015|December 9, 2015|July 17, 2007|Yes|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT00503984||169111|
NCT00504010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MH-07-0202|The Role of Arnica on Muscle Pain Following Eccentric Exercise|The Role of Arnica on Muscle Pain Following Eccentric Exercise|Arnica|The University of Texas Health Science Center, Houston|No|Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 6, 2009|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00504010||169109|
NCT00531050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2217|Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol|A Double-blind, Randomized, Cross-over, Placebo-controlled, 2-part Study to Compare the Effect of Exercise and High-dose Salbutamol on Maximal Heart-rate in Patients With COPD Following Therapeutic Doses of Inhaled QAB149 and Salmeterol||Novartis|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|27|||Both|40 Years|75 Years|No|||April 2012|April 23, 2012|September 17, 2007||No||No|July 29, 2011|https://clinicaltrials.gov/show/NCT00531050||167066|
NCT00531336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK06-001839-18|MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen|Comparison of Combined Therapy of Intravitreal Injection of Avastin and Macugen Versus Mono-Therapy The MAAM Study - a Pilot Study||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|N/A|No|||October 2008|June 30, 2009|September 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00531336||167044|
NCT00527007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCR06012|External Cooling in Septic Shock Patients|Impact of External Cooling in Septic Shock Patients|sepsis-cool|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||August 2008|July 21, 2010|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00527007||167374|
NCT00527020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT1109727|First Time in Human Study With GSK1018921|See Detailed Description||GlaxoSmithKline|No|Completed|August 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527020||167373|
NCT00527033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-045|A Study of YM178 in Patients With Symptomatic Overactive Bladder|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder||Astellas Pharma Inc|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|842|||Both|20 Years|80 Years|No|||July 2013|July 15, 2013|September 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00527033||167372|
NCT00527579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070209|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FBR||National Institutes of Health Clinical Center (CC)||Completed|September 2007|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|65 Years|No|||November 2013|February 19, 2014|September 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00527579||167330|
NCT00527566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000012/1;BWH|Mepolizumab As a Steroid-Sparing Treatment Option in the Churg Strauss Syndrome|Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome|MATOCSS|Brigham and Women's Hospital|No|Active, not recruiting|September 2007|August 2009|Anticipated|August 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|N/A|No|||April 2009|April 16, 2009|September 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00527566||167331|
NCT00495079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS407|Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia|A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (Vincristine Sulfate Liposomes Injection) in Adult Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients With Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy||Spectrum Pharmaceuticals, Inc||Completed|May 2007|March 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|June 28, 2007|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00495079||169783|
NCT00506168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-01-024|Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer|Phase II Study of Irinotecan in Combination With Capecitabine in Previously Untreated Patients With Metastatic Colorectal Cancer||National Cancer Center, Korea|No|Terminated|November 2001|July 2007|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2007|July 23, 2007|July 23, 2007|||The study drugs are not covered anymore by insurance.|No||https://clinicaltrials.gov/show/NCT00506168||168948|
NCT00496535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-001.011|A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer|A Phase I/II Safety, Tolerability, and "Proof of Concept" Study of TNFerade™ Biologic in Combination With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) for Patients With Unresectable Recurrent Head and Neck Cancer||GenVec||Completed||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||May 2011|February 22, 2012|July 2, 2007||||||https://clinicaltrials.gov/show/NCT00496535||169676|
NCT00506753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA018851-02|Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail|Prison Study: Motivation and Skills for THC/ETOH+ Teens in Jail|SMART|University of Rhode Island|Yes|Completed|September 2004|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|205|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||June 2012|June 15, 2012|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506753||168903|
NCT00507013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 392-03|Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose|The QuickClose Study: Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose: a Prospective, Non-Randomized Clinical Study||CardioDex|No|Completed|July 2007|September 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|8|||Both|18 Years|N/A|No|||April 2008|April 22, 2008|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00507013||168883|
NCT00507026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-005|Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery|Randomized, Double-Blind, Active-and Placebo-Controlled Study of the Analgesic Efficacy and Safety of Repeated Dosing of DIC075V Versus Parenteral Ketorolac and Placebo in Acute Post-Operative Pain After Elective Orthopedic Surgery||Javelin Pharmaceuticals|No|Completed|July 2007|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|277|||Both|18 Years|85 Years|No|||January 2009|February 11, 2009|July 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507026||168882|
NCT00507637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0703/1|Blepharospasm Short Interval|Prospective, Open-label, Single-arm, Single-center Trial to Investigate the Tolerability of NT 201 and Quality of Life of Patients in the Treatment of Blepharospasm With Shortened Injection Intervals||Merz Pharmaceuticals GmbH|No|Terminated|August 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||February 2012|February 3, 2012|July 25, 2007||No|primary efficacy endpoint not attainable.|No||https://clinicaltrials.gov/show/NCT00507637||168836|
NCT00507650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR0008241|Increasing Fluids in Older Adults to Prevent & Treat Pressure Ulcers|Supplement Fluid & Collagen Deposition||University of California, San Francisco|Yes|Completed|September 2003|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|63|||Both|60 Years|N/A|No|||March 2015|March 5, 2015|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00507650||168835|
NCT00507923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0035|Effects of Tibetan Yoga on Fatigue and Sleep in Cancer|Effects of Tibetan Yoga on Fatigue and Sleep in Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2006|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|480|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507923||168814|
NCT00507936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-850|Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain|A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain||AbbVie|No|Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|280|||Both|18 Years|75 Years|No|||January 2013|January 15, 2013|July 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507936||168813|
NCT00503672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5343|Assessment of Activity in Pregnancy Using an Actigraph|Assessment of Activity in Pregnancy Using an Actigraph||University of California, Irvine|No|Completed|January 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant Women|October 2012|October 18, 2012|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00503672||169135|
NCT00503971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARZO|Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.|Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment||Spanish Lung Cancer Group|No|Terminated|December 2007|December 2011|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2008|October 19, 2012|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00503971||169112|
NCT00504270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS20454|A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.|A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis||Hoffmann-La Roche||Completed|July 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|July 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00504270||169089|
NCT00504283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS 20569|An Analgesia Protocol for Acute Renal Colic in the Emergency Department|An Analgesia Protocol for Acute Renal Colic in the DHMC Emergency Department||Dartmouth-Hitchcock Medical Center|Yes|Completed|February 2007|October 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|65 Years|No|||October 2007|October 17, 2007|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00504283||169088|
NCT00531063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2306E1|This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus|A 2-year Extension to a 1-year Multicenter, Randomized, Open Label, Parallel Group Study of the Safety, Tolerability and Efficacy of Two Doses (1.5 and 3 mg/Day) of Everolimus With Steroids and Optimized Administration of Cyclosporine in de Novo Renal Transplant Recipients.||Novartis||Completed|November 2001|||August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|237|||Both|18 Years|65 Years||||November 2011|November 1, 2011|September 17, 2007||||No||https://clinicaltrials.gov/show/NCT00531063||167065|
NCT00531076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC 2006/194|Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer|Phase I Study of Concurrent Bevacizumab (Avastin) With Involved-field Thoracic Radiotherapy for Inoperable Non-squamous Non-small Cell Lung Cancer, Followed by Both Concurrent and Maintenance Bevacizumab||VU University Medical Center|No|Terminated|October 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||January 2011|April 4, 2011|September 17, 2007||No|Study terminated due to toxicity|No||https://clinicaltrials.gov/show/NCT00531076||167064|
NCT00531089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAG-1|Rituximab in Patients With Relapsed or Refractory TTP-HUS|A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed/Refractory Thrombotic Thrombocytopenic Purpura (TTP) - Hemolytic Uremic Syndrome (HUS)||McMaster University|Yes|Recruiting|December 2007|January 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2007|May 18, 2010|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531089||167063|
NCT00526734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA-2006-001|High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma|A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM)||National Cancer Institute (NCI)||Recruiting|February 2006|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|70 Years|No|||September 2007|August 9, 2013|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526734||167394|
NCT00526747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008469|Erythropoietin Resistance in Anemia of Chronic Kidney Disease|Novel Biomarkers of Erythropoietin Resistant Anemia Among Patients With Chronic Kidney Disease||Duke University|Yes|Completed|August 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|N/A||2|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|CKD anemia clinic patients|November 2008|April 9, 2013|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526747||167393|
NCT00527046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A257-102|Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults|A Randomized, Double Blind, Placebo Controlled, Five Parallel Group Study Of The Effect Of CP-424,391 On Physical Performance And Body Composition In Older Subjects||Pfizer||Terminated|December 1999|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|396|||Both|65 Years|84 Years|No|||January 2012|January 30, 2012|September 6, 2007||||||https://clinicaltrials.gov/show/NCT00527046||167371|
NCT00527345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12657-CP-001|Children's Exposures/Health Effects/Diesel Exhaust|Children's Exposure and Health Effects From Diesel Exhaust Before and After Switch of Schoool Bus Fleets||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|March 2005|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|450|||Both|6 Years|11 Years|No|||April 2015|April 13, 2015|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00527345||167348|
NCT00527917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR07001|A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.|A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Efficacy and Safety of Uracyst® (Intravesical Sodium Chondroitin Sulfate) Versus Vehicle Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.||Watson Pharmaceuticals|No|Completed|September 2007|September 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||December 2009|December 7, 2009|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527917||167304|
NCT00528203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|517|Establishing a Repository of Blood and DNA Samples From People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Genotype-Phenotype Database and Sample Repository)|Comprehensive Sickle Cell Centers (CSCC) Collaborative Genotype-Phenotype Database and Sample Repository|Gen/Phen|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|August 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3640|Samples With DNA|Plasma, Lymphocytes, Whole blood, RBC hemolysate, DNA|Both|N/A|N/A|No|Non-Probability Sample|All adult and pediatric patients who are enrolled in the C-Data project are eligible for        this study. (C-Data eligibility: All adult and pediatric patients who have been seen        within the last 24 months in the hospital or clinical setting and are expected to return        episodically or regularly for care at 1 of the CSCC are eligible for inclusion in the        C-Data project.)|November 2008|November 6, 2008|September 10, 2007||No|Funds for study ended September 30, 2008.|No||https://clinicaltrials.gov/show/NCT00528203||167282|
NCT00527891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1051|Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions|Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions||M.D. Anderson Cancer Center|No|Completed|June 2004|||September 2007|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|N/A|N/A|No|Non-Probability Sample|Patients scheduled and are eligible for an MRI of the abdomen or MRI of the liver or MRI        of the kidney examination at UT MD Anderson Cancer Center.|July 2012|July 30, 2012|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00527891||167306|
NCT00505908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052007-034|Non-Interventional F-Two Isoprostane Trial (NIFTI)|Non-Interventional F-Two Isoprostane Trial|NIFTI|University of Texas Southwestern Medical Center|No|Recruiting|July 2007|December 2013|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|50 Years|No|Non-Probability Sample|Patients who meet inclusion criteria and have experienced a trauamtic head injury.|February 2011|February 17, 2011|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00505908||168968|
NCT00505648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/077/HP|Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)|Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline®|DRESS2|University Hospital, Rouen|No|Terminated|January 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|80 Years|No|||March 2015|March 23, 2015|July 20, 2007|No|Yes|Side effects valuation|No||https://clinicaltrials.gov/show/NCT00505648||168987|
NCT00506441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-A05|A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia||Mitsubishi Tanabe Pharma Corporation|No|Completed|September 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|July 24, 2007|Yes|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT00506441||168927|
NCT00506454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201|Lipid Infusion in Dialysis Patients With Endotoxemia|A Phase II, Double-Blind, Placebo-Controlled, Randomized Study of the Effects of a Lipid Emulsion (Lipidose) on Endotoxin Levels in Patients on Chronic Hemodialysis|LIPIDOSE|Sepsicure|Yes|Completed|August 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|July 23, 2007|Yes|Yes||No|June 10, 2011|https://clinicaltrials.gov/show/NCT00506454||168926|There was no significant difference between endotoxin activity assay values in the active versus placebo recipients in this study.
NCT00506181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|probiotics-HMO-CTIL|Probiotics: is it Really That Good? Cost-Effectiveness of Treating the in-Patient|Phase 3 Study of Probiotics, to Provide a Legitimate Reason for the Administration of Probiotic Therapy in the Hospitalized Patient, Particularly in Patients on Antibiotic Therapy||Hadassah Medical Organization|No|Not yet recruiting|July 2007|July 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|N/A|No|||July 2007|July 23, 2007|July 22, 2007||||No||https://clinicaltrials.gov/show/NCT00506181||168947|
NCT00506467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0668|Vibration Response Imaging (VRI) in Lung Cancer Patients|Vibration Response Imaging (VRI) in Patients Who Are Candidates for Undergoing Surgical Resection Due to Lung Cancer or Other Intrathoracic Malignancy||M.D. Anderson Cancer Center|No|Completed|November 2006|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients diagnosed with lung cancer or other intrathoracic malignancy.|July 2012|July 31, 2012|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00506467||168925|
NCT00507663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 00-0100|Elder Surgery - Functional Recovery Following Beta Blockade|Elder Surgery - Functional Recovery Following Beta Blockade||Icahn School of Medicine at Mount Sinai|Yes|Completed|September 2002|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|359|||Both|65 Years|N/A|No|||March 2016|March 14, 2016|July 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507663||168834|
NCT00507949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO-EC-EPOC-01|Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight|Randomized Trial,Comparative With Placebo, Double Blind, to Evaluate the Effect of the Treatment With 320 mg/d of Megestrol Acetate in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) and Loss of Body Weight. Pilot Study||Rottapharm Spain|No|Completed|October 2006|September 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|No|||June 2011|June 7, 2011|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00507949||168812|
NCT00503698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1630-1453|The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis|Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis|OPPORTUNITY|Novo Nordisk A/S|Yes|Terminated|July 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|712|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|July 18, 2007|Yes|Yes|See termination reason in detailed description|No|December 15, 2009|https://clinicaltrials.gov/show/NCT00503698||169133|Trial terminated early due to slow recruitment, which largely reduced the power of showing differences. The end of trial visit was used to describe week 104.
NCT00503997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0582|Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer|Phase II Trial: Efficacy and Toxicity of Induction Pemetrexed (ALIMTA) and Oxaliplatin (ELOXATIN) in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma||Vanderbilt-Ingram Cancer Center|Yes|Completed|December 2006|June 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|July 17, 2007|Yes|Yes||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00503997||169110|The two cohorts of pemetrexed and oxaliplatin patients represented similar populations, thus the response data were combined.
NCT00505219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI 55-0705-1|Bone Repair Cell (BRC) Treatment of Patients With Osteonecrosis of the Femoral Head|Multi-center Clinical Trial of the Application of Tissue Repair Cell (TRC) Therapy of Osteonecrosis of the Femoral Head|ON-CORE|Vericel Corporation|No|Completed|September 2007|December 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|75 Years|No|||January 2013|January 8, 2013|July 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505219||169020|
NCT00530751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1Z07|Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation|Patient Perspectives on Sharing Family Medical Histories||Case Comprehensive Cancer Center|No|Withdrawn|March 2007|||October 2008|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care center|October 2015|October 1, 2015|September 13, 2007||No|PI left|No||https://clinicaltrials.gov/show/NCT00530751||167088|
NCT00530764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA0701|A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.|A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.|SPRAY|GW Pharmaceuticals Ltd.|Yes|Completed|November 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|360|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|September 13, 2007|Yes|Yes||No|March 2, 2011|https://clinicaltrials.gov/show/NCT00530764||167087|
NCT00526760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-402|Long-term Clinical Study Evaluating the Safety and Efficacy of Dexmedetomidine in ICU Subjects|A Phase 3, Open-Label Study Evaluating the Safety and Efficacy of Dexmedetomidine in ICU Subjects Requiring Greater Than 24 Hours of Continuous Sedation||Hospira, Inc.|No|Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|20 Years|N/A|No|||June 2015|June 29, 2015|September 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00526760||167392|
NCT00527332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr 2006-002520-41|Effects of General Anesthesia and Spinal-Morphine Anesthesia on Recovery and Comfort After Benign Abdominal Hysterectomy|General Anesthesia Versus Spinal Anesthesia Combined With Intrathecal Morphine in Abdominal Hysterectomy for Benign Gynecological Diseases. A Randomized Open Controlled Study.||University Hospital, Linkoeping|Yes|Completed|March 2007|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|180|||Female|18 Years|60 Years|No|||January 2012|January 24, 2012|September 7, 2007||No||No|November 14, 2011|https://clinicaltrials.gov/show/NCT00527332||167349|
NCT00527605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI108898|Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)|A Randomized, Double-blind, Placebo-controlled, Six-month Parallel-group Study to Assess Efficacy and Safety of Dutasteride 0.5mg Once Daily in Chinese Patients With Benign Prostatic Hyperplasia (BPH), Followed by a 12-month Open-label Treatment Phase||GlaxoSmithKline|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Male|50 Years|N/A|No|||May 2011|March 15, 2012|September 10, 2007||No||No|February 22, 2010|https://clinicaltrials.gov/show/NCT00527605||167328|
NCT00529646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD791-001|Single-Dose Safety Study of APD791 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability, Pharmacokinetics, and Pharmacodynamics of APD791 Administered to Healthy Adult Subjects||Arena Pharmaceuticals|No|Completed|July 2007|||||Phase 1|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|||Anticipated|90|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||December 2008|December 29, 2008|September 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529646||167171|
NCT00529659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0773-005|A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)|A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients With Sarcopenia||Merck Sharp & Dohme Corp.||Completed|October 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|170|||Female|65 Years|N/A|No|||January 2015|January 29, 2015|September 11, 2007|Yes|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT00529659||167170|
NCT00529945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA0012|PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness|The Paradigm IV Trial - PFx Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness|Paradigm IV|Cierra|No|Suspended|August 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||December 2007|December 18, 2007|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00529945||167148|
NCT00530205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5506|Effects of Radiation Therapy on the Body in Patients With Stage III Non-Small Cell Lung Cancer|An Observation of the Change in Percent Lean Body Mass of Stage III Non-Small Cell Lung Cancer Undergoing Radiation Treatment||Case Comprehensive Cancer Center|No|Withdrawn|February 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|50 Years|75 Years|No|Probability Sample|Primary care center|July 2011|July 13, 2011|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530205||167128|
NCT00528463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|edm1|Pre-emptive Sciatic Bloc to Prevent Lower Limb Phantom Pain|a Prospective Case Series of Pre-emptive Pre-amputation Sciatic Nerve Block to Prevent Lower Limb Phantom Pain||Université de Sherbrooke|No|Completed|January 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Both|N/A|N/A|No|||September 2007|February 1, 2010|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528463||167262|
NCT00528736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/198/05|Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks|||Charite University, Berlin, Germany|No|Completed|August 2005|April 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|82|||Both|N/A|48 Hours|No|||September 2007|September 12, 2007|September 10, 2007||||No||https://clinicaltrials.gov/show/NCT00528736||167241|
NCT00505336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVUH 042|The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure|The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure||St Vincent's University Hospital, Ireland|No|Completed|April 2006|December 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Both|N/A|N/A|No|||February 2009|February 10, 2009|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505336||169011|
NCT00505635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM03-0218|Biochemotherapy With Temozolomide for Metastatic Melanoma|Biochemotherapy With Temozolomide, Velban, Cisplatin, Interleukin-2, Interferon-alpha and Thalidomide for Metastatic Melanoma With Optional Intrathecal Interleukin-2 Treatment||M.D. Anderson Cancer Center|No|Terminated|March 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||March 2012|March 26, 2012|July 20, 2007||No|Slow accrual|No|March 26, 2012|https://clinicaltrials.gov/show/NCT00505635||168988|
NCT00506194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH 94-09-09|Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control|Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control Is Associated With Improvement of ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients||Taipei Veterans General Hospital, Taiwan|Yes|Completed|October 2005|December 2011|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|80 Years|No|||September 2013|September 30, 2013|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00506194||168946|
NCT00505921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-645|Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma|Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52||M.D. Anderson Cancer Center|No|Terminated|March 2003|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|27|||Both|N/A|70 Years|No|||November 2011|November 8, 2011|July 20, 2007||No|Slow Accrual.|No|September 30, 2011|https://clinicaltrials.gov/show/NCT00505921||168967|Early termination due to slow accrual.
NCT00506805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1311001|Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies|A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma||Esanex Inc.|No|Completed|June 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||May 2012|May 25, 2012|July 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00506805||168899|
NCT00507065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLI381-314A|Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)|A Phase III, Randomized, Multicenter, Double-blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of ADDERALL XR With an Open Label Extension, in the Treatment of Adolescents Aged 13-17 With ADHD||Shire|No|Completed|May 2003|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|329|||Both|13 Years|17 Years|No|||November 2007|March 4, 2015|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00507065||168879|
NCT00507078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522315-38198|Biomarkers in Obstructive Sleep Apnea Surgery|Biomarkers in Obstructive Sleep Apnea Surgery||University of California, San Francisco|No|Completed|June 2005|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|N/A|N/A|No|||May 2012|May 18, 2012|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00507078||168878|
NCT00507351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0841|Ambulatory Cancer Pain Management: A Feasibility Study|Ambulatory Cancer Pain Management: A Feasibility Study||M.D. Anderson Cancer Center|No|Completed|July 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.|July 2012|July 31, 2012|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507351||168857|
NCT00507364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qwerty-HMO-CTIL|Treatment of Anal Fissure by Activated Human Macrophages|Treatment of Anal Fissure by Activated Human Macrophages||Hadassah Medical Organization||Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|75 Years||||July 2007|July 25, 2007|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00507364||168856|
NCT00507377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61657|Foreshortened Esophagus and Its Surgical Therapy|Frequency, Predictors, Intraoperative Assessment and Outcome of Foreshortened Esophagus and Its Surgical Therapy in Patients Treated for Gastro-Esophageal Reflux Disease (GERD)|GERDSurgery|University of Bologna|Yes|Active, not recruiting|September 2005|July 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|180|||Both|18 Years|N/A|No|||July 2007|July 25, 2007|July 25, 2007||||No||https://clinicaltrials.gov/show/NCT00507377||168855|
NCT00507676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9909-30|Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing|Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing||Indiana University|Yes|Completed|October 2000|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|220|Samples Without DNA|We collect hair samples to analyzed for nicotine and cotinine.|Both|2 Months|2 Years|No|Non-Probability Sample|We are recruiting infants with asthma and wheezing from pulmonary outpatient clinics at        Riley Hospital for children. The full term healthy infants were recruited by        advertisements in the local Indy's Child Magazine. These children were volunteers from        Indianapolis and surrounding counties.|January 2011|March 29, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507676||168833|
NCT00507962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0568|Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement|A Phase I Study Dose Escalation Clinical Study Of Hepatic Intraarterial Cisplatin, In Combination With Systemic Intravenous Liposomal Doxorubicin Administered Every Four Weeks to Patients With Advanced Cancer And Dominant Liver Involvement||M.D. Anderson Cancer Center|No|Completed|March 2005|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|N/A|N/A|No|||August 2012|August 1, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507962||168811|
NCT00503659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|335/06/FFM|Comparison of Two Methods of Bronchial Methacholine Provocation|Comparison of Two Methods of Bronchial Methacholine Provocation: PC 20 FEV1 Versus PD 20 FEV1||Johann Wolfgang Goethe University Hospitals|Yes|Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|48|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00503659||169136|
NCT00504023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-029|Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva|A Pilot Study of Topical Imiquimod Therapy for the Treatment of Recurrent Extramammary Paget's Disease||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2007|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||March 2015|March 24, 2015|July 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00504023||169108|
NCT00504881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01254|Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy|An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.||UCB Pharma|No|Completed|October 2007|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|480|||Both|16 Years|70 Years|No|||April 2015|April 29, 2015|July 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00504881||169044|
NCT00531102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT733739|Effect of Establishing Functional Residual Capacity During Newborn Resuscitation on Oxygenation|Effects of Oxygen and Functional Residual Capacity on the Oxygen Saturations of Infants ≥ 35 Weeks Gestation During Delivery Room Resuscitation.||University of Calgary|No|Recruiting|February 2008|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|N/A|1 Minute|No|||May 2008|May 27, 2008|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531102||167062|
NCT00527358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-4924|Evaluation of SAFER Latinos' Program to Prevent Youth Violence|Evaluation of SAFER Latinos' Program to Prevent Youth Violence||Centers for Disease Control and Prevention|No|Completed|September 2006|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1400|||Both|12 Years|24 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00527358||167347|
NCT00527592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-07-01|A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research|No|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||May 2012|May 11, 2012|September 10, 2007|Yes|Yes||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00527592||167329|None specified.
NCT00527904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-304|A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)|A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 in Subjects Who Are at Risk for Developing NSAID-associated Ulcers||POZEN|Yes|Completed|March 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|239|||Both|18 Years|N/A|No|||August 2010|August 27, 2010|September 10, 2007|Yes|Yes||No|May 28, 2010|https://clinicaltrials.gov/show/NCT00527904||167305|
NCT00528762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0113|Mexican and African American Family Focus Groups on Puberty|Mexican and African American Family Focus Groups on Puberty||M.D. Anderson Cancer Center|No|Completed|November 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|37|||Female|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants are females aged 6-12 years old that are of Mexican American or African        American descent and their parents.|July 2012|July 26, 2012|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528762||167239|
NCT00497874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44MH060522|An Expert System to Reduce Depression in Primary Care|An Expert System to Reduce Depression in Primary Care||Pro-Change Behavior Systems|No|Completed|July 2003|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|902|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|July 5, 2007||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00497874||169573|There was only a single follow up assessment administered at 9 months post-baseline.The study attrition rate was > 30%.
NCT00530452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG100649-2-01|Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects|Double-Blind, Placebo Controlled Phase II Repeat Dose Study of the Safety and Efficacy of Three Parallel Loading and Maintenance Dose Regimens of CG100649 Versus Placebo for the Treatment of Primary Osteoarthritis in Male Subjects||CrystalGenomics, Inc.|No|Recruiting|October 2007|September 2008|Anticipated|September 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Male|18 Years|75 Years|No|||June 2008|June 12, 2008|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530452||167109|
NCT00530478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-04-023|Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment|||Samsung Medical Center|Yes|Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|16 Years|80 Years||||July 2007|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530478||167108|
NCT00505934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01275|Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy|Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy||UCB Pharma|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|1 Month|4 Years|No|||June 2015|June 22, 2015|July 20, 2007|Yes|Yes||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00505934||168966|
NCT00506493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURE-AF/Persistent|Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent|Medtronic Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF)/Persistent Study|CURE-AF/Perst|Medtronic Cardiovascular|Yes|Completed|September 2007|October 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|July 22, 2007|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00506493||168923|Slow/delayed enrollmentMedical management of subjects by non-investigators leading to medication washout protocol deviationsMissing endpoint data (attrition) due to cohort demographics (old age, dementia, relocation, etc.)
NCT00506480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|319-08.07|Assessment of Endometrial Receptivity in Recipients of Donated Oocytes|Phase 1 Study of Endometrial Markers of Endometrial Receptivity in Oocyte Donation|ERPOD|Hadassah Medical Organization|No|Not yet recruiting|August 2007|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Female|18 Years|51 Years|No|||July 2007|February 4, 2010|July 22, 2007||||No||https://clinicaltrials.gov/show/NCT00506480||168924|
NCT00506792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAU145A2201|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis|A Two-part, Randomized, Double-blind, Placebo-controlled, Ascending Single-dose, Adaptive Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAU145 Administered Via a Nasal Spray Pump to Patients With Cystic Fibrosis||Novartis|No|Completed|July 2007|November 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|50 Years|No|||May 2012|May 2, 2012|July 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506792||168900|
NCT00507104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pitfunction_TBI_SAH|Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)|Prospective Longitudinal Study on Pituitary Functions After TBI and/or SAH||University of Erlangen-Nürnberg Medical School|No|Recruiting|September 2006|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|100|||Both|15 Years|N/A|No|||July 2007|September 27, 2007|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00507104||168876|
NCT00507117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC05-17017|Ezopiclone Improves the Quality of Overnight Polysomnography|Prospective, Randomized, Placebo Controlled Trial Assessing the Effects of Ezopiclone on the Quality of Overnight Polysomnography and CPAP Titration||Walter Reed Army Medical Center|Yes|Completed|March 2007|October 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2007|November 29, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00507117||168875|
NCT00507130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP131|A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled,Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple-Dose Subcutaneous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody,When Administered to Adults With Mild Persistent Asthma||MedImmune LLC|No|Completed|July 2007|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|65 Years|No|||October 2013|October 17, 2013|July 23, 2007|Yes|Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00507130||168874|
NCT00507390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200306ver2|Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia|The Effect of Omega-3 Polyunsaturated Fatty Acid Supplements on Microvolt T Wave Alternans in Patients With Ventricular Arrhythmia||University of Dundee|Yes|Completed|January 2007|August 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|45|||Both|21 Years|80 Years|No|||February 2009|February 26, 2009|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507390||168854|
NCT00507689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-203-0107|Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant|A Phase 2, Open-Label Randomized Study to Evaluate the Efficacy and Safety of the Combination Product, Emtricitabine/Tenofovir Disoproxil Fumarate in the Presence or Absence of Hepatitis B Immunoglobulin (HBIg) in Preventing Recurrence of Chronic Hepatitis B (CHB) Post-Orthotopic Liver Transplant (OLT)||Gilead Sciences|No|Completed|September 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|75 Years|No|||February 2014|February 12, 2014|July 25, 2007|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT00507689||168832|
NCT00507975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060604|Study of Nicotine Patch in Pregnancy (SNIPP)|Assessment of the Effectiveness of Nicotine Replacement Therapies (Nicotine Patches Delivering Nicotine 16 h/24 h) in 400 Pregnant Smokers. Randomized, Placebo-controlled, Multicenter, National Study. The SNIPP.|SNIPP|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2007|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|404|||Female|18 Years|50 Years|No|||July 2007|December 12, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507975||168810|
NCT00503685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13936|Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy|A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy||ImClone LLC|No|Completed|June 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|N/A|No|||October 2011|October 12, 2011|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503685||169134|
NCT00504894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701008933|Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes|Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes|Amygdala|Weill Medical College of Cornell University|No|Active, not recruiting|March 2007|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|January 28, 2015|July 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00504894||169043|
NCT00504582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS01-565|Fibrin Melanoma Axillary Node Study in Patients With Melanoma|A Randomized Trial Evaluating the Use of Fibrin Tissue Adhesive Following Axillary Node Dissection in Patients With Melanoma||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2002|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504582||169066|
NCT00504595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2207|Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis|A 12-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR20) and to Determine a Biomarker Profile in Adult Patients With Established Rheumatoid Arthritis Responding to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) as Compared to Healthy Subjects Exposed to ACZ885||Novartis|No|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2012|August 2, 2012|July 19, 2007|Yes|Yes||No|January 20, 2011|https://clinicaltrials.gov/show/NCT00504595||169065|
NCT00504608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24070|A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure|A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure||Merck KGaA||Completed|April 2003|April 2004|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|150|||Female|21 Years|37 Years||||May 2014|May 22, 2014|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00504608||169064|
NCT00504907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA9881-01|Safety Study of Oral BTA9881 to Treat RSV Infection|A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects||Biota Scientific Management Pty Ltd|Yes|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|63|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504907||169042|
NCT00527059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEV1068|Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure|Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure||University of Roma La Sapienza|No|Not yet recruiting|October 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|N/A|N/A|No|||September 2007|September 7, 2007|September 7, 2007||||No||https://clinicaltrials.gov/show/NCT00527059||167370|
NCT00528476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-68|Risk Factors for Recurrent Urinary Tract Infection in Children|Role of Clinical and Urodynamic Risk Factors for Recurrent Urinary Tract Infection in 5-18 Years Old Children||Kaunas University of Medicine|No|Completed|November 2004|January 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||2|Actual|161|||Both|5 Years|18 Years|No|||September 2007|September 11, 2007|September 10, 2007||||No||https://clinicaltrials.gov/show/NCT00528476||167261|
NCT00529308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5480|Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome|Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome|TMS|Yale University|No|Completed|July 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||August 2015|August 13, 2015|September 13, 2007|Yes|Yes||No|November 13, 2012|https://clinicaltrials.gov/show/NCT00529308||167197|
NCT00529048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INK-GLUKOSE1|Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes|Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes Using Increasing Amounts of Oral Glucose Challenges||Herlev Hospital|No|Completed|October 2007|September 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|16|Samples With DNA|p-Glucose p-Glucagon p-insulin p-c-pep. p-GLP-1 p-GIP Buffy coat s-paracetamol|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Patients (Cases) will be recruted from the diabetes clinic at Depatment of        Endocrinology at Herlev Hospital        The control subjects will be recruted through the lokal papers, and individualy matched by        age, sex and BMI to a patient befor enrollment.|October 2009|October 19, 2009|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00529048||167217|
NCT00529061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401|Establishing a Database of People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Data Project [C-Data])|Comprehensive Sickle Cell Centers Collaborative Data Project (C-Data)|C-Data|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|March 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|3640|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All adult and pediatric patients who have been seen within the last 24 months in the        hospital or clinical setting, and are expected to return episodically or regularly for        care at one of the CSCCs, are eligible for inclusion in the C-Data project.|November 2008|November 6, 2008|September 12, 2007||No|Funds for study ended September 30, 2008.|No||https://clinicaltrials.gov/show/NCT00529061||167216|
NCT00497588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bs-86-01-48-5497|the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy|||Tehran University of Medical Sciences|Yes|Recruiting|March 2007|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|33|||Both|N/A|N/A|No|||July 2013|July 10, 2013|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497588||169595|
NCT00497887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|276-2005|Genetic- and Biological-Markers of Predisposition to Atherosclerosis: Leipzig-Heart Study|Observational Study for Identification of Genetic- and Biological-Markers of Predisposition to Atherosclerosis: Leipzig-Heart Study (LE-Heart)|LE-Heart|University of Leipzig|No|Recruiting|December 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|serum, plasma, whole blood (DNA), blood cells|Both|18 Years|85 Years|No|Non-Probability Sample|Patients assigned to coronary angiography|January 2010|October 18, 2010|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00497887||169572|
NCT00498186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0710|Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)|An Open-label Extension Trial to Determine Safety and Tolerability of Long-term Transdermal Application of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome||UCB Pharma|No|Completed|July 2003|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|295|||Both|18 Years|75 Years|No|||October 2011|September 24, 2014|July 6, 2007|Yes|Yes||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00498186||169549|
NCT00506207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-166|A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy|A Phase I and Pharmacokinetic Study of S-1 Combined With Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy|TIROX|National Cancer Center, Korea|No|Active, not recruiting|September 2006|December 2009|Anticipated|||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506207||168945|
NCT00506220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2007|||||N/A|N/A|N/A||||||||||||||July 14, 2009|July 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506220||168944|
NCT00505986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-JB-0507-607-29|Genomic Endometrial Expression in Obesity|||Instituto Valenciano de Infertilidad, IVI VALENCIA||Completed|June 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00505986||168962|
NCT00506233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0541|Feasibility Study of Collecting Multicenter Chronic GVHD Data|Feasibility Study of Collecting Multicenter Chronic GVHD Data||M.D. Anderson Cancer Center|No|Completed|August 2006|||September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|2 Years|N/A|No|Non-Probability Sample|Participants with chronic graft-versus host disease (GvHD) at UT MD Anderson Cancer        Center.|July 2012|July 30, 2012|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506233||168943|
NCT00506818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2006.2076(REK)|Cognitive and Emotional Impairment After Stroke|Cognitive and Emotional Impairment After Stroke||Sykehuset Asker og Baerum|No|Completed|February 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|1||Anticipated|250|||Both|N/A|N/A||||September 2009|September 18, 2009|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506818||168898|
NCT00507091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00038|Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination|A Phase I Open Label Study to Asses the Safety and Tolerability of ZD6474 (Vandetanib)in Combination With Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as First or Second Line Therapy in Patients With Metastatic Colorectal Adenocarcinoma.||AstraZeneca||Completed|August 2005|June 2008|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507091||168877|
NCT00506831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9598|Imatinib in Systemic Sclerosis|A Pilot Study of Imatinib in the Treatment of Refractory Systemic Sclerosis||Stanford University||Completed|July 2007|||September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||July 2012|July 10, 2012|July 24, 2007|No|Yes||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00506831||168897|Open label, uncontrolled study. Small study population at a single center.
NCT00507143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-206|Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan|A Clinical Study for the Evaluation of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on the Pharmacokinetics and Treatment Effects of Irinotecan in Patients With Colorectal and Gastric Cancer||National Cancer Center, Korea|No|Recruiting|August 2006|December 2008|Anticipated|||N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00507143||168873|
NCT00507403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRR/04/PG-SPAXIM|Infliximab and Methotrexate in Ankylosing Spondylitis|Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis|SPAXIM|University Hospital, Tours|Yes|Completed|October 2007|December 2009||October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|65 Years|No|||February 2010|February 2, 2010|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00507403||168853|
NCT00507416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05009|Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone|Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone|UPFRONT|Millennium Pharmaceuticals, Inc.||Completed|June 2007|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|502|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|July 25, 2007|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00507416||168852|
NCT00507429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC4T4-302|Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer|A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT]|FACT|OXiGENE|Yes|Terminated|August 2007|November 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2014|May 12, 2014|July 25, 2007|Yes|Yes|Low rate of subject accrual|No|August 16, 2013|https://clinicaltrials.gov/show/NCT00507429||168851|The study was to enroll 180 subjects. Enrollment was terminated early due to low accrual rate. Eighty subjects were enrolled.
NCT00507988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GW0630|Complex Problem Solving Training in Schizophrenic Patients|Complex Problem Solving Training in Schizophrenic Patients||Heidelberg University|Yes|Completed|August 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|45 Years|No|||May 2009|May 14, 2009|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507988||168809|
NCT00508001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00072|Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)|A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg, and BSC Plus Placebo in Patients With Inoperable Hepatocellular Carcinoma (HCC)||AstraZeneca|No|Completed|July 2007|June 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|July 25, 2007|Yes|Yes||No|May 9, 2011|https://clinicaltrials.gov/show/NCT00508001||168808|
NCT00503711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200L00004|Phase I Chinese PK|An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor||AstraZeneca||Completed|September 2006|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|July 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503711||169132|
NCT00503724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000557572|Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors|Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors||Pediatric Brain Tumor Consortium|Yes|Completed|June 2007|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|21 Years|No|||March 2012|March 2, 2012|July 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00503724||169131|
NCT00503737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25737|Pilot Study of the National Colorectal Cancer Roundtable Toolbox (NCCRT) to Increase Colorectal Cancer Screening Rates|||Penn State University|Yes|Not yet recruiting|September 2007|September 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|15|||Both|30 Years|N/A|Accepts Healthy Volunteers|||July 2007|November 2, 2007|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503737||169130|
NCT00495261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311/2006|Development and Validation of a Mindfulness Intervention for Problem Gambling: An Exploratory Study|Development and Validation of a Mindfulness Intervention for Problem Gambling: An Exploratory Study||Centre for Addiction and Mental Health|No|Completed|February 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00495261||169769|
NCT00495274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXS105205|Bioequivalence and Food Effect Study in Healthy Volunteers|See Detailed Description||GlaxoSmithKline|No|Completed|July 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00495274||169768|
NCT00495560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26135|A Pilot Study of Priming Before Induction Termination of Pregnancy|A Pilot Study of Priming Before Induction Termination of Pregnancy||Boston University|No|Completed|January 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 3, 2008|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00495560||169747|
NCT00528216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C201|Study of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function|A Randomized, Controlled, Single-Blind Study to Investigate the Effect of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function In Healthy Volunteers||NeurogesX||Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2008|March 4, 2008|September 10, 2007||||||https://clinicaltrials.gov/show/NCT00528216||167281|
NCT00528229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 313267|Multi-Slice CT of the Chest( MSCT Findings After Lung Transplantation)|||Rigshospitalet, Denmark|Yes|Recruiting|September 2007|||||N/A|Observational|Time Perspective: Longitudinal|||||||Both|18 Years|N/A||||June 2007|September 11, 2007|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528229||167280|
NCT00528775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000563948|Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages|A Phase II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Advanced Obstructing Endobronchial Lung Cancer||Roswell Park Cancer Institute|Yes|Terminated|August 2007|March 2014|Actual|November 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|September 10, 2007|Yes|Yes|drug cannot be prepared commercially|No|May 9, 2014|https://clinicaltrials.gov/show/NCT00528775||167238|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.
NCT00497341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTR2007|Antibiotic Prophylaxis in Total Knee Prosthesis|Randomised And Double Blind Study To Evaluate The Best Moment To Infuse The Prophylactic Antibiotic In Knee Arthroplasty Performed Under Ischemia||Hospital Clinic of Barcelona|No|Completed|January 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1332|||Both|18 Years|90 Years|No|||February 2016|February 17, 2016|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497341||169614|
NCT00497601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSV-AMBE II-KA-706|A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar|A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar).||Banaras Hindu University|No|Completed|February 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||September 2008|September 11, 2008|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497601||169594|
NCT00498836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-203|Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma|A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma||Clavis Pharma|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|July 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00498836||169500|
NCT00498199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.432|Visual Impairment, Oscillopsia and Multiple Sclerosis|Visual Impairment, Oscillopsia and Multiple Sclerosis||Hospices Civils de Lyon||Terminated|April 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Patients with established multiple sclerosis|July 2007|September 29, 2010|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498199||169548|
NCT00505726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-555|Reflectance Confocal Imaging in Cervical Cancer Patients|Reflectance Confocal Imaging of Cervical Intraepithelial Neoplasia (CIN)||M.D. Anderson Cancer Center|Yes|Completed|November 2001|September 2007|Actual|September 2007|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|||Female|18 Years|N/A|No|Non-Probability Sample|Women, 18 years of age or older, who are already scheduled for colposcopy to detect or        treat cervical lesions.|July 2012|July 31, 2012|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505726||168982|
NCT00506246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006L00667|Efficacy and Safety Study of Two Propofol Formulations|A Multi-Center, Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy and Safety of Propofol(Propofol®-Lipuro) in Total Intravenous Anaesthesia||B. Braun Melsungen AG|No|Completed|June 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|65 Years|No|||February 2008|February 22, 2008|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00506246||168942|
NCT00506259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070076|Treatment Strategies for Children With Smith-Magenis Syndrome|A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)||National Institutes of Health Clinical Center (CC)||Recruiting|July 2007|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|75|||Both|3 Years|45 Years|No|||February 2016|February 13, 2016|July 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00506259||168941|
NCT00506532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC063344ctil|The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study|The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study||Rabin Medical Center||Recruiting|January 2005|December 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|42|||Both|16 Years|68 Years|No|||July 2007|July 23, 2007|July 15, 2007||||No||https://clinicaltrials.gov/show/NCT00506532||168920|
NCT00506506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-358|Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease|Randomized Controlled Trial Examining the Effect of N-Acetylcysteine on Serum Creatinine in Patients With Stage 3 Chronic Kidney Disease||Lawson Health Research Institute|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|60|||Both|18 Years|N/A|No|||April 2009|April 14, 2009|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00506506||168922|
NCT00506519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 90010-I21|Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis|Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn® (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis||LEO Pharma|Yes|Terminated|July 2007|March 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||August 2010|August 23, 2010|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506519||168921|
NCT00506545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04888|Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)|Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Idiopathic Cough||Merck Sharp & Dohme Corp.|No|Completed|January 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|July 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00506545||168919|
NCT00506844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-165|Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer|A Phase II Study of Pre-Operative Concurrent Chemoradiotherapy With Cetuximab, Irinotecan, and Capecitabine in Resectable Rectal Cancer|ERBIRIX|National Cancer Center, Korea|No|Active, not recruiting|May 2006|May 2010|Anticipated|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||July 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506844||168896|
NCT00507156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 326257|Postconditioning in the Treatment of Acute ST-segment Elevation Myocardial Infarction|Postconditioning Used to Limit Final Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction|POSTCON|Rigshospitalet, Denmark||Active, not recruiting|July 2007|||November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00507156||168872|
NCT00507169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40776ORII/05IA01|SVT-40776 in Patients Suffering From Overactive Bladder Syndrome|||Salvat||Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||June 2011|June 7, 2011|July 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507169||168871|
NCT00507442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05008|Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients|Phase 1/2 Study of VELCADE® (Bortezomib), Dexamethasone, and Revlimid® (Lenalidomide) Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid Versus VELCADE, Dexamethasone and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma|EVOLUTION|Millennium Pharmaceuticals, Inc.|No|Completed|August 2007|November 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|158|||Both|18 Years|N/A|No|||April 2012|July 18, 2013|July 25, 2007|Yes|Yes||No|November 28, 2011|https://clinicaltrials.gov/show/NCT00507442||168850|
NCT00507455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-058|Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction|A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)||Astellas Pharma Inc|No|Completed|June 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|222|||Male|45 Years|N/A|No|||July 2014|July 14, 2014|July 25, 2007|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT00507455||168849|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00504036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060408|Efficacy of Preoperative Intra Gastric Balloon in Morbidly Obese Patients Selected for Gastric By-pass|Medico Economic Evaluation of a Temporary (6 Months) Intra-gastric Balloon in Morbidly Obese Patients Before a Gastric By-pass. A Randomised Multicenter Study Comparing the Usual Strategy to Two Types of Gastric Balloon|BIGPOM|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|314|||Both|18 Years|75 Years|No|||October 2008|October 31, 2011|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504036||169107|
NCT00504296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I188|SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Clinical and Pharmacokinetic Study of SB939 in Patients With Advanced Cancer||Canadian Cancer Trials Group|Yes|Completed|June 2007|June 2011|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00504296||169087|
NCT00504309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G214|Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides|Omacor: Measures of Endothelial Function and triGleride Alteration|OMEGA|Penn State University|No|Completed|July 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|28|||Both|21 Years|65 Years|No|||June 2008|July 14, 2010|July 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00504309||169086|
NCT00495287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILG-AML 02/06|A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)|Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program||Northern Italy Leukemia Group|Yes|Active, not recruiting|November 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|16 Years|65 Years|No|||April 2015|April 22, 2015|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495287||169767|
NCT00495573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26224-A|HSV-2 Shedding Resolution After Acyclovir Treatment|Half-life and Pattern of Resolution of Herpes Simplex Virus Type 2 (HSV-2) Shedding After Beginning Acyclovir Treatment||University of Washington|No|Completed|June 2007|March 2012|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|36|Samples With DNA|whole blood, genital swab specimens|Both|18 Years|N/A|No|Non-Probability Sample|HSV-2 seropositive men and women with a history of at least 3 clinical recurrences of        genital herpes within the year prior to the screening visit. Participants will be        recruited from the community.|March 2012|March 21, 2012|June 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00495573||169746|
NCT00528489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 070|Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Given Alone, With IL-12 DNA, or With a Dose Escalation of IL-15 DNA, in Healthy, HIV-1-uninfected Adults Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|September 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00528489||167260|
NCT00497107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICOG-CC01|Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer|Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer|ICOG|Iwate Medical University|Yes|Recruiting|July 2007|May 2013|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|79 Years|No|||July 2008|July 30, 2008|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497107||169632|
NCT00498537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0024|Spironolactone for Reducing Proteinuria in Diabetic Nephropathy|Spironolactone for Reducing Proteinuria in Diabetic Nephropathy||VA Office of Research and Development|No|Completed|January 2003|June 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||May 2008|October 16, 2008|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498537||169522|
NCT00498810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/241|COMplete Versus PArtial Open inCisional Hernia Repair (COMPAC-TRIAL)|COMplete Versus PArtial Open inCisional Hernia Repair (COMPAC-TRIAL)|COMPAC|University Hospital, Ghent|No|Terminated|September 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|July 9, 2007||No|patients had to be converted to the other study arm|No||https://clinicaltrials.gov/show/NCT00498810||169501|
NCT00498550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00149955|Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual|Cannabis and Schizophrenia: Effects of Clozapine||Dartmouth-Hitchcock Medical Center|Yes|Completed|October 2000|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||December 2011|December 15, 2011|July 6, 2007|Yes|Yes||No|September 28, 2011|https://clinicaltrials.gov/show/NCT00498550||169521|
NCT00494559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAISE|The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers|Phase 4 Study of Pioglitazone on Neointima Volume and Inflammatory Markers in Diabetic Patients||Korea University Anam Hospital|Yes|Completed|July 2007|July 2015|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494559||169822|
NCT00498849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701236|The Changes of Patterns of Microarray in Patients With Obstructive Sleep Apnea|The Changes of Patterns of Microarray in Patients With Obstructive Sleep Apnea||National Taiwan University Hospital|Yes|Recruiting|February 2005|December 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2005|July 8, 2007|July 8, 2007||||No||https://clinicaltrials.gov/show/NCT00498849||169499|
NCT00494845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07020074|Mindfulness Meditation for Chronic Low Back Pain in Older Adults|Mindfulness Meditation for Chronic Low Back Pain in Older Adults||University of Pittsburgh|Yes|Completed|July 2007|September 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|N/A|No|||January 2016|January 13, 2016|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494845||169800|
NCT00505999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0141|Etiology of Multiple Myeloma: A Case-Control Study|Etiology of Multiple Myeloma: A Case-Control Study||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2006|||July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood and saliva samples that will be used for special tests to look for any biological      factors associated with Multiple Myemloma (MM).|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with Multiple Myeloma and healthy controls.|September 2015|September 15, 2015|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00505999||168961|
NCT00506272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Emory IRB: 805-2006|Inpatient Self Monitoring and Administration Study (ISMAS)|Inpatient Self Monitoring and Administration Study (ISMAS)|ISMAS|Atlanta VA Medical Center|Yes|Active, not recruiting|December 2007|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|July 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506272||168940|
NCT00506285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20405|Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD|Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD||University of Utah|No|Completed|June 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|65 Years|No|||January 2015|January 15, 2015|July 23, 2007|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT00506285||168939|
NCT00506558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-CSM-382|The CSM Trial: A Multicenter Study Comparing Ventral to Dorsal Surgery for Cervical Spondylotic Myelopathy|The CSM Trial: A Multicenter Study Comparing Ventral to Dorsal Surgery for Cervical Spondylotic Myelopathy|CSM|Greenwich Hospital|Yes|Completed|November 2006|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|40 Years|85 Years|No|||August 2012|August 28, 2012|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00506558||168918|
NCT00506571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-261|Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer|Phase II Study of S-1 Combined With Irinotecan and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer|TIROX2|National Cancer Center, Korea|No|Recruiting|July 2007|June 2010|Anticipated|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||April 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506571||168917|
NCT00506584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPPF 001-2007|Randomized Study of Human-Milk Based Nutrition Versus Formula in Premature Infants|A Randomized Study of Human Milk-Based Versus Bovine-based Nutrition for Very Low Birth Weight Pre-Term Infants||Prolacta Bioscience|Yes|Completed|July 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|260|||Both|N/A|21 Days|No|||February 2010|February 16, 2010|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00506584||168916|
NCT00506857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM99-251|Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support|Phase I/II Trial of Fludarabine in Combination With Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients With Hematologic Malignancies||M.D. Anderson Cancer Center|No|Completed|November 2003|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|N/A|75 Years|No|||January 2012|January 24, 2012|July 23, 2007||No||No|January 24, 2012|https://clinicaltrials.gov/show/NCT00506857||168895|
NCT00507468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABM-MI-10|Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone|Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone|TABMMI|BioCardia, Inc.|Yes|Completed|December 2005|August 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||November 2009|November 2, 2009|July 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00507468||168848|
NCT00507702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0017|Identification of Key Blood Molecular Markers for Immunotherapy|Identification of Key Blood Molecular Markers for Immunotherapy||Stanford University|Yes|Suspended|July 2006|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Tumors occur predominantly in the adult population after age 30, regardless of gender and        ethnic background. Therefore, our study population will consist mainly of adult subjects.        We do not have any exclusion criteria based on age range, gender or ethnic background.|July 2012|July 5, 2012|July 24, 2007||No|Improving assay methods|No||https://clinicaltrials.gov/show/NCT00507702||168831|
NCT00503750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0495-2006|Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)|Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer||Emory University|Yes|Completed|April 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||June 2012|June 16, 2012|July 17, 2007|Yes|Yes||No|March 26, 2012|https://clinicaltrials.gov/show/NCT00503750||169129|
NCT00504049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03NS048875-01A2|Wavelet Analysis of Electromyography (EMG) in Cerebral Palsy|Wavelet Analysis of Surface EMG in Cerebral Palsy||Shriners Hospitals for Children|No|Completed|March 2007|March 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|32|||Both|7 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with spastic, diplegic cerebral palsy|January 2009|July 21, 2010|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00504049||169106|
NCT00504062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5254C00769|Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma|A Randomized, Open-label, Parallel-group, 6 Week Treatment, Multi-center, Phase III Study to Investigate the Efficacy and Safety of 100ug and 200ug Twice Daily of Budesonide Turbuhaler® and 50ug and 100umg Twice Daily of Fluticasone Diskus® in Japanese Children With Bronchial Asthma Aged 5-15||AstraZeneca|No|Completed|October 2006|October 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|240|||Both|5 Years|15 Years|No|||August 2011|August 23, 2011|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00504062||169105|
NCT00504322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502007770|Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma|Phase II, Randomized, Double-blinded, Placebo-Control, Toxicity/Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Stage I, II or III Esophageal Carcinoma|cd40|Weill Medical College of Cornell University|Yes|Withdrawn|July 2011|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||December 2015|December 16, 2015|July 19, 2007|Yes|Yes|No funding available.|No||https://clinicaltrials.gov/show/NCT00504322||169085|
NCT00504335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARC006-025|Safety and Pharmacokinetic Study of BIO 300 Capsules|A Dose Escalation Trial Evaluating the Safety and Pharmacokinetic Profiles of BIO 300 Capsules in Healthy Male and Female Volunteers||Humanetics Corporation|No|Completed|June 2007|October 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00504335||169084|
NCT00496197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851011|Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis|Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis||Pfizer|Yes|Completed|July 2007|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|282|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|July 3, 2007|Yes|Yes||No|May 12, 2011|https://clinicaltrials.gov/show/NCT00496197||169701|
NCT00496522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0915|Proton Beam Therapy for Chondrosarcoma|Phase II Evaluation of Proton Beam Therapy for Skull Base Chondrosarcoma||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2006|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|N/A|No|||July 2015|July 16, 2015|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00496522||169677|
NCT00496834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-330|LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)|A Randomized, Open-label, Comparative, Non-inferiority, Multicenter Study to Compare Efficacy of Losartan Potassium Group and Carvedilol Group on Arterial Stiffness in Essential Hypertension Patients||Merck Sharp & Dohme Corp.||Completed|February 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|July 3, 2007|Yes|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00496834||169653|
NCT00497094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|471/2004|Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis|Stenting vs. Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis - a Randomized Controlled Trial||Vienna General Hospital|No|Completed|March 2004|October 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|148|||Both|N/A|N/A|No|||February 2013|February 27, 2013|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497094||169633|
NCT00497900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005767-26|The Effect of Calcium and Vitamin D in Patients With Heart Failure||KarViDII|Hvidovre University Hospital|Yes|Completed|August 2007|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||March 2012|June 2, 2015|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00497900||169571|
NCT00494598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC2983|The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion|The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion||Columbia University|No|Completed|March 2007|June 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|all patients undergoing aortic arch surgery|October 2008|July 31, 2013|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494598||169819|
NCT00494611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC3683|A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients|A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients||St. Luke's-Roosevelt Hospital Center|No|Terminated|September 2007|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|90 Years|No|||June 2010|May 18, 2011|June 28, 2007|Yes|Yes|Unable to recruit subjects in timely fashion for the study|No||https://clinicaltrials.gov/show/NCT00494611||169818|
NCT00498862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709069|Catecholamines Can Attenuate Intermittent Hypoxia-Induced Expression of TNF in Human Monocytes|||National Taiwan University Hospital|Yes|Recruiting|September 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2006|July 9, 2007|July 8, 2007||||No||https://clinicaltrials.gov/show/NCT00498862||169498|
NCT00494871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12620|Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation|Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation||Bayer|Yes|Completed|June 2007|January 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1280|||Both|20 Years|N/A|No|||April 2015|April 1, 2015|June 29, 2007||No||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00494871||169798|
NCT00494884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ADE02|Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin|A Multicenter, Randomized, Double-blind, Parallel-group Study to Investigate the Glucose Lowering Effect, Safety and Tolerability of 24 Weeks Treatment With Vildagliptin 100 mg o.d. Versus Placebo Followed by a 12 Weeks Treatment Period With Open-label Vildagliptin 100 mg o.d. as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin||Novartis||Completed|June 2007|||July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|85 Years||||July 2009|July 13, 2009|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00494884||169797|
NCT00494572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU 10856|Montelukast With Status Asthmaticus, Ages 6-18|Pharmacokinetics and Pharmacodynamics of Montelukast in Children, Ages 6 Through 18 Years Old, With Status Asthmaticus Unresponsive to Conventional Treatment||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|December 2006|October 2010|Anticipated|January 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|52|||Both|6 Years|18 Years|No|||November 2008|December 15, 2008|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494572||169821|
NCT00494585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0070|CEP-701 for PH-negative Myelofibrosis|Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis||M.D. Anderson Cancer Center|Yes|Completed|June 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|June 28, 2007|Yes|Yes||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00494585||169820|
NCT00506012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2000-0633|Pilot Efficacy Study of T2000 in Myoclonus Dystonia|Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Myoclonus Dystonia: An Open Label Sequential Dose Escalation Study||Taro Pharmaceuticals USA||Terminated|August 2007|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|75 Years|No|||November 2013|December 19, 2013|July 20, 2007||No|Slow Recruitment of eligible patients|No||https://clinicaltrials.gov/show/NCT00506012||168960|
NCT00506597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0183|Erwinase Study in Patients With Acute Lymphoblastic Leukemia|Erwinia L-Asparaginase (Erwinase) Study in Patients With Acute Lymphoblastic Leukemia||M.D. Anderson Cancer Center|No|Completed|May 2007|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|N/A|No|||September 2014|September 4, 2014|July 20, 2007|No|Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00506597||168915|
NCT00506870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2006/04|Benefit of Self-monitoring of Anticoagulation Instrument|Economic and Medical Evaluation of Self-monitoring of Anticoagulation in a Population of Patients Recently Fitted With a Mechanical Heart Valve Compared to Conventional Anticoagulation Follow-up|4A|University Hospital, Bordeaux|Yes|Completed|June 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|919|||Both|18 Years|N/A|No|||December 2010|December 13, 2010|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506870||168894|
NCT00506883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC 004-06-3001|MPC-004 for the Treatment of an Acute Gout Flare|A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 1 Week, Dose Comparison Study to Evaluate the Efficacy, Safety, and Tolerability of MPC-004 in Patients With an Acute Gout Flare|AGREE|Takeda|No|Completed|April 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|185|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 30, 2012|July 23, 2007|Yes|Yes||No|August 12, 2009|https://clinicaltrials.gov/show/NCT00506883||168893|
NCT00507182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNS99-100|Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions|Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions||M.D. Anderson Cancer Center|No|Active, not recruiting|July 1999|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|395|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507182||168870|
NCT00508014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59768|Assessing the Effectiveness of Concurrent Peer Review for Patients With Cardiovascular Disease and Diabetes|Concurrent Peer Review Visits to Reduce Cardiovascular Risk Factors||University of Rochester|No|Completed|December 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|727|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508014||168807|
NCT00503763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMMSS-01|Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma|Open -Label Phase IIa Trial of the Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma|PSMMSS|Meir Medical Center|No|Withdrawn|September 2007|March 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||July 2007|April 15, 2015|July 18, 2007||Yes|We found out that there is another study on the same issue|No||https://clinicaltrials.gov/show/NCT00503763||169128|
NCT00494702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIO51O5|Oxygen Toxicity in the Resuscitation in Extremely Premature Infants|Achievement of a Targeted Saturation in Extremely Low Gestational Age Neonates Resuscitated With Low or High Oxygen Concentration: A Prospective Randomized Trial|OXTOX|Fundacion Para La Investigacion Hospital La Fe|Yes|Completed|April 2005|September 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|N/A|3 Minutes|No|||October 2008|October 14, 2008|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494702||169811|
NCT00495027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066589-02|Brief Cognitive-Behavioral Treatment for Victims of Mass Violence|Brief Cognitive-Behavioral Treatment for Victims of Mass Violence||Boston University|No|Completed|March 2002|August 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|N/A|No|||June 2007|June 28, 2007|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00495027||169787|
NCT00497315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOGA 0502|Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|A Randomized Multicenter Phase II Study Of Induction Therapy With Pemetrexed And Cisplatin Followed By Chemoradiation With Pemetrexed Versus Chemoradiation With Pemetrexed Followed By Consolidation Therapy With Pemetrexed And Cisplatin In Patients With Stage III Non-Small Cell Lung Cancer: Paccora Trial|PACCORA|University Hospital, Antwerp|No|Completed|February 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2009|April 9, 2009|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497315||169616|
NCT00498160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-7392-041698|Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion|1) Induction of Donor Specific Tolerance in Recipients of Kidney Allografts by Donor Bone Marrow Cell Infusion (Deceased Donors) and 2) Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion||University of Louisville|Yes|Active, not recruiting|January 2005|December 2024|Anticipated|June 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|65 Years|No|||March 2016|March 16, 2016|July 6, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00498160||169551|
NCT00498173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077600|Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism|Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism||Massachusetts General Hospital|Yes|Recruiting|July 2007|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|5 Years|15 Years|No|||May 2015|May 28, 2015|July 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00498173||169550|
NCT00497614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOHP05-DM/PETRA|Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)|18F-FDG Positron Emission Tomography to Study the Response to Adalimumab in Rheumatoid Arthritis. A Monocentric Pilot Study|PETRA|University Hospital, Tours|No|Completed|May 2006|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||December 2008|December 4, 2008|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497614||169593|
NCT00497627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 38-2006|Quality of Life and Cardiometabolic Risk Factors in Patients After Debanding|Quality of Life and Cardiometabolic Risk Factors in Patients After Debanding||University of Zurich|No|Active, not recruiting|January 2007|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|N/A||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Follow up of debanding patients regarding cardiometabolic risk factors|July 2013|July 8, 2013|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497627||169592|
NCT00498563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2006024|Effects of Mild Hypobaric Hypoxia on Sleep and Post-sleep Performance|Investigation to Determine the Effects of Mild Hypobaric Hypoxia on Sleep and Post-Sleep Neurobehavioral Performance||Oklahoma State University Center for Health Sciences|No|Completed|October 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Basic Science|1||Actual|34|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00498563||169520|
NCT00498576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4730-AL-CTIL|Melatonin and Adiponectin in Hypertensive Kidney Transplant|||Sheba Medical Center|No|Completed|September 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|group1- patients from the kidney transplant unit, sheba medical center group2- patients        from hypertension unit,sheba medical center|June 2009|June 29, 2009|July 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00498576||169519|
NCT00498212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-11|A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease|A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV™ in Adults With End-Stage Renal Disease||Dynavax Technologies Corporation|Yes|Terminated|July 2007|October 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|41|||Both|40 Years|70 Years|No|||August 2015|August 19, 2015|July 5, 2007|Yes|Yes|Voluntary halt of further dosing due to an FDA Clinical Hold issued in relation to Dynavax    study DV2-HBV-10|No||https://clinicaltrials.gov/show/NCT00498212||169547|
NCT00498225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023017|Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer|Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)|GEST|Taiho Pharmaceutical Co., Ltd.|Yes|Completed|July 2007|June 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|834|||Both|20 Years|79 Years|No|||November 2012|November 1, 2012|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00498225||169546|
NCT00498238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ronit1|The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism|The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients||Assaf-Harofeh Medical Center|No|Completed|July 2003|September 2005|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|34|||Both|18 Years|N/A|No|||July 2007|July 6, 2007|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498238||169545|
NCT00498888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007030|The Long Term Outcomes of Rehabilitation and Drug Treatment for in Urgency Urinary Incontinence|Is the a Difference Between Rehabilitation Treatment, Pelvic Floor Muscle Training, Bladder Training and Anticholinergic Drug Treatment in UUI in the Long Term: A Study of Impairment, Quality of Life, and Cost Effectiveness|UUI|Assuta Hospital Systems|Yes|Completed|June 2007|November 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|164|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00498888||169496|
NCT00494897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-RI/96|PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia|PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia||PETHEMA Foundation|Yes|Completed|June 1996|December 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|374|||Both|15 Years|N/A|No|||May 2009|May 15, 2009|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00494897||169796|
NCT00495183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAF-MT|Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence|Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence||Hospital Universitari Vall d'Hebron Research Institute|Yes|Recruiting|January 2009|July 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|60 Years|No|||May 2010|May 26, 2010|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00495183||169775|
NCT00495417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Affiris 001|Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease|Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Phase I Pilot Study to Assess Tolerability and Safety of Repeated s.c. Administration of a Single-dose of Affitope AD01 Applied With or Without Adjuvant to Patients With Mild to Moderate Alzheimer's Disease||Affiris AG|Yes|Completed|July 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|50 Years|N/A|No|||September 2009|October 18, 2010|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495417||169757|
NCT00506025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-4896|Effectiveness of Cranberry Ingestion on Bacterial Adhesion: An Adjunct Study|Effectiveness of Cranberry Ingestion on Bacterial Adhesion: Adjunct to Pilot Study of Daily Cranberry Ingestion of Cranberry Juice for the Prevention of Asymptomatic Bacteriuria in Pregnancy||University of California, Irvine|No|Completed|August 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|N/A|3||Actual|51|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 28, 2010|July 24, 2007||No||No|December 3, 2009|https://clinicaltrials.gov/show/NCT00506025||168959|Our study methodology could have been improved with a series of timed urine collections such as collections at pre-treatment, 2, 4 and 6 hours after ingestion of the cranberry juice cocktail and placebo to determine time of maximal effect.
NCT00506298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-401-001|Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes|A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin.||Zalicus|No|Completed|July 2007|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||May 2009|May 12, 2009|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00506298||168938|
NCT00507195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pinocchio|Postanesthesia Cognitive Recovery and Neuropsychologic Complications|Post Operative Cognitive Recovery and Neuropsychological Complications After General Anesthesia. A Comparison Between Different Techniques of Anesthesia: A Multi-Center Observational Study||University of Roma La Sapienza|Yes|Recruiting|May 2007|||||N/A|Observational|Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|1200|||Both|18 Years|N/A|No|||May 2007|July 24, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00507195||168869|
NCT00507208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F07032314|Dynasplint Therapy for Trismus in Head and Neck Cancer|Dynasplint Therapy for Trismus in Head and Neck Cancer|HNO 0602|University of Alabama at Birmingham|No|Suspended|July 2007|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||March 2015|March 12, 2015|July 25, 2007||No|Initially study met accrual & then increased enrollment. Now the sponsor has put the trial on    hold due to financial reasons and hope to re-open soon.|No||https://clinicaltrials.gov/show/NCT00507208||168868|
NCT00507481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4627|Evaluation of Risk Factors of Sleep Quality in Intensive Care Unit|Evaluation of Risk Factors of Sleep Quality in Critically Ill Patients||University of Turin, Italy|No|Completed|January 2006|September 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|80 Years|No|Probability Sample|ICU postsurgical patients who needed mechanical ventilation for more than 48 hr admitted        to the general ICU|June 2008|June 3, 2008|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507481||168847|
NCT00507715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAN-EC-LDOPA-FI|Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk|Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk||Rottapharm Spain|No|Completed|September 2006|November 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|18|||Both|60 Years|80 Years|No|||July 2007|July 25, 2007|July 25, 2007||||No||https://clinicaltrials.gov/show/NCT00507715||168830|
NCT00507728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1024|Pharmacogenetics, Emotional Reactivity and Smoking|Pharmacogenetics, Emotional Reactivity and Smoking||M.D. Anderson Cancer Center|Yes|Active, not recruiting|December 2005|||December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|375|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|July 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507728||168829|
NCT00508027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01FD003080-01A1|Simvastatin (Zocor) Therapy in Sickle Cell Disease|Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease||Children's Hospital & Research Center Oakland|Yes|Completed|June 2007|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|13 Years|N/A|No|||August 2013|August 20, 2013|July 26, 2007|No|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00508027||168806|
NCT00498966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 231|Ph II Study of Perifosine for Patients With Carcinoma of the Kidney|Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor||AEterna Zentaris|No|Completed|July 2007|October 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||November 2011|February 14, 2014|July 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00498966||169490|
NCT00494715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALID|Preventing ESRD in Overt Nephropathy of Type 2 Diabetes|A Prospective, Randomized, Probe Trial to Evaluate Whether,at Comparable Blood Pressure Control,Combined Therapy With ACEI BEN and ARB VAL Reduces Progression to ESRD More Effectively Than BEN or VAL Alone in High Risk Patients With Type 2 Diabetes and Overt Nephropathy|VALID|Mario Negri Institute for Pharmacological Research|No|Active, not recruiting|May 2007|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|102|||Both|40 Years|80 Years|No|||March 2016|March 15, 2016|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00494715||169810|
NCT00495040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0977|Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2006|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||December 2015|December 2, 2015|June 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00495040||169786|
NCT00497848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIH, Denmark|The Compliance Project Concerning People With Schizophrenia|Individual Versus System Orientated Interventions in Handling Drug Related Problems in People With Schizophrenia||Ministry of the Interior and Health, Denmark|Yes|Completed|May 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|70|||Both|23 Years|N/A|No|||July 2007|June 23, 2011|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00497848||169575|
NCT00497861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPMFMA1|Comparison of Activator Manipulation Versus Manual Side Posture Manipulation in Patients With Low Back Pain|Comparison of Mechanical Force, Manually Assisted Activator Manipulation Versus Manual Side Posture Manipulation in Patients With Low Back Pain: a Randomized Pilot Study||Cleveland Chiropractic College|No|Completed|December 2004|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2007|July 6, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497861||169574|
NCT00497354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHSCA01|Does a Low Volume Ultrasound-Guided Technique Reduce Common Complications of Interscalene Brachial Plexus Block?|Does a Low Volume Ultrasound-Guided Technique Reduce Common Complications of Interscalene Brachial Plexus Block?||Sunnybrook Health Sciences Centre|No|Completed|July 2007|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|70 Years|No|||June 2010|June 14, 2010|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00497354||169613|
NCT00497913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-02-53-4207|Dysport® Injection in the Treatment of Chronic Lateral Epicondylitis||DCLE|Tehran University of Medical Sciences|Yes|Completed|August 2007|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|80 Years|No|||April 2008|April 22, 2008|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00497913||169570|
NCT00498264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHK12121977|Effectiveness of Physical Exercise in Women With Fibromyalgia|Effectiveness of Physical Exercise on Decrease of Pain in Patients With Fibromyalgia:Randomized Clinical Trial||Federal University of São Paulo|Yes|Recruiting|January 2005|October 2007|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Anticipated|90|||Female|35 Years|55 Years|No|||June 2007|July 9, 2007|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00498264||169543|
NCT00498589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2006-1|Comparison of Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis|A Controlled, Randomized, Double-blind, Multicenter Study, Comparing Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis|METEOR|Centre Hospitalier Universitaire de Besancon|Yes|Completed|September 2007|June 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|No|||February 2015|February 4, 2015|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498589||169518|
NCT00498875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0390|Depression and Adherence in Head and Neck Cancer|Depression and Adherence in Head and Neck Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2005|||March 2017|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Probability Sample|Study participants with stage I-IV Head and Neck Cancer.|September 2015|September 24, 2015|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00498875||169497|
NCT00498602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134K1-2201|Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease|Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease||Pfizer|Yes|Completed|November 2007|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|July 9, 2007|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT00498602||169517|
NCT00494923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG-SFB539-R|Early Diagnosis, Pathogenesis and Progression of Open Angle Glaucoma|Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)||University of Erlangen-Nürnberg Medical School|No|Recruiting|January 1999|December 2020|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|Samples With DNA|whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|December 2013|December 11, 2013|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00494923||169794|
NCT00494624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VINKU|Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children||VINKU|University of Turku|No|Recruiting|September 2000|May 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|300|||Both|3 Months|15 Years|No|||June 2007|June 29, 2007|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00494624||169817|
NCT00494910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-094|Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients|A Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2007|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|253|||Both|21 Years|N/A|No|||August 2015|August 14, 2015|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00494910||169795|
NCT00506896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0599/04|Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients|Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study||Federal University of São Paulo|Yes|Completed|July 2004|January 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||July 2007|July 20, 2007|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00506896||168892|
NCT00506909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytocin Schizophrenia|Oxytocin Add on Study for Stable Schizophrenic Patients|Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antipsychotic Medication in Schizophrenia Patients|Oxytocin|University of California, San Diego|No|Suspended|March 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|July 23, 2007|No|Yes|Break in funding|No||https://clinicaltrials.gov/show/NCT00506909||168891|
NCT00507221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32274-B|Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression|Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression|THE or PHE|University of Washington|Yes|Completed|February 2008|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|948|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507221||168867|
NCT00507494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNTx|Influence of Pioglitazone for Renal Transplant Function in Diabetics|Influence of Pioglitazone for Renal Transplant Function in Diabetics - a Double Blind Randomised Placebo Controlled Cross Over Study||Technische Universität Dresden|Yes|Completed|July 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|30 Years|75 Years|No|||October 2011|October 27, 2011|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507494||168846|
NCT00498069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-1|Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)|Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease||Harvest Technologies|No|Completed|November 2007|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||June 2014|March 17, 2015|July 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00498069||169558|
NCT00507741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-007|Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)|Protocol EC-FV-02: A Phase II Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers||Endocyte|No|Completed|August 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Female|18 Years|N/A|No|||December 2014|December 18, 2014|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507741||168828|
NCT00498667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cc-NHL2615_CTIL|The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma|Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma||Rambam Health Care Campus|No|Withdrawn|December 2006|December 2014|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|None Retained|no biopsies are to be retained|Both|18 Years|70 Years|No|Probability Sample|all patients with agressive non hodgkin lymphoma who had interim pet/ct during therapy|May 2015|May 5, 2015|July 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00498667||169512|
NCT00498979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3Y06|Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers|Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons||Case Comprehensive Cancer Center|Yes|Completed|May 2007|January 2012|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00498979||169489|
NCT00494481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00046|E3 Breast Cancer Taxotere Combination|A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).||AstraZeneca|No|Completed|January 2006|January 2009|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Female|18 Years|N/A|No|||April 2011|April 27, 2011|June 28, 2007|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00494481||169828|
NCT00495053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ION-02|Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder Syndrome and Detrusor Overactivity|A Phase 1 Multicenter Study of Three Escalating Doses of hMaxi-K Gene Transfer in Female Participants With Overactive Bladder Syndrome and Detrusor Overactivity||Ion Channel Innovations|Yes|Completed|April 2007|November 2009|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|June 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00495053||169785|
NCT00495066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-045|Compassionate Use Trial for Unresectable Melanoma With Ipilimumab|A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma||Bristol-Myers Squibb|No|No longer available||||||N/A|Expanded Access|N/A|||||||Both|16 Years|N/A|No|||May 2013|May 30, 2013|June 29, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00495066||169784|
NCT00495586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06/31|Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease|Situations That do Not Require Antibiotics for Acute Exacerbations of Mild-to-moderate Chronic Obstructive Pulmonary Disease|TRANCE|Catalan Society of Family Medicine|No|Completed|October 2007|July 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|318|||Both|40 Years|N/A|No|||March 2012|March 11, 2012|July 2, 2007||No||No|January 8, 2012|https://clinicaltrials.gov/show/NCT00495586||169745|The required sample size could not be achieved. This clinical trial was only partially funded by an independent academic institution without any other source of funding. However, due differences obtained the sample size allowed for a power of 80%.
NCT00495885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTE6672|Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus|Efficacy and Safety of 2 mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study|SAMS12|Sanofi||Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|848|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|July 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00495885||169723|
NCT00503906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20060913|Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Bevacizumab, and Gemcitabine as First-Line Therapy in Treating Patients With Metastatic Breast Cancer|A Phase II Study of Abraxane, Bevacizumab and Gemcitabine for First Line Metastatic Breast Cancer||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|June 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|July 17, 2007|Yes|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00503906||169117|
NCT00497640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED4890507E|CPAP Titration Using an Artificial Neural Network: A Randomized Controlled Study|CPAP Titration Using an Artificial Neural Network: A Randomized Controlled Study||State University of New York at Buffalo|Yes|Withdrawn|May 2007|June 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|80 Years|No|||September 2009|January 14, 2016|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497640||169591|
NCT00498251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER03-160|Prevention of Lung Edema After Thoracic Surgery|Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study||University Hospital, Geneva|No|Completed|September 2004|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||June 2007|July 9, 2007|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498251||169544|
NCT00498914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-009|Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects|A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects||Astellas Pharma Inc|Yes|Terminated|June 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|July 10, 2007|Yes|Yes|Futility boundary at interim analysis not met|No||https://clinicaltrials.gov/show/NCT00498914||169494|
NCT00494637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L06.10.058|The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy|||Lenox Hill Hospital|No|Terminated|July 2007|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|468|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|June 29, 2007||No|Not reaching recruitment and endpoint goals|No||https://clinicaltrials.gov/show/NCT00494637||169816|
NCT00494650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064662-02|Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses|Cognitive Behavioral Treatment of Post-Traumatic Stress Disorder in Clients With Severe Mental Illness (in New Jersey)||Dartmouth-Hitchcock Medical Center|Yes|Completed|April 2008|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494650||169815|
NCT00494936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 03-0908|Effects of HIV and Hepatitis C Virus on the Brain|HIV/HCV: Neuropsychiatric and Neurophysiological Features||Icahn School of Medicine at Mount Sinai|No|Completed|May 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|78|||Both|18 Years|65 Years|No|Probability Sample|HIV / HCV Coinfected, HIV moninfected, & HCV monoinfected|May 2015|May 21, 2015|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494936||169793|
NCT00494949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3002|Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients|A Clinical Safety (Phase Ib/II) Increasing Dose Study of MP4 (Hemospan) in Orthopedic Surgery Patients||Sangart|Yes|Completed|April 2003|August 2006|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494949||169792|
NCT00495209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0876|Pre-Surgical Qigong Therapy for Women With Breast Cancer|Pre-Surgical Qigong Therapy for Women With Breast Cancer||M.D. Anderson Cancer Center|No|Completed|July 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|7|||Female|18 Years|N/A|No|Non-Probability Sample|Women with breast cancer who are awaiting surgery.|August 2012|August 1, 2012|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00495209||169773|
NCT00495456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMC 1-07 (CLEAR)|Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Study|Cardiovascular Longitudinal Evaluation & Assessment of Risk Study|CLEAR|Monash University|Yes|Recruiting|August 2007|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants of current and future cardiovascular trials at the Centre of Clinical        Research Excellence, Department of Epidemiology & Preventive Medicine, Monash University,        Melbourne.|June 2015|June 2, 2015|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495456||169754|
NCT00495469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2110375|Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive|A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects||GlaxoSmithKline|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|70 Years|No|||February 2013|February 21, 2013|June 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00495469||169753|
NCT00495482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-14/06-1|Incurable Ill Patients Attitudes Towards Euthanasia and Assisted Suicide|Incurable Ill Patients Attitudes to Euthanasia and Assisted Suicide: A Prospective, Multi-Centre Trial in Palliative Care Units in Saxony|ESPIL|Klinikum St. Georg gGmbH|No|Completed|September 2006|January 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|Patients with incurable illness|November 2012|November 12, 2012|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495482||169752|
NCT00506922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-132|Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT|Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After Matched-Unrelated Donor Blood and Marrow Transplantation||M.D. Anderson Cancer Center|No|Completed|September 2000|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|150|||Both|N/A|N/A|No|||August 2012|April 6, 2015|July 20, 2007||No||No|March 1, 2011|https://clinicaltrials.gov/show/NCT00506922||168890|
NCT00506935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#05-10-091-01|Assessment of GVG for the Treatment of Methamphetamine Dependence|Phase 1 Study of Vigabatrin (GVG) for Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)||Completed|July 2006|June 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|17|||Both|18 Years|55 Years|No|||August 2008|August 6, 2008|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506935||168889|
NCT00497757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-7494-041698|Induction of Donor Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion|1) Induction of Donor-Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion 2) Induction of Donor-Specific Tolerance by Donor Facilitating Cell (FC): Stem Cell Infusion in Recipients of Hepatic Allografts||University of Louisville|Yes|Completed|July 2003|||October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|70 Years|No|||October 2015|October 29, 2015|July 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00497757||169582|
NCT00498056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAVE 100|Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa|A Phase IIB Test-of-Concept, Randomized, Double-Blind, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Persons||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|July 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00498056||169559|
NCT00498082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-STLUC-GAS-01|Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease|Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|September 2007|September 2008|Anticipated|||N/A|Observational|Time Perspective: Longitudinal|||||||Both|18 Years|75 Years|No|||September 2007|September 5, 2007|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498082||169557|
NCT00498095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX/06-054|A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies|Experience of C4d Staining in Renal Allograft Biopsies||Hospital Authority, Hong Kong||Completed|July 2006|December 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A||Non-Probability Sample|All renal allograft biopsies performed in Princess Margaret Hospital from 1st April 2002        to 31st March 2006 on Chinese patients who were ≥ 18 years old were retrospectively        reviewed. Renal transplantations were either cadaveric or living-donor related performed        in Hong Kong or Mainland China. All recipients' sera produced negative cross-match tests        with donor lymphocytes before transplantation and were ABO compatible. Finally, 52 renal        biopsies were included. 38 (73.1%) of them were performed for unexplained acute renal        deterioration whilst the rest were done for delayed graft function.|June 2011|June 14, 2011|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498095||169556|
NCT00498381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361701235|The Induction of IL-6 by NF-kB in PBMC in OSA||OSA|National Taiwan University Hospital|Yes|Completed|August 2005|August 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Male|18 Years|N/A|No|||February 2005|July 8, 2007|July 8, 2007||||No||https://clinicaltrials.gov/show/NCT00498381||169534|
NCT00498680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2431-ctil|Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i|A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment||Rambam Health Care Campus|No|Recruiting|March 2007|June 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|46|||Male|35 Years|65 Years|No|||January 2007|October 21, 2010|July 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00498680||169511|
NCT00494728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0351|Smoking Cessation for Depressed Smokers|Smoking Cessation Intervention for Depressed Smokers: Treatment Development||M.D. Anderson Cancer Center|Yes|Active, not recruiting|June 2007|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|202|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 27, 2015|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494728||169809|
NCT00498732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701064R|Dissection of Differentially Expressed Genes and Pathways in Patients With OSAS Before and After CPAP Treatment|Dissection of Differentially Expressed Genes and Pathways in Patients With Obstructive Sleep Apnea Syndrome Before and After CPAP Treatment||National Taiwan University Hospital|Yes|Completed|June 2007|July 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|From patients who were referred to sleep lab for suspect sleep apnea, we selected 50 male        patients with age> 18 y/o. with severe OSAS, which were confirmed with by overnight PSG.        All were free from neurologic events, chronic pulmonary disease, active infection and        substance abuse. Female patients and patients under 18 y/o were excluded. All 50 subjects        were treated with 4-week CPAP. All study subjects were admitted, on the day of baseline        measurement and four weeks after CPAP use, for clinical evaluation, blood sampling and        PSG. And all anti-hypertensive therapy was remained unchanged during the 4-week follow-up        period. Changes of parameters, before and after CPAP treatment, were compared between two        groups.|November 2010|November 30, 2010|July 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00498732||169507|
NCT00495326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12146 CARINEMO|Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)|Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)|CARINEMO|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|December 2007|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|570|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495326||169764|
NCT00496548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Urinary PGE-M CD|Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity|Urinary PGE-M, A Metabolite of PGE2: A Novel Biomarker of Crohn's Disease Activity||Vanderbilt University|Yes|Active, not recruiting|August 2007|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00496548||169675|
NCT00530413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xUTHSC-07|Study of Phenobarbital Inhibition of Catamenial Epilepsy|Study of Phenobarbital Inhibition of Catamenial Epilepsy||University of Toledo Health Science Campus|No|Withdrawn|March 2007|||March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|45 Years|No|||December 2014|December 9, 2014|September 13, 2007||No|IRB needs updated|No||https://clinicaltrials.gov/show/NCT00530413||167112|
NCT00530387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Kerr|Multi-Centre European Photopatch Test Study|A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe.||NHS Tayside|No|Completed|July 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|1000|||Both|18 Years|N/A|No|||July 2011|August 3, 2011|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530387||167114|
NCT00530400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFX93LS06|Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgical Site Infection in Herniated Disk Surgery|Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Single-Dose Cefuroxime Prophylaxis in Herniated Disk Surgery||Centre Hospitalier Universitaire Vaudois|No|Completed|April 1994|March 2000|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1369|||Both|19 Years|N/A|No|||September 2007|September 14, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530400||167113|
NCT00530777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32462-A|HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding|HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding|VIP|University of Washington|Yes|Completed|April 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Female|18 Years|N/A|No|||March 2012|March 22, 2012|September 13, 2007||No||No|March 22, 2012|https://clinicaltrials.gov/show/NCT00530777||167086|Unable to evaluate the effect of valacyclovir on MTCT or on change in HIV-1 RNA among women who were eligible for HAART. Underpowered to detect association between treatment and mother to child HIV transmission.
NCT00530790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107846|Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome|Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory||GlaxoSmithKline||Completed|August 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|79 Years|No|||March 2011|April 11, 2013|September 14, 2007||||No|February 2, 2009|https://clinicaltrials.gov/show/NCT00530790||167085|
NCT00521768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT20|Effectiveness of Prolonged Exposure of PTSD in a Community Setting of PTSD Sufferers|||HaEmek Medical Center, Israel||Withdrawn||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|0|||Both|6 Years|18 Years|No|||July 2015|July 6, 2015|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00521768||167769|
NCT00517400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364/3.8.07(HMO)|Deep Transcranial Magnetic Stimulation (TMS)- Treatment for Post Traumatic Stress Disorder|Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device- Treatment for Post Traumatic Stress Disorder||Hadassah Medical Organization||Completed|February 2008|July 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||July 2010|April 19, 2015|August 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00517400||168102|
NCT00517413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20881|LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.|An Open Label Study to Assess the Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Monthly Administration of Intravenous or Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia||Hoffmann-La Roche||Completed||December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517413||168101|
NCT00517686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-HS-07-002|Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT)|Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT)|FIT|Kaiser Permanente|Yes|Completed|July 2008|September 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|16584|||Both|N/A|N/A|No|||August 2012|August 1, 2012|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517686||168080|
NCT00517998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-C06-002|Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study|Phase 1 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema||Aeris Therapeutics|Yes|Completed|May 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|40 Years|N/A|No|||January 2010|January 14, 2010|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517998||168056|
NCT00519207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010747|Evaluation of Topical Liposomal Lidocaine and Oral Sucrose for Treatment of Pain in Newborns Undergoing Venipuncture|Evaluation of Topical Liposomal Lidocaine and Oral Sucrose for Treatment of Pain in Newborn Infants Undergoing Venipuncture: A Randomized Controlled Trial||The Hospital for Sick Children|Yes|Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|330|||Both|N/A|7 Days|No|||July 2011|July 18, 2011|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519207||167964|
NCT00519519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78:10/03-098|Optimal Dose of Omeprazole After Endoscopic Treatment of Bleeding Peptic Ulcers|Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers||Singapore General Hospital|No|Completed|July 2004|November 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|90 Years|No|||October 2008|October 29, 2008|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519519||167940|
NCT00496119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0038|Proton Beam Therapy for Chordoma Patients|Phase II Evaluation of Proton Beam Therapy for Skull Base Chordoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|September 2006|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|N/A|N/A|No|||October 2015|October 15, 2015|July 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496119||169707|
NCT00528658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCEM06-07/DG2041095|Cost-Effectiveness of Two Painkillers for Treating Pain After Limb Injuries|Cost-Effectiveness Analysis of Oral Paracetamol and Ibuprofen for Treating Pain After Soft Tissue Limb Injuries: Double-Blind, Randomised Controlled Trial||Chinese University of Hong Kong|No|Completed|January 2005|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|783|||Both|16 Years|N/A|No|||January 2009|January 28, 2009|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528658||167247|
NCT00528931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-855|A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture|A Phase 1, Open-Label Study to Assess the Pharmacokinetics and Safety of a Single Injection of AA4500 0.58 mg in Subjects With Dupuytren's Contracture||Endo Pharmaceuticals|No|Completed|September 2007|March 2008|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 11, 2007|No|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00528931||167226|
NCT00529256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61-6498|Evaluation of Organisational Changes to Promote Smoking Cessation|Evaluation of Organisational Changes to Promote Smoking Cessation|ESCMMP|Great Lakes Research Into Practice Network|Yes|Completed|December 2001|April 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|87|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2005|September 12, 2007|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00529256||167201|
NCT00529555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-PER-05-001|Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis|A 9 Month,3-arm Multicenter Clinical Trial of Treatment With Periocline Gel (2.1% Minocycline HCl) for Adjunctive Use to Scaling and Root Planing (SRP) in Adults With Periodontal Disease.||Sunstar Americas|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|602|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|September 11, 2007|No|Yes||No|July 10, 2013|https://clinicaltrials.gov/show/NCT00529555||167178|
NCT00529230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-451|Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes|Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes||M.D. Anderson Cancer Center|No|Terminated|December 2001|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|46|Samples Without DNA|Blood draws to assess gonadal function.|Male|18 Years|N/A|No|Non-Probability Sample|Males on chronic opioid therapy for cancer-related pain syndromes.|July 2012|July 31, 2012|September 13, 2007||No|Low accrual rate.|No||https://clinicaltrials.gov/show/NCT00529230||167203|
NCT00529542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19286|A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol|A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol||Milton S. Hershey Medical Center|No|Completed|December 2004|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|40 Years|No|||September 2014|September 15, 2014|September 12, 2007|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00529542||167179|
NCT00530140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUN-90-2006|Idiotypic Vaccination for Follicular Lymphoma Patients|Idiotypic Vaccination for Poor-prognosis Follicular Lymphoma Patients in First Relapse|FLIDVAX2006|Clinica Universidad de Navarra, Universidad de Navarra|No|Recruiting|October 2007|September 2022|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||October 2011|October 5, 2011|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00530140||167133|
NCT00530153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL 369-3|School Intervention Study of Nutrition, Wellbeing and Dental Health|School Intervention Study of Nutrition, Wellbeing and Dental Health||National Institute for Health and Welfare, Finland||Active, not recruiting|April 2007|May 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|769|||Both|13 Years|14 Years||||September 2009|September 29, 2009|September 14, 2007||||No||https://clinicaltrials.gov/show/NCT00530153||167132|
NCT00531115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-06-05|Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.|Multicentre, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With Oxaliplatin and Capecitabine (XELOX) for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Terminated|November 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|70 Years|N/A|No|||February 2013|February 19, 2013|September 17, 2007||No|According to the study design, in the first step the number of responses was lower than the    number required (< 7).|No||https://clinicaltrials.gov/show/NCT00531115||167061|
NCT00531128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070219|The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol|A Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy Metabolism||National Institutes of Health Clinical Center (CC)||Completed|September 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|N/A|No|||May 2015|June 12, 2015|September 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00531128||167060|
NCT00526773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC27020|Enhancing Heart Failure Self-Care|Enhancing Heart Failure Self-Care||Christiana Care Health Services|No|Completed|January 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|95 Years|No|||October 2010|October 11, 2010|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526773||167391|
NCT00526786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-00016-00|Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus|A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)|ICE|CSA Medical, Inc.|Yes|Terminated|September 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|85 Years|No|||March 2014|March 12, 2014|September 5, 2007|Yes|Yes|Business Reasons|No||https://clinicaltrials.gov/show/NCT00526786||167390|
NCT00526799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN06-111|Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer|A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111||Hoosier Cancer Research Network|Yes|Terminated|September 2007|August 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|September 5, 2007||No|Study closed to accrual due unfavorable interim analysis|No|December 15, 2015|https://clinicaltrials.gov/show/NCT00526799||167389|
NCT00521430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000561542|Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease|NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING||National Cancer Institute (NCI)||Completed|April 2004|September 2008|Actual|May 2008|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|65 Years|No|||October 2007|March 25, 2013|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00521430||167795|
NCT00521443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-05/04|Cryosurvival of Embryos From Dysmorphic Oocytes|||V.K.V. American Hospital, Istanbul||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||12|||||Female|18 Years|45 Years||||August 2007|August 24, 2007|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00521443||167794|
NCT00521456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191578-006|A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery|||Allergan||Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||August 2009|September 29, 2009|August 23, 2007|Yes|Yes||No|August 19, 2009|https://clinicaltrials.gov/show/NCT00521456||167793|
NCT00521781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI IRB#0407-0035|Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer|Phase II Trial of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Adenocarcinoma of the Prostate||The Methodist Hospital System|No|Terminated|August 2007|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|August 24, 2007||No|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00521781||167768|
NCT00518323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002368|A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients|A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|201|||Both|12 Years|17 Years|No|||November 2010|March 25, 2014|August 16, 2007|Yes|Yes||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00518323||168032|No information about longer-term (ie, >6 weeks) efficacy and safety in adolescents or in young (<12 years) children with schizophrenia. Results with doses less than 1.5 mg or more than 12 mg cannot be extrapolated from the data.
NCT00517699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19652|A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.|An Open Label Study of the Effect of Rituxan, High Dose Methotrexate and High Dose Cytarabine on Response Rate in Patients With Primary Central Nervous System Lymphoma.||Hoffmann-La Roche||Terminated|September 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|August 16, 2007||No|Study was terminated early due to lack of enrollment.|No|June 9, 2014|https://clinicaltrials.gov/show/NCT00517699||168079|The study was terminated early due to lack of enrollment.
NCT00518011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20063|A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.|A Randomized, Open Label Study Comparing the Effect of First-line Therapy With Tarceva + Gemcitabine Versus Gemcitabine Monotherapy on Treatment Response in Treatment-naïve Patients With Advanced Non-small Cell Lung Cancer||Hoffmann-La Roche||Completed|August 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518011||168055|
NCT00518297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-352|DDI HV (ATV - Merck)|Open Label, Multiple Dose, Sequential, Drug-Drug Interaction Study to Assess the Pharmacokinetics and Safety of Atazanavir and Raltegravir Co-Administered Twice Daily in Healthy Subjects||Bristol-Myers Squibb|No|Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|February 3, 2010|August 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00518297||168034|
NCT00518310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10351|Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis|Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study||Thorax National Institute|Yes|Recruiting|May 2005|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|45 Years|79 Years|No|||August 2007|August 16, 2007|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00518310||168033|
NCT00518934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-04-064|Study for Safety and Efficiency of Therapeutic Angiogenesis for Patients With Limb Ischemia by Transplantation of Human Cord Blood Mononuclear Cell|||Samsung Medical Center||Recruiting||||||Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||||||Both|N/A|60 Years||||May 2007|August 20, 2007|August 19, 2007||||No||https://clinicaltrials.gov/show/NCT00518934||167985|
NCT00519220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105235|Outcome of Symptoms in Patients Undergoing a Heller Myotomy|Short and Long Term Outcomes of Heller Myotomy|Achalasia|University of South Florida|No|Recruiting|December 2006|December 2017|Anticipated|||N/A|Observational|N/A||1|Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with achalasia who have had laparoscopic Heller myotomies at Tampa General        Hospital.|August 2012|August 14, 2012|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519220||167963|
NCT00519233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007001|AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer|A Phase I Investigation of the Intravenous Administration of AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer||Astellas Pharma Inc|Yes|Completed|September 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||April 2014|April 30, 2014|August 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00519233||167962|
NCT00519532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0915|Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease|A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease||UCB Pharma|No|Terminated|July 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||September 2010|October 17, 2014|August 21, 2007|Yes|Yes|Due to clinical trial supplies shortage|No|March 17, 2010|https://clinicaltrials.gov/show/NCT00519532||167939|Because the manufacturing process for rotigotine patches was changed, enrollment into SP915 was stopped in April 2008 to ensure sufficient trial medication for all subjects enrolled at that time to complete the trial according to the protocol.
NCT00528138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-0045-07-07|Hyperbilirubinemia in Acute Appendicitis as a Predictor of Perforation|Prospective Study Comparing Hyperbilirubinemia, CRP, White Blood Cell Count, and Other Clinical Parameters for the Preoperative Diagnosis of Perforated Acute Appendicitis||Cirujanos la Serena|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|132|||Both|15 Years|N/A|No|Non-Probability Sample|Patients suspected of having acute appendicitis|November 2009|November 9, 2009|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528138||167287|
NCT00528671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications|Effects of Very Low Dose Oral Anticoagulation on Thromboembolism and Bleeding Events in Patients With Mechanical Heart Valve Replacement|ESCAT III|Heart and Diabetes Center North-Rhine Westfalia|Yes|Terminated|January 2006|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1571|||Both|18 Years|85 Years|No|||December 2013|December 10, 2013|September 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528671||167246|
NCT00528970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200L2-301|A Study Evaluating IV MOA-728 for the Treatment of POI In Subjects After Ventral Hernia Repair|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus After Ventral Hernia Repair||Valeant Pharmaceuticals International, Inc.||Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|500|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|September 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528970||167223|
NCT00528983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA PH US 2007 CL005|Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia|A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).||Celgene Corporation|No|Active, not recruiting|September 2007|April 2016|Anticipated|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|September 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00528983||167222|
NCT00529568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPL108390|Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease|Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)||GlaxoSmithKline|No|Completed|October 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|759|||Both|18 Years|N/A|No|||March 2013|October 10, 2013|September 12, 2007|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00529568||167177|
NCT00529581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22029|A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment||Cognition Pharmaceuticals, LLC|No|Completed|November 2006|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|65 Years|No|||May 2008|May 23, 2008|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529581||167176|
NCT00529880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-008|Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML|||Cooperative Study Group A for Hematology|No|Recruiting|December 2004|October 2007|Anticipated|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|19|||Both|60 Years|80 Years|No|||September 2007|September 26, 2007|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529880||167153|
NCT00530166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013087|Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of JNJ-18054478 in Subjects With Asthma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||June 2014|June 3, 2014|September 13, 2007|Yes|Yes|Lack of efficacy following an interim analysis|No||https://clinicaltrials.gov/show/NCT00530166||167131|
NCT00526812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 744-C-0401|A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas|A Phase I Dose-finding and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent or Refractory Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Mixed Oligo-astrocytoma (AOA), Glioblastoma Multiforme (GBM) or Gliosarcoma (GS), With or Without Concurrent Treatment With Enzyme-inducing Anticonvulsant Therapy||Reata Pharmaceuticals, Inc.|No|Completed|November 2005|||December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|September 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526812||167388|
NCT00526838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL228-002|Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies||Exelixis||Terminated|September 2007|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|September 6, 2007|No|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00526838||167387|
NCT00527371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 010-0706-01|PVP Compared to TURP for the Treatment of Benign Hyperplasia of the Prostate|Prospective Controlled Trial Comparing Photoselective Vaporization of the Prostate (PVP-120W) to Transurethral Resection of the Prostate (TURP) for the Treatment of Benign Hyperplasia of the Prostate (BPH)|PVP|St. Joseph's Healthcare Hamilton|No|Completed|January 2008|October 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Male|41 Years|N/A|No|||November 2014|November 19, 2014|September 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00527371||167346|
NCT00527930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-BR-0703, H-0706-009-209|Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer|Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (MBC) Previously Treated With or Resistant to an Anthracycline and Taxane|TORCH|Seoul National University Hospital|No|Completed|September 2007|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|September 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00527930||167303|
NCT00517712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAPLSG2004|Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia|Molecular Remission With Arsenic Trioxide in Acute Promyelocytic Leukemia: Indian APL Study Group - IAPLSG|IAPLSG04|Christian Medical College, Vellore, India|No|Recruiting|June 2004|July 2009|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|No|||August 2007|August 16, 2007|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00517712||168078|
NCT00518024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL 525/1-1|Safety and Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus|Safety and Effectiveness of Bilateral Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation) in the Treatment of Chronic Tinnitus||University Hospital Tuebingen|Yes|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|75 Years|No|||June 2010|June 28, 2010|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00518024||168054|
NCT00518037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1253-006|Quality of Life in Patients With Nonmelanoma Skin Cancer|Quality of Life in Patients With Nonmelanoma Skin Cancer||Northwestern University|No|Completed|June 2006|October 2006|Actual|October 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|112|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|nonmelanoma skin cancer patients|May 2014|May 22, 2014|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00518037||168053|
NCT00517738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIIBH-Ref.1639/GAS 166-09/11-1|Effect of Physical Training Program on Health-related Quality of Life in Cirrhosis|Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|February 2007|May 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|29|||Both|18 Years|70 Years|No|||October 2015|October 7, 2015|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517738||168076|
NCT00518609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 07 Phase I|Prevention of Infection in Indian Neonates - Phase I Observational Study|Prevention of Infection in Indian Neonates - Phase I Observational Study||NICHD Global Network for Women's and Children's Health|Yes|Completed|July 2003|July 2006|Actual|||Phase 1|Observational|Time Perspective: Prospective||1|Actual|1326|||Both|N/A|60 Days|Accepts Healthy Volunteers|||July 2014|July 29, 2014|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00518609||168010|
NCT00518895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGENDA|Trial of Dacarbazine With or Without Genasense in Advanced Melanoma|A Multicenter, Randomized, Double-blind Study of Dacarbazine With or Without Genasense in Chemotherapy-naive Subjects With Advanced Melanoma and Low LDH (The AGENDA Trial)|AGENDA|Genta Incorporated|Yes|Completed|July 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2009|November 4, 2011|August 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00518895||167988|
NCT00518908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 34-2007|Organ Protection With Sevoflurane Postconditioning|Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion: Postconditioning||University of Zurich|No|Completed|January 2008|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|90 Years|No|||July 2011|July 18, 2011|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518908||167987|
NCT00518947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH050634|Pharmacotherapy of Treatment-Resistant Mania|Pharmacotherapy of Treatment-Resistant Mania|TRM|University of Pittsburgh|No|Completed|November 1994|June 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00518947||167984|
NCT00518960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0003-02|The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome|The Effects of ProAlgaZyme Novel Algae Infusion on HDL Cholesterol and C-Reactive Protein in Individuals With Metabolic Syndrome||Health Enhancement Products, Inc.|No|Active, not recruiting|April 2007|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|70 Years|No|||August 2007|August 17, 2007|August 17, 2007||||No||https://clinicaltrials.gov/show/NCT00518960||167983|
NCT00519246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2579-4FW|Comparison of Pain Therapeutic Effects After Benign Mastectomy|Clinical Comparison of Postoperative Pain Therapeutic Effects After Benign Mastectomy|COPTEAM|Nanjing Medical University|Yes|Completed|February 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|2000|||Female|18 Years|64 Years|No|||March 2009|March 30, 2009|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519246||167961|
NCT00519259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-0009-1|Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1|Tolerability, Safety, and Pharmacokinetics of Repeated Sublingual Doses of Lobeline||National Institute on Drug Abuse (NIDA)||Active, not recruiting|February 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2006|October 25, 2007|June 29, 2006||||||https://clinicaltrials.gov/show/NCT00519259||167960|
NCT00528424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-858|AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease|A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease||Endo Pharmaceuticals|No|Completed|December 2007|May 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|286|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 11, 2007|Yes|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00528424||167265|
NCT00528398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93139|Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia|Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)||City of Hope Medical Center|Yes|Completed|September 1994|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|16 Years|60 Years|No|||December 2015|December 15, 2015|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528398||167267|
NCT00528411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00048|A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin|A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD)||AstraZeneca|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|123|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|September 10, 2007|Yes|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00528411||167266|
NCT00529243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4908|Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects|Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen|CHEER|Kaiser Permanente|No|Completed|September 2007|September 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|September 12, 2007|Yes|Yes||No|May 9, 2011|https://clinicaltrials.gov/show/NCT00529243||167202|A limitation of our study was the lack of a separate control arm. However, patients did serve as their own control by virtue of at least 6 months of HIV-1 ribonucleic acid(RNA)levels below the level of quantification before enrollment in the study.
NCT00529607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IZKF BIOMAT Aachen TVB 119|Diagnostics for the Reperfusion Injury Following MI|New Imaging and Diagnostic Techniques for the Assessment of Reperfusion Injury in Myocardial Infarction.||RWTH Aachen University|Yes|Completed|September 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|Biomarkers for Infarction and Inflammation|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  patients with acute ST elevation myocardial infarction and consecutive percutaneous             coronary intervention of the infarct-related artery (first myocardial infarction and             recurrent myocardial infarction, as long as infarct-related artery is occluded for             the first time)          -  written informed consent        or 30 patients with stable CAD (control group 1) or 30 healthy volunteers regarding        cardiovascular diseases (control group 2)|March 2009|March 19, 2009|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00529607||167174|
NCT00529269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AKR03|Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms|Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal Symptoms||Novartis||Completed|December 2006|||June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00529269||167200|
NCT00529594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|519/06|Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation|Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation||University of Sao Paulo|No|Completed|August 2006|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|17 Years|N/A|No|||March 2007|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00529594||167175|
NCT00529893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612093M|Efficacy of Atomoxetine in the Neuropsychological Tests Among Children With ADHD|Efficacy of Atomoxetine in the Neuropsychological Tests Among Children With ADHD||National Taiwan University Hospital|Yes|Active, not recruiting|July 2007|||April 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|30|||Both|10 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are diagnosed as DSM-IV, Attention Deficit Hyperactivity Disorder (ADHD).|October 2013|October 18, 2013|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00529893||167152|
NCT00530803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MontefioreMC|The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children|The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children||Montefiore Medical Center|Yes|Completed|September 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|4 Years|12 Years|No|||October 2009|October 26, 2009|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530803||167084|
NCT00530816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-004|Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma|An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma||Onyx Pharmaceuticals||Completed|September 2007|July 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|164|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|September 14, 2007|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00530816||167083|
NCT00527943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04736|Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)||Merck Sharp & Dohme Corp.|Yes|Terminated|December 2007|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12944|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|September 7, 2007|Yes|Yes|The trial was terminated at the request of the Data and Safety Monitoring Board.|No|May 9, 2014|https://clinicaltrials.gov/show/NCT00527943||167302|Prior to the planned study completion, the Data Safety Monitoring Board recommended that all participants stop treatment and that the study be closed-out. The protocol-defined target number of primary efficacy endpoints had been reached by this time.
NCT00528242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLx-2101-07-04|Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease|A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease.||Kadmon Corporation, LLC|No|Completed|June 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|September 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528242||167279|
NCT00528255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso-Obs-203|Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)|A Multicenter, Open-Label, Phase II Study of the Pharmacokinetics and Safety of the100 Mcg Misoprostol Vaginal Insert (MVI 100) in Women Requiring Cervical Ripening and Induction of Labor|Miso-Obs-203|Ferring Pharmaceuticals|No|Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 15, 2012|September 10, 2007|Yes|Yes|PK portion will be included in a future protocol|No||https://clinicaltrials.gov/show/NCT00528255||167278|
NCT00521820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-00-TL-OPI-504|Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure|A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Subjects With Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild to Moderate Congestive Heart Failure||Takeda|Yes|Terminated|June 2000|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|518|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|August 25, 2007|Yes|Yes|Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated    subjects compared to glyburide treated subjects.|No||https://clinicaltrials.gov/show/NCT00521820||167765|
NCT00517452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-098|Platelet Rich Plasma Study in Lower Extremity Bypass Surgery|Phase 2-3 Observational Wound Care Study Comparing Application of Platelet Rich Plasma With Standard of Care Wound Closure in Vascular Patients Requiring a Groin Incision.|PRP|Lawson Health Research Institute|No|Completed|May 2007|December 2007|Actual|||Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|81|||Both|35 Years|90 Years|No|Probability Sample|Vascular surgical patients scheduled for elective lower extremity bypass        surgery,aortoiliac revascularizations and endovascular AAA repair requiring a groin        incision|January 2011|January 4, 2011|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517452||168098|
NCT00517465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP20945|A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple-ascending-dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of R1511 in Type 2 Diabetic (T2D) Patients||Hoffmann-La Roche||Completed|September 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517465||168097|
NCT00517725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R76-CCM S78/407|Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure|Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function|CARNEBI|Centro Cardiologico Monzino|No|Completed|July 2007|May 2010|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|80 Years|No|||September 2010|September 15, 2010|August 16, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00517725||168077|
NCT00518050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-128|Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns|Melanoma Survivors: Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns||Memorial Sloan Kettering Cancer Center||Completed|October 2006|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|160|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible melanoma survivors will be initially identified and screened using the Melanoma        DMT Database. We will select a random sample from the database.|July 2015|July 15, 2015|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00518050||168052|
NCT00518336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109616 (Y7)|Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil|Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil||GlaxoSmithKline||Completed|November 2007|September 2010|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|433|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|August 17, 2007|Yes|Yes||No|July 12, 2010|https://clinicaltrials.gov/show/NCT00518336||168031|Interim analysis at Year 7 and Year 8 are superseded by the final analysis at Year 9.
NCT00518349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST161006|Colonoscope Passive Bending Function|Evaluation of a Novel Colonoscope Designed for Easier Passage Through Flexures: A Randomised Study||Norwegian Department of Health and Social Affairs|No|Active, not recruiting|August 2003|December 2009|Anticipated|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|120|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518349||168030|
NCT00518622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-004|Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)|A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|July 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|40|||Both|18 Years|55 Years|No|||August 2015|August 11, 2015|August 17, 2007|No|Yes||No|August 10, 2009|https://clinicaltrials.gov/show/NCT00518622||168009|
NCT00518921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12484|Capadenoson in Angina Pectoris|Phase IIa Efficacy and Safety Trial of Capadenoson in Patients With Chronic Stable Angina||Bayer|No|Withdrawn|March 2008|November 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|35 Years|75 Years|No|||January 2011|January 12, 2011|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518921||167986|
NCT00529672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-325|Surgery or Noninvasive Therapy for Varicose Veins|Randomized Single Center Comparative Study of the Treatment of Insufficient Greater Saphenous Vein: Surgery vs Ultrasound Guided Sclerotherapy With Foam and Endovenous Laser Therapy|Magna|Erasmus Medical Center|No|Recruiting|May 2007|May 2011|Anticipated|May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|80 Years|No|||November 2010|November 15, 2010|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529672||167169|
NCT00529685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0068|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld||||||N/A|N/A|N/A||||||||||||||August 26, 2010|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529685||167168|
NCT00530218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98074|Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant|Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant||City of Hope Medical Center||Completed|March 1999|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|61|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530218||167127|
NCT00528177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328-07137 1.2007.1463|Morphine vs. Oxycodone for Postoperative Pain Management|Phase 4: A Comparison of Intravenous Administration of Morphine vs. Oxycodone for Postoperative Pain Management Following Laparoscopic Hysterectomy or Myomectomy||Oslo University Hospital|No|Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|70 Years|No|||June 2007|July 3, 2011|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528177||167284|
NCT00528684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 007|Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas|A Phase I/II Clinical Trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN® for the Treatment of Patients With Histologically Confirmed Recurrent Malignant Gliomas||Oncolytics Biotech|Yes|Completed|July 2006|June 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2011|September 30, 2014|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528684||167245|
NCT00528697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-888|A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD)||AbbVie|Yes|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|278|||Both|6 Years|12 Years|No|||January 2013|January 21, 2013|September 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528697||167244|
NCT00529009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URT-14/BIO|Pharmacokinetic Investigation of UDCA in Bile and Serum|||Dr. Falk Pharma GmbH|No|Completed|May 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2010|May 5, 2010|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529009||167220|
NCT00529932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELECT-AMI|A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction|SELECT-AMI|Onze Lieve Vrouw Hospital|Yes|Terminated|September 2007|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|20 Years|75 Years|No|||April 2015|April 21, 2015|September 13, 2007||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00529932||167149|
NCT00530192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI-CA-001|Molecular Profiling Protocol (SCRI-CA-001)|A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers||Scottsdale Healthcare|Yes|Completed|September 2006|March 2009||March 2009|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||July 2009|July 9, 2009|September 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00530192||167129|
NCT00529906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612114R|Endophenotype, Molecular Genetic Study on Attention-Deficit/Hyperactivity Disorder|Endophenotype, Molecular Genetic Study on Attention-deficit/ Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|August 2007|August 2010|Anticipated|||N/A|Observational|Observational Model: Family-Based||1|Anticipated|200|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments|Both|7 Years|18 Years|No|Non-Probability Sample|The sample will consist of 200 children and adolescents with ADHD, aged 7-18.|December 2009|December 14, 2009|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00529906||167151|
NCT00530179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0307003|FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma|FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma|PET Chop|AHS Cancer Control Alberta|Yes|Active, not recruiting|July 2007|||August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||August 2011|December 6, 2011|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530179||167130|
NCT00530426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010513|Heart Failure Registry|ADHERE Core II - Acute Decompensated HEart Failure REgistry||Scios, Inc.||Completed|September 2001|February 2005|Actual|||Phase 4|Observational|Time Perspective: Retrospective||||150000|||Both|18 Years|N/A|No|||October 2007|January 30, 2014|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530426||167111|
NCT00531141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 07-078-VK|The Optical Coherence Tomography in Age-Related Macular Degeneration Study: The OCT in AMD Study|Reproducibility of Retinal Thickness Measurements by Optical Coherence Tomography in Age-Related Macular Degeneration The OCT in AMD Study||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|||Both|50 Years|N/A|No|Probability Sample|primary care clinic|June 2009|June 23, 2009|September 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00531141||167059|
NCT00531154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|heling-HMO-CTIL|Evaluation of the Dental Health Condition in Obesity Patients Before and After Bariatric Surgery|||Hadassah Medical Organization||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2007|September 17, 2007|September 17, 2007||||No||https://clinicaltrials.gov/show/NCT00531154||167058|
NCT00496275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00054|Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC|A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.||AstraZeneca|No|Completed|August 2006|May 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|17|||Both|18 Years|N/A|No|||April 2009|April 8, 2009|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00496275||169695|
NCT00496847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB023/07|Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect|Study on the Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect - A Double-blind, Controlled, Randomised,Parallel,Multi-centre Study||Virchow Group|No|Completed|August 2007|August 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|75 Years|No|||November 2009|December 15, 2014|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496847||169652|
NCT00496574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-102-06-KE|Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma|Evaluation of Long-term Clinical Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma||Medical Universtity of Lodz|Yes|Recruiting|May 2006|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|8 Years|18 Years|No|||February 2013|February 6, 2013|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496574||169673|
NCT00496587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0433|Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma|Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2007|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||June 2015|June 25, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496587||169672|
NCT00517764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155/2006|Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression|The Role of Childhood Adversity and Genetic Polymorphisms in the Serotonin and Brain-Derived Neurotrophic Factor Systems in the Sensitization to Stress in First-Onset Major Depression (Blue Sky Project)||Centre for Addiction and Mental Health|No|Completed|December 2006|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|299|||Both|16 Years|29 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517764||168074|
NCT00518102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012010|The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])|A Matched Cohort Study of Regranex (Becaplermin) and the Risk of Cancer||Ethicon, Inc.||Active, not recruiting|January 1998|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|4431|||Both|20 Years|N/A|No|Probability Sample|Patients with similar characteristics who were treated or who were not treated with        REGRANEX (becaplermin) between January 1998 and June 2003 identified in a health insurance        claims database.|December 2012|December 20, 2012|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518102||168049|
NCT00518076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OF.262/2006-CEP|Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant|||University of Sao Paulo|Yes|Recruiting|September 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|17 Years|30 Years|Accepts Healthy Volunteers|||August 2007|August 17, 2007|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00518076||168051|
NCT00518089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198782-005|A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis|||Allergan||Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|859|||Both|1 Year|N/A|No|||October 2011|October 24, 2011|August 16, 2007|Yes|Yes||No|June 15, 2010|https://clinicaltrials.gov/show/NCT00518089||168050|
NCT00518362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0701|To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)|To Compare the Efficacy and Safety of TW vs Valsartan in the DN||Nanjing University School of Medicine|Yes|Completed|July 2007|March 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|35 Years|65 Years|No|||April 2009|May 25, 2010|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518362||168029|
NCT00518635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB3711|Low Dose Growth Hormone in Obese PCOS Women|Effects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Metabolic Profile, Adipocyte IGF-I and Insulin Signaling, Intramyocellular Lipids, and Cortisol Metabolism in Obese Women With Polycystic Ovary Syndrome (PCOS)||Oregon Health and Science University|No|Withdrawn|October 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Female|21 Years|45 Years|No|||February 2013|February 18, 2013|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518635||168008|
NCT00530257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-3-3588|Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory|Effect of OROS-Methylphenidate (Concerta) on Different Domains of Attention and Working Memory in Children With Attention-Deficit/Hyperactivity Disorder|CHOP|Children's Hospital of Philadelphia|No|Completed|June 2004|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|6 Years|12 Years|No|||November 2011|November 15, 2011|September 13, 2007|Yes|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00530257||167124|
NCT00528164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HDO50895-01|Team PLAY (Positive Lifestyles for Active Youngsters)|Treating Childhood Obesity With Family Lifestyle Change|Team PLAY|University of Tennessee|Yes|Completed|September 2006|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|270|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528164||167285|
NCT00528450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-108|Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia|Phase II Study of Combined All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy||Memorial Sloan Kettering Cancer Center||Terminated|September 2007|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|120 Years|No|||December 2015|December 23, 2015|September 10, 2007|Yes|Yes|Lack of accrual|No|December 23, 2015|https://clinicaltrials.gov/show/NCT00528450||167263|
NCT00528437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 05-40 H12853|Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors|NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors||New York University School of Medicine|Yes|Completed|October 2005|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|6 Months|21 Years|No|||January 2016|January 25, 2016|September 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00528437||167264|
NCT00529022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0030|Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer|Phase I Trial of Sequential Azacitidine and Valproic Acid Plus Carboplatin in the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer||M.D. Anderson Cancer Center|No|Completed|August 2007|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|N/A|No|||February 2013|February 19, 2013|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00529022||167219|
NCT00529282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014206|A Study of Ceftobiprole in Patients With Fever and Neutropenia.|Multicenter, Randomized, Double-Blind Study of Ceftobiprole Versus Comparators in the Treatment of Patients With Fever and Neutropenia||Basilea Pharmaceutica|No|Terminated|October 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|September 11, 2007|Yes|Yes|Study discontinued due to administrative reasons unrelated to safety|No|January 26, 2010|https://clinicaltrials.gov/show/NCT00529282||167199|No analysis was performed due to early termination of the study.
NCT00530439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029|Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women|Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women|LiP|Odense University Hospital|No|Completed|October 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|360|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2008|July 15, 2011|September 13, 2007||No||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00530439||167110|
NCT00530829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCPDCID-4678|Impact of Home Zinc Treatment for Acute Diarrhea in Children|Clinical Effectiveness and Preventive Impact of Home Zinc Treatment for Acute Diarrhea in Children: A Cluster-randomized Field Trial in Rural Western Kenya||Centers for Disease Control and Prevention|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3000|||Both|2 Months|4 Years|Accepts Healthy Volunteers|||March 2010|March 8, 2010|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00530829||167082|
NCT00530842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.334|Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD|Effect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients (a Randomised, Double-blind, Double Dummy, 16 (2 x 8) Weeks, Crossover Study).||Boehringer Ingelheim||Completed|September 2007|||January 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||Actual|344|||Both|40 Years|75 Years|No|||September 2013|November 27, 2013|September 17, 2007||||No|December 30, 2009|https://clinicaltrials.gov/show/NCT00530842||167081|
NCT00496860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-801-01-06|Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies|Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies||Altor Bioscience Corporation|Yes|Completed|May 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|July 3, 2007|No|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT00496860||169651|
NCT00497367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2030|Safety Study to Assess the Feasibility of Use in Humans of the TAXUS Petal Bifurcation Coronary Stent System|A Prospective, Single-arm, Multicenter 2-phase Feasibility Study to Assess the TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System (TAXUS Petal)for the Treatment of de Novo Atherosclerotic Bifurcation Lesions||Boston Scientific Corporation|No|Completed|July 2007|June 2013|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|80 Years|No|||March 2015|March 25, 2015|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497367||169612|
NCT00497120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 2/27/99|A Combined Surgical and Medical Approach in Mild Sleep Apnea|||University Hospital, Antwerp||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||July 2007|July 5, 2007|July 4, 2007||||No||https://clinicaltrials.gov/show/NCT00497120||169631|
NCT00517790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-880|Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)|An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)||AbbVie|No|Completed|August 2007|June 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||January 2013|March 29, 2013|August 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517790||168072|
NCT00528788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001559|How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis|Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease||Duke University|Yes|Completed|September 2007|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||August 2012|January 20, 2016|September 10, 2007|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT00528788||167237|
NCT00528801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480|Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease|Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Disease||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|December 2004|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|212|||Both|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|212 participants, 160 will have sickle cell anemia, 52 will be matched controls based on        gender, age, and education level|December 2009|May 12, 2010|September 10, 2007||No||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00528801||167236|As a cross-sectional study, follow-up of patients not included. Age range of cases and controls not weighted enough to include elder population. Functional or perfusion brain measures not included. Biologic and genetic risk factors not included.
NCT00518375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E1-100154|Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus|A Comparative, Open-Label Study to Evaluate Graft Function in de Novo Renal Allograft Recipients Treated With Either a 'Reduced Dose' or a 'Standard Dose' of Cyclosporine in Combination With Sirolimus and Corticosteroids||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2000|May 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||250|||Both|18 Months|N/A|No|||August 2007|August 16, 2007|July 27, 2007||||No||https://clinicaltrials.gov/show/NCT00518375||168028|
NCT00518648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_RP1.1|Reduction of Falls in the Elderly - Parkinson's Disease|Reduction of Falls in the Elderly - Parkinson's Disease|REFINE-PD|Radboud University|No|Completed|August 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|187|||Both|20 Years|80 Years|No|||November 2010|November 22, 2010|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518648||168007|
NCT00529321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG4040.01|Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus|Open-label, Dose-escalating, Phase I Study of TG4040 (MVA-HCV) in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus (HCV Genotype 1)||Transgene||Completed|December 2006|September 2010|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|65 Years|No|||September 2010|September 2, 2010|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00529321||167196|
NCT00530023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP195/Z25|Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness|Pilot Study To Identify Effective Methods Of Training Pump Naïve Subjects To Use The Paradigm® 722 System And To Describe Clinical Effectiveness Compared To Subjects Continuing With Multiple Dose Injections (MDI) of Insulin|STAR2|Medtronic Diabetes|No|Completed|February 2006|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|70 Years|No|||May 2011|May 9, 2011|September 13, 2007|No|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00530023||167142|
NCT00527878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070218|Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome|A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations||National Institutes of Health Clinical Center (CC)||Terminated|September 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|2 Years|N/A|No|||February 2013|February 1, 2013|September 8, 2007||No|Failure to enroll adequate patient numbers due to small number of eligible patients|No|February 1, 2013|https://clinicaltrials.gov/show/NCT00527878||167307|
NCT00529035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-083|Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease|A Phase I Study of Ultra-Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2007|June 2016|Anticipated|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|September 11, 2007|Yes|Yes||No|August 9, 2012|https://clinicaltrials.gov/show/NCT00529035||167218|
NCT00528710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUHREC06|Efficacy of S-Adenosylmethionine in Fibromyalgia|Double-Blind, Placebo-Controlled Trial of the Impact of S-Adenosyl-L-Methionine (SAM-e) on the Mood and Other Symptoms in Fibromyalgia||Deakin University|No|Completed|November 2006|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||September 2007|September 11, 2007|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528710||167243|
NCT00528723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/033004/002/06|Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma|Multicentre, Multinational, Randomised, Double Blind, Double Dummy, Active Drug Controlled, Parallel Group Study Design Clinical Trial of the Efficacy and Tolerability of Beclomethasone Dipropionate 250 Mcg Plus Salbutamol 100 Mcg in HFA pMDI Fixed Combination vs. Beclomethasone Dipropionate 250 Mcg Plus Salbutamol 100 Mcg in CFC pMDI (Clenil® Compositum 250) Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma||Chiesi Farmaceutici S.p.A.|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|64 Years|No|||April 2010|April 21, 2010|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528723||167242|
NCT00528996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205.14|An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.|A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|September 2007|||May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|2080|||Both|40 Years|N/A|No|||April 2014|April 30, 2014|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00528996||167221|
NCT00529633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614929-1|The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients|Phase 3 Study: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients|ICM|University of California, Davis|Yes|Terminated|September 2007|December 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||July 2012|September 25, 2012|September 12, 2007|Yes|Yes|We could not recruit patients willing to be enrolled|No||https://clinicaltrials.gov/show/NCT00529633||167172|
NCT00529919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F050124003|Effects of Medium Chain Triglyceride Oil, Versus Olive Oil, for Weight Loss|The Effects of a Weight Loss Diet Containing Medium Chain Triglyceride Oil, Versus Olive Oil, on Body Composition in Free-Living Adults|Muffin|University of Alabama at Birmingham|No|Completed|March 2005|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|53|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||September 2007|September 12, 2007|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529919||167150|
NCT00527072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014500|PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept|A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab (REMICADE�) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL�)||Centocor Ortho Biotech Services, L.L.C.|No|Completed|July 2007|October 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|217|||Both|18 Years|75 Years|No|||August 2012|August 28, 2012|September 6, 2007|Yes|Yes||No|May 28, 2010|https://clinicaltrials.gov/show/NCT00527072||167369|
NCT00527384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16014-CP-001|Biomarker Analysis of Stress|Biomarker Signatures of Biological, Chemical, or Psychological Stress||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|October 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|N/A|N/A|No|||April 2015|April 13, 2015|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527384||167345|
NCT00527397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171105|Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes|An Open-Label, Uncontrolled Long-Term Safety Study Of CP-464,005 (Inhaled Insulin) In Japanese Patients With Type 1 Or Type 2 Diabetes||Pfizer|No|Terminated|August 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|16 Years|75 Years|No|||July 2009|October 5, 2009|September 7, 2007|No|Yes|See termination reason in detailed description.|No|July 15, 2009|https://clinicaltrials.gov/show/NCT00527397||167344|As a result of Pfizer's decision (18 Oct 2007) to return the worldwide rights for CP-464,005 (insulin human [rDNA origin]) Inhalation Powder) to Nektar, from which Pfizer licensed inhaled insulin technology, it was decided to terminate this study.
NCT00495638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070181|Pulmonary Hypertension, Hypoxia and Sickle Cell Disease|Pulmonary Hypertension and the Hypoxic Response in SCD||National Institutes of Health Clinical Center (CC)||Completed|June 2007|December 2014||||N/A|Observational|N/A|||Actual|29|||Both|3 Years|20 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|June 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00495638||169741|
NCT00527618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31203-D|Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV|A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons||University of Washington|No|Completed|December 2007|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|September 7, 2007|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00527618||167327|Our findings are limited by the high loss to follow up, which is especially problematic in cross-over studies.
NCT00527631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176/2005|Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer|Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer: Pilot Trial of a Phase I/II Study|OVAR-IMRT-01|Heidelberg University|No|Recruiting|July 2006|November 2012|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Female|18 Years|75 Years|No|||August 2007|September 7, 2007|September 7, 2007||||No||https://clinicaltrials.gov/show/NCT00527631||167326|
NCT00497653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01HD35629 P2|Oral Administration of DCI to Women With PCOS|Determination if Oral DCI Administration to Women With PCOS Increases Total DCI Content in Urine and Blood...|PCOS|Virginia Commonwealth University|Yes|Terminated|February 2001|July 2009|Actual|July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|13|||Female|18 Years|40 Years|No|||November 2011|November 15, 2011|July 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00497653||169590|
NCT00528515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG-NKEBN/364-A/2005|Desflurane Versus Propofol Anesthesia for Off-Pump CABG|Comparison of Desflurane and Propofol Anesthesia for Off-Pump Coronary Artery Bypass Grafting Surgery||Medical University of Gdansk|No|Completed|February 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|75 Years|No|||May 2008|May 15, 2008|September 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528515||167258|
NCT00528502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0147|Lidocaine Supplement for Minimal Invasive Parathyroid Surgery|Prevention of Laryngeal Reflexes in Minimal Invasive Parathyroid Surgery by the Use of Topical Lidocaine||M.D. Anderson Cancer Center|Yes|Withdrawn|June 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||December 2012|December 5, 2012|September 11, 2007||No|Terminated due to no patient enrollment.|No||https://clinicaltrials.gov/show/NCT00528502||167259|
NCT00528814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|519|Effectiveness of a School-Based Hand Sanitizer Program on Reducing Asthma Exacerbations|Effect of a School Based Hand Sanitizer Program on Asthma||University of Alabama at Birmingham|Yes|Completed|January 2009|May 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|527|||Both|5 Years|12 Years|No|||December 2013|December 3, 2013|September 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00528814||167235|
NCT00529100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10259|Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer|A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|December 2005|September 2012|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|September 12, 2007|Yes|Yes||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00529100||167213|
NCT00529074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO-1053537|Epidural Anesthesia /Analgesia Versus PCA for Laparoscopic Complex Ventral Hernia Repair: A Randomized Controlled Trial|Epidural Anesthesia /Analgesia Versus PCA for Laparoscopic Complex Ventral Hernia Repair: A Randomized Controlled Trial||University of Missouri-Columbia|No|Withdrawn|February 2006|August 2013|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2011|September 20, 2011|September 11, 2007||No|never activated|No||https://clinicaltrials.gov/show/NCT00529074||167215|
NCT00529087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200K1-3356|Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain|A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain||Valeant Pharmaceuticals International, Inc.||Completed|August 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|460|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|September 11, 2007|Yes|Yes||No|December 24, 2009|https://clinicaltrials.gov/show/NCT00529087||167214|
NCT00529334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMC 2007-153|A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast|A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast for Women With Stage 0, 1, or IIA (<=3cm) Breast Cancer|CK-PBI|Georgetown University|Yes|Withdrawn|September 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|45 Years|N/A|No|||November 2013|November 19, 2013|September 12, 2007|||PI left institution|No||https://clinicaltrials.gov/show/NCT00529334||167195|
NCT00529347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF-3200B0-113478-1|Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern|The Effect of Positive End Expiratory Pressure (PEEP) on the Breathing Pattern During Neurally Adjusted Ventilatory Assist (NAVA)||University Hospital Inselspital, Berne|No|Completed|September 2007|July 2009|Actual|January 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|85 Years|No|||September 2009|September 7, 2009|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00529347||167194|
NCT00529360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L 9471|Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL|Clofarabine in Combination With Cytarabine and Total Body Irradiation Followed by Allogeneic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia and Acute Non-Lymphoblastic Leukemia||New York Medical College|Yes|Completed|June 2007|March 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|N/A|30 Years|No|||March 2016|March 23, 2016|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00529360||167193|
NCT00529698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSP-001|Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein|A Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat Protein in HIV-1 Uninfected Adult Volunteers|ISSP-001|Istituto Superiore di Sanità|Yes|Completed|January 2004|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2007|February 28, 2011|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00529698||167167|
NCT00530985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR0024|Preserving Function Among Disability Applicants|Preserving Function Among Disability Applicants: A Motivational Enhancement Approach to Benefits Counseling||VA Office of Research and Development|No|Completed|February 2007|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||June 2009|June 30, 2009|September 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00530985||167071|
NCT00528190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006768|Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis|Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial||Ottawa Hospital Research Institute|Yes|Completed|October 2007|May 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|6 Years|N/A|No|||September 2011|September 23, 2011|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528190||167283|
NCT00531167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT 111098|Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B|Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B||Korea University|Yes|Completed|April 2007|October 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|16 Years|75 Years|No|||October 2012|October 18, 2012|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531167||167057|
NCT00529295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR95-IRB-116|Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term|||China Medical University Hospital|No|Completed|June 2005|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|220|||Female|18 Years|45 Years|No|||September 2006|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00529295||167198|
NCT00529620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5184|Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal|Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal||London School of Hygiene and Tropical Medicine|Yes|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1833|||Both|2 Months|59 Months|Accepts Healthy Volunteers|||May 2010|May 26, 2010|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00529620||167173|
NCT00494806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0887|Effects of Rocking on Postoperative Ileus Duration Study|The Effects of Rocking Chair Motion on Postoperative Ileus Duration, Subjective Pain and Time to Discharge Following Abdominal Surgery||M.D. Anderson Cancer Center|Yes|Completed|July 2005|February 2007|Actual|February 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|66|||Both|21 Years|N/A|No|||July 2012|July 31, 2012|June 29, 2007||No||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00494806||169803|
NCT00494819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700916|Validity of ADHD Subtypes Using Neuropsychological Measure|Discriminate Validity of ADHD Subtypes Using Neuropsychological Test||National Taiwan University Hospital|Yes|Completed|September 2005|August 2006|Actual|||N/A|Observational|Observational Model: Case Control||1|Actual|122|||Both|7 Years|10 Years|No|Non-Probability Sample|children with ADHD|August 2008|November 12, 2012|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00494819||169802|
NCT00495118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002017|A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.|Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85.||Janssen, LP||Completed|October 2001|March 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|314|||Both|18 Years|N/A|No|||May 2010|May 16, 2011|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00495118||169780|
NCT00495352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-095-PP-05A|The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia|1. The Pharmacogenetic Study of Interaction Among Antipsychotics, Readiness to Change, and Pharmacological Intervention for Smoking Cessation Among Schizophrenic Patients 2. Stages of Change and Outcomes of Nicotine Replacement Therapy in Chronic Schizophrenic Patients|PSIAARP|Yu-Li Hospital|Yes|Completed|January 2006|December 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|360|||Both|16 Years|65 Years|No|||April 2010|April 13, 2010|June 30, 2007||||No||https://clinicaltrials.gov/show/NCT00495352||169762|
NCT00496288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102/07 (HT4351)|Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer|Phase II Multicenter Clinical Trial of Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer||Assaf-Harofeh Medical Center|Yes|Recruiting|March 2008|||March 2023|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Female|30 Years|90 Years|No|||June 2008|April 4, 2011|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496288||169694|
NCT00495963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ehics committee, Sir Ganga Ram|Diagnosis of Ventilator- Associated Pneumonia in Children: A Comparative Study of Bronchoscopic and Non-Bronchoscopic Methods|||Sir Ganga Ram Hospital|No|Completed|January 2003|September 2003|Actual|||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|N/A|12 Years|No|||July 2007|October 16, 2008|July 2, 2007||||No||https://clinicaltrials.gov/show/NCT00495963||169719|
NCT00496262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI3023_2001|Human Fibrinogen - Pharmacokinetics|Pharmacokinetics of Haemocomplettan® P in Subjects With Congenital Fibrinogen Deficiency||CSL Behring|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|6 Years|N/A|No|||February 2011|September 21, 2011|July 3, 2007|No|Yes||No|May 19, 2009|https://clinicaltrials.gov/show/NCT00496262||169696|
NCT00528307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2006-03|Changes in Myocardial Perfusion During Chronic Multi Site Biventricular Versus Right Ventricular Apex Pacing in Patients With Normal Left Ventricular Function Undergoing His Bundle Ablation for Drug-refractory Atrial Fibrillation|Changes in Myocardial Perfusion During Chronic Multi Site Biventricular Versus Right Ventricular Apex Pacing in Patients With Normal Left Ventricular Function Undergoing His Bundle Ablation for Drug-refractory Atrial Fibrillation|SOS|R&D Cardiologie|No|Terminated|October 2007|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528307||167274|
NCT00528827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardene® I.V. 1406|A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension|A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension||Facet Biotech|Yes|Withdrawn|September 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|2 Years|16 Years|No|||March 2012|March 15, 2012|September 10, 2007|Yes|Yes|Due to the sale of Cardene IV, the sponsor has stopped enrollment and withdrawn the study. No    safety issues were identified.|No||https://clinicaltrials.gov/show/NCT00528827||167234|
NCT00528840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-856|Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease|A Phase 3, Open-Label Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease|JOINT-I|Endo Pharmaceuticals|No|Completed|October 2007|April 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 11, 2007|Yes|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00528840||167233|
NCT00529373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-018|A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|September 2007|June 2020|Anticipated|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16716|||Female|65 Years|N/A|No|||February 2016|February 4, 2016|September 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529373||167192|
NCT00529386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOTOX-CP|Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|A Prospective Pilot Randomized Sham Controlled Study to Evaluate the Safety and Efficacy of Botox™ for the Treatment of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome||Queen's University|No|Completed|January 2006|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|N/A|No|||June 2009|September 13, 2011|September 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529386||167191|
NCT00529711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/IGK-KAL/DNA/04|The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients|The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients||Innogene Kalbiotech Pte. Ltd|No|Completed|July 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|45 Years|80 Years|No|||September 2007|September 12, 2007|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529711||167166|
NCT00529997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST-A-01|Dynamic Stabilization for Lumbar Spinal Stenosis With Stabilimax NZ® Dynamic Spine Stabilization System|Clinical Study Comparing Dynamic Stabilization of the Lumbar Spine With the Stabilimax NZ® Dynamic Spine Stabilization System to Posterolateral Instrumented Fusion - In Patients With Lumbar Spinal Stenosis||Applied Spine Technologies|Yes|Terminated|February 2007|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|480|||Both|21 Years|N/A|No|||August 2010|August 10, 2010|September 13, 2007|Yes|Yes|Company has ceased operation|No||https://clinicaltrials.gov/show/NCT00529997||167144|
NCT00530010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 1365-001|Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma||Northwestern University|Yes|Recruiting|December 2004|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with unresectable cancer primarily in the liver with the liver being the only        site of disease or the dominant site of disease|October 2015|October 6, 2015|September 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00530010||167143|
NCT00530998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071115, 140015|Minimally Invasive Surgery: Using Natural Orfices|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Trans-Vaginal Appendectomy and Cholecystectomy|NOTES|University of California, San Diego|No|Recruiting|September 2007|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Female|18 Years|75 Years|No|Non-Probability Sample|Group #1: NOTES Appendectomy - Transvaginal approach:        Subjects will be female between the ages of 18-75 who present to the emergency room and        are subsequently diagnosed with acute appendicitis. Following diagnosis, investigators        will determine if the procedure can be completed via the transvaginal approach. If the        patient satisfies the listed criteria then researchers will present study information and        offer participation.        Group # 2: NOTES Cholecystectomy - Transvaginal approach:        Female subjects, between the ages of 18-75 who present in the UCSD surgery clinic for        elective cholecystectomy will be offered participation in this study.|March 2016|March 17, 2016|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00530998||167070|
NCT00531284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-007|Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma|Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma||Onyx Pharmaceuticals|No|Active, not recruiting|September 2007|December 2015|Anticipated|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|17||Actual|184|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|September 14, 2007|Yes|Yes||No|October 5, 2015|https://clinicaltrials.gov/show/NCT00531284||167048|
NCT00528749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RespEffort|Non-Invasive Measurement of Respiratory Effort|Non-Invasive Measurement of Respiratory Effort||Walter Reed Army Medical Center|No|Recruiting|February 2007|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|20|||Both|18 Years|N/A||||August 2007|September 11, 2007|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528749||167240|
NCT00530855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0904|Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures|A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects With Partial-onset Seizures||UCB Pharma||Completed|February 2008|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|322|||Both|16 Years|70 Years|No|||May 2015|May 18, 2015|September 14, 2007|Yes|Yes||No|May 18, 2015|https://clinicaltrials.gov/show/NCT00530855||167080|
NCT00498771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #006-116|Aquatic Exercise Study for Breast Cancer Patients With Lymphedema|Aquatic Exercise Study for Breast Cancer Patients With Lymphedema||Baylor Research Institute|No|Completed|July 2006|June 2013|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|21 Years|90 Years|No|||June 2013|June 17, 2013|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498771||169504|
NCT00526851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE17Z06|Oral Cancer Screening Among Nursing Home Dentists in Ohio|Oral Cancer Screening: Practices, Knowledge and Opinions of Ohio Nursing Home Dentists||Case Comprehensive Cancer Center|No|Completed|March 2007|January 2009|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|37|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nursing Home Dentists in Ohio|February 2014|February 4, 2014|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00526851||167386|
NCT00495131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705080M|Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients|Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan||National Taiwan University Hospital|Yes|Completed|June 2006|July 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|N/A|No|||September 2009|September 7, 2009|June 29, 2007||No||No|December 21, 2008|https://clinicaltrials.gov/show/NCT00495131||169779|
NCT00495365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005104|A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.|Evaluation of Dose Conversion From Variable Dosing Intervals of Darbepoetin Alfa to Variable Dosing Intervals of Epoetin Alfa in Patients With the Anemia of Chronic Kidney Disease||Ortho Biotech Products, L.P.|No|Terminated|June 2003|September 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|8|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|June 29, 2007|||This study was stopped due to slow enrollment|No||https://clinicaltrials.gov/show/NCT00495365||169761|
NCT00495651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12136 TEMPRANO|Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)|Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)|TEMPRANO|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|March 2008|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2073|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495651||169740|
NCT00496301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOGUG-02-06|Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC|Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)|SOGUG-02-06|Spanish Oncology Genito-Urinary Group|Yes|Completed|November 2006|December 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496301||169693|
NCT00496626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-030|An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)|An Immunogenicity and Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years||Merck Sharp & Dohme Corp.||Completed|July 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|600|||Both|9 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|July 3, 2007|Yes|Yes||No|February 8, 2010|https://clinicaltrials.gov/show/NCT00496626||169669|
NCT00496873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0818|Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan|A Single-Center, Open-Label Study to Evaluate the Safety and Efficacy of Nipent, Cytoxan, and Rituxan ("PCR") in the Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin's Lymphoma or Bulky Lymphoma||M.D. Anderson Cancer Center|No|Completed|June 2005|||December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496873||169650|
NCT00496600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050612|Phase I Study of Patupilone and RAD001|Phase I Study of Patupilone and RAD001 in Patients With Refractory Solid Tumor Malignancy||Rutgers, The State University of New Jersey|No|Completed|July 2007|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|July 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00496600||169671|
NCT00496613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-090|Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors|Chemotherapy-Induced Cognitive Change and DNA Damage in Breast Cancer Survivors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|200|||Female|50 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Survivors Healthy women|July 2015|July 21, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496613||169670|
NCT00497380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81167|Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery|Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery||Texas A&M University|No|Active, not recruiting|April 2009|February 2018|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|32|||Female|30 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497380||169611|
NCT00497393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-130607|Clinical Decision Unit (CDU) - Evaluation of a Novel Approach to Address Emergency Department Overcrowding|Clinical Decision Unit (CDU) - Evaluation of a Novel Approach to Address Emergency Department Overcrowding||University of Alberta|No|Completed|July 2007|December 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|6217|||Both|17 Years|N/A|No|||September 2008|September 11, 2008|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497393||169610|
NCT00528853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15660A|Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation|Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation. Can We Help Diagnose Acute Rejection and Better Predict Bronchiolitis Obliterans?||University of Chicago|No|Completed|August 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|65 Years|No|Non-Probability Sample|Lung transplant patients meeting inclusion criteria will be recruited from the lung        transplant clinic.|September 2013|September 4, 2013|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528853||167232|
NCT00528528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013516|An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants|A Phase IIa Randomized, Open-Label Study of Telaprevir (VX-950) Administered Every 12 or Every 8 Hours in Combination With Either Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol) in Treatment-Naive Subjects With Chronic Genotype 1 Hepatitis C Infection||Tibotec BVBA|No|Completed|October 2007|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|166|||Both|18 Years|65 Years|No|||June 2014|June 13, 2014|September 10, 2007||No||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00528528||167257|
NCT00529425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-VF-20060072 - femoral neck|Postoperative Analgesia With Local Infiltration After Femoral Neck Fracture|Postoperative Analgesia With Local Infiltration After Femoral Neck Fracture vs. Traditional Treatment of Pain With Opioids||Odense University Hospital|Yes|Completed|January 2008|December 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A||||April 2010|May 5, 2010|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00529425||167188|
NCT00529438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-0501|RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies|A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies||Reata Pharmaceuticals, Inc.||Completed|April 2006|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|September 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529438||167187|
NCT00529113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-0702|Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer|A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer||Reata Pharmaceuticals, Inc.||Terminated|September 2007|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|33|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|September 12, 2007|Yes|Yes|To pursue other indications|No||https://clinicaltrials.gov/show/NCT00529113||167212|
NCT00529126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C209|Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy|A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy||Pacira Pharmaceuticals, Inc|No|Completed|September 2007|July 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|September 12, 2007|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00529126||167211|
NCT00529399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAD65 (IND)|Effects of Recombinant Human Glutamic Acid Decarboxylase . . .|Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-alum) on the Progression of Type 1 Diabetes in New Onset Subjects||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|February 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|126|||Both|3 Years|45 Years|No|||May 2013|May 30, 2013|September 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529399||167190|
NCT00529412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSM-CC-01|Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction|Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial||Nihon University|Yes|Completed|August 2003|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|N/A|79 Years|No|||June 2007|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00529412||167189|
NCT00529724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0024|Body Weight Gain, Parkinson, Subthalamic Stimulation|Mechanisms of Body Weight Gain in Patients With Parkinson's Disease After Subthalamic Stimulation||University Hospital, Clermont-Ferrand|No|Recruiting|September 2007|June 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|32|||Both|18 Years|70 Years|No|||January 2011|January 18, 2011|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00529724||167165|
NCT00529737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0434|Effect on Clip Markers After Vacuum-Assisted Biopsy by Postprocedure Mammogram|The Effect on Clip Markers Migration After Vacuum-Assisted Biopsy by Postprocedure Mammogram||M.D. Anderson Cancer Center|Yes|Completed|December 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|61|||Female|N/A|N/A|No|||July 2012|July 26, 2012|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00529737||167164|
NCT00527215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010212|Phase 2 Study of Darbepoetin Alfa Extended Dosing|A Study of Darbepoetin Alfa Administered Once Every Four Weeks in Chronic Renal Insufficiency (CRI) Subjects With Anemia||Amgen||Completed|March 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||May 2009|May 21, 2009|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527215||167358|
NCT00530868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061229006|Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer|A Phase II, Randomized, Open Label Trial of Pre-operative (Neoadjuvant)Letrozole (Femara) vs. Letrozole in Combination With Avastin in Post Menopausal Women With Newly Diagnosed Operable Breast Cancer||University of Alabama at Birmingham|Yes|Active, not recruiting|October 2007|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|19 Years|N/A|No|||February 2016|February 23, 2016|September 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530868||167079|
NCT00498784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91458|HR-QoL and Sexuality in Mirena Inserted Contraception Users|A Multicenter, Open Labelled, Uncontrolled, Phase IV Clinical Study to Evaluate the Health-related Quality of Life and Sexual Well-being in Young (18-35) Healthy Mirena Users Switching From OC, Over the First Year Post-insertion.||Bayer|No|Completed|November 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 21, 2013|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498784||169503|
NCT00498797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00055|E3-Hormone Refractory Prostrate Cancer Taxotere Combination|A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)||AstraZeneca|No|Completed|December 2005|September 2008|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|86|||Male|18 Years|N/A|No|||April 2011|April 27, 2011|July 9, 2007||||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00498797||169502|
NCT00494546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2044|High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer|High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer||VA Puget Sound Health Care System|No|Completed|January 1999|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|568|||Male|40 Years|80 Years|No|||June 2007|June 28, 2007|June 28, 2007||||No||https://clinicaltrials.gov/show/NCT00494546||169823|
NCT00495690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/7/46/03-RHN|Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease|Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Mortality and Severe Disease Requiring Hospitalization||Society for Applied Studies|No|Completed|November 2004|May 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|2012|||Both|N/A|4 Weeks|No|||September 2011|September 14, 2011|June 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00495690||169737|
NCT00496015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107137|Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A|Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Vaccine GSK1024850A and DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) and Assessment of Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage||GlaxoSmithKline||Completed|July 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|750|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||May 2012|May 3, 2012|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496015||169715|
NCT00496314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-20-06|Physician's Comfort Level and Satisfaction Study With The e2TM Collector Compared to the Spatula/CytoBrush Technique|Clinical Study Assessing Physician's Comfort Level and Satisfaction When Using The e2TM Cervical Cell Collector Compared to the Standard Spatula/CytoBrush Technique||CytoCore, Inc.|No|Terminated|May 2007|January 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|||June 2008|June 13, 2008|July 2, 2007||No|Terminated for lack of resources to complete.|No||https://clinicaltrials.gov/show/NCT00496314||169692|
NCT00496340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15009|Phase II Trial of Pentostatin and Targeted Busulfan|Phase II Trial of Pentostatin and Targeted Busulfan as a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Using Laboratory-Guided (CD4-guided) Immunosuppression.|Pento & tBU|H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 2007|August 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||March 2014|May 30, 2014|June 29, 2007|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00496340||169690|Bone marrow chimerism data were available for only 38 patients at day +28 and for only 36 patients at day +100.
NCT00496886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR050969|Determining How the Nervous System Processes Pain in Adults With Fibromyalgia|Imaging the Cognitive Modulation of Pain||University of Wisconsin, Madison|No|Completed|April 2006|June 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|137|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community and primary care clinic samples.|February 2013|October 1, 2015|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00496886||169649|
NCT00497133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KA-20070023|Alpha-Cell Sensitivity to GLP-1 in Patients With Type 2 Diabetes|||University of Copenhagen|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Blood for further analyzes and buffy coat|Both|40 Years|75 Years|Accepts Healthy Volunteers||Patients with type 2 diabetes mellitus and matched control subjects.|June 2008|June 3, 2008|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497133||169630|
NCT00497406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-4-0027/ethics 22128|A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Tx & IMRT Tomo to Reduce Xerostomia|A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Transfer Procedure and Intensity Modulated Radiation Therapy (Helical Tomotherapy) to Reduce Dryness of Mouth (Xerostomia) in Head and Neck Cancer Patients After Surgery||AHS Cancer Control Alberta|Yes|Active, not recruiting|December 2005|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|46|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00497406||169609|
NCT00497419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06199|Reperfusion Time in ST Segment Elevation Myocardial Infarction (STEMI)|Evaluation of a Fast Track for Patients With STEMI||University Hospital, Geneva|Yes|Completed|January 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2008|August 19, 2008|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497419||169608|
NCT00529152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA30-0307|Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients|A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia||ApoPharma|Yes|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|10 Years|No|||August 2009|August 25, 2009|September 12, 2007||No||No|June 26, 2009|https://clinicaltrials.gov/show/NCT00529152||167209|
NCT00529139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH - SLED - 01|Hannover Dialysis Outcome Study|The Hannover-Dialysis-Outcome (HAN-D-OUT)-Study: Comparison of Standard Versus Intensified Extended Dialysis in Treatment of Patients With Acute Kidney Injury in the Intensive-Care Unit|HAND-OUT|Hannover Medical School|No|Completed|July 2003|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|80 Years|No|||September 2007|September 14, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00529139||167210|
NCT00529763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-160|Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects|A Phase II Study to Determine the Activity of Dasatinib Administered Orally (PO) at a Dose of 100 mg Once Daily (QD) in Chronic Phase Chronic Myelogenous Leukemia (CML), at a Dose of 70 mg Twice Daily (BID) in Advanced Phase Chronic Myelogenous Leukemia (CML) Chinese Subjects Who Are Resistant to or Intolerant of Imatinib Mesylate (Gleevec®)||Bristol-Myers Squibb|No|Active, not recruiting|November 2007|December 2015|Anticipated|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|September 13, 2007|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00529763||167162|
NCT00529750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8261|Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension|Comparative Trial of the Effects of Irbesartan vs Atenolol on the Endothelial Function of Hypertensive Patients With Metabolic Syndrome||Sanofi||Completed|July 2002|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Male|18 Years|80 Years|No|||January 2011|January 11, 2011|September 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00529750||167163|
NCT00530036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 06-298|Burden of Urinary Incontinence in Home Care Patients in the State of Geneva|||University Hospital, Geneva|No|Active, not recruiting|January 2004|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||2|Actual|699|||Both|N/A|N/A|No|||August 2007|September 14, 2007|September 14, 2007||||No||https://clinicaltrials.gov/show/NCT00530036||167141|
NCT00530296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/08710-8|CBT to Treat Depression in Renal Patients|Effectiveness of Cognitive Behavioral Therapy in Patients With End-Stage Renal Disease in Hemodialysis and With Depression|CBTRPat|Federal University of São Paulo|No|Recruiting|June 2005|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|80 Years|No|||September 2007|September 14, 2007|September 14, 2007||||No||https://clinicaltrials.gov/show/NCT00530296||167121|
NCT00530582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAD 108 ex|Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women|Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women||Max-Planck-Institute of Psychiatry|No|Completed|November 2003|July 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|10|||Female|54 Years|70 Years|Accepts Healthy Volunteers|||September 2007|September 14, 2007|September 14, 2007||||No||https://clinicaltrials.gov/show/NCT00530582||167100|
NCT00498498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S001.2|Observational Endothelin and Markers of Cellular Apoptosis In CSF Head Injury|A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury|Endothelin|Virginia Commonwealth University|No|Completed|July 2007|December 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|51|Samples Without DNA|CSF, plasma|Both|18 Years|70 Years|No|Probability Sample|Fifty patients will be enrolled in this trial. Subjects will be eligible who have severe        traumatic brain injury (the majority of patients) or moderate TBI together with lesions on        CT scans sufficient to warrant placement of ventriculostomy catheter.|November 2011|November 15, 2011|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498498||169525|
NCT00495378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005128|RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia|Retrospective Review of Alternate PROCRIT Dosing In Patients With Chemotherapy Related Anemia||Ortho Biotech, Inc.|No|Terminated|November 2002|March 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||June 2007|July 2, 2007|June 29, 2007|||This study was stopped due to slow enrollment after enrolling 25 of 200 patients.|No||https://clinicaltrials.gov/show/NCT00495378||169760|
NCT00494832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31416-A|Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery|Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery||University of Washington|Yes|Completed|February 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||September 2012|September 12, 2012|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494832||169801|
NCT00496353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2461-002|MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)|A Phase I/II Dose Escalation and Proof-of-Concept Study of MK2461 in Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.||Completed|June 2007|November 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496353||169689|
NCT00496366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040608|Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer|Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer||Rutgers, The State University of New Jersey|No|Active, not recruiting|July 2007|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||November 2015|November 5, 2015|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496366||169688|
NCT00496067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-06-008|Uterine Artery Occlusion for Fibroid Related Bleeding|An Evaluation of a Doppler-Guided Uterine Artery Occlusion Device as Treatment for the Reduction of Fibroid-Associated Bleeding||Ethicon, Inc.|Yes|Terminated|April 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Female|25 Years|50 Years|No|||March 2011|March 8, 2011|July 3, 2007||No|Data required further pilot work to be undertaken.|No||https://clinicaltrials.gov/show/NCT00496067||169711|
NCT00496080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-06-004|Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding|A Pivotal Study of Doppler Guided Uterine Artery Occlusion as Treatment for the Reduction of Fibroid Associated Bleeding|DUAO|Ethicon, Inc.|Yes|Terminated|June 2007|October 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Female|25 Years|50 Years|No|||September 2012|September 6, 2012|July 3, 2007|Yes|Yes|Trial terminated early due to results from a similar study.|No|June 19, 2012|https://clinicaltrials.gov/show/NCT00496080||169710|Study was terminated early because 6 mo interim analysis of parallel European study showed that device was not meeting the primary endpoint. Target enrollment was 200 subjects, but results are based on 87 subjects who were treated with the device.
NCT00495976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hot drink|Study to Investigate the Effects of Hot Drinks on Nasal Airway Resistance and Symptoms of Common Cold|A Pilot Study to Investigate the Effects of Hot Drinks on Nasal Airway Resistance and Symptoms of Common Cold||Cardiff University|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|March 21, 2008|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495976||169718|
NCT00495989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/197|Saliva and Dental Calculus in Handicapped People|The Relationship Between Saliva and Dental Calculus in a Population of Institutionalized Handicapped Persons||University Hospital, Ghent|No|Completed|June 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|5 Years|N/A|No|||April 2009|April 9, 2009|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00495989||169717|
NCT00496002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-PSI-5268-06-305|Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus|A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus|QUASH 1|Pharmasset||Terminated|August 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|16 Years|N/A|No|||April 2009|April 23, 2009|July 2, 2007|||The study was terminated in the interest of patient safety.|No||https://clinicaltrials.gov/show/NCT00496002||169716|
NCT00496639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YIG482|Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes|Stent vs. Angioplasty for Treatment of Thrombosed AV Grfats: Long-Term Outcomes||National Kidney Foundation|No|Recruiting|October 2006|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|19 Years|N/A|No|||May 2008|May 21, 2008|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496639||169668|
NCT00497172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRDIT 00-02/02|Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial|An Italian Multicenter, Randomized, Single Blind Study of the Sirolimus Eluting Stent in the Treatment Of Diabetic Patients With De Novo Coronary Artery Lesions|DESSERT|Cordis Corporation|Yes|Completed|January 2004|April 2009|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2010|February 3, 2010|July 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00497172||169627|
NCT00497146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-030|The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4|The PRIMO Study: Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4|PRIMO|AbbVie|Yes|Completed|February 2008|March 2012|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|N/A|No|||March 2013|March 8, 2013|July 3, 2007|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00497146||169629|
NCT00497159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM05|A Study of the Novel Drug Dimebon in Patients With Huntington's Disease|A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease|DIMOND|Medivation, Inc.|Yes|Completed|July 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|29 Years|N/A|No|||May 2015|May 16, 2015|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00497159||169628|
NCT00498290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-51|The Protocol of Enhanced Recovery After Surgery in Colorectal Surgery|The Protocol of Enhanced Recovery After Surgery in Colorectal Surgery|ERAS|Fudan University|Yes|Recruiting|September 2006|March 2010|Anticipated|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|80 Years|No|||March 2009|March 24, 2009|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00498290||169541|
NCT00498303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V44P11S|Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008|A Phase III, Multicenter, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2007/2008 When Administered to Adult and Elderly Subjects||Novartis|No|Completed|June 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention||||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 21, 2008|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00498303||169540|
NCT00529165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN04277490|The Necessity of an Injection-Meal-Interval in Patients With Type 2 Diabetes Mellitus and Therapy With Human Insulin|||University of Jena|No|Completed|July 2007|January 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|80 Years|No|||January 2009|January 12, 2009|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00529165||167208|
NCT00529178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV123-246|Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease|A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine the Efficacy and Safety of Pravastatin 80 mg Administered Once Daily to Hypercholesterolemic Subjects With Chronic, Well Compensated Liver Disease||Bristol-Myers Squibb|Yes|Completed|December 2002|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|232|||Both|18 Years|80 Years|No|||April 2011|April 12, 2011|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529178||167207|
NCT00529451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2339|Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg|An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension||Novartis|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1613|||Both|18 Years|N/A|No|||February 2011|February 28, 2011|September 12, 2007||No||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00529451||167186|
NCT00529776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 38/2004|Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy|Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy||Medical University of Vienna|No|Completed|September 2005|May 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|89 Years|No|||June 2008|June 10, 2008|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529776||167161|
NCT00529789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11664|Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder|F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder||Eli Lilly and Company|No|Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|7 Years|17 Years|No|||October 2011|October 18, 2011|September 12, 2007|Yes|Yes||No|September 22, 2009|https://clinicaltrials.gov/show/NCT00529789||167160|The Results Record was revised as a result of correcting identified errors in the number of participants with potentially significant changes in blood pressure.
NCT00529802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15599B|Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer|An Exploratory Study Evaluating FDG-PET as a Predictive Marker for mTOR Directed Therapy With RAD001 in Metastatic Renal Cell Cancer||University of Chicago|Yes|Completed|September 2007|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2010|August 12, 2010|September 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529802||167159|
NCT00530049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-098|Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure|Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2007|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1745|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment        team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer        Center (MSKCC), or specified plastic surgeon at outside institution.|October 2015|October 9, 2015|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530049||167140|
NCT00530309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP107865|Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus|Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus-||GlaxoSmithKline|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|20 Years|70 Years|No|||May 2012|June 21, 2012|September 14, 2007||||No||https://clinicaltrials.gov/show/NCT00530309||167120|
NCT00530322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q1909/68|Adhesion Formation Following Laparoscopic and Open Colorectal Surgery|Adhesion Formation Following Laparoscopic and Open Colorectal Surgery||University of Surrey|No|Completed|June 2006|September 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||2|Actual|46|||Both|18 Years|N/A|No|||September 2007|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530322||167119|
NCT00530595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-01|Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients|||Saitama Medical University|No|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|30 Years|80 Years|No|||September 2007|September 14, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530595||167099|
NCT00530608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHZ/2007/1|Electrophysiological Properties of the Pulmonary Veins|Electrophysiological Properties of the Pulmonary Veins||Universitätsklinikum Hamburg-Eppendorf|No|Completed|June 2006|November 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|75 Years|No|Probability Sample|First review of the data base with respect to study outcome was performed after 35        enrolled patients. As a result, the results were already significant and the study was        stopped prematurely.|June 2008|February 9, 2010|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530608||167098|
NCT00526942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-203-2007|Behavioral and Physiological Effects of Visual Training|Computer-Based Cognitive Training in Normal Healthy Aging: Pilot Study of Behavioral and Physiological Effects of Visual Sweeps Training Exercise, 2-Arm Model||Posit Science Corporation|No|Recruiting|August 2007|August 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 10, 2007|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00526942||167379|
NCT00526955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0827070108|Duration and Force Variations in Applied Kinesiology Manual Muscle Testing|Duration and Force Variations in Applied Kinesiology Manual Muscle Testing||Logan College of Chiropractic||Completed|November 2007|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|August 6, 2008|September 7, 2007||||No||https://clinicaltrials.gov/show/NCT00526955||167378|
NCT00526968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVT 101/1002|The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function|A Double Blind, Placebo Controlled Study to Investigate the Role of NMDA Receptor NR2B Subunit Selective Antagonism on Cognitive Functions and Neurophysiology in Healthy Subjects as Measured With MRI||Evotec Neurosciences GmbH|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|19|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2008|February 14, 2008|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00526968||167377|
NCT00498511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64/07|Gastrointestinal Evaluation in Young Men With Iron Deficiency Anemia|Prospective Evaluation of the Gastrointestinal Tract in Young Men With Iron Deficiency Anemia||Assaf-Harofeh Medical Center|No|Not yet recruiting|August 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Male|18 Years|40 Years|No|||June 2007|July 12, 2007|July 8, 2007||||No||https://clinicaltrials.gov/show/NCT00498511||169524|
NCT00498524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001258|Risk of Life-threatening Heart Rhythm Disturbances in Siblings|The Sibling Concordance for Implantable Cardioverter-defibrillator Therapies in Ischemic Cardiomyopathy Study|SIBFIB|Duke University|No|Completed|July 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2047|||Both|18 Years|N/A|No|Non-Probability Sample|Post-MI population with LV dysfunction and an implantable cardioverter-defibrillator.|December 2012|December 6, 2012|July 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00498524||169523|
NCT00495170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0976|Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|Phase II Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2006|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|N/A|N/A|No|||November 2015|November 19, 2015|June 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00495170||169776|
NCT00495391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-2025|Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C|Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin|STEALTHC-2|Romark Laboratories L.C.|Yes|Completed|July 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|July 2, 2007|Yes|Yes||No|November 18, 2013|https://clinicaltrials.gov/show/NCT00495391||169759|
NCT00495664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-002|Titanium Nitride Oxide Coated Stents and Paclitaxel Eluting Stents for Acute Myocardial Infarction|Titanium Nitride Oxide Coated Stents Versus Paclitaxel Eluting Stents for Acute Myocardial Infarction|TITAX AMI|The Hospital District of Satakunta|Yes|Completed|December 2005|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|425|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|July 2, 2007||||No||https://clinicaltrials.gov/show/NCT00495664||169739|
NCT00496938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-377|XIENCE V: SPIRIT WOMEN|A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions||Abbott Vascular|Yes|Completed|July 2007|July 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1600|||Female|18 Years|N/A|No|||May 2015|May 12, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496938||169645|
NCT00496028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8180C00023|Phase I Study in Patients With Solid Tumours|A Phase I, Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin and/or Paclitaxel Chemotherapy in Patients With Solid Tumours||AstraZeneca|Yes|Completed|March 2007|March 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496028||169714|
NCT00496327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V210-056|Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)|Evaluation of Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX (V210)in Healthy Indian Children||Merck Sharp & Dohme Corp.||Completed|June 2005|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|12 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496327||169691|
NCT00496899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-AM-355-CITL|Clinical Evaluation of New Computerized Labor Monitoring System|Clinical Evaluation of New Computerized Labor Monitoring System.|CLM|Barnev Ltd|No|Terminated|June 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|3|||Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Laboring women reffered to maternity center in active labor (3 -7 cm)dilatation and        contraction|July 2007|May 8, 2008|July 4, 2007||No|The study was stopped prematurally due to low recruiting|No||https://clinicaltrials.gov/show/NCT00496899||169648|
NCT00496912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DA016065-01|Management of Hepatitis C in HIV-Infected and Uninfected IDUs|Management of Hepatitis C in HIV-Infected and Uninfected IDUs||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2004|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|70 Years|No|||April 2009|April 17, 2009|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00496912||169647|
NCT00496925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA- 07-4651-JZ-CTIL|Examining the Usage of Dopamine Blockers in OCD Patients|Examining the Usage of Dopamine Blockers in OCD Patients||Sheba Medical Center|No|Completed|November 2007|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|63|||Both|18 Years|N/A|No|Probability Sample|Outpatient and Inpatients|January 2010|January 31, 2010|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00496925||169646|
NCT00497185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706|Mindfulness-based Cognitive Therapy for Patients With Functional Disorders|Mindfulness-based Cognitive Therapy for Patients With Functional Disorders. A Randomized Controlled Trial||University of Aarhus|No|Completed|June 2007|June 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|50 Years|No|||November 2011|November 11, 2011|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497185||169626|
NCT00498030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|453-04|Predicting Insulin Resistance in American Indian Youth|Predicting Insulin Resistance in American Indian Youth||University of Nebraska|Yes|Completed|December 2005|November 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|202|Samples Without DNA|Samples are only retained until specific tests are completed. Some tests are done in the      clinical lab and some tests are done in the research lab.|Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Native American youth between ages of 5 and 18 who are eligible for health care at Rosebud        Sioux Reservation (Rosebud, SD) and willing to be measured and participate in a 2 hour        glucose tolerance test and who have parental consent.|April 2010|April 14, 2010|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00498030||169561|
NCT00530075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102|Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis|Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis||Nippon Kayaku Co.,Ltd.|No|Completed|December 2003|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|80 Years|No|||September 2007|February 13, 2008|September 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00530075||167138|
NCT00529464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0582|Spectroscopy Versus Standard Care in Cervical Cancer Patients|A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia||M.D. Anderson Cancer Center|Yes|Terminated|November 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Female|18 Years|N/A|No|||December 2012|December 4, 2012|September 12, 2007||No|Two participants enrolled, both inevaluable.|No|September 1, 2009|https://clinicaltrials.gov/show/NCT00529464||167185|This study was terminated due to difficulty enrolling subjects.
NCT00530660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810703|Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)|An Open-label Phase II Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Heterologous Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Young Adult Population (Follow Up to Study 810501)||Nanotherapeutics, Inc.|Yes|Completed|September 2007|October 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|141|||Both|18 Years|46 Years|Accepts Healthy Volunteers|||December 2008|October 7, 2015|September 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00530660||167094|
NCT00530686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-095|Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment|Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment||Baylor Research Institute|Yes|Recruiting|April 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530686||167093|
NCT00530062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-404-04-167|Comparison of Single-Dose Efficacy of an Albuterol Breath Activated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered Dose Inhaler (HFA-MDI) (Both Using the Same Hydrofluoroalkane Propellant) in Asthmatics|Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability||Teva Pharmaceutical Industries|Yes|Completed|January 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|7 Years|70 Years|No|||October 2015|October 7, 2015|September 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530062||167139|
NCT00530335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11821|Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)|An Open-Label Pilot Study for Atomoxetine in Adult Subjects With Attention Deficit/Hyperactivity Disorder||Eli Lilly and Company|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|September 14, 2007|Yes|Yes||No|April 22, 2009|https://clinicaltrials.gov/show/NCT00530335||167118|
NCT00530621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9820|Study of Enzastaurin Versus Placebo With Pemetrexed for Patients With Advanced or Metastatic Lung Cancer|A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl Versus Placebo Concurrently With Pemetrexed (Alimta®) as Second-Line Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company|Yes|Completed|September 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||October 2009|October 16, 2009|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530621||167097|
NCT00530634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99077|Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer|Multimodality Therapy for Stages II and III Non-Small Cell Lung Cancer: Surgical Resection Followed by Sequential Administration of Gemcitabine Plus Cisplatin Chemotherapy and Radiation Therapy||City of Hope Medical Center||Terminated|August 1999|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|120 Years|No|||October 2015|October 7, 2015|September 13, 2007|Yes|Yes|Poor accrual|No|August 19, 2015|https://clinicaltrials.gov/show/NCT00530634||167096|Study was closed early due to poor accrual. Reported data are not statistically powered to provide meaningful conclusions
NCT00531011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-380 RCT|EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease|EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.|EXecutive|Abbott Vascular|No|Completed|September 2007|June 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|September 14, 2007|Yes|Yes||No|May 16, 2011|https://clinicaltrials.gov/show/NCT00531011||167069|
NCT00531271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA302|ABI-008 Trial in Patients With Metastatic Breast Cancer|A Phase I/II Trial of ABI-008 (Nab-Docetaxel) in Patients With Metastatic Breast Cancer||Celgene Corporation|No|Terminated|November 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||June 2009|June 11, 2009|September 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00531271||167049|
NCT00531310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA8191|Reduced Intensity AlloSCT in(CML) With Persistent Disease|A Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Chronic Myeloid Leukemia (CML) and Adoptive Cellular Immunotherapy Only in Patients With Persistent Disease and Matched Family Donors|CML|Columbia University|Yes|Terminated|January 2003|June 2010|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|N/A|30 Years|No|||April 2011|April 12, 2011|September 15, 2007||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00531310||167046|
NCT00495144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-401|A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors|A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors||Threshold Pharmaceuticals|Yes|Completed|June 2007|June 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|June 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00495144||169778|
NCT00495157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|494|Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)|Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)|BASALT|Milton S. Hershey Medical Center|Yes|Completed|June 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|342|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|June 28, 2007|Yes|Yes||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00495157||169777|
NCT00495703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tactic|The Activity Intervention for Chemobrain|Exercise Intervention for Chemotherapy-Related Cognitive Dysfunction|TACTIC|Vanderbilt University|No|Completed|February 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 4, 2008|July 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00495703||169736|
NCT00495404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 98-149|Health Outcomes From Opioid Therapy for Chronic Pain|Health Outcomes From Opioid Therapy for Chronic Pain||VA Office of Research and Development|Yes|Completed|August 2001|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|2||Actual|135|||Both|18 Years|65 Years|No|||June 2007|April 6, 2015|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00495404||169758|
NCT00495677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7691009|A Phase 2 Study Of PF-00232798 In HIV Positive Patients|A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798||Pfizer|No|Completed|June 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|43|||Male|18 Years|55 Years|No|||August 2013|August 26, 2013|June 29, 2007|Yes|Yes||No|August 26, 2013|https://clinicaltrials.gov/show/NCT00495677||169738|
NCT00496652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 19|DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC|DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck||Danish Head and Neck Cancer Group|Yes|Active, not recruiting|November 2007|November 2016|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496652||169667|
NCT00496665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-402|ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer|A Phase I Study of ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|July 2007|March 2009|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496665||169666|
NCT00497705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070186|Genes Causing Ebstein's Anomaly|Genes Causing Congenital Ebstein's Anomaly||National Institutes of Health Clinical Center (CC)||Completed|July 2007|||July 2009|Actual|N/A|Observational|Time Perspective: Prospective|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2009|September 26, 2015|July 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00497705||169586|
NCT00498017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX/06-044|Infections After Renal Transplantation: Diseases Pattern in Hong Kong|Infections After Renal Transplantation: Diseases Pattern in Hong Kong||Hospital Authority, Hong Kong||Completed|July 2006|December 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|58|||Both|18 Years|N/A||Non-Probability Sample|Over a period of 4.5 years, between 1/1/2000 and 30/6/2005, there were totally 58 new        cases in our renal transplantation clinic. 36 of them were male, 22 of them were female        (Male to female ratio is 1.64:1). All were single-organ recipients. Majority of them        (57/58 or 98.3%) were receiving their first renal transplantation, the only exception was        a women receiving her second renal transplantation during the study period. Majority        (57/48 or 98.3%) of them were cadaveric renal transplantation (CRT). One living-related        renal transplantation (LDRT) had been performed in Hong Kong during the study period.        Majority of the renal transplantation were performed in Mainland China (48/58 or 82.8%),        whilst the remaining 10 operations (17.2%) were performed in Hong Kong.|June 2011|June 14, 2011|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00498017||169562|
NCT00497718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-02142007|The Effect of Chiropractic Manipulation on Spine-related Pain and Balance in Older Adults|The Effect of Chiropractic Manipulation on Spine-related Pain and Balance in Older Adults||Cleveland Chiropractic College|No|Completed|February 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 16, 2010|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497718||169585|
NCT00498355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3872s|Lucentis for Inflammatory Macular Edema Trial|Effect of Ranibizumab on Refractory Macular Edema in Uveitis|LIME|University of California, San Francisco|Yes|Completed|July 2007|December 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|July 9, 2007|Yes|Yes||No|June 20, 2012|https://clinicaltrials.gov/show/NCT00498355||169536|Limitations of the study include a small sample size and lack of a control group.
NCT00498368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001944|Rituximab in Progressive IgA Nephropathy|A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy||Mayo Clinic|Yes|Completed|February 2009|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|July 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00498368||169535|
NCT00529490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/CT-KB/DNA/02|Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG Pats|The Efficacy and Safety of Hypertonic Lactate Solution as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG (Coronary Artery Bypass Grafting) Patients||Innogene Kalbiotech Pte. Ltd|No|Completed|March 2002|June 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|75 Years|No|||September 2007|September 12, 2007|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529490||167183|
NCT00530348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMMS323|Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One|A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis|CARE-MS I|Sanofi|Yes|Completed|August 2007|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|581|||Both|18 Years|50 Years|No|||November 2014|November 17, 2014|September 13, 2007|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00530348||167117|
NCT00530647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-08-133|fMRI Study of Brain Neural Network and Plasticity After Stroke|||Samsung Medical Center|Yes|Recruiting||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|20 Years|70 Years||||October 2006|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530647||167095|
NCT00530088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564841|Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat|Photodynamic Therapy With Photofrin® for Treatment of Dysplasia, Carcinoma In Situ and Stage I Carcinoma of the Oral Cavity and the Larynx: A Pilot Study||Roswell Park Cancer Institute|Yes|Terminated|October 2001|October 2010|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|September 13, 2007|Yes|Yes|new competing studies|No|January 29, 2014|https://clinicaltrials.gov/show/NCT00530088||167137|Due to the study's early termination, as a result of new competing studies, target accrual was not reached.
NCT00531024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-043-0505|Systemic Avastin Therapy in Age-Related Macular Degeneration|Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration|BEAT-AMD|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|August 2005|March 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||April 2009|April 20, 2009|September 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00531024||167068|
NCT00531297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 05/072/2B|Endoscopic Posterior Mesorectal Resection in T1 Rectal Cancer|Endoscopic Posterior Mesorectal Resection in T1 Rectal Cancer||Cantonal Hospital of St. Gallen|No|Recruiting|December 2005|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531297||167047|
NCT00531037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nature - RGST01|Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers|Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers|NATURE|LivaNova|No|Completed|June 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1440|||Both|N/A|N/A|No|Non-Probability Sample|Patient primo-implanted with a Symphony ™ DR2550, Symphony ™ D 2450, Reply DR, Reply D        pacemaker or any similar or higher range device less than three months ago, programmed in        SafeR/AAISafeR mode.|January 2015|January 9, 2015|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531037||167067|
NCT00518544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS107-17-1|Hemostatic Effect of Various Colloid Solutions|Hemostatic Effect of Various Colloid Solutions According to Blood Types||Samsung Medical Center|Yes|Recruiting|July 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|No|||August 2007|August 16, 2007|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00518544||168015|
NCT00518830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040434|Treatment of Postnatal Depression for Low-Income Mothers in Primary Care in Santiago, Chile|Randomized Clinical Trial for the Treatment of Postnatal Depression|DPP|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile|No|Completed|March 2004|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Female|18 Years|N/A|No|||July 2007|August 20, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00518830||167993|
NCT00518843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10208 (K23 MH01923)|Family Therapy for Adolescent Bulimia Nervosa|Family Therapy for Adolescent Bulimia Nervosa: A Controlled Comparison||University of Chicago|No|Completed|April 2001|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|12 Years|19 Years|No|||September 2013|September 4, 2013|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518843||167992|
NCT00494858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH071641|Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa|Treatment of Bulimia Nervosa: Dysregulated Subtype||National Institute of Mental Health (NIMH)|No|Recruiting|July 2007|May 2011|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Female|18 Years|65 Years|No|||April 2009|April 29, 2009|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00494858||169799|
NCT00495443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peterio-06|Enhanced Safety Aesthetic Laser System|Peterio™ – an Add-on Device for Enhanced Safety of Aesthetic Laser Treatments||Scilex Ltd.|No|Not yet recruiting|September 2007|September 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|75 Years|No|||July 2007|July 1, 2007|July 1, 2007||||No||https://clinicaltrials.gov/show/NCT00495443||169755|
NCT00496041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/208|Belgian Prospective Multicentre Registry on the Performance of the Smart Stent in the Superficial Femoral Artery According to the New Tasc II-classification|Belgian Prospective Multicentre Registry on the Performance of the Smart Stent in the Superficial Femoral Artery According to the New Tasc II-classification||University Hospital, Ghent|No|Recruiting|July 2007|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496041||169713|
NCT00496054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-021|Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)|Evaluation of Safety,Tolerability and Immunogenicity of Vaccination With Rotateq (V260) in Healthy Infants in India||Merck Sharp & Dohme Corp.||Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||January 2015|January 5, 2015|July 3, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00496054||169712|
NCT00496678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1U01CA116924|Trial of Patient Navigation-Activation|RCT of Primary Care-based Patient Navigation-Activation||University of Rochester|No|Completed|April 2007|August 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|900|||Both|18 Years|N/A|No|||December 2007|August 6, 2013|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496678||169665|
NCT00496691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-MH63008-5|HIV Prevention for Youth With Severe Mental Illness|HIV Prevention for Youth With Severe Mental Illness||Rhode Island Hospital|Yes|Completed|April 2002|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|718|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496691||169664|
NCT00496379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-268|ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases|A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases||Dana-Farber Cancer Institute|No|Terminated|July 2007|January 2012|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||March 2013|March 12, 2013|July 3, 2007|Yes|Yes|This study has closed to accrual early due to slow accrual.|No|November 30, 2012|https://clinicaltrials.gov/show/NCT00496379||169687|
NCT00497198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI196-19|Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes|An Exploratory Study of MCI-196 for Treatment of Type 2 Diabetes in Randomized, Double-Blind, Parallel-Assignment, Placebo-Controlled Manner||Mitsubishi Tanabe Pharma Corporation|No|Completed|October 2005|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|20 Years|N/A|No|||June 2012|June 3, 2012|July 5, 2007||No||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00497198||169625|
NCT00497432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.028|Hyperbaric Oxygen Treatment in Patients With White Matter Hyperintensities|Hyperbaric Oxygen Treatment In Patients With White Matter Hyperintensities On Magnetic Resonance Imaging and Neurologic Deficits||St. Luke's Hospital, Chesterfield, Missouri|No|Completed|July 2007|November 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|50 Years|N/A|No|Probability Sample|Patients with neurological Symptom or deficits who demonstrate evidence of small vessel        disease of the brain by leukoencephalopathy|May 2013|May 30, 2013|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497432||169607|
NCT00497445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-P-62|The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease|Additional Exercise Therapy in Patients With Peripheral Arterial Disease: The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease.|NETP-extra|Atrium Medical Center|No|Completed|December 2005|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|N/A|N/A|No|||November 2009|November 5, 2009|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00497445||169606|
NCT00497731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00001|AZD1152 in Patients With Advanced Solid Malignancies-Study 1|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2 Hour Intravenous Infusion on Two Dose Schedules in Patients With Advanced Solid Malignancies||AstraZeneca|No|Terminated|May 2005|April 2009|Anticipated|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||June 2009|June 19, 2009|July 5, 2007||No|Efficacy seen in the solid tumour patient population was not sufficient to continue research    with AZD1152 monotherapy in solid tumors at that time.|No||https://clinicaltrials.gov/show/NCT00497731||169584|
NCT00530725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTICC Trial|Management of Occult Pneumothoraces in Mechanically Ventilated Patients|Prospective Randomized Trial of the Management of Occult Pneumothoraces in Mechanically Ventilated Patients|OPTICC|University of Calgary|No|Recruiting|August 2006|June 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530725||167090|
NCT00521742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-00-TL-OPI-520|Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease|A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Patients With Type 2 (Non-Insulin-Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I)||Takeda|Yes|Completed|March 2001|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|300|||Both|18 Years|79 Years|No|||February 2012|February 27, 2012|August 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521742||167771|
NCT00529828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL15599.081.07|Health Effects of CLA Versus Industrial Trans Fatty Acids|Health Effects of CLA Versus Industrial Trans Fatty Acids in Healthy Volunteers (CLARINeT-Study)|CLARINeT|Wageningen University|No|Completed|September 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 10, 2008|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529828||167157|
NCT00529841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-19704|Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia|A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia||Baylor College of Medicine|No|Completed|January 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|3 Years|18 Years|No|||September 2015|September 10, 2015|September 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00529841||167156|
NCT00517647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC04-22|Atomoxetine Pilot Study in Preschool Children With ADHD|Atomoxetine Pilot Study in Preschool Children With ADHD||University of Arizona|No|Completed|April 2004|||March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|3 Years|5 Years|No|||July 2012|July 5, 2012|August 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517647||168083|
NCT00517660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE-04-0071/ER-1|Source Profiling of Biohazardous Aerosols in Hospitals|Source Profiling of Biohazardous Aerosols in Hospitals||Hospital Authority, Hong Kong||Completed|March 2006|June 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A||Non-Probability Sample|60 from each groups. Healthy subjects - recruited from voluntary basis. LRTI - recruited        from patient wards with consent. URTI - recruited from out-patient clinic with consent.|August 2013|August 21, 2013|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517660||168082|
NCT00530361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014266|An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)|A Double-Blind, Randomized, Placebo-Controlled Study of Nesiritide Administered After Induction of Anesthesia in Heart Failure Patients With Renal Insufficiency Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (NAPA-CS)||Scios, Inc.|No|Withdrawn||September 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2011|July 21, 2011|September 13, 2007|||Study was withdrawn prior to patient dosing based on a business decision.|||https://clinicaltrials.gov/show/NCT00530361||167116|
NCT00530699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00008|Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)|A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1152 in Japanese Patients With Acute Myeloid Leukaemia.||AstraZeneca|Yes|Completed|November 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||September 2009|September 10, 2009|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530699||167092|
NCT00530712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2424|Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis|The US StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol STent SYstem II|DURABILITY II|Medtronic Endovascular|Yes|Completed|August 2007|July 2013|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|287|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|September 14, 2007|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00530712||167091|
NCT00517985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1JUSX026|Duloxetine for Perimenopausal Depression|Duloxetine for Perimenopausal Depression||University of Arizona|No|Completed|February 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|40 Years|N/A|No|||July 2012|July 5, 2012|March 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517985||168057|
NCT00518258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-MH78228-2|Neuroimaging Studies of Depression in Parkinson's Disease|Neuroimaging Studies of Depression in Parkinson's Disease||University of Kentucky|No|Completed|July 2006|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Neurology clinics, community sample|April 2013|May 16, 2013|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518258||168037|
NCT00495430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB013|Vibration Response Imaging in Healthy Subjects|Passive Acoustic Imaging With the Vibration Response Imaging Device in Healthy Subjects||Deep Breeze|No|Active, not recruiting|December 2004|July 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|310|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects who presented for complete physical examination as required by place of        employment. Convenience sample - consecutive healthy subjects who meet study criteria are        included in the study.|June 2009|June 15, 2009|July 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00495430||169756|
NCT00496093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110-011|Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)|Safety, Tolerability and Immunogenicity of Pneumovax 23 (V110) in Healthy Adults in India||Merck Sharp & Dohme Corp.|No|Completed|October 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|133|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 6, 2015|July 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00496093||169709|
NCT00495716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32545-B|Effect of HSV-2 Suppressive Therapy on Sexual Behavior|Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission||University of Washington|No|Active, not recruiting|January 2008|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|June 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00495716||169735|
NCT00496964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT_PMR_3700|Botox for Non-surgical Lateral Release in Patellofemoral Pain|Botox for Non-surgical Lateral Release in Patellofemoral Pain||Virginia Commonwealth University|No|Terminated|May 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|40 Years|No|||April 2011|April 22, 2011|July 5, 2007||No|Insufficient recruitment in a reasonable time + expiration of study medication|No|March 14, 2011|https://clinicaltrials.gov/show/NCT00496964||169643|Early termination due to small number of subjects. No statistical analysis of data due to small number of subjects.
NCT00496951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6468|Vagal Tone and Neonatal Abstinence Syndrome|Vagal Tone and Neonatal Abstinence Syndrome|NAS|Johns Hopkins University|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|N/A|1 Day|No|Non-Probability Sample|Drug exposed infants|February 2013|February 20, 2013|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00496951||169644|
NCT00497211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 3/39/123|Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction|||University Hospital, Antwerp|No|Recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|20 Years|80 Years|No|||July 2007|July 5, 2007|July 4, 2007||||No||https://clinicaltrials.gov/show/NCT00497211||169624|
NCT00497744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX/05-020|A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis|Research Study on the Pharmacokinetic Profile of Intraperitoneal Cefepime in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis||Hospital Authority, Hong Kong||Completed|November 2005|December 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6|||Both|18 Years|N/A||Non-Probability Sample|4 males and 2 females, of age 57.83 +/-11.63 years with urinary creatinine clearance of        0.87+/-2.06ml/min/1.73m2 and admitted for CAPD peritonitis were enrolled. After collection        of peritoneal dialysate for cell count and microbiological work-up, all subjects were        loaded with 2g cefepime IP and dwelled for 6 hours. This was followed by 250mg cefepime in        each subsequent 6-hourly peritoneal dialysis exchange. Plasma cefepime levels were        determined at time 0, 1, 2, 4, 8, 12, 16, 24, 48, 72, 96, 120 hrs. Pharmacokinetic        analyses were then performed.|June 2011|June 14, 2011|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00497744||169583|
NCT00530101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1177-04-806|The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity|The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity||University of Miami|No|Completed|July 2004|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|65 Years|No|||June 2008|June 3, 2008|September 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530101||167136|
NCT00498043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.462|A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma|Randomized Phase II Study of Two Associations of Rituximab and Chemotherapy, With a PET -Driven Strategy, in Patients From 18 to 59 With DLBCL CD20+ Lymphoma and 2 or 3 Adverse Prognostic Factors of the Age-adjusted IPI|LNH2007-3B|Hospices Civils de Lyon|Yes|Completed|July 2007|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|59 Years|No|||August 2014|August 12, 2014|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00498043||169560|
NCT00530738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0503|Safety and Efficacy of Longterm HPN With Two Lipid Emulsions|Efficacy, Safety and Quality of Life of a Long-term Home Parenteral Nutrition Regimen With Either LIPIDEM® or LIPOFUNDIN® MCT a Mono-center, Randomized, Double Blind Study||B. Braun Melsungen AG|No|Completed|September 2007|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|80 Years|No|||July 2014|July 17, 2014|September 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00530738||167089|
NCT00521157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11899 revised|Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction|Naltrexone Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction - a Randomised Study||University of Oslo|No|Completed|January 2006|December 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|19 Years|N/A|No|||May 2009|May 4, 2009|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521157||167815|
NCT00522002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2007-306|CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study|Connective Tissue Disease Leg Ulcer Etiology Study|CLUE|Georgetown University|No|Completed|August 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with refractory lower extremity ulcers|July 2009|July 14, 2010|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522002||167751|
NCT00522015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIVA|Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy|Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study|psp|University Hospital Tuebingen|Yes|Recruiting|February 2008|February 2010||December 2009||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|N/A|No|||August 2007|February 14, 2008|August 27, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00522015||167750|
NCT00521755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF-01|Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System|Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System||Seraffix|No|Completed|December 2008|February 2010|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||June 2009|June 8, 2011|August 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00521755||167770|
NCT00517972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC#06-102;IND76801|Omacor for Perimenopausal Depression|Omacor for Perimenopausal Depression||University of Arizona|No|Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|40 Years|N/A|No|||March 2012|March 27, 2012|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517972||168058|
NCT00518245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRC-022|Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)|A Prospective, Open Label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus no Enoxaparin in Subjects With Chest Pain Syndrome and no ECG or Biomarker Abnormalities|IDEAL|Canadian Heart Research Centre|Yes|Terminated|August 2007|August 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 16, 2007||No|Low rate of patient recruitment. Cannot achieve sample size.|No||https://clinicaltrials.gov/show/NCT00518245||168038|
NCT00518271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E1-100193|Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients|A Phase II, Open-Label, Concentration-Controlled, Randomized, 6-Month Study of 'Standard Dose' Tacrolimus + Sirolimus + Corticosteroids Compared to 'Reduced Dose' Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2000|June 2002|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|N/A|No|||August 2007|August 16, 2007|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00518271||168036|
NCT00518284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVR002|Prevention of Restenosis Following Revascularization|A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA)||Celgene|No|Terminated|January 2008|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|6|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|August 16, 2007|Yes|Yes|Study was terminated due to changing sponsor priorities, and was not based on safety or    outcomes data.|No|February 21, 2012|https://clinicaltrials.gov/show/NCT00518284||168035|
NCT00518583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06BR01|Phase II Study in Patients With Operable Breast Cancer|A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu||Aptium Oncology Research Network|No|Active, not recruiting|October 2006|September 2009|Anticipated|January 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|21 Years|N/A|No|||January 2010|January 14, 2010|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518583||168012|
NCT00495196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X07-0079|Cardiovascular Responses in Congestive Heart Failure With Cheyne- Stokes Respiration|Cardiovascular Response to Peripheral Chemoreceptor Stimulation in Congestive Heart Failure With Cheyne- Stokes Respiration||ResMed|No|Completed|June 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 25, 2010|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00495196||169774|
NCT00495729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXS104092|15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.|A Single-blind, Randomised, Placebo-controlled, 15 Day Repeated-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-649868 and Its Interaction With the CYP3A4 Isoenzyme in Healthy Male Subjects.||GlaxoSmithKline|No|Completed|April 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|36|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|June 29, 2007||||No||https://clinicaltrials.gov/show/NCT00495729||169734|
NCT00496405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC|Unilateral Bevacizumab for Bilateral Diabetic Macular Edema|The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study.||Asociación para Evitar la Ceguera en México|No|Completed|April 2007|October 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|13|||Both|30 Years|90 Years|No|||October 2007|October 11, 2007|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00496405||169685|
NCT00496392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-019-IM|Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)|An Open Label, Comparative, Randomised, Balanced Crossover Trial Comparing Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq®) in Breakthrough Pain in Patients With Cancer||Nycomed|Yes|Completed|January 2007|October 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496392||169686|
NCT00529217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5269|Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)|Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)|TMS|New York State Psychiatric Institute|Yes|Completed|May 2006|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||November 2013|September 16, 2014|September 13, 2007||No||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00529217||167204|
NCT00497224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-Tar-725|Phase II Trial of Erlotinib in Advanced Pancreatic Cancer|Phase II Trial of Erlotinib in Advanced Pancreatic Cancer||University Health Network, Toronto|Yes|Completed|November 2006|June 2013|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497224||169623|
NCT00497237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/033011/005/06|Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma|Prospective, Randomised, Open-label, Multicentre, Active Drug Controlled, Parallel Group Design Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate 400 Mcg + Formoterol 24 Mcg pMDI Via HFA-134a (Foster™) vs. Fluticasone Propionate 500 Mcg + Salmeterol Xinafoate 100 Mcg DPI (Seretide Diskus®) in the 6 Months Stepdown Treatment of Adult Patients With Controlled Asthma|FORTE|Chiesi Farmaceutici S.p.A.|No|Completed|April 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|382|||Both|18 Years|65 Years|No|||April 2010|April 21, 2010|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497237||169622|
NCT00497458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART2|Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects|Phase II Study of Testosterone Replacement in Women Experiencing Aromatase Inhibitor Side-Effects in Adjuvant Therapy for Breast Cancer|ART2|Chavah Pty Ltd|No|Active, not recruiting|July 2007|June 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|85 Years|No|||April 2009|April 7, 2009|July 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00497458||169605|
NCT00497471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IronMal|RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants|The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission||Hospital Clinic of Barcelona|Yes|Terminated|February 1995|July 1999|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|832|||Both|N/A|1 Day|Accepts Healthy Volunteers|||July 2007|July 5, 2007|July 5, 2007|||Follow-up end in 1999|No||https://clinicaltrials.gov/show/NCT00497471||169604|
NCT00497484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP-IA-rhGH|Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)|Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)||University of Milan||Active, not recruiting||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|1 Year|18 Years|No|||June 2007|July 5, 2007|July 5, 2007||||No||https://clinicaltrials.gov/show/NCT00497484||169603|
NCT00530114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070664|Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Fixed Dose Study of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia||Amgen||Completed|March 2008|February 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530114||167135|
NCT00530374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009576|Impact of Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent|Impact of Oral Iron Supplementation With Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent - A Non-Inferiority Safety Trial||The Hospital for Sick Children|Yes|Completed|November 2007|April 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|268|||Both|1 Year|2 Years|No|||May 2009|May 25, 2009|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530374||167115|
NCT00521170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00373|Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.|Randomized, Monocenter, Double Blind, Placebo-controlled, Single Oral Dose, Three-way Cross Over Study, to Compare Levocetirizine and Desloratadine on Allergen-induced Wheal and Flare Reaction During 24 Hours in 18 Adult Allergic Volunteers.||UCB Pharma||Completed|November 2004|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years||||September 2009|December 13, 2013|August 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00521170||167814|
NCT00521417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aker2004-77|Short- and Long-term Group Psychotherapy|A Randomized Controlled Study of the Efficacy of Analytic Oriented Group Psychotherapy for Psychiatric Outpatients|KOLG-P|University of Oslo|Yes|Active, not recruiting|August 2005|August 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|70 Years|No|||January 2010|January 11, 2010|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521417||167796|
NCT00517387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00629|The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression|The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression||University of British Columbia|No|Completed|September 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|64|||Both|19 Years|65 Years|No|||November 2010|November 12, 2010|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00517387||168103|
NCT00522028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-96107 (REK)|Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial|Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial|SIPH|Oslo University Hospital|No|Active, not recruiting|October 1998|June 2015|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|191|||Both|50 Years|80 Years|No|Probability Sample|Primary care clinic|June 1996|July 3, 2011|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522028||167749|
NCT00522041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-C-01|A Study to Determine the Effect of Nitroglycerin Ointment on the Pain Associated With Chronic Anal Fissures|A Randomized. Double-Blind, Placebo-Controlled, Multi-National Study to Determine the Effect of Cellegesic Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With a Chronic Anal Fissure||Prostrakan Pharmaceuticals|No|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|75 Years|No|||May 2009|May 6, 2009|August 28, 2007||||No||https://clinicaltrials.gov/show/NCT00522041||167748|
NCT00517673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTI107248|To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single Doses Of GSK945237 In Healthy Subjects|A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK945237 and the Effect of Food on Single Oral Doses of GSK945237 in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|July 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|68|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|March 15, 2012|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517673||168081|
NCT00518596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN 07 Phase II|Prevention of Infection in Indian Neonates - Phase II Probiotics Study|Prevention of Infection in Indian Neonates - Phase II Probiotics Study||NICHD Global Network for Women's and Children's Health||Completed|July 2005|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|284|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||December 2013|December 16, 2013|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00518596||168011|
NCT00518882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1797|Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes|LEAD-6|Novo Nordisk A/S|No|Completed|August 2007|April 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|467|||Both|18 Years|80 Years|No|||November 2014|November 13, 2014|August 20, 2007|Yes|Yes||No|February 23, 2010|https://clinicaltrials.gov/show/NCT00518882||167989|
NCT00495755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI 07-057|Campath in Chronic GVHD|An Open Label Phase I Trial of Alemtuzumab (Campath 1-H) Therapy for Refractory Chronic Graft-vs-Host Disease||Dana-Farber Cancer Institute|No|Completed|July 2007|October 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|July 2, 2007|Yes|Yes||No|April 14, 2013|https://clinicaltrials.gov/show/NCT00495755||169733|
NCT00496106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4526|Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes|Stress, Immunity & Cervical Cancer: Biobehavioral Outcomes of a Randomized Trial|CXR01|University of California, Irvine|No|Recruiting|August 2007|February 2011|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|939|||Female|21 Years|N/A|No|||December 2010|December 15, 2010|July 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00496106||169708|
NCT00496418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-07203a|Peristomal Mesh for Prophylaxis of Parastomal Hernia|Randomized Controlled Open Interventional Study for Evaluation of Use of Peristomal Mesh for Prophylaxis of Parastomal Hernia||Oslo University Hospital||Completed|July 2007|November 2014|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||January 2015|January 12, 2015|July 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00496418||169684|
NCT00496704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000549901|Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan|A Phase I/II Study to Determine the Safety and Efficacy of Second-Line Treatment With XELOX Plus Gemcitabine in Irinotecan Pre-Treated Advanced Colorectal Cancer Patients||National Cancer Institute (NCI)||Recruiting|January 2007|||August 2009|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|July 3, 2007||||No||https://clinicaltrials.gov/show/NCT00496704||169663|
NCT00528944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB6328|Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity|Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity||Columbia University|No|Completed|January 2006|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|73|||Both|18 Years|81 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective trial in all outpatients with emphysema referred for full pulmonary        function testing to the pulmonary diagnostic unit.|July 2015|July 2, 2015|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528944||167225|
NCT00528957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-104-0352|Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children|A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Active Antiretroviral Therapy||Gilead Sciences|Yes|Active, not recruiting|December 2006|December 2017|Anticipated|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|2 Years|11 Years|No|||November 2015|November 23, 2015|January 3, 2007|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT00528957||167224|
NCT00529503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG040-0005|A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL|A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)||Seattle Genetics, Inc.|Yes|Terminated|September 2007|May 2011|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|75 Years|No|||February 2015|February 6, 2015|September 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529503||167182|
NCT00529516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109821|Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults|Observer Blind Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals Influenza Vaccine GSK576389A Administered to Adults Over 65 Years Previously Vaccinated With the Same Vaccine, Compared to Fluarix™||GlaxoSmithKline||Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|1252|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|June 14, 2012|September 13, 2007|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00529516||167181|
NCT00529854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-00922|SIC-IR Billing and Documentation|Surgical and Trauma Intensive Care Unit Documentation and Billing Improvements With Medical Informatics|SIC-IR|MetroHealth Medical Center|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Observational|Time Perspective: Prospective||2|Actual|814|||Both|18 Years|N/A|No||All surgical and trauma intensive care unit patients addmitted to our reional Level I        trauma center|February 2008|February 26, 2008|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00529854||167155|
NCT00529529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2338|Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma|A 26-week Treatment, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Assess the Safety of Indacaterol (300 and 600 µg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 µg b.i.d.) as an Active Control||Novartis||Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|805|||Both|12 Years|N/A|No|||August 2011|August 25, 2011|September 12, 2007|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00529529||167180|
NCT00529867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC protocol No. 1210|Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria|A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya||Dafra Pharma|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|267|||Both|6 Months|59 Months|No|||January 2008|January 17, 2008|September 12, 2007||||No||https://clinicaltrials.gov/show/NCT00529867||167154|
NCT00530127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA29-0207|A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia|A Six-month Double-blind, Randomized, Placebo-controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia||ApoPharma|Yes|Completed|April 2008|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|80|||Both|7 Years|35 Years|No|||May 2010|May 31, 2010|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530127||167134|
NCT00511095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-14|Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine|An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV™||Dynavax Technologies Corporation|Yes|Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|207|||Both|11 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|July 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511095||168572|
NCT00502801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012931|An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia|A Phase 2 Study of Doripenem In The Treatment of Nosocomial and Ventilator-Associated Pneumonia In Hospitals||PriCara, Unit of Ortho-McNeil, Inc.|No|Completed|August 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|July 16, 2007||No||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00502801||169201|
NCT00511758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0230|Digital Imaging Aid for Assessment of Cervical Dysplasia|Pilot Study of a Digital Imaging Aid for Assessment of Cervical Dysplasia||M.D. Anderson Cancer Center|No|Terminated|June 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.|July 2012|July 31, 2012|August 2, 2007||No|Low accrual rate.|No||https://clinicaltrials.gov/show/NCT00511758||168521|
NCT00485511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH96-TD-I-111-TM103|A Trial of Hydroxyurea in Spinal Muscular Atrophy|A Randomized, Double-Blind, Placebo-Controlled Trial of Hydroxyurea in Spinal Muscular Atrophy||Kaohsiung Medical University Chung-Ho Memorial Hospital||Completed|June 2007|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|4 Years|N/A||||February 2010|February 11, 2010|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485511||170508|
NCT00481897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCCR-07065-01|Worksite Nutrition Study|Worksite Nutrition Study||Physicians Committee for Responsible Medicine|Yes|Completed|May 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 6, 2012|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481897||170780|
NCT00481923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5031|Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients|A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 With or Without Hypocaloric Diet in Obese Patients|REBA|Sanofi||Completed|May 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|156|||Both|18 Years|N/A|No|||April 2009|April 17, 2009|June 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00481923||170779|
NCT00481585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.01.041|The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture|The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture||Hackensack University Medical Center|Yes|Terminated|May 2007|||July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Female|N/A|N/A|No|Probability Sample|13 subjects - Subjects of this pilot study are limited to those female patients who are        undergoing therapeutic or prophylactic mastectomy procedures conducted by the department        of Surgery at HUMC.|February 2014|February 1, 2014|May 30, 2007||No|study team failed to complete timely reviews, study suspended|No||https://clinicaltrials.gov/show/NCT00481585||170804|
NCT00481598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF Grant Number: 1-2006-74|Non Invasive Assessment of Liver Glycogen Kinetics and ATP Synthesis in Type1 Diabetics|Non Invasive Assessment of Liver Glycogen Kinetics and ATP Synthesis in Type1 Diabetics||Landsteiner Institut|Yes|Completed|January 2006|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 11, 2008|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481598||170803|
NCT00482170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-3326|Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept|A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-injector and the Etanercept Prefilled Syringe) in Patients With Psoriasis.||Pfizer||Completed|September 2007|September 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|June 1, 2007||No||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00482170||170761|
NCT00482183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-NAPN-16586|Comparison Between Pioglitazone and SES With type2 DM|Comparison of Bare Metal Stent With Pioglitazone Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus.||Showa University|No|Completed|July 2003|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|38|||Both|20 Years|90 Years|No|||June 2007|June 4, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00482183||170760|
NCT00481884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0827|Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients|Phase III Trial to Compare RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients||M.D. Anderson Cancer Center|Yes|Completed|May 2007|||January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|N/A|N/A|No|||January 2012|January 18, 2012|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481884||170781|
NCT00486928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/8009|Twenty-five-year Experience With the Medtronic-Hall Valve Prosthesis|Twenty-five-year Experience With the Medtronic-Hall Valve Prosthesis|Hall-Kaster|Oslo University Hospital|No|Completed|May 2004|May 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|816|||Both|N/A|N/A|No|Probability Sample|All consecutive patients undegoing AVR during inclusion period|July 2011|July 22, 2011|June 14, 2007||||No||https://clinicaltrials.gov/show/NCT00486928||170399|
NCT00508794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0522|Effects of Yoga in Breast Cancer Patients|Biobehavioral Effects of Yoga During Breast Cancer Treatment||M.D. Anderson Cancer Center|Yes|Active, not recruiting|March 2006|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|180|||Female|18 Years|N/A|No|||November 2015|November 23, 2015|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00508794||168747|
NCT00509041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558362|Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma|A Phase II Study of Dasatinib (NSC #732517) in Patients With Previously Treated Malignant Mesothelioma||Alliance for Clinical Trials in Oncology|No|Completed|August 2007|December 2012|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|July 30, 2007|Yes|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00509041||168728|
NCT00509340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077503|Cognitive Behavioral Therapy to Help HIV Infected Adults With Depression to Adhere to Antiretroviral Therapy|Cognitive Behavioral Adherence Intervention for Depressed HIV Patients||RAND|Yes|Terminated|June 2007|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|60 Years|No|||June 2013|June 20, 2013|July 30, 2007||No|Inability to recruit enough eligible participants at study site.|No||https://clinicaltrials.gov/show/NCT00509340||168705|
NCT00509353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558042|N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma|Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma, A Phase I Study||Children's Hospital Los Angeles|Yes|Completed|January 2007|May 2012|Actual|October 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|1 Year|30 Years|No|||August 2014|August 28, 2014|July 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00509353||168704|
NCT00509639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET/01|Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease|Phase III Study to Evaluate the Effect of 10% Metronidazole Ointment, Applied Topically Three Times a Day in and Around the Anus and the Change in Perianal Crohn's Disease Activity||S.L.A. Pharma AG|No|Completed|May 2005|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509639||168683|
NCT00509899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-251|Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis|A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)||Incyte Corporation|No|Active, not recruiting|June 2007|September 2016|Anticipated|December 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|July 30, 2007|Yes|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT00509899||168663|
NCT00510198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603|Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure|PRECEDE-HF -Prospective, Randomized Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure|PRECEDE-HF|Medtronic Cardiac Rhythm Disease Management|Yes|Terminated|October 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|120|||Both|18 Years|N/A|No|||June 2009|June 8, 2009|July 31, 2007|Yes|Yes|Study enrollment significantly below protocol expectation|No||https://clinicaltrials.gov/show/NCT00510198||168641|
NCT00510497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Riddler 055794|Autologous Dendritic Cell Vaccine in HIV1 Infection|Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells||University of Pittsburgh|Yes|Completed|July 2007|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|August 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510497||168618|
NCT00502515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY5807|Dose-effect of SSR180575 in Diabetic Neuropathy|A Multi-center, Randomized, Double-blind, Placebo Controlled Study of the Effect of SSR180575 at Two Doses for 24 Weeks Treatment on the Rate of Regeneration of Epidermal Nerve Fibers in Patients With Mild Diabetic Peripheral Neuropathy||Sanofi||Completed|July 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|309|||Both|18 Years|65 Years|No|||January 2010|January 19, 2010|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00502515||169223|
NCT00502814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-305|3-Dimensional Form and Soft Tissue Biomechanics of the Breast|3-Dimensional Form and Soft Tissue Biomechanics of the Breast||M.D. Anderson Cancer Center|No|Terminated|January 2003|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with Breast Cancer.|February 2012|February 20, 2012|July 16, 2007||No|Sample size too small for data analysis.|No||https://clinicaltrials.gov/show/NCT00502814||169200|
NCT00503100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR458107CTIL|Somatosensory Evoked Potentials and Pain Thresholds in Term and Preterm-Born Adolescents After Early Exposure to Pain; a Quantitative Study|||Soroka University Medical Center|Yes|Terminated|August 2007|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|10|||Both|15 Years|18 Years|No|Non-Probability Sample|Four groups of 20 adolescents (aged 14 years or older), two of which are full term and        preterm-born who were exposed to painful procedures during the neonatal period. The other        two groups are term and preterm-born adolescents who were not exposed to such procedures.|May 2015|May 20, 2015|July 17, 2007||No|Difficulties in recruiting|No||https://clinicaltrials.gov/show/NCT00503100||169178|
NCT00503074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-6609-J01|Starting Healthy Staying Healthy Pilot Trial|Starting Healthy Staying Healthy Pilot Trial||University of Washington|Yes|Completed|July 2007|July 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00503074||169180|
NCT00503087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC 07- TL -268 CTIL|Evaluation of Pain Reduction in the Administration of Saline Injections by the Usage of Pneumatic Skin Flattening|Evaluation of Pain Reduction in the Administration of Saline Injections by the Usage of Pneumatic Skin Flattening (PSF)||PalJect Ltd.|Yes|Recruiting|August 2007|July 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2007|August 7, 2007|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503087||169179|
NCT00485251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CShan|Prospective Randomized Trial of Hand-assisted Laparoscopic Right Hemicolectomy vs Total Laparoscopic Right Hemicolectomy|||Pamela Youde Nethersole Eastern Hospital|Yes|Completed|February 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2009|November 23, 2009|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485251||170527|
NCT00486161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18C403|Acylated Ghrelin Response to Acute Exercise in Obesity|Evaluation of Acylated Ghrelin Response Following Acute Exercise in Relation to Adiposity, Metabolic Homeostasis and Growth Hormone Secretion|aeroghre|Istituto Auxologico Italiano|Yes|Completed|March 2004|December 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Actual|16|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 12, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00486161||170458|
NCT00481325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN148-015|Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder|A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder||Bristol-Myers Squibb|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|260|||Female|18 Years|65 Years|No|||September 2015|September 23, 2015|May 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00481325||170824|
NCT00481338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS2006-0146|Prevalence,Natural History,Prognosis Factor,QualityofLife,Health Care Consumption and Social Consequences of Symptomatic Knee and Hip Osteoarthritis in France|Knee and Hip OsteoArthritis Long Term Assessment. Prevalence, Natural History, Prognosis Factor, Quality of Life, Health Care Consumption and Social Consequences of Symptomatic Knee and Hip Osteoarthritis in France|KHOALA|Central Hospital, Nancy, France|Yes|Active, not recruiting|April 2007|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|878|||Both|40 Years|75 Years|No|||July 2015|July 31, 2015|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481338||170823|
NCT00482482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308/2006|Yoga in Unipolar and Bipolar Disorders|The Safety and Effectiveness of Yoga as Augmentation in Improving Residual Depressive Symptoms in Unipolar and Bipolar Disorders.||Centre for Addiction and Mental Health|No|Completed|September 2007|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||December 2012|December 4, 2012|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00482482||170738|
NCT00486941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN-Umea 02-512|Lifestyle Intervention in Primary Health Care - the Björknäs Study|A Randomized Trial of Lifestyle Intervention in Primary Health Care for the Modification of Cardiovascular Risk Factors - the Björknäs Study||Umeå University|No|Completed|February 2003|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|151|||Both|18 Years|65 Years|No|||July 2007|July 18, 2007|June 14, 2007||||No||https://clinicaltrials.gov/show/NCT00486941||170398|
NCT00486954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104578|Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer|A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer||GlaxoSmithKline|No|Completed|July 2007|October 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|20 Years|N/A|No|||January 2013|June 12, 2013|June 13, 2007||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00486954||170397|
NCT00500851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138/2007|Evaluation of Jejunal Placement of Enteral Feeding Tubes|Evaluation of Two Methods of Jejunal Placement of Enteral Feeding Tubes in Critically Ill Patients: Endoscopic Versus Electromagnetic Method (CORTRAK™)||Medical University of Vienna|Yes|Completed|May 2007|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|66|||Both|18 Years|N/A|No|||February 2009|November 29, 2010|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500851||169349|
NCT00509054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preventing parastomal hernia|Prevention of Parastomal Hernia With a Mesh|Randomised Clinical Trial of the Use of a Prosthetic Mesh to Prevent Parastomal Hernia||Sundsvall Hospital|Yes|Completed|January 2001|July 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|54|||Both|20 Years|N/A|No|||January 2001|April 15, 2008|July 30, 2007||||No||https://clinicaltrials.gov/show/NCT00509054||168727|
NCT00509067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077849|Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia|Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia|STAR-1|Georgetown University|No|Completed|November 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|July 30, 2007|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00509067||168726|
NCT00501371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS for BPH-LUTS|MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia|Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia||Health Ever Bio-Tech Co., Ltd.|No|Terminated|July 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Male|40 Years|N/A|No|||December 2011|December 13, 2011|July 10, 2007||No|Study terminated for re-design. A new IND study (US FDA, July 2009) will be conducted in US    and Taiwan. Termination not related to safety concerns.|No||https://clinicaltrials.gov/show/NCT00501371||169309|
NCT00501696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H43034-30200-02|A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone|A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54)||University of California, San Francisco|Yes|Completed|February 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|86 Years|No|||February 2007|May 15, 2008|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501696||169285|
NCT00509925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1761|Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes|Effect of Insulin Detemir Compared to Insulin NPH Combined With Insulin Aspart on Energy Expenditure in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Terminated|July 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|July 31, 2007|Yes|Yes|See detailed description|No|April 19, 2010|https://clinicaltrials.gov/show/NCT00509925||168662|This open-label study was terminated prematurely due to 2 unplanned interim analyses having been performed. At this point, only 23 out of the planned 30 patients had been randomised into the study.
NCT00501969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0516|An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease|An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa||UCB Pharma|No|Completed|August 2004|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|395|||Both|31 Years|N/A|No|||March 2012|September 24, 2014|July 16, 2007|Yes|Yes||No|December 8, 2009|https://clinicaltrials.gov/show/NCT00501969||169264|
NCT00502255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072036|Telemonitoring in Patients With Heart Failure|Telemonitoring in Patients With Heart Failure|TEHAF2|Maastricht University Medical Center|Yes|Completed|October 2007|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|382|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502255||169243|
NCT00502229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2006c|Therapy for Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin|What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study.||University Magna Graecia||Withdrawn|January 2010|||January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|35 Years|No|||April 2013|April 5, 2013|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00502229||169245|
NCT00502242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E5-4439|Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus|A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus||Pfizer|Yes|Completed|December 2007|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|July 16, 2007|Yes|Yes||No|August 13, 2014|https://clinicaltrials.gov/show/NCT00502242||169244|
NCT00502827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0784|Smoking Cessation for HIV/AIDS Patients|An Innovative Telephone Intervention for HIV-Positive Smokers||M.D. Anderson Cancer Center|Yes|Completed|January 2004|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|706|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502827||169199|
NCT00499252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0126R|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Gynecologic Oncology Group||Completed|June 2007|||July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|N/A|N/A|No|||March 2015|March 19, 2015|July 10, 2007|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00499252||169469|
NCT00503451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2110|A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors|A Phase IB, Study to Investigate the Effect of Ketoconazole, a CYP3A4 Inhibitor, on Oral LBH589 and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors.||Novartis||Completed|September 2007|||April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|July 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00503451||169152|
NCT00503464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#R03 HS016065-01|"Assessing Barriers to ADA Guideline Adherence"|"Assessing Barriers to American Diabetes Association Guideline Adherence"||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|September 2006|||||N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 18, 2012|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503464||169151|
NCT00481624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0210|Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia|A Phase II Trial Using Intravenous Iron in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia Treated With 120,000 Units Epoetin Alfa Every Three Weeks|Procrit|James Graham Brown Cancer Center|Yes|Withdrawn|May 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|June 1, 2007|Yes|Yes|The study was stopped because of lack of funding.|No||https://clinicaltrials.gov/show/NCT00481624||170801|
NCT00486421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529883|Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura|A Pilot Study of Rituximab in Combination With Corticosteroids for the Initial Treatment of Immune Thrombocytopenic Purpura||Mayo Clinic|Yes|Completed|January 2007|November 2008|Actual|May 2008|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|21 Years|N/A|No|||October 2014|October 15, 2014|June 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00486421||170438|
NCT00486434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC021C2301|Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis||Nordic Bioscience A/S||Completed|May 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1176|||Both|51 Years|80 Years|No|||October 2012|October 22, 2012|June 13, 2007|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00486434||170437|
NCT00486720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-064|Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)|A Randomized Phase IIa Study of Vorinostat in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome||Merck Sharp & Dohme Corp.||Terminated|June 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|June 14, 2007|Yes|Yes||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00486720||170415|This trial was terminated because the pre-specified futility criterion was met.
NCT00486395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08 005|Will CPAP Reduce Length Of Respiratory Support In Premature Infants?|Offering Less Invasive Ventilation in Infants Born 28 to 32 Weeks Gestation: A Randomized Controlled Trial.|OLIVIA|Children's & Women's Health Centre of British Columbia|Yes|Terminated|September 2007|February 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|126|||Both|28 Weeks|32 Weeks|No|||February 2012|February 8, 2012|June 13, 2007||No|Decreasing recruitment|No||https://clinicaltrials.gov/show/NCT00486395||170440|
NCT00486408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 071|Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults|A Phase 1B Open-label Clinical Trial to Expand the Characterization of the Immune Responses to the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy, HIV-1-uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2007|November 2012|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00486408||170439|
NCT00486707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0996|Ovarian Cancer Patient Questionnaire on Genetic Testing|Questionnaire for Ovarian Cancer Patients Regarding Acceptance and Willingness to Undergo Genetic Testing||M.D. Anderson Cancer Center|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|237|||Female|18 Years|N/A|No|Non-Probability Sample|Study participants with a diagnosis of ovarian cancer.|July 2012|July 31, 2012|June 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00486707||170416|
NCT00487461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0857|Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage|Randomized Double Blind Study Using Simvastatin for the PRevention Aof Vasospasm in Aneurysmal Subarachnoid Hemorrhage||University of Illinois at Chicago|No|Terminated|May 2007|June 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|25|||Both|18 Years|85 Years|No|||October 2015|October 22, 2015|June 15, 2007||No|Study PI left the institution and study was stopped at that time.|No|July 22, 2015|https://clinicaltrials.gov/show/NCT00487461||170358|Early termination leading to small numbers of subjects analyzed and Primary Physician leaving institution before study completion.
NCT00500591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0018|Prevalence of Endometrial Abnormalities In Obese Women|Prevalence of Endometrial Abnormalities In Obese Women||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2004|||June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood samples used to look at different hormone levels related to risk of endometrial      abnormalities. An endometrial biopsy will be performed to collect a tissue sample.|Female|30 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study participants with a measured BMI greater than or equal to 30 kg/m^2 (obese) or less        than or equal to 25 kg/m^2 (lean) at the time of enrollment.|June 2015|June 25, 2015|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500591||169368|
NCT00501163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0574|Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients|Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients||Washington University School of Medicine|No|Recruiting|August 2007|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|90|||Both|10 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|The inclusion criteria for the schizophrenia/schizoaffective group are: i) aged 18-55        years; ii) otherwise healthy and meets DSM-IV criteria for schizophrenia, any type, or        schizoaffective disorder iii) able to give informed consent.        The inclusion criteria for children are: i) age 10-18 years; ii) otherwise healthy and        meets DSM-IV criteria for one or more childhood-onset psychiatric disorder iii) able to        give assent and have a guardian able to provide informed consent.        The inclusion criteria for the healthy controls are: aged 18-55 years; ii) otherwise        healthy and do not meet DSM-IV criteria for any Axis I psychiatric illness; iii) able to        give informed consent.|March 2010|March 16, 2010|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00501163||169325|
NCT00501176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|¨2006/220-31/4|Preoperative Stent Study|Randomized Study Comparing the Effect of Plastic Stents to That of Expandable Metal Stents Prior to Pancreaticoduodenectomy||Karolinska Institutet|Yes|Recruiting|December 2006|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||June 2014|June 11, 2014|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00501176||169324|
NCT00501384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI4522|Satavaptan Dose-Ranging Study in the Prevention of Ascites|Study for the Prevention of Ascites (SPA): Comparison of Fixed Doses of SR121463B Versus Placebo in the Reduction of Recurrence of Cirrhotic Ascites|SPA|Sanofi|Yes|Completed|April 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|151|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|July 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00501384||169308|
NCT00501397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2108197|A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers|An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK189075||GlaxoSmithKline|No|Completed|February 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|July 13, 2007||||||https://clinicaltrials.gov/show/NCT00501397||169307|
NCT00501709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39-42C|Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus|||University of California, San Francisco|Yes|Active, not recruiting|February 2004|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501709||169284|
NCT00501956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPN 24332|Intradialytic Parenteral Nutrition in Hemodialysis Patients|Randomized Study on the Effect of Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients|IDPNHD|Fresenius Kabi|No|Completed|July 2004|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00501956||169265|
NCT00502840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19071|A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.|An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070).||Hoffmann-La Roche||Completed|July 2007|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|193|||Both|18 Years|75 Years|No|||September 2014|September 3, 2014|July 17, 2007||No||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00502840||169198|
NCT00502528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BQ123AMI12/06|Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction|Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction||Medical University of Vienna|Yes|Completed|May 2007|August 2012|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||April 2013|April 27, 2013|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502528||169222|
NCT00498992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000553120|Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer|Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients||National Cancer Institute (NCI)||Recruiting|July 2006|||||N/A|Interventional|Primary Purpose: Supportive Care|||Anticipated|20|||Both|18 Years|N/A|No|||July 2009|September 19, 2013|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00498992||169488|
NCT00499265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000553460|Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|A Randomized, Open Label, Phase II Proof of Concept Study of WX-671 in Combination With Gemcitabine vs.Gemcitabine Alone in Patients With Locally Advanced, Non Resectable Pancreatic Cancer in Order to Evaluate the Anti-Tumor Activity of the Combination Therapy||Wilex|No|Completed|April 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499265||169468|
NCT00499499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7107-A001-101|A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors|A Phase I Open-Label, Single-Arm, Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors||Eisai Inc.||Suspended|July 2007|August 2010|Anticipated|June 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|July 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499499||169450|
NCT00499785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000555118|Physical and Mental Assessment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Inpatient Functional and Cognitive Assessment in Older Adults With Acute Myelogenous Leukemia||Comprehensive Cancer Center of Wake Forest University|No|Completed|June 2007|January 2012|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|60 Years|120 Years|No|Non-Probability Sample|patients with acute leukemia >= 60 years of age|October 2015|October 22, 2015|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499785||169430|
NCT00485862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6066|Combination Therapy in Patients With Depression|Noradrenergic Augmentation of SSRI Therapy in Patients With Depression Unresponsive or Incompletely Responsive to SSRI Monotherapy||Eli Lilly and Company||Completed|June 2003|January 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|N/A|No|||June 2007|June 11, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485862||170481|
NCT00486187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD105195|Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study|Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study||Canadian Cardiovascular Research Network|No|Completed|April 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|40 Years|80 Years|No|||January 2016|January 27, 2016|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00486187||170456|
NCT00486200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15L-CL-101|A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes|A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes||Astellas Pharma Inc|No|Completed|June 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|695|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|June 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486200||170455|
NCT00486447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-189-03|Perfusion Imaging and CT -Understanding Relative Efficacy|A Prospective Multi-center Study Comparing Cardiac Computed Tomography (CT) Using a 64-detector Row Volumetric Computed Tomography (VCT) Scanner for the Detection of Coronary Artery Disease With Cardiac Radionuclide Imaging.|PICTURE|GE Healthcare|Yes|Completed|June 2007|December 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|249|||Both|18 Years|N/A|No|||March 2010|March 25, 2010|June 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486447||170436|
NCT00486967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAT001|Insulin Resistance : Heart Failure|Insulin Resistance: A New Target in Heart Failure||University of Dundee|Yes|Recruiting|August 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||||||Both|30 Years|90 Years|Accepts Healthy Volunteers|||June 2007|June 13, 2007|June 13, 2007||||No||https://clinicaltrials.gov/show/NCT00486967||170396|
NCT00486980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-312|Intramuscular Peramivir for the Treatment of Uncomplicated Influenza|A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR PERAMIVIR IN SUBJECTS WITH UNCOMPLICATED ACUTE INFLUENZA||BioCryst Pharmaceuticals||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||January 2008|January 28, 2008|June 14, 2007|||This study was withdrawn for administrative reasons. The dose ranging plan for the program was    revised".|||https://clinicaltrials.gov/show/NCT00486980||170395|
NCT00487227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7G2CDCH|Effects of Low Doses of Caffeine on Mood, Physiology and Mental Function|Levels of Caffeine Lower Than Those Found in Decaffeinated Beverages Exert Effects on Cognition, Mood, and Autonomic Activity||Northumbria University|No|Completed|June 2005|November 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|4||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|June 15, 2007||||No||https://clinicaltrials.gov/show/NCT00487227||170376|
NCT00484744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 04-054|Acetaminophen Versus Ibuprofen for the Control of Immediate and Delayed Pain Following Orthodontic Separator Placement|Acetaminophen Versus Ibuprofen for the Control of Immediate and Delayed Pain Following Orthodontic Separator Placement||University of Missouri, Kansas City|No|Completed|June 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|35|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||April 2013|April 24, 2013|June 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00484744||170566|
NCT00484757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Narkorex|Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition||NARKOREX|Zentrum für Integrative Psychiatrie|No|Active, not recruiting|June 2007|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 2, 2009|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484757||170565|
NCT00501423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-034|Antiplatelet Drug Resistances and Ischemic Events|Antiplatelet Drug Resistances and Ischemic Events|ADRIE|University Hospital, Geneva|Yes|Completed|June 2006|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|771|||Both|18 Years|N/A|No|Probability Sample|Documented symptomatic ischemic atherothrombotic disease|January 2014|January 30, 2014|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501423||169305|
NCT00501748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7620-25392-04|Safety and Tolerability of Rituximab in Neuromyelitis Optica|Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis||University of California, San Francisco|Yes|Completed|January 2004|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|86 Years|No|||September 2011|September 23, 2011|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501748||169281|
NCT00500864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCFMRP8518/2003|Magnesium Loading in Chronic Obstructive Pulmonary Disease|Effects of Acute Intravenous Magnesium Loading on Pulmonary Function Parameters and Maximal Exercise Capacity of Patients With Chronic Obstructive Pulmonary Disease in Stable Clinical Conditions.||University of Sao Paulo|No|Completed|August 2004|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|24|||Male|45 Years|80 Years|No|||June 2008|June 27, 2008|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500864||169348|
NCT00501982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM/PR/5000/002/04|Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study|An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome|Curpap|Chiesi Farmaceutici S.p.A.||Completed|March 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|208|||Both|25 Weeks|28 Weeks|No|||March 2015|March 18, 2015|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00501982||169263|
NCT00502268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBPTH-CC1|Vitamin D and Carboxy PTH Fragments in Coronary Calcification|A Prospective, Randomized, Open-Label Trial Investigating the Effect of 1 Alpha Hydroxy Vitamin D2 on the Development of Coronary Calcification in New ESRD Patients Using the 1-84/7-84 PTH Ratio to Determine Dosing||Southeast Renal Research Institute|No|Withdrawn|February 2008|July 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|80 Years|No|||July 2011|July 20, 2011|July 16, 2007||No|study never initiated|No||https://clinicaltrials.gov/show/NCT00502268||169242|
NCT00501722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI4521|Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites|SR121463B in Cirrhotic Ascites Treatment With Hyponatraemia: A Placebo-Controlled, Dose-Comparison Study|Hypo~CAT|Sanofi|Yes|Completed|April 2004|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|110|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|July 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00501722||169283|
NCT00501735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-203|Forodesine in the Treatment of Cutaneous T-Cell Lymphoma|Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma||BioCryst Pharmaceuticals|Yes|Completed|July 2007|December 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501735||169282|
NCT00502554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4584|Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation|Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation||Hannover Medical School|Yes|Terminated|August 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||May 2008|July 25, 2011|July 16, 2007|Yes|Yes|insufficient patient recruitment and ECP capacity|No||https://clinicaltrials.gov/show/NCT00502554||169220|
NCT00503113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA20341|A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.|A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.||Hoffmann-La Roche||Completed|July 2007|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|801|||Female|60 Years|N/A|No|||May 2011|May 17, 2011|July 17, 2007|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00503113||169177|
NCT00503126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-07-01|Bivalirudin as a Procedural Anticoagulant in Pediatrics|Bivalirudin (Angiomax®) As A Procedural Anticoagulant In The Pediatric Population Undergoing Intravascular Procedures For Congenital Heart Disease||The Medicines Company|Yes|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|N/A|16 Years|No|||November 2011|November 8, 2011|July 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00503126||169176|
NCT00499005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Ref: D/04/209|Carbetocin Versus Syntometrine for the Third Stage of Labour|Carbetocin Versus Syntometrine for the Third Stage of Labour Following Vaginal Delivery - A Double-blind Randomised Trial||National University Hospital, Singapore|Yes|Completed|November 2006|July 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|720|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00499005||169487|
NCT00499018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL-DLCL04|Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma|A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells.|DLCL04|Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|January 2006|September 2013|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|399|||Both|18 Years|60 Years|No|||February 2011|February 14, 2011|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499018||169486|
NCT00500656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE049 #2102|Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)|Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)|FAST2|Shire|Yes|Completed|March 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|85|||Both|18 Years|N/A|No|||May 2014|January 29, 2015|July 12, 2007|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00500656||169364|
NCT00486174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMED-090-07|Methylene Blue in Sepsis: A Randomized Controlled Trial|Intermittent Bolus Infusion of Methylene Blue to Reduce Norepinephrine Requirements in Sepsis: A Randomized Controlled Trial|SMURF|Queen's University|Yes|Withdrawn|June 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2008|May 26, 2008|June 12, 2007|Yes|Yes|primary site withdrew due to competing study: never enrolled any subjects.|No||https://clinicaltrials.gov/show/NCT00486174||170457|
NCT00483925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES 511|Cardiovascular Risk Factors and LCH in Adults|CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES||Laikon General District Hospital, Athens|No|Recruiting|September 2005|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|June 7, 2007|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483925||170629|
NCT00483938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21035|IMPROVE Study(The Individualized Management With PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.|A Randomized, Open Label Study to Evaluate the Effect of 48 or 72 Weeks of Treatment With Pegasys Plus Copegus Combination Therapy on Sustained Viral Response in Non-genotype 2/3 Patients With Chronic Hepatitis C Who Show a Response at Week 12||Hoffmann-La Roche||Completed|June 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00483938||170628|
NCT00486733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-20028|Study to Determine if Shock Wave Therapy Applied to Traumatic Wounds of the Extremity Improves Healing Time|Prospective Randomized Trial of Standard Wound Care Versus Standard Wound Care Plus Shock Wave Therapy for Traumatic Wounds of the Extremity|CWI|Walter Reed Army Medical Center|Yes|Recruiting|April 2007|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|213|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 18, 2012|June 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00486733||170414|
NCT00484497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS2006/0492|Evaluation of a Food Supplement on Sleep Quality|A Randomized, Double-Blind, Placebo-Controlled Trial for the Evaluation of a Food Supplement on Sleep Quality in Primary Insomnia Patient|Cyclamax|Persee Medica|No|Completed|September 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|105|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||June 2007|June 8, 2007|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00484497||170585|
NCT00484510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC074406MP2F|High Dose Ascorbic Acid Treatment of CMT1A|A Randomized, Placebo-controlled, Double Masked 120 Subject "Futility Design" Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A.||Wayne State University|Yes|Completed|April 2007|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|13 Years|70 Years|No|||March 2013|March 4, 2013|June 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00484510||170584|
NCT00502021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flaxseed01|Use of Flaxseed(Alpha Linolenic Acid) Powder in Morbidly Obese Patients With Systemic Inflammation|Inflammatory Indicators and Arterial Stiffness in Patients With Severe Obesity. Response to Supplementation of Alpha Linolenic Acid||University of Sao Paulo|No|Recruiting|August 2007|October 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|90|||Both|18 Years|65 Years|No|||September 2012|September 27, 2012|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502021||169260|
NCT00500890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0398|Treatment of Tumors of the Choroid Plexus Epithelium|A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors||M.D. Anderson Cancer Center|Yes|Active, not recruiting|September 2005|||September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||October 2015|October 15, 2015|July 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00500890||169346|
NCT00501761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0454|Physical Activity After Endometrial Cancer|Social Cognitive Theory and Physical Activity After Endometrial Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2005|||May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|326|Samples With DNA|Saliva samples 5 times per day for 2 consecutive days.|Female|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants that have survived endometrial cancer and healthy participants that        have no history of invasive cancer.|November 2015|November 23, 2015|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501761||169280|
NCT00501774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sabo-1|A Search for Helicobacter Pylori in Localized Vulvodynia|A Laboratory and Clinical Search for the Presence of H. Pylori and Treatment Against it in Localized Vulvodynia (Vestibulitis, Vestibulodynia).||Western Galilee Hospital-Nahariya|No|Completed|May 2004|June 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Actual|27|||Female|18 Years|50 Years|No|||July 2007|July 13, 2007|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501774||169279|
NCT00501995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-11-17-02|High Dose Cyclophosphamide for Treatment of Scleroderma|High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma)||Johns Hopkins University|No|Completed|February 2001|May 2010|Actual|July 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||October 2015|October 21, 2015|July 13, 2007|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT00501995||169262|
NCT00502008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-2-2007|Effect of Coccinia Cordifolia Extract on Blood Sugar of Newly Diagnosed Diabetics|Efficacy of Coccinia Cordifolia Extract in Improving Blood Glucose Levels of Newly Diagnosed Diabetic Patients||St. John's Research Institute|No|Completed|November 2005|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|60|||Both|35 Years|60 Years|No|||July 2007|July 16, 2007|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502008||169261|
NCT00502541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS FL-005|Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema|A Multicenter, Randomized, Masked, Controlled Study to Evaluate Retisert, and Intravitreal Fluocinolone Acetonide Implant, in the Treatment of Patients With Diabetic Macular Edema||Bausch & Lomb Incorporated|Yes|Completed|September 2001|September 2006|Actual|September 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|July 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00502541||169221|
NCT00499798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000553297|Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors|Temozolomide Induced Changes in Semen/Sperm Analysis in Men With Newly Diagnosed, Progressive or Recurrent Primary Malignant Brain Tumors||Comprehensive Cancer Center of Wake Forest University|No|Completed|August 2004|September 2014|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Male|18 Years|60 Years|No|Non-Probability Sample|patients recieving temozolimide for malignant brain tumor|July 2013|September 29, 2014|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499798||169429|
NCT00499811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00272|Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction|Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction||National Cancer Institute (NCI)||Completed|June 2007|||August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2011|February 21, 2014|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499811||169428|
NCT00502853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21081|A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.|Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.||Hoffmann-La Roche||Completed|October 2007|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|July 17, 2007||No||No|July 16, 2014|https://clinicaltrials.gov/show/NCT00502853||169197|
NCT00503139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-4426|Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan|Long Term Safety and Efficacy From Special Surveillance for Etanercept in Japan||Pfizer|No|Completed|June 2007|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|684|||Both|N/A|N/A|No|Non-Probability Sample|Hospital and Rheumatology clinic|February 2014|February 14, 2014|July 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00503139||169175|
NCT00512382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|688 special|The Nature of Reflux-respiratory Symptoms Association in Difficult to Treat Wheezing\Coughing Babies|The Nature of Reflux-respiratory Symptoms Association in Difficult to Treat Asthmatic/Wheezing Babies Using Impedance and Wheezy Monitoring||Wolfson Medical Center|Yes|Completed|March 2007|September 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|15|||Both|1 Month|18 Months|Accepts Healthy Volunteers|Probability Sample|We studied 23 consecutive Difficult to treat infants and children suspected of suffering        from both RS and GER with chronic respiratory symptoms. However, four dropted due to        technical problems wiht the equipment. In 19 patients We fully analyzed the respiratory        sounds one minute during and one minute before and one minute after each GER episode, and        in all parental markings of cough.|September 2011|September 4, 2011|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512382||168473|
NCT00500383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNREB#07-0689-CE|Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)|Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)||University Health Network, Toronto|No|Completed|October 2009|July 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|372|||Female|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases are recruited from three participating high-risk screening centres: Familial Breast        and Ovarian Cancer Programs at Mount Sinai Hospital and/or Princess Margaret Hospital        (Toronto, Ontario, Canada), the Juravinski Cancer Center (Hamilton, Ontario, Canada) and        Women's College Hsopital (toronto, Ontario, Canada). Controls are recruited from the        respective geographical locations.|March 2016|March 22, 2016|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500383||169384|
NCT00500396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGFROP|Vascular Endothelial Growth Factor in Stage V ROP|Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V.||Asociación para Evitar la Ceguera en México|No|Completed|March 2007|June 2007|Actual|||Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|2 Months|10 Years|No|||November 2007|November 21, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500396||169383|
NCT00508365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD109701|Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives|A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of Carvedilol CR and Lisinopril||GlaxoSmithKline||Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|40|||Both|65 Years|N/A|No|||October 2010|October 14, 2010|July 26, 2007||||||https://clinicaltrials.gov/show/NCT00508365||168780|
NCT00508599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-163|The Effects of Two Days of Bedrest on Insulin Resistance in Type 2 Diabetics|Effect of a 2-Day Bed Rest on Metabolic and Cardiovascular Risk Factors in Type 2 Diabetic Patients||University of New Mexico|Yes|Completed|May 2003|February 2006|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508599||168762|
NCT00485901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6409|Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia|A Double-Blind Randomized Comparison of the Efficacy and Safety of Intramuscular Olanzapine and Intramuscular Haloperidol in Acutely Agitated Patients With Schizophrenia||Eli Lilly and Company||Completed|July 2004|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485901||170478|
NCT00485914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B031120-Project 3|Work Interventions to Improve Employment Outcomes for Persons With Rheumatoid Arthritis and Osteoarthritis|Worksite Vocational Rehabilitation Intervention to Improve Employment Outcomes for Persons With Arthritis?||University of Missouri-Columbia||Completed|October 2003|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|89|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2010|January 27, 2010|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485914||170477|
NCT00483613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Alonso|Effects of Treatment of Chronic Stress in Patients With Lupus|||University Hospital Virgen de las Nieves|Yes|Completed|December 2003|July 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|45|||Both|18 Years|N/A|No|||June 2007|June 6, 2007|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483613||170653|
NCT00483626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thorax-001-2003|Hemodynamic Response After Six Months of Sildenafil|Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment||University of Chile|No|Recruiting|August 2003|June 2007|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|16 Years|75 Years|No|||April 2007|June 6, 2007|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483626||170652|
NCT00484237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-3324|A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Safety and Efficacy of Etanercept 10 mg Twice Weekly and 25 mg Once Weekly in Japanese Subjects With Active Rheumatoid Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2007|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|20 Years|75 Years|No|||December 2007|December 3, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484237||170605|
NCT00484549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0019|Fabry : National Initiative of Screening|National, Multicenter, Prospective Study of Screening of Fabry Disease in a Population of Men Over 28 Days Old and Less Than 55 Years, Hospitalized for an Ischemic Stroke.|FIND|University Hospital, Clermont-Ferrand||Completed|March 2007|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|889|||Male|N/A|55 Years|No|||December 2009|December 18, 2009|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484549||170581|
NCT00484198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0011-A-U301|Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|Yes|Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1820|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|June 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00484198||170608|
NCT00484211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR008|Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)|NGR008: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) Previously Treated With no More Than One Systemic Therapeutic Regimen||MolMed S.p.A.|No|Completed|December 2006|April 2013|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484211||170607|
NCT00484523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/09|Constitution of a Standardized Neural Imaging Database in Healthy Subjects|Constitution of a Standardized Neural Imaging Database in Healthy Subjects||Assistance Publique Hopitaux De Marseille||Completed|July 2007|||January 2010|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484523||170583|
NCT00484536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C32322|Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323|Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323.||UCB Pharma|Yes|Terminated|May 2007|July 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|232|||Both|18 Years|55 Years|No|||March 2011|September 2, 2011|June 8, 2007|Yes|Yes|The study was discontinued due to unfavorable interim analysis|No||https://clinicaltrials.gov/show/NCT00484536||170582|
NCT00501202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010366|Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of RWJ 333369 for the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy.||SK Life Science||Completed|March 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|75 Years|No|||January 2013|January 15, 2013|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501202||169322|
NCT00502294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-416|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis||Facet Biotech|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2008|June 23, 2009|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00502294||169240|
NCT00501449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0783|Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes|Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2007|||May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|581|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of MEN1 or MEN2.|October 2015|October 28, 2015|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501449||169304|
NCT00502567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00008|A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors|A Phase 1, Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2171 and Selected Chemotherapy Regimens When Given in Combination to Patients With Advanced Solid Tumors||AstraZeneca||Completed|January 2005|June 2011|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|104|||Both|18 Years|N/A|No|||July 2011|July 26, 2011|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00502567||169219|
NCT00502866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HS016029-01|Study to Assess the Use of a Simple Lab Test to Screen for Rickets in Children|The Feasibility of Assessing the Prevalence of Rickets in Children||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|June 2006|June 2008|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|246|||Both|6 Months|15 Months|Accepts Healthy Volunteers|Non-Probability Sample|breastfed children|October 2006|January 7, 2014|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00502866||169196|
NCT00499031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0227E|Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix||Gynecologic Oncology Group||Completed|June 2007|||January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|July 10, 2007|Yes|Yes||No|May 22, 2014|https://clinicaltrials.gov/show/NCT00499031||169485|
NCT00502281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2006e|Controlled Ovarian Stimulation Followed by Timed Intercourse or Intrauterine Insemination in Infertile PCOS Patients|Timed Intercourse Versus Intrauterine Insemination in Infertile Patients Undergoing Gonadotropin Ovarian Stimulation||University Magna Graecia||Suspended|January 2007|||March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|35 Years|No|||April 2013|April 5, 2013|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00502281||169241|
NCT00500058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI105618|A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18|A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma"||GlaxoSmithKline|No|Completed|July 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|N/A|No|||October 2011|May 31, 2012|July 10, 2007||||||https://clinicaltrials.gov/show/NCT00500058||169409|
NCT00500071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-310|Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD|A Prospective, Open-Label, Multi-Center, Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) 20-70mg in Children Aged 6-12 Diagnosed With ADHD||Shire||Completed|July 2007|April 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|318|||Both|6 Years|12 Years|No|||January 2011|January 14, 2011|July 10, 2007|No|Yes||No|May 26, 2009|https://clinicaltrials.gov/show/NCT00500071||169408|
NCT00500084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14294|Phase III ALTU-135 CP Safety Trial|An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy|DIGEST CP|Anthera Pharmaceuticals|Yes|Terminated|December 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|July 10, 2007|Yes|Yes|Sponsor decision.|No||https://clinicaltrials.gov/show/NCT00500084||169407|
NCT00508885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 06-0462|The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients|The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients||Washington University School of Medicine|No|Completed|October 2006|July 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A||||July 2007|July 26, 2007|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00508885||168740|
NCT00508092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q1602/168|Combined Nerve Blockade and Local Infiltration Anesthesia in Appendectomy - A Blinded Randomized Study|Combined Nerve Blockade and Local Infiltration Anesthesia in Appendectomy - A Blinded Randomized Study||Royal Berkshire NHS Foundation Trust|No|Completed|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|75|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2008|April 22, 2008|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00508092||168801|
NCT00508105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB2006489-0H|Comparing Two Surgical Methods of Fixation of Subscapularis During Shoulder Arthroplasty|Comparison of Two Methods of Fixation of Subscapularis During Shoulder Arthroplasty||Ottawa Hospital Research Institute|No|Completed|November 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508105||168800|
NCT00509483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRN 833/02|Three-Year Follow-up of Radioiodine Therapy for Goitre|Long-Term Follow-up and Outcome of Administering Recombinant Human Thyrotropin as an Adjuvant of Therapy With Radioiodine in the Outpatient Treatment of Multinodular Goitres||University of Sao Paulo|No|Completed|January 2002|December 2006||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||40|||Both|20 Years|N/A|No|||October 2008|October 16, 2008|July 27, 2007||||No||https://clinicaltrials.gov/show/NCT00509483||168694|
NCT00509496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070174|Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)|Yes|Terminated|June 2007|July 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||December 2012|January 4, 2013|July 30, 2007|Yes|Yes|Low accrual|No|October 31, 2012|https://clinicaltrials.gov/show/NCT00509496||168693|
NCT00483639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0397|Study of Anxiety and Avoidance of Others in Patients Previously Treated for Head and Neck Cancer|Social Anxiety and Avoidance in Head and Neck Cancer Patients||Vanderbilt-Ingram Cancer Center|Yes|Completed|November 2003|January 2008|Actual|March 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|||Both|21 Years|70 Years|No|Probability Sample|People who have been treated for head and neck cancer.|March 2013|March 13, 2013|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483639||170651|
NCT00483951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070157|Cardiovascular Disease Screening|Suburban/NHLBI Cardiovascular Disease Screening Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|June 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00483951||170627|
NCT00484224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qwer1234-HMO-CTIL|Audiological Disturbances in Vitiligo|||Hadassah Medical Organization||Not yet recruiting||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|3 Years|50 Years|Accepts Healthy Volunteers|||May 2007|June 7, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484224||170606|
NCT00484796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN47041942|Trigeminus-evoked Somatosensory Potentials in Patients Undergoing Carotid Surgery|Comparison of Trigeminus-evoked Somatosensory Potentials (TRI-SEP) and Medianus-evoked Somatosensory Potentials (MED-SEP) in Patients Undergoing Carotid Surgery|TRISEP|Klinikum St. Georg gGmbH|No|Completed|October 2006|February 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing carotid surgery|October 2012|October 26, 2012|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484796||170562|
NCT00484562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060507|Prospective Study Comparing Different Modalities of Oxygen Delivery During Assessment of Functional Exercise Capacity|A Randomized, Multi-arm Repeated Measures Prospective Study Comparing Different Modalities of Portable Oxygen Delivery During Assessment of Functional Exercise Capacity||University of Missouri-Columbia|No|Completed|May 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|39|||Both|N/A|N/A|No|||February 2011|February 24, 2011|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484562||170580|
NCT00484783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-06-13|Transluminal Flexible Endoscopic Procedure in Foregut and Urologic Surgery|Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery|NOTES|University Hospital Case Medical Center|Yes|Completed|August 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|75 Years|No|||December 2014|December 12, 2014|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484783||170563|
NCT00510302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-452|Melanoma Risk-Reduction Among Patients and Family Members|Melanoma Risk-Reduction Practices Among Melanoma Patients and Their Family Members||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2002|||November 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).|June 2015|June 22, 2015|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510302||168633|
NCT00510640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9277-06|Thyroid Cancer and Sunitinib|Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer|THYSU|University Hospital, Bordeaux|Yes|Completed|August 2007|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510640||168607|
NCT00502307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-07-201|A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma|A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma||AVEO Pharmaceuticals, Inc.|No|Completed|October 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|272|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00502307||169239|
NCT00502580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0684|Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions|Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions||M.D. Anderson Cancer Center|No|Completed|July 2005|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|Samples With DNA|Pictures of suspicious and normal oral cavity lesions along with small sample of oral lesion      (2-4 mm each, the size of a small eraser) will be removed or biopsied from the areas imaged.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with lesions of the oral cavity mucosa.|July 2012|July 26, 2012|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00502580||169218|
NCT00510900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508103|Effects of Left Atrial Appendage Occlusion|Effects of Left Atrial Appendage Occlusion||University of Pittsburgh|Yes|Withdrawn|August 2005|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510900||168587|
NCT00511173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-14171|Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm|Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing||Creighton University|No|Completed|August 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Both|19 Years|90 Years|No|||December 2012|December 7, 2012|August 1, 2007||No||No|April 17, 2012|https://clinicaltrials.gov/show/NCT00511173||168566|
NCT00511186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP REN 01-01|A Study in Sepsis Patients With Renal Failure|A Phase-IIa, Double-blind, Randomized, Placebo-controlled Study on the Safety and Early Efficacy of Alkaline Phosphatase in Sepsis Patients With Renal Failure||AM-Pharma|Yes|Terminated|May 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|80 Years|No|||March 2012|March 30, 2012|August 2, 2007||No|sufficient POC to switch development from bovine AP to recombinant AP|No||https://clinicaltrials.gov/show/NCT00511186||168565|
NCT00511537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-9907-CC99251|Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders|Standard of Care Trial: Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders||University of California, San Francisco|Yes|Completed|January 1999|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|16 Years|54 Years|No|Non-Probability Sample|Patients with Hematopoeietic Disorders|August 2013|August 1, 2013|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511537||168538|
NCT00499278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-271|JOINTS Study - Joint Replacement Outcome in Inpatient Rehabilitation Facilities and Nursing Treatment Sites|Joint Replacement Outcome in Inpatient Rehabilitation Facilities and Nursing Treatment Sites|JOINTS|MedStar National Rehabilitation Network|No|Completed|November 2005|February 2007|Actual|||N/A|Observational|Observational Model: Natural History, Time Perspective: Longitudinal|||Actual|2384|||Both|21 Years|N/A|No|||July 2007|July 9, 2007|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00499278||169467|
NCT00511836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-018|ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults|The Effects of VIVITROL® on Alcohol-Related Cue-Induced Craving and BOLD [Blood Oxygen-level-dependent] Functional Magnetic Resolution Imaging (fMRI) Signal Activation Patterns||Alkermes, Inc.|No|Completed|July 2007|October 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||December 2010|December 9, 2010|August 2, 2007|Yes|Yes||No|June 10, 2010|https://clinicaltrials.gov/show/NCT00511836||168515|The study was powered to detect whether VIVITROL blocks the fMRI BOLD signal increase in response to alcohol-related cues as compared to placebo. Results of the secondary endpoints should be interpreted with caution.
NCT00511849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181050|Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors|Phase I Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Malignancies||Pfizer|No|Completed|November 2005|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2010|February 16, 2010|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00511849||168514|
NCT00511862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G040148|TheraSphere for the Treatment of Liver Metastases|TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer, Neuroendocrine Cancer or Non-colorectal/Non-neuroendocrine Cancer||BTG International Inc.|No|Completed|January 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|18 Years|N/A|No|||February 2014|June 5, 2014|August 2, 2007|No|Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00511862||168513|
NCT00511875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25234|Evaluation of Doxycyline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy|Evaluation of Effect of Doxycyline Verses Placebo on Diabetic Retinopathy Progression and Retinal Function in Patients With Severe Non-proliferative or Mild or Moderate (Non-high-risk) Proliferative Diabetic Retinopathy|POC1|Penn State University|Yes|Completed|July 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|August 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00511875||168512|
NCT00512122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPaNIC 2007 1-2-2|Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients|Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients|EPaNIC|Katholieke Universiteit Leuven|Yes|Active, not recruiting|August 2007|December 2021|Anticipated|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4640|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00512122||168493|
NCT00508612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|497|Effectiveness of an Anger and Stress Management Program on Reducing Blood Pressure Levels in Youth|Impact of LifeSkills Training on Blood Pressure in Youth||National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|April 2007|March 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|259|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00508612||168761|
NCT00508638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|508|Identifying High- and Low-Risk Heart Failure Patients in the Emergency Department (The Stratify Study)|Improving Heart Failure Risk Stratification in the ED|Stratify|Vanderbilt University|No|Active, not recruiting|May 2007|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|This will be a convenience sample of patients presenting to the emergency department for        care.|June 2015|June 1, 2015|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508638||168759|
NCT00509184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIR 2006-001212-72|Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma|Therapy of Nodal Follicular Lymphoma (Grade I/II) Clinical Stage I or II Using Involved Field Radiotherapy in Combination With Rituximab|MIR|Heidelberg University|Yes|Completed|March 2008|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|75 Years|No|||July 2013|July 21, 2013|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509184||168717|
NCT00483327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-685|Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate|Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate||New York University School of Medicine|Yes|Completed|June 2007|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||November 2013|November 20, 2013|June 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00483327||170674|
NCT00483353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011058|Effect of a Nasal Bolus Allergen Challenge on Inflammatory Markers|A Pilot Study to Explore the Effect of a Nasal Bolus Allergen Challenge on Inflammatory Markers in Subjects With Seasonal Allergic Rhinitis||Pfizer||Completed|July 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||6|||Both|18 Years|65 Years|No|||June 2008|June 12, 2008|June 5, 2007||||No||https://clinicaltrials.gov/show/NCT00483353||170673|
NCT00484250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240|Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other|||Mashhad University of Medical Sciences|Yes|Completed|September 2005|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Both|N/A|N/A|No|||June 2007|June 8, 2007|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484250||170604|
NCT00484575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000293-23|Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting|Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting||Karolinska Institutet|No|Completed|June 2007|December 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||June 2007|May 19, 2010|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484575||170579|
NCT00484822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO-BEMI-01-2006|Bemiparin Randomized Trial on Bridging Oral Anticoagulants in Invasive Procedures (BERTA Study)|Multicentric, Randomized, Controlled, Double-blind Clinical Trial to Assess Perioperative Bridging Therapy With Sodium Bemiparin vs Calcium Unfractionated Heparin in Invasive Procedures, Outpatient Surgery and Laparoscopy Surgery in Patients Receiving Long-term Oral Anticoagulant Therapy|BERTA|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Terminated|February 2007|May 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||February 2010|February 3, 2010|June 8, 2007||No|The study has been halted prematurely due to a low recruitment.|No||https://clinicaltrials.gov/show/NCT00484822||170560|
NCT00484809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101511|Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children|A Post-Marketing Surveillance Looking at Safety of Enbrel (Etanercept) in Adults With Active Rheumatoid Arthritis (RA) and Children With Juvenile Rheumatoid Arthritis (JRA).||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2004|February 2006|Actual|||Phase 4|Observational|Time Perspective: Prospective||||100|||Both|4 Years|N/A|No|||December 2007|December 11, 2007|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484809||170561|
NCT00485056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-IIT-006|Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study)|Pioglitazone on Cardiac Function and Large Arteries (PICCOLA)|PICCOLA|Imperial College London|Yes|Completed|April 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|N/A|N/A|No|||August 2009|August 5, 2013|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485056||170542|
NCT00485069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108862|REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study|Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety -||GlaxoSmithKline||Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|20 Years|N/A|No|||November 2010|November 18, 2010|June 11, 2007||||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00485069||170541|
NCT00485407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8226|Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine|Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study||Eli Lilly and Company||Completed|July 2003|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|377|||Both|6 Years|16 Years|No|||June 2007|October 31, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485407||170516|
NCT00511225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-14571|Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease|Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease|Neph|Creighton University|No|Completed|September 2007|September 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|19 Years|N/A|No|||June 2012|June 29, 2012|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00511225||168562|
NCT00511238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-003|Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma|An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma||Onyx Pharmaceuticals|No|Completed|August 2007|October 2012|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|August 1, 2007|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00511238||168561|
NCT00510614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030019|Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study|Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study||University of Pittsburgh|Yes|Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|37|||Female|18 Years|45 Years|No|||February 2011|February 16, 2011|August 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00510614||168609|
NCT00510627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-PM-032006|Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases|A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy|Prometheus|Boston Scientific Corporation|No|Withdrawn|August 2007|December 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|682|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|July 31, 2007|||Boston Scientific has decided to close the Study.|No||https://clinicaltrials.gov/show/NCT00510627||168608|
NCT00510913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-98-002|A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure|Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure|CRAF|Astellas Pharma Inc|Yes|Completed|February 1999|September 2000|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|12 Years|N/A|No|||July 2007|July 31, 2007|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00510913||168586|
NCT00511550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-2508|Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors|Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors||University of California, San Francisco|Yes|Completed|August 2005|November 2007||||N/A|Observational|Time Perspective: Prospective||||15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2007|March 3, 2008|August 3, 2007||||No||https://clinicaltrials.gov/show/NCT00511550||168537|
NCT00511563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI109244|A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679|A Double-blind, Randomised, Placebo-controlled, Three-period Crossover Study to Investigate the Pharmacodynamic Effect of Two CRF-1 Antagonists GSK561679 and GW876008 on Meal Induced Cortisol Responses in Patients With IBS.||GlaxoSmithKline|No|Withdrawn|August 2007|||November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||February 2015|February 26, 2015|August 2, 2007||No|Cancelled before active due to the results of emerging scientific data|No||https://clinicaltrials.gov/show/NCT00511563||168536|
NCT00511888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-07|Nebivolol Versus Carvedilol in Patients With Heart Failure|Effects of Nebivolol Versus Carvedilol in Hypertensive Patients With Chronic Heart Failure||IRCCS San Raffaele|Yes|Terminated|January 2004|June 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|160|||Both|53 Years|76 Years|No|||August 2007|October 16, 2008|August 3, 2007|||is finish|No||https://clinicaltrials.gov/show/NCT00511888||168511|
NCT00512395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STZ 13/04|Influence of Epidural Analgesia in Elective Laparoscopic Colorectal Resections|Influence of Epidural Analgesia in Elective Laparoscopic Colorectal Resections||University Hospital, Basel, Switzerland|No|Completed|November 2004|January 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512395||168472|
NCT00508118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001612|NICardipine Neuroprotection in AortiC Surgery (NICNACS)|NICardipine Neuroprotection in AortiC Surgery (NICNACS)|NICNACS|Duke University|No|Terminated|January 2008|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||January 2013|July 29, 2014|July 25, 2007|Yes|Yes|3/7 subjects experienced hypotension. Study was terminated.|No|September 21, 2011|https://clinicaltrials.gov/show/NCT00508118||168799|This study was terminated early because of safety concerns in the active treatment group. In 3 patients randomized, the blind was broken in 3 because of refractory hypotension and acidosis requiring vasopressor therapy. All 3 were on active drug.
NCT00508378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN00-409|Chemotherapy-Related Toxicities In Ovarian Cancer Patients|Chemotherapy-Related Toxicities In Ovarian Cancer Patients: Preference Assessments of Patients, Family Members, Ancillary Staff and Gynecologic Oncologists, and Patients' Quality of Life||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2001|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|288|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ovarian cancer patients, their family members, and doctors and nurses from the UTMDACC        Gynecologic Oncology Clinic.|September 2015|September 30, 2015|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00508378||168779|
NCT00508625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050190|A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab|A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects With Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy With or Without Bevacizumab||Amgen||Completed|November 2007|February 2012|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|213|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|July 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00508625||168760|
NCT00508391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G070019|Interventricular Delay of Lumax HF-T for Heart Failure|Clinical Investigation to Study Safety and Efficacy of the Interventricular Delay Feature of the Lumax HF-T Device for Heart Failure.||Biotronik, Inc.|No|Completed|July 2007|August 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||January 2010|January 21, 2010|July 26, 2007|Yes|Yes||No|October 27, 2009|https://clinicaltrials.gov/show/NCT00508391||168778|
NCT00508664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP(F)+Radiation+/-Cetuximab|Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)|Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx|DeLOS II|University of Leipzig|No|Completed|July 2007|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|75 Years|No|||June 2015|June 1, 2015|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00508664||168757|
NCT00508924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG-E04|Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)|A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in Comparison With Unfractionated Heparin, Clopidogrel and Aspirin||Mitsubishi Tanabe Pharma Corporation||Completed|August 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|140|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|July 26, 2007||||No|November 6, 2012|https://clinicaltrials.gov/show/NCT00508924||168737|
NCT00508898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2007.261-T|The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria|The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria||Chinese University of Hong Kong|No|Withdrawn|May 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||January 2009|July 31, 2015|July 27, 2007||No|Funding problem; trial abandoned.|No||https://clinicaltrials.gov/show/NCT00508898||168739|
NCT00508911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH103002|A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills.|An Open-label, Repeat-dose, Single-sequence Study to Investigate the Effects of Once-daily Repeat Oral Administration of GW876008 125mg on the Pharmacokinetics of the Combined Oral Contraceptive in Female Volunteers||GlaxoSmithKline||Terminated|June 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00508911||168738|
NCT00509210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX06-950-012|Study of Telaprevir in Subjects With Hepatic Impairment|||Vertex Pharmaceuticals Incorporated|Yes|Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||||||Both|18 Years|65 Years|No|||October 2008|October 28, 2008|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509210||168715|
NCT00483964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI #04T-512|A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia|A Randomized, Controlled ,Clinical Trial of a Herbal Combination of Aqueous Extracts of Bacopa Monnieri and Nardostachys Jatamansi in the Treatment of Schizophrenia, Compared to Standard Anti-Psychotic Drugs||Q.Mundewadi Ayurvedic Research & Charitable Trust|No|Completed|September 2005|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|60 Years|No|||October 2007|October 9, 2007|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483964||170626|
NCT00483977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7771010|A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee|A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicentre Study To Assess The Efficacy And Tolerability Of PF-00592379 In Patients With Moderate To Severe Pain Due To Osteoarthritis||Pfizer|Yes|Terminated|June 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|113|||Both|18 Years|75 Years|No|||April 2011|April 22, 2011|June 6, 2007|Yes|Yes|Met criteria for study futility at interim analysis|No||https://clinicaltrials.gov/show/NCT00483977||170625|
NCT00484263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T10716|The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis|The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis.||The Alfred|Yes|Completed|December 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484263||170603|
NCT00484588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0918X-101828|A Multi-Center Observational Surveillance Study of VAP Causing Bacteria|A Multi-Center Observational Surveillance of VAP Causing Bacteria Study||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|May 2005|December 2006||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||||500|||Both|N/A|N/A|No|||June 2007|June 8, 2007|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484588||170578|
NCT00484289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-129|A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis|A Phase III, Multi-center, Open-label, Uncontrolled, Long-term Study to Evaluate the Safety of Abatacept (BMS-188667) in Japanese Subjects With Rheumatoid Arthritis Having Completed Clinical Studies IM101-071, IM101-034, and Also Special DMARD Failures||Bristol-Myers Squibb|No|Completed|December 2006|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|217|||Both|20 Years|N/A|No|||June 2013|June 18, 2013|June 7, 2007|Yes|Yes||No|May 25, 2012|https://clinicaltrials.gov/show/NCT00484289||170601|
NCT00484614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEM-06-01|Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer|Prospective Multicenter Study of the Role of Positron Emission Mammography (PEM) in Pre-Surgical Planning for Breast Cancer||Naviscan PET Systems|Yes|Active, not recruiting|September 2006|March 2009|Anticipated|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|472|||Female|25 Years|N/A|No|||December 2008|September 2, 2009|June 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00484614||170576|
NCT00485082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907162|Disclosing a Cystic Fibrosis Diagnosis to a Dating Partner|Disclosure of a Cystic Fibrosis Diagnosis to a Dating Partner||National Institutes of Health Clinical Center (CC)||Completed|June 2007|||March 2008|Actual|N/A|Observational|Time Perspective: Retrospective||||50|||Both|21 Years|35 Years|No|||August 2009|August 26, 2009|June 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00485082||170540|
NCT00484835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Electrocoag Forceps in TAH|Are Sutures Required in Total Abdominal Hysterectomy? A Randomised Control Trial|Randomised Control Trial Comparing Hysterectomy Using Electrocoagulation Forceps With the Traditional Clamp & Suture Technique of Richardson Abdominal Hysterectomy||Southern Health|Yes|Not yet recruiting|September 2007|August 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2007|August 7, 2007|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484835||170559|
NCT00511251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-LF-07226-CTIL|Analysis of Induced Sputum and Lung Biopsies by SEM: a Tool to Identify Source of Exposure of Workers to Hazardous Dust|||Tel-Aviv Sourasky Medical Center|No|Completed|January 2005|April 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||August 2007|August 2, 2007|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511251||168560|
NCT00511264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-10|Laparoscopic Ultrasound Guided Tissue Sampling in Patients With Cancer of the Upper Gastrointestinal Tract|Prospective Evaluation of the Impact of Laparoscopic Ultrasound (LUS) Guided Fine-Needle Aspiration or Tru-Cut Biopsy in Patients With Upper GI Tract Cancer||Odense University Hospital|No|Completed|May 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|No|||May 2008|May 27, 2008|August 1, 2007||||No||https://clinicaltrials.gov/show/NCT00511264||168559|
NCT00510926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML/021|Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase|CML/021 "A Phase II Exploratory Study of IMATINIB High Dose (800mg/gg) in the Treatment of Newly Diagnosed Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase"||University of Bologna||Completed|January 2004|November 2006||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||80|||Both|18 Years|N/A|No|||August 2007|August 2, 2007|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00510926||168585|
NCT00511199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05724|Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)|A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE)||Merck Sharp & Dohme Corp.|No|Completed|May 2006|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2152|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|August 2, 2007|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00511199||168564|
NCT00511212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCSGO-0701|Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive Tract|Clinical Study of Intravenous Immunoglobulin (IVIG) in Combination Therapy With Antibacterial Agents for Surgical Site Infection of the Lower Digestive Tract||Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group|Yes|Withdrawn|August 2007|June 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||August 2007|July 20, 2011|August 1, 2007|||No eligible patient.|No||https://clinicaltrials.gov/show/NCT00511212||168563|
NCT00512161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701008942|Placement of Permanent Pacemaker Study|A Retrospective Study to Determine the Frequency of Indications That Lead to the Placement of Permanent Pacemakers After Cardiac Surgery||Weill Medical College of Cornell University|No|Active, not recruiting|June 2007|December 2012|Anticipated|December 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiopulmonary Bypass Patients without a pacemaker already in place|March 2012|March 16, 2012|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00512161||168490|
NCT00508443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-446|Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)|Phase I/II Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS) for the Treatment of Metastatic Spine Disease||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2002|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|N/A|N/A|No|||February 2016|February 4, 2016|July 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00508443||168774|
NCT00512408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-07|Testosterone Improves Exercise Oxygen Uptake, Insulin Resistance and Muscle Strength in Elderly Patients With Chronic Heart Failure|Long-Acting Testosterone Improves Exercise Oxygen Uptake, Insulin Resistance and Muscle Strength in Elderly Patients With Chronic Heart Failure||IRCCS San Raffaele||Terminated|July 2006|March 2007|Actual|||N/A|Observational|Time Perspective: Prospective||2|||||Male|56 Years|76 Years||||August 2007|October 16, 2008|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512408||168471|
NCT00508131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408svillalp|Effectiveness of Iron-Fortified Milk on Iron Status and Anemia in Young Children in Mexico|||Instituto Nacional de Salud Publica, Mexico|No|Completed|May 2003|July 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|798|||Both|12 Months|30 Months|Accepts Healthy Volunteers|||July 2007|July 26, 2007|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00508131||168798|
NCT00508404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060314|Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer|A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer||Amgen|No|Completed|May 2007|June 2012|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|July 26, 2007|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT00508404||168777|
NCT00508651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP150|A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age|An Expanded Phase1/2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-560, A Live, Attenuated Recombinant Parainfluenza Virus Type 3 (PIV3) Vaccine, Administered Intranasally to Healthy Infants 1 to <12 Mos. of Age||MedImmune LLC|No|Terminated|October 2007|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|1 Month|11 Months|Accepts Healthy Volunteers|||November 2011|November 28, 2011|July 27, 2007|Yes|Yes|The study was closed prior to enrollment of Cohort 2 due to a non-safety related sponsor    decision.|No|September 8, 2011|https://clinicaltrials.gov/show/NCT00508651||168758|Cohort 2 was not enrolled due to a sponsor decision.
NCT00510081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1253-013|An Evaluation of an Injectable Material for Correction of Wrinkles|An Open Label Evaluation of the Safety and Efficacy of Calcium Hydroxylapatite (Radiesse®) Injection in the Correction of Jowl-Associated Chin Notches||Northwestern University|No|Withdrawn|July 2007|February 2009||February 2009||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|40 Years|65 Years|No|||December 2014|December 5, 2014|July 31, 2007|Yes|Yes|The study was not executed. No subjects were enrolled.|No||https://clinicaltrials.gov/show/NCT00510081||168650|
NCT00510094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-5013|Effectiveness of Treatment for Relational Aggression in Urban African American Girls|Determining the Efficacy of a Relational Aggression Intervention for Urban African American Girls||Children's Hospital of Philadelphia|No|Completed|October 2007|May 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Female|N/A|N/A|No|||June 2015|June 3, 2015|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00510094||168649|
NCT00509535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-AD-003|Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic Probands|Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic Probands Biomedical Findings With Vitreoscilla Filiformis||L'Oreal|Yes|Completed|January 2005|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|75|||Both|6 Years|70 Years|Accepts Healthy Volunteers|||July 2007|July 30, 2007|July 30, 2007||||No||https://clinicaltrials.gov/show/NCT00509535||168691|
NCT00483665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC_06_112|Vasovist Endoleak Study|Detection of Endoleak by Vasovist-Enhanced Magnetic Resonance Imaging||UMC Utrecht|No|Completed|June 2006|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients after more than 1 year who have a stable or growing aneurysm according to        diameters measured on CT angiography images and no evidence of endoleak on recent CT        angiography|November 2008|November 17, 2008|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483665||170649|
NCT00484029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C301|Nasal Carbon Dioxide (CO2)for the Treatment of Temporomandibular Disorders (TMD)Related Pain|A Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Nasal CO2 in the Symptomatic Treatment of Temporomandibular Disorders||Capnia, Inc.|No|Completed|February 2007|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||August 2010|August 18, 2010|June 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00484029||170621|
NCT00485446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-JB-0304-307-10|Thrombophilia and Thyroid Autoimmunity in Implantation Failure and Recurrent Miscarriage|||Instituto Valenciano de Infertilidad, IVI VALENCIA||Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Female|18 Years|37 Years||||June 2007|June 12, 2007|June 12, 2007||||No||https://clinicaltrials.gov/show/NCT00485446||170513|
NCT00484601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS0327|Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma|Phase II Study of Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma||Sidney Kimmel Comprehensive Cancer Center|No|Terminated|October 2004|September 2010|Anticipated|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484601||170577|
NCT00485121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05080|Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis|Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis||Canadian Cardiovascular Research Network|No|Completed|April 2007|April 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|40 Years|80 Years|No|||May 2008|November 24, 2010|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00485121||170537|
NCT00485134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC.2006.0007|Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection|||Walter Reed Army Institute of Research (WRAIR)|No|Completed|May 2007|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2010|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485134||170536|
NCT00485433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402-C-207|Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair|A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair.||Pacira Pharmaceuticals, Inc|No|Completed|June 2007|August 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|98|||Male|18 Years|N/A|No|||July 2013|July 3, 2013|June 11, 2007|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00485433||170514|
NCT00512174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4629-ZD-CTIL|Prospective Trial to Evaluate Efficacy and Accuracy of a Portable Ultrasound Scanner for Non-Invasive Bladder Volume Measurement (BladderScan BVI3000) in Patients After Radical Cystectomy and Bladder Reconstruction|Prospective Trial to Evaluate Efficacy and Accuracy of a Portable Ultrasound Scanner for Non-Invasive Bladder Volume Measurement (BladderScan BVI3000) in Patients After Radical Cystectomy and Bladder Reconstruction||Sheba Medical Center|No|Recruiting|August 2007|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2007|August 6, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512174||168489|
NCT00511576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103 PH US 2007 CL001|Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors|A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination With Docetaxel (Taxotere®) in Subjects With Advanced Solid Malignancies||Mirati Therapeutics Inc.|No|Terminated|August 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|August 3, 2007|No|Yes|Celgene terminated its collaboration agreement with MethylGene for the development of    MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.|No||https://clinicaltrials.gov/show/NCT00511576||168535|
NCT00511901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220045106|Prevalence and Treatment of Anemia in Rehabilitation Patients|Prevalence and Treatment of Anemia in Patients Admitted to Subacute Rehabilitation Hospital||Rutgers, The State University of New Jersey|Yes|Terminated|November 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|60 Years|N/A|No|||November 2011|December 27, 2013|August 3, 2007||No|Study enrollment was suspended in response to an FDA alert regarding the study drug. The study    was subsequently terminated|No|August 27, 2013|https://clinicaltrials.gov/show/NCT00511901||168510|Limited number of eligible subjects, burdensome protocol requirements impeded recruitment, controversy concerning safety of epoetin alpha which led to early termination of study
NCT00511914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P1S|Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture, Using the Strain Composition 2007/2008, When Administered to Adult and Elderly Subjects||Novartis|No|Completed|July 2007|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|135|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 18, 2013|August 3, 2007|Yes|Yes||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00511914||168509|
NCT00508456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0066|Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM|A Phase I Study of Dietary Methionine Restriction and Temodar® (Temozolomide) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Terminated|August 2004|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|N/A|No|||January 2012|January 12, 2012|July 27, 2007||No|Low Accrual|No||https://clinicaltrials.gov/show/NCT00508456||168773|
NCT00508183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB2006862-01H|Types of Fixation in Arthroscopic Rotator Cuff Repair|Single Row Versus Double Row Fixation in Arthroscopic Cuff Repair; a Randomized Controlled Sutdy.||Ottawa Hospital Research Institute|No|Completed|April 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|October 24, 2011|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508183||168794|
NCT00512135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0609/1|Safety and Efficacy of IncobotulinumtoxinA (Xeomin) in the Treatment of Glabellar Frown Lines|A Prospective, Open-label, Multicenter, Repeat-dose Trial to Investigate the Safety and Efficacy of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines||Merz Pharmaceuticals GmbH|No|Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|796|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|August 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512135||168492|
NCT00512148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL004|Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury|An Open Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury||Tengion|Yes|Terminated|July 2007|April 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|August 3, 2007|Yes|Yes|24 months follow up completed without substantial change to the profile.|No|December 20, 2010|https://clinicaltrials.gov/show/NCT00512148||168491|
NCT00508157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-489|A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome|A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome||Bristol-Myers Squibb|No|Terminated|November 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|65 Years|No|||November 2013|November 20, 2013|July 26, 2007|Yes|Yes|Slow Accrual|No|June 22, 2010|https://clinicaltrials.gov/show/NCT00508157||168796|Following a review of all studies in development, a strategic decision was made to terminate this study due to slow accrual. Patients randomized and treated at the time of study termination could continue the study as per protocol until completion.
NCT00508417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907198|Malaria Incidence in Infants in Bancoumana, Mali|Malaria Incidence in Infants in Bancoumana, Mali||National Institutes of Health Clinical Center (CC)||Completed|July 2007|February 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|6 Weeks|6 Months|No|||February 2011|February 12, 2011|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00508417||168776|
NCT00509795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0605|Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)|A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration|VIEW1|Regeneron Pharmaceuticals|Yes|Completed|August 2007|July 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1217|||Both|50 Years|N/A|No|||December 2012|December 20, 2012|July 31, 2007|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00509795||168671|
NCT00509808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Wolff|Evaluation of an Electro-stimulator for the Treatment of Xerostomia|Safety and Performance Evaluation of an Electro-stimulator Mounted on an Intra-oral Removable Appliance (Saliwell GenNarino) for the Treatment of Xerostomia|GenNarino|Saliwell Ltd.|No|Completed|January 2007|April 2010|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||April 2010|April 5, 2010|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00509808||168670|
NCT00509561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558804|Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer|A Randomised Phase II/III Multi-Centre Clinical Trial of Definitive Chemotherapy, With or Without Cetuximab, in Carcinoma of the Oesophagus||Wales Cancer Trials Unit|Yes|Active, not recruiting|February 2008|||September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|259|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509561||168689|
NCT00510367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-193|Primary Breast Cancer Occurring Concomitant With Pregnancy|Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2001|||August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|N/A|N/A|No|||October 2015|October 14, 2015|July 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510367||168628|
NCT00510380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIG/07072|Epigenetic Markers in Growth Restricted Human Pregnancies: a Case-controlled Study|Epigenetic Markets in Growth Restricted Human Pregnancies: A Case- Control Study||National University Hospital, Singapore|Yes|Completed|April 2007|April 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Female|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Babies from Chinese women with single pregnancies|September 2009|September 18, 2009|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00510380||168627|
NCT00483678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-043|Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners|A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2007|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 24, 2015|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00483678||170648|
NCT00484874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0703|Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma|A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|June 2007|||January 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484874||170556|
NCT00483990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSD502-PE-003|Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers|A Phase I, Double-blind, Stratified, Parallel Group, Placeob-controlled Study of the Safety, Tolerability and Pharmacokinetics of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times Daily for 21 Days in Healthy Male Volunteers||Plethora Solutions Ltd|No|Completed|March 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||16|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 14, 2010|June 6, 2007||||No||https://clinicaltrials.gov/show/NCT00483990||170624|
NCT00484003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981CZA01|A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis|A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis||Novartis||Completed|October 2004|December 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|2 Years|12 Years|No|||February 2008|February 13, 2008|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484003||170623|
NCT00484016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0155|Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC|Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected Non Small Cell Lung Cancer||Washington University School of Medicine|No|Completed|February 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|45|||Both|18 Years|88 Years|No|||August 2013|August 9, 2013|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00484016||170622|
NCT00484276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR010|Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma|NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen|NGR010|MolMed S.p.A.|No|Completed|May 2007|April 2013|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484276||170602|
NCT00485459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8160|Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD|Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company||Completed|February 2004|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|106|||Both|6 Years|16 Years|No|||June 2007|June 11, 2007|June 11, 2007||||||https://clinicaltrials.gov/show/NCT00485459||170512|
NCT00481234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH2002_D414/02|Heart Rate Variability for Prediction of Perioperative Events|Heart Rate Variability for Prediction of Incidence of Cardiac Ischemia and Cardiovascular Events After General Anesthesia in High Risk Patients||University of Schleswig-Holstein|No|Completed|June 2002|December 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|2002|||Both|18 Years|N/A|No|||May 2007|May 31, 2007|May 31, 2007||||No||https://clinicaltrials.gov/show/NCT00481234||170831|
NCT00484848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM007|Functional Evaluation of Two Types of Totally Implanted Venous Ports|Functional Evaluation of Conventional Venous Access Port (Celsite®) Versus Venous Access Port With Tangential Outlet (Vortex®) : a Prospective Randomized Pilot Study||Universitaire Ziekenhuizen Leuven|No|Completed|September 2004|March 2005|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|N/A|No|||January 2009|January 23, 2009|June 7, 2007||||No||https://clinicaltrials.gov/show/NCT00484848||170558|
NCT00484861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070163|Effect of Diet on Vascular Disease in Pre-Menopausal Women|The Effect of Diet on Vascular Disease: A Study of African American and Caucasian Women||National Institutes of Health Clinical Center (CC)||Completed|June 2007|||||N/A|Observational|Time Perspective: Prospective|||Actual|47|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00484861||170557|
NCT00481533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-07|Ergot and Oxytocin During Cesarean Delivery Following Failure to Progress in Labour|Prophylactic Ergonovine-Oxytocin Versus Oxytocin During Cesarean Delivery Following Failure to Progress in Labour||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|June 2005|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|47|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00481533||170808|
NCT00511966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR009241|Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol|Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol||Janssen-Cilag, S.A.|No|Terminated||November 2002|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1049|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Gastroesophageal Reflux and symptomatic.|April 2010|May 18, 2011|August 2, 2007|||Due to the achievement of minimum required sample size and new changes in local regulations.|No||https://clinicaltrials.gov/show/NCT00511966||168505|
NCT00511589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-pre01|Chagas Disease Diagnostic - Inconclusive Serology|PCR in Blood Cultures of Individuals With Positive and Inconclusive Serology for Chagas' Disease||UPECLIN HC FM Botucatu Unesp||Completed||||||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|60 Years|No|||August 2007|March 23, 2011|August 3, 2007||||No||https://clinicaltrials.gov/show/NCT00511589||168534|
NCT00511602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDC-INS-0008|Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes|Efficacy and Safety of Inhaled Technosphere Insulin Compared to Technosphere Placebo in Patients With Type 2 Diabetes Mellitus Following Diabetes Education||Mannkind Corporation||Completed|December 2003|December 2005|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|80 Years|No|||April 2012|April 27, 2012|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00511602||168533|
NCT00511927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH Deficiency in CHF|Growth Hormone Deficiency in Chronic Heart Failure: an Observational Study|Observational Study on Prevalence and Prognostic Value of Growth Hormone Deficiency in Patients With Chronic Heart Failure||Federico II University|No|Completed|July 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|250|Samples Without DNA|Sera of the patients at time-points upon recruitment and after 12 months|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with chronic heart failure due to left ventricular systolic dysfunction|February 2014|February 18, 2014|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00511927||168508|
NCT00511940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-MD-20|Acamprosate in the Treatment of Binge-Eating Disorder|||Lindner Center of HOPE||Completed|April 2007|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||June 2011|June 21, 2011|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00511940||168507|
NCT00508469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD-06-03|Adherence Assessment With Travalert Dosing Aid|Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5%||Alcon Research|No|Completed|October 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|July 26, 2007|Yes|Yes||No|June 8, 2012|https://clinicaltrials.gov/show/NCT00508469||168772|
NCT00512421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIB002-HMO-CTIL|Navigated EM Total Knee Replacement: Accuracy Study|Phase 2 Study of Computer Assisted Surgery vs Conservative Surgery- Accuracy Study.||Hadassah Medical Organization||Terminated||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|men and women that are candidates for total knee replacement.|August 2011|September 15, 2011|August 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00512421||168470|
NCT00508144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0957|Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer|Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Completed|September 2005|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|July 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00508144||168797|
NCT00508937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM3717|Dietary Protein and Insulin Sensitivity Study|The Effects of Increased Dietary Protein Intake on Insulin Sensitivity in Stable Weight Individuals, Independent of Dietary Content of Carbohydrate and Saturated Fat||Children's Hospital & Research Center Oakland|No|Completed|February 2007|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508937||168736|
NCT00509548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH-TG100801-002|Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD|An Open-Label Randomized Pilot Study of Safety and Preliminary Efficacy of TG100801 in Patients With Choroidal Neovascularization Due to Age-Related Macular Degeneration||TargeGen|No|Terminated|July 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|50 Years|N/A|No|||March 2010|March 25, 2010|July 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509548||168690|
NCT00509834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP IC 01-01|A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia|A Phase-IIa, Double-blind, Randomized Study on the Tolerability and Early Efficacy of hLF1-11 in Hospitalized Patients With Proven Candidaemia. (SLIC: Study of Lactoferrin Peptide in Infections With Candida)|SLIC|AM-Pharma|Yes|Withdrawn|July 2008|January 2009|Anticipated|January 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||April 2008|June 29, 2015|July 31, 2007||No|Patient population not available|No||https://clinicaltrials.gov/show/NCT00509834||168668|
NCT00509821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11491|Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Patients With Newly Diagnosed Glioblastoma|Enzastaurin Before and Concomitant With Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma Without Methylation of the Promoter Gene of MGMT Enzyme - a Phase II Study||Eli Lilly and Company|No|Active, not recruiting|October 2007|March 2016|Anticipated|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509821||168669|
NCT00510107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-GI-72|Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC|A Randomized Phase II Trial of Weekly Docetaxel/Cisplatin Versus Weekly Docetaxel/Oxaliplatin in Previously Untreated Patients With Advanced Gastric Cancer||Gachon University Gil Medical Center|No|Recruiting|July 2007|July 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||July 2007|July 31, 2007|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00510107||168648|
NCT00483691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTT|Trial of Home Visitation Among Infants With Failure To Thrive|Growth and Development Longitudinal Follow-Up|FTT|University of Maryland|Yes|Active, not recruiting|January 1989|May 2010|Anticipated|December 1995|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Actual|130|||Both|1 Month|24 Months|Accepts Healthy Volunteers|||September 2008|September 17, 2008|June 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00483691||170647|
NCT00483704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-031|Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura||Merck Sharp & Dohme Corp.|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1935|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|May 15, 2007|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT00483704||170646|
NCT00484887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO-5006-1076737|Characterization of Explanted Hernia Meshes From Human Subjects: A Multi-Center, Prospective Study|Characterization of Explanted Hernia Meshes From Human Subjects: A Multi-Center, Prospective Study||University of Missouri-Columbia|No|Recruiting|April 2007|December 2017|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Explanted mesh from surgical procedures.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Surgical patients at the University of Missouri Healthcare system.|August 2009|August 17, 2009|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484887||170555|
NCT00484302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CapOpus|Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis|Cannabis and Psychosis. Randomized Clinical Trial: Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis|CapOpus|Bispebjerg Hospital|Yes|Completed|September 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|35 Years|No|||January 2011|January 24, 2011|June 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00484302||170600|
NCT00481260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100706.EMC|Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous|Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous||HaEmek Medical Center, Israel|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed at the pediatric Hematology Unit of laboratory data from the        thalassemia screening in northern Israel|September 2009|September 3, 2009|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481260||170829|
NCT00481273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVIDA|AVIDA The Vidaza® (Azacitidine) Patient Registry|AVIDA The Vidaza® (Azacitidine) Patient Registry|AVIDA|Celgene|No|Completed|October 2006|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|479|||Both|N/A|N/A|No|Probability Sample|Community-based hematology/oncology centers|December 2013|December 31, 2013|May 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00481273||170828|
NCT00481208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2006-0146|Diurnal Intraocular Pressure and Peripapillary Retinal Blood Flow in Medically Controlled Open-Angle Glaucoma|Diurnal Intraocular Pressure and Peripapillary Retinal Blood Flow in Medically Controlled Open-Angle Glaucoma|IOPMG|Yonsei University|No|Completed|March 2006|November 2006|Actual|||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||Actual|70|||Both|20 Years|70 Years|No|||May 2007|May 31, 2007|May 31, 2007||||No||https://clinicaltrials.gov/show/NCT00481208||170833|
NCT00481221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5210906.EMC|Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter|Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter. A Clinical Retrospective Study.||HaEmek Medical Center, Israel|No|Recruiting|March 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|300|||Female|17 Years|50 Years|No|Probability Sample|All pregant women attending to the Mother's and Child stations in northern Israel|August 2015|August 30, 2015|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481221||170832|
NCT00481546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547233|Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations|Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis)|LCA|University of Pennsylvania|Yes|Active, not recruiting|July 2007|June 2026|Anticipated|June 2026|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|8 Years|N/A|No|||May 2015|May 26, 2015|May 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00481546||170807|
NCT00512213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00/07 CHV|Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery|Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery: A Single-center Double-blinded Controlled Randomized Superiority Trial||University of Lausanne Hospitals|No|Completed|September 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|90 Years|No|||April 2012|April 21, 2012|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512213||168486|
NCT00512434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN/06/PR/IMOCA|Percutaneous Autologous Bone-marrow Grafting for Open Tibial Shaft Fracture|Injection of Concentrated Autologous Bone-marrow (IMOCA) and Bone Union of Open Tibial Shaft Fracture: Randomized Study to Assess Efficiency of IMOCA in Addition to Standard of Care.|IMOCA|University Hospital, Tours|Yes|Completed|September 2007|September 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|17 Years|N/A|No|||January 2016|January 5, 2016|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512434||168469|
NCT00512447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 62/07|Normal Values of Brain Oxygenation|Normal Values of Cerebral Oxygenation||University Hospital, Basel, Switzerland|No|Completed|July 2007|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|171|||Both|25 Years|95 Years|No|Non-Probability Sample|Patients undergoing elective surgery|September 2010|September 13, 2010|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512447||168468|
NCT00508170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0519|Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection|Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection||M.D. Anderson Cancer Center|No|Completed|March 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|252|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosed squamous cell carcinoma of the head and neck that participated in        the molecular epidemiology study LAB00-062 of head and neck cancer between 1995 and 2005.|July 2012|July 27, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508170||168795|
NCT00508430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8825-CL-0007|ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy|ASP 8825 Phase II Study—A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy||Astellas Pharma Inc|Yes|Terminated|July 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|199|||Both|20 Years|79 Years|No|||December 2008|December 4, 2008|July 26, 2007|Yes|Yes|An independent DMC determined continuation was unlikely to demonstrate a statistically    significant advantage of ASP8825 over placebo on the primary endpoint|No||https://clinicaltrials.gov/show/NCT00508430||168775|
NCT00508482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI12B05-1|A Clinical Standardization Study of the Preferred Acupuncture Treatment Protocol to Treat Functional Constipation|A Clinical Standardization Study of the Preferred Acupuncture Treatment Protocol to Treat Functional Constipation||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|April 2008|November 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|475|||Both|18 Years|75 Years|No|||May 2014|May 22, 2014|July 26, 2007|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT00508482||168771|Spontaneous bowel movements were used as the primary outcome in our trial rather than complete, spontaneous bowel movements. Outcomes of follow-up were not the mean value of weekly data.
NCT00508677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060104|Mazindol in Children With ADHD : Open-label, Efficacy, Safety and Pharmacokinetic Pilot Trial|Mazindol in Children With Attention Deficit Hyperactivity Disorder Design Study to Explore the Effectiveness, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Orally Administered Doses of Mazindol.|MAZDAH|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|6 Years|12 Years|No|Probability Sample|childrens|July 2007|September 30, 2009|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508677||168756|
NCT00508963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Infectious Diseases|Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis|Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis||University of California, San Francisco||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2014|December 12, 2014|July 27, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00508963||168734|
NCT00508976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHH#07-005|Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic|Evaluation of Aerosolized Bupivacaine Versus Pre-incision Lidocaine Versus Instilled Liquid Bupivacaine Versus Post-operative Bupivacaine Injection for Optimization of Post-operative Pain Control in Laparoscopic Bariatric Surgical Patients||Pinnacle Health System|Yes|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508976||168733|
NCT00508989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070196|Niacin to Improve Blood Flow in People With Sickle Cell Disease|Niacin Therapy to Improve Endothelial Function in Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|July 2007|December 2015|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 25, 2015|July 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00508989||168732|
NCT00509275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W0027-08|A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)|A Phase Ib, Randomized, Double Blind, Placebo Controlled Study to Investigate the Pharmacokinetics, Safety and Efficacy of 3 Different Doses of W0027 and Placebo Capsules in Subjects With Clinically and Mycologically Proven MTTP||GlaxoSmithKline|No|Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|65 Years|No|||October 2010|July 12, 2011|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509275||168710|
NCT00509288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070175|Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)|Yes|Completed|June 2007|July 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2012|December 27, 2012|July 30, 2007|Yes|Yes||No|November 14, 2012|https://clinicaltrials.gov/show/NCT00509288||168709|
NCT00509223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-09-06-01|GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes|Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes and Obstructive Sleep Apnea||ResMed|No|Completed|July 2007|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|416|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|July 29, 2007|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00509223||168714|
NCT00509236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-073|Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)|A Multicenter, Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|October 2007|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|30 Years|N/A|No|||March 2015|March 23, 2015|July 27, 2007|Yes|Yes||No|February 13, 2012|https://clinicaltrials.gov/show/NCT00509236||168713|
NCT00509249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00180|Aflibercept in Treating Patients With Myelodysplastic Syndromes|A Phase II Study of VEGF Trap (NSC 724770) in Patients With MDS||National Cancer Institute (NCI)|Yes|Terminated|September 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2012|January 7, 2015|July 30, 2007|Yes|Yes|Early termination for discouraging results|No|December 12, 2014|https://clinicaltrials.gov/show/NCT00509249||168712|Study was terminiated after completion of the first stage due to a lack of activity (no hematological responses were observed).
NCT00510757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0426070090|Multi Cervical Unit Measures of Cervical Isometric Strength and Range of Motion: A Pilot Study|||Logan College of Chiropractic||Recruiting|June 2007|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consenting males and females between the ages of 18 and 65.|October 2008|October 16, 2008|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510757||168598|
NCT00511030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 06-084E|Assessment of Stability of Mail-in Capillary Hemoglobin A1c Test Kit|Assessment of Stability and Ease of Use of a Mail-in Capillary Blood Hemoglobin A!c Sample Kit||Children's Mercy Hospital Kansas City|No|Completed|July 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|None Retained|Capillary blood|Both|1 Year|17 Years|No|Non-Probability Sample|Male and females, age 1-17, receiving care in the Endocrine clinic at Children's Mercy        Hospital who require HbA1c for standard of care.|July 2007|January 21, 2008|August 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00511030||168577|
NCT00510133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRNVAC1 CP06-151|A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)|A Phase II Study of Active Immunotherapy With GRNVAC1, Autologous Mature Dendritic Cells Transfected With mRNA Encoding Human Telomerase Reverse Transcriptase, in Patients With Acute Myelogenous Leukemia in Complete Clinical Remission||Asterias Biotherapeutics, Inc.|No|Completed|July 2007|August 2014|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|July 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510133||168646|
NCT00510146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11218|Olanzapine Treatment of Patients With Bipolar I Disorder|Efficacy and Safety of Olanzapine in the Treatment of Patients With Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison With Placebo||Eli Lilly and Company|Yes|Completed|August 2007|July 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|514|||Both|18 Years|64 Years|No|||April 2011|April 26, 2011|July 30, 2007|Yes|Yes||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00510146||168645|
NCT00484627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT000491-01|Effects of Creatine and Resistance Exercise Training in People With HIV Infection|Ergogenic Effects of Creatine Supplementation in HIV Infection||National Center for Complementary and Integrative Health (NCCIH)|No|Completed|August 2001|October 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|43|||Both|18 Years|65 Years|No|||June 2007|June 8, 2007|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484627||170575|
NCT00485186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D429/05|Gene Polymorphisms Influencing Steroid Synthesis and Action|Investigation of Gene Polymorphisms Influencing Steroid Synthesis and Action in Patients With Deficient Steroid Biosynthesis and Disorders of Sex Development||University of Schleswig-Holstein|No|Withdrawn|June 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Inclusion Criteria:          -  Disorders of Sex Development          -  Congenital Adrenal Hyperplasia          -  Congenital Adrenal Hypoplasia          -  Adrenal Insufficiency          -  Mineralocorticoid Deficiency          -  Salt-loss|September 2013|September 4, 2013|June 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00485186||170532|
NCT00485199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDMH2007-china|Pneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole|Pneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole|RDMH|Peking University|Yes|Completed|January 2005|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|90 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485199||170531|
NCT00485147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 2005-04|Locomotion and Global Positioning System in Arterial Disease|Study of Human Locomotion With Global Positioning System. Application to Patients With Peripheral Arterial Disease|Starter-GPS|University Hospital, Angers|No|Completed|March 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|June 28, 2012|June 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00485147||170535|
NCT00481286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7U18HS016093|Improving Outcomes Using Collaborative Group Clinics to Empower Older Patients|Improving Outcomes for Multiple Morbidities Using Collaborative Group Clinics to Empower Older Patients|EPIC|Baylor College of Medicine|No|Completed|April 2007|September 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|129|||Both|50 Years|90 Years|No|||October 2009|October 20, 2009|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481286||170827|
NCT00481299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178/04|Insulin Resistance in Women With Prolactinoma|Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists||Universidade Federal do Rio de Janeiro|Yes|Completed|October 2004|September 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|2004|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||April 2007|May 30, 2007|May 30, 2007||||No||https://clinicaltrials.gov/show/NCT00481299||170826|
NCT00481247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-056|A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML|An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia|DASISION|Bristol-Myers Squibb|Yes|Completed|August 2007|December 2013|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|515|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|May 30, 2007|Yes|Yes||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00481247||170830|
NCT00481819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR4KTxCN01|A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With MMF and Steroids in Patients Undergoing Kidney Transplantation and a Pharmacokinetics Study.||Astellas Pharma Inc|No|Completed|July 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|May 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00481819||170786|
NCT00481832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT185|Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma|Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma||Stanford University|Yes|Active, not recruiting|January 2007|June 2019|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|70 Years|No|||August 2015|August 4, 2015|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481832||170785|
NCT00512525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETV2007|Ghrelin Decreases Insulin Sensitivity|Intravenous Ghrelin Infusion Decreases Insulin Sensitivity in Healthy Young Men||University of Aarhus|No|Completed|January 2003|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 8, 2009|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512525||168462|
NCT00508495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-01270-A016|Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-Containing Solutions in Post-Surgical Hip Replacement Pain|Single-Dose Comparison of the Analgesic Efficacy, Safety and Tolerability of Two Paracetamol 1%-Containing Solutions and Placebo in a Post-Surgical Total Hip Replacement Model||Baxter Healthcare Corporation|No|Completed|August 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|75 Years|No|||August 2011|August 10, 2011|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508495||168770|
NCT00512187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISONDI 1|Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial|Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial||Universita di Verona|No|Completed|November 2005|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||||||Both|18 Years|80 Years|No|||August 2007|August 6, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512187||168488|
NCT00512200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 75/07|Postoperative Cognitive Dysfunction in Geriatric Patients|Postoperative Cognitive Dysfunction in Geriatric Patients: the Role of Intraoperative Cerebral Perfusion and Perioperative Anticholinergic Medication||University Hospital, Basel, Switzerland|No|Completed|July 2007|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|280|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing elective major surgery under general anesthesia|October 2015|October 14, 2015|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512200||168487|
NCT00512460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0506|RTA 744 Injection in Patients With Leptomeningeal Disease|A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis||M.D. Anderson Cancer Center|No|Completed|September 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512460||168467|
NCT00512473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050113|Growth Hormone Signaling in Vivo in Humans|Growth Hormone (GH) Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background and gh Receptor Blockade||University of Aarhus|No|Completed|September 2005|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Basic Science|3||Actual|8|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2007|August 6, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512473||168466|
NCT00512486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP158|A Sequential Dose-Escalation Study in Subjects With Mild Asthma|A Multi-Center, Open-Label, Single Administration, Sequential Dose Escalation of BIW-8405/MEDI-563 in Subjects With Mild Asthma||MedImmune LLC|Yes|Completed|November 2006|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 26, 2008|August 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00512486||168465|
NCT00509301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0602|Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme|Open-label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme||Peregrine Pharmaceuticals|No|Completed|November 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|July 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00509301||168708|
NCT00508690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMTO PREV07-01|Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics|Randomized Controlled Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics||Japan Multinational Trial Organization|Yes|Completed|September 2007|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|584|||Both|20 Years|N/A|No|||September 2012|September 18, 2012|July 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00508690||168755|
NCT00508950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-1000|Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay|Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Pneumococcal Opsonophagocytic Assay Development.||Pfizer|No|Recruiting|August 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment|1||Anticipated|108|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00508950||168735|
NCT00509262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-063|Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|Yes|Completed|October 2007|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|426|||Both|30 Years|N/A|No|||April 2015|April 27, 2015|July 27, 2007|Yes|Yes||No|February 28, 2012|https://clinicaltrials.gov/show/NCT00509262||168711|
NCT00509847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP SSTI 01-01|A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis|A Phase-IIa, Double-blind, Randomized, Controlled Study on the Tolerability and Early Efficacy of hLF1-11 in Hospitalized Patients With Bacteremia Due to Staphylococcus Epidermidis|LIST|AM-Pharma|Yes|Withdrawn|February 2009|October 2009|Anticipated|July 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||January 2010|May 26, 2014|July 31, 2007||No|conduct (recruitment) not feasible within timeframe|No||https://clinicaltrials.gov/show/NCT00509847||168667|
NCT00510159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/S4|Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis|Randomized Double Blind Clinical Trial in Mali, Comparing the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel in the Treatment of S. Haematobium in Children||Dafra Pharma|No|Completed|August 2007|December 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|800|||Both|6 Years|15 Years|No|||July 2007|January 17, 2008|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00510159||168644|
NCT00510172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060086|Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2|Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2||Glostrup University Hospital, Copenhagen|Yes|Recruiting|December 2006|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|55 Years|No|||July 2007|July 30, 2007|July 30, 2007||||No||https://clinicaltrials.gov/show/NCT00510172||168643|
NCT00509574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200702006M|Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy|Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy||National Taiwan University Hospital|No|Recruiting|March 2007|February 2010|Anticipated|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|blood samples are obtained for genomic DNA extraction.|Both|21 Years|80 Years|No|Probability Sample|Hyperlipidemic patients meeting the criteria of NCEP ATPIII for drug treatment at internal        medicine clinic of National Taiwan University Hospital.|November 2010|December 10, 2010|July 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00509574||168688|
NCT00511056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT Amendment II to 006|Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy|Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy|ARB|The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|September 2007|December 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|700|Samples With DNA|Blood samples required to provide Viral Load data and CD4 cell count|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 500 subjects were surveyed from the HIVNAT 006 long term follow up cohort. A        sample size as large as this is likely to yield accurate results as to the true        relationship between sexual risk behavior and adherence to HIV medications.|July 2011|July 7, 2011|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511056||168575|
NCT00511069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML/033-26866138-CAN|Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia|A Phase II Study of Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia||University of Bologna||Completed|July 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|3|||Both|18 Years|N/A|No|||November 2008|November 21, 2008|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511069||168574|
NCT00511043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008648|PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma|Phase II Open Label Study of PTK787/ZK222584 in Adults Patients With Refractory or Relapsed Diffuse Large Cell Lymphoma||Duke University|Yes|Terminated|November 2005|June 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|August 1, 2007|Yes|Yes|Manufacturer stopped drug development|No||https://clinicaltrials.gov/show/NCT00511043||168576|
NCT00484640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#RO1 HS 016335-01|Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing|Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing||Agency for Healthcare Research and Quality (AHRQ)|Yes|Not yet recruiting|June 2007|May 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|260|||Both|40 Years|N/A|No|||June 2007|June 8, 2007|June 4, 2007||||No||https://clinicaltrials.gov/show/NCT00484640||170574|
NCT00485212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01327078|Compression Bandage in Local Infiltration Analgesia Afte Total Knee Arthroplasty|The Effect of a Compression Bandage in Local Infiltration Analgesia After Total Knee Arthroplasty||Hvidovre University Hospital|No|Completed|January 2007|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|No|||May 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485212||170530|
NCT00485225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3270-201|Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain|An Open-Label, Two-Stage, Phase II Study to Explore the Titration Schedule for Transitioning Opioid-Experienced Patients With Non-Malignant Moderate to Severe Chronic Pain From Current Opioid Therapy to EN3270.||Durect|No|Completed|June 2007|July 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|77|||Both|18 Years|65 Years|No|||December 2011|February 21, 2012|June 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00485225||170529|
NCT00485160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chammerman2|Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA|Comparison of Intravenous Ibuprofen vs. Continuous Indomethacin in the Treatment of Patent Ductus Arteriosus||Shaare Zedek Medical Center|No|Completed|February 2002|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|3 Weeks|No|||June 2007|July 20, 2011|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485160||170534|
NCT00485173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFUSE® Bone Graft PEEK ACDF|INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial|A Pivotal Clinical Investigation of INFUSE® Bone Graft With a PEEK Interbody Spacer and an Anterior Cervical Plate in Patients With Cervical Degenerative Disc Disease at a Single Level.|ACDF|Medtronic Spinal and Biologics|Yes|Completed|June 2007|June 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|18 Years|N/A|No|||December 2012|February 14, 2013|June 8, 2007|Yes|Yes||No|December 14, 2012|https://clinicaltrials.gov/show/NCT00485173||170533|
NCT00481871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-009|Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies|A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies||Spectrum Pharmaceuticals, Inc||Completed|May 2007|August 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|June 1, 2007|Yes|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00481871||170782|
NCT00481559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR001-CLN-pro016|Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity|An Open-Label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate Toxicity||BTG International Inc.||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||January 2014|January 16, 2014|May 30, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00481559||170806|
NCT00481858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC011|Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis|A CLL Research Consortium (CRC) Phase II Study of Kinetic Biomarker for Chronic Lymphocytic Leukemia (CLL) Prognosis|CRC011|KineMed|No|Completed|July 2005|January 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|150|Samples With DNA|CLL cells|Both|18 Years|N/A|No|Non-Probability Sample|CLL patients|February 2011|February 25, 2011|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481858||170783|
NCT00512499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-091|Strategies to Treat Osteoporosis Following a Fragility Fracture|Osteoporosis and Peripheral Fractures: Treatment and Investigation Multidisciplinary at the chUS|OPTIMUS|Université de Sherbrooke|Yes|Active, not recruiting|February 2007|June 2016|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|1800|||Both|50 Years|95 Years|No|||December 2014|December 2, 2014|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00512499||168464|
NCT00512512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00007226|Transoral Endoscopic Liver Biopsy During Laparoscopic Gastric Bypass|Transoral Endoscopic Liver Biopsy During Laparoscopic Gastric Bypass||Johns Hopkins University|No|Completed|June 2007|June 2009|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Morbid Obese patients who are already approved for gastric bypass surgery.|July 2009|June 30, 2010|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512512||168463|
NCT00508196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190906ver3|Endothelial Function and Cardiac Output in RV Pacing|Endothelial Function and Cardiac Output in Right Ventricular Pacing||University of Dundee|Yes|Completed|November 2006|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|22|||Both|21 Years|85 Years|No|||July 2007|July 26, 2007|July 25, 2007||||No||https://clinicaltrials.gov/show/NCT00508196||168793|
NCT00509314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561703036|The Mechanism of Melanocyte Self-Assembly on Biomaterials and the Functional Analysis|The Mechanism of Melanocyte Self-Assembly on Biomaterials and the Functional Analysis||National Taiwan University Hospital|Yes|Recruiting|May 2006|December 2016|Anticipated|||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||Anticipated|400|||Both|18 Years|60 Years|No|||May 2006|July 29, 2007|July 29, 2007||||No||https://clinicaltrials.gov/show/NCT00509314||168707|
NCT00509327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004DR4256|Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery|Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery||University Hospital, Basel, Switzerland|No|Completed|November 2004|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|90 Years|No|||April 2007|July 30, 2007|July 30, 2007||||No||https://clinicaltrials.gov/show/NCT00509327||168706|
NCT00508703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0047|Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy|Pilot Study of Intensity Modulated Radiotherapy (IMRT) to Pelvis Post-Hysterectomy With Analysis of Clinical Target Volume Motion and Relation to Position and Volume of Bladder and Rectum During Course of Radiotherapy for Use in Optimization of Margin Size||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2003|||September 2017|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Female|N/A|N/A|No|Non-Probability Sample|Women treated with a hysterectomy for carcinoma of the uterine cervix or endometrium who        require post-operative radiation or chemoradiation therapy because of positive pelvic        lymph nodes or other high-risk local findings.|September 2015|September 30, 2015|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508703||168754|
NCT00508716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-03|Health Literacy in Patients With Congestive Heart Failure|A Randomized-Controlled Trial of a Health Literacy Tailored Educational Intervention for Hospitalized Congestive Heart Failure Patients||Griffin Hospital|No|Completed|March 2007|December 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|50 Years|N/A|No|||March 2015|March 25, 2015|July 26, 2007||No||No|March 15, 2015|https://clinicaltrials.gov/show/NCT00508716||168753|
NCT00509860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM03-0002|Irinotecan (Camptosar) in Patients With Advanced Sarcomas|A Phase II Study of Irinotecan (Camptosar) in Patients With Advanced Sarcomas||M.D. Anderson Cancer Center|No|Completed|March 2003|January 2012|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|N/A|N/A|No|||December 2012|December 28, 2012|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509860||168666|
NCT00510458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study - An Open Label, Prospective, Post-market, Multi-center Clinical Evaluation of the LFIT™ Anatomic CoCr Femoral Heads With X3® Inserts|LFIT|Stryker Orthopaedics|No|Active, not recruiting|April 2007|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|August 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00510458||168621|
NCT00510471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-12|Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma|A Phase 2 Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With Follicular Non-Hodgkin's Lymphoma (fNHL) Following Primary Treatment With Rituximab and Chemotherapy (R-Chemo)||Genitope Corporation||Terminated|May 2007|||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||March 2008|March 14, 2008|July 31, 2007||||No||https://clinicaltrials.gov/show/NCT00510471||168620|
NCT00510445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRN163L CP14A005|Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer|A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer||Geron Corporation|No|Completed|July 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00510445||168622|
NCT00511420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cocoa products|Effects of Cocoa Products on Cardiovascular Disease Risk Factors|Effects of Cocoa Products on Cardiovascular Disease Risk Factors|CoCD|University Rovira i Virgili|No|Completed|April 2005|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|113|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2007|August 2, 2007|August 2, 2007||||No||https://clinicaltrials.gov/show/NCT00511420||168547|
NCT00511407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-002|Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure|A Multi-Center, Randomized, Phase II Study To Assess Safety and Efficacy With the Renal Assist Device (RAD) In Patients With Acute Renal Failure||RenaMed Biologics|Yes|Completed|March 2004|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|80 Years|No|||November 2012|November 29, 2012|August 2, 2007||||||https://clinicaltrials.gov/show/NCT00511407||168548|
NCT00484900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/57/01|Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria|Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria||Dafra Pharma|No|Completed|May 2006|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1390|||Both|6 Months|N/A|No|||June 2007|March 25, 2008|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484900||170554|
NCT00484666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Topo Txt|A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer|A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer|Topo Txt|Carilion Clinic|Yes|Completed|May 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|18 Years|N/A|No|||February 2013|February 5, 2013|June 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00484666||170572|
NCT00481312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005013|Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)|A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Midazolam for Continuous Sedation of Ventilated Patients in Intensive Care Unit|MIDEX|Orion Corporation, Orion Pharma|Yes|Completed|June 2007|October 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|501|||Both|18 Years|N/A|No|||November 2009|May 4, 2012|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00481312||170825|
NCT00485472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0905|Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Osteoarthritis of the Knee||UCB Pharma|No|Terminated|March 2007|January 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|194|||Both|40 Years|75 Years|No|||September 2011|September 19, 2014|June 12, 2007|No|Yes|Based on the outcome of the planned first interim analysis, it was decided not to continue the    trial. No safety concerns were identified.|No|August 12, 2009|https://clinicaltrials.gov/show/NCT00485472||170511|
NCT00481611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906176|Cancer Markers Associated With Occupational Exposure to Trichloroethylene|A Cross-Sectional Study of Occupational Exposure to Trichloroethylene, Chromosomal Aberrations, and Related Biomarkers in Guangdong, China||National Institutes of Health Clinical Center (CC)||Completed|June 2006|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|125|||Both|18 Years|50 Years|No|||October 2015|November 5, 2015|June 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00481611||170802|
NCT00481572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1124|Continuous Infusion of Terlipressin in Septic Shock|Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock. A Randomized, Controlled, Pilot Trial. "THE TERLIVAP STUDY"||University of Roma La Sapienza|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||February 2008|February 26, 2008|May 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00481572||170805|
NCT00481845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0008|Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer|Randomized Phase II Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer||Stanford University|Yes|Terminated|January 2008|December 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|N/A|No|||March 2011|March 3, 2011|May 31, 2007||No|Low accrual|No||https://clinicaltrials.gov/show/NCT00481845||170784|
NCT00482456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 286/2004|Homocysteine After Nitrous Oxide Anesthesia|Influence of the MTHFR 677C>T Mutation on Homocysteine Levels After Nitrous Oxide Anesthesia.||Medical University of Vienna|No|Completed|January 2005|March 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|140|||Both|18 Years|N/A|No|||May 2007|June 1, 2007|June 1, 2007||||No||https://clinicaltrials.gov/show/NCT00482456||170740|
NCT00508209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG 16-07|Bortezomib and High-dose Melphalan at Myeloma Relapse|Phase II Study of Bortezomib Dexamethasone and High-dose Melphalan in Patients With Relapse After High-dose Melphalan With Autologous Stem Cell Support||Nordic Myeloma Study Group|Yes|Active, not recruiting|July 2007|September 2010|Anticipated|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508209||168792|
NCT00508222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007217-01H|Kaletra Monotherapy in HIV/HCV Co-infected Subjects|A Pilot, Prospective, Open-label Study to Evaluate the Safety and Efficacy of Kaletra® Monotherapy in HIV/HCV Co-infected Subjects.||Ottawa Hospital Research Institute|No|Completed|June 2007|April 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2012|May 28, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00508222||168791|
NCT00508521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4078-R|Treatment of Hand Dysfunction After Stroke|Treatment of Hand Dysfunction After Stroke||VA Office of Research and Development|No|Completed|January 2007|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|21 Years|N/A|No|||December 2013|December 19, 2013|July 27, 2007||No||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00508521||168768|This was a small pilot feasibility study providing data for future work.
NCT00508534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9106339|A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy People|An Open-Label Study to Evaluate the Effects of Repeat Dosing of Esomeprazole on the Pharmacokinetics of SB-751689 in Healthy Adult Subjects||GlaxoSmithKline||Completed|July 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|July 26, 2007||||||https://clinicaltrials.gov/show/NCT00508534||168767|
NCT00508508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|429|Effectiveness of Peer Support in Improving Heart Failure Self-Management and Care|Mobilizing Peer Support for Effective Heart Failure Self-Management||University of Michigan|Yes|Completed|April 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|266|||Both|21 Years|N/A|No|||July 2011|June 17, 2013|July 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00508508||168769|
NCT00508729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A15-1|Effect of Traditional Chinese Medicine on GI Function Recovery and Nutrition Support in SAP|Effect of Traditional Chinese Medicine on Gastrointestinal Function Recovery and Nutrition Support in Severe Acute Pancreatitis||Tianjin Nankai Hospital|No|Not yet recruiting|October 2007|October 2010|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|300|||Both|18 Years|70 Years|No|||July 2007|July 29, 2007|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00508729||168752|
NCT00508742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3006|Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Infants in Israel.||Pfizer|No|Completed|December 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1866|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||May 2013|May 6, 2013|July 26, 2007|Yes|Yes||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00508742||168751|Study designated analysis of effect of 13vPnC on serotypes 6A+19A, changed prior to unblinding, to effect on 6A’+19A. Serotype 6A found to include serotype 6A isolates and isolates of newly identified serotype 6C. Serotype 6A assessed as 6A+6C (6A’).
NCT00509002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0089|Iressa Study in Patients With Salivary Gland Cancer|Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198)||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2004|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||May 2015|May 18, 2015|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00509002||168731|
NCT00509587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00199|Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer|A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma||National Cancer Institute (NCI)||Completed|June 2007|||July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2013|April 1, 2014|July 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00509587||168687|
NCT00509873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198782-004|A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis|||Allergan||Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|578|||Both|1 Year|N/A|No|||October 2011|October 24, 2011|July 30, 2007|Yes|Yes||No|June 15, 2010|https://clinicaltrials.gov/show/NCT00509873||168665|
NCT00510185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Italian Elderly ACS Study|Early Aggressive Versus Initially Conservative Therapy in Elderly Patients With Non-ST-Elevation Acute Coronary Syndrome|Italian Elderly ACS Study||Niguarda Hospital|Yes|Completed|October 2007|June 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|313|||Both|74 Years|N/A|No|||February 2012|February 22, 2012|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510185||168642|
NCT00510783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002266|IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures|IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures||Emory University|Yes|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|July 31, 2007||No||No|January 8, 2011|https://clinicaltrials.gov/show/NCT00510783||168596|Several patients were lost to follow-up.
NCT00510770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAP-1-LT|CPAP in Liver Transplant|Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia in Liver Transplant||University of Turin, Italy|Yes|Recruiting|December 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||February 2009|February 17, 2009|August 1, 2007||||No||https://clinicaltrials.gov/show/NCT00510770||168597|
NCT00511433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05723|Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)|A Randomized, Open-Label, Comparative Trial to Evaluate the Effects on Ovarian Function of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 ug Ethinyl Estradiol (EE)||Merck Sharp & Dohme Corp.|No|Completed|October 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|August 2, 2007|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00511433||168546|
NCT00511446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO STO-0601|Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer|Phase II Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer||Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|August 2007|January 2013|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511446||168545|
NCT00511745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR009238|Safety of Rabeprazole in Patients Under Multiple Treatments|Safety of Rabeprazole in Patients Under Multiple Treatments||Janssen-Cilag, S.A.|No|Terminated||November 2002|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2157|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving rabeprazole and a concomitant drug (one or more) such a non-steroidal        anti-inflammatory drugs (NSAID), benzodiazepines or corticoids|April 2010|May 18, 2011|August 2, 2007|||Due to the achievement of minimum required sample size and new changes in local regulations.|No||https://clinicaltrials.gov/show/NCT00511745||168522|
NCT00484913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LW05|Effects of Abdominal Hot Compresses on Indocyanine Green Elimination in Healthy Subjects|Effects of Abdominal Hot Compresses on Indocyanine Green Elimination – a Randomized Cross Over Study in Healthy Subjects||University Hospital Freiburg|No|Completed|September 2003|December 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2007|June 8, 2007|June 8, 2007||||No||https://clinicaltrials.gov/show/NCT00484913||170553|
NCT00485524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-177|Comparison of NIRS and Serum Lactate to Predict Poor Post-operative Outcomes|A Retrospective Evaluation of the Utility of NIRS Compared With Serum Lactate Levels in Predicting Poor Post-Operative Outcome After Repair of Complex Congenital Heart Disease||Children's Healthcare of Atlanta|No|Completed|January 2002|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|12|||Both|N/A|1 Month|No|Non-Probability Sample|pediatric cardiac population that is less than one month of age requiring intra-operative        cardiopulmonary bypass.|July 2008|March 14, 2012|June 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00485524||170507|
NCT00485485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0362|Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer|Phase II Study of Imatinib Mesylate and Docetaxel in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer||M.D. Anderson Cancer Center|No|Completed|January 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|June 12, 2007||No||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00485485||170510|Study was closed to enrollment early due to low enrollment. Study enrolled 7 participants over approximately 2 years with a planned enrollment of up to 58.
NCT00485498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6704|Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics|Managing Acute Schizophrenia, a Double Blind Comparison Between Two Atypical Antipsychotics - Olanzapine and Risperidone||Eli Lilly and Company||Completed|April 2003|December 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|60 Years|No|||June 2007|June 11, 2007|June 11, 2007||||No||https://clinicaltrials.gov/show/NCT00485498||170509|
NCT00482157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0022|Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance|Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance||Stanford University||Active, not recruiting|February 2007|November 2008|Anticipated|November 2007|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|24|||Male|45 Years|N/A|No|||June 2009|June 23, 2009|May 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00482157||170762|
NCT00482469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-2-004|The DIEP-Flap as a Model of Ischemia-Reperfusion|The DIEP-Flap as a Model of Ischemia-Reperfusion||Maastricht University Medical Center|Yes|Completed|April 2007|November 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|Samples With DNA|Frozen tissue.|Female|18 Years|N/A|No|Probability Sample|Clinical patients hospitalized for surgery.|January 2009|January 6, 2009|June 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00482469||170739|
NCT00482729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-079|MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)|A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)||Merck Sharp & Dohme Corp.||Completed|June 2007|April 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1246|||Both|18 Years|78 Years|No|||February 2015|February 20, 2015|May 31, 2007|Yes|Yes||No|December 9, 2009|https://clinicaltrials.gov/show/NCT00482729||170720|Site 079011301 was non-compliant with Good Clinical Practice (GCP). Data from the 4 patients at this site are included in the Participant Flow summary, but are excluded from all other summaries and analyses.
NCT00482989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP152|A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus|A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus||MedImmune LLC|Yes|Completed|June 2007|September 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|June 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00482989||170700|
NCT00509028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5254C00006|Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma|An Open-label, Multi-center, Long Term Study to Investigate the Safety and Efficacy of Budesonide Turbuhaler® Treatment for 48 Weeks (Following 6 Weeks Phase III Study) in Japanese Children With Bronchial Asthma Aged 5 Years to 15 Years Old||AstraZeneca|No|Completed|December 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|241|||Both|5 Years|15 Years|No|||July 2012|July 24, 2012|July 17, 2007|Yes|Yes||No|October 6, 2009|https://clinicaltrials.gov/show/NCT00509028||168729|
NCT00508755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4036-I|Feasibility and Practice Characteristics of FNS and Gait Robot|Feasibility and Practice Characteristics of FNS and Gait Robot||VA Office of Research and Development|No|Completed|August 2005|August 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|21 Years|N/A|No|||April 2014|April 8, 2014|July 27, 2007|No|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT00508755||168750|This was a feasibility study to determine the possibility of combining two technologies. Further study of the combined treatment is needed to determine whether the feasible combined treatment is more effective than other methods.
NCT00509015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRIORI1/01|Mass-Drug Administration to Reduce Malaria Transmission|Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine|MDATRANS|Radboud University|Yes|Completed|February 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|6000|||Both|1 Year|N/A|No|||August 2008|August 12, 2008|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509015||168730|
NCT00509600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0215|Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia|Phase IIA Window Study of Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia||M.D. Anderson Cancer Center|Yes|Terminated|September 2004|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|6 Months|18 Years|No|||August 2012|August 1, 2012|July 27, 2007||No|Slow enrollment; study terminated.|No|August 31, 2009|https://clinicaltrials.gov/show/NCT00509600||168686|Early termination due to low accrual. Rare disease with less than 100 cases diagnosed per year.
NCT00509613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO 2006_01|Phase 1 Study With Sorafenib and Sirolimus|Phase 1 Dose Escalation Study With Sorafenib in Combination With Sirolimus in Patients With Solid Tumor||Radboud University|No|Completed|June 2007|||May 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||September 2009|September 17, 2009|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509613||168685|
NCT00509626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000555830|Physical Activity or Usual Care in Preventing Weight Gain in Women With Stage I or Stage II Breast Cancer Undergoing Chemotherapy|A Physical Activity Intervention to Prevent Weight Gain in Breast Cancer Patients||Fox Chase Cancer Center||Completed|June 2007|||July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|380|||Female|18 Years|N/A|No|||February 2010|February 11, 2010|July 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00509626||168684|
NCT00509886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00000722|Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating|Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating||Northwestern University|Yes|Completed|June 2007|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00509886||168664|
NCT00510211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11610|An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.|An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.||Eli Lilly and Company|No|Completed|April 2007|May 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1131|||Both|18 Years|N/A|No|Non-Probability Sample|Patients observed in outpatient settings (ambulatory and community)|July 2009|July 31, 2009|July 30, 2007||||No||https://clinicaltrials.gov/show/NCT00510211||168640|
NCT00510484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.3.126|Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis|A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis||Solvay Pharmaceuticals|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|12 Years|N/A|No|||August 2009|May 26, 2010|August 1, 2007|Yes|Yes||No|May 29, 2009|https://clinicaltrials.gov/show/NCT00510484||168619|Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and include events started prior to the 1st administration but which worsened after the 1st intake.
NCT00510796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-694|Combined Colon and Endometrial Cancer Screening in Women With HNPCC|A Pilot Study for Combined Colon and Endometrial Cancer Screening in Women at High-Risk for Colon and Endometrial Cancer||M.D. Anderson Cancer Center|No|Completed|March 2002|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Female|18 Years|N/A|No|Non-Probability Sample|UT MDACC Female patients determined to be in a high risk group for either colon and/or        endometrial cancer.|February 2016|February 15, 2016|July 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00510796||168595|
NCT00510809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QB840230|Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy|Safety and Efficacy of Policosanol Monotherapy and When Added to Chronic Statin Therapy: A Pilot Study||University of Kansas Medical Center|No|Completed|July 2007|May 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|August 1, 2007|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00510809||168594|
NCT00511082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252-07-801-01|Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma|Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma||Otsuka Beijing Research Institute|Yes|Recruiting|December 2007|December 2009|Anticipated|September 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||July 2008|July 1, 2008|August 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00511082||168573|
NCT00500435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0098|Extraperitoneal Lymph Node Dissection in Patients With Cervical Cancer|A Pilot Study of Laparoscopic Extraperitoneal Lymph Node Dissection in Patients With Locally Advanced Cervical Cancer||M.D. Anderson Cancer Center|No|Completed|October 2003|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|65|||Female|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with stage IB2-IVA cervical cancer.|March 2012|March 22, 2012|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500435||169380|
NCT00500695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220045018|Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness|Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness||Rutgers, The State University of New Jersey|No|Completed|May 2006|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500695||169361|
NCT00500955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRL-49653/137|Rosiglitazone on Microalbuminuria in Type 2 Diabetics|A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|April 2000|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||336|||Both|40 Years|80 Years|No|||October 2010|October 1, 2010|July 12, 2007||||||https://clinicaltrials.gov/show/NCT00500955||169341|
NCT00522808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP104|A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers|A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease|CP104|Arrow Therapeutics|Yes|Terminated|August 2007|May 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Male|18 Years|60 Years|No|||September 2008|September 26, 2008|August 29, 2007||No|Need for re-formulation|No||https://clinicaltrials.gov/show/NCT00522808||167691|
NCT00523042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1616|Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma|Inhaled Preprandial Human Insulin With the AERx® iMS Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Asthma: A 52-week, Open-label, Multinational, Randomised, Parallel Trial to Investigate Long-term Safety|iINHALE 9|Novo Nordisk A/S|No|Terminated|August 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2014|April 17, 2015|August 29, 2007|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00523042||167673|
NCT00523016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI REB # 07-045|Acupuncture Treatment to Reduce Burning Pain in Spinal Cord Injury|A Pilot Study Investigating the Feasibility of Using Acupuncture Treatment to Reduce Below-Level Neuropathic Pain in Spinal Cord Injury.|APSCI|Toronto Rehabilitation Institute|Yes|Completed|September 2007|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523016||167675|
NCT00514982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070205|Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome|An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|N/A|No|||March 2011|September 26, 2015|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514982||168281|
NCT00523601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NKR-SER-2007/2|Quetiapine Efficacy in Bipolar Depression Study|A 8-Week, Multicenter, Open-Label, Observational Study of the Efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Adult Patients With Bipolar Depression|QUEEN|AstraZeneca|No|Completed|June 2007|December 2007|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|18 Years|65 Years|No|||April 2008|October 3, 2008|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523601||167630|
NCT00523913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD105720|A Study Of BRL49653C For The Treatment Of Type 2 Diabetes|Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus -Long-term Study of Rosiglitazone Maleate-||GlaxoSmithKline||Completed|November 2005|April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|70|||Both|20 Years|N/A|No|||October 2010|October 1, 2010|August 31, 2007||||No||https://clinicaltrials.gov/show/NCT00523913||167606|
NCT00523926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002725|TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis|An Open-label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of TMC207 in Treatment-na�ve Subjects With Sputum Smear Positive Pulmonary Tuberculosis.||Tibotec BVBA||Completed|May 2005|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|75|||Both|18 Years|65 Years|No|||August 2012|August 14, 2012|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523926||167605|
NCT00524186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000562762|Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer|Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers||Roswell Park Cancer Institute|Yes|Active, not recruiting|May 2007|May 2016|Anticipated|August 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|120 Years|No|||March 2016|March 1, 2016|August 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00524186||167586|
NCT00524199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-472|Effects of Mesna on Homocysteine in Kidney Failure|The Effects of 12 mg/kg Intravenous Mesna on Plasma Total Homocysteine Concentration in Patients With End-Stage Renal Disease Requiring Hemodialysis||Lawson Health Research Institute||Completed|March 2007|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||August 2007|August 31, 2007|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00524199||167585|
NCT00514150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-02-30-3595(1)|Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN)|Comparing Sodium Bicarbonate Plus Isotonic Normal Saline Versus Isotonic Normal Saline Alone to Prevent Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Randomized Controlled Trial||Tehran University of Medical Sciences|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|265|||Both|18 Years|N/A|No|||September 2008|September 4, 2008|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514150||168342|
NCT00514397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-CNS-2007-04|Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma|A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas||National Cancer Institute (NCI)||Recruiting|January 2008|||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|43|||Both|2 Years|21 Years|No|||June 2009|August 9, 2013|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00514397||168325|
NCT00502333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-20|The Influence of Coping Strategies and Catastrophizing on Patients With Back and Neck Pain|The Influence of Coping Strategies and Catastrophizing on Patients With Back and Neck Pain Treated Within the Spanish National Health Service||Kovacs Foundation|Yes|Completed|November 2006|April 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1400|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients treated within the Spanish National Health Service for subacute or chronic neck        or back pain|March 2014|March 11, 2014|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502333||169237|
NCT00502346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102|A Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers||Prism Pharmaceuticals|No|Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|4||Anticipated|342|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2008|August 22, 2008|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00502346||169236|
NCT00502905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-011|Busulfan and Fludarabine in Patients With AML and MDS|A Phase II Study of High-Dose Intravenous Busulfan and Fludarabine With Allogeneic Marrow and Peripheral Blood Progenitor Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Completed|October 2003|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|66 Years|No|||May 2012|May 23, 2012|July 16, 2007||No||No|April 17, 2012|https://clinicaltrials.gov/show/NCT00502905||169193|
NCT00503204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00057|Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour|A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard Therapy||AstraZeneca|No|Completed|September 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503204||169170|
NCT00499590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU301|Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD|A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).|COBALT|OPKO Health, Inc.|Yes|Terminated|August 2007|May 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|338|||Both|50 Years|N/A|No|||September 2014|September 29, 2014|July 10, 2007|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT00499590||169444|Study was terminated early.
NCT00499889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-901|Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients|Imatinib Mesylate, Busulfan, Fludarabine, Antithymocyte Globulin and Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Terminated|February 2003|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|N/A|70 Years|No|||April 2012|April 19, 2012|July 10, 2007||No|Support issue.|No|September 30, 2011|https://clinicaltrials.gov/show/NCT00499889||169422|Study completed early due to support issues.
NCT00499317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-11-160M|Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)||CP/CPPS|Children's Hospital Boston|Yes|Recruiting|January 2007|June 2012|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|DNA sample via saliva and urine samples will be collected and stored.|Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are collecting individuals and families with symptoms and diagnoses of CP/CPPS and        their family members (with or without symptoms) from North America (United States and        Canada)|July 2011|July 21, 2011|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00499317||169464|
NCT00499902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA009|Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke|Phase 2, Multicenter, Open-Label, Two-Stage Study to Evaluate the Safety and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS-1)||ARCA Biopharma, Inc.|Yes|Terminated|June 2007|May 2008|Anticipated|May 2008|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|85 Years|No|||April 2008|April 22, 2008|July 10, 2007|Yes|Yes|CO Phase 2 data did not show sufficient improvement in cath opening at higher    dose/concentration evaluated. Nuvelo ended further clinical dev of alfimeprase.|No||https://clinicaltrials.gov/show/NCT00499902||169421|
NCT00500188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0023|Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST|A Prospective, Randomized, Phase II Study of Preoperative Plus Postoperative Imatinib Mesylate (Gleevec, Formerly STI-571) in Patients With Primary, Recurrent, or Metastatic Resectable, Kit-Expressing, Gastrointestinal Stromal Tumor (GIST)||M.D. Anderson Cancer Center|Yes|Completed|July 2003|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|N/A|N/A|No|||August 2011|August 4, 2011|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00500188||169399|
NCT00500123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 9556|Alpha-1 Coded Testing(ACT) Study|Alpha-1 Coded Testing(ACT) Study|ACT|Medical University of South Carolina|Yes|Recruiting|January 2001|January 2050|Anticipated|January 2050|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|Samples With DNA|A blood card is mailed to the participants home. The provide lancet is used for fingerstick      collection of sufficient bloodspots to genotype for alpha-1 antitrypsin (AAT) deficiency      alleles and to estimate an AAT level.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals choosing to test at home for alpha-1 antitrypsin deficiency.|March 2016|March 14, 2016|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500123|50 Years|169404|
NCT00500136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1078398|The Psychosocial Effect of Thoughts of Personal Mortality on Cardiac Risk Assessment by Medical Students|The Effects of Religion and Motivation on Medical Decision Making: A Terror Management Approach||University of Missouri-Columbia|Yes|Completed|January 2007|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Basic Science|4||Actual|49|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2007|July 10, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500136||169403|
NCT00500149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-311|A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)|A Phase IIIb, Randomized, Double-Blind, Multi-Center, Placebo- Controlled, Dose-Optimization, Cross-Over, Analog Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder||Shire||Completed|June 2007|December 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|6 Years|12 Years|No|||February 2011|March 3, 2015|July 10, 2007|Yes|Yes||No|December 2, 2008|https://clinicaltrials.gov/show/NCT00500149||169402|
NCT00500162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29059|Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma|Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma|CLARA|Galderma|No|Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|N/A|No|||March 2009|March 5, 2009|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500162||169401|
NCT00523055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:078|Ultrasound-guided Supraclavicular Brachial Plexus Blockade|Ultrasound-guided Supraclavicular Brachial Plexus Blockade: A Pharmacokinetic Study of Lidocaine and Adrenaline||University of Manitoba|Yes|Recruiting|May 2008|||April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|75 Years|No|||April 2011|April 25, 2011|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00523055||167672|
NCT00523068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/s0501/26|Pharmacological vs Surgical Treatment for Mixed Incontinence|Randomized Pilot Study on the Treatment of Mixed Urinary Incontinence: Pharmacological Treatment (Tolterodine SR) vs Surgery With Tension Free Vaginal Tape||Imperial College London|No|Not yet recruiting|September 2007|January 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|35 Years|70 Years|No|||August 2007|November 6, 2007|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523068||167671|
NCT00523029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH072631|Developing a Self-Management Program for People With Depression and Chronic Medical Illness|Self-Management of Depression and Medical Illness||University of Southern California||Completed|February 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|70 Years|No|||December 2013|December 9, 2013|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00523029||167674|
NCT00523302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#17365|A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia|A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia||Medical University of South Carolina|Yes|Completed|July 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2012|January 24, 2012|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523302||167653|
NCT00523614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2007_02|Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism|Use of OCs Containing Dienogest and Risk of Venous Thromboembolism||Center for Epidemiology and Health Research, Germany|No|Completed|July 2007|June 2008|Actual|||N/A|Observational|Observational Model: Case Control||2|Actual|3400|||Female|15 Years|49 Years|No|Non-Probability Sample|Cases: women between 15 and 49 years old with a VTE diagnosed in Germany between 2002 and        2007        Controls: population sample|March 2010|March 19, 2010|August 30, 2007||No||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00523614||167629|This is an observational study. The possibility of bias and residual confounding cannot be entirely eliminated.
NCT00523627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907215|Effects of Diet Changes on Metabolism|Study of Short-Term Metabolic Adaptation: Prediction of Weight Change and Effects of Macronutrient Manipulations||National Institutes of Health Clinical Center (CC)||Recruiting|August 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|224|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523627||167628|
NCT00524225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030210|IL-11 in Adults With Von Willebrand Disease Undergoing Surgery|Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery||University of Pittsburgh|Yes|Terminated|February 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|August 31, 2007|Yes|Yes|Recruitment slow as single center conducting in rare disease|No|July 22, 2014|https://clinicaltrials.gov/show/NCT00524225||167583|There were too few subjects for reporting in a manuscript.
NCT00524212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-10-B640-A1205-22345|How to Improve Diagnosis in Infective Endocarditis|Ph. D Student, Jane Byriel Knudsen, Aarhus University||University of Aarhus|No|Completed|March 2007|May 2009|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|761|Samples Without DNA|A venous blood sample was obtained from each patients and all samples were centrifuged and      immediately frozen.|Both|18 Years|N/A|No|Probability Sample|The cohort was selected from all the patients admitted to the tertiary hospital (the        initial diagnosis was infective endocarditis)|January 2010|January 19, 2010|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524212||167584|
NCT00524797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 7-260 S|Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy|Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy||Ziv Hospital|No|Recruiting|September 2007|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|80 Years|No|||September 2007|September 2, 2007|September 2, 2007||||No||https://clinicaltrials.gov/show/NCT00524797||167540|
NCT00524498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018-06-002|A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma|A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma||Otsuka Pharmaceutical Co., Ltd.|Yes|Completed|September 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|N/A|No|||October 2015|October 13, 2015|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524498||167562|
NCT00503230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018079|Reducing Ethnic Health Disparities: Motivating HIV+ Latinos to Quit Smoking|Reducing Ethnic Health Disparities: Motivating HIV+ Latinos to Quit Smoking|AURORA|Butler Hospital|Yes|Completed|October 2005|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503230||169168|
NCT00499083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072-06|Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer|Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic||University of Nebraska|Yes|Active, not recruiting|May 2006|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|19 Years|N/A|No|||July 2011|July 6, 2011|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499083||169481|
NCT00499109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15005|Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC|Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy Versus Standard of Care for 1st Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|May 2007|November 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|275|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|July 10, 2007|Yes|Yes||No|September 12, 2013|https://clinicaltrials.gov/show/NCT00499109||169479|
NCT00500175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK061815|Novel Home Care Device for High-Risk Diabetic Patients|Novel Home Care Device for High-Risk Diabetic Patients|TempTouchRM|Diabetica Solutions Inc.|Yes|Recruiting|January 2007|June 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|2||Anticipated|110|||Both|18 Years|80 Years|No|||July 2007|July 11, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500175||169400|
NCT00499915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15214|NICU Asthma Education and Secondhand Smoke Reduction Study|Preventing Respiratory Illness Among Premature Infants: An Asthma Education and Secondhand Smoke Reduction Study||University of Rochester|No|Completed|February 2007|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|165|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|July 10, 2007||No||No|September 15, 2015|https://clinicaltrials.gov/show/NCT00499915||169420|
NCT00499876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG_9|The Effect of Malaria on Disease Progression of HIV/AIDS|The Effect of Malaria on Disease Progression of HIV/AIDS in Kumasi, Ghana||Gates Malaria Partnership|Yes|Active, not recruiting|October 2007|March 2009|Anticipated|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|197|||Both|19 Years|N/A|No|||March 2009|March 5, 2009|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00499876||169423|
NCT00500461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2106213|Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705|A Single-Centre, Open-Label, Sequential Ascending Cross Over Study to Examine Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Ascending Single Doses, Nominally 10, 30, 70 and 110µg Intravenous Doses and a Single 250µg Oral Dose of GSK233705 in Healthy Volunteers.||GlaxoSmithKline||Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|9|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500461||169378|
NCT00500734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-359|Cardiomyopathy Tissue Bank in a Cancer Population|Cardiomyopathy Tissue Bank in a Cancer Population||M.D. Anderson Cancer Center|No|Recruiting|December 2002|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood and tissue collection. This blood may be studied in the future to try to find possible      genetic or biochemical markers that may be the cause of CHF.|Both|2 Months|N/A|No|Non-Probability Sample|Patients diagnosed with heart disease and that may be at a high risk for the development        of heart failure.|February 2016|February 24, 2016|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500734||169358|
NCT00522197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000562055|ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia|A Phase II Trial of ACAPHA in Former Smokers With Intraepithelial Neoplasia||British Columbia Cancer Agency|Yes|Completed|September 2002|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|90|||Both|45 Years|74 Years|No|||March 2012|March 7, 2012|August 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00522197||167736|
NCT00522210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-20635|Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes|A Comparison of Insulin Detemir in a BID Insulin Regimen Versus a TID Insulin Regimen in Children With Type 1 Diabetes: A Randomized Controlled Trial||University of Calgary|Yes|Completed|March 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|6 Years|17 Years|No|||March 2011|August 29, 2014|August 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00522210||167735|
NCT00523081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073918-01A1|Study of Adolescence and Depression|Brief, Primary Care Cognitive Behavioral Therapy (CBT) for Unmedicated Youth|STAND|Kaiser Permanente|Yes|Completed|October 2006|January 2014|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|212|||Both|12 Years|18 Years|No|||July 2012|January 30, 2014|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523081||167670|
NCT00523341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060289|Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis||Amgen|No|Completed|August 2007|August 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4550|||Female|60 Years|94 Years|No|||September 2015|September 14, 2015|August 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00523341||167650|
NCT00523354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swiss EE-Study Group|Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis|Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis|IEE|Swiss EE Study Group|Yes|Completed|August 2007|October 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|70 Years|No|||April 2009|April 6, 2009|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523354||167649|
NCT00523315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OKR-ARI-2007/1|APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)|A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer|APOLLO|AstraZeneca|No|Completed|May 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|862|||Female|18 Years|N/A|No|Non-Probability Sample|Department of Surgery or Department of Hemato-oncology in 36 hospitals|May 2011|May 19, 2011|August 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00523315||167652|
NCT00523328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104RA205|BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)|An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects With Rheumatoid Arthritis Who Previously Participated in Study 104RA203||Biogen|Yes|Terminated|August 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|August 17, 2007|Yes|Yes|Analysis of data from 104RA203 failed to meet primary endpoint.|No||https://clinicaltrials.gov/show/NCT00523328||167651|
NCT00523939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009742|DepoCyt for Active Lymphomatous or Leukemic Meningitis|Phase II Study of Intrathecal Therapy With DepoCyt for Active Lymphomatous or Leukemic Meningitis||Duke University|No|Terminated|June 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||November 2012|June 7, 2013|August 31, 2007|Yes|Yes|Low accrual.|No|February 16, 2011|https://clinicaltrials.gov/show/NCT00523939||167604|Adverse events for both arms, lymphomatous and leukemic, were combined due to low accrual and early study termination.
NCT00523952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-CEE-01|Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients|A 12-week, Exploratory, Non-comparative, Multi-centre Study to Evaluate the Efficacy and Safety of 0.1% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis||Astellas Pharma Inc|No|Completed|January 2004|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|303|||Both|16 Years|N/A|No|||August 2014|August 28, 2014|August 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00523952||167603|
NCT00524238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030196|Metabolic Changes in Hypothyroid Patients|Impact of Hypothyroidism on Glucose, Lipid, and Amino Acid Turnover||University of Aarhus|No|Completed|March 2004|August 2006|Actual|August 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 7, 2008|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524238||167582|
NCT00524251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N11|The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients|||AstraZeneca|No|Completed|June 2004|March 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|990|||Both|18 Years|N/A|No|||September 2008|September 16, 2008|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00524251||167581|
NCT00524264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191578-005|A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery|||Allergan||Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|N/A|No|||August 2009|September 29, 2009|August 30, 2007|Yes|Yes||No|August 19, 2009|https://clinicaltrials.gov/show/NCT00524264||167580|
NCT00524537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-134|A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)|A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)||AbbVie|No|Completed|September 2007|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5067|||Both|18 Years|99 Years|No|Non-Probability Sample|Crohn's patients who have been prescribed adalimumab according to the local label.|December 2015|December 21, 2015|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524537||167559|
NCT00524511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12462|Comparison Study of Wound Closure at Time of Cesarean Delivery: Dermabond Glue Versus Surgical Staples|A Comparative Study of Closure Techniques After Cesarean Section: Staples vs. Dermabond||University of Massachusetts, Worcester|No|Terminated|September 2007|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Female|N/A|N/A|No|||January 2013|January 24, 2013|August 31, 2007||No|Poor enrollment, much data was missing as patients were lost to follow up|No|October 24, 2012|https://clinicaltrials.gov/show/NCT00524511||167561|
NCT00503243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-301|Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis|A Phase III, Randomized, Multi-Centre, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) Versus SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis||Shire||Completed|September 2003|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|280|||Both|18 Years|N/A|No|||November 2007|June 6, 2014|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00503243||169167|
NCT00499096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-018-06F|Self-Management Addressing Heart Disease Risk Trial|Cardiovascular Risk Factors in Veterans With Bipolar Disorder|SMAHRT|VA Office of Research and Development|No|Completed|May 2008|November 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|118|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|July 9, 2007||No||No|October 17, 2014|https://clinicaltrials.gov/show/NCT00499096||169480|
NCT00499122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20071167|Oxidized Glutathione (NOV-002), Doxorubicin, Cyclophosphamide, and Docetaxel in Treating Women With Newly Diagnosed Stage IIB, or Stage IIIC Breast Cancer|Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|May 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||August 2013|July 25, 2014|July 10, 2007|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00499122||169478|
NCT00499330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-140503|Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer|A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Recruiting|June 2007|||March 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1258|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499330||169463|
NCT00499603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0790|Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer|Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2007|April 2015|Anticipated|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Female|18 Years|N/A|No|||December 2014|December 1, 2014|July 9, 2007|No|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT00499603||169443|
NCT00499616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL0531|Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma|Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma||Children's Oncology Group|Yes|Active, not recruiting|October 2007|||June 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|464|||Both|N/A|12 Years|No|||July 2014|July 18, 2014|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499616||169442|
NCT00499941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 9059|Alpha-1 Foundation Research Registry|Alpha-1 Foundation Research Registry||Medical University of South Carolina|Yes|Recruiting|April 2000|June 2050|Anticipated|June 2050|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals of all ages who are diagnosed with severe alpha-1 antitrypsin deficiency or        the carrier state|March 2016|March 14, 2016|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00499941|50 Years|169418|
NCT00500240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0107|Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)|Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia||M.D. Anderson Cancer Center|No|Terminated|April 2004|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|15 Years|N/A|No|||June 2015|June 2, 2015|July 10, 2007||No|Terminated early due to futility.|No|June 5, 2013|https://clinicaltrials.gov/show/NCT00500240||169395|Study terminated early due to futility at the pre-determined interim analysis point.
NCT00500448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Palmieri-Smith|An Intervention of Electrical Stimulation in Osteoarthritis|The Efficacy of Neuromuscular Electrical Stimulation for Improving Quadriceps Activation in Women With Medial Tibiofemoral Osteoarthritis||University of Michigan|No|Completed|July 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Female|50 Years|62 Years|No|||September 2009|September 24, 2009|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00500448||169379|
NCT00500487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH066641|Therapeutic Schools: Affect Management and HIV Prevention|Therapeutic Schools: Affect Management and HIV Prevention||Rhode Island Hospital|Yes|Completed|April 2003|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|420|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||October 2009|January 9, 2015|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500487||169376|
NCT00500500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-29-00240-127|Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease|Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.||Ipsen||Terminated|July 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|85 Years|No|||October 2013|October 10, 2013|July 11, 2007||No|Inability to recruit sufficient number of patients|No||https://clinicaltrials.gov/show/NCT00500500||169375|
NCT00522821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUWP2005.01|Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response|Treatment in Patients With Recurrent Infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response|Subklasse|Sanquin|No|Completed|November 2007|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|55|||Both|5 Years|N/A|No|||April 2015|April 3, 2015|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522821||167690|
NCT00523380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN028-1802|Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer|An Open-Label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients With Persistent or Progressive Disease After, or Relapse Within One Year of, Completion of Standard First Line Therapy||Novo Nordisk A/S|No|Completed|October 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||October 2013|October 24, 2013|August 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00523380||167647|
NCT00523393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006573-24|Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells|Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells in Patients With Type 2 Diabetes: a Partially Double-Blind, Randomized, Three-Arm Unicenter Study||Heidelberg University|No|Recruiting|August 2007|May 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|75|||Both|35 Years|70 Years|No|||February 2009|February 12, 2009|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523393||167646|
NCT00523367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-L-147|COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI|COPD Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole)|GERD/COPD|University of Florida|Yes|Terminated|August 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|40 Years|N/A|No|||January 2013|January 15, 2013|August 30, 2007||No|terminated due to enrollment|No|March 8, 2012|https://clinicaltrials.gov/show/NCT00523367||167648|
NCT00523640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13662A|A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma|A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma||University of Chicago|Yes|Terminated|March 2005|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|August 30, 2007|Yes|Yes|Too slow accrual|No|August 15, 2011|https://clinicaltrials.gov/show/NCT00523640||167627|Trial was designed with a maximum target accrual of 55 patients. The trial was halted early because emerging data with VEGF inhibitors challenged clinical relevance of the study and availability of multiple therapies challenged accrual.
NCT00523653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB 07-004|The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study|||McGill University Health Center|No|Recruiting|January 2008|December 2008|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with Dilated cardiomyopathy followed at the Heart Function Clinic and their        families|March 2008|March 17, 2008|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523653||167626|
NCT00523965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLCombo 07|Combination Therapy in Indian Visceral Leishmaniasis|A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL)||Banaras Hindu University|Yes|Completed|September 2007|February 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|624|||Both|12 Years|60 Years|No|||January 2009|May 25, 2010|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00523965||167602|
NCT00524576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108988|Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine|Administration of a Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine.||GlaxoSmithKline||Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|144|||Both|17 Years|22 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|August 31, 2007|Yes|Yes||No|May 14, 2009|https://clinicaltrials.gov/show/NCT00524576||167556|
NCT00524589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000563197|Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|Phase II Study of Weekly Intravenous 1,25 Dihydroxycholecelciferol (Calcitriol) + Dexamethasone in Androgen Independent Prostate Cancer||Roswell Park Cancer Institute|Yes|Terminated|April 2006|September 2010|Actual|July 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|N/A|N/A|No|||January 2014|January 27, 2014|August 31, 2007|Yes|Yes|closed due to futility|No|January 27, 2014|https://clinicaltrials.gov/show/NCT00524589||167555|
NCT00524875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8657|Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients|||hahid Beheshti University of Medical Sciences|Yes|Recruiting|January 2007|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|80|||Both|N/A|N/A|No|||August 2007|September 4, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00524875||167534|
NCT00524888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sutvsglu-HMO-CTIL|Suturing vs Biological Adhesive in Simple Lacerations of Hand|Suturing Vs Adhesion for Hand Lacerations in the ER A Randomized Prospective Study|sutvsglu|Hadassah Medical Organization||Not yet recruiting|September 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||August 2007|September 4, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00524888||167533|
NCT00524524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 501-109|An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors|An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors||ArQule|No|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|August 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00524524||167560|
NCT00502957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9654-26326|Biofeedback Treatment for Functional Constipation|Biofeedback for Functional Constipation: Efficacy and Predictive Factors of Success||University of California, San Francisco|Yes|Completed|March 2005|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|N/A|N/A|No|||August 2009|June 24, 2010|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502957||169189|
NCT00503256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0117|Genetic Study of Chronic Lymphocytic Leukemia Families|Genetic Study of Chronic Lymphocytic Leukemia Families||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2003|||September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Blood and cheek cell sample collection that will be used for special tests to look for genes      that may play a role in the development of CLL.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with chronic lymphocytic leukemia (CLL) and their living unaffected or        affected relatives.|October 2015|October 19, 2015|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00503256||169166|
NCT00500253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-56-07-KE|Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma|Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma||Medical Universtity of Lodz|Yes|Recruiting|February 2007|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|6 Years|18 Years|No|||February 2013|February 6, 2013|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500253||169394|
NCT00499343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0242|G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients|A Randomized Study Comparing Chemotherapy Followed by G-CSF Alone Versus G-CSF Plus GM-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas||M.D. Anderson Cancer Center|Yes|Completed|January 2004|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|N/A|70 Years|No|||June 2013|June 3, 2013|July 9, 2007||No||No|March 3, 2009|https://clinicaltrials.gov/show/NCT00499343||169462|
NCT00499629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3213A1-1000|Study Evaluating the Safety of FXR-450 in Healthy Subjects|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of FXR-450 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 12, 2008|July 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499629||169441|
NCT00499642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098B1-133|Study Evaluating the Effect of Lecozotan SR on the QTc Interval|A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|June 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00499642||169440|
NCT00501111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00010|Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease|A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease|Sirocco|AstraZeneca|No|Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|659|||Both|60 Years|85 Years|No|||July 2014|July 22, 2014|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501111||169329|
NCT00501124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-402|Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV|Phase IV Study to Evaluate the Safety and Efficacy of Clevudine Compared With Clevudine and Vaccine in Patients Chronically Infected With HBV, HBeAg(+)||Bukwang Pharmaceutical|No|Completed|May 2007|||July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|60 Years|No|||August 2009|December 21, 2010|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501124||169328|
NCT00500201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAA105737|A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.|A Single Blind, Double Dummy, Placebo Controlled, Randomized, 2 Period Crossover Study to Assess the Relative Bioavailability of a 120mg Tablet Compared to Two 60 mg SB-773812 Tablets in Healthy Volunteers||GlaxoSmithKline|No|Completed|May 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500201||169398|
NCT00500474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tk19661217|Effects of Endolymphatic Sac Drainage With Steroids for Meniere’s Disease|Clinical Study of Endolymphatic Sac Drainage With or Without Steroids for Intractable Meniere's Disease|EDSS|Osaka University|Yes|Completed|April 1996|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|197|||Both|N/A|N/A|No|||July 2007|July 23, 2007|July 11, 2007||||No||https://clinicaltrials.gov/show/NCT00500474||169377|
NCT00500773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1807/07|Investigation of Cardiac Function and Cardiovascular Risk Factors in Marathon Runners- The Munich Marathon Study|Investigation of Myocardial Injury, Ventricular Dysfunction and Cardiovascular Risk Factors in Different Groups of Marathon Runners|MMS|Technische Universität München|Yes|Completed|July 2007|May 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Male|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male marathon runners with no more than one treated cardiovascular risk factor        aged 30-60 years. Participation of at least a 1/2 marathon in recent history.|April 2014|April 30, 2014|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500773||169355|
NCT00522834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4783-08|Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma|A Randomized, Double-blind, Phase 3 Trial of Elesclomol (STA-4783) in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects With Stage IV Metastatic Melanoma (SYMMETRY)||Synta Pharmaceuticals Corp.|Yes|Terminated|August 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|630|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|August 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00522834||167689|
NCT00523406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK049/2005|Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (in Combination With Intravitreal Triamcinolone Acetate)|||Medical University of Vienna|No|Completed|August 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|90 Years|No|||May 2013|May 2, 2013|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523406||167645|
NCT00523679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RKR-SYM-2007/1|Symbicort SMART (Symbicort Maintenance And Reliever Therapy)|SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice|SMART|AstraZeneca|No|Completed|July 2007|July 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|12 Years|N/A|No|Probability Sample|Hospital Outpatient Clinics|July 2009|July 10, 2009|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523679||167624|
NCT00523692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK2939|Remission Induction in Very Early Rheumatoid Arthritis|Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy|RIVERA|University Hospital Birmingham|No|Not yet recruiting|September 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2007|August 30, 2007|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523692||167623|
NCT00523666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTI001|Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)|Diffusion Tensor Weighted MRI in Alzheimer's Disease: Prediction and Mapping of Symptomatic and Disease Modifying Treatment Effects of Galantamine (Reminyl®)||Ludwig-Maximilians - University of Munich|Yes|Recruiting|September 2006|September 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|95 Years|Accepts Healthy Volunteers|||August 2007|August 29, 2007|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523666||167625|
NCT00524277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000562261|Vaccine Therapy in Treating Patients With Breast Cancer|Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients||San Antonio Military Medical Center|Yes|Active, not recruiting|January 2007|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|August 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00524277||167579|
NCT00514527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-ORI-SD001|A Study for Patients With Complicated Skin and Skin Structure Infections|Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)|SIMPLIFI|Targanta Therapeutics Corporation|No|Completed|August 2007|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|294|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514527||168315|
NCT00502697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070684|Tennessee Connections for Better Birth Outcomes|Tennessee Connections for Better Birth Outcomes|BBO|Vanderbilt University|No|Completed|November 2006|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|236|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|July 16, 2007||No||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00502697||169209|
NCT00502970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302-Med/ERC-04|Short Course of Interferon Treatment in Patients With HCV Infection|A Randomized Trial Comparing a Short Course Versus Standard Treatment in Patients With Chronic Hepatitis C Virus Infection|STAR|Aga Khan University|Yes|Completed|May 2004|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|50 Years|No|||January 2008|January 9, 2008|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502970||169188|
NCT00503269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA/dd|Local Anaesthetic Day-Care Haemorrhoidectomy Challenges Traditional Concepts - a Randomised Controlled Trial|Cost Effectiveness of Local Anaesthetic Day Surgical Haemorrhoidectomy||East Kent Hospitals University NHS Foundation Trust|Yes|Completed|July 2005|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|N/A|N/A|No|||October 2008|October 16, 2008|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00503269||169165|
NCT00503282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uc.ctil|Urinary Catheter Exchange on Admission of Septic Elderly With Permanent Catheter Before Initiation of Antibiotics|||Shaare Zedek Medical Center|No|Not yet recruiting|October 2007|October 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|65 Years|95 Years|No|||July 2007|July 17, 2007|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503282||169164|
NCT00503295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 014|Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung|A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung||Oncolytics Biotech|No|Completed|June 2007|April 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|16 Years|N/A|No|||May 2012|September 30, 2014|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503295||169163|
NCT00499382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0578|Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging|Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging||M.D. Anderson Cancer Center|No|Terminated|September 2004|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|N/A|N/A|No|Non-Probability Sample|Study participants with advanced cancer scheduled to have a positron emission        tomography/computed tomography (PET/CT) scan and a nuclear medicine (NM) cardiac scan.|July 2012|July 31, 2012|July 10, 2007||No|Slow accrual; study terminated.|No||https://clinicaltrials.gov/show/NCT00499382||169459|
NCT00499356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK55909|Shear and Pressure Reducing Insoles for the Diabetic Foot|Shear and Pressure Reducing Insoles for the Diabetic Foot|GlideSoft|Diabetica Solutions Inc.|Yes|Completed|May 2002|January 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|299|||Both|18 Years|80 Years|No|||July 2007|July 10, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00499356||169461|
NCT00499655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06254|Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer|A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Erlotinib (Tarceva) and Celecoxib (Celebrex) Versus Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients||City of Hope Medical Center|Yes|Active, not recruiting|November 2007|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499655||169439|
NCT00499928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9106327|A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women|An Open-Label Study to Investigate the Excretion and Metabolic Disposition of a Single, Oral Dose of [14C]-SB-751689 (a Calcium-Sensing Receptor Antagonist) in Healthy Male Subjects and Healthy Postmenopausal Female Subjects||GlaxoSmithKline||Completed|April 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|July 10, 2007||||||https://clinicaltrials.gov/show/NCT00499928||169419|
NCT00500552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK 2848, 05/Q2707/325|Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy|Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)|METAL-HCM|University Hospital Birmingham|Yes|Completed|December 2006|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|80 Years|No|||August 2010|November 3, 2010|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500552||169371|
NCT00500214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ilioinguinal nerve excision|Ilioinguinal Nerve Excision in Open Mesh Repair of Inguinal Hernia,a Randomized Clinical Trial|||hahid Beheshti University of Medical Sciences|No|Completed|April 2005|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||||||Both|18 Years|N/A|No|||July 2007|July 11, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500214||169397|
NCT00500227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52030-728|Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery|Observational Study to Evaluate, in Acromegalic Patients With Disease Persistence After Surgery, Those Histopathologic, Clinical, Morphologic and Biochemical Factors Predictors of Hormonal Control Under Somatostatin Analogue Treatment|ESPORA|Ipsen||Completed|September 2007|July 2012|Actual|July 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Acromegalic patients with persistence of the disease who attend specialized visits        (Endocrinologist) at the Spanish hospitals.|July 2012|July 30, 2012|July 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00500227||169396|
NCT00523094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB032|Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure|Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure||Deep Breeze|No|Suspended|September 2007|July 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients evaluated for lung surgery who will undergo perfusion scan|June 2009|June 15, 2009|August 29, 2007||No|Enrollment was too slow and principal investigator moved to another country|No||https://clinicaltrials.gov/show/NCT00523094||167669|
NCT00523419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11814|Chemotherapy for Patients With Osteosarcoma|Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas||Eli Lilly and Company|No|Completed|September 2007|June 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|August 29, 2007|Yes|Yes||No|June 23, 2010|https://clinicaltrials.gov/show/NCT00523419||167644|
NCT00523432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15424A|A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies|A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies||University of Chicago|No|Completed|August 2007|December 2010|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|N/A|No|||September 2013|September 4, 2013|August 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00523432||167643|
NCT00523705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805778|Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study|Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study||University of Pennsylvania|No|Terminated|February 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Female|15 Years|19 Years|No|||June 2012|May 29, 2014|August 30, 2007|Yes|Yes|Enrollment too slow.|No|June 13, 2012|https://clinicaltrials.gov/show/NCT00523705||167622|
NCT00523978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-023|A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation|A Randomized, Controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation.|Stop-AF|Medtronic Atrial Fibrillation Solutions|No|Completed|October 2006|July 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|75 Years|No|||July 2012|July 25, 2012|August 31, 2007|Yes|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00523978||167601|
NCT00524290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07080043|Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol|Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol||University of Pittsburgh|Yes|Recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|acinetobacter infections|December 2015|December 16, 2015|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524290||167578|
NCT00524303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT109096|Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.|Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer||GlaxoSmithKline|No|Active, not recruiting|August 2007|October 2015|Anticipated|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Female|18 Years|N/A|No|||October 2013|January 16, 2014|August 31, 2007|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00524303||167577|
NCT00524316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000563261|Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Phase II Study of SUNITINIB MALATE (Sutent) and Chemoembolization in Patients With Unresectable Hepatocellular Cancer||Roswell Park Cancer Institute|Yes|Terminated|April 2007|May 2014|Actual|December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|August 31, 2007|Yes|Yes|low accrual|No|December 26, 2013|https://clinicaltrials.gov/show/NCT00524316||167576|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.
NCT00514865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2333POU007|Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder||Ono Pharmaceutical Co. Ltd||Completed|June 2007|June 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|278|||Both|18 Years|55 Years|No|||November 2013|November 30, 2013|August 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514865||168290|
NCT00515125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELIA0001|Community Oral Nutrition Support Trial|A Randomised Trial of Oral Nutritional Supplements Versus Dietary Advice on Clinical Nutrition in the Community.||University of Southampton|No|Completed|August 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|50 Years|N/A|No|||June 2015|September 10, 2015|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515125||168270|
NCT00524550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7573|Postprandial Insulin Secretion and Appetite Regulation After Moderate Alcohol Consumption|Effect of Moderate Alcohol Consumption on Postprandial Insulin Secretion, Appetite Regulation, Glucose Homeostasis and Insulin Resistance.||TNO||Completed|August 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|24|||Female|20 Years|44 Years|Accepts Healthy Volunteers|||May 2008|August 11, 2010|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00524550||167558|
NCT00524563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07080042|Clinical Outcomes and Global Epidemiology -Data Coordinating Center|Clinical Outcomes and Global Epidemiology -Data Coordinating Center||University of Pittsburgh|Yes|Active, not recruiting|July 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|acinetobacter infection|December 2015|December 16, 2015|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524563||167557|
NCT00499369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00784|Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy|Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab With Either FOLFOX, OPTIMOX or XELOX||National Cancer Institute (NCI)||Terminated|June 2007|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||March 2014|July 25, 2014|July 10, 2007|Yes|Yes|Due to inadequate accrual, study was terminated and limited outcome data was reported.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT00499369||169460|Due to inadequate accrual, study was terminated and limited outcome data was reported.
NCT00499668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0513|Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer|A Pilot Study of Aprepitant Versus Ondansetron for the Treatment of Opioid Induced Nausea and Vomiting||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn|August 2007|March 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|July 10, 2007|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00499668||169438|
NCT00499954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM9 diabetes_sensor|Investigation of Correlation Between Concentrations of Glucose in Blood and Interstitial Fluid in Type 1 Diabetics|An Open, Mono-Centre Trial to Investigate the Correlation Between Concentrations of Glucose in Arterialized Venous Blood and Subcutaneous Interstitial Fluid Applying Different Extracorporeal Sensor Techniques in Type 1 Diabetics||Medical University of Graz|No|Completed|February 2006|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|16|||Both|19 Years|60 Years|No|||April 2006|July 11, 2007|July 11, 2007||||No||https://clinicaltrials.gov/show/NCT00499954||169417|
NCT00499694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000518085|Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel|Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Male|18 Years|N/A|No|||August 2014|August 9, 2014|July 10, 2007|No|Yes||No|August 9, 2014|https://clinicaltrials.gov/show/NCT00499694||169436|Small sample size, correlative ERCC testing conducted in only a subset of patients (14 of 30 pts) and the findings of this study are hypothesis generating however validation in larger sample size would be needed.
NCT00500526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4626/2004HCFMRP-USP|Effects of Singing in Chronic Obstructive Pulmonary Disease|Effects of Singing on Dyspnea, Quality of Life and Pulmonary Function Parameters of COPD Patients in Stable Conditions.||University of Sao Paulo|No|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|50 Years|80 Years|No|||June 2008|June 27, 2008|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500526||169373|
NCT00500539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025C2303|Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.|An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma||Novartis||Completed|July 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|12 Years|N/A|No|||May 2011|May 31, 2011|July 11, 2007|Yes|Yes||No|November 17, 2010|https://clinicaltrials.gov/show/NCT00500539||169372|
NCT00500786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT006-AngQb 01|Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb|||Cytos Biotechnology AG|Yes|Completed|November 2004|April 2007|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 20, 2012|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500786||169354|
NCT00500565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0046|Pain Management Following TRAM Flap for Breast Reconstruction|Randomized, Double Blind, Controlled Trial of Two Methods of Postoperative Pain Management Following Free Transverse Rectus Abdominous Musculocutaneous (TRAM) Flap for Breast Reconstruction||M.D. Anderson Cancer Center|No|Completed|December 2003|June 2008|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|N/A|N/A|No|||October 2013|October 10, 2013|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500565||169370|
NCT00500513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0208|Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials|Assessment of the Reliability of Implanted Fiducials for Tracking of Respiratory-Induced Tumor Motion||M.D. Anderson Cancer Center|No|Completed|April 2004|December 2011|Actual|June 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||January 2013|January 30, 2013|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500513||169374|
NCT00501319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-320|Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery|Longitudinal Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery||M.D. Anderson Cancer Center|No|Completed|April 2003|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|127|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with Non-Small Cell Lung Cancer.|November 2011|November 7, 2011|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501319||169313|
NCT00501332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CL-30166|Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy|A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.||Maxygen Holdings Ltd.|Yes|Recruiting|July 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501332||169312|
NCT00523107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP012|PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care|PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care||PhytoHealth Corporation|No|Completed|August 2007|April 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|N/A|N/A|No|||June 2009|November 3, 2015|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00523107||167668|
NCT00513760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32711|Transporter Mediated Uptake of Montelukast|Characterization of Transporter Mediated Uptake of Montelukast in Humans|TPORT|Nemours Children's Clinic|No|Recruiting|June 2007|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|27|||Both|15 Years|18 Years|No|||January 2014|January 23, 2014|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513760||168369|
NCT00514033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108344|A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children|Open, Multicentric, PMS Study to Monitor Safety and Reactogenicity of GlaxoSmithKline Biologicals' Poliomyelitis Vaccine (Inactivated)-Poliorix, Administered in Korean Children as a Primary Vaccination in Healthy Subjects Aged 2 to 6 Months or as a Booster Vaccination in Subjects Aged 4 to 6 Years||GlaxoSmithKline||Completed|July 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|349|||Both|2 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|Korean children between two and six months of age (primary vaccination) or between four        and six years of age (booster vaccination) at the time of vaccination.|March 2012|March 15, 2012|August 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00514033||168350|
NCT00523991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.365|Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).|A 24 Week, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by HandiHaler Once-daily Plus PRN Albuterol (Salbutamol) vs. Placebo Plus PRN Albuterol (Salbutamol) in Chronic Obstructive Pulmonary Disease Subjects Naive to Maintenance Therapy||Boehringer Ingelheim||Completed|April 2007|||July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|457|||Both|40 Years|80 Years|No|||May 2014|May 12, 2014|July 9, 2007||||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00523991||167600|For individual outcome measures, only timepoints that had data collected are presented here.
NCT00515151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-0102|Prevention of Catheter-Associated Infection With the Skin Disinfectant Octenidine Dihydrochloride|Skin Disinfection With Octenidine Dihydrochloride for the Prevention of Catheter-Associated Infections - A Double-Blind, Randomized, Controlled Trial||University Hospital Freiburg|Yes|Completed|May 2002|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|400|||Both|18 Years|N/A|No|||August 2007|August 10, 2007|August 10, 2007||||No||https://clinicaltrials.gov/show/NCT00515151||168268|
NCT00524914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602308|Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study|Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study.|APODOUL|University Hospital, Toulouse|No|Completed|September 2007|March 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|30 Years|70 Years|No|||April 2008|April 10, 2008|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524914||167531|
NCT00503321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENCITJ-GC01|Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma|Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma|eNCIT-Japan|Eastern Network of Cancer Immunological Therapy, Japan|Yes|Terminated|October 2006|August 2011|Anticipated|August 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|20 Years|N/A|No|||January 2009|January 22, 2009|July 16, 2007||No|Patients' enrollment was not sufficient.|No||https://clinicaltrials.gov/show/NCT00503321||169161|
NCT00503334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-POB-03-IT|Preoperative Oral Nutritional Supplement (preOP Booster) in Visceral Surgery|Efficacy and Tolerability of a Preoperative Oral Nutritional Supplement (preOP Booster) Versus Placebo in Visceral Surgery||Fresenius Kabi|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|80 Years|No|||November 2008|December 5, 2008|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00503334||169160|
NCT00499148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ82|Efficacy Study Testing Herbal Extract on Metabolic Parameters in Subjects With Type 2 Diabetes|Effect of Herbal Extract on Metabolic Parameters in Subjects With Type 2 Diabetes||Abbott Nutrition|No|Completed|August 2006|October 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|59|||Both|18 Years|75 Years|No|||April 2009|July 29, 2010|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00499148||169476|
NCT00504933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 1704/RAE|Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis|Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.||Faes Farma, S.A.|No|Completed|May 2005|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|683|||Both|12 Years|70 Years|No|||April 2012|April 4, 2012|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504933||169040|
NCT00499681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0660|PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE|A Phase II Neo-Adjuvant Study of Letrozole in Combination With Lapatinib in Post -Menopausal Patients With HER2-Positive and Hormone Receptor-Positive Operable Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|July 2007|December 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Female|18 Years|N/A|No|||August 2012|August 7, 2012|July 10, 2007|Yes|Yes|slow accrual|No|October 17, 2011|https://clinicaltrials.gov/show/NCT00499681||169437|Due to the restrictive nature of the eligibility criteria, only a total of 6 out of the planned 36 patients were accrued in 2 years, leading to early termination of the study. Hence, both clinical and correlative data were deemed uninterpretable.
NCT00499967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-197-0101|Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection||Gilead Sciences|No|Completed|August 2007|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|202|||Both|18 Years|50 Years|No|||April 2009|April 7, 2009|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499967||169416|
NCT00500266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3000|Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects|A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, & Reactogenicity of a 13vPnC Vaccine in Ambulatory Elderly Adults Aged 68 Years & Older Who Received 1 or More Doses of 23vPS Vaccine at Least 3 Years Before Study Enrollment||Pfizer|No|Completed|May 2008|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1053|||Both|68 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 11, 2011|July 9, 2007|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00500266||169393|
NCT00500799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070191|Brain Changes in Blepharospasm|Role of the Cortical Medial Frontal Areas in Blepharospasm||National Institutes of Health Clinical Center (CC)||Completed|July 2007|April 2009||||N/A|Observational|Time Perspective: Prospective||||72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|September 26, 2015|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500799||169353|
NCT00500812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-210-101|A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries|A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury||Vertex Pharmaceuticals Incorporated|Yes|Completed|February 2005|February 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|48|||Both|16 Years|70 Years|No|||May 2012|March 9, 2015|July 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00500812||169352|
NCT00501137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00928|A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine|A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine|BCGov-01|University of British Columbia|Yes|Completed|July 2007|December 2010|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|830|||Female|9 Years|26 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00501137||169327|
NCT00523120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 7-264S|Topical Voltaren in Otitis Externa|Topical Voltaren as an Alternative Treatment for Otitis Externa||Sieff Medical Center|No|Suspended|September 2008|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|August 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00523120||167667|
NCT00523133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA012696-01A1|Research on Individualized Treatment for Alcoholism|Posttreatment Effects of Naltrexone|RITA|Indiana University|Yes|Completed|September 2000|July 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|185|||Both|21 Years|65 Years|No|||August 2007|August 30, 2007|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523133||167666|
NCT00514059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM07-01|Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine|Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age.||Norwegian Institute of Public Health|No|Completed|April 2007|June 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|83|||Both|15 Years|16 Years|Accepts Healthy Volunteers|||April 2007|August 8, 2007|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00514059||168348|
NCT00514046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070189|Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer|Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2007|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|5 Years|18 Years|No|||July 2015|August 15, 2015|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514046||168349|
NCT00514293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000561066|Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Bexarotene (Targretin) Capsules With Tretinoin and Chemotherapy in Patients With Advanced Non-small-cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|January 2007|||December 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||August 2008|January 9, 2014|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514293||168332|
NCT00514540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0097|Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer|Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma||M.D. Anderson Cancer Center|No|Completed|May 2006|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Male|18 Years|N/A|No|||January 2014|January 16, 2014|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514540||168314|
NCT00514280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907199|Tobacco Smoke and Lead Exposure During Pregnancy|Tobacco Smoke and Lead Exposure During Pregnancy: Intervention to Reduce Effects on Birth-Weight and Gestational Age||National Institutes of Health Clinical Center (CC)||Completed|August 2007|May 2011||||N/A|Observational|N/A|||Anticipated|400|||Female|18 Years|49 Years|No|||May 2011|May 12, 2011|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514280||168333|
NCT00515801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 57/07 SB|Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM|Effect of a Sulfonylurea Compound on the Glucagon Response to Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus||University Hospital, Basel, Switzerland|Yes|Completed|June 2007|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|50 Years|No|||March 2012|March 8, 2012|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515801||168220|
NCT00514839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150268661|Brief Intervention for Prescription Drug Misuse in General Hospital|Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital|MIMIK|University of Luebeck|Yes|Completed|November 2005|February 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|69 Years|No|||April 2014|April 1, 2014|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514839||168292|
NCT00502983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0250|Molecular Epidemiology of Acute Myelogenous Leukemia|Molecular Epidemiology of Acute Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2003|||September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Blood sample collection to look for any biologic factors associated with AML.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|UT MDACC Patients with Acute Myelogenous Leukemia and healthy controls, all 18 years of        age or older and Texas residents.|September 2015|September 30, 2015|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502983||169187|
NCT00502996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19385|A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.|An Expanded Access Program to Assess the Safety of MabThera in Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|February 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|235|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00502996||169186|
NCT00499161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030017|Effect of Patient-Centered Care (PCC) on Patient Satisfaction at Hospital Discharge|Effect of Patient-Centered Care (PCC) on Patient Satisfaction at Hospital Discharge|PCC|University of Pittsburgh|Yes|Completed|April 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|80|||Both|19 Years|N/A|No|||February 2008|February 15, 2008|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00499161||169475|
NCT00499395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0513|Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer|Detection of Residual Colorectal Liver Metastases Within 24 Hours After RFA With 18-F FDG PET||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|July 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499395||169458|
NCT00500305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 10946|The Use of B-Type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants|||University of Virginia|No|Completed|April 2004|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|N/A|4 Months|No|||March 2007|July 10, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500305||169390|
NCT00499980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-04117|Near Infrared/ Ultrasound Dual Modal Imaging for Breast Cancer Diagnosis|A Prospective Pilot Clinical Trial Evaluating the Utility of a Dynamic Near Infrared Imaging Device for Characterizing Suspicious Breast Lesions|NIR|Ohio State University|Yes|Completed|March 2005|August 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|50|||Female|18 Years|N/A|No|||July 2007|July 11, 2007|July 11, 2007||||No||https://clinicaltrials.gov/show/NCT00499980||169415|
NCT00505492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-535|Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy|A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus.||M.D. Anderson Cancer Center|No|Terminated|February 2002|December 2010|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|N/A|N/A|No|||September 2011|September 13, 2011|July 19, 2007||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00505492||168999|
NCT00500279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0611-011-188|Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial||mini-COREA|Seoul National University Hospital|No|Recruiting|November 2006|October 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|30 Years|75 Years|No|||July 2007|July 10, 2007|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00500279||169392|
NCT00505804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2004/02026|A Comparison of Dexmedetomidine and Haloperidol in Patients With Intensive Care Unit (ICU)-Associated Agitation and Delirium|A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium|Dex|Austin Health|No|Completed|January 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00505804||168976|
NCT00505817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-MM-0706-307-19|GnRH Agonist and Antagonists in an Oocyte Donation Program|||Instituto Valenciano de Infertilidad, IVI VALENCIA||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||||||Female|18 Years|34 Years||||January 2009|January 9, 2009|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00505817||168975|
NCT00500825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|486/2003|Influence of Therapeutic Hypothermia on Resting Energy Expenditure|Influence of Therapeutic Hypothermia on Resting Energy Expenditure in Patients After Cardiopulmonary Resuscitation||Medical University of Vienna|Yes|Completed|July 2005|May 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Residents of Vienna|May 2008|May 15, 2008|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500825||169351|
NCT00500838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40004384|CRT-D Based Impedance Monitoring Study|CRT-D Based Impedance Monitoring Feasibility Study||St. Jude Medical|No|Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00500838||169350|
NCT00501150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAMK1021|Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections|A Prospective Implementation of an IV-oral Switch Policy to Treat Proven or Suspected Infections Due to Resistant Gram Positive Bacteria in a London Hospital Trust||Imperial College London||Completed|September 2005|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|16 Years|N/A|No|||November 2005|May 27, 2015|July 12, 2007||||No||https://clinicaltrials.gov/show/NCT00501150||169326|
NCT00513513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010612|TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously|A Phase II, Open Label Trial in Treatment na�ve, HIV 1 Infected Subjects Who Will Receive TMC114/Rtv as a Monotherapy||Tibotec Pharmaceuticals, Ireland|No|Terminated|September 2006|October 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|7|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|August 6, 2007|||Poor recruitment.|No||https://clinicaltrials.gov/show/NCT00513513||168388|
NCT00514072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000559937|Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer|A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation||Kael-GemVax Co., Ltd.||Active, not recruiting|March 2007|||September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Male|18 Years|N/A|No|||August 2012|August 8, 2012|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514072||168347|
NCT00514085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I189|Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma|A Phase II Study of Interleukin-21 (IL-21) in Patients With Metastatic or Recurrent Malignant Melanoma||Canadian Cancer Trials Group|Yes|Completed|July 2007|July 2012|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514085||168346|
NCT00514306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-102|Study of Intermittent OSI-906 Dosing|A Phase I Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients With Advanced Solid Tumors||Astellas Pharma Inc|No|Completed|June 2007|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|79|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|August 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00514306||168331|
NCT00514332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF7683|Comparison Between Colorectal Stents and Primary Surgery in Obstructive Colonic Cancer. A Randomized, Controlled Study|Etude Prospective Multicentrique randomisée Comparant Deux stratégies thérapeutiques Pour Les Cancers Coliques en Occlusion : stratégie Chirurgicale Exclusive Versus stratégie thérapeutique Avec Stent Colique Initial||University Hospital, Montpellier|No|Terminated|December 2002|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||August 2007|August 8, 2007|August 8, 2007|||enrolling participants stopped|No||https://clinicaltrials.gov/show/NCT00514332||168330|
NCT00514566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChristianMCLudhiana|PDS vs Polyamide for Midline Abdominal Closure|Is Polydioxanone 'THE' Suture of Choice for Midline Abdominal Closure? Results of a Prospective Randomized Clinical Trial|PPMAC|Christian Medical College and Hospital, Ludhiana, India|Yes|Terminated|October 2004|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|64|||Both|12 Years|N/A|No|||August 2007|August 8, 2007|August 8, 2007|||Unacceptable incidence of wound dehiscence in the PDS group|No||https://clinicaltrials.gov/show/NCT00514566||168312|
NCT00514579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-DCB|Adult Double Cord Blood Transplant Study|A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults With Hematologic Malignancy||Center for International Blood and Marrow Transplant Research|Yes|Completed|August 2007|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|22 Years|50 Years|No|||March 2014|March 7, 2014|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514579||168311|
NCT00514553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070204|Informed Choice Regarding Invasive Prenatal Testing|Deliberation With and Without Attention: Can We Enhance Informed Choices About Invasive Prenatal Testing? A Proof of Principle Study||National Institutes of Health Clinical Center (CC)||Completed|August 2007|May 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|37|||Female|18 Years|55 Years|No|||May 2011|June 1, 2011|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514553||168313|
NCT00514852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9818-002|Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye|||Allergan|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|N/A|No|||November 2009|November 10, 2009|August 8, 2007||No||No|May 19, 2009|https://clinicaltrials.gov/show/NCT00514852||168291|
NCT00515138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-CC06253|A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant|A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant||University of California, San Francisco|Yes|Terminated|May 2007|November 2011|Actual|November 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||April 2012|April 11, 2012|August 9, 2007|No|Yes|Investigator left institution. 7 patients accrued and there is insufficient data to analyze.|No||https://clinicaltrials.gov/show/NCT00515138||168269|
NCT00503347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0603|Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus|A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus||Peregrine Pharmaceuticals||Completed|July 2007|June 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|July 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00503347||169159|
NCT00503360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAD448B2101|Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension|A Multicenter, Randomized, Placebo-Controlled, Double-Masked, 4-Arm Parallel Group Study to Assess the Tolerability, Safety and Efficacy of Two Doses of SAD448 in Subjects With Ocular Hypertension||Novartis||Completed|April 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|65 Years||||April 2008|April 23, 2008|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503360||169158|
NCT00503386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJGene_SYat-sen_06_01|Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting|A Phase II,Multicenter,Randomized,Double-blind,Cross-over Study of Palonosetron Compared With Granisetron in Prevention of Chemotherapy-induced Nausea and Vomiting in Asian Population||Hangzhou Jiuyuan Gene Engineering Co. Ltd.,|Yes|Completed|April 2006|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|144|||Both|18 Years|70 Years|No|||September 2010|September 16, 2010|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00503386||169157|
NCT00499993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-93-52030-077|Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly|Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly||Ipsen||Completed|January 2001|May 2003|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|July 11, 2007||||No||https://clinicaltrials.gov/show/NCT00499993||169414|
NCT00500292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00047|A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer|A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Irinotecan and Fluoropyrimidine Regimen||AstraZeneca|No|Active, not recruiting|March 2007|March 2016|Anticipated|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|109|||Both|18 Years|120 Years|No|||December 2015|December 2, 2015|July 3, 2007|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00500292||169391|
NCT00505258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013807|Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia|Randomized, Open-Label Study Evaluating the Safety and Rate of Bacterial Clearance of Ceftobiprole 500 Milligram Every 8 Hours Compared to Conventional Therapy in the Treatment of Hospitalized Subjects With Staphylococcus Aureus Bacteremia||Basilea Pharmaceutica|No|Withdrawn||April 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|July 19, 2007|||The study was withdrawn due to lack of an appropriate patient population.|||https://clinicaltrials.gov/show/NCT00505258||169017|
NCT00505232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELTAMO-LCM-04-02|Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)|Induction Treatment With Anti-CD20 Plus Hyper-CVAD and Methotrexate/Cytarabine Followed by Consolidation Treatment With Y90 Ibritumomab-Tiuxetan in Patients With Mantle Cell Lymphoma|LCM-04-02|CABYC|No|Completed|January 2006|May 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||December 2011|December 30, 2011|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505232||169019|
NCT00505245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS99-094|M.D. Anderson Symptom Inventory (MDASI) Validation Study in Cancer Patients|Measuring the Symptom Distress of Cancer Patients: Development of a New Assessment System||M.D. Anderson Cancer Center|No|Recruiting|April 1999|||April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4500|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals, over 18 years of age, diagnosed with an advanced cancer.|February 2016|February 29, 2016|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505245||169018|
NCT00505505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1781964|Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy|Effects of Intensive Insulin Therapy on Mortality, Morbidity and Long Term Neurologic Outcome in Neurosurgical Intensive Care Patients||University of Roma La Sapienza|Yes|Recruiting|January 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|80 Years|No|||July 2007|August 6, 2008|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505505||168998|
NCT00505518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001508|Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home|Feasibility and Effectiveness of Telepsychiatry for Collaborative Management of Chinese Americans With Psychiatric Disorders in a Nursing Home||Massachusetts General Hospital|Yes|Completed|September 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|July 19, 2007||No||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00505518||168997|Many subjects in the study suffered from dementia and psychotic symptoms, thus their responses may not be reliable.
NCT00505830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Autisme AQ|Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ|Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)||Groupe Francais d'Epidemiologie Psychiatrique|No|Recruiting|July 2007|July 2009|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||4|Anticipated|450|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00505830||168974|
NCT00506090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|423/2224-A|Safety and Efficacy of Different Intervals of Pulsed Dye Laser Sessions on Improvement of Surgical Scars|The Effect of Different Intervals of 595-nm Pulsed Dye Laser Sessions on Improvement of Surgical Scars: A Double Blind Randomised Clinical Trial||Tehran University of Medical Sciences|No|Withdrawn|July 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|80 Years|No|||October 2009|October 4, 2009|July 23, 2007||No|Because of unsatisfactory results of previous trial which assessed the effect of different    onset times of PDL on surgical scars.|No||https://clinicaltrials.gov/show/NCT00506090||168954|
NCT00506103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHHN|The No-Tie Technique Using the Harmonic Scalpel in Total Thyroidectomy With Central Neck Dissection: A Prospective Randomized Study|||Soonchunhyang University Hospital|Yes|Completed|October 2006|June 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|N/A|N/A|No|||July 2007|July 25, 2007|July 21, 2007||||No||https://clinicaltrials.gov/show/NCT00506103||168953|
NCT00506077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0249-016|MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia||Merck Sharp & Dohme Corp.||Completed|December 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|21 Years|55 Years|No|||July 2015|July 31, 2015|July 24, 2007|Yes|Yes||No|October 13, 2010|https://clinicaltrials.gov/show/NCT00506077||168955|
NCT00506337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A15|Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis|Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis||Tianjin Nankai Hospital|Yes|Recruiting|October 2006|October 2009|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years||||July 2007|July 29, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506337||168935|
NCT00506350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109817|Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults|Evaluate the Reactogenicity & Immunogenicity of 1 or 2 Booster Administrations of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults Aged Between 19 & 61 Years||GlaxoSmithKline||Completed|August 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|9||Actual|350|||Both|19 Years|61 Years|Accepts Healthy Volunteers|||January 2010|February 4, 2011|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506350||168934|
NCT00513773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070535|Inflammation and Risk Prediction in Patients With Abdominal Aortic Aneurysm|Inflammation and Risk Prediction in Patients With Abdominal Aortic Aneurysm||Vanderbilt University|No|Recruiting|July 2008|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Serum/plasma for biomarker analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients with abdominal aortic aneurysm|July 2011|July 25, 2011|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513773||168368|
NCT00514345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-PK-2007-02|CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide|CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children||National Cancer Institute (NCI)||Recruiting|July 2007|||||N/A|Observational|N/A|||Anticipated|300|||Both|N/A|20 Years|No|||June 2009|August 9, 2013|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00514345||168329|
NCT00514592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EJ-0418|Additional Neurological Symptoms Before Surgery of the Carotid Arteries - A Prospective Study (ANSYSCAP)|Additional Neurological Symptoms Before Surgery of the Carotid Arteries - A Prospective Study|ANSYSCAP|Umeå University|No|Completed|August 2007|March 2011|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|230|||Both|18 Years|90 Years|No|Probability Sample|All patients with a carotid stenosis >50%, preliminary eligable for CEA in the northern        region of Sweden|September 2013|September 16, 2013|August 9, 2007||No||No|July 8, 2013|https://clinicaltrials.gov/show/NCT00514592||168310|
NCT00514904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109495|Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects|Non-Inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Versus Mencevax™ in Healthy Subjects Aged 2 Through 10 Years of Age||GlaxoSmithKline||Completed|September 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1505|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|August 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514904||168287|
NCT00514917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976J_3503|A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)|A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy|Rising PSA|Sanofi|Yes|Terminated|July 2007|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|413|||Male|18 Years|N/A|No|||August 2013|August 30, 2013|August 2, 2007|Yes|Yes|Company decision to discontinue the study, not due to any safety or efficacy concerns|No|August 30, 2013|https://clinicaltrials.gov/show/NCT00514917||168286|
NCT00514878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H54427-30684|Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)|Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)|Apfel-PDNV|University of California, San Francisco|No|Completed|August 2007|November 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients scheduled for elective outpatient surgery|December 2008|October 30, 2009|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514878||168289|
NCT00514891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVK-2006-7041-99|Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts|Evaluation of the Impact on Mortality and Morbidity of the WHO Recommended Vitamin A Supplementation at First Immunisation Contact After 6 Months of Age||Bandim Health Project|Yes|Terminated|August 2007|December 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|9500|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||January 2011|February 26, 2011|August 8, 2007||No|Reccomended by DSMB after review of planned interim analyses.|No||https://clinicaltrials.gov/show/NCT00514891||168288|
NCT00515164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-C07-001|US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study|Phase 2 Study of the 20 mL Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema||Aeris Therapeutics|Yes|Completed|August 2007|December 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|40 Years|N/A|No|||October 2011|October 21, 2011|August 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515164||168267|
NCT00515177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705M09301|Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study|Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study|MVP#1|University of Minnesota - Clinical and Translational Science Institute|No|Completed|August 2007|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||February 2013|February 20, 2013|August 10, 2007|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00515177||168266|
NCT00515190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-265|Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma|A Randomized Phase II Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma||National Cancer Center, Korea|No|Recruiting|July 2007|August 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|N/A|No|||December 2007|December 21, 2007|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515190||168265|
NCT00515203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060195|Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects|A Randomized, Double-Blind, Placebo-controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Pediatric Subjects With Chronic Immune (Idiopathic) Thrombocytopenic Purpura||Amgen||Completed|July 2007|August 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|1 Year|17 Years|No|||July 2014|July 18, 2014|August 9, 2007||||No|October 28, 2010|https://clinicaltrials.gov/show/NCT00515203||168264|
NCT00515463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060237|A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density|A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density||Amgen||Completed|May 2007|March 2009|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|311|||Female|18 Years|N/A|No|||August 2013|August 27, 2013|August 9, 2007||||No|June 18, 2010|https://clinicaltrials.gov/show/NCT00515463||168244|
NCT00499707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|712753/007|Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects|A Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Fixed Dose Rosiglitazone/Metformin Combination Therapy Compared to Both Rosiglitazone and Metformin Monotherapies in Drug Naive Type 2 Diabetes Mellitus Subjects||GlaxoSmithKline|No|Completed|October 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|453|||Both|18 Years|70 Years|No|||May 2013|April 14, 2015|July 9, 2007||||||https://clinicaltrials.gov/show/NCT00499707||169435|
NCT00499720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA-US-205-0111|Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection|Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression||Gilead Sciences||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|6 Years|N/A||||July 2011|July 29, 2011|July 9, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00499720||169434|
NCT00504946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-168-05-KE|Pharmacological Modulations of Allergen-Specific Immunotherapy|The Effect of Glucocorticosteroid and Vitamin D3 Administration and Montelukast Treatment on Early Clinical and Immunological Effect of Allergen-Specific Immunotherapy in Asthmatic Children, Double-Blind, Placebo-Controlled Study||Medical Universtity of Lodz|Yes|Completed|September 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|85|||Both|6 Years|18 Years|No|||April 2008|April 8, 2008|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504946||169039|
NCT00505557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|621125-1|Dual-Plane Breast Augmentation: Axillary Approach With Assistant of Endoscope|||Chinese Academy of Sciences|Yes|Completed|May 2006|April 2008|Actual|April 2007|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||||||Female|18 Years|40 Years|No|||June 2009|June 23, 2009|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505557||168994|
NCT00505544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0598|Measuring Sleep Disturbance Among Cancer Patients|The Brief Sleep Disturbance Scale: Measuring Sleep Disturbance Among Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2005|||August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|570|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants with a pathological diagnosis of cancer and community dwelling adults        who attend a meeting of a designated service organization.|October 2015|October 26, 2015|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505544||168995|
NCT00505531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P 000025|Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics|Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics||Massachusetts General Hospital|No|Active, not recruiting|June 2007|December 2014|Anticipated|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|93|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects whose chronic pain is not well controlled on narcotic pain medicine.|July 2014|July 2, 2014|July 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00505531||168996|
NCT00505843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0657-006|A Study of MK0657 in Parkinson's Disease Patients (0657-006)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate Effectiveness of Single-Dose MK0657 in Combination With Levodopa on Motor Symptoms and Dyskinesias in Patients With Parkinson's Disease||Merck Sharp & Dohme Corp.||Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|40 Years|80 Years|No|||January 2015|January 28, 2015|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505843||168973|
NCT00506116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR4007-9|Promoting Effective Recovery From Labor Urinary Incontinence (PERL)|Promoting Effective Recovery From Labor Urinary Incontinence: Prevention Reducing Birthing Risk|PERL|University of Michigan|No|Completed|July 1996|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2007|July 30, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506116||168952|
NCT00506376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-741|Simple Versus Radical Hysterectomy for Stage I Cervical Cancer|Simple Versus Radical Hysterectomy for Stage I Cervical Cancer: Preferences of Women at High-Risk for Developing Cervix Cancer vs. Women Diagnosed With Cervix Cancer||M.D. Anderson Cancer Center|No|Completed|January 2003|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|85|||Female|18 Years|N/A|No|Non-Probability Sample|Participants at high-risk for cervical cancer and those already diagnosed with cervical        cancer.|February 2016|February 25, 2016|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00506376||168932|
NCT00506363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|423/2224-B|Safety and Efficacy of Different Onset Times of Treatment With Pulsed Dye Laser on Improvement of Surgical Scars|The Effect of Different Onset Times of Treatment With 595-nm Pulsed Dye Laser on Improvement of Surgical Scars: A Double Blind Randomised Clinical Trial||Tehran University of Medical Sciences|No|Terminated|January 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|15|||Both|18 Years|80 Years|No|||October 2009|October 4, 2009|July 23, 2007||No|The trial was terminated on May 2008 after inclusion of 10 patients due to low recruitment and    patient compliance.|No||https://clinicaltrials.gov/show/NCT00506363||168933|
NCT00506675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-135|Combined Patching-Atropine for Residual Amblyopia|A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia|ATS11|Jaeb Center for Health Research|Yes|Terminated|October 2007|September 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|3 Years|9 Years|No|||May 2012|May 16, 2012|July 20, 2007|Yes|Yes|Poor enrollment and infeasibility of ever reaching the necessary sample size|No|September 14, 2010|https://clinicaltrials.gov/show/NCT00506675||168909|This trial was stopped after 18 months due to inadequate recruitment.
NCT00513786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06133|Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma|A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|August 2007|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Female|18 Years|N/A|No|||July 2015|July 25, 2015|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00513786||168367|
NCT00514358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU10826|Fluconazole Pharmacokinetics in Infants|A Multicenter, Open Label Pharmacokinetic Study of Fluconazole in Infants||Children's Hospital of Philadelphia|Yes|Completed|November 2005|June 2007|Actual|June 2007|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|N/A|119 Days|No|Non-Probability Sample|Premature and term infants less than 90 days of age who are receiving fluconazole as        standard of care therapy.|July 2011|July 6, 2011|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514358||168328|
NCT00514605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01|Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection|A Study to Evaluate the Point-of-Care Use and Laboratory Investigational Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection||bioLytical Laboratories|No|Completed|July 2007|||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|1||Anticipated|2500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 10, 2007|August 8, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00514605||168309|
NCT00514930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicenter hexablate protocol|Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver|A Multicentre Prospective Clinical Trial of a New Bipolar Radiofrequency Ablation/Aspirator Device (Hexablate) in the Management of Primary and Secondary Liver Cancers||University of Thessaly||Recruiting|February 2007|August 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|85 Years||||August 2007|August 9, 2007|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00514930||168285|
NCT00514943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.28|BIBW 2992 (Afatinib) in Head & Neck Cancer|A Randomized, Open-label Phase II Study of BIBW 2992 Versus Cetuximab (Erbitux) in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy With a Cross-over Period for Progressing Patients||Boehringer Ingelheim||Completed|August 2007|July 2013|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|August 9, 2007||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00514943||168284|
NCT00515476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4031215|Effect of Exercise Training on the Function of the High Density Lipoprotein (HDL)-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Metabolic Syndrome(HERMET-Study)|Randomized, Clinical Trial to Study the Effect of Exercise Training on the Function of HDL-Cholesterol, Endothelial Function, Oxidative Stress and Regenerative Capacity of Endothelial Progenitor Cells in Patients With Metabolic Syndrome|HERMET|Hannover Medical School||Completed|June 2007|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|24|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||November 2009|June 22, 2010|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00515476||168243|
NCT00515788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0135|DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis|Phase I Study of Temozolomide and Intrathecal DepoCyt in Patients With Neoplastic Meningitis||M.D. Anderson Cancer Center|No|Terminated|February 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|August 13, 2007||No|Study terminated due to slow accrual with no expansion to additional phase.|No||https://clinicaltrials.gov/show/NCT00515788||168221|
NCT00516503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N06CA|Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer|The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study||Alliance for Clinical Trials in Oncology|Yes|Completed|February 2008|January 2010|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|211|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|August 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516503||168166|
NCT00516113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L&E-5|A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria|A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine When Used for the Treatment of Premenstrual Dysphoria||Karolinska Institutet|No|Completed|October 2000|November 2002|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|N/A|No|||August 2007|December 6, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00516113||168196|
NCT00516126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194/06|Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery|Goal-orientated Therapy of Perioperative Disturbance in Hemostasis With MULTIPLATE and ROTEM in Cardiac Surgery Patients Under Platelets Inhibitors||University Hospital, Basel, Switzerland|Yes|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery|January 2013|January 10, 2013|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00516126||168195|
NCT00516139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEP105972|Lamotrigine Extended-Release In Elderly Patients With Epilepsy|Lamotrigine Extended-Release in Elderly Patients With Epilepsy||GlaxoSmithKline|No|Completed|August 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|65 Years|N/A|No|||August 2012|August 16, 2012|August 13, 2007|Yes|Yes||No|July 15, 2011|https://clinicaltrials.gov/show/NCT00516139||168194|
NCT00504621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-4-015|The Influence of Personality on Pulmonary Fibrosis and Sarcoidosis|The Influence of Personality on Quality of Life, Fatigue, Prognosis, and Health Care Consumption in Pulmonary Fibrosis and Sarcoidosis||Maastricht University Medical Center|No|Completed|August 2007|January 2009|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|450|||Both|18 Years|N/A|No|Non-Probability Sample|Sarcoidosis patients diagnosed according to WASOG guidelines and IPF patients diagnosed        according ATS guidelines.|March 2014|March 25, 2014|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504621||169063|
NCT00504634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0751|Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma|A Phase II Trial of Bortezomib (Velcade) After Allogenic Peripheral Blood Stem Cell or Bone Marrow Transplantation for Patients With Multiple Myeloma||M.D. Anderson Cancer Center|No|Completed|January 2004|May 2010|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|70 Years|No|||September 2011|September 14, 2011|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504634||169062|
NCT00504959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2402|Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)||Novartis||Completed|July 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|234|||Both|50 Years|N/A|No|||March 2016|March 2, 2016|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504959||169038|
NCT00505882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032007-054|Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes|The Pilot Study:Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes||University of Texas Southwestern Medical Center|Yes|Withdrawn|July 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|12 Years|70 Years|No|||May 2009|May 8, 2009|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00505882||168970|
NCT00505869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0022|A Mood Management Intervention for Pregnant Smokers|A Mood Management Intervention for Pregnant Smokers||M.D. Anderson Cancer Center|Yes|Completed|August 2004|April 2010|Actual|April 2010|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|338|Samples Without DNA|Saliva sample for cotinine.|Female|16 Years|N/A|No|Probability Sample|Patients who are pregnant smokers who may be under stress.|August 2012|August 1, 2012|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00505869||168971|
NCT00505856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L06-158|Dermabond Skin Adhesives vs Skin Staples for Closure of Repeat Cesarean Section Skin Incisions|Dermabond Skin Adhesives vs Skin Staples for Closure of Repeat Cesarean Section Skin Incisions||Texas Tech University Health Sciences Center|No|Terminated|July 2007|December 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2008|December 11, 2008|July 23, 2007|||Resident project--resident left institution and was not picked up by anyone else|No||https://clinicaltrials.gov/show/NCT00505856||168972|
NCT00506129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM03-0279|Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma|Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)||M.D. Anderson Cancer Center|No|Completed|September 2003|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|70 Years|No|||June 2015|June 19, 2015|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00506129||168951|
NCT00506389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05707|A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)|A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia||Merck Sharp & Dohme Corp.|No|Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|419|||Both|18 Years|65 Years|No|||August 2015|August 4, 2015|July 23, 2007|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT00506389||168931|
NCT00506402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-104|A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies|A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies||CASI Pharmaceuticals, Inc.||Completed|November 2006|April 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2009|May 4, 2009|July 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00506402||168930|
NCT00506714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-030430|Walking Aids in the Management of Hip Osteoarthritis|Walking Aids in the Management of Hip Osteoarthritis||Arthritis Foundation|No|Completed|July 2007|September 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|July 20, 2007||No||No|February 6, 2012|https://clinicaltrials.gov/show/NCT00506714||168906|
NCT00506688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muko-D-GSH-4|Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients|Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis Patients||Mukoviszidose Institut gGmbH|Yes|Completed|July 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|153|||Both|8 Years|N/A|No|||July 2012|July 6, 2012|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00506688||168908|
NCT00506701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25|Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension|Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease||Herlev Hospital|Yes|Withdrawn|February 2008|February 2010|Anticipated|February 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|45 Years|85 Years|No|||July 2007|March 17, 2015|July 23, 2007||No|due to lack of finance|No||https://clinicaltrials.gov/show/NCT00506701||168907|
NCT00506961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-RSV-RT-01|Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia|A Phase IV, Randomized, Open-label, Parallel-arm, Comparative and Forced- Titration Study to Compare the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Patients With Type 2 DM and Dyslipidemia||Taipei Veterans General Hospital, Taiwan|No|Completed|June 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|90|||Both|20 Years|75 Years|No|||December 2011|December 5, 2011|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00506961||168887|
NCT00514956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSD-ACEP-SMI-MU-1|Effect of Emotional Freedom Technique and Diaphragmatic Breathing on Post Traumatic Stress Disorder (PTSD)|Effect of Emotional Freedom Technique and Diaphragmatic Breathing on PTSD||Soul Medicine Institute|Yes|Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 21, 2009|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514956||168283|
NCT00515216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070433|Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors|Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study||Vanderbilt University|No|Completed|August 2007|November 2013|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 9, 2007|Yes|Yes||No|February 11, 2015|https://clinicaltrials.gov/show/NCT00515216||168263|
NCT00515502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC4108123|Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease|See Detailed Description||GlaxoSmithKline|No|Completed|June 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|24|||Both|40 Years|75 Years|No|||February 2014|March 27, 2014|August 9, 2007||||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00515502||168241|
NCT00515827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5244|Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load|A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2007|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||November 2013|November 19, 2014|August 10, 2007|Yes|Yes||No|January 25, 2011|https://clinicaltrials.gov/show/NCT00515827||168218|
NCT00515840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/014|GPIAG and Leicester Asthma and Dysfunctional Breathing (GLAD) Study: a Randomised Controlled Study|GPIAG and Leicester Asthma and Dysfunctional Breathing (GLAD) Study: a Randomised Controlled Study|GLAD|University of Aberdeen|Yes|Completed|October 2003|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|182|||Both|17 Years|70 Years|No|||November 2015|November 4, 2015|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515840||168217|
NCT00516165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-352|RAD001 in Advanced Hepatocellular Carcinoma|A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma||Massachusetts General Hospital|Yes|Completed|August 2007|November 2011|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2014|March 16, 2014|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516165||168192|
NCT00516516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-06-00233|Oral Carnitine for Cramps in Pregnancy|Oral L-Carnitine for the Treatment of Muscle Cramps in Pregnancy: A Randomized, Controlled Trial||University of Southern California|Yes|Not yet recruiting|August 2007|January 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|16 Years|N/A|No|||August 2007|August 14, 2007|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516516||168165|
NCT00515489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR009214|Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients|Aggressiveness and Agitation of Acute Psychotic Patients: Influence in Safety and Effectiveness of Risperidone Treatment||Janssen-Cilag, S.A.|No|Terminated|November 2001|August 2002|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1882|||Both|18 Years|65 Years|No|Non-Probability Sample|Acute Psychotic symptoms in Schizophrenia; Schizoaffective disorder and Schizophreniform        disorders in patients that required an admission into a hospital and in which physicians        considered the use of risperidone as treatment under clinical practice|March 2011|May 18, 2011|August 10, 2007|||Due to the achievement of minimum required sample size and new changes in local regulations.|No||https://clinicaltrials.gov/show/NCT00515489||168242|
NCT00504088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHT-P-06-003|Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia|Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia|PROOF|FoxHollow Technologies||Terminated|October 2006|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||August 2007|August 19, 2008|July 17, 2007|||Company decision to halt study|No||https://clinicaltrials.gov/show/NCT00504088||169103|
NCT00505271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-104|Safety and Efficacy Study Using Rexin-G for Breast Cancer|Phase I/II Evaluation of Safety and Efficacy of Pathotropic Nanoparticles Bearing a Dominant Negative Cyclin G1 Construct (Rexin-G) as Intervention for Recurrent or Metastatic Breast Cancer||Epeius Biotechnologies|Yes|Completed|July 2007|June 2011|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|July 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505271||169016|
NCT00505284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-227|An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy||Eisai Inc.|No|Completed|June 2007|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|352|||Both|18 Years|N/A|No|||February 2013|June 26, 2014|July 20, 2007|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00505284||169015|
NCT00505895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-518|FM 140 vs FM100 Study in Patients With Multiple Myeloma|A Randomized Phase II Trial of Fludarabine/Melphalan 140 VS. Fludarabine/Melphalan 100 Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation for Patients With Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Completed|January 2002|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|70 Years|No|||October 2014|October 3, 2014|July 20, 2007||No||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00505895||168969|
NCT00506142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS408 (formerly IST401)|Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma|A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma||Spectrum Pharmaceuticals, Inc|Yes|Completed|November 2007|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|July 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506142||168950|
NCT00506415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713D2340|Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline|A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline||Novartis||Completed|June 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1584|||Both|50 Years|85 Years|No|||September 2012|September 17, 2012|July 20, 2007|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00506415||168929|
NCT00506727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLI381-404|Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD|A Randomized, Double-Blind, Parallel-Group, Analog Classroom Study, Evaluating ADDERALL XR Versus STRATTERA, Dosed Once Daily, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD)||Shire||Completed|August 2003|August 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|215|||Both|6 Years|12 Years|No|||November 2007|March 4, 2015|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00506727||168905|
NCT00506987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04887|Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)|Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Idiopathic Cough||Merck Sharp & Dohme Corp.|No|Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506987||168885|
NCT00507299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|778899|A Safe Environment for Every Kid (SEEK) II|A Safe Environment for Every Kid II: Preventing Child Maltreatment - A Role for Pediatrics|SEEK2|University of Maryland|No|Completed|June 2002|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|2004|||Both|1 Month|70 Years|Accepts Healthy Volunteers|||July 2007|July 25, 2007|July 25, 2007||||No||https://clinicaltrials.gov/show/NCT00507299||168861|
NCT00506974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.002|Enhancing Slow Wave Sleep With Sodium Oxybate|Enhancing Slow Wave Sleep With Sodium Oxybate to Reduce the Behavioral and Physiological Impact of Sleep Loss||St. Luke's Hospital, Chesterfield, Missouri|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 25, 2008|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00506974||168886|
NCT00507286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. 2005-166|Efficacy and Safety Study of Combined Oral and Injection Therapy for Erectile Dysfunction|Efficacy and Safety Study of Using Oral Sildenafil and Intracavernosal Alprostadil Injection as a Combined Pharmacotherapy for Men With Difficult to Treat Erectile Dysfunction.||Keogh Institute for Medical Research|Yes|Active, not recruiting|May 2007|December 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Male|20 Years|N/A|No|||July 2007|January 27, 2009|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507286||168862|
NCT00514644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EJ-8404|Stroke and Panorama - Analyzing Carotid Endocalcifications (SPACE)|Stroke and Panorama - Analyzing Carotid Endocalcifications|SPACE|Umeå University|No|Completed|August 2007|February 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|266|||Both|18 Years|90 Years|No|||January 2012|January 9, 2012|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514644||168307|
NCT00517179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2006.017-T|Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS|Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS for the Treatment of Benign Prostatic Hyperplasia||Hospital Authority, Hong Kong||Completed|April 2006|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Male|50 Years|80 Years||||June 2011|June 14, 2011|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517179||168119|
NCT00517192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.71|Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI|A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to That of Prezista® (Darunavir, DRV/r) in Three-class (NRTI, NNRTI, and PI) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients||Boehringer Ingelheim||Terminated|September 2007|||September 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|August 15, 2007||||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00517192||168118|
NCT00514189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0379|Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines|Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines||M.D. Anderson Cancer Center|No|Terminated|July 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||July 2012|July 27, 2012|August 8, 2007|No|Yes|Terminated early due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00514189||168340|
NCT00515281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15405A|Inhaled Nitric Oxide and Neuroprotection in Premature Infants|Inhaled Nitric Oxide and Neuroprotection in Premature Infants|NOVA2|University of Chicago|Yes|Active, not recruiting|May 2008|April 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|484|||Both|N/A|72 Hours|No|||May 2015|May 14, 2015|August 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515281||168258|
NCT00515918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C030104-30671773|The Effect of Early Iron Deficiency on Developmental Brain and Behavior in Infants||IDBB|Zhejiang University|Yes|Not yet recruiting|September 2007|September 2010|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||2|||||Both|N/A|36 Months||||August 2007|August 13, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00515918||168211|
NCT00516243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00858|Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer|Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer||National Cancer Institute (NCI)|No|Completed|July 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|21 Years|65 Years|No|||April 2014|September 11, 2014|August 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00516243||168186|
NCT00512733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9291-26992|Validation of Dietary Calcium Questionnaires Using Diet Records|Validation of Dietary Calcium Questionnaires Using Diet Records||University of California, San Francisco|No|Completed|March 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|160|||Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults|August 2014|August 8, 2014|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512733||168446|
NCT00516854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1617- 01|A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study|A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study||Hospital Authority, Hong Kong||Recruiting|June 2002|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A||||July 2010|July 6, 2010|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00516854||168144|
NCT00504972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608008669|Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies|Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies||Weill Medical College of Cornell University|Yes|Recruiting|June 2007|June 2010|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2011|January 3, 2011|July 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00504972||169037|
NCT00505570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA010E|PRIMA PFO Migraine Trial|Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial)|PRIMA|St. Jude Medical|Yes|Terminated|May 2006|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|107|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|July 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00505570||168993|
NCT00505583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-1110|Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy|A Randomized, Double-Blind, Triple-Dummy, 3-Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Formulation of MOA-728 in Subjects on Stable Methadone Maintenance||Valeant Pharmaceuticals International, Inc.||Withdrawn|July 2007|December 2007|Anticipated|December 2007|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|July 16, 2007||||||https://clinicaltrials.gov/show/NCT00505583||168992|
NCT00506155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0620|Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer|A Phase II Clinical Trial of Neoadjuvant Chemotherapy With M-VAC Plus Avastin in Patients With Locally Advanced Urothelial Cancer||M.D. Anderson Cancer Center|No|Completed|June 2007|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00506155||168949|
NCT00506428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0077|Effects of Chronic Sleep Restriction in Young and Older People|Sleep, Aging, and Circadian Rhythm Disorders||National Institute on Aging (NIA)|No|Recruiting|December 2006|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2009|April 28, 2009|April 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00506428||168928|
NCT00506740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-06-0002|Harmonic™ vs. Electrocautery in Abdominoplasties|A Randomized, Prospective, Parallel Group Study Comparing the Harmonic™ to Electrocautery in Abdominoplasties||Ethicon Endo-Surgery|No|Completed|October 2006|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|1||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00506740||168904|
NCT00507000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT/pr7898/Med/14/1179/2006|Pulmonary Tuberculosis and Vitamin D|Role of Oral Vitamin D as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters. (Double-blind, Randomized, Placebo-Controlled, Clinical Trial)||Indian Council of Medical Research|Yes|Active, not recruiting|May 2008|September 2012|Anticipated|September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|No|||July 2009|January 26, 2011|July 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00507000||168884|
NCT00507312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-03/06|Assessment of Myocardial Disease in Man Using Novel Non-invasive Diagnostic Tools|Assessment of Myocardial Disease in Man Using Novel Non-invasive Diagnostic Tools||Monash University|No|Terminated|October 2007|December 2010|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|July 25, 2007||No|Suspended while we determine if usable data can be collected from this device.|No||https://clinicaltrials.gov/show/NCT00507312||168860|
NCT00507585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0160|Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin|A Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Avastin for Patients With Advanced Solid Tumors Metastatic to the Liver||M.D. Anderson Cancer Center|No|Completed|June 2006|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|N/A|N/A|No|||July 2012|July 26, 2012|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507585||168839|
NCT00507572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0518|Collection of Outcomes Data for Pregnant Patients With Cancer|Collection of Outcomes Data for Pregnant Patients With Cancer||M.D. Anderson Cancer Center|No|Recruiting|December 2005|||December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|500|||Female|N/A|N/A|No|Non-Probability Sample|Study participants that are or were pregnant when diagnosed with cancer.|December 2015|December 21, 2015|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507572||168840|
NCT00507845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMIP_L_01961|Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina|Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina|RAFEHELP|Sanofi||Completed|June 2007|||April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|271|||Both|21 Years|N/A|No|||April 2009|April 16, 2009|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00507845||168820|
NCT00507858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0082|Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer|A Phase I Dose Escalation Study of Pemetrexed in Patients With Advanced Head and Neck Squamous Cell Cancer||M.D. Anderson Cancer Center|No|Completed|September 2005|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00507858||168819|
NCT00516945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE04-0046/FR-2|A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers|A Randomized Controlled Study Comparing the Impact of Prophylactic Versus Deferred Lamivudine on the Delivery of Cytotoxic Chemotherapy in Hepatitis B Surface-antigen Positive Patients With Malignant Solid Tumor||Hospital Authority, Hong Kong||Completed|September 2004|June 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|110|||Both|18 Years|75 Years||||July 2013|September 3, 2013|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00516945||168137|
NCT00516958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OIS-005|Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections|An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections||Oculus Innovative Sciences, Inc.|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|65|||Both|18 Years|N/A|No|||January 2008|January 7, 2008|August 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516958||168136|
NCT00513357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0901|Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients|A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients||M.D. Anderson Cancer Center|Yes|Completed|June 2006|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|August 6, 2007||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00513357||168400|
NCT00513370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W10-151|A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis|A Canadian Open-Label Access Program to Evaluate the Safety and the Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis|PRIDE|Abbott|No|Completed|September 2007|||September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|203|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|August 6, 2007||No||No|August 21, 2009|https://clinicaltrials.gov/show/NCT00513370||168399|
NCT00513890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 7873|Interest of Non Invasive Ventilation Versus Oxygen During the Intial Managment of Infant With Bronchiolitis|Interest of Non Invasive Ventilation Versus Oxygen During the Intial Managment of Infant With Bronchiolitis Who Didn't Require Mechanical Ventilation||University Hospital, Montpellier|Yes|Completed|October 2006|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|N/A|6 Months|No|||April 2012|October 23, 2013|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513890||168361|
NCT00516256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0254|CHESS: Human and Computer Mentors for Prostate Cancer Patients|CHESS: Human and Computer Mentors for Prostate Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2007|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|654|||Male|18 Years|N/A|No|||September 2015|September 30, 2015|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516256||168185|
NCT00515580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYEEI IRB 07.20|Minimally Invasive Tongue Suture For Obstructive Sleep Apnea|Minimally Invasive Genioglossus And Hyoid Advancement For Obstructive Sleep Apnea Using Silhouette Sutures: A Pilot Study||West Side ENT|No|Terminated|August 2007|August 2009|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||December 2012|December 18, 2012|August 12, 2007||No|Results from first few subjects was not significantly improved over standard, traditional    procedures.|No||https://clinicaltrials.gov/show/NCT00515580||168236|
NCT00516178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FN-3200BO-102064|Intravenous Fish Oil in Critically Ill Cardiac Patients|Effects of Intravenous n-3 Polyunsaturated Fatty Acid Administration in Critically Ill Cardiac Surgery and Myocardial Infarction Patients|FO-cardiac|Centre Hospitalier Universitaire Vaudois|No|Completed|January 2008|April 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|31|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516178||168191|
NCT00516191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-2408|A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma|A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma|DMV|University of California, San Francisco|Yes|Withdrawn|October 2004|December 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|August 13, 2007||No|low accrual|No||https://clinicaltrials.gov/show/NCT00516191||168190|
NCT00513331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHS07.0017|Barrett's Esophagus & Gastroesophageal Reflux Disease|The Valley Hospital Center for Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD)||Valley Health System|No|Completed|July 2007|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Observational|Time Perspective: Prospective||3|Actual|125|Samples With DNA|Tissue and blood for future analysis|Both|18 Years|N/A|No|Probability Sample|Referred Patients with underlying disease of BE or GERD|December 2013|December 31, 2013|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00513331||168402|
NCT00512993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 36|Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy|A Randomized, Multicenter, Open Phase III Study Comparing the Postoperative Use of Zoledronic Acid Versus no Treatment in Patients With Histological Tumor Residuals After Preoperative Anthracycline and Taxane Containing Chemotherapy for Primary Breast Cancer|NATAN|German Breast Group|Yes|Completed|December 2004|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|654|||Female|18 Years|N/A|No|||March 2015|March 4, 2015|August 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00512993||168426|
NCT00505297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001140|A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography|A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography||University of California, San Francisco|Yes|Completed|August 2004|July 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||2|Actual|18|||Female|40 Years|N/A|Accepts Healthy Volunteers|||October 2006|July 20, 2007|July 20, 2007||||No||https://clinicaltrials.gov/show/NCT00505297||169014|
NCT00505596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD049686|Expanded Prenatal Testing Options and Informed Choice|Expanded Prenatal Testing Options and Informed Choice|EPIC|University of California, San Francisco|No|Completed|December 2007|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|744|||Female|18 Years|50 Years|No|||October 2014|October 17, 2014|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505596||168991|
NCT00503152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARIETY|Preventing Microalbuminuria in Type 2 Diabetes|A Prospective, Randomized, Probe Trial to Evaluate Whether, at Comparable Blood Pressure Control, Combined Therapy With the ACEI Benazepril and the ARB Valsartan, Reduces the Incidence of Microalbuminuria More Effectively Than BEN or VAL Alone in Hypertensive Patients With Type 2 Diabetes and High-normal Albuminuria|VARIETY|Mario Negri Institute for Pharmacological Research|No|Active, not recruiting|May 2007|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|613|||Both|40 Years|80 Years|No|||March 2016|March 15, 2016|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503152||169174|
NCT00503165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StaMen|A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix|A Phase IV, Single Group Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of a Licensed Hib and Meningococcal C Conjugate Combined Vaccine (Menitorix)||Public Health England|No|Completed|July 2007|August 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|April 30, 2008|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503165||169173|
NCT00499044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC #18-2007|A Comparison of Two Cognitive Batteries in People With Schizophrenia|CDR Versus MATRICS Cognitive Batteries in Patients With Schizophrenia||North Suffolk Mental Health Association|No|Completed|December 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|65 Years|No|||November 2009|November 25, 2009|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00499044||169484|
NCT00499291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000554709|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors|Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors||Eastern Cooperative Oncology Group||Withdrawn|September 2006|||October 2007|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|120 Years|No|||October 2015|October 6, 2015|July 10, 2007||||No||https://clinicaltrials.gov/show/NCT00499291||169466|
NCT00499850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00037|Phase I FOLFOX Combination|A Phase I,Open Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as First and Second Line Therapy in Patients With Advanced Colorectal Adenocarcinoma.||AstraZeneca||Completed|August 2005|April 2008|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2009|April 3, 2009|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499850||169425|
NCT00499863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-409|Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD|A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)||Noven Therapeutics|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Both|13 Years|17 Years|No|||June 2015|June 23, 2015|July 10, 2007|Yes|Yes||No|April 24, 2009|https://clinicaltrials.gov/show/NCT00499863||169424|
NCT00507871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0033|Transmission and the Respiratory Tract in Cryptosporidiosis|Prevalence and Clinical Presentation of Respiratory Cryptosporidiosis Among Children With Diarrhea in Mulago Hospital, Uganda||Tufts University||Completed|October 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1||480|||Both|9 Months|36 Months|No|Non-Probability Sample|Children attending the Acute Care Unit at Mulago Hospital, Kampala, Uganda|September 2007|December 2, 2009|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00507871||168818|
NCT00503529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|690701|TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)|Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223)||Pfizer|Yes|Completed|July 2007|September 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|314|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503529||169146|
NCT00503542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03HS016050-01|Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network|Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network|VCAT|Agency for Healthcare Research and Quality (AHRQ)|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||September 2007|January 7, 2014|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503542||169145|
NCT00503555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO3 HS 16023-01|Creation of a PBRN to Study Healthcare Delivery to a Transitioning Community|Creation of a PBRN to Study Healthcare Delivery to a Transitioning Community||Agency for Healthcare Research and Quality (AHRQ)||Recruiting|June 2006|October 2006|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A|No|||October 2006|August 29, 2007|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503555||169144|
NCT00513630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD002|Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease|Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease|SPREADDIMCAD|Shanghai Jiao Tong University School of Medicine|Yes|Completed|June 2004|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|304|||Both|N/A|80 Years|No|||December 2010|April 25, 2011|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513630||168379|
NCT00514423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GL0509|How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs|How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs||Technische Universität München||Completed|September 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|896|||Both|18 Years|67 Years|No|||August 2014|August 28, 2014|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00514423||168323|
NCT00514709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL204|Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants|Immunogenicity Study of the Antibody Persistence and Booster Effect of DTaP-Hep B-PRP-T Combined Vaccine at 12 to 18 Months of Age Following a Primary Series at 6, 10 and 14 Weeks of Age in Healthy Filipino Infants Having Received Hepatitis B Vaccine at Birth||Sanofi|Yes|Completed|September 2007|April 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1843|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||November 2013|November 18, 2013|August 9, 2007||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT00514709||168302|
NCT00515853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM GSU 0132|The Role of Biofeedback in Improving Continence After Anterior Resection|||University of Southampton|Yes|Recruiting|November 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2|||110|||Both|18 Years|N/A|No|||June 2008|June 3, 2008|August 10, 2007||||No||https://clinicaltrials.gov/show/NCT00515853||168216|
NCT00515866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU36-29|Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer|A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 in Combination With Gemcitabine in the Treatment of Patients With Advanced Solid Tumours||AstraZeneca|No|Completed|August 2007|July 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515866||168215|
NCT00517153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGT-918-007|Miglustat in Niemann-Pick Type C Disease|A Phase II Randomized Controlled Study of Miglustat in Adult and Juvenile Patients With Niemann-Pick Type C Disease||Actelion|No|Completed|January 2002|January 2008|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|4 Years|N/A|No|||March 2010|March 24, 2010|August 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517153||168121|
NCT00524485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 28204|Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis|A Pilot Study to Investigate the Use of Topical Levulan® With Vbeam® Laser for the Treatment of Actinic Keratoses||Roswell Park Cancer Institute|Yes|Terminated|May 2005|May 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|August 31, 2007||No|Withdrawn due to low accrual|No||https://clinicaltrials.gov/show/NCT00524485||167563|
NCT00524784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLX-APO-101IL-HMO-CTIL|Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD|Phase 1/2a, Multicenter, Open-Label Study Designed to Evaluate the Safety, Tolerability and Preliminary Efficacy of ApoCell Administration, a Donor Apoptotic Cell-Based Product, for the Prevention of Acute Graft Versus Host Disease (GvHD) in Subjects With Hematologic Malignancies Undergoing Allogeneic Sibling HLA-Matched Hematopoietic Stem Cell Transplantation (HSCT)||Hadassah Medical Organization|Yes|Active, not recruiting|June 2009|April 2016|Anticipated|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Both|18 Years|60 Years|No|||June 2009|June 10, 2015|September 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00524784||167541|
NCT00513591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000756|Duke Autoimmunity in Pregnancy Registry|Duke Autoimmunity in Pregnancy Registry|DAP Registry|Duke University|No|Recruiting|August 2007|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples With DNA|Blood samples will be collected and stored for future analysis.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with autoimmune disease.|August 2015|October 11, 2015|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00513591||168382|
NCT00513604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070176|Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma|A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)|Yes|Completed|June 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|158|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|August 6, 2007|No|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00513604||168381|
NCT00505310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-168|Biobehavioral Effects of Emotional Expression in Cancer|Biobehavioral Effects of Emotional Expression in Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2002|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|710|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00505310||169013|
NCT00502619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27101|Assessment of Acupuncture to Improve Function, Exercise Capacity, and Pain|Pilot Study to Determine the Efficacy and Feasibility of a Structured Acupuncture and Treadmill Program to Treat Chronic Low Back Pain Patients to Improve Function, Exercise Capacity, and Pain Control.||VA Maryland Health Care System|Yes|Terminated|September 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||July 2011|August 2, 2011|July 16, 2007||No|Inadequate recruitment of study subjects and inadequate retention.|No||https://clinicaltrials.gov/show/NCT00502619||169215|
NCT00503178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/098|Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)|Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)||University Hospital, Ghent|No|Recruiting|April 2006|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||December 2014|December 4, 2014|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503178||169172|
NCT00503191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRI001-01|NeuroModulation Technique Treatment of Autism|Intention-based Therapy for Autism Spectrum Disorder: Promising Results of a Wait-List Control Study in Children|NMT|NeuroModulation Technique Research Institute||Completed|July 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|5 Years|10 Years|No|||January 2014|January 19, 2014|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00503191||169171|
NCT00499057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRT-HDR|Partial Breast Irradiation With Interstitial High Dose Rate Brachytherapy|Interstitial High Dose-Rate Brachytherapy for Partial Breast Irradiation in Early Breast Cancer: Results of Phase II Prospective Study||University Of Perugia|No|Recruiting|August 2003|August 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|40 Years|85 Years|No|||June 2010|December 19, 2014|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00499057||169483|
NCT00499304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL13873.09406|Forced Oscillation Technique (FOT) and Expiratory Flow Limitation (EFL)|Diagnosing Expiratory Flow Limitation in COPD Patients With the Forced Oscillation Technique Using Linear Regression in the Time Frequency Domain||Medical Center Alkmaar|No|Completed|November 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Stable GOLD 2-4 COPD patients|June 2008|June 5, 2008|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499304||169465|
NCT00499538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1109|Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects|A Single Dose Bioavailability Study of 3 New Formulations of SKI-606 (500 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2007|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 18, 2007|July 9, 2007||||No||https://clinicaltrials.gov/show/NCT00499538||169447|
NCT00499551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iontophoresis001|A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis|A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device||Asociación para Evitar la Ceguera en México|Yes|Withdrawn|September 2007|September 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|15 Years|90 Years|No|||July 2008|July 8, 2008|July 9, 2007|||The drug needed for the study is not available in Mexico anymore.|No||https://clinicaltrials.gov/show/NCT00499551||169446|
NCT00499512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0283|Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer|Evaluation of the Role of Spirituality in Coping With and Surviving Ovarian, Primary Peritoneal or Fallopian Tube Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2005|||August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|115|||Female|N/A|N/A|No|Non-Probability Sample|Patients with newly diagnosed ovarian, primary peritoneal or fallopian tube cancer.|March 2015|March 27, 2015|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499512||169449|
NCT00499525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07B1|Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer|A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer||Northwestern University|Yes|Active, not recruiting|June 2007|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|120 Years|No|||September 2015|September 24, 2015|July 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00499525||169448|
NCT00499824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDI Project 4/2006|GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets|GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets|GIANT|International Diabetes Institute, Australia|No|Completed|January 2007|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|386|||Both|30 Years|75 Years|No|||May 2010|May 3, 2010|July 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00499824||169427|
NCT00499837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamada-AAT (inhaled)-003|Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients|Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients||Kamada, Ltd.|No|Completed|September 2007|July 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|21|||Both|5 Years|N/A|No|||December 2009|December 30, 2009|July 11, 2007||||No||https://clinicaltrials.gov/show/NCT00499837||169426|
NCT00500097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0321/1874|Diabetic Retinopathy and Diabetic Macular Edema Screening by Non-Physicians With Limited Training|||Ministry of Health, Thailand|Yes|Completed|May 2005|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|||Actual|840|||Both|15 Years|80 Years|No|||July 2007|July 27, 2007|July 11, 2007||||No||https://clinicaltrials.gov/show/NCT00500097||169406|
NCT00500110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0112|Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer|Neoadjuvant Hormonal Ablation, Imatinib Mesylate and Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|June 2003|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Male|N/A|N/A|No|||August 2012|April 6, 2015|July 10, 2007||No||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00500110||169405|
NCT00514436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES 08711|Case Management and Environmental Control in Asthma|||Washington University School of Medicine|No|Completed|January 1997|January 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|189|||Both|2 Years|8 Years|No|||December 2015|December 8, 2015|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00514436||168322|
NCT00522548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A-US49|Study of Gastrointestinal Side Effects in African American Kidney Transplant Recipients Treated With CellCept or Myfortic|A Phase IV Randomized, Open Label, Comparative, Single Center Study to Assess Gastrointestinal Adverse Effect Outcomes of De Novo African American Kidney Transplant Recipients Treated With Prograf (Tacrolimus) or Its Generic Equivalent/CellCept (Mycophenolate Mofetil) or Its Generic Equivalent/Corticosteroids Versus Prograf (Tacrolimus) or Its Generic Equivalent/Myfortic (Enteric Coated Mycophenolate Sodium)/Corticosteroids||University of Pennsylvania|No|Terminated|March 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|75 Years|No|||February 2011|February 18, 2011|August 27, 2007|Yes|Yes|enrollment halted in order to have all patients complete follow-up by Jan 2011|No||https://clinicaltrials.gov/show/NCT00522548||167711|
NCT00515008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003621|Tai Chi Mind-Body Therapy for Fibromyalgia|Tai Chi Mind-Body Therapy for Fibromyalgia: a Pilot Single-Blind Randomized Controlled Trial.||Tufts Medical Center|Yes|Completed|June 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|21 Years|N/A|No|||February 2016|February 9, 2016|August 9, 2007||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00515008||168279|
NCT00515021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070183|Diurnal Variation of Plasminogen Activator Inhibitor-1|The Effects of Night-Time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1||Vanderbilt University|No|Active, not recruiting|April 2007|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|65 Years|No|||January 2009|January 27, 2009|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00515021||168278|
NCT00514969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML003|Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase|Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase. A Phase II Study|CML003|University of Bologna||Completed|August 2000|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||July 2007|August 9, 2007|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00514969||168282|
NCT00516880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW05-236T/899|Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?|Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?||Hospital Authority, Hong Kong||Recruiting|March 2006|November 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|20 Years|75 Years||||July 2010|July 6, 2010|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00516880||168142|
NCT00523887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013990|Fentanyl for Treatment Pain Caused by Radiotherapy|Post-Marketing Surveillance of Durogesic for Treatment Pain Caused by Radiotherapy||Johnson & Johnson Taiwan Ltd||Completed|August 2005|September 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|19 Years|N/A|No|||April 2010|April 26, 2010|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523887||167608|
NCT00523900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000428|Effectiveness of Quaker Complete Nutrition Supplements for Malnourished Adults|Effectiveness of Quaker Complete Nutrition Supplements for Malnourished Adults||Johns Hopkins Bloomberg School of Public Health|No|Completed|August 2007|December 2008|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||August 2007|October 19, 2009|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00523900||167607|
NCT00502879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-1109|Study Evaluating Etanercept 25mg or 50mg Administered Subcutaneously to Healthy Chinese Male Subjects|A Randomized, Open-Label, Single-Dose Administration, Parallel-Group Study of the Pharmacokinetics of Etanercept, 25mg or 50 mg, Administered Subcutaneously to Healthy Chinese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|July 2007|August 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 4, 2007|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502879||169195|
NCT00502892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0079|Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors|A Phase I Study of a Novel Chemotherapeutic Regimen: Topotecan, Ifosfamide and Carboplatin (TIC) in Children and Young Adults With Solid Tumors-- A Limited Multi-Institution Study||M.D. Anderson Cancer Center|No|Completed|August 2004|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|45 Years|No|||July 2012|July 31, 2012|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502892||169194|
NCT00503217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-JB-0205-307-9|GnRH Agonist and Intrauterine Insemination|Effect of GnRH Agonist Administration at the Time of Implantation in Intrauterine Insemination Cycles: A Randomized Controlled Trial||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|2||||||Female|18 Years|38 Years|Accepts Healthy Volunteers|||October 2009|October 2, 2009|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503217||169169|
NCT00499577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000552988|Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma|Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells||National Cancer Institute (NCI)||Completed|December 2006|||February 2009|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|4||Anticipated|56|||Both|18 Years|80 Years|No|||August 2009|January 9, 2014|July 10, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00499577||169445|
NCT00499070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000553058|Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment|TCR Vbeta Repertoire and PNH Clones in Children With Refractory Cytopenia (RC). An Open Nonrandomised Multi-Center Prospective Study||University Hospital Freiburg|No|Completed|January 2007|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|119|Samples With DNA|Bone Marrow Peripheral blood cells|Both|N/A|17 Years|No|Non-Probability Sample|All patients with MDS|January 2015|January 15, 2015|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499070||169482|
NCT00522561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701039|Lower Limb Mechanical Characteristics: Effect on Running Mechanics and Energetics|Lower Limb Mechanical Characteristics: Effect on Running Mechanics and Energetics||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|January 2008|March 2008|Actual|February 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||June 2009|June 9, 2009|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522561||167710|
NCT00516360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T32AI007464|Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants|Chlorhexidine and the Prevention of Central Catheter Related Infections in Neonates||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|July 2007|August 2008|Anticipated|August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|6 Months|No|||August 2007|May 28, 2008|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00516360||168177|
NCT00516334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000088|Study of Bedside EEG to Evaluate Brain Injury in Premature Newborns|Advanced Electrophysiological Studies of the Premature Newborn Infant Brain: Understanding Brain Injury|BrainZ|Brigham and Women's Hospital|No|Active, not recruiting|May 2006|May 2013|Anticipated|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|36 Months|No|Non-Probability Sample|Infants <29 weeks gestational age|July 2012|July 26, 2012|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00516334||168179|
NCT00516347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-HCRC-MREC-02/2/57|Studying Genes for Barrett's Esophagus in Brothers and Sisters|A Sibling Pair Study To Identify Barrett's Oesophagus Susceptibility Genes||National Cancer Institute (NCI)||Recruiting|June 2002|||||N/A|Observational|N/A|||Anticipated|400|||Both|N/A|N/A|No|||October 2007|August 9, 2013|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516347||168178|
NCT00545779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20430|BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.|'An Open-label Study of Patient Preference With Monthly Bonviva Therapy in Women With Post-menopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate.'||Hoffmann-La Roche||Completed|December 2006|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|655|||Female|N/A|N/A|No|||January 2014|January 20, 2014|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545779||165952|
NCT00550199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 120|LBH589 and Gemcitabine in the Treatment of Solid Tumors|A Phase I Study of LBH589 in Combination With Gemcitabine in the Treatment of Solid Tumors||SCRI Development Innovations, LLC|No|Terminated|November 2007|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|October 26, 2007|No|Yes|Study terminated due to LBH589 toxicity.|No||https://clinicaltrials.gov/show/NCT00550199||165623|
NCT00545805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0001|Surgical Removal of Visceral Fat Tissue (Omentectomy) Associated to Bariatric Surgery: Effects on Insulin Sensitivity|Effects of the Surgical Removal of Visceral Fat Tissue (Omentectomy) on Insulin Sensitivity in Grade III Obese Volunteers Subjected to Bariatric Surgery||University of Campinas, Brazil|No|Completed|October 2005|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|50 Years|No|||February 2013|February 17, 2013|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545805||165950|
NCT00546052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-331|A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)|52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome||Merck Sharp & Dohme Corp.||Completed|September 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1738|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|October 17, 2007|No|Yes||No|January 8, 2009|https://clinicaltrials.gov/show/NCT00546052||165931|
NCT00546039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2BV10|Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer|Effects of Synthetic Genistein Supplementation on Blood and Tissue Biomarkers in Patients With Localized Prostate Cancer||University Hospital, Aker|Yes|Active, not recruiting|April 2007|January 2009|Anticipated|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|47|||Male|18 Years|N/A|No|||September 2008|September 29, 2008|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546039||165932|
NCT00546312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G990299|Clinical Study of Thoracic Excluder Endoprosthesis to Treat Descending Thoracic Aortic Diseases|A Clinical Study Evaluating Use of the Thoracic EXCLUDER Endoprosthesis in the Treatment of Descending Thoracic Aortic Diseases|Gore Thoracic|Arizona Heart Institute|No|Active, not recruiting|February 2000|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|332|||Both|18 Years|N/A|No|||May 2009|May 25, 2010|October 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546312||165911|
NCT00546975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.33.CLI|Effect of Oral Nutritional Supplements With Specialized Nutrients on Functional Recovery and Morbidity After Gastrointestinal Surgery|||Charite University, Berlin, Germany|Yes|Terminated|October 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||||||Both|50 Years|80 Years|No|||October 2007|June 24, 2011|October 18, 2007||No|Compliance unacceptably low.|No||https://clinicaltrials.gov/show/NCT00546975||165862|
NCT00547287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7925|Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations|Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Multinational Assessment of Treatment Preference||Eli Lilly and Company|No|Completed|November 2002|May 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2760|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547287||165840|
NCT00548561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT01|Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines|A Clinical Trial on TopotectTM (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents||Onxeo|No|Completed|June 2001|July 2003|Actual|July 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|N/A|No|||November 2013|October 20, 2015|October 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00548561||165746|
NCT00515229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APA-II|Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo|Protocol for a Phase II-Study Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo - Randomised, Double-Blinded, Placebo-Controlled, Cross Over - Study -||University Hospital Tuebingen|Yes|Completed|October 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|50 Years|No|||August 2007|August 10, 2007|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00515229||168262|
NCT00515242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002560|Therapeutic Massage for Generalized Anxiety Disorder|Therapeutic Massage for Generalized Anxiety Disorder|CALM|Group Health Cooperative|Yes|Completed|September 2007|August 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|70 Years|No|||March 2014|March 20, 2014|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00515242||168261|
NCT00515255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPL-2003-1-POCD-001|Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)|Open-Label Exploratory Investigation Of NPL-2003 In Adolescents With Obsessive Compulsive Disorder||Neuropharm||Terminated|July 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|12 Years|17 Years|No|||April 2012|April 26, 2012|August 10, 2007|Yes|Yes|Recruitment Goal of 20 Not Met|No||https://clinicaltrials.gov/show/NCT00515255||168260|
NCT00525109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010535|Elevated Serum HDL in Four Generations of a Nashville Family|Elevated Serum HDL in Four Generations of a Nashville Family||Vanderbilt University|No|Terminated|June 2004|June 2009|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|26|Samples With DNA|Plasma, Serum, DNA|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Family|January 2009|January 27, 2009|September 4, 2007||No|Unable to complete enrollment due lack of family interest.|No||https://clinicaltrials.gov/show/NCT00525109||167517|
NCT00525408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-60/1260|A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer|Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.|HRPC|Cadila Pharnmaceuticals|Yes|Terminated|November 2007|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Male|18 Years|N/A|No|||March 2012|March 9, 2012|September 1, 2007|Yes|Yes|Interim Analysis report indicates trial futility|No||https://clinicaltrials.gov/show/NCT00525408||167494|
NCT00525668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006323-39|Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)|Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)|SuniMS|Charite University, Berlin, Germany|Yes|Completed|September 2007|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|60 Years|No|||January 2016|January 20, 2016|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525668||167474|
NCT00526279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-ATA-2007/2|COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus|A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension|COMBAT|AstraZeneca|No|Completed|June 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9000|||Both|18 Years|N/A|No|Probability Sample|Primary Care|November 2010|November 30, 2010|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00526279||167428|
NCT00526292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-035|Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant|Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant||Memorial Sloan Kettering Cancer Center||Completed|August 2007|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|120 Years|No|||January 2016|January 14, 2016|September 5, 2007|Yes|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT00526292||167427|
NCT00526578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-139|Pancreatic Cancer Genetic Epidemiology (PACGENE) Study|Pancreatic Cancer Genetic Epidemiology (PACGENE) Study||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2002|||June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|4770|Samples With DNA|Blood sample will be collected.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MDACC pancreatic cancer patients and family members (two or more) of someone with        pancreatic cancer, all over over the age of 18.|June 2015|June 3, 2015|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526578||167406|
NCT00526591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE21806|Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer|Randomized Phase II Study of Two Different Doses of RAD-001 (Everolimus) as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer||Case Comprehensive Cancer Center|Yes|Active, not recruiting|September 2007|||July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|N/A|No|||June 2012|June 14, 2012|September 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526591||167405|
NCT00522574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL019-001|A Safety Study of XL019 in Adults With Myelofibrosis|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Myelofibrosis||Exelixis|Yes|Terminated|August 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2011|April 4, 2011|August 27, 2007|No|Yes|Due to emerging safety data|No||https://clinicaltrials.gov/show/NCT00522574||167709|
NCT00522587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/242|Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance|Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance||University Hospital, Ghent|No|Completed|April 2008|December 2011|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|40|||Both|18 Years|60 Years|No|||January 2013|January 29, 2013|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00522587||167708|
NCT00516672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109693|Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors.|A Phase I, Open-Label, Multiple Dose of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors.||GlaxoSmithKline|No|Completed|September 2007|October 2015|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|20 Years|N/A|No|||March 2016|March 21, 2016|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00516672||168155|
NCT00516646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0527|The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure|A Double-blind, Placebo-controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure|BENEFICIAL|Synvista Therapeutics, Inc|No|Completed|August 2007|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||April 2009|January 12, 2010|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516646||168157|
NCT00550212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1108|Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects|An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects||Puma Biotechnology, Inc.|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|October 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00550212||165622|
NCT00545532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV20234|A Study of Tamiflu (Oseltamivir) for Treatment of Influenza in Immunocompromised Patients.|A Double-blind, Randomized, Stratified Multi-center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza||Hoffmann-La Roche||Recruiting|February 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|195|||Both|1 Year|N/A|No|||March 2016|March 1, 2016|October 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00545532||165971|
NCT00546065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00088|APE-Study: Ablation of Barrett's Mucosa vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs. Placebo for Symptomatic Reflux Control After Successful Barrett's Ablation|APE-Study: Tumor-free Survival After Ablation of Barrett's Mucosa Plus Esomeprazole vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs Placebo for Symptomatic Reflux Control After Successful Ablation of Barrett's Mucosa|APE|HSK Wiesbaden|Yes|Terminated|August 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|68|||Both|18 Years|N/A|No|||November 2011|November 25, 2011|October 16, 2007||No|Intermediate results have shown a significant difference in the outcome of ablation and    non-ablation patients. Therefore, the study was stopped.|No||https://clinicaltrials.gov/show/NCT00546065||165930|
NCT00546325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIMON_L_01661|REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents|REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents|REASSURE|Sanofi||Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|358|||Both|18 Years|75 Years|No|||December 2010|December 9, 2010|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546325||165910|
NCT00546351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0746|Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.|A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.||UCB Pharma|No|Completed|May 2004|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|621|||Both|18 Years|N/A|No|||March 2012|September 19, 2014|October 16, 2007|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00546351||165909|
NCT00546650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP101-005|Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®|A Phase I, Single Center, Open Label, Randomized, Single-Dose, Five-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® in Healthy Volunteers||Teva Pharmaceutical Industries|No|Completed|November 2007|March 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00546650||165887|
NCT00546949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSSL-16279|Treatment of Lumbar Spinal Stenosis; Comparison of Two Different Surgical Methods; Mini-invasive Decompression to X-stop|Treatment of Lumbar Spinal Stenosis; Comparison of Two Different Surgical Methods; Mini-Invasive Decompression to X-Stop (LSSS)|LSSS|Norwegian University of Science and Technology|Yes|Terminated|March 2007|December 2013|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|50 Years|85 Years|No|||February 2016|February 24, 2016|October 18, 2007||No|analysis at 50% inclusion showed 4 times larger reoperation rate in X-stop group|No||https://clinicaltrials.gov/show/NCT00546949||165864|
NCT00548249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMTI-SFP-2|Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis|A Dose Ranging Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) Versus Control in Subjects With ESRD Receiving Chronic Hemodialysis.||Rockwell Medical Technologies, Inc.|Yes|Completed|August 2007|January 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|131|||Both|18 Years|N/A|No|||February 2011|February 7, 2011|October 19, 2007|Yes|Yes||No|November 10, 2010|https://clinicaltrials.gov/show/NCT00548249||165770|AE tabulation best summarizes the primary safety outcome.Lack of accuracy in analytical method for measuring iron concentration in inflow and outflow from dialysis machine impaired ability to assess secondary outcome of amount SFP transferred.
NCT00548262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851015|This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis|Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients||Pfizer|No|Completed|February 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||December 2010|December 15, 2010|October 19, 2007|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00548262||165769|Protocol registration indicated timeframes for EIVT and/or Week 2 F/U for time to event, mortality, vital signs, and labs; however, analyses were continuous and reported from baseline to EIVT (up to Day 42), Week 2 F/U, or Week 6 telephone F/U visit.
NCT00548275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJF57412|Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence|Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence|Project RED|Yale University|No|Completed|July 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||July 2014|July 8, 2014|October 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00548275||165768|
NCT00525083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050806|Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C|Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C||Vanderbilt University|No|Terminated|June 2005|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|Samples With DNA|Plasma, HDL preps, genomic DNA|Both|18 Years|N/A|No|Non-Probability Sample|Patients with HDL above 100 mg/dl and with personal or family history of early        atherosclerosis|June 2015|June 1, 2015|September 4, 2007||No|PI left for another institution|No||https://clinicaltrials.gov/show/NCT00525083||167519|
NCT00525694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC27009|Zero Calorie Drink Products|Determination of Clinically Significant Carbohydrates Added to Zero Calorie Drink Products|GGT|Christiana Care Health Services|No|Completed|February 2007|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 24, 2011|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00525694||167472|
NCT00525707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-051-306|Tezosentan in Acute Heart Failure|Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.|VERITAS 1|Actelion|Yes|Completed|April 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|735|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|August 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00525707||167471|
NCT00525954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-CVD2222|PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease|Phospholipase Levels And Serological Markers of Atherosclerosis 2: An Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease|PLASMA 2|Anthera Pharmaceuticals||Completed|September 2007|December 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|120|||Both|18 Years|N/A|No|||January 2008|January 3, 2008|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00525954||167452|
NCT00525967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217/2005|Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain|Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain: A Randomized, Double-Blind Study||Faculdade de Medicina do ABC|No|Recruiting|February 2006|October 2007|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2007|September 5, 2007|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00525967||167451|
NCT00525681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIMONA-PILOT|Interaction Between Rimonabant and Cyclosporine and Tacrolimus|The Effect of Rimonabant Treatment on Cardiovascular Risk Factors in Renal Transplant Recipients -- Pilot Safety Study|RIMONA-PILOT|University of Oslo School of Pharmacy|No|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00525681||167473|
NCT00525915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0703|Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma|An Oxaliplatin-Based Phase II Randomized Study of Induction Chemotherapy Followed by Preoperative Chemoradiotherapy or Preoperative Chemoradiotherapy in Patients With Resectable Esophageal or Gastroesophageal Carcinoma||M.D. Anderson Cancer Center|Yes|Completed|April 2005|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|76 Years|No|||January 2015|January 27, 2015|September 4, 2007|Yes|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT00525915||167455|
NCT00526305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-Ph-2000|LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive|LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive||PETHEMA Foundation|Yes|Completed|January 2000|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|65 Years|No|||January 2010|January 3, 2010|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526305||167426|
NCT00526565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT003928-01A1|Randomized Trial of Tapas Acupressure for Weight Loss Maintenance|Randomized Trial of Tapas Acupressure for Weight Loss Maintenance|LIFE|Kaiser Permanente|Yes|Completed|January 2008|February 2011|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|472|||Both|30 Years|85 Years|No|||October 2011|October 4, 2011|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526565||167407|
NCT00522847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/263/07/L|Biochemical Factors for a Dry Eyed Population|Biochemical Factors for a Dry Eyed Population|GARNET|University of Waterloo|No|Completed|May 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|Tears|Female|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|community sample|February 2009|February 12, 2009|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522847||167688|
NCT00517049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APM4083g|A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)|A Phase II, Single-Arm, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of Multiple Doses of PRO95780 Administered Intravenously in Combination With Rituximab in Patients With Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy||Genentech, Inc.||Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||June 2010|June 18, 2010|August 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517049||168129|
NCT00545818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-SHO-0001|Study Comparing OsseoSpeed™ Implants of Two Different Lengths in the Upper and Lower Posterior Jaw|An Open, Prospective, Randomized, Multi-center Study Comparing OsseoSpeed™ Implant 6 mm With OsseoSpeed™ Implant 11 mm in the Posterior Maxilla and Mandible. A 5-year Follow-up Study.||Dentsply Implants|No|Active, not recruiting|November 2007|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|20 Years|70 Years|No|||March 2016|March 23, 2016|October 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00545818||165949|
NCT00546988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSMM V|Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years|Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III||University of Wuerzburg|No|Recruiting|October 2001|January 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|60 Years|No|||October 2007|October 17, 2007|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00546988||165861|
NCT00546364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-131|Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer|IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or Capecitabine Plus Docetaxel in the Treatment of Metastatic Breast Cancer|IXTEND|R-Pharm|No|Terminated|February 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|October 17, 2007|Yes|Yes|Slow Accrual|No|May 6, 2011|https://clinicaltrials.gov/show/NCT00546364||165908|
NCT00546663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS001|Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis|A Pilot Study to Evaluate the Tolerability of Inhaled 7% Hypertonic Saline in Infants With Cystic Fibrosis|ISIS Pilot|CF Therapeutics Development Network Coordinating Center|Yes|Completed|September 2007|July 2008|Actual|May 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|12 Months|30 Months|No|||August 2011|August 22, 2011|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546663||165886|
NCT00548314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.109|Dermal Substitute and Topical Negative Pressure in Burns|Application of a Dermal Substitute and Topical Negative Pressure to Improve the Healing of Burn Wounds|VAC-M|Association of Dutch Burn Centres|Yes|Completed|October 2007|February 2011|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548314||165765|
NCT00547651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR PH GL 2007 CL001|AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy|AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy||Celgene|Yes|Completed|September 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|637|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|October 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547651||165814|
NCT00547664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPC200710|Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients|||HPC Healthcare, Inc.|Yes|Completed|January 2008|October 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547664||165813|
NCT00524810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPYTTOLE|Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer|A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer||ARCAGY/ GINECO GROUP|No|Completed|February 2004|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Female|18 Years|N/A|No|||June 2011|June 29, 2011|September 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00524810||167539|
NCT00524823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 7-251 S|Early Detection of Prostate Cancer by FACS||FACS|Ziv Hospital|Yes|Recruiting|August 2007|||||Phase 4|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||4|Anticipated|40|||Male|60 Years|90 Years|Accepts Healthy Volunteers|||August 2007|September 4, 2007|September 3, 2007||||No||https://clinicaltrials.gov/show/NCT00524823||167538|
NCT00525720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0038|Brachytherapy for Prostatic Carcinoma Patients|Transperineal Interstitial Permanent Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2006|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Male|18 Years|N/A|No|||March 2016|March 22, 2016|September 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00525720||167470|
NCT00525980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0339|Cancer Genetics CD-ROM for Hispanics|Interactive CD-ROM on Cancer Genetics for Hispanics||M.D. Anderson Cancer Center|Yes|Completed|February 2007|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|37|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 8, 2013|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525980||167450|
NCT00526318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPOH-NB2004-HR|Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma|Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR)||National Cancer Institute (NCI)||Recruiting|January 2007|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|360|||Both|N/A|21 Years|No|||July 2015|July 15, 2015|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526318||167425|
NCT00526604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Work and LBP|Work Related Rehabilitation in Patients With Low Back Pain|A Study on the Effect of Employment Follow-up on Return to Work in Sick Listed Patients With Low Back Pain||Oslo University Hospital|Yes|Terminated|January 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|260|||Both|18 Years|65 Years|No|||December 2008|July 3, 2011|September 6, 2007||No|The study was stopped, as the another multicentre-RCT on the same patients started.|No||https://clinicaltrials.gov/show/NCT00526604||167404|
NCT00525928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707-003|Mood and Anti-craving Effects of Varenicline in Psychiatric Inpatients|Assessment of Response to Open-label Treatment With Varenicline in Psychiatric Inpatients||Butler Hospital||Withdrawn|October 2007|October 2008|Anticipated|October 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|September 4, 2007|||insufficient recuirment|No||https://clinicaltrials.gov/show/NCT00525928||167454|
NCT00525941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-34060-IR-0702|An Exploratory Study of NBI-34060 Capsules and Next Day Functioning|An Exploratory Phase IIIb, Single-Blind, Outpatient Study to Assess Next-Day Functioning in Adult Primary Insomnia Patients Following the Administration of NBI-34060 Capsules During the Night||Neurocrine Biosciences|No|Withdrawn|September 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|64 Years|No|||April 2015|April 23, 2015|September 5, 2007|Yes|Yes|Study discontinued due to Approvable decision|No||https://clinicaltrials.gov/show/NCT00525941||167453|
NCT00522249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC IRB#0806-0132|Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC|A Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic Renal Cell Carcinoma||The Methodist Hospital System|No|Terminated|May 2007|July 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 27, 2007||No|PI decision|No||https://clinicaltrials.gov/show/NCT00522249||167732|
NCT00522262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16649|Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial|Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial||AHS Cancer Control Alberta|No|Completed|June 2002|July 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|320|||Female|50 Years|74 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00522262||167731|
NCT00522223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-376|Sexual Functioning in Cervical Cancer Survivors|Sexual Functioning and Quality of Life in Women With Cervical Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2002|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|165|||Female|N/A|N/A|No|Non-Probability Sample|Women with history of cervical cancer.|September 2015|September 30, 2015|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522223||167734|
NCT00522236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P5S|Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Elderly Subjects||Novartis|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|56|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 24, 2012|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522236||167733|
NCT00522860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5025|A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery|A Randomised Controlled Trial of Non-absorbable (Silk) Sutures Verses Absorbable (Vicryl) Sutures During the Surgical Treatment of Trachomatous Trichiasis||London School of Hygiene and Tropical Medicine|Yes|Completed|March 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1300|||Both|18 Years|N/A|No|||January 2012|January 11, 2012|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522860||167687|
NCT00522873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91508|Endometrial Safety Study|A Double-blind, Randomized, Multi-center Study to Investigate the Endometrial Safety of a Continuous, Combined, Oral Estrogen/Progestin Preparation (17b-estradiol [E2] / Drospirenone [DRSP]) and to Compare the Bleeding Pattern of Subjects Treated With E2 / DRSP With the Bleeding Pattern of Subjects Treated With E2 / Norethisterone Acetate (NETA) When Used for Hormone Therapy (HT) for 1 Year in Post-menopausal Women||Bayer|No|Completed|August 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|662|||Female|40 Years|65 Years|No|||December 2014|December 10, 2014|August 29, 2007|Yes|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT00522873||167686|
NCT00549588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-058 ex 03/04|Sunscreen and After-sun-lotion Protection in Polymorphic Light Eruption|The Efficacy of a Sunscreen With SPF30 and a After-sun-lotion in the Prevention of Polymorphic Light Eruption||Medical University of Graz|No|Completed|February 2004|August 2006|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|14|||Both|19 Years|N/A|No|||September 2009|September 29, 2009|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549588||165670|
NCT00549601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DES07|Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease|A Multi-center, Randomised, Open-label Study to Evaluate Convenience and Safety of Change in the Mode of Administration of Rivastigmine (From Capsules to a Transdermal Patch) in Patients With Alzheimer's Disease|KAPA|Novartis||Completed|September 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|142|||Both|60 Years|N/A|No|||February 2011|February 24, 2011|October 24, 2007||No||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00549601||165669|
NCT00549614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061218|Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure|Effect of 4 Weeks Treatment With Acipimox on Left Ventricular Function, Work Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure|ACME|University of Aarhus|No|Completed|October 2007|May 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|30 Years|80 Years|No|||October 2009|October 6, 2009|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00549614||165668|
NCT00549393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00006799|Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit|Impact of Daily Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit||Johns Hopkins University|No|Completed|February 2008|June 2012|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5659|||Both|2 Months|25 Years|No|||September 2015|September 1, 2015|October 24, 2007|Yes|Yes||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00549393||165685|
NCT00549874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKB 276|Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes|Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes||University of Michigan|Yes|Completed|February 2002|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|30 Years|75 Years|No|||October 2007|November 8, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549874||165648|
NCT00550173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10725|A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer|A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|November 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|247|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|October 25, 2007|Yes|Yes||No|January 10, 2013|https://clinicaltrials.gov/show/NCT00550173||165625|
NCT00546676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4018|Ketek in CAP / AECB in Ambulatory Adult Patients|A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator||Sanofi||Completed|May 2004|December 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|174|||Both|18 Years|N/A|No|||November 2007|November 13, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546676||165885|
NCT00546689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-02|Correlation Between Intestinal Parasites and Serum Level of Eosinophils and IgE in Individuals With HIV or AIDS|Phase 1 Correlation Between Intestinal Parasites and Serum Level of Eosinophils and IgE in Individuals With HIV or AIDS||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2007|August 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Sample of Blood Sample of Feces|Both|18 Years|60 Years|No|Probability Sample|primary care clinic|October 2007|April 17, 2008|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546689||165884|
NCT00547300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-03|Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-Release (ER) for Hypertension|Tolerability of Nebivolol Compared With Metoprolol ER in Patients With Mild to Moderate Hypertension Taking Hydrochlorothiazide||Forest Laboratories||Completed|October 2007|October 2008||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|80 Years|No|||January 2009|January 12, 2009|October 19, 2007||||||https://clinicaltrials.gov/show/NCT00547300||165839|
NCT00547950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A02-2|A Multiple-Centered, Prospective Cohort Study: the Second Prevention Trial for Ischemic Stroke With Deng Zhan Sheng Mai Capsule（SPIRIT—DZSM-2）|A Model Study on the Comprehensive Treating Protocol of Secondary Prevention and Effect Evaluation of Ischemic Stroke With Traditional Chinese Medicine||Guangzhou University of Traditional Chinese Medicine|Yes|Not yet recruiting|November 2007|October 2009|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12000|||Both|40 Years|75 Years|No|||October 2007|October 28, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00547950||165792|
NCT00548587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5555-G000-202|Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome|A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Clinical Events and Biomarkers in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome||Eisai Inc.|Yes|Completed|October 2007|August 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|600|||Both|45 Years|80 Years|No|||November 2015|January 5, 2016|October 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548587||165744|
NCT00549471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180907.ctil|Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy|Improvement After Botulinum Toxin A Injections to the Upper Extremities in Children With Cerebral Palsy||Shaare Zedek Medical Center|No|Terminated|September 2007|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|8 Years|11 Years|No|||April 2011|April 20, 2011|October 24, 2007|No|Yes|no funding|No||https://clinicaltrials.gov/show/NCT00549471||165679|
NCT00524836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00349|Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis|A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Perennial Allergic Rhinitis.||UCB Pharma|No|Completed|September 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|71|||Both|18 Years|60 Years|No|||September 2009|December 13, 2013|September 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00524836||167537|
NCT00524849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446ECN05|Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis|Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases||Fudan University|No|Completed|November 2006|January 2010|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|75 Years|No|||September 2010|September 13, 2010|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524849||167536|
NCT00525733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA-0610-0607|Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)|A Phase II, Randomized Trial of Open-Label Truvada With Darunavir/Ritonavir Versus Multiclass Therapy With Truvada, Darunavir/Ritonavir, Maraviroc and Raltegravir in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects||Rockefeller University|No|Completed|October 2007|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2015|February 24, 2015|September 5, 2007|Yes|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT00525733||167469|
NCT00525993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoBrazil_EtoricoxibAnkle2007|Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols|Efficacy and Safety of the Non-Steroidal Anti-Inflammatory Drug Etoricoxib in the Treatment of Acute Ankle Sprain in Sports: A Randomized Double-Blind Comparative Study Among 2 Treatments in the Acute Phase||Núcleo de Estudos em Esportes e Ortopedia, Brazil|Yes|Not yet recruiting|December 2008|September 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||October 2008|October 20, 2008|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525993||167449|
NCT00526006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-00673-145|PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena|||University Hospital Koge|Yes|Recruiting|September 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2007|September 5, 2007|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526006||167448|
NCT00526331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0231|Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy|Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy||M.D. Anderson Cancer Center|Yes|Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|September 5, 2007||No||No|December 8, 2011|https://clinicaltrials.gov/show/NCT00526331||167424|
NCT00526617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-862|A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients|A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)||Abbott|No|Completed|August 2007|||June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|September 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00526617||167403|
NCT00522275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0756|Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures|An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients With Partial Seizures||UCB Pharma|No|Completed|October 2004|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|308|||Both|16 Years|70 Years|No|||April 2015|April 7, 2015|August 27, 2007|Yes|Yes||No|October 28, 2010|https://clinicaltrials.gov/show/NCT00522275||167730|
NCT00522288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003H0114|Effects of Contact Lens Wear on Children's Self-Perceptions|Adolescent and Child Health Initiative to Encourage Vision Empowerment (ACHIEVE) Study|ACHIEVE|Ohio State University|Yes|Completed|September 2003|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|484|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|August 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00522288||167729|
NCT00522600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI0717|Eye Drop Use in Glaucoma Patients Through Patient Surveys and Video Observations|Evaluation of Eye Drop Administration in Glaucoma Patients||Robin, Alan L., M.D.|No|Completed|February 2007|July 2007|Actual|||N/A|Observational|Time Perspective: Prospective||3|Actual|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|173 subjects enrolled and 222 video recordings were made. Ages ranged from 21-94 years old        (mean:67 yrs) and subjects were 55% female and 70% caucasian.|July 2009|July 21, 2009|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522600||167707|
NCT00522886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-03-009|Phase I Cetuximab and Concurrent Radio-chemotherapy|Determination of the Toxicity of Standard Dose Cetuximab Together With Concurrent Individualised, Isotoxic Accelerated Radiotherapy and Cisplatin-vinorelbine for Patients With Stage III Non-small Cell Lung Cancer: A Phase I Study||Maastricht Radiation Oncology|Yes|Completed|April 2007|||July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522886||167685|
NCT00549627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4727|Evaluation of the PediGuard™ for Pedicle Screw Insertion|Evaluation of the PediGuard™ for Pedicle Screw Insertion||Shriners Hospitals for Children|No|Suspended|August 2005|December 2010|Anticipated|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|108|||Both|N/A|N/A|No|||February 2009|February 3, 2009|October 24, 2007|Yes|Yes|New funding sources being sought|No||https://clinicaltrials.gov/show/NCT00549627||165667|
NCT00549887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11760|An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin|Resource Utilisation and Patient Satisfaction With SWitching INsulin (SWING)|SWING|Eli Lilly and Company|No|Completed|September 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2459|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Type II Diabetes treated with a regimen which includes any rapid-acting        analog insulin or any short-acting human insulin|March 2010|March 15, 2010|October 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00549887||165647|
NCT00546390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protect|Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study|Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study||University of Alberta|No|Completed|November 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2012|February 14, 2012|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00546390||165906|
NCT00547027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG 017294|Promoting Physical Activity Among Patients With Type 2 Diabetes|Promoting Physical Activity Among Patients With Type 2 Diabetes in a Community-Based Clinic||Florida State University|No|Completed|April 2006|July 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 4, 2015|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00547027||165858|
NCT00547339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000571546|Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer|A Phase I and II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer (SBRT Prostate)||National Cancer Institute (NCI)||Recruiting|July 2006|||October 2010|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Male|18 Years|N/A|No|||June 2010|February 18, 2011|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547339||165837|
NCT00547352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9152|Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection|Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference||Eli Lilly and Company|No|Completed|June 2004|June 2005|Actual|||Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|160|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547352||165836|
NCT00547001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHN002140HI|Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes|A Comparison of Hormonal Therapy: Tapering Regimens for Mediating Hot Flashes||Hartford Hospital|No|Recruiting|August 2007|November 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|235|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||July 2008|July 17, 2008|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00547001||165860|
NCT00547014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1221001|First Safety Study in Humans of a Single Dose of CPG 52364|Oral Administration Of CPG 52364 In Healthy Subjects: A Phase 1, Within-Cohort Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose, Single-Center Study||Pfizer|No|Completed|September 2007|April 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2009|March 18, 2009|October 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547014||165859|
NCT00547326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/397|The Effect of Osteopatic Cranial Techniques on the Audiometric and Tympanometric Values in Children Suffering From Otitis Media With Effusion.|The Effect of Osteopatic Cranial Techniques on the Audiometric and Tympanometric Values in Children Suffering From Otitis Media With Effusion.||University Hospital, Ghent|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|7 Years|No|||April 2008|April 7, 2008|October 19, 2007||No|Ethics Committee approval denied|No||https://clinicaltrials.gov/show/NCT00547326||165838|
NCT00547976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080006|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis||National Institutes of Health Clinical Center (CC)||Completed|October 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|89 Years|No|||April 2012|April 26, 2012|October 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00547976||165790|
NCT00548886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008105|Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients|Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients|LEAP|Emory University|No|Terminated|February 2008|June 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|7|||Both|3 Years|18 Years|No|||February 2015|February 20, 2015|October 22, 2007||No|Lack of enrollment|No|February 20, 2015|https://clinicaltrials.gov/show/NCT00548886||165722|Slow enrollment lead to an early termination of the study
NCT00548899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 45|Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer|Phase II Study of Neoadjuvant Epirubicin, Cyclophosphamide (EC) + Sorafenib Followed by Paclitaxel (P) + Sorafenib in Women With Previously Untreated|SOFIA|German Breast Group|Yes|Completed|November 2007|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|N/A|No|||March 2015|March 6, 2015|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548899||165721|
NCT00524862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06368|Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death|Selective Strategy to Manage Arrhythmia Risk and Therapy With ICD|SMART-ICD|St. Michael's Hospital, Toronto|Yes|Terminated|October 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5000|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|August 29, 2007||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00524862||167535|
NCT00525122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/60|Treatment of M.Graves With Radioactive Iodine: Follow-up Study|||Medisch Centrum Rijnmond-Zuid, Netherlands|No|Recruiting|September 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of 18 years and older with hyperthyroidism who are eligible for treatment with        radioactive iodine.|May 2008|May 21, 2008|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525122||167516|
NCT00525421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1113-30233-01|A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus|A Randomized, Placebo-Controlled, Double-Blind Trial of a Two Week Course of Curcuminoids in Oral Lichen Planus||University of California, San Francisco|No|Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|N/A|No|||August 2013|August 5, 2013|September 4, 2007|Yes|Yes||No|May 22, 2013|https://clinicaltrials.gov/show/NCT00525421||167493|
NCT00525746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0490|Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)|Molecular Epidemiology of Treatment-Related Acute Myeloid Leukemia/Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2006|||March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Saliva or blood sample collected for special tests that will look for biologic factors      associated with treatment-related AML/MDS.|Both|18 Years|N/A|No|Non-Probability Sample|Participants, 18 years or older, with a confirmed diagnosis of AML or MDS (cases), or        treated for a primary malignancy (controls).|October 2015|October 21, 2015|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525746||167468|
NCT00526019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-07-20088|Persistence of Airway Inflammation and Remodeling in Subjects With Symptomatic or Complete Asthma Remission|Characteristics of Symptomatic Asthma Remissions||Laval University|No|Completed|September 2007|February 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|85|Samples Without DNA|Serum|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects wiil be offered to volunteer from advertisements in newspaper. Subjects with        asthma or in remission of asthma from primary care clinics will be offered to participate.|February 2012|February 20, 2012|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526019||167447|
NCT00526344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-07- sep-biop|Bronchoscopy With Bronchial Biopsies Sub-study of: Persistence of Airway Inflammation and Remodeling in Asthma Remission|Bronchoscopy and Bronchial Biopsies. Sub-study of: Characteristics of Asthma Remissions||Laval University|No|Withdrawn|September 2007|March 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|36|Samples With DNA|Tissue (bronchial biopsies)|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with current asthma or in remission of asthma from primary care clinics will be        allowed to participate to this study. Healthy subjects will also be invited by        advertisements in newspapers to volunteer for this study.|February 2011|February 10, 2011|September 5, 2007||No|No funding, study not done|No||https://clinicaltrials.gov/show/NCT00526344||167423|
NCT00526630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-06-19-07|Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease|Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study||University of Cincinnati|Yes|Completed|December 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|35 Years|85 Years|No|||April 2015|April 13, 2015|September 5, 2007||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00526630||167402|
NCT00522301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-080|Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission|A Phase II Trial of Oral Sorafenib (Bay43-9006) In Women With Epithelial Ovarian, Fallopian Tube Or Peritoneal Carcinoma In Second Or Greater Remission||Memorial Sloan Kettering Cancer Center||Terminated|July 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|120 Years|No|||February 2016|February 1, 2016|August 28, 2007|Yes|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT00522301||167728|Early termination as it would not meet it's primary endpoint of improved survival. None of the patients completed the study.
NCT00522613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-05CGREE-01|Recovery Group Pilot|Recovery Group Pilot||Kaiser Permanente|No|Completed|July 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Actual|50|||Both|18 Years|N/A|No|||September 2006|February 3, 2009|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522613||167706|
NCT00512902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST1571EUS210|A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis|Pilot Study to Examine The Use of Imatinib (Gleevec) For The Treatment of Active Alveolitis in Systemic Sclerosis||University of California, Los Angeles|No|Completed|August 2007|December 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|August 6, 2007|Yes|Yes||No|April 20, 2012|https://clinicaltrials.gov/show/NCT00512902||168433|Open label, small.
NCT00513214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052073|Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus|A Phase 1/2a, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of XOMA 052 in Subjects With Type 2 Diabetes Mellitus||XOMA (US) LLC|Yes|Completed|July 2007|February 2010|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|70 Years|No|||September 2011|September 30, 2011|August 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00513214||168410|
NCT00549640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005407|Testing Methylphenidate for Smoking Abstinence|Efficacy of Methylphenidate for Treating Tobacco Dependence||Mayo Clinic|Yes|Completed|January 2008|May 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 15, 2011|October 24, 2007|Yes|Yes||No|September 8, 2010|https://clinicaltrials.gov/show/NCT00549640||165666|
NCT00549900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107336|A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females|Safety and Immunogenicity Study of the HPV Vaccine (GSK-580299) in Healthy, Chinese, Female Subjects||GlaxoSmithKline||Completed|December 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|October 18, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00549900||165646|
NCT00545519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0946|A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma|A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma||Washington University School of Medicine|Yes|Completed|October 2006|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|October 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00545519||165972|
NCT00545545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CL-PGG-CRC0713|Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma|A Phase 1b, Safety, PK, and Efficacy, Multicenter, Dose-Escalating Study of Imprime PGG in Combination With Cetuximab With and Without Irinotecan Therapy in Patients With Recurrent/Progressive Colorectal Carcinoma Following Treatment With a 5-FU Regimen.||Biothera|Yes|Completed|October 2007|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|48|||Both|18 Years|75 Years|No|||March 2010|March 30, 2010|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545545||165970|
NCT00547040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3775|Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients|Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients|ASCIT|Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2006|October 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|serum, plasma, urine|Both|18 Years|90 Years|No|Non-Probability Sample|incident renal transplant recipients|October 2011|October 5, 2011|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00547040||165857|
NCT00548015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG000279|Helping Hands: Promoting Hand Hygiene in Hospital Nurses|HELPING HANDS: a Comparison of Short- and Long Term Effects of Alternative Strategies for Promoting Hand Hygiene in Hospital Nurses.||Radboud University|Yes|Active, not recruiting|March 2008|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|900|||Both|N/A|N/A|No|||October 2007|September 30, 2009|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548015||165787|
NCT00548327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080002|The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype|Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Atomoxetine on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype|Atomoxetine|National Institutes of Health Clinical Center (CC)|No|Terminated|October 2007|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|October 19, 2007|Yes|Yes|The scientific director decided to terminate: low priority study with slow accrual|No|February 13, 2013|https://clinicaltrials.gov/show/NCT00548327||165764|
NCT00548340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-3104|VEC-162 Study in Adult Patients With Primary Insomnia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20 mg/Day and 50 mg/Day) in the Treatment of Primary Insomnia||Vanda Pharmaceuticals||Completed|November 2007|June 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|322|||Both|18 Years|64 Years|No|||October 2014|October 8, 2014|October 19, 2007|Yes|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT00548340||165763|
NCT00548600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-1992-Iridium|Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy With Temporary Iridium Implant Plus External Beam Radiation in Carcinoma of the Prostate|A Randomized Clinical Trial Comparing Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy Using a Combination of a Temporaory Iridium Implant Plus External Beam Radiation in Surgically Staged B2 and C Carcinoma of the Prostate||Ontario Clinical Oncology Group (OCOG)|No|Completed|May 1992|September 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Male|N/A|75 Years|No|||October 2007|October 22, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00548600||165743|
NCT00547677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000571611|Stereotactic Radiosurgery in Treating Patients With Liver Metastases|A Phase I Trial of Stereotactic Radiosurgery for Patients With Hepatic Metastases (SBRT Liver)||National Cancer Institute (NCI)||Active, not recruiting|July 2004|||December 2007|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|27|||Both|18 Years|N/A|No|||January 2008|February 6, 2009|October 19, 2007||||No||https://clinicaltrials.gov/show/NCT00547677||165812|
NCT00547989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 05-105.5|Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?|Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?||Maastricht University Medical Center|No|Completed|October 2006|May 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Female|18 Years|N/A|No|||June 2014|June 10, 2014|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00547989||165789|
NCT00548041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11007|Rapid HIV Testing Program in the Emergency Department|Pilot Study to Evaluate a Rapid HIV Testing Program in the Emergency Department||Temple University|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 19, 2007||No||No|April 20, 2015|https://clinicaltrials.gov/show/NCT00548041||165786|
NCT00548353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3207-003|A Study of Gastric Delay in Migraine Patients (3207-003)|A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks||Merck Sharp & Dohme Corp.||Completed|August 2007|February 2010|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|45 Years|No|||December 2014|December 18, 2014|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548353||165762|
NCT00548366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSouthwestern 062007-066|Sodium Restriction in the Management of Cirrhotic Ascites|Comparison of Efficacy of 2 Gram Versus 4 Gram Sodium Restriction in the Management of Cirrhotic Ascites||University of Texas Southwestern Medical Center|No|Terminated|October 2007|September 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|75 Years|No|||September 2010|September 10, 2010|October 22, 2007||No|Failure to recruit.|No||https://clinicaltrials.gov/show/NCT00548366||165761|
NCT00525135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valproic Acid|Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer|A Phase II Trial of Valproic Acid (Depakote ER ®) in Patients With Advanced Thyroid Cancers of Follicular Origin, Who Are Thyroglobulin Positive/RAI Unresponsive||University of California, San Francisco|Yes|Terminated|August 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|August 28, 2007||No|PI left university and study was halted prematurely. No data was analyzed.|No|January 21, 2015|https://clinicaltrials.gov/show/NCT00525135||167515|
NCT00525434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF-EB -01|Evaluation of Safety and Efficacy of Using Seraffix LTB - System for Excisional Biopsy Wounds Closure|Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System for Excisional Biopsy Wounds Closure||Seraffix|No|Terminated|November 2008|November 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||May 2008|June 8, 2011|September 4, 2007||No|sponsor has decide to pospone this study|No||https://clinicaltrials.gov/show/NCT00525434||167492|
NCT00515723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063985-04|Glucose and Lipid Metabolism on Antipsychotic Medication|Glucose and Lipid Metabolism on Antipsychotic Medication|Glulipid|Washington University School of Medicine|Yes|Completed|September 2001|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|18 Years|60 Years|No|||February 2011|February 25, 2011|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515723||168225|
NCT00516074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWCD|A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes|A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes||AstraZeneca|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|75 Years|No|||March 2015|March 19, 2015|August 10, 2007|Yes|Yes||No|April 24, 2009|https://clinicaltrials.gov/show/NCT00516074||168199|
NCT00516048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWBO|An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes|An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes||AstraZeneca|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|20 Years|N/A|No|||March 2015|March 19, 2015|August 10, 2007|Yes|Yes||No|April 29, 2009|https://clinicaltrials.gov/show/NCT00516048||168201|
NCT00516425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM-CCH-ACTION|Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer|Adjuvant Cytotoxic Chemotherapy In Older Women||National Cancer Institute (NCI)||Recruiting|January 2007|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1000|||Female|70 Years|N/A|No|||September 2007|August 6, 2013|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516425||168172|
NCT00526357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.P. #06-2750|Effect of Dietary Supplements With Fish Oil on Mannitol-induced Airway Sensitivity & Inflammation in Persons With Asthma|The Effect of Dietary Supplementation With Encapsulated Fish Oil on Mannitol-induced Airway Sensitivity and Inflammation in Persons With Asthma||Firestone Institute for Respiratory Health|No|Completed|August 2007|March 2012|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|No|||March 2012|March 15, 2012|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526357||167422|
NCT00526370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP07-2351|Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests|Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests||University of Aarhus|No|Completed|August 2007|July 2008|Actual|February 2008|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|72|Samples With DNA|Tampon self-test from cervix|Female|23 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|50 women in out-patient gynecological ward in account of cervical cell changes and 50        women in the national screening program for cervical cancer, included by their G.P.|August 2008|August 12, 2008|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526370||167421|
NCT00526643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPA-2|CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients|Gemcitabine Versus Cisplatin and Gemcitabine in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer in Poor Physical Condition (Performance Status 2)|CAPPA-2|National Cancer Institute, Naples|No|Suspended|November 2007|February 2016|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526643||167401|
NCT00517062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1844|Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates|Effects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Adipocyte Insulin-like Growth Factor-I (IGF-I) and IGF-I/Insulin Receptor Density and Regulation of Cortisol Metabolism in GH Deficient Adults||Oregon Health and Science University|Yes|Completed|January 2006|January 2012|Actual|January 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|75 Years|No|||May 2012|May 2, 2012|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517062||168128|
NCT00522626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1490|Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment|Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment||Johns Hopkins University|No|Completed|August 2006|August 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Female|18 Years|40 Years|No|Non-Probability Sample|OPioid exposed pregnancies|February 2013|February 29, 2016|August 29, 2007||No||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00522626||167705|Difficulty in recruiting leading to small number of subjects analyzed
NCT00513526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-052|Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection|A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men||AIDS Malignancy Consortium|No|Completed|November 2007|October 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Male|18 Years|N/A|No|||August 2015|August 27, 2015|August 6, 2007|Yes|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00513526||168387|
NCT00549913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSF0106|Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)|A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation.||Mesoblast, Ltd.|Yes|Completed|October 2007|September 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|6|||Both|18 Years|N/A|No|||September 2013|November 6, 2014|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549913||165645|
NCT00549926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yokohama-ACS|Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and Atorvastatin in Acute Coronary Syndrome (Yokohama-ACS)|Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and Atorvastatin in Acute Coronary Syndrome (Yokohama-ACS)|Yokohama-ACS|Yokohama City University Medical Center|No|Completed|October 2007|February 2010|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|20 Years|N/A|No|||February 2010|February 16, 2010|October 25, 2007||||No||https://clinicaltrials.gov/show/NCT00549926||165644|
NCT00546377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-077|Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer|A Phase I-II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Previously Treated Patients With Chronic Lymphocytic Leukemia and Other Low Grade B-Cell Neoplasms||Memorial Sloan Kettering Cancer Center|No|Completed|July 2005|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546377||165907|
NCT00547066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hA20-07|Study of Veltuzumab (hA20) at Different Doses in Patients With ITP|A Phase I/II Study of Immunotherapy With Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients With Chronic Immune Thrombocytopenic Purpura||Immunomedics, Inc.|No|Active, not recruiting|November 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547066||165855|
NCT00547378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 1634|InSite for Over Active Bladder|Prospective, Multicenter Trial Evaluating the Safety and Efficacy of InterStim® Therapy in Subjects With Symptoms of Overactive Bladder (InSite OAB)|InSite - OAB|MedtronicNeuro|No|Active, not recruiting|October 2007|November 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|571|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00547378||165834|
NCT00548613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-02-I|Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium|Phase I Study to Determine the Safety and Feasibility of the Use of a Combination Stem Cell Therapy in Patients With Acute Myocardial Infarction||TCA Cellular Therapy|No|Completed|October 2007|March 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||April 2011|April 27, 2011|October 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00548613||165742|
NCT00548626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15497A|Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer|EMUNE-07 Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer|EMUNE-07|University of Chicago|No|Completed|October 2007|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|47|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548626||165741|
NCT00548054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-WC-01|Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants|Safety and Immunogenicity of a Killed Oral Cholera Vaccine Among Infants 10 Weeks to Less Than 12 Months of Age When Given Concomitantly With EPI Vaccines||International Vaccine Institute|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|300|||Both|10 Weeks|11 Months|Accepts Healthy Volunteers|||May 2015|May 1, 2015|October 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00548054||165785|
NCT00516971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1925-02|The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population|The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population||Hospital Authority, Hong Kong||Recruiting|January 2003|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|80 Years||||July 2010|July 6, 2010|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00516971||168135|
NCT00517205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.309|Study on 'The Use of Non-contrast Helical Computerized Tomogram in Predicting Treatment Outcomes of Upper Ureteric Stone by Extracorporeal Shock Wave Lithotripsy Using the Sonolith 4000+ Lithotripter'|The Use of Non-contrast Helical Computerized Tomogram in Predicting Treatment Outcome of Upper Ureteric Stone by Extracorporeal Shock Wave Lithotripsy Using the Sonolith 4000+ Lithotripter||Hospital Authority, Hong Kong||Completed|October 2004|December 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A||Non-Probability Sample|Patient suffered upper ureteric stone|June 2011|June 14, 2011|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517205||168117|
NCT00517218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL305|This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)|A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense® (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia||Genta Incorporated||Withdrawn|June 2006|June 2009||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|February 7, 2008|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00517218||168116|
NCT00524901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTR-ECG-2|Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia|An Open Label Study to Evaluate the Effect of Intravenous Erythropoietin on Erythropoietin Receptor Signaling and Markers for Apoptosis, Myocardial Damage and Renal Dysfunction in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|DREAM|University Medical Center Groningen|No|Completed|September 2007|April 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||February 2013|February 13, 2013|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524901||167532|
NCT00525148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.22|LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations|LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations||Boehringer Ingelheim||Completed|August 2007|August 2015|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|September 3, 2007||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00525148||167514|
NCT00525161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-BRE-41-BP|Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer|A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer||University of Kentucky|Yes|Terminated|October 2007|January 2015|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||January 2015|January 12, 2015|September 3, 2007|Yes|Yes|Slow accrual and loss of funding|No|December 18, 2014|https://clinicaltrials.gov/show/NCT00525161||167513|Early termination of study due to slow accrual.
NCT00525447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG040-0006|Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma|A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)||Seattle Genetics, Inc.|No|Completed|August 2007|February 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2014|October 7, 2014|August 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00525447||167491|
NCT00516412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 36/06|Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Everolimus (RAD001) for the Treatment of Patients With Relapsed or Therapy Resistant Mantle Cell Lymphoma||Swiss Group for Clinical Cancer Research|Yes|Completed|August 2007|August 2012|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516412||168173|
NCT00516438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU36-93|Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan|A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Topotecan in the Treatment of Patients With Advanced Solid Tumours||AstraZeneca|No|Completed|July 2007|November 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2010|December 7, 2010|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516438||168171|
NCT00516724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU36-96|Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel|A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours||AstraZeneca|No|Active, not recruiting|June 2007|December 2016|Anticipated|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|192|||Both|18 Years|130 Years|No|||March 2016|March 2, 2016|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516724||168151|
NCT00516386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P-000737|Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents|Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents||Massachusetts General Hospital|Yes|Completed|March 2007|December 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Female|12 Years|18 Years|No|||December 2013|December 10, 2013|August 13, 2007|Yes|Yes||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00516386||168175|A limitation of our study is that this was not a randomized controlled trial of rhIGF-1 versus placebo.
NCT00516399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012488-01-00|A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine|A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine||University of California, Los Angeles|Yes|Terminated|March 2008|December 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|1 Month|N/A|No|||December 2014|December 3, 2014|August 14, 2007|No|Yes|The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of    povidone-iodine to Natamycin.|No||https://clinicaltrials.gov/show/NCT00516399||168174|
NCT00526656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE24806|Sunitinib in Treating Patients With Locally Advanced Bladder Cancer|Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder||Case Comprehensive Cancer Center|Yes|Completed|September 2007|March 2011|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|September 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526656||167400|
NCT00526669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT109747|Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib|An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer||GlaxoSmithKline|No|Completed|March 2008|January 2015|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|68|||Both|18 Years|N/A|No|||July 2015|December 24, 2015|September 6, 2007|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00526669||167399|
NCT00512915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B84|Avoid FFS - Use of the Atrial Pacemaker Lead 1699 With Very Short Tip Ring Spacing to Avoid Far Field Sensing|Atriale Vorhofsonde 1699 Mit Sehr Kurzem Bipolabstand Zur Vermeidung Von Far Field Sensing|Avoid FFS|St. Jude Medical|No|Completed|December 2006|August 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|204|||Both|18 Years|N/A|No|||March 2009|March 4, 2009|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512915||168432|
NCT00517335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH046001|Evaluating the Brain's Response to Natural Versus Artificial Sweetener in Women Who Have Had an Eating Disorder|The Evaluation of Brain Neuronal Activity in Response to Natural (Sucrose) and Artificial (Sucralose) Taste Stimuli- Does Caloric Content Matter to the Brain?||University of California, San Diego||Completed|May 2005|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|60|Samples With DNA|If desired subjects have a chance to be a part of a DNA blood draw aspect of the study|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will include women between the ages of 18 and 45 who have recovered from        anorexia or bulimia nervosa for over 1 year and have no current medical problems.|April 2015|March 7, 2016|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00517335||168107|
NCT00517348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3192K1-1000|Study Evaluating IMA-026 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-026 Administered Subcutaneously or Intravenously to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 24, 2009|August 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00517348||168106|
NCT00517361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15578A|Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer|A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer||University of Chicago|Yes|Terminated|August 2007|April 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|August 14, 2007|Yes|Yes|This study has been terminated due to poor accrual|No|January 22, 2014|https://clinicaltrials.gov/show/NCT00517361||168105|
NCT00513539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558540|Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery|Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study|Photostent-02|University College, London|Yes|Completed|July 2007|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00513539||168386|
NCT00546078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109628|Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America|Safety and Immunogenicity Study of an Additional Dose of HPV Vaccine (580299) in Young, Adult Women in North America.||GlaxoSmithKline||Completed|January 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|116|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||March 2011|June 7, 2012|October 17, 2007|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00546078||165929|
NCT00545844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-383|Singulair(R) In Asthma And Allergic Rhinitis (0476-383)|An 8 Week Study to Evaluate the Effectiveness of Adding Montelukast to Inhaled Corticosteroid (ICS) to the ICS/Long-Acting Beta 2-Agonist Therapy in Adult Subjects With Asthma and Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|April 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|313|||Both|15 Years|N/A|No|||February 2015|February 6, 2015|October 16, 2007|No|Yes||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00545844||165947|
NCT00546091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080001|Calibrating Imaging Techniques to Study Blood Flow|Calibration of Non-Invasive Non-Ionizing Imaging Techniques to Study Vasculature of Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 2007|October 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|February 19, 2014|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546091||165928|
NCT00547105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000571634|Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer|A Phase II Trial of Erlotinib (Tarceva®) in Combination With Stereotactic Body Radiation Therapy (SBRT) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Recruiting|June 2007|||July 2010|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|October 19, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00547105||165853|
NCT00547391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diary nr 106/2007|Recurrent Throat Infections and Tonsillectomy|Recurrent Throat Infections and Tonsillectomy||Oulu University Hospital|No|Completed|November 2007|June 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|13 Years|N/A|No|||February 2012|April 17, 2012|October 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00547391||165833|
NCT00547703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8918|Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia|Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia||Cleveland Clinic Florida|No|Terminated|February 2008|June 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||June 2012|June 7, 2012|October 19, 2007||No|Not enough participants - only 5 since the study started|No|February 20, 2012|https://clinicaltrials.gov/show/NCT00547703||165810|We were unable to recruit an adequate number of patients to make any meaningful conclusion.
NCT00516984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUIRB 12024|Osteopathic Manipulative Treatment and Its Relationship to Autonomic Nervous System Activity|Osteopathic Manipulative Treatment and Its Relationship to Autonomic Nervous System Activity as Demonstrated by Heart Rate Variability||University of Oklahoma|No|Completed|January 2005|October 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2008|August 21, 2008|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00516984||168134|
NCT00517231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-pre02|Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment|||UPECLIN HC FM Botucatu Unesp|No|Withdrawn|June 2005|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|80 Years|No|||July 2015|July 6, 2015|August 14, 2007||No|The investigator left the research center and the study was not carried out|No||https://clinicaltrials.gov/show/NCT00517231||168115|
NCT00517244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH071754|Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders|Child Anxiety Disorders: Parenting and Temperament Effects||Rhode Island Hospital|No|Completed|October 2006|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|180|||Both|8 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|March 2016|March 10, 2016|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00517244||168114|
NCT00525174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-136|Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children|A Randomized Trial of Full-time Bangerter Filters Versus Part-time Daily Patching for the Treatment of Moderate Amblyopia in Children|ATS10|Jaeb Center for Health Research|Yes|Completed|November 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|186|||Both|3 Years|9 Years|No|||January 2012|January 6, 2012|August 31, 2007||No||No|April 22, 2011|https://clinicaltrials.gov/show/NCT00525174||167512|Compliance assessment was based on parents' diaries and judgment by the researchers. Because we did not use an objective method to measure occlusion or spectacle wear, we cannot guarantee that the patients adhered to their prescribed regimens.
NCT00525460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-382|Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function|A Pilot Study of Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function||Dana-Farber Cancer Institute|No|Completed|April 2006|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Female|18 Years|N/A|No|Non-Probability Sample|Women 40 years of age or younger when diagnosed with ovarian cancer who chose to have        surgery that allowed them to keep their reproductive organs|October 2015|October 3, 2015|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525460||167490|
NCT00515424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRKI983A2101|Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension|A Multicenter, Randomized, Placebo-Controlled, Latanoprost-Controlled, Parallel Group Study to Assess the Tolerability, Safety and Efficacy of RKI983 Ophthalmic Solution Given Twice a Day Over One Week in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension||Novartis||Completed|July 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||90|||Both|18 Years|N/A||||December 2007|December 19, 2007|August 9, 2007||||||https://clinicaltrials.gov/show/NCT00515424||168247|
NCT00516451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-006|Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors|Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors||Bristol-Myers Squibb||Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||July 2008|October 10, 2008|August 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00516451||168170|
NCT00517101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMSC-07-VA-318-CTIL|Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy|||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|September 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|August 15, 2007|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517101||168125|
NCT00516750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIC-UHA-GU-03-01|Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin|Phase II Clinical Trial Concerning Gene Expression Profiling to Predict the Chemosensitivity of Invasive Bladder Cancer||National Cancer Institute (NCI)||Terminated|July 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|20 Years|80 Years|No|||March 2008|July 9, 2013|August 14, 2007|||Withdrawn due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00516750||168149|
NCT00516737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-081|Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine||Merck Sharp & Dohme Corp.||Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|August 13, 2007|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00516737||168150|In the Adverse Events section, all non-serious adverse experiences reported are post-treatment, up to the time of taking rescue medication or 14 days post-dose, whichever comes first.
NCT00517075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5977R|Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms and Social Dysfunction in Schizophrenia Patients||New York State Psychiatric Institute|No|Terminated|September 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|55 Years|No|||April 2012|April 27, 2012|August 14, 2007|Yes|Yes|Unable to adequately recruit subjects.|No||https://clinicaltrials.gov/show/NCT00517075||168127|
NCT00516685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 07-03|Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV|A Phase II/III Trial to Assess the Safety, Immunogenicity and Preliminary Efficacy of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Administered to Patients With Non-Small-Cell Lung Cancer (NSCLC) After Receiving Conventional First Line Chemotherapy|NSCLC|Bioven Sdn. Bhd.||Terminated|July 2007|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|August 14, 2007||No|Due to inability of patient enrollment, decision taken to terminate in the interests of    patients and later Malaysia is incorporated into global Phase 3 trial.|No||https://clinicaltrials.gov/show/NCT00516685||168154|
NCT00516698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N063I|Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer|Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy||Alliance for Clinical Trials in Oncology|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|140|Samples With DNA|blood samples|Female|18 Years|N/A|No|Non-Probability Sample|Postmenopausal women with breast cancer.|July 2015|July 5, 2015|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516698||168153|
NCT00516711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 5-2006|Role of Volatile Anesthetics for Hepatic Protection|Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion||University of Zurich|No|Completed|March 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2007|September 14, 2010|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516711||168152|
NCT00512928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-3-032|Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers|Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers||Maastricht University Medical Center|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2008|March 25, 2008|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512928||168431|
NCT00513253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF101950|A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib|Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib||GlaxoSmithKline|No|Withdrawn|April 2008|May 2008|Anticipated|May 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|August 6, 2007|||It was determined not to be needed based on the clinical development plan of Tykerb.|||https://clinicaltrials.gov/show/NCT00513253||168408|
NCT00513240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD5550101|Erythropoetin Neuroprotection for Neonatal Cardiac Surgery|Erythropoetin Neuroprotection for Neonatal Cardiac Surgery||Baylor College of Medicine|Yes|Active, not recruiting|September 2006|September 2016|Anticipated|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|62|||Both|N/A|30 Days|No|||July 2015|July 20, 2015|August 7, 2007|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT00513240||168409|
NCT00514098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-015|Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials|An Observational Cohort Study of Women Following HIV-1 Seroconversion in Microbicide Trials||Microbicide Trials Network|No|Recruiting|August 2008|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood and urine collection, pelvic, vaginal, and cervicovaginal sampling|Female|N/A|N/A|No|Probability Sample|Women who are diagnosed with HIV-1 during participation in previous microbicide trials|September 2014|September 17, 2014|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514098||168345|
NCT00514111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-16|Factors Associated to Success of Hepatitis C Therapy|Factors Associated to Success of Hepatitis C Therapy||UPECLIN HC FM Botucatu Unesp|Yes|Completed|August 2007|December 2008|Actual|July 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|70 Years|No|Probability Sample|HVC patients attended in SAE e HD.|March 2009|March 19, 2009|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514111||168344|
NCT00545857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20064114|Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus|Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus||Stony Brook University|Yes|Completed|June 2002|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|6 Years|18 Years|No|||May 2012|May 30, 2012|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545857||165946|
NCT00545870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238/2006|Bevacizumab Versus Ranibizumab for Diabetic Retinopathy|A Randomized, Double-masked Study With Intraocular Bevacizumab Compared With Intravitreal Ranibizumab in Patients With Persistent Diabetic Macular Edema or Persistent Active Neovascularisation Following Lasercoagulation||Medical University of Vienna|No|Completed|June 2008|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545870||165945|
NCT00546702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3505|Glulisine + Lantus in Type I Patients|Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine During 26 Weeks of Therapy||Sanofi|No|Completed|September 2004|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|142|||Both|18 Years|N/A|No|||June 2009|June 12, 2009|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00546702||165883|
NCT00546715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-002|A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects|Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|95|||Both|18 Years|49 Years|No|||October 2015|October 20, 2015|October 17, 2007|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT00546715||165882|
NCT00515931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIST-RT-2007|Radiation Therapy as Palliative Treatment of GIST|Radiation Therapy as Palliative Treatment of GIST Progressing During or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study|GIST-RT|Helsinki University|No|Completed|August 2007|October 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|N/A|No|||October 2014|October 6, 2014|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515931||168210|
NCT00515944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0709/1|Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products|||Merz Pharmaceuticals GmbH||Completed|August 2007|June 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|||Anticipated|30|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2009|March 31, 2009|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00515944||168209|
NCT00516269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-372|Methylphenidate Study in Breast or Gastrointestinal Cancer Patients|A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Breast or Gastrointestinal Cancer Patients||M.D. Anderson Cancer Center|Yes|Terminated|August 2004|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|August 14, 2007||No||No|September 18, 2012|https://clinicaltrials.gov/show/NCT00516269||168184|Early termination due to slow accrual.
NCT00516282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07C1|VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma|A Phase I/II Trial of Cloretazine® (VNP40101M) and Temodar® (Temozolomide) for Patients With Malignant Glioma in First Relapse or Progression||Northwestern University|Yes|Terminated|August 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2011|August 24, 2011|August 14, 2007|No|Yes|The pharmaceutical collaborator filed for bankruptcy and as a result, the study was unable to    move into the phase II portion.|No||https://clinicaltrials.gov/show/NCT00516282||168183|
NCT00516581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-13|Occurrence of Pneumocystis Pneumonia in HIV-Infected Patients and the Interference of the HAART|Occurrence of Pneumocystis Pneumonia in HIV-Infected Patients and the Interference of the Highly Active Antiretroviral Therapy||UPECLIN HC FM Botucatu Unesp|Yes|Completed|February 2003|February 2005|Actual|||Phase 3|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|376|||Both|18 Years|70 Years|No|Probability Sample|376 HIV-infected or AIDS patients were studied from January 1992 to December 2002|September 2008|September 4, 2008|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516581||168162|
NCT00513097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0914|Curbing Tobacco Use in Suburban and Rural Schools|Curbing Tobacco Use in Suburban and Rural Schools||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2006|||January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2384|||Both|14 Years|16 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00513097||168419|
NCT00513409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110031|Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule|Phase II, Observer-blind Follow-up Study to Assess reacto-and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine (GSK1024850A), When Given as Booster in Primed Children or as 2-dose Catch-up in Unprimed Children.||GlaxoSmithKline||Completed|August 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|163|||Both|18 Months|21 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|August 7, 2007|Yes|Yes||No|March 11, 2009|https://clinicaltrials.gov/show/NCT00513409||168396|
NCT00513669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMAL03|Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania|A Phase Ib Double-blind Randomized Placebo Controlled Age-deescalating Trial of Two Virosome Formulated Anti-malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-immune Tanzanian Volunteers|PMAL03|Swiss Tropical & Public Health Institute|Yes|Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|5 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513669||168376|
NCT00515112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15393B|Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer|A Randomized, Double Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer||University of Chicago|Yes|Terminated|July 2007|August 2012|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Male|18 Years|N/A|No|||May 2014|May 12, 2014|August 9, 2007|Yes|Yes|This study has been terminated due to poor accrual|No|May 12, 2014|https://clinicaltrials.gov/show/NCT00515112||168271|
NCT00515437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-SIAL-201|A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients||Solstice Neurosciences|Yes|Completed|July 2007|September 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|54|||Both|18 Years|85 Years|No|||June 2009|June 30, 2009|August 10, 2007|No|Yes||No|May 12, 2009|https://clinicaltrials.gov/show/NCT00515437||168246|
NCT00515736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-102-02|Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome|Influence Of Early Antioxidant Supplements On Clinical Evolution And Organ Function In Critically Ill Cardiac Surgery, Major Trauma And Subarachnoid Hemorrhage Patients|Etude-AOX|Centre Hospitalier Universitaire Vaudois|Yes|Terminated|January 2003|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|80 Years|No|||April 2008|July 29, 2010|August 13, 2007||No|enrollment was completed|No||https://clinicaltrials.gov/show/NCT00515736||168224|
NCT00517114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW04-204 T/526|Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients|Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients||Hospital Authority, Hong Kong||Completed|January 2005|December 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|80 Years||||October 2013|October 22, 2013|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517114||168124|
NCT00516477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAV2-hRPE65v2-101|Safety Study in Subjects With Leber Congenital Amaurosis|A Phase 1 Safety Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 Into the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-101]||Spark Therapeutics|Yes|Active, not recruiting|September 2007|July 2024|Anticipated|July 2024|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|8 Years|N/A|No|||February 2015|February 2, 2015|August 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00516477||168168|
NCT00512668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03098|Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer|Phase Ib Study of Limited Androgen Ablation and Two Dose Levels of Temsirolimus (NSC#683864) in Patients With Prostate Cancer Who Have a Biochemical Relapse After Prostatectomy and/or Radiotherapy||National Cancer Institute (NCI)||Terminated|September 2007|||January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|N/A|N/A|No|||January 2013|January 4, 2013|August 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512668||168451|
NCT00512681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-264|A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer|A Phase II Study of S-1 Combined With Irinotecan and Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma|TIROX2|National Cancer Center, Korea|No|Completed|July 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512681||168450|
NCT00517088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-pre03|Level of Physical Activities in Patients Before and After Breast Cancer Treatment|Level of Physical Activities in Patients Before and After Breast Cancer Treatment|PABC|UPECLIN HC FM Botucatu Unesp|Yes|Completed|May 2006|March 2007|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|2007|||Female|20 Years|90 Years|Accepts Healthy Volunteers|||August 2007|May 29, 2014|August 14, 2007||||Yes||https://clinicaltrials.gov/show/NCT00517088||168126|
NCT00517374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN100|A Multi-Centre Clinical Study in Spinal Cord Injury Patients in Mainland China and Hong Kong|A Multi-Centre Clinical Study in Spinal Cord Injury Patients in Mainland China and Hong Kong||China Spinal Cord Injury Network|No|Completed|September 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|65 Years|No|Non-Probability Sample|Each study enrolled Hospital in China and Hong Kong is expected to recruit 20 chronic        spinal cord injury patients, who have never had any cell therapy treatment for spinal cord        injur before.|September 2015|September 24, 2015|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517374||168104|
NCT00513552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-257|Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis|Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis||Medstar Research Institute|No|Recruiting|January 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|90 Years|No|||August 2007|August 7, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00513552||168385|
NCT00513266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000559146|Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery|Oxaliplatin-CPT-11-5-FU-Leucovarin + Bevacizumab and Cetuximab (OCFL-BC) as a Combination Regimen for Systemic Treatment of Advanced Colorectal Carcinoma With Potentially Resectable Liver and/or Lung Metastases. A Phase II Study||National Cancer Institute (NCI)||Active, not recruiting|June 2007|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|70 Years|No|||June 2009|August 6, 2009|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00513266||168407|
NCT00513279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBU107640|To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334|A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers||GlaxoSmithKline||Completed|June 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00513279||168406|
NCT00514618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334-06|Outpatient Cervical Ripening With Orally Administered Misoprostol in Diabetics|Outpatient Cervical Ripening and Labor Induction With Orally Administered Misoprostol for Term Pregnancies Complicated by Diabetes Mellitus||University of California, Irvine|No|Terminated|March 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 4, 2011|August 9, 2007|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00514618||168308|
NCT00546104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007578|Phase II Dasatinib Study in Advanced Breast Cancer|A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer||Duke University|No|Completed|October 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|October 16, 2007|Yes|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00546104||165927|
NCT00547690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9179|Acupuncture in Stroke Rehabilitation|Electro-acupuncture and Strengthening Exercise for Hemiplegic Elbow and Wrist Joints||University of Kansas Medical Center|No|Terminated|April 2003|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|N/A|No|||June 2012|June 4, 2012|October 18, 2007||No|Expired IRB approval|No||https://clinicaltrials.gov/show/NCT00547690||165811|
NCT00548002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210275|Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia||FINLEVO|Helsinki University|No|Completed|January 1999|August 2002|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|430|Samples With DNA|Whole blood|Both|18 Years|N/A|No||Adult patients with at least 1 blood culture positive for Staphylococcus aureus were        included within 1 to 7 days of blood culture sampling.|October 2007|October 22, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00548002||165788|
NCT00516997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821000-191100|Increase Infusion Rates of Intravenous Fat Emulsions|Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants During the First Week of Life||OSF Healthcare System|No|Completed|June 2005|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|N/A|2 Days|No|||August 2007|August 15, 2007|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00516997||168133|
NCT00517257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA2580025|Atorvastatin for the Treatment of Retinal Vein Occlusion|Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO)|ATORVO|University of Toronto|Yes|Recruiting|August 2007|September 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 23, 2008|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00517257||168113|
NCT00516594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 205UC|The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption|The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption on Blood Lipids Risk Factors for Heart Disease in Healthy "Normal" and Hyperlipidemic Subjects||University of Toronto||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 16, 2009|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00516594||168161|
NCT00513422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-IM-LEGS-L|The Long-term Evaluation of Glucosamine Sulphate Study|The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis.|LEGS|University of Sydney|No|Active, not recruiting|October 2007|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|600|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||June 2010|June 29, 2010|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513422||168395|
NCT00513682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT20CF07-01|Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)|Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)||Forest Laboratories|Yes|Completed|July 2007|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|7 Years|11 Years|No|||March 2014|March 5, 2014|August 7, 2007|Yes|Yes||No|November 3, 2010|https://clinicaltrials.gov/show/NCT00513682||168375|No limitations
NCT00515450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0998-B1|Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis|A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis||Benesis Corporation|No|Completed|July 2007|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Both|16 Years|N/A|No|||July 2010|July 29, 2010|August 10, 2007||||No||https://clinicaltrials.gov/show/NCT00515450||168245|
NCT00516061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-12-008|Relationship of Peritoneal Solute Transport Rate With VEGF in Children Undergoing Peritoneal Dialysis|||Samsung Medical Center|Yes|Recruiting|December 2006|December 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Anticipated|40|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||December 2006|August 13, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00516061||168200|
NCT00516087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21000-NATELLA|LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)|Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes to Patients With EBV-Positive Nasopharyngeal Carcinoma|NATELLA|Baylor College of Medicine|Yes|Completed|August 2007|July 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|N/A|No|||May 2014|May 22, 2014|August 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00516087||168198|
NCT00516490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-47/07|GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles|||V.K.V. American Hospital, Istanbul|No|Completed|September 2006|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|570|||Female|18 Years|45 Years|No|||August 2007|August 14, 2007|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516490||168167|
NCT00516828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I186|Sorafenib and Low Dose Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS||Canadian Cancer Trials Group|No|Completed|July 2007|January 2013|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|60 Years|N/A|No|||July 2012|October 5, 2015|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516828||168146|
NCT00516841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206OC201|A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer|||Facet Biotech|No|Terminated|August 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|N/A|No|||August 2012|August 21, 2012|August 14, 2007|Yes|Yes|Decision to terminate recruitment based on lack of efficacy|No||https://clinicaltrials.gov/show/NCT00516841||168145|
NCT00512941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-15|Laboratory Profile of Hepatitis B and C in Users of a Reference Service|Laboratory Profile of Hepatitis B and C in Users of a Reference Service||UPECLIN HC FM Botucatu Unesp|Yes|Completed|June 2007|August 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||7|Actual|531|||Both|18 Years|N/A|No|Probability Sample|Patients with laboratory tests positive for hepatitis B and/or C|September 2008|September 4, 2008|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512941||168430|
NCT00512655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP MM 19-08-12-05-30-08|Trial to Reduce Falls Incidence Rate in Frail Elderly|Randomized Controlled Trial to Reduce Falls Incidence Rate in Frail Elderly|CP|Radboud University|No|Terminated|January 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|320|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2010|July 6, 2010|August 7, 2007||No|Extremely difficult recruitment. Preliminary analysis showed no effect of the intervention.|No||https://clinicaltrials.gov/show/NCT00512655||168452|
NCT00513305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18477/3059/AM/US-CA|Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia|An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide Compared With Low-Dose Cytarabine Alone for the Treatment of Elderly Patients With Acute Myeloid Leukemia||Teva Pharmaceutical Industries||Terminated|October 2007|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|60 Years|N/A|No|||July 2012|July 24, 2012|August 6, 2007|Yes|Yes|Study has been stopped by sponsor decision|No|July 29, 2010|https://clinicaltrials.gov/show/NCT00513305||168404|In September 2009, the sponsor decided to stop the study due to difficulty in enrollment. The study was stopped prior to the first planned interim analysis. Most of the analysis planned in the protocol was not performed.
NCT00513565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS 105510|A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers|A Randomised, Placebo-controlled, Double-dummy, Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GSK561679 and Lorazepam (Comparator) in Healthy Subjects||GlaxoSmithKline|No|Completed|September 2007|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|22|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|August 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00513565||168384|
NCT00513799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9000C4|The Natural History of Community-Associated MRSA Infections and Decolonization Strategies|The Natural History of Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections and an Evaluation of Decolonization Strategies|StLStaRS|Washington University School of Medicine|Yes|Completed|March 2007|December 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|300|||Both|6 Months|N/A|No|||July 2015|July 7, 2015|August 8, 2007||No||No|March 2, 2011|https://clinicaltrials.gov/show/NCT00513799||168366|
NCT00514384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Serial Biomarker in ADHF|Serial Measurements of Biomarker in Patients With Acute Decompensated Heart Failure|Prognostic Value of Serial Biomarker Measurements in Patients With ADHF||University Hospital, Basel, Switzerland|No|Completed|February 2007|December 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Both|18 Years|N/A|No|Probability Sample|Patients with ADHF not requiering ICU|December 2014|December 2, 2014|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514384||168326|
NCT00547365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000572104|Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction|Therapeutic Potential of Human Immune Globulin Intravenous (IGIV) in Patients With Cardiac-Associated Light Chain (AL) Amyloidosis||University of Tennessee|No|Completed|October 2007|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|October 19, 2007|Yes|Yes||No|February 4, 2013|https://clinicaltrials.gov/show/NCT00547365||165835|
NCT00546741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-026|Drug Interaction With Metformin|Pharmacokinetic Drug Interaction Study With Dapagliflozin and Metformin in Healthy Subjects||AstraZeneca|No|Completed|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|October 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00546741||165880|
NCT00546754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-333|BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)|BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure With|EASE|Merck Sharp & Dohme Corp.||Completed|May 2007|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|808|||Both|18 Years|75 Years|No|||October 2015|October 9, 2015|October 17, 2007|No|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00546754||165879|
NCT00546767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0123|Home-Based Assessment for Alzheimer Disease Prevention|Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer Disease Prevention Research in People Over 75 Years Old|HBA|Alzheimer's Disease Cooperative Study (ADCS)|Yes|Completed|September 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|640|||Both|75 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 15, 2014|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00546767||165878|
NCT00517270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1932-02|A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study|High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study.||Hospital Authority, Hong Kong||Recruiting|March 2003|April 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A||||July 2010|July 6, 2010|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517270||168112|
NCT00512837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/047|Mobile Phone Based Structured Intervention|A Mobile Phone Based Structured Intervention to Achieve Asthma Control in Patients With Uncontrolled Persistent Asthma: Pragmatic Randomised Controlled Trial||University of Aberdeen|Yes|Completed|November 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Anticipated|312|||Both|12 Years|N/A|No|||June 2008|January 20, 2016|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512837||168438|
NCT00513110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/099|A Possible Therapeutic Role for Adenosine During Inflammation|A Possible Therapeutic Role for Adenosine During Inflammation||Radboud University|No|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|33|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2007|September 30, 2009|August 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00513110||168418|
NCT00512824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A011-CPDI|Calcium, Probiotics and Acute Diarrheal Disease Among Indonesian Children|Calcium, Probiotics and Acute Diarrheal Disease Among Indonesian Children Aged 1-6 Years in Low Socio-economic Urban Area of East Jakarta||Wageningen University|Yes|Completed|August 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|494|||Both|1 Year|6 Years|Accepts Healthy Volunteers|||January 2011|January 7, 2011|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512824||168439|
NCT00513435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00192|Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)||National Cancer Institute (NCI)|Yes|Completed|July 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2013|April 2, 2014|August 6, 2007|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00513435||168394|
NCT00513448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311M53442|Promoting Physical Activity for Persons With Multiple Sclerosis|Comparing Individualized Rehabilitation to a Group Wellness Intervention for Persons With Multiple Sclerosis||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2005|November 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|75 Years|No|||August 2007|August 7, 2007|August 7, 2007||||No||https://clinicaltrials.gov/show/NCT00513448||168393|
NCT00513695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6488|Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer|A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer||University of Washington|No|Active, not recruiting|June 2007|||August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|N/A|N/A|No|||January 2016|January 5, 2016|August 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00513695||168374|
NCT00515762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALOPER-2|Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling|Pilot Trial of Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling (ELASTO-GEL CAPS)in Breast Cancer Patients||Hospital San Carlos, Madrid|Yes|Completed|May 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Female|18 Years|75 Years|No|||June 2010|August 8, 2011|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515762||168223|
NCT00515775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00015|Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children|||Technische Universität Dresden||Completed|September 2005|October 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|27|||Both|6 Years|18 Years|No|Probability Sample|Allergic asthmatics|October 2008|February 12, 2009|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515775||168222|
NCT00516100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05LUN01|Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC|Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer||Aptium Oncology Research Network|No|Active, not recruiting|January 2006|August 2012|Anticipated|January 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||January 2010|January 14, 2010|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00516100||168197|
NCT00516776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5.2007.910|The Innate Immune System and Inflammatory Bowel Disease|The Innate Immune System and Inflammatory Bowel Disease||Norwegian University of Science and Technology|No|Recruiting|June 2007|December 2023|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|400|Samples With DNA|Intestinal biopsies Plasma/serum Peripheral blood monocytes|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients from endoscopy unit and outpatients clinic with ulcerative colitis, Crohn's        disease and healthy controls|February 2016|February 9, 2016|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516776||168148|
NCT00517127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|431/2005|Crystalloids Versus Colloids During Surgery|A Comparison of Crystalloids vs. Colloids for Intraoperative Goal-directed Fluid Management|CC|Medical University of Vienna|Yes|Recruiting|September 2006|February 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1112|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517127||168123|
NCT00513292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00341|Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery|A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|July 2007|||June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Female|18 Years|N/A|No|||April 2015|August 26, 2015|August 6, 2007|Yes|Yes||No|July 14, 2015|https://clinicaltrials.gov/show/NCT00513292||168405|
NCT00514410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G0373|Folate Augmentation of Treatment - Evaluation for Depression: a Randomised Controlled Trial|Folate Augmentation of Treatment - Evaluation for Depression: a Randomised Controlled Trial|FolATED|Bangor University|Yes|Completed|July 2007|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|730|||Both|18 Years|N/A|No|||February 2009|October 11, 2011|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514410||168324|
NCT00514137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00208|Sunitinib in Treating Patients With Relapsed Multiple Myeloma|A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma||National Cancer Institute (NCI)|Yes|Completed|September 2007|August 2010|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2013|May 12, 2014|August 8, 2007|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT00514137||168343|
NCT00514371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA200-003|A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma|Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma|TIME-2|Bristol-Myers Squibb||Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514371||168327|
NCT00516555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06/1130|EBIS: The Eindhoven Breech Intervention Study|Ebis: The Eindhoven Breech Intervention Study||Catharina Ziekenhuis Eindhoven|Yes|Completed|October 2007|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|Samples Without DNA|Blood samples for thyroid hormone status (Tsh, Ft4, anti-TPO)|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women with breech presentation at term in the region of Eindhoven, The        Netherlands.|March 2013|March 18, 2013|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00516555||168163|
NCT00516932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001300|Pharmacogenomics of Antidepressant Response in Children and Adolescents|Pharmacogenomics of Antidepressant Response in Children and Adolescents|PARCA|Duke University|Yes|Completed|May 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|211|Samples With DNA|Salivary DNA retained at the Duke Center for Human Genetics|Both|7 Years|17 Years|No|Non-Probability Sample|Males and Females        Age 7 -17 years        Pre-specified disorder of anxiety disorder, depressive disorder, eating disorder, or        obsessive-compulsive disorder.|April 2015|April 16, 2015|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516932||168138|
NCT00546442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-02446-19|Treatment Insulin Resistence in HCV G-1 Patient|Effect of Treatment of Insulin Resistance in Patients With Chronic Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a in Combination With Ribavirin in Current Clinical Practice|TRIC-1|Valme University Hospital|Yes|Completed|May 2006|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|65 Years|No|||October 2007|October 17, 2007|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00546442||165903|
NCT00546455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061257|A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity|Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver||University of California, San Diego|No|Recruiting|December 2007|April 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||July 2010|February 11, 2013|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546455||165902|
NCT00546780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA200-004|A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse|Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse|BMS TIME-1|Bristol-Myers Squibb|Yes|Completed|February 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546780||165877|
NCT00547092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7002|Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection|A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction||Eli Lilly and Company|No|Completed|October 2003|November 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|386|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547092||165854|
NCT00517283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-EW-GWAM|A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes|A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes||AstraZeneca|No|Completed|January 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|17|||Both|25 Years|75 Years|No|||January 2015|February 20, 2015|August 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517283||168111|
NCT00512850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-1999-P-001674/10|Folic Acid in Preventing Colorectal Polyps in Patients With Previous Colorectal Polyps|The Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS) Folic Acid Prevention Trial||Brigham and Women's Hospital|No|Active, not recruiting|May 1996|January 2020|Anticipated|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|672|||Both|N/A|75 Years|No|||July 2015|July 21, 2015|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512850||168437|
NCT00513123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN98-258|Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia|A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia||M.D. Anderson Cancer Center|No|Completed|September 2002|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Female|18 Years|N/A|No|Non-Probability Sample|Women 18 and older with an abnormal PAP.|July 2012|July 31, 2012|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513123||168417|
NCT00513162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0370|Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases|Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases||M.D. Anderson Cancer Center|No|Completed|July 2007|||September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||September 2012|September 18, 2012|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513162||168414|
NCT00513461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00897|S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate in Preventing Liver Cancer in Patients With Chronic Hepatitis C Infection|A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP||National Cancer Institute (NCI)|No|Active, not recruiting|October 2007|December 2013|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|August 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00513461||168392|
NCT00513474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558480|Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant|Rasburicase to Prevent Graft -Versus-Host Disease||Massachusetts General Hospital|Yes|Completed|January 2008|March 2013|Actual|March 2013|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|25|||Both|18 Years|65 Years|No|||May 2015|May 8, 2015|August 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00513474||168391|
NCT00513487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPJMR0052107|Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity|Assessment of the Effects of Multiple Nasal Antigen Challenges With Dust Mite Allergen on Local and Systemic Allergic Inflammation and Bronchoreactivity in Subjects With Allergic Rhinitis Sensitive to House Dust Mite - a Feasibility and Site Evaluation Study||Novartis|No|Completed|July 2007|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 14, 2008|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00513487||168390|
NCT00516464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4295|Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy|Evaluation of Ranibizumab on the Ease of Procedure and Complication Rate in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy||Retina Associates, Kansas City|No|Recruiting|August 2007|August 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|No|||August 2007|August 14, 2007|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516464||168169|
NCT00516802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU36-73|A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine|A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours||AstraZeneca|Yes|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516802||168147|
NCT00515528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15232B|Vaccination Plus Ontak in Patients With Metastatic Melanoma|Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma||University of Chicago|Yes|Active, not recruiting|April 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|August 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515528||168240|
NCT00515541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1068|Lovaza's Effect on the Activation of Platelets|Effect of the Omega n3 Fatty on Human Platelet Function|LEAP|Invitrox|Yes|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 27, 2013|August 10, 2007|Yes|Yes||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00515541||168239|Major limitation for this pilot study was the small number of patients analyzed per group. Despite the small numbers we were able to show the statistical significance for a change in the platelet surface charge with Lovaza.
NCT00515554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD18|HD18 for Advanced Stages in Hodgkins Lymphoma|||University of Cologne|Yes|Active, not recruiting|May 2008|December 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1500|||Both|18 Years|60 Years|No|||October 2015|October 30, 2015|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515554||168238|
NCT00512954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2671|Causes, Characteristics and Mechanisms of Infective Exacerbations in Subjects With Asthma and Chronic Obstructive Pulmonary Disease (COPD)|A Prospective One Year Study of the Causes, Characteristics, Mechanisms and Kinetics of Exacerbations in Subjects With Asthma||McMaster University|No|Completed|April 2007|July 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Probability Sample|Asthmatics with 1 or more exacerbation in last calendar year.|July 2009|January 18, 2011|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512954||168429|
NCT00512967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 03-112|The Occurence of Inflammation and Oxidative Stress in Lung Diseases|The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants||Maastricht University Medical Center|No|Completed|September 2005|June 2006|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Actual|76|Samples With DNA|blood samples were collected|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|lung patients visiting the out-patient clinic of the Academic Hospital Maastricht|February 2008|February 25, 2008|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00512967||168428|
NCT00512980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVAG-14 pilot|PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma|A Randomized Phase II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Patients With Intermediate Stage Hodgkin's Lymphoma||University of Cologne|No|Terminated|August 2008|||November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||||||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|August 7, 2007||No|lower recruitment rates as expected|No||https://clinicaltrials.gov/show/NCT00512980||168427|
NCT00513318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC2407|Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies|Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies||University of California, San Francisco|Yes|Terminated|August 2004|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|70 Years|No|Non-Probability Sample|Adults with hematopoietic malignancies ages 55 to 70.|August 2013|August 1, 2013|August 7, 2007||No|Insufficient enrollment to justify keeping open.|No||https://clinicaltrials.gov/show/NCT00513318||168403|
NCT00512694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008875|Duke Lupus Registry|Duke Lupus Registry||Duke University|No|Recruiting|July 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Blood samples will be collected for future research.|Both|18 Years|N/A|No|Non-Probability Sample|Any patients with lupus.|August 2015|August 7, 2015|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512694||168449|
NCT00512707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD047722-01A1|Effect of Testosterone in Men With Erectile Dysfunction|Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction|TED|Boston University|Yes|Completed|November 2006|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|152|||Male|40 Years|70 Years|No|||March 2012|March 6, 2012|August 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00512707||168448|
NCT00515567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14514A|Explanted Lung Tissues With Pulmonary Fibrosis|Utilization of Explanted Lungs for Isolation of Tissue Samples and Primary Cell Lines to Study Pulmonary Fibrosis||University of Chicago|No|Recruiting|February 2006|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|explanted lung tissue|Both|18 Years|N/A|No|Non-Probability Sample|Subjects listed for lung transplant|June 2015|June 11, 2015|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00515567||168237|
NCT00515606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210586|Noninvasive Positive Pressure Ventilation Using Helium:Oxygen Versus Air:Oxygen in Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease Patients Exposed to Sulfur Mustard|||Baqiyatallah Medical Sciences University||Completed|February 2007|June 2007||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|||||||Male|38 Years|59 Years||||February 2007|August 13, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00515606||168234|
NCT00515619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0774|Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures|An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures||UCB Pharma|No|Completed|December 2004|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|376|||Both|16 Years|70 Years|No|||June 2015|June 16, 2015|August 13, 2007|Yes|Yes||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00515619||168233|
NCT00515632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRF2593-307|Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy|A Randomized, Double-blind, Parallel-group, Placebo and Active Comparator (Pioglitazone)-Controlled Clinical Study to Determine the Efficacy and Safety of Balaglitazone in Patients With Type 2 Diabetes on Stable Insulin Therapy|BALLET|Rheoscience A/S|No|Completed|July 2007|October 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|409|||Both|18 Years|N/A|No|||July 2010|July 22, 2010|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515632||168232|
NCT00546468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|_NCCCTS-052|Clinical Study on Laparoscopic Gastrectomy for Early Gastric Cancer (COACT_0301)|Prospective Randomized Trial of Laparoscopy-assisted Distal Gastrectomy (LADG) Versus Open Distal Gastrectomy (ODG) in Patients With Early Gastric Cancer (EGC)|NCC052|National Cancer Center, Korea|Yes|Completed|June 2003|December 2010|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|80 Years|No|||May 2012|May 22, 2012|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00546468||165901|
NCT00515593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-004-DE|PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)|Non-interventional Open Single Arm, Multicentre Study to Observe the Use of Preotact in Patients With Severe Postmenopausal Osteoporosis||Nycomed|Yes|Completed|September 2006|July 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with severe postmenopausal osteoporosis|May 2012|May 4, 2012|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515593||168235|
NCT00517296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061178|Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas|EUS Guided Treatment With Humira for Crohn's Perianal Fistulas||Vanderbilt University|No|Active, not recruiting|January 2008|December 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|August 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517296||168110|
NCT00512863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-757|A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma|A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma||Abbott|No|Withdrawn|August 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|272|||Both|18 Years|65 Years|No|||November 2007|November 5, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00512863||168436|
NCT00513136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC2007-46|Fatigue Intervention Trial for Breast Cancer Survivors|A Randomized Trial to Evaluate a Family-focused Mind Body Medicine Intervention to Reduce Fatigue Among Breast Cancer Survivors||Mercy Medical Center|No|Completed|May 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|N/A|N/A|No|||April 2012|April 18, 2012|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513136||168416|
NCT00512876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU# 07-23022|Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization|Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization||Walter Reed Army Medical Center||Completed|August 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|August 6, 2007||No||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00512876||168435|
NCT00513734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003171|A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically Ill|Randomised Trial Comparing the Efficacy of Ocular Lubricant (Lacrilube) and Polyacrylamide Hydrogel Dressing (Geliperm) for the Prevention of Exposure Keratopathy in the Critically Ill||Barts & The London NHS Trust|Yes|Completed|September 2004|February 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||August 2007|August 8, 2007|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00513734||168371|
NCT00513747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-10501|Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia|A Phase III Intergroup CLL Study of Asymptomatic Patients With Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation With Later Treatment in the High Risk Genetic Subset With IGVH Unmutated Disease||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|January 2008|December 2033|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00513747||168370|
NCT00514007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-101|Study of Continuous OSI-906 Dosing|A Phase I Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients With Advanced Solid Tumors||Astellas Pharma Inc|No|Completed|December 2006|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|August 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00514007||168352|
NCT00514020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0716|Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer|Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study||Vanderbilt-Ingram Cancer Center|Yes|Completed|August 2007|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|August 8, 2007|Yes|Yes||No|September 18, 2012|https://clinicaltrials.gov/show/NCT00514020||168351|
NCT00515814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-PT-2005|Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors|A Prospective Open Pilot Study With Functional Placebo-control to Evaluate the Efficacy and Tolerability/Safety of a Subretinal Implant in Blind Patients in Accordance With ICH/GCP Guidelines||Retina Implant AG|Yes|Completed|September 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|78 Years|No|||June 2011|June 8, 2011|August 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00515814||168219|
NCT00516152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-2214|Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT|Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation||University of California, San Francisco|Yes|Completed|November 2002|November 2007|Actual|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|15 Years|61 Years|No|||January 2009|January 22, 2009|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00516152||168193|
NCT00516542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOL-06019-L|Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer|A Phase I Study of DHEA in Combination With Letrozole in ER- Breast Cancer||OHSU Knight Cancer Institute|Yes|Terminated|June 2007|December 2010|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|60 Years|N/A|No|||July 2012|July 23, 2012|August 14, 2007|No|Yes|Study was terminated due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00516542||168164|
NCT00516893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS201|Natalizumab High Titer Immunogenicity and Safety|A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis||Biogen|No|Completed|October 2006|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|113|||Both|18 Years|55 Years|No|||May 2014|May 1, 2014|August 14, 2007|Yes|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00516893||168141|
NCT00516906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-010691|Clinical Performance of a Chlorhexidine Antimicrobial Dressing|Clinical Performance of a Chlorhexidine Antimicrobial Dressing||3M|No|Completed|October 2007|January 2008|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|August 14, 2007|No|Yes||No|March 3, 2010|https://clinicaltrials.gov/show/NCT00516906||168140|This trial evaluated the dressing for it's securement and ease of use adaption into healthcare practices compared to a standard transparent dressing. The sample size was too small to evaluate any effect on Catheter Related-Bloodstream Infection.
NCT00516919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF-06-018|Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons|Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons||Yale University|No|Completed|August 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|August 15, 2007||No||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00516919||168139|
NCT00513019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703M03384|Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation|A Double-Blind Study of Lamictal in Neurotic Excoriation||University of Chicago|Yes|Completed|August 2007|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||August 2013|August 6, 2013|August 7, 2007|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00513019||168425|
NCT00513032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-081(02-006)|Interaction Between Anaesthetics and Methylene Blue|Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery||University Hospital, Geneva|No|Completed|January 2005|April 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||2|Actual|22|||Both|18 Years|N/A|No|||August 2007|August 7, 2007|August 7, 2007||||No||https://clinicaltrials.gov/show/NCT00513032||168424|
NCT00513578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558127|Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome|Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS||National Cancer Institute (NCI)||Active, not recruiting|January 2007|||January 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2009|January 3, 2014|August 6, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00513578||168383|
NCT00515879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078308|Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia|D-cycloserine Enhancement of Exposure in Social Phobia||Boston University|Yes|Completed|December 2007|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|August 10, 2007|Yes|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00515879||168214|
NCT00513825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-02-30-3595(2)|Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN|The Evaluation of the Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN) in Patients With Pulmonary Edema,Severe Heart Failure or Uncontrolled Hypertension||Tehran University of Medical Sciences|No|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|72|||Both|18 Years|N/A|No|||November 2008|November 23, 2008|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513825||168365|
NCT00513851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-930-102|Phase 1 Study of OSI-930 in Cancer Patients|A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients With Advanced Solid Tumors||Astellas Pharma Inc|No|Completed|April 2006|September 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|August 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00513851||168364|
NCT00515294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC R49-CE000946|Acute and Residual Effects of Caffeinated Beer|Acute and Residual Effects of Beer VS. Caffeinated Beer On Simulated Driving||Boston University|Yes|Recruiting|October 2006|October 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|144|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00515294||168257|
NCT00515307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRC 85-15|Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia|In-Vitro Transdifferentiation of Mesenchymal Stem Cells to Hepatocytes and Allogenic Transplantation of Hepatocytes to the Patients With Homozygous Familial Hypercholesterolemia||University of Tehran|Yes|Completed|June 2007|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|N/A|N/A|No|||August 2008|August 28, 2008|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00515307||168256|
NCT00516607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26054|Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas|Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|July 2007|||November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516607||168160|
NCT00517023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q1907/13|Eastbourne Syncope Assessment Study II|Eastbourne Syncope Assessment Study II|EaSyAS II|Eastbourne General Hospital|No|Recruiting|August 2007|August 2009|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|240|||Both|16 Years|N/A|No|||May 2008|May 6, 2008|August 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00517023||168131|
NCT00517036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073765|Omega-3 Fatty Acids for Treating Adults With Major Depression|Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters||Cedars-Sinai Medical Center|Yes|Completed|July 2006|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|196|||Both|18 Years|80 Years|No|||April 2013|April 2, 2013|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00517036||168130|
NCT00513175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC2101-CC01251|Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia|Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia||University of California, San Francisco|Yes|Completed|October 2001|November 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||44|||Both|16 Years|75 Years|No|Probability Sample|Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia|November 2012|November 7, 2012|August 7, 2007||||No||https://clinicaltrials.gov/show/NCT00513175||168413|
NCT00513188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20060912|Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma|A Pilot Study of the Efficacy of the Chop-Montak Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma||University of Miami Sylvester Comprehensive Cancer Center|Yes|Withdrawn|February 2007|||June 2008|Actual|N/A|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|65 Years|No|||August 2013|July 25, 2014|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00513188||168412|
NCT00513201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Second University of Naples|Lyspro Insulin vs Regular Insulin in Cirrhotic Patients|||Second University of Naples|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|48 Years|67 Years||||August 2007|August 7, 2007|August 7, 2007||||No||https://clinicaltrials.gov/show/NCT00513201||168411|
NCT00513149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612040R|Platelet Function Assessment for Atherothrombotic Patients|Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study||National Taiwan University Hospital|Yes|Recruiting|July 2006|July 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|80 Years|No|||January 2011|January 20, 2011|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00513149||168415|
NCT00546611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-019|The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)|A Phase I, Single-Centre, Open-Label, Fixed-Dose Study of the Safety and Efficacy of up- to Three-Days Application of 0.05% PEP005 Topical Gel in the Treatment of Patients With Common Wart(s) (Verruca[e] Vulgaris) on the Dorsal Hand||Peplin|No|Withdrawn|October 2007|||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 18, 2007|||No enrolement|No||https://clinicaltrials.gov/show/NCT00546611||165890|
NCT00546624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0777-026|GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)|||Merck Sharp & Dohme Corp.||Completed|November 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|38|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00546624||165889|
NCT00546923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B-101568|Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients|A Randomized, Double-Blind, Placebo-Controlled, Pilot Study To Evaluate The Efficacy And Safety Of Venlafaxine Extended-Release In Depressed And Anxious Patients With Multiple, Unexplained Somatic Symptoms||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2004|June 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||210|||Both|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546923||165866|
NCT00516867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 290815|Does Sunbed Radiation With Mainly UVA Provoke Cutaneous Vitamin D Synthesis in Humans?|Sunbed Radiation Provoke Cutaneous Vitamin D Synthesis in Humans, a Randomized Controlled Trial||Bispebjerg Hospital|No|Completed|February 2006|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|41|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|August 15, 2007|August 14, 2007||||No||https://clinicaltrials.gov/show/NCT00516867||168143|
NCT00517140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2003.118|Vaginal Birth After Caesarean Section - Effect on Maternal Psychosocial Function|Vaginal Birth After Caesarean Section - Effect on Maternal Psychosocial Function||Hospital Authority, Hong Kong||Completed|September 2003|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|262|||Female|N/A|N/A||||June 2011|June 14, 2011|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517140||168122|
NCT00512720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-174|Clinical Outcomes of Three Different Percutaneous Revascularization Strategies for the Treatment of Lifestyle Limiting Claudication: A Retrospective Analysis|Clinical Outcomes of Three Different Percutaneous Revascularization Strategies for the Treatment of Lifestyle Limiting Claudication: A Retrospective Analysis|FIX-IT Retro|Spectrum Health Hospitals|No|Completed|August 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|355|Samples With DNA|blood|Both|18 Years|90 Years|No|Probability Sample|male and female over the age of 18 who have had Three Different Percutaneous        Revascularization Strategies|February 2013|February 20, 2013|August 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512720||168447|
NCT00516204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAT-CRE-2007/3|Diabetic Under 70 (Diabetics Below 70)|Diabetic Under 70 (Diabetics Below 70)||AstraZeneca||Completed|July 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|685|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female secondary prevention patients with: coronary disease with event: acute        coronary syndrome, status post MI, PTCA, CABG, angiographically verified), PAVK (min. IIb        or S.p. revascularization), stroke/TIA, carotis-plaque (asymptomatic min. 70% or S.p.        revascularization), Diabetes Mellitus (type I, II)|October 2014|October 29, 2014|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00516204||168189|
NCT00517166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAQ 06-010|Survey of Tourniquet Use in a Combat Support Hospital|Survey of Tourniquet Use in a Combat Support Hospital||United States Army Institute of Surgical Research|No|Completed|August 2006|March 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|584|||Both|18 Years|65 Years|No|Non-Probability Sample|Combat soldiers on whom tourniquet was applied.|December 2011|December 19, 2011|August 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00517166||168120|
NCT00512746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558413|Screening for Lung Cancer in Current or Past Smokers With Chronic Obstructive Pulmonary Disease|A Randomised Controlled Trial of Surveillance for the Early Detection of Lung Cancer in an at Risk Group [Lung-SEARCH Trial]||University College, London|Yes|Completed|August 2007|||March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1569|||Both|N/A|N/A|No|||December 2011|December 20, 2011|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512746||168445|
NCT00513617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|485|Effectiveness of Arginine as a Treatment for Sickle Cell Anemia|Arginine Supplementation in Sickle Cell Anemia: Physiological and Prophylactic Effects|Arginine|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|June 2004|January 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|128|||Both|5 Years|N/A|No|||June 2009|June 19, 2009|August 6, 2007|Yes|Yes||No|February 23, 2009|https://clinicaltrials.gov/show/NCT00513617||168380|Adult enrollment was slower than expected. Adult subjects were more likely than peds to drop-out due to SCD pain crisis. Higher doses of arginine (such as used in animal studies) were limited by number of daily pills required.
NCT00514163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JACCRO PC-01|GEM vs GEM+TS-1 for Advanced Pancreatic Cancer|Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer||Japan Clinical Cancer Research Organization|Yes|Completed|June 2007|December 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|20 Years|75 Years|No|||June 2011|June 27, 2011|August 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00514163||168341|
NCT00515892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-8015-1003|Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin'd Lymphoma (NHL)|NHL|Cambridge Antibody Technology|No|Recruiting|August 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||August 2007|August 10, 2007|August 10, 2007||||No||https://clinicaltrials.gov/show/NCT00515892||168213|
NCT00515905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 20-2004|One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators|Lung: One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators After Deflation and Re-expansion of the Lung During Thoracic Surgery||University of Zurich|No|Completed|October 2004|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|76|||Both|18 Years|75 Years|No|||March 2008|September 14, 2010|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515905||168212|
NCT00516217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50602|Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma||Alliance for Clinical Trials in Oncology|No|Completed|June 2008|February 2015|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|120 Years|No|||November 2015|November 23, 2015|August 14, 2007|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00516217||168188|
NCT00516230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-2007-04-080|Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer|Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer||Samsung Medical Center|Yes|Recruiting|January 2006|December 2011|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|200|||Both|N/A|N/A|No|||August 2007|August 13, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00516230||168187|
NCT00516295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00369|Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma|A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma||National Cancer Institute (NCI)|Yes|Completed|February 2008|January 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Both|1 Year|29 Years|No|||July 2014|August 20, 2014|August 14, 2007|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00516295||168182|In preparing to re-open for randomized enrollment in November, 2008 the study committee was asked to amend the study and the decision was made to close AEWS0521 for administrative purpose.
NCT00516308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHT-P-07-004|A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease|A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease|NightHawk|FoxHollow Technologies|No|Terminated|August 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|N/A|N/A|No|||January 2008|January 16, 2008|August 13, 2007|||Other|No||https://clinicaltrials.gov/show/NCT00516308||168181|
NCT00516321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPL103922|Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease|Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin||GlaxoSmithKline|No|Completed|October 2007|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|687|||Both|18 Years|N/A|No|||August 2012|October 10, 2013|August 13, 2007|Yes|Yes||No|March 22, 2012|https://clinicaltrials.gov/show/NCT00516321||168180|
NCT00515957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20996|Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)|Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody Administration to Patients With EBV-Positive Nasopharyngeal Carcinoma|DELLA|Baylor College of Medicine|Yes|Withdrawn|August 2007|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||April 2012|April 13, 2012|August 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00515957||168208|
NCT00517010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715285|Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration|Phase 1 Pilot Open Label Prospective Observational Study of Safety and Tolerability of Lucentis Combined With Proton Beam Irradiation in Treating Exudative Age-related Macular Degeneration||University of California, Davis|No|Completed|May 2007|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|50 Years|N/A|No|||August 2010|August 18, 2010|August 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00517010||168132|
NCT00516633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVFOU-8215|Intervention Study to Improve Adherence in Asthma|Does Improved Information in the Form of Group Discussions With Parents of Newly Diagnosed Asth-Matic Children Lead to a Better Quality of Life for the Families, an Improved Adherence and Better Devel-Opment of the Lung Function of the Children?||Värmland County Council, Sweden|Yes|Completed|April 1998|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|6 Years|No|||August 2007|August 14, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00516633||168158|
NCT00512889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-250|Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma|A Pilot Study of the Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma||Dana-Farber Cancer Institute|Yes|Completed|August 2007|January 2013|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|August 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512889||168434|
NCT00513500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-A-00-00020-00-5|Zambia Integrated Management of Malaria and Pneumonia Study|Zambia Integrated Management of Malaria and Pneumonia Study|ZIMMAPS|Boston University|Yes|Completed|June 2007|September 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3125|||Both|6 Months|5 Years|No|||July 2010|July 13, 2010|August 7, 2007||No||No|April 27, 2010|https://clinicaltrials.gov/show/NCT00513500||168389|Imbalance in enrollment. More patients enrolled in the control arm possibly due to many control community health workers working full time and available to see patients all day.
NCT00546637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221009|Fesoterodine "add-on" Male Overactive Bladder Study|A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An "Add-On" Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.||Pfizer||Completed|November 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|947|||Male|40 Years|N/A|No|||February 2011|February 15, 2011|October 18, 2007|Yes|Yes||No|January 11, 2010|https://clinicaltrials.gov/show/NCT00546637||165888|
NCT00546962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-02-014R|Tissue Bank for Pulmonary Diseases|Tissue Bank for Pulmonary Diseases||Children's Hospital Boston|Yes|Recruiting|April 1999|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Cystic Fibrosis Patients, Pulmonary Patients|May 2011|May 12, 2011|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546962||165863|
NCT00546936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4145s|Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis|Ranibizumab vs PDT for Presumed Ocular Histoplasmosis||Barnes Retina Institute|Yes|Recruiting|October 2007|April 2010|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||April 2009|April 15, 2009|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546936||165865|
NCT00514657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCB-1D-01|Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2|Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2 (Randomised Controlled Phase II Clinical Trial)||Kaken Pharmaceutical|No|Completed|December 2001|February 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|91|||Both|20 Years|65 Years|No|||August 2007|August 9, 2007|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00514657||168306|
NCT00514670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01-0014|A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program|A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program||Children's Hospital Boston|No|Completed|March 2006|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|285|||Both|N/A|N/A|No|||August 2007|August 9, 2007|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00514670||168305|
NCT00514995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McElroy|Sodium Oxybate in the Treatment of Binge Eating Disorder|||Lindner Center of HOPE||Completed|August 2007|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|21 Years|65 Years|No|||June 2011|June 21, 2011|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514995||168280|
NCT00525356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSTEAD trial|INSTEAD Trial: INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection|INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection|INSTEAD|Medtronic Cardiovascular|Yes|Completed|February 2002|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|N/A|N/A|No|||September 2007|October 28, 2015|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525356||167498|
NCT00525642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX-619|Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer|A Chinese Multi-Center,Randomized Study of Combination or Sequential Use of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy for Node Positive Breast Cancer||Fudan University|Yes|Active, not recruiting|June 2003|June 2015|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|603|||Female|18 Years|70 Years|No|||August 2007|September 4, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00525642||167476|
NCT00513344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.38.MET|Efficacy of Polyphenols From Milk and Dark Chocolate|Efficacy of Polyphenols From Milk and Dark Chocolate||Nestlé|No|Completed|June 2008|April 2012|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|6|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|August 6, 2007||No||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00513344||168401|
NCT00514683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.30|Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis|A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.||Boehringer Ingelheim||Completed|August 2007|||June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|432|||Both|40 Years|N/A|No|||January 2015|January 5, 2015|August 9, 2007||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00514683||168304|There were numerous additional pre-specified endpoints. Full results are available under the BI Transparency web page ( http://trials.boehringer-ingelheim.com/trial_results.html )
NCT00514696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-CS008|Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia|Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia|PR-CS008|La Jolla Pharmaceutical Company|Yes|Completed|February 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|August 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00514696||168303|
NCT00515268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC103711|Endotoxin Challenge Study For Healthy Men and Women|A Double Blind, Placebo Controlled, Repeat Dose Study to Compare the Effectiveness of Two Doses of GSK256066 With Placebo in Reducing Lung Inflammation Following Segmental LPS Challenge in Healthy Volunteers||GlaxoSmithKline|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00515268||168259|
NCT00522522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01292|Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy|Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy Until Being Confirmed (EPILIVE Study)||UCB Pharma|Yes|Completed|February 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|400|||Both|16 Years|N/A|No|Non-Probability Sample|Patients being diagnosed of any kind of EPILEPSY (criteria ILAE 2005) and with diagnosis        being confirmed by a Neurologist over the last 6 months.|May 2012|May 29, 2012|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00522522||167713|
NCT00522535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYTHAGORAS|Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft|Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft|PYTHAGORAS|Lombard Medical|Yes|Active, not recruiting|April 2006|January 2018|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|21 Years|N/A|No|||June 2015|June 17, 2015|August 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00522535||167712|
NCT00512759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALACTIC|Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study|Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC)|GALACTIC|University Hospital, Basel, Switzerland|Yes|Recruiting|September 2007|September 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|770|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00512759||168444|
NCT00513045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPG20066126|A Self-Help Method for Nightmares|A Self-Help Method for Nightmares|Nightmares|Utrecht University|Yes|Completed|April 2007|November 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|399|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 18, 2008|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513045||168423|
NCT00516009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-7-247S|Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica|Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica||Ziv Hospital|No|Recruiting|August 2007|July 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||August 2007|August 13, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00516009||168204|
NCT00516620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 04-016C|Fruits, Vegetables, and Whole Grains: A Community-based Intervention|Fruits, Vegetables, and Whole Grains: A Community-based Intervention||University of Toronto|No|Completed|January 2005|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|960|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00516620||168159|
NCT00517309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-011|Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)|Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease|FUTURE|Merck Sharp & Dohme Corp.||Completed|December 2001|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|1877|||Female|16 Years|23 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|August 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517309||168109|
NCT00517322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112|Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan|Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan||Università degli Studi dell'Insubria|Yes|Recruiting|August 2007|August 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|65 Years|No|||August 2007|August 15, 2007|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517322||168108|
NCT00550186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-420-071206|Effect of Preload on Bladder Retention Volume During Spinal Anesthesia|The Effect of Intravascular Preload on Bladder Retention Volume During Spinal Anesthesia Induced Detrusor Blockade||Rijnstate Hospital|No|Recruiting|October 2007|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|150|||Both|20 Years|60 Years|No|||October 2007|October 26, 2007|October 26, 2007||||No||https://clinicaltrials.gov/show/NCT00550186||165624|
NCT00545792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-042|Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers|A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers||Dana-Farber Cancer Institute|Yes|Completed|May 2007|October 2013|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|N/A|No|||September 2015|September 10, 2015|October 15, 2007||No||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00545792||165951|
NCT00546026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sloan01|Does Mid-Gestation Placental Function Assessment Reduce Psychological Distress in Women With High-Risk Pregnancies?|Does Mid-Gestation Placental Function Assessment Reduce Psychological Distress in Women With High-Risk Pregnancies?||Mount Sinai Hospital, Canada|No|Not yet recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Female|18 Years|N/A||||October 2007|October 17, 2007|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00546026||165933|
NCT00546286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507A-153|A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)|A 12 Week, Open-Label, Study to Evaluate the Effectiveness of Dorzolamide-Timolol as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH)||Merck Sharp & Dohme Corp.||Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546286||165913|
NCT00546299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-42361|Gas Usage for Those With COPD Who Experience Low Oxygen Levels During Activities Only|Ambulatory Gas Usage in Patients With COPD and Exertional Hypoxemia||West Park Healthcare Centre|No|Completed|February 2003|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|27|||Both|N/A|N/A|No|||October 2007|October 17, 2007|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00546299||165912|
NCT00546598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05024|Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System|DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System PMA Post-approval Study||DePuy Orthopaedics|No|Terminated|January 2006|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|21 Years|80 Years|No|||June 2014|June 25, 2014|October 17, 2007|No|Yes|Sponsor withdrew PMA|No||https://clinicaltrials.gov/show/NCT00546598||165891|
NCT00547248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109509|Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines|Booster Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in Children Who Completed the Primary Vaccination Course in Study 107007||GlaxoSmithKline||Completed|October 2007|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|756|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||March 2011|March 10, 2011|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547248||165843|
NCT00547261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED5710|Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer|Phase I Dose Escalation and Pharmacokinetic Study of SSR97225 Administered as a 1 Hour IV Infusion D1 Every 3 Weeks (Arm A) or Administered as a 1hour IV Infusion D1, D8, D15 Every 3 Weeks (Arm B) in Patients With Refractory Solid Tumors||Sanofi||Terminated|October 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||April 2009|April 16, 2009|October 18, 2007|No|Yes|Due to lack of supply of the investigational product.|No||https://clinicaltrials.gov/show/NCT00547261||165842|
NCT00547274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-034|Dyslipidemia in Type 2 Diabetes (0767-034)|||Merck Sharp & Dohme Corp.||Terminated|July 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|111|||Both|21 Years|N/A|No|||June 2015|June 11, 2015|October 19, 2007||||No||https://clinicaltrials.gov/show/NCT00547274||165841|
NCT00525096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELAROM|Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer|A Multicenter Randomized Phase III, Double-blind Study Comparing Efficacy of the Association of Exemestane and Celecoxib Versus Exemestane and Placebo in Menopausal Patients With Metastatic Breast Cancer.||ARCAGY/ GINECO GROUP|No|Completed|July 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|157|||Female|18 Years|N/A|No|||June 2011|June 29, 2011|September 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00525096||167518|
NCT00525369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-IL-6-1|IL 6 Measurement Using a New Densitometric Bedside (POC) Test|||Charite University, Berlin, Germany|No|Completed||||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||||||Both|18 Years|90 Years||||September 2007|September 4, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00525369||167497|
NCT00525382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00334|Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria|A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU)||UCB Pharma|No|Completed|August 2003|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|134|||Both|18 Years|60 Years|No|||September 2009|December 11, 2013|September 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00525382||167496|
NCT00525395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VETF01|Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol|Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients|VETF|Istituti Fisioterapici Ospitalieri|Yes|Recruiting|April 2007|June 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||June 2010|June 1, 2010|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525395||167495|
NCT00525655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1037|Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)|Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2007|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|55|||Both|13 Years|24 Years|No|||May 2015|May 11, 2015|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525655||167475|
NCT00525902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e2434|Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis|An Open-label, Multicenter, Phase II Trial of Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis||Oregon Health and Science University||Completed|January 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||April 2012|April 6, 2012|September 4, 2007||No||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00525902||167456|2 had to discontinue for methodologic reasons (pregnancy, loss to follow up wk 42), leading to their classification as failures. As a three-center study, differences between the study population are possible.
NCT00526266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROM-ACEP-SMI-IMCSR-1|Evaluating Physiological Markers of Emotional Trauma: A Randomized Controlled Comparison of Mind-Body Therapies|Evaluating Physiological Markers of Emotional Trauma: A Randomized Controlled Comparison of Mind-Body Therapies||Soul Medicine Institute|Yes|Recruiting|September 2007|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|35|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526266||167429|
NCT00513864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3919|Assessment of Opioid Analgesia in Sickle Cell|Non-Invasive Assessment of Opioid Analgesia in Children With Sickle Cell Disease||Children's Research Institute|Yes|Withdrawn|November 2006|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|7 Years|18 Years|No|||December 2014|December 19, 2014|August 8, 2007||No|lack of funding|No||https://clinicaltrials.gov/show/NCT00513864||168363|
NCT00513877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-10 ICORG|Bortezomib in Treating Patients With Malignant Pleural Mesothelioma|An Open Label Phase II Multicentre Clinical Trial of Single Agent Bortezomib in Patients With Malignant Pleural Mesothelioma||ICORG- All Ireland Cooperative Oncology Research Group||Completed|May 2006|||December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||January 2013|December 30, 2014|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513877||168362|
NCT00526513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_01913|Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus|Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus|SCALE|Sanofi|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|188|||Both|18 Years|65 Years|No|||September 2010|September 10, 2010|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526513||167410|
NCT00526539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reverse hybrid vs cemented THR|Is There Increased Polyethylene Wear and Increased Periprosthetic Bone Loss in Femur in Reverse Hybrid Technique Compared With Conventional Cemented Technique in Total Hip Replacement?|||Oslo University Hospital||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|||||||Both|N/A|75 Years||||September 2007|July 3, 2011|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00526539||167409|
NCT00526552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-CRE-2007/3|Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)|RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)|RAPID|AstraZeneca|No|Completed|June 2007|December 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|Diabetic Mellitus patients with hypercholesteromia in Korean tertiary care centers|March 2010|March 29, 2010|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526552||167408|
NCT00522795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-E-215|Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)|BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001||Brown University|Yes|Completed|August 2007|April 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|19 Years|N/A|No|||June 2014|June 26, 2014|August 28, 2007|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00522795||167692|
NCT00547053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-06-0290|Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis|A Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis||Children's Hospital Boston|Yes|Completed|December 2006|January 2011|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|6 Years|N/A|No|||May 2011|May 12, 2011|October 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547053||165856|
NCT00546130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNCLC-01|Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer|Feasibility Study for Multicenter Randomized Controlled Phase III Clinical Trial of Cisplatin + Irinotecan Therapy and Cisplatin + Irinotecan + Krestin Therapy for Extensive-Stage Disease (ED) Small Cell Lung Cancer|RNCLC|University of Toyama|Yes|Recruiting|November 2007|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|74 Years|No|||August 2008|September 2, 2008|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546130||165925|
NCT00536484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221014|Fesoterodine Flexible Dose Study|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.||Pfizer|No|Completed|August 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|896|||Both|18 Years|N/A|No|||September 2009|September 10, 2009|September 25, 2007|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00536484||166654|
NCT00536497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBA109358|Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.|A 2 Part Open-label, Randomised, Crossover Study to Compare the Effects of Formulation, Food and Particle Size on the Pharmacokinetic Profiles of a Single 175mg Dose of GW842166X in Healthy Male and Female Volunteers||GlaxoSmithKline|No|Withdrawn|September 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|September 25, 2007|||Compound terminated|||https://clinicaltrials.gov/show/NCT00536497||166653|
NCT00536185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003411-01A1|Heart & Health Study|Variation in the ALOX5 Gene and Response to Omega-3 Fatty Acid Supplements||USDA, Western Human Nutrition Research Center|No|Completed|December 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|166|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||August 2011|August 3, 2011|September 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00536185||166677|
NCT00536731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5897C00003|Symbicort Rapihaler Therapeutic Equivalence Study|A 6-week, Phase III, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy and Safety of 2 Actuations Symbicort®pMDI® 40/2.25 μg Twice Daily Compared With 1 Inhalation Symbicort Turbuhaler® 80/4.5 μg Twice Daily and 1 Inhalation Pulmicort®Turbuhaler® 100 μg Twice Daily|ESTHER|AstraZeneca|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|742|||Both|12 Years|N/A|No|||August 2012|August 14, 2012|September 27, 2007|Yes|Yes||No|April 1, 2009|https://clinicaltrials.gov/show/NCT00536731||166635|
NCT00537056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENAL0013|Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI|Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI||Stanford University|Yes|Completed|October 2007|April 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|September 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00537056||166611|
NCT00537082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D1201|Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)|A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis||Novartis||Completed|September 2007|||February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|171|||Both|18 Years|60 Years|No|||April 2011|April 19, 2011|September 26, 2007||No||No|February 21, 2011|https://clinicaltrials.gov/show/NCT00537082||166610|
NCT00537667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000211|The SPECTRA Study|A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.||Swedish Orphan Biovitrum||Terminated|August 2001|June 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||December 2008|November 25, 2009|September 27, 2007|||The safety profile of combination therapy became unacceptable.|No||https://clinicaltrials.gov/show/NCT00537667||166565|
NCT00538200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELIA002|Chronic Obstructive Pulmonary Disease (COPD) Nutrition Support Trial|A Randomised Trial of Oral Nutritional Supplements Versus Dietary Advice on Clinical Outcomes in Patients With COPD||University of Southampton|No|Completed|January 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|85|||Both|50 Years|N/A|No|||December 2014|December 5, 2014|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00538200||166524|
NCT00538213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110263|Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults|Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (≥66 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Will be Used as Reference||GlaxoSmithKline||Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|133|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2012|August 2, 2012|October 1, 2007|Yes|Yes||No|April 5, 2012|https://clinicaltrials.gov/show/NCT00538213||166523|
NCT00548392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6263|Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement|Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement||Fred Hutchinson Cancer Research Center|No|Completed|May 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|None Retained|none/not applicable|Female|18 Years|N/A|No|Non-Probability Sample|outpatient clinic|December 2008|December 29, 2008|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548392||165759|
NCT00538187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00253|Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma|Phase I Study of GX15-070 (NSC # 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Terminated|December 2007|||April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||May 2013|December 3, 2015|October 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00538187||166525|
NCT00538525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2011-022|Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer|||King Faisal Specialist Hospital & Research Center||Completed|September 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||May 2012|May 26, 2012|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538525||166499|
NCT00538850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-05-001|Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain|A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain||INSYS Therapeutics Inc||Completed|October 2007|October 2010|Actual|February 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|130|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|October 1, 2007|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00538850||166475|
NCT00539214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.639|Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease|Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment||Boehringer Ingelheim||Completed|March 2007|||December 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1192|||Both|18 Years|N/A|No|Non-Probability Sample|PD patients|October 2013|October 31, 2013|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00539214||166448|
NCT00539513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOCD-2|N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder|A Double-Blind Study of N-Acetylcysteine Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder and Depression||Yale University|No|Terminated|June 2006|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||March 2013|March 25, 2013|October 2, 2007||No|Researchers terminated study due to limited enrollment.|No|December 21, 2012|https://clinicaltrials.gov/show/NCT00539513||166425|
NCT00548847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002219|Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation|A Pilot Phase II Study of Immunotherapy for the Treatment of AML, ALL, BP CML, and MDS Relapsed After Allogeneic Transplantation||Emory University|Yes|Active, not recruiting|January 2007|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|1 Year|N/A|No|||August 2015|August 13, 2015|October 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548847||165724|
NCT00549133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9130|Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol|Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol|IREDIS|Sanofi|No|Completed|October 2003|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|40 Years|65 Years|No|||October 2007|October 24, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549133||165704|
NCT00549146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO40055|Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease|See Detailed Description||GlaxoSmithKline|No|Completed|November 2003|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||290|||Both|40 Years|80 Years|No|||February 2011|April 11, 2013|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549146||165703|
NCT00549445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1425|Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in COPD||University of Alabama at Birmingham|No|Completed|August 2007|July 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|53|Samples Without DNA|Serum and Plasma|Both|40 Years|N/A|No|Non-Probability Sample|Community|August 2012|August 29, 2012|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549445||165681|
NCT00548548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4200g|A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer|A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer|AVAGAST|Genentech, Inc.||Completed|September 2007|November 2013|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|774|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|October 23, 2007|Yes|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT00548548||165747|
NCT00548834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87011|Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis|Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD||UCB Pharma|No|Completed|June 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|220|||Both|18 Years|75 Years|No|||February 2010|September 3, 2013|October 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00548834||165725|
NCT00549458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH Urogynecology|Randomized Controlled Trial Comparing Traditional Pelvic Floor Rehabilitation to Pilates in Increasing Pelvic Muscles Strength.|||Atlantic Health System|No|Completed|April 2006|March 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549458||165680|
NCT00549692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-OM-8301|Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy|Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy|IgAN|Kuhnil Pharmaceutical Co., Ltd.|No|Completed|November 2007|September 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|152|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00549692||165662|
NCT00546143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2208|Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma|Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab||Novartis|No|Completed|July 2007|||August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|55 Years|No|||September 2010|September 1, 2010|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00546143||165924|
NCT00537680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-III-002|Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia|A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|IONIA|Santhera Pharmaceuticals|Yes|Completed|December 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|8 Years|17 Years|No|||February 2012|February 2, 2012|September 7, 2007|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00537680||166564|
NCT00537043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD110733|A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure|An Open-label, Randomized, Crossover, Repeat-dose Study to Evaluate the Steady-State Pharmacokinetic Profile of the Final Fixed Dose Combination (FDC) Formulation of COREG CR and Lisinopril as Compared to COREG CR in Subjects With Essential Hypertension||GlaxoSmithKline||Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|60 Years|No|||October 2010|October 13, 2010|September 27, 2007||||||https://clinicaltrials.gov/show/NCT00537043||166612|
NCT00537979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W10-129|Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis|Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis||Abbott|No|Completed|September 2007|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|September 28, 2007|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00537979||166541|
NCT00538551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #2021-048|Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases|Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|January 2007|July 2015|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|14 Years|85 Years|No|Non-Probability Sample|Lymphoma database|December 2011|December 11, 2011|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538551||166497|
NCT00538889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098B1-134|Study Evaluating a Combined Administration of Lecozotan SR and Citalopram in Young Healthy Subjects|Combined Administration of Lecozotan SR and Citalopram: a Double Blind, Multiple Dose Study in Young Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2007|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 9, 2007|October 1, 2007||||No||https://clinicaltrials.gov/show/NCT00538889||166472|
NCT00548717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI 07-197|Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation|Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease Prophylaxis After Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Terminated|October 2007|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|October 23, 2007|Yes|Yes|First two patients enrolled after trial reopened, developed grade III-IV acute GVHD and    subsequently passed away.|No|September 29, 2014|https://clinicaltrials.gov/show/NCT00548717||165734|Early termination leading to small numbers of subjects analyzed. Results are reported for transparency only, and should not be used to extrapolate significant conclusions.
NCT00538863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-06-007|Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain|Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain||INSYS Therapeutics Inc|No|Completed|December 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|319|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|October 1, 2007|Yes|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT00538863||166474|
NCT00538876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704009108|Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML|Phase I Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)||Weill Medical College of Cornell University||Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2011|June 29, 2011|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538876||166473|
NCT00548379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1963|Kabul Vitamin D Supplementation Trial|The Effect of Vitamin D Supplementation on the Incidence of Pneumonia in Children in Afghanistan: a Randomized Controlled Trial||London School of Hygiene and Tropical Medicine|Yes|Active, not recruiting|November 2007|July 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3048|||Both|1 Month|11 Months|Accepts Healthy Volunteers|||May 2008|May 15, 2008|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548379||165760|
NCT00548665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNSF 3200B0-116097|Carotid Plaque Screening Trial in Smokers|Impact of Carotid Plaque Screening on Smoking Cessation and Control of Other Cardiovascular Risk Factors: A Randomized Controlled Trial.|CAROSS|University of Lausanne|No|Completed|November 2007|December 2012|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Screening|2||Actual|536|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548665||165738|
NCT00548678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-007|Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers|Open-Label, Randomized, Single-Dose, Four-Treatment Crossover Study to Evaluate Platelet Function in Healthy Adult Males After Administration of IV Diclofenac Sodium, Oral Diclofenac Potasssium, IV Ketorolac Tromethamine, and Acetylsalicylic Acid||Javelin Pharmaceuticals|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 15, 2008|October 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548678||165737|
NCT00547963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-BAI-013709|Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use|Reducing Injury, ETOH and THC Use Among ED Patients||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Active, not recruiting|December 2003|December 2008|Anticipated|December 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|554|||Both|18 Years|N/A|No|||October 2008|October 7, 2008|October 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00547963||165791|
NCT00548288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAM19382CE|Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty|Phase 1 Study of the Effect of Local Pamidronate Application in Preventing Periprosthetic Bone Loss After Total Cemented Hip Arthroplasty||General and Teaching Hospital Celje|No|Not yet recruiting|November 2007|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Anticipated|40|||Both|50 Years|80 Years|No|||October 2007|October 22, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00548288||165767|
NCT00548301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-603-007|Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)|||Sirion Therapeutics, Inc.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||June 2011|June 29, 2011|October 22, 2007||||||https://clinicaltrials.gov/show/NCT00548301||165766|
NCT00548574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-302|Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis|A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, in Subjects With Mild to Moderate Ulcerative Colitis||Shire|No|Completed|December 2003|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|343|||Both|18 Years|N/A|No|||November 2007|March 3, 2015|October 23, 2007||||No||https://clinicaltrials.gov/show/NCT00548574||165745|
NCT00549705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001294|Registry of Hospitalized Patients Treated With Fondaparinux|Registry of Hospitalized Patients Treated With Fondaparinux||Brigham and Women's Hospital|No|Completed|July 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|220|||Both|N/A|N/A|No|Non-Probability Sample|BWH hospitalized patients receiving Fondaparinux|September 2009|September 15, 2009|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549705||165661|
NCT00548860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT07017|Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients|A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients||Luitpold Pharmaceuticals|Yes|Completed|October 2007|July 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2018|||Female|N/A|N/A|No|||July 2015|July 8, 2015|October 22, 2007|Yes|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00548860||165723|
NCT00550030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-257 ex 05/06|Etanercept Plus UVB-311nm Phototherapy in Psoriasis|Prospective, Randomized Half-side Study on the Efficacy of UVB-311nm Phototherapy in Patients With Psoriasis Undergoing Etanercept Treatment||Medical University of Graz|No|Completed|August 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00550030||165636|
NCT00546403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538a-633|Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia|An Eight Week, Double-Blind, Placebo Controlled, Adjunctive Study of the Primary Effects of the Use of Flexible Doses of Modafinil 50mg to 200mg, on the Negative Symptoms, Cognition, and Excessive Daytime Sleepiness in Schizophrenic Patients||Veterans Medical Research Foundation|No|Completed|February 2003|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|65 Years|No|||October 2007|February 20, 2009|October 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00546403||165905|
NCT00549978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-KOB-0702|Safety and Pharmacokinetics of Probucol and Cilostazol|Phase IV, Safety and Pharmacokinetics of Probucol and Cilostazol When Coadministered in Healthy Subjects||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|October 2007|August 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|October 25, 2007||||No||https://clinicaltrials.gov/show/NCT00549978||165640|
NCT00545584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-078|Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)|Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy||Merck Sharp & Dohme Corp.|No|Completed|April 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1512|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|October 16, 2007|Yes|Yes||No|April 19, 2011|https://clinicaltrials.gov/show/NCT00545584||165967|
NCT00546156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-130|Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer|A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|October 2007|December 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||March 2013|March 22, 2013|October 17, 2007|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00546156||165923|
NCT00546793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hA20-08|Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL|Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia||Immunomedics, Inc.|No|Completed|January 2008|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546793||165876|
NCT00547118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041206|The Effects of Rimonabant, on Weight and Metabolic Risk Factors|The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia||University of Maryland|Yes|Terminated|November 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|55 Years|No|||February 2015|February 24, 2015|October 19, 2007|Yes|Yes|Withdrawn due to medication withdrawal from the EMEA|No|May 5, 2014|https://clinicaltrials.gov/show/NCT00547118||165852|
NCT00538226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tali725|Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg|To Evaluate the Increase of Local Circulation in the Leg Using the Flowaid Device||Rosenblum, Jonathan I., DPM|Yes|Completed|October 2007|November 2007|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|90 Years|No|||March 2008|March 3, 2008|September 29, 2007||||No||https://clinicaltrials.gov/show/NCT00538226||166522|
NCT00548093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471002|PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib|A Phase 2, Open Label, Two Arm Trial To Evaluate The Efficacy Of PF-00299804 In Patients With Advanced NSCLC After Failure Of At Least One Prior Chemotherapy And Erlotinib||Pfizer|No|Completed|April 2008|May 2012|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548093||165782|
NCT00548418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1098 / 201110266|Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer|Phase II Trial of Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer||Washington University School of Medicine|Yes|Completed|February 2007|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||July 2014|July 28, 2014|October 23, 2007|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT00548418||165757|
NCT00548067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVEA489A2104|Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension|A Multi-center, Multiple Dose, Open-label, Four-cohort, Parallel Study to Assess the Pharmacokinetic Drug Interaction Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension.||Novartis|No|Completed|September 2007|March 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|111|||Both|18 Years|60 Years|No|||September 2010|September 24, 2010|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00548067||165784|
NCT00548080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-055|Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)|A Non-Comparative, Multicenter, Open-Label, Study to Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia||Merck Sharp & Dohme Corp.||Completed|March 2006|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|131|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 19, 2007||||No||https://clinicaltrials.gov/show/NCT00548080||165783|
NCT00548951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-205-05|Alzheimer Patients and the Snoezelen Program|The Connection Between Sensory Deprivation and Social Withdrawal in Clients of a Long Term Care Facility Living With Alzheimer's Disease and the Effects of a Snoezelen Program.||Queen's University|No|Completed|September 2005|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT00548951||165717|
NCT00549276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Samsung Medical Center|Randomized Comparison of Curved Cutter Stapler and Linear Stapler|||Samsung Medical Center|Yes|Completed|May 2006|November 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||60|||||Both|20 Years|N/A|No|Probability Sample|60 patients were randomly assigned to either linear staplers or the CCS during low        anterior resection for mid to low rectal cancers|May 2006|October 23, 2007|October 23, 2007||||No||https://clinicaltrials.gov/show/NCT00549276||165694|
NCT00549289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-603-006|Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)|||Sirion Therapeutics, Inc.||Completed||||||Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|2 Years|N/A||||October 2007|October 24, 2007|October 24, 2007||||||https://clinicaltrials.gov/show/NCT00549289||165693|
NCT00549731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000062|Participant Database for Autism Research Studies|Participant Database for Persons Interested in Autism Research Studies: Recruiting, Pre-Screening and Diagnostic Assessment||Massachusetts General Hospital|No|Recruiting|June 2005|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult/Pediatric|April 2012|May 31, 2013|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00549731||165659|
NCT00549744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA107948|Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing|A Randomized, Double-blind, Double-dummy, Placebocontrolled,Three-period, Incomplete Block, Crossover Study, to a Investigate the Effect of 14 Days Repeat Inhaled Dosing With GSK256066 in Mild/Moderate Asthmatic Patients.||GlaxoSmithKline|No|Completed|November 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|72|||Female|18 Years|65 Years|No|||February 2011|May 31, 2012|October 25, 2007||||No||https://clinicaltrials.gov/show/NCT00549744||165658|
NCT00549991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1415|Analyzing Genes That May Increase the Risk of Developing High Blood Pressure|Fine Mapping of Hypertension Genes Detected by Admixture Mapping in the FBPP||Case Western Reserve University|No|Completed|August 2007|June 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|8687|Samples With DNA|Whole blood|Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Previously collected genetic samples from African American participants in the Family        Blood Pressure Program (FBPP) study and from African American, Mexican American, Nigerian,        and Jamaican participants enrolled in other clinical studies will be examined.|April 2009|November 26, 2013|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549991||165639|
NCT00545909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19913|BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis|A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis.||Hoffmann-La Roche||Completed|March 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|585|||Female|55 Years|85 Years|No|||March 2016|March 1, 2016|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545909||165942|
NCT00549159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0026-06 dd20070920|CavatermTM vs TCRE in Women With DUB|Multicenter Randomized Clinical Trial to Evaluate the Safety and Effectiveness of Cavaterm TM Thermal Balloon Endometrial Ablation in Women With Dysfunctional Uterine Bleeding Compared to Transcervical Resection of the Endometrium (TCRE)||Pnn Medical A/S|No|Recruiting|October 2007|October 2009|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|158|||Female|30 Years|60 Years|No|||May 2008|May 19, 2008|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549159||165702|
NCT00546117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO# 07-0762|A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion|A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion||Washington University School of Medicine|Yes|Completed|October 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|2 Years|12 Years|No|||September 2011|September 27, 2011|October 17, 2007||No||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00546117||165926|
NCT00514202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0024|Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)|Dextroamphetamine Treatment for Comorbid Cocaine Dependence and ADHD||The University of Texas Health Science Center, Houston|Yes|Terminated|August 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||February 2012|February 21, 2012|August 7, 2007|Yes|Yes|Investigator left UTHSC-Houston|No||https://clinicaltrials.gov/show/NCT00514202||168339|
NCT00514215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000559667|Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer|Percutaneous Cryotherapy and Aerosolized GM-CSF for Pulmonary Metastases and Primary Lung Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|August 8, 2007|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00514215||168338|Small sample size.
NCT00546429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04077|DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial|Clinical Trial to Monitor the Clinical Effectiveness of the DePuy ATN Trochanteric Nailing System in the Treatment of Trochanteric Fractures of the Proximal Femur|ATN|DePuy Orthopaedics|No|Completed|September 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||February 2012|February 28, 2012|October 17, 2007|No|Yes||No|September 29, 2010|https://clinicaltrials.gov/show/NCT00546429||165904|
NCT00546728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPHC 2007-02|The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes|The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance||St. Paul Heart Clinic|No|Completed|October 2007|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|October 17, 2007|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00546728||165881|unblinded study design
NCT00515034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012934|A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia|A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventilator Associated Pneumonia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|146|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|August 10, 2007|Yes|Yes||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00515034||168277|open-label study design and limited number of subjects in the comparator group
NCT00547417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7006|To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections|An Open-Label Study to Evaluate the Efficacy and Safety of Tadalafil Administered "On Demand" to Men of Various Populations With Erectile Dysfunction||Eli Lilly and Company|No|Completed|July 2003|March 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1933|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547417||165831|
NCT00547443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000571535|Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Randomized Phase I/II Study Of Sorafenib In Combination With High Does Chemoradiation In Patients With Stage IIIA/B Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Terminated|July 2007|||July 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||October 2008|October 19, 2010|October 19, 2007|Yes|Yes|Withdrawn as the sponsor has stopped the drug for NSCLC population|||https://clinicaltrials.gov/show/NCT00547443||165830|
NCT00547456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.02.097|Consequences of Nocturnal and Daytime Hypoxemia in COPD|||Northwell Health|No|Terminated|October 2005|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 18, 2007||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00547456||165829|
NCT00537381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013249|An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer|A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer||Centocor, Inc.|Yes|Completed|May 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Male|18 Years|N/A|No|||June 2013|June 12, 2013|September 27, 2007|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00537381||166587|Treatment with intetumumab/placebo was permanently discontinued after a planned, preliminary review of interim analysis data. Therefore, study treatment with intetumumab was not completed for some participants.
NCT00537394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5241|Optimizing Treatment for Treatment-Experienced, HIV-Infected People|The Optimized Treatment That Includes or Omits NRTIs Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2008|April 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|517|||Both|16 Years|N/A|No|||December 2015|December 8, 2015|September 27, 2007|Yes|Yes||Yes|June 14, 2013|https://clinicaltrials.gov/show/NCT00537394||166586|
NCT00537654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI109882|A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State|See Detailed Description||GlaxoSmithKline||Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|81|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|September 28, 2007||||||https://clinicaltrials.gov/show/NCT00537654||166566|
NCT00547729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-05-04/HP-12-04|Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS)|Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients: A Prospective, Multi-center, Non-randomized, Open Label Study.|HOMEOSTASIS|St. Jude Medical|Yes|Completed|March 2005|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|October 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547729||165808|
NCT00547742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0011|Correlation of PET-CT Studies With Serum Protein Analysis|Correlation of PET-CT Studies With Serum Protein Analysis||Stanford University||Completed|July 2005|June 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients having PET/CT scans|July 2010|July 16, 2010|October 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00547742||165807|
NCT00547768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455A_4144|Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.|||Sanofi|No|Completed|November 2002|December 2002|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|36|||Both|12 Years|55 Years|No|||January 2011|January 10, 2011|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00547768||165806|
NCT00548405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMMS32400507|Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two|A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy|CARE-MS II|Sanofi|Yes|Completed|October 2007|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|840|||Both|18 Years|55 Years|No|||January 2015|January 6, 2015|October 22, 2007|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00548405||165758|Efficacy analysis was not performed for Alemtuzumab 24 mg as recruitment to this arm was closed early to reduce overall sample size, duration of enrollment period, overall duration of study.
NCT00548119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-01|NeoCart Phase 2 Clinical Trial|A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee||Histogenics Corporation|No|Completed|December 2006|March 2014|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|No|||March 2014|March 25, 2014|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548119||165780|
NCT00548743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HS014744-02|Translating Research Into Practice for Postpartum Depression|Practice Based Clinical Trial of Screening, Diagnosis and Follow up Management for Postpartum Depression in Family Medicine Practices.|TRIPPD|Olmsted Medical Center|Yes|Recruiting|September 2005|August 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|3000|||Female|18 Years|45 Years|No|||October 2007|December 3, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00548743||165732|
NCT00548691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT07018|Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients|A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients||Luitpold Pharmaceuticals|Yes|Completed|October 2007|July 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|513|||Both|18 Years|85 Years|No|||May 2015|May 11, 2015|October 22, 2007|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00548691||165736|
NCT00548704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT02|A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines|A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents||Onxeo|No|Completed|April 2002|August 2005|Actual|August 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||November 2013|October 20, 2015|October 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00548704||165735|
NCT00549315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G020150|Clinical Study of Thoracic Aortic Aneurysm Exclusion|Clinical Study of Thoracic Aortic Aneurysm Exclusion Using the VALIANT System|Valiant|Arizona Heart Institute|No|Recruiting|October 2002|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||May 2009|May 14, 2009|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549315||165691|
NCT00549549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191219|Celebrex In Acute Gouty Arthritis Study|A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis||Pfizer|Yes|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|402|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|October 24, 2007|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00549549||165673|Patients Global Evaluation of study medication data was collected at Day 9 only.
NCT00549809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-04|Comparison Between IMV and SIMV/PS for Ventilatory Support of Children: a Randomized Clinical Trial|Comparison Between IMV and SIMV/PS for Ventilatory Support of Children: a Randomized Clinical Trial||UPECLIN HC FM Botucatu Unesp|No|Completed|October 2005|June 2007|Actual|February 2007|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|70|||Both|N/A|4 Years|No|||June 2008|June 27, 2008|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00549809||165653|
NCT00549484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC#23049|Thrombopoietin Levels and Platelet Transfusion in Neonates|Thrombopoietin Levels Following Platelet Transfusion in Neonates With Thrombocytopenia||Christiana Care Health Services|No|Completed|May 2003|September 2004|Actual|September 2004|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|20|Samples With DNA|Blood samples were collected pre and post platelet transfusion. Samples included platelet      count, thrombopoietin, and platelet factor 4.|Both|N/A|6 Months|Accepts Healthy Volunteers|Probability Sample|Infants who require platelet transfusion|January 2008|January 16, 2008|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549484||165678|
NCT00549757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100E2337|Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality|ALTITUDE|Novartis||Terminated|October 2007|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8606|||Both|35 Years|N/A|No|||April 2014|April 1, 2014|October 24, 2007|Yes|Yes|Lack of benefit and safety concern|No|February 3, 2014|https://clinicaltrials.gov/show/NCT00549757||165657|
NCT00550004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-RP-Pan-P2-001|Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine|Randomized, Double Blind, Placebo Controlled, Phase 2 Study Evaluating the Efficacy & Safety of RP101 or Placebo in Combination With Gemcitabine Administered as First-Line Treatment to Subjects With Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma|RP101|SciClone Pharmaceuticals|Yes|Terminated|September 2007|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|153|||Both|18 Years|N/A|No|||October 2009|June 6, 2011|October 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00550004||165638|
NCT00550017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA190-002|A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)|A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)||Bristol-Myers Squibb|No|Terminated|December 2007|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00550017||165637|
NCT00514228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 77/06|Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|Continuous Sunitinib Treatment in Patients With Unresectable Hepatocellular Carcinoma A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Completed|July 2007|February 2009|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||June 2012|June 25, 2012|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514228||168337|
NCT00514462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS07040|Carpal Tunnel Syndrome Treated With 830nm Diode Laser|Instiutional Review Board of Chung Shan Medical University Hospital|CTS|Chung Shan Medical University|Yes|Recruiting|July 2007|August 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2007|August 9, 2007|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00514462||168320|
NCT00545922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 3.2007.1668|Cognitive Behavioral Therapy for Anxiety and Depression in COPD|Cognitive Behavior Therapy for Anxiety and Depression for Patients With Chronic Obstructive Pulmonary Disease (COPD): A Randomized, Controlled Clinical Trial in an Outpatient Pulmonary Clinic.||University of Bergen|No|Completed|April 2005|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|40 Years|N/A|No|||October 2007|November 14, 2007|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545922||165941|
NCT00515320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPL-2008-4-AUTUS-004|Study of Fluoxetine in Autism|Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.|SOFIA|Neuropharm|Yes|Completed|August 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|5 Years|17 Years|No|||April 2012|April 26, 2012|August 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515320||168255|
NCT00515333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-014-001|TRx0014 in Patients With Mild or Moderate Alzheimer's Disease|An Exploratory Placebo-Controlled, Dose-Ranging Study of the Effects of TRx0014 30 MG TID, 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type||TauRx Therapeutics Ltd|No|Completed|August 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|323|||Both|N/A|N/A|No|||February 2008|February 19, 2008|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515333||168254|
NCT00537992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-CI-03-2007|Blue-Blocking IOLs in Combined Surgery|Blue Light-Filter IOLs in Vitrectomy Combined With Cataract Surgery: Results of a Randomized Controlled Clinical Trial.||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|October 2004|March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Actual|60|||Both|50 Years|N/A|No|||October 2007|October 1, 2007|October 1, 2007||||No||https://clinicaltrials.gov/show/NCT00537992||166540|
NCT00548106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor461707ctil|Safety Study of Infant Formula With Partially Hydrolized Whey|Evaluation of a New Cow's Milk Infant Formula Containing Partially Hydrolized Whey||Soroka University Medical Center|Yes|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|N/A|30 Days|No|||July 2010|June 13, 2012|October 22, 2007||No|Study withdrawn due to the company decision|No||https://clinicaltrials.gov/show/NCT00548106||165781|
NCT00548132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00424-0805-01 (BJH Foundation)|Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)|Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)||Washington University School of Medicine|Yes|Completed|February 2006|May 2009|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1088|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|October 22, 2007||No||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00548132||165779|
NCT00548756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-377|Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy|A Phase III Prospective Randomized Trial Comparing Radiosurgery With Versus Without Whole Brain Radiotherapy for 1-3 Newly Diagnosed Brain Metastases||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2001|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548756||165731|
NCT00548769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4M109079|Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients|See Detailed Description||GlaxoSmithKline||Completed|April 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|37|||Both|18 Years|65 Years|No|||October 2010|October 13, 2010|October 23, 2007||||No||https://clinicaltrials.gov/show/NCT00548769||165730|
NCT00548964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1225 (002)|Continuation Ketamine in Major Depression|Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2007|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|21 Years|80 Years|No|||May 2014|May 22, 2014|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548964||165716|
NCT00549302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10263|Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs|An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension||Eli Lilly and Company|No|Completed|December 2005|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|357|||Both|12 Years|N/A|No|||April 2013|April 1, 2013|October 23, 2007|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00549302||165692|
NCT00548977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKUH-1|Genetic Studies Spermatogenic Failure|||National Cheng-Kung University Hospital|Yes|Completed|January 2001|February 2005|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|283|Samples With DNA|whole blood|Male|14 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Patient visited our outpatient clinic|October 2007|October 24, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00548977||165715|
NCT00548639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1415|The STATIN CHOICE Decision Aid for Type 2 Diabetes Patients|The STATIN CHOICE Decision Aid for Type 2 Diabetes Patients||Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|August 2007|||April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|152|||Both|21 Years|N/A|No|||May 2009|May 4, 2009|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548639||165740|
NCT00548652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00469|Role of Apathy in the Effectiveness of Weight Loss Interventions|Role of Apathy in the Effectiveness of Weight Loss Interventions in Obese Patients||VA Nebraska Western Iowa Health Care System|No|Completed|August 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|125|||Both|21 Years|70 Years|No|||April 2011|March 19, 2014|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548652||165739|
NCT00549172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06157|Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear|Efficacy of Arthroscopic Partial Resection for the Degenerative Tear of the Medial Meniscus of a Knee||University of Tampere|Yes|Completed|October 2007|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||August 2013|March 16, 2015|October 24, 2007||No||No|March 16, 2015|https://clinicaltrials.gov/show/NCT00549172||165701|
NCT00549185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED6828|Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma|An Open-label Multi-dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)||Sanofi|No|Completed|October 2007|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|October 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00549185||165700|
NCT00548912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-3267|Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease|||West Penn Allegheny Health System||Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||October 2007|October 23, 2007|October 23, 2007||||No||https://clinicaltrials.gov/show/NCT00548912||165720|
NCT00549198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNA109586|KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects|Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects|ASSERT|GlaxoSmithKline||Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|392|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|October 24, 2007||No||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00549198||165699|
NCT00549211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTB109039|A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.|A Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of GSK557296 in a Randomized, Single-Blind, Placebo-Controlled, Dose-Rising Design, and to Evaluate the Effect of Food on Single Oral Doses of GSK557296 in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|October 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|October 23, 2007||||||https://clinicaltrials.gov/show/NCT00549211||165698|
NCT00549497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIG110405|A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers|See Detailed Description||GlaxoSmithKline|No|Completed|September 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549497||165677|
NCT00549510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD108407|Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.|A Non-randomized, Open-label, Single-dose, Crossover Study to Evaluate the Dose Proportionality of the Final Fixed Dose Combination Formulation of COREG CR™ and Lisinopril.||GlaxoSmithKline||Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|October 23, 2007||||||https://clinicaltrials.gov/show/NCT00549510||165676|
NCT00549770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2201|Efficacy and Safety of LCZ696A in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension||Novartis|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|1334|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|October 5, 2007|Yes|Yes||No|August 10, 2012|https://clinicaltrials.gov/show/NCT00549770||165656|
NCT00515645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708061|Cardiac Autonomic Functions During Head-out Immersion and During Head Down Tilt|Cardiac Autonomic Functions During Head-out Immersion and During Head Down Tilt|IMMERSION|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|April 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00515645||168231|
NCT00545597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD039276|A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy|A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Terminated|March 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|N/A|No|||October 2007|March 1, 2012|October 16, 2007|Yes|Yes|Upon recommendation of DSMB|No||https://clinicaltrials.gov/show/NCT00545597||165966|
NCT00545610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34976|ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)|A 12-Month Follow-Up Study to Protocol 24779 (A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia [ACT34-CMI])||Baxalta US Inc.|No|Completed|October 2007|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|||Both|21 Years|81 Years|No|Probability Sample|Subjects who have received treatment with Auto-CD34+ cells (1 x 10^5 (+/-10%) CD34+        cells/kg or 5 x 10^5 (+/-10%) CD34+ cells/kg)or with placebo (saline plus 5% autologous        plasma) and who have completed the final study visit (Month 12) of the core therapeutic        study 24779|July 2010|June 26, 2015|October 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00545610||165965|
NCT00545623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003377-01|Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence|Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence||Boston University|No|Completed|April 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|130|||Both|18 Years|N/A|No|||August 2014|August 31, 2014|October 15, 2007||No||No|July 25, 2014|https://clinicaltrials.gov/show/NCT00545623||165964|
NCT00545935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-2007b|Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso|Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso: RCT in the Frame of the A8 Project of SFB 544||Heidelberg University||Completed|July 2007|October 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||186|||Both|6 Months|59 Months||||February 2009|February 2, 2009|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545935||165940|
NCT00545948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000657|Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer|Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy|TOP0703|Duke University|Yes|Terminated|December 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|October 16, 2007|Yes|Yes|Study terminated due to reproducibility issues with genomics prediction model.|No|May 7, 2014|https://clinicaltrials.gov/show/NCT00545948||165939|
NCT00546806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0623-A|University Health Network Whiplash Intervention Trial|The University Health Network Whiplash Intervention Trial: A Randomized Controlled Trial of the Effectiveness and Cost-effectiveness of Three Programs of Care for the Treatment of Whiplash-associated Disorders|WIT|University Health Network, Toronto|No|Completed|February 2008|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|340|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00546806||165875|
NCT00547131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05117|Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors|A Pilot Feasibility Study of Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Temozolomide||City of Hope Medical Center||Completed|January 2006|May 2009|Actual|May 2008|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|October 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547131||165851|
NCT00547144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0003|Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer|A Phase I/II Trial of Intratumoral Dendritic Cell Immunotherapy in Combination With Gemcitabine and Stereotactic Radiosurgery in Unresectable Pancreatic Cancer||Stanford University|Yes|Completed|October 2005|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2012|November 6, 2012|October 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547144||165850|
NCT00547482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC CR TAN2006-067|The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study|The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study||MetaCure (USA), Inc.|Yes|Terminated|September 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|70 Years|No|||April 2008|December 15, 2010|October 4, 2007|No|Yes|Protocol design under review.|No||https://clinicaltrials.gov/show/NCT00547482||165827|
NCT00547404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/11/07|Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma|An Open Label, Multicenter Phase I Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma||Piramal Enterprises Limited|No|Withdrawn|December 2008|July 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|October 19, 2007|No|Yes|Not to expose the patients to subtherapeutic dose|No||https://clinicaltrials.gov/show/NCT00547404||165832|
NCT00547794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 310|AVJ Ablation Followed by Resynchronization Therapy in Patients With CHF and AF|AVERT-AF: Atrio-VEntricular Junction Ablation Followed by Resynchronization Therapy in Patients With Congestive Heart Failure and Atrial Fibrillation|AVERT-AF|St. Jude Medical|Yes|Terminated|June 2007|November 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|N/A|No|Probability Sample|Patient with history of permanent AF and CHF|May 2015|May 6, 2015|October 19, 2007||No|Difficulty in patient enrollment|No||https://clinicaltrials.gov/show/NCT00547794||165804|
NCT00548431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO HDM-6MP pilot study|NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia|Phase II Study of Individual 6-mercaptopurine(6MP) Dose Increments in Children With Acute Lymphoblastic Leukemia (ALL) Receiving High-dose Methotrexate (HDM) and PEG-asparaginase||Rigshospitalet, Denmark|Yes|Completed|December 2007|May 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|1 Year|18 Years|No|||June 2013|June 30, 2013|October 23, 2007||No||No|June 24, 2009|https://clinicaltrials.gov/show/NCT00548431||165756|
NCT00540657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL009_282|A Phase II Study of CCX282-B in Patients With Celiac Disease|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease||ChemoCentryx|No|Completed|October 2007|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||July 2008|July 21, 2008|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00540657||166339|
NCT00540670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5555-J081-206|A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease|A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease||Eisai Inc.||Completed|October 2007|||March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|240|||Both|45 Years|80 Years|No|||February 2010|May 9, 2013|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540670||166338|
NCT00548730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC07/06VA14|Comparison Trial of White Light, Autofluorescence and Narrow Band Imaging Bronchoscopy|A Clinical Comparison Trial of White Light Bronchoscopy, Autofluorescence Bronchoscopy and Narrow Band Imaged Bronchoscopy|NWA|Maimonides Medical Center|No|Recruiting|October 2007|December 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Endobronchial biopsies of normal and abnormal mucosa for histopathology|Both|18 Years|N/A|No|Non-Probability Sample|Any patient with known or suspected malignancies of the lung and with a medical indication        for a bronchoscopy|January 2009|February 6, 2009|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548730||165733|
NCT00549341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-ST-01|PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia|A Phase I, Single-dose, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety of PurTox for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia and to Explore Dose-associated Efficacy||Mentor Worldwide, LLC|No|Completed|May 2006|March 2009|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|30 Years|75 Years|No|||May 2014|May 23, 2014|October 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549341||165689|
NCT00512772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220072383|Improved Use of Antibiotic Guidelines in Hospital Environment|Improved Use of Antibiotic Guidelines in in Hospital Environment: Research on an Implementation Model and the Role of the Hospital Pharmacist.||Katholieke Universiteit Leuven|No|Completed|October 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|823|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the hospital with a diagnosis of community-acquired pneumonia or        community-acquired pyelonephritis|July 2010|December 17, 2010|August 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00512772||168443|
NCT00512785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRP197-T301/ONO-8025-12|Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder|An Open-label Study to Evaluate the Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder||Ono Pharmaceutical Co. Ltd||Completed|August 2007|||May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|435|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00512785||168442|
NCT00548925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-014|A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain|A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 Versus Placebo in Subjects With Diabetic Neuropathic Pain||AbbVie|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|75 Years|No|||January 2013|January 11, 2013|October 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548925||165719|
NCT00513383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-401|Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck|Phase I Study Panitumumab Plus Chemoradiotherapy and Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck||Massachusetts General Hospital|Yes|Active, not recruiting|April 2006|December 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|August 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00513383||168398|
NCT00513643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISPS_Dose-ranging|Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses|Pharmacodynamic and Pharmacokinetic Properties of Insulin Aspart: Dose - Ranging vs. Human Soluble Insulin||Profil Institut für Stoffwechselforschung GmbH|No|Completed|April 2002|June 2002|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 8, 2007|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00513643||168378|
NCT00513903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|498|Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases|Enhanced Continuity of Pharmacy Care for Cardiovascular or Pulmonary Diseases|IowaCOC|University of Iowa|No|Completed|March 2008|October 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|954|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513903||168360|
NCT00515073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-418|Papillary Serous Carcinoma of the Endometrium|A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium||M.D. Anderson Cancer Center|No|Completed|April 2001|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|N/A|N/A|No|||May 2014|May 30, 2014|August 9, 2007||No||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00515073||168274|
NCT00545636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4879-ZS-CTIL|The Influence of Education of Medical Team on Duration of Fasting Before Elective Medical Interventions Performed Under General Anesthesia in Children|The Influence of Education of Medical Team on Duration of Fasting Before Elective Medical Interventions Performed Under General Anesthesia in Children||Sheba Medical Center|No|Withdrawn|March 2008|||March 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|1||Actual|0|||Both|N/A|18 Years|No|||June 2012|June 7, 2012|October 16, 2007||No|unfortunately lacked manpower to carry out the study|No||https://clinicaltrials.gov/show/NCT00545636||165963|
NCT00545649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O687-03-GAU|Development of Treatments Aiming at Improvement of Function in Patients With Chronic Widespread Pain|Development of Treatments Aiming at Improvement of Function in Patients With Chronic Widespread Pain||Göteborg University|No|Completed|May 2004|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|164|||Female|18 Years|60 Years|No|||September 2007|October 16, 2007|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545649||165962|
NCT00514722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC2207|Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies|Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies||University of California, San Francisco|Yes|Terminated|October 2002|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|55 Years|No|||August 2013|August 13, 2013|August 8, 2007|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00514722||168301|
NCT00514735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFI-30|Tailored Treatment of Permanent Atrial Fibrillation|Tailored Treatment of Permanent Atrial Fibrillation - TTOP-AF|TTOP-AF|Medtronic Atrial Fibrillation Solutions|Yes|Completed|May 2007|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|70 Years|No|||April 2012|April 11, 2012|August 8, 2007|Yes|Yes||No|January 25, 2012|https://clinicaltrials.gov/show/NCT00514735||168300|- The study population was mostly Caucasian men.
NCT00546832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-07-14|Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II|The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study II||Mika Pharma GmbH|No|Completed|October 2007|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|650|||Both|40 Years|N/A|No|||October 2010|October 11, 2010|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546832||165873|
NCT00546845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XXS|Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study|Xpert Stent Versus Balloon Angioplasty in Complex Lesions of Small Arteries Below the Knee|XXS|University Hospital Tuebingen|No|Recruiting|September 2007|June 2014|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||October 2007|August 4, 2011|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546845||165872|
NCT00547495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5139|Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Tadalafil Administered "On Demand" to Patients With Erectile Dysfunction||Eli Lilly and Company|No|Completed|March 2004|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|343|||Male|20 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547495||165826|
NCT00547508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7004|To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking|A Randomized, Double-Blind, Parallel, Placebo-Controlled Study in Men With Erectile Dysfunction to Evaluate the Efficacy and Safety of Tadalafil When Sexual Attempts Occur at Specific Time Points After Dosing||Eli Lilly and Company|No|Completed|October 2002|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|485|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547508||165825|
NCT00547781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-JD-0704-307-12|Implantation Failure and PGD|||Instituto Valenciano de Infertilidad, IVI VALENCIA||Completed|July 2007|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|250|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 30, 2012|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00547781||165805|
NCT00548145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSK-07098|The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease||PIT-ROAD|Osaka University||Terminated|November 2007|March 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|20 Years|85 Years|No|||May 2012|May 14, 2012|October 22, 2007||No||No|December 28, 2011|https://clinicaltrials.gov/show/NCT00548145||165778|
NCT00548444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB018|T−Cell Turnover Following Vaccination With MVA85A|Measurement of Human T−Cell Turnover Following Vaccination With the Tuberculosis Vaccine MVA85A||University of Oxford|No|Completed|October 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 15, 2010|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548444||165755|
NCT00548457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4130-PC-CTIL|Endothelial Function in Patients With Ectatic Compared to Normal Coronary Arteries|Endothelial Function in Patients With Ectatic Compared to Normal Coronary Arteries||Sheba Medical Center|No|Recruiting|May 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|76|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients were recruited after passing cardiac catherization and diagnosed as having        ectatic arteries.|January 2008|January 28, 2008|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548457||165754|
NCT00548990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0088|The Immune Function Intervention Trial|Physical Activity, Aging and Immune Function|ImFIT|National Institute on Aging (NIA)|Yes|Completed|August 2002|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|150|||Both|62 Years|82 Years|Accepts Healthy Volunteers|||January 2009|January 23, 2009|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00548990||165714|
NCT00549354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-005|Abdominal Aortic/Aorto-Iliac Aneurysm Endoluminal Graft Study|Endologix Bifurcated PowerLink System Clinical Study||Arizona Heart Institute|No|Active, not recruiting|August 2000|December 2012|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||October 2007|June 2, 2015|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549354||165688|
NCT00549848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTXVI|Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia||St. Jude Children's Research Hospital|Yes|Recruiting|October 2007|November 2019|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|531|||Both|N/A|18 Years|No|||February 2016|February 9, 2016|October 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549848||165650|
NCT00512798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC PHI 0241|Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma|(Inhibition of NF-kB Signaling in Melanoma Therapy) A Phase I/II Clinical Trial of PS-341, a Proteasome Inhibitor, in Combination With an Extended Continuous Oral Schedule of Temozolomide in Patients With Advanced Refractory Solid Tumors With the Phase II Component Only in Patients With Melanoma||Vanderbilt-Ingram Cancer Center|Yes|Terminated|June 2003|March 2008|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|August 6, 2007|Yes|Yes|This study was terminated due to lack of efficacy|No|June 27, 2012|https://clinicaltrials.gov/show/NCT00512798||168441|
NCT00512811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121a25|Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients|Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients: a Double-Blind Randomized Study||Baqiyatallah Medical Sciences University|Yes|Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||||||Male|32 Years|83 Years||||August 2007|August 7, 2007|August 7, 2007||||No||https://clinicaltrials.gov/show/NCT00512811||168440|
NCT00513071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02842|AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC)||National Cancer Institute (NCI)||Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|N/A|No|||December 2012|October 1, 2014|August 6, 2007|Yes|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT00513071||168421|
NCT00513058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558406|Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer|Phase I Study Evaluating the Combination of Lapatinib + Vinorelbine in Patients With Locally Advanced or Metastatic Breast Cancer Overexpressing HER2||UNICANCER|Yes|Completed|June 2007|April 2012|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||January 2014|January 13, 2014|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00513058||168422|
NCT00513396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB chest - 1/2005|High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis|A Randomized Control Trial Of High-Dose Isoniazid Adjuvant Therapy For Multidrug Resistant Tuberculosis||GSVM Medical College|No|Completed|January 2004|December 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|134|||Both|18 Years|N/A|No|||July 2007|August 6, 2007|August 6, 2007||||No||https://clinicaltrials.gov/show/NCT00513396||168397|
NCT00513656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN2001|A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain|A Randomised, Double-blind, Active-controlled, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Cancer Pain||Mundipharma Research GmbH & Co KG|No|Completed|September 2007|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|July 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00513656||168377|
NCT00513916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000560821|Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women|Effects of Soy on Estrogens in Breast Fluid and Urine||National Cancer Institute (NCI)||Completed|July 2006|February 2012|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|2||Anticipated|100|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||April 2009|December 18, 2013|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513916||168359|
NCT00515372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-258|Depression Treatment and Screening in Ovarian Cancer Patients|Depression Treatment and Screening in Ovarian Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2002|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|588|||Female|18 Years|N/A|No|||November 2015|November 23, 2015|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515372||168251|
NCT00515385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGAWN1-01|A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults|A Phase 1, Randomized, Double-Blind, Dose-Escalation Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of MGAWN1, a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus, in Healthy Adults||MacroGenics|Yes|Completed|August 2007|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 14, 2009|August 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00515385||168250|
NCT00514449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602032|Systematic Evaluation of Antiviral Medication in Schizophrenia|A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients|SEAMS|University of Pittsburgh|No|Active, not recruiting|June 2007|February 2010|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|50 Years|No|||February 2011|February 17, 2011|August 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514449||168321|
NCT00515047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN GENE 04|Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis|Genetics of Atopic Dermatitis - Eczema Herpeticum|Genetics|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2006|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|900|Samples With DNA|Skin scrapings and blood collection may occur|Both|8 Months|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|African-American, Caucasian, and Non-Hispanic people ages 8 months to 80 years|April 2014|April 1, 2014|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515047||168276|
NCT00547521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-173|Phase IIIB Subcutaneous Abatacept Monotherapy Study|A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate||Bristol-Myers Squibb|No|Completed|December 2007|February 2014|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|October 19, 2007|Yes|Yes||No|October 15, 2010|https://clinicaltrials.gov/show/NCT00547521||165824|
NCT00547534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULYM07054|Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma|Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma|BVR|University of Rochester|Yes|Completed|October 2007|October 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|October 18, 2007|Yes|Yes||No|April 6, 2011|https://clinicaltrials.gov/show/NCT00547534||165823|19 patients received a full 6 cycles of therapy. All patients received at least one cycle of therapy, 25 patients received at least 4 cycles. Reasons for early termination included progressive disease and toxicity
NCT00547469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP733-07-010|A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of DDP733 in Female Patients With Irritable Bowel Syndrome With Constipation||Dynogen Pharmaceuticals|Yes|Recruiting|October 2007|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|360|||Female|18 Years|65 Years|No|||April 2008|April 7, 2008|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547469||165828|
NCT00547807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHS 52/06|Non-Nutritive Sucking and Swaddling for Pain Relief in Term Neonates: Randomised Controlled Trial|Non-Nutritive Sucking and Swaddling for Pain Relief in Term Neonates: a Randomised Controlled Trial||Sociedade Hospital Samaritano|No|Recruiting|January 2007|||February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|N/A|5 Days|No|||February 2009|February 25, 2009|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00547807||165803|
NCT00548158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUB-071127|Effect of Pioglitazone Therapy for Type 2 Diabetes on Vision|Preliminary Safety Study of Pioglitazone Therapy for Diabetes on Macular Thickness and Vision in Type 2 Diabetes||University of California, San Diego|No|Completed|October 2004|April 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|19|||Both|30 Years|75 Years|No|Probability Sample|Male or female patients with type 2 diabetes mellitus on insulin therapy, 30-75 years of        age with Hgb 1c values between 7.5 - 10% and a BMI of < 40kg/m2. Patients were enrolled if        they have been on a stable anti-hypertensive and lipid regimen for 90 days prior to study        randomization.|October 2007|October 19, 2007|October 19, 2007||||No||https://clinicaltrials.gov/show/NCT00548158||165777|
NCT00540345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960057|Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C|Four Arms, Multicenter, Open Label Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|October 2006|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|300|||Both|18 Years|N/A|No|||December 2014|December 24, 2014|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00540345||166363|
NCT00536081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-2-6 STUDY|Various G-CSF Regimens to Prevent Infection During Chemotherapy|Primary G-CSF Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Breast Cancer Patients at Risk of Febrile Neutropenia||Academisch Ziekenhuis Maastricht|No|Terminated|January 2008|December 2010|Anticipated|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|172|||Female|18 Years|N/A|No|||December 2009|December 22, 2009|September 25, 2007||No|More cases of Febrile Neutropenia were observed in experimental group compared to standard    treatment.|No||https://clinicaltrials.gov/show/NCT00536081||166685|
NCT00536380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04849|Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)|A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)||Merck Sharp & Dohme Corp.|No|Completed|September 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|314|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|September 26, 2007|No|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00536380||166662|Due to poor enrollment (even after extending the enrollment period), only 314 participants (not 600 participants) were randomized to the study and hence the study was inconclusive due to the lacking of statistical power and robustness.
NCT00536393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS 0804|Treatment of Disseminated High Grade Lymphoma|Phase III Study of Treatment of Disseminated and Agressive Lymphoma R CHOP Versus R CLOP( With Liposomal Doxorubicin)||French Innovative Leukemia Organisation|Yes|Completed|October 2000|October 2004|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|60 Years|75 Years|No|||September 2007|October 31, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536393||166661|
NCT00536406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074865|Evaluating a Behavioral Activities Treatment Program for Depressed Nursing Home Residents|BE-ACTIV: Treating Depression in Nursing Homes|BE-ACTIV|University of Louisville|Yes|Active, not recruiting|August 2007|November 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|N/A|No|||April 2013|April 19, 2013|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00536406||166660|
NCT00549003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZRDT 2005|Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar|Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar|ZRDT|Karolinska University Hospital|No|Completed|February 2005|August 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|9346|||Both|N/A|N/A|No|||October 2007|October 24, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549003||165713|
NCT00549016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G020035|Clinical Study of Aneurysm Exclusion|Clinical Study of Aneurysm Exclusion Using PTFE Encapsulation of Nitinol Stents|EndoMed|Arizona Heart Institute|No|Recruiting|November 2002|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549016||165712|
NCT00536614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004309-69|Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer|A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Cetuximab to Evaluate the Efficacy in Patients With Locally Advanced or Metastatic EGFR-EGFR-Positive Pancreatic Cancer. SpaCe Trial|SPaCe-01|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|No|Completed|May 2005|September 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||September 2007|September 27, 2007|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00536614||166644|
NCT00513929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-ZN-01-EC|Zinc as Adjunct to Treatment of Pneumonia|Effects of Zinc as an Adjunct to Treatment of Pneumonia in Young Children|EcuaPAZ|Corporacion Ecuatoriana de Biotecnologia|Yes|Recruiting|August 2007|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|450|||Both|2 Months|59 Months|No|||January 2009|January 27, 2009|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00513929||168358|
NCT00513942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPH-EPAM-335|Effects of Fetal Movement Counting in Third Trimester of Pregnancy|Effects of Fetal Movement Counting - a Randomized Controlled Trial of an Unselected Population||Norwegian Institute of Public Health|No|Completed|August 2007|September 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|1200|||Female|16 Years|N/A|No|||October 2014|October 17, 2014|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513942||168357|
NCT00513084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCT-POCI/DES/57705/2004|Promotion of Exercise and Health in Obesity|Moderators and Mediators of Physical Activity, Body Weight, and Body Composition Change During Obesity Treatment in Women|PESO|Technical University of Lisbon|No|Active, not recruiting|July 2004|July 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|259|||Female|25 Years|50 Years|No|||July 2007|August 7, 2007|August 7, 2007||||No||https://clinicaltrials.gov/show/NCT00513084||168420|
NCT00514774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001927|Ursodiol in Huntington's Disease|Ursodiol in Huntington's Disease|UDCA-HD|Oregon Health and Science University|Yes|Active, not recruiting|August 2007|June 2009|Anticipated|June 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|21|||Both|18 Years|N/A|No|||February 2009|February 4, 2009|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514774||168297|
NCT00515060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANS00-339|Psychophysical Studies of Cancer Therapy-Induced Pain|Psychophysical Studies of Cancer Therapy-Induced Pain: A Feasibility Study||M.D. Anderson Cancer Center|No|Recruiting|January 2001|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, 18 years or older, with advanced cancer experiencing cancer therapy-induced        pain.|November 2015|November 19, 2015|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00515060||168275|
NCT00515346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060029|Study to Evaluate the Safety & Performance of the Xpert(TM) Stent in Treating Below-the-knee Lesions in Patients Undergoing Percutaneous Intervention for Chronic CLI.|Phase 1 Study of Xpert(TM) Nitinol Stenting for Critically Ischemic Lower Limbs|XCELL|VIVA Physicians|Yes|Completed|July 2006|September 2011|Actual|December 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|89 Years|No|||December 2013|December 16, 2013|August 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515346||168253|
NCT00515697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13921|A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma|Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy||Eli Lilly and Company|No|Completed|November 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|August 13, 2007|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00515697||168227|
NCT00515710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAV2-hFIX16-LTFU-01|LTFU for Gene Transfer Subjects With Hemophilia B|A Long-Term Follow-Up Study in Subjects With Sever Hemophilia B Who Received Adeno-Associated Viral Vectors Expressing Human Factor IX||Spark Therapeutics|Yes|Active, not recruiting|August 2007|August 2019|Anticipated|August 2019|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|9|||Male|18 Years|N/A|No|Non-Probability Sample|Prior gene therapy study subjects receiving AAV2-hFIX16.|February 2016|February 26, 2016|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515710||168226|
NCT00514748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|621125-2|A Bilateral Interconnected DIEP Flap Based on One Vessel Pedicle for Breast Reconstruction|||Chinese Academy of Sciences|No|Completed|January 2007|May 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|65 Years|No|||June 2009|June 23, 2009|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514748||168299|
NCT00514761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00011|Phase II Efficacy Study of AZD6244 in Colorectal Cancer|A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.||AstraZeneca|No|Completed|September 2006|July 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|August 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514761||168298|
NCT00515658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rambam2141_CTIL|Antidepressant Effect of Theta-Burst rTMS|Antidepressant Effect of Theta-Burst rTMS||Rambam Health Care Campus|Yes|Recruiting|March 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|No|||August 2007|August 13, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00515658||168230|
NCT00515996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-A6-418-2|Genetic Abnormalities and Biological Changes of Panic Disorder Patients After Pharmacotherapy|Genetic Abnormalities and Changes of Autonomic Nervous System, Serotonin System, and Neuroendocrine System According to Pharmacotherapy in Panic Disorder||Samsung Medical Center|No|Recruiting|January 2006|December 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Longitudinal||1|Anticipated|80|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2007|August 13, 2007|August 13, 2007||||No||https://clinicaltrials.gov/show/NCT00515996||168205|
NCT00547157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062079|Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Amgen|Yes|Completed|November 2007|March 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|October 18, 2007|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00547157||165849|
NCT00547170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO06040005|Doxycycline Prophylaxis at Vacuum Aspiration Trial|Efficacy and Side-Effects of Two Dosing Regimens of Doxycycline at Surgical Abortion: A Randomized Double-Blind Trial|Tu Du Doxy|University of Pittsburgh|No|Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1000|||Female|18 Years|N/A|No|||May 2008|May 14, 2008|October 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00547170||165848|
NCT00539292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020010078|Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis|A Multi-Centre, Prospective Randomized Trial to Evaluate Routine Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis||The Hospital for Sick Children|No|Completed|September 2005|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|N/A|30 Days|No|||October 2007|October 2, 2007|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00539292||166442|
NCT00547820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBrook2518CTIL|Urinary Sensor for Cystourethrography|Urinary Sensor for Cystourethrography||Rambam Health Care Campus||Completed|July 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|1 Month|10 Years|No|||October 2007|October 27, 2009|October 20, 2007||||No||https://clinicaltrials.gov/show/NCT00547820||165802|
NCT00547833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03DC006827-01A1|Partial Word Knowledge Growth in Children With LLD|Partial Word Knowledge Growth in Children With LLD||University of Missouri-Columbia|No|Completed|May 2006|December 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|January 2010|January 15, 2010|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00547833||165801|
NCT00539981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC04|Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok|Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49||Protein Sciences Corporation|No|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|4648|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2011|May 16, 2011|October 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539981||166391|
NCT00536952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 06N2|Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy|A Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation and Chemotherapy||Northwestern University|Yes|Active, not recruiting|February 2008|December 2016|Anticipated|October 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|36|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|September 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00536952||166619|
NCT00536341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CLL 02|Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated and Untreated Patients With Chronic Lymphocytic Leukemia||SCRI Development Innovations, LLC|No|Active, not recruiting|January 2008|January 2016|Anticipated|April 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00536341||166665|
NCT00536354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFernandes|Postural Orientation In The Use Of School Backpacks|Effects Of Postural Orientation In The Use Of School Backpacks In Elementary School Students||University of Sao Paulo|Yes|Completed|August 2005|December 2005|Actual|||Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|7 Years|10 Years||||September 2007|September 26, 2007|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00536354||166664|
NCT00536367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0241|Validation of a Mortality Prediction Model for Acutely Decompensated Heart Failure Patients|Validation of a Mortality Prediction Model for Acutely Decompensated Heart Failure Patients||Ohio State University|No|Completed|January 2006|March 2008|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|226|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00536367||166663|
NCT00537251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4023|32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus|32-Week, Open, Randomized, Cross-Over, Local, Multicenter Clinical Trial Comparing Insulin Glargine in Combination With Insulin Analogue (Insulin Lispro) to NPH Insulin in Combination With Regular Insulin in Type 1 Diabetes Mellitus Patients in an Intensified Insulin Regimen.||Sanofi||Completed|November 2001|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Both|18 Years|65 Years|No|||September 2007|September 28, 2007|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00537251||166597|
NCT00537485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-07-001|A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients|A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa||Otsuka Pharmaceutical Co., Ltd.|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|30 Years|79 Years|No|||February 2014|February 3, 2014|September 27, 2007||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00537485||166579|
NCT00513955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000559820|Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma||Plymouth Hospitals NHS Trust|Yes|Completed|June 2006|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513955||168356|
NCT00514241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JA-250-N|Evaluate Use of Gravitational Platelet Separation System on Leg Wound Healing in Coronary Bypass Surgery|A Clinical Study to Evaluate the Use of Gravitational Platelet Separation System on Leg Wound Healing in Coronary Bypass Surgery||Biomet, Inc.||Completed|January 2006|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514241||168336|
NCT00514501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-BP23|Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome|Open-label, Phase 2 Study of the Safety and Efficacy of B-methyl-P-(123I)- Iodophenyl-pentadecanoic Acid (Iodofiltic Acid I 123) For Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (Spect) in Adults With Symptoms Consistent With Acute Coronary Syndrome (ACS).|Zeus-ACS|Molecular Insight Pharmaceuticals, Inc.|Yes|Completed|May 2007|December 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|510|||Both|40 Years|N/A|No|||November 2015|December 15, 2015|August 8, 2007|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00514501||168317|
NCT00514800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0002|Home Blood Pressure Monitoring Trial|Community Based Trial of Home Blood Pressure Monitoring With Nurse Led Support in Patients With Stroke or TIA Recently Discharged From Hospital||St George's, University of London|No|Completed|March 2007|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|360|||Both|16 Years|N/A|No|||August 2007|June 5, 2015|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514800||168295|
NCT00549029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200708077R|The Association of Genetic Polymorphisms With Statin-Induced Myopathy.|Association Analysis Between Single Nucleotide Polymorphisms in Statin-Related Genes and The Incidence of Myopathy Among Statin-Treated Patients||National Taiwan University Hospital|No|Recruiting|August 2007|January 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|150|Samples With DNA|whole blood|Both|21 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|National Taiwan University Hospital|October 2007|October 24, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549029||165711|
NCT00549042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMT 1077-301|Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain|A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS® Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients With Chronic Low Back Pain||Mallinckrodt||Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|75 Years|No|||March 2012|March 20, 2012|October 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549042||165710|
NCT00515970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E.03.26007.1|Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas|Prospective Randomized Trial: Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas||University Hospital Tuebingen|Yes|Suspended|December 2007|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|N/A|N/A|No|||June 2010|June 14, 2010|August 13, 2007||No|Problems with the electronic data collection program|No||https://clinicaltrials.gov/show/NCT00515970||168207|
NCT00515983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4484/04|Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells|Phase I Clinical Trial of a Therapeutic Vaccine Composed of Autologous Dendritic Cells Loaded With Allogeneic Apoptotic Tumor Cells in Patients With Melanoma Stages IIB, IIC, III and IV||José Mordoh, M.D., Ph.D.||Completed|October 2004|December 2005|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|16|||Both|17 Years|60 Years|No|||August 2007|August 10, 2007|August 10, 2007||||No||https://clinicaltrials.gov/show/NCT00515983||168206|
NCT00516022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mistletoe.ctil|Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination.|Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination: Randomized Phase II Study|Iscador|Rambam Health Care Campus|No|Completed|April 2007|May 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516022||168203|
NCT00538967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00.146|The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm|The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm||Leiden University Medical Center|No|Completed|May 2002|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Actual|60|||Both|N/A|N/A|No|||October 2007|October 2, 2007|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00538967||166466|
NCT00538980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-104|Dasatinib in Polycythemia Vera|The Use of Dasatinib (SPRYCEL) in Treating Patients With Polycythemia Vera (PV): A Phase II, Non-Randomized Study||Weill Medical College of Cornell University||Completed|April 2007|||October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2009|October 20, 2009|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538980||166465|
NCT00539695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20971-IL2 for GvHD|Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD|Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis|IL2 for GVHD|Baylor College of Medicine|Yes|Completed|June 2007|March 2014|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|70 Years|No|||January 2016|January 11, 2016|October 2, 2007|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00539695||166413|
NCT00539643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-099|Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma|A Randomized Single Blind Controlled Trial of Beads vs. Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma (HCC)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2007|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539643||166416|
NCT00539656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0606|Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers|Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies|Cord Blood|Sidney Kimmel Comprehensive Cancer Center|No|Terminated|October 2007|||December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|6 Months|55 Years|No|||October 2013|October 24, 2013|October 2, 2007|No|Yes|The manufacturer discontinued necessary reagents.|No||https://clinicaltrials.gov/show/NCT00539656||166415|
NCT00540358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11485|A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer|A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without BSI-201, in Patients With ER, PR and HER2-negative Metastatic Breast Cancer||Sanofi|No|Completed|October 2007|June 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Female|18 Years|N/A|No|||December 2012|December 21, 2012|October 4, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00540358||166362|
NCT00540683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2004-3626|Measurement of the Distribution of Optical Properties in Adult Human Muscle|Measurement of the Distribution of Optical Properties in Adult Human Muscle||University of California, Irvine|No|Recruiting|October 2004|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from outpatient clinic at University Of California        Irvine, and staffs and students.|February 2016|February 5, 2016|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540683||166337|
NCT00536627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001682-15|Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis|Randomised, Opened, Multicentre Phase I/II Trial in Patients With Chronic Hepatitis B With HBV VL < 12 IU/ml and Under Treatment With NRTI, Which Evaluated Efficacy and Tolerance of Vaccination With Naked DNA on Viral Replication After Analogs' Treatment Interruption. ANRS HB02 VAC-ADN|VAC-ADN|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|January 2008|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||December 2011|December 16, 2011|September 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00536627||166643|
NCT00536640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-2006-NSCLC-01|Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab|Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabin/Cisplatin Plus Bevacizumab|INNOVATIONS|Aktion Bronchialkarzinom e.V.|Yes|Completed|November 2007|May 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536640||166642|
NCT00536926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124|Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation|Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation - an Open, Randomised Trial|TeleTx|Hannover Medical School|No|Completed|July 2007|July 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|18 Years|N/A|No|||October 2008|July 19, 2011|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536926||166621|
NCT00536939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11396|Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer|A Randomized, Double-Blind, Phase 2 Trial of Paclitaxel Plus Bevacizumab and Enzastaurin Versus Paclitaxel Plus Bevacizumab and Placebo for Locally Recurrent or Metastatic Breast Cancer||Eli Lilly and Company|Yes|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|September 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00536939||166620|
NCT00537511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-SCLC-002|A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide|A Multicenter, Phase I/IIA, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose and To Evaluate the Safety Profile of CC-4047 Administered in Combination With Cisplatin and Etoposide in Patients With Extensive Disease Small Cell Lung Cancer||Celgene|No|Terminated|February 2008|December 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|September 27, 2007|Yes|Yes|This study was terminated for administrative reasons.|No|March 6, 2013|https://clinicaltrials.gov/show/NCT00537511||166577|
NCT00513968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB110_HB_I|Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine|A Single Center, Randomized, Open-label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-week Period||Genexine, Inc.|No|Completed|July 2007|December 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|60 Years|No|||August 2012|August 3, 2012|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513968||168355|
NCT00513981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-NAG-2005-13|High-Dose Methotrexate in Treating Young Patients With Solid Tumors|Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time||National Cancer Institute (NCI)||Completed|March 2007|August 2009|Actual|March 2008|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|N/A|21 Years|No|||June 2009|June 25, 2013|August 8, 2007||||No||https://clinicaltrials.gov/show/NCT00513981||168354|
NCT00514254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-093|Risk Factors for Endometrial Cancer in Black Women|Endometrial Cancer in Black Women||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2007|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|59|Samples With DNA|saliva/buccal specimens|Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Black women (including African-American, African, Afro-Caribbean women) with endometrial        cancer and controls will be recruited at MSKCC, SUNY Downstate Medical Center and        Montefiore Medical Center hospitals. Controls will be black (including African-American,        African, Afro-Caribbean) women without history of cancer, who have intact uteri, and will        be identified in gynecology clinics. Controls will also be recruited at the Breast        Examination Center of Harlem (BECH), an affiliate of MSKCC, providing high quality        screening services to a minority community.|March 2015|March 24, 2015|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00514254||168335|
NCT00514514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE13|Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen|Multi-center, Open-label, Prospective, Randomized, Parallel Group, Long-term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI-free Regimen and a CNI-low Dose Regimen||Novartis||Completed|July 2007|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|756|||Both|18 Years|70 Years|No|||March 2016|March 23, 2016|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514514||168316|
NCT00514475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002003-17|Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma|High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment||Oslo University Hospital|Yes|Completed|November 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|65 Years|No|||May 2008|May 3, 2012|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514475||168319|
NCT00514488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICSG/CML022|Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)|A Phase III Study Comparing Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) in the Treatment of Newly Diagnosed High Risk Chronic Myeloid Leukemia in Chronic Phase|CML022|University of Bologna|No|Completed|June 2004|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|18 Years|N/A|No|||July 2007|August 9, 2007|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00514488||168318|
NCT00514787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RAT-SYM-2007/1|Be SMART NIS, Moderate to Servere Asthma Patient Observation|Be SMART NIS, Moderate to Servere Asthma Patient Observation||AstraZeneca|No|Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|900|||Both|N/A|N/A|No|||March 2009|March 26, 2009|August 9, 2007||||No||https://clinicaltrials.gov/show/NCT00514787||168296|
NCT00515086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2410|Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)|A Phase II Trial of RAD001 in Patients With Recurrent Glioblastoma Multiforme||Novartis||Terminated|August 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|August 10, 2007|Yes|Yes|Early termination due to slow enrollment and protocol-defined stopping rule.|No|December 15, 2010|https://clinicaltrials.gov/show/NCT00515086||168273|Due to the early termination of this study, the analysis of some of the planned objectives is not included in this clinical study report.
NCT00548483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-107|Comparison of High Dose and Low Dose Dexamethasone in Preventing Post-Extubation Airway Obstruction in Adults|Phase 2 Study of Comparison of High Dose and Low Dose Dexamethasone in Preventing Post-Extubation Airway Obstruction in Adults||Mackay Memorial Hospital|Yes|Recruiting|April 2007|May 2008|Anticipated|March 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|95 Years|No|||May 2008|May 27, 2008|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548483||165752|
NCT00548496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9108914|A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius|A Proof-of-Concept Study Of SB-751689 In Men And Post-menopausal Women With A Fractured Distal Radius||GlaxoSmithKline|No|Terminated|September 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|86|||Both|35 Years|80 Years|No|||September 2015|September 3, 2015|October 23, 2007||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00548496||165751|
NCT00515359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-140|RCT for Intermittent Versus Continuous Propofol Sedation for Pediatric Brain and Spine MRI Studies|RCT for Intermittent Versus Continuous Propofol Sedation for Pediatric Brain and Spine MRI Studies||Spectrum Health Hospitals|No|Completed|June 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|1 Month|18 Years|No|||December 2009|January 26, 2010|August 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00515359||168252|
NCT00516373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU36-92|A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)|A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.||AstraZeneca|Yes|Active, not recruiting|July 2005|December 2016|Anticipated|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|130 Years|No|||March 2016|March 23, 2016|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516373||168176|
NCT00516659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELT206|ETEC Logistics Trial (TREK)|A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting|Trek|Intercell USA, Inc.|Yes|Completed|May 2006|December 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|201|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|August 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00516659||168156|
NCT00538993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H97HA01144|Improving Provider Counseling Interventions in HIV Practice|||Johns Hopkins University|No|Active, not recruiting|September 2003|October 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|425|||Both|18 Years|N/A|No|||September 2007|October 1, 2007|October 1, 2007||||No||https://clinicaltrials.gov/show/NCT00538993||166464|
NCT00539006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFU105924|Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS|R, DB, PC, AC, One-Week, Cross-Over, MC Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg FFNS and 200mcg FPNS in Adult Subjects With SAR||GlaxoSmithKline||Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|377|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|October 2, 2007||No||No|November 14, 2008|https://clinicaltrials.gov/show/NCT00539006||166463|
NCT00539669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976I_2502|TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian|||Sanofi||Completed|March 2003|||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Female|18 Years|N/A|No|||October 2007|October 3, 2007|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00539669||166414|
NCT00535808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/270|Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study|Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: a Randomized Study||University Hospital, Ghent|No|Completed|October 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|N/A|18 Years|No|||July 2012|July 12, 2012|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535808||166706|
NCT00535821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57121|Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock|A Multi-center Randomized Comparison of a Minimally-invasive Cardiovascular Hemodynamic Optimization (MiCHO) Protocol Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock Patients Presenting to the Emergency Department|MiCHO|Loma Linda University|No|Terminated|June 2007|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|September 24, 2007||No|slow enrollement unavailable technology|No|May 22, 2014|https://clinicaltrials.gov/show/NCT00535821||166705|
NCT00539994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALB110247|Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus||GlaxoSmithKline|No|Completed|September 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|May 21, 2015|October 4, 2007|No|Yes||No|January 9, 2009|https://clinicaltrials.gov/show/NCT00539994||166390|
NCT00540007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0233 / 201104227|Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma|A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma||Washington University School of Medicine|Yes|Active, not recruiting|September 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540007||166389|
NCT00535834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907214|Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154|Data Analysis for 00-C-0154, A Randomized Phase II Study of a PSA-based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy||National Institutes of Health Clinical Center (CC)||Completed||March 2011|Actual|||N/A|Observational|N/A||||48|||Male|18 Years|N/A|No|||March 2012|March 14, 2012|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00535834||166704|
NCT00535847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX06-950-107|A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy|A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who Did Not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response||Vertex Pharmaceuticals Incorporated|Yes|Completed|October 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|117|||Both|18 Years|70 Years|No|||July 2014|July 9, 2014|September 25, 2007|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00535847||166703|
NCT00536094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH074552|School-based Treatment for Anxious Children|School-Based CBT for Anxious African-American Children||Johns Hopkins University|Yes|Completed|October 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|7 Years|17 Years|No|||April 2012|September 23, 2013|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00536094||166684|
NCT00536653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55/99|Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer|Long Term Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer, With Stratification of Treatment Based on Presenting Values||Wirral University Teaching Hospital NHS Trust|Yes|Completed|October 1999|January 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|618|||Male|N/A|N/A|No|||August 2007|September 27, 2007|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00536653||166641|
NCT00537264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/1/27/18/226|A Comparison of Computerised Versus Interviewer-Administered Approach for Assessing Health-Related Quality of Life|A Randomized Controlled Trial Comparing Computer- Versus Interviewer-Administered Approach for Assessing Health-Related Quality of Life in Multi-Ethnic Singapore||Singapore General Hospital|No|Completed|November 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|4800|||Both|21 Years|N/A|No|||June 2009|June 22, 2009|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537264||166596|
NCT00537277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1849|Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs|A Titrate-To-Target Study of the Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs With / Without Once Daily Basal Insulin Therapy|IMPROVE|Novo Nordisk A/S|No|Completed|October 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|September 28, 2007|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00537277||166595|
NCT00537290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 27022|A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome|A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome (RITAPS)|RITAPS|Hospital for Special Surgery, New York|Yes|Completed|September 2007|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||April 2014|April 4, 2014|September 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00537290||166594|
NCT00537303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1833|Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes|Comparison of the Efficacy and Safety of Step-wise Addition of Short Acting Insulin Analogue Insulin Aspart to Once Daily Insulin Detemir and Oral Anti-diabetic Treatment in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|296|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|September 28, 2007|Yes|Yes||No|July 16, 2010|https://clinicaltrials.gov/show/NCT00537303||166593|
NCT00513708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLO-NIAAA-015616|Facilitating Aftercare for Alcohol Detox Patients|Helping Alcoholics Link to Substance Abuse Treatment Programs After Being in the Hospital for Detoxification||State University of New York at Buffalo|No|Completed|July 2007|August 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||April 2011|April 15, 2011|August 7, 2007||No||No|February 14, 2011|https://clinicaltrials.gov/show/NCT00513708||168373|
NCT00513721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-087|Retrospective Study of Positive Biopsy Specimens on Patients Undergoing a Prostatectomy|Do Positive Lateral Biopsy Cores on TRUS Directed Biopsies Predict Capsular Penetration and Positive Surgical Margins?||William Beaumont Hospitals|No|Completed|July 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|400|||Male|18 Years|N/A|No|Non-Probability Sample|Males having undergone surgery for prostate cancer at William Beaumont Hospital-Royal Oak,        Michigan|May 2009|May 4, 2009|August 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00513721||168372|
NCT00546897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0907|Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities|Phase II Trial of Lenalidomide in Older Patients (>/= 60 Years) With Untreated Acute Myeloid Leukemia Without Chromosome 5q Abnormalities||Washington University School of Medicine|Yes|Completed|February 2007|March 2012|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|60 Years|N/A|No|||September 2014|September 26, 2014|October 17, 2007|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00546897||165868|
NCT00514267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-025|An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors|A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors||Astellas Pharma Inc|No|Completed|May 2007|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|August 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00514267||168334|
NCT00547846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP013|A Phase II Clinical Study of PDC-748 in Patients With Acute Cough|A Phase II Clinical Study of PDC-748 in Patients With Acute Cough||PhytoHealth Corporation|Yes|Completed|October 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||||||Both|20 Years|N/A|No|||January 2009|January 8, 2009|October 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547846||165800|
NCT00514813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD490-402|Dynepo Long-Term Safety Study|An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease||Shire|No|Terminated|June 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|152|||Both|18 Years|N/A|No|||November 2009|June 6, 2014|August 9, 2007||No|The termination of the study is not linked to a product recall or result of any safety signal.    Rather it was sponsor's commercial decision to withdraw the MA|No|August 18, 2009|https://clinicaltrials.gov/show/NCT00514813||168294|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.
NCT00515398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM-CL-001|A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease|A Multicenter Study to Evaluate and Characterize the Effects of Pharmacological Chaperones in Cell Lines Derived From Blood and Skin Samples From Patients With Pompe Disease||Amicus Therapeutics|No|Completed|August 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|30|Samples With DNA|White blood cells|Both|N/A|N/A|No|Non-Probability Sample|Patients with Pompe disease|June 2008|June 4, 2008|August 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00515398||168249|
NCT00515411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-103|Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma|A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|October 2006|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|August 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00515411||168248|
NCT00548808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11541|A Study for Type 2 Diabetic Patients|Comparison of Insulin Lispro Low Mixture With Insulin Glargine When Initiating and Intensifying Insulin Therapy As Required in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Oral Antihyperglycemic Medication||Eli Lilly and Company|No|Completed|November 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|426|||Both|30 Years|79 Years|No|||August 2010|August 20, 2010|October 22, 2007|Yes|Yes||No|August 20, 2010|https://clinicaltrials.gov/show/NCT00548808||165727|
NCT00515671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAC 05-254|Illness Management and Recovery for Veterans With Severe Mental Illness|Illness Management and Recovery for Veterans With Severe Mental Illness||VA Office of Research and Development|No|Completed|January 2008|September 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||September 2014|April 6, 2015|August 10, 2007||No||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00515671||168229|Low attendance in both groups, may not have had enough "exposure" Study embedded in a treatment-rich environment, cannot sort out other impacts on outcomes.
NCT00515684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2006-0234|Corneal Thinning During Topical Bevacizumab Therapy|||Yonsei University|Yes|Withdrawn|May 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|0|||Both|N/A|N/A||||April 2015|April 29, 2015|August 13, 2007|||Side effect can increase the risk of the research|No||https://clinicaltrials.gov/show/NCT00515684||168228|
NCT00549055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751026|A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.|A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration (AMD) In Real Life (Macureli Study).|MACURELI|Pfizer|No|Completed|November 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|38|||Both|N/A|N/A|No|Probability Sample|Patients who obtained reimbursement for Macugen, recruited by retina specialists from        ophthalmology centres with experience in intravitreal injections.|February 2011|February 15, 2011|October 23, 2007||No||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00549055||165709|
NCT00549380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G990189|Clinical Study of Aneurysm Exclusion|A Clinical Study of Aneurysm Exclusion Using Endologix, Inc. Endoluminal Technology|Endologix|Arizona Heart Institute|No|Active, not recruiting|October 1999|October 2010|Anticipated|October 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|18 Years|N/A|No|||May 2009|May 25, 2010|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549380||165686|
NCT00540371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-1999-2154|Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain Birthmark at High Fluences|Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain||University of California, Irvine|No|Completed|December 1999|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|136|||Both|1 Month|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|August 2015|August 5, 2015|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540371||166361|
NCT00536419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG-06450|Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents|Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents||Federal University of Rio Grande do Sul||Recruiting|September 2007|September 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|53|||Both|19 Years|29 Years|No|||September 2007|September 26, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536419||166659|
NCT00536666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-CKD-01|A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients|A Non-Comparative Open-Label Study of Iron Oligosaccharide in Chronic Kidney Disease Patients With a Need for Parenteral Iron||Pharmacosmos A/S|No|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|182|||Both|18 Years|N/A|No|||October 2008|October 7, 2008|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00536666||166640|
NCT00536679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103268|Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers|An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of Two Different Formulations of GSK163090 and the Effect of Food on the Pharmacokinetics of a Tablet Formulation in Healthy Male and Female Volunteers||GlaxoSmithKline||Completed|September 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00536679||166639|
NCT00536692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG003-202|Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)|Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)||CoMentis|No|Completed|September 2007|April 2008|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||April 2008|April 3, 2008|September 26, 2007||||||https://clinicaltrials.gov/show/NCT00536692||166638|
NCT00536458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 02|Treatment of Localized Low Grade Lymphomas|Phase III Study of Treatment of Localized Lymphomas: Radiotherapy Versus Radio-Chemotherapie||French Innovative Leukemia Organisation|Yes|Completed|March 1999|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|79 Years|No|||September 2007|October 31, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536458||166656|
NCT00536965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAT-CRE-2007/1|Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets|Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets||AstraZeneca||Completed|July 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|951|||Both|18 Years|70 Years|No|Non-Probability Sample|Male and female type II diabetics with: coronary disease with event: acute coronary        syndrome, status post MI, PTCT, CABG, angiographically verified), or proven        atherosclerotic progression (PAVK min. IIb or S.p. revascularization, stroke/TIA,        carotis-plaque: asymptomatic min. 70% or S.p. revascularization)|October 2014|October 29, 2014|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536965||166618|
NCT00536978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0230|Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies|T-Cell or Natural Killer (NK) Cell Adback in Patients With Lymphoid Malignancies Receiving Allogeneic Stem Cell Transplantation With Campath-IH Containing Conditioning Regimens||M.D. Anderson Cancer Center|No|Completed|September 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|70 Years|No|||April 2012|April 23, 2012|September 27, 2007|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00536978||166617|
NCT00537316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04807|Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)|Comparison of the Efficacy and Safety of Infliximab, as Monotherapy or in Combination With Azathioprine, Versus Azathioprine Monotherapy in Moderate to Severe Active Ulcerative Colitis (Part 1) Comparison of Maintenance Versus Intermittent Infliximab Treatment in Maintaining Remission: A Follow-Up of Efficacy and Safety (Part 2)||Merck Sharp & Dohme Corp.|No|Terminated|July 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|242|||Both|21 Years|N/A|No|||March 2015|March 30, 2015|September 28, 2007|Yes|Yes|Infusion reactions during re-induction cycles after a period of no treatment in another study    [P04563, NCT0358670]|No|November 11, 2011|https://clinicaltrials.gov/show/NCT00537316||166592|
NCT00537329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851016|Anidulafungin In Treatment Of Candidemia In Asian Subjects|A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients||Pfizer|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2010|March 4, 2010|September 25, 2007|Yes|Yes||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00537329||166591|
NCT00537563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4017|AMS VS MOXI Ketek vs Avelox in AMS|||Sanofi||Completed|December 2002|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|351|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|September 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537563||166573|
NCT00546910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11148|Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double Blind Comparison of the Effects of Atomoxetine Versus Placebo on Neuropsychological Outcomes Across the Day in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) by Use of a Computer Based Continuous Performance Test (cb CPT)||Eli Lilly and Company|No|Completed|October 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|6 Years|12 Years|No|||August 2010|August 4, 2010|October 17, 2007|Yes|Yes||No|May 21, 2010|https://clinicaltrials.gov/show/NCT00546910||165867|
NCT00513994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002|MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects|MQX-503 Applied to the Fingers vs. Nitroglycerin Ointment 2%, USP, Applied to the Chest: A Pharmacokinetic Comparison in Normal Subjects||MediQuest Therapeutics|No|Completed|August 2007|October 2007|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2008|April 8, 2008|August 7, 2007||||No||https://clinicaltrials.gov/show/NCT00513994||168353|
NCT00514826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1413|Study to Investigate Sleep Apnea Patients at Altitude|Study to Investigate Sleep Apnea Patients at Altitude||University of Zurich|No|Completed|August 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|40|||Both|20 Years|N/A|No|||May 2010|May 25, 2010|August 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00514826||168293|
NCT00515099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN028AI|Study of Antithymocyte Globulin for Treatment of New-onset T1DM|Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus|START|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|August 2007|July 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|58|||Both|12 Years|35 Years|No|||January 2016|January 15, 2016|August 10, 2007|Yes|Yes|Slow accrual|No|February 10, 2014|https://clinicaltrials.gov/show/NCT00515099||168272|Enrollment for this trial was closed at 58 participants and did not meet the planned sample size of 66 participants due to slow accrual.
NCT00548470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06I/C34-0|Varenicline Effects In Schizophrenic Smokers|Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking||Nathan Kline Institute for Psychiatric Research|No|Completed|June 2007|December 2010|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||May 2012|May 17, 2012|October 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00548470||165753|
NCT00548782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H84763129001|Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome|Paleolithic Diets and Metabolic Control in Type 2 Diabetes Mellitus||University of California, San Francisco|No|Completed|September 2007|||June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 20, 2013|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548782||165729|
NCT00549107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-365|Prophylactic Use of Levosimendan Versus Milrinone in Open Heart Surgery in Infants|Phase 2 Prospective, Randomized, Double-Blind Pilot Study on Cardiac Output Following Corrective Open Heart Surgery in Children Less Than One Year: Use of Levosimendan Versus Milrinone.|Levomil|Ludwig Boltzmann Gesellschaft|Yes|Recruiting|September 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|12 Months|No|||October 2007|October 24, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549107||165706|
NCT00516035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 241|Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults|Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H7N3 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|August 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00516035||168202|
NCT00549406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-PREV-INT-452|Visual Training Program to Improve Balance and Prevent Falls in Older Adults|Visual Processing and Postural Reactions: Development and Pilot Testing of a "Visual Training" Program to Improve Balance Control and Prevent Falls in Older Adults||Sunnybrook Health Sciences Centre|No|Completed|June 2008|February 2012|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Both|64 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549406||165684|
NCT00549666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050246|A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects|A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects|OC-DDI|Sunovion|Yes|Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|23|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549666||165664|
NCT00549679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC101939|Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients||GlaxoSmithKline|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|104|||Both|40 Years|75 Years|No|||October 2012|October 25, 2012|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549679||165663|
NCT00540410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAMF_L_02873|Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks|A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal||Sanofi|No|Completed|September 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|366|||Both|N/A|N/A|No|||June 2010|June 22, 2010|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00540410||166358|
NCT00540020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F292BL-C9|Rehabilitation of Traumatic Brain Injury in Active Duty Military Personnel and Veterans|Rehabilitation of Traumatic Brain Injury in Active Duty Military Personnel and Veterans: DVBIC Randomized Clinical Trial of Two Rehabilitation Approaches||Walter Reed Army Medical Center||Completed|July 1996|May 2003|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|360|||Both|18 Years|N/A|No|||October 2007|October 4, 2007|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540020||166388|
NCT00540033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR94-IRB-14|Probiotics Reduce Incidence of Necrotizing Enterocolitis for Very Low Birth Weight Infants|Phase 2 Study of Oral Probiotics Reduce the Incidence and Severity of Necrotizing Enterocolitis for Very Low Birth Weight Infants -Multi-Center Randomized Control Trial||China Medical University Hospital|Yes|Terminated|February 2005|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|217|||Both|N/A|3 Weeks|Accepts Healthy Volunteers|||October 2007|October 4, 2007|October 3, 2007|||terminated because of enough case number|No||https://clinicaltrials.gov/show/NCT00540033||166387|
NCT00540384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980291|Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy|A Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) Administered by Subcutaneous (SC) Injection for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy||Amgen||Completed|July 1999|June 2002|Actual|March 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|405|||Both|N/A|N/A|No|||May 2013|May 6, 2013|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540384||166360|
NCT00540397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006CB504801|TCM Etiological Study on the Theory of XuSunShengJi in Liver Cirrhosis|Traditional Chinese Medicine Etiological Study on the Theory of XuSunShengJi in Liver Cirrhosis||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||October 2007|October 5, 2007|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00540397||166359|
NCT00536107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913C00046|Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy||AstraZeneca|No|Terminated|October 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|September 26, 2007|Yes|Yes||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00536107||166683|This study was terminated early because the purpose of this study had been fulfilled by other supporting data, and due to small number of patients enrolled (14 patients).
NCT00536120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS404|The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis|A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis||Biogen|No|Completed|January 2008|December 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|60 Years|No|||March 2014|March 27, 2014|September 25, 2007|No|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00536120||166682|
NCT00537030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL07P2|Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia|Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase®; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|Yes|Active, not recruiting|February 2008|||February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|1 Year|30 Years|No|||March 2016|March 21, 2016|September 27, 2007||No||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00537030||166613|
NCT00536432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 4.2|Early Re-intervention in Infants and Small Children After Correction of Tetralogy of Fallot|Early Re-intervention in Infants and Small Children After Correction of Tetralogy of Fallot: Prospective Analysis of Myocardial Benefit Using Cardiac MRI and Echocardiography||Competence Network for Congenital Heart Defects|No|Completed|September 2007|June 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|93|||Both|N/A|7 Years|No|Probability Sample|children, <8 years, with tetralogy of Fallot|October 2010|June 5, 2012|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536432||166658|
NCT00536991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 68905|Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer|A Phase I/II Study of Oral Calcitriol in Combination With Ketoconazole in Androgen Independent Prostate Cancer||Roswell Park Cancer Institute|Yes|Active, not recruiting|October 2006|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|89|||Male|18 Years|N/A|No|||August 2015|August 17, 2015|September 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00536991||166616|
NCT00537602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-056-201|Miglustat / OGT 918 in the Treatment of Cystic Fibrosis|Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation||Actelion|No|Terminated|November 2007|March 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|12 Years|N/A|No|||February 2010|February 11, 2010|September 28, 2007||No|Methodology applied did not meet all criteria required per guidelines|No||https://clinicaltrials.gov/show/NCT00537602||166570|
NCT00537914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP00-401|Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)|Long-term Phase IV Multicentre Study on the Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)||Sandoz|No|Active, not recruiting|October 2007|March 2021|Anticipated|March 2021|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|4 Years|18 Years|No|||March 2016|March 21, 2016|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00537914||166546|
NCT00547209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-08|Effect of Nitrous Oxide on Intravenous Closed-loop Anesthesia|Anesthésie Totale Intraveineuse en " Boucle d'Asservissement " guidée Par l'Index Bispectral : Effet de l'Adjonction de Protoxyde d'Azote (Effect of Nitrous Oxide on Intravenous Closed-loop Anesthesia)|Drone-N2O|Hopital Foch|No|Completed|October 2007|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|672|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|October 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00547209||165845|
NCT00547183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8702|Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection|A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5 mg and 5 mg) Administered Once Daily to Men With Diabetes Mellitus and Erectile Dysfunction||Eli Lilly and Company|No|Completed|October 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|298|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547183||165847|
NCT00547196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02165|Study of Four Different Chemotherapy Regimens With or Without Total-Body Irradiation Followed by Umbilical Cord Blood Transplant in Treating Patients With Relapsed or Refractory Hematologic Cancer|Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units||City of Hope Medical Center|Yes|Active, not recruiting|August 2005|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|10|||Both|N/A|120 Years|No|||February 2016|February 10, 2016|October 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547196||165846|
NCT00547547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05122|High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer|A Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine||City of Hope Medical Center|Yes|Completed|April 2006|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|October 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547547||165822|
NCT00547560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3183A1-102|Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population|An Ascending Multiple Dose Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GSI-953 Administered Orally To Healthy Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|49|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 1, 2011|October 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00547560||165821|
NCT00547573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5874|Determine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection|A Multinational, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil Administered "On Demand" to Asian Men With Erectile Dysfunction||Eli Lilly and Company|No|Completed|April 2003|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|367|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547573||165820|
NCT00548171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110804|Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination|Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting.||GlaxoSmithKline||Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|205|||Both|28 Years|N/A|Accepts Healthy Volunteers|||February 2011|March 27, 2014|October 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548171||165776|
NCT00548184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20464|Lapatinib and Trastuzumab With or Without Endocrine Therapy|A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients||Baylor Breast Care Center|Yes|Completed|September 2008|January 2014|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|65 Years|No|||July 2014|July 22, 2014|October 19, 2007|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00548184||165775|
NCT00548197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-A-57|Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment|Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment||Iran University of Medical Sciences|No|Recruiting|February 2007|December 2007|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|90 Years|No|||October 2007|October 22, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00548197||165774|
NCT00549432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G020149|Clinical Study of Abdominal Aortic Aneurysm Exclusion (TALENT Abdominal)|Clinical Study of Abdominal Aortic Aneurysm Exclusion Using the TALENT Enhanced LPS Endoluminal Stent-Graft System|l|Arizona Heart Institute|No|Active, not recruiting|October 2002|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549432||165682|
NCT00549367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACHIN001|The Role of Diet Education and Nutritional Counselling in the Ongoing Care of People Living With HIV in Thailand|The Role of Diet Education and Nutritional Counselling in the Ongoing Care of People Living With HIV in Thailand (TACH001)|TACH001|Thai Red Cross AIDS Research Centre|No|Recruiting|November 2007|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|153|||Both|18 Years|70 Years|No|||February 2011|May 11, 2015|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00549367||165687|
NCT00545831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/100/HP|Effect of Taurolidin on Prevention of Bloodstream Infection|Prevention of Central Veinous Device Related Sepsis Relapse With Taurolidine in Patients on Parenteral Nutrition in Long-term Home|Nutrilock|University Hospital, Rouen|No|Terminated|October 2007|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|75 Years|No|||March 2013|March 4, 2013|October 16, 2007||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT00545831||165948|
NCT00535899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-578|Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)|Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)|SPArKLE-AS|The Cleveland Clinic|No|Terminated|September 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|N/A|No|||May 2008|May 22, 2008|September 25, 2007|||unable to find subjects meeting inclusion criteria|No||https://clinicaltrials.gov/show/NCT00535899||166699|
NCT00536133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDPG05/01|Role of Zinc in Recurrent Acute Lower Respiratory Infections|Role of Zinc in Recurrent Acute Lower Respiratory Infections||Jawaharlal Nehru Medical College|Yes|Completed|April 2006|July 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|208|||Both|6 Months|59 Months|No|||August 2009|August 3, 2009|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00536133||166681|
NCT00535860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 82-000-04|Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis|A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) in Comparison to Subcutaneous Injection of Forteo in Postmenopausal Women With Osteoporosis||TransPharma Medical|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Female|55 Years|85 Years|No|||July 2009|July 9, 2009|September 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535860||166702|
NCT00535873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0715|Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older|A Phase II Study of Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia Age 65 or Older.||M.D. Anderson Cancer Center|Yes|Completed|October 2007|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|65 Years|N/A|No|||June 2013|June 19, 2013|September 25, 2007|Yes|Yes||No|June 19, 2013|https://clinicaltrials.gov/show/NCT00535873||166701|
NCT00536445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124-2007|Use of NAVA in Intubated Preterm|Use of Neurally Adjusted Ventilatory Assist (NAVA) in an Intubated Premature Infant: A Case Control Study on the Servoi Ventilator||Sunnybrook Health Sciences Centre|No|Withdrawn|October 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|1|||Both|N/A|N/A|No|||July 2011|July 27, 2011|September 25, 2007||No|Another institution performed the study|No||https://clinicaltrials.gov/show/NCT00536445||166657|
NCT00536159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R50 MC00045-04 R2|Medicaid Enhanced Prenatal/Postnatal Services Using a Nurse-Community Health Worker Team|Improving the Health and Development of Low-Income Pregnant Women||Michigan State University|No|Completed|January 1997|August 2000|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|613|||Female|16 Years|N/A|No|||September 2007|September 26, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00536159||166679|
NCT00536172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079420|Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment|Prevention of Depression in Patients Being Treated for Head and Neck Cancer|PROTECT|University of Nebraska|Yes|Completed|December 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|19 Years|N/A|No|||February 2014|February 20, 2014|September 25, 2007|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00536172||166678|
NCT00537966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFZ-ZPHI-01.01|Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study|Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study||University of Zurich|No|Recruiting|January 2002|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2016|||Both|18 Years|90 Years|No|||September 2007|May 12, 2009|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00537966||166542|
NCT00537004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0125|Language in Primary Progressive Aphasia|Language in Primary Progressive Aphasia||Northwestern University|No|Recruiting|May 2007|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Participants with PPA will be recruited from the Northwestern University Alzheimer's        Disease Center Core registry, the Northwestern University Neurobehavior and Memory Clinic,        and from those who contact the center that are interested in PPA research.|October 2015|October 14, 2015|September 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00537004||166615|
NCT00537342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001130-41|Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)|Prospective, Randomised, Double Blind, Placebo Controlled Study of Treatment With Sublingual Immunotherapy of Depigmented and Polymerised Allergen Extract of O. Europaea in Two Groups of Patients With Allergic Rhinitis /Rhinoconjunctivitis||Laboratorios Leti, S.L.|No|Completed|October 2007|December 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|55 Years|No|||December 2010|December 16, 2010|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537342||166590|
NCT00537589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04-06A|Ultrasound Guided Arthrocentesis|Randomized Control Trial of Ultrasound-Guided Peripheral Arthrocentesis|UGA|Carolinas Healthcare System|No|Completed|December 2004|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|132|||Both|18 Years|N/A|No|||September 2007|October 3, 2007|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00537589||166571|
NCT00537355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV1-SAR-11|An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of TOLAMBA™ in the Control of Symptoms of Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model||Dynavax Technologies Corporation|No|Completed|September 2007|May 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|55 Years|No|||February 2016|February 26, 2016|September 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00537355||166589|
NCT00547235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2215.00|Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection|Protocol For The Emergency Use Of Adoptive Immunotherapy With CMV-Specific T Cells Following HLA-Matched Unrelated Donor Bone Marrow Transplant Of An Infant With ADA-SCIDs And Pre Transplant CMV Infection||Fred Hutchinson Cancer Research Center||No longer available|September 2007|||December 2012|Anticipated|N/A|Expanded Access|N/A|||||||Female|N/A|1 Year|No|||August 2010|August 23, 2010|October 19, 2007|No|Yes|No accrual|||https://clinicaltrials.gov/show/NCT00547235||165844|
NCT00547586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-2201|Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid- Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain||Valeant Pharmaceuticals International, Inc.|Yes|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|120|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|October 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547586||165819|
NCT00547599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7989|Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects|Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction?||Eli Lilly and Company|No|Completed|April 2003|January 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|659|||Male|18 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547599||165818|
NCT00547885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI 07-002|Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain|Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-Malignant Pain||Norwegian University of Science and Technology|Yes|Completed|October 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||December 2014|December 30, 2014|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00547885||165797|
NCT00547898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP303-101|Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea|Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 Doses of Crofelemer Orally Twice Daily for the Treatment of HIV-Associated Diarrhea|ADVENT|Valeant Pharmaceuticals International, Inc.|Yes|Completed|October 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|350|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|October 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00547898||165796|
NCT00547859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 503|Relationship Between Microcirculatory Flow Alterations and Tissue Metabolism|Correlation Between Microcirculatory Flow and Rectal Anaerobe Cellular CO2 Production in Patients After Cardiac Surgery||Medical Centre Leeuwarden|No|Completed|November 2007|November 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|post cardiac surgery patients in the first two hours of ICU treatment|November 2008|November 25, 2008|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00547859||165799|
NCT00547872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCV-MO-07-001|Exercise Testing to Screen for Unknown Coronary Artery Disease in Diabetic Patients: Does it Contribute to a Risk Reduction in Very High Risk Patients?|Screening Asymptomatic Patients With Diabetes for Unknown Coronary Artery Disease: an Open-label Randomized Study Comparing Exercise Testing Strategy With Management Based on Pharmacological/Behavioral Treatment of Traditional Risk Factors|DADDY-D|Azienda Unita' Sanitaria Locale Di Modena|Yes|Completed|September 2007|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|50 Years|69 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00547872||165798|
NCT00548509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0167-J081-191|The Effect of Vitamin K2 on Bone Turnover|Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study||Eisai Inc.||Completed|February 2002|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Female|49 Years|90 Years|No|||October 2007|October 23, 2007|October 23, 2007||||No||https://clinicaltrials.gov/show/NCT00548509||165750|
NCT00548795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1424|Viral-Related Neutrophil Response and Condition Severity in People With ARDS|A Prospective Assessment of Viral-induced Adaptation of Neutrophil Response in ARDS - Ancillary to ARDS Network Trials||National Jewish Health|Yes|Completed|August 2007|July 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|132|||Both|18 Years|N/A|No|Non-Probability Sample|Adults diagnosed with Acute Lung Injury [ALI] or Acute Respiratory Distress Syndrome        [ARDS] admitted to Intensive Care Units that are ARDSNet sites in Colorado.|July 2009|September 26, 2014|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548795||165728|
NCT00540098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290060/552|Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder|A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder|Exparox|University of Göttingen|No|Completed|September 2001|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|60 Years|No|||October 2007|October 4, 2007|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00540098||166382|
NCT00540111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-01|Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals.|Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals on Highly Active Antiretroviral Therapy||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2005|October 2007|Actual|July 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|60 Years|No|||February 2010|February 9, 2010|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540111||166381|
NCT00536146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907216|The Stress-Hormone System in Alcohol-Dependent Subjects|Trauma, Stress and Persistence of HPA Dysregulation in Alcoholism||National Institutes of Health Clinical Center (CC)||Completed|September 2007|January 2009||||N/A|Observational|Time Perspective: Prospective||||70|||Male|21 Years|60 Years|No|||January 2009|January 30, 2009|September 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00536146||166680|
NCT00535912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC 98|Phase III Study Treatment of CLL B and C|A Multicentric Phase III Study in Patients With CLL B and C < 60 Years Not Treated: 6 Montly CHOP + 6 CHOP Every 3 Months Versus 3 Montly CHOP + Intensification and Autograft||French Innovative Leukemia Organisation|Yes|Completed|January 1999|March 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|60 Years|No|||September 2007|October 31, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00535912||166698|
NCT00536718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRN-CRUK-GLACIER|Genetics of Women With Lobular Carcinoma in Situ of the Breast|GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope||National Cancer Institute (NCI)||Recruiting|June 2007|||||N/A|Observational|N/A|||Anticipated|3000|||Female|N/A|60 Years|Accepts Healthy Volunteers|||September 2007|August 9, 2013|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536718||166636|
NCT00538538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2007-073|Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)|Use of Subretinal Ranibizumab (Lucentis) in the Management of Submacular Hemorrhage in Neovascular Age-Related Macular Degeneration (AMD)||William Beaumont Hospitals|No|Withdrawn|September 2007|October 2008|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 19, 2009|October 1, 2007|Yes|Yes|This condition can now be managed in the office with an injection of Lucentis.|No||https://clinicaltrials.gov/show/NCT00538538||166498|
NCT00536705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#p2192v1|Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma|||Shanghai Jiao Tong University School of Medicine||Completed|January 2009|March 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|112|Samples Without DNA|Subjects inhaled hypertonic saline (3%) via an ultrasonic nebulizer with the output set at      maximum for 20 minutes. To collect sputum, subjects were asked to expectorate the sputum      onto a plastic Petri dish after the 20-min period of inhalation. During the inducing      procedure, macroscopic characteristics of the sputum were recorded and adequate plugs of      sputum were separated from saliva and processed immediately after expectoration.The complete      blood count, platelet count, and serum biochemical analyses were done meanwhile.|Both|6 Years|14 Years|No|Probability Sample|After screening 200 patients, we randomized 120 patients aged 6 to 14 years with a history        of physician-diagnosed asthma .These patients randomized into montelukast group and        placebo group.|January 2009|July 26, 2011|September 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00536705||166637|
NCT00537017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05175|Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)|A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 5 mg BID (Protocol No. P05175)||Merck Sharp & Dohme Corp.|Yes|Completed|November 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|30 Years|N/A|No|||January 2015|January 30, 2015|September 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537017||166614|
NCT00537953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-Bol/LC-1339|Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia|EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA||Centro de Investigaciones Bioclínicas de la Fundación Fader|No|Recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Male|18 Years|65 Years|No|||September 2007|September 28, 2007|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00537953||166543|
NCT00538499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000565803|Fentanyl With or Without Bupivacaine in Reducing Pain in Patients Undergoing Video-Assisted Chest Surgery|Optimal Pain Management After Video-Assisted Thoracic Surgery||Roswell Park Cancer Institute|Yes|Completed|October 2004|September 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|N/A|N/A|No|||December 2012|December 4, 2012|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538499||166501|
NCT00538512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUVACS|Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4|Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4|FLUVACS|University of Michigan|No|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1952|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2009|August 8, 2011|October 1, 2007||No||No|August 8, 2011|https://clinicaltrials.gov/show/NCT00538512||166500|
NCT00547612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070222|Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer|Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma||National Institutes of Health Clinical Center (CC)||Completed|September 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Diagnostic|||Anticipated|33|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|October 19, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00547612||165817|
NCT00547911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080012|Augmenting Effects of L-DOPS With Carbidopa and Entacapone|L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone||National Institutes of Health Clinical Center (CC)|No|Terminated|October 2007|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 17, 2014|October 19, 2007|Yes|Yes|Study terminated due to contamination droxidopa|No|June 17, 2014|https://clinicaltrials.gov/show/NCT00547911||165795|Study was prematurely terminated due to a small amount of DOPAL contamination in the droxidopa. Because of the early termination only a small number of subjects were enrolled in each condition. Recently, the FDA has approved droxidopa.
NCT00547924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 11-2006|Transoesophageal Echocardiography in Liver Transplantation|Transoesophageal Echocardiography in Liver Transplantation: Left Ventricular Function During Reperfusion||University of Zurich|No|Completed|April 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|17|||Both|18 Years|75 Years|No|Probability Sample|Patients on waiting list for liver transplantation|April 2014|April 9, 2014|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00547924||165794|
NCT00548223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A02|The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule|Model Study on the Comprehensive Treating Protocol and Effect Evaluation of Ischemic Stroke With Traditional Chinese Medicine|SPIRITDZSM1|Guangzhou University of Traditional Chinese Medicine|Yes|Completed|December 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3143|||Both|40 Years|75 Years|No|||August 2013|August 5, 2013|October 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00548223||165772|
NCT00548210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DERMO0501|Effectivity of Dermatix in Promoting Scar Maturation|Dermatix; A Randomized Controlled Trial Measuring Effectivity of Dermatix in Promoting Scar Maturation of Hypertrophic Scars.||Association of Dutch Burn Centres||Recruiting||||||Phase 3|Observational|Time Perspective: Prospective|||Anticipated|25|||Both|18 Years|N/A|No|||October 2007|October 22, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00548210||165773|
NCT00548821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cervix Cancer Research|Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer|A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer||National University Hospital, Singapore|Yes|Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|21 Years|N/A|No|||May 2008|May 13, 2008|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00548821||165726|
NCT00549939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5722|Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction|12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension|ALFACHIN|Sanofi|Yes|Completed|October 2007|December 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|172|||Both|2 Years|16 Years|No|||October 2014|October 21, 2014|October 25, 2007|Yes|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00549939||165643|
NCT00549952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|256-KOB-0701|Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients|Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Recruiting|October 2007|March 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective|||||||Both|19 Years|N/A|No|||October 2007|October 25, 2007|October 25, 2007||||No||https://clinicaltrials.gov/show/NCT00549952||165642|
NCT00549965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_4035|Satisfaction and Compliance of Risedronate in PMO|A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg||Sanofi||Completed|October 2003|||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|202|||Female|55 Years|80 Years|No|||October 2007|October 26, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549965||165641|
NCT00549068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_4031|POWER Point of Care Effect on Satisfaction of Treatment|Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study||Sanofi||Completed|February 2003|November 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2433|||Female|18 Years|N/A|No|||December 2009|December 4, 2009|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549068||165708|
NCT00549081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHEA for LR in IVF.CTIL|DHEA Supplementation for Low Ovarian Response IVF Patients|||Shaare Zedek Medical Center|No|Not yet recruiting|January 2008|December 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|43 Years|No|||October 2007|October 24, 2007|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00549081||165707|
NCT00545558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AI065256-01|Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV|Antiretroviral Therapy and the Hepatitis C Virus|ART and HCV|University of Cincinnati|No|Completed|April 2006|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|October 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00545558||165969|
NCT00545571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20826|MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.|A Single Arm, Open Label, Interventional Multicenter Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous Mircera for the Maintenance of Hemoglobin Levels in Hemodialysis Patients With Chronic Renal Anemia.||Hoffmann-La Roche||Completed|October 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545571||165968|
NCT00545883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GBE-NEX-2006/1|Impact of GERD on Daily Life (NIS)|An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life of GERD in Patients With Erosive Gastroesophageal Reflux Disease.|Alegria|AstraZeneca|No|Completed|June 2006|March 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2001|||Both|18 Years|N/A|No|Non-Probability Sample|Primary & Specialty care units|January 2012|January 25, 2012|October 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00545883||165944|
NCT00535925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246813579|Nephropathy In Type 2 Diabetes and Cardio-renal Events|Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events.|NID-2|Second University of Naples|Yes|Active, not recruiting|March 2003|September 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|850|||Both|40 Years|70 Years|No|||December 2011|December 20, 2011|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535925||166697|
NCT00535938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGN/MMC B00705|MDs on Botox Utility (MOBILITY)|||Allergan|No|Completed|September 2007|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1372|||Both|14 Years|N/A|No|Non-Probability Sample|Community sample|September 2014|September 4, 2014|September 25, 2007|Yes|Yes||No|September 4, 2014|https://clinicaltrials.gov/show/NCT00535938||166696|
NCT00540449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002689|TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.|A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.||Tibotec Pharmaceuticals, Ireland|Yes|Completed|May 2008|December 2011|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|694|||Both|18 Years|99 Years|No|||January 2016|January 8, 2016|October 4, 2007|Yes|Yes||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00540449||166355|
NCT00536471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11669|A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients|Duloxetine Versus Placebo in Patients With Major Depressive Disorder (MDD): Assessment of Energy and Vitality in MDD||Eli Lilly and Company|No|Completed|September 2007|December 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|776|||Both|18 Years|65 Years|No|||November 2009|November 17, 2009|September 25, 2007|Yes|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00536471||166655|
NCT00537641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC2000|Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)|Prevalence and Severity of Nocturnal Oxygenation and Ventilation Failure in Patients With Amyotrophic Lateral Sclerosis Using Noninvasive Ventilation||Columbia University|No|Completed|May 2007|June 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with ALS who are using nocturnal noninvasive ventilation to treat respiratory        insufficiency will be screened for eligibility as below.|July 2015|July 2, 2015|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00537641||166567|
NCT00547716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-48|Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection|The Effect of Omega-3 Fatty Acids (Omacor@) on the Response Rate to Antiviral Therapy in Patients With Chronic Hepatitis C Infection||Truman Medical Center|No|Withdrawn|June 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|October 19, 2007|Yes|Yes|Lack of study enrollment.|No||https://clinicaltrials.gov/show/NCT00547716||165809|
NCT00537368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013699|First Study of the Safety of CNTO 888 in Patients With Solid Tumors|A Phase 1 Study of CNTO 888, a Human Monoclonal Antibody Against CC-Chemokine Ligand 2 in Subjects With Solid Tumors||Centocor, Inc.||Completed|September 2007|March 2010|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|N/A|No|||October 2010|October 21, 2010|September 28, 2007||||||https://clinicaltrials.gov/show/NCT00537368||166588|
NCT00537628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brahms|Biomarkers in Acute Heart Failure|Biomarkers in Acute Heart Failure: An International, Multi-Center Trial Evaluating the Prognostic and Diagnostic Utility of Biomarkers in Patients With Heart Failure Presenting With Shortness of Breath|BACH|Brahms AG|No|Completed|March 2007|June 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1641|Samples Without DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|Emergency Department|July 2008|July 30, 2008|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537628||166568|
NCT00538174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-025|Phase I Multiple-Ascending Dose (Japan)|A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects|MAD|AstraZeneca|No|Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|20 Years|70 Years|No|||March 2015|March 20, 2015|October 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00538174||166526|
NCT00538824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708009381|Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma|DexTR|Weill Medical College of Cornell University|No|Active, not recruiting|December 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2008|December 2, 2008|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538824||166476|
NCT00539175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swislocki-1|Treatment of Painful Diabetic Neuropathy With Photon Stimulation|Treatment of Painful Diabetic Neuropathy With Photon Stimulation||East Bay Institute for Research and Education|No|Completed|October 2004|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|85 Years|No|||October 2007|October 3, 2007|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00539175||166451|
NCT00539188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOCD-3|N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD|A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder||Yale University|No|Terminated|September 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|65 Years|No|||March 2013|March 25, 2013|October 2, 2007||No|Study terminated due to poor subject compliance.|No|December 21, 2012|https://clinicaltrials.gov/show/NCT00539188||166450|
NCT00539201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRR110198|GSK706769 A First Time in Human Study For Males and Females|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects||GlaxoSmithKline||Terminated|September 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|October 2, 2007||||||https://clinicaltrials.gov/show/NCT00539201||166449|
NCT00547625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9120|Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems|A Multicenter, Parallel-Arm, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Tadalafil Administered Once Daily to Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia|PILUTS|Eli Lilly and Company|No|Completed|October 2004|July 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|275|||Male|45 Years|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00547625||165816|
NCT00547638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07CS005|Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure|Multicenter, Prospective, Randomized Controlled Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Closure of Simple, Thoroughly Cleansed, Trauma-induced Wounds in the Emergency Department||Ethicon, Inc.|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|1 Year|N/A|No|||August 2013|August 2, 2013|October 17, 2007|Yes|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00547638||165815|The percentages of participants who withdrew prematurely from the study from each group could represent a possible study limitation.
NCT00547937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO-OE-SAHS|Sleep Apnea and Oxidative Stress and Nitric Oxide|Nitrate and Oxidative Stress in Sleep Apnea Syndrome. Effect of Continuous Positive Airway Pressure||Sociedad Española de Neumología y Cirugía Torácica|Yes|Completed|May 2001|December 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|31|||Male|N/A|N/A|Accepts Healthy Volunteers|||October 2007|November 7, 2007|October 22, 2007||||No||https://clinicaltrials.gov/show/NCT00547937||165793|
NCT00548236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-266|The Active After Cancer Trial (AACT)|Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)|AACT|Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2007|July 2014|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00548236||165771|
NCT00548522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAHREB4503|Pancreatic Islet Mass in Pregnancy in Type 1 Diabetes|Pancreatic Islet Mass in Pregnancy - Pilot Study||University of Alberta|No|Terminated|August 2007|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Actual|12|Samples Without DNA|Plasma Samples kept for batching of antibody assays|Female|18 Years|40 Years|No|Non-Probability Sample|Pregnant women with Type 1 diabetes|May 2014|May 20, 2014|October 23, 2007||No|Difficulty in finding staff to help with study|No||https://clinicaltrials.gov/show/NCT00548522||165749|
NCT00548535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDI1007|Is Self-Reported Quality Assessment in Surgery Reliable?|||University of Zurich|No|Recruiting|January 2007|January 2008||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|90 Years|No|||October 2007|October 23, 2007|October 23, 2007||||No||https://clinicaltrials.gov/show/NCT00548535||165748|
NCT00549120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB104954|Optimising the Propranolol Block Model|A Study to Optimise the Propranolol Block Model for Assessment of the Pharmacological Activity of Bronchodilators in Healthy Volunteers.||GlaxoSmithKline|No|Completed|August 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|6||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00549120||165705|
NCT00549718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050229|Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia|A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia||Sunovion|Yes|Completed|October 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|489|||Both|18 Years|75 Years|No|||June 2014|June 5, 2014|October 24, 2007|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT00549718||165660|
NCT00549419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-06|Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Abdominal Surgery|Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Patients Undergoing Major Abdominal Surgery|REPEAT|Klinikum Ludwigshafen|Yes|Completed|October 2007|April 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2009|December 21, 2009|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00549419||165683|
NCT00549653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1106502|A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men|A Randomized, Single Blind, Repeat Dose, Placebo-controlled, Single-period, Parallel Group Study to Investigate the Safety, Tolerability and Potential Pharmacokinetic Interactions Between GW856553 and Rosuvastatin (10mg), When Co-administered in Healthy Adult Male Subjects||GlaxoSmithKline|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|44|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|May 31, 2012|October 24, 2007||No||||https://clinicaltrials.gov/show/NCT00549653||165665|
NCT00545896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESWT 001 - 2003|Extracorporeal Shockwave Treatment for Chronic Soft Tissue Wounds|Safety and Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Chronic Soft Tissue Wounds||AUVA|No|Completed|September 2003|September 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|282|||Both|18 Years|N/A|No|||August 2009|July 15, 2011|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545896||165943|
NCT00521846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070155|ExploR™ Modular Radial Head Data Collection|ExploR™ Modular Radial Head Data Collection||Vanderbilt University|No|Recruiting|August 2007|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521846||167763|
NCT00521859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0844|Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies|Dose Escalation Trial of Cloretazine (VNP40101M) and Hematopoietic Cell Transplantation for Patients With Selected, Poor-Prognosis Hematologic Malignancies||M.D. Anderson Cancer Center|No|Completed|August 2007|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||July 2012|July 27, 2012|August 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00521859||167762|
NCT00517491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52030-725|Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)|A Pilot Study to Evaluate the Correlation Between Plasma Lanreotide Levels and GH/IGF-1 Dynamics and Clinical Improvement in Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)||Ipsen||Withdrawn|May 2008|December 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||June 2008|September 29, 2015|August 16, 2007|||Administrative reasons|No||https://clinicaltrials.gov/show/NCT00517491||168095|
NCT00517504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC03-59|Methylphenidate Study in Young Children With Developmental Disorders|Methylphenidate Study in Young Children With Developmental Disorders||University of Arizona|No|Completed|May 2001|||March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|48|||Both|36 Months|84 Months|No|||July 2012|July 3, 2012|August 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517504||168094|
NCT00517777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1113|Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage|Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome||Università degli Studi dell'Insubria|Yes|Recruiting|August 2007|August 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|70 Years|No|||August 2007|August 15, 2007|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517777||168073|
NCT00503893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P80-099|Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies|Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies||M.D. Anderson Cancer Center|No|Recruiting|December 1980|||December 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Blood sample(s) for genetic testing. Also, tissue samples, and/or bodily fluids (whether      healthy or cancerous) left over from surgeries or procedures performed as part of standard      care. The purpose of this clinical research study is to find out why some people develop      cancers and tumors, why some families have more cancers than others, and whether certain      genes or regions of DNA affect a person's risk of getting cancer.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with familial and sporadic Wilm's tumor, genitourinary anomalies,        Beckwith-Wiedemann hemihypertrophy and/or aniridia, and family members of patients.|November 2015|November 17, 2015|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503893||169118|
NCT00504140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P96-221|Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma|Phase II Study of Recombinant Interferon Alpha and Etoposide in Patients With Relapsed Osteosarcoma||M.D. Anderson Cancer Center|Yes|Completed|November 1996|March 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|5 Years|70 Years|No|||August 2012|August 1, 2012|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00504140||169099|
NCT00504699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0110005172|Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients|Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study||New York Medical College|No|Active, not recruiting|January 2002|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|45 Years|No|||April 2012|April 25, 2012|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504699||169057|
NCT00504127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT 3012-X-302|Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee|A Phase 3, 53 Weeks Study on Analgesic Efficacy and Safety of Naproxcinod (HCT 3012): 26-Week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks)- and Naproxen (26 Weeks)-Controlled, Multicenter Study of Naproxcinod (375 mg Bid and 750 mg Bid) With a 26-Week Naproxen-Controlled Safety Follow-up in Subjects With Osteoarthritis of the Knee, and a 1-week Post-treatment Safety Follow-up||NicOx|Yes|Completed|April 2007|||December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1020|||Both|40 Years|N/A|No|||June 2011|June 16, 2011|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00504127||169100|
NCT00505011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17072007|Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease|Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.||University of Campinas, Brazil|No|Completed|February 1998|February 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional|||Actual|1998|||Both|2 Years|N/A|Accepts Healthy Volunteers|||July 2007|July 19, 2007|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00505011||169034|
NCT00501813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hcc-002|Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion|A Randomized Controlled Trial of Multimodality Therapy in the Treatment of Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion|MDTforHCC|Sun Yat-sen University|Yes|Recruiting|October 2006|July 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||January 2010|July 29, 2010|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501813||169276|
NCT00501826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0328|Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma|Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|July 2007|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||March 2016|March 23, 2016|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501826||169275|
NCT00502645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM10_CS-1|Clinical Risk Assesment of CS-1 Decision Support System|SINGLE-CENTER,OPEN,NON-CONTROLLED FEASIBILITY STUDY ON THE PERFORMANCE OF THE CS-1 DECISION SUPPORT SYSTEM WITH INCORPORATED SOFTWARE-ALGORITHM eMPC USED FOR BLOOD GLUCOSE CONTROL OVER 72 HOURS IN CRITICALLY ILL PATIENTS AT THE INTENSIVE CARE UNIT||Medical University of Graz|No|Completed|April 2007|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|N/A|No|||July 2007|July 15, 2007|July 15, 2007||||No||https://clinicaltrials.gov/show/NCT00502645||169213|
NCT00502385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00002|Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML|||AstraZeneca|Yes|Completed|April 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|54|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00502385||169233|
NCT00502918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-AM-279-CTIL|Clinical Feasibility of Computerized Labor Monitor (CLM) -Heart Application (HA)|Feasibility Study -Clinical Feasibility of Computerized Labor Monitor (CLM) -Heart Application||Barnev Ltd|No|Terminated|February 2008|August 2008|Actual|July 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|3|||Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Laboring women reffered to the maternity center in active labor (3cm - 7 cm) dilataion and        contraction|July 2007|December 27, 2009|July 17, 2007||No|The study was terimnated - low rate of cases|No||https://clinicaltrials.gov/show/NCT00502918||169192|
NCT00519194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051.13|CONcomitant eValuation of Epicor Left atRial Therapy for AF|CONcomitant eValuation of Epicor Left atRial Therapy for AF|CONVERT-AF|St. Jude Medical|Yes|Terminated|April 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|80 Years|No|||May 2014|May 14, 2014|August 20, 2007|Yes|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT00519194||167965|
NCT00519805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000561532|Dalteparin in Preventing Blood Clots in Patients With Lung Cancer|FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer||National Cancer Institute (NCI)||Recruiting|August 2007|||August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|2200|||Both|18 Years|N/A|No|||March 2008|August 5, 2011|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00519805||167918|
NCT00519818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070211|Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia|A Phase 2, Open Label, Crossover Pharmacokinetic and Pharmacodynamic Study to Compare Chronocort Versus Cortef in Patients With CAH||Diurnal Limited|No|Completed|August 2007|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|16 Years|60 Years|No|||February 2016|February 26, 2016|August 22, 2007|No|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00519818||167917|
NCT00520039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS5172007|Osteopathic Otitis Media Research Study|Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry|OOMRS|West Virginia School of Osteopathic Medicine|Yes|Completed|September 2007|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Months|2 Years|No|||November 2009|October 5, 2015|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520039||167900|
NCT00520741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0902|Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures|A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures|ALEX-MT|UCB Pharma|No|Completed|August 2007|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|426|||Both|16 Years|70 Years|No|||July 2015|July 13, 2015|August 24, 2007|Yes|Yes||No|November 26, 2013|https://clinicaltrials.gov/show/NCT00520741||167846|
NCT00520728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTUI1|Efficacy of an Occupational Time Use Intervention for People With Serious Mental Illness|Efficacy of an Occupational Time Use Intervention||Queen's University|Yes|Completed|August 2007|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520728||167847|
NCT00520988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPD08FLA00228|Improving Blood Pressure in Colorado|Improving Blood Pressure in Colorado||Kaiser Permanente|No|Completed|March 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|290|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|August 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00520988||167828|
NCT00521560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL 2004-R4|A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas|Phase I/II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy With Simultaneous Application of Zevalin and BEAM Followed by Autologous Peripheral Stem Cell Transplantation in Relapsed and Refractory CD 20+ Non-Hodgkin's Lymphoma|escZ-BEAM|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|Yes|Completed|March 2006|August 2012|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|No|||February 2013|February 13, 2013|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521560||167785|
NCT00521573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1129|Effects of Chocolate on Coronary Vasomotion in Patients After Heart Transplantation|||University of Zurich|No|Completed||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|20 Years|80 Years||||August 2007|August 27, 2007|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00521573||167784|
NCT00527956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY 07-009|Facilitation and Barriers to Breastfeeding in the NICU|||McGill University Health Center|No|Completed|September 2007|April 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|8|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 6, 2008|September 10, 2007||||No||https://clinicaltrials.gov/show/NCT00527956||167301|
NCT00528268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22183|Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy|Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy|STOPSMA|University of Utah|Yes|Completed|July 2007|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|N/A|6 Months|No|||June 2015|June 14, 2015|September 10, 2007|Yes|Yes||No|June 14, 2015|https://clinicaltrials.gov/show/NCT00528268||167277|
NCT00500409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB006/05|Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis|Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis. A Randomized Controlled Open-label Multicentre Study in India||Virchow Group|No|Completed|December 2005|July 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Female|45 Years|75 Years|No|||July 2007|December 15, 2014|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500409||169382|
NCT00500422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1002|Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients|Phase I Study of a Combination of Doxil, Velcade, and Gemcitabine in Advanced Cancer||M.D. Anderson Cancer Center|No|Completed|January 2005|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|N/A|N/A|No|||February 2013|February 11, 2013|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00500422||169381|
NCT00500669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0011|A Randomised Study to Assess Betadine in the Groin Wound of Patients Undergoing Primary Varicose Vein Surgery|A Randomised, Blinded Study to Assess the Effect of Betadine in the Groin Wound of Patients Undergoing Primary Varicose Vein Surgery||Royal Hobart Hospital|No|Recruiting|June 2004|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 15, 2010|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500669||169363|
NCT00500682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRM-306|A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|July 2007|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1020|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|July 11, 2007|Yes|Yes||No|February 15, 2015|https://clinicaltrials.gov/show/NCT00500682||169362|
NCT00500942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-374|Pain Quantification and Pain Management in Interventional Radiology (IR)|Pain Quantification and Management for Standard Interventional Radiology (IR) Procedures With Subsequent Patient Satisfaction Analysis||M.D. Anderson Cancer Center|No|Completed|January 2003|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|374|||Both|N/A|N/A|No|Non-Probability Sample|Patients having a standard procedure performed in Interventional Radiology.|August 2012|August 1, 2012|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500942||169342|
NCT00502099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG161190-06|Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4|Phase 4 Comparative Study of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4||Ain Shams University|Yes|Completed|January 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|60 Years|No|||October 2012|October 21, 2012|July 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00502099||169254|
NCT00501228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-300|Tissue Repair in Stem Cell Transplant Recipients|RhG-CSF (Filgrastim) Treatment of Severe Epithelial/Endothelial or Solid Organ-Specific Tissue Damage In Stem Cell Transplant Recipients||M.D. Anderson Cancer Center|No|Terminated|February 2003|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||July 2012|July 31, 2012|July 12, 2007||No||No|March 3, 2009|https://clinicaltrials.gov/show/NCT00501228||169320|Study was closed because of the very limited number of patients enrolled. Patients eligible for enrollment were not willing to undergo 4 weekly cycles of G-CSF treatment because of the well known side effect of bone pain.
NCT00501241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007003|Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation|A Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation||Procter and Gamble|No|Terminated|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|214|||Both|18 Years|75 Years|No|||February 2008|June 16, 2009|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501241||169319|
NCT00502073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-603-005|Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)|||Sirion Therapeutics, Inc.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||June 2011|June 29, 2011|July 13, 2007||||||https://clinicaltrials.gov/show/NCT00502073||169256|
NCT00502398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC074490CTIL|Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?|||Rabin Medical Center|No|Recruiting|September 2007|||||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 14, 2007|July 15, 2007||||No||https://clinicaltrials.gov/show/NCT00502398||169232|
NCT00502931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML003|A Systematic Review on the Accuracy and Reliability the BodyGem/MedGem Metabolic Devices|A Systematic Review on the Accuracy and Reliability of a Hand-Held Indirect Calorimeter for Assessing Energy Needs in Adults & Children||Microlife|No|Completed|November 2006|||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|N/A|N/A||||July 2007|July 16, 2007|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502931||169191|
NCT00502944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073445|Two Approaches to Routine HIV Testing in a Hospital Emergency Department|Optimizing Strategies for Universal HIV Testing (The USHER Trial)||Massachusetts General Hospital|Yes|Completed|February 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|4855|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|July 16, 2007||No||No|May 3, 2012|https://clinicaltrials.gov/show/NCT00502944||169190|
NCT00519831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-LCCC-0503|Vinflunine and Cetuximab as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Vinflunine and Cetuximab in the Second Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|August 2007|November 2009|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 21, 2007|No|Yes|Drug unavailable|No||https://clinicaltrials.gov/show/NCT00519831||167916|
NCT00520065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK06|Comparison of Nutritional Products for People With Type 2 Diabetes|Comparison of Nutritional Products for People With Type 2 Diabetes||Abbott Nutrition|No|Completed|August 2007|November 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|75 Years|No|||August 2007|July 2, 2008|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00520065||167898|
NCT00520052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57/03|Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer|Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer||Wirral University Teaching Hospital NHS Trust|Yes|Completed|August 2003|August 2005|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Male|N/A|N/A|No|||August 2007|August 22, 2007|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00520052||167899|
NCT00520377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scil-MD05-C01|Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation|Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation||Scil Technology GmbH|No|Active, not recruiting|January 2005|May 2008|Anticipated|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||April 2008|April 22, 2008|August 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00520377||167874|
NCT00520429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC001|Transforming Psychotherapy for Chronically Ill Patients|Transforming Psychotherapy for Chronically Ill Patients||VA Office of Research and Development|No|Completed|August 2007|September 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|January 5, 2009|August 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00520429||167870|
NCT00520442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fracture Pain|Acute Pediatric Fracture Analgesia Study|Ibuprofen Versus Acetaminophen With Codeine In Acute Pediatric Forearm Fractures||Medical College of Wisconsin|No|Completed|September 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|335|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||March 2008|March 6, 2008|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00520442||167869|
NCT00521001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0675|Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery|A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma||Alliance for Clinical Trials in Oncology|No|Completed|January 2008|December 2010|Actual|December 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521001||167827|
NCT00521209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000561559|Patient-Directed Lifestyle Change and Health Promotion Program or Usual Care in Low-Income, Uninsured Participants in Los Angeles County, California|Improving Health Habits: Self-Care Priorities||Jonsson Comprehensive Cancer Center|No|Active, not recruiting|March 2008|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|97|||Both|18 Years|120 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521209||167811|
NCT00527644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1090979|Clinical Evaluation of Spring-Type Laparoscopic Clip Technology|Clinical Evaluation of Spring-Type Laparoscopic Clip Technology||University of Missouri-Columbia|No|Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 9, 2010|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527644||167325|
NCT00527657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0595|Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients|A Phase I Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain||M.D. Anderson Cancer Center|No|Completed|February 2006|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00527657||167324|
NCT00527969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT1001-2006-2|Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L|Cognitive, Emotional, Physical, and Psychosocial Effects of Three Weeks' Prospective Double-Blind Placebo Controlled Cross-Over Exposure to Panax Quinquefolius L (REMEMBER-fX), With Optional Six Months' Open Label Follow-up|REMEMBER-fX|Afexa Life Sciences Inc|No|Completed|July 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|72|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||March 2008|March 10, 2008|September 10, 2007||||No||https://clinicaltrials.gov/show/NCT00527969||167300|
NCT00527982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0104|Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer|Celecoxib as Adjuvant Biologic Therapy in Patients With Early Stage Head and Neck and Lung Cancer||M.D. Anderson Cancer Center|No|Terminated|September 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|September 10, 2007||No|Termination due to poor accrual.|No|January 6, 2011|https://clinicaltrials.gov/show/NCT00527982||167299|
NCT00528281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF109462|A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase|A Single-arm, Two-stage Phase II Study of Lapatinib and Pemetrexed in the Second Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer||GlaxoSmithKline|No|Completed|September 2007|May 2009|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2011|May 31, 2012|September 11, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00528281||167276|
NCT00501254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROM-EC-ECC-01|Pharmacodynamic Trial, of Slow Release ASA, in Platelet Functionalism, a Long Term Treatment Period|Randomised Clinical Trial, Parallel, Double Blind, to Evaluate the Influence of the ASA-SR (Slow-Release) in the Platelet Parameters and the Oxidative Status, in Patients With Coronary Disease of Chronic Evolution During 12 Months||Rottapharm Spain||Completed|February 2005|February 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||July 2007|July 17, 2007|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501254||169318|
NCT00501527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001437-18|Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense|Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense in Patients Suffering From Allergic Rhinoconjunctivitis and/or Asthma||Laboratorios Leti, S.L.|No|Completed|September 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|12 Years|50 Years|No|||December 2010|December 16, 2010|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501527||169298|
NCT00501540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO07203|Lithium for Low-Grade Neuroendocrine Tumors|A Phase II Clinical and Biological Study of Lithium Carbonate in Patients With Low-Grade Neuroendocrine Tumors||University of Wisconsin, Madison|Yes|Completed|July 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|July 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501540||169297|
NCT00501566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI5563|Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites|SR121463B in Cirrhotic Ascites Treatment With Normonatraemia: A Placebo-Controlled, Dose-Comparison Study|Normo~CAT|Sanofi|Yes|Completed|April 2004|January 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|148|||Both|18 Years|N/A|No|||July 2007|July 13, 2007|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501566||169295|
NCT00501579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-601A-001|Study of Difluprednate in the Treatment of Uveitis|||Sirion Therapeutics, Inc.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||||||Both|2 Years|N/A||||August 2008|August 27, 2008|July 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501579||169294|
NCT00502086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIUHCV-07|Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.|Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study.||Catalysis SL|Yes|Completed|May 2005|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||February 2010|February 10, 2011|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00502086||169255|
NCT00502424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2304|The Effectiveness of a Nighttime Positioning Hand Splint in Patients With Rheumatoid Arthritis|Study of the Effectiveness of a Positioning Hand Splint for Wrist, Fingers and Thumb in Patients With Arthritis Rheumatoid||Federal University of São Paulo|Yes|Completed|July 2004|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||April 2007|July 16, 2007|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502424||169230|
NCT00502437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|376-11.05.07HMO-CTIL|The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations|||Hadassah Medical Organization||Not yet recruiting||||||N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double-Blind|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2007|November 28, 2010|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502437||169229|
NCT00519545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCA 05-04|Prayer as a Possible Adjuvant Treatment for Breast Cancer|Prayer as a Possible Adjuvant Treatment for Breast Cancer - A Randomized Partially Blinded Controlled Clinical Trial Evaluating the Effect of Prayer on Humoral and Biochemical Parameters in Stage I-IV Breast Cancer||Southwestern Regional Medical Center|No|Completed|March 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|15|||Female|21 Years|80 Years|No|||January 2012|January 23, 2012|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519545||167938|
NCT00519844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1670|Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction|Assessment of Satisfaction With Growth Hormone Treatment in Children Born Small for Gestational Age: Benefits of Galenic Form of the Product||Novo Nordisk A/S|No|Completed|July 2005|January 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Both|6 Years|15 Years|No|||November 2015|November 11, 2015|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00519844||167915|
NCT00519857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06468|Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)|A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group,Placebo Controlled Clinical Trial of the Effects of Tibolone (Org OD-14 1.25mg) on the Incidence of New Vertebral Fractures in Osteoporotic Postmenopausal Women.|LIFT|Merck Sharp & Dohme Corp.|Yes|Completed|June 2001|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4534|||Female|60 Years|85 Years|No|||May 2014|May 22, 2014|August 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00519857||167914|
NCT00520403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19983|A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.|An Open-label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Standard Therapy on Progression-free Survival in Patients With Metastatic Renal Cell Cancer.||Hoffmann-La Roche||Completed|September 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|August 23, 2007||No||No|August 14, 2014|https://clinicaltrials.gov/show/NCT00520403||167872|
NCT00520416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-06-00263|Prospective, Non-Randomized Evaluation of Carbon Dioxide Gas as a Contrast Agent in Comparison With Iodinated Contrast in Endovascular Aneurysm Repair|||University of Southern California|No|Recruiting|October 2006|August 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||1|||||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2007|August 22, 2007|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00520416||167871|
NCT00526864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUTM2007-035|Measuring Herpes Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand|Measuring Herpes Zoster and Post-Herpetic Neuralgia Associated Burden of Illness and Health Care Utilization and Costs in Thailand||Mahidol University|No|Completed|May 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|180|||Both|20 Years|N/A|No|Probability Sample|total of 180 clinically diagnosed herpes zoster patients, either aged ‡ 50 years and        otherwise healthy, or ‡ 20 years with HIV infection, or ‡ 20 years and currently receiving        chemotherapy or immunosuppressive agents.|September 2015|September 21, 2015|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00526864||167385|
NCT00520754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00315|Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children|The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years.||UCB Pharma|No|Completed|December 2001|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|2 Months|24 Months|No|||September 2009|December 11, 2013|August 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00520754||167845|
NCT00527085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010141|12-month Study of AMG 073 in Renal Osteodystrophy|A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism||Amgen||Completed|October 2001|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527085||167368|
NCT00521014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-085|GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma|A Phase II Study of GM-CSF (Sargramostim) and Rituximab Following Autologous Transplantation For Relapsed Follicular Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|October 2007|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|70 Years|No|||November 2015|November 18, 2015|August 24, 2007|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00521014||167826|
NCT00527670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO-1057938|Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias|Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias||University of Missouri-Columbia|No|Recruiting|August 2007|August 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Tissue samples.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Surgical patients at the University of Missouri Healthcare system.|August 2009|August 17, 2009|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527670||167323|
NCT00527995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sildenafil_ED_2001|Acute Effects of Sildenafil on Endothelial Function in People With Diabetes|Acute Effects of Sildenafil on Flow Mediated Dilatation and Cardiovascular Autonomic Nerve Function in Type 2 Diabetic Patients||Ruhr University of Bochum|No|Completed|August 2001|June 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|35 Years|70 Years|No|||September 2007|September 10, 2007|September 10, 2007||||No||https://clinicaltrials.gov/show/NCT00527995||167298|
NCT00528294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/010|Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area|Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area||University Hospital, Ghent|No|Active, not recruiting|February 2007|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528294||167275|
NCT00528541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedAff-BTX-0616|Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia|||Allergan||Completed|September 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|September 10, 2007|Yes|Yes||No|November 14, 2011|https://clinicaltrials.gov/show/NCT00528541||167256|
NCT00500968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/3:3|Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail|Randomized Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail||Karolinska Institutet|Yes|Completed|November 2006|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|N/A|No|||September 2007|April 6, 2011|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500968||169340|
NCT00500981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20855|Internal Jugular Vein Ultrasound Measures and Fluid Responsiveness in Post-Operative Cardiac Surgical Patients|Do Internal Jugular Vein Measurements Made By Ultrasound Correlate With Fluid Responsiveness in Ventilated Post-Operative Cardiac Surgical Patients?||University of Calgary|No|Completed|June 2007|December 2008|Actual|October 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00500981||169339|
NCT00500994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070190|Neurobiology of Psychogenic Movement Disorder and Non-Epileptic Seizures|Neurobiological Studies of Psychogenic Movement Disorders and Non-Epileptic Seizures||National Institutes of Health Clinical Center (CC)||Recruiting|July 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|305|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|January 1, 2016|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00500994||169338|
NCT00501267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3C109868|A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder|A Randomized, Repeat Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Solabegron (GW427353) in Combination With Oxybutynin in Healthy Adult Subjects.||GlaxoSmithKline||Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|July 13, 2007||||||https://clinicaltrials.gov/show/NCT00501267||169317|
NCT00501553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-41-5263|Vitamin D in Patients With Heart Failure||KarViD|Hvidovre University Hospital|Yes|Completed|June 2005|May 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|18 Years|N/A|No|Probability Sample|Heart Failure patients|July 2007|June 23, 2011|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501553||169296|
NCT00501618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06I/C02-1|Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder|An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder||Manhattan Psychiatric Center|Yes|Completed|November 2006|July 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|59 Years|No|||April 2015|April 14, 2015|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501618||169291|
NCT00501878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I50138|2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides|2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides||Khon Kaen University|Yes|Completed|May 2007|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|70 Years|No|||March 2012|March 7, 2012|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501878||169271|
NCT00501839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2006a|Clomiphene Citrate in Infertile PCOS Patients|How Long Should First-line Treatment be Continued in Infertile PCOS Patients Who Ovulate Under Clomiphene Citrate? A Randomized Controlled Clinical Study.||University Magna Graecia||Withdrawn|August 2008|||September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|35 Years|No|||April 2013|April 5, 2013|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501839||169274|
NCT00501852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2205|Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium|A Randomized, Double-blind, Placebo-controlled, 4 Period Incomplete Block Cross-over, Multi-center, Multiple Dose (7 Days) Dose-ranging Study to Assess the Efficacy and Safety of 4 Doses of NVA237 in Patients With Stable COPD, Compared to Seven Days Treatment With Tiotropium (18μg Once Daily, Open Label) as an Active Control||Novartis||Completed|July 2007|||December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|83|||Both|40 Years|N/A|No|||December 2010|May 3, 2012|July 13, 2007||No||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00501852||169273|
NCT00501865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAP109169|Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers|An Open, Randomised, Two-period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of GW273225 Administered Immediately After Food and Administered in the Fasted State to Healthy Male and Female Volunteers.||GlaxoSmithKline|No|Completed|August 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|July 13, 2007||||||https://clinicaltrials.gov/show/NCT00501865||169272|
NCT00502372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ93|Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)|Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate||Central Arkansas Veterans Healthcare System|Yes|Terminated|December 2008|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|90 Years|No|||December 2015|December 14, 2015|July 13, 2007||No|VA never granted approval following suspension of enrollment.|No||https://clinicaltrials.gov/show/NCT00502372||169234|
NCT00499135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00245|Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors|Pharmacodynamic Study of Sunitinib Malate in Patients With Renal Cell Cancer and Other Advanced Solid Malignancies||National Cancer Institute (NCI)||Active, not recruiting|May 2007|||July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00499135||169477|
NCT00502658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-001, WIRB 20070167|Dietary Supplements and Personal Energy Tracking Device to Promote and Maintain Healthy Weight|Evaluation of Dietary Supplements (Shakes and Supplements) and Personal Energy Tracking Device to Promote and Maintain Healthy Weight||Pharmanex|No|Completed|July 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|3||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|July 12, 2007||||No||https://clinicaltrials.gov/show/NCT00502658||169212|
NCT00502671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20592|A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.|An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C.||Hoffmann-La Roche||Completed|July 2007|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|July 17, 2007||No||No|August 6, 2015|https://clinicaltrials.gov/show/NCT00502671||169211|
NCT00502684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392-22.6.07 / 2358 HMO-CTIL|Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery|Perioperative Administration of COX 2 Inhibitors and Beta Blockers in Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence||Kaplan Medical Center|No|Recruiting|June 2014|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|32|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 29, 2014|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00502684||169210|
NCT00530491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM 140/07|Prospective Trial to Reduce Morbidity and Mortality After Lung Surgery in Patients With Reduced Pulmonary Capacity|Prospective Randomized Controlled Trial to Reduce Morbidity and Mortality After Lung Surgery in Patients With FEV1 < 70% of Expected Value or < 1.5L||University of Ulm|No|Recruiting|September 2007|October 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||September 2007|February 1, 2008|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530491||167107|
NCT00530504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2611|Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study|Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study|CREATE PAS|Medtronic Endovascular|Yes|Completed|May 2007|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1500|||Both|18 Years|N/A|No|||August 2015|September 24, 2015|September 14, 2007|Yes|Yes||No|July 28, 2015|https://clinicaltrials.gov/show/NCT00530504||167106|
NCT00530881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-Prot201|Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Establish Proof of Concept With PHX1149 in Patients With Type 2 Diabetes Mellitus||Phenomix|No|Completed|April 2006|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|70 Years|No|||September 2007|September 17, 2007|September 14, 2007||||No||https://clinicaltrials.gov/show/NCT00530881||167078|
NCT00530894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-06-US|THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial|THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve|PARTNER|Edwards Lifesciences|Yes|Active, not recruiting|April 2007|March 2017|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|3285|||Both|N/A|N/A|No|||February 2014|February 7, 2014|September 14, 2007||||||https://clinicaltrials.gov/show/NCT00530894||167077|
NCT00530907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0676|Valproic Acid and Bevacizumab in Patients With Advanced Cancer|Phase I Study of Valproic Acid Given in Combination With Bevacizumab in Patients With Advanced Cancer to Determine Safety and Tolerability||M.D. Anderson Cancer Center|No|Completed|June 2007|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|N/A|N/A|No|||November 2013|January 7, 2015|September 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00530907||167076|
NCT00520078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701034R|Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection|Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection||National Taiwan University Hospital|Yes|Recruiting|August 2007|August 2008|Anticipated|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|100|||Both|20 Years|N/A|No|||February 2007|August 21, 2007|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00520078||167897|
NCT00531193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204HV101|Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers|An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of BIIB014 at Multiple Dose Levels in Healthy Male Volunteers||Biogen|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 29, 2008|September 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00531193||167055|
NCT00527098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070108|Optimal Fluid Resuscitation for Trauma Patients|Optimal Fluid Resuscitation for Trauma Patients||University of Miami|No|Completed|October 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|119|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult Trauma Patients|February 2013|February 20, 2013|September 6, 2007||No||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00527098||167367|
NCT00527111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05102|Pre-op Rectal ChemoRad +/- Cetuximab|A Randomized Phase II Trial of Pre-operative Chemoradiotherapy With or Without Cetuximab (ERBITUX(R)) in Locally-advanced Adenocarcinoma of the Rectum||US Oncology Research|No|Completed|February 2007|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|September 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00527111||167366|
NCT00527410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 744-C-0601|A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis|A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis|LMD|Reata Pharmaceuticals, Inc.|No|Terminated|October 2006|||December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|September 7, 2007|Yes|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT00527410||167343|
NCT00527423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0702|Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD|A Randomized, Single-Masked , Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects With Neovascular Age-related Macular Degeneration||Regeneron Pharmaceuticals|No|Completed|August 2007|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|157|||Both|50 Years|N/A|No|||June 2013|June 10, 2013|September 6, 2007|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT00527423||167342|
NCT00527683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-152|Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence|Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees||New York University School of Medicine|Yes|Completed|April 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|55 Years|No|||April 2008|April 7, 2008|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00527683||167322|
NCT00527696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:044|Trial Comparing TVT SECUR System and Trans Vaginal Obturator Tape for Surgical Management of Stress Urinary Incontinence|Randomized Clinical Trial Comparing TVT SECUR System (TVT S) and Trans Vaginal Obturator Tape (TVT-O) for Surgical Management of Stress Urinary Incontinence||University of Manitoba|Yes|Terminated|May 2008|October 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|September 10, 2007||No|statistical Significance was reached for primary outcome|No||https://clinicaltrials.gov/show/NCT00527696||167321|
NCT00528554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG-07-HT-01|Laser Acupuncture Against Nausea in Children|Laser Acupuncture to Alleviate Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy. A Prospective, Double-Blinded, Placebo-Controlled Clinical Trial||University Children Hospital Homburg|No|Recruiting|September 2007|September 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|25|||Both|N/A|17 Years|No|||September 2007|September 17, 2007|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528554||167255|
NCT00500708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDx_000003|Diagnostic Investigation of Sudden Cardiac Event Risk|Identifying Markers That Predict Ventricular Arrhythmia Risk|DISCERN|CardioDx|Yes|Suspended|July 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|whole blood, buffy coat, spun plasma, saliva|Both|18 Years|90 Years|No|Probability Sample|Patient's with ventricular dysfunction (low ejection fraction) undergoing implantation of        ICD or CRT-D for primary prevention. Patient's may be enrolled at time of implant or        during follow-up in electrophysiology clinic as long as full device records are available        since time of implant.|November 2014|November 25, 2014|July 11, 2007||No|Lack of patients with appropriate therapy|No||https://clinicaltrials.gov/show/NCT00500708||169360|
NCT00500721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3173A1-1120|Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine|An Open-Label, Single-Dose Desipramine, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 10, 2008|July 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00500721||169359|
NCT00501280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0350|Genetic Susceptibility in Migrant Farmworker Children|Biomarkers of Genetic Susceptibility in Environmentally-Exposed Migrant/Seasonal Farmworker Women and Their Children||M.D. Anderson Cancer Center|No|Completed|June 2004|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|768|Samples With DNA|10 teaspoons of blood drawn and a urine sample from each mother/child.|Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Migrant or seasonal farmworker (MSF) woman who has a child attending the Migrant Education        Program, or a child of a MSF woman, or a woman who has never worked in agriculture        (non-MSF) but has a child attending the ESL Bilingual Education, Immigrant or the Main        Stream Programs in the Goose Creek Consolidated School District in Harris County, TX, or        in the La Joya School District in Hidalgo County, TX.|April 2013|April 1, 2013|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501280||169316|
NCT00501592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-203|Study of INT-747 in Patients With Diabetes and Presumed NAFLD|An Exploratory Study of INT-747 in Patients With Type 2 Diabetes Mellitus and Presumed Nonalcoholic Fatty Liver Disease||Intercept Pharmaceuticals|Yes|Completed|July 2007|April 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|75 Years|No|||April 2012|April 17, 2012|July 13, 2007|No|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00501592||169293|
NCT00501631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-014|ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence|Efficacy and Safety of VIVITROL® in Adults Completing Inpatient Treatment for Alcohol Dependence||Alkermes, Inc.|No|Completed|July 2007|March 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|65 Years|No|||September 2011|September 20, 2011|July 12, 2007|Yes|Yes||No|March 23, 2011|https://clinicaltrials.gov/show/NCT00501631||169290|
NCT00502138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pramlintide Infusion in IDDM|A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes|A Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Pramlintide Acetate When Administered by Subcutaneous Infusion in a Basal-Bolus Manner as an Adjunct to Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes||University Diabetes & Endocrine Consultants|Yes|Completed|July 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||January 2013|January 15, 2013|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502138||169251|
NCT00502112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG033-0002|A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)|A Phase I Combination Trial of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) and Lenalidomide (Revlimid®) in Patients With Myelodysplastic Syndromes (MDS)||Seattle Genetics, Inc.|No|Completed|March 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|July 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00502112||169253|
NCT00502125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-494|In Vivo Confocal Imaging of Oral Mucosa|A Pilot Study: In Vivo Reflectance Confocal Imaging for Detection of Neoplasia of Oral Mucosa||M.D. Anderson Cancer Center|No|Completed|January 2003|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Tissue samples will be removed.|Both|N/A|N/A|No|Non-Probability Sample|Patients with oral lesions.|July 2012|July 31, 2012|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00502125||169252|
NCT00503009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZA109895|Study Of RV-39 In Patients Who Also Have Asthma|An Exploratory Study to Evaluate the Response of Salmeterol Plus Fluticasone Propionate vs Fluticasone Propionate Alone to Experimental Nasal Inoculation With Rhinovirus||GlaxoSmithKline|No|Terminated|October 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|40 Years|No|||February 2011|May 31, 2012|July 17, 2007|Yes|Yes|lack of data|No|July 6, 2009|https://clinicaltrials.gov/show/NCT00503009||169185|Due to the small sample size, efficacy measures were not analyzed.
NCT00503022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885F2201|Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration|A Randomized, Double-Masked, Multi-Center Phase I Study of 6 Months Duration to Assess the Safety and Tolerability of Intravenous ACZ885 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration||Novartis||Completed|July 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|50 Years|N/A||||December 2007|December 19, 2007|July 17, 2007||||No||https://clinicaltrials.gov/show/NCT00503022||169184|
NCT00530231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-05-041|Capsule Endoscopic Miss Rates Determined by Back-to-Back Capsule Endoscopy|Capsule Endoscopic Miss Rates Determined by Back-to-Back Capsule Endoscopy||Samsung Medical Center|Yes|Recruiting||||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||||||Both|15 Years|N/A||||May 2007|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530231||167126|
NCT00530244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSULLI03A0|Use of Formula Fortified With DHA in Infants With Cystic Fibrosis|The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)|DHA|University of Massachusetts, Worcester|Yes|Completed|March 2003|October 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|76|||Both|N/A|56 Days|No|||February 2012|February 16, 2012|September 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00530244||167125|
NCT00530517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX001-0701|A Study on the Usability of the Needle-Free Intraject® System in Adult Patients During Acute Migraine Attack|A Multi-Center, Open-Label, Single-Dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject® System in Adult Patients During Acute Migraine Attack||Zogenix, Inc.|Yes|Completed|September 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|54|||Both|18 Years|N/A|No|||February 2008|February 7, 2008|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530517||167105|
NCT00531180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0698|4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies|Phase II Trial Comparing 4-Dimensional Computed Tomography Derived Ventilation Versus SPECT/CT Tc-99m Aerosol Ventilation in Patients With Thoracic Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2007|||November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|36|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with esophageal or lung cancer.|October 2015|October 1, 2015|September 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00531180||167056|
NCT00530920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.107|Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients|A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-state Pharmacokinetics and Short-term Efficacy and Safety in HIV-1 Positive Treatment naïve Patients||Boehringer Ingelheim||Completed|October 2007|||May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|85|||Both|18 Years|65 Years|No|||May 2014|May 27, 2014|September 17, 2007||Yes||No|May 15, 2009|https://clinicaltrials.gov/show/NCT00530920||167075|
NCT00527124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00174|Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Randomized, Phase II Trial of AZD2171, Docetaxel, and Prednisone Compared to Docetaxel and Prednisone in Patients With Metastatic, Hormone Refractory Prostate Cancer||National Cancer Institute (NCI)|Yes|Terminated|November 2007|November 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Male|18 Years|N/A|No|||August 2014|March 25, 2015|September 7, 2007|Yes|Yes|Closure was recommended by CTEP due to slow accrual.|No|July 9, 2013|https://clinicaltrials.gov/show/NCT00527124||167365|Closure was recommended by CTEP due to slow accrual.
NCT00527137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000100|NESP Pediatric Study|An Open-label, Randomized, Non-inferiority Study of Novel Erythropoiesis Stimulating Protein (NESP) and Recombinant Human Erythropoietin (rHuEPO) for the Treatment of Anemia in Pediatric Subjects With Chronic Renal Insufficiency (CRI) or End-stage Renal Disease (ESRD) Receiving Dialysis||Amgen||Completed|August 2000|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||May 2013|May 6, 2013|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527137||167364|
NCT00527436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25918|Fish Oil and Biomarkers of Cardiovascular Risk|Fish Oil and Biomarkers of Cardiovascular Risk||Penn State University|Yes|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|||||||Both|20 Years|79 Years|Accepts Healthy Volunteers|||September 2007|September 6, 2007|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527436||167341|
NCT00528320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITAC06|Clinical Evaluation of Cardiac Resynchronization Therapy (CRT) Using the Ovatio CRT Implantable Cardioverter-defibrillator (ICD) System|Clinical Evaluation of Cardiac Resynchronization Therapy With Implantable Cardioverter-defibrillator Therapy||ELA Medical, Inc.||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||November 2013|November 26, 2013|September 10, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00528320||167273|
NCT00528333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG033-0003|A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML|A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML||Seattle Genetics, Inc.|Yes|Completed|September 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|211|||Both|60 Years|N/A|No|||December 2014|December 17, 2014|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528333||167272|
NCT00528866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0621|Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy|Adjuvant 3DCRT/IMRT in Combination With Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 2008|||December 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Male|18 Years|N/A|No|||March 2015|March 26, 2015|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528866||167231|
NCT00501007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA018203|Predictors of Treatment Outcome for Smokers With and Without Schizophrenia|Predictors of Treatment Outcome for Smokers With and Without Schizophrenia||Rutgers, The State University of New Jersey|No|Completed|February 2005|January 2013|Actual|December 2012|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|203|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals from mental health centers in Central New Jersey or non-psychiatric controls        from the community|December 2013|December 6, 2013|July 11, 2007||No||No|January 7, 2013|https://clinicaltrials.gov/show/NCT00501007||169337|
NCT00501020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49653/284|Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin|A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA When Added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy When Administered to Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|April 2001|February 2003|Actual|February 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||750|||Both|18 Years|75 Years|No|||October 2010|October 1, 2010|July 12, 2007||||No||https://clinicaltrials.gov/show/NCT00501020||169336|
NCT00501033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4|A Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter|A Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter||Western Galilee Hospital-Nahariya|No|Completed|January 2006|May 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 2, 2008|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501033||169335|
NCT00501046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRM-307|A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment of Quality of Life||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|July 2007|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1015|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|July 11, 2007|Yes|Yes||No|February 15, 2015|https://clinicaltrials.gov/show/NCT00501046||169334|
NCT00501293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-410|Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD|A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)||Noven Therapeutics|No|Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|13 Years|17 Years|No|||June 2015|June 23, 2015|July 12, 2007|No|Yes||No|October 5, 2009|https://clinicaltrials.gov/show/NCT00501293||169315|
NCT00501605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00001|Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases|A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases||AstraZeneca|Yes|Completed|February 2003|February 2006|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|N/A|No|||January 2009|January 20, 2011|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501605||169292|
NCT00502450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4560|Is There Hearing Loss After Acute Mastoiditis|||Rabin Medical Center||Withdrawn|September 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|0|||Both|4 Years|18 Years|No|Non-Probability Sample|Tertiary care clinic|July 2007|July 18, 2013|July 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00502450||169228|
NCT00502463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASOG-HNO1|Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial|Induction by Docetaxel/Cisplatin/5-Fluorouracil (TCF) Prior to Radiotherapy With Concomintant Cetuximab in Locally Advanced Inoperable Head and Neck Tumours - a Methodical Trial|ASOG-HNO1|Austrian South Oncology Group|No|Active, not recruiting|June 2007|December 2013|Anticipated|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||July 2009|July 30, 2009|July 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00502463||169227|
NCT00501891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000404|Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma|A Phase II Study of Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma||Duke University|Yes|Completed|July 2007|November 2009|Actual|December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||March 2013|May 17, 2013|July 13, 2007|Yes|Yes||No|February 6, 2013|https://clinicaltrials.gov/show/NCT00501891||169270|
NCT00502411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-336|Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma|A Phase I Study of Post-Operative Concurrent Chemoradiation for Extremity and Trunk Soft Tissue Sarcoma||M.D. Anderson Cancer Center|No|Completed|January 2003|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|No|||November 2015|November 17, 2015|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00502411||169231|
NCT00499408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000554969|Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer|Phase II Trial of Vitamin D and Soy Supplementation for Biochemically Recurrent Prostate Cancer Following Definitive Local Therapy||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|April 2007|||December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|120 Years|No|||January 2014|September 29, 2015|July 10, 2007|Yes|Yes||No|November 15, 2013|https://clinicaltrials.gov/show/NCT00499408||169457|only the most severe of each type of adverse event during treatment was recorded.
NCT00499421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0428|Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy|Evaluation of Intraprostatic Fiducial Markers For Targeting of External Beam Radiation Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2005|||September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Male|N/A|N/A|No|Non-Probability Sample|Study participants with prostate cancer that will be treated with external beam radiation        therapy.|April 2015|April 17, 2015|July 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00499421||169456|
NCT00529958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20966|Comparison of Three Methods for Anterior Cruciate Ligament Reconstruction|A Randomized Clinical Trial Comparing Three Methods for Anterior Cruciate Ligament Reconstruction: Patellar Tendon, Quadruple Semitendinosus/Gracilis and Double-Bundle Semitendinosus/Gracilis Grafts.||University of Calgary|No|Active, not recruiting|September 2007|December 2020|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|330|||Both|14 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00529958||167147|
NCT00529971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015005|A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV|A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV||Mount Sinai Hospital, Canada|No|Completed|December 2003|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Male|18 Years|70 Years|No|||September 2007|October 2, 2007|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00529971||167146|
NCT00529984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX701|A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies|A Phase I/II Study of Active Immunotherapy With CEA(6D)VRP Vaccine(AVX701)in Patients With Advanced or Metastatic Malignancies Expressing CEA or Stage III Colon Cancer|CEA(6D)VRP|AlphaVax, Inc.|Yes|Completed|September 2007|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|28|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|September 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00529984||167145|
NCT00530933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q0405/13|Tibial Nerve Stimulation for Faecal Incontinence|Prospective Randomised Placebo Controlled Study Into Percutaneous and Transcutaneous Tibial Nerve Stimulation for Faecal Incontinence||London North West Healthcare NHS Trust|No|Recruiting|September 2007|April 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||September 2007|September 15, 2007|September 15, 2007||||No||https://clinicaltrials.gov/show/NCT00530933||167074|
NCT00531206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.112|Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.|Observational Non-interventional Study About Antiretroviral Combination Treatment With Aptivus in Combination With Low-dose Ritonavir in HIV Type 1 Infected Patients||Boehringer Ingelheim||Completed|August 2006|||January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Non-Probability Sample|Patients|February 2014|February 24, 2014|September 17, 2007||||No|January 28, 2010|https://clinicaltrials.gov/show/NCT00531206||167054|
NCT00531219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071114, 140016|Minimally Invasive Surgery: Using Natural Orifice Translumenal Endoscopic Surgery (NOTES)|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Transgastric Appendectomy and Cholecystectomy|NOTES|University of California, San Diego|No|Recruiting|February 2008|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|75 Years|No|Non-Probability Sample|There will be 2 groups in this study: Of special note, the inclusion criteria clearly        states subjects must be seen within 36 hours of the onset of pain and have an ASA        Classification of I. This is intended to avoid obtaining informed consent from a subject        who is in severe pain and incapable of making an informed decision, as well as avoid        coercion. An ASA Classification of I defines a healthy normal individual.          1. Group 1 will be transgastric laparoscopic assisted appendectomy          2. Group 2 will be transgastric laparoscopic assisted cholecystectomy|March 2016|March 17, 2016|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531219||167053|
NCT00526903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17388|Recurrent Abdominal Pain in Children|Recurrent Abdominal Pain in Children||Baylor College of Medicine|Yes|Completed|January 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|168|||Both|7 Years|18 Years|No|||March 2016|March 4, 2016|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526903||167382|
NCT00526877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013873|An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment|Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres||Johnson & Johnson Taiwan Ltd|No|Completed|July 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526877||167384|
NCT00527709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.01.025|Hold Parameters on Likely Cardiovascular Depressant Medications|Hold Parameters on Likely Cardiovascular Depressant Medications (HOLD)||Hackensack University Medical Center||Active, not recruiting|August 2006|||August 2006||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A||||February 2014|February 1, 2014|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527709||167320|
NCT00527722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0268|Evaluation of the Bio-Seal Biopsy Track Plug|A Prospective Randomized Multi-Centered Study and Efficacy Evaluation of the Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedures||M.D. Anderson Cancer Center|Yes|Completed|September 2005|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|77|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|September 10, 2007|Yes|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00527722||167319|
NCT00527735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-041|Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)|A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer||Bristol-Myers Squibb|Yes|Completed|February 2008|December 2011|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|334|||Both|18 Years|N/A|No|||June 2012|June 11, 2012|September 7, 2007|Yes|Yes||No|February 23, 2012|https://clinicaltrials.gov/show/NCT00527735||167318|
NCT00527449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3305000|Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel|Neoadjuvant Chemotherapy With 3x Epirubicin/Docetaxel Followed by 3x Carboplatin/Docetaxel in Patients With Primary Breast Cancer|ETCat01|Klinikum Weissenfels|No|Completed|May 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||January 2010|January 14, 2010|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527449||167340|
NCT00528567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20289|BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer|An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.||Hoffmann-La Roche||Completed|December 2007|June 2014|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2591|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|September 11, 2007||No||No|February 28, 2013|https://clinicaltrials.gov/show/NCT00528567||167254|
NCT00528580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15420A|Statins for the Early Treatment of Sepsis|Statins for the Early Treatment of Sepsis|SETS|University of Chicago|Yes|Active, not recruiting|February 2008|December 2013|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528580||167253|
NCT00528879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-014 LT|A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone||AstraZeneca|No|Completed|September 2007|May 2010|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|915|||Both|18 Years|77 Years|No|||September 2015|September 30, 2015|September 11, 2007|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT00528879||167230|
NCT00528892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRAL|Switching From PI to RALtegravir in HIV Stable Patients|An Open-label, Randomized, 48-Week Study to Assess the Safety, Tolerability and Activity of Raltegravir When Replacing the Ritonavir-boosted PI Component of HAART in HIV-Infected Individuals With Viral Load Suppression on a Ritonavir-Boosted PI Containing Regimen.|SPIRAL|Hospital Clinic of Barcelona|Yes|Completed|January 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|N/A|No|||May 2008|March 30, 2010|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528892||167229|
NCT00500747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-002|Chiron Corp HCV E1/E2 Vaccine|A Phase I Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Chiron Corporation's HCV E1E2/MF59 Vaccine Administered to Healthy HCV-Negative Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2003|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|June 9, 2011|July 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00500747||169357|
NCT00501059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12198|A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease|ARRIVE|Bayer|Yes|Active, not recruiting|July 2007|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12551|||Both|55 Years|N/A|No|||March 2016|March 10, 2016|July 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00501059||169333|
NCT00501072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0644|Safety and Efficacy of RT-CGMS in Patients With Type 1 Diabetes Mellitus Treated With an Implantable Pump|Use of a Real Time Continuous Glucose Monitoring System (RT-CGMS) in Type 1 Diabetes Patients on Continuous Intraperitoneal Insulin Infusion (CIPII. A Feasibility Study|IP_RT-CGMS|Medical Research Foundation, The Netherlands|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2008|April 8, 2008|July 12, 2007||||No||https://clinicaltrials.gov/show/NCT00501072||169332|
NCT00501306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0337-2|Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men|Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men||Laser Surgery Care|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|195|||Male|18 Years|85 Years|No|Non-Probability Sample|Patients seen in the clinical practice that either had screening for dysplasia, stopped        having screening or returned for screening after a period of absence.|June 2011|June 21, 2011|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501306||169314|
NCT00502190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050322|Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG (EPEGE)|Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG|EPEGE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2007|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Female|18 Years|N/A|No|||April 2007|November 9, 2011|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502190||169248|
NCT00502710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20779|A Study of DPP-IV (3) in Patients With Type 2 Diabetes.|A Randomized, Double-blind Dose-ranging Study of the Effect of DPP-IV (3) on HbA1c, Other Efficacy Parameters, Pharmacokinetics and Safety in Patients With Type 2 Diabetes (BC20779)||Hoffmann-La Roche||Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|289|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00502710||169208|
NCT00502723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K060402|Multicentric Study Comparing Carcinological and Functional Results of Surgery|Prostate Cancer: Multicentric Study Comparing Carcinological and Functional Results of Surgery|PROPENLAP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|December 2007|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1440|||Male|18 Years|70 Years|No|||January 2008|July 27, 2012|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00502723||169207|
NCT00502164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00003|Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer|A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.|AZD2171IL/0003|AstraZeneca||Completed|March 2004|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|N/A|No|||January 2009|January 20, 2011|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00502164||169250|
NCT00503308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0319|HIV Testing Strategies in the Perinatal Setting|Patient Perspectives and Testing Uptake With Abbreviated Versus Standard HIV Consenting in the Prenatal Setting: A Randomized-Controlled, Non-Inferiority Trial||University of California, San Francisco|No|Completed|October 2006|February 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|281|||Female|16 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 6, 2015|July 16, 2007||No||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00503308||169162|
NCT00504075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMX02|A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura||Bio Products Laboratory|No|Completed|September 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|70 Years|No|||February 2013|February 26, 2013|July 18, 2007|Yes|Yes||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00504075||169104|
NCT00504348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IICT-FK506-01|Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus|An Open-label Clinical Trial of the Combination Treatment of Tacrolimus and Corticosteroid in Polymyositis/Dermatomyositis Patients With Interstitial Pneumonitis, With Comparison Against Corticosteroid-treated Historical Controls|IMPPACT|Tokyo Medical and Dental University|No|Active, not recruiting|July 2007|January 2011|Anticipated|January 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|74 Years|No|||July 2010|July 28, 2010|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504348||169083|
NCT00530530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8825-CL-0003|ASP8825 - Study in Patients With Restless Legs Syndrome|ASP8825 Phase ⅡStudy—A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP8825 in Patients With Restless Legs Syndrome||Astellas Pharma Inc|No|Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|474|||Both|20 Years|80 Years|No|||October 2014|October 28, 2014|September 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00530530||167104|
NCT00530543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01-039|Effects of Gait Training With Assistance of a Robot-Driven Gait Orthosis in Hemiparetic Patients After Stroke|||Samsung Medical Center|Yes|Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|16 Years|80 Years||||May 2007|September 13, 2007|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530543||167103|
NCT00530556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8445|Insomnia and Daytime Function in Osteoarthritis|Effect of Zolpidem vs Placebo on Insomnia and Daytime Function in Patients With Insomnia Associated With Osteoarthritis||Sanofi||Completed|March 2003|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|170|||Both|45 Years|N/A|No|||February 2012|February 15, 2012|September 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00530556||167102|
NCT00530569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17924|Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy|Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy|HER 2|AHS Cancer Control Alberta|Yes|Active, not recruiting|August 2007|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|80 Years|No|Probability Sample|Albertan women with breast cancer who will undergo Herceptin therapy as part of their        treatment at some point during a one-year period.|January 2012|January 24, 2013|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00530569||167101|
NCT00530946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841058|A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin|A Multi-Center, Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin In The Treatment Of Concurrent Hypertension And Hyper-LDL-Cholesterolemia||Pfizer|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|165|||Both|20 Years|79 Years|No|||March 2009|April 28, 2009|September 13, 2007||No||No|March 10, 2009|https://clinicaltrials.gov/show/NCT00530946||167073|
NCT00530972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001192-34|Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies|Treatment of Patients With Chronic Hepatitis C Co-infected With HIV Relapsers or Non Responders, Previous Exposed to Sub-optimal Therapies: Open, Pilot Trial|PILOT-NR|Hospital Carlos III, Madrid|Yes|Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||September 2009|September 4, 2009|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00530972||167072|
NCT00531232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOMDS02507|A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)|A Phase IIa Open-label, Dose Confirmation Study of Oral Clofarabine in Adult Patients Previously Treated for Myelodysplastic Syndromes(MDS)||Sanofi|No|Completed|September 2007|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|September 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531232||167052|
NCT00527475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAP AMD Trial|Ranibizumab and Reduced Fluence PDT for AMD|Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration|RAP|Texas Retina Associates|No|Completed|May 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|N/A|No|||June 2013|June 5, 2013|September 9, 2007|Yes|Yes||No|April 19, 2013|https://clinicaltrials.gov/show/NCT00527475||167338|
NCT00526890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000562780|Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II, Multi-Center Trial||Roswell Park Cancer Institute|Yes|Terminated|October 2006|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|September 7, 2007|Yes|Yes|lack of efficacy|No|January 8, 2015|https://clinicaltrials.gov/show/NCT00526890||167383|
NCT00528034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-239|Lymphoscintigraphy in Patients With Vaginal Cancer|Lymphoscintigraphy and Selective Lymphatic Mapping in Patients With Invasive Vaginal Cancer||M.D. Anderson Cancer Center|No|Completed|September 2002|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Female|N/A|N/A|No|||July 2012|July 31, 2012|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528034||167295|
NCT00528047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRLX93936-0001|Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors|A Phase I, Multi-center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily for Five Days Followed by a 23-Day Rest Period in Patients With Advanced Solid Tumors||Prolexys Pharmaceuticals|No|Completed|August 2007|November 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|September 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00528047||167294|
NCT00528008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC07.33|A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections|Povidone-iodine vs. Chlorhexidine Gluconate - A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections||Memorial University of Newfoundland|No|Terminated|December 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|268|||Female|19 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 8, 2012|September 10, 2007||No|Study was stopped following interim analysis.|No||https://clinicaltrials.gov/show/NCT00528008||167297|
NCT00528021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCG20-0582-001|A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation|A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation||BTG International Inc.|No|Completed|August 2007|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|230|||Both|2 Years|70 Years|No|||November 2010|November 30, 2010|September 10, 2007|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00528021||167296|
NCT00528606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-857|AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Dupuytren's Contracture|CORD-I|Endo Pharmaceuticals|No|Completed|August 2007|October 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 11, 2007|Yes|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00528606||167251|
NCT00529815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU # 07-13023|Continuous Glucose Monitoring in Patients With Type 2 Diabetes|A Pilot Study to Determine the Impact of Real-Time Continuous Glucose Monitoring (CGM) on Patients With Type 2 Diabetes|CGM|Walter Reed Army Medical Center|Yes|Active, not recruiting|September 2007|September 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|80 Years|No|||June 2009|February 24, 2010|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00529815||167158|
NCT00500760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062080|Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer|A Phase 2, Randomized Trial of Chemoradiation With or Without Panitumumab in Subjects With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Amgen||Completed|October 2007|November 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|July 12, 2007|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT00500760||169356|
NCT00501644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-231|Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer|A Phase II Study of Chemoimmunotherapy for Patients With Potentially Platinum Sensitive Müllerian (Epithelial Ovarian, Peritoneal, or Fallopian Tube) Carcinomas||M.D. Anderson Cancer Center|No|Completed|January 2003|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Female|N/A|N/A|No|||August 2012|August 1, 2012|July 12, 2007||No||No|December 23, 2010|https://clinicaltrials.gov/show/NCT00501644||169289|
NCT00502177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1106|Quality of Life Questionnaire for Pediatric Patients Undergoing Peritoneal Perfusion|Quality of Life Questionnaire for Pediatric Patients Undergoing Continuous Hyperthermic Peritoneal Perfusion With Cisplatin||M.D. Anderson Cancer Center|No|Recruiting|June 2007|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|1 Year|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their        parents/caregivers.|January 2016|January 21, 2016|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502177||169249|
NCT00502203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-229|Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus|A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus||M.D. Anderson Cancer Center|No|Completed|August 2001|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|N/A|N/A|No|||December 2011|December 5, 2011|July 16, 2007||No||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00502203||169247|
NCT00502216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA_TOL-AA15632|Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers|Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers||Yale University|Yes|Completed|July 2007|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||August 2010|August 30, 2010|July 13, 2007||No||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00502216||169246|
NCT00502476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI06-003|Multicenter Trial of Daily Chlorhexidine Bathing to Reduce Nosocomial Infections|Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE|CBET|Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Recruiting|August 2007|September 2009|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|14000|||Both|18 Years|N/A|No|||August 2007|August 6, 2007|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502476||169226|
NCT00502736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20684|A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.|An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Bone Pain in Patients With Breast Cancer and Skeletal Metastases||Hoffmann-La Roche||Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||January 2014|January 20, 2014|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00502736||169206|
NCT00502749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-329|Exercise Program for Adolescents and Young Adults With Cancer|Feasibility, Safety, and Effect of an Exercise Program for Adolescents and Young Adults With Cancer||M.D. Anderson Cancer Center|No|Completed|February 2003|October 2010|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|37|||Both|12 Years|25 Years|No|||October 2011|October 14, 2011|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502749||169205|
NCT00503802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30678-D|Randomized Clinical Trial of Nasal Turbinate Reduction to Improve Continuous Positive Airway Pressure (CPAP) Outcomes for Sleep Apnea|Turbinate Reduction & CPAP Use: A Randomized Blinded OSA (TURBO) Trial|TURBO|University of Washington|Yes|Completed|July 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|80 Years|No|||June 2013|June 17, 2013|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503802||169125|
NCT00503815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI-800-302|BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|A Safety and Efficacy Evaluation of BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy||Braintree Laboratories|No|Completed|July 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind|||Anticipated|360|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|July 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503815||169124|
NCT00530270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|516|Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease|Randomized Trial of Oral Dexamethasone for Acute Chest Syndrome||Children's Hospital Medical Center, Cincinnati|Yes|Terminated|December 2006|November 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|5 Years|N/A|No|||March 2013|March 29, 2013|September 14, 2007|Yes|Yes|Study was closed June 23, 2008 due to low enrollment.|No|July 16, 2009|https://clinicaltrials.gov/show/NCT00530270||167123|Primary limitation of this study is that is was terminated prior to enrolling all of the subjects necessary to address the primary question.
NCT00530283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20682|PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy|The Clinical Utility of PET-CT in the Management of Squamous Cell Carcinoma of the Neck Nodes With Unknown Primary Malignancy||AHS Cancer Control Alberta|No|Completed|August 2007|July 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|58|||Both|18 Years|N/A|No|Non-Probability Sample|18 years|August 2011|January 18, 2012|September 13, 2007||||No||https://clinicaltrials.gov/show/NCT00530283||167122|
NCT00526916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070208|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28||National Institutes of Health Clinical Center (CC)||Completed|September 2007|September 2014|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 6, 2014|September 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00526916||167381|
NCT00527163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907217|Role of Nitric Oxide in Malaria|Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria||National Institutes of Health Clinical Center (CC)||Completed|September 2007|March 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|650|||Both|1 Year|5 Years|No|||March 2015|March 31, 2015|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00527163||167362|
NCT00527176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B40320072108|Pulse Corticosteroid Therapy and Effect on Brain Water Diffusivity|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|September 2007|September 2007||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|N/A|No|||September 2007|September 7, 2007|September 7, 2007||||No||https://clinicaltrials.gov/show/NCT00527176||167361|
NCT00527488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS25|Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.|A Single-centre, Open-label, Randomised Explorative Pharmacokinetic/Pharmacodynamic Study of the Gonadotropin-releasing Hormone Receptor Antagonist Degarelix (FE 200486) in Patients With Benign Prostatic Hyperplasia.||Ferring Pharmaceuticals|No|Completed|October 2007|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Male|55 Years|75 Years|No|||April 2015|April 14, 2015|September 10, 2007|Yes|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT00527488||167337|
NCT00527150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051069|Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers|A Phase 1, Investigator And Subject Blind (Sponsor Open), Randomized, Placebo Controlled, Parallel Group, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Varenicline Amt-8 Controlled Release Formulation In Adult Smokers||Pfizer|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|48|||Both|18 Years|55 Years|No|||January 2010|January 7, 2010|September 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00527150||167363|
NCT00527462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/06 UFP-SFB DFG|Study to Explore the Effects of Two Hour Inhalation of Ultrafine Carbon Black Particles on Airway Inflammation in Asthmatics|Mono-Center, Double-Blind, Cross-Over Study to Explore the Effects of Two Hour Inhalation of Ultrafine Carbon Black Particles Versus Filtered Air on Airway Inflammation Induced by Segmental Allergen Challenge in Asthmatics||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|September 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|45 Years|No|||April 2008|April 28, 2008|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00527462||167339|
NCT00528060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003203-12|Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada|Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3|ANRS134COPHAR3|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528060||167293|
NCT00528073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETIC/03/06|Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease|A Phase II, Multicentre, Double-blind, Randomised, Dose Range Finding Placebo Controlled Study of Rifaximin-EIR Tablet: Clinical Effectiveness and Tolerability in the Treatment of Moderate, Active Crohn's Disease||Alfa Wassermann S.p.A.|Yes|Completed|September 2007|October 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|410|||Both|18 Years|75 Years|No|||February 2010|February 19, 2010|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528073||167292|
NCT00528346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44NS050642-06|Treatment Of Chronic Pain Using Real Time fMRI|Treatment Of Chronic Pain Using Real-time Functional MRI Trial||Omneuron|No|Active, not recruiting|September 2007|August 2011|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|21 Years|60 Years|No|||April 2011|April 25, 2011|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528346||167271|
NCT00529477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB3-AIR|The Effects Of Methacholine Challenge Administered Using Three Different Nebulizers On Small Airways Function|The Effects of Methacholine Challenge Administered Using Three Different Nebulizers on Small Airways Function||McMaster University|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|8|||Both|18 Years|65 Years|No|||October 2009|October 20, 2009|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00529477||167184|
NCT00529204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H80-MC-X006|Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease|Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease||University of California, Davis|Yes|Terminated|October 2007|February 2010|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|70 Years|No|||December 2014|December 22, 2014|September 12, 2007|Yes|Yes|Lack of recruitment|No|December 8, 2014|https://clinicaltrials.gov/show/NCT00529204||167205|
NCT00501085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedAff-LBAP201|LAP-BAND AP Early Experience Trial (APEX)|||Apollo Endosurgery, Inc.||Completed|June 2007|November 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|521|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample|January 2015|January 15, 2015|July 11, 2007|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT00501085||169331|
NCT00501098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004432-70|Prophylaxis of Fungal Invasive Infections in Leukemia|A Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy of Caspofungin as Prophylactic Treatment of Invasive Fungal Infections in Patients With Acute Leukemia Undergoing Induction Chemotherapy|PROFIL-C|Northern Italy Leukemia Group|Yes|Completed|January 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2009|September 21, 2009|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501098||169330|
NCT00501670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109999|VZV PCR Sampling Validation Study|A Non-therapeutic Study to Validate the Sampling Method to Confirm Presence of Varicella-zoster Virus (VZV) DNA by PCR in Clinical Samples From Lesions Collected From Adults (≥50 Years) With Clinically Diagnosed Herpes Zoster||GlaxoSmithKline||Completed|August 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|Samples With DNA|lesion samples|Both|50 Years|N/A|No|Non-Probability Sample|German male or female patients aged 50 years or older who are clinically diagnosed with HZ        by the investigator including the presence of a typical HZ rash.|January 2014|January 9, 2014|June 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00501670||169287|
NCT00503035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM02-592|Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers|Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2003|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|N/A|No|||November 2015|November 23, 2015|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503035||169183|
NCT00503048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-268-03-KE|Markers of Atopy in Children With Presumed Early Exposure to Allergens, Unhygienic Conditions, and Infections|Markers of Atopy in Children With Presumed Early Exposure to Allergens, Unhygienic Conditions, and Infections||Medical Universtity of Lodz|Yes|Completed|December 2003|November 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|915|Samples With DNA|whole blood samples|Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children.|December 2008|December 23, 2008|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503048||169182|
NCT00503061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890C00017|A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART|A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database||AstraZeneca||Completed|June 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1000|||Both|N/A|N/A|No|Non-Probability Sample|Population comes from Primary Care Clinics and Pulmonary Experts|November 2010|November 30, 2010|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503061||169181|
NCT00502489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4242|Computer Driven Management of Weaning Following Prolonged Mechanical Ventilation|Computer Driven Management of Weaning Following Prolonged Mechanical Ventilation: a Pilot Study||Rabin Medical Center|No|Not yet recruiting|October 2007|November 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|60 Years|85 Years|No|||May 2007|July 16, 2007|July 15, 2007||||No||https://clinicaltrials.gov/show/NCT00502489||169225|
NCT00502762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMO-LU-51|Topotecan for Irinotecan-Refractory SCLC|Salvage Treatment With Topotecan in Patients With Irinotecan-Refractory Small Cell Lung Cancer||Gachon University Gil Medical Center|No|Active, not recruiting|September 2004|August 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||March 2008|March 10, 2008|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502762||169204|
NCT00531245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-01-024|A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer|A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer||Samsung Medical Center|Yes|Completed|August 2006|March 2009|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|18 Years|75 Years|No|||August 2007|June 29, 2009|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531245||167051|
NCT00526929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990151|Fixed Dose NESP Study in Subjects With CRI|A Pilot Study Evaluating Once Every Other Week Administration of Fixed Doses of Novel Erythropoiesis Stimulating Protein (NESP) to Subjects With Chronic Renal Insufficiency (CRI)||Amgen||Completed|May 2000|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||May 2009|May 21, 2009|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00526929||167380|
NCT00527189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98765|Balance Impairment and Falls Risk in People With Lower Limb Arthritis, and Can These be Improved With Exercise?|Which Measures of Balance Best Discriminate Balance Impairment and Falls Risk in People With Lower Limb Arthritis, and Can These be Improved With Exercise?||National Ageing Research Institute, Australia|No|Completed|January 2006|April 2007|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 7, 2007|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00527189||167360|
NCT00527202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTXneurop-1|Efficacy Study of Botox to Treat Neuropathic Pain|Randomized Placebo-Controlled Study of the Efficacy of Botulinum Toxin Type A (Botox) in Spontaneous Pain and Allodynia Related to Traumatic Nerve Injury or Postherpetic Neuralgia||Hospital Ambroise Paré Paris|No|Completed|June 2004|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||September 2007|September 7, 2007|September 7, 2007||||No||https://clinicaltrials.gov/show/NCT00527202||167359|
NCT00528372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-013 LT|A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise||AstraZeneca|No|Completed|September 2007|July 2010|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|1067|||Both|18 Years|77 Years|No|||September 2015|September 30, 2015|September 11, 2007|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT00528372||167269|Group 2 (patients with enrollment baseline HbA1c >10% and ≤2%) was an exploratory group, included to obtain initial efficacy and safety data. No comparator arm was included. Thus, only key safety and efficacy analyses were performed for Group 2.
NCT00528619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181084|A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors|Phase I Study Of SU011248 In Combination With Pemetrexed, Pemetrexed/Cisplatin And Pemetrexed/Carboplatin In Patients With Advanced Solid Malignancies||Pfizer|No|Completed|November 2006|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|September 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00528619||167250|
NCT00527748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1092357|Foot and Ankle Range of Motion (Stretching) Apparatus|The Use of a New Foot and Ankle Range of Motion (Stretching) Apparatus in Subjects With Stiff Ankles||University of Missouri-Columbia|No|Terminated|September 2007|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|September 7, 2007||No|PI no longer with the University of Missouri, the study will not be continued.|No||https://clinicaltrials.gov/show/NCT00527748||167317|
NCT00527761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1037|Taxotere/Temodar/Cisplatin Study in Melanoma Patients|Phase I Study of TTC (Taxotere/Temodar/Cisplatin) in Metastatic Melanoma Patients||M.D. Anderson Cancer Center|No|Completed|August 2004|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00527761||167316|
NCT00528905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00011|Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia|A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study With 3 Oral Groups of AZD3480 During 12 Weeks Treatment of Cognitive Deficits in Patients With Schizophrenia|HALO|AstraZeneca|No|Completed|August 2007|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|55 Years|No|||November 2008|November 21, 2008|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00528905||167228|
NCT00528359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAD-001|β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS|Phase 1 Study of Insulin Sensitivity, Adjusted β-Cell Function and Adiponectin Among Lean Drug-naïve Schizophrenic Subjects Treated With Atypical Antipsychotic Drugs|SANAT|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|October 2005|February 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|36|||Both|18 Years|55 Years|No|||March 2008|March 10, 2008|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528359||167270|
NCT00528593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 NS32228- ninds|Epoetin Alfa for HIV-Associated Neuropathy Trial|A Randomized, Multi-center Pilot Study to Evaluate the Efficacy and Safety of Epoetin Alfa (Procrit) in the Treatment of HIV-associated Sensory Neuropathy||Washington University School of Medicine||Withdrawn|November 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|September 11, 2007|Yes|Yes|lack of pharmaceutical support|No||https://clinicaltrials.gov/show/NCT00528593||167252|
NCT00528918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meyer - 012|Comparison of Apidra to Regular Insulin in Hospitalized Patients|Comparison of Apidra to Regular Insulin in Hospitalized Patients|Apidra|Carl T. Hayden VA Medical Center|Yes|Completed|June 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|N/A|N/A|No|||August 2007|July 23, 2014|September 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00528918||167227|
NCT00521404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1008-A-U201|Open-label Study of CS1008 for Subjects With Untreated and Unresectable Pancreatic Cancer|Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer||Daiichi Sankyo Inc.|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521404||167797|
NCT00501657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061025|Effects of Sitagliptin on Gastric Emptying in Healthy Subjects|Effects of Sitagliptin on Gastric Emptying in Healthy Subjects||Royal Adelaide Hospital|No|Completed|July 2007|December 2011|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|October 27, 2015|July 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00501657||169288|
NCT00501943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9924-29155-05|Neuroprotection With Riluzole Patients With Early Multiple Sclerosis|Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis||University of California, San Francisco|Yes|Completed|July 2006|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|43|||Both|18 Years|55 Years|No|||March 2014|March 11, 2014|July 12, 2007|Yes|Yes||No|November 19, 2013|https://clinicaltrials.gov/show/NCT00501943||169266|
NCT00501904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2006b|Metformin in Infertile PCOS Patients|Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients||University Magna Graecia|Yes|Recruiting|April 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|35 Years|No|||December 2015|December 1, 2015|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501904||169269|
NCT00501917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGIC Cell-5|MAGIC Cell-5-Combicytokine Trial|Single Center, Prospective, Randomized, Partly-Double Blinded, Controlled Trial to Assess the Safety and Feasibility of Intracoronary Cell Infusion Mobilized With G-CSF and Darbepoetin and Their Effects on Improvement of Cardiac Function in Patients With Myocardial Infarction: Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Erythropoietin Mobilization and Intra-Coronary Cell Infusion –5-Combination Cytokine Therapy Trial|MAGIC Cell-5|Seoul National University Hospital|Yes|Recruiting|March 2007|February 2010|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|116|||Both|15 Years|80 Years|No|||July 2007|July 13, 2007|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501917||169268|
NCT00507754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1095|Latent Tuberculosis Infection in Cancer Patients|Latent Mycobacterium Tuberculosis Infection Among Cancer Patients||M.D. Anderson Cancer Center|No|Completed|June 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|Samples With DNA|A blood sample will be collected and used to perform the T-SPOT. TB test.|Both|N/A|N/A|No|Non-Probability Sample|Study participants with cancer at risk for developing active tuberculosis (TB).|September 2011|September 22, 2011|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507754||168827|
NCT00507767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00227|Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma||National Cancer Institute (NCI)||Completed|July 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2013|September 17, 2014|July 26, 2007|Yes|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT00507767||168826|
NCT00503399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11716|Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis|Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men|EuroGIOPS|Eli Lilly and Company|No|Completed|July 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Male|25 Years|N/A|No|||October 2011|March 12, 2012|July 16, 2007|Yes|Yes||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00503399||169156|
NCT00503412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00019|Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors|A Phase 1, Open Label, Non-Randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients With Solid Metastatic Tumours||AstraZeneca|Yes|Completed|November 2005|May 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2009|January 15, 2009|July 16, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00503412||169155|
NCT00499174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR11|Observation or Radical Treatment in Patients With Prostate Cancer|A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favourable Risk Prostate Cancer [START]||Canadian Cancer Trials Group|Yes|Terminated|June 2007|January 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Male|18 Years|N/A|No|||July 2012|October 5, 2015|July 10, 2007|Yes|Yes|Not meeting accrual target.|No||https://clinicaltrials.gov/show/NCT00499174||169474|
NCT00504361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605008516|Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)|Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)|Q-BC|Weill Medical College of Cornell University|No|Completed|May 2006|May 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|This protocol is designed to collect a small amount of blood for extraction of DNA (genetic      material) for the study of the genetic basis of lung disease. Genomic DNA will be extracted,      and genome wide SNP analysis and promoter sequences for genes will be obtained. The goal is      to find single nucleotide polymorphims (SNP), small changes in single genes that affect      disease risk, to see if they correlate with lung disease.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals visiting the Medicine Department at the Hamad Medical Corporation, Qatar for        standard clinical care will be recruited.        Controls will be obtained from volunteers without a history of lung disease. Family        members of patients may be asked to participate in the study.|December 2013|December 19, 2013|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504361||169082|
NCT00504647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q2707/352|Biventricular Pacing in Hypertrophic Cardiomyopathy|Diastolic Ventricular Interaction and the Effects Of Biventricular Pacing in Hypertrophic Cardiomyopathy||University Hospital Birmingham|No|Recruiting|June 2006|August 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||July 2007|July 18, 2007|July 18, 2007||||No||https://clinicaltrials.gov/show/NCT00504647||169061|
NCT00531258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011007|TMS in the Treatment of the Sequelae of Closed Brain Injury|The Use of Non Invasive Brain Stimulation in the Treatment of the Sequelae of Closed Brain Injury||Bayside Health|No|Recruiting|October 2007|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||May 2008|May 5, 2008|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531258||167050|
NCT00527800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC- PEPFAR CoAg#U62P024421|Interactions Between HIV and Malaria in African Children|Interactions Between HIV and Malaria in African Children|TCC|University of California, San Francisco|No|Completed|August 2007|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|351|||Both|6 Weeks|9 Months|Accepts Healthy Volunteers|||October 2013|October 9, 2013|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00527800||167313|
NCT00527813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.474|Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome|Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome|Proseva|Hospices Civils de Lyon|Yes|Completed|January 2008|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|474|||Both|18 Years|N/A|No|||November 2011|May 6, 2015|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00527813||167312|
NCT00528086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00019885|A Pilot, Randomized Controlled Trial of Group Visits for Persons With Parkinson's Disease|A Single Center, Randomized Controlled, Pilot Study Comparing Group Visits Versus Routine Clinical Care for Participants With Parkinson's Disease (PD).|GROUP-PD|University of Rochester|Yes|Completed|September 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|30 Years|N/A|No|Probability Sample|Study participants will be recruited from Drs. Dorsey, Biglan, and Marshall's patient        populations from the Parkinson disease clinic at the University of Rochester Neurology        group.|May 2010|May 24, 2010|September 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00528086||167291|
NCT00528099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3192K1-1001|Study Evaluating IMA-026 in Healthy Japanese Males|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-026 Administered Subcutaneously or Intravenously to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2007|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2009|July 22, 2009|September 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00528099||167290|
NCT00528112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91665|Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study|Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years||Bayer|No|Completed|August 2007|June 2013|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2885|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2013|August 5, 2013|September 11, 2007|Yes|Yes||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00528112||167289|
NCT00528125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG-07-H-02|Laser Acupuncture for Pain Prevention in Neonates|Laser Acupuncture for Pain Prevention in Neonates Undergoing Heel Prick. A Prospective, Randomized, Double-Blinded Clinical Trial||University Children Hospital Homburg|No|Completed|September 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|28 Days|Accepts Healthy Volunteers|||March 2008|March 19, 2008|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528125||167288|
NCT00527774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0702|Effect of HCV Infection on Insulin Resistance and Malnutrition-Inflammation Complex Syndrome in Regular Hemodialysis Patients|Impact of Hepatitis C Virus Infection on Insulin Resistance and Inflammatory Biomarkers in Patients With Maintenance Hemodialysis||St. Martin De Porress Hospital|Yes|Recruiting|August 2007|September 2007|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|N/A|No|||September 2007|September 10, 2007|September 10, 2007||||No||https://clinicaltrials.gov/show/NCT00527774||167315|
NCT00527787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-301|Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen|6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers||POZEN|Yes|Completed|September 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|434|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|September 10, 2007|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00527787||167314|
NCT00529191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5-4824|Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)|Phase II, Double Blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin in Subjects With Newly Diagnosed Type 1 Diabetes Mellitus.|TIDM|Children's Hospital of Philadelphia|Yes|Completed|July 2007|July 2013|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|10 Years|19 Years|No|||October 2015|October 7, 2015|September 13, 2007|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00529191||167206|
NCT00521144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00252|Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors|Phase I/II Study of Obatoclax Mesylate (GX15-070MS), a Bcl-2 Antagonist, Plus Topotecan in Relapsed Small Cell Lung Carcinoma||National Cancer Institute (NCI)|Yes|Completed|August 2007|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2013|April 14, 2015|August 24, 2007|Yes|Yes||No|October 11, 2013|https://clinicaltrials.gov/show/NCT00521144||167816|
NCT00501345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-674|Aspirin in Patients With Myocardial Infarction and Thrombocytopenia|Effects of Aspirin on Platelet Function and Clinical Outcome in Patients With Thrombocytopenia, Neoplasm, and Myocardial Infarction||M.D. Anderson Cancer Center|No|Terminated|February 2002|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||July 2012|July 27, 2012|July 13, 2007||No|Low accrual, study terminated.|No|September 24, 2009|https://clinicaltrials.gov/show/NCT00501345||169311|A change in hospital practice where patients with thrombocytopenia now routinely receive aspirin for acute coronary syndromes makes it difficult to obtain a baseline thromboelastogram.
NCT00507234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-080|Study in Subjects Greater Than 40 Years of Age With COPD|A 6-Week Trial to Compare the Efficacy and Safety of Concomitant Treatment With Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease||Dey|Yes|Completed|March 2007|April 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|128|||Both|40 Years|N/A|No|||July 2009|November 10, 2010|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00507234||168866|
NCT00507247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0622|Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus|Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Bloodstream Infections||M.D. Anderson Cancer Center|Yes|Completed|May 2006|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||November 2014|April 6, 2015|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507247||168865|
NCT00501930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2109799|A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers|A Randomized, Placebo-Controlled, Double-Blind, Repeat Dose, Dose Escalation Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Supratherapeutic Doses of GSK189075 Administered for 3 Days in Healthy Volunteers||GlaxoSmithKline|No|Completed|April 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|July 13, 2007||||||https://clinicaltrials.gov/show/NCT00501930||169267|
NCT00507520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 235U|Almond Dose Response Study.|The Effect of Almonds on Coronary Heart Disease Risk Factors: Dose Response Study.||University of Toronto||Completed|December 1999|September 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|27|||Both|40 Years|70 Years|No|||July 2007|July 25, 2007|July 24, 2007||||No||https://clinicaltrials.gov/show/NCT00507520||168844|
NCT00507780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070193|Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy|Use of the GnRH Agonist Leuprolide Acetate (Lupron(Registered Trademark)) to Preserve Ovarian Function in Women Undergoing Chemotherapy||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2007|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|0|||Female|10 Years|21 Years|No|||July 2010|March 20, 2012|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00507780||168825|
NCT00508040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051032|Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a|Evaluation of Birdshot RETINE CHOROIDOPATHY Treatment by Either Steroid or Interferon alpha2a|BIRDFERON|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2007|January 2013|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||October 2008|January 22, 2013|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00508040||168805|
NCT00503776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0554|Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia|Randomized Pilot Trial of Chemoradiation Plus or Minus Amifostine to Assess Potential Nutritional, Inflammatory and Physical Outcomes Related to Xerostomia, Mucositis and Dysphagia||Vanderbilt-Ingram Cancer Center|Yes|Terminated|January 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|42|||Both|21 Years|N/A|No|||October 2012|October 23, 2012|July 17, 2007|Yes|Yes|funding became unavailable|No|November 3, 2011|https://clinicaltrials.gov/show/NCT00503776||169127|
NCT00503789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33715|The Effect of Infant Feeding on Stool Characteristics|The Effect of Infant Feeding on Stool Characteristics||Mead Johnson Nutrition|No|Completed|August 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|280|||Both|N/A|30 Days|Accepts Healthy Volunteers|||September 2008|September 4, 2008|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503789||169126|
NCT00504660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0600|6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients|Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma and Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Completed|September 2003|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|12 Years|N/A|No|||December 2011|December 6, 2011|July 18, 2007||No||No|December 6, 2011|https://clinicaltrials.gov/show/NCT00504660||169060|
NCT00504673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1659|Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes|Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes|PREDICTIVE™|Novo Nordisk A/S|No|Completed|April 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|277|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|July 19, 2007||||No||https://clinicaltrials.gov/show/NCT00504673||169059|
NCT00527228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274/02|Deflazacort in Dysferlinopathies|Deflazacort in Dysferlinopathies (LGMD2B/MM) - a Double Blind, Placebo-controlled Clinical Study||Ludwig-Maximilians - University of Munich|Yes|Completed|September 2003|September 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00527228||167357|
NCT00527501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-07|IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension|IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|136|||Both|18 Years|N/A|No|||February 2008|April 12, 2012|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00527501||167336|
NCT00527514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8663-402|Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension|A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension||Daiichi Sankyo Inc.|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|18 Years|N/A|No|||November 2009|November 4, 2009|September 10, 2007|Yes|Yes||No|May 5, 2009|https://clinicaltrials.gov/show/NCT00527514||167335|
NCT00527527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0401|Chiropractic Dosage for Lumbar Stenosis|Chiropractic Dosage for Lumbar Stenosis||National University of Health Sciences|Yes|Completed|September 2007|||January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|50 Years|N/A|No|||October 2011|October 7, 2011|September 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00527527||167334|
NCT00527826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO107227|Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV|A 12 Month Open-label Randomized Parallel Group Study to Investigate the Influence of Salmeterol Xinafoate/Fluticasone Propionate Either in Fixed Combination or Separately Via Diskus Inhalers on the Course of the Disease and Frequency of Exacerbations in Subjects With Severe and Very Severe COPD.||GlaxoSmithKline||Completed|November 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|214|||Both|40 Years|N/A|No|||October 2012|October 25, 2012|September 10, 2007||No||No|March 10, 2010|https://clinicaltrials.gov/show/NCT00527826||167311|
NCT00519701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3297|Hydroxyurea in Young Children With Sickle Cell Anemia|Effects of Hydroxyurea on the Prevention of Chronic Organ Damage in Young Children With Sickle Cell Anemia||Duke University|No|Completed|April 2002|February 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Months|5 Years|No|||August 2007|August 22, 2007|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00519701||167926|
NCT00519714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNAI-MNA-001|A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)||Montreal Heart Institute|No|Completed|September 2007|November 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|195|||Both|18 Years|N/A|No|||January 2009|June 18, 2010|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519714||167925|
NCT00528632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-0012-09-07|Gallbladder Cholesterolosis, Body Mass Index and Serum Cholesterol and Triglycerides|Association of Gallbladder Cholesterolosis to Body Mass Index and Levels of Serum Cholesterol and Triglycerides.||Cirujanos la Serena|No|Completed|March 2008|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|406|||Both|15 Years|N/A|No|Non-Probability Sample|Patients operated on elective basis for symtomatic gallbladder lithiasis|July 2009|August 9, 2011|September 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00528632||167249|
NCT00528385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-4/RAAS/02|Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System|Influence of Adding Aldosterone Receptor Blocker to Dual Renin-Angiotensin-Aldosterone System Blockade on Proteinuria||Medical University of Gdansk||Completed|March 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||September 2007|September 11, 2007|September 11, 2007||||No||https://clinicaltrials.gov/show/NCT00528385||167268|
NCT00520247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005L01101|Effect of Enalapril Plus Folic Acid on Blood Pressure and Glycometabolism|Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial||Anhui Medical University|Yes|Completed|September 2005|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|443|||Both|28 Years|75 Years|No|||August 2007|August 22, 2007|August 17, 2007||||No||https://clinicaltrials.gov/show/NCT00520247||167884|
NCT00528645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01831|AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer|Phase II Study of the c-SRC Inhibitor AZD0530 After Four Cycles of Cytoreductive Chemotherapy for Patients With Extensive Stage Small Cell Lung Carcinoma||National Cancer Institute (NCI)||Completed|November 2007|May 2013|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2012|May 29, 2014|September 10, 2007|Yes|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00528645||167248|
NCT00520624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-EIL-07-ELITE|Treatment of Exercise-induced Laryngomalacia in Elite Athletes||EIL|Bispebjerg Hospital|No|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Anticipated|95|||Both|12 Years|N/A|No|||November 2013|November 5, 2013|August 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00520624||167855|
NCT00520676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11626|Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer|A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|October 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|August 22, 2007|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00520676||167851|
NCT00520689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/264/07/M|Multipurpose Disinfecting Solution Compatibility With a Silicone Hydrogel Contact Lens|Multipurpose Solution Compatibility With a Silicone Hydrogel Lens|Amethyst|University of Waterloo|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|25|||Both|17 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520689||167850|
NCT00520923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11757|A Study for Patients With Schizophrenia|A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia||Eli Lilly and Company|No|Completed|September 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|654|||Both|18 Years|65 Years|No|||October 2009|October 16, 2009|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520923||167833|
NCT00520897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|038-00|Integrase Inhibitor (MK-0518) Viral Decay|Effect of Integrase Inhibitor (MK-0518) on Decay of Low Level Viral Replication in HIV Reservoirs in Infected Individuals Who Initiated Conventional Antiretroviral Therapy During the Chronic Phase of Infection||Canadian Immunodeficiency Research Collaborative||Completed|April 2007|November 2011|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||June 2012|June 4, 2012|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00520897||167835|
NCT00520910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070203|Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing Ultraviolet A (UVA) Premutagenic and Photoaging Markers|Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers|Heliocare|University of Miami|No|Active, not recruiting|August 2007|May 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|October 18, 2010|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00520910||167834|
NCT00501358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEP-SAHS|Sleep Apnea and Tromboembolic Disease|Assessment of Sleep Apnea Syndrome as a Risk Factor for Venous Thromboembolism||Sociedad Española de Neumología y Cirugía Torácica|Yes|Recruiting||||||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|N/A|N/A||||July 2007|July 13, 2007|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00501358||169310|
NCT00501683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2105264|A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers|A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects||GlaxoSmithKline|No|Completed|November 2006|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|8|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|July 13, 2007||||||https://clinicaltrials.gov/show/NCT00501683||169286|
NCT00502502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANS02-495|Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients|Feasibility Study of the Assessment of Symptom-Related Cytokines in Lung and GI Cancer Patients Undergoing Chemoradiation Therapy||M.D. Anderson Cancer Center|No|Completed|November 2002|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|205|Samples With DNA|Blood samples will be collected to study the levels of cytokines in your blood.|Both|18 Years|N/A|No|Non-Probability Sample|Study participants with lung, esophageal, gastric, colorectal or anal cancer.|July 2012|July 18, 2012|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502502||169224|
NCT00502775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFU109047|Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine|A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis||GlaxoSmithKline|No|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|680|||Both|12 Years|N/A|No|||June 2015|June 15, 2015|July 17, 2007|||||November 17, 2008|https://clinicaltrials.gov/show/NCT00502775||169203|
NCT00502788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503|Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)|Thalassemia Clinical Research Network - Hepatitis C Clinical Trial|HepC|New England Research Institutes|Yes|Completed|May 2003|August 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|44 Years|No|||March 2014|March 3, 2014|July 16, 2007|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00502788||169202|
NCT00503477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00023|A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan|A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies||AstraZeneca|Yes|Completed|October 2005|January 2009|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|75 Years|No|||June 2009|June 11, 2009|July 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00503477||169150|
NCT00503828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siriraj CEU 50-001|Derris Scandens Benth Extract VS Naproxen in Knee OA|The Efficacy and Safety of Derris Scandens Benth Extract and Naproxen for Therapy of Patients With Knee Osteoarthritis||Mahidol University|Yes|Completed|July 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|120|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2009|January 11, 2010|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00503828||169123|
NCT00507793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E1-4351|Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus|An Open-Label Study to Evaluate the Efficacy and Safety of Cyclosporine Reduction in de Novo Renal Allograft Recipients Receiving Sirolimus: a Dose Comparative Study||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|April 2000|June 2002|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|385|||Both|18 Years|N/A|No|||July 2007|July 26, 2007|July 26, 2007||||No||https://clinicaltrials.gov/show/NCT00507793||168824|
NCT00503841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000554965|Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer|A Pilot Study of the Effect of Erlotinib (Tarceva®) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1α||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|December 2007|May 2010|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||March 2013|March 27, 2013|July 17, 2007|Yes|Yes|All enrolled participants were screen failures, no data were collected for outcome measures.|No|January 9, 2013|https://clinicaltrials.gov/show/NCT00503841||169122|
NCT00508053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Millbourn|When Closing Midline Incisions, do Small Stitches Reduce the Risk for Incisional Hernia, Wound Infection or Dehiscence?|||Sundsvall Hospital|No|Completed|January 2001|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|737|||Both|18 Years|N/A|No|||July 2007|July 27, 2007|July 25, 2007||||No||https://clinicaltrials.gov/show/NCT00508053||168804|
NCT00527241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U49CE000508|Efficacy Trial of Raices Nuevas|Efficacy Trial of Raices Nuevas||Centers for Disease Control and Prevention|No|Completed|November 2006|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|160|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00527241||167356|
NCT00527254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TeleDiabecom 200501|Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient|||Province of Malaga Health Department|No|Completed|October 2003|June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|328|||Both|30 Years|N/A|No|||September 2007|September 7, 2007|September 7, 2007||||No||https://clinicaltrials.gov/show/NCT00527254||167355|
NCT00518817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrasher|The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy|||Baylor College of Medicine|No|Not yet recruiting|August 2007|August 2009|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|60|||Both|1 Month|65 Years|No|||August 2007|August 20, 2007|August 17, 2007||||No||https://clinicaltrials.gov/show/NCT00518817||167994|
NCT00519103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lundberg-1|Resistance Exercise Reduces the Expression of Inflammation and Fibrosis Associated Genes in Autoimmune Myositis Patients|||Karolinska Institutet|No|Completed|December 2002|March 2003|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|80 Years|No|||August 2007|August 29, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00519103||167972|
NCT00519740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214/06/FFM|Influence of Nutrition on Nasal and Bronchial Affliction in Patients With Allergy on Grass-Pollen|Influence of Nutrition on Nasal and Bronchial Affliction in Patients With Allergy on Grass-Pollen After Low-Dosed Specific Bronchial Provocation||Johann Wolfgang Goethe University Hospitals|Yes|Completed|August 2006|December 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 3, 2009|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00519740||167923|
NCT00519753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMS-06-12|Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav|Safety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany||Alcon Research|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|522|||Both|18 Years|N/A|No|||January 2010|April 17, 2012|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00519753||167922|
NCT00519467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-714703/003|Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria|An Open, Randomised, Multi-Centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate||GlaxoSmithKline||Completed|June 2003|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|120|||Both|18 Years|60 Years|No|||August 2007|August 21, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00519467||167944|
NCT00519974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-087|Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women|Decision-Making About Breast Reconstruction After Mastectomy Among Ethnic Minority Women: An Exploratory Study of Qualitative Themes||Memorial Sloan Kettering Cancer Center||Completed|July 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Female|18 Years|N/A|No|Non-Probability Sample|Black and Latina female breast cancer patients who have undergone or scheduled to undergo        mastectomy within the past 3 years will be identified by their physicians (e.g., medical        oncologists, breast surgeon, plastic surgeon) at MSKCC and RLCCCP or by the advocacy        center to which they belong.|September 2015|September 29, 2015|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519974||167905|
NCT00519987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-PK-002|Multiple Dose Pharmacokinetics of Intranasal Ketamine|An Open Label, Single Center Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Administrations of 30 mg PMI-150 (Intranasal Ketamine) in Healthy Adult Volunteers||Javelin Pharmaceuticals|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 9, 2008|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00519987||167904|
NCT00520260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sch012007|Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase|Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients||Florida Eye Microsurgical Institute|Yes|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||February 2009|February 17, 2009|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00520260||167883|
NCT00520273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000487|A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA|A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA||Hoffmann-La Roche||Completed|August 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|March 1, 2016|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520273||167882|
NCT00520637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2208-01|A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)|A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 (PEG-SN38) Administered Every 3 Weeks in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)||Enzon Pharmaceuticals, Inc.||Completed|May 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label||||34|||Both|18 Years|N/A||||October 2009|October 8, 2009|August 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520637||167854|
NCT00521183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20057104|Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain|Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With External Brain Radiation for Metastatic Carcinoma to the Brain||University of Miami|Yes|Completed|June 2007|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|21 Years|N/A|No|||November 2014|November 24, 2014|August 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00521183||167813|
NCT00520936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10294|A Study of Pemetrexed in Children With Recurrent Cancer|A Phase II Study of Pemetrexed in Children With Recurrent Malignancies||Eli Lilly and Company|Yes|Completed|September 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|N/A|22 Years|No|||February 2011|February 23, 2011|August 24, 2007|Yes|Yes||No|February 1, 2011|https://clinicaltrials.gov/show/NCT00520936||167832|
NCT00506636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561705025|Tissue Engineering for Hair Follicle Regeneration|Study of Tissue Engineering for Hair Follicle Regeneration||National Taiwan University Hospital|Yes|Recruiting|May 2006|December 2016|Anticipated|||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional|||Anticipated|400|||Both|18 Years|60 Years|No|||May 2006|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506636||168912|
NCT00506649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Improved ICU Outcomes With Protocolized Management of Analgesia, Sedation and Delirium|Comparison of no Protocol vs Protocolized Approach to Pain, Sedation and Delirium Management in the ICU||Maisonneuve-Rosemont Hospital|No|Completed|August 2003|November 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|1214|||Both|18 Years|N/A|No|||July 2007|July 23, 2007|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00506649||168911|
NCT00506662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1808|Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes|The Effect of Insulin Detemir on Glucose Control in Ageing Subjects With Type 2 Diabetes.|3L|Novo Nordisk A/S|No|Terminated|July 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|70 Years|N/A|No|||June 2012|June 26, 2012|July 24, 2007|Yes|Yes|See termination reason in detailed description|No|October 19, 2010|https://clinicaltrials.gov/show/NCT00506662||168910|Trial terminated prematurely due to low recruitment, and thus it was not possible to assess efficacy in this trial due to the small number of patients in each treatment group.
NCT00506948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0435|Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)|Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Terminated|September 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|75 Years|No|||January 2014|January 7, 2014|July 20, 2007||No|Halted due to high incidence of veno-oclusive disease of the liver.|No|January 7, 2014|https://clinicaltrials.gov/show/NCT00506948||168888|A decision to terminate this trial was made due to the high incidence of veno-occlusive disease of the liver in participants receiving this graft-versus-host disease (GVHD) prophylaxis regimen.
NCT00507507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-203-0101|A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)|A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B||Gilead Sciences|Yes|Completed|September 2007|August 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|69 Years|No|||July 2015|July 7, 2015|July 25, 2007|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00507507||168845|
NCT00503854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0936|Fatigue and Symptom Burden in Febrile Neutropenia|Fatigue and Symptom Burden in Febrile Neutropenia||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2007|||May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with solid tumors at low risk for outpatient treatment of febrile neutropenia.|February 2016|February 18, 2016|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00503854||169121|
NCT00504101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20070104|Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma|Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma||University of Miami Sylvester Comprehensive Cancer Center|Yes|Withdrawn|June 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||August 2013|July 25, 2014|July 17, 2007|No|Yes|Temporarily closed to accrual pending availablity of drug.|No||https://clinicaltrials.gov/show/NCT00504101||169102|
NCT00504374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0273|Gene Polymorphisms and Symptoms in Lung Cancer Patients|Gene Polymorphisms and Symptoms in Lung Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2006|||June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|320|Samples With DNA|Leftover blood sample to look at certain genes in your blood that may affect your symptoms.      If you did not have blood collected in the previous lung cancer study, you will have a blood      sample (one tablespoon) drawn when you first agree to participate in this study.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with lung cancer.|February 2016|February 1, 2016|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504374||169081|
NCT00504985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0266|Fatigue in Emergency Center Patients|Fatigue and Its Symptom Cluster Related to Inflammatory Cytokine Profiles in Cancer Patients Seeking Emergency Care||M.D. Anderson Cancer Center|No|Terminated|August 2005|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|Samples Without DNA|About 1 tablespoon of blood drawn for cytokine testing.|Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients admitted to the UT MD Anderson Cancer Center Emergency Center who are        seeking emergency care for fever, pain, shortness of breath, or cancer therapy-related        gastrointestinal toxicities.|July 2012|July 26, 2012|July 18, 2007||No|Low Accrual|No|March 26, 2010|https://clinicaltrials.gov/show/NCT00504985||169036|Early termination led to small numbers of subjects, too little data to analyze.
NCT00504998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-105|Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer|Phase I/II Evaluation of Safety and Efficacy of Rexin-G for Recurrent or Metastatic Pancreatic Cancer||Epeius Biotechnologies|Yes|Completed|July 2007|June 2011|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|N/A|No|||February 2010|June 9, 2011|July 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00504998||169035|
NCT00526981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/733-31/1-4|Prone Position for Non-intubated Patients With Acute Respiratory Failure|Prone Position for Non-intubated Patients With Acute Respiratory Failure||Karolinska University Hospital|No|Recruiting|September 2007|||December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526981||167376|
NCT00519116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E1-100539|Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients|An Open-Label, Concentration-Controlled, Randomized, 6-Month Study of 'Standard Dose' Tacrolimus + Sirolimus + Corticosteroids Compared to 'Reduced-Dose' Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2000|August 2001||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||150|||Both|18 Years|N/A|No|||August 2007|August 20, 2007|July 27, 2007||||No||https://clinicaltrials.gov/show/NCT00519116||167971|
NCT00518856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-A-00-03-00020-00-4|Lufwanyama Neonatal Survival Project|Lufwanyama Neonatal Survival Project|LUNESP|Boston University|No|Completed|September 2006|July 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3559|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|March 29, 2011|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518856||167991|
NCT00519142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-1510-CT-003|Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus|A Rapid Onset and Short Duration Insulin Secretogogue, Mitiglinide, in Combination With Metformin Versus Metformin Alone in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial for 6 Months||Elixir Pharmaceuticals|No|Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|367|||Both|18 Years|75 Years|No|||September 2009|September 16, 2009|August 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00519142||167969|
NCT00519766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1392|Examining a New Biomarker of Nicotine Use Among Pregnant Women Who Participated in the New England SCRIPT|Assessment of Nicotine Metabolism Among Underserved Pregnant Women From NE SCRIPT|SCRIPT|Memorial Hospital of Rhode Island|No|Completed|September 1997|November 2002|Actual|March 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|252|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 22, 2014|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519766||167921|
NCT00519792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 638-CLP-08|Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment|Phase Ib Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Omega DUROS® and Ribavirin in Subjects With Chronic Hepatitis C Previously Treated With Pegylated Interferon and Ribavirin||Intarcia Therapeutics|No|Completed|August 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||June 2011|June 6, 2011|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00519792||167919|
NCT00520000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0412|Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Trial of Carboplatin and Abraxane in Patients With Solid Tumors||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|December 2004|September 2007|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00520000||167903|
NCT00520286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CSP-1026-1|Ph2 Modafinil Meth - 1|Phase2, Double-blind, Placebo-controlled Trial of Modafinil for the Treatment of Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)|Yes|Completed|December 2007|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 24, 2011|August 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520286||167881|
NCT00520299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2005-007|Phase I/II Study of ADI-SS PEG 20,000mw in Patients With Advanced Metastatic Melanoma|Phase I/II Study of ADI-SS PEG 20,000mw in Patients With Advanced Metastatic Melanoma||Ludwig Institute for Cancer Research|No|Completed|July 2007|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|August 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520299||167880|
NCT00520650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-06-P01|Health Evaluation of Abilify Long-term Therapy|Health Evaluation of Abilify Long-term Therapy|HEALTH|Taiwan Otsuka Pharm. Co., Ltd|No|Completed|August 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|245|||Both|18 Years|65 Years|No|||December 2009|December 15, 2009|August 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00520650||167853|
NCT00520663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXS109139|Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug|An Open-label Study to Determine the Excretion, Balance and Pharmacokinetics of SB649868 After a Single Oral Administration of 14C-SB649868 in Healthy Volunteers||GlaxoSmithKline|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|8|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|August 23, 2007||||No||https://clinicaltrials.gov/show/NCT00520663||167852|
NCT00521794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5301|Characteristics of Andersen-Tawil Syndrome|Andersen-Tawil Syndrome: Genotype-Phenotype Correlation and Longitudinal Study||University of Rochester|Yes|Completed|November 2007|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|Samples With DNA|Blood samples|Both|10 Years|N/A|No|Non-Probability Sample|Individuals with a clinically confirmed diagnosis of Andersen-Tawil Syndrome (ATS)        enrolled across seven sites in the United States, England, Italy and Canada|January 2013|January 15, 2013|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521794||167767|
NCT00517426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R77-CCM S79/407|Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure|||Centro Cardiologico Monzino|No|Completed|July 2007|August 2012|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|August 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517426||168100|
NCT00517439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV19865|A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.|A Randomized, Double-blinded Study to Evaluate the Safety and Effect on Sustained Virological Response of HCV Polymerase Inhibitor Pro-drug in Combination With PEGASYS Plus Copegus, Compared With the Currently Approved Combination of PEGASYS Plus Copegus, in Treatment-naïve Patients With Chronic he||Hoffmann-La Roche||Completed|December 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|516|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|August 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517439||168099|
NCT00521521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX_FR1_236|Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer|A Multicenter, Randomized, Phase II Study of the Combination of Docetaxel (TAXOTERE) and Concomitant Radiotherapy With or Without Cisplatin in Patients With Locally Advanced Head and Neck Cancer|TAX200006|Sanofi|No|Completed|July 2001|||May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|70 Years|No|||December 2009|December 4, 2009|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521521||167788|
NCT00521534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02345|Impact of Resynchronization Therapy on Sleep Disordered Breathing in Advanced Congestive Heart Failure|Impact of Resynchronization Therapy on Sleep Disordered Breathing in Advanced Congestive Heart Failure|IMPACT|VA Pittsburgh Healthcare System|No|Completed|March 2006|November 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the electrophysiology service of the VAPHS for CRT implant are        eligible.|September 2012|September 17, 2012|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521534||167787|
NCT00507273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0294|Gastrointestinal Stromal Tumors (GIST) Registry|Gastrointestinal Stromal Tumors (GIST) Registry Protocol: reGISTry||M.D. Anderson Cancer Center|No|Completed|August 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1800|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with a gastrointestinal stromal tumor (GIST).|August 2012|August 1, 2012|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00507273||168863|
NCT00507546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6010-R|Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia|Melatonin Replacement for Treatment of Sleep Disruption||VA Office of Research and Development|No|Completed|July 2007|July 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|July 25, 2007|Yes|Yes||No|September 13, 2013|https://clinicaltrials.gov/show/NCT00507546||168842|
NCT00507533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAP-2-H|Early Application of CPAP in Hematologic|Early Application of CPAP in Hematologic Neutropenic Patients Avoid Acute Respiratory Failure|HEMOCPAP|University of Turin, Italy|Yes|Completed|October 2005|||November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|80 Years|No|||February 2009|February 17, 2009|July 25, 2007||||No||https://clinicaltrials.gov/show/NCT00507533||168843|
NCT00507260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0515|Nutritional Assessment Intervention to Improve Cancer-Related Fatigue|A Pilot Study to Evaluate a Nutritional Assessment Intervention to Improve Cancer-Related Fatigue Among Post-Allogeneic Blood and Marrow Transplantation Recipients||M.D. Anderson Cancer Center|Yes|Completed|September 2006|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|July 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00507260||168864|
NCT00504387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/036/06|Burning Mouth Disorder (BMD) - A Neuropathic Pain Disorder|Burning Mouth Disorder (BMD) - a Neuropathic Pain Disorder? An Investigation Using Qualitative and Quantitative Sensory Testing (QST)||Charite University, Berlin, Germany|No|Recruiting|April 2007|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Tertiary care clinic|December 2012|December 20, 2012|July 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00504387||169080|
NCT00504114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01AR046905|MR Imaging of Knee Osteoarthritis and Acute Knee Injuries|MR Imaging of Knee Osteoarthritis and Acute Knee Injuries||University of California, San Francisco|No|Completed|August 2006|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|139|Samples Without DNA|Bone/cartilage tissue will be collected after the total knee replacement surgery. The tissue      will further studied using advanced MR imaging techniques.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment flyers are posted at different UCSF campuses and those staff and students.        Patient eligibility will determined initially bye the referring orthopedist.|December 2013|December 11, 2013|July 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00504114||169101|
NCT00502320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-006R|Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder|Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder|SAM-SAD|Lehigh Valley Hospital|No|Completed|September 2006|July 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||October 2009|October 2, 2009|July 13, 2007|Yes|Yes||No|July 21, 2009|https://clinicaltrials.gov/show/NCT00502320||169238|
NCT00502593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107066|Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children|A Phase II, Randomized, Open, Controlled Study to Evaluate the Safety and Immunogenicity of Different Formulations of a Pandemic Influenza Vaccine Candidate (Split Virus Formulation Adjuvanted With AS03) Given Following a Two-administration Schedule (21 Days Apart) in Children Between 3 and 9 Years of Age.||GlaxoSmithKline|No|Completed|July 2007|April 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|12||Actual|138|||Both|3 Years|9 Years|Accepts Healthy Volunteers|||April 2014|May 1, 2014|July 16, 2007|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00502593||169217|
NCT00502606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191061HMO-CTIL|a Clinical Study.the Effect of Addition of Insoluble Antibacterial Nanoparticles(IABN) in Resin Base Provisional Cement|Clinical Study :The Effect of Antibacterial Nanoparticles, Incorporated in Provisional Resin Based Cement, on S.Mutans in the Margins of Provisional Restorations|IABN|Hadassah Medical Organization|No|Active, not recruiting|February 2007|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|hadassah dental patients|October 2009|January 5, 2010|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502606||169216|
NCT00519129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF-Colon-1|Improving Quality of Colonoscopy Using a 3D-imager|Magnetic Endoscopic Imaging Versus Standard Colonoscopy in a Routine Colonoscopy Setting: A Randomised Controlled Trial||Sorlandet Hospital HF|Yes|Completed|August 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 17, 2011|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519129||167970|
NCT00518557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMCERE-123456|Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis|Combination Treatment of TACE With Recombinant Human Endostatin Administrated Via Hepatic Artery in Hepatocellular Carcinoma|TACE HCC|Southeast University, China|Yes|Recruiting|April 2007|December 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2009|January 21, 2009|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00518557||168014|
NCT00519181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-SO-2006-17|Safety and Efficiency Study of Valproic Acid In HAM/TSP|Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP|VALPROHAM|University Hospital Pierre Zobda-Quitman|Yes|Terminated|March 2006|June 2007|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|80 Years|No|||August 2007|August 20, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00519181||167966|
NCT00519428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5476|Does Dual Therapy Hasten Antidepressant Response?|Combining Antidepressants to Hasten Remission From Depression||New York State Psychiatric Institute|Yes|Completed|August 2007|March 2012|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|245|||Both|18 Years|65 Years|No|||June 2012|June 26, 2012|August 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00519428||167947|
NCT00519441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104802|Do Patients Who Have Had Surgery for Achalasia Suffer From Reflux|Gastroesophageal Reflux in Patients With Achalasia||University of South Florida|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519441||167946|
NCT00519727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 325568-CS1|Safety Study of ISIS 325568 in Healthy Volunteers|A Phase I, Double-Blind, Placebo-Controlled, Dose- Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 325568 Administered to Healthy Volunteers||Ionis Pharmaceuticals, Inc.|No|Completed|August 2007|June 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 15, 2008|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519727||167924|
NCT00519155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scil-MD05-C02|Pilot Study on MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery|Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects||Scil Technology GmbH|No|Active, not recruiting|July 2007|November 2008|Anticipated|October 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||April 2008|April 21, 2008|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519155||167968|
NCT00520026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKZ 01 GI9920 / 01 GI0220|Suicide Prevention by Lithium - the Lithium Intervention Study||SUPLI|University of Schleswig-Holstein|No|Terminated|January 2001|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|167|||Both|18 Years|N/A|No|||August 2007|August 22, 2007|August 22, 2007|||number of enrolled individuals after 5 years still off the estimated sample size|No||https://clinicaltrials.gov/show/NCT00520026||167901|
NCT00519779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003912-01A1|Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention|Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention||National Center for Complementary and Integrative Health (NCCIH)|No|Completed|July 2007|December 2010|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|March 22, 2012|August 21, 2007|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00519779||167920|
NCT00520013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-039|Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors|A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors||Dana-Farber Cancer Institute|Yes|Completed|August 2007|November 2013|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|N/A|No|||June 2015|June 11, 2015|August 22, 2007|Yes|Yes||No|April 8, 2015|https://clinicaltrials.gov/show/NCT00520013||167902|
NCT00520312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1396|Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease|Magnetic Resonance in Peripheral Arterial Disease||Northwestern University|Yes|Completed|October 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|519|Samples With DNA|Plasma, serum, and whole blood samples are stored for future analysis|Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Ankle Brachial Index less than 1 in participants|April 2014|April 7, 2014|August 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00520312||167879|
NCT00520325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2232-03|A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia|A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia||Enzon Pharmaceuticals, Inc.||Withdrawn|June 2007|August 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|17 Years|No|||February 2009|September 4, 2012|August 23, 2007|No|Yes|Sponsor decision to terminate the study|No||https://clinicaltrials.gov/show/NCT00520325||167878|
NCT00521807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26035831907|Hypnosis as a Treatment of Chronic Widespread Pain in General Practice. A Pilot Study.|||University of Oslo|No|Completed|March 2001|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A||||August 2007|October 17, 2008|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00521807||167766|
NCT00507559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01|The Pivotal Study of the Aptus Endovascular AAA Repair System|The Pivotal Study of the Aptus Endovascular AAA Repair System|STAPLE-2|Aptus Endosystems|Yes|Active, not recruiting|September 2007|March 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|21 Years|N/A|No|||February 2012|February 14, 2012|July 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00507559||168841|
NCT00503503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881Y1-4460|Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan|Safety and Efficacy From Large Scale All Cases Surveillance for Etanercept in Japan||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2005|October 2007|Actual|October 2007|Actual|Phase 4|Observational|Time Perspective: Prospective|||||||Both|11 Years|90 Years|No|||December 2007|December 20, 2007|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00503503||169148|
NCT00507832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST-Pr-2-2005|Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease|Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease|CASM981CDE21|University Hospital Muenster|Yes|Completed|April 2007|October 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||February 2009|July 6, 2010|July 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00507832||168821|
NCT00503867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STX 0106|SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma|A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma||Sirtex Medical|Yes|Terminated|May 2008|June 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|July 18, 2007|Yes|Yes|low patient recruitment|No||https://clinicaltrials.gov/show/NCT00503867||169120|
NCT00507806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-815-401|Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke|Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke||ImaRx Therapeutics|Yes|Terminated|March 2005|May 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||July 2007|July 25, 2007|July 25, 2007|||for administrative reasons|No||https://clinicaltrials.gov/show/NCT00507806||168823|
NCT00507819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2007-4-5034|Sildenafil After the Fontan Operation|The Sildenafil After Fontan Operation Study|SAFO|Children's Hospital of Philadelphia|No|Completed|December 2007|July 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|8 Years|40 Years|No|||May 2015|May 4, 2015|July 25, 2007|Yes|Yes||No|February 9, 2011|https://clinicaltrials.gov/show/NCT00507819||168822|Characteristics of screened but not enrolled subjects was not evaluated, so enrolled subjects may not be a representative sample from the group at large. Safety of Sildenafil over a prolonged (>6week) period of continuous use was not evaluated.
NCT00505323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00100-53|Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Palliadal Lesion : Evaluation of Safety and Effectiveness|Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Pallidal Lesion : Evaluation of Safety and Effectiveness|CORDYS|University Hospital, Clermont-Ferrand||Completed|September 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||July 2014|July 4, 2014|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00505323||169012|
NCT00504686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 06-14|Patients With Neck Pain Likely to Benefit From Thoracic Spine Thrust Mobilization|Validation of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Thoracic Spine Thrust Mobilization: A Randomized Clinical Trial||Franklin Pierce University|No|Completed|January 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||February 2009|February 2, 2009|July 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00504686||169058|
NCT00501514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 96-0870-001|Effects of Growth Hormone on Exercise Capacity|Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients With Chronic Heart Failure||Federico II University|Yes|Completed|November 1997|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||January 2009|January 28, 2009|July 12, 2007||||No||https://clinicaltrials.gov/show/NCT00501514||169299|
NCT00502047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAN-EC-HIPERL-02|Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia|Multicentre, Comparative, Double-Blind, Two-Arm Parallel Clinical Trial of the Effects of Treatment With Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia||Rottapharm Spain|No|Completed|September 2005|July 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|255|||Both|20 Years|N/A|No|||July 2007|July 16, 2007|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502047||169258|
NCT00502060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00004|Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer|A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer||AstraZeneca|Yes|Completed|August 2004|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|65|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|July 13, 2007||||No||https://clinicaltrials.gov/show/NCT00502060||169257|
NCT00518570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levetiracetam and PMDD|Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)|A Pilot Study: Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder|pmdd|Berkshire Health Systems|No|Completed|November 2003|October 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2007|August 17, 2007|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00518570||168013|
NCT00519493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061027|A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids|A Two Part Study: An Investigator-initiated, Single-center, Single-blinded, Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids||University of Miami|No|Active, not recruiting|August 2007|March 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|12 Years|N/A|No|||June 2008|October 18, 2010|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519493||167942|
NCT00519506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN/US-002-II-PE|A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli|A Phase II Study to Evaluate the Efficacy of Anti-Fibrin Humanized Monoclonal Antibody(DI-DD3B6/22-80B3) Fab' Fragment (ThromboView®) Conjugated With Technetium-99m in the Detection of Pulmonary Emboli||Agen Biomedical|No|Completed|September 2007|October 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|18 Years|N/A|No|||April 2009|April 12, 2009|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00519506||167941|
NCT00519168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0013|Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival|Sleep, Circadian, Hormonal Dysregulation, and Breast Cancer Survival||Stanford University|Yes|Active, not recruiting|September 2006|August 2017|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|125|Samples Without DNA|Saliva and blood|Female|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|women with breast cancer|May 2013|May 31, 2013|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519168||167967|
NCT00519454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-024|Estrogen and Gender Biased Autoimmunity|Estrogen and Gender Biased Autoimmunity in Systemic Lupus Erythematosus||The Center for Rheumatic Disease, Allergy, & Immunology|No|Recruiting|April 2005|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female subjects with SLE and still cycling, not on hormones, compared to normal controls,        female subjects still cycling, also not on hormones and not diagnosed with SLE.|September 2010|September 3, 2010|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519454||167945|
NCT00520351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/265/07/L|Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)|Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)||University of Waterloo|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|17 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 20, 2010|August 21, 2007|No|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00520351||167876|
NCT00520364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502007757|In Vitro Fertilization and Pregnancy After Use of Chemotherapy|||New York Medical College|No|Enrolling by invitation|September 2014|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|Samples Without DNA|serum|Female|18 Years|42 Years|No|Non-Probability Sample|Infertile women|September 2014|September 25, 2014|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520364||167875|
NCT00520338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 117/2007|Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial|Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial||Mahidol University|No|Completed|August 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2010|November 6, 2010|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520338||167877|
NCT00520702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0222|3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy|A Randomized Trial to Compare Time to Common Toxicity Criteria for Adverse Effect (CTC AEC) 3.0 Grade. 3 Treatment Related Pneumonitis (TRP) in Patients With Locally Advanced Non-Small Cell Lung Carcinoma (NSCLC) Receiving Concurrent Chemoradiation Radiation Treated With 3-Dimensional Conformal Radiation Therapy (3D CRT, ARM 1) Versus Intensity Modulated Radiation Therapy (IMRT, ARM 2) Using 4-Dimensional CT Planning and Image Guided Adaptive Radiation Therapy (IGART)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2007|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|168|||Both|18 Years|80 Years|No|||September 2015|September 30, 2015|August 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520702||167849|
NCT00520949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-Med|Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection|Quadruple Therapy Using Esomeprazole, Colloidal Bismuth Subcitrate, Amoxicillin-Clavulanate, and Furazolidone in Patients Who Failed to Eradicate H. Pylori With Triple Therapy|QT-Hp|Aga Khan University|Yes|Completed|October 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|176|||Both|18 Years|70 Years|No|||April 2009|April 7, 2009|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00520949||167831|
NCT00521469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0750805694|A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control|A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control||Logan College of Chiropractic||Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|||||||Both|18 Years|60 Years||||August 2007|October 16, 2008|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521469||167792|
NCT00521196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000145|Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)|Phase 2 Study of the Effect of Transcranial Direct Current Stimulation (tDCS) on Pain and Headache Frequency in Migraine.||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|July 2007|June 2008|Anticipated|June 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|65 Years|No|||December 2008|December 1, 2008|August 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00521196||167812|
NCT00521495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003293|Carpal Tunnel Syndrome and Static Magnetic Field Therapy|Carpal Tunnel Syndrome and Static Magnetic Field Therapy|CTS/SMF|National College of Natural Medicine|No|Active, not recruiting|September 2006|August 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||November 2009|November 23, 2009|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521495||167790|
NCT00521508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608118|Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy|Role of CD4+CD25+FoxP3+ Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|April 2008|September 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2010|September 28, 2010|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521508||167789|
NCT00517478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98/07|Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI|||Assaf-Harofeh Medical Center|No|Not yet recruiting|August 2007|February 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|50|||Both|18 Years|88 Years|No|||July 2007|August 16, 2007|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517478||168096|
NCT00517751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSS-006-COA|Condition of Approval Study|Treatment of Lumbar Spinal Stenosis With X-STOP® PEEK Spacer in Moderately Symptomatic Patients|COAST|Medtronic Spine LLC|No|Terminated|August 2007|April 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|176|||Both|50 Years|N/A|No|||January 2016|January 14, 2016|August 15, 2007||No|Due to Medtronic's voluntary withdrawal of PMA P040001 for X-STOP systems; post-approval study    costs outweighed business benefits for marketing X-STOP in US.|No|December 1, 2015|https://clinicaltrials.gov/show/NCT00517751||168075|Study strengths include collection of 5-year data and radiographic examinations. Study weaknesses include single-arm design and early termination of the study without reaching the desired sample size.
NCT00503516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO-EC-DEM-02|Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients|Multicenter, Double Blind, Randomized, Clinical Trial, Controlled With Placebo, to Evaluate the Effect of the Treatment With 320 mg/Day of Megestrol Acetate During 24 Weeks in the Weight Loss in Mixed Dementia Patients.||Rottapharm Spain|No|Terminated|June 2007|February 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|65 Years|95 Years|No|||June 2011|June 7, 2011|July 17, 2007||No|Difficulties to recruit the patients following the inclusion criteria|No||https://clinicaltrials.gov/show/NCT00503516||169147|
NCT00503880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032-07|Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes|A Dose Escalation Phase I/II Study of Clofarabine Plus Cytarabine With Growth Factor Priming in Patients Who Are Not Felt to be Candidates for More Aggressive Treatment, With Int-2 and High-Risk MDS||University of Nebraska||Terminated|May 2007|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|19 Years|N/A|No|||February 2011|February 3, 2011|July 17, 2007|No|Yes|Funding|No||https://clinicaltrials.gov/show/NCT00503880||169119|
NCT00503490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpex-203|Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis|Phase I, Single and Multi-Dose, Placebo Controlled, Randomized, Dose-Escalation Study to Evaluate the Safety, Tolerability and PK Profile of MP-376 Using the PARI eFlow Nebulizer for 14 Days to CF Patients||Forest Laboratories|Yes|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|N/A|No|||April 2008|April 22, 2008|July 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00503490||169149|
NCT00501800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD044876|Genetic Epidemiology of Ovarian Aging|Genetic Epidemiology of Ovarian Aging||University of California, San Francisco|No|Active, not recruiting|November 2006|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|1250|Samples With DNA|Blood, urine|Female|25 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Study Population will be drawn from members of Northern California Kaiser Permanente        Health Plan utilizing the Kaiser Permanente Division of Research database to identify        potentially eligible subjects.|September 2013|September 27, 2013|July 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00501800||169277|
NCT00502034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLAR 01|Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.|Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).||Gruppo Oncologico Italiano di Ricerca Clinica|Yes|Completed|July 1994|June 2012|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|75 Years|No|||July 2013|July 9, 2013|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502034||169259|
NCT00502359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|keinen|Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose|Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose Values in Pregnancy||University of Zurich|No|Completed|April 2005|December 2006|Actual|||Phase 4|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|2005|||Female|N/A|N/A|No|||July 2007|July 19, 2007|July 16, 2007||||No||https://clinicaltrials.gov/show/NCT00502359||169235|
NCT00502632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1372P|Dornase Alfa and Urokinase for Kids With Pleural Empyema|Multicentre Randomized Double-Blinded Trial of Intrapleural Dornase Alfa and Urokinase vs Urokinase Alone for Complicated Parapneumonic Effusions in Children|DUKE|Azienda Ospedaliera di Padova|No|Recruiting|October 2007|October 2009|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|1 Year|16 Years|No|||May 2008|May 9, 2008|July 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00502632||169214|
NCT00518869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP010|Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue|||PhytoHealth Corporation|No|Terminated|September 2007|December 2009|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|17 Years|75 Years|No|||November 2015|November 3, 2015|August 18, 2007||No|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT00518869||167990|
NCT00519480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2110243|A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin|A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered With Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|48|||Both|30 Years|64 Years|No|||May 2011|May 31, 2012|August 20, 2007||No||||https://clinicaltrials.gov/show/NCT00519480||167943|
NCT00520390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2208-02|A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)|A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38) Administered Weekly for 3 Weeks in 4-Week Cycles in Patients With Advanced Solid Tumors or Ymphoma (EZN-2208-02)||Enzon Pharmaceuticals, Inc.|No|Completed|May 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||34|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|August 23, 2007||||No||https://clinicaltrials.gov/show/NCT00520390||167873|
NCT00520715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FQ/EPI|Epidemiology of Fluoroquinolone Resistance in Human Commensal Flora in Patients Hospitalised in Medical Wards|Epidemiology and Risk Factors Study of the Carriage of Fluoroquinolone Resistant Bacteria in the Commensal Flora of Patients Hospitalised in Medical Wards||Association Pour le Recherche en Infectiologie et en Médecine Interne|No|Completed|June 2007|December 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|640|||Both|18 Years|N/A|No|Non-Probability Sample|adults patients at hospital admission hospital stay >24 hours informed consent required|June 2015|June 22, 2015|July 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00520715||167848|
NCT00520962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199402-1369/516|Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk|New Physiopathogenics Mechanisms Susceptible of Pharmacological Developments (Insulin Resistance and Atherosclerosis)||IRCCS San Raffaele|Yes|Completed|June 1997|May 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||2|Actual|1997|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||August 2007|August 24, 2007|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00520962||167830|
NCT00520975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00504|First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU|A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients With HER-2/NEU Over-Expressing Metastatic Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2007|||October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|489|||Both|18 Years|N/A|No|||September 2015|December 17, 2015|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520975||167829|
NCT00521482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMZ/05|Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma|Intensive Dose Temozolomide Treatment or Temozolomide With Thalidomide Treatment in Recurrent Glioblastoma After Standard Therapy:a Randomized Phase II Trial||University of Zurich|No|Not yet recruiting|September 2007|January 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2007|August 27, 2007|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00521482||167791|
NCT00521547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K08AT001695-01|To Study the Mechanisms of Acupuncture Through Functional Magnetic Resonance Imaging and Peripheral Neurosensory Testing|Healthy Subject Studies to Assess the Effect of Different Electroacupuncture Parameters on Analgesia, Peripheral Sensory Thresholds and Central Pain Processing.||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|September 2003|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2007|August 27, 2007|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00521547||167786|
NCT00521833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8380|Surgically Induced Astigmatism of Temporal Versus Nasal Clear Corneal Phacoemulsification|||hahid Beheshti University of Medical Sciences|Yes|Completed|June 2005|August 2006|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||August 2007|September 4, 2007|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00521833||167764|
NCT00544778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00050|Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma|Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas||City of Hope Medical Center||Terminated|August 2001|||November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|65 Years|No|||August 2014|August 19, 2014|October 13, 2007|Yes|Yes|The study was terminated prematurely due to withdrawal of support by the sponsor.|No|June 12, 2014|https://clinicaltrials.gov/show/NCT00544778||166026|The study was terminated…protocol objectives not met. It was closed prematurely due to withdrawal of support by the sponsor. Subjects have been followed, but there is not enough data generated to continue following the subjects.”
NCT00544791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32/07|The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment|The Effect of Melatonin on Memory and Other Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI): A Placebo- Controlled Study.|MCI|Assaf-Harofeh Medical Center|No|Recruiting|October 2007|October 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|90 Years|No|||June 2007|October 15, 2007|October 14, 2007||||No||https://clinicaltrials.gov/show/NCT00544791||166025|
NCT00545129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091003|A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone|Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy And Safety Study Of Tanezumab As Add-On Therapy To Opioid Medication In Patients With Pain Due To Bone Metastases||Pfizer|Yes|Completed|April 2009|February 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|October 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00545129||166002|
NCT00533247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC01|Arthroplasty Inflammation Prophylaxis With Celecoxib|Preemptive Anti-Inflammatory Use of Celecoxib in Knee Arthroplasty Surgery: a Double Blinded, Placebo-Controlled Study.||Zanbilowicz, Adam, DPM MS|Yes|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533247||166900|
NCT00533000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-214|Smoking Cessation and Postoperative Complications|Short Term Perioperative Smoking Cessation and the Effect on Postoperative Complications. A Randomized Clinical Trial.||Karolinska Institutet|No|Active, not recruiting|January 2004|January 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|584|||Both|18 Years|79 Years|No|||September 2007|June 10, 2008|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533000||166919|
NCT00534690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/06|Does PEP Compensate the Reduction of Tidal Volume During One Lung Ventilation?|Lowering VT and Increasing PEP During One-Lung Ventilation (OLV), Impact on Oxygenation|REVOLU|University Hospital, Bordeaux|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|88|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534690||166791|
NCT00534937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-4372|Flexitouch Compression System for Venous Stasis Ulcer|A Randomized Trial of the Flexitouch Compression System as an Adjunctive Treatment for Venous Stasis Ulcer||West Penn Allegheny Health System|Yes|Terminated|September 2007|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|90 Years|No|||January 2013|January 28, 2013|September 24, 2007||No|Ineffective Recruitment (Business Decision)|No|November 29, 2012|https://clinicaltrials.gov/show/NCT00534937||166772|The study was terminated early due to lack of enrollment which ultimately lead to a limited number of subjects to include in an analysis.
NCT00534703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO782|Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure|Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device|SERCA-LVAD|Imperial College London|Yes|Terminated|July 2014|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|70 Years|No|||September 2015|February 23, 2016|September 24, 2007||No|Early termination following Trial Steering Committee recommendation|No||https://clinicaltrials.gov/show/NCT00534703||166790|
NCT00534092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSS-004-LTO|Long-Term Outcomes for Lumbar Spinal Stenosis Patients Treated With X STOP®|Long-term Outcomes Among Patients With Lumbar Spinal Stenosis Treated With the X STOP® Interspinous Process Decompression System: Five-Year Follow-up of IDE Patient Cohorts||Medtronic Spine LLC|No|Completed|December 2006|June 2010|Actual|||Phase 4|Observational|Observational Model: Cohort||1|Actual|69|||Both|50 Years|N/A|No|Non-Probability Sample|Patients who received implants and completed participation in the Pivotal, CAP, or COS        studies and has the implant intact and is willing and able to provide consent and return        to the clinic for evaluation or complete study questionnaires.|March 2015|March 23, 2015|September 20, 2007||No||No|June 2, 2011|https://clinicaltrials.gov/show/NCT00534092||166837|
NCT00535496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05698|Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)|Comparison of the T4/T1 Ratio Measured by Means of the TOF Watch® SX With the Reappearance of T4 Measured by Means of a Peripheral Nerve Stimulator in Adult Subjects Receiving 4.0 mg.Kg-1 Sugammadex at 15 Minutes After Rocuronium||Merck Sharp & Dohme Corp.|No|Completed|September 2007|February 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|91|||Both|18 Years|64 Years|No|||February 2015|February 26, 2015|September 25, 2007|No|Yes||No|May 1, 2013|https://clinicaltrials.gov/show/NCT00535496||166730|
NCT00521339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-004|Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis|A Phase 2, Open-label Multi-center Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Apremilast in Subjects With Recalcitrant Plaque-type Psoriasis||Celgene|Yes|Completed|August 2007|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|August 24, 2007|Yes|Yes||No|October 14, 2014|https://clinicaltrials.gov/show/NCT00521339||167802|
NCT00521677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP1|Comparison Between Two Methods of Oral Care on the Incidence of VAP|||HaEmek Medical Center, Israel|Yes|Completed|September 2007|October 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|August 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521677||167776|
NCT00518518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN-3-06-KE|Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen|Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study.||Medical Universtity of Lodz|Yes|Completed|March 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|6 Years|17 Years|No|||May 2009|May 14, 2009|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518518||168017|
NCT00518531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060232|Denosumab Adherence Preference Satisfaction Study|A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate in Postmenopausal Women With Low Bone Mineral Density||Amgen||Completed|September 2007|June 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|55 Years|N/A|No|||July 2014|July 14, 2014|August 16, 2007||||No|July 1, 2010|https://clinicaltrials.gov/show/NCT00518531||168016|
NCT00518206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2002-013|Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma|A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM® Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma||Ludwig Institute for Cancer Research|No|Completed|December 2003|November 2012|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518206||168041|
NCT00518219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0702|To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)|To Compare the Efficacy and Safety of TW vs Valsartan in the MN||Nanjing University School of Medicine|Yes|Completed|July 2007|September 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|65 Years|No|||March 2009|May 25, 2010|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518219||168040|
NCT00518505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105238|Assessing Outcomes After Surgery for Gastroesophageal Reflux Disorder|Long and Short Term Outcomes After Laparoscopic Surgery for Gastroesophageal Reflux Disease|GERD|University of South Florida|No|Recruiting|December 2006|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 14, 2012|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518505||168018|
NCT00523718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOCD-1|Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder|A Double-blind Study of Riluzole Augmentation in Serotonin Reuptake Inhibitor-refractory Obsessive-compulsive Disorder and Depression||Yale University|No|Completed|September 2006|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|August 29, 2007||No||No|February 22, 2016|https://clinicaltrials.gov/show/NCT00523718||167621|
NCT00518440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0697-272|A Multi-Center Trial to Study Acute Liver Failure in Adults|A Multi-Center Trial to Study Acute Liver Failure in Adults|ALFSG|University of Texas Southwestern Medical Center|Yes|Recruiting|January 1998|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Serum, Plasma, Urine, DNA and Tissue if available are collected and stored at the NIDDK      Central Repository|Both|18 Years|N/A|No|Non-Probability Sample|Patients who have acute liver injury or acute liver failure and meet inclusion and        exclusion criteria|November 2015|November 30, 2015|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518440||168023|
NCT00518453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V78P5S|Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008|A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Ph.Eur, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects||Novartis|No|Completed|July 2007|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|129|||Both|18 Years|84 Years|Accepts Healthy Volunteers|||November 2011|November 4, 2011|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518453||168022|
NCT00518752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07NU018-1|Effects of Oral Care in the Neuroscience ICU|Comprehensive Oral Care for the Intubated Neuroscience ICU Patient: A Comparison of the Safety and Efficacy Between 2 Protocols||St. Joseph's Hospital and Medical Center, Phoenix|No|Completed|May 2007|November 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518752||167999|
NCT00518765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2318|Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet|A Single-center, Placebo-controlled Study of the Effects of Ascending Single Oral Doses of Aliskiren Compared With Captopril on Renal Hemodynamics in Healthy Volunteers on a Low and High Sodium Diet "Renin Inhibition and the Kidney"||Novartis|No|Completed|October 2005|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2010|October 5, 2010|August 20, 2007||||Yes||https://clinicaltrials.gov/show/NCT00518765||167998|
NCT00544505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#931-006|Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)|||King Faisal Specialist Hospital & Research Center||Active, not recruiting|September 2007|September 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|N/A|70 Years|No|||December 2011|December 11, 2011|October 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544505||166046|
NCT00541775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-801|Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)|A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.||Completed|June 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|273|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|October 5, 2007|Yes|Yes||No|May 17, 2010|https://clinicaltrials.gov/show/NCT00541775||166254|
NCT00542126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GnRHFETsupport.CTIL|Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles|||Shaare Zedek Medical Center|No|Not yet recruiting|December 2007|September 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|38 Years|No|||September 2007|October 9, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00542126||166227|
NCT00533858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2007-083|Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients|||Seoul National University Hospital|Yes|Recruiting|September 2007|September 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|65 Years|N/A||||October 2008|October 18, 2008|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00533858||166854|
NCT00534417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSSMBC0606|Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer|Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer||Accelerated Community Oncology Research Network|No|Completed|October 2007|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||December 2012|December 28, 2012|September 20, 2007|Yes|Yes||No|December 28, 2012|https://clinicaltrials.gov/show/NCT00534417||166812|
NCT00534105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-121|Lipid Metabolism in Gestational Diabetes|Study of Lipid Metabolism in Gestational Diabetes||Baystate Medical Center|No|Completed|September 2007|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|106|||Female|16 Years|40 Years|No|Non-Probability Sample|Pregnant women|July 2013|July 2, 2013|September 21, 2007||No||No|July 2, 2013|https://clinicaltrials.gov/show/NCT00534105||166836|
NCT00534118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564827|Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant|Cellular Infusions in Patients With Recurrent or Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplant||Roswell Park Cancer Institute|Yes|Active, not recruiting|October 2003|||June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|N/A|76 Years|No|||July 2015|July 7, 2015|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534118||166835|
NCT00535002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA016511-1|The Effect of Yohimbine on Cocaine Cue Reactivity|SCOR on Sex and Gender Factors Affecting Women's Health||Medical University of South Carolina|No|Completed|September 2007|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|113|Samples With DNA|whole blood saliva|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include subjects meeting diagnostic criteria for current cocaine        dependence (DSM-IV). Subjects will be recruited through local media advertisements        (newspaper, radio, and television), the Institute of Psychiatry Center for Drug and        Alcohol Programs, the Charleston Center, the Ralph H. Johnson VA Medical Center, and the        Dorchester Alcohol and Drug Commission. Women will be included in the study. In our        previous studies, approximately 50% of subjects have been female. African Americans will        be recruited into the protocol. Charleston's population is 64% Caucasian, 35% African        American and 2% Other. In a previous study, 59% of the subjects were women, 36% were        White, 62% African American, and 2% Other, and expect that the racial spectrum will be        similar.|March 2013|March 27, 2013|September 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535002||166767|
NCT00535275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0702|NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy|Comparison of 2 Chemotherapy Regimens in Non-small-cell Lung Cancer (NSCLC) Patients Relapsing After Surgery and Peri-operative Chemotherapy. A Randomized Phase III Study.||Intergroupe Francophone de Cancerologie Thoracique|Yes|Terminated|September 2007|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|75 Years|No|||February 2015|February 12, 2015|September 25, 2007||No|Final analysis done, follow-up of patients no more necessary|No||https://clinicaltrials.gov/show/NCT00535275||166747|
NCT00535509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #2061-048|Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer|Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer||King Faisal Specialist Hospital & Research Center|No|Completed|June 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|285|||Female|N/A|N/A|No|||December 2015|December 16, 2015|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535509||166729|
NCT00535522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-285_101|A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer|A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer||Millennium Pharmaceuticals, Inc.|No|Completed|August 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|September 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535522||166728|
NCT00535782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA19923|A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis|A Mechanism of Action Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) on Lipids, Arterial Stiffness, and Markers of Atherogenic Risk in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA).||Hoffmann-La Roche||Completed|October 2007|January 2011|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|75 Years|No|||November 2012|November 8, 2012|September 24, 2007|Yes|Yes||No|August 8, 2012|https://clinicaltrials.gov/show/NCT00535782||166708|
NCT00521963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0088-07-EMC|Intraarticular Injection of Infliximab|Interventional Study: Administration of Intraarticular Injection of Infliximab in Patients With Inflammatory Arthritis Who Failed Intraarticular Injection of Corticosteroids||HaEmek Medical Center, Israel|No|Withdrawn|March 2010|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||June 2015|June 25, 2015|August 17, 2007|||poor accrual|No||https://clinicaltrials.gov/show/NCT00521963||167754|
NCT00517621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAMINE|Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire|A Multicenter Prospective Phase II Study Evaluating Peripheral Neurotoxicity by Using FACT-GOG/NTX Questionnaire in Patients With Ovarian Cancer in Relapse Treated by Paclitaxel +/- EPO. Validation of a French Version of This Questionnaire||ARCAGY/ GINECO GROUP||Completed|February 2006|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|N/A|No|||February 2011|February 24, 2011|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00517621||168085|
NCT00517946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES101509|A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.|An Investigation to Evaluate the Technique of MRI as an Assessment of the Effect of Anti-allergy Drug Treatment on Internal Nasal and Sinus Mucosal Anatomy Following Intranasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis.||GlaxoSmithKline|No|Completed|March 2007|April 2007|Actual|April 2007|Actual|N/A|Observational|N/A||1|Actual|21|||Both|18 Years|60 Years|No|||August 2013|August 30, 2013|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517946||168060|
NCT00523458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanford Protocol ID: 95564|A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV||OPTI-NNRTI|Stanford University|Yes|Terminated|July 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|5|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|August 29, 2007||No|A delay in protocol approval and approval of laboratory sites in Salvador, Brazil left too    little time for completion of enrollment into the study.|No||https://clinicaltrials.gov/show/NCT00523458||167641|
NCT00518804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reitzel 2007|Functional Behavioural Skill Training for Young Children With Severe Autism|||McMaster University|No|Recruiting|August 2007|August 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|3 Years|10 Years|No|||July 2008|December 4, 2008|August 17, 2007||||No||https://clinicaltrials.gov/show/NCT00518804||167995|
NCT00523445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Varenicline07|The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia|Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial||Inje University|Yes|Completed|September 2007|July 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||August 2009|August 3, 2009|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523445||167642|
NCT00524030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081047|Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures|A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures||Pfizer|Yes|Terminated|September 2007|June 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|August 30, 2007|Yes|Yes|See termination reason in detailed description.|No|April 11, 2012|https://clinicaltrials.gov/show/NCT00524030||167597|External Data Monitoring Committee (DMC) determined study met criteria to stop early for positive efficacy. Exit rate was the basis for primary analysis and is what is reported here.
NCT00518466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-102 / AA42851|Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults|A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Immediate Release Phentermine in Obese Adults||VIVUS, Inc.|No|Completed|July 2007|December 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|64|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|August 16, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00518466||168021|
NCT00518778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07070159|Fusariosis in Solid-Organ Transplant Recipients|Fusariosis in Solid-Organ Transplant Recipients||University of Pittsburgh|Yes|Completed|August 2007|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Solid organ transplant patients diagnosed with fusariosis|December 2009|December 2, 2009|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518778||167997|
NCT00541489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT3012-X-303|Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip|A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Bid and Naproxen 500 mg Bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT3012) 750 mg Bid, in Patients With Osteoarthritis of the Hip||NicOx|Yes|Completed|June 2007|||September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|800|||Both|40 Years|N/A|No|||February 2009|February 19, 2009|October 8, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00541489||166275|
NCT00541762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 86/05|Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects|Mechanistic Study (Physiology)||University Hospital, Basel, Switzerland|No|Completed|January 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|34|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541762||166255|
NCT00533013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4807-OK-CTIL|Comprehensive Heart Failure Disease Management Community Program|Comprehensive Program for Disease Management in Heart Failure Patients in the Community||Sheba Medical Center|No|Completed|August 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1360|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533013||166918|
NCT00533533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-10-047|A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer|A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer|DO for AGC|Samsung Medical Center|Yes|Completed|January 2006|June 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|70 Years|No|||November 2006|January 12, 2009|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533533||166879|
NCT00533546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|537|Activated Protein C in Acute Stroke Trial|Activated Protein C in Acute Stroke Trial|APCAST|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|September 2007|December 2010|Anticipated|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|September 19, 2007|Yes|Yes|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00533546||166878|
NCT00533871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003H0020|Study to Determine if Serum BNP Levels Are Elevated in Pregnant Women With Pre-Eclampsia|Utilization of Serum BNP to Distinguish Pre-Eclampsia From Hypertension in Pregnancy||Ohio State University|No|Completed|February 2003|June 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||3|Actual|61|||Female|18 Years|N/A|No|||September 2007|September 21, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00533871||166853|
NCT00534430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99041|Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer|Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies||City of Hope Medical Center||Active, not recruiting|January 2000|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|16 Years|50 Years|No|||January 2016|January 28, 2016|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534430||166811|
NCT00535015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-CTP0002|Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer|A Randomized, Double-Blind, Pilot Study Comparing the Safety and Efficacy of Betamarc Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of CACS in Patients With Advanced NSCLC||Anaborex|Yes|Terminated|October 2007|August 2008|Anticipated|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||July 2008|July 19, 2008|September 23, 2007|Yes|Yes|Objectives of study could not be met within a reasonable timeframe.|No||https://clinicaltrials.gov/show/NCT00535015||166766|
NCT00535301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4348|Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair|Outcome After Anterior Vaginal Prolapse Repair: A Randomized Controlled Trial||Kaiser Permanente|No|Completed|January 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Female|21 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|September 24, 2007||No||No|May 4, 2011|https://clinicaltrials.gov/show/NCT00535301||166745|-Small number of subjects, Single surgeon, Medium follow-up, Limited ability to detect uncommon adverse events and small differences in quality of life and sexual symptom scores, Concurrent pelvic reconstructive and anti-incontinence procedures
NCT00535288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06472|Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause||Merck Sharp & Dohme Corp.|No|Completed|September 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|946|||Female|40 Years|65 Years|No|||May 2015|May 27, 2015|September 24, 2007|Yes|Yes||No|June 16, 2014|https://clinicaltrials.gov/show/NCT00535288||166746|
NCT00535535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHU-0616|Fructose-Induced Palmitate Synthesis in Overweight Subjects|Fructose-Induced Palmitate Synthesis in Overweight Subjects||Rockefeller University||Completed|August 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|September 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00535535||166727|
NCT00517959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRT Trial|SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors|Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial|SCRT|Tata Memorial Hospital|Yes|Active, not recruiting|May 2001|June 2017|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|3 Years|25 Years|No|||June 2012|December 8, 2012|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517959||168059|
NCT00518232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012508|A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder|The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate||Johnson & Johnson Taiwan Ltd||Completed|September 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|520|||Both|6 Years|19 Years|No|||April 2010|April 26, 2010|August 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00518232||168039|
NCT00523484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OKR-CAS-2007/1|Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts|An Observational Study to Assess Correlation Between Prostate Specific Antigen & Beck Anxiety Index in Prostate Cancer Patients Under Hormonal Therapy|CHAMPION|AstraZeneca|No|Completed|May 2007|||November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Male|18 Years|N/A|No|Non-Probability Sample|Advanced prostate cancer patients who were being treated by hormonal agents|January 2010|January 25, 2010|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523484||167639|
NCT00524095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIN2005|Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis|Bronchiectasis in COPD Patients : Role of Prophylaxis With Inhaled Steroids and Antibiotic on the Natural History of the Disease||University of Milan|Yes|Terminated|September 2006|February 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|210|||Both|45 Years|85 Years|No|||March 2009|March 12, 2009|August 31, 2007||No|we decided not to go on treatment phase|No||https://clinicaltrials.gov/show/NCT00524095||167593|
NCT00523731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-003|ACPs in Severe PAD/CLI by Direct Intramuscular Injection|A Study of Blood-Borne Autologous Angiogenic Cells Precursors Therapy in Patients With Critical Limb Ischemia||TheraVitae Ltd.|Yes|Completed|January 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|80 Years|No|||February 2007|August 30, 2007|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523731||167620|
NCT00523744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489ADE06|Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension|An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Amlodipine 10 mg Plus Valsartan 160 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combination of an Angiotensin Receptor Blocker (Olmesartan 20 mg) Plus Amlodipine 10 mg||Novartis|No|Completed|July 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|257|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|August 30, 2007||No||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00523744||167619|
NCT00524043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013771|An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|August 30, 2007|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00524043||167596|No information from this study about efficacy and safety with treatment beyond 6 weeks. Study not designed to establish efficacy of 6 mg dose relative to 1.5 mg dose. No information on efficacy of paliperidone ER doses between 1.5 and 3 mg.
NCT00524056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014314|A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor|A Randomized, Double Blind, Placebo-Controlled, Crossover, Proof of Concept Study to Evaluate the Effectiveness and Safety of Carisbamate in the Treatment of Essential Tremor||SK Life Science||Completed|August 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|85 Years|No|||January 2013|January 15, 2013|August 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00524056||167595|
NCT00518479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG/03/001|Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression|Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression||University of Leeds|No|Completed|September 2003|April 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|25 Years|80 Years|No|||August 2012|August 15, 2012|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518479||168020|
NCT00518492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-1002|Study Evaluating the Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500|Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|73|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2009|September 15, 2009|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518492||168019|
NCT00532740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 1365-002|Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery|A Humanitarian Device Exemption Compassionate Use Protocol of TheraSphere for Treatment of Unresectable Metastatic Cancer to the Liver||Northwestern University|Yes|Recruiting|December 2004|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic cancer of the liver who are not surgical resection candidates.|October 2015|October 7, 2015|September 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532740||166939|
NCT00532753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS Protocol #2007-4-42|Evaluating the Hunger Project in Ghana|Evaluating the Hunger Project's Scaling-up of Epicenter Strategy in Ghana||University of California, Berkeley||Recruiting|August 2007|May 2016|Anticipated|August 2010||Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|20000|||Both|N/A|N/A||||July 2008|July 31, 2008|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532753||166938|
NCT00533884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000565963|Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic|Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers||Vanderbilt University|No|Active, not recruiting|October 2007|October 2012|Anticipated|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed upper aerodigestive system cancers (head and neck, lung, and        esophagus)|August 2011|August 2, 2011|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533884||166852|
NCT00534131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0704/30|Anterior Perineal Plane for Ultra Low Anterior Resection of the Rectum|A Multicentre Trial of the Anterior Perineal PlanE for Ultra Low Anterior Resection of the Rectum (The APPEAR Technique) in the Prevention of Permanent Stoma in Benign and Malignant Disease|APPEAR|Queen Mary University of London|Yes|Recruiting|April 2004|March 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|16 Years|N/A|No|||June 2008|July 27, 2010|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534131||166834|
NCT00534443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3530|Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment|A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease||University of Athens|Yes|Completed|February 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|150|||Both|18 Years|N/A|No|||June 2008|August 8, 2011|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534443||166810|
NCT00534716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-33/07|Cannabis Cigarettes Used for Doping: Delta-9-Tetrahydrocannabinol (THC) Urine Detection|Cannabis and Doping - Pharmacokinetics of Smoked Cannabis Under Controlled Clinical Conditions||Federal Office of Sports, Switzerland|Yes|Completed|September 2007|May 2008|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|12|Samples Without DNA|Plasma, urine|Male|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male subjects; light (max. 1/month), infrequent Cannabis smokers, medium (max.        15/month) tobacco smokers experienced in the inhalation technique; age 20-30 years; body        weight 75+/-15 kg, normal medical history physical examination, passed laboratory tests        (safety lab), normal lung functions (spirometry).|May 2008|May 6, 2008|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534716||166789|
NCT00535028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QGUY/2004/IL4-13/-01|A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)|A Phase IIa Study To Investigate The Effects of AER 001 on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration.||Aerovance, Inc.|No|Completed|January 2005|May 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00535028||166765|
NCT00535041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2011-031|Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA|Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA||King Faisal Specialist Hospital & Research Center|Yes|Completed|September 2007|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|N/A|No|||January 2016|January 4, 2016|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00535041||166764|
NCT00535314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-C-0704|Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma|A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma||Reata Pharmaceuticals, Inc.|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00535314||166744|
NCT00535327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE 190-002|Test of Digital Breast Tomosynthesis vs. Regular Mammography in Detecting Breast Cancer in Women Undergoing Diagnostic Mammography|A Multicenter Study to Test Digital Breast Tomosynthesis (DBT) Compared to Full-Field Digital Mammography (FFDM) in Detecting Breast Cancer. Part 2. Women Undergoing Diagnostic Mammography||GE Healthcare|No|Completed|August 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Female|18 Years|N/A|No|Non-Probability Sample|Women referred for diagnostic mammogram|May 2010|May 13, 2010|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535327||166743|
NCT00535561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22-5|Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism|Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism: A Randomized, Double Blinded Study||Duzce University|No|Completed|June 2007|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|23 Years|73 Years|No|||February 2012|February 16, 2012|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00535561||166725|
NCT00535548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552|Hematopoietic Stem Cell Therapy in Chronic Wounds Using a Pressure Sore Model|Effect of Hematopoietic Stem Cells in Chronic Wounds Using a Pressure Sore Model: A Pilot Study on Feasibility, Safety and Potential Effects||University Hospital, Basel, Switzerland|Yes|Recruiting|January 2007|December 2007|Anticipated|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|||||||Both|18 Years|50 Years|No|||September 2007|September 24, 2007|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00535548||166726|
NCT00522899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BarnesDeborahE-1|The Mental Activity and eXercise Trial for Seniors|The Effects of Mental Activity and Exercise on Cognitive Function in Older Adults Who Self-Report a Recent Decline in Memory or Thinking|MAX|University of California, San Francisco|Yes|Completed|August 2007|June 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|126|||Both|65 Years|N/A|No|||April 2012|April 6, 2012|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522899||167684|
NCT00523146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GF-2006-001|Treatment of Primary Menstrual Pain With Kanion Capsule|Treatment of Primary Dysmenorrhea With Kanion Capsule (GF) A Randomized, Double-blind, Placebo-controlled, Repeated-Dose and Multi-Center Clinical Phase II Trial||Lianyungang Kanion Group, Ltd.|Yes|Completed|April 2007|February 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||||||Female|18 Years|45 Years|No|||February 2010|February 2, 2010|August 29, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00523146||167665|
NCT00523159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Nr: 2006-006370-25|IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease|Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease|IMA901-202|immatics Biotechnologies GmbH|Yes|Completed|May 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||February 2010|July 9, 2012|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523159||167664|
NCT00523172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB08102007|Clinical Assessment of Two Manipulative Protocols in Treatment of Hip Osteoarthritis|A Randomized Clinical Trial Comparing Two Manipulative Protocols to Assess Changes in Pain, ROM, Quality of Life, Cost and Risk for Falls in Subjects With Hip Osteoarthritis||Cleveland Chiropractic College|No|Active, not recruiting|October 2007|October 2010|Anticipated|January 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|40 Years|85 Years|No|||July 2010|July 16, 2010|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523172||167663|
NCT00523185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77757|A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal|A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal||Stanford University|Yes|Completed|May 2003|November 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|19 Years|N/A|No|||August 2007|August 29, 2007|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523185||167662|
NCT00524381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-ENBREL-1|Etanercept Treatment in the Early Course of Polymyalgia Rheumatica|The Effect of Etanercept on the Early Clinical Course of Polymyalgia Rheumatica (Pilot Study)||Bispebjerg Hospital|Yes|Completed|August 2007|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 22, 2010|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00524381||167571|
NCT00523757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHF-G533000207|Aldosterone Blockade in Heart Failure|Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic|ARCTIC-D|University of Alberta|No|Completed|August 2007|April 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|90 Years|No|||April 2010|April 5, 2010|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523757||167618|
NCT00524667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCM-001|HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia|HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia||CancerCare Manitoba|No|Terminated|January 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|August 31, 2007||No|Terminated due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00524667||167550|
NCT00524004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 233|Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD|Protective Efficacy of Orally Delivered Bovine Immunoglobulin, Specific for CS17 Fimbriae and CS17 Minor Fimbrial Adhesin CsbD Against Challenge With a CS17 Strain of Enterotoxigenic Escherichia Coli (ETEC)|BIgGII|Johns Hopkins Bloomberg School of Public Health|No|Completed|February 2007|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2007|November 26, 2007|August 31, 2007||||No||https://clinicaltrials.gov/show/NCT00524004||167599|
NCT00524017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0644 CDR0000562250|Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract|Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|May 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||January 2012|January 27, 2012|August 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00524017||167598|
NCT00519077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13503A|Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck|Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) as Monotherapy in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck||University of Chicago|Yes|Completed|March 2005|May 2013|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|August 17, 2007|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00519077||167974|
NCT00519090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2302|Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib|ENEST|Novartis|Yes|Terminated|October 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|August 17, 2007|Yes|Yes|This study was terminated due to limited enrollment.|No|November 11, 2010|https://clinicaltrials.gov/show/NCT00519090||167973|
NCT00533260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NNL-SER-2007/1|A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)|A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel®|SEQUEL|AstraZeneca||Completed|July 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|128|||Both|18 Years|N/A|No|Probability Sample|The patients who were considered for participation were patients who were being treated        with quetiapine according to the Core Data Sheet and who were on a stable dosing regime.        They could have been patients with schizophrenia or patients experiencing a manic episode        associated with a bipolar disorder. Quetiapine was administered to the patients in regular        practice.|December 2010|December 7, 2010|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533260||166899|
NCT00533897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-167|Phase IIIB Subcutaneous Missed Dose Study|A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis||Bristol-Myers Squibb|No|Completed|November 2007|February 2014|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|September 20, 2007|Yes|Yes||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00533897||166851|
NCT00534144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER0701|Comparison Between Effects of Two Iron Preparations on Protein in the Urine|A Randomized Controlled Trial of the Effect of IV Iron on Proteinuria in Non-Dialysis Chronic Kidney Disease Patients||Watson Pharmaceuticals|No|Completed|September 2007|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|74|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00534144||166833|
NCT00534157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004H0126|Study of Eye Pressure as a Predictor of Intracranial Pressure in the Acutely Head-Injured Population|Intraocular Pressure as a Predictor of Intracranial Pressure in the Acutely Head-Injured Population||Ohio State University|No|Completed|June 2004|April 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Actual|37|||Both|18 Years|N/A|No|||March 2007|September 21, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534157||166832|
NCT00534170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH-001 NICED 010|Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea|Randomized Controlled Field Trial of a Probiotics to Assess Its Role in The Prevention of Acute Diarrhoeal Diseases in Children|Yakult|Indian Council of Medical Research|Yes|Active, not recruiting|June 2007|January 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|4000|||Both|12 Months|59 Months|Accepts Healthy Volunteers|||June 2007|September 21, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534170||166831|
NCT00534183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPMETS001|Metabolic Profile and Anthropometric Changes in Schizophrenia|Metabolic Profile and Anthropometric Changes in Schizophrenia|MetS|Central Institute of Psychiatry, Ranchi, India|Yes|Completed|June 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|3||Actual|2006|||Both|18 Years|40 Years|No|||September 2007|September 21, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534183||166830|
NCT00534456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060172|An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial|Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Darbepoetin Alfa Treatment on Cardiac Function and Disease Specific Biomarkers in Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia: An Exploratory Sub-study for the RED-HF™ Trial||Amgen||Terminated|January 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|September 20, 2007|||Study terminated|No||https://clinicaltrials.gov/show/NCT00534456||166809|
NCT00534729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#0971-024|Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA|||King Faisal Specialist Hospital & Research Center|Yes|Completed|September 2007|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|N/A|No|||January 2016|January 4, 2016|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534729||166788|
NCT00535054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.11|Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms|An Open Study to Assess the Safety and Patients' Satisfaction Tears Again* in the Treatment of Dry Eye Symptoms||Trima, Israel Pharmaceutical Products|Yes|Completed|September 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|25 Years|85 Years|No|||February 2010|February 7, 2010|September 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00535054||166763|
NCT00535340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5895|An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder|An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients With Generalized Anxiety Disorder With an Optional Twenty-Four Week Extension|GEMINI|Sanofi||Terminated|March 2007|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|60 Years|N/A|No|||March 2009|March 10, 2009|September 25, 2007|No|Yes|reprioritization of indications|No||https://clinicaltrials.gov/show/NCT00535340||166742|
NCT00535353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I187|AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase I Study of AZD2281 in Combination With Irinotecan in Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer||Canadian Cancer Trials Group|No|Completed|August 2007|February 2015|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|70 Years|No|||February 2015|February 13, 2015|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535353||166741|
NCT00535587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR008150-04|Testing Mestinon and Exercise in Fibromyalgia|Maximizing Exercise Effectiveness in Fibromyalgia||Oregon Health and Science University||Completed|September 2002|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|178|||Both|21 Years|65 Years|No|||March 2011|March 23, 2011|September 21, 2007||No||No|March 21, 2011|https://clinicaltrials.gov/show/NCT00535587||166723|6 discontinued due to medical reasons unrelated to the study 4 were unwilling to complete1 relocated
NCT00535600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907226|Effects of Bariatric Surgery on Insulin|Effects of Bariatric Surgery on Changes in Insulin Secretion and Insulin Action||National Institutes of Health Clinical Center (CC)||Recruiting|September 2007|March 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|January 27, 2015|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535600||166722|
NCT00535574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRM250850|Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia|Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial||Beersheva Mental Health Center|Yes|Completed|November 2008|May 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|60 Years|No|||May 2011|July 25, 2012|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535574||166724|
NCT00522665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI05-102|Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer|Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102||Hoosier Cancer Research Network|Yes|Completed|August 2007|February 2015|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|August 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00522665||167702|
NCT00522678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZA102928|Repeat Dose GW685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Volunteers|A Randomised, Double Blind, Placebo Controlled, Parallel Group, 14 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled GW685698X Containing Magnesium Stearate in Healthy Subjects||GlaxoSmithKline|No|Completed|February 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|March 7, 2007||||No||https://clinicaltrials.gov/show/NCT00522678||167701|
NCT00522912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5024|A Trial of Epilation Verses Surgery for Minor Trichiasis|A Randomised Controlled Trial of Epilation Verses Immediate Surgery for the Management of Minor Trachomatous Trichiasis||London School of Hygiene and Tropical Medicine|Yes|Completed|March 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1300|||Both|18 Years|N/A|No|||January 2012|January 11, 2012|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522912||167683|
NCT00523471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-6-0076/ethics 23586|Blood Test to Measure DNA Damage in Blood|Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity||AHS Cancer Control Alberta|Yes|Terminated|July 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Male|N/A|N/A|No|Non-Probability Sample|community sample|April 2012|February 24, 2016|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523471||167640|
NCT00523770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACDU-001|Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development of Assays to Detect S. Pneumoniae|An Exploratory Study in Healthy Elderly Subjects to Collect Urine for the Development of Assays to Detect Streptococcus Pneumoniae.||GlaxoSmithKline||Completed|September 2007|||September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Urine sample|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Residents of Belgium and Finland|September 2008|September 2, 2008|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523770||167617|
NCT00524407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005125|Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy|The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia||Ortho Biotech Clinical Affairs, L.L.C.||Completed|July 1996|November 2002|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|273|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00524407||167569|
NCT00524394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0021|Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation|Characteristics of Cord Blood Immunologic Parameters of Infants < 32 Weeks Gestation|AOS|The University of Texas Health Science Center, Houston|Yes|Terminated|August 2007|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|Samples Without DNA|Serum only|Both|N/A|3 Days|No|Non-Probability Sample|Premature infants|November 2015|November 5, 2015|August 30, 2007||No|recruitment not possible|No|July 17, 2013|https://clinicaltrials.gov/show/NCT00524394||167570|Early termination leading to small numbers of subjects analyzed
NCT00525252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bacl001|Efficacy of Baclofen in the Treatment of Alcohol Addiction|Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study||Catholic University of the Sacred Heart|Yes|Completed|February 2003|November 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2|||86|||Both|18 Years|75 Years|No|||September 2007|September 4, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00525252||167506|
NCT00525265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-06-004|A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)|A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)||Otsuka Pharmaceutical Co., Ltd.|No|Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|85 Years|No|||November 2013|November 6, 2013|September 3, 2007||No||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00525265||167505|
NCT00524342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040157|IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia|Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory Menorrhagia||University of Pittsburgh|Yes|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Female|18 Years|45 Years|No|||December 2014|December 4, 2014|August 31, 2007|Yes|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00524342||167574|
NCT00524329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N13|Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage|SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response|Synchronise|AstraZeneca||Completed|January 2006|October 2007|Actual|March 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1220|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting at general practitioner|September 2008|September 25, 2008|August 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00524329||167575|
NCT00533559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0274-B|Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl|Mechanism of Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion - Effect of Buphenyl||University Health Network, Toronto|No|Completed|September 2007|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|10|||Male|35 Years|60 Years|Accepts Healthy Volunteers|||August 2007|June 24, 2010|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533559||166877|
NCT00533598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0557-006|A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)|||Merck Sharp & Dohme Corp.||Completed|September 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|21 Years|65 Years|No|||August 2015|August 11, 2015|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533598||166874|
NCT00533611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-056|Effect of MK0524A on Flushing Caused by Niacin (0524A-056)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients||Merck Sharp & Dohme Corp.||Completed|April 2007|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||330|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533611||166873|
NCT00533910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00006863|Rifaximin in Minimal Hepatic Encephalopathy|Effect of Rifaximin on Driving Performance, Psychometric Test Performance and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy: Randomized, Double-blind, Placebo-controlled Trial.||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Completed|October 2007|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||March 2013|March 19, 2013|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533910||166850|
NCT00534742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-30671807|Fangshan / Family-based Ischemic Stroke Study In China|A Family-based Ischemic Stroke Study on Association and Interactions of Multi-pathway Genetic Polymorphisms|FISSIC|Peking University|No|Recruiting|June 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples With DNA|serum, white cells|Both|18 Years|N/A|No|Non-Probability Sample|Ischemic stroke probands will be enrolled in two parts: incident cases from primary care        clinic and prevalent cases from communities, and their family members will be recuited in        communities.|December 2011|December 13, 2011|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534742||166787|
NCT00535067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0761|Neuropathic Pain in Survivors of Breast Cancer|Neuropathic Pain in Survivors of Breast Cancer||M.D. Anderson Cancer Center|No|Completed|September 2007|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|239|||Both|18 Years|N/A|No|Non-Probability Sample|Breast Cancer survivors.|January 2015|January 7, 2015|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00535067||166762|
NCT00531440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2307E1|This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.|A 2 Year Extension to a 1 Year Multicenter, Randomized, Open Label, Parallel Group Study of the Safety, Tolerability and Efficacy of Two Doses (1.5 and 3 mg/Day) of Everolimus (RAD001) With Basiliximab, Corticosteroids and Optimized Administration of Cyclosporine in de Novo Renal Transplant Recipients.||Novartis||Completed|November 2001|||August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|256|||Both|18 Years|65 Years||||November 2011|November 1, 2011|September 17, 2007||||No||https://clinicaltrials.gov/show/NCT00531440||167037|
NCT00531453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-MMY-2043|A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma|A Phase 2, Randomized Study of VELCADE® (Bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (Bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who Are Candidates for Autologous Transplantation||Millennium Pharmaceuticals, Inc.||Completed|October 2007|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|70 Years|No|||January 2012|January 25, 2012|September 14, 2007|Yes|Yes||No|April 9, 2010|https://clinicaltrials.gov/show/NCT00531453||167036|
NCT00531765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC 2071003|Sodium Bicarbonate in Preventing Contrast Induced Nephropathy|Sodium Bicarbonate in Preventing Contrast Induced Nephropathy (SIPCIN): A Randomized Controlled Study|SIPCIN|King Faisal Specialist Hospital & Research Center|No|Completed|June 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|No|||July 2010|July 24, 2010|September 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531765||167013|
NCT00531427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3025|Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee|Randomized, Double-blind, Placebo-controlled With Open-label Run-in Assessing Efficacy, Tolerability,Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects w/Moderate to Severe, Chronic Pain Due to OA of Knee||Purdue Pharma LP|No|Completed|September 2007|November 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|567|||Both|40 Years|N/A|No|||September 2012|September 5, 2012|September 17, 2007|Yes|Yes||No|July 28, 2010|https://clinicaltrials.gov/show/NCT00531427||167038|
NCT00523198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-413|Correlation Salivary Cortisol and Free Serum Cortisol to Total Serum Cortisol in MICU Septic Shock|Correlation Between Salivary Cortisol and Free Serum Cortisol Compared to Total Serum Cortisol in MICU Patients With Septic Shock||The University of Texas Health Science Center, Houston|No|Completed|February 2007|October 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|MICU patients with septic shock|December 2014|December 2, 2014|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523198||167661|
NCT00523497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV67-07|Efects of Noninvasive Mechanical Ventilation and Conventional Mechanical Ventilation in Patients With Severe Comunity Pneumonia|Noninvasive Mechanical Ventilation in Severe Community-Acquired Pneumonia and Acute Hypoxemic Respiratory Failure. A Prospective, Randomized and Controlled Study|NIMV AND SCAP|Hospital Privado del Sur|Yes|Terminated||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|18 Years|80 Years||||August 2007|August 30, 2007|August 30, 2007|||Interim analysis of the present study showed a significant decrease in mortality rate (p=    0.04) as well as in the number of days at the ICU p=0.0002.|No||https://clinicaltrials.gov/show/NCT00523497||167638|
NCT00523796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CVN-CRE-2007/1|InPractice Survey on the Treatment of Hypercholesterolemia|InPractice Survey on the Treatment of Hypercholesterolemia||AstraZeneca|No|Completed|February 2007|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|primary care|February 2011|February 15, 2011|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523796||167615|
NCT00524069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 68805|Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|A Pilot Study of Bevacizumab Based Peri-Operative Therapy for Operable Pancreatic Adenocarcinoma||Roswell Park Cancer Institute||Withdrawn|January 2007|||November 2007|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|August 31, 2007|Yes|Yes|Withdrawn due to no accrual|No||https://clinicaltrials.gov/show/NCT00524069||167594|
NCT00524108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07080212|Retrospective Analysis of Clinical Features in Ventriculoperitoneal Shunt Infectionsin Adults|Retrospective Analysis of Clinical Features in Ventriculoperitoneal Shunt Infections and Time to Re-Implantation in Adults||University of Pittsburgh|Yes|Completed|August 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|350|||Both|18 Years|N/A|No|Probability Sample|VP shunt infection|August 2012|August 14, 2012|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524108||167592|
NCT00524693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-146-R|Montelukast in Acute RSV Bronchiolitis|A Double-Blind Placebo Controlled Randomized Trial of Montelukast in Acute Respiratory Syncytial Virus Bronchiolitis||Ziv Hospital|No|Completed|January 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|N/A|2 Years||||September 2007|September 4, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00524693||167548|
NCT00524706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC-07-01|Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer|Phase I/II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) in Patients With Untreated Metastatic Colorectal Cancer||Shizuoka Cancer Center|Yes|Active, not recruiting|August 2007|April 2011|Anticipated|||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|42|||Both|20 Years|74 Years|No|||November 2008|November 12, 2008|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00524706||167547|
NCT00524680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000562742|Vitamin D in Treating Patients With Prostate Cancer|Study of Serum 25(OH) D3 Level Variability in Response to Different Doses of Oral Vitamin D Supplementation in Prostate Cancer Patients||Roswell Park Cancer Institute|Yes|Completed|June 2007|March 2013|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|148|||Male|18 Years|120 Years|No|||September 2015|September 30, 2015|August 31, 2007|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT00524680||167549|
NCT00524355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GVN-NEX-2007/1|Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD|Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of the Gastroesophageal Reflux Disease||AstraZeneca|No|Completed|March 2007|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|2717|||Both|18 Years|N/A|No|Probability Sample|primary care clinics, private clinics and out-patient department at hospitals in cities        and provinces of Viet Nam|July 2009|July 16, 2009|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00524355||167573|
NCT00524368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013783|A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)|A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects|ODIN|Tibotec Pharmaceuticals, Ireland|Yes|Completed|October 2007|October 2011|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|590|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|August 30, 2007|Yes|Yes||No|August 27, 2010|https://clinicaltrials.gov/show/NCT00524368||167572|
NCT00524615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPIRANT-1|Addition of Spironolactone in Patients With Resistant Arterial Hypertension|Addition of Spironolactone in Patients With Resistant Arterial Hypertension|ASPIRANT|University Hospital Olomouc|No|Recruiting|September 2007|December 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524615||167553|
NCT00533572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97822|Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer|Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer||Stanford University||Terminated|August 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with RDEB|May 2015|May 22, 2015|September 20, 2007|No|Yes|Study was suspended until FDA approved the IND. Study has since been terminated and a new    screening process has been implemented.|No||https://clinicaltrials.gov/show/NCT00533572||166876|
NCT00533585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0818|BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Completed|May 2006|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00533585||166875|
NCT00534196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000562726|Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer|Japanese Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation [J-POPS]||National Cancer Institute (NCI)||Active, not recruiting|July 2005|||December 2015|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|7000|||Male|N/A|N/A|No|||July 2009|December 17, 2013|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00534196||166829|
NCT00534209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20057158|Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy|Phase I/II Clinical Trial of Immunotherapy With an Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer That Have Completed First Line Chemotherapy||University of Miami Sylvester Comprehensive Cancer Center|Yes|Terminated|February 2007|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 20, 2007|Yes|Yes|Per request of Principal Investigator this study was closed.|No|January 17, 2013|https://clinicaltrials.gov/show/NCT00534209||166828|Study closed early due to low enrollment. A minimum of 2 patients were required for Phase 1. Only 1 patient enrolled.
NCT00534469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99040|Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission|Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients </=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as the Preparative Regimen||City of Hope Medical Center||Active, not recruiting|October 2000|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|60 Years|No|||January 2016|January 28, 2016|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534469||166808|
NCT00535366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1249.1|Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD|A Randomised, Phase II, Double-Blind, Double-Dummy, Four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 mcg Bid, MDI), Ciclesonide (400 mcg qd, MDI), Ciclesonide (800 mcg qd, MDI) or Placebo in Free Combination With Open-Label Tiotropium (18 mcg qd, HandiHaler) and Salmeterol (50 mcg Bid, Diskus) in Patients With COPD.||Boehringer Ingelheim||Completed|October 2007|||September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|103|||Both|40 Years|N/A|No|||May 2014|May 22, 2014|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00535366||166740|
NCT00535379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT-Nr. 2007-002142-37|SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme|SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies|SURGE01-07|Medical University Innsbruck|Yes|Active, not recruiting|October 2007|January 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2009|August 27, 2010|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535379||166739|
NCT00535613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0069|Propofol in Emergence Agitation|Does a Single Dose of Propofol Decrease the Incidence of Emergence Agitation in Children?||University of Wisconsin, Madison|No|Completed|August 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|12 Months|6 Years|No|||October 2015|October 9, 2015|September 23, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00535613||166721|
NCT00531466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV650-014|Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury|AV650-014: A Four Week, Prospective, Randomized, Double Blind, Placebo-Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV650 in Patients With Spasticity Due to Spinal Cord Injury||Avigen|No|Terminated|September 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||November 2008|November 3, 2008|September 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00531466||167035|
NCT00531479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851009|Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis|A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis||Pfizer|Yes|Completed|July 2008|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|459|||Both|16 Years|N/A|No|||April 2012|April 3, 2012|September 14, 2007|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT00531479||167034|
NCT00531778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 04-30 H11938|NYU Ovarian Cancer Early Detection Program Blood and Genetics|NYU Ovarian Cancer Early Detection Program Blood and Genetics||New York University School of Medicine|No|Terminated|June 2004|November 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|890|Samples With DNA|whole blood, serum, plasma, urine, ovarian tissue|Female|18 Years|N/A|No|Probability Sample|women noted to be at increased risk for developing ovarian cancer|January 2011|January 10, 2011|September 18, 2007||No|insufficient funding and resource|No||https://clinicaltrials.gov/show/NCT00531778||167012|
NCT00531960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20571|A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.|A Randomized, Open-label Study Comparing the Anti-tumor Effect of Treatment With Tarceva Plus Avastin Versus Chemotherapy Plus Avastin in Patients With Advanced Non-small Cell Lung Cancer||Hoffmann-La Roche||Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|September 18, 2007||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00531960||166998|
NCT00523510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513446|Feasibility and Pilot Efficacy of Flash-heated Breast Milk to Reduce Maternal-to-Child-Transmission of HIV in Tanzania|Feasibility and Pilot Efficacy of Flash-heated Breast Milk for Reduction of Maternal-to-Child Transmission of HIV in Tanzania|Flash-heat|University of California, Davis|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|144|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 13, 2012|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523510||167637|
NCT00523783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NKR-SER-2007/1|Seroquel Long-Term NIS for Schizophrenia Patients|24-Week Naturalistic Observational Study of Efficacy of Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder|SELECT|AstraZeneca|No|Completed|May 2007|May 2008|Actual|November 2007|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|65 Years|No|||August 2007|October 3, 2008|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523783||167616|
NCT00523809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0873|Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor||M.D. Anderson Cancer Center|No|Terminated|August 2007|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||December 2012|December 21, 2012|August 31, 2007||No|Slow accrual.|No|December 21, 2012|https://clinicaltrials.gov/show/NCT00523809||167614|
NCT00524121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000563268|Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer|Phase II Study of Erlotinib (Tarceva®) and Radiotherapy for Elderly Patients With Esophageal Carcinoma||Roswell Park Cancer Institute|Yes|Completed|March 2006|October 2011|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|65 Years|N/A|No|||February 2015|February 19, 2015|August 31, 2007|Yes|Yes||No|August 23, 2013|https://clinicaltrials.gov/show/NCT00524121||167591|
NCT00524420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32656-D|Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain|Transcranial Magnetic Stimulation (TMS) in the Treatment of Chronic Widespread Pain (CWP)||University of Washington|Yes|Completed|February 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Female|18 Years|65 Years|No|||April 2013|April 13, 2013|August 30, 2007|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00524420||167568|
NCT00524433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-051-307|Tezosentan in the Treatment of Acute Heart Failure|Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.|VERITAS 2|Actelion||Completed|April 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|713|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|August 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00524433||167567|
NCT00525304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078168|A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition|Optimizing Chronic Illness Self-Management for Individuals With Schizophrenia||University of Maryland|No|Recruiting|September 2007|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|64 Years|No|||March 2009|May 7, 2015|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525304||167502|
NCT00525603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0269|CFAR Study in Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) in High-Risk Previously Untreated Patients With CLL||M.D. Anderson Cancer Center|No|Completed|June 2005|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|69 Years|No|||January 2013|January 25, 2013|September 4, 2007||No||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00525603||167479|
NCT00525005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-0701|Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer|A Phase II Study of Docetaxel, Oxaliplatin and S-1 (DOS) in Patients With Advanced Gastric Cancer||Hallym University Medical Center|No|Completed|August 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|70 Years|No|||September 2012|September 20, 2012|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525005||167524|
NCT00525018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561701022|Brain Activation During Thermal Stimulation in Neuropathic Pain|Brain Activation During Thermal Stimulation in Neuropathic Pain||National Taiwan University Hospital|Yes|Recruiting|January 2007|July 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|80|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2007|September 3, 2007|September 3, 2007||||No||https://clinicaltrials.gov/show/NCT00525018||167523|
NCT00525278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00348|To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis|Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Seasonal Allergic Rhinitis (SAR)||UCB Pharma|No|Completed|August 2003|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|67|||Both|18 Years|60 Years|No|||September 2009|December 13, 2013|September 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00525278||167504|
NCT00524992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070212|Evaluation of Albuminuria HIV-Infected Patients|Prospective Evaluation of Albuminuria in HIV Positive Patients||National Institutes of Health Clinical Center (CC)||Completed|August 2007|December 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|134|||Both|8 Years|N/A|No|||December 2014|December 16, 2015|September 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00524992||167525|
NCT00524641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RVN-SYM-2007/1|Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler|A Patient Follow-up Program to Assess Asthma Control in Patients Using Symbicort® as Maintenance and Relief Therapy in a Single Inhaler (Symbicort® SMART: Budesonide/Formoterol 160/4.5 Mcg, 1 or 2 Inhalations x 2 Times Plus Additional Inhalations as Needed)||AstraZeneca|No|Completed|July 2007|April 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1254|||Both|18 Years|N/A|No|Probability Sample|Hospital out-patient departments and private clinics in all areas of Vietnam|July 2009|July 8, 2009|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00524641||167552|
NCT00524654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0411060017|The Effects of Cervical Spine Manipulation On Postural Control|||Logan College of Chiropractic||Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524654||167551|
NCT00533299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/028/DDI|Hydralazine Valproate for Ovarian Cancer|Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer.||National Institute of Cancerología|Yes|Recruiting|August 2007|December 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|211|||Female|18 Years|N/A|No|||August 2007|September 20, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533299||166896|
NCT00534768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5551813|Postoperative Treatment After Endoscopic Sinus Surgery|Postoperative Treatment After Endoscopic Sinus Surgery||Kuopio University Hospital||Completed|January 2003|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|70 Years||||January 2008|January 11, 2008|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00534768||166785|
NCT00535080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN.15.SPR.001|Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease|Compassionate Use of Metvix® (Methyl Aminolevulinate) PDT in Subjects With Field Actinic Keratoses, Large/Multiple Superficial BCCs, or Bowen's Disease||Galderma||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2009|October 27, 2009|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00535080||166761|
NCT00535093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT4152|An Assessment of Rapid Streptococcal Tests in Community Clinics in Israel|A Comparison of Available Rapid Streptococcus A Tests in Community Clinics in Israel: Accuracy, Ease of Use and Acceptability.||Meir Medical Center|No|Completed|October 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|7000|||Both|3 Years|N/A|No|||September 2009|May 2, 2010|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535093||166760|
NCT00535106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05290|SmartCPR Trial: An Analysis of a Waveform-Based Automated External Defibrillation (AED) Algorithm on Survival From Out-of-Hospital Ventricular Fibrillation|An International, Randomized, Controlled Prehospital Trial of a Waveform-Based Automated External Defibrillation Algorithm for the Management of Ventricular Fibrillation|SmartCPR|New York City Fire Department|Yes|Completed|May 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|900|||Both|N/A|N/A|No|||October 2009|October 18, 2009|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535106||166759|
NCT00535392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01274|Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy|Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.||UCB Pharma|No|Completed|September 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|4 Years|16 Years|No|||March 2011|August 30, 2011|September 25, 2007|Yes|Yes||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00535392||166738|
NCT00535626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61|Trident® Tritanium™ Acetabular Shell Revision Study|A Post-market, Non-randomized, Open Label, Multi-center Clinical Study of the Trident Tritanium Acetabular Shell||Stryker Orthopaedics|No|Active, not recruiting|November 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|245|||Both|21 Years|85 Years|No|||February 2016|February 19, 2016|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535626||166720|
NCT00531492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASID-06-CE-56|Efficacy of Continuous Skin to Skin Care (Technique Kangaroo: TK) After Birth for Low Birth Weight (LBW) Infants and Their Mothers in Developing Countries|Randomized Controlled Trial of Continuous Skin to Skin Care (Technique Kangourou: TK) for Low Birth Weight (LBW) Infants and Their Mothers at University Hospital Center of Mahajanga (Centre Hospitalier Universitaire de Mahajanga: CHUM), Madagascar|EtudeTK|Foundation for Advanced Studies on International Development|No|Completed|August 2007|March 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|N/A|24 Hours|No|||December 2011|December 8, 2011|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531492||167033|
NCT00532610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2107489|A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults|A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial to Investigate the Effect of GSK189075 on Cardiac Repolarization as Compared to Placebo and a Single Dose of Moxifloxacin in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|78|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|September 18, 2007||||||https://clinicaltrials.gov/show/NCT00532610||166948|
NCT00531973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITE Randomized Pilot Study|A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging|Liposomal Doxorubicin-Investigational Chemotherapy-Tissue Doppler Imaging Evaluation (LITE) Randomized Pilot Study|LITE|Catholic University, Italy|No|Recruiting|January 2007|December 2009|Anticipated|August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|65 Years|No|||February 2009|February 17, 2009|September 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531973||166997|
NCT00523835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010155|Body Composition, Bone Mineral Density, Insulin Sensitivity and Echocardiographic Measurements in Klinefelter Syndrome|||University of Aarhus|No|Completed|April 2002|November 2004|Actual|||N/A|Observational|Observational Model: Natural History, Time Perspective: Cross-Sectional||2||140|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|August 31, 2007|August 31, 2007||||No||https://clinicaltrials.gov/show/NCT00523835||167612|
NCT00524147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU92-AE1-B36|Drainage of Tuberculous Pleural Effusions|Drainage of Tuberculous Pleural Effusions||Taipei Medical University Hospital|No|Completed|October 2003|December 2006|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|64|||Both|16 Years|N/A|No|||December 2010|December 28, 2010|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524147||167589|
NCT00524134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC3821|P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.|An Open-label Pilot Study Using Carvedilol-CR as a P-glycoprotein Inhibitor as Adjunct Therapy in the Treatment of Medically-refractory Epilepsy||Columbia University|Yes|Terminated|December 2008|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|10 Years|75 Years|No|||April 2015|April 10, 2015|August 31, 2007||No|PI left the institution.|No||https://clinicaltrials.gov/show/NCT00524134||167590|
NCT00524719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN # 05-014|Comparison of Three Fixation Techniques for Displaced Distal Radius Fractures|A Prospective Randomised Trial Comparing Open Reduction and Internal Fixation, Non-Spanning External Fixation, and Closed Reduction With Percutaneous Fixation in Displaced Distal Radius Fractures With Joint Congruity|DRF|McGill University Health Center|No|Active, not recruiting|January 2007|May 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|324|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524719||167546|
NCT00525031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0143|Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients|Randomized Phase II Neoadjuvant Study of Temozolomide Alone or With Pegylated Interferon-alpha 2b in Patients With Resectable AJCC Stage IIIB/IIIC or Stage IV (M1a) Metastatic Melanoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2006|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|August 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00525031||167522|
NCT00525317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral magnesium in pregnance|Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ?|Does Oral Magnesium Substitution Relieve Magnesium Induced Leg Cramps ?||Oslo University Hospital|No|Completed|January 2002|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|38 Years|No|||December 2013|December 16, 2013|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525317||167501|
NCT00525616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/101/HP|Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid|Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.|Rituximab2|University Hospital, Rouen|No|Completed|December 2008|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|80 Years|No|||September 2014|September 5, 2014|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00525616||167478|
NCT00525863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMHC-4602|Oxygen Therapy in Schizophrenia|Oxygen Therapy in Schizophrenia||Beersheva Mental Health Center|Yes|Recruiting|January 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|45 Years|No|||May 2008|May 26, 2008|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00525863||167459|
NCT00525876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0309|Non-Myeloablative Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen for Advanced/Recurrent Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Completed|January 2005|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|N/A|70 Years|No|||November 2011|November 2, 2011|September 4, 2007||No||No|November 2, 2011|https://clinicaltrials.gov/show/NCT00525876||167458|
NCT00525850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC26177|High Fat Diet II on Weight Loss|Effect of High Saturated Fat No Starch Diet vs. Low Saturated Fat, Low Trans Fat, High Fiber Diet on Weight Loss and Markers of Atherosclerotic Cardiovascular Disease|HFD|Christiana Care Health Services|No|Completed|December 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00525850||167460|
NCT00526188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91531|Efficacy and Safety of Primovist in Chinese Patients|A Multicenter, Open-label Phase III Study of the Efficacy and Safety of Primovist as a Contrast Agent for Enhanced MR Imaging of Focal Liver Lesions in Chinese Patients||Bayer|Yes|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|234|||Both|18 Years|75 Years|No|||April 2015|April 13, 2015|September 6, 2007||No||No|October 5, 2009|https://clinicaltrials.gov/show/NCT00526188||167434|
NCT00525564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS106875|Effects of Salmeterol on Walking Capacity in Patients With COPD|Effects of Salmeterol on Walking Capacity in Patients With COPD||Laval University|No|Completed|May 2006|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|28|||Both|50 Years|80 Years|No|||September 2007|September 5, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00525564||167482|
NCT00525577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGI-1067-052|ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study|AGI-1067 as a Novel Antidiabetic Agent Evaluation Study|ANDES|AtheroGenics|Yes|Active, not recruiting|August 2007|September 2008|Anticipated|June 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1012|||Both|18 Years|75 Years|No|||February 2008|February 4, 2008|September 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00525577||167481|
NCT00525226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004249|Evaluating the Effects of Stress in Pregnancy|Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability||Emory University|Yes|Completed|September 2007|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1431|Samples With DNA|Plasm, serum, and urine samples are processed and stored at each research visit.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women of child bearing potential between the ages of 18 to 45 years of age with or without        a history of depression or anxiety disorders.|November 2013|November 19, 2013|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525226||167508|
NCT00525239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66999|HIV Antiretroviral Drugs and Metabolism|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|March 2004|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 15, 2011|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525239||167507|
NCT00533923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002P000219|Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders|Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders||Beth Israel Deaconess Medical Center|No|Active, not recruiting|December 2002|||January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|65 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00533923||166849|
NCT00534508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-30|Distribution of Tacrolimus in Skin, Atopic Dermatitis|A Study to Determine the Distribution of Tacrolimus in the Skin and the Systemic Pharmacokinetics of Tacrolimus in Adult Patients With Moderate to Severe Atopic Dermatitis Following First and Repeated Application of the Tacrolimus Ointment.||Astellas Pharma Inc|No|Completed|December 2000|July 2001|Actual|July 2001|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534508||166805|
NCT00535119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00258|Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer|A Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies||National Cancer Institute (NCI)||Completed|September 2007|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||April 2015|May 21, 2015|September 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00535119||166758|
NCT00534872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXS109143|A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population|A Single-centre, Open Label, Single-dose, Four Parallel Cohorts Study to Investigate the Pharmacokinetics, Safety and Tolerability of SB-649868 10mg in Healthy Female "Non-childbearing Potential", Healthy Male and in Healthy Elderly Subjects||GlaxoSmithKline||Withdrawn|October 2007|October 2007|Anticipated|October 2007|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|September 24, 2007|||The study was stoppend before recruitment start for preclinical safety finding in rats.|No||https://clinicaltrials.gov/show/NCT00534872||166777|
NCT00535171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIREG_L_01927|Venous Thromboembolism Taskforce Audit Program|Venous Thromboembolism Taskforce Audit Program||Sanofi||Completed|June 2007|||August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8764|||Both|18 Years|N/A|No|Probability Sample|Venous thromboembolism in medical patients bedridden due to acute illness.|January 2010|January 21, 2010|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535171||166754|
NCT00535691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-32|Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis|A Randomised, Multi-centre, Double-blind, Pharmacokinetic Study of Tacrolimus Ointment (0.03%) in Paediatric Patients (Aged 3 Months to 24 Months) With Atopic Dermatitis Following First and Repeated Once Daily or Twice Daily Application of the Tacrolimus Ointment||Astellas Pharma Inc|No|Completed|April 2003|December 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|53|||Both|3 Months|24 Months|No|||August 2014|August 28, 2014|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00535691||166715|
NCT00532285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-05-150|Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer|Phase II Study of Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer||National Cancer Center, Korea|No|Terminated|September 2005|August 2009|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|N/A|N/A|No|||September 2007|June 22, 2011|September 19, 2007||No|terminated|No||https://clinicaltrials.gov/show/NCT00532285||166973|
NCT00533117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5401R|Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder|Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder||New York State Psychiatric Institute|Yes|Completed|March 2001|December 2012|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|110|||Both|18 Years|55 Years|No|||September 2013|September 25, 2013|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533117||166910|
NCT00533403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0686-002|MK0686 in Postsurgery Dental Pain (0686-002)|||Merck Sharp & Dohme Corp.||Completed|July 2004|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|114|||Both|18 Years|45 Years|No|||June 2015|June 25, 2015|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533403||166889|
NCT00533416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070225|Safety of ON 01910.Na in Patients With Myelodysplasia|A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8||National Institutes of Health Clinical Center (CC)||Completed|September 2007|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|85 Years|No|||April 2015|May 5, 2015|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00533416||166888|
NCT00524446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS-2007-02-19|Controlled Trial to Test the Efficacy of Lipid-based Nutrient Supplements to Prevent Severe Stunting Among Infants|A Single-centre, Randomised, Single-blind, Parallel Group Clinical Trial in Rural Malawi, Testing the Growth Promoting Effect of Long-term Complementary Feeding of Infants With a High-energy, Micronutrient Fortified Spread|LCNI-5|University of Tampere|Yes|Completed|January 2008|January 2014|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|840|||Both|6 Months|6 Months|Accepts Healthy Volunteers|||May 2014|May 20, 2014|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524446||167566|
NCT00524732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD511|Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age|||Sanofi|No|Completed|September 2004|September 2005|Actual|December 2004|Actual|N/A|Observational|Time Perspective: Cross-Sectional||9|Actual|7156|||Both|7 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and Adolescents 7 to 19 Years of Age, who have previously recieved Tetanus and        Diphtheria Toxoids Vaccine|January 2014|January 10, 2014|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524732||167545|
NCT00525330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104-003|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone||ActivX Biosciences, Inc.||Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|213|||Both|18 Years|70 Years|No|||August 2013|August 14, 2013|September 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00525330||167500|
NCT00525343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-06-AVX|Avonex 15 Year Long Term Follow-up Study|Avonex® Fifteen Year Long Term Follow Up of Patients With Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs|15yASSURANCE|Biogen|No|Completed|March 2007|September 2008|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|122|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients having completed at least 2 years of treatment (Avonex® or placebo) in the        original Avonex® pivotal trial.|March 2010|March 5, 2010|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525343||167499|
NCT00525629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P000255|The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome|The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome||Beth Israel Deaconess Medical Center|No|Completed|February 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00525629||167477|
NCT00526214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0704-028-205|Administration of Celecoxib for Treatment of Intracerebral Hemorrhage : A Pilot Study|Multi-center, Prospective Randomized, Comparative Open With Blinded Endpoints (PROBE) Trial to Assess the Safety and Effectiveness of Administration of Celecoxib in Patients With Intracerebral Hemorrhage|ACE-ICH|Seoul National University Hospital|Yes|Completed|October 2007|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2010|March 26, 2010|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526214||167432|
NCT00525291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83/07 ethics comm. Giessen|Triple Target Treatment (3T) Which Combines Stimulation With Amplitude Modulated Middle Frequency (AM-MF), Electromyography (EMG)-Triggered Stimulation and EMG-Biofeedback Compared With EMG-Biofeedback in Anal Incontinence|Prospective, Randomized Multicenter Study to Assess the Outcome of Conservative 3T Treatment With EMG-Biofeedback|3T-AI|University of Giessen|Yes|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||January 2009|February 17, 2009|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525291||167503|
NCT00525590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIA-001|Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer|A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer||Eisai Inc.|Yes|Completed|September 2007|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00525590||167480|
NCT00525824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D356FC00003|12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe|A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD|GRAVITY|AstraZeneca||Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1743|||Both|18 Years|N/A|No|||May 2011|May 11, 2011|September 5, 2007|Yes|Yes||No|September 3, 2009|https://clinicaltrials.gov/show/NCT00525824||167462|
NCT00534482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-034|Evaluation of the "Americans in Motion - Healthy Interventions" Project|The Impact of Brief Primary Care Counseling and Novel Physiological Measures on Patient Physical and Emotional Health|AIM-HI|American Academy of Family Physicians|No|Completed|July 2007|October 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|4||Anticipated|950|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 9, 2011|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534482||166807|
NCT00534755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2051-029|Prospective & Retrospective Data Collection of Breast Cancer Cases From 2000 to Present|||King Faisal Specialist Hospital & Research Center|Yes|Completed|June 2005|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10000|||Female|N/A|N/A|No|||December 2011|February 24, 2016|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534755||166786|
NCT00532012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 5001|Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®|An Open-Label, Partially Randomized, Cross-Over, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® in Order to Determine Optimum Doses of Meglumine and RhuDex®||MediGene|No|Completed|September 2007|November 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2008|July 15, 2008|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532012||166994|
NCT00532025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRN-TOM1 KKS 2006-010|Sorafenib in Resected Non-small Cell Lung Carcinoma|A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment Following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients Not Eligible for Cisplatin-based Adjuvant Chemotherapy|SIRN|Johannes Gutenberg University Mainz|Yes|Terminated|September 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|134|||Both|18 Years|N/A|No|||July 2009|July 24, 2009|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532025||166993|
NCT00533156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMI 07-02|Plug Arterial Closure System (PACS, 7F)|Feasibility Study of the 7F Ensure Medical Plug Arterial Closure System (PACS, 7F)|PACS 7F|Cordis Corporation|No|Completed|July 2007|August 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|85 Years|No|||February 2012|February 27, 2012|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533156||166907|
NCT00535444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#G06-08-103-02A|Health and Faith Working to Control Blood Pressure|Health and Faith Working Together to Control Blood Pressure||University of California, Los Angeles|No|Completed|September 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||September 2007|November 8, 2007|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00535444||166734|
NCT00535405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-128|A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)|A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart Disease||Merck Sharp & Dohme Corp.||Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1289|||Both|65 Years|N/A|No|||January 2015|January 19, 2015|September 25, 2007|Yes|Yes||No|April 26, 2010|https://clinicaltrials.gov/show/NCT00535405||166737|
NCT00535639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-01|Tolerability of ALK Tree Tablet|A Randomised, Multiple Dose, Dose Escalation, Double-Blind, Placebo-Controlled Phase I Study Investigating the Safety of ALK Tree Tablet in Adult Subjects With Birch Pollen Induced Rhinoconjunctivitis (With/Without Asthma).||ALK-Abelló A/S||Completed|October 2007|||December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|65 Years||||February 2008|February 28, 2008|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00535639||166719|
NCT00541385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-007-07|Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients|Phase III Comparative, Open-Labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria||Medicines for Malaria Venture|Yes|Completed|October 2007|November 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|534|||Both|N/A|12 Years|No|||January 2009|January 21, 2009|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541385||166283|
NCT00532857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-235|Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab|Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab in Patients With HER2 Positive Operable Breast Cancer|PGH|National Cancer Center, Korea|No|Completed|March 2007|September 2011|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|20 Years|80 Years|No|||January 2012|January 1, 2012|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532857||166930|
NCT00532870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mfms1861964|Laparoscopic Intraperitoneal Mesh Repair of Ventral Hernia: Comparison to Conventional Mesh Repair|||Mansoura University|Yes|Completed|March 2003|December 2004|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|30 Years|N/A||||September 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00532870||166929|
NCT00532883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAMPS-St. Jude|Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease|Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial||St. Jude Children's Research Hospital|Yes|Terminated|January 2007|August 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Both|5 Years|N/A|No|||January 2010|January 14, 2013|September 20, 2007|No|Yes|Enrollment has been terminated due to a slow rate of enrollment.|No|April 1, 2010|https://clinicaltrials.gov/show/NCT00532883||166928|This study was stopped early due to slow enrollment. It should therefore be viewed as a pilot study.
NCT00533988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94/4/4.1;7902114|Central Venous Catheter-Related Infection|Central Venous Catheter-Related Infection: A Prospective Randomized Double-Blind Study||University of Witwatersrand, South Africa|No|Completed|January 1996|December 1999|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|118|||Both|18 Years|N/A|No|||September 2007|September 28, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00533988||166844|
NCT00524745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV01|Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil|Comparison of the Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Vaccine to Prevent HPV Infection||PATH|No|Completed|October 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|903|||Female|11 Years|13 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|August 31, 2007||No||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00524745||167544|
NCT00525044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.490|Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat|Double-blind, Randomized, Placebo-controlled Trial to Investigate the Efficacy and Tolerance of Ambroxol Lozenges 20 mg in the Treatment of Sore Throat in Patients With Acute Viral Pharyngitis||Boehringer Ingelheim||Completed|August 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|249|||Both|16 Years|65 Years|No|||April 2014|April 30, 2014|September 3, 2007||||No||https://clinicaltrials.gov/show/NCT00525044||167521|
NCT00525057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0743|DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study|DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2006|||July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|N/A|No|||September 2015|September 11, 2015|September 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00525057||167520|
NCT00521027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE025VJT|Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers|A Prospective, Comparative, Single-Centre Clinical Evaluation to Investigate the Skin-to-Skin Time of the First Surgical Debridement of Lower Extremity Ulcers With VERSAJET™ Hydrosurgery System and Conventional Debridement Techniques.||Smith & Nephew Medical Ltd|No|Completed|April 2006|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||August 2007|August 23, 2007|August 23, 2007||||No||https://clinicaltrials.gov/show/NCT00521027||167825|
NCT00521885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVH IRB# 2-20070508|Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients|Arixtra(Fondaparinux) vs. Lovenox (Enoxaparin) in Prevention of DVT in Acute Medically Ill, Non-surgical Patients|BRiEF|Lehigh Valley Hospital|Yes|Terminated|September 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|50|||Both|40 Years|N/A|No|||September 2014|September 18, 2014|August 24, 2007|No|Yes|Study stopped due to lack of accrual|No||https://clinicaltrials.gov/show/NCT00521885||167760|
NCT00525889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN018AI|Proleukin and Rapamune in Type 1 Diabetes|A Phase I Trial of Proleukin and Rapamune in Recent-onset Type 1 Diabetes Mellitus (ITN018AI)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2007|September 2013|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|45 Years|No|||March 2014|March 25, 2014|September 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00525889||167457|
NCT00526201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-AAMC-0944|Help Arthritis With Exercise in West Virginia|Arthritis Benefits of a Physical Activity Program in West Virginia: Evaluation of EnhanceFitness|HARE|Centers for Disease Control and Prevention|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|85 Years|No|||December 2015|December 22, 2015|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526201||167433|
NCT00525837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707-002|Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers|Systematic Assessment of Response to Open-label Treatment With Varenicline in Depressed Outpatient Smokers||Butler Hospital|No|Completed|September 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||October 2014|October 3, 2014|September 4, 2007|No|Yes||No|October 4, 2010|https://clinicaltrials.gov/show/NCT00525837||167461|
NCT00534248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-022|Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)|A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age||Merck Sharp & Dohme Corp.||Completed|October 2007|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|22439|||Both|50 Years|59 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|September 21, 2007|Yes|Yes||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00534248||166825|
NCT00534495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 AR070015|Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults|Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)||Montefiore Medical Center|No|Completed|November 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Months|19 Years|No|||November 2015|November 5, 2015|September 24, 2007|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT00534495||166806|
NCT00532909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR0006|Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer|A Phase I Trial of Vandetanib Combined With Capecitabine, Oxaliplatin and Bevacizumab for the First-Line Treatment of Metastatic Colorectal Cancer||Stanford University||Completed|July 2006|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532909||166926|
NCT00532922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RCN-SYM-2006/1|A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®|A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®|Symb NIS|AstraZeneca|Yes|Completed|April 2007|November 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|310|||Both|6 Years|N/A|No|Non-Probability Sample|Natural History, longitudinal, defined population|June 2009|June 8, 2009|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00532922||166925|
NCT00532935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-066|MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)|A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of the MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|517|||Both|18 Years|78 Years|No|||December 2015|December 16, 2015|September 19, 2007|Yes|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00532935||166924|Unknown to the Sponsor and the investigators, two patients in the study were randomized twice (each at two different sites). Data for these patients were deemed unreliable and excluded from all analyses (efficacy and safety).
NCT00534586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603/01|Anesthetics and Auditory, Visceral, and Heat Evoked Potentials|Influence of Anesthetics on Sedation and Antinociception: an Analysis of Auditory Evoked, Visceral Evoked and Heat Evoked Potentials||Technische Universität München|No|Completed|December 2005|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|60|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2005|September 24, 2007|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00534586||166799|
NCT00534599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1441L00016|Generalized Anxiety Disorder Adjunct Study|A Multicenter, Rand., Double-blind, Parallel-group, Pbo-controlled Study of the Efficacy and Safety of SEROQUEL® XR Compared With Pbo as an Adjunct to Treatment in Patients With Generalized Anxiety Disorder Who Demonstrate Partial or No Response to a SSRI or SNRI Alone or in Combination With a Benzo||AstraZeneca||Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|409|||Both|18 Years|65 Years|No|||April 2011|April 12, 2011|September 24, 2007|Yes|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00534599||166798|
NCT00535132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014347|Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone|A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|September 24, 2007|Yes|Yes||No|July 17, 2009|https://clinicaltrials.gov/show/NCT00535132||166757|
NCT00531986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCS-Projekt Nr.: 490|HIV - Monotherapy in Switzerland (MOST-ch)|HIV- Monotherapy in Switzerland (MOST- ch)|MOST|Cantonal Hospital of St. Gallen|Yes|Terminated|January 2007|December 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2009|May 29, 2009|September 18, 2007||No|Unexpectedely high rates of treatment-failure|No||https://clinicaltrials.gov/show/NCT00531986||166996|
NCT00541398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0-204-03-9-9|Antipsychotic Polypharmacy: Prevalence, Background and Consequences|Antipsychotic Polypharmacy: Prevalence, Background and Consequences||Glostrup University Hospital, Copenhagen|No|Completed|January 2008|October 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|222|||Both|18 Years|64 Years|No|||October 2009|October 30, 2009|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541398||166282|
NCT00541411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2031-065|Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma|||King Faisal Specialist Hospital & Research Center||Active, not recruiting|June 2003|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||April 2012|April 16, 2012|October 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541411||166281|
NCT00533715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-2303-BA-CTIL|Forced Inspiratory Flow Volume Curve in Healthy Young Children|Forced Inspiratory Flow Volume Curve in Healthy Young Children||Sheba Medical Center|No|Completed|January 2003|October 2005|Actual|||N/A|Observational|Primary Purpose: Screening, Time Perspective: Cross-Sectional||1|Actual|157|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||September 2007|September 20, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533715||166865|
NCT00534534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00126A|Decrease of Recurrent Pancreatitis|Randomized Clinical Trial of the Effect of Standard Versus Intensive Intervention Protocol in Attempting to Reduce Recurrent Episodes of Acute Alcoholic Pancreatitis||University of Tampere|No|Completed|January 2001|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2007|September 24, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534534||166803|
NCT00534547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS07009|Duodenal Exclusion for the Treatment of Type 2 Diabetes|Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM)||Medtronic - MITG|No|Withdrawn||||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|50 Years|No|||July 2015|July 23, 2015|September 24, 2007||No|business reasons|No||https://clinicaltrials.gov/show/NCT00534547||166802|
NCT00524472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-470|Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery|The Effect of Hyperinsulinemic Glucose Control on Outcomes Following Cardiac Surgery||Outcomes Research Consortium|Yes|Recruiting|July 2007|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|418|||Both|18 Years|90 Years|No|||October 2012|October 15, 2012|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524472||167564|
NCT00520104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-PK-008|Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine|A Randomized, Open Label, Single Center, Single-Dose Study to Assess the Effects of Certain Nasal Medications on the Pharmacokinetics, Safety and Tolerability of PMI-150 (Intranasal Ketamine Hydrochloride) 30 mg||Javelin Pharmaceuticals|No|Active, not recruiting|August 2007|March 2008|Anticipated|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|February 27, 2008|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00520104||167895|
NCT00524758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oculusgen 2006-02-20|Oculusgen (Ologen) Glaucoma MMC Control in Estonia|Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery||Pro Top & Mediking Company Limited|Yes|Recruiting|July 2007|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|N/A|No|||October 2011|October 24, 2011|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524758||167543|
NCT00524771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2007_03|Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)|Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)|TASC|Center for Epidemiology and Health Research, Germany|Yes|Completed|September 2007|June 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|34100|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women prescribed hormonal contraceptives by gynecologists|March 2014|March 3, 2014|September 4, 2007||No||No|March 3, 2014|https://clinicaltrials.gov/show/NCT00524771||167542|In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.
NCT00520767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000555016|Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease|A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|September 2007|December 2016|Anticipated|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|120 Years|No|||February 2016|February 12, 2016|August 24, 2007|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT00520767||167844|Mix of previously treated & newly diagnosed pts (populations which may have different prognoses), plus the relatively small trial size limit conclusions one can draw re: relative efficacy of MDV (vs CyBorD or Mel-Dex, for example)
NCT00521612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75736|Sevoflurane vs. Isoflurane for Low-Flow General Anaesthesia for Abdominal Surgery|Prospective Randomised Controled Trial: Comparison of Volatile Anaesthetics Sevoflurane vs. Isoflurane for Low-Flow General Anaesthesia for Abdominal Surgery||General Hospital Dubrovnik|Yes|Completed|September 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|82|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521612||167781|
NCT00517842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005-228-T|A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease|A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease||Hospital Authority, Hong Kong||Completed|October 2005|September 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|160|||Both|30 Years|N/A||||July 2013|September 3, 2013|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517842||168068|
NCT00517855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTX-100B-102|Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers|A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single-Dose Escalation Study of the Safety and Pharmacokinetics of Intravenous Doses of PRTX-100 in Healthy Adult Subjects||Protalex, Inc.|No|Completed|June 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2008|May 1, 2008|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517855||168067|
NCT00526487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004|Clinical Study to Assess Safety and Effectiveness of the Zenith® Dissection Endovascular System in Patients With Aortic Dissection|Evaluation of the Safety and Effectiveness Performance of the Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissection Involving the Descending Thoracic Aorta||Cook|No|Active, not recruiting|December 2007|December 2016|Anticipated|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2015|December 29, 2015|September 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526487||167412|
NCT00526474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04737|Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)||Merck Sharp & Dohme Corp.|Yes|Completed|September 2007|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26449|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|September 6, 2007|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00526474||167413|Prior to the completion of the study, based on a communication from the Data and Safety Monitoring Board, all participants who had experienced a stroke either before or during the study had study drug discontinued.
NCT00531817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21136|A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)|ROSE|Hoffmann-La Roche||Completed|October 2007|March 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|619|||Both|18 Years|N/A|No|||August 2012|August 13, 2012|September 18, 2007|Yes|Yes||No|July 6, 2010|https://clinicaltrials.gov/show/NCT00531817||167009|
NCT00531830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Children with PDD -31CTIL|Assessment of Factors Which Predict Improvement in Children With PDD After a Year of Integrative Therapy|Assessment of Factors Which Predict Improvement in Children With PDD After a Year of Integrative Therapy||BeerYaakov Mental Health Center|No|Not yet recruiting|September 2007|September 2011|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||2|Anticipated|60|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||September 2007|September 25, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00531830||167008|
NCT00534027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060295|A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer|A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer||Amgen||Completed|January 2008|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|172|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534027||166841|
NCT00531791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO-110754|Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation|Effects of Fluticasone/Salmeterol (Advair®) in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation||Laval University|No|Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|40 Years|N/A|No|||June 2011|June 16, 2011|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531791||167011|
NCT00541099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000555019|Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Evaluation of Bevacizumab and Weekly Docetaxel in Elderly (≥ 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 2008|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|75 Years|N/A|No|||August 2014|August 5, 2014|October 5, 2007|Yes|Yes||No|August 5, 2014|https://clinicaltrials.gov/show/NCT00541099||166305|The increased use of pemetrexed in the front line setting affected accrual.
NCT00541450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-068|A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)|A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|492|||Both|18 Years|78 Years|No|||May 2015|May 4, 2015|October 5, 2007|Yes|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00541450||166278|
NCT00541463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0639-112|A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)|A Multicenter, Open-Label, Randomized, Study to Compare the Efficacy and Safety of Indinavir 800 mg b.i.d. Plus Ritonavir 100 mg b.i.d. Plus Two NRTIs vs. Nelfinavir 1250 mg b.i.d. Plus Two NRTIs in HIV-1 Seropositive Patients Who Have Failed or Are Intolerant to an NNRTI Containing Regimen||Merck Sharp & Dohme Corp.||Completed|January 2001|May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|330|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00541463||166277|
NCT00541684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-946|Health Assessment Study (0954-946)|A Randomized, Double-Blind, Two Arm, Parallel Group Health Assessment Study of Losartan or Atenolol in Patients With Mild to Moderate Hypertension||Merck Sharp & Dohme Corp.||Completed|July 2001|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|143|||Male|40 Years|49 Years|No|||December 2014|December 19, 2014|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541684||166261|
NCT00541697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-807|Eze/Simva Switch Study in Diabetics (0653A-807)|A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes.||Merck Sharp & Dohme Corp.||Completed|January 2005|October 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|648|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541697||166260|
NCT00542048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 4003|A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases|An Open-label, Uncontrolled, Phase II Trial Evaluating the Single-dose and Steady-state Pharmacokinetics of EndoTAG®-1 and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma||MediGene|No|Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|No|||November 2009|February 8, 2010|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00542048||166233|
NCT00520455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037249C|Randomized Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia|Randomized Controlled Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia||University of Washington|No|Completed|January 2004|June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|177|||Female|16 Years|60 Years|No|||November 2007|November 13, 2007|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00520455||167868|
NCT00520468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0253|Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS|Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS||M.D. Anderson Cancer Center|No|Completed|June 2004|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||August 2012|August 1, 2012|August 23, 2007||No||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00520468||167867|
NCT00521248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA018207-01|Buprenorphine for the Treatment of Neonatal Abstinence Syndrome|Buprenorphine for the Treatment of Neonatal Abstinence Syndrome||National Institute on Drug Abuse (NIDA)|Yes|Completed|April 2004|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||December 2009|October 20, 2011|August 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521248||167808|
NCT00517556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25239|Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea|Continuous Administration of a Monophasic Oral Contraceptive in the Treatment of Primary Dysmenorrhea|Dysmenorrhea|Milton S. Hershey Medical Center|No|Completed|August 2007|April 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|May 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00517556||168090|
NCT00518167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL151-6|The Finnish Diabetes Prevention Study|The Finnish Diabetes Prevention Study: A Follow-up Study on the Effect of a Dietary and Exercise Intervention in the Prevention of Diabetes and Its Vascular Complications|DPS|National Institute for Health and Welfare, Finland|Yes|Active, not recruiting|November 1993|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|522|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 31, 2011|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518167||168044|
NCT00518180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P18|A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents|A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents||Novartis|No|Completed|July 2007|October 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1620|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|August 17, 2007|Yes|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00518180||168043|
NCT00521222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1135|Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes|Arg/Arg Genotype and Long Acting Beta Agonists in Asthma. Improved Quality of Care for Patients With Asthma.|ARGARG|Columbia University|Yes|Active, not recruiting|June 2007|November 2013|Anticipated|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|89|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521222||167810|
NCT00521235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPII-2007-10|Effect of Different Working Conditions on Risk Factors in Dentists Versus Trainers|Effects of Different Working Condition on Risk Factors in Dentists Versus Trainers. A Combined Crosssectional and Longitudinal Trial With Student and Senior Employees.||University of Erlangen-Nürnberg Medical School|No|Not yet recruiting|June 2012|December 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|19 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|male and female students of dentistry male and female students of sports male dentists        male teachers of physical education|August 2011|August 10, 2011|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521235||167809|
NCT00526227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111|SecuraTM ICD Clinical Evaluation Study|Clinical Study to Evaluate System Safety and Clinical Performance of the SecuraTM ICD||Medtronic Bakken Research Center|No|Completed|October 2007|October 2008|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|September 6, 2007||No||No|January 13, 2009|https://clinicaltrials.gov/show/NCT00526227||167431|
NCT00526253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMI-WW-02-003|To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction|A Multicenter Study to Assess the Safety and Cardiovascular Effects of Myocell™ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)|MARVEL|Bioheart, Inc.|Yes|Active, not recruiting|September 2007|||February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|170|||Both|18 Years|80 Years|No|||January 2015|January 26, 2015|September 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526253||167430|
NCT00522145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL647-203|Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib|A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib||Kadmon Corporation, LLC|Yes|Completed|May 2007|February 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|August 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00522145||167740|
NCT00522158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 05/75|Effects of Achieving Very Low LDL-Cholesterol After Treatment With Statins on Steroidogenesis and Cognition|||Baskent University|Yes|Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Both|40 Years|85 Years||||August 2007|August 28, 2007|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00522158||167739|
NCT00532636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2439|Head Position Angles in Children|Head Position Angles in Children to Open the Upper Airway||Medical University Innsbruck|Yes|Terminated|January 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|78|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||March 2009|March 25, 2009|September 18, 2007|||Recruitment completed|No||https://clinicaltrials.gov/show/NCT00532636||166946|
NCT00534300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVN3ICD|Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker|Intravenous Infusion of n-3 Polyunsaturated Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)||Aalborg Universitetshospital|Yes|Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|8|||Both|18 Years|80 Years|No|||April 2015|April 15, 2015|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534300||166821|
NCT00534313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-158|Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis|A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis||Bristol-Myers Squibb|No|Terminated|November 2007|May 2011|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|191|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|September 20, 2007|Yes|Yes|Lack of efficacy with respect to skin-related lesions in the short-term phase|No|October 29, 2010|https://clinicaltrials.gov/show/NCT00534313||166820|
NCT00534781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-107WW|Achilles Tendinosis Study; Comparison of Radiofrequency to Surgical MicroDebridement|Radiofrequency-based Plasma Microdebridement Compared to Surgical Microdebridement for Treating Achilles Tendinosis: A Prospective, Randomized, Controlled Multi-Center Study"||ArthroCare Corporation|No|Completed|September 2007|September 2010|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 10, 2013|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534781||166784|
NCT00534794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-408|Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis|A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model||Merck Sharp & Dohme Corp.||Completed|October 2007|||January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|September 20, 2007|Yes|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00534794||166783|
NCT00534807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA183-033|A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer|Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer||Bristol-Myers Squibb|No|Withdrawn|September 2007|November 2008|Anticipated|November 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||October 2007|August 31, 2015|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00534807||166782|
NCT00540865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH075897|Effectiveness of Case Management Versus Case Management Plus Problem-solving Therapy to Treat Depression in Low-income Elders|Case Management and Problem Solving Therapy for Depressed, Homebound, Low-Income Elders||Weill Medical College of Cornell University|Yes|Completed|May 2007|October 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|187|||Both|60 Years|95 Years|No|||December 2014|December 9, 2014|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540865||166323|
NCT00540878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9108307|A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women|An Open-Label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400mg SB-751689 (a Calcium-Sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females||GlaxoSmithKline||Completed|April 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|October 4, 2007||||||https://clinicaltrials.gov/show/NCT00540878||166322|
NCT00541112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000565937|Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery|Phase II Multicenter Study of the Impact of the Therapeutic Sequence of Radiochemotherapy (50 Gy + Capecitabine + Oxaliplatin + Cetuximab) Followed by Total Mesorectal Excision Surgery Then Post-Surgery Chemotherapy (FOLFOX 4 + Cetuximab) in Synchronous Locally Advanced or Metastatic Cancers of the Rectum With Metastases Resectable From the Start (T3-4 Nx or T2 N+ M1).||National Cancer Institute (NCI)||Recruiting|July 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|103|||Both|18 Years|80 Years|No|||October 2007|February 19, 2009|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541112||166304|
NCT00533845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/04/IVA4|Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery|Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery||Maimonides Medical Center|No|Completed|September 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||May 2013|May 25, 2013|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533845||166855|
NCT00542061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Picasso 04-008|Monitoring Asthma and COPD in Primary Care|Clinical Effectiveness and Cost-effectiveness of a Monitoring System for Patients With COPD and Asthma With Persistent Obstruction in Primary Care; a Multicentre Randomised Nested Clinical Trial|Monaco|Radboud University|No|Completed|March 2005|April 2008|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2|||200|||Both|25 Years|N/A|No|||October 2007|March 8, 2010|October 8, 2007||||No||https://clinicaltrials.gov/show/NCT00542061||166232|
NCT00542334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/02S(E)|Prevalence of Nocturnal Hypoglycemia in Children on a Type 1 Diabetes (TID) Insulin Regimen Using a Continuous Glucose Monitoring System (CGMS)|Prevalence of Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes on a Standard (TID) Insulin Regimen Using a Continuous Glucose Monitoring System (CGMS) - A Pilot Study||Children's Hospital of Eastern Ontario|No|Completed|September 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|30|||Both|2 Years|18 Years|No|Non-Probability Sample|Children and adolescents with type 1 diabetes|November 2008|January 25, 2010|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542334||166211|
NCT00520780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-CARS-02|Ferinject® Assessment in Patients With IRon Deficiency and Chronic Heart Failure (FAIR-HF)|A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency|FAIR-HF|Vifor Inc.|Yes|Completed|April 2007|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|456|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00520780||167843|
NCT00521040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00306|Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR|Evaluation of the Efficacy and Safety of Levocetirizine During 8 Weeks Preceding and Following the Anticipated Onset of the Grass Pollen Season in Subjects Suffering From Seasonal Allergic Rhinitis Associated With Pollen-induced Asthma||UCB Pharma|No|Completed|February 2004|July 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|459|||Both|12 Years|N/A|No|||September 2009|December 11, 2013|August 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00521040||167824|
NCT00521053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-MM-02|Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma|A Phase 2 Study of Intralesional PV-10 in the Treatment of Metastatic Melanoma||Provectus Pharmaceuticals|No|Completed|September 2007|June 2012|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 24, 2007|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00521053||167823|
NCT00521911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROJECT9999|Detection and Treatment of Depression in Patients Admitted to the General Hospital|||Radboud University|Yes|Recruiting|August 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2008|December 24, 2008|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521911||167758|
NCT00517868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URG101-104|Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis|URG101 Pharmacodynamic and Safety Study: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Cross-Over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.||Urigen|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||April 2008|April 7, 2008|August 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517868||168066|
NCT00517881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20944|A Study of Subcutaneous Mircera for the Maintenance Treatment of Pre-Dialysis Patients With Chronic Renal Anemia.|An Open Label Study to Assess the Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Monthly Administration of Subcutaneous Mircera in Pre-dialysis Patients With Chronic Renal Anemia||Hoffmann-La Roche||Completed|July 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517881||168065|
NCT00518193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERBUS|Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix||ERBUS|ARCAGY/ GINECO GROUP|Yes|Terminated|April 2007|September 2008|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||June 2011|June 29, 2011|August 14, 2007||No|high rate of medullar aplasia with infectious troubles.|No||https://clinicaltrials.gov/show/NCT00518193||168042|
NCT00521586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3001|Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine|A Phase 3, Randomized, Double-blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vpnc Administered 5 Years After Initial 13vpnc Vaccination||Pfizer|No|Completed|September 2007|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1116|||Both|50 Years|59 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|August 24, 2007|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT00521586||167783|
NCT00521599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04828|A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)|A Study of the Therapeutic Equivalency of MF DPI 100 mcg and 200 mcg Inhalers in Corticosteroid-Dependent Subjects With Moderate Asthma||Merck Sharp & Dohme Corp.|No|Completed|May 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|672|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|August 27, 2007|Yes|Yes||No|February 26, 2010|https://clinicaltrials.gov/show/NCT00521599||167782|
NCT00521872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33-2006|Stapled Trans Anal Rectal Resection (STARR) for Outlet Obstruction: Functional and Morphological Outcome|Stapled Trans Anal Rectal Resection (STARR) for Outlet Obstruction: Functional and Morphological Outcome||University of Zurich|No|Completed|April 2004|October 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||August 2007|June 25, 2008|August 27, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00521872||167761|
NCT00517517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810701|Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)|An Open-Label Phase I/II Study to Assess the Safety and Immunogenicity of Two Doses of a Vero Cell Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Volunteers Aged 21 to 45 Years||Nanotherapeutics, Inc.|Yes|Completed|July 2007|February 2008|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||September 2011|October 7, 2015|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517517||168093|
NCT00526500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNRC-AAU-07-1|Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Brain Injury.|Effect of Proprioceptive Stimulation With Passive Gait Training on the Cortical Activity in Patients With Impaired Consciousness Due to Severe Brain Injury.||University of Aarhus|No|Recruiting|August 2006|May 2009|Anticipated|May 2009|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2008|November 10, 2008|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526500||167411|
NCT00533442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000176|Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients|Tacrolimus and Mycophenolate Mofetil vs Tacrolimus and Sirolimus in SPK, Pancreas After Kidney or Pancreas Transplant Alone||University of Miami|No|Active, not recruiting|September 2000|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|190|||Both|18 Years|65 Years|No|||June 2015|June 3, 2015|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533442||166886|
NCT00533754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 06-076-VK|Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population|Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population||Rudolf Foundation Clinic|No|Active, not recruiting|July 2006|November 2007|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|||||||Both|55 Years|N/A|No|||September 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533754||166862|
NCT00544752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-563|Indoor Temperature and Sleep Apnea|Indoor Temperature and Sleep Apnea||Umeå University||Completed|January 2005|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|40|||Both|N/A|N/A|No|||April 2011|April 13, 2011|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544752||166028|
NCT00544765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 24|Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer|A Multi-center Randomized Phase III Study Evaluating 4 Cycles of Docetaxel, Doxorubicin and Cyclophosphamide Versus 4 Cycles of Vinorelbine and Capecitabine in Patients Not Sufficiently Responding to 2 Cycles of TAC and 4 Cycles of TAC Versus 6 Cycles of TAC in Patients Sufficiently Responding to 2 Cycles of TAC as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer|GeparTrio|German Breast Group|Yes|Completed|September 2002|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2014|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|July 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00544765||166027|
NCT00545090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19937|ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.|An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva||Hoffmann-La Roche||Completed|August 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|561|||Female|N/A|85 Years|No|||December 2015|December 1, 2015|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545090||166005|
NCT00545103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-314|Prevention of Recurrence of Diverticulitis|A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.|PREVENT2|Shire|No|Completed|December 2007|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|592|||Both|18 Years|N/A|No|||February 2013|June 6, 2014|October 16, 2007|Yes|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT00545103||166004|
NCT00545441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006|A Randomized Clinical Trial Comparing Surgisis AFP to Advancement Flap for the Repair of Anal Fistulas|A Randomized Clinical Trial Comparing Surgisis AFP to Advancement Flap for the Repair of Anal Fistulas|Surgisis® AFP|Cook|No|Completed|June 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|October 16, 2007|No|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT00545441||165978|
NCT00541125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564089|G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer|Phase II, Multicenter Study Evaluating G-CSF as Primary Prophylaxis for Neutropenia Associated With First-line Chemotherapy Regimen FOLFIRI and Bevacizumab in Patients With Metastatic Colorectal Cancer Who Are Homozygous for UGT1A1*28 Polymorphism, the Promoter of the Gene Encoding for the Enzyme UGT1A1||Federation Francophone de Cancerologie Digestive|Yes|Completed|November 2007|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|74 Years|No|||October 2007|March 3, 2014|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541125||166303|
NCT00541424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1112|Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma|Feasibility of Combined CT Colonography and PET Imaging for Detection of Colonic Involvement by Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Withdrawn|September 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have newly diagnosed mantle cell lymphoma.|December 2012|December 5, 2012|October 8, 2007||No|No study recruitment due to time constraints and lack of support.|No||https://clinicaltrials.gov/show/NCT00541424||166280|
NCT00541437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBL L-13|Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet|An Open-Label Study to Investigate the Efficacy and Safety of Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet||Genovate Biotechnology Co., Ltd.,|No|Completed|May 2006|February 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|12|||Both|20 Years|75 Years|No|||October 2007|October 9, 2007|October 8, 2007||||No||https://clinicaltrials.gov/show/NCT00541437||166279|
NCT00535262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5439|A Pilot Study Assessing EmSam in Bipolar Depression|A Pilot Study Assessing Efficacy, Safety, and Tolerability of EmSam in Bipolar Depression||New York State Psychiatric Institute|Yes|Terminated|March 2007|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||May 2013|October 24, 2014|September 24, 2007|No|Yes|Current lack of medication support.|No|October 1, 2014|https://clinicaltrials.gov/show/NCT00535262||166748|Early termination due to lack of financial support; only 3 participants were entered into the study; no data was analyzed.
NCT00542087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-805|Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)|A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Etoricoxib 60 mg and Diclofenac Sodium 150 mg in Patient With Osteoarthritis of the Knee or Hip||Merck Sharp & Dohme Corp.||Completed|March 2002|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|516|||Both|40 Years|N/A|No|||April 2015|April 8, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542087||166230|
NCT00542347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1054-07|Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole|Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole||Queen's University|No|Recruiting|September 2007|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00542347||166210|
NCT00521274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRI IRB#0407-0036|Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer|A Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (HRPC)||The Methodist Hospital System|No|Terminated|August 2007|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|August 23, 2007|Yes|Yes|Oxford BioMedica halted TroVax injections|No||https://clinicaltrials.gov/show/NCT00521274||167806|
NCT00521625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALIVE1|Epidemiologic Multicenter Study on Mechanical Ventilation Management in Children With Acute Lung Injury|Epidemiologic Multicenter Study on Mechanical Ventilation Management in Children With Acute Lung Injury - Phase 1 PALIVE 1 (for Pediatric Acute Lung Injury Mechanical VEntilation Strategies)|PALIVE1|St. Justine's Hospital|No|Completed|June 2007|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|N/A|18 Years|No|||May 2008|May 21, 2008|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521625||167780|
NCT00521638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3206K2-104|Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma|A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|September 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521638||167779|
NCT00521898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIIOS.2005.14|Descemet Membrane Endothelial Keratoplasty (DMEK)|Prospective Clinical Study on Descemet Membrane Endothelial Keratoplasty (DMEK)|DMEK|Netherlands Institute for Innovative Ocular Surgery|Yes|Recruiting|February 2005|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|N/A|No|||June 2015|June 2, 2015|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521898||167759|
NCT00517569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-12_HIV_I|Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients|Phase I Study for Assessment of Safety of Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients||Genexine, Inc.|No|Recruiting|August 2006|December 2009|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|50 Years|No|||May 2008|May 8, 2008|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517569||168089|
NCT00517894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL-5|Dose-Dense Therapy in Aggressive Lymphoma|Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma||Arbeitsgemeinschaft medikamentoese Tumortherapie||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|70 Years||||August 2007|August 15, 2007|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00517894||168064|
NCT00517907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIF1BMT-HMO-CTIL|Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD)|Phase I Clinical Trial to Assess Safety of Synthetic Preimplantation Factor (PIF-1) in Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Stem-Cell Transplantation|PIF1GVHD|Hadassah Medical Organization||Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|14 Years|70 Years|No|||August 2008|June 10, 2015|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517907||168063|
NCT00517920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-879|Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)|An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)||AbbVie|No|Completed|September 2007|June 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|August 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517920||168062|
NCT00517933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018538|Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis|Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis|STEP-IPF|Duke University|Yes|Completed|August 2007|October 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|August 15, 2007|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00517933||168061|Findings are limited to patients with advanced IPF. It is unknown if treatment effect was driven by particular subgroup of patients. Study was too short and enrolled too few to assess duration of effect.
NCT00517530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20999|A Dose-Escalating Study of Obinutuzumab in Patients With CD20+ Malignant Disease (GAUGUIN)|An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease.||Hoffmann-La Roche|No|Completed|September 2007|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|134|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|August 16, 2007||No||No|July 14, 2015|https://clinicaltrials.gov/show/NCT00517530||168092|Pharmacodynamic results were limited because number of participants was inversely proportional to length of follow-up. In other words, there were fewer participants still in the trial as the follow-up period became longer.
NCT00517543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109385|A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability|A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553||GlaxoSmithKline||Completed|August 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|August 16, 2007||||||https://clinicaltrials.gov/show/NCT00517543||168091|
NCT00517816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP21029|A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.|A Randomized, Double-blind, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Pharmacodynamic Biomarkers of an Intravenous Infusion of R1671 in Patients With Mild, Intermittent Asymptomatic Asthma||Hoffmann-La Roche||Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|43|||Both|18 Years|50 Years|No|||March 2016|March 1, 2016|August 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00517816||168070|
NCT00517829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06063|Docetaxel+Oxali+/-Cetux Met Gastric/GEJ|Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With or Without Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma||US Oncology Research|No|Completed|July 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 15, 2007|Yes|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT00517829||168069|
NCT00517803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-220|Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies|Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies: A Randomized, Placebo-Controlled Trial||Lawson Health Research Institute|Yes|Active, not recruiting|September 2007|August 2009|Anticipated|August 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2009|July 6, 2009|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00517803||168071|
NCT00544466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04199|Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies||City of Hope Medical Center|Yes|Active, not recruiting|June 2006|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|7 Years|N/A|No|||September 2015|September 24, 2015|October 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544466||166049|
NCT00545454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT5488|Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis|Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis (RA): A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study of 90 µg Administered Once Daily and 90 µg Once Every Other Day|ACCORD-RA|Sanofi|Yes|Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|79|||Both|18 Years|75 Years|No|||January 2009|January 15, 2009|October 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00545454||165977|
NCT00545142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-KOB-0701|Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness|Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder|SMART-A|Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|October 2007|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|280|||Both|18 Years|65 Years|No|||June 2010|June 24, 2010|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545142||166001|
NCT00540891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8472|The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score|The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score|ALF-ACUTE|Sanofi||Completed|February 2003|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|372|||Male|50 Years|N/A|No|||October 2007|October 4, 2007|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540891||166321|
NCT00540904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Silva|Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate|Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate||Barretos Cancer Hospital|Yes|Completed|September 2007|September 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00540904||166320|
NCT00541138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02191|Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors|A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases||City of Hope Medical Center||Completed|May 2003|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541138||166302|
NCT00534976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-377|The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared With Placebo, on Exercise-Induced Bronchoconstriction (EIB) in Pediatric Patients Aged 4 to 14 Years||Merck Sharp & Dohme Corp.||Completed|February 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|364|||Both|4 Years|14 Years|No|||July 2015|July 7, 2015|September 21, 2007|Yes|Yes||No|March 11, 2011|https://clinicaltrials.gov/show/NCT00534976||166769|
NCT00534989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2041-050|Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT|Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT||King Faisal Specialist Hospital & Research Center||Completed|September 2007|December 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||December 2015|December 16, 2015|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534989||166768|
NCT00541710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RODA-12254|Effect of Genistein in Women With Metabolic Syndrome|Genistein Use in Postmenopausal Women With Metabolic Syndrome||University of Messina|No|Completed|October 2007|September 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|45 Years|70 Years|No|||September 2012|September 13, 2012|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541710||166259|
NCT00541723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0617/1|Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles|A Prospective, Randomized, Double-Blind, Multicenter Trial to Investigate the Efficacy and Safety of NT 201 in Comparison to Placebo and to Compare Two Different Application Schemes of NT 201 in the Treatment of Lateral Periorbital Wrinkles||Merz Pharmaceuticals GmbH|No|Completed|September 2007|May 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|111|||Both|18 Years|60 Years|No|||March 2012|March 7, 2012|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541723||166258|
NCT00542074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-9276-001|Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence|Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence||University of Washington|No|Completed|June 2003|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|223|||Both|18 Years|N/A|No|||October 2007|October 29, 2007|October 8, 2007||||No||https://clinicaltrials.gov/show/NCT00542074||166231|
NCT00542100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL-2-001|PCMRI - an MRI/TRUS System for the Evaluation of the Prostate||PCMRI|TopSpin Medical|No|Not yet recruiting|November 2007|November 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Male|25 Years|80 Years|Accepts Healthy Volunteers|||October 2007|October 9, 2007|October 7, 2007||||No||https://clinicaltrials.gov/show/NCT00542100||166229|
NCT00542113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 00-301H R25 015646|Diabetes Virtual Trek: Obesity and Diabetes Prevention Through Science Enrichment|Diabetes Virtual Trek Prevention: Obesity and Diabetes Prevention Through Science Enrichment|DvtENERGY|Colorado State University|No|Completed|September 2001|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1703|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00542113||166228|
NCT00521651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905190|PRelationship Between Physical Activity and Cancer Ris|Physical Activity and Its Components in Relation to Plasma Inflammatory Markers of Cancer Risk Among Chinese Adults||National Institutes of Health Clinical Center (CC)||Completed|July 2005|||||N/A|Observational|N/A|||Anticipated|620|||Both|40 Years|70 Years|No|||November 2012|May 2, 2013|August 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00521651||167778|
NCT00521924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04644|Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)|Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-therapy||Merck Sharp & Dohme Corp.|No|Terminated|June 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|19 Years|65 Years|No|||March 2015|March 18, 2015|August 27, 2007||No|Slow Enrollment|No|April 3, 2009|https://clinicaltrials.gov/show/NCT00521924||167757|
NCT00517582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|495|Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema|Study of a Bradykinin Receptor Blocker in Angiotensin Converting Enzyme Inhibitor-Associated Angioedema||Vanderbilt University|No|Terminated|September 2007|December 2015|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||December 2015|December 16, 2015|August 15, 2007|Yes|Yes|This study was stopped to allow initiation of a mult-center study|No||https://clinicaltrials.gov/show/NCT00517582||168088|
NCT00517595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALJBNSCLC0602|Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC|A Phase II Study of Pemetrexed and Gemcitabine Plus Bevacizumab as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer||Accelerated Community Oncology Research Network|No|Completed|August 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|65 Years|N/A|No|||March 2012|March 8, 2012|August 16, 2007|Yes|Yes||No|October 11, 2011|https://clinicaltrials.gov/show/NCT00517595||168087|
NCT00517608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-2005|Monopolar Scissors vs Bipolar Vessel Sealer vs Ultrasonic Shears: A Prospective Randomized Study in Laparoscopic Colorectal Surgery|||University of Zurich|No|Completed|August 2005|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|95 Years|No|||August 2007|August 20, 2007|August 16, 2007||||No||https://clinicaltrials.gov/show/NCT00517608||168086|
NCT00518791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-IP5.1|Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial|Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial||Radboud University|No|Completed|August 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|301|||Both|20 Years|80 Years|No|||October 2010|November 4, 2010|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518791||167996|
NCT00518141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-06085 (REK)|Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)|Use of Acetylsalicylic Acid and Terbutalin in ART||Sykehuset Telemark|No|Completed|March 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|300|||Female|18 Years|39 Years|No|||July 2011|July 20, 2011|August 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00518141||168046|
NCT00518154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ref. 1663|Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response|Pilot Study of an ACh-E Inhibitor Upon Immune Activation Markers in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy (HAART) Showing an Incomplete Immune Response.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|September 2007|January 2009|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|N/A|No|||April 2009|April 16, 2009|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518154||168045|
NCT00518427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4057|Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine|A Multicenter Clinical Trial to Evaluate Quality of Life in Patients With Type 2 Diabetes Before and After Changing Therapy to a Combination of Insulin Glargine and Oral Antidiabetic Drugs in a Real Life Situation|QoL|Sanofi||Completed|October 2005|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518427||168024|
NCT00518128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR024130|Measuring Effectiveness in Sleep Apnea Surgery|Measuring Effectiveness in Sleep Apnea Surgery||University of California, San Francisco|No|Completed|July 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518128||168047|
NCT00545116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nestec 06.34|Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women|Short-term Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women: a Randomized Placebo-controlled Trial||Nestlé|No|Completed|October 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|144|||Female|50 Years|N/A|Accepts Healthy Volunteers|||January 2014|October 5, 2015|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545116||166003|
NCT00545155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG028942-01|Screening and Interventions in an Acute Care Setting|Screening and Interventions in an Acute Care Setting||University of Rochester|No|Completed|June 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|187|||Both|65 Years|N/A|No|Non-Probability Sample|Geriatric EMS patients|May 2015|May 22, 2015|October 16, 2007||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00545155||166000|administration of one measure was done by individuals not blinded to another, potentially improving the concurrent criterion validity results.a number of subjects did not consent or could not consent to participate in the study.
NCT00532714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-201|Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC|Phase II Study of Irinotecan Plus Capecitabine in Patients With Antracycline and Taxane Pretreated Metastatic Breast Cancer||National Cancer Center, Korea|No|Completed|August 2006|December 2011|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|75 Years|No|||December 2011|December 27, 2011|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532714||166941|
NCT00532727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2006/10003|Triple Negative Breast Cancer Trial|Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic or Recurrent Locally Advanced ER-, PR- and HER2- Breast Cancer.|TNT|Institute of Cancer Research, United Kingdom|Yes|Active, not recruiting|January 2008|July 2015|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||March 2014|March 21, 2014|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532727||166940|
NCT00545467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705030M|Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents|Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents: Combination of Pharmacogenomics and Therapeutic Drug Monitoring||National Taiwan University Hospital|No|Completed|August 2007|July 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|65 Years|No|||January 2012|May 16, 2012|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00545467||165976|
NCT00533221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-GH|Pilot Study of Growth Hormon to Treat SMA Typ II and III|Can Treatment With Human Growth Hormone Increase Strength in Spinal Muscular Atrophy Type II and III?||University Hospital Freiburg|Yes|Completed|October 2007|August 2011|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|6 Years|35 Years|No|||December 2013|December 17, 2013|September 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00533221||166902|
NCT00533234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116-U-001|ExploR® Modular Radial Head Data Collection|ExploR® Modular Radial Head Data Collection||Biomet, Inc.|No|Terminated|December 2009|June 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|4|||Both|N/A|N/A|No|Non-Probability Sample|The study population will be implanted with the ExploR® Modular Radial Head.|March 2012|March 14, 2012|September 20, 2007|No|Yes|There was a lack of business need to continue this data collection.|No||https://clinicaltrials.gov/show/NCT00533234||166901|
NCT00533520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4155s|Evaluation of Dosing Interval of Higher Doses of Ranibizumab|Evaluation of Dosing Interval of Higher Doses of Ranibizumab|BGB/IST|Tennessee Retina|Yes|Completed|September 2007|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|37|||Both|50 Years|95 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533520||166880|
NCT00534950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#0981-019|Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck|||King Faisal Specialist Hospital & Research Center|Yes|Completed|September 2007|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|N/A|No|||December 2011|February 24, 2016|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534950||166771|
NCT00534963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0066|Optimal Catheter Placement During Sonohysterography: Comparison of Cervical to Uterine Placement|Optimal Catheter Placement During Sonohysterography: A Randomized Clinical Trial Comparing Cervical to Uterine Placement||University of Wisconsin, Madison|Yes|Completed|December 2004|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|69|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2007|October 1, 2015|September 23, 2007||||No||https://clinicaltrials.gov/show/NCT00534963||166770|
NCT00541736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHM-GTN-2007-08|Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine|Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine||Danish Headache Center|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2008|May 28, 2008|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00541736||166257|
NCT00541749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN3958g|A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus||Genentech, Inc.||Completed|February 2007|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|65 Years|No|||September 2011|September 21, 2011|October 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541749||166256|
NCT00534391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59/50|Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage|Dose Antibiotic Need in Hordeolum After Incision and Curettage? : A Randomized, Placebo-controlled Trial||Chulalongkorn University|Yes|Recruiting|September 2007|December 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2010|November 22, 2010|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534391||166814|
NCT00534404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511|A Randomized Trial of Internet Access to Nicotine Patches|iQuit Smoking: A Randomized Trial of Internet Access to Nicotine Patches|iQS|University of Michigan|Yes|Completed|March 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2485|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|September 21, 2007||No||No|January 21, 2015|https://clinicaltrials.gov/show/NCT00534404||166813|
NCT00521664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEI 1224/01|A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups|Prospective Randomized Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups: 1)in Patients With Acute Myeloid Leukemia After Intensive Chemotherapy and 2) After Autologous Blood Stem Cell Transplantation||Technische Universität Dresden|Yes|Completed|September 2004|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|16 Years|80 Years|No|||May 2011|May 18, 2011|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521664||167777|
NCT00521937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06FB/DE02|Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer|A Prospective, Randomised, Multi-centre, Blind-observer, Controlled, Parallel-group Study Comparing the Efficacy and Safety of DERMAGEN® Versus Conventional Treatment in the Treatment of Diabetic Neuropathic Foot Ulcer|DERMAGEN®|Laboratoires Genévrier|No|Active, not recruiting|January 2009|December 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|388|||Both|18 Years|N/A|No|||December 2010|December 14, 2010|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521937||167756|
NCT00521950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|945-07-606|Cost-effectiveness of TPMT Pharmacogenetics|Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.|TOPIC|Radboud University|No|Completed|September 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|853|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00521950||167755|
NCT00565383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0897-002|The Effect of Combined Spinal-Epidural Analgesia on the Success of External Cephalic Version (ECV) for Breech Position|The Effect of Combined Spinal-Epidural Analgesia on the Success of External Cephalic Version for Breech Position|Version|Northwestern University|No|Completed|August 2002|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Female|18 Years|55 Years|No|||June 2013|June 12, 2013|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565383||164486|
NCT00565682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOLAAR|Pain Post Abdominal Laparoscopy Prevention With Arcoxia|Pain Post Abdominal Laparoscopy Prevention With Arcoxia||Hospital Vozandez|No|Completed|April 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|70 Years|No|||November 2007|November 29, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565682||164464|
NCT00565695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI-07-002|Evaluation of the Aspheric ReSTOR Intraocular Lens (IOL) After Routine Cataract Extraction|Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction||Medical University of South Carolina|No|Completed|October 2007|September 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|20|||Both|40 Years|80 Years|No|Probability Sample|aspheric ReSTOR multifocal intraocular lens (IOL)|October 2010|October 1, 2010|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565695||164463|
NCT00565994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUHSC IRB #13137|A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure|A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure According to Their Method of Vascular Access||University of Oklahoma|No|Completed|January 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|60|Samples Without DNA|serum|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patients of Dr. William Jennings and Dr. Pranay Kathuria undergoing        dialysis therapy as outpatients. Dialysis and pre-dialysis patients will be recruited from        Dr. Pranay Kathuria's practice. Normal volunteers will be recruited from family members of        the pre-dialysis patients, Internal Medicine patients already scheduled to have blood        drawn for other reasons, or from faculty/staff/student volunteers who are not otherwise        involved with the study and are not in a subordinate role to any of the study        investigators.|September 2010|September 27, 2010|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565994||164441|
NCT00566943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1007, Rev C|Reinforcement of Surgical Staple Lines Using Peri-Strips Dry (PSD) With Veritas Collagen Matrix|Synovis Life Technologies, Inc., Peri-Strips Dry With Veritas Collagen Matrix Staple Line Reinforcement. The RESULTS Trial|RESULTS|Synovis Surgical Innovations|No|Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||July 2011|May 23, 2012|November 29, 2007|Yes|Yes||No|December 18, 2009|https://clinicaltrials.gov/show/NCT00566943||164371|
NCT00566956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0288|Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection|Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection Improves Pregnancy Outcome in In-vitro Fertilization: a Randomised Controlled Trial||Birmingham Women's NHS Foundation Trust|Yes|Terminated|October 1999|June 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|20 Years|39 Years|Accepts Healthy Volunteers|||November 2007|July 20, 2015|November 30, 2007||No|The study was terminated because it is very difficult to recruit more patients.|No||https://clinicaltrials.gov/show/NCT00566956||164370|
NCT00567502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-401|Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments|A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments||Shire|Yes|Completed|May 2005|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3647|||Both|N/A|N/A|No|Probability Sample|Patients receiving cytoreductive therapy for the treatment of at-risk essential        thrombocytopenia (ET).|May 2014|October 15, 2015|December 4, 2007|No|Yes||No|March 25, 2015|https://clinicaltrials.gov/show/NCT00567502||164329|Results for other adverse events (excluding SAEs) was reported under OM 1 due to limitation in basic result’s format, as SAEs and non-SAEs were not planned to be reported separately.
NCT00567515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUS 2007-1|Safety and Effectiveness of Left Atrial Appendage Occlusion|||AtriCure, Inc.|Yes|Completed|September 2007|November 2012|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567515||164328|
NCT00567879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589C2204|A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed on or After Trastuzumab|A Phase Ib/IIa Trial of Panobinostat in Combination With Trastuzumab in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed During or Following Therapy With Trastuzumab||Novartis||Completed|April 2008|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567879||164300|
NCT00568165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Code IDRCD : 2007- A00640 - 53|EMEPIC : Value of a Mobile Team of Cardiologist Using Echocardiography for Managing Patients With Acute Heart Failure|Value of a Mobile Team of Cardiologist Using Echocardiography for Managing Patients With Acute Heart Failure|EMEPIC|University Paris 7 - Denis Diderot|No|Completed|February 2008|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|504|||Both|18 Years|N/A|No|||August 2010|October 25, 2010|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568165||164278|
NCT00568178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-326|An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))|A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension||Merck Sharp & Dohme Corp.|No|Completed|June 2007|March 2011|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|306|||Both|12 Months|17 Years|No|||April 2015|April 7, 2015|December 3, 2007|Yes|Yes||No|August 11, 2009|https://clinicaltrials.gov/show/NCT00568178||164277|
NCT00534677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|297-Med/ERC-04|The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed|Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices||Aga Khan University|Yes|Completed|May 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|No|||September 2007|December 4, 2007|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534677||166792|
NCT00535795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#0971-004|Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA|A Phase III Study to Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA||King Faisal Specialist Hospital & Research Center|Yes|Completed|September 2007|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|N/A|N/A|No|||December 2011|February 24, 2016|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535795||166707|
NCT00531700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-07-0347|Testing a Personally Controlled Health Record to Ameliorate Influenza at MIT|Test of the PING/INDIVO Personal Health Record System at MIT|Indivo at MIT|Children's Hospital Boston||Completed|October 2007|January 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 30, 2009|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531700||167018|
NCT00531713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4-T3 hypothyreose|Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism|Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study.|T4-T3|Copenhagen University Hospital at Herlev|No|Completed|April 2003|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|No|||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00531713||167017|
NCT00531882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot Healthy Volunteers|Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers|A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects||University Hospital Case Medical Center|No|Recruiting|September 2007|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2008|August 15, 2008|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531882||167004|
NCT00532155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10261|A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer|A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer|VITAL|Sanofi|Yes|Completed|September 2007|October 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|913|||Both|18 Years|N/A|No|||January 2012|November 30, 2012|September 19, 2007|Yes|Yes||No|August 17, 2012|https://clinicaltrials.gov/show/NCT00532155||166983|
NCT00532441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI06-101|Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas|Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101||Hoosier Cancer Research Network|Yes|Terminated|September 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 18, 2007||No|Terminated due to funding issues.|No|December 10, 2015|https://clinicaltrials.gov/show/NCT00532441||166961|No statistical correlations with PFS and OS could be performed due to the small number of KRAS mutations.
NCT00533273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX CC 859|Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease Followed by an Open-Label Extension Phase|CORD-II|Endo Pharmaceuticals|No|Completed|August 2007|January 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|September 20, 2007|Yes|Yes||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00533273||166898|
NCT00565396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003ZD002|Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3|Multi-Center,Double-Blind,Randomized,Controlled Clinical Trial of Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3|FLIP|Shanghai Municipal Health Bureau|Yes|Active, not recruiting|September 2004|July 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|75 Years|No|||November 2007|November 29, 2007|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565396||164485|
NCT00565409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-4423|Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis|PRESERVE|Pfizer|No|Completed|March 2008|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|834|||Both|18 Years|70 Years|No|||August 2015|August 4, 2015|November 28, 2007|Yes|Yes||No|May 7, 2012|https://clinicaltrials.gov/show/NCT00565409||164484|
NCT00565708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577892|Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers|Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial|ASCOLT|National Cancer Centre, Singapore|Yes|Recruiting|December 2008|June 2022|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565708||164462|
NCT00566657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6145|Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions|A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions|TAMARIS|Sanofi|Yes|Completed|November 2007|August 2012|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|525|||Both|50 Years|N/A|No|||July 2013|July 31, 2013|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566657||164392|
NCT00566670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00024816|Protein Intake, Nutrition and Cardiovascular Diseases in Stage V CKD|Protein Intake, Nutrition and Cardiovascular Disease in Stage V CKD on Hemodialysis||University of Utah|Yes|Active, not recruiting|September 2007|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|We will draw 30 ml of blood four times (months 1, 6, 12 and 18) for plasma/serum/DNA      samples.Urine Collection: If patients are making more than ½ cup (200 ml) of urine a day.|Both|18 Years|N/A|No|Non-Probability Sample|115 patients from different dialysis centers in Utah and 35 patients from Vanderbilt        University.|December 2013|December 9, 2013|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566670||164391|
NCT00567580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0534|Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer|A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy||Radiation Therapy Oncology Group|Yes|Active, not recruiting|February 2008|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1792|||Male|18 Years|N/A|No|||March 2015|March 31, 2015|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567580||164323|
NCT00567593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK59961|Gene Regulation by Thiazolidinediones|Gene Regulation by Thiazolidinediones|GReaT|University of Pennsylvania|No|Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|December 3, 2007|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00567593||164322|
NCT00567242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC007387-01A1|Treating Intention In Aphasia: Neuroplastic Substrates|Treating Intention In Aphasia: Neuroplastic Substrates||University of Florida|Yes|Completed|March 2007|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|95 Years|No|||April 2012|April 30, 2012|November 30, 2007||No||No|March 6, 2012|https://clinicaltrials.gov/show/NCT00567242||164349|Patients who had aphasia were enrolled. Groups were equated for anomia severity, but not type of aphasia. Aphasia types were not evenly distributed between groups which may affect results.Intention subjects were older than Control Subjects.
NCT00567255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-303|A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects|A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects||Orexigen Therapeutics, Inc|Yes|Completed|December 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1496|||Both|18 Years|65 Years|No|||November 2014|November 18, 2014|November 30, 2007|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT00567255||164348|
NCT00567268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451163|Drug Use Investigation Of Gabapentin|Drug Use Investigation Of Gabapen||Pfizer|No|Completed|August 2007|May 2014|Actual|May 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1273|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A9451163 prescribes the Gabapentin|September 2015|September 30, 2015|November 16, 2007||No||No|April 23, 2015|https://clinicaltrials.gov/show/NCT00567268||164347|
NCT00567528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #0600210|Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes|Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes||Akron Children's Hospital|No|Terminated|May 2006|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|12 Years|19 Years|No|||January 2012|January 13, 2015|December 3, 2007||No|Study was not producing meaningful data.|No||https://clinicaltrials.gov/show/NCT00567528||164327|
NCT00567541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-BBPM-001|An Implantable Microstimulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects|Feasibility Study of the Bioness Battery-Powered Microstimulator (BBPM) to Treat Chronic Shoulder Pain in Chronic Post-Stroke Subjects|BBPM|Bioness Inc|No|Completed|June 2007|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|85 Years|No|||November 2011|August 18, 2015|December 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00567541||164326|
NCT00568529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XELOX-AGC|Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer|Phase II Study on Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer||Fudan University|No|Suspended|October 2007|February 2010|Anticipated|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||August 2009|May 25, 2010|December 5, 2007||No|There are not enough patients enrolled.|No||https://clinicaltrials.gov/show/NCT00568529||164250|
NCT00568828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MacTEL Supplement|MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin|Pilot Study to Evaluate the Changes of Macular Pigment Optical Density in Patients With Idiopathic Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin|MacTEL-Supp|The Lowy Medical Research Institute Limited|No|Recruiting|December 2007|February 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|80 Years|No|Non-Probability Sample|12 patients with Macular Teleangiectasia|December 2007|December 5, 2007|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568828||164228|
NCT00568841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005393-73|Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)|A Phase-II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET for Early Prediction of Non-progression in Patients With Advanced NSCLC Treated With Erlotinib and to Associate PET Findings With Molecular Markers|ERLOPET|Lung Cancer Group Cologne|Yes|Active, not recruiting|October 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2009|September 16, 2009|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568841||164227|
NCT00531661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-06-04|CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients|CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients|CHAMPION|CardioMEMS|Yes|Completed|September 2007|November 2014|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|550|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|September 18, 2007|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00531661||167021|
NCT00531921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-03|Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival|Correlation of Donor Proinflammatory mRNA Profiles With Early Outcomes of Thoracic and Abdominal Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|313|Samples With DNA|Blood and tissue samples to evaluate the heart, kidney, liver, and lung|Both|N/A|70 Years|No|Non-Probability Sample|Transplant patients evaluated for the association between proinflammatory mRNA expression        from donor samples and subsequent development of early organ dysfunction|June 2013|June 3, 2013|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531921||167001|
NCT00531895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O021|An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache|An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache||Kraepelin Psiquiatria Clinica|No|Completed|April 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|55 Years|No|||August 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00531895||167003|
NCT00532519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|horcoop-hmo-ctil|Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis|||Hadassah Medical Organization|Yes|Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|70 Years||||September 2007|September 19, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00532519||166955|
NCT00532532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV650-018|Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis|AV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis||Avigen|No|Terminated|September 2007|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||November 2008|November 3, 2008|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532532||166954|
NCT00532545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6715|Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis|Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis||Eli Lilly and Company|No|Completed|April 2003|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|50 Years|N/A|No|||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532545||166953|
NCT00532454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-198|Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen|A Clinical Study for the Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen in Patients With Metastatic Breast Cancer||National Cancer Center, Korea|No|Terminated|June 2006|December 2007|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|N/A|No|||September 2007|February 9, 2010|September 19, 2007||No|planned to design a prospective study|No||https://clinicaltrials.gov/show/NCT00532454||166960|
NCT00532805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5701|The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency|QUANTitative Chest Computed Tomography UnMasking Emphysema Progression in Alpha-1 Antitrypsin Deficiency|QUANTUM-1|Medical University of South Carolina|Yes|Completed|August 2007|April 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|Samples With DNA|50 cc of serum at visits baseline, 6 months, 12 months, 18 months, 24 months and 36 months      will be retained. These are kept at the University of Florida in the laboratory of Dr. Mark      Brantly.      There is an associated but independent DNA collection that is done if the patient is willing      through an independent study and consent process with the University of Florida Alpha-1 DNA      and Tissue Bank. This is a public resource with a scientific advisory committee with samples      available for researcher access.|Both|18 Years|N/A|No|Non-Probability Sample|Individuals with alpha-1 antitrypsin who have nearly normal lung function tests.        Participants will be identified from patients of the investigators, physician referral,        and the Alpha-1 Foundation Research Registry.|December 2012|December 17, 2012|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532805||166934|
NCT00566007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-R-21|The Effect of Ozone Therapy for Lumbar Herniated Disc|Trial on the Effect of Ozone Therapy for Lumbar Herniated Disc With Criteria for Surgery||Kovacs Foundation|Yes|Suspended|December 2008|April 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|156|||Both|18 Years|75 Years|No|||March 2014|March 11, 2014|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566007||164440|
NCT00566020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA106052|A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -|Study SCA106052, a Clinical Evaluation of BW430C (Lamotrigine) in Bipolar I Disorder- Long-term Extension Study (Extension of Study SCA104779 (NCT00550407))||GlaxoSmithKline||Completed|May 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|20 Years|N/A|No|||September 2013|April 23, 2015|November 28, 2007||No||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00566020||164439|
NCT00566332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WM1|Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia|Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma||French Study Group on Chronic Lymphoid Leukemia|Yes|Completed|June 2001|December 2014|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|414|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566332||164417|
NCT00566033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAURO-001|Multiple Intervention and AUdit in Renal Diseases to Optimize Care|Multiple Intervention and AUdit in Renal Diseases to Optimize Care: the MAURO Study.|MAURO|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|Yes|Completed|January 2006|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|788|||Both|18 Years|75 Years|No|||January 2012|January 27, 2012|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566033||164438|
NCT00566345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|720703|Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)|Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII)||Baxter Healthcare Corporation|Yes|Completed|November 2007|December 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3670|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2009|July 21, 2009|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566345||164416|
NCT00567307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFUBMC-IRB00004134|Polypill For Prevention of Cardiovascular Disease|The Feasibility of a Polypill Clinical Trial for Primary Prevention of Cardiovascular Disease: A Pilot Study||Wake Forest School of Medicine|No|Completed|January 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|216|||Both|40 Years|N/A|No|||February 2009|May 25, 2010|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00567307||164344|
NCT00567606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|536-01-FB|Prevention of Osteoporosis in Breast Cancer Survivors|Prevention of Osteoporosis in Breast Cancer Survivors||University of Nebraska|Yes|Completed|April 2002|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|249|||Female|35 Years|75 Years|No|||January 2010|January 12, 2010|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567606||164321|
NCT00567619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GAT-NEX-2007/1|LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)|LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)||AstraZeneca||Completed|July 2007|||||N/A|Observational|Time Perspective: Prospective||||900|||Both|N/A|N/A|No|||February 2008|February 14, 2008|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00567619||164320|
NCT00567632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Rose|Generation of Standard Laboratory Values for Pneumococci Antibodies|Generation of Standard Laboratory Values for Pneumococci Antibodies||Johann Wolfgang Goethe University Hospitals|Yes|Completed|October 2006|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples Without DNA|human serum|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|any clinically and immunologically healthy subject of any age undergoing selective surgery|October 2007|January 14, 2011|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567632||164319|
NCT00567281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073673-02|Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations|Bilateral rTMS Clinical Trial for Persistent Auditory Hallucinations||Yale University|Yes|Active, not recruiting|October 2007|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|55 Years|No|||June 2015|June 8, 2015|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567281||164346|
NCT00567294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR047782|Evaluating Ways to Improve Medication Use Among People With Osteoporosis|Improving Medication Adherence for Osteoporosis: A Community-Based Randomized Controlled Trial||Brigham and Women's Hospital|Yes|Completed|November 2007|January 2011|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2087|||Both|65 Years|N/A|No|||May 2012|May 14, 2012|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00567294||164345|
NCT00567554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 44|Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer|A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer|GeparQuinto|German Breast Group|Yes|Completed|October 2007|October 2015|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|2600|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567554||164325|
NCT00567567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL0532|Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma|Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma||Children's Oncology Group|Yes|Active, not recruiting|November 2007|||February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|665|||Both|N/A|30 Years|No|||April 2015|February 2, 2016|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567567||164324|
NCT00568204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EvangelicalSynodMC|Study of Effectiveness of Mexyn-A|Proof of Concept of MEXYN-A|Mexyn-A|Evangelical Synod Medical Centre|Yes|Completed|March 2002|September 2005|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|279|||Both|5 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 16, 2013|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00568204||164275|
NCT00568542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8514077463|Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy|Pilot Study to Assess the Effect of Low Dose Epoetin Beta Administered for Six Month in Patients With Ischemic Heart Failure Subjected to Percutaneous Coronary Intervention (PCI)|EPOHeart|Charite University, Berlin, Germany|No|Completed|May 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|45 Years|75 Years|No|||August 2009|August 3, 2009|December 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568542||164249|
NCT00568854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10182007-744|Immunobiology of Diabetes and Tuberculosis|Converging Epidemics: Immunobiology of Diabetes Mellitus and Tuberculosis Infection||Stanford University|Yes|Terminated|April 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|December 4, 2007||No|Additional funding was not secured|No||https://clinicaltrials.gov/show/NCT00568854||164226|
NCT00564434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2005.812|Postoperative Delirium in Hip Fracture Patients|Postoperative Delirium in Hip Fracture Patients||Ullevaal University Hospital|No|Completed|May 2005|January 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||||364|Samples With DNA|whole blood, serum|Both|65 Years|N/A|No||Patients with hip fracture admitted to Ulleval Hospital and Diakonhjemmet Hospital|November 2007|November 27, 2007|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00564434||164559|
NCT00531349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-532|Regional Anesthesia and Endometrial Cancer Recurrence|Regional Anesthesia and Endometrial Cancer Recurrence|ECA/R|Outcomes Research Consortium|Yes|Terminated|November 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|85 Years|No|||September 2009|September 21, 2009|September 17, 2007||No|Lack of study population|No||https://clinicaltrials.gov/show/NCT00531349||167043|
NCT00531934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20829|A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.|A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy||Hoffmann-La Roche||Completed|October 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|75 Years|No|||February 2015|February 5, 2015|September 18, 2007||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT00531934||167000|
NCT00532220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ro 200-5450|Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial|Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial||University Hospital, Basel, Switzerland|Yes|Completed|December 2007|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|75 Years|No|||August 2015|August 25, 2015|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532220||166978|
NCT00531908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061012|Physiopathology of Sodium Retention in Acromegaly|Physiopathology of Sodium Retention in Acromegaly|AcromEnaC|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||August 2008|December 6, 2011|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531908||167002|
NCT00532558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-475_306|Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg vs Placebo in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension||Takeda|No|Terminated|October 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|657|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|September 18, 2007||No|Overall profile of the compound does not offer significant clinical advantage to patients over    currently available lipid lowering agents|No||https://clinicaltrials.gov/show/NCT00532558||166952|
NCT00532571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoQ10 with PSP/CBD|Effects of Coenzyme Q10 in PSP and CBD|Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study||Lahey Clinic|No|Completed|January 2004|September 2005||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|40 Years|N/A|No|||September 2007|September 19, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532571||166951|
NCT00532467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN002|Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers|Phase I, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of SRX251 Capsules in Healthy Volunteers||Azevan Pharmaceuticals|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|March 11, 2008|September 18, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00532467||166959|
NCT00532480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607-22|Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine|Duloxetine Effects on Brain fMRI Response to Emotionally Valenced Pictures in the Treatment of Patients With Major Depression||Indiana University|No|Completed|September 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||March 2013|March 5, 2013|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532480||166958|
NCT00532493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|563|Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD (PACT)|CSP #563 - Prazosin and Combat Trauma PTSD (PACT)|PACT|VA Office of Research and Development|Yes|Completed|January 2010|May 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|September 18, 2007|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT00532493||166957|
NCT00532506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP1001|Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus|||Sanwa Kagaku Kenkyusho Co., Ltd.||Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|20 Years|74 Years|No|||October 2008|October 8, 2008|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00532506||166956|
NCT00533065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-003|Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone|Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone|GH-003|Ludwig Boltzmann Gesellschaft|No|Completed|September 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|80|||Both|70 Years|80 Years|Accepts Healthy Volunteers|||August 2009|August 6, 2009|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533065||166914|
NCT00533312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-026|MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)|A Multicenter, Randomized, Double-Blinded, Parallel-Design Study to Evaluate the Lipid-Altering Efficacy of 2 Formulations of MK0524A Compared to NIASPAN (TM)||Merck Sharp & Dohme Corp.||Completed|February 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|407|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533312||166895|
NCT00533039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIDER001|sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial|sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial|SPIDER-PCI|University Health Network, Toronto|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|164|||Both|18 Years|N/A|No|||June 2008|October 8, 2009|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533039||166916|
NCT00533286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF 57-0-0|Do Benzodiazepines Improve the Outcome of Mechanical Physiotherapy for Lumbar Disk Prolapse|Do Benzodiazepines Improve the Outcome of Mechanical Physiotherapy for Lumbar Disk Prolapse: a Prospective Randomized Clinical Trial||University Hospital Tuebingen|Yes|Completed|August 2002|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|75 Years|No|||September 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533286||166897|
NCT00565435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0232|Chiari Study Looking at Use of Duragen Versus Duraguard|Duragen vs. Duraguard in Chiari Surgery||University of Illinois at Chicago|No|Enrolling by invitation|May 2002|December 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Subjects diagnosed with symptomatic Chiari I Malformation|November 2008|November 13, 2008|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565435||164482|
NCT00565734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM-I 07|Surgical Treatment of Cervical Spondylotic Myelopathy|An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy||AO Clinical Investigation and Documentation|No|Completed|November 2007|January 2015|Actual|September 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|479|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic CSM who referred for surgical consultation to the corresponding        participating site's orthopedic or neurosurgery services will be eligible for this study.|March 2015|March 5, 2015|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565734||164460|
NCT00566683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.010-T|Comparison Between Nurse-Administered Propofol Sedation and Diazemuls / Pethidine in Outpatient Colonoscopy|Nurse-Administered Propofol Sedation by PCA Pump Versus Diazemuls / Pethidine in Outpatient Colonoscopy: A Randomized Controlled Study||North District Hospital|No|Completed|July 2005|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|65 Years|No|||November 2007|November 30, 2007|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566683||164390|
NCT00567320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC 000000000|Efficacy of Varenicline in Methadone-Stabilized Cocaine Users|Efficacy of Varenicline in Methadone-Stabilized Cocaine Users||Yale University|Yes|Completed|March 2007|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|31|||Both|18 Years|55 Years|No|||January 2013|January 31, 2013|December 3, 2007||No||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00567320||164343|
NCT00567892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0689|Collaborative Tinnitus Research at Washington University|Collaborative Tinnitus Research at Washington University|CTRWU|Washington University School of Medicine|Yes|Completed|January 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|60 Years|No|||August 2012|August 23, 2012|December 3, 2007|Yes|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00567892||164299|Excluding subjects with Beck Depression Index of above 14 we treated an exclusive group of the Very bothered tinnitus patients, which may not be representative of the tinnitus population as a whole.
NCT00568191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 06-007-VK1|Stratus Versus Cirrus OCT in AMD|Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Recruiting|October 2007|December 2007|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|55 Years|N/A|No|Non-Probability Sample|Patients aged > 55 years of either sex presenting with age-related macular degeneration|December 2007|December 4, 2007|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568191||164276|
NCT00568217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fs07hr|Antipyretics for Preventing Recurrences of Febrile Seizures|Antipyretics for Preventing Recurrences of Febrile Seizures||University of Oulu|No|Completed|September 1997|August 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|231|||Both|3 Months|4 Years|No|||December 2007|December 8, 2007|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568217||164274|
NCT00568230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-023P|Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device to Reduce Mitral Regurgitation|An Open-Label, Single-Arm Feasibility Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty (PTMA) Device Used to Reduce Mitral Regurgitation.|PTOLEMY|Viacor|Yes|Completed|April 2006|November 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|50 Years|80 Years|No|||November 2008|November 5, 2008|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00568230||164273|
NCT00532662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-02-78-56790|Postoperative Analgesia by Epidural vs IV Ketamine Concurrent With Caudal Anesthesia in Pediatric Orthopedic Surgery|Intravenous Versus Caudal Supplementation of Ketamine for Postoperative Pain Control in Children,A Double-blind Controlled Clinical Trial.||Tehran University of Medical Sciences|Yes|Recruiting|November 2007|July 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|12 Years|No|||November 2010|November 17, 2010|September 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532662||166945|
NCT00532675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2206|Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.|A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Oral Lenalidomide & Dexamethasone in Adult Patients With Multiple Myeloma||Novartis||Active, not recruiting|April 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532675||166944|
NCT00532948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO18517|A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas|A Dose-escalation Study of Xeloda Plus Radiation Therapy in Pediatric Patients With Newly Diagnosed Non-disseminated, Intrinsic Brainstem Gliomas and High Grade Gliomas.||Hoffmann-La Roche||Completed|May 2007|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|3 Years|21 Years|No|||October 2015|February 17, 2016|September 20, 2007|Yes|Yes||No|December 28, 2015|https://clinicaltrials.gov/show/NCT00532948||166923|
NCT00533169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0807|ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma|A Phase I Study of ZD6474 (Zactima) Alone and in Combination With Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma||M.D. Anderson Cancer Center|No|Terminated|September 2007|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|2 Years|N/A|No|||December 2011|December 13, 2011|September 19, 2007|No|Yes|Lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00533169||166906|
NCT00531362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSI1|Enteric Coating as a Factor in Aspirin Resistance|Enteric Coating as a Factor in Aspirin Resistance||Royal College of Surgeons, Ireland|No|Completed|September 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|Samples Without DNA|Serum samples will be collected and stored for later analysis|Both|N/A|N/A|No|Non-Probability Sample|Patients attending the cardiac outpatients clinic or the cat lab of Beaumont hospital,        Dublin, Ireland|September 2009|September 28, 2009|September 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00531362||167042|
NCT00532233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2202|SD, IL-13 Production Rate in IPF|A Open-label, Multi-center Study, With a Single Intravenous Dose of QAX576 to Determine IL-13 Production in Patients With Idiopathic Puilmonary Fibrosis||Novartis|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|40 Years|80 Years|No|||November 2012|November 27, 2012|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00532233||166977|
NCT00532168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANZ-3|Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl|Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study.|ADVANZ-3|Hospital Clinic of Barcelona|No|Completed|September 2007|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532168||166982|
NCT00532181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS Protocol 2007-3-48|Micro-Health Insurance in Cambodia|A Randomized Control Trial of Micro-Health Insurance in Cambodia||University of California, Berkeley||Not yet recruiting|April 2008|December 2011|Anticipated|||Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||||||Both|N/A|N/A||||September 2007|September 19, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532181||166981|
NCT00533351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201781-504|Safety and Efficacy of AGN201781 in Neuropathic Pain|||Allergan|No|Terminated|March 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|September 19, 2007|Yes|Yes|This study was terminated early due to low enrollment.|No|December 15, 2011|https://clinicaltrials.gov/show/NCT00533351||166893|This study was terminated early due to low enrollment (only 9 of the required 40 subjects had been enrolled). Due to the low number of patients who completed the treatment period of the study, no analyses were performed.
NCT00533364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBG-2-01|Effect of SBG in Patients With Breast Cancer|A Phase I/II Study to Assess the Effect of Soluble Beta-1,3/1,6-glucan in Combination With Standard Therapy in Patients With Breast Cancer||Biotec Pharmacon ASA||Completed|January 2007|January 2010|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||February 2010|February 17, 2010|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533364||166892|
NCT00532818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/027/ICI|Hydralazine Valproate for Cervical Cancer|Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.||National Institute of Cancerología|Yes|Recruiting|July 2007|December 2010|Anticipated|September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|143|||Female|18 Years|N/A|No|||March 2009|March 27, 2009|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532818||166933|
NCT00533936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000557417|Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer|Adjuvant Trastuzumab vs Observation in Locally Advanced Breast Cancer Treated With Neoadjuvant Trastuzumab||National Cancer Institute (NCI)||Recruiting|September 2006|||December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|160|||Both|18 Years|65 Years|No|||March 2008|August 23, 2013|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533936||166848|
NCT00533052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 DK73536 (completed)|Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment|Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|October 2007|May 2008|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|21 Years|70 Years|No|||January 2011|January 31, 2011|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533052||166915|
NCT00566046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2006-006518-13|Prevention of Post-traumatic Seizures With Levetiracetam|Prospective, Randomized, Double-blind Study Assessing the Effects of Levetiracetam Compared to Placebo in the Prevention of Early Epileptic Seizures and Late Epilepsy in Patients With Severe Traumatic Brain Injury|TRACK|Rennes University Hospital|Yes|Terminated|November 2007|May 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|23|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|November 29, 2007||No|Sponsor decision because of to small enrollment|No||https://clinicaltrials.gov/show/NCT00566046||164437|
NCT00566358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0002|Surgical Treatment of Non-obese Type 2 Diabetic Patients With Duodenal Exclusion|Lightening the Hormonal Mechanisms of Surgical Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Surgery||University of Campinas, Brazil|No|Completed|January 2006|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|60 Years|No|||July 2010|July 20, 2010|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566358||164415|
NCT00567931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00268|1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery|A Phase 1 Study of 1-Methyl-D-tryptophan in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|October 2007|September 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|December 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00567931||164296|
NCT00531518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58920|Early Detection and Intervention for the Prevention of Psychosis|Early Detection and Intervention for the Prevention of Psychosis Project|EDIPP|Maine Medical Center|Yes|Completed|October 2007|September 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3337|||Both|12 Years|25 Years|No|||October 2015|October 22, 2015|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531518||167031|
NCT00531531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFC#16/2007|Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of People With Cystic Fibrosis|Control and Prevention of Respiratory Infections in Cystic Fibrosis Patients: an Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of Infected Persons Through Coughing and Conversation.||University of Florence||Completed|September 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|42|||Both|14 Years|60 Years|No|Non-Probability Sample|People with CF attending the CF Center of Tuscany, aged 14 or older, with documented        pulmonary Pseudomnas aeruginosa infection.|August 2011|August 22, 2011|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531531||167030|
NCT00531544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2061 043|A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248|A SU011248 Expanded Access Protocol for Metastatic RCC Patients Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248||King Faisal Specialist Hospital & Research Center|Yes|Completed|February 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|350|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|September 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531544||167029|
NCT00567905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tpe-2007-IRB-05|Effect of Green Tea Extract on Type 2 Diabetes|Effect of Green Tea Extract on Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial|GTT-DM|Taipei Hospital, Taiwan|Yes|Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|20 Years|65 Years|No|||January 2009|January 12, 2009|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567905||164298|
NCT00567918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ-506D-AC10|Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis|Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients||Astellas Pharma Inc|Yes|Completed|May 2004|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|6 Years|N/A|No|||April 2008|April 3, 2008|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567918||164297|
NCT00532337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5334POE003|Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis|A Multi-centre, Randomized, Double Blind, Parallel Group Study to Investigate Efficacy and Safety of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis||Ono Pharmaceutical Co. Ltd||Completed|October 2007|||July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|285|||Female|55 Years|75 Years|No|||June 2012|June 12, 2012|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532337||166969|
NCT00532961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|372|Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex|A Randomized, Double-masked, Parallel Comparison of Ocular Tolerance and IOP Effects of Zylet vs TobraDex Administered Four Times Daily for Four Weeks in Healthy Volunteers||Bausch & Lomb Incorporated|No|Completed|February 2005|June 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532961||166922|
NCT00532974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-HIV-1090|A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)|A Phase 1 Safety and Immunogenicity Study of the Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) Administered Using a Biojector 2000 Needle Free Immunization Device in HIV-1 Infected Individuals Receiving Potent Combination Antiretroviral Therapy (ART)|EP1090|Epimmune|Yes|Active, not recruiting|October 2006|April 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|60 Years|No|||December 2007|December 19, 2007|September 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532974||166921|
NCT00531375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07 003|The Effect of Silicone Hydrogel Contact Lenses on Conjunctival Flora|||University of Melbourne||Completed|September 2007|September 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 17, 2008|September 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531375||167041|
NCT00531401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCA-FTS-201|Study of Salirasib to Treat Non-Small Cell Lung Cancer|Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study||Concordia Pharmaceuticals, Inc|No|Completed|September 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|71|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|September 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531401||167040|
NCT00531726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDDS|Berlin Deep Brain Stimulation Depression Study|Investigation of Efficacy and Safety of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression in a Multicenter, Double-blind, Prospectivly-designed Delayed-onset Study (Tiefe Hirnstimulation Zur Behandlung Therapieresistenter Depressionen-eine Multizentrische, Doppelblinde, Prospektive Studie Mit Einem Delayed-onset Design)|BDDS|Charite University, Berlin, Germany|Yes|Recruiting|September 2007|September 2013|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|25 Years|80 Years|No|||September 2007|July 13, 2011|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531726||167016|
NCT00532194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001346-41|An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer|A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer|ICON6|Medical Research Council|Yes|Active, not recruiting|July 2007|December 2016|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|486|||Female|18 Years|N/A|No|||September 2015|September 21, 2015|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532194||166980|
NCT00532207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8736|Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis|Efficacy and Safety of Teriparatide 20 Micrograms in the Treatment of Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|November 2003|December 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|55 Years|N/A|No|||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532207||166979|
NCT00533637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLA-C004P|Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis|A Double-Blind, Randomized, Placebo-Controlled, Cross-Over, Allergen Challenge Study to Evaluate Taste and Local Tolerance of NLA Nasal Spray in Patients With Allergic Rhinitis||Biolipox AB|No|Completed|September 2007|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|50 Years|No|||September 2007|February 29, 2008|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533637||166871|
NCT00533663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0007|Healing Touch During Chemotherapy Infusions for Women With Breast Cancer|Healing Touch During Chemotherapy Infusions for Women With Breast Cancer||Stanford University||Completed|April 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Female|18 Years|70 Years|No|||June 2013|June 3, 2013|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533663||166869|
NCT00533676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-015|Endpoint Validation Study (0524A-015)|A Randomized, Double-Blind, Placebo-Controlled Endpoint Selection and Questionnaire Validation Study to Assess the Niacin Induced Flushing Caused by NIASPAN (TM)||Merck Sharp & Dohme Corp.||Completed|August 2004|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment||||165|||Both|18 Years|70 Years|No|||July 2015|July 29, 2015|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533676||166868|
NCT00533338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0888|Weight Gain Prevention for Breast Cancer Survivors|Weight Gain Prevention for Breast Cancer Survivors||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2007|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533338||166894|
NCT00533624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A-US10|Myfortic vs. Cellcept in Kidney Transplant Recipients|Head to Head Comparison of Myfortic vs. Cellcept in the Treatment of Kidney Transplant Recipients Using Our Current Center Standardized Concomitant Immunosuppressive Protocol||University of Miami|No|Completed|December 2004|February 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||September 2007|September 19, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533624||166872|
NCT00566696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFLEX|Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies|A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation||St. Jude Children's Research Hospital|Yes|Active, not recruiting|November 2007|January 2017|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|N/A|21 Years|No|||December 2015|December 23, 2015|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566696||164389|
NCT00566384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91692|Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido|Multi-center, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Daily Oral 100 mg Dehydroepiandrosterone (DHEA) Over 6 Treatment Cycles as a Concomitant Therapy to Oral Contraceptives (OC) to Alleviate Complaints of Reduced Libido in Women With Acquired Female Sexual Dysfunction (FSD) Associated With OC-use||Bayer|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|35 Years|No|||November 2014|November 30, 2014|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566384||164413|
NCT00566709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0157/2006|Near Infrared Spectroscopy (NIRS) as Transfusion Indicator in Neurocritical Patients|Phase II Study of Usefulness of Near Infrared Spectroscopy to Optimize Red Blood Cells Transfusion in Neuro Critical Ill Patients With Severe Traumatic Brain Injury, Subarachnoid Hemorrhage or Intracerebral Hemorrhage.||Hospitales Universitarios Virgen del Rocío|Yes|Completed|June 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|16 Years|N/A|No|||February 2016|February 12, 2016|November 29, 2007||No||No|November 20, 2015|https://clinicaltrials.gov/show/NCT00566709||164388|Limited adherence to the protocol in the rSO2 arm
NCT00566722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-238|Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy|Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy||Abbott|No|Completed|January 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|152|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|December 1, 2007|Yes|Yes||No|April 28, 2010|https://clinicaltrials.gov/show/NCT00566722||164387|
NCT00566969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA R01DA014537|Cocaine Withdrawal and Pharmacotherapy Response|Cocaine Withdrawal and Pharmacotherapy Response|Carvedilol|Yale University|Yes|Completed|September 2007|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Actual|77|||Both|18 Years|65 Years|No|||July 2015|July 7, 2015|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00566969||164369|
NCT00566982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-50718|A Clinical Study to Evaluate the Safety of Ospemifene|Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo||Shionogi Inc.||Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|426|||Female|40 Years|80 Years|No|||March 2013|May 21, 2013|November 30, 2007|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00566982||164368|
NCT00566995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080020|Phase II Study of Vandetanib in Individuals With Kidney Cancer|A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors||National Institutes of Health Clinical Center (CC)|Yes|Completed|November 2007|March 2015|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|December 1, 2007|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT00566995||164367|
NCT00532051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00006612-IOL|Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography|Guiding the Treatment of Anterior Eye Diseases With Optical Coherence Tomography|OCT IOL|Oregon Health and Science University|Yes|Recruiting|April 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|patients seeking cataract surgery with implantation of monofocal IOLs (including toric        IOLs) but not multifocal or accommodative IOLs.|April 2015|April 21, 2015|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532051||166991|
NCT00532038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMK-304|A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.|An Open-Label, Long-Term Safety Study to Evaluate the Safety of ThermoProfen™ for the Treatment of Mild to Moderate Pain Associated With Osteoarthritis of the Knee||ZARS Pharma Inc.|No|Terminated|September 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|179|||Both|18 Years|75 Years|No|||March 2012|March 14, 2012|September 18, 2007|Yes|Yes|Corporate decision|No||https://clinicaltrials.gov/show/NCT00532038||166992|
NCT00532688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/07|N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure|Randomised Control Pilot Trial of n-Acetylcysteine in the Treatment of Chronic Heart Failure With Coexistent Chronic Renal Failure.||Bayside Health|No|Recruiting|September 2007|February 2008|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|75 Years|No|||September 2007|September 19, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00532688||166943|
NCT00533494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor166899ctil|The Effect of Patients' Participation in Improving Diabetes Care|||Soroka University Medical Center|No|Completed|January 2000|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||||||Both|30 Years|N/A|No|||April 2003|November 11, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533494||166882|
NCT00533507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109861|Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix||GlaxoSmithKline||Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|230|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||February 2011|January 5, 2012|September 20, 2007|Yes|Yes||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00533507||166881|
NCT00531414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-OSM-401|Inspiratory Flow Using the Osmohaler|Inspiratory Flow and VOlumes in Asthmatic and Healthy Individuals Using the Osmohaler||Pharmaxis|No|Completed|November 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|6 Years|69 Years|Accepts Healthy Volunteers|||April 2008|April 7, 2008|September 16, 2007||||No||https://clinicaltrials.gov/show/NCT00531414||167039|
NCT00531739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURGIWRAP(TM)|SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery|Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery||Cytori Therapeutics|No|Completed|March 2006|July 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2010|October 5, 2010|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00531739||167015|
NCT00532584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709009398|Effect of Steroids on Gene Expression in the Healthy Smokers Lungs|Effect of Inhaled Steroids in Combination With a Long Acting Bronchodilator on Gene Expression in the Lungs of Healthy Smokers||Weill Medical College of Cornell University|No|Withdrawn|February 2011|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|September 19, 2007|Yes|Yes|Study not initiated due to funding.|No||https://clinicaltrials.gov/show/NCT00532584||166950|
NCT00532844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTN-002|A Phase 2, Pharmacokinetic Study of the Effects of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction|A Phase 2, Randomized, Open-label, 2-Treatment, 2-Sequence, 2-Period Crossover, Pharmacokinetic (PK) Study to Compare the Plasma Concentrations of BH4 in Subjects With Endothelial Dysfunction Following 14 Days of Treatment by Each of 2 Regimens: 6R-BH4 With Vitamin C and 6R-BH4 Alone||BioMarin Pharmaceutical|No|Completed|September 2007|March 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||April 2009|December 15, 2014|September 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532844||166931|
NCT00532831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-Phen-OB-1243|Characterisation of Asthma in Obese Subjects|Characterisation of Asthma in Obese Subjects. Relationships Between Asthma and Obesity, Potential Mechanisms by Which Obesity Can Contribute to Asthma and Modify Treatment Responses||Laval University|No|Completed|August 2005|July 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|44|Samples Without DNA|serum plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects wiil be selected from the Hospital asthma primary care clinic and from        advertisements in newspapers. Their will be offered to participate to the study|February 2012|February 20, 2012|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532831||166932|
NCT00533078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007DR2232|Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies|Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies (LUNCH1)|LUNCH1|University Hospital Inselspital, Berne|No|Completed|November 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533078||166913|
NCT00533091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP151|A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis|A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis||MedImmune LLC|Yes|Completed|April 2008|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||May 2012|May 25, 2012|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00533091||166912|
NCT00533689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-MG-209-CTIL|Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2008|January 2010|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Anticipated|2008|||Both|50 Years|90 Years||||September 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533689||166867|
NCT00533377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3241010|ACTiF- Assessment of Closed Tibial Fractures|A Randomized, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of CP-533,536 In Subjects With Closed Fracture Of The Tibial Shaft||Pfizer|No|Completed|January 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|276|||Both|17 Years|N/A|No|||February 2012|February 15, 2012|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533377||166891|
NCT00533650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0429-005|Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)|||Merck Sharp & Dohme Corp.||Completed|April 2001|April 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Female|50 Years|75 Years|No|||May 2014|May 5, 2014|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533650||166870|
NCT00534261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-BNL 99-01|Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?|Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®)|FLAIR|Biogen|Yes|Completed|November 1999|February 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|284|||Both|18 Years|70 Years|No|||December 2007|December 11, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534261||166824|
NCT00534222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NNL-SER-2005/1|Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect|Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect|UPTAQE|AstraZeneca|No|Completed|September 2005|December 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|387|||Both|18 Years|N/A|No|Probability Sample|Psychiatrist' patients|April 2009|December 13, 2011|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00534222||166827|
NCT00534235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-001|Post-Approval Clinical Trial Comparing the Long Term Safety and Effectiveness Coflex vs. Fusion to Treat Lumbar Spinal Stenosis|Post-Approval Study to Investigate The Long Term (5-Year) Survivorship of Coflex Compared to Control Fusion Study Patients||Paradigm Spine||Active, not recruiting|October 2012|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|396|||Both|N/A|N/A|No|||October 2014|October 28, 2014|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534235||166826|
NCT00566397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0341002|A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease|A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|December 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|402|||Both|50 Years|N/A|No|||March 2013|March 19, 2013|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566397||164412|
NCT00535457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4786-ZS-CTIL|The Effects of Pre-operative Magic Tricks Performance on Pre-operative Anxiety in Children|The Effects of Pre-operative Magic Tricks Performance on Pre-operative Anxiety in Children||Sheba Medical Center|No|Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|0|||Both|3 Years|12 Years|No|||June 2012|June 7, 2012|September 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00535457||166733|
NCT00535717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHS RIA|Role of Uttarbasti in the Management of Mutra Marga Sankoch (Urethral Stricture)|Role of Uttarbasti in the Management of Mutra Marga Sankoch (Urethral Stricture)||Maharashtra University of Health Sciences|Yes|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 25, 2007|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00535717||166713|
NCT00531557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT022|Double Protease Inhibitor to Darunavir Switch Study|Phase IV Cohort Study Assessing Feasibility of Substituting Double Ritonavir-boosted Protease Inhibitors With Ritonavir-boosted Darunavir in HIV-infected Individuals With Viral Suppression on Highly Active Antiretroviral Therapy.||St Stephens Aids Trust|No|Completed|September 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531557||167028|
NCT00567008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806565|Chantix for Treating Cocaine Dependence|A Double-Blind Placebo-Controlled Pilot Trial of Varenicline (Chantix) for the Treatment of Cocaine Dependence||University of Pennsylvania|Yes|Completed|December 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|No|||October 2013|October 14, 2013|December 3, 2007|Yes|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00567008||164366|This study was a small preliminary trial, and thus was underpowered for anything less than large effects.
NCT00567021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312004007|German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms|German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms||AstraZeneca|No|Completed|September 2005|December 2005|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|67130|||Both|N/A|N/A|No||PC and internist|January 2008|January 28, 2008|December 3, 2007||||No||https://clinicaltrials.gov/show/NCT00567021||164365|
NCT00567645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16716|Sympathetic Innervation of the Heart and Cardiac Resynchronization Therapy(CRT)|Identification of the Role of Sympathetic Innervation in Heart Failure Patients Treated With Cardiac Resynchronization Therapy. A Pilot Study|PET-CRT|University Medical Center Groningen|No|Recruiting|July 2007|December 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|15|||Both|18 Years|85 Years|No|Non-Probability Sample|chronic heart failure patients with CRT|June 2012|June 18, 2012|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567645||164318|
NCT00531843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6693-30799-01|The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients|The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients||University of California, San Francisco|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|105|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|September 17, 2007|No|Yes||No|June 10, 2013|https://clinicaltrials.gov/show/NCT00531843||167007|
NCT00532987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC0003|Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer|Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer||Stanford University|Yes|Terminated|December 2003|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|30 Years|N/A|No|Non-Probability Sample|History of histologically-confirmed rectal cancer with treatment or undergoing treatment        at Stanford University Hospital.|February 2012|February 24, 2012|September 20, 2007||No|unknown|No||https://clinicaltrials.gov/show/NCT00532987||166920|
NCT00532350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAT370A2103|Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Efficacious Dose of QAT370 Compared to Open-label Tiotropium Bromide Following Once Daily Dosing for 7 Days in COPD Patients||Novartis|No|Completed|July 2007|January 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|22|||Both|40 Years|80 Years|No|||September 2010|September 1, 2010|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00532350||166968|
NCT00565851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00587|Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer|A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer||National Cancer Institute (NCI)|Yes|Recruiting|December 2007|||March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1038|||Female|18 Years|N/A|No|||October 2015|March 24, 2016|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565851||164452|
NCT00566449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014608|A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.|A Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Investigate the Safety and Efficacy of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Male|18 Years|64 Years|No|||April 2014|April 24, 2014|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566449||164408|
NCT00531752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8801004|A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).|A Phase Iia, Randomized, Double Blind, Placebo Controlled, Three-treatment, Two-period Crossover Study Of The Efficacy And Safety Of Two Doses Of Pf-03654746 In Adults With Attention Deficit Hyperactivity Disorder||Pfizer|No|Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|55 Years|No|||January 2016|January 22, 2016|September 18, 2007|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT00531752||167014|Instead of time to sustained response, data for percentage of sustained responders in time-sensitive ADHD symptom scale (TASS) total score was reported as per planned analysis.
NCT00531947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9303-P0605|Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression|A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression||Somerset Pharmaceuticals|No|Completed|July 2007|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|308|||Both|12 Years|17 Years|No|||December 2013|December 12, 2013|September 18, 2007||No||No|December 27, 2012|https://clinicaltrials.gov/show/NCT00531947||166999|
NCT00533104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC Région 2003 / R11-05 / 95|Cell Therapy in Chronic Limb Ischemia|Critical Limb Ischemia Treatment by Local Intra-Muscular Injection of Autologous Mononuclear Cells||CHU de Reims|Yes|Completed|October 2004|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2009|February 5, 2009|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533104||166911|
NCT00533390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0017.1.009.000-03|Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg|Anti-retroviral Efficacy, Tolerance and Other Pharmacologic Interactions of the Non Nucleoside Analog Efavirenz in Association With Rifampicin to Treat Tuberculosis and AIDS|IPEC-EFV|Oswaldo Cruz Foundation|No|Terminated|January 2007|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|September 19, 2007||No|Lack of financial support and low inclusion rate|No||https://clinicaltrials.gov/show/NCT00533390||166890|
NCT00533702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13920|A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma|Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma||Eli Lilly and Company|Yes|Completed|November 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|September 17, 2007|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00533702||166866|
NCT00533130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRM-2008-TYO|Evaluation of the AO Pediatric Classification for Long Bones Fractures Like a Guide for Treatment and Prognosis|Phase 2/3 Eficacy Study of the AO Pediatric Classification in Treatment and Prognosis of Long Bones Fractures|AO-PC|Hospital Cruz Roja Mexicana|Yes|Recruiting|August 2007|July 2008|Anticipated|||Phase 1/Phase 2|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||1|Anticipated|100|||Both|N/A|16 Years|Accepts Healthy Volunteers|||September 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533130||166909|
NCT00533975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071015|A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy|A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy||University of California, San Diego|No|Not yet recruiting|September 2007|December 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533975||166845|
NCT00534846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tore20mg|The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia|The Effect of Toremifene Treatment to the Magnetic Resonance Imaging Findings in Women Suffering From Premenstrual Mastalgia||Satakunta Central Hospital|No|Completed|April 2007|February 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 12, 2009|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534846||166779|
NCT00534859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050017|PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI|PROTECT I, A Prospective Feasibility Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI|PROTECT I|Abiomed Inc.|No|Completed|August 2006|March 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|40 Years|80 Years|No|||March 2011|March 18, 2011|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534859||166778|
NCT00533949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0617|High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|November 2007|||May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|500|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533949||166847|
NCT00533962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01|IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients|Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Glaucoma Patients||Federal University of São Paulo|No|Active, not recruiting|August 2007|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|80 Years|No|||September 2007|September 21, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533962||166846|
NCT00535704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA021736-01|Preventing Substance Use and Risky Behavior Among Rural African American Youth|Preventing Substance Use and Risky Behavior Among Rural African American Youth||National Institute on Drug Abuse (NIDA)|No|Completed|November 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|502|||Both|14 Years|17 Years|No|||April 2014|September 23, 2014|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535704||166714|
NCT00531856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C201|Safety and Tolerability Study of Inhaled Carbon Monoxide in Kidney Transplant Patients|A Prospective, Multicenter, Single-blind, Placebo-controlled, Safety and Tolerability Study of the Effects of Carbon Monoxide for Inhalation in Patients Receiving Kidney Transplants.||INO Therapeutics|Yes|Withdrawn|August 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|September 18, 2007|Yes|Yes|Clinical Hold pending additional data review and protocol amendment|No||https://clinicaltrials.gov/show/NCT00531856||167006|
NCT00532064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0921|Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers|Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2007|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|During the standard-of-care blood draws, additional blood will be drawn to test troponin I      and/or T and BNP levels.|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with advanced cancer receiving sunitinib malate or sorafenib chemotherapy.|April 2015|April 6, 2015|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532064||166990|
NCT00532077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9108122|A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women|An Exploratory, Open Label, Multicenter Parallel Group Study to Evaluate the Effects of Single and Repeat Dosing of SB-751689 (400 mg or 100 mg) or rhPTH(1-34) on the Fractional Renal Excretion of Calcium and Phosphate in Healthy Postmenopausal Females.||GlaxoSmithKline||Completed|August 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|September 17, 2007||||||https://clinicaltrials.gov/show/NCT00532077||166989|
NCT00532389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2207|Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma|A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Bortezomib in Adult Patients With Multiple Myeloma||Novartis||Completed|October 2007|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|September 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00532389||166965|
NCT00532363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-ORPA-1171|Obesity and Asthma:a Specific Phenotype|Obesity-related Pseudo-asthma (ORPA): Description of a Novel Clinical Entity|ORPA|Laval University|No|Completed|September 2005|September 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|44|Samples Without DNA|Serum plasma|Female|18 Years|N/A|No|Non-Probability Sample|Subjects will be selected from advertisements in newspapers and from the hospital primary        care asthma clinic and will be offered to participate to the study.|February 2012|February 20, 2012|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532363||166967|
NCT00565864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002265|Neurocognitive and Metabolic Effects of Mild Hypothyroidism|Neurocognitive and Metabolic Effects of Mild Hypothyroidism||Oregon Health and Science University|No|Completed|August 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|324|||Both|20 Years|75 Years|No|||November 2013|November 7, 2013|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565864||164451|
NCT00533182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070229|Influenza in People With Normal and Weakened Immune Systems|Influenza in the Non-immunocompromised and Immunocompromised Host||National Institutes of Health Clinical Center (CC)||Recruiting|September 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|2 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533182||166905|
NCT00533195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/01/07|Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis|UVA1 Phototherapy Versus 5-MOP UVA Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis||Medical University of Vienna|No|Completed|October 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533195||166904|
NCT00533208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-005|MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)|||Merck Sharp & Dohme Corp.||Completed|July 2003|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|766|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533208||166903|
NCT00566189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0004|New Frontiers on Bariatric Surgical Procedures: Classical Bypass for Type-2 Diabetic Patients With Obesity Grade I|New Frontiers on Bariatric Surgical Procedures. Classical Bypass for Type 2 Diabetic Patients With BMI Between 30 and 34.9 kg/m2||University of Campinas, Brazil|No|Completed|August 2007|December 2012|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|60 Years|No|||March 2013|March 7, 2013|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566189||164427|
NCT00532246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8135|Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo|A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo||Eli Lilly and Company|No|Completed|March 2003|August 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|147|||Female|55 Years|N/A|No|||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532246||166976|
NCT00532597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMCIRB 07-01|Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients|Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients||Eulji General Hospital|Yes|Recruiting|April 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2007|September 19, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00532597||166949|
NCT00531505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002571|Obesity and Memory, mRNA, Body Composition, Comorbidity Scale|Morbid Obesity and Memory, Visceral and Subcutaneous mRNA Analysis, Body Composition, and Comorbidity Scale.|2a|Oregon Health and Science University|Yes|Terminated|March 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|Samples With DNA|Liver and fatty samples were voluntarily given by participant consent.|Both|18 Years|N/A|No|Non-Probability Sample|Subset population of LABS-1 study population.|October 2015|October 14, 2015|September 18, 2007||No|Surgeon mistakenly removed liver and fat tissue from a non-LABS2a participant|No||https://clinicaltrials.gov/show/NCT00531505||167032|
NCT00532298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110620|Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over|Non-Inferiority of GlaxoSmithKline Biologicals' Influenza Vaccine (GSK576389A) 1 Container Over 2 Container Presentation in Adults Aged 65 Years and Over||GlaxoSmithKline||Completed|September 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|1596|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 23, 2012|September 19, 2007|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00532298||166972|
NCT00532311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-475_307|Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg or Placebo When Co-administered With Statins in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension||Takeda|No|Terminated|July 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|411|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|September 18, 2007|Yes|Yes|Overall profile of the compound does not offer significant clinical advantage to patients over    currently available lipid lowering agents|No||https://clinicaltrials.gov/show/NCT00532311||166971|
NCT00533143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322 CEC|Non-invasive Ventilation in Terminally Ill Cancer Patients|Multicenter, Randomised Study of the Use of Non-Invasive Ventilation (NIV) Versus Oxygen Therapy (O2) in Reducing Dyspnea in End-stage Solid Cancer Patients With Respiratory Failure and Distress||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|200|||Both|18 Years|85 Years|No|||July 2012|July 16, 2012|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533143||166908|
NCT00533728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBG-2-02|Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma|A Phase I Study to Determine the Safety and Effect of Soluble Beta-Glucan (SBG) in Combination With Rituximab and COP/CHOP in Patients With Non'Hodgkin's Lymphoma||Biotec Pharmacon ASA|No|Completed|September 2007|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|N/A|No|||March 2009|March 2, 2009|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533728||166864|
NCT00534001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000565103|Bupropion in Helping Adults Stop Smoking|A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation||Roswell Park Cancer Institute|Yes|Completed|January 2006|July 2015|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|97|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|September 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534001||166843|
NCT00534014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-319B|Vitamin C and Cardiovascular Risk|Vitamin C Therapy in Type 2 Diabetes and Cardiovascular Risk||University of New Mexico|Yes|Completed|January 2006|May 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|8|||Both|18 Years|75 Years|No|||March 2008|March 31, 2008|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00534014||166842|
NCT00535431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QGUY/2005/AER 001/-03|Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics|A Study To Investigate The Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatic Subjects||Aerovance, Inc.|No|Completed|December 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||September 2007|September 22, 2007|September 22, 2007||||No||https://clinicaltrials.gov/show/NCT00535431||166735|
NCT00534521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-145|Posterior Tibial Nerve Stimulation vs. Sham|Posterior Tibial Nerve Stimulation vs. Sham||William Beaumont Hospitals|No|Completed|September 2007|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 24, 2007|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00534521||166804|
NCT00531570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 04-31 H11941|Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma|Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma||New York University School of Medicine|No|Completed|February 2005|April 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|21 Years|N/A|No|Non-Probability Sample|Women must have a complex adnexal mass (as defined per ultrasound) which requires surgical        intervention|September 2010|September 22, 2010|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00531570||167027|
NCT00531583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2001-004|Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor|Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor||King Faisal Specialist Hospital & Research Center|Yes|Completed|March 2001|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|350|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|September 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531583||167026|
NCT00532090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21321|A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.|Multiple Ascending Dose (MAD) Study of R4733 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors||Hoffmann-La Roche||Completed|November 2007|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00532090||166988|
NCT00532376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601008320|fMRI Investigation of Depression in Patients With Epilepsy|fMRI Investigation of Depression in Patients With Epilepsy||Weill Medical College of Cornell University|No|Withdrawn|September 2005|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2009|February 6, 2009|September 19, 2007|||Enrollment by invitation only|No||https://clinicaltrials.gov/show/NCT00532376||166966|
NCT00532402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-A-S-1|Continuous and Discontinuous Determination of Propofol Concentration in Breathing Gas|Continuous and Discontinuous Determination of Propofol Concentration in Breathing Gas - Compared With Propofol Concentration in Plasma (Before and) After Lung Passage and Neurophysiological Parameters||University of Luebeck|No|Completed|September 2007|December 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|90 Years|No|Probability Sample|Patients having general anesthesia for cardiac and non-cardiac operation|October 2012|October 29, 2012|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532402||166964|
NCT00565045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD054749|Treatments for Recovery of Hand Function in Acute Stroke Survivors|Contralaterally Controlled Functional Electrical Stimulation for Hemiparetic Hand||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|July 2007|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|80 Years|No|||May 2013|May 7, 2013|November 27, 2007|No|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00565045||164512|
NCT00565266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547|Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)|Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)|TALC|Milton S. Hershey Medical Center|Yes|Completed|May 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|210|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|November 28, 2007||No||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00565266||164495|
NCT00565279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASF1057-301|Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis|Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial.||Astion Pharma A/S|No|Completed|December 2007|June 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||June 2008|June 2, 2008|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565279||164494|
NCT00532701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709014M|Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR|Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response||National Taiwan University Hospital|Yes|Completed|November 2007|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|880|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532701||166942|
NCT00566150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05T-681|Levetiracetam in the Management of Bipolar Depression|Levetiracetam in the Management of Bipolar Depression||Yale University|No|Completed|October 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|November 29, 2007|Yes|Yes||No|October 2, 2009|https://clinicaltrials.gov/show/NCT00566150||164429|
NCT00566176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2005-1|Sole-Therapy Treatment of Atrial Fibrillation|Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation|RESTORE SR II|AtriCure, Inc.||Active, not recruiting|October 2005|February 2017|Anticipated|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|No|||February 2013|February 4, 2013|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566176||164428|
NCT00565877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13466A|The Application of Neck Ultrasound in the Assessment of Peripherally Inserted Central Catheter (PICC) Tip Position|A Randomized, Controlled Trial Evaluating Post-Insertion Neck Ultrasound in Peripherally Inserted Central Catheter Procedures||University of Chicago|No|Completed|October 2004|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|300|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565877||164450|
NCT00566826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR054479|Perioperative Intervention to Improve Post-TKR Support and Function|Perioperative Intervention to Improve Post-TKR Support and Function||University of Massachusetts, Worcester|Yes|Completed|June 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|21 Years|N/A|No|||February 2013|February 24, 2013|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566826||164380|
NCT00532259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-2007-01|CT-011 MAb in DLBCL Patients Following ASCT|Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation||CureTech Ltd|Yes|Completed|October 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|September 19, 2007|Yes|Yes||No|September 22, 2013|https://clinicaltrials.gov/show/NCT00532259||166975|
NCT00532272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-05-149|Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC|A Phase II Non-randomized, Parallel Group Study of Goserelin or Leuprorelin Plus Letrozole in Premenopausal Patients Versus Letrozole Alone in Postmenopausal Patients With Metastatic Breast Cancer||National Cancer Center, Korea|No|Completed|October 2005|August 2010|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Female|18 Years|N/A|No|||September 2007|June 24, 2011|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532272||166974|
NCT00535145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014341|Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease|A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease||Ortho-McNeil Janssen Scientific Affairs, LLC|No|Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|September 24, 2007|No|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00535145||166756|Please see the Clinical Study Report Synopsis for results on the primary outcome measure.
NCT00531999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT023|Raltegravir Insulin Sensitivity Study|An Open Label Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment With Lopinavir / Ritonavir (400 / 100 mg Twice Daily) or Raltegravir 400 mg Twice Daily in HIV Negative Male Volunteers.||St Stephens Aids Trust|No|Completed|October 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|18|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531999||166995|
NCT00532896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-Ch-BAR-Pneu-20086|Impact of Weight Loss Following Bariatric Surgery on Pulmonary Function in Patients With Morbid Obesity|Impact of Weight Loss Following Bariatric Surgery on Pulmonary Function in Patients With Morbid Obesity||Laval University|No|Completed|April 2006|May 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|Samples Without DNA|serum plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects on the waiting list for bariatric surgery at Laval Hospital will be offered to        participate to the study.|February 2012|February 20, 2012|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532896||166927|
NCT00533741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0021|SARS Coronavirus Vaccine (SARS-CoV)|Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV) Vaccine Administered by the Intramuscular Route||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||January 2012|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2010|November 29, 2012|September 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00533741||166863|
NCT00534573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCK4569|Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation|Comparison of Benzamide Derivates (Amisulpride, Moclobemide and Tiapride) as Treatment of Clozapine-induced Hypersalivation: Pilot Double Phase Study: Open and Double-blind|CIH|Beersheva Mental Health Center|No|Completed|November 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|60 Years|No|||November 2009|July 25, 2012|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534573||166800|
NCT00532324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-13145(CMH)/2623-001(NU)|Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns|Community-Acquired Methicillin Resistant Staphylococcus Aureus (CA-MRSA) Vaginal and Nasal Colonization in Pregnant Women and Frequency of CA-MRSA Infections in Previously Healthy Term and Near-Term Neonates||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|January 2008|January 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2009|March 10, 2011|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532324||166970|
NCT00535665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PanFlu-2001|Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine|The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion， Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study||Sinovac Biotech Co., Ltd|Yes|Completed|September 2007|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|402|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2007|November 8, 2007|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00535665||166717|
NCT00535678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE 190-001|Testing Digital Breast Tomosynthesis vs. Regular Mammogram in Detecting Breast Cancer in Women Having Screening Mammogram|A Multicenter Study to Test Digital Breast Tomosynthesis (DBT) Compared to Full-Field Digital Mammography (FFDM) in Detecting Breast Cancer. Part 1. Women Undergoing Screening Mammography||GE Healthcare|No|Completed|June 2007|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|N/A|No|Non-Probability Sample|Women referred for normal screening mammogram|April 2010|May 13, 2010|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535678||166716|
NCT00531622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10290|An Eight-Week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder|An Eight-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Saredutant 100 mg Once Daily in Combination With Escitalopram 10 mg Once Daily in Patients With Major Depressive Disorder||Sanofi|Yes|Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|615|||Both|18 Years|65 Years|No|||February 2009|February 13, 2009|September 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531622||167024|
NCT00531869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS Protocol #2007-7-27|Safe Water Techniques in Kenya|A Study of End-User Preferences for and Use of POU Safe Water Technologies in Kenya||University of California, Berkeley||Recruiting|May 2008|October 2010|Anticipated|May 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||||||Both|N/A|N/A||||July 2008|July 31, 2008|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531869||167005|
NCT00564798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00243|Shapedown BC Program Evaluation|Shapedown BC Program Evaluation||University of British Columbia|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|119|||Both|6 Years|18 Years|No|Probability Sample|A prospective evaluation study of the "Shapedown" BC program (Canada) for children aged        6-18 years.|January 2012|January 27, 2012|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564798||164531|
NCT00565071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/HD20/4758U|Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness|Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness||Makerere University|Yes|Recruiting|October 2006|December 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|102087|||Both|3 Months|N/A|No|||March 2012|March 27, 2012|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565071||164510|
NCT00565058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2040AML201|Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)|A Phase II Simon Two-stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI 2040 in Combination With High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML)||Aptose Biosciences Inc.|No|Completed|August 2007|February 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|60 Years|No|||April 2015|June 29, 2015|November 27, 2007|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT00565058||164511|
NCT00565292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-011|A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)|||Merck Sharp & Dohme Corp.||Completed|July 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|75 Years|No|||February 2015|February 24, 2015|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00565292||164493|
NCT00565591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA1101C|Study Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI|A Stepwise, Rising Dose Study of Male Subjects With Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI Compared With Placebo Acu-30™ DPI||Respirics Inc.|No|Completed|November 2007|February 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|45 Years|No|||February 2008|February 12, 2008|November 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00565591||164471|
NCT00565903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0192 / 201012830|Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome|Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome|PPB|Children's Research Institute|No|Recruiting|March 2005|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|We are collecting blood samples or saliva samples. When available, we also collect tumor      samples from prior surgical procedures.|Both|N/A|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Families who have a child or adult with pleuropulmonary blastoma or cystic nephroma are        invited to participate.|December 2015|December 11, 2015|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565903||164448|
NCT00565539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526F06|Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection|A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection||ZymoGenetics|Yes|Completed|December 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|70 Years|No|||October 2009|October 6, 2009|November 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00565539||164474|
NCT00565552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dermatix01|Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage|Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage for Standardised Total Ear Reconstruction||University of Schleswig-Holstein|No|Recruiting|January 2007|January 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|9 Years|N/A|No|||November 2007|November 29, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565552||164473|
NCT00565565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12356|Single Dose Escalation Study in Patients With Chronic Heart Failure|Proof of Concept Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics of a Single Oral Dose of BAY60-4552 in Patients With Biventricular Chronic Heart Failure and Pulmonary Hypertension in a Non-randomized, Non-blinded, Dose Escalation Design.||Bayer|No|Completed|October 2007|April 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00565565||164472|
NCT00565890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nrntokyo|Supplemental Thyroxine Treatment for Preterm Infants With Hypothyroxinemia|Randomized Controlled Clinical Trial of Thyroxine Supplementation for Very-low-birth-weight Infants With Hypothyroxinemia During the First Month of Age||Tokyo Women's Medical University|Yes|Completed|December 2005|June 2013|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|4 Weeks|No|||June 2013|June 3, 2013|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565890||164449|
NCT00566514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200604-7|The Role of Ribose in Patients Diagnosed With Fibromyalgia|The Role of D-RIbose in Patients Diagnosed With Fibromyalgia||Bioenergy Life Science, Inc.|No|Suspended|July 2006|July 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|78 Years|No|||March 2008|March 10, 2008|November 29, 2007||No|Protocol Under Review|No||https://clinicaltrials.gov/show/NCT00566514||164403|
NCT00566527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRV02C|Comparative Study of Immunogenicity and Safety of a 2-Dose Regimen of ProQuad® Manufactured With rHA|An Open-Label, Randomised, Comparative, Multi-Centre Study of the Immunogenicity and Safety of a 2-Dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age||Sanofi Pasteur MSD|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1260|||Both|9 Months|N/A|Accepts Healthy Volunteers|||April 2009|April 3, 2009|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566527||164402|
NCT00534274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT01 - UC-0140/0505|Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy|Study of Positron Emission Tomography With 3'-Deoxy-3'-[18F] Fluoro-thymidine ([18F]-FLT) for the Evaluation of Response to Neoadjuvant Chemotherapy for Cancers of the Breast||UNICANCER|No|Completed|November 2006|September 2013|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|97|||Female|18 Years|65 Years|No|||December 2014|December 14, 2014|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00534274||166823|
NCT00534820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2041015|Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease|||King Faisal Specialist Hospital & Research Center|Yes|Completed|June 2004|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|450|||Both|N/A|N/A|No|||December 2015|December 16, 2015|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534820||166781|
NCT00535652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-07|Concentration of Ertapenem in Colorectal Tissue|Konzentrationen Von Ertapenem in Kolorektalem Gewebe||University of Ulm|Yes|Completed|September 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|90 Years|No|||February 2009|April 5, 2010|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535652||166718|
NCT00532623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-04-092|Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer|A Phase II Study of Gemcitabine in Combination With Vinorelbine vs. Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer||National Cancer Center, Korea|No|Completed|May 2004|October 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|N/A|No|||September 2007|June 24, 2011|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00532623||166947|
NCT00533429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11398|Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy|Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2010|February 16, 2010|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533429||166887|
NCT00534287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2006-006984-21|Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock|Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem (Meronem®) Versus a Combination Therapy With Moxifloxacin (Avalox®) on Organ Dysfunction in Patients With Severe Sepsis and Septic Shock|MaxSep|Kompetenznetz Sepsis|Yes|Completed|October 2007|June 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534287||166822|
NCT00534560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TON/03/07-CLIN|Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache|Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension|TEMPUS|Minster Research Ltd|No|Completed|October 2007|March 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|542|||Both|18 Years|65 Years|No|||March 2009|March 30, 2009|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534560||166801|
NCT00535158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-000613|Vitamin D 2 to Dialysis Patients|Vitamin D and Muscle Strength in the Dialysis Population|D2D|Brigham and Women's Hospital|No|Not yet recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535158||166755|
NCT00535743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05944|Dose-Finding Trial With Sugammadex at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Subjects of ASA Class 1-3 (19.4.206)(P05944)|A Multi-Center, Randomized, Safety Assessor-Blinded, Placebo- Controlled, Phase II, Parallel Dose-Finding Trial in Subjects of ASA 1-3 to Assess the Efficacy and Safety of 5 Doses of Sugammadex Administered at 3 and 15 Minutes After Administration of 1.0 and 1.2 mg/kg Rocuronium Bromide||Merck Sharp & Dohme Corp.|No|Completed|March 2004|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|September 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535743||166711|
NCT00535756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.4.008|Creon After Pancreatic Surgery|One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year||Abbott|No|Completed|April 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||August 2011|August 16, 2011|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535756||166710|
NCT00564525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-12430|Study of Medication for Functional Abdominal Pain in Children|Evaluation of the Efficacy of Amitriptyline in Children With Abdominal Pain of Non-Organic Origin||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|October 2002|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|8 Years|17 Years|No|||November 2007|November 27, 2007|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00564525||164552|
NCT00564785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWA-2007-001|Synera™ for Epidural Needle Insertion|A Randomized, Double-Blind, Controlled Trial of the Synera™ vs. Lidocaine for Epidural Needle Insertion in Laboring Women||IWK Health Centre|No|Completed|February 2007|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|33|||Female|18 Years|N/A|No|||January 2007|November 27, 2007|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00564785||164532|
NCT00565084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-057|Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)|A Randomized, Placebo-Controlled Single-Dose 3-Period Crossover Study to Assess the Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain||Merck Sharp & Dohme Corp.||Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|45 Years|N/A|No|||March 2015|March 23, 2015|November 28, 2007|No|Yes||No|November 18, 2008|https://clinicaltrials.gov/show/NCT00565084||164509|
NCT00565097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO 2007/010;ABR NL16194.091.0|Lanreotide as Treatment of Polycystic Livers|Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers|LOCKCYST|Radboud University|No|Completed|October 2007|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|88 Years|No|||February 2009|February 16, 2009|November 28, 2007||||No||https://clinicaltrials.gov/show/NCT00565097||164508|
NCT00565305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200305053|Healing Touch Breast Cancer Study|Quality of Life and Immunity During Breast Cancer Treatment||University of Iowa|Yes|Completed|June 2003|November 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|150|||Both|18 Years|N/A|No|||June 2012|June 16, 2012|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565305||164492|
NCT00565604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0107|Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins|Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins The RELIEVE Study|RELIEVE|Vascular Solutions, Inc|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|November 28, 2007||No||No|January 26, 2010|https://clinicaltrials.gov/show/NCT00565604||164470|
NCT00566202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014617|A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression|A Phase IIa Multicenter, Randomized, Double-blind, Double-dummy, and Placebo- and Active Controlled Study to Investigate the Safety and Efficacy of JNJ-18038683 Administered to Subjects With Major Depressive Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|60 Years|No|||August 2014|August 1, 2014|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566202||164426|
NCT00566501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-G000-328|Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease|Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease||Eisai Inc.||Completed|December 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|915|||Both|45 Years|91 Years|No|||May 2012|June 26, 2014|November 29, 2007|Yes|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT00566501||164404|
NCT00566215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0003|Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study|Clinical and Hormonal Study of a New Surgical Treatment of Type 2 Diabetes Mellitus: Duodenal Exclusion Associated With Omentectomy||University of Campinas, Brazil|No|Terminated|July 2007|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|60 Years|No|||July 2010|July 22, 2010|November 30, 2007||No|Benefit of duodenal exclusion alone less than expected for treatment of type 2 diabetes; an    additional effect of combination with omentectomy not observed|No||https://clinicaltrials.gov/show/NCT00566215||164425|
NCT00566852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0614|Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors|A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy||Radiation Therapy Oncology Group|Yes|Active, not recruiting|March 2008|||November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|554|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|December 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566852||164378|
NCT00566865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-1510-CT-002|Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil|A Double-Blind, Placebo-Controlled Study to Assess the Effect of Gemfibrozil Co-Administration on the Pharmacokinetics and Pharmacodynamics of Mitiglinide in Healthy Volunteers||Elixir Pharmaceuticals|No|Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 16, 2009|December 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00566865||164377|
NCT00567151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0711-022-225|Co-Infection of NTM in Patients With Smear Positive Pulmonary TB|Detection of Nontuberculous Mycobacterial co-Infection Using Duplex PCR for Mycobacterial Hsp 65 Gene and Its Clinical Significance in Patients With Smear Positive Pulmonary Tuberculosis||Seoul National University Hospital|No|Completed|December 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Sputa with positive AFB smear|Both|N/A|N/A|No|Non-Probability Sample|Patients visited Seoul National University Hospital|June 2009|June 20, 2009|December 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00567151||164356|
NCT00534833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL205|Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™|Immunogenicity Study of the Antibody Persistence and Booster Effect of DTaP-Hep B-PRP-T Combined Vaccine or Tritanrix HepB/Hib™ at 15 to 18 Months of Age Following a Primary Series at 6, 10 and 14 Weeks of Age in Healthy Filipino Infants||Sanofi|Yes|Completed|September 2007|March 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|362|||Both|15 Months|18 Months|Accepts Healthy Volunteers|||September 2013|September 19, 2013|September 24, 2007||No||No|September 19, 2013|https://clinicaltrials.gov/show/NCT00534833||166780|
NCT00531804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN19866|A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.|A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4909832 Following Intravenous Infusion in AD Patients||Hoffmann-La Roche||Completed|December 2006|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|50 Years|90 Years|No|||March 2016|March 1, 2016|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531804||167010|
NCT00542919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11503|A Study for Patients With Non-Hodgkin's Lymphomas|A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas||Eli Lilly and Company|No|Active, not recruiting|November 2007|February 2017|Anticipated|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|64|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542919||166166|
NCT00542932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0703/151|The Effects of a Home Exercise Video Programme for Patients With COPD|The Effects of a Home Exercise Video Programme for Patients With Chronic Obstructive Pulmonary Disease:Pilot Study||King's College Hospital NHS Trust|Yes|Completed|October 2005|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|N/A|N/A|No|||October 2007|October 11, 2007|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00542932||166165|
NCT00543569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0485-CL-U201|A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients|A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients||Astellas Pharma Inc|Yes|Completed|February 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|323|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|October 11, 2007|Yes|Yes||No|November 6, 2015|https://clinicaltrials.gov/show/NCT00543569||166117|
NCT00543920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0777-020|A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)|||Merck Sharp & Dohme Corp.||Completed|August 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|70 Years|No|||November 2015|November 25, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543920||166091|
NCT00544206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK07|Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes|Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes||Abbott Nutrition|No|Completed|October 2007|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|75 Years|No|||September 2008|September 22, 2008|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544206||166069|
NCT00544193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97087|Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer|Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies||City of Hope Medical Center||Completed|December 1997|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|16|||Both|18 Years|70 Years|No|||June 2015|June 3, 2015|October 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544193||166070|
NCT00531596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9303-P0602|Evaluation of Adhesion and Dermal Tolerability of EMSAM|A PHASE IV, OPEN-LABEL STUDY OF THE ADHESION AND DERMAL TOLERABILITY OF EMSAM (SELEGILINE TRANSDERMAL SYSTEM) IN HEALTHY ADULT SUBJECTS OF TWO AGE GROUPS (18 - 64 YEARS, AND 65 YEARS AND OLDER)||Somerset Pharmaceuticals|No|Completed|April 2007|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00531596||167025|
NCT00568646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-105|Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer|A Phase 2 Study of Oral MKC 1, Administered Twice Daily for 14 Consecutive Days in a 28-Day Cycle, in Patients With Unresectable or Metastatic Pancreatic Cancer Who Have Failed at Least One Prior Chemotherapy Regimen in Either the Neoadjuvant, Adjuvant, or First-line Metastatic Setting||CASI Pharmaceuticals, Inc.||Completed|November 2007|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568646||164242|
NCT00568945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12679|Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.|Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation by Administration of Capadenoson in a Dose of 4 mg Once Daily for Five Days||Bayer|No|Completed|January 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|75 Years|No|||October 2014|October 28, 2014|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00568945||164221|
NCT00564811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-03|Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)|Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom) on the Nutritional State and Liver Biochemistry in Hepatitis C Patients.||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2003|September 2004|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|24 Years|70 Years|No|||May 2015|May 27, 2015|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00564811||164530|
NCT00564824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4913-MS-CTIL|The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease|The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects & in Patients With Ischemic Heart Disease||Sheba Medical Center|No|Completed|November 2007|January 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2010|February 24, 2010|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00564824||164529|
NCT00565318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BENFO-1|Benfotiamine in Diabetic Nephropathy|A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy|Benfo|University Medical Center Groningen|No|Completed|December 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Both|40 Years|75 Years|No|||November 2009|November 13, 2009|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565318||164491|
NCT00565331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRT06|Rituximab for Prevention of Rejection After Renal Transplantation|A Prospective Randomized Study on the Efficacy and Safety of the Prophylactic Use of Rituximab, Added to Standard Immunosuppressive Treatment in Comparison With Standard Immunosuppressive Treatment Alone in Renal Transplantation||Radboud University|No|Completed|December 2007|June 2015|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565331||164490|
NCT00565617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR - 16908|Epidural Cortical Stimulation for Depression|A Pilot Safety and Efficacy Study of Epidural Prefrontal Cortical Stimulation (EpCS) in Severe Treatment Resistant Depression|EpCS-D|Medical University of South Carolina|Yes|Active, not recruiting|October 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5|||Both|21 Years|80 Years|No|||July 2009|July 6, 2009|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565617||164469|
NCT00565630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Drops vs. spray administration|Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops|Pilot Study on Bioavailability of Vigamox Administered as Drops vs. as Spray||Advanced Ophthalmic Pharma|No|Withdrawn|January 2008|March 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|16|||Both|18 Years|N/A|No|||November 2007|February 24, 2009|November 28, 2007||No|Replaced with ongoing study|No||https://clinicaltrials.gov/show/NCT00565630||164468|
NCT00565942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM in Swedish primary care|Exploring Integrative Medicine in Swedish Primary Care|Integrative Medicine for Back and Neck Pain - A Pragmatic Randomized Clinical Pilot Trial||Karolinska Institutet|No|Active, not recruiting|September 2004|January 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||November 2007|November 28, 2007|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565942||164445|
NCT00565916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|489|Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism|Role of Estrogen/SERMS on Cardiac Fatty Acid Metabolism (Aim #1- Human Studies)|Estrogen|Washington University School of Medicine|No|Completed|August 2004|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 27, 2012|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565916||164447|
NCT00565929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0042|Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects|MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2008|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|August 1, 2013|November 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00565929||164446|
NCT00566540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06026|Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer|Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Hypopharynx: Incorporation of Intensity Modulated Radiotherapy and Submandibular Gland Transfer to Minimize Treatment Morbidity; Correlative Imaging/Molecular Markers.||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|December 2007|||February 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566540||164401|
NCT00566878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03406|Pompe Lactation Sub-Registry|A Sub-Registry to Determine the Presence of Alglucosidase Alfa in Breast Milk From Women With Pompe Disease Treated With Alglucosidase Alfa.||Sanofi|No|Recruiting|March 2012|December 2021|Anticipated|November 2021|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|5|||Female|N/A|N/A|No|Non-Probability Sample|Females diagnosed with Pompe Disease and Lactating|March 2016|March 3, 2016|December 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00566878||164376|
NCT00566891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-1-2007|Safety of High-dose Tirofiban During Coronary Angioplasty|Safety of High-dose Tirofiban in Patient Undergoing Coronary Angioplasty.|SANTISS|S. Anna Hospital|Yes|Completed|December 2007|February 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2000|||Both|N/A|N/A|No|||February 2009|February 1, 2011|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566891||164375|
NCT00535418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345EDE01|Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers|Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers||Novartis||Completed|June 2000|||July 2002|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||April 2012|April 18, 2012|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535418||166736|
NCT00542620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1813|Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial|A Randomised, Multicentric, Open Labelled, Parallel Group Trial With Insulin Aspart and Insulin Detemir, Investigating the Glycaemic Effect and Profile in Children With Type 1 Diabetes, of Two Separate Levemir® + NovoRapid® Injections and Extemporaneous Mixing - The Paediatric MIXING Trial|MIXING|Novo Nordisk A/S|No|Completed|September 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|6 Years|18 Years|No|||October 2014|October 24, 2014|October 10, 2007|Yes|Yes||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00542620||166189|
NCT00542633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject™-08J|An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus|An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus||Biodel|No|Completed|December 2006|||August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|472|||Both|30 Years|70 Years|No|||July 2015|July 28, 2015|October 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542633||166188|
NCT00543257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB-R01LM009256|Parents at the Center: Information Management in ADHD - Clinical Trial|Parents at the Center: Information Management in ADHD - Clinical Trial||Children's Hospital Boston|No|Active, not recruiting|December 2007|June 2009|Anticipated|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|224|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Parents of school-age children with ADHD|March 2009|March 26, 2009|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00543257||166140|
NCT00543296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013641|Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment|Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment||Duke University|No|Completed|March 2004|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||June 2014|March 12, 2015|October 11, 2007|No|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00543296||166138|
NCT00543244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709053R|Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan|Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan||National Taiwan University Hospital|Yes|Recruiting|January 2006|December 2008|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C virus infection who receive pegylated interferon plus        ribavirin for an overall of 24-48 weeks|February 2008|November 20, 2008|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00543244||166141|
NCT00543556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-012|MK0767 in Type 2 Diabetes (0767-012)|||Merck Sharp & Dohme Corp.||Terminated|October 2001|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|514|||Both|21 Years|75 Years|No|||June 2015|June 12, 2015|October 5, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00543556||166118|
NCT00543959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0533-005|Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)|An Efficacy and Tolerability Study of MK0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Terminated|June 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|346|||Both|18 Years|70 Years|No|||June 2015|June 22, 2015|October 5, 2007|Yes|Yes|This study is being discontinued based on data suggesting that none of the doses tested    demonstrated both glycemic & body fluid benefits vs. the comparitor|No||https://clinicaltrials.gov/show/NCT00543959||166088|
NCT00545480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19358|SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.|A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.||Hoffmann-La Roche||Completed|July 2006|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|596|||Female|55 Years|N/A|No|||August 2015|August 17, 2015|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545480||165975|
NCT00544479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180964CTIL|No Routine CXR After Bronchoscopy|Is Routine Chest-X-Ray Necessary After Bronchoscpy With Thransbronchial Biopsie? A Prospective Study||Shaare Zedek Medical Center||Completed|March 2015|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|N/A|No|Probability Sample|All consecutive patients with bronchoscopy and transbronchial biopsies will be enrolled in        this study.|May 2015|May 19, 2015|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544479||166048|
NCT00544492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S50619|Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients|Study of Pain, Anxiety, Complications Related to AV Fistula Cannulation in Chronic Hemodialysis Patients. A. Buttonhole vs. Rope Ladder Technique B. Catheters With Cylindrical Point vs. Catheters With Bevel Point in Rope Ladder Technique||Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2007|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|No|||December 2011|December 17, 2011|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544492||166047|
NCT00568958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA_OMALLEY-AA016621|Naltrexone for Heavy Drinking in Young Adults|Naltrexone for Heavy Drinking in Young Adults||Yale University|Yes|Completed|February 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|25 Years|No|||July 2014|July 22, 2014|December 4, 2007|Yes|Yes||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00568958||164220|
NCT00564551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 21076|Effect of Increased Intake of Low Fat Dairy Products on Weight Loss and Insulin Resistance|Impact of High Milk Product and Calcium Intake During Weight Loss on Markers of Insulin Resistance||University of Calgary|No|Completed|October 2007|October 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|20 Years|65 Years|No|||January 2010|January 19, 2010|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564551||164550|
NCT00565110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAPt-C NorrisCCC|Treating Depression Among Low-Income Patients With Cancer|Effectiveness Study of a Stepped Care Depression Algorithm for Patients With Cancer|ADAPt-C|University of Southern California|Yes|Active, not recruiting|July 2004|December 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|472|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00565110||164507|
NCT00565344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medicaid Disenrollment|Medicaid Disenrollment: Intrastate Emergency Department Impact|Medicaid Disenrollment: Intrastate Emergency Department Impact||Vanderbilt University|No|Completed|July 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5000000|||Both|N/A|N/A|No|Non-Probability Sample|Data will be obtained through two datbases. All patients visiting an ED in Tennessee over        a 3 year period are included.|November 2007|June 13, 2013|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00565344||164489|
NCT00565357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-HD042639-01A3|Silicone Earplugs for VLBW Newborns in Intensive Care|Silicone Earplugs for VLBW Newborns in Intensive Care: Feasibility, Sound Attenuation, and Outcomes From a Randomized Clinical Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|June 2002|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|34|||Both|N/A|7 Days|No|||November 2007|November 27, 2007|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00565357||164488|
NCT00565643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB No. 07023|Seprafilm® Adhesion Barrier and Cesarean Delivery|A Multicenter, Randomized, Controlled Trial of Seprafilm® Adhesion Barrier to Reduce Adhesion Formation Following Cesarean Delivery||Winthrop University Hospital|Yes|Completed|November 2007|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|753|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 10, 2014|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565643||164467|
NCT00565656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-PP-05|A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts|A Phase II Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to IPSS) With Excess of Marrow Blasts||Centre Hospitalier Universitaire de Nice|No|Terminated|July 2007|July 2010|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|60 Years|N/A|No|||June 2009|December 7, 2011|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565656||164466|
NCT00565955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vivek|Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children|Effect Of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children Between 5-15 Years of Age - A Randomized, Double Blind, Placebo Controlled Trial|Montelukast|All India Institute of Medical Sciences, New Delhi|Yes|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|5 Years|15 Years|No|||November 2008|November 13, 2008|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565955||164444|
NCT00566228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0681|Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma|Randomized, Double-Blind Phase III Clinical Trial Comparing Outcomes of Immunologic Autograft Engineering Versus Standard Autograft Collection in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma||Mayo Clinic|Yes|Active, not recruiting|December 2007|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566228||164424|
NCT00566553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009628|The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women|The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women: A Pilot Study||Mayo Clinic|No|Completed|February 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|39|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566553||164400|
NCT00542321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMCSCCMAACN|Pilot Study of Lateral Rotation Interventions for Efficacy and Safety in ICU Care|Multi-site Randomized Clinical Trial of Horizontal Positioning to Prevent and Treat Pulmonary Complications in Mechanically Ventilated Critically Ill Patients||The University of Texas Health Science Center, Houston|Yes|Completed|September 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|October 9, 2007||No||No|October 2, 2012|https://clinicaltrials.gov/show/NCT00542321||166212|Reliance on chest X-ray interpretation only for detection of preventable pulmonary complications; small pilot study; kinetic therapy bed turn angle was less than 45 degrees
NCT00542646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PLS-2005-001|Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System|Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System||PeriTec Biosciences Ltd.|No|Recruiting|November 2006|November 2010|Anticipated|||Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||November 2007|November 27, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542646||166187|
NCT00542958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N06-10089|Study of NK012 in Patients With Refractory Solid Tumors|A Phase I Dose-escalation Study of NK012 Administered Intravenously as a Single Dose Every Three Weeks in Patients With Refractory Solid Tumors||Nippon Kayaku Co.,Ltd.|No|Completed|March 2007|December 2011|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|October 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00542958||166163|
NCT00542971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0977|Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)|Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral VEGF, RAF and FLT3 Inhibitor, in Patients With High-risk MDS and AML||M.D. Anderson Cancer Center|No|Completed|October 2007|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|15 Years|60 Years|No|||June 2012|June 12, 2012|October 10, 2007||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00542971||166162|
NCT00542685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361017|A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder|A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder||Pfizer|Yes|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|551|||Both|18 Years|65 Years|No|||November 2012|November 9, 2012|October 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542685||166184|
NCT00542997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1460|Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy|A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency||CSL Behring|No|Completed|September 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|2 Years|65 Years|No|||August 2011|August 2, 2011|October 11, 2007|No|Yes||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00542997||166160|
NCT00543270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP00-005/CP04-001|Powerlink Bifurcated Stent Graft Long-Term Follow-up Study|Endologix Powerlink Long-Term Follow-up Study||Endologix|Yes|Completed|October 2005|November 2009|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|231|||Both|18 Years|N/A|No|||February 2010|February 22, 2010|October 10, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00543270||166139|
NCT00543972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10219|Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia|An Open Label, Dose-Escalation Safety and Pharmacokinetic Study of AVE9633 Administered as a Single Agent by Intravenous Infusion on Day 1, Day 4 and Day 7 of a 4-Week Cycle in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML)||Sanofi|No|Terminated|September 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|October 12, 2007|No|Yes|due to absence of evidence of clinical activity up to toxic doses|No||https://clinicaltrials.gov/show/NCT00543972||166087|
NCT00543985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK067036 (Echo substudy)|Exercise and the Metabolic Syndrome With Weight Regain (Echocardiography Substudy to Evaluate Effect on Diastolic Function)|||University of Missouri-Columbia|No|Recruiting|October 2007|October 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||June 2008|June 11, 2008|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00543985||166086|
NCT00543933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-491|Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease|Acute Effect of Inhaled Nitric Oxide on Pulmonary Insufficiency in Congenital Heart Disease||The Cleveland Clinic|No|Active, not recruiting|October 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|October 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00543933||166090|
NCT00540917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-1999-2250|Measurement Skin Temperature During Pulsed Laser Exposure|Phase II Clinical Trial is to Compare Epidermal Temperature Measurements During 1.Laser Treatment at Standard Treatment Energies 2.Cryogen Spray Cooling (CSC) Plus Laser Treatment. 3.Contact Cooling Plus Laser Treatment.||University of California, Irvine|No|Completed|July 2002|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Both|7 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|October 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540917||166319|
NCT00544219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 38/07|PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone|Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|September 2007|March 2016|Anticipated|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|18 Years|80 Years|No|||October 2015|October 8, 2015|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544219||166068|
NCT00564538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|424-07|A Study of Thymoglobulin and Tacrolimus in Liver Transplant|A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function|thymo|University of Nebraska|Yes|Enrolling by invitation|December 2007|December 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||November 2007|November 27, 2007|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00564538||164551|
NCT00564837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10339|Home Vs. Physiotherapy Supervised Rehabilitation After ACL Reconstruction|Comparison of Home Vs. Physiotherapy-Supervised Rehabilitation Programs Following Reconstruction of the Anterior Cruciate Ligament (ACL)||University of Calgary|No|Completed|September 1999|February 2001|Actual|February 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564837||164528|
NCT00565123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF- 12/2003|Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis|A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis||Laser Microsurgery Centre, Poland|No|Completed|September 2004|January 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|70 Years|No|||November 2007|November 28, 2007|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00565123||164506|
NCT00565968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001344|Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg|A Phase I Dose Escalation Trial to Evaluate Safety and Efficacy of Oral Sorafenib (Nexavar) With Regional Melphalan Via Normothermic Isolated Limb Infusion (ILI) in Patients With Intransit Extremity Melanoma||Duke University||Completed|October 2007|||August 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|November 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00565968||164443|
NCT00566267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00887|A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet|A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet|LOCUST|Philadelphia Veterans Affairs Medical Center|No|Completed|April 2006|November 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|58|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2007|November 30, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566267||164421|
NCT00566579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE500830|Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions|Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions: a Randomized Controlled Trial|Cryotherapy|Khon Kaen University|No|Terminated|December 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|30 Years|N/A|Accepts Healthy Volunteers|||December 2007|August 2, 2010|November 30, 2007||No|Lack of additional funding|No|June 1, 2010|https://clinicaltrials.gov/show/NCT00566579||164398|
NCT00566592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61990 (completed)|The Effect of Ethanol on Overnight Glucose Regulation in Type 2|The Effect of Ethanol on Overnight Glucose Regulation in Type 2 Diabetes Mellitus||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|January 2005|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|24|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566592||164397|
NCT00566566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4861-YW-CTIL|Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors|Adipocytokines as Predictors of the Metabolic Syndrome in Survivors of Childhood Acute Lymphoblastic Leukemia||Sheba Medical Center|No|Not yet recruiting|January 2008|December 2008|Anticipated|||N/A|Observational|Observational Model: Cohort||1|Anticipated|150|Samples Without DNA|Serum leptin, resistin ,adiponectin ,CRP, PAI ,TNF-α, IL-6 will be taken as part of initial      blood test screening in patients following an overnight fast. Adiponectin and leptin levels      will be determined by RIA (Linco, St. Charles, MO), Insulin, will be determined by      chemiluminescent immunometric method (Immulite 2000, Diagnostic Products Corporation, Los      Angeles, CA).|Both|6 Years|45 Years|No|Non-Probability Sample|Hematoncological pediatric clinic|November 2007|November 30, 2007|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566566||164399|
NCT00566241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGF-1 in Cystic Fibrosis|IGF-1 Therapy in Patients With Cystic Fibrosis|An Investigation Into the Use of IGF-1 Therapy in Patients With Cystic Fibrosis||Stony Brook University|Yes|Terminated|June 2008|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|November 30, 2007|Yes|Yes|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00566241||164423|
NCT00566254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-312|Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)|A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures||Eisai Inc.|No|Completed|December 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|6 Years|17 Years|No|||February 2013|May 9, 2013|November 29, 2007||No||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00566254||164422|
NCT00567489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31998|IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients|Multi-Center, Prospective, Randomized Trial To Demonstrate Improved Metabolic Control of PEN VS Dianeal Only in Diabetic CAPD and APD Patients - The Impendia Trial|Impendia|Baxter Healthcare Corporation|No|Completed|January 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567489||164330|
NCT00567463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-EATA-550|Early Antiinflammatory Treatment of Asthma|Early Anti-inflammatory Treatment of Asymptomatic or Mildly Symptomatic Airway Hyperresponsiveness|EATA|Laval University|No|Terminated|December 1998|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Actual|83|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|February 10, 2011|December 4, 2007||No|Completed|No||https://clinicaltrials.gov/show/NCT00567463||164332|
NCT00567476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025ABR01|Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma|A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma||Novartis||Completed|November 2007|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|12 Years|75 Years|No|||June 2011|June 28, 2011|December 4, 2007|Yes|Yes||No|April 26, 2011|https://clinicaltrials.gov/show/NCT00567476||164331|
NCT00542659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-02-019|Biochemical Marker to Predict the Recurrence of Atrial Fibrillation After Surgical Maze Procedure|Plasma ANP and NT-pro-BNP, Atrial Anatomical Change May Determine the Outcome of Maze Operation||Samsung Medical Center|No|Completed|February 2005|February 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|86|Samples Without DNA|plasma mRNA|Both|30 Years|75 Years|No|Non-Probability Sample|The patients who have valvular heart disease with atrial fibrillation and are scheduled        for operation|July 2011|July 22, 2011|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542659||166186|
NCT00542945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danish-ICD-001|Danish ICD Study in Patients With Dilated Cardiomyopathy|A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study|DANISH|Danish Study Group|Yes|Active, not recruiting|December 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|October 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542945||166164|
NCT00542360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0636|Marketing Fall Prevention Classes to Older Adults in Faith-Based Congregations|Marketing Fall Prevention Classes to Older Adults in Faith-Based Congregations: Cluster Randomized Controlled Trial||University of Colorado, Denver|No|Completed|October 2007|January 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|51|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 5, 2015|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00542360||166209|
NCT00542984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6680|Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis|Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|August 2003|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|55 Years|85 Years|No|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542984||166161|
NCT00543010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-018|MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)|||Merck Sharp & Dohme Corp.||Terminated|November 2002|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|247|||Both|21 Years|80 Years|No|||June 2015|June 11, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543010||166159|
NCT00543023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6972|A Study of the Treatment of Postmenopausal Women With Osteoporosis|Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|June 2003|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Female|55 Years|85 Years|No|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00543023||166158|
NCT00543036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH 30107|Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction|||Shalvata Mental Health Center||Recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||||||Both|21 Years|70 Years|No|||August 2007|October 11, 2007|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00543036||166157|
NCT00543595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0916-005|MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)|||Merck Sharp & Dohme Corp.||Completed|August 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|154|||Both|18 Years|65 Years|No|||May 2015|May 21, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543595||166115|
NCT00535769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001456|Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use|Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use||Massachusetts General Hospital|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 18, 2012|September 24, 2007||No||No|May 15, 2012|https://clinicaltrials.gov/show/NCT00535769||166709|
NCT00543582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103 PH US 2007 CL002|MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma|A Phase 2, Open-label Trial to Evaluate the Efficacy and Safety of MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma, and to Evaluate the Pharmacokinetics of Different Formulations of MGCD0103||Mirati Therapeutics Inc.|No|Terminated|October 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|October 11, 2007|Yes|Yes|Celgene terminated its collaboration agreement with MethylGene for the development of    MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.|No||https://clinicaltrials.gov/show/NCT00543582||166116|
NCT00543946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3205K2-1002|Single Ascending Dose of GAP-134 as a 24-Hour IV Infusion in Healthy Japanese Males|Ascending Single Dose Study of The Safety, Tolerability, Pharmacokinetics, of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|56|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00543946||166089|
NCT00532103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH90003-01|Assessing Treatment Emergent Suicidal Ideation in Patients With Major Depression|Suicide Assessment Methodology Study (SAMS)|SAMS|National Institute of Mental Health (NIMH)|Yes|Completed|July 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|75 Years|No|Non-Probability Sample|Fifteen primary care and specialty care clinics across the country.|September 2008|September 19, 2008|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532103||166987|
NCT00532116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9303-P0601|PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly|Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers||Somerset Pharmaceuticals|No|Completed|April 2007|August 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532116||166986|
NCT00541151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC0605|MiniArc Study: Long-Term Effectiveness Trial for AMS Sling Systems|Long-Term Effectiveness Trial for AMS Sling Systems|MiniArc|American Medical Systems|No|Active, not recruiting|September 2007|November 2010|Anticipated|August 2010|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|188|||Female|18 Years|N/A|No|Non-Probability Sample|Females 18 years or older who have confirmed SUI|August 2010|August 26, 2010|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541151||166301|
NCT00541476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081178|Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica|Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Undergoing Symptomatic Treatment With Lyrica||Pfizer||Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 4|Observational|Time Perspective: Prospective|||Actual|746|||Both|18 Years|N/A|No|||November 2008|November 20, 2008|October 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541476||166276|
NCT00564174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33762|Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT|A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss|HepASA|Mount Sinai Hospital, Canada|Yes|Terminated|March 2000|September 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Female|18 Years|44 Years|No|||November 2007|November 26, 2007|November 26, 2007|||interim analysis found no difference in LB rate and lower than expected event rate|No||https://clinicaltrials.gov/show/NCT00564174||164579|
NCT00564564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|968/05|Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-Compulsive Disorder Patients|Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-Compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-Trial.|QCAT|University of Sao Paulo|Yes|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||February 2008|February 4, 2008|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564564||164549|
NCT00564850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-54-52014-143|Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty|Phase III, Multicentre, Non-comparative, Open and Single Stage Study to Assess the Efficacy and Safety of Pamoate of Triptorelin 11.25 MG in Children With Precocious Puberty|DECAPUB|Ipsen|No|Completed|October 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|N/A|No|||February 2012|February 9, 2012|November 27, 2007||No||No|November 1, 2011|https://clinicaltrials.gov/show/NCT00564850||164527|
NCT00565669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI-07-003|Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms|Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms||Medical University of South Carolina|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565669||164465|
NCT00566280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003072|Molecular Breast Imaging in Patients With a History of Bloody Nipple Discharge|Molecular Breast Imaging: Evaluation of a New Technique Using Scintimammography as an Additional Diagnostic Tool for Women Presenting With a History of Bloody Nipple Discharge and Negative Routine Imaging Studies - A Pilot Study||Mayo Clinic|No|Completed|October 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Female|25 Years|75 Years|No|||January 2012|January 4, 2012|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566280||164420|
NCT00566605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|466.07|Outcomes in a Comparison of Manual Penetrating Keratoplasty and the IntraLase® Enabled Keratoplasty|Visual Outcomes in a Comparison of Manual Penetrating Keratoplasty and the IntraLase® Enabled Keratoplasty||Hospital Oftalmologico de Sorocaba|Yes|Active, not recruiting|August 2007|August 2008|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2007|November 30, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566605||164396|
NCT00566618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0900|Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis|Phase I/II Study of Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2007|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00566618||164395|
NCT00566917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVM III-07|Comparison Between Transvaginal Mesh and Traditional Surgery for Pelvic Organ Prolapse|A Randomised Controlled Trial of Transvaginal Mesh (PROLIFT) Versus Anterior Colporrhaphy in Anterior Vaginal Wall Prolapse||Karolinska Institutet|Yes|Completed|December 2007|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|400|||Female|18 Years|N/A|No|||May 2008|January 28, 2010|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566917||164373|
NCT00566904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43AR052998|New Topical Treatment for Continued Pain After Shingles|Phase 1 Novel Topical Treatment for Post-herpetic Neuralgia||Biomedical Development Corporation|Yes|Completed|September 2006|September 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 29, 2011|September 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566904||164374|
NCT00567216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nsc96-2314-B-075-037-MY3|Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding|A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol|GVO-nadolol|Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|April 2007|July 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||June 2010|June 6, 2010|December 2, 2007||||No||https://clinicaltrials.gov/show/NCT00567216||164351|
NCT00567840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-824-CL-007|PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis|A Phase IIa Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of 14 Days' Treatment With Four Oral Doses of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis||Global Alliance for TB Drug Development|No|Completed|August 2007|December 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|68|||Both|18 Years|64 Years|No|||August 2015|January 12, 2016|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567840||164303|
NCT00567853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEMO3D.Reg|Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair|Clinical Investigation Of The Sorin 3D Annuloplasty Ring For Mitral Repair|MEMO3D|Sorin Group USA, Inc.|No|Completed|August 2007|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|278|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567853||164302|
NCT00567827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006AA02Z4A9|Pathogen Identification of Bacterial Pneumonia Via DNA Detection|Identification of Bacterial Species and Their Antibiotic-Resistant Spectrum in Sputum Specimen From the Patients With Pneumonia Via Nuclear Acid Detection Assay||Peking University People's Hospital|Yes|Completed|December 2007|December 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2896|Samples With DNA|DNA extracted from sputum specimen|Both|18 Years|N/A|No|Probability Sample|Greater than 18 years of age. Cough present greater than one day and a history of fever        and X-ray evidence of pneumonia.|June 2010|June 23, 2010|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567827||164304|
NCT00568126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001090|Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females|A Double-Blind, Placebo Controlled Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females|MGH|Massachusetts General Hospital|No|Completed|November 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|80 Years|No|||June 2011|June 10, 2011|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568126||164281|
NCT00542672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1397|Evaluating Parental Influences on Obesity Among Mexican American Children|Parental Influences on Obesity Among Mexican American Children||University of California, San Francisco|No|Completed|August 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|831|||Both|8 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mexican American children ages 8-10 whose parent is a member of Kaiser Permanente, an HMO|May 2013|May 20, 2013|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542672||166185|
NCT00542373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0802|Fluorescence & Reflectance Imaging to Detect Oral Neoplasia|Fluorescence & Reflectance Imaging to Detect Oral Neoplasia||M.D. Anderson Cancer Center|No|Recruiting|August 2007|||August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542373||166208|
NCT00534924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2007-002520-16|The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels|The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels|IRI in MRI|Medical University of Vienna|Yes|Recruiting|August 2007|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2007|September 24, 2007|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00534924||166773|
NCT00535223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-010-06F|Group Based Exposure Therapy for Combat-Related PTSD|Group Based Exposure Therapy for Combat PTSD: RCT and Feasibility Study||VA Office of Research and Development|No|Completed|July 2007|August 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Male|N/A|N/A|No|||March 2015|March 23, 2015|September 24, 2007||No||No|December 22, 2014|https://clinicaltrials.gov/show/NCT00535223||166750|
NCT00535236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-002|A Study of an Investigational V212/Heat-Treated VZV Vaccine in Immunocompromised Adults (V212-002)(COMPLETED)|A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults||Merck Sharp & Dohme Corp.||Completed|November 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|341|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00535236||166749|
NCT00532129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO20927|A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.|An Open-label Study to Characterize the Safety and Response Rate of MabThera (Rituximab) Plus Chlorambucil in Previously Untreated Patients With CD20-positive B-cell Chronic Lymphocytic Leukemia||Hoffmann-La Roche||Completed|October 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00532129||166985|
NCT00544804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-077518|Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2|A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer||University of California, San Francisco||Completed|August 2007|December 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||July 2014|July 1, 2014|October 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544804||166024|
NCT00545168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-302-07|Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice|A Phase 3 Comparative Safety and Efficacy Study Between NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects > 6 Months of Age With Pediculosis Capitis||ParaPRO LLC|No|Completed|September 2007|May 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|480|||Both|6 Months|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|October 15, 2007|Yes|Yes||No|August 2, 2012|https://clinicaltrials.gov/show/NCT00545168||165999|
NCT00532766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRC06-535|Evaluating Pharmacokinetics and Pharmacodynamics of Jusline|Bioequivalence of Jusline Following Subcutaneous Administration in Healthy Subjects||King Saud University|Yes|Completed|November 2006|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2007|September 24, 2007|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00532766||166937|
NCT00532779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-301|A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects|A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects||Orexigen Therapeutics, Inc|Yes|Completed|October 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1742|||Both|18 Years|65 Years|No|||November 2014|November 18, 2014|September 19, 2007|Yes|Yes||No|October 20, 2014|https://clinicaltrials.gov/show/NCT00532779||166936|
NCT00532415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-62|Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy|Clinical Evaluation of the Safety and Efficacy of Triamcinolone Acetonide Suspension for Visualization During Vitrectomy Surgery||Alcon Research|No|Completed|September 2007|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00532415||166963|
NCT00532428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8149|Long Term Effects of Raloxifene Treatment on Bone Quality|Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study||Eli Lilly and Company|No|Completed|April 2003|September 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Female|55 Years|85 Years|No|||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532428||166962|
NCT00564577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 193 (B)|Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17|Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli (ETEC) Challenge Strains That Express CS17||Johns Hopkins Bloomberg School of Public Health|No|Completed|September 2006|June 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|13|||Both|15 Years|45 Years|Accepts Healthy Volunteers|||November 2007|November 27, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564577||164548|
NCT00564590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004548|SThe Effects of Melatonin on GERD Symptoms|The Effects of Melatonin on GERD Symptoms and Esophageal Acid Exposure||Rabin Medical Center|No|Not yet recruiting|October 2008|January 2011|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||November 2007|November 26, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564590||164547|
NCT00565370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0701|Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC)|A Phase I-II Study of Sorafenib (Nexavar®) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer|XP+Sorafenib|Asan Medical Center|No|Completed|November 2007|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||August 2015|August 1, 2015|November 28, 2007||No||No|December 15, 2013|https://clinicaltrials.gov/show/NCT00565370||164487|
NCT00565981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUSALEM|A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response|Subcutaneous MabCampath® (Alemtuzumab) and Oral Fludara® (Fludarabinephosphate) for the Treatment of Refractory or Relapsed Chronic Lymphocytic Leukemia in 2nd or 3rd Line of Treatment: A Pilot Trial (FLUSALEM) for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Active, not recruiting|March 2004|December 2008|Anticipated|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|19 Years|75 Years|No|||June 2008|June 4, 2008|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565981||164442|
NCT00566306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231109|Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation|Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation||Helsinki University|No|Completed|February 2007|August 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|No|||August 2008|August 25, 2008|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566306||164419|
NCT00566319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q2502/29|Can Structured Education Promote Physical Activity in Those Identified With an Increased Risk of Developing Diabetes|A Randomised Controlled Trial to Investigate the Effect of a Structured Educational Programme on Physical Activity Levels and Glucose Tolerance in People With Impaired Glucose Tolerance|PREPARE|University Hospitals, Leicester|Yes|Completed|October 2006|April 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|103|||Both|18 Years|N/A|No|||November 2007|November 25, 2008|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566319||164418|
NCT00566631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013162|An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia|Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia|PERTAIN|Janssen-Cilag International NV|No|Completed|July 2007|May 2009|Actual|May 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|294|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|November 29, 2007|Yes|Yes||No|April 3, 2013|https://clinicaltrials.gov/show/NCT00566631||164394|
NCT00566644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-POET|Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome|Prevention of Endometrial Tumors (POET)||National Cancer Institute (NCI)||Terminated|July 2007|August 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|600|||Female|35 Years|65 Years|No|||October 2008|July 9, 2013|November 30, 2007||No|Withdrawn due to poor accrual|No||https://clinicaltrials.gov/show/NCT00566644||164393|
NCT00566930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic cervical pain UQTR|Preventive Care of Chronic Cervical Pain and Disabilities|Preventive Care of Chronic Cervical Pain and Disabilities; Comparison of Spinal Manipulative Therapy and Individualized Home Exercise Programs||Université du Québec à Trois-Rivières|Yes|Completed|October 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|117|||Both|18 Years|60 Years|No|||September 2012|September 13, 2012|November 30, 2007||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00566930||164372|
NCT00567229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mskcc 07-070|Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma|Phase II Study of Lenalidomide and Rituximab for Patients With Relapsed and/or Refractory CD20+ Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Terminated|November 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|120 Years|No|||October 2015|October 19, 2015|December 1, 2007|Yes|Yes|Lack of Accrual|No|October 19, 2015|https://clinicaltrials.gov/show/NCT00567229||164350|
NCT00567866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72900|Methamphetamine-Quetiapine Interactions in Humans|Methamphetamine-Quetiapine Interaction in Humans: A Pilot Study||University of Arkansas|Yes|Terminated|January 2008|September 2009|Actual|September 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|50 Years|No|||July 2010|July 12, 2010|December 3, 2007|Yes|Yes|Study was terminated due to insufficient funds|No||https://clinicaltrials.gov/show/NCT00567866||164301|
NCT00568139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wue-ACC-Mitotane|Evaluation of Side Effects of Mitotane|Evaluierung Von Nebenwirkungen Einer Therapie Mit Mitotane Beim Nebennierenkarzinom- Evaluation of Side Effects of Mitotane in Adrenocortical Carcinoma||University of Wuerzburg|No|Recruiting|January 2008|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Serum, plasma, and urine samples will be collected.|Both|N/A|N/A|No|Non-Probability Sample|Patients with adrenocortical carcinoma treated in our center|September 2015|September 6, 2015|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568139||164280|
NCT00568152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR02-2006|Effect of Apple Flavanols on Risk of Cardiovascular Disease|Effect of Apple Flavanols on Risk of Cardiovascular Disease|FLAVO|Institute of Food Research|Yes|Completed|May 2006|May 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|26|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568152||164279|
NCT00542698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004009|Changing Physical Activity Behavior in Individuals With Type 2 Diabetes Using Counceling and Information From Continuous Glucose Monitoring|Changing Activity Behavior With Glucose Sensor Feedback||National Institute of Nursing Research (NINR)||Completed|July 2004|December 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|19 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542698||166183|
NCT00534664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THBC-HCC-01|Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma|Phase II Study to Determine the Effectiveness of Intrabuccally Administered Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma|TheraBionic|University of Sao Paulo|No|Completed|October 2005|February 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|N/A|No|||September 2007|September 24, 2007|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00534664||166793|
NCT00531674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPH472|Efficacy of 3 Nutritional Supplements to Improve Diverse Outcomes in Children Under 2 Years of Age and Pregnant Women|||Mexican National Institute of Public Health|No|Completed|September 2005|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||||||Both|6 Months|12 Months|Accepts Healthy Volunteers|||November 2012|November 6, 2014|September 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00531674||167020|
NCT00531687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Relapse testis cancer 2007|Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer|Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer||Rigshospitalet, Denmark|No|Suspended|September 2007|February 2016|Anticipated|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|70 Years|No|||February 2012|May 6, 2015|September 18, 2007||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00531687||167019|
NCT00532142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-04-010-0204|The ROVO Study: Radial Optic Neurotomy for CVO|A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion - Radial Optic Neurotomy for CVO The ROVO Study||Rudolf Foundation Clinic|No|Completed|April 2005|August 2009|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||||||Both|18 Years|N/A||||October 2009|October 29, 2009|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00532142||166984|
NCT00531635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2001-051|Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|July 2002|June 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|N/A|N/A|No|||December 2011|December 11, 2011|September 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00531635||167023|
NCT00531648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feeding disorder-33CTIL|Relationships Between Toddlers With Feeding Disorder and SPD and Their Parents|The System of Relationships Between Parents and Their Toddlers, With Eating Disorders and Sensory Processing Disorders Within Meal and Play Situations||BeerYaakov Mental Health Center|No|Not yet recruiting|September 2007|November 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|6|||Both|12 Months|30 Months||||September 2007|September 18, 2007|September 18, 2007||||No||https://clinicaltrials.gov/show/NCT00531648||167022|
NCT00532792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA101|A/H5N1 Dose Ranging Study With Adjuvant Patch|A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Administered With and Without an Adjuvant Patch in Healthy Adults||Intercell USA, Inc.|Yes|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|501|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2012|March 13, 2012|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00532792||166935|
NCT00533026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11707|Duloxetine - Warfarin Pharmacodynamic Study|Evaluation of the Effect of Duloxetine on the Pharmacodynamics of Warfarin at Steady-State in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2008|September 26, 2008|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533026||166917|
NCT00565136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC0610|Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms|Evaluation of the Outcomes of Restoring Pelvic Floor Support Using TOPAS, AMS Pelvic Floor Support System, in Women With Moderate Fecal Incontinence Symptoms|TOPAS|ASTORA Women’s Health|No|Completed|September 2007|December 2012|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|21 Years|N/A|No|||December 2015|December 11, 2015|November 27, 2007||No||No|May 1, 2013|https://clinicaltrials.gov/show/NCT00565136||164505|This study was not powered to statistically evaluate device performance.
NCT00565149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 25007|PROOF: PROtein OverFeeding Effect on Body Weight|Dietary Protein Content Determines Weight Gain During High Fat Overfeeding|PROOF|Pennington Biomedical Research Center|Yes|Active, not recruiting|March 2005|March 2016|Anticipated|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00565149||164504|
NCT00556010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEIL-HMO-CTIL|Intraoperative Three Dimensional Fluoroscopy Compared to Standard Fluoroscopy for the Assessment of Reduction of Ankle Fractures With Syndesmosis Disruption|Intraoperative Three Dimensional Fluoroscopy Compared to Standard Fluoroscopy for the Assessment of Reduction of Ankle Fractures With Syndesmosis Disruption||Hadassah Medical Organization||Completed|January 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|patients with fracture in the ankle with Syndesmosis disruption|April 2011|July 19, 2012|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00556010||165185|
NCT00556374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050209|Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy|A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy.||Amgen|Yes|Active, not recruiting|December 2006|October 2019|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|3420|||Female|45 Years|100 Years|No|||October 2015|October 6, 2015|November 8, 2007|Yes|Yes||No|October 6, 2015|https://clinicaltrials.gov/show/NCT00556374||165157|
NCT00557609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-204|Phase 2 Study in Patients With MiT Tumors|A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors||ArQule|No|Completed|October 2007|February 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|13 Years|N/A|No|||February 2013|February 6, 2013|November 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00557609||165072|
NCT00556621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574107|Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer|Phase 1-2 Study of the Association of Gemzar ® - Cisplatin-concurrent Radiotherapy in Patients With Non-metastatic Tumors of the Bladder|GEMCIRAV|Institut du Cancer de Montpellier - Val d'Aurelle|No|Completed|June 2005|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556621||165140|
NCT00556634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAEI_EFV|Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage|Randomized, Double-Blinded Clinical Trial to Evaluate the Incidence and Severity of Neuropsychiatric Side Effects and Antiviral Efficacy of Efavirenz Given as a Stepped Dosage Over 2 Weeks Versus the Usual Dosage in HIV-Infected Patients.||Sociedad Andaluza de Enfermedades Infecciosas|Yes|Completed|April 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||January 2009|January 14, 2009|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00556634||165139|
NCT00556998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501081|A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents|An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Adolescents Aged 12 To <17 Years Who Are At High Risk For Systemic Fungal Infection||Pfizer|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|26|||Both|12 Years|17 Years|No|||February 2012|February 27, 2012|November 9, 2007|Yes|Yes||No|August 2, 2010|https://clinicaltrials.gov/show/NCT00556998||165115|
NCT00557011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRP104.201|NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD|A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD)||New River Pharmaceuticals|No|Completed|September 2004|December 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|6 Years|12 Years|No|||May 2011|May 23, 2011|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00557011||165114|
NCT00557284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32032|Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens||IMMUNOe International Research Centers|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|1 Year|8 Years|No|||March 2015|March 31, 2015|November 9, 2007|Yes|Yes||No|July 30, 2013|https://clinicaltrials.gov/show/NCT00557284||165096|
NCT00557557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-096|Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases|A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin and 5-fluorouracil (5-FU) Followed by Hepatic Arterial Infusion of FUDR for Patients With Unresectable Colorectal Liver Metastases||University of Pittsburgh|Yes|Completed|July 2007|August 2014|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|November 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00557557||165076|
NCT00557895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960129|Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders|Evaluation and Long Term Follow-up of Patients With Allergic and Inflammatory Disorders||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|August 1996|||||N/A|Observational|Time Perspective: Prospective|||Actual|288|||Both|2 Years|80 Years|No|||November 2015|December 15, 2015|November 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00557895||165051|
NCT00558194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 DK73536-2|Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment (Part 2)|Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|August 2009|January 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|70 Years|No|||March 2011|March 15, 2011|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00558194||165028|
NCT00564447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-102|Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers|A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration||Merck Sharp & Dohme Corp.||Completed|December 2007|||December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|8||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 20, 2011|November 20, 2007|Yes|Yes||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00564447||164558|
NCT00568503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX028A2102|Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Partially Blinded, Single-dose, Cross-over Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide (Positive Control) and Placebo in Mild-to-moderate COPD Patients||Novartis|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|29|||Both|40 Years|75 Years|No|||April 2011|April 27, 2011|December 5, 2007||||No||https://clinicaltrials.gov/show/NCT00568503||164252|
NCT00564382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Emergency001|CMR in the Assessment of Patient With ACS in the Emergency Room|Cardiac MRI for the Diagnosis of Unstable Angina/ NSTEMI in the Emergency Room||University of Calgary|Yes|Completed|November 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2011|October 2, 2011|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564382||164563|
NCT00564369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106879-42-RGAT|CDC HIV Testing Guidelines: Unresolved Ethical Concerns|CDC HIV Testing Guidelines: Unresolved Ethical Concerns||Rhode Island Hospital|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2009|November 25, 2013|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564369||164564|
NCT00564707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-20034|Comparison of Biofeedback vs. Botox Injection to Treat Levator Ani Syndrome|Comparison of Biofeedback Therapy and Botulinum Toxin Type A Injections for Treatment of Painful Levator Ani Syndrome in Women: A Randomized, Prospective Trial||Walter Reed Army Medical Center|Yes|Recruiting|August 2007|August 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 26, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564707||164538|
NCT00566059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDUCCI|Computed Tomographic Angiography or Conventional Coronary Angiography in Clinical Decision Making|Comparison Between Invasive Coronary Angiography and Dual-Source Computed Tomography|CARDUCCI|University Medical Center Groningen|No|Completed|May 2006|May 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|50 Years|N/A|No|Probability Sample|Patients over 50 years of age, scheduled for elective coronary angiography|November 2007|November 30, 2007|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566059||164436|
NCT00566072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001/181|The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial|The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial||University Hospital, Ghent|No|Completed|May 2001|May 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|21|||Both|18 Years|65 Years|No|||December 2007|December 4, 2007|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566072||164435|
NCT00565747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK001|Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF|The Effect of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) During in Vitro Culture of Human Embryos on Subsequent Implantation Rates.|GM-CSF|Origio A/S|No|Completed|November 2007|September 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1332|||Female|25 Years|39 Years|No|||April 2015|April 28, 2015|November 28, 2007||No||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00565747||164459|
NCT00565760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q8003-010|Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain|A Double-Blind, Multi-Center Extension Study to Evaluate the Safety and Efficacy of Q8003 in Patients With Acute Moderate to Severe Pain||QRxPharma Inc.|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|November 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565760||164458|
NCT00555750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-HRC-2005-P-001997|Sleep Loss and Mechanisms of Impaired Glucose Metabolism|The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia||Brigham and Women's Hospital|No|Completed|March 2006|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|25 Years|55 Years|No|||November 2013|November 15, 2013|November 7, 2007|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00555750||165205|
NCT00555763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1410|Assessment of a New Goldmann Applanation Tonometer|Assessment of a New Goldmann Applanation Tonometer||University Hospital Inselspital, Berne|No|Completed|August 2007|July 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|157|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 13, 2011|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00555763||165204|
NCT00556023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671016|A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer|A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer||AstraZeneca|No|Completed|June 2008|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|November 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556023||165184|
NCT00556036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003p-000549|Hormone Dynamics and Bone Mineral Density in Anorexia Nervosa v. Hypothalamic Amenorrhea|Hormone Dynamics and Bone Mineral Density in Anorexia Nervosa v. Hypothalamic Amenorrhea||Massachusetts General Hospital|Yes|Completed|March 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|61|Samples Without DNA|whole blood, serum, urine, saliva, optional DNA substudy.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample and referrals by specialists|December 2011|December 15, 2011|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00556036||165183|
NCT00556647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL12541.075.06|Fast-track Diagnosis for Lung Cancer Suspects With PET-CT and EUS|A Prospective, Open, Single Center, Study of One-day Diagnostic Track for Lung Cancer Suspects From Chest X-ray Using PET-CT and Subsequent Multiple Endoscopic Investigations. (Including Bronchoscopy, EUS-FNA)||Isala|Yes|Completed|September 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|297|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients suspected of lung cancer|April 2013|April 5, 2013|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556647||165138|
NCT00556660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV51 001|Evaluation of [123I] AV51 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|||Institute for Neurodegenerative Disorders|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 23, 2008|November 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00556660||165137|
NCT00556673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149A2204|Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma|An Exploratory, Multi-centre, Double-blind, Placebocontrolled Crossover Study, to Investigate the Bronchodilatory Efficacy of a Single Dose of Indacaterol in Fixed Combination With Mometasone Furoate Delivered Via a MDDPI (Twisthaler®) in Adult Patients With Persistent Asthma Using Open Label Seretide® Accuhaler® (50/250 Mcg b.i.d.) as an Active Control||Novartis|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||March 2013|March 11, 2013|November 9, 2007|Yes|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT00556673||165136|
NCT00557037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yale 0703002467|A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer|A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer||MEI Pharma, Inc.||Completed|November 2007|November 2009|Actual|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||April 2010|April 6, 2010|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00557037||165112|
NCT00557050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2007-0062|Acute Hamstring Strains in Danish Elite Soccer - Prevention and Rehabilitation|Acute Hamstring Strains in Danish Elite Soccer - Prevention and Rehabilitation||Amager Hospital|No|Enrolling by invitation|January 2008|March 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|November 9, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00557050||165111|
NCT00557297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00031|NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler|NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler|SYMCO|AstraZeneca|No|Completed|October 2007|September 2008|Actual|||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|250|||Both|18 Years|N/A|No|||September 2008|September 24, 2008|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00557297||165095|
NCT00557570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950072|Evaluation and Monitoring of Patients With HIV Infectionn|Clinical, Virologic, and Immunologic Evaluation and Monitoring of Patients With Known or Suspected HIV Infection||National Institutes of Health Clinical Center (CC)||Completed|February 1995|||October 2009|Actual|N/A|Observational|N/A||||600|||Both|18 Years|N/A|No|||October 2009|September 26, 2015|November 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00557570||165075|
NCT00557882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-336|Efficacy Study of Vaginal Mesh for Anterior Prolapse|A Randomized Clinical Trial of Vaginal Mesh for Anterior Prolapse|VAMP-A|Medstar Research Institute|Yes|Completed|June 2007|November 2011|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Female|21 Years|N/A|No|||September 2015|September 21, 2015|November 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00557882||165052|
NCT00557908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VWD PN|The Von Willebrand Disease (VWD) International Prophylaxis Study|The VWD International Prophylaxis (VIP) Study|VIP|Skane University Hospital|Yes|Completed|June 2007|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|105|||Both|N/A|N/A|No|||April 2015|April 6, 2015|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557908||165050|
NCT00557921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG104|Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease|COGENT-1|Cogentus Pharmaceuticals|Yes|Terminated|December 2007|November 2009|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5000|||Both|21 Years|N/A|No|||January 2009|January 27, 2009|November 12, 2007|Yes|Yes|Terminated by Sponsor|No||https://clinicaltrials.gov/show/NCT00557921||165049|
NCT00559442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-169/2007|Susceptibility to High Altitude Pulmonary Edema in Subjects With Increased Hypoxic Pulmonary Vasoconstriction|Susceptibility to High Altitude Pulmonary Edema in Subjects With Increased Pulmonary Artery Pressure During Exercise in Normoxia and at Rest in Hypoxia||Heidelberg University|No|Completed|June 2007|July 2011|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2007|September 5, 2013|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559442||164938|
NCT00559455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALI_L_02859|Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma|Phase II Study of Oxaliplatin + 5-FluoroUracil/Leucovorin (Eloxatin+5-FU/LV) in Patients With Unresectable Hepatocellular Carcinoma||Sanofi|No|Completed|September 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|75 Years|No|||June 2011|June 27, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559455||164937|
NCT00533455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3232-A|Gabapentin for the Treatment of Neuroleptic-Induced Tremor|A 4 Week, Parallel-Design, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Treatment of Neuroleptic-Induced Tremor: Clinical and Instrumental Ratings of Outcome.||Minneapolis Veterans Affairs Medical Center|No|Terminated|March 2004|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|40|||Both|18 Years|N/A|No|||September 2007|September 21, 2007|September 19, 2007|||Failure to recruit due to polypharmacy|No||https://clinicaltrials.gov/show/NCT00533455||166885|
NCT00533793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS I-040202/01|Adjunctive Therapy to Treat Tibial Shaft Fractures|A Phase II Randomized, Controlled, Open-labeled (Dose-blinded) Dose Finding Study of the Safety and Efficacy of I-040202 in the Treatment of Patients With Acute Open Tibial Shaft Fractures|TSF|Kuros Biosurgery AG|No|Completed|April 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|201|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533793||166859|
NCT00568815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESHAP-DLBCL|Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL||Fudan University|No|Completed|April 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568815||164229|
NCT00564980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-061|PRCT: Comparing Two Procedures for Ulno-Carpal Abutment Syndrome.|A Randomized Prospective Study Comparing TFCC Debridement and Wafer Procedure With TFCC Debridement and Ulnar Shortening Osteotomy for Ulno-Carpal Abutment Syndrome. (UAS Study)|UAS|Simon Fraser Orthopaedic Fund|No|Terminated|July 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|16 Years|N/A|No|||May 2015|May 19, 2015|November 27, 2007|Yes|Yes|Inability to recruit required number of subjects.|No||https://clinicaltrials.gov/show/NCT00564980||164517|
NCT00564993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 4.3 Fallot-stress|Cardiac Function Under Stress for Early Detection of the Right Ventricular Insufficiency After Repair of Tetralogy of Fallot|Cardiac Imaging Under Exercise Stress Test for Early Assessment of Right Ventricular Function in Patients With Tetralogy of Fallot and Pulmonary Regurgitation||Competence Network for Congenital Heart Defects|No|Terminated|November 2007|May 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|53|||Both|14 Years|N/A|No|||August 2011|June 5, 2012|November 28, 2007||||No||https://clinicaltrials.gov/show/NCT00564993||164516|
NCT00564720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.13|Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer|Phase II Study of Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Patients With Locally Advanced or Metastatic Pancreatic Cancer||Hellenic Oncology Research Group|No|Terminated|December 2006|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|75 Years|No|||February 2013|February 14, 2013|November 27, 2007||No|Due to poor accrual of the study|No||https://clinicaltrials.gov/show/NCT00564720||164537|
NCT00564941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AHU02|Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload|Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload||Novartis||Completed|December 2007|||July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|309|||Both|18 Years|80 Years|No|||September 2011|September 8, 2011|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00564941||164520|
NCT00565214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705009179|Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers|Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers||Weill Medical College of Cornell University|No|Completed|September 2007|October 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2010|October 27, 2010|November 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00565214||164499|
NCT00565474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LESTX-ES-01|Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant|A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled, 6-month Study to Establish the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vascular Graft Disease in de Novo Renal Transplant Patients||Novartis||Completed|September 2001|||October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|84|||Both|18 Years|70 Years|No|||November 2011|November 1, 2011|November 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565474||164479|
NCT00566371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701-1315|The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents|The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia||Rhode Island Hospital|No|Completed|June 2005|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|6 Years|17 Years|No|||November 2007|August 13, 2010|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566371||164414|
NCT00555776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gaba-tinntus-145|Effect of Gabapentin on Idiopathic Subjective Tinnitus|Phase 2 Effect of Gabapentin on Idiopathic Subjective Tinnitus||Islamic Azad University of Mashhad|Yes|Active, not recruiting|January 2007|October 2008|Anticipated|April 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||August 2008|January 5, 2009|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00555776||165203|
NCT00555789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEB071A2203E1|24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients|A 24 Month Extension to a 12-month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients||Novartis||Terminated|October 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|November 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555789||165202|
NCT00556049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-212|Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma|Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma||Massachusetts General Hospital|No|Completed|December 2007|December 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 7, 2007||No||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00556049||165182|
NCT00556062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-INF-4005|Phase IV Clinical Trial of an Influenza Split Vaccine Anflu|The Clinical Trial for Three Consecutive Lots of Influenza Split Vaccine Anflu by Randomized, Double-Blind and Controlled Design||Sinovac Biotech Co., Ltd||Completed|September 2007|November 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|566|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2007|November 8, 2007|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00556062||165181|
NCT00557076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4951-R|The Efficacy of Familiar Voice Stimulation During Coma Recovery|Can Neural Adaptation After Severe Brain Injury be Facilitated?|FAST|VA Office of Research and Development|Yes|Completed|July 2008|September 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|November 8, 2007||No||No|October 21, 2014|https://clinicaltrials.gov/show/NCT00557076||165110|A limitation is achieved sample size. Given restrictive eligibility criteria, enrollment was lower than planned.
NCT00557973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-B-065|A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury|Multiple-Dose Efficacy and Safety Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury||Indivior Inc.|No|Completed|December 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|November 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00557973||165045|
NCT00556686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614581|Salivary Catecholamines in Aphthous Stomatitis (Canker Sores)|Salivary Catecholamines in Aphthous Stomatitis||University of California, Davis|No|Withdrawn|August 2006|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All subjects will be sampled from the community.|April 2015|April 20, 2015|November 8, 2007||No|We are currently modifying the study|No||https://clinicaltrials.gov/show/NCT00556686||165135|
NCT00556699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACF4325g|A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma|An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics, and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed Following Previous Rituximab Therapy||Genentech, Inc.||Completed|December 2007|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2011|March 18, 2014|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556699||165134|
NCT00557024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rfa-004|Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|RT-RFA|Sun Yat-sen University|Yes|Recruiting|November 2007|July 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||November 2008|November 17, 2008|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00557024||165113|
NCT00557323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-402|Long-term Effect of Lanthanum Carbonate on Bone|A Long-term, Observational Study to Monitor Mortality, Bone-related Adverse Events and the Safety of Subjects Who Were Recruited Into Study SPD405-309||Shire|No|Completed|August 2005|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|N/A|N/A|No|Non-Probability Sample|Any patients from study SPD405-309 who were exposed to lanthanum carbonate|May 2011|March 4, 2015|November 12, 2007|No|Yes||No|May 19, 2011|https://clinicaltrials.gov/show/NCT00557323||165093|
NCT00558207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-205|A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma|A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma||ArQule|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|November 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558207||165027|
NCT00557310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11996|A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide|The Effects of Teriparatide on Bone Microarchitecture as Determined by High Resolution Magnetic Resonance Imaging and Digital Topological Analysis||Eli Lilly and Company|No|Completed|November 2007|May 2011|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|45 Years|85 Years|No|||October 2011|October 7, 2011|November 9, 2007|Yes|Yes||No|October 7, 2011|https://clinicaltrials.gov/show/NCT00557310||165094|
NCT00557583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBY-376-001|Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults|A Randomized, Double-blinded, Placebo-controlled, Sequential, Single Ascending Dose Evaluation of the Safety and Pharmacokinetics of VBY-376 in Healthy Adults||Virobay Inc.|No|Completed|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|November 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00557583||165074|
NCT00559156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574125|Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|Phase 2 Study Assessing the Impact of Parenteral Administration of the Immunomodulater Oral IMPACT® for Postoperative Radiochemotherapy in Patients With Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|June 2005|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559156||164959|
NCT00558883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI(I)DA|AI(I)DA Acarbose and the Subclinical Inflammation|Placebo Controlled Investigation on Action of Acarbose on the Sub-Clinical Inflammation and Immune Response in Early Type 2 Diabetes and Atherosclerosis Risk||GWT-TUD GmbH|Yes|Completed|January 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|30 Years|75 Years|No|||April 2008|April 10, 2008|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558883||164979|
NCT00533806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079217|Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder|Family Based Treatment for Early Childhood OCD||Rhode Island Hospital|Yes|Completed|October 2007|January 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|5 Years|8 Years|No|||March 2013|March 7, 2013|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00533806||166858|
NCT00564733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6566|FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer|FDG-PET Based Chemotherapy Selection for Metastatic Non-Small Cell Lung Cancer||University of Washington|No|Completed|October 2007|March 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|November 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00564733||164536|
NCT00565006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-012|A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)|||Merck Sharp & Dohme Corp.||Completed|July 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|N/A|||Actual|22|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00565006||164515|
NCT00565227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.026|Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.|A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies||University of Michigan Cancer Center|Yes|Terminated|April 2007|September 2009|Actual|November 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2010|January 14, 2010|November 27, 2007|Yes|Yes|closed due to toxicity|No||https://clinicaltrials.gov/show/NCT00565227||164498|
NCT00534612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/038/CCI|Diagnostic Accuracy of Fine Needle Aspiration in Parotid Tumors|Accuracy of Fine Needle Aspiration Biopsy in the Pre-Operative Diagnosis of Malignancy in Patients With Parotid Gland Masses||National Institute of Cancerología|No|Recruiting|January 2003|December 2007|Anticipated|||Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2003|September 24, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534612||166797|
NCT00565773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005064|Belatacept Post Depletional Repopulation to Facilitate Tolerance|Use of Belatacept During Post Depletional Repopulation to Facilitate Tolerance in Renal Allograft Recipients||Emory University|Yes|Active, not recruiting|December 2007|August 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565773||164457|
NCT00565786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.H011|ArCom® and ArComXL® Polyethylene Data Collection|A Prospective Clinical Data Collection of ArCom® and ArComXL® Polyethylene||Biomet, Inc.|No|Active, not recruiting|July 2004|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|150|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include patients requiring total hip replacement.|February 2015|June 17, 2015|November 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565786||164456|
NCT00566085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002067|New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer|Molecular Breast Imaging: Evaluation of a New Technique Using Scintimammography as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer - A Pilot Study||Mayo Clinic|No|Completed|January 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Female|18 Years|90 Years|No|||January 2012|January 4, 2012|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566085||164434|
NCT00556738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/09|Intrapulmonary Percussive Ventilation (IPV) Versus Nasal Continuous Positive Airway Pressure Ventilation (nCPAP) in Transient Respiratory Distress of the Newborn|Intrapulmonary Percussive Ventilation and Nasal Continuous Positive Airway Pressure Ventilation in Transient Respiratory Distress of the Newborn: A Randomized Controlled Trial|HFPV|University Hospital, Bordeaux|No|Completed|November 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||May 2010|May 12, 2010|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556738||165132|
NCT00557349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1058337|Ulcer Prevention Study in Post Gastric Bypass Patients|A Randomized, Double-Blind Clinical Trial Comparing Zegerid Capsule to Famotidine in Preventing Anastomotic (Marginal) Ulcers in Post Gastric Bypass Patients||University of Missouri-Columbia|No|Active, not recruiting|November 2006|November 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2007|November 27, 2007|November 12, 2007||||No||https://clinicaltrials.gov/show/NCT00557349||165091|
NCT00557375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHIRB 2007-036|Brain Tumor Treatment Satisfaction Survey|Treatment Satisfaction Survey for Brain Tumor Patients and Their Caregivers||Methodist Healthcare|No|Recruiting|June 2007|November 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|700|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Brain tumor patients and their caregivers|September 2009|September 17, 2009|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557375||165089|
NCT00557986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF07-01|Local Surgery for Metastatic Breast Cancer|The Effect of Primary Surgical Treatment on Survival in Patients With Metastatic Breast Cancer at Diagnosis||Federation of Breast Diseases Societies|Yes|Completed|November 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|281|||Female|N/A|N/A|No|||November 2012|December 4, 2012|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557986||165044|
NCT00556712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO18192|A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic NSCLS Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy||Hoffmann-La Roche||Completed|January 2006|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|889|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|November 9, 2007||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00556712||165133|
NCT00558220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLSG 5_02|R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas|Phase II Study of Intensive Induction (R-MegaCHOP/ESHAP)Followed By Intensive Consolidation (BEAM) In Treatment Of High-Risk Aggressive B-Cell Lymphomas|R-MCEB|Czech Lymphoma Study Group|No|Completed|May 2002|October 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|65 Years|No|||November 2007|November 10, 2007|February 12, 2007||||No||https://clinicaltrials.gov/show/NCT00558220||165026|
NCT00557622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIR109164|Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)|Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study -||GlaxoSmithKline|No|Terminated|January 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|20 Years|65 Years|No|||February 2012|April 11, 2013|November 12, 2007||No|difficulty in achieving target enrollment numbers|No|September 2, 2009|https://clinicaltrials.gov/show/NCT00557622||165071|
NCT00557336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1523|Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age|Evaluation of Efficacy and Safety of Somatropin in SGA Children Due to IUGR||Novo Nordisk A/S|No|Completed|July 2003|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|160|||Both|4 Years|14 Years|No|||June 2012|June 28, 2012|November 12, 2007||||No||https://clinicaltrials.gov/show/NCT00557336||165092|
NCT00557596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-201|A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer|A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer||Aegera Therapeutics|No|Terminated|September 2007|November 2009|Anticipated|November 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2009|November 30, 2009|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00557596||165073|
NCT00558597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154|Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation|Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation||Hannover Medical School|No|Recruiting|March 2008|December 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|BAL (broncho alveolar lavage) urine|Both|18 Years|70 Years|No|Probability Sample|patients after lung transplantation|September 2008|July 19, 2011|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558597||164999|
NCT00554970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0010-CL-P202|A Study of 2 Doses of MAP0010 in Adult Asthmatics|A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 in Adult Asthmatics|P202|Allergan|No|Completed|November 2007|March 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|45 Years|No|||December 2013|December 9, 2013|October 30, 2007|No|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00554970||165265|
NCT00555282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0507|Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of Two Different Central Venous Catheters (CVC)|Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of a Standard Central Venous Catheter (CVC) in Comparison to a Coated CVC||B. Braun Melsungen AG||Completed|November 2005|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|680|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555282||165241|
NCT00534079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pulmozyme-nasal-cf|Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical Study||University of Jena|Yes|Completed|September 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|5 Years|N/A|No|||December 2014|December 3, 2014|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534079||166838|
NCT00564746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB681323/011|To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males|An Open Label Study to Determine the Excretion Balance and Pharmacokinetics of [14C]SB-681323, Administered as a Single Dose of an Oral Solution to Healthy Adult Male Subjects.||GlaxoSmithKline||Completed|September 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||January 2012|October 2, 2014|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564746||164535|
NCT00534053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070504|Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial|Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial||University of California, San Diego|No|Recruiting|June 2007|October 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|800|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 20, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00534053||166840|
NCT00534326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ort-07-06-06|Standard Reaming Versus Reaming/Irrigating/Aspirating for Intramedullary Nailing of Femoral Shaft Fractures|Standard Reaming Versus Reaming/Irrigating/Aspirating for Intramedullary Nailing of Femoral Shaft Fractures|STAFF|Greenville Health System|No|Active, not recruiting|December 2006|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|85 Years|No|||February 2016|February 10, 2016|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00534326||166819|
NCT00534339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10042|EasyBand GOAL Trial|||Allergan||Withdrawn|December 2010|February 2016|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2010|October 3, 2014|September 21, 2007|Yes|Yes|This study was withdrawn to further optimize the device. No patients were enrolled in the    trial.|No||https://clinicaltrials.gov/show/NCT00534339||166818|
NCT00534898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMR250850MHC|Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients|Comparison Efficacy of Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients: Double-blind Placebo Controlled Study||Beersheva Mental Health Center|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||||||Both|18 Years|60 Years||||September 2007|June 28, 2010|September 24, 2007||No|The study withdrawn due to lack financial support|No||https://clinicaltrials.gov/show/NCT00534898||166775|
NCT00534885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HA-4006|Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine|The Phase Ⅳ Clinical Trial to Evaluate the Safety, Immunogenicity, and Immune Persistence of Three Consecutive Lots of an Inactivated Hepatitis A Vaccine in Healthy Children||Sinovac Biotech Co., Ltd|Yes|Completed|March 2006|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|400|||Both|12 Months|10 Years|Accepts Healthy Volunteers|||November 2015|November 22, 2015|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534885||166776|
NCT00535184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE 190-003|Test of Digital Breast Tomosynthesis vs. Common Mammography to Detect Breast Cancer for Women Undergoing Breast Biopsy|A Multicenter Study to Test Digital Breast Tomosynthesis (DBT) Compared to Full-Field Digital Mammography (FFDM) in Detecting Breast Cancer. Part 3. Women Undergoing Breast Biopsy||GE Healthcare|No|Completed|August 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Female|18 Years|N/A|No|Non-Probability Sample|Women referrd for breast biopsy because of one or more abnormalities seen on routine        screening mammography; who are also asymptomatic|March 2012|March 21, 2012|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00535184||166753|
NCT00535470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007NMMF-202-US|An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides|An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response||Yaupon Therapeutics|No|Completed|July 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|N/A|No|||August 2012|August 7, 2012|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00535470||166732|
NCT00556751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406|Evaluating Electrocardiogram (ECG) Abnormalities From Young Adulthood Through Middle Age|Epidemiology and Mechanisms of ECG Abnormalities: Young Adulthood to Middle Age|CARDIA ECG|National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|January 1985|September 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5115|||Both|18 Years|N/A|No|Non-Probability Sample|CARDIA study participants, which included black and white men and women, 18- to        30-years-old at the time of study entry from 1985 to 1986, and balanced on sex, race, and        education status|December 2007|February 17, 2016|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00556751||165131|
NCT00557648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH065369|Evaluating the Effectiveness of Early Cognitive Behavioral Therapy With or Without Parental Involvement in Treating Anxious Children|Early Interventions for Anxious Children||University of Minnesota - Clinical and Translational Science Institute|No|Completed|October 2002|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|7 Years|11 Years|No|||May 2014|May 23, 2014|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557648||165069|
NCT00557999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0009.0.140.000-06|Mechanical Ventilation Weaning Protocol in the Coronary Care Unit|Evaluation of the Effects of the Use of Mechanical Ventilation Weaning Protocol in the Coronary Care Unit: A Randomized Study||Hospital de Base|No|Completed|March 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||November 2007|November 13, 2007|November 13, 2007||||No||https://clinicaltrials.gov/show/NCT00557999||165043|
NCT00557934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cond-07-1|Right Ventricular Contractility Reserve Following Repair of Tetralogy of Fallot|Evaluation of Right Ventricular Contractility Reserve Function During Dobutamine Stress in Patients Following Surgical Repair of Tetralogy of Fallot|TOF-Cond|University Hospital Tuebingen|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|4 Years|N/A|No|||September 2008|September 17, 2008|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557934||165048|
NCT00557635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0026|Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow|Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow||University Hospital, Clermont-Ferrand||Suspended|January 2008|December 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||September 2009|September 22, 2009|November 12, 2007||No|no recruited patients|No||https://clinicaltrials.gov/show/NCT00557635||165070|
NCT00558623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10345/9910CONT|Dietary Calcium Supplementation to Reduce Blood Lead in Pregnancy|Controlled Trial in Pregnancy of Dietary Supplements for Suppression of Bone Resorption and Mobilization of Lead Into Plasma||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|January 2001|April 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|670|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2007|November 14, 2007|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00558623||164998|
NCT00558558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0370|Haelan and Nutrition in Cancer Patients|A Phase II Study Examining the Role of Fermented Soy Beverage for Improving Cancer-Associated Anorexia and Cachexia||M.D. Anderson Cancer Center|No|Terminated|October 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||September 2011|September 2, 2011|November 13, 2007|Yes|Yes|Study terminated due to low recruitment.|No|September 2, 2011|https://clinicaltrials.gov/show/NCT00558558||165002|
NCT00558571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.4|4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Oral Doses of BI 10773 as Tablets in Female and Male Patients With Type 2 Diabetes||Boehringer Ingelheim||Completed|January 2008|||April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|78|||Both|18 Years|70 Years|No|||July 2014|July 16, 2014|November 14, 2007||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00558571||165001|
NCT00558857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065.5|Dynamic Substrate Mapping (DSM) for Ischemic VT|Clinical Feasibility of Using Dynamic Substrate Mapping to Guide Ablation of Ischemic Ventricular Tachycardia|DSM|St. Jude Medical|No|Terminated|July 2007|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||February 2011|February 16, 2011|November 14, 2007||Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT00558857||164981|
NCT00558870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0641|Role of Methadone As Co-Opioid Analgesic|Role of Methadone As Co-Opioid Analgesic in Cancer Patients||M.D. Anderson Cancer Center|Yes|Terminated|November 2007|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|November 14, 2007||No|Low Accrual.|No||https://clinicaltrials.gov/show/NCT00558870||164980|
NCT00554983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0702rB|Efficacy and Safety From a Recombinant Folding Variant of Bet v 1|A Multicentre Randomised Placebo-controlled Double-blind Pivotal Clinical Trial for the Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v 1-FV||Allergopharma GmbH & Co. KG|No|Completed|September 2007|May 2012|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|60 Years|No|||November 2013|November 7, 2013|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554983||165264|
NCT00533468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-130|"Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."|"Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."||State University of New York at Buffalo|Yes|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|70|||Both|N/A|60 Days|No|||March 2011|March 23, 2011|September 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00533468||166884|
NCT00533481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0557-015|Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)|||Merck Sharp & Dohme Corp.||Completed|February 2004|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|497|||Both|18 Years|65 Years|No|||June 2014|June 30, 2014|September 19, 2007||||No||https://clinicaltrials.gov/show/NCT00533481||166883|
NCT00533780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0003|Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer|Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer||Stanford University||Completed|January 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|70 Years|No|||June 2010|June 1, 2010|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533780||166860|
NCT00567073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03506|Pompe Pregnancy Sub-Registry|A Sub-Registry to Observe the Effect of Myozyme (Alglucosidase Alfa) Treatment on Pregnancy and Infant Growth in Women With Pompe Disease||Sanofi|No|Recruiting|November 2011|January 2030|Anticipated|January 2030|Anticipated|Phase 4|Observational|N/A||4|Anticipated|20|Samples Without DNA|Blood|Female|N/A|N/A|No|Non-Probability Sample|Pregnant Females with Pompe disease and/or infants born to females with Pompe disease.        Participants may or may not be receiving therapy.|October 2015|October 27, 2015|December 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00567073||164361|
NCT00567086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGX424MIG2001|Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine|A Double-Blind, Placebo-Controlled, Parallel Group Multicenter Study to Assess the Safety, Tolerance and Efficacy of a Single Subcutaneous Dose of TEZAMPANEL in Patients With Acute Migraine||TorreyPines Therapeutics|No|Completed|October 2006|August 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|306|||Both|18 Years|65 Years|No|||December 2007|December 3, 2007|December 3, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00567086||164360|
NCT00533767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0013|Hantavirus Transmission in Households in Chile|Prospective Follow Up of Household Contacts and Hantavirus Transmission Study Among Index and Additional Cases in Chile||University of New Mexico|No|Completed|July 2007|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|197|||Both|2 Years|N/A|No|Non-Probability Sample|76 index cases with hantavirus cardiopulmonary syndrome and their close household contacts|December 2014|December 5, 2014|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00533767||166861|
NCT00534352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014485|A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).|A Multicenter Study to Evaluate the Pharmacokinetic Profile and Safety of TMC125 Plus Tenofovir DF/Emtricitabine All Dosed Once Daily With and Without Darunavir (PREZISTA™)/ Ritonavir Once Daily in Antiretroviral naïve HIV-1 Infected Subjects||Tibotec, Inc||Completed|January 2008|March 2009|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|September 21, 2007|Yes|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00534352||166817|
NCT00534625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTI-04-C07-202|Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients|Phase 2 Study of the Assessment of Pulmonary Function, Safety, Tolerability, and PK of Zileuton Injection in Patients With Chronic Stable Asthma||Critical Therapeutics|No|Completed|September 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|12 Years|N/A|No|||March 2008|March 19, 2008|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00534625||166796|
NCT00534638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106636|Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents|Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix™) Administered in Healthy Adolescents||GlaxoSmithKline||Completed|October 2007|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|34206|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|September 24, 2007|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00534638||166795|Interim analyses of demographic and immunogenicity data up to Month 7 are presented. Safety and effectiveness results will be updated once the data become available.
NCT00535210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01073|The Effect of an Exercise Program on Physical Function After a Spinal Cord Injury|The Effects of a Group Exercise Program on Function in Spinal Cord Injury Rehabilitation: A Pilot Randomized Controlled Trial||University of British Columbia|No|Terminated|September 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|9|||Both|16 Years|50 Years|No|||January 2014|January 29, 2014|September 24, 2007||No|Unsuccessful recruiting patients, never got beyond pilot testing of patients|No||https://clinicaltrials.gov/show/NCT00535210||166751|
NCT00535197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSC/003|Autologous Bone Marrow Stem Cells in Ischemic Stroke.|A Phase I/II Safety and Tolerability Study Following the Autologous Infusion of Immuno-selected CD34+ Subset Bone Marrow Stem Cells Into Patients With Acute Total Anterior Circulation Ischaemic Stroke||Imperial College London|Yes|Completed|September 2007|December 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|30 Years|80 Years|No|||July 2012|February 15, 2016|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535197||166752|
NCT00535730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-012|ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)|A Phase III Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With PNEUMOVAX™ 23 in Subjects 60 Years of Age and Older||Merck Sharp & Dohme Corp.||Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|473|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 1, 2015|September 21, 2007|Yes|Yes||No|January 21, 2009|https://clinicaltrials.gov/show/NCT00535730||166712|
NCT00567671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVX-001|Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia or Progressive Keratoconus|CL|Emory University|Yes|Completed|December 2007|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|14 Years|N/A|No|||July 2009|September 1, 2010|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567671||164316|
NCT00556764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAM-PD-02|Development of Cognitive Assessment Tools in Parkinson Disease|Development of Cognitive Assessment Tools in Parkinson Disease|ANAM|Institute for Neurodegenerative Disorders|No|Completed|July 2007|March 2011|Actual|March 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|75|||Both|30 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|November 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00556764||165130|
NCT00557661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIL-CDNP-CT002|Safety Study of CD-NP in Heart Failure|A Multi-Center, Ascending Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CD-NP Infusions in Patients With Congestive Heart Failure||Nile Therapeutics|No|Completed|November 2007|December 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2009|March 23, 2009|November 12, 2007||||No||https://clinicaltrials.gov/show/NCT00557661||165068|
NCT00557687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-5|Prediction of Ovarian Response|Prediction of Ovarian Response After Ovarian Stimulation for in Vitro Fertilization||Aristotle University Of Thessaloniki||Completed|May 2005|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Serum|Female|18 Years|39 Years|No|Non-Probability Sample|Women undergoing ovarian stimulation with gonadotropins and GnRH antagonists for IVF|February 2015|February 25, 2015|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557687||165067|
NCT00567944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCB4-001|Use of the BrainPort® Balance Device to Improve Balance in Adults With Balance Deficits Due to Stroke|A Substitute Vestibular Information System Using the BrainPort® Balance Device for Adults With Chronic Vestibular Dysfunction Following Stroke||Wicab|No|Completed|June 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567944||164295|
NCT00557362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9332-31301-01|Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer|Mycotic Ulcer Treatment Trial Therapeutic Exploratory Study|MUTT_TE|University of California, San Francisco|No|Completed|November 2007|August 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|16 Years|N/A|No|||November 2013|November 18, 2013|November 9, 2007||No||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00557362||165090|
NCT00558896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574742|CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis|A Phase II Trial of CC-4047 Plus Dexamethasone in Patients With Relapsed of Refractory Multiple Myeloma or Amyloidosis||Mayo Clinic|Yes|Active, not recruiting|November 2007|||September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|378|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|November 14, 2007|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT00558896||164978|
NCT00557947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06CS005|Prineo (Dermabond Protape) Versus Sutures for Full-thickness Surgical Incisions|Multi-centre Study to Show Equivalence of Prineo (Dermabond Protape) to Intradermal Sutures for Skin Closure of Full-thickness Surgical Incisions||Ethicon, Inc.|No|Completed|August 2007|April 2009|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|November 9, 2007||No||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00557947||165047|Limitations of this study include the fact that the patient served as her own control. Additionally, as in many device studies, because of the obvious difference in the investigated and the control devices, blinding was limited.
NCT00557960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLI381-316|ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD|A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With ADDERALL XR and STRATTERA Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Shire|No|Completed|February 2004|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|36|||Both|19 Years|25 Years|No|||March 2009|December 10, 2010|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00557960||165046|
NCT00558909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1224.4|4 Weeks Treatment of Type II Diabetic Patients With BI 44847|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Selected Oral Doses of BI 44847 as Tablet in Female and Male Patients With Type 2 Diabetes.||Boehringer Ingelheim||Completed|June 2007|||November 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|80|||Both|21 Years|70 Years|No|||April 2014|April 30, 2014|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00558909||164977|
NCT00558233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCDA-05-162-01|Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid|Overcoming Literacy Barriers in Colorectal Cancer Screening|InfoPC|Wake Forest School of Medicine|No|Completed|November 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|350|||Both|50 Years|75 Years|No|||April 2010|April 20, 2010|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00558233||165025|
NCT00558246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07CS003|Study of Prineo (Dermabond Protape) Versus Sutures in Breast Procedures|Multi-centre Study to Show Equivalence of Prineo (DERMABOND PROTAPE) to Intradermal Sutures for Skin Closure of Full-thickness Surgical Incisions Associated With Breast Procedures||Ethicon, Inc.|No|Completed|August 2007|October 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|November 9, 2007||No||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00558246||165024|Limitations of this study include the fact that the patient served as her own control. Additionally, as in many device studies, because of the obvious difference in the investigated and the control devices, blinding was limited.
NCT00558584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA-2006-001|Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy|Multicentre, Randomized, Double-blind, Prospective Investigation on the Effects of Immunoadsorption on Cardiac Function in Patients With Dilated Cardiomyopathy||University Medicine Greifswald|Yes|Recruiting|December 2007|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||November 2015|November 13, 2015|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558584||165000|
NCT00565019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUPTRNS_STRD_RCT|Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture|The Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Patients With Dupuytren's Contracture: a Randomized Controlled Study||Sunnybrook Health Sciences Centre|No|Completed|November 2007|June 2013|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565019||164514|
NCT00533819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07GS006CHS|Exercise Intervention in Female School Children: Effect on Blood Pressure, Body Mass Index (BMI), and Maths Scores|A Phase II Non Randomized Community Intervention Trial in 4 Public Sectors Schools in Karachi. Exercise Intervention in Female School Children: Effect on Blood Pressure, BMI, and Maths Scores||Aga Khan University|No|Recruiting|September 2007|May 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|280|||Female|9 Years|11 Years|No|||October 2008|October 14, 2008|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533819||166857|
NCT00533832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D02|Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)|A Multicernter, Pivotal, Safety and Efficacy Study of the NeuroCtybernetic Prosthesis (NCP(R)) System in Patients With Depression||Cyberonics, Inc.|Yes|Completed|July 2000|July 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|80 Years|No|||September 2007|September 21, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00533832||166856|
NCT00566813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND11807-2004-0532|Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression|Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression||University of Illinois at Chicago|Yes|Active, not recruiting|November 2004|December 2013|Anticipated|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||October 2007|August 5, 2011|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566813||164381|
NCT00567398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34202|IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients|Multi-center,Prospective, Randomized Trial ToDemonstrate Improved Metabolic Control of PEN VS Dianeal In Diabetic CAPD and APD Patients - The Impendia Trial|Impendia|Baxter Healthcare Corporation|No|Completed|April 2008|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567398||164337|
NCT00534066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002H0262|Utility of Serial BNP Levels in Emergency Department CHF|The Utility of Serial BNP Levels as a Predictor of Adverse Outcomes in Emergency Department CHF||Ohio State University|No|Completed|September 2002|June 2006|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||2|Actual|52|||Both|18 Years|N/A|No|||April 2007|September 21, 2007|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00534066||166839|
NCT00534365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFHA 07-01|Study Comparing TVT With TVT-SECUR for the Treatment of Stress Urinary Incontinence|A Randomized Trial Comparing Tension-free Vaginal Tape (TVT) to the TVT-SECUR for the Surgical Treatment of Stress Urinary Incontinence|SECURiTy|The Cleveland Clinic|Yes|Completed|August 2007|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|281|||Female|21 Years|N/A|No|||August 2013|August 27, 2013|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00534365||166816|
NCT00534651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1265|Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease|Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease||University of Zurich|No|Completed|November 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|37|||Both|30 Years|80 Years|No|||March 2010|March 15, 2010|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00534651||166794|
NCT00534911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606136|Reducing Depressive Symptoms in Physically Ill Youth|Reducing Depressive Symptoms in Physically Ill Youth||University of Pittsburgh|Yes|Active, not recruiting|September 2007|December 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|9 Years|17 Years|No|||January 2016|January 4, 2016|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00534911||166774|
NCT00567970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579232|Stereotactic Radiation Therapy in Treating Patients With Liver Metastases|A Phase I Dose Finding Pilot Study of Stereotactic Body Radiotherapy for the Treatment of Liver Metastasis||Mayo Clinic|Yes|Active, not recruiting|April 2007|||September 2015|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|December 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00567970||164293|
NCT00535483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS3|Closed Loop Insulin Therapy in Type 1 Diabetics Based on Blood Microdialysis, Online Sensors and an eMPC Algorithm|An Open, Mono-centre Pilot Study to Investigate a Novel Technique to Establish Glycaemic Control for Critically Ill Patients, Tested in Type 1 Diabetic Subjects for a Period of 30 Hours.||Medical University of Graz|No|Completed|August 2007|September 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|4|||Both|18 Years|65 Years|No|||April 2014|April 3, 2014|September 24, 2007||||No||https://clinicaltrials.gov/show/NCT00535483||166731|
NCT00567684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0381|Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors|Pilot Study Assessing the Technical Efficacy of Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) With Particular Focus on Patients at Risk of Urothelial Tumors||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2007|||November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|135|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567684||164315|
NCT00568607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DICE-NK/T|Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma|Phase II Study of a Combination Chemotherapy of DICE in the Patients With NK/T Cell Lymphoma||Fudan University|No|Recruiting|March 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||September 2010|September 7, 2010|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568607||164245|
NCT00568620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#070770|The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus|The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus||Vanderbilt University|Yes|Completed|May 2008|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568620||164244|
NCT00558259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.63|Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE|Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.|RE-SONATE|Boehringer Ingelheim||Completed|November 2007|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|1353|||Both|18 Years|N/A|No|||February 2014|June 17, 2014|November 13, 2007||||No|January 31, 2012|https://clinicaltrials.gov/show/NCT00558259||165023|
NCT00568243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080031|Visual Motor Coordination|Visual Motor Coordination||National Institutes of Health Clinical Center (CC)||Recruiting|November 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 20, 2015|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568243||164272|
NCT00559195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574173|Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors|Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor||National Cancer Institute (NCI)||Completed|November 2005|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Supportive Care|||Anticipated|40|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559195||164956|
NCT00559481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 93506|Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy|Effect of Oral Ketoconazole on the Pharmacokinetics of Oral Dexamethasone and Oral Hydrocortisone in Patients With Androgen Independent Prostate Cancer||Roswell Park Cancer Institute||Withdrawn|October 2007|||September 2008|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Male|N/A|N/A|No|||January 2013|January 31, 2013|November 15, 2007|No|Yes|Withdrawn due to low accrual|No||https://clinicaltrials.gov/show/NCT00559481||164935|
NCT00566800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000576425|Erlotinib in Treating Patients With Barrett Esophagus|Chemoprevention Trial Using Erlotinib in Barrett's Esophagus With High-Grade Dysplasia||National Cancer Institute (NCI)||Recruiting|July 2007|||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||January 2008|September 16, 2013|December 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00566800||164382|
NCT00534378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11903|Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector|Phase I, Open-Label, Single-Center Study to Evaluate the Safety and Dose Linearity of Intramuscular Administration of Midazolam Using|AAS|U.S. Army Office of the Surgeon General|Yes|Completed|July 2006|December 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||September 2007|September 21, 2007|September 20, 2007||||No||https://clinicaltrials.gov/show/NCT00534378||166815|
NCT00567723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-404|Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)|A Phase-IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects Treated With Lanthanum Carbonate (Fosrenol)||Shire|No|Active, not recruiting|April 2006|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2105|||Both|18 Years|N/A|No|Probability Sample|Patients for the Historical Control and Concomitant Therapy Groups will be selected from        the United States Renal Data System (USRDS). The Test Group will consist of patients who        have had a minimum of 12 consecutive weeks of exposure to Fosrenol (lanthanum carbonate).|April 2014|April 16, 2015|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567723||164312|
NCT00567710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL - 1020 IIb|A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study|A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone||BioLineRx, Ltd.|No|Completed|July 2008|September 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|360|||Both|18 Years|65 Years|No|||June 2010|June 27, 2010|December 4, 2007||Yes||||https://clinicaltrials.gov/show/NCT00567710||164313|
NCT00568321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091005|RN624 For Pain Of Post-Herpetic Neuralgia|A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of RN624 In Adult Patients With Post-Herpetic Neuralgia||Pfizer|Yes|Completed|November 2007|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|N/A|No|||October 2009|October 21, 2009|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568321||164266|
NCT00568659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111|The Specific Lung Elastance in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients in Supine and Prone Position|The Specific Lung Elastance in ALI/ARDS Patients in Supine and Prone Position||Policlinico Hospital|No|Completed|December 2007|January 2015|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568659||164241|
NCT00568672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000512-82|Optimal Duration of Olanzapine Add-on Therapy in Major Depression|Optimal Duration of Olanzapine Add-on Therapy in Major Depression: a Placebo-Controlled, Randomized, Phase III, Pilot Study in Parallel Group Design|OLA-D|Charite University, Berlin, Germany|Yes|Withdrawn|October 2007|April 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||April 2008|April 23, 2008|December 5, 2007||No|Withdrawn because of personal ressources before inclusion of the first patient|No||https://clinicaltrials.gov/show/NCT00568672||164240|
NCT00568334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109705|Study of Two Formulations of GSK Biologicals' Varicella Vaccine|Study of Two Formulations of GSK Biologicals' Varicella Vaccine Given as a 2-dose Course in the Second Year of Life||GlaxoSmithKline|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|244|||Both|11 Months|21 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|December 5, 2007||||No||https://clinicaltrials.gov/show/NCT00568334||164265|
NCT00568295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-090|A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee|A Four-Week Comparative Study Evaluating Acetaminophen Extended Release (3900 mg/Day) and Rofecoxib (12.5 mg/Day and 25 mg/Day)in the Treatment of Osteoarthritis of the Knee||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 1999|October 2000|Actual|October 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|403|||Both|40 Years|N/A|No|||August 2011|August 19, 2011|December 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00568295||164268|
NCT00568633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT190|Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML|A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission||Stanford University|Yes|Terminated|August 2007|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|50 Years|75 Years|No|||November 2013|November 22, 2013|December 4, 2007||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00568633||164243|
NCT00559234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080017|Potential Research Participants for Future Studies of Inherited Eye Diseases|Evaluation and Treatment Protocol for Potential Research Participants With Inherited Ophthalmic Diseases||National Institutes of Health Clinical Center (CC)||Completed|November 2007|October 2008||||N/A|Observational|Time Perspective: Prospective||||400|||Both|N/A|N/A|No|||October 2008|September 26, 2015|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559234||164953|
NCT00557089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010903|The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis|Randomized, Placebo-controlled Trial on the Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis||The Hospital for Sick Children|No|Completed|January 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|6 Years|18 Years|No|||August 2013|August 30, 2013|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00557089||165109|
NCT00557388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-3-086|Dietary Strategies to Promote Muscle Protein Anabolism in the Elderly|Dietary Strategies to Promote Muscle Protein Anabolism in the Elderly||Maastricht University Medical Center|Yes|Completed|December 2007|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|10||Actual|120|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2011|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557388||165088|
NCT00567333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP07639|Individualized Chiropractic and Integrative Care for Low Back Pain|Individualized Chiropractic and Integrative Care for Low Back Pain||Northwestern Health Sciences University|Yes|Completed|June 2007|December 2013|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||May 2015|May 9, 2015|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567333||164342|
NCT00567346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0602|Efficacy and Safety of Grass Pollen Sublingual Immunotherapy|A Randomised, DB, Plcb Controlled, Multicentre, Multinational Phase II/III Study to Assess the Efficacy and Safety of Three Different Dose Regimens of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis||Artu Biologicals|Yes|Completed|December 2006|March 2008|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|605|||Both|18 Years|50 Years|No|||May 2010|May 4, 2010|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567346||164341|
NCT00567658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070730|Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas|Effect of Aggressive Acid Suppression With Esomeprazole on Vocal Cord Granulomas: Randomized Placebo-Controlled Trial||Vanderbilt University|No|Withdrawn|February 2008|January 2010|Anticipated|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||August 2013|September 4, 2013|December 3, 2007|No|Yes|The decision of terminate the study was reached due to difficulties surrounding recruitment    and enrollment of subjects since the inception of the study.|No||https://clinicaltrials.gov/show/NCT00567658||164317|
NCT00555360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-185|Enhancing Caregiver Support for Heart Failure Patients: the CarePartner Study|Enhancing Caregiver Support for Patients With Heart Failure||VA Office of Research and Development|No|Completed|June 2009|December 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|372|||Both|N/A|N/A|No|||August 2015|August 12, 2015|November 6, 2007||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT00555360||165235|
NCT00555633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-015 ex 04/05|Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients|Regular Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients, Particularly in Xeroderma Pigmentosum and Basal Cell Nevus Syndrome||Medical University of Graz|No|Completed|October 2004|February 2006|Actual|||N/A|Observational|N/A||1|Actual|13|||Both|19 Years|N/A|No|Non-Probability Sample|Primary care clinic|September 2009|September 29, 2009|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555633||165214|
NCT00558272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8180C00034|Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease|A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.||AstraZeneca|Yes|Completed|February 2008|August 2012|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||May 2013|May 23, 2013|November 13, 2007|Yes|Yes||No|May 27, 2011|https://clinicaltrials.gov/show/NCT00558272||165022|Non-compliant patients were excluded from the biomarker analysis, in order to accurately assess effects due to treatment. The compliance criteria did not apply to the zoledronic acid arm, which led to an imbalance in the number of subjects analysed.
NCT00558285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2203|Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Determine the Effect of QVA149 on Mean 24-hours Heart Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|257|||Both|40 Years|N/A|No|||November 2012|November 28, 2012|November 12, 2007||No||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00558285||165021|
NCT00568568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20070176|Metabolic Studies- Interactions Between GH and Insulin in GHDA|Metabolic Studies- Interactions Between GH and Insulin in GHDA. Insulin Resistance and GH Treatment: Dependence of Ambient GH Level Among Patients Treated With GH and Healthy Control Subjects||University of Aarhus|No|Completed|December 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568568||164247|
NCT00568594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPL180A2201|Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)|A First-in-human, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose (Healthy Volunteers and CHD Patients) and Multiple Dose (CHD Patients) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180||Novartis|No|Completed|November 2007|||September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|176|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|December 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568594||164246|
NCT00568555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10232007-756|Effects of Low Dose Naltrexone in Fibromyalgia|Effects of Low Dose Naltrexone in Fibromyalgia||Stanford University||Completed|June 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|December 4, 2007|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00568555||164248|
NCT00568867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11072007-830|Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample|Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample||Stanford University|Yes|Completed|September 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|Samples With DNA|tumor tissue sample|Both|18 Years|N/A|No|Non-Probability Sample|Any adult patient with a tumor who is scheduled to undergo surgery to either remove or        biopsy the tumor.|April 2011|April 7, 2011|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568867||164225|
NCT00564759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/59|Gene Therapy for Chronic Granulomatous Disease|Phase I/II Gene Therapy Study for X-Linked Chronic Granulomatous Disease|CGD|Johann Wolfgang Goethe University Hospitals|No|Active, not recruiting|January 2004|December 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Male|18 Years|N/A|No|||November 2007|November 27, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564759||164534|
NCT00556491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15087|Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery|Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery||St. Louis University|Yes|Completed|December 2007|December 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|90 Years|No|||March 2015|March 5, 2015|November 9, 2007||No||No|January 11, 2015|https://clinicaltrials.gov/show/NCT00556491||165148|
NCT00564460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-2007|On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)|On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)||University of Alberta|No|Withdrawn|February 2008|February 2011|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|310|||Male|18 Years|N/A|No|||November 2009|November 4, 2009|November 26, 2007||No|Change of practice pattern. Green light laser|No||https://clinicaltrials.gov/show/NCT00564460||164557|
NCT00564473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERB.INTMED.08|Use of Herbal Medicine in Internal Medicine Wards|Use of Herbal Medicine Among Patients Hospitalized in a Department of Internal Medicine: A Cross-Sectional Survey||Shaare Zedek Medical Center|No|Completed|June 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|patients hospitalized in a department of internal medicine|October 2010|October 28, 2010|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00564473||164556|
NCT00564486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APA-304|Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain|Phase 3 Randomized, Double-Blind Placebo-Controlled, Multicenter, Parallel-Group, Repeated-Dose Study of the Analgesic Efficacy & Safety of IV Acetaminophen Versus Placebo for the Treatment of Postop Pain||Mallinckrodt|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|244|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|November 26, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00564486||164555|One subject was randomized to receive IV APAP 1 g, but was administered IV APAP 650 mg. The subject was included in 1g IV APAP group for efficacy purposes and included in IV APAP 650 mg safety group for AE purposes.
NCT00566462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-226|Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT|Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT||Eisai Inc.||Terminated|October 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|30 Years|N/A|No|||November 2012|November 20, 2012|November 29, 2007|Yes|Yes|Study stopped due to lack of efficacy.|No|November 20, 2012|https://clinicaltrials.gov/show/NCT00566462||164407|This study was terminated at the sponsor request after only 1 subject was enrolled and completed the study and therefore the data is limited. Similiar research in this area have required a minimum of 5-6 completers to develop a valid analysis.
NCT00566475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#5302|School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus|School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus||State University of New York - Upstate Medical University|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|5 Years|14 Years|No|||December 2009|December 29, 2009|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566475||164406|
NCT00566488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016482|Parathyroid and Thymus Transplantation in DiGeorge #931|Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931||Duke University|Yes|Active, not recruiting|January 2005|June 2027|Anticipated|August 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|24 Months|No|||September 2015|September 3, 2015|November 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00566488||164405|
NCT00567099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0059|Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole|Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole||New Mexico VA Healthcare System|Yes|Recruiting|August 2003|September 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|May 24, 2010|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567099||164359|
NCT00567112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-009|Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)|An Open-Label, Randomized, Partially Fixed-Sequence, 4-Period Crossover Study to Assess the Pharmacokinetics After Administration of the DFC and OCT Formulations and the Food Effect on the OCT Formulation of MK-0941 in Patients With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|November 2007|April 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|70 Years|No|||March 2015|March 12, 2015|November 30, 2007|No|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT00567112||164358|
NCT00567736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISCI-07|Efficacy of Disci/Rhus Toxicodendron Comp.®, in Patients With Chronic Low Back Pain|Prospective Randomized Controlled Multicentre Trial for Patients With Chronic Low Back Pain Comparing Disci/Rhus Toxicodendron Comp.®, Placebo and Waiting List Group|DISCI|Charite University, Berlin, Germany|No|Completed|August 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|150|||Both|30 Years|75 Years|No|||August 2009|July 10, 2012|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567736||164311|
NCT00567983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13717A|Topical Cyclosporine and Disease Progression|Topical Cyclosporine and Disease Progression||Innovative Medical||Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 23, 2008|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567983||164292|
NCT00567359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-259|Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR|A Phase II Trial of Adjuvant Erlotinib in Patients With Resected, Early Stage Non-Small Cell Lung Cancer (NSCLC) With Confirmed Mutations in the Epidermal Growth Factor Receptor (EGFR)||Massachusetts General Hospital|Yes|Active, not recruiting|December 2007|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00567359||164340|
NCT00567372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00922|POSTERIOR SUB-TENON'S Avastin|POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA||Asociación para Evitar la Ceguera en México|No|Recruiting|June 2008|June 2009|Anticipated|November 2008|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|25 Years|90 Years|No|||December 2008|December 5, 2008|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00567372||164339|
NCT00567385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1515|Liquid Somatropin Formulation in Children With Growth Hormone Deficiency|An Open, Multi-centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin® SimpleXx® in Children With GH Deficiency||Novo Nordisk A/S|No|Completed|March 2003|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|176|||Both|3 Years|18 Years|No|||June 2012|June 28, 2012|November 30, 2007||||No||https://clinicaltrials.gov/show/NCT00567385||164338|
NCT00567697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCC study 2007|A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO|A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO||Aleris Helse|Yes|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|50 Years|N/A|No|||January 2012|January 18, 2012|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567697||164314|
NCT00568009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S320.2.003|Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function|Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function||Solvay Pharmaceuticals|Yes|Terminated|October 2007|November 2008|Anticipated|November 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|300|None Retained|Not aplicable|Both|18 Years|85 Years|Accepts Healthy Volunteers||Congestive Heart Failure, Impaired Renal Function|April 2008|April 18, 2008|December 4, 2007|Yes|Yes|additional enrolment criteria made patients' recruitment not feasible anymore|No||https://clinicaltrials.gov/show/NCT00568009||164290|
NCT00568022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-117|A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer|A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane||R-Pharm|Yes|Completed|February 2008|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|20 Years|N/A|No|||February 2016|February 9, 2016|December 3, 2007||No||No|June 3, 2011|https://clinicaltrials.gov/show/NCT00568022||164289|
NCT00568347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061697A|Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange|Evaluation of the Effects of Varying Doses of Inhaled Corticosteroids on Suppression of Total Exhaled, Bronchial, and Alveolar Nitric Oxide as Markers of Endogenous Inflammation in Patients With Moderate-to-severe COPD||Gelb, Arthur F., M.D.|Yes|Completed|January 2006|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Actual|39|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|COPD|March 2015|March 13, 2015|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568347||164264|
NCT00568971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCF-AGC|Study of Weekly DCF to Treat Advanced Gastric Cancer|Phase II Study of Weekly Docetaxol Combined With Cisplatin and 5-Fu in Patients With Advanced Gastric Cancer||Fudan University|No|Terminated|April 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||August 2009|January 26, 2010|December 5, 2007||No|The study has finished.|No||https://clinicaltrials.gov/show/NCT00568971||164219|
NCT00568984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3017|Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes|Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|November 2002|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|324|||Both|18 Years|N/A|No|||January 2012|June 5, 2012|December 4, 2007||||No||https://clinicaltrials.gov/show/NCT00568984||164218|
NCT00559572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH079047|Effects of Motivating People With Schizophrenia to Exercise|Motivating Persons With Schizophrenia to Exercise||The University of Tennessee Knoxville|Yes|Completed|November 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|22 Years|N/A|No|||January 2013|January 14, 2013|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559572||164928|
NCT00555061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC106489|Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.|An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months||GlaxoSmithKline|No|Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|2 Months|24 Months|No|||October 2012|November 1, 2012|November 6, 2007|Yes|Yes||No|August 10, 2009|https://clinicaltrials.gov/show/NCT00555061||165258|
NCT00555074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROTA-1|Sodium Tungstate in Obesity|Efficacy of Oral Sodium Tungstate (200 mg/Day)on Weight Loss in Subjects With Grade I-II Obesity|TROTA-1|Hospital Clinic of Barcelona|No|Completed|November 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|No|||May 2008|March 30, 2010|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00555074||165257|
NCT00567957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP01|Remifentanil for General Anesthesia in Preeclamptics|Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients||Istanbul University||Not yet recruiting|February 2008|December 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Female|18 Years|45 Years|No|||December 2007|December 4, 2007|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567957||164294|
NCT00568269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMIL II|Randomized Multicentre Study Comparing TEP With Lichtenstein Repair for Primary Inguinal Hernia|Randomized Multicentre Study Comparing TEP With Lichtenstein Repair for Primary Inguinal Hernia||Uppsala University Hospital||Completed|November 1996|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1513|||Male|30 Years|70 Years|No|||December 2007|December 5, 2007|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568269||164270|
NCT00568282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0017|Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients|Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)||Stanford University|Yes|Recruiting|February 2007|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with advanced stage NSCLC who are either newly diagnosed, or who have evidence of        disease progression.|October 2013|October 23, 2013|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568282||164269|
NCT00556231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 07/198|Multi-site Near Infrared Spectroscopy (NIRS) Monitoring of Children During Exercise|Use of Multi-site Near Infrared Spectroscopy (NIRS) Monitoring for Global Hemodynamic Assessment During Exercise Testing in Children With and Without Heart Disease||Medical College of Wisconsin|No|Completed|November 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|51|||Both|6 Years|20 Years|No|Non-Probability Sample|Children and adolescents from age 6 to 20 undergoing exercise stress testing|January 2013|January 2, 2013|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00556231||165168|
NCT00556257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921037|Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients|A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients||Pfizer|Yes|Withdrawn|August 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|70 Years|No|||May 2008|May 27, 2008|November 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556257||165166|
NCT00568256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07092603|Mind/Body Medicine and IBD Flare-Up|Mind/Body Medicine and IBD Flare-Up||Rush University Medical Center|Yes|Completed|November 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|70 Years|No|||February 2012|February 24, 2012|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568256||164271|
NCT00564499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-RB-COPD-2005/1|SYMBICORT® in the Treatment of COPD|A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners|SRP COPD|AstraZeneca|No|Completed|March 2006|May 2007|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|patients|January 2011|January 27, 2011|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564499||164554|
NCT00564512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577580|Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP|Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL)||French Innovative Leukemia Organisation|Yes|Completed|November 2007|July 2013|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|65 Years|No|||April 2009|July 24, 2013|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00564512||164553|
NCT00568880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577505|Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma||National Cancer Institute (NCI)||Recruiting|November 2007|||November 2009|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|December 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568880||164224|
NCT00556842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM1AR063386-01|Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures (The HEALTH Study)|Hip Fracture Evaluation With Alternatives of Total Hip Arthroplasty Versus Hemi-Arthroplasty: A Multi-Centre Randomized Trial Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Patients With Displaced Femoral Neck Fractures||Boston University|Yes|Recruiting|March 2009|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1434|||Both|50 Years|N/A|No|||July 2015|July 22, 2015|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556842||165125|
NCT00557154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-9400847-018LA|Ultrasound Assisted Peripheral Venous Access in Young Children|Ultrasound Assisted Peripheral Venous Access in Young Children: A Pilot and Feasibility Randomized Controlled Trial||University of California, Davis|No|Completed|August 2003|July 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|N/A|7 Years|No|||November 2007|November 8, 2007|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00557154||165104|
NCT00556816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 14887.075.06|Chronic Obstructive Pulmonary Disease (COPD) Outpatient on Demand Clinic|COPD-C: COPD Outpatient on Demand Clinic. Study to Determine the Efficacy and Safety of on Demand Outpatient Clinics in COPD Patients|COPD-C|Isala|Yes|Completed|September 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|40 Years|N/A|No|||September 2015|September 17, 2015|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556816||165126|
NCT00566839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED2112025|Randomized Comparison of Awake Nonresectional Versus Nonawake Resectional Lung Volume Reduction Surgery|Randomized Comparison of Thoracoscopic Lung Volume Reduction Surgery Performed by Resectional Surgical Technique Under General Anesthesia or by a Non-Resectional Technique in Awake Patients Under Sole Epidural Anesthesia||University of Rome Tor Vergata|Yes|Completed|December 2002|October 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||October 2007|November 30, 2007|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566839||164379|
NCT00567125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PW 205|Comparison of Systemic Response After Laparoscopies Performed With Standard and Low-Pressure Pneumoperitoneum|A Comparative Study of Angiogenic and Cytokine Responses After Laparoscopic Cholecystectomy Performed With Standard-Pressure and Low-Pressure Pneumoperitoneum||Medical University of Lublin|No|Completed|January 2006|March 2006|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|40|Samples Without DNA|serum|Both|18 Years|70 Years|No|Probability Sample|patients with cholelithiasis and indications for surgical treatment; the median age of the        patients included in the study was 48,5 and ranged from 18 to 70 years. The ratio of        female to male patients was identical within each group and amounted 7:3.|December 2007|December 3, 2007|December 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00567125||164357|
NCT00567411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU # 06-23016|Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty|Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty||Walter Reed Army Medical Center|Yes|Recruiting|August 2006|June 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|43|||Both|18 Years|N/A|No|||November 2007|December 4, 2007|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567411||164336|
NCT00567424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEC107055|GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures|An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized||GlaxoSmithKline||Withdrawn|July 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|July 20, 2006|||No longer viable|||https://clinicaltrials.gov/show/NCT00567424||164335|
NCT00567996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2336|Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control|A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control||Novartis||Completed|November 2007|||January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1002|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|December 4, 2007||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00567996||164291|
NCT00568308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR88302|Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma|A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma|PATHWAY|Progen Pharmaceuticals|Yes|Terminated|December 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|December 4, 2007|Yes|Yes|Commercial decision to discontinue the study|No||https://clinicaltrials.gov/show/NCT00568308||164267|
NCT00568360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0014|Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer|Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer||Stanford University||Terminated|February 2004|August 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients with newly diagnosed head and neck cancer as well as those being seen for        routine follow up with no evidence of current disease and healthy volunteers are eligible        for this study.|May 2012|May 16, 2012|December 4, 2007||No|Research cancelled; equipment broke|No||https://clinicaltrials.gov/show/NCT00568360||164263|
NCT00568373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705-32|Gastric Pacemaker Implantation for Gastroparesis|Gastric Electric Stimulation-Enterra Therapy for the Treatment of Chronic Intractable (Drug Refractory) Nausea and Vomiting Secondary to Gastroparesis of Diabetic or Idiopathic Etiology|HUD|Indiana University|No|Recruiting|June 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||July 2015|July 20, 2015|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568373||164262|
NCT00568386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-07-02|Acute Comfort and Blur of Systane and Optive|Acute Comfort and Blurring Profile Evaluation Comparing Systane Lubricant Eye Drops to Optive Lubricant Eye Drops||Alcon Research|No|Completed|November 2007|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 31, 2012|December 5, 2007||No||No|December 18, 2008|https://clinicaltrials.gov/show/NCT00568386||164261|
NCT00568698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11012007-783|A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients|A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients||Stanford University||Completed|January 2004|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|18|||Both|N/A|2 Years|No|||July 2009|July 7, 2009|December 4, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00568698||164238|
NCT00568685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11710|Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder||Eli Lilly and Company|No|Completed|November 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Both|6 Years|18 Years|No|||January 2010|January 19, 2010|December 4, 2007|Yes|Yes||No|November 11, 2009|https://clinicaltrials.gov/show/NCT00568685||164239|
NCT00559533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21280|A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors|A Multi-center, Open-label, Phase I Study of Single Agent R7112 Administered Orally in Patients With Advanced Malignancies, Except All Forms of Leukaemia||Hoffmann-La Roche||Completed|December 2007|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559533||164931|
NCT00559546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS7/E5/07|Montelukast as a Controller of Atopic Syndrome|Montelukast as a Controller of Atopic Syndrome|MONTAS|Helsinki University|No|Completed|March 2007|July 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|40 Years|No|||November 2007|November 15, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559546||164930|
NCT00555048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1981.00|Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation From HLA-Class I or Class II Mismatched, Unrelated Donors||Fred Hutchinson Cancer Research Center|No|Terminated|September 2007|||October 2010|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|1|||Both|N/A|50 Years|No|||January 2011|January 4, 2011|November 6, 2007|No|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00555048||165259|
NCT00556270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Matri Matrix II 07/10|Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain|Matrifen for Therapy of Severe, Chronic Pain.|MATRIX II|Nycomed|No|Completed|November 2007|May 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients|May 2012|May 4, 2012|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00556270||165165|
NCT00555685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2007/04048-7|Hypertonic Saline Solution in Heart Failure|Hypertonic Saline Solution in Decompensated Heart Failure||University of Sao Paulo|Yes|Completed|February 2008|December 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00555685||165210|
NCT00568893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7159|An Open Label Study of Severe Sepsis in Adults|An Open Label Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis and Multiple Organ Dysfunctions A Phase IV Protocol||Eli Lilly and Company|No|Completed|January 2003|October 2003|Actual|||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|18 Years|N/A|No|||December 2007|December 5, 2007|December 5, 2007||||No||https://clinicaltrials.gov/show/NCT00568893||164223|
NCT00568906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11062007-807|Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma|Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma||Stanford University||Recruiting|February 2002|June 2011|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Lung tissue or pleural fluid.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who agree to participate in this study will be those who are undergoing wedge        resection, lobectomy on pneumonectomy for clinically diagnosed lung carcinoma or        metastatic tumors to the lung, or who are undergoing therapeutic or diagnostic        thoracentesis for malignant pleural effusion.|July 2010|July 2, 2010|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568906||164222|
NCT00556218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0311|Meditation and Cognitive Function in Women With Breast Cancer|Feasibility Study of Meditation, Cognitive Function, and Quality of Life in Women With Breast Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2007|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00556218||165169|
NCT00556205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-202|Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma|Phase II, Randomized Trial of Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma||Massachusetts General Hospital|No|Withdrawn|September 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 7, 2007||No|Toxicity of combination from other trials|No||https://clinicaltrials.gov/show/NCT00556205||165170|
NCT00556478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSD502-PE-002|Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation|A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled Study, With Open-label Follow on, to Evaluate the Efficacy, Safety and Tolerability of PSD502 in Subjects With Premature Ejaculation (PE)|PSD502-PE-002|Plethora Solutions Ltd|No|Completed|October 2007|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|256|||Male|18 Years|N/A|No|||September 2015|September 2, 2015|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556478||165149|
NCT00557466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149B2201|A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Multi-center, Parallel Group, Double Blind, Placebo and Formoterol Controlled 14 Day Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Patients With COPD||Novartis||Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|568|||Both|40 Years|N/A|No|||November 2012|December 12, 2012|November 13, 2007||No||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00557466||165082|
NCT00557180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1423|Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications|Obesity, Inflammation and Response to Therapy in Asthma - Ancillary to Asthma Clinical Research Network (ACRN) Trials||National Jewish Health|Yes|Completed|October 2007|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|33|Samples Without DNA|Plasma Serum|Both|18 Years|N/A|No|Non-Probability Sample|Participants in the BASALT and TALC studies. Participants will receive the BASALT and TALC        study drugs as determined in those protocols NCT00495157, NCT00565266. This study is        ancilary to those trials and observational only and does not have any control over study        drug allocation|September 2014|September 24, 2014|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00557180||165103|
NCT00557765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-184|Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area|Production of Gamma-Interferon by Circulating Lymphocytes Exposed to Antigens Specific of Mycobacterium Tuberculosis: Contribution to the Identification of Latent Tuberculosis Infection in Contact Tracing||University Hospital, Geneva|Yes|Completed|October 2004|January 2006|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|295|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects screened after exposure to a case of active and contagious tuberculosis in        the Geneva area|November 2007|November 13, 2007|November 13, 2007||||No||https://clinicaltrials.gov/show/NCT00557765||165061|
NCT00567164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91698|Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ|A Multicenter, Open-label, Three-arm, Active-controlled Study to Assess the Efficacy and Safety of the Oral Contraceptive SH T00186D (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in Two Flexible Extended Regimens and a Conventional Regimen of YAZ in 1756 Healthy Females for 1 Year||Bayer|No|Completed|October 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1887|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|December 3, 2007|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00567164||164355|The Flexible (extended) Regimen no. 1 Group was enrolled under slightly different eligibility criteria for age, BMI, and fertility status than the other two treatment groups. This did not affect the results or interpretation of the results.
NCT00567177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0421|Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease|Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease||Innovative Medical||Completed|November 2007|April 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|13 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 29, 2010|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00567177||164354|
NCT00567450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-002254-31|Ropivacaine Versus Ropivacaine Plus Mepivacaine for Sciatic Block|Ropivacaine 0.75% vs Ropivacaine 0.75% Plus Mepivacaine 1.5% for Subgluteal Sciatic Bloc: a Prospective Double Blind Randomized Controlled Study||Centre Hospitalier Universitaire, Amiens|No|Completed|September 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567450||164333|
NCT00567437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002221|Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis|Utility of Exercise-induced NT-pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis|AS-BNP|Duke University|No|Terminated|December 2007|December 2008|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|October 23, 2012|December 4, 2007||No|Poor patient enrollment from clinic secondary to investigator illness.|No||https://clinicaltrials.gov/show/NCT00567437||164334|
NCT00567762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ-506D-AC09|Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis|A Randomized, Placebo-controlled, Double-masked Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Vernal Keratoconjunctivitis||Astellas Pharma Inc|Yes|Completed|February 2004|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|6 Years|N/A|No|||August 2014|August 29, 2014|December 3, 2007||||No||https://clinicaltrials.gov/show/NCT00567762||164309|
NCT00567749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-HIV02.01|Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population|Clinical Sensitivity of the Clearview® COMPLETE HIV 1/2, PMA # BP050009 and the Clearview® HIV 1/2 STAT-PAK®, PMA #BP050010 in the 12 - 17 Year Old Pediatric Population||Chembio Diagnostic Systems, Inc.|Yes|Completed|December 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Whole blood, plasma and serum|Both|12 Years|17 Years|No|Non-Probability Sample|The patient population intended for this study (study participants) consists of a minimum        of 10 individuals, known to have previously tested positive for HIV antibodies, who are        between 12 and 17 years of age. The patients should not be on HAART, however, the sponsor        reserves the option to include a limited number of HAART patients for investigational        purposes. The number of HAART patients enrolled will depend on the available pediatric HIV        positive participant pool. HAART patients will be clearly identified and will be        additional to the enrollment needed to meet the study objectives.|June 2008|June 25, 2008|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567749||164310|
NCT00568399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO 07-0331|Sodium Thiosulfate Treatment of Vascular Calcification in ESRD|The Effect of Sodium Thiosulfate Treatment on Vascular Calcification in End Stage Renal Failure Patients||Washington University School of Medicine|Yes|Completed|December 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|December 5, 2007||No||No|September 26, 2011|https://clinicaltrials.gov/show/NCT00568399||164260|This study did not enroll a prospective, randomized, placebo controlled, double-blind control group; therefore conclusive statements about the risks and benefits of thiosulfate cannot be made.
NCT00568711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB043-31|Controlled Trial: 5-Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus|Controlled Trial: 5-Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus||Chosun University Hospital|Yes|Recruiting|September 2006|December 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|476|||Both|18 Years|N/A|No|||December 2007|December 5, 2007|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568711||164237|
NCT00564187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8484|Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice|Prospective, Multicentric, Randomized, Open, Comparative Phase IV Study Evaluating the Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice||Sanofi|No|Completed|February 2003|December 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||November 2007|November 27, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00564187||164578|
NCT00564200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004858-27|MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning|MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning|MINIALO-VELCAD|PETHEMA Foundation|Yes|Completed|November 2007|October 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|66 Years|No|||October 2014|October 27, 2014|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564200||164577|
NCT00555373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB Pr. No.: 20101428|Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression|Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression|CNI-W|Pediatric Nephrology of Alabama|Yes|Completed|November 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Both|N/A|19 Years|No|||February 2013|February 22, 2013|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00555373||165234|
NCT00555646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-10-PS-21|Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis|A Phase 2 Study of Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for the Treatment of Plaque Psoriasis||Provectus Pharmaceuticals|No|Terminated|November 2007|July 2009|Anticipated|June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|November 7, 2007|Yes|Yes|Change of dose regimen (new protocol)|No||https://clinicaltrials.gov/show/NCT00555646||165213|
NCT00555945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06042011_REGAIN_v1.0|Re-Evaluation of GAmma3 Intramedullary Nails in Hip Fracture (REGAIN)|Re-Evaluation of GAmma3 Intramedullary Nails in Hip Fracture: A Multi-Centre Randomized Controlled Trial of Gamma3 Intramedullary Nails Versus Sliding Hip Screws in the Management of Intertrochanteric Fractures of the Hip|REGAIN|Stryker Trauma GmbH|No|Completed|May 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|50 Years|N/A|No|||June 2011|June 24, 2011|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555945||165190|
NCT00555698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6577|Deep Brain Stimulation for Depression|Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression||The Cleveland Clinic|Yes|Completed|January 2004|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|No|||September 2015|September 11, 2015|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555698||165209|
NCT00555919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91484|ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer|Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer||Bayer|No|Completed|March 2008|March 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Female|18 Years|N/A|No|||October 2014|October 9, 2014|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00555919||165192|
NCT00555932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010745|Modern Ultrasound Techniques in the Evaluation of Cerebral Venous Sinuses in Neonates|Utility of Modern Ultrasound Techniques in the Evaluation of Cerebral Venous Sinuses in Neonates||The Hospital for Sick Children|No|Completed|May 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|58|||Both|N/A|28 Days|No|||May 2008|May 19, 2015|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00555932||165191|
NCT00556855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDO-CHD001|Comparison Study With E-DO in Chronic Hand Dermatitis|A 4-Week Randomized, Double-Blind, Placebo-Controlled, Right-Left Comparison Study With E-DO in Chronic Hand Dermatitis||HenKan Pharmaceutical Co., Ltd.|No|Completed|December 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|20 Years|N/A|No|||January 2009|January 9, 2009|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00556855||165124|
NCT00556868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241/2004|The Influence of Having Breakfast on Cognitive Performance and Mood|The Influence of Having Breakfast on Cognitive Performance and Mood in High School Students||University of Ulm|No|Completed|October 2005|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|104|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||November 2007|November 9, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00556868||165123|
NCT00556504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM-700-01-04|The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection|TCM-700C Phase II Trial The Effects of Adding a Chinese Formulation (TCM-700C) on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection|TCM-700C|TCM Biotech International Corp.|No|Completed|July 2007|May 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|20 Years|65 Years|No|||July 2014|August 4, 2014|November 8, 2007|No|Yes||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00556504||165147|
NCT00557492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-035|Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer|Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma||University of Pittsburgh|Yes|Active, not recruiting|December 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00557492||165081|
NCT00557778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CBR-CRE-2007/1|Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia|Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia|PRECAVER|AstraZeneca|No|Completed|November 2007|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|600|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|April 2011|April 27, 2011|November 13, 2007||||No||https://clinicaltrials.gov/show/NCT00557778||165060|
NCT00567190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC4129g|A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPATRA)|A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer|CLEOPATRA|Genentech, Inc.||Active, not recruiting|February 2008|July 2017|Anticipated|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|808|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|December 3, 2007|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00567190||164353|The survival data at the time of the data cut-off were not mature.
NCT00567203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9131004|A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia|A Phase 1B Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-3463275 In Adjunctive Treatment Of Cognitive Deficits In Schizophrenia||Pfizer|No|Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|No|||October 2008|October 1, 2008|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00567203||164352|
NCT00567801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S 991228|CRAIL - Controlled Reperfusion of the Acutely Ischemic Limb|Prospektive, Randomisierte Multicenter-Studie Zur Optimierung Der Therapie Der Akuten Ischämie Der Unteren Extremitäten Durch Die Kontrollierte Extremitätenreperfusion (Prospective, Randomized Multicenter - Study for Optimization of Therapy of the Acute Ischemic Limb by Controlled Reperfusion)|CRAIL|University Hospital Freiburg|Yes|Terminated|September 2002|September 2010|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||July 2008|July 25, 2008|December 4, 2007||||No||https://clinicaltrials.gov/show/NCT00567801||164306|
NCT00568074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1555|Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes|Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|December 2003|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|131|||Both|30 Years|N/A|No|||September 2009|September 23, 2009|December 4, 2007||||No||https://clinicaltrials.gov/show/NCT00568074||164285|
NCT00567788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R353/11/2004|Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study|Comparison of Bimatoprost and Lataprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study||Singapore National Eye Centre|Yes|Active, not recruiting|July 2006|July 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|N/A|No|||November 2007|December 4, 2007|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00567788||164307|
NCT00567775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1274|Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes|Comparison of Pharmacokinetic Profiles of Human Soluble Insulin With Insulin Inhalation Solution in Paediatric Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|October 2002|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27|||Both|6 Years|17 Years|No|||July 2012|July 9, 2012|November 30, 2007||||No||https://clinicaltrials.gov/show/NCT00567775||164308|
NCT00568035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QR-333-002|Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy|Phase II Study of QR-333 for the Treatment of Symptomatic Diabetic Peripheral Neuropathy||Quigley Pharma, Inc.|No|Completed|December 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||January 2009|January 7, 2009|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568035||164288|
NCT00568724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGM-01|Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis|Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis||University of Aarhus|No|Completed|November 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|45|Samples With DNA|Urine and frozen pelvic tissue|Both|3 Months|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children referred to surgical treatment of congenital hydronephrosis caused by ureteral        obstruction.|September 2012|September 13, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568724||164236|
NCT00568737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6669|The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death|Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Early Stage Severe Sepsis||Eli Lilly and Company|Yes|Completed|November 2002|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2640|||Both|18 Years|N/A|No|||December 2007|December 5, 2007|December 5, 2007||||No||https://clinicaltrials.gov/show/NCT00568737||164235|
NCT00564239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVV-001-2007|Psychological Prevention of Internalizing Disorders|Efficacy of Child-centered Cognitive-Behavioral Prevention of Internalizing Disorders and the Impact of Simultaneous Parent Training||Philipps University Marburg Medical Center|No|Recruiting|November 2007|May 2012|Anticipated|May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|8 Years|12 Years|No|||August 2010|August 27, 2010|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564239||164574|
NCT00564252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84-5-6886|Topical Finasteride in the Treatment of Idiopathic Hirsutism|The Efficacy of Topical Finasteride in the Treatment of Idiopathic Hirsutism||Iran University of Medical Sciences|Yes|Completed|February 2006|October 2006|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|56|||Female|N/A|N/A|No|||November 2007|November 26, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564252||164573|
NCT00564265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-0047-11-07|Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo|Outcomes of Surgical Treatment of Gastrointestinal Stromal Tumors in the IV Region of Chile||Cirujanos la Serena|No|Completed|January 2008|August 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|24|||Both|15 Years|N/A|No|Non-Probability Sample|All patients operated on for GIST|September 2010|August 9, 2011|November 26, 2007||No||No|November 3, 2008|https://clinicaltrials.gov/show/NCT00564265||164572|
NCT00564213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BQ -1-07-ARVO|Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds|Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds|BQ-01-07-ARVO|Instituto de Olhos de Goiania|Yes|Completed|March 2005|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|36|||Both|21 Years|N/A|No|||November 2007|November 25, 2008|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564213||164576|
NCT00564226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6271|SSR240600C Treatment in Women With Overactive Bladder|A Placebo Controlled Randomized, 12-week, Dose-ranging, Double-blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C in Women With Overactive Bladder Including Urge Urinary Incontinence|BILADY|Sanofi|Yes|Completed|November 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|345|||Female|18 Years|70 Years|No|||September 2009|September 22, 2009|November 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00564226||164575|
NCT00555659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1094241|Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody Fusions|Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody|Aegis|Columbia Orthopaedic Group, LLP|Yes|Completed|September 2007|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Any person who comes into the clinic and gives consent to participate in this prospective        study.|August 2013|August 8, 2013|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555659||165212|
NCT00555672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181128|Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer|A Phase I Study Of Sunitinib Malate In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer||Pfizer|No|Completed|August 2008|August 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2011|December 12, 2011|November 8, 2007|No|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00555672||165211|
NCT00555958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBLOC|Vagal Blocking for Obesity Control|VBLOC™ Clinical Trial: Vagal Block for Obesity Control||EnteroMedics|Yes|Active, not recruiting|November 2005|September 2014|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|25 Years|60 Years|No|||February 2012|February 1, 2012|November 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555958||165189|
NCT00556244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704053M|Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling|Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling||National Taiwan University Hospital|No|Recruiting|April 2007|November 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Years|80 Years|No|||April 2007|November 8, 2007|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00556244||165167|
NCT00556517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2007-0063|Acute Hamstring Strains in Danish Elite Soccer - Diagnosis and Biomechanical Tests|Acute Hamstring Strains in Danish Elite Soccer - Diagnosis and Biomechanical Tests||Amager Hospital|No|Enrolling by invitation|January 2008|March 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male soccer players playing in one of the top 4 divisions in Denmark in the 2007/08        season.|September 2007|November 9, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00556517||165146|
NCT00556894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-203RA|Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis||Can-Fite BioPharma|No|Completed|February 2008|April 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|230|||Both|18 Years|75 Years|No|||August 2011|February 24, 2015|November 8, 2007|Yes|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT00556894||165122|
NCT00556907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-06-9|Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast|Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT.||University of Southern California|No|Terminated|October 2007|November 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|40 Years|N/A|No|||March 2015|March 25, 2015|November 8, 2007|Yes|Yes|Lack of Funding|No||https://clinicaltrials.gov/show/NCT00556907||165121|
NCT00557193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL0631|Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)||Children's Oncology Group|Yes|Active, not recruiting|January 2008|||September 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|242|||Both|N/A|1 Year|No|||September 2015|September 11, 2015|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00557193||165102|
NCT00558116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101010|Treatment of Carpal Tunnel Syndrome With Dynamic Splinting|Treating Carpal Tunnel Syndrome With Dynamic Splinting: A Randomized, Controlled, Trial||Advanced Centers for Orthopaedic Surgery and Sports Medicine|No|Recruiting|May 2007|December 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 10, 2008|November 12, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00558116||165034|
NCT00558402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002226|Meditation or Education for Alzheimer Caregivers|Meditation for Alzheimer Caregivers: Stress & Physiology||Oregon Health and Science University|Yes|Completed|November 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|50 Years|85 Years|No|||October 2014|October 27, 2014|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558402||165013|
NCT00567814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECA-001|A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction|A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Metyrapone and Oxazepam in the Treatment of Cocaine Addiction||Embera NeuroTherapeutics, Inc.|No|Completed|December 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|50 Years|No|||December 2008|December 30, 2008|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567814||164305|
NCT00568087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #3852-B|N-acetylcysteine in Alcohol Dependence|N-acetylcysteine in Alcohol Dependence||Minneapolis Veterans Affairs Medical Center|Yes|Completed|December 2007|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||August 2013|August 28, 2013|December 4, 2007||No||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00568087||164284|
NCT00568061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT 44|Nitric Oxide in Myocardial Infarction Size|The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size|NOMI|INO Therapeutics|Yes|Terminated|June 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|December 3, 2007|Yes|Yes|Slow Enrollment|No|August 3, 2010|https://clinicaltrials.gov/show/NCT00568061||164286|
NCT00568048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 50/07|Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|Temozolomide Combined With Bevacizumab in Metastatic Melanoma. A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Completed|December 2007|October 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568048||164287|
NCT00564304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|will004-HMO-CTIL|NPD Measurement in Infants|Nasal Potential Difference Measurement in Infants||Hadassah Medical Organization||Not yet recruiting|March 2008|March 2010|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|6 Years|No|Probability Sample|children below age of 6 years who suspected for Cystic Fibrosis|November 2007|November 26, 2007|November 25, 2007||||No||https://clinicaltrials.gov/show/NCT00564304||164569|
NCT00564317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mb/19.10.05|KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Trial for the Treatment of Traumatized Children After War in Sri Lanka|KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Trial for the Treatment of Traumatized Children After War in Sri Lanka||University of Konstanz|No|Completed|September 2004|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|48|||Both|11 Years|15 Years|No|||November 2007|November 26, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564317||164568|
NCT00564616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200708079R|Simulation-Based Study of Adding Video Communication to Dispatch Instruction|A Randomized Controlled Study Focused on Impact of Adding Video Communication to Dispatch Instruction on the Quality of CPR, Including Chest Compressions and Rescue Breaths, in Simulated Cardiac Arrests||National Taiwan University Hospital|Yes|Completed|April 2007|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|16 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 26, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564616||164545|
NCT00564629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APF-303|Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males|A Phase III, Randomized, Double-Blind, Double-Dummy, Single-Dose Study of the Efficacy and Safety of Intravenous Acetaminophen Versus Oral Acetaminophen for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males||Mallinckrodt|No|Completed|August 2007|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|105|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|November 26, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00564629||164544|Protocol and statistical analysis plan were amended to clarify endpoints prior to database lock and analysis.
NCT00564876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001278|Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer|Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC).|TOP0706|Duke University|Yes|Terminated|November 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|November 26, 2007|Yes|Yes|Lack of accrual, study closed.|No|February 16, 2011|https://clinicaltrials.gov/show/NCT00564876||164525|Limitations for this trial were the trial was stopped due to poor enrollment.
NCT00564603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2579-5FW|Continuous Infusion of Dexamethasone Plus Tramadol Adjunct to Morphine PCA After Abdominal Hysterectomy|Intravenous Continuous Infusion of Dexamethasone Plus Tramadol Combined With Standard Morphine Patient-Controlled Analgesia After Total Abdominal Hysterectomy|DTMPCA|Nanjing Medical University|Yes|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Female|19 Years|64 Years|No|||April 2008|April 17, 2008|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564603||164546|
NCT00564863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 240|Dose-Finding Study of CS19 Expressing ETEC Challenge Strains|Strain and Dose-Finding Study of DS26-1 and WS0115A Enterotoxigenic E. Coli (ETEC) Challenge Strains That Express CS19 Fimbriae||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|September 2007|May 2008|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2007|November 27, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564863||164526|
NCT00555087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/1084|Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate|Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV.|Nebidolocal|Hospital Santa Fe|Yes|Recruiting|May 2007|January 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|70 Years|No|||November 2007|November 5, 2007|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00555087||165256|
NCT00555100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-017|Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma|A Multicenter, Phase I Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma||Celgene|Yes|Completed|July 2007|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||January 2011|January 26, 2011|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00555100||165255|
NCT00555113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Evolution of Visual Impairment During Pseudoxanthoma Elasticum|Evolution of Visual Impairment During Pseudoxanthoma Elasticum||European Georges Pompidou Hospital|No|Completed|January 2000|September 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|38|||Both|N/A|N/A|No|Non-Probability Sample|patients with pseudoxanthoma elasticum confirmed by the Department of Genetics according        to the usual clinical, histological or genetic criterion.|November 2007|November 6, 2007|November 6, 2007||||No||https://clinicaltrials.gov/show/NCT00555113||165254|
NCT00556296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRP104.301|Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD|A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder||New River Pharmaceuticals||Completed|October 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|297|||Both|6 Years|12 Years|No|||June 2011|June 20, 2011|November 7, 2007||||No||https://clinicaltrials.gov/show/NCT00556296||165163|
NCT00555386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14697|Soy, Selenium and Breast Cancer Risk|A Pilot Study to Determine the Effect of Dietary Intervention on Novel Biomarkers of Breast Cancer Risk.||University of East Anglia||Completed|April 2007|August 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|27|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 24, 2008|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555386||165233|
NCT00555399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0709|Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)|Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2007|||November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|135|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555399||165232|
NCT00556543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 579|Clinical Study of the U-Plate Fracture Repair System to Treat Rib Fractures|Clinical Evaluation of the U-plate Fracture Repair System for the Fixation of Rib Fractures||Oregon Health and Science University|Yes|Completed|November 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|November 9, 2007|No|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00556543||165144|
NCT00556569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08-253|Evaluation of CHAM JAM (Previously Known as the Moving Smart) Intervention in Increasing Physical Activity in Bronx Elementary School Students|Evaluation of CHAM JAM (Previously Known as the Moving Smart) Intervention in Increasing Physical Activity in Bronx Elementary School Students||Montefiore Medical Center|Yes|Completed|December 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10098|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556569||165143|
NCT00556595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPVA-PAF|Primary Anatomical Versus Primary Electrophysiological Approach in Circumferential Pulmonary Vein Ablation|Circumferential Pulmonary Vein Ablation in Paroxysmal Atrial Fibrillation: Randomized Comparison Between a Primary Anatomical Versus a Primary Electrophysiological Approach|CPVA-PAF|University Hospital, Bonn|No|Not yet recruiting|November 2007|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2007|November 9, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00556595||165142|
NCT00556608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06CZIFCH/Hai06|Efficacy Study of Intra-articular Hyaluronic Acid in the Knee Osteoarthritis|Efficacy Evaluation of Intra-articular Hyaluronic Acid (Sinovial®) vs Synvisc® in the Treatment of Symptomatic Knee Osteoarthritis. A Double-blind, Controlled, Randomised, Parallel-group Non-inferiority Study||IBSA Institut Biochimique SA|No|Completed|November 2007|May 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|381|||Both|40 Years|80 Years|No|||November 2012|December 3, 2012|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556608||165141|
NCT00556530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1390|Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome|Genetic Modifiers of 22q11.2 Deletion Syndrome||National Heart, Lung, and Blood Institute (NHLBI)|No|Recruiting|August 2000|January 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood and saliva samples|Both|N/A|N/A|No|Non-Probability Sample|People with 22q11.2 deletion syndrome|August 2009|August 7, 2009|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00556530||165145|
NCT00557232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-01-2007-ARVO|Intraocular Bevacizumab (Avastin) for Rubeosis Iridis|The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion||Instituto de Olhos de Goiania|Yes|Completed|November 2006|November 2011|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 25, 2011|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00557232||165099|
NCT00557505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9301001|A Study Of PF-03732010 In Patients With Advanced Solid Tumors|A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of PF-03732010 In Patients With Advanced Solid Tumors||Pfizer|No|Completed|December 2007|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|November 12, 2007|No|Yes||No|January 10, 2012|https://clinicaltrials.gov/show/NCT00557505||165080|Results are not provided because development of the study drug was terminated, as neither anti-tumor activity nor pharmacodynamic modulation was observed.
NCT00557206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-04-033|Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer|Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck||Minneapolis Veterans Affairs Medical Center|No|Terminated|April 2005|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|November 9, 2007||No|Funding was terminated|No||https://clinicaltrials.gov/show/NCT00557206||165101|
NCT00557219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG-NKEBN/225/2007|Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery|Influence of Fenoldopam and Ketanserin on Function and Kidney Injury Parameters in Patients With Increased Risk of Acute Kidney Failure After Cardiac Surgery||Medical University of Gdansk|No|Suspended|April 2008|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|November 9, 2007|Yes|Yes|Main cooperator finished cooperation|No||https://clinicaltrials.gov/show/NCT00557219||165100|
NCT00558441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL-1.2-002|Prospective Data Collection of IVMRI Cases|Prospective Data Collection in Clinical Cases Where Coronary Plaque Lipid Characterization by IVMRI Was Performed During Diagnostic or Interventional Catheterization Procedures|MIRACLE|TopSpin Medical|No|Not yet recruiting|November 2007|November 2013|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|N/A|No|||November 2007|November 14, 2007|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00558441||165011|
NCT00558142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC0606|Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material|Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material||University of Edinburgh|No|Completed|February 2008|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|90|||Male|45 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00558142||165032|
NCT00568100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2222|Effect of Pressure Support Ventilation and Neurally Adjusted Ventilatory Assist (NAVA) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effect of Pressure Support Ventilation and Neurally Adjusted Ventilatory Assist (NAVA) in COPD Patients||Policlinico Hospital|No|Completed|April 2010|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568100||164283|
NCT00568113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Shahin|N-Acetyl Cysteine for Prevention of Preterm Birth|Oral N-Acetyl Cysteine Can Prevent Preterm Labour in Multiparae With Previous Preterm Labour|NAC|Assiut University|No|Completed|July 2007|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2007|December 4, 2007|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568113||164282|
NCT00568464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCD/IE-ESFT|Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)|Phase II Study of VCD/IE in the Treatment of the Patients With Ewing's Sarcoma Family of Tumors||Fudan University|No|Terminated|March 2007|September 2009|Anticipated|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|10 Years|65 Years|No|||July 2009|July 6, 2009|December 5, 2007||No|The enrollment is slower than expected|No||https://clinicaltrials.gov/show/NCT00568464||164255|
NCT00564343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor425606ctil|a Water Training Program to Improve Balance in Chronic Stroke Patients|a Water Training Program to Improve Balance in Chronic Stroke Patients: Cross- Sectional Pre-Post Study Design||Soroka University Medical Center|Yes|Completed|November 2007|June 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|65 Years|80 Years|No|Non-Probability Sample|The subjects of the exercise group will be recruited from Sha'ar Ha'negev Swimming pool        and from patients that get a Physical Therapy treatment Kupat Holim Clalit.|November 2007|December 15, 2008|November 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00564343||164566|
NCT00568438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0011|Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample|Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples||Stanford University|Yes|Recruiting|October 2000|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|Samples Without DNA|Cases will be identified from clinic patient medical records and linked to pathology      reports. The surgical pathology record number will thus be obtained and used to retrieve the      archival blocks and slides. Approximately three representative blocks will be selected and      4-6 four micron thick sections will be cut on a microtome. Cases with limited archived      diagnostic material will not be selected nor blocks where there is little materials.|Female|18 Years|N/A|No|Non-Probability Sample|Cases will be identified from clinic patient medical records and linked to pathology        reports. The surgical pathology record number will thus be obtained and used to retrieve        the archival blocks and slides. In addition, all these participants will be clinical        patients of the Protocol Director, thus the Physician will always be familiar with the        participants.|February 2014|February 14, 2014|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568438||164257|
NCT00568451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC057F|Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma|Releasing the Cancer Patient's Immune System From Down-regulation With Timed Delivery of Standard Chemotherapy||Mayo Clinic|Yes|Terminated|June 2006|April 2012|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|120 Years|No|||March 2014|November 25, 2015|December 5, 2007|Yes|Yes|Slow accrual.|No|November 1, 2011|https://clinicaltrials.gov/show/NCT00568451||164256|This trial was stopped prior to achieving its accrual goals due to slow enrollment rate. Early termination leading to small numbers of subjects analyzed.
NCT00568412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1401920|A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis|A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents||Bayer|No|Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|2 Years|17 Years|No|||February 2015|February 15, 2015|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00568412||164259|
NCT00568425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAL0002-|QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT|Quality of Life and Functional Outcomes After Combined Modality Therapy for Anal Cancer: A Comparison of Conventional Versus Intensity-Modulated Radiation Therapy (ANAL0002)||Stanford University|Yes|Terminated|September 2005|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|30 Years|70 Years|No|Non-Probability Sample|Histologically confirmed diagnosis of squamous cell carcinoma of the anus|November 2012|November 29, 2012|December 4, 2007||No|Inadequate response to SRC letter|No||https://clinicaltrials.gov/show/NCT00568425||164258|
NCT00564642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5344-21-07-86|Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity|Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity||National Research Institute of Tuberculosis and Lung Disease, Iran|Yes|Completed|November 2007|April 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|60 Years|90 Years|No|||April 2009|April 21, 2009|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00564642||164543|
NCT00564655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011192|Regional Anesthesia Block of the Transversus Abdominis Plane in Children Undergoing Gastric Tube Insertion|Regional Anesthesia Block of the Transversus Abdominis Plane in Children Undergoing Gastric Tube Insertion||The Hospital for Sick Children|No|Terminated|October 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|1 Year|10 Years|No|||July 2013|July 23, 2013|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00564655||164542|
NCT00564889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0685|Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis|A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis||Mayo Clinic||Completed|December 2007|June 2012|Actual|February 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|November 28, 2007|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00564889||164524|
NCT00565162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4041|Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus|A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating Lantus(Insulin Glargine) Therapy to Determine Metabolic and Economic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus||Sanofi|No|Completed|November 2003|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|124|||Both|18 Years|N/A|No|||August 2008|August 22, 2008|November 28, 2007||||No||https://clinicaltrials.gov/show/NCT00565162||164503|
NCT00556309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2006-5031|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.|OCT|University of California, Irvine|No|Completed|January 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic|August 2015|August 5, 2015|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00556309||165162|
NCT00556322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO18602|A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer Who Have Experienced Disease Progression During Platinum-based Chemotherapy||Hoffmann-La Roche||Completed|March 2006|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|424|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|November 9, 2007||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00556322||165161|
NCT00556387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 86674|Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection|Possible Neuroprotective Effects of Ketamine in Children With Severe Traumatic Brain Injury||University of Arkansas|No|Withdrawn|December 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|1 Month|16 Years|No|||October 2013|October 31, 2013|November 9, 2007|Yes|Yes|This study has been withdraw from the IRB. The PI has transferred to another university. The    IND was transferred.|No||https://clinicaltrials.gov/show/NCT00556387||165156|
NCT00556283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODS-HJH-4|RCT: STARR vs Biofeedback|Outcomes of Stapled Trans-Anal Rectal Resection (STARR) vs. Biofeedback in the Treatment of Outlet Obstruction Associated With Rectal Intussusception and Rectocele: A Multi-center Randomized Controlled Trial|ODS II|Ethicon Endo-Surgery (Europe) GmbH|Yes|Completed|February 2004|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Female|18 Years|N/A|No|||December 2013|December 17, 2013|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00556283||165164|
NCT00556920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD106094|Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components|A Randomized, Open-label, Single-dose, Three-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of COREG CR™ and Lisinopril to COREG CR and ZESTRIL||GlaxoSmithKline||Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|November 9, 2007||||||https://clinicaltrials.gov/show/NCT00556920||165120|
NCT00557817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJE0301|Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)|Darbepoetin-alpha and i.v. Iron Administration After Autologous Hematopoietic Stem Cell Transplantation : a Prospective Randomized Trial||University Hospital of Liege|No|Completed|March 2004|August 2008|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|125|||Both|16 Years|69 Years|No|||August 2008|January 8, 2010|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557817||165057|
NCT00557830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVJARCC0702|Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma|Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)||Accelerated Community Oncology Research Network|No|Terminated|January 2008|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|November 9, 2007|Yes|Yes|The study was closed to enrollment when it became clear that enrollment was too slow to    complete the full enrollment target within the time frame allowed.|No|December 3, 2012|https://clinicaltrials.gov/show/NCT00557830||165056|The decision to close the study was made by the funder , Bayer HealthCare Pharmaceuticals, in collaboration with ACORN due to the low rate of accrual in light of study timelines and the lack of funds beyond the current level of support from Bayer.
NCT00557791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU302|Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)|A Phase 3, Randomized, Double-masked, Parallel-assignment and Dose-finding Study of Intravitreal Bevasiranib Sodium, Administered Every 8 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).|CARBON|OPKO Health, Inc.|Yes|Withdrawn|November 2009|July 2012|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|50 Years|N/A|No|||February 2011|March 5, 2015|November 13, 2007|Yes|Yes|Study never initiated|No||https://clinicaltrials.gov/show/NCT00557791||165059|
NCT00557804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2007-001|Monitoring in Congestive Heart Failure Study|Multi-Sensor Monitoring in Congestive Heart Failure Study|MUSIC|Corventis, Inc.|No|Completed|December 2007|||December 2009|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|362|||Both|18 Years|N/A|No|Non-Probability Sample|primary care and heart failure clinics|February 2010|February 2, 2010|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00557804||165058|
NCT00557843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-758|Continuous Bupivacaine Infusion Following Colonic Surgery|Influence of Continuous Bupivacaine Infusion on Tissue Oxygenation Following Colonic Surgery||Outcomes Research Consortium|No|Completed|November 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|80 Years|No|||January 2011|February 28, 2011|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557843||165055|
NCT00558155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1st Dept Surg|The Impact of Immunostimulating Nutrition on the Outcome of Surgery|Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.||Jagiellonian University|No|Completed|June 2001|December 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|214|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2007|November 13, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00558155||165031|
NCT00568776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND005-AD201|ELND005 in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease||Transition Therapeutics Ireland Limited|Yes|Completed|December 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|353|||Both|50 Years|85 Years|No|||December 2014|December 1, 2014|December 4, 2007|Yes|Yes||No|September 27, 2011|https://clinicaltrials.gov/show/NCT00568776||164232|The two high dose groups of ELND005 were discontinued before study end, so the efficacy analysis was based only on placebo and ELND005 250 mg bid groups.
NCT00568789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-375-060|Safety of Ramelteon in Elderly Subjects|A Study of the Safety of Ramelteon in Elderly Subjects||Takeda|No|Completed|June 2006|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Both|65 Years|N/A|No|||February 2012|February 27, 2012|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00568789||164231|
NCT00564356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-3017-OS-CTIL|The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment|The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment||Sheba Medical Center|No|Recruiting|July 2007|December 2010|Anticipated|August 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|N/A|N/A|No|||July 2009|July 19, 2009|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564356||164565|
NCT00568763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579004|Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma|Endogenous Heat-shock Vaccines for Melanoma A Feasibility Study||Mayo Clinic|Yes|Active, not recruiting|November 2005|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|23|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|December 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00568763||164233|
NCT00568750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 56/07|Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors|Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. A Multi Center Phase II Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|December 2007|December 2016|Anticipated|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00568750||164234|
NCT00564278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5516/#6609R|Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression|Motivational Antidepressant Therapy for Hispanics||New York State Psychiatric Institute|No|Completed|February 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|217|||Both|18 Years|79 Years|No|||August 2014|February 11, 2016|November 26, 2007||No||No|August 6, 2015|https://clinicaltrials.gov/show/NCT00564278||164571|Focused only on Hispanics, so applicability to other populations unknown.
NCT00564291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 044/07|Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT)|Evaluation of Retinal Structure With High Resolution OCT||University Hospital Inselspital, Berne|No|Recruiting|January 2007|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||7|Anticipated|700|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|healthy subjects and patients with macular diseases|January 2016|January 6, 2016|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564291||164570|
NCT00565188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 01-092.3|Application of ATP Infusions in Palliative Home Care|Application of Adenosine 5'-Triphosphate (ATP) Infusions in Palliative Home Care||Maastricht University Medical Center|Yes|Completed|March 2002|October 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||November 2007|November 28, 2007|November 28, 2007||||No||https://clinicaltrials.gov/show/NCT00565188||164501|
NCT00565422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD-09|Efficacy of Escitalopram in the Treatment of Internet Addiction|Efficacy of Escitalopram in the Treatment of Internet Addiction||Icahn School of Medicine at Mount Sinai|No|Completed|December 2002|October 2004|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||May 2008|May 23, 2008|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565422||164483|
NCT00565175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006636-22|Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia|Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia||Helsinki University|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||March 2012|March 19, 2012|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565175||164502|
NCT00555971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 05-066|Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization|A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization||The Cleveland Clinic|No|Completed|May 2006|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555971||165188|
NCT00556335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL13097.075.06|Pneumothorax Therapy: Manual Aspiration Versus Conventional Chest Tube Drainage|A Prospective, Randomised Trial in Pneumothorax Therapy: Manual Aspiration Versus Conventional Chest Tube Drainage|pneumothorax|Isala|Yes|Completed|April 2007|April 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|85 Years|No|||April 2013|April 5, 2013|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556335||165160|
NCT00556400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080022|Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones|Treatment of Menorrhagia in Women With Thrombocytopenia: Comparison of Platelet Transfusion Alone to Platelet Transfusion With Continuous Oral Contraceptive Pills||National Institutes of Health Clinical Center (CC)|No|Terminated|November 2007|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Female|12 Years|55 Years|No|||July 2013|July 11, 2013|November 9, 2007||No|Early termination because of insufficient accrual.|No|May 21, 2013|https://clinicaltrials.gov/show/NCT00556400||165155|Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.
NCT00556933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286-03|Improved Induction and Maintenance Immunosuppression in Kidney Transplantation|Prospective, Randomized 2 x 2 Factorial Trial of Rabbit Anti-thymocyte Globulin Induction (Single vs. Alternate Day Administration) at Renal Transplantation, With Delayed Calcineurin-inhibitor Withdrawal vs. Minimization||University of Nebraska|No|Completed|April 2004|June 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|180|||Both|18 Years|65 Years|No|||February 2015|February 16, 2015|November 9, 2007|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT00556933||165119|The trial is designed for analysis as 1st, rATG dosing, and 2nd, CNI withdrawal status. Results published as analysis of 2 induction protocols followed by analysis of 2 CNI maintenance regimens. Potential limitations = single-center & non-blinded.
NCT00556946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2003-3286|Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains|Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains|PDT/PDL|University of California, Irvine|Yes|Completed|August 2005|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556946||165118|
NCT00557518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0424|Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria|A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria||Synvista Therapeutics, Inc|No|Terminated|November 2007|November 2009|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||January 2009|January 29, 2009|November 12, 2007||No|Study has been terminated early due to financial constraints.|No||https://clinicaltrials.gov/show/NCT00557518||165079|
NCT00558129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSS0702|Effects of X-STOP® Versus Laminectomy Study|Prospective Randomized Trial Comparing X-STOP® Interspinous Process Decompression® System Versus Laminectomy for Treatment of Neurogenic Intermittent Claudication|EXELS|Medtronic Spine LLC|No|Withdrawn|November 2007|November 2011|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||January 2012|January 20, 2012|November 12, 2007||||No||https://clinicaltrials.gov/show/NCT00558129||165033|
NCT00558428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.5|Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension|An Eight-week Randomized, 4-arm, Double-blind Study to Compare the Efficacy and Safety of Combinations of Telmisartan 40mg + Amlodipine 5mg Versus Telmisartan 80mg + Amlodipine 5mg Versus Amlodipine 5mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy||Boehringer Ingelheim||Completed|October 2007|||September 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|1098|||Both|18 Years|N/A|No|||May 2014|June 17, 2014|October 29, 2007||||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00558428||165012|
NCT00557856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8471001|A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors|A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of Pf-03446962 In Patients With Advanced Solid Tumors||Pfizer|No|Completed|November 2007|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||September 2015|September 27, 2015|November 12, 2007|No|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT00557856||165054|Results for tumor vascular function adopting dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) was not reported as per change in planned analysis.
NCT00557869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMR-02-TECH-01|Optimization of Cardiac-MR Protocols|Optimization of Native Cardiac-MR Protocols||Medical University of Graz|Yes|Completed|October 2002|September 2011|Actual|September 2011|Actual|N/A|Observational|N/A||1|Actual|122|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|December 2011|December 18, 2011|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557869||165053|
NCT00558506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABATACEPT-AS-01|Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis|Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis|Aba-AS-01|Charite University, Berlin, Germany|No|Recruiting|January 2008|December 2009|Anticipated|October 2009||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||September 2007|February 25, 2008|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00558506||165006|
NCT00568516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3550-CL-0003|Phase II Study of ASP3550 in Patients With Prostate Cancer|Phase II Study of ASP3550 - A Maintenance-dose Finding Study in Patients With Prostate Cancer||Astellas Pharma Inc|No|Completed|October 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Male|20 Years|N/A|No|||October 2014|October 28, 2014|December 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00568516||164251|
NCT00564395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16541|Detemir: Role in Type 1 Diabetes|Detemir: Role in Type 1 Diabetes||Baylor College of Medicine|Yes|Completed|August 2007|May 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|10 Years|25 Years|No|||September 2015|September 10, 2015|November 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00564395||164562|
NCT00564668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2000-1611|Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes|A 24-week, Randomised, Multi-centre, Double-blind, Parallel-group Trial to Investigate the Safety and the Efficacy of NN2000-Mix30 Compared to NN-X14Mix30 NovoRapid®30Mix) in Subjects With Type 2 Diabetes Mellitus on a Twice Daily Regimen||Novo Nordisk A/S|No|Completed|June 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|126|||Both|20 Years|N/A|No|||November 2013|November 21, 2013|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00564668||164541|
NCT00564681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-090|Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia|||Allergan|No|Completed|December 2007|December 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|242|||Both|18 Years|75 Years|No|||December 2015|December 4, 2015|November 26, 2007|Yes|Yes||No|November 14, 2012|https://clinicaltrials.gov/show/NCT00564681||164540|
NCT00564330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00118|In Vivo Quantification of Dental Demineralisation Using OCT With and Without Esomeprazole|In Vivo Quantification of Dental Demineralisation Using Optical Coherence Tomography Before and After Double-blind, Randomised Treatment With Esomeprazole or Placebo of Patients With Dental Erosions||Brain-Gut Research Group|No|Completed|November 2007|May 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564330||164567|
NCT00564694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574769|Studying a Quality of Life Questionnaire in Patients With Colorectal Cancer|Validation of an EORTC Quality of Life Questionnaire Module for Patients With Colorectal Cancer||National Cancer Institute (NCI)||Completed|May 2007|||June 2009|Actual|N/A|Observational|N/A|||Anticipated|350|||Both|18 Years|N/A|No|||August 2009|October 28, 2013|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00564694||164539|
NCT00564928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-04|A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer|A Phase 2 Open-Label Study to Investigate the Pharmacodynamics and Clinical Activity of IPI-504 in Patients With Castration-Resistant Prostate Cancer Stratified by Prior Chemotherapy|IPI-504-04|Infinity Pharmaceuticals, Inc.|No|Completed|November 2007|July 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Male|18 Years|N/A|No|||December 2012|December 7, 2012|November 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00564928||164521|
NCT00565721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-135-003|A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis|A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging||GE Healthcare|No|Completed|November 2007|September 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|November 28, 2007|Yes|Yes||No|June 3, 2014|https://clinicaltrials.gov/show/NCT00565721||164461|
NCT00555984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Case 4306|Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors|Effect of Total Intravenous Anesthesia Versus Anesthesia With Volatile Agents on Inflammatory Markers Following Elective Craniotomy for Primary Brain Tumor|TIVA|The Cleveland Clinic|Yes|Completed|September 2007|March 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|80 Years|No|||August 2012|August 1, 2012|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555984||165187|
NCT00556348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-02-2007-ARVO|Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration|Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration||Instituto de Olhos de Goiania|Yes|Completed|November 2005|November 2008|Actual|October 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2011|November 19, 2011|November 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00556348||165159|
NCT00556361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28781 Bhutta|Use of Ketamine Prior to Cardiopulmonary Bypass in Children|Use of Ketamine Prior to Cardiopulmonary Bypass in Children||Arkansas Children's Hospital Research Institute||Completed|July 2004|November 2007|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|N/A|1 Year|No|||November 2007|November 9, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00556361||165158|
NCT00556413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574149|Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Study Evaluating the Efficacy and Safety of cétuximab Associated With the Protocol FOLFIRINOX (LV5FU Simplified Combined With Irinotecan and Oxaliplatin) in the First Line Treatment in Patients With Metastatic Colorectal Cancer Expressing EGFR or Not||National Cancer Institute (NCI)||Completed|September 2005|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|75 Years|No|||May 2011|May 13, 2011|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556413||165154|
NCT00556959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLON-301|Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)||Addrenex Pharmaceuticals, Inc.|No|Completed|October 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|236|||Both|6 Years|17 Years|No|||August 2008|March 23, 2010|November 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556959||165117|
NCT00556972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK172OS|A Feasibility Study of a Fecal Incontinence Management System for Medical Use|A Feasibility Study of a Fecal Incontinence Management System for Medical Use||Coloplast A/S|No|Terminated|January 2008|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|November 9, 2007|No|Yes|Due to numerous delays in study start-up process...|No|August 2, 2011|https://clinicaltrials.gov/show/NCT00556972||165116|No overall conclusions could be drawn, due to the limited amount of data (N=4 due to delays and low recruitment rate). A new study, with a higher sample size needs to be executed, if the objectives set in this study are to be investigated thoroughly.
NCT00557245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32528-A|Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples|Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples|Partners PrEP|University of Washington|Yes|Completed|May 2008|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|4758|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|November 8, 2007|Yes|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT00557245||165098|
NCT00557258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.652|Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs|Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs||Boehringer Ingelheim||Completed|November 2007|||November 2007|Actual|N/A|Observational|N/A|||Actual|14956|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|November 9, 2007||||||https://clinicaltrials.gov/show/NCT00557258||165097|
NCT00557531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040.01|Safety and Feasibility of the Injectable BL-1040 Implant|Safety and Feasibility of the Injectable BL-1040 Implant||BioLineRx, Ltd.|Yes|Active, not recruiting|March 2008|January 2014|Anticipated|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2012|February 2, 2012|November 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00557531||165078|
NCT00557544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rc 32/07|Trial on Metoclopramide and Ketoprofen in Acute Migraine of Childhood|Randomized Controlled Trial on the Effectiveness of Metoclopramide Alone or in Combination With Ketoprofen in Acute Migraine of Child||IRCCS Burlo Garofolo|Yes|Not yet recruiting|February 2009|June 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|6 Years|17 Years|No|||January 2009|January 28, 2009|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00557544||165077|
NCT00558168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-IPEP-0104|Electronic Study for Anastrozole Pharmacovigilance Evaluation|Electronic Study for Anastrozole Pharmacovigilance Evaluation|E-SAFE|AstraZeneca|No|Completed|January 2004|July 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|1850|||Female|N/A|N/A|No|||July 2008|July 25, 2008|November 13, 2007||||No||https://clinicaltrials.gov/show/NCT00558168||165030|
NCT00558493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB-406|Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients|Phase lV Study to Evaluate the Safety and Effectiveness of Switching Treatment From Lamivudine to Clevudine in the Chronic Hepatitis B Patients With Suboptimal Virologic Response During Lamivudine Treatment||Bukwang Pharmaceutical|No|Completed|November 2007|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|60 Years|No|||July 2012|July 24, 2012|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558493||165007|
NCT00558181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-CLL-001|High-dose Methylprednisolone and Rituximab in High Risk B-CLL|Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients With High Risk Chronic B Lymphocytic Leukemia|LT-CLL-001|Vilnius University|No|Completed|September 2007|December 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2010|February 22, 2010|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558181||165029|
NCT00564408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC20070049|Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine Patients|Experimental Study That Investigates the Effect of an Acetylcholine Analogue in Terms of Headache and Changes in Intra- and Extra-cerebral Vessels During and After Infusion of Carbachol||Danish Headache Center|No|Completed|August 2007|February 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|50 Years|No|||July 2009|July 31, 2009|November 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00564408||164561|
NCT00564421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08648|Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)|A Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Dose Safety and Efficacy Study of Epinastine Nasal Spray vs. Placebo in Subjects With Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|December 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|798|||Both|12 Years|N/A|No|||February 2016|February 24, 2016|November 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00564421||164560|
NCT00568477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-518-HEE-0200-S|Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation|Prospective, Randomized, Open, 2-arm National Multi-center Study to Evaluate the Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation.|Rituximab 2006|Technische Universität München|Yes|Terminated|December 2007|December 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2008|September 30, 2009|December 5, 2007||No|lacking recruitment|No||https://clinicaltrials.gov/show/NCT00568477||164254|
NCT00568490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0016|Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers|Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers||Stanford University||Recruiting|September 1998|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|blood, tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed patients with head and neck cancer|May 2015|May 20, 2015|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00568490||164253|
NCT00568802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11012007-781|A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients|A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients||Stanford University||Active, not recruiting|January 2004|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||24|||Both|1 Year|10 Years|No|||December 2008|December 2, 2008|December 4, 2007||||||https://clinicaltrials.gov/show/NCT00568802||164230|
NCT00564902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRY1|The Zeaxanthin and Visual Function Study|Randomized, Double Blind, Lutein Controlled Study of Zeaxanthin and Visual Function in Atrophic Age Related Macular Degeneration Patients|ZVF|Chrysantis, Inc.|Yes|Completed|November 2007|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|60|||Both|45 Years|90 Years|No|||March 2012|March 28, 2012|November 27, 2007|Yes|Yes||No|November 11, 2011|https://clinicaltrials.gov/show/NCT00564902||164523|
NCT00564915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98NR04|RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy|RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy||Institute of Child Health|No|Completed|December 2001|July 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|145|||Both|2 Years|16 Years|No|||November 2007|November 28, 2007|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00564915||164522|
NCT00564954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124EUS19|A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting||Novartis||Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|6 Years|12 Years|No|||April 2012|April 20, 2012|November 27, 2007|Yes|Yes||No|November 25, 2008|https://clinicaltrials.gov/show/NCT00564954||164519|
NCT00564967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS1|A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy|A Comparison Between Internet-based Self-help Therapy and Group Therapy for Social Phobia - A Clinical Equivalence Trial Using Cognitive Behavioural Therapy (CBT)|IS1|Karolinska Institutet|Yes|Completed|November 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|16 Years|N/A|No|||August 2009|October 25, 2010|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00564967||164518|
NCT00565448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10339|Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents|International Randomized Study to Evaluate the Addition of Docetaxel to the Combination of Cisplatin-5-fluorouracil (TCF) vs. Cisplatin-5-fluorouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma (NPC) in Children and Adolescents||Sanofi|Yes|Completed|November 2007|January 2012|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|1 Month|21 Years|No|||July 2015|July 2, 2015|November 29, 2007|Yes|Yes||No|March 5, 2010|https://clinicaltrials.gov/show/NCT00565448||164481|
NCT00565461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELT203|LT Vaccine Patch Self-Administration Study|A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician||Intercell USA, Inc.|No|Completed|November 2007|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|160|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|November 28, 2007|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00565461||164480|
NCT00565201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002727|Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients|Evaluation of BOTOX® (Botulinum Toxin Type A) in Combination With Rehabilitation Therapy for the Treatment of Wrist and Hand Muscle Overactivity in Post-Stroke Patients|Botox/Rehab|Emory University|No|Completed|October 2007|December 2011|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00565201||164500|
NCT00555997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000623|A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder|Geodon|Massachusetts General Hospital|No|Completed|March 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|65 Years|No|||June 2014|June 23, 2014|November 7, 2007||No||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00555997||165186|
NCT00555451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE3286-0102|Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects|A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days||Harbor Therapeutics|No|Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2010|May 11, 2010|November 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555451||165228|
NCT00546507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-06-13|Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I|The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study I||Mika Pharma GmbH|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|650|||Both|40 Years|N/A|No|||October 2010|October 11, 2010|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546507||165898|
NCT00519324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C1201|Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer|A Single Arm, Multi-center Phase II Study of RAD001 in Patients With Advanced Gastric Carcinoma Whose Cancer Has Progressed Despite Prior Treatment||Novartis||Completed|August 2007|||January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|20 Years|N/A|No|||April 2012|April 24, 2012|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519324||167955|
NCT00519337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHIT002743HE|Impact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation|The Impact of Ascorbic Acid Therapy on Inflammatory Mediators in Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression Trial IV (AFIST IV) Pilot Study|AFIST|Hartford Hospital|Yes|Completed|October 2008|April 2011|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519337||167954|
NCT00518388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0101|Perceptions of Cervical Cancer Among Asian Americans|Perceptions of Cervical Cancer and Human Papillomavirus Among Asian Americans||M.D. Anderson Cancer Center|No|Completed|August 2007|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|29 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants that are self identified as Korean, Filipino, or Vietnamese.|January 2016|January 14, 2016|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00518388||168027|
NCT00518661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07070356|Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species|Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species||University of Pittsburgh|Yes|Active, not recruiting|August 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|quinolone resistant|December 2015|December 16, 2015|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518661||168006|
NCT00518674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01329190|Local Anesthetics After Total Knee Arthroplasty|Local Anesthetics After Total Knee Arthroplasty: Intra- vs. Extraarticular Administration? A Randomized, Double-Blind, Placebo-Controlled Study||Hvidovre University Hospital|No|Active, not recruiting|January 2007|September 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||July 2007|August 20, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00518674||168005|
NCT00519896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6494|Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer|Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation||University of Washington|No|Completed|July 2007|September 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00519896||167911|
NCT00519285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6546|Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer|A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer|VENICE|Sanofi|Yes|Completed|August 2007|April 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1224|||Male|18 Years|N/A|No|||August 2013|August 2, 2013|August 21, 2007|Yes|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT00519285||167958|Pain response initially defined as a key secondary endpoint together with PSA response, time to occurence of SRE and PFS was finally considered as an exploratory endpoint in final statistical analysis plan.
NCT00520845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0730|Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer|A Phase II Trial of Celecoxib Plus Chemotherapy [Docetaxel or Pemetrexed] in Patients With Previously Treated, "COX Dependent" Recurrent Non-Small Cell Lung Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|October 2007|October 2014|Anticipated|September 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||October 2014|October 5, 2014|August 24, 2007|Yes|Yes|slow accrual|No|October 5, 2014|https://clinicaltrials.gov/show/NCT00520845||167839|
NCT00521092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00229|Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma|Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa||National Cancer Institute (NCI)||Withdrawn|January 2009|||October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2012|May 2, 2014|August 24, 2007|No|Yes|No participants enrolled.|No||https://clinicaltrials.gov/show/NCT00521092||167820|
NCT00521105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-2-05-1823-DP|Assessment of an Alternative Model of Follow-up of Children and Adolescents With Type 1 Diabetes|Assessment of an Alternative Model Using Telemedicine Follow-up of Children and Adolescents With Type 1 Diabetes||University of Calgary|No|Completed|August 2005|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|82|||Both|1 Year|17 Years|No|||October 2011|October 5, 2011|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521105||167819|
NCT00548938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHIRB #2007-040|Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM|A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed by Metronomic Therapy With Temozolomide for Newly Diagnosed Malignant High Grade Glioma||Methodist Healthcare|Yes|Terminated|October 2007|October 2010|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|72 Years|No|||September 2009|September 17, 2009|October 23, 2007||No|Principal Investigator has left the institution|No||https://clinicaltrials.gov/show/NCT00548938||165718|
NCT00549237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 07 - 096|Perioperative Nutrition in Gastric Bypass Surgery|Perioperative Nutrition in Gastric Bypass Surgery for Morbid Obesity||University Hospital, Geneva|No|Completed|November 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||August 2013|September 5, 2013|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549237||165697|
NCT00540527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNTHESIS|Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS)|SYNTHESIS: a Randomized Controlled Trial on Intra-arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke. Start up Phase.||Niguarda Hospital|Yes|Completed|January 2004|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|80 Years|No|||October 2012|October 24, 2012|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540527||166349|
NCT00535977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR07-2004|Broccoli, Peas and PIN|A Human Intervention Trial Studying Gene Expression in High-Grade Prostatic Intraepithelial Neoplasia Following Consumption of Broccoli or Peas||Institute of Food Research|No|Completed|April 2005|April 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Male|30 Years|70 Years|No|||September 2007|September 26, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00535977||166693|
NCT00545688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO20697|A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.|A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer||Hoffmann-La Roche||Completed|June 2006|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|417|||Female|18 Years|N/A|No|||December 2015|December 16, 2015|October 16, 2007||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00545688||165959|
NCT00545974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-53:memantineplacebo|Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia|A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia||University of California, San Francisco|Yes|Completed|October 2007|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|40 Years|80 Years|No|||December 2013|December 13, 2013|October 16, 2007|Yes|Yes||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00545974||165937|Lower enrollment than planned may have limited ability detect a treatment effect; Small size of semantic dementia group limits generalizability of results to FTD syndrome;Newer tools have been developed to better capture FTD-specific behaviors.
NCT00546195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908011|Infant Immune Response to Bacterial Infection|Expression Profiling of Bacterial Lipopolysaccharide Activated Neutrophil in Pre-Term, Term Infants and Adults||National Institutes of Health Clinical Center (CC)||Completed|October 2007|March 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|September 26, 2015|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546195||165920|
NCT00546208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4838-DZ-CTIL|Unilateral Cutaneous Ureterostomy - Long Term Follow up|Bladder Function Following Temporary Unilateral Cutaneous Ureterostomy - Long Term Follow up|ureterostomy|Sheba Medical Center|No|Recruiting|February 2008|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|adolescents and adults who had been operated in our institution for severe bilateral        congenital hydro-ureteronephrosis|March 2008|March 13, 2008|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546208||165919|
NCT00518401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01-I|Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia|Phase I Study of A Combination Stem Cell Therapy is Safe and Feasible in the Development of Mature Stable Vessels in Ischemic Limbs|mesendo|TCA Cellular Therapy|No|Completed|June 2007|October 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2010|April 27, 2011|August 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00518401||168026|
NCT00518414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3378|The Evaluation of Cow Milk-Based Formulas|The Evaluation of Cow Milk-Based Formulas - Study A||Mead Johnson Nutrition|No|Completed|April 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|136|||Both|N/A|18 Days|Accepts Healthy Volunteers|||September 2015|September 24, 2015|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518414||168025|
NCT00519051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040432|A Randomized Clinical Trial for Depressed Mothers at Primary Care Level|Efectividad de la Farmacoterapia Monitorizada en Pacientes Deprimidas de la atención Primaria de Salud y su repercusión Sobre la Salud Mental de Sus Hijos|DMH|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile|No|Completed|March 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|345|||Female|18 Years|N/A|No|||August 2007|August 20, 2007|August 17, 2007||||No||https://clinicaltrials.gov/show/NCT00519051||167976|
NCT00519012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19760629|Benefits of Switching Antidepressants Following Early Nonresponse|Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2||Oizumi Hospital|Yes|Recruiting|August 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||September 2009|September 26, 2009|August 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00519012||167979|
NCT00519298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-1110|Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects|A Double-Blind, Placebo-Controlled, Balanced, 4-Way, Incomplete Block Design to Evaluate the Effects of a Single Administration of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG (qEEG) in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 21, 2008|August 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00519298||167957|
NCT00519311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401647|RCT of an Intervention to Improve the Health of Adolescents With Intellectual Disability|RCT of an Intervention to Improve the Health of Adolescents With Intellectual Disability|Ask|The University of Queensland|No|Completed|January 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|732|||Both|10 Years|20 Years|Accepts Healthy Volunteers|||May 2015|May 31, 2015|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519311||167956|
NCT00520143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03907|Alglucosidase Alfa Temporary Access Program|Alglucosidase Alfa Temporary Access Program|ATAP|Sanofi||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||February 2014|February 4, 2014|August 21, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00520143||167892|
NCT00520169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-PK-007|Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine|A Randomized, Open Label, Single Center, Single-Dose, Cross-Over Study to Determine the Absolute Bioavailability and the Nasopharyngeal Absorption of PMI-150 (Intranasal Ketamine) in Healthy Adult Volunteers||Javelin Pharmaceuticals|No|Completed|July 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|January 9, 2008|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00520169||167890|
NCT00520130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070195|Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System|Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2007|March 2017|Anticipated|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|74 Years|No|||January 2016|March 4, 2016|August 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520130||167893|
NCT00520572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1520C00001|A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)|A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine||AstraZeneca||Completed|August 2007|March 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|385|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|August 22, 2007|Yes|Yes||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00520572||167859|Hybrid ACR, ACRn, individual ACR components, Erythrocyte sedimentation rate, Short-form-36, Rheumatoid Arthritis Quality of Life, Patient Assessment of Fatigue and DEXA X-ray scanning did not provide extra information so are not presented
NCT00520858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross2002|Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women|Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women||Queen's University|No|Completed|September 2003|||||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|145|||Both|65 Years|80 Years||||April 2008|April 21, 2008|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00520858||167838|
NCT00521352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5517|Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression|Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder (PD) With Comorbid Major Depression|rTMS|New York State Psychiatric Institute|Yes|Completed|October 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||November 2013|September 16, 2014|August 23, 2007||No||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00521352||167801|
NCT00521690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1764|The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD|Safety and Therapeutic Effect of Insulin Detemir in Taiwanese Patients With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets With OAD With/Without Once-daily NPH Insulin Treatment||Novo Nordisk A/S|No|Completed|December 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|30 Years|N/A|No|||November 2014|November 25, 2014|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00521690||167775|
NCT00521703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HICF 001-07|Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children|Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children and Teenagers||Hospital Infantil Cândido Fontoura|No|Completed|August 2007|April 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|8 Years|18 Years|No|||May 2008|May 22, 2008|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00521703||167774|
NCT00550095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AEG03|To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus|A 24 Week, Multi-centre, Open Label, Non Controlled Study to Assess the Efficacy of Valsartan in Reducing Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus||Novartis|No|Completed|June 2007|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|509|||Both|35 Years|75 Years|No|||May 2012|May 6, 2012|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00550095||165631|
NCT00545701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPA11|Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults|||Sanofi||Completed|October 2007|September 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00545701||165958|
NCT00549523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19AT003264-01|A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults|A Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of Lessertia Frutescens (L.)Goldblatt and J.C. Manning (Syn. Sutherlandia Frutescens (L.)R. Br.)in HIV-infected South African Adults||University of Missouri-Columbia|Yes|Completed|April 2008|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|4||Actual|133|||Both|21 Years|65 Years|No|||May 2014|May 27, 2014|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549523||165675|
NCT00549536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3242|The Effect of Calcium Supplementation on Insulin Resistance and 24h Blood Pressure|The Effect of Oral Calcium Supplementation on Insulin Sensitivity, Intracellular Cationic Concentrations and the Transmembrane Sodium/Hydrogen Exchanger Activity in Subjects With Type 2 Diabetes and Hypertension||Aristotle University Of Thessaloniki|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|85 Years|No|||June 2008|July 2, 2008|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00549536||165674|
NCT00549783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGN/HO/SPA/001-191622|BOTOX® Economic Spasticity Trial (BEST)|||Allergan|No|Completed|October 2007|July 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|85 Years|No|||July 2012|July 18, 2012|October 24, 2007|Yes|Yes||No|November 14, 2011|https://clinicaltrials.gov/show/NCT00549783||165655|
NCT00550043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-231|A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis|A Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis||Incyte Corporation|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|70 Years|No|||March 2015|March 9, 2015|October 24, 2007|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00550043||165635|
NCT00550056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeEl-Ug-01|Treatment of Posttraumatic Stress Disorder by Trained Lay Counsellors in an African Refugee Settlement|Talking About Traumatic Events - A Randomized Controlled Dissemination Study of the Treatment of PTSD in an African Refugee Settlement||University of Konstanz|No|Completed|January 2003|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|277|||Both|18 Years|N/A|No|||October 2007|October 25, 2007|October 25, 2007||||No||https://clinicaltrials.gov/show/NCT00550056||165634|
NCT00550069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4821-IM-CTIL|Observational Study of Infants Born at 34 to 37 Weeks of Gestation Until the Age of 1 Year|Late Preterm Infants:Clinical Course and Outcome From Birth Through Out the First Year of Life.||Sheba Medical Center|No|Not yet recruiting|December 2007|January 2009|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|30 Days|Accepts Healthy Volunteers|Non-Probability Sample|All infants born at a gestational age of 34-37 weeks in 3 medical centers in Israel|December 2007|December 24, 2007|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550069||165633|
NCT00550082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-002346|3 Screen Electronic Alert|Multi-Screen Electronic Alert for Venous Thromboembolism Prevention||Brigham and Women's Hospital|No|Completed|July 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|880|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients at Brigham and Women's Hospital from medical and surgical services        who are 18 yrs old or older and are at a moderate to high risk for venous thromboembolism        (VTE)|February 2012|February 9, 2012|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00550082||165632|
NCT00546234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233372|Tiotropium for Smoking Asthmatics Study|Assessing Treatment Options for Smokers With Asthma.||University of Alberta|No|Withdrawn|November 2007|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|No|||August 2014|August 26, 2014|October 16, 2007||No|No subjects enrolled and no ongoing funding.|No||https://clinicaltrials.gov/show/NCT00546234||165917|
NCT00546000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT 0434-01-01|Cutivate Lotion HPA Axis Pediatric Study|A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population||Fougera Pharmaceuticals Inc.|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|3 Months|12 Months|No|||June 2014|June 25, 2014|October 16, 2007|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00546000||165935|
NCT00546520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-125|Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)|A 3-period Double-blind, Cross-over Study on the Onset of Action of Inhaled Ciclesonide (7 Days of 400 Mcg Sid Versus 800 Mcg Bid Versus Placebo) on Airway Responsiveness to Adenosine Monophosphate (AMP), Sputum Eosinophiles and Exhaled Breath Nitric Oxide (NO) in Patients With Asthma||Takeda|No|Completed|April 2002|June 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|21|||Both|18 Years|45 Years|No|||October 2007|May 4, 2012|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546520||165897|
NCT00546819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-017|ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)|A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids||Merck Sharp & Dohme Corp.||Completed|October 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|309|||Both|60 Years|N/A|No|||February 2016|February 2, 2016|October 17, 2007|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00546819||165874|
NCT00519025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07080006|Risk Factors for Linezolid Resistance in Staphylococcus Aureus|Risk Factors for Linezolid Resistance in Staphylococcus Aureus||University of Pittsburgh|Yes|Active, not recruiting|August 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|360|||Both|18 Years|N/A|No|Probability Sample|linezolid resistance to staph aureus|December 2015|December 16, 2015|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00519025||167978|
NCT00519038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPSEEIC2004-EXART12MARCHE|Experimental Prospective Study on the Effectiveness and Efficiency of the Implementation of Clinical Pathways|Experimental Prospective Study on the Effectiveness and Efficiency of the Implementation of Clinical Pathways|EPSEEIC2004|Agenzia Regionale Sanitaria delle Marche|Yes|Completed|March 2003|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|424|||Both|18 Years|N/A|No|||August 2007|August 20, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00519038||167977|
NCT00519363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-316|Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors|Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors.||The Center for Rheumatic Disease, Allergy, & Immunology|No|Completed|September 2007|December 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|60 Years|No|||September 2009|March 23, 2010|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519363||167952|
NCT00519597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGSKAS-4731|Continuous Positive Airway Pressure (CPAP) Treatment in Coronary Artery Disease and Sleep Apnea|Randomized Intervention With CPAP in Coronary Artery Disease and Sleep Apnea - RICCADSA Trial|RICCADSA|Skaraborg Hospital|Yes|Completed|December 2005|May 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|511|||Both|N/A|N/A|No|||July 2013|July 8, 2013|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519597||167934|
NCT00519909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF-01-144/02|The Effect of Calcium on Fecal Fat and Energy Excretion|||University of Copenhagen|No|Recruiting|August 2007|February 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2007|August 22, 2007|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00519909||167910|
NCT00519623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN2007001|Transdermal Basal Insulin Patch Study in Type 1 Diabetes|Pharmacokinetic/Pharmacodynamic Study of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients||Altea Therapeutics|No|Completed|August 2007|December 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||December 2010|December 3, 2010|August 2, 2007|No|Yes||No|December 3, 2010|https://clinicaltrials.gov/show/NCT00519623||167932|This was a small exploratory study to evaluate the PK, PD and tolerability of a selected Basal Insulin PassPort(r) System configuration in C-peptide negative type 1 diabetes subjects.
NCT00520546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12K3-S-140708|Clinical Value of FEC-PET Combined With Endorectal MRI for Pre-therapeutic Staging of Prostate Cancer|Clinical Value of [18]Fluoroethylcholine Positron-Emission-Tomography Combined With Endorectal Magnetic Resonance Imaging by Software Fusion for Pre-therapeutic Staging of Prostate Cancer|FEC-PET/MRI|German Federal Armed Forces|Yes|Completed|December 2007|June 2011|Actual|February 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|44|||Male|50 Years|N/A|No|||June 2012|June 3, 2012|August 23, 2007||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00520546||167861|
NCT00520507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-263-07|An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients|An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients||Queen's University|No|Completed|October 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520507||167864|
NCT00520520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-STU-26|Influence of Mild Therapeutic Hypothermia on Leukocyte Count||INCA|Charite University, Berlin, Germany||Terminated|December 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|||||Both|18 Years|90 Years||Probability Sample|Survivors in out of hospital cardiac arrest|July 2009|August 3, 2015|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520520||167863|
NCT00520533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2007-004|Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma|A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma||Ludwig Institute for Cancer Research|No|Terminated|February 2008|September 2012|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|August 22, 2007||No|Closed prematurely due to toxicity|No||https://clinicaltrials.gov/show/NCT00520533||167862|
NCT00521118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000561984|Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor|A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-Metastatic Gestational Trophoblastic Neoplasia||National Cancer Institute (NCI)||Recruiting|October 2007|||June 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Female|N/A|N/A|No|||March 2011|March 29, 2011|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521118||167818|
NCT00521365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00017|Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.|A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder.|EMMY|AstraZeneca||Completed|May 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|65 Years|No|||March 2012|June 12, 2012|August 24, 2007||No||No|August 11, 2010|https://clinicaltrials.gov/show/NCT00521365||167800|Open label, non comparative study
NCT00521378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP 01-2007-01|A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus|A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus||Diasome Pharmaceuticals|No|Completed||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 10, 2009|August 23, 2007||||No||https://clinicaltrials.gov/show/NCT00521378||167799|
NCT00517634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZA109912|Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects|A 12-week, Randomised, Double-blind, Placebo-controlled, Three-period, Cross-over Pilot Study Comparing the Effect of Salmeterol/Fluticasone Propionate, Fluticasone Propionate and Placebo on Perpheral Blood Eosinophils and Serum IL-5 in Response to Allergen Challenge in Asthma Subjects When Allergen Challenge is Administered at 1 Hour or 11-12 Hours Post-dose of the Dosing Interval||GlaxoSmithKline|No|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|23|||Both|18 Years|55 Years|No|||March 2014|March 13, 2014|August 16, 2007|Yes|Yes||No|July 23, 2009|https://clinicaltrials.gov/show/NCT00517634||168084|
NCT00549562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709-24|Study of Paliperidone ER in Adolescents and Young Adults With Autism|A Prospective, Open-Label Study of Paliperidone ER in Adolescents and Young Adults With Autism||Indiana University|Yes|Completed|November 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|12 Years|21 Years|No|||May 2015|May 14, 2015|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00549562||165672|
NCT00545714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21135|A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.|An Open Label Study to Assess the Effect of First Line Treatment With MabThera in Combination With Fludarabine and Cyclophosphamide, Followed by MabThera Monotherapy, on Response Rate in Patients With Chronic Lymphocytic Leukemia.||Hoffmann-La Roche||Active, not recruiting|November 2007|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545714||165957|
NCT00549796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_000230|Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery|Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery||Johns Hopkins University|Yes|Completed|April 2006|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|18876|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549796||165654|
NCT00545675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-KOB-0702|Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness|Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote|SMART-M|Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|December 2007|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|65 Years|No|||December 2009|August 10, 2010|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545675||165960|
NCT00546221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07105|Promoting Wellbeing for Women With Depression: A Pragmatic Randomised Controlled Trial (RCT) of an Exercise Programme|Pragmatic Randomised Controlled Trial of a Preferred Intensity Exercise Programme to Improve Physiological and Associated Psychological, Social, and Wellbeing Outcomes of Women Living With Depression||University of Nottingham|No|Completed|November 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Female|18 Years|90 Years|No|||March 2011|March 2, 2011|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546221||165918|
NCT00546013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Abdominal Aortic Aneurysms and Pseudoexfoliation Syndrome|Abdominal Aortic Aneurysms Are Associated With Pseudoexfoliation Syndrome||European Georges Pompidou Hospital|No|Terminated|December 2001|July 2002|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|208|||Both|60 Years|N/A|No|Non-Probability Sample|in patients suffering from abdominal aortic aneurism as part of a routine clinical yearly        follow-up and hypertensive patients without abdominal aortic aneurism and that were more        than 60 years old to have similar mean ages in both groups, as pseudoexfoliation and        abdominal aortic aneurism are age-related disorders|October 2007|October 17, 2007|October 17, 2007|||all patients required included|No||https://clinicaltrials.gov/show/NCT00546013||165934|
NCT00546559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-200406|Differential Metabolic Effects of Statins|||Gachon University Gil Medical Center|Yes|Completed|January 2004|March 2008||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective|||||||Both|25 Years|75 Years||||August 2008|August 28, 2008|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546559||165894|
NCT00546572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3005|Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|938|||Both|70 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 12, 2011|October 18, 2007|Yes|Yes||No|April 29, 2011|https://clinicaltrials.gov/show/NCT00546572||165893|
NCT00546247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA190-001|A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)|A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)||Bristol-Myers Squibb|No|Terminated|January 2008|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546247||165916|
NCT00546260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-113|Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI|Randomized Trial to Evaluate Effect of Adjunctive Antiplatelet Therapy With Intravenous PRT060128, a Selective P2Y12-Receptor Inhibitor, Before Primary Percutaneous Intervention (PCI) in ST-Elevation Myocardial Infarction (STEMI) Patients|ERASE-MI|Portola Pharmaceuticals|Yes|Terminated|November 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||December 2010|December 28, 2010|October 16, 2007|Yes|Yes|Administrative reasons.|No|November 23, 2010|https://clinicaltrials.gov/show/NCT00546260||165915|Because Part II of the study was not completed and Part I had a small sample size, no conclusions could be drawn regarding efficacy.
NCT00546533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101101|Study Evaluating the Efficacy and Safety of Etanercept|Open-Label Evaluation Of The Efficacy And Safety Of Etanercept In Patients With Active Rheumatoid Arthritis (RA)||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|January 2003|February 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|N/A|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546533||165896|
NCT00546546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2004-2|Early Immunosuppressants in Crohn's Disease|Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease|RAPID|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|July 2005|June 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||August 2011|April 26, 2015|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00546546||165895|
NCT00519662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0011|Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors|Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors||Sunesis Pharmaceuticals|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2009|March 5, 2009|August 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00519662||167929|
NCT00519675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAP00731|Alitretinoin in the Treatment of Chronic Hand Eczema|Open Label Treatment of Patients With Chronic Hand Dermatitis Who Have Participated in a Previous Clinical Trial Involving Oral Alitretinoin||Basilea Pharmaceutica|No|Completed|May 2007|||||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|80 Years|No|||July 2010|July 16, 2010|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00519675||167928|
NCT00519350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074016|Towards a High-fat Feeding Intervention Study: Identification of Markers for Inflammation and Organ Damage|Towards a High-fat Feeding Intervention Study: Identification of Markers for Inflammation and Organ Damage||Maastricht University Medical Center|Yes|Completed|August 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|24|Samples Without DNA|plasma|Both|18 Years|N/A|No|Probability Sample|Patients in Maastricht University Hospital area undergoing one of selected types of        surgery|March 2010|March 30, 2010|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519350||167953|
NCT00519610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105982|Assessing Outcome After H-graft Shunt Placement|A Study Assessing Patient Outcomes After Placement of H-graft Portacaval Shunts for the Treatment of Portal Hypertension|PHTN|University of South Florida|No|Completed|July 2007|July 2010|Actual|||N/A|Observational|N/A||1|Actual|66|||Both|18 Years|N/A|No|Probability Sample|Patients with portal hypertension|August 2012|August 14, 2012|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519610||167933|
NCT00520156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-17021|Analysis of the Prevalence and Characteristics of Concomitant Sleep and Headache Disorders, and the Efficacy of CPAP Treatment for Headache Among Those Patients Diagnosed With Obstructive Sleep Apnea|Analysis of the Prevalence and Characteristics of Co-Morbid Sleep and Headache Disorders in Patients Being Evaluated at the WRAMC Sleep Disorders Laboratory, and the Efficacy of CPAP Treatment on Headache Burden in Obstructive Sleep Apnea Patients With a Co-Morbid Headache Disorder||Walter Reed Army Medical Center|Yes|Not yet recruiting|August 2007|August 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|600|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2007|August 21, 2007|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00520156||167891|
NCT00520195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-306 (med06-100)|Stair Instead of Elevator Use at Work: Cardiovascular Primary Preventive Effects on Hospital Employees.|||University Hospital, Geneva|No|Completed|March 2007|July 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|77|||Both|18 Years|N/A||||August 2007|August 21, 2007|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00520195||167888|
NCT00520559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/MRE04/32|T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients|Incidence of Cardiac Complications in Patients With Cardiac Siderosis During 1 Year Follow−up and the Normal T2* Ranges in LVF, MI and Normal Population.||Imperial College London|No|Completed|January 2007|August 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|665|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2007|August 23, 2007|August 23, 2007||||No||https://clinicaltrials.gov/show/NCT00520559||167860|
NCT00520182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT3645|Dietary Interventions in Type 2 Obese Diabetic Patients in the Community|Community Trial to Assess the Effect of Nutritional Intervention Models on Medical Outcomes Among Obese Type 2 Diabetic Patients|DIPAC|Ben-Gurion University of the Negev|No|Active, not recruiting|March 2004|February 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|259|||Both|30 Years|65 Years|No|||September 2007|September 19, 2007|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00520182||167889|
NCT00521716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WF-01|Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation|A Single Arm, Uni-Center, Prospective Clinical Investigation to Evaluate Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation||OrthoMediTec|Yes|Suspended|September 2007|December 2009|Anticipated|March 2008|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|75 Years|No|||February 2008|January 9, 2009|August 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00521716||167773|
NCT00521729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070202|Metabolism and Thyroid Hormone Changes During Exposure to Cold Temperatures|Thyroid Hormones Homeostasis and Energy Metabolism Changes During Exposure to Cold Temperature in Humans||National Institutes of Health Clinical Center (CC)||Completed|August 2007|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind|1||Actual|160|||Both|18 Years|60 Years|No|||January 2016|January 16, 2016|August 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00521729||167772|
NCT00521976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD9253|Risk Markers in the Acute Coronary Syndromes|An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.|RACS|Helse Stavanger HF|No|Completed|November 2002|December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|871|Samples Without DNA|Serum, Citrated plasma, EDTA-plasma and packed red blood cells are kept in suitable aliquots      at -80 degrees Celcius.|Both|18 Years|N/A|No|Probability Sample|871 men and women admitted with chest pain and potential acute cornary syndrome (ACS) at        the Stavanger University Hospital between November 2002 and October 2003.|May 2015|May 19, 2015|August 27, 2007||No||No|January 9, 2009|https://clinicaltrials.gov/show/NCT00521976||167753|
NCT00521989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-102-006|CRx-102 Osteoarthritis Multicenter Evaluation Trial|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension|COMET-1|Zalicus|Yes|Terminated|August 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|279|||Both|40 Years|N/A|No|||March 2014|March 26, 2014|August 27, 2007|Yes|Yes|CRx-102-006 study results, negative|No|February 10, 2014|https://clinicaltrials.gov/show/NCT00521989||167752|
NCT00522639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02-117|Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation|Determination of the Predictive Value of FDG-PET-CT Scans, Blood Proteins and Blood Cells for the Prognosis for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation|FDG-PET lung|Maastricht Radiation Oncology|No|Terminated|October 2008|June 2009|Actual|||Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|August 29, 2007||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00522639||167704|
NCT00522652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-478-001|Phase I Trial of PX-478|A Phase 1 Trial of Oral PX-478 (a HIF-1α Inhibitor) in Patients With Advanced Solid Tumors or Lymphoma||Oncothyreon Inc.|No|Completed|August 2007|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|August 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00522652||167703|
NCT00549835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00008179|Acupuncture for Mucositis Pain in Cancer Care|Acupuncture for Mucositis Pain in Cancer Care||Johns Hopkins University|No|Withdrawn|August 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|70 Years|No|||March 2015|April 7, 2015|October 24, 2007|||Inadequate funding|No||https://clinicaltrials.gov/show/NCT00549835||165651|
NCT00549822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-109|Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer|A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive, Hormone Receptor Positive, Metastatic Breast Cancer||Massachusetts General Hospital|Yes|Completed|October 2007|September 2013|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|October 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00549822||165652|
NCT00545987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHO-0614|Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers|Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/N-t, by Ichor TriGrid™ in Vivo Electroporation to HIV-Uninfected, Healthy Volunteers|ADVAX-EP|Rockefeller University|Yes|Completed|September 2007|April 2011|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|October 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00545987||165936|
NCT00545727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-CH-N182|Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes|Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|July 2006|August 2006|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|7 Years|16 Years|No|||September 2007|October 16, 2007|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545727||165956|
NCT00545740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-313|Prevention of Recurrence of Diverticulitis|A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.|PREVENT1|Shire|No|Completed|November 2007|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|590|||Both|18 Years|N/A|No|||February 2013|June 6, 2014|October 16, 2007|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00545740||165955|
NCT00546585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0023|Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults|A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H7N7 Vaccine in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|126|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2010|August 15, 2013|October 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546585||165892|
NCT00537797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0757 / 201103045|Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules|Limited Neck FDG-PET Imaging for Indeterminate Thyroid Nodules||Washington University School of Medicine|No|Completed|August 2004|February 2014|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|84|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537797||166555|
NCT00546858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-183|Relationship of Interstitial Cystitis to Vulvodynia|Part A: STUDY OF THE RELATIONSHIP OF INTERSTITIAL CYSTITIS TO VULVODYNIA||William Beaumont Hospitals|No|Completed|October 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of Interstitial Cystitis from the practices of Dr Ananias Diokno        and Dr Kenneth Peters will be mailed a survey.|May 2009|May 4, 2009|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546858||165871|
NCT00546871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160601|Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects|Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases||Baxalta US Inc.|No|Completed|October 2007|September 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|24 Months|N/A|No|||April 2015|June 26, 2015|October 18, 2007|Yes|Yes||No|November 15, 2011|https://clinicaltrials.gov/show/NCT00546871||165870|
NCT00546884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704S06282|Intervention to Improve Expression of End of Life Preferences for Homeless Persons|Intervention to Improve Expression of End of Life Preferences for Homeless Persons|SELPH|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|November 2007|November 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 24, 2009|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00546884||165869|
NCT00538642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000000010002968|Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone|Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone||The University of Texas Health Science Center at San Antonio|Yes|Completed|August 2007|November 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|October 2, 2007|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00538642||166490|
NCT00538655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27.004|A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence|A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence||California Pacific Medical Center Research Institute|Yes|Completed|January 2008|June 2011|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|50 Years|No|||May 2013|May 30, 2013|October 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00538655||166489|
NCT00518713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13110A|Clobazam in Patients With Lennox-Gastaut Syndrome|Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome||Lundbeck LLC|Yes|Completed|August 2007|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|238|||Both|2 Years|60 Years|No|||January 2012|January 6, 2012|August 20, 2007|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00518713||168002|
NCT00518726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71P5S|Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Surface Antigen, Inactivated, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects||Novartis||Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 14, 2011|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518726||168001|
NCT00518739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2461-001|MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)|A Phase I Dose Escalation Study of MK2461 in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.||Completed|February 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|August 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00518739||168000|
NCT00519688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940813|UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma|A Phase II Study of Tegafur/Uracil(UFUR) Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)||National Taiwan University Hospital|No|Completed|July 2006|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||October 2011|October 13, 2011|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00519688||167927|
NCT00519961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000485|A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery|A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery||Hoffmann-La Roche||Recruiting|February 2007|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1800|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|August 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00519961||167906|
NCT00519636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFU105927|Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS|R, DB, PC, AC, One-Week, Cross-Over, MCStudy to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcgFluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhiniti||GlaxoSmithKline|No|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|360|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|August 21, 2007||No||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00519636||167931|
NCT00519649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110474|Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.|An Open, Phase IV, Single-group, Multicentre Study to Assess the Long-term Persistence of Antibodies Against Hepatitis B and the Immune Response to a Hepatitis B (HBV) Vaccine Challenge in Children Aged 7-8 Years of Age and Previously Vaccinated in Infancy With GSK Biologicals' HBV Vaccine (Engerix™-B).||GlaxoSmithKline||Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|301|||Both|7 Years|8 Years|Accepts Healthy Volunteers|||March 2013|August 13, 2015|August 21, 2007|Yes|Yes||No|December 17, 2008|https://clinicaltrials.gov/show/NCT00519649||167930|
NCT00520208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-507-P2|Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL|A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1)|STAR-1|CytRx|No|Completed|September 2007|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00520208||167887|
NCT00519922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KneeOAExercise-1|A Study of the Effectiveness of Different Types of Exercise for People With Knee Osteoarthritis|Efficacy of Kinesthesia, Balance and Agility Exercise Training as Treatment of Knee Osteoarthritis: A Pilot Study|KBA Exercise|The Arthritis Research Institute of America|No|Completed|January 2008|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|50 Years|N/A|No|||July 2008|July 21, 2008|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519922||167909|
NCT00520585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-15-11-2006|Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes|Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes|ATORVA|Masaryk University|No|Not yet recruiting|August 2007|November 2007|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2007|August 22, 2007|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00520585||167858|
NCT00520871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Water-Blueberry Study|The Water-Blueberry Study|The Effect of Blueberry Juice on Cardiovascular Risk Factors, and Markers of Antioxidant Status, Oxidative Stress Status and Inflammation.||University of Oslo|No|Completed|March 2003|April 2004|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|62|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||August 2007|August 24, 2007|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00520871||167837|
NCT00526682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHACT010|The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids|The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases||Gateway Health Alliance|Yes|Completed|January 2007|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|72|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||September 2007|September 6, 2007|September 6, 2007||||No||https://clinicaltrials.gov/show/NCT00526682||167398|
NCT00526695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-2005|Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion|Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion, Leukocyte/Thrombocyte Activation, and Endothelial Function After Tourniquet-Induced Ischemia/Reperfusion Injury in the Forearm of Volunteers||University of Zurich|No|Recruiting|January 2005|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||July 2008|July 17, 2008|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00526695||167397|
NCT00522314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1233R020|Airway Clearance in Bronchiectasis: is Non-Invasive Ventilation a Useful Adjunct in Moderate to Severe Disease?|Airway Clearance in Bronchiectasis: is Non-Invasive Ventilation a Useful Adjunct in Moderate to Severe Disease?A Pilot Study.||University of Ulster|Yes|Completed|October 2003|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||August 2007|August 28, 2007|August 28, 2007||||No||https://clinicaltrials.gov/show/NCT00522314||167727|
NCT00549328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109609|Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer|A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer||GlaxoSmithKline||Terminated|February 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|October 23, 2007|Yes|Yes|Study enrolment was delayed in starting and too slow to support further development in this    setting|No|December 22, 2009|https://clinicaltrials.gov/show/NCT00549328||165690|
NCT00550160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKNT_1|The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children|The Clinical Impact of Seasonal Intermittent Preventive Treatment (IPT) and Home Management of Malaria (HMM) Using AQ+AS in Ghanaian Children Under 5 Years of Age - a Cluster Randomised Placebo Controlled Trial.|KNUST-COMDIS|Kwame Nkrumah University of Science and Technology|No|Completed|April 2007|October 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1490|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||September 2015|September 17, 2015|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550160||165626|
NCT00550134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-130|Cognitive Changes Associated With Breast Cancer Treatment|Cognitive Changes Associated With Breast Cancer Treatment||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|80|Samples With DNA|blood|Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potential subjects for the study will be identified MSKCC's clinic.        Healthy control group participants will be recruited through advertisements and flyers        which will be available/advertised in the community. Health control participants will also        be recruited by asking survivors if they have a friend who might want to volunteer for the        study.|January 2016|January 19, 2016|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550134||165628|
NCT00550147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0307-31 (IRB#)|Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.|An Open-Label Study of Quetiapine Added to Oros Methylphenidate in the Treatment of ADHD and Aggressive Behavior||Indiana University|Yes|Completed|February 2004|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|12 Years|17 Years|No|||May 2015|May 8, 2015|October 25, 2007||No||No|April 3, 2009|https://clinicaltrials.gov/show/NCT00550147||165627|There were no unanticipated limitations/caveats. All of the typical caveats of open-label studies apply: As a result, bias, placebo effects, demand characteristics, and other non-treatment related effects may have contributed to results.
NCT00550108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000420|Management of Incidentally Discovered Pancreatic Cysts|A Prospective Study of the Management of Incidentally Discovered Pancreatic Cysts||Massachusetts General Hospital|Yes|Terminated|October 2007|October 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||June 2008|June 23, 2008|October 24, 2007||No|Inability to enroll subjects.|No||https://clinicaltrials.gov/show/NCT00550108||165630|
NCT00550121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHFVIT|Does Ascorbic Acid Reduce Sympathoexcitation in CHF?|||Radboud University||Completed|August 2007|April 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||||||Both|20 Years|80 Years||||October 2008|October 13, 2008|October 25, 2007||||No||https://clinicaltrials.gov/show/NCT00550121||165629|
NCT00546273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA/MI/01|Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers|Double-Blind, Randomized, Placebo-Controlled Phase I Study, to Study the Tolerability and Immunogenicity of 4 RUTI Antituberculous Vaccine Different Doses (5, 25, 100 y 200µg of FCMtb) in Healthy Volunteers||Germans Trias i Pujol Hospital|Yes|Completed|April 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2009|May 14, 2009|October 16, 2007||No||No|October 31, 2008|https://clinicaltrials.gov/show/NCT00546273||165914|
NCT00537810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501027352|Treatment of Binge Eating in Obese Patients in Primary Care|Treatment of Binge Eating in Obese Patients in Primary Care||Yale University|Yes|Completed|September 2007|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|104|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|September 27, 2007||No||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00537810||166554|
NCT00538343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 744-C-0703|RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases|A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases||Reata Pharmaceuticals, Inc.|No|Terminated|October 2007|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|N/A|No|||November 2014|November 13, 2014|September 28, 2007|Yes|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT00538343||166513|
NCT00538681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10722|Study for Patients With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo|Randomized, Double-Blind, Placebo Controlled, Phase 2 Study of Pemetrexed and Cisplatin Plus Enzastaurin Versus Pemetrexed and Cisplatin Plus Placebo in Chemonaive Patients With Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|September 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||October 2009|October 16, 2009|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538681||166487|
NCT00519064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P3|Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases|A Phase III, Randomized, Controlled, Observer-blind, Single-center Study to Compare Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases||Novartis||Completed|November 2006|May 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|361|||Both|18 Years|60 Years|No|||February 2012|February 20, 2012|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519064||167975|
NCT00524927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/61|Safety and Efficacy of Methoxyflurane for Treatment of Incident Pain|A Phase IV, Randomized, Double Blind, Single Centre, Placebo Controlled Study to Assess the Safety and Efficacy of Methoxyflurane [Penthrox] for the Treatment of Incident Pain in Participants Undergoing a Bone Marrow Biopsy Procedure||Medical Developments International Limited|Yes|Completed|September 2007|November 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 27, 2010|September 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00524927||167530|
NCT00519935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK59067B (completed)|Testing MST to Improve Adherence Among Youth With Chronic Poor Metabolic Control|Adherence to IDDM Regimen in Urban Youth||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|July 2001|March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|10 Years|16 Years||||March 2010|March 1, 2010|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00519935||167908|
NCT00519948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5320|Comfort and Cleaning Evaluation of Multipurpose Solutions in Contact Lens Patients|||Innovative Medical||Completed||June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label|||Actual|20|||Both|18 Years|N/A||||June 2008|June 16, 2008|August 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00519948||167907|
NCT00520611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00985|Evaluating the Effectiveness of Financial Incentives in Promoting Weight Loss Among Obese Individuals.|Evaluating the Effectiveness of Financial Incentives in Promoting Weight Loss Among Obese Individuals.||University of Pennsylvania|No|Completed|June 2007|December 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||January 2010|June 10, 2015|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520611||167856|
NCT00520598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V505-001|Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)|A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women||Merck Sharp & Dohme Corp.|Yes|Completed|October 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|511|||Female|16 Years|26 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|August 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520598||167857|
NCT00520884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB805400|Ghrelin in Older Women|A Pilot Study of Ghrelin in Healthy and Frail Older Women||University of Pennsylvania|Yes|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Female|70 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 23, 2011|August 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520884||167836|
NCT00521391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200-0637200|Physical Activity as an Aid for Smoking Cessation|Physical Activity as an Aid for Smoking Cessation: a Randomized Controlled Trial|PHASMO|University of Lausanne Hospitals|No|Terminated|April 2003|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2007|August 24, 2007|August 24, 2007|||End of the recruitment|No||https://clinicaltrials.gov/show/NCT00521391||167798|
NCT00526708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-CRE-2007/2|Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )|RUSH (Evaluating the Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension in Real World Practice)|RUSH|AstraZeneca|No|Completed|May 2007|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Hypertensive hypercholesteromia patients in Korean tertiary care centers|November 2010|November 30, 2010|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526708||167396|
NCT00526721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-CRE-2007/6|Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION|An Observational, Non-interventional, Multi-center Study to Evaluate Efficacy and Tolerability of High Dose Rosuvastatin in High Risk Patients After Titration|REVORUTION|AstraZeneca|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1482|||Both|18 Years|N/A|No|Probability Sample|Hypercholesteromia patients with high risk according to NCEP ATP III guideline in Korean        tertiary care centers|March 2012|March 19, 2012|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526721||167395|
NCT00522327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calendow/CMWF|Remote Simultaneous Medical Interpreting and Medical Outcomes|Remote Simultaneous Medical Interpretation: Medical Outcomes|RSMI|New York University School of Medicine|No|Completed|November 2004|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|1200|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00522327||167726|
NCT00522340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31202-B|Exercise After an ICD|Anti-Arrhythmic Effects of Exercise After an Implantable Cardioverter Defibrillator (ICD)||University of Washington|Yes|Completed|November 2007|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|21 Years|N/A|No|||November 2014|November 7, 2014|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00522340||167725|
NCT00549575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/4-A|L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)|L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial||Nantes University Hospital||Terminated|July 2000|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Female|18 Years|55 Years|No|||October 2007|October 25, 2007|October 24, 2007|||terminated|No||https://clinicaltrials.gov/show/NCT00549575||165671|
NCT00537238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081157|Pregabalin Versus Levetiracetam In Partial Seizures|A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures||Pfizer|Yes|Completed|October 2007|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|509|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|September 27, 2007|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00537238||166598|Results for BPRS were provided as change in scores at Week 16 compared to baseline instead of absolute scores as per planned analysis.
NCT00545766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 35|Vinflunine in Hormone Refractory Prostate Cancer (HRPC)|A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)||SCRI Development Innovations, LLC|No|Completed|May 2007|January 2009|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Male|18 Years|N/A|No|||February 2013|February 25, 2013|October 15, 2007|No|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT00545766||165953|
NCT00545753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-301-07|Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice|A Phase 3 Comparative Safety and Efficacy Study Between NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects >6 Months of Age or Older With Pediculosis Capitis||ParaPRO LLC|No|Completed|September 2007|May 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|558|||Both|6 Months|N/A|Accepts Healthy Volunteers|||September 2012|September 10, 2012|October 15, 2007|Yes|Yes||No|August 2, 2012|https://clinicaltrials.gov/show/NCT00545753||165954|
NCT00537199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1008|OraTest in Combination With Visual Examination and Visual Examination Alone|Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401)||M.D. Anderson Cancer Center|No|Terminated|February 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|45 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 11, 2009|September 26, 2007|Yes|Yes|Study terminated early as per request by sponsor, Zila Biotechnology, Inc.|No|December 11, 2009|https://clinicaltrials.gov/show/NCT00537199||166601|Early termination by sponsor resulted in only 1 patient enrolled and no analysis.
NCT00537459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTP108172|A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation|A Randomized, Double-blind, Placebo-controlled, Two-session Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an 16448 in Healthy Males With Premature Ejaculation.||GlaxoSmithKline|No|Completed|December 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|18|||Male|18 Years|45 Years|No|||February 2011|March 15, 2012|January 25, 2007||||No||https://clinicaltrials.gov/show/NCT00537459||166581|
NCT00538356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS042|Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function|IN-TIME: Influence of Home Monitoring on the Clinical Status of Heart Failure Patients|IN-TIME|Biotronik SE & Co. KG|No|Completed|July 2007|August 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|720|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538356||166512|
NCT00538668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602008378|Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody|Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer Using 177Lu-J591 Antibody: Dose Fractionation Regimen||Weill Medical College of Cornell University|Yes|Recruiting|August 2007|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|30|||Male|21 Years|85 Years|No|||May 2015|May 7, 2015|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538668||166488|
NCT00539708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS 041130|Non-Invasive Ventilation After Extubation in Hypercapnic Patients|Non-Invasive Ventilation After Extubation in Hypercapnic Patients||Hospital Clinic of Barcelona|No|Completed|May 2005|April 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|106|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00539708||166412|
NCT00519376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C110165|A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.|A Randomised, Single-dose, Dose Ascending, Double-blind, Placebo Controlled, Four-way, Incomplete Block Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With Magnesium Stearate in COPD Patients.||GlaxoSmithKline|No|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|20|||Both|40 Years|N/A|No|||September 2013|December 5, 2013|August 21, 2007|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00519376||167951|
NCT00519389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5N1 VLP-1|Safety, Reactogenicity and Immunogenicity of an H5N1 VLP|A Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant)||Novavax|Yes|Completed|July 2007|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|230|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|June 12, 2013|August 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00519389||167950|
NCT00525200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSO OE-1|p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer|p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer: A Multicenter, Randomized Controlled, Predictive Marker Clinical Trial|PANCHO|Medical University of Vienna|Yes|Completed|June 2007|December 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|170|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525200||167510|
NCT00520221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707015R|Intrapleural Minocycline Following Simple Aspiration for Primary Spontaneous Pneumothorax|Intrapleural Minocycline Following Simple Aspiration for Initial Treatment of Primary Spontaneous Pneumothorax: a Retrospective Study||National Taiwan University Hospital|No|Completed|January 2004|July 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||1|Actual|64|||Both|15 Years|50 Years|No|||January 2004|August 22, 2007|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00520221||167886|
NCT00520234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSG-01|Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)|A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting|MSG-01|Mycoses Study Group|Yes|Completed|August 2007|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|222|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|August 21, 2007||No||No|March 15, 2011|https://clinicaltrials.gov/show/NCT00520234||167885|
NCT00525486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL prevention Nifedipine|Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery|Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery:A Prospective Interventional Study||The Baruch Padeh Medical Center, Poriya|No|Terminated|December 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 22, 2010|September 2, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00525486||167488|
NCT00525759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14707|Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer|A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer|ANZAC|Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|July 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||November 2010|November 3, 2010|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00525759||167467|
NCT00521131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00333|Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites|Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites||UCB Pharma|No|Completed|September 2002|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|453|||Both|12 Years|N/A|No|||September 2009|December 13, 2013|August 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00521131||167817|
NCT00526032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0564|Melanoma Detection by Oblique-Incidence Optical Spectroscopy|Melanoma Detection by Oblique-Incidence Optical Spectroscopy||M.D. Anderson Cancer Center|No|Completed|September 2006|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|490|||Both|N/A|N/A|No|Non-Probability Sample|Participants having lesions on the skin that may be cancerous.|January 2012|January 26, 2012|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526032||167446|
NCT00526045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2101|Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients|A Phase I Dose Escalation, Multi-center, Open-label Study of AUY922 Administered IV on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies Including Phase II Expansion Arms in Patients With Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer.||Novartis||Completed|July 2007|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|117|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|September 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00526045||167445|
NCT00526383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060219|Do Antidepressants Induce Metabolic Syndromes METADAP Study|Do Antidepressants Induce Metabolic Syndromes|METADAP|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2007|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|624|||Both|18 Years|70 Years|No|||September 2007|April 16, 2014|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526383||167420|
NCT00522691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHV120/07|Efficacy of Sacral Nerve Stimulation Before Definitive Implantation|Efficacy of Sacral Nerve Stimulation Before Definitive Implantation: a Multicenter Randomized, Double Blind, Crossover Trial|SNStest|University of Lausanne Hospitals|Yes|Withdrawn|September 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||June 2015|June 23, 2015|August 28, 2007||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00522691||167700|
NCT00522925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCO-C-008|A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension|Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension||Ligand Pharmaceuticals|No|Completed|August 2007|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|280|||Both|30 Years|80 Years|No|||September 2011|September 13, 2011|August 29, 2007|No|Yes||No|January 18, 2010|https://clinicaltrials.gov/show/NCT00522925||167682|
NCT00549861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gadovist001|Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR|Characterization of Irreversible Myocardial Injury in Dilated Forms of Cardiomyopathies by Gadobutrol (Gadovist®)-Enhanced Cardiovascular Magnetic Resonance Imaging||University of Calgary|Yes|Completed|September 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|N/A|N/A|No|||October 2011|October 2, 2011|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549861||165649|
NCT00537836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91544|ZK283197 for Treatment of Vasomotor Symptoms|A Double-blind, Randomized, Placebo and Active Controlled, Multicenter Study to Investigate Efficacy and Safety After Oral Administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and Placebo Once Daily for 8 Weeks in Postmenopausal Women With Hot Flushes||Bayer|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|116|||Female|45 Years|65 Years|No|||April 2015|April 8, 2015|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537836||166552|
NCT00537472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6106|Low Dose Spinal Bupivacaine for Total Knee Replacement and Recovery Room Wait Time|Low Dose Spinal Bupivacaine for Total Knee Arthroplasty and Recovery Room Wait Time||Queen's University|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|N/A|N/A|No|||April 2009|April 16, 2009|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537472||166580|
NCT00537212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0-001|Study of the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy|A Single-Center, Prospective, Single-Blinded, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy||Bagel, Jerry, M.D.|Yes|Completed|June 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||||||Both|18 Years|N/A|No|||February 2012|February 1, 2012|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537212||166600|
NCT00537225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1NR9197-2|Multifactor Risk Reduction for Optimal Management of PAD|Multifactor Risk Reduction for Optimal Management of PAD|VIGOR2|Palo Alto Veterans Institute for Research|Yes|Active, not recruiting|September 2006|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|300|||Both|50 Years|90 Years|No|||October 2014|October 27, 2014|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00537225||166599|
NCT00539032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA47|Immunology and Safety of Menactra® in Children in Saudi Arabia|Evaluation of the Response to a Single Dose of Menactra® in Children Aged 5 to 8 Years Who Had Previously Received Two Doses of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide Vaccine Before Age 2 Years in Saudi Arabia||Sanofi||Completed|September 2007|February 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|238|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|October 2, 2007|No|Yes||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00539032||166461|
NCT00538720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0425|Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)|Pilot Study to Detect and Assess the Effect of Vitamin D Replacement on Gland Size by 4DCT in Patients With Primary Hyperparathyroidism (PHPT)||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2007|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Both|21 Years|N/A|No|||September 2015|September 11, 2015|October 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00538720||166484|
NCT00538070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 DA 022276-01|A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia|The Effects of Glycine Transport Inhibition on Brain Glycine Concentration|Sarc|Massachusetts General Hospital|Yes|Completed|August 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|65 Years|No|||September 2012|September 17, 2012|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538070||166534|
NCT00539721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04937|A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)|A Randomized, Double-Blind, Double-Dummy, Dose-Ranging, Active- and Placebo-Controlled Study of Single-Dose Oral Rolapitant Monotherapy for the Prevention of Postoperative Nausea and Vomiting (PONV)||Merck Sharp & Dohme Corp.|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|619|||Female|18 Years|N/A|No|||October 2013|October 8, 2013|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539721||166411|
NCT00519402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-433|Outcomes of Partial Versus Complete Tonsillectomy for Obstructive Sleep Disordered Breathing|||The Cleveland Clinic||Withdrawn||||||N/A|Observational|N/A|||||||Both|5 Years|28 Years||||August 2007|March 26, 2008|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00519402||167949|
NCT00519415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13425678|Comparative Results of Maxillary Deficiency Treatment by Tongue Plate and Facemask in Growing Patients|This Study is to Apply the Tongue Force to Correct the Dentofacial Deformities||hahid Beheshti University of Medical Sciences|No|Completed|September 2007|November 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519415||167948|
NCT00525213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004834-33|Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate|A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Stable Methotrexate|ROBUST|OxyPharma|No|Completed|October 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|224|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525213||167509|
NCT00525187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onychomycosis|Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients|Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients||Vésale Hospital|No|Completed|December 2000|January 2005|Actual|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Cross-Sectional|||Actual|100|||Both|18 Years|80 Years|No|||August 2007|September 4, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00525187||167511|
NCT00525473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701077M|Correlation of Genetic Polymorphism of Azathioprine Metabolizing Enzymes and Correlation to Clinical Adverse Effects|Correlation of Genetic Polymorphism of Two Azathioprine Metabolizing Enzymes and Their Correlation to Clinical Adverse Effects||National Taiwan University Hospital|Yes|Completed|February 2007|January 2008|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|166|||Both|20 Years|N/A|No|Probability Sample|Chinese Han patients|January 2012|May 16, 2012|September 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00525473||167489|
NCT00525772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY/M1-121|Effect of Ciclesonide on Exercise Induced Bronchoconstriction|Effect of Ciclesonide on Exercise Induced Bronchoconstriction||McMaster University|Yes|Completed|November 2001|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|12 Years|30 Years|No|||October 2009|October 20, 2009|September 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00525772||167466|
NCT00525785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0769|Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)|A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach and Gastroesophageal Junction||M.D. Anderson Cancer Center|No|Completed|January 2004|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|September 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00525785||167465|
NCT00526058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDLc-A-US2-0406|(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol|Randomized Multicenter Crossover Study to Compare the Plasmat® Futura Heparin Induced Extracorporeal Lower Density Lipo-Protein (LDL) Precipitation (H.E.L.P.) Apheresis System to the Approved Secura System in the Reduction of LDL-c in Patients With Hypercholesterolemia|FUTURA|B. Braun Medical Inc.|No|Completed|August 2007|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|25 Years|70 Years|No|||July 2013|July 15, 2013|September 5, 2007|Yes|Yes||No|May 25, 2010|https://clinicaltrials.gov/show/NCT00526058||167444|
NCT00526071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAB-CL-205|Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study|Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease||Amicus Therapeutics|No|Completed|September 2007|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|65 Years|No|||December 2013|December 19, 2013|September 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526071||167443|
NCT00526084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709144|Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan|Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan||National Taiwan University Hospital|No|Recruiting|March 2007|December 2009|Anticipated|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||Anticipated|500|||Both|1 Year|18 Years|No|||December 2005|September 5, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00526084||167442|
NCT00526396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAD-1|STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study|Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer.|STAD-1|National Cancer Institute, Naples|No|Active, not recruiting|September 2007|July 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|70 Years|No|||April 2015|April 8, 2015|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526396||167419|
NCT00522704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCich-07-08-7403|Correlation Between Access Blood Flow and Extracorporeal Blood Flow|Correlation Between Access Blood Flow and Extracorporeal Blood Flow||Instituto Nacional de Cardiologia Ignacio Chavez|Yes|Recruiting|March 2008|June 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Chronic Kidney Dissease K-DIGO 5d in hemodialysis.|November 2014|November 4, 2014|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522704||167699|
NCT00522717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR009228-02|Enhancing Recovery After Cardiac Surgery|Enhancing Recovery After Cardiac Surgery||University of California, Los Angeles|Yes|Completed|July 2005|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|808|||Both|45 Years|N/A|No|||November 2015|November 30, 2015|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522717||167698|
NCT00522938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-2797-005|Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR-2797 and Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer||Chroma Therapeutics|Yes|Terminated|December 2007|April 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|2|||Both|18 Years|N/A|No|||February 2012|June 27, 2012|August 29, 2007|No|Yes|Very poor recruitment of patients to the study|No||https://clinicaltrials.gov/show/NCT00522938||167681|
NCT00536900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA012952|Clinical Trial of Abstinence-Linked Money Management|Abstinence-Linked Money Management||Yale University|Yes|Completed|June 2004|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|September 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00536900||166623|
NCT00536913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5897C00004|Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma|A 4-week, Open-label, Randomized, Multi-centre, Parallel-group Study Evaluating the Safety and Efficacy of 4 Actuations Symbicort® (Budesonide/Formoterol) HFA pMDI 40/2.25 μg Twice Daily, With and Without Spacer, in Children (6-11 Years) With Asthma|Spacer|AstraZeneca|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|6 Years|11 Years|No|||April 2012|April 5, 2012|September 26, 2007||||No|February 16, 2009|https://clinicaltrials.gov/show/NCT00536913||166622|
NCT00537875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5336-18-06-86|Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens|Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens||National Research Institute of Tuberculosis and Lung Disease, Iran|Yes|Completed|September 2007|September 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00537875||166549|
NCT00538369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008519|Combining Observational and Physiologic Sedation Assessment Tools|Combining Observational and Physiologic Sedation Assessment Tools|COST|Duke University|Yes|Terminated|November 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||October 2007|October 11, 2015|October 1, 2007|No|Yes|Lack of equipoise|No||https://clinicaltrials.gov/show/NCT00538369||166511|
NCT00538382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN02- PK/PD of artesunate|Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo|Phase I Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo||NICHD Global Network for Women's and Children's Health|Yes|Completed|May 2007|December 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|51|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|September 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00538382||166510|
NCT00537823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0182|Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement|Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases||Washington University School of Medicine|No|Terminated|June 2007|July 2011|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|September 27, 2007|Yes|Yes|Poor accrual.|No||https://clinicaltrials.gov/show/NCT00537823||166553|
NCT00538694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-00-05|Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia|A Randomized, Double-Blind, Phase III, Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae||Cubist Pharmaceuticals LLC||Completed|October 2000|September 2001|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||October 2007|July 16, 2015|October 1, 2007||||||https://clinicaltrials.gov/show/NCT00538694||166486|
NCT00538733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707009285|Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma|A Phase II Study of Thalidomide (THALOMID®), Clarithromycin (BIAXIN®), Lenalidomide(REVLIMID®), and Dexamethasone (DECADRON®) for Subjects With Newly Diagnosed Multiple Myeloma|T-BiRD|Weill Medical College of Cornell University|No|Recruiting|October 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2011|January 3, 2011|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538733||166483|
NCT00538746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1500|Effect of Increased Muscular Work During Different Weaning Strategies in Critically Ill Patients|||Università degli Studi dell'Insubria||Recruiting|February 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||||||Both|18 Years|N/A||||October 2007|October 2, 2007|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00538746||166482|
NCT00539045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610008782|Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction|Diagnostic Utility of Contrast Echocardiography for Detection of Left Ventricular Thrombi Post ST Elevation Myocardial Infarction||Weill Medical College of Cornell University|No|Recruiting|March 2007|March 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cross-sectional population of subjects enrolled following ST-elevation myocardial        infarction.|September 2010|September 24, 2010|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539045||166460|
NCT00539305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29975-A|Hormone and Information Processing Study|Testosterone Supplementation in Men With MCI|HIP|University of Washington|Yes|Completed|July 2009|May 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Male|60 Years|90 Years|No|||July 2014|July 10, 2014|October 3, 2007||No||No|March 15, 2013|https://clinicaltrials.gov/show/NCT00539305||166441|
NCT00539318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS0733|Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers|Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|August 2007|July 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|GI cancer|August 2009|August 13, 2009|October 2, 2007||No|Low Recruitment|No||https://clinicaltrials.gov/show/NCT00539318||166440|
NCT00540046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Post Abortion Copper T IUD|Immediate vs. Delayed Insertion of Copper T 380A IUD After Termination of Pregnancy Over 12-weeks Gestation|Immediate vs. Delayed Post-abortal Copper T 380A IUD Insertion in Cases Over 12 Weeks of Gestation||New York University School of Medicine|No|Completed|April 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|215|||Female|16 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 23, 2015|October 4, 2007||No||No|January 1, 2015|https://clinicaltrials.gov/show/NCT00540046||166386|IUD presence not always confirmed by a provider at 6-month visit but self-reported.Study not powered to detect a difference in expulsion rates due to prohibitively high sample size.Very high-risk population.
NCT00540059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zx-002|Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial|Quality Assurance Project in Patients With Advanced Prostate Carcinoma - Evaluation of Tolerability, Quality of Life and Usage of Zoladex 10,8 SafeSystem||AstraZeneca||Completed|June 2005|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Actual|1950|||Male|N/A|N/A|No|||August 2007|October 4, 2007|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00540059||166385|
NCT00524602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEREOTAXIS study|The Use of Remote Magnetic Navigation in Catheter Ablation of Heart Arrythmia|A Nonrandomized Observertionel Study That Will Show the Utility and the Safety by Using the Remote Magnetic Navigation of Ablationcatheters and the Stereotaxis Equipment||Rigshospitalet, Denmark|No|Recruiting|June 2007|June 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|N/A|N/A|No|||August 2007|August 10, 2011|August 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00524602||167554|
NCT00524940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC37|Trial to Describe the Safety and Immunogenicity of Fluzone®|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)||Sanofi|No|Completed|August 2007|December 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 17, 2014|September 4, 2007|Yes|Yes||No|February 24, 2009|https://clinicaltrials.gov/show/NCT00524940||167529|
NCT00525811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK-2005-0111|Development of a Web-Based Interactive Patient Decision Aid for the Treatment of Acute Low Back Pain and Depression|||University Hospital Freiburg|Yes|Completed|June 2007|May 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|741|||Both|18 Years|65 Years|No|||June 2008|June 23, 2008|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00525811||167463|
NCT00525499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-J9-201|A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Dose-Ranging Clinical Study to Evaluate the Safety and Efficacy of ASC-J9 Cream Applied Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris||AndroScience Corp|No|Completed|August 2007|July 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|186|||Both|12 Years|N/A|No|||November 2011|November 16, 2011|August 31, 2007|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00525499||167487|
NCT00525512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.368|Tiotropium In Exercise|A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)||Boehringer Ingelheim||Completed|August 2007|||June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|519|||Both|40 Years|N/A|No|||September 2013|November 27, 2013|September 3, 2007||||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00525512||167486|
NCT00525798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC021A2303|A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D||Nordic Bioscience A/S|Yes|Completed|March 2007|November 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4665|||Female|55 Years|85 Years|No|||October 2012|October 22, 2012|September 5, 2007|Yes|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT00525798||167464|
NCT00526110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0290|Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients|A Phase I/II Study of Docetaxel, 5-Fluorouracil and Oxaliplatin (D-FOX) in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction||M.D. Anderson Cancer Center|No|Completed|August 2004|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|September 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526110||167440|
NCT00526097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122.56|Dulcolax vs Placebo in Functional Constipation|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks Treatment With Bisacodyl (Dulcolax) Tablets 10mg Administered Orally, Once Daily, in Patients With Functional Constipation.||Boehringer Ingelheim||Completed|September 2007|||June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|368|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|September 5, 2007||||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00526097||167441|
NCT00526409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-AR-N-2005|LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia|LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia|LAL-AR-N-2005|PETHEMA Foundation|Yes|Completed|June 2005|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|16 Years|No|||October 2014|October 27, 2014|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526409||167418|
NCT00522353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 20085|Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults|Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults.||University of Calgary|No|Completed|January 2007|August 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2008|May 21, 2008|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00522353||167724|
NCT00523523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03HDo51624-01A2|Training the Arm and Hand After Stroke Using Auditory Rhythm Cues|Auditory Rhythm Cues + Task Practice: Effects on UE Motor Function Post-stroke||University of Florida|No|Completed|August 2007|June 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|21 Years|95 Years|No|||June 2010|February 3, 2012|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523523||167636|
NCT00523822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0524070092|Sacroiliac Orthopedic Blocking and Cervical Spine Function|||Logan College of Chiropractic||Completed||||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|20 Years|30 Years|Accepts Healthy Volunteers|||August 2008|August 1, 2008|August 31, 2007||||No||https://clinicaltrials.gov/show/NCT00523822||167613|
NCT00537498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-UK.2/AVK|Urokinase Therapy in Diabetic Foot Syndrome|Phase II Study of Urokinase Therapy for Treatment of Angiopathic or Angioneuropathic Diabetic Foot Syndrome||medac GmbH|No|Completed|February 2002|December 2006|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||September 2007|March 24, 2010|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00537498||166578|
NCT00537888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYH-CMU|Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week|Diagnosis of Pulmonary Candidiasis||Capital Medical University|Yes|Recruiting|September 2007|December 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|14 Years|85 Years|No|||July 2009|December 13, 2010|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00537888||166548|
NCT00537901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #2041-082|First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study|First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study||King Faisal Specialist Hospital & Research Center||Completed|October 2007|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|N/A|No|||December 2015|December 16, 2015|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00537901||166547|
NCT00538707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1382|Effect of Mental Stress on Platelet Function|Effect of Mental Stress on Platelet Function in Healthy Subjects||University of Zurich|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|32|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||February 2010|February 9, 2010|October 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00538707||166485|
NCT00539019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11-17-03-EE|Quantification and Derivation of Metabolic Needs in Children During Burn Rehabilitation|||Shriners Hospitals for Children||Withdrawn|October 2006|||||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|5 Years|18 Years|No|Probability Sample|burned, pediatrics pooled from inpatient acute population|June 2012|June 18, 2012|October 1, 2007||No|indirect calorimetry no longer employed at the institution; calorimeter is not    accurate/reliable|No||https://clinicaltrials.gov/show/NCT00539019||166462|
NCT00539071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070580|High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone|High Dose Risperidone Consta for Patients With Schizophrenia With Unsatisfactory Response to Standard Dose Risperidone or Long-Acting Injectable||Vanderbilt University|No|Recruiting|April 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||November 2010|November 1, 2010|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539071||166459|
NCT00539357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-08-121-02|A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder|||University of California, Los Angeles|Yes|Completed|August 2005|March 2006|Actual|||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||October 2007|October 2, 2007|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00539357||166437|
NCT00539370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070213|Human Samples and Data Repository|Laboratory of Immunology/National Eye Institute Repository||National Institutes of Health Clinical Center (CC)||Completed|August 2007|||||N/A|Observational|Time Perspective: Prospective||||0|||Both|N/A|N/A|No|||June 2012|June 13, 2012|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00539370||166436|
NCT00539331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00040|Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients|A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of Pac/Carb Alone and in Combination With AZD2171 and Pac/Carb||AstraZeneca|No|Terminated|September 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||May 2011|May 30, 2011|October 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539331||166439|
NCT00539344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG1005-CLN-01|A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma|A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma||Angiochem Inc|No|Completed|October 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|63|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|October 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00539344||166438|
NCT00540436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB107816|Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension|Study AMB107816, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open-Label Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A -<Classification: Exploratory and Confirmatory Clinical Trial>||GlaxoSmithKline||Completed|August 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|October 5, 2007||No||No|August 10, 2009|https://clinicaltrials.gov/show/NCT00540436||166356|
NCT00535886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM6222|The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study|The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study||Children's Hospital & Research Center Oakland|No|Completed|November 2005|April 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|15|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|May 5, 2008|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00535886||166700|
NCT00524953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UV-GVHD - HMO-CTIL|Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT|Phase I - Clinical Trial to Assess Safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation||Hadassah Medical Organization|No|Withdrawn|September 2007|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|14 Years|70 Years|No|||August 2007|June 10, 2015|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00524953||167528|
NCT00524966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Harmonic|Randomized Controlled Trial of Bipolar Versus Ultrasonic Hemostasis Techniques in Thyroidectomy|Randomized Controlled Trial of Bipolar Versus Ultrasonic Hemostasis Techniques in Thyroidectomy||University of California, San Francisco|Yes|Completed|August 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|July 7, 2011|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524966||167527|
NCT00526448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005940-99|Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients|Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4|PERICO|Hospital Carlos III, Madrid|Yes|Recruiting|June 2007|February 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Both|18 Years|75 Years|No|||January 2009|January 28, 2009|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526448||167415|
NCT00522093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJ-100|Efficacy and Safety of TJ-100 in the Treatment of Chronic Constipation|||Showa Inan General Hospital|Yes|Completed|August 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|89 Years|No|||October 2009|August 21, 2011|August 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00522093||167744|
NCT00525525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07105|Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma|A Phase II Study of Bevacizumab Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation|AVF4120s|University of California, San Francisco|Yes|Completed|September 2007|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|September 4, 2007|Yes|Yes||No|October 28, 2014|https://clinicaltrials.gov/show/NCT00525525||167485|
NCT00525538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCMFRO-07|Evaluation Conformal Radiotherapy for Gynecologic Cancer|||Istanbul University|No|Completed|August 2006|||||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|||||||Female|N/A|N/A||||August 2007|September 4, 2007|September 4, 2007||||No||https://clinicaltrials.gov/show/NCT00525538||167484|
NCT00526422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101884|DPBRN Assessment of Caries Diagnosis & Caries Treatment|Assessment of Caries Diagnosis & Caries Treatment||Dental Practice-Based Research Network|No|Completed|February 2006|January 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|532|||Both|22 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The questionnaire was administered to all enrolled DPBRN dentist        practitioner-investigators, defined as those who had comptled a DPBRN Enrollment        Questionnaire who were 22 years or older and do at least some restorative dentistry in        their practice.|June 2011|June 14, 2011|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526422||167417|
NCT00522054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|587-03244|Tai Chi for Patients With Rheumatoid Arthritis|Tai Chi for Patients With Rheumatoid Arthritis: A Quantitative and Qualitative Study||Diakonhjemmet Hospital|No|Completed|September 2004|March 2005|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|70 Years|No|||August 2007|August 27, 2007|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00522054||167747|
NCT00522379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0921|Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch|A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease||UCB Pharma|No|Completed|July 2007|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|514|||Both|30 Years|N/A|No|||December 2012|October 17, 2014|August 28, 2007|Yes|Yes||No|July 3, 2012|https://clinicaltrials.gov/show/NCT00522379||167723|
NCT00522392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00521|Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone|Randomized Phase III Trial of Consolidation Therapy With Bortezomib (Velcade®)-Lenalidomide (Revlimid®) -Dexamethasone (VRD) Versus Bortezomib (Velcade®)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen||National Cancer Institute (NCI)|Yes|Terminated|September 2007|July 2014|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||May 2015|June 23, 2015|August 28, 2007|Yes|Yes|Slow accrual|No|March 5, 2015|https://clinicaltrials.gov/show/NCT00522392||167722|
NCT00523211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04405|Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)|Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E3)||Merck Sharp & Dohme Corp.|Yes|Completed|July 2007|March 2011|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|506|||Both|16 Years|N/A|No|||September 2015|September 24, 2015|August 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00523211||167660|
NCT00523224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-002|ACPs Combined With CABG in Patients With CHF|A Study of Combined Coronary Artery Bypass Grafting (CABG) and Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Congestive Heart Failure Due to Ischemic Heart Disease||TheraVitae Ltd.|Yes|Recruiting|January 2006|September 2007|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|80 Years|No|||May 2007|August 30, 2007|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523224||167659|
NCT00523848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000563183|Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma|Phase II Study of VDT (VELCADE, Doxil® and Thalidomide) as Frontline Therapy for Patients With Previously Untreated Multiple Myeloma (MM)||Roswell Park Cancer Institute|Yes|Completed|June 2006|October 2012|Actual|September 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|August 31, 2007|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00523848||167611|
NCT00537849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU-PC-002|Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate 500 (SB-500) System in Canada|Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate 500 (SB-500) System in Canada||SonaCare Medical|No|Withdrawn|December 2007|March 2008|Anticipated|March 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|40 Years|80 Years|No|||April 2008|September 28, 2009|September 27, 2007||No|Sponsor withdrew request to conduct study|No||https://clinicaltrials.gov/show/NCT00537849||166551|
NCT00537862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AKR02|Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients|Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients ; A Prospective, Open Label, Multi-center Study||Novartis||Completed|May 2006|||February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|200|||Both|18 Years|65 Years||||November 2011|November 1, 2011|October 1, 2007||||No||https://clinicaltrials.gov/show/NCT00537862||166550|
NCT00538083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Griffin Hospital IRB 2005-12|Cocoa and Endothelial Function in Adults With Elevated BMI|Dark Chocolate and Cocoa Ingestion and Endothelial Function: A Randomized, Placebo Controlled, Cross-Over Trial|Chocolate|Griffin Hospital|No|Completed|August 2005|May 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|45|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||September 2007|September 28, 2007|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00538083||166533|
NCT00538096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP137|A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma|A Phase I, Multicenter, Open-Label, Single-Arm, Dose-Escalation, Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 in Adults With B-Cell Non-Hodgkin's Lymphoma Not Eligible for Curative Therapy||MedImmune LLC|No|Withdrawn|September 2007|May 2010|Anticipated|March 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|60 Years|No|||September 2008|September 4, 2008|September 28, 2007|No|Yes|Replacing this trial with a new trial.|No||https://clinicaltrials.gov/show/NCT00538096||166532|
NCT00538109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #2071-008|An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase||King Faisal Specialist Hospital & Research Center||Completed|October 2007|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||December 2015|December 15, 2015|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538109||166531|
NCT00538395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #981-020|Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer|||King Faisal Specialist Hospital & Research Center||Active, not recruiting|September 2007|September 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||December 2011|December 11, 2011|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538395||166509|
NCT00538408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0041|Whole Body Magnetic Resonance Angiography in Ischemic Patients|Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia||Copenhagen University Hospital at Herlev|Yes|Recruiting|September 2007|January 2010|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|||February 2009|February 1, 2009|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538408||166508|
NCT00539084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP40|A Study to Assess the Safety and Efficacy of a Microneedle Device for Local Anesthesia|A Controlled Comparative Pilot Study to Assess the Safety and Efficacy of the MicronJet Microneedle Device Following Intradermal Injection of Lidocaine for Local Anesthesia||NanoPass Technologies Ltd|No|Completed|October 2007|November 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|May 8, 2013|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00539084||166458|
NCT00539383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG1005-CLN-02|A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer|A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer||Angiochem Inc|No|Completed|October 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|56|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|October 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00539383||166435|
NCT00539396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-101|A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine|A Phase 2 Randomized, Open Label, Multi-Center Study of the Use of Prandial Inhaled Technosphere Insulin in Combination With Basal Subcutaneous Lantus as Basal Insulin Versus Prandial Subcutaneous NovoRapid in Combination With Basal Subcutaneous Lantus Insulin in Subjects With Type 1 Diabetes Mellitus||Mannkind Corporation|No|Completed|March 2005|December 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|110|||Both|18 Years|80 Years|No|||October 2009|October 12, 2009|October 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00539396||166434|
NCT00540072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-CAP-00-08|Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae|||Cubist Pharmaceuticals LLC||Completed|July 2001|February 2002|Actual|February 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|||||||Both|18 Years|N/A||||October 2007|July 16, 2015|October 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540072||166384|
NCT00539734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/362-003-2|Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration|Electrophysiologic Changes After Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration||Prince of Songkla University|Yes|Completed|August 2007|February 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|45 Years|N/A|No|||April 2011|April 11, 2011|October 2, 2007||No||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00539734||166410|Small number of participants
NCT00524979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Voice -200CTIL|Digital Voice Analysis in Patients With Schizophrenia|Digital Voice Analysis in Patients With Schizophrenia||BeerYaakov Mental Health Center|Yes|Completed|October 2007|November 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Schizophrenic patients          -  Other mental disease patients          -  Healthy people|May 2008|May 15, 2008|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00524979||167526|
NCT00525551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-OAS1|Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis|Acetylcystein Vid Stapedotomi||Karolinska University Hospital|No|Completed|September 2007|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|September 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00525551||167483|
NCT00526461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000563238|Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer|A Phase I Study Light Dose for Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-Small Cell Carcinoma in Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study||Roswell Park Cancer Institute|Yes|Completed|February 2004|April 2014|Actual|June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|September 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00526461||167414|
NCT00526123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341.26|Dialysis Catheter Comparative Clinical Trial|A Randomized, Open-label Comparison of the Performance and Longevity of a Split-tip Versus a Symmetric Tip Hemodialysis||Tyco Healthcare Group|No|Completed|September 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|599|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|September 5, 2007||No||No|August 30, 2012|https://clinicaltrials.gov/show/NCT00526123||167439|
NCT00526136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235-SR-202-AF|Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study|Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study||Cardiome Pharma|No|Completed|March 2007|July 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|735|||Both|18 Years|85 Years|No|||December 2008|December 17, 2008|September 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00526136||167438|
NCT00522405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-39/29.1.2007|Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma|||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|October 2007|October 2014|Anticipated|August 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|12 Years|80 Years|No|||August 2007|July 13, 2012|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00522405||167721|
NCT00522067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P4|Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.|A Phase II, Open Label, Uncontrolled, Multi-Center Study to Support Annual Strain Update and to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects Aged 18-64 Years Affected by Chronic Diseases||Novartis|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Both|18 Years|64 Years|No|||January 2012|January 2, 2012|August 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00522067||167746|
NCT00522080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-CIR-07|Screening for Hip and Knee Osteoarthritis in the General Population: Predictive Value of a Questionnaire and Prevalence Estimates|Screening for Hip and Knee Osteoarthritis in the General Population: Predictive Value of a Questionnaire and Prevalence Estimates||Centre Hospitalier Universitaire de Nice|Yes|Terminated|March 2005|December 2005|Actual|||N/A|Observational|Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Cross-Sectional|||||||Both|40 Years|75 Years|Accepts Healthy Volunteers|||August 2007|August 27, 2007|August 27, 2007|||terminated study|No||https://clinicaltrials.gov/show/NCT00522080||167745|
NCT00523237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAL-eve study|RAL-eve Study: Raltegravir Substitution Study|Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study||Stanford University|No|Completed|October 2007|December 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||October 2011|October 31, 2011|August 29, 2007|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00523237||167658|
NCT00523250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR102-CS201|Ocular Hypotensive Efficacy of AR-102|A Phase II, First-in-human Dose-escalation, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure||Aerie Pharmaceuticals|No|Completed|September 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|82|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|August 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00523250||167657|
NCT00523536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|486|Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk|Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Evaluation of a Navigator-Nurse Care Team on Hypertension and Cardiovascular Disease Risk||Denver Health and Hospital Authority|No|Completed|May 2007|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|800|||Both|21 Years|74 Years|No|||April 2009|August 29, 2013|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523536||167635|
NCT00523549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489AUS01|The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction|A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction||Novartis|No|Completed|November 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|229|||Both|45 Years|N/A|No|||April 2012|April 19, 2012|August 30, 2007|Yes|Yes||No|December 6, 2010|https://clinicaltrials.gov/show/NCT00523549||167634|
NCT00524459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 75506|Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery|Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Locally Advanced Operable Breast Cancer||Roswell Park Cancer Institute|Yes|Terminated|May 2007|||August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|6|||Female|N/A|64 Years|No|||August 2014|August 21, 2014|August 31, 2007|Yes|Yes|Terminated by sponsor due to lack of funding|No|August 6, 2014|https://clinicaltrials.gov/show/NCT00524459||167565|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.
NCT00537524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P6|Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years|A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years||Novartis|Yes|Completed|September 2007|May 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|471|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537524||166576|
NCT00537537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AIN01|To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)|An Open Label, Response Adaptive Study of Telbivudine in Adults With HBeAg Positive Compensated CHB||Novartis||Completed|August 2007|||June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|N/A||||May 2012|May 3, 2012|September 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537537||166575|
NCT00537550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL2000|Adult ALL Treatment at Diagnosis|GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis|LAL2000|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|July 2000|June 2006|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|14 Years|60 Years|No|||September 2007|September 28, 2007|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00537550||166574|
NCT00538135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064027/Z/01/Z|BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder|BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder|BOSCOT|University of Aberdeen|No|Completed|February 2002|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|65 Years|No|||September 2007|September 29, 2007|September 29, 2007||||No||https://clinicaltrials.gov/show/NCT00538135||166529|
NCT00538148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4014|Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD|A Multicenter, Multinational, Randomized, DB Controlled Study of the Efficacy & Safety of Oral Telithromycin 800 mg Once QD for 5 Days vs Azithromycin in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD.||Sanofi|No|Completed|November 2002|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|668|||Both|45 Years|N/A|No|||February 2012|February 15, 2012|October 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00538148||166528|
NCT00538122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070591|Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment|Evaluating the Risks of Arrhythmia and Sudden Death Associated With Antipsychotic Drugs by Assessing the T Wave Abnormalities in the Holter Electrocardiogram||Vanderbilt University|No|Completed|July 2007|September 2008|Actual|July 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|65 Years|No|Non-Probability Sample|Adults diagnosed wtih schizophrenia, bipolar or schizoaffective disorder|January 2009|January 23, 2009|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538122||166530|
NCT00538421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-07294b (REK)|Opioid-potentiated Volative Anaesthetic Vs. Remifentanil And Propofol During Abdominal Aortic Aneurysm Surgery|Opioid-potentiated Volative Anaesthetic(Sevoflurane)Compared to Remifentanil and Propofol During Abdominal Aortic Aneurysm Surgery|ABSENT|Sykehuset i Vestfold HF|No|Completed|March 2008|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|193|||Both|18 Years|N/A|No|||March 2013|March 8, 2013|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538421||166507|
NCT00538434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Res-05-0002|Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years|An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years||Teva Pharmaceutical Industries|Yes|Completed|February 2008|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|226|||Both|5 Years|18 Years|No|||August 2013|August 16, 2013|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538434||166506|
NCT00538447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #2051-056|Prospective Database for Chronic Myelogenous Leukemia|||King Faisal Specialist Hospital & Research Center||Active, not recruiting|June 2007|June 2020|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|2000|||Both|N/A|N/A|No|||December 2011|December 11, 2011|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538447||166505|
NCT00539097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-04-23-05|Evaluation Perioperative Nutrition on Donor Site Healing in Patients Undergoing Reconstructive Burn Surg|||Shriners Hospitals for Children||Terminated|June 2005|||October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|6 Years|24 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|October 1, 2007||No|change in donor site care protocol; donor site healing is a study endpoint|No||https://clinicaltrials.gov/show/NCT00539097||166457|
NCT00539110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04-07-01|Differential Effects of Zolpidem Versus Ramelteon in Burned Children|Differential Effects of Zolpidem Versus Ramelteon on Nocturnal Sleep in Pediatric Burn Patients: A Prospective, Randomized Crossover Trial With Polysomnographic Recordings|Sleep3|Shriners Hospitals for Children|Yes|Completed|December 2009|November 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|3 Years|18 Years|No|||September 2014|September 13, 2014|October 2, 2007||No||No|May 25, 2014|https://clinicaltrials.gov/show/NCT00539110||166456|
NCT00539409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-66 Main|Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus|Effects on Diabetic Metabolic Integrity With Treatment of Pulsatile Intravenous Insulin Therapy as Evidenced by Monitoring of Diabetic Complications.||Florida Atlantic University|Yes|Terminated|November 2006|June 2012|Anticipated|November 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|750|||Both|21 Years|85 Years|No|||August 2009|August 25, 2009|October 3, 2007||No|Administrative|No||https://clinicaltrials.gov/show/NCT00539409||166433|
NCT00539422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Role of cytochrome P450 2D6|Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases|Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism, Oxidative Stress and Ferretin in Benign and Malignant Breast Diseases||Mansoura University|No|Completed|January 2006|April 2007|Actual|||N/A|Observational|Observational Model: Case Control, Primary Purpose: Screening, Time Perspective: Cross-Sectional||3|||||Female|33 Years|63 Years|Accepts Healthy Volunteers|||October 2007|October 3, 2007|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00539422||166432|
NCT00540085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003005-27|Pharmacodynamic Trial on Rocuronium in Obese Patients|Pharmacodynamic Trial on Rocuronium in Obese Patients||Rigshospitalet, Denmark|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|51|||Both|18 Years|65 Years|No|||October 2009|October 15, 2009|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540085||166383|
NCT00540423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108109|Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) -A Multicenter Study in Subjects With Chronic ITP Receiving a Double-Blind, Placebo-Controlled, Short-Term Treatment Followed by an Open-Label, Uncontrolled, Long-Term Treatment- <Phase II/III Study>||GlaxoSmithKline|No|Completed|September 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|N/A|No|||March 2011|March 29, 2011|October 5, 2007||No||No|August 11, 2009|https://clinicaltrials.gov/show/NCT00540423||166357|
NCT00539747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908005|Making Sense of a Positive Genetic Test Result for Huntington Disease|Meaning Making Among Asymptomatic Individuals With a Positive Presymptomatic Genetic Test Result for Huntington Disease||National Institutes of Health Clinical Center (CC)||Completed|October 2007|August 2008||||N/A|Observational|Time Perspective: Retrospective||||50|||Both|18 Years|N/A|No|||August 2008|September 26, 2015|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00539747||166409|
NCT00539760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110394|A Phase I Rheumatoid Arthritis Study in Healthy Volunteers|A Phase I, Randomized, Observer- and Subject-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1827771 in Healthy Volunteers||GlaxoSmithKline|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 23, 2012|October 4, 2007||No||||https://clinicaltrials.gov/show/NCT00539760||166408|
NCT00526149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-90061|BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors|Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|July 2007|||September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|76|||Both|18 Years|N/A|No|||October 2013|October 4, 2013|September 5, 2007||||No||https://clinicaltrials.gov/show/NCT00526149||167437|
NCT00526435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-AAMC-0975|Evaluation of Walk With Ease in Arthritis|Evaluation of the Walk With Ease Program Among People With Arthritis|WWE|Centers for Disease Control and Prevention|No|Completed|October 2007|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|468|||Both|18 Years|90 Years|No|||March 2011|March 23, 2011|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526435||167416|
NCT00522756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-05-045|Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy|Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy (PARACHUTE) - Pilot Study|PARACHUTE|McGill University Health Center|No|Recruiting|May 2006|March 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|August 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00522756||167695|
NCT00522106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRADIT-01|The Effectiveness of Behavioral Graded Activity in Patients With Osteoarthritis of the Hip and/or Knee|The Effectiveness of Behavioral Graded Activity in Patients With Osteoarthritis of the Hip and/or Knee: a Randomized Controlled Trial|GRADIT|Netherlands Instititute for Health Services Research|No|Active, not recruiting|May 2001|May 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|50 Years|80 Years|No|||August 2007|August 28, 2007|August 28, 2007||||No||https://clinicaltrials.gov/show/NCT00522106||167743|
NCT00522431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOR01C|A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone|An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males||Prostrakan Pharmaceuticals||Completed|August 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Male|18 Years|75 Years|No|||January 2014|January 24, 2014|August 28, 2007|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT00522431||167719|
NCT00522743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc073243ctil|Growth and Metabolic Response to GH and GnRHa Treatment Versus GH Alone in Boys Born SGA.|Two Arms, Open, Controlled, Prospective, Intervention Study to Evaluate the Growth and Metabolic Response to Growth Hormone and Gonadotropin-releasing Hormone Agonist Treatment Versus Growth Hormone Alone in Boys Born SGA||Rabin Medical Center|No|Completed|May 2005|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Male|9 Years|13 Years|No|||July 2010|July 13, 2010|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522743||167696|
NCT00522730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELLIFA-02|Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure|Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition.|SELLIFA|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|August 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|85 Years|No|||September 2009|September 2, 2009|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522730||167697|
NCT00522951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91569|SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study|Multi-center, Randomized, Controlled, Single-blind, Intra-individual Comparisons of 2 Dose of Gadobutrol 1.0 Molar and Gadoteridol (ProHance) Crossover Studies With Corresponding Blinded Image Evaluation Following Multiple Injections of 0.1 mmol/kg bw of Gadobutrol and Gadoteridol in Patients With Known or Suspected Brain Metastasis||Bayer|No|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|165|||Both|20 Years|N/A|No|||October 2013|October 22, 2013|August 29, 2007||No||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00522951||167680|
NCT00523861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P6281|Moderate Alcohol Consumption, Glucose Metabolism and Gastric Emptying|The Effect of Moderate Alcohol Consumption on Glucose Metabolism and Gastric Emptying in Healthy, Lean and Overweight Young Men||TNO||Completed|May 2005|June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|||Actual|17|||Male|18 Years|40 Years||||August 2007|September 10, 2007|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523861||167610|
NCT00524160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR001981|A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis|Open-Label Study To Assess The Effect On Pain Control Of Durogesic (Fentanyl Transdermic Therapeutic System) Treatment In Subjects With Rheumatoid Arthritis Or Osteoarthritis Of The Knee Or Hip.||Janssen Pharmaceutica N.V., Belgium||Completed|July 2001|December 2002|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|264|||Both|18 Years|N/A|No|||November 2010|November 24, 2010|August 31, 2007||||No||https://clinicaltrials.gov/show/NCT00524160||167588|
NCT00524173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070207|Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B|Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B||National Institutes of Health Clinical Center (CC)||Recruiting|August 2007|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|August 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00524173||167587|
NCT00537576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV-005|Safety Study of Lactobacillus Administered Vaginally to Healthy Women|A Phase I Study of the Safety of LACTIN-V Administered Vaginally to Healthy Women||Osel, Inc.|No|Completed|November 2007|April 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|12|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|May 6, 2009|September 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537576||166572|
NCT00537927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05-28|LACH-Trial: LAparoscopic Correction of Hernia|The Effect of Mesh Fixation Technique on Postoperative Pain in Laparoscopic Correction of Incisional and Ventral Abdominal Wall Hernias.|LACH|Ziekenhuisgroep Twente|Yes|Completed|August 2005|January 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|215|||Both|18 Years|80 Years|No|||January 2009|February 17, 2009|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00537927||166545|
NCT00537940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081143|Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures|A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.||Pfizer|Yes|Completed|February 2008|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|484|||Both|18 Years|80 Years|No|||November 2014|November 12, 2014|September 28, 2007|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00537940||166544|
NCT00538460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-085|Evaluate the Effectiveness and Cost of Stress Cardiac Magnetic Resonance Imaging (MRI) for Non-invasive Evaluation of Lesions Discovered on Computed Tomography Angiography (CCTA)|Dual-Source CT and STress Cardiac Magnetic Resonance Assessment in the Triage of Patients With Suspected Acute Coronary Syndromes (D-STAT)|DSTAT|William Beaumont Hospitals|Yes|Terminated|September 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers over 18 years of age; both genders|February 2010|February 26, 2010|October 1, 2007||No|Lack of staff and funding.|No||https://clinicaltrials.gov/show/NCT00538460||166504|
NCT00538759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060198|Radiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis|RADiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis|RADAR|Minneapolis Heart Institute Foundation|Yes|Terminated|September 2007|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|75 Years|N/A|No|||May 2013|May 9, 2013|October 1, 2007|Yes|Yes|Funding shortfall|No||https://clinicaltrials.gov/show/NCT00538759||166481|
NCT00538798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070082|PET Imaging of Brain mGluR5 Receptors Using [18F]SP203|PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 and [11C]SP203||National Institutes of Health Clinical Center (CC)||Completed|September 2007|March 2015|Actual|||N/A|Interventional|Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|October 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00538798||166478|
NCT00539123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DA014718-05A1|Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia|Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia||Yale University|Yes|Recruiting|September 2007|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|65 Years|No|||June 2009|June 3, 2009|October 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00539123||166455|
NCT00539136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS-110300|A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers|An Open-label, Single-dose, Non-randomized, Balanced Design Three-way Cross-over Study to Examine the Variability in Absorption of GSK561679 Using Gamma Scintigraphy, PillCam™ SB Capsule and the Acoustic Vest in Healthy Males Volunteers||GlaxoSmithKline||Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|October 3, 2007||||||https://clinicaltrials.gov/show/NCT00539136||166454|
NCT00539435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-124|Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes|Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes||Florida Atlantic University|Yes|Terminated|September 2007|September 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|21 Years|85 Years|No|||August 2009|August 25, 2009|October 3, 2007||No|Administrative|No||https://clinicaltrials.gov/show/NCT00539435||166431|
NCT00539773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2011-073|Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder|Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder||King Faisal Specialist Hospital & Research Center||Completed|September 2007|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||December 2015|December 16, 2015|October 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539773||166407|
NCT00539786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-03-071|The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD|Clinical Usefulness of Proton Pump Inhibitor Test for Identifying Gastroesophageal Reflux Disease in Patients With Extraesophageal Symptoms||Samsung Medical Center||Recruiting|March 2006|||April 2011|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 14, 2014|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00539786||166406|
NCT00540124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11658|Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Pilot Study to Evaluate the Efficacy and Safety of Tadalafil and Tamsulosin Once-a-Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|151|||Male|45 Years|N/A|No|||November 2010|November 18, 2010|October 3, 2007|Yes|Yes||No|June 1, 2009|https://clinicaltrials.gov/show/NCT00540124||166380|
NCT00540462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes01|Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus|Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus|T2DM|Min-Sheng General Hospital|Yes|Recruiting|August 2007|December 2008|Anticipated|August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|30 Years|60 Years|No|||October 2008|November 13, 2008|October 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00540462||166354|
NCT00526162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112|ConsultaTM CRT-D Clinical Evaluation Study|Clinical Study to Evaluate System Safety and Clinical Performance of the ConsultaTM CRT-D Device||Medtronic Bakken Research Center|No|Completed|October 2007|October 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|September 6, 2007||No||No|February 6, 2009|https://clinicaltrials.gov/show/NCT00526162||167436|
NCT00526175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-BR/2001|LAL-BR/2001: Study Treatment to Low Risk ALL|LAL-BR/2001: Study Treatment to Low Risk ALL||PETHEMA Foundation|Yes|Completed|June 2001|December 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|N/A|15 Years|No|||January 2016|January 16, 2016|September 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00526175||167435|
NCT00522119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1403|Analysis of Genes That Predispose People to Develop High Blood Pressure|Genetic and Functional Analyses of Chromosome 1 Hypertension Susceptibility||National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|August 2003|July 2006|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2007|July 15, 2008|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00522119||167742|
NCT00522418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-100|Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients|An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy||Cyberonics, Inc.|Yes|Terminated|February 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2012|January 9, 2015|August 27, 2007|Yes|Yes|Insufficient enrollment|No|April 2, 2010|https://clinicaltrials.gov/show/NCT00522418||167720|This study was terminated as a result of a decision by Cyberonics, Inc. The decision to terminate the study was primarily due to insufficient enrollment. The decision was not the result of a safety or efficacy signal.
NCT00523263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaDa-trial|Dacron vs Dardik for Fem-Pop Bypass|Heparin Bonded and Collagen Coated Polyester or Human Umbilical Vein for Femoropopliteal Bypass: a Prospective Randomised Multicentre Trial.|DaDa|Radboud University|No|Completed|January 1996|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|31 Years|89 Years|No|||August 2007|August 30, 2007|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523263||167656|
NCT00522964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2RR024130|Educational Intervention on Weight Management in Chinese-American Children|Educational Intervention on Weight Management in Chinese American Children|ABC|University of California, San Francisco|Yes|Completed|May 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|80|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||August 2009|August 16, 2009|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522964||167679|
NCT00523575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-3-098|Nutritional Intervention in Hip Fracture Patients|Effectiveness and Cost-effectiveness of Nutritional Screening and Intervention in Elderly Subjects After Hip Fracture||Maastricht University Medical Center|Yes|Completed|August 2007|June 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|55 Years|N/A|No|||July 2011|July 19, 2011|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00523575||167632|
NCT00523874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00126|Recurrence of Acute Alcoholic Pancreatitis|Recurrence of Acute Alcoholic Pancreatitis||University of Tampere|No|Completed|January 2001|May 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal|||Actual|120|||Both|18 Years|N/A|No|||January 2001|August 31, 2007|August 31, 2007||||No||https://clinicaltrials.gov/show/NCT00523874||167609|
NCT00519558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1518|Growth Hormone Deficiency in Adults (GHDA)|Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency||Novo Nordisk A/S|No|Completed|May 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|121|||Both|18 Years|65 Years|No|||June 2012|June 28, 2012|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00519558||167937|
NCT00519870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA04/127|Losartan Therapy in Pulmonary Hypertension|Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension||Baskent University||Completed|January 2005|July 2005||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||August 2007|August 22, 2007|August 22, 2007||||No||https://clinicaltrials.gov/show/NCT00519870||167913|
NCT00520091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0203|Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer|A Pilot Study of the Biologic Efficacy and Safety of the Addition of Celecoxib to a Program of Induction Chemotherapy and Neo-Adjuvant Chemo-Radiotherapy for the Treatment of Esophageal Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|March 2005|September 2010|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|August 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00520091||167896|
NCT00537615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361010|An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers|A Phase 1 Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0332334 In Six Healthy Male Volunteers||Pfizer||Completed|September 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 16, 2010|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00537615||166569|
NCT00539149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIT1|Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children|Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.|COMIT1|Menzies School of Health Research|Yes|Completed|April 1996|March 2001|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|126|||Both|N/A|12 Months|Accepts Healthy Volunteers|||October 2007|May 21, 2010|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00539149||166453|
NCT00539162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-022|Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women|Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women||M.D. Anderson Cancer Center|No|Recruiting|July 2001|||July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|9500|Samples With DNA|Yearly blood draw of 2 to 3 tablespoons, with CA-125 analysis performed each time. Urine      specimen obtained at each UT MDACC visit.|Female|50 Years|74 Years|No|Non-Probability Sample|Study participants considered to be at low risk for ovarian cancer.|February 2016|February 19, 2016|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00539162||166452|
NCT00538473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110223|Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults|Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (≥67 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Will be Used as Reference.||GlaxoSmithKline||Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|68|||Both|67 Years|N/A|Accepts Healthy Volunteers|||May 2012|June 21, 2012|October 1, 2007|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00538473||166503|
NCT00538772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNC-001|An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy|An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy||British Columbia Cancer Agency|No|Withdrawn|July 2008|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Approx. 40ml of blood for correlative studies will be drawn at predetermined time points:      baseline, after cycle 1, at time of treatment failure/discontinuation of protocol therapy.      10 unstained slides from original patient specimen (nephrectomy specimens only) will be      collected within 6 months after enrollment.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects from Canadian centres who have agreed to participate in the trial entitled "A        randomized trial of Temsirolimus and Sorafenib as second line therapy in patients with        advanced renal cell carcinoma who have failed first line Sunitinib therapy" will be        approached to participate in this Exploratory Biomarker study|November 2010|November 3, 2010|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00538772||166480|
NCT00538785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP124-S2|A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children With Hemodynamically Significant Congenital Heart Disease||MedImmune LLC|Yes|Completed|October 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1236|||Both|N/A|24 Months|No|||February 2012|February 14, 2012|October 1, 2007|Yes|Yes||No|January 11, 2012|https://clinicaltrials.gov/show/NCT00538785||166479|
NCT00540137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra-CT 2007-002405-47|The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects|A Randomised Prospective Study Assessing Changes in Neurocognitive Function, Using a Computerised Test Battery, in Treatment Naïve HIV-1 Positive Subjects Commencing Two Different Antiretroviral Regimens||Imperial College London|No|Completed|July 2007|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|16 Years|N/A|No|||May 2010|May 20, 2014|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540137||166379|
NCT00540150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97/04/FFM|Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy|Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy in a Randomized Study Depending on Mite-Depot Supplement in Children and Adolescents With Allergic Bronchial Asthma.||Johann Wolfgang Goethe University Hospitals|Yes|Completed|May 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|6 Years|18 Years|No|||September 2007|October 4, 2007|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00540150||166378|
NCT00540475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040328|Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry|The Pennsylvania Idiopathic Pulmonary Fibrosis State-wide Research Registry|PA-IPF|University of Pittsburgh|Yes|Recruiting|September 2007|November 2050|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|9999|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF)|January 2016|January 4, 2016|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00540475|5 Years|166353|
NCT00535951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2109|Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma|A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 on Dextromethorphan, a CYP2D6 Substrate, and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors||Novartis||Completed|November 2007|||January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|September 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00535951||166695|
NCT00536198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH072955|Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder|Symptom Onset Antidepressant Treatment for PMDD||Weill Medical College of Cornell University|No|Active, not recruiting|September 2007|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|48 Years|No|||June 2012|June 27, 2012|September 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00536198||166676|
NCT00536211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095378|Physical Inactivity and Insulin Resistance in Skeletal Muscle.|Physical Inactivity and Insulin Resistance in Skeletal Muscle.||University of Kansas Medical Center|No|Withdrawn|June 2009|December 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|September 25, 2007|Yes|Yes|protocol not approved by VA R&D|No||https://clinicaltrials.gov/show/NCT00536211||166675|
NCT00522132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDCTP/MMV07-01|Phase II Artesunate Study in Severe Malaria|Phase II Randomized, Double-Blind Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous Artesunate in Children With Severe Malaria||Medicines for Malaria Venture|Yes|Completed|September 2007|December 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|6 Months|10 Years|No|||September 2011|September 15, 2011|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522132||167741|
NCT00522171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-06-0009|Harmonic Versus Electro Surgery in Lower Body Lift Procedures|A Randomized, Prospective, Parallel Group Study Comparing the Harmonic™ to Electro Surgery in Lower Body Lift Procedures|LBL|Ethicon Endo-Surgery|No|Terminated|September 2007|April 2009|Actual|February 2009|Actual|Phase 4|Observational|N/A||1|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Post massive weight loss|November 2009|November 30, 2009|August 27, 2007||No|This study was terminated early due to lack of adequate enrollment.|No|October 19, 2009|https://clinicaltrials.gov/show/NCT00522171||167738|
NCT00522444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-10-38|Nebulized Magnesium Sulfate in Pediatric Asthma|Nebulized Magnesium Sulfate Compared to Saline in Addition to Albuterol and Ipratropium Treatments in Moderate to Severe Pediatric Asthmatic Patients: A Randomized Controlled Clinical Trial||Children's Hospital Medical Center, Cincinnati|Yes|Terminated|September 2007|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|34|||Both|7 Years|18 Years|No|||August 2007|February 5, 2014|August 28, 2007|Yes|Yes|institution in Canada is conducting a similar clinical trial with potential of validating use.|Yes||https://clinicaltrials.gov/show/NCT00522444||167718|
NCT00522977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLOND1CTIL|Echo-Cardiographic Assessment of Cardiovascular Characteristics During Pregnancy and Postpartum Periods|||Hillel Yaffe Medical Center|No|Recruiting|August 2007|September 2009|Anticipated|||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy women in first trimester of pregnancy.|February 2008|February 25, 2008|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522977||167678|
NCT00522990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT9283/0002|Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias|A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies||Astex Pharmaceuticals|No|Terminated|September 2006|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|August 29, 2007|Yes|Yes|Recommended Phase II dose determined|No||https://clinicaltrials.gov/show/NCT00522990||167677|
NCT00523003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-06-120|A Controlled Trial of Protein Enrichment of Meal Replacements for Weight Reduction With Retention of Lean Body Mass|A Controlled Trial of Protein Enrichment of Meal Replacements for Weight Reduction With Retention of Lean Body Mass||University of California, Los Angeles|No|Completed|May 2004|March 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 16, 2008|August 28, 2007||||No||https://clinicaltrials.gov/show/NCT00523003||167676|
NCT00523562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 140/04/CE/FBM|Effects of Macronutrients on Hepatic Lipids, Plasma Triglycerides, and Insulin Sensitivity|Study of the Role of Insulin Resistance in the Pathogenesis of the Metabolic Syndrome and of Non-alcoholic Steatohepatitis|MACRONUTR|University of Lausanne|No|Completed|July 2006|January 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|41|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2010|October 27, 2010|August 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00523562||167633|
NCT00519272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0530|Barriers to Cervical Cancer Care|A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2006|||July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|N/A|N/A|No|Non-Probability Sample|Patients with newly diagnosed cervical cancer or precancerous lesions (CIS) seen in the        Gynecologic-Oncology or Colposcopy Clinic at Lyndon B. Johnson General Hospital in        Houston, Texas.|June 2015|June 16, 2015|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519272||167959|
NCT00519883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAE Study|Randomized Anastrozole Exercise Trial|Randomized Anastrozole Exercise Trial (The RAE Study)|RAE|British Columbia Cancer Agency|No|Active, not recruiting|December 2007|||July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||August 2014|August 21, 2014|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00519883||167912|
NCT00520117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-024|Assessing the Psychosocial Burden in Women With an Abnormal Pap Results After Screening Interventions|Assessing the Psychosocial Burden in Women With an Abnormal Pap Results After Screening Interventions||Mahidol University|No|Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|151|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients having pap-smear at Ratchawithi Hospital|August 2007|December 27, 2013|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00520117||167894|
NCT00520481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13934|Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer|Phase 2 Single Arm, Open-Label Study of IMC-A12 in Asymptomatic, Chemotherapy-Naïve Patients With Metastatic Androgen-Independent Prostate Cancer||Eli Lilly and Company|No|Completed|August 2007|August 2013|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Male|18 Years|N/A|No|||January 2014|January 22, 2014|August 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520481||167866|
NCT00538811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|648-Med|Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders|Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin||Aga Khan University|Yes|Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2010|October 26, 2010|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00538811||166477|
NCT00539838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT4071g|A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)|A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus|BEGIN|Genentech, Inc.||Terminated|December 2007|September 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|16 Years|N/A|No|||January 2013|January 17, 2013|October 3, 2007|Yes|Yes|The study was terminated prematurely when the decision was made that ocrelizumab was not    likely to benefit this patient population.|No||https://clinicaltrials.gov/show/NCT00539838||166402|
NCT00539851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#040639|Risk Factors for Diabetes After Stem Cell Transplantation|Risk Factors for Developing Diabetes Mellitus After Allogenic Stem Cell Transplantation||Vanderbilt University|No|Completed|November 2005|March 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|65 Years|No|Non-Probability Sample|The patients will be enrolled through the Endocrinology, Hematology and Stem Cell        Transplantation Clinics at Vanderbilt University Medical Center.|March 2010|March 18, 2010|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00539851||166401|
NCT00538161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P000113|Effect of Low Tidal Volume Ventilation in Improving Oxygenation and Thus Reducing Acute Lung Injury in the Cardiac Surgical Patient|Effect of Low Tidal Volume Ventilation in Improving Oxygenation and Thus Reducing Acute Lung Injury in the Cardiac Surgical Patient||Beth Israel Deaconess Medical Center|No|Completed|October 2007|January 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|September 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00538161||166527|
NCT00538486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOT-ACME 1|A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients|Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1)|HOT-ACME|Third Military Medical University|Yes|Completed|February 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|360|||Both|30 Years|70 Years|No|||May 2013|May 12, 2013|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538486||166502|
NCT00535964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03MH077692|Evaluating the Relationship Between Tobacco Use, Anxiety Sensitivity, and Panic in Adolescents|Anxiety Sensitivity, Tobacco Use, and Panic Among Adolescents||University of Arkansas, Fayetteville|No|Completed|June 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|12 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Participants will be 180 psychologically healthy adolescents, evenly divided across the        various stages of smoking uptake (i.e., non-smokers, tried smoking, experimenters, regular        smokers, and daily smokers).|April 2013|April 9, 2013|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535964||166694|
NCT00536224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0750112Z|Chest Pain Observation Unit Risk Reduction Trial|Brief Intervention to Promote Cardiovascular Risk Reduction in Patients Admitted to Chest Pain Observation Units||University of Iowa|Yes|Active, not recruiting|September 2007|September 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|30 Years|N/A|No|||March 2009|March 12, 2009|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00536224||166674|
NCT00536237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-011|MK0524A Phase IIb Study (0524A-011)(COMPLETED)|Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients||Merck Sharp & Dohme Corp.||Completed|August 2004|December 2006|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|154|||Both|18 Years|70 Years|No|||August 2015|August 24, 2015|September 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00536237||166673|
NCT00536510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-048|Effect of MK0524A on Cholesterol Levels (0524A-048)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Lipid-Altering Efficacy and Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.||Completed|April 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|646|||Both|18 Years|70 Years|No|||September 2015|September 1, 2015|September 26, 2007|Yes|Yes||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00536510||166652|
NCT00536744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN07-DERM01|Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers|Use of the dermaPACE™ (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care in the Treatment of Diabetic Foot Ulcers||SANUWAVE, Inc.|No|Completed|October 2007|September 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|September 26, 2007|Yes|Yes||No|March 7, 2014|https://clinicaltrials.gov/show/NCT00536744||166634|
NCT00536770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-017|A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer|A Randomized Phase 2 Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Subjects With Advanced Pancreatic Adenocarcinoma||Novacea|No|Suspended|September 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|N/A|No|||November 2007|November 2, 2007|September 26, 2007|||DSMB|No||https://clinicaltrials.gov/show/NCT00536770||166633|
NCT00537095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00079|Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer|A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy||AstraZeneca|No|Completed|September 2007|June 2012|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|September 27, 2007||Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00537095||166609|
NCT00537108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29138|Community-Based Care Management For Teen/Young Adult Mothers and Fathers|BRIDGES: A Randomized Trial of Community-Based Care Management For Teen/Young Adult Mothers and Fathers|BRIDGES|University of Maryland|No|Completed|August 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|12 Years|18 Years|No|||May 2015|May 26, 2015|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00537108||166608|
NCT00537121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564857|Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer|Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers||Roswell Park Cancer Institute|Yes|Completed|November 2006|June 2013|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|September 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537121||166607|
NCT00522184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-PP-04|Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study|Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis||Centre Hospitalier Universitaire de Nice|Yes|Completed|February 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||August 2007|August 27, 2007|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00522184||167737|
NCT00518115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP110125|Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only|A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|361|||Both|18 Years|75 Years|No|||May 2014|June 19, 2014|August 17, 2007|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT00518115||168048|
NCT00522457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-ERT-BC-04|Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy|Phase II Study Of The Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Overexpressing (3+ Or 2+/FISH+) Metastatic Breast Cancer Progressing After Trastuzumab Treatment||Neovii Biotech|Yes|Terminated|January 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||April 2011|April 28, 2011|August 28, 2007|Yes|Yes|change in development plan, not due to safety concerns.|No|March 1, 2011|https://clinicaltrials.gov/show/NCT00522457||167717|The study was prematurely terminated. This decision was based on strategic changes in the company's research and development program and resulted in limited patient data.
NCT00522470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 06/299|Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels|Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels in Diabetic Women||Baskent University|Yes|Completed||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||||||Female|45 Years|65 Years||||May 2008|May 7, 2008|August 27, 2007||||No||https://clinicaltrials.gov/show/NCT00522470||167716|
NCT00522769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH073796|Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents|Development of CBT Model for Adolescent Bulimia Nervosa|claire|Kaiser Permanente|No|Completed|September 2005|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Female|12 Years|18 Years|No|||February 2010|February 12, 2010|August 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00522769||167694|
NCT00523588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805209|Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser|Single Blind, Controlled, Single-Center Study of Laser Treatment in Cutaneous Lupus Erythematosus||University of Pennsylvania|Yes|Completed|March 2007|January 2010|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|June 24, 2010|August 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00523588||167631|
NCT00523276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0048|SARS Survivor Evaluations|Immune Responses, Transmission and Nucleotide Polymorphisms in Families With SARS Virus Infections||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||3|Actual|0|Samples With DNA|Sera, PBMCs|Both|4 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult (> 18 yo) SARS survivors and family members. Adult matched controls|April 2011|April 25, 2013|August 30, 2007||||No||https://clinicaltrials.gov/show/NCT00523276||167655|
NCT00519571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL-01|Evaluation of the Safety and Efficacy of Using ImplantLock Device - Dental Implant Accessory|Evaluation of the Safety and Efficacy of Using ImplantLock Device - Dental Implant Accessory||Innovative Implant Solutions|No|Not yet recruiting|July 2008|July 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2008|May 8, 2008|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00519571||167936|
NCT00520806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLX.CHF.003|Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure|A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure|RELAX-AHF|Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies|Yes|Completed|October 2007|September 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1161|||Both|18 Years|N/A|No|||May 2012|October 26, 2012|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00520806||167842|
NCT00520819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAS|Oslo Antioxidant Study|Dietary Antioxidant Intervention in Smoking Middle-Aged and Elderly Men||University of Oslo|No|Completed|February 2003|March 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|102|||Male|45 Years|75 Years|Accepts Healthy Volunteers|||August 2007|August 24, 2007|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00520819||167841|
NCT00521066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-06-005|GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse|A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Pelvic Organ Prolapse||Ethicon, Inc.|No|Completed|June 2007|June 2010|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Female|18 Years|N/A|No|Non-Probability Sample|Women over 18 with symptomatic pelvic organ prolapse of ICS POP-Q Stage II or III,        suitable for surgical repair|May 2014|May 5, 2014|August 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00521066||167822|
NCT00521261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000561787|Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Immune Consolidation With Allogeneic Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Allogeneic Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphoma (Phase I)||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|October 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521261||167807|
NCT00521287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-321|Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection|Adjustment of Optimal Immune System by Using Cytokine Cocktails Before Applying DC Vaccine||Mackay Memorial Hospital|No|Recruiting|October 2006|December 2009|Anticipated|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|N/A|Accepts Healthy Volunteers|||August 2007|February 29, 2008|August 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00521287||167805|
NCT00539474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/089|"The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"|"The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"|ROLL|UMC Utrecht|Yes|Completed|January 2008|November 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|316|||Female|18 Years|N/A|No|||December 2011|December 22, 2011|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00539474||166428|
NCT00539487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.523|Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives|TOP -Study Telmisartan - Therapy of Hypertension and Life-style Changes in Cardiovascular Risk Patients||Boehringer Ingelheim||Completed|January 2007|||November 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|5827|||Both|18 Years|N/A|No|Non-Probability Sample|hypertensive patients|November 2013|November 7, 2013|September 25, 2007||||No||https://clinicaltrials.gov/show/NCT00539487||166427|
NCT00539500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0374|Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma|Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma||M.D. Anderson Cancer Center|No|Terminated|October 2007|||September 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||September 2012|September 7, 2012|October 2, 2007|Yes|Yes|Slow Accrual.|No||https://clinicaltrials.gov/show/NCT00539500||166426|
NCT00540202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QALE07|Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children|Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children|QALE|Makerere University|Yes|Recruiting|September 2007|April 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|302|||Both|6 Months|5 Years|No|||October 2007|October 4, 2007|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540202||166374|
NCT00540215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0050|GLP-2 (Glucagonlike Peptide-2) and Blood Flow|The Role of GLP-2 in Univercal Changes in Blood Flow in Humans||Glostrup University Hospital, Copenhagen|Yes|Completed|October 2007|February 2008|Actual|January 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|15|||Both|20 Years|60 Years|No|||October 2007|February 10, 2011|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540215||166373|
NCT00539448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_01578|Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study|Phase IV, Open Label, Non-comparative, Multi-center, Study of the Effects of Both Insulin Glargine & Insulin Glulisine in Type I Diabetes Mellitus Patients.|GLANS|Sanofi|No|Completed|April 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|45 Years|No|||September 2009|September 24, 2009|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00539448||166430|
NCT00539461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.638|Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life|Sifrol® (Pramipexole) Impact on RLS Related Quality of Life: A 12-weeks Observational Study in Patients With Primary RLS||Boehringer Ingelheim||Completed|February 2007|||November 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2023|||Both|18 Years|N/A|No|Non-Probability Sample|RLS patients|October 2013|October 31, 2013|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00539461||166429|
NCT00539799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091040|Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis|Corticosteroids in the Maintenance Therapy of Proliferative Lupus Nephritis: a Randomized Pilot Study|SIMPL|Cambridge University Hospitals NHS Foundation Trust|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||May 2008|May 28, 2008|October 4, 2007|||Local pharmacy unwilling to comply with study protocol|No||https://clinicaltrials.gov/show/NCT00539799||166405|
NCT00539812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-STU_016315__0111-001|Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women|Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women||The University of Tennessee Knoxville|Yes|Recruiting|May 2007|May 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Female|N/A|N/A|No|||December 2012|December 17, 2012|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00539812||166404|
NCT00539825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC6108697|Effect of GSK704838 In Healthy Volunteers|A Randomized Double-blind, Placebo-controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK704838 and Tiotropium Bromide||GlaxoSmithKline||Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00539825||166403|
NCT00536250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102012241|Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth|Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth||Yale University|Yes|Recruiting|September 2001|December 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|255|||Both|8 Years|22 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and Adolscents seen at the Yale Pediatric Obesity Clinic.|March 2015|March 16, 2015|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00536250||166672|
NCT00536523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007NT031|Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Women's Cancer Center Protocol #52: Alterations in Serum Serotonin Levels as a Mechanism for Chemotherapy Induced Constipation||University of Minnesota - Clinical and Translational Science Institute|Yes|Terminated|April 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|Samples With DNA|A blood sample (5 ml red top tube) will be drawn before the patient's first chemotherapy      treatment, after the 3rd cycle of chemotherapy, at the post chemotherapy follow-up visit      (approximately 30 days after chemotherapy is completed) and approximately 4 months after      completion of chemotherapy at the time of a routine follow-up visit. Whenever possible, the      blood will be drawn at the same time blood is being collected for clinical purposes      therefore flexibility is allowed in the timing of the research related bloods.|Female|18 Years|N/A|No|Probability Sample|Women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer.|August 2014|August 21, 2014|September 27, 2007|No|Yes|Funding unavailable|No||https://clinicaltrials.gov/show/NCT00536523||166651|
NCT00536783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0072|Schizophrenia Sensory Gating Deficit With Quetiapine|Schizophrenia Sensory Gating Deficit With Quetiapine||New Mexico VA Healthcare System|Yes|Completed|April 2004|March 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|18 Years|18 Years|Accepts Healthy Volunteers|||September 2007|December 20, 2007|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00536783||166632|
NCT00537134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-80799|Trial on Endovascular Aneurysm Management|Safety and Efficacy of Endovascular Treatment of Unruptured Intracranial Aneurysms in the Prevention of Aneurysmal Haemorrhages: A Randomized Comparison With Indefinite Deferral of Treatment in 2002 Patients Followed for 10 Years|TEAM|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Suspended|September 2006|September 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2002|||Both|18 Years|N/A|No|||July 2015|November 2, 2015|September 26, 2007||No|The CIHR Financial support was withdrawn because of insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00537134||166606|
NCT00518687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V710-003|Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)|A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery||Merck Sharp & Dohme Corp.|Yes|Terminated|December 2007|August 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8031|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|August 17, 2007|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT00518687||168004|
NCT00518700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5321|Comfort Evaluation of a New MPS vs. Replenish in Contact Lens Patients|||Innovative Medical||Completed||April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|||Actual|24|||Both|18 Years|N/A||||April 2008|April 21, 2008|August 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00518700||168003|
NCT00522496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20216|Proteomics of Severe Traumatic Brain Injury: A Feasibility Study|Proteomics of Severe Traumatic Brain Injury: A Feasibility Study||University of Calgary|No|Recruiting|July 2007|August 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|N/A|No|Non-Probability Sample|All patients referred to Foothills Medical Centre, the regional trauma centre for Southern        Alberta|February 2009|February 20, 2009|August 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00522496||167715|
NCT00522509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neoadjuvant HAIC|Preoperative Hepatic Arterial Infusion Chemotherapy|Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases||IRCCS San Raffaele||Active, not recruiting|December 1995|||||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||||||Both|18 Years|90 Years|No|||May 2007|August 28, 2007|August 28, 2007||||No||https://clinicaltrials.gov/show/NCT00522509||167714|
NCT00522782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSBUPR-0062|Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children|Phase IV Study of the Effect of Nebulized Budesonide on Exhaled Nitric Oxide in Children, Four to Six Years of Age, With Asthma||AAADRS Clinical Research Center|Yes|Completed|August 2007|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|4 Years|6 Years|No|||January 2009|January 22, 2009|August 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00522782||167693|
NCT00523289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT029|Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block|||University of Sao Paulo|Yes|Active, not recruiting|October 2007|July 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|August 29, 2007||||No||https://clinicaltrials.gov/show/NCT00523289||167654|
NCT00518999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-07-SHA|Emotional and Cognitive Abilites of Schizophrenia Patients at Various Time Points|Emotional and Cognitive Abilites of Schizophrenia Patients at Various Time Points||Shalvata Mental Health Center|Yes|Not yet recruiting|August 2007|August 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal||1|Anticipated|120|||Both|18 Years|65 Years|No|||August 2007|August 20, 2007|August 20, 2007||||No||https://clinicaltrials.gov/show/NCT00518999||167980|
NCT00519584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-459|Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone|Duration of Interscalene Nerve Blocks With Ropivacaine Alone, Ropivacaine Mixed With Dexamethasone, and Ropivacaine Alone Combined With Systemic Dexamethasone|Ropivacaine|Outcomes Research Consortium|No|Withdrawn|July 2007|March 2009|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|120|||Both|18 Years|70 Years|No|||January 2009|January 16, 2009|August 21, 2007||No|Collected study data was not usable due to process miscommunications|No||https://clinicaltrials.gov/show/NCT00519584||167935|
NCT00518973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051027|Trial of Quetiapine in Anorexia Nervosa|Double-blind Placebo-controlled Trial of Quetiapine in Anorexia Nervosa||University of California, San Diego|No|Recruiting|July 2006|May 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||December 2009|February 16, 2010|August 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00518973||167982|
NCT00518986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/4024/ES/US|Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression|Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder||Teva Pharmaceutical Industries||Completed|October 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|249|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|August 17, 2007|Yes|Yes||No|March 30, 2010|https://clinicaltrials.gov/show/NCT00518986||167981|
NCT00520494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB06_005CR|Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency|A Multicenter Study on the Efficacy and Safety of Vivaglobin® in Previously Untreated Patients (PUPs) With Primary Immunodeficiency (PID)||CSL Behring|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|1 Year|70 Years|No|||June 2013|June 12, 2013|August 23, 2007|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00520494||167865|
NCT00520832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0524070091|A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys|A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys||Logan College of Chiropractic||Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Both|18 Years|40 Years|No|||October 2008|October 16, 2008|August 23, 2007||||No||https://clinicaltrials.gov/show/NCT00520832||167840|
NCT00521079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D00343-000|EMPOWER Clinical Trial: Vagal Blocking for Obesity Control|EMPOWER Clinical Trial: Vagal Blocking for Obesity Control|EMPOWER|EnteroMedics|Yes|Active, not recruiting|August 2007|June 2013|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||September 2008|September 5, 2008|August 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521079||167821|
NCT00521300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-71-98 (REK)|Preoperative Octreotide Treatment of Acromegaly|Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas|POTA|St. Olavs Hospital|No|Completed|September 1999|May 2010|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|80 Years|No|||May 2014|May 30, 2014|August 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00521300||167804|
NCT00521326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP01|Diagnosis and Characterization of Coronary Artery Stenosis by Doppler Ultrasound|Diagnosis and Characterization of Coronary Artery Stenosis by Transthoracic Doppler Ultrasound||Hillel Yaffe Medical Center|No|Not yet recruiting|August 2007|||||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A||||March 2007|August 24, 2007|August 24, 2007||||No||https://clinicaltrials.gov/show/NCT00521326||167803|
NCT00539864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC06|Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV|Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64||Protein Sciences Corporation|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|602|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|October 4, 2007|Yes|Yes||No|May 16, 2011|https://clinicaltrials.gov/show/NCT00539864||166400|
NCT00539877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-05-017|Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding|Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding||Samsung Medical Center|Yes|Completed|October 2004|August 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00539877||166399|
NCT00549250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710007R|Human Papillomavirus 6/11 in the Lower Airway of Neonates|Human Papillomavirus 6/11 in the Lower Airway of Neonates||National Taiwan University Hospital|No|Completed|November 2007|May 2010|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|114|Samples With DNA|Bronchial lavage fluid|Both|N/A|1 Month|No|Non-Probability Sample|All intubated neonates younger than 1 month-old admitted to our neonatal intensive care        unit.|June 2010|July 1, 2010|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00549250||165696|
NCT00549263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR110549|Bioequivalence Study of SB797620 in Healthy Japanese Volunteers|A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone (RSG) and Glimepiride (GLIM)(4mg/2mg) Compared to Concomitant Dosing of RSG 4mg Tablet and GLIM 1mg Commercial Tablet x 2 (4mg+2mg) in Japanese Healthy Male Subjects||GlaxoSmithKline|No|Withdrawn|February 2008|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|October 23, 2007|||No subjects enrolled, bio equivalence study, canceled before active.|No||https://clinicaltrials.gov/show/NCT00549263||165695|
NCT00540163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.402|Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea|Improvement in Physical Functioning (SF-36 Activity Score) in COPD Patients With Exercise-induced Dyspnoea on Treatment With Spiriva® 18 Microgram (Capsules Containing 18 μg Tiotropium).||Boehringer Ingelheim||Completed|April 2007|||November 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1296|||Both|18 Years|N/A|No|Probability Sample|patients of office-based pulmonology practices|October 2013|November 27, 2013|September 21, 2007||||No||https://clinicaltrials.gov/show/NCT00540163||166377|
NCT00540176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCA 10002|The Safety and Efficacy of DCA for the Treatment of Brain Cancer|A Phase II Open-labeled, Double-arm Clinical Study of Dichloroacetate (DCA) in Malignant Gliomas and Glioblastome Multiforme (GBM) Patients||University of Alberta|Yes|Completed|October 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2010|October 10, 2014|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540176||166376|
NCT00540189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00007791|Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children|Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children||University of Michigan|No|Recruiting|May 2008|November 2011|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|2 Years|17 Years|No|||June 2008|June 3, 2008|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540189||166375|
NCT00540488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRDB09|Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas|Randomized, Double Blind, Three Way Crossover Comparison of Glucose and Insulin Responses During a Meal Glucose Tolerance Test in Subjects With Type 2 Diabetes Consuming Disease-Specific Versus Standard Nutritional Formula||Abbott Nutrition||Completed|August 2002|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|54|||Both|18 Years|75 Years||||October 2007|October 12, 2007|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00540488||166352|
NCT00540501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAI108166|A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects|Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects||GlaxoSmithKline||Withdrawn|October 2007|October 2007|Anticipated|October 2007|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 27, 2010|October 4, 2007|Yes|Yes|Contract agreement not reached|No||https://clinicaltrials.gov/show/NCT00540501||166351|
NCT00540514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA031|Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Celgene|Yes|Completed|November 2007|February 2013|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1052|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|October 4, 2007|Yes|Yes||No|June 7, 2013|https://clinicaltrials.gov/show/NCT00540514||166350|
NCT00545662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-HD042|Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)|Citicoline Brain Injury Treatment Trial|COBRIT|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Terminated|July 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1213|||Both|18 Years|70 Years|No|||November 2012|November 16, 2012|October 16, 2007|Yes|Yes|Trial stopped due to futility.|No|November 29, 2011|https://clinicaltrials.gov/show/NCT00545662||165961|
NCT00545961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diary nr 41/2007|Middle Meatal Bacteriology During Acute Respiratory Infection in Children|Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study||Oulu University Hospital|No|Not yet recruiting|November 2007|December 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|13 Years|No|||October 2007|October 18, 2007|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00545961||165938|
NCT00546169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-027-DE|Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)|Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)||Nycomed|Yes|Completed|June 2007|July 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|care clinic|August 2008|May 4, 2012|October 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00546169||165922|
NCT00546182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-200405|Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity|Phase 4 Study of Simvastatin That Affects Insulin Sensitivity||Gachon University Gil Medical Center|Yes|Completed|January 2004|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective|||||||Both|25 Years|75 Years|No||overweight hypercholesterolemic patients|October 2007|October 17, 2007|October 17, 2007||||No||https://clinicaltrials.gov/show/NCT00546182||165921|
NCT00546481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20884|A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.|A Randomized, Open Label Study of the Effect of Intravenous Mircera on the Hemoglobin Response Rate in Patients With Chronic Kidney Disease Who Are on Dialysis.||Hoffmann-La Roche||Completed|November 2007|April 2010|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|October 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00546481||165900|
NCT00546494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B-101547|Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission|A Study Of The Utility Of Effexor® (Venlafaxine) In Achieving Response And Maintaining Remission Among Taiwanese Patients With Depression||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|February 2004|March 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||350|||Both|N/A|N/A|No|||October 2007|October 18, 2007|October 18, 2007||||No||https://clinicaltrials.gov/show/NCT00546494||165899|
NCT00553124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000572089|Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial)||National Cancer Institute (NCI)||Recruiting|December 2005|||||Phase 3|Interventional|Primary Purpose: Prevention||||3400|||Both|18 Years|N/A|No|||October 2007|January 9, 2014|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553124||165402|
NCT00553631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-GCB-039|Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease|A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease||Shire|No|Completed|January 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|2 Years|N/A|No|||February 2014|July 16, 2015|November 1, 2007|Yes|Yes||No|July 12, 2010|https://clinicaltrials.gov/show/NCT00553631||165363|Participants aged 2-4 years: 4 participants (23.5%) in imiglucerase group and 0 participants in GA-GCB group.
NCT00552513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRN: MCT-79654|Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes|An International Randomised Trial of Early Versus Delayed Invasive Strategies in Patients With Non-ST Segment Elevation Acute Coronary Syndromes|TIMACS|Population Health Research Institute|Yes|Completed|May 2005|February 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3031|||Both|21 Years|N/A|No|||May 2014|May 27, 2014|October 30, 2007||No||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00552513||165449|
NCT00551044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96/02|Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer|Bicalutamide Monotherapy Preserves Bone Mineral Density, Muscle Strength and Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer||Wirral University Teaching Hospital NHS Trust|Yes|Completed|August 2003|August 2005|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|N/A|N/A|No|||August 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551044||165560|
NCT00552487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/05|Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis|Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis||University of Wuerzburg|Yes|Completed|October 2005|July 2006|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|October 31, 2007|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552487||165451|
NCT00553163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMRP proposal no IBD 0213|Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial|Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial||Queen Mary University of London|Yes|Terminated|October 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|16 Years|75 Years|No|||November 2013|November 7, 2013|November 2, 2007||No|Unable to recruit sufficient numbers of patinets in the time available|No||https://clinicaltrials.gov/show/NCT00553163||165399|
NCT00552799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06002|RCT to Investigate if Prophylactic Antibiotics Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg|Randomised Controlled Trial to Investigate Whether Prophylactic Antibiotics Can Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH I)|PATCH1|University of Nottingham|Yes|Completed|July 2006|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|274|||Both|16 Years|N/A|No|||July 2012|July 23, 2012|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552799||165427|
NCT00553137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fluc trial tz|Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania|Oral Candidiasis in HIV Infected Individuals in Tanzania|SDVS2WK|Netherlands Organisation for Scientific Research|Yes|Completed|November 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||May 2008|May 2, 2008|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553137||165401|
NCT00553150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N057K|Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma|Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|March 2009|||January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553150||165400|
NCT00550225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB108115|Succinate Salt Version of GSK961081 for Healthy Volunteers|A Randomised, Double-blind, Dose Escalating Study in Healthy Volunteers to Assess the Safety, Tolerability, Extra Pulmonary Pharmacodynamics and Pharmacokinetics of Single Doses of GSK961081 (Succinate Salt)||GlaxoSmithKline|No|Completed|November 2007|January 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 26, 2007||||No||https://clinicaltrials.gov/show/NCT00550225||165621|
NCT00550238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-015|A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis|A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease||ACADIA Pharmaceuticals Inc.||Active, not recruiting|July 2007|||December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|40 Years|N/A|No|||February 2014|February 17, 2014|October 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00550238||165620|
NCT00550602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000112|Tracheobronchomalacia: Treatment Outcomes|Tracheobronchomalacia: Treatment Outcomes||Beth Israel Deaconess Medical Center|No|Completed|January 2002|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|21 Years|N/A|No|Non-Probability Sample|Adult population with suspected symptomatic tracheal and/or bronchial collapse referred to        our institution by a Pulmonologist or Thoracic Surgeon.|April 2010|April 21, 2010|October 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00550602||165593|
NCT00550264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P001975; BWH|Study of Physician Awareness of and Communication About Patient Readmissions to the Hospital|Physician Awareness of and Communication About Hospital Readmissions||Brigham and Women's Hospital|No|Completed|February 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550264||165618|
NCT00536328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL401611|What is the Predictive Value of the Reflux Impact Scale|What is the Value of the Use of Validated Questionnaire (Reflux Impact Scale) for Predicting Treatment Success With PPI|PREDICT|AstraZeneca||Terminated|October 2007|June 2008|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|938|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting at general practitioner|July 2008|July 7, 2008|September 26, 2007||No|due to very low recruitment. For this reason, there will be no further analysis and reporting    of this study.|No||https://clinicaltrials.gov/show/NCT00536328||166666|
NCT00536601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 72806|High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors|Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Selected Solid Tumors||Roswell Park Cancer Institute|Yes|Active, not recruiting|June 2006|||July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|174|||Both|4 Years|N/A|No|||December 2015|December 8, 2015|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536601||166645|
NCT00540956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564106|Natural Killer Cells in Older Patients With Acute Myeloid Leukemia|Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission.||National Cancer Institute (NCI)||Completed|November 2006|||May 2011|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|65 Years|N/A|No|||July 2009|May 13, 2011|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00540956||166316|
NCT00540969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N06C6|Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases|A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases||Alliance for Clinical Trials in Oncology|No|Terminated|February 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|October 5, 2007|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00540969||166315|
NCT00541164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-19|Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease|Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study||Memorial Medical Center|No|Completed|September 2007|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|23|||Both|18 Years|75 Years|No|||June 2010|July 11, 2013|October 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541164||166300|
NCT00541177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB960209-3|Study of Myopia Prevention in Children With Low Concentration of Atropine|Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine||Min-Sheng General Hospital|Yes|Recruiting|April 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|7 Years|12 Years|No|||October 2007|October 9, 2007|October 6, 2007||||No||https://clinicaltrials.gov/show/NCT00541177||166299|
NCT00541502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-06-P04|Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder|A Obervational, Prospective Study to Evaluate the Effectiveness of Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder in Taiwan||Genovate Biotechnology Co., Ltd.,|No|Not yet recruiting|November 2007|October 2008|Anticipated|||N/A|Observational|Time Perspective: Prospective|||||||Both|12 Years|25 Years||||October 2007|October 9, 2007|October 8, 2007||||No||https://clinicaltrials.gov/show/NCT00541502||166274|
NCT00537433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB06-168|Improving Parental Understanding of Medication Instructions Through a Pictogram-Based Intervention|An RCT to Reduce Liquid Medication Dosing Errors and Improve Adherence in Caregivers of Young Children Through a Pictogram-Based Intervention||New York University School of Medicine|No|Completed|July 2006|January 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|251|||Both|1 Month|8 Years|Accepts Healthy Volunteers|||September 2007|September 28, 2007|September 28, 2007||||No||https://clinicaltrials.gov/show/NCT00537433||166583|
NCT00551603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWG_03_07|Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules|Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules|VAES|Anemia Working Group Romania|No|Completed|July 2006|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2009|August 3, 2009|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00551603||165517|
NCT00560976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor419105ctil|Serum NGAL Levels in Hemodialysis (HD) Patients; Relation to Iron Status, HD and Intravenous (IV) Iron Administration|Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels in Hemodialysis (HD) Patients; Relation to Iron Status, Hemodialysis, and Intravenous (IV) Iron Administration||Soroka University Medical Center|No|Recruiting|December 2005|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|88 Years|No|||April 2013|April 17, 2013|November 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00560976||164822|
NCT00551590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITEX-02|Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus|A Randomized, Placebo-Controlled, 4-period, Crossover Study to Assess the Impact of MK-0431 (Sitagliptin) on Incretin Effect and the Role of Specific Incretin Hormones in Patients With Type 2 Diabetes Mellitus||Ludwig-Maximilians - University of Munich|Yes|Completed|December 2007|September 2011|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|24|||Both|30 Years|70 Years|No|||October 2011|October 3, 2011|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00551590||165518|
NCT00552175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12191|A Study for the Treatment of Diabetic Peripheral Neuropathic Pain|A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain||Eli Lilly and Company|Yes|Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|339|||Both|20 Years|79 Years|No|||March 2010|March 26, 2010|October 31, 2007|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00552175||165474|The protocol-specified primary analyses for this study were comparisons between combined duloxetine arms (40 mg + 60 mg) and placebo. The study was powered on combined duloxetine arms and statistical comparisons were not performed among single arms.
NCT00553176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014140|The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry|Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry|TREAT|Janssen Biotech, Inc.|No|Completed|August 1999|May 2012|Actual|May 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6273|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with Crohn's Disease|March 2013|March 1, 2013|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00553176||165398|
NCT00553189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070203|Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas|A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|August 2007|September 2011|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||September 2011|September 26, 2015|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553189||165397|
NCT00553449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005692|Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.|A Randomised, Controlled, Parallel-group, Open-label Study to Evaluate Different Dosing Regimens of Rabeprazole in Controlling Nocturnal Heartburn Symptoms in Patients With Gastroesophageal Reflux Disease.||Janssen-Ortho Inc., Canada||Completed|July 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|N/A|No|||March 2010|May 16, 2011|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00553449||165377|
NCT00553436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-07-0004|Evaluation of an Endoscopic Suturing System for Tissue Apposition in Colonic Polypectomy|Evaluation of an Endoscopic Suturing System for Tissue Apposition in Colonic Polypectomy||Ethicon Endo-Surgery|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|21 Years|N/A|No|||April 2010|April 20, 2010|November 2, 2007||No||No|October 20, 2009|https://clinicaltrials.gov/show/NCT00553436||165378|
NCT00553670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0707-022-212|Mechanism and Predictor of Side Branch Jailing|Predictor and Mechanism of a Side Branch Jail After Main Branch Stent Implantation in Bifurcation Lesions|PRESSURE|Seoul National University Hospital|Yes|Completed|November 2007|May 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with bifurcating coronary artery lesion in left anterior descending coronary        artery|March 2011|March 28, 2011|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00553670||165360|
NCT00554528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-APN-01|Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level|Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level|PROCERV|Centre Hospitalier Universitaire de Nice|No|Completed|May 2007|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|55 Years|No|||September 2015|September 29, 2015|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554528||165296|
NCT00550251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC2|Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients? Formal Study|Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients? Formal Study||Sue Ryder Care|No|Recruiting|July 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||May 2015|May 24, 2015|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550251||165619|
NCT00550277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 49|LBH589 Treatment for Refractory Clear Cell Renal Carcinoma|A Phase II Study of LBH589 in the Treatment of Patients With Refractory Clear Cell Renal Carcinoma||SCRI Development Innovations, LLC|No|Completed|January 2008|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|October 26, 2007|No|Yes||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00550277||165617|
NCT00545181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612-58 (Study #)|Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial|Recurrent Bacterial Vaginosis (RBV): Efficiency of Metronidazole in Comparison to Metronidazole and Intravaginal Acidifying Gel: A Randomized Investigator-blinded Controlled Trial||Indiana University|Yes|Completed|September 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Female|18 Years|50 Years|No|||January 2010|January 6, 2010|October 15, 2007||No||No|December 2, 2009|https://clinicaltrials.gov/show/NCT00545181||165998|
NCT00545493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135/02|Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis|Efficacy of Tacrolimus and i.v.-Immunoglobulins in Rasmussen Encephalitis With Start of Treatment in the Acute Disease Stage. Prospective, Randomised, Open Parallel Group Study||University Hospital, Bonn|No|Active, not recruiting|November 2002|April 2010|Anticipated|April 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|N/A|N/A|No|||April 2009|April 9, 2009|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545493||165974|
NCT00540982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96032|Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction|Pilot Pharmacokinetic Study of Dose Adjustment of Vinorelbine in Patients With Varying Degree of Liver Dysfunction||City of Hope Medical Center|Yes|Completed|December 1996|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|October 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00540982||166314|
NCT00541190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07060240|Absorptive Clearance in the Cystic Fibrosis Airway|Absorptive Clearance in the Cystic Fibrosis Airway||University of Pittsburgh|Yes|Completed|October 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 3, 2012|October 5, 2007|No|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00541190||166298|
NCT00541515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc004706ctil|Closing the Loop Between Glucose Sensor and Insulin Pump-developing an Algorithm|Closing the Loop Between Glucose Sensor and Insulin Pump-developing an Algorithm||Rabin Medical Center|No|Active, not recruiting|October 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|10 Years|65 Years|No|||November 2015|November 26, 2015|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541515||166273|
NCT00537771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5392L00023|Liver Safety Under Upfront Arimidex vs Tamoxifen|A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer|HEART|AstraZeneca|No|Completed|September 2007|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|384|||Female|N/A|N/A|No|||December 2012|December 20, 2012|September 27, 2007|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00537771||166557|
NCT00537784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trombocytakilles|Platelet Concentrate in Achilles Tendon Repair|||University Hospital, Linkoeping|No|Completed|September 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||June 2013|June 17, 2013|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537784||166556|
NCT00551616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914-004|Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception|||HRA Pharma|Yes|Completed|April 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2321|||Female|16 Years|N/A|No|||June 2010|June 16, 2010|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551616||165516|
NCT00551876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-021|Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)|A Randomized, Double-Blind, Parallel, Multicenter Study to Evaluate the Efficacy and Safety of Simvastatin Monotherapy Compared With Simvastatin Plus Ezetimibe (SCH 58235) in Type 2 Diabetic Patients Treated With Thiazolidinediones||Merck Sharp & Dohme Corp.||Completed|December 2001|January 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|214|||Both|30 Years|75 Years|No|||October 2015|October 13, 2015|October 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551876||165496|
NCT00552188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIA-2291-03|Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event||Tallikut Pharmaceuticals, Inc.|Yes|Completed|October 2007|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|80 Years|No|||June 2013|June 6, 2013|October 31, 2007|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00552188||165473|
NCT00552201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACTIQUE|TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic|Randomized Therapeutic Study of a Treatment by Tacrolimus Adapted or Not According to the Genotype of the Cytochrome P450 3A5 After Renal Transplantation||Centre Hospitalier Universitaire, Amiens|Yes|Completed|April 2006|December 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|18 Years|65 Years|No|||August 2009|May 26, 2010|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552201||165472|
NCT00553683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573370|Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer|Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer)||Rutgers, The State University of New Jersey||Active, not recruiting|October 2007|July 2014|Anticipated|February 2014|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||January 2014|January 11, 2014|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553683||165359|
NCT00553696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181127|Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer|A Phase 1 Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer||Pfizer|Yes|Completed|November 2007|March 2014|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|20 Years|N/A|No|||March 2015|March 3, 2015|November 2, 2007|No|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT00553696||165358|
NCT00552812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060057|Coarctation Of the Aorta Stent Trial|Coarctation Of the Aorta Stent Trial|COAST|Johns Hopkins University|Yes|Completed|October 2007|July 2015|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|8 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|October 31, 2007|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00552812||165426|
NCT00554229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00014|A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases|A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.|ENTHUSE M1|AstraZeneca|Yes|Completed|November 2007|August 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|896|||Male|18 Years|N/A|No|||April 2012|January 15, 2016|November 2, 2007|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00554229||165319|
NCT00554541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-617|Lower Extremity Venous Hemodynamics in Obese Patients Without Clinically Significant Venous Disease|Lower Extremity Venous Hemodynamics in Obese Patients Without Clinically Significant Venous Disease||The Cleveland Clinic|No|Terminated|November 2007|January 2009|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients of the Cleveland Clinic Foundation.|February 2009|February 2, 2009|November 5, 2007||No|Lack of study subjects|No||https://clinicaltrials.gov/show/NCT00554541||165295|
NCT00554567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCTUtilizationStudy2007|Utilization of HIV Clinical Services in Rural India|Utilization of Decentralized HIV Testing and Care Services in Rural Maharashtra, India||Institute of Health Management, Pachod, India|Yes|Completed|January 2007|February 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2008|March 7, 2016|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554567||165294|
NCT00550290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.07.26.E2|Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy|Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy||Aultman Health Foundation|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Female|18 Years|N/A|No|||June 2009|June 24, 2009|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550290||165616|
NCT00550303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1123|Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens|An Open-Label, Single-Dose, Non-Randomized, 4-Period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2007|November 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|28|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||December 2007|December 18, 2007|October 25, 2007||||No||https://clinicaltrials.gov/show/NCT00550303||165615|
NCT00544830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05190|Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Androgen Deprivation Therapy for Metastatic Prostate Cancer|Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer||City of Hope Medical Center|Yes|Active, not recruiting|July 2006|||December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|18 Years|120 Years|No|||February 2016|February 5, 2016|October 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544830||166022|
NCT00545194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPESS Study|Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess|Randomized Study on Removable PGE2 Vaginal Insert Versus PGE2 Intravaginal Gel for Cervical Priming and Labour Induction in Term Pregnancy||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|January 2002|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|446|||Female|18 Years|45 Years|No|||October 2007|October 16, 2007|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545194||165997|
NCT00545207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19357|A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.|A Randomized, Double-blind Study of the Effect of Oral Monthly Bonviva on in Vivo Bone Micro-architecture Parameters in Post-menopausal Women With Osteopenia||Hoffmann-La Roche||Completed||September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Female|55 Years|75 Years|No|||December 2010|January 18, 2011|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545207||165996|
NCT00545506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|The Influence of a Warmed Surgical Bandage System on Subcutaneous Tissue Oxygen Tension After Cardiac Surgery|The Influence of a Warmed Surgical Bandage System on Subcutaneous Tiisue Oxygen Tension After Cardiac Surgery||Medical University of Vienna|Yes|Terminated|November 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|3|||Both|18 Years|80 Years|No|||August 2010|August 30, 2010|October 16, 2007||No|lack of eligible patients|No|July 22, 2010|https://clinicaltrials.gov/show/NCT00545506||165973|Tissue oxygen tension maybe difficult to measure in the sternal wound
NCT00541853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPKDCCB|CCB Safety Study in Treatment of Hypertension of ADPKD|Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients||Kyorin University|Yes|Not yet recruiting|December 2007|November 2012|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|60 Years|No|||October 2007|October 17, 2007|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00541853||166248|
NCT00541203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-120|Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests|Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests|CT-MPACT|William Beaumont Hospitals|Yes|Completed|October 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers over 18 years of age; both genders; referred from participating cardiologist's        offices|March 2012|March 20, 2012|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541203||166297|
NCT00541541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Audicor-Pacing|Acoustic Cardiographic Assessment of Heart Function and the Role of Phrenic Nerve Stimulation|Acoustic Cardiographic Assessment of Heart Function and the Role of Phrenic Nerve Stimulation Following Open Heart Surgery||Luzerner Kantonsspital|Yes|Completed|February 2007|||May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||||||Both|18 Years|N/A|No|||April 2013|April 16, 2013|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541541||166272|
NCT00541827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|assente|Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis|Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Completed|October 2007|August 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|muscle tissue, platelets, plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult ICU-admitted severely septic and septic shock patientes; adult ICU-admitted        cardiogenic shock patients; surgical patients|September 2013|September 26, 2013|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541827||166250|
NCT00542386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E08|A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia|A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups)||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|December 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|642|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|October 10, 2007|Yes|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT00542386||166207|
NCT00553202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML05P1|Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia|Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study||Children's Oncology Group|Yes|Active, not recruiting|January 2008|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|158|||Both|N/A|30 Years|No|||June 2015|January 11, 2016|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553202||165396|
NCT00552292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25/1|Complications in Hypertension and Obesity|National Investigation of Cardiovascular Complications in Arterial Hypertension and Obesity||Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|No|Recruiting|December 2007|January 2017|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|Samples With DNA|Blood, urine, serum|Both|18 Years|90 Years|No|Non-Probability Sample|Age and sex-matched sample of subjects older 18 age|May 2015|May 18, 2015|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552292||165465|
NCT00551889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00191|Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer|Phase I Trial of Oral Cyclophosphamide in Combination With Celecoxib in Patients With Advanced Malignancies||City of Hope Medical Center||Completed|September 2001|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|57|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|October 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551889||165495|
NCT00552214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-001-TW1-Amendment 1.1|Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor Specimens|Evaluation of a TMA Assay for the Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens||Novartis||Enrolling by invitation|August 2007|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|10500|||Both|17 Years|65 Years||||October 2007|November 5, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00552214||165471|
NCT00552227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6038|Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus|The Effect of Protein Kinase C (PKC) β Specific Inhibitor on Oxidant Stress in Patient With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|September 2002|July 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|35 Years|N/A|No|||October 2007|October 30, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00552227||165470|
NCT00552240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1512|Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)|Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone||Boehringer Ingelheim||Completed|September 2007|||March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|September 28, 2007||||No|March 16, 2011|https://clinicaltrials.gov/show/NCT00552240||165469|
NCT00552253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612016M|Levothyroxine Treatment in Thyroid Benign Nodular Goiter|Levothyroxine Treatment in Thyroid Benign Nodular Goiter||National Taiwan University Hospital|Yes|Completed|October 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|90 Years|No|||December 2010|December 21, 2010|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00552253||165468|
NCT00553215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574081|Quality of Life in Patients With Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]||National Cancer Institute (NCI)||Recruiting|December 2005|||||Phase 3|Observational|N/A||||2700|||Both|18 Years|N/A|No|||February 2010|January 9, 2014|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553215||165395|
NCT00552825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3889-OE-CTIL|Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children|Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years||Sheba Medical Center|No|Completed|October 2005|October 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|35|||Both|3 Years|7 Years|No|Non-Probability Sample|All pediatric patients (age 3-7 years) with hemato-onclogic diseases that were treated at        the Hemato-Oncology Department, and were sent to the pediatric pulmonary unit at the Safra        children's hospital, Sheba medical center, Ramat-Gan, Israel, to perform lung function        tests, as a part of a 3-year follow-up study.|November 2007|November 1, 2007|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00552825||165425|
NCT00553475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081163|Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy|Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy||Pfizer|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|314|||Both|18 Years|N/A|No|||July 2010|July 16, 2010|November 2, 2007|Yes|Yes||No|March 10, 2010|https://clinicaltrials.gov/show/NCT00553475||165375|
NCT00553969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709M15829|Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease|Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial)|DETECT|University of Minnesota - Clinical and Translational Science Institute|No|Completed|November 2007|December 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|101|||Both|19 Years|N/A|No|||December 2014|December 9, 2014|November 5, 2007|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00553969||165338|
NCT00553982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aue1|Patellar Resurfacing in Total Knee Arthroplasty|Patellar Resurfacing in Total Knee Arthroplasty. A Prospective, Randomised and Double Blind Study.||Sykehuset Innlandet HF||Active, not recruiting|October 2007|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|85 Years|No|||January 2015|January 13, 2015|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553982||165337|
NCT00553709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006DR3327|Study of Nicotine for the Prevention of PONV|The Role of Transcutaneous Nicotine in the Prevention of Postoperative Nausea and Vomiting in Non-smokers|NicoPONV|University Hospital, Geneva|Yes|Terminated|October 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|80 Years|No|||September 2009|September 28, 2009|November 2, 2007||No|Unexpected difficult recruitment. Study drug expired|No||https://clinicaltrials.gov/show/NCT00553709||165357|
NCT00554242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26356|Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function|Chronic Study of the Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function in Patients With Coronary Artery Disease||Boston University|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|40|||Both|21 Years|80 Years|No|||June 2009|June 16, 2009|November 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00554242||165318|
NCT00554255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108543|A Study of SB751689 in Japanese Postmenopausal Women|Phase I Study of SB751689 - Single and Multiple Oral Dose Study in Japanese Postmenopausal Women -||GlaxoSmithKline|No|Completed|October 2006|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Anticipated|18|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2013|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00554255||165317|
NCT00554268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0375|Trial of PBI-05204 in Advanced Cancer Patients|An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients||M.D. Anderson Cancer Center|No|Completed|October 2007|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||April 2013|February 17, 2016|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00554268||165316|
NCT00554281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAHREB6344|Using Glucose Sensors to Prevent Hypoglycemia|Paradigm Real Time Continuous Glucose Monitoring Device for the Prevention of Hypoglycemia||University of Alberta|No|Completed|October 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|70 Years|No|||September 2011|September 12, 2011|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554281||165315|
NCT00554580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 030428|Continuous Positive Airway Pressure for Acute Pulmonary Edema|Effect of Continuous Positive Airway Pressure on Short Term Inhospital Prognosis for Acute Pulmonary Edema|CPAP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2004|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|N/A|No|||March 2010|March 29, 2010|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554580||165293|
NCT00550953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.14|Filtered Trial for Telmisartan 40mg Non-responder|Filtered Trial for Telmisartan 40mg Non-responder||Boehringer Ingelheim||Completed|October 2007|||July 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|314|||Both|20 Years|N/A|No|||December 2013|December 12, 2013|October 26, 2007||||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00550953||165567|
NCT00551187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V504-001|A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)|A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women||Merck Sharp & Dohme Corp.||Completed|October 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|620|||Female|16 Years|26 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|October 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551187||165549|
NCT00551447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-023|A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)|A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c)||Merck Sharp & Dohme Corp.||Completed|January 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|616|||Both|18 Years|80 Years|No|||October 2015|October 12, 2015|October 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551447||165529|
NCT00545220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X060817006|Problem Solving Training and Low Vision Rehabilitation|Problem Solving Training and Low Vision Rehabilitation||University of Alabama at Birmingham||Completed|October 2007|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|430|||Both|19 Years|N/A|No|||February 2016|February 17, 2016|September 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00545220||165995|
NCT00540696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000220|Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa|An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa (NESP)||Amgen||Completed|September 2001|September 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540696||166336|
NCT00540709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901 4036|PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro|||Sanofi||Completed|November 2002|September 2003|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|58|||Both|18 Years|70 Years|No|||February 2012|February 15, 2012|October 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00540709||166335|
NCT00541892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-05249|Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine|Sibling Oocyte Study of Medium for IVF/ICSI With no Human Serum Albumine||Sykehuset Telemark||Withdrawn|September 2007|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|38 Years|No|||May 2015|May 19, 2015|October 9, 2007||No|senior coworker retired|No||https://clinicaltrials.gov/show/NCT00541892||166245|
NCT00541905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-0605/1|Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia|Prospective, Single-arm, Multicenter Trial to Investigate the Efficacy and Safety of NT 201 and the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Patients With Cervical Dystonia||Merz Pharmaceuticals GmbH||Completed|September 2007|May 2010|Actual|October 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|75 Years|No|||June 2013|June 3, 2013|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541905||166244|
NCT00542204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS017179-01|Use of Online Personalized Health Record System to Promote Self-Management of Diabetes|Patient-Centered Online Disease Management Using a Personal Health Record System|EMPOWER-D|Palo Alto Medical Foundation|Yes|Completed|March 2008|August 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|415|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00542204||166221|
NCT00542438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0278|Home-Based Measures of Physical Activity and Body Composition|Feasibility and Validity of Home-Based Measures of Physical Activity and Body Composition||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2007|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|75|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542438||166203|
NCT00542451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-199|Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer|A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2007|December 2021|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|420|||Female|18 Years|N/A|No|||March 2014|March 17, 2014|October 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542451||166202|
NCT00541788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/285|Evaluation of the Efficacy and Safety of Common Sage in Controlling Hot Flashes in Prostate Cancer Patients Treated by Androgen Deprivation|Evaluation of the Efficacy and Safety of Common Sage in Controlling Hot Flashes in Prostate Cancer Patients Treated by Androgen Deprivation||University Hospital, Ghent|No|Completed|October 2007|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||September 2010|September 16, 2010|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541788||166253|
NCT00541801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Audicor-Oncology|Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography|Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography in Patients With Cytostatic Therapies||Luzerner Kantonsspital|Yes|Completed|March 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||||||Both|18 Years|N/A|No|||June 2011|June 22, 2011|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541801||166252|
NCT00552305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0615|To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures|An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-term Oral SPM 927 as Adjunctive Therapy in Patients With Partial Seizures||UCB Pharma||Completed|August 2001|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|370|||Both|N/A|N/A|No|||September 2011|September 19, 2014|October 30, 2007|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00552305||165464|
NCT00552552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41100133|Development and Evaluation of a Cancer-Related Fatigue Patient Education Program|Development and Evaluation of a Cancer-Related Fatigue Patient Education Program|FIBS|University of Bremen||Not yet recruiting|January 2008|December 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2007|November 1, 2007|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552552||165446|
NCT00553462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-30605|Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|March 2008|||January 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553462||165376|
NCT00552864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMAneste001|Comparison of Ropivacaine and Levobupivacaine in High Thoracic Epidural Anesthesia|High Thoracic Epidural Anesthesia and Postoperative Analgesia With Ropivacaine or Levobupivacaine for Coronary Surgery: A Prospective Randomized Double-Blind Comparison||Centro Cardiologico Monzino|No|Completed|January 2003|June 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|80 Years|No|||October 2007|October 31, 2007|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552864||165422|
NCT00553228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL07-01|Pertussis Maternal Immunization Study|Immunization of Women With Diphtheria and Tetanus Toxoids Combined With Acellular Pertussis (Tdap) During the Mid Third Trimester of Pregnancy: An Evaluation of the Potential for Immunological Protection for the Neonate||Dalhousie University|Yes|Active, not recruiting|November 2007|December 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553228||165394|
NCT00553514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27818|AS900672-Enriched in Ovulation Induction|A Phase II, Multicentre, Randomised, Assessor-blinded, Active-comparator, Parallel-group Dose Finding Trial to Evaluate AS900672-enriched Versus Follitropin Alfa (GONAL-f®) in Oligo-anovulatory Infertile Women Undergoing Ovulation Induction (OI)||Merck KGaA||Terminated|December 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|71|||Female|18 Years|36 Years|No|||January 2014|January 20, 2014|November 1, 2007||No|The study was terminated after Merck Serono had taken the decision not to pursue the    development of AS900672-enriched in ovulation induction|No|May 29, 2013|https://clinicaltrials.gov/show/NCT00553514||165372|The study was terminated after Merck Serono had taken the decision not to pursue the development of AS900672-enriched in ovulation induction
NCT00553488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDT-ADD-07-002|Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating|A Mono Center Open Labeled, Randomized Study Examining the Effects of Intra-Dermal vs Subcutaneous Application of Regular Insulin or Rapid Acting Insulin Analogue on Postprandial Glycemic Excursions in Patients With Type 1 Diabetes||Becton, Dickinson and Company|No|Completed|September 2007|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Male|18 Years|55 Years|No|||August 2008|August 21, 2008|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00553488||165374|
NCT00553722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Shavit|Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?|Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?||Shaare Zedek Medical Center|No|Not yet recruiting|November 2007|November 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|27|||Both|16 Years|80 Years|No|||October 2007|November 5, 2007|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00553722||165356|
NCT00553995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23068|Effect of Salsalate on Bed Rest-Induced Vascular Dysfunction|Effect of Physical Inactivity on Endothelial Function||Boston University|No|Active, not recruiting|May 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|November 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00553995||165336|
NCT00554008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002184|Comparative Study of Laparoscopic Versus Open Appendectomy in Children|Randomized, Prospective, Single Blinded Trial of Laparoscopic Versus Open Appendectomy in Children||Oregon Health and Science University|Yes|Completed|December 2007|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|400|||Both|N/A|18 Years|No|||May 2012|May 25, 2012|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554008||165335|
NCT00554294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05HS026|Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial|Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial|trinkfit|Research Institute of Child Nutrition, Dortmund||Completed|April 2006|December 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2950|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||May 2009|May 27, 2009|November 5, 2007||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00554294||165314|
NCT00551174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA17904|A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment|Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550||Hoffmann-La Roche||Completed|October 2004|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|781|||Female|N/A|N/A|No|||July 2011|July 20, 2011|October 29, 2007|Yes|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00551174||165550|
NCT00550966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|077/25/2006|Efficacy of a Psychoeducative Program for Improving Quality of Life in Fibromyalgic Patients [Study Protocol]|Efficacy of a Psychoeducative Program for Improving Quality of Life in Fibromyalgic Patients [Study Protocol]|FIBRO-Qol|Institut Catala de Salut|No|Enrolling by invitation|September 2007|February 2010|Anticipated|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|109|||Both|18 Years|75 Years|No|||September 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00550966||165566|
NCT00540722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00018|Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|January 2008|||June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540722||166334|
NCT00540995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05013|Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer|Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Advanced Myeloid Malignancies||City of Hope Medical Center|Yes|Active, not recruiting|September 2006|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|6 Years|55 Years|No|||October 2015|October 8, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540995||166313|
NCT00541216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ephedrine-hmo-ctil|Ephedrine for the Treatment of Congenital Myasthenia|||Hadassah Medical Organization|No|Enrolling by invitation|October 2007|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|12 Years|75 Years||||October 2007|October 9, 2007|October 7, 2007||||No||https://clinicaltrials.gov/show/NCT00541216||166296|
NCT00541866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0012|Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans|Phase 1b/2, Open-Label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of Voreloxin Injection in Combination With Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia||Sunesis Pharmaceuticals|No|Completed|August 2007|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|October 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00541866||166247|
NCT00541879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 04-257 RR25 RR 020469|Obesity and Diabetes Prevention Through Science Enrichment|Type 2 Diabetes Knowledge: Obesity and Diabetes Prevention Through Science Enrichment|DKENERGY|Colorado State University|No|Completed|August 2001|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2909|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541879||166246|
NCT00541814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3367|Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function|Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial|CNIM-SRT|University Hospital Birmingham|Yes|Recruiting|October 2007|February 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2008|September 5, 2008|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00541814||166251|
NCT00541840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS01-07|Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma|Phase I-II, Not-Randomized, Multicenter Clinical Trial to Evaluate Safety and Efficacy of Sorafenib (BAY-43-9006) in Combination With Ifosfamide in Soft Tissue Sarcoma.||Grupo Espanol de Investigacion en Sarcomas|Yes|Recruiting|October 2007|April 2010|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|72 Years|No|||May 2008|May 8, 2008|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541840||166249|
NCT00552331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RL-003|Evaluation of the Effects of Less Invasive Stabilization System (LISS) Plating Techniques in Distal Femoral Fractures|Prospective Randomized Clinical Study to Evaluate the Effects of Less Invasive Stabilization System (LISS) Plating Techniques in Distal Femoral Fractures||Nova Scotia Health Authority|No|Completed|March 2003|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|N/A|No|||May 2009|June 27, 2011|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00552331||165463|
NCT00552578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD0400907A|Buprenorphine as a Treatment in Opiate Dependent Pain Patients|A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients||State University of New York at Buffalo|No|Terminated|October 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|November 1, 2007||No|"Tapering doses" protocol arm was not effective for treatment retention outcome.|No|January 21, 2009|https://clinicaltrials.gov/show/NCT00552578||165444|
NCT00552565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARDIS-1|Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)|A Randomized, Double-Blind, Placebo-Controlled Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)|ARDIS-1|AGI Therapeutics, Inc.|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|711|||Both|18 Years|70 Years|No|||June 2009|June 10, 2009|October 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00552565||165445|
NCT00552877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOIV-20070043|The SOURT OUT IV TRIAL|Randomized Clinical Comparison of the Xience V and the Cypher Coronary Stents in Non-selected Patients With Coronary Heart Disease|SORT OUT IV|Odense University Hospital|Yes|Completed|August 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2678|||Both|18 Years|N/A|No|||August 2009|August 12, 2009|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552877||165421|
NCT00552890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atkins-hmo-ctil|Modified Atkins Diet and Type 2 Diabetic Patients|Influende of a Modified Atkins Diet on Glucose Metabolism and Weight Loss in Obese Type 2 Diabetic Patients - A Randomized Controlled Trial||Hadassah Medical Organization|Yes|Completed|December 2001|February 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|35 Years|75 Years|No|||December 2001|November 1, 2007|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00552890||165420|
NCT00553748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0008186|Phase I, Open Label, Single Center Safety Study of [F-18]FLT|A Phase I, Open Label, Single Center Safety Study of [F-18]FLT||Siemens Molecular Imaging|No|Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|N/A|No|||July 2008|July 1, 2008|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553748||165354|
NCT00553501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50701|Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma|A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)||Alliance for Clinical Trials in Oncology|No|Completed|March 2008|July 2014|Actual|July 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|November 2, 2007|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00553501||165373|
NCT00553735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-05-034|The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye|The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye||Massachusetts Eye and Ear Infirmary|No|Completed|August 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553735||165355|
NCT00554021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDMC-CV0001|Infections Related Central Venous Catheters|Infections Associated With the Use of Central Venous Catheters Related in Critical Care Center.|CVL|National Defense Medical College, Japan|Yes|Completed|November 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|We will use the DNA from the only clinical isolated bacteria.|Both|14 Years|95 Years|No|Probability Sample|Critical Care staff|June 2009|June 10, 2009|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554021||165334|
NCT00554034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol C-4|Effect of Herbal Extracts on Gingival Inflammation|The Effect of Herbal Extracts on Inflammatory Enzymes in the Gingiva: a Dose Finding Study.||Shaare Zedek Medical Center||Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2009|December 19, 2010|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00554034||165333|
NCT00550641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-2006|Pool-based Exercise in Fibromyalgia Management|Pool-based Exercise in Fibromyalgia Management: a Prospective Randomized Comparison Between Stretching and Ai Chi||Universidad de Granada|No|Completed|March 2006|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|70 Years|No|||September 2007|April 5, 2010|October 26, 2007||||No||https://clinicaltrials.gov/show/NCT00550641||165590|
NCT00550940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705066R|Emotion/Behavior Problems, Neuropsychological Functioning, and Parental Adjustment in Children With Epilepsy|Emotion/Behavior Problems, Neuropsychological Functioning, and Parental Adjustment in Children and Adolescents With Epilepsy||National Taiwan University Hospital|Yes|Completed|July 2007|December 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|65|||Both|6 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|clinical sample|April 2012|May 16, 2012|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00550940||165568|
NCT00550979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001406|Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk|Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk||Brigham and Women's Hospital|No|Recruiting|September 2007|January 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|96|Samples With DNA|blood and urine|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Black and white women who have had uncomplicated pregnancies or pregnancies complicated by        gestational diabetes in the past 5 years|August 2013|August 28, 2013|October 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00550979||165565|
NCT00551486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071027|Pyrosequencing of the BRAFV600E Mutation|Diagnostic Value of Pyrosequencing for the BRAFV600E Mutation in Ultrasound-Guided Fine-Needle Aspiration Biopsy Samples of Thyroid Incidentalomas||Chungnam National University|Yes|Completed|June 2006|December 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|101|Samples With DNA|Fine needle aspiration samples of thyroid nodule|Both|20 Years|N/A|No|Non-Probability Sample|1. Patients with thyroid nodule larger than 1 cm, or nodule smaller than 1 cm that             required further evaluation because of suspicious ultrasound findings          2. The average size of the nodules was 1.0 cm.|October 2007|October 30, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551486||165526|
NCT00540735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2006-01|Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas|Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas - A Prospective, Multicentric and Randomized Study.|CK/PDT|University Hospital, Angers|Yes|Terminated|April 2008|November 2009||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||80|||Both|18 Years|N/A|No|||October 2007|February 3, 2010|October 5, 2007|||Big difficulties to enroll patients|No||https://clinicaltrials.gov/show/NCT00540735||166333|
NCT00540748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392-06154 1.2006.1683 (REK)|Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful?|Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful ?|oxystudien|Asker & Baerum Hospital|No|Completed|October 2007|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2009|April 15, 2010|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540748||166332|
NCT00541008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000569863|Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer|Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP||National Cancer Institute (NCI)||Recruiting|September 2007|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|92|||Both|18 Years|N/A|No|||August 2011|August 13, 2011|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541008||166312|
NCT00541229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-077|Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)|A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Clinical Trial of Sitagliptin 100 mg and Sitagliptin 200 mg in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet and Exercise||Merck Sharp & Dohme Corp.||Completed|August 2007|July 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|103|||Both|30 Years|65 Years|No|||February 2015|February 24, 2015|October 5, 2007|No|Yes||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00541229||166295|The pre-specified rule for non-superiority of sitagliptin 200 mg compared with 100 mg was met at the planned interim analysis. As such, the trial was terminated as pre-specified.
NCT00541242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-034|Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|December 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|586|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|October 5, 2007|Yes|Yes||No|September 19, 2011|https://clinicaltrials.gov/show/NCT00541242||166294|
NCT00541255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1408|A Long-Term Examination of Asthma From Childhood Through Adolescence|Epidemiology of Asthma and Allergic Disease: Risk and Prognosis in a Cohort From Birth to Adolescence||Isle of Wight NHS Trust|No|Active, not recruiting|September 2007|December 2016|Anticipated|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Whole blood, serum, saliva, urine|Both|17 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of around 1500 unselected subjects (now age 18) who were        recruited at birth. This is a homogenous population with 99% being Caucasians.|October 2015|October 6, 2015|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541255||166293|
NCT00541281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 04-001|Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer|Randomized Phase Ii Trial Of Weekly Docetaxel, Estramustine And Prednisone Versus Docetaxel And Prednisone In Patient With Hormone-Resistant Prostate Cancer||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|December 2003|February 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Male|18 Years|N/A|No|||October 2009|October 26, 2009|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00541281||166291|
NCT00542230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080004|Blood Sampling for Research Related to Sickle Cell Disease|High Sensitivity Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|October 2007|||||N/A|Observational|Time Perspective: Prospective|||Actual|31|||Both|8 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542230||166219|
NCT00542243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0499-B|A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy|A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of PROSCAR in Men With Initial Negative Prostate Biopsies|Prostress|University Health Network, Toronto|No|Completed|February 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|19|||Male|18 Years|N/A|No|||December 2015|December 7, 2015|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00542243||166218|
NCT00541554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-06-P05|Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia|Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial||Genovate Biotechnology Co., Ltd.,|No|Not yet recruiting|October 2007|February 2009|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|12 Years|65 Years|No|||October 2007|October 9, 2007|October 8, 2007||||No||https://clinicaltrials.gov/show/NCT00541554||166271|
NCT00541567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S319.2.002|BMS-646256 in Obese and Overweight Type 2 Diabetics|A Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Multicenter, Dose-Ranging Phase IIb Trial to Assess Glycemic and Weight Loss Efficacy and Safety of BMS-646256 in Overweight and Obese Patients With Type 2 Diabetes Inadequately Controlled by Diet and Exercise Only or With Metformin or Sulfonylurea Monotherapy||Solvay Pharmaceuticals|Yes|Withdrawn|March 2008|June 2010|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|70 Years|No|||January 2008|January 8, 2008|October 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00541567||166270|
NCT00543153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0435|The Exceptional Patient in Cancer Care|The Exceptional Patient in Cancer Care||M.D. Anderson Cancer Center|No|Completed|August 2007|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, 18 years of age or older, dianosed with cancer that were considered by their        physicians as having exceptional course of survival related to their specific disease        state.|July 2012|July 27, 2012|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00543153||166148|
NCT00542191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJCC 07-03|Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer|Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer||Leo W. Jenkins Cancer Center|No|Recruiting|July 2007|June 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|75 Years|No|||October 2014|October 23, 2014|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00542191||166222|
NCT00552344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87088|A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease|A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085||UCB Pharma|No|Completed|May 2008|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|403|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|October 31, 2007|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT00552344||165462|
NCT00552591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 6142|Family Heart Health Program: Randomized, Controlled Trial|Family Heart Health Program: Randomized, Controlled Trial|FHHP-RCT|Ottawa Heart Institute Research Corporation|No|Completed|September 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|426|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552591||165443|
NCT00553241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007020|Short-Term Prognosis Evaluation of Transient Ischemic Attack Patients Using ABCD2 Score|Phase 1 of Clinical Trial of Risk Factor, Prognosis, Imaging and Standard Management of Transient Ischemic Attack.||Capital Medical University|No|Recruiting|June 2007|January 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|patients diagnosed with transient will be enrolled in this study|January 2009|January 29, 2009|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553241||165393|
NCT00553254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471003|Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer|A Phase 1/2, Open Label, Single Arm Trial To Determine The Recommended Phase 2 Dose And Evaluate The Efficacy Of Pf 00299804 In Patients In Korea With Kras Wild Type Advanced NSCLC, Which Is Refractory To Chemotherapy And Erlotinib Or Gefitinib||Pfizer|No|Completed|February 2008|July 2014|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553254||165392|
NCT00554047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADE 072510|Comparison of Effectiveness and Costs of Post-diagnosis Treatment in Dementia|Effectiveness and Costs of Post-diagnosis Treatment in Dementia Coordinated by Multidisciplinary Memory Clinics in Comparison to Treatment Coordinated by General Practitioners|AD-Euro|Radboud University|No|Completed|December 2007|July 2010|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|220|||Both|N/A|N/A|No|||August 2010|January 7, 2011|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554047||165332|
NCT00553761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654/06|PERG and mfPERG in Band Atrophy|Pattern Electroretinogram and Multifocal Pattern Electroretinogram For the Detection of Neural Loss in Patients With Permanent Temporal Visual Field Defect From Chiasmal Compression||University of Sao Paulo|No|Completed|August 2006|July 2009|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with band atrophy from chismal compression and controls|November 2007|August 4, 2011|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00553761||165353|
NCT00554307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL IRB 328.07|Brain, Gut and Kidney Blood Flow During Medical Closure of PDA|Comparison of Cerebral, Renal and Mesenteric Perfusion Using Near Infrared Spectroscopy in Neonates During Patent Ductus Arteriosus Closure With Ibuprofen or Indomethacin.||University of Louisville|No|Withdrawn|November 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Preterm infants with patent ductus arteriosus requiring medical intervention|January 2015|January 22, 2015|November 2, 2007||No|Not able to enroll patients|No||https://clinicaltrials.gov/show/NCT00554307||165313|
NCT00554606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2211|Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis|A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis||Novartis|No|Completed|October 2007|||August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|75 Years|No|||May 2012|May 1, 2012|November 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00554606||165292|
NCT00550329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1251009|Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets|An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets Manufactured At Brooklyn, New York Versus At Barceloneta, Puerto Rico In Healthy Subjects||Pfizer||Completed|October 2007|November 2007|Actual|||Phase 1|Observational|Time Perspective: Prospective||||32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 26, 2007||||No||https://clinicaltrials.gov/show/NCT00550329||165614|
NCT00550342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 DK77329 (completed)|Rituximab Treatment of Focal Segmental Glomerulosclerosis|Anti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|60 Years|No|||April 2012|April 12, 2012|October 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00550342||165613|
NCT00550654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070230|Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain|A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligo||National Institutes of Health Clinical Center (CC)|No|Terminated|October 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 25, 2007|Yes|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00550654||165589|
NCT00540761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P000646|Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique|Natural History of Vulnerable Coronary Plaques||Massachusetts General Hospital|Yes|Recruiting|May 2007|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|320|||Both|21 Years|N/A|No|||February 2015|February 26, 2015|September 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540761||166331|
NCT00541021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564099|Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas.||National Cancer Institute (NCI)||Recruiting|December 2006|||December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|104|||Both|18 Years|N/A|No|||July 2009|December 13, 2009|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541021||166311|
NCT00541268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005606-45|Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality|A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study|DANISH|Danish Study Group|Yes|Active, not recruiting|February 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541268||166292|
NCT00541294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES104272|Diagnosis of Tuberculosis Infection in HIV Co-infected Children|Diagnosis of Tuberculosis Infection in HIV Co-infected Children|ThrasherIGRA|Case Western Reserve University|No|Recruiting|October 2007|September 2010|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|250|||Both|3 Months|15 Years|No|Non-Probability Sample|HIV seropositive and seronegative South African children (6months to 15years) with and        without M.tb exposure|August 2010|August 2, 2010|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541294||166290|
NCT00541580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOLD-001-HMO-CTIL|Comparative Results of Conservatively and Surgically Treated Adolescents With Triplane and Juvenile Tillaux Ankle Fractures After Skeletal Maturity|||Hadassah Medical Organization||Terminated||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|25 Years||Probability Sample|adolescents with triplane and juvenile Tillaux ankle fractures|September 2011|September 15, 2011|October 7, 2007||||No||https://clinicaltrials.gov/show/NCT00541580||166269|
NCT00541944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wue-CONA-33/07|Establishment of an Algorithm for a Clinical Classfication of Hypoosmolar Hyponatremia||CONA|University of Wuerzburg|No|Recruiting|April 2007|December 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|120|Samples Without DNA|Serum, plasma and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated in an University Hospital in Germany|April 2008|April 25, 2008|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00541944||166241|
NCT00541957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067779|Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients|Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients||Butler Hospital|No|Completed|April 2007|January 2010|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||July 2011|July 6, 2011|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00541957||166240|
NCT00542802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpIc 1151|Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis|Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis|EpIc|Scienze Neurologiche Ospedaliere|No|Recruiting|September 2007|June 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|630|||Both|18 Years|N/A|No|||May 2008|May 26, 2008|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00542802||166175|
NCT00542217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOBG-CL-001|Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection|Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG™ Injection in Healthy Adult Subjects||Biothera|Yes|Completed|December 2005|April 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542217||166220|
NCT00542464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOBG-CL-002|Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG™ Injection in Healthy Adult Subjects||Biothera|Yes|Completed|May 2006|September 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542464||166201|
NCT00542477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-001-US-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2008|||||N/A|N/A|N/A||||||||||||||April 29, 2008|October 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542477||166200|
NCT00553527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070144|Biomet Humeral Stem Data Collection|Biomet Humeral Stem Data Collection||Vanderbilt University|No|Terminated|July 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|2|||Both|18 Years|N/A|No|||August 2009|August 5, 2009|November 1, 2007||No|Sponsor decided to terminate the project due to low multi-center enrollment.|No||https://clinicaltrials.gov/show/NCT00553527||165371|
NCT00552604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-01|MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study|Randomised, Double-blind, Placebo-controlled Phase III Trial to Determine the Efficacy and Safety of a Standardised Oral Extract of Cannabis Sativa for the Symptomatic Relief of Muscle Stiffness and Pain in Multiple Sclerosis.|MUSEC|Institut fur Klinische Forschung, Germany|Yes|Terminated|June 2006|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|64 Years|No|||March 2015|March 24, 2015|November 1, 2007||No|due to recruitment problems / based on recommendation of Independent Review Board|No||https://clinicaltrials.gov/show/NCT00552604||165442|
NCT00552903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHKS-Z80|Randomised Trial of Health Coaching in Secondary Prevention of Diabetes and Heart Disease|Randomised Trial of Health Coaching in Secondary Prevention of Diabetes and Heart Disease|TerVa|Paijat-Hame Hospital District||Active, not recruiting|November 2007|May 2010|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|45 Years|N/A|No|||February 2009|February 3, 2009|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552903||165419|
NCT00553800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-TH-007|Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer|Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer|NSCLC|Fox Chase Cancer Center|No|Active, not recruiting|March 2007|April 2017|Anticipated|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|70 Years|N/A|No|||February 2016|February 4, 2016|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00553800||165350|
NCT00553813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI 287-06|A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer|A Phase 2, Open Label, Single Arm Trial of TPI 287 in Patients With Advanced, Unresectable Pancreatic Cancer After Prior Treatment With a Gemcitabine-based Therapy||Cortice Biosciences, Inc.||Terminated|October 2007|April 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|November 2, 2007|Yes|Yes|Insufficient funding|No||https://clinicaltrials.gov/show/NCT00553813||165349|
NCT00554073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB-angio herlev 2|Whole Body Magnetic Resonance Angiography in Ischemic Patients at 1.5 and 3T|Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia: A Comparison Between 1.5 and 3T MRI-systems||Copenhagen University Hospital at Herlev|Yes|Suspended|May 2008|August 2009|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with intermittent claudication (pheripheral arterial disease)|August 2009|August 18, 2009|November 5, 2007||No|It was not possible to perform 2 MRI studies in each patient due to practical problems. The    study was not suspended due to safety issues.|No||https://clinicaltrials.gov/show/NCT00554073||165331|
NCT00554320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP07066|Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain|Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain||Summa Health System|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|55 Years|No|||September 2009|September 17, 2009|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00554320||165312|
NCT00554619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB107818|A Study to Evaluate GSK1325760A - a Long-Term Extension Study|Study AMB107818, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open Label Study of GSK1325760A to Evaluate the Safety and Efficacy of GSK1325760A - a Long-term Extension Study -||GlaxoSmithKline||Completed|February 2008|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||October 2012|November 1, 2012|November 5, 2007||No||No|October 20, 2011|https://clinicaltrials.gov/show/NCT00554619||165291|
NCT00550355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6261002|Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Subject and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PD-0360324 in Patients With Rheumatoid Arthritis Receiving Methotrexate||Pfizer|No|Completed|August 2007|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|78|||Both|21 Years|70 Years|No|||July 2009|July 13, 2009|October 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00550355||165612|
NCT00550381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3235A1-1000|Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects|Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of HKI-357 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|October 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00550381||165610|
NCT00550992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000570260|Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia|International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia|Interfant06|Dutch Childhood Oncology Group|Yes|Recruiting|June 2007|||June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|445|||Both|N/A|1 Year|No|||February 2014|February 14, 2014|October 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00550992||165564|
NCT00551473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAV110285|Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.|An Open-Label Study of the Development of Pharmacodynamic Tolerance to 7-days Administration of Lavoltidine 40mg||GlaxoSmithKline|No|Completed|May 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551473||165527|
NCT00551213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04721|A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)|A Fixed-Sequence, Open-Label Study to Determine the Activity of SCH 717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed or Recurrent Colorectal Cancer||Merck Sharp & Dohme Corp.|No|Completed|November 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 29, 2007|Yes|Yes||No|November 10, 2015|https://clinicaltrials.gov/show/NCT00551213||165547|
NCT00551226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314-07|Follow up of Autoantibodies in Active Tuberculosis|Follow up of Autoantibodies in Active Tuberculosis||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2007|November 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Serum of patients|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with active tuberculosis who are currently receiving anti tuberculosis        drugs|October 2007|October 29, 2007|October 27, 2007||||No||https://clinicaltrials.gov/show/NCT00551226||165546|
NCT00551512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBP 06-01|Phase I Clinical and Pharmacokinetic (PK) Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors|Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors||CanBas Co. Ltd.|No|Completed|November 2006|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|N/A|No|||October 2011|October 31, 2011|October 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551512||165524|
NCT00541593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-164|Natural Orifice Translumenal Endoscopic Surgery (NOTES) Cystgastrostomy for the Treatment of Pancreatic Pseudocysts|Natural Orifice Translumenal Endoscopic Surgery (NOTES) Cystgastrostomy for the Treatment of Pancreatic Pseudocysts||Baystate Medical Center|No|Terminated|September 2007|June 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|October 7, 2007||No|SurgAssist device is no longer clinically available.|No|June 23, 2011|https://clinicaltrials.gov/show/NCT00541593||166268|Early termination due to the company that made the device going out of business; the company that acquired it chose not to market the device. Given the lack of clinical support, we chose to terminate the study.
NCT00541918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG-NKBEN/560/2006|COGNITIVE - Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations|COGNITIVE - Comparison of Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations||Medical University of Gdansk|No|Withdrawn|June 2007|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|55 Years|80 Years|No|||October 2015|October 27, 2015|October 9, 2007|Yes|Yes|study suspended due to staff indisposition|No||https://clinicaltrials.gov/show/NCT00541918||166243|
NCT00541931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10622|Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women|Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women||Stanford University||Completed|October 2007|January 2012|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541931||166242|
NCT00541606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAMPERED|Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes|Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED)|PAMPERED|Lahey Clinic|Yes|Completed|September 2000|July 2004|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|285|||Both|18 Years|N/A||||May 2009|May 15, 2009|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00541606||166267|
NCT00541619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE-No.3210|Sympathetic Overactivity in Essential Hypertension|Sympathetic Overactivity in Essential Hypertension||University of Erlangen-Nürnberg Medical School||Withdrawn|October 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients with primary hypertension.|April 2013|April 16, 2013|October 9, 2007||No|No patients could be recruited.|No||https://clinicaltrials.gov/show/NCT00541619||166266|
NCT00541970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110659|Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs|Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing||GlaxoSmithKline||Completed|October 2007|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|961|||Female|9 Years|25 Years|Accepts Healthy Volunteers|||April 2014|October 29, 2015|October 9, 2007|Yes|Yes||No|October 18, 2012|https://clinicaltrials.gov/show/NCT00541970||166239|If appropriate, describe significant limitations of the trial. Examples: Early termination leading to small number of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.
NCT00541983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052071|Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus|A Phase I, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus||XOMA (US) LLC|Yes|Completed|September 2007|February 2010|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|No|||May 2010|May 2, 2010|October 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00541983||166238|
NCT00541996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153A1-1116|Study Comparing Bioavailability of Oral Formulations of Vabicaserin|A Randomized, Open-Label, Single-Dose, 4-Period Crossover, Comparative Bioavailability Study of 3 Sustained- Release Formulations and an Immediate- Release Formulation of Vabicaserin (SCA-136) in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|August 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|||||||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 3, 2007|October 5, 2007||||||https://clinicaltrials.gov/show/NCT00541996||166237|
NCT00542256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0735535T|tDCS and Physical Therapy in Stroke|Effects of Transcranial DC Stimulation Coupled With Constraint Induced Movement Therapy on Motor Function in Stroke Patients||Beth Israel Deaconess Medical Center|Yes|Recruiting|September 2007|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||May 2008|May 9, 2008|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542256||166217|
NCT00542503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|478|Using Magnetic Resonance Imaging to Predict People Who Are Likely to Develop Flash Pulmonary Edema (The PREDICT Study)|Vascular Stiffness and Pulmonary Congestion|PREDICT|Wake Forest Baptist Health|Yes|Completed|June 2007|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|579|||Both|55 Years|85 Years|No|Non-Probability Sample|People with diabetes, high blood pressure, or coronary artery disease|December 2014|December 10, 2014|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00542503||166198|
NCT00542516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC524/04|Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty|Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty: Hydroxyethyl Starch Versus Ringer's Lactate||University of Sao Paulo|Yes|Completed|September 2006|November 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00542516||166197|
NCT00542529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CL-PGG-SCM0611|Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone|Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Single-Center Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone in Healthy Subjects||Biothera|Yes|Completed|November 2006|December 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542529||166196|
NCT00543439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-313|Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII|An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A||Pfizer|Yes|Recruiting|December 2007|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|6 Months|15 Years|No|||March 2016|March 23, 2016|October 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00543439||166127|
NCT00543452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-567|Effect of Oxygen on Core Temperature|Effect of Oxygen on Core Temperature||Umeå University||Completed|February 2005|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|N/A|N/A|No|||March 2011|April 6, 2011|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00543452||166126|
NCT00553306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2179.00|Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma|Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center|Yes|Completed|September 2007|||August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|75 Years|No|||April 2011|April 21, 2011|November 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00553306||165388|
NCT00553774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR#H47369-28112|Effect of Cocoa Flavanols on Vascular Function|Effect of Cocoa Flavanols on Vascular Function in Optimally Treated Coronary Artery Disease Patients: Interaction Between Endothelial Progenitor Cells, Reactivity of Micro- and Macrocirculation|Cocoa|University of California, San Francisco|No|Completed|March 2007|February 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|25|||Both|18 Years|N/A|No|||February 2007|May 5, 2008|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553774||165352|
NCT00553787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-303|Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions|A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions||VIVUS, Inc.|Yes|Completed|November 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2487|||Both|18 Years|70 Years|No|||September 2012|September 5, 2012|November 3, 2007|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00553787||165351|
NCT00554645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ø-2003-1-40|GRIB Forsoeget-2004|Multi-Disciplinary Group Intervention Versus Traditional Information Towards Severely Overweight Children and Their Families -|GRIB-2004|Forskningspuljen|No|Completed|January 2004|November 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|10 Years|15 Years|No|||November 2007|November 5, 2007|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00554645||165289|
NCT00554086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6876L00008|Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.|Phase 2 Trial of Maximum Androgen Blockade (MAB) Dose Escalation From 50 mg to 150 mg Bicalutamide (Casodex) for Biochemical Failure in Prostate Cancer Patients|CHICS|Canadian Urology Research Consortium|No|Completed|November 2005|September 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Male|18 Years|N/A|No|||May 2011|May 13, 2011|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554086||165330|
NCT00554333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID01C|Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine|An Open-Label, Multi-Centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine Administered by Intradermal Route (Flu-ID 15μg) Versus an Inactivated Adjuvanted Influenza Vaccine Administered by Intramuscular Route in Subjects 65 Years of Age or Older||Sanofi Pasteur MSD|No|Completed|October 2007|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|790|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 3, 2009|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00554333||165311|
NCT00550407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA104779|An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients|Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients||GlaxoSmithKline|No|Completed|November 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|215|||Both|20 Years|N/A|No|||June 2011|May 31, 2012|October 26, 2007||||No|May 24, 2010|https://clinicaltrials.gov/show/NCT00550407||165608|
NCT00554632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-168|Birth Control Pill vs Birth Control Patch Study|The Effects of Oral Contraceptive Pills vs Hormonal Patch on Coagulation Parameters|PvP|University of Vermont|Yes|Completed|April 2003|August 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||October 2007|November 6, 2007|November 6, 2007||||No||https://clinicaltrials.gov/show/NCT00554632||165290|
NCT00550368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|688|Clinical Experiment of Helicobacter Pylori Transmission|Effect of Gastric Acid and H. Pylori Infection on Infection With Enteropathogenic E. Coli||Stanford University||Completed|August 2005|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|35 Years|59 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550368||165611|
NCT00550667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705065R|Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood|Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood||National Taiwan University Hospital|Yes|Recruiting|October 2007|June 2013|Anticipated|||N/A|Observational|Observational Model: Case Control||1|Anticipated|1120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample & clinical sample|April 2012|May 16, 2012|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00550667||165588|
NCT00551239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573364|Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma|A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|August 2007|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2008|May 20, 2011|October 22, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00551239||165545|
NCT00551785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2007_01|Surveillance Study of Women Taking Intrinsa®|The Multinational Postmarketing Observational Study of Women Prescribed Intrinsa|EMPOWER|Center for Epidemiology and Health Research, Germany|Yes|Terminated|September 2007|June 2012|Actual|June 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|328|||Female|N/A|N/A|No|Non-Probability Sample|Women prescribed estrogen therapy or estrogen therapy in combination with Intrinsa|March 2015|March 24, 2015|October 30, 2007||No|The marketing authorization for Intrinsa was withdrawn.|No||https://clinicaltrials.gov/show/NCT00551785||165503|
NCT00552058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87085|Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease|Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.||UCB Pharma|No|Completed|March 2008|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|75 Years|No|||October 2011|October 14, 2011|October 18, 2007|Yes|Yes||No|October 8, 2010|https://clinicaltrials.gov/show/NCT00552058||165482|
NCT00541047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000571528|Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)|RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery||National Cancer Institute (NCI)||Recruiting|October 2007|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|4000|||Male|N/A|N/A|No|||July 2009|February 19, 2012|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541047||166309|
NCT00541333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYEE100907|Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration|Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration||The New York Eye & Ear Infirmary|Yes|Suspended|December 2007|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|50 Years|N/A|No|||May 2013|May 2, 2013|October 9, 2007|No|Yes|Reviewing data|No||https://clinicaltrials.gov/show/NCT00541333||166287|
NCT00541632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010737|BacLite Rapid MRSA Clinical Performance|BacLite Rapid MRSA Clinical Performance||3M|No|Terminated|October 2007|March 2008|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 14, 2008|October 6, 2007|||performance variability|No||https://clinicaltrials.gov/show/NCT00541632||166265|
NCT00541645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lib001-HMO-CTIL|Transient Osteoporosis of Pregnancy: A Possible Peptide Mediator|||Hadassah Medical Organization||Suspended||||||N/A|Observational|Time Perspective: Prospective|||||||Female|18 Years|45 Years||||March 2008|March 17, 2008|October 7, 2007||||No||https://clinicaltrials.gov/show/NCT00541645||166264|
NCT00542880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5892C00016|Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®|A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 μg, Compared With Seretide® Diskus® 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each.|SPEED|AstraZeneca|No|Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|442|||Both|40 Years|N/A|No|||July 2012|July 27, 2012|October 10, 2007|Yes|Yes||No|August 4, 2009|https://clinicaltrials.gov/show/NCT00542880||166169|
NCT00542893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPK105|A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine|A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma||Genta Incorporated|No|Completed|April 2006|September 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 11, 2012|October 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00542893||166168|
NCT00543218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6573|PTH Comparison in Post Menopausal Women|Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|December 2002|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Female|55 Years|85 Years|No|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00543218||166143|
NCT00542269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AGB01|Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome|A Twelve Week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Ramipril/Amlodipine (300/10/5-10 mg) Compared to the Combinations of Ramipril/Amlodipine (10/5-10 mg) and Aliskiren/Amlodipine (300/5-10 mg) in Patients With Essential Hypertension and Metabolic Syndrome Not Adequately Responsive to Amlodipine 5-10 mg|ALTO|Novartis|No|Terminated|March 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|178|||Both|18 Years|75 Years|No|||April 2011|April 26, 2011|October 9, 2007||No|Early termination of the study due to slow recruitment.|No|January 6, 2011|https://clinicaltrials.gov/show/NCT00542269||166216|
NCT00542555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT3012-X-301/301E|Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee|301: A Phase 3 Study of the Analgesic Efficacy and Safety of HCT 3012: A Parallel, Randomized, Double Blind, 13 Week Placebo and Naproxen Controlled, Multicenter Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Patients With Osteoarthritis of the Knee, Followed by Its Extension (301E): A Parallel, Randomized, Open-Label, Multicenter, 52-Week Follow-up Safety Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Subjects With Osteoarthritis of the Knee||NicOx|Yes|Completed|December 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|918|||Both|40 Years|N/A|No|||June 2011|June 16, 2011|October 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542555||166194|
NCT00542542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0961|Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery|Prospective Randomized Clinical Trial to Evaluate the Use of Paravertebral Blocks in Reconstructive Breast Surgery||M.D. Anderson Cancer Center|Yes|Completed|September 2007|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|89|||Female|18 Years|N/A|No|||March 2015|March 31, 2015|October 10, 2007||No||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00542542||166195|The study completed with measurement reporting issues (inconsistencies) leading to uninterpretable data.
NCT00542815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E10|A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia|A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia||Mitsubishi Tanabe Pharma Corporation|No|Completed|November 2007|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|632|||Both|N/A|N/A|No|||September 2014|September 24, 2014|October 10, 2007||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT00542815||166174|
NCT00554099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007020|Asacol Acute Diverticulitis(DIVA)Study|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period||Warner Chilcott|No|Completed|November 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|117|||Both|35 Years|85 Years|No|||April 2013|April 15, 2013|November 2, 2007|Yes|Yes||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00554099||165329|
NCT00553540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOI|A Randomized Prospective Study to Evaluate the Effectiveness of Orthopedic Spinal Supports in the Treatment of Low Back Pain|A Randomized Prospective Study to Evaluate the Effectiveness of Orthopedic Spinal Supports in the Treatment of Low Back Pain||Cleveland Clinic Florida|Yes|Completed|October 2006|August 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|February 19, 2015|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553540||165370|
NCT00554385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-178|A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|The Long-term Safety and Tolerability of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study||Abbott|Yes|Terminated|November 2007|||August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|283|||Both|6 Years|12 Years|No|||August 2011|August 18, 2011|November 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554385||165307|
NCT00554658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00015|Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients|Quetiapine Induced Neuroplasticity in Schizophrenic Patients: A Combined Transcranial Magnetic Stimulation (TMS) and Voxel-based Morphometry (VBM) Study||University of Regensburg|No|Completed|March 2008|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|65 Years|No|||October 2011|October 21, 2011|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554658||165288|
NCT00550394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA|Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults|Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Alcohol Use in Adolescents & Young Adults||University of Cincinnati|No|Completed|April 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|12 Years|25 Years|No|||October 2014|October 1, 2014|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550394||165609|
NCT00550680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20952|A Study of Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous Mircera for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|February 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00550680||165587|
NCT00550420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA102677|Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers|An Open-label Extension Study of the Long-term Safety and Efficacy of Rosiglitazone Extended-release (RSG XR) in Subjects With Mild-to-moderate Alzheimer's Disease (REFLECT-5)||GlaxoSmithKline||Terminated|October 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|383|||Both|51 Years|91 Years|No|||November 2013|November 21, 2013|October 25, 2007|Yes|Yes|Based on preliminary parent study results|No||https://clinicaltrials.gov/show/NCT00550420||165607|
NCT00550693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biopatch 400-05-005|Trial Evaluating the Efficacy of a Chlorhexidine-Impregnated Sponge (BIOPATCH®) to Reduce Catheter-Related Bloodstream Infections in Hemodialysis Patients|A Crossover Intervention Trial Evaluating the Efficacy of a Chlorhexidine-Impregnated Sponge (BIOPATCH®) to Reduce Catheter-Related Bloodstream Infections in Hemodialysis Patients||Washington University School of Medicine|Yes|Completed|April 2004|March 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|85 Years|No|||October 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00550693||165586|
NCT00550706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDU2724_CTIL|Drug Utilization Prevalence in a Pediatric Care Medical Center|Drug Utilization Prevalence in a Pediatric Care Medical Center||Rambam Health Care Campus|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|567|||Both|1 Month|18 Years|No|Non-Probability Sample|Admitted children for medical treatment in two different pediatric departments|June 2013|June 10, 2013|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00550706||165585|
NCT00551005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01036|Etoposide and Celecoxib in Patients With Advanced Cancer|Phase I Trial of Oral Etoposide in Combination With Celecoxib in Patients With Advanced Malignancies||City of Hope Medical Center||Completed|December 2001|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|58|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|October 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551005||165563|
NCT00551525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0622|Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer|A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 2008|||September 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|October 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551525||165523|
NCT00553904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26708|Effect of Cranberry Juice on Endothelial Function|Long-Term Effects of Cranberry Juice on Endothelial Function in Patients With Coronary Artery Disease||Boston University|No|Completed|February 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|40|||Both|21 Years|80 Years|No|||June 2009|June 16, 2009|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00553904||165343|
NCT00541060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061009|Study of Factors of Genetic Susceptibility Associated to Severe Caries Phenotype|Study of Factors of Genetic Susceptibility Associated to Severe Caries Phenotype in Young Patients. First Approach by Systematic Screening of Candidate Genes|Cariogene|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|390|||Both|2 Years|30 Years|Accepts Healthy Volunteers|||November 2010|December 17, 2010|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00541060||166308|
NCT00541346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD485-420-Lock|A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms|Phase III Study of Autism Co-Morbid for Attention Deficit Hyperactivity Disorder||University of Oklahoma|Yes|Completed|September 2007|February 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|6 Years|11 Years|No|||December 2013|December 19, 2013|October 8, 2007||No||No|November 15, 2010|https://clinicaltrials.gov/show/NCT00541346||166286|
NCT00542568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-001-02|Safety and Efficacy of Sustained Erythropoietin Therapy|Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients Using EPODURE Biopump||Medgenics Medical Israel Ltd.|Yes|Completed|August 2008|January 2013|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|75 Years|No|||April 2014|April 16, 2014|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542568||166193|
NCT00542581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI 07-001|Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.|Evaluation of the Acrysof Toric SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.00 D.|TORILIOL|Medical University of South Carolina|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|21 Years|N/A|No|||October 2010|August 11, 2011|October 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00542581||166192|
NCT00542607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00324|Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis|Trial to Compare the Efficacy and Safety of Levocetirizine 5 mg od and Fexofenadine 120 mg od in Reducing Symptoms of Seasonal Allergic Rhinitis in Grass Pollen Sensitized Adults||UCB Pharma|No|Completed|September 2002|December 2002|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|94|||Both|18 Years|55 Years|No|||September 2009|December 11, 2013|October 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00542607||166190|
NCT00542906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701023|Functional Organization of Somatosensory Responses in the Secondary Somatosensitive Area and Insula|Functional Organization of Somatosensory Responses in the Secondary Somatosensitive Area (SII) and Insula : an fMRI Study||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 16, 2009|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00542906||166167|
NCT00543231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPKS106|A Phase I Study of G3139 Subcutaneous in Solid Tumors|A Pharmacokinetic and Safety Assessment of G3139 Administered by Subcutaneous Injection to Patients With Solid Tumors||Genta Incorporated||Completed|December 2005|December 2006||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|8|||Both|18 Years|N/A|No|||December 2005|October 11, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00543231||166142|
NCT00543517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-023|Study A - MK0767 Monotherapy Study|||Merck Sharp & Dohme Corp.||Terminated|February 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|99|||Both|21 Years|78 Years|No|||February 2015|February 9, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543517||166121|
NCT00542854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB-07-08-0308|iPod and Other MP3 Players on ICDs and Pacemakers in Children|A Pilot Study on the Effects of Digital Music Players on Implantable Cardioverter Defibrillators and Pacemakers in Pediatrics and Congenital Heart Disease||Children's Hospital Boston|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|100|||Both|4 Years|55 Years|No|Probability Sample|Children and adults with congenital heart disease who have an implanted pacemaker or        defibrillator|January 2009|January 27, 2009|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542854||166171|
NCT00542867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-CB-CRE-2006/01|Pan-European Survey on the Under Treatment of Hypercholesterolemia|Pan-European Survey on the Under Treatment of Hypercholesterolemia|CEPHEUS|AstraZeneca|No|Completed|January 2006|November 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|6500|||Both|18 Years|N/A|No|||November 2007|November 19, 2007|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00542867||166170|
NCT00542828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThymoHEM01206|Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome|A Phase II Study of the Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in Patients With Low and Intermediate-1 Risk Myelodysplastic Syndrome|RISE|Sanofi|No|Terminated|October 2007|July 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|70 Years|No|||March 2015|March 17, 2015|October 10, 2007|Yes|Yes|Study terminated due to slow enrollment.|No|April 7, 2010|https://clinicaltrials.gov/show/NCT00542828||166173|The study was terminated early due to a slow enrollment rate; therefore, only safety data were collected from participants for 45 days following the last day of infusion (Day 5).
NCT00542841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5607|Examining Genetic Differences Among People With 21-Hydroxylase Deficiency|Modifier Genes in 21-Hydroxylase Deficiency||Icahn School of Medicine at Mount Sinai|Yes|Completed|August 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|99|||Both|18 Years|50 Years|No|||December 2015|December 10, 2015|October 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542841||166172|
NCT00554346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709062M|A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction|A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction||National Taiwan University Hospital|Yes|Completed|May 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|16 Years|35 Years|No|||June 2010|June 20, 2010|November 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00554346||165310|
NCT00554359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK.002|A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery|A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients Undergoing Major Cardiovascular Surgery||Quark Pharmaceuticals|Yes|Completed|August 2007|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|16|||Both|21 Years|85 Years|No|||February 2011|February 22, 2011|November 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554359||165309|
NCT00554398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTEGRAL|Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression|Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression||Germans Trias i Pujol Hospital|No|Completed|November 2007|September 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||November 2009|November 12, 2009|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554398||165306|
NCT00554671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAB 06-269|Pharmacist-led Group Medical Visits to Help With Diabetes Management|Group Intervention for DM Guideline Implementation|MEDIC-1 year|VA Office of Research and Development|Yes|Completed|May 2008|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||October 2014|April 6, 2015|November 5, 2007||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00554671||165287|
NCT00554684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-171|Treatment Intensity/Factors Predicting Short and Long Term Outcomes in Elderly Critically Ill Patients|Treatment Intensity and Factors Predicting Short and Long Term Outcomes in Elderly and Very Elderly Patients Admitted to Intensive Care Units||St. Luke's-Roosevelt Hospital Center|No|Completed|July 2007|August 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|399|||Both|65 Years|N/A|No|Probability Sample|Critically Ill Elderly Patients|August 2012|August 22, 2012|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554684||165286|
NCT00550433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1117|Study Evaluating Bazedoxifene/CE in Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Clinical and Commercial Formulations of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2007|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|35 Years|70 Years|Accepts Healthy Volunteers|||January 2008|January 11, 2008|October 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00550433||165606|
NCT00550732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05090|A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)|A Phase II Study on Treatment of Refractory Fungal Infections With Posaconazole. The "TIP" Study.|TIP|Merck Sharp & Dohme Corp.|Yes|Completed|December 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|13 Years|N/A|No|||August 2015|August 4, 2015|October 29, 2007|No|Yes||No|September 11, 2013|https://clinicaltrials.gov/show/NCT00550732||165584|
NCT00551018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04875|Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)|Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects||Merck Sharp & Dohme Corp.|Yes|Completed|December 2007|October 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|October 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551018||165562|
NCT00553072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIMS-001|Magnesium Sulphate in Perinatal Asphyxia|Magnesium Sulphate in Perinatal Asphyxia: A Randomized Placebo Controlled Trial.|Magsulf|Sheri Kashmir Institute of Medical Sciences|Yes|Completed|September 2004|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|6 Hours|No|||November 2013|November 29, 2013|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553072||165406|
NCT00553085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2006.2943|Anxiety Disorders in Children - Association With Neurodevelopmental Delay/Disorder|Anxiety Disorders in Children - Association With Neurodevelopmental Delay/Disorder and Temperament/Personality. A Clinical Case-control Study||Regionsenter for barn og unges psykiske helse|No|Completed|September 2007|March 2014|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|141|Samples Without DNA|Saliva for measuring Cortisol|Both|7 Years|13 Years|Accepts Healthy Volunteers|Probability Sample|Consecutive patient sampling|June 2014|June 19, 2014|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553085||165405|
NCT00554437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-Prevention Funding|Kenosha County Falls Prevention Study|Kenosha County Falls Prevention Study: An Intermediate-intensity, Community-based, Multifactorial Intervention||University of Wisconsin, Madison|No|Completed|May 2002|June 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|349|||Both|65 Years|N/A|No|||November 2008|October 1, 2015|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00554437||165303|
NCT00554450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-007|Renal Impairment in Type 2 Diabetic Subjects|The Pharmacodynamics, Pharmacokinetics, and Safety of Dapagliflozin in Type 2 Diabetic Subjects With Mild, Moderate, and Severe Renal Impairment||AstraZeneca|No|Completed|March 2006|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|November 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00554450||165302|
NCT00542022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812-008|Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)|A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0812 in Rheumatoid Arthritis Patients||Merck Sharp & Dohme Corp.||Completed|June 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|149|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542022||166235|
NCT00542282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB033|Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma|Evaluation of Vibration Response Imaging (VRI) in Chronic Obstructive Pulmonary Disease and Asthma Patients Before and After Bronchodilators||Deep Breeze|No|Completed|November 2006|August 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients who are either suspected of pulmonary obstruction or already diagnosed and are        scheduled to perform a spirometry test with pre and post administration of bronchodilators        will be enrolled in this study|June 2009|June 15, 2009|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542282||166215|
NCT00542308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN205|Zalutumumab in Non-curable Patients With SCCHN|An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.||Genmab|Yes|Completed|January 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|90|||Both|18 Years|N/A|No|||January 2012|August 12, 2014|October 10, 2007|Yes|Yes||No|August 12, 2014|https://clinicaltrials.gov/show/NCT00542308||166213|This was an uncontrolled single-arm open-label trial with no formal statistical tests planned.
NCT00542594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OFR-ARI-2005/1|Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy|A Report Upon a Cohort of Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy for Hormone-dependant Breast Cancer. Long-term Tolerance Evaluation|ARIES|AstraZeneca|No|Terminated|November 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1840|||Female|N/A|N/A|No|Probability Sample|Woman seen by their physician in the current care setting and for whom a treatment with        anastrozole is decided by the physician (adjuvant treatment of breast cancer in        postmenopausal women with hormone receptor positive status)|February 2013|February 6, 2013|October 9, 2007|No|Yes|No results are avaialble as the study did not complete according to the protocol|No||https://clinicaltrials.gov/show/NCT00542594||166191|
NCT00536796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAT-CRE-2007/2|Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets|Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets||AstraZeneca||Completed|September 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1096|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female secondary prevention patients with: coronary disease with event: acute        coronary syndrome, status post MI, PTCA, CABG, angiographically verified), PAVK (min. IIb        or S.p. revascularization), stroke/TIA, carotis-plaque (asymptomatic min. 70% or S.p.        revascularization), Diabetes Mellitus (type I, II)|October 2014|October 29, 2014|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536796||166631|
NCT00536809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF108991|Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer|A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer||GlaxoSmithKline|No|Completed|September 2007|November 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||February 2011|March 15, 2012|September 27, 2007|Yes|Yes||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00536809||166630|Phase II of the study was terminated due to lake of interest. Two participants were enrolled prior to termination. Due to the small sample size in Phase II, the data were not analyzed. The two participants' data were analyzed with Phase I data.
NCT00543543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-001|Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)|A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|September 2007|October 2016|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|14840|||Female|16 Years|26 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 12, 2007|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00543543||166119|
NCT00543530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0831-908|Pediatric Expanded Access Program-Oral Solution (0831-908)|A Noncomparative,Open, Multisite Study to Monitor the Safety and Tolerability of Efavirenz Oral Solution Given in Combination Antiretroviral Therapy (ART) in ART-naive or Experienced HIV-1 Infected Patients Age 3 to 16 Years Who Have Failed Therapy or Are Intorerant to Their Current ART Regimen||Merck Sharp & Dohme Corp.||Completed|March 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|3 Years|16 Years|No|||November 2015|November 26, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00543530||166120|
NCT00543894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-HB-MER-2005/1|Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients|Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A Prospective, Observational, Multicenter Study (ANTHICUS)|ANTHICUS|AstraZeneca|No|Completed|February 2006|||||N/A|Observational|Time Perspective: Prospective|||Actual|500|||Both|N/A|N/A||||June 2007|August 11, 2008|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00543894||166093|
NCT00543192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC 07703|Sexual Functioning in Endometrial Cancer|Sexual Functioning in Endometrial Cancer Survivors||University of Wisconsin, Madison|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|73|||Female|19 Years|N/A|No|Non-Probability Sample|University of Wisconsin Gynecologic Oncology and Radiation Oncology Clinics|September 2009|September 30, 2015|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00543192||166145|
NCT00543205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPK103|Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment|A Pharmacokinetic Study of Genasense® (Bcl-2 Antisense Oligonucleotide) in Combination With Dacarbazine (DTIC) in Subjects With Advanced Melanoma and Normal or Impaired Hepatic Function||Genta Incorporated|No|Terminated|August 2005|May 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||March 2009|November 4, 2011|October 10, 2007|No|Yes|Terminated due to very slow enrollment|No||https://clinicaltrials.gov/show/NCT00543205||166144|
NCT00553553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|St. Vincent's Hospital Ireland|Efficacy of Multimodal Opioid Therapy During Hepatic Resection Surgery|Efficacy Of IV Morphine vs Remifentanil-Intrathecal Morphine Analgesia During Hepatic Resection Surgery|RITM-IVM|St Vincent's University Hospital, Ireland|No|Recruiting|September 2007|June 2008|Anticipated|May 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|No|||December 2008|December 30, 2008|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553553||165369|
NCT00553852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-5|Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity|Evaluation of GH/IGF-I Axis and of Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity: Relationships With Body Composition|GH&LASGB|Federico II University|Yes|Completed|July 2007|March 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|No|||March 2008|March 27, 2008|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00553852||165347|
NCT00553865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OJP-2028-II|Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets|A 8-Week, Randomized, Double-blind, Parallel Designed, Phase II Multi-center Clinical Trial to Evaluate the Antihypertensive Efficacy and the Safety of OJP-2028 Tablets in Patients With the Uncomplicated Essential Hypertension||Jeil Pharmaceutical Co., Ltd.|No|Completed|November 2007|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|120|||Both|18 Years|75 Years|No|||September 2014|September 10, 2014|November 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00553865||165346|
NCT00554112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-017-07F|Regulation of B-Cell Function & Glucose Tolerance in Older People|Regulation of B-Cell Function & Glucose Tolerance in Older People||VA Office of Research and Development|Yes|Terminated|November 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|60 Years|80 Years|No|||August 2011|August 10, 2011|November 5, 2007||No|PI left the VA, per Central Office|No||https://clinicaltrials.gov/show/NCT00554112||165328|
NCT00554372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-IT-HEP007|A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma|A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma||SillaJen, Inc.|Yes|Completed|August 2008|February 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2011|January 6, 2016|November 2, 2007|Yes|Yes||No|May 12, 2015|https://clinicaltrials.gov/show/NCT00554372||165308|
NCT00552760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006R|Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder|A Double-Blind, Randomized, Placebo-Controlled Trial of Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder.|Ram-TIME|Lehigh Valley Hospital|Yes|Completed|November 2007|May 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|No|||March 2014|March 17, 2014|October 31, 2007|Yes|Yes||No|May 29, 2010|https://clinicaltrials.gov/show/NCT00552760||165430|
NCT00552773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|434-083|Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis|A Randomized, Double-blind, Placebo Controlled, Parallel Group Trial of Cyclamen Europaeum Extract Nasal Spray 10% (v/v) in the Treatment of Subjects With Acute Sinusitis||Dey|Yes|Completed|November 2007|December 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|70 Years|No|||November 2011|May 31, 2013|October 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00552773||165429|
NCT00552786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704018M|Antioxidation Medication for Noise-induced Hearing Loss|Antioxidation Medication for Noise-induced Hearing Loss||National Taiwan University Hospital|No|Completed|November 2007|March 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|53|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||November 2009|July 1, 2010|November 1, 2007||No||No|March 29, 2009|https://clinicaltrials.gov/show/NCT00552786||165428|No text entered.
NCT00550446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921035|A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis|A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis||Pfizer|No|Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|386|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|October 25, 2007|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00550446||165605|
NCT00550745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-020|ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)|A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age||Merck Sharp & Dohme Corp.||Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|11999|||Both|60 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|October 29, 2007|Yes|Yes||No|January 7, 2010|https://clinicaltrials.gov/show/NCT00550745||165583|
NCT00550758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McH-Spir- preschool_CTIL|Spirometry and Methacholine Challenge Test in Asthmatic Children Age 3-6years|The Effect of Singular (Montelukast) 4mg on Hypersensitivity of the Airways in Children 3-5 Years Old. + Extended Study Hyprsensitivity of the Airways in Asthmatic Children Age 3-6years|MCH-preschool|Rambam Health Care Campus|Yes|Terminated|May 2004|April 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|84|||Both|3 Years|6 Years|No|||October 2007|October 29, 2007|October 20, 2007|||the study has recently ended, all information gathred as planed|No||https://clinicaltrials.gov/show/NCT00550758||165582|
NCT00551031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID29|Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects|Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.||Sanofi|Yes|Completed|October 2007|November 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|2098|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 13, 2011|October 29, 2007|Yes|Yes||No|October 13, 2011|https://clinicaltrials.gov/show/NCT00551031||165561|
NCT00551252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIMe/01/06|A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma|A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit||Gruppo Italiano MEsotelioma|Yes|Not yet recruiting|January 2008|December 2009|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|75 Years|No|||October 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551252||165544|
NCT00550771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05048|Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)|Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy in Patients With HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH||Merck Sharp & Dohme Corp.||Completed|July 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|181|||Female|18 Years|N/A|No|||October 2015|October 1, 2015|October 29, 2007||No||No|August 26, 2011|https://clinicaltrials.gov/show/NCT00550771||165581|Any follow-up data from this study should be considered with caution as the planned 2-year follow-up was curtailed because of administrative reasons.
NCT00551265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0243|Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy|A Randomized Pilot Trial of Consolidation With an Adjuvant Ovarian Cancer Vaccine Oregovomab (Ovarex ®) With/Without Single-Dose Cyclophosphamide After a Complete Clinical Response to Second-Line Taxane/Platinum-Based Therapy to Determine Immune Response and Time to Progression in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Withdrawn|October 2007|||January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|October 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551265||165543|
NCT00552084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543|Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation|Fish Oil for Atrial Fibrillation - Effect and Mechanisms||Vanderbilt University|Yes|Completed|November 2007|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Both|21 Years|N/A|No|||November 2014|November 18, 2014|October 31, 2007|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT00552084||165480|We determined recurrence of Atrial Fibrillation(AF) by both routine and symptomatic TTM transmissions. We did not examine the effect of therapy on total AF burden. Sample size was relatively small, and included a heterogeneous patient population.
NCT00553605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3481065|Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic|A Double-Blind, Double-Dummy, Randomized, Multicenter Study Comparing The Analgesic Efficacy And Safety Of Parecoxib 40mg I.V. To Ketoprofen 100mg I.V. In Renal Colic|NAP|Pfizer|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|65 Years|No|||December 2012|December 20, 2012|November 2, 2007||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00553605||165365|PR at all time points, proportion of participants with >= 1 grade improvement in PR 30 min were replaced by PR at 30 and 120 min; number of participants with response in PI included; time to RM reported as number, due to change in planned analysis.
NCT00550472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H18-05|The Effect of a Probiotic Intervention in Healthy Subjects and Patients With Atopic Dermatitis|Intervention Study on the Effects of a Probiotic Yoghurt Drink on the Immune System and Further Physiological Parameters in Patients With Atopic Dermatitis and Healthy Persons||University of Jena|Yes|Completed|December 2004|July 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2008|April 10, 2008|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550472||165603|
NCT00550485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L3/2005|Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene|Blood-brain-barrier Permeability of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene: Effect on Sleep and Procedural Learning||Max-Planck-Institute of Psychiatry|No|Suspended|October 2007|June 2016|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|October 29, 2007||No|Reconsidering study methods and design|No||https://clinicaltrials.gov/show/NCT00550485||165602|
NCT00541671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27002|Prevention of Narcotic-Induced Nausea|Prevention of Narcotic-induced Nausea With Promethazine, a Randomized, Double-blind Placebo-controlled Trial||Christiana Care Health Services|No|Terminated|February 2007|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 12, 2014|October 5, 2007||No|Terminated: recruiting or enrolling participants has halted prematurely and will not resume;    participants are no longer being examined or treated|No|May 29, 2012|https://clinicaltrials.gov/show/NCT00541671||166262|Early termination due to small numbers of subjects and incomplete data for analysis
NCT00542035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-221|A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction|||Array BioPharma|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|103|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 6, 2012|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542035||166234|
NCT00542295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMTO601|Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome|Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial||Laboratoires Mayoly Spindler|Yes|Completed|July 2007|September 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||September 2008|September 30, 2008|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542295||166214|
NCT00536536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0706-10090|Evaluating the Transferability of a Successful, Hospital-based, Childhood Obesity Clinic to Primary Care: a Pilot Study|Evaluating the Transferability of a Successful, Hospital-based, Childhood Obesity Clinic to Primary Care: a Pilot Study||University of Bristol|No|Completed|April 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|5 Years|17 Years|No|||February 2009|August 23, 2011|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536536||166650|
NCT00537420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-002|A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects|A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients||Nastech Pharmaceutical Company, Inc.|No|Completed|October 2007|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|551|||Both|18 Years|65 Years|No|||September 2008|September 12, 2008|September 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537420||166584|
NCT00543907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000232/1|Outcomes of a Deep Inferior Epigastric Perforator Flap Program|Outcomes of a Deep Inferior Epigastric Perforator Flap Program||Beth Israel Deaconess Medical Center|No|Recruiting|September 2007|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2400|||Female|20 Years|70 Years|No|Non-Probability Sample|All women who have undergone mastectomy for breast cancer between 2001 and 2007 at the        BIDMC.|January 2016|January 11, 2016|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00543907||166092|
NCT00543881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01MG531|Telemedical Interventional Monitoring in Heart Failure|Telemedical Interventional Monitoring in Heart Failure (TIM-HF)|TIM-HF|Charite University, Berlin, Germany|Yes|Completed|January 2008|October 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|710|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00543881||166094|
NCT00553878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURC/CUOG-AVIAS-0601|Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer|Multi Center Double Blind Study Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer|AVIAS|Canadian Urology Research Consortium|Yes|Active, not recruiting|March 2007|December 2012|Anticipated|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Anticipated|100|||Male|45 Years|80 Years|No|||December 2011|July 31, 2012|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00553878||165345|
NCT00554125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSH-LCI-FJ-0002|Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria|A Prospective Randomised, Open-Labeled Study Comparing Sirolimus Versus FK506 In OLT for Patients With HCC Exceeding Milan Criteria||Fudan University|Yes|Recruiting|August 2007|August 2013|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|220|||Both|18 Years|75 Years|No|||October 2007|November 5, 2007|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00554125||165327|
NCT00554138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rosudip01|The Effect of Rosuvastatin on Adenosine Metabolism|Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.||Radboud University||Completed|November 2007|April 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 22, 2008|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00554138||165326|
NCT00550836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N064B|Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer|Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine vs. Erlotinib and Gemcitabine in Patients With Untreated, Metastatic Pancreatic Adenocarcinoma||Alliance for Clinical Trials in Oncology|No|Completed|March 2009|May 2013|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|October 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00550836||165576|
NCT00550849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-C-0701|Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction|Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 (CDDO-Me) Administered Orally for 14 Days in Patients With Hepatic Dysfunction||Reata Pharmaceuticals, Inc.|No|Terminated|April 2007|November 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||November 2007|November 6, 2007|October 26, 2007|||Enrollment discontinued after second cohort completed.|No||https://clinicaltrials.gov/show/NCT00550849||165575|
NCT00554190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOT 1.0|Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel|A Prospective, Multi-Center, Randomized, Controlled, Subject-Blinded Study to Evaluate the Safety and Effectiveness of AdvaCoat Sinus Gel Following Endoscopic Ethmoid Sinus Surgery||Carbylan Therapeutics, Inc.|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|85 Years|No|||March 2009|April 22, 2009|November 2, 2007||No||No|November 14, 2008|https://clinicaltrials.gov/show/NCT00554190||165322|
NCT00554762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBA110877|Dose Response and Efficacy of GW842166 in Pain|A Phase I, Placebo Controlled, Randomised, Double Blind Two-way Crossover Study to Investigate the Dose Response and Efficacy of Single and Repeat Doses of GW842166 in Healthy Volunteers Using Pharmacodynamic Pain Assessments.||GlaxoSmithKline|No|Withdrawn|November 2007|March 2008|Anticipated|March 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|November 5, 2007||No|Compound terminated|No||https://clinicaltrials.gov/show/NCT00554762||165280|
NCT00550524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3087|Stem Cell Transplantation for the Treatment of Knee Osteoarthritis|Phase 1 Study of Bone Marrow - Derived Stem Cell for the Treatment of Knee Osteoarthritis||Tehran University of Medical Sciences|Yes|Enrolling by invitation|December 2007|November 2010|Anticipated|November 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|40 Years|70 Years|No|||November 2010|November 19, 2010|October 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00550524||165599|
NCT00550537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC-THO-0640|Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients With Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Treated With the EGFR-TKI, Erlotinib||Vanderbilt-Ingram Cancer Center|Yes|Active, not recruiting|October 2007|||December 2012|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|October 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00550537||165598|
NCT00550784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00067|Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Phase I Trial of Tandem Chemotherapy Cycles as Consolidation Therapy for High-Risk Epithelial Ovarian and Primary Peritoneal Cancer Utilizing Intraperitoneal Paclitaxel/IV Cyclophosphamide Followed by IV Topotecan/Intraperitoneal Cisplatin/IV Melphalan Using Hematopoietic Stem Cell Support||City of Hope Medical Center||Completed|January 2001|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Actual|8|||Female|N/A|60 Years|No|||October 2014|October 3, 2014|October 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00550784||165580|
NCT00552097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02578|Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)|Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial)|ENHANCE|Merck Sharp & Dohme Corp.|No|Completed|June 2002|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|720|||Both|30 Years|75 Years|No|||April 2015|April 22, 2015|October 31, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00552097||165479|
NCT00554164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETAL trial|Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas|Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas|PETAL|University Hospital, Essen|Yes|Active, not recruiting|November 2007|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|696|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554164||165324|
NCT00563186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-PHE-81963|Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled Trial|Physical Plant Design and Engineering Controls and the Prevention of Nosocomial Infections and Antibiotic Resistant Organism Colonization Events - A Proposal for a Prospective Controlled Trial||University of Calgary|No|Recruiting|June 2007|October 2009|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|3600|||Both|18 Years|N/A|No|||March 2009|March 6, 2009|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00563186||164653|
NCT00535990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070449|Minimally Invasive Surgery (MIS) Database for the Purpose of Research|Minimally Invasive Surgery (MIS) Database Looking at Patterns of Care, Outcomes, and Prognostic Analysis for the Purpose of Research||University of California, San Diego|No|Completed|September 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All male and female patients undergoing surgery at this center for either obesity surgery        or for miimally invasive surgery.|August 2010|August 27, 2010|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00535990||166692|
NCT00536263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05170|PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)|An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients||Merck Sharp & Dohme Corp.|No|Completed|September 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|671|||Both|18 Years|65 Years|No|||February 2015|February 25, 2015|September 26, 2007|No|Yes||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00536263||166671|
NCT00536822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-06-04-01|Antioxidant Status During Burn Rehabilitation|Prospective Assessment of Antioxidant Status of Pediatric Patients During Burn Rehabilitation||Shriners Hospitals for Children|Yes|Withdrawn|June 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|None Retained|No specimens.|Both|3 Years|19 Years|No|Non-Probability Sample|pediatric burn|June 2013|June 15, 2013|September 27, 2007||No|Study withdrawn due to hospital emphasis on funded studies.|No||https://clinicaltrials.gov/show/NCT00536822||166629|
NCT00536562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-251|Cardiac Rehabilitation for TIA Patients|Comprehensive Cardiac Rehabilitation Programming For Patients Following Transient Ischemic Attack|CR-TIA|Lawson Health Research Institute|Yes|Active, not recruiting|September 2007|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||March 2014|March 26, 2014|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536562||166648|
NCT00537147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 242|Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3'delta30 Chimeric Virus Vaccine (WN/DEN4delta30), a Live Attenuated Vaccine for West Nile Encephalitis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|September 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537147||166605|
NCT00537160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-04-26-01|Diet and Exercise in Overweight Children Postburn|The Impact of a Diet and Exercise Program in Overweight Pediatric Patients During Burn Rehabilitation||Shriners Hospitals for Children|Yes|Withdrawn|April 2006|October 2012|Actual|October 2012|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|10 Years|18 Years||||October 2012|October 25, 2012|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00537160||166604|
NCT00544440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016906|An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma|An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma||Janssen Research & Development, LLC|Yes|Completed|October 2007|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Male|18 Years|N/A|No|||July 2014|July 3, 2014|October 15, 2007|Yes|Yes||No|August 28, 2013|https://clinicaltrials.gov/show/NCT00544440||166051|
NCT00544453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-308-01|Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC|Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Molecular NeuroImaging|No|Terminated|October 2007|July 2008|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|2|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 20, 2009|October 12, 2007|No|Yes|Preliminary data showed [123I] MNI-308 not a useful tool in detection of AD.|No||https://clinicaltrials.gov/show/NCT00544453||166050|
NCT00554411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0757|Assessing Ocular Surface Changes After Changing Glaucoma Medications|Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.||University of Colorado, Denver|No|Completed|November 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|patients will be selected from the ophthalmology clinic of the principal investigator|January 2013|January 29, 2013|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00554411||165305|
NCT00554424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/12/180|Local Anaesthetic for Transvaginal Egg Collection in IVF|A Randomised Controlled Trial of Intravaginal Lignocaine Injection Versus Placebo for Analgesia During Oocyte Recovery in an IVF Cycle||The Fertility Centre, New Zealand|Yes|Completed|March 2002|July 2002|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|75|||Female|N/A|N/A|No|||November 2007|November 5, 2007|November 3, 2007||||No||https://clinicaltrials.gov/show/NCT00554424||165304|
NCT00551564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIX110434|Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate|See Detailed Description||GlaxoSmithKline||Completed|July 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|October 29, 2007||||||https://clinicaltrials.gov/show/NCT00551564||165520|
NCT00553930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAEI_IFN_1|Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients|Efficacy of Low Dose Pegylated Interferon-α 2a Plus Ribavirin for the Treatment of Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients.|SAEI_IFN_1|Sociedad Andaluza de Enfermedades Infecciosas|Yes|Completed|November 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||May 2010|May 16, 2010|November 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00553930||165341|
NCT00554476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-246910-06|Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis|Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis: A Randomized Clinical Trial||Azad University of Medical Sciences|Yes|Terminated|January 2003|April 2006||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||50|||Both|18 Years|70 Years|No|||November 2007|November 5, 2007|November 5, 2007|||Because the sample volume was completed during three years.|No||https://clinicaltrials.gov/show/NCT00554476||165300|
NCT00550459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-04-246|Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients|A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients|INSIGHT|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|August 2007|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|50 Years|N/A|No|||April 2011|April 26, 2011|October 25, 2007|Yes|Yes||No|August 5, 2010|https://clinicaltrials.gov/show/NCT00550459||165604|Pilot study powered only for serum Na+ improvements. Trial lacked sufficient power to detect changes in neurocognitive test scores and SF-12 and HDS outcomes.
NCT00551798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I04016|Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade|Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade|MIBI|University Hospital, Limoges|No|Completed|March 2005|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|N/A|No|||March 2005|May 16, 2011|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551798||165502|
NCT00552734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0834|Improved Glycemic Control in Adult Subjects With Type 1 Diabetes on MDI Using Insulin Guidance Software|Glycemic Control and Prevention of Hypoglycemia in Intensively Treated Subjects With Type 1 Diabetes Using Accu-Chek® Advisor Insulin Guidance Software||University of Colorado, Denver|No|Completed|July 2005|May 2007|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|123|||Both|18 Years|60 Years|No|Non-Probability Sample|123 adult subjects ages 18-60 with type 1 diabetes on mulitiple daily injections|August 2015|August 10, 2015|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552734||165432|
NCT00562913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12347|Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin|Phase I Open-label, Non-randomized, Non-placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Tumor Response Profile of Sorafenib as Continuous Dosing in Combination With Cyclophosphamide and Doxorubicin in Patients With Advanced, Refractory Solid Tumors||Bayer|No|Completed|December 2007|March 2010|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2013|November 24, 2013|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562913||164674|
NCT00563173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVC-201|Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients|A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C® in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naïve Patients With Low Viral Load||Tripep AB|Yes|Active, not recruiting|October 2007|April 2010|Anticipated|April 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|65 Years|No|||February 2010|February 9, 2010|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00563173||164654|
NCT00553644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00483|Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid™, CC-5013) (NSC #703813) for Relapsed/Refractory Mantle Cell Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|November 2007|||December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||December 2015|January 22, 2016|November 2, 2007|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00553644||165362|
NCT00553657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKB105190|The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Standardization of Fluid Intake on the Variability of Measured Voiding Parameters in Female Patients With Idiopathic Overactive Bladder||GlaxoSmithKline||Completed|August 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|1||Actual|55|||Female|18 Years|N/A|No|||October 2010|October 13, 2010|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553657||165361|
NCT00536549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korean Health 21 R & D Project|Effect of Real Time Continuous Glucose Monitoring System on the Management of Type 2 Diabetes|||Korea University|Yes|Completed|February 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|127|||Both|20 Years|80 Years|No|||May 2008|May 19, 2008|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536549||166649|
NCT00536835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLK107427|Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma|A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects With Advanced Solid Tumor or Non-Hodgkins Lymphoma||GlaxoSmithKline||Completed|August 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||February 2011|May 31, 2012|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00536835||166628|
NCT00536861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC 2005/177|Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer|A Phase I Study of Radiotherapy Concurrent With Erlotinib (Tarceva®) in the Treatment of Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)||VU University Medical Center|No|Completed|May 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||April 2008|May 27, 2008|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536861||166626|
NCT00536874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-113|Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|A Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2007|September 2017|Anticipated|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 27, 2007|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00536874||166625|
NCT00536848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRRC HIV-Probiotics15|The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients|The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial||National Institute for Medical Research, Tanzania|No|Active, not recruiting|October 2007|August 2008|Anticipated|August 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Female|18 Years|45 Years|No|||January 2009|January 29, 2009|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536848||166627|
NCT00537446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC7394|Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis|Effect of Noninvasive Positive Pressure Ventilation on Pulmonary Function Testing in Amyotrophic Lateral Sclerosis||Columbia University|No|Recruiting|September 2007|||August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|80 Years|No|||October 2011|October 12, 2011|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00537446||166582|
NCT00537407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 025-HCV-207|A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment|An Open-label, Randomized, 5-arm, Parallel-group Study of the Effects on Viral Kinetics, Safety and Pharmacokinetics of Different Dosing Regimens of Debio 025 in Combination With Peginterferon Alpha-2a and Ribavirin in Chronic HCV Genotype 1 Patients Who Are Non Responders to Standard Peginterferon Alpha and Ribavirin Treatment||Debiopharm International SA|Yes|Completed|September 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|60 Years|No|||February 2016|February 12, 2016|September 28, 2007|Yes|Yes||No|April 1, 2015|https://clinicaltrials.gov/show/NCT00537407||166585|
NCT00537693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21133|Cytokine Removal by CRRT in Pediatric Sepsis|Cytokine Removal by CRRT in Pediatric Sepsis: A Comparison of Convection Versus Diffusion||Sunnybrook Health Sciences Centre||Completed|September 2007|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Year|21 Years|No|||September 2010|September 1, 2010|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00537693||166563|
NCT00537706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907224|Choosing Healthful Interventions|Engaging Low-Income Urban Residents in Prioritizing Interventions to Address Socio-Economic Determinants of Health||National Institutes of Health Clinical Center (CC)||Completed|September 2007|October 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|442|||Both|18 Years|64 Years|No|||October 2011|April 5, 2012|September 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00537706||166562|
NCT00551317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPL110077|A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of Darapladib (SB480848) in Healthy Japanese Male Subjects||GlaxoSmithKline|No|Completed|July 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|18|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 29, 2007||||||https://clinicaltrials.gov/show/NCT00551317||165539|
NCT00552474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-01|Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease|A Clinical Evaluation of Bilateral Stimulation of the Subthalamic Nucleus (STN) Using the ANS Totally Implantable Deep Brain Stimulation System as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-responsive Parkinson's Disease That Are Not Adequately Controlled With Medication.||St. Jude Medical|Yes|Active, not recruiting|October 2005|June 2016|Anticipated|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|80 Years|No|||November 2015|November 17, 2015|October 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00552474||165452|
NCT00551850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-412-07-102|A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients|A Phase I, Multi-Center, Dose-Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of AV-412 Administered Orally Three Times Weekly to Subjects With Advanced Solid Tumors||AVEO Pharmaceuticals, Inc.|No|Completed|October 2007|May 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||September 2011|September 30, 2011|October 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551850||165498|
NCT00551863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017295-01A1|Developing Violence Prevention Therapy for Substance Abusers|Development of Violence Therapy for Substance Abusers||University of Michigan|No|Completed|June 2004|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00551863||165497|
NCT00554697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-782|Diabetes Mellitus Type II and Tissue Oxygenation|Influence of Diabetes Mellitus Type II on Tissue Oxygenation in the Perioperative Period||Outcomes Research Consortium|Yes|Terminated|November 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|35 Years|65 Years|No|Non-Probability Sample|We will include 30 patients who have more than a five-year history of insulin-dependent        type-2 diabetes mellitus and 30 non-diabetic patients|February 2009|February 5, 2009|November 6, 2007||No|Unable to recruit subjects|No||https://clinicaltrials.gov/show/NCT00554697||165285|
NCT00551278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLN-US-IU-2006.00|Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer|GeneSearch™ Breast Lymph Node (BLN) Assay for Molecular Testing Protocol||Janssen Diagnostics, LLC|No|Completed|October 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|Samples With DNA|Samples of the tissue homogenate and extracted RNA will be retained and may be used for for      further testing.|Both|18 Years|N/A|No|Probability Sample|Patients with a previous diagnosis of breast cancer scheduled for sentinel lymph node        dissection.|January 2016|January 11, 2016|October 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551278||165542|
NCT00551538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7505|24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine|Twenty-Four-Hour Plasma Glucose Profiles Observed in Patients With Type 2 Diabetes During Therapy Consisting of Oral Agent(s) Plus Twice-Daily Insulin Lispro Low Mixture or Once-Daily Insulin Glargine||Eli Lilly and Company|No|Completed|May 2003|December 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|21 Years|80 Years|No|||October 2010|October 12, 2010|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551538||165522|
NCT00552448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20076812|Use of High Frequency Chest Compression in Pediatric Status Asthmaticus|Use of High Frequency Chest Compression (HFCC) in Pediatric Status Asthmaticus||Texas Tech University Health Sciences Center|Yes|Terminated|October 2007|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|2 Years|21 Years|No|||October 2015|October 9, 2015|November 1, 2007||No|Continuing review not submitted to IRB within 365 days.|No||https://clinicaltrials.gov/show/NCT00552448||165454|
NCT00562328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574754|Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia|Antibody Therapy With Alemtuzumab, Rituximab and GM-CSF for Initial Treatment of High Risk Chronic Lymphocytic Leukemia||Mayo Clinic||Active, not recruiting|January 2008|||August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|November 21, 2007|Yes|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00562328||164719|
NCT00553384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVO-0619|Physiological Effects of Androstadienone Exposure|Physiological Effects of Androstadienone Exposure||Rockefeller University|No|Completed|December 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|68|Samples With DNA|Blood|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult women between 18-35 years of age.|February 2012|February 16, 2012|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00553384||165382|
NCT00553423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06GS013MED|Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage|Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage||Aga Khan University|Yes|Recruiting|November 2007|November 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|N/A|No|||October 2007|November 2, 2007|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553423||165379|
NCT00554216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-302|Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults|A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI ≥ 35||VIVUS, Inc.|Yes|Completed|November 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1267|||Both|18 Years|70 Years|No|||September 2012|September 5, 2012|November 3, 2007|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00554216||165320|
NCT00536029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2007-0009|MicroRNA Expression and Function in Cutaneous Malignant Melanoma|MicroRNA Expression and Function in Cutaneous Malignant Melanoma||Rigshospitalet, Denmark|No|Completed|February 2007|June 2007|Actual|||N/A|Observational|Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal||1|Actual|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|September 26, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536029||166689|
NCT00536042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|open mino|Open-Label Trial of the Use of Minocycline in the Treatment of Asthma|Open-Label Trial of the Use of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma||State University of New York - Downstate Medical Center|No|Active, not recruiting|October 1997|March 2008|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|75 Years|No|||September 2007|September 26, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536042||166688|
NCT00536302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gelita TM 1|A Placebo-Controlled Study of Collagen Hydrolysate in Subjects With Knee Osteoarthritis (OA)|A Single Center, Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Clinical Trial to Evaluate the Sensitivity of Magnetic Resonance Imaging to Detect Change in Cartilage Structure and Composition in 30 Participants Diagnosed With Osteoarthritis of the Knee and Treated With Collagen Hydrolysate|NMR|GELITA|Yes|Completed|March 2007|January 2009|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|49 Years|90 Years|No|||February 2009|February 5, 2009|September 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00536302||166668|
NCT00536887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFR|Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction|Phase 4 Study of Atorvastatin 10mg vs. 40mg in Follow-up CFR in AMI Patients||Korea University Anam Hospital|Yes|Completed|July 2005|September 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||April 2012|April 6, 2012|September 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00536887||166624|
NCT00537173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG COE-02|Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study||Hoosier Cancer Research Network|Yes|Terminated|September 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|11|Samples With DNA|Blood and tumor samples|Female|18 Years|N/A|No|Probability Sample|Study population is limited to patients with advanced breast cancer who are receiving        paclitaxel + Avastin|April 2011|April 27, 2011|September 26, 2007||No|Lack of Accrual|No||https://clinicaltrials.gov/show/NCT00537173||166603|
NCT00542139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPROSPAN- HMO-CTIL|Evaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee|Evaluation of the Efficacy of Diprospan Injection to the Knee on Rehabilitation of Patients With Bilateral Knee Osteoarthritis After TKR of the Contralateral Knee.||Hadassah Medical Organization|No|Completed|December 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|N/A|No|||October 2007|November 9, 2008|October 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00542139||166226|
NCT00542152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2006-3|Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis|A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis|CYSIF|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|June 2007|October 2010|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|October 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00542152||166225|
NCT00537719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP107030|Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.|A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal||GlaxoSmithKline||Completed|December 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|September 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00537719||166561|
NCT00537732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKP-219|Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing|Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing|GERD|Robert Bosch Gesellschaft für Medizinische Forschung mbH|Yes|Terminated|April 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|20 Years|70 Years|No|||February 2014|February 24, 2014|September 27, 2007||No|recruitment problems|No||https://clinicaltrials.gov/show/NCT00537732||166560|
NCT00538018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR3647A_4015|Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas|||Sanofi|No|Completed|January 2003|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|978|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|October 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00538018||166538|
NCT00552149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BINGO|Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin|A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination With Cetuximab in Patients With Advanced Biliary Cancer.||Gustave Roussy, Cancer Campus, Grand Paris|Yes|Completed|October 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||October 2007|June 12, 2012|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552149||165476|
NCT00552162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOTES HMO-CTIL|NOTES Transvaginal Cholecystectomy and Appendectomy|NOTES Transvaginal Cholecystectomy and Appendectomy||Hadassah Medical Organization||Recruiting|June 2008|July 2020|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|50 Years|No|||May 2008|July 26, 2015|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552162||165475|
NCT00553410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574249|Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer|SOLE, Study of Letrozole Extension, A Phase III Trial Evaluating the Role of Continuous Letrozole Versus Intermittent Letrozole Following 4 to 6 Years of Prior Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone-Receptor Positive, Node Positive Early Stage Breast Cancer|SOLE|International Breast Cancer Study Group|Yes|Active, not recruiting|August 2007|||December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4884|||Female|18 Years|N/A|No|||March 2015|March 13, 2015|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553410||165380|
NCT00552500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD 43625|Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia|Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia|DepIVGTT|Washington University School of Medicine|No|Active, not recruiting|February 2003|December 2010|Anticipated|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|60 Years|No|||March 2010|March 16, 2010|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552500||165450|
NCT00554710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01872|Top Down Versus Step Up Strategies in Crohn's Disease|The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux||Belgian IBD Research Group|No|Completed|May 2001|January 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|16 Years|75 Years|No|||November 2007|November 6, 2007|November 6, 2007||||No||https://clinicaltrials.gov/show/NCT00554710||165284|
NCT00562068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000576439|Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma|CHOP-Campath, A Pilot Study of CHOP Plus Campath for the Primary Treatment of ALK-ve Peripheral T Cell Lymphoma [CHOP-CAMPATH]||National Cancer Institute (NCI)||Recruiting|May 2007|||May 2009|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||November 2008|August 23, 2013|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562068||164739|
NCT00562341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/09/VA18|Effect of Lap-Band Induced Weight Loss on Serum PSA Levels|Effect of Lap-Band Induced Weight Loss on Serum PSA Levels, Testosterone, Estrogen and Other Serum Markers||Maimonides Medical Center|No|Recruiting|November 2007|December 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|blood samples|Male|20 Years|60 Years|No|Probability Sample|Patients asked to enroll will be obese men who are undergoing bariatric surgery, lap-band        surgery, at Maimonides Medical Center.|September 2007|November 21, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00562341||164718|
NCT00562627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003030-41|Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty|Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty||Asker & Baerum Hospital|No|Completed|November 2007|July 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|N/A|No|||August 2011|August 5, 2011|November 21, 2007||No||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00562627||164696|
NCT00553956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET_IPT|A Randomized Controlled Clinical Trial With Orphans and Widows Who Experienced the Rwandan Genocide|Phase 1:Epidemiological Study of PTSD and Comorbid Disorders in Widows and Orphans Who Experienced the Rwandan Genocide Phase 2: A Randomized Controlled Clinical Trial With Orphans and Widows Who Experienced the Genocide Carried Out by Trained Local Psychologists -NET/IPT Versus Waiting List-||University of Konstanz||Recruiting|August 2007|February 2009|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|17 Years|N/A|No|||November 2007|November 5, 2007|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00553956||165339|
NCT00550576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2142_CTIL|Antibodies to Digoxin for Bipolar Disorder|Antibodies to Digoxin for Bipolar Disorder||Rambam Health Care Campus|No|Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|65 Years|No|||June 2013|June 10, 2013|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00550576||165595|
NCT00550589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-046|Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus|Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women||AIDS Malignancy Consortium|No|Completed|September 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|120 Years|No|||November 2015|November 17, 2015|October 26, 2007|Yes|Yes||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00550589||165594|
NCT00536315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001418|Tracheal Mechanics During Bronchoscopy|Tracheal Mechanics During Bronchoscopy||Beth Israel Deaconess Medical Center|No|Completed|March 1999|June 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy control subjects recruited from subjects volunteering for CT or bronchoscopic        studies and patients referred for evaluation of possible tracheomalacia.|February 2010|February 3, 2010|September 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00536315||166667|
NCT00536575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MM 14|Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients|Phase I/II Trial of Sorafenib and Weekly Bortezomib in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma||SCRI Development Innovations, LLC|No|Completed|November 2007|August 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|September 26, 2007||No||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00536575||166647|The 15% response rate was substantially lower than the designed rate of 60% for this trial. Coupled with the influx of new compounds for the treatment of multiple myeloma it was decided that this study should be closed early.
NCT00536588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03816|A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)|A Phase 1 Study of the Safety and Tolerability of Intravesical Administration of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder||Merck Sharp & Dohme Corp.|No|Completed|September 2006|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|September 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00536588||166646|
NCT00540930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-816|Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy|A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma||Shields, Shields and Associates|Yes|Active, not recruiting|April 2007|April 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|N/A|No|||October 2007|October 5, 2007|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00540930||166318|
NCT00540943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG108925|Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer|A Phase I, Open Label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Irinotecan and Cetuximab for the Relapsed or Refractory Metastatic Colorectal Cancer||GlaxoSmithKline|No|Completed|July 2007|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2011|March 15, 2012|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00540943||166317|
NCT00537186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-CHF-01|A Study of Iron Oligosaccharide in CHF Patients|A Non-Comparative Open-Label Study of Iron Oligosaccharide in CHF Patients With Iron Deficiency (Either Absolute or Functional) Anaemia and a Need for Parenteral Iron||Pharmacosmos A/S|No|Completed|June 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2008|October 7, 2008|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00537186||166602|
NCT00585962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-064|Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate|A Phase II Study Using Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate||Massachusetts General Hospital|Yes|Active, not recruiting|February 2004|||March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Male|18 Years|N/A|No|||December 2007|December 27, 2007|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00585962||162942|
NCT00582101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01MH078783-01|Family-Based HIV Prevention for Latinos|Family-Based HIV Prevention for Latinos||Rhode Island Hospital|Yes|Completed|May 2007|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582101||163236|
NCT00582309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 06-288|Comparative Trial Between 3 Types of Insulin Infusion Protocols|Comparative Trial Between Computer-Guided Intravenous Infusion Protocol Versus a Standard Insulin Infusion Algorithm Versus a Simple Calculated Infusion Protocol in Medical and Surgical ICU||University of New Mexico|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|December 19, 2007||No||No|September 12, 2009|https://clinicaltrials.gov/show/NCT00582309||163221|Limitations of trial. Variable length of stay the first 48 hours was analyzed as the sample size decreased after that.
NCT00582075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F020522015|Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases|Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases|RAD0102|University of Alabama at Birmingham|Yes|Completed|July 2002|June 2015|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|19 Years|N/A|No|||August 2015|August 17, 2015|December 20, 2007||No||No|July 6, 2015|https://clinicaltrials.gov/show/NCT00582075||163238|
NCT00582491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607001659|Modafinil, Sleep, and Cognition in Cocaine Dependence|Modafinil, Sleep, and Cognition in Cocaine Dependence||Yale University|Yes|Completed|August 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|44|||Both|18 Years|65 Years|No|||September 2012|September 6, 2012|December 21, 2007||No||No|August 6, 2012|https://clinicaltrials.gov/show/NCT00582491||163207|
NCT00582738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001H2301|Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection|A Randomized, Controlled, Open Label, Two Arms, Exploratory Study to Evaluate the Effect of Everolimus on Histologically Assessed Fibrosis Progression (Ishak-Knodell) in Liver Transplant Recipients With Recurrent Hepatitis C Viral Infection as Compared to Standard Treatment.|REVERT|Novartis||Terminated|December 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|No|||August 2012|August 2, 2012|December 12, 2007||No||No|January 10, 2012|https://clinicaltrials.gov/show/NCT00582738||163188|
NCT00582725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO02401|R-CHOP + GM-CSF for Previously Untreated LCL in Elderly|Phase II Trial of Rituximab-CHOP (R-CHOP) Plus GM-CSF for Previously Untreated Diffuse Large Cell Lymphoma in the Elderly||University of Wisconsin, Madison|Yes|Completed|March 2002|November 2010|Actual|December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|60 Years|N/A|No|||May 2014|May 23, 2014|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582725||163189|
NCT00582959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-037|Feasibility Study of Cone Beam Imaging for Radiation Therapy Treatment Verification|Feasibility Study of Cone Beam Imaging for Radiation Therapy Treatment Verification||Memorial Sloan Kettering Cancer Center||Completed|April 2004|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|N/A|N/A|No|||February 2014|February 5, 2014|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582959||163171|
NCT00583414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G980198|Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients|Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients||The Cleveland Clinic|Yes|Recruiting|September 1998|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583414||163137|
NCT00583687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-3107-UHB-1316|Pulse Contour Analysis and Tissue Oxymetry in Changing Vascular Tone|Pulse Contour Analysis and Tissue Oxymetry in Changing Vascular Tone||University Hospital Inselspital, Berne||Completed|December 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00583687||163116|
NCT00550901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000570420|Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of Cis-Diamminedicholoroplatinum in Combination With ICRF-187 in the Treatment of Advanced Malignancies||City of Hope Medical Center||Completed|February 2001|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00550901||165571|
NCT00550914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01-005|Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP|A Multi-Center, Randomized, Controlled Trial of the Pulsed Dye Laser for Juvenile Onset Recurrent Respiratory Papillomatosis||Massachusetts Eye and Ear Infirmary|No|Completed|January 2007|June 2009|Actual|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|34|||Both|1 Year|12 Years|No|Probability Sample|Children with severe JORRP|July 2010|July 6, 2010|October 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00550914||165570|
NCT00551122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000572096|Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors|Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer|GemTIP|University of Southampton|Yes|Recruiting|November 2006|||April 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|16 Years|60 Years|No|||October 2007|January 22, 2013|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00551122||165554|
NCT00551382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142/06|Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study|Phase 3 Study of Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children||Assaf-Harofeh Medical Center|No|Recruiting|November 2007|June 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||March 2010|March 16, 2010|October 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551382||165534|
NCT00551655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL109413|Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients|Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients||AIDS Arms Inc.|No|Completed|May 2007|September 2007|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|684|||Both|18 Years|N/A|No|Non-Probability Sample||October 2007|November 5, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551655||165513|
NCT00551928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-209|Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients|A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS|MPRvsMEL200|Fondazione Neoplasie Sangue Onlus|Yes|Active, not recruiting|June 2007|August 2011|Anticipated|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|65 Years|No|||March 2010|March 16, 2010|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00551928||165492|
NCT00551941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/341|A Prospective Randomized Controlled Trial on the Use of Bone Morphogenetic 7 (BMP-7) (OP-1®) and Demineralized Bone Matrix in Tibial Non-union|A Prospective Randomised Controlled Trial on the Use of BMP-7 (OP-1®) and Demineralised Bone Matrix in Tibial Non-union||University Hospital, Ghent|No|Suspended|October 2007|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 30, 2007||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT00551941||165491|
NCT00551954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDA a4|Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes|||Technische Universität Dresden|No|Completed|July 2006|||July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|35 Years|75 Years|No|||February 2013|February 28, 2013|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00551954||165490|
NCT00586027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI/NT-proBNP-12-2007|Is There a Correlation of Natriuretic Propeptide Type B With an Intraoperative Low Cardiac Output?|Prospective Observational Study in Patients Undergoing Cardiac Surgery: Part 2: Is There a Correlation of Natriuretic Propeptide Type B With an Intraoperative Low Cardiac Output?||Klinikum Ludwigshafen|No|Completed|July 2008|April 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|150 patients undergoing cardiac surgery, being monitored with a Swan-Ganz catheter and an        intraoperatively before cardiopulmonary bypass measured cardiac index <2L/min/m².|November 2009|November 23, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586027||162937|
NCT00586014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0074|High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma|High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma||Duke University|Yes|Completed|May 1997|February 2008|Actual|January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||May 2013|July 7, 2014|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586014||162938|
NCT00582322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-007|Genetic Studies in Breast Cancer|Genetic Studies in Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|February 1992|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|483|Samples With DNA|blood|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with breast cancer seen at MSKCC and healthy family members.|July 2009|July 17, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582322||163220|
NCT00582504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14317|Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine|A Phase 2 Open-Label, Safety and Immunogenicity Study of a Single Dose of Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried, TC-83, NDBR-102, as Primary Immunization in Healthy Adults At Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus|VEE TC-83|U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|September 2007|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00582504||163206|
NCT00582764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-091|Quantitative Dynamic Contrast Enhanced Breast MRI|Quantitative Dynamic Contrast Enhanced Breast MRI||Memorial Sloan Kettering Cancer Center||Completed|September 2005|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|116|||Female|N/A|N/A|No|Non-Probability Sample|Participants will be selected at the time of the MRI interventional procedure by the        radiologist who is protocoling the MRI examinations and who is an investigator on this        protocol. Any known breast lesion, benign or malignant, will be appropriate for evaluation        with DCE MRI. Pathology results will be obtained for each patient as a result of surgery        or MRI guided biopsy, allowing correlation between the pathology and DCE MRI data.|July 2015|July 7, 2015|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582764||163186|
NCT00582751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-141|Volumetric Analysis in the Assessment of Therapy Response by CT|Volumetric Analysis in the Assessment of Therapy Response by CT||Memorial Sloan Kettering Cancer Center||Completed|November 2007|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|90 patients from 3 different sections will be accrued (30 liver lesions, 30 lung lesions,        30 lymph node lesions).|November 2010|November 1, 2010|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582751||163187|
NCT00582998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F010316003|Vacuum Assisted Closure as a Treatment for Soft Tissue Injuries|Vacuum Assisted Closure as a Treatment for Soft Tissue Injuries Sustained as a Result of Calcaneus, Tibial Plateau and Pilon Fractures|VAC-ST|University of Alabama at Birmingham|No|Completed|June 2001|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|189|||Both|19 Years|N/A|No|||September 2013|September 18, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00582998||163168|
NCT00582972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0179|Does Omeprazole Decrease Intestinal Calcium Absorption?|Does Omeprazole Decrease Intestinal Calcium Absorption?||University of Wisconsin, Madison|Yes|Completed|January 2008|December 2010|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2013|February 14, 2013|December 19, 2007||No||No|July 6, 2012|https://clinicaltrials.gov/show/NCT00582972||163170|
NCT00582985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105ST101|Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer|An Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable||Tracon Pharmaceuticals Inc.|No|Completed|December 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582985||163169|
NCT00576303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20977|A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.|An Open Label Study to Assess the Maintenance of Haemoglobin Levels, Safety and Tolerability of Monthly Administration of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anaemia Who Are Currently Receiving Epoetin Alfa or Beta.||Hoffmann-La Roche||Completed|February 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576303||163673|
NCT00576316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00027|Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia|Symbicort Maintenance And Reliever Therapy - Experience in Real Life Setting in Malaysia - SMARTER Study|SMARTER|AstraZeneca|No|Completed|January 2008|November 2008|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|201|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|December 17, 2007||||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00576316||163672|
NCT00583973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614206-2|Effect of Parenteral Iron Therapy on Inflammatory Response and Oxidative Stress Chronic Hemodialysis|The Effect of Parenteral Iron Therapy on the Systemic Inflammatory Response and Oxidative Stress in Chronic Hemodialysis Patients||University of California, Davis|Yes|Recruiting|January 2007|January 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Chronic hemodialysis patients--stage V CKD|December 2007|December 31, 2007|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00583973||163094|
NCT00550615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244-07-FB|Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129)||University of Nebraska|Yes|Active, not recruiting|September 2007|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|47|||Both|19 Years|N/A|No|||December 2013|December 13, 2013|October 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00550615||165592|
NCT00550927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11182|Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer|A Phase 1 Safety Evaluation of Oral Enzastaurin in Combination With Bevacizumab in Patients With Advanced/Metastatic Cancer||Eli Lilly and Company||Completed|November 2006|September 2012|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|42|||Both|18 Years|N/A|No|||June 2012|May 14, 2013|October 22, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00550927||165569|
NCT00551135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081171|Surgical Pain After Inguinal Hernia Repair (SPAIHR)|A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair||Pfizer|No|Completed|January 2008|September 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|425|||Male|17 Years|75 Years|No|||June 2010|June 8, 2010|October 26, 2007|Yes|Yes||No|June 8, 2010|https://clinicaltrials.gov/show/NCT00551135||165553|
NCT00551395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-1|Timing of Treatment Completion in Staged Selective Laser Trabeculoplasty (SLT): Early vs. Late Completion|Timing of Treatment Completion in Staged Selective Laser Trabeculoplasty (SLT): Early vs. Late Completion||Queen's University|No|Terminated|September 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|October 29, 2007|Yes|Yes|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00551395||165533|
NCT00551408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDICEM07-012|Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension|The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.||Unidad de Investigacion Clinica en Medicina S.C.|No|Active, not recruiting|August 2007|February 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|Samples With DNA|whole blood.|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with IPAH between 18 and 70 years of age of either gender were invited to        participate in the study|October 2007|October 30, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551408||165532|
NCT00551668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1199/8.1/D/II|A Prospective, Randomized Study of Operative and Nonoperative Treatment for Primary Traumatic Patellar Dislocation|A Prospective, Randomized Study of Operative and Nonoperative Treatment for Primary Traumatic Patellar Dislocation in Young Adults With a Median 7-Year Follow-Up||Finnish Defense Forces|No|Completed|January 1998|December 2000|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|N/A|No|||October 2007|October 30, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551668||165512|
NCT00551681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2006-04|Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure|Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure|CONTRACT|R&D Cardiologie|No|Recruiting|November 2007|July 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00551681||165511|
NCT00551967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P000337|Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA|Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary Total Hip Arthroplasty Using Radiostereometric Analysis (RSA)||Massachusetts General Hospital|No|Recruiting|October 2007|December 2022|Anticipated|December 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|75 Years|No|||April 2015|April 14, 2015|October 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551967||165489|
NCT00586274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11428|Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT|A Phase I Study Evaluating The Use Of Rft5-Dga To Deplete Alloreactive Cells For Patients With Fanconi Anemia After Haploidentical Stem Cell Transplantation|RAFHAS|Baylor College of Medicine|Yes|Terminated|March 2002|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|64 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|December 21, 2007|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00586274||162919|
NCT00586287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 06/022/1B|Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon|Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon||Cantonal Hospital of St. Gallen|No|Completed|January 2007|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00586287||162918|
NCT00582127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-UK-01|Evaluation of the COGNISION(TM) System as an Event-related Potential (ERP) Collection System.|Evaluation of a Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease||Neuronetrix, Inc.|No|Completed|January 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients and family from the University of Kentucky Sanders Brown Center for Aging|December 2010|December 22, 2010|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582127||163234|
NCT00586300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR047595|Community-Based Programs for Improving Physical Function in People With Early Knee Osteoarthritis|Multidimensional Intervention in Early Osteoarthritis (The Knee Study)||University of Arizona|No|Completed|June 2003|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|294|||Both|35 Years|64 Years|No|||June 2012|June 20, 2012|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00586300||162917|
NCT00582114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306-13|Hypertension in Hemodialysis Patients (Aim 3)|Hypertension in Hemodialysis Patients||Indiana University|Yes|Terminated|August 2005|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 20, 2007||No|Stopped by data safety monitoring board|No|October 5, 2015|https://clinicaltrials.gov/show/NCT00582114||163235|
NCT00582335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-003|Identification of New Colorectal Cancer Genes|Identification of New Colorectal Cancer Genes||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 1998|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|337|Samples With DNA|Blood Tissue (tumor)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|families seen at MSKCC with at least two first-degree relatives affected with colorectal        cancer|January 2016|January 4, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582335||163219|
NCT00582517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F000330008|Compass Hinge Stabilization of Knee Dislocations: A Randomized Trial|Compass Hinge Stabilization of Knee Dislocations: A Randomized Trial|CKH|University of Alabama at Birmingham|No|Completed|August 2000|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|N/A|No|||September 2013|September 18, 2013|December 18, 2007|No|Yes||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00582517||163205|
NCT00583011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmniocentesisPain|Local Anesthesia and Pain Perception During an Amniocentesis|Local Anesthesia and Pain Perception During Amniocentesis: A Randomized Placebo-controlled Trial||University of Oklahoma|No|Completed|October 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|70|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583011||163167|
NCT00583362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112626|A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02|A Multi-Center, Open-Label, Continuation Trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 2 Protocol LBSL02||GlaxoSmithKline|Yes|Active, not recruiting|November 2004|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|298|||Both|18 Years|N/A|No|||November 2013|November 20, 2014|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583362||163141|
NCT00583427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704758|Sulodexide Treatment in Patients With Dense Deposit Disease|Sulodexide Treatment in Patients With Dense Deposit Disease||University of Iowa|Yes|Withdrawn|December 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|0|||Both|5 Years|20 Years|No|||June 2015|June 10, 2015|December 20, 2007|Yes|Yes|This study put on inactive status due to no identifiable subjects to enter the protocol.|No||https://clinicaltrials.gov/show/NCT00583427||163136|
NCT00583726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00012524|The Women's Healthy Lifestyle Study|Motivational Interviewing for Weight Maintenance||University of Michigan|Yes|Completed|December 2007|November 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|99 Years|No|||December 2012|November 30, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583726||163113|
NCT00583999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000513532|The Role of Leptin Receptors in NASH|Leptin, Soluble Leptin Receptor and Adiponectin in Non Alcoholic Steatohepatitis|NASH|University of California, Davis|Yes|Completed|January 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|104|Samples With DNA|Liver biopsy specimes, serum|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients scheduled for bariatric surgery|November 2012|November 1, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00583999||163092|
NCT00550628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-114|Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer|Pilot Study of Ex-Vivo Molecular Polyp Imaging Using 18-F Fluorodeoxyglucose (FGD) Positron Emission Tomography (PET) in the Determination of Protein and Gene Expression Signatures of Premalignant Polyps||Memorial Sloan Kettering Cancer Center||Completed|September 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples With DNA|tissue|Both|15 Years|N/A|No|Non-Probability Sample|MSK clinic|December 2015|December 22, 2015|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00550628||165591|
NCT00551694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMA110541|A Second Study to Determine the Effect of GSK256073A on HVTs|A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|4|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 29, 2007||||||https://clinicaltrials.gov/show/NCT00551694||165510|
NCT00551980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1130SD2006.1911|The Efficacy of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Working Community|Effectiveness of a Workplace Cognitive and Physical Program in Reducing Headache,Neck and Shoulder Pain in an Extensive Working Community. A Randomized Controlled Trial||University of Turin, Italy|No|Completed|October 2007|November 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2895|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|November 12, 2009|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00551980||165488|
NCT00552357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1417|Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation|Clinical Risk Factors for Primary Graft Dysfunction||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|December 2007|October 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1150|Samples Without DNA|Blood samples|Both|13 Years|68 Years|No|Non-Probability Sample|People undergoing lung transplantation|July 2009|July 14, 2009|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552357||165461|
NCT00551148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4251068|A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia|PD 0200390 Dose-ranging Trial: A Randomized, Double-blind, Placebo-controlled, 5-way Crossover, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia||Pfizer|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|92|||Both|18 Years|64 Years|No|||July 2012|July 17, 2012|October 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551148||165552|
NCT00551161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-50|Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease|An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease||Northwell Health|No|Completed|August 2007|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|50 Years|N/A|No|||December 2013|December 20, 2013|October 29, 2007|No|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00551161||165551|
NCT00551421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00241|Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer|A Phase I/II Trial of Pertuzumab in Combination With Cetuximab and Irinotecan in Previously Treated Metastatic Colorectal Cancer||National Cancer Institute (NCI)|Yes|Completed|October 2007|June 2012|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|March 11, 2015|October 30, 2007|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT00551421||165531|Combination intolerable due to overlapping toxicities of diarrhea, rash and mucositis; a unique rash with desquamation seen in most patients across all dose levels. Correlative study inconclusive with too few patients and timepoints with results.
NCT00551434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22852|Effect of Creatine and L-Arginine on Endothelial Function|Effect of Creatine and L-Arginine on Endothelial Function in Patients With Coronary Artery Disease||Boston University|No|Completed|August 2002|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|119|||Both|18 Years|80 Years|No|||October 2007|October 30, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551434||165530|
NCT00552916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRA 5973|Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke|Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke||Toronto Rehabilitation Institute|No|Recruiting|October 2007|November 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|65 Years|No|||August 2008|August 19, 2008|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552916||165418|
NCT00553267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.6|Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension|An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy||Boehringer Ingelheim||Completed|November 2007|||October 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|947|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|October 8, 2007||||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00553267||165391|
NCT00553280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081164|A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy|An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For Pain Associated With Diabetic Peripheral Neuropathy||Pfizer|No|Completed|February 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||April 2011|April 22, 2011|November 2, 2007||No||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00553280||165390|
NCT00553293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF02-035/03|Nordic Luveris Study|Recombinant LH Supplementation to Recombinant FSH During the Final Days of Controlled Ovarian Stimulation for IVF: a Multicentre, Prospective, Randomized, Controlled Trial||Rigshospitalet, Denmark|No|Completed|August 2003|November 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|526|||Female|21 Years|40 Years|No|||November 2007|November 2, 2007|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553293||165389|
NCT00585754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512000886|Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse|Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse||Yale University|Yes|Recruiting|April 2006|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||July 2015|July 28, 2015|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00585754||162958|
NCT00586326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-700|MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ|MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)|DCIS|Hologic, Inc.|No|Completed|August 2003|April 2011|Actual|January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|133|||Female|45 Years|N/A|No|||November 2012|November 2, 2012|December 21, 2007|Yes|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT00586326||162915|
NCT00582348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-094|Physical Activity and Inactivity in Lung Cancer Survivors|Physical Activity and Inactivity in Lung Cancer Survivors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2005|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|188|||Both|N/A|N/A|No|Probability Sample|Eligible lung cancer survivors will be identified by the Thoracic DMT Data Manager from        the Thoracic Surgical Database.|January 2016|January 4, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582348||163218|
NCT00582530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-132|Men Undergoing Radical Prostatectomy|Serum Protein Profiling to Characterize Patient Risk in Men Undergoing Radical Prostatectomy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2004|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Whole Blood|Male|18 Years|N/A|No|Non-Probability Sample|Urology Clinic at MSKCC|August 2015|August 26, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582530||163204|
NCT00582790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 2003-170|Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer|Phase II Study of Interleukin-2 in Combination With Zoledronic Acid in Patients With Untreated Metastatic Renal Cell Carcinoma||University of Wisconsin, Madison|Yes|Terminated|August 2003|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|December 19, 2007|Yes|Yes|slow accrual|No|September 30, 2011|https://clinicaltrials.gov/show/NCT00582790||163184|
NCT00582777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AASK ABPM Pilot (completed)|African American Study of Kidney Disease and Hypertension ABPM Pilot Study|African American Study of Kidney Disease and Hypertension ABPM Pilot Study||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||April 2012|April 12, 2012|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00582777||163185|
NCT00583024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200605710|Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer|Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer|APP22|University of Iowa|Yes|Active, not recruiting|December 2007|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Male|18 Years|90 Years|No|||September 2015|September 11, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583024||163166|
NCT00584077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-132|Assessment of Cough Reflex in Lung Transplant Recipients|Assessment of Cough Reflex in Lung Transplant Recipients||The University of Texas Medical Branch, Galveston|No|Completed|April 2000|October 2007|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Single or double lung or heart-lung transplant recipients|July 2013|August 24, 2015|December 20, 2007||No||No|July 3, 2013|https://clinicaltrials.gov/show/NCT00584077||163086|The limitations of this trial are that the results apply to lung transplant recipients
NCT00585039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC176|Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)|Comparison of Hospital Admission Rates and Plasma(s)-Albuterol Levels in Children Treated With Racemic Albuterol Versus Levalbuterol for Acute Asthma Exacerbations: A Randomized Double-Blind Clinical Trial|Xopenex|Phoenix Children's Hospital|Yes|Completed|September 2005|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|101|||Both|6 Years|17 Years|No|||September 2011|September 2, 2011|December 20, 2007|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00585039||163012|
NCT00584012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200311038|A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer|A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer||University of Iowa|Yes|Terminated|April 2004|April 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|19 Years|90 Years|No|||June 2009|June 18, 2009|December 21, 2007|Yes|Yes|Funding issues|No||https://clinicaltrials.gov/show/NCT00584012||163091|
NCT00583752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200605706|Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21|Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy|APP21|University of Iowa|Yes|Active, not recruiting|December 2007|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Male|18 Years|90 Years|No|||September 2015|September 11, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583752||163111|
NCT00551707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-102-007|Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA)|MARS-1|Zalicus|Yes|Completed|October 2007|January 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|51|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|October 29, 2007|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT00551707||165509|
NCT00551720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA012344|Motivation and Patch Treatment for HIV-Positive Smokers|Motivation and Patch Treatment for HIV-Positive Smokers|Positive PATHS|National Institute on Drug Abuse (NIDA)|Yes|Completed|January 1999|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|444|||Both|18 Years|70 Years|No|||October 2007|October 30, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551720||165508|
NCT00551733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573340|Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL||National Cancer Institute (NCI)||Recruiting|August 2007|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Female|18 Years|N/A|No|||April 2008|December 15, 2010|October 30, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00551733||165507|
NCT00552370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4045|Glycemic Optimization Treatment Study|A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus®(Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes.|GOT|Sanofi||Completed|March 2003|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|5062|||Both|18 Years|N/A|No|||July 2009|July 20, 2009|October 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00552370||165460|
NCT00552617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05971|A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.208B)(P05971)(COMPLETED)|A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part B: Caucasian Subjects||Merck Sharp & Dohme Corp.|No|Completed|September 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|10||Actual|100|||Both|20 Years|65 Years|No|||June 2015|June 5, 2015|October 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00552617||165441|
NCT00552630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3361|Penicillamine Chelation for Children With Lead Poisoning|A Phase 2/3 Trial of d-Penicillamine Chelation in Lead-Poisoned Children||FDA Office of Orphan Products Development|Yes|Withdrawn|September 2007|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|16 Years|No|||December 2007|March 24, 2015|November 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00552630||165440|
NCT00552643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH1-07-01|Study to Evaluate Polyheal-1 in Treatment of Recalcitrant Wounds|Study to Evaluate Polyheal-1 in Treatment of Recalcitrant Wounds||Polyheal Ltd.|No|Recruiting|May 2008|||May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2009|October 27, 2009|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552643||165439|
NCT00552929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05974|A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.209B)(P05974)(COMPLETED)|A Multi -Center, Randomized, Open -Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at 1-2 PTC After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part B: Caucasian Subjects.||Merck Sharp & Dohme Corp.|No|Completed|October 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|65 Years|No|||June 2015|June 8, 2015|October 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00552929||165417|
NCT00552942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Randomized Controlled Trial of Laparoscopic Gastric Bypass Plus Omentectomy Versus Laparoscopic Gastric Bypass Alone in Improving Diabetic Indices|Randomized Controlled Trial of Laparoscopic Gastric Bypass Plus Omentectomy Versus Laparoscopic Gastric Bypass Alone in Improving Diabetic Indices||Legacy Health System|No|Recruiting|July 2006|July 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2007|November 1, 2007|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00552942||165416|
NCT00585767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200311391|Functional, Dynamic, and Anatomic MR Urography|Functional, Dynamic, and Anatomic MR Urography||University of California, Davis|No|Withdrawn|April 2001|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been diagnosed with obstructive uropathy|December 2007|May 15, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00585767||162957|
NCT00585715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5138|Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening|Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening|IH062905|University of California, Irvine|Yes|Completed|October 2006|January 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|40 Years|N/A|No|||August 2015|September 4, 2015|December 26, 2007|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00585715||162961|Small sample size
NCT00585728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0134 (CC07206)|CT Virtual Proctoscopy for Staging and Volume Assessment for Rectal Cancer|CT Virtual Proctoscopy for Staging and Volume Assessment for Rectal Cancer||University of Wisconsin, Madison|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00585728||162960|
NCT00585741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-2006-0280|Pilot Study of 18F-FLT PET|Pilot Study of 18F-FLT Pet Imaging in Cancer Patients||University of Wisconsin, Madison|Yes|Terminated|December 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Female|18 Years|N/A|No|||February 2012|February 22, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585741||162959|
NCT00586352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 1351|Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease|Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease||Indiana University|Yes|Active, not recruiting|January 2006|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|48|||Both|6 Years|18 Years|No|||June 2011|June 22, 2011|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586352||162913|
NCT00582166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO04405|Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance|Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma||University of Wisconsin, Madison|Yes|Completed|September 2004|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00582166||163232|
NCT00582140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 2004-0365|Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer|Phase I Study of a DNA-based Vaccine Targeting Prostatic Acid Phosphatase (PAP) in Patients With Stage D0 Prostate Cancer||University of Wisconsin, Madison|Yes|Completed|March 2005|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Male|18 Years|N/A|No|||July 2015|July 22, 2015|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582140||163233|
NCT00582361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F010316004|Vacuum Assisted Closure as a Treatment for Open Fractures|Vacuum Assisted Closure as a Treatment for Open Fractures|VAC-OF|University of Alabama at Birmingham|No|Completed|June 2001|January 2010|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|19 Years|N/A|No|||May 2012|August 5, 2013|December 20, 2007||No||No|July 27, 2011|https://clinicaltrials.gov/show/NCT00582361||163217|None Noted.
NCT00582543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-113|MRI/MRSI in Risk Assessment of Prostate Cancer Patients|MRI/MRSI in Risk Assessment of Prostate Cancer Patients||Memorial Sloan Kettering Cancer Center||Completed|October 2005|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|357|||Male|N/A|N/A|No|||October 2011|October 14, 2011|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582543||163203|
NCT00583037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-242|24-Hour NAVA Ventilation in Acute Respiratory Failure|FEASIBILITY OF 24 Hrs VENTILATION WITH NEURALLY ADJUSTED VENTILATORY ASSIST (NAVA) IN PATIENTS WITH ACUTE RESPIRATORY FAILURE||St. Michael's Hospital, Toronto|No|Completed|May 2006|May 2008|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|N/A|No|||May 2009|May 29, 2009|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583037||163165|
NCT00583388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-008907|The Role of L-arginine in the Endothelial Dysfunction|The Efficacy of L-arginine in Preventing Early Morning Endothelial Dysfunction||Mayo Clinic|Yes|Withdrawn|June 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|0|Samples Without DNA|whole blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|April 2015|April 27, 2015|December 20, 2007|Yes|Yes|PI is leaving the Institution, IRB will close the protocol.|No||https://clinicaltrials.gov/show/NCT00583388||163139|
NCT00583401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-011|PFO ACCESS Registry|Patent Foramen Ovale Closure With the AMPLATZER PFO OCCLUDER in Patients With Recurrent Cryptogenic Stroke Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy||St. Jude Medical||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||November 2015|November 16, 2015|December 21, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00583401||163138|
NCT00585052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200305074|A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer|A Phase II Study of the Synergistic Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer||University of Iowa|Yes|Recruiting|August 2003|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Female|18 Years|N/A|No|||December 2010|December 20, 2010|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585052||163011|
NCT00551200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP1204-003 (HPN-100-003)|Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders|A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|October 2007|December 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|October 26, 2007|Yes|Yes||No|August 28, 2013|https://clinicaltrials.gov/show/NCT00551200||165548|
NCT00551460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0535|S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia|S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia||Southwest Oncology Group|Yes|Active, not recruiting|November 2007|||June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|October 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551460||165528|
NCT00552396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2101-103|An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma|An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma||Innate Pharma|Yes|Completed|May 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2012|May 24, 2012|May 21, 2007|Yes|Yes||No|March 2, 2012|https://clinicaltrials.gov/show/NCT00552396||165458|
NCT00551993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-652|Laparoscopic Versus Robotic Assisted Laparoscopic Sacrocolpopexy for Vaginal Prolapse|Conventional Laparoscopic Versus Robotic Assisted Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial||The Cleveland Clinic|Yes|Completed|September 2006|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Female|21 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00551993||165487|
NCT00552383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199700189 (AHFMR)|The Edmonton Randomised Controlled Trial of NIDCAP - Based Developmental Care|The Impact of Developmental Care in the Neonatal Intensive Care Unit: The Edmonton Randomised Controlled Trial of NIDCAP (Newborn Individualised Developmental Care and Assessment Program)|NIDCAP|University of Alberta|No|Completed|September 1998|December 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|N/A|1 Week|No|||October 2007|October 31, 2007|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552383||165459|
NCT00553319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5502/6569R.|Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence|A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence|CAMP|New York State Psychiatric Institute|Yes|Completed|December 2007|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|139|||Both|18 Years|60 Years|No|||August 2014|August 20, 2014|November 2, 2007|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00553319||165387|The dropout rate was relatively low, however, there were dropouts, and this does introduce uncertainly into the outcome assessment. Since all patients received CBT we cannot conclude whether CBT is necessary to derive benefit from the medication.
NCT00553332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00251|Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery|A Phase 2 Study of AZD6244 in Biliary Cancers||National Cancer Institute (NCI)||Active, not recruiting|November 2007|||January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553332||165386|
NCT00553839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3384|Pharmacokinetics of Ketamine in Infants and Children|Pharmacokinetics of Ketamine in Infants and Children||Stanford University|No|Completed|July 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|N/A|17 Years|No|||August 2014|February 4, 2016|November 5, 2007||No||No|February 4, 2016|https://clinicaltrials.gov/show/NCT00553839||165348|
NCT00585780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705002691|Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse|Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse||Yale University|Yes|Recruiting|September 2009|August 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|55 Years|No|||July 2015|July 28, 2015|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00585780||162956|
NCT00586313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608-17|Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)|Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)|NAFLD|Indiana University|Yes|Completed|January 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|70 Years|No|||October 2015|October 27, 2015|December 21, 2007||No||No|March 17, 2014|https://clinicaltrials.gov/show/NCT00586313||162916|The small sample size and low-risk population.
NCT00574652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004039-31|Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients|ANRS HC 21 VASCU IL-2, Evaluation of the Cellular Immune Response, Clinical Efficacy and Tolerance After IL-2 Therapy in HCV-related Vasculitis Patients, Resistant to Conventional Therapy.||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|March 2008|September 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||January 2008|January 23, 2013|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574652||163796|
NCT00574912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#060887-Lantus Glargine|Characteristics of Glargine in Type 2 Diabetics|A Comparison of PK/PD Dose Response Characteristics of Glargine in Type 2 Diabetics||Vanderbilt University|No|Completed|March 2007|January 2010|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||July 2015|July 2, 2015|December 13, 2007||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00574912||163776|
NCT00575458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005p002466|Splinting for Dupuytren's Contracture Release|Prospective Randomized Comparison of Dynamic Versus Static Splinting After Dupuytren's Contracture Release||Massachusetts General Hospital|No|Completed|June 2005|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Orthopaedic Hand Clinic|November 2010|November 15, 2010|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575458||163736|
NCT00575471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS011-A-J204|Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled 12-Week Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes.||Daiichi Sankyo Inc.|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|250|||Both|20 Years|75 Years|No|||February 2009|February 27, 2009|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00575471||163735|
NCT00582803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-059|Adherence to Intensive Surveillance for Hereditary Breast Cancer|Adherence to Intensive Surveillance for Hereditary Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|May 2003|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|85|||Female|25 Years|N/A|No|Non-Probability Sample|unaffected women over age 25 who are at elevated risk for breast cancer by virtue by a        hereditary predisposition|July 2009|July 9, 2009|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582803||163183|
NCT00583050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010002|Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts|Endovascular Exclusion of Thoracoabdominal Aortic Aneurysms or Abdominal Aneurysms Utilizing Fenestrated/Branched Stent-Grafts||The Cleveland Clinic|Yes|Recruiting|February 2001|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1220|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583050||163164|
NCT00583063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15328B|Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers|A Pharmacokinetic Interaction Study of Rapamycin (Sirolimus) and SU11248 (Sunitinib) in Patients With Advanced Solid Tumors||University of Chicago|Yes|Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||March 2011|June 11, 2013|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583063||163163|
NCT00585611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 2005-430|Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients|Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients||University of Wisconsin, Madison|Yes|Terminated|December 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||May 2011|October 1, 2015|December 26, 2007|Yes|Yes|Unable to recruit into the study|No||https://clinicaltrials.gov/show/NCT00585611||162969|
NCT00551746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-126|The Purple Grape Juice Study|Anti-thrombotic Effects of Long Term Consumption of Purple Grape Juice in Healthy People||Intermountain Health Care, Inc.|No|Completed|July 2007|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 13, 2011|October 29, 2007||No||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00551746||165506|
NCT00552006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE 1390/2-1|Treatment of Formerly Abducted Children (FAC) in Uganda|A Randomized Controlled Clinical Trial (RCCT) to Test the Effectiveness of Narrative Exposure Therapy (NET) Versus an Attention Control Condition (AC) in Reducing Trauma Related Symptoms in Formerly Abducted Children and Former Child Soldiers Suffering From Posttraumatic Stress Disorder (PTSD)||University of Konstanz|No|Completed|November 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Both|12 Years|25 Years|No|||July 2008|March 7, 2011|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552006||165486|
NCT00552019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-405-f-S|Intraocular Pressure (IOP) Assessed by Dynamic Contour Tonometer (DCT) and Goldman Applanation Tonometry (GAT)|Inflammatory Changes of Corneal Thickness and Influence on Assessment of Intraocular Pressure||St. Franziskus Hospital|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|tertiary referral center|November 2009|November 17, 2009|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552019||165485|
NCT00552409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31615-D|Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease|Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease||University of Washington|Yes|Completed|December 2007|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|October 31, 2007||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00552409||165457|
NCT00552656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-20060914|Long Term Efficacy and Safety of Firebird Sirolimus-Eluting Stent In Complex Coronary Lesions|Prospective, Multicenter Study of Firebird Sirolimus-Eluting Stent for Treatment of Complex Coronary Lesions. Clinical and Angiographic Outcomes of FIREMAN Study|FIREMAN|Xijing Hospital|Yes|Enrolling by invitation|January 2007|August 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|the study enrolls a group of high risk population who have angiographic results of complex        coronary lesions.|August 2008|August 11, 2008|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552656||165438|
NCT00552955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080016|Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women|Effect of Fasting on the Size of Lymphangioleiomyomas in Patients With Lymphangioleiomyomatosis||National Institutes of Health Clinical Center (CC)||Completed|October 2007|March 2016||||N/A|Observational|N/A|||Actual|35|||Female|18 Years|80 Years|No|||March 2016|March 22, 2016|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552955||165415|
NCT00553345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574080|Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT]||National Cancer Institute (NCI)||Recruiting|December 2005|||||Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention||||515|||Both|18 Years|N/A|No|||February 2010|January 9, 2014|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553345||165385|
NCT00553566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574078|Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [COHORT]||National Cancer Institute (NCI)||Recruiting|December 2005|||||Phase 3|Observational|N/A||||1600|||Both|18 Years|N/A|No|||February 2010|January 9, 2014|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553566||165368|
NCT00574925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-QBE-0201|Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients|Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD)||University of Zurich|No|Completed|November 2003|October 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2007|December 17, 2007|December 13, 2007||||No||https://clinicaltrials.gov/show/NCT00574925||163775|
NCT00586040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006p001528|Photochemical Tissue Bonding|Photochemical Tissue Bonding (PTB) for Excisional Wound Healing|PTB|Massachusetts General Hospital|No|Completed|September 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 9, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586040||162936|
NCT00575172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN0949|Nippon Ultra-Rapid Insulin and Diabetic Complication Evaluation-Study (NICE-Study)|To Investigate Whether the Postprandial Blood Sugar Level as Achieved Using Ultrarapid-Acting Type Insulin Could Prevent Great Vessel Disorder in Japanese Type 2 Diabetic Patients.||Osaka Saiseikai Nakatsu Hospital|Yes|Completed|March 2003|December 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|346|||Both|20 Years|85 Years|No|Probability Sample|Japanese outpatients and inpatients aged 20 years or more but younger than 85 years. Men        or women. Patients with type 2 diabetes based on the diagnostic standard of the Japanese        Diabetes Society/American Diabetes Association. No specific restriction on the current        treatment. Patients having switched treatment are also accepted.|December 2007|January 7, 2008|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575172||163757|
NCT00575185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709M16341|Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection|Randomized, Placebo-Controlled, Double-Blind Study to Assess Clinical and Antiviral Activity of Valomaciclovir (EPB 348) in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection (Mono 6)|Mono6|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2007|February 2010|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|15 Years|N/A|No|||March 2015|March 13, 2015|December 14, 2007|Yes|Yes||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00575185||163756|
NCT00575484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00904-0407-01|Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction|Hypertonic Saline With Furosemide and a Normosodic Diet for the Treatment of Decompensated Congestive Heart Failure With Prerenal Physiology||Barnes-Jewish Hospital|Yes|Terminated|November 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575484||163734|
NCT00551083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1143107|Efficacy Study of a Computer Decision Support System to Treat Depression|A Pilot Efficacy Trial of a Computer Decision Support System Compared to Usual Care for Depression Treatment in Primary Care|CDSS-D|University of Texas Southwestern Medical Center|No|Completed|March 2005|June 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551083||165557|
NCT00551330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05057|Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)|Vicriviroc in Combination Treatment With an Optimized ART Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057)||Merck Sharp & Dohme Corp.|Yes|Completed|September 2007|May 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|16 Years|N/A|No|||December 2015|December 18, 2015|October 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551330||165538|
NCT00575731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11082007-857|Behavioral Strategies for Weight Management|Behavioral Strategies for Weight Management||Stanford University||Completed|July 2006|May 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00575731||163715|
NCT00576017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003526|A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).|Randomised Study to Evaluate the Efficacy and Safety of Fentanyl-TTS Versus Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDs (Non-steroidal Anti-inflammatory Drugs).||Janssen-Cilag, S.A.||Completed|October 2003|March 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|December 14, 2007||||No||https://clinicaltrials.gov/show/NCT00576017||163694|
NCT00583089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECODE|Decompensation Detection Study|Decompensation Detection Study||Boston Scientific Corporation|No|Completed|March 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients|August 2011|August 1, 2011|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583089||163161|
NCT00551499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113|Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF|Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF|Morpheus|Medtronic Bakken Research Center|No|Completed|June 2005|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||October 2007|October 30, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551499||165525|
NCT00551759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000571857|Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer|A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy With Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients With Operable Adenocarcinoma of the Esophagus||Eastern Cooperative Oncology Group|No|Terminated|June 2008|April 2016|Anticipated|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|October 30, 2007|Yes|Yes|The study used a two-stage design. After stage one, the study was terminated due to excess    toxicity.|No|January 17, 2014|https://clinicaltrials.gov/show/NCT00551759||165505|
NCT00552032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05155|Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)|A Double-blind Placebo-controlled, Randomized, Parallel-group, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy SNORE Study|SNORE|Merck Sharp & Dohme Corp.|No|Completed|August 2007|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|2 Years|11 Years|No|||February 2016|February 23, 2016|October 31, 2007|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00552032||165484|The results of this study as presented are drawn from the clinical study report and should be reviewed with caution as there were inaccuracies in the database resulting from medication errors in some participants.
NCT00552422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC3728|Domperidone for Gastroparesis in Solid Organ Transplantation|Domperidone for Gastroparesis Associated With Solid Organ Transplantation||Columbia University|No|Terminated|March 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|October 31, 2007|Yes|Yes|Lack of perceived need for domperidone in this population|No|June 2, 2015|https://clinicaltrials.gov/show/NCT00552422||165456|
NCT00552669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Rodriguez|Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents|Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.|ORAR III|Centro de estudios en Cardiologia Intervencionista|Yes|Completed|January 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|200|||Both|18 Years|N/A|No|||May 2009|May 27, 2010|November 1, 2007||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00552669||165437|It was an open label design. Multiple approved DES designs were used. Health Care system in Argentina differs from other world ones.
NCT00552968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208-2007|Pain Prevalence in the Trauma Population|Pain Prevalence in the Trauma Population at Sunnybrook Hospital||Sunnybrook Health Sciences Centre|No|Completed|September 2007|September 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|16 Years|N/A|No|Non-Probability Sample|Patients that have been admitted to hospital due to a traumatic injury.|October 2011|October 6, 2011|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552968||165414|
NCT00552981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELI-2007|Effectiveness of Local Application of Warm Air in Patients With Common Cold (HELI Study)|Effectiveness of Local Application of Warm Air in Patients With Common Cold (HELI Study)|HELI|Charite University, Berlin, Germany|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|60 Years|No|||July 2012|July 9, 2012|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552981||165413|
NCT00553358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF106903|Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study|Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer|Neo ALTTO|GlaxoSmithKline|Yes|Active, not recruiting|January 2008|January 2019|Anticipated|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|455|||Female|18 Years|N/A|No|||April 2015|April 22, 2015|November 1, 2007|Yes|Yes||No|May 26, 2011|https://clinicaltrials.gov/show/NCT00553358||165384|
NCT00553891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04367|Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)|Double Blind, Placebo Controlled Trial, Evaluating the Role of Nasonex® in the Management of Nasal Obstruction Secondary to Adenoids Hypertrophy in Children||Merck Sharp & Dohme Corp.|No|Terminated|May 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|285|||Both|2 Years|11 Years|No|||August 2015|August 12, 2015|November 5, 2007|No|Yes|No enrollment because of war in the study country.|No||https://clinicaltrials.gov/show/NCT00553891||165344|
NCT00554151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAARS CIP Version 5|Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study|Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study (MAARS) for Treatment of Patients With Mitral Valve Regurgitation in Open Surgical Repair|MAARS|St. Jude Medical|Yes|Completed|July 2007|April 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|75 Years|No|||February 2010|June 20, 2011|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00554151||165325|
NCT00586066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-p-001651|Memantine and Cognitive Dysfunction in Bipolar Disorder|Memantine and Cognitive Dysfunction in Bipolar Disorder||Massachusetts General Hospital|Yes|Completed|November 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||July 2013|July 1, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586066||162934|
NCT00586079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003248|Deep Brain Stimulation in Patients With Parkinson's Disease|The Effect of Deep Brain Stimulation on Movement-Related Cortical Potentials in Patients With Parkinson's Disease||Mayo Clinic|No|Completed|July 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|40 Years|82 Years|No|||April 2015|March 17, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586079||162933|
NCT00586053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1221-00|Unprepped CT Colonography|"CTC of the Unprepped Colon: Optimization & Validation"||Mayo Clinic|No|Completed|August 2000|December 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1255|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mayo Clinic patients scheduled for colonoscopy.|February 2010|February 10, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586053||162935|
NCT00586339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107863|Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in HIV Infected Females|Evaluation of the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in Adult Human Immunodeficiency Virus (HIV) Infected Female Subjects||GlaxoSmithKline||Completed|January 2008|July 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|150|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|December 21, 2007|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00586339||162914|
NCT00582179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F010316005|Vacuum Assisted Closure as a Treatment for Draining Hematomas|Vacuum Assisted Closure as a Treatment For Draining Hematomas (Vacuum Assisted Closure in the Management of Traumatic Extremity Wounds)|VAC-DH|University of Alabama at Birmingham|No|Completed|September 2001|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|19 Years|N/A|No|||September 2013|September 28, 2013|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582179||163231|
NCT00582374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeriodontalPreTermBirth|Periodontal Disease and Preterm Birth|Periodontal Disease, Inflammatory Markers, and Preterm Birth||University of Oklahoma|No|Terminated|March 2005|March 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|None Retained|Gingival crevicular fluid (GCF) and Vaginal Fluid|Female|15 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women from the OU Medical Center Women's Clinic|June 2008|December 11, 2008|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582374||163216|
NCT00582556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO02807|Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy|Phase II Trial of Zometa on Bone Mineral Density on Patients With Stage D Prostate Cancer Undergoing Androgen Ablation Therapy||University of Wisconsin, Madison|Yes|Completed|April 2003|March 2013|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Male|18 Years|N/A|No|||June 2014|June 2, 2014|December 19, 2007|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT00582556||163202|
NCT00582816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT06407|Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors|Reduced Intensity Haploidentical Transplantation With NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors, BMT06407||University of Wisconsin, Madison|Yes|Terminated|August 2008|May 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|6 Months|25 Years|No|||February 2016|February 19, 2016|December 19, 2007|No|Yes|toxicity|No||https://clinicaltrials.gov/show/NCT00582816||163182|
NCT00583102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200104050|Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML|A Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Patients With Refractory or Relapsed Acute Myeloid Leukemia||University of Iowa|Yes|Recruiting|June 2001|June 2021|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2010|December 20, 2010|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583102||163160|
NCT00551577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIMOVAR-1|Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial|Prospective, Randomized Phase II Clinical Trial to Select Primary Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer Stage FIGO IIIC and IV|PRIMOVAR-1|University Hospital, Bonn|No|Recruiting|March 2003|January 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||October 2007|October 30, 2007|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551577||165519|
NCT00583076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-908|Safety and Efficacy of AST-120 in the Treatment of Pouchitis|A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis||Ocera Therapeutics|Yes|Completed|February 2007|May 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||June 2014|June 2, 2014|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583076||163162|
NCT00583778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB04-00127|A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation|A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation||MetroHealth Medical Center|Yes|Completed|August 2004|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|45 Years|No|||December 2007|August 19, 2010|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583778||163109|
NCT00585351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 5K12RR017700-04|Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting|Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting (AIRDOC)|AIRDOC|University of Iowa|Yes|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|100|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|December 26, 2007||No||No|August 16, 2011|https://clinicaltrials.gov/show/NCT00585351||162989|Some procedural errors by the helicopter crew at the start of the trial, reliability of the stroke diagnosis from the outside hospital, and the possibility for a lower consent rate if a higher risk profile medication were used instead of Ranitidine.
NCT00585624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06206|Preoperative Nutritional Support in Esophagectomy or Pancreaticoduodenectomy|Preoperative Nutritional Support Reduces Postoperative Stay and Incidence of Complications in Patients Undergoing an Esophagectomy or Pancreaticoduodenectomy||University of Wisconsin, Madison|No|Completed|April 2007|October 2009|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|344|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00585624||162968|
NCT00551772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ3110291|A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.|An Open-Label, Randomised, Two-Part Crossover Study to Assess the Pharmacokinetics of a Single Dose of SB-742457 Formulated as a Capsule and a Tablet in Healthy Elderly Volunteers.||GlaxoSmithKline||Completed|August 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||December 2008|December 23, 2008|October 29, 2007||||||https://clinicaltrials.gov/show/NCT00551772||165504|
NCT00552045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS053998-01A1|Epilepsy Phenome/Genome Project|Epilepsy Phenome/Genome Project: A Phenotype/Genotype Analysis of Epilepsy|EPGP|University of California, San Francisco|Yes|Active, not recruiting|November 2007|April 2014|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4150|Samples With DNA|whole blood|Both|N/A|60 Years|No|Non-Probability Sample|EPGP will recruit persons with specific forms of epilepsy.|January 2014|January 15, 2014|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00552045||165483|
NCT00552695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20076689|Lidocaine Patches Prior to Intravenous Insertion|Phase II Study of Lidoderm Patches Prior to Intravenous Catheter Insertion.||Stony Brook University|No|Completed|August 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|45|||Both|3 Years|N/A|No|||October 2012|October 19, 2012|October 31, 2007||No||No|October 16, 2009|https://clinicaltrials.gov/show/NCT00552695||165435|
NCT00552708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD108412|A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.|A Randomized, Open-label, Single-dose, Crossover Study to Demonstrate the Bioequivalence of the Final Fixed Dose Combination (FDC) Formulation (COREG CR & Lisinopril) to COREG CR & ZESTRIL Employed in the Phase III Factorial Study||GlaxoSmithKline||Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|October 31, 2007||||||https://clinicaltrials.gov/show/NCT00552708||165434|
NCT00552721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 02 323948|Physical Therapy After Anti-spastic Treatment in Children With Cerebral Palsy|Physical Therapy With Versus Without Strength Training After Botulinum-toxin Treatment in Children With Cerebral Palsy||Hvidovre University Hospital|Yes|Completed|October 2007|July 2009|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|7 Years|18 Years|No|||September 2009|September 4, 2009|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552721||165433|
NCT00552682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBROHIV|Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+|Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+||Germans Trias i Pujol Hospital|Yes|Completed|January 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|70 Years|No|||July 2009|July 20, 2009|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552682||165436|
NCT00552994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVUS-20070043|Comparison of Coronary Xience V and the Cypher Select+ Stents in Diabetic Patients|A Danish Prospective Randomized Multicenter Comparison of the Xience V and the Cypher Select+ Stents in Unselective Patients With Diabetes Mellitus. An Intravascular Ultrasound Study.|DIABEDES IV|Odense University Hospital|Yes|Completed|August 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2009|July 9, 2010|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552994||165412|
NCT00553007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGU070001|The Relation Between Periodontal Disease and Metabolic Syndrome|The Relation Between Periodontal Disease and Metabolic Syndrome||Aichi Gakuin University|No|Recruiting|October 2007|October 2009|Anticipated|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|20 Years|N/A|No|||October 2007|November 1, 2007|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00553007||165411|
NCT00553020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4050|Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes|Assessment of Duration of Metabolic Effect of a Single Bolus of Subcutaneous Injected Lantus Compared to NPH-Insulin(Protaphan)in Patients With Type 2 Diabetes||Sanofi||Completed|April 2004|July 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|16|||Both|40 Years|65 Years|No|||October 2007|October 31, 2007|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00553020||165410|
NCT00553592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XTL B07-001|Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes|A Double-Blind, Randomized, Placebo-Controlled, Parallel, Multicenter Study of the Safety and Efficacy of Two Dosages of Bicifadine SR in Adult Outpatients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy||XTL Biopharmaceuticals|No|Recruiting|September 2007|December 2008|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|336|||Both|18 Years|N/A|No|||November 2007|November 2, 2007|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00553592||165366|
NCT00551070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00604|Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer|A Phase II Trial of AZD6244 (NSC #748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum||National Cancer Institute (NCI)||Active, not recruiting|December 2007|||July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|19 Years|N/A|No|||July 2014|June 10, 2015|October 22, 2007|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT00551070||165558|Study began with 100mg BID mix & drink (MD) formulation. AstraZeneca (AZ) switched to hydrogen-sulfate capsule (HC). AZ deemed 100mg BID MD equivalent to 50mg BID HC. As of 12/31/2010, patients got 50mg BID HC; four patients were on treatment then.
NCT00582569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-101|Breast MRI Spectroscopy, Department of Defense (DOD)|Breast MRI Spectroscopy, Department of Defense (DOD)||Memorial Sloan Kettering Cancer Center||Completed|February 2006|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|146|||Female|18 Years|N/A|No|Non-Probability Sample|Include women with lesions, > or = to 1 centimeter that will undergo a diagnostic MRI        exam, an MRI guided biopsy, or an MRI guided needle localization, such as women with        breast cancer or women with clinical and/or mammographic findings suspicious for breast        masses. However, any known breast lesion, benign or malignant, will be appropriate for        evaluation with MR spectroscopy.|May 2013|May 9, 2013|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582569||163201|
NCT00586365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001670|Naproxen for the Prevention of HO After Complex Elbow Trauma|Effectiveness of Naproxen for the Prevention of Heterotopic Ossification After Complex Elbow Trauma: a Prospective Randomized Trial|Naproxen|Massachusetts General Hospital|No|Withdrawn|October 2007|October 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 20, 2012|December 14, 2007||No|Too difficult to satisfy all the inclusion criteria.|No||https://clinicaltrials.gov/show/NCT00586365||162912|
NCT00586378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITAC05|Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study|Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study|Post-Ovatio|ELA Medical, Inc.|No|Completed|April 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586378||162911|
NCT00586391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19384-CRETI-NH|CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL|Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia|CRETI-NH|Baylor College of Medicine|Yes|Active, not recruiting|February 2009|February 2033|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|N/A|N/A|No|||November 2015|November 25, 2015|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586391||162910|
NCT00583154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI-801-101|A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults|A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults||Braintree Laboratories|No|Completed|October 2007|April 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583154||163157|
NCT00583167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050001|CNS (Central Nervous System) Viral Dynamics and Cellular Immunity During AIDS|CNS Viral Dynamics and Cellular Immunity During AIDS||Vanderbilt University|Yes|Completed|March 2006|July 2010|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|4|Samples With DNA|whole blood, plasma, CSF|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3        months, and with plasma HIV-1 RNA >20,000 copies/mL. Individuals with past ART experience        must have the ability to construct an ART regimen predicted to completely suppress plasma        HIV-1 RNA, based on results of viral susceptibility testing that is done as a routine part        of clinical practice.|May 2014|May 27, 2014|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583167||163156|
NCT00583453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200703765|Celecoxib as a Post-tonsillectomy Pain Medication|Perioperative Use of Celecoxib to Improve Pain Control in Patients Undergoing Tonsillectomy: a Randomized, Double Blind, Placebo-controlled Trial||University of Iowa|No|Active, not recruiting|July 2007|December 2014|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583453||163134|
NCT00583791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-005|Closure of Muscular Ventricular Septal Defects With The AMPLATZER® Muscular VSD Occluder|||St. Jude Medical|Yes|Active, not recruiting|July 2000|October 2008|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|18 Years|No|||December 2007|July 24, 2009|December 20, 2007|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00583791||163108|
NCT00584090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4|Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease|||University of South Florida|No|Withdrawn|November 2007|||April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|80 Years|No|||October 2010|November 30, 2012|December 21, 2007|Yes|Yes|Study withdrawn with intent of persuing larger, multi-site study.|No||https://clinicaltrials.gov/show/NCT00584090||163085|
NCT00583115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702-21|Safety Study of Gleevec® in Children With Pulmonary Hypertension|A Phase II Study of Gleevec® (Imatinib Mesylate, NSC 716051 Formerly ST1571) in Children With Pulmonary Hypertension||Indiana University|Yes|Terminated|October 2007|December 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|8 Years|18 Years|No|||September 2015|September 28, 2015|December 20, 2007|Yes|Yes|Unable to enroll subjects|No|July 21, 2015|https://clinicaltrials.gov/show/NCT00583115||163159|
NCT00583128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST014|Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome|A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome||Ocera Therapeutics|No|Completed|August 2007|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|80 Years|No|||June 2014|June 2, 2014|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583128||163158|
NCT00583440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Bogenschutz-AA015419|12-step Facilitation for the Dually Diagnosed|12-step Facilitation for the Dually Diagnosed|TSFDD|University of New Mexico|No|Completed|September 2005|May 2011|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583440||163135|
NCT00584714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-014-A|Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent|Long-Term Follow-Up of Selected Patients Enrolled in Phase 3 Clinical Trial 127-014 Using PB127 Ultrasound Imaging Agent||Point Biomedical|No|Terminated|October 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with low/very low pre-test probability of coronary artery disease enrolled in        Protocol 127-014 who did not have or were not schedule to undergo coronary angiography at        the time of enrollment and did not have a clinical outcome during the initial 6 month        follow-up period.|July 2008|July 1, 2008|December 20, 2007|Yes|Yes|Discontinued PB127 development program for business reasons|No||https://clinicaltrials.gov/show/NCT00584714||163037|
NCT00584727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0714A|In-office Evaluation of Two Toric Soft Contact Lenses and a Spherical Soft Contact Lens|Evaluation of Fit and Visual Acuity of the Cypress Toric Lens in Two Phases: Part A: A Non-Dispensing Comparison to SofLens66® Toric and Acuvue® 2||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|96|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|December 20, 2007|Yes|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00584727||163036|
NCT00585871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200602703|Clonidine to Prevent Implantable Cardiovertor Defibrillator Firing|Clonidine to Prevent Implantable Cardiovertor Defibrillator Firing||University of Iowa|Yes|Terminated|May 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|85 Years|No|||August 2013|December 9, 2013|December 29, 2007||No|could not recruit|No||https://clinicaltrials.gov/show/NCT00585871||162949|
NCT00585884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-1383|Following the Use of Gel Prosethetics in Breast Reconstruction|Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Gel-filled Mammary Prostheses in Patients Who Are Undergoing Primary Breast Reconstruction or Revision||University of California, Irvine|Yes|Active, not recruiting|January 2000|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Female|N/A|N/A|No|Non-Probability Sample|women over 18 undergoing breast reconstruction|February 2013|February 6, 2013|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00585884||162948|
NCT00552071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11482|Ultrasound Guided Sandostatin LAR Injection in Acromegaly|Does Ultrasound-Guidance Improve the Delivery and Efficacy of Intramuscular (IM) Injection of Sandostatin LAR in the Treatment of Acromegaly||Cedars-Sinai Medical Center|No|Recruiting|July 2007|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2010|August 18, 2010|October 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00552071||165481|
NCT00552435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-001|Micropulse 810 Nanomolar (nm), Diode Laser for Diffuse Diabetic Macular Edema|Phase 2 Study of Micropulse 810nm Diode Laser Photocoagulation for Treatment of Diffuse Diabetic Macular Edema||Federal University of São Paulo||Recruiting|March 2007|November 2008|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552435||165455|
NCT00552136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-MG-001|Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study|Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study||Nova Scotia Health Authority||Recruiting|February 2005|April 2020|Anticipated|April 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2009|May 15, 2015|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00552136||165477|
NCT00553033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPSLIVER1|Laparoscopic Liver Resection|Prospective Evaluation of Laparoscopic Liver Resection||IRCCS San Raffaele||Recruiting|September 2005|December 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients udergoing liver resection for benign or malignant tumors|October 2007|November 1, 2007|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00553033||165409|
NCT00553046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N°159|Last 3 Months of Life in Home Ventilated Patients|Italian Multicenter Survey on the Last 3 Months of Life in Patients Ventilated at Home||Fondazione Salvatore Maugeri|No|Completed|January 2005|April 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|180|||Both|18 Years|80 Years|No|Probability Sample|Home MV patients in the last 3 months of life|October 2007|February 3, 2016|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00553046||165408|
NCT00553059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0841|Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer|Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone With or Without Dronabinol for the Prevention of Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy||M.D. Anderson Cancer Center|Yes|Completed|May 2008|||August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|62|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553059||165407|
NCT00553371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573199|Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer|Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT)||National Cancer Institute (NCI)||Recruiting|April 2006|||||N/A|Observational|N/A|||Anticipated|300|||Male|18 Years|N/A|No|||October 2007|August 23, 2013|November 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00553371||165383|
NCT00553579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCO2-2241|The Relationship of Residence Time and Visual Effect of Optive and Systane in Dry Eye Subjects|The Relationship of Residence Time and Visual Effect of Optive and Systane in Dry Eye Subjects||Southern California College of Optometry|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects for this investigation will be sourced from an existing, secure dry eye        subject database. These subjects will have been screened for dry eye using a consistent        protocol (Diagnostic monograph, J. Paugh, January 2007). Subjects who have taken part in a        prior study undergoing this same eligibility visit protocol within the past 18 months will        not be required to repeat the visit.|May 2008|May 19, 2008|November 1, 2007||||No||https://clinicaltrials.gov/show/NCT00553579||165367|
NCT00554749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2006.2116|What Treatment Works for Children With Selective Mutism?|What Treatment Works for Children With Selective Mutism? A Treatment Pilot Study||Regionsenter for barn og unges psykiske helse|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|3 Years|9 Years|No|||November 2010|November 18, 2010|November 6, 2007||No||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00554749||165281|
NCT00586404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0048|The Study of Barrett's Esophagus: What Are the Factors of Progression|Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project|BEST|Midwest Biomedical Research Foundation|Yes|Suspended|November 2007|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients who have histologically confirmed Barrett's Esophagus|October 2015|October 19, 2015|December 21, 2007||No|The protocol is being reviewed and potentially revised. Recruitment is currently suspended.|No||https://clinicaltrials.gov/show/NCT00586404||162909|
NCT00582192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-096|Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists'Communication Styles|Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists' Communication Styles||Memorial Sloan Kettering Cancer Center||Completed|July 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with certain types of cancers that are eligible for studies at Memorial        Sloan-Kettering Cancer Center.|April 2009|April 30, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582192||163230|
NCT00582829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-043|Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients|Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients||Memorial Sloan Kettering Cancer Center||Completed|June 2003|May 2008|Actual|May 2008|Actual|Phase 0|Observational|N/A||3|Anticipated|213|||Both|40 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 6, 2008|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582829||163181|
NCT00582582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 2001-484|Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer|Phase II Evaluation of Docetaxel Randomized With Doxercalciferol or Placebo in Patients With Advanced Prostate Cancer||University of Wisconsin, Madison|Yes|Terminated|April 2002|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|N/A|No|||April 2009|September 30, 2015|December 19, 2007|Yes|Yes|Lack of drug supply for doxercalciferol for this study|No||https://clinicaltrials.gov/show/NCT00582582||163200|
NCT00582842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-042|Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer|Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|May 2002|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1800|||Male|N/A|N/A|No|Non-Probability Sample|All eligible MSKCC patients (including patients from the regional network sites: Commack,        Basking Ridge, Rockville Centre and Sleepy Hollow) will be approached by consenting        professionals and invited to participate in the study.|June 2015|June 1, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582842||163180|
NCT00583180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4975-2008-01|Sensory Function After Wound Instillation of Capsaicin|Cutaneous Sensory Function After Wound Instillation of Capsaicin During Groin Hernia Repair||Rigshospitalet, Denmark|No|Completed|January 2008|January 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|42|||Male|18 Years|N/A|No|Non-Probability Sample|Adult males with primary unilateral groin hernia|January 2008|January 29, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583180||163155|
NCT00583193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1J-US-X024|Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder|A Study of the Effectiveness and Tolerability of Duloxetine (Cymbalta) in the Treatment of PTSD.||New Mexico VA Healthcare System|Yes|Recruiting|December 2005|June 2008|Anticipated|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2007|December 20, 2007|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583193||163154|
NCT00583466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00008376|Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection|Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection||Johns Hopkins University|Yes|Recruiting|May 2007|May 2008|Anticipated|May 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2007|December 20, 2007|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583466||163133|
NCT00584103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHDH 07|Evaluation of Upper Extremity Prosthesis|Evaluation of an Inexpensive Upper Extremity Prosthesis||University of Oklahoma|No|Completed|January 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|89 Years|No|||December 2013|December 10, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584103||163084|
NCT00584428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OU 9206|High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer|High Dose Chemotherapy With Autologous Bone Marrow Transplantation in the Treatment of Metastatic Breast Cancer||University of Oklahoma|No|Completed|June 1992|March 2002|Actual|March 2002|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Female|18 Years|70 Years|No|||May 2015|May 26, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584428||163059|
NCT00584441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-256|Menstrual Differences in Airway Inflammation in Asthma|Menstrual Differences in Airway Inflammation in Asthma||The University of Texas Medical Branch, Galveston|No|Completed|September 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|6|Samples Without DNA|Serum Eosinophil Cationic Protein (ECP) samples will be obtained. The 5ml blood samples for      measuring ECP levels will be collected in silica gel-containing tubes. After centrifuging,      the supernatant will be frozen and ECP levels will bemeasured using an ELISA kit|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females diagnosed with asthma, with either regular menstral cycles or on monophasic oral        contraceptives, with or without pre-mentstual asthma symptoms|February 2013|February 11, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584441||163058|
NCT00584740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2202|Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single iv Infusions of AIN457 10 mg/kg (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Active Crohn's Disease||Novartis|No|Terminated|August 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|No|||March 2015|March 24, 2015|December 21, 2007|Yes|Yes|The study was terminated prematurely after futility criterion was met at planned interim    analysis of 41 patients.|No|January 28, 2015|https://clinicaltrials.gov/show/NCT00584740||163035|
NCT00585065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00015291|CRT Pilot Study for Children With Heart Failure|Cardiac Resynchronization Therapy for Children and Adolescents With Advanced Hearth Failure: A Pilot Study||University of Utah|No|Completed|January 2006|January 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|7|||Both|1 Year|18 Years|No|Probability Sample|Primary care clinic|January 2016|January 7, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00585065||163010|
NCT00582049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-030|Research on the Environment and Children's Health: Retinoblastoma|Research on the Environment and Children's Health: Retinoblastoma||Memorial Sloan Kettering Cancer Center||Completed|August 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|78|Samples With DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|The subjects (cases) will be children with sporadic heritable RBL and their parents.        Parents of children without RBL will be identified and will participate as controls.|June 2008|July 3, 2008|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582049||163240|
NCT00554723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQSTR03 - CHIMES|CHInese Medicine NeuroAid Efficacy on Stroke Recovery|A Double Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine NeuroAid Efficacy on Stroke Recovery|CHIMES|CHIMES Society|Yes|Completed|May 2007|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1100|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554723||165283|
NCT00551291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20559|A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.|An Open Label Study of the Effects of a Combination of NeoRecormon, CellCept and Prednisone on Hematological Parameters and Cytogenesis in Patients With Low or Intermediate Risk Myelodysplastic Syndromes.¿||Hoffmann-La Roche||Completed|July 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00551291||165541|
NCT00551304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-020 & TP-039|Native Kidney Denervation in Patients With End Stage Renal Disease|Native Kidney Denervation in Patients With End Stage Renal Disease||Medtronic Vascular|Yes|Completed|October 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||November 2012|November 2, 2012|October 26, 2007||||No||https://clinicaltrials.gov/show/NCT00551304||165540|
NCT00552747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fenofibrate|Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease|The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal||National Heart Institute, Mexico|Yes|Completed|October 2007|January 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|76|||Male|18 Years|60 Years|No|||May 2008|March 9, 2011|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00552747||165431|
NCT00553098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.00|Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders|Hematopoietic Cell Transplantation for Treatment of Patients With Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine With or Without Campath®||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|June 2006|||March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|54 Years|No|||February 2016|February 26, 2016|November 2, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00553098||165404|
NCT00553111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-09390|Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission|Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission||Jacobi Medical Center||Completed|November 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|168|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 2007|November 2, 2007|November 2, 2007||||No||https://clinicaltrials.gov/show/NCT00553111||165403|
NCT00553917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 0708-10|Study to Evaluate the Effectiveness of Certain Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants During Pregnancy and Evaluate Newborn Outcomes|Study of the Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy||Indiana University|Yes|Terminated|November 2007|December 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|18|Samples With DNA|whole Blood Plasma human milk|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women up to 26 weeks gestation currently diagnosed with depression.|June 2011|June 21, 2011|November 5, 2007||No|Poor recruitment to experimental arms and study remained unfunded|No||https://clinicaltrials.gov/show/NCT00553917||165342|
NCT00554736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614299-2|Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen|A Randomized, Double-blind, Placebo-controlled Trial of Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen||University of California, Davis|Yes|Withdrawn|May 2006|August 2008|Anticipated|December 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|November 5, 2007||No|Sponsor suspended study do to funding|No||https://clinicaltrials.gov/show/NCT00554736||165282|
NCT00550810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBCC-0707001|Sutent Maintenance After Response to Taxotere|A Phase II Study of SU011248 for Maintenance Therapy in Hormone Refractory Prostate Cancer After First Line Chemotherapy|SMART|AHS Cancer Control Alberta|Yes|Active, not recruiting|October 2007|November 2012|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||September 2011|December 6, 2011|October 26, 2007||||No||https://clinicaltrials.gov/show/NCT00550810||165578|
NCT00550823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|362-07|Cardiac Computarized Tomography in Infective Endocarditis|The Use of Cardiac Computarized Tomography in Infective Endocarditis|cardiac CT|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2007|November 2008|Anticipated|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|90 Years|No|||October 2007|October 29, 2007|October 27, 2007||||No||https://clinicaltrials.gov/show/NCT00550823||165577|
NCT00583206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706755|Muscle Atrophy in Sepsis|Biochemical Pathways to Skeletal Muscle Atrophy in Human Sepsis||University of Iowa|No|Recruiting|December 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Muscle RNA; blood|Both|18 Years|N/A|No|Non-Probability Sample|Severe sepsis|July 2008|July 22, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583206||163153|
NCT00583219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|359-06|Botulin-A Toxin Instillations and Overactive Bladder|Botulin-A Toxin/Dimethyl Sulfoxide Bladder Instillations for Treatment of Voiding Dysfunction Secondary to Detrusor Hyperreflexia and Detrusor Instability in Women||Mayo Clinic|No|Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||March 2014|March 14, 2014|December 20, 2007|Yes|Yes||No|March 14, 2014|https://clinicaltrials.gov/show/NCT00583219||163152|
NCT00582387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-011|Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer|Pilot Study: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2004|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|Samples With DNA|blood, urine and tissue|Both|21 Years|N/A|No|Non-Probability Sample|Urology clinic|December 2015|December 16, 2015|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582387||163215|
NCT00582400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-267|A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver|A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver||The University of Texas Medical Branch, Galveston|No|Terminated|September 2004|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||January 2010|February 18, 2016|December 19, 2007|Yes|Yes|recruiting or enrolling participants has halted prematurely and will not resume; participants    are no longer being examined or treated|No|July 1, 2015|https://clinicaltrials.gov/show/NCT00582400||163214|
NCT00583856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614968-1|Computer Modeling With Reconstruction of Maxillofacial Skeleton|Is Computer Modeling and Intra-Operative Navigation Helpful With Reconstruction of the Maxillofacial Skeleton?||University of California, Davis|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|3|||Both|11 Years|50 Years|No|Probability Sample|UCDMC Patients with specific complex fractures|December 2010|December 16, 2010|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00583856||163103|
NCT00584142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA109168|Mindfulness-based Stress Reduction in Breast Cancer Recovery|Effects of MBSR in Early Stage Breast Cancer Recovery||University of South Florida|Yes|Completed|March 2006|June 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|84|||Female|21 Years|N/A|No|||December 2007|June 14, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00584142||163081|
NCT00584116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614760|Balloon Aortic Valvuloplasty During Surgical Aortic Valve Replacement|Balloon Aortic Valvuloplasty During Surgical Aortic Valve Replacement|BAV-SAVR|University of California, Davis|Yes|Completed|March 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient with severe symptomatic calcific aortic stenosis (AS) referred for elective        surgical aortic valve replacement.|January 2014|January 31, 2014|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00584116||163083|
NCT00584129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060123002|Pre-treatment Exercises Versus Post-treatment Exercises for Dysphagia|Determining the Efficacy of Pre-treatment Swallowing Therapy as a Means to Improve Dysphagia Quality of Life When Compared to Post-Treatment Therapy.||University of Alabama at Birmingham|No|Completed|February 2006|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|19 Years|N/A|No|||March 2015|March 12, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00584129||163082|
NCT00584467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513134|Genetic and Inflammatory Markers in Cardiovascular Disease (GEM) Registry|Genetic and Inflammatory Markers in Cardiovascular Disease (GEM) Registry|GEM|University of California, Davis|Yes|Active, not recruiting|January 2005|November 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|Samples With DNA|blood/serum|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will mainly include individuals who are scheduled to undergo cardiac        catheterization at UC Davis Medical Center, but may include other eligible individuals.        Subjects may also include individuals who have objective evidence of the extent of        arteriosclerosis of the coronary, femoral or carotid arteries.|June 2008|June 4, 2008|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00584467||163056|
NCT00584753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715040|Molecular Imaging of Breast Cancer With Breast PET/CT|Molecular Imaging of Breast Cancer With Breast PET/CT||University of California, Davis|No|Terminated|April 2007|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|4|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 11, 2013|December 26, 2007|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT00584753||163034|
NCT00584454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13480|Safety Evaluation of a Q-fever Vaccine, NDBR 105|Continued Evaluation of the Safety of Q Fever Vaccine, Phase I, Inactivated, Freeze Dried, NDBR 105, in Those at Risk of Exposure to Coxiella Burnetii, A Phase 2 Study||U.S. Army Medical Research and Materiel Command|No|Suspended|February 2006|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|17 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|December 20, 2007|No|Yes|Awaiting close out|No||https://clinicaltrials.gov/show/NCT00584454||163057|
NCT00585637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-342|Vitamin D for Chemoprevention|Defining Optimal Doses of Vitamin D for Chemoprevention in Blacks.||Dana-Farber Cancer Institute|Yes|Completed|October 2007|December 2013|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|328|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|December 24, 2007|No|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT00585637||162967|
NCT00550797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI ASM8-205|Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma|A Multi-center, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of 14-day Inhaled TPI ASM8 in Subjects With Asthma||Pharmaxis|No|Completed|January 2008|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||November 2013|November 18, 2013|October 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00550797||165579|
NCT00551057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2007|Expression of Inflammatory Proteins in Pancreatic Cancer|Expression of Inflammatory Proteins in Pancreatic Cancer||University of Zurich|No|Recruiting|October 2007|October 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|None Retained|To investigate the expression of different inflammatory proteins in cancer and normal      pancreatic tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with pancreatic cancer or chronic pancreatitis|October 2007|September 16, 2010|October 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551057||165559|
NCT00551811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR2100597|Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone.|A Randomised, Double-blind, Placebo Controlled, 3-way Crossover Study to Evaluate the Pharmacodynamics of SB-656933-AAA Following Single Doses in Healthy Adult Subjects Undergoing Ozone Challenge.||GlaxoSmithKline||Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551811||165501|
NCT00551824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITOMYCIN|Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children|Evaluation of Topical Mitomycin C as Adjuvant Drug to Endoscopic Esophageal Dilation in Children||Federal University of São Paulo|No|Recruiting|October 2007|March 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|10|||Both|6 Months|18 Years|No|||October 2007|April 7, 2008|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551824||165500|
NCT00552110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04500|Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)|Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|July 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|707|||Both|12 Years|N/A|No|||May 2015|May 27, 2015|October 30, 2007|Yes|Yes||No|May 15, 2009|https://clinicaltrials.gov/show/NCT00552110||165478|Subject symptom data were not collected during the post-treatment period. Thus, daily diary data for rebound congestion was not analyzed.
NCT00553397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RELIVE-02|Live Lung Donor Retrospective Study|Live Lung Donor Retrospective Study (RELIVE-02)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|369|||Both|N/A|N/A|No|Non-Probability Sample|Adults who have donated a lung at either the University of Southern California or        Washington University between 1993 and 2006|June 2013|June 5, 2013|November 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00553397||165381|
NCT00553618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0008|Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients|Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma|DTIC|James Graham Brown Cancer Center|Yes|Recruiting|August 2007|August 2020|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|November 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00553618||165364|
NCT00550498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3086|Stem Cell Transplantation in Ocular Lesions of Behcet's Disease|Phase 1 Study of Bone Marrow - Derived Stem Cell in the Treatment of Ocular Lesions of Behcet's Disease||Tehran University of Medical Sciences|Yes|Terminated|December 2007|July 2013|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|16 Years|N/A|No|||November 2015|November 9, 2015|October 27, 2007||No|No improvement obtained in 3 cases. Retinal detachment observed in 2 cases|No||https://clinicaltrials.gov/show/NCT00550498||165601|
NCT00550511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULABD-1|Randomized Study Evaluating the Role of Surgeon-Performed Ultrasound in the Management of the Acute Abdomen|Randomized Study Evaluating the Role of Surgeon-Performed Ultrasound in the Management of the Acute Abdomen||Karolinska Institutet|Yes|Completed|February 2004|June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|800|||Both|18 Years|N/A|No|||October 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00550511||165600|
NCT00551837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-12-14|Immune Response to Influenza Vaccination|Immune Response to Influenza Vaccination||The Cleveland Clinic||Completed|November 2006|May 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Lung and kidney transplant recipients, patients with chronic kidney disease and healthy        controls|May 2008|May 5, 2008|October 30, 2007||||No||https://clinicaltrials.gov/show/NCT00551837||165499|
NCT00583232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506-19|Protein and Energy Metabolism in Pediatric Crohn's Disease|Protein and Energy Metabolism in Pediatric Crohn's Disease||Indiana University|Yes|Active, not recruiting|February 2006|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|34|||Both|6 Years|18 Years|No|||June 2011|June 22, 2011|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583232||163151|
NCT00583245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00331110|Improving Walking in Older Adults With Knee Osteoarthritis|Optimizing Mobility in Older Adults With Knee Osteoarthritis||University of Iowa|No|Completed|December 2007|December 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|60 Years|N/A|No|||June 2010|June 24, 2010|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583245||163150|
NCT00583479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0203-32|Prospective Study of Celiac Block Injection: 1 vs. 2|A Prospective Study of Celiac Block Technique: One Injection or Two?||Indiana University|No|Completed|June 2002|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583479||163132|
NCT00583492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostate4809|Randomized Trial of Suicide Gene Therapy and Prostate Cancer|A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile|ReCAP|Henry Ford Health System|Yes|Completed|December 2007|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Male|18 Years|N/A|No|||February 2016|February 18, 2016|December 20, 2007|Yes|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00583492||163131|
NCT00584506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715801-1|Computer Aided Evaluation of Orbital Volume|Computer Aided Evaluation of Orbital Volume||University of California, Davis|Yes|Completed|November 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|250|||Both|3 Years|90 Years|No|Probability Sample|Patients with complex maxillofacial and orbital trauma that underwent operative repair of        orbital fractures. Computer tomography scans from a cohort of patients with normal CT data        sets will also be collected to assess "normative" orbital volumes.|December 2010|December 16, 2010|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00584506||163053|
NCT00584792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614379|Diet, Genetic Variation and Prostate Cancer Among African Americans|Diet, Genetic Variation and Prostate Cancer Among African Americans||University of California, Davis|Yes|Completed|August 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|102|Samples With DNA|Serum collected for Ancestry Imformative Markers (AIMS) testing along with PSA and CRP.|Male|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|African American males between the ages of 35 and 75.|December 2007|December 22, 2007|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00584792||163031|
NCT00583804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST12-PHP-2004|Implanted Myoelectric Control for Restoration of Hand Function in Spinal Cord Injury|Implanted Myoelectric Control for Restoration of Hand Function in Spinal Cord Injury||MetroHealth Medical Center|No|Active, not recruiting|April 1989|January 2019|Anticipated|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583804||163107|
NCT00583817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G000101|Endovascular Exclusion of Thoracic Aortic Aneurysms|Endovascular Exclusion of Thoracic Aortic Aneurysms||The Cleveland Clinic|Yes|Recruiting|May 2001|December 2020|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|459|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583817||163106|
NCT00583830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1012-C1072|A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer|A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab in Combination With Carboplatin and Paclitaxel as First Line Therapy in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)|NSCLC|Human Genome Sciences Inc.|No|Completed|January 2007|February 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|111|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583830||163105|
NCT00584480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715202-1|Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism|Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism|HBOT|University of California, San Francisco|Yes|Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|3 Years|8 Years|No|||August 2012|August 1, 2012|December 22, 2007||No||No|September 13, 2011|https://clinicaltrials.gov/show/NCT00584480||163055|1) Small sample size 2) Lack of control group prevented an examination of whether changes in clinical measure of disease severity were due to HBOT or other factors.
NCT00584766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OU 8701|Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer|Intensive Combination Chemotherapy With Autologous Bone Marrow Rescue for Metastatic Breast Cancer After Intitial Cytoreduction With Standard Agents: A Phase II Study||University of Oklahoma|No|Completed|October 1987|May 2002|Actual|May 2002|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|55 Years|No|||May 2015|May 28, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584766||163033|
NCT00584779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451160|An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis|An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis||Pfizer|No|Terminated|October 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|8|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2008|March 11, 2009|December 21, 2007||Yes|See detailed description for termination reason|No||https://clinicaltrials.gov/show/NCT00584779||163032|
NCT00585091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00011909|The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment|The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment||University of Utah|Yes|Completed|October 2003|August 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|85 Years|No|||June 2012|June 12, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585091||163008|
NCT00585078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-398|Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma|Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2004|July 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|December 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585078||163009|
NCT00586196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006p-000193|Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period|Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period|SHARP|Beth Israel Deaconess Medical Center|Yes|Completed|January 2007|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|16|||Both|70 Years|N/A|No|||August 2014|August 21, 2014|December 21, 2007|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT00586196||162925|
NCT00582647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-032|Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract|Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites.||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2000|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|Tissue, Blood, Peritoneal, Pleural, Cyst, and Other gastrointestinal fluid|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic|September 2015|September 24, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582647||163195|
NCT00582660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F001228004|Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib|Randomized, Placebo-Controlled, Phase 2B Evaluation of Cyclooxygenase-2 Activity in Surgically Resected Primary Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib|UAB0040|University of Alabama at Birmingham|Yes|Completed|December 2001|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|90 Years|No|||July 2014|July 15, 2014|December 20, 2007|Yes|Yes||No|February 2, 2011|https://clinicaltrials.gov/show/NCT00582660||163194|The most prominent factor that limited enrollment was this period of time was at the point that the FDA released its finding about the possible cardiac risks associated with Rofecoxib (VIOXX).
NCT00551551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3PN|Prenatal Pelvic Floor Prevention (3PN)|Urinary Postpartum Handicap Prevention: Pelvic Floor Exercises vs Control. Multicentric Randomized Trial||Centre Hospitalier Universitaire de la Réunion|No|Completed|November 2007|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|280|||Female|18 Years|N/A|No|||July 2013|July 25, 2013|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00551551||165521|
NCT00552461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2990s|Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis|Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis|PAP|East Carolina University|Yes|Recruiting|January 2007|December 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552461||165453|
NCT00564096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-218CTIL|Transcranial Magnetic Stimulation (TMS) in Schizophrenia|A Prospective Multicenter Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Schizophrenia Experiencing Auditory Hallucinations||BeerYaakov Mental Health Center|No|Recruiting|October 2008|December 2011|Anticipated|November 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|60 Years|No|||October 2009|March 2, 2010|November 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00564096||164585|
NCT00564109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 10-2003|Are the Pancreatic Serum Proteins Pancreatic Stone Protein (PSP) and Pancreatitis-Associated Protein (PAP) Predictive for the Development of Sepsis? Retrospective Study in Trauma Patients With Soft Tissue Defects.|||University of Zurich|No|Recruiting|August 2005|January 2008||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|15|||Both|18 Years|65 Years|No|Probability Sample|Trauma patients|November 2007|March 17, 2008|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564109||164584|
NCT00554177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 07-0900|A Clinical Trial for Post Traumatic Stress Disorder|Mifepristone After Trauma to Enhance Resilience|MATTER|Icahn School of Medicine at Mount Sinai|Yes|Completed|September 2007|December 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|November 2, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554177||165323|
NCT00554463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0623|G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer|A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|January 2008|||August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|5|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 6, 2007|Yes|Yes||No|September 23, 2014|https://clinicaltrials.gov/show/NCT00554463||165301|This study stopped accrual early due to unmet targeted accrual goals, therefore no analyses were performed. The small number of patients would not have provided meaningful results.
NCT00560118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574147|Fotemustine in Treating Patients With Metastatic Melanoma|Phase II Study of the Predictive Value of the Expression of Tumoral MGMT With Respect to the Therapeutic Response of Fotemustine in Patients With Metastatic Malignant Melanoma||National Cancer Institute (NCI)||Completed|August 2003|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||December 2008|May 13, 2011|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560118||164888|
NCT00560612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA IRB# 00993|Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)|Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)||Durham VA Medical Center||Completed|January 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|55 Years|No|||March 2011|March 31, 2011|November 19, 2007||No||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00560612||164850|
NCT00583869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061204006|Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients|The Role of Pregabalin in the Treatment of Post-Operative Pain in Fracture Patients|LYRICA|University of Alabama at Birmingham|Yes|Completed|May 2007|August 2009|Actual|August 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Both|19 Years|70 Years|No|||May 2012|January 5, 2014|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583869||163102|
NCT00583882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614292-1|Central Venous Catheter Replacement Strategies in Patients With Acute Burn Injury|A Prospective, Randomized Study to Evaluate the Risks Related to Central Venous Catheter Replacement Strategies in Patients With Acute Burn Injury||Shriners Hospitals for Children|No|Recruiting|July 2006|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|300|||Both|N/A|N/A|No|||December 2007|December 26, 2007|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00583882||163101|
NCT00583505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-008 E/C|Emergency/Compassionate Use - Membranous VSD Occluder|||St. Jude Medical||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||October 2015|October 21, 2015|December 20, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00583505||163130|
NCT00583518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-008-ES|STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)|Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis||Nycomed|Yes|Completed|November 2007|February 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Female|18 Years|N/A|No|||May 2012|May 4, 2012|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583518||163129|
NCT00583843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200602784|Ultrasound Targeting for the Lumpectomy Cavity|Evaluation of Change in the Lumpectomy Cavity During Radiation Therapy by Weekly Ultrasound and by Daily Ultrasound During the Radiation Boost Dose||University of Iowa|Yes|Completed|June 2006|December 2011|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Women and men who have had lumpectomy for the definitive treatment of breast cancer and        have a defined cavity from this procedure.|January 2014|January 14, 2014|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583843||163104|
NCT00584831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0725|Effect of Eye Movement on Toric Lens Orientation and Visual Acuity|Development and Implementation of a Clinical Test to Investigate the Change in Vision With Soft Toric Contact Lenses During Eye Movements||Johnson & Johnson Vision Care, Inc.|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|19||Actual|40|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|December 20, 2007|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00584831||163028|
NCT00584155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lactated Ringers - Berryhill|Protection From Cisplatin Ototoxicity by Lactated Ringers|Evaluation of Lactated Ringers for Protection From Cisplatin Ototoxicity.||University of Oklahoma|No|Withdrawn|July 2006|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2010|May 26, 2015|December 20, 2007|Yes|Yes|PI left the university.|No||https://clinicaltrials.gov/show/NCT00584155||163080|
NCT00585104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19266|Myocardial Hemodynamic Effects of Levosimendan|Myocardial Hemodynamic Effects of Levosimendan||University of Utah|Yes|Completed|September 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|December 21, 2007|Yes|Yes||No|February 11, 2010|https://clinicaltrials.gov/show/NCT00585104||163007|Of the ten (10) patients enrolled, only 6 patients completed the study protocol for which we collected data. The data is insufficient to provide a formal summary for publication.
NCT00585390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Richtand #1|Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia|Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Essential Fatty Acid Deficiency Replacement in Early Schizophrenia||University of Cincinnati|No|Completed|January 2008|November 2009|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|25 Years|No|||July 2011|August 1, 2011|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585390||162986|
NCT00585403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBMC Exercise|Exercise Changes to Peripheral Blood Mononuclear Cells in Children|PBMC, Exercise and Children: Initial Mechanisms||University of California, Irvine|Yes|Recruiting|September 2004|February 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|160|Samples With DNA|Peripheral blood mononuclear cells, plasma, serum, mRNA|Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Early and late pubertal boys and girls recruited from Orange County, CA|November 2010|November 5, 2010|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00585403||162985|
NCT00585650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5092|Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet|Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet||University of California, Irvine|Yes|Completed|May 2007|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||October 2011|October 5, 2011|December 26, 2007|Yes|Yes||No|May 12, 2011|https://clinicaltrials.gov/show/NCT00585650||162966|
NCT00585897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010382|Effect of Discontinuation of Sugar Sweetened Beverages|Title: Effects of Discontinuation of Sugar Sweetened Beverages on Hemoglobin A1c, Fasting and Post Prandial Blood Glucose in Type 2 Diabetics||Duke University|No|Completed|January 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|N/A|No|||December 2012|October 11, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00585897||162947|
NCT00585364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCOR|Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA|SCCOR in Host Factors in Chronic Lung Diseases: Mechanisms of Immune Tolerance and Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients With Cystic Fibrosis|ABPA|University of Pittsburgh|No|Completed|March 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|79|Samples With DNA|The CF subject's blood will be processed to establish a cell line (lymphocyte      transformation) for a source of DNA for future genetic studies.|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female subjects with CF who have A. fumigatus in cultures of airway flora and        receive clinical care at the Antonio J. and Janet Palumbo Cystic Fibrosis Center at        Children's Hospital of Pittsburgh. Age (± 1 year) and sex matched healthy, non CF controls        will also be recruited.|February 2016|February 12, 2016|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00585364||162988|
NCT00585377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI24377|Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer|AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer||University of Utah|Yes|Completed|August 2007|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|December 21, 2007|Yes|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT00585377||162987|
NCT00583336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDX 07-07-0277|Physician Preference Study of ShuntCheck - Madsen|Physician Preference Study of the Utility of ShuntCheck to Detect Cerebrospinal Fluid (CSF) in Patients With Ventriculo-Peritoneal CSF Shunts||NeuroDx Development|No|Recruiting|September 2007|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|85 Years|No|||June 2015|June 22, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583336||163143|
NCT00583349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1114|Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer|A Combined Phase I & II Trial of Intravesicular Abraxane, a Nanoparticle Albumin-bound Paclitaxel, for Treatment-refractory Transitional Cell Carcinoma of the Urinary Bladder|Abraxane|Columbia University|Yes|Recruiting|December 2007|||June 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583349||163142|
NCT00583674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060439|Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma|A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma||Amgen||Completed|December 2007|June 2012|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|171|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583674||163117|
NCT00563459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014317|Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.|A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects With Partial Onset Seizures||SK Life Science|Yes|Terminated|November 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|89|||Both|16 Years|N/A|No|||January 2013|January 25, 2013|November 21, 2007|Yes|Yes|Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this    indication were terminated.|No||https://clinicaltrials.gov/show/NCT00563459||164632|
NCT00563810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3147K1-103|Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|October 2004|April 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research||||72|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2007|November 23, 2007|November 21, 2007||||||https://clinicaltrials.gov/show/NCT00563810||164607|
NCT00563823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCA-CCTC-CAMEL02|Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery|A Phase II Study to Evaluate the Efficacy and Safety of PTK787 in Patients With Metastatic Cutaneous Melanoma||National Cancer Institute (NCI)||Completed|February 2006|October 2010|Actual|September 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|34|||Both|18 Years|N/A|No|||April 2008|August 1, 2013|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00563823||164606|
NCT00554775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573254|WBRT & Erlotinib in Advanced NSCLC and Brain Metastases|A Randomised Phase II Double Blind Placebo Controlled Trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Multiple Brain Metastases [TACTIC]|TACTIC|University College, London|Yes|Terminated|January 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||December 2011|December 9, 2011|November 6, 2007||No|IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was    not met.|No||https://clinicaltrials.gov/show/NCT00554775||165279|
NCT00559845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19884|A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer.|An Open Label Neoadjuvant Study to Assess the Effect of Avastin on Tumor Response in Patients With Inflammatory or Locally Advanced Breast Cancer||Hoffmann-La Roche||Completed|February 2008|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559845||164908|
NCT00550550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05239|Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma||Merck Sharp & Dohme Corp.|Yes|Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|345|||Both|5 Years|17 Years|No|||October 2015|October 9, 2015|October 29, 2007|Yes|Yes||No|August 7, 2012|https://clinicaltrials.gov/show/NCT00550550||165597|
NCT00551096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0129.cc|Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors|A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.||University of Colorado, Denver|Yes|Completed|October 2007|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|October 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551096||165556|
NCT00551343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07/045|Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome|Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.||Garvan Institute of Medical Research|No|Recruiting|October 2007|September 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551343||165537|
NCT00584181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-247|High-resolution Computed Tomography (HRCT) Evaluation of Airway Distensibility in Lung Transplant Recipients|High Resolution Computed Tomographic Evaluation of Airway Distensibility in Lung Transplant Recipients: A Pilot Study||The University of Texas Medical Branch, Galveston|No|Active, not recruiting|August 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who participated in the "Assessment of Cough Reflex in Lung Transplant        Recipients" study who meet the specific inclusion/exclusion criteria for this study|July 2015|August 24, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584181||163078|
NCT00584194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-12592|Safety and Immunogenicity Study of Rift Valley Fever Vaccine|Parts A&B: Evaluation of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200), A Phase 2 Study|RVF|U.S. Army Medical Research and Materiel Command|No|Completed|June 2004|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|278|||Both|17 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 7, 2014|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00584194||163077|
NCT00584168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexamethasone, UPPP - Houck|Using Dexamethasone After Uvulopalatopharyngoplasty|Decreasing Morbidity After Uvulopalatopharyngoplasty With the Use of Dexamethasone - A Randomized Double Blinded Placebo Controlled Trial||University of Oklahoma|No|Completed|March 2005|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 1, 2012|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00584168||163079|
NCT00584493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671028|Treatment Use Study for Advanced Melanoma.|Treatment Use Study of CP-675,206 for Advanced Melanoma||Pfizer|No|No longer available|May 2008|||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||December 2009|December 11, 2009|December 21, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00584493||163054|
NCT00586235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002982|Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization|Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization||Mayo Clinic|Yes|Completed|February 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with kidney or liver tumors|May 2012|May 25, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586235||162922|
NCT00586248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002237|A Pilot Study on Pacemaker Interference From Peripheral Nerve Stimulator for Regional Anesthesia|A Pilot Study on Pacemaker Interference From Peripheral Nerve Stimulator for||Mayo Clinic|Yes|Completed|March 2006|October 2007|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|3rd degree av block atrial fibrilation chf|May 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586248||162921|
NCT00584805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14568|Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine|A Multi-Site Phase 2 Open-Label, Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 in Healthy Adults At Risk for Exposure to Eastern Equine Encephalitis Virus|EEE|U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|February 2008|December 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584805||163030|
NCT00585416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2006-0099|Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer|A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001)||University of Wisconsin, Madison|Yes|Terminated|June 2006|March 2009|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|N/A|No|||April 2009|September 30, 2015|December 21, 2007|Yes|Yes|Further evaluation of phase I dosing|No||https://clinicaltrials.gov/show/NCT00585416||162984|
NCT00585663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMIPP|Accuracy of Radiolabeled Fatty Acid Analog, BMIPP, in the Late Detection of Decreased Blood Flow to the Heart|Phase 2 Study of the Safety and Efficacy of ß-Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid for Identification of Ischemic Myocardium Using SPECT in Adults With Symptoms Consistent With Acute Coronary Syndrome|ZEUSS-ACS|Yale University|Yes|Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|600|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 25, 2009|December 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585663||162965|
NCT00585923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-014|C-Tek™ Fusion Study|A Multi-Center Clinical Investigation of Slotted Hole Versus Fixed Hole C-Tek™ Anterior Cervical Plates||Biomet, Inc.|No|Terminated|April 2002|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|75 Years|No|||May 2012|May 27, 2015|December 21, 2007|Yes|Yes|Due to lack of follow-up information|No|November 11, 2009|https://clinicaltrials.gov/show/NCT00585923||162945|Early termination of this study because the doctor involved in the study decided that he did not want to participate in the study any more. The site also did not have very good follow-up on all of their patients
NCT00586209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10511-01RY|L-Glutamine Therapy for Sickle Cell Anemia|A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia||Los Angeles Biomedical Research Institute|Yes|Completed|January 2003|November 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586209||162924|
NCT00586222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004285|Omega 3 Fatty Acid Trial|Neurometabolic Effects of the Essential Polyunsaturated Fatty Acids in Early-Onset Bipolar Disorder: A Magnetic Resonance Spectroscopy Study||Mayo Clinic|No|Completed|January 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|19|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586222||162923|
NCT00585910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-002180|Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD|Efficacy and Safety/Tolerability of OROS MPH (Concerta) Plus Atomoxetine (ATMX) in Children and Adolescents (Age 6-17) With Attention Deficit Hyperactivity Disorder (ADHD)||Massachusetts General Hospital|No|Completed|January 2004|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|6 Years|17 Years|No|||November 2012|November 8, 2012|December 21, 2007|Yes|Yes||No|September 22, 2009|https://clinicaltrials.gov/show/NCT00585910||162946|Open trial so may have been biased;Small sample size which may have underestimated findings;Used a priori definition of partial response. However, our definition of ATMX partial responders has not been validated.
NCT00583700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200211003|Trental & Vitamin E for Radiation-Induced Fibrosis|Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study||University of Iowa|Yes|Completed|February 2003|June 2012|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Both|20 Years|N/A|No|||October 2012|December 18, 2012|December 20, 2007|Yes|Yes||No|October 18, 2012|https://clinicaltrials.gov/show/NCT00583700||163115|Small, single-institutional study. Smaller clinical trials are prone to imbalances in patient characteristics across treatment arms. t tests applied to small studies can be unduly influenced by data that contain outliers or are skewed.
NCT00583713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI-800-202|An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters|||Braintree Laboratories|No|Completed|August 2007|June 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 29, 2010|December 20, 2007|Yes|Yes||No|September 17, 2010|https://clinicaltrials.gov/show/NCT00583713||163114|
NCT00582920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-133|Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer|Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 2006|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|10|||Female|18 Years|110 Years|No|||December 2015|December 23, 2015|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582920||163174|
NCT00582933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-055|Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor|Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor For the Treatment of Lymphohematopoietic Disorders||Memorial Sloan Kettering Cancer Center||Completed|May 2001|April 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|96|||Both|N/A|54 Years|No|||December 2015|December 22, 2015|December 21, 2007|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00582933||163173|
NCT00582946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43DC008499-01|Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding|Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding||National Institute on Deafness and Other Communication Disorders (NIDCD)|Yes|Completed|May 2006|October 2006|Actual|||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|16|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 19, 2007|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582946||163172|
NCT00583609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851-PP-03|A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children|||Braintree Laboratories|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|16 Years|No|||September 2009|September 24, 2009|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583609||163122|
NCT00553943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-C5R 2006|Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis|Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis||Lymphoma Study Association|Yes|Recruiting|July 2007|June 2013|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|106|||Both|18 Years|60 Years|No|||October 2010|October 22, 2010|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00553943||165340|
NCT00554203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22844|Sulfasalazine and Endothelial Function|Effect of Sulfasalazine on Endothelial Function||Boston University|No|Completed|July 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|80 Years|No|||May 2008|May 13, 2008|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00554203||165321|
NCT00554489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573938|Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy|A Feasibility Study of a Physical Activity Intervention in Older Adult Inpatients With Acute Leukemia||Comprehensive Cancer Center of Wake Forest University|No|Completed|July 2007|April 2011|Actual|November 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Both|50 Years|N/A|No|||July 2012|July 12, 2012|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554489||165299|
NCT00554502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOP-IgAN|Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy|Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy|STOP-IgAN|RWTH Aachen University|Yes|Completed|February 2008|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00554502||165298|
NCT00550563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 99207|DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements|Identification of 24-Hydroxylase Polymorphisms and Splicing Variants That Modulate Vitamin D Oxidative Metabolism and Serum Pharmacokinetics in Patients With Colorectal Cancer on Cholecalciferol Therapy||Roswell Park Cancer Institute|Yes|Completed|August 2007|July 2010|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|October 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00550563||165596|
NCT00550862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-202|Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)|A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis||Intercept Pharmaceuticals|Yes|Completed|October 2007|December 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|165|||Both|18 Years|70 Years|No|||February 2012|February 10, 2012|October 27, 2007|No|Yes||No|June 10, 2011|https://clinicaltrials.gov/show/NCT00550862||165574|
NCT00551109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1-1|SA4503 8-Week Study in Major Depressive Disorder (MDD)|A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment With SA4503, Once Daily for 8 Weeks, in Subjects With Major Depressive Disorder||M's Science Corporation|Yes|Completed|November 2007|September 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||December 2008|December 17, 2008|October 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00551109||165555|
NCT00551356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7354|Lispro Mix 25 vs. Glargine in Type 2 Diabetics|Comparison of the Insulin Therapies: Insulin Lispro Low Mix (25%) and Insulin Glargine in Patients With Diabetes Mellitus Type 2|IOOL|Eli Lilly and Company|No|Completed|November 2002|July 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|30 Years|75 Years|No|||October 2007|October 29, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00551356||165536|
NCT00585429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0335|Evaluation of Kidney Disease in Liver Transplant Recipients|Kidney Disease in Advanced Liver Disease Patients: A Study of Kidney Damage by a Urinary Cytokine/Chemokine Multiplex Assay||University of Wisconsin, Madison|No|Withdrawn|September 2006|||December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects on the liver transplant wait list, subjects who have received a liver transplant        at least 6 months prior to enrollment, or subjects who have normal liver function and are        about to undergo kidney biospy for diagnostic purposes.|October 2015|October 6, 2015|December 26, 2007||No|key personnel left institution|No||https://clinicaltrials.gov/show/NCT00585429||162983|
NCT00585676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|436-07|Impact of Antenatal Betamethasone on Plasma Glucose Levels|Impact of Antenatal Betamethasone on Plasma Glucose Levels||University of California, Irvine|No|Recruiting|November 2007|||May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Female|18 Years|50 Years|No|Probability Sample|Pregnant women receiving corticosteroids|December 2014|December 5, 2014|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00585676||162964|
NCT00584519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281162|Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight|Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight (CRESSOB)|CRESSOB|Pfizer|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|430|||Both|18 Years|N/A|No|Probability Sample|Community sample. Patients >17 years older with diagnosis of Schizophrenia (DSM-IV TR) and        Overweight (BMI more or equal to 25 Kg/m2)|July 2010|July 6, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00584519||163052|
NCT00584818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-013|Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease|A Phase 2 Dose-Finding Clinical Trial of CARDIOsphere® (PB127) in Normal Volunteers and in Patients With Known or Suspected Coronary Artery Disease||Point Biomedical|No|Completed|November 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|205|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 23, 2008|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584818||163029|
NCT00585949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045878|Age and Endothelial Progenitor Cell Mobilization|"The Effects of Age on Endothelial Progenitor Cell Mobilization in Humans"|AGE-PCI|Emory University|No|Active, not recruiting|July 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|136|||Both|N/A|N/A|No|Non-Probability Sample|Patients|January 2016|January 13, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00585949||162943|
NCT00585117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 2006-0282|Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients|||University of Wisconsin, Madison|Yes|Terminated|December 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|9|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|December 21, 2007|Yes|Yes|change in imaging priorities|No||https://clinicaltrials.gov/show/NCT00585117||163006|
NCT00585143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-070|Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly|Pharmacokinetics of ABT-335 and Rosuvastatin in Subjects With Normal Renal Function and Renal Impairment||AstraZeneca|No|Completed|January 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|75 Years|No|||September 2012|September 27, 2012|December 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00585143||163005|
NCT00582296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-144|Multi-Organ Screening Recommendations in Patients With Lynch Syndrome|Adherence to Comprehensive, Multi-Organ Screening Recommendations in Patients With Lynch Syndrome||Memorial Sloan Kettering Cancer Center||Recruiting|December 2004|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seeking genetic counseling with or without genetic testing for colorectal cancer        risk and/or suspected Lynch Syndrome will be recruited and offered enrollment during their        first counseling visit at the Clinical Genetics Service at MSKCC|February 2016|February 17, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582296||163222|
NCT00582270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-012|Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma|Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|February 2003|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|Follicular and non-follicular non-Hodgkin's lymphoma|August 2014|August 13, 2014|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582270||163224|
NCT00583375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTI-2006-01|GEM OS™1 Bone Graft Compared to Autologous Bone Graft in Foot and Ankle Fusions|A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of GEM OS™1 Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions||BioMimetic Therapeutics|Yes|Completed|April 2007|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|396|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583375||163140|
NCT00554515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFHCC 06-149|The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma|The High-Dose Aldesleukin (IL-2) "Select" Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma|SELECT|Dana-Farber Cancer Institute|Yes|Active, not recruiting|November 2006|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|80 Years|No|||September 2015|September 1, 2015|November 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554515||165297|
NCT00554788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARET0321|Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma|A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma||Children's Oncology Group|Yes|Active, not recruiting|February 2008|||February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|10 Years|No|||November 2015|November 4, 2015|November 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554788||165278|
NCT00551902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-2|Effect of an Anterior Chamber Infusion System on Trabeculectomy Outcomes|Effect of an Anterior Chamber Infusion System on Trabeculectomy Outcomes||Queen's University|No|Withdrawn|September 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|October 29, 2007||No|Efficacy study indicated that further study is not warranted|No||https://clinicaltrials.gov/show/NCT00551902||165494|
NCT00550875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6078-PG-OSL-137|Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis|A Randomised Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Sublingual Immunotherapy With a Depigmented and Polymerized Grass Pollen Extracts in Patients Suffering From Allergic Rhinoconjunctivitis.|GPIT|Laboratorios Leti, S.L.|Yes|Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|60 Years|No|||July 2011|July 12, 2011|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00550875||165573|
NCT00552526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ketogenic diet|Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy|Comparing Ketogenic Diet With the Most Appropriate Antiepileptic Drug- a Randomized Study of Children With Mental Retardation and Drug Resistant Epilepsy||Oslo University Hospital|Yes|Active, not recruiting|November 2007|December 2013|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|15 Years|No|||March 2009|March 18, 2009|October 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00552526||165448|
NCT00552539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06431|Syphilis Video Tool to Promote Knowledge and Testing in the ED|Video Tool to Promote Syphilis Knowledge and Testing in the Emergency Department||Jacobi Medical Center|No|Completed|June 2006|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|220|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2007|October 31, 2007|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552539||165447|
NCT00552838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|579-2002 Emory IRB|The Impact of an Antimicrobial Utilization Program on Antimicrobial Use|The Impact of an Antimicrobial Utilization Program on Antimicrobial Use in a Large Public Hospital: A Randomized Controlled Trial||Washington University School of Medicine|Yes|Completed|October 2002|August 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|785|||Both|18 Years|85 Years|No|||September 2007|October 31, 2007|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00552838||165424|
NCT00552851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA 6290010|Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant|Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study||University of Wuerzburg|Yes|Recruiting|June 2006|December 2010|Anticipated|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552851||165423|
NCT00585442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22714|Effects of Vitamin D on Renin Expression in Hypertensive Patients|Effects of Calcitriol (1α, 25-[OH]2 Vitamin D3) on Renin Expression in Hypertensive Patients Without Vitamin D Deficiency||University of Utah|Yes|Completed|May 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|55 Years|N/A|No|||July 2011|July 28, 2011|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585442||162982|
NCT00585936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joslin 06-32|Imaging Inflammation in Autoimmune Diabetes|Evaluation of Magnetic Nanoparticle Enhanced Imaging in Autoimmune Diabetes||Joslin Diabetes Center|Yes|Completed|September 2007|March 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|30|Samples Without DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is to be drawn from the general population, diabetes clinic        population, and at risk individuals as previously identified in prior family studies.|November 2011|November 9, 2011|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00585936||162944|
NCT00582088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14350|Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83|A Phase 2 Open-Label, Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205 When Used as a Booster After TC-83 Primary Immunization in Healthy Adults At-Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus|VEE C-84|U.S. Army Medical Research and Materiel Command|No|Suspended|January 2008|June 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|December 19, 2007|Yes|Yes|temporary hold|No||https://clinicaltrials.gov/show/NCT00582088||163237|
NCT00586261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002245|Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function|Does Chronic Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function in Non-Diabetic Patients With Chronic Kidney Disease?||Mayo Clinic|No|Terminated|March 2006|July 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|December 21, 2007|Yes|Yes|Low enrollment because of the specifics of the inclusion criteria|No|November 13, 2012|https://clinicaltrials.gov/show/NCT00586261||162920|The study was stopped early due to low enrollment because of the specifics of the inclusion criteria.
NCT00582062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-022|Detection of Peritoneal Micrometastasis in Gastric and Pancreatic Cancer in Peritoneal Wash Samples|Detection of Peritoneal Micrometastasis in Gastric and Pancreatic Cancer in Peritoneal Wash Samples||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2006|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Eligible patients will be those with a diagnosis of gastric or pancreatic cancer who        present to the Surgical Services at Memorial Sloan-Kettering Cancer Center, who are        candidates for surgical treatment, and are scheduled for laparoscopy.|April 2015|April 28, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582062||163239|
NCT00582283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO02505|NM404 as an Imaging Agent in Patients With NSCLC|NM404 as an Imaging Agent in Patients With Non-small Cell Lung Cancer (NSCLC)||University of Wisconsin, Madison|Yes|Active, not recruiting|January 2004|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-small cell lung cancer treated at University of Wisconsin Hospital and        Clinics|February 2016|February 18, 2016|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582283||163223|
NCT00582478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-120|Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients|Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2001|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|650|||Female|18 Years|N/A|No|Non-Probability Sample|First time breast cancer patients|November 2015|November 2, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582478||163208|
NCT00582673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2203|Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa|A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa||Novartis|No|Completed|October 2007|||May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|30 Years|85 Years|No|||May 2010|May 13, 2010|December 21, 2007||||No||https://clinicaltrials.gov/show/NCT00582673||163193|
NCT00582699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-117|Depression, Cytokines and Pancreatic Cancer|Depression, Cytokines and Pancreatic Cancer||Memorial Sloan Kettering Cancer Center||Completed|November 2005|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|80|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Recruitment of patients will take place primarily in the Ambulatory Care Facility on 53rd        street in the GI Oncology Clinic treating pancreatic cancer.        Healthy control subjects with depression will be recruited from the New York Hospital        Payne Whitney Clinic outpatient facilities and MSKCC. Healthy control subjects without        depression will be recruited from contacts supplied by study participants (e.g. spouses,        relatives and friends) and from Memorial Hospital staff volunteers.|April 2014|April 9, 2014|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582699||163191|
NCT00582712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO07312|An Initial Study of Lithium in Patients With Medullary Thyroid Cancer|An Initial Study of Lithium in Patients With Medullary Thyroid Cancer||University of Wisconsin, Madison|Yes|Terminated|January 2008|April 2012|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|December 19, 2007|Yes|Yes|Budget/Funding|No||https://clinicaltrials.gov/show/NCT00582712||163190|
NCT00582686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F990923008|Open Reduction Internal Fixation of Calcaneus Fractures With and Without Bone Graft|Prospective Comparison of Open Reduction Internal Fixation of Calcaneus Fractures With and Without Tricortical Iliac Crest Bone Grafting|CALCANEUS|University of Alabama at Birmingham|No|Completed|May 2000|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|19 Years|N/A|No|||September 2013|September 28, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00582686||163192|
NCT00583739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707733|Yoga to Reduce Cancer Fatigue|Effect of a Yoga Intervention on Fatigue, Distress, and Quality of Life in Breast Cancer Patients: A Randomized Pilot Study||University of Iowa|Yes|Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|66|||Both|18 Years|N/A|No|||December 2008|December 3, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583739||163112|
NCT00583310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC0714|Telephone-Based Lifestyle Intervention to Reduce Blood Pressure in Prehypertensive Patients|Telephone-Based Lifestyle Intervention to Reduce Blood Pressure in Prehypertensive Patients||New York University School of Medicine|No|Terminated|January 2007|July 2012|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|December 20, 2007||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00583310||163145|
NCT00583323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2051-02|Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET|Diphenoxylate / Atropine to Decrease Bowel Activity During F-18 FDG PET||Mayo Clinic|Yes|Completed|February 2003|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 20, 2014|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583323||163144|
NCT00583648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-urineprotocol|Does Implementing a Urinanylsis Protocol Based on Symptoms Decrease Length of Stay in the Emergency Department?|A Randomized Controlled Trial Showing the Effect of Patient Lenght of Stay in the Emergency Department Through Utilizing a Urinalysis Nursing Protocol.||University of California, Los Angeles|No|Not yet recruiting|February 2008|February 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|150|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 20, 2007|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583648||163119|
NCT00550888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIP1234|Comparison of Uterine Exteriorization Versus in Situ Repair at Cesarean Section: a Randomized Clinical Trial||EXT|Instituto Materno Infantil Prof. Fernando Figueira||Completed|August 2005|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||||||Female|13 Years|44 Years||||August 2007|June 8, 2010|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00550888||165572|
NCT00551369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0618|Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery|A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Operable Stage I/II Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|December 2007|||May 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|October 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00551369||165535|
NCT00551629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V419-002|A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)|Safety, Tolerability, and Immunogenicity of Four Different Formulations of a Liquid Hexavalent Combination Vaccine, HR5I (Haemophilus Influenzae Type b Conjugate, Recombinant Hepatitis B Surface Antigen, Diphtheria Toxoid, Tetanus Toxoid, 5-Component Acellular Pertussis Vaccine, and Inactivated Poliovirus Type 1, 2, and 3), When Administered to Healthy Hepatitis B Vaccine-Naïve Infants at 2, 3, 4, and 12 to 14 Months of Age||Merck Sharp & Dohme Corp.|Yes|Completed|May 2001|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|708|||Both|6 Weeks|9 Weeks|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00551629||165515|
NCT00552266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pavel1|Methylphenidate in ADHD With Trichotillomania|Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania||Geha Mental Health Center|No|Recruiting|October 2007|October 2009|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|6 Years|18 Years|No|||October 2007|October 31, 2007|October 31, 2007||||No||https://clinicaltrials.gov/show/NCT00552266||165467|
NCT00552279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109179|Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 Administered According to an Alternative Dosing Schedule as Compared to the Standard Dosing Schedule in Young Female Subjects Aged 15-25 Years||GlaxoSmithKline||Completed|November 2007|July 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|805|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||August 2012|September 6, 2012|October 30, 2007|Yes|Yes||No|February 12, 2010|https://clinicaltrials.gov/show/NCT00552279||165466|
NCT00551642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT27|Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies|The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants||INO Therapeutics|Yes|Active, not recruiting|May 2005|June 2015|Anticipated|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|800|||Both|N/A|26 Hours|No|||May 2015|May 5, 2015|October 30, 2007||No||No|September 3, 2010|https://clinicaltrials.gov/show/NCT00551642||165514|
NCT00551915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V419-003|A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)|Safety, Tolerability, and Immunogenicity of 3 Different Formulations of a Liquid Hexavalent Combination Vaccine, HR5I When Administered to Healthy Hepatitis B Vaccine-Naive Infants at 2, 4, 6, and 12-14 Months of Age||Merck Sharp & Dohme Corp.|No|Completed|May 2001|January 2003|Actual|January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|756|||Both|6 Weeks|9 Weeks|Accepts Healthy Volunteers|||October 2015|October 29, 2015|October 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00551915||165493|
NCT00585468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15121|Pharmacokinetic Profile of Myfortic (Enteric Coated Mycophenolate Sodium) in a Rapid Steroid Withdrawal Protocol|Pharmacokinetic Profile of Myfortic (Enteric Coated Mycophenolate Sodium) in a Rapid Steroid Withdrawal Protocol in Combination With Tacrolimus in Stable Renal Transplant Recipients in the Fed and Fasting State||University of Utah|No|Completed|December 2007|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585468||162980|
NCT00585702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH075921|Antimanic Drug Use in Pregnancy|Antimanic Drug Use in Pregnancy|AMUP|University of Pittsburgh|No|Completed|August 2006|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|201|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Age 18 or older Pregnant at 20 weeks or more English-speaking DSM-IV diagnosis of BP, any        subtype|September 2013|September 30, 2013|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00585702||162962|
NCT00585689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.061|Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer|A Phase Two Trial of Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder||University of Michigan Cancer Center|Yes|Completed|December 2007|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|December 26, 2007|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00585689||162963|
NCT00580840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87077|Dosing Flexibility Study in Patients With Rheumatoid Arthritis|A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.|DoseFlex|UCB Pharma|No|Completed|December 2007|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|333|||Both|18 Years|N/A|No|||March 2012|August 26, 2014|December 21, 2007|Yes|Yes||No|December 14, 2011|https://clinicaltrials.gov/show/NCT00580840||163333|
NCT00581061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5720|Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy|Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy||University of California, Irvine|Yes|Terminated|June 2008|February 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|80 Years|No|||October 2010|October 5, 2010|December 21, 2007||No|Study subjects were not compliant with study protocols.|No|March 11, 2010|https://clinicaltrials.gov/show/NCT00581061||163316|
NCT00576069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070934|Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma|Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers||Gelb, Arthur F., M.D.|Yes|Recruiting|October 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|10 Years|95 Years|No|Non-Probability Sample|Chronic Asthmatics|March 2015|March 13, 2015|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576069||163690|
NCT00576355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH070570|Interpersonal and Social Rhythm Therapy for Adolescents With Bipolar Disorder|Adjunctive Psychotherapy for Teens With Bipolar Disorder||University of Washington|No|Completed|December 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|12 Years|19 Years|No|||June 2012|June 19, 2012|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576355||163669|
NCT00576368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_5007|An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice|An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice||Sanofi||Completed|June 2003|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4464|||Both|18 Years|N/A|No|||December 2007|December 28, 2007|December 17, 2007||||No||https://clinicaltrials.gov/show/NCT00576368||163668|
NCT00576628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20978|A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients.|An Open Label Study to Assess the Effect on Anemia Correction, Maintenance of Haemoglobin Levels, Safety and Tolerability of Monthly Administration of Subcutaneous Mircera in Pre-dialysis Patients With Chronic Renal Anemia Not Currently Treated With ESA.||Hoffmann-La Roche||Completed|April 2008|January 2011|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||June 2011|June 15, 2011|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576628||163648|
NCT00576641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6657|Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma|A Phase l Trial of Tumor Associated Antigen Pulsed Dendritic Cell Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma||Cedars-Sinai Medical Center|Yes|Completed|May 2007|April 2012|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|N/A|No|||October 2014|October 29, 2014|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00576641||163647|
NCT00576979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05021|Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|Phase I-II Study of Escalating Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy in Combination With Etoposide (VP16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients With Poor Risk Acute Lymphocytic Leukemia (ALL) or Poor Risk Acute Myelogenous Leukemia (AML)||City of Hope Medical Center|Yes|Active, not recruiting|February 2008|||February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|7 Years|55 Years|No|||October 2015|October 16, 2015|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576979||163622|
NCT00576927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000460|Improving Sleep in Nursing Homes|Improving Sleep in Nursing Homes||Emory University|Yes|Completed|October 2007|May 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 12, 2014|December 17, 2007|No|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00576927||163625|Low power to detect statistically significant effects of the interventions on outcomes; Inability to examine predictors of responsiveness because of the small sample size and the large number of predictors of response.
NCT00576940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1st Dept Surg Enteral|Standard and Immunostimulating Enteral Nutrition in Surgical Patients|Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial|ImmuniEteral|Jagiellonian University|No|Completed|June 2004|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|80 Years|No|||September 2007|December 18, 2007|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576940||163624|
NCT00576953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2007|||||N/A|N/A|N/A||||||||||||||November 11, 2008|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576953||163623|
NCT00573391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-05|Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2|A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone||University of Arkansas|Yes|Terminated|August 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|December 12, 2007||No|low accrual|No|April 15, 2011|https://clinicaltrials.gov/show/NCT00573391||163891|early termination due to low accrual, no analyses
NCT00573404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0621|Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors|A Phase I Study of Imatinib Mesylate and SU011248 for Patients With Gastrointestinal Stromal Tumors||Vanderbilt-Ingram Cancer Center|Yes|Terminated|July 2007|March 2011|Actual|September 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2011|November 12, 2011|December 13, 2007|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00573404||163890|
NCT00573690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0613|Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors|A Two Arm Phase I Trial of Sorafenib in Combination With Cisplatin/Etoposide or Carboplatin/Pemetrexed in Patients With Solid Tumors||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|September 2007|February 2011|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00573690||163870|
NCT00573937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003051|Methadone Versus Morphine for Cancer-Related Pain|Methadone Versus Morphine for Moderate to Severe Cancer-Related Pain: A Double-Blind Randomized Parallel Group Study||Mayo Clinic|No|Terminated|August 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|70 Years|No|||January 2016|January 21, 2016|December 12, 2007|Yes|Yes|Slow accrual.|No|October 4, 2010|https://clinicaltrials.gov/show/NCT00573937||163851|Due to slow accrual of subjects, the study was terminated after one subject started in the standard control group (morphine). No subject received investigational study drug (methadone). Therefore no data were analyzed.
NCT00583986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-357|Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD|A Study to Determine the Reliability of a Top Mount Actuation Indicator When Used With Levalbuterol Tartrate HFA MDI in Adult and Pediatric Subjects With Asthma or Chronic Obstructive Pulmonary Disease||Sunovion|No|Completed|September 2005|March 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|4 Years|N/A|No|||February 2012|February 21, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00583986||163093|
NCT00584636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSBUPR0034|Pulmicort Respules on Relapse Rates After Treatment in the ED|Nebulized Budesonide After Discharge From a Pediatric Emergency Department in Preventing Asthma Relapse: A Randomized, Double-Blind, Placebo Controlled Trial.|Budesonide|Phoenix Children's Hospital|Yes|Withdrawn|October 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|8 Years|No|||September 2011|September 2, 2011|December 20, 2007|Yes|Yes|study halted prematurely before enrollment of first patient|No||https://clinicaltrials.gov/show/NCT00584636||163043|
NCT00584948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715426-1|Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome|Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine||University of California, Davis|Yes|Recruiting|September 2007|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|180|||Both|30 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 25, 2010|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584948||163019|
NCT00584649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1364|Ablation of Inappropriate Sinus Tachycardia|Ablation of Inappropriate Sinus Tachycardia Syndrome by Targeting Cardiac Neural Input|IST|University of Oklahoma|No|Recruiting|April 2004|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584649||163042|
NCT00584974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360-029|A Safety, Efficacy and Tolerability Study of SEP-225289|A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features)||Sunovion|No|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|523|||Both|18 Years|55 Years|No|||February 2012|February 21, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584974||163017|
NCT00584987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15059B|Intranasal Steroids and Oxymetazoline in Allergic Rhinitis|A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa||University of Chicago|Yes|Completed|June 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|December 21, 2007|Yes|Yes||No|July 8, 2013|https://clinicaltrials.gov/show/NCT00584987||163016|
NCT00574366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0523|Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer|A Phase I/II Trial of an Oral MTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination With an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, Tarceva™) In Patients With Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|December 2005|February 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574366||163818|
NCT00574665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#060227-SCCOR-Q1|Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1|SCCOR in Hemostatic and Thrombotic Diseases Project 5 - Metabolic Causes of Thrombosis in Type 2 Diabetes||Vanderbilt University|No|Completed|October 2006|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574665||163795|
NCT00575497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR002MFD|More Frequent Dialysis (>3 Treatments Per Week)|Study of Clinical Outcomes of More Frequent Hemodialysis|MFD|Satellite Healthcare|No|Recruiting|January 2005|January 2010|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|300|||Both|N/A|N/A|No|||December 2007|December 17, 2007|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575497||163733|
NCT00575510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-245|Intervention to Improve Follow-up of Abnormal Pap Test|Intervention to Improve Follow-up of Abnormal Pap Test||The University of Texas Medical Branch, Galveston|Yes|Completed|October 2005|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|341|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|December 14, 2007||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00575510||163732|
NCT00575757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCUHM10107|Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV|Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV||Virginia Commonwealth University|Yes|Active, not recruiting|July 2007|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|sera, liver tissue|Both|18 Years|80 Years|No|Non-Probability Sample|HIV positive with abnormal liver enzymes in the absence of HCV/HBV coinfections.|June 2015|June 3, 2015|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575757||163713|
NCT00576082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3977|Borrelia Species in Cutaneous Lyme Borreliosis|DIVERSITY OF BORRELIA SPECIES INVOLVED IN CUTANEOUS MANIFESTATIONS OF LYME BORRELIOSIS IN FRANCE||University Hospital, Strasbourg, France|No|Recruiting|March 2008|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Cutaneous biopsy specimen|Both|18 Years|N/A|No|Probability Sample|Every adult patient presenting with either erythema migrans, borrelial lymphocytoma or        acrodermatitis chronica atrophicans|November 2015|November 4, 2015|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576082||163689|
NCT00576095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01MH050604-10|Clinical and Biological Characteristics of Psychotic Depression|Hypothalamic-Pituitary-Adrenal (HPA)/ Dopamine Axis in Psychotic Depression||Stanford University|No|Completed|August 2005|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|73|Samples With DNA|serum|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Major depression with psychosis Major depression without psychosis Healthy controls|March 2014|March 12, 2014|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00576095||163688|
NCT00576381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-4-4757|Understanding Dexmedetomidine in Neonates After Open Heart Surgery|The Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Neonates Following Open Heart Surgery|Dex|Children's Hospital of Philadelphia|No|Completed|April 2006|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|30 Days|No|||April 2013|April 10, 2013|December 17, 2007|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00576381||163667|
NCT00576654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01057|Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery|A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)|Yes|Recruiting|December 2007|||February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|March 3, 2016|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00576654||163646|
NCT00576667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10143|An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (NASH)||Sanofi|Yes|Terminated|January 2008|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||June 2009|June 12, 2009|December 18, 2007|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00576667||163645|
NCT00577278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05149|Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma|A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan||City of Hope Medical Center|Yes|Active, not recruiting|January 2007|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|69 Years|No|||November 2015|November 27, 2015|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577278||163600|
NCT00577265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S43|An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication|An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication According to Instructions Received From Their Physician (AMD).|INVOLVE|AstraZeneca|No|Completed|November 2004|||||N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients|January 2011|January 27, 2011|December 18, 2007||||No||https://clinicaltrials.gov/show/NCT00577265||163601|
NCT00577590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487|Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes|Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes||Washington University School of Medicine|No|Completed|October 2003|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|70 Years|No|||May 2014|May 2, 2014|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577590||163579|
NCT00573378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.128|Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia|A Combination of Imatinib or Nilotinib Together With Pegylated Interferon-α2b in Chronic-Phase Chronic Myeloid Leukemia: A Phase II Pilot Study Targeting Both the Primitive and Differentiated CML Progenitor Populations||University of Michigan Cancer Center|Yes|Active, not recruiting|October 2007|October 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573378||163892|
NCT00573417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34-02|A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia|A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia||North Suffolk Mental Health Association|No|Completed|September 2003|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||August 2009|August 11, 2009|December 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573417||163889|
NCT00573703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2007|Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence|A Comparison Between Laparoscopic Burch Colposuspension and Transobturatory Tape (TOT) for the Treatment of Female Urinary Stress Incontinence||University Magna Graecia|Yes|Withdrawn|September 2007|||December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|80 Years|No|||April 2013|April 5, 2013|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573703||163869|
NCT00573950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cilostaar|Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness|Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study)||Korea University Anam Hospital|No|Recruiting|December 2007|December 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|80 Years|No|||December 2007|December 13, 2007|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573950||163850|
NCT00584363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040514008|Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection|Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)|SPORE|University of Alabama at Birmingham|Yes|Recruiting|June 2004|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|600|Samples With DNA|Specimens are frozen and stored|Both|19 Years|N/A|No|Non-Probability Sample|Adults 19 years of age or older, pancreatic cancer patients at the University of Alabam at        Birmingham.|July 2015|December 7, 2015|December 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584363||163064|
NCT00584376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Pregabalin (Lyrica) for the Treatment of Essential Tremor|A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor||University of South Florida|Yes|Completed|December 2007|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||June 2012|June 15, 2012|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584376||163063|
NCT00584038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-060|Improving Adolescent Adherence to Hormonal Contraception|Improving Adolescent Adherence to Hormonal Contraception||The University of Texas Medical Branch, Galveston|Yes|Completed|January 2006|March 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1155|||Female|16 Years|24 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584038||163089|
NCT00584389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2006/117/PGMS|The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition|The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition||University of Surrey|No|Terminated|July 2007|May 2010|Anticipated|April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||April 2010|April 16, 2010|December 11, 2007||No|Suspension of licence for rimonabant by European Medicines Agency|No||https://clinicaltrials.gov/show/NCT00584389||163062|
NCT00573573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-HT-CTP1|Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|January 2007|July 2009|Anticipated|March 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|N/A|N/A|No|||March 2009|March 23, 2009|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573573||163877|
NCT00573586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USHIFU-CABC-PC002|Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada|Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate® 500 (SB-500) System in Canada||SonaCare Medical|No|Not yet recruiting||March 2009|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|40 Years|80 Years|No|||March 2010|March 5, 2010|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573586||163876|
NCT00573885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000578191|Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum|Phase II Trial of Polyphenon E in Former Smokers With Abnormal Sputa||British Columbia Cancer Agency|Yes|Completed|January 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|45 Years|74 Years|No|||March 2012|March 7, 2012|December 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573885||163855|
NCT00574132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN115727-301|Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.||JANSSEN Alzheimer Immunotherapy Research & Development, LLC||Completed|December 2007|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1331|||Both|50 Years|88 Years|No|||October 2013|October 30, 2013|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574132||163836|
NCT00585312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191193|Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)|A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis|CHIP|Pfizer|Yes|Terminated|September 2006|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|106|||Both|10 Years|17 Years|No|||October 2014|October 28, 2014|January 1, 2008|Yes|Yes|See termination reason in detailed description.|No|October 28, 2014|https://clinicaltrials.gov/show/NCT00585312||162992|The study was early terminated and, due to the low number of participants, no efficacy analysis was performed. Only descriptive statistics was performed.
NCT00585559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHGN15431|Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm|Inhibition of Lipid Peroxidation and Cerebral Vasospasm by an Acetaminophen-Based Regimen in Patients With Aneurysmal Subarachnoid Hemorrhage||Vanderbilt University|Yes|Enrolling by invitation|April 2007|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|120|||Both|20 Years|N/A|No|||December 2015|December 4, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585559||162973|
NCT00585793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0206|Relationship Between HIV-1 Subtype and ARV Response|Study of the Relationship Between HIV-1 Subtype and Antiretroviral (ARV) Response in Ugandan Children|RELATES|University of Wisconsin, Madison|No|Completed|July 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|Samples Without DNA|Plasma obtained from participants|Both|4 Months|16 Years|Accepts Healthy Volunteers|Probability Sample|Children $ ,monthe to 16 years|September 2015|September 29, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00585793||162955|
NCT00575523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atropinePEI|Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy|Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy|atropinePEI|Medical University of Vienna|Yes|Completed|October 2003|January 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|31|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575523||163731|
NCT00575783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72409 (completed)|Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM|Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM||Yale University|Yes|Completed|August 2005|August 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|51|||Both|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1A) T1DM subjects with severe hypoglycemia unawareness and awaiting islet cell        transplantation will be referred by participating islet transplantation centers.        Group 1B) T1DM subjects with severe hypoglycemia unawareness but not awaiting islet cell        transplantation will be from the greater New Haven, CT area.        Group 2)T1DM, not optimally controlled and without hypoglycemia unawareness will be from        the greater New Haven, CT area.        Group 3) Non-Diabetics from the greater New Haven CT area.|January 2012|January 25, 2012|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575783||163712|
NCT00576407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009955|Thymus Transplantation in DiGeorge Syndrome #668|Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668||Duke University|Yes|Active, not recruiting|November 2001|June 2027|Anticipated|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||September 2015|September 3, 2015|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576407||163665|
NCT00576394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25760|Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients|Impact of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes Following Coronary Artery Bypass Graft Surgery in Diabetic Patients||American Heart Association|Yes|Completed|October 2006|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|90 Years|No|||June 2015|June 22, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576394||163666|
NCT00576680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-325|RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors|Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2008|September 2015|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576680||163644|
NCT00576693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS058728-01A1|Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis|Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis|SAMMPRIS|Medical University of South Carolina|Yes|Completed|October 2008|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|451|||Both|30 Years|80 Years|No|||June 2014|June 10, 2014|December 7, 2007|Yes|Yes||No|May 6, 2014|https://clinicaltrials.gov/show/NCT00576693||163643|
NCT00576706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-KOA-0701i|PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity|A Phase III, Randomized, Double-dummy, Double Blind, Misoprostol-comparative Clinical Trial to Evaluate the Efficacy and Safety of Mucosta® Tablet in the Prevention of NSAID-induced Gastrointestinal Complications|PRESENT|Korea Otsuka Pharmaceutical Co.,Ltd.||Completed|December 2007|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|396|||Both|19 Years|N/A|No|||November 2011|November 15, 2011|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576706||163642|
NCT00576992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0014|Demographics and Findings of Upper Endoscopy Patients|A Clinical Study of Demographics and Findings During Endoscopy in Patients With Abdominal Pain, Dyspepsia, GERD, and Associated Symptoms||Midwest Biomedical Research Foundation|No|Recruiting|January 2003|January 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is a Veteran population presenting to a VA Hospital upper endoscopy        unit|October 2015|October 19, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576992||163621|
NCT00577304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-005|A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon|A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon||MediQuest Therapeutics|No|Active, not recruiting|December 2007|March 2008|Anticipated|March 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|70 Years|No|||April 2008|February 3, 2010|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577304||163599|
NCT00577603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1712-05|Evaluate and Compare the Rate of Para-Stomal Herniation After Permanent Stoma Formation|A Controlled, Randomized Study to Evaluate and Compare the Rate of Para-Stomal Herniation After Permanent Stoma Formation With and Without Reinforcement With a Collagen Mesh||Mayo Clinic|Yes|Completed|January 2006|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 24, 2013|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577603||163578|
NCT00573729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2006-5401|Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks: Comparison of 577 nm Versus 595 nm Wavelengths|Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks: Comparison of 577 nm Versus 595 nm Wavelengths||University of California, Irvine|No|Completed|March 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|6 Months|N/A|No|||August 2015|August 5, 2015|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00573729||163867|
NCT00573716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-14240|Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents|A Comparison of Bone Mineral Density Changes During Treatment With Risperidone or Aripiprazole in Adolescents||Creighton University|No|Completed|October 2006|October 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|60|||Both|11 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from psychiatry clinic and community resources|August 2011|August 3, 2011|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573716||163868|
NCT00574236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0130|Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer|A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer||University of Wisconsin, Madison|Yes|Terminated|February 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||January 2013|January 16, 2013|December 13, 2007|Yes|Yes|no additional funding|No||https://clinicaltrials.gov/show/NCT00574236||163828|
NCT00574470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200511718|Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD|Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD||University of Iowa|Yes|Completed|January 2006|January 2009||||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||October 2007|November 28, 2011|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574470||163810|
NCT00576914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006 BAI02A02[1]-01|Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer|Adjuvant Vinorelbine Plus Cisplatin Versus Vinorelbine Plus Cisplatin Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer (Phase III Study, Randomized, Open, Multi-center)||Chinese Academy of Sciences|Yes|Recruiting|June 2007|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1108|||Both|18 Years|70 Years|No|||March 2009|March 8, 2010|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576914||163626|
NCT00577512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-32|UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE|UARK 2006-32: Phase II Study of Rapidly Recycled High Dose DTPACE (HD-DTPACE) for Untreated or Previously Treated, High-Risk Multiple Myeloma (MM)||University of Arkansas|No|Completed|April 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|December 18, 2007||No||No|April 19, 2011|https://clinicaltrials.gov/show/NCT00577512||163584|
NCT00577759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004061|Community and Clinician Partnership for Prevention|Community and Clinician Partnership for Prevention|C2P2|Duke University|No|Completed|February 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|9|||Both|18 Years|N/A|No|||October 2012|February 12, 2015|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00577759||163566|
NCT00584675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200714988-1|Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers|Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers||University of California, Davis|No|Withdrawn|February 2007|February 2008|Anticipated|January 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 18, 2015|December 26, 2007||No|Funding was never received so no patients were enrolled.|No||https://clinicaltrials.gov/show/NCT00584675||163040|
NCT00585000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3671022|A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma|A Phase 1, Open Label, Single Arm Study To Establish The Safety Of Administering CP 675,206 As A One Hour Infusion In Patients With Surgically Incurable Stage III Or Stage IV Melanoma||AstraZeneca|No|Terminated|December 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|December 21, 2007|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00585000||163015|
NCT00585806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 2005-0408|Assessment of Cardiac Functional Reserve in Heart Failure With Preserved Ejection Fraction (HF-PEF)|Assessment of Cardiac Functional Reserve in Heart Failure With Preserved Ejection Fraction (HF-PEF)|DobStress|University of Wisconsin, Madison|No|Completed|December 2005|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential subjects will be identified from the heart failure population scheduled for        visits to the heart failure clinic, use of the GIM Funneling Project and the University of        Wisconsin Institute on Aging.|February 2010|October 1, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585806||162954|
NCT00586092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008797|A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors|A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid||Duke University|No|Completed|September 2005|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586092||162932|
NCT00586105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11559|Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)|A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma||Bayer|No|Completed|December 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|December 21, 2007||No||No|February 1, 2010|https://clinicaltrials.gov/show/NCT00586105||162931|The median for ´Overall Survival (OS)´ and the median for ´Overall Response Duration´ reported are the median of each distribution including the censored data. The correct estimates of these medians were not evaluable.
NCT00575536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050822|Optical Stimulation Rhizotomy Study|Optical Stimulation in Peripheral Nerves in Selective Rhizotomy Cases|Rhizotomy|Vanderbilt University|No|Recruiting|January 2006|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples Without DNA|abnormal spinal nerves that have been surgically removed|Both|3 Years|17 Years|No|Probability Sample|Children over the age of 3 and younger than 17 years who have failed appropriate medical        therapy for spasticity and are recommended for Rhizotomy surgery|December 2014|December 19, 2014|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575536||163730|
NCT00575796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011227|Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)|Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)||The Hospital for Sick Children|Yes|Active, not recruiting|October 2007|October 2019|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|18 Years|No|||November 2014|November 19, 2014|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575796||163711|
NCT00575809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20050218H|Incidence and Factors Associated With the Development and Severity of Oral Mucositis|Incidence and Factors Associated With the Development and Severity of Oral Mucositis in Patients Undergoing High-Dose Chemotherapy and Peripheral Blood Stem Cell Transplantation||The University of Texas Health Science Center at San Antonio|No|Recruiting|May 2005|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing hematopoietic stem cell transplantation|November 2015|November 2, 2015|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575809||163710|
NCT00576420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550602|Fibrin Sealant Vascular Surgery Study|Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-apr for Hemostasis in Subjects Undergoing Vascular Surgery||Baxter Healthcare Corporation|No|Completed|December 2007|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|101|||Both|N/A|N/A|No|||October 2012|October 26, 2012|December 18, 2007|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00576420||163664|
NCT00576433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21271|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.|An Open Label Study to Evaluate the Safety and Effect on Treatment Response of MabThera in Patients With Rheumatoid Arthritis Following Inadequate Response to One Prior Anti-TNF Inhibitor||Hoffmann-La Roche||Completed|December 2007|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576433||163663|
NCT00576719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068277|Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia|Intensive Treatment of Adolescent Panic and Agoraphobia||Boston University|Yes|Completed|March 2005|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|12 Years|17 Years|No|||February 2014|February 19, 2014|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576719||163641|
NCT00576732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014740|A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder|Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2007|March 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|96|||Both|5 Years|17 Years|No|||April 2014|April 24, 2014|December 17, 2007|Yes|Yes||No|September 2, 2010|https://clinicaltrials.gov/show/NCT00576732||163640|
NCT00577005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA017782-04|Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients|Levetiracetam (Keppra) Treatment for Cocaine Dependence in Methadone-Maintained Patients|Keppra-DB|National Institute on Drug Abuse (NIDA)|Yes|Active, not recruiting|July 2007|October 2008|Anticipated|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||August 2008|August 11, 2008|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577005||163620|
NCT00577317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0236|Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer|A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy||Gynecologic Oncology Group||Terminated|December 2007|||July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|2|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577317||163598|
NCT00577616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM06055|Ruptured Aorta-iliac Aneurysms: Endo vs. Surgery|Randomized Study Comparing Endovascular Repair Versus Conventional Repair for Ruptured Aorta-iliac Aneurysms|ECAR|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2007|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||July 2013|October 22, 2014|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577616||163577|
NCT00574249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-060|Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment|A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)|BELIEVE|Abbott|No|Completed|November 2007|||October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|730|||Both|18 Years|N/A|No|||April 2011|April 11, 2011|December 12, 2007|Yes|Yes||No|October 29, 2009|https://clinicaltrials.gov/show/NCT00574249||163827|
NCT00573963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11|Efficacy of the Transversus Abdominus Plane (TAP) Block for Post-Cesarean Delivery Analgesia|Determination of the Efficay of the Transversus Abdominis Plane (TAP) Block as Part of a Multimodal Regimen for Post-cesarean Delivery Analgesia: a Double Blinded Placebo-controlled Study.||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|December 2007|November 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 29, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573963||163849|
NCT00574808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDOCC|Improved Delivery of Cardiovascular Care Through Outreach Facilitation|Improved Delivery of Cardiovascular Preventive Care (IDOCC) Through Outreach Facilitation|IDOCC|Bruyere Research Institute|No|Completed|April 2007|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|194|||Both|40 Years|N/A|No|||October 2014|October 3, 2014|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574808||163784|
NCT00574262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinPathStroke|Quality Assessment in Acute Stroke Care|Quality of Acute Stroke Care Evaluated With a Clinical Pathway on a 16 Bed Stroke Unit - a Prospective Trial|QuASt|University Hospital Muenster|No|Recruiting|October 2007|April 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|patients with an acute ischemic stroke admitted to the stroke unit of the university        hospital in Muenster, Germany|November 2007|January 12, 2010|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00574262||163826|
NCT00584051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PURCELL|Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity|The Purpose of This Study is to Examine the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity||University of South Florida|No|Terminated|October 2007|October 2009|Actual|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|CHEEK SWAB FOR DNA SAMPLES, BLOOD SAMPLES FOR IGE AND ANP LEVELS|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will include three groups; an asthma group, an allergic rhinitis group, and a        healthy control group. Participants will be between 18-40 years of age and will meet        inclusion/exclusion criteria outlined below. The study will continue for a total of 1        year. Study subjects will keep a diary of symptoms using a validated asthma subjective        questionnaire (Juniper). Serum levels of atrial natriuretic peptide and serum IgE, will be        obtained at the initial visit and then at regular intervals depending on the study group        (table 1).|February 2010|February 10, 2010|December 21, 2007||No|investigator closed study|No||https://clinicaltrials.gov/show/NCT00584051||163088|
NCT00584064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-006 - E/C|Emergency/Compassionate Use PFO Occluder|||St. Jude Medical||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|60 Years||||January 2016|January 7, 2016|December 20, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00584064||163087|
NCT00584402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715241|Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation|Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation||University of California, Davis|No|Completed|April 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584402||163061|
NCT00584662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFRIN STUDY|Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion|Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion||University of South Florida|No|Terminated|January 2005|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||July 2008|June 27, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584662||163041|
NCT00585325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0106|Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes|Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes.||University of Wisconsin, Madison|No|Completed|October 2004|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 4, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00585325||162991|
NCT00585572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0037|Wisconsin Brain Donor Program|University of Wisconsin-Madison: Wisconsin Brain Donor Program (WBDP)|WBDP|University of Wisconsin, Madison|No|Enrolling by invitation|March 2007|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|N/A||1|Anticipated|500|Samples Without DNA|Brain tissue, blood, cerebrospinal fluid, spinal cord, peripheral nerves, and skeletal      muscles, central/peripheral nervous tissue, as well as skeletal muscle tissue.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants agree to autopsy and brain/tissue/sample donation for research purposes only.|October 2014|October 22, 2014|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00585572||162972|
NCT00585585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nelson #1|Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features|A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features||University of Cincinnati|Yes|Completed|December 2006|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||January 2011|January 27, 2011|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585585||162971|
NCT00582205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WalkerIP|Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma|Feasibility Trial of Intraperitoneal Chemotherapy in Stage IA, IB, IC, II, III, IV and Recurrent Platinum Sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma and Stage III and IV Uterine Cancer||University of Oklahoma|No|Terminated|January 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|December 19, 2007|Yes|Yes|Study completed per investigator.|No||https://clinicaltrials.gov/show/NCT00582205||163229|
NCT00575211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAC II|Study Looking at the Recovery of New Onset Cardiomyopathy|Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy||University of Pittsburgh|Yes|Completed|January 2004|March 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|373|Samples With DNA|At time of enrollment, 30cc of blood will be obtained: 10cc for plasma banking for      neurohormones and cytokine analysis, 10 cc for DNA banking and genotyping, 5 cc for      evaluation of gene expression of inflammatory markers from circulating leukocytes and 5 cc      for serum banking. Ten ccs of blood for cytokine analysis will also be collected at one      month and six months after entry. A blood specimen for repeat analysis of serum mediator      (5ccs in a red top tube) will be drawn at six months and sent to the University of      Pittsburgh. All blood samples will be kept for 10 years. Access to the banked DNA will be      limited to investigations at the University of Pittsburgh and each site of this multi-center      trial. These samples will be available without any identifying information (name, social      security number and medical record number). In addition, a Certificate of Confidentiality      has been obtained from the NIH for further subject protection.|Both|18 Years|N/A|No|Non-Probability Sample|New onset Cardiomyopathy patient with symptoms less than 6 months|January 2016|January 14, 2016|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575211||163754|
NCT00575224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-183|Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9|Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9: a Phase IV, Randomized, Open-labeled, Multicenter Trial Comparing 24-week vs. 48-week Therapy||Pacific Health Foundation|No|Completed|October 2004|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2009|November 23, 2009|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575224||163753|
NCT00575822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135-01885|A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD|Endoscopic Full-Thickness Plication for the Treatment of Gastroesophageal Reflux Disease: A Randomized, Sham-Controlled Trial||NDO Surgical, Inc.|No|Terminated|January 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|N/A|No|||May 2008|July 15, 2008|December 14, 2007|Yes|Yes|Sponsoring company ceased business operations.|No||https://clinicaltrials.gov/show/NCT00575822||163709|
NCT00576108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD7040-NP02|A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)|||Kalypsys, Inc.|No|Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|85 Years|No|||July 2008|July 18, 2008|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576108||163687|
NCT00576446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9789|Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients|A Phase l Trial of Surgical Resection With Gliadel Wafer Placement Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate for Patients With Malignant Glioma|Gliadel Wafer|Cedars-Sinai Medical Center|Yes|Completed|April 2007|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00576446||163662|
NCT00576459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|420-003|Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema|A Randomized, Controlled Pilot Study to Evaluate the Safety and Efficacy of Intravitreal Fluocinolone Acetonide (0.5mg and 2mg) Implants in Patients With Clinically Significant Diabetic Macular Edema||Bausch & Lomb Incorporated|No|Completed|March 2003|July 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||July 2011|December 7, 2011|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576459||163661|
NCT00576771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222222|Effects of Different Assisted Mechanical Ventilation in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilatory Assist (NAVA) and Controlled by Patient|Effects of Different Assisted Mechanical Ventilation in ALI/ARDS Patients: PSV, NAVA and Controlled by Patient||Policlinico Hospital|No|Completed|August 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576771||163637|
NCT00576745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26298|A Comparison Of The 3M TM S Surgical Skin Closure System To The Standard Vicryl Suture Closure of Sternotomy Incisions During Cardiac Surgery|Comparison Of The 3M Surgical Skin Closure System To The Standard Vicryl Suture Closure Of Sternotomy Incisions||American Heart Association|Yes|Completed|September 2007|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|90 Years|No|||July 2012|July 17, 2012|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576745||163639|
NCT00576758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21003|GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma|An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma||Hoffmann-La Roche||Completed|January 2008|March 2013|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|December 18, 2007||No||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00576758||163638|
NCT00577018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-25|Efficacy and Safety Study of the Effect of Dose-Titration of Prucalopride for The Treatment of Chronic Constipation|A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dose-Titration on the Safety and Efficacy and R108512 Tablets in Subjects With Chronic Constipation||Movetis|No|Completed|August 1998|September 1999|Actual|September 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|755|||Both|18 Years|N/A|No|||December 2007|May 28, 2008|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577018||163619|
NCT00577031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21380|OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.|Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'||Hoffmann-La Roche||Completed|February 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|205|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|December 18, 2007||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00577031||163618|
NCT00577044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 05-120 T/783|Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong|Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong: Natural History and Development of Liver Complications||Hospital Authority, Hong Kong||Active, not recruiting|June 2004|December 2007|Anticipated|||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|80 Years||||June 2008|December 15, 2008|July 6, 2007||||No||https://clinicaltrials.gov/show/NCT00577044||163617|
NCT00577330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYG-01-2006|Efficacy of Myalgesin™ to Support Joint Function in Patients With Knee Osteoarthritis|The Efficacy of Myalgesin™ for the Support of Joint Function in Patients With Osteoarthritis of the Knee — A Prospective Randomized Controlled Study||ProThera, Inc.|No|Active, not recruiting|May 2006|January 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|50 Years|N/A|No|||December 2007|December 19, 2007|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577330||163597|
NCT00577343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705-31|Hospital Acquired and Community Acquired MRSA in GI Lab|Hospital Acquired and Community Acquired Methicillin Resistant Staph Aureus in the Outpatient Gastrointestinal Lab: A Prospective Study of Prevalence||Indiana University|No|Withdrawn|April 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|buccal swab for saliva|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|gastrointestinal lab of oupatient and inpatients|February 2016|February 29, 2016|December 19, 2007||No|study lacked funding to recruit|No||https://clinicaltrials.gov/show/NCT00577343||163596|
NCT00577629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007096|Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma|Dose-Intensive Chemotherapy Combined With Monoclonal Antibody Therapy and Targeted Radioimmunotherapy for Untreated Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma||Duke University|No|Active, not recruiting|June 2005|February 2021|Anticipated|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|December 18, 2007|Yes|Yes||No|March 4, 2013|https://clinicaltrials.gov/show/NCT00577629||163576|
NCT00573430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00015|ARIA (Atacand Renoprotection In NephropAthy Pt.)|A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy|PCR|AstraZeneca|No|Completed|December 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|70 Years|No|||August 2011|August 19, 2011|December 13, 2007|Yes|Yes||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00573430||163888|
NCT00573755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC0731|Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer|Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer||Mayo Clinic|Yes|Terminated|December 2007|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|120 Years|No|||October 2015|January 7, 2016|December 13, 2007|Yes|Yes|lack of participant accrual|No|February 10, 2014|https://clinicaltrials.gov/show/NCT00573755||163865|
NCT00574496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-147|Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma|An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2007|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|65 Years|No|||October 2015|October 9, 2015|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574496||163808|
NCT00573989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000578838|Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer|Phase I/II Clinical Trial of Combined Pre-Irradiation With Pemetrexed and Erlotinib Followed by Maintenance Erlotinib for Recurrent and Second Primary Squamous Cell Carcinoma of the Head and Neck||Comprehensive Cancer Center of Wake Forest University|Yes|Recruiting|March 2008|||March 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|120 Years|No|||October 2015|October 22, 2015|December 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573989||163847|
NCT00584025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5|Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease|||University of South Florida|No|Withdrawn|December 2007|||August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|80 Years|No|||June 2008|June 2, 2008|December 21, 2007|Yes|Yes|Study withdrawn due to personnel limitations.|No||https://clinicaltrials.gov/show/NCT00584025||163090|
NCT00576589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7211006|Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones|A Phase 1, 2-Part, Randomized, Subject And Investigator Blinded, Placebo-Controlled, Cross-Over Trial To Evaluate The Safety, Tolerability And Pharmacokinetics Of CE-326,597 In Obese, Adult Subjects With Asymptomatic Cholelithiasis||Pfizer|No|Completed|January 2008|September 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|January 14, 2010|December 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00576589||163651|
NCT00584688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0825|A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study|A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study||University of South Florida|Yes|Terminated|February 2007|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||March 2009|June 14, 2012|December 21, 2007|No|Yes|Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT00584688||163039|
NCT00584701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715817-1|Pharmacogenomics in Autism Treatment|Pharmacogenomics in Autism Treatment|PG|University of California, San Francisco|Yes|Completed|January 2008|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|4 Years|18 Years|No|||June 2012|June 18, 2012|December 22, 2007|No|Yes||No|September 6, 2011|https://clinicaltrials.gov/show/NCT00584701||163038|
NCT00585013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHECP1|Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass|A Trial of Inhaled Nitric Oxide (NO) as an Anti-Inflammatory and Anti-Reperfusion Agent in the Treatment of Infants and Children Undergoing Cardiopulmonary Bypass for Repair of Congenital Heart Disease||Washington University School of Medicine|Yes|Completed|January 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|N/A|16 Years|No|||November 2015|November 3, 2015|December 20, 2007|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00585013||163014|
NCT00585026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Duam|Randomized Clinical Trial of Bifocal Lenses Versus Computer-specific Progressive Addition Lenses|Randomized Clinical Trial of Bifocal Lenses Versus Computer-specific Progressive Addition Lenses on Symptoms and Performance on a Computer||University of Alabama at Birmingham||Terminated|October 2006|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|40|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2009|June 14, 2011|December 21, 2007|||PI left UAB; protocol administratively terminated by UAB IRB.|No||https://clinicaltrials.gov/show/NCT00585026||163013|
NCT00586118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA06104|Inhalative Sedation in ICU With Sevoflurane Via Anaesthetic Conserving Device Compared to Propofol|||Klinikum Ludwigshafen|No|Completed|December 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|80 Years|No||120 patients, scheduled for elective major surgery and postoperative admission to the ICU,        are screened the day before surgery for potential in- and exclusion criteria.|December 2007|January 3, 2008|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586118||162930|
NCT00586131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11043|Arterial pH and N-balances in APD|Effect of Arterial pH on N-balances of Patients Undergoing Automated Peritoneal Dialysis||Los Angeles Biomedical Research Institute|Yes|Completed|September 2003|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||September 2014|September 29, 2014|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586131||162929|
NCT00581971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F020703003|Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer|Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck|RAD0201|University of Alabama at Birmingham|Yes|Completed|September 2002|March 2012|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|19 Years|N/A|No|||March 2013|March 13, 2013|December 20, 2007||No||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00581971||163246|
NCT00581984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-089|McGhan Medical Silicone-Filled Breast Implant Adjunct Study|McGhan Medical Silicone-Filled Breast Implant Adjunct Study||Memorial Sloan Kettering Cancer Center||Completed|September 1998|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1016|||Female|N/A|N/A|No|Non-Probability Sample|Females who are candidates for breast reconstructio|October 2013|October 14, 2013|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581984||163245|
NCT00582855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAQW051A2104|Effect of AQW051 in Patients With Memory Impairment|A 4-week, Parallel-group, Randomized, Double-blind, Placebo-controlled, Adaptive Proof of Concept Study of AQW051 at up to Three Dose Levels for the Treatment of Patients With Findings Consistent With Mild Alzheimer's Disease (AD) or Amnestic Mild Cognitive Impairment (Amnestic MCI)||Novartis|No|Terminated|December 2007|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|55 Years|85 Years|No|||February 2011|February 3, 2011|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00582855||163179|
NCT00575237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP230819|A Simple Clinical Maneuver to Reduce Laparoscopy Induced Shoulder Pain|A Simple Clinical Maneuver to Reduce Laparoscopy Induced Shoulder Pain: A Randomized Clinical Trial||Phelps, Paul, M.D.|No|Completed|February 2004|February 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Female|15 Years|65 Years|No|||December 2007|December 17, 2007|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575237||163752|
NCT00575835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77/2006|Oral Vitamin D Supplementation in Elderly Women|Oral Vitamin D Supplementation in Elderly Women: Twice a Day or Three Times a Year? A Randomised Controlled Trial||Helsinki University|No|Completed|October 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|70 Years|80 Years|Accepts Healthy Volunteers|||December 2007|December 26, 2007|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575835||163708|
NCT00575848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC #1-2007|Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia|A Trial of the Effects of Glycine Loading on Clinical Symptoms and Logical Memory in Patients With Schizophrenia||North Suffolk Mental Health Association|No|Terminated|December 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|16|||Male|18 Years|65 Years|No|||November 2009|November 25, 2009|December 14, 2007||No|Slow enrollment and due to personnel change there was no viable way to quantify glycine levels    through imaging|No||https://clinicaltrials.gov/show/NCT00575848||163707|
NCT00575861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000|Zileuton and Exhaled Nitric Oxide in Asthmatics|Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics||Gelb, Arthur F., M.D.|Yes|Completed|September 2005|November 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|19|||Both|21 Years|80 Years|No|||December 2007|December 18, 2007|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575861||163706|
NCT00576121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610001945|Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction|Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction||Yale University|No|Recruiting|July 2008|August 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients will be recruited by a physician referral into the study. Patients will be        referred to the study by the cardiologist in the cardiac catheterization lab at Yale New        Haven Hospital. Patient recruitment will be limited to patients who are English speakers.        Informed consent will be obtained by Dr. Albert Sinusas, MD.|January 2010|January 13, 2010|December 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576121||163686|
NCT00577356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07028|Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer|Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer||Benaroya Research Institute|Yes|Terminated|February 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|N/A|No|||November 2010|January 18, 2011|December 18, 2007|Yes|Yes|Safety reasons, though no safety issues arose.|No|September 13, 2010|https://clinicaltrials.gov/show/NCT00577356||163595|the trial was closed prior to planned accrual of 30 patients due to an external report from the randomized trial of docetaxel and CG1940/CG8711 resulting in a higher incidence of deaths compared to docetaxel alone in metastatic prostate cancer.
NCT00576784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS-K-013|Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin|Multi Center, Open Label Study to Evaluate the Influence of Pioglitazone Treatment Over 6 Months on Metabolic Control in Type II Diabetic Patients Previously Treated With Insulin|PIOswitch|IKFE Institute for Clinical Research and Development|No|Completed|April 2005|April 2007|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|75 Years|No|||December 2007|December 17, 2007|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576784||163636|
NCT00577057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC-2006-120|Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer|Randomized Trial to Evaluate the Therapeutic Gain by Changing the Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and the Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma||Hospital Authority, Hong Kong||Not yet recruiting|September 2006|August 2013|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|798|||Both|18 Years|70 Years||||August 2013|August 21, 2013|December 18, 2007||||No||https://clinicaltrials.gov/show/NCT00577057||163616|
NCT00573742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRO-ATA-2007/1|Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients|Non-interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or add-on Therapy.||AstraZeneca|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1940|||Both|18 Years|N/A|No|Non-Probability Sample|hypertensive patients not at BP target (according to ESC Guideline for the management of        hypertension, 2003), already treated with candesartan cilexetil 16 mg/day|August 2010|August 18, 2010|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00573742||163866|
NCT00577655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXR-302-25-105|Chronic-Dose Safety and Efficacy Study of an Albuterol Metered Dose Inhaler (MDI) Inhaler Using a Hydrofluoroalkane (HFA) Propellant In Pediatric Asthmatics|Phase 3 Study to Evaluate the Chronic-dose Safety and Efficacy of Albuterol-HFA-MDI Relative to Placebo in Pediatric Asthmatics||Teva Branded Pharmaceutical Products, R&D Inc.|No|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|4 Years|11 Years|No|||April 2012|April 11, 2012|December 18, 2007|Yes|Yes||No|July 21, 2009|https://clinicaltrials.gov/show/NCT00577655||163574|
NCT00573976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT07019|Study to Assess the Validity and Reliability of the Spinal Cord Independence Measure (SCIM III)|United States Multi-Center Study to Assess the Validity and Reliability of the Spinal Cord Independence Measure (SCIM III)||University of California, Irvine|No|Completed|September 2007|September 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|660|||Both|18 Years|N/A|No|Non-Probability Sample|The characteristics of the proposed subject population include:          -  Males and females 18 years of age or older          -  Adults who are competent to give informed consent          -  Subjects who are able to read or speak English|November 2010|November 2, 2010|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573976||163848|
NCT00574522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-HIV-CTP1|Energy Specific Far Infrared Radiation Treatment for AIDS|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for HIV/AIDS||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|February 2008|November 2009|Anticipated|August 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||August 2009|August 14, 2009|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574522||163806|
NCT00574535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4260|Reproductive Hormones And Pre-Clinical Cardiovascular Disease (CVD) In Women|Reproductive Hormones And Pre-Clinical CVD In Women||Cedars-Sinai Medical Center|Yes|Completed|January 1995|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|269|||Female|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Women in LAAS Study|August 2012|August 24, 2012|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00574535||163805|
NCT00574002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-68e|Establishing Safe Drainage Limits for Pleural Chest Tube Removal.|Defining the Threshold for Safe Chest Tube Removal.||Truman Medical Center|No|Withdrawn|December 2007|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Surgery patients|May 2015|May 11, 2015|December 12, 2007||No|Low study enrollment; re-evaluating study protocol and study selection criteria.|No||https://clinicaltrials.gov/show/NCT00574002||163846|
NCT00576602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH21299|A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant|A Randomized, Open Label Study to Evaluate the Effect of Subcutaneous Mircera, Versus no ESA Therapy, on Hemoglobin Levels in Chronic Kidney Disease Patients With Anemia After Kidney Transplant.||Hoffmann-La Roche||Terminated||February 2010|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|318|||Both|18 Years|N/A|No|||September 2008|September 22, 2008|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576602||163650|
NCT00585598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0198|Evaluation of Supralaryngeal Airway Removal During Initial Resuscitation of the Trauma Patient|Evaluation of Supralaryngeal Airway Removal During Initial Resuscitation of the Trauma Patient||University of Wisconsin, Madison|No|Completed|August 2006|July 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All trauma patients arriving in the trauma bay with an ETC (combitube) or King LT-D in        place will be included. The Trauma Chief resident and/or Andrea Williams, Trauma Program        Specialist, will identify patients coming into the UWHC ED with supralaryngeal airways.        They will concurrently or retrospectively (within 72 hours) collect data from the subjects        chart or WISCR. Many of the patients arrive as unidentified persons with unknown ages.        Therefore, pediatric patients will also be included. In addition, most have no consentable        family readily available and the patients will not have their clinical course altered in        any way by being part of this study.|October 2015|October 6, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00585598||162970|
NCT00585819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-2007-0109|Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study|Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study||University of Wisconsin, Madison|Yes|Withdrawn|May 2007|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||December 2011|December 30, 2011|December 21, 2007|Yes|Yes|lack of interest|No||https://clinicaltrials.gov/show/NCT00585819||162953|
NCT00585832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL088567-01A1|Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure|Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure|DASH-4-Teens|University of Cincinnati|Yes|Completed|February 2008|October 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|11 Years|18 Years|No|||June 2015|June 3, 2015|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00585832||162952|
NCT00582413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-137|Quality of Life and Development of Measures in Patients With Cancer of the Oral Cavity|Prospective Evaluation of Quality of Life and Development of Measures in Patients With Cancer of the Oral Cavity||Memorial Sloan Kettering Cancer Center||Completed|December 2004|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|164|||Both|N/A|N/A|No|Non-Probability Sample|Patients seen on the Head and Neck Surgery Service, Radiation Oncology Service, Medical        Oncology Service and Dental Service.|October 2014|October 15, 2014|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582413||163213|
NCT00582595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK6657_3a|LABS-3 Psychosocial|Psychosocial Issues and Bariatric Surgery||University of Pittsburgh|Yes|Active, not recruiting|January 2007|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be selected from bariatric surgical candidates at participating LABS        sites in New York and Fargo, ND.|January 2016|January 7, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00582595||163199|
NCT00582868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0421|Use of Brain Oxygen Tension Level and Cleaved-tau Protein to Detect Vasospasm After SAH|Brain Oxygen Tension Level, Cerebral Perfusion and Cleaved-tau Protein for Detection of Cerebral Vasospasm and Independent Predictor of Poor Outcome After Aneurysmal Subarachnoid Hemorrhage||University of Wisconsin, Madison|Yes|Terminated|May 2007|May 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Cerebrospinal fluid Whole blood|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with subarachnoid hemorrhage|April 2012|October 1, 2015|December 19, 2007||No|Insufficient subject enrollment|No||https://clinicaltrials.gov/show/NCT00582868||163178|
NCT00575549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311-07-FB|Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo|Prospective Analysis and Comparison of Conventional Stress Echocardiograms and Real-Time Myocardial Contrast Stress Echocardiogram; for Bristol-Myers Squibb Medical Imaging: The Definity RT-P During DSE Database||University of Nebraska||Available||||||N/A|Expanded Access|N/A|||||||Both|19 Years|N/A||||July 2012|July 19, 2012|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575549||163729|
NCT00575874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS011-A-J205|Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Dose and Active Comparator-Controlled Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes|RAISE|Daiichi Sankyo Inc.|No|Completed|August 2007|January 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|150|||Both|20 Years|75 Years|No|||February 2009|February 6, 2009|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00575874||163705|
NCT00575887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-RO-2005-1|Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma|Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas||Marmara University|Yes|Completed|August 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2013|November 3, 2013|December 17, 2007||No||No|November 3, 2013|https://clinicaltrials.gov/show/NCT00575887||163704|
NCT00576134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3866|The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement|Artificial Larynx : Intralaryngeal Prosthesis With Valve in Major Swallowing Troubles||University Hospital, Strasbourg, France|No|Completed|February 2008|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00576134||163685|
NCT00576147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infrascanner-052306|A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection|A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection||InfraScan, Inc.|No|Completed|July 2006|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|431|||Both|N/A|N/A|No|||December 2013|December 19, 2013|December 14, 2007|No|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00576147||163684|
NCT00577642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-144|Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates|A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates||Massachusetts General Hospital|No|Completed|October 2007|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577642||163575|
NCT00573443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-AVR-123|Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)|STAR|Avanir Pharmaceuticals|Yes|Completed|December 2007|September 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|326|||Both|18 Years|80 Years|No|||June 2013|June 5, 2013|December 13, 2007|Yes|Yes||No|July 18, 2011|https://clinicaltrials.gov/show/NCT00573443||163887|
NCT00577668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01|A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)|UARK 2007-01, A Phase II Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) and Autologous Transplantation for Patients Relapsing or Progressing After Tandem Transplantation||University of Arkansas|No|Withdrawn|April 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|December 18, 2007||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00577668||163573|
NCT00573456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-DM-CTP1|Far Infrared Radiation Treatment for Diabetes|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Diabetes||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2006|April 2009|Anticipated|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||August 2009|August 14, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573456||163886|
NCT00573469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9421C00002|Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease|A Multicentre, Double-blind, Randomised, Parallel-group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease||AstraZeneca|No|Completed|October 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|65 Years|No|||July 2012|July 2, 2012|December 13, 2007|Yes|Yes||No|March 18, 2009|https://clinicaltrials.gov/show/NCT00573469||163885|
NCT00574561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10057|Magnetocardiography (MCG) in Subjects Undergoing CT Angiography (CTA)|Magnetocardiography (MCG) in Subjects Undergoing CT Angiography (CTA)||Cedars-Sinai Medical Center|No|Withdrawn|July 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing CT angiography to evaluate their coronary arteries for the presece of        heart disease.|November 2009|November 16, 2009|December 14, 2007|No|Yes|sponsor funding|No||https://clinicaltrials.gov/show/NCT00574561||163803|
NCT00574574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R14764|Effects of Anthocyanin on Skin Health and Markers of Cardiovascular Disease Risk|Biological Effects of an Anthocyanin Rich Dietary Supplement on Skin Ageing and Markers of Inflammation in Post-Menopausal Women||University of East Anglia|No|Completed|August 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|62|||Female|N/A|70 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574574||163802|
NCT00575094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-3331|Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects|A Phase 3, Multicenter, Open-label Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects With Community-acquired Pneumonia||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||June 2011|June 2, 2011|December 13, 2007||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00575094||163763|
NCT00583765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5793|Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration|Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration||University of Alberta|Yes|Completed|April 2005|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|17 Years|80 Years|No|Non-Probability Sample|1. Male or female between 17 and 80 years of age.          2. Critically ill intensive care unit patient.          3. Renal failure requiring continuous venovenous hemodiafiltration.          4. Likely to survive for at least 72 hours|June 2008|June 2, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583765||163110|
NCT00586157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001633|Study of Medication Patch to Treat Children Ages 6-12 With ADHD|Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)||Massachusetts General Hospital|No|Completed|September 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|6 Years|12 Years|No|||November 2012|November 9, 2012|December 21, 2007|Yes|Yes||No|November 22, 2010|https://clinicaltrials.gov/show/NCT00586157||162928|
NCT00581997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2201|QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis|A Randomized, Double-blinded, Placebo Controlled, Multiple-dose, Multi-center Pilot Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Doses of QAX576 in Patients With Pulmonary Fibrosis Secondary to System Sclerosis||Novartis|No|Terminated|December 2007|||April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||May 2012|May 2, 2012|December 21, 2007|Yes|Yes|Concerns about risk of bronchoscopy procedure in the selected patient population and frequency    of SAEs observed to date.|No||https://clinicaltrials.gov/show/NCT00581997||163244|
NCT00582218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-008|Family Access to Care Study (FACS)|Family Access to Care Study (FACS)||Memorial Sloan Kettering Cancer Center||Completed|February 2003|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients/clients and their families at HIV/AIDS care centers|January 2009|January 13, 2009|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582218||163228|
NCT00582426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995AIC04|Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea|LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea|LARCID|Novartis||Completed|April 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|139|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|December 21, 2007||No||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00582426||163212|Limitations were the small number of patients who received irinotecan and small proportion of patients with grade III and IV diarrhea. It is not possible to generalize our results for these populations. Study wasn’t blinded or placebo-controlled.
NCT00582439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061229004|The Use of RIA to Harvest Bone Graft for Treatment of Non-unions and Fractures|The Use of the Reamer-Irrigator-Aspirator (RIA) to Harvest Bone Graft for Treatment of Non-unions and Fractures|RIA|University of Alabama at Birmingham|No|Completed|January 2007|September 2009|Actual|May 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|19 Years|65 Years|No|||September 2013|September 28, 2013|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00582439||163211|
NCT00582608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-066|Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9|Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9||Memorial Sloan Kettering Cancer Center||Completed|October 2001|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|1 Year|50 Years|No|||June 2009|June 4, 2009|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582608||163198|
NCT00582621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-069|Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders|Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders||Memorial Sloan Kettering Cancer Center||Recruiting|July 2000|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood or alternatively, subjects may provide a saliva or buccal cell sample|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Clinical Genetics Service at MSKCC or to the MSKCC outpatient clinics of the Lymphoma,        Multiple Myeloma or Leukemia Services in the Department of Medicine.|February 2016|February 22, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582621||163197|
NCT00583531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007216|Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis|A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis||Ocera Therapeutics|No|Terminated|March 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||June 2014|June 2, 2014|December 20, 2007|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00583531||163128|
NCT00575562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN330-US-01|Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer|Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|June 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||December 2007|June 22, 2010|December 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00575562||163728|
NCT00575575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196781|Research on Suicidal Ideation of University Students in Harbin City and Cognitive Behavior Therapy|the Research on Suicidal Ideation of University Students in Harbin City and Intervention on Them||Harbin Medical University|Yes|Completed|June 2007|February 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|355|||Both|17 Years|35 Years|Accepts Healthy Volunteers|||February 2009|February 25, 2009|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575575||163727|
NCT00576160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB9215|Improving Medication Adherence in Post-ACS Patients|Improving Med Adherence in Post-ACS Patients: Phase 1B Dose-Finding RCT||Columbia University|Yes|Terminated|August 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|22|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|December 14, 2007||No|This was a dosing study to determine acceptability. Participants found protocol burdensome and    so we terminated.|No||https://clinicaltrials.gov/show/NCT00576160||163683|
NCT00577070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-204CTIL|Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression|||BeerYaakov Mental Health Center|No|Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2009|October 5, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577070||163615|
NCT00576797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001794|Genomic Tools for Studying the Ecology of the Human Vaginal Microflora|Genomic Tools for Studying the Ecology of the Human Vaginal Microflora|VM|Emory University|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|396|Samples With DNA|vaginal secretions|Female|12 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asian, African American, Hispanic, or Cauasian women between the ages of 12 to 45 years        old|February 2016|February 1, 2016|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576797||163635|
NCT00576810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1062.7|Sodium Picosulphate vs. Placebo in Functional Constipation|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks Treatment With Sodium Picosulfate [Dulcolax®, Laxoberal®]Drops 10 mg Administered Orally, Once Daily, in Patients With Functional Constipation||Boehringer Ingelheim||Completed|October 2007|||January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|367|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|October 29, 2007||||No||https://clinicaltrials.gov/show/NCT00576810||163634|
NCT00577083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0501-30|Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates|Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates||Indiana University|Yes|Completed|November 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|100|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 11, 2007|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT00577083||163614|
NCT00577369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-12-5096|A Pilot Study to Measure Blood Levels of Desflurane in Children|A Pilot Study to Measure Blood Levels of Desflurane in Children||Children's Hospital of Philadelphia|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|1 Year|18 Years|No|||September 2009|September 14, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577369||163594|
NCT00574015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2200|The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache|The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache||Albany Medical College|No|Completed|December 2007|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||September 2010|March 21, 2014|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574015||163845|
NCT00574275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10547|Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer|A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer|VANILLA|Sanofi|Yes|Terminated|December 2007|November 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|546|||Both|18 Years|N/A|No|||July 2011|September 24, 2012|December 14, 2007|Yes|Yes|Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to    gemcitabine would be unable to demonstrate improved survival|No|August 17, 2012|https://clinicaltrials.gov/show/NCT00574275||163825|As the study was terminated due to futility, some changes were made to the planned analyses, and the analyses for the following outcome measures were not performed:Objective Response Rate (ORR)Clinical Benefit
NCT00574587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-10-374|Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis|Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel and Trastuzumab Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer||Albert Einstein College of Medicine of Yeshiva University|Yes|Active, not recruiting|December 2007|January 2016|Anticipated|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Female|18 Years|N/A|No|||July 2015|July 13, 2015|December 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574587||163801|
NCT00574860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3285-301|EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer|A Phase 3, Multi-center, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of EN3285 for the Prevention or Delay to Onset of Severe Oral Mucositis in Patients With Head and Neck Cancer Receiving Chemoradiotherapy||Endo Pharmaceuticals|Yes|Terminated|December 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|240|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|December 14, 2007|Yes|Yes|Additional research|No||https://clinicaltrials.gov/show/NCT00574860||163780|
NCT00584415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010971|Navi-Star Thermo-Cool Catheter For Ablation of Atrial Fibrillation|Navi-Star Thermo-Cool Catheter For Ablation of Atrial Fibrillation||University of Oklahoma|No|Completed|February 2004|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|90 Years|No|||July 2014|July 1, 2014|December 20, 2007|Yes|Yes||No|July 5, 2013|https://clinicaltrials.gov/show/NCT00584415||163060|
NCT00582010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070112003|Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation|Effects of Inhaled Nitric Oxide on Ischemia-Reperfusion Injury in Human Liver During Transplantation||University of Alabama at Birmingham|No|Completed|April 2008|October 2012|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|19 Years|80 Years|No|||October 2014|November 5, 2014|December 20, 2007|Yes|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT00582010||163243|
NCT00582023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAI 971423990|Role of Positive Affect in Adjustment to HIV|CHAI Study: Coping, HIV, and Affect Interview Study|CHAI|University of California, San Francisco|No|Completed|September 2004|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|160|||Both|18 Years|N/A|No|Non-Probability Sample|Adults newly diagnosed with HIV in the San Franicsco Bay Area.|November 2013|November 21, 2013|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582023||163242|
NCT00582231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001|Penile Injection Anxiety|Penile Injection Anxiety||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|126|||Male|N/A|N/A|No|Non-Probability Sample|Participants that are starting penile injections therapy.|January 2016|January 4, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582231||163227|
NCT00582881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030724|Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus|Immune Response to Small Nuclear Ribonucleoprotein Autoantigens||University of Miami|No|Recruiting|October 2007|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Serum, cells, DNA, urine|Both|18 Years|100 Years|No|Non-Probability Sample|Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), mixed connective tissue        disease (MCTD) or undifferentiated connective tissue disease (UCTD)|October 2015|October 20, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582881||163177|
NCT00583258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMHXATRAL2007|A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones|A Randomized, Double-Blinded Placebo-Controlled Trial of Alfuzosin (Xatral)in the Management of Distal Ureteral Calculi||St. Michael's Hospital, Toronto|No|Withdrawn|October 2007|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||July 2015|July 30, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583258||163149|
NCT00583271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0205-04B|A Prospective Study of EUS Guided Celiac Block|A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness||Indiana University|No|Completed|June 2002|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|127|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with abdominal pain from documented chronic pancreatitis or pancreatic cancer        that are referred for EUS-guided celiac block.|September 2014|September 3, 2014|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00583271||163148|
NCT00583895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-UOP-C201|Safety and Efficacy Study of ImCOOH Cream in Patients Suffering From Moderate Atopic Dermatitis|Phase IIa, Randomized, Double-blind, Placebo-controlled, Intra-individual Left-right Limb Comparison Trial in 25 Patients With Moderate Atopic Dermatitis to Investigate the Efficacy, Local Irritation, Safety, Tolerability and Pharmacokinetics of Twice Daily Topical Applications With 10% ImCOOH Cream for 14 Days With an Additional Morning Application on Day 15.||Valletta Health B.V.|No|Terminated|December 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|70 Years|No|||February 2010|February 26, 2010|December 20, 2007||No|Recruitment problems; insufficient number of new recruits|No||https://clinicaltrials.gov/show/NCT00583895||163100|
NCT00583908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0710 pt 3|Evaluation of Orientation and Visual Acuity of Four Toric Soft Contact Lenses When Head is Tilted at 90 Degrees|Clinical and Theoretical Evaluation of Factors Affecting Soft Toric Lens Performance: Part 3||Johnson & Johnson Vision Care, Inc.|No|Completed|November 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|12||Actual|14|||Both|18 Years|50 Years|No|||May 2015|May 5, 2015|December 21, 2007|Yes|Yes||No|August 18, 2009|https://clinicaltrials.gov/show/NCT00583908||163099|
NCT00575588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00001|52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period|A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.||AstraZeneca|Yes|Completed|December 2007|August 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|891|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|December 14, 2007|Yes|Yes||No|August 10, 2010|https://clinicaltrials.gov/show/NCT00575588||163726|
NCT00575601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|850-39-4796|Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients|Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients : A Prospective Randomized Double Blind Placebo Controlled Trial||Tehran University of Medical Sciences|Yes|Completed|August 2007|April 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|120|||Female|20 Years|40 Years|No|||June 2009|June 30, 2009|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575601||163725|
NCT00577096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 29287|Effects of Exercise in Combination With Epoetin Alfa|Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma||University of Arkansas|Yes|Completed|October 2001|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|N/A|N/A|No|||April 2015|April 2, 2015|December 17, 2007||No||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00577096||163613|Patients with hemoglobin <8 g/dl received RBC transfusions according to the transplantation protocol. Analysis may have missed specific disease-related influences on hemoglobin. Randomization should have distributed disease risks equally for groups.
NCT00577382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-145|SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma|A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2007|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577382||163593|
NCT00577395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007075|Bone Microarchitecture in Osteopenic Postmenopausal Women|A 12-month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing 150 mg Once-a-month Risedronate and Placebo Using 3-dimensional Micro MRI (Magnetic Resonance Imaging).||Warner Chilcott|No|Terminated|July 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Female|40 Years|57 Years|No|||April 2013|April 15, 2013|December 19, 2007|Yes|Yes||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00577395||163592|NOTE: The study was terminated early (after 5 months), prior to acquiring any efficacy endpoints; consequently, NO subject efficacy analyses were performed
NCT00577681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1422|Understanding the Increased Risk of Cardiovascular Disease in People With HIV|Lipoproteins, HIV, and Antiretroviral Therapy in SMART||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2002|January 2006|Actual|January 2006|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|5472|Samples Without DNA|The plasma specimens will be collected using EDTA plasma tubes. For each specimen, four      transport tubes (Sarstedt 2.0 mL Micro Tube), each containing 1 mL of plasma, will be      prepared and labeled with preprinted bar coded labels. The preprinted bar coded labels      specify the patient identification code (PID), visit and specimen type, and the protocol and      vial ID. Specimens will be frozen at negative 70 degrees Celcius and shipped on dry ice to a      central repository, Advanced Biomedical Laboratories, Cinnaminson, New Jersey, where they      will be scanned and put into storage. Paperwork documenting the specimens will be processed      by the SDMC, and electronic files will be sent to the central repository.|Both|18 Years|N/A|No|Probability Sample|This study will utilize patient data and specimens already collected from the previous        parent study, SMART.|December 2014|December 11, 2014|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577681||163572|
NCT00573482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK02-021 (completed)|A Cafeteria Based Study of Weight Gain Prevention|A Cafeteria Based Study of Weight Gain Prevention|Cafeteria|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|September 2002|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|106|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 24, 2010|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573482||163884|
NCT00573768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOPO-PE-201|Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel in Patients With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Once or Twice Daily in Patients With Acute Ankle Sprain||Novartis|No|Completed|November 2007|July 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|271|||Both|18 Years|75 Years|No|||October 2010|April 18, 2012|December 13, 2007||No||No|July 28, 2010|https://clinicaltrials.gov/show/NCT00573768||163864|
NCT00573781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56/2007|Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism|Systems Biology Approach to Understand Dietary Modulation of Gene Expression and Metabolic Pathways in Subjects With Abnormal Glucose Metabolism (Sysdimet)|Sysdimet|University of Eastern Finland|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|106|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573781||163863|
NCT00574028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT07006|Inflammatory Bowel Disease Research Registry|The University of California Irvine Medical Center Inflammatory Bowel Disease Research Registry||University of California, Irvine|No|Completed|August 2007|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|138|||Both|18 Years|N/A|No|Non-Probability Sample|The characteristics of the proposed subject population include:          -  Subjects, male or female, 18 years of age or older          -  Patients receiving or seeking medical care at UCI Medical Center diagnosed with IBD.          -  Subjects who are unable to read or speak English          -  Adults who are competent to give informed consent          -  Subjects of any race or ethnicity|December 2014|December 9, 2014|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00574028||163844|
NCT00574041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-8002|How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose|An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY)|TODAY|Biogen|No|Terminated|June 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||September 2008|September 2, 2008|December 12, 2007|No|Yes|Terminated due to poor recruitment|No||https://clinicaltrials.gov/show/NCT00574041||163843|
NCT00574288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101876|Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma|Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study||Janssen Research & Development, LLC|Yes|Active, not recruiting|March 2008|August 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574288||163824|
NCT00574548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3010|Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS|A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|720|||Both|60 Years|64 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|December 13, 2007|Yes|Yes||No|February 1, 2011|https://clinicaltrials.gov/show/NCT00574548||163804|
NCT00574327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0035|Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry|A Prospective Study To Define The Role Of Various Factors In Development And Progression Of Gastroesophageal Reflux Disease (GERD) And Barrett's Esophagus And The Creation Of A Registry.||Midwest Biomedical Research Foundation|No|Recruiting|January 2006|January 2020|Anticipated|October 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|3000|Samples With DNA|Serum samples from participating patients will be collected and frozen for measurements of      insulin, glucose, lipid panel, CRP and adiponectin levels. Biopsies obtained from esophagus      during endoscopy and blood samples will be frozen for future biomarker and cDNA microarray      studies and histochemistry.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients must be eligible for care at the Kansas City VA Medical Center. Those        presenting to the Kansas City VA endoscopy laboratory for their "standard BE surveillance"        endoscopy. Patients with a history of BE will be identified and contacted from the        existing databank. Patients with newly diagnosed BE in the endoscopy laboratory after        their procedure is completed and biopsy results are available. Patients undergoing upper        endoscopy for evaluation of GERD symptoms. Control group of patients undergoing upper        endoscopy for any reason other than the ones stated above.|October 2015|October 19, 2015|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574327||163821|
NCT00574600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 073/SAAVI 102|Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults|A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|November 2008|January 2013|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00574600||163800|
NCT00574613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD002-P144-07|Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis|Phase II, Multicenter, Randomized, Double-blind, Intraindividually Placebo Controlled Clinical Trial, to Evaluate Efficacy and Safety of p144 Topical Administration for Skin Fibrosis in Patients With Systemic Sclerosis||ISDIN|No|Completed|September 2007|September 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||February 2013|February 8, 2013|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574613||163799|
NCT00585338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-ASLMS-2003-3086|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser||University of California, Irvine|No|Completed|December 2007|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00585338||162990|
NCT00582036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucose Control|Glucose Control In Hematopoetic Stem Cell Transplant|Glucose Control In Hematopoetic Stem Cell Transplant||University of Oklahoma|No|Terminated|February 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|December 19, 2007||No|study terminated due to lack of enrollment|No|January 6, 2011|https://clinicaltrials.gov/show/NCT00582036||163241|This study was terminated early due to lack of enrollment.
NCT00582244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKI 2006-3470|Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial|Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial|EVA project|The Netherlands Cancer Institute|No|Not yet recruiting|January 2008|December 2010|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|325|||Female|30 Years|50 Years|No|||December 2007|December 19, 2007|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582244||163226|
NCT00582452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-127|Attitudes Towards Prophylactic Colectomy in Hereditary Non-polyposis Colorectal Cancer (HNPCC) Patients|Attitudes Towards Prophylactic Colectomy in HNPCC Patients||Memorial Sloan Kettering Cancer Center||Completed|November 2004|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Unaffected patients who are at high risk for developing colon cancer based on family        history and/or mutation status, and affected patients who are at high risk for        metachronous colorectal tumors due to mutation status.|December 2009|December 9, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00582452||163210|
NCT00582634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2004-0248|Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer|Phase II Study of Adjuvant Cisplatin and Docetaxel in Non-small Cell Lung Cancer||University of Wisconsin, Madison|Yes|Completed|September 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582634||163196|
NCT00583284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delayed Enhancement CT|The Use of CT to Identify Damaged Heart Muscle in Patients Undergoing Ventricular Tachycardia Ablation.|Utility of Delayed-Enhancement Multi-Detector Computed Tomography Imaging in Identifying Arrhymogenic Substrate in Patients Undergoing Catheter Ablation for Ventricular Tachycardia||The Cleveland Clinic|No|Terminated|November 2006|March 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|21 Years|N/A|No|Non-Probability Sample|Patients coming to Cleveland Clinic for catheter ablation for ventricular tachycardia|June 2008|June 10, 2008|December 20, 2007||No|key study staff left foundation|No||https://clinicaltrials.gov/show/NCT00583284||163147|
NCT00583544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-2216-232-CLP-001|A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers|A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.|SRD|Targacept Inc.|No|Completed|January 2007|February 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2008|July 17, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583544||163127|
NCT00583557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBRA99|A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01|A Multi-Center, Open-Label, Continuation Trial of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) Who Completed the Phase 2 Protocol LBRA01||Human Genome Sciences Inc.|Yes|Terminated|January 2005|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|December 20, 2007|Yes|Yes|Sponsor decision - not related to safety|No|April 7, 2011|https://clinicaltrials.gov/show/NCT00583557||163126|
NCT00584857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040628007 (UAB 0403)|A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer|A Phase II Study of Combination Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Advanced Stage or Recurrent Carcinoma of the Endometrium||University of Alabama at Birmingham|Yes|Completed|July 2004|October 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|19 Years|N/A|No|||April 2015|April 3, 2015|December 21, 2007|Yes|Yes||No|September 23, 2011|https://clinicaltrials.gov/show/NCT00584857||163026|
NCT00585156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR#2005-0300|The Effects of Celecoxib on Bone Ingrowth|The Effects of Celecoxib on Bone Ingrowth in Porous Coated Titanium Ceramic Implants in Humans||University of Utah|No|Terminated|June 2008|September 2008|Actual|September 2008|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|9|||Male|18 Years|95 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|December 26, 2007|No|Yes|New clinical finding with Celebrex and cardiac concerns.|No||https://clinicaltrials.gov/show/NCT00585156||163004|
NCT00585169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705002703*|Memantine Treatment Study of Pathological Gambling|A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling||Yale University|No|Completed|December 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|21 Years|75 Years|No|||March 2013|March 5, 2013|December 25, 2007|Yes|Yes||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00585169||163003|
NCT00575900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc003187ctil|Low Carbohydrates in Obese Adolescents|Comparison Between Low Carbohydrate Low Fat, Low Carbohydrate High Fat and Balanced Low Fat Diets in the Treatment of Obesity in Adolescents- a Randomized Controlled Trail.||Rabin Medical Center|No|Completed|March 2005|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|55|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||December 2007|December 16, 2007|December 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00575900||163703|
NCT00576472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEMFX2|Learning Impairments Among Survivors of Childhood Cancer|Learning Impairments Among Survivors of Childhood Cancer||St. Jude Children's Research Hospital|No|Completed|January 2000|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|469|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||February 2013|February 27, 2014|December 17, 2007|Yes|Yes||No|October 28, 2011|https://clinicaltrials.gov/show/NCT00576472||163660|
NCT00576485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|490/06|Spherical Aberration and Contrast Sensitivity in IOLs|Spherical Aberration and Contrast Sensitivity in Eyes Implanted With Aspheric and Spherical Intraocular Lenses: Clinical Comparative Study|IOLs|Federal University of Minas Gerais|Yes|Completed|February 2005|December 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||December 2007|October 17, 2008|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576485||163659|
NCT00577408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5307|Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial. A Free Treatment for Opiate Abuse.|Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial|Depot-BNT|New York State Psychiatric Institute|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|60 Years|No|||October 2012|October 16, 2012|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577408||163591|
NCT00577694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0708|Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Nonrandomized Dose-escalation Study of Clofarabine in Combination With Gemtuzumab Ozogamicin for Relapsed/Refractory Acute Myeloid Leukemia (AML) for Patients Less Than 60 Years-old||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|November 2007|August 2015|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|No|||October 2015|October 7, 2015|December 19, 2007|No|Yes|funding unavailable|No||https://clinicaltrials.gov/show/NCT00577694||163571|
NCT00573495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08107|Multipeptide Vaccine for Advanced Breast Cancer|A Study of hTERT/Survivin Multi-peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|November 2007|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573495||163883|
NCT00573794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-223|Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis|A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis||AbbVie|No|Active, not recruiting|November 2007|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573794||163862|
NCT00573807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-SCIA-CTP1|Energy Specific Far Infrared Radiation Treatment for Sciatica|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Sciatica.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|January 2006|December 2008|Anticipated|March 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|N/A|N/A|No|||January 2009|January 2, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573807||163861|
NCT00573820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-PC-CTP1|Far Infrared Radiation Treatment for Prostate Cancer|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|January 2006|December 2008|Anticipated|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|N/A|N/A|No|||August 2009|August 14, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573820||163860|
NCT00574054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-DEM-CTP1|Far Infrared Radiation Treatment of Dementia and Other Mental Illness|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Dementia and Other Related Mental Illness.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|February 2008|March 2009|Anticipated|January 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|2 Years|N/A|No|||August 2009|August 14, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00574054||163842|
NCT00574301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS 07050|Percutaneous Removal and Margin Ablation for Breast Cancer|Percutaneous Removal and Margin Ablation for Breast Cancer||University of Arkansas|No|Completed|March 2002|October 2011|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|18 Years|90 Years|No|||July 2013|July 24, 2013|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574301||163823|
NCT00574314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 4269|Women's Health Research Registry|Women's Health Research Registry||Cedars-Sinai Medical Center|No|Terminated|July 2004|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|839|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All adult English-speaking women|August 2015|August 10, 2015|December 14, 2007||No|No more funding|No||https://clinicaltrials.gov/show/NCT00574314||163822|
NCT00574626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123-92|Randomized Trial Comparing Autologous PBSCT to BMT for Pts Receiving High-Dose Chemo & Transplant for Recurrent NHL|Randomized Trial Comparing Autologous Peripheral Blood Stem Cell Transplantation to Bone Marrow Transplantation for Patients Receiving High-Dose Chemotherapy and Transplantation for Recurrent Non-Hodgkin's Lymphoma||University of Nebraska|No|Completed|December 1991|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|16 Years|65 Years|No|||August 2011|August 31, 2011|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574626||163798|
NCT00574899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-053|Prostate Biomarker Study|Multi-Institutional Inter-SPORE Prostate Biomarker Study||Memorial Sloan Kettering Cancer Center||Completed|May 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|Samples With DNA|tissue, serum, plasma, and lymphocytes|Male|35 Years|N/A|No|Non-Probability Sample|11 cancer centers in the USA|October 2015|October 18, 2015|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574899||163777|
NCT00585845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC07001|Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment|A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment||Anza Therapeutics, Inc.|Yes|Terminated|December 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2009|February 19, 2009|December 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00585845||162951|
NCT00582465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8994-14731|Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus|Bone Mineral Density of Children and Adolescents With Systemic Lupus Erythematosus|BMD|University of California, San Francisco|No|Active, not recruiting|September 2003|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|425|Samples With DNA|Serum|Both|7 Years|22 Years|No|Non-Probability Sample|Children and adolescents with SLE|October 2014|October 25, 2014|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00582465||163209|
NCT00582894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reduced-Intensity|Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases|Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases||University of Oklahoma|Yes|Completed|February 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|75 Years|No|||March 2011|March 23, 2011|December 19, 2007||No||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00582894||163176|
NCT00582907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1FD003435-01|Rilonacept for Treatment of Familial Mediterranean Fever (FMF)|Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF)||The Cleveland Clinic|Yes|Completed|August 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|4 Years|N/A|No|||February 2013|February 5, 2013|December 19, 2007|Yes|Yes||No|August 25, 2012|https://clinicaltrials.gov/show/NCT00582907||163175|Small sample size - accounted for in study design and analysis plan.Carry over/lag effect of rilonacept - sensitivity analysis of shifting course time frame showed similar results.Heterogeneity of FMF mutationsDifferent age groups
NCT00584207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412085|Radiofrequency Ablation of Uterine Fibroids|Radiofrequency Ablation of Uterine Fibroids||University of California, Davis|No|Terminated|March 2004|July 2008|Actual|March 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||April 2009|April 21, 2009|December 21, 2007|Yes|Yes|Unsufficient referrals for recruitment|No||https://clinicaltrials.gov/show/NCT00584207||163076|
NCT00584220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0714B|Evaluation of Two Toric Soft Contact Lenses After Two Weeks of Wear|Evaluation of Fit and Visual Acuity of the Investigational Toric Lens in Two Phases: Part B: A Dispensing Cross-over Comparison to SofLens66 Toric||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|December 20, 2007|Yes|Yes||No|August 21, 2009|https://clinicaltrials.gov/show/NCT00584220||163075|
NCT00584532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412146-5|Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.|Effects of a Genistein Concentrated Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.|GCP|University of California, Davis|Yes|Completed|November 2003|December 2007|Actual|December 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Male|N/A|N/A|No|||December 2007|December 22, 2007|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00584532||163051|
NCT00584844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-12775|Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine|A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4||U.S. Army Medical Research and Materiel Command|No|Completed|October 2004|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|484|||Both|17 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 8, 2012|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00584844||163027|
NCT00585182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20115|Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT|Venous Thromboembolism Prevention in the Morbidly Obese Medically Ill Patient: A Pharmacological Analysis of the Predictability of Prophylactic Weight-Based Enoxaparin Dosing.||University of Utah|Yes|Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|December 21, 2007||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00585182||163002|This study was limited by a relatively small sample size, lack of long-term clinical outcome data, and the use of only a single anti-Xa level, rather than repeat measures.
NCT00576498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00225(PS0036)|Novel Imaging Techniques in Barrett's Esophagus|Detection Of Intestinal Metaplasia And High Grade Dysplasia In Barrett's Esophagus Using Novel Imaging Techniques - A Randomized Controlled Trial.||Midwest Biomedical Research Foundation|No|Completed|October 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|130|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576498||163658|
NCT00576511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-BEL-6|Effect of Prucalopride in Patients With Severe Chronic Idiopathic Constipation|A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Severe Chronic Constipation||Movetis|No|Completed|December 1994|February 1996|Actual|February 1996|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|75 Years|No|||December 2007|May 28, 2008|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576511||163657|
NCT00576823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6269|Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology|12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension|Alfahydro|Sanofi|Yes|Completed|December 2007|October 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|2 Years|16 Years|No|||October 2014|October 21, 2014|December 18, 2007|Yes|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00576823||163633|This was an exploratory, open-label, non-comparative trial. Analyses were purely descriptive.
NCT00577421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002157|Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO|An Extension Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO||Warner Chilcott|No|Completed|June 2003|January 2006|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|55 Years|N/A|No|||September 2011|September 27, 2011|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577421||163590|
NCT00577434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-4-4822|Pharmacokinetics and Pharmacodynamics of Pentobarbital in Neonates, Infants, and Children Following Open Heart Surgery|The Pharmacokinetics and Pharmacodynamics of a Single Dose of Pentobarbital for Clinically Indicated Sedation for Neonates, Infants, and Children Recovering From Open Heart Surgery||Children's Hospital of Philadelphia|No|Terminated|April 2006|December 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|None Retained|Blood|Both|N/A|6 Years|No|Probability Sample|All patients enrolled in this study will be postoperative from cardiac surgery adn have        require sedation for a procedure or diagnostic imaging.|July 2008|March 11, 2015|December 18, 2007||No|Sluggish enrollment|No||https://clinicaltrials.gov/show/NCT00577434||163589|
NCT00577707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-103|Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)|A Phase II Study of Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)||Memorial Sloan Kettering Cancer Center||Completed|November 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|December 18, 2007|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00577707||163570|
NCT00573508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-010|Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-center Study of VESIcare® (Solifenacin Succinate) in Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life VIBRANT: VESIcare® Investigation of BotheR And Quality of Life iN subjecTs With OAB|VIBRANT|Astellas Pharma Inc|No|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|768|||Both|18 Years|N/A|No|||September 2010|September 7, 2010|December 12, 2007|Yes|Yes||No|February 2, 2010|https://clinicaltrials.gov/show/NCT00573508||163882|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00573833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-120|Internal Radiation Therapy in Treating Patients With Prostate Cancer|A Pilot Study of High Dose Rate Brachytherapy as Definitive Management for Intermediate Risk Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|November 2007|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|N/A|No|||September 2014|September 11, 2014|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573833||163859|
NCT00573846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT07005|Phenotypic Characteristics of Inflammatory Bowel Disease in Southeast Asian Population - A Multi-centered US Study|Phenotypic Characteristics of Inflammatory Bowel Disease in Southeast Asian Population - A Multi-centered US Study||University of California, Irvine|No|Withdrawn|July 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be selected from the IBD registry maintained at respective institutions.        Subjects from the Indian sub-continent will be identified using their country of birth,        parents' ethnicity, number of years since leaving the country of birth, and number of        years residing in the United States.|January 2015|January 26, 2015|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573846||163858|
NCT00574067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1DA021579-01A1|Prison Buprenorphine|Buprenorphine for Prisoners||Friends Research Institute, Inc.|Yes|Completed|September 2008|||March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|213|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00574067||163841|
NCT00574080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-15|UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide|UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients||University of Arkansas|No|Terminated|July 2006|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2011|June 1, 2011|December 12, 2007||No|low accrual|No|May 4, 2011|https://clinicaltrials.gov/show/NCT00574080||163840|Early termination led to small numbers of subjects to be analyzed. Less than 10% of the target accrual were enrolled before termination of study.
NCT00574639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044868|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2|Mechanisms of Hypoglycemia-Associated Autonomic Dysfunction. The Effect of Alprazolam on Exercise Induced Hypoglycemia.|Alp Ex|University of Maryland|Yes|Active, not recruiting|July 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574639||163797|
NCT00579059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62-U-007|Maxim® Knee Pop-Top® Tibia vs. Regular Maxim® Knee Tibia|A Randomized Data Collection of the Maxim® Knee System With Removable Molded Polyethylene Tibia and the Regular Maxim® Knee System||Biomet, Inc.|No|Terminated|May 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|December 17, 2007|Yes|Yes|The study sponsor canceled the study.|No|May 20, 2009|https://clinicaltrials.gov/show/NCT00579059||163468|Study was terminated after enrollment failed to produce sufficient data to be analyzed.
NCT00579072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-084|The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older|The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older||Memorial Sloan Kettering Cancer Center|No|Recruiting|August 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|||Male|65 Years|N/A|No|Non-Probability Sample|Prostate Cancer Patients|February 2016|February 8, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579072||163467|
NCT00585858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0437|Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant|Cytokine Kinetics Assay to Assess the Presence or Absence of Tolerance in Organ Transplant Recipients||University of Wisconsin, Madison|No|Terminated|September 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Kidney or liver transplant recipients|October 2015|October 13, 2015|December 26, 2007||No|PI leaving institution|No||https://clinicaltrials.gov/show/NCT00585858||162950|
NCT00586170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-027|A Observational Study on Adjunctive Use of Pulsed Electromagnetic Fields in the Treatment of 5th Metatarsal Non-Union Fracture|A Observational Study on Adjunctive Use of Pulsed Electromagnetic Fields in the Treatment of 5th Metatarsal Non-Union Fracture: Effect on Clinical Outcome and Growth Factor Synthesis||Biomet, Inc.|No|Terminated|November 2007|August 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects who have been diagnosed with a 5th Metatarsal Non-Union for a minimum of three        months.|September 2012|May 27, 2015|December 21, 2007|No|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00586170||162927|
NCT00583583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-004 E/C|Emergency/Compassionate Use - AMPLATZER Duct Occluder|||St. Jude Medical||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||January 2015|January 28, 2015|December 20, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00583583||163124|
NCT00583596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-004|Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder|||St. Jude Medical|Yes|Completed|October 1999|February 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|436|||Both|N/A|N/A|No|||January 2015|January 28, 2015|December 20, 2007|Yes|Yes||Yes|January 17, 2014|https://clinicaltrials.gov/show/NCT00583596||163123|
NCT00583921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614770|Ventricular Rate Regularization for Improved Quality of Life in Patients With CHF and AF|Randomized Study of Ventricular Rate Regularization for Improved Quality of Life in Patients With Congestive Heart Failure and Atrial Fibrillation.|VRR|University of California, Davis|Yes|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|85 Years|No|Probability Sample|Patients implanted with a new Guidant ICD/ CRT-D: Indication for CRT-D and ICD with        history of atrial fibrillation. Patients with new implants will not be enrolled until        their three month follow up visit in the pacemaker clinic.        Patients currenlty implanted with a Guidant ICD/ CRT-D: More than 20% atrial fibrillation        burden as recorded by defibrillator follow up report or with history of atrial        fibrillation.|March 2013|March 26, 2013|December 26, 2007||No|no subjects enrolled|No||https://clinicaltrials.gov/show/NCT00583921||163098|
NCT00584545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715362-1|Simultaneous Fluoroscopic and Manometric Measures of the Oropharyngeal Phase of Deglutition|Simultaneous Fluoroscopic and Manometric Measures of the Oropharyngeal Phase of Deglutition||University of California, Davis|No|Withdrawn|June 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|UCDMC otolaryngology primary clinic|December 2015|December 6, 2015|December 26, 2007||No|Study never got started.|No||https://clinicaltrials.gov/show/NCT00584545||163050|
NCT00584558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09343|Long-Term Follow-Up of Patients Undergoing Catheter Ablation|Long-Term Follow-Up of Patients Undergoing Catheter Ablation||University of Oklahoma|No|Recruiting|December 2000|November 2050|Anticipated|November 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing catheter ablation at the OU Medical Center|March 2011|March 2, 2011|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584558||163049|
NCT00584870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091004|RN624 In Adult Patients With Chronic Low Back Pain|Phase II Randomized, Double-Blind, Placebo And Active Controlled, Multicenter, Parallel Group Proof Of Concept Study Of The Analgesic Effects Of RN624 In Adult Patients With Chronic Low Back Pain||Pfizer|No|Completed|July 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|N/A|No|||October 2009|October 1, 2009|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584870||163025|
NCT00585195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081001|A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer|Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of PF-02341066, A C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer|PROFILE 1001|Pfizer|No|Recruiting|April 2006|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|565|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00585195||163001|
NCT00585455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0410027131|Vascular Effects of Sertraline in Heart Failure|Effects of Chronic Sertraline Hydrochloride Administration on Vascular Endothelial and Autonomic Function in Patients With Chronic Heart Failure||Yale University|No|Terminated|January 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|Samples Without DNA|Plasma and serum|Both|21 Years|N/A|No|Non-Probability Sample|chronic heart failure patients with concomitant depression|July 2009|July 22, 2009|December 22, 2007||No|PI change in institution|No||https://clinicaltrials.gov/show/NCT00585455||162981|
NCT00576836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016144 #932|Thymus Transplantation Dose in DiGeorge #932|Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1||Duke University|Yes|Active, not recruiting|February 2006|June 2027|Anticipated|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|N/A|N/A|No|||March 2015|March 31, 2015|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576836||163632|
NCT00576849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HES2007|A Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients|Phase 4 Study of a Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients||Klinikum Ludwigshafen|Yes|Completed|December 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|80 Years|N/A|No|||January 2009|May 25, 2010|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576849||163631|
NCT00577109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20452|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.|An Open Label Study to Assess the Effect of FOLFIRI Plus Avastin and Cetuximab on Progression-Free Survival in Patients With Previously Untreated Metastatic Colorectal Cancer.||Hoffmann-La Roche||Terminated||June 2012|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||June 2008|June 17, 2008|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577109||163612|
NCT00577135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017634|Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)|Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)||Duke University|Yes|Completed|February 2008|February 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|308|||Both|18 Years|N/A|No|||April 2013|July 15, 2014|December 18, 2007|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00577135||163610|
NCT00577447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|398-05|Docosahexaenoic Acid in the Treatment of Autism|A Randomized, Double-Blind, Placebo-Controlled Trial of Docosahexaenoic Acid Supplementation in Children With Autism||Mayo Clinic|No|Completed|October 2005|November 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|3 Years|10 Years|No|||April 2015|April 27, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577447||163588|
NCT00577460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.634|Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD|Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)||Boehringer Ingelheim||Completed|December 2007|||June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|391|||Both|32 Years|N/A|No|||April 2014|May 7, 2014|December 19, 2007|Yes|Yes||No|June 16, 2011|https://clinicaltrials.gov/show/NCT00577460||163587|
NCT00577720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005107|Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate|Study to Assess the Efficacy, Safety and Pharmacokinetics of Risedronate Upon Oral Administration of a 35 mg Delayed-Release, a 50 mg Delayed-Release or a 35 mg Immediate-Release Administered Weekly for 13 Weeks to Postmenopausal Women||Warner Chilcott|No|Completed|July 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|181|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||November 2011|December 6, 2011|December 19, 2007|Yes|Yes||No|August 12, 2011|https://clinicaltrials.gov/show/NCT00577720||163569|
NCT00573521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07100136|Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms|Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms||University of Pittsburgh|Yes|Active, not recruiting|November 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|450|Samples Without DNA|No genetic testing will be performed on any of the samples being obtained. The biologic      samples will be under the control of the principal investigator of this research project. To      protect confidentiality, all personal identifiers (i.e., name, social security number, and      birth date) will be removed (de-identified) and replaced with a specific code number. The      information linking these code numbers to the corresponding subjects' identities will be      kept in a separate, secure location. The investigators on this study will keep the samples      indefinitely. If a subject withdraws and provides the request in writing, samples collected      and not already processed will be destroyed. All samples will be kept in the investigator's      laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.|Both|18 Years|N/A|No|Non-Probability Sample|ESBL positive cultures|December 2015|December 16, 2015|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573521||163881|
NCT00574093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952AIT03|Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD|12 Months Case Series Open Study to Assess the Safety and Efficacy of Intravitreal Injection of Lucentis (Ranibizumab 0.5 mg)Used in Combination With Visudyne (Verteporfin PDT) in Naive Subjects With Subfoveal CNV Secondary to AMD|Luvi|Fondazione G.B. Bietti, IRCCS|Yes|Completed|January 2008|October 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|50 Years|95 Years|No|||October 2009|October 29, 2009|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574093||163839|
NCT00574340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044875-SCCOR-Q4|Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4|SCCOR in Hemostatic and Thrombotic Diseases Project 5 - Metabolic Causes of Thrombosis in Type 2 Diabetes||University of Maryland|Yes|Completed|May 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|December 13, 2007||No||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00574340||163820|
NCT00578552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005262|Gabapentin for Smoking Cessation|Gabapentin for Smoking Abstinence||Mayo Clinic|No|Completed|October 2007|May 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 15, 2011|December 19, 2007||No||No|November 1, 2010|https://clinicaltrials.gov/show/NCT00578552||163507|The original intent was to enroll a total of 120 subjects. However, due to the high study dropout rate, a review of the primary endpoint was performed after 80 subjects were enrolled and a decision was made to discontinue further enrollment.
NCT00578786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMB-320/321-E|A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)|A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)||Gilead Sciences|Yes|Completed|February 2004|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|383|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|December 19, 2007|Yes|Yes||No|April 12, 2012|https://clinicaltrials.gov/show/NCT00578786||163489|Analysis included those not enrolling in this study but received AMB in 1 of the 2 parent studies. At Year 3, almost half of those randomized to 2.5 mg were titrated to 5 mg and 10 mg; a third starting at 5 mg were titrated to 10 mg.
NCT00586183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002093|Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome|Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome||Mayo Clinic|No|Completed|March 2006|December 2006|Actual|December 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Both|18 Years|N/A|No|||March 2006|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586183||162926|
NCT00583934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513668-3|Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?|Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?||University of California, Davis|No|Completed|September 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|19|Samples With DNA|tissue|Both|18 Years|N/A|No|Probability Sample|Subject population will be recruited from the clinical practice of the investigators.|July 2010|July 12, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00583934||163097|
NCT00584233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214750|Evaluation of Breast CT|Evaluation of Breast CT||University of California, Davis|No|Recruiting|December 2004|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Female|35 Years|N/A|No|||December 2015|December 18, 2015|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584233||163074|
NCT00584571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01 KD57100-05A2|Randomized Controlled Trial of Treating Rectal Hypersensitivity - Comparing Escitalopram With Sensory Adaptation Training|||Georgia Regents University|No|Recruiting|December 2007|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00584571||163048|
NCT00584584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2104|An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever|A Proof of Concept Study of the Effects of QAX576 (an Interleukin-13 Monoclonal Antibody) on Allergic Inflammation Following Out of Allergy Season Repeated Nasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis Sensitive to Timothy Grass Pollen||Novartis|No|Completed|December 2007|||August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|No|||September 2010|September 1, 2010|December 21, 2007||||No||https://clinicaltrials.gov/show/NCT00584584||163047|
NCT00584883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 0327|A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme|A Phase I Study of ABT 510 and Concurrent Temozolomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme||University of Alabama at Birmingham|Yes|Completed|August 2003|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|19 Years|N/A|No|||May 2012|May 16, 2012|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00584883||163024|
NCT00584896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-014|Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease|A Phase 3 Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive Technology Using PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Artery Disease II|POINT II|Point Biomedical|Yes|Terminated|October 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|N/A|No|||July 2008|July 1, 2008|December 20, 2007|Yes|Yes|Discontinued PB127 development program for business reasons|No||https://clinicaltrials.gov/show/NCT00584896||163023|
NCT00585975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-S&E-0802071-P|Efficacy and Safety of Bromfenac Ophthalmic Solution|||Bausch & Lomb Incorporated|No|Completed|October 2007|||July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|568|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|December 21, 2007|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00585975||162941|
NCT00585988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292-U-010|A Clinical Investigation of Recovery Following Hip Resurfacing or Total Hip Arthroplasty|Functional Recovery Following Hip Resurfacing or Total Hip Arthroplasty in Patients Matched By Age, Gender, and Activity Level||Biomet, Inc.|No|Withdrawn|June 2007|September 2010|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585988||162940|
NCT00586001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH070693-02|A Unified Treatment for Anxiety Disorders|Phase 3 of The Development of A Unified Treatment for Anxiety Disorders||Boston University|No|Completed|September 2005|November 2010|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2011|November 29, 2011|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586001||162939|
NCT00576862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4046|Extension to Study HMR1964A/3011 in Belgium|Multicenter,Open,Uncontrolled,Clinical Extension Trial in Subjects With Type I Diabetes Previously Participating in Study HMR1964A/3011 in Belgium||Sanofi||Completed|November 2002|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2007|December 28, 2007|December 17, 2007||||No||https://clinicaltrials.gov/show/NCT00576862||163630|
NCT00576550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-1588|A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema|A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema||ACO Hud Nordic AB|No|Completed|October 2007|May 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|53|||Both|18 Years|N/A|No|||December 2007|October 10, 2008|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576550||163654|
NCT00577122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607-18 IUCRO-0154|Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer|MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial||Indiana University|Yes|Completed|July 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|December 18, 2007||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT00577122||163611|
NCT00577148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10144|An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).||Sanofi|Yes|Terminated|February 2008|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||June 2009|June 12, 2009|December 18, 2007|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00577148||163609|
NCT00577161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIX303|Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL|Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) vs Fludarabine and Rituximab (F-R) for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma||CTI BioPharma|Yes|Terminated|September 2007|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2008|September 19, 2008|December 17, 2007|Yes|Yes|closed to enrollment|No||https://clinicaltrials.gov/show/NCT00577161||163608|
NCT00577473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000083|Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)|A Double-blind, Randomized, 6 Week, Parallel-group Design Clinical Trial in Patients With Mildly to Moderately Active Ulcerative Colitis to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day|ASCEND I|Warner Chilcott|No|Completed|February 2001|February 2003|Actual|February 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|65 Years|No|||September 2011|September 14, 2011|December 19, 2007|Yes|Yes||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00577473||163586|
NCT00577733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061010|Study of the Physiology of the Asthma of the Obese Subjects. Breathing Obesity Asthma Study (BOA)|Pathophysiological Study of Obesity-related Asthma|BOA|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2008|November 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|204|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|obese with AHR, obese without AHR and healthy non obese|December 2007|September 17, 2013|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577733||163568|
NCT00573534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5522|Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse|Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence||New York State Psychiatric Institute|No|Completed|March 2008|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|11 Years|15 Years|No|||December 2012|December 9, 2012|December 12, 2007|No|Yes||No|August 15, 2011|https://clinicaltrials.gov/show/NCT00573534||163880|
NCT00573859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5156|The Reinforcing Mechanisms of Smoking in Adult ADHD|The Reinforcing Mechanisms of Smoking in Adult ADHD||University of California, Irvine|Yes|Completed|September 2006|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|27|||Both|18 Years|45 Years|No|||September 2011|September 23, 2011|December 12, 2007||No||No|August 15, 2011|https://clinicaltrials.gov/show/NCT00573859||163857|
NCT00574106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-CAN-CTP1|A Study to Evaluate the Effect of Far Infrared Radiation for Cancer Treatment|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation for Cancer Treatment||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|February 2008|October 2009|Anticipated|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||August 2009|August 14, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00574106||163838|
NCT00574119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 070824|Effect of Aldosterone on Energy Starvation in Heart Failure|Effect of Aldosterone on Energy Starvation in Heart Failure||Vanderbilt University|No|Active, not recruiting|December 2007|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|June 1, 2015|December 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574119||163837|
NCT00574353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-151|Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients|A Feasibility Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients||Memorial Sloan Kettering Cancer Center||Recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00574353||163819|
NCT00577525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070126|Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome|Viral Infection of Lymphoid Cells Occuring at the First Manifestation of Idiopathic Nephrotic Syndrome|Nephrovir|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2007|February 2012|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|401|Samples With DNA|whole blood, serum, red cells and DNA|Both|1 Year|16 Years|No|Non-Probability Sample|From the thirty nine units of general pediatrics and pediatric nephrology covering the        Parisian area|February 2014|February 26, 2014|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577525||163583|
NCT00582257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-118|Early Onset and Familial Gastric Cancer Registry|Early Onset and Familial Gastric Cancer Registry||Memorial Sloan Kettering Cancer Center||Recruiting|December 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2500|Samples With DNA|Germline DNA and Tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment        team, the protocol investigator, or research team at MSK or collaborating centers. If the        investigator is a member of the treatment team, s/he will screen their patient's medical        records for suitable research study participation and discuss the study and their        potential for enrolling in the research study. Potential subjects contacted by their        treating physician will be referred to the investigator/research staff of the study.|September 2015|September 21, 2015|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00582257||163225|
NCT00583297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDx_000001|Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial|Identifying Genetic Markers That Predict Microvolt T-wave Alternans Status and Arrhythmia Risk in Patients With Ischemic Heart Disease||CardioDx|Yes|Completed|January 2007|December 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Whole blood and saliva.|Both|18 Years|N/A|No|Non-Probability Sample|The target population for the ABCD genetic sub-study includes all living individuals        currently enrolled in the ABCD trial (total study enrollment=629; 566 analyzed in the        trial) Participants of the ABCD trial underwent TWA and EPS testing to determine their        risk for ventricular arrhythmia and most have received an implantable cardioverter        defibrillator (ICD). The ABCD trial collected extensive longitudinal clinical data        including medical and medication histories, incidence of ventricular arrhythmias,        defibrillator shocks, other cardiovascular events, and mortality.|June 2011|June 6, 2011|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583297||163146|
NCT00583947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-029|A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects|A Cumulative Dose Safety and Tolerability Crossover Study of Arformoterol Tartrate Inhalation Solution and Levalbuterol Hydrochloride Inhalation Solution in Pediatric Subjects (Aged 2 to 11 Years of Age) With Asthma||Sunovion|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|2 Years|11 Years|No|||January 2012|February 21, 2012|December 21, 2007|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00583947||163096|Sample size was determined outside of statistical considerations. All data recorded at/after Visit 8 for 6 subjects, misdosed with ARF 7.5mcg instead of ARF 15mcg in open-label period, were excluded from the planned efficacy, PK and safety analyses.
NCT00584246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome|Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome||University of South Florida|No|Withdrawn|November 2007|||August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|80 Years|No|||June 2008|June 2, 2008|December 21, 2007|Yes|Yes|Study withdrawn due to budget (personnel) limitations.|No||https://clinicaltrials.gov/show/NCT00584246||163073|
NCT00584259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614348-2|Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux|Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux||University of California, Davis|No|Completed|May 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|7|||Both|18 Years|N/A|No|||July 2010|July 12, 2010|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00584259||163072|
NCT00584272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715210-1|Retrospective Study on the Outcome of Cleft Palate Repair: Comparing US Surgical and Ethicon Suture Materials|Retrospective Study on the Outcome of Cleft Palate Repair: Comparing US Surgical and Ethicon Suture Materials||University of California, Davis|No|Active, not recruiting|March 2007|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|||Both|1 Year|10 Years|No|Probability Sample|UCDMC pediatric clinic|July 2012|July 3, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00584272||163071|
NCT00584909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060328016 (UAB 0604)|A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus|A Phase II Study of Paclitaxel and Carboplatin in Patients With Intermediate-Risk Adenocarcinoma of the Endometrium||University of Alabama at Birmingham|Yes|Terminated|March 2006|September 2011|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|19 Years|N/A|No|||January 2012|February 28, 2012|December 21, 2007|Yes|Yes|low accrual|No|September 21, 2011|https://clinicaltrials.gov/show/NCT00584909||163022|This study was terminated early due to slow accrual. 4 patients withdrew from the study due to side-effects from the treatment. All 9 patients were evaluable for toxicity and PFS.
NCT00585208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11-06-04|Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance|A Randomized, Double-Blind, Placebo-Controlled Study of Add-On Ramelteon in Ambulatory Bipolar I Disorder With Clinically Significant Sleep Disturbance||Lindner Center of HOPE|No|Terminated|December 2007|December 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||May 2013|May 8, 2013|December 20, 2007|Yes|Yes|sponsor terminated study|No||https://clinicaltrials.gov/show/NCT00585208||163000|
NCT00585221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00022172|Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients|A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients||University of Utah|Yes|Terminated|July 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|December 21, 2007|Yes|Yes|PI terminated at the recommendation of DSMC & IRB|No|June 15, 2012|https://clinicaltrials.gov/show/NCT00585221||162999|
NCT00585481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A07-006|Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children|Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children - BREVI (Brazilian Respiratory Virus in Premature Infants) Study||Abbott|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|310|Samples With DNA|white cells and nasopharyngal aspirate|Both|N/A|35 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Infants < 35 wGA born into or transferred to a participating hospital meeting all of the        inclusion criteria and none of the exclusion criteria specified in the protocol will be        selected to participate. Subjects will be identified in the NICU or newborn nursery and        enrolled in the study 24 hours prior to confirmed hospital discharge or up to 72 hours        after maternity hospital discharge date.|November 2011|December 15, 2011|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00585481||162979|
NCT00576563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02|Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer|Rectal Cancer: Determination of the Predictive Value by Use of FDG-PET-CT Scans and Blood Proteins for the Prognosis of Patients With Rectal Cancer||Maastricht Radiation Oncology|Yes|Active, not recruiting|March 2007|March 2016|Anticipated|January 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|January 27, 2016|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576563||163653|
NCT00576875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007678|Duke Conte Center for the Neuroscience of Depression in Late Life|Conte Centers for the Neuroscience of Depression||Duke University|No|Completed|August 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|795|Samples With DNA|Blood for DNA; Post-mortem brain tissue|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic; Outpatient psychiatry clinic; Inpatient psychiatry clinic;        Self-referral|February 2012|February 20, 2012|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576875||163629|
NCT00577499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84063|Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis|Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis||University of Arkansas|No|Terminated|October 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|adult cystic fibrosis clinic|March 2015|March 3, 2015|December 18, 2007||No|Recruitment was suboptimal|No||https://clinicaltrials.gov/show/NCT00577499||163585|
NCT00577746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0306-37|Clinical Impact of EUS in Staging NSCLC|The Clinical Impact of Endoscopic Ultrasound (EUS) in Staging Non-small Cell Lung Cancer (NSCLC)||Indiana University|No|Completed|June 2006|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|Potentially resectable lung cancer subjects see at thoracic oncology clinics and        gastroenterolgy lab.|September 2014|September 3, 2014|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577746||163567|
NCT00573547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-13860|Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease|A 12-Week Open-Label Trial of Once-Weekly Fluoxetine for the Treatment of Depression in Patients With End-Stage Renal Disease||Creighton University|No|Withdrawn|February 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|65 Years|No|||August 2011|August 15, 2011|December 12, 2007||No|Principal Investigator decided not to initiate the study.|No||https://clinicaltrials.gov/show/NCT00573547||163879|
NCT00573560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US PARACHUTE Protocol|Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients|A Feasibility Trial to Evaluate the VPD Implant System - Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease|PARACHUTE|CardioKinetix, Inc|Yes|Completed|December 2007|June 2014|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|74 Years|No|||July 2014|July 21, 2014|December 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00573560||163878|
NCT00573872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F050103003|A Study of Spinal Radiosurgery|A Phase II Study of Spinal Radiosurgery|RAD0408|University of Alabama at Birmingham|Yes|Active, not recruiting|April 2005|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|N/A|No|||January 2016|January 13, 2016|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573872||163856|
NCT00577993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM97-261|Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients|Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma||M.D. Anderson Cancer Center|No|Active, not recruiting|March 1998|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|210|||Both|N/A|76 Years|No|||September 2015|September 8, 2015|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00577993||163549|
NCT00576342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-47|Patient Preference Study|A Single Dose Patient Preference Study Comparison in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|December 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576342||163670|
NCT00578266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-006216|Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia|Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors||Mayo Clinic|Yes|Recruiting|February 2007|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|60 Years|No|||March 2016|March 23, 2016|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00578266||163529|
NCT00577200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABuv110507|Safety of Driving After Minor Surgery With Monitored Anesthesia Care|The Safety of Driving in Patients After Minor Surgery With Monitored Anesthesia Care|MACDrive|Rush University Medical Center|No|Active, not recruiting|January 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|625|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577200||163605|
NCT00577213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47573|Diagnosis of Hemangiomas and Vascular Malformations|Diagnosis of Hemangiomas and Vascular Malformations Using Non-invasive Imaging Devices||University of Arkansas|Yes|Completed|February 2007|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|56|||Both|N/A|75 Years|No|Non-Probability Sample|Subjects with vascular lesions from the patient populations at Arkansas Children's        Hospital (ACH) and the University of Arkansas for Medical Sciences (UAMS) will be        recruited for the study. Approximately 45 subjects from Arkansas Children's Hospital and        approximately 10 subjects from the University of Arkansas for Medical Sciences will be        recruited for a total of 55.|October 2012|October 25, 2012|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577213||163604|
NCT00573651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gardasil in JIA|Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis|Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis|CHASE|University Hospital Case Medical Center|Yes|Recruiting|November 2007|November 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Female|9 Years|26 Years|No|||June 2013|June 17, 2013|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573651||163872|
NCT00583570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB06-01323|Phosphorus Improvement Pilot Study|Phosphorus Improvement Pilot Study||MetroHealth Medical Center|No|Completed|May 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|279|||Both|18 Years|N/A|No|||March 2009|March 31, 2009|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583570||163125|
NCT00583622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0368|Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients|Bevacizumab Combined With High-Dose Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Patients With Advanced Epithelial Ovarian Cancer||M.D. Anderson Cancer Center|No|Terminated|December 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|70 Years|No|||April 2013|April 10, 2013|December 20, 2007||No|Slow Accrual|No|February 26, 2013|https://clinicaltrials.gov/show/NCT00583622||163121|
NCT00583635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB File # 2003-0119|Early Pregnancy Antioxidant Supplementation in the Prevention of Preeclampsia|Minimizing Early Pregnancy Oxidative Stress to Maximize Healthy Pregnancy Outcome: Reducing Preeclampsia and Reproductive Loss With Antioxidant-Rich Tablet Supplementation Initiated in the First Trimester||University of Mississippi Medical Center|No|Completed|May 2004|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|684|Samples Without DNA|Blood to be analyzed for various markers, then discarded, none to be retained.|Female|18 Years|44 Years|No|Non-Probability Sample|Patients cared for in the University of Mississippi Medical Center|October 2012|October 3, 2012|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00583635||163120|
NCT00584298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995A2101|Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Women With Irritable Bowel Syndrome to Evaluate Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide.||Novartis|No|Completed|January 2008|||April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|50|||Female|18 Years|65 Years|No|||May 2009|May 7, 2009|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584298||163069|
NCT00584597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAUMEEL_S_Krempl|A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis|The Safety and Efficacy of the Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis|TRAUMEEL|University of Oklahoma|Yes|Completed|October 2005|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 10, 2010|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584597||163046|
NCT00585234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00014137|Tools for the Objective Clinical Assessment of Pediatric Spinal Deformity|Tools for Objective Clinical Assessment of Pediatric Spinal Deformity and the Results of Surgical Intervention--Simultaneous Measurement of Sagittal and Coronal Balance and Symmetry With Digital Photography.||University of Utah|No|Withdrawn|December 2005|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Center|December 2014|December 8, 2014|December 21, 2007|Yes|Yes|Study has been withdrawn.|No||https://clinicaltrials.gov/show/NCT00585234||162998|
NCT00585247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2006-4815|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks|Aldara|University of California, Irvine|Yes|Completed|November 2006|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||August 2015|August 5, 2015|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585247||162997|
NCT00585260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0071|Mannitol Bronchoprovocation Challenge Ancillary Study/ACRN|Mannitol Bronchoprovocation Challenge Ancillary Study Protocol to Best Adjustment Strategy for Asthma Over Long Term||University of Wisconsin, Madison|No|Completed|December 2007|January 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Anticipated|320|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585260||162996|
NCT00585273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200703764|Antipsychotics and Blood Vessel Function|Cardiovascular Complications of First-line, Second-generation Antipsychotics||University of Iowa|No|Completed|September 2007|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|44|||Both|18 Years|50 Years|No|Non-Probability Sample|Thirty patients, 18 - 50 years of age, who are being started on a first-line,        second-generation, antipsychotic associated with weight gain (risperidone, olanzapine, or        quetiapine) for the treatment of an affective or psychotic disorder, will be invited to        participate. Participants must not have taken any of these antipsychotics or clozapine in        the preceding three months. Another twenty psychiatric controls not taking antipsychotic        medications will also be enrolled. Statistically, controls will serve primarily to compare        changes in flow-mediated dilation over time rather than for direct comparison of variables        between groups. Participation will be voluntary and initiated upon clinician or        self-referral.|December 2015|December 2, 2015|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585273||162995|
NCT00585494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2007-0199|Prevalence of Inpatient Hyperglycemia: Risks, Complications and Outcomes|Prevalence of Inpatient Hyperglycemia: Risks, Complications and Outcomes||University of Wisconsin, Madison|No|Completed|December 2007|August 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|302|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|University of Wisconsin orthopedic clinic patients ages 18 and older|January 2011|October 1, 2015|December 27, 2007||No||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00585494||162978|
NCT00585507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-016|Efficacy and Safety of 500mg of Fulvestrant|A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2004|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585507||162977|
NCT00576901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20561|A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.|"An Open Label Study to Assess the Effect of Neoadjuvant Treatment With Docetaxel + Xeloda + Avastin on Pathological Response Rate in Inflammatory or Locally Advanced Breast Cancer"||Hoffmann-La Roche||Terminated|November 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|N/A|No|||July 2014|July 17, 2014|December 18, 2007||No|The sample for statistical analysis of results could not be recruited within the specified    timeframe upon retirement of the original principal investigator.|No|May 16, 2014|https://clinicaltrials.gov/show/NCT00576901||163627|
NCT00576888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW07/226|Registry for Vascular Anomalies Associated With Coagulopathy|International Registry for Vascular Anomalies Associated With Coagulopathy|VAC|Medical College of Wisconsin|No|Recruiting|November 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|30|Samples With DNA|Buccal swab, tissue biopsy if available|Both|N/A|N/A|No|Non-Probability Sample|All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia        (MLT) or with a vascular anomaly with coagulopathy|March 2016|March 16, 2016|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576888||163628|
NCT00581048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#051158|Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics|Oxidant Stress and Allergic Asthma||Vanderbilt University|Yes|Completed|December 2006|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|43|||Both|18 Years|50 Years|No|||July 2012|July 12, 2012|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581048||163317|
NCT00581386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-04-254|Clinical Comparison of the Disposable Laryngeal Tube Suction, Esophageal Tracheal Combitube and Proseal Laryngeal Mask Airway|A Randomized Clinical Comparison Of The King Systems Disposable Laryngeal Tube Suction (LTS-D), The Esophageal Tracheal Combitube (ETC) And The Proseal Laryngeal Mask Airway (PLMA) In Adult Patients||The University of Texas Health Science Center, Houston|No|Completed|May 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|218|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|December 20, 2007||No||No|July 28, 2009|https://clinicaltrials.gov/show/NCT00581386||163291|
NCT00581659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N07-011a|Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions|Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions||National Advanced Driving Simulator|No|Recruiting|November 2007|March 2008|Anticipated|March 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|24|||Both|25 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who currently wear spherical contact lenses and believe they have little or no        astigmatism and are licensed drivers.|December 2007|December 19, 2007|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581659||163270|
NCT00581932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199901018|Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine|Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine||University of Iowa|No|Recruiting|October 2001|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|whole blood, saliva|Both|18 Years|65 Years|No|Non-Probability Sample|Psychiatric clinic, Inpatient Psychiatry unit|June 2012|June 22, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581932||163249|
NCT00581945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885B2204|Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-blind, Placebo Controlled, Exploratory Study to Assess the Safety and Efficacy of Multiple Doses of ACZ885 in Chronic Obstructive Pulmonary Disease (COPD) Patients||Novartis|No|Completed|January 2007|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|147|||Both|40 Years|80 Years|No|||June 2011|June 28, 2011|December 21, 2007|Yes|Yes||No|May 26, 2011|https://clinicaltrials.gov/show/NCT00581945||163248|
NCT00576615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-139|Propofol's Hypnotic and Memory Effects|CNS Targets of Propofol's Hypnotic and Memory Effects||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2002|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|MSKCC clinics|June 2015|June 1, 2015|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00576615||163649|
NCT00577226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32975|Shilla Growth Permitting Spinal Instrumentation System for Treatment of Scoliosis in the Immature Spine|Use of the Shilla Growth Permitting Spinal Instrumentation System/Technique for the Treatment of Scoliosis in the Immature Spine||Arkansas Children's Hospital Research Institute|No|Terminated|April 2005|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|1 Year|10 Years|No|Probability Sample|The patients whose data is observed are those who have undergone the shilla surgical        technique.|July 2010|July 21, 2010|December 18, 2007||No|IRB has requested additional information regarding IDE|No||https://clinicaltrials.gov/show/NCT00577226||163603|
NCT00577252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPING1424|Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis|Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis||Akron Children's Hospital|No|Completed|October 2007|April 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|13 Years|19 Years|No|Non-Probability Sample|Adolescents age 13-19 with CF at a single CF center.|November 2009|November 23, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577252||163602|
NCT00577538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060358|Prevalence of Lymphoma in IBD|Prevalence and Risk Factor for Lymphoproliferative Disease in Patients With Inflammatory Bowel Disease||Indiana University|No|Completed|April 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|7|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with both Inflammatory bowel disease and lymphoma over the last 30        years.|August 2015|August 7, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577538||163582|
NCT00577564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606-59|EUS-CPN: A Retrospective Review|Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN): A Retrospective Review of Safety||Indiana University|No|Completed|July 2006|December 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|All patients that underwent a EUS-CPN over a ten year period at Indiana University Medical        Center will be considered.|September 2012|September 11, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577564||163581|
NCT00573352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-OA-CTP1|Far Infrared Radiation Treatment for Osteoarthritis|Phase 1 Study to Determine the Efficacy of Using Energy Specific Far Infrared (FIR) Radiation for the Treatment of Arthritis and Other Related Diseases||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|September 2006|December 2008|Anticipated|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|N/A|N/A|No|||January 2009|January 2, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573352||163894|
NCT00573664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-10|The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section|The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section: A Randomized Placebo-controlled Trial||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Terminated|November 2007|February 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 29, 2009|December 12, 2007||No|Interim analysis showed a significant reduction in the pain scores|No||https://clinicaltrials.gov/show/NCT00573664||163871|
NCT00583661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCOR® Pediatric|Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device|A Prospective, Multi-center, Single Arm Study to Access the Safety and Probable Benefit of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device [EXCOR Pediatric]||Berlin Heart, Inc|Yes|Completed|May 2007|December 2011|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|N/A|16 Years|No|||March 2013|March 13, 2013|December 20, 2007|Yes|Yes||Yes|January 25, 2012|https://clinicaltrials.gov/show/NCT00583661||163118|
NCT00583960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715177-1|Office-based Radial Expansion Balloon Dilation of the Esophagus and Trachea|Office-based Radial Expansion Balloon Dilation of the Esophagus and Trachea||University of California, Davis|No|Withdrawn||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|UCDMC Otolaryngology Voice and Swallowing Center patients|June 2015|June 9, 2015|December 26, 2007||No|PI chose not to proceed with study.|No||https://clinicaltrials.gov/show/NCT00583960||163095|
NCT00584610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-211|The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots|The Effect of a Levonorgestrel-releasing Intrauterine Device Versus a Copper Containing Intrauterine Device on Coagulation Parameters||University of Vermont|Yes|Recruiting|December 2007|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||January 2010|January 15, 2010|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584610||163045|
NCT00584922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13165|Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation|Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation||University of Oklahoma|No|Recruiting|January 2007|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients 18-80 scheduled to undergo catheter ablation of atrial fibrillation|March 2011|March 2, 2011|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584922||163021|
NCT00584935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060213003|Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid|Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid||University of Alabama at Birmingham|No|Completed|January 2006|May 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|19 Years|N/A|No|||August 2011|August 5, 2011|December 26, 2007|Yes|Yes||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00584935||163020|Genentech closed trial before site was able to enroll 5 patients.
NCT00585533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI12555|A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer||University of Utah|Yes|Completed|June 2004|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|December 26, 2007|Yes|Yes||No|June 4, 2012|https://clinicaltrials.gov/show/NCT00585533||162975|
NCT00585520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609001804|Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues|Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues||Yale University|Yes|Completed|September 2007|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|60|||Both|18 Years|50 Years|No|||February 2014|February 10, 2014|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00585520||162976|
NCT00577174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DK080658|Mitochondrial Function in Pediatric Obesity|Mitochondrial Function in Pediatric Obesity||Massachusetts General Hospital|No|Active, not recruiting|June 2007|October 2012|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Case Control||2|Anticipated|110|Samples With DNA|Whole blood, serum, white blood cells|Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy and obese children from clinical practices and the local community|April 2012|April 27, 2012|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577174||163607|
NCT00577187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712.0|Placement of CS/LV Pacing Leads With EnSite NavX Guidance|Placement of Coronary Sinus/Left Ventricular Leads With EnSite NavX Guidance||St. Jude Medical|No|Withdrawn|June 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||June 2012|June 11, 2012|December 18, 2007||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00577187||163606|
NCT00581074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060035|Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults|Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults|GJW|Vanderbilt University|No|Completed|March 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Anticipated|90|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00581074||163315|
NCT00576056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-047|Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC|Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Plus Oral Sorafenib (BAY 43-9006, Nexavar®) for Unresectable Hepatocellular Carcinoma (HCC)||University of Pittsburgh|Yes|Terminated|January 2008|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|100 Years|No|||December 2015|December 3, 2015|December 14, 2007|Yes|Yes|Bayer Healthcare is no supplying the study drug|No||https://clinicaltrials.gov/show/NCT00576056||163691|
NCT00581399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hs#2006-5196|A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery|A Prospective, Randomized, Multicenter Clinical Study on the High Vacuum Body Cavity Drainage Systems Following Open Heart Surgery|NO-NUMO|University of California, Irvine|Yes|Completed|September 2006|September 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|94|||Both|18 Years|N/A|No|||October 2011|October 27, 2011|December 20, 2007||No||No|April 25, 2011|https://clinicaltrials.gov/show/NCT00581399||163290|
NCT00575744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS 04959|Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation|Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation||University of Arkansas|No|Completed|December 1998|October 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|699|||Female|18 Years|N/A|No|||July 2013|July 24, 2013|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575744||163714|
NCT00576030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/061/06|Action of Caffeinated and Decaffeinated Espresso on Autonomic Function|Short-term Autonomic Effects of Caffeinated and Decaffeinated Espresso in Young Healthy Individuals||Charite University, Berlin, Germany||Terminated|January 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|77|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|July 2, 2010|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00576030||163693|
NCT00576043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endosim|Effect of Virtual Endoscopy Simulator Training on Real Patient Endoscopy|Effect of Virtual Endoscopy Simulator Training on Real Patient Endoscopy: A Randomized, Controlled Trial|endosim|Medical University of Vienna|No|Completed|March 2004|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|24|||Both|N/A|N/A|No|||March 2008|March 25, 2008|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576043||163692|
NCT00576329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000517|Topical 0.4% Ketorolac and Vitreoretinal Surgery|Topical 0.4% Ketorolac for the Inhibition of Miosis During Vitreoretinal Surgery: a Randomized, Placebo-controlled, Double-masked Study||Emory University|No|Completed|November 2006|October 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576329||163671|
NCT00577577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSM-110-1001|Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1|A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1||Insmed Incorporated|Yes|Active, not recruiting|December 2007|March 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|60|||Both|21 Years|65 Years|No|||July 2008|July 21, 2008|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577577||163580|
NCT00573365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 06-46|LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis|LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis: A Prospective, Randomized, Controlled Study||University of California, Irvine|Yes|Completed|March 2007|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|December 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00573365||163893|
NCT00573924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-06-00014|Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers|Prospective Randomized Comparison of the Effect of Frequent Oral Dosing Versus Constant IV Infusion of Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers||University of Southern California|No|Completed|February 2006|December 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||February 2011|February 4, 2011|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573924||163852|
NCT00584285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709737|Corneal Topographer Fluorescein Patterns|Objective and Subjective Correlation Between Clinical Fluoroscein Patterns and Theoretical Patterns Using the Medmont Corneal Topographer||University of Iowa|No|Recruiting|November 2007|||December 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|0|||Both|18 Years|N/A|No|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00584285||163070|
NCT00584311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6123-G62368|MRI and Ultrasound Findings in Patients With Gout and Normal Plain Radiographs|||University of South Florida||Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|18 Years|80 Years|No|||June 2008|June 6, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584311||163068|
NCT00584324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB No: 12634|Depth of Anesthesia on Implicit Memory|The Effect of Depth of Anesthesia on Implicit Memory||University of Oklahoma|Yes|Completed|March 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|70|||Both|55 Years|90 Years|No|||February 2012|February 1, 2012|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00584324||163067|
NCT00584337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-091|Coronary CT Angiography as the Primary Initial Method of Evaluating Patients With Subacute Chest Pain (CT PRIME)|Coronary CT Angiography as the Primary Initial Method of Evaluating Patients With Subacute Chest Pain (CT PRIME)|CTPRIME|William Beaumont Hospitals|Yes|Withdrawn|January 2008|June 2010|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Volunteers over 18 years of age; both genders; referred from participating cardiologist's        offices|April 2009|April 21, 2009|December 20, 2007||No|It was decided to not proceed with the study at this time.|No||https://clinicaltrials.gov/show/NCT00584337||163066|
NCT00584350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-70-M5|Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP|Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP|NEPHRON|Université de Sherbrooke|Yes|Recruiting|November 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|330|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00584350||163065|
NCT00584623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715188-1|Simultaneous Fluoroscopic and Endoscopic Examination of the Oropharyngeal Phase of Deglutition|Simultaneous Fluoroscopic and Endoscopic Examination of the Oropharyngeal Phase of Deglutition||University of California, Davis|No|Withdrawn|March 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Adult clinic population in the UCD Otolaryngology Clinic|December 2015|December 6, 2015|December 26, 2007||No|Did not find interested patients.|No||https://clinicaltrials.gov/show/NCT00584623||163044|
NCT00584961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281161|BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder|BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder|BIMET|Pfizer|No|Completed|May 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|553|||Both|18 Years|N/A|No|Probability Sample|Community sample. Patients >17 years older with diagnosis of Bipolar Disorder (DSM-IV TR)|February 2010|February 9, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00584961||163018|
NCT00585286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5328|Fractional Resurfacing Device for Treatment of Acne Scarring|Evaluation of a Novel Fractional Resurfacing Device for the Treatment of Acne Scarring||University of California, Irvine|Yes|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||December 2013|December 13, 2013|December 26, 2007|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00585286||162994|There were no major limitations to this trial. The trial was completed without any technical problems or major complications.
NCT00585299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0212023115|Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD|Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD||Yale University|No|Completed|October 2006|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|10 Years|21 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00585299||162993|
NCT00585546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HARPS|Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure|Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.|HARPS|University of Michigan|Yes|Recruiting|July 2007|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|October 27, 2008|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00585546||162974|
NCT00580567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-00-004|Impulsivity in Pathological Gambling|Impulsivity in Pathological Gambling: A Cross Sectional Analysis on Tests of Impulsivity Between Pathological Gamblers and a Non-pathological Control Group.||University of California, Los Angeles|No|Completed|March 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|June 2013|June 3, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00580567||163354|
NCT00580580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-03-FB|Detection of Coronary Stenosis With Intravenous Microbubbles|The Detection of Coronary Stenosis With Intravenous Mircrobubbles and Contrast Pulse Sequence Low Mechanical Index Imaging||University of Nebraska|No|Withdrawn|February 2012|March 2014|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|0|||Both|19 Years|N/A|No|||July 2012|July 19, 2012|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580580||163353|
NCT00580827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA013441|Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers|Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers||Yale University|Yes|Completed|September 2003|||March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|126|||Both|18 Years|65 Years|No|||December 2007|December 25, 2007|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00580827||163334|
NCT00538031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03092|Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Randomized Pilot Trial of Oral Cyclophosphamide Versus Oral Cyclophosphamide With Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||City of Hope Medical Center|Yes|Active, not recruiting|December 2003|||July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|27|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|October 1, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00538031||166537|
NCT00538330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #93-107|Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer|||King Faisal Specialist Hospital & Research Center||Active, not recruiting|September 2007|September 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|2000|||Both|N/A|N/A|No|||December 2011|December 11, 2011|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538330||166514|
NCT00538044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gan1|Simvatstatin Used to Treat Pulmonary Hypertension|the Clinical Research Using Simvastatin as a Medication to Treat Advanced Secondary Pulmonary Hypertension||Capital Medical University|Yes|Not yet recruiting|January 2009|January 2012|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||||||Both|12 Years|70 Years|No|||September 2007|October 1, 2007|October 1, 2007||||No||https://clinicaltrials.gov/show/NCT00538044||166536|
NCT00538928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS 4012-001-07|Extrapulmonary Interventional Ventilatory Support in Severe Acute Respiratory Distress Syndrome (ARDS)|Extrapulmonary Interventional Ventilatory Support for Lung Protection in Severe Acute Respiratory Distress - a Prospective Randomized Multi Centre Study|Xtravent|University of Regensburg|Yes|Completed|September 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2009|March 1, 2011|October 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00538928||166469|
NCT00539266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07.058|Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia|Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients|ABC|Leiden University Medical Center|No|Recruiting|October 2007|October 2012|Anticipated|October 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|108|||Both|16 Years|N/A|No|||October 2007|July 5, 2011|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00539266||166444|
NCT00539279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-009-07S|Treatment of Older Veterans With Chronic Posttraumatic Stress Disorder|Treatment of Older Veterans With Chronic Posttraumatic Stress Disorder||VA Office of Research and Development|No|Completed|March 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Male|60 Years|N/A|No|||August 2015|August 11, 2015|October 2, 2007||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT00539279||166443|Early termination leading to smaller numbers of subjects analyzed at post-treatment and follow-up; Results generalize only to older male combat veterans who were treatment-seeking for PTSD
NCT00539240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-022-04F|Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI|Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI||VA Office of Research and Development|Yes|Completed|April 2006|November 2011|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|236|||Both|18 Years|80 Years|No|||July 2014|July 29, 2014|October 3, 2007||No||No|February 7, 2014|https://clinicaltrials.gov/show/NCT00539240||166446|Recruitment challenges, including difficulty finding patients who "fail" PPI but had not already been prescribed doubled dose. Necessitated a no-cost extension to complete recruitment
NCT00539253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06108|Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI|Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization Using Functional Triple-Phase MultiHance-Enhanced MRI||Sidney Kimmel Comprehensive Cancer Center|No|Completed|September 2007|December 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|18 Years|80 Years|No|||May 2014|May 27, 2014|October 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00539253||166445|
NCT00539968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04467|A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)|An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel||Merck Sharp & Dohme Corp.|No|Terminated|June 2007|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|October 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00539968||166392|
NCT00540332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070201|A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy|A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy||Swedish Orphan Biovitrum||Withdrawn|October 2007|September 2008|Anticipated|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||January 2009|February 27, 2009|October 4, 2007|||The 20070201 study was terminated based on evaluation of Palifermin solid tumor data.|No||https://clinicaltrials.gov/show/NCT00540332||166364|
NCT00540618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP082|A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis|A Phase II Randomized, Placebo-Controlled, Double-Blind Study of MEDI-507, A Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis.||MedImmune LLC|No|Completed|September 2001|July 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|420|||Both|18 Years|65 Years|No|||November 2007|November 27, 2007|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00540618||166342|
NCT00536055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC - 07 - BC-07309|Dyadic Coping in Breast and Prostate Cancer Patients and Their Spouses|Dyadic Coping in Breast and Prostate Cancer Patients and Their Spouses - A Pilot Stdy||Tel-Aviv Sourasky Medical Center||Not yet recruiting|October 2007|August 2008|Anticipated|||N/A|Observational|Observational Model: Defined Population, Time Perspective: Longitudinal|||Anticipated|40|||Both|18 Years|N/A|No|||September 2007|September 26, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536055||166687|
NCT00536068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGWR0206|Platelet Inhibition by Aspirin, Acetaminophen and NSAID|||Kantonsspital Graubünden|No|Completed|August 2006|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|11|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2007|September 27, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536068||166686|
NCT00558545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-202|A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer|A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer||Aegera Therapeutics|No|Terminated|November 2007|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||November 2009|November 30, 2009|November 13, 2007|Yes|Yes|Avastin approved for first-in-line treatment.|No||https://clinicaltrials.gov/show/NCT00558545||165003|
NCT00558831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU1884|Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris|A Split-face, Paired-comparison Pilot Study to Evaluate the Safety and Efficacy of Topical Benzoyl Peroxide 2.5% Cream Alone Versus Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion for Mild to Moderate Acne Vulgaris||Northwestern University|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|35 Years|No|||January 2011|January 12, 2011|November 13, 2007||No||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00558831||164983|
NCT00555867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033GR/0002|Patient's Anastrozole Compliance to Therapy Programme|A Randomised in Practice Evaluation of the Influence of Patient's Understanding of Her Disease and Therapy on Persistence and Compliance to Adjuvant Therapy for Post-menopausal Hormone Sensitive Early Breast Cancer|PACT|AstraZeneca|No|Terminated|October 2006|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4923|||Female|18 Years|N/A|No|Probability Sample|Postmenopausal women with hormone receptor positive primary breast cancer scheduled for        upfront adjuvant endocrine treatment with anastrozole according to the current standard        medical practice|December 2011|December 22, 2011|November 7, 2007||No|High drop-out rate leads to the conclusion: not enough data will be available to perform    proper analyses of data collected after follow-up month 24 visit|No||https://clinicaltrials.gov/show/NCT00555867||165196|
NCT00555880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD426-404|Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension|A Multi-Center, Double-Blind, Randomized, Placebo-controlled, Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Subjects With Moderate to Severe Neurogenic Orthostatic Hypotension||Shire||Completed|September 2004|March 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|N/A|No|||June 2010|May 5, 2015|November 8, 2007||||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00555880||165195|
NCT00559429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0467|Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer|Phase I Trial With a Combination of Docetaxel +153 Sm-EDTMP (Samarium 153) in Patients With Hormone-Refractory Prostate Cancer|Tax-Sam|Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|December 2004|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||December 2008|December 16, 2008|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00559429||164939|
NCT00554918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-TRAPEZE-2100|Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy|A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) Plus Strontium-89 in Hormone Refractory Prostate Cancer Metastatic to Bone.||National Cancer Institute (NCI)||Completed|February 2005|June 2013|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|300|||Male|18 Years|N/A|No|||April 2008|August 6, 2013|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554918||165268|
NCT00555542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2006-005|An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis|B Cell Depletion Therapy in Rheumatoid Arthritis: An Analysis of Peripheral Blood T Cell Subsets||Chinese University of Hong Kong|No|Completed|July 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|70 Years|No|||May 2008|May 7, 2008|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555542||165221|
NCT00555841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST 03-103|Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue|Safety and Efficacy of Oral Acetyl-l-carnitine (ALC) in Non-anemic Potentially Curable Breast Cancer Subjects Undergoing Adjuvant Radiation Therapy Who Have Moderate to Severe Fatigue||Sigma-Tau Research, Inc.|Yes|Terminated|March 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|N/A|No|||August 2012|August 27, 2012|November 7, 2007|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00555841||165198|
NCT00555854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|028|Self-care Behaviour Treatment in Patients With Diabetes - a Randomised Controlled Trial|Can a Behavioural Modifying Intervention Increase the Self-care and the Effect of the Diabetes Treatment in Chronically Ill Patients With Diabetes||Odense University Hospital|No|Completed|December 2005|November 2010|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|349|||Both|18 Years|N/A|No|||May 2008|February 23, 2011|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00555854||165197|
NCT00537745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18816/6075/DP/US|Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders|Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders-a Pilot Study||Pacific Institute for Research and Evaluation|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|September 28, 2007||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00537745||166559|Fourteen subjects were consented, and began the screening process. Two subjects did not meet entry criteria and 1 withdrew consent prior to injection. Of the remaining 11 subjects, 7 received 3, 2 received 2, and 2 received 1 injection(s).
NCT00537758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK049587|Treatment for Obesity and Binge Eating Disorder|Treatment for Obesity and Binge Eating Disorder||Yale University||Completed|July 2002|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|125|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2007|September 27, 2007|September 27, 2007||||No||https://clinicaltrials.gov/show/NCT00537758||166558|
NCT00538629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281171|Noninterventional Study in Bipolar Disorder and Schizophrenia With Zeldox|Noninterventional Study (NIS) in Patients With Bipolar Disorder (Manic or Mixed Episodes) and Schizophrenia Undergoing Treatment With Zeldox||Pfizer|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|471|||Both|18 Years|N/A|No|Probability Sample|Psychiatric outpatients|July 2009|August 21, 2009|October 1, 2007||No||No|April 30, 2009|https://clinicaltrials.gov/show/NCT00538629||166491|In this noninterventional study, patients received Zeldox in compliance with the Summary of Product Characteristics (SPC) and based solely on therapeutic need. Data were included from 2 patients <18 years; the SPC does not address this age group.
NCT00538954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEdinburgh|Optimised Recovery With Accelerated Nutrition and GI Enhancement|A Randomised Controlled Trial of Optimised Surgical Recovery: the Potential Synergy Between Enhanced Gastrointestinal Motility and Oral Nutritional/ Metabolic Support|ORANGE|University of Edinburgh|No|Completed|August 2006|August 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|64|||Both|18 Years|80 Years|No|||October 2007|November 4, 2010|October 2, 2007||||No||https://clinicaltrials.gov/show/NCT00538954||166467|
NCT00538291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05033|Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment|CA225103: A Phase II Study of a Combination of Cetuximab and Capecitabine in Patients With Metastatic Colorectal Cancer After Progression on Previous Fluoropyrimidine Containing Therapy||City of Hope Medical Center||Terminated|August 2005|||February 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|October 1, 2007|Yes|Yes|Study was terminated early due to lack of efficacy.|No|June 12, 2014|https://clinicaltrials.gov/show/NCT00538291||166517|Study was terminated due to a lack of efficacy (less than 2 of 13 patients responded to treatment in the first stage of a Simon's two stage design).
NCT00538304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-035|A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|September 28, 2007|Yes|Yes||No|September 19, 2011|https://clinicaltrials.gov/show/NCT00538304||166516|
NCT00543998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2002-2672|Near Infrared Transillumination of the Paranasal Sinuses|Near Infrared Transillumination of the Paranasal Sinuses||University of California, Irvine|No|Completed|May 2003|June 2005|Actual|June 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Both|15 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic,|August 2015|August 5, 2015|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00543998||166085|
NCT00538941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1124_Chocolate_CHF|Effects of Chocolate in Patients With Chronic Heart Failure|Effects of Swiss Dark Chocolate on Endothelial and Baroreceptor Function and Markers of Inflammation in Patients With Chronic Heart Failure||University of Zurich|No|Completed|November 2005|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|30 Years|80 Years|No|||October 2009|October 27, 2009|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538941||166468|
NCT00544011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564118|Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma||National Cancer Institute (NCI)||Recruiting|April 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|47|||Both|18 Years|80 Years|No|||July 2009|June 23, 2011|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544011||166084|
NCT00544518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bfls071012|Impact of Benfluorex Versus Metformin on Glucose Control and Insulin Secretion in Chinese Type 2 Diabetic Patients|||Fourth Military Medical University|Yes|Active, not recruiting|October 2007|October 2008|Anticipated|September 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||May 2008|May 21, 2008|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544518||166045|
NCT00544531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76/05|The Cytogenetic Constitution of Embryos Resulting From Immature Oocytes (M1)|||Assaf-Harofeh Medical Center|No|Completed|October 2005|March 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|23907|||Female|25 Years|35 Years|Accepts Healthy Volunteers|||September 2005|October 15, 2007|October 14, 2007||||No||https://clinicaltrials.gov/show/NCT00544531||166044|
NCT00544817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CNS 09|Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme|A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme||SCRI Development Innovations, LLC|No|Completed|April 2007|August 2010|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|October 15, 2007||No||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00544817||166023|
NCT00554944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-409|Intraoperative Goal-directed Fluid Management|Intraoperative Goal-directed Fluid Management in Lean and Obese Patients||Outcomes Research Consortium|Yes|Terminated|June 2007|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|85 Years|No|||September 2009|September 17, 2009|November 6, 2007||No|not progressing as anticipated|No||https://clinicaltrials.gov/show/NCT00554944||165267|
NCT00555230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2007-004|Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis|Effects of HMG-coA Reductase Inhibitor on Progression of Carotid Intima-Media Thickness and Arterial Stiffness in Rheumatoid Arthritis||Chinese University of Hong Kong|No|Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||December 2008|January 26, 2011|November 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00555230||165245|
NCT00555243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW IRB 042006-034|Laparoscopic Simulator Training and Its Impact on Surgical Education|An Evaluation of Validated Laparoscopic Skills Simulators and the Impact on Operating Room Performance||University of Texas Southwestern Medical Center|No|Completed|August 2005|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|108|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2007|January 18, 2013|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00555243||165244|
NCT00555529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9022006|Systemic Endothelial Abnormalities in COPD|Systemic Endothelial Abnormalities in COPD Measured by Radial Artery Applanation Tonometry (RAAP)||Imperial College London||Active, not recruiting|January 2006|November 2008|Anticipated|||N/A|Observational|N/A||2|Anticipated|36|||Male|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Smokers, COPD|November 2007|November 7, 2007|November 7, 2007||||No||https://clinicaltrials.gov/show/NCT00555529||165222|
NCT00555256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0562 / 201101709|A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)|SU/Rapamycin|Washington University School of Medicine|Yes|Completed|November 2007|December 2012|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|November 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00555256||165243|
NCT00555269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB vs IFCG|Membrane Blue Versus Infracyanine Green|Comparison of Macular Function and Visual Fields After Membrane Blue or Infracyanine Green Staining in Vitreoretinal Surgery||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|October 2004|December 2005|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|30|||Both|40 Years|90 Years|No||Patients with a macular pucker or a macular hole, without any other retinal disease|April 2009|April 20, 2009|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555269||165242|
NCT00556777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574074|Radiation Therapy During Surgery in Treating Older Women With Stage I Breast Cancer|Phase 2 Study Evaluating the Feasibility and the Reproducibility of Concentrated Radiotherapy and Focalized Electrontherapy During Surgery for the Treatment of Older Patients With Breast Cancer||National Cancer Institute (NCI)||Completed|January 2004|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|42|||Female|65 Years|N/A|No|||December 2007|May 12, 2011|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556777||165129|
NCT00538057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZA105871|Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects|A Randomised, Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Pharmacodynamics and Pharmacokinetics of GW685698X and GW642444M When Administered Separately and in Combination as a Single Dose From a Novel Dry Powder Device in Healthy Subjects||GlaxoSmithKline|No|Completed|October 2007|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|October 1, 2007||||No||https://clinicaltrials.gov/show/NCT00538057||166535|
NCT00538317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-452|GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction|Comparison of Administration of Tirofiban in the Ambulance or in the Cathlab in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty|AGIR2|Hospices Civils de Lyon|Yes|Completed|July 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|No|||November 2008|November 21, 2008|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538317||166515|
NCT00542399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc004543ctil|Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections|Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections in Children and Adolescence With Type 1 Diabetes Mellitus.||Rabin Medical Center|No|Completed|November 2007|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|18 Years|No|||July 2010|November 1, 2011|October 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00542399||166206|
NCT00543608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICLA-20-PNE1|Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia|Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens||Arpida AG|Yes|Terminated|November 2007|May 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|October 11, 2007|||Trial terminated due to financial resource limitations|No||https://clinicaltrials.gov/show/NCT00543608||166114|
NCT00543621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Welltech Study|An Intervention Program to Control Diabetes|An Intervention Program to Control Diabetes||Abbott Nutrition|No|Completed|May 2005|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|150|||Both|18 Years|70 Years||||October 2007|October 12, 2007|October 12, 2007||||No||https://clinicaltrials.gov/show/NCT00543621||166113|
NCT00539617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#064511|Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery|A Single-Arm, Phase II Study of Tarceva Plus FOLFOX6 in Patients With Unresectable or Metastatic Cancer of Esophagus or Gastroesophageal Junction||University of California, San Francisco|Yes|Terminated|October 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|October 2, 2007|Yes|Yes|For slow accrual|No|September 12, 2012|https://clinicaltrials.gov/show/NCT00539617||166418|Early termination leading to small numbers of subjects analyzed.
NCT00539630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976F_3501|TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN|||Sanofi||Completed|November 2002|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|86|||Both|18 Years|70 Years|No|||October 2007|October 3, 2007|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00539630||166417|
NCT00544232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 49|Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)|Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF ± Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage ± Darbepoetin Alfa in Patients With Primary Breast Cancer||German Breast Group|Yes|Completed|August 2002|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|720|||Female|18 Years|65 Years|No|||February 2016|February 12, 2016|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544232||166067|
NCT00544245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437846|Is Monitoring Activity Important for Short- and Long-term Weight Loss?||UHPAWS|University of Hawaii|No|Completed|October 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|83|||Both|30 Years|60 Years|No|||August 2011|August 14, 2011|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544245||166066|
NCT00544284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04032|Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment|A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors||City of Hope Medical Center||Completed|January 2005|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|October 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544284||166063|
NCT00544258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-013|Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005|A Phase I, Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005, When Applied as 0.05% PEP005 Topical Gel to a 100 cm2 (5 cm x 20 cm) Contiguous Actinic Keratosis(AK) Treatment Area on the Extensor (Dorsal Aspect) Forearm.||Peplin|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|N/A|No|||May 2008|February 11, 2015|October 14, 2007||||No||https://clinicaltrials.gov/show/NCT00544258||166065|
NCT00544271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263855/035|Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.|Phase IIIb Study to Evaluate Immunogenicity, Antibody Persistency & Reactogenicity of DTPa - INFANRIX & dTpa - BOOSTRIX Vaccines Admnd to Healthy Children Previously Primed With 3 Doses of DTPa Vaccine Compared to Placebo (HAVRIX®JUNIOR).||GlaxoSmithKline|No|Terminated|May 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Actual|720|||Both|18 Months|20 Months|Accepts Healthy Volunteers|||September 2011|September 29, 2011|October 15, 2007||||No||https://clinicaltrials.gov/show/NCT00544271||166064|
NCT00544544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000751|Riluzole in the Treatment of Bipolar Depression|Riluzole in the Treatment of Bipolar Depression: A Study of the Association Between Clinical Response and Change in Brain Glutamate Levels as Measured by Proton Magnetic Resonance Spectroscopy||Mclean Hospital|No|Completed|June 2007|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||March 2012|March 9, 2012|October 12, 2007|No|Yes||No|June 24, 2010|https://clinicaltrials.gov/show/NCT00544544||166043|
NCT00544557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4463|Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis|Observational Study Of The Use Of Enbrel (Registered) (Etanercept) In Routine Clinical Practice To Treat Ankylosing Spondylitis (as) Patients: An Effectiveness, Safety, And Health Economic Evaluation||Pfizer|No|Completed|October 2007|May 2014|Actual|May 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1715|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an established diagnosis of Ankylosing Spondylitis|April 2015|April 23, 2015|October 15, 2007||No||No|April 23, 2015|https://clinicaltrials.gov/show/NCT00544557||166042|
NCT00559169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN-TWH-VER-001|Verapamil and Catamenial Epilepsy|Study of Verapamil in Refractory Catamenial Epilepsy||University Health Network, Toronto|No|Withdrawn|February 2009|December 2010|Anticipated|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|60 Years|No|||November 2007|April 7, 2010|November 14, 2007|||protocol changed and a new study using verapamil in epilepsy will be started in the near    future|No||https://clinicaltrials.gov/show/NCT00559169||164958|
NCT00559182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8033-001|A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)|A Phase I Dose Escalation Study of MK-8033 in Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|December 2007|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|November 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00559182||164957|
NCT00565487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU 25709|Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer|Phase I Study of Combination of Capecitabine and Erlotinib Concurrent With Radiotherapy in Patients With Non-Operable Locally Advanced Pancreatic Cancer||Penn State University|Yes|Active, not recruiting|December 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|80 Years|No|||November 2012|November 30, 2012|November 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00565487||164478|
NCT00565500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|635-IFL-0508-017|Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin|A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.||G. d'Annunzio University|No|Completed|April 2003|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|75 Years|No|||November 2007|November 29, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565500||164477|
NCT00565513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2001|Cryptorchidism: Impact of in Utero Exposure to Xenobiotics With Hormonal Action|Cryptorchidism: Impact of in Utero Exposure to Xenobiotics With Hormonal Action and Multidisciplinary||Centre Hospitalier Universitaire de Nice|No|Completed|April 2002|April 2006|Actual|||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|283|||Male|N/A|1 Year|Accepts Healthy Volunteers|||November 2007|November 29, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00565513||164476|
NCT00554957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0930-AE|Perception of Musculoskeletal Injury in Professional Dancers|Perception of Musculoskeletal Injury in Professional Dancers, an International Comparison||University Health Network, Toronto|No|Completed|April 2007|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Actual|266|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Professional Dancers|February 2009|February 12, 2009|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00554957||165266|
NCT00556153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB# 04-09011|[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children|[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children||Children's Hospital Medical Center, Cincinnati|No|Withdrawn|February 2013|February 2013|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|5 Years|15 Years|No|Non-Probability Sample|Children ages 5-15 years, with brain tumors|January 2013|January 7, 2013|November 7, 2007|No|Yes|No participants ever enrolled.|No||https://clinicaltrials.gov/show/NCT00556153||165174|
NCT00566098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0770|Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma|Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma||Sidney Kimmel Comprehensive Cancer Center||Completed|November 2007|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|120 Years|No|||October 2015|October 30, 2015|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566098||164433|
NCT00566111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06T-812|Ceftriaxone in the Management of Bipolar Depression|Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression||Yale University|Yes|Recruiting|September 2007|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||October 2009|October 14, 2009|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566111||164432|
NCT00556452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.055|Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen|Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen||University of Michigan Cancer Center|No|Completed|October 2007|September 2012|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|N/A|70 Years|No|||January 2015|January 2, 2015|November 8, 2007|Yes|Yes||No|November 26, 2014|https://clinicaltrials.gov/show/NCT00556452||165151|
NCT00566735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001051|The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning|The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning|Galantamine|Massachusetts General Hospital|No|Completed|July 2004|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|90 Years|No|||November 2012|November 2, 2012|December 3, 2007||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00566735||164386|The limitations of this study include a small sample size, absence of an optimal galantamine dose determination, and the inclusion of a heterogenous population including MDD, bipolar disorder, and schizoaffective order.
NCT00542711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curcumol-HMO-CTIL|Bio-availability of a New Liquid Tumeric Extract|Liquid Tumeric Extract for Increasing Bio-availability of Curcumin in the Human Body: Pharmacokinetic Study.||Hadassah Medical Organization||Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|October 10, 2007||No|Technical difficulties|No||https://clinicaltrials.gov/show/NCT00542711||166182|
NCT00542724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject™-06J|An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus|An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus||Biodel|No|Completed|September 2006|||July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|462|||Both|18 Years|70 Years|No|||July 2015|July 30, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542724||166181|
NCT00542412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIL_CA1_401|CARE Canadian ALS Riluzole Evaluation|Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls||Sanofi|No|Completed|January 2001|December 2004|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|414|||Both|18 Years|75 Years|No|||October 2007|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542412||166205|
NCT00543309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0735070N|Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery|Impact of Empiric Nesiritide or Milrinone Infusion on Early Postoperative Recovery Following Fontan Surgery: a Randomized, Double-blind, Placebo-controlled Clinical Trial||Children's Hospital Boston|Yes|Terminated|October 2007|July 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|106|||Both|N/A|N/A|No|||November 2013|November 1, 2013|October 10, 2007|Yes|Yes|DSMB recommended termination based on interim outcomes analysis|No||https://clinicaltrials.gov/show/NCT00543309||166137|
NCT00543101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-142|Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors|A Randomized, Controlled Trial to Evaluate the Efficacy of Substituting Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors in Individuals With Virologic Suppression for at Least 12 Weeks|DVD|Community Research Initiative of New England|Yes|Completed|October 2007|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|October 11, 2007||No||No|April 12, 2010|https://clinicaltrials.gov/show/NCT00543101||166152|The foremost problem was the small number of participants enrolled. By the time we were open for enrollment, most clinicians in the community had already switched their patients from dual boosted regimens to darunavir/ritonavir.
NCT00543348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHIRB4244|RCT of the Cutting Balloon Versus a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses|A Randomised-Controlled Study Comparing the Peripheral Cutting BalloonTM (Boston Scientific Co.) With a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses||Henry Ford Health System|No|Recruiting|September 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||October 2007|October 11, 2007|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00543348||166134|
NCT00543049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 2.11|Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor|Phase II Trial in Platinum-refractory Ovarian Cancer: A Randomized Multicenter Trial With SU11248 to Evaluate Dosage, Tolerability, Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Monotherapy||AGO Study Group|No|Completed|September 2007|||June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Female|18 Years|N/A|No|||March 2014|March 6, 2014|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00543049||166156|
NCT00543062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-001-102|Staccato Prochlorperazine Thorough QT/QTc Study|Thorough QT/QTc Study of Staccato® Prochlorperazine for Inhalation in Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|November 5, 2008|October 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00543062||166155|
NCT00543075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPK104|Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function|A Phase I Pharmacokinetic Study of Genasense® in Subjects With Normal Renal Function and Mildly and Moderately Impaired Renal Function||Genta Incorporated|No|Completed|May 2006|September 2009|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|23|||Both|18 Weeks|N/A|Accepts Healthy Volunteers|||June 2008|March 11, 2012|October 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00543075||166154|
NCT00543322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHFJ-100008|PET Study of the Nicotinic Receptors in Human|PET Study of the Nicotinic Receptors in Human : Brain Distribution and Quantification||Commissariat A L'energie Atomique||Terminated|July 2001|July 2006|Actual|||Phase 1/Phase 2|Observational|Time Perspective: Prospective|||||||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2007|October 11, 2007|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00543322||166136|
NCT00543335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0352|Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer|Phase I Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Terminated|January 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|October 11, 2007||No|Lack of Accrual.|No||https://clinicaltrials.gov/show/NCT00543335||166135|
NCT00543634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713E1-1138|Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women|Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin®/MPA (PREMPRO®) and MPA Suspension (Provera®) in Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||June 2010|June 17, 2010|October 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00543634||166112|
NCT00543647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEN 0201|Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People|A Double-blind, Cross-over, Placebo-controlled Study Evaluating the Effect of Fenofibrate 160 mg Tablets on Glomerular Filtration Rate and Other Renal Function Test in Healthy Subjects||Solvay Pharmaceuticals|No|Completed|August 2002|March 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2007|January 16, 2015|October 12, 2007||||No||https://clinicaltrials.gov/show/NCT00543647||166111|
NCT00543660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIIOS.1998.04|Descemet Stripping (Automated) Endothelial Keratoplasty (DSEK or DSAEK)|Descemet Stripping (Automated) Endothelial Keratoplasty (DSEK or DSAEK)|DSAEK|Netherlands Institute for Innovative Ocular Surgery|Yes|Recruiting|March 1998|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|21 Years|N/A|No|||June 2015|June 2, 2015|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00543660||166110|
NCT00544869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-06-006|A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)|Phase 3 Open-label, Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure) — an Investigation of the Safety of Treatment Beyond 7 Days and the Effect of Dose Escalation to 30 mg||Otsuka Pharmaceutical Co., Ltd.|No|Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|20 Years|85 Years|No|||December 2013|December 24, 2013|October 15, 2007||No||No|November 5, 2013|https://clinicaltrials.gov/show/NCT00544869||166020|
NCT00544882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-DSG-302|A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021|A Prospective, Multicenter, Randomized, Double-Blind Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With the Oral Contraceptive Regimen DR-1021||Teva Pharmaceutical Industries|No|Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|October 12, 2007|Yes|Yes||No|May 8, 2014|https://clinicaltrials.gov/show/NCT00544882||166019|
NCT00544570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000567466|High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma|High Dose Sequential Therapy for Poor Risk Recurrent or Refractory Hodgkin's Disease||City of Hope Medical Center||Completed|April 1998|December 2007|Actual|December 2007|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|64 Years|No|||February 2010|February 5, 2010|October 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544570||166041|
NCT00544856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cogT001|Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease|||Ludwig-Maximilians - University of Munich||Completed|October 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2|||39|||Both|55 Years|95 Years||||January 2009|January 28, 2009|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544856||166021|
NCT00555555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBI 07-03|Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients|A Post-marketing Observation Study to Assess the Efficacy and Safety of the FVIII/VWF Complex (Human,) Alphanate(R), in Preventing Excessive Bleeding During Surgery in Subjects With Congenital Type 3 Von Willebrand Disease||Grifols Biologicals Inc.|Yes|Recruiting|September 2007|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|7 Years|N/A|No|||February 2014|February 17, 2014|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555555||165220|
NCT00555568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4464-R|Mechanisms of Action and Outcome|Mechanisms of Action and Outcome in Peer Support Groups|Peer Support|VA Office of Research and Development|No|Completed|January 2007|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|298|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 6, 2007||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT00555568||165219|
NCT00565253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3052001|Inhaled Nitric Oxide in Pulmonary Embolism|Inhaled Nitric Oxide in Pulmonary Embolism, a Randomized, Double-Blind Placebo-Controlled Study||Medical University of Vienna|No|Completed|March 2005|December 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|November 28, 2007||||No||https://clinicaltrials.gov/show/NCT00565253||164496|
NCT00565526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080018|Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome|Clinical and Laboratory Evaluation of the Autonomic Nervous System in Primary Sjogren's Syndrome||National Institutes of Health Clinical Center (CC)||Completed|November 2007|April 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|28|||Both|18 Years|65 Years|No|||April 2014|April 11, 2014|November 29, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00565526||164475|
NCT00556166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5072|Enterra Therapy Gastric Stimulation System|Enterra Therapy Gastric Stimulation System|Enterra|Columbia University|No|Terminated|October 2004|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2011|February 1, 2011|November 8, 2007||No|Principal investigator left institution.|No||https://clinicaltrials.gov/show/NCT00556166||165173|
NCT00566124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opus 1|Basal Insulins - Pharmacodynamics|No Evidence for Essential Differences Between the Effects of Insulin Glargine, Insulin Detemir and NPH Insulin on Glucose Metabolism After a Single Injection as Assessed by 24-h Euglycemic Clamp Studies in Healthy Humans||University of Aarhus|No|Completed|January 2005|May 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||November 2007|November 30, 2007|November 30, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566124||164431|
NCT00566137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-08-018|Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient|Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient|Scleroderma|Northwell Health|No|Completed|February 2006|February 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|75 Years|No|Probability Sample|Males, Females and Minorities        Age range of subjects 18-75 years old|March 2010|March 8, 2010|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566137||164430|
NCT00566410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23596|A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours|A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours|DCA|AHS Cancer Control Alberta|Yes|Completed|December 2007|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566410||164411|
NCT00566423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-030|Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)|Biomarkers in the Diagnosis and Assessment of PAH|Biomarkers|Northwell Health|No|Completed|May 2007|June 2010|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|65 Years|No|||June 2011|June 22, 2011|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566423||164410|
NCT00566774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000847/1|A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies|Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial: a Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies|MI FREEE|Brigham and Women's Hospital|Yes|Completed|November 2007|November 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|5860|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566774||164384|
NCT00566787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2003-1|Concomitant Treatment of Permanent Atrial Fibrillation|A Prospective, Multi-center Study With Case Matched Controls to Evaluate the Safety and Efficacy of the AtriCure Bipolar System for the Treatment of Continuous Atrial Fibrillation as Adjunct Therapy to Elective Open Heart Surgery|RESTORE SR|AtriCure, Inc.||Completed|January 2005|November 2010|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|80 Years|No|||January 2012|January 23, 2012|December 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00566787||164383|
NCT00567047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2115|Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment|An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate or Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Daily Doses of 50 mg Vildagliptin for 14 Days||Novartis|No|Completed|July 2007|||January 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2009|March 24, 2009|December 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00567047||164363|
NCT00542165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8819|Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy|Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy||Sanofi|No|Completed|March 2004|December 2004|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|166|||Male|50 Years|N/A|No|||October 2007|October 10, 2007|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00542165||166224|
NCT00543114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-097|Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL|A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL||Dana-Farber Cancer Institute|Yes|Terminated|October 2007|December 2012|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2010|September 2, 2015|October 10, 2007|Yes|Yes|lack of efficacy and tolerability|No||https://clinicaltrials.gov/show/NCT00543114||166151|
NCT00542737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|518|Evaluating a Web-Based Ventilator Management Educational Program for Clinicians (The Lung Injury Knowledge Network [LINK] Study)|Improving Ventilator Management and Preventing Injury to Patients With Acute Respiratory Failure|LINK|Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|February 2009|July 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|July 9, 2013|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00542737||166180|
NCT00543725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002704|TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors|A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.||Tibotec Pharmaceuticals, Ireland|Yes|Completed|June 2008|February 2012|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|680|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|October 11, 2007|Yes|Yes||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00543725||166106|
NCT00543361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-020|Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)|A Double-Blind, Randomized, Active-Controlled MK0767 and Metformin Comparator Study in Type 2 Diabetic Patients Inadequately Controlled on Diet and Exercise||Merck Sharp & Dohme Corp.||Terminated|May 2003|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|382|||Both|21 Years|78 Years|No|||June 2015|June 11, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00543361||166133|
NCT00543673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK53|Tolerance of Healthy, Term Infants to Infant Formulas|Tolerance of Healthy, Term Infants to Infant Formulas||Abbott Nutrition|No|Completed|September 2007|June 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|180|||Both|N/A|8 Days|Accepts Healthy Volunteers|||June 2008|July 3, 2008|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00543673||166109|
NCT00543686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165/07/FFM|Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma|A Randomised Controlled Open-Label Phase IV Mono Centre Study to Compare the Response Profiles of Montelukast Versus Fluticasone in Children With Pre-School Asthma|LOS|Johann Wolfgang Goethe University Hospitals|Yes|Completed|August 2007|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|6 Years|No|||February 2009|February 3, 2009|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00543686||166108|
NCT00544297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-018|A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand|A Multi-center, Open-label Study to Examine the Safety and Toleration of 0.05% PEP005 Topical Gel in Patients With Actinic Keratoses on the Dorsum of the Hand||Peplin|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|October 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544297||166062|
NCT00544024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCZVED-3620|Mefloquine Bioequivalence Among 3 Commercially Available Tablets.|Mefloquine Bioequivalence Among Three Commercial Tablet Formulations in Peruvian Subjects With Uncomplicated Plasmodium Falciparum Malaria||Centers for Disease Control and Prevention|No|Completed|March 2004|March 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|39|None Retained|Whole blood was obtained for analysis, but has been subsequently disposed after completion      of drug analysis.|Both|N/A|N/A|No|Probability Sample|Thirty-nine adult subjects were initially enrolled in the study ranging in age from 18-61        years with a mean of 36 years. Seventy-two percent of the volunteer patients were male.|October 2007|October 12, 2007|October 12, 2007||||No||https://clinicaltrials.gov/show/NCT00544024||166083|
NCT00544908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07024|Dasatinib in Treating Patients With Stage IV Pancreatic Cancer|A Phase II Clinical Trial of Dasatinib in Patients With Metastatic Pancreatic Cancer||City of Hope Medical Center||Terminated|September 2007|||October 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|October 13, 2007|Yes|Yes|Toxicity|No|August 19, 2015|https://clinicaltrials.gov/show/NCT00544908||166017|Study was terminated early due to toxicity.
NCT00544934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLY-002|Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects|A Dose-ranging Study to Evaluate the Safety, Metabolism and Therapeutic Dosing of Three Multiple Dose Levels of GLY-230 in Healthy and Diabetic Subjects||Glycadia|No|Completed|February 2007|October 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|42|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 15, 2007||||No||https://clinicaltrials.gov/show/NCT00544934||166015|
NCT00545233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21301|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.|A Randomized, Open-label Study of the Effect of PEGASYS ® Plus COPEGUS® With or Without Concomitant Pioglitazone (Actos®) on Early Viral Kinetics in Treatment-naive Patients With Chronic Hepatitis C, Genotype-1, and Insulin Resistance||Hoffmann-La Roche||Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|October 16, 2007|Yes|Yes||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00545233||165994|
NCT00545246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD10091|A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients|A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Docetaxel Administered Every 3 Weeks in Patients With Advanced Solid Malignancies||Sanofi|No|Completed|October 2007|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||October 2013|October 12, 2013|October 16, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00545246||165993|
NCT00565240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHIRL-07-59|Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women|Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women Protocol: WHIRL-07-2971||University of Saskatchewan||Completed|November 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|41|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2010|April 20, 2010|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00565240||164497|
NCT00565032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9899015|Postpartum Thyroid Measures and Mood|Postpartum Thyroid Measures and Mood||Oklahoma State University Center for Health Sciences|No|Completed|January 2000|August 2001|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were patients from two Oklahoma State University Center for Health Sciences        (OSUCHS) clinics in Tulsa, Oklahoma.|January 2010|January 26, 2010|November 27, 2007||||No||https://clinicaltrials.gov/show/NCT00565032||164513|
NCT00557726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|780023|Diagnosis and Management of Inflammatory and Infectious Diseases|Diagnosis and Management of Inflammatory and Infectious Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|February 1978|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|2 Years|N/A|No|||September 2015|January 20, 2016|November 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00557726||165064|
NCT00557739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-191-001|Study of CRx-191 to Assess Activity in Plaque Psoriasis|A Single-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Activity of CRx-191 in Reducing the Psoriatic Infiltrate Band Thickness in Plaque Psoriasis||Zalicus|No|Completed|November 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|20|||Both|18 Years|70 Years|No|||December 2007|September 24, 2008|November 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00557739||165063|
NCT00565799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-178|A Pilot Study of Metabolic Effects of Omentectomy|A Pilot Study of Metabolic Effects of Omentectomy in Obese Patients With Type 2 Diabetes Mellitus Treated With Laparoscopic Adjustable Gastric Banding (LAGB)|OMT|New York University School of Medicine|Yes|Terminated|November 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|64 Years|No|||November 2015|November 18, 2015|November 28, 2007||No|Conflicting interim data|No||https://clinicaltrials.gov/show/NCT00565799||164455|
NCT00558311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-054-301|Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping|A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping.|CONSCIOUS-2|Actelion|Yes|Completed|November 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1157|||Both|18 Years|75 Years|No|||March 2012|March 9, 2012|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558311||165019|
NCT00566436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04.04|Remote Endarterectomy Versus Suprageniculate Femoropopliteal Bypass|The Surgical Treatment of Long Occlusions of the Superficial Femoral Artery: Initial Success and Long Term Results of Remote Endarterectomy Versus Suprageniculate Bypass Surgery|REVAS|St. Antonius Hospital|No|Active, not recruiting|October 2004|March 2012|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||November 2007|November 29, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00566436||164409|
NCT00566761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECRVO|Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO|Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion|MECROV|Asociación para Evitar la Ceguera en México|Yes|Recruiting|June 2007|March 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||November 2007|November 30, 2007|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00566761||164385|
NCT00558961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0506PI|Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients|A Phase I-II Trial of Gleevec (Imatinib Mesylate) in Combination With Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia (CLL) Patients|GL-CLB-001|Jewish General Hospital|No|Terminated|October 2005|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2007|April 14, 2010|November 15, 2007||No|Unsatisfactory enrollment|No||https://clinicaltrials.gov/show/NCT00558961||164973|
NCT00542178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|509|Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)|Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|October 2003|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|3472|||Both|40 Years|79 Years|No|||November 2013|November 22, 2013|October 9, 2007||No||No|April 27, 2012|https://clinicaltrials.gov/show/NCT00542178||166223|The glycemia trial was stopped early, potentially underestimating the reported effect of glycemia treatment on diabetic retinopathy.
NCT00543127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2006-10|Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol|A Randomized, Multicentral, Phase III Study of Parallel Groups to Compare the Efficiency and Tolerance of Fulvestrant Administered for Three Years in Combination With Anastrozol for 5 Years Versus Anastrozol for 5 Years as Adjuvant Hormonotherapy in Postmenopausal Women With Early Breast Cancer and + HRs.||Spanish Breast Cancer Research Group|No|Terminated|November 2007|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|872|||Female|18 Years|80 Years|No|||October 2011|October 25, 2011|October 11, 2007||No|Unjustified decision of company that funded the trial.|No||https://clinicaltrials.gov/show/NCT00543127||166150|
NCT00542750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K12 DA 000357 NAC MJ Pilot|An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents|An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents|NAC MJ Pilot|Medical University of South Carolina|Yes|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|12 Years|20 Years|No|||February 2009|February 12, 2009|October 10, 2007||Yes||||https://clinicaltrials.gov/show/NCT00542750||166179|
NCT00543088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-NB-SER-2006/1|Effectiveness of Anti-Psychotic in GPs Setting|SERENITY: Evaluating the Effectiveness of Atypical Antipsychotics in the Community - a Prospective, Multicentre, Observational Study to Evaluate the Impact on Quality of Life of GP-Bases Management of Antipsychotic Treatment in Belgium.|Serenity|AstraZeneca|No|Completed|January 2007|June 2008|Actual|||N/A|Observational|Time Perspective: Prospective||1||250|||Both|18 Years|65 Years|No|||April 2009|April 22, 2009|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00543088||166153|
NCT00543738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-028|MK0767 and Metformin Combination Study (0767-028)|||Merck Sharp & Dohme Corp.||Terminated|June 2003|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|114|||Both|21 Years|78 Years|No|||June 2015|June 16, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543738||166105|
NCT00543751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-025|Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)|||Merck Sharp & Dohme Corp.||Terminated|January 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|610|||Both|21 Years|78 Years|No|||June 2015|June 16, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543751||166104|
NCT00544037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91713|BENEFIT Extension Study|Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis||Bayer|No|Completed|September 2007|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|283|None Retained|Population of Benefit Studies|Both|23 Years|50 Years|No|Non-Probability Sample|This observational study may include all patients who were randomized into and treated at        least once in the BENEFIT study 304747, inclusive of patients who prematurely discontinued        study participation in either study 304747 or study 305207, and patients who did not        transfer from study 304747 to study 305207.|March 2012|March 2, 2012|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544037||166082|
NCT00544050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01052|Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old|An Open-Label, Single Dose, Pharmacokinetic Study of 20 mg/kg of Levetiracetam Oral Solution in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old||UCB Pharma|No|Completed|September 2002|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|1 Month|4 Years|No|||September 2009|November 14, 2013|October 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544050||166081|
NCT00544310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-GYN-001|Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil|A Prospective, Controlled, Randomized, Multi-Center, Exploratory Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil||OMRIX Biopharmaceuticals||Active, not recruiting|January 2008|October 2008|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1|||25|||Female|18 Years|45 Years|No|||August 2008|August 19, 2008|October 15, 2007||||No||https://clinicaltrials.gov/show/NCT00544310||166061|
NCT00544323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cobiHMO|Alveolar Bone Loss Around 3 Different Designs of Dental Implant: Prospective Comparative Clinical Trail|Alveolar Bone Loss Around 3 Different Designs of Dental Implant: Prospective Comparative Clinical Trail||Hadassah Medical Organization||Not yet recruiting|November 2007|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1|||25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2007|February 1, 2009|October 14, 2007||||No||https://clinicaltrials.gov/show/NCT00544323||166060|
NCT00544583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S206/2007|Continuous Versus Interrupted Abdominal Wall Closure After Emergency Midline Laparotomy|Continuous Versus Interrupted Abdominal Wall Closure After Emergency Midline Laparotomy: CONTINT - A Randomized Controlled Study|CONTINT|Heidelberg University|Yes|Recruiting|November 2007|April 2012|Anticipated|April 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544583||166040|
NCT00541034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-051|Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia|Phase II Study of Pentostatin With Cyclophosphamide and Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia||Memorial Sloan Kettering Cancer Center||Completed|May 2005|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|120 Years|No|||January 2016|January 7, 2016|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00541034||166310|
NCT00545259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071B2101|Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation|An Open-label, Two-period, Multi-center, Single Dose Study to Assess the Pharmacokinetics of AEB071 in de Novo Liver Transplant Patients||Novartis|No|Completed|October 2007|||February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||February 2008|April 8, 2011|October 15, 2007||||No||https://clinicaltrials.gov/show/NCT00545259||165992|
NCT00545272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149A2201|A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma|A Randomized, Multi-center, Parallel Group, Double Blind, Placebo and Formoterol Controlled 14 Day Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma||Novartis||Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|392|||Both|12 Years|75 Years|No|||November 2012|December 12, 2012|October 16, 2007||No||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00545272||165991|
NCT00564772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78958|Raltegravir Kaletra Pharmacokinetics|An Open-Label, Sequential, 3-Period Study to Evaluate Pharmacokinetics of Coadministered Raltegravir (Isentress) and Lopinavir-Ritonavir (Kaletra) in Healthy Adults|RAL-KAL|Allina Hospitals and Clinics|No|Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2008|June 16, 2008|November 27, 2007||Yes||No||https://clinicaltrials.gov/show/NCT00564772||164533|
NCT00557427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REM-1/MDA|Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression|Open-labeled Randomized Comparative Study of the Efficacy and Tolerability of Two Times Daily 250mg Hypericum Versus Once Daily 20 - 40 mg Fluoxetine in Adolescent Patients With Mild to Moderate Depression||Rafa Laboratories|No|Terminated|January 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|18 Years|No|||June 2011|June 23, 2011|November 13, 2007||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00557427||165085|
NCT00557440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149A2202|Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma|A Multi-center, Randomized, Double-blind, Double Dummy, Placebo and Active Controlled Crossover Study, to Investigate the 24 Hour FEV1 Profile of a Single Dose of QMF TWISTHALER Device in Adult Patients With Persistent Asthma||Novartis||Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|75 Years|No|||April 2009|February 15, 2013|November 12, 2007|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00557440||165084|
NCT00558051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-063|Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer|Phase I Evaluation of Semi-continuous Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer||University of Pittsburgh|Yes|Active, not recruiting|January 2008|December 2015|Anticipated|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|9|||Both|18 Years|80 Years|No|||December 2015|December 23, 2015|November 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00558051||165039|
NCT00558064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.13|Filtered Trial for Amlodipine Non-responder|Filtered Trial for Amlodipine Non-responder||Boehringer Ingelheim||Completed|October 2007|||September 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|531|||Both|20 Years|N/A|No|||December 2013|June 24, 2014|October 29, 2007||||No|November 10, 2009|https://clinicaltrials.gov/show/NCT00558064||165038|
NCT00565812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6171016|A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee|A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study to Investigate the Safety and Efficacy of Orally Administered SD-6010 in Subjects With Symptomatic Osteoarthritis of the Knee|ITIC|Pfizer|Yes|Completed|November 2007|November 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|5077|||Both|40 Years|N/A|No|||February 2013|February 20, 2013|November 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00565812||164454|
NCT00565838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-05|Quality-of-Life Outcomes After Autologous Fascial Sling and TVT: a Prospective Randomized Trial|Clinical and Quality-of-Life Outcomes After Autologous Fascial Sling and Tension-Free Vaginal Tape: a Prospective Randomized Trial||UPECLIN HC FM Botucatu Unesp|No|Completed|January 2001|November 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Female|18 Years|80 Years|No|Probability Sample|Community sample|November 2007|November 28, 2007|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00565838||164453|
NCT00558688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00000312|A Photodynamic Therapy for Treatment of Actinic Keratoses|A Photodynamic Therapy for Treatment of Actinic Keratoses||Northwestern University|No|Completed|August 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|90 Years|No|||February 2015|February 19, 2015|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558688||164993|
NCT00558675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-001-HMC|A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy|A Phase I/II Study of Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) Conjugated With CD3/CD28-coated Microbeads in Patients With Relapsed or Refractory Hematological Malignancy||Immunovative Therapies, Ltd.|No|Completed|December 2009|March 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|25|||Both|18 Years|N/A|No|||November 2012|February 19, 2015|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558675||164994|
NCT00559260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-02-0004|Evaluation of Cardiorespiratory Events in Subjects Undergoing an Upper and/or Lower Endoscopy Under Current Sedation Practices|Evaluation of Cardiorespiratory Events in Subjects Undergoing an Upper and/or Lower Endoscopy Under Current Sedation Practices While Being Passively Monitored||Ethicon Endo-Surgery||Completed|January 2003|||||N/A|Observational|Time Perspective: Prospective||||300|||Both|18 Years|N/A|No|||September 2008|September 12, 2008|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559260||164951|
NCT00559559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR06002HV|PAtient NOtifier Feature for Reduction of Anxiety|PAtient NOtifier Feature for Reduction of Anxiety: A Multicenter ICD Study|Panoramic|St. Jude Medical|No|Completed|December 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|362|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559559||164929|
NCT00542425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA058-05-002|Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis|A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis||Radius Health, Inc.|No|Completed|April 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|222|||Female|55 Years|85 Years|No|||June 2010|June 30, 2010|October 10, 2007|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00542425||166204|
NCT00542789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00001|Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID|A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use||AstraZeneca|No|Completed|August 2007|February 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|343|||Both|20 Years|N/A|No|||May 2010|May 10, 2010|October 11, 2007||||No|February 16, 2010|https://clinicaltrials.gov/show/NCT00542789||166176|
NCT00543140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-06-0001/CI-07-0006|Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band|A Post Implantation/Post Market Evaluation of Safety and Quality of Life in Subjects Implanted With the Swedish Adjustable Gastric Band (SAGB) During Protocol CI-02-0006|SAGB-PM|Ethicon Endo-Surgery|No|Completed|August 2006|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|303|||Both|18 Years|60 Years|No|||February 2016|February 9, 2016|August 28, 2007|Yes|Yes||No|January 11, 2016|https://clinicaltrials.gov/show/NCT00543140||166149|
NCT00543374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 610|Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease|A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease||Mesoblast, Ltd.|Yes|Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|70 Years|No|||May 2014|May 19, 2014|October 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00543374||166132|
NCT00543712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APM4171g|A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)|A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma||Genentech, Inc.||Terminated|June 2007|||May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|October 12, 2007|Yes|Yes|Efficacy not evident in this population.|No||https://clinicaltrials.gov/show/NCT00543712||166107|
NCT00543764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000266/1|Intraoperative Pathway in DIEP Flap Breast Reconstruction|Intraoperative Pathway in DIEP Flap Breast Reconstruction||Beth Israel Deaconess Medical Center|No|Completed|January 2005|February 2011|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|150|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing breast reconstruction|May 2012|May 25, 2012|October 12, 2007||No||No|October 19, 2010|https://clinicaltrials.gov/show/NCT00543764||166103|More patient enrollment is necessary to ascertain long term outcomes
NCT00543777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0107|Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease|Validation Study of Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease||M.D. Anderson Cancer Center|No|Recruiting|September 2007|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|N/A|N/A|No|||March 2016|March 14, 2016|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00543777||166102|
NCT00544063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564073|Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer|Phase I Study Evaluating the Feasibility of Chemotherapy With Capecitabine, Irinotecan, and Oxaliplatin in Patients With Metastatic Carcinoma||National Cancer Institute (NCI)||Recruiting|October 2006|||December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|33|||Both|18 Years|75 Years|No|||July 2009|December 13, 2009|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544063||166080|
NCT00544336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0737|Family Quality of Life Among Families With a Member Who is a Cancer Patient|Assessment of Family Quality of Life Among Families With a Member Who is a Cancer Patient||Vanderbilt-Ingram Cancer Center|Yes|Completed|August 2007|May 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|366|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Family members of a patient with cancer|September 2012|September 7, 2012|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544336||166059|
NCT00545298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP 1|Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers|An Investigation of the Topical Application of Gaseous Nitric Oxide on Safety and Efficacy in Venous Stasis Leg Ulcers of the Lower Extremities||Nitric BioTherapeutics, Inc|Yes|Terminated|October 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|October 16, 2007|Yes|Yes|Strategic direction of the sponsor changed|No|August 8, 2012|https://clinicaltrials.gov/show/NCT00545298||165989|Early termination due to small number of subjects enrolled
NCT00544596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00273|R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer|A Phase 1 Study of R-(-)-Gossypol (AT-101) in Combination With Cisplatin and Etoposide in Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2007|||July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||June 2012|April 1, 2014|October 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544596||166039|
NCT00544609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOGUG-07-01|Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent|Phase I Trial of Sorafenib in Combination With Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent|SOGUG-07-01|Spanish Oncology Genito-Urinary Group|Yes|Completed|December 2007|May 2012|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544609||166038|
NCT00544895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHM-CT-2006-036534|Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants|Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants|NEOBRAIN|Hannover Medical School|No|Completed|October 2007|October 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|whole blood, urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Preterm newborns with a gestational age < 28wks|June 2011|June 22, 2011|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544895||166018|
NCT00545324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-323|First Step With Singulair® Therapy (0476-323)|A 12 Week Multicenter, Open-Label, Randomized, Observational Study Comparing Singulair® 10 Mg As Controller Monotherapy In Adults With Mild Asthma "To Low Dose" Inhaled Corticosteroid Treatment|FIRST|Merck Sharp & Dohme Corp.||Completed|September 2002|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|399|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545324||165987|
NCT00545337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1964A_3505UA|Glulisine + Lantus in Type I Patients|26-week, International Multicenter, Open, Non-randomized Phase III Clinical Trial for Evaluation of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Subjects With Type 1 Diabetes Mellitus Also Using Insulin Glargine||Sanofi|No|Completed|September 2004|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|19 Years|N/A|No|||October 2009|October 15, 2009|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00545337||165986|
NCT00545285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001955|Long-Term Multi-center Evaluation of E-Poly and Regenerex|Long-Term Multi-center Evaluation of E-Poly and Regenerex Cementless Acetabular Components: Clinical and Radiographic Outcomes||Massachusetts General Hospital|No|Active, not recruiting|November 2007|May 2023|Anticipated|May 2023|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1000|||Both|20 Years|75 Years|No|||September 2014|September 24, 2014|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00545285||165990|
NCT00557141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-299/2007|Observational Study Regarding Adherence, Drug Use, Will to Take Part in Shared Decisioning in Asthma Outpatients|AsthmaCare Study Covering Adherence, Drug Use, Will to Take Part in Shared Decisioning in Asthma Outpatients||Heidelberg Metasystems GmbH|No|Active, not recruiting|January 2008|August 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care outpatiens of private practices in Germany, Age > 18 years, Asthma with        irregular or regular use of short acting beta-agonists and / or: Asthma treatment with        inhaled steroids, Ability to understand the questionnaire|January 2009|January 8, 2009|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00557141||165105|
NCT00557752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06001-00|Efficacy of Non-Invasive Mechanical Ventilation in Early Hypoxia Secondary to Thoracic Trauma|Non-Invasive Ventilation in Early Severe Posttraumatic Hypoxia: a Randomized Controlled Trial||Hospital Virgen de la Salud|Yes|Terminated|September 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||February 2009|February 6, 2009|November 13, 2007||No|Review Board stopped the study after interim analysis reaching stopping rule for efficacy.|No||https://clinicaltrials.gov/show/NCT00557752||165062|
NCT00558350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68/07|Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery|Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery||University Hospital, Basel, Switzerland|No|Completed|April 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|20 Years|90 Years|No|Probability Sample|all patients undergoing lobectomy or segmentectomy for lung cancer at a single institution|March 2012|March 14, 2012|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00558350||165016|
NCT00558701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-07-003|Microcurrent for Healing Autogenous Skin Donor Sites|Prospective, Randomized, Controlled Study of the Efficacy of a Silver-coated Nylon Dressing Plus Active or Sham Microcurrent for Healing Autogenous Skin Donor Sites||United States Army Institute of Surgical Research|No|Active, not recruiting|December 2007|December 2013|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||June 2013|June 17, 2013|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00558701||164992|
NCT00558727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-1-002|Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Protocol RH-1-002: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Dose-escalation Study of RH-1 Administered as a 3-hour Intravenous Infusion in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma||Spectrum Pharmaceuticals, Inc||Terminated|November 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558727||164991|
NCT00558038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST015|Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy|Comparison of Different Treatment Regimens in Patients With Stage 1-2 Type C Hepatic Encephalopathy: AST-120 vs Lactulose|AST015|Ocera Therapeutics|No|Completed|September 2007|June 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||May 2014|May 27, 2014|November 9, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558038||165040|
NCT00559273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH20052|A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.|An Open-label, Randomized, Multicenter, Parallel-group Study to Demonstrate Correction of Anemia Using Once Every 4 Weeks Subcutaneous Injections of Mircera in Patients With Chronic Kidney Disease Who Are Not on Dialysis.||Hoffmann-La Roche||Completed|December 2007|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559273||164950|
NCT00558987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW-101251|Parenting Videos In Primary Care|Enhancing Anticipatory Guidance About Discipline for Low-Income Families: A Video Intervention Project||Johns Hopkins University|No|Completed|February 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|122|||Both|13 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 28, 2009|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00558987||164972|
NCT00559000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mb|The Efficacy of KIDNET in the Treatment of Traumatized Refugee Children in Germany|The Efficacy of KIDNET in the Treatment of Traumatized Refugee Children in Germany||University of Konstanz|No|Completed|December 2003|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|7 Years|16 Years|No|||November 2007|November 15, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559000||164971|
NCT00559247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-002|A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects|Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-650032 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|60 Years|No|||September 2010|September 10, 2010|November 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559247||164952|
NCT00555724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212ST101|Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors|A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors||Biogen||Completed|January 2008|July 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2011|June 7, 2012|October 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00555724||165207|
NCT00544089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/06|Chromosomal and Morphological Structure of Mature and Immature Male Germ Cells and Recognition of IL-18 in Testicular Tissue of Azoospermic Men|||Assaf-Harofeh Medical Center|No|Completed|March 2006|September 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|25907|||Male|22 Years|39 Years|Accepts Healthy Volunteers|||March 2006|October 15, 2007|October 14, 2007||||No||https://clinicaltrials.gov/show/NCT00544089||166078|
NCT00543387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5108-001|Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4)|A Phase I Investigation of MK-5108 and MK-5108 With Docetaxel in Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|March 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00543387||166131|
NCT00543400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOM-M118-006|Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)|A Randomized, Multi-center, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI) And A Pharmacokinetic, Pharmacodynamic and Heparin Antibody Substudy|EMINENCE|Momenta Pharmaceuticals, Inc.|Yes|Completed|September 2007|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|503|||Both|19 Years|N/A|No|||April 2013|April 30, 2013|October 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00543400||166130|
NCT00544635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1253-010|The Effect Of Light On Scar Appearance|The Effect Of Light On Scar Appearance||Northwestern University|No|Terminated|November 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|October 12, 2007|Yes|Yes|Study personnel left institution before study completion.|No||https://clinicaltrials.gov/show/NCT00544635||166036|
NCT00544648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0746|Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC|A Phase I/II Study of Nab-Paclitaxel and Carboplatin With Concurrent Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC)||Vanderbilt-Ingram Cancer Center|Yes|Terminated|November 2007|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|October 13, 2007|Yes|Yes|Ph I completed. Funding became unavailable causing Ph II to cease after two patients were    enrolled.|No|March 19, 2014|https://clinicaltrials.gov/show/NCT00544648||166035|This Phase I/II study progressed into Phase II, but terminated shortly thereafter due to lack of funding.
NCT00544076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04071|Sildenafil Citrate and Alprostadil in Treating Patients Undergoing Bilateral Nerve-Sparing Robotic-Assisted Prostatectomy for Nonmetastatic Prostate Cancer|Erectile Dysfunction Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy (BNS-RAP) for Prostate Cancer||City of Hope Medical Center|Yes|Completed|January 2006|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|110|||Male|18 Years|65 Years|No|||June 2015|June 3, 2015|October 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544076||166079|
NCT00545311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2103|Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Inhaled NVA237 Doses at Four Dose Levels in COPD Patients||Novartis|No|Completed|July 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|40|||Both|40 Years|75 Years|No|||December 2007|December 27, 2007|October 15, 2007||||No||https://clinicaltrials.gov/show/NCT00545311||165988|
NCT00544674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-2001|PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer|A Phase II, Multi-Center, Open-Label, Trial of PR104 in Treatment Naive and Sensitive-relapse Small Cell Lung Cancer||Proacta, Incorporated||Terminated|August 2007|January 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|October 13, 2007|Yes|Yes|Terminated early due to discovery of new mechanism of activation.|No|June 13, 2011|https://clinicaltrials.gov/show/NCT00544674||166034|Decision to close study early based on new data showing that PR104A could also be activated under oxic conditions in tumors that express high levels of AKR1C3. SCLC does not express meaningful levels of the enzyme aldo keto reductase 1C3 (AKR1C3).
NCT00544622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INR50|Structured Stroke Management Improves Outcome at 6 Months|Structured Stroke Management Improves Outcome at 6 Months||Kantonsspital Baden|Yes|Completed|January 2002|March 2003||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|20 Years|N/A||||October 2008|October 16, 2008|October 12, 2007||||No||https://clinicaltrials.gov/show/NCT00544622||166037|
NCT00544921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLY-001|Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects|Phase 1 Study of Anti-glycation Agent GLY-230||Glycadia|No|Completed|October 2005|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|7||Actual|54|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544921||166016|
NCT00545350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM06076, K060209|Exercise Intervention to Prevent Fall-related Fractures and Other Injuries : The Ossébo Study|Randomized Controlled Trial of Prevention of Fall-related Fractures and Other Injuries by Physical Exercise Among Community Dwelling Elderly Women|Ossébo|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|706|||Female|75 Years|90 Years|Accepts Healthy Volunteers|||May 2012|April 2, 2014|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545350||165985|
NCT00545363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19982|A Study of Adherence to Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP).|A Randomized Open-label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-menopausal Osteoporosis Supported by a Patient Relationship Program||Hoffmann-La Roche||Completed|May 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|717|||Female|55 Years|85 Years|No|||February 2016|February 1, 2016|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545363||165984|
NCT00541307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPR 07-03|GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)|Post Marketing Study of the GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease (VIPER)|VIPER|W.L.Gore & Associates|No|Completed|October 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|October 9, 2007|Yes|Yes||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00541307||166289|
NCT00541320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTI102595|Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)|Dose Ranging Trial for the Evaluation of the Safety and Efficacy of GW813893 in the Prophylaxis of Venous Thromboembolism Post Total Knee Replacement Surgery.||GlaxoSmithKline||Withdrawn|February 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|0|||Both|18 Years|85 Years|No|||April 2013|April 1, 2013|February 12, 2007|||No longer viable|No||https://clinicaltrials.gov/show/NCT00541320||166288|
NCT00557453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cholecystitis-HMO-CTIL|The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial|The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial||Hadassah Medical Organization|Yes|Completed|April 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|70 Years|No|Probability Sample|Patients admitted through the emergency department that are diagnosed with acute        cholecystits and meet the inclusion criteria will be given the opportunity to participate        in the trial. Informed consent is required. Patients may withdraw from the study at any        time without giving reasons and without jeopardizing further treatment.|April 2010|July 12, 2010|November 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00557453||165083|
NCT00558363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI109924|ARTS - AVODART After Radical Therapy For Prostate Cancer Study|A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men With Prostate Cancer and Biochemical Failure (PSA Increase) After Radical Therapy With Curative Intent|ARTS|GlaxoSmithKline|No|Completed|November 2007|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|294|||Both|18 Years|85 Years|No|||December 2011|March 15, 2012|November 13, 2007|Yes|Yes||No|November 10, 2011|https://clinicaltrials.gov/show/NCT00558363||165015|
NCT00558740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 66/07/CE/FBM|Effects of Dietary Proteins on Hepatic Lipid Metabolism|Effects of Dietary Proteins on Hepatic Lipid Metabolism||University of Lausanne|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|22|||Male|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|November 2009|February 9, 2012|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558740||164990|
NCT00558324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cornea 1|Corneal Flap Thickness Planed vs Measured After LASIK by Using Tree Different Systems Cut|Corneal Flap Thickness Planed vs Measured After LASIK by Using Tree Different Systems Cut||Asociación para Evitar la Ceguera en México|Yes|Completed|February 2007|October 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 12, 2007|November 7, 2007||||No||https://clinicaltrials.gov/show/NCT00558324||165018|
NCT00558337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS353-CTP 01|Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease|An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients||Osmotica Pharmaceutical Corp.|Yes|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|30 Years|80 Years|No|||January 2009|January 13, 2009|November 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00558337||165017|
NCT00559286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIX-MK-01|Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels|Influence of the Angiotensin Receptor Blocker Telmisartan on the Red Blood Cell Function and the Microcirculatory Perfusion|ITEM|RWTH Aachen University|Yes|Terminated|December 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|N/A|No|||January 2009|January 28, 2009|November 15, 2007||No|logistic reasons, patients could not be recruited|No||https://clinicaltrials.gov/show/NCT00559286||164949|
NCT00554801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C5067-R|Central Auditory Processing Disorders Associated With Blast Exposure|Central Auditory Processing Disorders Associated With Blast Exposure||VA Office of Research and Development|No|Completed|October 2007|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 12, 2014|November 5, 2007||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00554801||165277|
NCT00555737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-23|Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)|Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy||Given Imaging Ltd.|No|Completed|November 2003|July 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|N/A|No|Probability Sample|clinic paitnets with known Gluten sensitivity (Celaic).|November 2007|March 25, 2009|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00555737||165206|
NCT00542763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|myf-01-049|Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome|Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome - An Open Label Pilot Trial||University Hospital Muenster|No|Completed|April 2005|September 2007|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Both|18 Years|75 Years|No|||August 2004|October 10, 2007|October 10, 2007||||No||https://clinicaltrials.gov/show/NCT00542763||166178|
NCT00542776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09-0345|Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine|Impact of Immunosuppression in Patients With Inflammatory Bowel Disease on Responsiveness to Influenza Vaccine||Children's Hospital Boston|Yes|Completed|October 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|146|Samples Without DNA|Blood for seroprotection rate and antibody titers|Both|5 Years|N/A|No|Non-Probability Sample|Patients aged 5 years and older with documented inflammatory bowel disease (Crohn's        disease, ulcerative colitis, indeterminate colitis)|December 2007|April 30, 2008|October 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00542776||166177|
NCT00543465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0782-003|12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)|||Merck Sharp & Dohme Corp.||Terminated|August 2004|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|49|||Both|45 Years|N/A|No|||June 2015|June 1, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543465||166125|
NCT00543413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8141-006|A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)|A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Assess the Efficacy and Tolerability of MK8141 in Hypertensive Patients||Merck Sharp & Dohme Corp.||Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|160|||Both|35 Years|65 Years|No|||October 2015|October 15, 2015|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00543413||166129|
NCT00543426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06DZ19728|Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis|Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis||Shanghai University of Traditional Chinese Medicine|Yes|Completed|September 2007|June 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||June 2009|March 6, 2013|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00543426||166128|
NCT00544102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080008|Insulin Resistance and Atherosclerosis in Women With Lupus|Insulin Resistance and Atherosclerosis in a Sample of Women With Systemic Lupus Erythematosus||National Institutes of Health Clinical Center (CC)||Completed|October 2007|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|50|||Female|30 Years|55 Years|No|||May 2015|May 20, 2015|October 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00544102||166077|
NCT00544115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01089|Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders|A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders||City of Hope Medical Center||Active, not recruiting|September 2001|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|260|||Both|N/A|120 Years|No|||December 2015|December 30, 2015|October 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544115||166076|
NCT00544947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/S0704/67|Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids for Caesarean Section|Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids: a Comparison Between Diamorphine and Fentanyl Combined With Postoperative Morphine PCA Using a Carbon Dioxide Tension and Pulse Oximetry Sensor (TOSCA)||NHS Greater Clyde and Glasgow|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Elective caesarean section Healthy pregnant women|February 2009|February 3, 2009|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544947||166014|
NCT00544687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-191-002|Phase I Study of Topical CRx-191 in Normal Healthy Volunteers|A Phase I, Single-Center, Randomized, Vehicle and Active-Controlled Study to Assess and Compare the Atrophy-Causing Potential of Topical CRx-191 Formulations in Healthy Volunteers||Zalicus|No|Completed|September 2007|November 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|November 14, 2007|October 15, 2007||||No||https://clinicaltrials.gov/show/NCT00544687||166033|
NCT00540774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2002-2805|Optical Sensor for Photodynamic Detection of Oral Pathology|Optical Sensor for Photodynamic Detection of Oral Pathology||University of California, Irvine|No|Recruiting|April 2003|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be recruited from University of Californis Irvine and Orange Country        Dentists.|February 2016|February 5, 2016|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540774||166330|
NCT00541359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03109|Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors|A Phase I Trial of PS-341 in Combination With Topotecan in Advanced Solid Tumor Malignancies||City of Hope Medical Center|Yes|Completed|January 2004|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541359||166285|
NCT00540787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4|A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation|A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation||Biosense Webster, Inc.||Completed|August 2003|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|112|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|October 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540787||166329|
NCT00558077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2003|Second-Line Treatments for Anovulatory Infertility in PCOS Patients|Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial||University Magna Graecia|Yes|Completed|February 2003|October 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|35 Years|No|||November 2007|November 13, 2007|November 13, 2007||||No||https://clinicaltrials.gov/show/NCT00558077||165037|
NCT00558376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4884-SBH-CTIL|Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy|Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy - An Investigator Blinded Prospective Controlled Trial||Sheba Medical Center|No|Terminated|January 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||May 2009|May 4, 2009|November 13, 2007||No|Study terminated due to FDA alert regarding Fleet phosphosoda|No||https://clinicaltrials.gov/show/NCT00558376||165014|
NCT00554840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28948|Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia|Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia||University of Maryland|Yes|Enrolling by invitation|November 2007|December 2009|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|64 Years|No|||June 2008|June 5, 2008|November 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554840||165274|
NCT00559013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1011, Rev C|Peri-Strips Dry (PSD) Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery|Peri-Strips Dry With Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery||Synovis Surgical Innovations|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Both|18 Years|N/A|No|||July 2011|May 23, 2012|November 14, 2007||No||No|December 15, 2009|https://clinicaltrials.gov/show/NCT00559013||164970|
NCT00555412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-102|Staccato Loxapine Multidose PK|Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Staccato® Loxapine for Inhalation in Subjects on Chronic, Stable Antipsychotic Regimens||Alexza Pharmaceuticals, Inc.|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|65 Years|No|||June 2013|June 24, 2013|November 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00555412||165231|
NCT00554814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL010|Interest of Biofer ® Compound Used in Blédilait Follow on Milk in Infant With Latent Iron Deficiency|Interest of Biofer ® Compound Used in Blédilait Follow on Milk and Growing Milk on Iron Status Evolution in Infant With Latent Iron Deficiency||Bledina|Yes|Suspended|November 2007|December 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|249|||Both|6 Months|12 Months|No|||November 2008|November 14, 2008|November 6, 2007||No|insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00554814||165276|
NCT00554827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-010|Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma|A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma||Spectrum Pharmaceuticals, Inc||Completed|August 2007|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|November 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554827||165275|
NCT00555178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-116 ex 06/07|Regulatory T Cells (Tregs) in Polymorphic Light Eruption|Regulatory T Cells (Tregs) in Polymorphic Light Eruption||Medical University of Graz|No|Completed|March 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|92|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic patients and community sample|May 2015|May 6, 2015|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555178||165249|
NCT00542490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1524|Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer|Phase II Trial of Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel Chemotherapy in Patients With Stage I-IIb Papillary Serous, Clear Cell and Endometrioid Endometrial Cancer With High-Intermediate Risk Factors||University of Oklahoma|No|Active, not recruiting|September 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|October 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00542490||166199|
NCT00543478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB|Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome|Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome|SBIBS|Aga Khan University|Yes|Recruiting|October 2007|July 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|60 Years|No|||October 2007|October 12, 2007|October 12, 2007||||No||https://clinicaltrials.gov/show/NCT00543478||166124|
NCT00544349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564063|Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery|Phase II Study Evaluating the Effectiveness of the Association of Chemotherapy LV5FU2 Simplified and Cetuximab With Intra-arterial Hepatic Chemotherapy Using Oxaliplatin in Patients With Colorectal Cancer and Nonresectable Hepatic Metastases||National Cancer Institute (NCI)||Completed|October 2006|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|75 Years|No|||July 2009|May 14, 2011|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544349||166058|
NCT00544128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMCJ-H19-466|Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment|A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study)||International Medical Center of Japan|Yes|Completed|October 2007|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|20 Years|N/A|No|||March 2015|March 27, 2015|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544128||166075|
NCT00544362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564075|Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery|Neoadjuvant Treatment for Operable Esophageal Cancer With 5-fluorouracil, Cisplatin, and Cetuximab and Concurrent Radiotherapy: Phase I/II Study||National Cancer Institute (NCI)||Recruiting|July 2007|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|75 Years|No|||October 2007|December 3, 2011|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544362||166057|
NCT00544700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/06|Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer|Bevacizumab Maintenance Versus no Maintenance After Stop of First-line Chemotherapy in Patients With Metastatic Colorectal Cancer. A Randomized Multicenter Phase III Non-inferiority Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|October 2007|December 2017|Anticipated|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544700||166032|
NCT00544960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-204|A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer|A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)||Ascenta Therapeutics|No|Completed|September 2007|April 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||August 2010|August 24, 2010|October 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544960||166013|
NCT00544986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5391L00001|A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer|A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer||AstraZeneca|No|Completed|June 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 29, 2013|October 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544986||166012|
NCT00540800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREAST-10|BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer|Phase III Multicenter Study of the Effects on Quality of Life of Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer|BREAST-10|National Cancer Institute, Naples|No|Completed|February 2004|December 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Female|N/A|70 Years|No|||January 2016|January 13, 2016|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00540800||166328|
NCT00558090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07.15A/OPCIC|The Optimization of Procedural Pain Control in Intensive Care Unit (ICU) Patients|Randomised Clinical Trial of the Optimization of Procedural Pain Control in ICU Patients|OPCIC|St. Antonius Hospital|No|Completed|February 2008|February 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|85 Years|No|||October 2008|March 29, 2010|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00558090||165036|
NCT00558103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG108838|Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer|A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer||GlaxoSmithKline|Yes|Completed|December 2007|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|163|||Female|18 Years|N/A|No|||January 2013|January 31, 2013|November 9, 2007|Yes|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00558103||165035|
NCT00559312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO110755|The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD|A 6-week Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Fluticasone 250μg/Salmeterol 50μg Combination (FSC 250/50) on Exertional Dyspnea in Patients With Symptomatic Mild COPD||Queen's University|Yes|Completed|December 2007|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|41 Years|N/A|No|||December 2012|December 14, 2012|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559312||164947|
NCT00559338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0603-412|Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department|Acutely Decompensated Heart Failure in a County Emergency Department: A Double Blind Randomized Controlled Comparison of Nesiritide vs. Placebo Treatment||University of Texas Southwestern Medical Center|No|Completed|December 2003|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||November 2007|November 15, 2007|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00559338||164946|
NCT00559026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS-DTIC-melvacc1|Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients|Phase I/II Clinical Trial for the Evaluation of the Interaction Between Chemotherapy and Immunotherapy in Melanoma Patients|DTIC-melvacc|Istituto Superiore di Sanità|Yes|Completed|September 2004|September 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||November 2007|November 15, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559026||164969|
NCT00555152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00875|Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ|Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer||National Cancer Institute (NCI)|Yes|Completed|January 2008|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Female|21 Years|N/A|No|||August 2014|October 22, 2015|November 6, 2007|Yes|Yes||No|July 24, 2015|https://clinicaltrials.gov/show/NCT00555152||165251|
NCT00555165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT-UK|A Study of an Implantable Miniature Telescope in Patients With With End-Stage AMD|A Prospective Multicenter Clinical Study of the Implantable Miniature Telescope* in Patients With Central Vision Impairment Associated With AMD: IMT-UK Protocol (*IMT by Dr. Isaac Lipshitz)||VisionCare Ophthalmic Technologies, Inc.|No|Completed|November 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|55 Years|N/A|No|||November 2012|November 13, 2012|November 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00555165||165250|
NCT00555711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP 2005-4775|Monitoring Neural Tissues Properties by Modulated Imaging (MI)|Monitoring Neural Tissues Properties by Modulated Imaging (MI)|MI|University of California, Irvine|No|Withdrawn|November 2008|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|August 2015|August 5, 2015|November 7, 2007||No|no subject|No||https://clinicaltrials.gov/show/NCT00555711||165208|
NCT00555477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.044|Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure|Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure||University of Michigan Cancer Center|Yes|Terminated|August 2007|September 2013|Actual|December 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Female|18 Years|60 Years|No|||May 2014|May 19, 2014|November 6, 2007|Yes|Yes|The study was stopped after 69 subjects were enrolled because of poor accrual.|No|April 16, 2014|https://clinicaltrials.gov/show/NCT00555477||165226|Because of poor accrual, the trial was closed after 69 of a planned 150 patients were enrolled.
NCT00555490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IsfahanUMS|Long-Term Effect of Soy Consumption on Cardio-Renal Indices and CRP in Type 2diabetes With Nephropathy|Soy-Protein Intake, Cardio-Renal Indices and C-Reactive Protein in Type 2 Diabetes With Nephropathy: a 4-y Randomized Clincal Trial||Isfahan University of Medical Sciences||Completed|April 2001|September 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|41|||Both|N/A|N/A|No|||November 2007|November 7, 2007|November 7, 2007||||No||https://clinicaltrials.gov/show/NCT00555490||165225|
NCT00543790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3208A1-1001|Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women|A Randomized, Placebo-Controlled, Double-Blind, Sponsor-Unblinded, Multiple-Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PRA-027 Administered Orally To Cycling Or Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 27, 2010|October 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00543790||166101|
NCT00543803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1492|Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients|Observational Non-interventional Study Evaluating the Safety and Efficacy of Truvada + Nevirapine||Boehringer Ingelheim||Completed|February 2006|||December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|334|||Both|18 Years|N/A|No|Non-Probability Sample|HIV Patients|May 2014|May 13, 2014|October 8, 2007||||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00543803||166100|
NCT00543868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0782-001|MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)|||Merck Sharp & Dohme Corp.||Completed|June 2004|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|462|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 10, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543868||166095|
NCT00544141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-115-44|Clinical Evaluation of the Care On Line Thermometer|||Medisim Ltd|No|Recruiting||||||N/A|Observational|N/A|||||||Both|1 Year|18 Years|Accepts Healthy Volunteers|Probability Sample|Children (1-18 years old) in the pediatric or emergency department, with or without fever.|April 2008|April 23, 2008|October 14, 2007||||No||https://clinicaltrials.gov/show/NCT00544141||166074|
NCT00543816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-030|MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)|||Merck Sharp & Dohme Corp.||Terminated|August 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|100|||Both|21 Years|N/A|No|||June 2015|June 22, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543816||166099|
NCT00543829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gepardo|German Preoperative Adriamycin Docetaxel Study|A Randomised, Controlled, Open Phase II b Study Comparing a Combination of Dose-Intensified Doxorubicin and Docetaxel With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast (T>=3cm N0-2 M0)||German Breast Group|Yes|Completed|April 1998|June 1999|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|18 Years|70 Years|No|||October 2007|October 16, 2007|October 12, 2007||||No||https://clinicaltrials.gov/show/NCT00543829||166098|
NCT00543842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0080|Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer|Phase I/II Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Rectal Cancer||M.D. Anderson Cancer Center|No|Completed|December 2007|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00543842||166097|
NCT00544401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP.IVF.07|Hypnopuncture for In Vitro Fertilization (IVF)|Effect of Hypnosis and Acupuncture (Hypnopuncture) on Pregnancy Rates Following Assisted Reproductive Treatment (IVF/ICSI): A Pilot Study||Shaare Zedek Medical Center|No|Terminated|November 2008|||August 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 8, 2010|October 15, 2007||No|Lack of participants|No||https://clinicaltrials.gov/show/NCT00544401||166054|
NCT00544713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9818-001|Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery|||Allergan|No|Completed|September 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|228|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 9, 2011|October 12, 2007||No||No|June 29, 2009|https://clinicaltrials.gov/show/NCT00544713||166031|
NCT00544375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2001-2011|Measurements of Anemia and Physiologic Tissue Response to Blood Transfusions in VLBW Infants Using Quantitative NIRS|Non-Invasive Measurements of Anemia and Physiologic Tissue Response to Blood Transfusions in Very Low Birth Weight Infants Using Quantitative Near-Infrared Spectroscopy||University of California, Irvine|No|Completed|June 2002|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|N/A|1 Month|No|Non-Probability Sample|primary care clinic|August 2015|August 5, 2015|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544375||166056|
NCT00545376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-12|Effect of OMT on Asthma Symptoms in Southwest Virginia|The Use of Osteopathic Manipulation in a Clinic and Home Setting to Address Pulmonary Distress as Related to Asthma in Southwest Virginia||Edward Via Virginia College of Osteopathic Medicine|Yes|Completed|October 2007|February 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|5 Years|55 Years|No|||September 2007|February 11, 2008|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545376||165983|
NCT00544999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564068|Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia|Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse||National Cancer Institute (NCI)||Recruiting|September 2007|||April 2010|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|21|||Both|18 Years|65 Years|No|||July 2009|September 16, 2013|October 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00544999||166011|
NCT00541073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564058|Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery|Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma||National Cancer Institute (NCI)||Completed|June 2007|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||July 2009|May 14, 2011|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541073||166307|
NCT00541086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000570041|Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery|A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer||Gruppo Italiano Mammella (GIM)|Yes|Active, not recruiting|March 2007|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|3600|||Female|18 Years|N/A|No|||January 2015|January 20, 2015|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00541086||166306|
NCT00541658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007008|A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis|A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, & 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis.||Warner Chilcott|No|Completed|October 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|923|||Female|50 Years|N/A|No|||April 2013|April 15, 2013|October 5, 2007|Yes|Yes||No|April 13, 2011|https://clinicaltrials.gov/show/NCT00541658||166263|
NCT00542009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7211005|A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight|A 12-Week, Phase 2A, Randomized, Subject And Investigator Blinded, Placebo-Controlled Trial To Evaluate The Safety, Tolerability And Efficacy Of CE-326,597 On Glucose Control And Body Weight In Overweight Adult Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Completed|December 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|252|||Both|18 Years|65 Years|No|||November 2012|November 5, 2012|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00542009||166236|
NCT00559039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901015|Effects of Fetal, Infant, and Early Childhood Exposures on Adult Cancer Risk in Women|Fetal, Infant and Early Childhood Antecedents of Cancer in Women: Maternal Cohort Study of the Nurses' Health Studies||National Institutes of Health Clinical Center (CC)||Completed|October 2000|October 2006|Actual|||N/A|Observational|N/A|||Anticipated|128700|||Female|18 Years|89 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559039||164968|
NCT00559299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTP110333|Patient Tolerability Study of GSK163090|A Randomized, Single-blind, Placebo-controlled, 2 Part Study to Evaluate the Safety and Tolerability of GSK163090 at Single and Repeat Doses in Subjects With MDD||GlaxoSmithKline|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|65 Years|No|||February 2011|March 15, 2012|November 14, 2007||||||https://clinicaltrials.gov/show/NCT00559299||164948|
NCT00559052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIO16IP07-01|An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)|An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI).||Axcan Pharma|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|22|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|November 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559052||164967|
NCT00559351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6P05C01320|RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus|Possibilities for Improvement of an Outcome of the Treatment in Squamous Cell Carcinoma of the Thoracic Esophagus - a Multicenter Randomized Clinical Phase III Trial.||Ministry of Scientific Research and Information Technology, Poland|No|Terminated|December 2001|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|75 Years|No|||September 2007|November 15, 2007|November 15, 2007|||difficulty in recruitment|No||https://clinicaltrials.gov/show/NCT00559351||164945|
NCT00555126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Polytrauma-007|Forced Air Versus Endovascular Warming in Polytrauma Patients|A Comparison of Forced-air With Endovascular Warming for Treatment of Accidental Hypothermia in Polytrauma Victims|FAEWPP|Medical University of Vienna|Yes|Suspended|May 2008|January 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||July 2010|July 27, 2010|November 6, 2007||No|Not enough patients|No||https://clinicaltrials.gov/show/NCT00555126||165253|
NCT00559364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIO16EPI07-01|Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea|A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency||Forest Laboratories|No|Completed|November 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||January 2014|January 27, 2014|November 14, 2007|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT00559364||164944|Results for percentage of stool characteristics per bowel movement and number of days with at least 1 stool of specific characteristic were not reported due to change in planned analysis.
NCT00555425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA020576-01A1|Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence|Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence||Yale University|No|Completed|July 2008|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|65 Years|No|||July 2013|July 19, 2013|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00555425||165230|
NCT00556426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-RC-1332|Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.|The Bard® Recovery® Filter Registry (EVEREST) for Patients Who Are Candidates for an Optional (Retrievable) Inferior Vena Cava Filter That Undergo Placement of the Bard® Recovery® Filter.|EVEREST|C. R. Bard|Yes|Completed|December 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||May 2012|May 25, 2012|November 8, 2007|Yes|Yes||No|May 26, 2009|https://clinicaltrials.gov/show/NCT00556426||165153|
NCT00543166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T101090002|Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue|Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue||Helsinki University|Yes|Active, not recruiting|February 2003|December 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|80 Years|No|||October 2007|November 2, 2007|October 9, 2007||||No||https://clinicaltrials.gov/show/NCT00543166||166147|
NCT00544414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98147|Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer|Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy||City of Hope Medical Center||Active, not recruiting|April 2000|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|120 Years|No|||December 2015|December 30, 2015|October 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00544414||166053|
NCT00544427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2003-3025|Near Infrared Optical Coherence Tomography of the Upper Aero-Digestive Tract|Near Infrared Optical Coherence Tomography of the Upper Aero-Digestive Tract||University of California, Irvine|No|Recruiting|August 2003|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be sekected from University of California Iriven Medical Cente        department of Otolarygology/Head and neck surgery, Chao Digestive Diseases Center,        Neonatal Intensive Care Unit and Beckman laser Institute and Children Hospital of Orange        Pediatric Department.|February 2016|February 5, 2016|October 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00544427||166052|
NCT00543855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-431|A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)|Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II||Eisai Inc.||Completed|November 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|167|||Both|50 Years|N/A|No|||March 2013|March 5, 2013|October 4, 2007||No||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00543855||166096|
NCT00544154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87014|Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis|Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate||UCB Pharma|No|Completed|October 2002|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|247|||Both|18 Years|75 Years|No|||September 2009|September 3, 2013|October 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544154||166073|
NCT00545051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20088|A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.|A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women||Hoffmann-La Roche||Completed|May 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Female|50 Years|85 Years|No|||March 2016|March 1, 2016|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545051||166008|
NCT00545064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507A-152|Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)|A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s)|DISCOVER|Merck Sharp & Dohme Corp.||Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|176|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 16, 2007|No|Yes||No|August 20, 2009|https://clinicaltrials.gov/show/NCT00545064||166007|
NCT00545012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N164|A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures|A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)||UCB Pharma|No|Completed|May 2000|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Both|4 Years|17 Years|No|||September 2009|September 16, 2013|October 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00545012||166010|
NCT00545025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110674|Revaccination With Influenza Vaccine GSK1247446A|Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656||GlaxoSmithKline||Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|243|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|October 15, 2007|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00545025||166009|
NCT00540839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-303|A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)|A Phase III Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Prospectively Evaluate Efficacy of Montelukast in Patients Aged 6 Months to 5 Years With Chronic Asthma||Merck Sharp & Dohme Corp.|No|Withdrawn|November 2007|||March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|5 Years|No|||June 2015|June 9, 2015|October 4, 2007|Yes|Yes|Based on input from regulatory agencies, it is not necessary to conduct this study. An ongoing    study was sufficient for regulatory purposes.|No||https://clinicaltrials.gov/show/NCT00540839||166325|
NCT00539526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-LUM-07-003|Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues|||Allergan|No|Completed|September 2007|September 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|October 2, 2007|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00539526||166424|
NCT00540813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBM-VS-56|Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions|Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions|PEPCAD V|Heart Centre Rotenburg|No|Active, not recruiting|October 2007|October 2016|Anticipated|May 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00540813||166327|
NCT00540826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12067|Treatment Compliance in Children and Adolescents on ADHD Medication|Treatment Adherence and Compliance in Children and Adolescents on ADHD Medication and Emotional Expression in Clinical Practice|COMPLY|Eli Lilly and Company|No|Completed|November 2007|June 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|518|||Both|6 Years|17 Years|No|Non-Probability Sample|Children and adolescents who are newly initiated on medication approved for the treatment        of ADHD in a routine clinical setting.        Participating physicians may be office or hospital based psychiatrists and pediatricians        throughout Germany.|August 2009|August 26, 2009|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00540826||166326|
NCT00540241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11826|Performance Status During Treatment With Pemetrexed in Patients With NSCLC|Performance Status and Influencing Factors During Second-Line Treatment With Pemetrexed in Patients With Stage III/IVNon Small Cell Lung Cancer|PERFORMANCE|Eli Lilly and Company|No|Completed|September 2007|March 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|542|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with NSCLC Stage IIIa/b or IV who have previously been treated with chemotherapy        and are starting second-line treatment with single-agent pemetrexed are eligible for this        observational study. Patients must have received one prior chemotherapy regimen. Patients        who received prior neoadjuvant or adjuvant therapy are also eligible. Both, in- and        outpatients are eligible.|March 2011|March 28, 2011|October 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00540241||166371|
NCT00541372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWO-07001|Needle Length In Obese Insulin-Using Diabetic Subjects|The Influence of the Needle Length on Long Term Glycaemic Control in Insulin Using Obese Diabetic Subjects|INOBESE|University Medical Center Groningen|No|Completed|September 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|130|||Both|18 Years|80 Years|No|||March 2009|March 13, 2009|October 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00541372||166284|
NCT00559065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906205|A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China|A Case - Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China||National Institutes of Health Clinical Center (CC)||Completed|July 2006|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|3860|||Both|21 Years|90 Years|No|||October 2015|October 20, 2015|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559065||164966|
NCT00554853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM11806|PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease|Peroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease|RA PPAR|University of Michigan|No|Completed|November 2007|January 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|144|||Both|21 Years|N/A|No|||January 2013|January 17, 2013|November 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00554853||165273|
NCT00555139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH108571|A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder|Double-blind, Randomized, Placebo and Alprazolam-controlled Three-period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-like fRMI Activity of GW876008 and GSK561679 After Single-dose Administration in Subjects With Social Anxiety Disorder (SAD)||GlaxoSmithKline||Completed|March 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|64 Years|No|||October 2010|October 13, 2010|November 5, 2007||||No||https://clinicaltrials.gov/show/NCT00555139||165252|
NCT00555191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-136/2006(REK)|Fructose Malabsorption in Northern Norway|Fructose Malabsorption in Northern Norway. Fructose Malabsorption and Irritable Bowel Syndrome.|FINN|University Hospital of North Norway|No|Active, not recruiting|September 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00555191||165248|
NCT00555204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-876|Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors||Abbott|Yes|Terminated|November 2007|||June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|337|||Both|55 Years|90 Years|No|||August 2011|August 19, 2011|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555204||165247|
NCT00555438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701017|Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.|Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux,in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. PROPICE Study|PROPICE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|451|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|November 7, 2007||No||No|September 15, 2010|https://clinicaltrials.gov/show/NCT00555438||165229|
NCT00556439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 AR070018|Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis|Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu's Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Completed|December 2008|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|15 Years|N/A|No|||December 2015|December 22, 2015|November 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00556439||165152|
NCT00543179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/064|Treatment of the Dumping Syndrome With Lanreotide Autogel®|Treatment of the Dumping Syndrome With Lanreotide Autogel®||Radboud University|Yes|Recruiting|October 2007|||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||October 2007|October 11, 2007|October 11, 2007||||No||https://clinicaltrials.gov/show/NCT00543179||166146|
NCT00545077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2006-11/GBG 51|Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer|Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment Compared to Endocrine Treatment Alone, in Postmenopausal Women With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line Treatment||Spanish Breast Cancer Research Group|Yes|Completed|November 2007|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|378|||Female|18 Years|80 Years|No|||October 2014|May 18, 2015|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545077||166006|
NCT00545415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-07-3-043|The Effect of Fruit and Fruit Juice on Plasma Total Antioxidant Capacity|The Effect of Fruit and Fruit Juice on Plasma Total Antioxidant Capacity||Maastricht University Medical Center|No|Completed|January 2008|November 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|24|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 15, 2009|October 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00545415||165980|
NCT00544388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00379|Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects|Trial to Compare the Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects Exposed to Pollen Challenge in an Environmental Exposure Unit (EEU).||UCB Pharma|No|Completed|April 2004|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|570|||Both|16 Years|N/A|No|||September 2009|December 13, 2013|October 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00544388||166055|
NCT00540852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2002-2306|Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy|Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy||University of California, Irvine|No|Completed|June 2002|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|77|||Female|21 Years|75 Years|No|Non-Probability Sample|primary care clinic|August 2015|August 5, 2015|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540852||166324|
NCT00545389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-202|Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476|A Phase II, Randomized, Multi-Centre, Double-Blind, Parallel-Group, Dose-Ranging, Exploratory Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (Mesalazine) Once Daily||Shire||Completed|February 2003|October 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|38|||Both|18 Years|N/A|No|||November 2007|June 18, 2009|October 16, 2007||||No||https://clinicaltrials.gov/show/NCT00545389||165982|
NCT00545402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21273|A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.|A Randomized, Open Label Study Comparing the Effect of CellCept With Therapeutic Drug Monitoring, Tacrolimus and a Corticosteroid-sparing Regimen Versus Fixed Dose CellCept, Tacrolimus and Corticosteroids Maintained up to 6 Months, on Acute Rejection and Safety in Liver Transplant Patients.||Hoffmann-La Roche||Completed|November 2007|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|October 16, 2007||No||No|June 9, 2014|https://clinicaltrials.gov/show/NCT00545402||165981|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT00539539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30707-A|Automated Real-time Feedback on CPR Study|Controlled Study of the Clinical Effectiveness of Automated Real-Time Feedback on CPR Process Conducted at a Subset of ROC Sites||University of Washington|Yes|Completed|February 2007|September 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1586|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|October 2, 2007||No||No|December 30, 2010|https://clinicaltrials.gov/show/NCT00539539||166423|Open label study - providers not blinded to intervention. High rates of missing CPR process measures.
NCT00539890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-014|Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus|A Phase 3 Randomized, Open Label, Multi-Center Comparative Study of Technosphere /Insulin Versus Rapid Acting Insulin in Subjects With Type-2 Diabetes Mellitus Receiving Lantus as Basal Insulin||Mannkind Corporation||Completed|November 2005|July 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||0|||Both|18 Years|80 Years|No|||October 2009|October 12, 2009|October 3, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00539890||166398|
NCT00540228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110794|Study to Evaluate an Influenza Vaccine Candidate|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza Vaccine GSK1247446A With Various Formulations in Subjects Aged 18-64 Years||GlaxoSmithKline||Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|1006|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2013|May 9, 2013|October 4, 2007|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00540228||166372|
NCT00536003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER: 04-196|Vaginal Progesterone to Prevent Preterm Delivery in Women With Preterm Labor|Prevention of Preterm Delivery With Vaginal Progesterone in Women With Preterm Labor|4P|University Hospital, Geneva|No|Terminated|July 2006|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|384|||Female|18 Years|N/A|No|||June 2012|June 5, 2012|September 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00536003||166691|
NCT00540540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-1995-563|Measurements of Breast Tissue Optical Properties|Measurements of Breast Tissue Optical Properties||University of California, Irvine|No|Recruiting|December 1995|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|653|||Female|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from University of California Irvine Medical Clinic and        Cancer Center.|February 2016|February 23, 2016|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540540||166348|
NCT00540553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAR109935|Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males|A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers||GlaxoSmithKline|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|126|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|October 4, 2007||||||https://clinicaltrials.gov/show/NCT00540553||166347|
NCT00558753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABuv102007|Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA|A Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset Complex Regional Pain Syndrome After Total Knee Arthroplasty|PregTKA|Rush University Medical Center|No|Completed|April 2006|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|21 Years|80 Years|No|||July 2012|July 25, 2012|November 14, 2007|Yes|Yes||No|January 11, 2012|https://clinicaltrials.gov/show/NCT00558753||164989|
NCT00558454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iron for LBW infants|Iron Supplementation of Marginally Low Birth Weight Infants|Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g|JOHN|Umeå University|Yes|Active, not recruiting|March 2004|November 2014|Anticipated|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|380|||Both|39 Days|45 Days|Accepts Healthy Volunteers|||June 2012|June 4, 2012|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558454||165010|
NCT00558467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.644|Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria|A Randomized, Double-blind, Placebo-controlled, Flexible Dose Study to Evaluate Efficacy and Safety of Pramipexole Immediate Release (0.125-0.5mg/Day) Versus Placebo for 6 Weeks in Children and Adolescents (Age 6-17 Inclusive) Diagnosed With Tourette Disorder According to DSM IV Criteria.||Boehringer Ingelheim||Completed|January 2008|||June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|6 Years|17 Years|No|||March 2014|May 7, 2014|November 14, 2007|Yes|Yes||No|June 18, 2010|https://clinicaltrials.gov/show/NCT00558467||165009|
NCT00559091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0620KB|A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia|A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes|Borden-001|Jewish General Hospital|No|Completed|April 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2009|May 6, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559091||164964|
NCT00558766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080023|Motor Cortex Reward Signaling in Parkinson Disease|Motor Cortex Reward Signaling in Parkinson Disease||National Institutes of Health Clinical Center (CC)||Completed|November 2007|June 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|35|||Both|45 Years|70 Years|No|||June 2011|June 14, 2011|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558766||164988|
NCT00554866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2-018|L-arginine Concentrations and CPS Polymorphisms in VLBW Infants|Carbamoyl-phosphate Synthase Gene Polymorphisms Influencing Plasma L-arginine Concentrations in Preterm Infants||Maastricht University Medical Center|No|Completed|July 2007|December 2014|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|477|||Both|N/A|12 Hours|No|||October 2015|October 27, 2015|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554866||165272|
NCT00554905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rfa-001|Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma|Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma|RFA and TACE|Sun Yat-sen University|Yes|Recruiting|October 2006|June 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||February 2009|February 6, 2009|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554905||165269|
NCT00554879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU # 07-23024|Acupuncture Treatment of Dry Eye|Acupuncture Treatment of Dry Eye||Walter Reed Army Medical Center|Yes|Completed|November 2007|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 26, 2011|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554879||165271|
NCT00555464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3429|Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas|A Phase II, Randomized, Clinical Trial Assessing Efficacy And Safety Of Oral Prednisolone vs Intravenous Vincristine In The Treatment Of Infantile||Medical College of Wisconsin|Yes|Terminated|November 2007|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|N/A|6 Months|No|||June 2013|June 4, 2013|November 7, 2007|Yes|Yes|The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas|No|February 19, 2013|https://clinicaltrials.gov/show/NCT00555464||165227|The limitations of this trial include early termination of enrollment leading to small numbers of subjects analyzed.
NCT00556127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIMURELL-DLBCL|Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma|Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive|DLBCL|Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie|No|Completed|June 2002|September 2006|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|60 Years|No|||November 2007|November 8, 2007|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00556127||165176|
NCT00556140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000990|The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression|The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability|Abilify|Massachusetts General Hospital|No|Completed|June 2003|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|80 Years|No|||July 2012|July 11, 2012|November 8, 2007||No||No|June 1, 2012|https://clinicaltrials.gov/show/NCT00556140||165175|We had several limitations to the study. The sample size was small, and we used an open and uncontrolled study design. We also excluded subjects who currently or recently abused alcohol, recreational drugs, and/or prescription drugs.
NCT00543491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-027|MK0767 and Sulfonylurea Combination Study (0767-027)|||Merck Sharp & Dohme Corp.||Terminated|May 2003|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|129|||Both|21 Years|78 Years|No|||June 2015|June 11, 2015|October 5, 2007||||No||https://clinicaltrials.gov/show/NCT00543491||166123|
NCT00543504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0638|Bevacizumab in Multiple Phase I Combinations|A Phase 1 Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2007|||October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|354|||Both|N/A|N/A|No|||December 2015|December 18, 2015|October 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00543504||166122|
NCT00538239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-011|Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)|A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas|SUCCEED|Merck Sharp & Dohme Corp.|Yes|Completed|October 2007|December 2012|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|711|||Both|13 Years|N/A|No|||February 2015|February 12, 2015|September 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538239||166521|
NCT00538252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|involvementincontext|Parental Involvement and Children's Extra-Familial Contexts|Parental Involvement, Extra-Familial Contexts and Prevention of Drug Use Risk||University of Pittsburgh|Yes|Completed|May 2007|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|731|||Both|2 Years|3 Years|No|Non-Probability Sample|731 toddlers and their families followed from age 2 to 9 recruited on the basis of low        socioeconomic status, and the presence of family (e.g., parental depression, drug use) and        child (disruptive behavior) risk.|December 2013|December 10, 2013|October 1, 2007||||No||https://clinicaltrials.gov/show/NCT00538252||166520|
NCT00544726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc074491ctl|Rehabilitation for Patients With Pulmonary Arterial Hypertension|||Rabin Medical Center|No|Enrolling by invitation|February 2008|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||October 2007|April 6, 2008|October 15, 2007||||No||https://clinicaltrials.gov/show/NCT00544726||166030|
NCT00539565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH99LG21|RCT of Steroids Following Kasai Portoenterostomy for Biliary Atresia.|Phase IIIb Study of Corticosteroids as Post-Operative Adjuvant Therapy in Biliary Atresia||King's College Hospital NHS Trust|No|Enrolling by invitation|January 2000|September 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|100 Days|No|||September 2007|October 3, 2007|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00539565||166422|
NCT00539578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0777-022|Treatment of Patients With Anxiety Disorder (0777-022)|A Double-Blind, Mulitcenter, Placebo-Controlled, Flexible-Dose Replicate Study of MK0777 Gel Extrusion Module (GEM) 3 mg B.I.D. to 8 mg B.I.D. in the Treatment of Outpatients With Generalized Anxiety Disorder||Merck Sharp & Dohme Corp.||Completed|September 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|270|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539578||166421|
NCT00539227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0194|A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy|A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy||M.D. Anderson Cancer Center|No|Completed|October 2007|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|37|||Female|N/A|N/A|No|Non-Probability Sample|Patients with breast cancer.|August 2013|August 23, 2013|October 2, 2007||No||No||https://clinicaltrials.gov/show/NCT00539227||166447|
NCT00540267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMD07|Bone Density in Patients With Schizophrenia|Bone Mineral Density in the Korean Patients With Chronic Schizophrenia With Alcohol Abuse||Inje University|No|Completed|November 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case Control||1|Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|people with schizophrenia, gaed between 18-80 years, with no endocrine disorder|October 2008|November 3, 2008|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540267||166369|
NCT00540280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2031-059|Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer|||King Faisal Specialist Hospital & Research Center||Suspended|October 2003|October 2013|Anticipated|October 2003|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||March 2011|March 6, 2011|October 4, 2007|Yes|Yes|Follow up only|No||https://clinicaltrials.gov/show/NCT00540280||166368|
NCT00540566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMPP-1996-200|Optical Biopsy of Human Skin in Conjunction With Laser Treatment|Optical Biopsy of Human Skin in Conjunction With Laser Treatment||University of California, Irvine|No|Completed|June 1999|July 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic, community sample|August 2015|August 5, 2015|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540566||166346|
NCT00540579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 105|CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas|A Phase I/II Study of CC-4047 in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas||SCRI Development Innovations, LLC|Yes|Completed|November 2007|January 2011|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|October 5, 2007|No|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT00540579||166345|
NCT00540293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581157|Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study|A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label Study Assessing The Percentage Of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 MG, 20 MG, And 40 MG.|AT GOAL|Pfizer|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|425|||Both|18 Years|80 Years|No|||March 2009|August 14, 2009|October 4, 2007|Yes|Yes||No|May 8, 2009|https://clinicaltrials.gov/show/NCT00540293||166367|
NCT00536276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-9-26-1|Evaluation of Vitamin D Status in Children With Acute Burns|Vitamin D Deficiency in Acutely Injured Pediatric Burn Patients: Incidence, Etiology, Metabolic Sequelae and Prevention|VitaminD|Shriners Hospitals for Children|Yes|Completed|March 2003|April 2011|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|6 Months|18 Years|No|||May 2012|May 8, 2012|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00536276||166670|
NCT00536289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSC HR # 10870|Blunt Needles do Not Reduce Needlestick Injuries to Doctors During Suturing After Child-Birth|The Use of Blunt Needles Does Not Reduce Needlestick Injury During Obstetrical Laceration Repair||Medical University of South Carolina|No|Completed|January 2005|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|438|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2006|September 26, 2007|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00536289||166669|
NCT00558480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1066|Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis|A Double Blind, Placebo Controlled Randomized Trial of Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Children Aged 5-14 Years With Latent Tuberculosis.||Medical Research Council Unit, The Gambia|No|Withdrawn|July 2009|December 2012|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558480||165008|
NCT00558792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP 108|Coronary MDCTA With Iopamidol Injection 370|A Phase II Multicenter Randomized Double Blind Dose Finding Study of Iopamidol Injection 370 in Multidetector Computed Tomographic Angiography (MDCTA) in Patients With Suspected Coronary Artery Stenosis||Bracco Diagnostics, Inc|No|Completed|November 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|210|||Both|30 Years|N/A|No|||October 2012|October 18, 2012|November 13, 2007|Yes|Yes||No|August 13, 2012|https://clinicaltrials.gov/show/NCT00558792||164986|
NCT00558805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921708|Family Intervention for Suicidal Youth: Emergency Care|Family Intervention for Suicidal Youth: Emergency Care|FISP|Centers for Disease Control and Prevention|Yes|Completed|October 2003|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|10 Years|18 Years||||October 2007|November 14, 2007|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00558805||164985|
NCT00558818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR-404|Long-term Study With Clevudine|A Phase lV Study to Evaluate the Long-term Safety and Efficacy of Clevudine in the Patients Chronically Infected With Hepatitis B Virus||Bukwang Pharmaceutical|No|Completed|June 2007|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|60 Years|No|||July 2012|July 24, 2012|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558818||164984|
NCT00559377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00257|FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer|A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer||National Cancer Institute (NCI)|No|Completed|November 2007|May 2014|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Female|18 Years|N/A|No|||December 2013|June 3, 2015|November 15, 2007|Yes|Yes||No|October 29, 2014|https://clinicaltrials.gov/show/NCT00559377||164943|Small number of subjects enrolled and events limit meaningful statistical analysis.
NCT00559078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Malouf|Qualitative Research on Women With Congenital Adrenal Hyperplasia|Health-related Quality of Life, Mental Health and Psychotherapeutic Considerations for Women Diagnosed With a Disorder of Sexual Development: Congenital Adrenal Hyperplasia|CAH|Lehigh University|No|Completed|July 2007|May 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|16|||Female|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women diagnosed with CAH (either simple-virilizing or salt-losing types) living in the        United States|November 2009|November 6, 2009|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559078||164965|
NCT00555503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-383|Registry of Mastectomy for Breast Cancer Risk Reduction|Registry of Mastectomy for Breast Cancer Risk Reduction||Georgetown University|No|Enrolling by invitation|November 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Patient operative specimens, blood samples, and saliva samples.|Both|18 Years|70 Years|No|Non-Probability Sample|Patients are enrolled from the plastic surgery, breast surgery, or oncology clinics at        Georgetown University Hospital who are at elevated risk for breast cancer. Please note        that the Registry can only enroll Georgetown University Hospital patients.|February 2015|February 11, 2015|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555503||165224|
NCT00555516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH96-TD-I-111-003|A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy|A Phase I/II Double-Blind, Randomized, Placebo-Control Pilot Study to Evaluate the Safety and Pharmacodynamic Activities of EW02 in Reducing Neutropenia Caused by Breast Cancer Chemotherapy||Tri-Service General Hospital|Yes|Recruiting|November 2007|June 2009|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|20 Years|70 Years|No|||November 2007|November 7, 2007|November 7, 2007||||No||https://clinicaltrials.gov/show/NCT00555516||165223|
NCT00555217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|565|VA NEPHRON-D: Diabetes iN Nephropathy Study|CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)|VA NEPHRON-D|VA Office of Research and Development|Yes|Terminated|July 2008|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|1448|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|November 7, 2007||No|It was stopped primarily because of safety concerns along with low conditional power to detect    a treatment effect on the primary outcome.|No|April 17, 2015|https://clinicaltrials.gov/show/NCT00555217||165246|In October, 2012 the DMC recommended that study treatment be stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.
NCT00567034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-0002381/3|Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects|Augmenting Zyprexa With Naltrexone: Normalization of the Weight Gain Side Effect and the CNS Reward and Sensory Function|Zyprexa|Mclean Hospital|No|Completed|December 2006|December 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|21 Years|55 Years|No|||October 2013|October 24, 2013|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00567034||164364|
NCT00544167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 112|Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer|A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer||SCRI Development Innovations, LLC|No|Completed|May 2007|April 2011|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||March 2013|March 25, 2013|October 15, 2007||No||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00544167||166072|
NCT00544180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISED_L_01686|ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week|Record on Satisfaction of Patients With Actonel 35 mg Once a Week||Sanofi|No|Terminated|May 2005|||September 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|55 Years|80 Years|No|||September 2009|September 24, 2009|October 15, 2007||No|The trial was terminated due to lack of compliance with GCP regulations.|No||https://clinicaltrials.gov/show/NCT00544180||166071|
NCT00545428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Patrocinio|Mastoid Bone Autograft for Dorsal Nasal Augmentation|Mastoid Bone Autograft for Dorsal Nasal Augmentation||Federal University of Uberlandia|No|Completed|April 2006|December 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|No|||February 2009|February 3, 2009|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00545428||165979|
NCT00538603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #2051-062|Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)|Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)||King Faisal Specialist Hospital & Research Center||Completed|June 2005|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||December 2015|December 16, 2015|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538603||166493|
NCT00538616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002077|Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion|A Phase IV Single Center Cross Over Clinical Study Comparing Two Different Sedations Strategies for Mechanically Ventilated Patients With Neurological Critical Illness|PrePARE|Duke University|No|Completed|January 2008|April 2010|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|September 28, 2007|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00538616||166492|
NCT00539903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07112001326|Physical Activity and Immigrant Health||FAM|Norwegian School of Sport Sciences||Completed|August 2008|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|||||||Male|25 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 5, 2009|October 4, 2007||||No||https://clinicaltrials.gov/show/NCT00539903||166397|
NCT00539916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/03|Effects of Regular and Consequent Citrus Fruits Consumption on Vascular Protection|Effects of Regular and Consequent Citrus Fruit Consumption on Vascular Protection Specific Role of the Component Phytomicronutrients|AGRUVASC|University Hospital, Bordeaux|No|Completed|October 2007|March 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 15, 2008|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00539916||166396|
NCT00540254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002157|Behavioral Insomnia Therapy With Chronic Fatigue Syndrome|Behavioral Insomnia Therapy With Chronic Fatigue Syndrome||Duke University|Yes|Completed|September 2007|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|65 Years|No|||March 2010|February 28, 2013|October 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00540254||166370|
NCT00539591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL06|Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma|Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma||St. Jude Children's Research Hospital|No|Active, not recruiting|October 2007|September 2018|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|N/A|21 Years|No|||July 2015|August 4, 2015|October 2, 2007|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00539591||166420|The study closed early due to poor accrual to stratum B1.
NCT00539929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6201-A001-201|Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis|Proof of Principle, Randomized, Parallel-Group, Double-Blind, Vehicle-Controlled, Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis||Eisai Inc.|No|Completed|September 2007|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|October 3, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00539929||166395|
NCT00540306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2005-4760|Monitoring Functional Variation in the Breast During Menstrual Cycle by Using Diffuse Optical Spectroscopy|Monitoring Functional Variation in the Breast During Menstrual Cycle by Using Diffuse Optical Spectroscopy||University of California, Irvine|No|Completed|February 2006|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic, community sample|August 2015|August 5, 2015|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540306||166366|
NCT00540319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA015597|The Health in Pregnancy (HIP) Study|Prevention for Prenatal Health: the Health in Pregnancy (HIP) Study|HIP|University of California, San Francisco|Yes|Completed|June 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|410|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 5, 2013|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00540319||166365|
NCT00540592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110847|Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A|Observer Blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A With Various Formulations in Adults Aged 65 Years and Above||GlaxoSmithKline||Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|10||Actual|2007|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 8, 2012|October 5, 2007|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00540592||166344|
NCT00536016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JO642701|A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD|A Phase 1 Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients With Neovascular AMD||Jerini Ophthalmic|Yes|Completed|September 2007|December 2009|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|50 Years|N/A|No|||September 2010|September 20, 2010|September 25, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00536016||166690|
NCT00558779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49/07|Surgical Manipulation of the Aorta and Cerebral Infarction|Surgical Manipulation of the Ascending Aorta and Cerebral Infarction Following CABG||University of Wuerzburg|Yes|Recruiting|November 2007|May 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||November 2007|November 21, 2007|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00558779||164987|
NCT00558844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-106|Multidose Safety and Tolerability Study of (Arikace™) for Inhalation In Cystic Fibrosis Patients|Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikace™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.||Insmed Incorporated|Yes|Completed|June 2007|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|6 Years|N/A|No|||May 2012|May 3, 2012|November 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558844||164982|
NCT00559104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97133|Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|High-Dose Therapy and Autologous Stem Cell Transplantation During Remission in Poor-Risk Age-Adjusted International Prognostic Index High and High-Intermediate Risk Group Patients With Intermediate Grade and High-Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma||City of Hope Medical Center|Yes|Completed|October 1998|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|59 Years|No|||July 2015|July 17, 2015|November 15, 2007|Yes|Yes||No|July 17, 2015|https://clinicaltrials.gov/show/NCT00559104||164963|
NCT00559117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-111001 (VB-111)|A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer|A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer||Vascular Biogenics Ltd. operating as VBL Therapeutics|Yes|Active, not recruiting|November 2007|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|November 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00559117||164962|
NCT00559130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01|Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis|Multi-Center, Efficacy Study of the MedaSorb CytoSorb™ Hemoperfusion Device as an Adjunctive Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) or Acute Lung Injury (ALI) in the Setting of Sepsis||MedaSorb Technologies, Inc|Yes|Completed|November 2007|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||June 2011|June 6, 2011|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559130||164961|
NCT00554892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060233|Rectal Cancer Surgery Without Mechanical Bowel Preparation|ClinicalTrial in Rectal Cancer Surgery Without Mechanical Bowel Preparation|PREPACOL|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2007|August 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|November 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00554892||165270|
NCT00556075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPE-201|Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis|A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis||Repros Therapeutics Inc.|Yes|Terminated|November 2007|July 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Female|18 Years|48 Years|No|||August 2014|August 8, 2014|November 7, 2007|Yes|Yes|Clinical hold for safety|No|June 24, 2014|https://clinicaltrials.gov/show/NCT00556075||165180|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with complete study data.
NCT00556088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 121|LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors|A Phase I Study of LBH589 in Combination With Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors||SCRI Development Innovations, LLC|No|Completed|December 2007|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2010|December 29, 2010|November 8, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00556088||165179|
NCT00567060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01001|Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)|A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)||UCB Pharma|No|Completed|May 2000|January 2004|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|676|||Both|50 Years|89 Years|No|||September 2009|December 13, 2013|November 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00567060||164362|
NCT00544739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 P05B 013 28|Premature Coronary Artery Disease in Women - Risk Factors and Prognosis|Premature Coronary Artery Disease in Women - Risk Factors and Prognosis|PRECADIW|Institute of Cardiology, Warsaw, Poland|No|Completed|April 2005|September 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|670|Samples With DNA|whole blood, serum|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Consecutive women with onset of evident CAD before 55 years of age (admitted to        coronary angiography because of acute coronary syndrome, stable angina or        revascularization procedure Controls: age-matched healthy women selected from participants        examined between 2004-2006 in the National Health Survey - WOBASZ study with negative        history of exertional chest pain, angina, hospitalization of revascularization procedures        or coronary treatment|January 2012|January 16, 2012|October 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00544739||166029|
NCT00538564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00004434|Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia|Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia||Johns Hopkins University|No|Terminated|November 2006|December 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Male|18 Years|45 Years|No|||September 2007|July 26, 2010|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538564||166496|
NCT00538577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-03-30-6110|Outcome and Related Factors of Necrotizing Fasciitis of the Limb|||Tehran University of Medical Sciences|Yes|Completed|September 2007|September 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|N/A|No|Non-Probability Sample|The Patients with diagnosis of necrotiying faciitis|October 2009|October 4, 2009|September 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00538577||166495|
NCT00538590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ologen-Koln|Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery|Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery||Pro Top & Mediking Company Limited|Yes|Completed|July 2007|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2012|April 1, 2012|September 29, 2007||No||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00538590||166494|Stat Methods and limited sample size.
NCT00538902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-705|Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate|A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate||Abbott|No|Completed|August 2007|December 2009|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|October 1, 2007||No||No|November 23, 2009|https://clinicaltrials.gov/show/NCT00538902||166471|
NCT00538915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-7101|Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)|Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)||Biotest Pharmaceuticals Corporation|No|Completed|September 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|6 Years|75 Years|No|||February 2012|February 23, 2012|October 1, 2007|Yes|Yes||No|January 4, 2012|https://clinicaltrials.gov/show/NCT00538915||166470|
NCT00539604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMIS-CAD|Non Invasive Multicenter Italian Study for Coronary Artery Disease|Phase IV Multicenter, Intra-Individually Controlled, Comparison Study to Evaluate the Negative Predictive Value of 16-64 Slice MDCT Imaging in Patients Scheduled for Coronary Angiography||Società Italiana di Radiologia Medica||Completed|July 2004|June 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||350|||Both|18 Years|80 Years|No|||November 2006|October 3, 2007|October 3, 2007||||No||https://clinicaltrials.gov/show/NCT00539604||166419|
NCT00539955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-STU_014193_0111-001-M|Brief Intervention to Reduce Drinking Among Batterers|Brief Intervention to Reduce Drinking Among Batterers||The University of Tennessee Knoxville|Yes|Active, not recruiting|July 2003|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|253|||Male|N/A|N/A|No|||December 2012|December 17, 2012|September 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00539955||166393|
NCT00539942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070727009|Study of Arixtra to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy|Extended Deep Venous Thrombosis Prophylaxis in Gynecologic Oncology Surgery With Intermittent Compression Devices (ICD) With or Without Postoperative Arixtra: A Randomized Controlled Trial||University of Alabama at Birmingham|Yes|Terminated|April 2007|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|7|||Female|19 Years|85 Years|Accepts Healthy Volunteers|||February 2012|February 7, 2012|October 3, 2007|Yes|Yes|Problems with accrual|No|February 7, 2012|https://clinicaltrials.gov/show/NCT00539942||166394|This trial was terminated early due to poor enrollment and recruitment and the very small number of subjects analyzed. As such, the data is uninterpretable.
NCT00540631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0106ac|Multicenter Trial of Immunotherapy With House Dust Mite Allergoid|A Multicentre Randomized Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale|ACRI|Allergopharma GmbH & Co. KG|No|Completed|October 2007|December 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|60 Years|No|||February 2013|February 8, 2013|October 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00540631||166341|
NCT00540644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704-06; IUCRO-0170|Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma|Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma||Indiana University|Yes|Completed|October 2007|August 2014|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|October 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00540644||166340|
NCT00540605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-002|Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery|Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel Among Healthy Term Gravidas||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed||January 2010|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|October 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00540605||166343|
NCT00558519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-10403|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|November 2007|||January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|16 Years|39 Years|No|||July 2015|July 31, 2015|November 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00558519||165005|
NCT00558532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-66|Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment|Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment||University of Cincinnati|No|Terminated|October 2007|November 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Whole blood, plasma, fat tissue|Both|N/A|N/A|No|Probability Sample|All patients undergoing an operation for morbid obesity will be candidates for inclusion        in the study as will all candidates who are undergoing abdominoplasty or other abdominal        operations post bariatric surgery.|December 2008|December 5, 2008|November 14, 2007||No|Investigator Retired.|No||https://clinicaltrials.gov/show/NCT00558532||165004|
NCT00559468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05949|Org 25969 After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (19.4.312)(P05949)(COMPLETED)|A Multi -Center, Randomized, Parallel Group, Safety Assessor Blinded Trial Comparing Efficacy and Safety of 4.0 mg.Kg-1 Org 25969, Administered at T1 3-10% After Continuous Infusion of Rocuronium, and Pharmacokinetics of Rocuronium, Between Subjects Receiving Maintenance Anesthesia Using Propofol and Subjects Receiving Maintenance Anesthesia Using Sevoflurane||Merck Sharp & Dohme Corp.|No|Completed|December 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|20 Years|65 Years|No|||May 2015|May 5, 2015|November 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559468||164936|
NCT00559143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111 Version 1.0- 01/May/2007|Biventricular Alternative Pacing|Better Pacing - Biventricular Pacing as Alternative Method in Patients With Disturbances of AV Conduction and Preserved LV Function|BETTER|Medtronic Hellas Medical Devices ΑEE|No|Withdrawn|November 2007|July 2011|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|75 Years|No|||June 2011|June 7, 2011|November 15, 2007||No|No patients enrolled for long period of time. No scientific interest any more|No||https://clinicaltrials.gov/show/NCT00559143||164960|
NCT00559403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065867|Effect of HIV/STD Risk Reduction Program on South African Adolescents|South African Adolescent Health Promotion Project||University of Pennsylvania|No|Completed|October 2004|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1057|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559403||164941|
NCT00559390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0956-023|Research Study for Children With a Mother or Sister With Polycystic Ovary Syndrome|Metabolic Syndrome in PCOS: Precursors and Interventions|PCOS|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|July 2006|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Actual|136|Samples With DNA|Whole Blood, Serum and Plasma|Female|8 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Overweight girls between the ages of 8 and 12|April 2013|April 3, 2013|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559390||164942|
NCT00559416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080024|Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy|Immunologic and Virologic Response in HIV Infected Progressors After Infusion of Lymphocytes From HIV Infected "Elite" Long-Term Non-Progressors||National Institutes of Health Clinical Center (CC)||Recruiting|November 2007|October 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|100 Years|No|||October 2015|January 29, 2016|November 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00559416||164940|
NCT00555802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-1534|The Effect of Motor Control Exercise Versus General Exercise on Lumbar Local Stabilizing Muscles Thickness|The Effect of Motor Control Exercise Versus General Exercise on Lumbar Local Stabilizing Muscles Thickness||Zahedan University of Medical Sciences|No|Completed|April 2006|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|49|||Both|20 Years|80 Years|No|||November 2007|January 25, 2008|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00555802||165201|
NCT00555815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.05.01.30.-17|Intraoperative Hygiene Measures and Surgical Site Infections|Intraoperative Hygiene Measures and Rates of Surgical Wound Infection in General Surgery||University Hospital Inselspital, Berne|No|Completed|July 2005|January 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1032|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients undergoing general surgery in university hospital|November 2007|November 8, 2007|November 8, 2007||||No||https://clinicaltrials.gov/show/NCT00555815||165200|
NCT00555828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMT-AB001|Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction|A Phase 1b/2a Dose Escalation Study to Assess the Safety and Feasibility of Transendocardial Delivery of 3 Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction||Angioblast Systems|Yes|Recruiting|March 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|25|||Both|18 Years|N/A|No|||June 2009|February 16, 2010|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555828||165199|
NCT00556101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB-angio herlev 4|Patient Acceptance of Whole Body Magnetic Resonance Angiography|Whole Body Magnetic Resonance Angiography: Questionnaire Examination of Patient Acceptance.||Copenhagen University Hospital at Herlev|Yes|Completed|November 2007|July 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|81|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with pheripheral arterial disease|August 2009|August 18, 2009|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00556101||165178|
NCT00556114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2004-3555|A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging|A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging||University of California, Irvine|No|Completed|January 2007|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic and community sample.|August 2015|August 5, 2015|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00556114||165177|
NCT00538265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0404003|Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation|Evaluation of the Benefit of Antithymocyte Induction Therapy on Hepatic Fibrosis in de Novo Hepatitis C Virus Liver Transplant Patients.|BEFIRTH|University Hospital, Toulouse|No|Completed|May 2005|January 2011|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||February 2011|February 2, 2011|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538265||166519|
NCT00538278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #2051-057|Prospective Database for Acute Myeloblastic Leukemia|||King Faisal Specialist Hospital & Research Center|Yes|Active, not recruiting|October 2007|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|2000|||Both|N/A|N/A|No|||December 2011|December 11, 2011|October 1, 2007||No||No||https://clinicaltrials.gov/show/NCT00538278||166518|
NCT00538005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551557|Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma|A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma||National Cancer Institute (NCI)||Recruiting|May 2007|||July 2009|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||July 2009|January 9, 2014|October 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00538005||166539|
NCT00569868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-05|UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma|UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma||University of Arkansas|No|Completed|August 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 18, 2011|December 7, 2007||No||No|April 14, 2011|https://clinicaltrials.gov/show/NCT00569868||164154|
NCT00570414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s8197.03|Airway Management in Children Undergoing Adenotonsillectomies|Airway Management in Children Undergoing Adenotonsillectomies Under General Anesthesia; a Comparison of the Endotracheal Tube and the Laryngeal Mask Airway||Sykehuset Telemark|Yes|Completed|March 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|3 Years|16 Years|No|||January 2009|January 14, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570414||164113|
NCT00570674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-069|Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck|A Phase I/II Trial of Abraxane in Combination With Carboplatin, Erbitux and Intensity Modulated Radiation Therapy (IMRT)for Treatment of Locally Advanced Squamous Cancer of the Head and Neck||Dana-Farber Cancer Institute|Yes|Active, not recruiting|November 2007|June 2016|Anticipated|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570674||164095|
NCT00601809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUSBOCA|(Gastrografin Use in Small Bowel Obstruction Caused by Adherences)|Gastrografin Use in Small Bowel Obstruction Caused by Adherences|GUSBOCA|University of Bologna|No|Completed|September 2003|November 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||January 2008|January 25, 2008|January 14, 2008||||No||https://clinicaltrials.gov/show/NCT00601809||161757|
NCT00601822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH082706|Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa|Cognitive Remediation Therapy for Anorexia Nervosa||Stanford University|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00601822||161756|
NCT00602901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP01423|Elderly Back Pain: Comparing Chiropractic to Medical Care|Elderly Back Pain: Comparing Chiropractic to Medical Care|HRSA4|Palmer College of Chiropractic|No|Completed|July 2004|March 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|55 Years|N/A|No|||September 2015|September 3, 2015|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602901||161679|
NCT00603187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32716-W|ACY-7 Oral Administration of Acyline|Oral Administration of the GnRH Antagonist Acyline in Normal Men Part II: Multiple-dose Pharmacokinetics (Acyline-7/MER 104-02)|ACY-7|University of Washington|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 10, 2011|January 15, 2008|Yes|Yes||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00603187||161658|
NCT00600587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLC-0702|Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)|Phase Ⅱ Study of Induction Erlotinib Therapy in Stage III A(N2) Non-small Cell Lung Cancer Proceeding to Mediastinoscopy/PET and Thoracotomy/Radiotherapy||Guangdong Provincial People's Hospital|Yes|Completed|September 2007|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2013|June 23, 2013|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600587||161849|
NCT00573092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1411|Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs|Genome-Wide Case-Only Study of Antihypertensive Drug-Gene Interactions||University of Washington|No|Recruiting|September 2007|September 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|7900|Samples With DNA|Previously collected and new samples with DNA|Both|30 Years|79 Years|No|Non-Probability Sample|Data and specimens for this study will be collected from three population-based studies:        Group Health population, Cardiovascular Heart Study, and Jackson Heart Study. The Group        Health population will provide new DNA samples; the Cardiovascular Heart and Jackson Heart        studies will provide existing DNA specimens to replicate the study findings from the Group        Health population. The Cardiovascular Heart Study involves Americans over the age of 65.        The Jackson Heart Study is a cardiovascular disease study in African Americans.|January 2012|January 4, 2012|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573092||163914|
NCT00602537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060353-02|Antidepressant Therapy in Treating Bipolar Type II Major Depression|Treatment of Bipolar Type II Major Depression||University of Pennsylvania|Yes|Completed|December 2007|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602537||161703|
NCT00602914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP-1-001|A Pilot Study to Assess the Safety, PK and PD of Insulin Injected Via MicronJet or Conventional Needle|An Open Label Study in Healthy Volunteers and Diabetes Mellitus Type II Subjects to Determine the Safety, Pharmacokinetics and Pharmacodynamics Profile of Insulin Injected by the MicronJet Device|MicronJet|NanoPass Technologies Ltd|No|Completed|March 2008|July 2009|Actual|December 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||April 2008|May 8, 2013|December 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00602914||161678|
NCT00563745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N°158|Telemedicine for Patients With Chronic Respiratory Insufficiency|Randomised Trial on Telemedicine to Save Health Care Requests for Patients With Severe Chronic Respiratory Failure.||Fondazione Salvatore Maugeri|No|Completed|April 2004|April 2007|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|240|||Both|12 Years|85 Years|No|||March 2015|March 5, 2015|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00563745||164612|
NCT00563758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW03-313 T/313|A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation|A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation||Hospital Authority, Hong Kong||Terminated|December 2004|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|250|||Both|18 Years|N/A||||June 2011|June 14, 2011|August 15, 2007||||No||https://clinicaltrials.gov/show/NCT00563758||164611|
NCT00564018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW-052006-056|Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH|Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH||University of Texas Southwestern Medical Center|No|Terminated|September 2006|April 2011|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|6 Years|18 Years|No|||November 2007|June 12, 2012|November 26, 2007|Yes|Yes|Presumed loss of clinical equipoise between the agents being investigated|No||https://clinicaltrials.gov/show/NCT00564018||164591|
NCT00564031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166/99|Hormonal Replacement Therapy and Small Artery Function|Hormonal Replacement Therapy and Small Artery Function|HRT|Karolinska University Hospital|No|Completed|January 2003|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|66|||Female|50 Years|60 Years|Accepts Healthy Volunteers|||November 2007|November 26, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564031||164590|
NCT00560105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002|Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute|A Proof of Principal Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute in Adults With Chronic Obstructive Pulmonary Disease. A FDA 510(k) Equivalency Study||Medical Acoustics LLC|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|No|||March 2015|March 4, 2015|November 15, 2007||No||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00560105||164889|
NCT00556790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263/2003 USZ|Fast Track in Open Colonic Surgery - A Multicentric Randomized Controlled Trial|Fast Track in Open Colonic Surgery - A Multicentric Randomized Controlled Trial||University of Lausanne Hospitals|No|Terminated|November 2004|January 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|85 Years|No|||November 2007|November 9, 2007|November 9, 2007|||interim analysis|No||https://clinicaltrials.gov/show/NCT00556790||165128|
NCT00560066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P14|Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions|A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture (Optaflu®) or in Embryonated Hen Eggs (Agrippal®) in Adults and Elderly With and Without Underlying Medical Conditions, and to Evaluate the Immunogenicity in a Subset of Subjects With Underlying Medical Conditions||Novartis||Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1398|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|November 16, 2007|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00560066||164892|Because cTIV was not available, the second part of the study was not performed. In addition, as deviations from protocol procedures and GCP were identified at some sites, data collected for this study were not used to support licensure of cTIV.
NCT00560079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03T-356|Efficacy of Allopurinol and Dypiridamole in Acute Mania|A Double-Blind, Randomized, Placebo-Controlled 4-Week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole in Acute Bipolar Mania.||Hospital Espirita de Porto Alegre|No|Completed|November 2003|April 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|65 Years|No|||November 2007|September 19, 2008|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00560079||164891|
NCT00560326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-33|Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis|A Long-term, Non-comparative Study to Evaluate the Safety and Efficacy of Tacrolimus Oint¬Ment in Paediatric Patients||Astellas Pharma Inc|No|Completed|June 2003|December 2006|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|6 Months|30 Months|No|||August 2014|August 28, 2014|November 16, 2007||||No||https://clinicaltrials.gov/show/NCT00560326||164872|
NCT00569270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061693|Dynamic Hyperinflation and Tiotropium|Simplified Detection of Dynamic Hyperinflation Using Metronome Paced Hyperventilation and the Effect of Tiotropium in Patients With COPD||Gelb, Arthur F., M.D.|Yes|Completed|October 2006|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|85 Years|No|||October 2012|October 4, 2012|December 6, 2007||No||No|August 20, 2011|https://clinicaltrials.gov/show/NCT00569270||164198|
NCT00569556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3823-A|Effect of Care Management on Diabetes Outcomes|Effect of Care Management on Diabetes Outcomes||Minneapolis Veterans Affairs Medical Center|No|Completed|September 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||June 2009|June 11, 2009|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569556||164177|
NCT00569543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081-05|Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Undergoing Treatment for Newly Diagnosed Breast Cancer|Effects of Therapeutic Agents on Estrogens in the Breast||University of Nebraska|No|Completed|May 2005|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|Samples With DNA|Urine|Female|19 Years|N/A|No|Non-Probability Sample|Women newly diagnosed with breast cancer that will be given tamoxifen or an aromatase        inhibitor for therapeutic reasons.|May 2013|May 14, 2013|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569543||164178|
NCT00570193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBS-100-388|Photodynamic and Pharmacologic Treatment of CNV|Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)|PBS|Mid-Atlantic Retina Consultations, Inc.||Completed|December 2006|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|N/A|N/A|No|||July 2012|July 6, 2012|December 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00570193||164130|
NCT00570206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-07-0487|An Evaluation of Motivational Interviewing to Increase Compliance in a Probation Setting|An Evaluation of Motivational Interviewing to Increase Compliance in a Probation Setting (Enhancing Communication and Officer Responsivity; ENCORE)|ENCORE|The University of Texas Health Science Center, Houston||Completed|January 2008|October 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 21, 2009|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00570206||164129|
NCT00600067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-230|A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults|A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults||VIVUS, Inc.|No|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|70 Years|No|||September 2012|September 5, 2012|January 11, 2008|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00600067||161888|
NCT00600613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-129|Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy|A Pilot Study to Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy||Memorial Sloan Kettering Cancer Center||Completed|January 2006|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|95 Years|No|||April 2015|April 17, 2015|January 14, 2008||No||No|April 7, 2015|https://clinicaltrials.gov/show/NCT00600613||161847|
NCT00602511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSG 17/07|Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma|Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma||Nordic Myeloma Study Group|No|Completed|October 2007|December 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2011|February 8, 2011|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602511||161705|
NCT00603499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-161-0027|Magnesium and Metabolic Syndrome|Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome||Instituto Mexicano del Seguro Social|Yes|Completed|July 2006|November 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|40 Years|75 Years|No|||January 2008|January 16, 2008|January 16, 2008||||No||https://clinicaltrials.gov/show/NCT00603499||161634|
NCT00603512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921039|Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone||Pfizer|Yes|Completed|January 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|140|||Both|20 Years|70 Years|No|||December 2012|December 16, 2012|January 17, 2008|Yes|Yes||No|November 14, 2012|https://clinicaltrials.gov/show/NCT00603512||161633|
NCT00604110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0028|Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%|Interest in Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%||University Hospital, Clermont-Ferrand||Enrolling by invitation|February 2008|October 2008|Anticipated|September 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2008|January 29, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604110||161587|
NCT00599820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC 010|Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks|OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab||Asociación para Evitar la Ceguera en México||Active, not recruiting|November 2005|May 2006||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 2008|January 23, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00599820||161907|
NCT00572611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 459-13|Human Mass Balance Study With Bilastine|A Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Bilastine Following Oral Administration to Healthy Volunteers||Faes Farma, S.A.|No|Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572611||163950|
NCT00572624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|488|Effect of Abdominal Obesity on Heart Metabolism and Function|Altered Myocardial Fatty Acid Metabolism In Obesity||Washington University School of Medicine|No|Recruiting|June 2003|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|136|Samples With DNA|1 tablespoon of blood with DNA|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include both overweight and lean subjects.|May 2011|May 11, 2011|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572624||163949|
NCT00573105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/421|Laparoscopic Ventral Hernia Repair by Heavy Weight or Lighter Weight Mesh (COMPOSIX-trial)|Laparoscopic Ventral Hernia Repair by Heavy Weight or Lighter Weight Mesh (COMPOSIX-trial)||University Hospital, Ghent|No|Terminated|February 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|December 11, 2007||No|slow inclusion rate|No||https://clinicaltrials.gov/show/NCT00573105||163913|
NCT00573118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FactorVIII|Severe Pregnancy Complications Are Associated With Elevated Factor VIII Plasma Activity|A Retrospective Analysis of Possible Association Between Severe Pregnancy Complications and Elevated Factor VIII Plasma Activity.||Tel-Aviv Sourasky Medical Center|No|Active, not recruiting|January 2000|January 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Female|18 Years|45 Years|No|Non-Probability Sample|women who had either normal pregnancy or complicated pregnancy|December 2007|December 12, 2007|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573118||163912|
NCT00568997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2311|10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus|A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)|PEER|Valeant Pharmaceuticals International, Inc.|Yes|Recruiting|June 2004|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|8000|||Both|2 Years|17 Years|No|Non-Probability Sample|Children (ages 2-17 years)|March 2013|January 20, 2015|December 5, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00568997||164217|
NCT00569010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0291|Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)|Randomized Phase I/II Study of 5-Azacytidine in Combination With Cytosine Arabinoside in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High Risk Myelodysplastic Syndrome - "SPORE"||M.D. Anderson Cancer Center|Yes|Completed|December 2005|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|December 5, 2007||No||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00569010||164216|
NCT00569023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4496-YR-CTIL|Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene|Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene||Sheba Medical Center|No|Completed|July 2007|July 2010|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|75 Years|No|||June 2012|June 26, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569023||164215|
NCT00564057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44758|Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine|Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine||Università degli Studi dell'Insubria|No|Recruiting|September 2007|September 2009|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||November 2007|December 5, 2007|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564057||164588|
NCT00560339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20051601|Does Lung Impedance Correlate With Changes in BNP in Stable and Acutely Decompensated Heart Failure Patients?|Does Lung Impedance Correlate With Changes in BNP in Stable and Acutely Decompensated Heart Failure Patients?|IMPEDE-HF|Southern New Jersey Cardiac Specialists|No|Recruiting|September 2005|January 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving with an implantable cardioverter defibrillator (ICD) with or without        cardiac resynchronization therapy (CRT).|November 2007|November 15, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00560339||164871|
NCT00556803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rfa-003|TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|TACE-RFA|Sun Yat-sen University|Yes|Recruiting|November 2007|June 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||November 2008|November 17, 2008|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00556803||165127|
NCT00560950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110-007|Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)|A Multicenter, Open-Label Study of the Safety, Tolerability, and Immunogenicity of Revaccination With PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.) in Older Adults||Merck Sharp & Dohme Corp.||Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|143|||Both|59 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 26, 2015|November 19, 2007|Yes|Yes||No|March 30, 2009|https://clinicaltrials.gov/show/NCT00560950||164824|Open-label non-randomized group of subjects enrolled in this extension. Subjects recruited from original study which completed five years previously.
NCT00560586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|388.03|Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome|Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome||University of Louisville|No|Active, not recruiting|August 2005|August 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|62|||Both|6 Years|12 Years|No|||July 2007|November 16, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00560586||164852|
NCT00560599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12550-01|A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection|A 2X2 Phase III Open-label Clinical Trial of Therapy for Patients With Recurrent Methicillin Resistant Staphylococcus Aureus Infections: Topical Nasal & Body Decolonization and/or Environmental Decontamination vs. Standard of Care|PRIMO|Los Angeles Biomedical Research Institute|Yes|Completed|April 2007|December 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|350|||Both|1 Month|N/A|No|||September 2013|September 25, 2013|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560599||164851|
NCT00569569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFC012007|Retaane® in Age-Related Macular Degeneration|Retaane® in Age-Related Macular Degeneration||Rudolf Foundation Clinic|No|Completed|February 2006|March 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|90 Years|No|||December 2007|December 6, 2007|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569569||164176|
NCT00602199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582475|ABT-510 in Treating Patients With Metastatic Melanoma|A Phase II Study of Anti-angiogenesis Therapy for Metastatic Melanoma Using ABT-510||Mayo Clinic||Completed|November 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|42|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602199||161728|
NCT00602550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIDO-03|Bioequivalency Study of Zidovudine Under Fasting Conditions|A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|June 2003|June 2003|Actual|June 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 7, 2008|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00602550||161702|
NCT00602563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH087623-04|Attention Training for Generalized Anxiety Disorder|Attention Training for Generalized Anxiety Disorder (Attention Training and Relaxation for GAD: Testing the Efficacy of Home-Delivery)||San Diego State University|Yes|Recruiting|December 2007|April 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602563||161701|
NCT00600392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009277|DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)|Transcriptomal Analysis of Peripheral Blood and Skeletal Muscle in Patients Undergoing CRT Using Oligonucleotide Arrays|Medusa PH|Duke University|No|Completed|January 2006|December 2011|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples With DNA|Serum TNF alpha, IL-1, IL6, CRP, uric acid, albumin, BNP, IGF-1 and growth hormone at      baseline and at 6 months.      50 ml of blood will be collected at baseline and at 6 months. It will be divided into      aliquots as follows; 10 ml in Pax-gene tubes for mRNA extraction, 20 ml for various other      biomarkers, 10 ml for proteomics and 10 ml will be stored for any future use.      Approximately a 5x5 - 7x7mm muscle biopsy will be obtained from the mid thigh region of each      subject at baseline and at six months|Both|18 Years|80 Years|No|Non-Probability Sample|Patients who are scheduled for a CRT-D device|November 2012|January 15, 2016|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00600392||161864|
NCT00570219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS05BENVAL|The Effect of Valproate on Benzodiazepine Withdrawal Severity|The Effect of Valproate Treatment on Withdrawal Severity in Benzodiazepine Dependent Opioid Maintenance Treatment Patients||Helsinki University|No|Completed|February 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2008|October 16, 2008|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570219||164128|
NCT00570427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0091|Improving Depression Treatment for Older Minority Adults|Improving Depression Treatment for Older Minority Adults||National Institute on Aging (NIA)|Yes|Completed|February 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|60 Years|N/A|No|||February 2009|February 24, 2009|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570427||164112|
NCT00572312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-4/ATOR/01|Optimalization of Nephroprotection Using Atorvastatin (Sortis)|Influence of Adding Atorvastatin to Dual Renin-Angiotensin-Aldosterone System Blockade on Proteinuria||Medical University of Gdansk||Completed|February 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||December 2007|December 12, 2007|December 12, 2007||||No||https://clinicaltrials.gov/show/NCT00572312||163972|
NCT00572598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM03748|Pilot Study of 18F Fluoropaclitaxel (FPAC)|Pilot Study of 18F Fluoropaclitaxel (FPAC) in Breast Cancer Patients and Normal Volunteers: Dosimetry and Imaging Feasibility||Virginia Commonwealth University|No|Completed|May 2005|March 2008|Actual|March 2008|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2012|January 11, 2012|December 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00572598||163951|
NCT00599833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHNT-PACER|Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery|Locally Advanced Pancreatic Cancer: Phase II Study of Cetuximab and 3-D Conformal Image Guided Radiotherapy (PACER)||National Cancer Institute (NCI)||Completed|May 2007|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|44|||Both|18 Years|N/A|No|||August 2009|June 25, 2013|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599833||161906|
NCT00573131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR016-CLN-pro003|Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer|A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer||BTG International Inc.|Yes|Terminated|January 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 11, 2007|Yes|Yes|OncoGel did not show any impact on overall tumor response|No|April 17, 2014|https://clinicaltrials.gov/show/NCT00573131||163911|Study prematurely terminated due to lack of efficacy in primary endpoint.
NCT00569036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA191-002|Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors|A Phase I Multiple Ascending Dose Study of BMS-754807 in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|April 2008|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569036||164214|
NCT00569361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 2005|Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic Disease|Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic||Centre Hospitalier Universitaire de Nice|No|Completed|November 2004|October 2005|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|80|||Both|6 Years|17 Years|No|||June 2009|June 8, 2009|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569361||164192|
NCT00560092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-006|Intrathecal Magnesium and Postoperative Analgesia|Effects of a Single Dose of Intrathecal Magnesium Sulfate on Postoperative Morphine Consumption After Total Hip Replacement||University Hospital, Clermont-Ferrand||Completed|January 2004|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|56 Years|93 Years|No|||April 2013|April 2, 2013|June 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00560092||164890|
NCT00559819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMoric111207|Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving|Validation of Driving Simulator Measures and Calibration to Blood Alcohol Concentration Standards for Impaired Driving|ALCDrive|Rush University Medical Center|No|Active, not recruiting|February 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559819||164910|
NCT00559832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039/2006|Prevention of Acute Mountain Sickness by Intermittent Hypoxia|Prevention of Acute Mountain Sickness by Sleeping at Simulated Altitude (Normobaric Hypoxia)||Heidelberg University|No|Completed|March 2006|July 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|75|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2007|November 15, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559832||164909|
NCT00560989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1382|Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis|Shared Genetic Susceptibility in CBD and Sarcoidosis||National Jewish Health|No|Completed|March 2007|March 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|400|Samples With DNA|DNA specimens|Both|18 Years|80 Years|No|Non-Probability Sample|This study will use specimens from two well-established disease popultions: a CBD        population previously recruited at the National Jewish Medical and Research Center and a        sarcoidosis population derived from the previous NHLBI study, A Case-Control Etiologic        Study of Sarcoidosis (ACCESS).|September 2014|September 24, 2014|November 16, 2007||||No||https://clinicaltrials.gov/show/NCT00560989||164821|
NCT00561002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC38|Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2007-2008 Formulation)||Sanofi|No|Completed|October 2007|June 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||January 2014|January 17, 2014|November 19, 2007|Yes|Yes||No|July 20, 2009|https://clinicaltrials.gov/show/NCT00561002||164820|
NCT00560352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-181|Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma|A Phase I Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma||Bristol-Myers Squibb|No|Terminated|February 2008|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|November 16, 2007|No|Yes||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00560352||164870|The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase.
NCT00602212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03E701|Virtual Reality as Anxiety Management Tool for Generalized Anxiety Disorder|The Potential of Virtual Reality as Anxiety Management Tool: a Randomised Controlled Study in a Sample of Patients Affected by Generalized Anxiety Disorder|INTREPID|Istituto Auxologico Italiano|No|Completed|February 2008|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||January 2008|September 8, 2011|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602212||161727|
NCT00604136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS269- HMO-CTIL|Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy|Treatment of Metastatic Melanoma Patients With Tumor Infiltrating Lymphocytes and IL-2 Following a Regimen of Non-myeloablative Lymphocyte Depleting Chemotherapy||Hadassah Medical Organization|Yes|Recruiting|July 2008|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604136||161585|
NCT00604149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-35|Cardiac AResT And GENEtic|Etude Multicentrique en Population de la susceptibilité génétique à Faire Une Mort Subite|CARTAGENE|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|January 2008|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|2332|Samples With DNA|whole blood to obtain DNA|Both|18 Years|75 Years|No|Non-Probability Sample|all subjects in out-of-hospital cardiac arrest and treated by medical mobil emergency        medical care|June 2015|June 24, 2015|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00604149||161584|
NCT00603525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110634|Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy|A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Patients With Active Rheumatoid Arthritis Who Have Previously Had an Inadequate Response to One or More TNF Antagonist Therapies||GlaxoSmithKline|No|Terminated|January 2008|July 2013|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||April 2014|May 22, 2014|January 16, 2008||No|Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical    development of autoimmune indications on the subcutaneous delivery.|No|October 20, 2011|https://clinicaltrials.gov/show/NCT00603525||161632|
NCT00603538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021019|Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer|Phase 1, Dose Escalation Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer||Pfizer|Yes|Completed|January 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|20 Years|74 Years|No|||March 2013|March 5, 2013|January 17, 2008||No||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00603538||161631|
NCT00603551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 16417|Screening of Bone Mineral Density in Women Who Have Received Chemotherapy|Screening of Bone Mineral Density in Women Who Have Received Chemotherapy||Medical University of South Carolina|No|Recruiting|November 2006|November 2008|Anticipated|November 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Female|18 Years|N/A|No|Probability Sample|The study population consists of postmenopausal women with breast or gynecological cancers        who were treated with chemotherapy. The subjects either received their chemotherapy or        follow-up at the Hollings Cancer Center at the Medical University of South Carolina.|July 2008|July 18, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00603551||161630|
NCT00601484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091010|An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis|A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of PF-04383119 For The Treatment Of Pain Associated With Interstitial Cystitis||Pfizer|No|Completed|March 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601484||161781|
NCT00601497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 11630|Effects of Electrical Stimulation on Osteoarthritis of the Knee|Effects of Electrical Stimulation on Osteoarthritis of the Knee||University of Virginia|No|Completed|December 2004|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|50 Years|N/A|No|||January 2008|January 25, 2008|January 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00601497||161780|
NCT00571519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS011-A-U302|Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|Yes|Terminated|November 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|94|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|December 11, 2007|Yes|Yes|DSPD focussing on Study 301 to confirm clinical profile before proceeding.|No||https://clinicaltrials.gov/show/NCT00571519||164030|
NCT00571805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Varenicline/Smoking|Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt|Placebo-controlled Study of Varenicline Effects on Nicotine Withdrawal Followed by a Test of Smoking Topography, Reward, and Reinforcement|VarenSmoke|New York University School of Medicine|No|Withdrawn|September 2007|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571805||164009|
NCT00572065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707009291|Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis|Prospective Pilot Trial of Arsenic Trioxide (Trisenox®) in Combination With Cytosine Arabinoside in Patients With Advanced or Transformed Myelofibrosis||Weill Medical College of Cornell University|No|Active, not recruiting|December 2007|December 2010|Anticipated|December 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2010|September 24, 2010|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572065||163990|
NCT00572078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0706-05 IUCRO-0171|Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors|Phase I Dose-Escalation Drug-Interaction Study of Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors||Indiana University|Yes|Active, not recruiting|July 2008|January 2017|Anticipated|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|December 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00572078||163989|
NCT00572091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-055P|Aachen Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device to Reduce Mitral Regurgitation|An Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device Used to Reduce Mitral Regurgitation|PTOLEMY|Viacor|Yes|Completed|February 2007|November 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|50 Years|N/A|No|||November 2008|November 5, 2008|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00572091||163988|
NCT00572884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200311123-8|Metabolism of the Insecticide Permethrin|CCRC:Identification and Development of Biological Markers of Human Exposure to the Insecticide Permethrin||University of California, Davis|No|Completed|February 2006|November 2007|Actual|||N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2007|December 11, 2007|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572884||163930|
NCT00572897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0548-00101|Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis|Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|August 2007|August 2020|Anticipated|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|65 Years|No|||October 2013|October 23, 2013|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572897||163929|
NCT00572910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V710-005|A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients With End-Stage Renal Disease on Chronic Hemodialysis||Merck Sharp & Dohme Corp.||Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|206|||Both|18 Years|80 Years|No|||March 2015|March 16, 2015|December 11, 2007|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00572910||163928|
NCT00573144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002180|Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction|Nesiritide Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction|Believe II|Mayo Clinic|No|Completed|September 2006|April 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|59|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|December 13, 2007|Yes|Yes||No|September 2, 2014|https://clinicaltrials.gov/show/NCT00573144||163910|
NCT00569049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11052007-799|Molecular Analysis of Breast Cancer|Molecular Analysis of Breast Cancer||Stanford University|Yes|Active, not recruiting|May 1996|||May 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|99999|Samples With DNA|tumor, normal tissue and blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing breast cancer procedures|April 2012|April 4, 2012|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00569049||164213|
NCT00564083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARD|Randomized Controlled Trial Comparing Acellular Collagen Biomesh (Pelvisoft) to Polypropylene Mesh(Pelvitex) for Sacral Colpopexy|||Atlantic Health System|No|Completed|December 2005|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|March 21, 2011|November 26, 2007||||No||https://clinicaltrials.gov/show/NCT00564083||164586|
NCT00556179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACTO_L_02399|Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis|Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole.||Sanofi||Completed|September 2007|||December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|122|||Female|18 Years|50 Years|No|||January 2009|January 21, 2009|November 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00556179||165172|
NCT00556465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3046|Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy|Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy||Shiraz University of Medical Sciences|No|Completed|January 2007|June 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|75 Years|No|||November 2007|November 9, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00556465||165150|
NCT00561327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2132V1|PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites|||German Heart Institute|No|Recruiting|September 2007|||||N/A|Observational|Time Perspective: Retrospective||2|||||Both|19 Years|80 Years|No|||July 2007|November 16, 2007|November 16, 2007||||No||https://clinicaltrials.gov/show/NCT00561327||164795|
NCT00561301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-012A|Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma|Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma||Cooperative Study Group A for Hematology|No|Recruiting|November 2006|October 2009|Anticipated|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|15 Years|65 Years|No|||November 2007|November 18, 2007|November 18, 2007||||No||https://clinicaltrials.gov/show/NCT00561301||164797|
NCT00561314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574344|High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer|An Evaluation of Focal Ablation Therapy Using High-Intensity Focused Ultrasound in the Treatment of Localized Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Completed|July 2007|January 2012|Actual|February 2009|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|33|||Male|45 Years|80 Years|No|||July 2009|August 23, 2013|November 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00561314||164796|
NCT00557102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574153|Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung|Frontline Chemotherapy "Reinforced" for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX|ERBIFORT|National Cancer Institute, France||Completed|September 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|November 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00557102||165108|
NCT00557115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0703/093|Early Pulmonary Rehabilitation Following Acute COPD Exacerbation|Early Pulmonary Rehabilitation (PR) Following Hospitalisation For Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)||King's College Hospital NHS Trust|No|Recruiting|January 2006|January 2009|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|90 Years|No|||November 2007|November 9, 2007|November 9, 2007||||No||https://clinicaltrials.gov/show/NCT00557115||165107|
NCT00557128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD108410|Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.|A Randomized, Open-label, Single-dose, 3-period Crossover Study to Assess the Effect of Food on the Pharmacokinetics of the Final Fixed Dose Combination Formulation of COREG CR and Lisinopril in the Fed and Fasted State.||GlaxoSmithKline||Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|October 24, 2007||||||https://clinicaltrials.gov/show/NCT00557128||165106|
NCT00603213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR16840|Correlation of Intrathoracic Impedance Measures With Blood Plasma Volume in Congestive Heart Failure|Correlation of Intrathoracic Impedance Measure With Blood Plasma Volume in Congestive Heart Failure|Optivol|Medical University of South Carolina|No|Completed|January 2007|February 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|15 mls of blood will be drawn to assay for plasma analytes including but not limited to      MMPs, TIMPs and collagen propeptides.|Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 years or older with NYHA Class II-IV CHF of at least six months duration        who have been implated with a device capable of serial impedance measurement will be        recruited.|May 2013|May 21, 2013|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603213||161656|
NCT00603226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57/2007|Slow Coronary Artery Flow: Influence on Morbidity and Mortality|Slow Coronary Artery Flow: Influence on Morbidity and Mortality||Hillel Yaffe Medical Center|Yes|Recruiting|January 2008|July 2008|Anticipated|July 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent coronary angiography in the Hillel Yaffe Medical Center|January 2008|January 16, 2008|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603226||161655|
NCT00599573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13295|Pharmacotherapy for HIV+ Stimulant Dependent Individuals|Pharmacotherapy for HIV+ Stimulant Dependent Individuals||University of Virginia|Yes|Recruiting|October 2007|December 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|65 Years|No|||April 2010|April 12, 2010|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599573||161926|
NCT00599859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIA-05-01|Effects of Lactose on Fecal Microflora|Differential Biologic Impact of Lactose Consumption in Lactase Persistent and Non-persistent Populations: Evaluation of Microflora and Insulin/Glycemic Response|ELM|Sir Mortimer B. Davis - Jewish General Hospital|Yes|Completed|September 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|57|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599859||161904|
NCT00569881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donnenfeld2|Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK|Effect of Gatifloxacin 0.3% and Moxifloxacin 0.5% on Epithelial Wound Healing After Photorefractive Keratectomy||Donnenfeld, Eric, M.D.|Yes|Completed|January 2007|March 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presented to the practice of a cornea trained ophthalmic consultant.|December 2007|December 7, 2007|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569881||164153|
NCT00569894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA162|A Post Marking Study to Evaluate the Safety of FluMist in Children|A Post Marketing Evaluation of the Safety of FluMist in Children 24-59 Months of Age in a Managed Care Setting||MedImmune LLC|No|Completed|October 2007|June 2011|Actual|June 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|29296|||Both|24 Months|59 Months|Accepts Healthy Volunteers|Probability Sample|The populations to be assessed are FluMist recipients, TIV recipient controls, and        unvaccinated controls.        Members of the Kaiser Permanente Health Care Plan may be included in this study as part of        routine care at their participating health centers within the Kaiser Permanente health        maintenance organization (HMO) of Northern California.|March 2012|March 6, 2012|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569894||164152|
NCT00572039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01EY015839|Improving Function in Age-Related Macular Degeneration|Improving Function in Age-Related Macular Degeneration|IF-AMD|Thomas Jefferson University|Yes|Completed|August 2005|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|241|||Both|65 Years|N/A|No|||September 2015|September 14, 2015|December 10, 2007||No||No|August 11, 2015|https://clinicaltrials.gov/show/NCT00572039||163992|
NCT00572052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEEDLEN-2168|Comparison of Glycemic Control Achieved With 2 Different Needles|Comparison of Glycemic Control Achieved With a 31 Gauge x 6 mm NovoFine® Needle vs. a BD 29 Gauge x 12.7 mm Ultra-Fine® Needle in Subjects With Diabetes Mellitus and a BMI Exceeding 30 kg/m2: An Open Label, Randomized, Two-Period Crossover Study||Novo Nordisk A/S|No|Completed|December 2002|October 2003|Actual|October 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|62|||Both|18 Years|60 Years|No|||October 2013|October 24, 2013|December 4, 2007||||No||https://clinicaltrials.gov/show/NCT00572052||163991|
NCT00572351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 6110|The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels|The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels||Cedars-Sinai Medical Center|Yes|Completed|January 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Female|21 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 27, 2012|January 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572351||163969|
NCT00572637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-CEP\I\01|Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas|An Open-Label, Dose-escalation, Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, and Pharmacodynamics of the Proteosome Inhibitor CEP 18770 Given Intravenously as Single Agent in Patients With Advanced Solid Tumours or Non-Hodgkin's Lymphomas||Ethical Oncology Science|No|Completed|November 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||May 2010|May 19, 2010|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572637||163948|
NCT00572325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRONC CONCURR MLD|Concurrent Chemo-radiation Form NSCLC to a Individualized MLD|Concurrent Chemo-radiotherapy for Stage III Non-small Cell Lung Cancer ta an Individualized MLD|BRONC CONC MLD|Maastricht Radiation Oncology|No|Completed|August 2006|May 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|18 Years|N/A|No|Non-Probability Sample|-  Histological or cytological proven NSCLC          -  UICC stage I-III          -  Performance status 0-2          -  FeV 1 and DLCO at least 30% of the age-predicted value|July 2010|July 20, 2010|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572325||163971|
NCT00572338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 91-004|Therapeutic Research in Multiple Myeloma|UARK 91-004 Therapeutic Research in Multiple Myeloma||University of Arkansas|No|Completed|August 2003|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6388|Samples With DNA|-  A bone marrow aspirate and biopsy        -  Blood        -  Fine Needle aspirates        -  Swabs of skin, throat, other sites|Both|18 Years|N/A|No|Probability Sample|Samples will be studied in the laboratory and in experimental animal models. These        analyses and animal models may help to better understand multiple myeloma and to better        select the appropriate treatment for all participants with multiple myeloma.|August 2015|August 12, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572338||163970|
NCT00569062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKI108574|A Study of GW856553X For the Treatment of Depression|A Randomized, Double Blind, Placebo Controlled Study to Explore the Antidepressant Properties of P38a Kinase Inhibitor GW856553X 15mg Compared to PBO in Subjects With Major Depressive Disorder Exhibiting Symptoms of Loss of Energy and Interest and Psychomotor Retardation, for a Six Week Treatment Period||GlaxoSmithKline|No|Terminated|September 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|December 5, 2007|Yes|Yes|Negative data from a GSK PoC study in RA combined with evidence of greater sensitivity of    toll-like receptor pathways to p38 inhibition.|No||https://clinicaltrials.gov/show/NCT00569062||164212|
NCT00569075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-04|Apoptic Biomarkers of Periodontal Disease|Apoptotic Biomarkers of Periodontal Disease||University of Michigan|No|Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|Samples Without DNA|saliva and plaque|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|healthy adults with healthy gums or those with periodontitis|February 2009|June 24, 2010|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569075||164211|
NCT00569400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN729-1541|Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes|Comparison of Efficacy and Safety of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|May 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|241|||Both|18 Years|N/A|No|||September 2011|July 4, 2012|December 5, 2007||||No||https://clinicaltrials.gov/show/NCT00569400||164189|
NCT00569413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281207HMO-CTIL|A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality|A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality||Hadassah Medical Organization|Yes|Suspended|April 2011|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|A group of healthy volunteers from the general public. A group of patients who suffer from        sexual disorder from a primary care clinic.|June 2010|June 9, 2010|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569413||164188|
NCT00555581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27049|Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis|Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis||Hospital for Special Surgery, New York|Yes|Active, not recruiting|August 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00555581||165218|
NCT00555594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cornea2|Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization|Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization||Asociación para Evitar la Ceguera en México|Yes|Completed|September 2006|October 2007|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||November 2007|November 7, 2007|November 7, 2007||||No||https://clinicaltrials.gov/show/NCT00555594||165217|
NCT00556192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLE-2005-006|Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus|Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy Restore Peripheral B Cell Abnormalities in Systemic Lupus Erythematosus(SLE)?||Chinese University of Hong Kong|No|Completed|June 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|70 Years|No|||February 2012|February 10, 2012|November 8, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00556192||165171|
NCT00561340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356-05-FB|Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication|Caloric Supplementation During Long-Term Pharmacological Treatment of ADHD in Young Children||University of Nebraska|No|Completed|January 2006|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|5 Years|9 Years|No|||January 2015|January 25, 2015|November 16, 2007|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT00561340||164794|This is a follow-up study of 5 and 6 year olds who completed a DBPC study of atomoxetine for ADHD. Data is confounded by subjects having entered the study on different pre-study and concurrent pharmacotherapy. The population is small.
NCT00561353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012607|A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection|A Blinded, Randomized, Placebo-controlled Trial in Genotype 1 Hepatitis C-Infected Subjects to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeated Doses of TMC435350, With or Without Peginterferon Alpha-2a and Ribavirin||Tibotec Pharmaceuticals, Ireland|Yes|Completed|January 2008|May 2010|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|10||Actual|121|||Both|18 Years|70 Years|No|||May 2014|May 14, 2014|November 19, 2007|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00561353||164793|
NCT00561548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 - PP - 2006|Impact of Anti-Tumor Necrosis Factor (TNF) Antibodies on the T-lymphocyte and Macrophage Cooperation in Crohn Disease|Impact of Anti-TNF Antibodies on the T-lymphocyte and Macrophage Cooperation in the Crohn Disease||Centre Hospitalier Universitaire de Nice|No|Terminated|May 2007|April 2009|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2009|May 27, 2011|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561548||164778|
NCT00561522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-07-RCT-LCI1|Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection|Capecitabine as Adjuvant Chemotherapy to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection: a Randomized Controlled Trial||Fudan University|Yes|Active, not recruiting|November 2007|July 2012|Anticipated|July 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|79 Years|No|||August 2009|July 20, 2010|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561522||164780|
NCT00561535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEFD 2007-01|Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS Patients|Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS||Assistance Publique - Hôpitaux de Paris|No|Completed|October 2007|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2011|January 26, 2011|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561535||164779|
NCT00603824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHIRB # 2007-058|Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)|Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia||Methodist Healthcare|No|Withdrawn|January 2008|July 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|January 4, 2008|No|Yes|PI relocated|No||https://clinicaltrials.gov/show/NCT00603824||161609|
NCT00570739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-411|Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.|Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes||Daiichi Sankyo Inc.|No|Completed|November 2007|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|502|||Both|18 Years|79 Years|No|||July 2010|July 19, 2010|December 10, 2007|Yes|Yes||No|April 6, 2010|https://clinicaltrials.gov/show/NCT00570739||164090|
NCT00570752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM119-014|Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis|A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients||Bristol-Myers Squibb|Yes|Completed|December 2008|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|75 Years|No|||November 2015|November 6, 2015|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570752||164089|
NCT00601133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0799|Function and Balance for Inpatient Rehabilitation|Quantitative and Clinical Description of Postural Instability in Patient Who Underwent Acute Inpatient Rehabilitation and at Follow-Up||M.D. Anderson Cancer Center|No|Completed|January 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have completed acute inpatient rehabilitation at MDACC|January 2013|January 9, 2013|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00601133||161807|
NCT00571272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 6001|Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)|Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis|LOGIC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|November 2007|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1150|Samples With DNA|Blood plasma and serum samples with DNA|Both|N/A|25 Years|No|Non-Probability Sample|The study population will consist of 400 participants with Alagille syndrome, 400 with        alpha-1 trypsin deficieny (of which up to 25 may be siblings of participants), 300 with        PFIC (or BRIC), and 50 with bile acid synthesis defects.|April 2015|April 15, 2015|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00571272||164049|
NCT00572104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095877|Efficacy of Plyometrics to Increase Bone Mass in Men With Osteopenia|Efficacy of Plyometrics to Increase Bone Mass in Men With Osteopenia||University of Missouri-Columbia|Yes|Completed|January 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Male|25 Years|60 Years|No|||August 2014|August 13, 2014|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00572104||163987|
NCT00572377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 11268|Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder|Safety and Efficacy of Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder||Cedars-Sinai Medical Center|Yes|Terminated|May 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2008|June 19, 2008|December 12, 2007|No|Yes|The investigator at Cedars stopped this study due to problems collecting payment from the    sponsor.|No||https://clinicaltrials.gov/show/NCT00572377||163967|
NCT00572650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2117|Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients|An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of LAF237 and Its Metabolites in Mild Renal Impaired Patients Compared to Age, Sex and Weight-matched Healthy Volunteers Following Daily Doses of 100 mg LAF237 for 14 Days||Novartis|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 30, 2012|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572650||163947|
NCT00572923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRONC 45, 1.5|Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans|Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans|BRONC 45 15|Maastricht Radiation Oncology|No|Completed|August 2006|February 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|52|||Both|18 Years|N/A|No|Non-Probability Sample|-  Histological or cytological proven SCLC          -  UICC stage I-III, "limited disease"          -  Performance status 0-2          -  FeV 1 and DLCO at least 30% of the age-predicted value|June 2009|June 16, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572923||163927|
NCT00572936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405-05-FB|Circadian Rhythms of Aqueous Humor Dynamics in Humans|Circadian Rhythms of Aqueous Humor Dynamics in Humans||University of Nebraska|No|Completed|November 2005|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 29, 2010|December 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572936||163926|
NCT00573157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28113|The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis|A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects With Lupus Nephritis in Combination With Mycophenolate Mofetil Therapy.||EMD Serono|Yes|Terminated|December 2007|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|16 Years|N/A|No|||February 2016|February 22, 2016|December 11, 2007|Yes|Yes|The study was terminated due to unanticipated safety issues|No|February 22, 2016|https://clinicaltrials.gov/show/NCT00573157||163909|The study was terminated due to unanticipated safety issues.
NCT00569426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEEDLEN-1637|Evaluating the Use of Two Different Needles in Subjects With Diabetes|An Open-label, Randomised, Multi-centre Cross-over Trial in Diabetes Patients Evaluating Preference, Injection Pressure, Pain Perception and Handling When Injections Are Performed With Two Different Needles i.e. NovoFine® 32 Gauge Tip x 6mm and NovoFine® 30 Gauge x 8mm Using a FlexPen® Disposable Insulin Injection Pen||Novo Nordisk A/S|No|Completed|April 2005|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|119|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|December 4, 2007||||No||https://clinicaltrials.gov/show/NCT00569426||164187|
NCT00569686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13107|Lovaza Therapy of Peripheral Arterial Disease|Lovaza Therapy of Peripheral Arterial Disease||University of Virginia|No|Withdrawn|September 2007|February 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|80 Years|No|||March 2010|March 3, 2010|December 6, 2007||No|No subject meeting criteria|No||https://clinicaltrials.gov/show/NCT00569686||164167|
NCT00569699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023019|Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)|Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)||Taiho Pharmaceutical Co., Ltd.|Yes|Completed|October 2007|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|65 Years|N/A|No|||November 2012|November 1, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569699||164166|
NCT00570570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 020 08|Muscular Strengthening for Paretic Knee Flexor and Extensor by Conventional Physiotherapy on Chronic Hemiplegic Stroke Patients|Muscular Strengthening for Paretic Knee Flexor and Extensor by Conventional Physiotherapy on Chronic Hemiplegic Stroke Patients|RenforcHémi|University Hospital, Toulouse|No|Completed|May 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|80 Years|No|||August 2015|August 19, 2015|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570570||164102|
NCT00555893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 UO1 IP000124-01|Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza|Monitoring Influenza Severity on Tamiflu (MIST)||Marshfield Clinic Research Foundation|No|Completed|January 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|194|||Both|1 Year|79 Years|No|||January 2015|January 13, 2015|November 7, 2007|Yes|Yes||No|January 7, 2015|https://clinicaltrials.gov/show/NCT00555893||165194|
NCT00555906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481004|An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.|Phase 1/2 Open-label Study Of The Safety And Efficacy Of Pd 0332991 In Combination With Bortezomib And Dexamethasone In Patients With Refractory Multiple Myeloma||Pfizer|No|Completed|January 2008|March 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|November 8, 2007|Yes|Yes||No|March 4, 2015|https://clinicaltrials.gov/show/NCT00555906||165193|
NCT00561015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013513|A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection|A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection||Tibotec BVBA|No|Completed|December 2007|May 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|52|||Both|18 Years|65 Years|No|||June 2013|June 7, 2013|November 19, 2007||No||No|March 8, 2013|https://clinicaltrials.gov/show/NCT00561015||164819|
NCT00561860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-70411|Use of a Remote-Monitoring System to Diagnose and Treat Obstructive Sleep Apnea|Use of a Remote-Monitoring System to Diagnose and Treat Obstructive Sleep Apnea||University of British Columbia|No|Completed|November 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|19 Years|N/A|No|||March 2014|March 14, 2014|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00561860||164755|
NCT00561561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021861|Sensorimotor Gating in Schizophrenia|Sensorimotor Gating in Schizophrenia||Emory University|No|Active, not recruiting|June 2001|December 2016|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|500|Samples With DNA|Blood and extracted DNA|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with schizophrenia and their family members; healthy controls and their family        members|October 2015|October 9, 2015|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561561||164777|
NCT00570765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-201|Study of INT-747 as Monotherapy in Patients With PBC|A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis||Intercept Pharmaceuticals|Yes|Completed|November 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|70 Years|No|||January 2012|January 9, 2012|December 7, 2007|No|Yes||No|June 9, 2011|https://clinicaltrials.gov/show/NCT00570765||164088|
NCT00570778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2204|Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo Controlled, Multicentre Study to Determine the Effect of QVA149 on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|154|||Both|40 Years|N/A|No|||January 2013|January 23, 2013|December 10, 2007|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00570778||164087|
NCT00571025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0126|Risk Evaluation and Education for Alzheimer's Disease|Genetic Risk Assessment and Counseling for Alzheimer's Disease|REVEAL I|National Institute on Aging (NIA)|Yes|Completed|August 2000|April 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|301|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2009|July 22, 2009|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00571025||164068|
NCT00570479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Texas Retina DC-02|Prophylactic Anecortave Acetate in Patients With a Retisert Implant|Prevention of Steroid-induced Glaucoma Using Anecortave Acetate||Texas Retina Associates|No|Completed|September 2006|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|12|||Both|10 Years|80 Years|No|||June 2012|June 3, 2012|December 9, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00570479||164109|
NCT00570492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR101782|Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects With Perennial Allergic Rhinitis||GlaxoSmithKline|No|Completed|November 2007|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|474|||Both|5 Years|8 Years|No|||June 2012|May 16, 2013|December 6, 2007|Yes|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00570492||164108|
NCT00570505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBMI-001|Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2|||Apollo Endosurgery, Inc.|Yes|Completed|November 2007|November 2013|Actual|October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|18 Years|55 Years|No|||March 2015|March 12, 2015|December 10, 2007|Yes|Yes||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00570505||164107|
NCT00571545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-5302-B05|The Effect of Exercise on Mood After Traumatic Brain Injury|The Effect of Exercise on Mood After Traumatic Brain Injury||University of Washington|No|Completed|April 2004|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|16 Years|70 Years|No|||June 2008|June 2, 2008|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571545||164029|
NCT00571012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006662|Aqueous Outflow Facility Changes With Posture|Aqueous Outflow Facility Changes With Posture||Mayo Clinic|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young volunteers aged 18-45 will be recruited from Mayo Clinic employees and        students, and local area residents.|November 2009|November 24, 2009|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00571012||164069|
NCT00572117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIL-NIAAA-016340-01|Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder|Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder||Stanford University|No|Completed|August 2007|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572117||163986|
NCT00572364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00001|Open Label, Dose Escalation Phase I Study of AZD2281|A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies||AstraZeneca|No|Completed|November 2007|June 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|74 Years|No|||August 2009|August 19, 2009|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572364||163968|
NCT00572949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4039|Magnetocardiography (MCG) in the Diagnosis of Chest Pain Syndrome|Magnetocardiography (MCG) in the Diagnosis of Chest Pain Syndrome||Cedars-Sinai Medical Center|No|Withdrawn|October 2004|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|398|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with chest pain syndrome|November 2009|November 16, 2009|December 12, 2007||No|sponsor funding|No||https://clinicaltrials.gov/show/NCT00572949||163925|
NCT00573170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX109011/TRX109013|TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Migraine Pain, Studies 1 and 2 of 2||GlaxoSmithKline|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|375|||Both|18 Years|65 Years|No|||November 2010|November 30, 2010|December 12, 2007|Yes|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT00573170||163908|Enrolled participants included all those entering the screening part of the study. Randomized participants included only those who completed screening and completed the 2-week butalbital wash-out, and were successfully randomized to study drug.
NCT00569088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006CB504807|Study of the Pathogenesis and Molecular Mechanism of "YURE" in Internal Intractable Diseases|"973" Project for Pathology of Traditional Chinese Medicine||Nanjing University of Traditional Chinese Medicine|Yes|Recruiting|November 2007|December 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|75 Years|No|||July 2009|July 7, 2009|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00569088||164210|
NCT00569101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0706-049-211|A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis|A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis||Seoul National University Hospital|Yes|Active, not recruiting|September 2007|March 2008|Anticipated|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||December 2007|December 4, 2007|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00569101||164209|
NCT00570050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Insulin-MDD|Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder|A Randomized, Double-blind, Placebo-controlled Cross-over Trial Evaluating the Effect of Intranasal Insulin on Depressive Symptoms in Individuals With Major Depressive Disorder Insufficiently Responsive to Antidepressant Therapy||University Health Network, Toronto|No|Completed|June 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|60 Years|No|||February 2015|February 20, 2015|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00570050||164140|
NCT00570336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-1027-01|Study of CTS-1027 in Hepatitis C Patients|A Dose Response Study of CTS-1027 in Hepatitis C Patients||Conatus Pharmaceuticals Inc.|Yes|Completed|December 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|87|||Both|18 Years|N/A|No|||September 2010|September 14, 2010|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570336||164119|
NCT00570583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006424|Neurocognitive Outcomes of Depression in the Elderly|Geriatric Depression: Risk Factors for Adverse Outcomes|NCODE|Duke University|No|Active, not recruiting|December 1995|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|795|Samples With DNA|serum, white cells|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic Outpatient psychiatry clinic Inpatient psychiatry clinic Self-referral|June 2015|June 5, 2015|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570583||164101|
NCT00560365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000576476|Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer|A Randomised Controlled Trial to Assess the Cost-effectiveness of Intensive Versus no Scheduled Follow-up in Patients Who Have Undergone Resection for Colorectal Cancer With Curative Intent. (FACS - Follow-up After Colorectal Surgery)||National Cancer Institute (NCI)||Recruiting|March 2004|||December 2013|Anticipated|N/A|Observational|N/A|||Anticipated|4760|||Both|50 Years|N/A|No|||August 2009|August 5, 2011|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560365||164869|
NCT00560625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0030-07EMC|Does Inhaled Busedonide or Fluticasone Impair Adrenal Function?|Low Dose(1mcg) ACTH Stimulation Test for Assessment of the Hypothalamus-Pituitary-Adrenal Axis in Patients Treated With Inhaled Busedonide or Fluticasone.||HaEmek Medical Center, Israel|No|Recruiting|May 2007|December 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|hospital-based respiratory diseases clinic|November 2007|November 18, 2007|November 18, 2007||||No||https://clinicaltrials.gov/show/NCT00560625||164849|
NCT00560638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|439|Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye|A Double-Masked, Randomized, Placebo-Controlled Study of Loteprednol Etabonate Ophthalmic Suspension, 0.5% for the Treatment of Dry Eye Used Either TID or QID for a 2 Week Period||Bausch & Lomb Incorporated|No|Completed|November 2005|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|119|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|November 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00560638||164848|
NCT00561028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5105/2001|Chlamydia and Mycoplasma in Coronary Artery Disease|Prevalence of Chlamydia Pneumoniae and Mycoplasma Pneumoniae in Different Forms of Obstructive Coronary Artery Disease||Hospital de Base|No|Completed|March 2002|November 2004|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|138|Samples Without DNA|Blood sample - serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group 1 and 2 - selected after admission in coronary care unit. Group 3 - selected from        out-patient cardiology clinic. Group 4 - selected from the blood donation unit.|November 2007|November 19, 2007|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561028||164818|
NCT00561574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05697|A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)|A Randomized Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of Org 50081|Jade|Merck Sharp & Dohme Corp.|No|Completed|January 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|259|||Both|65 Years|N/A|No|||May 2015|May 18, 2015|November 19, 2007|Yes|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00561574||164776|
NCT00561873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN001-PED04|Nimotuzumab in Children With HGG|Phase-II-Study of Efficacy of OSAG 101 (Theraloc®) for Adolscent Patients With Recurrent High Grade Glioma||Oncoscience AG|Yes|Completed|June 2004|February 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|3 Years|20 Years|No|Non-Probability Sample|children, adolescents|November 2007|November 20, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00561873||164754|
NCT00562133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_01896|Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes|Effect of Prandial Treatment With Insulin Glulisine Compared to Regular Human Insulin on Postprandial Endothelial Function and Microvascular Stress in Type 2 Diabetic Patients||IKFE Institute for Clinical Research and Development|No|Completed|December 2006|March 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|40 Years|70 Years|No|||November 2007|November 20, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00562133||164734|
NCT00570791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|441-04|Effect of Central Corneal Thickness On IOP Using Various Tonometers|The Effect of Central Corneal Thickness On Intraocular Pressure Measurements With the Goldman Applanation Tonometer, Ocular Blood Flow Pneumatonometer,Tono Pen,Pascal Dynamic Contour Tonometer, and Schiotz Tonometer|CCT|University of Nebraska|No|Completed|February 2004|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|166|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Clinic Patients, City Residents|July 2011|February 14, 2014|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570791||164086|
NCT00571038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAB 06-086|Working With Veterans Organizations to Improve Blood Pressure|Working With Veterans Organizations to Improve Blood Pressure|POWER|VA Office of Research and Development|No|Completed|February 2008|December 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|404|||Both|N/A|N/A|No|||August 2014|April 6, 2015|December 7, 2007||No||No|October 10, 2014|https://clinicaltrials.gov/show/NCT00571038||164067|
NCT00571285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004539|Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease|Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease|VIDIP PILOT|Emory University|No|Suspended|June 2007|December 2015|Anticipated|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|89 Years|No|||December 2014|December 16, 2014|December 7, 2007||No|Funding and staffing in the works|No||https://clinicaltrials.gov/show/NCT00571285||164048|
NCT00571558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00842|Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia|Phase I Study of Photodynamic Therapy Using Pulsed Dye Laser and Oral Aminolevulinic Acid in Patients With Oral Leukoplakia||National Cancer Institute (NCI)||Terminated|March 2008|November 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2013|October 8, 2014|December 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00571558||164028|
NCT00571818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-00FB|The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients|The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients||University of Nebraska|No|Completed|November 2000|June 2010|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|31|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571818||164008|
NCT00572663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-4/NAC/01|Optimalization of Nephroprotection Using N-Acetylcysteine|The Effect of N-Acetylcysteine on Proteinuria and Markers of Tubular Injury in Non-Diabetic Patientswith Chronic Kidney Disease-Placebo Controlled, Randomized,Open, Cross-Over Study||Medical University of Gdansk||Completed|January 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|65 Years|No|||December 2007|December 12, 2007|December 12, 2007||||No||https://clinicaltrials.gov/show/NCT00572663||163946|
NCT00569114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP2001-101|Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients|A Phase 1 Dose-Escalation Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients||Tragara Pharmaceuticals, Inc.|No|Completed|October 2007|November 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2010|March 16, 2010|December 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00569114||164208|
NCT00569439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035-00|A Study on the Effects of Dextrose Solutions on the Course of Labor|A Randomized Controlled Trial Comparing Normal Saline With and Without Dextrose on the Course of Labor in Nulliparas||MemorialCare|No|Completed|November 2000|June 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|301|||Female|18 Years|50 Years|No|||June 2006|December 6, 2007|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569439||164186|
NCT00569712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577434|Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol|A Pilot Comparative Study of the Genomic Molecular and Clinical Profiles of Patients With Lung Cancer, COPD, or Asthma Treated With Symbicort Turbuhaler||British Columbia Cancer Agency|No|Completed|January 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|45 Years|74 Years|No|||March 2012|March 7, 2012|December 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00569712||164165|
NCT00570037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004990|Feasibility of Cocooning Immunization Strategy With Influenza Vaccine|Prevention of Influenza in Infants by Immunization of Their Contacts in the Household|Piiitch|Duke University|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|544|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|June 17, 2013|December 7, 2007||No||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00570037||164141|
NCT00570349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT 50|Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis|Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis||INO Therapeutics|Yes|Completed|July 2004|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|12 Years|N/A|No|||April 2015|April 16, 2015|December 6, 2007|Yes|Yes||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00570349||164118|
NCT00571129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5551812|Endoscopic Dacryocystorhinostomy Prospective Research|Recovery After Endoscopic Dacryocystorhinostomy||Kuopio University Hospital|No|Active, not recruiting|September 2004|December 2016|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|90 Years|No|||March 2016|March 10, 2016|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571129||164060|
NCT00571142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-ret|Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema|Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)||Asociación para Evitar la Ceguera en México|No|Recruiting|November 2007|February 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|25 Years|60 Years|No|||December 2007|December 7, 2007|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00571142||164059|
NCT00560378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-21|Long-term Safety of Protopic in Atopic Eczema|A Long-term, Open Label, Noncomparative Study to Evaluate the Safety of 0.1% Tacrolimus (FK506) Ointment for Treatment of Atopic Dermatitis||Astellas Pharma Inc|Yes|Completed|June 1998|June 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|789|||Both|2 Years|N/A|No|||September 2014|September 17, 2014|November 16, 2007||||No||https://clinicaltrials.gov/show/NCT00560378||164868|
NCT00560391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-180|Dasatinib in Combination With Revlimid (and Dexamethasone)|A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel®) With Lenalidomide (Revlimid®) and Dexamethasone in Subjects With Relapsed and/ or Refractory Multiple Myeloma||Bristol-Myers Squibb|No|Completed|May 2008|November 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|35|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|November 16, 2007|No|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00560391||164867|
NCT00560651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCL|German Corneal Cross Linking Register|German Corneal Cross Linking Register||St. Franziskus Hospital|No|Recruiting|November 2007|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|7500|||Both|N/A|N/A|No|Probability Sample|Patients treated with Corneal Cross Linking in Germany|November 2015|November 21, 2015|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560651||164847|
NCT00560664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-01-C-01-OT|Comparison of Autologous Chondrocyte Implantation Versus Mosaicoplasty: a Randomized Trial|Phase 3 Study Comparison of Autologous Chondrocyte Implantation Versus Mosaicoplasty|Cartipatch|University Hospital, Brest|No|Completed|April 2007|August 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|50 Years|No|||July 2014|July 30, 2014|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560664||164846|
NCT00561587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87, 1, 2007_01_30|Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study|Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Completed|November 2007|February 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2008|April 15, 2011|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561587||164775|
NCT00562744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-9-4379|Effect of Simulation on PALS Training|The Effect of High-Fidelity Simulation on Pediatric Advanced Life Support Training in Pediatric Housestaff: a Randomized Trial||Children's Hospital of Philadelphia|No|Completed|January 2006|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|51|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2007|November 21, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562744||164687|
NCT00562146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJTTH-ICU-07-011|Rate of Postpyloric Migration of Spiral Nasojejunal Tubes in Brain Injured Patients|Rate of Postpyloric Migration of Spiral Nasojejunal Tubes in Brain Injured Patients||Capital Medical University|Yes|Completed|December 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|No|Probability Sample|Acute brain injured patients admitted to Neuro-ICU will be consecutively enrolled.|October 2008|October 27, 2008|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562146||164733|
NCT00571311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080032|Parental Permission and Adolescent Assent and Decision-Making in Clinical Research|Parental Permission and Adolescent Assent and Decision Making in Clinical Research||National Institutes of Health Clinical Center (CC)||Completed|December 2007|||||N/A|Observational|Time Perspective: Prospective|||Actual|294|||Both|13 Years|18 Years|No|||December 2015|December 24, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571311||164046|
NCT00571584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HEAM-1510|High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors|rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa||Novo Nordisk A/S|No|Completed|November 2002|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|24|||Male|N/A|N/A|No|||May 2012|May 21, 2012|December 11, 2007||||No||https://clinicaltrials.gov/show/NCT00571584||164026|
NCT00571571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610008834|Application and Evaluation of Transference Focused Psychotherapy Modified for Adolescents|Application and Evaluation of Transference Focused Psychotherapy Modified for Adolescents|TFP-A|Weill Medical College of Cornell University|No|Recruiting|October 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|14 Years|21 Years|No|||January 2011|January 3, 2011|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571571||164027|
NCT00571298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-091|Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma|A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|November 2007|May 2015|Anticipated|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|December 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00571298||164047|
NCT00572130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-110|Phase II Study of Intravenous Rexin-G in Osteosarcoma|A Phase II Study of Intravenous Rexin-G in Recurrent or Metastatic Osteosarcoma||Epeius Biotechnologies|Yes|Completed|December 2007|June 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|10 Years|N/A|No|||February 2010|June 9, 2011|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572130||163985|
NCT00572390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oestrogen withdrawal|Oestrogen Withdrawal in Hypopituitary Women|Oestrogen Withdrawal in Hypopituitary Women||University of Aarhus|No|Completed|January 2001|February 2002|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|38|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2007|December 12, 2007|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572390||163966|
NCT00571831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Toshi-1|The Effect of a Blue Light Filtering IOL|The Effect of a Blue Light Filtering Intraocular Lens on Blood Retinal Barrier After Cataract Surgery||Showa University|No|Completed|February 2003|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|50 Years|80 Years|No|||December 2007|December 11, 2007|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571831||164007|
NCT00573183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0031|Stimulant Abuser Groups to Engage in 12-Step|Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement|STAGE-12|University of Washington|Yes|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|471|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|December 13, 2007||No||No|June 4, 2013|https://clinicaltrials.gov/show/NCT00573183||163907|
NCT00569127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00778|Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor|Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients||National Cancer Institute (NCI)||Active, not recruiting|December 2007|||January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|427|||Both|N/A|N/A|No|||September 2014|January 5, 2015|December 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569127||164207|
NCT00569452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000278|Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate|Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate||Hoffmann-La Roche||Completed|January 2006|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|12|||Both|18 Years|N/A||||June 2010|March 1, 2016|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569452||164185|
NCT00569465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2004-004203-38|N-Acetylcysteine and Arginine Administration in Diabetic Patients|Effects of Arginine and N-Acetylcysteine Administration on Nitric Oxide Production and Arterial Blood Pressure in Hypertensive Diabetic Patients.|NACARGPAO|University of Turin, Italy|No|Terminated|January 2005|January 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|40 Years|70 Years|No|||December 2007|December 6, 2007|December 6, 2007||No|End of the study|No||https://clinicaltrials.gov/show/NCT00569465||164184|
NCT00569738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061267-HMO-CTIL|Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors|Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors||Hadassah Medical Organization|No|Recruiting|December 2008|December 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|neuroendocrine tumor clinic|February 2009|February 16, 2009|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569738||164164|
NCT00569751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2200|TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program|TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program|ARRIVE 2|Boston Scientific Corporation|No|Completed|October 2004|July 2008|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5016|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|December 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00569751||164163|
NCT00570063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241006|Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo|A Phase 2, Multicenter, Double Blind, Randomized, Fixed Dose, Parallel Group, 3 Week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of PF-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia||Pfizer|No|Terminated|November 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||September 2009|September 25, 2009|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570063||164139|
NCT00571155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELLO-Study 2007|Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery|Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study)||University Hospital Tuebingen|No|Completed|December 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2009|August 19, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571155||164058|
NCT00571168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EmNa (2001-004956-38)|Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy|Randomised, Placebo Controlled, Single-center, Double-blind Clinical Trial to Investigate Efficacy and Safety of Aprepitant Combined With Kevatril and Dexamethasone Versus Placebo Combined With Kevatril and Dexamethasone in Prevention of Acute and Delayed High-dose Chemotherapy-induced Nausea and Vomiting in Subjects With Multiple Myeloma Receiving an Autologous Peripheral Blood Stemcell Transplantation.|EmNa|Heidelberg University|No|Recruiting|July 2005|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|362|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571168||164057|
NCT00560690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83/53|The Effect of Adding Metformin to the Treatment of Hepatitis C|Effect and Safety of Adding Metformin to the Standard Treatment of Hepatitis C on Sustained Viral Response||Tehran University of Medical Sciences|No|Completed|December 2007|December 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|15 Years|65 Years|No|||April 2015|April 2, 2015|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560690||164844|
NCT00561041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA_KAM_012187|Aftercare for Adolescents Treated for Alcohol Abuse and Dependence|Maintenance of Treatment Gains in Adolescents With Alcohol Related Disorders||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|No|Completed|November 2005|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|177|||Both|13 Years|18 Years|No|||November 2007|November 19, 2007|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561041||164817|
NCT00561366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALS-003|A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS|A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With Amyotrophic Lateral Sclerosis (ALS)||CytRx|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|November 16, 2007|Yes|Yes|Not moving forward with program.|No||https://clinicaltrials.gov/show/NCT00561366||164792|
NCT00562159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05238|Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma||Merck Sharp & Dohme Corp.|Yes|Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|November 20, 2007|Yes|Yes||No|August 7, 2012|https://clinicaltrials.gov/show/NCT00562159||164732|
NCT00562458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ARO-HCH-2006/1|Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer|ARIMIDEX Study ( Non-interventional Study to Evaluate Arimidex in Adjuvant Therapy in Partial or Complete Response or Stabilized Disease After First Line Chemotherapy in Postmenopausal Women With Advanced Breast Cancer)||AstraZeneca|No|Completed|December 2006|||||N/A|Observational|Time Perspective: Prospective||1|Actual|200|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal patients with advanced breast cancer in whom a partial or complete response        or stabilized disease were obtained with first line chemotherapy, by tumoral response        assessment.|February 2013|February 4, 2013|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562458||164709|
NCT00562991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B30020072436|Monitoring Asthma Treatment Using Exhaled Nitric Oxide|Monitoring Asthma Treatment Using Exhaled Nitric Oxide|NOASTHMA|University Hospital, Antwerp|No|Completed|October 2007|December 2009|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|99|||Both|5 Years|14 Years|No|Probability Sample|asthmatic children|November 2007|June 15, 2011|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562991||164668|
NCT00571597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM10695|Short Term Outcomes From Minimally Invasive Surgery for the Treatment of Atrial Fibrillation|Prospective Analysis of the Wolf Minimaze Procedure for Treatment of Atrial Fibrillation||Virginia Commonwealth University|No|Completed|March 2007|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|118|||Both|18 Years|85 Years|No|Non-Probability Sample|Eligible subjects will be male or females age 18-85 that have elected to undergo or have        undergone a minimally invasive "minimaze" surgery for the treatment of atrial firillation|April 2014|April 10, 2014|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571597||164025|
NCT00571870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0710-050-001|Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study|Study on the Effect of GnRH Antagonist on hCG Day on Outcomes of Controlled Ovarian Hyperstimulation With GnRH Antagonist Flexible Multiple-dose Protocols||Seoul National University Bundang Hospital|No|Completed|November 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|No|||August 2009|August 20, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571870||164005|
NCT00571844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007858|ENCORE: Exercise and Nutritional Interventions for Cardiovascular Health|Behavioral Treatment of High Blood Pressure|ENCORE|Duke University|Yes|Completed|October 2003|July 2013|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|144|||Both|35 Years|N/A|Accepts Healthy Volunteers|||November 2013|July 11, 2014|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571844||164006|
NCT00572416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140-02FB|Fatigue in Breast Cancer: A Behavioral Sleep Intervention|Fatigue in Breast Cancer:A Behavioral Sleep Intervention||University of Nebraska|No|Completed|April 2003|June 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|220|||Both|19 Years|N/A|No|||December 2007|December 12, 2007|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572416||163964|
NCT00572403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298-2007|Risk Factors Contributing to the Development of Microalbuminuria|Risk Factors Contributing to the Development of Microalbuminuria Over a 5 Year Period||Sunnybrook Health Sciences Centre||Completed|December 2007|April 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|45 Years|N/A|No|Non-Probability Sample|Participants returning for a 4-5 year follow-up visit as part of an ongoing research        project will be screened for microalbuminuria and invited to participate if they meet the        appropriate criteria.|March 2011|March 4, 2011|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572403||163965|
NCT00573196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-BPC-CTP1|Far Infrared Radiation Treatment for Bipolar Condition|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Bipolar Condition||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|September 2006|June 2008|Anticipated|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||August 2009|August 14, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573196||163906|
NCT00573209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-EDS-CTP1|Energy Specific Far Infrared Radiation Treatment for Erectile Dysfunction|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Erectile Dysfunction.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|August 2007|May 2009|Anticipated|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|N/A|N/A|No|||August 2009|August 14, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573209||163905|
NCT00570089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 10465|Microvascular Coronary Disease In Women: Impact Of Ranolazine|Microvascular Coronary Disease In Women: Impact Of Ranolazine||Cedars-Sinai Medical Center|Yes|Completed|April 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|N/A|N/A|No|||January 2016|January 14, 2016|December 7, 2007|No|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00570089||164138|This was a pilot study.
NCT00570609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-20070909|CPR Training in 7th Grade Students|CPR Training in 7th Grade Students||Lehigh Valley Hospital|Yes|Completed|January 2008|June 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Both|N/A|N/A|No|||April 2012|April 25, 2012|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570609||164100|
NCT00570622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRRPIO|Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis|Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis||Medical University of Vienna|Yes|Completed|December 2004|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||November 2008|November 24, 2008|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570622||164099|
NCT00570830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9145|Retisert and Cataract Surgery in Patients With Severe Uveitis|Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients With Severe Uveitis||Duke University|Yes|Completed|September 2006|May 2008|Actual|November 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||August 2008|August 29, 2014|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570830||164083|
NCT00570843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710009485|Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses|Phase 4 Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses||Bp Consulting, Inc||Completed|March 2008|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 19, 2010|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570843||164082|
NCT00570856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110|Trial of Folic Acid Effect on Hcy and cIMT After Kidney Tx|Clinical Trial of Effectiveness of Folic Acid Therapy on Homocysteine Level and Carotid Intima-Media Thickness After Kidney Transplantation||hahid Beheshti University of Medical Sciences|No|Terminated|June 2005|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|60|||Both|25 Years|65 Years|No|||December 2007|December 14, 2007|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570856||164081|
NCT00571181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/14|Automated Anesthesia During Bronchoscopy|Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison Between Manual Perfusion and Automated Perfusion During Rigid Bronchoscopy||Hopital Foch|No|Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||April 2009|April 5, 2009|December 9, 2007||No||No||https://clinicaltrials.gov/show/NCT00571181||164056|
NCT00561054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-000537-35|Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC|Open-Label, Uncontrolled, Multicenter, Phase II Study Evaluating the Efficacy and Safety of Cetuximab in Combination With Cisplatin & Gemcitabine as First-Line Therapy in Patients With Advanced Non Small Cell Lung Cancer|Coimbra|Grupo Portugues de Estudo do Cancro do Pulmao|No|Recruiting|March 2007|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||November 2007|November 19, 2007|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561054||164816|
NCT00561379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 04/4-O|Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab|Frontline Therapy of Diffuse Large B Cell Lymphoma of the Adult ( 18 to 60 Years Old): Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14 -Rituximab. Multicentric Randomized Prospective Trial.||Nantes University Hospital||Completed|April 2005|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|60 Years|No|||June 2013|June 12, 2013|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00561379||164791|
NCT00562484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-USF-06-28|A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults|A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to < 65 Years.|CSL's IVV|CSL Limited||Completed|March 2008|January 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|7500|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2011|August 7, 2011|November 20, 2007|Yes|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00562484||164707|
NCT00563602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONHEMO-2006|Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response|Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|August 2007|November 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|80 Years|No|||November 2007|November 22, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563602||164622|
NCT00563615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR/03-030|Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method|Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method||Hospital Authority, Hong Kong||Recruiting|November 2004|October 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563615||164621|
NCT00563927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L/M-77 TO PYH08/79|Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)|Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma||Hospital Authority, Hong Kong||Active, not recruiting|March 1999|October 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|340|||Both|N/A|70 Years||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563927||164598|
NCT00563940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUG 044/07|Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema|Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema||University Hospital Inselspital, Berne|No|Completed|March 2007|February 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|30|||Both|20 Years|80 Years|No|Probability Sample|Patients with clinical significant macular edema|September 2011|September 5, 2011|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00563940||164597|
NCT00571883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577728|Neck Surgery in Treating Patients With Early-Stage Oral Cancer|SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck||National Cancer Institute (NCI)||Active, not recruiting|January 2007|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|652|||Both|16 Years|120 Years|No|||July 2009|December 11, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571883||164004|
NCT00572156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS316|rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency|Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 rhIGF-1) Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency: A Six-year, Randomized, Multi-center, Open-label, Parallel-group, Active Treatment Controlled, Dose Selection Trial||Ipsen|Yes|Terminated|December 2007|March 2012|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|106|||Both|5 Years|N/A|No|||November 2015|November 10, 2015|December 10, 2007|Yes|Yes|The study was prematurely terminated due to strategic reasons.|No|August 6, 2015|https://clinicaltrials.gov/show/NCT00572156||163983|The study was prematurely terminated once the last subject had completed three years of treatment (compared to the six years planned in protocol Amendment) for strategic reasons.
NCT00572143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-REK NORD 79/2006|Follow-up After Surgery for Colon Cancer. General Practice vs. Surgical-based Follow-up?|Should the Surgeon or the General Practitioner (GP) Follow up Patients After Surgery for Colon Cancer? A Randomized Controlled Trial Focusing on Quality of Life, Cost-effectiveness and Serious Clinical Events.|ONKOLINK|University Hospital of North Norway|No|Completed|June 2007|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|180|||Both|20 Years|75 Years|No|||January 2016|January 26, 2016|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572143||163984|
NCT00572702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR/9309-3 IGA|Randomized,Multicentric Study to Treat Prolapse After Hysterectomy With Amreich Procedure or Total Prolift Procedure|Open, Randomized, Prospective, Comparative, Multicentric to Treat Prolapse of Vaginal Cuff After Hysterectomy With Amreich Procedure or Total Prolift Procedure||Charles University, Czech Republic|No|Recruiting|January 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||July 2009|July 31, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572702||163944|
NCT00572689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exenatide.GDM|Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes|Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes||Georgetown University|Yes|Withdrawn|August 2013|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|0|||Female|18 Years|50 Years|No|||August 2015|August 20, 2015|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572689||163945|
NCT00572962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/268|Prospective Clinical Observational Cohort Study to Evaluate the Use of a Tissue Separating Mesh (Proceed®) in Laparoscopic Ventral Hernia Repair|Prospective Clinical Observational Cohort Study to Evaluate the Use of a Tissue Separating Mesh (Proceed®) in Laparoscopic Ventral Hernia Repair||University Hospital, Ghent|No|Active, not recruiting|January 2008|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572962||163924|
NCT00569764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|snh002|Effect on Metabolic Parameters of Abilify in SPR|The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia||Seoul National Hospital|No|Recruiting|December 2007|October 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|blood sampling|Both|18 Years|65 Years|No|Probability Sample|patients with schizophrenia who want to change an antipsychotics due to metabolic side        effects|June 2009|June 9, 2009|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569764||164162|
NCT00569777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003-002|Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers|A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers||Vistakon Pharmaceuticals||Completed|October 2007|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|310|||Both|8 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 18, 2015|November 27, 2007|Yes|Yes||No|October 4, 2010|https://clinicaltrials.gov/show/NCT00569777||164161|
NCT00569790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023018|Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer|Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer||Taiho Pharmaceutical Co., Ltd.|Yes|Completed|October 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|20 Years|N/A|No|||November 2012|November 1, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569790||164160|
NCT00570115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ecoera-001|Left Atrial Volume and Function Evaluation in Patients With Obstructive Sleep Apnea|Left Atrial Volume and Function in Patients With Obstructive Sleep Apnea Assessed by Real Time Three Dimensional Echocardiography||Associação Fundo de Incentivo à Pesquisa|No|Completed|June 2007|November 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|The investigators recruited 56 recently diagnosed OSA patients, confirmed by full        polysomnography (PSG), referred to Sleep Laboratory of Psychobiology Department of Federal        University of Sao Paulo, Brazil, according to the following inclusion criteria: both        genders aging from 29 to 70 years old, with apnea-hypopnea index (AHI) >5 events/hour of        sleep. Control group comprised 50 healthy community subjects without OSA confirmed by full        PSG, matched by age, gender, and BMI.|December 2007|May 7, 2012|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570115||164136|
NCT00570128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-219|Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome|A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome||Eisai Inc.||Completed|December 2007|December 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|10 Years|17 Years|No|||August 2009|August 4, 2009|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570128||164135|
NCT00570167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH7306|Comparison of Hip Resurfacing and Cementless Metal-on-metal Total Hip Arthroplasty|Comparison of Hip Resurfacing and Cementless Metal-on-metal Total Hip Arthroplasty - Prospective Randomized Clinival Trial||Helsinki University|No|Completed|November 2006|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|71|||Both|18 Years|60 Years|No|||August 2009|August 3, 2009|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00570167||164132|
NCT00570635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL820-201|A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib|A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib||Exelixis|Yes|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|December 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570635||164098|
NCT00570869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-20070911|Training Mothers of Infants in Infant Cardiopulmonary Resuscitation (CPR)|Training Mothers of Infants in Infant Cardiopulmonary Resuscitation (CPR) Using a 22-Minute Instructional DVD and Infant Manikin||Lehigh Valley Hospital|Yes|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Female|18 Years|N/A|No|||April 2012|April 25, 2012|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570869||164080|
NCT00561600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04062|Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System|A Randomized, Prospective, Comparative, Multi-Center Clinical Evaluation of the DePuy ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System Study|ASR|DePuy Orthopaedics|No|Completed|November 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|265|||Both|20 Years|75 Years|No|||April 2014|April 7, 2014|November 20, 2007|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00561600||164774|At study inception, information on whether or not an adverse event was deemed to be serious was not collected. Because of this caveat, the Sponsor has reported all adverse events that occurred.
NCT00561886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPF0601T|Change of Inspiratory Peak Flow in COPD|Change of Inspiratory Peak Flow After Bronchial Dilatation on Patients With Moderate to Severe COPD||Johannes Gutenberg University Mainz|Yes|Completed|April 2007|October 2007|Actual|||Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|40 Years|N/A|No|||November 2007|November 20, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00561886||164753|
NCT00563667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2003.353|Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation|Effect of Pterygium Excision on IOL Power Calculation: Concurrent Cataract and Pterygium||Hospital Authority, Hong Kong||Active, not recruiting|December 2003|December 2004|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563667||164617|
NCT00563693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2007.980|Chronic Heart Failure - Cheyne Stokes Respiration - CS2 (3C-study)|Open Randomized Study of Patients With Chronic Heart Failure and Cheyne Stokes Respiration Pattern, Treated With ASV. (Adaptive Servo Ventilator).|3C|University of Oslo|No|Completed|September 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||December 2015|December 2, 2015|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00563693||164615|
NCT00563628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASCAL001|Changes in Macular Thickness After Patterns Scan Laser|Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment.||Asociación para Evitar la Ceguera en México|No|Recruiting|October 2007|February 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|25 Years|95 Years|No|||November 2007|November 23, 2007|November 22, 2007||||No||https://clinicaltrials.gov/show/NCT00563628||164620|
NCT00563017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW / EX / 04 - 038|Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone|Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone||Hospital Authority, Hong Kong||Recruiting|October 2004|November 2005|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563017||164666|
NCT00563316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062010|Panitumumab DDI Irinotecan|A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer||Amgen||Completed|January 2008|March 2011|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|75 Years|No|||July 2011|July 7, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563316||164643|
NCT00572715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X070927001|Acute Kidney Injury in Neonates|Acute Kidney Injury in Neonates||University of Alabama at Birmingham|No|Withdrawn|January 2010|January 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Inclusion criteria - Families of infants (birthweight >1500g) be asked to participate in        the study.        Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe        hydronephrosis or other known renal abnormalities will be excluded|February 2010|March 5, 2015|December 11, 2007||No|Investigator's decision:Did not open to enrollment|No||https://clinicaltrials.gov/show/NCT00572715||163943|
NCT00572988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528-01-FB|Symptom Management Intervention in Elderly Coronary Artery Bypass Patients|Symptom Management Intervention in Elderly CABG Patients||University of Nebraska|No|Completed|May 2002|January 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|232|||Both|65 Years|N/A|No|Non-Probability Sample|All subjects 65 and older who are admitted for a first time CABG surgery.|January 2010|January 12, 2010|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572988||163922|
NCT00573222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RHR-SYM-2007/1|Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma|Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma||AstraZeneca||Completed|November 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|330|||Both|18 Years|N/A|No|Non-Probability Sample|pulmonology clinics|November 2010|November 30, 2010|December 13, 2007||||No||https://clinicaltrials.gov/show/NCT00573222||163904|
NCT00572429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715081|Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART|Effects of Mixed Exercise Regime and L-Carnitine Supplementation on Kinetics of Triglyceride-rich Lipoproteins in HIV Patients on HAART|HIV|University of California, Davis|No|Withdrawn|July 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||December 2012|December 17, 2012|December 11, 2007||No|no subjects enrolled,study never started|No||https://clinicaltrials.gov/show/NCT00572429||163963|
NCT00569140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH 1000|A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration|A Phase 1, Single Ascending Dose Trial to Establish the Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Monotherapy and of E10030 Given in Combination With Lucentis®0.5 Mg/Eye in Subjects With Neovascular Age-Related Macular Degeneration||Ophthotech Corporation|No|Completed|December 2007|December 2008|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|50 Years|N/A|No|||January 2010|January 21, 2010|December 4, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569140||164206|
NCT00569153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-700_201|Safety Study of TAK-700 in Subjects With Prostate Cancer.|A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects|TAK-700|Millennium Pharmaceuticals, Inc.|No|Completed|April 2008|February 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|123|||Male|18 Years|N/A|No|||June 2013|July 1, 2013|December 4, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00569153||164205|
NCT00572975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-5-3733|Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea|MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea|MBT|Children's Hospital of Philadelphia|Yes|Completed|August 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|8 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 26, 2008|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572975||163923|
NCT00570102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195003|Nutritional Prevention Pilot Trial for Type 1 Diabetes|Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study|MIP|Helsinki University|No|Completed|February 1995|January 2008|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|230|||Both|N/A|7 Days|Accepts Healthy Volunteers|||November 2012|November 27, 2012|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570102||164137|
NCT00570388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062166|Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence|Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence||Institute of Addiction Medicine|No|Recruiting|March 2007|September 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||January 2008|January 15, 2008|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00570388||164115|
NCT00570362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-001|Systemic Glutathione Level in Normal Tension Glaucoma|Evaluation of Systemic Glutathione Level in Patients With Normal Tension Glaucoma||The Catholic University of Korea|No|Completed|March 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|49|Samples Without DNA|serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients of tertiary referred center|December 2007|July 14, 2010|December 7, 2007||No||No|June 11, 2010|https://clinicaltrials.gov/show/NCT00570362||164117|
NCT00571194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75611|Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients|A Single-dose Pilot Study to Evaluate the Pharmacokinetics of Pravastatin Given as an Oral Dose in Pediatric and Adolescent Subjects 12 Months to 16 Years of Age Receiving Continuous Cycling Peritoneal Dialysis||Arkansas Children's Hospital Research Institute|No|Completed|September 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|7|||Both|12 Months|18 Years|No|||August 2009|August 31, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571194||164055|
NCT00570882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOSG_AMC_0701|Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)|A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma||Asan Medical Center|No|Completed|October 2007|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570882||164079|
NCT00571701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01DC007946-01A2|Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis|A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis||Northwell Health|Yes|Completed|February 2008|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|2 Years|N/A|No|||May 2015|May 13, 2015|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571701||164017|
NCT00563004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBcare1|The Effect of DBcare, a Food Supplement on Diabetes Control|A Double-blind Placebo Controlled Study Studying the Efficacy of DBCARE in Improving Diabetes Control||Meir Medical Center|No|Completed|August 2008|September 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00563004||164667|
NCT00563290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00226|Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia|A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)|No|Completed|November 2007|October 2014|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||March 2015|May 21, 2015|November 22, 2007|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00563290||164645|3 patients were treated with Dasatinib 100 mg PO twice daily and 4 patients were treated with Daatinib 70 mg PO twice daily.
NCT00563303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 06/6-L|Treatment of Polytraumatisms With Corticoids|Interest of Treatment of Polytraumatisms With Corticoids (Hydrocortisone) for Patient With Relative Adrenocortical Insufficiency|Hypolyte|Nantes University Hospital|No|Completed|November 2006|July 2009|Actual|November 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|15 Years|N/A|No|||April 2010|April 20, 2010|September 26, 2006||No||No||https://clinicaltrials.gov/show/NCT00563303||164644|
NCT00559715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIBERA_2007-004721-23|Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab|Prevention of Vision Loss in Patients With Age-Related Neovascular Macular Degeneration by Intravitreal Injection of Bevacizumab and Ranibizumab in a Typical Outpatient Setting|VIBERA|Klinikum Bremen-Mitte, gGmbH|Yes|Recruiting|August 2008|August 2010|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|366|||Both|50 Years|N/A|No|||March 2009|March 25, 2009|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559715||164917|
NCT00559728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_3763|Magnetic Resonance Imaging (MRI) Analysis of Coronary Artery Plaque Components|||Johns Hopkins University|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|65 Years|No|Non-Probability Sample|Male and Females 18 - 65 scheduled to undergo a clinically-indicated coronary artery CT        scan.|September 2015|September 3, 2015|November 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559728||164916|
NCT00560040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miller 01|Myocardial Injury is Not Related to Training Levels Among Recreational Participants in the Silicon Valley Marathon|Myocardial Injury is Not Related to Training Levels Among Recreational Participants in the Silicon Valley Marathon||Stanford University|Yes|Completed|January 2006|October 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|53|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2007|November 16, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00560040||164894|
NCT00562770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-666|Oral Valganciclovir Versus Valacyclovir|Open Label, Phase II Randomized Study of Oral Valganciclovir Versus Valacyclovir for Prophylaxis of Cytomegalovirus Reactivation in Patients Receiving Alemtuzumab (Campath).||M.D. Anderson Cancer Center|No|Completed|September 2003|July 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|16 Years|N/A|No|||July 2012|July 27, 2012|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562770||164685|
NCT00562783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW04-223 T/545|A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis|A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis||Hospital Authority, Hong Kong||Completed|January 2005|May 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|80 Years||||October 2013|October 22, 2013|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00562783||164684|
NCT00559676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574159|Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer|Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|March 2005|||May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||July 2009|May 13, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559676||164920|
NCT00573001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12115 DAYANA|Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)|Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde|DAYANA|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|July 2008|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573001||163921|
NCT00573248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4296|Nicotine and Behavior in Adult ADHD|Nicotine and Behavioral Regulation in Adult ADHD||University of California, Irvine|Yes|Completed|August 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|78|||Both|18 Years|45 Years|No|||September 2011|September 1, 2011|December 12, 2007||No||No|April 1, 2011|https://clinicaltrials.gov/show/NCT00573248||163902|
NCT00573235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07090323|Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli|Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli||University of Pittsburgh|Yes|Active, not recruiting|October 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|300|Samples Without DNA|All samples provided to the investigators are deidentified by the honest broker and will be      coded with numbers. The information linking these code numbers to the corresponding      subjects' identities will be kept in a separate, secure location that only the honest broker      has access to. The investigators on this study will keep the samples indefinitely. Samples      will be kept in the investigator's laboratory located in Scaife Hall, room 812, 3500 Terrace      Street. At no time with the research investigators have access to any patient identifers.|Both|18 Years|N/A|No|Non-Probability Sample|All patients with E. coli, Klebsiella species and Proteus species infections during the        time period of the study will be reviewed.|December 2015|December 16, 2015|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573235||163903|
NCT00569491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2021|TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program|TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program|ARRIVE|Boston Scientific Corporation|No|Completed|February 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2585|||Both|18 Years|N/A|No|||September 2008|September 24, 2008|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569491||164182|
NCT00569803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-046|Subcutaneous Pharmacokinetics Study|Pharmacokinetics, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects||Bristol-Myers Squibb|No|Completed|December 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|7||Actual|47|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|October 10, 2008|November 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00569803||164159|
NCT00569478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Berg|The Effect of Rehabilitation for Patients Living With an Implantable Cardioverter Defibrillator|The Effect of Rehabilitation for Patients Living With an ICD|ICD-rehab|Rigshospitalet, Denmark|No|Completed|October 2007|October 2011|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|196|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569478||164183|
NCT00569829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G04-06-117-04|Modular Cognitive Behavioral Therapy for the Treatment of Child Anxiety Disorders in Elementary School Settings|A Randomized, Controlled Trial of Modular CBT for Child Anxiety Disorders in Elementary School Settings|KATES|University of California, Los Angeles|No|Completed|January 2004|June 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|12 Years|No|||March 2012|March 28, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569829||164157|
NCT00570375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07092512|The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome|Phase II of Erlotinib an Epidermal Growth Factor Receptor Inhibitor in the Treatment of Myelodysplastic Syndrome||University of Cincinnati|No|Withdrawn|November 2007|November 2012|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2009|April 16, 2009|December 6, 2007|No|Yes|Rami Komrokji, MD author of this protocol no longer is at the University of Cincinnati and    this study has been withdrawn.|No||https://clinicaltrials.gov/show/NCT00570375||164116|
NCT00571441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002786|Estimating Volume Using LiDCO|Estimating Volume Using LiDCO Versus Other Measures of Volume|EVOLVE|Duke University|No|Completed|December 2007|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Neurologically injured patients|March 2009|January 20, 2016|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571441||164036|
NCT00571454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ|Culturally Sensitive Depression Care Management for Latino Primary Care Patients|Culturally Sensitive Depression Care Management for Latino Primary Care Patients||Butler Hospital|Yes|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|38|||Both|18 Years|65 Years|No|||October 2009|October 28, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571454||164035|
NCT00571428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-903|Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD|Modified-blind, Randomized, Multicenter, Single Dose, Two-way Crossover Study of Arformoterol Tartrate Inhalation Solution 15 Micrograms Twice A Day Versus 30 Micrograms Once A Day in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Sunovion|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|45 Years|N/A|No|||February 2012|February 21, 2012|December 10, 2007|Yes|Yes||No|March 13, 2009|https://clinicaltrials.gov/show/NCT00571428||164037|Single day/dose; small numbers of subjects; difference between arms (2mL vs 4mL per dose); Predefined +/-0.07L equivalence is arbitrarily lower than the clinically recognized 0.1L. Hence, clinical efficacy & safety conclusions are difficult to reach.
NCT00561938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 07/3-Q|Confocal Laser Endomicroscopy|Confocal Laser Endomicroscopy in the Digestive Tract: A Multicentre French Pilot Study.||Nantes University Hospital||Completed|June 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|18 Years|70 Years|No|||February 2009|February 24, 2009|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00561938||164749|
NCT00562185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574034|Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer|A Phase I/II Study of Intravenous Doxil and Intraperitoneal Carboplatin as Salvage Therapy in Patients With Recurrent Ovarian Cancer||National Cancer Institute (NCI)||Completed|May 2008|||March 2009|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Female|18 Years|N/A|No|||March 2009|March 19, 2009|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562185||164730|
NCT00562198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939121|PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding|Effects of Single Doses of Stalevo 200 and Levodopa/Carbidopa 200/50mg on Striatal 11C-Raclopride Binding Potential in Parkinson's Disease Patients With Wearing-Off Symptoms;an Open, Randomised, Active-Controlled,Two-Period Crossover Study.||Orion Corporation, Orion Pharma|No|Terminated|January 2008|May 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|45 Years|80 Years|No|||June 2008|June 12, 2008|November 19, 2007|No|Yes|Illogistical results found in interim evaluation.|No||https://clinicaltrials.gov/show/NCT00562198||164729|
NCT00560053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETHEMA MM-2000|Pethema Multiple Myeloma 2000|Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response||PETHEMA Foundation|Yes|Completed|January 2000|February 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|N/A|69 Years|No|||November 2008|November 26, 2008|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00560053||164893|
NCT00563966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smokingmothers-HMO-CTIL|The Stress Responses of Fetuses and Infants Whose Mothers Smoked During Pregnancy|The Stress Responses of Fetuses and Infants Whose Mothers Smoked During Pregnancy: Genes, Hormones and Psychological Modulators||Hadassah Medical Organization|No|Recruiting|April 2008|December 2008|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|DNA samples + salivery cortisol|Female|22 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Women who smoked during pregnancy|November 2007|May 9, 2008|November 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00563966||164595|
NCT00559702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS102|Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)|A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis||Biogen|No|Completed|October 2007|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|76|||Both|18 Years|65 Years|No|||September 2014|September 5, 2014|November 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559702||164918|
NCT00572767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000/001|Evaluation of the Effect of Dextro-Amphetamin Added to Physiotherapy in Patients After Stroke|Evaluation of the Therapeutic Effect of Amphetamine in Association to Physiotherapy on Motor Recovery After Stroke: a Randomised, Double-Blinded, Placebo-Controlled Trial||Reha Rheinfelden|No|Terminated|January 2001|September 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|December 12, 2007|Yes|Yes|Intended length of study ended|No||https://clinicaltrials.gov/show/NCT00572767||163939|
NCT00573014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB04-00110|Cervical Spine Clearance in Obtunded Trauma Patients|Evaluating the Need for Magnetic Resonance Imaging of the Cervical Spine in Obtunded Trauma Patients|CSclearance|MetroHealth Medical Center|No|Recruiting|October 2006|September 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Subjects will include all patients (including children) after blunt trauma in whom        cervical spine injury has not been ruled out admitted to MetroHealth Medical Center from        10/1/2004-9/30/2006. We are excluding patients with an obvious neurologic deficit        attributable to the cervical spine. We are excluding patients with abnormalities of the        cervical spine that are identified on either plain films or CT. We are also excluding        those patients in whom the cervical spine can be cleared clinically due to normal mental        status.|December 2007|December 12, 2007|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00573014||163920|
NCT00569166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579010|Three Different Programs of Paced Breathing in Treating Hot Flashes in Women|Paced Breathing for Hot Flashes: A Randomized Phase II Study||Mayo Clinic||Completed|March 2007|||February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|105|||Female|18 Years|120 Years|No|||November 2011|January 7, 2016|December 5, 2007||No||No|September 13, 2011|https://clinicaltrials.gov/show/NCT00569166||164204|
NCT00569179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612-26/ IUCRO-0179|A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies|A PHASE I TRIAL OF ALLOREACTIVE NK CELLS INFUSION FOLLOWING TRANSPLANTATION OF HAPLOTYPE MISMATCHED, KIR MISMATCHED HIGHLY PURIFIED CD34 CELLS IN PATIENTS WITH ADVANCED OR REFRACTORY MYELOID MALIGNANCIES||Indiana University|Yes|Terminated|August 2007|December 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||August 2015|August 28, 2015|December 5, 2007|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00569179||164203|
NCT00569192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0010-CL-P301|A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Study Investigating the Safety and Efficacy Over 12 Weeks Treatment Period of MAP0010 in Asthmatic Infants and Children 12 Months to 8 Years of Age||Allergan|No|Completed|December 2007|January 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|360|||Both|12 Months|8 Years|No|||December 2013|December 9, 2013|December 5, 2007|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00569192||164202|
NCT00569816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSHCK-Anae07/06|Continuous Versus Repetitive Sevoflurane Administration for Preconditioning|A Comparison Between Continuous and Repetitive Sevoflurane Administration for Preconditioning During Coronary Artery Bypass Surgery||University of Schleswig-Holstein|No|Completed|January 2005|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|80 Years|No|||November 2007|December 6, 2007|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569816||164158|
NCT00569504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|snh001|Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics|Prevalence of the Metabolic Syndrome in Patients With Schizophrenia Taking Antipsychotics||Seoul National Hospital|No|Recruiting|December 2007|September 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples Without DNA|blood sampling|Both|18 Years|65 Years|No|Probability Sample|DSM-IV diagnosis of schizophrenia|June 2009|June 11, 2009|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569504||164181|
NCT00570141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9310-002-004|OASIS Wound Matrix (Oasis) Mechanism of Action|Case Study Documentation of Subjects With Either Diabetic Foot Ulcers or Venous Stasis Ulcers Being Treated With OASIS||Healthpoint|No|Completed|October 2007|April 2010|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|December 6, 2007|No|Yes||No|June 9, 2010|https://clinicaltrials.gov/show/NCT00570141||164134|
NCT00570154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080028|Relation of White Blood Cell Function to Diabetes|Pilot Study of Monocyte Biology in Insulin Sensitive, Resistant and Diabetic Subjects||National Institutes of Health Clinical Center (CC)||Completed|November 2007|||October 2009|Actual|N/A|Observational|Time Perspective: Prospective||||100|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||October 2009|March 15, 2011|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570154||164133|
NCT00570648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13114|A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization|A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization||University of Virginia|No|Completed|June 2007|June 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2008|August 6, 2008|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570648||164097|
NCT00570661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/05/2357/19|Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)|Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)|SOJIA|Italfarmaco|No|Completed|August 2006|August 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|2 Years|25 Years|No|||January 2012|May 23, 2013|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570661||164096|
NCT00570921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-BRE-43-NP|Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure|A Phase II Study of Combined Fulvestrant (Faslodex) and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure|BRE-43|University of Kentucky|Yes|Completed|April 2008|January 2015|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|45 Years|N/A|No|||January 2015|January 8, 2015|December 7, 2007|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00570921||164076|Potential toxicities of mammalian target of rapamycin (mTOR) inhibitors and our observation that a third of patients had no benefit from this strategy, we need to identify biomarkers that correlate with treatment benefit for better patient selection.
NCT00570895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21063|Effect of Vitamin C on Iron Absorption|Effect of Ascorbic Acid on Iron Absorption From Ferrous Fumarate||Baylor College of Medicine|No|Completed|January 2008|May 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|22|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||June 2008|June 3, 2008|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570895||164078|
NCT00570908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20924|Brain Mets - Capecitabine Plus Sunitinib and WBRT|A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer||Baylor Breast Care Center|Yes|Terminated|February 2009|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||August 2014|September 8, 2014|December 7, 2007|Yes|Yes|Due to poor accrual this study is being closed to accrual|No|July 22, 2014|https://clinicaltrials.gov/show/NCT00570908||164077|
NCT00570934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hillmanlJRA|Supplimentation With 2000IU Vitamin D, 1gm Calcium or Both on Calcium Absorption and BMC in Children With JRA|Effect ofSupplimentation With 2000IU Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis||University of Missouri-Columbia|No|Completed|March 1995|February 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|3 Years|15 Years|No|||December 2007|December 10, 2007|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570934||164075|
NCT00571987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS 29143|Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation|Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation|eRFA|University of Arkansas|No|Completed|September 2004|December 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Female|18 Years|N/A|No|||October 2015|October 28, 2015|December 11, 2007|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT00571987||163996|
NCT00600340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/BC1.3.005|2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab|A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of HER2-negative Locally Recurrent or Metastatic Breast Cancer||Central European Cooperative Oncology Group|Yes|Completed|April 2008|November 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|560|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600340||161868|
NCT00600353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10862|Multi-day Doses in Prevention of Nausea and Emesis|Combined Use of Multi-Day Doses of Palonosetron and Aprepitant With Low Doses Dexamethasone in Prevention of Nausea and Emesis Among Patients With Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant: A Pilot Study||University of Kansas Medical Center|Yes|Completed|October 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 18, 2011|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600353||161867|
NCT00572234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260-07-FB|Bupropion in the Treatment of Methamphetamine Dependence|Bupropion in the Treatment of Methamphetamine Dependence||University of Nebraska|Yes|Recruiting|June 2007|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|No|||January 2010|January 13, 2010|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572234||163977|
NCT00572247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH077282-01A1|The Psychiatric Rehabilitation Approach to Weight Loss|The Intervention Involves Education on Nutrition and Physical Activity. Outcomes Evaluate Changes in BMI.||University of Kansas Medical Center|Yes|Completed|January 2007|December 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|133|||Both|18 Years|65 Years|No|||March 2012|March 5, 2012|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572247||163976|
NCT00572260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000856|A Pilot Study of Daptomycin for Antimicrobial Prophylaxis|A Pilot Study of Daptomycin for Antimicrobial Prophylaxis in Patients Undergoing Cardiac Valve Replacement and Coronary Artery Bypass Grafting (CABG) Who Are at Increased Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus (MRSA)||Duke University|No|Terminated|January 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|No|||November 2012|July 17, 2014|December 12, 2007|Yes|Yes|Study closed. PI left the institution.|No|March 29, 2011|https://clinicaltrials.gov/show/NCT00572260||163975|Premature termination of the study due to departure of the PI resulted in falling short of enrollment goal (enrolled - 11 enrolled/goal - 100) leading to uninterpretable data.
NCT00563030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG-NKEBN/272/2007|Bands in Peripheral Blood After Coronary Artery Bypass Grafting With and Without Cardiopulmonary Bypass|Comparison of Granulocyte Subsets in Peripheral Blood After Coronary Bypass Grafting Operations With and Without Use of Cardiopulmonary Bypass||Medical University of Gdansk|No|Completed|December 2007|May 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|Samples Without DNA|blood on EDTA vials for automatical morphology analysis and manual blood-smear preparation.|Both|18 Years|N/A|No|Non-Probability Sample|Patients qualified for elective CABG with or without cardiopulmonary bypass. If possible,        patient will be matched by age, sex, left ventricle ejection fraction, number of grafts,        and major comorbidities (diabetes mellitus, arteriosclerosis).|November 2009|November 2, 2009|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00563030||164665|
NCT00563342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0027|Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients|Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients|Ethanol|University Hospital, Clermont-Ferrand||Terminated|June 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|October 7, 2008|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00563342||164641|
NCT00563654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.332|Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up|Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo on the Successful Rate of Trial Without Catheter in Patients With Acute Urinary Retention With Long Term Follow up||Hospital Authority, Hong Kong||Terminated|October 2005|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Male|50 Years|N/A||||June 2011|June 15, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563654||164618|
NCT00563979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 152/07|Enhancement of Macular Pigment Density by Oral Lutein Supplementation|Enhancement of Macular Pigment Density by Oral Lutein Supplementation|EMPOLS|University Hospital Inselspital, Berne|No|Completed|July 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|50 Years|N/A|No|||June 2015|June 10, 2015|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00563979||164594|
NCT00559689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hamamatsu-17-43|Study of Inhaled Glucocorticosteroid Administration in Asthma Patients|Phase 4 Study of Once-Daily Inhaled Glucocorticosteroid Administration in Asthma Patients||Hamamatsu University|No|Completed|November 2005|March 2007|Actual|||Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|24|||Both|20 Years|80 Years|No|Probability Sample|University Hospital|March 2009|March 13, 2009|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559689||164919|
NCT00560287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190H09|Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis|Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode||Fondazione Salvatore Maugeri|Yes|Recruiting|January 2008|August 2010|Anticipated|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|20 Years|80 Years|No|||March 2010|March 26, 2010|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560287||164875|
NCT00573027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8221|Heart Disease of the Small Arteries in Women and Men|Coronary Microvascular Disease and Endothelial Function in Women and Men||Cedars-Sinai Medical Center|Yes|Recruiting|November 2005|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|634|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573027||163919|
NCT00573274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09|Measuring Cardiac Output and Stroke Volume Using the Physioflow Impedance Device in Pregnant Patients|Pilot Study Measuring Cardiac Output and Stroke Volume Using Non-Invasive Thoracic Impedance With the Physioflow Impedance Device in Pregnant Patients Undergoing Cesarean Section Under Spinal Anesthesia||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers having an elective cesarean section.|July 2009|July 29, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573274||163900|
NCT00573261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009557|A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy|Pregabalin|Duke University|No|Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 11, 2014|December 12, 2007|Yes|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT00573261||163901|The study has a high dropout, which might have reduced the power of the analysis. One of the major reasons that many patients were not able to participate was an inability to commit to the relatively intense and frequent assessments.
NCT00569517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21955|Cognitive Behavioral Therapy for Obesity|The Effect of Brief Group Cognitive Behavioral Therapy on Decreasing Metabolic Syndrome Risk Factors in Obese Patients Treated With Atypical Antipsychotics||VA Office of Research and Development|No|Completed|January 2008|March 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569517||164180|
NCT00569842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710-11/ IUCRO-0207|Investigation of the Cylex® ImmuKnow® Assay|Investigation of the Cylex® ImmuKnow® Assay||Indiana University|Yes|Completed|November 2007|December 2012|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|None Retained|None to be retained.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for        any of the following disorders are eligible:          1. Acute leukemia          2. Non-Hodgkin's Lymphoma          3. Chronic lymphocytic leukemia          4. Hodgkin's disease          5. Multiple myeloma          6. Myelodysplastic Syndromes          7. Myeloproliferative Disorders          8. Aplastic Anemia          9. Chronic myelogenous leukemia|September 2014|September 10, 2014|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569842||164156|
NCT00569855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06611|Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery|Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery||University of Arkansas|No|Completed|February 2001|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|785|||Both|N/A|18 Years|No|||February 2011|February 3, 2011|December 6, 2007|Yes|Yes||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00569855||164155|
NCT00571220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK67561 (completed)|Mechanisms of Diabetes Control After Weight Loss Surgery|Mechanisms of Diabetes Control After Weight Loss Surgery||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|September 2005|December 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|blood samples|Both|21 Years|60 Years|No|Non-Probability Sample|Morbidly obese patients with type 2 diabetes of less than 5 years duration|February 2011|February 9, 2011|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00571220||164053|
NCT00600873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13023|R(+)PPX High Dose Treatment of ALS|Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months||Bennett, James P., Jr., M.D., Ph.D.|Yes|Completed|August 2007|January 2009|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|30 Years|80 Years|No|||September 2010|September 10, 2010|January 5, 2008|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00600873||161827|
NCT00571467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTX-100A-201|Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP|An Open Label, Sequential, Dose Escalation, Repeat-dose Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRTX-100 in Adult Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)||Protalex, Inc.|Yes|Terminated|December 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|December 10, 2007|Yes|Yes|Terminated due to recruitment not meeting expectations.|No||https://clinicaltrials.gov/show/NCT00571467||164034|
NCT00602160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT001495-01A1|Therapeutic Effect of Chinese Herbal Medicine on Food Allergy|Investigation of the Efficacy of the Food Allergy Herbal Formula (FAHF-2TM) in Patients With Food Allergy - Phase II Trial|FAHF-2|Li, Xiu-Min, M.D.|Yes|Recruiting|December 2007|June 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|68|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 3, 2010|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00602160||161731|
NCT00571207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL 402-1|Oral Fluid Screening Devices|Scientific Evaluation of Oral Fluid Screening Devices and Preceding Selection Procedures||National Institute for Health and Welfare, Finland|No|Completed|April 2008|October 2010|Actual|||N/A|Observational|N/A||2|Anticipated|250|Samples With DNA|Oral fluid and whole blood are collected. However, no DNA testing will be carried out. The      research focuses on drug and medicine concentrations in these matrices.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Drivers suspected of driving under the influence of drugs. Also drivers who are not        suspected of driving under the influence.|August 2011|August 31, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571207||164054|
NCT00604435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endostar B-01|Neoadjuvant Endostatin and Chemotherapy for Breast Cancer|Phase II Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-line Therapy in Patients With Breast Cancer||Xijing Hospital|Yes|Completed|February 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|69|||Female|18 Years|70 Years|No|||January 2010|January 18, 2010|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00604435||161562|
NCT00600899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT2007-005180-10|Home Infusors for Analgesia After Foot Surgery|Use of Home Pumps for Analgesia After Ambulatory Foot Surgery - Comparison of Two Infusion Rates - a Randomized, Double-Blind Study||Frederiksberg University Hospital|Yes|Enrolling by invitation|September 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|80 Years|No|||January 2009|January 28, 2009|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600899||161825|
NCT00601146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-122|Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease|Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease||Dana-Farber Cancer Institute|No|Active, not recruiting|November 2006|December 2016|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|||Both|18 Years|N/A|No|Non-Probability Sample|Survivors of Hodgkin's disease seen for follow-up at the Brigham and Women's Hosptial        Department of Radiation Oncology, the Lance Armstrong Adult Survivorship Clinic and the        David B. Perini Jr. Childhood Cancer Survivor Clinic at the Dana Farber-Cancer Institute|February 2016|February 17, 2016|January 15, 2008||No||No|January 19, 2016|https://clinicaltrials.gov/show/NCT00601146||161806|
NCT00601159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709GP|Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC|Phase Ⅱ Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC||Fudan University|No|Completed|September 2007|September 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|75 Years|No|||June 2011|July 1, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00601159||161805|
NCT00563043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASCAL002|Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment|Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment.||Asociación para Evitar la Ceguera en México|No|Recruiting|October 2007|February 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|25 Years|95 Years|No|||December 2007|December 5, 2007|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00563043||164664|
NCT00563056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3505|An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma|Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy & Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent & Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma||Mundipharma Research Limited||Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|227|||Both|12 Years|N/A|No|||August 2012|August 9, 2012|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00563056||164663|
NCT00563355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE2000.241|A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients|A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients||Hospital Authority, Hong Kong||Completed|February 2001|November 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|66|||Both|N/A|75 Years||||June 2011|June 14, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563355||164640|
NCT00563680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060283|A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors|A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors||Amgen||Completed|October 2007|August 2012|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|16 Years|N/A|No|||August 2014|January 16, 2015|November 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00563680||164616|
NCT00559741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574065|Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer|Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|October 2005|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|80 Years|No|||May 2011|May 12, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559741||164915|
NCT00559754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20382|A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.|An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer||Hoffmann-La Roche||Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Female|18 Years|N/A|No|||November 2014|November 5, 2014|November 15, 2007||No||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00559754||164914|
NCT00559767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906210|Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium|Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium||National Institutes of Health Clinical Center (CC)||Completed|June 2006|April 2012||||N/A|Observational|N/A|||Anticipated|2860|||Both|21 Years|N/A|No|||April 2012|September 26, 2015|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559767||164913|
NCT00560027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20064046|Case Management Study for Postpartum Depression and Intimate Partner Violence|Screening, Referral and Case Management for Postpartum Depression and Intimate Partner Violence in an Urban Pediatric Practice||Johns Hopkins University|No|Completed|July 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|173|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560027||164895|
NCT00560534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB-angio herlev 3|Whole Body Magnetic Resonance Angiography With Subsystolic Venous Compression|Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia. Experience With Venous Compression.||Copenhagen University Hospital at Herlev|Yes|Completed|June 2008|March 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with peripheral arterial disease|August 2009|August 18, 2009|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560534||164856|
NCT00560872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-07-022-GOE|Remote Magnetic Navigation For Cavotricuspid Isthmus Ablation|Randomized Controlled Study of Remote Magnetic Catheter Navigation for Cavotricuspid Isthmus Mapping and Ablation in Patients With Typical Atrial Flutter||University Hospital Goettingen|No|Completed|August 2007|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2009|December 22, 2009|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560872||164830|
NCT00569257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS-108-040|Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors|Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors||AEterna Zentaris|No|Completed|December 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Female|18 Years|N/A|No|||December 2011|December 12, 2011|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569257||164199|
NCT00569530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10842-31630-01|Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide|Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide|TOLSURF Pilot|University of California, San Francisco|No|Active, not recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|N/A|14 Days|No|||April 2014|April 10, 2014|December 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569530||164179|
NCT00569231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46487|Study With Candida Antigen for Treatment of Warts|A Phase 1 Study to Evaluate the Immunologic Mechanisms Underlying Wart Resolution After Intralesional Immunotherapy With Candida Antigen||University of Arkansas|No|Completed|February 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|50 Years|No|||December 2010|December 29, 2010|December 6, 2007|Yes|Yes||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00569231||164201|
NCT00569244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91587|SH T00186 in the Treatment of Primary Dysmenorrhea|A Multi-center, Open-label, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of an Extended Flexible Regimen of the Combined Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Beta-cyclodextrin Clathrate and 3 mg Drospirenone) Compared to the Conventional Regimen of SH T00186D in the Treatment of Primary Dysmenorrhea||Bayer|No|Completed|December 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|223|||Female|18 Years|40 Years|No|||October 2014|October 28, 2014|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569244||164200|
NCT00570180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-MMY-2016|Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma|An Open-label Phase II Study of the Efficacy of Combination Bortezomib-containing Regimens in the Treatment of Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma||University Health Network, Toronto|Yes|Active, not recruiting|November 2007|September 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00570180||164131|
NCT00570401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mskcc 06-143|Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib|A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib||Memorial Sloan Kettering Cancer Center||Completed|June 2006|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|120 Years|No|||December 2015|December 16, 2015|December 7, 2007|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00570401||164114|
NCT00600886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230C2305|Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly|A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly||Novartis||Active, not recruiting|February 2008|March 2016|Anticipated|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|358|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|January 14, 2008|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00600886||161826|
NCT00602173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO-03|Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions|A Single Dose, Randomized, Three-Period, Three-Treatment, Crossover Bioequivalency Study of Cilostazol 100 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|May 2003|May 2003|Actual|May 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602173||161730|
NCT00571714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|159-07-FB|Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients|Comparison of Standard Therapy,Peginterferon Alpha-2a + Ribavirin for 48 Weeks VS Peginterferon Alph-2a + Ribavirin + Betaine for 12 Weeks Followed by 36 Weeks Standard Therapy in Untreated Adults With Chronic Hepatitis C Genotype 1||University of Nebraska|Yes|Terminated|April 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|19 Years|70 Years|No|||June 2010|June 23, 2010|December 11, 2007|Yes|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00571714||164016|
NCT00600041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPPO1-2004-11-01|Placebo-Controlled Crossover Study for the Investigation of the Effect of Pantoprazole on Cardiac Contractility|Heart Issues of PantoPrazOle (HIPPO)|HIPPO|Herzzentrum Goettingen|No|Completed|May 2005|November 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2008|March 22, 2009|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00600041||161890|
NCT00601510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581134|Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer|A Phase I Study of Capecitabine, Cisplatin and Imatinib in Patients With Unresectable or Metastatic Gastric Cancer.||Technische Universität München||Completed|November 2007|January 2012|Actual|January 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00601510||161779|
NCT00601523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.633|Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).|Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).||Boehringer Ingelheim||Completed|January 2008|||June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|511|||Both|30 Years|N/A|No|||March 2014|June 3, 2014|January 15, 2008|Yes|Yes||No|June 6, 2011|https://clinicaltrials.gov/show/NCT00601523||161778|
NCT00601835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDC01|Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td|Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age||Sanofi|No|Completed|May 2004|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3651|||Both|11 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 15, 2008|Yes|Yes||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00601835||161755|
NCT00563706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153A1-2203|Study Evaluating Vabicaserin in Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects With Acute Exacerbations of Schizophrenia||Pfizer|Yes|Completed|December 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|199|||Male|18 Years|65 Years|No|||February 2014|February 3, 2014|November 21, 2007|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00563706||164614|Because of the failure of all vabicaserin doses to meet the primary efficacy objective, the study was terminated prematurely and planned analyses of secondary efficacy endpoints were not performed.
NCT00563732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098B1-1142|Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin|An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Lecozotan SR and a Single Oral Dose of Digoxin When Administered Orally to Healthy Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 8, 2008|November 21, 2007||||||https://clinicaltrials.gov/show/NCT00563732||164613|
NCT00563992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4973R|Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder|Pharmacotherapy of High-Risk Bipolar Disorder||New York State Psychiatric Institute|Yes|Completed|January 2001|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|75 Years|No|||April 2012|April 30, 2012|November 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00563992||164593|
NCT00564005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRI-EX97-9742PI|Mechanism and Efficacy of Rehabilitation Approaches|Mechanisms and Long-term Effects of Separate vs. Coupled Rehabilitation Approaches After Stroke||Chang Gung Memorial Hospital|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|90|||Both|40 Years|75 Years|No|||September 2014|February 10, 2015|November 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00564005||164592|
NCT00560573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021015|Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer|Phase 1, Dose Escalation Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer||Pfizer|No|Completed|November 2007|March 2010|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|November 15, 2007|No|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00560573||164853|A total of 46 patients were enrolled in this study but only 45 of them were evaluable because 1 patient was enrolled but did not participate due to early symptomatic deterioration prior to starting treatment.
NCT00560937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA IRB# 00924|Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia|Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia||Durham VA Medical Center||Completed|June 2005|April 2008|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|November 19, 2007|Yes|Yes||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00560937||164825|
NCT00560300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK35423 (completed)|Regulation of Bone Formation in Renal Osteodystrophy|Regulation of Bone Formation in Renal Osteodystrophy||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|November 2000|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|61|||Both|2 Years|21 Years|No|||January 2010|January 12, 2010|November 13, 2007||||No||https://clinicaltrials.gov/show/NCT00560300||164874|
NCT00560313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P4|Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults|A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age||Novartis|Yes|Completed|July 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|November 16, 2007||No||No|June 6, 2011|https://clinicaltrials.gov/show/NCT00560313||164873|
NCT00603928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRMA-5-07|Placebo Interventions in General Practice|Placebo Interventions in General Practice||University of Zurich|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|general practitioners and pediatricians in medical practice of the canton Zurich in        Switzerland|November 2008|November 19, 2008|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603928||161601|
NCT00603317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051056|Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid|Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid|INWARA|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||May 2010|July 9, 2010|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603317||161648|
NCT00603304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X021004002|Complementary and Alternative Medicine for Urological Symptoms(CAMUS)|Complementary and Alternative Medicine for Urological Symptoms (CAMUS)|CAMUS|University of Alabama at Birmingham|Yes|Completed|February 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|369|||Male|45 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 12, 2012|December 20, 2007|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00603304||161649|
NCT00603902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-011|BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management|A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients||Arena Pharmaceuticals|No|Completed|January 2008|August 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|4008|||Both|18 Years|65 Years|No|||January 2013|January 4, 2013|January 16, 2008|Yes|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00603902||161603|
NCT00603915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-774|A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer|Phase II Trial of Gemcitabine and Cisplatin/Carboplatin (GC) Plus Erlotinib in Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer||University Health Network, Toronto|Yes|Completed|June 2006|April 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|January 17, 2008|Yes|Yes||No|May 6, 2011|https://clinicaltrials.gov/show/NCT00603915||161602|
NCT00604266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0216|Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study|Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study.|PET/MRCP|University of Toronto|No|Withdrawn|August 2007|August 2008|Anticipated|August 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Fifteen patients with potentially resectable hilar cholangiocarcinomas, as determined by        conventional imaging modalities, will be recruited. In order to minimize false positive        uptake of 18F-FDG due to inflammatory changes, patients will be recruited either before        biliary stenting, or after biliary stenting if there is no clinical evidence of active        cholangitis.|June 2008|June 26, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604266||161575|
NCT00599677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006CB5045012|Randomized Controlled Trial of Acupuncture for Functional Dyspepsia|Randomized Controlled Trial of Acupuncture for Functional Dyspepsia||Chengdu University of Traditional Chinese Medicine|Yes|Completed|November 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|720|||Both|18 Years|65 Years|No|||November 2011|November 8, 2011|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00599677||161918|
NCT00600522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP-MHV|Alternative Surgical Policy for Central Liver Tumors|Ultrasound-Guided Conservative Heopatecomy for Tumors Invading the Middle Hepatic Vein at the Caval Confluence as Alternative to Mesohepatectomy and Trisectionectomy||University of Milan|No|Completed|January 2004|May 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|N/A|N/A|No|Non-Probability Sample|Patients carriers of hepatocellular carcinoma or colorectal cancer liver metastases        addressed to surgical resection|January 2008|January 14, 2008|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600522||161854|
NCT00600717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 06-04-23|Normative High-frequency MEG Database for Children|Localizing Sensorimotor, Auditory, Visual and Language Cortices With Magnetoencephalography|MEG|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|November 2006|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Since this study focuses on normal MEG data, only normal subjects will be studied. Since        women, girls, and minorities are included in the population to whom recruiting materials        are directed, we anticipate that subject selection will be equitable.|February 2012|February 8, 2012|June 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00600717||161839|
NCT00600483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-SWI-001|Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection|A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection||Innocoll|Yes|Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1502|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|January 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600483||161857|
NCT00601341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11730|Effects of Lumbosacral Joint Mobilization/Manipulation on Lower Extremity Muscle Neuromuscular Response|Effects of Lumbosacral Joint Mobilization/Manipulation on Lower Extremity Muscle Neuromuscular Response||University of Virginia|No|Terminated|May 2005|November 2009|Actual|May 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 23, 2010|January 14, 2008||No|Anticipated that results would not be conclusive|No||https://clinicaltrials.gov/show/NCT00601341||161791|
NCT00601354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH066330|Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder|Comparing Orlistat/Alli to Orlistat/Alli Plus Guided Self-help Group Therapy in Overweight Binge Eaters||Stanford University|No|Completed|September 2007|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|January 4, 2008|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00601354||161790|
NCT00601367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.118|Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder|A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD||Sprout Pharmaceuticals, Inc|Yes|Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|480|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|January 15, 2008|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00601367||161789|
NCT00600054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB1000-013|Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma|Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma||YM BioSciences|Yes|Completed|October 2007|December 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|3 Years|18 Years|No|||July 2011|July 4, 2011|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600054||161889|
NCT00601185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009|Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.|Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo||Memorial Sloan Kettering Cancer Center||Recruiting|February 2006|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|115|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00601185||161803|
NCT00601536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITH-11|Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions.||Roxane Laboratories|No|Completed|April 2003|May 2003|Actual|May 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601536||161777|
NCT00571051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT003459|MEG Study of Mindfulness Based Stress Reduction|MEG Study of Mindfulness Based Stress Reduction||National Center for Complementary and Integrative Health (NCCIH)||Recruiting|October 2007|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 13, 2009|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00571051||164066|
NCT00571064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-415|The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility|A 12-Week, Multicenter, Open Label Study To Evaluate The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility||Eisai Inc.||Completed|January 2008|||December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|50 Years|N/A|No|||October 2013|October 29, 2013|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571064||164065|
NCT00602368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581286|Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia|Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia: A Pilot Study||British Columbia Cancer Agency|No|Active, not recruiting|December 2010|January 2016|Anticipated|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|114|||Female|19 Years|N/A|No|||January 2015|January 28, 2015|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602368||161716|
NCT00603343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-Number 200400124330|Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence|Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial||APOGEPHA Arzneimittel GmbH|Yes|Completed|June 2004|December 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|303|||Both|5 Years|10 Years|No|||January 2008|January 16, 2008|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603343||161646|
NCT00603356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-930-103|Phase I Study of OSI-930 and Erlotinib in Cancer Tumors|A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors||Astellas Pharma Inc|No|Completed|November 2007|July 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00603356||161645|
NCT00603642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060216|P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura|A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura||Amgen||Completed|October 2007|April 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|20 Years|N/A|No|||February 2011|February 4, 2011|January 17, 2008||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00603642||161623|
NCT00603941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-U103|A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy|A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer||Daiichi Sankyo Inc.|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603941||161600|
NCT00603967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0918|Effect of Aromatase Inhibitors on Bones and Genes|Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms||Washington University School of Medicine|No|Completed|March 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|151|||Female|40 Years|N/A|No|||May 2013|May 22, 2013|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00603967||161598|
NCT00604279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013150|A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia|A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects With Schizophrenia||Xian-Janssen Pharmaceutical Ltd.|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|452|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|January 17, 2008|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT00604279||161574|
NCT00604292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-102|Evaluation of the PillCam Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure||Given Imaging Ltd.|No|Completed|June 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients that are indicated for colonoscopy, who are suspected or known to suffer from        colonic diseases|March 2010|March 10, 2010|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00604292||161573|
NCT00603629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6788-31516-01|Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues|A Pilot Study Determining Mechanisms of Acute Asthma Exacerbations Through Detailed Molecular Analysis of Airway Secretions and Tissues|MAST-X|University of California, San Francisco|No|Completed|January 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|Samples With DNA|whole blood, DNA, RNA, sputum, nasopharyngeal swab|Both|18 Years|75 Years|No|Non-Probability Sample|People with acute asthma who seek treatment in the Emergency Department or who require        admission to the hospital for their asthma|September 2011|September 20, 2011|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603629||161624|
NCT00599950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cornea 4|Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C|Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C.||Asociación para Evitar la Ceguera en México|Yes|Completed|January 2007|November 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||November 2007|January 23, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00599950||161897|
NCT00600197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-03-41-5465|Biopsychosocial Education and Chronic Low Back Pain|The Effectiveness of Biopsychosocial Education on Quality of Life and Disability of Individuals Suffering From Chronic Low Back Pain||Tehran University of Medical Sciences|Yes|Active, not recruiting|July 2008|September 2012|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|January 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00600197||161879|
NCT00600210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3963s|Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer|AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer||Leo W. Jenkins Cancer Center|Yes|Withdrawn|January 2008|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|January 11, 2008|No|Yes|low patient accrual|No||https://clinicaltrials.gov/show/NCT00600210||161878|
NCT00600535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016933|A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer|A Pharmacokinetics Study to Assess the Oral Administration of CB7630 (Abiraterone Acetate) Capsule Formulation and Tablet Formulation in Patients With Prostate Cancer||Cougar Biotechnology, Inc.|No|Completed|July 2007|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Male|18 Years|N/A|No|||April 2013|April 16, 2013|January 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00600535||161853|
NCT00600730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#040025-Brain and Hypo|The Effects of Antecedent Hypoglycemia or Exercise on the Response of the Brain to Subsequent Hypoglycemia|The Effects of Antecedent Hypoglycemia or Exercise on the Response of the Brain to Subsequent Hypoglycemia||Vanderbilt University|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|January 14, 2008||No|Funding not available. Could not start this study.|No||https://clinicaltrials.gov/show/NCT00600730||161838|
NCT00601016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Mccuaig|A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy|A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy||St. Justine's Hospital|No|Completed|March 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|2 Months|12 Months|No|||January 2008|January 24, 2008|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00601016||161816|
NCT00601393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070426|Effectiveness of Internet-Based Cognitive Behavioral Therapy for Treating Mothers With Depression|Interactive Internet Intervention for Depressed Mothers||Oregon Research Institute|No|Completed|September 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|N/A|N/A|No|||January 2012|January 25, 2012|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00601393||161788|
NCT00601705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Y07|Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach|A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia||Case Comprehensive Cancer Center|Yes|Active, not recruiting|January 2008|||June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601705||161764|
NCT00602056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X050713007|Low Cost Interventions to Improve Adherence to Childhood Immunization Schedule|A Randomized Controlled Trial of Low Cost Interventions to Improve Adherence to Childhood Immunization Schedule in a Low Literacy Population in Pakistan||University of Alabama at Birmingham|Yes|Completed|November 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|1506|||Both|N/A|365 Days|No|||January 2008|January 13, 2008|January 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00602056||161738|
NCT00603798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW01-0703 / 0705|Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)|A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment With Imiquimod Creams for Actinic Keratoses||Graceway Pharmaceuticals, LLC|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|490|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|January 16, 2008|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00603798||161611|
NCT00603811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX102-01|Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults|A Multicenter, Double-blind, Randomized, Escalating Dose-ranging Study to Investigate the Safety and Immunogenicity of the VAX102 Influenza Vaccine in Healthy Adults||VaxInnate Corporation|Yes|Completed|September 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603811||161610|
NCT00569608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIHLaFe|Early Hospital Discharge Program in Neonatology|Early Discharge Program From a Regional Reference Neonatal Intensive Care Unit|EDNEO|Fundacion Para La Investigacion Hospital La Fe|No|Completed|January 2005|October 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|140|||Both|36 Weeks|42 Weeks|No|||June 2005|December 6, 2007|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569608||164173|
NCT00569946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061035|Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)|Phase 2 Study Of AG-013736 As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer||Pfizer|No|Completed|December 2007|August 2013|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|20 Years|N/A|No|||July 2014|July 16, 2014|December 7, 2007|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00569946||164148|
NCT00569959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03363-05-A|Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients|Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients||HealthPartners Institute|No|Completed|November 2006|June 2007|Actual|||N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|November 25, 2015|December 6, 2007||||No||https://clinicaltrials.gov/show/NCT00569959||164147|
NCT00570271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/004/07|Placebo Effects on Blood Pressure|Physiological Effects of Placebo Interventions to Increase or Decrease Blood Pressure||Charite University, Berlin, Germany|No|Recruiting|April 2007|February 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Anticipated|90|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2007|December 7, 2007|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00570271||164124|
NCT00571324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-1-5131|Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism|An Open Label Pilot Study of the Effects of the Glucagon-like Peptide-1 Receptor Antagonist, Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism||Children's Hospital of Philadelphia|No|Completed|August 2007|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|10|||Both|7 Years|60 Years|No|||March 2015|March 12, 2015|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571324||164045|
NCT00571610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-020P|Montreal Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device|A Single-Center, Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Implantable Device Used to Reduce Mitral Valve Regurgitation.|PTOLEMY|Viacor|Yes|Completed|April 2006|November 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|40 Years|75 Years|No|||November 2008|November 5, 2008|November 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00571610||164024|
NCT00603057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.040|Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer|Using Functional Image and Circulating Molecular Markers to Predict Tumor Response and Lung Toxicity in Treatment of Lung Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|May 2007|September 2016|Anticipated|September 2013|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients|November 2015|November 16, 2015|January 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00603057||161667|
NCT00603070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS017029-01|Electronic Prescribing and Electronic Transmission of Discharge Medication Lists|Electronic Prescribing and Electronic Transmission of Discharge Medication Lists to Improve Ambulatory Medication Safety||Weill Medical College of Cornell University|No|Completed|March 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|130|||Both|N/A|N/A|No|Probability Sample|Physicians and Nurse Practitioners from 2 office practices in the Ambulatory Care Network        at NYPH, Associates in Internal Medicine (AIM) on the Columbia campus and Cornell Internal        Medicine Associates (CIMA) on the Cornell campus.|February 2012|February 17, 2012|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00603070||161666|
NCT00603083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2007-003890-20|Postoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia|Postoperative Pain Treatment in Total Hip Arthroplasty A Randomized Double-blinded Placebo-controlled Study to Assess the Effect of Local Analgesia||Vejle Hospital|Yes|Completed|January 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|January 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603083||161665|
NCT00603668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hLL1-02|Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL|A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)||Immunomedics, Inc.|No|Completed|August 2008|February 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603668||161621|
NCT00603980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-002-102|Abuse Liability of Staccato Alprazolam|Abuse Liability Study of Staccato® Alprazolam for Inhalation in Subjects With Histories of Sedative Abuse||Alexza Pharmaceuticals, Inc.|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|March 20, 2009|January 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00603980||161597|
NCT00603993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M05-775|Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|A Non-Randomized, Open-Label, Roll-Over Study With Self Injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis||Abbott|No|Completed|March 2006|||November 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|20 Years|N/A|No|||June 2011|June 17, 2011|January 10, 2008||No||No|October 16, 2009|https://clinicaltrials.gov/show/NCT00603993||161596|Due to the small population, statistical tests were not performed.
NCT00604305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6666476CTIL|Comperative Trial Between an Accommodative Iol and Monofocal Iol|A Randomized Single Blind Comparative Study of the Acuity's C-Well Accommodating Intra Occular Lens (AIOL) Against Alcon's Acrysof||Shaare Zedek Medical Center|No|Withdrawn|March 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|65 Years|No|||June 2012|June 10, 2012|January 17, 2008||No|Company could not supply the accommodating intraocular lenses for the study|No||https://clinicaltrials.gov/show/NCT00604305||161572|
NCT00599690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cornea 3|Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma.|Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma.||Asociación para Evitar la Ceguera en México|Yes|Completed|January 2006|September 2007|Actual|January 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|January 28, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00599690||161917|
NCT00599703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-043|Language Function in Patients With Brain Tumors|Reorganization of Language Function in Patients With Brain Tumors||Memorial Sloan Kettering Cancer Center||Completed|May 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinics|July 2009|July 7, 2009|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599703||161916|
NCT00599963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2007.409-T|Paricalcitol for the Treatment of Immunoglobulin A Nephropathy|Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study||Chinese University of Hong Kong|Yes|Withdrawn|January 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||January 2009|July 31, 2015|January 2, 2008||No|Funding problem.|No||https://clinicaltrials.gov/show/NCT00599963||161896|
NCT00600223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-104|Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches|Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Reconstruction Approaches||Memorial Sloan Kettering Cancer Center||Completed|October 2005|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinic|October 2010|October 8, 2010|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00600223||161877|
NCT00600236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0018|HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population|HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population||Asociación para Evitar la Ceguera en México||Completed|September 2004|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|300|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00600236||161876|
NCT00600795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070875|Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus|Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus||Vanderbilt University|Yes|Recruiting|January 2008|July 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|CSF|Both|18 Years|N/A|No|Probability Sample|Primary care clinic and neurology clinic|April 2011|April 1, 2011|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00600795||161833|
NCT00600808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPLG-003|Sustained Release Formulation of Somatropin (rDNA Origin)for Injection|A Phase II/IIIa, Assessor Blinded (Partially Blinded), Randomised, Active-Controlled, Multicentre, Parallel-Group Study of the Safety, Efficacy and pk/pd of LB03002 Administered Weekly in Children With Growth Failure Due to GH Deficiency.||BioPartners GmbH|Yes|Completed|June 2003|June 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|51|||Both|4 Years|10 Years|No|||July 2007|January 15, 2008|July 23, 2007||||No||https://clinicaltrials.gov/show/NCT00600808||161832|
NCT00600743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-101|Effect of a CCK-1R Agonist on Food Intake in Humans|Effect of a CCK-1R Agonist on Food Intake in Humans|GSK|St. Luke's-Roosevelt Hospital Center|No|Completed|January 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600743||161837|
NCT00600756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00039|Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone|A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting|RECOVER|AstraZeneca||Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|798|||Both|18 Years|65 Years|No|||October 2012|October 2, 2012|January 9, 2008|Yes|Yes||No|October 20, 2010|https://clinicaltrials.gov/show/NCT00600756||161836|
NCT00601029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDEAMC 07-25|Rhabdomyolysis in Basic Training|Rhabdomyolysis in Basic Training||Martin Army Community Hospital|No|Completed|January 2008|September 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|499|Samples With DNA|Serum and stored blood|Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Military Basic Trainee at Ft. Benning undergoing Infantry Basic Training Male > 18 years        old|April 2012|April 18, 2012|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00601029||161815|
NCT00601042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM 07-01|Serbian Smoking Reduction/Cessation Trial (2SRT)|Randomized, Placebo-controlled, Double-blind, Phase IV Trial to Assess the Efficacy of a Traditional Swedish Smokeless Tobacco Product ("Snus") to Reduce or Replace Cigarette Smoking Among Adult Smokers in Serbia|2SRT|Swedish Match AB|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|319|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00601042||161814|
NCT00602459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00441|Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia|A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Active, not recruiting|January 2008|||December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|418|||Both|18 Years|N/A|No|||November 2014|April 22, 2015|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602459||161709|
NCT00602472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.18|BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea||Boehringer Ingelheim||Completed|February 2008|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1058|||Both|18 Years|80 Years|No|||February 2014|February 27, 2014|January 15, 2008||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00602472||161708|
NCT00569322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01817-03-C|Admission Glucose ICU Study|Evaluation of Admission Blood Glucose Levels in the Intensive Care Unit||HealthPartners Institute|No|Completed|December 2003|September 2004|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2007|November 25, 2015|December 5, 2007||||No||https://clinicaltrials.gov/show/NCT00569322||164194|
NCT00569335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01023020|Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer|Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer||Taiho Pharmaceutical Co., Ltd.|Yes|Completed|October 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|20 Years|N/A|No|||November 2012|November 1, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569335||164193|
NCT00569972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4251037|A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia|PD 0200390 Dose Ranging Trial: A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia||Pfizer|No|Completed|October 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|682|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2012|July 17, 2012|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569972||164146|
NCT00569985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04047|Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma|A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs||City of Hope Medical Center|Yes|Active, not recruiting|June 2007|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||October 2015|October 16, 2015|December 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00569985||164145|
NCT00569998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS236-1544|Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin|An Open-label, Multi-centre, Multi-national, Comparative, Randomised, Cross-over Trial Evaluating Preference as Well as Performance, Acceptance, Handling and Safety of NovoPen™ 4 (MS236) Versus NovoPen 3® in Insulin Treated Diabetic Patients||Novo Nordisk A/S|No|Completed|August 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|208|||Both|9 Years|N/A|No|||July 2012|July 17, 2012|December 4, 2007||||No||https://clinicaltrials.gov/show/NCT00569998||164144|
NCT00570284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2111|A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors|A Phase Ib Open-label, Multicenter Cross-over Study to Investigate the Effect of Food on the Rate and Extent of Oral LBH589 Absorption in Patients With Advanced Solid Tumors||Novartis||Completed|November 2007|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|December 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570284||164123|
NCT00571623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001842|Automated Chest Physiotherapy to Improve Outcomes in Neuro|Automated Chest Physiotherap to Improve Outcomes in Neurocritical Care: An Intracranial Pressure Study|ACTION-ICP|Duke University|No|Completed|September 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|40 subjects with a neurological diagnosis and current ICP in situ.|August 2008|July 8, 2014|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571623||164023|
NCT00602706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582552|Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant|A Phase I/II Dose Escalation Study Assessing the Toxicity and Efficacy of 153-Samarium-EDTMP in Place of TBI in the Conditioning Regimen for PBSCT for Patients With Multiple Myeloma||Mayo Clinic||Completed|January 2000|July 2010|Actual|June 2003|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|76|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00602706||161691|
NCT00602719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOLP-02|Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zolpidem Tartrate Tablets 10 MG Under Fed Conditions||Roxane Laboratories|No|Completed|March 2004|March 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602719||161690|
NCT00602732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH075013|Interpersonal Treatment Program to Prevent Depression and Post-Traumatic Stress Disorder in Low-Income Pregnant Women With Partner Abuse|Intervention for Low-income Pregnant Women With Partner Abuse||Butler Hospital|Yes|Completed|September 2005|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00602732||161689|
NCT00603681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066001|Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation|Non-Inferiority Study; Comparison of Polyethylene Glycol Solution With and Without Electrolytes for Treatment of Chronic Constipation in Elderly Institutionalised Patients: a Double-Blind, Randomised, Parallel-Group, Multicentre Study|PEGorion|Orion Corporation, Orion Pharma|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|65 Years|N/A|No|||October 2008|October 6, 2008|January 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603681||161620|
NCT00603954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJB0702P1|Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings|Allogeneic Hematopoietic Cell Transplantation With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings||University Hospital of Liege|No|Completed|December 2007|March 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|N/A|75 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00603954||161599|
NCT00604006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-02/07|SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)|SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)||Monash University|No|Completed|September 2008|January 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|60 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|January 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00604006||161595|
NCT00603720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0086|Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling|PET Detection of the Effects of Aging on the Human Heart. Aim#1-Impact of Aging on Myocardial Remodeling: Role of Nitric Oxide||Washington University School of Medicine|No|Completed|September 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|59|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|January 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603720||161617|
NCT00604318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dathyrca 1|Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer|Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer?||Copenhagen University Hospital at Herlev|Yes|Completed|February 2008|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|75 Years|No|||January 2013|January 9, 2013|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604318||161571|
NCT00599716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-001|Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome|A Phase 3, Multicenter, Randomized, Double-Masked Study of Safety and Efficacy of Vismed® in Dry Eye Syndrome||Lantibio|No|Completed|December 2006|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2009|January 8, 2009|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599716||161915|
NCT00599976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 007|Comparison of Pulmonary Vein Isolation Versus AV Nodal Ablation With Biventricular Pacing for Patients With Atrial Fibrillation With Congestive Heart Failure (PABA CHF)|Randomized Controlled Trial of Pulmonary Vein Antrum Isolation vs. AV Node Ablation With Bi-Ventricular Pacing for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure (PABA CHF)|PABA CHF|Azienda Policlinico Umberto I|No|Completed|November 2002|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||December 2007|January 23, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00599976||161895|
NCT00600249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENEO|Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.|Phase II Pilot Study Evaluating the Neoadjuvant Combination "Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and "Triple Negative" Breast Cancer Patients. TENEO Study.||Centre Jean Perrin|No|Completed|January 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|N/A|No|||March 2014|March 19, 2014|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600249||161875|
NCT00600262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-004|Intravitreal Bevacizumab for Diabetic Retinopathy|Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.||Asociación para Evitar la Ceguera en México||Completed|December 2005|June 2006||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|N/A|N/A|No|||January 2008|January 23, 2008|June 29, 2006||||No||https://clinicaltrials.gov/show/NCT00600262||161874|
NCT00600769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263|Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)|Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)||The University of Texas Health Science Center at Tyler|No|Active, not recruiting|January 1991|||November 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|N/A|No|||November 2007|January 14, 2008|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600769||161835|
NCT00600782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110347|Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region|Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.||GlaxoSmithKline||Completed|February 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|45|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600782||161834|
NCT00601055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH076829|Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease|Treating Older Patients With Major Depression and Severe COPD||Weill Medical College of Cornell University|Yes|Active, not recruiting|February 2008|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|50 Years|95 Years|No|||June 2015|June 2, 2015|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00601055||161813|
NCT00601068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32936|Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis|Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis of the Jaws (BON)||University of Florida|Yes|Completed|December 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|35|Samples With DNA|biopsy tissue submitted from bone biopsies|Both|30 Years|90 Years|No|Probability Sample|patients who develop exposed bone in their mouth and are on an oral bisphosphonate|July 2012|January 3, 2013|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00601068||161812|
NCT00603148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060433|The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications|The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications in Patients Undergoing Invasive Procedures in the Hybrid Cardiac Catheterization/Cardiac Surgery Suite||Vanderbilt University|Yes|Completed|September 2006|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|475|Samples With DNA|Whole Blood|Both|18 Years|70 Years|No|Probability Sample|patients undergoing procedures in a hybrid interventional cardiology/cardiac surgery suite|December 2013|December 16, 2013|October 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00603148||161660|
NCT00569621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOXOPH1|A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow|A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow||Medical University of Vienna|Yes|Completed|March 2007|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2007|December 5, 2007|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569621||164172|
NCT00569634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07H-821001|Agreement Between Venous and Arterial Blood Gas Measurements in the Intensive Care Unit|Agreement Between Venous and Arterial Blood Gas Measurements in the Intensive Care Unit|AVANTI|University of California, Los Angeles|Yes|Completed|January 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||December 2008|December 2, 2008|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569634||164171|
NCT00569647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|277444040|Preoperative Anxiety in Pediatric Reconstructive Burn Patients: The Role of Virtual Reality Hypnosis|Preoperative Anxiety in Pediatric Reconstructive Burn Patients: The Role of Virtual Reality Hypnosis||Shriners Hospitals for Children|Yes|Completed|November 2005|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Both|14 Years|21 Years|No|||November 2007|December 6, 2007|November 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00569647||164170|
NCT00569660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0033|Ph II Study of Azacitidine in Myelofibrosis|Phase II Study of Azacitidine in Myelofibrosis||M.D. Anderson Cancer Center|No|Completed|June 2005|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|December 6, 2007||No||No|September 21, 2009|https://clinicaltrials.gov/show/NCT00569660||164169|
NCT00570804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0791|Combined Treatment for Tobacco and Alcohol Use in Puerto Rico|Oral Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use||M.D. Anderson Cancer Center|Yes|Active, not recruiting|December 2007|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|370|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570804||164085|
NCT00571090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.IBU.0.01.00.00/511|Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules|Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules||Istanbul Science University|No|Completed|June 2003|July 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|735|||Both|15 Years|89 Years|No|Probability Sample|Endocrinology Clinic|March 2014|March 28, 2014|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571090||164063|
NCT00572442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13939|Magnetocardiography (MCG) in Asymptomatic Individuals - Pilot Trial|Magnetocardiography (MCG) in Asymptomatic Individuals - Pilot Trial||Cedars-Sinai Medical Center|No|Withdrawn|December 2007|December 2009|Anticipated|November 2009|Anticipated|N/A|Observational|N/A||4|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|individuals without symptoms or history of heart disease|November 2009|November 16, 2009|December 12, 2007||No|sponsor funding|No||https://clinicaltrials.gov/show/NCT00572442||163962|
NCT00572455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0191001|Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.|A 2-Stage, Phase 2, Double-Masked, Randomized, Vehicle Controlled, Dose Response Trial Of PF-04217329 And The Marketed Formulation Of Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.||Pfizer|Yes|Completed|December 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|14||Actual|317|||Both|18 Years|N/A|No|||February 2011|February 25, 2011|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572455||163961|
NCT00602784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC41-201|Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine|Double Blind, Randomized, Multicenter, Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine Together With Polyarginine, HCV Peptide Vaccine Alone, or Polyarginine Alone, in Patients With Chronic HCV Having Not Responded to or Relapsed From Primary Standard HCV Therapy||Valneva Austria GmbH|No|Completed|November 2002|September 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|66|||Both|18 Years|65 Years|No|||October 2012|October 18, 2012|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00602784||161685|
NCT00603408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0913|Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer|Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters||Washington University School of Medicine|No|Terminated|December 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||July 2013|July 22, 2013|December 28, 2007|Yes|Yes|Study was discontinued due to lack of accrual.|No||https://clinicaltrials.gov/show/NCT00603408||161641|
NCT00603421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 05062|Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients|Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients||Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2009|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|318|||Both|18 Years|40 Years|No|||February 2016|February 24, 2016|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603421||161640|
NCT00603694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0023-CE|Hippocampal Radiation Exposure and Memory|Hippocampal Radiation Exposure and Memory: A Pilot Study||University Health Network, Toronto|Yes|Recruiting|September 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients who have consented to GK radiosurgery or cranial radiation.|January 2008|January 9, 2009|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603694||161619|
NCT00604019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA-02102801|Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock|Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock||Rush University Medical Center|Yes|Completed|March 2003|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|January 3, 2008||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00604019||161594|
NCT00604331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYR-2008-01|Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation|Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation||Herzzentrum Goettingen|No|Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|85 Years|No|||December 2010|December 7, 2010|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604331||161570|
NCT00604344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1476|Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes|A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With Insulin Requiring Diabetes Mellitus on a Basal-bolus Regimen||Novo Nordisk A/S|No|Completed|April 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|401|||Both|20 Years|N/A|No|||January 2012|January 23, 2012|January 17, 2008||||No||https://clinicaltrials.gov/show/NCT00604344||161569|
NCT00599729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/07|Measurement of Gait Spatio-Temporal Characteristics in Knee Osteoarthritis Patients|||Assaf-Harofeh Medical Center|No|Recruiting|January 2008|||July 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|40 Years|N/A|No|Probability Sample|patients with knee osteoarthritis evaluated by an orthopedic surgeon. patient will be        recruted from the outpatient clinic at "asaf Harofe" medical center, Zrifin, Israel and        APOS medical center, Herzlya, Israel|December 2007|January 23, 2008|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00599729||161914|
NCT00599989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581427|Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer|Accelerated Partial Breast Irradiation||National Cancer Institute (NCI)||Active, not recruiting|January 2005|||January 2010|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Female|18 Years|N/A|No|||July 2009|July 8, 2009|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599989||161894|
NCT00600002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 02-69|Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma|A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma||University of California, Irvine|Yes|Active, not recruiting|June 2004|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600002||161893|
NCT00600548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-18506|Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)|Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control||Hospital Universitário Professor Edgard Santos|Yes|Completed|July 2007|July 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|180|||Both|2 Years|65 Years|No|||March 2010|April 14, 2010|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00600548||161852|
NCT00602108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583007|Radiation Therapy in Treating Women Undergoing Lumpectomy for Stage I or Stage IIA Breast Cancer|Phase II Study of Intra-operative Electron Irradiation and Hypofractionated External Beam Irradiation After Lumpectomy in Patients With Stage T1N0M0 or T2N0M0 Breast Cancer||Mayo Clinic|Yes|Completed|January 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Female|21 Years|N/A|No|||August 2011|August 9, 2011|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602108||161734|
NCT00602134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|439-09|Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions|A Pharmacokinetic Study to Assess the Single-Dose Bioequivalence of a Potential Generic Formulation of a 6-Mercaptopurine 50 mg Tablet Compared to a Marketed 6-Mercaptopurine 50 mg Tablet, Purinethol®, When Administered to Healthy Male Subjects, in the Fasted State||Roxane Laboratories|No|Completed|November 2002|November 2002|Actual|November 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00602134||161733|
NCT00601796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14744|Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer|Combination Immunotherapy for Lung Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|October 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2013|May 15, 2013|January 19, 2008|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00601796||161758|
NCT00601107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECTPS02507|A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis|A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis||Sanofi|Yes|Completed|April 2008|June 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|111|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|January 15, 2008|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT00601107||161809|
NCT00601445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0090|Homeostatic Sleep Regulation in Older Persons|Homeostatic Sleep Regulation in Older Persons||National Institute on Aging (NIA)|No|Completed|September 1999|March 2004|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Anticipated|58|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2008|May 28, 2008|October 24, 2007||||No||https://clinicaltrials.gov/show/NCT00601445||161784|
NCT00601081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27127|Human Milk Fortifier and Cytokine Profile|Alterations in the Cytokine Profile of Premature Infants After Human Milk Fortifier||Christiana Care Health Services|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|Samples With DNA|Blood and stool|Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants hospitalized in the newborn intensive care unit.|July 2008|July 23, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601081||161811|
NCT00601094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-06-008|Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase I Trial of CCL21 Gene Modified Dendritic Cells In Non-Small Cell Lung Cancer||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|February 2009|||January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|21 Years|N/A|No|||September 2015|October 1, 2015|January 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00601094||161810|
NCT00601731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P5E1|Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months|A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months Who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infants||Novartis||Completed|February 2008|September 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|382|||Both|40 Months|63 Months|Accepts Healthy Volunteers|||October 2014|October 14, 2014|January 15, 2008|Yes|Yes||No|October 28, 2011|https://clinicaltrials.gov/show/NCT00601731||161762|
NCT00569673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0186F|Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer|A Phase II Evaluation of Docetaxel (NSC #628503) Plus Trabectedin (Yondelis®), R279741, IND # 101018) With Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Gynecologic Oncology Group||Completed|March 2008|||January 2012|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Female|18 Years|N/A|No|||May 2014|May 27, 2014|December 6, 2007|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00569673||164168|
NCT00569374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol / IRB # 79045|Safety and Tolerability of Modafinil for Methamphetamine Dependence|Safety and Tolerability of Modafinil for Methamphetamine Dependence||University of Arkansas|No|Completed|September 2007|||September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 30, 2010|December 5, 2007|Yes|Yes||No|November 6, 2009|https://clinicaltrials.gov/show/NCT00569374||164191|
NCT00569387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0205|Vaccine Study for Surgically Resected Pancreatic Cancer|A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer||NewLink Genetics Corporation|Yes|Completed|December 2007|December 2014|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|December 5, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569387||164190|
NCT00570297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-158|Genetic Influences of Albuterol Response In Children With Bronchiolitis|Genetic Influences of Albuterol Response In Children With Bronchiolitis||Connecticut Children's Medical Center|No|Active, not recruiting|December 2007|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|2 Years|No|Probability Sample|Children hospitalized in the intensive care unit with bronchiolitis|February 2015|February 3, 2015|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00570297||164122|
NCT00570544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000|Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema|Effectiveness of Tiotropium to Maintain Inspiratory Capacity Against Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in COPD Patients With Lung CT Scored Emphysema||Gelb, Arthur F., M.D.|Yes|Completed|August 2004|August 2005|Actual|||Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|29|||Both|40 Years|85 Years|No|Non-Probability Sample|patients with moderate to severe copd from tertiary care pulmonary clinic|December 2007|August 13, 2008|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570544||164104|
NCT00571337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2005-1|Stop Infliximab in Patients With Crohn's Disease|Prospective Study of Predictive Factors of Sustained Remission of Crohn's Disease After Stopping Infliximab|STORI|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|December 2005|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||July 2010|July 22, 2010|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00571337||164044|
NCT00571350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARISFC|Anterior Vaginal Wall Reconstruction|Anterior Vaginal Wall Reconstruction: Anterior Colporrhaphy Reinforced With Tension Free Vaginal Tape Underneath Bladder Base||Hippocration General Hospital|No|Enrolling by invitation|January 2005|December 2007|Anticipated|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Female|50 Years|77 Years|No|||December 2007|December 10, 2007|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571350||164043|
NCT00572741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59538|Treating Oxidative Stress and the Metabolic Pathology of Autism|Treating Oxidative Stress and the Metabolic Pathology of Autism||Arkansas Children's Hospital Research Institute|Yes|Recruiting|June 2008|June 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|3 Years|7 Years|No|||January 2012|January 18, 2012|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572741||163941|
NCT00572754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Drycirc Vz10d|Phase II Trial to Evaluate the Safety and Efficacy of the Dry Circumcision Method|Phase II Trial to Evaluate the Safety and Efficacy of the Dry Circumcision||Progressus|Yes|Recruiting|November 2007|March 2008|Anticipated|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Male|21 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 12, 2007|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572754||163940|
NCT00604370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001981|Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge|VTE Prophylaxis Across the Continuum of Care: High Risk Patients at Hospital Discharge||Brigham and Women's Hospital|No|Completed|February 2008|December 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2500|||Both|17 Years|N/A|No|Non-Probability Sample|Acutely ill medical and surgical patients who were hospitalized at BWH and who are at risk        for DVT.|February 2012|February 9, 2012|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00604370||161567|
NCT00604383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4743|Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study|Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.||Eli Lilly and Company|No|Completed|March 2001|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|685|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|January 17, 2008|No|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00604383||161566|
NCT00603109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611008841|Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome|Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.|PWS|Weill Medical College of Cornell University|Yes|Recruiting|August 2007|August 2008|Anticipated|June 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|35 Years|No|||January 2011|January 3, 2011|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603109||161663|
NCT00603434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CPU-Methylphenidate-0001|Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)|Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 16, 2009|January 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00603434||161639|
NCT00603447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-006|Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma|Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma||Onyx Pharmaceuticals|No|Active, not recruiting|May 2008|March 2016|Anticipated|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|January 16, 2008|No|Yes||No|May 15, 2015|https://clinicaltrials.gov/show/NCT00603447||161638|
NCT00603707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122205|Assessment of Whole Gut Transit Time Using the SmartPill Capsule|Assessment of Whole Gut Transit Time Using the SmartPill Capsule: a Multi-Center Study|WholeGut|The SmartPill Corporation|No|Completed|October 2006|June 2008|Actual|June 2008|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|178|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with constipation referred to a tertiary motility center|August 2008|August 28, 2008|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603707||161618|
NCT00600561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSR-HIV-Trial-Seedgrant|Mindfulness Meditation Training in HIV|Biobehavioral Effects of Mindfulness-Based Stress Reduction in HIV|MBSR|University of California, Los Angeles|No|Completed|June 2005|January 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600561||161851|
NCT00604032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029-066-09-001|Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%|Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%||Coria Laboratories, Ltd.|No|Completed|January 2008|February 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|March 26, 2008|January 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00604032||161593|
NCT00604357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRON07|CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment|A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients With Impaired Renal Function. (PATRON-Study)|PATRON07|University of Regensburg|No|Completed|December 2008|August 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604357||161568|
NCT00599742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH22/2007.CTIL|Comorbidity Between Balance and Childhood Anxiety|Comorbidity Between Balance and Childhood Anxiety: Treatment of Anxiety by Training of Balance||Lev-Hasharon Mental Healtlh Center|Yes|Recruiting|December 2007|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|64|||Both|8 Years|14 Years|No|||January 2008|January 23, 2008|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599742||161913|
NCT00600275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGT226A2101|A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer|A Phase I/II, Multi-center, Open-label Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer||Novartis||Completed|December 2007|||March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600275||161873|
NCT00593905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-4590|Pharmacogenomics in Pulmonary Arterial Hypertension|Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes||West Penn Allegheny Health System|Yes|Recruiting|July 2005|July 2013|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|1300|Samples With DNA|Whole Blood|Both|N/A|N/A|No|Non-Probability Sample|Patients must have been diagnosed with WHO Group 1 Pulmonary Arterial Hypertension:        Idiopathic, Familial or Associated with (APAH) Collagen vascular disease, congenital        systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins , other (thyroid        disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic        telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated        with significant venous or capillary involvement, Pulmonary veno-occlusive disease,        Pulmonary-capillary hemangiomatosis. Patients currently therapy must include sitaxsentan,        bosentan, or ambrisentan OR patients must have previously been treated with sitaxsentan,        bosentan or ambrisentan for 4 months or longer.|January 2012|January 20, 2012|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593905||162349|
NCT00602485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R07026|The Effect of Action Control Based Intervention on Adherence After Cardiac Rehabilitaiton|The Effect of Action Control Based Interventions on Adherence to Prescribed Exercise and Diet Regimens for Patients Completing a Cardiac Rehabilitation Program Intervetnion on||Summa Health System|No|Completed|June 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Both|21 Years|N/A|No|||September 2009|September 17, 2009|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602485||161707|
NCT00601744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0584|Social-Psychological Aspects of Orbital Exenteration|Social-Psychological Aspects of Survivorship in Cancer Patients After Orbital Exenteration: Issues Stemming From Alterations of Normal Facial Appearance||M.D. Anderson Cancer Center|No|Completed|January 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient diagnosis of orbital or head and neck cancer and a history of orbital        exenteration. Family member or close friend of a patient with a diagnosis of orbital or        head and neck cancer and a history of orbital exenteration.|January 2013|January 9, 2013|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601744||161761|
NCT00601757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH071766|Depression Prevention for Pregnant Women on Public Assistance|Depression Intervention for Financially Disadvantaged Pregnant Women.||Women and Infants Hospital of Rhode Island|Yes|Completed|January 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|207|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00601757||161760|
NCT00570024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 7320|The Effects of Traditional Acupuncture on Mechanisms of Coronary Heart Disease|The Effects of Traditional Acupuncture on Mechanisms of Coronary Heart Disease||Cedars-Sinai Medical Center|Yes|Completed|January 2006|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|145|||Both|21 Years|N/A|No|||August 2012|August 24, 2012|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570024||164142|
NCT00570011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|822|Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients|Efficacy of Two Different Dose Regimens of Somatropin in Growth Hormone Deficient Adult Patients||Eli Lilly and Company|Yes|Completed|June 1997|December 1998|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||December 2007|December 10, 2007|December 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570011||164143|
NCT00570557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06354|Development of a Web-Based Course to Maintain Skills in Nurses Trained to Screen for Dysphagia|Development of a Web-Based Course to Maintain Skills in Nurses Trained to Screen for Dysphagia||University Health Network, Toronto||Completed|September 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|96|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2012|January 9, 2012|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00570557||164103|
NCT00571077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-31-7-02|Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study|Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study||Hadassah Medical Organization|No|Completed|January 2002|December 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|None Retained|No biospecimens are retained|Both|18 Years|N/A|No|Non-Probability Sample|Patients over the age of 18 with thyroid nodules scheduled for surgery.|December 2007|May 12, 2008|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571077||164064|
NCT00572169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72023|UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy|A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance||University of Arkansas|Yes|Active, not recruiting|November 2006|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|177|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572169||163982|
NCT00599794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004138|A Simple Clinical Tool to Help Assess Patient Volume (Fluid) Status|A Simple Clinical Tool to Help Assess Patient Volume (Fluid) Status||Mayo Clinic|No|Completed|January 2006|January 2008|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers, then critically ill patients already in the intensive care unit who        are felt to have intravascular volume depletion.|January 2008|January 23, 2008|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599794||161909|
NCT00599768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081175|Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.|Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.||Pfizer|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|325|||Both|18 Years|N/A|No|Non-Probability Sample|patients of non-headache pain for more than 30 days and those whose age is more than 18        years old|November 2009|November 19, 2009|January 11, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00599768||161911|
NCT00599781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150291|Gene Therapy for ADA-SCID|Treatment of ADA-SCID by Gene Therapy on Somatic Cells||IRCCS San Raffaele|No|Completed|March 1992|January 2007|Actual|July 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||December 2007|January 23, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00599781||161910|
NCT00600288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08634|Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)|A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% and Placebo in Subjects With Dry Eye Disease||Merck Sharp & Dohme Corp.||Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||December 2014|December 21, 2014|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600288||161872|
NCT00600301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-OO13|Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study|||Asociación para Evitar la Ceguera en México||Recruiting||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|90 Years||||January 2008|January 23, 2008|June 30, 2006||||No||https://clinicaltrials.gov/show/NCT00600301||161871|
NCT00600314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0405 REE|Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease|Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|April 2005|April 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|7 Years|30 Years|No|Non-Probability Sample|High risk population: patients who are at high risk of developing acute or chronic Graft        versus Host Disease (GVHD) following an allogeneic transplant.        GVHD population: patients with active GHVD, either acute or chronic|October 2010|October 7, 2010|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00600314||161870|
NCT00600327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2209|Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™|Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™|CABERNET|Boston Scientific Corporation|No|Completed|December 2001|June 2007|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|488|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600327||161869|
NCT00600821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061030|A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.|Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer||Pfizer|Yes|Completed|April 2008|October 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|January 3, 2008|Yes|Yes||No|April 20, 2012|https://clinicaltrials.gov/show/NCT00600821||161831|
NCT00600834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-106|Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease|A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 3 to 5 Chronic Kidney Disease Undergoing MRI With the Injection of ProHance||Bracco Diagnostics, Inc|No|Completed|February 2008|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|172|None Retained|Fixed tissue samples|Both|N/A|N/A|No|Non-Probability Sample|A total of 1000 patients in 2 cohorts who are going to receive or have received PROHANCE        during an MRI examination as part of their routine clinical management. The cohorts are        defined as:        COHORT 1-        600 patients of any age, with moderate CKD (stage 3, i.e., with eGFR stably comprised        between 30 and 59 mL/min/1.73m2);        COHORT 2-        400 patients of any age, with severe CKD or kidney failure (stages 4 and 5, i.e., with        eGFR below 30 mL/min/1.73m2).|October 2014|October 31, 2014|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00600834||161830|
NCT00600847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04685|A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions|An Exploratory Phase IV, Randomised, Double-Blind, Placebo Controlled Crossover Study to Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Experimentally Induced Urticaria Lesions|AUDACU|Charite University, Berlin, Germany|Yes|Completed|November 2006|||November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|75 Years|No|||January 2008|January 15, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00600847||161829|
NCT00599755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-083|Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)|A Multicenter Phase Ib Trial to Measure [18F]-Fluorodeoxyglucose Uptake by Positron Emission Tomography in Stage IIIB and IV Non-Small Cell Lung Cancer Before and After Chemotherapy With Gemcitabine and Cisplatin or Carboplatin||Merck Sharp & Dohme Corp.|No|Completed|January 2009|April 2011|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|68|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|January 7, 2008|No|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00599755||161912|
NCT00600015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 160|Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)|A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|December 26, 2007||No||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00600015||161892|
NCT00601770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC41-202|Virological Response Study of the HCV Vaccine IC41|Open-label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV||Valneva Austria GmbH|No|Completed|February 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|55 Years|No|||February 2014|February 10, 2014|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00601770||161759|
NCT00601120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-287|RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma|Pilot Feasibility Protocol of RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Withdrawn|June 2007|||June 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|January 15, 2008|Yes|Yes|This protocol was never officially opened and no patients were recruited.|No||https://clinicaltrials.gov/show/NCT00601120||161808|
NCT00601471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12966|Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation, Ankle Range of Motion, and Functional Outcome Scores in Individuals With Chronic Ankle Instability|Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation, Ankle Range of Motion, and Functional Outcome Scores in Individuals With Chronic Ankle Instability||University of Virginia|No|Completed|April 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|50 Years|No|||June 2010|June 23, 2010|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00601471||161782|
NCT00593385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atrium 701|Atrium iCAST Iliac Stent Pivotal Study|Atrium iCAST Iliac Stent Pivotal Study|iCARUS|Atrium Medical Corporation|Yes|Completed|October 2007|May 2014|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|January 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593385||162389|
NCT00593918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7K08HL071742-05|Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children|Innate Immunity and RSV Infection in Children|IIRI|University of Wisconsin, Madison|Yes|Completed|November 2003|June 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|91|Samples With DNA|Nasal samples Supernatant from Peripheral mononuclear cell stimulation cultures DNA|Both|N/A|24 Months|Accepts Healthy Volunteers|Probability Sample|Children who present with viral upper respiratory infections or bronchiolitis to their        primary care physician. Upon consent, children willl have cheek samples for genotyping and        nasal secretion samples to determine RSV infection.|September 2015|September 30, 2015|January 3, 2008||No||No|June 19, 2009|https://clinicaltrials.gov/show/NCT00593918||162348|Subject withdraw before blood draw on second visit and small numbers recruited lead to small numbers of subjects analyzed.
NCT00602147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HEM 0750|Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan|Genetic Analysis of Toxicity Associated With High-Dose Melphalan||Vanderbilt-Ingram Cancer Center|No|Terminated|July 2007|April 2010|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|95|Samples With DNA|Blood sample or cheek cells will be collected.|Both|18 Years|N/A|No|Non-Probability Sample|People who have been diagnosed with multiple myeloma and have received or will be        receiving high-dose melphalan.|March 2013|March 12, 2013|January 22, 2008||No|The original PI on this study left VICC, thus study was closed.|No||https://clinicaltrials.gov/show/NCT00602147||161732|
NCT00602836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582676|Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab Followed by Consolidation With Lenalidomide for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||Mayo Clinic|Yes|Active, not recruiting|February 2008|December 2015|Anticipated|December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|January 12, 2008|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00602836||161682|
NCT00602849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERT-01|Bioequivalency Study of Sertraline Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fasting Conditions||Roxane Laboratories|No|Completed|June 2003|July 2003|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602849||161681|
NCT00571116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 06-08|Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy|Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (Phase 1b)||University of California, Irvine|Yes|Terminated|September 2006|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|December 6, 2007|Yes|Yes|Halted because of slow accrual and lack of study funding|No||https://clinicaltrials.gov/show/NCT00571116||164061|
NCT00571363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003DS10|A Randomised Study Comparing Tissue Conservation in Conventional Versus Mohs' Surgery of Basal Cell Carcinoma|A Randomised Study Comparing Tissue Conservation in Conventional Versus Mohs' Surgery of Basal Cell Carcinoma||NHS Tayside|Yes|Completed|January 2004|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|N/A|No|||December 2007|December 11, 2007|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571363||164042|
NCT00570310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-072|Neuropathic Pain Syndrome Patient Study (MK-0000-072)|A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug||Merck Sharp & Dohme Corp.||Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|December 7, 2007|No|Yes||No|January 13, 2010|https://clinicaltrials.gov/show/NCT00570310||164121|
NCT00570323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 20431|Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer|A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|PACT001|Baylor Breast Care Center|Yes|Active, not recruiting|December 2007|December 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570323||164120|
NCT00571103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Black2|Acamprosate in the Treatment of Pathological Gambling|Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling||University of Iowa|No|Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571103||164062|
NCT00572182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000578114|MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer|A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies||Pediatric Brain Tumor Consortium|Yes|Terminated|July 2008|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|3 Years|21 Years|No|||March 2012|March 2, 2012|December 11, 2007|No|Yes|This Phase I study was permanently closed to patient accrual on February 23, 2011, due to the    discontinuation of support from MERCK.|No||https://clinicaltrials.gov/show/NCT00572182||163981|
NCT00572728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00266|Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer|3'-Deoxy-3'-18F Fluorothymidine PET/CT in Predicting Response To Chemotherapy Before Surgery in Patients With Locally Advanced Breast Cancer||National Cancer Institute (NCI)|Yes|Completed|December 2008|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|90|||Both|18 Years|N/A|No|||August 2014|December 10, 2015|December 11, 2007|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT00572728||163942|
NCT00572468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-013-07S|Statin Therapy Versus Placebo Prior to Prostatectomy|Pre-Operative Statin Therapy Versus Placebo in Human Prostate Cancer||VA Office of Research and Development|Yes|Active, not recruiting|December 2007|December 2014|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Anticipated|44|||Male|21 Years|N/A|No|||August 2014|August 18, 2014|December 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00572468||163960|
NCT00572481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS 78076|Axillary Reverse Mapping|ARM: Axillary Reverse Mapping|ARM|University of Arkansas|No|Recruiting|May 2007|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572481||163959|
NCT00599807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP00B-114864|Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients|Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial||University of Zurich|No|Completed|January 2008|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|273|||Both|60 Years|N/A|No|||October 2014|October 27, 2014|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599807||161908|
NCT00592007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-060769|Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer|Phase II Trial Evaluating Addition of Fulvestrant to Erlotinib in Patients With Stage IIIB/IV NSCLC Who Are Stable on Erlotinib and Exhibit Positivity for Estrogen or Progesterone Receptor||University of California, San Diego|Yes|Terminated|September 2007|July 2012|Anticipated|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|December 26, 2007||No|Study was terminated due to slow subject accrual|No||https://clinicaltrials.gov/show/NCT00592007||162492|
NCT00592527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1569|Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes|Evaluation of Insulin Detemir in Combination With OADs in Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|April 2004|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|132|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|January 2, 2008||||No||https://clinicaltrials.gov/show/NCT00592527||162452|
NCT00592540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060486|Unrelated Donor BMT for Treatment of Patients With PGK Deficiency|Unrelated Donor Bone Marrow Transplantation for Definitive Treatment of Patients With Phosphoglycerate Kinase (PGK) Deficiency||Vanderbilt University|No|Active, not recruiting|June 2006|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|3 Years|12 Years|No|||May 2011|May 12, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00592540||162451|
NCT00600574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML-2007|Ai Chi Versus Stretching in Fibromyalgia Management|A Randomized Controlled Trial Comparing the Efficay and Tolerability of Ai Chi Versus Stretching in Fibromyalgia Management: a Six Months Study||Universidad de Granada|No|Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|70 Years|No|||December 2014|December 1, 2014|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600574||161850|
NCT00601458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-063|Bunionectomy Study (0000-063)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Pregabalin and Naproxen Sodium on Postoperative Pain After Bunionectomy||Merck Sharp & Dohme Corp.||Completed|July 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|65 Years|No|||March 2015|March 23, 2015|January 15, 2008|Yes|Yes||No|December 23, 2009|https://clinicaltrials.gov/show/NCT00601458||161783|
NCT00593658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F030604005|Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome|Open Label Single Arm Pilot Study of Pentoxifylline in Advanced Hepatopulmonary Syndrome||University of Alabama at Birmingham|Yes|Terminated|June 2004|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|19 Years|N/A|No|||January 2008|March 6, 2015|January 3, 2008||No|Poor tolerability of drug and side effects|No||https://clinicaltrials.gov/show/NCT00593658||162368|
NCT00593398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0010|Malarial Immunity in Pregnant Cameroonian Women|Malarial Immunity in Pregnant Cameroonian Women||University of Hawaii|No|Recruiting|September 2008|September 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1376|Samples With DNA|Serum samples and biopsies of placental tissue|Female|N/A|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cameroonian women who are pregnant and living in the city of Yaounde or the village of        Ngali II and Ntouessong in Soa district|December 2010|December 12, 2010|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593398||162388|
NCT00593411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4323|Neurological Surgery & Affiliated Services De-Identified Clinical Outcomes Database|Neurological Surgery & Affiliated Services De-Identified Clinical Outcomes Database|MDAnalyze|University of California, Irvine|Yes|Recruiting|June 2005|June 2015|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All UCI patients with central nervous disorder, spinal disease or peripheral nerve        disorder|April 2011|April 1, 2011|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593411||162387|
NCT00593671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sdbroc0|Preimplantation Genetic Screening in Women Over 35 Year|Preimplantation Genetic Screening for Aneuploidy in Embryos After in Vitro Fertilization in Women Over 35: a Prospective Controlled Randomized Study.||Katholieke Universiteit Leuven|No|Completed|June 2002|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|35 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 14, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593671||162367|
NCT00593931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200210591|Development Of New Techniques For Functional Magnetic Resonance Imaging Of The Brain|Development Of New Techniques For Functional Magnetic Resonance Imaging Of The Brain||University of California, Davis|No|Terminated|May 1999|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|215|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 3, 2008|Yes|Yes|Principal Investigator is deceased|No||https://clinicaltrials.gov/show/NCT00593931||162347|
NCT00594217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13368|Determining How Quickly Progesterone Slows LH Pulse Frequency|Determining the Rapidity With Which Exogenous P Suppresses Daytime LH (GnRH) Pulse Frequency in Women During the Follicular Phase of the Menstrual Cycle|CRM001|University of Virginia|No|Recruiting|November 2007|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|72|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594217||162325|
NCT00602498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461-08|Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions|A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|March 2003|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00602498||161706|
NCT00602862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sorafenib-mAbs|Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250|The Effect of Sorafenib (Nexavar®) on 111-Indium Labeled Chimeric Monoclonal Antibody G250 or 111-Indium Labeled Bevacizumab (Avastin®) Uptake in Patients With Clear Cell RCC (ccRCC)||Radboud University|Yes|Completed|July 2007|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|26|||Both|18 Years|N/A|No|||February 2012|November 29, 2013|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00602862||161680|
NCT00571376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060550|Evaluating the Impact on Quality and Costs of Regional Clinical Data Exchange Programs in New York State|Evaluating the Impact on Quality and Costs of Regional Clinical Data Exchange Programs in New York State||Weill Medical College of Cornell University|No|Enrolling by invitation|July 2008|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients and health care providers in the communities of the regional health information        organizations, including those in ambulatory care practices, hospitals, long-term care        facilities, home care programs and emergency departments.|June 2013|June 17, 2013|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571376||164041|
NCT00571896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATE002472HE|The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery|The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery: a Randomized Double Blinded Placebo Controlled Trial||Hartford Hospital|No|Completed|January 2008|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|N/A|No|||January 2012|January 3, 2012|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571896||164003|
NCT00572494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOTRONIK Reference 27-1|AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment|Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment|AMS-INSIGHT1|Flanders Medical Research Program|Yes|Completed|July 2005|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|50 Years|N/A|No|||February 2008|February 7, 2008|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572494||163958|
NCT00572507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0701|Multi-center Study to Evaluate the Safety and Efficacy of Aesculap MonoMax® for Abdominal Wall Closure|A Historically-controlled Single-arm Multi-center Prospective Trial to Evaluate the Safety and Efficacy of Aesculap MonoMax® Suture Material for Abdominal Wall Closure After Primary Median Laparotomy|ISSAAC|Aesculap AG|No|Completed|December 2007|July 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572507||163957|
NCT00572780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070759|Can CT Enteroclysis Predict the Outcome of Crohn's Disease|Can CT Enteroclysis Predict the Response to Therapy and Outcome in Patient With Crohn's Disease||Indiana University|No|Completed|August 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|125|||Both|18 Years|N/A|No|Non-Probability Sample|Crohn's disease patients that have had a CT Enteroclysis as part of their clinical        evaluation for symptomatic Crohn's disease will be eligible. Subjects who were later        diagnosied with bowel malignancy and subjects with a period of follow-up of less than 1        year(without surgery) will be excluded.|August 2015|August 7, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572780||163938|
NCT00572793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11063|A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk|A Nested Case-Controlled Study Evaluating the Utility of Placental Protein 13 (PP13) In-vitro Diagnostic Kit as a Diagnostic Aiding Tool in Assessment of the Risk for Developing Preeclampsia Necessitating Delivery Before 37 Weeks (Early-preeclampsia) Based on First Trimester Blood Testing of Pregnant Women With Low and Unknown Risk||University of Kansas Medical Center|No|Completed|November 2007|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|431|Samples Without DNA|Maternal serum - placental protein 13 level|Female|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients seen or referred to the obstetrical clinic|July 2015|July 7, 2015|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572793||163937|
NCT00591500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-087|A Model for Genetic Susceptibility: Melanoma|A Model for Genetic Susceptibility: Melanoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 1999|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|4082|Samples With DNA|buccal swabs tissue|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population-based registries in the United States|April 2015|April 28, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591500||162531|
NCT00591734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MEL 16|RAD001 Plus Bevacizumab in Metastatic Melanoma|A Phase II Trial of RAD001 Plus Bevacizumab in the Treatment of Patients With Metastatic Melanoma||SCRI Development Innovations, LLC|No|Completed|January 2008|October 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|December 26, 2007|No|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00591734||162513|
NCT00592020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220/07|Short Transverse Versus Conventional Hockey Stick Incision in Kidney Transplantation|"Short Transverse" Versus Conventional "Hockey Stick" Incision in Kidney Transplantation||University Hospital Inselspital, Berne|No|Completed|January 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00592020||162491|
NCT00600028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG-0747|Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide|Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide||Johns Hopkins University|Yes|Completed|December 2007|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|50 Years|N/A|No|||September 2012|September 18, 2012|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600028||161891|
NCT00592553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-007-DMD|Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD)|A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy||PTC Therapeutics|Yes|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|174|||Male|5 Years|N/A|No|||September 2013|September 6, 2013|January 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592553||162450|
NCT00592813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NINR 1R01NR010815-01A2|Efficacy of a Post-Rehabilitation Exercise Intervention|Efficacy of a Post-Rehabilitation Exercise Intervention||Boston University|Yes|Completed|April 2008|November 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|60 Years|N/A|No|||April 2013|April 22, 2013|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592813||162431|
NCT00600860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|883|European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes of IPSS Low and Intermediate-1 Subtypes|A Prospective, Multicenter European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes of IPSS Low and Intermediate-1 Subtypes|EUMDS|Radboud University|No|Recruiting|April 2008|December 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Urine and blood|Both|18 Years|N/A|No|Probability Sample|Clinic|February 2016|February 2, 2016|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600860||161828|
NCT00590681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15149A|Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme|Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study||University of Chicago|Yes|Completed|February 2007|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590681||162593|
NCT00593944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1342-02|Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase 1, Open-Label, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients With CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia|MDX1342-02|Bristol-Myers Squibb|No|Completed|August 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|January 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00593944||162346|
NCT00594230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MDS 07|LBH589 in Refractory Myelodysplastic Syndromes (MDS)|A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients||SCRI Development Innovations, LLC|No|Terminated|January 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|December 19, 2007|No|Yes|Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and    led to early termination of the study.|No|August 22, 2012|https://clinicaltrials.gov/show/NCT00594230||162324|Results of a planned interim analysis demonstrated that the regimen did not demonstrate sufficient evidence of efficacy necessary to justify further enrollment. Per protocol, the results of this analysis led to early termination of the study.
NCT00594503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU IRB #6625|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Traumatic Brain Injury|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Traumatic Brain Injury||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|January 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||January 2015|January 1, 2015|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594503||162303|
NCT00594516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014242|Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain|A Randomized, Double-Blind, 2-Period, Crossover Study to Establish the Dose Equivalence and Direct Conversion Between Immediate Release (IR) and Extended-Release (ER) CG5503 in Subjects With Moderate-to-Severe, Chronic Low Back Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2007|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|January 3, 2008|Yes|Yes||No|April 28, 2009|https://clinicaltrials.gov/show/NCT00594516||162302|
NCT00594243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0404190|Feasibility of Mindfulness Meditation for Adults 65+ With Chronic Low Back Pain|||University of Pittsburgh|No|Completed|May 2004|June 2005|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|65 Years|N/A|No|||January 2008|January 14, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594243||162323|
NCT00571389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biocytics0001|Isolation and Culture of Circulating Tumor Cells From Peripheral Blood|A Pilot Study to Facilitate Development of an Ex Vivo Device Kit for Circulating Tumor Cell Harvesting, Banking, and Apoptosis-Viability Assay||BioCytics, Inc.|Yes|Recruiting|November 2007|June 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood cells, tumor cells, plasma, discarded tissue (inc. tissue obtained from biopsies,      paracentesis, pleuracentesis), leukapheresis products|Both|19 Years|N/A|No|Non-Probability Sample|The population of patients to be enrolled for this study will be adults (males and        females) with histological proven metastatic solid tumors seen for routine cancer care at        participating community cancer clinic sites. Patients on clinical trials with experimental        study drugs will be allowed to participate in this observational pilot study.|November 2009|November 9, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571389||164040|
NCT00571662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|389-00|Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant|Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation||University of Nebraska|Yes|Completed|December 2000|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|19 Years|75 Years|No|||December 2010|December 2, 2010|December 11, 2007|Yes|Yes||No|October 19, 2010|https://clinicaltrials.gov/show/NCT00571662||164020|
NCT00570817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070009|Prevention of Methotrexate Induced Nephrotoxicity and Prolonged Drug Elimination Time With 12 Hours Prehydration|Nephrotoxicity Induced by High-Dose Methotrexate Infusions to Children With Malignant Diseases||University of Aarhus|Yes|Completed|June 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Both|1 Year|21 Years|No|||January 2011|November 4, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570817||164084|
NCT00571636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO 01/2005|Continuous Infusion of Fentanyl in Preterm on MV|Efficacy and Safety of Continuous Infusion of Fentanyl for Pain Control in Preterm Newborn on Mechanical Ventilation||St. Orsola Hospital|Yes|Completed|December 2007|July 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|128|||Both|N/A|32 Weeks|No|||October 2011|October 8, 2011|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571636||164022|
NCT00571909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009690|Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study|Evaluation and Treatment of Chronic Pain in Autosomal Dominant Polycystic Kidney Disease||Mayo Clinic|Yes|Recruiting|May 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571909||164002|
NCT00571922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcamprosateMethamphetamine|A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction|A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence|AcampMet|New York University School of Medicine|No|Completed|July 2007|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|99 Years|No|||November 2015|November 6, 2015|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571922||164001|
NCT00572819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-004083-52|Hysteroscopy After Pretreatment With Misoprostol and Estradiol Trial|Does Self-Administered Vaginal Misoprostol Result in Cervical Ripening in Postmenopausal Women After 14 Days Pre-Treatment With Estradiol?||Ullevaal University Hospital|Yes|Completed|January 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||May 2009|May 22, 2009|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572819||163935|
NCT00573053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:157|Effects of Targeting Lower Arterial Oxygen Saturations on the Development of Control of Breathing in Very Preterm Infants|Effects of Targeting Lower Arterial Oxygen Saturations on the Development of Control of Breathing in Very Preterm Infants||University of Manitoba|No|Completed|November 2007|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|26|||Both|N/A|70 Days|No|||January 2011|April 18, 2011|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00573053||163917|
NCT00573040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRONC MLD|Radiotherapy for NSCLC to a Individualized MLD|Radiotherapy for Stage I-III Non-small Cell Lung Cancer to an Individualized MLD|BRONC MLD|Maastricht Radiation Oncology|No|Completed|August 2005|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|-  Histological or cytological proven NSCLC          -  UICC stage I-III          -  Performance status 0-2          -  FeV 1 and DLCO at least 30% of the age-predicted value|July 2010|July 20, 2010|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573040||163918|
NCT00573287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG 62157-02|First Episode Schizophrenia and Cannabis-Related Disorder Study|Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder||Dartmouth-Hitchcock Medical Center|Yes|Completed|June 2006|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|17 Years|45 Years|No|||March 2013|March 1, 2013|December 12, 2007|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00573287||163899|
NCT00592293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-326|Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas|Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas||Massachusetts General Hospital|Yes|Recruiting|September 2006|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|30 Years|No|||February 2016|February 25, 2016|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592293||162470|
NCT00592566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP2003|Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis|An Open Randomized Controlled Trial of Desmopressin, and Dexamethasone as Adjunctive Therapy in Patients With Pulmonary Hemorrhage Associated With Leptospirosis||Mahidol University|No|Terminated|July 2003|October 2006|Actual|October 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|15 Years|90 Years|No|||December 2007|January 11, 2008|January 1, 2008||No|Numbe of eligible patients has been decreased over time.|No||https://clinicaltrials.gov/show/NCT00592566||162449|
NCT00592579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-CL-004|A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma|Phase 2, Open-Label, Safety, and Efficacy Study of 2-Methoxyestradiol Administered to Patients With Plateau Phase or Relapsed Multiple Myeloma||CASI Pharmaceuticals, Inc.||Completed|March 2001|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2009|February 25, 2009|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592579||162448|
NCT00592267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001247|Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder|A Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder||Massachusetts General Hospital|No|Recruiting|September 2001|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|4 Years|17 Years|No|Non-Probability Sample|Children and Adolescents with symptoms of bipolar disorder|November 2015|November 9, 2015|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592267||162472|
NCT00593138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-p-001610|Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate|A Randomized Open-label Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate (20 mg, 30 mg, and 40 mg) as Measured With C-11 Altropane in Healthy Adult Volunteers||Massachusetts General Hospital|No|Completed|December 2006|December 2009|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593138||162408|
NCT00593424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07407|Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins|Effect of Changing the Diet to Low Fat/High Carbohydrate or High Monounsaturated Fat/Low Carbohydrate on Fasting and Post Fat Load Lipoproteins of Diabetics With Moderate Hypertriglyceridemia||University of Arkansas|No|Completed|August 2002|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|15|||Both|18 Years|75 Years|No|||September 2011|September 1, 2011|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593424||162386|
NCT00592826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3|HMP (Home Macular Perimeter) -Usability Trial|Phase III Study of the Usability of the HMP Device||Notal Vision Ltd|Yes|Completed|November 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|25|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited in community centers and clinics and will include up to 25        people aged >50 years (Age-related Macular Degeneration age group). The group will be        heterogeneous in terms of education, age, ethnic background, and gender. The subjects will        be enrolled in one site in the USA In order to get 20 completed subjects, and based of        assumption of 25% attrition- 25 subjects will be recruited to the study|April 2015|April 13, 2015|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00592826||162430|
NCT00592839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-ENJ-401|Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women|A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of SCE-B on Nocturnal Vasomotor Symptoms in Postmenopausal Women||Teva Pharmaceutical Industries|No|Completed|December 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|157|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|December 20, 2007|Yes|Yes||No|February 4, 2010|https://clinicaltrials.gov/show/NCT00592839||162429|
NCT00593372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|g1-10532-03-07|Treatment of Language and Memory in Patients With Alzheimer's Disease|Treatment of Language and Memory in Patients With Alzheimer's Disease: A Comparison Between Drug Therapy and Drug Therapy Plus Behavioral Intervention||University of Arkansas|No|Completed|August 2003|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|21 Years|N/A|No|||July 2010|July 27, 2010|January 2, 2008||No||No|April 27, 2010|https://clinicaltrials.gov/show/NCT00593372||162390|Recruitment of participants was the major limitation of the trial. Alzheimer's patients at facility were asked to participate in so many studies, that participation in this one was challenging.
NCT00593112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002180|Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate|A Pilot Study of Proton Magnetic Spectroscopy in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Before and After Treatment With Osmotic-controlled Release Oral Delivery System (OROS) Methylphenidate||Massachusetts General Hospital|No|Completed|November 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|December 28, 2007|Yes|Yes||No|January 7, 2011|https://clinicaltrials.gov/show/NCT00593112||162410|
NCT00593125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yale-0508000534|Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-Maintained Patients.|Levetiracetam (Keppra) Tolerability and Efficacy in Cocaine Abusing Methadone-Maintained Patients.|Keppra|National Institute on Drug Abuse (NIDA)|No|Active, not recruiting|January 2007|August 2008|Anticipated|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||August 2008|August 11, 2008|December 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593125||162409|
NCT00601874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILO-01|Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions|A Single Dose, Two-Treatment, Two-Period, Two Sequence Crossover Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601874||161752|
NCT00601887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELO-T15-PVFD-1|Bioequivalency Study of Meloxicam Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 15 mg Meloxicam Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|March 2005|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601887||161751|
NCT00603876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU FY08 GRF|Efficacy of Almonds Added to Chronic Statin Therapy|Efficacy of Almonds Added to Chronic Statin Therapy||University of Kansas Medical Center|No|Completed|July 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||May 2013|May 20, 2013|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603876||161605|
NCT00594789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2007:165|Closing The Post Fracture Care Gap In Manitoba|Closing The Post Fracture Care Gap In Manitoba||University of Manitoba|No|Active, not recruiting|June 2008|July 2016|Anticipated|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|4264|||Both|50 Years|N/A|No|||August 2015|August 19, 2015|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594789||162281|
NCT00590668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROTEA|Safety Monitoring of Patients Having Pulmonary Vein Ablation|Pulmonary Vein Ablation for Atrial Fibrillation: Safety Monitoring by Transesphoageal Echo, Intracardiac Echo and Computed Tomography and Assessment of Predictors of Recurrence and of Hypercoagulable State|ROTEA|The Cleveland Clinic|No|Recruiting|May 2004|May 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Pulmonry vein ablation subjects at the Cleveland Clinic|January 2008|January 10, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590668||162594|
NCT00594529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-206|Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers|||Kyoto University||Recruiting|January 2008|May 2013|Anticipated|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|20 Years|80 Years|No|||August 2009|June 22, 2011|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00594529||162301|
NCT00591279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-035|Cancer Control Following Polypectomy|Cancer Control Following Polypectomy||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|February 1981|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|110|Samples With DNA|fecal occult blood|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing colorectal cancer screening|February 2016|February 2, 2016|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00591279||162548|
NCT00571402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH062555|Evaluating the Effectiveness of Family-Focused Psychoeducation in Treating Adolescents With Bipolar Disorder|Family-Focused Psychoeducation for Bipolar Adolescents||University of California, Los Angeles|Yes|Completed|July 2001|September 2005|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|12 Years|17 Years|No|||March 2014|March 24, 2014|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571402||164039|
NCT00571415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM10390|Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition|Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition||Virginia Commonwealth University|No|Suspended|March 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Female|18 Years|N/A|No|Probability Sample|University hospital clinic|December 2015|December 4, 2015|December 11, 2007||No|Due to competing studies no further subjects could be recruited.|No||https://clinicaltrials.gov/show/NCT00571415||164038|
NCT00571649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12839|Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients|Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study|MAGELLAN|Bayer|Yes|Completed|December 2007|November 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8101|||Both|40 Years|N/A|No|||November 2014|November 28, 2014|December 11, 2007|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00571649||164021|A heterogeneous population (with different acute medical illnesses and severity of illness) was included in the trial. VTE risk in acute medical illnesses is moderate [with no thromboprophylaxis] .
NCT00572195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP10005|RNS® System LTT Study|RNS® System Long-term Treatment (LTT) Clinical Investigation||NeuroPace|Yes|Active, not recruiting|April 2006|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|230|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|December 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00572195||163980|
NCT00573313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA_HAL-014562|Effects of SAMe in Patients With Alcoholic Liver Disease|Effects of SAMe in Patients With Alcoholic Liver Disease||University of California, Davis|No|Completed|September 2005|September 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 7, 2013|December 12, 2007||No||No|February 6, 2013|https://clinicaltrials.gov/show/NCT00573313||163897|Relatively small numbers of subjects analyzed with 13 each completers in the treatment and placebo groups. Within each group, violation of protocal by resumption of alcohol intake accounted for dropouts.
NCT00573300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORRC#10-2005|Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study|Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative RT-PCR Study||North Suffolk Mental Health Association|No|Completed|January 2006|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Schizophrenia patients|August 2009|August 11, 2009|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573300||163898|
NCT00593450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-137|Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial|Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)||University of Pennsylvania|Yes|Active, not recruiting|February 2008|July 2016|Anticipated|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1208|||Both|50 Years|N/A|No|||May 2015|May 26, 2015|January 3, 2008|Yes|Yes||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00593450||162384|
NCT00593710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01816|Losartan Versus Atenolol for the Treatment of Marfan Syndrome|A Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan Syndrome||University of British Columbia|Yes|Completed|January 2008|December 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|12 Years|25 Years|No|||July 2012|July 11, 2012|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593710||162364|
NCT00592280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|047-07-FB|Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation|Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation||University of Nebraska|Yes|Terminated|October 2007|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|19 Years|65 Years|No|||April 2010|April 16, 2010|December 17, 2007|Yes|Yes|Logistic problems with adequately timely organ collection and transport|No||https://clinicaltrials.gov/show/NCT00592280||162471|
NCT00593437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1053|T-score Comparability Between GE Lunar Prodigy and Norland Excel Densitometers|T-score Comparability Between GE Lunar Prodigy and Norland Excel Densitometers|Wildwood|University of Wisconsin, Madison|No|Completed|February 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|35|||Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ambulatory women age ≥ 40 who have recently had a spine and hip DXA at the Wildwood Clinic        on a Norland Excel densitometer|April 2010|October 1, 2015|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593437||162385|
NCT00593684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #005-206|The Safety Evaluation of Silver Alginate (Algidex™) Dressing in Very Low Birth Weight (VLBW) Infants|||Baylor Research Institute||Completed|April 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|N/A|72 Hours|No|||July 2015|July 27, 2015|January 4, 2008|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00593684||162366|
NCT00593697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol number FBCSG-01-2007|The Synergism Or Long Duration (SOLD) Study|A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer|SOLD|Finnish Breast Cancer Group|Yes|Completed|January 2008|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2168|||Female|18 Years|N/A|No|||March 2015|March 5, 2015|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593697||162365|
NCT00594256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07I/C36-0|Sodium Oxybate in Schizophrenia With Insomnia|Open Label, Pilot Study of Adjunctive Xyrem (Sodium Oxybate) for the Treatment of Schizophrenia and Associated Sleep Disturbances||Nathan Kline Institute for Psychiatric Research|No|Completed|May 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|45 Years|No|||January 2016|January 5, 2016|January 3, 2008|Yes|Yes||No|June 6, 2011|https://clinicaltrials.gov/show/NCT00594256||162322|Open Label Small sample
NCT00594542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn IRB-806101|Comparison of the Total Dose and Efficacy of Two Lidocaine Concentrations Needed for Cutaneous Surgery Local Anesthesia|A Randomized, Double Blind Comparison of the Total Dose of 1.0% Lidocaine With 1:100,000 Epinephrine Versus 0.5% Lidocaine With 1:200,000 Epinephrine Needed to Achieve Effective Anesthesia During Mohs Micrographic Surgery||University of Pennsylvania|Yes|Completed|June 2007|September 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|149|||Both|18 Years|N/A|No|||January 2008|January 3, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00594542||162300|
NCT00604227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2005|Pulmonary Function at High-Altitude|Interstitial Pulmonary Edema After Rapid Ascent to High Altitude (Margherita Hut, 4559 m)||Heidelberg University|No|Completed|July 2005|August 2005|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|January 29, 2008|January 17, 2008||||No||https://clinicaltrials.gov/show/NCT00604227||161578|
NCT00602225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6562|Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Dose Escalation Study of Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients||University of Washington|No|Completed|December 2007|||March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|70 Years|No|||May 2015|May 5, 2015|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00602225||161726|
NCT00591292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBL1002|Phase I Study in Advanced Solid Tumors|IBL1002:Phase I Study of Indibulin in Advanced Solid Tumors||Ziopharm||Active, not recruiting|June 2007|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591292||162547|
NCT00591305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-008287A|New Therapy of Laryngeal Papilloma In Children|Voice Preserving Therapy of Laryngeal Papilloma In Children||Boston University|Yes|Terminated|September 2007|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|1|||Both|10 Years|21 Years|No|||July 2014|July 17, 2014|December 31, 2007|Yes|Yes|insuffient resource for recruitment|No||https://clinicaltrials.gov/show/NCT00591305||162546|
NCT00571675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-205|A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)||Ascenta Therapeutics|No|Completed|October 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||November 2010|November 8, 2010|December 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00571675||164019|
NCT00571935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1507|Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes|Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|August 2003|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|61|||Both|N/A|7 Years|No|||September 2011|June 5, 2012|December 11, 2007||||No||https://clinicaltrials.gov/show/NCT00571935||164000|
NCT00572208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gabapentin01|Gabapentin for Postoperative Pain Management After Cardiac Surgery With Median Sternotomy|Gabapentin for Postoperative Pain Management After Cardiac Surgery With Median Sternotomy||University of Aarhus|Yes|Recruiting|January 2008|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572208||163979|
NCT00600600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|660|Tigecycline for Treatment of Rapidly Growing Mycobacteria|Use of Tigecycline for Treatment of Serious Infection Due to Rapidly Growing Mycobacteria (Especially M.Abscessus)||The University of Texas Health Science Center at Tyler|No|Active, not recruiting|April 2002|||April 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|10 Years|N/A|No|||January 2008|January 14, 2008|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600600||161848|
NCT00601172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKV110721|A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.|A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting.||GlaxoSmithKline|No|Completed|March 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|710|||Both|18 Years|N/A|No|||March 2011|January 4, 2013|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601172||161804|
NCT00569283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577508|Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant|Donor Natural Killer Cell Infusion for the Prevention of Relapse or Graft Failure After HLA-Haploidentical Familial Donor Bone Marrow Transplantation-A Phase I Study||National Cancer Institute (NCI)||Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|N/A|65 Years|No|||January 2008|March 25, 2013|December 6, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00569283||164197|
NCT00600405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2958|The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients|The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients||Maine Medical Center|No|Completed|August 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||January 2008|January 14, 2008|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600405||161863|
NCT00600418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rpat2CTIL|Identifying Toddlers and Their Parents Who Are Suffering From Posttraumatic Distress Following War and Terror|Identifying Posttraumatic Distress Among Toddlers and Their Parents Following Ongoing Exposure to Terrorism or War||Herzog Hospital|Yes|Completed|April 2007|December 2008|Actual|April 2008|Actual|Phase 0|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|500|||Both|1 Year|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Families with children between the age 1-6 years|September 2013|September 3, 2013|August 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00600418||161862|
NCT00592852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001840|Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder|A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder||Massachusetts General Hospital|No|Terminated|December 2005|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|6 Years|17 Years|No|||November 2012|November 13, 2012|December 28, 2007|Yes|Yes|Slow subject recruitment.|No|July 28, 2011|https://clinicaltrials.gov/show/NCT00592852||162428|
NCT00593957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD2408|Trial of Dextromethorphan in Rett Syndrome|Trial of Dextromethorphan in Rett Syndrome||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Terminated|August 2004|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|2 Years|15 Years|No|||July 2013|March 26, 2014|January 4, 2008|No|Yes|Study changed to a placebo controlled trial of dextromethorphan|No|March 8, 2013|https://clinicaltrials.gov/show/NCT00593957||162345|The trial was terminated due to the FDA requiring a placebo controlled trial instead of the ongoing open label trial. As recruitment was delayed,the total number of participants was also less than anticipated.
NCT00593970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 06-190part2|Influenza Vaccine in Pregnancy Part 2|Knowledge Possessed by Pregnant Women Regarding Influenza Vaccination During Pregnancy||St. Michael's Hospital, Toronto|No|Completed|November 2007|January 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Female|14 Years|46 Years|Accepts Healthy Volunteers|Non-Probability Sample|A multi-ethnic group of pregnant women|November 2009|April 14, 2010|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593970||162344|
NCT00593463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA010017-01|Drug Discrimination in Methadone-Maintained Humans Study 1|Drug Discrimination in Methadone-Maintained Humans Study 1|OMDD1|University of Arkansas|Yes|Completed|September 2006|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|40|||Both|18 Years|65 Years|No|||March 2011|March 10, 2011|January 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00593463||162383|
NCT00594269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F06001|Dementia Antipsychotics And Antidepressants Discontinuation Study|Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT.|DESEP|Sykehuset Innlandet HF|Yes|Completed|August 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|149|||Both|N/A|N/A|No|||February 2011|February 22, 2011|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594269||162321|
NCT00594555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST1571AU235 / Komrokji|A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia|A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Acute Myeloid Leukemia||University of Cincinnati|No|Withdrawn|November 2007|November 2008|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2008|October 29, 2008|January 3, 2008|Yes|Yes|Principal Investigator resigned position with the University of Cincinnati, closing study at    this site will reopen study in new position|No||https://clinicaltrials.gov/show/NCT00594555||162299|
NCT00594802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|systemic reaction protocol|Systemic Reactions to Allergen Immunotherapy Amd Skin Testing|Systemic Reactions to Allergen Immunotherapy Amd Skin Testing|chackos|University of South Florida|No|Completed|August 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Male and female subjects who are receiving skin testing or allergen immunotherapy from one        allergy practice.|July 2008|August 5, 2010|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00594802||162280|
NCT00601562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIDO-04|Bioequivalency Study of Zidovudine Under Fed Conditions|A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|June 2003|June 2003|Actual|June 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 7, 2008|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00601562||161775|
NCT00604240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27164|Telephone Follow-up From an Intensive Care Nursery|Telephone Follow-up From an Intensive Care Nursery: What do Parents Actually Remember?||Christiana Care Health Services|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|175|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Parents/caregivers of infants who are hospitalized in the NICU|January 2009|January 26, 2009|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604240||161577|
NCT00604253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1477|Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone|Comparison of Efficacy and the Safety of Insulin Detemir and Insulin NPH as add-on to Current OHA Therapy in Subjects With type2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|December 2003|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|362|||Both|20 Years|N/A|No|||June 2012|June 19, 2012|January 17, 2008||||No||https://clinicaltrials.gov/show/NCT00604253||161576|
NCT00590967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0300 / 201105362|A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy|A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy With Concurrent Weekly Cisplatin in Patients With Stage I-IVA Cervical Cancer Who Have FDG PET Positive Pelvic or Para-Aortic Lymph Nodes||Washington University School of Medicine|No|Terminated|May 2003|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Female|18 Years|N/A|No|||August 2013|August 2, 2013|December 31, 2007|Yes|Yes|Due to low accrual|No||https://clinicaltrials.gov/show/NCT00590967||162572|
NCT00590980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0599|Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)|The Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS) Study|VERiTAS|University of Illinois at Chicago|No|Completed|July 2008|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|Neurology/Neurosurgery Clinic|January 2015|January 30, 2015|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590980||162571|
NCT00590993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-136|Magnetic Resonance Imaging and Spectroscopy of the Prostate|Magnetic Resonance Imaging and Spectroscopy of the Prostate||Memorial Sloan Kettering Cancer Center|No|Completed|December 2000|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1005|||Male|18 Years|N/A|No|Probability Sample|Urology and Radiology prostate cancer patients seen at Memorial Sloan-Kettering Cancer        Center|February 2013|February 27, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590993||162570|
NCT00603239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWCG|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin||AstraZeneca|No|Completed|January 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|January 17, 2008|Yes|Yes||No|July 20, 2010|https://clinicaltrials.gov/show/NCT00603239||161654|
NCT00603252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111149|Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults|Evaluate the Effect of Risk Factors That Influence the Immunogenicity of GSK Biologicals Twinrix Compared to Hepatitis A and Hepatitis B Vaccines Given Separately and to Show the Non-inferiority Between the Vaccines in Adults||GlaxoSmithKline|No|Completed|January 2008|June 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|213|||Both|41 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 22, 2014|January 16, 2008||||No||https://clinicaltrials.gov/show/NCT00603252||161653|
NCT00571688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-BIP-4005|Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?|Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?|Consta|Vanderbilt University|Yes|Completed|November 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||June 2015|June 1, 2015|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571688||164018|
NCT00571961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511000791|Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)|Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)||Yale University|No|Completed|January 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|December 11, 2007||No||No|May 25, 2012|https://clinicaltrials.gov/show/NCT00571961||163998|
NCT00571948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2XIKers|Modification in Complementary Food Composition to Improve the Status of Iron and Fatty Acids in Infants.|Dortmund Intervention Trial for Optimization of Infant Nutrition|DINO|Research Institute of Child Nutrition, Dortmund|No|Completed|September 2005|March 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|132|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||May 2015|May 4, 2015|December 11, 2007||No||No|May 1, 2009|https://clinicaltrials.gov/show/NCT00571948||163999|
NCT00572520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078012|Effectiveness of Behavioral Treatments for Obesity and Major Depression in Women|Treating Co-morbid Obesity and Major Depressive Disorder||University of Massachusetts, Worcester|Yes|Completed|July 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Female|21 Years|65 Years|No|||April 2013|April 17, 2013|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572520||163956|
NCT00572806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1501|Initiation of Insulin Aspart in Type 2 Diabetes|Evaluation of the Initiation of Insulin Treatment Using Insulin Aspart on Blood Glucose Profile in Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|February 2003|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Both|30 Years|N/A|No|||September 2011|June 5, 2012|December 12, 2007||||No||https://clinicaltrials.gov/show/NCT00572806||163936|
NCT00601549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941007|A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT)|A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT)||National Taiwan University Hospital|Yes|Recruiting|January 2000|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|85 Years|No|||December 2012|December 5, 2012|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601549||161776|
NCT00602940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12045|Acupuncture for Polycystic Ovarian Syndrome|The Influence of Acupuncture on Ovulation and Reproductive Hormones||University of Virginia|No|Active, not recruiting|January 2006|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||May 2010|May 20, 2010|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602940||161676|
NCT00601848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583050|Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura|A Phase II Study of Pleural Photodynamic Therapy for Patients With Non-small Cell Lung Cancer and Pleural Spread||Abramson Cancer Center of the University of Pennsylvania||Active, not recruiting|November 2004|||July 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|120 Years|No|||February 2016|February 17, 2016|January 25, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00601848||161754|
NCT00601861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN028-1801|Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer|A Single Arm, Single-centre, Open-label, Exploratory Trial of Recombinant Interleukin-21 Administered Subcutaneously for 4 Weeks as Neo-adjuvant Treatment Prior to Sentinel Lymph Node/Complete Lymph Node Dissection Followed by 8 Weeks of Adjuvant Treatment in Subjects With Stage III Malignant Melanoma||Novo Nordisk A/S|No|Terminated|February 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|January 3, 2008|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT00601861||161753|
NCT00600951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-136|Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease|A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 3 to 5 Chronic Kidney Disease Undergoing MRI With the Injection of MultiHance||Bracco Diagnostics, Inc|No|Completed|January 2008|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|366|Samples Without DNA|fixed tissue samples|Both|N/A|N/A|No|Non-Probability Sample|A total of 1000 patients in 2 cohorts who are going to receive or have received MULTIHANCE        during an MRI examination as part of their routine clinical management. The cohorts are        defined as:        COHORT 1 - 600 patients of any age, with moderate CKD (stage 3, i.e., with eGFR stably        comprised between 30 and 59 mL/min/1.73m2); COHORT 2 - 400 patients of any age, with        severe CKD or kidney failure (stages 4 and 5, i.e., with eGFR below 30 mL/min/1.73m2).|October 2014|October 31, 2014|January 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00600951||161821|
NCT00600964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX004|A Phase I/II Study of GX15-070MS in Untreated CLL|A Multi-Center, Open-Label, Phase I/II Study of Single-Agent GX15-070MS Administered Every 2 to 3 Weeks to Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL)||Teva Pharmaceutical Industries|No|Completed|September 2004|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00600964||161820|
NCT00592865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030917|Risk Factors for Adult-Onset Brain Tumors|Genetic Epidemiology of Adult Brain Tumors||Vanderbilt University|No|Enrolling by invitation|October 2003|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|750|Samples With DNA|Mouthwash and salvia samples. Toenail samples are also collected.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|"Case" subjects will be identified from the patients referred to neurology/neurosurgery        clinics. Cases, when enrolled in the study, will be asked to identify potential "controls"        by providing the name and phone number of the same-sex in-law nearest in age to the case        and/or the name of a same-sex friend will also be sought.|January 2008|January 11, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00592865||162427|
NCT00592891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU IRB #5209|Oxygen Toxicity of HBOT in Chronic Brain Injury|Oxygen Toxicity Effects Using Los-Pressure Hyperbaric Oxygen Therapy in the Treatment of Chronic Brain Injury||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|April 2002|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||January 2015|January 1, 2015|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592891||162426|
NCT00593164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRS-01-07-02|Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients With Intravenous Infusion of Magnesium Sulfate|Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients With Intravenous Infusion of Magnesium Sulfate||Life Recovery Systems|Yes|Not yet recruiting|November 2016|April 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593164||162406|
NCT00593476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Temple U - 10854|Pilot Study to Assess Pre-packaged, Portion-controlled Meal Plan on Weight Loss|A Pilot Study to Assess the Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control|NS|Temple University|No|Completed|March 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|75 Years|No|||January 2008|June 28, 2013|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593476||162382|
NCT00601224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080010|Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia|Social Cognition and Interaction Training for Schizophrenia||University of North Carolina, Chapel Hill|Yes|Completed|June 2007|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||March 2013|March 28, 2013|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601224||161800|
NCT00601198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH190-06|A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer|Phase II Study of the Efficacy of Amifostine (Ethyol) in Reducing the Incidence and Severity of Oxaliplatin-Induced Neuropathy in Patients With Colorectal Cancer||University of Cincinnati|No|Terminated|October 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|January 14, 2008|Yes|Yes|Funding support withdrawn|No||https://clinicaltrials.gov/show/NCT00601198||161802|
NCT00601211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILO-02|Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions|A Single Dose, Two-Treatment, Two-Period, Two Sequence Crossover Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601211||161801|
NCT00601575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITH-09|Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions|A Single Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalency Study of 450 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|October 2002|November 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00601575||161774|
NCT00602602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000580812|Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer|A Phase II Study of Gemcitabine, Oxaliplatin and Bevacizumab Followed by 5-Fluorouracil, Oxaliplatin, Bevacizumab and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer||National Cancer Institute (NCI)||Recruiting|March 2007|||December 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602602||161698|
NCT00599924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181048|Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors|Phase I Study Of SU011248 In Combination With Oxaliplatin, Leucovorin, And 5-Fluorouracil In Patients With Advanced Solid Malignancies||Pfizer|No|Completed|September 2005|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|January 11, 2008|No|Yes||No|November 4, 2009|https://clinicaltrials.gov/show/NCT00599924||161899|
NCT00599937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL93|APL93: Timing of CxT and Role of Maintenance|Assessment of the Optimal Timing of Chemotherapy With or After ATRA and the Role of Maintenance||Groupe d'etude et de travail sur les leucemies aigues promyelocytaires|No|Completed|January 1993|December 1998|Actual|December 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|576|||Both|N/A|N/A|No|||December 2007|January 23, 2008|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599937||161898|
NCT00602966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-336-2|Oocyte Cryopreservation: Slow Cooling Versus Vitrification Techniques on Oocyte Survival|Oocyte Cryopreservation: Comparison of Slow Cooling Versus Vitrification Techniques on Oocyte Survival, Fertilization, and Embryo Development||University of Connecticut Health Center|No|Completed|July 2006|May 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|14|||Female|21 Years|36 Years|Accepts Healthy Volunteers|Probability Sample|The Center for Advanced Reproductive Services patient population|October 2011|October 26, 2011|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602966||161674|
NCT00603265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33CL231|Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy||Cubist Pharmaceuticals LLC|No|Completed|November 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|226|||Both|18 Years|75 Years|No|||June 2015|June 4, 2015|January 17, 2008|No|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT00603265||161652|
NCT00602576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000580808|Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma|RANDOMIZED PHASE II STUDY COMPARING TWO SCHEDULES OF TEMOZOLOMIDE IN COMBINATION WITH BAY43-9006 IN PATIENTS WITH ADVANCED MELANOMA||National Cancer Institute (NCI)||Active, not recruiting|January 2005|||March 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|167|||Both|18 Years|N/A|No|||August 2009|August 12, 2009|January 25, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00602576||161700|
NCT00602589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011395|A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects|An Open-label, Randomized, 3-way Crossover Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2002|November 2002|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|May 17, 2011|January 7, 2008||||||https://clinicaltrials.gov/show/NCT00602589||161699|
NCT00603850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP-PU3|Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP)|Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP) in Intermediate Age Related Macular Degeneration Patients|HMP|Notal Vision Ltd|Yes|Completed|January 2008|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|50 Years|N/A|No|Probability Sample|Subjects diagnosed as intermediate AMD in at least one eye|April 2015|April 13, 2015|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00603850||161607|
NCT00603863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hPAM4-02|Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer|A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.||Immunomedics, Inc.|No|Completed|January 2008|December 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603863||161606|
NCT00571974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51439|Treatment of Oral Premalignant Lesions With 5-ALA PDT|A Combined Phase I/II Single Site Study to Determine the Safety and Efficacy of Photodynamic Therapy (PDT) Utilizing 5-aminolevulinic Acid (5-ALA) and PDT in the Treatment of Premalignant Oral and/or Oropharynx Lesions.||University of Arkansas|No|Completed|January 2007|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||March 2015|March 4, 2015|December 5, 2007|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00571974||163997|Since all but one subject responded to treatment, no correlative analysis of response with change in expression of p53 or Ki-67 was undertaken.
NCT00572221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002|Improving the Quality of Care in Nursing Homes|Improving the Quality of Care in Nursing Homes||Hebrew Rehabilitation Center, Boston|No|Completed|February 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|4316|||Both|N/A|N/A|No|||March 2013|March 18, 2013|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572221||163978|
NCT00572832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32090|Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting|Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting||University of Pittsburgh|Yes|Completed|September 2007|August 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|23 Years|Accepts Healthy Volunteers|||August 2010|August 11, 2010|December 11, 2007||No||No|September 3, 2009|https://clinicaltrials.gov/show/NCT00572832||163934|One participant in the Standard group did not respond to any of the vaccine HPV types. Eleven participants in the Alternate group either did not receive Dose 3 or were out of window, compared with only one participant in the Standard group.
NCT00602953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042007-021|Role of Pancreatic Triglyceride Content in Beta-cell Function|Role of Pancreatic Triglyceride Content in Beta-cell Function||University of Texas Southwestern Medical Center|Yes|Completed|September 2007|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||5|Actual|101|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We enroll adult volunteers of all ethnicities who have no contraindications to the study        procedures or use medications that interfere with our measurements.|January 2013|January 22, 2013|October 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00602953||161675|
NCT00600639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSM2004-78|Non-Invasive Mechanical Ventilation in Elderly Patients|Non-Invasive Mechanical Ventilation in Elderly Patients Affected by Acute Hypercapnic Respiratory Failure:A Randomized Control Study vs Standard Medical Therapy A Multicentric Randomized Controlled Trial||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Terminated|January 2004|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|76 Years|N/A|No|||January 2008|July 16, 2012|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600639||161845|
NCT00601952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074970|Information Processing Modification in PTSD (Oct. 18)|Information Processing Modification in PTSD||San Diego State University|Yes|Completed|July 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Male|18 Years|N/A|No|||July 2009|December 13, 2013|January 15, 2008||No||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00601952||161746|
NCT00601965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080151|Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults|CBT Augmentation of SSRI Treatment for Geriatric GAD||Veterans Medical Research Foundation|Yes|Completed|October 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|73|||Both|60 Years|N/A|No|||April 2009|June 13, 2013|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601965||161745|
NCT00600626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1486|Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes|Comparison of Basal Bolus Treatment With Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2004|July 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|394|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|January 14, 2008||||No||https://clinicaltrials.gov/show/NCT00600626||161846|
NCT00600938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2206|Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload|A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions|CORDELIA|Novartis|Yes|Completed|November 2007|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|197|||Both|10 Years|65 Years|No|||August 2014|August 13, 2014|January 14, 2008|Yes|Yes||No|February 21, 2014|https://clinicaltrials.gov/show/NCT00600938||161822|
NCT00601237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0463|Effectiveness of a Cell Phone-Based Program for Abstinence and HIV Risk Prevention|Text Messaging for Abstinence and HIV Risk Prevention: The 411 on Safe Text||University of Colorado, Denver|No|Completed|October 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|103|||Male|16 Years|20 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00601237||161799|
NCT00601250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.17|Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (One Dose, e.g. 5 mg), Administered Orally Once Daily Over 24 Weeks, With an Open Label Extension to 80 Weeks (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy||Boehringer Ingelheim||Completed|January 2008|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|701|||Both|18 Years|80 Years|No|||December 2013|December 11, 2013|January 15, 2008||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00601250||161798|
NCT00602277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00234|Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy|A Phase 1 Study of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) (NSC 729968) in Patients With Ovarian, Primary Peritoneal and Fallopian Tube Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|April 2008|||July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|January 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00602277||161723|
NCT00602290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077650|Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression|The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients||University of California, Los Angeles|Yes|Completed|February 2008|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|181|||Both|60 Years|N/A|No|||August 2014|August 28, 2014|January 23, 2008|Yes|Yes||No|June 8, 2014|https://clinicaltrials.gov/show/NCT00602290||161722|
NCT00600912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMOF 5178|Influence of of a Lipid Emulsion on Inflammatory Response and Hepatic Function|Inflammatory Response and Hepatic Function in Patients Requiring Parenteral Nutrition: Comparison of a Lipid Emulsion Based ob Soybean Oil, Medium-Chain Triglycerides, Olive Oil and Fish Oil Versus a Lipid Emulsion Based on Olive and Soybean Oil||Klinikum Ludwigshafen|No|Completed|December 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|No|||December 2009|December 2, 2009|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600912||161824|
NCT00600925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-SWI-002|A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection|A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in General Surgical Subjects at Higher Risk for Surgical Wound Infection||Innocoll|Yes|Completed|January 2008|September 2010|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|600|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00600925||161823|
NCT00602251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERB-02|Bioequivalency Study of Terbinafine Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|March 2004|April 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602251||161725|
NCT00602264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503/5052006|Adipokines and Ghrelin Concentrations in Different Stages of Anorexia Nervosa|Adipocytokine and Ghrelin Concentrations in Different Stages of Anorexia Nervosa||Istanbul University|No|Completed|February 2006|May 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|41|||Female|16 Years|32 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with anorexia nervosa and constitutionally thin healthy subjects|January 2008|January 25, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602264||161724|
NCT00602615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORE-02|Bioequivalency Study of Torsemide Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602615||161697|
NCT00603291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-010|BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus|A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients With Type 2 Diabetes Mellitus Managed With Oral Hypoglycemic Agent(s)||Arena Pharmaceuticals|No|Completed|December 2007|October 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|604|||Both|18 Years|65 Years|No|||January 2013|January 4, 2013|January 17, 2008|Yes|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00603291||161650|
NCT00600184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT002|Clinic-Based AMES Treatment of Stroke|Clinic-Based Assisted Movement and Enhanced Sensation Treatment of Stroke|AMES|AMES Technology|Yes|Terminated|January 2008|February 2013|Anticipated|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||December 2012|December 4, 2012|December 31, 2007||No|Funding unavailable at this time for this particular study.|No||https://clinicaltrials.gov/show/NCT00600184||161880|
NCT00599625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11453|Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study|Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study||University of Virginia|No|Recruiting|October 2004|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||March 2011|March 4, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00599625||161922|
NCT00599638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0261002|A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia|A Two Week Double-Blind Placebo-Controlled Crossover Study To Compare The Efficacy And Safety Of A Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Patients With Post-Herpetic Neuralgia||Pfizer||Completed|March 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|N/A|No|||October 2009|October 7, 2009|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599638||161921|
NCT00603278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFA109685|A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.|See Detailed Description||GlaxoSmithKline|No|Completed|December 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|622|||Both|12 Years|N/A|No|||May 2011|June 6, 2013|December 27, 2007|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00603278||161651|
NCT00603577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XALIP_C_02090|Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens|A Multi-center, Randomized, Double Blind, Placebo Controlled Phase III Study to Assess the Efficacy of Xaliproden in Patients With Oxaliplatin-induced Peripheral Sensory Neuropathy (PSN) Following Adjuvant Chemotherapy for Colon Cancer|XENON|Sanofi|Yes|Terminated|January 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||January 2010|January 19, 2010|January 17, 2008|Yes|Yes|development of product discontinued|No||https://clinicaltrials.gov/show/NCT00603577||161628|
NCT00603590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301/148|Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease|Phase II Study of Heart Polypill in Primary Prevention of Cardiovascular Disease - Safety and Efficacy|Polypill|Tehran University of Medical Sciences|Yes|Completed|November 2006|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|475|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|January 1, 2008||No||No|April 13, 2009|https://clinicaltrials.gov/show/NCT00603590||161627|Incomplete follow up Because of differences in systolic blood pressure at baseline, final analysis will take account of baseline differences
NCT00600106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9260|Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study|WISE Ancillary Study Data Analyses:Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis||Cedars-Sinai Medical Center|Yes|Active, not recruiting|April 2006|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|48|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|postmenopausal women|August 2012|August 24, 2012|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00600106||161885|
NCT00572559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|766-INF-0026-126|Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus|A Randomized, Open Label, Multi-Center Clinical Trial, Comparing Microbiologic Response To Linezolid And Vancomycin In Ventilator-Associated Pneumonia (VAP) Due To Methicillin Resistant Staphylococcus Aureus (MRSA)||Pfizer|No|Completed|November 2002|January 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||June 2010|June 8, 2010|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572559||163954|
NCT00572533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K25DK072085|Intelligent Control Approach to Anemia Management|Intelligent Control Approach to Anemia Management (AIM 4)||University of Louisville|No|Completed|April 2011|August 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|62|||Both|18 Years|N/A|No|||October 2012|December 19, 2012|December 11, 2007|No|Yes||No|October 15, 2012|https://clinicaltrials.gov/show/NCT00572533||163955|Single-center designSmall sample sizeHomogenous populationOnly maintenance dosing phase tested
NCT00573066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-5-3770|Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery|The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery|InfantDex|Children's Hospital of Philadelphia|Yes|Completed|May 2004|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|1 Month|24 Months|No|||February 2013|February 28, 2013|December 11, 2007|Yes|Yes||No|March 12, 2010|https://clinicaltrials.gov/show/NCT00573066||163916|
NCT00570258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2004-19|Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy|Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy||University of Arkansas|No|Active, not recruiting|September 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Female|18 Years|55 Years|No|||January 2016|January 6, 2016|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570258||164125|
NCT00602342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERB-01|Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|March 2004|April 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602342||161718|
NCT00602355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074919|Effectiveness of Sertraline Alone and Interpersonal Psychotherapy Alone in Treating Women With Postpartum Depression|Placebo Controlled Trial of Sertraline and Interpersonal Psycho-Therapy for Postpartum Depression||Women and Infants Hospital of Rhode Island|Yes|Completed|February 2008|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Female|18 Years|50 Years|No|||December 2014|December 9, 2014|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602355||161717|
NCT00602680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY10400|Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease|A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease||Sanofi|Yes|Terminated|January 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1|||Both|55 Years|90 Years|No|||July 2009|July 17, 2009|January 16, 2008|Yes|Yes|Insufficient expected benefit risk|No||https://clinicaltrials.gov/show/NCT00602680||161693|
NCT00601601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581302|Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix|Genomics Approach to Id Novel Targets & Markers for Early Detection And Intervention In Cancer (Cervical)||British Columbia Cancer Agency||Completed|December 2004|May 2011|Actual|April 2009|Actual|N/A|Observational|N/A||1|Actual|80|||Female|19 Years|N/A|No|Probability Sample|All patients attending Vancouver General Hospital and referred to colposcopy for loop        electrocautery excision procedure (LEEP).|March 2012|March 7, 2012|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00601601||161772|
NCT00601926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06111|Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase II Trial Of Avastin (Bevacizumab) In Patients With Metastatic Papillary Renal Cell Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Terminated|February 2008|May 2013|Actual|August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|January 22, 2008|Yes|Yes|Poor patient accrual. Attempts to open at other sites unsuccessful.|No|June 20, 2014|https://clinicaltrials.gov/show/NCT00601926||161748|This trial closed early due to poor patient accrual. Attempts to open this trial at other sites were not successful.
NCT00601939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045774|Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships|Group Interventions for Abused, Suicidal Black Women||Emory University|Yes|Recruiting|March 2008|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Female|18 Years|64 Years|No|||January 2016|January 13, 2016|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601939||161747|
NCT00602303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORE-01|Bioequivalency Study of Torsemide Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 7, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602303||161721|
NCT00602992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0427-CE|Exploring the Role of 3T MRI in Gamma Knife Radiosurgery|Exploring the Role of 3T MRI in Gamma Knife Radiosurgery: A Pilot Study||University Health Network, Toronto|Yes|Recruiting|August 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients who have consented to Gamma Knife radiosurgery.|September 2007|January 9, 2009|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00602992||161672|
NCT00601588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERT-02|Bioequivalency Study of Sertraline Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fed Conditions||Roxane Laboratories|No|Completed|June 2003|July 2003|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601588||161773|
NCT00601900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00477|Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer|Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|May 2008|||June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|394|||Female|18 Years|N/A|No|||February 2015|April 23, 2015|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601900||161750|
NCT00601913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581171|Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery|CCCWFU 60307 - Pilot Study to Evaluate the Anti-tumor Effect of Erlotnib Administered Befor Surgery in Operable Patients With Squamous Cell Carcinoma of the Head and Neck (HNSCC)||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|March 2008|||October 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|120 Years|No|||February 2016|February 10, 2016|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00601913||161749|
NCT00602979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710009433|Comparison Study in Adult Surgical Patients of 5 Airway Devices|Prospective, Randomized Comparison of Intubating Conditions With Airtraq Optical, Storz DCI Video, McGRATH Video, GlideScope Video, & Macintosh Laryngoscope in Randomly Selected Elective Adult Surgical Patients||Weill Medical College of Cornell University|No|Completed|April 2008|July 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|5||Actual|240|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602979||161673|
NCT00603603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0598|Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity|Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity|Peri-Op|Washington University School of Medicine|No|Recruiting|February 2008|||December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|556|||Female|12 Years|50 Years|Accepts Healthy Volunteers|||May 2009|May 26, 2009|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00603603||161626|
NCT00600496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00004|A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)|A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors||AstraZeneca|Yes|Active, not recruiting|December 2007|December 2016|Anticipated|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|211|||Both|18 Years|130 Years|No|||January 2016|January 7, 2016|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00600496||161856|
NCT00599651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11851|Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)|Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)||University of Virginia|No|Terminated|June 2005|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|380|||Both|N/A|72 Hours|No|||May 2010|May 6, 2010|December 29, 2007||No|Study was closed due to extremely low enrollment|No||https://clinicaltrials.gov/show/NCT00599651||161920|
NCT00599664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-001|Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones|Double-Blind, Placebo-Controlled, Two-Center, Pharmacokinetic Study Evaluating the Systemic Absorption and Safety of OMS201 in Subjects Undergoing Ureteroscopic Treatment of Unilateral Ureteral- or Renal Collecting System-Located Stones||Omeros Corporation|No|Completed|December 2007|September 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||April 2010|April 28, 2010|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599664||161919|
NCT00599898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC070048CTIL|Nifedipine Compared to Atosiban for Treating Preterm Labor|Nifedipine Compared to Atosiban for Treating Preterm Labor. A Randomized Controlled Trial.||HaEmek Medical Center, Israel|No|Completed|January 2008|February 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Female|N/A|N/A|No|||March 2012|March 12, 2012|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00599898||161901|
NCT00600119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-IN-NX003|A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients With Opioid-Induced Constipation (OIC)||AstraZeneca|No|Completed|December 2007|April 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|January 11, 2008|Yes|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT00600119||161884|
NCT00600145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13222|Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward|Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward||University of Virginia|Yes|Withdrawn|September 2007|July 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2011|April 26, 2011|January 10, 2008|Yes|Yes|PI decision|No||https://clinicaltrials.gov/show/NCT00600145||161883|
NCT00602186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-1|Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction|Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction||Tabriz University|Yes|Active, not recruiting|July 2005|March 2008|Anticipated|March 2007|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|20 Years|70 Years|No|||January 2008|January 26, 2008|April 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00602186||161729|
NCT00602524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILO-03|Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Sequence Crossover Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|August 2004|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602524||161704|
NCT00572845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11352|Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation|Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation||Virginia Commonwealth University|No|Terminated|January 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 19, 2016|December 11, 2007||No|Unable to recruit enough participants.|No||https://clinicaltrials.gov/show/NCT00572845||163933|
NCT00604448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pulse_Canada_481556|The Effect of Eating Pulses for 8 Weeks on Satiety and Metabolic Syndrome Risk Factors in Overweight Individuals|The Effect of Frequent Consumption of Pulses for Eight Weeks on Blood Lipids and on Glycemic and Satiety Hormones Response in Overweight and Obese Subjects||University of Toronto|No|Completed|February 2008|December 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|35 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604448||161561|
NCT00599846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-30|The Natural History of Geographic Atrophy Progression (GAP) Study|||Alcon Research|No|Terminated|December 2007|||December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|55 Years|N/A|No|Non-Probability Sample|Patients showing signs of geographic atrophy secondary to age-related macular degeneration        with no CNV lesion.|February 2010|February 26, 2010|January 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00599846||161905|
NCT00570518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL 403-2|Alcohol and Other Psychoactive Substances in Road Traffic - a Case-control Study|DRUID Work Package 2 - Epidemiology||National Institute for Health and Welfare, Finland|No|Recruiting|September 2007|October 2011|Anticipated|||N/A|Observational|Observational Model: Case Control||2|Anticipated|4500|Samples With DNA|Whole blood and oral fluid are collected for the study. However, no DNA determinations are      done at any point of the study. The laboratory where the samples are analysed does not      analyse DNA. DNA is not relevant for this study.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|drivers of motorised vehicles and bicycles in general road traffic or drivers of motorised        vehicles and bicycles, injured or killed in road traffic accidents|September 2011|September 30, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570518||164106|
NCT00601263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AT002647|Safety Study of Chinese Herbal Therapy to Treat Asthma|Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase I||Icahn School of Medicine at Mount Sinai|No|Completed|October 2006|July 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|35|||Both|18 Years|55 Years|No|||December 2009|December 29, 2009|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00601263||161797|
NCT00601276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM-0315|Comparison of Two Pharmacological Treatments of Pedophilia|Comparative Controlled Clinical Trial of Two Pharmacological Treatments of Pedophilia|PCNET|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Terminated|December 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|60 Years|No|||December 2007|July 10, 2009|December 3, 2007||No||No||https://clinicaltrials.gov/show/NCT00601276||161796|
NCT00601614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0615|Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery|Phase I Study of ZD6474 and Temozolomide in Patients With Advanced Cancer||Mayo Clinic||Withdrawn|January 2008|||January 2010|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|January 24, 2008|No|Yes|no enrollment|No||https://clinicaltrials.gov/show/NCT00601614||161771|
NCT00603044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15868B|Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome|Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome||University of Chicago|No|Completed|January 2008|August 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|2 Years|12 Years|No|||April 2015|April 29, 2015|January 3, 2008|Yes|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00603044||161668|
NCT00603330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJB0703P1|Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function|Infusion of Mesenchymal Stem Cells as Treatment for Steroid-Resistant Grade II to IV Acute GVHD or Poor Graft Function: a Multicenter Phase II Study||University Hospital of Liege|No|Recruiting|January 2008|April 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 26, 2015|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603330||161647|
NCT00602316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581176|Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer|Using Magnetic Resonance Techniques to Improve the Characterisation and Localisation of Breast Cancer. A Pilot Observational Study Testing the Accuracy of Multifunctional Magnetic Resonance Techniques in Predicting the Presence, Distribution and Nature of Breast Lesions in Women With Known Breast Cancer||National Cancer Institute (NCI)||Recruiting|November 2007|||September 2009|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|||Anticipated|20|||Female|18 Years|N/A|No|||June 2009|August 23, 2013|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00602316||161720|
NCT00602641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00522|Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma|An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid™) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2008|November 2021|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|N/A|No|||March 2015|June 9, 2015|January 18, 2008|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT00602641||161695|
NCT00602667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJYC07|Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma|Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma||St. Jude Children's Research Hospital|No|Recruiting|November 2007|December 2023|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|315|||Both|N/A|5 Years|No|||January 2016|January 28, 2016|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602667||161694|
NCT00603005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-1-015|Adherence Improvement in Glaucoma Patients|Adherence Improvement in Glaucoma Patients||Maastricht University Medical Center|Yes|Completed|October 2007|January 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|4||Actual|802|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00603005||161671|
NCT00602628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMH-CCR2981|Radiation Therapy Planning Techniques in Reducing Damage to Normal Tissue in Women Undergoing Breast-Conserving Surgery for Ductal Carcinoma of the Breast|WILL MULTIFUNCTIONAL MAGNETIC RESONANCE TECHNIQUES, DETAILED HISTOPATHOLOGICAL ANALYSIS AND PRONE TREATMENT POSITION IMPROVE ACCURACY OF TARGET VOLUME LOCALISATION & DEFINITION AND REDUCE EXPOSURE OF NORMAL TISSUES IN BREAST RADIOTHERAPY?||National Cancer Institute (NCI)||Completed|November 2007|January 2009|Actual|July 2008|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|60|||Female|18 Years|N/A|No|||January 2009|June 25, 2013|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00602628||161696|
NCT00603616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32871-B|Induction of Clinical Response Using Rifaximin in Crohn's Disease|A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease||University of Washington|No|Recruiting|November 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||June 2012|June 13, 2012|January 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603616||161625|
NCT00603889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-07-02|Development of a Skin Test for the Na-ASP-2 Hookworm Antigen|Development of a Skin Test to Detect Immediate-type Hypersensitivity to the Experimental Na-ASP-2 Hookworm Antigen||Albert B. Sabin Vaccine Institute|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|January 17, 2008|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00603889||161604|
NCT00600509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N165|Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method|Bridging Study of L059(Levetiracetam) in Patients With Epilepsy by Double Blind Method||UCB Pharma|No|Completed|January 2001|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|216|||Both|16 Years|65 Years|No|||September 2009|September 16, 2013|January 14, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00600509||161855|
NCT00600158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED001|Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy|Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy||University of Virginia|No|Completed|April 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|75 Years|No|||January 2008|January 23, 2008|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00600158||161882|
NCT00600171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C109575|Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.|A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma||GlaxoSmithKline||Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|614|||Both|12 Years|N/A|No|||May 2014|May 22, 2014|January 11, 2008|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00600171||161881|
NCT00599911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11918A|Dose-finding Study With Lu AA24530 in Major Depressive Disorder|Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced, Dose-finding Study of Lu AA24530 in Major Depressive Disorder||H. Lundbeck A/S|No|Completed|October 2007|April 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|652|||Both|18 Years|65 Years|No|||September 2010|September 24, 2010|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00599911||161900|
NCT00600704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUH 1975 AK|Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery|Impact of Fluid Restriction Policy Added to Intra-Operative Cell Salvage in Reducing the Use of Red Cells in Cardiac Surgery||Larissa University Hospital|No|Completed|November 2007|March 2011|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|192|||Both|N/A|N/A|No|||March 2011|May 9, 2011|January 14, 2008||No||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00600704||161840|
NCT00601328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALC-07|Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Calcitriol Tablets, 0.25 mg, Under Fasting Conditions||Roxane Laboratories|No|Completed|July 2003|August 2003|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601328||161792|
NCT00602927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806623|Effects of Varenicline on Brain Activity During Nicotine Abstinence|Neural Substrates of Varenicline's (Chantix®) Efficacy for Smoking Cessation||University of Pennsylvania|Yes|Completed|November 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 6, 2011|January 15, 2008||No||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00602927||161677|
NCT00603200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701008974|Effect of Large Volume Paracentesis on Fatigue in Cirrhosis|The Effect of Large Volume Paracentesis on Fatigue in Cirrhosis||Weill Medical College of Cornell University|No|Recruiting|January 2008|December 2009|Anticipated|June 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with cirrhosis and refractory ascites.|November 2010|November 4, 2010|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00603200||161657|
NCT00604123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014041|A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adult Men or Women Allergic to Mountain Cedar Pollen||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604123||161586|
NCT00600366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1566|Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes|Efficacy and Safety of Biphasic Insulin Aspart 30 in Insulin Naive Type 2 Diabetic Patients With Secondary OHA Failure||Novo Nordisk A/S|No|Completed|March 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|71|||Both|35 Years|N/A|No|||June 2012|June 15, 2012|January 14, 2008||||No||https://clinicaltrials.gov/show/NCT00600366||161866|
NCT00600379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4780-DT-CTIL|Virtual Reality Training Program for Ambulatory Patients With Chronic Gait Deficits After Stroke|A Randomized Controlled Trial of a Virtual Reality Training Program for Ambulatory Patients With Mild-to-moderate Chronic Gait Deficits After Stroke||Sheba Medical Center|No|Completed|January 2008|October 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|16 Years|65 Years|No|||June 2011|June 15, 2011|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600379||161865|
NCT00570531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.117|Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma|Phase II Trial of Pre-Operative Chemoradiation Plus Bevacizumab, Followed by Surgery, and Post-Operative Adjuvant Bevacizumab for Patients With Loco-Regional Esophageal Carcinoma||University of Michigan Cancer Center|Yes|Terminated|June 2007|June 2013|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|No|||January 2015|January 5, 2015|December 10, 2007|Yes|Yes|The study was unable the accrue the required number of patients within a reasonable time.|No|January 5, 2015|https://clinicaltrials.gov/show/NCT00570531||164105|The study was unable the accrue the required number of patients within a reasonable time and therefore the primary objective was not analyzed.
NCT00601978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200AUS15|Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off|A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event-Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease and End-of-Dose Wearing Off||Novartis|Yes|Withdrawn|August 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|45 Years|75 Years|No|||April 2012|April 27, 2012|January 11, 2008|No|Yes|Business decision brand strategy; no patients enrolled|No||https://clinicaltrials.gov/show/NCT00601978||161744|
NCT00601991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HEM 0652|A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia|A Multi-Center Phase 2 Study of Vascular Endothelial Growth Factor (VEGF) Trap as a Single Agent in Acute Myeloid Leukemia||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn|March 2007|October 2009|Actual|March 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|January 17, 2008|Yes|Yes|Another study was opened.|No||https://clinicaltrials.gov/show/NCT00601991||161743|
NCT00602329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000580810|MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer|A Phase II Study Assessing Tumor Blood Flow as Measured by Dynamic Contrast Enhanced MRI in Patients With Metastatic Colorectal Cancer Receiving FOLFOX Alone Versus Patients Randomized to Receive FOLFOX Plus Bevacizumab at 5mg/kg or 10mg/kg.||National Cancer Institute (NCI)||Recruiting|February 2006|||December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|3||Anticipated|120|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|January 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602329||161719|
NCT00603369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH061149|HIV, Abuse, and Psychiatric Disorders Among Youth|HIV, Abuse, and Psychiatric Disorders Among Youth|Project STAR|Rhode Island Hospital|Yes|Completed|September 1999|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|212|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||February 2009|February 5, 2009|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603369||161644|
NCT00603382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFA109687|A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.|See Detailed Description||GlaxoSmithKline|No|Completed|December 2007|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|599|||Both|12 Years|N/A|No|||June 2013|August 15, 2013|December 27, 2007|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00603382||161643|
NCT00603395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-6|A Prospective Clinical Study On A Total Hip Resurfacing System|A Prospective Clinical Study On A Total Hip Resurfacing System||St. Anna Ziekenhuis, Geldrop, Netherlands|No|Completed|September 2004|May 2014|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|298|||Both|N/A|N/A|No|||May 2014|May 15, 2014|December 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603395||161642|
NCT00602693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS022|T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer|Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|July 2007|July 2016|Anticipated|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602693||161692|
NCT00603018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO06110005|PET Imaging Study of Recovered Anorexics|PET Imaging of Dopaminergic Transmission and Serotonin Markers in Anorexia Nervosa||University of Pittsburgh|Yes|Completed|June 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|October 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00603018||161670|
NCT00603031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0076|Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus|Effect of GLP-1 and GIP on the Maximal Insulin Secretory Capacity in Type-1 Diabetes Mellitus||Hvidovre University Hospital|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|9|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|January 20, 2011|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00603031||161669|
NCT00603655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UABC4268|Effect of Glycemic Load on Body Composition|Assessment of Glycemic Load on Body Composition Among Overweight and Obese Adults During 12 Month Period||Universidad Autonoma de Baja California|Yes|Terminated|January 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|29|||Both|18 Years|N/A|No|||December 2008|December 30, 2008|January 16, 2008||No|Higher drop out than expected. Lower Statistical Power.|No||https://clinicaltrials.gov/show/NCT00603655||161622|
NCT00595933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dry Mouth_Krempl|Comparing Over-the-counter Dry Mouth Remedies After Radiation|A Comparative Trial of Over-the-counter Dry Mouth Remedies for Dry Mouth After Radiation to the Head and Neck||University of Oklahoma|No|Completed|March 2005|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|28|||Both|13 Years|N/A|Accepts Healthy Volunteers|||June 2010|May 26, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595933||162198|
NCT00595946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBD0631|Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone|A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)|OPAL|Sucampo Pharma Americas, LLC|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|January 4, 2008|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT00595946||162197|
NCT00595959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9000-0001-03 CELLO|CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings|CLiRpath® Excimer Laser System to Enlarge Lumen Openings|CELLO|Spectranetics Corporation|Yes|Completed|November 2006|April 2008|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|85 Years|No|||June 2011|June 13, 2011|January 4, 2008|Yes|Yes||No|February 23, 2009|https://clinicaltrials.gov/show/NCT00595959||162196|Non-randomized study
NCT00596531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003412|Clinical Trial of Acamprosate for Tinnitus|Clinical Trial of Acamprosate for Tinnitus||Oregon Health and Science University|Yes|Active, not recruiting|January 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||February 2010|February 12, 2010|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596531||162152|
NCT00596817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11985A|Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes|A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|December 2007|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|639|||Both|18 Years|75 Years|No|||February 2014|February 13, 2014|January 8, 2008||No||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00596817||162130|
NCT00597103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR016CF|Comparison of Dialysis Therapies on Cognitive Function|Comparison of Dialysis Therapies on Cognitive Function||Satellite Healthcare|No|Recruiting|December 2007|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Subjects with Chronic Kidney Disease (CKD) who require renal replacement therapy and who        are currently receiving dialysis.|December 2007|January 8, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597103||162109|
NCT00597389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-326|Propranolol Administration and Prevention of Child PTSD in Child Trauma Victims|The Efficacy of Early Propranolol Administration at Preventing/Reducing PTSD Symptoms in Child Trauma Victims: Pilot.||Kent State University|Yes|Completed|February 2004|February 2006|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|29|||Both|10 Years|18 Years|No|||January 2008|January 17, 2008|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597389||162088|
NCT00597376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pamlab-Cerefolin NAC-001-01|Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints|A Six-month, Double-blind, Placebo-controlled, Single Site Study of Cerefolin NAC on Blood Homocysteine, Oxidative Stress, and Beta-amyloid Biomarkers That May Potentiate Inflammation and Neuronal Damage in Older Individuals With Memory Complaints Who Have Not Been Clinically Diagnosed With Mild Cognitive Impairment, Vascular Dementia, or Alzheimer's Disease||Rush University Medical Center|No|Completed|November 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|60 Years|N/A|No|||May 2013|May 20, 2013|January 9, 2008||No||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00597376||162089|No limitations or caveats to report.
NCT00591006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH078182|Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes|Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes||University of Texas Southwestern Medical Center|No|Completed|January 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|December 27, 2007|Yes|Yes||No|July 8, 2013|https://clinicaltrials.gov/show/NCT00591006||162569|The sample size in this pilot study was modest; The duration of exposure to hydrocortisone was subacute;
NCT00591799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G000058|Jarvik 2000 Heart as a Bridge to Cardiac Transplantation - Pivotal Trial|Clinical Protocol for Evaluation of the Jarvik 2000 Heart Assist System||Jarvik Heart, Inc.|Yes|Completed|April 2005|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591799||162508|
NCT00591812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-038|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2000|||||N/A|N/A|N/A||||||||||||||December 26, 2007|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591812||162507|
NCT00603122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1189|Acclimatization Mechanisms During Ascent to 7500m|Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology||University of Zurich|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 18, 2014|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00603122||161662|
NCT00603135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNeuro_Keppra_|Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus|Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus|Keppra|University Hospital, Basel, Switzerland|Yes|Withdrawn|January 2008|March 2010|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|N/A|No|||March 2015|March 9, 2015|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00603135||161661|
NCT00602771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00278|Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia|A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML)||National Cancer Institute (NCI)|No|Completed|January 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|70 Years|N/A|No|||June 2014|October 1, 2014|January 19, 2008|Yes|Yes||No|January 8, 2013|https://clinicaltrials.gov/show/NCT00602771||161686|
NCT00604058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV25|Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly|Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine Administered Intradermally vs Full Doses of Inactivated Poliomyelitis Vaccine Administered Intramuscularly in Healthy Philippines Infants||Sanofi|Yes|Completed|January 2008|December 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|236|||Both|42 Days|50 Days|Accepts Healthy Volunteers|||January 2014|January 20, 2014|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604058||161591|
NCT00604396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1530|Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes|Safety and Efficacy of Insulin Detemir Combined With OAD Versus Insulin NPH Combined With OAD in Type 2 Mellitus||Novo Nordisk A/S|No|Completed|March 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|477|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|January 17, 2008||||No||https://clinicaltrials.gov/show/NCT00604396||161565|
NCT00590928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13H1-CM1|Gastric pH in Critically Ill Patients|Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study.||Medical University of Vienna|No|Completed|July 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|80 Years|No|||December 2007|December 26, 2007|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590928||162575|
NCT00595309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-311|Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51|Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.||Valneva Austria GmbH|No|Completed|December 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|198|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|January 4, 2008||No||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00595309||162243|
NCT00595608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/S0802/45|Sterimar vs Saline Sprays in Nasal Surgical Aftercare - a Blinded, Randomised Trial|Sterimar vs Saline Sprays in Nasal Surgical Aftercare - a Blinded, Randomised Trial||NHS Grampian|Yes|Not yet recruiting|February 2008|February 2010|Anticipated|February 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|16 Years|N/A|No|||December 2007|January 15, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595608||162222|
NCT00595621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9459|Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis|Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis||University of Kansas Medical Center|Yes|Completed|February 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||May 2015|May 1, 2015|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595621||162221|
NCT00595920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-00|Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis|An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00|OLTERMS|Opexa Therapeutics, Inc.|Yes|Terminated|November 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|N/A|N/A|No|||February 2014|February 16, 2016|January 3, 2008|No|Yes|Financial Constraints|No|January 13, 2014|https://clinicaltrials.gov/show/NCT00595920||162199|
NCT00595972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECF/endo-MGC|Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer|Phase II Trial of Epirubicin Cisplatin and FU Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer||Fudan University|No|Completed|November 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|No|||September 2010|June 27, 2011|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00595972||162195|
NCT00596232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-05418|Investigating Mucinase Activity in Airway Disease|Investigating Mucinase Activity in Airway Disease|Mucinase|University of California, San Francisco|No|Recruiting|April 2003|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|225|Samples Without DNA|Sputum|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers are recruited from community advertisements and health clinics|November 2015|November 12, 2015|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00596232||162175|
NCT00596245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT400-108|Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets|Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets Administered Two Hours Apart on Chromosomal Aberrations in Peripheral Blood Lymphocytes||GlaxoSmithKline|Yes|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|42|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596245||162174|
NCT00596544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-124|Sexual Functioning After Primary Treatment of Ovarian Cancer|Sexual Functioning After Primary Treatment of Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Terminated|November 2004|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|||Female|18 Years|N/A|No|Non-Probability Sample|MSKCC clinic|November 2015|November 25, 2015|January 8, 2008||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00596544||162151|
NCT00597116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00075|An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma|A Randomized Phase II Trial To Evaluate The Efficacy And Safety Of Vandetanib (ZD6474, ZACTIMA ™) Versus Vinorelbine In Patients With Inoperable Or Relapsed Malignant Mesothelioma.||AstraZeneca|No|Terminated|December 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||September 2012|September 14, 2012|January 9, 2008|Yes|Yes|Recruitment stopped according to early stopping rule (by protocol)|No|April 27, 2011|https://clinicaltrials.gov/show/NCT00597116||162108|Early termination leading to small number of subjects analyzed.
NCT00594282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9673|Use of a Radiolucent Pad to Reduce Mammography Among African Americans|Use of a Radiolucent Pad to Reduce Mammography Among African Americans||University of Kansas Medical Center|Yes|Completed|September 2005|||July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|300|||Female|40 Years|N/A|No|||September 2008|September 10, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00594282||162320|
NCT00594568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7666|Effect of LY450139 on the Long Term Progression of Alzheimer's Disease|Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo||Eli Lilly and Company|Yes|Completed|March 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1537|||Both|55 Years|N/A|No|||March 2015|March 13, 2015|January 11, 2008|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT00594568||162298|Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.
NCT00594581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1011|Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males|A Single-Site, Double-Blind, Phase II Trial to Investigate the Safety, Toleration, Systemic Exposure and Anti-Scarring Potential of Different Applications of Intradermal Juvista (Avotermin) in Male Subjects Aged 18-45 Years||Renovo|No|Completed|October 2003|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 2, 2008|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00594581||162297|
NCT00597662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUP-002|Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis|Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis||University Hospital Tuebingen||Completed|January 2008|||April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Female|18 Years|60 Years|No|||June 2008|June 9, 2008|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597662||162067|
NCT00597870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10837-01|Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions|Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions||Los Angeles Biomedical Research Institute|Yes|Recruiting|May 2002|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597870||162051|
NCT00591318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5418|A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis|IV Ceftriaxone for Refractory Psychosis: a Controlled Trial||Research Foundation for Mental Hygiene, Inc.|No|Recruiting|August 2007|||August 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|55 Years|No|||September 2009|September 17, 2009|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591318||162545|
NCT00591565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-MD-15|An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants|An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants||State University of New York - Upstate Medical University||Completed|June 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|December 26, 2007|Yes|Yes||No|September 6, 2012|https://clinicaltrials.gov/show/NCT00591565||162526|open label design without placebo control
NCT00591838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0691 / 201012832|A Phase I/II Trial of Stereotactic Body Radiation Therapy|A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT) Dose Escalation in the Treatment of Patients With Inoperable Stage I/II Non-Small Cell Lung Cancer Arising Within the Zone of the Proximal Bronchial Tree|SBRT|Washington University School of Medicine|No|Recruiting|September 2006|August 2019|Anticipated|August 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 31, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591838||162505|
NCT00601406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581139|Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer|Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER)||National Cancer Institute (NCI)||Recruiting|March 2006|||February 2008|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|2200|||Both|N/A|N/A|No|||April 2008|August 23, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00601406||161787|
NCT00601419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281286|Drug Use Investigation of Somatropin for GHD-ADULTS.|Drug Use Investigation of GENOTROPIN for GHD-ADULTS.||Pfizer|No|Completed|March 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|230|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6281286 prescribes the Somatropin.|December 2013|December 17, 2013|January 15, 2008|No|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00601419||161786|
NCT00601432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010621|A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation|An Open-label, Randomized, 2-way Crossover Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2002|December 2002|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 5, 2010|December 6, 2007||||||https://clinicaltrials.gov/show/NCT00601432||161785|
NCT00602095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMS2007|Labour Induction With Misoprostol, Dinoprostone and Bard Catheter|A Randomised Comparison Between Intravaginal Dinoprostone Intravaginal Misoprostol and Transcervical Balloon Catheter for Labour Induction|LI|Karolinska University Hospital|Yes|Completed|December 2004|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|592|||Female|18 Years|N/A|No|||January 2008|January 15, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00602095||161735|
NCT00602433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07CC4|Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib|Evaluation of Hormonal Changes in Women on Erlotinib Therapy||Northwestern University|No|Completed|December 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|blood will be tested for different sex hormones as well as glucose metabolism|Female|18 Years|N/A|No|Non-Probability Sample|Subjects have advanced nonsmall cell lung cancer and have been taking erlotinib as part of        anticancer therapy for at least 3 months.|April 2011|April 14, 2011|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00602433||161711|
NCT00604409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC04043|Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer|Phase I Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer||Fox Chase Cancer Center|Yes|Completed|April 2006|January 2015|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00604409||161564|
NCT00604422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-107|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis||Given Imaging Ltd.|No|Completed|April 2007|March 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|70 Years|No|Probability Sample|Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative        colitis disease        The study population will consist of subjects who fulfill all the inclusion criteria and        none of the exclusion criteria.|March 2010|March 10, 2010|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00604422||161563|
NCT00595322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-092|Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma|Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595322||162242|
NCT00595335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-006130|Trial of Rituximab for Graves' Ophthalmopathy|Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy||Mayo Clinic|Yes|Completed|April 2008|September 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||December 2015|December 30, 2015|January 1, 2008|Yes|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT00595335||162241|
NCT00595634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03618-07-A|INTUIT Hip Fracture Outcome Study|Intramedullary Nailing for Treatment of Unstable InterTrochanteric (INTUIT) Hip Fracture Outcome Study.|INTUIT|Smith & Nephew, Inc.|No|Terminated|January 2008|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|50 Years|N/A|No|Probability Sample|Patients presenting with unilateral unstable intertrochanteric hip fracture (as defined by        Hennepin County Medical Center intertrochanteric hip fracture classification system, Kyle        et al, 1979) without other lower extremity fractures.|March 2014|March 31, 2014|January 4, 2008||No|Could not power primary endpoint due to lost to follow-up rate|No||https://clinicaltrials.gov/show/NCT00595634||162220|
NCT00595985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sorafenib-MGC|Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer|Phase II Trial of Sorafenib as Second Line Therapy in Patients With Advanced or Metastatic Gastric Cancer||Fudan University|No|Terminated|July 2007|January 2009|Anticipated|January 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||July 2009|July 6, 2009|January 7, 2008||No|low response rate, no evidence of PFS or OS improved.|No||https://clinicaltrials.gov/show/NCT00595985||162194|
NCT00596284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078925|Cognitive Behavior Therapy for Treating Anxiety in People With Dementia|Cognitive Behavior Therapy for Anxiety in Dementia||Baylor College of Medicine|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|50 Years|N/A|No|||August 2015|August 12, 2015|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00596284||162171|
NCT00596258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-003|A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)|A Two-Stage Phase 2 Study Of Dose-Intense 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix|TG-003|Tigris Pharmaceuticals|No|Completed|November 2007|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||May 2009|May 21, 2009|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596258||162173|
NCT00596830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021016|Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology|Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer||Pfizer|Yes|Terminated|April 2008|September 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|681|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|January 3, 2008|Yes|Yes|See termination reason in detailed description.|No|September 25, 2013|https://clinicaltrials.gov/show/NCT00596830||162129|The study was terminated early due to futility. CP-751,871 will not undergo further development in the indication of advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
NCT00594295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-1098|Follow-up of Bone Quality in Long-Term Bone Marrow Transplant Survivors|Follow-up of Bone Quality in Long-Term Bone Marrow Transplant Survivors||University of Wisconsin, Madison|No|Completed|June 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|whole blood, serum|Both|N/A|N/A|No|Non-Probability Sample|Bone marrow transplant patients at least 6 years post transplant|April 2010|October 1, 2015|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594295||162319|
NCT00590707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00041873|Post-Operative Delirium in Elderly Surgical Patients|A Strategy to Reduce the Incidence of Post-Operative Delirium in Elderly Patients|STRIDE|Johns Hopkins University|Yes|Recruiting|January 2005|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Both|65 Years|N/A|No|||February 2016|February 25, 2016|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590707||162591|
NCT00591019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 65171|Use of Modafinil in the Treatment of Tinnitus|Use of Modafinil in the Treatment of Tinnitus||University of Arkansas|No|Terminated|August 2006|June 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|7|||Both|20 Years|99 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|December 27, 2007|Yes|Yes|Terminated early due to lack of change in primary and secondary outcome measures.|No|February 28, 2011|https://clinicaltrials.gov/show/NCT00591019||162568|Study was terminated early due to lack of change in primary and secondary outcome measures.
NCT00594815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-146|Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma||Memorial Sloan Kettering Cancer Center|No|Completed|August 2002|February 2016|Actual|February 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|N/A|No|||February 2016|February 25, 2016|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00594815||162279|
NCT00591331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-107-07|Phototoxicity Potential of NatrOVA Creme Rinse - 1%|Phase 1 Evaluation of the Phototoxic Potential of NatrOVA Creme Rinse - 1% in Healthy Volunteers||ParaPRO LLC|No|Completed|December 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|May 16, 2008|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591331||162544|
NCT00591578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491_301|Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension|A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension||Takeda|No|Completed|December 2007|March 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|984|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|December 27, 2007|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00591578||162525|For the Non-Serious Adverse Event Table, the total number of participants affected is based on the AEs with ≥5% in each phase, calculated separately.
NCT00591539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0487|Carotid Artery Disease in Childhood Cancer Survivors|Carotid Artery Disease in Long-Term Survivors of Childhood Cancer||M.D. Anderson Cancer Center|No|Terminated|December 2007|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|N/A|21 Years|No|Non-Probability Sample|Long-term survivors of pediatric cancers who received radiation therapy to the neck as        part of their treatment at M.D. Anderson Cancer Center.|July 2012|July 27, 2012|December 28, 2007||No|Slow Accrual.|No||https://clinicaltrials.gov/show/NCT00591539||162528|
NCT00591552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI-001|Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.|Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy. A Single Center Prospective Randomized Controlled Study.||Sentara Cardiovascular Research Institute|No|Recruiting|December 2007|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|75 Years|No|||December 2007|January 10, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591552||162527|
NCT00602797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|339-07|Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-small Cell Lung Cancer||University of Nebraska|Yes|Recruiting|December 2007|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|70 Years|N/A|No|||April 2014|April 1, 2014|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00602797||161684|
NCT00602823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561701002|Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)|Ex Vivo Monocyte and Lymphocyte Stimulation Tests and Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)||National Taiwan University Hospital||Completed|February 2006|May 2006||||N/A|Observational|N/A||||20|||Both|N/A|N/A|No|||February 2006|January 25, 2008|March 22, 2007||||No||https://clinicaltrials.gov/show/NCT00602823||161683|
NCT00603460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01808|DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer|A Phase-I/II Randomized Trial of Maintenance Vaccination Combined With Metronomic Cyclophosphamide w/wo Adoptive Transfer of CD3/CD28-CoStimulated T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer Previously Vaccinated DCVax-L||University of Pennsylvania|Yes|Withdrawn|January 2012|March 2013|Anticipated|January 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|13|||Female|18 Years|N/A|No|||September 2010|September 21, 2010|January 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603460||161637|
NCT00603473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451162|A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures|An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects||Pfizer|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|3 Years|15 Years|No|||January 2011|January 24, 2011|January 16, 2008||No||No|December 6, 2010|https://clinicaltrials.gov/show/NCT00603473||161636|
NCT00603759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3058|COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma|the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial||Tehran University of Medical Sciences|Yes|Active, not recruiting|April 2006|August 2009|Anticipated|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|20 Years|N/A|No|||January 2008|January 16, 2008|January 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00603759||161614|
NCT00603733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN 35.3.11|Canadian Active & Maintenance Modified Pentasa Study|A Multicentre, Randomised, Double-blind, Non-inferiority Trial Comparing the Efficacy and Safety of a New Modified Oral Extended Release Pentasa® (Mesalamine) 500 mg Tablet to the Currently Marketed Pentasa® (Mesalamine) 500 mg Tablet in Subjects With Active Mild to Moderate Ulcerative Colitis Treated With 4 g/Day for 8 Weeks and in Maintenance of Remission of Ulcerative Colitis in Subjects Treated With 2 g/Day for 24 Weeks|CAMMP|Ferring Pharmaceuticals|No|Completed|October 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|343|||Both|18 Years|75 Years|No|||November 2014|November 10, 2014|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00603733||161616|
NCT00603746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFA109684|A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.|A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent an||GlaxoSmithKline|No|Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|627|||Both|12 Years|N/A|No|||April 2015|April 9, 2015|December 27, 2007|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00603746||161615|
NCT00603772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029-066-09-002|Clinical Evaluation of the Photoallergy Potential of Atralin Gel|Clinical Evaluation of the Photoallergy Potential of Atralin Gel (Tretinoin Gel 0.05%)||Coria Laboratories, Ltd.|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|May 5, 2008|January 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00603772||161613|
NCT00591227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07070902|Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.|Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care||Rush University Medical Center|No|Completed|May 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|80 Years|No|||April 2011|April 8, 2011|December 27, 2007|Yes|Yes||No|April 8, 2011|https://clinicaltrials.gov/show/NCT00591227||162552|
NCT00599560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tk19661218|Vasopressin and V2 Receptor in Meniere's Disease|Vasopressin and V2 Receptor in Meniere's Disease||Osaka University|No|Completed|April 1998|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|20 Years|80 Years|No|||January 2008|January 22, 2008|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599560||161927|
NCT00595348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG003|Korean Hereditary Breast Cancer Study|Korean Hereditary Breast Cancer Study|KOHBRA|Korean Breast Cancer Study Group|Yes|Recruiting|November 2007|May 2017|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2250|Samples With DNA|DNA, Serum, plasma, Whole blood|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All Medical Center including personal breast clinic, general hospital, university        hospital, cancer institute in Korea|May 2011|May 9, 2011|January 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00595348||162240|
NCT00595647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASKET-SAVAGE EKBB# 278/07|Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions|BAsel Stent Kosten Effektivitäts Trial - SAphenous Venous Graft Angioplasty Using Glycoprotein IIb/IIIa Receptor Inhibitors and Drug-Eluting Stents|BASKET-SAVAGE|University Hospital, Basel, Switzerland|Yes|Terminated|February 2008|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||April 2015|April 19, 2015|January 4, 2008||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00595647||162219|
NCT00595660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17251-10/10/1386|Best Needle Size for FNA of Palpable Breast Mass:Randomised Controlled Study|Best Needle Size for FNA of Palpable Breast Mass:Randomised Controlled Study||Kashani Social Security Hospital|No|Not yet recruiting|February 2008|||February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|250|||Female|18 Years|N/A|No|||January 2008|January 15, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595660||162218|
NCT00595673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-007|Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007|||Point Biomedical|Yes|Completed|July 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|428|||Both|18 Years|N/A|No|||July 2008|July 1, 2008|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595673||162217|
NCT00595998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP-SS1|Sensitivity and Specificity of the Home Macular Perimeter (HMP)|Sensitivity and Specificity of the Home Macular Perimeter|HMP|Notal Vision Ltd|Yes|Completed|January 2008|November 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|42|||Both|50 Years|N/A|No|Probability Sample|The study population will include 30 subjects suspected to have newly onset CNV secondary        to AMD in at least one eye, or Intermediate AMD in at least one eye, and who consent to        participate in the study.|January 2009|January 27, 2009|January 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00595998||162193|
NCT00596271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-308|Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440|Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study||Valneva Austria GmbH|No|Completed|September 2005|August 2008|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|192|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|January 4, 2008|No|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00596271||162172|
NCT00593983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT2|Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials (the ACT2 Project)|Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials||New York University|No|Completed|May 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|540|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00593983||162343|
NCT00593996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1224|Evaluation of Potential Vitamin D Effects on Muscle: a Pilot Study|Evaluation of Potential Vitamin D Effects on Muscle: a Pilot Study||University of Wisconsin, Madison|No|Completed|July 2006|||May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|70 Years|N/A|Accepts Healthy Volunteers|||May 2010|October 1, 2015|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00593996||162342|
NCT00590720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP143|A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction||MedImmune LLC|Yes|Terminated|March 2008|October 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|50 Years|No|||February 2014|February 4, 2014|December 26, 2007|Yes|Yes|Study is replaced by MI-CP198 per CPM.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT00590720||162590|
NCT00590746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0239|Bedside Assessment of Fall Risk in Emergency Department Elders|Bedside Assessment of Fall Risk in Emergency Department Elders||Ohio State University|No|Completed|December 2007|September 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|||Both|60 Years|N/A|No|Non-Probability Sample|Patients aged 60 and older who present to the Ohio State University Medical Center        Emergency Department|February 2014|February 11, 2014|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590746||162589|
NCT00591032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-Innere-565|Approach to a Quantitative Follow-up of Non-thyroidal Illness Syndrome|Development of Rational and Standardized Diagnostics and Staging for a Differentiated Risk Stratification of Non-thyroidal Illness Syndrome|AQUA FONTIS|Ruhr University of Bochum|Yes|Active, not recruiting|May 2007|October 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|590|Samples Without DNA|Kryobase with serum and urine samples|Both|N/A|N/A|No|Non-Probability Sample|Critically ill patients treated at three intensive care units of the Bergmannsheil        university hospitals and that comply with the eligibility criteria.|February 2015|February 12, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591032||162567|
NCT00591344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS028127|The Effect of Exercise on Individuals With Parkinson's Disease|The Effect of Exercise on Individuals With Parkinson's Disease||University of Illinois at Chicago|No|Completed|October 2007|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|50 Years|67 Years|No|||February 2015|February 16, 2015|December 26, 2007||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT00591344||162543|
NCT00592098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-1589 / 2PX-SP-01|2PX (Topical Strontium Chloride Hexahydrate) in Patients With Post-Amputation Stump Pain.|A Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Persistent, Moderate-to-Severe Lower Limb Post-Amputation Stump Pain.||SantoSolve AS|No|Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||December 2007|January 10, 2008|December 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00592098||162485|
NCT00592111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-016|A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)|A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)||Memorial Sloan Kettering Cancer Center||Completed|March 1996|January 2008|Actual|February 1999|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|N/A|21 Years|No|||December 2015|December 21, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592111||162484|
NCT00603486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 348|SuperSTAT Noninvasive Blood Pressure Monitor Evaluation|SuperSTAT Noninvasive Blood Pressure Monitor Evaluation||GE Healthcare|No|Active, not recruiting|November 2007|July 2008|Anticipated|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Neonates in the NICU and newborn areas and/or infants.|July 2008|July 22, 2008|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00603486||161635|
NCT00590954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-044|Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas|Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2006|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590954||162573|
NCT00603785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07030836|Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis|Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test||University of California, San Francisco|No|Withdrawn|January 2008|April 2008|Anticipated|April 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||June 2014|June 10, 2014|January 11, 2008|No|Yes|Insufficient funds available|No||https://clinicaltrials.gov/show/NCT00603785||161612|
NCT00604071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP-V4|Sensitivity of the Home Macular Perimeter (HMP)|Sensitivity of the Home Macular Perimeter (HMP) in the Detection of Visual Field Abnormalities in Patients With Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD)- PILOT Study|HMP|Notal Vision Ltd|Yes|Completed|November 2007|November 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|||Both|50 Years|N/A|No|Probability Sample|62 completed subjects with new choroidal neovascularization AMD in at least one eye|April 2015|April 13, 2015|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00604071||161590|
NCT00592033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-41-0569|Effect of Oxygen in Normoxaemic COPD Patients Who Desaturate During Exercise|Effect of Ambulatory Oxygen in Normoxaemic COPD Patients Who Desaturate During Exercise. A Randomised Placebo Controlled Trial of Patients Who Participate in Pulmonary Rehabilitation||Hvidovre University Hospital|No|Completed|May 2007|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00592033||162490|
NCT00595023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeneSearch BLN Timing Study|GeneSearch Breast Lymph Node (BLN) Assay Timing Study|GeneSearch Breast Lymph Node (BLN) Assay Timing Study||Janssen Diagnostics, LLC|No|Terminated|December 2007|December 2009|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|233|||Both|18 Years|N/A|No|Probability Sample|Intraoperative use of the GeneSearch™ BLN Assay to make a decision for an axillary lymph        node dissection in patients with invasive carcinoma of the breast.|January 2010|January 11, 2016|January 4, 2008|Yes|Yes|GeneSearch™ BLN Assay has been voluntarily withdrawn from the US market.|No||https://clinicaltrials.gov/show/NCT00595023||162263|
NCT00595049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-416|Pulmonary Artery Remodelling With Bosentan|Open Label, Non Comparative Study to Investigate the Effect of Bosentan on Pulmonary Artery Remodelling in Pulmonary Arterial Hypertension (PAH).||Actelion||Completed|May 2006|June 2010|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00595049||162262|
NCT00595062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-101|Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study|Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study||Memorial Sloan Kettering Cancer Center|Yes|Completed|October 2002|July 2013|Actual|January 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|60 Years|N/A|No|||December 2015|December 21, 2015|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00595062||162261|
NCT00595686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1311002|Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies|A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies||Esanex Inc.|No|Completed|January 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595686||162216|
NCT00595699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD-116|Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy|Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy. A Double-blind, Placebo-controlled Study.||Conrad, Erich J., M.D.|No|Completed|November 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||January 2008|July 14, 2011|January 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595699||162215|
NCT00594308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705-20 IUCRO-0196|In-Vivo Activated T-Cell Depletion to Prevent GVHD|In-Vivo Activated T-Cell Depletion to Prevent GVHD||Indiana University|Yes|Terminated|October 2007|||October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||September 2014|September 26, 2014|January 4, 2008||No|Treatment ineffective|No|August 5, 2011|https://clinicaltrials.gov/show/NCT00594308||162318|Four patients experienced grade 3-4 GVHD and this study was stopped.
NCT00594321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715482|Evaluation of Fracture Fixation With Energy and Cement in Tumors of the Spine|Evaluation of Fracture Fixation With Energy and Cement in Tumors of the Spine|EFFECTS|University of California, Davis|Yes|Withdrawn|July 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|December 21, 2007|No|Yes|Sponsor closed the trial before it began|No||https://clinicaltrials.gov/show/NCT00594321||162317|
NCT00596297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBEVI|Preoperative Bevacizumab for Vitreous Hemorrhage|Intra-Operative and Postoperative Intraocular Bleeding After Pars Plana Vitrectomy for Vitreous Hemorrhage in Diabetic Patients Previously Treated With Intravitreal Bevacizumab|IBEVI|University of Sao Paulo|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2008|October 2, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00596297||162170|
NCT00596557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004765|Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up|Phase IV: Effect of Everolimus and CNI Minimalization on Renal Function.|CRAD001AILO2|Rabin Medical Center|No|Completed|February 2008|July 2011|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596557||162150|
NCT00594828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA/05/16|Patient Self Testing of Warfarin Therapy|Randomized Controlled Trial of Patient Self-Testing of Warfarin Therapy Using an Internet Based Expert System||University College Cork|No|Active, not recruiting|July 2006|April 2008|Anticipated|April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2008|January 7, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594828||162278|
NCT00594841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC 02-Nov-07|Non-operative Versus Operative Treatment of Acute Acromioclavicular Joint Dislocation|A Multicenter Randomized Clinical Trial of Non-operative Versus Operative Treatment of Acute Acromioclavicular Joint Dislocation|ACJoint|St. Michael's Hospital, Toronto|No|Completed|January 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|16 Years|65 Years|No|||March 2014|March 19, 2014|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594841||162277|
NCT00590772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2003-114|The Role of Montelukast in Rhinitis and Sleep|Phase 4- The Role of Montelukast on Perennial Rhinitis and Associated Sleep Disturbance and Daytime Somnolence||Penn State University|No|Completed|May 2003|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|16 Years|65 Years|No|||October 2014|October 20, 2014|December 26, 2007||No||No|July 21, 2009|https://clinicaltrials.gov/show/NCT00590772||162587|
NCT00591045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGCCG-0701|Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer|A Randomized Phase II Multicenter Controlled Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer||Peking University|Yes|Not yet recruiting|January 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|263|||Both|30 Years|70 Years|No|||December 2007|January 10, 2008|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00591045||162566|
NCT00591058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM601-007|Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma|A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma||TransMolecular||Active, not recruiting|February 2008|February 2010|Anticipated|February 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|36|||Both|18 Years|N/A|No|||July 2009|July 16, 2009|December 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00591058||162565|
NCT00592176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070323011|The Effect of Bevacizumab (Avastin) on Pterygium|The Effect of Bevacizumab (Avastin) on Pterygium||University of Alabama at Birmingham|No|Completed|August 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|N/A|No|||May 2012|May 20, 2014|December 26, 2007|Yes|Yes||No|May 21, 2012|https://clinicaltrials.gov/show/NCT00592176||162479|Initially we aimed for 10 to 15 subjects but only enrolled 5 subjects.
NCT00592423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-10-3977|CPAP and Lateral Neck Rotation on Anesthetized Children|Effect of Neck Rotation and Continuous Positive Airway Pressure (CPAP) on Upper Airway Anatomy in Anesthetized Children - an MRI Study||Children's Hospital of Philadelphia|No|Terminated|January 2005|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|N/A|5 Years|No|||September 2009|September 14, 2009|January 2, 2008||No|Preliminary data was inconclusive to warrant keeping the study open.|No||https://clinicaltrials.gov/show/NCT00592423||162460|
NCT00592670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#040912-HAAF-T1DM-Q6|Hypoglycemia Associated Autonomic Failure in Type 1 DM|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6||Vanderbilt University|No|Completed|March 2005|October 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00592670||162441|
NCT00592683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000413|Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents|A Randomized Placebo Controlled Clinical Trial of Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents Ages 6-17 With Bipolar Spectrum Disorder||Massachusetts General Hospital|No|Terminated|December 2007|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|6 Years|17 Years|No|||March 2012|March 9, 2012|December 28, 2007|Yes|Yes|Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.|No|July 15, 2011|https://clinicaltrials.gov/show/NCT00592683||162440|
NCT00603174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJ 2537|Use of Neurally Adjusted Ventilatory Assist in Infants Respiratory Failure|Use of Neurally Adjusted Ventilatory Assist in Infants With Acute Respiratory Failure: a Case Study on Servo I|NAVA|St. Justine's Hospital|No|Completed|January 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|12 Months|No|||September 2012|September 18, 2012|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00603174||161659|
NCT00591240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4872R|A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection|A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection||VA Office of Research and Development|No|Completed|July 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients at risk for urinary tract infections.|November 2011|November 17, 2011|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00591240||162551|
NCT00592046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL1001|A Phase I Trial of ZIO-101 in Hematologic Cancers|A Phase I Trial of ZIO-101 in Hematologic Cancers||Ziopharm|Yes|Completed|May 2005|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592046||162489|
NCT00604084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2007/006|Veron Scabies Education and Eradication Program|Veron Scabies Education and Eradication Program|VSEEP|Edward Via Virginia College of Osteopathic Medicine|Yes|Completed|May 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1057|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2009|March 9, 2009|January 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604084||161589|
NCT00604097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-11-3995|Preventing Youth Suicide in Primary Care: A Family Model|Preventing Youth Suicide in Primary Care: A Family Model||Children's Hospital of Philadelphia|Yes|Completed|September 2004|August 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00604097||161588|
NCT00593151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S07-200-02-003|Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C|An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics, and Viral Kinetics of Two Doses of LocteronTM (Poly ActiveTM - Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C|PLUS|Biolex Therapeutics, Inc.|Yes|Completed|January 2008|March 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00593151||162407|
NCT00599274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-862|Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis|A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS)|PROOF|Biogen|Yes|Completed|August 2002|May 2003|Actual|||N/A|Observational|Observational Model: Case-Only||2|Actual|136|||Both|18 Years|50 Years|No|Probability Sample|subjects with relapsing remitting Multiple Sclerosis taking AVONEX® or Rebif®.|January 2010|January 26, 2010|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599274||161948|
NCT00595712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-09-30-4111|Results of Opening-wedge High Tibial Osteotomy Using Iliac Crest Allograft Compared to Iliac Crest Autograft|||Tehran University of Medical Sciences|Yes|Completed|September 2007|February 2010|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|60 Years|No|||May 2010|May 22, 2010|January 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00595712||162214|
NCT00593775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3497|The Effect of Laser Assisted Hatching in Thawing Cycles: a Prospective Randomized Controlled Study|The Effect of Laser Assisted Hatching in Thawing Cycles: a Prospective Randomized Controlled Study||Katholieke Universiteit Leuven|No|Recruiting|February 2006|||July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|540|||Both|18 Years|47 Years|Accepts Healthy Volunteers|||December 2007|January 14, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593775||162359|
NCT00594022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0707-VSOM-MS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2007|||||N/A|N/A|N/A||||||||||||||January 14, 2008|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594022||162340|
NCT00594035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRS-05-001|Study to Evaluate Safety and Effectiveness of Spinal Sealant|A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery||Integra LifeSciences Corporation|Yes|Completed|September 2005|April 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|75 Years|No|||September 2014|September 4, 2014|January 2, 2008|Yes|Yes||No|October 30, 2009|https://clinicaltrials.gov/show/NCT00594035||162339|
NCT00593723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1070 / 201105499|IMRT Tomotherapy for Esophagus Cancer|IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients|IMRT|Washington University School of Medicine|No|Active, not recruiting|December 2006|November 2016|Anticipated|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00593723||162363|
NCT00594607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-04147|Effect of Nephral 400 ST Dialysis Membrane on Coagulation in Hemodialysis|A Comparing Study of Nephral 400 ST and Fx8 Dialysis Membranes on Coagulation During Hemodialysis||Oslo University Hospital|No|Completed|September 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|N/A|No|||May 2008|July 3, 2011|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594607||162295|
NCT00594854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-303|Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec|6-Month, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study of Gastric Ulcer Incidence With PN400 (Esomeprazole/Naproxen) Versus Diclofenac/Misoprostol in Subjects at High Risk for Developing NSAID-Associated Ulcers||POZEN|Yes|Terminated|September 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||August 2010|August 27, 2010|December 19, 2007|Yes|Yes|POZEN agreed with FDA to stop study due to low and inadequate enrollment|No|May 28, 2010|https://clinicaltrials.gov/show/NCT00594854||162276|Early termination due to small number of subjects.
NCT00590759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAG 05-02|Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms|A Clinical Evaluation of the GORE TAG Thoracic Endoprosthesis in the Primary Treatment of Descending Thoracic Aortic Aneurysms||W.L.Gore & Associates|No|Completed|August 2005|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|21 Years|N/A|No|||August 2014|August 6, 2014|December 20, 2007|Yes|Yes||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00590759||162588|
NCT00592137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66108 (completed)|Calcium, Dairy, and Body Fat in Adolescents|Calcium, Dairy, and Body Fat in Adolescents||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|April 2004|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|43|||Both|12 Years|15 Years|No|||January 2010|January 12, 2010|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00592137||162482|
NCT00592397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 4.2005.2187|Prestudy: Lifestyle and Cardiovascular Disease|Prestudy: Lifestyle and Cardiovascular Disease||Norwegian University of Science and Technology|Yes|Completed|March 2006|April 2006|Actual|April 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 2, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592397||162462|
NCT00592410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061022|The Effects of Intensive Insulin on Somatic and Visceral Protein Turnover in Acute Kidney Injury (AKI)|The Effects of Intensive Insulin on Somatic and Visceral Protein Turnover in Acute Kidney Injury (AKI)||Vanderbilt University|No|Withdrawn|February 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2011|August 4, 2011|December 18, 2007||No|no enrollment|No||https://clinicaltrials.gov/show/NCT00592410||162461|
NCT00592436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000239|Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder|A Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder||Massachusetts General Hospital|No|Terminated|March 2003|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|663|||Both|6 Years|17 Years|No|Non-Probability Sample|Children with symptoms of ADHD|May 2015|May 5, 2015|December 28, 2007||No|New protocol developed for recruitment of children for all child studies|No||https://clinicaltrials.gov/show/NCT00592436||162459|
NCT00592449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR054871|Sleep in Osteoarthritis Project|Sleep Disturbance, Central Pain Modulation, and Clinical Pain in Osteoarthritis (The SOAP Study)|SOAP|Johns Hopkins University|Yes|Completed|April 2008|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|6||Anticipated|190|||Both|35 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 10, 2014|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592449||162458|
NCT00592696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16039|TRIAD Project: Qualitative Study of Adolescent Depression and Smoking|TRIAD Project: Qualitative Study of Adolescent Depression and Smoking||Drexel University|No|Completed|December 2006|February 2010|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|||Both|12 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents ages 12-19 who live with their parental guardian who meet criteria for major        depression and who smoke cigarettes.|March 2014|March 27, 2014|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592696||162439|
NCT00594776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15198|Vascular CT Assessment of Structural Autograft and Allograft Healing|Vascular CT Assessment of Structural Autograft and Allograft Healing||University of Rochester|No|Completed|November 2006|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|10 Years|100 Years|No|Non-Probability Sample|Patients are recruited from the general practice of 3 of our investigators. Patients will        have received an structural allograft or vascularized autograft for the treatment of bone        cancer.|February 2016|February 8, 2016|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594776||162282|
NCT00594971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15273887|A Shared Care Approach for Seriously Ill Cancer Patients Between General Practice, Discharge Department and a Specialist Palliative Care Team|A Shared Care Approach for Seriously Ill Cancer Patients Between General Practice, Discharge Department and a Specialist Palliative Care Team||University of Aarhus|Yes|Withdrawn|April 2008|November 2010|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|270|||Both|18 Years|N/A|No|||January 2011|January 10, 2011|January 7, 2008||No|Recruitment problems has forced us to change the design of this study from a clinical trial to    a comparative study of 3 different groups of patients.|No||https://clinicaltrials.gov/show/NCT00594971||162267|
NCT00594984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-025|Phase I/II Combination With Irinotecan- Erbitux|A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs Placebo in Combination With Erbitux and Irinotecan K-Ras Wildtype Subjects With Metastatic Colorectal Cancer||Bristol-Myers Squibb|Yes|Completed|May 2008|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594984||162266|
NCT00590941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0122|Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma|Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma||Washington University School of Medicine|No|Completed|February 2005|April 2011|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590941||162574|
NCT00591214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A3|Safety and PK Study of MP-424 to Treat Chronic Hepatitis C|A Phase I, Open-Label, Single-Dose Study of MP-424 in Patients With Genotype 1b Hepatitis C||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|20 Years|65 Years|No|||April 2014|April 15, 2014|December 26, 2007||No||No|September 19, 2012|https://clinicaltrials.gov/show/NCT00591214||162553|
NCT00592605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84287|Thyroid Disease Serum Repository|Thyroid Disease Serum Repository||University of Arkansas|No|Recruiting|May 2007|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|October 2015|October 1, 2015|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00592605||162446|
NCT00592618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|346147SLEEP|Effect of NAC on Sleep Apnea|||Assaf-Harofeh Medical Center||Not yet recruiting||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|20 Years|85 Years||||May 2007|January 11, 2008|January 1, 2008||||No||https://clinicaltrials.gov/show/NCT00592618||162445|
NCT00593177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAN-PTH (1-34)-USA-002|A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis|A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of 0.10% or 0.05% PTH (1-34) Gel Versus Placebo Gel in the Treatment of Mild to Moderate Plaque Psoriasis.||Manhattan Pharmaceuticals|No|Completed|October 2007|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|65 Years|No|||July 2008|August 18, 2008|January 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593177||162405|
NCT00593190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0097-07-EMC|Intracameral Gas SF6 (Sulfur Hexafluoride) Injection for Acute Hydrops in Keratoconus|||HaEmek Medical Center, Israel|No|Recruiting|January 2008|||December 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00593190||162404|
NCT00593203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030372|Brain Tissue Specimen Collection|Molecular Neurosurgical Tissue Bank||Vanderbilt University|No|Enrolling by invitation|May 2003|||December 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Brain Tissue, blood and cerebral spinal fluid|Both|N/A|N/A|No|Non-Probability Sample|infant through Adults|January 2008|January 2, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00593203||162403|
NCT00595361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002199|How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment|The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma|SECS|Brigham and Women's Hospital|Yes|Completed|January 2008|March 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|50 Years|No|||September 2015|September 21, 2015|January 7, 2008|No|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT00595361||162239|
NCT00595374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1582|Efficacy and Safety of Insulin Detemir in Type 1 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart to Insulin NPH Plus Insulin Aspart in Adults With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|December 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|114|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|January 7, 2008||||No||https://clinicaltrials.gov/show/NCT00595374||162238|
NCT00594009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-142|Venovenous CO2 Removal in Patients With COPD and Acute Respiratory Failure|Safety and Efficacy of Venovenous Carbon Dioxide Removal in Patients With Chronic Obstructive Pulmonary Disease and Acute Respiratory Failure|VVCCO2R|The University of Texas Medical Branch, Galveston|No|Terminated|January 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|December 17, 2007||No|due to loss of key personnel due to illness and sabbatical of thePI|No||https://clinicaltrials.gov/show/NCT00594009||162341|
NCT00594048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.1069|The Effects of Device-guided Breathing Exercises on Blood Pressure in Patients With Hypertension|The Effects of Device-guided Breathing Exercises on Blood Pressure in Patients With Hypertension. A Randomized, Single-blind, Controlled Trial||Medical Research Foundation, The Netherlands|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2011|October 25, 2011|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00594048||162338|
NCT00594594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-213|Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury|A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled Trial for Efficacy in the Use of Adjuntive Probiotic Therapy in Reducing Urinary Tract Infections in Those Individual With Spinal Cord Injury||Lawson Health Research Institute|Yes|Terminated|September 2007|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|2|||Both|18 Years|80 Years|No|||July 2009|July 6, 2009|January 4, 2008||No|Unable to recruit enough patients to continue on with the study.|No||https://clinicaltrials.gov/show/NCT00594594||162296|
NCT00594334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010706|Effect of Actonel on Periodontal Health of Postmenopausal Women|Effect of Actonel on Periodontal Health of Postmenopausal Women||University Hospital Case Medical Center|No|Recruiting|January 2008|January 2011|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|240|||Female|40 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 25, 2009|January 3, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00594334||162316|
NCT00594620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9639|Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy|A Prospective Trial of Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy||University of Kansas Medical Center|No|Completed|August 2004|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Male|18 Years|N/A|No|||May 2011|May 10, 2011|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594620||162294|
NCT00591591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44NS040597|Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers|Absolute Near-Infrared Brain Oximeter|NIRS-OSAS|ISS, Inc.|Yes|Completed|August 2007|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|309|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 10, 2011|December 21, 2007||No||No|September 22, 2010|https://clinicaltrials.gov/show/NCT00591591||162524|
NCT00591864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003397|Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation|Comparison of Magnetic Resonance Imaging and Molecular Breast Imaging in Breast Diagnostic Evaluation|MBI|Mayo Clinic|No|Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|89|||Female|25 Years|N/A|No|||June 2014|June 6, 2014|December 21, 2007||No||No|March 7, 2014|https://clinicaltrials.gov/show/NCT00591864||162503|
NCT00591643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77-030|Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)|Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)||Memorial Sloan Kettering Cancer Center||Completed|July 1977|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|93|||Both|N/A|N/A|No|||December 2015|December 23, 2015|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00591643||162520|
NCT00591877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0045|A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients|A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients||Midwest Biomedical Research Foundation|No|Withdrawn|December 2012|January 2015|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|December 27, 2007||No|Unable to enroll elegible subjects. No subjects enrolled, study closed.|No||https://clinicaltrials.gov/show/NCT00591877||162502|
NCT00591890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBL1003|Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans|Phase IB Study to Evaluate the Biological Activity of Indibulin Using Positron-Emission Tomography (PET) Scans||Ziopharm||Completed|October 2007|March 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591890||162501|
NCT00592150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13072|Effect of Gene Variants on Dopamine Receptor Natriuretic Responses|Effect of Gene Variants on Dopamine Receptor Natriuretic Responses (RMC033)||University of Virginia|No|Active, not recruiting|June 2007|June 2013|Anticipated|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00592150||162481|
NCT00592163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGC1002|Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas|Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas||Ziopharm||Active, not recruiting|December 2007|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592163||162480|
NCT00592462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0539|Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases|Whole Body MRI for Detection of Cancer Metastases||M.D. Anderson Cancer Center|No|Completed|December 2007|||December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Breast cancer patients with a high suspicion or confirmed bone metastases.|December 2015|December 7, 2015|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00592462||162457|
NCT00592475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-089|A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients|A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic Patients||Cumberland Pharmaceuticals|No|Completed|December 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|January 2, 2008|Yes|Yes||No|May 24, 2010|https://clinicaltrials.gov/show/NCT00592475||162456|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00592709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030258|Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry|Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry||Vanderbilt University|No|Completed|May 2003|||December 2010|Actual|N/A|Observational|N/A||1|Anticipated|150|Samples With DNA|Brain Tissue|Both|2 Years|85 Years|No|Non-Probability Sample|Age 2 years through Age 85 years old|June 2013|June 14, 2013|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592709||162438|
NCT00594997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P001033|A School-Based Intervention to Reduce Lyme Disease|A School-Based Intervention to Reduce Lyme Disease||Brigham and Women's Hospital|No|Active, not recruiting|April 2004|December 2015|Anticipated|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4101|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594997||162265|
NCT00595010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH076972|Effectiveness of a Multi-Component Evidence-Based Parent Training Program in Reducing Child Maltreatment|Developing Multi-Component Evidence Based Practice in Child Abuse Service Systems||University of Oklahoma|Yes|Active, not recruiting|September 2007|November 2012|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|94|||Both|N/A|N/A|No|||January 2012|January 19, 2012|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00595010||162264|
NCT00591526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL2000|A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)|A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed Acute Promyelocytic Leukemia (APL)||Groupe d'etude et de travail sur les leucemies aigues promyelocytaires|Yes|Completed|June 2000|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|250|||Both|N/A|N/A|No|||January 2008|January 11, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00591526||162529|
NCT00591253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-491-011|Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension||Takeda|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|413|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|December 27, 2007|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00591253||162550|
NCT00591266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-491-010|Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Amlodipine 5 mg in Subjects With Essential Hypertension||Takeda|No|Completed|October 2007|April 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|566|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|December 27, 2007|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00591266||162549|
NCT00591513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-672|Autologous Engineered Skin Substitutes for Closure of Skin Wounds|Autologous Engineered Skin Substitutes for Closure of Burn Wounds||University of Cincinnati||Terminated|February 1998|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|144|||Both|N/A|75 Years|No|||July 2015|July 14, 2015|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591513||162530|
NCT00591747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1836|Strength Training for Older Breast Cancer Survivors|Strength Training for Older Breast Cancer Survivors||OHSU Knight Cancer Institute|Yes|Completed|November 2005|June 2011|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|106|||Female|50 Years|90 Years|No|||May 2015|May 26, 2015|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00591747||162512|
NCT00600080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0729|A Comparison of Two Daily Disposable Contact Lenses|The Comparative Clinical Performance of the Etafilcon A Lens and the DAILIES AquaComfort Plus Lens||Johnson & Johnson Vision Care, Inc.|No|Completed|December 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|December 21, 2007|Yes|Yes||No|October 20, 2011|https://clinicaltrials.gov/show/NCT00600080||161887|
NCT00593229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71221|International Registry and Biorepository for TMA(Thrombotic Microangiopathy)|An Observational Study of All Forms of Thrombotic Microangiopathy in Pediatric Patients||Northwell Health|No|Terminated|January 2007|||October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|6|Samples With DNA|Serum, plasma, urine, and DNA|Both|6 Months|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric patients, 6 months - 18 years|June 2013|June 18, 2013|January 2, 2008||No|study stopped at this site, as investigator left the institution|No||https://clinicaltrials.gov/show/NCT00593229||162401|
NCT00595387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P001521|Effectiveness of Cognitive Behavioral Therapy for Treating Depression in People With Bipolar I Disorder|Cognitive-Behavior Therapy for Bipolar Disorder||Massachusetts General Hospital|Yes|Completed|September 2006|January 2013|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|64 Years|No|||April 2015|April 28, 2015|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00595387||162237|
NCT00594373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFV 010|Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women|Effect of Repeated Applications of Tenofovir Gel on Mucosal Mediators of Immunity and Intrinsic Antimicrobial Activity of Cervicovaginal Secretions in Women at Low Risk for HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed||April 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00594373||162313|
NCT00590785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-041|Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)|Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 1996|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|N/A|No|||November 2015|November 25, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590785||162586|
NCT00594347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNA19|Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar|Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal Vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed With Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) in Thailand.||Sanofi|Yes|Completed|November 2007|April 2009|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|339|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||June 2015|June 16, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00594347||162315|
NCT00594360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36/154-150775|Evaluation of Effect of Exercise on Prescription - a Psychological Perspective|Exercise on Prescription: Effects and Comparison of Psychological Parameters Physical Activity, Physical Fitness, and Health Physical Between Participants in a Danish Version of Exercise on Prescription.|EoP|University of Southern Denmark|Yes|Active, not recruiting|November 2005|May 2008|Anticipated|May 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2007|January 3, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594360||162314|
NCT00591604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-250|High-Dose Vitamin D Deficiency in Burn Injury|Use of High-Dose Vitamin D to Treat Vitamin D Deficiency Following Severe Burn Injury in Children I: A Pilot Study|VitaminD|The University of Texas Medical Branch, Galveston|No|Withdrawn|February 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|5 Years|18 Years|No|||November 2012|November 13, 2012|December 26, 2007||No|hurricane caused closure of hospital with PI not associated with Shriners Hospital for    children|No||https://clinicaltrials.gov/show/NCT00591604||162523|
NCT00591617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA020210|Optimizing Outcomes Using Suboxone for Opiate Dependence|Optimizing Outcomes Using Suboxone for Opiate Dependence|OpBup|University of California, Los Angeles|Yes|Completed|September 2006|December 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|202|||Both|15 Years|N/A|No|||January 2013|January 28, 2013|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00591617||162522|
NCT00591656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sece-2|Systemic Consolidation Therapy After Primary Chemoradiation Therapy for Locally Advanced Cervical Cancer|A Phase II Study of Systemic Consolidation Therapy With Paclitaxel Plus Carboplatin Following Primary Chemoradiation for Locally Advanced Cervical Cancer||Seoul National University Hospital|Yes|Recruiting|November 2007|November 2012|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|69|||Female|20 Years|80 Years|No|Probability Sample|Care clinic|December 2007|December 31, 2007|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00591656||162519|
NCT00592189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-209|Study of Donated Amnion, Fetal Placental Membrane, as Skin Substitute for Burn Patients|Fetal Membrane as a New Coverage Material|Amnion|The University of Texas Medical Branch, Galveston|No|Completed|December 1999|June 2014|Actual|June 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1164|||Female|16 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00592189||162478|
NCT00592202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0732|Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents|Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents||University of Illinois at Chicago|No|Completed|December 2004|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|14 Years|17 Years|No|||March 2014|March 31, 2014|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592202||162477|
NCT00593320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0658|Stereotactic Radiosurgery (SRS) for Spine Metastases|Stereotactic Radiosurgery (SRS) for One or Two Localized Spine Metastases|SRS|Washington University School of Medicine|No|Terminated|September 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|January 2, 2008|Yes|Yes|Due to low accrual|No|February 18, 2015|https://clinicaltrials.gov/show/NCT00593320||162394|
NCT00592722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN100b|A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients|A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients||China Spinal Cord Injury Network|No|Completed|December 2007|March 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|60 Years|No|Non-Probability Sample|Hospital|July 2009|July 2, 2009|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592722||162437|
NCT00592735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVH H06/151|Effects of Medical and Surgical Weight Loss on Metabolism|The Role of Adipocyte-Derived Inflammatory Cytokines in the Pathogenesis of Diabetes, Dyslipidaemia, Atherosclerosis and Gastro-Oesophageal Reflux Disease: the Effects of Medical and Surgical Weight Loss|BOS|Garvan Institute of Medical Research|No|Recruiting|May 2007|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|serum, tissue|Both|18 Years|70 Years|No|Non-Probability Sample|morbidly obese subjects with type 2 diabetes or metabolic syndrome|January 2008|January 11, 2008|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00592735||162436|
NCT00591760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH replacement in CHF|Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial|Correction of Growth Hormone Deficiency in Patients With Chronic Heart Failure: a Randomized, Controlled, Single-blind Study||Federico II University|No|Completed|December 2004|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|80 Years|No|||March 2009|October 17, 2012|December 20, 2007||No||No|March 23, 2009|https://clinicaltrials.gov/show/NCT00591760||162511|
NCT00591773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-491-009|Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension||Takeda|No|Completed|September 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|551|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|December 27, 2007|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00591773||162510|
NCT00603837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13223|Warming Mattress Versus Polyethylene Wrapping to Prevent Hypothermia in Preterm Newborns.|Thermal Defense of Extremely Low Gestational Age Newborns (ELGANs) During Resuscitation: Exothermic Mattresses vs. Polyethylene Wrap||University of Oklahoma|Yes|Completed|May 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|24 Weeks|28 Weeks|Accepts Healthy Volunteers|||October 2009|October 12, 2009|December 19, 2007|Yes|Yes||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00603837||161608|Technical difficulties with the polyethylene wrap were the main limitations (variation of use, heat loss during pulse oximeter adjustment).
NCT00592306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG in Lung Transplantation|Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation|A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.||University of California, Los Angeles|Yes|Recruiting|January 2006|September 2009|Anticipated|September 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|65 Years|No|||June 2008|June 4, 2008|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592306||162469|
NCT00592592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-188|Proton RT for the Treatment of Pediatric Rhabdomyosarcoma|A Phase II Trial of Proton RT for the Treatment of Pediatric Rhabdomyosarcoma||Massachusetts General Hospital|Yes|Recruiting|October 2004|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|21 Years|No|||February 2016|February 25, 2016|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592592||162447|
NCT00600431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Melanocytic Nevi in Children Under Chemotherapy|Melanocytic-Nevi-Counts During Chemotherapy of Children With Malignancies.||Medical University of Graz|No|Completed|February 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study group: children suffering from malignancies requiring chemotherapy were recruited        consecutively at the department of pediatric oncology        Control group: children were recruited consecutively at our department for pigmented skin        lesions at the department of dermatology|January 2008|January 24, 2008|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600431||161861|
NCT00593242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000412|Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy|Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study 1. Phase I Study of Feasibility and Safety.||Duke University|No|Active, not recruiting|January 2008|March 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|N/A|14 Days|No|||March 2016|March 11, 2016|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00593242||162400|
NCT00593736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-375-044|Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals With Delayed Sleep Phase Syndrome (DSPS)||Takeda|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|132|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|January 2, 2008|Yes|Yes||No|July 31, 2009|https://clinicaltrials.gov/show/NCT00593736||162362|
NCT00593749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEP - 10520|Healthy Corner Store Initiative|Healthy Corner Store Initiative|HCSI|Temple University|No|Completed|September 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|5 Years|15 Years|No|||January 2008|June 28, 2013|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593749||162361|
NCT00593489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-851|Advancing Insulin Prescribing in General Practice|Advancing INSIGHT Methods in General Practice|AIM@GP|Lawson Health Research Institute|No|Active, not recruiting|July 2006|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|240|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593489||162381|
NCT00593502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV21118|Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age|A Double-Blind, Randomized, Placebo-Controlled Study of Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age|ETOPOM|Hospital District of Southwestern Finland|Yes|Completed|February 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|409|||Both|1 Year|3 Years|No|||June 2009|June 18, 2009|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593502||162380|
NCT00593762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E 19/05|ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures|Investigation of Laboratory Resistance to Aspirin and Clopidogrel and Its Clinical Relevance in Patients With Peripheral Arterial Occlusive Disease Requiring Interventional Procedures||Johann Wolfgang Goethe University Hospitals|No|Suspended|May 2005|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood, serum|Both|18 Years|85 Years|No|Non-Probability Sample|patients with peripheral arterial occlusive disease (PAOD) requiring a catheter        interventional procedure|January 2008|March 15, 2010|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593762||162360|
NCT00590798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRUT|Star-Close Early Ambulation Trial|Star-Close Early Ambulation Trial|STRUT|Ohio State University|No|Completed|April 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|58|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590798||162585|
NCT00591357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21387|Efficacy of Loperamide in Treating Patients for C. Difficile Colitis and Diarrheal Disease of Unknown Cause Associated With Antibiotic Therapy|Study of the Efficacy of Loperamide in Treating Patients for Clostridium Difficile Colitis and Diarrheal Disease of Unknown Cause Associated With Prior Antibiotic Therapy.|loperamide|VA Medical Center, Houston|No|Recruiting|October 2007|||December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2007|January 16, 2008|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00591357||162542|
NCT00591409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05956|A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.208A)(P05956)(COMPLETED)|A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part A: Japanese Subjects||Merck Sharp & Dohme Corp.|No|Completed|January 2006|December 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|100|||Both|20 Years|65 Years|No|||August 2015|August 4, 2015|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591409||162538|
NCT00591071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|432|Impact of 2 Blood Glucose Levels on Hospital Mortality in Patients Admitted in ICU|Multicentre Randomized Trial Assessing the Impact of Maintaining 2 Blood Glucose Levels on Hospital Mortality in Patients Admitted to the ICU (INSUREA STUDY)|INSUREA|Poissy-Saint Germain Hospital|Yes|Recruiting|January 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||December 2007|February 13, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00591071||162564|
NCT00591630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1018|Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation|Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2007|||November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|70 Years|No|||February 2016|February 18, 2016|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591630||162521|
NCT00592215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010268|Second Trimester Labor Induction|A Pilot Study of Mifepristone Followed by Misoprostol in Women Undergoing Second Trimester Abortion||Johns Hopkins University|Yes|Terminated|March 2008|October 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 9, 2009|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00592215||162476|
NCT00593619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB13767|Trial Comparing the Safety of Two Different Intravenous Iron Formulations|A Randomized Double-Blind Safety Comparison of Intravenous Iron Dextran Versus Iron Sucrose in an Adult Non-Hemodialysis Outpatient Population: A Pilot Study||London Health Sciences Centre|Yes|Suspended|January 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2009|March 2, 2009|January 3, 2008||No|Interim Analysis and review by Data Safety Monitoring Board|No||https://clinicaltrials.gov/show/NCT00593619||162371|
NCT00593333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F030211012|Intramedullary Nailing of the Femur:Trochanteric vs Piriformis Starting Portals|Intramedullary Nailing of the Femur: A Comparison of the Trochanteric and Piriformis Starting Portals|TROCHNAIL|University of Alabama at Birmingham|No|Completed|June 2003|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|19 Years|N/A|No|||August 2012|September 5, 2013|December 20, 2007|No|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00593333||162393|
NCT00603564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPOVeRSO 01|Helmet Continuous Positive Airway Pressure Versus Oxygen Venturi in Acute Respiratory Failure in CAP: CAPOVeRSO|A Comparison of CPAP Delivered by Helmet and O2 Therapy With Venturi Mask for the Treatment of Acute Respiratory Failure in Community-acquired Pneumonia|CAPOVeRSO|University of Milan|Yes|Terminated|January 2006|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||October 2009|October 26, 2009|January 16, 2008||No|The study was prematurely interrupted because patients randomized to CPAP reached the endpoint    quicker than anticipated in the protocol|No|September 11, 2009|https://clinicaltrials.gov/show/NCT00603564||161629|Limitations of our study are mainly related to the early reaching of the end-point of the CPAP group. We were not able to evaluate the safety of the CPAP application and to address conclusions on its efficacy on outcomes.
NCT00604201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080046|Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome|Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|4 Years|75 Years|No|||June 2015|March 11, 2016|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604201||161580|
NCT00599599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH071201-01A1|Stress-Reducing Interventions in HIV+ Patients: Pilot|Pilot Intervention for PTSD, Nonadherence, and HIV Risk|PEACH|Kent State University|Yes|Active, not recruiting|April 2005|February 2010|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2009|March 4, 2009|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599599||161924|
NCT00599612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107806|To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males|An Open Label Study to Determine the Safety, Tolerability, Excretion Balance and Pharmacokinetics of [14C]GW856553, Administered as a Single Dose of an Oral Solution to Healthy Adult Male Subjects.||GlaxoSmithKline|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|6|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599612||161923|
NCT00591786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05957|A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.209A)(P05957)(COMPLETED)|A Multi -Center, Randomized, Open -Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at 1-2 PTC After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part A: Japanese Subjects.||Merck Sharp & Dohme Corp.|No|Completed|December 2005|October 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|65 Years|No|||August 2015|August 4, 2015|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591786||162509|
NCT00592059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sece-1|Systemic Consolidation Therapy After Chemoradiation Therapy Following Operation for High Risk Early Stage Cervical Cancer|A Phase II Study of Systemic Consolidation Therapy With Paclitaxel Plus Carboplatin Following Radical Hysterectomy and Adjuvant Chemoradiation for High Risk Early Stage Cervical Cancer||Seoul National University Hospital|Yes|Recruiting|November 2007|November 2012|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|77|||Female|20 Years|75 Years|No|Probability Sample|Care clinic|December 2007|December 31, 2007|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592059||162488|
NCT00593216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25852|Diagnosis Of Vertigo With New Imaging|New Diagnosis Of Vestibular Vertigo With Functional MRI||Boston University|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|June 2011|June 21, 2011|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00593216||162402|
NCT00593528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIC07-JMP/TIPS-PTFE|PTFE Covered Stents Versus Naked Stents in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)|Randomized Study With Medico-economic Evaluation Comparing the Use of PTFE Covered Stents vs Naked Stent in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)||University Hospital, Tours|No|Completed|February 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00593528||162378|
NCT00593515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F31MH064999|Effects of Parental Behavior on Child Anxiety Regulation|Effects of Parental Behavior on Child Anxiety Regulation||University of California, Los Angeles|No|Completed|March 2000|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|6 Years|13 Years|No|||January 2008|January 3, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593515||162379|
NCT00593788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113 / 02|The Gaps-in-Noise Test: Gap Detection Thresholds in Normal-Hearing Young Adults|The Gaps-in-Noise Test: Gap Detection Thresholds in Normal-Hearing Young Adults||University of Sao Paulo|No|Completed|March 2003|June 2004|Actual|June 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|31 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal-hearing adults between 18 and 31 years of age were evaluated, including 50 males        (mean age 24.72 years) and 50 females (mean age 23.77 years). The youngest male subject        was 18 years old, and the youngest female subject was 18.16 years old. In contrast, the        oldest male subject was 31.5 years old, and the oldest female subject was 31.83 years old.        All of the participants in the study were students or employees of the University of        Guarulhos.|January 2008|January 14, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593788||162358|
NCT00594867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACETAASA|The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers|Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.||University of Illinois at Chicago|No|Completed|December 2006|November 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2007|January 4, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00594867||162275|
NCT00594880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIDS-ES 10401|Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection|Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection||The Wistar Institute|Yes|Completed|January 2008|May 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||January 2015|January 28, 2015|January 4, 2008|Yes|Yes||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00594880||162274|The follwing limitations of this study should be noted:Small number of participants enrolledLack of a control arm interrupting ART without immunotherapy
NCT00590811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC - 14/11/2007|Prevalence of Menstrual Cycle Related Pain Complains in Adolescents and Young Adults|Prevalence of Menstrual Cycle Related Pain Complains in Adolescents and Young Adults||University Hospital, Gasthuisberg|No|Completed|January 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Anticipated|200|||Female|12 Years|25 Years|No|Non-Probability Sample|3rd year high school girls and 1st year university young females having a routine visit to        the school doctor or student doctor.|January 2010|August 31, 2010|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00590811||162584|
NCT00590824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2007-0087|Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma|A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma||University of Wisconsin, Madison|Yes|Active, not recruiting|December 2007|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|15 Years|N/A|No|||June 2015|June 3, 2015|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590824||162583|
NCT00591903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908037|Pilot Study to Assess the Proteome in Human Atrial Tissue|Pilot Study to Assess the Proteome in Human Atrial Tissue||National Institutes of Health Clinical Center (CC)||Completed|December 2007|September 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|80 Years|No|||September 2011|September 24, 2011|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00591903||162500|
NCT00591916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-388|New Treatment for Donor Sites|New Treatment for Donor Sites|Donors|The University of Texas Medical Branch, Galveston|No|Withdrawn|January 2006|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|N/A|90 Years|No|||December 2012|December 10, 2012|December 26, 2007|Yes|Yes|Donor site material (scarlet red ) came back on the market, therefore new treatements for    donor sites was not needed.|No||https://clinicaltrials.gov/show/NCT00591916||162499|
NCT00592748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-533|Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine|Randomized Study of Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine||Massachusetts General Hospital|Yes|Active, not recruiting|June 1999|||January 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592748||162435|
NCT00593060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-172|Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer|A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer||Massachusetts General Hospital|Yes|Completed|October 2007|October 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593060||162414|
NCT00593073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10174|Use of Novel Tailored Reminders in Rural Primary Care|Use of Novel Tailored Reminders in Rural Primary Care||University of Kansas Medical Center|Yes|Completed|July 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|707|||Both|50 Years|N/A|No|||September 2008|September 10, 2008|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00593073||162413|
NCT00593346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-1205 / 201011816|Evaluation of Accelerated Partial Breast Brachytherapy|Evaluation of Accelerated Partial Breast Brachytherapy as the Sole Method of Radiation Therapy for Stage 0, 1 and II Lymph Node Negative Breast Carcinoma||Washington University School of Medicine|No|Completed|March 2004|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|January 2, 2008|Yes|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00593346||162392|
NCT00593086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-06-024|Virtual Reality in Burn Pain Management|The Use of Virtual Reality Video Games to Control Procedural Pain During Burn Wound Care||United States Army Institute of Surgical Research|No|Completed|June 2007|June 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||February 2013|February 25, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00593086||162412|
NCT00593099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26254|A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder|A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder||National Institute on Drug Abuse (NIDA)|No|Completed|April 2004|June 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||December 2007|December 28, 2007|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00593099||162411|
NCT00604214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11940|Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock||Eli Lilly and Company|Yes|Completed|March 2008|February 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1696|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|January 24, 2008|Yes|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00604214||161579|
NCT00600444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSC01/08|PORTAS 2, Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port|Randomized Controlled Trial Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port|PORTAS2|Heidelberg University|No|Completed|February 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||May 2008|January 26, 2010|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600444||161860|
NCT00600652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061210|FCM Analysis GR in Steroid-Treatment Patients|Flow Cytometric Analysis of Glucocorticoid Receptor Using Monoclonal Antibody and Fluoresceinated Ligand Probes in Glucocorticoid-Resistant and -Sensitive Patients||Changhai Hospital|Yes|Enrolling by invitation|December 2006|||December 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|150|Samples With DNA|introcellular and exocellular proteins in peripheral blood mononuclear cells of subjects|Both|15 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|one hundred patients, including 50 SLE and 50 NS, who will receive GC therapy, were        studied. Of them, fifty were GC-resistant patients (25 male and 25 female; 20 without        treatment and 30 relapse) and fifty were GC-sensitive ones( 25 male and 25 female; 20        without treatment and 30 relapse ). Controls were 50 healthy volunteers (25 male and 25        female). All participants gave their informed consent, and this investigation was approved        by Changhai hoapital ethics committee.|January 2008|January 24, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00600652||161844|
NCT00600665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|420|Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease|Computerized PAINRelieveIt for Adult Sickle Cell Disease||University of Illinois at Chicago|No|Completed|February 2007|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|279|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600665||161843|
NCT00604162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-53|PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon|Evaluation of PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon|MA-53|Given Imaging Ltd.|No|Completed|October 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|332|||Both|18 Years|75 Years|No|||August 2010|June 10, 2012|January 24, 2008||No||No|July 7, 2010|https://clinicaltrials.gov/show/NCT00604162||161583|
NCT00604175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5240|Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women|A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2008|November 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|319|||Female|13 Years|45 Years|No|||August 2015|August 11, 2015|January 17, 2008|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT00604175||161582|
NCT00604188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05042|A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)|A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users||Merck Sharp & Dohme Corp.|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|188|||Both|15 Years|N/A|No|||June 2015|June 23, 2015|January 17, 2008||No||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00604188||161581|
NCT00599586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006CB5045011|Randomized Controlled Trial of Treating Migraine With Acupuncture|Randomized Controlled Trial of Treating Migraine With Acupuncture||Chengdu University of Traditional Chinese Medicine|Yes|Completed|November 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|480|||Both|18 Years|65 Years|No|||June 2010|June 27, 2010|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00599586||161925|
NCT00599872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLIT07-01|Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies|Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused By Ragweed Pollen||Greer Laboratories|No|Completed|March 2008|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|430|||Both|18 Years|50 Years|No|||December 2014|January 6, 2015|December 20, 2007|Yes|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00599872||161903|
NCT00592943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001659|PET Study Examining the Dopaminergic Activity of Armodafinil in Adults|A PET Study Examining the Dopaminergic Activity of Armodafinil in Adults||Massachusetts General Hospital|No|Completed|October 2007|May 2010|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|December 28, 2007|Yes|Yes||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00592943||162422|Extracellular dopamine could compete with [11C] altropane, causing an overestimation of DAT occupancy. Time between scans and menstrual cycle could be sources of variability. Brain pathology although unlikely in normal subjects, is possible.
NCT00592969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1570|Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes|Evaluation of Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart or Insulin NPH in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|December 2003|November 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|164|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|January 2, 2008||||No||https://clinicaltrials.gov/show/NCT00592969||162421|
NCT00594399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-252|Enhancing Fitness in Older Pre-diabetic Veterans|Enhancing Fitness in Older Overweight Vets With Impaired Fasting Glucose||VA Office of Research and Development|No|Completed|October 2008|June 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|302|||Both|60 Years|N/A|No|||August 2014|April 6, 2015|January 3, 2008||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00594399||162311|
NCT00593801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12008|Erythropoietin Treatment in Extremely Low Birth Weight Infants|Multicentre, Blinded, Randomised, Controlled Study on the Efficacy and Safety of Early or Late Epoetin Beta Treatment in Premature Infants (500- 999g Birth Weight)for Prevention or Treatment of Anaemia of Prematurity|EPO|Charite University, Berlin, Germany|Yes|Completed|May 1998|June 1999|Actual|June 1999|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|219|||Both|N/A|3 Days|No|||January 2008|January 4, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593801||162357|
NCT00594061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA/NU G070130-S001|Iowa/Nucleus 10/10 mm and Nucleus Freedom Feasibility Study|Iowa/Nucleus 10/10 mm and Nucleus Freedom Cochlear Implants Implanted Bilaterally in Children Ages 12-24 Months||University of Iowa|Yes|Enrolling by invitation|December 2007|May 2020|Anticipated|May 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||June 2015|June 4, 2015|January 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594061||162337|
NCT00590837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/13|Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old|Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old|LAM-SA 2007|University Hospital, Bordeaux|Yes|Completed|February 2008|December 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|459|||Both|60 Years|N/A|No|||April 2014|April 1, 2014|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00590837||162582|
NCT00591084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing-001|Ginsenoside-Rd for Acute Ischemic Stroke|Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke: A Randomized, Double-blind, Placebo-controlled, Phase Ⅱ, Multicenter Trial||Xijing Hospital|Yes|Completed|September 2005|September 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|199|||Both|18 Years|75 Years|No|||December 2007|August 30, 2010|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00591084||162563|
NCT00591669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11971|Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography|Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography||University of Virginia|No|Terminated|May 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|10|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|December 26, 2007|Yes|Yes|Data storage damage plus unexpected loss of funding|No||https://clinicaltrials.gov/show/NCT00591669||162518|
NCT00591682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0407|MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors|Phase I Dose Escalation Study to Determine the Safety and Pharmacokinetics of MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors||Metastatix, Inc.|No|Suspended|November 2007|March 2009|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||March 2008|March 24, 2008|December 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00591682||162517|
NCT00591370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-138|Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma|Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma||Memorial Sloan Kettering Cancer Center|Yes|Completed|January 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|16 Years|N/A|No|||October 2015|October 17, 2015|December 26, 2007|No|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT00591370||162541|
NCT00591383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBL1004|Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors|Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors||Ziopharm||Active, not recruiting|January 2008|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591383||162540|
NCT00591396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL1002|A Phase I Trial of ZIO-101 in Solid Tumors|A Phase I Trial of ZIO-101 in Solid Tumors: Protocol # SGL1002||Ziopharm||Completed|July 2005|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591396||162539|
NCT00591929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-12-06-03|Use of Continuous Passive Motion in the Post-Operative Treatment of Intra-articular Knee Fractures|Use of Continuous Passive Motion in the Post-Operative Treatment of Intra-articular Knee Fractures||Greenville Health System|No|Completed|December 2006|March 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||March 2013|March 11, 2013|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00591929||162498|
NCT00592228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0706-026-210|Proper Fractional Flow Reserve Criteria for Intermediate Lesions in the Era of Drug-eluting Stent|Deferral of Angioplasty According to Fractional Flow Reserve vs. Routine Drug-eluting Stent Implantation in Intermediate Coronary Stenosis|DEFER-DES|Seoul National University Hospital|Yes|Terminated|January 2007|January 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2010|December 20, 2010|December 17, 2007||No|due to slow enrollment|No||https://clinicaltrials.gov/show/NCT00592228||162475|
NCT00592488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050730|Acetyl-L-Carnitine in the Treatment of Septic Shock|Prospective, Randomized, Placebo-controlled, Double-Blinded, Phase II Pilot Study of Acetyl-L-carnitine in the Treatment of Patients With Septic Shock|ALC|Vanderbilt University|No|Completed|August 2006|September 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|January 2, 2008|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00592488||162455|
NCT00592800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-1-5125|Understanding Probability in Children|Evaluation of the Understanding of Probability in Children||Children's Hospital of Philadelphia|No|Terminated|August 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|165|||Both|11 Years|18 Years|No|Probability Sample|This prospective study will involve one or two encounters with each child and a parent at        the Anesthesia Resource Center (ARC) at The Children's Hospital of Philadelphia (CHOP) and        the second visit at CHOP during the post-operative phase of recovery prior to discharge        from the hospital.|September 2009|September 14, 2009|January 2, 2008||No|Lack of study funding & resources|No||https://clinicaltrials.gov/show/NCT00592800||162432|
NCT00598364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSUeIRB2844|Molecular Markers in Thyroid Cancer|Molecular Markers in the Diagnostic and Prognostic Evaluation of Thyroid Cancer||OHSU Knight Cancer Institute|No|Completed|February 2007|October 2010|Actual|October 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|847|||Both|1 Year|N/A|No|Non-Probability Sample|Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent        thyroidectomy and/or neck dissection as standard of care.|December 2014|December 5, 2014|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598364|13 Years|162015|
NCT00600457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOPS-1|Modified Polyurethane Film Dressing For Skin Graft Donor Sites|Modified Polyurethane Film Dressing For Skin Graft Donor Sites||Klinik Bogenhausen|No|Completed|March 2007|September 2007|Actual|August 2007|Actual|N/A|Observational|N/A||1|Actual|30|||Both|18 Years|N/A|No|||December 2008|December 15, 2008|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00600457||161859|
NCT00600470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH063272|Effectiveness of Collaborative Services in Primary Care for Treating Children With Behavior Disorders|Collaborative Mental Health Services for Behavior Disorders in Primary Care|SKIP|University of Pittsburgh|Yes|Completed|September 2000|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|858|||Both|5 Years|12 Years|No|||May 2015|May 29, 2015|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00600470||161858|
NCT00600691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01188|The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy|The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy||University of British Columbia|No|Terminated|March 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|29|||Male|N/A|N/A|No|||January 2014|January 29, 2014|January 14, 2008||No|Did not achieve enrollment goal and decided to terminate early|No||https://clinicaltrials.gov/show/NCT00600691||161841|
NCT00600990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKO101287|Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients|See Detailed Description||GlaxoSmithKline|No|Completed|December 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|624|||Female|18 Years|55 Years|No|||April 2015|April 14, 2015|January 15, 2008||||||https://clinicaltrials.gov/show/NCT00600990||161818|
NCT00599885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TELLME|Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes|||Korea University Anam Hospital||Completed|September 2007|||July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|80 Years|No|||September 2015|September 2, 2015|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599885||161902|
NCT00600093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4332|Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine|Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine||Rabin Medical Center|No|Terminated|January 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||July 2011|July 24, 2011|January 13, 2008||No|PI leaving the institute for a fellowship.|No||https://clinicaltrials.gov/show/NCT00600093||161886|
NCT00593255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1634|Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes|A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficiency and Safety Profile of Insulin Aspart (NovoRapid®) and Human Soluble Insulin (Novolin® R) as Meal Related Insulin in a Three Times Daily Regimen With One Injection of Novolin® N at Bedtime in Chinese Type 1 and 2 Diabetics||Novo Nordisk A/S|No|Completed|July 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|220|||Both|18 Years|65 Years|No|||May 2012|May 24, 2012|January 2, 2008||||No||https://clinicaltrials.gov/show/NCT00593255||162399|
NCT00594074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008809|Alcohol in the Treatment of Obesity|Alcohol in the Treatment of Obesity||Duke University|No|Terminated|April 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|18|||Female|21 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 23, 2013|January 4, 2008||No|Unable to recruit subjects|No||https://clinicaltrials.gov/show/NCT00594074||162336|
NCT00594087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 05-255|Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)|Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime Fatigue||University of Vermont|Yes|Completed|December 2006|June 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|64 Years|No|||December 2008|December 31, 2008|January 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594087||162335|
NCT00594412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080034|MRI to Measure Liver Fat Content|Validation of (1)H-Magnetic Resonance Spectroscopy for Quantification of Hepatic Triglyceride Content||National Institutes of Health Clinical Center (CC)||Completed|December 2007|June 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|53|||Both|18 Years|N/A|No|||June 2011|September 26, 2015|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594412||162310|
NCT00594893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDV-05061503|Study Comparing Mini-Incision Versus 2-Incision Approach for Total Hip Replacement|A Prospective Randomized Trial of Mini Incision and 2-Incision Total Hip Arthroplasty||Rush University Medical Center|No|Completed|June 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594893||162273|
NCT00590850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-07-03-04|Non-Operative Versus Operative Treatment for High-Energy Midshaft Clavicle Fractures|A Multicenter, Prospective, Randomized Trial of Non-Operative Versus Operative Treatment for High-Energy Midshaft Clavicle Fractures||Greenville Health System|No|Enrolling by invitation|October 2003|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|85 Years|No|||February 2016|February 10, 2016|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590850||162581|
NCT00591422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGC1001|Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas|Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas||Ziopharm||Active, not recruiting|August 2007|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591422||162537|
NCT00591097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2005-1376|Normal Reference Ranges for Urinary Metabolites and Supersaturation Indices in Pediatric Populations|Determining Normal Reference Ranges for Urinary Metabolites and Supersaturation Indices in the Pediatric Population||University of Wisconsin, Madison|No|Completed|October 2006|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|||Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|All normal, healthy volunteer children between the ages of 3 and 18, inclusive, with no        personal or first relative family history of urolithiasis. Both boys and girls will be        enrolled with an effort to enroll an equal number of children of all ages after toilet        training.|December 2013|December 17, 2013|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00591097||162562|
NCT00591942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ivoclar Vivadent Crown-Bridge|Outcome Evaluation of Ceramic Crowns Using Two Different Dental Cements|Outcome Evaluation of All Ceramic Crowns and Fixed Partial Dentures Bonded With Two Different Dental Cements.||University of Iowa|No|Completed|November 2004|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591942||162497|
NCT00592241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-UA-01|Self Operating of the ADI Insulin Pump By Intended Users - A Usability Study|Self Operating of the ADI Insulin Pump By Intended Users - A Usability Study||NiliMedix|Yes|Completed|November 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|April 6, 2008|December 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00592241||162474|
NCT00592761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03DC004942|Treatment of Dysphagia Using the Mendelsohn Maneuver|Treatment of Dysphagia Using the Mendelsohn Maneuver||University of Arkansas|No|Completed|July 2003|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|N/A|No|||July 2010|July 27, 2010|December 27, 2007||No||No|January 25, 2010|https://clinicaltrials.gov/show/NCT00592761||162434|
NCT00592774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-218|Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Tolerability Titration Study To Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)||Eisai Inc.||Completed|January 2008|March 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|146|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|January 3, 2008|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00592774||162433|
NCT00592501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-089|Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma|A Phase II Study of Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma||Massachusetts General Hospital|Yes|Active, not recruiting|October 2006|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592501||162454|
NCT00592514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45976|Thyroid Dysfunction in Head and Neck Surgery Patients|Thyroid Dysfunction in Head and Neck Surgery Patients Treated With Intraoperative Oral Administration With Povidone-iodine 10% Solution||University of Arkansas|No|Completed|July 2005|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|August 2011|August 31, 2011|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00592514||162453|
NCT00598052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-7.1.08-CTIL|Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy|Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy- a Double-Blind Placebo-Controlled Study||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|December 2007|October 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2008|March 30, 2008|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598052||162038|
NCT00598065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-025|The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules|The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules||Memorial Sloan Kettering Cancer Center|Yes|Completed|March 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|N/A|No|||December 2009|December 2, 2009|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598065||162037|
NCT00600678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-PRX-02-DE|Gastric Emptying Study After Administration of a High Caloric Sip Feed|Characterisation of Gastric Emptying of a High Caloric Sip Feed Using the Paracetamol Absorption Method: Intraindividual Comparison of Paracetamol Pharmacokinetics After Oral co-Administration With Sip-Feed and After Intravenous Administration in Healthy Volunteers of Both Genders in an Open, Single Centre Study||Fresenius Kabi|No|Completed|November 2007|January 2008|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2008|May 14, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00600678||161842|
NCT00601315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461-07|Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions|A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 250 mg Clarithromycin Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|April 2003|May 2003|Actual|May 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|September 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00601315||161793|
NCT00602017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLO-01|Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 10 mg Amlodipine Besylate Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|April 2004|May 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602017||161741|
NCT00602030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0401|Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLC|A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease||Syndax Pharmaceuticals|Yes|Completed|December 2007|March 2012|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|132|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00602030||161740|
NCT00600977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAL LALA SA1|Liposomal Anthracyclin in the Treatment of Elderly ALL|A Multicentric Phase II-III Randomized Study Safety of Intraveinous Liposomal Pegylated Doxorubicin Versus Continuous Infusion of Doxorubicin During Induction Treatment of Acute Lymphoblastic Leukemia in Patients||French Innovative Leukemia Organisation|Yes|Completed|March 2002|October 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|55 Years|N/A|No|||June 2008|June 25, 2008|September 26, 2007||||No||https://clinicaltrials.gov/show/NCT00600977||161819|
NCT00601627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N064A|Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery|Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients With Locally Advanced Pancreatic Cancer||Alliance for Clinical Trials in Oncology|No|Completed|June 2009|May 2013|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601627||161770|
NCT00594386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0715|An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease|An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.|SP715|UCB Pharma|No|Completed|August 2002|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|258|||Both|31 Years|N/A|No|||September 2010|September 24, 2014|December 24, 2007|Yes|Yes||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00594386||162312|
NCT00594100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPS 05-05|GORE Embolic Protection With Reverse Flow|The Embolic Protection With Reverse Flow Study of the GORE Neuro Protection System in Carotid Stenting of Subjects At High Risk for Carotid Endarterectomy|EMPiRE|W.L.Gore & Associates|Yes|Completed|July 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|245|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|December 20, 2007|Yes|Yes||No|March 19, 2009|https://clinicaltrials.gov/show/NCT00594100||162334|
NCT00594685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|556|Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)|HIT Observational Thromboembolism Study (A TMH CTN Study)|HOT|New England Research Institutes|Yes|Terminated|January 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Serum, plasma, and packed cells will be retained at Day 1 and Day 35 (+/- 7 days)|Both|6 Months|N/A|No|Non-Probability Sample|Inpatients at participating clinical centers who have a diagnosis of isolated        Heparin-Induced Thrombocytopenia (HIT), determined by a fall in platelet count after        heparin treatment and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked        ImmunoSorbent Assay (ELISA) test|March 2013|March 11, 2013|January 7, 2008||No|Low accrual rate|No|October 1, 2009|https://clinicaltrials.gov/show/NCT00594685||162289|Early termination of study due to low enrollment. Due to the early termination, the central laboratory tests necessary for analyzing outcomes 11, 12, and 13 were not performed.
NCT00594633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-122|Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors|Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors||Memorial Sloan Kettering Cancer Center||Completed|October 2004|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00594633||162293|
NCT00594646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK PEP 2007|HIV Non Occupational Post-Exposure Prophylaxis (PEP)|A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1||Fenway Community Health|No|Completed|February 2008|August 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|January 7, 2008|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT00594646||162292|Limitations of the current study included:Reliance on self-reports to measure adherenceStudy population almost exclusively male (reflecting the demographics of people who call Fenway Health's hotline after an acute sexual exposure)
NCT00594906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AR054041|Use of Teriparatide to Accelerate Fracture Healing|Use of Teriparatide to Accelerate Fracture Healing||University of Rochester|No|Terminated|January 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|55 Years|N/A|No|||March 2013|December 3, 2014|January 7, 2008|Yes|Yes|The study was terminated due to poor enrollment.|No|October 24, 2012|https://clinicaltrials.gov/show/NCT00594906||162272|Early termination leading to small numbers of subjects analyzed.
NCT00591435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH_Hanss|Influence of Resident Training on Intra-operative Workflow|Resident Training Affects Intra-Operative Workflow and Costs||University of Schleswig-Holstein|Yes|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|Healthy subjects scheduled for one of the three defined procedures (defined by German        Diagnose Related Groups ID) under general or regional anesthesia|November 2007|March 23, 2010|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00591435||162536|
NCT00591162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-304|Bone Disease in Severely Burned Children|Bone Disease in Severely Burned Children||The University of Texas Medical Branch, Galveston|No|Terminated|October 1992|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|254|||Both|5 Years|18 Years|No|||June 2014|June 5, 2014|December 26, 2007||No|terminated due to PI lab/duties affected by natural disaster.|No||https://clinicaltrials.gov/show/NCT00591162||162557|
NCT00591695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAES-1|Enteral Stents for Colonic Obstruction|Prospective, Randomised European Multicentric Study, Comparing Enteral Stent Followed by Elective Surgery Versus Emergency Surgical Treatment in Malignant Colonic Obstruction|ESCO|European Association for Endoscopic Surgery|Yes|Active, not recruiting|January 2008|July 2018|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|N/A|N/A|No|||January 2016|January 20, 2016|December 29, 2007||No||No||https://clinicaltrials.gov/show/NCT00591695||162516|
NCT00591955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0206|Infected Elders in the Emergency Department: Outcomes and Processes of Care|Infected Elders in the Emergency Department: Outcomes and Processes of Care||Ohio State University|No|Completed|January 2006|September 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|213|||Both|65 Years|N/A|No|Non-Probability Sample|Patients aged 65 or older who present to the Emergency Department with signs that could be        consistent with infection|July 2013|July 11, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591955||162496|
NCT00591968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/039|Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican Community|Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican Community||Edward Via Virginia College of Osteopathic Medicine|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|106|||Both|13 Years|N/A|Accepts Healthy Volunteers|||July 2008|May 6, 2009|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00591968||162495|
NCT00592254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001856|Screening Protocol for Adults With ADHD|A Screening Protocol for Adults With Attention Deficit Hyperactivity Disorder||Massachusetts General Hospital|No|Recruiting|December 2002|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|55 Years|No|Non-Probability Sample|Adults with symptoms of ADHD|November 2015|November 9, 2015|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592254||162473|
NCT00597597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-TAR-721|Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer|A Phase II Open-Label Trial to Evaluate the Efficacy and Toxicity of Tarceva (Erlotinib) in Women With Metastatic, Hormone Receptor Negative and Her2-Negative Breast Cancer||Rush University Medical Center|Yes|Terminated|April 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||December 2012|December 31, 2012|January 9, 2008|Yes|Yes|not enough patients enrolled|No||https://clinicaltrials.gov/show/NCT00597597||162072|
NCT00597818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU0621|Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury|A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients||Sucampo Pharma Americas, LLC|No|Completed|August 2007|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|40 Years|70 Years|No|||June 2010|June 2, 2010|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597818||162055|
NCT00597831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-491/251007|Regulation of Intracerebral Pressure During Electroconvulsive Therapy|Regulation of Intracerebral Pressure During Electroconvulsive Therapy. Does Systemic Bloodpressure Reflect the Intracranial Pressure?||Rijnstate Hospital|No|Completed|January 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|N/A|No|Non-Probability Sample|All patients indicated for unilateral ECT treatment in the Rijnstate Hospital with the        diagnosis major depression and psychotic depressionaccording to DSM IV-TR classification.        Patients who already started treatment and patients just starting ECT and are of age > 18        years.|October 2010|October 25, 2010|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597831||162054|
NCT00598078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-015|Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor|Multiple-dose, Double-blind, Placebo-controlled, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Sodium Oxybate (Xyrem) in Subjects With Moderate to Severe Essential Tremor||Jazz Pharmaceuticals|No|Completed|December 2007|December 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|19|||Both|50 Years|75 Years|No|||December 2011|December 15, 2011|January 9, 2008|Yes|Yes||No|September 13, 2011|https://clinicaltrials.gov/show/NCT00598078||162036|
NCT00598091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012976|A Phase I/Expansion Study of Dasatinib|A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer|Gem/Dsat|Duke University|Yes|Terminated|April 2007|May 2012|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2012|September 4, 2015|December 26, 2007|No|Yes|Low accrual, unable to meet endpoint in timely manner|No||https://clinicaltrials.gov/show/NCT00598091||162035|
NCT00601003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0706|Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma|A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.||Spectrum Health Hospitals|Yes|Recruiting|February 2008|December 2020|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|21 Years|No|||October 2015|October 7, 2015|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601003||161817|
NCT00601302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLO-02|Bioequivalency Study of Amlodipine Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 10 mg Amlodipine Besylate Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|April 2004|May 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601302||161794|
NCT00602381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITH-08|Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions|A Single Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalency Study of 450 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|November 2002|November 2002|Actual|November 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|September 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00602381||161715|
NCT00601289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577534|Temozolomide in Treating Patients With Invasive Pituitary Tumors|An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors||Jonsson Comprehensive Cancer Center|Yes|Withdrawn|December 2009|||October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|January 25, 2008|Yes|Yes|funding term ended|No||https://clinicaltrials.gov/show/NCT00601289||161795|
NCT00602004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.059|Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan|Early and Late Cardiac Effects of Arteriovenous Fistula Creation for Haemodialysis in End-stage Renal Failure and Their Possible Attenuation||Melbourne Health|Yes|Completed|October 2006|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|52|||Both|18 Years|80 Years|No|||May 2015|May 8, 2015|March 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00602004||161742|
NCT00594113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1CA119098-01|"Touch 2 Screen" Multi-media Colorectal Cancer Screening Intervention|Tailored Touch-Screens for Colorectal Cancer Prevention in Urban Core Clinics||University of Kansas Medical Center|No|Completed|August 2007|January 2012|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|470|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 18, 2012|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594113||162333|
NCT00594919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0246.0.000.140-07|Neutrophil Gelatinase-Associated Lipocalin: Biomarker of Acute Kidney Injury After Cardiac Surgery|Neutrophil Gelatinase-Associated Lipocalin(NGAL): Early Biomarker of Acute Kidney Injury After Cardiac Surgery||Hospital de Base|No|Recruiting|October 2007|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|All patients aged greater than 18 years undergoing elective cardiac surgery for coronary        artery bypass grafting and / or valve replacement, in need of cardiopulmonary bypass and        with the prospect of minimum hospital length stay of 48 hours in ICU, will be candidates        for participation in this study.|February 2009|February 3, 2009|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594919||162271|
NCT00594659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88268|Development and Efficacy Test of Computerized Treatment for Marijuana Dependence|Development and Efficacy Test of Computerized Treatment for Marijuana Dependence||Dartmouth-Hitchcock Medical Center|No|Completed|November 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|January 7, 2008||No||No|April 16, 2013|https://clinicaltrials.gov/show/NCT00594659||162291|
NCT00594672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080043|Age-Related Eye Disease Study (AREDS) Follow-Up|Age-Related Eye Disease Study (AREDS) and AREDS2 Follow-Up||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|January 2008|||||N/A|Observational|Time Perspective: Prospective|||Actual|111|||Both|50 Years|N/A|No|||November 2015|December 2, 2015|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00594672||162290|
NCT00591110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X060908004|Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program|Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program|inCharge|University of Alabama at Birmingham|No|Completed|June 2008|December 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|177|||Both|60 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 26, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00591110||162561|
NCT00591123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORI GI-05|Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia|A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia||Translational Oncology Research International|Yes|Completed|December 2007|||June 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591123||162560|
NCT00591136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBL1001|Phase I Study of Indibulin in Patients With Solid Tumors|Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors||Ziopharm||Completed|April 2003|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00591136||162559|
NCT00591448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0380|Study in the Use of Virtual Reality as an Adjunct to Pain Control in Burn Patients|Improvement of Pain Management in Burn Patients Using Virtual Reality in Conjunction With Standard Opioids and Sedatives||University of Wisconsin, Madison|No|Completed|October 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|6 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 16, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591448||162535|
NCT00591708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR40553|Calcium Metabolism in Asian Adolescents|Calcium Metabolism in Asian Adolescents||Purdue University|Yes|Completed|July 2004|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|34|||Both|11 Years|15 Years|No|||December 2007|January 10, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591708||162515|
NCT00596752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0777|Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV|Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)|ESPECIAL|UCB Pharma|Yes|Completed|March 2004|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|840|||Both|45 Years|N/A|No|||February 2015|February 26, 2015|December 21, 2007|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00596752||162135|
NCT00597337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAR-IST-4-027656-STP|Effectiveness of the FearNot!v.2.0 Software in Reducing Bullying Victimisation Among Primary School Children|Using a Virtual Learning Environment to Reduce Bullying: Evaluation of the FearNot!v.2.0 Intervention in Primary Schools in England and Germany||University of Warwick|No|Completed|November 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1129|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||October 2008|December 17, 2008|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597337||162092|
NCT00597350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27031|Effect of Fenugreek on Blood Sugar and Insulin in Diabetic Humans|Pilot Study of the Effect of Fenugreek on Blood Sugar and Insulin in Diabetic Humans|Fenugreek|Pennington Biomedical Research Center|No|Completed|November 2007|February 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|Samples Without DNA|Whole blood drawn for glucose and insulin levels.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|December 2015|December 17, 2015|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597350||162091|
NCT00601653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH082629|Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder|CBT and Dieting: Effects on Psychopathology and Weight in BED||Yale University|No|Completed|September 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|60 Years|No|||July 2012|July 20, 2012|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00601653||161768|
NCT00601666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOLP-01|Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zolpidem Tartrate Tablets 10 MG Under Fasting Conditions||Roxane Laboratories|No|Completed|March 2004|March 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 5, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00601666||161767|
NCT00602043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00270|F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer|A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|September 2008|September 2014|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Female|18 Years|N/A|No|||August 2014|December 16, 2014|January 23, 2008|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00602043||161739|
NCT00601640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581429|Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin|Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm||University of Arizona|Yes|Completed|January 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|184|||Both|40 Years|N/A|No|||September 2010|September 28, 2010|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00601640||161769|
NCT00602758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068197|Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV|ART Adherence: Enhanced Counseling and Observed Therapy||University of Missouri, Kansas City|No|Completed|December 2004|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|252|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00602758||161687|
NCT00594126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP14A004|Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma|A Phase 1 Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Refractory or Relapsed Multiple Myeloma||Geron Corporation|No|Completed|November 2007|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|January 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00594126||162332|
NCT00594932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRF 06-23|Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis|Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis||Oklahoma Medical Research Foundation|No|Completed|November 2006|April 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|14 Years|70 Years|No|||December 2012|December 26, 2012|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594932||162270|
NCT00594945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001|Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures|A Phase 2a, Open-label,Proof -Of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures||Jazz Pharmaceuticals|No|Completed|December 2007|June 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|No|||May 2014|May 29, 2014|January 7, 2008|Yes|Yes||No|June 26, 2013|https://clinicaltrials.gov/show/NCT00594945||162269|
NCT00590863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH090003-02|Combining Medications to Enhance Depression Outcomes|Combining Medications to Enhance Depression Outcomes|CO-MED|National Institute of Mental Health (NIMH)|Yes|Completed|March 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|665|||Both|18 Years|75 Years|No|||April 2009|April 21, 2014|December 26, 2007|No|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT00590863||162580|Detailed results avaiable. A. J. Rush et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes: a single-blind randomized study. American Journal of Psychiatry, 2011; 168:689-701.
NCT00591149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10635|Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer|Phase II Trial Of Oxaliplatin With Docetaxel Followed By Epidermal Growth Factor Antibody (EGFR-AB) Cetuximab In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)||University of Kansas Medical Center|Yes|Terminated|June 2007|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|December 27, 2007|Yes|Yes|Study was stopped due to termination of funding|No||https://clinicaltrials.gov/show/NCT00591149||162558|
NCT00591461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003558|Study of Endoscopic Barrett's Esophagus Diagnosis|A Prospective Study on the Interobserver Agreement of Endoscopic Barrett's Esophagus||Oregon Health and Science University|No|Suspended|December 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Esophageal biopsies|Both|18 Years|80 Years|No|Non-Probability Sample|Study participants must be older than 18 years of age who are having an endoscopy        performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth,        dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.|September 2009|September 28, 2009|December 31, 2007||No|Suspended to modify recruitment process|No||https://clinicaltrials.gov/show/NCT00591461||162534|
NCT00591474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB3848|The Influence of Probiotics on Vancomycin-Resistant Enterococcus|The Influence of Probiotics on Vancomycin-Resistant Enterococcus||Oregon Health and Science University|Yes|Recruiting|December 2007|||November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2007|January 10, 2008|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00591474||162533|
NCT00596505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704021M|Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy|Intravitreal Bevacizumab (Avastin) Pretreatment for Reducing Intraoperative and Postoperative Preretinal Hemorrhage in Primary Diabetic Vitrectomy With Silicone Oil Infusion||National Taiwan University Hospital|Yes|Completed|April 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|41|||Both|20 Years|80 Years|No|Probability Sample|Consecutive patients undergoing primary pars plana vitrectomy with silicone oil infusion        for complications of proliferative diabetic retinopathy will be recruited for the        prospective study.|January 2008|January 16, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596505||162154|
NCT00596765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroPsy_Ex2007|Neuropsychological Cognitive Behavioral Therapy for Patients With Acquired Brain Injury|Phase 2 Study of Neuropsychological Therapy for Patients With Acquired Brain Injury Focusing on the Role of Psychosocial Adjustment Using a Cognitive Behavioral Approach||Philipps University Marburg Medical Center|No|Active, not recruiting|September 2007|November 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||April 2014|April 16, 2014|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596765||162134|
NCT00597077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41552|Atrial Fibrillation and Congestive Heart Failure Trial|Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial||Montreal Heart Institute|Yes|Completed|April 2001|October 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1376|||Both|18 Years|N/A|No|||January 2008|February 1, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597077||162111|
NCT00597064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APITA|Inflammatory, Functional and Image Composite Measure to Define Asthma Control|Inflammatory, Functional and Image Composite Measure to Define Asthma Control|APITA|Federal University of São Paulo|Yes|Recruiting|July 2006|March 2008|Anticipated|March 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Both|16 Years|80 Years|No|||November 2007|January 16, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597064||162112|
NCT00597649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XTL B07-002|A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|An Open-Label 52-Week Safety Study of Bicifadine SR in Adult Outpatients With Chronic Peripheral Neuropathic Pain Associated With Diabetic Peripheral Neuropathy||XTL Biopharmaceuticals|No|Terminated|October 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|90 Years|No|||June 2009|June 29, 2009|January 9, 2008|Yes|Yes|The 001 trial did not show benefit versus placebo|No||https://clinicaltrials.gov/show/NCT00597649||162068|
NCT00597883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA4811|Neuropsychometric Outcome After Carotid Endarterectomy|Neurologic and Neuropsychometric Outcome in Patients Undergoing Carotid Endarterectomy|CEA|Columbia University|No|Completed|March 2003|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|585|Samples With DNA|serum plasma DNA (via buccal samples will be obtained using a buccal cell collection swab)|Both|18 Years|N/A|No|Non-Probability Sample|Columbia University/NY Presbyterian Hospital|February 2015|February 4, 2015|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597883||162050|
NCT00597610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-127|Evaluating The Response to Pre-Operative Chemotherapy and/or Radiation Therapy For Rectal Cancer Using Three-Dimension Transrectal Ultrasound|Evaluating The Response to Pre-Operative Chemotherapy and/or Radiation Therapy For Rectal Cancer Using Three-Dimension Transrectal Ultrasound (3-D TRUS) - A Pilot Project||Memorial Sloan Kettering Cancer Center|Yes|Completed|November 2003|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|84|||Both|N/A|N/A|No|||September 2012|September 26, 2012|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597610||162071|
NCT00597623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 051007|Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis|Randomized Double Blind Placebo-controlled Trial of the Efficacy of an Anti-TNF Alpha Agent (Adalimumab, Humira®) in Patients With Incapacitating Hand Osteoarthritis Refractory to Usual Treatment|DORA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2008|December 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|40 Years|80 Years|No|||May 2012|July 25, 2012|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00597623||162070|
NCT00597636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-038|Genetic Susceptibility to Lung Cancer in Never Smokers|Genetic Susceptibility to Lung Cancer in Never Smokers||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2005|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|238|Samples With DNA|Blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MSKCC clinics|January 2016|January 13, 2016|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00597636||162069|
NCT00597844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-036|Improving Functional Outcomes in Patients With Unilateral Vocal Cord Paralysis: Assessment of Adaptation Using Functional Magnetic Resonance Imaging|Improving Functional Outcomes in Patients With Unilateral Vocal Cord Paralysis: Assessment of Adaptation Using Functional Magnetic Resonance Imaging||Memorial Sloan Kettering Cancer Center||Completed|July 2005|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597844||162053|
NCT00597857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-025|Prevention of Posttraumatic Stress Disorder (PTSD) With Early Hydrocortisone Treatment: Pilot|Prevention of PTSD With Early Hydrocortisone Treatment: Pilot||Kent State University|Yes|Recruiting|June 2005|November 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|65|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00597857||162052|
NCT00601679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN0013|Improvement of Patients With Chronic Heart Failure Using NT-proBNP|Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study|EXIMPROVECHF|St. Michael's Hospital, Toronto|No|Active, not recruiting|December 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00601679||161766|
NCT00601692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-061|Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer|A Phase I Trial of Irinotecan, Radiation Therapy and Escalating Doses of Docetaxel With Cisplatin in Locally Advanced Esophageal Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 2003|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|January 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00601692||161765|
NCT00602420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584341|Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)|Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial||University of Rochester|Yes|Completed|June 2008|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|510|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|January 22, 2008|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT00602420||161712|
NCT00602394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITH-12|Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|May 2003|May 2003|Actual|May 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602394||161714|
NCT00602407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO-05|Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions|A Single Dose, Randomized, Two-Period, Two-Treatment, Crossover Bioequivalency Study of Cilostazol 50 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|February 2004|March 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2008|January 31, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00602407||161713|
NCT00603096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38/2006/2|Use of Polysomnography for Non-Invasive Ventilation Settings' Optimization|Interest of Using Nocturnal Polysomnography for Non-Invasive Ventilation (NIV) Settings' Optimization in Obesity-Hypoventilation Syndrome (OHS)|NIV-OHS|Tyco Healthcare Group|No|Recruiting|June 2006|June 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|20 Years|75 Years|No|||January 2008|January 15, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00603096||161664|
NCT00594438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061204007|Randomized, Prospective Comparison of Two Femoral Reaming Systems|Randomized, Prospective Comparison of Two Femoral Reaming Systems|RIA|University of Alabama at Birmingham|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|50 Years|No|||November 2013|November 23, 2013|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00594438||162308|
NCT00594724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-093|Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging|Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging||Memorial Sloan Kettering Cancer Center|Yes|Completed|November 2002|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|99|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 11, 2014|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594724||162286|
NCT00594958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-309|Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51|Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.||Valneva Austria GmbH|No|Completed|September 2006|September 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|636|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|January 4, 2008|No|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00594958||162268|
NCT00590889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|979|Artificial Valve Endocarditis Reduction Trial|Artificial Valve Endocarditis Reduction Trial|AVERT|St. Jude Medical|Yes|Terminated|July 1998|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|807|||Both|N/A|N/A|No|||November 2015|November 18, 2015|December 26, 2007||No|A post-PMA begun in 1998; enrollment halted in 2000 due to an anomaly in one study arm. The    protocol required annual study visits after 2000.|No|June 22, 2015|https://clinicaltrials.gov/show/NCT00590889||162578|This study was terminated early. No final report was created.
NCT00590876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66108a_0304025134|The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus|The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function and Brain Fuel Utilization in Patients With Type 1 Diabetes and Hypoglycemia Unawareness||Yale University|No|Completed|December 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing pancreatic islet cell allotransplantation at the University of        Minnesota        Patients who are seen at Diabetes Clinics at Yale School of Medicine        Nondiabetic, healthy subjects from New Haven and surrounding communities|October 2011|October 26, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590876||162579|
NCT00590902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-010|Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer|Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer||Memorial Sloan Kettering Cancer Center|Yes|Completed|March 2002|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|N/A|N/A|No|||December 2015|December 15, 2015|December 26, 2007|No|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00590902||162577|
NCT00591188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT-003|Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens|Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens||Kidney Cancer Research Bureau|Yes|Completed|December 2006|||May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|80 Years|No|||April 2009|April 30, 2009|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00591188||162555|
NCT00591981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC06504|Thoracic OncoGeriatric Assessment (TOGA) Trials|Preoperative Oncogeriatric Assessment for Thoracic Malignancies|TOGA|University of Wisconsin, Madison|No|Completed|August 2007|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|70 Years|N/A|No|Non-Probability Sample|geriatric oncology patients with thoracic neoplasms of the lung, esophagus, pleura and        thymus.|July 2015|July 22, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591981||162494|
NCT00591994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTOSUL 01/2007|Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography|Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography|piribedil|Faculdade de Medicina de Valenca|No|Completed|November 2006|||December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||December 2007|March 6, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591994||162493|
NCT00596518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7941014|A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function|A Phase 1, Open-Label Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PF-00734200 Administered To Subjects With Various Degrees Of Renal Impairment And Normal Renal Function||Pfizer|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|77 Years|Accepts Healthy Volunteers|||October 2008|June 10, 2010|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596518||162153|
NCT00596778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq836/03|Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery|Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery||University of Sao Paulo|No|Terminated|February 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|21 Years|72 Years|Accepts Healthy Volunteers|||January 2008|January 16, 2008|January 8, 2008|Yes|Yes|terminated|No||https://clinicaltrials.gov/show/NCT00596778||162133|
NCT00596791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Santen-77552|Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops|Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops||Santen Oy|No|Completed|January 2008|August 2008|Actual|July 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596791||162132|
NCT00596804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hA20-01EU|Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma|A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma||Immunomedics, Inc.|No|Completed|March 2004|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596804||162131|
NCT00597090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-017|The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections|The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections||Memorial Sloan Kettering Cancer Center|No|Completed|February 2003|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|319|Samples With DNA|We will genotype the genes of innate immune receptors to identify genetic polymorphisms      associated with higher frequency of invasive infections or susceptibility to lymphoma. All      specimens will be processed in the Infectious Diseases Laboratory at MSKCC. RNA will be      extracted from peripheral blood mononuclear cells (PBMCs). Genotyping will be done from      genomic DNA or from cDNA generated from RNA by RT-PCR. Cell lines will be created from PBMCs      and will be analyzed in functional assays for responses to bacterial and fungal products      (cytokine secretion, upregulation of cell surface molecules). All patient samples including      genomic DNA, RNA, cDNA and cell lines will be banked in the Infectious Disease laboratory at      MSKCC.|Both|N/A|N/A|No|Probability Sample|The population for this study is composed of patients with leukemia. It is projected that        the marginal probability of an allelic variant in the TLR and an infection is 0.12 and        0.30 respectively in this patient population.|January 2011|January 19, 2011|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597090||162110|
NCT00597363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 433/2004|Neptune Pad ® Compared to Conventional Manual Compression|Neptune Pad ® Compared to Conventional Manual Compression for Access Site Management After Peripheral Percutaneous Transluminal Procedures||Vienna General Hospital|Yes|Completed|January 2006|January 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|201|||Both|N/A|N/A|No|||January 2008|January 17, 2008|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597363||162090|
NCT00597896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-069|Cognitive Enhancement in Bipolar Disorder|Cognitive Enhancement in Bipolar Disorder||Northwell Health|No|Completed|October 2005|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||June 2015|June 10, 2015|January 8, 2008|Yes|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00597896||162049|
NCT00590694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETAIL Study for PED in AMD|Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments|Determining Optimal Treatment Algorithms for Macular Degeneration Pigment Epithelial Detachments Treated With Intraocular Lucentis|DETAIL|Pacific Eye Associates|No|Completed|October 2006|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|50 Years|N/A|No|||April 2012|April 10, 2012|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590694||162592|
NCT00598117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-083|Quality Of Life Outcomes Following Treatment for Esophageal Cancer|Quality Of Life Outcomes Following Treatment for Esophageal Cancer||Memorial Sloan Kettering Cancer Center|No|Completed|August 2003|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|409|||Both|18 Years|N/A|No|Non-Probability Sample|This is a descriptive study comprising two cohorts of esophageal cancer patients. The        first cohort will be followed prospectively and will include patients newly diagnosed with        esophageal cancer prior to treatment. QOL assessments will be administered pre-surgery, at        first post-operative visit, and at 6 and 12 months post surgery. The second cohort will be        a cross sectional sample and include patients more than 18 months post treatment, without        evidence of disease who will undergo one QOL assessment. This is a preliminary        investigation and it is hoped that we will be able to base future research questions on        our results of this study.|June 2013|June 26, 2013|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598117||162033|
NCT00598416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-NORTH-AA015201|Psychoeducation for Hepatitis and Alcohol Behaviors|Psychoeducation for HCV and Alcohol Behaviors||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Completed|September 2006|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|556|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598416||162011|
NCT00602069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080786|Cognitive Behavioral Therapy for Treating Recently Abused Women With Post-Traumatic Stress Disorder|Treatment of PTSD in Recently Battered Women Living in Shelters||The University of Akron|Yes|Completed|May 2008|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||June 2013|June 21, 2013|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00602069||161737|
NCT00602082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCA-CCTC-NET-01|Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors|A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors||National Cancer Institute (NCI)||Completed|August 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|84|||Both|18 Years|N/A|No|||June 2009|August 6, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00602082||161736|
NCT00601718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 2302|Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma|A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma||University of Washington|No|Completed|December 2007|||June 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00601718||161763|
NCT00602745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10203|S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen|A Multicenter, Open-Label, Randomized Study Comparing Efficacy and Safety of S-1 as Single Agent Versus 5-FU Bolus for the Treatment of Patients With Metastatic Pancreatic Cancer Previously Treated With a Gemcitabine-Based Regimen|S-1 Pancreas|Sanofi|Yes|Terminated|February 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||December 2010|December 16, 2010|January 16, 2008|Yes|Yes|Following the termination of development and commercialization agreement for S-1 with Taiho    Pharmaceutical|No||https://clinicaltrials.gov/show/NCT00602745||161688|
NCT00602446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584690|Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant|Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload||Masonic Cancer Center, University of Minnesota|Yes|Terminated|August 2007|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|70 Years|No|||November 2012|November 6, 2012|January 24, 2008|Yes|Yes|Due to slow accrual of patients|No|March 16, 2010|https://clinicaltrials.gov/show/NCT00602446||161710|
NCT00604045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075321|DoD PTSD November 13 - Information Processing Modification in the Treatment of PTSD|Information Processing Modification in the Treatment of PTSD||San Diego State University|Yes|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2008|February 11, 2014|January 16, 2008||No||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00604045||161592|
NCT00594737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baycrest.Ebixa.FTD-001|Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia|An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia||Rotman Research Institute at Baycrest|Yes|Completed|October 2007|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|40 Years|80 Years|No|||June 2012|June 1, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594737||162285|
NCT00590915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erwinase|Erwinase Master Treatment Protocol|Erwinase Master Treatment Protocol|EMTP|Phoenix Children's Hospital||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||April 2012|April 11, 2012|December 26, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00590915||162576|
NCT00591201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGMREUMA.001.2007|Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies|Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension.||Hospital General de Mexico|Yes|Completed|June 2002|September 2007|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|N/A|18 Years|No|||December 2007|January 16, 2008|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00591201||162554|
NCT00591175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-117|A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers|A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|December 2001|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1072|Samples Without DNA|Salvia|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Smokers who are also patients at the NYU College of Dentistry|November 2015|November 2, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00591175||162556|
NCT00591487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMS-LIPO-001|Safety and Efficacy of Lidocaine Infiltration in Suction Assisted Lipectomy|Safety and Efficacy of Lidocaine Infiltration in Suction Assisted Lipectomy With Tumescent Technique. A Randomized, Double Blinded, Controlled Trial.||Hospital Militar de Santiago|No|Enrolling by invitation|December 2007|||December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2007|January 10, 2008|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00591487||162532|
NCT00591721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G070006|Teleconference Fatigue Management for People With Multiple Sclerosis|Effectiveness of a Teleconference Delivered Fatigue Management Program for People With Multiple Sclerosis||University of Illinois at Chicago|No|Completed|November 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|December 26, 2007||No||No|August 19, 2011|https://clinicaltrials.gov/show/NCT00591721||162514|Use of self-report rather than objective measures of MS disability. Only the participants were blinded to their allocation status. Co-intervention was tracked, but there is no way to know whether other interventions contributed to the results.
NCT00560794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT103-202|Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)|Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia||Amgen Research (Munich) GmbH|Yes|Completed|January 2008|November 2014|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2014|January 12, 2015|November 19, 2007||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT00560794||164836|
NCT00560807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R21 AT004263|Manual Therapy Dosage Factorial Study|Manual Therapy Dosage Factorial Study||McMaster University||Withdrawn||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|0|||Both|21 Years|60 Years|No|||September 2015|September 22, 2015|November 19, 2007||No|The study was stopped because the study never received funding|No||https://clinicaltrials.gov/show/NCT00560807||164835|
NCT00559663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1242|Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile|Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile|FEAST-CAL|LifeBridge Health|Yes|Completed|September 2006|April 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2007|November 16, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559663||164921|
NCT00561184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P1E1|Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine|A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects||Novartis|No|Completed|October 2007|June 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00561184||164806|
NCT00561197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-101-CS-102|An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer|An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer||Ascenta Therapeutics|No|Terminated|August 2007|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|November 19, 2007|Yes|Yes|Drug not being developed for this indication|No||https://clinicaltrials.gov/show/NCT00561197||164805|
NCT00561210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCNF 0501|Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients|Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients||Nestlé||Completed|November 2003|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|15 Years|70 Years|No|||November 2013|November 18, 2013|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00561210||164804|
NCT00561652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5027-R|Education/Exercise and Chiropractic for Chronic Back Pain|Education/Exercise and Chiropractic for Chronic Back Pain||VA Office of Research and Development|Yes|Completed|April 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|November 19, 2007||No||No|November 6, 2014|https://clinicaltrials.gov/show/NCT00561652||164770|
NCT00561964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9079|Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria|Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria|PRIME|Sanofi||Completed|January 2004|July 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|241|||Both|30 Years|75 Years|No|||November 2007|November 22, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00561964||164747|
NCT00561977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRG 93-033|Cancer Dietary Objectives Study|Finding a Simple Message to Improve Dietary Quality for Cancer and Heart Disease|CanDo|University of Massachusetts, Worcester|No|Completed|May 2007|February 2009|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|36|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|November 20, 2007||No||No|January 18, 2010|https://clinicaltrials.gov/show/NCT00561977||164746|
NCT00561990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAG101-PCS07|Nimotuzumab in Adults With Pancreatic Cancer|A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER||Oncoscience AG|Yes|Completed|September 2007|January 2014|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|N/A|2||Anticipated|188|||Both|18 Years|100 Years|No|||October 2015|October 13, 2015|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561990||164745|
NCT00562575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLx-4090-07-03|Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides|A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values||Kadmon Corporation, LLC|No|Completed|May 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562575||164700|
NCT00562835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot.cm.P662(A.1552)/C.E./2007|Steroids in Patients With Early ARDS|Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS)||Catholic University of the Sacred Heart|No|Not yet recruiting|February 2008|February 2009|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2007|November 21, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562835||164680|
NCT00562848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOT107043|A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040|A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects||GlaxoSmithKline|No|Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562848||164679|
NCT00563407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-1-0090|Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy|Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy||AHS Cancer Control Alberta|Yes|Terminated|July 2006|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Female|18 Years|N/A|No|Probability Sample|Female patients with early breast cancer (carcinoma insitu , T1-2, N0-1) treated with        lumpectomy.|September 2011|February 23, 2016|November 21, 2007||No|accrual goal met|No||https://clinicaltrials.gov/show/NCT00563407||164636|
NCT00563381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.389|Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.|Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).||Boehringer Ingelheim||Completed|January 2008|||April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|7376|||Both|40 Years|N/A|No|||July 2012|November 27, 2013|November 22, 2007||||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00563381||164638|
NCT00563394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-78-303|MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers|MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers||MacroChem Corporation|No|Completed|August 1994|July 1996|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|584|||Both|18 Years|N/A|No|||November 2007|November 21, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563394||164637|
NCT00574483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBL-DD-07-C-H-2002|Treatment of Advanced Renal Cell Carcinoma With Quinacrine|An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma||Cleveland BioLabs|No|Withdrawn|November 2007|January 2008|Anticipated|January 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2008|July 31, 2015|December 13, 2007|Yes|Yes|reevaluation of compound development|No||https://clinicaltrials.gov/show/NCT00574483||163809|
NCT00574821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11958|Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)|Assessing the Utility of Magnetocardiography in Patients With Hypertrophic Cardiomyopathy||Cedars-Sinai Medical Center|No|Withdrawn|July 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|16 Years|N/A|No|Non-Probability Sample|We will enroll a total of twenty patients identified to have hypertrophic cardiomyopathy.|November 2009|November 16, 2009|December 14, 2007|No|Yes|sponsor funding|No||https://clinicaltrials.gov/show/NCT00574821||163783|
NCT00575640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-03|Hydralazine as a Demethylating Agent in Rectal Cancer|Hydralazine as a Demethylating Agent in Rectal Cancer||University of Arkansas|No|Withdrawn|November 2004|||May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|December 14, 2007||No|No enrollment|No||https://clinicaltrials.gov/show/NCT00575640||163722|
NCT00575081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060232|Physiological Brain Atlas Development|Physiological Brain Atlas Development|Brain Atlas|Vanderbilt University|Yes|Recruiting|August 2006|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|7 Years|90 Years|No|Probability Sample|patients who have already consented to having DBS surgery for Parkinson's Disease,        Dystonia, Essential Tremor, and OCD|December 2014|December 19, 2014|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00575081||163764|
NCT00575913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8935|Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study|ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study|ALEX-XL|Sanofi||Completed|September 2003|March 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|118|||Male|18 Years|N/A|No|||April 2008|April 8, 2008|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575913||163702|
NCT00576186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27168|Validation of the Gated Blood Pool SPECT: ERNA vs 3D Echo|Validation of the Gated Blood Pool SPECT: Comparison to ERNA and 3-dimensional Echocardiography.||Yale University|No|Recruiting|February 2005|January 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Each patient scheduled to undergo clinically requested ERNA imaging for assessment of LV        function in the Yale University Cardiovascular Nuclear Imaging Laboratory will be an        eligible candidate and will be asked to participate. Based on our referral pattern it will        include both patients with cardiac and non-cardiac disease, the later usually consist of        patients undergoing chemotherapy.|January 2010|January 13, 2010|December 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576186||163681|
NCT00563329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 03-103 T/103|Smoking Reduction Intervention for Smokers Not Willing to Quit Smoking: a Randomised Control Trial|Smoking Reduction Intervention for Smokers Not Willing to Quit Smoking: a Randomised Control Trial||Hospital Authority, Hong Kong||Completed|October 2004|July 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|||Anticipated|3826|||Both|18 Years|N/A||||October 2013|October 22, 2013|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563329||164642|
NCT00560495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574135|Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|The Combination of Radiotherapy With the Anti-Angiogenic Agent Tetrathiomolybdate (TM) in the Treatment of Stage I-IIIB Non-Small Cell Lung Cancer (NSCLC): A Phase I Study||Roswell Park Cancer Institute||Withdrawn|May 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|November 16, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00560495||164859|
NCT00560274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21362|A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.|An Open Label Study to Evaluate the Safety of NeoRecormon in the Treatment of Anemia in Patients With Chronic Hepatitis C Who Are Treated With Pegylated Interferon + Ribavirin Combination Therapy||Hoffmann-La Roche||Completed|March 2008|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560274||164876|
NCT00560508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.610|A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period|A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER||Boehringer Ingelheim||Completed|November 2007|||November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|1 Year|N/A|No|||July 2014|July 29, 2014|November 16, 2007|Yes|Yes||No|November 25, 2010|https://clinicaltrials.gov/show/NCT00560508||164858|
NCT00561158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK48134 (completed)|Eat Well Live Well Nutrition Program|Dietary Changes in African American Women By Activation|EWLW|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|June 1994|May 1998|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|398|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561158||164808|
NCT00561171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP635CRD05|Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria|A Phase IIa, Double-Blind, Randomized, Parallel-Design, Four-Week Study to Investigate the Efficacy and Safety of Two Different Doses of the Renin-Inhibitor SPP635 Once Daily in Type II Diabetic Patients With Mild to Moderate Hypertension and Albuminuria||Speedel Pharma Ltd.|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||November 2008|November 20, 2008|November 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00561171||164807|
NCT00561691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAG101-BSC05|Nimotuzumab in Children With Intrinsic Pontine Glioma|Phase III Study on the Effectiveness of OSAG 101 (Theraloc®)in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents||Oncoscience AG|Yes|Completed|April 2006|January 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|||Both|3 Years|20 Years|No|Non-Probability Sample|children and adolescents|March 2013|March 27, 2013|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561691||164768|
NCT00561444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0302|Quality of Life Study for Prostate Cancer Patients|A Comprehensive, Multimodality Quality of Life Study for Prostate Cancer Patients||M.D. Anderson Cancer Center|No|Recruiting|November 2007|||November 2017|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1448|||Male|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with prostate cancer.|December 2015|December 29, 2015|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561444||164786|
NCT00561678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-0217|Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve|Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve||Icahn School of Medicine at Mount Sinai|Yes|Completed|February 2008|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|403|||Both|68 Years|N/A|No|||May 2014|May 14, 2014|November 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00561678||164769|
NCT00563095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 1942-02|A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer|A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma||Hospital Authority, Hong Kong||Recruiting|March 2004|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563095||164660|
NCT00563108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 03-312 T312|Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation|A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.||Hospital Authority, Hong Kong||Recruiting|June 2004|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563108||164659|
NCT00563784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1023|TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2007|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|November 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00563784||164609|
NCT00564070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078571|CBT for Adherence and Depression in Diabetes|CBT for Adherence and Depression in Diabetes||Massachusetts General Hospital|Yes|Completed|June 2007|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|80 Years|No|||March 2013|March 7, 2013|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00564070||164587|
NCT00563771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8720|Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome|Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome||Sanofi|No|Completed|March 2003|January 2004|Actual|||Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|N/A|18 Years|No|||January 2008|January 24, 2008|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563771||164610|
NCT00564044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRPD160851|The Immune Reactivity of Biofilms in Vaginal Mesh Erosion.|Does the Immune Reactivity of Bacteria Cause Vaginal Mesh (Polypropylene) Erosion? - A Ultrastructural, Microbiological and Immunohistochemical Analysis.||Chang Gung Memorial Hospital|No|Active, not recruiting|August 2007|July 2009|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|82|||Female|20 Years|80 Years|No|||August 2007|November 26, 2007|November 25, 2007||||No||https://clinicaltrials.gov/show/NCT00564044||164589|
NCT00559780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKF:01058/00|Muscle Function in Elderly Postoperative Patients|Muscle Function in the Elderly After Hip-Replacement Surgery - Effects of Long Term Disuse and Physical Training||Bispebjerg Hospital|No|Completed|May 2000|December 2003|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|60 Years|N/A|No|||November 2007|November 15, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559780||164912|
NCT00575055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN115727-302|Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.||JANSSEN Alzheimer Immunotherapy Research & Development, LLC||Completed|December 2007|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1121|||Both|50 Years|88 Years|No|||October 2013|October 30, 2013|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00575055||163766|
NCT00575068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-20|Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma|A Phase I/II Trial of Anti-CD80 Monoclonal Antibody (IDEC-114) Therapy for Patients With Relapsed or Refractory Follicular Lymphoma||Biogen|No|Completed|January 2002|November 2010|Actual|September 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2011|June 7, 2012|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00575068||163765|
NCT00575653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH000274A|Safety Study of GBS Following Menactra Meningococcal Vaccination|Risk of Guillain-Barré Syndrome Following Meningococcal Conjugate (MCV4) Vaccination||Harvard Pilgrim Health Care|No|Active, not recruiting|March 2005|August 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|6000000|||Both|11 Years|21 Years|No|Non-Probability Sample|The primary study population will include adolescent health plan members 11-<19 years of        age. A secondary cohort will include members 19-<22 years of age. Older adolescents are        excluded from the primary cohort because an unknown proportion of immunizations to older        individuals may be provided by colleges or other out-of-plan providers, and not be        identifiable in health plan records.|December 2007|December 19, 2007|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575653||163721|
NCT00575354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2579-6FW|Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision|Anesthesia With Sevoflurane and Isoflurane for Excision Surgeries in Benign Breast Tumors|CSIABTEC|Nanjing Medical University|Yes|Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Female|18 Years|64 Years|No|||April 2008|April 18, 2008|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575354||163744|
NCT00575939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDS 070711|Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV|Assessment of the Use of a Metabolically-friendly Antiretroviral Regimen to Slow Down the Rate of Progression in Carotid Artery Intima-medial Thickness in Adults With HIV||University Hospital Case Medical Center|No|Completed|November 2007|November 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|Samples Without DNA|Stored plasma and serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|80 HIV-infected adults older than 18 years of age, ART-naïve with CD4 count of at least        400 cells/mm3        The control group will be adults, healthy controls with no active infection or        inflammatory condition, who are matched by gender and age to the HIV positive group|December 2014|December 18, 2014|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575939||163700|
NCT00575926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFGrants2000.MKS|Lingzhi for Cancer Children|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Clinical Effects of Ganoderma Lucidum (Ling Zhi) in Children With Cancer||Chinese University of Hong Kong|No|Completed|September 2002|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|2 Years|18 Years|No|||December 2007|December 17, 2007|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575926||163701|
NCT00576524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-12-5712|Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During Dialysis|Application of Impedance Threshold Device Technologies to Treat and Prevent Intradialytic Hypotension in Children Undergoing Hemodialysis|ITD|Children's Hospital of Philadelphia|No|Terminated|September 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|8 Years|18 Years|No|||January 2013|January 22, 2013|December 17, 2007|Yes|Yes|Completion not feasible. THERE ARE NO RESULTS FROM THIS TRIAL|No|December 12, 2012|https://clinicaltrials.gov/show/NCT00576524||163656|
NCT00560261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061013|Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease|Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease|VOLCADREP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2008|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|120|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||July 2012|August 2, 2012|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560261||164877|
NCT00561223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12768|Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)|The Effect of Iloprost on Gas Exchange and Pulmonary Mechanics in Patients With COPD|Iloprost|University of Oklahoma|Yes|Completed|September 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||January 2014|January 6, 2014|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00561223||164803|
NCT00560820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2123|Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload|Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload||Novartis||Completed|September 2007|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|November 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00560820||164834|
NCT00560833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06459|Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause||Merck Sharp & Dohme Corp.|No|Completed|October 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|943|||Female|40 Years|65 Years|No|||May 2015|May 11, 2015|November 16, 2007|Yes|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT00560833||164833|
NCT00562029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|djb-2007|Study of Duodenal-Jejunal Bypass(DJB) as a Potential Cure for Type 2 Diabetes Mellitus|Modified Duodenal Switch Procedure "Duodenal-Jejunal Bypass" (Diabetes Surgery) As A Potential Cure for Type 2 Diabetes Mellitus in Non-Obese Patients- a Pilot Project to Validate a Prospective Randomized Control Trial|DJB|Sound Shore Medical Center of Westchester|Yes|Completed|November 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||May 2015|May 19, 2015|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00562029||164742|
NCT00562003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061005016 (UAB 0643)|Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients|A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (Ad5-Delta 24 RGD)for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients (Infectivity Enhanced Virotherapy for Ovarian Cancer)|Ad5Delta24RGD|University of Alabama at Birmingham|Yes|Completed|June 2007|June 2010|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|19 Years|N/A|No|||January 2011|January 25, 2011|November 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00562003||164744|
NCT00562016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7182007|Protect II, A Prospective, Multicenter Randomized Controlled Trial|PROTECT II: A Prospective, Multi-center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump (IABP)in Patients Undergoing Non Emergent High Risk PCI|PROTECT II|Abiomed Inc.|Yes|Terminated|October 2007|September 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|452|||Both|18 Years|90 Years|No|||March 2011|March 18, 2011|November 19, 2007|Yes|Yes|Futility on primary endpoint.Study confounded by statistically significant differences between    the two arms re: atherectomy, duration of support.|No||https://clinicaltrials.gov/show/NCT00562016||164743|
NCT00562588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.182|EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA|EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study||Boehringer Ingelheim||Completed|July 2007|||February 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|551|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|July 6, 2007||||No|January 29, 2010|https://clinicaltrials.gov/show/NCT00562588||164699|
NCT00562263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11113|Barriers to Effective Weight Loss in Overweight Adolescents|Barriers to Effective Weight Loss in Overweight Adolescents Enrolled in an Intensive, Team-based, Family-centered Lifestyle Modification Program|TEENS|Virginia Commonwealth University|Yes|Completed|October 2007|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|257|||Female|11 Years|18 Years|Accepts Healthy Volunteers|||March 2014|March 28, 2014|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562263||164724|
NCT00562276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 2535|Immediate Versus Delayed Intrauterine Device (IUD) Insertion Following First Trimester Suction Aspiration Procedures|Immediate Versus Delayed IUD Insertion Following Suction Aspiration Between 5 and 12 Weeks Gestation: a Randomized Trial|PAIR|Oregon Health and Science University|Yes|Completed|May 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|578|||Female|18 Years|N/A|No|||September 2012|September 12, 2012|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562276||164723|
NCT00562562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15148|A Pilot MRI Study of Osteopathic Manipulative Treatment of Acute Low Back Pain|A Pilot MRI Study of Osteopathic Manipulative Treatment of Acute Low Back Pain|MRI-OMT|Ohio University|No|Recruiting|September 2007|August 2008|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|18 Years|55 Years|No|||November 2007|November 21, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562562||164701|
NCT00563420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 1621-01|Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer|Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer||Hospital Authority, Hong Kong||Completed|November 2002|June 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Diagnostic|||Anticipated|400|||Both|40 Years|N/A||||October 2013|October 22, 2013|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563420||164635|
NCT00563433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-78-304|MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers|MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers||MacroChem Corporation|No|Completed|August 1994|July 1996|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|342|||Both|18 Years|N/A|No|||November 2007|November 21, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563433||164634|
NCT00563446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWC/EX/05-041|Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia|Conversion From Once Weekly Recombinant Human Erythropoietin to Once Monthly Darbepoetin Alfa for the Treatment of Renal Anemia in Continuous Ambulatory Peritoneal Dialysis Patients||Hospital Authority, Hong Kong||Completed|July 2005|May 2006|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|16|||Both|N/A|N/A||||June 2011|June 14, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563446||164633|
NCT00559806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01-322606|The Effect of Aging and Immobilisation on Muscle|The Effect of Aging and Immobilisation on Muscle||Bispebjerg Hospital|No|Completed|January 2007|May 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Male|20 Years|80 Years|Accepts Healthy Volunteers|||November 2007|November 15, 2007|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559806||164911|
NCT00574509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-96|BEAM+131I-Anti-B1 & Autologous Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma|BEAM + 131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma||University of Nebraska|No|Active, not recruiting|March 1996|December 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|19 Years|70 Years|No|||January 2013|January 8, 2013|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574509||163807|
NCT00575666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000731|Intranasal Insulin Treatment in Patients With Schizophrenia|Intranasal Insulin Treatment in Patients With Schizophrenia||University of Massachusetts, Worcester|Yes|Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||November 2012|November 15, 2012|December 14, 2007||No||No|April 27, 2012|https://clinicaltrials.gov/show/NCT00575666||163720|
NCT00575952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9920|Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer|A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure||Gynecologic Oncology Group||Active, not recruiting|January 2008|||January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|N/A|N/A|No|||December 2014|December 23, 2014|December 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00575952||163699|
NCT00576199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21358|A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer|A Phase II Single Arm, Multi-centre Study of Bevacizumab (Avastin®) Pre- and Post-transarterial Chemoembolisation (TACE) Treatment for Localized Unresectable Hepatocellular Carcinoma (HCC)||Hoffmann-La Roche||Completed|February 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|December 18, 2007||No||No|August 18, 2014|https://clinicaltrials.gov/show/NCT00576199||163680|
NCT00576537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3368|Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors|Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System||Cedars-Sinai Medical Center|Yes|Completed|March 2001|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||February 2013|February 18, 2013|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576537||163655|
NCT00560521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oliveira-1|Continuous Positive Airway Pressure on Tuberculosis Pleural Effusion|Effect of Continuous Positive Airway Pressure on Fluid Absorption Among Patients With Pleural Effusion Due to Tuberculosis||Universidade Federal do Rio de Janeiro|Yes|Completed|March 2005|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2007|November 16, 2007|November 16, 2007||||No||https://clinicaltrials.gov/show/NCT00560521||164857|
NCT00560885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2007-1|AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation|AtriCure Synergy Bipolar RF Energy Lesions for Permanent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery|ABLATE|AtriCure, Inc.|Yes|Completed|November 2007|December 2012|Actual|December 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|November 19, 2007|Yes|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00560885||164829|
NCT00559988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT|Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk|The IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients With ICD and CRT-D Devices|IMPACT|Biotronik, Inc.|Yes|Terminated|February 2008|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|2718|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|November 15, 2007||No||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00559988||164898|This study was stopped early when the primary endpoint met futility criteria. Continuation might possibly have changed the outcome; however, it was unlikely to demonstrate a meaningful clinical benefit for the intervention under investigation.
NCT00560001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS 2003-2 FAST TRACK|MD.2 Medication Dispenser Medication Adherence Study|Medication Dispenser: MD2: Improving Health Outcomes||Interactive Medical Developments|Yes|Recruiting|January 2006|May 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|600|||Both|60 Years|N/A|No|||November 2007|October 7, 2009|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00560001||164897|
NCT00560014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPIDS|Nutrient Levels Alter Transplant Outcome|Role of Immunonutrient Levels in Preventing Complications After Renal Transplantation||University of Cincinnati|No|Completed|September 1997|May 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|54|||Both|N/A|N/A|No|||October 2007|November 16, 2007|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00560014||164896|
NCT00561470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10262|Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen|A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen|VELOUR|Sanofi|Yes|Completed|November 2007|June 2012|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1226|||Both|18 Years|N/A|No|||March 2012|September 27, 2012|November 20, 2007|Yes|Yes||No|August 17, 2012|https://clinicaltrials.gov/show/NCT00561470||164784|
NCT00561457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-1021|A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System|A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System|Luminexx|C. R. Bard|No|Completed|June 2003|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|18 Years|N/A|No|||April 2011|April 6, 2011|November 20, 2007|Yes|Yes||No|May 26, 2009|https://clinicaltrials.gov/show/NCT00561457||164785|
NCT00562302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-1053|Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure|A Prospective, Randomized, Multi-centered Safety and Efficacy Evaluation of the Bio-Seal Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy||Angiotech Pharmaceuticals|No|Completed|April 2005|August 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|339|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|November 20, 2007|Yes|Yes||No|February 4, 2013|https://clinicaltrials.gov/show/NCT00562302||164721|
NCT00562289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060406|Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence|Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence|CLOSE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|900|||Both|16 Years|60 Years|No|||November 2015|November 13, 2015|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562289||164722|
NCT00562874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609-55|Nutrition Intervention in Drug Naive HIV-infected Kenyan Women and Their Children|Increasing Animal Source Foods in Diets of HIV-Infected Kenyan Women and Their Children|HNP|Indiana University|No|Completed|June 2006|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|808|||Both|6 Months|N/A|Accepts Healthy Volunteers|||April 2013|April 3, 2013|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562874||164677|
NCT00562887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-222|Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease|A Phase 2B, Multi-Center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects With Moderately to Severely Active Crohn's Disease.||Abbott|Yes|Terminated|November 2007|||April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|246|||Both|18 Years|74 Years|No|||August 2011|August 18, 2011|November 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562887||164676|
NCT00562861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH78060-01A1|Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram|Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram||Tufts Medical Center|Yes|Completed|November 2007|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|64 Years|No|||June 2015|June 22, 2015|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562861||164678|
NCT00563147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-07-102|A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma|A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma||AVEO Pharmaceuticals, Inc.|No|Completed|November 2007|February 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||September 2011|September 30, 2011|November 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00563147||164656|
NCT00563160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(193-h)in QE/EC/I|Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery|Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery||Hospital Authority, Hong Kong||Recruiting|May 2005|February 2007|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|75 Years||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563160||164655|
NCT00555295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-AS-389-CTIL|Laparoscopic Colorectal Surgery For Cancer- Long Term Survival|Survival After Laparoscopic Colorectal Surgery||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2007|February 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples Without DNA|Colonic Resection|Both|N/A|N/A|No|Non-Probability Sample|Patients with Colon Cancer|June 2007|November 7, 2007|October 27, 2007||||No||https://clinicaltrials.gov/show/NCT00555295||165240|
NCT00555308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMED 094-07|Emergency Department Targeted Ultrasound for the Detection of Hydronephrosis|Emergency Department Targeted Ultrasound for the Detection of Hydronephrosis||Queen's University|No|Completed|November 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|16 Years|65 Years|No|||July 2009|July 21, 2009|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555308||165239|
NCT00563797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSS # ER0004|Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence|Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence||Yale University|Yes|Completed|August 2007|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|21|||Both|21 Years|65 Years|No|||July 2014|July 8, 2014|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00563797||164608|
NCT00575107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0319|A System for Lengthening Contraction Training of Muscle|A System for Lengthening Contraction Training of Muscle|LCT|University of Michigan|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|36|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||January 2010|August 3, 2011|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575107||163762|
NCT00575120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-21003|Endothelial Function Assessed With BOLD-MRI|Assessment of Endothelial Function Using Blood Oxygen Level-Dependent MRI (BOLD-MRI)|EFBOLD-MRI|University of Calgary|Yes|Completed|September 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|15|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 2, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00575120||163761|
NCT00575679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTS-AL0757|Behavior and Driving Safety Study|Behavior and Driving Safety Study|BADS|University of California, Davis|No|Active, not recruiting|January 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|No|||October 2012|October 27, 2012|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575679||163719|
NCT00575692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-06-CMR-01|Magnetic Resonance Imaging in the Diagnosis of Pulmonary Hypertension|Magnetic Resonance Imaging in the Diagnosis of Pulmonary Hypertension||Medical University of Graz|Yes|Completed|December 2006|December 2013|Actual|December 2013|Actual|N/A|Observational|N/A||2|Actual|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cardiac MR is recommended to all patients with suspected, latent and manifest PH who are        investigated by right heat catheter in the Department of Pulmonology. Patients with        pacemaker, agoraphobia or other standard MR contraindications are excluded from the study.|May 2014|May 27, 2014|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575692||163718|
NCT00576212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0157-E|Impact of a Telephone-based Support Intervention on the Long-term Well-being of Women Undergoing Termination of Pregnancy for Fetal Anomaly|The Impact of a Telephone-based Support Intervention on the Long-term Well-being of Women Undergoing Termination of Pregnancy for Fetal Anomaly|TOPFA|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Withdrawn|September 2007|September 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|19 Years|N/A|No|||July 2009|July 29, 2009|December 17, 2007|||Study halted prematurely, prior to enrollment of first participant.|No||https://clinicaltrials.gov/show/NCT00576212||163679|
NCT00576225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGT307|CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL|Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL||CTI BioPharma|Yes|Active, not recruiting|September 2007|January 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Female|18 Years|N/A|No|||May 2013|May 20, 2013|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00576225||163678|
NCT00576238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO/02/08|Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser|A Multi Centre, Parallel, Randomised Study of the Skin Tolerance of Betamethasone Creams on Atopic Eczema and the Influence of Moisturiser Treatment on the Recurrence of Eczema||ACO Hud Nordic AB|No|Completed|January 2004|February 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|65 Years|No|||October 2008|October 10, 2008|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00576238||163677|
NCT00576251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-19|TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension|||Alcon Research|No|Completed|October 2007|March 2008||February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|2 Years|N/A|No|||February 2010|February 23, 2010|December 17, 2007|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00576251||163676|
NCT00560898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001418|Comparison of Two Multi-Purpose Solution and Lens Material Combinations on Corneal Barrier Function|Comparison of Two Multi-Purpose Solution and Contact Lens Material Combinations on Human Corneal Barrier Function||Southern California College of Optometry|No|Completed|September 2007|March 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2008|May 19, 2008|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00560898||164828|
NCT00560547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21349|A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.|An Open Label Study to Assess the Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Monthly Administration of Mircera in Hemodialysis Patients With Chronic Renal Anemia.||Hoffmann-La Roche||Withdrawn|October 2007|October 2009|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||February 2008|February 15, 2008|November 16, 2007||No|The study was cancelled before any patients were enrolled, due to operational reasons.|No||https://clinicaltrials.gov/show/NCT00560547||164855|
NCT00560846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER: 07-123|Perioperative Nutrition in Upper Gastrointestinal (GI) Cancer Surgery|Perioperative Nutrition in Upper GI Cancer Surgery (Oesophagectomy or Gastrectomy)||University Hospital, Geneva|No|Terminated|November 2007|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|November 19, 2007||No|Insufficient recruitment over time.|No||https://clinicaltrials.gov/show/NCT00560846||164832|
NCT00560859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804695|Childhood Adenotonsillectomy Study for Children With OSAS|A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome|CHAT|University of Pennsylvania|Yes|Completed|October 2007|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|453|||Both|5 Years|9 Years|No|||November 2015|November 10, 2015|November 19, 2007||No||No|July 13, 2015|https://clinicaltrials.gov/show/NCT00560859||164831|Children under 5 years of age, in whom OSAS is common, were not included. Children on medications for ADHD or with prolonged oxygen-hemoglobin desaturation were also excluded, so results cannot be extrapolated to such children.
NCT00561483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-834|Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure|Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure||The Cleveland Clinic|No|Recruiting|November 2007|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|Patients admitted to the hospital with decompensated heart failure|June 2011|June 21, 2011|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561483||164783|
NCT00561704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADL|Adiponectin in Obese Women With T2DN and Effects by RAS Blocker|Adiponectin in Obese Women With T2DN and Effects by RAS Blocker||Shanghai Jiao Tong University School of Medicine|Yes|Completed|April 2007|October 2007|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Female|30 Years|N/A|No|||November 2007|November 20, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00561704||164767|
NCT00562601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870163|LCI Apheresis to Obtain Plasma or White Blood Cells|Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|October 1987|||||N/A|Observational|N/A|||Actual|858|||Both|2 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562601||164698|
NCT00562614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLx-2101-07-08|Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension|A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5 mg or 10 mg Once Daily for up to 14 Days in Patients With Hypertension||Kadmon Corporation, LLC|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|70 Years|No|||January 2015|January 8, 2015|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562614||164697|
NCT00563121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROP001|VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V|Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V||Asociación para Evitar la Ceguera en México|Yes|Completed|March 2007|June 2007|Actual|||Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|1 Month|10 Years|No|||November 2007|November 23, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563121||164658|
NCT00563134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR/04-018|A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult|A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults||Hospital Authority, Hong Kong||Suspended|October 2005|December 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|1800|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563134||164657|
NCT00554996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4623-R|Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study|Bacterial Interference for Prevention of Catheter-Associated UTI||VA Office of Research and Development|Yes|Completed|August 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|50 Years|N/A|No|||September 2015|September 25, 2015|November 5, 2007|Yes|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT00554996||165263|Our trial was a small study with no control group.
NCT00555607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOAIR|Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease|Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease|BIOAIR|Karolinska Institutet|No|Active, not recruiting|March 2002|December 2017|Anticipated|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|233|||Both|18 Years|80 Years|No|||June 2011|September 14, 2015|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555607||165216|
NCT00555620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181126|Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer|A Phase 1 Study Of Sunitinib Malate In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer||Pfizer|No|Completed|May 2008|December 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|November 6, 2007|No|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00555620||165215|
NCT00575367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-101|Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers|A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration||Merck Sharp & Dohme Corp.|No|Completed|March 2008|||October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 20, 2011|December 14, 2007|Yes|Yes||No|August 10, 2009|https://clinicaltrials.gov/show/NCT00575367||163743|
NCT00575380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-103|Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery|A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery||Merck Sharp & Dohme Corp.|No|Completed|December 2007|||June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|116|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 20, 2011|December 12, 2007|Yes|Yes||No|June 9, 2009|https://clinicaltrials.gov/show/NCT00575380||163742|
NCT00575146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGO|Ketogenic Diet for Recurrent Glioblastoma|Ketogenic Diet for Patients With Recurrent Glioblastoma|ERGO|University Hospital Tuebingen|No|Completed|December 2007|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|December 17, 2007||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00575146||163759|Because of the small number of patients efficacy cannot be concluded by the results of the study
NCT00575705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30DK074038|UAB Recessive PKD Research and Translational Core Center|The ARPKD Clinical and Genetic Resource (UAB Recessive PKD Research and Translational Core Center)|UAB RPKDCC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Active, not recruiting|November 2005|November 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Blood-derived DNA and lymphocytes for EBV-immortalized cell lines.|Both|N/A|35 Years|No|Non-Probability Sample|In view of the genetics and demographics of ARPKD in North America, we estimate that 50%        of the subjects will be female; that 90% of the subjects will be Caucasian and the        remainder will belong to the following racial/ethnic categories: 5% African-Americans; 3%        Hispanics; 1% Asians; and 1% or less will be other categories.|March 2011|March 15, 2011|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00575705||163717|
NCT00575965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-175|Simvastatin in Waldenstrom's Macroglobulinemia|Phase II Study of Simvastatin in Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Terminated|November 2007|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|December 16, 2007||No|Slow accrual led to early study termination.|No|December 19, 2012|https://clinicaltrials.gov/show/NCT00575965||163698|Slow accrual led to early study termination.
NCT00576264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11388|Stem Cells Found in the Abdominal Cavity in Humans|Peritoneal Cavity Derived Stem Cells: A Pilot Study||Cedars-Sinai Medical Center|No|Recruiting|April 2007|February 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|peritoneal fluid|Both|18 Years|60 Years|No|Probability Sample|subjects undergoing scheduled elective intra-abdominal surgery|December 2007|June 24, 2011|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00576264||163675|
NCT00560560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021006|Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments|A Phase II, Single Arm Study Of CP-751,871 In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum||Pfizer|No|Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|November 15, 2007|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00560560||164854|
NCT00561236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002507EMC|Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function|Low Dose (1mcg ) ACTH Stimulation Test for Assessment of the Hypothalamo- Pituitary- Adrenal Axis in Patients Treated With Intravitreal Injection of Triamcinolone Acetonide||HaEmek Medical Center, Israel|No|Recruiting|April 2007|January 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|hospital-based ophtalmologic clinic|November 2007|November 18, 2007|November 18, 2007||||No||https://clinicaltrials.gov/show/NCT00561236||164802|
NCT00561249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/453|Randomized Prospective Trial on the Use of Laser Assisted Hatching (LAH) for Transfer of Frozen/Thawed Embryos in Human IVF/ICSI|Randomized Prospective Trial on the Use of Laser Assisted Hatching (LAH) for Transfer of Frozen/Thawed Embryos in Human IVF/ICSI||University Hospital, Ghent|No|Completed|December 2007|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|293|||Female|18 Years|N/A|No|||January 2014|January 24, 2014|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00561249||164801|
NCT00561743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010927|A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients|A Phase II Study to Assess the Safety and Efficacy of DBd Combination Therapy (DOXIL/CAELYX) [Doxorubicin HCL Liposome Injection], VELCADE [Bortezomib] and Dexamethasone) for Previously Untreated Multiple Myeloma Patients||Janssen-Ortho Inc., Canada||Completed|November 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Both|18 Years|70 Years|No|||April 2010|June 7, 2011|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561743||164764|
NCT00561717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12962|A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis|A Four-Way Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray and Antihistaminic Agents in Adult Subjects With Allergen Induced Seasonal Allergic Rhinitis|GEYSER|Bayer|No|Completed|October 2007|February 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|70|||Both|18 Years|65 Years|No|||May 2013|May 5, 2013|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00561717||164766|
NCT00561730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN 20/40 Panther 07/10|Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)|Pantoprazole 20 mg/40 mg for the Treatment of Gastroesophageal Reflux Disease (GERD)|PANTHER|Nycomed|No|Completed|October 2007|December 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1995|||Both|12 Years|N/A|No|Non-Probability Sample|Outpatients|May 2012|May 4, 2012|November 12, 2007||No||No|August 23, 2010|https://clinicaltrials.gov/show/NCT00561730||164765|
NCT00562042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-10006|Risk Stratification for Patients Presenting With Acute Pulmonary Embolism (PE)|Risk Stratification for Patients Presenting With Acute Pulmonary Embolism (PE)||Walter Reed Army Medical Center|No|Terminated|June 2004|January 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients diagnosed with acute pulmonary embolism|November 2007|November 20, 2007|November 20, 2007|||Study was stopped due to slow accrual of patients.|No||https://clinicaltrials.gov/show/NCT00562042||164741|
NCT00562055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061060|Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.|Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.||Pfizer||Withdrawn|November 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|55 Years|No|||June 2008|June 19, 2008|November 19, 2007|||This study was withdrawn due to business reasons.|No||https://clinicaltrials.gov/show/NCT00562055||164740|
NCT00558636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12621|A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)||Bayer|Yes|Terminated|September 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|November 9, 2007||No|Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in    NSCLC and increased mortality in subjects with squamous subtype.|No|November 13, 2009|https://clinicaltrials.gov/show/NCT00558636||164997|Due to early termination of the study, no comparison of treatments was possible. This study also provided limited opportunity to distinguish between Adverse Events associated with sorafenib and events associated with the underlying lung disease.
NCT00562315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006468|FACBC PET/CT for Recurrent Prostate Cancer|18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).||Emory University|Yes|Completed|October 2007|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|128|||Male|18 Years|N/A|No|||July 2015|July 23, 2015|November 20, 2007|No|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT00562315||164720|
NCT00559208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-103|Children's Aid Societies: Differential Response and Wraparound Prevention Trial|The Comparative Effects and Expense of Augmenting Usual Children's Aid Society (CAS) Care With a Regional Differential Response and Wraparound Prevention Service for Children||Hamilton Children's Aid Society|Yes|Completed|October 2006|December 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|135|||Both|1 Year|80 Years|No|Probability Sample|Clients of CAS going on to protective custody cases|November 2009|June 22, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559208||164955|
NCT00562900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrS_10-07|Robotic Assisted Versus Laparoscopic Cholecystectomy - Outcome and Cost Analyses of a Case-Matched Control Study|Robotic Assisted Versus Laparoscopic Cholecystectomy -||University of Zurich|No|Completed|December 2004|February 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2007|November 23, 2007|November 7, 2007||||No||https://clinicaltrials.gov/show/NCT00562900||164675|
NCT00555347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 07011901|Use of Armodafinil for Fatigue in Sarcoidosis|Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis||University of Cincinnati|No|Completed|October 2007|August 2011|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2013|May 26, 2015|November 7, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00555347||165236|
NCT00560131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiac function in CRPS|Evaluation of Autonomic Cardiac Function in Patients With CRPS|Evaluation of Autonomic Cardiac Function in Patients With Complex Regional Pain Syndrome||Danish Pain Research Center|No|Completed|June 2007|January 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|October 2008|October 10, 2008|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560131||164887|
NCT00575432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 213/04|Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy|Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy in Renal Transplantation and Kidney Disease||University Hospital Inselspital, Berne|No|Recruiting|November 2004|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575432||163738|
NCT00575445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eNO/ACT Study|The Use of Exhaled Nitric Oxide in Conjunction With the Asthma Control Test to Determine Asthma Control in Pediatric Patients|||Akron Children's Hospital|No|Terminated|November 2007|March 2015|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|6 Years|18 Years|No|Non-Probability Sample|Pediatric pulmonary clinic|March 2015|March 24, 2015|December 14, 2007||No|Nitric Oxide analyzer not functioning properly|No||https://clinicaltrials.gov/show/NCT00575445||163737|
NCT00575393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0622|Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase I Dose Escalation Study of the PKC Inhibitor, Aurothiomalate (ATM) in Patients With Advanced Non-Small Cell Lung Cancer||Mayo Clinic|Yes|Active, not recruiting|January 2007|||September 2015|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|27|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|December 15, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00575393||163741|
NCT00575406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL-14|Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma|Multicentre Study to Determine the Cardiotoxicity of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone) Compared to R-COMP (Rituximab, Cyclophosphamide, Liposomal Doxorubicin, Vincristin and Prednisolone) in Patients With Diffuse Large B-Cell Lymphoma (NHL-14)|NHL-14|Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Completed|December 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575406||163740|
NCT00576004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_ML_001|Pelvic Organ Prolapse Repair With or Without Concomitant Burch Colposuspension in Patients With Urinary Incontinence|Pelvic Organ Prolapse Repair With or Without Concomitant Burch Colposuspension in Patients With Urinary Incontinence: A Randomised Surgical Trial||University Of Perugia|No|Completed|January 2002|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Female|18 Years|75 Years|No|||December 2007|December 17, 2007|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00576004||163695|
NCT00575978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-23|Hydralazine as Demethylating Agent in Breast Cancer|Hydralazine as Demethylating Agent in Breast Cancer||University of Arkansas|No|Withdrawn|June 2004|December 2009|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Female|18 Years|N/A|No|||March 2015|March 3, 2015|December 14, 2007||No|IRB request|No||https://clinicaltrials.gov/show/NCT00575978||163697|
NCT00575991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2006-0300|Effect of Conjugated Linoleic Acid on Body Fat in Overweight Children|Effect of CLA Supplementation on Body Fat Accretion Among Children Who Are Overweight or at Risk of Overweight||University of Wisconsin, Madison|Yes|Completed|January 2007|September 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575991||163696|
NCT00576576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000701|Evaluation of Atorvastatin on Atherosclerosis Composition|The Evaluation of Atorvastatin on Wall Shear Stress, Atherosclerosis Composition, and Microvascular Function in Patients With Moderate Coronary Disease||Emory University|Yes|Completed|July 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|December 17, 2007|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT00576576||163652|No adverse events to report.
NCT00561262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574367|High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer|An Evaluation of Hemi-ablation Therapy Using High-Intensity Focused Ultrasound in the Treatment of Localized Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Completed|May 2006|April 2011|Actual|October 2009|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Male|N/A|79 Years|No|||June 2009|August 23, 2013|November 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00561262||164800|
NCT00560911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOG60+|Major Outcomes in Elderly Patients With Self-Management of Oral Anticoagulation (SPOG60+)|Impact of Self-Management of Oral Anticoagulation in the Elderly in Terms of Mortality and Morbidity: a Randomized Controlled Trial - SPOG 60+|SPOG60+|Medical University of Graz|No|Completed|March 2002|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|216|||Both|60 Years|N/A|No|||November 2007|November 17, 2007|November 17, 2007||||No||https://clinicaltrials.gov/show/NCT00560911||164827|
NCT00560924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG-1458|Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women|Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women (RUTI) in Post-menopausal Women With Signs of Urogenital Ageing (UGA)||Novo Nordisk A/S|No|Terminated|March 2003|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|6|||Female|N/A|N/A|No|||March 2012|March 19, 2012|November 19, 2007|||Trial prematurely discontinued due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00560924||164826|
NCT00561509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11539|Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months|A Prospective, Observational Study Comparing the Frequency of Treatment-Emergent Sexual Dysfunction Over 8 Weeks in Patients With Major Depressive Disorder Treated With Either Duloxetine Hydrochloride or a Selective Serotonin Reuptake Inhibitor Antidepressant and Evaluated Over 6 Months||Eli Lilly and Company|No|Completed|November 2007|June 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1626|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population will consist of sexually active male and female patients, 18 years        or older with a primary diagnosis of MDD, for whom the treating clinician makes a decision        to treat with a SSRI or SNRI antidepressant. Eligible patients must agree to participate        in the collection of data, and must not present with treatment resistant depression or        have sexual dysfunction at study entry.|July 2009|July 13, 2009|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561509||164781|
NCT00561756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-100|Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma|Phase I Trial to Assess Safety and Immunogenicity of Xenogeneic CD20 DNA Vaccination With Patients With B-Cell Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|October 2007|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00561756||164763|
NCT00561769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATA 2005-21|Luteal Phase Commencing of Growth Hormone|Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response||Gulhane School of Medicine|Yes|Completed|January 2005|November 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|61|||Female|20 Years|40 Years|No|Non-Probability Sample|poor response to previous COH in the same center|November 2007|November 20, 2007|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561769||164762|
NCT00558662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU Study No-05-000003|Randomized Clinical Trial (RCT) to Compare the Efficacy of Coban 2 Versus SSB in the Treatment of Venous Leg Ulcers|Randomized Controlled Clinical Study to Assess the Clinical Efficacy of the 3M™ Coban™ 2 Layer Compression System Compared to a Short-stretch Compression Bandage in the Treatment of Venous Leg Ulcers||3M|Yes|Completed|November 2007|September 2011|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|N/A|No|||March 2011|November 17, 2011|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00558662||164995|
NCT00558948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06120|Musculoskeletal Outcomes After Bone Marrow Transplant|Musculoskeletal Outcomes After Bone Marrow Transplant||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|May 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|48|||Both|8 Years|30 Years|No|Non-Probability Sample|Survivors of bone marrow transplant (autologous and allogeneic) who are at least 1 year        from transplant.|August 2009|August 18, 2009|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00558948||164974|
NCT00558922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-203|A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer|A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer||Aegera Therapeutics|No|Terminated|September 2007|October 2009|Anticipated|August 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||July 2009|July 29, 2009|November 13, 2007|Yes|Yes|Unacceptable Neurotoxicity (2 cases)|No||https://clinicaltrials.gov/show/NCT00558922||164976|
NCT00558935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24/06|The Effect of Alcohol on ABCA1 Expression and Lipid Metabolism|||Bayside Health||Terminated|October 2007|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 9, 2011|November 14, 2007|||It was found that 20g of alcohol daily had no effect on ABCA1 expression or HDL levels.|No||https://clinicaltrials.gov/show/NCT00558935||164975|
NCT00559520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2004|The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery|The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery||Centre Hospitalier Universitaire de Nice|No|Completed|February 2002|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|250|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559520||164932|
NCT00555009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281289|Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury|Placebo Controlled Trial on the Efficacy of Growth Hormone Replacement Therapy in Patients With Growth Hormone Deficiency After Traumatic Brain Injury.||Pfizer|No|Terminated|March 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|55 Years|No|||March 2009|June 1, 2010|October 24, 2007|No|Yes|See termination reason in detailed description.|No|December 22, 2009|https://clinicaltrials.gov/show/NCT00555009||165262|
NCT00559494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17007|Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury|A Pilot Study to Assess Clinical Safety and Tolerance of Minocycline and Spinal Perfusion Pressure Augmentation in Acute Spinal Cord Injury||University of Calgary|Yes|Completed|June 2004|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|52|||Both|16 Years|N/A|No|||March 2013|March 15, 2013|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559494||164934|
NCT00555022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC5108696|Effect of GSK1160724 In Healthy Volunteers|A Randomized Double-blind, Placebo-controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK1160724 and Tiotropium Bromide||GlaxoSmithKline||Completed|December 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|November 6, 2007||||No||https://clinicaltrials.gov/show/NCT00555022||165261|
NCT00560144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21200|A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.|Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.||Hoffmann-La Roche||Completed|December 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Both|2 Years|17 Years|No|||October 2015|October 1, 2015|November 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00560144||164886|
NCT00559858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCA-CCTC-CAPP-IT|Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer|A Randomised Placebo-controlled Study Evaluating the Role of Pyridoxine in Controlling Capecitabine-induced Hand-foot Syndrome||National Cancer Institute (NCI)||Active, not recruiting|December 2004|||December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|270|||Both|18 Years|N/A|No|||December 2008|August 1, 2013|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559858||164907|
NCT00560157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCNF 0401|Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients|Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients||Nestlé|No|Completed|December 2002|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|89 Years|No|||November 2013|November 18, 2013|November 6, 2007||||No||https://clinicaltrials.gov/show/NCT00560157||164885|
NCT00574834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044872-Ramipril|Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes|Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis||University of Maryland|Yes|Terminated|March 2007|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|17|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 13, 2007||No|Lack of funding|No|December 10, 2015|https://clinicaltrials.gov/show/NCT00574834||163782|Early termination leading to small numbers of subjects analyzed. No conclusions drawn.
NCT00574847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009555|Responses of Myocardial Ischemia to Escitalopram Treatment|Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)|REMIT|Duke University|Yes|Completed|September 2006|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|21 Years|90 Years|No|||July 2015|July 8, 2015|December 12, 2007|Yes|Yes||No|June 11, 2015|https://clinicaltrials.gov/show/NCT00574847||163781|
NCT00579579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-151|Functional Outcomes and Quality of Life in Patients Undergoing Surgery for Rectal Cancer|Functional Outcomes and Quality of Life in Patients Undergoing Surgery for Rectal Cancer||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|November 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|229|||Both|18 Years|N/A|No|Non-Probability Sample|Participants are being asked to take part in this study because they have rectal cancer        and are planning on having surgery done at MSKCC.|August 2015|August 11, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579579||163428|
NCT00575419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-3673|Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure|Dose Escalation Study Of I.V. And Intra-Aortic N-Acetylcysteine For The Prevention Of Contrast Induced Nephropathy In Patients With Stage 3 Renal Failure Undergoing Contrast Imaging Studies: A Phase I Trial|CIN-NAC|Oregon Health and Science University|Yes|Recruiting|November 2007|December 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|85 Years|No|||November 2012|November 28, 2012|December 14, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00575419||163739|
NCT00576277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV411-010|Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain|A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of AV411 to Assess Its Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in the Treatment of Neuropathic Pain||Avigen|Yes|Completed|September 2006|November 2007|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|70 Years|No|||April 2007|December 17, 2007|December 17, 2007||||No||https://clinicaltrials.gov/show/NCT00576277||163674|
NCT00580073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0197 (CO06207)|Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum|A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum||University of Wisconsin, Madison|Yes|Completed|December 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||October 2010|October 15, 2010|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580073||163391|
NCT00580333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-202|Preoperative Cisplatin and Bevacizumab in ER-, PR-, Her-2 Negative Breast Cancer|A Phase II Trial of Preoperative Cisplatin and Bevacizumab in ER-, PR-, Her-2 Negative Breast Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|September 2007|December 2013|Anticipated|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580333||163371|
NCT00560963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2491|Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine|Combination of Antiangiogenic Therapy Using the mTOR-inhibitor RAD001 and Low Dose Chemotherapy for Locally Advanced and/or Metastatic Pancreatic Cancer - a Dose Finding Study||Novartis||Completed|October 2007|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560963||164823|
NCT00557401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-B-057|An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD|A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of XP19986 in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)||Indivior Inc.|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|156|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|November 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00557401||165087|
NCT00561496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A04-095|Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel|Single Dose and 14-Day Once or Twice-Daily Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel||CONRAD|No|Completed|March 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|49|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2008|May 27, 2008|November 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00561496||164782|
NCT00561275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-454|Safety Study of Multiple Peptide Vaccine to Esophageal Cancer|Phase 1 Study of Multiple Peptide Vaccine Therapy and GM-CSF in Treating Patients With Esophageal Cancer||Japanese Foundation for Cancer Research|No|Completed|October 2007|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|75 Years|No|||July 2008|July 10, 2008|November 14, 2007||||No||https://clinicaltrials.gov/show/NCT00561275||164799|
NCT00558012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612018|Zoledronic Acid for Osteoporosis in the Elderly|Maintenance of Skeletal Integrity in Frail Elders|ZEST|University of Pittsburgh|Yes|Completed|December 2007|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|181|||Female|65 Years|N/A|No|||July 2015|July 9, 2015|November 13, 2007|Yes|Yes||No|June 15, 2015|https://clinicaltrials.gov/show/NCT00558012||165042|
NCT00558025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.636|Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease|A Double-blind, Double-dummy, Randomized, Parallel Groups Study to Assess the Efficacy, Safety and Tolerability of Switching Patients With Early Parkinson's Disease (PD) From Pramipexole IR to Pramipexole ER or Pramipexole IR||Boehringer Ingelheim||Completed|October 2007|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|30 Years|N/A|No|||May 2012|May 7, 2014|November 12, 2007|Yes|Yes||No|May 26, 2009|https://clinicaltrials.gov/show/NCT00558025||165041|There were no serious adverse events in the trial and no non-serious adverse events with an incidence >5%.
NCT00558298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002023|A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.|Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open Label Follow up Trial of RIS-INT-57 and RIS-INT-61.||Janssen, LP||Completed|February 2000|February 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|811|||Both|18 Years|N/A|No|||April 2010|May 16, 2011|November 12, 2007||||No||https://clinicaltrials.gov/show/NCT00558298||165020|
NCT00558649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP39|A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines|A Pilot, Controlled, Comparative and Single Blinded Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines Administered Intradermally Using Microneedle Injectors as Compared With Standard Dose Intramuscular Flu Vaccines as Reference.|NANOVAX|NanoPass Technologies Ltd|No|Completed|May 2007|December 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|180|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2007|May 8, 2013|May 27, 2007||||No||https://clinicaltrials.gov/show/NCT00558649||164996|
NCT00563199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTWC/CREC/325/04|A Randomized Controlled Trial of a Nurse Delivered Stage-matched Smoking Cessation Intervention to Promote Heart Health of Cardiac Patients|A Randomized Controlled Trial of a Nurse Delivered Stage-matched Smoking Cessation Intervention to Promote Heart Health of Cardiac Patients||Hospital Authority, Hong Kong||Completed|March 2002|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|||Anticipated|1824|||Both|N/A|N/A||||June 2011|June 14, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563199||164652|
NCT00559221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-007A|FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML|Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia||Cooperative Study Group A for Hematology|No|Recruiting|December 2004|June 2008|Anticipated|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|15 Years|60 Years|No|||November 2007|October 13, 2008|November 15, 2007||||No||https://clinicaltrials.gov/show/NCT00559221||164954|
NCT00559507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00191|Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery|A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer||National Cancer Institute (NCI)||Completed|October 2007|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2013|April 2, 2014|November 15, 2007|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00559507||164933|
NCT00563836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-CAT-OC-02|Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer|Multicenter, Single-arm, Phase II Study of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intra- and Postoperatively in Patients With Epithelial Ovarian Cancer||Neovii Biotech|Yes|Completed|November 2007|August 2010|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Female|18 Years|N/A|No|||August 2012|October 2, 2012|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00563836||164605|
NCT00563849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWA486_4021|Leflunomide + Methotrexate in Rheumatoid Arthritis|An Open-Label, Multi-Center Study to Evaluation of Leflunomide Plus Methotexate for the Treatment of Rheumatoid Arthritis in DMARDs:(Disease-Modifying Antirheumatic Drug) na¿ve or Restart (Skip DMARDs More Than 4 Weeks) Subjects.||Sanofi|No|Completed|May 2003|August 2004|Actual|||Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|75 Years|No|||December 2007|December 3, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563849||164604|
NCT00555035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ING111207|GSK1349572 First Time in Human Study|A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects||GlaxoSmithKline||Completed|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|November 5, 2007||||||https://clinicaltrials.gov/show/NCT00555035||165260|
NCT00555321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-045|Belatacept in Liver Transplant Recipients|Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients||Bristol-Myers Squibb|Yes|Terminated|January 2008|June 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|260|||Both|18 Years|70 Years|No|||September 2012|September 17, 2012|November 7, 2007|Yes|Yes||No|September 17, 2012|https://clinicaltrials.gov/show/NCT00555321||165238|
NCT00555334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-002|Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|LAM-RFA|Sun Yat-sen University|Yes|Recruiting|November 2007|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||March 2009|March 31, 2009|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00555334||165237|
NCT00564122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070904|The Accuracy of an Artificially-intelligent Stethoscope|A Comparison of the Accuracy of an Artificially-Intelligent Stethoscope Versus Pediatric Cardiologists in the Assessment of Pediatric Patients Referred to a Cardiologist for the Assessment of a Heart Murmur||Akron Children's Hospital|Yes|Completed|December 2007|June 2008|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The patient must present to a consulted Cardiologist for a 1st non-primary care murmur        evaluation. This will usually occur in an outpatient Pediatric Cardiology clinic site.|October 2011|October 31, 2011|November 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00564122||164583|
NCT00560170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKUH-01/HR-95-112|Vascular Effects of Ezetimibe/Simvastatin and Simvastatin on Atherosclerosis|Rho-kinase in Patients With Atherosclerosis: Effects of Statins A Randomized Clinical Trial Comparing Ezetimibe/Simvastatin and Simvastatin||National Cheng-Kung University Hospital|No|Completed|September 2007|February 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|40 Years|80 Years|No|||February 2010|February 23, 2010|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560170||164884|
NCT00560404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21208|A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.|A Randomized, Open Label Study to Compare the Effect of Once Monthly Administration of Subcutaneous Mircera Versus Epoetin Alfa on Maintenance of Hemoglobin Levels, Safety and Tolerability in Dialysis Patients With Chronic Renal Anemia.¿||Hoffmann-La Roche||Completed||December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|233|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560404||164866|
NCT00560677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA IRB# 01175|Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)|Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation|SAPPHIRE|Durham VA Medical Center|No|Active, not recruiting|March 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|Samples With DNA|Serum and cells collected.|Both|18 Years|72 Years|No|Non-Probability Sample|Veterans with schizophrenia or schizoaffective disorder.|January 2016|January 20, 2016|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560677||164845|
NCT00575133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1450|Prospective Cohort Study in Patients With NAFLD|Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)||University of Zurich|No|Recruiting|December 2007|November 2027|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Liver biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-alcoholic fatty liver disease|February 2012|February 23, 2012|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00575133||163760|
NCT00579345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P4E2|Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup|A Phase III, Single-Blind, Multi-Center, Extension Study to Evaluate Safety and Tolerability of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adult and Elderly Subjects Who Participated in Study V58P4, With Subset Analyses of Immunogenicity and Evaluation of Concomitant Polysaccharide Pneumococcal Vaccine (Elderly).||Novartis|No|Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|1522|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 24, 2012|December 19, 2007||No||No|September 5, 2011|https://clinicaltrials.gov/show/NCT00579345||163446|
NCT00573612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 0708-62|Exercise-based Motivational Interviewing for Fibromyalgia|Exercise-based Motivational Interviewing for Fibromyalgia||Indiana University|No|Completed|December 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|65 Years|No|||March 2011|April 5, 2012|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573612||163874|
NCT00575718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-094|Smoking Cessation Intervention for Cancer Patients|Presurgical Smoking Cessation Intervention for Cancer Patients: The Resolve Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2002|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|204|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00575718||163716|
NCT00579787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-148|Prospective Study Assessing Emotional, Sexual and Quality of Life Concerns Of Women Undergoing Removal of the Cervix Versus Removal of the Uterus,Ovaries and Fallopian Tubes For Treatment Of Early Stage Cervical Cancer|A Prospective Study Assessing the Emotional, Sexual and Quality of Life Concerns Of Women Undergoing Radical Trachelectomy Versus Radical Hysterectomy For Treatment Of Early Stage Cervical Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 2004|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|72|||Female|18 Years|45 Years|No|Non-Probability Sample|Women with early stage cervical cancer undergoing either radical trachelectomy or radical        hysterectomy|November 2010|November 30, 2010|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579787||163413|
NCT00579800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-091|Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation|Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|76|||Female|21 Years|N/A|No|||February 2016|February 2, 2016|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579800||163412|
NCT00579813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32677|Mechanisms Underlying Metabolic Syndrome in Obesity|Mechanisms Underlying Metabolic Syndrome in Obesity||University of Arkansas|No|Completed|April 2005|January 2011|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|December 20, 2007|Yes|Yes||No|February 22, 2011|https://clinicaltrials.gov/show/NCT00579813||163411|
NCT00580320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-03740|Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma|Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma||Virginia Commonwealth University|Yes|Completed|September 2004|November 2013|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00580320||163372|
NCT00575198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDIRB-200715709|Drainage Amount for Removal of Thoracostomy Tube|Non-inferiority Randomized Trial Evaluating Removal of Thoracostomy Tubes Independent of the Drainage Amount Versus Removal When the Drainage Amount Is Low|DARTT|University of California, Davis|Yes|Active, not recruiting|December 2007|December 2012|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|14 Years|N/A|No|||October 2012|October 26, 2012|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575198||163755|
NCT00557414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709060R|Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome|Serial Changes of sTREM-1 Levels in Patients With Acute Respiratory Distress Syndrome||National Taiwan University Hospital|Yes|Completed|October 2007|March 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|63|Samples Without DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|patients admitted into ICU of a medical center in Taiwan|May 2008|May 8, 2008|November 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00557414||165086|
NCT00562081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2394|The Virtual Asthma Clinic|Evaluation of an Internet-based Approach to Long-term Treatment of Asthma.|VAC|University of Alberta|No|Suspended|March 2005|June 2007|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|70 Years|No|||January 2009|January 4, 2010|November 20, 2007|||Poor recruitment.|No||https://clinicaltrials.gov/show/NCT00562081||164738|
NCT00561288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20619|Effects of Acetaminophen on Hurt Feelings|Effects of Acetaminophen on Hurt Feelings||University of Toronto|No|Completed|November 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|17 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 23, 2008|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00561288||164798|
NCT00557700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/378|Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma|Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma||University Hospital, Ghent|No|Completed|January 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||June 2010|June 15, 2010|November 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00557700||165066|
NCT00562653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sourasky medical centrs|Autoantibodies and Clinical Symptoms in Infective Endocarditis Patients|Study of Autoantibodies in Infective Endocarditis||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|November 2007|November 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|None Retained|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|infective endocarditis patients|November 2007|November 21, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00562653||164694|
NCT00562926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC-2004, 247|Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong Chinese|Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong Chinese||Hospital Authority, Hong Kong||Completed|July 2004|June 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||Anticipated|32|||Both|18 Years|N/A||||August 2013|August 20, 2013|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562926||164673|
NCT00563212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9583|A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis|A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis||New York University School of Medicine|Yes|Active, not recruiting|January 2007|June 2016|Anticipated|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|40 Years|75 Years|No|||March 2016|March 8, 2016|November 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00563212||164651|
NCT00563225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_3506|20 Week Bridging Study in Type II DM|A Multicenter, Non-Comparative, Open, Phase III Study to Evaluate the Efficacy and Safety of Insulin Glargine on Subjects With Type 2 Diabetes Mellitus||Sanofi|No|Completed|October 2002|April 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|90|||Both|40 Years|80 Years|No|||November 2007|November 23, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563225||164650|
NCT00563472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR3081|Feasibility Study Into the Contraceptive Effect of Estetrol|A Feasibility Study Into the Contraceptive Effect of Estetrol Alone or Combined With Either Progesterone or Desogestrel by Daily Oral Administration to Healthy Female Volunteers for 28 Days.||Pantarhei Bioscience|No|Completed|November 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|November 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00563472||164631|
NCT00563485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.313-T|Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up|Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily in the Successful Rate of Trial Without Catheter in Acute Urinary Retention With Long Term Follow up||Hospital Authority, Hong Kong||Terminated|October 2005|November 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Male|50 Years|N/A||||June 2011|June 15, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563485||164630|
NCT00563862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L/M-78 to PYH 08/79|Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)|Prospective Randomized Study on Therapeutic Gain Achieved By Chemoradiation And/Or Accelerated Radiation For T3-4N0-1M0 Nasopharyngeal Carcinoma||Hospital Authority, Hong Kong||Terminated|July 1999|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|465|||Both|N/A|70 Years||||June 2011|June 14, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563862||164603|
NCT00564148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVAST-ro-1|Intravitreal Avastin in Proliferative Retinopathies|Intravitreal Injections With Avastin in Proliferative Retinopathies Related to the Production of VEGF Having Different Causes|SITE-App|Ophthalmological Association Edelweiss|No|Completed|July 2007|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||June 2008|July 20, 2011|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00564148||164581|
NCT00564135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-0424C|Postoperative Urinary Retention and Urinary Track Infection (UTI) After Laparoscopic Assisted Vaginal Hysterectomy (LAVH) for Benign Disease|Postoperative Urinary Retention and UTI After LAVH for Benign Disease||Chang Gung Memorial Hospital|No|Completed|March 2007|July 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Female|34 Years|68 Years|No|||August 2008|June 2, 2015|November 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00564135||164582|
NCT00564161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|606060-HMO-CTIL|VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants|VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants||Hadassah Medical Organization|No|Not yet recruiting|January 2008|January 2009|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|CSF.|Both|25 Weeks|40 Weeks|No|Non-Probability Sample|preterm infants.|November 2007|November 26, 2007|November 25, 2007||||No||https://clinicaltrials.gov/show/NCT00564161||164580|
NCT00560417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11647|Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide|A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide||Eli Lilly and Company|No|Completed|November 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|339|||Both|18 Years|74 Years|No|||January 2011|January 12, 2011|November 15, 2007|Yes|Yes||No|November 12, 2010|https://clinicaltrials.gov/show/NCT00560417||164865|
NCT00560703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-101-BLEPH-201|Treatment of Patients With Blepharitis and Facial Rosacea|Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients With Facial Rosacea||Galderma|No|Completed|November 2007|July 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||December 2011|December 9, 2011|November 16, 2007|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00560703||164843|
NCT00560716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC116-06-01|A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors|A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors||Cyclacel Pharmaceuticals, Inc.|No|Terminated|June 2007|November 2009|Anticipated|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2007|October 21, 2009|November 16, 2007|No|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00560716||164842|
NCT00574873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-3000|Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML|A Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia||Pfizer|No|Completed|February 2008|May 2015|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|502|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|December 13, 2007|Yes|Yes||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00574873||163779|
NCT00574886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267-00|Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy|Pilot Trial for Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy||University of Nebraska|Yes|Completed|July 2000|April 2008|Actual|March 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|19 Years|N/A|No|||December 2013|December 13, 2013|December 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00574886||163778|
NCT00573638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-02-266|Effects of Xal-Ease on Patient Compliance With Xalatan|The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops|Xal-Ease|Georgia Regents University|No|Recruiting|February 2005|December 2009|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|40 Years|80 Years|No|||August 2008|August 7, 2008|December 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00573638||163873|
NCT00579592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2005-0454|Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation|A Pilot Study of Campath-1H Induction Therapy Combined With Rituximab®, Myfortic™ and a Short Course of Calcineurin Inhibitor Therapy to Allow for a Long Term Calcineurin Inhibitor Free Regimen After Renal Transplantation||University of Wisconsin, Madison|Yes|Terminated|April 2006|April 2007|Actual|March 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|December 17, 2007|Yes|Yes|Higher than expected rate of acute rejection|No||https://clinicaltrials.gov/show/NCT00579592||163427|
NCT00579826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10587|Study of Breast Cancer Prevention by Letrozole in High Risk Women|Study of Breast Cancer Prevention by Letrozole in High Risk Women||University of Kansas Medical Center|Yes|Completed|October 2006|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|55|||Female|30 Years|69 Years|No|||October 2015|October 30, 2015|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579826||163410|
NCT00580086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-146|Monitoring Response to Neoadjuvant Chemotherapy by the Use of Breast Proton MR Spectroscopy|Monitoring Response to Neoadjuvant Chemotherapy by the Use of Breast Proton MR Spectroscopy||Memorial Sloan Kettering Cancer Center|Yes|Completed|November 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|Participants are asked to take part in this study because they have breast cancer and are        scheduled to receive chemotherapy treatment before having surgery.|December 2009|December 23, 2009|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00580086||163390|
NCT00574964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200408035|Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme|Phase II Treatment of Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme Treated With Gliadel Wafers, Surgery and Limited Field Radiation Plus Concomitant Temozolomide Followed by Temozolomide|Temodar|University of Iowa|Yes|Terminated|October 2005|October 2010|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|85 Years|No|||March 2010|March 22, 2010|December 14, 2007|Yes|Yes|PI left the institution.|No||https://clinicaltrials.gov/show/NCT00574964||163773|
NCT00562094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN 20/40 PULS 07/10|Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)|Pantoprazole for the Treatment of GERD Associated Symptoms Focusing on Sleep Disorders.|PULS|Nycomed|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8616|||Both|12 Years|N/A|No|Non-Probability Sample|Outpatients|May 2012|May 4, 2012|November 12, 2007||No||No|September 1, 2010|https://clinicaltrials.gov/show/NCT00562094||164737|
NCT00557713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVACROSS|XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma|Treatment of Induction With XELOX-Bevacizumab in Locally Advanced Rectal Adenocarcinoma: Phase II Study||Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials|No|Recruiting|February 2007|October 2013|Anticipated|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||November 2007|November 13, 2007|November 13, 2007||||No||https://clinicaltrials.gov/show/NCT00557713||165065|
NCT00562354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3004|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years|A Phase 3, Open-Label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13vPnC When Administered to Healthy Japanese Adults Aged >= 65 Years and 50 to 64 Years in Japan Who Have Not Received a Previous Dose of 23-Valent Pneumococcal Polysaccharide Vaccine||Pfizer|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|271|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 5, 2011|November 20, 2007|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00562354||164717|
NCT00562666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB 2007-A00249-44|Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells|Immunotherapy of Hepatocellular Carcinoma by Hepatic Intra Arterial Injection of Autologous Gamma-delta T Lymphocytes: A Phase I Study|ICAR|Rennes University Hospital|Yes|Terminated|February 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562666||164693|
NCT00562679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-032|Coronary Artery Disease and Sleep Apnea|Long Term Effects of Sleep Apnea in Patients With Coronary Artery Disease||Umeå University||Completed|March 1992|October 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|408|||Both|N/A|70 Years|No|Probability Sample|Patiens with coronary artery disease beeing referred for evaluation of coronary        intervention|June 2008|July 1, 2008|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562679||164692|
NCT00562939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001588-31|Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults|Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults|ITAP|University of Aarhus|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|97|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00562939||164672|
NCT00563537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC05-PC / SLA|Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis|Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis||University Hospital, Tours|Yes|Recruiting|January 2007|December 2010|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2010|March 18, 2010|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00563537||164626|
NCT00563498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1432-00|Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients|A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.||Hospital Authority, Hong Kong||Recruiting|July 2004|June 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|40|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563498||164629|
NCT00563511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC1966-02|A Randomized Controlled Trial on Smoking Cessation and Adherence Intervention on Patients With Erectile Dysfunction|A Randomized Controlled Trial on Smoking Cessation and Adherence Intervention on Patients With Erectile Dysfunction||Hospital Authority, Hong Kong||Completed|January 2004|August 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|||Anticipated|1210|||Male|18 Years|N/A||||June 2011|June 15, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563511||164628|
NCT00563524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3199K2-1105|Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis|An Ascending Multiple Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ILV-094 Administered Subcutaneously Or Intravenously To Subjects With Psoriasis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2007|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|November 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00563524||164627|
NCT00559585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-174|Methotrexate-Inadequate Response Study|A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate||Bristol-Myers Squibb|No|Completed|January 2008|September 2014|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2492|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|November 15, 2007|Yes|Yes||No|April 29, 2011|https://clinicaltrials.gov/show/NCT00559585||164927|
NCT00559871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-II-004|Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.|Fjord|Juvantia Pharma Ltd|Yes|Completed|October 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|180|||Both|30 Years|N/A|No|||June 2009|June 2, 2009|November 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559871||164906|
NCT00560742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG04050|Efficacy Study of Intramuscular or Intracoronary Injection of Autologous Bone Marrow Cells to Treat Scarred Myocardium|Efficacy of the Mode of Delivery of Autologous Bone Marrow Cells Into Heart Scar Muscle for the Recovery of Contractile Function||University Hospitals, Leicester||Completed|November 2002|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|N/A|No|||November 2007|November 16, 2007|November 16, 2007||||No||https://clinicaltrials.gov/show/NCT00560742||164840|
NCT00561067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM6Y35XM|Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP)|Evaluation of the Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study VS Methylprednisolone (MP)||Niguarda Hospital|Yes|Suspended|April 2008|||July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2012|February 20, 2012|November 19, 2007|Yes|Yes|Italian Medicines Agency decision|No||https://clinicaltrials.gov/show/NCT00561067||164815|
NCT00561392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DDE15|Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease|A 24-week, Multi-center, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE10-26)|ADEPT|Novartis||Completed|November 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|208|||Both|50 Years|N/A|No|||April 2012|April 10, 2012|November 19, 2007||No||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00561392||164790|
NCT00575159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGI107465|A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus|A Double-blind, Randomized, Single Ascending Dose Escalation, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 Administered to Subjects With Type 1 Diabetes Mellitus||GlaxoSmithKline||Completed|March 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|No|||May 2013|May 13, 2013|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00575159||163758|
NCT00579319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37639|Use of Breast MRI for Local Staging|Use of Breast MRI for Local Staging||University of Arkansas|No|Withdrawn|April 2005|April 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Female|21 Years|N/A|No|Non-Probability Sample|Patients undergoing breast MRI at a community practice in Northwest Arkansas|March 2015|March 3, 2015|December 20, 2007||No|There were no subjects ever enrolled. Study was closed at the IRB.|No||https://clinicaltrials.gov/show/NCT00579319||163448|
NCT00574145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0633|Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer|Examining the Effect of Healing Touch on Radiotherapy-induced Fatigue||Vanderbilt-Ingram Cancer Center|Yes|Completed|February 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|44|||Female|21 Years|75 Years|No|||August 2012|August 4, 2012|December 14, 2007||No||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00574145||163835|
NCT00574379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 2607/RAE|Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR|A Multi-Center Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in The Treatment of the Symptoms of Seasonal Allergic Rhino-Conjunctivitis With Allergy to Mountain Cedar Pollen||Faes Farma, S.A.|No|Completed|December 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|805|||Both|12 Years|N/A|No|||January 2009|January 9, 2009|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574379||163817|
NCT00574678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS 71853|Analyzing the Composition of Tears to Identify Cancer|ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)|ACT|University of Arkansas|No|Completed|December 2006|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574678||163794|
NCT00574691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM 06-01EU|ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis Trial) EU|ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis) Trial|ECLIPSE|Cordis Corporation|Yes|Completed|June 2007|October 2007|Actual|||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|85 Years|No|||February 2012|February 27, 2012|December 13, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574691||163793|
NCT00574951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0170L|AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Gynecologic Oncology Group|Yes|Completed|December 2007|||July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574951||163774|
NCT00561782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5023-R|MR Spectroscopy as a Diagnostic and Outcome Measure in Pain and SCI|MR Spectroscopy (MRS) as a Diagnostic and Outcome Measure in Pain and SCI|MRS|VA Office of Research and Development|No|Completed|October 2007|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|94|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Both spinal cord injured (85) and able-bodied (25) subjects will be studied. Of those with        spinal cord injury, 60 will be those who experience central neuropathic pain and 25 will        not. An additional 25 people who screen positive for mild to moderate TBI symptoms and        pain attributable to TBI will be studied.|September 2014|September 16, 2014|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00561782||164761|
NCT00561795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG110190|Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors|A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors||GlaxoSmithKline|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Female|18 Years|N/A|No|||March 2011|March 15, 2012|November 19, 2007||||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00561795||164760|As defined in the protocol, a review of the safety data in Arm A showed that >=2 participants in each regimen of Arm A experienced dose-limiting toxicities. Thus the study was closed to further enrollment and no participants were enrolled into Arm B.
NCT00562107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSWER - IBSY02|Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication|Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication|ANSWER|LivaNova|Yes|Completed|December 2007|April 2013|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|650|||Both|N/A|N/A|No|||September 2014|September 26, 2014|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562107||164736|
NCT00562640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-155|Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)|A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Carcinomas||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Female|18 Years|120 Years|No|||December 2015|December 14, 2015|November 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00562640||164695|
NCT00562952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/07|Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients|Nt-proBNP Guided Prevention of Cardiovascular Events in a Population of Diabetic Patients Without a History of Cardiac Disease|PONTIAC|Medical University of Vienna|No|Completed|November 2007|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|19 Years|95 Years|No|||May 2012|May 2, 2012|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00562952||164671|
NCT00563238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200708711|Beta-Blocker Before Extubation|Use of Prophylactic Beta Blockade to Prevent Peri-Extubation Cardiac Ischemia and Congestive Heart Failure||University of Iowa|No|Recruiting|November 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2008|July 22, 2008|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00563238||164649|
NCT00563888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOSS-B6|Change of Neural Network Indicators Through Narrative Treatment of PTSD in Torture Victims|Change of Neural Network Indicators Through Narrative Treatment of PTSD in Torture Victims||University of Konstanz|No|Active, not recruiting|January 2007|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||November 2007|November 23, 2007|November 23, 2007||||No||https://clinicaltrials.gov/show/NCT00563888||164601|
NCT00563875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070180|Laboratory Aspirin Resistance in Diabetics and Non-Diabetics|Laboratory Aspirin Resistance in Coronary Artery Disease Patients With or Without Diabetes Mellitus||University of Aarhus|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 9, 2008|November 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00563875||164602|
NCT00559884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGW111057|A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects|An Open-label, Randomized, Single Dose, Crossover Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Modified Release Formulations of GSK189075 in Healthy Volunteers||GlaxoSmithKline|No|Completed|November 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|November 14, 2007||||||https://clinicaltrials.gov/show/NCT00559884||164905|
NCT00559897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543463|Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study Evaluating the Effect of Zolendronic Acid on Standardized Uptake Value (SUV) on FLT PET Scans in Non-Small Cell Lung Cancer (NSCLC)||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|March 2008|April 2011|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|November 15, 2007|Yes|Yes|Slow accrual|No|January 26, 2015|https://clinicaltrials.gov/show/NCT00559897||164904|None of the participants were evaluable.
NCT00560183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q8003-007|Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain|A Placebo-controlled, Randomized, Double-blind Study of the Safety and Efficacy of Q8003 in the Management of Post-bunionectomy Pain||QRxPharma Inc.|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|November 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00560183||164883|
NCT00560196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD2007LG|Pain Processing in Anxiety and Depression|Pain, Anxiety and Depression in Patients With Panic Anxiety Disorders Without Pain or Depression Without Pain Compared With Healthy Volunteers||Danish Pain Research Center|Yes|Completed|November 2007|February 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|71|||Female|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient clinic Primary care clinic Community sample|August 2009|January 20, 2016|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560196||164882|
NCT00562471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADH-02-1|Safety and Efficacy Study of a Hydrogel, Applied Following Removal of Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of Postoperative Adhesion Formation|A Controlled Randomized Multicenter Study to Assess the Safety and Performance of Adhibit™ Adhesion Prevention Gel in Myomectomy Surgery||Angiotech Pharmaceuticals|No|Completed|July 2003|January 2005|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|76|||Female|18 Years|N/A|No|||November 2007|November 21, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00562471||164708|
NCT00562757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMI-HIP|Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias|The Harbinger ICD Patient (HIP) Study|HIP|Harbinger Medical, Inc.|No|Active, not recruiting|September 2003|October 2009|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|320|||Both|18 Years|N/A|No|Non-Probability Sample|Post myocardial infarction patients who received an ICD are included. Enrollment is at        eight sites - four in the USA and four in three European countries. The enrollment sites        are hospitals and teaching institutions.|November 2007|November 20, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00562757||164686|
NCT00579332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041001|Effects of Brassica or Indole-3-Carbinol on Prostatectomy Patients With PSA Recurrence|Effects of Brassica or Indole-3-Carbinol on Prostatectomy Patients With PSA Recurrenc||Vanderbilt University|Yes|Completed|January 2005|December 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|16|||Male|40 Years|N/A|No|||December 2007|December 21, 2007|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00579332||163447|
NCT00579085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16078-2-1 version 2|Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS|Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS||Drexel University|Yes|Completed|September 2006|November 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||June 2010|June 15, 2010|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579085||163466|
NCT00573898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07060252|Daptomycin Study - Collection of Pharmacokinetic Samples in Patients With Renal Failure|Pharmacokinetics of Daptomycin in Patients Receiving Continuous Veno-Venous Hemodiafiltration (CVVHDF)||University of Pittsburgh|Yes|Completed|March 2008|December 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|5|Samples Without DNA|All of your biologic samples will be under the control of the principal investigator of this      research project. To protect your confidentiality, all personal identifiers (i.e., name,      social security number, and birth date) will be removed (de-identified) and replaced with a      specific code number. The information linking these code numbers to the corresponding      subjects' identities will be kept in a separate, secure location. The investigators on this      study will keep the samples indefinitely. Samples will be kept in the investigator's      laboratory located in Scaife Hall, room 812, 3500 Terrace Street. You may request to have      your samples destroyed if you withdraw. The request must be in writing and samples collected      and not already processed will be destroyed.|Both|18 Years|N/A|No|Non-Probability Sample|patients receiving daptomycin|February 2011|February 17, 2011|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573898||163854|
NCT00574171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO07201 (LAP109859)|Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma|A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)||University of Wisconsin, Madison|Yes|Completed|September 2007|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|December 13, 2007|Yes|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00574171||163833|
NCT00574158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12496-CP-004|Pathogenesis and Genetics of Environmental Asthma Ozone Study|Project 2: Genetic Regulation of Ozone Induced Inflammation in Humans.||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|July 2005|June 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|170|Samples With DNA|plasma, and ebc collected.|Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults, 18-35 y of age, both genders.|September 2014|September 25, 2014|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574158||163834|
NCT00574392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-136|Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo|Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo||Memorial Sloan Kettering Cancer Center|No|Completed|November 2006|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|dermatology outpatient clinic|December 2015|December 17, 2015|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00574392||163816|
NCT00574704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT005-AllQbG10 03|A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis|Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy||Cytos Biotechnology AG||Completed|September 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|65 Years|No|||February 2013|June 4, 2013|December 14, 2007||No||No|February 14, 2013|https://clinicaltrials.gov/show/NCT00574704||163792|
NCT00574977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-041|Safety Study of Modified Vaccinia Virus to Cancer|A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection||University of Pittsburgh|Yes|Completed|May 2008|July 2014|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00574977||163772|
NCT00561808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30/2007|In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF|In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF|IVM|Hillel Yaffe Medical Center|Yes|Completed|January 2008|January 2009|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||March 2010|March 8, 2010|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561808||164759|
NCT00561821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05709|Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)|A Double-Blind, Randomized, Parallel Group, Placebo- Controlled Sleep Laboratory Efficacy and Safety Study With Org 50081 in Elderly Subjects With Chronic Primary Insomnia||Merck Sharp & Dohme Corp.|No|Completed|November 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|538|||Both|65 Years|N/A|No|||June 2015|June 11, 2015|November 19, 2007|Yes|Yes||No|June 30, 2014|https://clinicaltrials.gov/show/NCT00561821||164758|
NCT00562393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCESS|Effects of Excess Energy Intake on Metabolic Risk|Effects of Excess Energy Intake on Metabolic Risk|EXCESS|Garvan Institute of Medical Research|No|Completed|April 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|41|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562393||164714|
NCT00562406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-06104G|Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)|Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)|RABAMES|Klinikum Ludwigshafen|No|Completed|November 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562406||164713|
NCT00562367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000836|Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones|Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones||Massachusetts General Hospital|No|Completed|October 2001|September 2004|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2007|November 21, 2007|November 20, 2007||||No||https://clinicaltrials.gov/show/NCT00562367||164716|
NCT00562380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMGEN-479|AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma|A Phase 1, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 479 in Subjects With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|October 2005|June 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|64|||Both|18 Years|N/A|No|||April 2010|July 17, 2013|November 21, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00562380||164715|
NCT00563251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 04-165 T/487|Effectiveness of Azithromycin Therapy in Improvement of Symptoms and Lung Function in Patients With Bronchiolitis Obliterans After Bone Marrow Transplantation|Azithromycin Therapy for Bronchiolitis Obliterans Syndrome After Allogenic Bone Marrow Transplantation||Hospital Authority, Hong Kong||Completed|April 2005|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A||||June 2011|June 14, 2011|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563251||164648|
NCT00563563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-401|A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent|An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR) in Combination With Bupropion Sustained Release (SR) in Overweight and Obese, Nicotine-Dependent Subjects||Orexigen Therapeutics, Inc|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||October 2012|October 31, 2012|November 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00563563||164625|
NCT00559611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0353|Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)|Prospective Comparison of Endobronchial Ultrasound Needle Biopsy Versus Mediastinoscopy for Staging of Mediastinal Nodes in Patients With Clinical Stage IIIA Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2007|||October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|November 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00559611||164925|
NCT00559598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904272|Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer|Use of Serum Proteome on the Early Diagnosis of Malignant Biliary-Pancreatic Disease||National Institutes of Health Clinical Center (CC)||Completed|August 2004|April 2009|Actual|||N/A|Observational|N/A|||Anticipated|502|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 7, 2012|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559598||164926|
NCT00560209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-1101-26|Study of ONO-1101 in Patients Scheduled for Coronary Angiography|Study of ONO-1101 in Patients Scheduled for Coronary Angiography, a Double-Blind, Randomized,Placebo-Controlled, Parallel Group, Multi-Center Study||Ono Pharmaceutical Co. Ltd||Completed|November 2007|||November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|183|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560209||164881|
NCT00560430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPUK0106|Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients|Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients|METATEL|Ludwig-Maximilians - University of Munich|No|Completed|November 2007|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|56|||Both|19 Years|60 Years|No|||May 2008|July 14, 2010|November 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00560430||164864|
NCT00560443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 30/07|RCT on Ketorolac and Tramadol in Bone Fractures Pain of Child|Randomized Controlled Trial on Effectiveness of Ketorolac and Tramadol in Not Compound Fractures of Child||IRCCS Burlo Garofolo|Yes|Not yet recruiting|April 2009|October 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|4 Years|17 Years|No|||January 2009|January 28, 2009|November 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00560443||164863|
NCT00560729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCNF 0402|Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients|Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients||Nestlé|No|Terminated|October 2003|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|63|||Both|70 Years|N/A|No|||November 2013|November 18, 2013|November 6, 2007||||No||https://clinicaltrials.gov/show/NCT00560729||164841|
NCT00561626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-3-088|Effects of High-Fat and Low-Fat Diet on the Gut|Effects of a High-Fat and a Low-Fat Diet on Early Biomarkers of Metabolic Stress in Blood and Gene Expression in the Small Intestine of Healthy Subjects||Maastricht University Medical Center|No|Completed|January 2008|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2008|December 11, 2008|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561626||164772|
NCT00561925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1486|VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients|A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)||Boehringer Ingelheim||Completed|November 2007|||November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1068|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|November 20, 2007||||No|December 13, 2011|https://clinicaltrials.gov/show/NCT00561925||164750|For the lead-in-period with NVP IR 200mg QD, MedDRA Version 12.1 was used for AE/SAE reporting.
NCT00577772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002721|Transit Time and Bacterial Overgrowth Using SmartPill Capsule|An Exploratory Assessment of Small Bowel Transit Time and Small Bowel Bacterial Overgrowth Using the SmartPill Capsule||Mayo Clinic|No|Terminated|November 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|17|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|December 17, 2007||No|Enrollment Goal Not Met|No|August 30, 2012|https://clinicaltrials.gov/show/NCT00577772||163565|The study was terminated early because enrollment goals were not met.
NCT00573599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-050|Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department|Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department||United States Naval Medical Center, Portsmouth|Yes|Completed|February 2007|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|50 Years|No|||December 2007|December 13, 2007|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573599||163875|
NCT00574418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-UF-CTP1|Far Infrared Radiation Treatment for Uterine Fibroids|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Uterine Fibroids||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|January 2006|September 2008|Anticipated|March 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||January 2009|January 2, 2009|December 12, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574418||163814|
NCT00574431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICU Nutr Bern|ICU Nutrition Study Bern|Implementation of an Evidence-based Nutritional Management Protocol in Critically Ill Patients:Does Clinical Outcome Improve?||University Hospital Inselspital, Berne|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||March 2011|July 13, 2015|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574431||163813|
NCT00574405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29256|Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy|Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy|ktpump|Arkansas Children's Hospital Research Institute|No|Completed|April 2005|March 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|8 Years|18 Years|No|||November 2011|November 23, 2011|December 12, 2007||No||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00574405||163815|Post hoc analysis demonstrated that the study design was weakened by an underestimation of the sample size per group needed to determine a statistically significant result for our primary outcome measure.
NCT00574717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004H0157|Enhancement of Emmetropization in Hyperopic Infants|Enhancement of Emmetropization in Hyperopic Infants||Ohio State University|No|Terminated|December 2007|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|8 Weeks|20 Weeks|No|||October 2012|October 18, 2012|December 11, 2007||No|Lack of funding support for continued recruitment, enrollment, treatment|No||https://clinicaltrials.gov/show/NCT00574717||163791|
NCT00575250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.180405|Education for Osteoporosis in Persons With Existing Fractures|Osteoporosis Education Clinic Study||University of Adelaide|No|Completed|January 2004|December 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|152|||Both|50 Years|N/A|No|||December 2007|December 17, 2007|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575250||163751|
NCT00561834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0446|Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy|Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION)|NAION|University of Colorado, Denver|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|21 Years|N/A|No|||October 2012|October 22, 2012|November 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00561834||164757|
NCT00561847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05062|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2007|||||N/A|N/A|N/A||||||||||||||April 2, 2013|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00561847||164756|
NCT00562120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8801003|A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge|A Randomized, Double Blind, Double Dummy, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of An H3 Receptor Antagonist (PF-03654746) On Congestion Following A Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis.||Pfizer|No|Completed|December 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|21|||Both|19 Years|55 Years|No|||March 2014|March 10, 2014|November 19, 2007|Yes|Yes||No|March 10, 2014|https://clinicaltrials.gov/show/NCT00562120||164735|
NCT00562705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc004623ctil|Effects of Growth Hormone (GH) Treatment on Eating Regulation|Effects of Growth Hormone Treatment on Eating Regulation and Comparison Between the Growth Responses With or Without Nutritional Intervention in Short Stature Children||Rabin Medical Center|No|Completed|January 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|2 Years|18 Years|No|||July 2013|July 15, 2013|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562705||164690|
NCT00562692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-02/05|Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease|Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease|BNP in OAD|The Alfred|No|Terminated|September 2007|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|November 21, 2007|No|Yes|Recruitment very difficult. Study drug expired so we have stopped the study.|No||https://clinicaltrials.gov/show/NCT00562692||164691|
NCT00563576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6363|Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation|Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation||Columbia University|No|Completed|September 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|71|||Female|18 Years|N/A|No|||December 2012|December 11, 2012|November 21, 2007||No||No|October 11, 2010|https://clinicaltrials.gov/show/NCT00563576||164624|
NCT00563589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 03-09 R/353|Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation|A Randomized Single-center Trial of Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation||Hospital Authority, Hong Kong||Recruiting|August 2003|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|30|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563589||164623|
NCT00563901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402|Analyzing How Genetics May Affect Response to High Blood Pressure Medications|GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT||University of Alabama at Birmingham||Completed|September 2000|May 2004|Actual|May 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|37939|Samples With DNA|Blood samples with DNA|Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population samples will be taken from adults who are high risk for high blood        pressure in the ALLHAT study, which included a randomized trial of the four high blood        pressure drugs chlorthalidone, amlodipine, lisinopril, and doxazosin.|January 2008|March 2, 2014|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00563901||164600|
NCT00561080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X06-Z-305|Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Subjects ≥ 70 Years|An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 1-dose Regimen and Different 2-dose Regimens of a Zoster Vaccine (Live), ZOSTAVAX ®, in Subjects ≥ 70 Years of Age||Sanofi Pasteur MSD||Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|750|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00561080||164814|
NCT00559910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631011|A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 (0.5, 3, 6 And 10 MG) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).||Pfizer|Yes|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|230|||Both|40 Years|80 Years|No|||April 2011|April 22, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559910||164903|
NCT00559936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-12-077|Topical Avastin for Treatment of Corneal Neovascularization|Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization||Massachusetts Eye and Ear Infirmary|No|Completed|February 2007|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||October 2012|October 2, 2012|November 14, 2007|Yes|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT00559936||164902|
NCT00561899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC1089|Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children|Comparison of Safety, Tolerability and Efficacy of Three Drug Combinations for Intermittent Preventive Treatment in Children Aged 1-5 Years in an Area of Seasonal Malaria Transmission in Upper River Division, The Gambia||Gates Malaria Partnership|Yes|Completed|August 2007|June 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1295|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561899||164752|
NCT00561912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0962|Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma|Phase II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Interferon Alfa-2b in Advanced Renal Cell Carcinoma||M.D. Anderson Cancer Center|No|Terminated|October 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2011|November 22, 2011|November 20, 2007||No|Low accrual.|No|November 22, 2011|https://clinicaltrials.gov/show/NCT00561912||164751|
NCT00562172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_02193|Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)|Lantus vs Sulfonylurea as add-on Therapy in Type 2 Diabetic Patients Failing Metformin Monotherapy: Comparison of Effects on Beta Cell Function and Metabolic Profile.||Sanofi|No|Completed|September 2007|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|70 Years|No|||July 2012|July 16, 2012|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00562172||164731|
NCT00561405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06356|A Comparison of Two Intensive Walking Training Interventions in Community Dwelling Individuals With History of Stroke|A Motor Learning Based Walking Program Versus Body Weight Supported Treadmill Training in Community Dwelling Adults Within One Year of Stroke Onset: A Randomized Controlled Trial||McMaster University|No|Completed|December 2006|June 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|40 Years|N/A|No|||September 2011|September 23, 2011|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561405||164789|
NCT00561951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221005|Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.||Pfizer|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|951|||Both|20 Years|N/A|No|||July 2011|July 11, 2011|November 19, 2007|Yes|Yes||No|January 11, 2010|https://clinicaltrials.gov/show/NCT00561951||164748|
NCT00562224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0402|Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients|Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer||Pharmacyclics|No|Completed|November 2007|September 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|November 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00562224||164727|
NCT00562497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265|Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD||Mesoblast, Ltd.|Yes|Completed|September 2007|May 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|70 Years|No|||May 2012|December 2, 2014|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562497||164706|
NCT00573911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002453|Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus|Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus||Mayo Clinic|Yes|Completed|August 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|80 Years|No|||January 2013|January 16, 2013|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00573911||163853|
NCT00574444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1096837|Transvaginal Diagnostic Study in Women With Pelvic Pain|Laparoscopic Assisted Transvaginal Endoscopic Diagnostic Peritoneoscopy in Women With Pelvic Pain||University of Missouri-Columbia|No|Withdrawn|January 2008|January 2010|Anticipated|January 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 13, 2007||No|Investigator moved to another institution.|No||https://clinicaltrials.gov/show/NCT00574444||163812|
NCT00574730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-01|CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma|CHOP/Rituximab Followed by Maintenance Pegylated Interferon-Alpha (PEG Intron)With the Treatment of Patients With Anthracycline Naïve Indolent/Follicular Non-Hodgkin's Lymphoma||University of Nebraska|Yes|Completed|May 2001|June 2012|Actual|August 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|19 Years|75 Years|No|||January 2013|January 8, 2013|December 12, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00574730||163790|
NCT00574990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 05-275|Minimizing Harm From ADEs by Improving Nurse-Physician Communication|Minimizing Harm From ADEs by Improving Nurse-Physician Communication|MED-COMM|VA Office of Research and Development|No|Completed|January 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|39|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|VA Physicians, Nurses, and Pharmacists had worked at least one year in the VA and were        familiar with the VA's electronic health record, CPRS.|May 2015|May 22, 2015|December 12, 2007||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00574990||163771|
NCT00575263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20060051H|Sodium Channel Expression in Human Teeth|Sodium Channel Expression in Human Teeth||The University of Texas Health Science Center at San Antonio|No|Completed|January 2006|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|250|Samples Without DNA|Extracted teeth including pulpal tissue|Both|16 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy patients presenting to the dental clinic with an indication for extraction of        their normal third molar(wisdom) teeth or diseased teeth that are associated with pain.|September 2015|September 21, 2015|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575263||163750|
NCT00562419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-322.002|CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan|Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme||Adnexus, A Bristol-Myers Squibb R&D Company|No|Active, not recruiting|October 2007|December 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||October 2010|October 26, 2010|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562419||164712|
NCT00562432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM-07-001|A Randomized Study to Demonstrate the Safety and Feasibility of Plexisyl-AF in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|A Randomized Study to Demonstrate the Safety and Feasibility of Plexisyl-AF Administered to the Epicardial Fat Pads in Patients Undergoing Open-chest Coronary Artery Bypass Grafting (CABG)||LoneStar Heart, Inc.|No|Completed|February 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Male|18 Years|70 Years|No|||September 2008|March 8, 2011|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562432||164711|
NCT00562718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574761|Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery|A Pilot Safety And Feasibility Study Of Concurrent Capecitabine (Xeloda) And External Beam Irradiation In The Adjuvant Treatment Of High Risk Early Stage Breast Cancer.||National Cancer Institute (NCI)||Active, not recruiting|September 2004|||September 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|November 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562718||164689|
NCT00562731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-0403-010|Open-Label Study of ARD-0403 in Testosterone Deficient Men|A Phase III, Open-Label Follow-on Study for Long-Term Safety and Efficacy of Testosterone Cream, in Testosterone Deficinet Men Completing Study ARD-0403-004|ARD-0403-010|Ardana Bioscience Ltd||Terminated|October 2007|June 2008|Anticipated|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Male|18 Years|N/A|No|||March 2008|March 28, 2008|November 21, 2007|||Company strategic decision|No||https://clinicaltrials.gov/show/NCT00562731||164688|
NCT00562965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K4-3301|Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)|An Open-Label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (CMC-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, CD22-Positive, Follicular B-Cell Non-Hodgkin's Lymphoma||Pfizer|Yes|Terminated|November 2007|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|29|||Both|18 Years|N/A|No|||December 2012|December 22, 2012|November 21, 2007|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00562965||164670|
NCT00559949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01056|AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine|Phase 2 Study of AZD6244 Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2007|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559949||164901|
NCT00560755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRV01C|ProQuad® rHA Safety|An Open-Label, Multi-Centre Study of the Safety of a 2-Dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life||Sanofi Pasteur MSD|No|Completed|October 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|3340|||Both|12 Months|22 Months|Accepts Healthy Volunteers|||April 2009|April 3, 2009|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560755||164839|
NCT00561613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A02-081|Postcoital Testing of the SILCS Diaphragm|A Phase I Postcoital Testing and Safety Study of the SILCS Diaphragm, Prototype VI||CONRAD|No|Completed|August 2003|October 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 19, 2007|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00561613||164773|
NCT00561093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 DK78012 (completed)|Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients|Pilot/Feasibility Randomized Control Trial to Examine the Effect of Oral Nutritional Supplements With Anti-inflammatory/Anti-oxidative Properties and Pentoxiphylline on Malnutrition-inflammation-cachexia Syndrome in Maintenance Hemodialysis Patients|AIONID|Los Angeles Biomedical Research Institute|Yes|Completed|February 2008|May 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|93|||Both|18 Years|85 Years|No|||May 2015|May 20, 2015|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00561093||164813|
NCT00561106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC 6-8-02|Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s Palsy|Treatment Bell´s Palsy: Prednisone vs Prednisone Valacyclovir|PVBP|Universidad de la Republica|No|Completed|December 2002|December 2003|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|14 Years|82 Years|No|||November 2007|November 19, 2007|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561106||164812|
NCT00561639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01053-50|Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis|Benefit of Septifast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis|SEPTIFAST|University Hospital, Grenoble|Yes|Completed|December 2007|November 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|Samples Without DNA|serum tube will routinely be kept in the serum bank for subsequent analysis|Both|N/A|N/A|No|Non-Probability Sample|All patients with onco-hematologic or cancerous pathology, or hematologic disease with        chemotherapy and/or radiotherapy and/or some other immunosuppressant treatment in progress        presenting an infection requiring hospitalisation and meeting the following criteria :        Sepsis and with or without organ dysfunction|July 2010|July 8, 2010|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00561639||164771|
NCT00562211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2465CTIL|Efficacy of a New Topical Anesthetic|A Single-blind, Randomized, Controlled Trial to Assess the Efficacy of a New Topical Anesthetic in Reducing Pain Associated With Venipuncture in Children.||Rambam Health Care Campus|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||November 2007|May 5, 2014|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562211||164728|
NCT00562809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8829|The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension|A Multicenter, Open-Label Study Assessing the Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Hypertension Not Controlled by Monotherapy||Sanofi||Completed|July 2003|August 2004|Actual|||Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1005|||Both|18 Years|N/A|No|||November 2007|November 26, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562809||164682|
NCT00574184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513528|Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)|Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)|PANPI|University of California, Davis|Yes|Completed|August 2005|March 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10|||Male|50 Years|N/A|No|Non-Probability Sample|Subjects will include males who are scheduled to undergo cardiac catheterization or        peripheral arteriography at UC Davis Medical Center who have erectile dysfunction and poor        response to oral phosphodiesterase-5 inhibitors (Viagra, Cialis and Levitra) as determined        by their response to a standardized questionnaire. Dissatisfaction will be defined as a        score of 21 or less on the ILEF-5 (International Index of Erectile Function        questionnaire).|March 2008|March 25, 2008|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00574184||163832|
NCT00574457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133JT68|Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study|Improving Cardiovascular Risk Prediction Using Hand-Held Carotid Ultrasonography Study|MERC-CIMT|University of Wisconsin, Madison|No|Completed|September 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|355|||Both|40 Years|70 Years|No|||September 2015|September 29, 2015|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00574457||163811|
NCT00574743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A2401|Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients|A 12-month, Single-blind, Randomized, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of ERL080A Compared With MMF in de Novo Heart Recipients||Novartis||Completed|January 2002|||April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|65 Years||||November 2011|November 1, 2011|December 14, 2007||||No||https://clinicaltrials.gov/show/NCT00574743||163789|
NCT00574756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070480|Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction|The Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction||University of California, San Diego||Recruiting|December 2007|July 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2007|December 14, 2007|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574756||163788|
NCT00575003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT003-QbG10 08|Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis|Double-Blind, Placebo-Controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis||Cytos Biotechnology AG||Completed|December 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|65 Years|No|||April 2009|April 24, 2009|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575003||163770|
NCT00575016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-518|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder|||Allergan||Terminated|December 2007|July 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|80 Years|No|||September 2015|September 17, 2015|December 13, 2007|Yes|Yes|The study was terminated early due to enrollment challenges.|No|September 9, 2011|https://clinicaltrials.gov/show/NCT00575016||163769|Due to recruitment difficulties, study enrollment was stopped early.
NCT00575276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070426|Study of Pain Perception Between Males and Females Following Laparoscopic Cholecystectomy|Sex-Dependent Modulation of Clinical Outcomes Following Laparoscopic Cholecystectomy||The University of Texas Health Science Center at San Antonio|No|Completed|August 2006|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|102|Samples With DNA|1 cm biopsies of the body and fundus of the excised gallbladder. Two 4ml blood samples      collected for DNA analysis with future studies.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient General Surgery patients indicated for Laparoscopic Cholecystectomy|March 2012|March 7, 2012|December 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00575276||163749|
NCT00575302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 300 versus 450|Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age|Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age||Centre Hospitalier Chretien|No|Withdrawn|December 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|38 Years|42 Years|No|||April 2010|April 12, 2010|December 17, 2007||No|36 cases were included and the 4 centers and they are unable to increase their recruitment to    obtain the 400 cases necessary to reach statistical significance.|No||https://clinicaltrials.gov/show/NCT00575302||163748|
NCT00562445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRRA-HDA2007|Adrenal Insufficiency in Critical Emergencies in Digestive Diseases|Evaluation of the Incidence and Relevance of the Adrenal Insufficiency in Critical Emergencies in Digestive Diseases (GI Bleeding and Acute Pancreatitis)||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|May 2007|May 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|75|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients admitted to our centre that meet inclusion criteria and do not meet exclusion        criteria|November 2007|November 21, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562445||164710|
NCT00563914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT10420|A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria|An Open Label, 4 Escalating Dose, Randomized Multicentre Study Evaluating the Safety and Activity of Ferroquine Associated With Artesunate Versus a Positive Calibrator (Amodiaquine Associated With Artesunate) in African Adult Patients With Uncomplicated Malaria||Sanofi|Yes|Completed|October 2007|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Male|18 Years|65 Years|No|||December 2009|December 18, 2009|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00563914||164599|
NCT00562978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98153|Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|A Phase I/II Trial of Escalating Dose of Yttrium-90-labeled Anti-CD20 Monoclonal Antibody in Combination With High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplantation for Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma||City of Hope Medical Center||Active, not recruiting|September 1999|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|60 Years|No|||January 2016|January 6, 2016|November 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562978||164669|
NCT00563264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007666|KAN-DO: A Family-based Intervention to Prevent Childhood Obesity|KAN-DO: A Family-based Intervention to Prevent Childhood Obesity|KAN-DO|Duke University|Yes|Completed|October 2007|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|832|||Both|2 Years|N/A|Accepts Healthy Volunteers|||August 2013|July 10, 2014|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00563264||164647|
NCT00559975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V95P1|Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine|A Phase 1, Randomized, Controlled, Observer-Blinded, Dose Escalation Study of the Safety, Tolerability and Immunogenicity of a Single Dose of Adjuvanted Influenza Vaccine Combined With CpG7909 in Healthy Adults||Novartis||Completed|October 2007|May 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2009|November 4, 2009|November 16, 2007||||No||https://clinicaltrials.gov/show/NCT00559975||164899|
NCT00560248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF2007-001|The BEACON Registry: Best Expert Agreement for Care of Occult Myocardial Infarction (MI) Nationally|The BEACON Registry: Best Expert Agreement for Care of Occult MI Nationally|BEACON|The Cleveland Clinic|Yes|Terminated|November 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1897|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the Emergency Department with chest pain.|February 2010|February 18, 2010|November 16, 2007||No|Loss of funding|No||https://clinicaltrials.gov/show/NCT00560248||164878|
NCT00560456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2006/09|Chronic Sleep Restriction and Driving|Chronic Sleep Restriction and Driving in Healthy Subjects or Snorers : Interindividual Vulnerability and Recovery Factors|PRIVASOM|University Hospital, Bordeaux|No|Completed|November 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|40|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 19, 2010|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560456||164862|
NCT00560469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DK080386|Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies|Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies||University of Vermont|No|Completed|January 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|Samples With DNA|Adipose tissue, plasma|Both|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|September 2010|February 1, 2011|November 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00560469||164861|
NCT00560768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prediction - ITAC06 Eu|Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications|Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications|Prediction|LivaNova|No|Completed|December 2007|October 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|198|||Both|N/A|N/A|No|||January 2015|January 9, 2015|November 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00560768||164838|
NCT00561119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-03-003|Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer|Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Pts With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel(GP) as 1st-line Chemotherapy||Samsung Medical Center|Yes|Active, not recruiting|May 2007|December 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|326|||Female|18 Years|N/A|No|||November 2010|November 8, 2010|November 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00561119||164811|
NCT00561418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07047|Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma|Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|November 2007|May 2013|Actual|November 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|November 20, 2007|No|Yes||No|April 20, 2015|https://clinicaltrials.gov/show/NCT00561418||164788|
NCT00562510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH-RAL-01|Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery|A Phase 3, Randomized, Double Blinded, Placebo Controlled Study of Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery||The Huesped Foundation|Yes|Terminated|August 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||June 2015|June 5, 2015|November 21, 2007||No|recruitment lower than estimated|No||https://clinicaltrials.gov/show/NCT00562510||164705|
NCT00562523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12438|Sorafenib/Docetaxel Dose Escalation Trial|A Phase I Dose Escalation Study With Sorafenib Administered Continuously in Combination With Docetaxel Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.||Bayer|No|Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|November 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00562523||164704|
NCT00562822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mrc123456|Surgery Versus No Surgery for Osteoarthritis (OA) of the Knee|Arthroscopic vs. Non-surgical Treatment of Osteoarthritis of the Knee|MRC Knee|University of Western Ontario, Canada|Yes|Completed|January 1999|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00562822||164681|
NCT00562796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|555|Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity|Prevalence and Metabolic Consequences of Relative Growth Hormone Deficiency in Abdominal Obesity||Massachusetts General Hospital|No|Completed|November 2007|May 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|149|Samples With DNA|Samples will include serum, plasma, whole blood, and white blood cells|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include participants from the community at large who are able to        come to either the Massachusetts General Hospital (MGH) Weight Center or Massachusetts        Institute of Technology for study visits.|August 2011|August 22, 2011|November 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00562796||164683|
NCT00574197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9810|Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients|Assessment of Gastrointestinal Tolerability and Efficacy of Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients||Cedars-Sinai Medical Center|No|Completed|June 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2009|July 21, 2010|December 13, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00574197||163831|
NCT00574782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL950057|Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)|Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)|CHALLENGE|AstraZeneca||Completed|September 2003|||||N/A|Observational|Time Perspective: Prospective|||Actual|2660|||Both|18 Years|N/A|No|||December 2007|December 12, 2007|December 12, 2007||||No||https://clinicaltrials.gov/show/NCT00574782||163786|
NCT00574795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3003|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants|A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|193|||Both|2 Months|6 Months|Accepts Healthy Volunteers|||June 2012|June 28, 2012|December 13, 2007||No||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00574795||163785|
NCT00574769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-09-4|Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer|Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer||University of Southern California|Yes|Active, not recruiting|September 2007|September 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|18 Years|N/A|No|||October 2015|October 24, 2015|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00574769||163787|
NCT00575029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26835|Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate|Evaluation of the Time Course of Adrenal Suppression and Adrenal Recovery After Ingestion of Megestrol Acetate||University of Arkansas|No|Completed|April 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|7|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 27, 2011|December 13, 2007||No||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00575029||163768|funding became an issue limiting the number of patients enrolled
NCT00575614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBR-4|Prucalopride in Patients With Chronic Idiopathic Constipation|Study to Evaluate the Effect of a 1 mg o.d. Dose of Prucalopride in Patients With Chronic Idiopathic Constipation||Movetis|No|Completed|April 1997|March 1999|Actual|March 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Female|18 Years|N/A|No|||December 2007|May 28, 2008|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00575614||163724|
NCT00575627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pNNALTHCV|Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels|Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin||University of Turin, Italy|Yes|Recruiting|September 2007|September 2010|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||June 2008|June 3, 2008|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575627||163723|
NCT00563277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.274-T|Surgical Treatment of Concurrent Cataract and Primary Pterygium|Surgical Treatment of Concurrent Cataract and Primary Pterygium: A Randomized Control Trial||Hospital Authority, Hong Kong||Recruiting|October 2004|December 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563277||164646|
NCT00559962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|733-004|Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy||Aegerion Pharmaceuticals, Inc.|Yes|Completed|October 2007|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|260|||Both|18 Years|70 Years|No|||January 2014|January 15, 2014|November 15, 2007|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00559962||164900|
NCT00559624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATH001-CLN01|Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients|A Phase I/II Open Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients With B-cell Chronic Lymphocytic Leukemia||Advancell - Advanced In Vitro Cell Technologies, S.A.|Yes|Completed|December 2007|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|November 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559624||164924|
NCT00559637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20888|A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Treated With ESA or on Dialysis.|An Open Label Study of the Safety, Tolerability and Effect on Hemoglobin Correction of Monthly Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Currently Treated With ESA and Not on Dialysis.||Hoffmann-La Roche||Completed||January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00559637||164923|
NCT00560222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD051716-01A2|Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children|Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2008|October 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|555|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||October 2011|October 31, 2011|November 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00560222||164880|
NCT00560235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021020|Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors|A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors||Pfizer|No|Completed|March 2008|October 2012|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|10 Years|N/A|No|||October 2015|October 6, 2015|November 15, 2007|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00560235||164879|
NCT00561431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X030108004|High Dose CVVHDF Compared to Standard Dose CVVHDF|A Randomized Prospective Study Comparing High Dose Continuous Venovenous Hemodiafiltration (CVVHDF) to Standard Dose CVVHDF in Critically Ill Patients With Acute Renal Failure at the University of Alabama at Birmingham|CVVHDF|University of Alabama at Birmingham|Yes|Completed|July 2003|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|19 Years|N/A|No|||March 2015|March 24, 2015|November 19, 2007||No||No|November 11, 2009|https://clinicaltrials.gov/show/NCT00561431||164787|
NCT00560482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07TASQ08|Efficacy Study of ABR-215050 to Treat Prostate Cancer|Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer||Active Biotech AB|No|Completed|December 2007|August 2015|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|206|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|November 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00560482||164860|
NCT00560781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA IRB# 01023|Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs|Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs||Durham VA Medical Center||Completed|April 2006|May 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||February 2014|February 25, 2014|November 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00560781||164837|
NCT00561132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002/252/129|Study of Vanadium Supplement in Patients With Impaired Glucose Tolerance|Effect of Vanadium on Insulin Sensitivity in Patients With Impaired Glucose Tolerance||Unidad de Investigacion Medica en Epidemiologia Clinica|Yes|Completed|November 2003|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|40 Years|50 Years|No|||November 2007|November 19, 2007|November 19, 2007||||No||https://clinicaltrials.gov/show/NCT00561132||164810|
NCT00561145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 17278.081.07|Impaired Regulation of Energy Balance in Elderly People (Balance Study)|Impaired Regulation of Energy Balance in Elderly People and the Underlying Physiological Mechanisms.|Balance|Wageningen University|No|Completed|October 2007|March 2012|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|20 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|November 19, 2007||No||No|March 20, 2012|https://clinicaltrials.gov/show/NCT00561145||164809|
NCT00562237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S205.1.001|Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine|Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Surface Antigen Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.||Solvay Pharmaceuticals|No|Terminated|July 2007|September 2008|Anticipated|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Anticipated|400|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2008|October 24, 2008|November 20, 2007||No|This trial discontinued on 20 JUN 2008 because the interim immunogenicity results do not    justify these formulations as pandemic vaccine candidates|No||https://clinicaltrials.gov/show/NCT00562237||164726|
NCT00562250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-016|Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects|Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects||AstraZeneca|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|November 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00562250||164725|
NCT00562536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mount Sinai Hospital Toronto|Delayed Umbilical Cord Clamping in Infants Less Than 32 Weeks|Delayed Umbilical Cord Clamping in Infants Less Than 32 Weeks: A Randomized Controlled Trial|DUC|Mount Sinai Hospital, Canada|No|Not yet recruiting|November 2007|November 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|296|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||November 2007|November 21, 2007|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00562536||164703|
NCT00562549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLx-2101-07-05|Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension|A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension||Kadmon Corporation, LLC|No|Completed|July 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|80 Years|No|||January 2015|January 8, 2015|November 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00562549||164702|
NCT00563082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1393|Analyzing the Association of Gene Variants With Increased Risk of Coronary Heart Disease in Women With Systemic Lupus Erythematosus|Prothrombin Gene Varitaion and Risk of SLE and CHD||University of Pittsburgh|Yes|Completed|May 2000|August 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1254|Samples With DNA|DNA and serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include genetic samples from women with SLE and CHD and from        normal control women. The population will be 80.5% U.S. white women and 19.5% U.S. black        women.|March 2014|March 20, 2014|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563082||164661|
NCT00563069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2005.250-T|Premedication With Oral Midazolam in Patients Undergoing Rigid Cystoscopy: A Randomized, Double-blind, Placebo-controlled Trial|Premedication With Oral Midazolam in Patients Undergoing Rigid Cystoscopy: A Randomized, Double-blind, Placebo-controlled Trial||Hospital Authority, Hong Kong||Recruiting|September 2005|December 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|120|||Both|18 Years|80 Years||||July 2010|July 6, 2010|November 21, 2007||||No||https://clinicaltrials.gov/show/NCT00563069||164662|
NCT00563368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-301|A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults|A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults||VIVUS, Inc.|Yes|Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|756|||Both|18 Years|70 Years|No|||March 2015|March 10, 2015|November 21, 2007|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00563368||164639|
NCT00574210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 2507/EEC|PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-Arm)|A Randomized, Double-Blind, Placebo-Controlled, 5-Arm Parallel Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Steady State Efficacy of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in the Treatment of the Symptoms of Seasonal Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Mode||Faes Farma, S.A.|Yes|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|502|||Both|18 Years|65 Years|No|||January 2009|January 9, 2009|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574210||163830|
NCT00574223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT005-AllQbG10 04|A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis|Double-Blind, Placebo-Controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immunotherapy Combining Allergen With CYT003-QbG10 (CYT005-AllQbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis Due to House Dust Mite Allergy||Cytos Biotechnology AG||Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||April 2009|April 24, 2009|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00574223||163829|
NCT00575328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001471|Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females|A Double-Blind, Placebo Controlled Study of Maca Root for the Treatment of Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females||Massachusetts General Hospital|No|Completed|November 2007|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|80 Years|No|||June 2011|June 10, 2011|December 14, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00575328||163746|
NCT00575341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHEA2000 - V18.03.2003|Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency|Dehydroepiandrosterone(DHEA) Substitution in Adolescent and Young Women With Central Adrenal Insufficiency. A Multicenter, Randomised Double Blind Trial|DHEA2000|University Hospital Tuebingen|No|Completed|October 2003|April 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Female|13 Years|26 Years|No|||December 2007|December 17, 2007|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575341||163745|
NCT00575042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405-2006|Use of Fenofibrate for Primary Biliary Cirrhosis|Pilot Study of Fenofibrate for Primary Biliary Cirrhosis||University of Florida|No|Completed|August 2007|August 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|75 Years|No|||August 2011|December 2, 2011|December 13, 2007|Yes|Yes||No|December 2, 2011|https://clinicaltrials.gov/show/NCT00575042||163767|A major limitation is the uncontrolled nature of this study.
NCT00575315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU03488|HIV-HCV Coinfection: Impact of Immune Dysfunction|HIV-HCV Coinfection: Impact of Immune Dysfunction||Virginia Commonwealth University|Yes|Completed|July 2004|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|634|Samples With DNA|Sera|Both|18 Years|90 Years|No|Non-Probability Sample|HIV-HCV Coinfection|August 2014|August 19, 2014|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00575315||163747|
NCT00576173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014683|An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients|An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients||Johnson & Johnson Taiwan Ltd||Completed|December 2005|February 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|December 14, 2007||||No||https://clinicaltrials.gov/show/NCT00576173||163682|
NCT00559650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12480|Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667|Placebo Controlled, Randomized, Double-blind, Multi-center, Multinational Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 Given Intravenously in Patients With Decompensated Chronic Congestive Heart Failure||Bayer|Yes|Terminated|December 2007|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||December 2014|September 22, 2015|November 15, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00559650||164922|
NCT00563641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ColombianCNRNCPAP trial|Very Early Surfactant and NCPAP for Premature Infants With RDS|Very Early Surfactant Without Mandatory Ventilation In Premature Infants Treated With Early Continuous Positive Airway Pressure-A Randomized Controlled Trial|CNRNCPAP|Colombian Neonatal Research Network|Yes|Completed|January 2004|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|278|||Both|27 Weeks|31 Weeks|No|||November 2007|November 23, 2007|November 23, 2007||||No||https://clinicaltrials.gov/show/NCT00563641||164619|
NCT00563953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLTI0702|Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years|A Phase II, Open-Label, Multicenter Clinical Trial of Pegylated Liposomal Doxorubicin (Caelyx®) as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease or Age Over 65 Years.|CAPRICE|SOLTI Breast Cancer Research Group|No|Active, not recruiting|September 2007|February 2016|Anticipated|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|November 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00563953||164596|
NCT00590512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P002705|Dietary Salt Intake and Vascular Function|Dietary Salt Intake and Vascular Function||Brigham and Women's Hospital|No|Completed|March 2005|November 2012|Actual|November 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|133|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590512||162606|
NCT00590525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-13547|Inflammation as a Predictor in Cardioversion of Atrial Fibrillation|Inflammation as a Predictor in Cardioversion of Atrial Fibrillation||Creighton University|No|Completed|October 2004|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|19 Years|N/A|No|Probability Sample|Consecutive patients undergoing DC cardioversion at The Cardiac Center electrophysiology        lab who meet these criteria will be enrolled.|November 2009|November 27, 2009|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590525||162605|
NCT00587769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003998|Chantix & Bupropion for Smoking Cessation|Combination Pharmacotherapy With Chantix & Bupropion for Smoking Cessation (ChanBan)|ChanBan|Mayo Clinic|No|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 16, 2013|December 21, 2007|No|Yes||No|October 5, 2010|https://clinicaltrials.gov/show/NCT00587769||162807|
NCT00587405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2261-05|Cyrotherapy vs. APC in GAVE|Prospective Randomized Study of Cryotherapy Versus Argon Plasma Coagulation Therapy for Treatment Of Watermelon Stomach||Mayo Clinic|No|Completed|December 2007|April 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|85 Years|No|||April 2010|January 5, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587405||162834|
NCT00587704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002759|Paravertebral Blocks: Pilot Study to Compare Nerve Stimulation vs. Anatomic Landmarks in Inguinal Hernia Repair|Paravertebral Blocks Techniques: A Pilot Study to Compare Nerve Stimulation vs. Anatomic Landmarks for Patients Undergoing Inguinal Hernia Repair|PVB|Mayo Clinic||Completed|July 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||February 2010|February 22, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587704||162811|
NCT00620386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105|Endotracheal Intubation Using Bonfils Fibrescope Without Neuromuscular Blockade|Comparing Intubating Conditions and Hemodynamic Changes Between Macintosh Laryngoscopy and Bonfils Fibrescope During Endotracheal Intubation Without Neuromuscular Blockade||Tehran University of Medical Sciences|No|Completed|October 2006|August 2007|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|15 Years|60 Years|No|||February 2008|February 8, 2008|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00620386||160371|
NCT00620399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019511|A Study on the Use of a Brace Following Low Back Surgery|Lumbar Fusion With and Without Postoperative Bracing: A Randomized Prospective Study||Sunnybrook Health Sciences Centre|No|Completed|May 1996|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|80 Years|No|||February 2008|February 20, 2008|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00620399||160370|
NCT00621543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24902|Insertion of an Intrauterine Device (IUD) After Medical Abortion|Insertion of an IUD After Medical Abortion||Boston University|No|Completed|March 2006|September 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Female|18 Years|64 Years|No|||July 2011|July 12, 2011|January 28, 2008||No||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00621543||160283|21 women did not return for the 3 months follow-up. Some of the 21 women were contacted earlier 3 months, and none had had an expulsion. 2 women were ineligible at the first visit.
NCT00588952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103012310|Ketamine/Placebo Family History Positive Study|GABA Mechanisms Underlying the Vulnerability for Alcohol Dependence||Yale University|Yes|Completed|March 2001|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|102|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00588952||162719|
NCT00588965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-00418|Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects|Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects||MetroHealth Medical Center|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|December 26, 2007||No||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00588965||162718|
NCT00588978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25094|Impact of Diet and/or Exercise-Induced Weight Loss on Cardiovascular Risk Factors|Longitudinal Impact of Diet and/or Exercise-Induced Weight Loss on Metabolic Markers of Cardiovascular Disease||Yale University|No|Active, not recruiting|August 2003|December 2008|Anticipated|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||December 2007|January 8, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00588978||162717|
NCT00621270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCI-540-CL-001|Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety|A 6-Week Randomised Double-Blind, Placebo-Controlled Study of BCI-540 80 mg q.d. and 80 mg t.i.d. in the Treatment of Adults With Major Depressive Disorder and Concomitant Anxiety||BrainCells Inc.|No|Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|115|||Both|21 Years|60 Years|No|||October 2011|October 20, 2011|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00621270||160304|
NCT00580879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4575|Does Antenatal Fetal Head Circumference Predict Anal Sphincter Injury, a Prospective Study|Does Antenatal Fetal Head Circumference Predict Anal Sphincter Injury, a Prospective Study||University of California, Irvine|Yes|Completed|January 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|N/A|No|Non-Probability Sample|Women in 36 weeks and upto 42 weeks of pregnancy|January 2010|January 7, 2010|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00580879||163330|
NCT00577863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10586|Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy|B3D-MC-GHDF: Community Experience of Subjects With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy||Eli Lilly and Company|No|Completed|January 2008|December 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|N/A|No|||July 2009|July 13, 2009|December 18, 2007|Yes|Yes||No|May 5, 2009|https://clinicaltrials.gov/show/NCT00577863||163558|
NCT00577850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002095|Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose|Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis||Warner Chilcott|No|Completed|November 2002|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Female|40 Years|75 Years|No|||April 2013|April 15, 2013|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577850||163559|
NCT00578123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-094|Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy|Prospective Assessment of Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2005|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|959|||Male|N/A|N/A|No|||August 2015|August 11, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00578123||163539|
NCT00590044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005062a|Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)|Basal Insulin in the Management of Patients With Diabetic Ketoacidosis||Emory University|Yes|Completed|December 2007|August 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|80 Years|No|||November 2013|November 12, 2013|December 28, 2007|Yes|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00590044||162640|
NCT00590577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012550|Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|652|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|December 21, 2007|Yes|Yes||No|August 21, 2009|https://clinicaltrials.gov/show/NCT00590577||162601|No information on long-term (ie, more than 13-week) treatment; not designed to detect differences between doses of paliperidone palmitate; not designed to demonstrate efficacy for specific subgroups, such as subjects from a particular country
NCT00590590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDC-201-601-669020|Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort|||Lumara Health, Inc.||Completed|October 2007|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Female|18 Years|50 Years|No|||February 2012|February 29, 2012|December 26, 2007|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00590590||162600|The study was discontinued following enrollment of 106 of the planned 140 participants due to slow recruitment.
NCT00590564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-073|SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study|SHO-SAIKO-TO for Patients With Chronic Hepatitis C Who Are Intolerant to or Have Contraindication to Interferon-Based Therapy: A Phase II Study||Memorial Sloan Kettering Cancer Center||Completed|October 2002|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 21, 2007|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT00590564||162602|
NCT00586846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-074|Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma|Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma||Memorial Sloan Kettering Cancer Center||Completed|July 2003|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||December 2015|December 15, 2015|December 21, 2007|No|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00586846||162876|
NCT00586859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135-02420|Multi-Center Study of the NDO Surgical Plicator Utilizing Multiple Implants for the Treatment of GERD|Multi-Center Study of the NDO Surgical Plicator Utilizing Multiple Implants||NDO Surgical, Inc.|No|Terminated|May 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2008|May 29, 2008|December 21, 2007|Yes|Yes|Sponsoring company ceased business operations.|No||https://clinicaltrials.gov/show/NCT00586859||162875|
NCT00587132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231-06|Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma|Pilot Study Using Secretin and Iodinated Intravenous Contrast and 64-Channel CT in Patients at High Risk for Pancreatic Adenocarcinoma||Mayo Clinic|No|Terminated|November 2006|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|4|||Both|35 Years|N/A|No|||June 2013|June 19, 2013|December 21, 2007|Yes|Yes|Lack of funding|No|April 29, 2013|https://clinicaltrials.gov/show/NCT00587132||162854|The study was terminated early due to lack of funding.
NCT00587145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-190|Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer|Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer||National Cancer Center, Korea|No|Recruiting|May 2006|May 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|70 Years|No|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587145||162853|
NCT00586820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|859-05|Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI|Role of Endothelin in Microvascular Dysfunction Following Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction|BQ-123|Mayo Clinic|Yes|Completed|May 2005|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||June 2014|July 3, 2014|December 21, 2007|Yes|Yes||No|April 21, 2014|https://clinicaltrials.gov/show/NCT00586820||162878|
NCT00586833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001301|Heart Failure and a Preserved Ejection Fraction|The Role of Vascular Dysfunction in Limiting Cardiovascular Reserve in Patients With Heart Failure and a Preserved Ejection Fraction||Mayo Clinic|No|Completed|April 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|51|Samples With DNA|Blood is drawn to evaluate BNP and cGMP pre and post exercise.|Both|18 Years|N/A|No|Non-Probability Sample|HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an        existing Mayo database examining all incident cases of HF in Olmsted County.3 There are        currently >350 pre-identified subjects with HFpEF from this study who may be eligible,        which will greatly enrich the recruiting process.        Control Subjects will be recruited from the community. Control subjects will be matched        for age and gender to HFpEF subjects, but will have no history of HF hospitalization or        significant exertional dyspnea suggestive of "preclinical" HF.|October 2010|October 13, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586833||162877|
NCT00588003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-153|Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer|Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2004|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|45|||Female|45 Years|N/A|No|||December 2015|December 23, 2015|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00588003||162790|
NCT00587977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1994-04|Aortic Distensibility|ECG-Gated Multidetector CT of Aortic Distensibility FAMRI|FAMRI|Mayo Clinic|No|Completed|November 2004|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing imaging of their abdominal aortic aneurysm|November 2012|November 7, 2012|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00587977||162792|
NCT00588198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-125|Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma|Study of Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma||Memorial Sloan Kettering Cancer Center|No|Completed|October 1991|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|754|Samples With DNA|Bone marrow and blood|Both|N/A|N/A|No|Non-Probability Sample|Melanoma Patients seen at Memorial Sloan-Kettering Cancer Center (MSK)|October 2009|October 1, 2009|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588198||162776|
NCT00587990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070598|Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)|A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Intramyocardial Injection of Autologous Human Mesenchymal Stem Cells (MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction (MI) Undergoing Cardiac Surgery for Coronary Artery Bypass Grafting (CABG)|PROMETHEUS|University of Miami|Yes|Completed|November 2007|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|9|||Both|21 Years|80 Years|No|||October 2015|October 2, 2015|January 2, 2008|Yes|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT00587990||162791|
NCT00588432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2391-02|Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE)|Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE)||Mayo Clinic||Completed|April 2003|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Residents of the community and patients of the study investigators.|December 2009|December 3, 2009|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00588432||162758|
NCT00620412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7142|Probiotics to Enhance Immunogenicity of Influenza Vaccine in Healthy Adults|Lactobacillus GG to Enhance the Immunogenicity of Influenza Vaccine in Healthy Adults - Proof of Concept Study||Tufts Medical Center|Yes|Completed|September 2007|December 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|52|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2011|January 16, 2011|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00620412||160369|
NCT00620685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631005|A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate|A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate||Pfizer|No|Completed|March 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|N/A|No|||May 2011|May 16, 2011|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620685||160348|
NCT00619606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDD05/C05|To Determine the Efficacy of the TwinGuard in Oxygen Delivery During and Post Endoscopic Procedure|A Randomised, Parallel, Open Label Study to Determine the Efficacy of a New Oral-Nasal Oxygenating Device (TwinGuard) Compared to Standard Bite Block Plus Nasal Cannulae||Trawax Pty Limited|Yes|Completed|November 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Actual|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2008|February 20, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00619606||160431|
NCT00619619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A6-2000|Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder|Final Report: Multicenter, Open-Label, Safety, Tolerability, And Pharmacokinetic Study To Evaluate Single Ascending Doses And Subsequent Short-Term Administration Of Fixed Doses Of DVS SR Tablets In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Both|7 Years|17 Years|No|||February 2011|February 18, 2011|January 28, 2008|Yes|Yes||No|November 10, 2010|https://clinicaltrials.gov/show/NCT00619619||160430|
NCT00620958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079943|Cognitive Behavioral Therapy With Parental Involvement for Treating Children With Anxiety Disorders|Parent Mediation of Child Anxiety CBT Outcome||Florida International University|Yes|Active, not recruiting|August 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|336|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00620958||160327|
NCT00621283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P002499|Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population|RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population||Massachusetts General Hospital|No|Terminated|February 2008|December 2008|Actual|December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|2 Years|18 Years|No|||January 2009|January 27, 2009|January 22, 2008|Yes|Yes|Poor patient enrollment due to logistical issues|No||https://clinicaltrials.gov/show/NCT00621283||160303|
NCT00580892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2006-4982|Optical Coherence Tomography of Airway and Pleural Disorders|Optical Coherence Tomography of Airway and Pleural Disorders||University of California, Irvine|No|Recruiting|July 2007|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will be selcted from University of California Irvine Chao Cancer Center.|February 2016|February 5, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00580892||163329|
NCT00581139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9801009972|Psychological Influences on Postoperative Recovery|Psychological Influences on Postoperative Recovery|NIH|Yale University|Yes|Recruiting|April 2003|April 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|377|||Both|3 Years|12 Years|No|||October 2008|October 27, 2008|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00581139||163310|
NCT00581152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT07015|The Role of TBX3 in Human ES Cell Differentiation|The Role of TBX3 in Human ES Cell Differentiation||University of California, Irvine|No|Active, not recruiting|August 2007|August 2010|Anticipated|||N/A|Observational|Observational Model: Case-Only||1|Anticipated|4|Samples With DNA|NIH-approved cell lines will be available at the Sue and Bill Gross Stem Cell Research Core      Facility at the University of California, Irvine. Non-NIH-approved cell lines will be      obtained from Sue & Bill Gross Stem Cell Core at UC Irvine.|Both|N/A|N/A|No|Non-Probability Sample|No subjects will be consented for this study. Approximately 2 to 4 cell lines will be        collected.|December 2007|December 19, 2007|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00581152||163309|
NCT00581802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43AI062473-01|HIV Resistance and Treatment Strategies|Cohort Study to Understand Resistance and HIV Eradication (CURE): Observational Studies of Antiretroviral Drug Treatment Success and Failure||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2007|January 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|89|Samples With DNA|Plasma, white cells, and whole blood|Both|18 Years|65 Years|No|Non-Probability Sample|Participants will be recruited from the Comprehensive Care Clinic, a clinic that provides        care exclusively to HIV patients from middle Tennessee and surrounding states.        Participants are screened and identified with the inclusion and exclusion criteria from        the computerized medical records system. If the medical charts are tagged, the study nurse        will speak to the selected participant at the participant's following appointment.|May 2012|May 2, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581802||163259|
NCT00577889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00156|Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer|A Phase II Trial of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma||National Cancer Institute (NCI)|Yes|Completed|March 2008|May 2013|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||September 2013|July 23, 2014|December 19, 2007|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT00577889||163556|
NCT00577876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-073|Assessment of the Functional Significance of Accessory Pudendal Arteries|Assessment of the Functional Significance of Accessory Pudendal Arteries||Memorial Sloan Kettering Cancer Center||Completed|September 2006|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||October 2011|October 25, 2011|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577876||163557|
NCT00590304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53054|Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors|Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors|ADRA|Arkansas Children's Hospital Research Institute|No|Active, not recruiting|October 2006|December 2016|Anticipated|December 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|116|Samples With DNA|Optional buccal swab samples will be obtained from participants. This is done by touching      the inside of the participant's cheek to collect a sample of the cells in his/her mouth with      a cotton swab type applicator.|Both|4 Years|17 Years|No|Non-Probability Sample|Participants will be children with asthma, ages 4-17 years from the Mississippi Delta        region. The Mississippi Delta has been identified as one of the poorest,        medically-underserved regions of the United States, and includes the geographic regions of        Arkansas, Louisiana and Mississippi that are contiguous with the Mississippi River.        Participants for the study will be recruited from Eudora, Lake Village, Marvell and Elaine        public school districts. Since June 2008, the Dumas Public School District has been added        in the recruitment. These districts are located in the Delta region of Arkansas where more        than one-third of families with children 5-17 years are below the 2000 poverty line        (Census bureau). Students in these school districts are predominately of a miniority        population.|March 2015|March 6, 2015|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00590304||162621|
NCT00590603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008662|Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Arsenic Trioxide (Trisenox), Ascorbic Acid and Bortezomib Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma|AAV|Duke University|Yes|Terminated|July 2008|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2012|January 7, 2014|December 26, 2007|No|Yes|Poor accrual - terminated during Phase I; Phase II never started.|No||https://clinicaltrials.gov/show/NCT00590603||162599|
NCT00586599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707-69|Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis|Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis||Indiana University|No|Completed|August 2007|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|51|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586599||162894|
NCT00586911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458-00|Betaine in Patients With Nonalcoholic Steatohepatitis|A Randomized, Placebo-Controlled Trial of Betaine in Patients With Nonalcoholic Steatohepatitis (NASH)||Mayo Clinic|No|Completed|January 2003|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|70 Years|No|||April 2015|April 6, 2015|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586911||162871|
NCT00586872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007063|Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus|Endoscopic Mucosal Resection in Barrett's Esophagus||Mayo Clinic|No|Enrolling by invitation|October 2007|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|patients who have had endoscopic mucosal resection|December 2015|December 15, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586872||162874|
NCT00586885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1753-03|Effects of Alanine in Patients With Nonalcoholic Steatohepatitis|A Pilot Study: Therapeutic Effect of L-Alanine in Patients With Nonalcoholic Steatohepatitis||Mayo Clinic|No|Completed|February 2004|June 2006|Actual|June 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||October 2012|October 9, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586885||162873|
NCT00586898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-085|Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle|Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle||Memorial Sloan Kettering Cancer Center||Completed|July 2001|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|N/A|No|||February 2016|February 24, 2016|December 21, 2007|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00586898||162872|
NCT00587418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007047|L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients|L-arginine Supplement for the Prevention of Calcineurin Inhibitor Nephrotoxicity||Mayo Clinic|Yes|Completed|November 2008|July 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587418||162833|
NCT00587431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-076|Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer|Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer||Memorial Sloan Kettering Cancer Center||Completed|July 2003|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Male|18 Years|N/A|No|||August 2014|August 5, 2014|December 21, 2007|Yes|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT00587431||162832|
NCT00588211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-121|Measurement of Cancer-Related Risk Perception in Smokers|Measurement of Cancer-Related Risk Perception in Smokers||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2001|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Actual|1514|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  clinic patients Queens Hospital Center          -  students participants from Adelphi University|November 2015|November 25, 2015|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588211||162775|
NCT00620126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27882|The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis|The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis|UCHAT|University of Maryland|No|Completed|January 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|February 8, 2008||No||No|August 13, 2011|https://clinicaltrials.gov/show/NCT00620126||160391|Insufficient sample size to detect moderate differences in outcomes between armsDifferences between groups at baseline may have resulted in no overall difference between arms at one yearHigher rate of attrition than expected
NCT00621309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33109-A|Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions|Phase I Clinical Trial to Evaluate the Efficacy of Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions||University of Washington|No|Active, not recruiting|March 2008|September 2010|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2009|November 12, 2009|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621309||160301|
NCT00618709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-07-08|Dose-Escalation Safety and Pharmacokinetic Study of ATX-101|Phase 1, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of ATX-101 (Sodium Deoxycholate for Injection) Following Subcutaneous Injections in the Submental Area||Kythera Biopharmaceuticals|No|Completed|January 2008|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00618709||160499|
NCT00620178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSE-ATA-2008/1|Atacand (Candesartan) Real Life Study|A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a "Real-liFe" GP sEtting in Sweden|Real Life|AstraZeneca||Completed|March 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|14000|||Both|17 Years|N/A|No|Non-Probability Sample|Eligible subjects are all patients found in EPS systems at the participating centres, who        were prescribed candesartan (ATC-C09CA06) or losartan (C09CA01) for hypertension from 1        January 1999 - 31 December 2004 inclusive. The first found prescription is designated as        index.|December 2010|December 1, 2010|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620178||160387|
NCT00620971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.19|Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC|Sequential Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus Cisplatin/Docetaxel/Bevacizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer||Hellenic Oncology Research Group|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|75 Years|No|||June 2014|June 24, 2014|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00620971||160326|
NCT00621335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICOM 1010|A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt|A 12- Week Investigator Masked, Parallel Comparison of Tolerability of Combigan and Cosopt in the Treatment of Open Angle Glaucoma or Ocular Hypertension|CICOM1010|DBYAN Medicine Professional Corporation|Yes|Completed|March 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|64|||Both|40 Years|90 Years|No|Probability Sample|Community sample|February 2013|February 22, 2013|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00621335||160299|
NCT00581178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5818|Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation|Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation||University of California, Irvine|No|Terminated|April 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who will undergo surgery where a ureteral stent will likely be placed will be        offered enrollment into this study.|June 2013|June 24, 2013|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581178||163307|
NCT00581191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3233A1-1000|Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SLV-351 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 3, 2009|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581191||163306|
NCT00578422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-03-003|Clinical Implications of Peripheral Plaque Morphology|Clinical Implications of Peripheral Plaque Morphology||The Cleveland Clinic|Yes|Active, not recruiting|December 2003|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|143|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with PAD undergoing standard lower extremity angiography.|May 2013|May 2, 2013|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578422||163517|
NCT00578695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-LX3401|THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation|THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation||CardioKine Inc.|Yes|Completed|January 2007|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|652|||Both|18 Years|N/A|No|||November 2010|June 20, 2011|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578695||163496|
NCT00590317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0998-2005|Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department|Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department||Emory University|No|Completed|March 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 23, 2014|December 27, 2007||No||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00590317||162620|Small sample size due to limited enrollment. Fewer patient in the Odansetron group were discharged home suggesting a possibly sicker baseline group. Complete data sets were not available for all patients due to sedation and participation.
NCT00590616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-14035|Utility of Clinical Examination in the Noninvasive Prediction of Aortic Atheroma - A Prospective Study|Utility of Clinical Examination in the Noninvasive Prediction of Aortic Atheroma - A Prospective Study||Creighton University|No|Completed|February 2005|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|19 Years|N/A|No|Probability Sample|All patients referred for TEE examination, since the primary end-point would be diagnosis        of aortic atheromatous disease on TEE. Prevalence of aortic atheroma, based on previous        data at Creighton and other studies in any aortic atheroma ~50% and severe aortic atheroma        ~5%.|August 2014|August 11, 2014|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590616||162598|
NCT00586612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110215|Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants|Immunogenicity & Safety Study in Preterm & Full-term Infants of GSK Biologicals' Hib-MenC Vaccine, Menitorix™ Co-administered With Infanrix™ Penta & Prevenar™ at 2, 4, 6 Months & as a Booster With Infanrix™ IPV & Prevenar™ at 16-18 Months||GlaxoSmithKline||Completed|December 2007|November 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|313|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2011|November 17, 2011|December 21, 2007|Yes|Yes||No|December 17, 2009|https://clinicaltrials.gov/show/NCT00586612||162893|
NCT00586625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SAF-0405071-P|Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers|||Bausch & Lomb Incorporated|No|Completed|October 2007|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|861|||Both|3 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|December 21, 2007|Yes|Yes||No|October 8, 2009|https://clinicaltrials.gov/show/NCT00586625||162892|
NCT00586573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000067|Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS|An Open-Label Pilot Study of Namenda (Memantine Hydrochloride) in Adult Subjects With Attention Deficit Hyperactivity Disorder (ADHD) and ADHD NOS||Massachusetts General Hospital|No|Completed|March 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|55 Years|No|||May 2012|May 2, 2012|December 28, 2007|Yes|Yes||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00586573||162896|
NCT00586586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17563|Effectiveness Study of CBT for Anxiety in Children|Assessment and Treatment - Anxiety in Children and Adults (Child Part)|ATACA|Haukeland University Hospital|Yes|Completed|January 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|222|||Both|8 Years|15 Years|No|||July 2013|July 12, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586586||162895|
NCT00587171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-138|Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia|A Randomized Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia in Children 7 to <13 Years Old|ATS12|Jaeb Center for Health Research|Yes|Terminated|April 2008|October 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|7 Years|12 Years|No|||May 2012|May 16, 2012|December 10, 2007||No|This study was stopped due to insufficient recruitment.|No|April 22, 2011|https://clinicaltrials.gov/show/NCT00587171||162851|The study was stopped prior to achieving the goal of 45 subjects enrolled due to slow recruitment, leaving only 19 subjects enrolled.
NCT00587158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|256-06|Oral Paricalcitol in Kidney Transplant Recipients|Oral Paricalcitol in Kidney Transplant Recipients Receiving a Corticosteroid-free Immunosuppressive Regimen||Mayo Clinic|Yes|Completed|January 2007|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|December 21, 2007|Yes|Yes||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00587158||162852|
NCT00587444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|330-01|Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass|Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass|Heparin Dosing|Mayo Clinic|Yes|Completed|June 2001|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|90 Years|No|||October 2009|October 14, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587444||162831|
NCT00619515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE13807|Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer|Prospective Evaluation of Cyberknife Stereotactic Radiosurgery for Low and Low/Intermediate Risk Prostate Cancer||Case Comprehensive Cancer Center|Yes|Completed|December 2007|February 2013|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Male|N/A|N/A|No|||February 2013|February 27, 2013|February 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619515||160438|
NCT00619528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DK025243-25A2|HLA-Identical Sibling Renal Transplant Tolerance|HLA-Identical Sibling Renal Transplant Tolerance With Donor Hematopoietic Stem Cells and Campath-1H||Northwestern University|Yes|Active, not recruiting|July 2007|February 2021|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619528||160437|
NCT00619541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PISADUE|Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)|Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.|P2|Italian Trial in Medical Oncology|Yes|Completed|January 2007|January 2009|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||February 2009|February 25, 2009|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00619541||160436|
NCT00588237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-064|Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|A Phase II Study of Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer||Memorial Sloan Kettering Cancer Center||Completed|August 2006|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Female|18 Years|N/A|No|||December 2015|December 15, 2015|December 22, 2007|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT00588237||162773|
NCT00620139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-016|Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma|Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma||Memorial Sloan Kettering Cancer Center|No|Completed|March 2005|October 2013|Actual|October 2013|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|Samples Without DNA|Urine Blood Tissue|Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinics|October 2013|October 23, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00620139||160390|
NCT00618722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-06-03|Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat|Phase 1-2, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) for the Reduction of Subcutaneous Fat in the Submental Area|ATX-101|Kythera Biopharmaceuticals|No|Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|85|||Both|25 Years|65 Years|No|||June 2015|June 17, 2015|February 8, 2008||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00618722||160498|
NCT00619294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|743|Endothelial Dysfunction and Coronary Artery Spasm|Digital Tonometry for Measurement of Peripheral Artery Reactive Hyperemia as Non-invasive Test for Diagnosis of Coronary Artery Spasm||Kumamoto University|No|Completed|August 2006|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|||Female|40 Years|90 Years|No|Probability Sample|Kumamoto University Hospital|September 2013|September 25, 2013|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619294||160455|
NCT00620750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18816/6067/DP/US|Extended-release Naltrexone for Alcohol Dependence in Primary Care|Extended-release Naltrexone (Vivitrol) for the Treatment of Alcohol Dependence in Urban Primary Care: a Feasibility Study||New York University School of Medicine|No|Completed|July 2007|February 2010|Actual|November 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||August 2011|August 22, 2011|February 11, 2008|Yes|Yes||No|June 9, 2011|https://clinicaltrials.gov/show/NCT00620750||160343|There was no formal control arm. Drinking and satisfaction outcomes were self-reported, these outcomes and Adverse Event data were not available for those lost to follow-up. The drinking Timeline Follow-Back is subject to recall and response biases.
NCT00621803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0029|Lcr35 / ICU / P. Aeruginosa|Prevention of Gastric Colonisation by Antibiotic Resistant Pseudomonas Aeruginosa Strains Using Oral Probiotic in ICU-Patients||University Hospital, Clermont-Ferrand||Terminated|March 2003|October 2005|Anticipated|October 2004|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|400|||Both|18 Years|N/A|No|||February 2008|February 21, 2008|February 11, 2008||No|Recruiting or enrolling participants has halted and will not resume|No||https://clinicaltrials.gov/show/NCT00621803||160263|
NCT00622076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-P-47|Postoperative Catheterization After Anterior Colporrhaphy|Randomised Controled Multicenter Trial Regarding the Appropriate Length of Postoperative Catheterization After Anterior Colporrhaphy for Repair of Cystocele||Atrium Medical Center|Yes|Recruiting|January 2006|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Female|N/A|N/A|No|||January 2008|February 13, 2008|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622076||160242|
NCT00618202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BALS-C750-PVFS-2|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions||Roxane Laboratories|No|Completed|May 2005|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 18, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00618202||160537|
NCT00581516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5107|Molecular Urine Tests for Prostate Cancer|||University of California, Irvine|No|Completed|March 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Blood and Urine|Male|18 Years|N/A|No|Non-Probability Sample|A total of 100 male subjects who have clinically localized prostate cancer and are        scheduled to undergo a radical prostatectomy are anticipated in this study|June 2009|June 3, 2009|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581516||163281|
NCT00578149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-415|Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer|Bevacizumab and Carboplatin/Paclitaxel and Radiation in Stage III Non-Small Cell Lung Cancer||Dana-Farber Cancer Institute||Completed|May 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|December 19, 2007||||No||https://clinicaltrials.gov/show/NCT00578149||163537|
NCT00578162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-048|A Study of Survivorship Service Capacities Among Health Care Agencies in New York City|A Study of Survivorship Service Capacities Among Health Care Agencies in New York City||Memorial Sloan Kettering Cancer Center||Completed|April 2005|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|||||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We assume that the collective network of cancer care and support services can be        represented with data from no more than 300 New York City agencies, across all five        boroughs. Theseagencies would include hospitals, clinical diagnostic centers, and        community-based organizations.|January 2012|January 6, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578162||163536|
NCT00578175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110058|Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age|Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.||GlaxoSmithKline||Completed|November 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1851|||Both|12 Months|14 Months|Accepts Healthy Volunteers|||November 2012|January 31, 2013|December 20, 2007|Yes|Yes||No|March 5, 2010|https://clinicaltrials.gov/show/NCT00578175||163535|
NCT00578188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 43921|Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract|Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract||Arkansas Children's Hospital Research Institute|No|Withdrawn|February 2006|January 2008|Anticipated|January 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Serum, whole blood, tissue|Female|11 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|11-19 year old females from the Arkansas Children's Hospital Adolescent Center|June 2008|June 13, 2008|December 19, 2007||No|Study redesigned and re-submitted to UAMS IRB under different study title and IRB number.|No||https://clinicaltrials.gov/show/NCT00578188||163534|
NCT00578435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-005|Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis|Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis||Memorial Sloan Kettering Cancer Center||Completed|January 1994|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|1 Year|N/A|No|||September 2008|September 10, 2008|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578435||163516|
NCT00578448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-047|Belatacept Pharmacokinetic Trial in Renal Transplantation|An Open-label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen||Bristol-Myers Squibb|No|Completed|March 2008|September 2012|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|December 19, 2007|Yes|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00578448||163515|
NCT00590330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X07-10-0407|Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs|Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs||Children's Hospital Boston|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|55|Samples With DNA|sputum or throat culture|Both|1 Year|16 Years|No|Probability Sample|pulmonary clinic|May 2011|May 12, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590330||162619|
NCT00590629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDL3954|Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women|||Cedars-Sinai Medical Center|No|Completed|June 2002|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|43|||Female|18 Years|N/A|No|||December 2007|September 13, 2011|December 26, 2007||||No||https://clinicaltrials.gov/show/NCT00590629||162597|
NCT00586638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6151|Training Cognitive Control Processes in Older Adults|Pilot Study Using a Video Game to Train Cognitive Control Processes in Healthy Older Adults||Columbia University|No|Completed|December 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|60|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00586638||162891|
NCT00586963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006142|Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis|How Does Proton Pump Inhibitor Therapy Impact Quality of Life in Patients Newly Diagnosed With Erosive Reflux Esophagitis?|EE|Mayo Clinic|No|Completed|January 2008|December 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Non-Probability Sample|Patients age 18 and older, diagnosed with reflux esophagitis, being seen at Mayo Clinic        Rocheser.|August 2010|August 20, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586963||162867|
NCT00586924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-8015-1001|A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL)||MedImmune LLC|No|Completed|May 2007|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586924||162870|
NCT00586937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-057|Quality of Life in Lung Cancer Survivors|Quality of Life in Lung Cancer Survivors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2005|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|193|||Both|N/A|N/A|No|Probability Sample|Thoracic Surgery Database|July 2015|July 21, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586937||162869|
NCT00587483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005522|Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation|The Use of Amiodarone vs. Lidocaine and Placebo for the Prevention of Ventricular Fibrillation After Myocardial Reperfusion During Cardiopulmonary Bypass||Mayo Clinic|No|Completed|November 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|342|||Both|18 Years|N/A|No|||July 2011|August 9, 2011|December 21, 2007|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00587483||162828|Included a heterogeneous group of operations which possibly make our results applicable to “real world” perioperative care; dosing of amiodarone was higher than in previous investigations, but the dose may not have been large enough.
NCT00587470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1129-98|Angiotensin-II Blockade in Mitral Regurgitation|Angiotensin-II Blockade in Mitral Regurgitation||Mayo Clinic|Yes|Completed|August 1998|August 2001|Actual|August 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587470||162829|
NCT00619567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB1723|Cognitive Stimulation Program in AIDS|Pilot Study of an Internet-Based Cognitive Stimulation Program in AIDS||University of Pittsburgh|Yes|Completed|September 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619567||160434|
NCT00619827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO56.07 A|Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract|A Randomised, Double-blind, in Parallel Groups Placebo-controlled, Mono-centre, Phase I Study to Assess After Allergen Challenge in an Allergen Exposition Chamber the Effect and Its Time Course of Sublingual Immunotherapy (SLIT) Administered as 300IR Allergen-based Tablets Once Daily to Adults Suffering From Grass Pollen Rhinoconjunctivitis||Stallergenes|No|Completed|September 2007|August 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|50 Years|No|||October 2009|October 8, 2009|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619827||160414|
NCT00619840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6520-9979-06|Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD|Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD|EMMA|Medice Arzneimittel Pütter GmbH & Co KG|No|Completed|November 2004|||May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|363|||Both|18 Years|N/A|No|||February 2008|February 11, 2008|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00619840||160413|
NCT00620711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070984|Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy|IRB# 070984 "Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy"||Vanderbilt University|Yes|Completed|February 2008|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|6 Hours|No|||July 2014|July 30, 2014|February 7, 2008|No|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT00620711||160346|
NCT00621296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A7|Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C|Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C||Mitsubishi Tanabe Pharma Corporation|No|Completed|January 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|70 Years|No|||April 2014|April 16, 2014|February 12, 2008||No||No|September 19, 2012|https://clinicaltrials.gov/show/NCT00621296||160302|
NCT00619307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27571|Transition to Rebif New Formulation|A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen When Necessary (PRN) or as Prophylaxis|TRANSFER|Merck KGaA||Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|117|||Both|18 Years|60 Years|No|||January 2014|January 26, 2014|February 8, 2008|Yes|Yes||No|May 11, 2010|https://clinicaltrials.gov/show/NCT00619307||160454|
NCT00588328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-008|The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning|The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning||Memorial Sloan Kettering Cancer Center||Completed|March 2000|May 2010|Actual|July 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588328||162766|
NCT00620451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-011|Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate (AT-1001) in Active Celiac Disease|A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With AT-1001||Alba Therapeutics|No|Completed|February 2008|December 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|75 Years|No|||January 2010|July 12, 2012|February 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620451||160366|
NCT00581529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.020|Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy|Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy in Early Stage Breast Cancer After Breast-Conserving Surgery||University of Michigan Cancer Center|Yes|Terminated|November 2004|August 2014|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|40 Years|N/A|No|||October 2014|October 14, 2014|December 20, 2007||No|The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.|No|August 14, 2014|https://clinicaltrials.gov/show/NCT00581529||163280|The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.
NCT00581776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO05401|Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma|Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma||University of Wisconsin, Madison|Yes|Active, not recruiting|May 2005|August 2015|Anticipated|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|December 19, 2007|Yes|Yes||No|December 9, 2010|https://clinicaltrials.gov/show/NCT00581776||163261|
NCT00581789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0063|Erlotinib and Sunitinib in NSCLC|Phase I Study of Erlotinib and Sunitinib in Non-small Cell Lung Cancer||University of Wisconsin, Madison|Yes|Completed|August 2007|August 2011|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581789||163260|
NCT00581542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB #17454|Moxifloxacin vs. Polytrim for Conjunctivitis|A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.||University of Rochester|No|Completed|March 2007|March 2012|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|1 Year|18 Years|No|||December 2015|December 11, 2015|December 18, 2007|Yes|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT00581542||163279|No adverse events
NCT00578201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060503|FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer|Phase II Trial of FOLFOX in Combination With Cetuximab and Concomitant Radiotherapy in the Treatment of Esophageal Cancer Stage III|FOLFOX|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2007|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|80 Years|No|||May 2007|March 30, 2011|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00578201||163533|
NCT00622284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.20|Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes|A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy||Boehringer Ingelheim||Completed|February 2008|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1560|||Both|18 Years|80 Years|No|||December 2013|December 11, 2013|February 13, 2008||||No|November 30, 2011|https://clinicaltrials.gov/show/NCT00622284||160227|With the exception of HbA1c<6.5% and HbA1c<7.0% at Week52, all other endpoints are presented in the Week52 repeated analysis within the final clinical trial report, where discrepancies between interim and final results are also explained.
NCT00622596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0504027630|Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance|Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance|Project BEST|Yale University|Yes|Completed|October 2003|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|75 Years|No|||October 2015|October 19, 2015|February 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622596||160204|
NCT00622583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-06-007|International Hernia Mesh Registry|A Two-Year Follow-up, Post-Implantation, Multi-center, International Hernia Mesh Registry|IHMR|Ethicon, Inc.|No|Recruiting|September 2007|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic and patients of the investigators at local clinics or hospitals.|August 2015|November 9, 2015|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622583||160205|
NCT00618371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27XS050|Pilot Study of the Impact of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Undetectable Plasma Virus|Investigating the Source of HIV-1 Viremia in Patients on Antiretroviral Therapy Through Intensification With MK-0518||University of Pittsburgh|Yes|Recruiting|October 2007|March 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|N/A|No|||October 2008|October 13, 2008|September 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00618371||160525|
NCT00586950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHA_CAD05-01|123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients|Outcome Study on BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients|B-SAFE|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Completed|June 2006|September 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Probability Sample|Defined Population|February 2009|September 12, 2011|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586950||162868|
NCT00587184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004664|Confocal Microscopy in Barrett's Esophagus|The Use of Confocal Microscopy in Barrett's Esophagus||Mayo Clinic|No|Completed|July 2006|March 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|92|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have had confocal microscopy imaging in patients at the time of or clinically        indicated endoscopic surveillance and biopsies of BE.|November 2013|November 23, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587184||162850|
NCT00587496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6475|30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers|A 30-Day Double-Masked Study to Determine the Effect of Oral Valacyclovir or Oral Valacyclovir Plus Aspirin on the Shedding of Herpes Simplex Virus DNA in the Tears and Saliva of Volunteers Without Clinical Signs of Ocular Herpetic Disease||National Eye Institute (NEI)|Yes|Recruiting|April 2006|July 2008|Anticipated|July 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Both|20 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587496||162827|
NCT00587509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-001-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2003|||||N/A|N/A|N/A||||||||||||||December 1, 2011|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587509||162826|
NCT00587795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228-06|Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace|Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace||Mayo Clinic|No|Completed|April 2006|November 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||April 2012|October 23, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587795||162806|
NCT00619255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32685-C|Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial|Maternal Child Health Bureau Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial|ATRSCC|University of Washington|No|Active, not recruiting|March 2008|December 2015|Anticipated|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|300|||Both|12 Years|18 Years|No|||November 2013|November 25, 2013|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00619255||160458|
NCT00620152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X08-01-0047 (completed)|Nutrition Study for School Age Children|Randomized Trial of Telephone Interventions for Pediatric Obesity in School Age Children||Children's Hospital Boston|No|Completed|April 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||August 2010|August 20, 2010|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00620152||160389|
NCT00619853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4624-AB-CTIL|The Influence of MCIMT (Modified Constrained Induced Movement Therapy), Bilateral Intensive Treatment, and NDT Approach on the UL Function in Children With Hemiplegic Cerebral Palsy||CIMT|Sheba Medical Center|No|Completed|June 2007|October 2007||||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||||||Both|18 Months|N/A|Accepts Healthy Volunteers|||February 2008|February 20, 2008|February 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00619853||160412|
NCT00622349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELCWP-01041|Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer|A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer||European Lung Cancer Working Party|Yes|Completed|February 2004|December 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|707|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622349||160223|
NCT00618163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELO-T15-PVFS-1|Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 15 mg Meloxicam Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|March 2005|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 15, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00618163||160539|
NCT00619905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2101|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate|A Randomized, Double-Blind, Placebo-Controlled, Cohort Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 (Anti-Interleukin-1Beta Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis (RA) Despite Ongoing Treatment With Methotrexate (MTX) 15 mg or More Weekly for at Least 3 Months.||Novartis|No|Completed|December 2003|August 2005|Actual|August 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|75 Years||||February 2008|February 8, 2008|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619905||160408|
NCT00588835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 07.02|Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients|A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Cisplatin - Etoposide (CE) Treatment of Patients With Metastatic Lung Carcinoma (ACE).|ACE|Radboud University|No|Terminated|March 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||February 2010|March 1, 2010|December 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588835||162728|
NCT00621023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011792|Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome|A Pilot Phase II Study of Decitabine, Arsenic Trioxide and Ascorbic Acid for Patients With Myelodysplastic Syndrome||Duke University|Yes|Completed|November 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|December 26, 2007|Yes|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT00621023||160322|Enrollment stopped early, which lead to a small number of subjects analyzed. The subjects who were enrolled did complete the entire protocol and their data was analyzed.
NCT00581256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2004.038|A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer|A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|April 2006|December 2017|Anticipated|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581256||163301|
NCT00581555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-410|Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy|A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy||Pfizer|No|Completed|October 2007|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||March 2012|March 28, 2012|December 21, 2007||No||No|November 17, 2010|https://clinicaltrials.gov/show/NCT00581555||163278|
NCT00577902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 41011|Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation|Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation||University of Arkansas|No|Completed|June 2005|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|37|Samples Without DNA|Blood samples will be collected and nutritional risk evaluated, using the Patient-Generated      Subjective Global Assessment tool (PG-SGA). The PG-SGA and blood tests will be performed      before, at the end of XRT treatment and four to six weeks after treatment is completed.|Both|18 Years|N/A|No|Probability Sample|Patients presenting at the UAMS Head and Neck Clinic will be invited to participate in        this study according to the inclusion criteria listed:|February 2016|February 8, 2016|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577902||163555|
NCT00577915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-037|Breast MRI Spectroscopy|Breast MRI Spectroscopy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2003|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Female|N/A|N/A|No|||January 2016|January 4, 2016|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00577915||163554|
NCT00578474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-35|A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes|Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)||Alcon Research|No|Completed|December 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|911|||Both|6 Months|12 Years|No|||November 2012|November 29, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578474||163513|
NCT00578487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-U-005|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2005|||||N/A|N/A|N/A||||||||||||||February 11, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578487||163512|
NCT00622609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAG103114|Anti-MAG First Administration to Human|A Single-blind, Single Dose, Placebo Controlled, Parallel Group, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Ascending IV Doses of GSK249320 in Healthy Volunteers||GlaxoSmithKline|No|Completed|August 2007|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2011|March 15, 2012|February 13, 2008||||No||https://clinicaltrials.gov/show/NCT00622609||160203|
NCT00618384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOCRATES-072|TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)|Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)|SOCRATES|Heinrich-Heine University, Duesseldorf|No|Terminated|January 2008|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618384||160524|
NCT00618397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042006035|Pharmacokinetics of Low Dose Ketamine Infusion|Phase I Trial to Determine Steady State Pharmacokinetics and Sedative Effects of Low Dose Ketamine Infusion||University of Texas Southwestern Medical Center|No|Recruiting|June 2006|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|3 Years|18 Years|No|||June 2015|June 8, 2015|February 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00618397||160523|
NCT00618410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15835A|Intranasal CO2 for Allergic Rhinitis|Intranasal CO2 for Allergic Rhinitis||University of Chicago|No|Completed|February 2008|September 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|13|||Both|18 Years|45 Years|No|||December 2013|December 9, 2013|February 6, 2008|Yes|Yes||No|August 28, 2013|https://clinicaltrials.gov/show/NCT00618410||160522|
NCT00620191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC7231|Metformin in Amnestic Mild Cognitive Impairment|Metformin in the Prevention of Alzheimer's Disease|MCI|Columbia University|Yes|Completed|February 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|55 Years|90 Years|No|||March 2013|March 13, 2013|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620191||160386|
NCT00618670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0095|Home-based vs. Supervised Exercise for People With Claudication|Home-based vs. Supervised Exercise for Claudicants||National Institute on Aging (NIA)|Yes|Recruiting|September 2006|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|111|||Both|35 Years|N/A|No|||December 2009|December 18, 2009|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00618670||160502|
NCT00587197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1319-02|A Prospective Evaluation of Computerized Tomographic(CT) Scanning as a Screening Modality for Esophageal Varices|The Accuracy of Contrast Abdominal CT for the Detection of High-Grade Esophageal and Gastric Varices in Patients With Cirrhosis||Mayo Clinic|No|Completed|January 2003|December 2007|Actual|October 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|134|||Both|18 Years|75 Years|No|Non-Probability Sample|patients with cirrhosis|November 2009|November 9, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587197||162849|
NCT00618644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08|Ranibizumab for Neovascularization in Sickle Cell Retinopathy|A Phase I Study to Evaluate the Ocular and Non Ocular Safety of Ranibizumab in Treating Neovascularization Secondary to Sickle Cell Retinopathy||Kresge Eye Institute|No|Withdrawn|January 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|February 7, 2008|Yes|Yes|Withdrawn due to lack of eligible participants|No||https://clinicaltrials.gov/show/NCT00618644||160504|
NCT00618982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12913|Sorafenib Dose Escalation in Renal Cell Carcinoma|A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma.||Bayer|Yes|Completed|February 2008|January 2011|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 8, 2008||No||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00618982||160479|
NCT00619242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14374B|The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer|A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia|Barrett's|University of Chicago|Yes|Terminated|June 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||February 2014|February 10, 2014|February 6, 2008|No|Yes|Low accrual|No|September 23, 2009|https://clinicaltrials.gov/show/NCT00619242||160459|
NCT00619268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORAVA|Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma|Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.|TORAVA|Centre Leon Berard|Yes|Completed|February 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619268||160457|
NCT00619554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX000-0702|A Study on the Intraject Instructions for Use|Zogenix Intraject Instructions for Use Pilot Study||Zogenix, Inc.|No|Completed|July 2007|||August 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|19|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers from the community|February 2008|February 20, 2008|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00619554||160435|
NCT00620724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/065/HP|Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa|Maintenance Oral Nifedipine for Management of Symptomatic Placenta Previa : A Randomized Clinical Trial||University Hospital, Rouen||Completed|January 2008|September 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Female|18 Years|N/A|No|||July 2014|July 9, 2014|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00620724||160345|
NCT00620737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-B-001|Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars|||Fibrocell Technologies, Inc.|No|Withdrawn|February 2008|||December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|February 11, 2008|Yes|Yes|Company Decision|No||https://clinicaltrials.gov/show/NCT00620737||160344|
NCT00620425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX001-0703|A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs|A Single-Center, Open-label, Single-Arm Study to Evaluate the Effects of Repeat Doses of Subcutaneously Delivered Sumatriptan Via the Intraject System of Local Injection Site Signs in Healthy Adult Subjects.||Zogenix, Inc.|Yes|Completed|December 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|January 2, 2008|No|Yes||No|November 1, 2010|https://clinicaltrials.gov/show/NCT00620425||160368|
NCT00618436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-4-6-7|Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention|Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit|Keppra|University of Cincinnati|Yes|Completed|August 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|February 8, 2008||No||No|August 29, 2013|https://clinicaltrials.gov/show/NCT00618436||160520|
NCT00588120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1026-98|Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria|Investigations Into the Genotype and Phenotype of Unclassified Hyperoxaluria: Enteric Oxalate Absorption Study||Mayo Clinic|Yes|Active, not recruiting|December 1998|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|125|||Both|4 Years|N/A|No|||November 2015|November 30, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00588120||162782|
NCT00621569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F0408110045|ADAPT-Altering Diet for African American Populations to Treat Hypertension|A Culturally Appropriate Intervention in Hypertensive African-Americans Based on the DASH Diet—The ADAPT Hypertension Study = Altering Diet for African American Populations to Treat Hypertension|ADAPT|University of Alabama at Birmingham|No|Completed|January 2005|December 2011|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|122|||Both|25 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 15, 2013|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621569||160281|
NCT00581568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2003-3200|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling|CSC|University of California, Irvine|No|Completed|January 2004|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581568||163277|
NCT00581815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-014|Spectroscopy With Surface Coils and Decoupling|Spectroscopy With Surface Coils and Decoupling||Memorial Sloan Kettering Cancer Center||Completed|February 1997|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|582|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581815||163258|
NCT00578214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-000848|Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery|Randomized Controlled and Prospective Studies of Safety and Efficacy of Oral Midazolam for Perioperative Anxiolysis of Patients Undergoing Mohs Micrographic Surgery.||Mayo Clinic|Yes|Completed|March 2007|June 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|December 20, 2007||No||No|January 13, 2012|https://clinicaltrials.gov/show/NCT00578214||163532|The study was hindered by slow accrual and fell short of reaching the target number of patients.
NCT00581906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007|Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors|Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|February 2006|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|320|||Both|18 Years|N/A|No|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment        team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer        Center (MSKCC).|January 2016|January 21, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581906||163251|
NCT00618423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 07-023 (07-006)|The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery|The Effect of Perioperative Intravenous Low-dose Ketamine on Acute and Chronic Neuropathic Pain After Major Back Surgery. A Randomised, Placebo-controlled, Double-blind Study|KetaDol|University Hospital, Geneva|No|Completed|October 2007|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00618423||160521|
NCT00621062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAFPELS|Prospective Randomized Trial Comparing the New Endovenous Procedures Versus Conventional Surgery for Varicose Veins Due to Great Saphenous Vein Incompetence|Randomized Prospective Trial of Varicose Vein Surgery|RAFPELS|Uppsala University|Yes|Completed|January 2008|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|540|||Both|18 Years|75 Years|No|||March 2011|January 31, 2014|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621062||160319|
NCT00621348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL-1|Maintenance Intravenous Fluids in Children|A RCT to Evaluate the Effect of Normal Saline in 5% Dextrose at Maintenance Rate, N/5 Saline in 5% Dextrose at 2/3 Maintenance Rate and N/5 Saline in 5% Dextrose at Maintenance Rate on Incidence of Hyponatremia in Hospitalized Children.||All India Institute of Medical Sciences, New Delhi|No|Completed|September 2006|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|167|||Both|3 Months|12 Years|No|||August 2011|August 8, 2011|February 12, 2008||No||No|July 12, 2011|https://clinicaltrials.gov/show/NCT00621348||160298|
NCT00618657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 07-61|Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting|A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting||University of California, Irvine|Yes|Recruiting|February 2008|July 2019|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|21 Years|90 Years|No|||March 2014|March 3, 2014|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00618657||160503|
NCT00618969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO 07-122|Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors|A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States||University of Arizona|Yes|Completed|February 2008|February 2016|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618969||160480|
NCT00619580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08010298|Ampicillin-sulbactam Resistant E.Coli at UPMC|Ampicillin-sulbactam Resistant E.Coli at UPMC||University of Pittsburgh|Yes|Withdrawn|February 2008|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|E coli positive infections at UPMC|December 2014|December 5, 2014|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00619580||160433|
NCT00619866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-56418-0702|An Efficacy and Safety Study of NBI-56418 in Endometriosis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis||AbbVie|No|Completed|December 2007|August 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Female|18 Years|49 Years|No|||January 2013|January 2, 2013|January 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619866||160411|
NCT00621322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110345|Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults|Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.||GlaxoSmithKline||Completed|April 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|181|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621322||160300|
NCT00621556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P002500|Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas|RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas||Massachusetts General Hospital|No|Terminated|February 2008|December 2008|Actual|December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|90 Years|No|||January 2009|January 27, 2009|January 22, 2008|No|Yes|Poor patient enrollment due to logistical issues|No||https://clinicaltrials.gov/show/NCT00621556||160282|
NCT00619034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001697-84|Pharmacological Intervention in Diabetic Retinopathy|Pharmacological Intervention Against Diabetic Retinal Flow Disturbances.|XAVOT|University of Aarhus|Yes|Completed|September 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|87|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||December 2010|December 28, 2010|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619034||160475|
NCT00588536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-132|Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH|Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH)||Memorial Sloan Kettering Cancer Center||Completed|January 1995|June 2009|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||April 2015|April 16, 2015|December 26, 2007|Yes|Yes||No|April 16, 2015|https://clinicaltrials.gov/show/NCT00588536||162750|
NCT00588341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-076|Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection|Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection||Memorial Sloan Kettering Cancer Center||Completed|September 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 26, 2007|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00588341||162765|
NCT00588523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-089|Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma|A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2002|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||October 2015|October 9, 2015|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588523||162751|
NCT00581828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0159|Does Treatment of Hypovitaminosis D Increase Calcium Absorption?|Does Treatment of Hypovitaminosis D Increase Calcium Absorption?||University of Wisconsin, Madison|Yes|Completed|January 2005|December 2008|Actual|July 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 13, 2012|December 19, 2007||No||No|July 6, 2012|https://clinicaltrials.gov/show/NCT00581828||163257|
NCT00577928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060362|Value of Fecal Calprotectin|Correlation of Fecal Calprotectin Level With the Clinical, Endoscopic, Histologic and Radiologic Activity in Inflammatory Bowel diseaseThe Value of Fecal Calprotectin for the Diagnosis and Assessment of Inflammatory Bowel Disease||Indiana University|No|Completed|April 2006|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|171|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients who had calprotectin assays as part of their evaluations for lower        gastrointestinal symptoms in the Division of Gastroenterology at IU within the last 12        months will be considered eligible for the study.|August 2015|August 7, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577928||163553|
NCT00581334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4606|Robotic-assisted Laparoscopic Sacrocolpopexy|Robotic-assisted Laparoscopic Sacrocolpopexy: A Feasibility Study||University of California, Irvine|Yes|Completed|May 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||July 2013|July 18, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581334||163295|
NCT00581620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-100974|Study Evaluating Prevenar Immunogenicity in High Risk Children|To Evaluate the Humoral Immune Response to a Conjugated Pneumococcus Vaccine 7-Valent (Prevenar®) in Children From High Risk Groups.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2002|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|160|||Both|2 Months|9 Years|No|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581620||163273|
NCT00581633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061230|Acute Salt Handling in Orthostatic Intolerance|Acute Renal Salt Handling in Orthostatic Intolerance||Vanderbilt University|No|Active, not recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00581633||163272|
NCT00581893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200512712|Phenytoin and Driving Safety|Phenytoin and Driving Safety||University of Iowa|Yes|Recruiting|August 2005|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|30|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||December 2007|December 27, 2007|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581893||163252|
NCT00578773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-38|A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea|Safety and Efficacy of a Topical Otic Formulation in the Treatment of Peri-Operative Tube Otorrhea||Alcon Research|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|303|||Both|6 Months|12 Years|No|||November 2012|November 29, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578773||163490|
NCT00619918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-06-00271|Nebulized Hypertonic Saline for Bronchiolitis|Nebulized Hypertonic Saline for Treatment of Viral Bronchiolitis||Children's Hospital Los Angeles|Yes|Completed|February 2008|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|N/A|24 Months|No|||July 2013|July 29, 2013|February 8, 2008||No||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00619918||160407|Albuterol administered before each study treatmentDid not reach subject accrual goalsNumber of patients recruited from inpatient unit too small to analyze separately
NCT00619931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD791-002|A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers|||Arena Pharmaceuticals|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|50|||Both|19 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Healthy men and women|December 2008|December 29, 2008|February 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619931||160406|
NCT00619060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582627|Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers|A Phase I Study of Topical Myristyl Nicotinate Cream on Human Skin in Healthy Volunteers||University of Arizona|Yes|Completed|August 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|March 9, 2016|February 19, 2008|No|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00619060||160473|
NCT00619333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-2-073|Inactive FSH in Galactosemia|The Role of Inactive Follicle Stimulating Hormone in Ovarian Dysfunction in Galactosemia||Maastricht University Medical Center|No|Active, not recruiting|March 2007|||March 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Female|18 Years|N/A|No|||January 2010|January 11, 2010|February 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619333||160452|
NCT00618995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-079|A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 Diabetes||Merck Sharp & Dohme Corp.||Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|February 8, 2008|No|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00618995||160478|
NCT00619008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002753|Energy Balance Weight Regulation Study|Energy and Appetite Regulation by High and Low CHO Diets|BALANCE|National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|April 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|35|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 2, 2008|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00619008||160477|
NCT00618748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11682|Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed|Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed||Eli Lilly and Company|No|Completed|February 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|18 Years|75 Years|No|||July 2011|July 25, 2011|February 8, 2008|Yes|Yes||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00618748||160496|
NCT00619593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA079|Survival of Patients With Primary Prophylactic ICD Indication|Survival of Patients With Primary Prophylactic ICD Indication, Provided With Intensified Care After 1st ICD Therapy|SPIRIT-ICD|Biotronik SE & Co. KG|No|Completed|February 2008|July 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|504|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00619593||160432|
NCT00620984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5395|Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis|Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis: A Large Prospective Study||State University of New York - Upstate Medical University|No|Completed|August 2006|December 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|557|||Female|18 Years|N/A|No|Probability Sample|We will be enrolling 500 dyads (mother and newborn infant pairs) into the study over        approximately a three year period. Mothers will be age 18 years or older.|May 2015|May 29, 2015|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00620984||160325|
NCT00620997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|London HSC|Proparacaine vs Placebo for Corneal Injuries|Challenging the Dogma: Topical Proparacaine is Safe and Effective for the Emergency Department Management of Acute Traumatic Corneal Injuries|Dogma|London Health Sciences Centre|No|Completed|October 2005|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||September 2006|February 21, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00620997||160324|
NCT00621010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS21166-101|Safety Study of CTS21166 to Treat Alzheimer Disease|A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males|CTS|CoMentis|Yes|Completed|June 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|1||Actual|56|||Male|22 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 7, 2008|February 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621010||160323|
NCT00622063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 501-115|An Extension Study for Patients Previously Treated With ARQ 501|An Extension Study for Patients Previously Treated With ARQ 501||ArQule|No|Completed|December 2006|||September 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622063||160243|
NCT00622336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-012|A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma|Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 Monotherapy for Subjects With Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010||Celgene|No|Completed|December 2003|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|330|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|February 14, 2008|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00622336||160224|
NCT00587899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005543|Prophylactic Pulmonary Vein Isolation Study|A Randomized, Single-blind Prophylactic Pulmonary Vein Isolation Procedure Utilizing Bipolar Radiofrequency Ablation in Patients Undergoing Mitral Valve Surgery||Mayo Clinic|No|Terminated|January 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|December 22, 2007|Yes|Yes|enrollment has been lower than anticipated due to growth in the minimally invasive mitral    valve repair practice.|No||https://clinicaltrials.gov/show/NCT00587899||162798|
NCT00587938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1780-03|BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED|BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED: A Clinical Development Project||Mayo Clinic|No|Completed|December 2003|March 2005|Actual|March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|Samples Without DNA|Original protocol specifies a single 10 ml of blood is collected and frozen from each study      participant (N=200), to be available for research assays.|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Dyspneic patients:65 years or older presenting to the ED with chief complaint of shortness        of breath, were enrolled in a randomized, controlled trial.|December 2007|December 26, 2007|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00587938||162795|
NCT00588159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004145|Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia|Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study||Mayo Clinic|Yes|Completed|June 2007|March 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 24, 2011|December 18, 2007||No||No|December 28, 2010|https://clinicaltrials.gov/show/NCT00588159||162779|
NCT00588549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-015|Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases|Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases||Memorial Sloan Kettering Cancer Center|No|Completed|July 1998|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|204|||Both|18 Years|N/A|No|Non-Probability Sample|Memorial Sloan-Kettering Cancer Center patients with colorectal cancer|March 2009|March 18, 2009|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588549||162749|
NCT00581841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AR48768 - substudy|Repeatability of X-Ray, MRI, and Gait Analysis|Repeatability of X-Ray, MRI, and Gait Analysis||Mayo Clinic|No|Completed|November 2002|June 2003|Actual|June 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|May 2013|May 16, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581841||163256|
NCT00581854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO00401|Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma|Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma||University of Wisconsin, Madison|Yes|Completed|June 2000|March 2010|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|December 19, 2007|Yes|Yes||No|December 2, 2011|https://clinicaltrials.gov/show/NCT00581854||163255|
NCT00581347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCAIR|Primary Care and Adolescent Immunization for Rochester||PCAIR|University of Rochester||Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|7546|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||September 2008|September 14, 2010|December 19, 2007||No||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00581347||163294|
NCT00578240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-040|Molecular Studies and Clinical Correlations in Human Prostatic Disease|Molecular Studies and Clinical Correlations in Human Prostatic Disease||Memorial Sloan Kettering Cancer Center||Recruiting|April 1990|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|2500|Samples With DNA|Human tissue, body fluids, and blood Fresh tissue will be obtained from patients undergoing      a biopsy or surgical procedure as part of their standard therapy or as part of an      investigational research protocol. Previously stored pathology specimens may also be used.      Peripheral blood, bone marrow, urine, and other bodily fluids and samples will also be      obtained as needed.|Male|N/A|N/A|No|Non-Probability Sample|All patients meeting the eligibility criteria and receiving or seeking prostate cancer        treatment in the Genitourinary Oncology/Urology Services will be approached by a        consenting professional at a suitable point in their clinical course prior to biospecimen        collection.|January 2016|January 20, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00578240||163530|
NCT00578526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRUCE02|SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial|A Randomized, Placebo-controlled Phase II Study to Compare the Efficacy and Safety of SU011248 Versus Placebo in Patients With Advanced Urothelial Transitional Cell Carcinoma Who Have Failed or Are Intolerant to Cisplatin-based Chemotherapy|SPRUCE|AHS Cancer Control Alberta|Yes|Active, not recruiting|April 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||September 2011|January 18, 2012|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578526||163509|
NCT00578539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21079-REGALE|T-Reg Cell Kinetics, Stem Cell Transplant, REGALE|T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors|REGALE|Baylor College of Medicine|Yes|Terminated|October 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|N/A|No|||August 2014|August 28, 2014|December 19, 2007|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00578539||163508|
NCT00569907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03520-06-C|Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide|Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide||HealthPartners Institute|No|Completed|January 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|18|||Both|21 Years|N/A|No|Non-Probability Sample|Community sample.|August 2010|November 25, 2015|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569907||164151|
NCT00620763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC087|Calcium Retention as Influenced by Dietary Components That Induce an Acid Load|Calcium Retention in Postmenopausal Women as Influenced by Beef and Other Dietary Components That Induce an Acid Load||USDA Grand Forks Human Nutrition Research Center|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|22|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|January 18, 2008|No|Yes||No|December 31, 2008|https://clinicaltrials.gov/show/NCT00620763||160342|
NCT00621036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587504|Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma|A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With CNS Lymphoma||National Cancer Institute (NCI)||Recruiting|November 2007|||June 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2008|April 1, 2010|February 21, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00621036||160321|
NCT00621049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 142|Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC|Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Patients With Resected Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|December 2007|February 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|December 26, 2007|No|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT00621049||160320|
NCT00621829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHNR07702|Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms|Pilot Study of Supplemental Eicosapentanoic Acid (EPA)-Enriched Omega-3 Polyunsaturated Fatty Acids (n3-PUFA) in a Subset of Moderate to Severe Asthmatics With Polymorphisms of the Arachidonate 5-lipoxygenase (ALOX5) Gene||University of California, Davis|Yes|Completed|February 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2011|October 11, 2011|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621829||160261|
NCT00621842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L0971|Lamotrigine for Symptoms of Geriatric Bipolar Depression|Open-label, Prospective Trial of Lamotrigine for Symptoms of Geriatric Bipolar Depression|Geri-BD SAD|University Hospital Case Medical Center|Yes|Completed|January 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|60 Years|N/A|No|||December 2014|December 8, 2014|February 12, 2008|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00621842||160260|
NCT00622089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIO-503|Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients|An Open Label Follow-On Study of Safety and Pharmacodynamic Effects of 24 Weeks of Treatment With DIO-902 in Combination With Metformin and Atorvastatin in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-503)||DiObex|No|Terminated|January 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||May 2008|May 22, 2008|January 3, 2008|Yes|Yes|Program terminated|No||https://clinicaltrials.gov/show/NCT00622089||160241|
NCT00622388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111776|Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant|An Open-label, Single-arm. Multi-center Phase 2 Trial With Ofatumumab in Patients With Relapsed/Progressive Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Transplant or Relapse/Progression After Autologous Transplant||GlaxoSmithKline|Yes|Completed|December 2007|August 2014|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||January 2015|July 2, 2015|February 13, 2008|No|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00622388||160220|
NCT00618215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVZ-538/001/2001/RL000003|A Cluster Randomized Controlled Trial in Primary Oral Care|Impact of Multifaceted Peer Group Education to Improve Routine Oral Examinations in Primary Care A Cluster-Randomised Controlled Trial||Radboud University|No|Completed|September 2006|July 2007|Actual|June 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|1161|||Both|N/A|N/A|No|||February 2008|February 18, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00618215||160536|
NCT00619281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-11-2007|How Much Cardiac Output is Enough?|Prospective, Observational Study in Cardiac Surgery: How Much Cardiac Output is Enough?||Klinikum Ludwigshafen|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|600 patients undergoing cardiac surgery|November 2009|November 23, 2009|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00619281||160456|
NCT00620438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR 005|Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients|Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients||Makerere University|No|Active, not recruiting|February 2008|July 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|60 Years|No|||December 2010|December 3, 2010|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00620438||160367|
NCT00586742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001870|SLAP Lesions; a Comparison of Conservative and Operative Treatment. A Prospective, Randomized Study|SLAP Lesions; a Comparison of Conservative and Operative Treatment. A Prospective, Randomized Study||Lovisenberg Diakonale Hospital|No|Active, not recruiting|January 2008|April 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586742||162883|
NCT00621816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HD-4-3386|Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Pharmacodynamics of Sodium Nitroprusside During Prolonged Infusion in Pediatric Subjects||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|January 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|N/A|17 Years|No|||April 2011|December 2, 2011|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621816||160262|
NCT00622050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRBS 08-052|The Relationship of TV Viewing to Energy Balance in Adults|The Effects of Limiting TV Viewing on Diet, Exercise, and Sleep in Overweight and Obese Adults|TView|University of Vermont||Completed|January 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00622050||160244|
NCT00618176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA719A10|Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort|||Peking Union Medical College||Completed|January 2005|||September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|N/A|No|||March 2008|March 21, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00618176||160538|
NCT00587327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200440 CS09|Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions|A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Study Assessing the Effects of a Selective Oxytocin Antagonist (Barusiban) and a Mixed Oxytocin Antagonist - Vasopressin V1a Antagonist (Atosiban) Administered Intravenously on Luteal Phase Uterine Contractions in Oocyte Donors Supplemented With Vaginal Progesterone|OVANCON|Ferring Pharmaceuticals|No|Completed|November 2007|September 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|125|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587327||162839|
NCT00588133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216-00|A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery|A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery||Mayo Clinic|No|Completed|January 2004|August 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||November 2009|November 9, 2009|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00588133||162781|
NCT00588172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004310|Genetic Variation in OCT1 and Response to Metformin|Genetic Variation in OCT1 and Response to Metformin||Mayo Clinic|No|Withdrawn|June 2010|June 2011|Anticipated|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2010|August 16, 2010|December 22, 2007|Yes|Yes|No funding|No||https://clinicaltrials.gov/show/NCT00588172||162778|
NCT00588367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360-06|CT Pancreas Perfusion|CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study||Mayo Clinic|No|Completed|April 2006|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Mayo Clinic patients being seen in Pancreas Clinic.|April 2015|April 14, 2015|December 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588367||162763|
NCT00588354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002738|Epidural Clonidine for Lumbosacral Radiculopathy|Pilot Study of Transforaminal Epidural Injection of Clonidine for the Treatment of Acute Lumbosacral Radiculopathy||Mayo Clinic|No|Terminated|October 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 6, 2011|December 26, 2007||No|Targeted enrollment was not reached.|No|June 3, 2011|https://clinicaltrials.gov/show/NCT00588354||162764|Early termination leading to small numbers of subjects analyzed; did not measure analgesia during the expected analgesic peak of bolus administration, but 10 days after last injection; compared clonidine with an active control, rather than placebo.
NCT00581867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10896|Memory and Insulin in Early Alzheimer's Disease|Intranasal Insulin and Memory in Early Alzheimer's Disease|MAIN|University of Kansas Medical Center|Yes|Completed|October 2007|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|31|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|December 19, 2007|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT00581867||163254|
NCT00581880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-145|Measuring Hope and Hopelessness in Cancer|Measuring Hope and Hopelessness in Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 2005|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|288|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited in equal numbers from Memorial Hospital and Calvary Hospital or        Peter MacCallum Cancer Centre at each stage of data collection.|January 2009|January 14, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581880||163253|
NCT00573326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM 69J AJ9|Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement|Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study||Azienda Ospedaliera Universitaria Policlinico|Yes|Recruiting|February 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||September 2009|September 2, 2009|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573326||163896|
NCT00569296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577502|Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer|A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer||Roger Williams Medical Center|Yes|Terminated|November 2007|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|December 6, 2007|No|Yes|Funding ended|No||https://clinicaltrials.gov/show/NCT00569296||164196|
NCT00569582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-400|A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome|An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome|SEISMIC|Corcept Therapeutics|Yes|Completed|December 2007|||January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|December 5, 2007|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00569582||164175|
NCT00570726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.10|Treatment of Failing Blebs With Ranibizumab|Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy||The New York Eye & Ear Infirmary|No|Completed|June 2000|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|6|||Both|40 Years|N/A||||December 2007|October 14, 2014|December 9, 2007||||No||https://clinicaltrials.gov/show/NCT00570726||164091|
NCT00621582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.373|Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities|Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities||Boehringer Ingelheim||Completed|May 2006|||February 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4918|||Both|40 Years|N/A|No|Non-Probability Sample|primary care clinic|October 2014|October 14, 2014|February 13, 2008||||No|February 9, 2010|https://clinicaltrials.gov/show/NCT00621582||160280|
NCT00621595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06278|The Effects of Breakfast on Brain Function|The Effects of Breakfast on Cognitive Functioning||Arkansas Children's Hospital Research Institute|No|Completed|November 2000|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|166|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621595||160279|
NCT00590447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTLD-1, 3rd. amendment|Risk Stratified Sequential Treatment for CD20-positive PTLD|Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3)|PTLD-1/3|Charite University, Berlin, Germany|No|Active, not recruiting|December 2006|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|N/A|No|||January 2015|January 7, 2015|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590447||162610|
NCT00618683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2353|AV Nodal Reentrant Tachycardia Study|Localization of the Anterograde and Retrograde Components of the Reentrant Circuit of AV Nodal Reentrant Tachycardia|AVNRT|University of Oklahoma|No|Recruiting|March 2004|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|16 Years|80 Years|No|||February 2016|February 18, 2016|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00618683||160501|
NCT00618696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS039|Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia|MT2005-13R - Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 in Patients With Advanced Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Terminated|July 2005|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|February 19, 2008|No|Yes|Replaced with another study|No||https://clinicaltrials.gov/show/NCT00618696||160500|
NCT00618462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060417-09|Cognitive Behavioral Treatments for Pathological Gambling|Cognitive Behavioral Treatments for Pathological Gambling||University of Connecticut Health Center|Yes|Completed|August 2004|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|N/A|No|||December 2011|December 23, 2011|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00618462||160518|
NCT00618475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DK076980|Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Recruiting|August 2008|August 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|ESRD patients treated with hemodialysis|March 2011|March 15, 2011|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00618475||160517|
NCT00620165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00624|Efficacy of Levetiracetam in Essential Tremor|Efficacy of Levetiracetam in Patients With Essential Tremor||Southern California Institute for Research and Education|No|Completed|January 2005|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|25 Years|85 Years|No|||April 2009|April 16, 2009|February 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620165||160388|
NCT00587340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-071|A Survey of Sleep Problems in Survivors of Breast Cancer|A Survey of Sleep Problems in Survivors of Breast Cancer||Memorial Sloan Kettering Cancer Center|No|Completed|August 2006|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|256|||Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer Patients|September 2011|September 16, 2011|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587340||162838|
NCT00587028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|981-05|Cathartic-Free DECT Colonography for Detection of Colonic Polyps|Cathartic-Free Dual Energy Computerized Tomography (DECT) Colonography.||Mayo Clinic|No|Terminated|February 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|12|||Both|40 Years|99 Years|No|Non-Probability Sample|Mayo Clinic, Rochester, Minnesota and Mayo Clinic, Scottsdale, Arizona Colonoscopy        schedules.|January 2016|January 20, 2016|December 21, 2007||No|Administrative closed due to funding|No||https://clinicaltrials.gov/show/NCT00587028||162862|
NCT00587600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2138-00|Biomarkers in Phototherapy of Barrett's Esophagus|Biomarkers in Phototherapy of Barrett's Esophagus|BIOBAR|Mayo Clinic|Yes|Active, not recruiting|December 2002|September 2016|Anticipated|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|85 Years|No|||November 2015|November 23, 2015|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587600||162819|
NCT00587613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2006|||||N/A|N/A|N/A||||||||||||||August 7, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587613||162818|
NCT00587912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-043|AIDS and Cancer Specimen Bank (ACSB)|AIDS and Cancer Specimen Bank (ACSB)||Memorial Sloan Kettering Cancer Center||Completed|June 1997|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|65|Samples With DNA|Blood, urine, other bodily fluids (eg, pleural fluid), and tumor tissue obtained from      patients.|Both|18 Years|N/A|No|Non-Probability Sample|The Source of specimens will include patients screened for participation on protocols        conducted by the AIDS Malignancy Consortium, as well as other patients with HIV infection        and cancer who are not eligible for participation in AMC trials, and patients without HIV        who have malignancies associated with HIV or with immunosuppression.|April 2011|April 20, 2011|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00587912||162797|
NCT00588146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2400-05|Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia|Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia||Mayo Clinic|Yes|Terminated|January 2007|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|70 Years|No|||February 2013|February 19, 2013|December 26, 2007|Yes|Yes|Schering-Plough discontinued supplying study drug.|No|December 20, 2012|https://clinicaltrials.gov/show/NCT00588146||162780|The study was terminated early because Schering-Plough discontinued supplying study drug.
NCT00588185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-095|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|February 2003|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Male|N/A|N/A|No|||January 2016|January 4, 2016|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588185||162777|
NCT00588380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004153|GLP1R Polymorphisms and Response to GLP1|A Pilot Study Examining How Common Genetic Variation in GLP1R Alters Response to GLP1 Infusion||Mayo Clinic|No|Completed|November 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|88|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|December 22, 2007|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00588380||162762|This is a pilot study with limited power to detect / replicate effects. It will require independent replication of study results.
NCT00588575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-04 00|Ramanspectroscopy in Barrett's Esophagus|In-Vivo Raman Spectroscopy of Barrett's Esophagus||Mayo Clinic|No|Completed|October 2004|October 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|119|Samples Without DNA|esophageal biopsy|Both|18 Years|85 Years|No|Non-Probability Sample|Barrett's esophagus surveillance|September 2009|January 5, 2016|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588575||162747|
NCT00588887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-U-014|Total Knee Replacement With Duracon® and Vanguard™ Prostheses|||Biomet, Inc.|No|Terminated|June 2005|June 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include patients requiring total knee replacement.|August 2012|August 14, 2012|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588887||162724|
NCT00580996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060547|Water and the Gastropressor Response - Tachyphylaxis|Water and the Gastropressor Response - Tachyphylaxis (Specific Aim 1.2)||Vanderbilt University|No|Active, not recruiting|July 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|80 Years|No|||December 2014|December 18, 2014|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00580996||163321|
NCT00581009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2001-1616|The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients|The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients||University of California, Irvine|No|Recruiting|March 2001|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2010|November 1, 2010|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581009||163320|
NCT00569920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s8197.04|Nausea and Pain Prophylaxis During Thyroid Surgery|Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo||Sykehuset Telemark|Yes|Completed|September 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|70 Years|No|||January 2009|January 14, 2009|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00569920||164150|
NCT00569933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002226|Audio Recording for Improved Surgical Outcome (ARISO)|Audio Recording for Improved Surgical Outcome||Mayo Clinic|Yes|Completed|December 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00569933||164149|
NCT00570245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICER1|Safety and Efficacy Study of Nitric Oxide in Patients Going Through Lung Transplantation|A Pilot, Single Center Prospective, With Parallel Groups, Controlled and Open to Evaluate the Efficacy of Nitric Oxide for Inhalation in Lung Donors and in the Prevention of Reperfusion Injury.||INO Therapeutics|Yes|Completed|April 2005|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|65 Years|No|||January 2013|January 23, 2013|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00570245||164126|
NCT00580853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0702002390|The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior|The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior||Yale University|Yes|Active, not recruiting|April 2007|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|55 Years|No|||February 2016|February 10, 2016|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00580853||163332|
NCT00581438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082A-102378|Study Evaluating Approach to Treatment of Haemophilia A and B in Spain|Actual Approach to Treatment of Haemophilia A and B in Spain||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|52|||Both|N/A|N/A|No|Non-Probability Sample|People known to have Haemophilia A or B|December 2007|December 26, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581438||163287|
NCT00589966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000351|Coping in African American Prostate Cancer Survivors|Coping Skills Training Groups to Enhance Recovery From Prostate Cancer in African American Men|CAAPS|Duke University|Yes|Completed|May 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|62|||Male|N/A|N/A|No|||February 2013|February 28, 2013|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00589966||162646|
NCT00590213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7054TR/01|Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX|An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients|COMART|AstraZeneca|No|Completed|June 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|125|||Male|18 Years|N/A|No|||January 2008|January 23, 2008|December 28, 2007||||No||https://clinicaltrials.gov/show/NCT00590213||162628|
NCT00586495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12056|Long-term Extension From RCC Phase II (11515)|Extension Study for BAY43-9006 in Japanese Patients With Renal Cell Carcinoma||Bayer|No|Completed|December 2005|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|December 21, 2007||No||No|October 8, 2009|https://clinicaltrials.gov/show/NCT00586495||162902|
NCT00619021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002LS028|Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer|A Phase I Study Evaluating Bronchial Artery Infusion (BAI) of Gemcitabine in Recurrent or Progressive Non-Small Cell Lung Cancer||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2003|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|4|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|February 19, 2008|No|Yes|Funding and study drugs unavailable|No||https://clinicaltrials.gov/show/NCT00619021||160476|
NCT00586482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002759|Pilot Study: Preoperative Nicotine Lozenges|The Role of Nicotine Lozenges in Reducing Preoperative Exposure to Cigarette Smoke||Mayo Clinic|No|Completed|August 2006|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|December 21, 2007|Yes|Yes||No|November 26, 2014|https://clinicaltrials.gov/show/NCT00586482||162903|
NCT00587353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006180|Tobacco Use Intervention Among Radiation Oncology Patients|Tobacco Use Intervention Among Radiation Oncology Patients||Mayo Clinic|No|Completed|January 2008|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587353||162837|
NCT00587626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRG|Proposal to Evaluate the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain|Proposal to Evaluate the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain||McMaster University||Completed|August 2007|December 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|66 Years|No|||June 2010|June 24, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587626||162817|
NCT00587925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-024|Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer|A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Female|N/A|N/A|No|||February 2009|February 25, 2009|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00587925||162796|
NCT00587652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2114-02|Methylene Blue Chromoendoscopy in Barrett's Esophagus|A Prospective Trial of Methylene Blue Chromoendoscopy in Barrett's Esophagus||Mayo Clinic|No|Completed|December 2002|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting for surveillance upper endoscopy to assess Barrett's esophagus.|January 2010|January 5, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587652||162815|
NCT00587665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1896-05|Low Dose Ketamine as an Adjunct to Fentanyl in Outpatient Tonsillectomy|A Prospective Study of Low Dose Ketamine as an Adjunct to Fentanyl in Pediatric Patients Following Outpatient Tonsillectomy and Adenoidectomy||Mayo Clinic|No|Completed|August 2006|December 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|3 Years|12 Years|No|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587665||162814|
NCT00588588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002660|Bronchoscopy vs. Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP)|Bronchoscopy Versus Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP): Randomized Clinical Trial||Mayo Clinic|No|Withdrawn|January 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|December 22, 2007||No|Due to inability to get support for the study|No||https://clinicaltrials.gov/show/NCT00588588||162746|
NCT00577967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|355/05|Gabapentin - A Solution to Uremic Pruritus?|Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study||Hospital Authority, Hong Kong||Not yet recruiting|October 2005|March 2006|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|80|||Both|N/A|N/A||||July 2010|July 6, 2010|December 19, 2007||||No||https://clinicaltrials.gov/show/NCT00577967||163551|
NCT00577980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0316|Testosterone in Castration-Resistant Prostate Cancer|Testosterone Replacement Therapy in Castration-Resistant Prostate Cancer||M.D. Anderson Cancer Center|No|Withdrawn|December 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|N/A|N/A|No|||April 2013|April 25, 2013|December 17, 2007||No|Zero accrual and failure to generate multicenter interest.|No||https://clinicaltrials.gov/show/NCT00577980||163550|
NCT00580346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-01-02|Dynamic Laryngotracheal Separation for Aspiration|Dynamic Laryngotracheal Separation for Aspiration. Prevention of Silent Aspiration Pneumonia During Swallowing by an Implanted Stimulator||University Hospital Case Medical Center|No|Suspended|August 2004|July 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|3|||Both|18 Years|85 Years|No|||January 2009|February 17, 2009|December 21, 2007|Yes|Yes|Protocol currently reviewed for updating|No||https://clinicaltrials.gov/show/NCT00580346||163370|
NCT00580359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-263|S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer|A Randomized Phase II Study of S-1 Versus Capecitabine as First-Line Chemotherapy in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer||National Cancer Center, Korea|No|Recruiting|May 2007|June 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|60 Years|85 Years|No|||December 2007|December 26, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00580359||163369|
NCT00580593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS55200|Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)|Pilot Placebo-Controlled Trial of Early Noninvasive Ventilation for ALS||University of Michigan|No|Completed|April 2007|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|79 Years|No|||July 2013|July 9, 2013|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00580593||163352|
NCT00581451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3168A2-1005|Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects|A 3-Part, Randomized, Multiple-Dose, Sequential Design Study of Bifeprunox in Healthy Subjects in Order to Establish a Titration Regimen With an Improved Tolerability Profile||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Anticipated|144|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581451||163286|
NCT00581711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-10-5555|Improving Otitis Media Care With Clinical Decision Support|Improving Otitis Media Care With EHR-based Clinical Decision Support and Feedback|OMHIT|Children's Hospital of Philadelphia|No|Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|55779|||Both|2 Months|18 Years|No|||June 2012|June 15, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581711||163266|
NCT00589992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMH study #762|Ibutilide Administration During Pulmonary Vein Ablation|Atrial Fibrillation Mechanism Analysis Through Ibutilide Administration During Pulmonary Vein Ablation.|IBAD-AFIB|Ball Memorial Hospital|No|Recruiting|October 2007|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|80 Years|No|||January 2012|January 27, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00589992||162644|
NCT00590226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048954|Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes|Comparative Trial Between Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Type 2 Diabetes|DEAN|Emory University|Yes|Completed|December 2006|April 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|70 Years|No|||May 2014|June 6, 2014|December 27, 2007|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00590226||162627|
NCT00590460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-9938|Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia|Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia|Mafia|Baylor College of Medicine|Yes|Terminated|July 2001|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|N/A|No|||November 2013|November 21, 2013|December 26, 2007|Yes|Yes|slow accrual|No|July 2, 2012|https://clinicaltrials.gov/show/NCT00590460||162609|
NCT00590473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71692|Sacral Neuromodulation in Patients With IC|Sacral Neuromodulation: Bilateral Placement vs. Unilateral Placement in Patients With Interstitial Cystitis||Drexel University|No|Recruiting|April 2007|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|79 Years|No|||December 2007|December 26, 2007|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590473||162608|
NCT00619879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0307|Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies|Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|March 2007|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|21 Years|No|||March 2011|March 29, 2011|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619879||160410|
NCT00619892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703-22|A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients|An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder||Indiana University|Yes|Completed|February 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|February 11, 2008||No||No|July 27, 2015|https://clinicaltrials.gov/show/NCT00619892||160409|
NCT00587041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1483-05|Use of Oral Probiotics to Reduce Urinary Oxalate Excretion|Use of Oral Probiotics to Reduce Urinary Oxalate Excretion||Mayo Clinic|Yes|Completed|February 2006|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||April 2012|April 28, 2012|December 21, 2007||No||No|September 19, 2011|https://clinicaltrials.gov/show/NCT00587041||162861|Small sample size, low oxalate levels in diet
NCT00587093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-048|A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer|Multicenter Trial on Utility and Impact of Computed Tomography and Serum CA-125 in Management of Newly Diagnosed Ovarian Cancer||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|July 2001|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587093||162857|
NCT00587639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-000495|An Evaluation of Safety and Feasibility Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression|An Evaluation of Safety and Feasibility Using rTMS in Adolescents With Depression||Mayo Clinic|Yes|Completed|May 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|December 21, 2007|No|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00587639||162816|Limitations of the study include its open design, and small number of total participants.
NCT00587379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328-04|Effect of Chronic Statin and Viagra Therapy in Persons With Endothelial Cell Dysfunction|The Effect of Chronic Statin Therapy on Peripheral Arterial Tone Response to Sildenafil Citrate (Viagra), and on Erectile Function in Men With Coronary Artery Endothelial Cell Dysfunction||Mayo Clinic|No|Withdrawn|June 2004|May 2008|Anticipated|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||January 2012|January 12, 2012|December 21, 2007|Yes|Yes|Study closed per the request of PI due to lack of participant accrual|No||https://clinicaltrials.gov/show/NCT00587379||162836|
NCT00587678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10387|Comprehensive Magnetic Resonance of Peripheral Arterial Disease|Comprehensive Magnetic Resonance of Peripheral Arterial Disease||University of Virginia|No|Completed|January 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|30 Years|85 Years|No|||January 2012|January 3, 2012|December 21, 2007|Yes|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00587678||162813|
NCT00587951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2170-05|The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates|The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates||Mayo Clinic|Yes|Completed|December 2005|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients evaluated at Mayo Clinic and being considered for epilepsy surgery.|November 2007|January 7, 2008|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00587951||162794|
NCT00588627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2251-05|Capsaicin Cough Threshold in Chronic Cough Due to Postnasal Drip|Capsaicin Cough Sensitivity, Airway Inflammation and Neurogenic Peptides in Chronic Cough Associated With Postnasal Drip||Mayo Clinic|Yes|Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|Samples Without DNA|Mucus will be quantified and protease inhibitors will be added after collection. The      specimen will be coded to deidentify. It will be transported to laboratory for storage and      analysis. The mucus collected from the posterior nasopharynx will be frozen and assayed      simultaneously. Substance P and Neurokinin A will be measured by ELISA at the end of the      study period.|Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic, community samples|March 2010|March 8, 2010|December 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588627||162743|
NCT00588640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-017|Study of D-Methadone in Patients With Chronic Pain|A Phase I/II Study of D-Methadone in Patients With Chronic Pain||Memorial Sloan Kettering Cancer Center||Completed|October 2004|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|64|||Both|18 Years|N/A|No|||July 2008|July 24, 2008|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588640||162742|
NCT00588913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIC-CTR-GU-05-01|Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases|Phase I/II Study of Adoptive Immunotherapy Comprising Pyrophosphomonoester Antigen-stimulated T Cells, IL-2, and Nitrogen-containing Bisphosphonates in Patients With Stage IV Renal Cell Carcinoma||National Cancer Institute (NCI)||Completed|January 2006|August 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|20 Years|80 Years|No|||August 2009|July 9, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00588913||162722|
NCT00588926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221107-hmo-ctil|Changes of the Neuronal Activity in the Subthalamic Nucleus Under Remifentanil Sedation During Stereotactic Electrode Implantation|||Hadassah Medical Organization|No|Active, not recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|N/A|N/A|No|||December 2007|December 30, 2007|December 30, 2007||No||No||https://clinicaltrials.gov/show/NCT00588926||162721|
NCT00589225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|434-03|Primary Hyperoxaluria Mutation Genotyping|Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria||Mayo Clinic|Yes|Completed|December 2003|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|902|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 25, 2015|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00589225||162700|
NCT00589238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579522|Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery|Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Compared to Weekly Paclitaxel Alone Followed in Both Arms by Doxorubicin and Cyclophosphamide for Operable or Locally Advanced Basal-like Subtype Breast Cancer Correlating BRCA-1 mRNA and Protein Expression With Carboplatin Response||National Cancer Centre, Singapore||Terminated|January 2008|||July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|N/A|No|||June 2013|June 18, 2013|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00589238||162699|
NCT00573079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X070926014|Acute Kidney Injury in Premature Infants|Acute Kidney Injury in Premature Infants||University of Alabama at Birmingham|No|Completed|December 2007|||December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|237|||Both|N/A|N/A|No|Non-Probability Sample|Premature Infants 500-1500grams birthweight >=25 weeks gestation|February 2011|February 1, 2011|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00573079||163915|
NCT00580866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051196|Progressive Splinting Status Post Elbow Fractures and Dislocations|Multi-Center Controlled Trial of Static Progressive Splinting Status Post Elbow Fractures and Dislocations|JAS|Vanderbilt University|No|Terminated|September 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|December 19, 2007||No|low accrual|No||https://clinicaltrials.gov/show/NCT00580866||163331|
NCT00581100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-409|Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis|Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2007|October 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|December 21, 2007||No||No|August 3, 2010|https://clinicaltrials.gov/show/NCT00581100||163313|
NCT00589979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3260-003|Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee|Efficacy and Safety of the Lidocaine 5% Patch When Used as Adjunct Treatment in Patients With Osteoarthritis of the Knee Receiving Sub-Optimal Pain Relief From Their Current Analgesic Regimen||Endo Pharmaceuticals|No|Completed|March 2007|October 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|37 Years|N/A|No|||June 2011|June 13, 2011|December 26, 2007|Yes|Yes||No|December 22, 2009|https://clinicaltrials.gov/show/NCT00589979||162645|Due to operational issues, the modified intent-to-treat (MITT) population, consisting of all intent-to-treat (ITT) patients randomized on or after January 22, 2008, was added to the analysis plan; all efficacy data are presented for this population.
NCT00589745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998-9-1589|Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis|Measurement of Transepithelial Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis||Children's Hospital of Philadelphia|No|Recruiting|September 2003|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|N/A|N/A|No|||January 2016|January 4, 2016|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589745||162662|
NCT00589758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARVA|Tissue Doppler Assessment of Right Ventricular Performance in Acute Heeart Failure|Tissue Doppler Assessment of Right Ventricular Performance in Acute Heeart Failure|TARVA|The Cleveland Clinic|Yes|Recruiting|July 2006|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Probability Sample|patients admitted to H22 ICU|June 2008|June 10, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00589758||162661|
NCT00590239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0044|Barrett's Esophagus Related Neoplasia (BERN) Project|Endoscopic Detection of Early Neoplasia in Patients With Barrett's Esophagus|BERN|Midwest Biomedical Research Foundation|No|Recruiting|May 2007|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is a Veteran population presenting to a VA Hospital upper endoscopy        unit|October 2015|October 19, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590239||162626|
NCT00590499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJTTH-ICU-07-012|Agitation in Post Operative Neurosurgical Patients|A Prospective Survey of Emergent Agitation Following Craniotomy: Incidence, Risk Factors and Outcomes||Capital Medical University||Completed|July 2012|March 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|19 Years|N/A|No|Probability Sample|120 consecutive adult patients admitted to Neuro-ICU for post-operative care following        craniotomy|January 2014|January 29, 2014|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590499||162607|
NCT00586755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2165|Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma|Intensive Induction Therapy Followed by Early High Dose Chemotherapy and Bone Marrow Transplantation for Mantle Cell Lymphoma||Duke University|Yes|Completed|February 1998|November 2008|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586755||162882|
NCT00586781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Link-3|Study of the Scandinavian Total Ankle Replacement (STAR) for the Treatment of Bilateral Degenerative Ankle Disease|Investigational Device Exemption for the Scandinavian Total Ankle Replacement (STAR) - Bilateral Arm||Link America, Inc.|No|Completed|September 2001|||December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|December 21, 2007|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586781||162881|
NCT00587106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-044|Studies of Neurological Paraneoplastic Syndromes|Studies of Neurological Paraneoplastic Syndromes||Memorial Sloan Kettering Cancer Center||Completed|April 1988|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|Samples With DNA|blood and/or spinal fluid|Both|18 Years|N/A|No|Non-Probability Sample|Patients are selected from severals clinics within Memorial Sloan-Kettering Cancer Cetner|March 2009|March 27, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587106||162856|
NCT00587119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003586|Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis|Open-Label Pilot Study Evaluating Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis.|PBC|Mayo Clinic|No|Withdrawn|December 2007|July 2009|Anticipated|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|75 Years|No|||October 2010|October 1, 2010|December 21, 2007|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00587119||162855|
NCT00587691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-03|Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis|An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis|DES|Opexa Therapeutics, Inc.|Yes|Completed|July 2002|December 2008|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|65 Years|No|||June 2011|June 27, 2011|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00587691||162812|
NCT00587717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|485-02|The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue|The Acute Effect of Inflammatory Markers of Atherosclerotic Plaque in Humans||Mayo Clinic|No|Completed|September 2002|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587717||162810|
NCT00587964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-061|Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases|Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases||Memorial Sloan Kettering Cancer Center||Completed|June 2004|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 26, 2007||No||No|December 14, 2015|https://clinicaltrials.gov/show/NCT00587964||162793|
NCT00588614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363-06|High Risk Screening Breast MR Using a Rapid Imaging Exam|High Risk Screening Breast MR Using a Rapid Imaging Exam||Mayo Clinic|No|Completed|April 2006|February 2011|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|140|||Female|25 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|breast clinic patients|May 2012|May 29, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00588614||162744|
NCT00588419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-047|Quantification of Breast Sensation Following Postmastectomy Breast Reconstruction|Quantification of Breast Sensation Following Postmastectomy Breast Reconstruction||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2006|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|153|||Female|21 Years|N/A|No|Non-Probability Sample|Patients will be recruited by their attending surgeon when they return to their surgeon's        office for a postoperative appointment following their qualifying surgery|January 2016|January 13, 2016|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588419||162759|
NCT00588939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006186|Confocal Laser Microscopy in Non Erosive Reflux Disease|Confocal Laser Microscopy in Non Erosive Reflux Disease||Mayo Clinic|Yes|Completed|November 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|esophageal biopsy|Both|18 Years|85 Years|No|Non-Probability Sample|age 18 - 65 years symptoms of acid reflux disease|May 2013|May 17, 2013|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00588939||162720|
NCT00588653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2018-03|Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease|Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease||Mayo Clinic|No|Completed|January 2004|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|41|||Both|18 Years|70 Years|No|||December 2007|January 7, 2008|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588653||162741|
NCT00589251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301-06|Equivalency of Penicilloate Skin Test Reactivity Prepared by a Modified Alkaline Hydrolysis Technique|Equivalency of Penicilloate Skin Test Reactivity Prepared by a Modified Alkaline Hydrolysis Technique||Mayo Clinic|No|Withdrawn|June 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 28, 2007||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00589251||162698|
NCT00569595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 DK71065 (completed)|Improving Health Habits in Impoverished Populations|Improving Health Habits in Impoverished Populations||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 6, 2011|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00569595||164174|
NCT00581113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-10655|Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases|A Study of Neural Stem Cell (NSC) Preserving Whole Brain Radiation Therapy (WBRT) and Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases||Virginia Commonwealth University|Yes|Terminated|March 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|December 20, 2007||No|New research priorities|No|October 6, 2010|https://clinicaltrials.gov/show/NCT00581113||163312|Trial not completed. Insufficient data to analyze.
NCT00581126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A-100932|Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B|Evaluation of Efficacy and Safety of Benefix®- Coagulation Factor ix, Recombinant, in Previously Treated Patients With Hemophilia b.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2001|July 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|6 Years|N/A|No|||December 2007|December 26, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581126||163311|
NCT00581464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07100068|Healthier Hearts and Brains in Treating Smoking: The HABITS Study|Healthier Hearts and Brains in Treating Smoking: The HABITS Study|HABITS|University of Pittsburgh|Yes|Recruiting|November 2009|June 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00581464||163285|
NCT00589732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0077|Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent|Valsartan for SUPpression of Plaque Volume and Restenosis After Drug-Eluting Stent (The VAL-SUPPRESS TRial)|VAL-SUPPRES|CardioVascular Research Foundation, Korea|Yes|Completed|September 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|75 Years|No|||August 2012|August 7, 2012|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00589732||162663|
NCT00590278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1694TR/01|A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer|A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer|TOMUDEX|AstraZeneca|No|Completed|August 2002|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|49|||Both|18 Years|N/A|No|||January 2008|January 23, 2008|December 26, 2007||||No||https://clinicaltrials.gov/show/NCT00590278||162623|
NCT00590005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024906|Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)|Redox Determinants of Severe Asthma: A Substudy of the NHLBI Severe Asthma Research Program|SARP|Emory University|Yes|Completed|January 2003|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|225|||Both|6 Years|21 Years|No|Non-Probability Sample|The study population consists of children with physician-diagnosed asthma in the Atlanta,        Georgia area across a wide range of asthma severities (mild, moderate, severe)|January 2014|January 14, 2014|December 27, 2007||No||No|July 10, 2013|https://clinicaltrials.gov/show/NCT00590005||162643|
NCT00590252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-000545|Clinical Testing of New MR Pulse Sequences|Clinical Testing of New MR Pulse Sequences||Brigham and Women's Hospital|No|Recruiting|July 2007|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|None Retained|There are no biospecimens|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample.|May 2012|May 14, 2012|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590252||162625|
NCT00590265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD-9818|Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression|Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety|BPII-DEP-LT|Douglas Mental Health University Institute|Yes|Recruiting|January 2008|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||July 2014|July 28, 2014|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590265||162624|
NCT00586508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11394|Trial of Enzastaurin and Bevacizumab in Adults With Recurrent Malignant Gliomas|A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas||Eli Lilly and Company|No|Completed|November 2007|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2013|January 7, 2014|December 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586508||162901|
NCT00586521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11859|BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)|A Prospective Controlled Study on the Effect on Bleeding Events and Joint Function in Young Adults With Severe Hemophilia A After a 6 Month Prophylaxis Treatment Compared to on Demand Treatment||Bayer|No|Completed|February 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|30 Years|45 Years|No|||October 2014|October 27, 2014|December 21, 2007|Yes|Yes||No|April 3, 2009|https://clinicaltrials.gov/show/NCT00586521||162900|The short observation period of 6 months may be responsible for the lack of statistical significance between treatments in the subject's overall assessment of disease-related quality of life; however, a positive trend was noted.
NCT00586807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 1274|Metabolic Response to Infliximab in Pediatric Ulcerative Colitis|Metabolic Response to Infliximab in Pediatric Ulcerative Colitis||Indiana University|Yes|Terminated|June 2005|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|6 Years|18 Years|No|||January 2009|January 29, 2009|December 21, 2007||No|poor enrollment|No||https://clinicaltrials.gov/show/NCT00586807||162879|
NCT00587730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-01|Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System|Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System|Hawkeye|Mayo Clinic|No|Terminated|July 2001|August 2004|Actual|August 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|608|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|December 21, 2007||No|Recruiting or enrolling participants has halted prematurely and will not resume.|No||https://clinicaltrials.gov/show/NCT00587730||162809|
NCT00587457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-8015-1002|A Phase I,Multicenter, Dose Escalation Study of CAT-8015 in Patients With Chronic Leukemia|A Phase I, Multicenter, Dose-Escalation Study of CAT-8015 in Patients With Relapsed or Refactory Chronic Lymphocytic Leukemia (CLL) Prolymphocytic Leukemia (PLL) or, Small Lymphocytic Leukemia (SLL)||MedImmune LLC|No|Suspended|March 2007|January 2012|Anticipated|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|December 21, 2007|Yes|Yes|On hold due to lack of CTM supply|No||https://clinicaltrials.gov/show/NCT00587457||162830|
NCT00587054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-070|Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders|Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (>18 Years) With Lymphohematopoietic Disorders||Memorial Sloan Kettering Cancer Center||Completed|June 2001|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|55 Years|No|||May 2011|May 17, 2011|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00587054||162860|
NCT00587067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-120|A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy|A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2003|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587067||162859|
NCT00587080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 33-2006|Stapled TransAnal Rectal Resection (STARR): Clinical and Radiological Outcome|Stapled TransAnal Rectal Resection (STARR): Correlation Between Clinical and Radiological Outcome||University of Zurich|No|Completed|January 2004|August 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|90 Years|No||Patients with ODS and diagnosis of rectal redundancy (intussusception/rectoceles) in MR        defecography|December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587080||162858|
NCT00588393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002680|FolateScan in Autoimmune Disease|Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases||Mayo Clinic||Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 15, 2010|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588393||162761|
NCT00588601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-002-04|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2005|||||N/A|N/A|N/A||||||||||||||December 1, 2011|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588601||162745|
NCT00588224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-005231|3D Ultrasound Validation for Measuring Stomach Volume|Validation and Application of 3-dimensional Ultrasound for Measurement of Gastric Volumes in Healthy Subjects|3DUSstomach|Mayo Clinic|No|Completed|October 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|36|||Both|13 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|ealthy adolescents and adults: The study will screen up to 80 healthy adults or        adolescents in order to enroll 12 healthy adults for the first two aims, and 24 adolescent        healthy subjects for the third aim|July 2009|July 20, 2009|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00588224||162774|
NCT00620672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-70242|N-3 Fatty Acid Requirements for Human Development|To Compare Measures of Central Nervous System Maturity of Visual Acuity, Language, Mental and Motor Skill Development in Term Infants Following Maternal Supplementation Wit the n-3 Fatty Acid Docosahexaenoic Acid (DHA) During Gestation.||University of British Columbia|No|Active, not recruiting|May 2004|December 2015|Anticipated|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|400|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00620672||160349|
NCT00588666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-006|Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma|Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma||Memorial Sloan Kettering Cancer Center||Completed|May 2006|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|December 26, 2007|No|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00588666||162740|
NCT00589264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 RO1 HD045430|Zinc and Biobehavioral Development in Early Childhood|Zinc and Biobehavioral Development in Early Childhood||Johns Hopkins Bloomberg School of Public Health|No|Completed|July 2004|June 2009|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|251|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||September 2014|September 8, 2014|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00589264||162697|
NCT00589277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI R21 CA127818|Message Framing for Telephone Quitline Callers|Promoting Tobacco and Cancer Control: Message Framing for Telephone Quitline Callers||Yale University|Yes|Completed|August 2007|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2032|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|January 3, 2008||No||No|January 2, 2013|https://clinicaltrials.gov/show/NCT00589277||162696|
NCT00580099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4797|Assisted Exercise in Prematurity; Effects and Mechanisms|Assisted Exercise in Prematurity; Effects and Mechanisms||University of California, Irvine|Yes|Recruiting|September 2005|March 2012|Anticipated|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|100|||Both|30 Weeks|35 Weeks|No|||April 2011|April 8, 2011|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00580099||163389|
NCT00581165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-101781|Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept|Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2006|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|18 Years|N/A|No|||December 2007|December 26, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581165||163308|
NCT00581503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2006-4981|Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer|Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer||University of California, Irvine|No|Recruiting|March 2007|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Study Population will be identified at UCIMC, who is scheduled for prostatectomy,        endobronchial, transbronchial, and pleural biopsy will be recurited to participate in the        study.|February 2016|February 5, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581503||163282|
NCT00581477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030750|Treatment of Orthostatic Hypotension|Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms||Vanderbilt University|No|Enrolling by invitation|January 2004|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581477||163284|
NCT00581490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030292|Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche|Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche|PP|Vanderbilt University|Yes|Completed|August 2003|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|24|Samples With DNA|DNA sample from consented subjects and controls|Both|3 Years|9 Years|Accepts Healthy Volunteers|Probability Sample|Boys below the age of 9; girls below the age of 8 if Caucasian and below age 6 if African        American|June 2011|June 24, 2011|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00581490||163283|
NCT00589446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3804-HC-CTIL|Investigation of Embryoscopy in Recurrent Pregnancy Loss|Investigation of Embryoscopy in Recurrent Pregnancy Loss||Sheba Medical Center|No|Completed|January 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|N/A|N/A|No|||June 2009|June 28, 2009|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00589446||162684|
NCT00590291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeneQuest|Molecular Determinants of Coronaruy Artery Disease|Genetic Studies of Coronary Artery Disease and Arteriovenous Malformation (GeneQuest) Molecular Determinants of Coronary Artery Disease|GeneQuest|The Cleveland Clinic|Yes|Active, not recruiting|January 1995|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||2|Anticipated|2980|Samples With DNA|For each participant, 10 ml of blood for lymphoblastoid cell line immortalization, 10-20 ml      blood for DNA extraction, or two buccal swabs. If gene identified, blood samples from      children to identify the children affected with this gene will be obtained. When available,      biopsy tissues for extracting DNA, RNA, protein, or for cell biological studies will be      obtained. Human genomic DNA will be prepared from peripheral blood lymphocytes, biopsy      tissue, or cell lines derived from Epstein Barr virus transformed lymphocytes 15. DNA will      be used for a variety of purposes including linkage analysis and mutational screening.|Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with CAD or AVM and their family members and 500 normal control individuals The        total number enrolled is 2,980, and approximately 2,000 recruited at the Cleveland Clinic.        We will comply with the NIH guidelines by including women and members of minority groups        and their subpopulations in the study.|January 2012|January 23, 2012|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00590291||162622|
NCT00590538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-10-3023|Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)|A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygous Cystic Fibrosis Patients||Children's Hospital of Philadelphia|Yes|Terminated|February 2003|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|N/A|No|||June 2011|June 29, 2011|December 27, 2007|Yes|Yes|12/15/2008 Voluntarily placed on inactive status-requested by the PI|No|November 15, 2010|https://clinicaltrials.gov/show/NCT00590538||162604|No analysis was completed on data collected; More clinically efficacious compounds have been identified which suggested that completion of this study might not be as critical as when initially proposed; therefore, the study was terminated by PI.
NCT00590551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27208|Slings and Their Effect on Skin Pressure|Slings and Repositioning Devices: Their Effects on Skin Pressure||Christiana Care Health Services|No|Terminated|December 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 30, 2008|December 31, 2007||No|unable to recruit patients for study|No||https://clinicaltrials.gov/show/NCT00590551||162603|
NCT00586560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20159|Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)|A Phase 1 Trial of Escalating Doses of Karenitecin Plus Cyclophosphamide Administered Intravenously Daily for 5 Consecutive Days in Pediatric Patients With Refractory or Recurrent Solid Tumors|KTN10010|Baylor College of Medicine|Yes|Completed|February 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|12 Months|21 Years|No|||May 2012|May 11, 2012|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586560||162897|
NCT00586534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011048|Developing Computer Based Treatments for Addiction|Developing Computer Based Treatments for Addiction||Duke University|Yes|Completed|January 2007|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|60 Years|No|||March 2015|March 17, 2015|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586534||162899|
NCT00586794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 3.1 Sildenafil|Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients|Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients||Competence Network for Congenital Heart Defects|No|Terminated|December 2007|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|14 Years|N/A|No|||October 2010|June 5, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586794||162880|
NCT00586547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-9033|Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation|A Phase I Trial Evaluating The Use of RFT5-dgA to Deplete Alloreactive Cells PriorTo Haploidentical Stem Cell Transplantation||Baylor College of Medicine|Yes|Completed|July 2000|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2009|December 2, 2009|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586547||162898|
NCT00587756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-1STAGE|Alternative to Two-Stage Hepatectomy|One-Stage Ultrasound-Guided Hepatectomy for Multiple Bilobar Colorectal Metastases: a Feasible and Effective Alternative to Two-Stage Hepatectomy||University of Milan|No|Completed|September 2001|December 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|N/A|N/A|No|Probability Sample|Patients carriers of colorectal cancer liver metastases|December 2007|January 7, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00587756||162808|
NCT00587392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135-01928|Endoscopic Full-Thickness Plication for the Treatment of GERD: Long-Term Multicenter Results|Endoscopic Full-Thickness Plication for the Treatment of GERD: Long-Term Multicenter Results|LTFU|NDO Surgical, Inc.|No|Completed|December 2004|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Patients previously treated with the NDO Full-thickness Plicator in the original        open-label study and who met the long-term Follow-up (LTFU) protocol inclusion and        exclusion crieria were eligible for study participation.|December 2007|December 21, 2007|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587392||162835|
NCT00588406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.02.019|Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.|Emergency Department (ED) Use of Nebulized Budesonide as an Adjunct to Standardized Therapy in Acutely Ill Adults With Refractory Asthma: a Randomized, Double-blinded, Placebo-controlled Trial||Northwell Health|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|60 Years|No|||December 2015|December 15, 2015|December 21, 2007|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT00588406||162760|
NCT00588679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-035|Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla|Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla||Memorial Sloan Kettering Cancer Center||Recruiting|August 2006|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|308|||Male|21 Years|N/A|No|||September 2015|September 25, 2015|December 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588679||162739|
NCT00620698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIMALS|Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials|Electrical Impedance Myography as an Outcome Measure in ALS Clinical Trials||Beth Israel Deaconess Medical Center|No|Completed|May 2007|March 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|89|||Both|18 Years|85 Years|No|Probability Sample|Patients with amyotrophic lateral sclerosis (ALS)|September 2014|September 13, 2014|February 9, 2008||No||No|July 18, 2014|https://clinicaltrials.gov/show/NCT00620698||160347|
NCT00589290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080033|Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage|A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma||National Institutes of Health Clinical Center (CC)|No|Completed|December 2007|June 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|December 25, 2007||No||No|October 28, 2011|https://clinicaltrials.gov/show/NCT00589290||162695|
NCT00589550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06113|PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase I Study Of Peginterferon Alfa-2b (PEG-INTRON) With Sorafenib (Nexavar) In Patients With Unresectable Or Metastatic Clear Cell Renal Carcinoma (RCC).||Ohio State University Comprehensive Cancer Center|Yes|Terminated|February 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|January 5, 2008|No|Yes|low accrual|No|May 6, 2015|https://clinicaltrials.gov/show/NCT00589550||162676|Trial was terminated due to low patient accrual
NCT00580619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060662|Autonomic Nervous System and Chronic Fatigue Syndrome|Autonomic Nervous System and Chronic Fatigue Syndrome|CFS&ANS|Vanderbilt University|Yes|Active, not recruiting|April 2007|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580619||163350|
NCT00580632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-102389|Study Evaluating Workload, Clinical and Therapeutic Management of Psoriatic Arthritis|Workload, Clinical and Therapeutic Management of Psoriatic Arthritis||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|300|||Both|19 Years|N/A|No|Probability Sample|Psoriatic Arthritis Patients with a representative geographic sample|December 2007|May 13, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00580632||163349|
NCT00581763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8994-19045|Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies|Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies|APL|University of California, San Francisco|No|Completed|May 2001|June 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|Samples With DNA|Serum|Both|N/A|21 Years|No|Non-Probability Sample|Young group of SLE and APS subjects|June 2012|June 11, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581763||163262|
NCT00581750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-135|Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ|Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|October 2001|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|Samples Without DNA|Tissue|Female|N/A|N/A|No|Non-Probability Sample|Women seen at MSKCC breast clinic|August 2015|August 6, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581750||163263|
NCT00590018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-12030|Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease|Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease|Corti|Baylor College of Medicine|Yes|Completed|February 2003|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|N/A|1 Month|No|||February 2013|February 4, 2013|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00590018||162642|
NCT00590031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-045|Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.|Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.||Memorial Sloan Kettering Cancer Center||Completed|November 2002|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|December 26, 2007|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT00590031||162641|
NCT00620503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-002|Proellex® Pharmacokinetic Bridging Study II|Proellex® Pharmacokinetic Bridging Study II|PK|Repros Therapeutics Inc.|No|Completed|February 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||February 2010|February 8, 2010|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620503||160362|
NCT00620516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.337|Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients|Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study||Boehringer Ingelheim||Completed|March 2004|||December 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3008|||Both|40 Years|N/A|No|Probability Sample|3227|November 2013|November 18, 2013|February 4, 2008||||No||https://clinicaltrials.gov/show/NCT00620516||160361|
NCT00620815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V101P1|Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above|A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above||Novartis|No|Completed|November 2007|December 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|6||Actual|601|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|February 12, 2008|Yes|Yes||No|July 4, 2011|https://clinicaltrials.gov/show/NCT00620815||160338|
NCT00621114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study No 2007_MBR_003|Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application|Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application|ABBA|Gambro Dialysatoren GmbH|No|Completed|August 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|69|||Both|18 Years|85 Years|No|||January 2010|January 26, 2010|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00621114||160315|
NCT00621634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD06.067|Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia|Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia||Université de Montréal|Yes|Recruiting|February 2008|||June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|75 Years|No|||September 2007|February 21, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621634||160276|
NCT00621647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5077US/0046|Seroquel- Agitation Associated With Dementia|A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia.||AstraZeneca|No|Completed|September 2002|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|333|||Both|55 Years|N/A|No|||March 2009|March 24, 2009|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621647||160275|
NCT00621907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708097|Study : LEVOBUPIVACAINE Versus Placebo|Levobupivacïne Into Post-analgesia : Randomized Monocentric Study Against Placebo|LEVOBU|Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|50 Years|No|||September 2010|September 15, 2010|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00621907||160255|
NCT00622453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9609-31|Arrhythmias in Myotonic Muscular Dystrophy|A Registry of Arrhythmias in Myotonic Muscular Dystrophy|DM1|Indiana University|Yes|Active, not recruiting|September 1996|December 2017|Anticipated|January 2006|Actual|N/A|Observational|N/A||1|Actual|448|||Both|18 Years|N/A|No|Non-Probability Sample|Patient Recruitment: Will take place at the 230 hospital-affiliated MDA neuromuscular        clinics. Individuals with myotonic dystrophy will be identified in the MDA clinics these        will be asked to participate in the study.|July 2015|July 29, 2015|February 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622453||160215|
NCT00618280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIKOGEN_HHU_2006|Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail|Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail|NIKOGEN|Heinrich-Heine University, Duesseldorf|No|Completed|January 2008|August 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|101|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 1, 2012|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618280||160531|
NCT00618540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007UC002|Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis|Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2007|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|N/A|No|||July 2014|October 2, 2015|February 19, 2008|Yes|Yes|Slow accrual|No|April 22, 2015|https://clinicaltrials.gov/show/NCT00618540||160512|
NCT00618553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0063|Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting|The Efficacy of Pulmonary Rehabilitation in Improving Surgical Eligibility for Lung Resection||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2008|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|N/A|N/A|No|||November 2015|November 9, 2015|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00618553||160511|
NCT00619489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13004|Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease|Phase 2, Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease||Millennium Pharmaceuticals, Inc.|No|Completed|December 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||June 2014|June 19, 2014|February 11, 2008|No|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00619489||160440|
NCT00619762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC2007.01.01|Immediate Postmastectomy Breast Reconstruction|A Multicenter, Prospective, Open-Label Study to Assess the Clinical Outcomes of LTM Use in Two-Stage Breast Reconstruction Immediately Post Mastectomy||LifeCell|No|Completed|October 2007|December 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|Samples Without DNA|Tissue sample|Female|18 Years|N/A|No|Non-Probability Sample|women undergoing two-stage immediate breast reconstruction following a skin sparing        mastectomy will be recruited from up to ten (10) participating centers|April 2013|April 7, 2013|January 11, 2008|No|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00619762||160419|Small number of subjects and breasts analyzed.
NCT00621530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004736|Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement|Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity After Total Hip Arthroplasty||Wake Forest School of Medicine|Yes|Terminated|March 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|February 11, 2008|Yes|Yes|Terminated due to discontinuation of Acular PF (investigational medication)|No||https://clinicaltrials.gov/show/NCT00621530||160284|
NCT00621777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC# 2007-P-002221|A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder|Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking|SCRP|Massachusetts General Hospital|Yes|Completed|February 2008|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|February 12, 2008|Yes|Yes||No|May 1, 2015|https://clinicaltrials.gov/show/NCT00621777||160265|
NCT00621790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO/URC/ER/mm 64/DG|Fenoldopam and Acute Renal Failure|Efficacy of Fenoldopam in Reducing the Need for Renal Replacement Therapy After Cardiac Surgery. A Randomized Controlled Study.|FENO HSR|Università Vita-Salute San Raffaele||Completed|February 2008|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|667|||Both|18 Years|99 Years|No|||October 2015|October 13, 2015|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621790||160264|
NCT00619632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-08-364|Boosting Breastfeeding in Low-Income, Multi-ethnic Women: A Primary Care Based RCT|Boosting Breastfeeding in Low-Income, Multi-ethnic Women: A Primary Care Based RCT|BINGO|Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|February 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|666|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 13, 2015|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00619632||160429|
NCT00611325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003596|Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma|Phase II Trial of Avastin Plus Bortezomib for Patients With Recurrent Malignant Glioma||Duke University|Yes|Completed|May 2008|October 2013|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|January 28, 2008|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00611325||161052|
NCT00620529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 2008/049|The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome|A Clinical Trial to Measure the Effect of DHA-enriched Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat Content in the Polycystic Ovary Syndrome|fops|Keogh Institute for Medical Research|Yes|Completed|February 2008|February 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|50 Years|No|||January 2010|January 31, 2010|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00620529||160360|
NCT00619970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-06-00146|Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?|Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?|CAP&SIBO|Children's Hospital Los Angeles|Yes|Completed|February 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|115|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||June 2009|June 26, 2009|January 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619970||160403|
NCT00619658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07080379|The Feasibility of Simplified Telephone Follow-up After Medical Abortion|The Feasibility of Simplified Telephone Follow-up After Medical Abortion|SMART|University of Pittsburgh|Yes|Completed|February 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619658||160427|
NCT00619957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001092 and 2001092 OL|Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis|Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study||Warner Chilcott|No|Completed|June 2002|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|285|||Male|30 Years|N/A|No|||September 2011|September 20, 2011|February 11, 2008|Yes|Yes||No|May 23, 2011|https://clinicaltrials.gov/show/NCT00619957||160404|
NCT00621413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|isoray_cs131_pc01|Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer|Dosimetric and Morbidity Outcomes of Cs-131 Brachytherapy in Combination With External Beam Radiation Therapy in Subjects With Intermediate to High Risk Adenocarcinoma of the Prostate: An Observational Study||IsoRay Medical, Inc.|No|Enrolling by invitation|February 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|diagnosed patients with intermediate to high risk cancer of the prostate. Patient will be        in a Radiation Oncology setting.|February 2008|February 21, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621413||160293|
NCT00621660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4960-B04-01XAC|Acupuncture Versus Sham for Radiotherapy-Induced Emesis|Acupuncture Compared To Sham With a Placebo-Needle in Radiotherapy-Induced Nausea - a Randomised Controlled Study||University Hospital, Linkoeping|Yes|Completed|January 2004|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|N/A|No|||November 2007|February 21, 2008|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00621660||160274|
NCT00621920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL07.01|Efficacy Study of Bowel Preparation Before Colonoscopy|Efficacy Study of Bowel Preparation Before Colonoscopy||C.B. Fleet Company, Inc.|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|February 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00621920||160254|
NCT00622180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB file number 122007-003|The Efficacy of Hand NBUVB Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands|The Efficacy of Hand-Foot Narrow-Band UVB Versus Focal 308-nm Treatment in Inducing Repigmentation of Vitiligo After Minigrafting on the Dorsal Hands||University of Texas Southwestern Medical Center|No|Active, not recruiting|January 2008|April 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||February 2008|January 21, 2009|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622180||160235|
NCT00618566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDRR|Group Therapy Program for Women With Physical Disabilities|A Peer Implemented Cognitive Behavioral Group Therapy Intervention for Use With Women With Physical Disabilities With Secondary Depression|CBT-WPD|Oregon Health and Science University|Yes|Completed|October 2007|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|82|||Female|18 Years|N/A|No|||October 2012|October 15, 2012|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618566||160510|
NCT00618852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009083|Using Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates|A Randomized Controlled Trial of Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates||The Hospital for Sick Children|Yes|Recruiting|January 2007|June 2009|Anticipated|December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|N/A|44 Weeks|No|||February 2008|February 19, 2008|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00618852||160488|
NCT00619177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.273|Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of Life|Assessing the Impact of MOVALIS on Health Related Quality of Life||Boehringer Ingelheim||Completed|March 2007|||May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3569|||Both|18 Years|N/A|No|Non-Probability Sample|primary care and rheumatology clinics|January 2015|January 30, 2015|February 8, 2008||||No|May 22, 2009|https://clinicaltrials.gov/show/NCT00619177||160464|
NCT00620074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851014|Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)|Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment||Pfizer|Yes|Terminated|August 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||January 2010|January 21, 2010|February 8, 2008|Yes|Yes|See Detailed Description|No|January 21, 2010|https://clinicaltrials.gov/show/NCT00620074||160395|Due to low enrollment and early termination of the study, data was insufficient for descriptive or inferential analysis as planned; no significant treatment-related safety results were identified in the subjects treated with combination therapy.
NCT00620087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204-03|Molecular Breast Imaging in Women With Atypia and LCIS|Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ||Mayo Clinic|No|Completed|August 2003|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|81|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00620087||160394|
NCT00619775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-1007|Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial|Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial|CREATE|ev3|Yes|Completed|April 2004|October 2005|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|419|||Both|18 Years|N/A|No|||December 2008|December 5, 2008|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619775||160418|
NCT00620048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00002516|Stem Cell Study for Subjects With Congestive Heart Failure|Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40%||Losordo, Douglas, M.D.|No|Terminated|March 2008|||January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|21 Years|80 Years|No|||November 2011|March 30, 2015|February 7, 2008|Yes|Yes|Study terminated due to lack of funding.|No||https://clinicaltrials.gov/show/NCT00620048||160397|
NCT00622011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH070906|Risperidone and Zotepine in the Treatment of Delirium|Risperidone and Zotepine in the Treatment of Delirium||Changhua Christian Hospital|No|Recruiting|January 2008|January 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||January 2008|February 11, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00622011||160247|
NCT00622323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H80-PH-B006|Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients|Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients||AstraZeneca|No|Completed|February 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients at least 18 years of age and diagnosed with type 2 diabetes        mellitus treated in an ambulatory care setting and who are taking metformin, a        sulfonylurea, or a combination of metformin and sulfonylurea, but have not achieved        adequate glycemic control. Female patients eligible of becoming pregnant are required to        have some form of contraception while participating in the study.|January 2015|February 23, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622323||160225|
NCT00619086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_49_05|Steroid Before Thyroidectomy|Does a Single Dose of Steroid Before Thyroidectomy Improve Postoperative Nausea, Pain and Vocal Function?||University of Bern|No|Completed|November 2005|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|72|||Both|18 Years|N/A|No|||June 2008|June 6, 2008|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00619086||160471|
NCT00619099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACO-026|A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)|Randomized Open-label Phase 2 Study of Low Dose Dacogen® for Injection (Decitabine) in Patients With Low or Intermediate 1 Risk Myelodysplastic Syndromes||Eisai Inc.|No|Completed|May 2008|||March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|February 8, 2008|Yes|Yes||No|July 14, 2013|https://clinicaltrials.gov/show/NCT00619099||160470|
NCT00619112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000572434|Temozolomide in Treating Patients With Recurrent High-Grade Glioma|Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma||University of California, San Francisco|Yes|Completed|October 2007|September 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|February 19, 2008|Yes|Yes||No|June 17, 2013|https://clinicaltrials.gov/show/NCT00619112||160469|The trial reached enrollment. There were no unexpected toxicities.
NCT00618761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clamp01|Insulin Secretory Capacity in Insulin-independent Pancreas-Kidney Recipients Compared to Controls|Insulin Secretory Capacity in Insulin-independent Pancreas-Kidney Recipients Compared to Non-Diabetic Kidney Recipients, Insulin Independent Recipients of Beta-cell Grafts and Healthy Controls.||University Hospital, Gasthuisberg|Yes|Recruiting|October 2004|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2008|June 14, 2012|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00618761||160495|
NCT00618774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.16|An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination|An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination||Boehringer Ingelheim||Completed|January 2008|||October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|259|||Both|20 Years|N/A|No|||April 2014|June 17, 2014|February 8, 2008||||No|December 28, 2009|https://clinicaltrials.gov/show/NCT00618774||160494|
NCT00620542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D356IC00001|CRESTOR Athero Imaging Head to Head IVUS Study|Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)|SATURN|AstraZeneca||Completed|January 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|2333|||Both|18 Years|75 Years|No|||July 2012|July 11, 2012|February 6, 2008|Yes|Yes||No|May 22, 2012|https://clinicaltrials.gov/show/NCT00620542||160359|
NCT00620555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451165|A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures|A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)||Pfizer|No|Completed|May 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|3 Years|N/A|No|||November 2011|January 24, 2012|February 11, 2008||No||No|November 14, 2011|https://clinicaltrials.gov/show/NCT00620555||160358|
NCT00620828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000233|The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty|The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Trial||Duke University|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|67|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2013|June 2, 2015|February 12, 2008|Yes|Yes||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00620828||160337|
NCT00620841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDI-001|Gene Polymorphisms in Tacrolimus Drug Interactions|Gene Polymorphisms in Tacrolimus Drug Interactions in Renal Transplant Patients|DDI-TAC|Katholieke Universiteit Leuven|No|Completed|May 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40|Samples With DNA|DNA samples|Both|18 Years|75 Years|No|Non-Probability Sample|Renal transplant recipients treated with a calcineurin-inhibitor|January 2008|February 21, 2008|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00620841||160336|
NCT00620854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGL-OR0702|A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women|||Tarsa Therapeutics, Inc.|No|Completed|February 2008|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 30, 2012|February 12, 2008|Yes|Yes||No|April 22, 2009|https://clinicaltrials.gov/show/NCT00620854||160335|
NCT00620243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-064|Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.|Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.||Memorial Sloan Kettering Cancer Center|No|Completed|June 2004|November 2008|Actual|November 2008|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Female|18 Years|N/A|No|||January 2012|January 6, 2012|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620243||160382|
NCT00620256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-05|Adjunctive Study of AL-37807 Ophthalmic Suspension|Comparison of Safety and Efficacy of Al-37807 Ophthalmic Suspension vs. Timolol Gel Forming Solution and Vehicle, All Dosed Concomitantly With Xalatan in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|129|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|February 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620256||160381|
NCT00621426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0388-010|T-Wave Alternans in Dialysis Patients|T-Wave Alternans in Dialysis Patients||Northwestern University|No|Completed|April 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with end-stage renal disease (ESRD) treated with hemodialysis three (3) times per        week for at least 3 continuous months will be enrolled. No limitations for gender, race,        socioeconomic status or any other parameters will be applied.|March 2015|March 11, 2015|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621426||160292|
NCT00622206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 083|Pharmacokinetics of Low Dose Ritonavir|Pharmacokinetics of Low Dose Ritonavir in Thai Patients on a Saquinavir 1500 mg Based HAART Regimen||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|January 2008|August 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00622206||160233|
NCT00622219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA019570|Mentored Clinical Career Award in Adolescent Substance Abuse|Mentored Clinical Career Award in Adolescent Substance Abuse||Children's Hospital Boston|Yes|Active, not recruiting|March 2008|June 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|90|||Both|12 Years|21 Years|No|||January 2013|January 2, 2013|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00622219||160232|
NCT00622466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCC-02107|Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|October 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|February 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622466||160214|
NCT00622479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.|Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients With Advanced Renal Cell Carcinoma||Bayer|No|Terminated|May 2008|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|February 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622479||160213|
NCT00618293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI8021_5101|Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis|Phase 2 Study in Evaluation of the Efficacy and Safety of Haemate HS in This Clinical Setting (Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis)|HAVAS|Heinrich-Heine University, Duesseldorf|No|Withdrawn|January 2008|July 2011|Actual|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|February 8, 2008||No|No patient met the criteria for inclusion in the study.|No||https://clinicaltrials.gov/show/NCT00618293||160530|
NCT00618579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-402-003|Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin|A Randomised, Controlled Study Investigating the Safety and Anticoagulant Activity of Administration of Low-molecular-weight Heparin in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402 and the Safety and Anticoagulant Activity of Administration of TB-402 in Healthy Male Subjects Treated With Warfarin||ThromboGenics|No|Completed|February 2008|August 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00618579||160509|
NCT00618865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 93-2320-B-039-001|Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy|Omega-3 Polyunsaturated Fatty Acids in Women With Major Depressive Disorders During Pregnancy||National Science Council, Taiwan|No|Completed|June 2004|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|40 Years|No|||February 2008|February 8, 2008|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618865||160487|
NCT00618878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0423070088|Electroacupuncture and Laser Therapy on Neck Pain|The Effects of Electroacupuncture and Laser Therapy on Chronic Neck Pain, A Pilot Study||Logan College of Chiropractic|No|Recruiting|October 2008|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||October 2008|October 16, 2008|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618878||160486|
NCT00618904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1704|Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating|Clinical Efficacy of Probiotic Bacteria in Subjects With Irritable Bowel Syndrome (IBS), Functional Diarrhea, or Functional Bloating||University of North Carolina, Chapel Hill|No|Completed|December 2005|September 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|75 Years|No|||July 2013|July 8, 2013|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00618904||160485|
NCT00619502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L22|Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants|Immunogenicity and Safety Study of a Booster Dose of DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series at 2, 3 and 4 Months of Age in Healthy Turkish Infants||Sanofi|Yes|Completed|December 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|254|||Both|15 Months|18 Months|Accepts Healthy Volunteers|||February 2014|February 22, 2014|February 11, 2008||No||No|February 22, 2014|https://clinicaltrials.gov/show/NCT00619502||160439|
NCT00620100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976A_2504|To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent|A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel (Taxotere®) + Anthracycline (Epirubicin or Doxorubicin) x 4 Cycles Followed by Docetaxel (T) Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed > or = 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®-Based Chemotherapy||Sanofi||Terminated|September 2004|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||May 2009|May 29, 2009|February 11, 2008||No|the study was early terminated due to lack of recruitment.|No||https://clinicaltrials.gov/show/NCT00620100||160393|
NCT00619190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1792 GCRC-2491|Study of Aripiprazole to Treat Children and Adolescents With Autism|An Open Label Study of Aripiprazole in Children and Adolescents With Autism Spectrum Disorders|PAIRS|University of North Carolina, Chapel Hill|No|Completed|January 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|30 Months|17 Years|No|||February 2014|February 7, 2014|February 7, 2008|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00619190||160463|
NCT00620659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0249-015|Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)|Phase IIa, Randomized, Double-blind, Placebo-controlled, 3-period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate Safety & Efficacy of MK0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using nCPAP Therapy.||Merck Sharp & Dohme Corp.||Terminated|February 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|125|||Both|18 Years|64 Years|No|||April 2015|April 27, 2015|January 10, 2008|Yes|Yes||No|October 13, 2010|https://clinicaltrials.gov/show/NCT00620659||160350|
NCT00620360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279/07/CE/FBM|Acute Effect of Fructose on Lipid Metabolism and Gender Differences|Acute Effect of Fructose on Lipid Metabolism and Gender Differences||University of Lausanne|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00620360||160373|
NCT00622024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#06-0116-AE|Perioperative Depression and Postoperative Arrhythmia in Elective Coronary Bypass Graft Surgery|Perioperative Depression and Postoperative Arrhythmia in Elective Coronary Bypass Graft Surgery||University Health Network, Toronto|No|Completed|January 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|120|||Both|18 Years|85 Years|No|Non-Probability Sample|patients undergoing elective CABG surgery|February 2013|February 22, 2013|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00622024||160246|
NCT00622037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5338|Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality|||Bp Consulting, Inc||Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 2, 2010|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622037||160245|
NCT00618735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120ST103|Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB021 Administered Once or Twice Daily to Subjects With Advanced Solid Tumors||Biogen|Yes|Completed|February 2008|December 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||January 2011|June 7, 2012|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00618735||160497|
NCT00619983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003943|Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy|Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy||Wake Forest School of Medicine|No|Terminated|February 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|22|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|February 8, 2008||No|Study terminated due to low enrollment|No||https://clinicaltrials.gov/show/NCT00619983||160402|
NCT00619385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-003|A Safety and Pharmacokinetic Study of Proellex®|A Safety and Pharmacokinetic Study of 100 mg, 150 mg and 200 mg of Proellex® Taken for Seven Days by Healthy Adult Female Subjects|PK|Repros Therapeutics Inc.|No|Completed|February 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||August 2014|August 5, 2014|February 11, 2008|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT00619385||160448|
NCT00620269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-255|Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III|A Randomized Phase II Study of Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy According to EGFR Mutation Status in Patients With Unresectable Stage III NSCLC||National Cancer Center, Korea|Yes|Recruiting|February 2008|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|212|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00620269||160380|
NCT00620893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5339|Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).|||Bp Consulting, Inc||Completed|February 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00620893||160332|
NCT00620867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191063|Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)|A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee||Pfizer|No|Completed|October 2002|March 2003|Actual|March 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|393|||Both|40 Years|N/A|No|||November 2008|November 5, 2008|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620867||160334|
NCT00620880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVN-CAT-001A|IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy|Performance of CAST With Different Allergens in Patients With Cat Dander Allergy||University of Zurich|No|Completed|September 2005|September 2006|Actual|||N/A|Observational|Time Perspective: Prospective|||||||Both|18 Years|75 Years|No|||November 2008|November 19, 2008|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00620880||160333|
NCT00621153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00016|Candesartan Effect in Second Stage Arterial Hypertension|Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults|CAESAR|AstraZeneca|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|214|||Both|18 Years|70 Years|No|||April 2009|February 24, 2010|January 24, 2008|Yes|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00621153||160313|
NCT00621933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-Zymar-08-001|Surveillance of Ocular Surface Flora (SURFACE)|||Allergan|No|Completed|December 2007|November 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|399|Samples Without DNA|Culture Swabs of the conjunctiva and eyelids|Both|50 Years|N/A|No|Probability Sample|Cataract Surgery Patients|July 2012|July 16, 2012|February 13, 2008||No||No|October 17, 2011|https://clinicaltrials.gov/show/NCT00621933||160253|
NCT00622193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-ANAM-207|Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC||Helsinn Therapeutics (U.S.), Inc|Yes|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|228|||Both|18 Years|85 Years|No|||June 2011|June 8, 2011|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622193||160234|
NCT00622492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/219|Circulatory Changes During Venovenous (VV)- and Venoarterial (VA) Extracorporeal Membrane Oxygenation (ECMO)|ECMO in Newborn Infants: Circulatory Changes in Relation to Venovenous and Venoarterial Bypass. Implications for Peripheral Organ Circulation|ECMO|Radboud University||Recruiting|January 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|whole blood, urine|Both|N/A|N/A|No|Non-Probability Sample|newborn infants with PPHN admitted to the NICU Radboud University Medical Centre for ECMO        treatment consecutive patient sampling|February 2008|February 22, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00622492||160212|
NCT00618332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15624B|Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?|Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex?||University of Chicago|No|Completed|April 2008|July 2010|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|60 Years|No|||January 2014|January 21, 2014|February 6, 2008|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT00618332||160528|
NCT00622505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS129|Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients|Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma|Z-MARK|Novartis||Completed|November 2007|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|159|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|February 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622505||160211|
NCT00618319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120GS201|An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)|An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment||Biogen|No|Completed|February 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2011|September 17, 2015|February 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00618319||160529|
NCT00619203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P.03/07/499|Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis|Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis - A Prospective, Randomized, and Double-Blind Clinical Study Using a Two-by-Two Factorial Design|GLYIP|University of Malawi College of Medicine|No|Completed|March 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|466|||Both|2 Months|15 Years|No|||July 2012|July 9, 2012|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00619203||160462|
NCT00620113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-022|MK0822 Clinical Study in Patients With Involutional Osteoporosis (0822-022)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Dose-Finding Study of MK0822 in the Treatment of Involutional Osteoporosis||Merck Sharp & Dohme Corp.||Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|280|||Both|45 Years|85 Years|No|||March 2016|March 15, 2016|January 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620113||160392|
NCT00611754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC_7276|Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase II Study of Oxaliplatin in Combination With 5-Fluorouracil (5-FU) in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck||Sanofi||Completed|May 2000|February 2003|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|70 Years|No|||January 2008|January 28, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611754||161019|
NCT00619788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-003|FeMoropopliteal AngioSculpt™ SCoring BallOon CaTheter Study|Prospective, Multicenter, Non-randomized Clinical Trial Investigating the Safety and Efficacy of the AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for the Treatment of Femoropopliteal Stenotic Disease.|MASCOT|Flanders Medical Research Program|No|Completed|March 2008|October 2009|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2010|July 2, 2010|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00619788||160417|
NCT00612248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP0108|Functional Splint for Osteoarthritis of the Trapeziometacarpal Joint|Assessment of the Effectiveness of a Functional Splint for Osteoarthritis of the Trapeziometacarpal Joint on the Dominant Hand: A Randomized Controlled Study||Federal University of São Paulo|No|Completed|July 2005|December 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|No|||January 2008|January 29, 2008|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612248||160981|
NCT00612495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC_7496|Endometrial Cancer - LOHP Alone and With 5FU|Parallel Randomised Open Phase II Study of Oxaliplatin (L-OHP) Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Locally Advanced or Metastatic Endometrial Cancer Previously Treated With Cisplatin or Arboplatin||Sanofi||Completed|January 2001|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Female|18 Years|N/A|No|||January 2008|February 8, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612495||160962|
NCT00620945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF IRB # 06-494|Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-Pulmonary Bypass|Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-Pulmonary Bypass in Infants and Children With Congenital Heart Disease and to Assist Steady State Alfa-Blockade in the Intensive Care Phase||The Cleveland Clinic|Yes|Recruiting|June 2006|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|N/A|18 Years|No|||February 2008|February 11, 2008|February 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620945||160328|
NCT00622362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-000571-15|Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract|Depigmented and Polymerised Allergenic Extract of Dermatophagoides Pteronyssinus as Antiasthmatic Treatment for Children With Slight Allergic Asthma to Mites||Laboratorios Leti, S.L.|No|Suspended|January 2008|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|5 Years|14 Years|No|||January 2009|July 14, 2015|January 10, 2008||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00622362||160222|
NCT00622375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPPK1003|PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers|A Phase I, Single- And Multiple-Dose, Relative Bioavailability and Pharmacokinetic Study of Encapsulated Mesalamine Granules Administered Orally to Healthy Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|February 2008|May 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 21, 2009|February 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622375||160221|
NCT00619320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60MD002256 (Project 2 15378)|Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women|Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women||Virginia Commonwealth University|Yes|Completed|December 2008|October 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|380|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 11, 2013|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00619320||160453|
NCT00620009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0381|The Measurement of Empathy and Its Efficacy in Psychotherapy|The Measurement of Empathy and Its Efficacy in Psychotherapy|EMPATHY|University of Illinois at Chicago|No|Completed|June 2002|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||February 2008|February 11, 2008|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00620009||160400|
NCT00620282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1799|The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus|The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm||Novo Nordisk A/S|No|Completed|February 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|49|||Both|40 Years|70 Years|No|||October 2014|October 29, 2014|February 11, 2008|Yes|Yes||No|May 19, 2011|https://clinicaltrials.gov/show/NCT00620282||160379|
NCT00621192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN267200700051C|Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections|Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 Days) With Suspected or Complicated Intra-abdominal Infections||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|June 2008|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|90 Days|No|||March 2015|March 30, 2015|February 20, 2008|Yes|Yes||No|October 20, 2011|https://clinicaltrials.gov/show/NCT00621192||160310|
NCT00621179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IntegrinIVF|Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF|Do Endometrial Implantation Markers Predict in Vitro Fertilization-Embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension?|IntegrinIVF|Colorado Center for Reproductive Medicine|Yes|Completed|March 2003|February 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Female|21 Years|42 Years|No|||February 2008|February 13, 2008|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00621179||160311|
NCT00621439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002566|Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye|Exploratory Trial of Interferon Alpha-2b in Neoadjuvant Treatment of Ocular Melanoma||Emory University|No|Withdrawn|March 2007|||June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 28, 2013|February 11, 2008|Yes|Yes|no funding- study never began|No||https://clinicaltrials.gov/show/NCT00621439||160291|
NCT00621166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 093|Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women|The Pharmacokinetics and Safety of Generic Lopinavir/Ritonavir (200/50 mg Tablets) 400/100 mg q12h in Thai HIV-infected Pregnant Women||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|40 Years|No|||April 2012|April 3, 2012|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621166||160312|
NCT00621946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092007-057|Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder|Escitalopram in the Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial||University of Texas Southwestern Medical Center||Completed|March 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|70 Years|No|||January 2014|January 2, 2014|February 11, 2008|Yes|Yes||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00621946||160252|A limitation of this proof-of-concept study was the small sample size.
NCT00618618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-07-07|Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat|Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|73|||Both|25 Years|65 Years|No|||June 2015|June 17, 2015|February 8, 2008|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00618618||160506|
NCT00618631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908060|Effects of Smoking on Opioid Receptor Binding: A PET Study|Effects of Smoking on Opioid Receptor Binding Using [(11)C]Carfentanil: An Imaging PET Study||National Institutes of Health Clinical Center (CC)||Completed|January 2008|January 2015|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Screening|1||Anticipated|40|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|February 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00618631||160505|
NCT00618592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 02-117|Does Pre-operative Carbohydrate Loading Reduce Insulin Resistance and Improve Outcomes in Elective Surgical Patients?|Does Pre-operative Carbohydrate Loading Reduce Insulin Resistance and Improve Outcomes in Elective Surgical Patients?|Preop|St. Michael's Hospital, Toronto|Yes|Completed|February 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2009|July 21, 2010|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618592||160508|
NCT00618605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ad26.ENVA.01/IPCAVD-001|Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults|A Phase 1 Randomized, Double-Blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|February 2008|||July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|February 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00618605||160507|
NCT00618917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-054|MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)|Chemotherapy (Paclitaxel and Carboplatin)and Thoracic Radiotherapy With Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome Protection in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer: A Phase I-II Study|MnSOD|University of Pittsburgh|Yes|Suspended|November 2005|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|February 6, 2008|Yes|Yes|MnSOD currently being manufactured|No||https://clinicaltrials.gov/show/NCT00618917||160484|
NCT00618930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/320|Moviprep® Versus Fleet Phospho-Soda® (Golden Standard): A Study That Compared Two Laxatives on Patients Undergoing Colo-Rectal Cleansing Prior to an Abdominal Operation|Moviprep® Versus Fleet Phospho-Soda® (Golden Standard): A Study That Compared Two Laxatives on Patients Undergoing Colo-Rectal Cleansing Prior to an Abdominal Operation.||University Hospital, Ghent|No|Completed|February 2008|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2009|April 14, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00618930||160483|
NCT00619801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00426|Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin|A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin|PAL|UCB Pharma||Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|173|||Both|2 Years|6 Years|No|||February 2015|February 18, 2015|February 11, 2008|Yes|Yes||No|July 28, 2009|https://clinicaltrials.gov/show/NCT00619801||160416|
NCT00619814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00171|Is Barium Enema an Adequate Diagnostic Test for Patients With Positive FOBT?|Is Barium Enema an Adequate Diagnostic Test for Patients With Positive FOBT?|DCBE|VA Caribbean Healthcare System|Yes|Completed|September 2003|October 2005|Actual|October 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|50|||Both|50 Years|80 Years|No|||February 2008|February 20, 2008|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619814||160415|
NCT00611962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC_7407|Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin|Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors||Sanofi||Completed|December 2000|March 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27|||Both|18 Years|N/A|No|||January 2008|January 28, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611962||161003|
NCT00620373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1337-05 Part A|Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts|Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool in Women With Mammographically Dense Breasts and Increased Risk of Breast Cancer||Mayo Clinic|No|Completed|August 2005|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|969|||Female|25 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 30, 2014|December 21, 2007|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00620373||160372|
NCT00611975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH071543|Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning|Effect of Serotonin Reuptake Inhibitors on Gonadal Steroid Hormones||Weill Medical College of Cornell University|No|Completed|October 2005|September 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00611975||161002|
NCT00612508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU RES 2017|Hormonal Contraception and Vaginal Health|The Effects of Oral vs. Intravaginal Hormonal Contraception on Vaginal Health||Oregon Health and Science University|No|Completed|May 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|January 29, 2008|Yes|Yes||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00612508||160961|Did not fully recruit; small number of subject
NCT00588822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1191-04|Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance|A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)||Mayo Clinic|Yes|Terminated|January 2005|February 2011|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|21 Years|90 Years|No|||April 2014|April 3, 2014|December 20, 2007|No|Yes|Discontinuation due to the high response rate at the 1st stage and slow accrual.|No|February 12, 2014|https://clinicaltrials.gov/show/NCT00588822||162729|The study was discontinued at the first stage to the high response rate and slow accrual.
NCT00618449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1079-31932|Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger|Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger||University of California, San Francisco|No|Completed|January 2008|August 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1139|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2012|April 10, 2012|February 6, 2008||No||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00618449||160519|Prevalence of infection in communities was less than predicted, as was return of infection post-treatment, thus hypothesis could not be evaluated.
NCT00620464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05720|A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)|A Randomized, Double-Blind, Parallel Group, Bioequivalence Study of IMPLANON and Radiopaque IMPLANON||Merck Sharp & Dohme Corp.|No|Completed|May 2005|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|February 11, 2008|Yes|Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00620464||160365|
NCT00589693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014038|To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia|A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|April 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||December 2012|December 24, 2012|December 21, 2007|Yes|Yes|Observed lower cure rates and higher mortality rates in one of the treatment groups.|No|June 13, 2012|https://clinicaltrials.gov/show/NCT00589693||162666|41 patients (21 doripenem, 20 imipenem-cilastatin) were enrolled at 5 sites that were found to be Good Clinical Practice non-compliant and were excluded from the primary efficacy and safety analyses.
NCT00620295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586510|Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors|Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)||Masonic Cancer Center, University of Minnesota|Yes|Completed|March 2007|October 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|70 Years|N/A|No|||November 2012|November 6, 2012|February 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620295||160378|
NCT00620568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3170A1-1001|Study Evaluating Multiple Ascending Dose in Schizophrenia Patients|An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|50 Years|No|||August 2009|August 3, 2009|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620568||160357|
NCT00620581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRL29060/621|Luteal Phase Administration of Paroxetine for the Treatment of PMDD|Luteal Phase Administration of Paroxetine for the Treatment of PMDD: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women|PMDD|McMaster University||Completed||||||Phase 3|Interventional|N/A|1||||||Female|18 Years|45 Years|No|||November 2005|February 7, 2008|February 7, 2008||||No||https://clinicaltrials.gov/show/NCT00620581||160356|
NCT00621465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH059716,#4640R|Critical Time Intervention in the Transition From Hospital to Community in People With Severe Mental Illness|CTI in the Transition From Hospital to Community||New York State Psychiatric Institute|No|Completed|April 2002|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|59 Years|No|||December 2011|December 28, 2011|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00621465||160289|
NCT00621478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01HD43393|Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)|Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2008|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|259|||Both|3 Months|18 Years|No|||July 2012|December 14, 2012|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621478||160288|
NCT00621452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2154.00|Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma|A Pilot Study to Evaluate the Safety and Feasibility of Cellular Immunotherapy Using Genetically Modified Autologous CD20-Specific T Cells For Patients With Relapsed or Refractory Mantle Cell and Indolent B Cell Lymphomas||Fred Hutchinson Cancer Research Center|Yes|Completed|August 2007|||January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|N/A|No|||August 2014|August 4, 2014|February 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00621452||160290|
NCT00621673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12112|Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A|Assessment of the Risk of Inhibitor Formation in Subjects With Severe Hemophilia A When Switched From a Replacement Therapy With a rFVIII Produced by a Chinese Hamster Ovary (CHO) Cell Line to a rFVIII Produced by a Baby Hamster Kidney (BHK) Cell Line (Kogenate® FS).||Bayer|No|Terminated|May 2006|October 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Male|12 Years|60 Years|No|||December 2014|December 17, 2014|February 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00621673||160273|
NCT00622518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33097-B|Ear Drops for Children With Otitis Media|Ear Drops for Children With Otitis Media||University of Washington|Yes|Completed|February 2008|April 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|119|||Both|6 Months|11 Years|No|||November 2010|November 4, 2010|February 13, 2008||No||No|September 28, 2010|https://clinicaltrials.gov/show/NCT00622518||160210|
NCT00622531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTB-Centaur200603|Serial BNP Testing for Heart Failure Management|Utilizing, Studying, Evaluating BNP for Monitoring in Patients With Heart Failure (USE-BNP)|USE-BNP|Siemens Healthcare Diagnostics Inc|No|Terminated|January 2007|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|108|Samples Without DNA|plasma|Both|18 Years|N/A|No|Probability Sample|Cardiology or internal medicine clinics|November 2015|November 16, 2015|February 14, 2008|Yes|Yes|Study terminated due to insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00622531||160209|
NCT00610922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEON-02/2005-DHA|Docosaexahenoic Acid and Gross Motor Milestones in Infants|RCT of Supplemented Docosahexaenoic Acid and Gross Motor Development Milestones in Healthy Infants.||University of Milan|No|Completed|May 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|1160|||Both|N/A|7 Days|No|||January 2008|February 7, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610922||161082|
NCT00610935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812 311|Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza.||BioCryst Pharmaceuticals|Yes|Terminated|January 2007|September 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|75 Years|No|||December 2014|December 15, 2014|January 25, 2008|Yes|Yes|This study was terminated for administrative reasons.|No||https://clinicaltrials.gov/show/NCT00610935||161081|
NCT00618943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-09253|Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders|Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders||University of California, San Francisco||Completed|April 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|13 Years|25 Years|No|||December 2011|December 7, 2011|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00618943||160482|
NCT00618956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-12|A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure||Forest Laboratories|No|Completed|October 2007|||July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|321|||Both|18 Years|70 Years|No|||November 2009|November 10, 2009|January 31, 2008|Yes|Yes||No|July 29, 2009|https://clinicaltrials.gov/show/NCT00618956||160481|
NCT00619216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1203|Myfortic Conversion Trial in OLT Recipients With GI Intolerance|A Three-Month, Open-Label, Two Cohort Study to Investigate the Safety and Tolerability of Myfortic in Combination With Neoral (Cyclosporin) or Prograf (Tacrolimus) in Liver Transplant Recipients With GI Intolerance||University of North Carolina, Chapel Hill|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|75 Years|No|Non-Probability Sample|Recipients of Orthotopic Liver Transplants|June 2011|June 1, 2011|February 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619216||160461|
NCT00619229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0878|Alprostadil in Maculopathy Study (AIMS)|Confirmatory, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Dry Age-related Macular Degeneration.||UCB Pharma|Yes|Terminated|July 2006|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|50 Years|N/A|No|||November 2011|October 17, 2014|December 24, 2007|Yes|Yes|Interim Analysis: Optimization of study design required.|No|January 27, 2011|https://clinicaltrials.gov/show/NCT00619229||160460|
NCT00611988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607M89406|Self-Managed Walking Improves Function|Self-Managed Walking Improves Function in Patients With Diabetes Mellitus and Peripheral Arterial Disease||University of Kansas Medical Center|No|Completed|August 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|40 Years|N/A|No|||December 2013|December 9, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611988||161001|
NCT00612261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|koh003|Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion|Arteriovenous Crossing Sheathotomy Versus Intravitreal Triamcinolone Acetonide Injection for Treatment of Macular Edema Associated With Branch Retinal Vein Occlusion||Yonsei University|Yes|Completed|October 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||January 2008|January 25, 2008|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00612261||160980|
NCT00612521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007446-01H|Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis|Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis||Ottawa Heart Institute Research Corporation|No|Terminated|August 2007|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|January 25, 2008||No|At half the sample size, the results were negative with no benefit demonstrated with    adenosine.|No||https://clinicaltrials.gov/show/NCT00612521||160960|
NCT00619047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bone Density Study|The Role of Impact Activity in Peripubertal Bone Accrual|The Role of Impact Activity in Peripubertal Bone Accrual||State University of New York - Upstate Medical University|No|Completed|January 2002|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Female|10 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Subjects were recruited into the following three groups based on their exposure to        gymnastic activity. A) control, no gymnastic activity. B)retired gymnasts, who        participated at study onset, but stopped gymnastics activity during the course of the        study. C) active gymnast, who continues participation in gymnastics throughout the        duration of the study.|November 2009|November 18, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00619047||160474|
NCT00589706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12555|A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas|A Phase II Study o the Adjuvant Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFR-425) Monoclonal Antibody Radiolabeled With I-125 for High Grade Gliomas||Drexel University|Yes|Suspended|January 1985|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||December 2007|June 15, 2010|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00589706||162665|
NCT00589719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39931|Asthma in the Delta Region of Arkansas (ADRA): Prevalence and Morbidity|Asthma in the Delta Region of Arkansas (ADRA): Prevalence and Morbidity||Arkansas Children's Hospital Research Institute|No|Completed|August 2005|August 2008|Actual|May 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|964|||Both|4 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|During the 2005-2006 school year, primary caregivers of all students aged 4-17 years        attending public school in Eudora and Marvell Arkansas were asked to complete an asthma        screening survey regarding their child. The schools are located in two non-contiguous        counties in the Delta region of Arkansas and are in rural low-income areas of the state        where more than one-third of families with children 5-17 years old meet the 2000 poverty        line (Census bureau).|August 2008|August 25, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00589719||162664|
NCT00620594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235A2101|A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer|A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer||Novartis||Completed|December 2006|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|183|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|February 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620594||160355|
NCT00620607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN 102|huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas|A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas||ImmunoGen, Inc.||Withdrawn|May 2007|September 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2009|August 25, 2015|February 7, 2008|Yes|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00620607||160354|
NCT00620906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0524070094|Motion Capture Analysis of Sacroiliac Joint Motion After Manipulation|Motion Capture Analysis of Sacroiliac Joint Motion After Manipulation||Logan College of Chiropractic|No|Completed|January 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00620906||160331|
NCT00621712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study No 2007_MBR_001|Clinical Assessment of a New Catheter Surface Coating With Antimicrobial Properties|Clinical Assessment of a New Catheter Surface Coating With Antimicrobial Properties: Efficacy and Effect of Intensive Catheter and Exit Site Care Education||Gambro Dialysatoren GmbH|No|Completed|October 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|N/A|No|||March 2011|March 7, 2011|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00621712||160270|
NCT00621699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eze-Tacro|Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects|Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects||University Medicine Greifswald|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 12, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621699||160271|
NCT00621959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00430|A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis||UCB Pharma|No|Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|596|||Both|18 Years|65 Years|No|||January 2015|January 6, 2015|February 11, 2008|Yes|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00621959||160251|
NCT00621686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0776|Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme|Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|September 2008|||October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621686||160272|
NCT00618345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582257|Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Trial of RAD001 in Relapsed/Refractory Multiple Myeloma||Mayo Clinic|Yes|Completed|March 2005|August 2008|Actual|October 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00618345||160527|
NCT00610948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0621|Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment|A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|March 2008|January 2016|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|February 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610948||161080|
NCT00610961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071016|Induction Related BK Viremia in Renal Transplant Patients|The Induction Agent Effect on BK Viremia in Renal and Pancreas Transplant Patients|BK|University of Florida|No|Completed|October 2007|November 2009|Actual|April 2009|Actual|Phase 4|Observational|Observational Model: Case Control||2|Actual|60|||Both|18 Years|75 Years|No|Non-Probability Sample|de novo renal or renal/pancrease transplant patients|September 2011|September 26, 2011|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610961||161079|
NCT00611208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDA IND 100712|A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)|A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma||Angimmune LLC|Yes|Active, not recruiting|January 2008|June 2020|Anticipated|February 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|January 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00611208||161060|
NCT00611481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS047130|Study of Tai Chi Exercise and Balance in Persons With Parkinson's Disease|Phase II Study of Tai Chi Exercise in Relation to Balance in Persons With Parkinson's Disease||Oregon Research Institute|Yes|Completed|October 2008|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|195|||Both|40 Years|85 Years|No|||October 2011|October 10, 2011|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00611481||161040|
NCT00611455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110635|Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy|A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy||GlaxoSmithKline|No|Terminated|January 2008|July 2013|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||December 2013|May 8, 2014|January 16, 2008||No|Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical    development of autoimmune indications on the subcutaneous delivery.|No|September 21, 2011|https://clinicaltrials.gov/show/NCT00611455||161042|
NCT00611468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN ALSSRST0501|Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors|A Phase I, Dosage-finding and Pharmacokinetic Study of Intravenous Topotecan and Oral Erlotinib in Adults With Refractory Solid Tumors||Accelerated Community Oncology Research Network|No|Completed|June 2006|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|January 29, 2008|Yes|Yes||No|July 1, 2010|https://clinicaltrials.gov/show/NCT00611468||161041|
NCT00612001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000585166|Vaccine Therapy in Treating Patients With Malignant Glioma|Phase I Study of Glioma-Associated Antigen (GAA) Peptide-pulsed Dendritic Cell Vaccination in Malignant Glioma Patients||Jonsson Comprehensive Cancer Center|Yes|Completed|May 2006|October 2012|Actual|January 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2013|October 1, 2015|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612001||161000|
NCT00612014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-101-CL-G004|Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus||Tranzyme, Inc.|Yes|Completed|October 2007|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|78|||Both|18 Years|80 Years|No|||December 2012|December 5, 2012|January 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612014||160999|
NCT00612274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703002455|Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation|Pilot Study of Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute Graft Versus Host Disease in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation||Yale University|No|Active, not recruiting|October 2007|October 2014|Anticipated|October 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|N/A|No|||July 2013|July 15, 2013|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612274||160979|
NCT00612287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA022675|Sublingual Buprenorphine for Chronic Pain|Sublingual Buprenorphine for Chronic Pain in Patients at Risk for Drug Abuse||National Institute on Drug Abuse (NIDA)|No|Not yet recruiting|April 2009|August 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||April 2009|April 6, 2009|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612287||160978|
NCT00613327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013840|An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants|The Efficacy of Oxybutynin Chloride OROS in Patient-Reported Outcomes With Dose Escalation in Korean Overactive Bladder Patients||Janssen Korea, Ltd., Korea|No|Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|345|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|January 31, 2008|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00613327||160899|
NCT00589108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-01|Comparison of A Mobile-Bearing Total Knee System With A Fixed-Bearing Total Knee System In Cemented Total Knee Arthroplasty|A Prospective, Randomized, Controlled Study Comparing A Mobile-Bearing Total Knee System With A Fixed-Bearing Total Knee System In Cemented Total Knee Arthroplasty||Mayo Clinic|No|Completed|January 2001|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|240|||Both|40 Years|75 Years|No|||December 2012|December 10, 2012|December 21, 2007||No||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00589108||162708|
NCT00589121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0630|Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg|A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity||Radiation Therapy Oncology Group|Yes|Active, not recruiting|March 2008|||December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|January 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00589121||162707|
NCT00589134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|188|The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration|The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration||Yale University||Completed|January 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2010|July 15, 2010|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00589134||162706|
NCT00589407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARZ-001HMO-CTIL|Unilateral Blindness/ Unilateral Deafness-relation to Neck Pain|Unilateral Blindness/ Unilateral Deafness-relation to Neck Pain||Hadassah Medical Organization||Terminated||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Months|65 Years|No|Non-Probability Sample|study group: patients with unilateral blindness and unilateral deafness as the control        group: patients attending the eye ENT clinics for other reasons as control|March 2013|March 21, 2013|December 23, 2007||No|there is a problem in recruting the paricipents|No||https://clinicaltrials.gov/show/NCT00589407||162687|
NCT00589680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9137|Compliance With American Diabetes Association Treatment Guidelines for Adult Ketoacidosis|Compliance With American Diabetes Association Treatment Guidelines for Adult Ketoacidosis||Marshall University|No|Active, not recruiting|December 2007|July 2008|Anticipated|July 2008|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Those patients admitted to St. Mary's Medical Center with a diagnosis of DKA.|December 2007|January 9, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00589680||162667|
NCT00589433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF02-HMO-CTIL|Follow Up Study of Tear in the Rotator Culf|Follow Up Study of Tear in the Rotator Culf||Hadassah Medical Organization|No|Terminated||||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|35 Years|65 Years|No|Non-Probability Sample|primary care clinic|March 2013|March 21, 2013|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00589433||162685|
NCT00589186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579355|Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer|Phase II Clinical Trial of Tumour Vaccination By Intradermal Delivery of Autologous Dendritic Cells Transduced With Adenoviral Vector (AD5F35) Expressing Latent Membrane Protein-1 (LMP-1) and Latent Membrane Protein-2 (LMP-2) Genes in Combination With Celecoxib in Patient With Metastatic Nasopharyngeal Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|November 2007|||December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||December 2008|December 17, 2013|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00589186||162703|
NCT00589459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12258|Gender Differences in Prevalence of Undiagnosed Diabetes in ACS|A Pilot Study of Gender Differences in the Prevalence of Undiagnosed Diabetes in Acute Coronary Syndromes (ACS)||Yale University|No|Active, not recruiting|October 2001|December 2008|Anticipated|September 2005|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|103|||Both|30 Years|N/A|No|Probability Sample|Women and men admitted with an acute coronary syndrome who do not have a prior diagnosis        of diabetes|December 2007|January 8, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00589459||162683|
NCT00620919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P002501|Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis|RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis||Massachusetts General Hospital|No|Terminated|February 2008|December 2008|Actual|December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|90 Years|No|||January 2009|January 27, 2009|January 22, 2008|Yes|Yes|Poor patient enrollment due to logistical issues.|No||https://clinicaltrials.gov/show/NCT00620919||160330|
NCT00621205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152/2002|Gene Expression in Obesity and Insulin Resistance|Gene Expression in Adipose Tissue of Genes Involved in Obesity, Insulin Resistance and Lipid Metabolism Before and After Weight Loss or an Intensive Exercise Period|Genobin|University of Eastern Finland|No|Completed|October 2003|December 2005|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|75|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00621205||160309|
NCT00621218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9320-010-002|A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea|A Pilot Study to Compare Tretinoin Gel, 0.05% to Tretinoin Gel Vehicle When Dosed Once or Twice Daily in Female Subjects With Classical Rosacea||Coria Laboratories, Ltd.|No|Completed|February 2008|December 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|65 Years|No|||December 2008|December 17, 2008|February 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00621218||160308|
NCT00622245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12022A|Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression|Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder||H. Lundbeck A/S|No|Terminated|January 2008|November 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|166|||Both|18 Years|65 Years|No|||September 2010|September 24, 2010|February 12, 2008||No|Human metabolite not yet covered sufficiently by nonclinical data|No||https://clinicaltrials.gov/show/NCT00622245||160230|
NCT00622258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C1104|A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma||Novartis||Completed|March 2008|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|N/A|No|||September 2014|September 24, 2014|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00622258||160229|
NCT00622232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX496-USA-05-002-Rollover|A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial|A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-infusing Subjects Who Completed Participation in the VRX496-USA-05-002 Trial With Autologous T Cells Transduced With VRX496|Rollover|VIRxSYS Corporation|Yes|Active, not recruiting|December 2007|June 2023|Anticipated|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|February 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622232||160231|
NCT00610649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05704|Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)|Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder (Protocol No. P174001)||Merck Sharp & Dohme Corp.|No|Completed|September 2007|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|54|||Both|18 Years|65 Years|No|||May 2015|May 11, 2015|January 28, 2008|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00610649||161103|
NCT00610974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01394|Enhancing Walking in People With Incomplete Spinal Cord Injury: a Pilot Study|Enhancing Walking in People With Incomplete Spinal Cord Injury by Improving Swing Phase Activity: a Pilot Study||University of British Columbia|No|Completed|March 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|15|||Both|19 Years|65 Years|No|||September 2014|September 24, 2014|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610974||161078|
NCT00611221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00528|Massage Therapy Study: Massage Therapy and Labour Outcomes|Massage Therapy and Labour Outcomes; A Randomized Controlled Trial||University of British Columbia|No|Completed|January 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|77|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2011|April 26, 2011|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611221||161059|
NCT00611494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0398-A|Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors|A Single Centre, Prospective, Open-Label, Parallel Group, Randomized Study to Compare the Gastrointestinal Tolerability of Mycophenolate Mofetil (MMF, CellCept) and Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic) in Maintenance Transplant Patients Treated With Calcineurin Inhibitors|MOTOR-MPA|University Health Network, Toronto|No|Recruiting|January 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||February 2009|February 16, 2009|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00611494||161039|
NCT00611767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510000664|GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence|GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence||Yale University|Yes|Completed|November 2005|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|2|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||January 2008|November 2, 2012|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00611767||161018|
NCT00612781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ye-Whi 2006|Yellow Versus White Study|Influence of Blue-Light-Filter IOLs on Color Perception and Contrast Acuity. A Randomized, Double-Masked Study With Intraindividual Comparison.|YeWhi|Hospital Hietzing|No|Completed|December 2005|May 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|55 Years|80 Years|No|||January 2008|January 29, 2008|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612781||160940|
NCT00612794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-JE-GWBW|A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes|Multiple-Dose Study to Examine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2148568 Long-Acting Release in Japanese Patients With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|20 Years|75 Years|No|||January 2015|February 23, 2015|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612794||160939|
NCT00613041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-039|3-D Reconstruction of CT Scan Images in the Evaluation of Non-Specific Pulmonary Nodules|Pilot Study: 3-D Reconstruction of CT Scan Images in the Evaluation of Non-Specific Pulmonary Nodules||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2003|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who meet eligibility criteria will be recruited from the services that comprise        the Thoracic Disease Management Team (DMT), specifically the Divisions of Pulmonary        Medicine and Thoracic Surgery.|November 2015|November 25, 2015|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00613041||160920|
NCT00612807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008099|Treatment of Mood and Marriage Study (TOMMS)|Adapting Marital Therapy in Older Adults With Depression||Duke University|Yes|Completed|July 2006|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|60 Years|N/A|No|||March 2011|June 17, 2013|January 2, 2008||No||No|February 16, 2011|https://clinicaltrials.gov/show/NCT00612807||160938|Small sample size limits power to detect differences. Some participants reported difficulty understanding how to complete the questions, which may introduce additional variability into the data.
NCT00588848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-00504|Comparison of Continuous Positive Airway Pressure (CPAP) With Autoadjusting CPAP in the Treatment of Obstructive Sleep Apnea (OSA) in the Postoperative Setting|Postoperative Management of Obstructive Sleep Apnea With CPAP vs. an Autoadjusting CPAP Device: a Randomized Controlled Single Center Trial||MetroHealth Medical Center|No|Terminated|January 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||July 2013|July 18, 2013|January 3, 2008|Yes|Yes|Difficulty with enrollment|No|October 28, 2012|https://clinicaltrials.gov/show/NCT00588848||162727|Trial limitations include:1. Insufficient enrollment to adequately analyze data
NCT00589420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581020|Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy|A Phase II Study of Sorafenib in Combination With Docetaxel in Patients With Androgen-Independent Prostate Cancer||National Cancer Institute (NCI)||Recruiting|October 2006|||December 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Male|18 Years|N/A|No|||July 2009|July 7, 2009|December 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589420||162686|
NCT00589771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|674- MED|Saccharomyces Boulardii in Irritable Bowel Syndrome|Clinical and Cytokine Response to Saccharomyces Boulardii Therapy in Diarrhea Dominant Irritable Bowel Syndrome|SB-IBS|Aga Khan University|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|70 Years|No|||October 2012|October 14, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00589771||162660|
NCT00621244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2102|A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies|A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies||Novartis||Completed|March 2006|||August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621244||160306|
NCT00621738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1382|Effect of Mental Stress on Platelet Function in Healthy Subject|Effect of Mental Stress on Platelet Function in Healthy Subject||University of Zurich||Completed|December 2007|||December 2009|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects, aging 18-80 years|February 2010|February 9, 2010|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00621738||160268|
NCT00621491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 2273/03/067|Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation|Randomized Controlled Clinical Trial for Prevention of Thromboembolic Complications After Permanent Transvenous Leads Implantation in High-risk Patients||University of Sao Paulo|No|Completed|February 2004|July 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|101|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2008|October 25, 2012|February 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621491||160287|
NCT00621972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC3230|AV Fistula Salvage in Advanced CKD Using Sodium Bicarbonate Prophylaxis|A Prospective Observational Study on the Use of Iodinated Contrast for AV Fistula Salvage in Stage 4/5 CKD Using Bicarbonate Prophylaxis||Maine Medical Center|No|Recruiting|January 2008|January 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Stage 4 and 5 chronic kidney disease patients with AV fistula placed but have not        initiated dialysis.|January 2008|February 21, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621972||160250|
NCT00621985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01-0025|Dexamethasone Treatment of Congenital Adrenal Hyperplasia|Dexamethasone Treatment of Congenital Adrenal Hyperplasia||Children's Hospital Boston|No|Completed|April 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|9 Years|No|||January 2011|January 26, 2011|February 11, 2008|Yes|Yes||No|September 17, 2010|https://clinicaltrials.gov/show/NCT00621985||160249|
NCT00622271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTP1|Intervention Groups for Adolescents With Type 1 Diabetes Mellitus|Adjustment and Self-Management Intervention Groups for Adolescents With Type 1 Diabetes Mellitus and Their Parents.||Children's Hospital and Health System Foundation, Wisconsin|No|Completed|February 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|13 Years|17 Years|No|||November 2011|November 16, 2011|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622271||160228|
NCT00622557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-07-18|General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)|General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)|SOCRATES|University Hospital Case Medical Center|No|Recruiting|May 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200000|||Both|14 Years|95 Years|No|Non-Probability Sample|All patients receiving surgical, medical, or radiological services at University Hospitals        Case Medical Center,Richmond,or Geauga campuses.|December 2013|December 11, 2013|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00622557||160207|
NCT00622544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707M11722|A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome|A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome|MA|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2007|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|44|Samples Without DNA|Each urine sample will be assayed for albumin, total protein and creatinine. The following      definitions will be used:        -  Microalbuminuria: urine albumin:creatinine ratio (ACR) > 30 mcg/mg, on 3 consecutive           measurements spaced one month apart        -  Overt proteinuria: urine protein:creatinine ratio (UPC) > 0.2 mg/mg, on 3 consecutive           measurements spaced one month apart|Male|N/A|18 Years|No|Non-Probability Sample|The study population is comprised of approximately 30 males ranging in age from 0 - 18 at        the time of enrollment.|December 2013|December 12, 2013|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622544||160208|
NCT00610662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581295|Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia in Patients With An Abnormal Pap Smear|A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia Using a Second Generation Device||British Columbia Cancer Agency|No|Withdrawn|December 2010|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Observational|N/A|||Actual|0|||Female|18 Years|N/A|No|||April 2014|July 17, 2014|February 7, 2008|No|Yes|Study modified and has been running as CDR0000581286 instead.|No||https://clinicaltrials.gov/show/NCT00610662||161102|
NCT00611507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8107|A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer|A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer||Sanofi||Completed|November 2002|April 2004|Actual|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||March 2008|March 24, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611507||161038|
NCT00611247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07815|Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia|Phase II Study of Two Distinct Tailored Temozolomide Regimens for Patients With Acute Myeloid Leukemia Age > 60 Years and Poor Risk/Refractory Disease||Stanford University|Yes|Completed|December 2007|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|60 Years|N/A|No|||July 2014|July 7, 2014|January 25, 2008|Yes|Yes||No|April 29, 2014|https://clinicaltrials.gov/show/NCT00611247||161058|
NCT00611793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 56|PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies|A Phase I Trial of PTK787/ZK222584 in Combination With Bevacizumab (Avastin) in Patients With Refractory and/or Advanced Malignancies||SCRI Development Innovations, LLC|No|Completed|October 2004|January 2009|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2009|January 22, 2009|January 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00611793||161016|
NCT00612027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312004011|Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions|Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions||AstraZeneca|No|Completed|January 2006|||March 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29586|||Both|N/A|N/A|No|Probability Sample|general practitioners and internists|January 2008|February 8, 2008|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612027||160998|
NCT00612040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1835|Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes|A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|178|||Both|18 Years|75 Years|No|||November 2015|November 27, 2015|January 25, 2008|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT00612040||160997|
NCT00611780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00207|Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol|Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol|PROTECTION-II|Deutsches Herzzentrum Muenchen|Yes|Recruiting|January 2008|January 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||August 2008|August 26, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611780||161017|
NCT00612313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH039188-01|Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse|Pediatric MDD: Sequential Treatment With Fluoxetine and Relapse Prevention||University of Texas Southwestern Medical Center|Yes|Completed|February 2008|January 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|8 Years|17 Years|No|||December 2015|December 3, 2015|February 7, 2008|Yes|Yes||No|July 3, 2014|https://clinicaltrials.gov/show/NCT00612313||160976|Primary outcomes based on data through 30 weeks.Participants were not blinded to treatment assignment.
NCT00612547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTComMada|ACT for the Home Management in Malagasy Children|Assessment of the Use of Fixed Doses of Artesunate Plus Amodiaquine Combination for the Home Management of Presumed Malaria in Malagasy Children||National Malaria Control Programme, Madagascar|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1200|Samples With DNA|Whole blood|Both|2 Months|5 Years|No|Non-Probability Sample|community sample|February 2009|February 25, 2009|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612547||160958|
NCT00613366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU RES 3489|Misoprostol With Intrauterine Device Insertion|Effect of Prophylactic Misoprostol Prior to Intrauterine Device Insertion||Oregon Health and Science University|No|Completed|June 2007|December 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|January 29, 2008|Yes|Yes||No|June 1, 2012|https://clinicaltrials.gov/show/NCT00613366||160896|
NCT00588562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001702|Rare Kidney Stone Consortium Patient Registry|Rare Kidney Stone Consortium Registry for Hereditary Kidney Stone Diseases|RKSC|Mayo Clinic|Yes|Recruiting|July 2003|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort||4|Anticipated|730|||Both|N/A|100 Years|No|Non-Probability Sample|Individuals with Primary Hyperoxaluria, Dent Disease, Cystinuria and APRT Deficiency.|November 2015|November 30, 2015|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00588562||162748|
NCT00589147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2320-02|A Prospective, Randomized, Controlled Study Comparing Three Tibial Component Designs in Total Knee Arthoplasty|A Prospective, Randomized, Controlled Study Comparing Three Tibial Component Designs in Total Knee Arthoplasty||Mayo Clinic|No|Completed|August 2003|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|397|||Both|20 Years|85 Years|No|||May 2012|May 25, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00589147||162705|
NCT00589173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD300045|An Interactive Preventive Health Record (IPHR) to Promote Patient-Centered Preventive Care|An Interactive Preventive Health Record (IPHR) to Promote Patient-Centered Preventive Care||Virginia Commonwealth University|No|Completed|September 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5500|||Both|18 Years|75 Years|No|||July 2012|July 22, 2012|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00589173||162704|
NCT00589784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-135|Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma|Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma||Memorial Sloan Kettering Cancer Center||Completed|October 2007|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|December 26, 2007|Yes|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT00589784||162659|
NCT00589797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-01|Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease|Clinical Study to Evaluate the Safety and Effectiveness of the Aesculap Activ-L™ Artificial Disc in the Treatment of Degenerative Disc Disease||Aesculap Implant Systems|No|Active, not recruiting|January 2007|July 2017|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|414|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 23, 2013|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00589797||162658|
NCT00621751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-07-02A|Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression|Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial||Carolinas Healthcare System|Yes|Completed|February 2008|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|16 Years|75 Years|No|||August 2014|August 11, 2014|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00621751||160267|
NCT00613574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.396|RUSSE / Russian Spiriva® Safety & Efficacy Study|RUSSE / Russian Spiriva® Safety & Efficacy Study||Boehringer Ingelheim||Completed||October 2007||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|407|||Both|40 Years|N/A|No|Probability Sample|Physicians|March 2014|March 12, 2014|January 31, 2008||||No|October 29, 2009|https://clinicaltrials.gov/show/NCT00613574||160881|
NCT00609765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14961|Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors|Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|August 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||March 2011|November 21, 2013|January 24, 2008|Yes|Yes|Development of new chemotherapy standard of care for treatment rendered the trial obsolete.|No|February 21, 2011|https://clinicaltrials.gov/show/NCT00609765||161171|This trial only enrolled one patient and was closed because of development of a new chemotherapy standard of care for treatment of this cancer which we felt rendered the trial obsolete. The trial was open for only 7 months.
NCT00610051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-T02-07-0105|Alprostadil Continuous Intravenous Infusion in Bridging Cardiac Transplant in Severe Heart Failure Patients|Phase 3 Study of Alprostadil Continuous Intravenous Infusion in Bridging Cardiac Transplant in Severe Heart Failure Patients||Biopeutics Co., Ltd|Yes|Suspended|December 2012|December 2022|Anticipated|June 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|70 Years|No|||July 2015|July 21, 2015|January 14, 2008|Yes|Yes|DD issue|No||https://clinicaltrials.gov/show/NCT00610051||161149|
NCT00622570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 02/0642|Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension|Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension.||Hospital Universitari Son Dureta|No|Terminated|May 2002|December 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|15 Years|75 Years|No|||July 2007|February 22, 2008|February 14, 2008||No|Slowly recruitment rate. Intermediate analysis|No||https://clinicaltrials.gov/show/NCT00622570||160206|
NCT00618358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-072|Vascular Sealant Study|A Prospective, Randomized, Multi-Center, Two Arm Study to Evaluate the Safety and Effectiveness of the Vascular Sealant System Compared With Gelfoam/Thrombin for Control of Anastomosis Suture Line Bleeding in Patients Undergoing Vascular Reconstructive Surgery With PTFE Grafts|VSS|Georgetown University|Yes|Terminated|March 2007|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||January 2010|March 26, 2015|February 8, 2008|||Sponsor - Confluent Surgical terminated study re: surgical techniques Letter dated 4/31/2008|No||https://clinicaltrials.gov/show/NCT00618358||160526|
NCT00610675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05708|Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)|Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002.||Merck Sharp & Dohme Corp.|No|Completed|December 2006|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|346|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|January 9, 2008|No|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00610675||161101|
NCT00611286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSD-03-I|Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention|PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY|PRODIGY|Università degli Studi di Ferrara|Yes|Completed|December 2006|October 2012|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1700|||Both|18 Years|N/A|No|||October 2012|October 6, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00611286||161055|
NCT00611806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070831|Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia|A Placebo-Controlled Trial of Folate With B12 in Schizophrenia Patients With Residual Symptoms||Massachusetts General Hospital|Yes|Completed|December 2007|December 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|68 Years|No|||July 2014|July 31, 2014|February 7, 2008|Yes|Yes||No|July 31, 2014|https://clinicaltrials.gov/show/NCT00611806||161015|
NCT00611520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312005009|Symbicort in Chronic Obstructive Pulmonary Disease|Symbicort in Chronic Obstructive Pulmonary Disease|SYMBOL|AstraZeneca|No|Completed|September 2005|||December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64730|||Both|N/A|N/A|No|Non-Probability Sample|patients|January 2011|January 27, 2011|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00611520||161037|
NCT00611819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHRONOS|Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV|Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.||University of Valencia|No|Active, not recruiting|November 2005|December 2008|Anticipated|April 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|65 Years|No|||January 2008|January 25, 2008|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611819||161014|
NCT00612300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Gait Training for Persons With Stroke|The Lokomat Gait Orthosis Compared to Categorized Gait Training by Physical Therapists in Patients Early Post Stroke|GTS|University of Aarhus|No|Completed|June 2007|June 2009|Actual|June 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|30 Years|80 Years|No|||February 2010|February 16, 2010|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612300||160977|
NCT00612534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARX-C-001|A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement|A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement|ARX-F01|AcelRx Pharmaceuticals, Inc.|No|Completed|March 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|94|||Both|45 Years|80 Years|No|||January 2014|January 22, 2014|January 28, 2008|Yes|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT00612534||160959|
NCT00612573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-07907|Treatment of Moderate to Severe Facial Acne Vulgaris|Phase 2 Study Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 3 Doses of Doxycycline as Compared to Placebo in the Treatment of Moderate to Severe Facial Acne Vulgaris||Warner Chilcott|No|Completed|February 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|257|||Both|12 Years|45 Years|No|||April 2013|April 15, 2013|January 25, 2008|Yes|Yes||No|February 14, 2011|https://clinicaltrials.gov/show/NCT00612573||160956|
NCT00612820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPR110723|A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)|An 8 Day, Randomised, Double Blind, 3-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Fluticasone Propionate in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)||GlaxoSmithKline|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|May 31, 2012|January 29, 2008||||No||https://clinicaltrials.gov/show/NCT00612820||160937|
NCT00613080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0822|Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer|A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 2008|||January 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|February 9, 2008|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00613080||160917|
NCT00613093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4260|Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma|Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma||Duke University|Yes|Completed|October 2002|August 2008|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||November 2012|July 8, 2014|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613093||160916|
NCT00609856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 111/2004|Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes|Differences in Metabolic and Cardiovascular Effects of Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes||Skane University Hospital|No|Completed|April 2004|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|30 Years|75 Years|No|||January 2008|January 24, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609856||161164|
NCT00609869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14978|Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab|A Phase II Study of Lenalidomide (REVLIMID®) in Combination With Rituximab for Patients With CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|October 2007|August 2015|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|January 24, 2008|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00609869||161163|The 4 Mantle Cell participants were not evaluated for Outcome Measures due to their low enrollment.
NCT00588900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-80502|Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab|A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab||Alliance for Clinical Trials in Oncology|No|Terminated|March 2008|November 2011|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|December 20, 2007|Yes|Yes|Recruiting or enrolling participants halted prematurely due to low patient accrual.|No||https://clinicaltrials.gov/show/NCT00588900||162723|
NCT00588861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-U-011|Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Shell Using Simplex® or Palacos® Bone Cement|Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Acetabular Shell Using Simplex® or Palacos® Bone Cement||Biomet, Inc.|No|Terminated|September 2002|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|December 19, 2007|Yes|Yes|Study was terminated due to insufficient data and lack of patient follow-up|No|June 14, 2010|https://clinicaltrials.gov/show/NCT00588861||162726|Study was terminated prematurely after sponsor no longer distributed the products involved and follow-up failed to produce sufficient data to be analyzed.
NCT00588874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11946|Age Related Changes in Calciotropic Hormones and Their Impact on Male Osteoporosis|Pilot Study to Assess the Skeletal Effects of Age-Related Changes in Calcium and Vitamin D Metabolism in Men||Yale University|No|Active, not recruiting|October 2000|December 2008|Anticipated|July 2002|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|24|||Male|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men 50 yrs of age and older, without a known history of metabolic bone disease or        renal insufficiency|December 2007|January 8, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00588874||162725|
NCT00590070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REOPEN-AMI 2007-006794-93|THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction|Randomized Evaluation Of Intracoronary Nitroprusside vs Adenosine After Thrombus-aspiration During Primary PErcutaneous Coronary Intervention for the Prevention of No Reflow in Acute Myocardial Infarction|REOPEN-AMI|Catholic University of the Sacred Heart|Yes|Completed|January 2008|September 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|N/A|No|||March 2012|March 25, 2012|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00590070||162639|
NCT00609505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001547|Telemedicine vs. Face-to-Face Cancer Genetic Counseling|Telemedicine vs. Face-to-Face Cancer Genetic Counseling in Rural Oncology Clinics||Duke University|No|Completed|August 2008|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 21, 2012|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609505||161190|
NCT00609778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jolife 10-0|A Comparison of Conventional Adult Out-of-hospital Cardiopulmonary Resuscitation Against a Concept With Mechanical Chest Compressions and Simultaneous Defibrillation - LINC Study|A Comparison of Conventional Adult Out-of-hospital Cardiopulmonary Resuscitation Against a Concept With Mechanical Chest Compressions and Simultaneous Defibrillation|LINC|Jolife AB|Yes|Completed|January 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2500|||Both|18 Years|N/A|No|||June 2011|October 4, 2012|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609778||161170|
NCT00610350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV 2003|Levosimendan and Myocardial Protection|Levosimendan Pre-Treatment in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-Blind, Single Center, Prospective, Randomized, Placebo-Controlled Trial||University of Roma La Sapienza|No|Completed|January 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2008|February 6, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610350||161126|
NCT00610363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-GA-0619|Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy||Regeneron Pharmaceuticals|Yes|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||June 2011|September 27, 2013|January 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00610363||161125|
NCT00611260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715089|Improvement in Clinical Outcomes in Heart Failure Patients With ICDs That Practice Meditation|Does Meditation Improve Outcomes in Patients With Heart Failure Who Received Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy Defibrillators?||University of California, Davis|No|Completed|April 2007|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|85 Years|No|||March 2013|March 26, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611260||161057|
NCT00611273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACI 007-02|A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing|A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing||Advanced Cosmetic Intervention|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 23, 2014|January 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00611273||161056|
NCT00611546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-MD-thesis-nehad|Perenteral Nutrition and Oxidative Stress in Preterm Infants|Study of the Oxidant-Antioxidant Effects of Parenteral Nutrition in Preterm Neonates||Mansoura University|No|Completed|April 2003|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|N/A|7 Days|No|||January 2008|January 28, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00611546||161035|
NCT00611559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110478|Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children|Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children||GlaxoSmithKline||Completed|February 2008|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|283|||Both|18 Months|23 Months|Accepts Healthy Volunteers|||October 2015|October 29, 2015|January 29, 2008|Yes|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00611559||161034|
NCT00611533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0403026533|Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women|A Controlled Trial of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women||Yale University|No|Completed|May 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00611533||161036|
NCT00612066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586468|Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)|An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease||Jonsson Comprehensive Cancer Center|Yes|Terminated|April 2007|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|February 8, 2008|Yes|Yes|Low accrual and funding term ended|No|January 11, 2013|https://clinicaltrials.gov/show/NCT00612066||160995|Recruitment was a major limitation. Patients were available but were not interested in the study due to possible side effects of the study drug.
NCT00612053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI/167|Italian Registry on Unprotected Left Main|Italian Registry on Treatment for Unprotected Left Main Disease (Registro Italiano Sul Trattamento Del Tronco coMune Non protettO)|RITMO|University of Turin, Italy|Yes|Recruiting|May 2008|December 2015|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|N/A|N/A|No|Probability Sample|Patients with suspected coronary artery disease undergoing diagnostic coronary        angiography.|February 2010|June 28, 2010|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612053||160996|
NCT00609284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2007-01|Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux|Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux|GORTEC2007-01|Groupe Oncologie Radiotherapie Tete et Cou|Yes|Active, not recruiting|February 2008|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|406|||Both|18 Years|70 Years|No|||March 2015|March 23, 2015|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609284||161207|
NCT00609297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0731|Pain Control in Hospice Patients With Cancer-Related Pain|Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol Stage 2, Part A||Vanderbilt-Ingram Cancer Center|Yes|Completed|July 2007|May 2011|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in Alive hospice who have pain and their caregivers.|October 2012|October 23, 2012|February 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00609297||161206|
NCT00621075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.014|Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans|Correlation of Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans||Northwell Health|No|Completed|April 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Pulmonary Arterial Hypertension|March 2010|March 8, 2010|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00621075||160318|
NCT00609570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0920070111|Nutritional Supplements on Blood Pressure 2008|Effects of Nutritional Supplements on Blood Pressure and Heart Rate Variability||Logan College of Chiropractic|No|Recruiting|October 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|70 Years|No|||October 2008|October 27, 2008|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609570||161185|
NCT00609596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI111402|A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.|An Open Label, Randomized, Repeat Dose, 3 Period Cross Over Study to Determine the Bioequivalence of 3 Different Formulations of Tamsulosin at Steady State in Healthy Male Volunteers||GlaxoSmithKline||Completed|February 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|January 25, 2008||||||https://clinicaltrials.gov/show/NCT00609596||161184|
NCT00609609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1022|Photopheresis for the Treatment of Acute Graft Versus Host Disease|A Randomized Phase II Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination With Corticosteroids for the Initial Treatment of Acute Graft-Versus-Host Disease (GVHD)||M.D. Anderson Cancer Center|Yes|Completed|January 2008|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|N/A|N/A|No|||February 2016|February 9, 2016|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00609609||161183|
NCT00621868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0103|A Phase 2 Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|A Phase 2, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus||Astellas Pharma Inc|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|361|||Both|20 Years|75 Years|No|||January 2016|January 18, 2016|February 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00621868||160258|
NCT00622102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806634|Testing Strategies to Improving Warfarin Adherence|Testing Strategies to Improving Warfarin Adherence||University of Pennsylvania|Yes|Completed|December 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|101|||Both|21 Years|N/A|No|||December 2009|December 1, 2009|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00622102||160240|
NCT00589212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-700|GliaSite 1-3 Mets Study|A Phase II Study Utilizing Focal Radiation in Patients With 1-3 Brain Metastases||Hologic, Inc.|Yes|Completed|October 2003|March 2008|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2008|June 9, 2008|December 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589212||162701|
NCT00589199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB93-00133|Functional Electrical Stimulation for Production of Artificial Cough|Functional Electrical Stimulation for Production of Artificial Cough||Case Western Reserve University|No|Completed|December 1993|January 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||May 2012|May 23, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589199||162702|
NCT00590083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14097-LYPTAIST|Administration of Virus-Specific Cytotoxic T-Lymphocytes|Administration of Virus-Specific Cytotoxic T-Lymphocytes for the Prophylaxis and Therapy of Adenovirus Infection Post Allogeneic Stem Cell Transplant|LYPTAIST|Baylor College of Medicine|Yes|Completed|July 2003|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|N/A|No|||February 2014|February 14, 2014|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00590083||162638|
NCT00613275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01CA116892-03|Patient Navigation in the Safety Net:CONNECTeDD|Patient Navigation in the Safety Net:CONNECTeDD||Boston Medical Center|Yes|Completed|July 2005|September 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|4038|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00613275||160903|
NCT00613587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGT2007|Roflumilast In-Vitro Basophil Release|Effect of Roflumilast In-Vitro on Basophil Histamine, Leukotriene, IL-4 and IL13-release.||Creighton University|No|Completed|August 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|Samples Without DNA|Polymorphal Blood Mononuclar Cells will be stimulated to release various cytokines. The      supernatant of the stimulations will be stored for batched analysis.|Both|19 Years|65 Years|No|Probability Sample|Allergic Asthma, non-smoker|September 2012|October 8, 2012|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00613587||160880|
NCT00610090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMV-AUI-P2-001|Safety Study for the Treatment of Abdominal Aortic Aneurysms|A Phase II, Single-arm, Prospective Study of the Safety of the UniFit Aorto-uni-iliac Endoluminal Stent Graft for the Repair of Abdominal Aortic Aneurysms|UNITE|Duke Vascular, Inc.|Yes|Terminated|May 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||May 2015|August 23, 2015|January 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00610090||161146|
NCT00610103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6500-0702|Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy|A Phase 2 Clinical Study of KW-6500 (Apomorphine Hydrochloride) in Patients With Parkinson's Disease||Kyowa Hakko Kirin Company, Limited|No|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|N/A|No|||August 2012|August 30, 2012|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00610103||161145|
NCT00609466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574139|A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy|A Randomized, Double-blind, Parallel-group, Multi-center, Active- and Placebo-controlled Trial to Evaluate the Analgesic Efficacy and Safety of Multiple Doses of CG5503 IR for Postoperative Pain Following Bunionectomy||Grünenthal GmbH|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|291|||Both|18 Years|80 Years|No|||November 2011|November 10, 2011|January 24, 2008|Yes|Yes||No|September 16, 2009|https://clinicaltrials.gov/show/NCT00609466||161193|Lortab (hydrocodone/acetaminophen) was allowed as rescue medication.
NCT00609479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JOS-1|Comparison of Two Methods for Treatment of Colles´s Fracture|Comparison of External and Internal Fixationmethods for Distal Radius Fracture - a Randomized Study.||University of Aarhus|No|Completed|January 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2010|April 9, 2010|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609479||161192|
NCT00609492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109621|Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.|Safety, Reactogenicity and Immunogenicity Following Booster Dose of GSK Biologicals´ Pneumococcal Conjugate Vaccine When Co-administered With a Booster Dose of Infanrix-IPV/Hib in Preterm Born Children at 16-18 Months of Age||GlaxoSmithKline||Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|245|||Both|16 Months|18 Months|Accepts Healthy Volunteers|||March 2011|January 12, 2012|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00609492||161191|
NCT00610688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA 03-103|Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants|High Prevalence of Rickets and Subclinical Maternal and Childhood Vitamin D Deficiency in the Middle East: a Randomized Controlled Trial of Prenatal Vitamin D Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants||Children's Hospital Medical Center, Cincinnati|Yes|Completed|January 2008|April 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|192|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|December 27, 2007|Yes|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT00610688||161100|
NCT00610701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1059937|Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures|Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures||University of Missouri-Columbia|No|Terminated|March 2006|February 2014|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|January 25, 2008||No|Extremely low enrollment and very little follow-up for meaningful data|No|April 10, 2014|https://clinicaltrials.gov/show/NCT00610701||161099|
NCT00610064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK80_05|Brain Effects of Sacral Neuromodulation|Brain Effects of Sacral Neuromodulation in Patients With Refractory Lower Urinary Tract Dysfunction||University Hospital Inselspital, Berne|No|Completed|October 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610064||161148|
NCT00610376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHS1|Jerusalem Handwashing Study|A Controlled Trial to Assess the Effect of a Health Promotion Intervention on Hygiene Behavior and Illness Absenteeism in Jerusalem Preschools|JHS|Hebrew University of Jerusalem|No|Completed|September 2000|December 2001|Actual|December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1029|||Both|3 Years|4 Years|Accepts Healthy Volunteers|||January 2008|September 21, 2015|January 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00610376||161124|
NCT00611000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582113|Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia|Effect of Folate on Colonic and Blood Cells||National Cancer Institute (NCI)||Completed|June 2003|||January 2006|Actual|Phase 1|Interventional|Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|20|||Both|40 Years|72 Years|No|||February 2008|February 14, 2009|February 7, 2008||||No||https://clinicaltrials.gov/show/NCT00611000||161076|
NCT00612079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97_PPI-P50|The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers|||University of Zurich|No|Completed|September 2007|November 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00612079||160994|
NCT00612339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001022|Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas|Avastin in Combination With Temozolomide for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas||Duke University|Yes|Completed|August 2007|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||September 2012|May 20, 2013|January 29, 2008|Yes|Yes||No|August 9, 2012|https://clinicaltrials.gov/show/NCT00612339||160974|
NCT00611832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA021307|Evaluation of a Video-Based Media Series to Promote Effective Parenting|Evaluation of a Video-Based Media Series to Promote Effective Parenting|ParentMedia|Oregon Research Institute|No|Completed|May 2008|March 2014|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|318|||Both|20 Years|N/A|No|||March 2014|March 27, 2014|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00611832||161013|
NCT00613106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-CA-304|Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)|Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)|HZ-CA-304|Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|September 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|179|||Both|40 Years|81 Years|No|||April 2013|April 23, 2013|January 28, 2008|Yes|Yes||No|May 23, 2011|https://clinicaltrials.gov/show/NCT00613106||160915|
NCT00613119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080066|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Neurological Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|January 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|195|||Both|35 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 9, 2016|February 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613119||160914|
NCT00612326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-024|Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging|Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging||Memorial Sloan Kettering Cancer Center||Completed|June 2004|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be recruited through the outpatient clinics of the Departments of Urology        and Medical Oncology of MSKCC.|December 2015|December 16, 2015|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612326||160975|
NCT00612560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 99507|Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics|Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis|FABrC|Roswell Park Cancer Institute|Yes|Completed|November 2007|April 2014|Actual|January 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|28|||Female|18 Years|85 Years|No|||May 2014|May 7, 2014|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612560||160957|
NCT00621088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17972|A Prospective Randomised Multicenter Study Comparing the Sliding Hip Screw and the Intertan Nail in Trochanteric and Subtrochanteric Femoral Fractures|A Prospective Randomised Multicenter Study Comparing the Sliding Hip Screw and the Intertan Nail in Trochanteric and Subtrochanteric Femoral Fractures||Haukeland University Hospital||Completed|February 2008|March 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|60 Years|N/A|No|||September 2010|September 12, 2010|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00621088||160317|
NCT00621361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00054|Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients|A Phase I, Multi-Centre, Open-Label, Dose Selection Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Etoposide and Cisplatin (EP) as First Line Therapy for Lung Cancer Patients With Extensive Stage or Metastatic Disease for Whom EP Would be a Standard Therapy||AstraZeneca|No|Completed|February 2008|February 2012|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621361||160297|
NCT00621855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.67|RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome|RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)||Boehringer Ingelheim||Completed|March 2008|||October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|1878|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|February 13, 2008||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00621855||160259|
NCT00622414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01062|Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors|A Phase I Study of VEGF Trap (NSC# 724770, IND# 100137) in Children With Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|April 2008|||February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|1 Year|21 Years|No|||October 2011|February 21, 2014|February 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622414||160218|
NCT00589485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-U-012|Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement|Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement||Biomet, Inc.|No|Withdrawn|November 2006|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include patients who require total knee replacement.|July 2015|July 28, 2015|December 21, 2007|No|Yes|Sponsor did not fund the study|No||https://clinicaltrials.gov/show/NCT00589485||162681|
NCT00589498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-03|Fat Gain and Cardiovascular Disease Mechanisms|Fat Gain and Cardiovascular Disease Mechanisms||Mayo Clinic|Yes|Completed|December 2005|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|69|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00589498||162680|
NCT00589511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORP5183|Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study|||Cochlear||Completed|October 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|69|||Both|1 Year|18 Years|No|Non-Probability Sample|Children with bilateral severe to profound sensorineural hearing loss who undergo        implantation with the Nucleus Freedom Cochlear Implant System|August 2014|August 7, 2014|December 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589511||162679|
NCT00589472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00238|Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer|Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET)|TARGET|National Cancer Institute (NCI)|Yes|Completed|November 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|19 Years|N/A|No|||November 2015|November 20, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589472||162682|
NCT00590096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC# 88-12-2|I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma|I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma||Children's Hospital Medical Center, Cincinnati|No|Completed|January 1991|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|1380|||Both|N/A|N/A|No|Non-Probability Sample|Patients with histologically proven neuroblastoma or pheochromocytoma or strong suspicion        of neuroblastoma or pheochromocytoma|January 2007|August 24, 2009|December 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00590096||162637|
NCT00590109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-029|Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer|Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 1997|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5600|Samples With DNA|blood samples|Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A list of Jewish women diagnosed with breast cancer at Memorial Hospital after January        1994 will be generated from the hospital database. Patients that meet the study criteria        will have a letter sent to their oncologist asking permission to invite the patient to        participate in a study.|January 2016|January 4, 2016|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590109||162636|
NCT00609193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BITREC - Project I|Functional and Neurochemical Brain Changes in First-episode Bipolar Mania|Functional and Neurochemical Brain Changes in First-episode Bipolar Mania Following Successful Treatment With Lithium or Quetiapine||University of Cincinnati|No|Completed|January 2008|July 2015|Actual|June 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|81|||Both|12 Years|35 Years|No|Probability Sample|You are being asked to take part in this research study because you have been diagnosed        with bipolar disorder and are currently experiencing mania. Mania is identified by periods        of extreme elation or irritability, excessive energy, racing thoughts, difficulty        sleeping, poor judgment and/or reckless behavior. Bipolar disorder is an illness in which        people experience mania as well as mood swings into depression. To participate in this        study you must be at least 12 years old and no older than 35.|December 2015|December 3, 2015|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00609193||161211|
NCT00610116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C007-CL-106002|Electronic Repositioning With Acuity and Easytrak Leads|Electronic Repositioning With Acuity and Easytrak Leads|ERACE|Guidant Corporation|No|Completed|September 2006|September 2009|Actual|March 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610116||161144|
NCT00610129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-162|Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)|A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)||Memorial Sloan Kettering Cancer Center||Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 24, 2008|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00610129||161143|
NCT00610077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LET/SPIL/03/06|Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility|An Open, Randomized, Parallel-Group, Multicentric, Comparative Study of Letrozole With Clomiphene Citrate for Induction of Ovulation in Anovulatory Infertility.||Sun Pharmaceutical Industries Limited|No|Completed|December 2004|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Female|20 Years|38 Years|No|||January 2008|February 6, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610077||161147|
NCT00610987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1089017|Antibiotic Prophylaxis in Orthopaedic Traumatology|Antibiotic Prophylaxis in Orthopaedic Traumatology: A Prospective, Randomized Trial of Duration of Administration||University of Missouri-Columbia|No|Completed|January 2008|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|January 24, 2008||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT00610987||161077|
NCT00610714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8180C00015|AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer|A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy|OVERT-1|AstraZeneca|No|Completed|April 2008|January 2012|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|211|||Female|18 Years|N/A|No|||December 2012|December 14, 2012|January 23, 2008||No||No|May 3, 2011|https://clinicaltrials.gov/show/NCT00610714||161098|
NCT00611299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC Vcap 01|Dose-Response Study of Probiotic Bacteria BB-12 and CRL-431 in Healthy Young Adults|Dose-Response Study of Probiotic Bacteria Bifidobacterium Animalis Subsp. Lactis BB-12 and Lactobacillus Paracasei Subsp. Paracasei CRL-341 in Healthy Young Adults||University of Copenhagen||Completed|April 2003|November 2003||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind||||71|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2002|March 17, 2008|January 28, 2008||||No||https://clinicaltrials.gov/show/NCT00611299||161054|
NCT00619944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR 003|Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir|Lumefantrine Pharmacokinetics When Administered as a Fixed Dose Combination With Artemether in HIV Positive Patients on Lopinavir/Ritonavir||Makerere University|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|32|||Both|18 Years|60 Years|No|||December 2010|December 3, 2010|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00619944||160405|
NCT00612586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10534|Phase 2 Study of Enzastaurin With 5 FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer|A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5 FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer.||Eli Lilly and Company|Yes|Completed|February 2008|November 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|January 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612586||160955|
NCT00620477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/068|Evaluation of Arthroscopic Reconstruction of the Anterior Cruciate Ligament by One Night Hospital Stay or by Day Surgery: a Randomised, Prospective Clinical Trial|Evaluation of Arthroscopic Reconstruction of the Anterior Cruciate Ligament by One Night Hospital Stay or by Day Surgery: a Randomised, Prospective Clinical Trial||University Hospital, Ghent|No|Recruiting|July 2008|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00620477||160364|
NCT00613379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 140 2301|PRO 140 by IV Administration in Adults With HIV-1 Infection|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of PRO 140 by Intravenous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection||CytoDyn, Inc.|No|Completed|December 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||July 2013|November 16, 2015|January 30, 2008|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00613379||160895|
NCT00613392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25038|Antioxidant Supplementation in Trauma Patients|Antioxidant Supplementation in Trauma Patients||Boston Medical Center|No|Terminated|November 2007|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|85 Years|No|||October 2010|January 25, 2016|January 30, 2008||No|Supplement expired and unable to obtain more from company manufacturing|No||https://clinicaltrials.gov/show/NCT00613392||160894|
NCT00621881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT3012-X-105|A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects|A Phase 1, Repeated-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Naproxcinod 750 mg Bid Administered to Patients With Impaired Hepatic Function Compared to Matching Healthy Subjects||NicOx|Yes|Completed|January 2008|||April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|February 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00621881||160257|
NCT00622128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC003|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients|PAVeD|VA Office of Research and Development|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|N/A|N/A|No|||October 2010|October 14, 2010|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00622128||160238|
NCT00619125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1782|Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stress, and Bloating in IBS Diarrhea and Constipation Symptoms Using a Palm Pilot|A Proposal to Evaluate Time-specific Relationships Between Variables of Pain, Stress, and Bloating in the Onset of IBS Diarrhea and Constipation Symptoms Using Ecological Momentary Assessment (EMA)||University of North Carolina, Chapel Hill|No|Completed|April 2008|April 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|85|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|80 male and female subjects will be recruited: 20 with IBS D; 20 with IBS C; 20 with IBS        M; 20 control (no bowel symptoms).        We will target patients who have maintained a diagnosis of IBS with Diarrhea (IBS-D), IBS        with Constipation (IBS-C, IBS with Mixed Stool pattern (IBS-M), using Rome III Criteria as        well as control subjects without bowel symptoms. Subject participation will be limited to        patients who maintain mild or moderate symptom severity score on the functional bowel        disorders severity index (FBDSI.) providing they have at least 3 symptom episodes of pain        or discomfort in a given week, to assure adequate data collection.|October 2011|October 19, 2011|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00619125||160468|
NCT00619138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17650|Treatment of Social Phobia and Panic Disorder in Adults|A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults|TSPPA|Haukeland University Hospital|No|Completed|March 2008|December 2015|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00619138||160467|
NCT00589524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007193|Comparison of Coronary CT With IVUS in Heart Transplant Population|Comparison of Non-invasive Coronary CT With IVUS for the Detection of Coronary Artery Vasculopathy in a Cardiac Transplant Population||Mayo Clinic|No|Withdrawn|November 2007|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|80 Years|No|||January 2012|January 12, 2012|December 21, 2007|Yes|Yes|Difficult recruitment -|No||https://clinicaltrials.gov/show/NCT00589524||162678|
NCT00589810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI-PB-HG-2007-064-KLW|NIH Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal|NIH Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal|CardioGene|The Cleveland Clinic|No|Enrolling by invitation|August 2007|April 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|Samples With DNA|DNA|Both|18 Years|N/A|No|Non-Probability Sample|Cleveland Clinic patients already enrolled in the GeneBank study who have had left heart        catheterization and bare metal stenting|December 2007|December 26, 2007|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00589810||162657|
NCT00590343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTK787/ZK222584|Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors|An Open-label Phase II Study Evaluating the Safety and Efficacy of PTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors That Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms.|PTK787|Louisiana State University Health Sciences Center in New Orleans|Yes|Completed|November 2004|October 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590343||162618|
NCT00610454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01166|Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures|Trial Evaluating the Safety and Tolerability of Levetiracetam Intravenous 15-minute Infusion, Administered in b.i.d. Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 65 Years Suffering From Partial Onset Seizures||UCB Pharma|No|Completed|June 2004|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|16 Years|65 Years|No|||September 2009|December 5, 2013|January 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610454||161118|
NCT00610467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI-HS-2006-5162|Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis|Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis||University of California, Irvine|No|Recruiting|October 2006|||July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Female|21 Years|90 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|January 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00610467||161117|
NCT00610428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-001-201|Staccato Prochlorperazine in Patients With Migraine Headache|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache||Alexza Pharmaceuticals, Inc.|No|Completed|March 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 28, 2008|January 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610428||161120|
NCT00610441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05805|Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)|A Double Blind, Placebo Controlled, Randomized, Two Period 4-Arm Trial to Investigate the Dose-Related Efficacy and Safety of Org 26576 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)||Merck Sharp & Dohme Corp.|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|67|||Both|18 Years|50 Years|No|||May 2015|May 13, 2015|January 28, 2008|Yes|Yes||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00610441||161119|
NCT00610389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2007-01|Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors|Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors||Clinica Universidad de Navarra, Universidad de Navarra|No|Recruiting|February 2008|December 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||May 2010|May 7, 2010|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610389||161123|
NCT00610402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2006-5691|Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)|Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)||University of California, Irvine|No|Completed|July 2007|June 2008|Actual|July 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|57|Samples Without DNA|blood sample tear drop sample|Both|N/A|N/A|No|Non-Probability Sample|community sample|August 2015|August 5, 2015|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00610402||161122|
NCT00610415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0023|Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study|Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study||Stanford University||Completed|December 2007|||October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples With DNA|Tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients will have a diagnosis of squamous cell carcinoma|January 2013|January 28, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00610415||161121|
NCT00610727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC 04-001|Staccato Prochlorperazine Single Dose PK|Tolerability, Safety and Pharmacokinetics of a Single Dose of Staccato™ Prochlorperazine for Inhalation in Normal, Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2008|April 27, 2009|January 28, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00610727||161097|
NCT00611845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13087|Aprotinin US Special Access Protocol|Aprotinin US Special Access Protocol: An Open Label, Non-Comparative Treatment Protocol for the Use of Aprotinin in Patients Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass Who Are at Increased Risk of Blood Loss and Transfusion||Bayer|No|No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||June 2014|June 20, 2014|January 29, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00611845||161012|
NCT00620789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003416|Behavioral Insomnia Therapy For Those With Insomnia and Depression|Behavioral Insomnia Therapy For Those With Insomnia and Depression||Ryerson University|No|Recruiting|March 2008|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|477|||Both|21 Years|64 Years|No|||May 2013|May 30, 2013|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00620789||160340|
NCT00620802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG106|Pharmacodynamics of CGT 2168 Compared With Plavix®|A Phase I, Open-Label, Randomized, Multiple-Dose, Two-Way Crossover Study of the Pharmacodynamics of CGT 2168 Compared With Plavix®||Cogentus Pharmaceuticals|No|Completed|November 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 22, 2008|February 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620802||160339|
NCT00620204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01-018|Efficacy Study of Atorvastatin to Treat Variant Angina|Efficacy Study of Atorvastatin to Treat Variant Angina|ESAVA|Samsung Medical Center|No|Recruiting|January 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|N/A|N/A|No|||April 2009|April 2, 2009|February 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00620204||160385|
NCT00621374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32022-A|Management of Pain in Persons With Multiple Sclerosis|Pilot Study of CBT and Self-hypnosis Training for Pain in Persons With Multiple Sclerosis||University of Washington|No|Completed|February 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621374||160296|
NCT00620776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802307|Combined Treatment for Generalized Anxiety Disorder (GAD)|Combined Treatment for Generalized Anxiety Disorder (GAD)||University of Pennsylvania|Yes|Active, not recruiting|September 2006|June 2008|Anticipated|June 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2008|October 28, 2008|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620776||160341|
NCT00621608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA011-0708-01|Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers|A Prospective, Double-blind, Randomized, Controlled Clinical Trial Comparing Standard Wound Care With Adjunctive Hyperbaric Oxygen Therapy (HBOT) to Standard Wound Care Only for the Treatment of Chronic, Non-healing Ulcers of the Lower Limb in Patients With Diabetes Mellitus.|HBOT|St. Joseph's Healthcare Hamilton|No|Completed|April 2008|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00621608||160278|
NCT00621621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-010|CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)|CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)|PS-010|Medtronic Atrial Fibrillation Solutions|No|Completed|December 2006|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|February 13, 2008|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00621621||160277|Slow enrollment in the trial showed limited the amount of available data. Detailed subject data from the published literature was not available.
NCT00618813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS07P1|Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors|A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents With an Interval Compression Schedule in Newly Diagnosed Patients With Localized Ewing Sarcoma Family of Tumors||Children's Oncology Group|Yes|Completed|March 2008|||March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|30 Years|No|||September 2014|September 11, 2014|February 19, 2008|No|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00618813||160491|
NCT00618826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF3734s/B9E-US-I158|A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer|A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin as Frontline Therapy for Metastatic Breast Cancer||University of Cincinnati|No|Terminated|November 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||August 2010|August 27, 2010|February 7, 2008|Yes|Yes|PI left institution|No||https://clinicaltrials.gov/show/NCT00618826||160490|
NCT00619151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVSS-1H|CarboMedics Top Hat vs St. Jude Medical Regent Valve Comparing Sizing and Hemodynamics|A Randomized Study to Compare Sizing, Implant Techniques, & Hemodynamic Performance Between the CarboMedics Supra-annular Top Hat Valve and the St. Jude Medical Regent Valve in the Aortic Position.||Sorin Group USA, Inc.|No|Terminated|December 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|2|||Both|18 Years|N/A|No|||September 2011|November 7, 2011|January 10, 2008||No|Study stopped due to lack of elegible patient enrollment|No|June 7, 2011|https://clinicaltrials.gov/show/NCT00619151||160466|Early termination due to low enrollment resulted in only 2 patients. Insufficient data for analysis.
NCT00589537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-NCRI-TRISST-TE24|Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle|Trial of Imaging and Schedule in Seminoma Testis||National Cancer Institute (NCI)||Recruiting|March 2008|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|||Anticipated|660|||Male|16 Years|N/A|No|||July 2009|August 6, 2013|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00589537||162677|
NCT00589823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPO44/06/FCNS|Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids|A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Fentanyl Citrate Nasal Spray Compared to Immediate Release Morphine Sulphate in the Treatment of BTCP in Subjects Taking Regular Opioid Therapy||Archimedes Development Ltd|No|Completed|June 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|135|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589823||162656|
NCT00621998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH-91-02|Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia|A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia||Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan|Yes|Completed|July 2000|June 2004|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||February 2000|February 13, 2008|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00621998||160248|
NCT00609791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07157|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer|Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics||City of Hope Medical Center|Yes|Active, not recruiting|January 2008|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|120 Years|No|||January 2016|January 6, 2016|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00609791||161169|
NCT00609804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 162|Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib|Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib||SCRI Development Innovations, LLC|No|Completed|March 2008|November 2014|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 24, 2008|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT00609804||161168|
NCT00609817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-CS009|Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma|An Open-Label Phase 1/2 Study of the Safety and Efficacy of GCS-100 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma||La Jolla Pharmaceutical Company|Yes|Terminated|May 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|January 24, 2008|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00609817||161167|
NCT00611585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHR|A Safety and Efficacy Study of the Birmingham Hip Resurfacing System|Birmingham Hip Resurfacing System (BHR) Post Approval Study: A Prospective, Multi-Centered Study of the Birmingham Hip Resurfacing System|BHR|Smith & Nephew, Inc.|No|Active, not recruiting|September 2006|December 2026|Anticipated|December 2026|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|359|||Both|21 Years|75 Years|No|||February 2016|February 23, 2016|January 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00611585||161032|
NCT00610753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12132007-933|Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa|Family Therapy in the Treatment of Adolescent Anorexia Nervosa||Stanford University|Yes|Completed|July 2006|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|12 Years|18 Years|No|||February 2013|February 7, 2013|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00610753||161095|
NCT00610740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS071|CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer|WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer||Masonic Cancer Center, University of Minnesota|Yes|Completed|July 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|February 7, 2008|Yes|Yes||No|May 19, 2010|https://clinicaltrials.gov/show/NCT00610740||161096|
NCT00611013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI-HS-2002-2611|Magnetic Resonance Imaging and Spectroscopy at High Field|Magnetic Resonance Imaging and Spectroscopy at High Field||University of California, Irvine|No|Withdrawn|June 2002|||July 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|January 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00611013||161075|
NCT00619645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583059|Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers|Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan||University of California, Davis|Yes|Completed|June 2007|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619645||160428|
NCT00621140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.16|Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control|A Randomised, Double-blind, Placebo-controled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or Previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycemic Control||Boehringer Ingelheim||Completed|February 2008|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|503|||Both|18 Years|80 Years|No|||January 2014|January 22, 2014|January 14, 2008||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00621140||160314|
NCT00621387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-853-93|Study of Long-Term Antibiotic Treatment in Reactive Arthritis|Double-Blind, Placebo-Controlled Study of Three-Month Treatment With the Combination of Ofloxacin and Roxithromycin in Recent-Onset Reactive Arthritis||Helsinki University|No|Completed|November 1993|June 1998|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||November 2007|February 11, 2008|February 11, 2008||||No||https://clinicaltrials.gov/show/NCT00621387||160295|
NCT00621101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eze-Siro|Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects|Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects||University Medicine Greifswald|No|Completed|April 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 12, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621101||160316|
NCT00621400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 07/7-G|Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis|A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination With Melphalan and Dexamethasone in Subjects With Newly-diagnosed Light-chain (AL)-Amyloidosis||Nantes University Hospital|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|70 Years|No|||May 2010|May 9, 2011|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621400||160294|
NCT00622141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 038|Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®|Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir® in Thai Healthy Volunteers||The HIV Netherlands Australia Thailand Research Collaboration|No|Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|February 12, 2008||No|The study was never started because the sponsor decided not to manufacture the investigational    product.|No||https://clinicaltrials.gov/show/NCT00622141||160237|
NCT00622427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F071204001|Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia|Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia||University of Alabama at Birmingham|No|Completed|February 2008|December 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|19 Years|65 Years|No|||April 2013|April 2, 2013|February 13, 2008||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00622427||160217|
NCT00618254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAN-T1-PVFS-1|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|March 2005|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 18, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00618254||160533|
NCT00618514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0407|The BRILLIANT Study|Comparative Evaluation of the FDA-Cleared Bright Tip Laser Fiber Versus Commercially Available Bare Laser Fiber (the Control) in the Treatment of Reflux in the Greater Saphenous Vein (GSV) Using Endovenous Laser Therapy|BRILLIANT|Vascular Solutions, Inc|No|Terminated|June 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|93|||Both|18 Years|N/A|No|||June 2013|March 20, 2015|February 6, 2008||No|Sponsor decision|No|January 26, 2010|https://clinicaltrials.gov/show/NCT00618514||160514|Due to budgetary constraints, enrollment in the BRILLIANT trial was ended after 90 subjects (110 limbs) were enrolled in the study. This study had an insufficient sample size to perform the planned formal statistical hypothesis testing.
NCT00618527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H0039|Combination Therapy Using Cellcept and Rebif in RRMS|Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis||Ohio State University|Yes|Completed|August 2006|May 2012|Actual|May 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||November 2012|November 14, 2012|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00618527||160513|
NCT00589849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-13651|T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy|T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy||Creighton University|No|Completed|May 2006|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|19 Years|N/A|No|Non-Probability Sample|Hospitalized patients|September 2011|September 2, 2011|December 28, 2007||No||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00589849||162654|
NCT00589862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-14622|Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents|||Creighton University||Withdrawn|October 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|N/A|No|||November 2015|November 27, 2015|December 28, 2007|Yes|Yes|Failure to secure adequate funding|No||https://clinicaltrials.gov/show/NCT00589862||162653|
NCT00589836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 05-023|Assessment of Left Ventricular Torsion by Echocardiography Study|Assessment of LV Torsion by Tissue Doppler Echocardiography|LVTorsion|The Cleveland Clinic|No|Active, not recruiting|June 2005|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing cardiac echocardiography testing in the outpatient department|June 2008|October 22, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00589836||162655|
NCT00622310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0402|Energy Expenditure & Activity During & After Exercise-Induced Weight Loss|Energy Expenditure & Activity During & After Exercise-Induced Weight Loss||University of Colorado, Denver|No|Active, not recruiting|September 2007|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00622310||160226|
NCT00609830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arthritis Foundation|GIOP Prevention Among People With Rheumatoid Arthritis|Osteoporosis Prevention Among People With Rheumatoid Arthritis Receiving Oral Glucocorticoid Therapy||University of North Carolina, Chapel Hill|No|Completed|July 2001|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|273|||Both|18 Years|N/A|No|||January 2008|June 12, 2015|January 24, 2008||||No||https://clinicaltrials.gov/show/NCT00609830||161166|
NCT00610142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-OCT-AD-025|Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis|Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis|OCT-AD|Technische Universität Dresden|No|Completed|December 2007|January 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||June 2014|June 10, 2014|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610142||161142|
NCT00619073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPFS 2008-1|PACT (Platelet Activity After Clopidogrel Termination)|PACT (Platelet Activity After Clopidogrel Termination)|PACT|University of Massachusetts, Worcester|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|February 6, 2008|Yes|Yes||No|January 10, 2012|https://clinicaltrials.gov/show/NCT00619073||160472|
NCT00612092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00308|Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A Sequential Scan Protocol|Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A Sequential Scan Protocol|PROTECTION-III|Deutsches Herzzentrum Muenchen|Yes|Recruiting|May 2008|February 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||August 2008|August 26, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612092||160993|
NCT00611026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221046|Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.|12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder.||Pfizer|No|Completed|February 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|2417|||Both|18 Years|N/A|No|||January 2011|January 28, 2011|January 28, 2008|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00611026||161074|
NCT00611312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIRG-07-57789|Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease|Effects of Intense Cognitive Training on Standardized Measures of Cognition in Those With Very Mild Alzheimer's Disease||University of Kansas Medical Center|No|Completed|February 2008|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|60 Years|N/A|No|||October 2012|October 2, 2012|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611312||161053|
NCT00611572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508000517|GABA-glutamate Interactions and Psychosis|Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction||Yale University|No|Active, not recruiting|January 2007|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|15|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|January 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00611572||161033|
NCT00619346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05-013|Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects|Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects||Immtech Pharmaceuticals, Inc|No|Terminated|November 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 6, 2013|February 8, 2008|No|Yes|FDA Full Clinical Hold due to safety concerns, as of 12/21/07|No||https://clinicaltrials.gov/show/NCT00619346||160451|
NCT00620490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4068|Paravertebral Analgesia Associated With Intravenous Morphine PCA After Thoracotomy|Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia : Paravertebral Analgesia With a Catheter Associated With Intravenous Morphine Patient-controlled-analgesia (Pca)||University Hospital, Strasbourg, France|No|Completed|March 2008|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|80 Years|No|||March 2008|June 25, 2010|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00620490||160363|
NCT00621894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L4665-03|Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation|A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension||GlaxoSmithKline|No|Completed|March 2008|May 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||August 2011|July 26, 2012|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00621894||160256|
NCT00622167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001842|Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease|Comparison of Dual Source Computed Tomography (DSCT) With Integrated Backscatter Intravascular Ultrasound (IB-IVUS) and Contrast Angiography in the Assessment of Coronary Artery Disease||Massachusetts General Hospital|No|Terminated|January 2008|June 2009|Actual|April 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|February 12, 2008|Yes|Yes|Subject recruitment was slow, so enrollment has been closed.|No|July 28, 2011|https://clinicaltrials.gov/show/NCT00622167||160236|Study terminated after imaging 4 subjects due to slow enrollment. Results will not be analyzed.
NCT00622440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRC 5031|Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream|Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream|AIJP|University of California, San Francisco|Yes|Completed|March 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|February 13, 2008|Yes|Yes||No|July 17, 2014|https://clinicaltrials.gov/show/NCT00622440||160216|
NCT00618267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-07-NAT|ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.|Single Center, Pilot Study to Measure ATP Expression in Lymphocytes of MS Patients Undergoing Various Therapies by Means of Using the "ImmuKnow®" Test|Cylex|Biogen|Yes|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|About 1 ½ teaspoons of blood will be drawn.|Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with Multiple Sclerosis|March 2010|March 4, 2010|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00618267||160532|
NCT00619450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dyna 3D C-Arm|Siemens 3-D C-Arm CT of the Heart Chambers|Three Dimensional C-Arm Computed Tomography of the Heart Chambers|DynaC-Arm|The Cleveland Clinic|No|Recruiting|August 2007|October 2008|Anticipated|May 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female over age of 18 years and under 250 pounds undergoing a pulmonary vein        isolation or implantation of cardiac pacemaker at the Cleveland Clinic.|February 2008|February 19, 2008|February 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619450||160443|
NCT00619463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R49CE001171-01|Effects of Aerobic Exercise on Cognition, Mood and Fatigue Following TBI|Effects of Aerobic Exercise on Cognition, Mood and Fatigue Following TBI||Icahn School of Medicine at Mount Sinai|No|Completed|August 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00619463||160442|
NCT00619476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110748|A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)|Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)||XenoPort, Inc.|No|Completed|February 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|376|||Both|18 Years|N/A|No|||January 2013|July 15, 2013|February 7, 2008|Yes|Yes||No|April 26, 2011|https://clinicaltrials.gov/show/NCT00619476||160441|
NCT00618839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRATA2001|StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects|Open-Label, Controlled, Randomized, Comparative, Dose Escalation Study Of The Safety, Human Immunology, And Efficacy Of StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects In Patients Undergoing Sequential Skin Reconstruction Procedures||Stratatech|Yes|Completed|July 2006|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|February 7, 2008|Yes|Yes||No|May 8, 2009|https://clinicaltrials.gov/show/NCT00618839||160489|
NCT00619164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5555-J081-207|A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome|A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome||Eisai Inc.||Completed|November 2007|||September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|240|||Both|45 Years|80 Years|No|||February 2010|May 9, 2013|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00619164||160465|
NCT00621517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETSU-07-061f|Bupropion and Restless Legs Syndrome|Bupropion and Restless Legs Syndrome||East Tennessee State University|No|Completed|February 2008|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 4, 2012|February 12, 2008|Yes|Yes||No|March 4, 2012|https://clinicaltrials.gov/show/NCT00621517||160285|Possible Type II error as we were unable to recruit our target of 100 participants.
NCT00621764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC01|Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children|A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children||Sanofi|Yes|Completed|March 2008|May 2013|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|300|||Both|12 Months|5 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|February 12, 2008||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT00621764||160266|
NCT00590122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-19596|Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study|COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL||Baylor College of Medicine|No|Completed|October 2006|November 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|31 Years|80 Years|No|||March 2009|March 12, 2009|December 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00590122||162635|
NCT00618137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-AUVA|Inert Dusts and Pathology of Chronic Obstructive Pulmonary Disease|Longitudinal Assessment of Clinical and Molecular Pathology of Chronic Obstructive Lung Disease and the Possible Influence of Inert Dusts in Working Volunteers of the Greater Vienna Area||Medical University of Vienna|Yes|Completed|January 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|Samples With DNA|Transbronchial lung biopsies Blood serum|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Community sample of workers from the greater Vienna area|August 2012|August 23, 2012|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00618137||160541|
NCT00618150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sak 33-96 (REK)|Patient Education in Gastroesophageal Reflux Disease|Patient Education in Gastroesophageal Reflux Disease||Norwegian University of Science and Technology|No|Completed|September 1996|||December 1999|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|211|||Both|20 Years|75 Years|No|||February 2008|February 5, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00618150||160540|
NCT00610155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081173|A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients|A Methodology Study To Assess The Feasibility Of Using Functional Magnetic Resonance Imaging (fRMI) To Quantify The Effects Of Analgesic Drugs In Post-Traumatic Neuropathic Pain Subjects||Pfizer|No|Completed|September 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|75 Years|No|||September 2013|September 19, 2013|January 14, 2008|No|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00610155||161141|Results for primary outcome, BOLD activation signals(whole brain) was not available to reported, as DMAa, DMAc, TH and VIS were captured as COPE images only, which could not be included in basic results format.
NCT00619671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RituxanMGPilot|A Pilot Trial of Rituxan in Refractory Myasthenia Gravis|Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.||University of Vermont|Yes|Completed|April 2004|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2013|January 15, 2013|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619671||160426|
NCT00619359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-017|Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)|Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability & Efficacy of a Single Dose of Intravenous MK0517 for Prevention of Chemotherapy-Induced Nausea & Vomiting Associated With Cisplatin Chemo|EASE|Merck Sharp & Dohme Corp.||Completed|February 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2322|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|January 28, 2008|Yes|Yes||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00619359||160450|
NCT00619372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YI002-HMO-CTIL|Oral OKT3 in Combination With Beta-D-Glucosylceramide|Administration of Anti-CD3 (OKT3) in Combination With Beta-D-Glucosylceramide||Hadassah Medical Organization|Yes|Active, not recruiting|January 2008|June 2008|Anticipated|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|February 3, 2009|February 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00619372||160449|
NCT00612352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0304025194|Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism|Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism||Yale University|Yes|Completed|March 2001|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|182|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00612352||160973|
NCT00620217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBZ-KBN-099/P05/01|Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial|Therapeutic Angiogenesis Using Human VEGF-A165/bFGF Plasmid Injected Percutaneously Into the Ischemic Myocardium of "No-option" Coronary Artery Disease Patients; Double-blind Placebo Controlled Study|VIF-CAD|Institute of Cardiology, Warsaw, Poland|Yes|Completed|December 2004|May 2009|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||November 2009|November 27, 2009|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620217||160384|
NCT00620230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAK694A2102|Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects|A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Profile and Pharmacodynamic Effect of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects||Novartis|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|46|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|February 7, 2008||Yes||||https://clinicaltrials.gov/show/NCT00620230||160383|
NCT00615966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAV-CL002|Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients|A Phase 2, Two-Part Study of the Safety and Tolerability of Diannexin in Kidney Transplant Recipients||Alavita Pharmaceuticals Inc|Yes|Completed|February 2008|February 2010|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|58|||Both|21 Years|70 Years|No|||June 2011|June 24, 2011|February 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00615966||160706|
NCT00615979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOD-5279|Far Forward Battlefield Telemedicine: Evaluation of Handheld Ultrasound|Far Forward Battlefield Telemedicine:Ultrasound Guidance System (UGS)|DOD|The Cleveland Clinic|No|Active, not recruiting|March 2003|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|echocardiogram clinical schedule|December 2007|February 13, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00615979||160705|
NCT00616330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBC-302-602-622467|Vaginal Infection Study|||Lumara Health, Inc.||Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1443|||Female|16 Years|N/A|No|||February 2012|February 29, 2012|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616330||160678|
NCT00616577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57235|Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine|Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine: A Prospective, Randomized, Double-blinded, Controlled Study||Loma Linda University|No|Terminated|October 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|26|||Both|N/A|2 Years|No|||April 2015|April 2, 2015|February 4, 2008|Yes|Yes|PI is no longer here.|No|April 2, 2015|https://clinicaltrials.gov/show/NCT00616577||160660|
NCT00616551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2L-OCT-01 PR-301|Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients|Open Label, Randomized Study Comparing the Biological Efficacy & Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients||Ambrilia Biopharma, Inc.|No|Completed|April 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|65 Years|No|||October 2008|October 7, 2008|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616551||160662|
NCT00617682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC005974-03|Maternal Immunization To Prevent Infant Otitis Media|Maternal Immunization To Prevent Infant Otitis Media||National Institute on Deafness and Other Communication Disorders (NIDCD)|Yes|Completed|October 2000|December 2004|Actual|December 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|153|||Female|18 Years|N/A|No|||February 2008|February 14, 2008|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617682||160576|
NCT00617916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001|Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers|Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers||HyperMed|No|Completed|March 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|256|||Both|21 Years|85 Years|No|Probability Sample|Clinic population - diabetic patients at high risk for ulceration|June 2009|June 2, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617916||160558|
NCT00610532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0170|Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy|Evaluating Transporter Protein Inhibitors in Patients With Epilepsy||Ohio State University|No|Terminated|March 2006|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|January 28, 2008|Yes|Yes|Investigators decided not to continue|No|December 6, 2012|https://clinicaltrials.gov/show/NCT00610532||161112|problems with measurement led to uninterpretable data
NCT00617383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0327|AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS|Determine if the Presence of Characteristic MS-like Lesion(s) on Baseline MRI Predisposes to CIS/MS in Female MZ Twins Discordant for CIS/MS.|ARMS|The University of Texas Health Science Center, Houston|No|Completed|February 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples Without DNA|blood for serum and peripheral mononuclear cells; optional CSF - cerebrospinal fluid at      entry and exit from trail|Female|10 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|female monozygotic twins discordant for CIS/MS|February 2012|February 21, 2012|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617383||160598|
NCT00614003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-01-07-09|Evaluation of an Intervention Designed to Enhance the Quality of Decision Support Provided to Patients Making Decisions About End-of-life Place of Care|Efficacy of a Training Intervention on the Quality of Case Coordinators and Nurses' Decision Support for Patients Deciding About the Place of Care at the End Of-Life: A Randomized Control Trial||Ottawa Hospital Research Institute|No|Completed|April 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|90|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00614003||160851|
NCT00614016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQP 2007-001|A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers|A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers||HemaQuest Pharmaceuticals Inc.|No|Completed|January 2008|June 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 1, 2008|January 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614016||160850|
NCT00614029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX001-0601|A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System|A Randomized, Open-Label, Single-Dose, Four-way Crossover Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System Versus IMITREX STATdose at Three Injection Sites in Healthy Adults||Zogenix, Inc.|Yes|Completed|December 2006|||December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614029||160849|
NCT00614289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0347|Novel Topical Treatment of Hand Dermatitis (Eczema)|Phase 1 Study to Demonstrate Efficacy of Epikeia Coatings in a Human Clinical Trial||Biomedical Development Corporation|No|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2008|March 4, 2010|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614289||160831|
NCT00614302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.130|Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population|Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Patient Population||Boehringer Ingelheim||Completed|June 2007|||October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|428|||Both|18 Years|N/A|No|Non-Probability Sample|HIV patients|October 2009|October 1, 2009|January 31, 2008||||No||https://clinicaltrials.gov/show/NCT00614302||160830|
NCT00614315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-07-001|FLAIR™ Delivery System Study|A Prospective Observational Study of the FLAIR™ Endovascular Stent Graft Optimized Delivery System|FLAIR DS|C. R. Bard|No|Completed|December 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2010|October 20, 2010|December 18, 2007|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00614315||160829|
NCT00614653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0044|Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer|Phase I Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2008|||January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|January 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614653||160805|
NCT00620035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05702|A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)|An Open-Label, Non-Controlled Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator||Merck Sharp & Dohme Corp.|No|Completed|March 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|301|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|February 11, 2008|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00620035||160398|
NCT00620308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-005523|CD-NP in Subjects With Stable Chronic Heart Failure|A Human Physiologic Study to Evaluate the Renal and Neurohumoral Effects of a Novel Chimeric Natriuretic Peptide, CD-NP, in Subjects With Stable Chronic Heart Failure|CD-NP|Mayo Clinic|Yes|Completed|June 2008|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|19|||Both|21 Years|N/A|No|||August 2012|September 7, 2012|February 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620308||160377|
NCT00620321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11631|A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open-Label Phase 2 Trial of LY2181308 Sodium Administered in Combination With Idarubicin and Cytarabine to Patients With Refractory or Relapsed Acute Myeloid Leukemia||Eli Lilly and Company|No|Completed|March 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620321||160376|
NCT00620334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLES|Predicting the Diagnosis of Asthma|Predicting the Diagnosis of Asthma Based on History||University of South Florida|No|Completed|February 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male or female Females are eligible to participate only if they are currently non-pregnant        and non-lactating. All premenopausal women will undergo a urine pregnancy test at the        beginning of the study. Female subjects should not be enrolled if they plan to become        pregnant during the time of the study.|July 2008|August 9, 2010|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00620334||160375|
NCT00613249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 012|A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels|A Double-Blind, Randomized, Placebo-Controlled Phase I Study to Compare the Pharmacokinetics of Intravaginal Dapivirine Gel 4750, 0.05%, 2.5g and Dapivirine Gel 4789, 0.05%, 2.5g Formulations and to Assess the Safety as Compared to the Intravaginal HEC-Based Universal Placebo Gel, 2.5g in Healthy HIV-Negative Women.||International Partnership for Microbicides, Inc.|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|36|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2009|March 26, 2009|January 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613249||160905|
NCT00613262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR0002|A Prospective, Single Blinded Study for Predicting Colon Polyp Histology With Narrow Band Imaging|A Prospective, Single Blinded Study for Predicting Colon Polyp Histology With Narrow Band Imaging|NBI|Midwest Biomedical Research Foundation|Yes|Recruiting|April 2012|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|April 6, 2012|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613262||160904|
NCT00614159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5545UMU|Ketamine Compared to Propofol for Pediatric GI Endoscopy|||State University of New York - Upstate Medical University|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|34|||Both|1 Year|10 Years|No|Probability Sample|Pre-op setting, previously scheduled for GI Endoscopy|June 2009|June 30, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614159||160839|
NCT00614796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COACH|A Structured Lifestyle Intervention on Daily Physical Activity Level in COPD|A Study Evaluating the Effects of a Structured Lifestyle Intervention on Daily Physical Activity Level of COPD Patients in the First, Second and Third Echelon.|COACH|Groningen Research Institute for Asthma and COPD|No|Completed|November 2006|November 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|155|||Both|40 Years|80 Years|No|||November 2010|March 23, 2012|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614796||160795|
NCT00615433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050231|Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia|A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia.||Sunovion|Yes|Completed|January 2008|January 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|478|||Both|18 Years|75 Years|No|||May 2015|May 19, 2015|February 1, 2008|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT00615433||160746|
NCT00615446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181041|A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors|A Phase 1 Study Of SU011248 And Gemcitabine In Patients With Advanced Solid Tumors||Pfizer|No|Completed|March 2005|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||April 2010|April 29, 2010|February 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00615446||160745|
NCT00615706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|345-2004|Study to Evaluate the Impact of Obesity on Airway Inflammation and Mechanics in Asthmatics||ABI/BALA|Emory University|No|Completed|January 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|300|Samples With DNA|Serum, urine, DNA, exhaled breath condensate. For substudy participants, bronchoalveolar      lavage samples.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asthmatics and healthy volunteers|September 2008|September 22, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00615706||160726|
NCT00615992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.398|Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines|Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines||Boehringer Ingelheim||Completed|April 2007|||April 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|754|||Both|40 Years|N/A|No|Probability Sample|primary care|January 2016|January 13, 2016|January 24, 2008||||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00615992||160704|
NCT00616564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL0105|Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma|Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma||Mt. Sinai Medical Center, Miami|Yes|Completed|February 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|16 Years|90 Years|No|||May 2012|May 2, 2012|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616564||160661|
NCT00613405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#17195|Stress and Marijuana Cue-elicited Craving and Reactivity|Stress and Marijuana Cue-elicited Craving and Reactivity||Medical University of South Carolina|No|Completed|January 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|87|||Both|18 Years|65 Years|No|||April 2013|April 23, 2013|February 11, 2008||No||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00613405||160893|A control group of non-marijuana dependent individuals was not included, which may have provided further insight into the interactions of stress and cues both in the presence and absence of addiction.
NCT00613418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-1 - US|Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac Artery|Comparative Study of Safety and Efficacy of the SUPERA® Wire Interwoven Self-expanding Nitinol Stent and Currently Approved Stents for Patients With Iliac Lesions|I-WIN|IDev Technologies, Inc.|Yes|Withdrawn||||||Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00613418||160892|
NCT00609310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flav-Hoe-CCR|Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence|Dietary Supplementation With Bioflavonoids for the Prevention of the Recurrence of Neoplasia in Patients With Resected Colorectal Carcinoma||Technische Universität Dresden|No|Suspended|May 2015|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|382|||Both|50 Years|75 Years|No|||February 2012|February 2, 2012|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609310||161205|
NCT00609323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-403|Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)|A Randomized, Double-Blind, Crossover Study Comparing Pliaglis™ (Lidocaine and Tetracaine) Cream 7%/7% to Placebo Cream When Applied for 60 Minutes in the Treatment of Patients With Postherpetic Neuralgia||ZARS Pharma Inc.|No|Completed|January 2008|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00609323||161204|
NCT00610545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCM-UNICAMP - 620/2006|Atorvastatin in Perioperative Vascular Surgery - Pilot Study|Atorvastatin 80mg Versus Atorvastatin 20mg in Perioperative Vascular Surgery to Evaluate Cardiovascular Outcomes|APVS|University of Campinas, Brazil|Yes|Completed|July 2007|December 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|90 Years|No|||February 2009|February 13, 2009|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610545||161111|
NCT00610558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI-HS-2003-3252|Neocortical Epilepsies - Do They Progress?|Neocortical Epilepsies - Do They Progress?||University of California, Irvine|No|Completed|July 2003|September 2010|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|January 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00610558||161110|
NCT00610571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003970|Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas|Phase I Trial of Oral Topotecan Plus Temodar in the Treatment of Patients With Malignant Gliomas||Duke University|Yes|Completed|April 2004|April 2012|Actual|September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|January 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610571||161109|
NCT00609882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24721|Comparison of Humidified High Flow Nasal Cannula to Nasal CPAP in Neonates|Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates|HHFNC|University of Utah|Yes|Completed|December 2007|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|420|||Both|N/A|8 Weeks|No|||February 2013|February 5, 2013|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609882||161162|
NCT00609895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4038|The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing|The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing||Sanofi||Completed|January 2004|August 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|6 Years|75 Years|No|||March 2008|March 26, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609895||161161|
NCT00610181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0736|Magnetic Resonance Imaging in Patients With Breast Cancer|Magnetic Resonance Imaging (MRI) for Preoperative Staging of Patients With Invasive Lobular Carcinoma of the Breast||M.D. Anderson Cancer Center|No|Completed|January 2008|||June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|96|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with invasive lobular cancer of the breast.|June 2015|June 29, 2015|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610181||161139|
NCT00610506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7842|Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features|A Pilot Study -- An Open-Label, Rater-blinded, Flexible-dose, 8-week Trial of Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features.||Duke University|No|Completed|October 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||January 2008|May 30, 2013|January 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610506||161114|
NCT00611091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12603|Improving Posthospital Medication Management of Older Adults Through Health IT|Improving Posthospital Medication Management of Older Adults Through Health IT||University of Massachusetts, Worcester|No|Completed|August 2010|September 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|5077|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 12, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611091||161069|
NCT00620061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBD06S1|Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone|A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction||Sucampo Pharma Americas, LLC||Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|440|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|February 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00620061||160396|
NCT00620347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-285|Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer|A Phase II Study of Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer.||National Cancer Center, Korea|Yes|Completed|March 2008|September 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00620347||160374|
NCT00620620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-007-101|Staccato Zaleplon Single Dose PK|Safety, Tolerability, and Pharmacokinetics of a Single Dose of Staccato® Zaleplon for Inhalation in Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 13, 2013|February 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620620||160353|
NCT00620633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-055|Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation|A Phase I Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|February 2008|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|February 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00620633||160352|
NCT00620932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002501|Exercise Training Among Men With Prostate Cancer|Feasibility of Endurance Exercise Training on Cardiovascular Risk Factors Following Radical Prostatectomy Among Men With Localized Prostate Cancer; A Community-Based Intervention||Duke University|No|Withdrawn|January 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Male|18 Years|N/A|No|||October 2013|October 25, 2013|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00620932||160329|
NCT00609453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2605|Brain Imaging of Psychotherapy for Depression|Brain Imaging of Psychotherapy for Depression (Includes, "Reward System Recovery Following Behavioral Activation Therapy in Depression")||University of North Carolina, Chapel Hill|No|Completed|October 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 5, 2012|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609453||161194|
NCT00609752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_06_266|Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease|Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease||University Hospital Birmingham|Yes|Recruiting|February 2008|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|7 Years|17 Years|No|||December 2008|December 29, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609752||161172|
NCT00610025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOTES Trocar Study|Minimally Invasive Trocar Placement in Obesity Surgery|Transgastric Peritoneoscopy for Evaluation of the Abdominal Wall to Direct Laparoscopic Trocar Placement||Ohio State University|No|Completed|July 2007|November 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|60|||Both|18 Years|65 Years|No|||February 2013|February 11, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00610025||161151|
NCT00614471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20742|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.|A Randomized, Open Label Study of the Effect of Peginterferon Alfa-2a (40KD) (PEGASYS®) Plus Entecavir (Baraclude®) Combination Therapy on Quantitative Changes in HBeAg in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B||Hoffmann-La Roche||Completed|August 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|219|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00614471||160817|
NCT00614484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR #49168|Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer|Phase I/II Study of Combined Chemotherapy and High Dose, Accelerated Proton Radiation for the Treatment of Locally Advanced Non-Small Cell Lung Carcinoma||Loma Linda University|Yes|Terminated|August 1999|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|December 26, 2007||No|Low participant enrollment rates. Significant comparative data not obtained.|No|July 16, 2013|https://clinicaltrials.gov/show/NCT00614484||160816|Slow enrollment over a long time period limits the conclusions that can be drawn.
NCT00615082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT003654-01A1|The Balance Study Balancing Life and Reducing Stress For Those Providing Elder Care|Stress Reduction for Caregivers: A Randomized Controlled Pilot Study|Balance|HealthPartners Institute|Yes|Completed|February 2007|March 2011|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|78|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 6, 2011|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615082||160773|
NCT00615095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-012|Differential Risks for Melanoma: p16 and DNA Repair|Differential Risks for Melanoma: p16 and DNA Repair||Memorial Sloan Kettering Cancer Center||Completed|February 1997|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|323|Samples With DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Second or multiple primary melanoma cases will be identified at Memorial Sloan-Kettering        Cancer Center, the Yale University Pigmented Lesion Clinic, or from among those subjects        who participated in the earlier case-control study in Connecticut.        First primary melanoma cases will be identified and referred to the study staff by        participating physicians on the Melanoma Disease Management Team at Memorial        Sloan-Kettering Cancer Center.        Random digit dialing will be used to locate 100 population-based controls for this study.        We will use telephone prefixes in Connecticut|April 2011|April 19, 2011|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615095||160772|
NCT00615472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA4885|Intravenous Versus Inhalational Anesthesia in Parkinson's Disease|Intravenous General Anesthesia Versus Inhalational General Anesthesia in Parkinson's Disease||Columbia University|No|Terminated|October 2003|April 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|58|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|January 9, 2008||No|Lack of funding|No|June 2, 2015|https://clinicaltrials.gov/show/NCT00615472||160743|
NCT00615719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061756|Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation|Utility of 64-slice Multidetector CT Coronary Angiography in the Evaluation of Low to Intermediate Risk ED Patients|EDCCTA|Virginia Commonwealth University|No|Terminated|October 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency Department patients with chest pain considered suspicious for acute coronary        syndrome, who were to undergo standard nuclear perfusion imaging as part of their standard        care.|December 2011|December 7, 2011|December 25, 2007||No|Enrollment rate was too slow.|No|August 15, 2011|https://clinicaltrials.gov/show/NCT00615719||160725|Early termination leading to small numbers of subjects analyzed
NCT00616005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012939|Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide|Phase II Treatment of Adults With Primary Malignant Glioma With Irinotecan Plus Temozolomide||Duke University|Yes|Completed|November 2005|June 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|41|||Both|18 Years|N/A|No|||August 2010|August 14, 2014|February 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00616005||160703|
NCT00612833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHI-9980|A Randomized Controlled Trial of Three Vasectomy Techniques|A Randomized Controlled Trial of Three Vasectomy Techniques||FHI 360|Yes|Terminated|January 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||||||Male|21 Years|N/A|No|||September 2013|September 9, 2013|January 29, 2008||No|FHI 360 participation in the study was terminated due to lack of funding|No||https://clinicaltrials.gov/show/NCT00612833||160936|
NCT00612846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/99|Study Investigating the Best Method of Treatment of Bile Duct Stones in Higher Risk Patients|A Randomised Clinical Trial to Compare Endoscopic Sphincterotomy and Subsequent Laparoscopic Cholecystectomy With Primary Laparoscopic Bile Duct Exploration During Cholecystectomy in Higher Risk Patients With Choledocholithiasis||North Bristol NHS Trust|Yes|Terminated|March 2000|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|50 Years|N/A|No|||January 2008|January 29, 2008|January 29, 2008||No|Terminated early due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00612846||160935|
NCT00616876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZ-23/04|Lactulose Supplementation in Premature Infants|The Effects of Lactulose Supplementation to Enteral Feedings in Premature Infants - A Pilot Study||Bnai Zion Medical Center|No|Completed|February 2005|January 2007|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|28|||Both|23 Weeks|34 Weeks|No|||February 2008|February 14, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616876||160637|
NCT00617162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||August 27, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617162||160615|
NCT00613444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 590|Photodynamic Therapy in the Treatment of Acne|Photodynamic Therapy in the Treatment of Acne Vulgaris Using Non-Coherent Red Light (Derm 590)||University of Michigan|No|Withdrawn|February 2008|March 2010|Actual|February 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|15 Years|N/A|No|||April 2015|April 30, 2015|January 30, 2008||No|Study was never started due to logistical issues.|No||https://clinicaltrials.gov/show/NCT00613444||160890|
NCT00609336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6511|Combination Chemotherapy, Intensity-Modulated Radiation Therapy, and Surgery in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery|A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients With Locally Advanced, Resectable Pancreatic Adenocarcinoma||University of Washington|No|Active, not recruiting|January 2008|||November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|February 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00609336||161203|
NCT00609648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30641-B|Computer Assisted Relaxation Learning for Dental Offices|Distance Psychology for Treating Dental Fear in Rural Communities|CARL|University of Washington|No|Completed|January 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 15, 2013|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609648||161180|
NCT00611910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02707|Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions|Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts.|ISAR-CABG|Deutsches Herzzentrum Muenchen|Yes|Completed|November 2007|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|610|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00611910||161007|
NCT00610519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emc070167ctil|Treatment of Acute Pharyngo-Tonsillitis With Essential Oils of Aromatic Plants|Treatment of Acute Pharyngo-Tonsillitis With Essential Oils of Some Aromatic Medical Plants.||HaEmek Medical Center, Israel|Yes|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00610519||161113|
NCT00610792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-OVC-2001|Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens|An Open Label, Phase 2 Study of Biweekly VELCADE and Intermittent CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens||Millennium Pharmaceuticals, Inc.|Yes|Withdrawn|July 2006|||September 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|91|||Female|18 Years|75 Years|No|||July 2009|July 13, 2009|January 28, 2008||No|Study never submitted to IND. Study is being sponsored by Johnson and Johnson in the EU only.|No||https://clinicaltrials.gov/show/NCT00610792||161092|
NCT00611078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-088|Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study|Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study||Memorial Sloan Kettering Cancer Center|No|Completed|September 2004|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|56|Samples With DNA|blood, adipose tissue|Both|18 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Soft Tissue Sarcoma at Memorial Sloan Kettering Cancer Center.|January 2011|January 19, 2011|January 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00611078||161070|
NCT00611364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Vitorino|Physical Therapy for Hypertensive Elderly|Physical Therapy for Hipertensive Elderly: Effects in the Physical Activity and Exercise Adherence||Universidade Federal de Goias|Yes|Completed|March 2004|December 2005|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|60 Years|80 Years|No|||January 2008|October 17, 2008|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611364||161049|
NCT00611663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060241|Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus|VACCILUP "A Multicenter, Randomized Double-blind Trial Comparing Two Pneumococcal Vaccination Strategies in Patients With Systemic Lupus Erythematosus"|VACCILUP|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|May 2008|March 2016|Anticipated|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|65 Years|No|||December 2015|December 21, 2015|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611663||161026|
NCT00620646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-12-026|The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol|The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol in Clopidogrel Non-Responders After Drug-Eluting Stent Implantation|4C-DES|Samsung Medical Center|No|Completed|February 2008|February 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||February 2009|February 11, 2009|January 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00620646||160351|
NCT00621231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K101|The Protein (Meat) and Function Study|Effect of Normal Versus High Amounts of Protein Intake on Physiological Functions and Proteomics in Healthy Men|ProF|University of Copenhagen|No|Completed|September 2007|April 2008||December 2007|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Basic Science|2||||||Male|19 Years|40 Years|Accepts Healthy Volunteers|||May 2007|February 21, 2008|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00621231||160307|
NCT00621504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-08|Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia|CAP|Forest Laboratories|No|Completed|January 2008|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|606|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|February 11, 2008|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00621504||160286|
NCT00613886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 2005-4609|Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus|Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus|NPH|University of California, Irvine|No|Terminated|March 2006|April 2009|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|January 3, 2008||No|Funding was withdrawn by Codman as expected number of patient subjects enrolled did not meet    expected numbers.|No||https://clinicaltrials.gov/show/NCT00613886||160859|
NCT00613899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N°83_researchbookFSM2006|Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)|Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)||Fondazione Salvatore Maugeri|No|Completed|October 2007|October 2008|Actual|March 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|No|||July 2011|February 3, 2016|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00613899||160858|
NCT00614809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLC-0703|Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer|A Phase II Study of Gefitinib in Benefited Patients With Asymptomatic Brain Metastasis Advanced Non-Small Cell Lung Cancer by Chemotherapy||Guangdong Provincial People's Hospital|Yes|Active, not recruiting|December 2007|December 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2007|February 13, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614809||160794|
NCT00614822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24091|Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer|A Phase II Trial of Carboplatin, Bevacizumab and Pemetrexed in Advanced Non-Small Cell Lung Cancer|H3E-US-X072|Christiana Care Health Services|Yes|Active, not recruiting|November 2007|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614822||160793|
NCT00615108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.519|Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters|Safety and Effectiveness of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertension Patients||Boehringer Ingelheim||Completed|December 2006|||December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3148|||Both|20 Years|80 Years|No|Non-Probability Sample|Hypertension patients|February 2014|February 28, 2014|January 31, 2008||||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00615108||160771|
NCT00615485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Solid Pediatric Cancers|Longitudinal Study of Bone Mineral Density in Survivors of Solid Pediatric Cancers|Longitudinal Study of Bone Mineral Density in Survivors of Solid Pediatric Cancers||State University of New York - Upstate Medical University|No|Completed|January 2006|May 2013|Actual|May 2013|Actual|N/A|Observational|N/A||1|Actual|38|Samples Without DNA|bone specific alkaline phosphatase n-telopeptide|Both|7 Years|40 Years|No|Non-Probability Sample|The 38 patients from the SUNY Upstate Medical Center (Syracuse, NY) Pediatric Oncology        Long-term Survivor Clinic who were subjects in the original Georg Fund supported study        will comprise the patient population if they are locatable and willing to participate.        Patients must be less than 40 years of age to participate.|May 2013|May 29, 2013|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615485||160742|
NCT00615732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QENA-08|Qigong and Exercise for Neck Pain in Adults (QENA)|Prospective, Randomized Controlled Trial on the Effectiveness of Qigong and Exercise Therapy in Patients With Chronic Neck Pain|QENA|Charite University, Berlin, Germany|No|Completed|March 2008|October 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|123|||Both|20 Years|60 Years|No|||July 2012|July 9, 2012|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615732||160724|
NCT00616018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB #06-1187|Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days|Acetaminophen Adduct Formation in Alcohol Abstaining Subjects Administered Therapeutic Doses of Acetaminophen for Ten Consecutive Days|Non-Drinker|Denver Health and Hospital Authority|Yes|Completed|August 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 10, 2012|February 4, 2008|No|Yes||No|March 3, 2011|https://clinicaltrials.gov/show/NCT00616018||160702|One limitation is that this study did not include a placebo group. The study was limited to healthy volunteers. The ingestion of each dose and use of other medications was self-reported.
NCT00612859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01086|Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)|A Multicenter, Randomized, Double-Blind, PBO-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Levetiracetam Versus PBO for the Treatment of Social Anxiety Disorder (Generalized Type)||UCB Pharma|No|Completed|September 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|217|||Both|18 Years|70 Years|No|||September 2009|November 25, 2013|January 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612859||160934|
NCT00613132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005875|Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG|Phase I Dose Escalation of Gleevec in Combination With RAD001 Plus Hydroxyurea for Patients With Recurrent Malignant Glioma||Duke University|Yes|Completed|May 2005|January 2013|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613132||160913|
NCT00611390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emc070165ctil|Treatment of Acute Tracheitis and Laryngitis With Essential Oils of Aromatic Plants|Treatment of Acute Tracheitis and Laryngitis With Essential Oils of Some Aromatic Medical Plants.||HaEmek Medical Center, Israel|Yes|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00611390||161047|
NCT00611403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192371-014|Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients|Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients||Allergan||Completed|December 2007|June 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|21 Years|50 Years|No|||November 2011|November 17, 2011|January 28, 2008|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT00611403||161046|
NCT00611702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT GTCRP-01|Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)|Genomics of Chronic Renal Allograft Rejection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|588|Samples With DNA|Blood from both kidney donor and recipient and transplant kidney biopsy samples|Both|18 Years|75 Years|No|Non-Probability Sample|Individuals receiving a kidney transplant and individuals who are donating a kidney|May 2015|May 13, 2015|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00611702||161023|
NCT00610805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07050181|Cardiology Prevention in Systemic Lupus Erythematosus (SLE)|Cardiology Prevention Trial in Systemic Lupus Erythematosus||University of Pittsburgh|Yes|Withdrawn|November 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|19 Years|N/A|No|||January 2016|January 14, 2016|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610805||161091|
NCT00611104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581219|Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women|Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract||Mayo Clinic|Yes|Active, not recruiting|May 2008|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|PATIENT CHARACTERISTICS:          -  ECOG performance status 0-1          -  Female          -  Postmenopausal (defined as women who have had both ovaries removed or no menstrual             period for at least 12 consecutive months)          -  Able to give informed consent and complete food records alone or with assistance|March 2015|March 31, 2015|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00611104||161068|
NCT00611377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|delirium in rwc|Study on the Incidence of Delirium in a Respiratory Weaning Centre|Delirium in Patients Admitted to a Respiratory Weaning Centre: Analysis of Incidence and Risk Factor|delricu|Fondazione Salvatore Maugeri|No|Recruiting|January 2007|March 2008|Anticipated|February 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|80 Years|No|Non-Probability Sample|We will evaluate for the presence of delirium all the ventilator-dependent patients        admitted to our RWC. They will be monitored using the Intensive Care Delirium Screening        Checklist (ICDSC). This evaluation is based on a score based on 8 items obtained with a        simple examination by the attending physician. The final sum generates a score considered        normal (0-1), borderline (2-3) and pathologic (>4). All the patients, except those with        normal score, will also be evaluated by a psychiatrist, using the Diagnostic Manual of        Mental Disorders (DSM-IV), considered the gold standard. The score will be assessed at        patient's admission, at mid-hospital stay and at discharge.|January 2008|January 28, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611377||161048|
NCT00621257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DK076979-01A1|Vitamin D Levels in Children With IBD|Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.||Children's Hospital Boston|Yes|Recruiting|January 2008|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|120|||Both|5 Years|21 Years|No|||January 2009|January 27, 2009|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00621257||160305|
NCT00621725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00032|Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours|A Phase I, Open Label Study of the Pharmacokinetics and Safety of Cediranib (RECENTINTM, AZD2171) Following Single and Multiple Oral Doses in Patients With Advanced Solid Tumours With Various Degrees of Hepatic Dysfunction||AstraZeneca|No|Completed|January 2008|January 2014|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00621725||160269|
NCT00614172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53294|Proton Therapy for Early Stage Breast Cancer|Phase II Trial of Lumpectomy and Partial Breast Proton Therapy for Early Stage Breast Cancer||Loma Linda University|Yes|Active, not recruiting|February 2004|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|N/A|No|||March 2015|March 31, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00614172||160838|
NCT00614835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-098|Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus|A Pilot Study of Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus||Memorial Sloan Kettering Cancer Center||Completed|August 2001|January 2012|Actual|February 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|January 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614835||160792|
NCT00614848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP034|The ENDEAVOR II Clinical Trial: The Medtronic Endeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions|Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions|ENDEAVOR II|Medtronic Vascular|Yes|Completed|June 2003|July 2009|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1200|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00614848||160791|
NCT00615121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008270|Genetics of Peripheral Artery Genomics|Genetics of Peripheral Artery Disease||Duke University|No|Completed|June 2004|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|122|Samples With DNA|Peripheral artery samples collected from patients are stored in -80celcius refrigerator for      future analysis.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with peripheral artery occlusive disease.|January 2016|January 21, 2016|February 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00615121||160770|
NCT00616590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583565|Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer|Assessment of Insomnia in Patients With Head and Neck Cancer During Treatment||Vanderbilt University||Withdrawn|July 2007|||July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|21 Years|N/A|No|Probability Sample|cancer patients|June 2014|June 15, 2014|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00616590||160659|
NCT00615745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-EU-177-0111|ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla|A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla (Efavirenz/Emtricitabine/Tenofovir DF) on an Empty Stomach|ONCE|Gilead Sciences|No|Completed|April 2008|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||November 2011|November 18, 2011|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00615745||160723|
NCT00616031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIC-TRIL-C0702|Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|January 2008|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|150|||Both|40 Years|80 Years|No|||July 2009|August 9, 2013|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00616031||160701|
NCT00616317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614666-1|Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study|Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study|APS|University of California, Davis|No|Recruiting|September 2006|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric Nephrology Clinic at University of California, Davis|May 2015|May 26, 2015|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616317||160679|
NCT00609349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-250 ex 04/05|The Early Recognition of Pulmonary Arterial Hypertension|The Early Recognition of Pulmonary Arterial Hypertension||Medical University of Graz|No|Completed|April 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|52|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2012|January 11, 2012|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609349||161202|
NCT00609674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFU111439|A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR)||GlaxoSmithKline||Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|315|||Both|12 Years|N/A|No|||February 2011|August 21, 2014|January 24, 2008|Yes|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00609674||161178|
NCT00613145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 122|Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors|A Phase I Pharmacokinetic and Safety Study of Sorafenib + Capecitabine in Advanced Solid Tumors||SCRI Development Innovations, LLC|No|Completed|February 2008|May 2010|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00613145||160912|
NCT00613431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8080-A-U101|Effects of CS-8080 in Healthy Volunteers|A Randomized, Placebo-Controlled, Single Ascending Dose Study To Assess The Safety, Tolerability and Pharmacokinetics Of CS-8080 In Healthy Volunteers||Daiichi Sankyo Inc.|No|Completed|January 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2008|December 19, 2008|January 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613431||160891|
NCT00611143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-08-022|Atorvastatin for Prevention of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery|The Effects of Atorvastatin on the Occurrence of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery||Samsung Medical Center|No|Completed|May 2006|May 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|124|||Both|N/A|N/A|No|||January 2008|January 27, 2008|January 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00611143||161065|
NCT00611416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 279421|The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism|The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism in Man||University of Copenhagen|No|Completed|November 2005|February 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|15|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2009|February 6, 2009|August 21, 2007||||No||https://clinicaltrials.gov/show/NCT00611416||161045|
NCT00609908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.201|The Technique of Skin Stretching for Acute Burn Treatment and Scar Reconstruction|The Technique of Skin Stretching for Acute Burn Treatment and Scar Reconstruction: Clinical Applications and Working Mechanisms.||Association of Dutch Burn Centres|No|Completed|December 2007|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609908||161160|
NCT00609921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-0701|A Phase 1 Study of ARQ 197 in Patients With Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors||Kyowa Hakko Kirin Company, Limited|No|Completed|January 2008|||September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|20 Years|N/A|No|||September 2012|September 6, 2012|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609921||161159|
NCT00612196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-402-001|A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers|A Randomised, Phase I, Single Dose, Placebo-Controlled, Dose Escalation Study of TB-402, A Monocloncal Antibody Directed Against FACTOR VIII, Administered Intravenously in Healthy Male Volunteers.||ThromboGenics|No|Completed|March 2007|December 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|10||Actual|56|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00612196||160985|
NCT00612209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-103|A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients With Advanced Solid Tumors|ARQ 197|ArQule|No|Completed|April 2007|February 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612209||160984|
NCT00610818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB-6-24|Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation|Effect of Palifermin Therapy on Benign and Malignant Skin Tumors in Patients Undergoing High-Dose Chemotherapy With Autologous Stem Cell Transplantation|Palifermin|McGill University Health Center|No|Terminated|July 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|7|||Both|N/A|N/A|No|Non-Probability Sample|patients receiving palifermin for bone marrow transplantation.|January 2008|January 28, 2008|January 28, 2008||No|We did not see any effect of Palifermin on benign or malignant tumor growth|No||https://clinicaltrials.gov/show/NCT00610818||161090|
NCT00611117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27017|Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet|Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet||Pennington Biomedical Research Center|Yes|Active, not recruiting|May 2007|June 2020|Anticipated|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611117||161067|
NCT00612742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESTW007|Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women|BLOOM|BioSante Pharmaceuticals|Yes|Completed|January 2008|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3656|||Female|50 Years|N/A|No|||January 2013|January 4, 2013|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612742||160943|
NCT00612989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004058|Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM|Phase I Trial of a 5-day Regimen of Temodar Plus O6-Benzylguanine (O6-BG) in the Treatment of Patients With Recurrent / Progressive Glioblastoma Multiforme||Duke University|Yes|Completed|February 2005|July 2008|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|N/A|No|||January 2009|July 15, 2014|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612989||160924|
NCT00613002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESTW006|Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|BLOOM|BioSante Pharmaceuticals|No|Completed|December 2006|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|597|||Female|30 Years|65 Years|No|||January 2013|January 4, 2013|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00613002||160923|
NCT00613288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20070046|Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism|Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism||University of Aarhus|No|Completed|September 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|12|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613288||160902|
NCT00614510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR 05003|SynCardia CardioWest TAH-t Postmarket Surveillance Study|The SynCardia CardioWest Temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study||SynCardia Systems. Inc.|Yes|Completed|August 2006|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|196|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have been or will be implanted with the SynCardia Total Artificial Heart.|March 2015|July 28, 2015|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614510||160815|
NCT00614523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060198|Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)||Amgen|Yes|Terminated|July 2008|March 2016|Anticipated|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|250|||Both|18 Years|90 Years|No|||August 2013|August 9, 2013|January 31, 2008|Yes|Yes||No|January 20, 2012|https://clinicaltrials.gov/show/NCT00614523||160814|
NCT00614861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014659|Pain Satisfaction Survey|A Clinical Survey on Satisfaction of Pain Management in Patients With Non-cancer Pain in Taiwan||Johnson & Johnson Taiwan Ltd||Completed|September 2007|January 2008|Actual|January 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2929|||Both|18 Years|N/A|No|Probability Sample|Patients who have visited out patient department (OPD) who are treated actively for pain|May 2014|May 22, 2014|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614861||160790|
NCT00614874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-14592|The Use of Rosiglitazone to Treat Asthma|The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity||Creighton University|No|Completed|December 2008|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 1, 2011|January 31, 2008|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00614874||160789|Small sample size. Lack of placebo control arm.
NCT00615147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-040|Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population|Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population: A Correlation With Ct Pulmonary Angiogram in the Urgent Care Setting||Memorial Sloan Kettering Cancer Center||Completed|May 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|213|||Both|21 Years|N/A|No|Non-Probability Sample|Patients coming to MSKCC Urgent care unit|January 2012|January 6, 2012|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615147||160768|
NCT00615459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2331|A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control|A Phase III, Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, 3-period Incomplete Block, Multidose Crossover Study to Determine the Effect on Lung Function of Indacaterol (150 and 300 μg o.d.) in Patients With Moderate to Severe COPD, Using Tiotropium (18 μg o.d.) as an Active Control||Novartis|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|169|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 1, 2008||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00615459||160744|
NCT00615758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.03|Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV|ERLOTINIB, A TYROSINE KINASE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AS FIRST LINE TREATMENT, IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC). A PHASE II STUDY||Hellenic Oncology Research Group|No|Completed|October 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||December 2009|December 14, 2009|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615758||160722|
NCT00612612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00254|Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia|A Phase 1 Study of Obatoclax Mesylate (GX15-070MS) in Combination With Fludarabine-Based Chemoimmunotherapy in Previously Treated Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL)||National Cancer Institute (NCI)||Terminated|January 2008|||July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612612||160953|
NCT00609687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014310|Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis|Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis||Duke University|Yes|Completed|January 2007|January 2008|Actual|October 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|N/A|N/A|No|||January 2008|April 9, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609687||161177|
NCT00610831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI-HS-2007-5519|Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)|Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)||University of California, Irvine|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|40 Years|85 Years|No|||April 2011|April 1, 2011|January 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00610831||161089|
NCT00609661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H00286|Adult Stem Cell Response to Burn Injury|Comparison of Burn Severity and Patient Outcomes to the Subsets of Mesenchymal Stem Cells Identified in the Blood of Burn Victims||Ohio State University|No|Withdrawn|February 2008|June 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Whole Blood|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any patient who is consented following presentation to the Ohio State University Emergency        Department or directly admitted to the Ohio State University Burn Unit within three days        of a thermal burn|October 2012|October 5, 2012|January 24, 2008||No|Assay for stem cell analysis not available|No||https://clinicaltrials.gov/show/NCT00609661||161179|
NCT00611169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-09-007-001|The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction|The Effects of Facilitated Percutaeous Coronary Intervention Compared to Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction||Samsung Medical Center|Yes|Completed|January 2006|August 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||August 2007|February 7, 2008|January 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00611169||161063|
NCT00611442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2007.188|Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy|Single Dose Lubiprostone Along With Split-dose PEG Solution Without Dietary Restrictions for Bowel Cleansing Prior to Colonoscopy, a Randomized, Double-blind, Placebo Controlled Trial||Brooke Army Medical Center|Yes|Completed|October 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 3, 2012|January 29, 2008|Yes|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT00611442||161043|This study may be limited by the recruitment of outpatients as the only study participants. The study results might have also been affected by limiting the indication for colonoscopy to colorectal cancer screening.
NCT00612170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061043|A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.|A 14-week, Randomized, Double-blind, Placebo-controlled, Multi-center Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily (O.D.) in Patients With Fibromyalgia||Pfizer|Yes|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1129|||Both|18 Years|N/A|No|||April 2011|April 6, 2011|January 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612170||160987|
NCT00612430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000379|Ph II Bevacizumab + Etoposide for Pts w Recurrent MG|Phase II Trial of Bevacizumab Plus Etoposide for Patients With Recurrent Malignant Glioma||Duke University|Yes|Completed|March 2007|September 2011|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||May 2013|July 30, 2013|January 29, 2008|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT00612430||160967|
NCT00612755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Extrados|Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4|Open, Randomized, Multicenter Phase IV Study to Evaluate Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Patients Genotype 1 and/or 4||Hospital Clinico Universitario San Cecilio|No|Completed|October 2005|January 2008|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 29, 2008|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612755||160942|
NCT00613015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1DA021690|Stress and Medication Effects on Cocaine Cue Reactivity|Interdisciplinary Medication Development for Multiple Risk Factors in Relapse.||Medical University of South Carolina|Yes|Completed|May 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|109|||Both|18 Years|65 Years|No|||February 2016|February 8, 2016|February 8, 2008|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00613015||160922|
NCT00613314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.532|Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen|Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen (CENTER)||Boehringer Ingelheim||Completed|June 2007|||April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15268|||Both|45 Years|N/A|No|Non-Probability Sample|Primary care clinic|April 2014|April 30, 2014|January 31, 2008||||No|February 8, 2010|https://clinicaltrials.gov/show/NCT00613314||160900|
NCT00609245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 070849|Effect of Valproic Acid Concentration on Photic Response|Effect of Small Changes in Plasma Valproic Acid Concentration on the Photoparoxysmal Response||Vanderbilt University|Yes|Completed|December 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|15 Years|65 Years|No|||March 2011|March 21, 2011|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00609245||161209|
NCT00614536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014812|Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period|Observational Study: Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period||Janssen Korea, Ltd., Korea|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1142|||Both|18 Years|N/A|No|Non-Probability Sample|Among the patients who visit the department of otolaryngology with suspicious        laryngopharyngeal reflux ; Patients who need rabeprazole treatment according to the        doctor's discretion|April 2014|April 24, 2014|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614536||160813|
NCT00615134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21287|INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.|A Randomized, Open-label Study Evaluating the Antiviral Activity and Safety of 3 Month Fuzeon Induction With an Optimized Background Antiretroviral Regimen Versus OB Alone, in Fuzeon-naive HIV-1 Infected Patients With Virological Failure.||Hoffmann-La Roche||Completed|January 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00615134||160769|
NCT00615160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH A-105|PTK/ZK in Disseminated Malignant Melanoma|Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma||University of Schleswig-Holstein|Yes|Suspended|December 2006|||September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2007|January 11, 2011|January 31, 2008||No|Substance was withdrawn from further development.|No||https://clinicaltrials.gov/show/NCT00615160||160767|
NCT00616343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR#53157|Zonisamide in the Treatment of Essential Tremor|Pilot Study of Zonisamide in the Treatment of Essential Tremor||Loma Linda University|Yes|Terminated|June 2003|December 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|February 4, 2008|Yes|Yes|Principal Investigator left the study site on December 28, 2012.|No|June 12, 2014|https://clinicaltrials.gov/show/NCT00616343||160677|PI has left the institution and we are unable to accurately assess the data from the remaining records.
NCT00611858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-297|Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer|Phase II Study of Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer||Dana-Farber Cancer Institute|Yes|Terminated|January 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 29, 2008|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00611858||161011|
NCT00612105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRX-RET-E22-NP201|Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia||Valeant Pharmaceuticals International, Inc.|No|Completed|October 2007|December 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|85 Years|No|||November 2011|December 9, 2011|January 25, 2008|No|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00612105||160992|
NCT00612118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPR110982|A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis|A Randomised, Double Blind, 2-way Crossover Trial of 8 Days Repeat Dosing With Intranasal GSK256066 and Azelastine Hydrochloride in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)||GlaxoSmithKline|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|January 29, 2008||||No||https://clinicaltrials.gov/show/NCT00612118||160991|
NCT00612599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1526|Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes|Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Non-obese and Obese With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|September 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|75|||Both|30 Years|70 Years|No|||June 2012|June 15, 2012|January 28, 2008||||No||https://clinicaltrials.gov/show/NCT00612599||160954|
NCT00613457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEOP LLA 2000|Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia|AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia|AIEOP LLA 2000|Associazione Italiana Ematologia Oncologia Pediatrica|Yes|Completed|September 2000|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|2039|||Both|1 Year|17 Years|No|||January 2015|January 13, 2015|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00613457||160889|
NCT00613470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170-05|Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram|Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram|PGRN-SSRI|Mayo Clinic|No|Completed|March 2005|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|927|||Both|18 Years|85 Years|No|||December 2013|December 16, 2013|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613470||160888|
NCT00609934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDPDRO-004|Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone|A Phase I/II Study of Sorafenib and Palliative Radiotherapy in Patients With Advanced Renal Cell Carcinoma and Symptomatic Bony Metastases||University Health Network, Toronto|Yes|Completed|December 2007|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609934||161158|
NCT00609947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP057|Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.|A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries|ENDEAVORSVS|Medtronic Vascular|Yes|Completed|January 2008|September 2013|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|January 25, 2008|No|Yes||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00609947||161157|
NCT00611728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000931|Ph I SU011248 + Irinotecan in Treatment of Pts w MG|A Phase I Study of SU011248 Plus Irinotecan in the Treatment of Patients With Malignant Glioma||Duke University|No|Completed|March 2008|September 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2011|July 18, 2014|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00611728||161021|
NCT00611741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612002149|The Effect of Plasma Osmolality on Brain Glutamate|The Role of Cortical Glutamate and GABA in Brains Osmotic Regulation: A Pilot Study in Healthy Volunteers and in Patients With Schizophrenia|MRS|Yale University|Yes|Completed|March 2007|March 2012|Actual|March 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2012|February 6, 2016|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00611741||161020|
NCT00610220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010377|Cast Versus Splint in Children With Acceptably Angulated Wrist Fractures|Cast Versus Splint in Children With Minimally Angulated Fractures of the Distal Radius: a Randomized Controlled Trial.||The Hospital for Sick Children|Yes|Completed|January 2007|October 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|5 Years|12 Years|No|||May 2014|May 12, 2014|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610220||161136|
NCT00610233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 33/05|Effect of Deep Brain Stimulation on Lower Urinary Tract Function|Effect of Deep Brain Stimulation (DBS) on Lower Urinary Tract (LUT) Function||University Hospital Inselspital, Berne|No|Completed|June 2005|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610233||161135|
NCT00610246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP|A Study of Radiation With Sorafenib in Advanced Cancer|A Phase I Dose Escalation Study of Concurrent Low Dose Radiation With Sorafenib in Three Anatomically-based Independent Cohorts (Thorax, Abdomen, Pelvis)||University Health Network, Toronto|Yes|Completed|May 2007|||December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2011|October 19, 2011|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610246||161134|
NCT00611936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605001441|Effects of Atomoxetine Treatment in Humans|Effects of Atomoxetine Treatment in Humans||Yale University|Yes|Completed|June 2006|September 2009|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00611936||161005|
NCT00611949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 21013|Comparison of 2 Vials of Components of a Synthetic Geranium Oil|EPT 101: New Geranium Oil Formulation for the Treatment of Neuropathy Pain||Pennington Biomedical Research Center|No|Completed|May 2002|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00611949||161004|
NCT00611923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH072878|Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder|Androgen Hormones in PMDD||Weill Medical College of Cornell University|No|Completed|February 2005|December 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|48 Years|No|||June 2012|June 27, 2012|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00611923||161006|
NCT00612183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007002|Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma|Phase II Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-label Study)||SymBio Pharmaceuticals|Yes|Completed|December 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|20 Years|75 Years|No|||May 2010|July 21, 2010|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612183||160986|
NCT00612768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mekos 07 2P1/2 401|Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations|Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of PVP Formulations||Allerderm|No|Completed|January 2008|October 2009|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|February 19, 2013|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612768||160941|
NCT00613028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003768|Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan|Phase II Study of Bevacizumab Plus Either Temozolomide or Etoposide for (GBM) Patients Who Have Failed Bevacizumab Plus Irinotecan||Duke University|Yes|Completed|April 2008|January 2011|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|January 29, 2008|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00613028||160921|
NCT00613301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.549|Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa|Pramipexole Special Survey on Patients Without Concomitant Use of L-Dopa||Boehringer Ingelheim||Completed|February 2004|||September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|416|||Both|N/A|N/A|No|Non-Probability Sample|Parkinson's disease patients in daily clinical settings|May 2014|May 28, 2014|January 31, 2008||||No|September 8, 2010|https://clinicaltrials.gov/show/NCT00613301||160901|
NCT00609544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-AN-0704|Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia|A Multi-Center, Double-Blind, Placebo-Controlled Safety and Preliminary Efficacy Study of IL-1 Trap (Rilonacept) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia||Regeneron Pharmaceuticals|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2011|April 17, 2011|December 10, 2007|Yes|Yes|Unable to enroll patients|No||https://clinicaltrials.gov/show/NCT00609544||161187|
NCT00614549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01283|Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.|Long-term Evaluation of the Efficacy and Safety of Levetiracetam in Routine Clinical Practice in the Czech and Slovak Republics, Hungary, and Romania - Non-interventional Study||UCB Pharma|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2569|||Both|4 Years|N/A|No|Non-Probability Sample|Primary care clinics and hospitals.|May 2012|May 25, 2012|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614549||160812|
NCT00614562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK BE 250/07|Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)|Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)||University Hospital Inselspital, Berne|No|Completed|January 2008|December 2010|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||February 2011|February 2, 2011|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614562||160811|
NCT00614900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreKPH-08|Prevalence of Pulmonary Hypertension in COPD Patients|Prevalence and Influence of Pulmonary Hypertension in COPD Patients||University of Aarhus|No|Completed|March 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|117|Samples With DNA|Blood samples|Both|N/A|N/A|No|Non-Probability Sample|All patients have been admitted to hospital with an exacerbation in COPD in 2006.|September 2012|September 17, 2012|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614900||160787|
NCT00612625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 - 198/03|Near Normalisation of BG Improves the Potentiating Effect of GLP-1|Near Normalisation of Blood Glucose Improves the Potentiating Effect of GLP-1 on Glucose Induced Insulin Secretion in Patients With Type 2 Diabetes||Hvidovre University Hospital|No|Completed|February 2004|December 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2008|February 11, 2008|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00612625||160952|
NCT00612638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007681|Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas|Phase I Trail of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) Plus Irinotecan (CPT-11) (NSC 616348) in the Treatment of Patients With Recurrent / Progressive Cerebral Anaplastic Gliomas||Duke University|Yes|Completed|January 2005|July 2008|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||January 2009|June 18, 2013|January 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612638||160951|
NCT00612651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005027|PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas|A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas||Duke University|Yes|Completed|October 2005|June 2011|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612651||160950|
NCT00612872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLINDE 001|Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects|Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects|CLINDE|Institute for Neurodegenerative Disorders|No|Terminated|January 2008|December 2009|Actual|December 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|46|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 20, 2010|January 16, 2008|No|Yes|Results did not show reason to continue with study.|No||https://clinicaltrials.gov/show/NCT00612872||160933|
NCT00612885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107.270|Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study|Post Marketing Surveillance to Assess the Safety and Efficacy of Mobic® (Meloxicam) Intramuscular Injection (7.5mg ~ 15mg, q.d.) up to 3 Days (in Case of Need for Prolonged Treatment, Switch to Mobic® Capsule Therapy Was Possible) in Korean Patients With Osteoarthritis and Rheumatoid Arthritis (KFDA Regulatory Requirement PMS)||Boehringer Ingelheim||Completed|March 2004|August 2005|Actual|August 2005|Actual|Phase 4|Observational|N/A|||Actual|425|||Both|15 Years|N/A|No|||October 2013|October 31, 2013|January 30, 2008||||No||https://clinicaltrials.gov/show/NCT00612885||160932|
NCT00612365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1419|Association Between Abdominal Body Composition, Inflammation, and Risk for Cardiovascular Disease (The MESA ABD Study)|Abdominal Body Composition, Inflammation, and Cardiovascular Disease|MESA ABD|National Heart, Lung, and Blood Institute (NHLBI)|No|Active, not recruiting|September 2007|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1975|||Both|45 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will use data and specimens from participants in the MESA study for AAC who        have undergone CT scans of the abdomen.|February 2009|February 10, 2009|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00612365||160972|
NCT00609362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-223|The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells|The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells||University of Aarhus|Yes|Completed|January 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|57|||Female|60 Years|75 Years|Accepts Healthy Volunteers|||March 2011|March 29, 2011|January 24, 2008||No||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00609362||161201|
NCT00610584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/214/07|Acupuncture for Seasonal Allergic Rhinitis|Acupuncture for Seasonal Allergic Rhinitis (ACUSAR) - A Randomised Controlled Trial|ACUSAR|Charite University, Berlin, Germany|Yes|Completed|April 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|422|||Both|16 Years|45 Years|No|||October 2012|October 22, 2012|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610584||161108|
NCT00610597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-ALD|Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease|Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease||Erasme University Hospital|No|Completed|January 2005|January 2008|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|49|Samples Without DNA|plasma and peripheral blood mononuclear cell culture medium.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients of Erasme University Hospital|January 2008|January 28, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610597||161107|
NCT00611130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-01004|Vigabatrin for Treatment of Cocaine Dependence|Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study||Catalyst Pharmaceuticals, Inc.|No|Completed|January 2008|July 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|January 28, 2008|Yes|Yes||No|April 13, 2012|https://clinicaltrials.gov/show/NCT00611130||161066|Lack of subject medication compliance, site-to-site variability in medication compliance possibly indicative of differing site capabilities to attract subjects sufficiently motivated to stop using cocaine.
NCT00611689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 51|Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors|A Phase I Study to Determine the Safety of Imatinib in Combination With PTK787/ZK222584 in Patients With Refractory and/or Advanced Solid Tumors||SCRI Development Innovations, LLC|No|Completed|July 2004|April 2011|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|January 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00611689||161024|
NCT00611429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079700|An Educational and Supportive Counseling Program for Increasing Antiretroviral Use and Adherence in People With HIV|Preparing Patients to Start Antiretroviral Therapy: A Randomized Controlled Trial||University of California, San Francisco|No|Completed|May 2008|April 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|219|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00611429||161044|
NCT00616759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR#56164|The Effect on Cognition of Terminating ECT Induced Seizures With Propofol|The Effect on Cognition of Terminating ECT Induced Seizures With Propofol||Loma Linda University|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|45 Years|N/A|No|||December 2012|December 30, 2012|February 4, 2008||No||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00616759||160646|
NCT00616772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-158|Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood|Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial|FIRST|AbbVie|Yes|Completed|February 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|682|||Both|45 Years|N/A|No|||December 2013|December 3, 2013|February 5, 2008|Yes|Yes||No|September 13, 2013|https://clinicaltrials.gov/show/NCT00616772||160645|
NCT00612469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270/05|The Use of Antimicrobial Agents in the Inhibition of Mutans Streptococci in Children With Dental Caries|Sodium Fluoride, Chlorhexidine and Vancomycin Effect in the Inhibition of Mutans Streptococci in Children With Dental Caries: a Randomized, Double-Blind Clinical Trial||Universidade Federal do Ceara|No|Completed|October 2005|October 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|69|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||December 2007|January 29, 2008|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612469||160964|
NCT00612222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080056|Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization||National Institutes of Health Clinical Center (CC)|Yes|Terminated|January 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|February 8, 2008|Yes|Yes|The study was terminated due to low accrual.|No|March 13, 2012|https://clinicaltrials.gov/show/NCT00612222||160983|Early termination leading to small numbers of subjects analyzed.
NCT00612716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999LS060|Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia|Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|October 1999|December 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|55 Years|No|||January 2016|January 21, 2016|February 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612716||160945|
NCT00609219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-9935-NPC|T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC|Administration of EBV-Specific T-Lymphocytes to Patients With EBV-Positive Nasopharyngeal Carcinoma|NPC|Baylor College of Medicine|Yes|Completed|August 2001|June 2012|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|N/A|No|||October 2012|October 5, 2012|February 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00609219||161210|
NCT00609518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11652|A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer|Pemetrexed With Simplified Folate and Dexamethasone Supplementation Versus Pemetrexed With Standard Supplementation as Second-line Chemotherapy for Patients With Non-squamous Non-small Cell Lung Cancer||Eli Lilly and Company|No|Completed|February 2008|June 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|January 23, 2008|Yes|Yes||No|October 15, 2010|https://clinicaltrials.gov/show/NCT00609518||161189|
NCT00609531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0975|Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders|Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders||University of North Carolina, Chapel Hill|No|Completed|January 2007|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|12|||Both|10 Years|55 Years|No|||October 2012|October 5, 2012|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00609531||161188|
NCT00609843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PilotBladder-IGRT|Pilot Studie of Lipiodol Demarcation of the Tumour in Bladder Cancer|Lipiodol Demarcation of the Bladder Tumour in Adaptive Image-guided Radiotherapy: A Pilot Study. (Danish: Lipiodol Til Markering af blæretumoren i Forbindelse Med Adaptiv Billedvejledt strålebehandling: Et Pilotstudie.)||University of Aarhus|Yes|Completed|February 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|N/A|No|||July 2009|December 4, 2015|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609843||161165|
NCT00614887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070184|Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage|Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage|SAHENDO|Kuopio University Hospital|Yes|Completed|March 2006|January 2008|Actual|November 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|46|Samples Without DNA|serum and plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from acute subarachnoid hemorrhage and patients admitted for elective        aneurysm surgery.|January 2008|February 12, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614887||160788|
NCT00616044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Imbelloni&Gouveia|Continuous Spinal Anesthesia Versus Combined Spinal Epidural Block|Continuous Spinal Anesthesia Versus Combined Spinal Epidural Block for Major Orthopedic Surgeries. Study Prospective and Randomized.|Spinocath|Sao Jose do Rio Preto University|No|Not yet recruiting|March 2008|January 2009|Anticipated|February 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|N/A|No|||January 2008|February 14, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616044||160700|
NCT00612898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-301|Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection|A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase||Avexa|Yes|Terminated|February 2008|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|January 30, 2008|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00612898||160931|
NCT00613171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571E2205|Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis|A Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability of STI571 for the Treatment of Fibrosis in Patients With Systemic Sclerosis||Novartis|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|January 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613171||160910|
NCT00613158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1384|Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk|Atherosclerosis Risk Refinement - a Multi-Marker Approach Using Microarrays||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|March 2007|February 2010|Anticipated|August 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|120|||Female|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will include female participants from MESA with and without SA. This study will        also include healthy female participants from Northwestern University.|April 2009|April 27, 2009|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00613158||160911|
NCT00609960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3739-IK-CTIL|Clowns as Treatment for Preoperative Anxiety in Children: A Randomized Controlled Trial|Clowns as Treatment for Preoperative Anxietyin Children- a Randomized Controlled Trial||Sheba Medical Center|No|Completed|January 2006|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|3||Actual|65|||Both|2 Years|8 Years|No|||January 2008|February 6, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609960||161156|
NCT00610259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCUPsychiatry001|Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia|Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia - An Assessors-blinded, Randomized Controlled Effectiveness Trial||Nagoya City University|No|Completed|January 2008|August 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|70 Years|No|||September 2009|September 17, 2009|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00610259||161133|
NCT00610610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3610|Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome|Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome: A Randomized, Double Blind, Parallel Group, Flexible Dose, Placebo Controlled Trial.||Duke University|No|Completed|January 2002|December 2002|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||January 2008|June 19, 2013|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610610||161106|
NCT00610870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-04-049|Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention|Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction||Samsung Medical Center|No|Completed|July 2007|August 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|N/A|N/A|No|||March 2011|March 2, 2011|January 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00610870||161086|
NCT00610844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LungRFA_V1|Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors|Evaluation of Effectiveness of Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors||University Hospital Tuebingen||Completed|April 2004|||May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2007|February 15, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610844||161088|
NCT00610857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-125|Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma|Safety and Efficacy of Combination Biotherapy With High-dose Interferon Alfa-2b and Anti-CTLA4 Monoclonal Antibody for Recurrent Inoperable Stage III or Stage IV Melanoma||University of Pittsburgh|Yes|Completed|November 2006|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|37|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|January 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610857||161087|
NCT00616200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2899|Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)|The Effect of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome: A Prospective Pilot Study||University of North Carolina, Chapel Hill|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||October 2011|October 5, 2011|February 5, 2008||No||No|June 29, 2010|https://clinicaltrials.gov/show/NCT00616200||160688|Low N, lack of standard control group and specific overweight/obese female predominant population.
NCT00616213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-1004|PR104 and G-CSF in Treating Patients With Solid Tumors|A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given With Prophylactic G-CSF in Subjects With Solid Tumors||Proacta, Incorporated||Completed|February 2008|June 2009|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|February 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00616213||160687|
NCT00616226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2006|||||N/A|N/A|N/A||||||||||||||February 27, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616226||160686|
NCT00611715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0303|Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.|A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|November 2003|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|N/A|No|||August 2012|August 3, 2012|February 8, 2008|Yes|Yes|low accrual|No|March 12, 2012|https://clinicaltrials.gov/show/NCT00611715||161022|The total number of worst-grade toxicities will not match the total number of participants, as patients can have multiple events or no events.
NCT00612235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000357/2|Premenstrual Dysphoric Disorder and Antiepileptic Drugs|Comparison of Different Antiepileptic Drug Monotherapies for the Occurrence of Premenstrual Dysphoric Disorder Among Women With Epilepsy||Beth Israel Deaconess Medical Center|No|Recruiting|November 2007|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100|Samples Without DNA|serum|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Three regional epilepsy centers|March 2010|March 15, 2010|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612235||160982|
NCT00617071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584278|Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants|Tailored Navigation in CRC Screening||National Cancer Institute (NCI)||Recruiting|January 2007|||December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Health Services Research|||Anticipated|900|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||July 2009|December 17, 2013|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00617071||160622|
NCT00612482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06120537|Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education|Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education: A High School Pilot Study||Children's Hospital Boston|Yes|Completed|December 2006|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|225|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||March 2011|March 11, 2011|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612482||160963|
NCT00613054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000393|Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma|Phase I Study of Zactima (ZD6474) Plus Imatinib Mesylate and Hydroxyurea for Patients With Recurrent Malignant Glioma||Duke University|Yes|Completed|November 2007|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613054||160919|
NCT00613067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-0709-053|ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder|The Amplitude Change of the Auditory Evoked N1 Component as a Predictor of Response to Escitalopram Treatment in Patients With Generalized Anxiety Disorder|N1|Inje University|No|Completed|December 2007|May 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||June 2010|June 29, 2010|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00613067||160918|
NCT00613340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-20008-A|The Specificity of Cervical Facet Medial Branch Blocks|Randomized Study Comparing the Accuracy and Specificity of Cervical Facet Medial Branch Blocks With 0.25 ml and 0.5 ml of Local Anesthetic||Johns Hopkins University|No|Completed|January 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||August 2009|August 5, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613340||160898|
NCT00613353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0150|Sedentary Behavior in Overweight Women|Sedentary Behavior in Overweight Women||University of Mississippi Medical Center|Yes|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|38|||Female|18 Years|65 Years|No|Non-Probability Sample|Caucasian or African American women between the ages of 18 and 65.|November 2008|November 12, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613353||160897|
NCT00611039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRV 900100 QD|Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy|Clinical Pilot, Open, Comparative and Randomized Trial to Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy|DRV900100QD|Germans Trias i Pujol Hospital|No|Completed|February 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611039||161073|
NCT00614601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0305|Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer|A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer||NewLink Genetics Corporation|Yes|Terminated|January 2008|December 2014|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|January 31, 2008|Yes|Yes|Sponsor proceeded with a phase III study for same indication.|No||https://clinicaltrials.gov/show/NCT00614601||160808|
NCT00614614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110870|Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014|Immunogenicity & Safety Study of a Booster Dose of an Investigational Vaccination Regimen Given at 12-15 Months of Age or at 15-18 Months of Age (Co-administered With Infanrix®) in Primed Healthy Toddlers||GlaxoSmithKline||Completed|February 2008|August 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|1558|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||August 2012|August 30, 2012|January 31, 2008|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT00614614||160807|
NCT00614640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1049|Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults|A Phase I/II Study of the Safety, Tolerability, and Immunogenicity of a Topical Therapeutic DNA Dendritic Cell Vaccine (DermaVir Patch) in Children, Adolescents, and Young Adults With HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn||||November 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|6 Years|23 Years|No|||September 2013|September 4, 2013|February 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614640||160806|
NCT00611598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-003|DNA Repair and Genetic Susceptibility to Lung Cancer|DNA Repair and Genetic Susceptibility to Lung Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2003|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|218|Samples With DNA|-  30 ml. Blood in heparinized, green top tubes.        -  Fresh tumor or normal tissue, when available.        -  Tissue or cells from routine bronchoscopy, when available.|Both|N/A|N/A|No|Non-Probability Sample|MSKCC Clinic|October 2015|October 5, 2015|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611598||161031|
NCT00612911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTDil-1|Cell Therapy in Dilated Cardiomyopathy: Observational Study|Cell Therapy in Dilated Cardiomyopathy: A Safety and Feasibility Study Using Autologous Bone Marrow Mononuclear Cells||Ministry of Health, Brazil|No|Terminated|February 2005|August 2007|Actual|August 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with idiopathic dilated cardiomyopathy|January 2008|January 29, 2008|January 23, 2008||No|finish study as protocol|No||https://clinicaltrials.gov/show/NCT00612911||160930|
NCT00613184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kmc06037|Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses|Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses||Kern Medical Center|No|Active, not recruiting|November 2006|January 2008|Anticipated|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|150|||Both|N/A|18 Months|No|||January 2008|February 11, 2008|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00613184||160909|
NCT00609375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Universidad Javeriana|Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen|Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen in Adult Critically Ill Patients With Gram Negative Bacilli Bacteremia|CEFPK/PD|Javeriana University|Yes|Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||January 2008|February 6, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609375||161200|
NCT00613496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-1-2007|Irbesartan and Adhesion Molecules in AF|Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation|CREATIVE-AF|University of Magdeburg|Yes|Recruiting|May 2009|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613496||160887|
NCT00613509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL11|Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma|Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma||Sanofi|Yes|Terminated|June 2008|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|January 16, 2008|Yes|Yes|No safety concerns, the study was terminated due to slow enrollment. All enrolled patients    were followed per protocol.|No|September 14, 2010|https://clinicaltrials.gov/show/NCT00613509||160886|
NCT00610285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-110|A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases|A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases||Memorial Sloan Kettering Cancer Center||Completed|October 2005|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC Clinic|December 2015|December 17, 2015|January 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610285||161131|
NCT00610896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-07-02|CRM and Fusion Beats: Effects of Progressive Fusion on Intra-left Ventricular Mechanical Function|CRM and Fusion Beats: Effects of Progressive Fusion on Intra-left Ventricular Mechanical Function||Essentia Health|No|Completed|January 2008|September 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Pacemaker clinic or inpatient EP at St. Marys' Medical Center Duluth MN|August 2011|August 31, 2011|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00610896||161084|
NCT00610909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3611|Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)|Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)||Duke University|No|Completed|January 2002|December 2002|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||January 2008|June 19, 2013|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610909||161083|
NCT00610883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-042|LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma|LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|May 1990|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|21 Years|No|||December 2015|December 21, 2015|December 26, 2007|Yes|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT00610883||161085|
NCT00611156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B228-IHE-2006-NTG|Examination of the Effects of Four Different Spices on Energy Metabolism|Bioactive Food Ingredients and Energy Metabolism: The Effects of Ginger, Black Pepper, Horseradish and Mustard on Meal-Induced Thermogenesis and Fat Oxidation||University of Copenhagen|No|Completed|October 2006|June 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|22|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2007|February 7, 2008|January 28, 2008||||No||https://clinicaltrials.gov/show/NCT00611156||161064|
NCT00617084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.2 - IP090|Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent|RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention|RESOLUTE-AC|Medtronic Vascular|Yes|Completed|April 2008|February 2014|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2292|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|February 4, 2008||No||No|November 22, 2010|https://clinicaltrials.gov/show/NCT00617084||160621|
NCT00616473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|433-06|Quality End-of-Life Care in Nursing Homes|The Impact of Quality End-of-Life Care in Nursing Homes||University of Nebraska|No|Completed|January 2007|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|8500|||Both|19 Years|N/A|No|Non-Probability Sample|Nursing Homes in Nebraska and the Western half of Iowa, nursing home staff, and family        members/significant other of nursing home residents|February 2008|December 1, 2014|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616473||160667|
NCT00617292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5610|Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers|Long-Term Outcome in Offspring and Mothers of Dexamethasone-Treated Pregnancies at Risk for Classical Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency||Office of Rare Diseases (ORD)|Yes|Recruiting|January 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|233|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants in this study will include children who received prenatal dexamethasone        treatment as fetuses and their mothers.|December 2008|December 8, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00617292||160605|
NCT00617305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-300-0117|Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)|An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to a Phosphodiesterase Type-5 Inhibitor|ATHENA-1|Gilead Sciences|Yes|Completed|April 2008|July 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|16 Years|75 Years|No|||June 2012|June 22, 2012|February 6, 2008|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00617305||160604|
NCT00617604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0485-CL-E201|A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients|Efficacy and Safety of Alefacept in Combination With Tacrolimus, Mycophenolate Mofetil and Steroids in de Novo Kidney Transplantation - a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study||Astellas Pharma Inc|Yes|Completed|December 2007|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|218|||Both|18 Years|64 Years|No|||January 2016|January 5, 2016|February 6, 2008|Yes|Yes||No|January 5, 2016|https://clinicaltrials.gov/show/NCT00617604||160582|
NCT00617591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14986|Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)|Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®), Low Frequency Dexamethasone and Revlimid® (Dd-R) in Newly Diagnosed Multiple Myeloma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|January 2008|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||October 2013|December 16, 2013|February 5, 2008|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00617591||160583|
NCT00609271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-00111|Study of Macronutrients and Heart Disease Risk|Macronutrient Composition of Diet and Risk Factors for Cardiovascular Disease|MACRO|Tulane University Health Sciences Center|Yes|Completed|January 2008|January 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|148|||Both|22 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 31, 2013|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609271||161208|
NCT00609557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-3386-B01|A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain|A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain||University of Washington|No|Completed|September 2004|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|25|||Both|50 Years|80 Years|No|||January 2008|January 24, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609557||161186|
NCT00610493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0668|Bevacizumab and Temsirolimus in Patients With Advanced Malignancy|A Phase I Trial of Bevacizumab and Temsirolimus in Patients With Advanced Malignancy||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2008|||January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|183|||Both|N/A|N/A|No|||December 2015|December 18, 2015|January 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610493||161115|
NCT00618228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BALS-02|Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Randomized Crossover Bioequivalency Study of 750 mg Balsalazide Capsules Under Fasting Conditions||Roxane Laboratories|No|Completed|January 2004|January 2004|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 18, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00618228||160535|
NCT00618488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0922|Efficacy of Yogurt Containing BB12 in Subjects With GI Symptoms|Clinical Efficacy of Yogurt Containing Bifidobacterium Lactis (BB12) in Subjects With Functional Gastrointestinal Symptoms||University of North Carolina, Chapel Hill|No|Completed|February 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2008|February 19, 2008|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00618488||160516|
NCT00615771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01312008-991|Day of Embryo Transfer for Patients Undergoing In Vitro Fertilization|Embryo Transfer on Day 2 vs. Day 3 After Oocyte Retrieval in Patients Who Plan to Replace All Embryos After an In Vitro Fertilization Cycle||Stanford University|Yes|Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Female|18 Years|50 Years|No|||July 2011|July 21, 2011|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615771||160721|
NCT00611338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12192007-944|Efficacy of Group Intervention to Reduce Stress Symptoms|Efficacy of Group Intervention to Reduce Stress Symptoms||Stanford University||Recruiting|July 2006|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|290|||Both|18 Years|N/A|No|||December 2009|December 11, 2009|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611338||161051|
NCT00612378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACI 09-003|A Multi-center Acute Efficacy Trial of GFX For Reduction of Glabellar Furrowing|A Multi-center Acute Efficacy Trial of GFX For Reduction of Glabellar Furrowing||Advanced Cosmetic Intervention|Yes|Completed|September 2007|March 2008|Actual|February 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 23, 2014|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00612378||160971|
NCT00609401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2006-003137-32|Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)|A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma|ROSORC|Italian Trial in Medical Oncology|Yes|Completed|November 2006|May 2008|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||February 2009|February 25, 2009|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00609401||161198|
NCT00609973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cipro 1.1|Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease|Double-blind, Placebo Controlled, Randomized, Multicentre, Pilot Study on the Safety and Efficacy of Ciprofloxacin for Prophylactic Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease Patients||University of North Carolina, Chapel Hill|Yes|Completed|May 2008|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|33|||Both|18 Years|70 Years|No|||March 2013|March 21, 2013|January 24, 2008|Yes|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00609973||161155|
NCT00609388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX 001/07|Tacrolimus During the Implantation and the Effect on Ischemia-reperfusion Injury in Liver Transplantation|Evaluation of Tacrolimus (Prograf®) Intraportal Infusion During the Implantation and the Protective Effect on Ischemia-reperfusion Injury in Orthotopic Liver Transplant Recipients - Single Center Study|TAC-Infusion|Medical University of Vienna|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||December 2007|December 7, 2010|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609388||161199|
NCT00609700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-BR-35/07-1|Balanced Volume Replacement Therapy With Ringer's Acetate Solution in Burn Injury|Balanced Volume Replacement Therapy With Ringer's Acetate Solution in Burn Injury|VoLTRAB|Klinikum St. Georg gGmbH|No|Completed|December 2007|December 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|82|||Both|18 Years|80 Years|No|Probability Sample|patients within a 24-hours period after severe burn injury|October 2011|October 14, 2011|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609700||161176|
NCT00610623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anb006#2001|Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia|Proof of Concept Study to Investigate the Impact of Azithromycin Administered iv Versus Placebo on the Prevention of Pneumonia in Ventilated Patients Colonized by Pseudomonas Aeruginosa||Anbics Management-Services Ag|Yes|Terminated|April 2003|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|75 Years|No|||January 2008|January 28, 2008|January 24, 2008||No|The sponsor decided to stop the study prematurely because of financial issues|No||https://clinicaltrials.gov/show/NCT00610623||161105|
NCT00615901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-133|Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer|Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Female|18 Years|70 Years|No|||October 2015|October 28, 2015|February 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00615901||160711|
NCT00616239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082007-078|Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women|The Efficacy of Salicylic Acid Peels Combined With 4% Hydroquinone Cream Versus 4% Hydroquinone Cream Alone in the Treatment of Hispanic Women With Moderate to Severe Melasma||University of Texas Southwestern Medical Center|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|65 Years|No|||January 2014|January 9, 2014|February 4, 2008|Yes|Yes||No|August 26, 2013|https://clinicaltrials.gov/show/NCT00616239||160685|Two subjects did not complete the study were unable to come in for visits because of scheduling difficulties and had no adverse effects at the time of discontinuation.
NCT00611182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5476-31357-01|Dyspnea in Patients With Pulmonary Fibrosis|Dyspnea in Patients With Pulmonary Fibrosis||University of California, San Francisco|No|Completed|January 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|November 2013|November 15, 2013|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611182||161062|
NCT00611195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIBAS:UKBB_ANE_LR5|Remifentanil and Laryngeal Reflex Responses in Pediatric Patients With URI|Impact of Remifentanil Administration on Laryngeal Reflex Responses in Pediatric Patients With Upper Respiratory Anesthetized With Propofol||University Hospital, Basel, Switzerland|No|Completed|January 2008|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|62|||Both|25 Months|84 Months|No|||October 2015|October 29, 2015|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611195||161061|
NCT00617097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00013075|Paracervical Block in First Trimester Surgical Abortions|Paracervical Block With Ketorolac and Lidocaine in First Trimester Surgical Abortions||Johns Hopkins University|No|Completed|January 2008|June 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|December 28, 2007||No||No|June 9, 2014|https://clinicaltrials.gov/show/NCT00617097||160620|
NCT00617318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM001|Pomegranate Products for Prevention of Common Cold|Pomegranate Products for Prevention of Common Cold and Influenza-Like Symptoms: A Double- Blind, Placebo-Controlled Randomized Clinical Trial||Texas Heart Institute|Yes|Completed|January 2007|June 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|461|||Both|21 Years|49 Years|Accepts Healthy Volunteers|||November 2007|February 15, 2008|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617318||160603|
NCT00617331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0073|H9 Priming Study in Healthy Adults|A Randomized, Double-Blind, Clinical Trial Evaluating the Immunogenicity of an Inactivated Influenza A/H9N2 Vaccine Among Healthy Adults With and Without Prior Exposure to Influenza A/H2N2||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2008|January 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||July 2011|July 20, 2011|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617331||160602|
NCT00617838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5021612|Celiac Disease Prevention|Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization||Kuopio University Hospital|No|Active, not recruiting|October 2007|December 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|168|||Both|N/A|2 Months|Accepts Healthy Volunteers|||August 2013|August 22, 2013|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617838||160564|
NCT00617851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71P6|Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old|A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Consistency of Three Consecutive Lots of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs in Healthy Subjects Aged 18 to 49 Years||Novartis||Completed|November 2007|June 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|1507|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|February 6, 2008|Yes|Yes||No|February 3, 2010|https://clinicaltrials.gov/show/NCT00617851||160563|
NCT00617825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17504|Feasibility Study of Cryotherapy for Chronic Venous Disorders|Cryotherapy for Chronic Venous Disorders|Cryo|Medical University of South Carolina|Yes|Completed|September 2007|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|45 Years|N/A|No|||September 2007|August 4, 2011|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617825||160565|
NCT00610168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110806|Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.|Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting.||GlaxoSmithKline||Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|82|||Both|20 Years|24 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00610168||161140|
NCT00610480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092007-002|Effects of Tear Film Stability After Instillation Of OTC Artificial Drops|Effects of Systane® Versus Optive™ and Soothe™ Lubricating Eye Drops in Maintaining Tear Film Stability at Determined Time Points||University of Texas Southwestern Medical Center|Yes|Completed|November 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 13, 2009|January 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00610480||161116|
NCT00610766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. R00107|International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily Practice|International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily Practice|PROTECTION-I|Deutsches Herzzentrum Muenchen|Yes|Completed|January 2007|January 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1965|||Both|18 Years|N/A|No|Non-Probability Sample|patients with indication for cardiac imaging by MSCT|March 2008|March 14, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610766||161094|
NCT00618787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360.18|Prospective Randomized Double Blind Clinical Trial of Polyhexamethylene Biguanide Impregnated Foam Dressing|Prospective Randomized Double Blind Clinical Trial of Polyhexamethylene Biguanide Impregnated Foam Dressing||Tyco Healthcare Group||Completed|February 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|85 Years|No|||April 2010|April 9, 2010|January 10, 2008||No||No|July 29, 2009|https://clinicaltrials.gov/show/NCT00618787||160493|
NCT00618800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-38047/0-401-4974|Preventing Falls Through Enhanced Pharmaceutical Care|Preventing Falls Through Enhanced Pharmaceutical Care||University of North Carolina, Chapel Hill|No|Completed|August 2004|September 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||September 2011|September 16, 2011|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00618800||160492|
NCT00612131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-125|Medical Residents Performance: Effect of Simulation-Based Training|Medical Residents Performance in Maximum Barrier Precautions During Central Venous Catheter Placement: Effect of Simulation-Based Training||St. Luke's-Roosevelt Hospital Center|No|Completed|November 2007|||January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|47|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MEDICAL RESIDENTS|September 2007|October 15, 2012|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612131||160990|
NCT00612664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-006|Phase II, 2nd Line Melanoma - RAND Monotherapy|A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma||Bristol-Myers Squibb|No|Completed|March 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|158|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612664||160949|
NCT00609739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999LS032|Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation|Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Terminated|June 1999|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|18 Years|No|||January 2012|January 31, 2012|February 6, 2008|Yes|Yes|Low accrual|No|November 22, 2011|https://clinicaltrials.gov/show/NCT00609739||161173|Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.
NCT00610272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33028|Optimization of Radiotherapy in Treatment of Painful Bone Metastasis|Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis|bone mets|International Atomic Energy Agency|Yes|Completed|January 2008|August 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|650|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00610272||161132|
NCT00615654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Aquatic Physical Therapy in Fibromyalgia|A Randomized Clinical Trial of Aquatic Physiotherapy Program on Functional Capacity in Patients With Fibromyalgia.||Sao Camilo University Center|Yes|Completed|January 2007|April 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2008|October 17, 2008|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615654||160729|
NCT00615888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119/2005|Fast Track Management in Elective Open Infrarenal Aortic Aneurysm Repair|Prospective Randomized Controlled Trial to Evaluate Fast Track Recovery in Elective Open Infrarenal Aortic Aneurysm Repair||University of Ulm|Yes|Completed|September 2005|March 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2005|January 13, 2010|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615888||160712|
NCT00616252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR 002|Antiretroviral Drug Levels During and After Pregnancy|Comparison of the Pharmacokinetics of Antiretroviral Agents in HIV Infected Ugandan Women During and After Pregnancy||Makerere University|No|Completed|February 2008|September 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples With DNA|Human plasma Red cell pellets|Female|18 Years|39 Years|No|Non-Probability Sample|HIV positive women attending ante-natal care clinic at Mulago Hospital, Kampala Uganda|December 2010|December 3, 2010|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616252||160684|
NCT00616486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|psiy-266-07|rTMS in Treatment of Obsessive Compulsive Disorder (OCD)|A Multicentre, Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy, Safety, and Clinical Outcomes of Low Frequency, Repetitive Transcranial Magnetic Stimulation (Over Supplementary Motor Area (SMA) Applied Bilaterally and Simultaneously) Versus Sham (Placebo rTMS) Treatment for 6 Weeks, When Added to a Stable Pharmacotherapy in Subjects With Obsessive Compulsive Disorder (OCD).||Queen's University|No|Completed|January 2008|November 2012|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616486||160666|
NCT00616811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23138|Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency|A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With Vildagliptin (50 mg qd) Versus Sitagliptin (25 mg qd) in Patients With Type 2 Diabetes and Severe Renal Insufficiency||Novartis||Completed|January 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|85 Years|No|||January 2013|January 2, 2013|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616811||160642|
NCT00616785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584442|Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Phase II Trial Irinotecan and Cisplatin Induction Chemotherapy Followed by Radiotherapy Concurrently With Etoposide/Cisplatin in Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|June 2007|||November 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|41|||Both|18 Years|75 Years|No|||September 2008|February 6, 2009|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00616785||160644|
NCT00616798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN20372|A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.|Randomized, Double-blind, Placebo-controlled add-on Trial of the Safety and Efficacy of RO4917838 in Outpatients on Select Atypical Antipsychotics With Prominent Negative or Disorganized Thought Symptoms||Hoffmann-La Roche||Completed|March 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|323|||Both|18 Years|60 Years|No|||June 2014|June 23, 2014|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616798||160643|
NCT00617123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05183|Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Ocular Safety of SCH 530348 in Subjects Participating in the Schering-Plough P04737 Study (TRA^SM-Secondary Prevention Ocular Safety Study)||Merck Sharp & Dohme Corp.|Yes|Completed|July 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|258|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|February 4, 2008|Yes|Yes||No|May 9, 2014|https://clinicaltrials.gov/show/NCT00617123||160618|
NCT00617370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-065|Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility|Pilot Study of Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in High-Risk Breast Cancer: Feasibility||Memorial Sloan Kettering Cancer Center||Completed|November 2004|June 2008|Actual|July 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|February 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00617370||160599|
NCT00617864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707002880|The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome|The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome.||Yale University|Yes|Withdrawn|September 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|0|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|February 5, 2008||No|The syndrome of hyperstimulation is so rare that after one year no patients were eligible.The    study was withdrawn and never started.|No||https://clinicaltrials.gov/show/NCT00617864||160562|
NCT00613600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTF-GM|Safety and Effectiveness Study of a Fiber Supplement for Weight Loss|Safety and Efficacy of Glucomannan for Weight Loss||Rush University Medical Center|Yes|Completed|February 2008|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2011|December 1, 2011|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613600||160879|
NCT00622115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXA_C_02537|Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)|A Phase I, Pharmacokinetic and Tolerability Study of Intravenous Unfractionated Heparin After Subcutaneous Enoxaparin 1mg/kg Bid Repeated Administration in Healthy Subjects||Sanofi||Completed|July 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||March 2011|March 14, 2011|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622115||160239|
NCT00622401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-221|Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12|Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12||Dana-Farber Cancer Institute|Yes|Terminated|December 2009|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Female|18 Years|N/A|No|||February 2016|February 16, 2016|February 14, 2008|Yes|Yes||No|January 20, 2016|https://clinicaltrials.gov/show/NCT00622401||160219|In the conduct of the study, it became apparent that the setting of advanced breast cancer with malignant effusions/ascites for vaccine generation was a difficult setting for evaluation of an immune based therapy.
NCT00611871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 0703002443|The Use of Propranolol to Block Memory Reconsolidation in PTSD|The Use of Propranolol to Block Memory Reconsolidation in Post Traumatic Stress Disorders (PTSD)||Wayne State University|No|Terminated|September 2007|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Female|18 Years|45 Years|No|||August 2015|August 14, 2015|January 1, 2008||No|Low enrollment, grant term expired|No||https://clinicaltrials.gov/show/NCT00611871||161010|
NCT00612391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HURA1|Lateral Mini Approach vs Anterior Approach for Plating of Proximal Humerus Fracture|A Randomized Clinical Trail Comparing a Lateral Minimally Invasive Approach and the Traditional Anterior Approach for Plating of Proximal Humerus Fractures|HURA|Université de Montréal|No|Recruiting|November 2007|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||July 2015|July 7, 2015|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612391||160970|
NCT00612417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-402-002|Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402|A Randomised, Double-blind and Placebo-controlled Study Investigating the Pharmacodynamic Effects of Administration of Recombinant Human Factor VIII in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402||ThromboGenics|No|Completed|January 2008|June 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612417||160968|
NCT00612677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15010|Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem|Phase II Combination of Pemetrexed and Oxaliplatin in Patients With Recurrent Non-Small Cell Lung Cancer After Failure to Platinum Based Adjuvant Chemotherapy||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|June 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|January 29, 2008|Yes|Yes|slow accrual - the 1 patient accrued did not go on treatment|No|February 21, 2011|https://clinicaltrials.gov/show/NCT00612677||160948|Terminated due to slow accrual. Study closed before treatment started.
NCT00610636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9100015204|Treatment Outcomes of Hepatic Metastasis After FOLFOX-4 Therapy|Oncologic Outcomes of Surgical Versus Non-surgical Methods for the Treatment of Resectable Colorectal Liver-confined Metastases Converted From Initially Non-resectable Metastases by FOLFOX-4 Neoadjuvant Chemotherapy: A Randomized Clinical Trial||National Taiwan University Hospital|No|Recruiting|January 2002|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||December 2012|December 6, 2012|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00610636||161104|
NCT00609713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-4976|Bone Health of Obese Adolescents During Weight Loss|Bone Health of Obese Adolescents During Weight Loss||Children's Hospital of Philadelphia|No|Completed|January 2007|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|10 Years|14 Years|No|||February 2013|February 15, 2013|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609713||161175|
NCT00609726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X040909004|Prospective Evaluation of Idiopathic Pancreatitis: Role of Endoscopic Ultrasonography|Prospective Evaluation of Idiopathic Pancreatitis: Role of Endoscopic Ultrasonography||University of Alabama at Birmingham|Yes|Completed|December 2015|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|199|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women diagnosed with unexplained pancreatitis.|January 2015|January 21, 2016|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609726||161174|
NCT00609986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR #17383|IV Insulin Protocol in Diabetes and Renal Transplantation|Intravenous Insulin Protocol in Diabetes and Renal Transplantation Study||Medical University of South Carolina|Yes|Completed|July 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||August 2013|August 21, 2013|January 2, 2008||No||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00609986||161154|A limitation of the trial was that the majority of the patients enrolled in the study were African American, and therefore the findings cannot be extended to groups of other ethnic groups.
NCT00615927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008799|Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)|Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma||Duke University|Yes|Completed|February 2006|June 2012|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|March 13, 2013|February 3, 2008|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00615927||160709|
NCT00615940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX/60-006|Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer|A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer||Wilex|No|Completed|July 2008|April 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Female|18 Years|N/A|No|||January 2014|January 28, 2014|February 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00615940||160708|
NCT00617110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1064|Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies|Effects of Diesel Exhaust Particles on Influenza-induced Nasal Inflammation in Allergic Rhinitics and Non-allergic Individuals|FLAIR|University of North Carolina, Chapel Hill|No|Completed|January 2008|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|54|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617110||160619|
NCT00617344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD12|Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US|Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US||Sanofi|Yes|Completed|April 2008|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|260|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617344||160601|
NCT00617357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC2007.02.01|Repair of Infected or Contaminated Hernias|A Multicenter, Prospective, Observational Evaluation of Repair of Infected or Contaminated Hernias (RICH) Using LTM|RICH|LifeCell|No|Completed|September 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|January 14, 2008|Yes|Yes||No|August 16, 2012|https://clinicaltrials.gov/show/NCT00617357||160600|
NCT00617656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECP-BREC|Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma|Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer|BREC|Spanish Lung Cancer Group|Yes|Terminated|February 2008|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|400|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|February 5, 2008||No|No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental    arm over the control arm- would not be confirmed.|No||https://clinicaltrials.gov/show/NCT00617656||160578|
NCT00613717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD052069-01A2|Healthy Infant Development Project|Timing, Duration and Severity of Infant Iron Deficiency: Developmental Impacts||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|November 2009|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2371|||Both|N/A|5 Days|No|||March 2014|October 28, 2014|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00613717||160872|
NCT00617617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12835|The Specific Role of Isoflavones in Reducing Prostate Cancer Risk|The Specific Role of Isoflavones in Reducing Prostate Cancer Risk||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|February 2002|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|52|||Male|50 Years|80 Years|No|||February 2010|September 21, 2012|February 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00617617||160581|
NCT00617630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010070|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 1999|||||N/A|N/A|N/A||||||||||||||October 26, 2015|February 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617630||160580|
NCT00617877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_035|Antihypertensive Response to Losartan and Genetic Polymorphisms|Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide||Merck Sharp & Dohme Corp.||Completed|March 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|800|||Both|18 Years|60 Years|No|||July 2009|July 21, 2009|February 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00617877||160561|
NCT00613626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN06-113|Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer|A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113||Hoosier Cancer Research Network|Yes|Completed|January 2008|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 31, 2008|No|Yes||No|August 31, 2015|https://clinicaltrials.gov/show/NCT00613626||160877|The primary object analysis was under powered. The sample size calculation determined 34 subjects per arm, however the actual primary objective analysis was based on 31 subjects per arm.
NCT00613613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708M15441|Fenofibrate and Pharmacogenetic Impact in Dyslipidemia|The Impact of Genetic Determinants of Fenofibrate's Pharmacogenetics on Lipid Response|FPI|University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2008|December 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|56|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|January 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00613613||160878|
NCT00618241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 07.06|Pharmacokinetic Study on Raltegravir and Lamotrigine|The Influence of Raltegravir (MK-0518) on the Pharmacokinetics of Single-dose Lamotrigine in Healthy Male Subjects (GRANOLA)|GRANOLA|Radboud University|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|June 6, 2011|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00618241||160534|
NCT00618501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586176|Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Completed|October 2005|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|15 Years|N/A|No|||January 2009|March 25, 2013|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00618501||160515|
NCT00612144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIME_L_02861|Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM|A Multicenter, Randomized, Parallel-group, Open Study to Compare the Efficacy and Safety of Early Combination Therapy With Amaryl M to Metformin Uptitration in Type 2 DM Patients Inadequately Controlled on Metformin HCL||Handok Pharmaceuticals Co., Ltd.|No|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|30 Years|75 Years|No|||March 2013|March 26, 2013|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00612144||160989|
NCT00612157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC07-17022|Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Effect of Eszoplicone on Initial Continuous Positive Airway Pressure (CPAP) Compliance|CPAPASAP|Walter Reed Army Medical Center|Yes|Completed|January 2008|February 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|154|||Both|18 Years|64 Years|No|||February 2009|February 25, 2009|January 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612157||160988|
NCT00612404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312004008|Symptoms and Endoscopic Results in Consideration of Pretreatment|Symptoms and Endoscopic Results in Consideration of Pretreatment||AstraZeneca|No|Completed|September 2005|||December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16255|||Both|N/A|N/A|No|Probability Sample|gastroenterologists; specialists|January 2008|February 8, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00612404||160969|
NCT00614783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2701|Screening for Early Evidence of Diabetes|A Prospective, Multi-Center, Paired Data, Cohort Screening Trial Comparing SCOUT to the Fasting Plasma Glucose Test in Subjects at Risk for Diabetes|SEED|VeraLight, Inc.|No|Completed|May 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3478|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General population who are 'at risk' for pre-diabetes or diabetes.|December 2012|December 3, 2012|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614783||160796|
NCT00615043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL007|Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure|A Multi Center Study to Obtain Bladder Tissue Specimens From Subjects Undergoing Transurethral Resection of Bladder Tumor (TURBT) or Other Transurethral Biopsy Procedures||Tengion|No|Completed|February 2008|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|Samples Without DNA|Tissue|Both|18 Years|90 Years|No|Non-Probability Sample|Patients otherwise undergoing TURBT|December 2010|December 20, 2010|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615043||160776|
NCT00609999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002272|Ph I Dasatinib + Erlotinib in Recurrent MG|Phase I Study of Dasatinib Plus Erlotinib in Recurrent Malignant Glioma||Duke University|Yes|Completed|January 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||April 2012|July 15, 2014|January 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00609999||161153|
NCT00610012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM RCC|Tumor Registry of Advanced Renal Cell Carcinoma|Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy|RCC-Registry|iOMEDICO AG|No|Recruiting|December 2007|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Practitioners specialized in oncology and urology in Germany|February 2016|February 26, 2016|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00610012||161152|
NCT00610298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001H0215|Effects of Whole Body Vibration in Elderly Patients Requiring Rehabilitation: A Pilot Study|Effects of Whole Body Vibration in Elderly Patients Requiring Rehabilitation: A Pilot Study||Ohio State University|No|Withdrawn|October 2001|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|December 26, 2007||No|Another institution published results obviating the need for this study.No subjects ever    enrolled.|No||https://clinicaltrials.gov/show/NCT00610298||161130|
NCT00610311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080055|Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization||National Institutes of Health Clinical Center (CC)|Yes|Terminated|January 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|February 6, 2008|Yes|Yes|The study was terminated due to low accrual.|No|March 14, 2012|https://clinicaltrials.gov/show/NCT00610311||161129|Early termination leading to a small number of subjects analyzed.
NCT00615953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000557|American Norditropin Studies - Registry of Growth Hormone (GH) Patients|American Norditropin Studies: Web-Enabled Research (The ANSWER Program) ID#: HGH-2149|ANSWERProg|Duke University|Yes|Suspended|May 2007|May 2017|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|79|||Both|N/A|N/A|No|Non-Probability Sample|Patients on Norditropin Growth Hormone|June 2011|June 28, 2011|February 3, 2008|No|Yes|New Consent Forms necessary with new website|No||https://clinicaltrials.gov/show/NCT00615953||160707|
NCT00616499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582623|Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer|A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|November 2006|||November 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||September 2008|February 6, 2009|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00616499||160665|
NCT00616512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02582|A Randomized Controlled Trial of a Water Protocol for Clients With Thin Liquid Dysphagia|A Randomized Controlled Trial of a Water Protocol for Clients With Thin Liquid Dysphagia: a Pilot Project||University of British Columbia|No|Completed|April 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||June 2011|June 22, 2011|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616512||160664|
NCT00616538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI 2006-002|Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis|Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing Effect of Epiceram™ Device vs Standard of Care Therapy of Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) in Treatment of Atopic Dermatitis in Pediatric Subjects||Ceragenix Pharmaceuticals|No|Completed|December 2006|||April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|6 Months|18 Years|No|||February 2008|February 5, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616538||160663|
NCT00616824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070415|The Use of an Acellular Dermal Matrix in a Two-Staged Breast Reconstruction|The Use of an Acellular Dermal Matrix in a Two-Staged Breast Reconstruction The Use of an Acellular Dermal Matrix in a Two-Staged Breast Reconstruction After Mastectomy: A Double-Blinded, Randomized Trial||Vanderbilt University|Yes|Terminated|September 2007|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||February 2008|August 3, 2013|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616824||160641|
NCT00613730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060542|Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint|Phase II, Multi-center, Open-label, Single-Arm Study Using Gemcitabine and Panitumumab in the First-line Treatment of Subjects With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas|APPRISE 1|Amgen||Terminated|January 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||November 2013|November 15, 2013|January 31, 2008|||APPRISE closure prompted by SWOG S0205 not meeting primary endpoint-improving OS. APPRISE    enrollment closure due to similar design;no unexpected safety data|No|August 6, 2010|https://clinicaltrials.gov/show/NCT00613730||160871|
NCT00609622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181104|Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer|A Randomized, Phase 2B Study Of Sunitinib Plus Oxaliplatin, 5-Fluorouracil And Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX As First-Line Treatment In Patients With Metastatic Colorectal Cancer||Pfizer|No|Terminated|April 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|January 25, 2008|Yes|Yes|See termination reason in detailed description.|No|July 6, 2012|https://clinicaltrials.gov/show/NCT00609622||161182|Due to early study termination, not all data was analyzable.
NCT00617643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR 004|Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis|Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy||Makerere University|Yes|Completed|May 2008|December 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|60 Years|No|||December 2010|December 3, 2010|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617643||160579|
NCT00613665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPP002|Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults|Phase I, Randomized, Controlled, Single-blind, Dose-Ranging and Schedule-Finding Study of the Safety, Tolerability, and Immunogenicity of Chiron Helicobacter Pylori Vaccine in Healthy, Helicobacter Pylori-negative Adults||Novartis||Completed|February 2001|April 2002|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|7||Actual|113|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613665||160875|
NCT00613678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT|Exercise Plus Activity Strategy Training for Osteoarthritis|Exercise Plus Activity Strategy Training for Older Adults With Osteoarthritis||University of Michigan|No|Completed|July 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|54|||Both|62 Years|N/A|No|||August 2015|August 3, 2015|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613678||160874|
NCT00613652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2782C00008|A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies||AstraZeneca|Yes|Completed|January 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|75 Years|No|||July 2009|July 20, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613652||160876|
NCT00613964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiol001|The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure|The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure||Nara Medical University|Yes|Terminated|May 2009|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|80 Years|No|||February 2009|July 20, 2011|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613964||160853|
NCT00619398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR4LTxCN02|A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients and a Pharmacokinetics Study||Astellas Pharma Inc|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619398||160447|
NCT00619684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2161.00|Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant|A Phase II Study of Lenalidomide Following Allogeneic Stem Cell Transplant for Multiple Myeloma Patients Who Relapse or Have Disease Progression||Fred Hutchinson Cancer Research Center||Completed|February 2008|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|February 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619684||160425|
NCT00619697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1564|Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes|Comparison of Efficacy and Safety of Biphasic Insulin Aspart 30 Plus Metformin With Insulin Glargine Plus Glimepiride in Type 2 Diabetes|EUROMIX|Novo Nordisk A/S|No|Completed|December 2003|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|260|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|February 11, 2008||||No||https://clinicaltrials.gov/show/NCT00619697||160424|
NCT00611897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508000518|N-acetylcysteine and NMDA Antagonist Interactions|N-acetylcysteine and NMDA Antagonist Interactions||Yale University|No|Completed|January 2006|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|16|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|January 29, 2008||No||No|January 10, 2013|https://clinicaltrials.gov/show/NCT00611897||161008|
NCT00613197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0307|EPANOVA in Crohn's Disease, Study 1|A One Year, Multi-center, Randomised, Double-blind Placebo-controlled Parallel-groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/Day for Maintenance of Remission of Crohn's Disease.|EPIC-1|Tillotts Pharma AG|Yes|Completed|January 2003|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|384|||Both|18 Years|70 Years|No|||April 2013|April 3, 2013|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00613197||160908|
NCT00613535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-706-DHH|Knee Articular Cartilage Debridement in Conjunction With Partial Meniscectomy|Magnetic Resonance Imaging and Clinical Outcomes After Three Different Treatments for Articular Cartilage Lesions Concomitant With Partial Meniscectomy|MILE|Smith & Nephew, Inc.|No|Terminated|April 2008|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|60 Years|No|||May 2015|May 18, 2015|January 31, 2008||No|The correlation coefficient at the interim analysis with results for all three groups pooled,    did not reach the level of statistical significance of (p<0.05).|No||https://clinicaltrials.gov/show/NCT00613535||160884|
NCT00613522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2006/10|Role of Obstructive Sleep Apnea in Stroke Appearance|Role of Nocturnal Respiratory Disorders on Ischemic Stroke Occurrence|AVSAS|University Hospital, Bordeaux|No|Completed|November 2007|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|289|||Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases will be recruited in the stroke unit at the Bordeaux University hospital Controls        will be recruited among sex and age matched patients hospitalized at the        Bordeaux-University hospital for investigation of non-vascular disorder|March 2015|March 4, 2015|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00613522||160885|
NCT00609414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1392|Albumin Use in Burn Patients|Albumin Use in Burn Patients||University of North Carolina, Chapel Hill|No|Completed|January 2005|October 2008|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|460|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have 20% and greater Total Body Surface Area burns who received fluid        resuscitation for these injuries.|April 2011|April 15, 2011|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609414||161197|
NCT00615069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA 03-02|Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms|A Clinical Study Evaluating the Use of the GORE EXCLUDER® AAA Endoprosthesis - 31mm In the Primary Treatment of Infrarenal Abdominal Aortic Aneurysms||W.L.Gore & Associates|No|Completed|May 2006|June 2014|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|21 Years|N/A|No|||March 2015|March 23, 2015|December 20, 2007|Yes|Yes||No|March 26, 2009|https://clinicaltrials.gov/show/NCT00615069||160774|
NCT00615017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0620C00004|AZD9773 Dose Escalation Study|A Placebo-controlled, Double-blind, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients With Severe Sepsis||AstraZeneca|Yes|Completed|January 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|70|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|January 31, 2008|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00615017||160778|
NCT00615030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2305|Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Randomized, Double Blind, Double Dummy, Placebo Controlled, Multicenter, 4 Treatments, 3 Period Incomplete Block Crossover Study to Assess the Efficacy and Safety of Indacaterol 300 µg o.d. Dosed in the Evening in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Salmeterol 50 µg b.i.d. as Active Control||Novartis|No|Completed|January 2008|August 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|12||Actual|96|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 1, 2008||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00615030||160777|
NCT00615368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-185|Treatment With Erythropoietin and Cognition During Hypoglycaemia|The Effect of Intravenous Erythropoietin Treatment on Cognition During Hypoglycemia in Patients With Type 1 Diabetes.||Hillerod Hospital, Denmark|No|Completed|May 2008|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615368||160751|
NCT00616291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579579|Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer|Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14)||Baylor College of Medicine||Completed|April 2006|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Male|18 Years|N/A|No|||November 2012|November 5, 2012|February 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00616291||160681|
NCT00616837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-REK-N-134/2006|Remote Orthopedic Outpatient Consultation by Help of Telemedicine|Remote Orthopedic Outpatient Consultation by Help of Telemedicine||University Hospital of North Norway|No|Completed|November 2007|October 2014|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|400|||Both|N/A|N/A|No|||December 2015|December 16, 2015|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00616837||160640|
NCT00617136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/235|Perioperative Temperature Management|Perioperative Temperature Management: A Big Small Problem|HOT|VU University Medical Center|No|Completed|April 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|70|||Both|18 Years|85 Years|No|||December 2014|December 16, 2014|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00617136||160617|
NCT00609635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adult RSV RC# 4212|Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly|The Association Between Cytokine Genotype Polymorphisms and Severity of RSV-Induced Illness in the Elderly||West Penn Allegheny Health System|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|A buccal brushing (cells collected from the inside of the cheek) will be collected and      stored for DNA analysis.|Both|65 Years|N/A|No|Non-Probability Sample|inpatient or outpatient subjects with respiratory illnesses potentially caused by RSV|April 2009|April 3, 2009|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609635||161181|
NCT00610194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15505|Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients|A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients||Bayer|No|Completed|November 2007|August 2012|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00610194||161138|
NCT00617890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04720|A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed Osteosarcoma or Ewing's Sarcoma (Study P04720)|A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy||Merck Sharp & Dohme Corp.|No|Terminated|February 2008|August 2013|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|219|||Both|4 Years|N/A|No|||November 2015|November 9, 2015|January 17, 2008|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT00617890||160560|The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.
NCT00617669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00033|A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer|A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer|ENTHUSE M1C|AstraZeneca|Yes|Completed|January 2008|July 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1494|||Male|18 Years|N/A|No|||April 2012|September 4, 2012|January 24, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00617669||160577|
NCT00613977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007013|Comparison of Two Fetal Lung Maturity Tests|Pilot Study-A Cost and Time Savings Comparison of Lamellar Body Count and FLM II||Oklahoma State University Center for Health Sciences|Yes|Withdrawn|January 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|None Retained|Amniotic fluid for fetal lung maturity test|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women delivering a term infant by cesarean section at Oklahoma State University Medical        Center.|September 2011|September 19, 2011|January 31, 2008||No|Withdrawn|No||https://clinicaltrials.gov/show/NCT00613977||160852|
NCT00619411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5549|Interpersonal Psychotherapy for Depressed Adolescents and Parents|An Open Clinical Trial of Interpersonal Psychotherapy for Depressed Adolescence and Parents||New York State Psychiatric Institute|Yes|Completed|November 2007|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|12 Years|18 Years|No|||March 2012|March 8, 2012|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00619411||160446|
NCT00619710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3591IL/0079|Complicated Skin and Skin Structure Infections|A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-Cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections.||AstraZeneca||Completed|February 2001|April 2004|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|13 Years|N/A|No|||February 2008|February 20, 2008|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619710||160423|
NCT00619723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122007-039|Citicoline for Bipolar 1 Disorder and Cocaine Dependence|A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence.||University of Texas Southwestern Medical Center|No|Completed|April 2008|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 29, 2013|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00619723||160422|
NCT00619996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PISAUNO|Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer|Phase II Study of Sorafenib (Bay 43-9006) and Docetaxel in Metastatic Prostate Cancer|P1|Italian Trial in Medical Oncology|Yes|Completed|March 2007|January 2009|Actual|January 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|N/A|N/A|No|||February 2009|February 25, 2009|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00619996||160401|
NCT00613210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR463907CTIL|Sonographic Prediction of Preterm Delivery Between 24-34 Weeks of Gestation|Sonographic Prediction of Preterm Delivery Between 24-34 Weeks of Gestation||Soroka University Medical Center||Active, not recruiting|January 2008|||June 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|None Retained|sonographic measurments|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|women that visit a tetriary hospital for follow up|January 2008|February 11, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00613210||160907|
NCT00613548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoMIC|Moderate Mitral Regurgitation in CABG Patients|Moderate Mitral Regurgitation in CABG Patients|MoMIC|University of Aarhus|Yes|Recruiting|February 2008|June 2015|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||November 2008|November 10, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613548||160883|
NCT00609427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY-07-015|Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study|Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study||McGill University Health Center|No|Completed|May 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|65 Years|90 Years|No|||June 2010|June 1, 2010|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00609427||161196|
NCT00609440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mairabelo|Morquio's Syndrome: a Case Study|Morquio's Syndrome: a Case Study||Clínica de Hidroterapia e Recuperacao Funcional|No|Terminated|January 2006|May 2007|Actual|August 2006|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|N/A|N/A|Accepts Healthy Volunteers|||January 2008|October 17, 2008|January 25, 2008||No|terminated|No||https://clinicaltrials.gov/show/NCT00609440||161195|
NCT00610337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSE-C-01|Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury|A Phase IIb, Double-Blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Safety and Efficacy of Intraoperative Epidural Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury||BioAxone BioSciences, Inc.|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|62 Years|No|||February 2010|January 16, 2014|January 15, 2008|Yes|Yes|Due to a change of sponsor|No||https://clinicaltrials.gov/show/NCT00610337||161127|
NCT00615407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001136|A Pilot Evaluation of the Impact of Alcohol Use on Airway Inflammation and Mechanics in Asthmatics||AIM Asthma|Emory University|No|Withdrawn|January 2007|||||N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|0|Samples With DNA|Blood, urine, and exhaled breath condensate|Both|18 Years|65 Years|No|Non-Probability Sample|For this study, 40 non-smoking adults with asthma will be recruited—50% will be        non-drinking and 50% will be heavy alcohol users (≥3 standard drinks/day on average).|November 2013|November 14, 2013|February 4, 2008||No|Dr. Holguin is relocating.|No||https://clinicaltrials.gov/show/NCT00615407||160748|
NCT00615056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061034|A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen|A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen||Pfizer|No|Completed|March 2008|April 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|171|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|February 1, 2008|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00615056||160775|
NCT00615381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKG 2498-002|Supraphysiologic Insulin to Improve Outcomes After Surgical Treatment of Unruptured Cerebral Aneurysms|Clinical Trial of Euglycemia Maintenance With Supraphysiologic Insulin vs Conventional Intensive Insulin Therapy to Improve Outcomes (Neurologic, Neuropsychiatric, and Biomarkers) After Surgical Treatment of Unruptured Cerebral Aneurysms||Northwestern University|No|Withdrawn|January 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|January 21, 2008|Yes|Yes|Study was not initiated and has been withdrawn due to lack of appropriate cases|No||https://clinicaltrials.gov/show/NCT00615381||160750|
NCT00615667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGNS-001|Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)|||Sun Yat-sen University|Yes|Completed|June 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|14 Years|65 Years|No|||May 2015|May 19, 2015|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615667||160728|
NCT00615914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.547|Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole|Pramipexole Special Survey on Long-Term Use||Boehringer Ingelheim||Completed|February 2004|||March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1645|||Both|N/A|N/A|No|Non-Probability Sample|Parkinson's disease patients in daily clinical settings|June 2014|June 10, 2014|January 31, 2008||||No|September 8, 2010|https://clinicaltrials.gov/show/NCT00615914||160710|
NCT00616304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arginineSM1|Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria|Safety and Preliminary Efficacy, Pharmacokinetics, Pharmacodynamics of L-arginine in Severe Falciparum Malaria|ARGISM|Menzies School of Health Research|Yes|Suspended|February 2008|||March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|60 Years|No|||June 2013|June 24, 2013|February 4, 2008||No|Local circumstances & difficulties in site access has prevented continuation|No||https://clinicaltrials.gov/show/NCT00616304||160680|
NCT00616265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot-740|Effect of Continuous Positive Airway Pressure (CPAP) Treatment in the Control of Refractory Hypertension|Effect of CPAP Treatment in the Control of Refractory Hypertension||Sociedad Española de Neumología y Cirugía Torácica|Yes|Completed|June 2008|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|75 Years|No|||February 2012|February 28, 2012|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616265||160683|
NCT00616278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412150-5|National Cooperative Growth Study in CKD|National Cooperative Growth Study of Nutropin AQ, Nutropin, Protropin, and Nutropin Depot in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End-Stage Renal Disease (ESRD)|NCGS|University of California, Davis|Yes|Completed|October 2005|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|N/A|18 Years|No|Non-Probability Sample|pediatric clinic|November 2012|November 22, 2012|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616278||160682|
NCT00616850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57175|Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion|Treatment of Postoperative Pain After Total Knee Arthroplasty Using Intravenous Lidocaine Infusion in Combination With Patient Controlled Analgesia Versus Continuous Femoral Block Catheter in Combination With Patient Controlled Analgesia: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study.||Loma Linda University|No|Withdrawn|October 2007|July 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|No|||May 2014|May 20, 2014|February 4, 2008||No|Orthopedic surgeon that does our knee surgeries moved to a different location|No||https://clinicaltrials.gov/show/NCT00616850||160639|
NCT00616863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXCA-02|Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazapine 600 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|July 2004|July 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 14, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616863||160638|
NCT00617149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05208 (REK)|Effect of Regular Exercise in Prevention of Excessive Weight Gain in Pregnancy|Effect of Regular Exercise in Prevention of Excessive Weight Gain in Pregnancy. A Single Blind Randomized Controlled Trial||Norwegian School of Sport Sciences|No|Completed|November 2007|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|105|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00617149||160616|
NCT00610207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002|Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft|Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft (SurgiSIS AFP)|SurgiSIS AFP|Cook|No|Terminated|March 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||March 2012|December 29, 2015|January 24, 2008|Yes|Yes|Study stopped early due to staffing changes at the site.|No|April 25, 2011|https://clinicaltrials.gov/show/NCT00610207||161137|Early termination did lead to small patient numbers.
NCT00617903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1402140|Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea|A 12-week Exploratory, Multicenter, Double-blind, Vehicle-controlled Study to Investigate the Efficacy and Safety of Topical Azelaic Acid 15% Foam Twice Daily in Patients With Papulopustular Rosacea||Bayer|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||December 2013|December 26, 2013|January 22, 2008|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00617903||160559|
NCT00619424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG109607|A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors|A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors||GlaxoSmithKline|No|Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||November 2011|May 31, 2012|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00619424||160445|
NCT00619437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4620-RG-CTIL|Genetics of Schizophrenia|Genetics of Schizophrenia||Sheba Medical Center|No|Not yet recruiting|April 2008|December 2009|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Cell Lines / DNA|Both|18 Years|78 Years|No|Non-Probability Sample|schizophrenia|February 2008|February 10, 2008|February 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00619437||160444|
NCT00619736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3230A1-1001|Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male Subjects|Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of NSA-789 Administered Orally to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|56|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00619736||160421|
NCT00619749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4125|Polyphenols and Endothelial Function|Polyphenols Rich Fruit Juice Effects on Endothelial Function and Exercise Capacity||University Hospital, Strasbourg, France|No|Suspended|March 2008|March 2012|Anticipated|February 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||August 2011|August 18, 2011|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00619749||160420|
NCT00620022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2311|The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Novartis|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 8, 2008|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00620022||160399|
NCT00613223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001919|Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas|Phase I Dose Escalation of Vandetanib (Zactima, ZD6474) in Combination With Etoposide for Malignant Gliomas||Duke University|Yes|Completed|February 2008|May 2011|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613223||160906|
NCT00610038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050702|Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus|Sulfonylureas in Neonatal Diabetes Mellitus With Mutations of 2 Type of Subunits Kir6.2 and SUR1 of the Pancreatic Beta-cell ATP-sensitive K+ Channel.|GLIDKIR6-2|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2006|December 2011|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|N/A|No|||November 2012|November 16, 2012|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00610038||161150|
NCT00610324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRK-CHEX|Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients|Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients: an Open-Labelled Randomized Controlled Trial||King Edward Memorial Hospital|No|Completed|May 2004|December 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|512|||Both|13 Years|N/A|No|||January 2008|January 24, 2008|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00610324||161128|
NCT00614445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIC-301|The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy|A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy||Duchesnay Inc.|No|Completed|January 2008|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|280|||Female|18 Years|N/A|No|||August 2011|August 4, 2011|January 29, 2008|Yes|Yes||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00614445||160819|
NCT00614458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10493|MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection|10493 - MK-0518 Intensification and HDAC Inhibition in Depletion of Resting CD4+ T Cell HIV Infection||University of North Carolina, Chapel Hill|Yes|Terminated|April 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2011|October 24, 2011|January 31, 2008|Yes|Yes|Due to insufficient funds|No|April 15, 2011|https://clinicaltrials.gov/show/NCT00614458||160818|
NCT00615420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02297|A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer|A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer||British Columbia Cancer Agency|No|Completed|July 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|106|||Both|N/A|N/A|No|||May 2012|May 22, 2012|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00615420||160747|
NCT00615394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP3549/04|Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy|Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy in Dilated Cardiomyopathy - Technique and Early Results|STEMDILCARD|Instituto de Cardiologia do Rio Grande do Sul|Yes|Completed|April 2004|December 2006|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||February 2008|February 1, 2008|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615394||160749|
NCT00615693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2211|Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis|A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis||Novartis|No|Completed|July 2008|||October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|70 Years|No|||May 2012|May 31, 2012|February 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00615693||160727|
NCT00578305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA21056|A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate|A Randomized, Placebo Controlled, Multicenter Clinical Study Investigating Efficacy of Rituximab in the Inhibition of Joint Structural Damage Assessed by Magnetic Resonance Imaging in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate|SCORE|Hoffmann-La Roche||Completed|November 2007|May 2013|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|185|||Both|18 Years|80 Years|No|||March 2015|March 26, 2015|December 19, 2007||No||No|February 19, 2015|https://clinicaltrials.gov/show/NCT00578305||163526|
NCT00578591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19734|Rituximab for GVHD|CHIMERIC MONOCLONAL CD-20 ANTIBODY (RITUXIMAB) FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-AGVHD): A PILOT STUDY|Rituximab GVHD|Baylor College of Medicine|Yes|Withdrawn|June 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|70 Years|No|||July 2012|July 6, 2012|December 19, 2007|Yes|Yes|No eligible patients were identified so the study was terminated.|No||https://clinicaltrials.gov/show/NCT00578591||163504|
NCT00578838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-082|Magnetic Resonance Study of Liver in Chemotherapy|Magnetic Resonance Study of Liver in Chemotherapy||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|August 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|55|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There will be a total of 20 patients with metastatic colorectal cancer, 20 patients with        non-metastatic colorectal cancer and 11 healthy volunteers.|January 2016|January 4, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00578838||163485|
NCT00578851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.H021|A Clinical Investigation of the C2a-Taper™ Acetabular System|Post Approval Study of the C2a-Taper™ Acetabular System||Biomet, Inc.|No|Active, not recruiting|April 2006|October 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Multi-Center study conducted in the United states on patients who meed the inclusion /        exclusion criteria identified in the protocol.|April 2015|May 4, 2015|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578851||163484|
NCT00578812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G040081|PCM Cervical Disc System|A Prospective, Randomized, Controlled Clinical Investigation Comparing PCM® Cervical Disc Arthroplasty to Anterior Cervical Discectomy and Fusion: 2 Year Results From the US IDE Clinical Trial||NuVasive|No|Completed|January 2005|August 2014|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|494|||Both|18 Years|65 Years|No|||June 2015|June 8, 2015|December 19, 2007|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00578812||163487|
NCT00578825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR/04-009|A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome|A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome||Hospital Authority, Hong Kong||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|340|||Both|18 Years|N/A||||August 2013|August 21, 2013|December 20, 2007||||No||https://clinicaltrials.gov/show/NCT00578825||163486|
NCT00579397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0407|Markers of Inflammation in Hematopoietic Stem Cell Transplant|Markers of Inflammation in Hematopoietic Stem Cell Transplant||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|April 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|2.5 mL's of whole blood are obtained one time a week for the first 100 days of transplant|Both|N/A|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing a hematopoietic stem cell transplant at Children's Memorial Hospital|May 2009|May 26, 2009|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00579397||163442|
NCT00579644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|519-00 FB|Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone|Treatment of Early Rheumatoid Arthritis: Minocycline in Combination With Methotrexate Versus Methotrexate Alone||University of Nebraska|Yes|Completed|January 2001|May 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|19 Years|75 Years|No|||January 2010|January 12, 2010|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579644||163423|
NCT00579891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-006|Tissue and Serum Collection From Colorectal Cancer Patients|Tissue and Serum Collection From Colorectal Cancer Patients||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 1989|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|serum tissue|Both|N/A|N/A|No|Non-Probability Sample|Colorectal cancer patients undergoing surgical resection|February 2016|February 2, 2016|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579891||163405|
NCT00579878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-01|Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis|Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid Arthritis||University of Nebraska|Yes|Completed|December 1999|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|19 Years|80 Years|No|||January 2014|January 2, 2014|December 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579878||163406|
NCT00580138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DC005603|Real-Time Internet Evaluation of Swallowing|Real-Time Internet Evaluation of Oropharyngeal Dysphagia||University of Arkansas|No|Completed|May 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|21 Years|N/A|No|Non-Probability Sample|Individuals who have suffered a stroke and/or head and neck cancer and are referred for        evaluation of swallowing function.|October 2014|October 21, 2014|December 20, 2007||No||No|May 6, 2010|https://clinicaltrials.gov/show/NCT00580138||163386|
NCT00580151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-101|The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children|The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children|clonidine|The University of Texas Medical Branch, Galveston|No|Terminated|June 2004|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|4 Years|20 Years|No|||February 2015|February 10, 2015|December 18, 2007|Yes|Yes|Closed due to no response from PI to IRB|No|February 8, 2013|https://clinicaltrials.gov/show/NCT00580151||163385|No Adverse Events Recorded.
NCT00580112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014764|An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer|Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|127|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00580112||163388|
NCT00580125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7251006|Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia|A Phase 2, Multicenter, Double-Blind, Randomized, Fixed Dose, Parallel Group, 3-Week Inpatient Treatment Study To Evaluate The Dose-Response Relationship, Safety, Efficacy, And Pharmacokinetics Of PF-00217830 Compared With Placebo, Using Aripiprazole As A Positive Control, In The Treatment Of Acute Exacerbation Of Schizophrenia||Pfizer|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|164|||Both|18 Years|N/A|No|||January 2011|April 16, 2012|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580125||163387|
NCT00580398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-000838|Smoking Cessation Intervention for Thoracic Patients|A Pilot Smoking Cessation Study for Newly Diagnosed Lung Cancer Patients||Massachusetts General Hospital|No|Completed|January 2008|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|N/A|N/A|No|||November 2014|November 20, 2014|December 20, 2007||No||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00580398||163366|The generalizability of the findings are limited by a single study site. The statistical power to detect differences was limited by the small sample size of this pilot study.
NCT00598715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02407|Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents|Randomized Trial of Paclitaxel- vs Sirolimus-eluting Stents for Treatment of Coronary Restenosis in Sirolimus-eluting Stents|DESIRE-2|Deutsches Herzzentrum Muenchen|Yes|Completed|October 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|N/A|No|||September 2009|December 16, 2010|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598715||161990|
NCT00598975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-PIR-02|A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients|A Multicenter, Open-Label, Phase 2 Study to Determine the Dose, Safety and Efficacy of NKTR 102 (PEG-Irinotecan) in Combination With Cetuximab in Patients With Solid Tumors Refractory to Standard Treatment and to Evaluate the Safety and Efficacy of NKTR 102 or Irinotecan in Combination With Cetuximab in Second Line, Irinotecan and Cetuximab Naïve, Colorectal Cancer Patients With Metastatic or Locally Advanced Disease||Nektar Therapeutics|No|Completed|January 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598975||161970|
NCT00592319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-006617A|Celebrex (Celecoxib) Treatment of Laryngeal Papilloma|Voice-preserving Treatment of Laryngeal Papilloma||Boston University|No|Terminated|May 2005|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|64 Years|No|||August 2012|August 24, 2012|December 31, 2007|Yes|Yes|03/01/2009,due to date close to termination of this funding/study period|No|May 3, 2012|https://clinicaltrials.gov/show/NCT00592319||162468|We failed to recruit a total of 30 cases, due to (1) This disease is relative less common in clinic; and (2) particularly, more and more of patients now had a serious concern in safety of Celebrex due to news and warnings to public in recent years.
NCT00592332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#040908-HAAF-T1DM-Q2|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 2||Vanderbilt University|No|Completed|June 2005|June 2009|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00592332||162467|
NCT00595075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Takeda - 103113|Ramelteon for a Nap Prior to a Night Shift|Effects of Ramelteon on Sleep and Neurobehavioral Performance in a Simulated Night Shift Preceded by a Sleep Opportunity||Brigham and Women's Hospital|No|Completed|December 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|11|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|January 7, 2008||No||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00595075||162260|Circadian phase was not measured.
NCT00570232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070824015|UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer|Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer|UAB0718|University of Alabama at Birmingham|Yes|Completed|December 2007|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|N/A|N/A|No|||May 2015|May 4, 2015|December 6, 2007|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00570232||164127|
NCT00571259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR001AL|Prophylactic Antimicrobial Catheter Lock|Prophylactic Antimicrobial Catheter Lock in Hemodialysis Patients: A Randomized Controlled Clinical Trial|ALLOCK|Satellite Healthcare|No|Completed|September 2003|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|303|||Both|N/A|N/A|No|||December 2011|December 15, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571259||164050|
NCT00571506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26963|Effect of Thiazolidinedione Treatment Vascular Risk Markers|A Pilot Study to Determine the Effects of Short-term Thiazolidinedione Treatment on Vascular Risk Markers in Type 2 Diabetes Patients||University of Arkansas|No|Completed|May 2004|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|65 Years|No|||December 2009|December 8, 2009|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571506||164031|
NCT00578604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17035|Non-Invasive Assessment of Wound Healing With Optical Methods|Non-Invasive Assessment of Wound Healing With Optical Methods||Drexel University|No|Recruiting|September 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruited patients will be patients with diabetes who have chronic wounds and will likely        have other co-morbidities associated with chronic diabetes.        Control subjects do not have diabetes and do not have wounds.|May 2011|May 24, 2011|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00578604||163503|
NCT00578864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H20255|Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma|PEPI: Protracted Etoposide in a Phase II Upfront Window for Induction Therapy for High Risk Neuroblastoma|PEPI|Baylor College of Medicine|Yes|Completed|March 2007|March 2015|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|N/A|N/A|No|||June 2015|June 25, 2015|December 19, 2007|Yes|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT00578864||163483|
NCT00579137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21123-MASCI|Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders|CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders|MASCI|Baylor College of Medicine|Yes|Terminated|October 2007|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||June 2013|June 28, 2013|December 19, 2007|Yes|Yes|slow accrual|No|March 30, 2013|https://clinicaltrials.gov/show/NCT00579137||163462|
NCT00579410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0019|Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule|Evaluation of Esophageal and Gastric Acid Levels in Patients Presenting With Upper Gastrointestinal Symptoms Using a Novel PH System||Kansas City Veteran Affairs Medical Center|No|Completed|May 2004|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The subjects in this study were selected from veterans ages 18 and above presenting for an        upper endoscopy|March 2011|March 21, 2011|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00579410||163441|
NCT00579423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-064|Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer|A Pilot Multivalent Conjugate Vaccine Trial for Patients With Biochemically Relapsed Prostate Cancer||Memorial Sloan Kettering Cancer Center|Yes|Completed|November 2000|March 2009|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 17, 2009|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579423||163440|
NCT00580164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-p000239|The Role of Splinting in Fingertip Injuries|The Role of Splinting in Fingertip Injuries||Massachusetts General Hospital|No|Withdrawn|January 2006|December 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Orthopaedic Hand Clinic|December 2015|December 29, 2015|December 20, 2007||No|Very few subjects were enrolled. Therefore, the study was terminated.|No||https://clinicaltrials.gov/show/NCT00580164||163384|
NCT00580190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8821006|Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects|A Phase I, Randomized, Placebo Controlled, Parallel Group, Single Dose Study To Evaluate The Effects Of PF-00572778 And Alprazolam On A Naloxone Challenge In Healthy Adult Subjects||Pfizer|No|Terminated|September 2007|February 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 11, 2009|December 20, 2007|No|Yes|Date of termination was Feb. 7, 2008. Reasons of termination were due to elevation of liver    function tests and long elimination half-life of the compound.|No||https://clinicaltrials.gov/show/NCT00580190||163382|
NCT00580177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS BOOP|PHS, Lichtenstein Mesh, and PerFixPlug for Primary Inguinal Hernia Repair - 3 Years Results|Prolene Hernia System, Lichtenstein Mesh, and Plug-and-Patch for Primary Inguinal Hernia Repair - Three Year Outcome of a Prospective Randomised Controlled Trial|BOOP|Göteborg University|No|Completed|January 2000|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|472|||Male|30 Years|75 Years|No|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00580177||163383|
NCT00580424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-002|The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots|The Effect of Oral Norethindrone on Coagulation Parameters in Women at Increased Risk for Venous Thromboembolic Events||University of Vermont|Yes|Terminated|December 2007|July 2009|Anticipated|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Female|18 Years|52 Years|No|||December 2007|June 24, 2010|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580424||163364|
NCT00580411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#16934|A Timeline Study of Alcohol Use and Its Relationship to Insomnia|A Timeline Study of Alcohol Use and Its Relationship to Insomnia||National Institute on Drug Abuse (NIDA)|No|Completed|March 2007|May 2009|Actual|May 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|75|||Both|18 Years|70 Years|No|Non-Probability Sample|We wish to study individuals who meet lifetime criteria for alcohol dependence, abuse or        heavy drinking and who self-report current insomnia.|October 2015|October 6, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00580411||163365|
NCT00580645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0702002391|Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 2: Do Varenicline (Chantix) and Bupropion (Zyban) Change Alcohol Drinking?|Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 2: Do Varenicline (Chantix) and Bupropion (Zyban) Change Alcohol Drinking?||Yale University|Yes|Active, not recruiting|April 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|308|||Both|21 Years|N/A|No|||October 2015|October 8, 2015|December 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580645||163348|
NCT00592072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66108b_0505000079|Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes|Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes||Yale University|No|Completed|July 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|No|||January 2015|January 8, 2015|December 26, 2007||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT00592072||162487|No technical limitations were seen.
NCT00592085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0111|Combined Treatment for Tobacco and Alcohol Use|Combined Treatment for Tobacco and Alcohol Use||M.D. Anderson Cancer Center|Yes|Terminated|December 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|October 7, 2009|December 27, 2007||No|No patients registered; study terminated.|No|September 8, 2009|https://clinicaltrials.gov/show/NCT00592085||162486|
NCT00592371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59102|Head and Neck Cancer Screening and Serum Repository|Head and Neck Cancer Screening and Serum Repository||University of Arkansas|No|Completed|March 2006|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|Samples Without DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic|September 2012|September 4, 2012|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00592371||162464|
NCT00592345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-502|High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum|High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum||Massachusetts General Hospital|Yes|Active, not recruiting|May 1999|||March 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00592345||162466|
NCT00592631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405-16|Assessment Of The Effects Of Short and Long Term Use Of CPAP|Assessment of the Effects of Short and Long Term Use of Continuous Positive Airway Pressure on Airway Reactivity in Children and Adults With and Without Asthma||Indiana University|No|Terminated|February 2005|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Both|8 Years|60 Years|No|||January 2016|January 12, 2016|January 2, 2008||No|Key investigator resigned|No|November 12, 2015|https://clinicaltrials.gov/show/NCT00592631||162444|
NCT00592904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-228|Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)|A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)||Eisai Inc.||Completed|January 2008|July 2011|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|262|||Both|18 Years|N/A|No|||November 2015|December 17, 2015|January 3, 2008|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00592904||162425|
NCT00570986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-890|A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis||AbbVie|Yes|Completed|November 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1465|||Both|18 Years|N/A|No|||January 2013|February 6, 2013|December 7, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570986||164071|
NCT00570999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCt: 2007-003241-32|Palifermin After Haploidentical PBSCT|Randomised Placebo-Controlled Double-Blind Phase II Study Applying Palifermin to Improve T-cell Immune Reconstitution After Haploidentical Allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation|KGF Haplo Allo|European Group for Blood and Marrow Transplantation|Yes|Withdrawn|February 2008|January 2013|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||May 2012|May 9, 2012|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570999||164070|
NCT00581412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5858|Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates|Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates||University of California, Irvine|Yes|Completed|September 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|60|||Female|18 Years|N/A|No|Non-Probability Sample|Patients who underwent abdominal sacrocolpopexy|January 2010|January 7, 2010|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00581412||163289|
NCT00581425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0478|Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)|Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp||The University of Texas Health Science Center, Houston|Yes|Completed|December 2007|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|N/A|N/A|No|||January 2013|January 23, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581425||163288|
NCT00581698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-015|Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue|Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue||Memorial Sloan Kettering Cancer Center||Completed|January 1991|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|876|Samples With DNA|tissue (lymph node)|Both|N/A|N/A|No|Non-Probability Sample|Patients with primary melanomas Clark III and Breslow thickness > 1 mm, or Clark IV-V and        any Breslow thickness, and clinically negative regional nodes. Patients with a resectable        solitary intransit metastasis and clinically negative nodes will be considered for entry        on to this protocol on an individual basis.|September 2009|September 14, 2009|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581698||163267|
NCT00578877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONRAD C05-103|Contraceptive Effectiveness and Safety of the SILCS Diaphragm|Contraceptive Effectiveness and Safety Study of the SILCS Diaphragm: the Pivotal Study||CONRAD|Yes|Completed|January 2008|November 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|450|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578877||163482|
NCT00579163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-102|Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers|Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers||Memorial Sloan Kettering Cancer Center||Recruiting|December 1994|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood, Saliva, Tumor Tissue, Normal Tissue|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|February 2016|February 18, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579163||163460|
NCT00579150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5550C00004|Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy|Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy|Exenatide|AstraZeneca|Yes|Recruiting|January 2009|January 2020|Anticipated|January 2020|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Is pregnant and at least 18 years of age at the time of enrollment|January 2016|January 5, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579150||163461|
NCT00579436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74457|Effects of Fish Oils on Inflammation and Insulin Resistance|Effects of Fish Oils on Inflammation and Insulin Resistance||University of Kentucky|Yes|Active, not recruiting|January 2007|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|135|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579436||163439|
NCT00579657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mow_PROFIMET|Protein, Fiber, and Metabolic Syndrome - The PROFIMET Study|Effects of High Protein and High Cereal Fiber Diets on Insulin Sensitivity in Overweight and Obese Subjects With the Metabolic Syndrome - The PROFIMET Study|PROFIMET|German Institute of Human Nutrition|No|Completed|August 2007|July 2013|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|111|||Both|24 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 6, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00579657||163422|
NCT00579670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281156|Treatment of Schizophrenic Patients With Ziprasidone|Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)|TRITON|Pfizer|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with schizophrenia|September 2010|September 16, 2010|December 20, 2007|No|Yes||No|April 2, 2010|https://clinicaltrials.gov/show/NCT00579670||163421|Additional descriptive tables were identified as required after review of the originally planned study tables; many subjects included in the tables had received ziprasidone doses above those specified in the summary of product characteristics (SmPC).
NCT00580463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-125|Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors|Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors||Memorial Sloan Kettering Cancer Center||Completed|January 2000|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1128|Samples With DNA|Blood Spinal fluid|Both|N/A|N/A|No|Non-Probability Sample|The patient population will include adult and pediatric patients diagnosed with a primary        or metastatic central nervous system tumor.|March 2009|March 18, 2009|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00580463||163361|
NCT00580437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|142-03-FB|Pre-operative Evaluation of Kidney & Pancreas Transplant Patients|The Analysis of Data Collected During Angiography and Dobutamine Stress Contrast Echocardiograms in the Pre-Evaluation of Kidney and Pancreas Transplant Patients||University of Nebraska|Yes|Active, not recruiting|April 2003|April 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|19 Years|N/A|No|||August 2011|August 2, 2011|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00580437||163363|
NCT00580450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(ST 1472)|Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies|Phase I/II Clinical Trial on Thymosin Alfa 1 of Allogeneic Hematopoietic Transplantation||University Of Perugia|Yes|Not yet recruiting|December 2007|December 2010|Anticipated|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|9|||Both|18 Years|65 Years|No|||November 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00580450||163362|
NCT00580671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75185|Treatment for Adolescent Marijuana Abuse|Behavioral Treatment of Adolescent Marijuana Use||Dartmouth-Hitchcock Medical Center|No|Completed|November 2007|December 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|December 21, 2007||No||No|March 25, 2013|https://clinicaltrials.gov/show/NCT00580671||163346|
NCT00580684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101198|Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children|Long-Term Efficacy of Pneumococcal Conjugate 7-Valent Vaccine Versus Plain Polisaccharide Pneumococcus Vacine in Reducing Pneumococcal Nasopharyngeal Carriage of Children.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2003|August 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|101|||Both|2 Years|9 Years|Accepts Healthy Volunteers|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00580684||163345|
NCT00580658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060155|Humanitarian Device Exemption|Humanitarian Device Exemption for Medtronic Activa Dystonia Therapy|Dystonia IRB|Vanderbilt University|Yes|Approved for marketing|May 2006|May 2020|Anticipated|||N/A|Expanded Access|N/A|||||||Both|7 Years|N/A|No|||January 2010|January 11, 2010|December 13, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00580658||163347|
NCT00580905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070418|Role of Adenosine in the Release of VEGF and Cytokines|Role of Adenosine in the Release of VEGF and Cytokines||Vanderbilt University|No|Suspended|June 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|December 17, 2007||No|Study is being reevaluated|No||https://clinicaltrials.gov/show/NCT00580905||163328|
NCT00591825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10362|fMRI Study Examining Effects of D-cycloserine in Specific Phobia|An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia.||University of Kansas Medical Center|No|Completed|March 2006|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 12, 2013|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00591825||162506|
NCT00592384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31665-D|Project to Improve Symptoms and Mood in People With Spinal Cord Injury|A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study|PRISMS|University of Washington|Yes|Completed|July 2007|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|64 Years|No|||December 2014|December 31, 2014|January 1, 2008||No||No|June 11, 2014|https://clinicaltrials.gov/show/NCT00592384||162463|
NCT00592917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5204512|OSTPRE-Fracture Prevention Study|OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study|OSTPRE-FPS|Kuopio University Hospital|No|Completed|August 2002|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|3432|||Female|65 Years|N/A|No|||January 2008|January 11, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592917||162424|
NCT00581087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dromer|Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults|Double-blind, Randomised, Placebo-controlled Phase III Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults|DHEA-HTAP|University Hospital, Bordeaux|No|Active, not recruiting|January 2007|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2015|January 13, 2015|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00581087||163314|
NCT00578045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67363|UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies|UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies||University of Arkansas|No|Withdrawn|July 2006|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|December 18, 2007||No|no accrual|No||https://clinicaltrials.gov/show/NCT00578045||163545|
NCT00578058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC005972|Randomized Trial Of Tinnitus Retraining Therapy|Randomized Trial Of Tinnitus Retraining Therapy||University of Iowa|Yes|Completed|January 2004|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|180|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00578058||163544|
NCT00579189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-36|Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes|Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)||Alcon Research|No|Completed|January 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|776|||Both|6 Months|12 Years|No|||November 2012|November 29, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579189||163458|
NCT00579202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0002|Ease of Use Study for the Gambro Polyflux HD-C4 Small Dialyzer|The Gambro Polyflux HD-C4 Small Ease of Use Study||Gambro Renal Products, Inc.|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|N/A|Observational|N/A||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|The dialysis nursing staff will complete ease of use assessments following routine        dialysis therapy of adult (≥ 18 years of age) patients|December 2007|December 26, 2007|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579202||163457|
NCT00579462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-111|Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer|Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer||Memorial Sloan Kettering Cancer Center|No|Completed|January 2003|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|281|Samples With DNA|Whole Blood|Both|N/A|N/A|No|Non-Probability Sample|Patients being seen in Thoracic Oncology Clinic|November 2010|November 30, 2010|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579462||163437|
NCT00579449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014616|Evaluation of a Home Visiting Program for First Time Parents|Evaluation of a Home Visiting Program for First Time Parents||Duke University|No|Completed|March 2005|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|343|||Female|N/A|N/A|No|||September 2014|September 19, 2014|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579449||163438|
NCT00579904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513651-3|CCRC: The Effects of Walnuts, Walnut-Oil, Almonds and Fish Oils on Glucose Homeostasis in Polycystic Ovary Syndrome (PCOS)|CCRC: Walnuts, Walnut-Oil, Glucose Homeostasis, PCOS||University of California, Davis|Yes|Recruiting|April 2006|July 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Female|18 Years|45 Years|No|||January 2008|August 1, 2008|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00579904||163404|
NCT00580216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10295|Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation|A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation|BOREALIS-AF|Sanofi|Yes|Terminated|December 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3773|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|December 21, 2007|Yes|Yes|early discontinuation based on strategic sponsor decision not driven by any safety concern|No||https://clinicaltrials.gov/show/NCT00580216||163380|
NCT00580697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-4825|Prevalence of Lower Urinary Tract Symptoms in Women With Gynecologic Malignancy Planning to Undergo Surgical Management|Prevalence of Lower Urinary Tract Symptoms in Women With Gynecologic Malignancy Planning to Undergo Surgical Management||University of California, Irvine|Yes|Active, not recruiting|January 2006|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Have a diagnosis of a gynecologic malignancy: cervical, endometrial, or ovarian cancer,        and plan to have surgry for the cancer treatment.|May 2010|May 6, 2010|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00580697||163344|
NCT00580931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIRG-07-61197|Safety Study of Nicotinamide to Treat Alzheimer's Disease|Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease||University of California, Irvine|No|Active, not recruiting|January 2008|July 2014|Anticipated|July 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|95 Years|No|||December 2013|December 11, 2013|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00580931||163326|
NCT00580918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2003-3139|Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients|Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients||University of California, Irvine|No|Recruiting|October 2003|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mild Traumatic Brain Injury Normal health controls|October 2010|October 14, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00580918||163327|
NCT00581204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2006-5191|Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans|Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans||University of California, Irvine|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Army Medical Center, civilian and military|August 2015|August 5, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581204||163305|
NCT00592358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001525|Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder|Open-Label Study of Invega for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder||Massachusetts General Hospital|No|Terminated|November 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|6 Years|17 Years|No|||June 2012|June 4, 2012|December 28, 2007|Yes|Yes|Slow enrollment.|No|March 9, 2012|https://clinicaltrials.gov/show/NCT00592358||162465|
NCT00593541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200210689|Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging|Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging|CVMRI|University of California, Davis|No|Terminated|May 1999|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Noraml volunteers and patients with known or suspected cardiovascular disease|November 2015|November 30, 2015|January 3, 2008||No|Principal Investigator is deceased|No||https://clinicaltrials.gov/show/NCT00593541||162377|
NCT00593554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704-19 IUCRO-0184|Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies|A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies||Indiana University|Yes|Recruiting|December 2007|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|65 Years|No|||March 2015|March 6, 2015|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593554||162376|
NCT00592644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-006853A|Laser Treatment Of Vascular Lesions On Vocal Cords|Laser Atraumatic Treatment Of Ectasias On Vocal Cords||Boston University|No|Completed|March 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|64 Years|No|||March 2011|March 29, 2011|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00592644||162443|
NCT00592657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIMSONWEED|Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions|Incidence of Rhabdomyolysis Among Pediatric and Adolescent Patients Admitted for Jimsonweed (Datura Stramonium) Ingestions||Akron Children's Hospital|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|46|||Both|N/A|21 Years|No|Non-Probability Sample|Patients diagnosed with rhabdomyolysis/ myoglobinuria/ hemoglobinuria (in-patient,        out-patient, ER visit) at a CHMCA facility|July 2008|July 25, 2008|January 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00592657||162442|
NCT00592930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-04-072|Olanzapine in the Treatment of Anorexia Nervosa|Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa||Northwell Health|No|Completed|June 2000|December 2004||December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2|||20|||Female|12 Years|23 Years|No|||January 2008|January 11, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00592930||162423|
NCT00577798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|409-07|Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin|Cardiac MRI for Assessment of Cardiac Structure and Function Following Doxorubicin Based Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma||University of Nebraska|No|Active, not recruiting|November 2007|||December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|15|||Both|19 Years|N/A|No|||August 2010|August 19, 2010|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577798||163563|
NCT00578032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-150|Reconstructive Surgery For Head And Neck Cancer Patients|Reconstructive Surgery For Head And Neck Cancer Patients: A Prospective Analysis Of Quality Of Life And Symptom Relief||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|130|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with head and and neck malignancies hat require simultaneous surgical resection        and reconstruction of the ablative defect will be eligible to participate.|October 2015|October 6, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00578032||163546|
NCT00578071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002207|Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer|A Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin Chemotherapy With External Beam Radiation Therapy for the Treatment of Resectable, Locally Advanced/Unresectable or Metastatic Esophageal Cancer|POXX|Duke University|No|Completed|December 2007|June 2012|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|82 Years|No|||May 2015|May 22, 2015|December 18, 2007|Yes|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00578071||163543|
NCT00578084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604-76|Lung Cancer Location: a Repository|Lung Cancer Location: A Prospective Repository||Indiana University|No|Terminated|June 2006|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with known or suspected lung cancer will be identified by referral to the        thoracic surgeon or ultrasonographer at the Veterans Affairs Hospital or Indiana        University Medical Center.|September 2013|October 7, 2013|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00578084||163542|
NCT00578292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-14539-THALLO|Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO|Pilot Study of Allogeneic Stem Cell Transplantation From Unrelated Donors for Patients With Severe Homozygous Beta 0/+ Thalassemia or Severe Variants of Beta 0/+ Thalassemia|THALLO|Baylor College of Medicine|Yes|Active, not recruiting|February 2004|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|64 Years|No|||September 2015|September 9, 2015|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578292||163527|
NCT00578903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10915-SAA MUD|Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia|Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors (SAA MUD)||Baylor College of Medicine|Yes|Terminated|February 2002|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|60 Years|No|||January 2014|January 21, 2014|December 19, 2007|Yes|Yes||No|August 4, 2013|https://clinicaltrials.gov/show/NCT00578903||163480|
NCT00578916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-003|Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects|Pharmacokinetics and Metabolism of [14C] BMS-690514 in Healthy Male Subjects||Bristol-Myers Squibb|No|Completed|January 2008|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2008|July 30, 2008|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578916||163479|
NCT00579475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMB300|The Effect of Mifepristone on Uterine Fibroids and Breast Tissue|The Effect of Preoperative Treatment With Mifepristone on Uterine Fibroids and Breast Tissue||Karolinska Institutet|Yes|Completed|November 2004|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|No|||December 2007|May 22, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00579475||163436|
NCT00579683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-103|Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer|A Prospective Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|August 2004|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|228|Samples With DNA|Tumor biopsy material will be processed to obtain RNA for analysis of EGFR sequence.      Sequencing of additional candidate genes and other studies will follow if sufficient      material is available.|Both|N/A|N/A|No|Non-Probability Sample|Unresectable or metastatic non-small cell lung cancer (NSCLC)|February 2016|February 3, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579683||163420|
NCT00580203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-017|Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers|Collection of Tissue, Blood, and Other Specimens From Patients With Head and Neck Diseases to Study the Causes, Diagnosis, Prevention and Treatment of Cancers||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2004|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1307|Samples With DNA|Tissue and peripheral blood|Both|N/A|N/A|No|Non-Probability Sample|Patients with head and neck diseases who have had tissue, serum, urine, or other specimens        removed or collected for diagnostic or therapeutic purposes.|January 2016|January 13, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00580203||163381|
NCT00580229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U4164s|A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.|A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.||University of South Florida|No|Completed|December 2007|December 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||July 2012|July 16, 2012|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580229||163379|
NCT00580242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006|A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia|A Phase I Dose Escalating Study of Bortezomib and Lenalidomide in Patients With Untreated or Previously Treated, Primary and Secondary Non 5q- Del Myelodysplasia||Massachusetts General Hospital|Yes|Completed|November 2007|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580242||163378|
NCT00580476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-100|Assessing Depression in a Geriatric Cancer Population|Assessing Depression in a Geriatric Cancer Population||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|September 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|201|||Both|70 Years|N/A|No|Non-Probability Sample|Geriatric Patients with Breast or Prostate Cancer|January 2016|January 4, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00580476||163360|
NCT00580489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Helicopter Fentanyl|Lifeflight: Fentanyl Versus Morphine|Efficacy and Adverse Events of Morphine and Fentanyl in an Aeromedical Setting||MetroHealth Medical Center|No|Recruiting|August 2006|||December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|69 Years|No|||December 2007|December 21, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00580489||163359|
NCT00580710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0108012609|Investigation Into the Effects Upon Brain Response to Change in Cirucating Glose Levels in Diabetes Mellitus|Investigation Into the Effects Upon Brain Response to Change in Cirucating Glose Levels in Diabetes Mellitus||Yale University|Yes|Recruiting|August 2001|August 2018|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||7|Anticipated|250|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The recruited subjects will reflect the gender and ethnic distribution of the Yale and New        Haven community. The recruited subjects with type 1 diabetes will reflect the demographics        of the clinic population in New Haven. Subject selection is independent of race and sex.|February 2016|February 9, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00580710||163343|
NCT00581217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-4881|A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings|A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings With Regards to Healing Time, Cosmesis, Infection Rate, and Patient's Perceived Pain: a Pilot Study.||University of California, Irvine|No|Active, not recruiting|December 2007|September 2010|Anticipated|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Burn injured patients or patients who have had full thickness skin loss requiring skin        grafting and donor site dressings|May 2010|May 11, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581217||163304|
NCT00581230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0067|Evaluation of the Rapid Airway Management Positioner|An Evaluation Of The Rapid Airway Management Positioner (RAMP) In Obese Patients Undergoing Gastric Bypass Or Laparoscopic Gastric Banding (Lap-Band) Surgery|RAMP|The University of Texas Health Science Center, Houston|No|Completed|December 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||July 2008|July 25, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00581230||163303|
NCT00581243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3170A1-01001|Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients|An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|January 2008|May 2008|Anticipated|May 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|50 Years|No|||July 2009|July 20, 2009|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581243||163302|
NCT00591851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-126|Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility|Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility||Memorial Sloan Kettering Cancer Center|Yes|Completed|December 2004|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|N/A|No|||November 2014|November 24, 2014|December 26, 2007|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT00591851||162504|
NCT00592124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-001|Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women|Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|168|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|December 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00592124||162483|
NCT00593567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-TOP-001|Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer|A Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge Compared to Levofloxacin in Diabetic Patients With a Mild Infection of a Lower Extremity Skin Ulcer||Innocoll|No|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|80 Years|No|||March 2012|March 22, 2012|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593567||162375|
NCT00592982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73319|Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging|Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging||University of Arkansas|No|Completed|October 2006|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|October 2013|October 24, 2013|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00592982||162420|
NCT00592995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P001640|Creatine Safety and Tolerability in Premanifest HD: PRECREST|Creatine Safety and Tolerability in Premanifest HD: PRECREST|PRECREST|Massachusetts General Hospital|Yes|Completed|December 2007|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|26 Years|N/A|No|||January 2014|January 10, 2014|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00592995||162419|
NCT00581724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-068|Pain in Cancer Survivors|Pain in Cancer Survivors||Memorial Sloan Kettering Cancer Center||Completed|May 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Adult cancer survivors that were treated for cancer at Memorial Sloan-Kettering Cancer        Center (MSKCC) and it has been at least a year since you completed treatment.|January 2012|January 25, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581724||163265|
NCT00577811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-011|Evaluation of Enrollment, Dynamics of Care and Patient Outcomes in the NYS Medicaid HIV Special Needs Plans|Evaluation of Enrollment, Dynamics of Care and Patient Outcomes in the NYS Medicaid HIV Special Needs Plans||Memorial Sloan Kettering Cancer Center|No|Completed|February 2003|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|628|||Both|18 Years|N/A|No|Probability Sample|The NYSDOH AIDS Institute will obtain Case Report Forms from Special Need Plans. and if        they have agreed to receive mail and/or telephone calls regarding the plan they have        signed up for. All patients will be informed at the time they join a Special Needs Plan        that they may be contacted by evaluators working with the NYSDOH AIDS Institute who        willwant to ask them about enrollment and care in the plan. Patients who have not agreed        to receive mail will only be contacted by telephone.At this time, a call will be made to        conduct screening using the Enrollment module and ask the selected Special Needs Plan        patient about their willingness toparticipate in the study.|January 2009|January 14, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577811||163562|
NCT00578630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-123|Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients|Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Oncology/Bone Marrow Transplantation Patients||Memorial Sloan Kettering Cancer Center||Recruiting|October 2003|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|peripheral blood and buccal swab|Both|N/A|N/A|No|Non-Probability Sample|All Pediatric Oncology and Bone Marrow Transplantation Service patients with a        histologically proven tumor for whom there is an intent to treat with chemotherapy|September 2015|September 25, 2015|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578630||163501|
NCT00578318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006780 (9065)|African American Knowledge Optimized for Mindfully Healthy Adolescents|Treatment Engagement in Psychiatric Clinical Research and Care for Depressed African American Adolescents|AAKOMA|Georgetown University|Yes|Completed|June 2007|December 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|11 Years|17 Years|No|||May 2013|May 15, 2013|December 19, 2007||No||No|January 28, 2013|https://clinicaltrials.gov/show/NCT00578318||163525|We lost 3 participants prior to intervention completion of the intervention which impacted results.
NCT00578331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-69|Safety Study of Olopatadine Nasal Spray|Safety Study of Olopatadine Nasal Spray||Alcon Research|No|Completed|December 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|890|||Both|12 Years|N/A|No|||February 2010|February 23, 2010|December 19, 2007|Yes|Yes||No|July 7, 2009|https://clinicaltrials.gov/show/NCT00578331||163524|
NCT00578344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16447-SCALLOP|Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP|Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia|SCALLOP|Baylor College of Medicine|Yes|Terminated|July 2005|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|40 Years|No|||April 2014|April 22, 2014|December 19, 2007|No|Yes|Terminated due to no new subject enrollment during the last 3 year period.|No||https://clinicaltrials.gov/show/NCT00578344||163523|
NCT00579488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-051|Clinical Significance of Germline BRCA Mutations|Clinical Significance of Germline BRCA Mutations||Memorial Sloan Kettering Cancer Center||Recruiting|July 1996|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Blood, Saliva, Buccal cell, Urine or Stool Tissue analysis and correlation of germline      findings with somatic alterations within the tumor will be performed on a subset of      individuals who have tumor tissue stored under protocol #06-107. Patients will be asked to      fill out a baseline questionnaire on other medical, hormonal, and environmental risk      factors.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic|February 2016|February 25, 2016|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579488||163435|
NCT00579696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-027|The Queens Library HealthLink Project|The Queens Library HealthLink Project||Memorial Sloan Kettering Cancer Center||Completed|February 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|2789|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Low-Income areas in the borough of Queens|December 2015|December 16, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579696||163419|
NCT00580775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505000069|Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death|Effects of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death: Autonomic Function and Ventricular Repolarization Heterogeneity ( A KEEPS Ancillary Study)|KEEPS|Yale University|No|Completed|September 2005|December 2010|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|25|||Female|42 Years|58 Years|Accepts Healthy Volunteers|Probability Sample|Self-voluntary study subjects participating in the KEEPS parent study which is randomized,        double-blind, placebo controlled.|January 2015|January 20, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00580775||163338|
NCT00580723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5307|Effects of PRK 124 Lotion in Acne Rosacea|Effects of PRK 124 (0.125%) Lotion in Acne Rosacea||University of California, Irvine|Yes|Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|21 Years|N/A|No|||December 2013|December 16, 2013|December 21, 2007||No||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00580723||163342|
NCT00580736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2003-3442|Optical Clearing of the Skin in Conjunction With Laser Treatments|Optical Clearing of the Skin in Conjunction With Laser Treatments||University of California, Irvine|No|Completed|March 2004|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00580736||163341|
NCT00580749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 07080011, PRO 07080044|Study of Nutrition in Acute Pancreatitis|Feeding and Pancreatic Rest in Acute Pancreatitis|SNAP|University of Pittsburgh|Yes|Terminated|January 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||June 2013|January 26, 2016|December 21, 2007||No|not meeting enrollment criteria|No||https://clinicaltrials.gov/show/NCT00580749||163340|
NCT00580944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2006-4992|Combined Alexandrite and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks|Combined Alexandrite and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks||University of California, Irvine|No|Withdrawn|April 2007|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|N/A|No|||August 2015|August 5, 2015|December 18, 2007|Yes|Yes|No participant enrolled|No||https://clinicaltrials.gov/show/NCT00580944||163325|
NCT00593008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-115|Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer|A Phase 1 Study of Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer||Massachusetts General Hospital|Yes|Terminated|October 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593008||162418|
NCT00593268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031084|Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage|Biological Markers of Vasospasm in Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage||Vanderbilt University|No|Active, not recruiting|June 2004|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|150|Samples With DNA|cerebrospinal fluid and blood|Both|18 Years|N/A|No|Non-Probability Sample|18 years of age or older|January 2008|June 14, 2013|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00593268||162398|
NCT00593580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-03974|Bone Health in Gynecologic Cancers-does FOSAVANCE Help?|The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies.|FOSAVANCE|British Columbia Cancer Agency|Yes|Completed|February 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 27, 2011|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593580||162374|
NCT00593814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA 04-04|GORE EXCLUDER® Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms|A Clinical Evaluation of the GORE EXCLUDER® Bifurcated Endoprosthesis - Low Permeability in the Primary Treatment of Infrarenal Abdominal Aortic Aneurysms||W.L.Gore & Associates|No|Completed|June 2005|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|18 Years|N/A|No|||July 2010|July 13, 2010|December 20, 2007|Yes|Yes||No|April 20, 2010|https://clinicaltrials.gov/show/NCT00593814||162356|
NCT00581737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-083|Cognitive Functioning and Quality of Life in CNS Lymphoma|Cognitive Functioning and Quality of Life in CNS Lymphoma||Memorial Sloan Kettering Cancer Center||Completed|July 2000|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Primary Care Clinic|March 2012|March 2, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581737||163264|
NCT00577824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-JE-GWBB|Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)|Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled||AstraZeneca|No|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|181|||Both|20 Years|75 Years|No|||March 2015|March 20, 2015|December 18, 2007|Yes|Yes||No|November 23, 2009|https://clinicaltrials.gov/show/NCT00577824||163561|
NCT00578357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212/2007|A Personalized Feedback Intervention for Problem Gamblers|A Personalized Feedback Intervention for Problem Gamblers||Centre for Addiction and Mental Health|No|Completed|December 2007|July 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|209|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00578357||163522|
NCT00578617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003867|Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial|Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation - Pilot Trial|CABANA|Mayo Clinic|Yes|Completed|September 2006|June 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|90 Years|No|||December 2012|December 3, 2012|December 14, 2007|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00578617||163502|Limited number enrolled. Study was designed to demonstrate feasibility for a pivotal trial, but small enrollment limits the final conclusions that can be drawn from a simple 'time to first atrial fibrillation recurrence.'
NCT00579215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-141|Lung Cancer Informational Study (LCIS)|Lung Cancer Informational Study (LCIS)||Memorial Sloan Kettering Cancer Center||Completed|November 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|8|||Both|N/A|N/A|No|||March 2009|March 17, 2009|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579215||163456|
NCT00579228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMC-IRB-124-07|Vascular Risk Progression in Normal and Diabetic Control Subjects.|Vascular Risk Progression in Normal and Diabetes Control Subjects||University of Nebraska|No|Recruiting|March 2007|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|19 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Any patient with diabetes or healthy individuals|June 2008|June 2, 2008|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579228||163455|
NCT00580255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614766|Comparison Study of BNP and Thoracic Impedance Measurements on Arrhythmias|Does Elevated Brain Natriuretic Peptide (BNP) Reflect Changes in Thoracic Impedance Levels and Affect Occurrence of Atrial and Ventricular Arrhythmias?||University of California, Davis|No|Withdrawn|October 2006|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Teaspoon of blood drawn for testing of BNP levels.|Both|18 Years|85 Years|No|Non-Probability Sample|Potential candidates with criteria for implantable cardiac resynchronization therapy who        have or will undergo implantation of a Medtronic CRT-D device with thoracic impedance        measurement capabilities, will be eligible to enter the study if they meet all of the        inclusion criteria and none of the exclusion criteria. Patients will be enrolled in the        study either at the time of device implantation or if they have already undergone device        implantation will be enrolled at next routine outpatient clinic visit.|January 2013|January 7, 2013|December 20, 2007||No|resources not available|No||https://clinicaltrials.gov/show/NCT00580255||163377|
NCT00579917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-139|Behavioral Intervention For BMT/SCT Survivors|Cognitive Behavioral Intervention for BMT/SCT Survivors: Looking Forward|BMT/SCT|Memorial Sloan Kettering Cancer Center||Completed|January 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|133|||Both|18 Years|N/A|No|Probability Sample|Primary care clinics|January 2009|January 5, 2009|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579917||163403|
NCT00579930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-141|Cytogenetic and Molecular Genetic Studies in Bone Sarcomas|Cytogenetic and Molecular Genetic Studies in Bone Sarcomas||Memorial Sloan Kettering Cancer Center||Completed|December 1993|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|Samples With DNA|Tumor Tissue|Both|N/A|N/A|No|Non-Probability Sample|Primary Care Clinic|February 2016|February 24, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579930||163402|
NCT00580788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040081|One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study|Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation||University of Pittsburgh|Yes|Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Actual|14|||Both|24 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|December 20, 2007|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00580788||163337|Small number of subjects in each group Study limited to Caucasians Only one timepoint for follow-up was measure Study did not include saline infused controls
NCT00581282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2004-4019|Brain Imaging Studies of the Effects of Cocaine Abstinence|Brain Imaging Studies of the Effects of Cocaine Abstinence||University of California, Irvine|No|Recruiting|October 2006|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in cocaine dependency treatment program Normal Healthy Control Subjects|October 2010|October 14, 2010|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581282||163299|
NCT00581269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070990|Dietary Intervention and Exercise Training (DIET) in Moderate to Severe Chronic Kidney Disease|Dietary Intervention and Exercise Training (DIET) in Moderate to Severe Chronic Kidney Disease||Vanderbilt University|No|Terminated|December 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|65 Years|No|||November 2010|November 1, 2010|December 18, 2007||No|the Fellow conducting the study left the institution in 2009|No||https://clinicaltrials.gov/show/NCT00581269||163300|
NCT00593021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALTZMAN: 2007P-000991|Diagnostic Evaluation of Obscure Gastrointestinal Bleeding|Diagnostic Evaluation of Obscure Gastrointestinal Bleeding||Brigham and Women's Hospital|No|Withdrawn|October 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Adults over the age of 18 and able to give consent who are referred to the Brigham and        Women's Hospital Endoscopy Center or GI Clinic for the evaluation of obscure        gastrointestinal bleeding|August 2013|August 7, 2013|December 28, 2007||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00593021||162417|
NCT00593281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-05-06|INFUSE Morphine Study|INcreased Flow Utilizing Subcutaneously Enabled Morphine (INFUSE-Morphine) With and Without Human Recombinant Hyaluronidase (HYLENEX) and Intravenously|INFUSE|Halozyme Therapeutics|No|Completed|January 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00593281||162397|
NCT00593853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEUPR_L_01|Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy|A Phase II, Randomized, Double-blind, Placebo Controlled Trial of Methylphenidate Hydrochloride for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy||University Health Network, Toronto|Yes|Terminated|January 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Male|18 Years|85 Years|No|||June 2014|June 3, 2014|January 3, 2008|Yes|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00593853||162353|
NCT00593827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-132|Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer|Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients||R-Pharm|No|Completed|May 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|January 4, 2008|Yes|Yes||No|March 14, 2012|https://clinicaltrials.gov/show/NCT00593827||162355|
NCT00577837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003134|Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD|Active-controlled, Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density||Warner Chilcott|No|Completed|April 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|370|||Female|50 Years|85 Years|No|||April 2013|April 15, 2013|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00577837||163560|
NCT00578097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-79-52120-126|Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder|A Phase II, International, Multi-centre, Prospective, Randomised, Parallel-group, Double-blind, Dose-ranging, Placebo-controlled, 12-week, Study to Assess the Efficacy and Safety of a One Injection Cycle With Either Botulinum Toxin Type-A (Dysport® 125, 250 or 500 Units) or Placebo Followed by an Optional 6-month Extension Phase in the Symptomatic Treatment of Micturition Urgency and Frequency in Continent Female Subjects Suffering From Idiopathic Overactive Bladder.||Ipsen|No|Terminated|February 2008|December 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|81|||Female|18 Years|75 Years|No|||November 2015|November 30, 2015|December 18, 2007||No|The study was terminated early due to poor recruitment.|No||https://clinicaltrials.gov/show/NCT00578097||163541|
NCT00578370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD001-CI-07|Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test|A Phase I, Single-Center, Randomized, Vehicle-Controlled Study, Double-Blind for the Study Preparations and Observer-Blind for the Comparators to Determine the Antipsoriatic Efficacy and Tolerability of Topical Formulations With Ciclosporin in a Psoriasis Plaque Test||ISDIN|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|25|||Both|18 Years|N/A|No|||November 2008|November 4, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00578370||163521|
NCT00578383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001655|Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device|Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device|LFMS|Mclean Hospital|No|Completed|November 2007|March 2013|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|107|||Both|18 Years|70 Years|No|||March 2014|March 28, 2014|December 18, 2007||No||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00578383||163520|A limitation of the current trial was that it was underpowered to detect moderate but clinically significant benefits of LFMS in diagnostic subgroups.
NCT00578890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060218|a Randomized Controlled Trial Comparing Medical and Medical-surgical Treatment in Diabetic Foot Osteomyelitis|Comparison of Medical and Medical-surgical Management of Diabetic Foot Osteomyelitis|DIPIOS|Assistance Publique - Hôpitaux de Paris|No|Withdrawn|June 2008|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||June 2011|September 14, 2012|December 19, 2007||No|not enough recruitment|No||https://clinicaltrials.gov/show/NCT00578890||163481|
NCT00579176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P001911|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2007|||||N/A|N/A|N/A||||||||||||||August 7, 2008|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579176||163459|
NCT00579501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014767|Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma|A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|April 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|December 20, 2007|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT00579501||163434|
NCT00579748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS# 2005-4314|Optical Coherence Tomography of the Gastrointestinal Tract|Optical Coherence Tomography of the Gastrointestinal Tract|OCT|University of California, Irvine|Yes|Active, not recruiting|June 2005|August 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|Samples Without DNA|pinch biopsies blood|Both|18 Years|N/A|No|Non-Probability Sample|This study will involve the OCT imaging of patients undergoing endoscopy of the upper        digestive tract in the gastrointestinal endoscopy suite in the H. H. Chao Digestive        Diseases Center (CDDC) at UC Irvine Medical Center.        These patients will include: 1) patients with known Barrett's esophagus with or without        dysplasia, who are scheduled for surveillance endoscopy with biopsy or endoscopic mucosal        resection (EMR) 2) patients with early esophageal or gastric cancer who are undergoing        confirmatory endoscopy with biopsy or 3) patients with intestinal metaplasia with or        without dysplasia of the stomach who are undergoing endoscopy with biopsy or EMR.|December 2007|December 21, 2007|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00579748||163416|
NCT00579709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013734|Thymus Transplantation With Immunosuppression|Thymus Transplantation With Immunosuppression, #884|884|Duke University|Yes|Active, not recruiting|July 2002|June 2027|Anticipated|December 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||September 2015|September 3, 2015|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579709||163418|
NCT00579735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37640|Histologic Diagnoses of Incidentally Detected Lesions on MRI|Histologic Diagnoses of Incidentally Detected Lesions on MRI||University of Arkansas|No|Withdrawn|March 2005|March 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Female|21 Years|N/A|No|Non-Probability Sample|mammography clinic in Northwest Arkansas|March 2015|March 3, 2015|December 20, 2007||No|No subjects were ever enrolled. This study was closed at the IRB.|No||https://clinicaltrials.gov/show/NCT00579735||163417|
NCT00579943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05594|Regulation of Cerebral Blood Flow in Very Low Birth Weight Infants|Development of Cerebral Autoregulation in Very Low Birth Weight Infants||University of Arkansas|No|Completed|May 2001|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|7 Days|No|Non-Probability Sample|Neonatal Intensive Care Unit|June 2008|June 3, 2008|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579943||163401|
NCT00580957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060085|The Autonomic Nervous System and the Metabolic Syndrome|The Autonomic Nervous System and the Metabolic Syndrome||Vanderbilt University|No|Completed|August 2008|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|21|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|December 20, 2007|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00580957||163324|
NCT00581295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2013-9435|Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients|Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients||University of California, Irvine|No|Completed|March 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|93|||Both|18 Years|N/A|No|Non-Probability Sample|Trauma/Critically Care Patients|August 2015|August 5, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00581295||163298|
NCT00581581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00020479|CoolCap Followup Study-Coordination of Participating Centers|Long-term Follow-up After Head Cooling for Neonatal Encephalopathy||University of Rochester|No|Completed|September 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|62|||Both|6 Years|8 Years|No|Non-Probability Sample|Eligible children will be those who participated in the original randomized clinical        trial, "Brain Cooling for the Treatment of Perinatal Hypoxic-Ischemic Encephalopathy".        Infants enrolled in that study were randomized to cooling or standard care. Survivors to        7-8 years of age are eligible for this observational followup study.|March 2013|March 7, 2013|December 21, 2007||No||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00581581||163276|
NCT00593034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014553-03S1|Medical Office Intervention for Adolescent Drug Use - Attention Study Supplement|Medical Office Intervention for Adolescent Drug Use - Research Supplement for Under-represented Minorities||Children's Hospital Boston|Yes|Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|42|||Both|12 Years|21 Years|No|Non-Probability Sample|Participants in this study will be 12-21 year old patients who have been referred to the        Adolescent Substance Abuse Program for evaluation of drug or alcohol use and are        participating in the parent study, "Medical Office Intervention for Adolescent Drug        Abuse."|March 2011|March 7, 2011|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593034||162416|
NCT00593294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-12-2871|Oral Contraceptive and Cardiovascular Risk in PCOS|Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women||Federico II University|No|Completed|January 2006|December 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2007|January 14, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00593294||162396|
NCT00594451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|358-06-NH|Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity|Gene-Environment Interactions in RA Autoimmunity Disease Severity||University of Nebraska|Yes|Completed|October 2006|January 2013|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|800|Samples With DNA|All subjects will provide baseline serum and DNA.|Both|19 Years|N/A|No|Non-Probability Sample|Omaha VA patients|January 2010|June 18, 2013|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594451||162307|
NCT00594698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-005|Familiarization and Safety Study of PB127 Ultrasound Contrast Agent|A Familiarization and Safety Study of Myocardial Perfusion Contrast Echocardiography With PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Artery Disease||Point Biomedical|Yes|Completed|February 2002|September 2003|Actual|September 2003|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|18 Years|N/A|No|||January 2008|July 1, 2008|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594698||162288|
NCT00593840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0142 / 201106342|Phase II Trial Evaluating Elimination of Radiation Therapy|Phase II Trial Evaluating Elimination of Radiation Therapy To Pathological N0 Neck(s) With Intensity Modulated Postoperative Radiation Therapy||Washington University School of Medicine|No|Active, not recruiting|April 2007|February 2019|Anticipated|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|January 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593840||162354|
NCT00578110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTH_DEV_GLAU_02|Instrument for Glaucoma Early Detection and Monitoring|SBIR II Instrument for Glaucoma Early Detection and Monitoring|IGDM|Synabridge Corporation|No|Recruiting|January 2008|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|180|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||April 2010|April 1, 2010|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00578110||163540|
NCT00578656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT P01 AI 144236|An Interventional Study of Milk Allergy|The Impact of the Diet Containing Limited Amounts of Processed Milk Protein on the Natural History of IgE-Mediated Milk Hypersensitivity||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2004|February 2011|Actual|February 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|220|||Both|4 Years|25 Years|No|||July 2012|July 30, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00578656||163499|
NCT00578929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-01|Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients|Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients||Alcon Research|No|Completed|September 2007|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|2388|||Both|6 Years|11 Years|No|||February 2010|February 23, 2010|December 19, 2007|Yes|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00578929||163478|
NCT00578942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008380|Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath|Allogeneic Non-myeloablative Stem Cell Transplantation Utilizing Matched Family Member Stem Cells Purged Using Campath-1H||Duke University|Yes|Completed|May 2005|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|17 Years|N/A|No|||April 2014|April 25, 2014|December 19, 2007|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00578942||163477|
NCT00578643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14771-MUNCHR|Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease|HLA Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease|MUNCHR|Baylor College of Medicine|Yes|Recruiting|March 2004|November 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|N/A|No|||September 2015|September 21, 2015|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578643||163500|
NCT00579956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXTREC 018-06|A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis|A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis|ATOM|University of Oxford|Yes|Recruiting|December 2007|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|15 Years|N/A|No|||August 2007|June 3, 2008|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00579956||163400|
NCT00579969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|335-03|Comparison of Latanoprost Vs. Timolol|Comparison of the Effects of Latanoprost and Timolol on Aqueous Humor Dynamics in Ocular Hypertensive Patients||University of Nebraska|No|Completed|December 2003|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 29, 2010|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00579969||163399|
NCT00579761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM10420|Retrospective Review of Management of Infective Endocarditis|A Retrospective Review of the Management of Infective Endocarditis in Patients at Virginia Commonwealth University Medical Center From 1996-2006||Virginia Commonwealth University|No|Withdrawn||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All subjects that have undergone surgical treatment for infective endocarditis at VCU        medical Center from 1996 to present|December 2015|December 10, 2015|December 17, 2007||No|Per PI on 12/9/15 - No patients were ever enrolled in this study|No||https://clinicaltrials.gov/show/NCT00579761||163415|
NCT00579982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBI108884|An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder|An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects With a Mood Disorder||GlaxoSmithKline||Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|December 20, 2007|Yes|Yes||No|June 4, 2009|https://clinicaltrials.gov/show/NCT00579982||163398|
NCT00580502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H # 10686|Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Body Mass Index (BMI) Between 30-40 kg/m2|A Prospective Study to Evaluate the Safety and Efficacy of LAP-BAND® Adjustable Gastric Band (LAGB®) Operations for Patients With BMI Between 30-40 kg/m2 With Co-morbidities|LBMI|New York University School of Medicine|Yes|Completed|March 2004|September 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|60 Years|No|||March 2015|March 16, 2015|December 21, 2007|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT00580502||163358|
NCT00580762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508000519|Bariatric Surgery for ESRD Patients vs Control|Obesity, End-Stage Renal Disease and Kidney Transplantation||Yale University|Yes|Active, not recruiting|October 2005|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||June 2009|June 30, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00580762||163339|
NCT00580281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-142|Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors|Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors.||Memorial Sloan Kettering Cancer Center|Yes|Completed|November 2006|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|N/A|N/A|No|||October 2013|October 23, 2013|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00580281||163375|
NCT00580814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORIHS ID# 20055906|Brain Dopamine Function in Adults With ADHD|Brain Dopamine Function in Adults With ADHD|Brookhaven|University of California, Irvine|No|Completed|February 2006|April 2009|Actual|March 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|October 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00580814||163335|
NCT00580970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-10802|Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury|A Phase II Study to Prevent Radiation-Induced Rectal Injury With Lovastatin||Virginia Commonwealth University|Yes|Completed|April 2007|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|73|||Male|18 Years|N/A|No|||February 2016|February 25, 2016|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580970||163323|
NCT00581308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLX 06-04|Long-term Safety Study of the GORE® HELEX® Septal Occluder|GORE® HELEX® Septal Occluder Post-Approval Study||W.L.Gore & Associates|Yes|Completed|August 2006|October 2014|Actual|October 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|215|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|December 20, 2007|Yes|Yes||No|January 4, 2012|https://clinicaltrials.gov/show/NCT00581308||163297|
NCT00581321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050811|Oral Water Ingestion in Heart Transplant Patients|Acute Hemodynamic Effects of Oral Water in a Stable Cardiac Transplant Population||Vanderbilt University|No|Active, not recruiting|January 2006|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00581321||163296|
NCT00581594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4574|Traditional vs. Graft-augmented Posterior Colporrhaphy|Traditional vs. Graft-augmented Posterior Colporrhaphy: A Randomized Prospective Study||University of California, Irvine|Yes|Terminated|January 2006|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|128|||Female|18 Years|N/A|No|||August 2010|August 5, 2010|December 20, 2007||No|Could not meet recruitment, technology advancement.|No||https://clinicaltrials.gov/show/NCT00581594||163275|
NCT00593047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBT004|LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin|A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Statin Treatment in Patients With Dyslipidemia||Karo Bio AB|Yes|Completed|November 2007|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|75 Years|No|||May 2008|November 27, 2008|December 17, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593047||162415|
NCT00593307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10917|The Breakfast Study|The Effects of Low and High Glycemic Index Foods and Protein on Glycemic Response and Hunger|Breakfast|Temple University|No|Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|21 Years|65 Years|No|||January 2008|June 28, 2013|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593307||162395|
NCT00593593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104244|Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia|A Pharmacovigilance Study to Evaluate Safety of AVODART (Dutasteride) Administration 0,5 mg Once Daily, for 52 Weeks, in Subjects With Benign Prostate Hyperplasia||GlaxoSmithKline||Completed|December 2004|||||N/A|Observational|Time Perspective: Prospective||||1000|||Male|N/A|N/A|No|||October 2008|October 13, 2008|January 3, 2008||||No||https://clinicaltrials.gov/show/NCT00593593||162373|
NCT00593606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0908|Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine|A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease||UCB Pharma|No|Completed|July 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|September 24, 2014|December 21, 2007|Yes|Yes||No|December 17, 2008|https://clinicaltrials.gov/show/NCT00593606||162372|
NCT00594178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24179|Palliative Strategies in Spinal Cord Injury (SCI)|Palliative Strategies in Spinal Cord Injury (SCI)||University of Arkansas|No|Completed|October 2003|September 2010|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2010|December 13, 2010|January 3, 2008||No||No|October 1, 2010|https://clinicaltrials.gov/show/NCT00594178||162328|This was a pilot study to determine if a passive exercise bicycle would suppress the H-reflex after a spinal cord injury. We were not able to collect stable H-reflex data. However, the Dual-Energy X-ray Absortiometry (DEXA) scan data was useable.
NCT00594191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMV-HTP2003|Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension|Phase IV-II Randomized, Multicenter, Placebo-Controlled Double-Blind Clinical Trial Evaluating the Effects of Continuous Simvastatin Administration on Hepatic and Systemic Hemodynamics in Patients With Cirrhosis.||Hospital Clinic of Barcelona|Yes|Completed|March 2004|November 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|No|||January 2008|January 3, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594191||162327|
NCT00594139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL006|Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence|An Open Label Multi-center Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence||Tengion|Yes|Withdrawn|January 2008|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 3, 2008|Yes|Yes|Reprioritization of study programs|No||https://clinicaltrials.gov/show/NCT00594139||162331|
NCT00594425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC TA202B/06|Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne|||Photocure|No|Completed|February 2007|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|15 Years|40 Years|No|||August 2013|August 7, 2013|January 3, 2008|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00594425||162309|
NCT00578396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT07046|Phase I Biomarker Study of Dietary Grape-Derived Low Dose Resveratrol for Colon Cancer Prevention|Phase I Biomarker Study of Dietary Grape-Derived Low Dose Resveratrol for Colon Cancer Prevention||University of California, Irvine|Yes|Active, not recruiting|January 2008|January 2010|Anticipated|May 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 4, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00578396||163519|
NCT00578409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-062|Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data|Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data||Memorial Sloan Kettering Cancer Center||Completed|May 2004|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|758|Samples With DNA|In a first analytical step, using only the clinical and pathological variables used in the      original clinical mets castrate disease nomogram as inputs, supervised multivariate      analytical techniques (SMA) were used to generate a new predictive model for patient      survival. A similar approach will then be used to analyze a second group of approximately      223 pts in the state of a rising PSA14 after surgery or radiation therapy treated on a      sequential series of IRB approved trials testing conjugate vaccines also consented on IRB      protocol 90-40.|Male|N/A|N/A|No|Non-Probability Sample|Stage 1 - Population: Progressive Metastatic Disease Stage 2 - Population: Rising PSA|December 2015|December 16, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00578409||163518|
NCT00578669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHI0710-002|Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms|Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms||Butler Hospital|Yes|Completed|April 2008|November 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|August 26, 2014|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578669||163498|
NCT00578682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP144|A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557|A Phase I, Randomized, Double-Blind, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557, A Humanized Monoclonal Antibody With an Extended Half-Life Against Respiratory Syncytial Virus (RSV), in Healthy Adults||MedImmune LLC||Completed|December 2007|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578682||163497|
NCT00578955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-502-002|Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis|A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical and Anti-Microbial Efficacy and Safety of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone in the Treatment of Subjects With Blepharoconjunctivitis||InSite Vision|No|Completed|December 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|417|||Both|1 Year|N/A|No|||January 2012|January 27, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578955||163476|
NCT00579241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113-06-FB|Detection of Ultrasound Contrast Signals in the Cerebral Circulation|Detection of Ultrasound Contrast Signals in the Cerebral Circulation During Stress Echocardiography||University of Nebraska|No|Withdrawn|April 2006|April 2012|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 19, 2012|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00579241||163454|
NCT00579540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715060-1|Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels|CCRC: Prevention of Post-Prandial Hypoglycemia Using n-3/n-6 PUFA in PCOS|PCOS|University of California, Davis|Yes|Completed|September 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Female|18 Years|45 Years|No|||October 2012|October 25, 2012|December 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579540||163431|
NCT00580008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-144|Evaluation Using Computed Tomography Angiography (CTA) to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)|Evaluation Using CTA to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)|ELUCIDATE)|William Beaumont Hospitals|Yes|Active, not recruiting|December 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Serum banking|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Referrals from physicians' office Patients' self-referral Age greater than 18 years old        Both genders|April 2015|April 30, 2015|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00580008||163396|
NCT00579995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-05-FB|A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate|A Prospective, Randomized Trial Comparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Cardiac Catheterization|PROTECt|University of Nebraska|No|Recruiting|May 2005|January 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 25, 2010|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579995||163397|
NCT00580268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P001167|Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity|Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity||Massachusetts General Hospital|Yes|Completed|August 2005|July 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|118|Samples With DNA|serum, plasma, urine, whole blood, saliva, amniotic fluid, breast milk|Female|18 Years|45 Years|No|Non-Probability Sample|psychiatrists, referring obstetricians, community-based health centers, triage, and women        who have previously given written permission to be contacted about research studies within        the MGH Perinatal and Reproductive Psychiatry Program|August 2014|August 11, 2014|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00580268||163376|
NCT00581022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051131|Objective Sleep Disturbances in Orthostatic Intolerance|Assessment of Objective Sleep Disturbances in Orthostatic Intolerance||Vanderbilt University|No|Active, not recruiting|November 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients diagnosed with chronic orthostatic intolerance by the Vanderbilt Autonomic        Dysfunction Center|December 2014|December 18, 2014|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00581022||163319|
NCT00581035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6114A1-500|Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time|A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2006|May 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|712|||Both|42 Days|63 Days|Accepts Healthy Volunteers|||December 2007|December 26, 2007|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581035||163318|
NCT00580983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2-21|Optimized Intensity Modulated Irradiation for Head and Neck Cancer|Optimized Intensity Modulated Irradiation for Head and Neck Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|August 2003|May 2016|Anticipated|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|December 25, 2007||No||No|November 5, 2014|https://clinicaltrials.gov/show/NCT00580983||163322|No modeling of observer-rated posttherapy dysphagia was performed because of the small number (four) of patients with greater than, or equal to, Grade 2 after 6 months.
NCT00580541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2023-07|Effect of Liking on Fruit Intake|||The Miriam Hospital|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|April 19, 2012|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00580541||163355|
NCT00581607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOSAPAH-1|Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension|Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension|BOSAPAH|University of Cincinnati|Yes|Completed|April 2008|December 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00581607||163274|
NCT00593866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.018|Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer|A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer||University of Michigan Cancer Center|Yes|Completed|June 2006|October 2014|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|January 2, 2008|Yes|Yes||No|August 12, 2014|https://clinicaltrials.gov/show/NCT00593866||162352|
NCT00594152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS#92-16|Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)|Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)||Joslin Diabetes Center|No|Completed|January 1993|January 1995|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|75 Years|No|||January 2008|January 14, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00594152||162330|
NCT00594165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0702|An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.|An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.|SP512OL|UCB Pharma|No|Completed|June 2002|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|217|||Both|31 Years|N/A|No|||September 2010|September 24, 2014|December 24, 2007|Yes|Yes||No|November 6, 2009|https://clinicaltrials.gov/show/NCT00594165||162329|
NCT00594477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1077 / 201106403|Intensity Modulated Radiotherapy for Breast Cancer|Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study|IMRT|Washington University School of Medicine|No|Active, not recruiting|January 2008|December 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|January 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00594477||162305|
NCT00594490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-2192|Evaluating the Effectiveness and Outcomes of Silicone Breast Prosthetics|Adjunct Study for Silicone Gel-Filled Mammary Prosthesis||University of California, Irvine|Yes|Active, not recruiting|January 2001|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Female|18 Years|N/A|No|Non-Probability Sample|women undergoing breast reconstruction|November 2012|November 11, 2012|January 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00594490||162304|
NCT00594711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5703410|Monoamine Transporter Function and Autonomic Regulation During Psychodynamic Psychotherapy|||Kuopio University Hospital|Yes|Completed|January 2000|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|26|Samples With DNA|DNA, creatine, B-vitamin,BP from blood samples.|Both|18 Years|55 Years|No|Non-Probability Sample|Patiens of clinic|October 2011|October 28, 2011|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594711||162287|
NCT00578136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-4980|Analgesic Efficacy After Umbilical Hernia Repair in Children|A Randomized-Double Blinded Trial Comparing the Analgesic Efficacy and Side Effects of Rectus Sheath Block vs. Infiltration of Surgical Site for Post Operative Pain Control After Umbilical Hernia Repair Surgery||Children's Hospital of Philadelphia|No|Completed|November 2006|December 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|5 Years|17 Years|No|||July 2014|July 30, 2014|December 18, 2007||No||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00578136||163538|
NCT00578968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003434|Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation|Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation||Mayo Clinic|No|Completed|October 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|35 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|December 20, 2007|Yes|Yes||No|May 22, 2012|https://clinicaltrials.gov/show/NCT00578968||163475|
NCT00579254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841054|Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors|Real Life Experience With Caduet Evaluating Effectiveness, Safety and Tolerability in the Management of Cardiovascular Risk Factors (EXCEL Study)|EXCEL|Pfizer|No|Terminated|December 2007|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|112|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be treated in this study according to prevailing local clinical practice        following the locally approved product labeled recommendations|May 2009|June 18, 2009|December 20, 2007||No|See the termination reason in detailed description.|No|May 1, 2009|https://clinicaltrials.gov/show/NCT00579254||163453|The objectives for this terminated study could not be assessed due to limited data available. (Efficacy parameters were to include BP, heart rate, lipid profile, urine albumin.)
NCT00579514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-014|Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients|Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients||Memorial Sloan Kettering Cancer Center||Recruiting|March 2000|March 2020|Anticipated|March 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2530|||Both|N/A|N/A|No|||February 2016|February 15, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579514||163433|
NCT00579306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1202|Levels of Inflammatory Markers in the Treatment of Stroke—An SPS3 Ancillary Study|Levels of Inflammatory Markers in the Treatment of Stroke|LIMITS|Columbia University|Yes|Active, not recruiting|June 2005|August 2013|Anticipated|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1440|Samples Without DNA|blood serum|Both|30 Years|N/A|No|Probability Sample|Patients with a symptomatic small vessel stroke within prior 6 month and enrolled in SPS3|December 2012|December 6, 2012|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579306||163449|
NCT00580021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004|Clinical Outcomes in Hereditary Cancer|Clinical Outcomes in Hereditary Cancer||Memorial Sloan Kettering Cancer Center||Withdrawn|January 2006|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|Samples With DNA|Once potential subjects are identified, pathology records will be reviewed to establish      which of the potential subjects have archived pathology material available at MSKCC. It is      important to note that the material does not have to be tumor and, in fact, benign tissue,      such as uninvolved lymph node, will be sought by preference. However, tumor tissue will be      used if no benign tissue is available.|Both|N/A|N/A|No|Probability Sample|The subjects will be individuals with the disease of interest during the time period of        interest who described their religious preference at the time of registration to be        Jewish.|January 2016|January 27, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00580021||163395|
NCT00580034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009528|Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath|Allogeneic (Allo) Non-Myeloablative Stem Cell Transplantation (SCT) Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath-1H||Duke University|Yes|Completed|February 2003|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|17 Years|N/A|No|||May 2014|May 2, 2014|December 20, 2007|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00580034||163394|
NCT00572013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138-98|Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma|A Phase I/II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma||University of Nebraska|Yes|Completed|May 1998|September 2009|Actual|January 2001|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|19 Years|N/A|No|||December 2013|December 13, 2013|December 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00572013||163994|
NCT00580294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0464|A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)|A Pilot Study of Rapid Opioid Rotation and Titration of Oxymorphone||Icahn School of Medicine at Mount Sinai|No|Completed|November 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 19, 2007||No||No|November 25, 2015|https://clinicaltrials.gov/show/NCT00580294||163374|This was a pilot open-label study in a small number of participants. A larger randomized study with long-term follow-up and comparison to traditional protocols is necessary to affirm safety. (12 pts had 6 different chronic non-cancer pain diagnoses.)
NCT00581646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-110|Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance|Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance||Memorial Sloan Kettering Cancer Center|No|Completed|September 2006|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|179|||Female|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cervical cancer, Endometrial cancer, Leukemia, Non-Hodgkin's Lymphoma, Uterine cancer,        Vaginal cancer survivors and non-cancer infertile women|July 2015|July 7, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581646||163271|
NCT00580801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013714|An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 4 Hepatitis C Infection||Tibotec BVBA|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|No|||August 2013|August 27, 2013|December 20, 2007|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00580801||163336|
NCT00593632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-852|A Randomized Controlled Trial of High Dietary Fiber Intake on Serum Lipids|A Randomized Controlled Trial of High Dietary Fiber Intake on Serum Lipids||The Cleveland Clinic|No|Active, not recruiting|January 2008|December 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||June 2011|June 9, 2011|January 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00593632||162370|
NCT00593879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5231-023-CRD-003|Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder|A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of Mecamylamine 5.0 to 10 mg, in the Treatment of Major Depressive Disorder With Subjects Who Are Partial or Non- Responders to Citalopram Therapy.||Targacept Inc.|No|Completed|February 2005|August 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|70 Years|No|||January 2008|January 2, 2008|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00593879||162351|
NCT00593892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070425005|Inflammatory Cytokine Variations in Traumatic Injury Responses|Cytokine Liberation From Secondary Surgery in the Setting of the Second Hit Syndrome|Cytokine|University of Alabama at Birmingham|No|Completed|May 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|19 Years|N/A|No|Non-Probability Sample|UAB Patients treated for traumatic injuries|October 2013|October 27, 2013|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00593892||162350|
NCT00599235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC/2004/4/13|Sildenafil and Exercise Capacity in Hypertension|Effects of the Selective Phosphodiesterase Type 5 Inhibitor Sildenafil Citrate on Exercise Capacity and Vascular Function in Hypertensive Subjects||University of Edinburgh||Completed|March 2007|August 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|30|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||January 2008|April 7, 2010|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00599235||161951|
NCT00598910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S185.4.001|Effect of Omacor on Triglycerides in HIV Infected Subjects|A Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Investigate the Effect of Omacor (n-3 PUFA) on Lipid Parameters in HIV Infected Subjects Treated With HAART||Solvay Pharmaceuticals|No|Terminated|August 2007|March 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||March 2009|March 27, 2009|January 11, 2008||No|The study was discontinued prematurely on December 18 2008 due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00598910||161975|
NCT00594464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0882|A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery|An Explorative, Multicenter, Open-label Pilot Trial With Neupro® (Rotigotine Transdermal Patch) Once Daily Treatment Administered Perioperatively in Patients With Idiopathic Parkinson's Disease|NEUPOS|UCB Pharma|No|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|80 Years|No|||December 2010|September 24, 2014|December 21, 2007|Yes|Yes||No|May 11, 2009|https://clinicaltrials.gov/show/NCT00594464||162306|
NCT00578708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-008|Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER|||St. Jude Medical|Yes|Completed|September 2003|September 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|N/A|No|||March 2015|March 16, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578708||163495|
NCT00578981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003475|Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women|Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.||Mayo Clinic|No|Completed|August 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Actual|100|||Female|50 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00578981||163474|
NCT00579267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINI-KID Validation Study|Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)|Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)||University of South Florida|No|Completed|February 2004|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|230|||Both|6 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and adolescents between the ages of 6 and 18 years.|December 2007|February 13, 2009|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00579267||163452|
NCT00579527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011583|Phase I/II Thymus Transplantation With Immunosuppression #950|Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950|#950|Duke University|Yes|Active, not recruiting|March 2006|June 2027|Anticipated|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|N/A|N/A|No|||December 2015|December 10, 2015|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579527||163432|
NCT00579774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 03-0116|Effects of Glycoxidative Stress on Human Aging|Effects of Glycoxidative Stress on Human Aging||Icahn School of Medicine at Mount Sinai|No|Completed|January 2007|October 2011|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|438|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579774||163414|
NCT00580047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437-02-FB|Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants|Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant||University of Nebraska|Yes|Active, not recruiting|December 2003|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|110|||Both|19 Years|N/A|No|||January 2014|January 2, 2014|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00580047||163393|
NCT00580060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-142|Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity|Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity||Memorial Sloan Kettering Cancer Center||Completed|December 2003|June 2011|Actual|June 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||June 2011|June 9, 2011|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00580060||163392|
NCT00580515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-120|Trial of Family Focused Grief Therapy in Palliative Care and Bereavement|Randomized Controlled Trial of Family Focused Grief Therapy in Palliative Care and Bereavement||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|700|||Both|12 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 28, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00580515||163357|
NCT00580528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352-05-FB|Reducing Blood Pressure in Prehypertensive Older Rural Women Also Known as Wellness for Women: DASHing Toward Health|Modifying Lifestyle in Prehypertensive Older Rural Women||University of Nebraska|No|Completed|August 2006|May 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|289|||Female|40 Years|69 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00580528||163356|
NCT00572585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2210|Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis|A Randomized, Double Blind, Placebo Controlled, Parallel Group Design Study to Explore the Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis||Novartis||Terminated|April 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|No|||February 2013|February 12, 2013|December 12, 2007|Yes|Yes|The proof of concept (PoC) studies for uveitis and ulcerative colitis did not meet PoC    criteria for demonstrating adequate efficacy to move forward|No||https://clinicaltrials.gov/show/NCT00572585||163952|
NCT00581360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-124|Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck|Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Head and Neck Adenoid Cystic Carcinoma||University of Pittsburgh|Yes|Completed|November 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581360||163293|
NCT00581373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060553|Water and the Gastropressor Response - Diurnal Variability|Water and the Gastropressor Response - Diurnal Variability (Specific Aim 1.3)||Vanderbilt University|No|Active, not recruiting|August 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2014|December 18, 2014|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00581373||163292|
NCT00572572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QL05-37|Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors|Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen||Hoosier Cancer Research Network|Yes|Completed|December 2007|February 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|71|||Male|15 Years|N/A|No|||November 2012|November 19, 2012|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572572||163953|
NCT00581919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO04402|Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma|Phase II Trial of Bortezomib, Low Dose Dexamethasone, and Doxorubicin With Acetyl-L-Carnitine for Neuroprotection in Patients With Previously Treated Multiple Myeloma||University of Wisconsin, Madison|Yes|Completed|February 2004|December 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581919||163250|
NCT00593359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-571|Intraocular Pressure During Spine Surgery|The Effect of Lactated Ringer's Solution Versus Albumin and the Alpha-2 Agonist Brimonidine Versus Placebo on Intraocular Pressure During Prone Spine Surgery||The Cleveland Clinic|No|Completed|December 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|60|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing spinal surgery in the prone position for at least 5 hours.|February 2016|February 19, 2016|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00593359||162391|
NCT00593645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0702|Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation|A Non-Myeloablative Conditioning Regimen for Allogeneic Transplantation With Clofarabine, Cytarabine, and Thymoglobulin for Myelodysplastic Syndrome and Acute Myeloid Leukemia||Washington University School of Medicine|Yes|Terminated|November 2007|July 2009|Actual|December 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|January 2, 2008|Yes|Yes|toxicities were worse than expected|No|July 18, 2014|https://clinicaltrials.gov/show/NCT00593645||162369|Enrollment was halted after 3 of the first 7 patients expired on days 15/26/32. Predefined early stopping rules were defined that if three deaths occurred in the first 11 patients then it was unlikely to achieve a low treatment-related mortality.
NCT00594204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051080|Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking|A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)||Pfizer|No|Completed|April 2008|August 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|593|||Both|18 Years|65 Years|No|||July 2010|July 14, 2010|January 3, 2008|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00594204||162326|
NCT00598923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR043514|Preventing Epilepsy After Traumatic Brain Injury With Topiramate|Preventing Epilepsy After Traumatic Brain Injury: A Pilot, Single-Center Randomized Trial of Topiramate to Prevent Seizures After Moderate to Severe TBI|PEPTO|University of Pennsylvania|Yes|Recruiting|November 2004|February 2009|Anticipated|February 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|N/A|No|||January 2008|January 22, 2008|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598923||161974|
NCT00594750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01329|Mechanisms of Exacerbation of Asthma|Mechanisms of Exacerbation of Asthma|MECA|University of California, San Francisco|No|Recruiting|May 2006|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|115|Samples Without DNA|Sputum, whole blood|Both|18 Years|75 Years|No|Non-Probability Sample|emergency deparment, admitted patients in the ICU and inpatient wards|November 2015|November 12, 2015|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00594750||162284|
NCT00594763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050045|Venous Thrombosis in Turner Syndrome|The Risk of Venous Thrombosis in Women With Turner Syndrome||University of Aarhus|No|Active, not recruiting|June 2006|April 2008|Anticipated|April 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|60|Samples With DNA|Blood|Female|18 Years|N/A|No|Non-Probability Sample|Women with Turner syndrome|January 2008|January 31, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00594763||162283|
NCT00578721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 07-47|Trial of Aspirin and Arginine Restriction in Colorectal Cancer|Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients||University of California, Irvine|Yes|Recruiting|September 2008|December 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|24|||Both|18 Years|80 Years|No|||January 2013|January 28, 2013|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578721||163494|
NCT00578734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL4-AHRF-01|Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old|A Multicenter, Randomized, Masked, Placebo-Controlled Trial to Assess the Safety and Efficacy of Lucinactant in Acute Hypoxemic Respiratory Failure in Children Up to Two Years of Age|KL4-AHRF-01|Discovery Laboratories, Inc.|Yes|Completed|June 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|N/A|2 Years|No|||May 2012|May 1, 2012|December 19, 2007|No|Yes||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00578734||163493|
NCT00578994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.K016|A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System|A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System||Biomet, Inc.|Yes|Active, not recruiting|March 2006|June 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|388|||Both|18 Years|N/A|No|Non-Probability Sample|A Multi-center study conducted in the United States of patients who meet the FDA approved        indications for use. The Oxford Meniscal Unicompartmental Knee System is intended for use        in individuals with osteoarthritis or avascular necrosis limited to the medial compartment        of the knee and is intended to be implanted with bone cement.|April 2015|May 5, 2015|December 19, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578994||163473|
NCT00579280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ 1107|Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD|A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder.||University of South Florida|No|Active, not recruiting|July 2007|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|January 13, 2011|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579280||163451|
NCT00570947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-20070910|CPR Prescription Program|CPR Prescription Program||Lehigh Valley Hospital|Yes|Completed|December 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|162|||Both|45 Years|N/A|No|||April 2012|April 25, 2012|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570947||164074|
NCT00570960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13104|Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis|Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis||University of Virginia|Yes|Terminated|June 2007|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|December 10, 2007||No|drug product became unavilable|No|January 14, 2013|https://clinicaltrials.gov/show/NCT00570960||164073|The study was terminated early because the manufacturer of Dextran 70 ceased all production of the study drug approximately 10 months into the study. It was felt by the principle investigator that continuation of the study was impossible.
NCT00579566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-060|Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma|Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma||Memorial Sloan Kettering Cancer Center|No|Recruiting|June 2002|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Tissue, Blood|Both|N/A|N/A|No|Non-Probability Sample|Patients seen or referred by Memorial Sloan-Kettering Cancer physicians|January 2016|January 20, 2016|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579566||163429|
NCT00571480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 12291|Use Ear Acupuncture as Treatment for Low Back Pain During Pregnancy|Acupuncture and Low Back Pain During Pregnancy||Yale University|No|Completed|February 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|159|||Female|13 Years|46 Years|No|||July 2009|July 17, 2009|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00571480||164033|
NCT00571727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 1419|Long-Term Treatment With rhIGF-1 in GHIS|A Study of the Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) Treatment in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)||Ipsen||Completed|January 1990|December 2011|Actual|October 2004|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|2 Years|21 Years|No|||September 2015|September 29, 2015|December 10, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00571727||164015|
NCT00580307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1089377|Rhinogenic Headache Improvement After Nasal Operation|Surgical Correction of Contact Point Headaches - Randomized Controlled Trial. [Rhinogenic Headache Improvement After Nasal Operation] Trial|RHINO|University of Missouri-Columbia|No|Withdrawn|December 2007|June 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|December 12, 2007||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00580307||163373|
NCT00578799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT07053|Effects of Probiotics in Patients With Ulcerative Colitis|Effects of Probiotics in Patients With Ulcerative Colitis.||University of California, Irvine|Yes|Terminated|July 2008|January 2010|Anticipated|January 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||July 2009|July 1, 2009|December 18, 2007||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT00578799||163488|
NCT00572286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8144|Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study|Evaluation of Non-invasive Methods for the Detection of Acute Rejection in Heart Transplant Patients: Use of Echocardiography and Magnetocardiography (MCG) -Pilot Study||Cedars-Sinai Medical Center|No|Withdrawn|October 2005|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Probability Sample|Patients who will have heart transplantation or who have had heart transplantation|November 2009|November 16, 2009|December 12, 2007||No|sponsor funding|No||https://clinicaltrials.gov/show/NCT00572286||163974|
NCT00573339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 11753|Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing|Cardiac Magnetic Resonance Imaging Normal Reference Control Group Testing - Ancillary Study to Coronary Endothelial Function and Microvascular Disease in Women||Cedars-Sinai Medical Center|No|Recruiting|May 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|None Retained|BUN and Creatinine blood tests|Female|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women|August 2015|August 5, 2015|December 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00573339||163895|
NCT00572858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 6326|Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women|Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women||Cedars-Sinai Medical Center|Yes|Recruiting|January 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|None Retained|Blood Hormone draw for FSH, E2; Urine Pregnancy test; Fasting lipid (cholesterol) panel,      fasting insulin and fasting blood glucose levels; Reproductive hormones (FSH, LH, E1, E2,      bioE2, PO, freeT, SHBG, DHEA-S); Plasma levels of inflammatory and endothelial function      markers including but not limited to hsCRP, serum amyloid, endothelin-1, and ELAM; Fasting      Salivary Cortisol (stress hormone).|Female|N/A|55 Years|No|Non-Probability Sample|Premenopausal Women|August 2015|August 6, 2015|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572858||163932|
NCT00598637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02807|Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease|Prospective Randomized Trial of Everolimus- and Zotarolimus-eluting Stents for Treatment of Unprotected Left Main Coronary Artery Disease: ISAR-LEFT-MAIN-2|LEFT-MAIN-2|Deutsches Herzzentrum Muenchen|Yes|Completed|December 2007|February 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|650|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598637||161996|
NCT00598884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH079884|Effectiveness of an Internet-Based Self-Management Program in Treating Prolonged Grief Disorder|Internet-Based Self-Management Intervention for Prolonged Grief||Boston University|Yes|Completed|August 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|135|||Both|21 Years|N/A|No|||June 2013|June 21, 2013|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00598884||161977|
NCT00598897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|447|Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease|Open, Noncomparative Trial of Multidrug Regimens Containing Clarithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease||The University of Texas Health Science Center at Tyler|No|Active, not recruiting|August 1995|||July 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598897||161976|
NCT00598936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5840|A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients|A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients||University of California, Irvine|Yes|Terminated|November 2007|May 2009|Actual|May 2009|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects ≥18 year-old of age admitted to the University Hospital setting scheduled        for cardiac surgery or admitted for any cause to the Intensive Care Unit (ICU).|September 2011|September 1, 2011|December 24, 2007||No|Investigator considered the device with no clinical utility.|No||https://clinicaltrials.gov/show/NCT00598936||161973|
NCT00598949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3765|Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma|Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma||Cedars-Sinai Medical Center|No|Recruiting|January 2003|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|cell lines are established for future genetic analysis|Both|18 Years|N/A|No|Non-Probability Sample|tertiary referral center|December 2010|December 14, 2010|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00598949||161972|
NCT00599547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBMT AlloRIC-MMM|Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients|Allogeneic Stem Cell Transplantation After Dose-reduced Intensity Conditioning Regimen for Patients With Myelofibrosis With Myeloid Metaplasia (MMM): A Phase II-study||Universitätsklinikum Hamburg-Eppendorf|No|Completed|November 2002|December 2009|Actual|August 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599547||161928|
NCT00578461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-19164 REGKINE|T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE|T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation|REGKINE|Baylor College of Medicine|Yes|Terminated|October 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|64 Years|No|||August 2014|August 28, 2014|December 19, 2007||No||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00578461||163514|
NCT00579007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-001|Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations|Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|March 2003|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|224|||Female|25 Years|N/A|No|Non-Probability Sample|Women undergoing genetic counseling and testing for inherited breast or ovarian ccancer        risk will be assessed before their first genetic counseling session|April 2015|April 28, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579007||163472|
NCT00579293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-098|Development of a Computer Assisted Survivor Screening For Adult Survivors of Childhood Cancer|Development of a Computer Assisted Survivor Screening For Adult Survivors of Childhood Cancer||Memorial Sloan Kettering Cancer Center||Completed|August 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|49 Years|No|Non-Probability Sample|adult survivors of childhood cancer|July 2008|July 24, 2008|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579293||163450|
NCT00579553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progesterone75,643|Comparing IM vs. Vaginal Progesterone for Pre-term Birth|Comparing Intramuscular Versus Vaginal Progesterone for Prevention of Preterm Birth.||University of Oklahoma|Yes|Completed|October 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|264|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579553||163430|
NCT00579033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0959-A|Somatosensory Processing in Focal Hand Dystonia|Tactile Operant Conditioning To Alleviate Focal Hand Dystonia Symptoms||University Health Network, Toronto|No|Recruiting|May 2007|July 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2007|December 19, 2007|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00579033||163470|
NCT00571246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00030|The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder|The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder||Yale University|Yes|Withdrawn|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|65 Years|No|||August 2012|August 30, 2012|December 7, 2007||No||No||https://clinicaltrials.gov/show/NCT00571246||164051|
NCT00571233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2529|Biomarker Study for Heart Failure in Children With Single Ventricle Physiology|Identification of Biomarkers for Heart Failure in Children With Single Ventricle Physiology|BHFSVP|University of California, San Francisco|No|Completed|February 2007|January 2015|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|71|Samples With DNA|Serum|Both|1 Month|6 Years|No|Non-Probability Sample|Patients presenting to the UCSF Pediatric Heart Center.|May 2015|May 13, 2015|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00571233||164052|
NCT00571779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2007-2|AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIB|Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation|RESTORE SR IIB|AtriCure, Inc.||Withdrawn||||||Phase 2|Interventional|N/A|||||||Both|18 Years|80 Years|No|||February 2011|February 18, 2011|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00571779||164011|
NCT00572026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12189|Enhancing ADHD Driving Performance With Stimulant Medication|Enhancing ADHD Driving Performance With Stimulant Medication||University of Virginia|No|Recruiting|July 2007|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|14|||Both|18 Years|25 Years|No|||September 2009|September 2, 2009|December 10, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00572026||163993|
NCT00571740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0548|Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer|Randomized Phase II Trial of Cetuximab/Bevacizumab (CB) as Palliative First-Line Therapy in Patients With Advanced Colorectal Cancer Followed by FOLFOX+CB vs. FOLFOX+B||Alliance for Clinical Trials in Oncology||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|December 11, 2007|Yes|Yes|The study was not activated|No||https://clinicaltrials.gov/show/NCT00571740||164014|
NCT00571753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDANAT2|Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)|A Double-blind, Multicentre, Parallel Group, Randomised, Controlled Trial to Evaluate the Possible Benefit of Isoniazid Dose Adjustment According to the Genotype for NAT2 (Arylamine N-acetyltransferase Type 2) in Patients With Pulmonary Tuberculosis||University of Cologne|Yes|Terminated|June 2008|February 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|75 Years|No|||February 2011|February 25, 2011|December 11, 2007||No|Enrolling participants has halted prematurely due to a low recruitment rate.|No||https://clinicaltrials.gov/show/NCT00571753||164013|
NCT00572000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111040 (HPV-022 PRI)|Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule|Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule|HPV-022 PRI|National Institute for Control of Vaccine and Biologicals|Yes|Recruiting|November 2007|June 2008|Anticipated|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|222|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||October 2007|December 11, 2007|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00572000||163995|
NCT00572871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1097239|Hormonal and Bone Turnover Marker Response to an Acute Bout of Resistance or Plyometric Exercise|Hormonal and Bone Turnover Marker Response to an Acute Bout of Resistance or Plyometric Exercise||University of Missouri-Columbia|No|Completed|December 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|12|Samples Without DNA|serum plasma|Male|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male participants apparently healthy and non-sedentary free of disease that affects bone        and not have used or currently use any medication that affects bone.|March 2011|March 1, 2011|December 12, 2007||No||No||https://clinicaltrials.gov/show/NCT00572871||163931|
NCT00579605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273-06-FB|Motivational Interviewing to Promote Sustained Breastfeeding|Motivational Interviewing to Promote Sustained Breastfeeding (Native American Women)||University of Nebraska|Yes|Completed|August 2006|December 2007|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Female|17 Years|45 Years|Accepts Healthy Volunteers|||December 2007|December 21, 2007|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00579605||163426|
NCT00569309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07044|Vaccine Therapy in Treating Patients Who Have Undergone Autologous Stem Cell Transplant for High-Risk Lymphoma or Multiple Myeloma|Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation for High-Risk Lymphoma and Myeloma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|December 2007|||November 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2012|June 10, 2012|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00569309||164195|
NCT00598377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/233|Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease|Assessment of Adrenal Functions in Patients With Autosomal Dominant Polycystic Kidney Disease||Istanbul University|No|Completed|September 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|49|||Both|20 Years|56 Years|Accepts Healthy Volunteers|||February 2008|February 17, 2009|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00598377||162014|
NCT00598650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-432|A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies|A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies||Eisai Inc.||Completed|February 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|50 Years|N/A|No|||August 2014|August 29, 2014|January 10, 2008||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT00598650||161995|
NCT00598663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUR03|SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c|Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump|SWITCH|Medtronic|No|Completed|January 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|154|||Both|6 Years|70 Years|Accepts Healthy Volunteers|||September 2010|September 17, 2010|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00598663||161994|
NCT00598689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09-052|GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients|Efficacy, Tolerability and Comfort of GenTeal and GenTeal Gel, (0.3% Hypromellose) in the Pre- and Post- Operative Treatment of Patients Undergoing LASIK Surgery||Georgia Regents University|Yes|Completed|October 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|January 10, 2008||No||No|January 27, 2015|https://clinicaltrials.gov/show/NCT00598689||161992|
NCT00598702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APA-352|Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients|A Phase III Multi-Center, Open-Label, Prospective, Repeated Dose, Multi-Day Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients.||Mallinckrodt|No|Completed|January 2008|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|37 Weeks|16 Years|No|||May 2015|May 14, 2015|January 9, 2008|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00598702||161991|The original protocol required 50 subjects that completed 5 days of treatment. With protocol amendment 2, the criteria for enrollment/completion was reduced to 1 day of treatment. Subjects were required to have a minimum of 3 IV APAP doses per day.
NCT00599248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGC-03-01|Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee|A Phase 1 Study to Determin the Safety and Biological Activity of Cell-Mediated Gene Therapy Using TissueGene-C in Patients With Degenerative Joint Disease Prior to Total Knee Arthroplasty|TGC-03-01|TissueGene, Inc.|Yes|Completed|January 2007|May 2010|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||October 2010|October 13, 2010|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599248||161950|
NCT00578747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-RES07KWA|Do Skin Markings Reflect the Location of the Surgical Cavity During Daily Radiotherapy Treatment?|Development of Improved Target Volume Localization for Accelerated Partial Breast Irradiation- Stage I||British Columbia Cancer Agency|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|21|||Female|N/A|N/A|No|Non-Probability Sample|Women in the Fraser Valley, with Breast cancer that is suitable for treatment with a new        radiation treatment procedure called accelerated partial breast irradiation (APBI)|September 2015|September 2, 2015|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00578747||163492|
NCT00578227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110886|Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects|Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) Co-administered With a Commercially Available Vaccine in Healthy Female Adolescents||GlaxoSmithKline||Completed|December 2007|April 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|814|||Female|9 Years|15 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|December 20, 2007|Yes|Yes||No|November 27, 2009|https://clinicaltrials.gov/show/NCT00578227||163531|
NCT00578500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819|Fertility Preservation by Ovarian and Oocyte Cryopreservation|Study That Establishes the Potential of Fertility Preservation in Young Female Patients by Oocyte in Vitro Maturation and Cryopreservation and Ovarian Cortex Cryopreservation and Transplantation|HFPP|Hadassah Medical Organization|Yes|Recruiting|January 2000|January 2010|Anticipated|||Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|5 Years|35 Years|No|||January 2002|December 19, 2007|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00578500||163511|
NCT00578513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202-U-004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2000|||||N/A|N/A|N/A||||||||||||||February 11, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00578513||163510|
NCT00578760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aspirin-01|Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?|Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?||University Health Network, Toronto|No|Not yet recruiting|February 2008|February 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|N/A|No|||December 2007|December 19, 2007|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00578760||163491|
NCT00579020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-04|A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates|An Evaluation of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates||Alcon Research|No|Terminated|December 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|144|||Both|12 Years|N/A|No|||December 2012|December 3, 2012|December 19, 2007|Yes|Yes|Management decision|No||https://clinicaltrials.gov/show/NCT00579020||163471|
NCT00570973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOvsTIPS|Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy|A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy|ENDOvsTIPS|Medical University of Vienna|Yes|Completed|November 2004|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570973||164072|
NCT00581672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-125|Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men|Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Male|18 Years|N/A|No|Probability Sample|Black men with prostate cancer|October 2015|October 5, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00581672||163269|
NCT00581685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216-2007|Does Optimal Control of Pre-operative Chronic and Acute Pain Predict Improved Function After Orthopedic Surgery?|Does Optimal Pain Control With Pregabalin and Celecoxib Predict Improved Function After Total Hip Arthroplasty?||Sunnybrook Health Sciences Centre|No|Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00581685||163268|
NCT00571493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|438-05|VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma|Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma||University of Nebraska|Yes|Completed|April 2006|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|19 Years|N/A|No|||August 2015|August 11, 2015|December 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00571493||164032|
NCT00571766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral L-Arginine|Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy|Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy||University of Modena and Reggio Emilia|Yes|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2009|September 9, 2009|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571766||164012|
NCT00578006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-020|Internet-based System for Cancer Patients to Self-report Toxicity|Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|March 2004|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1007|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578006||163548|
NCT00572299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28727|Glucocorticoids Promote Osteoclast Survival|Glucocorticoids Promote Osteoclast Survival||University of Arkansas|No|Terminated|January 2004|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|3|Samples Without DNA|bone biopsy specimens|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|adults receiving aminobisphosphonate therapy to prevent osteoporosis from glucocorticoids,        postmenopausal bone loss or osteoporosis in males|August 2011|August 29, 2011|December 11, 2007||No|Terminated due to recruitment problems|No||https://clinicaltrials.gov/show/NCT00572299||163973|
NCT00578279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702-25|Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study|Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study||Indiana University|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2010|September 18, 2012|December 19, 2007|No|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00578279||163528|
NCT00579358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT07001|Molecular Basis of Congenital Heart Defects|Molecular Basis of Congenital Heart Defects||University of California, Irvine|No|Recruiting|November 2007|November 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|blood samples|Both|N/A|N/A|No|Non-Probability Sample|The characteristics of the proposed subject population include:          -  Children (male or female) who are able to give assent          -  Subjects diagnosed with congenital heart defects          -  Adults (male or female) who are competent to give informed consent          -  Subjects who are unable to read or speak English          -  Individuals of any ethnic origin|November 2010|November 5, 2010|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00579358||163445|
NCT00579371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149-03-FB|Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus|Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus||University of Nebraska|No|Enrolling by invitation|January 2008|January 2013|Anticipated|January 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|70 Years|No|||June 2010|June 25, 2010|December 17, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00579371||163444|
NCT00579384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014110|A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy|A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram Response in Patients With Photosensitive Epilepsy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|No|||April 2012|April 3, 2012|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579384||163443|
NCT00579098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-005460|The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation|Atorvastatin for Prevention of Atrial Fibrillation Recurrence Following Pulmonary Veins Isolation: A Double-Blind, Placebo-Controlled, Randomized Pilot Trial|ATTAC|Mayo Clinic|No|Completed|December 2007|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|90 Years|No|||March 2014|March 21, 2014|December 18, 2007||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00579098||163465|The population was restricted to patients who did not have an indication for statin treatment. The lack of transtelephonic or prolonged Holter monitoring likely resulted in underestimation of the rate of asymptomatic episodes of AF.
NCT00579111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19386|Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)|Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases||Baylor College of Medicine|Yes|Terminated|June 2007|October 2010|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|N/A|70 Years|No|||July 2012|July 3, 2012|December 19, 2007|Yes|Yes|slow accrual|No|July 3, 2012|https://clinicaltrials.gov/show/NCT00579111||163464|
NCT00579852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-149|Assess the Variability of Uni-Dimensional, Bi-Dimensional, and Volumetric CT Scan Measurement of Non-Small Cell Lung Cancer Tumors|A Prospective Trial to Assess the Variability of Uni-Dimensional, Bi-Dimensional, and Volumetric CT Scan Measurement of Non-Small Cell Lung Cancer Tumors||Memorial Sloan Kettering Cancer Center||Completed|November 2006|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|No|Non-Probability Sample|Thoracic Oncology Service at MSKCC clinic.|January 2008|January 31, 2008|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579852||163408|
NCT00580372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01332|UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma|Phase II Study of Intensive "TOTAL THERAPY" for Untreated or Minimally Treated Patients With Multiple Myeloma||University of Arkansas|No|Completed|August 2002|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|233|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00580372||163368|
NCT00579839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CordClampingElimian|Trial of Immediate vs. Delayed Cord Clamping in the Preterm Neonate|A Randomized Controlled Trial of Immediate Versus Delayed Cord Clamping in the Preterm Neonate||University of Oklahoma|Yes|Completed|October 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|December 18, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579839||163409|
NCT00598390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080048|PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP|PET Test/Retest Brain Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP||National Institutes of Health Clinical Center (CC)||Completed|January 2008|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|February 19, 2014|January 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00598390||162013|
NCT00598676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02607|3 Limus Agent Eluting Stents With Different Polymer Coating|Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting STents (ISAR-TEST 4): Prospective, Randomized Trial of 3-limus Agent-eluting Stents With Different Polymer Coatings|ISAR-TEST-4|Deutsches Herzzentrum Muenchen|Yes|Completed|September 2007|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2600|||Both|18 Years|N/A|No|||March 2010|March 12, 2010|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598676||161993|
NCT00599287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICHYPDEL/002|Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients|Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-Blind Pilot Trial||UMC Utrecht|Yes|Terminated|February 2008|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||February 2008|May 27, 2008|January 10, 2008||No|Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed    consent.|No||https://clinicaltrials.gov/show/NCT00599287||161947|
NCT00599313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05112|Phase II Sunitinib Prog Met AIPC|Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy||US Oncology Research|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|N/A|No|||May 2014|May 21, 2014|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599313||161946|
NCT00599261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10995|MAKE IT CLEAN, Impact of Pocket Revision on the Rate of Infection and Other Complications in Patients Requiring Pocket Manipulation for Generator Replacement and/or Lead Replacement or Revision: A Prospective Randomized Study|Impact of Pocket Revision on the Rate of Infection and Other Complications in Patients Requiring Pocket Manipulation for Generator Replacement and/or Lead Replacement or Revision: A Prospective Randomized Study||University of Kansas Medical Center|Yes|Completed|January 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|265|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599261||161949|
NCT00577954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051061|Multimodal Resonance Imaging for Outcome Prediction on Coma Patients|Multimodal Magnetic Resonance (MRI) Development in Comatose Patients for an Algorithm in the Prediction of Consciousness Recovery|MRI-Coma|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2006|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|417|||Both|18 Years|N/A|No|Non-Probability Sample|Traumatic brain injured patients, stroke patients, subarachnoid hemorrhage (SAH) patients        and cerebral anoxia patients|December 2008|December 10, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00577954||163552|
NCT00570440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9964|Continuous Use of COCs|Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills||FHI 360||Completed|August 2007|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|362|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||October 2011|October 28, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00570440||164111|
NCT00570687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-118|A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes|||Mannkind Corporation||Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||October 2014|October 9, 2014|December 7, 2007|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00570687||164094|
NCT00571792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|406-05|Evaluation of Airway Gene Expression in COPD and Controlled Populations|Evaluation of Airway Gene Expression in COPD and Controlled Populations||University of Nebraska|No|Recruiting|August 2006|September 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|Samples With DNA|Genetic testing involves identification of potential proteins and biomarkers produced from      the DNA and RNA analysis. Included are MMP12 and MMP9, Nrf-2 gene, heme oxygenases,      glutathione, sythesizing enzymes, thioredoxin reductase, NADPH dependent quinone reductase 1      as well as certain p450 members.|Both|45 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males or non-pregnant, non-nursing females who are of non-childbearing potential between        the ages of 45 and 70 years of age and who may be either life long non smokers, smokers        who do not demonstrate symptoms of COPD and smokers who do demonstrate symptoms of COPD|December 2007|December 11, 2007|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00571792||164010|
NCT00577785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL005|Study to Obtain Full Thickness Bladder Tissue From Subjects Undergoing Cystectomy Surgery|A Multi-Center Study to Obtain Full Thickness Bladder Tissue Specimen From Subjects Undergoing Cystectomy Surgery||Tengion|No|Completed|August 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|Samples Without DNA|Tissue|Both|18 Years|90 Years|No|Non-Probability Sample|Patients otherwise undergoing cystectomy|December 2010|December 20, 2010|December 18, 2007||No||No||https://clinicaltrials.gov/show/NCT00577785||163564|
NCT00578578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 6970|Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels|Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels|Omega-3|The Cleveland Clinic|Yes|Terminated|September 2005|August 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|19 Years|N/A|No|||December 2007|December 19, 2007|December 19, 2007||No|CRP is no longer SOC - enrollment halted and will analyze available data.|No||https://clinicaltrials.gov/show/NCT00578578||163505|
NCT00581958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-158|Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)|Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)||Memorial Sloan Kettering Cancer Center||Recruiting|November 2007|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|4 Years|100 Years|No|||March 2016|March 9, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00581958||163247|
NCT00579124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-3-4222|CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion|CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation With the CliniMACs Device for T and B Cell Depletion|CliniMACs|Children's Hospital of Philadelphia|Yes|Recruiting|March 2005|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|N/A|22 Years|No|||October 2015|October 19, 2015|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579124||163463|
NCT00578565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007133|Rituximab in Rheumatoid Arthritis Lung Disease|Rituximab for the Treatment of Rheumatoid Arthritis-Associated Interstitial Pneumonia: A Pilot Study||Mayo Clinic|No|Completed|May 2007|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||September 2012|September 25, 2012|December 19, 2007|Yes|Yes||No|May 21, 2012|https://clinicaltrials.gov/show/NCT00578565||163506|Given the small number of patients, it could not be determined whether patients with nonspecific interstitial pneumonia (NSIP) or usual interstitial pneumonia (UIP) were more likely to respond. Further research is needed in less advanced disease.
NCT00579631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-074|Adolescent Survivors of Cancer or Similar Illnesses|Health Behaviors in Adolescent Survivors of Cancer or Similar Illnesses||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2004|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|148|||Both|14 Years|19 Years|No|Non-Probability Sample|Memorial Sloan-Kettering Cancer Center's Department of Pediatrics|January 2016|January 13, 2016|December 20, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00579631||163424|
NCT00579865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-036|Quality Of Life in Patients With Malignant Biliary Obstruction|Impact of Biliary Drainage on Quality Of Life in Patients With Malignant Biliary Obstruction||Memorial Sloan Kettering Cancer Center||Completed|May 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|124|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinics|January 2010|January 13, 2010|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579865||163407|
NCT00579618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-102|Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging|Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging||Memorial Sloan Kettering Cancer Center||Recruiting|September 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Saliva or blood samples|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nursing homes, senior centers, health fairs or other community organizations.|February 2016|February 11, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00579618||163425|
NCT00580385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-094|Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors|Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|August 1997|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|750|||Both|N/A|N/A|No|||November 2015|November 16, 2015|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00580385||163367|
NCT00580606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CoFAR4|A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial|Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2007|December 2014|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|12 Years|40 Years|No|||December 2015|December 15, 2015|December 18, 2007|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00580606||163351|Refer to the original results published in the Journal of Allergy and Clinical Immunology, Vol 135, Number 5, page 1247 for a full description of the limitations of the current study.
NCT00598104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2103|Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma|A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal||Novartis|No|Withdrawn|January 2008|||December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||March 2016|March 2, 2016|January 9, 2008|Yes|Yes|Due to the lack of enrolment and complexity of design, this study in asthma was terminated. No    subjects have been dosed for this study.|||https://clinicaltrials.gov/show/NCT00598104||162034|
NCT00598403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM-ME1207/311|Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis|Multicentre, Prospective, Comparative, Randomized, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of Cefditoren Pivoxil vs. Ciprofloxacin in Uncomplicated Acute Cystitis||Tedec-Meiji Farma, S.A.|No|Completed|November 2007|June 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|611|||Female|18 Years|N/A|No|||June 2010|June 28, 2010|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598403||162012|
NCT00598962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|426|Use of Azithromycin and Rifabutin Administered Three Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease|Open, Noncomparative Trial of Multidrug Regimens Containing Azithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease||The University of Texas Health Science Center at Tyler|No|Active, not recruiting|December 1994|||November 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||November 2007|January 11, 2008|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598962||161971|
NCT00579046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 061011|Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease|Erythropoietin Treatment of Anemia Complicating Chronic Obstructive Pulmonary Disease: Functional Impact During Exertion|ELAB|Assistance Publique - Hôpitaux de Paris|Yes|Withdrawn|November 2008|October 2009|Anticipated|October 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|40 Years|75 Years|No|||October 2013|October 29, 2013|December 20, 2007||No|no patient recruiting|No||https://clinicaltrials.gov/show/NCT00579046||163469|
NCT00570466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK66724 (completed)|Computer Based Intervention for Type 2 Diabetes in Youth|Computer Based Intervention for Type 2 Diabetes in Youth: Phase 2||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|January 2008|December 2011|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|153|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|December 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00570466||164110|
NCT00570700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 06-60|Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer|BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy||University of California, Irvine|Yes|Completed|July 2007|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|December 6, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00570700||164093|
NCT00570713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-009-002|An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer|A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.||Morphotek|Yes|Completed|December 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|December 7, 2007|Yes|Yes||No|December 8, 2011|https://clinicaltrials.gov/show/NCT00570713||164092|
NCT00578019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F990825010|Comparison Between LISS Plating and Intramedullary (IM) Nailing for Supracondylar Femur Fractures|Prospective Comparison Between Less Invasive Stabilization System (LISS) Plating and Intramedullary Nailing for the Treatment of Supracondylar Femur Fractures|LISS|University of Alabama at Birmingham|No|Completed|December 1999|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|19 Years|N/A|No|||September 2013|September 28, 2013|December 18, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00578019||163547|
NCT00607386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-ELA-038|Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy|A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy||Shire|No|Completed|December 2007|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|N/A|5 Years|No|||February 2014|October 6, 2015|January 22, 2008|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT00607386||161339|
NCT00607061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/12-O|Synthesis of Glutathione From Low Birth Weight Newborn Babies|Synthesis of Glutathione in Erythrocytes From Low Birth Weight Newborn Babies : Effect of Cysteine in Vitro|glutathione|Nantes University Hospital|No|Terminated|October 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|35|||Both|N/A|9 Months|No|||September 2013|September 27, 2013|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607061||161363|
NCT00607373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012CS5|Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects|RADICHOL 1|Sanofi|Yes|Completed|July 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|12 Years|N/A|No|||October 2014|October 27, 2014|January 22, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00607373||161340|
NCT00608205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3307|Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer|A Phase III Randomized Trial Comparing Single Agent Cisplatin With the Combination of 5-Fluorouracil and Cisplatin, Concurrent With Radiation Therapy in Stage III and IV Squamous Cell Head and Neck Cancer||Case Comprehensive Cancer Center|Yes|Active, not recruiting|January 2008|February 2016|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|January 30, 2008|Yes|Yes||No|July 11, 2013|https://clinicaltrials.gov/show/NCT00608205||161279|
NCT00608543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042004-011|Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression|Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: Assessment of Symptom Reduction, Psychosocial Function, and Cognitive Function||University of Texas Southwestern Medical Center|No|Completed|October 2005|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||March 2012|October 24, 2012|January 23, 2008|Yes|Yes||No|November 15, 2011|https://clinicaltrials.gov/show/NCT00608543||161258|Note that because this is an augmentation trial, reported AEs are due to combined treatment with escitalopram, citalopram, or sertraline AND aripiprazole.
NCT00608244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP Tacro 2012|Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients|A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day||Veloxis Pharmaceuticals|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|65 Years|No|||August 2015|August 14, 2015|January 23, 2008|Yes|Yes||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00608244||161276|
NCT00608556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080067|Dyskinesia, Heterotaxy and Congenital Heart Disease|Ciliary Dysfunction as an Underlying Etiology Linking Primary Ciliary Dyskinesia With Heterotaxy and Complex Congenital Heart Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2008|October 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|3|||Both|2 Years|N/A|No|||October 2011|September 26, 2015|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00608556||161257|
NCT00608569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5234|Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults|International Trial of Modified Directly Observed Therapy Versus Self-Administered Therapy for Participants With First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen||AIDS Clinical Trials Group||Completed|March 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|529|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|January 21, 2008|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00608569||161256|
NCT00609128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998-381|Allergic Eye Disease Tear Mediators|Expression of Inflammatory Mediators in Allergic Conjunctivitis||University of Wisconsin, Madison|No|Recruiting|September 2000|September 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 30, 2008|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00609128||161216|
NCT00609141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00363|IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor|A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|January 2008|||September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|1 Year|21 Years|No|||June 2014|June 18, 2014|February 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00609141||161215|
NCT00604643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigational Plan #025|Talent Aortic Cuff Stent Graft System Compassionate Use Registry|Compassionate Use of the TALENT Aortic Cuff in the Treatment of Patients Previously Treated With the AneuRx Stent Graft System With Sub-Optimal Stent Graft Outcomes||Medtronic Endovascular|No|No longer available|October 2002|April 2012|Anticipated|July 2008|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||July 2015|July 31, 2015|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604643||161546|
NCT00596609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-4-5176|Intrathecal Morphine on Transcranial Electric Motor-Evoked Potentials|Effects of Intrathecal Morphine on Transcranial Electric Motor-Evoked Potentials in Patients Undergoing Posterior Spine Fusion|EIM|Children's Hospital of Philadelphia|No|Completed|August 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Both|11 Years|18 Years|No|Non-Probability Sample|Children ages 11-18 with idiopathic scoliosis who are scheduled to have a posterior spinal        fusion.|September 2009|September 14, 2009|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00596609||162146|
NCT00596622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH075025|FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder|Dysfunctional Cortico-Limbic Activity and Connectivity in Bipolar Disorder Before and After Lithium Treatment: An fMRI Study||Indiana University|No|Active, not recruiting|August 2007|June 2013|Anticipated|January 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||September 2012|March 25, 2013|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596622||162145|
NCT00605228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL994-02/2006 (FFS)|A Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation|A Randomised, Multicentre, Single-Blind, Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation.|NORMO|Norgine|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|85 Years|No|||January 2008|January 29, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00605228||161501|
NCT00605592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12839|UVA Islet Cell Transplantation in Patients With Type I Diabetes|UVA Islet Cell Transplantation in Patients With Type I Diabetes||University of Virginia|Yes|Active, not recruiting|January 2007|January 2012|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||February 2009|February 16, 2009|January 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00605592||161476|
NCT00638963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05225|Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)|Temozolomide in Metastatic Breast Cancer Patients at High Risk of Brain Recurrence: Impact on the Incidence of Brain Metastases (STOP)|STOP|Merck Sharp & Dohme Corp.|No|Terminated|October 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|January 10, 2008|No|Yes|Terminated due to poor accrual|No|June 23, 2011|https://clinicaltrials.gov/show/NCT00638963||158968|The primary outcome measure and the survival analyses could not be analyzed due to the low enrollment.
NCT00638976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fondazione Mediolanum 001/2007|INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial|INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial|INSTANT|Fondazione Mediolanum per Attività e Ricerche Cardiovascolari Onlus|Yes|Completed|November 2007|May 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|91|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00638976||158967|
NCT00638989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-354-0703|A Study to Assess Bioavailability and Pharmacokinetics of CAT 354|An Open-Label, Parallel-Group, Bioavailability Study to Assess the Pharmacokinetics of CAT-354 Following Subcutaneous and Intravenous Administration||MedImmune LLC|No|Completed|March 2008|August 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00638989||158966|
NCT00638196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22084|Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS|Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis|PLACATE-MS|University of Rochester|Yes|Terminated|March 2008|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|No|||August 2015|August 7, 2015|March 10, 2008|Yes|Yes|funding stopped due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT00638196||159027|
NCT00606190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5985 Aortic Arch|Prospective Randomized Study of Brain Protection During Aortic Arch Replacement|Prospective Randomized Study of Brain Protection During Aortic Arch Replacement||The Cleveland Clinic|Yes|Completed|June 2003|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|21 Years|74 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00606190||161430|
NCT00638170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72/2001|Cranberry Juice in the Prevention of Urinary Tract Infections in Children|The Efficacy of Cranberry Juice in the Prevention of Urinary Tract Infections in Children - Randomized, Placebo Controlled Multi-Center Study||University of Oulu|No|Completed|May 2001|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|262|||Both|1 Year|16 Years|No|||January 2008|February 13, 2009|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638170||159029|
NCT00607074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMRC/ERC/2001-2004/2281|Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh|Effects of Anti-Giardia and Antihelmintic Treatment on Infant Nutritional and Biochemical Status and Intestinal Permeability in Rural Bangladesh||University of Cambridge|No|Completed|June 2003|December 2006|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|410|||Both|3 Months|15 Months|Accepts Healthy Volunteers|||January 2008|February 4, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607074||161362|
NCT00607087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_C_02083|Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus|Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus|PUMP|Sanofi||Completed|January 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|289|||Both|18 Years|75 Years|No|||August 2010|August 26, 2010|January 23, 2008|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00607087||161361|
NCT00606840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2018-07|Weight Gain Prevention|Study to Prevent Weight Gain||The Miriam Hospital||Completed|January 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|35 Years|No|||April 2012|April 12, 2012|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606840||161380|
NCT00606853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-008|Enhanced and Attendance-based Prize CM in Community Settings|Enhanced and Attendance-based Prize CM in Community Settings||University of Connecticut Health Center|No|Completed|October 2003|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|443|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606853||161379|
NCT00607100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPESQ N. 1056/07|High-Resolution Optical Coherence Tomography for Detection of Retinal Nerve Fiber Layer Loss in Band Atrophy of the Optic Nerve|High-Resolution Optical Coherence Tomography for Detection of Retinal Nerve Fiber Layer Loss in Band Atrophy of the Optic Nerve||University of Sao Paulo|Yes|Active, not recruiting|December 2007|December 2008|Anticipated|March 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with band atrophy from chismal compression and controls|November 2008|November 11, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00607100||161360|
NCT00607672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051170|The RAS, Fibrinolysis and Cardiopulmonary Bypass|The RAS, Fibrinolysis and Cardiopulmonary Bypass||Vanderbilt University|No|Completed|August 2006|December 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|111|||Both|18 Years|80 Years|No|||September 2012|September 7, 2012|February 4, 2008||No||No|August 2, 2012|https://clinicaltrials.gov/show/NCT00607672||161317|We cannot exclude the possibility that our results may have been different if we studied a homogenous surgery population.
NCT00607412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AA015707|Alcohol Use Disorders (AUDs) and Post-traumatic Stress Disorder (PTSD) Treatment for Victims of Partner Violence|AUDs and PTSD Treatment for Victims of Partner Violence||University of California, San Diego|Yes|Completed|August 2007|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||June 2009|May 10, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00607412||161337|
NCT00639184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP04|BRAIN - Home Intervention Trial|Brain Research to Ameliorate Impaired Neurodevelopment (BRAIN): Home-based Intervention A Multicenter Trial of the Global Network for Women's and Children's Health Research|BRAIN-HIT|NICHD Global Network for Women's and Children's Health|Yes|Completed|June 2007|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|240|||Both|N/A|28 Days|Accepts Healthy Volunteers|||July 2014|July 29, 2014|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00639184||158951|
NCT00607932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581410|Brassica Vegetables or Indole-3-Carbinol in Treating Patients With PSA Recurrence After Surgery for Prostate Cancer|Effects of Bassica or Indole-3-Carbinol on Prostatectomy Patients With PSA Recurrence||Vanderbilt University|Yes|Completed|March 2005|November 2010|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Male|18 Years|N/A|No|||November 2010|November 29, 2010|February 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607932||161298|
NCT00608218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alves Artist 07/10|Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma|Ciclesonide for the Therapy of Asthma During the Cold Season.|ARTIST|Nycomed|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2100|||Both|12 Years|N/A|No|Non-Probability Sample|Outpatients|May 2012|May 4, 2012|January 23, 2008||||No||https://clinicaltrials.gov/show/NCT00608218||161278|
NCT00608231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070666|Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation|Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation||Vanderbilt University|Yes|Withdrawn|January 2008|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|January 7, 2008||No|Intraoperative recording could not be maintained for required period|No||https://clinicaltrials.gov/show/NCT00608231||161277|
NCT00608283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RELIVE-01|Live Kidney Donor Study|Live Kidney Donor Study (RELIVE-01)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|8951|||Both|N/A|N/A|No|Non-Probability Sample|People who will donate kidneys at one of the three transplant centers between August 2007        and June 2011|December 2012|December 11, 2012|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00608283||161275|
NCT00640367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNTHESIS EXPANSION|Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke|Synthesis Expansion: A Randomized Controlled Trial on Intra-Arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke|SYNTHESIS EXP|Niguarda Hospital|Yes|Completed|February 2008|July 2012|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|80 Years|No|||April 2014|April 24, 2014|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00640367||158861|
NCT00608842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-07-05|Phase 2 Study for the Treatment of Superficial Lipomas|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas||Kythera Biopharmaceuticals|No|Completed|November 2007|January 2010|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|January 23, 2008|Yes|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT00608842||161236|
NCT00609154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-041|Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates|Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|November 2007|November 2008|Anticipated|November 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2008|February 5, 2008|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00609154||161214|
NCT00604656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2000-1542|Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes|A Six Months, Multi-centre, Open, Randomised, Parallel Safety and Efficacy Comparison of NovoRapid® Produced by the Current Process and Insulin Aspart With the Same Formulation as NovoRapid®, Produced by the NN2000 Process in Subjects With Type 1 Diabetes on a Basal/Bolus Regimen||Novo Nordisk A/S|No|Completed|May 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|241|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|January 17, 2008||||No||https://clinicaltrials.gov/show/NCT00604656||161545|
NCT00604669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004573|TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients|Total Parenteral Nutrition(TPN)-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients||Emory University|Yes|Completed|June 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|170|||Both|18 Years|N/A|No|Probability Sample|All patients receiving TPN at Grady Memorial Hospital during the period of 1/01/06 to        12/31/06.|November 2013|November 20, 2013|January 17, 2008||No||No|December 8, 2008|https://clinicaltrials.gov/show/NCT00604669||161544|
NCT00596063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wosulin R/PK-PD/HV/FDA/07/v1|Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.|A Randomized, Single Center, Double Blind, Two Period, Crossover Glucose Clamp Study to Test for Bioequivalence Between Two Recombinant Human Soluble Insulins- Wockhardts Insulin Human Regular for Injection and Novolin R in Healthy Subjects||Wockhardt|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 26, 2012|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00596063||162188|
NCT00596076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-04-41-4972|Back School Efficacy on Low Back Pain and Quality of Life of Workers. COPCORD STUDY (Stage II)|The Efficacy of Back School on Low Back Pain and Quality of Life of Workers of a Pharmaceutics Company in Tehran Suburb. COPCORD Study (Stage II)||Tehran University of Medical Sciences|Yes|Completed|February 2008|September 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|No|||August 2010|August 13, 2010|January 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00596076||162187|
NCT00605241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN106593|A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward|A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward||GlaxoSmithKline||Completed|February 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|November 21, 2012|January 18, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00605241||161500|
NCT00605254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080062|PET Imaging of P-glycoprotein Function Using [11C]dLop|Brain and Whole Body Imaging of P-Glycoprotein Function Using [11C]dLop||National Institutes of Health Clinical Center (CC)||Completed|January 2008|September 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|58|||Both|18 Years|51 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|January 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00605254||161499|
NCT00637559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|315|Barrett's Esophagus - 315 - 3 Way Cross-Over|A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients||AstraZeneca||Completed|March 2002|April 2003|Actual|April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637559||159075|
NCT00637572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR-002|Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss|A Randomized, Open-labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace)||Par Pharmaceutical, Inc.|No|Completed|December 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|70 Years|No|||March 2008|August 17, 2015|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637572||159074|
NCT00637585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455A_4145|Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine|A Comparison of Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine||Sanofi||Completed|December 2002|July 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|42|||Both|12 Years|55 Years|No|||January 2011|January 10, 2011|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637585||159073|
NCT00638183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.315|Special Survey Long-term Treatment With Tiotropium on COPD|Special Survey Long-term Treatment||Boehringer Ingelheim||Completed|April 2005|||January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|385|||Both|20 Years|N/A|No|Probability Sample|COHORT|June 2014|June 18, 2014|March 11, 2008||||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00638183||159028|
NCT00638456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPI-106-01|Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis|Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial||University of California, San Diego|Yes|Completed|February 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|1 Year|N/A|No|||September 2009|September 9, 2009|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638456||159007|
NCT00606528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0841-T|FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy|FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy||University Health Network, Toronto|No|Completed|February 2008|||July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|54|Samples With DNA|Whole Blood Plasma Liver tissue from biopsy|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chronic HCV treatment-naive patients who are willing to begin antiviral therapy|July 2013|July 24, 2013|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606528||161404|
NCT00638651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071234|Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal|Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal||University of Miami|Yes|Completed|February 2008|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|March 12, 2008|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00638651||158992|
NCT00607113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0954|Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma|Exploratory Study of Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (AVF3961s) (CRAD001C2481)||M.D. Anderson Cancer Center|No|Completed|January 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|January 22, 2008|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00607113||161359|
NCT00607399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGX523-1A-001|Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors|A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, Ona Twice Daily, Interrupted Schedule in Patients With Advanced Cancer||SGX Pharmaceuticals, Inc.|No|Terminated|January 2008|June 2009|Anticipated|January 2009|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||July 2008|July 22, 2008|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607399||161338|
NCT00639405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 5260|Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas|Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism||State University of New York - Upstate Medical University|No|Terminated|September 2005|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects will be recruited from the Health Care Clinic|October 2008|April 26, 2011|March 12, 2008||No|Subject population not available.|No||https://clinicaltrials.gov/show/NCT00639405||158934|
NCT00639418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA156|A Study to Describe Pediatric Influenza Vaccine Coverage|An Observational Study to Describe Pediatric Influenza Vaccine Coverage Among Pediatricians in the United States||MedImmune LLC|No|Completed|August 2007|June 2011|Actual|March 2011|Actual|Phase 4|Observational|Time Perspective: Prospective||4|Actual|147494|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physician offices that were selected to participate in the study|September 2014|September 12, 2014|March 4, 2008||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT00639418||158933|
NCT00607685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R554/42/2007|5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy|Prospective Case-controlled Study Comparing 5-Fluorouracil vs 5-Fluorouracil With Viscoelastic (Hyaluronic Acid) Formulation for the Prevention of Subconjunctival Scarring Post-trabeculectomy||Singapore National Eye Centre|No|Completed|February 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|90 Years|No|||May 2010|May 11, 2010|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00607685||161316|
NCT00607945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0185|Dietary Fatty Acids as Complementary Therapy in Type 2 Diabetes Mellitus|Dietary Fatty Acids as Complementary Therapy in Type 2 Diabetes Mellitus|FACT|Ohio State University|Yes|Completed|January 2008|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|30 Years|70 Years|No|||March 2014|March 19, 2014|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607945||161297|
NCT00640120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSI-WZK-01|Wheeze Detection in Children During Dynamic Bronchial Situations Measured by WIM-PC™ Recording|Wheeze Detection in Children During Dynamic Bronchial Situations Measured by WIM-PC™ Recording||KarmelSonix Ltd.|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|asthmatic subjects or healthy subjects|March 2008|June 8, 2011|March 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00640120||158880|
NCT00640133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01MH076179|Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder|Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder||Butler Hospital|Yes|Active, not recruiting|March 2008|March 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640133||158879|
NCT00636701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4657-P|Improving Rehabilitation by Magnetic Brain Stimulation|Improving Rehabilitation by Magnetic Brain Stimulation: Improving Motor Recovery After Stroke||VA Office of Research and Development|No|Completed|September 2007|May 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|March 7, 2008||No||No|November 20, 2014|https://clinicaltrials.gov/show/NCT00636701||159141|
NCT00637026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0219|Ph II Early BC Pre-Surgical Biologic Study|A PreSurgical Study to Evaluate Molecular Alterations That Occur in Human Breast Cancer Tissue and Normal Skin After Short Term Exposure to ZD1839 (IRESSA) and to Correlate These Alterations With Pharmacokinetic Parameters.||AstraZeneca|No|Completed|July 2003|February 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|65|||Female|18 Years|N/A|No|||April 2009|April 22, 2009|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637026||159116|
NCT00640640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4739-ER-CTIL|The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)|The Effect of Intravitreal Bevacizumab & Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration|AMD|Sheba Medical Center|No|Recruiting|August 2007|February 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|50 Years|N/A|No|||March 2008|March 20, 2008|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00640640||158840|
NCT00636688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2000|Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: a Randomized Controlled Trial|Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: a Randomized Controlled Trial.||Second University of Naples|No|Completed|October 2000|October 2003|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||March 2008|April 17, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00636688||159142|
NCT00637312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01003|Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)|Clinical Trial Comparing the Blackstone Advent™ Cervical Disc to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of One Level Degenerative Disc Disease||Orthofix Inc.|Yes|Terminated|March 2008|February 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|March 10, 2008|Yes|Yes|Greater-than-anticipated rate of revisions|No|February 12, 2014|https://clinicaltrials.gov/show/NCT00637312||159094|The study was suspended for a high rate of adverse events in the treatment group. Enrollment was stopped and patients were followed for 36 months in the Advent group. Approval is not being pursued and thus no analysis has been completed.
NCT00596388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP-PU1|Usage of the Home Macular Perimeter (HMP)|Usage of the Home Macular Perimeter (HMP) in Intermediate Age Related Macular Degeneration Patients Pilot Study|HMP|Notal Vision Ltd|No|Completed|March 2008|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|50 Years|N/A|No|Probability Sample|• Subjects diagnosed as intermediate AMD|May 2013|May 14, 2013|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00596388||162163|
NCT00596401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sihp20076|The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer|The Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer and the Medical Care Cost in Iijima Town||Showa Inan General Hospital|No|Recruiting|September 2007|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3000|Samples Without DNA|serum|Both|19 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|People who live in Iijima town|May 2015|May 19, 2015|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596401||162162|
NCT00605267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D539BC00001|Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment|Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients||AstraZeneca||Completed|October 2007|December 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|197|||Female|20 Years|N/A|No|||August 2012|August 3, 2012|January 9, 2008||No||No|November 26, 2010|https://clinicaltrials.gov/show/NCT00605267||161498|
NCT00605280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751013|A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.|A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.||Pfizer|No|Completed|September 2005|July 2011|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|January 18, 2008|Yes|Yes||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00605280||161497|
NCT00638469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-133 ex 07/08|UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis|Prospective, Randomized Half-side Study on the Efficacy of UVB-311nm Phototherapy in Patients With Psoriasis After Partial Remission to Treatment With Adalimumab||Medical University of Graz|No|Recruiting|March 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638469||159006|
NCT00639223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806827|Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance|Red Yeast Rice vs. Pravastatin: A Double-Blind Randomized Comparative Study of Myopathic Symptoms||University of Pennsylvania|Yes|Completed|January 2008|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|21 Years|80 Years|No|||December 2009|December 9, 2009|March 14, 2008|Yes|Yes||No|December 9, 2009|https://clinicaltrials.gov/show/NCT00639223||158948|Small sample size precluded definitive conclusions.
NCT00639483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COXXNT-6570-001|Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia|A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia||Pfizer|No|Completed|March 2003|January 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|50 Years|No|||March 2009|March 12, 2009|March 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00639483||158928|
NCT00639496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7112LAMC01|Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)|Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)|IFIGENIA|Zambon SpA|Yes|Completed|March 2000|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|75 Years|No|||March 2008|March 4, 2015|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00639496||158927|
NCT00638664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 3149|Evaluation of the MRI in Measuring the Cardiac Chambers and Thoracic Great Vessels|Optimized MRI Evaluation of Maximal Temporal and Spatial Measurability of the Cardiac Chambers and Thoracic Great Vessels. A Comparison of MR Acquisition Pulse Sequences.||State University of New York - Upstate Medical University|No|Completed|May 1995|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cardiology Clinic Center Watch Website|May 2015|May 20, 2015|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00638664||158991|
NCT00638677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pacifierstudy20/8/2003|Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier|Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier||University of Turku|Yes|Completed|June 2004|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|106|||Both|1 Month|4 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638677||158990|
NCT00638950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP_H16-04|A Long-term Moderate Intervention With n-3 LC-PUFA-supplemented Dairy Products in Patients With Rheumatoid Arthritis|Long-term Moderate Intervention With n-3 LC-PUFA-supplemented Dairy Products: Effects on Pathophysiological Biomarkers in Rheumatoid Arthritis||University of Jena|Yes|Completed|September 2004|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|35 Years|74 Years|No|||February 2008|September 21, 2011|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00638950||158969|
NCT00638430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Humphrey30-2|The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test|The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test||Samsung Medical Center|No|Completed|March 2007|March 2008|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|40|||Both|27 Years|61 Years|Accepts Healthy Volunteers|Non-Probability Sample|tertiary care clinic|March 2008|March 12, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638430||159009|
NCT00638443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16697|Lumbar Stenosis Outcomes Research (LUSTOR)|Lumbar Stenosis Outcomes Research (LUSTOR)- A Randomized, Double-blind, Prospective Placebo Controlled Trial of Pregabalin in Patients With Lumbar Spinal Stenosis and Neuropathic Low Back Pain|LUSTOR|University of Rochester|Yes|Completed|March 2008|September 2010|Actual|March 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|37|||Both|50 Years|N/A|No|Probability Sample|Primary care clinic|November 2010|November 9, 2010|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638443||159008|
NCT00639197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007|UGIST: Ultrasound Guided Internal Jugular Short-Term Central Venous Catheters Tunneling|UGIST Pilot Trial: Ultrasound Guided Internal Jugular Short-Term Central Venous Catheters Tunneling. Does it Reduce the Technical Difficulty and Mechanical Complications?|UGIST|McMaster University|No|Recruiting|March 2008|||June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2008|April 10, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00639197||158950|
NCT00638911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.465|Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension|PMS Assessing the Safety and Efficacy of Telmisartan in Patients With Mild-to-moderate Essential Hypertension||Boehringer Ingelheim||Completed|September 2004|||October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33247|||Both|18 Years|N/A|No|Non-Probability Sample|patients|May 2012|May 18, 2012|March 6, 2008||||No||https://clinicaltrials.gov/show/NCT00638911||158972|
NCT00638924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802|Physiologic Variables in Healthy Women in Shuttle Walk Test|Analysis of Physiologic Variables in Healthy Women in Shuttle Walk Test||University of Campinas, Brazil|No|Completed|December 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Female|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|women, between 20 and 30 years old, healthy and sedentary|June 2012|June 13, 2012|March 12, 2008||No||No|May 6, 2012|https://clinicaltrials.gov/show/NCT00638924||158971|Small number of subjects, only females were analyzed making generalization impossible.
NCT00639678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1021-C1063|A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects|A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects||GlaxoSmithKline|Yes|Completed|March 2008|September 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|322|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|February 13, 2014|March 13, 2008|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00639678||158913|
NCT00639665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000P-002347|Cocoa, Polyphenols, and the Kidney in Healthy Subjects and in Subjects With Hypertension and Diabetes Mellitus|Cocoa, Polyphenols, and the Kidney in Healthy Subjects and in Subjects With Hypertension and Diabetes Mellitus||Brigham and Women's Hospital|No|Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|228|Samples With DNA|Whole red blood cells will be retained for DNA analysis. Subjects may "opt-out" of genetic      testing.|Both|18 Years|85 Years|No|Probability Sample|Diabetic (Type I and II)|March 2015|March 30, 2015|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639665||158914|
NCT00639912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAN1374|Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction.|Randomized Trial on the Effects of Hydration With Sodium Chloride Versus Sodium Bicarbonate to Prevent Contrast Induced Nephropathy, in Patients Undergoing Primary Coronary Interventions for Acute ST Elevation Myocardial Infarction.|CINIMA|Arcispedale Santa Maria Nuova-IRCCS|No|Completed|June 2007|October 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|599|||Both|18 Years|N/A|No|||March 2008|November 29, 2010|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639912||158896|
NCT00640380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-07-052|A Comparison Between Neurostimulation and Loss of Resistance for Cervical Paravertebral Blocks|A Comparison Between Neurostimulation and Loss of Resistance for Cervical Paravertebral Blocks||McGill University Health Center|No|Not yet recruiting|May 2008|October 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|90|||Both|18 Years|70 Years|No|||April 2008|April 7, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640380||158860|
NCT00640653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH062049|Effectiveness of an Abstinence-Only HIV/Sexually Transmitted Disease Risk-Reduction Intervention for Young African-American Adolescents|HIV/STD Prevention Interventions for Black Adolescents||National Institute of Mental Health (NIMH)|No|Completed|September 2001|August 2004|Actual|August 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|662|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2008|April 7, 2008|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00640653||158839|
NCT00637039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00002|Study of AZD8931 in Patients With Advanced Solid Malignancies|A Phase 1, Open-label, Multiple-dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|February 2008|December 2012|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||March 2013|March 11, 2013|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637039||159115|
NCT00637013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B07103|Operative Versus Non-operative Management of Subacromial Impingement|The Effectiveness and Cost-effectiveness of Operative Versus Non-operative Management of Subacromial Impingement||Central Finland Hospital District|Yes|Active, not recruiting|June 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|35 Years|N/A|No|||January 2016|January 27, 2016|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00637013||159117|
NCT00637325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP|Trastuzumab Optimization Trial in Breast Cancer|TOP Trial. A Randomised Phase III Clinical Trial of Trastuzumab (Herceptin) Optimization in Patients With Locally Advanced and/or Metastatic Breast Cancer Overexpressing HER2 After a First Line Chemotherapy Plus Trastuzumab.|TOP|Regione Lombardia||Recruiting|November 2007|April 2011|Anticipated|May 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|70 Years|No|||March 2008|March 10, 2008|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00637325||159093|
NCT00637624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-510-100108-Bahce|N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy|A Randomized Double-blind Study of N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy in Patients Treated for (Non)Small Cell Lung Cancer and Malignant Mesothelioma|NAC-PNP|Rijnstate Hospital||Recruiting|March 2008|February 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00637624||159070|
NCT00596973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS07007|Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients|Phase IV Study of Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients||Medtronic - MITG|Yes|Withdrawn|January 2008|March 2009|Actual|January 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|35 Years|65 Years|No|||November 2014|November 14, 2014|November 28, 2007||No|Business Reasons|No||https://clinicaltrials.gov/show/NCT00596973||162119|
NCT00637286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1223C00002|ZAP, US. Zomig for Appropriate for Primary Care|A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated.||AstraZeneca|No|Completed|July 2004|May 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|65 Years|No|||April 2009|April 3, 2009|February 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637286||159096|
NCT00637299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2008|Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial|Osteopathic Treatment May Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease||Fondazione Salvatore Maugeri|No|Completed|January 2008|November 2008|Actual|July 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|45 Years|70 Years|No|||October 2011|October 16, 2011|March 10, 2008||No||No|January 5, 2009|https://clinicaltrials.gov/show/NCT00637299||159095|
NCT00638690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016924|Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy||Cougar Biotechnology, Inc.|Yes|Completed|May 2008|October 2012|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1195|||Male|18 Years|N/A|No|||April 2014|April 10, 2014|March 13, 2008|Yes|Yes||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00638690||158989|
NCT00638703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC3-DB-01|Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria|PHOENIX|OxThera|No|Completed|October 2007|October 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|5 Years|N/A|No|||June 2011|May 7, 2013|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638703||158988|
NCT00640198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-10830|Memantine and Intensive Speech-Language Therapy in Aphasia|A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.||Gabinete Berthier y Martínez|No|Completed|March 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|69 Years|No|||March 2008|March 20, 2008|March 17, 2008||||No||https://clinicaltrials.gov/show/NCT00640198||158874|
NCT00639470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBPHS#5229|Parents Reading Comprehension of Their Child's Post-Operative Medicine Fact Sheets|Parents Reading Comprehension of Their Child's Post-Operative Medicine Fact||State University of New York - Upstate Medical University|No|Completed|August 2005|August 2008|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|N/A|No|||August 2008|August 12, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639470||158929|
NCT00639717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umcc 2008.003|Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant|Addition of Etanercept and Extracorporeal Photopheresis to Standard GVHD Prophylaxis in Patients Undergoing Reduced Intensity Unrelated Donor Hematopoietic Stem Cell Transplant||University of Michigan Cancer Center|Yes|Active, not recruiting|March 2009|September 2015|Anticipated|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|48|||Both|N/A|N/A|No|||September 2014|September 19, 2014|March 11, 2008|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00639717||158910|
NCT00638937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01053|AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy|A Phase 2 Study of AZD0530 in Patients With Advanced, Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Combination Chemotherapy||National Cancer Institute (NCI)|Yes|Completed|February 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||October 2013|June 22, 2015|March 18, 2008|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00638937||158970|
NCT00639444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPM-CE 204332|Risk of Celiac Disease and Age at Gluten Introduction|Infant Nutrition and Development of Celiac Disease in Genetically At-risk Babies: a Dietary Intervention Study at Weaning|CELIPREV|Università Politecnica delle Marche|No|Completed|September 2004|November 2013|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|703|||Both|N/A|6 Months|No|||December 2013|December 9, 2013|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639444||158931|
NCT00639457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 049393 (completed)|Exercise and Pioglitazone for HIV-Metabolic Syndromes|Exercise and Pioglitazone for HIV-Metabolic Syndromes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|January 2005|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||September 2013|September 16, 2013|March 18, 2008||No||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00639457||158930|No intervention and exercise training only control groups were not included. Intracellular mechanisms were not explored. Relatively small number of participants taking a variety of anti-HIV medication regimens.
NCT00639431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI P07-71044|Study to Assess the Efficacy of Direct Observation and Mental Visualization of Foot Movements to Treat Bilateral Lower Limb Phantom Limb Pain|Study to Assess the Efficacy of Direct Observation and Mental Visualization of Foot Movements to Treat Bilateral Lower Limb Phantom Limb Pain||Walter Reed Army Medical Center|No|Recruiting|December 2007|August 2014|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00639431||158932|
NCT00640159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20709|Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease|Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.||Baylor College of Medicine|No|Completed|January 2007|August 2008|Actual|June 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|30 Years|90 Years|No|||March 2009|March 12, 2009|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640159||158877|
NCT00639925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPCR1R2-1|Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer|Phase I Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer||Fukushima Medical University|Yes|Active, not recruiting|March 2007|March 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|80 Years|No|||March 2013|March 13, 2013|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00639925||158895|
NCT00640146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX2101|Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Phase 2 Study of Once-Daily Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures||Valeant Pharmaceuticals International, Inc.|No|Completed|October 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2011|July 17, 2011|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640146||158878|
NCT00636714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 07-282c|Comparison of 2 Methods to Achieve Tight Glucose Control in Cardiovascular ICU Patients|Randomized Controlled Trial of Nurse-directed vs Nomogram-directed Intensive Glucose Control in the CVICU||St. Michael's Hospital, Toronto|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636714||159140|
NCT00636727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000450|A Comparison of Arthrocentesis, Arthroscopy and Arthroplasty in the Treatment of Temporomandibular Joint Dysfunction|A Comparison of Arthrocentesis, Arthroscopy and Arthroplasty in the Treatment of Temporomandibular Joint Dysfunction|TMJ|Emory University|No|Completed|January 2007|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|89 Years|No|||November 2013|November 19, 2013|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00636727||159139|
NCT00637637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOSI-RO0402|External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases|Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study||National Cancer Institute (NCI)||Recruiting|September 2007|||June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|N/A|No|||December 2008|August 9, 2013|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00637637||159069|
NCT00637338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0571002|Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Placebo-Controlled, Sequential Parallel Group, Multiple Dose Escalation Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of 4, Once-Weekly Subcutaneous Doses Of PF-04603629 To Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Terminated|April 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|70 Years|No|||November 2008|July 30, 2009|March 10, 2008|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00637338||159092|
NCT00596414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHTJ-1|Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial|Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial||Erasme University Hospital|Yes|Completed|May 2003|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|80 Years|No|||December 2007|January 16, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596414||162161|
NCT00596427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-11A|Mechanisms of Glucose Lowering Effect of Colesevelam HCl|Effects of Colesevelam HCl on Hepatic Insulin Sensitivity, Gluconeogenesis, Glucose Absorption and Lipid Synthesis in Subjects With Type 2 Diabetes Mellitus||KineMed|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|30 Years|70 Years|No|||October 2012|October 10, 2012|January 8, 2008|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00596427||162160|
NCT00596453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010549|Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability|Impact of Antibiotic Treatment on PSA Variability||Johns Hopkins University|No|Terminated|January 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|31|||Male|40 Years|75 Years|No|||March 2014|March 10, 2014|January 8, 2008|Yes|Yes|Unable to recruit enough patients|No||https://clinicaltrials.gov/show/NCT00596453||162158|
NCT00637897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583652|Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer|Feasibility of Dose Titrating Paricalcitol (Zemplar) in Women Receiving Taxanes or Ixabepilone for Metastatic Breast Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|March 2008|March 2013|Actual|November 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|120 Years|No|||October 2015|October 22, 2015|March 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637897||159049|
NCT00638209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEG-KFO-2|Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2|Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Typ 2||University Hospital Tuebingen|No|Recruiting|February 2008|||May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2008|March 18, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638209||159026|
NCT00639743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030444|PEITHO Pulmonary Embolism Thrombolysis Study|Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients|PEITHO|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|November 2007|June 2015|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1005|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|March 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00639743||158908|
NCT00638560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-MR-2008-290208|Changes of Biomarkers in Response to Training and Antioxidant Treatment|Effects of Training and Antioxidant Treatment on Circulating Markers of Oxidative Stress and Skeletal Muscle mRNA Expression||University of Leipzig|No|Completed|March 2008|December 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Male|25 Years|35 Years|Accepts Healthy Volunteers|||February 2009|January 19, 2010|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638560||158999|
NCT00639730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00003359|Use of the Atkins Diet for Children With Sturge Weber Syndrome|Use of the Atkins Diet for Children With Sturge Weber Syndrome||Johns Hopkins University|Yes|Completed|May 2006|May 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|2 Years|18 Years|No|||May 2010|May 26, 2010|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639730||158909|
NCT00640458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481174|Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-Menopausal Women With Female Sexual Arousal Disorder|A Double Blind, Placebo Controlled 2-Way Cross-Over Study to Assess the Clitoral Engorgement Response as Measured by Non-Contrast Magnetic Resonance Imaging (MRI) in Women With Female Sexual Arousal Disorder (FSAD) When Administered a Single Dose of Sildenafil (100mg) Followed by Audio/Visual Sexual Stimulation||Pfizer|No|Completed|April 2004|March 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|45 Years|No|||April 2008|April 4, 2008|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640458||158854|
NCT00639951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-07/01|Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation|Multicentric, Randomized,Controlled and Comparative Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation||Instituto Bioclon S.A. de C.V.|No|Terminated|January 2008|March 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|6 Years|65 Years|No|||November 2015|November 19, 2015|March 13, 2008||No|Administrative reasons|No||https://clinicaltrials.gov/show/NCT00639951||158893|
NCT00639210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol number FBCSG-01-2004|BREAST CANCER AND EXERCISE|BREAST CANCER AND EXERCISE BREX: A Multicenter Phase III Open Randomised Trial of the Efficacy of Exercise in the Prevention of Long-Term Adverse Effects of Adjuvant Treatments and Breast Cancer Recurrences in Women With Primary Breast Cancer.|BREX|Finnish Breast Cancer Group|Yes|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|573|||Female|35 Years|68 Years|No|||March 2008|March 19, 2008|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639210||158949|
NCT00639691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025ACA01|A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy|A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy||Novartis||Completed|January 2005|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|6 Years|N/A|No|||May 2012|May 23, 2012|March 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00639691||158912|
NCT00639704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 3257|Improve Nuclear Medicine Heart Imaging, Compare MRI Results With Single Photon Emission Computed Tomography Imaging|Evaluation of EM-IntraSPECT Reconstruction Algorithm by Comparison of Transmission Images Reconstructed From SPECT Projections Alone With MRI Studies||State University of New York - Upstate Medical University|No|Completed|January 1996|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are being evaluated for cardiac function/perfusion|May 2015|May 13, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639704||158911|
NCT00636428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-24|Clinical Trial of Oral Midazolam in Pediatric Endoscopy|Clinical Trial of Oral Midazolam in Pediatric Endoscopy||Tabriz University|Yes|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|3 Years|17 Years|No|||April 2008|April 8, 2008|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636428||159161|
NCT00636441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001345|Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer|A Randomized Phase II Trial Evaluating the Performance of Genomic Expression Profiles to Direct the Use of Preoperative Chemotherapy for Early Stage Breast Cancer||Duke University|No|Terminated|April 2008|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|N/A|No|||October 2014|November 16, 2015|March 9, 2008|Yes|Yes|Study terminated due to reproducibility issues with genomics prediction model|No|May 7, 2014|https://clinicaltrials.gov/show/NCT00636441||159160|
NCT00640393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6007|Safety and Efficacy of Combining nbUVB to Etanercept in Patients|A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris||Innovaderm Research Inc.|No|Completed|April 2008|March 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|March 18, 2008||No||No|August 27, 2010|https://clinicaltrials.gov/show/NCT00640393||158859|
NCT00640406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0701|Comparison of Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting|A Randomized, Multi-centre, Prospective Study Comparing Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting in Patients With Hemodynamically Relevant Atherosclerotic Renal Artery Stenosis|RADAR|Biotronik AG|Yes|Completed|April 2008|March 2015|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640406||158858|
NCT00636415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intra-articular morphine|Intra-Articular Morphine Versus Bupivacaine on Knee Motion in Patients With Osteoarthritis|Intra-Articular Morphine Versus Bupivacaine on Knee Motion in Patients With Osteoarthritis: Randomized and Double-Blind Clinical Trial||Federal University of São Paulo|Yes|Completed|June 2004|December 2006|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|50 Years|90 Years|No|||March 2008|March 11, 2008|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636415||159162|
NCT00637351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111074|A Study in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic Assays|A Study to Collect Blood and Urine Samples in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic Assays||GlaxoSmithKline||Completed|March 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|21|Samples With DNA|whole blood, urine samples|Both|65 Years|N/A|No|Probability Sample|Elderly subjects with diagnosed pneumonia|January 2014|January 9, 2014|March 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637351||159091|
NCT00637975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUROPAIN01|Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain|Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain||Associazione Progetto Oncologia UMAN.A|Yes|Completed|September 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2011|February 1, 2011|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00637975||159043|
NCT00637936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 02 306766-B|Respiratory Effects of Perioperative Oxygen During General Anaesthesia|Perioperative Oxygen Fraction - Effects on the PaO2/FiO2-Index During Laparotomy||University of Copenhagen|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00637936||159046|
NCT00637949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOX189A2307|Safety of Lumiracoxib in Patients With Osteoarthritis|A 6-Week Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Clinical Saftey Study to Evaluate Incidence of Predefined Gastrointestinal Adverse Events and Peripheral Edema in Subjects With Primary Osteoarthritis Treated With COX189 400 mg o-do Using Rofecoxib 25 mg o.d. as a Comparator||Novartis||Completed|December 2000|March 2001|Actual|March 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|309|||Both|50 Years|90 Years|No|||March 2008|March 17, 2008|March 11, 2008||||||https://clinicaltrials.gov/show/NCT00637949||159045|
NCT00596440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805712|Assessment of a Teachable Moment for Smoking Cessation|Assessment of a Teachable Moment for Smoking Cessation|TM|University of Pennsylvania|No|Completed|August 2007|February 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|234|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|One group will be relatives/spouses of newly-diagnosed lung or head and neck cancer        patients and the second group will be relatives/spouses of orthopedic patients. All        participants will be regular smokers (i.e., smoke 10 cigarettes/day on average).|August 2015|August 20, 2015|January 8, 2008|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00596440||162159|
NCT00597038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15256|A Phase I/II Study of Dasatinib and Dacarbazine|A Phase I/II Study of Dasatinib and Dacarbazine in Patients With Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|November 2007|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||May 2012|November 21, 2013|January 8, 2008|Yes|Yes||No|May 22, 2012|https://clinicaltrials.gov/show/NCT00597038||162114|
NCT00597051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-0403-001|Study of 3 Doses of ARD-0403 in Testosterone Deficient Men|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Centre Study of the Pharmacokinetics and Tolerability of 3 Different Doses of ARD-0403 in Testosterone Deficient Men|ARD-0403-001|Ardana Bioscience Ltd|No|Completed|October 2005|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|42|||Male|18 Years|65 Years|No|||January 2008|January 16, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597051||162113|
NCT00638482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P011114|Dose-Dependent Effect of Thiazide in Dent's Disease Hypercalciuria|Pharmacodynamic Evaluation of the ANTICALCIURIC Effect of Hydrochlorothiazide in Dent's Disease|DESY|Assistance Publique - Hôpitaux de Paris|No|Terminated|July 2003|December 2005|Actual|December 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|3 Years|18 Years|No|||July 2003|March 17, 2008|March 12, 2008||No|terminated|No||https://clinicaltrials.gov/show/NCT00638482||159005|
NCT00639002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-255|A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma|A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma||Incyte Corporation|No|Completed|March 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|March 12, 2008|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00639002||158965|
NCT00637442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Bonn|Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)|Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)|CASL-AD-01|University Hospital, Bonn|No|Active, not recruiting|February 2008|||December 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|50 Years|80 Years|No|||July 2010|November 8, 2010|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00637442||159084|
NCT00637455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455A/4139|Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel|Single Center, Randomized,Double-Blind,Crossover Study Comparing the Effects of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel||Sanofi||Completed|September 2003|January 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 10, 2011|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637455||159083|
NCT00637468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S 020301|EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye|Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie|EAGLE|University Hospital Freiburg|Yes|Terminated|September 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|75 Years|No|||March 2008|March 17, 2008|March 11, 2008|||Due to results of conditional power analysis performed at the first interim analysis and due    to observed spectrum of adverse events.|No||https://clinicaltrials.gov/show/NCT00637468||159082|
NCT00640536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-1974/1|Right Ventricular Function in Obstructive Sleep Apnea|The Evaluation of Subclinical Right Ventricular Dysfunction in Obstructive Sleep Apnea Patients Without Systemic and Pulmonary Arterial Hypertension Using Velocity Vector Imaging||Florence Nightingale Hospital, Istanbul|Yes|Completed|June 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|53|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Tertiary care clinic, obstructive sleep apnea patients|November 2008|November 28, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640536||158848|
NCT00640471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO20|Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer|A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbitux®) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma||Canadian Cancer Trials Group|Yes|Completed|May 2008|January 2013|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|750|||Both|18 Years|N/A|No|||November 2012|July 16, 2013|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00640471||158853|
NCT00636467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS2PLUS|Axillary Sentinel Lymph Node Detection in Breast Cancers > 2 cm|Evaluation of the Technique of Axillary Sentinel Lymph Node (SLN) Detection in Breast Cancers > 2 cm|GAS2PLUS|Centre Leon Berard|No|Completed|March 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|249|||Female|18 Years|N/A|No|||September 2012|September 25, 2012|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00636467||159158|
NCT00636480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070921-103|Preoperative Skin Preparation Evaluation|Preoperative Skin Preparation Evaluation of One Test Product With a Positive and a Negative Control||CareFusion|No|Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|60|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636480||159157|
NCT00640185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-346|Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety, Tolerability and Efficacy of 40 mg QD and 80 mg QD ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)||AbbVie|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|160|||Both|18 Years|60 Years|No|||January 2013|January 10, 2013|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640185||158875|
NCT00636792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05011|A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma|A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma|VERTICAL|Millennium Pharmaceuticals, Inc.||Completed|February 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||January 2012|January 11, 2012|March 11, 2008|Yes|Yes||No|May 31, 2011|https://clinicaltrials.gov/show/NCT00636792||159134|
NCT00639938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI034235|Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda|A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV Transmission in Uganda||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2004|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|722|||Female|18 Years|N/A|No|||March 2008|April 1, 2008|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00639938||158894|
NCT00640172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-05112|Anemia in the Elderly|Anemia in the Elderly||Stanford University|No|Completed|August 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|343|Samples With DNA|blood, urine and bone marrow|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient elderly men and women (aged 65 years or older) with anemia, and corresponding        elderly controls and adult non-elderly controls.|March 2016|March 23, 2016|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00640172||158876|
NCT00640419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-345|Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of 0.7 mg/kg/Day and 1.4 mg/kg/Day of ABT-089 in the Treatment of Children With Attention Deficit-Hyperactivity Disorder (ADHD)||AbbVie|Yes|Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|121|||Both|6 Years|12 Years|No|||January 2013|January 10, 2013|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640419||158857|
NCT00636779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006850|BraveNet Integrative Medicine Descriptive Study|BraveNet Multi-Center Integrative Medicine Survey|BraveNet|Duke University|No|Completed|March 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|4340|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|500 patients from each of the nine participating Integrative Medicine Centers who are        seeing any type of clinicial on the day of their visit.|June 2011|June 12, 2011|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00636779||159135|
NCT00636740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MER-101-03|Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients|A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets To Intravenous Zometa 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients||Merrion Pharmaceuticals, LLC|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|18 Years|N/A|No|||February 2009|February 19, 2009|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636740||159138|
NCT00636753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-2007-0070|Antipsychotics and Metabolic Syndrome|||Glostrup University Hospital, Copenhagen|Yes|Suspended|September 2008|||July 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|None Retained|whole blood, serum/plasma|Male|18 Years|45 Years|No|Probability Sample|patients with debut of schizophrenia, controls from database|July 2010|July 29, 2010|March 7, 2008||No|this study has not finding place|No||https://clinicaltrials.gov/show/NCT00636753||159137|
NCT00637052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-520-211|A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia|||Array BioPharma||Completed|February 2008|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|17 Years|N/A|No|||September 2012|September 19, 2012|February 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637052||159114|
NCT00637663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0740-67-5|Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA|Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA||Pusan National University Hospital|Yes|Completed|February 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|70 Years|No|||March 2015|March 4, 2015|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00637663||159067|
NCT00637962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000781-20|Reactogenicity and Immunogenicity of Vaginal CNgp140|Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Nine Vaginal Immunisations With HIV CN54gp140 Glycoprotein|SG06RS02|St George's, University of London|No|Terminated|September 2007|January 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|23|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|March 11, 2008||No|IMP expired prior to completion of recruitment|No||https://clinicaltrials.gov/show/NCT00637962||159044|
NCT00638248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN01-CLD-000002/01|Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)|International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase I/II Trial of Desmoteplase in the Indication of Acute Ischemic Stroke|DEDAS|PAION Deutschland GmbH|Yes|Completed|March 2003|October 2004|Actual|October 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|85 Years|No|||March 2008|March 12, 2008|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638248||159023|
NCT00596193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20010247H|Neuropeptide Y (NPY) Regulation of Nociceptors|NPY Regulation of Nociceptors in Clinical Inflammation||The University of Texas Health Science Center at San Antonio|No|Completed|May 2001|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|11|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Dental Patients|March 2012|March 7, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00596193||162178|
NCT00596206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEFLU_R_01143|Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis|Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients|LEADER|Sanofi||Completed|December 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||October 2010|October 11, 2010|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00596206||162177|
NCT00588016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009651|Concentration of Itraconazole Solution in Nasal Secretions|Concentration of Itraconazole Solution in Nasal Secretions||Mayo Clinic|Yes|Completed|April 2007|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2015|April 12, 2015|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588016||162789|
NCT00639509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00283|IMC-A12 in Treating Patients With Advanced Liver Cancer|A Phase 2 Study of IMC-A12 (NSC742460) in Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|March 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2012|May 7, 2014|March 19, 2008|Yes|Yes||No|September 25, 2013|https://clinicaltrials.gov/show/NCT00639509||158926|
NCT00638313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0571001|Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Subcutaneous Doses Of PF-04603629 In Type 2 Diabetic Adult Subjects||Pfizer|No|Completed|August 2007|February 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|70 Years|No|||March 2008|July 30, 2009|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638313||159018|
NCT00638326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pecs-001|Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity|150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention|DOSER|University of Pecs|Yes|Terminated|March 2008|March 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|500|||Both|35 Years|75 Years|No|||March 2010|March 20, 2010|March 11, 2008||No|Greater differences between randomized patients than previously anticipated|No||https://clinicaltrials.gov/show/NCT00638326||159017|
NCT00639561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 06 12|Calibrated Diets and Human Intestinal Microflora|Effect of Controlled Diets on Structural and Functional Dynamic of the Human Intestinal Microflora|AlimIntest|University Hospital, Grenoble|No|Completed|February 2008|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2009|February 16, 2009|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639561||158922|
NCT00640042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K284-07-4001|Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza|AVINZA Control of Chronic Pain, Effectiveness and Safety Study (ACCESS 2008) A Multi-Center Study to Evaluate the Effectiveness and Tolerability of AVINZA for Chronic Moderate-Severe Pain: A Focus on Risk Minimization Assessment, Intervention and Outcomes|ACCESS 2008|Pfizer|No|Completed|March 2008|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1570|||Both|21 Years|N/A|No|||June 2012|June 6, 2012|March 13, 2008|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00640042||158886|
NCT00636805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002273|Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab|A Phase II Single Arm Trial of Palonosetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan in Combination With Bevacizumab||Duke University|No|Terminated|May 2008|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|63|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|February 27, 2008|Yes|Yes|Study was halted early after 63 subjects were enrolled due to slow accrual.|No|January 9, 2014|https://clinicaltrials.gov/show/NCT00636805||159133|
NCT00640432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191064|Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain|A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of The Safety, Tolerability And Efficacy Of Celecoxib 200 Mg Twice A Day (With A 400 Mg Attack Dose) Versus Sodium Diclofenac 75 Mg Twice A Day In Subjects With Acute Low Back Pain||Pfizer|No|Completed|October 2003|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|65 Years|No|||March 2008|April 2, 2008|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640432||158856|
NCT00640445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074432|Military to Civilian: Trial of an Intervention to Promote Postdeployment Reintegration|Military to Civilian: RCT of an Intervention to Promote Postdeployment Reintegration|M2C|Minneapolis Veterans Affairs Medical Center|No|Completed|June 2011|September 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|1292|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00640445||158855|
NCT00636454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR054626|Effectiveness of a Training Program in Improving Coping Skills in People With Arthritis Pain|Coping Skills Training for Arthritis: An Effectiveness Trial||Stony Brook University|No|Completed|May 2008|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|257|||Both|21 Years|N/A|No|||September 2013|September 25, 2013|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00636454||159159|
NCT00636766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|887/2005|Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque|Atherosclerotic Plaque Texture-Experimental and Clinical Study on the Diagnostic and Therapeutic Strategies of Atherosclerotic Plaque Vulnerability||Aristotle University Of Thessaloniki||Completed|September 2005|January 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Actual|300|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636766||159136|
NCT00637676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2802|Tunneled Pleural Catheter in Partially Entrapped Lung|Randomized Trial of Tunneled Pleural Catheter Versus Standard Chest Tube in Management of Malignant Pleural Effusion in Patients With Partial Entrapment of the Lung||Heidelberg University|Yes|Completed|July 2008|September 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2008|September 22, 2011|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00637676||159066|
NCT00637065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007OE002B|Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study|Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study.|B-PHIT|Royal Brompton & Harefield NHS Foundation Trust|Yes|Not yet recruiting|April 2008|August 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|80 Years|No|||March 2008|March 10, 2008|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00637065||159113|
NCT00637364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEP-BY02-01|High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain|An Open Label, Non-Randomized, Single-Center, Therapeutic Trial Examining the Feasibility, Safety, and Efficacy of FEP-BY02, a High Intensity Focused Ultrasound Tumor Treatment Device, in Patients With Pancreatic Cancer Pain|HIFU Pancreas|CMED HIFU Development Corporation|Yes|Suspended|March 2008|||July 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||January 2009|January 12, 2009|March 12, 2008|No|Yes|Sponsor is not proceeding with USA human trial at this time|No||https://clinicaltrials.gov/show/NCT00637364||159090|
NCT00637650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4638|Management of Fragments During Ureteroscopy|Should we Strive for Absolute "Stone Freedom" While Performing Holmium Laser Lithotripsy for Ureteral Stones? A Randomized Controlled Trial.||The Chaim Sheba Medical Center||Completed|June 2007|May 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|16 Years|N/A|No|||February 2009|February 9, 2009|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00637650||159068|
NCT00637429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALF-263/06|HIV-HBV Co-Infection and Liver Disease|Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) co-Infection and Liver Disease||Bayside Health|No|Recruiting|November 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|serum samples|Both|18 Years|N/A|No|Non-Probability Sample|HIV-HBV co-infected individuals from the Alfred Hospital, the Royal Melbourne Hospital and        high case load GP clinics who are referred to the Alfred Hospital|March 2008|April 1, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00637429||159085|
NCT00638508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/07/VA3|ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management|The Analgesic Efficacy of Continuous Infusion of Ketorolac and Ropivacaine at the Wound Site Using ON-Q Pump for Postoperative Pain Management||Maimonides Medical Center|Yes|Recruiting|June 2007|July 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|20 Years|80 Years|No|||March 2008|March 18, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638508||159003|
NCT00638755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C213|The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Effect of Nasal Carbon Dioxide on Nasal Congestion Via Acoustic Rhinometry in Subjects With Perennial Allergic Rhinitis||Capnia, Inc.|No|Completed|February 2008|July 2008||May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|20|||Both|19 Years|65 Years|No|||August 2010|August 17, 2010|March 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638755||158984|
NCT00596739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805770|A Study of the Pre- and Post-operative Semen Analyses and Reproductive Hormone Levels of Men Undergoing Weight-reduction Surgery|Weight Loss Surgery and Male Fertility||University of Pennsylvania|No|Active, not recruiting|November 2007|November 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood and Sperm|Male|18 Years|65 Years|No|Non-Probability Sample|Adult male subjects between the ages of 18-65 undergoing bariatric surgery|August 2011|August 8, 2011|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596739||162136|
NCT00588458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002976 0|The Value of CT Cholangiography in Primary Sclerosing Cholangitis|Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis||Mayo Clinic|Yes|Withdrawn|March 2007|February 2009|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|70 Years|No|||April 2015|April 27, 2015|December 26, 2007||No|There is no participant enrolled in this study since developing this trial and other    cholangiographic techniques are more available in our institute.|No||https://clinicaltrials.gov/show/NCT00588458||162756|
NCT00639522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-GC-01-2008|Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma|A Phase I Clinical Trial to Investigate the Maximum Tolerated Dose and Pharmacokinetics of Liposomal Paclitaxel With/Without Capecitabine in Chinese Cancer Patients With Advanced Gastric Carcinoma.||Nanjing Sike Pharmaceutical Co., Ltd.|No|Recruiting|May 2008|December 2009|Anticipated|September 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|65 Years|No|||April 2009|April 14, 2009|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639522||158925|
NCT00639080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Necessity for LLT|Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients|Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients||Endocrine Research Society|No|Completed|March 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|The study population are type 2 diabetes patients who attend St.Paul's Diabetes Teaching        and Training Centre (DTTC) and Dr. Hugh Tildesley's private office in Vancouver, BC        Canada.|August 2009|July 21, 2011|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639080||158959|
NCT00639756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IbSalut-M-001|The Effect of Allopurinol on Insulin Resistance and Blood Pressure|Phase 2 Study to Determine if Allopurinol Blocks Features of Metabolic Syndrome Induced by Fructose Ingestion||Hospital Mateo Orfila|No|Completed|June 2008|October 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 10, 2008|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00639756||158907|
NCT00639769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0164|Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck||Vanderbilt-Ingram Cancer Center|Yes|Completed|February 2002|July 2008|Actual|May 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|March 19, 2008|Yes|Yes||No|October 11, 2010|https://clinicaltrials.gov/show/NCT00639769||158906|
NCT00639795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13101.2 MMC 06-28|Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery|Prospective Randomized Trial Evaluating the Effects of Paravertebral Nerve Blocks on Postoperative Pain and the Perioperative Inflammatory Response Following Video Assisted Thorascopic Surgery|VATS_IM|Memorial Medical Center|Yes|Terminated|March 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|March 14, 2008||No|inadequate sample population|No||https://clinicaltrials.gov/show/NCT00639795||158904|
NCT00639808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-101-CL-002|Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis|Multicenter, Randomized, Double-Blind, Placebo Controlled, Crossover Single Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Effect on Gastric Emptying of TZP-101 IV Infusion in Diabetic Gastroparesis Patients||Tranzyme, Inc.|No|Completed|August 2006|March 2008|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||March 2008|March 19, 2008|March 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00639808||158903|
NCT00640211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPET B|A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B|A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B|PIPET B|Kirby Institute|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants in this study will be health care and other essential workers receiving long        term neuraminidase inhibitor prophylaxis.|April 2012|April 22, 2012|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640211||158873|
NCT00640484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0706-PR-0026|Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD|Evaluation of the Effect of 2 Weeks Treatment With CHF 4226 pMDI 2µg and 4µg, Given Once Daily in the Morning, on 24-Hour FEV1 in Patients With COPD||Chiesi Farmaceutici S.p.A.|No|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|57|||Both|40 Years|75 Years|No|||August 2010|August 24, 2010|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640484||158852|
NCT00637078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPO702|STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia)|Evaluation of a Primary Treatment Algorithm Using Combination Therapy for the Management of Patients With Hypertension and Hypercholesterolemia|STITCH2|University of Western Ontario, Canada|No|Completed|February 2008|December 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00637078||159112|
NCT00637377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91689|Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)|A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)|VIEW 2|Bayer|Yes|Completed|April 2008|August 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1240|||Both|50 Years|N/A|No|||November 2014|November 28, 2014|March 12, 2008|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00637377||159089|The conditional sequence of hypothesis testing had to stop after testing the first superiority hypothesis. Therefore, all further statistical tests are exploratory tests.
NCT00637390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.120|A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.|A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.||University of Michigan Cancer Center|Yes|Terminated|March 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|N/A|No|||June 2012|June 18, 2012|March 10, 2008|Yes|Yes|Genzyme will no longer supply the study drug for this trial as it does not believe the study    will not fully enroll within an appropriate time frame.|No||https://clinicaltrials.gov/show/NCT00637390||159088|
NCT00637403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100.2.C.002|Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension|An Open-Label, Single-Dose Study to Assess the Effect of Renal Impairment on the Pharmacokinetic Characteristics, Safety, and Tolerability of Megestrol Acetate||Par Pharmaceutical, Inc.|No|Terminated|May 2006|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|7|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2008|March 17, 2008|March 11, 2008|No|Yes|Difficulty finding the required subject population|No||https://clinicaltrials.gov/show/NCT00637403||159087|
NCT00639262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07P.381|Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors|Phase I Study of the Combination of Sorafenib and Radiation Therapy -/+ Temozolomide for the Treatment of Patients With Brain Metastases and Primary Brain Tumors||Thomas Jefferson University|Yes|Completed|March 2008|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00639262||158945|
NCT00637988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316|Barrett's Esophagus - 315 - 3 Way Cross Over|A Multicenter, Open-label, Four-way Crossover Study of the Effects of Esomeprazole, Aspirin and Rofecoxib on Prostaglandin (PGE2) Production, Cyclooxygenase-2 Enzyme Activity and PCNA Expression in Patients With Barrett's Esophagus||AstraZeneca||Completed|April 2002|June 2003|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637988||159042|
NCT00638001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|READ-LOBET-01|Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|March 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Male|13 Years|80 Years|No|||July 2014|July 10, 2014|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00638001||159041|
NCT00638261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-134 ex 07/08|Primary UVB-311nm and Adalimumab in Psoriasis Patients|Adalimumab in Primary Combination With UVB-311nm Half-side Phototherapy in Patients With Psoriasis||Medical University of Graz|No|Completed|March 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638261||159022|
NCT00638027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8049|Memantine for Spasticity in MS Patients|Memantine for Spasticity in MS Patients||University of Rochester|No|Completed|July 2006|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|70 Years|No|||November 2015|November 6, 2015|March 10, 2008|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00638027||159039|Small exploratory study that may have been hindered due to lack of adequate power.
NCT00638287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10638|Inter-Assay Growth Hormone and IGF-I Variability|Inter-Assay Growth Hormone and IGF-I Variability||Cedars-Sinai Medical Center|No|Withdrawn|November 2007|January 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|171|Samples With DNA|1. Group I Growth Hormone Deficiency (GHD): subjects with pituitary disease undergoing           testing for GH deficiency: GHRH-ARG Test, collect total of 84 cc whole blood.        2. Group II Acromegaly: subjects with suspicion for (or diagnosis of) acromegaly           undergoing OGTT Test, collect total of 48 cc whole blood.        3. Group III Normal Controls: subjects without evidence of pituitary dysfunction           undergoing OGTT Test, collect total of 136 cc whole blood.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|tertiary referral center|September 2008|October 3, 2008|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00638287||159020|
NCT00638300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor421306ctil|Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD)|Removal of Ligand-bound Iron During Intravenous Iron Administration in Hemodialysis by Large Pore Dialyzers||Soroka University Medical Center|No|Completed|March 2008|July 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|25|||Both|18 Years|88 Years|No|||March 2008|July 11, 2010|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638300||159019|
NCT00639054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|959593931/Emil Hermansen|The Molecular Characterization of Multiple Myeloma at Relapse|The Molecular Characterization of Multiple Myeloma at Relapse|MM-FISH/DNA|Rigshospitalet, Denmark|No|Completed|March 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|134|Samples With DNA|Peripheral whole blood Bone marrow|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed and/or treated at departments of hematology. Healthy controls.|January 2016|January 6, 2016|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00639054||158961|
NCT00639067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M08-01|Breath Test for Early Detection of Lung Cancer|Breath Test Assay for the Adjunctive Detection of Lung Cancer||Menssana Research, Inc.|No|Completed|June 2008|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|215|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group 1. Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT        Group 2. Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will        comprise patients who are undergoing medical evaluation for a pulmonary symptom such as        chronic unexplained cough or hemoptysis.        Group 3. Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found        to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD        or pulmonary infection.        Group 4. Apparently healthy individuals having no signs and symptoms of lung carcinoma.|May 2014|May 15, 2014|March 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00639067||158960|
NCT00588770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00507|Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2008|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588770||162733|
NCT00637143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-003|Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)|Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure||Astellas Pharma Inc|No|Completed|April 1999|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|12 Years|N/A|No|||September 2014|September 17, 2014|March 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637143||159107|
NCT00639288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP0036|Modification of Cognitive Processing Therapy (CPT-C) for PTSD and Alcohol Dependence|Modification of Cognitive Processing Therapy (CPT-C) for Posttraumatic Stress Disorder (PTSD) and Alcohol Dependence (AD)||Yale University|No|Completed|March 2008|April 2015|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|21 Years|65 Years|No|||March 2016|March 18, 2016|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00639288||158943|
NCT00605800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-017|Bone Marrow Derived Adult Liver Stem Cell Recruitment After Major Liver Resections: Correlation With Liver Regeneration and Hepatic Function|Bone Marrow Derived Adult Liver Stem Cell Recruitment After Major Liver Resections: Correlation With Liver Regeneration and Hepatic Function||Memorial Sloan Kettering Cancer Center||Withdrawn|March 2006|March 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MSKCC clinics Normal healthy volunteers|March 2009|March 18, 2009|January 17, 2008||No|Study was closed due to logistical issues.|No||https://clinicaltrials.gov/show/NCT00605800||161460|
NCT00636493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010864 (3964)|Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)|A Pilot Study of a Sustained-Release Fluocinolone Implant for Treatment of Retinal Vein Occlusion||Duke University|Yes|Completed|October 2002|May 2009|Actual|May 2009|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00636493||159156|
NCT00639964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00534-49|Exploration of the Lipid Metabolism During the Diabetic Pregnancies|Exploration of the Lipid Metabolism During the Diabetic Pregnancies and Research for New Biological Predictors to Nutritional Interventions|DIAMANT|University Hospital, Lille|Yes|Recruiting|January 2008|January 2013|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|210|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|April 8, 2010|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639964||158892|
NCT00639977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1196/07|Effect of Acupuncture on Intraocular Pressure|Effect of Acupuncture on Intraocular Pressure||Federal University of São Paulo|Yes|Completed|September 2007|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 19, 2008|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639977||158891|
NCT00639990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Respiratory Mechanics in Brain Injured Patients|Effects of PEEP in Brain Injury Patients||Università degli Studi dell'Insubria|No|Recruiting|June 2007|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||March 2008|March 12, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639990||158890|
NCT00637091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-2008-0031|Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions|A Phase II Trial of Cetuximab Plus Irinotecan as a 2nd-line Treatment in Patients With Metastatic Colorectal Cancer After Failure to Irinotecan That Express Wild-type KRAS With and Without Detectable EGFR Expression||Asan Medical Center|No|Completed|March 2008|September 2011|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||July 2014|July 17, 2014|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00637091||159111|
NCT00637104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS/03-2007|European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent|A European Multicenter, Randomized, Single Blind Study of the MAR-Tyn Cobalt Chromium TiN-Coated Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions|MARTIN|International Biomedical Systems S.p.A.|Yes|Recruiting|July 2008|June 2011|Anticipated|December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2010|February 8, 2010|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00637104||159110|
NCT00637416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10720|Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness|The Effect of Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness||University of Kansas Medical Center|No|Terminated|March 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|3 Years|18 Years|No|||September 2012|April 22, 2013|March 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637416||159086|
NCT00638521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31888-A|Immune-cell Membrane Trafficking|Trauma and Sepsis Induced Changes in Immune-cell Membrane Receptor Trafficking||University of Washington|No|Completed|June 2008|June 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|213|Samples Without DNA|whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Inclusion criteria:|December 2013|December 10, 2013|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638521||159002|
NCT00639782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONXSJM1|Prospective Randomized On-X Versus SJM Evaluation Trial|Thromboembolic Related Complications in a Randomized Trial of Previous and Current Generation Mechanical Valve Prostheses|PROSE|On-X Life Technologies, Inc.|Yes|Recruiting|July 2003|October 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|80 Years|No|||September 2015|September 4, 2015|February 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00639782||158905|
NCT00640003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00002180|Baclofen Treatment of Ataxia Telangiectasia|||Johns Hopkins University|No|Active, not recruiting|April 2007|February 2011|Anticipated|February 2011|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|12 Years|N/A|No|||December 2010|March 3, 2011|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00640003||158889|
NCT00640016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-354-0603|A Study to Assess the Efficacy, Safety,and Tolerability of CAT-354|A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354||MedImmune LLC|No|Terminated|March 2008|April 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|80 Years|No|||September 2012|September 11, 2012|March 13, 2008||No|Business decision|No||https://clinicaltrials.gov/show/NCT00640016||158888|
NCT00636506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMS052|Evaluate Improvement of Erectile Dysfunction After Placement of the AMS IPP 2005 Inflatable Penile Prosthesis|A Multi-Center Study to Assess the AMS IPP 2005 Inflatable Penile Prosthesis Cylinders, Pump and Reservoir.||American Medical Systems||Completed|August 2005|January 2008|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Male|21 Years|N/A|No|||March 2008|March 11, 2008|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636506||159155|
NCT00638534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6370|Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media|Evaluation of the Safety, Efficacy, Pharmacokinetics, and Acceptability of HMR3647 20 mg/kg qd for 5 Days With Acute Otitis Media (AOM) in Children (Multicenter, Open Label, Non Comparative Study)||Sanofi||Completed|February 2004|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|6 Months|16 Years|No|||October 2009|October 1, 2009|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638534||159001|
NCT00638547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2007-10|Intrathecal Enzyme Replacement for Hurler Syndrome|Intrathecal Enzyme Replacement Therapy For Patients With Mucopolysaccharidosis Type I (Hurler Syndrome)||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|January 2008|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|6 Months|3 Years|No|||January 2016|January 22, 2016|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638547||159000|
NCT00638781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN01-CLD-000001/01|Desmoteplase in Acute Ischemic Stroke (DIAS)|Multicentre, Multinational, Double-Blind, Placebo-Controlled, Randomised Phase II Trial of Desmoteplase (INN) in the Indication of Acute Ischaemic Stroke||PAION Deutschland GmbH|Yes|Completed|March 2001|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|104|||Both|18 Years|85 Years|No|||March 2008|March 12, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638781||158982|
NCT00639548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM-NMP4|ERPS, BIS and Entropy for Neuromonitoring in ICU Patients|Auditory Event-Related Potentials, BIS-Index and Entropy for the Discrimination of Different Levels of Sedation in the ICU Patients||University Hospital Inselspital, Berne|No|Completed|November 2004|September 2007|Actual|July 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients required an elective thoracic surgical intervention under general anesthesia and        who were scheduled to the ICU for postoperative care|March 2008|March 12, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639548||158923|
NCT00587808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-005202|Mechanisms in Heart Failure With Normal EF|Invasive Characterization of the Mechanisms Underlying Exertional Intolerance and Increased Filling Pressures in Patients With Heart Failure and a Preserved EF|HFpEF|Mayo Clinic|No|Completed|November 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|HFpEF subjects (NYHA class ≥II) defined by modified Framingham criteria4 (2 major or 1        major + 2 minor): Major criteria: paroxysmal nocturnal dyspnea or orthopnea, jugular        distension or venous pressure>16 mmHg, rales or pulmonary edema, cardiomegaly,        hepatojugular reflex, weight loss>4.5 kg in response to diuretics, BNP>400; Minor        criteria: ankle edema, nocturnal cough, exertional dyspnea, pleural effusion, HR>120,        hepatomegaly, vital capacity<2/3 normal, BNP>200, LA volume index>40cc/m2.|May 2011|February 6, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587808||162805|
NCT00588263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-087|Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer|Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individual With Cancer||Memorial Sloan Kettering Cancer Center|No|Recruiting|July 2000|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1905|Samples With DNA|Blocks or extracted DNA from patients who have identified themselves as Jewish will be      obtained and a determination will be made as to whether there is adequate material to      proceed without exhausting the block or extracted DNA.      Four unstained sections (research specimens) or paraffin "curls" will be cut from each      block. In those cases where a block containing normal resection margin or any other biopsy      of normal tissue are available, tissue will be cut from this block so as to preserve tumor      tissue for later investigators. It is not necessary for sections to be reviewed to confirm      that tumor is present in the section, since any germline DNA is adequate for this analysis.|Both|N/A|N/A|No|Non-Probability Sample|Cases will be identified in one of two ways. Pathology records will be reviewed for the        years 1985-present. All patients with diagnoses of pancreatic cancer, uterine        cancer,lymphoma, melanoma, cancer of the gallbladder and bile duct, stomach cancer, brain        cancer, ovarian cancer, colon cancer, head and neck cancer, lung cancer and breast        cancer(including DCIS) from 1985 to the present at MSKCC will be identified.|February 2016|February 11, 2016|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00588263||162771|
NCT00589082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSI 103-AMLE|DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML|DaunoXome (Liposomal Daunorubicin) Plus Ara-C Versus Daunorubicin Plus Ara-C in Elderly AML Patients.A Randomized Phase III Study.||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|October 2001|November 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|61 Years|75 Years|No|||December 2007|January 8, 2008|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00589082||162710|
NCT00638040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006979|The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression|The Gene Expression Studies of Tumor Microenvironments and Their Roles in Tumor Progression||Duke University|Yes|Withdrawn|September 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Female|18 Years|50 Years|No|Non-Probability Sample|The subjects will be de-identified and a system of patient identified will be used to        correlate with the clinical data. The patients will be recruited as described in the        original approved study. When patients with newly diagnosed cervix cancer are seen at Duke        in the GYN Oncology Division or Radiation Oncology, appropriate patients will be offered        protocol enrollment. Clinical faculty in both divisions also see new patients at satellite        clinics elsewhere in North Carolina and Virginia, and eligible patients may also be        enrolled from these encounters. We anticipate enrolling significant number of Spanish        speaking women having in mind the increased growth of Latino population in the area.|February 2013|July 9, 2014|March 12, 2008||No|the study has stopped due to no recruitment|No||https://clinicaltrials.gov/show/NCT00638040||159038|
NCT00605475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2213|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes|A Multi Center, Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered Intravenously to Patients With Type 2 Diabetes Mellitus||Novartis|No|Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|70 Years|No|||January 2012|January 10, 2012|January 18, 2008|Yes|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00605475||161483|
NCT00605488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-040|The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer|Pilot Study Investigating the Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2006|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00605488||161482|
NCT00606138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06120402|Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging|Investigation of Ranibizumab for the Treatment of Persistent Diabetic Neovascularization as Assessed by Super Wide-Field Angiography (Optos)||Rush University Medical Center|No|Completed|January 2008|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|January 9, 2008|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00606138||161434|
NCT00636818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12112|Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)|An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity Disorder||Eli Lilly and Company|No|Completed|March 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2010|October 20, 2010|March 7, 2008|Yes|Yes||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00636818||159132|
NCT00636831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hikari-0701|Prophylactic Antibiotic Use in Hernioplasty|Prophylactic Antibiotic Use in Inguinal Hernioplasty: A Placebo-controlled, Double-blind Trial|RCT-herniation|Nihon University||Completed|July 2007|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|400|||Both|20 Years|N/A|No|||February 2012|February 6, 2012|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00636831||159131|
NCT00637689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC-2192.00|Improving Outcomes Assessment in Chronic GVHD|Improving Outcomes Assessment in Chronic GVHD||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|September 2007|June 2018|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|601|Samples With DNA|Some centers are collecting serum, plasma, cells and urine.|Both|2 Years|N/A|No|Non-Probability Sample|People with chronic GVHD|August 2015|August 11, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00637689||159065|
NCT00638014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00006260|Rapid Sternal Closure System (TALON)|A Randomized, Controlled, Phase 4 Study of Sternal Plating (Rapid Sternal Closure System, KLS Martin L.P.) in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Complications.|TALON|Duke University|Yes|Completed|March 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|51|||Both|18 Years|N/A|No|||April 2011|April 5, 2011|March 12, 2008|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00638014||159040|
NCT00638274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Air versus Saline|Comparison of Loss of Resistance Techniques|Comparison of Loss of Resistance Technique With Air Versus Saline to Identify Epidural Space for Combined Spinal Epidural Labor Analgesia||Wake Forest School of Medicine|Yes|Completed|July 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|350|||Female|N/A|N/A|No|||February 2009|February 26, 2009|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638274||159021|
NCT00639041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H26_06|Changes in Blood Lipids After Long-term Consumption of n-3 LC-PUFA-Enriched Dairy Products|Changes in Blood Lipids After Long Time Consumption of n-3 LC-PUFA-enriched Dairy Products in Hypertriglyceridemic Patients: a Randomized, Double-blind, Cross-over Study||University of Jena|Yes|Completed|April 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|43 Years|69 Years|No|||February 2008|September 21, 2011|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639041||158962|
NCT00640224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0503013|Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study|Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives||Children's Hospital of Pittsburgh|No|Completed|March 2005|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|65|||Female|10 Years|20 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640224||158872|
NCT00640497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN019/ITC-001|Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease|A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins for the Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease||Henogen|Yes|Withdrawn|January 2010|January 2012|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|March 4, 2008||No|Unavailability of investigational product|No||https://clinicaltrials.gov/show/NCT00640497||158851|
NCT00637117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #007-082|Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.|A Phase I/II Study of Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.||Baylor Research Institute|Yes|Withdrawn|July 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|March 10, 2008|Yes|Yes|The study never opened and not sure if it ever will.|No||https://clinicaltrials.gov/show/NCT00637117||159109|
NCT00637130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-11|Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost|Safety and IOP Lowering Efficacy of Low Dose Travoprost Ophthalmic Solutions Dosed BID Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|October 2007|||January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|138|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|February 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637130||159108|
NCT00608751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1210|A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy|A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy in the Definitive Treatment of Head-and-Neck Cancer|IMRT|Washington University School of Medicine|No|Terminated|January 2007|January 2008|Actual|January 2008|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|January 2, 2008|No|Yes|Lack of accrual and software issues|No||https://clinicaltrials.gov/show/NCT00608751||161243|
NCT00639275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/050/HP|Deep Brain Stimulation and Digestive Symptomatology|Effects of Subthalamic Nucleus Deep Brain Stimulation on Gastrointestinal Symptoms and Motility in Parkinson's Disease.|SCPDig|University Hospital, Rouen|No|Completed|June 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|14|||Both|18 Years|70 Years|No|Non-Probability Sample|Parkinson's disease patients with subthalamic nucleus deep brain stimulation|January 2013|January 8, 2013|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00639275||158944|
NCT00640237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VD-1.CTIL|Interventional Trial of Vitamin D Deficiency in the Patients of General Departments|Vitamin D Deficiency in the Elder Patients of General Departments and Its Treatment During the Hospitalization||Rambam Health Care Campus|No|Recruiting|March 2008|August 2008|Anticipated|July 2008|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|65 Years|N/A|No|||March 2008|March 20, 2008|March 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00640237||158871|
NCT00588718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26128|A Biologic Validation of Biomarkers of Progressive NEC & Sepsis|A Biologic Sample Study for the Validation of Biomarkers of Progressive NEC & Sepsis|NEC|Nationwide Children's Hospital|No|Enrolling by invitation|April 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|740|Samples With DNA|Blood and Urine|Both|N/A|28 Weeks|No|Non-Probability Sample|Prematurely-born infants with with suspected necrotizing enterocolitis, sepsis or SIP who        meet study entry criteria|May 2015|May 5, 2015|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00588718||162736|
NCT00588731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710003164|Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia|Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia||Yale University|No|Completed|February 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||April 2014|April 1, 2014|December 29, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00588731||162735|
NCT00589654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-127|Menstrual Cycle Maintenance and Quality of Life: A Prospective Study|Menstrual Cycle Maintenance and Quality of Life: A Prospective Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 1997|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|810|||Female|18 Years|45 Years|No|Non-Probability Sample|Stage 1-3 breast cancer patients 18-45 years of age will be identified. Those with normal        menstrual cycles will be eligible.|January 2016|January 4, 2016|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589654||162669|
NCT00589667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-087|A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)|A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)||Memorial Sloan Kettering Cancer Center||Completed|September 2006|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|December 26, 2007|Yes|Yes||No|January 23, 2014|https://clinicaltrials.gov/show/NCT00589667||162668|
NCT00638794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAPT-DES|Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents|Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents|ADAPT-DES|Cardiovascular Research Foundation, New York|No|Completed|January 2008|January 2013|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|8575|||Both|18 Years|N/A|No|Probability Sample|Patient undergoing PCI in whom at least one DES is implanted and in whom PCI of all        treated lesions is successful (diameter stenosis <30% with TIMI 3 flow in all treated        lesions) without major complications (defined as freedom from procedural death,        intraprocedural stent thrombosis, procedural myocardial infarction or sustained vessel        closure, or need for emergency bypass graft surgery).|August 2012|January 22, 2013|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638794||158981|
NCT00605163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS050095_PostCEPT|A Longitudinal Observational Follow-up of the PRECEPT Study Cohort|A Longitudinal Observational Follow-up of the PRECEPT Study Cohort|PostCEPT|The Parkinson Study Group|No|Enrolling by invitation|August 2006|||August 2010|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|530|Samples With DNA|Whole blood|Both|30 Years|N/A|No|Non-Probability Sample|Parkinson disease patients who participated in the PRECEPT clinical trial.|March 2008|March 26, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00605163||161506|
NCT00605514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080065|Ebola and Marburg Virus Vaccines|VRC 206: A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|60 Years|No|||June 2010|June 22, 2010|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00605514||161481|
NCT00605826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33DA0404|A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence|A Randomized, Subject and Evaluator Blinded, Sham Controlled, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx for the Treatment of Fecal Incontinence||Q-Med Scandinavia, Inc.|No|Active, not recruiting|August 2006|December 2011|Anticipated|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||July 2011|July 13, 2011|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605826||161458|
NCT00605774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #040911- HAAF in T1DM, Q5|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q5|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 5||Vanderbilt University|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605774||161462|
NCT00605787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD18032|TTA in Treatment of Diabetes and Dyslipidemia|TTA in Treatment of Diabetes and Dyslipidemia|TODDY|Haukeland University Hospital|Yes|Completed|January 2002|December 2007|Actual|June 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|30 Years|60 Years|No|||January 2008|January 17, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00605787||161461|
NCT00606385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-GS-HBP1|Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC|Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for Patients With Hepatocellular Carcinoma|HCC|Seoul National University Hospital|Yes|Recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|20 Years|80 Years|No|||May 2015|May 19, 2015|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606385||161415|
NCT00606086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-5005-02|Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection|A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone, and GI-5005 Salvage of Standard of Care Failures, in Patients With Genotype 1 Chronic Hepatitis C Infection||GlobeImmune|Yes|Completed|December 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||May 2014|June 17, 2014|January 18, 2008|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00606086||161438|
NCT00606736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMU-007|Relativity Study Between Idiopathic Ventricular Arrhythmia and Sex Hormone Levels in Different Stages of Menstrual Cycle|Relativity Study Between Idiopathic Ventricular Arrhythmia and Sex Hormone Levels in Different Stages of Menstrual Cycle||Harbin Medical University|Yes|Withdrawn|January 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|whole blood, serum|Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 20 to 45 years with regular menstrual cycles.|January 2008|July 2, 2015|January 22, 2008||No|it's difficult to recruit enough participants eligible for this study|No||https://clinicaltrials.gov/show/NCT00606736||161388|
NCT00606749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC706-C08|Use of KC706 for the Treatment of Pemphigus Vulgaris|A Phase 2 Open-Label Uncontrolled Pilot Study of KC706 in Patients With Stable, Active Pemphigus Vulgaris||Kemia, Inc|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2008|June 18, 2008|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00606749||161387|
NCT00638768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010085.1|Effectiveness of Physiotherapy for Osteoporotic Spinal Fracture|Effectiveness of Physiotherapy for Vertebral Osteoporotic Fracture: a Randomised Controlled Pilot Trial||University of Melbourne|No|Completed|February 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|N/A|No|||March 2008|March 12, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638768||158983|
NCT00639535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 4493|Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities|Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities||State University of New York - Upstate Medical University|No|Completed|January 2002|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|56|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from Breast Care Clinic and local physicians.|May 2015|May 20, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639535||158924|
NCT00607581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-003-IT|Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis|An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis||IRCCS Policlinico S. Matteo|No|Completed|February 2008|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607581||161324|
NCT00636844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JL-001|Detection of Chemotherapy Induced Cardiotoxicity|Detection of Chemotherapy Induced Cardiotoxicity||George Washington University|No|Completed|January 2008|June 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|Samples With DNA|Blood sample for analysis of mRNA and oxidative stress markers|Both|18 Years|N/A|No|Non-Probability Sample|Oncology clinic patients|August 2012|March 11, 2013|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00636844||159130|
NCT00636857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKOISR10003|Postoperative Hyponatremia - Are There Gender Differences?|Postoperative Hyponatremia - Are There Gender Differences?||Karolinska University Hospital|No|Recruiting|March 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||June 2013|June 11, 2013|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00636857||159129|
NCT00637702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-543-103|A Study of ARRY-334543 in Patients With Advanced Cancer|||Array BioPharma||Completed|February 2008|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|March 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637702||159064|
NCT00609011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-6827-07-005|Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma|Dose Finding Phase 1 Study of the Treatment of Metastatic Melanoma With MPC-6827 in Combination With Temozolomide||Myrexis Inc.|No|Completed|March 2008|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2010|August 19, 2010|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00609011||161223|
NCT00604565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP-NIH-01|Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients|A Prospective, Randomized, Open-label, Multi-center, Controlled Clinical Trial of the Safety and Efficacy of Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate||Charles Drew University of Medicine and Science|No|Terminated|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|January 17, 2008|Yes|Yes|major planned changes to study design|No|March 11, 2015|https://clinicaltrials.gov/show/NCT00604565||161552|Study suspended after 1st 11 subjects enrolled. Study design changed significantly upon re-initiation, so 1st 11 subjects analyzed for safety only; no efficacy. Efficacy analysis from study after re-initiation is found under protocol NIH-FP-01 PRIME.
NCT00604578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080047|Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma|A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Allergic Asthma||National Institutes of Health Clinical Center (CC)||Withdrawn|January 2008|October 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||October 2009|November 16, 2011|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00604578||161551|
NCT00588484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2466-02|Ultrasound-based Intima-Media Thickness Measurements|Determination of the Precision and Clinical Utility of Ultrasound-based Intima-Media Thickness Measurements||Mayo Clinic|No|Completed|December 2002|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|128|||Both|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|75 Men and 75 women, ages 35-65, being seen either at the Mayo Clinic Cardiovascular        Clinic, or having an appointment for a carotid duplex ultrasound.|November 2012|November 7, 2012|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00588484||162754|
NCT00588757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4741-UR-CTIL|Comparison Between Two Optional IVC Filters Regardind Ease of Use,Complications and Outcome|Prospective Comparison Between OptEase and Gunter-Tulip||Sheba Medical Center|No|Not yet recruiting|March 2008|March 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2007|January 8, 2008|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00588757||162734|
NCT00595413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27905|Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)|A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate|AUGUST II|EMD Serono|No|Completed|September 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|311|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 7, 2008|No|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT00595413||162236|
NCT00595426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-033|A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery|A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty|PEARL|Astellas Pharma Inc|Yes|Completed|May 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|685|||Both|18 Years|N/A|No|||May 2010|March 19, 2013|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595426||162235|
NCT00605150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDE# 980006|HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC|A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma||Carolinas Healthcare System|Yes|Completed|January 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients will be selected from the population of patients with unresectable        cancer in the liver who are referred by surgeons and medical oncologists of        CarolinasHealthCare System and by other referring physicians in the geographic area for        regional therapy for liver cancer. Patients to be considered for treatment under this        protocol will have been referred to one of the clinicians.|February 2015|February 3, 2015|January 16, 2008||No||No|August 23, 2013|https://clinicaltrials.gov/show/NCT00605150||161507|
NCT00605813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501091|Special Investigation Of Long Term Use Of Sertraline.|Special Investigation Of Long Term Use Of J ZOLOFT.||Pfizer|No|Completed|September 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|542|||Both|N/A|N/A|No|Probability Sample|The patients to whom an investigator involved in A0501091 prescribes sertraline        hydrochloride.|August 2012|August 9, 2012|January 18, 2008|No|Yes||No|August 9, 2012|https://clinicaltrials.gov/show/NCT00605813||161459|
NCT00606125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11988|Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors|Phase I Study With Sorafenib in Combination With Carboplatin and Paclitaxel to Evaluate the Safety and Pharmacokinetics of This Combination in Patients With Solid Tumors||Bayer|No|Completed|May 2007|February 2009|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|January 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606125||161435|
NCT00606515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-PK-01-2008|Pharmacokinetics Study of Liposomal Paclitaxel in Humans|A Clinical Trial to Compare the Pharmacokinetics of Two Formulations of Taxane, Paclitaxel Injection and Liposomal Paclitaxel, in Humans|LPS-PK-H|Shandong Luye Pharmaceutical Co., Ltd.|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|75 Years|No|||February 2009|February 9, 2009|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606515||161405|
NCT00606112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-1436C-103|A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers|A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese Type 2 Diabetics||Genaera Corporation|No|Completed|January 2008|April 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|55 Years|No|||April 2009|April 14, 2009|January 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606112||161436|
NCT00606099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AUS03|Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B|A 26 Week Randomized, Open Label, Multi-center Study of the Efficacy and Safety of Telbivudine 600 mg Once Daily Versus Adefovir Dipivoxil 10mg Once Daily in Subjects With Compensated Chronic Hepatitis B and Sub-optimal Response to at Least 48 Weeks of Adefovir Dipivoxil 10 mg||Novartis||Withdrawn|November 2007|||November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|January 21, 2008|Yes|Yes|study was cancelled|No||https://clinicaltrials.gov/show/NCT00606099||161437|
NCT00606398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIAW1|Combined Resection of Colorectal Metastases|Combined Resection of Intra- and Extra-Hepatic Metastases From Colorectal Cancer: A Phase II Trial|CRC|University Health Network, Toronto|No|Completed|June 2007|January 2014|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606398||161414|
NCT00606996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DA021159-01|Group Therapy for Women Prisoners With Comorbid Substance Use and Depression|Group IPT for Women Prisoners With Comorbid Substance Use and Depression||Brown University||Completed|July 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|65 Years|No|||April 2013|April 17, 2013|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606996||161368|
NCT00607295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-OG-07-211|Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients|Prospective Randomized Study on Efficacy and Safety of Clino-san® in the Management of Vaginal Dryness in Breast Cancer Patients||Seoul National University Hospital|Yes|Completed|December 2007|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|98|||Female|20 Years|N/A|No|||July 2010|July 23, 2010|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00607295||161346|
NCT00607308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951005|A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease|A Phase 1, Randomized, Placebo-Controlled, Double Blind, Dose-Escalation, Multicenter Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|February 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|20|||Both|50 Years|85 Years|No|||December 2010|December 6, 2010|January 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607308||161345|
NCT00607334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24061316|Experimental Word Learning in Children With and Without Language Impairment|Experimental Word Learning in Children With Normal Development and Children With Language Impairment||University of Sao Paulo|No|Completed|July 2003|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|36 Months|47 Months|Accepts Healthy Volunteers|||October 2007|January 22, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607334||161343|
NCT00607594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00188|Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer|A Phase 2 Study of AZD0530 in Patients With Metastatic or Locally Advanced Gastric Carcinoma||National Cancer Institute (NCI)|Yes|Completed|January 2008|April 2012|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|February 1, 2008|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00607594||161323|
NCT00608127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUP-001-ISR|Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients|A Single - Arm Open - Label Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients||Verto LTD|No|Active, not recruiting|January 2007|August 2008|Anticipated|May 2008|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||May 2008|May 21, 2008|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608127||161284|
NCT00608140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002860|Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure|Surgery Versus Medical Treatment Alone for Patients With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure: SMMART-HF|SMMART-HF|Duke University|Yes|Terminated|March 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|N/A|No|||July 2013|July 9, 2014|January 24, 2008||No|Unable to recruit sufficient numbers of patients.|No|April 29, 2013|https://clinicaltrials.gov/show/NCT00608140||161283|
NCT00608452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-046|Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers|A Prospective Study of The Prevalence and Significance of Paraneoplastic Autoantibodies in Small Cell Lung Cancer and Cancer of The Breast, Ovary, Hodgkin's Disease, Neuroblastoma and Other Cancers||Memorial Sloan Kettering Cancer Center|Yes|Completed|July 1995|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|121|Samples Without DNA|blood samples for autoantibody determinations and HLA typing|Both|N/A|N/A|No|Non-Probability Sample|Patients with previous cancers or concurrent cancers. Patient has or may have,        newly-diagnosed or recurrent SCLC, or mixed small cell/non small cell lung cancer, or        neuroblastoma, or ovarian or breast cancer, or Hodgkin's disease in all cases confirmed by        pathological review.|November 2009|November 12, 2009|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608452||161264|
NCT00607880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30CA015083|Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy|A Prospective Randomized Study of the Vortex® Implantable Access Port Versus the BardPort™ Implantable Port in Cancer Patients Receiving Adjuvant Intravenous Chemotherapy||Mayo Clinic|Yes|Completed|June 2004|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|February 1, 2008|Yes|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00607880||161302|
NCT00608153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CGE-ATA-2007/1|Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide|Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide|CoCa|AstraZeneca|No|Completed|January 2007|September 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1773|||Both|N/A|N/A|No|Probability Sample|primary care ambulant patient|January 2008|February 5, 2008|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608153||161282|
NCT00608491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018064|Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)|CARdiorenal REScue Study in Acute Decompensated Heart Failure: CARRESS|CARRESS|Duke University|Yes|Completed|March 2008|June 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|January 25, 2008||No||No|February 18, 2013|https://clinicaltrials.gov/show/NCT00608491||161262|
NCT00608465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060369|Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity|Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity||Vanderbilt University|Yes|Recruiting|May 2006|May 2011|Anticipated|May 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 10, 2009|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608465||161263|
NCT00608764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1428|Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)|Genetic Epidemiology of Chronic Obstructive Pulmonary Disease|COPDGene|Brigham and Women's Hospital|No|Active, not recruiting|November 2007|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|10500|Samples With DNA|Genomic DNA, serum, and plasma will be collected and stored.|Both|45 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Particpants with COPD will include outpatient clinic patients, patients in registries,        previous study participants, and COPD Foundation volunteers.        Participants without COPD will include spouses and friends of study participants with COPD        and patients at primary care practices.|January 2016|January 11, 2016|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00608764||161242|
NCT00588783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-U-013|I-beam and Cruciate Tibial Components Used in Total Knee Replacement|||Biomet, Inc.|No|Terminated|August 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include patients requiring total knee replacement.|July 2013|July 22, 2013|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588783||162732|
NCT00588796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-04-017|Study of Fibrinogen Metabolism During Severe Trauma and Burns|Alteration in Fibrinogen Metabolism in Patients With Severe Burns and Traumatic Injuries||United States Army Institute of Surgical Research|No|Completed|February 2005|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Burn patients Trauma patients Healthy Volunteers|February 2015|February 2, 2015|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00588796||162731|
NCT00595738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000704|Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Heart Failure|Use of Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Patients With Advanced Heart Failure||Massachusetts General Hospital|No|Completed|December 2007|January 2011|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|We will be banking serum collected from peripheral blood draws, and blood draws from a      pulmonary artery catheter and arterial line.|Both|21 Years|N/A|No|Non-Probability Sample|The study population will consist of 30 patients admitted to the Massachusetts General        Hospital Coronary Care Unit (CCU) for PA catheter-directed therapy for advanced heart        failure. Only patients for whom the attending cardiologist has already decided upon        PA-catheter insertion will be recruited for the study.        Potential subjects will be identified by the CCU attending cardiologist, and a study nurse        will review each patient for the exclusion criteria as above. Final decisions on patient        eligibility will be made by Dr. Wang.|July 2011|July 19, 2011|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595738||162212|
NCT00604877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0092|Effects of Exercise on Endothelial Function in Stroke Patients|Effects of Exercise on Endothelial Function in Stroke Patients||National Institute on Aging (NIA)|Yes|Active, not recruiting|August 2003|May 2008|Anticipated|May 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|40 Years|85 Years|No|||January 2008|January 17, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604877||161528|
NCT00604890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTL0108|Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma|Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma||Berg, LLC|Yes|Completed|March 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|186|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604890||161527|
NCT00605527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|545|Understanding the Role of Genes and Biomarkers in the Blood Clotting Process in Children With Acute Lung Injury|Targeted Genomic Analysis of Coagulation Pathways in Acute Lung Injury|PALI|University of California, San Francisco|No|Recruiting|November 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Blood and plasma samples will be analyzed|Both|N/A|18 Years|No|Non-Probability Sample|Patients who are admitted to the University of California, San Francisco hospital and        participating sites including Children's Hospital of Oakland with ALI/ARDS.|October 2015|October 30, 2015|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605527||161480|
NCT00606437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009529|Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants|Total Body Irradiation With Fludarabine Conditioning Followed by Transplantation With Combined Umbilical Cord Blood Grafts||Duke University|Yes|Completed|September 2005|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|14 Years|65 Years|No|||May 2014|May 15, 2014|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606437||161411|
NCT00606411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-2008P000662|Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder||Massachusetts General Hospital|No|Recruiting|January 2008|||December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||March 2016|March 22, 2016|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606411||161413|
NCT00606424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHX4000|An Exploratory, Open Label, Single Center Study of [F-18]HX4|An Exploratory, Open Label, Single Center Study of [F-18]HX4|HX4|Siemens Molecular Imaging|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 29, 2009|January 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606424||161412|
NCT00606775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TN1966220|The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy|Carvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular Dystrophy||Suzuka Hospital|Yes|Recruiting|December 2007|December 2012|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Male|8 Years|45 Years|No|||December 2007|February 4, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606775||161385|
NCT00606762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Joshipura|Comparison Between Low Pressure Versus High Pressure Laparoscopic Cholecystectomy|A Prospective Randomized, Controlled Study Comparing Low Pressure Versus High Pressure Pneumoperitoneum During Laparoscopic Cholecystectomy.||Sterling Hospital|No|Completed|October 2006|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|26|||Both|N/A|N/A|No|||January 2008|February 4, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606762||161386|
NCT00607009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-04BSter-02-H|Project ALIVE (A Lifestyle Intervention Via Email)|Email-Based Diet and Activity Promotion in Worksites||Kaiser Permanente|Yes|Completed|July 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|797|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2008|February 4, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607009||161367|
NCT00607022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-2003-03|A Randomized Prospective Clinical Trial Comparing Single Tooth Implant 3 Loading Protocols|the Effects of 3 Loading Protocols on Dental Implant Stability in Healed Ridges||University of Iowa|Yes|Completed|December 2007|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607022||161366|
NCT00607321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP088|Bare Metal Bifurcation Stent Clinical Trial in Humans|The Medtronic Bare Metal Bifurcation Stent Clinical Trial in Humans|BRANCH|Medtronic Vascular|Yes|Completed|February 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|January 22, 2008||No||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00607321||161344|
NCT00607620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-ZATZICK_AA016102|Disseminating Organizational SBI Services at Trauma Centers|Disseminating Organizational SBI Services (DO-SBIS) at Trauma Centers|DO-SBIS|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Recruiting|September 2008|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|1100|||Both|18 Years|N/A|No|||November 2009|November 20, 2009|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00607620||161321|
NCT00607633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CGE-ATA-2007/2|Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH|Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy|CandLE|AstraZeneca|No|Completed|January 2007|October 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|686|||Both|N/A|N/A|No|Probability Sample|Ambulant patient|January 2008|February 5, 2008|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00607633||161320|
NCT00607607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-103|A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer|A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Recurrent or Resistant Epithelial Ovarian Cancer or Advanced Endometrial Cancer||CASI Pharmaceuticals, Inc.|No|Completed|January 2008|January 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|N/A|No|||January 2012|January 19, 2012|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607607||161322|
NCT00608179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #020690|Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia|Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia||Vanderbilt University|Yes|Completed|August 2002|December 2010|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|4||Actual|32|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00608179||161281|
NCT00608790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0058|Rapid Diagnosis of Pulmonary Tuberculosis|Diagnostic Yield of Induced Sputum for Rapid Diagnosis of Pulmonary Tuberculosis||University of Cape Town|No|Recruiting|February 2008|April 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|12 Years|N/A|No|||July 2012|July 23, 2012|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00608790||161240|
NCT00608803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM1002|Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors|A Phase I Study of ZIO-201-T in Combination With Doxorubicin in Subjects With Advanced, Refractory Solid Tumors for Which no Standard Therapy Exists and for Whom Treatment With Doxorubicin is Considered Medically Acceptable||Ziopharm|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 16, 2009|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608803||161239|
NCT00608777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD4311s|Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)|Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Mild Breakthrough in Moderate to Severe Plaque Psoriasis Patients Receiving Efalizumab ( Raptiva).||Derm Research, PLLC|No|Terminated|January 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|January 23, 2008|No|Yes|Withdrawal of marketing autorization of efalizumab by the EMEA.|No|March 5, 2012|https://clinicaltrials.gov/show/NCT00608777||161241|Study terminated due to withdrawal of Raptiva from the market. Study specifically designed to address a side effect associated with the administration of Raptiva. Therefore no data analysis completed for this study and no measuremnet of outcomes.
NCT00609050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR009285|Exercise Training Study for Patients With Cystic Fibrosis|Self-Regulated Exercise in CF: A Randomized Trial||University of Pittsburgh|Yes|Completed|March 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|10 Years|18 Years|No|||February 2016|February 18, 2016|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00609050||161221|
NCT00589394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005905|Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine|Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine||Mayo Clinic|Yes|Completed|July 2007|January 2010|Actual|December 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|December 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00589394||162688|
NCT00604591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF4151|Effects of Tolcapone on Frontotemporal Dementia|Investigation of the Dopamine System in Frontotemporal Dementia||Columbia University||Completed|January 2008|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|85 Years|No|||September 2015|September 8, 2015|January 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00604591||161550|
NCT00605176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW01-0702 / 0704|Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)|A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Four Weeks of Treatment With Imiquimod Creams for Actinic Keratoses||Graceway Pharmaceuticals, LLC|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|479|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|January 16, 2008|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00605176||161505|
NCT00605540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-06|Chronic Obstructive Pulmonary Disease Markers and Prognosis|Three-years Follow-up of Diagnostic and Prognostic Markers in Chronic Obstructive Pulmonary Disease||UPECLIN HC FM Botucatu Unesp|Yes|Completed|January 2008|February 2012|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|40 Years|95 Years|No|Non-Probability Sample|Pulmonary outpatient clinic|May 2014|September 2, 2014|January 18, 2008||No||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00605540||161479|We excluded patients with comorbidities; therefore, many patients seen in clinical practice may not have been well represented in our study.
NCT00606164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRY-201|Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Mild to Moderate Alzheimer's Disease||Blanchette Rockefeller Neurosciences Insitute|No|Not yet recruiting|April 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|9|||Both|50 Years|N/A|No|||January 2008|January 21, 2008|January 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00606164||161432|
NCT00605839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA-HenryBecton-DGM-01|Mobile Communication Technology for Adolescents With Diabetes|Adapting Mobile Communication Technology to Improve the Management of Adolescents With Diabetes||Indiana University|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|105|||Both|14 Years|18 Years|No|||November 2015|November 16, 2015|January 17, 2008|Yes|Yes||No|September 12, 2012|https://clinicaltrials.gov/show/NCT00605839||161457|This was a small pilot study to generate results for further work.
NCT00605852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH3110161|Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects|See Detailed Description||GlaxoSmithKline|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|January 18, 2008||||No||https://clinicaltrials.gov/show/NCT00605852||161456|
NCT00606151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07669|PeriOperative Bridging - Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents|Short-Term Outcomes of Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents||The Cleveland Clinic|No|Terminated|January 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|We intend to assess, in a prospective observational manner, the clinical course of        patients who have undergone stent implantation less than 6 months prior to a surgical        procedure requiring discontinuation of clopidogrel therapy and the efficacy of intravenous        antiplatelet therapy to prevent morbidity related to stent thrombosis.|March 2009|March 25, 2009|January 22, 2008||No|subject enrollment goals not met|No||https://clinicaltrials.gov/show/NCT00606151||161433|
NCT00606788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luebeck 0001|Therapy Study of Automated Protocolized vs. Physician-Directed Non-Protocolized Weaning|Comparison of Computer-Driven Protocolized Weaning With Physician-Directed Weaning in Surgical Intensive Care Unit (ICU) Patients||University of Luebeck|No|Suspended|November 2005|February 2007|Anticipated|January 2007|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||January 2008|February 12, 2008|January 16, 2008||No|Interim analysis indicated that sample size of study patients had to be highly increased to    obtain significant outcomes.|No||https://clinicaltrials.gov/show/NCT00606788||161384|
NCT00606450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-003|Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Comparison Study of CC-10004 in Subjects With Moderate-to-Severe Plaque-Type Psoriasis|PSOR-003|Celgene|Yes|Completed|April 2006|May 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|260|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00606450||161410|
NCT00607048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5021004|Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors|A Phase 1 Study Of CP- 870,893 In Combination With Paclitaxel And Carboplatin In Patients With Metastatic Solid Tumors||Hoffmann-La Roche|No|Completed|November 2007|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|85 Years|No|||November 2013|November 26, 2013|January 22, 2008|Yes|Yes||No|May 3, 2012|https://clinicaltrials.gov/show/NCT00607048||161364|
NCT00607035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J_Core_071226|The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)|The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)||Jichi Medical University|Yes|Completed|May 2006|May 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|30 Years|85 Years|No|||May 2008|November 19, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00607035||161365|
NCT00607347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF IRB 591-2007|Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers|Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers||University of Florida|Yes|Completed|February 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|24|||Both|18 Years|65 Years|No|||December 2009|September 16, 2011|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00607347||161342|
NCT00607919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11672|Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia|A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia||Eli Lilly and Company|No|Completed|March 2008|February 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|209|||Both|10 Years|16 Years|No|||November 2011|November 11, 2011|January 23, 2008|Yes|Yes||No|November 11, 2011|https://clinicaltrials.gov/show/NCT00607919||161299|
NCT00607893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|562|Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea|Oxidative Stress in Sleep Apnea and Cardiac Disease|SASS|Case Western Reserve University|Yes|Completed|September 2006|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|149|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00607893||161301|
NCT00608504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15462-3|Effects of Environmental Factors on Opiate Drug Choice in Opioid Dependent Individuals.|Biobehavioral Study of Opioid Drug Seeking Behavior: Study 3|DSC|Wayne State University|Yes|Completed|July 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|Samples With DNA|Whole blood|Both|18 Years|55 Years|No|Non-Probability Sample|Heroin dependent research volunteers|June 2012|June 1, 2012|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00608504||161261|
NCT00608816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #040910-HAAF in T1DM, Q4|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q4|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 4||Vanderbilt University|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608816||161238|
NCT00609063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552|The Effect of Statin Medications on Muscle Performance (The STOMP Study)|The Effect of Statins on Skeletal Muscle Function|STOMP|Hartford Hospital|Yes|Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|420|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 5, 2012|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00609063||161220|
NCT00609089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA021512-02|Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction|A Stage 1 Study of Community Reinforcement and Family Training for Treatment Drug Abuse Treatment Retention/HIV Risk Reduction||University of Cincinnati|No|Active, not recruiting|March 2008|June 2013|Anticipated|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||August 2012|August 13, 2012|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00609089||161219|
NCT00604617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0061|Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children|The Utility of Interferon-Gamma Release Assays in TB-HIV Co-infected Children||Case Western Reserve University|No|Recruiting|August 2007|July 2013|Anticipated|December 2012|Anticipated|Phase 4|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|800|||Both|3 Months|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will include 300 HIV-infected (HIV infection is a viral infection that        causes disease which destroys the body's ability to protect itself from infection and        disease.) children and 500 HIV-uninfected children, ages 3 months to 5 years, residing in        the Khayelitsha and Ravensmead/Uitsig Communities of the Western Cape Province, South        Africa.|August 2010|August 2, 2010|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00604617||161548|
NCT00595088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-07-01.CTIL|Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer|Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer||BioCancell Ltd.|No|Active, not recruiting|January 2008|October 2014|Anticipated|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|January 7, 2008|Yes|Yes||No|June 16, 2013|https://clinicaltrials.gov/show/NCT00595088||162259|
NCT00595101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9441003|A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.|A Phase 2, 28-Day Parallel-Group, Double-Masked, Dose Finding Study Comparing The Safety And Efficacy Of PF-03187207 To Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.||Bausch & Lomb Incorporated|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|128|||Both|20 Years|N/A|No|||November 2013|November 20, 2013|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595101||162258|
NCT00604903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAPIRUS II|Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal|||Boston Scientific Corporation|No|Completed|August 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00604903||161526|
NCT00605553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN115-CL01|Study to Evaluate SYN115 in Parkinson's Disease|A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease||Biotie Therapies Inc.|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|75 Years|No|||May 2014|June 19, 2015|January 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605553||161478|
NCT00606177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-06-004|A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|65 Years|No|||January 2014|January 16, 2014|January 19, 2008||No||No|November 28, 2013|https://clinicaltrials.gov/show/NCT00606177||161431|
NCT00606502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-012|Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment|A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment||Spectrum Pharmaceuticals, Inc||Completed|January 2008|August 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|January 22, 2008|Yes|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00606502||161406|The date of the CRF database cut-off for patients (no further case report form or query data entry) was 24 Jun 2010. As of the CRF data cut-off date, 3 patients, remained on therapy.
NCT00605865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501090|Drug Use Investigation of Jzoloft.|Drug Use Investigation of Jzoloft.||Pfizer|No|Completed|April 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2272|||Both|N/A|N/A|No|Probability Sample|The patients to whom an investigator involved in A0501090 prescribes sertraline        hydrochloride.|August 2012|August 28, 2012|January 18, 2008|No|Yes||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00605865||161455|
NCT00637858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR459407CTIL|Effect of Different Doses of Tomato Lycopene on Blood Pressure in Pre-hypertensive Otherwise Healthy Subjects|Effect of Different Doses of Tomato Lycopene on the Blood Pressure in Prehypertensives and Grade I Never Treated Otherwise Healthy Subjects||Soroka University Medical Center|No|Terminated|October 2008|January 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|130|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||July 2009|January 6, 2013|March 11, 2008|Yes|Yes|difficulty to enroll more subjects|No||https://clinicaltrials.gov/show/NCT00637858||159052|
NCT00606814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-05|Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors|A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors||Infinity Pharmaceuticals, Inc.|No|Completed|December 2007|December 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|January 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606814||161382|
NCT00606827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prato0701|Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy|Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy in Patients Undergoing Coronary Angiography||Ospedale Misericordia e Dolce|Yes|Completed|January 2005|March 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|500|||Both|N/A|N/A|No|||May 2012|May 6, 2012|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606827||161381|
NCT00606463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611.1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2008|||||N/A|N/A|N/A||||||||||||||February 14, 2011|January 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00606463||161409|
NCT00606476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAB-001-251|AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease|A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102||JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Yes|Terminated|December 2006|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|194|||Both|N/A|N/A|No|||August 2012|October 30, 2013|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00606476||161408|
NCT00606489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-010|Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients|A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Ibuprofen Injection (IVIb) for Treatment of Fever and Pain in Burn Patients||Cumberland Pharmaceuticals|Yes|Completed|November 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|N/A|N/A|No|||July 2011|July 18, 2011|January 22, 2008|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00606489||161407|
NCT00606801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 0706002768|Galantamine Effects on Cognitive Function in Abstinent Cocaine Users|Galantamine Effects on Cognitive Function in Abstinent Cocaine Users||Yale University|Yes|Completed|June 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|21 Years|50 Years|No|||February 2012|June 24, 2013|January 23, 2008||No||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00606801||161383|Relatively low medication dose and short duration of treatment. Multiple cognitive tests and outcome measures increase probability of Type 1 errors. Absence of non-addicted controls limits determination of a unique effect in abstinent users.
NCT00607360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0865-F2L|Integration of the Therapeutic Workplace in Drug Court|Integration of the Therapeutic Workplace in Drug Court||National Institute on Drug Abuse (NIDA)|No|Completed|August 2004|July 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|February 4, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607360||161341|
NCT00607646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044672-DHEA|Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 3||University of Maryland|Yes|Recruiting|October 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607646||161319|
NCT00607906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXO110461|First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050|A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered SB756050 in Healthy Volunteers and in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|January 23, 2008||||||https://clinicaltrials.gov/show/NCT00607906||161300|
NCT00607659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #99416|Immunopathogenesis of Chlamydia|Immunopathogenesis of Chlamydia Trachomatis Infection||Arkansas Children's Hospital Research Institute|No|Enrolling by invitation|January 2008|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Endocervical or vaginal swabs, rectal swabs, blood (whole and serum),urine|Female|11 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescent females between 11 and 21 years of age undergoing pelvic examinations or        screening for STIs at the Arkansas Children's Hospital Adolescent Center will be eligible        for recruitment|January 2012|January 18, 2012|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00607659||161318|
NCT00608192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020781|HIV and Hepatitis Care Coordination in Methadone Treatment|HIV and Hepatitis Care Coordination in Methadone Treatment||University of California, San Francisco|Yes|Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|489|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00608192||161280|
NCT00608517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 0552|Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil|The Treatment of Hematologic Malignancies With Single or Double Umbilical Cord Blood Unit Transplantation Followed by Graft-versus-Host Prophylaxis With Tacrolimus and Mycophenolate Mofetil||Vanderbilt-Ingram Cancer Center|Yes|Terminated|September 2005|May 2011|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|N/A|50 Years|No|||May 2012|May 12, 2014|January 31, 2008|No|Yes|slow accrual|No|October 11, 2010|https://clinicaltrials.gov/show/NCT00608517||161260|
NCT00608530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4767-I|Telehealth Outreach for Chronic Back Pain|Telehealth Outreach for Chronic Back Pain|TELE|VA Office of Research and Development|Yes|Completed|March 2008|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|75 Years|No|||February 2015|March 4, 2015|January 22, 2008||No||No|February 18, 2015|https://clinicaltrials.gov/show/NCT00608530||161259|The trial was viewed as a "proof-of-concept" and analyses were conducted on those who completed 8 weeks of treatment (ie, per protocol). This, along with of the small sample size and attrition, limits the strength of the evidence.
NCT00608829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAG 06-02|GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta|Evaluation of the GORE TAG® Thoracic Endoprosthesis - 45 mm for the Primary Treatment of Aneurysms of the Descending Thoracic Aorta||W.L.Gore & Associates|No|Completed|February 2007|September 2014|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|21 Years|N/A|No|||March 2015|March 4, 2015|December 20, 2007|Yes|Yes||No|August 18, 2010|https://clinicaltrials.gov/show/NCT00608829||161237|Enrollment into this trial was completed prematurely with 23 enrolled subjects. The 45mm TAG Device was approved based on the data collected and a descriptive statistical analysis. Follow up of enrolled subjects continued for 5 years.
NCT00609102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antioxidant trmt type 2|Antioxidant Treatment of Type 2 Diabetes|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||Completed|July 2008|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00609102||161218|
NCT00609115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT001|Sub-Acute Stroke Rehabilitation With AMES|Sub-Acute Stroke Rehabilitation With Assisted Movement With Enhanced Sensation|AMES|AMES Technology|Yes|Active, not recruiting|September 2007|December 2014|Anticipated|June 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|132|||Both|18 Years|80 Years|No|||January 2014|January 16, 2014|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00609115||161217|
NCT00604630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BfArM-4019639/2002|Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke|German Multicenter EPO Stroke Trial (Phase II/III)|ESS|Max-Planck-Institute of Experimental Medicine|Yes|Completed|January 2003|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|522|||Both|18 Years|N/A|No|||September 2008|October 21, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604630||161547|
NCT00595439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080040|Association Between Focal Dystonia and Complex Regional Pain Syndrome|The Association Between Focal Dystonia (FD) and Complex Regional Pain Syndrome (CRPS)||National Institutes of Health Clinical Center (CC)||Completed|December 2007|||October 2009|Actual|N/A|Observational|Time Perspective: Prospective||||90|||Both|18 Years|80 Years|No|||October 2009|October 22, 2009|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00595439||162234|
NCT00595465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-310|Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51|Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.||Valneva Austria GmbH|No|Completed|December 2007|June 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|389|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|January 4, 2008||No||No|June 1, 2012|https://clinicaltrials.gov/show/NCT00595465||162233|
NCT00605202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lakritsi ja hypokalemia|Effect of Licorice and Hydrochlorothiazide on Plasma Potassium|Effect of Licorice and Hydrochlorothiazide on Plasma Potassium||University of Oulu|No|Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2009|December 10, 2009|January 17, 2008||No||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00605202||161503|
NCT00605215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LAQ-302|BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)|A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With RRMS to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design.|BRAVO|Teva Pharmaceutical Industries|Yes|Completed|April 2008|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1331|||Both|18 Years|55 Years|No|||August 2013|August 16, 2013|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605215||161502|
NCT00605566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-NET-001|Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors|Tailored-dose Sorafenib Plus Metronomic Cyclophosphamide in Advanced Neuroendocrine Tumors (NET): a Phase II Clinical Trial Based on Individual Pharmacodynamic Assessment||University Health Network, Toronto|Yes|Completed|January 2008|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605566||161477|
NCT00637871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7054IL/0044|Casodex - Nolvadex Combination|Randomised, Double-blind, Placebo Controlled, Parallel-group, Multicentre Phase II Study to Assess Dose Response Relationship of Nolvadex (Oral Tablet) in Prophylactic Treatment of Gynaecomastia and Breast Pain Associated With CASODEX 150 mg (Oral Tablet), and to Assess the Tumour Control…..||AstraZeneca||Completed|November 2002|August 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Male|N/A|N/A|No|||January 2011|January 21, 2011|March 12, 2008||||||https://clinicaltrials.gov/show/NCT00637871||159051|
NCT00637884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455A_4148|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms||Sanofi||Completed|November 2003|February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|70|||Both|12 Years|N/A|No|||January 2011|January 10, 2011|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637884||159050|
NCT00631254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1179|CysLT1-r Expression Following Allergen Exposure in Asthma and Allergic Rhinitis|Modulation of the CysLT1-r Expression Following Allergen Exposure in Non Asthmatic Subjects With Allergic Rhinitis and Mild Allergic Asthmatic Subjects Using the Induced Sputum Technique.||Laval University|No|Recruiting|October 2003|January 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|45 Years|No|||November 2007|May 7, 2008|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631254||159552|
NCT00637494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-14|A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features|A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features||Corcept Therapeutics|No|Terminated|March 2008|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|292|||Both|22 Years|N/A|No|||March 2016|March 8, 2016|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637494||159080|
NCT00637507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFO-TGI-728-4-10-07|Study of a Novel Technique of Mechanical Ventilation in Patients With Severe Acute Respiratory Failure|Phase II/Phase III Study of the Effect of Combined High-frequency Oscillation and Tracheal Gas Insufflation on the Survival to Hospital Discharge of Patients With Severe Acute Respiratory Distress Syndrome|HFO-TGI-2|University of Athens|Yes|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|75 Years|No|||June 2014|June 21, 2014|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00637507||159079|
NCT00628134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07090095|Self-dispersing Liquids as Aerosol Drug Carriers|Self-dispersing Liquids as Aerosol Drug Carriers||University of Pittsburgh|Yes|Completed|March 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|February 22, 2008|No|Yes||No|June 19, 2013|https://clinicaltrials.gov/show/NCT00628134||159788|Our aerosol delivery method resulted in more peripheral distribution than was anticipated. The more peripheral deposition pattern likely affected the location and quantity of deposited calfactant available to cause transport.
NCT00628147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOE0011|Clinical Evaluation of Narrow Band Imaging Colonoscope|Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates||VA Palo Alto Health Care System|Yes|Completed|January 2006|March 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|284|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|March 3, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628147||159787|
NCT00628446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-040|Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury|Prevalence and Risk of Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury(SCI): A Pilot Study||Carolinas Healthcare System|Yes|Completed|September 2007|December 2009|Actual|November 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|45|||Male|45 Years|70 Years|No|Non-Probability Sample|Male,Spinal Cord Injuries|July 2015|July 27, 2015|February 26, 2008||No||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00628446||159764|
NCT00638339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-8053|Effects Of Invasive And Noninvasive Mechanical Ventilation On Sleep In The Intensive Care Unit (ICU)|Effects Of Invasive And Noninvasive Mechanical Ventilation On Sleep In The Icu||Tufts Medical Center|No|Recruiting|November 2006|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients undergoing invasive or noninvasive mechanical ventilation in        medical ICU and CCU at Tufts New England Medical Center|May 2012|May 30, 2012|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638339||159016|
NCT00629317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PISUI 2007-031|Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage|A Randomized, Double-Blind, Placebo-Controlled Trial of Methyl Aminolevulinate + Aktilite in Patients With Facial Photodamage||Universidad de Antioquia|No|Completed|February 2008|March 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|49|||Female|35 Years|75 Years|No|||March 2009|March 13, 2009|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629317||159700|
NCT00629564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-NEP-0012|An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)|An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)||AstraZeneca||Completed|September 2002|October 2002|Actual|October 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||January 2011|January 24, 2011|February 27, 2008||||||https://clinicaltrials.gov/show/NCT00629564||159682|
NCT00639106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-024|Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial|The Use of Alloderm in Two-Stage, Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|98|||Female|21 Years|75 Years|No|||April 2015|April 28, 2015|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00639106||158957|
NCT00630136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH080104|Effectiveness of the Consent Process|Effectiveness of the Consent Process Used for Outpatient Endoscopy||Children's Mercy Hospital Kansas City|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Gastroenterology primary care clinic|October 2008|March 23, 2010|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00630136||159638|
NCT00630149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3E-GH-0034|Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy|Open-Label Single-Arm Phase 2 Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy||Sun Yat-sen University||Completed|November 2007|January 2012|Actual|November 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00630149||159637|
NCT00604981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-05-HFC-24|Multisystemic Therapy (MST) for Obesity in African American Youth|Adapting Multisystemic Therapy to Improve Food Choices and Health Outcomes in Obese African American Youth||Wayne State University|No|Completed|May 2005|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|12 Years|17 Years|No|||January 2008|January 29, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604981||161520|
NCT00628017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH-92-TD-1095|Preliminary Study of Fish Oil and Dementia|The Effects of Omega-3 Fatty Acids Monotherapy in Alzheimer's Disease and Mild Cognitive Impairment: a Preliminary Randomized Double-Blind Placebo-Controlled Study||Taipei City Psychiatric Center, Taiwan|No|Completed|January 2003|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|55 Years|90 Years|No|||February 2008|February 24, 2008|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00628017||159797|
NCT00628706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC-phMRI-01|Investigating the Acute Effects of THC on Functional Brain Systems|Investigating the Acute Effects of THC on Functional Brain Systems|FIX|UMC Utrecht|Yes|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00628706||159745|
NCT00629473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI 0052-102|Phase 1 Clinical Trial in Patients With Advanced Malignancies|A Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies||Triphase Research and Development I Corporation|No|Completed|July 2007|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|86|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|February 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00629473||159689|
NCT00630318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710-67|Testing New Method of Analyzing MR Images|Imaging Protocol Design for Anti-Angiogenesis Tracking With MRI||Indiana University|No|Terminated|March 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Female|18 Years|N/A|No|||March 2012|March 30, 2012|February 28, 2008|Yes|Yes|Unable to accrue enough subjects to analyze data.|No||https://clinicaltrials.gov/show/NCT00630318||159624|
NCT00630331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P13|Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects|A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects||Novartis||Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|11404|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|February 28, 2008|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00630331||159623|
NCT00630058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A5|A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C|A Phase I, Open-Label, Two-Arm Study of MP-424 in Combination With Peginterferon Alfa 2b and Ribavirin in Patients With Genotype 1b Hepatitis C||Mitsubishi Tanabe Pharma Corporation|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|20 Years|65 Years|No|||April 2014|April 16, 2014|February 24, 2008||No||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00630058||159644|
NCT00630071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT 01|Diagnostic Value of Procalcitonin in Patients With Acute Appendicitis|A Prospective Study Investigating the Diagnostic Value of Procalcitonin in Patients With Acute Appendicitis||Ruhr University of Bochum|Yes|Completed|February 2008|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|Samples With DNA|1.5 ml whole blood|Both|14 Years|N/A|No|Non-Probability Sample|Surgical Emergency Room|October 2012|October 15, 2012|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00630071||159643|
NCT00630630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01088|Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy|A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Adult Female Subjects (18 to 40 Years of Age) With C1 Catamenial Epilepsy||UCB Pharma|No|Completed|November 2002|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|45 Years|No|||September 2009|November 25, 2013|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00630630||159600|
NCT00631631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTP-OS-403|Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma|Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE) for High-risk Osteosarcoma||Millennium Pharmaceuticals, Inc.|No|Completed|January 2008|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|205|||Both|2 Years|50 Years|No|Non-Probability Sample|Had diagnosis of high grade osteosarcoma with relapsed or recurrent disease, locally or        metastatic, with disease not completely resectable or who were unable to complete        recommended chemotherapy due to toxicity: relapse, recurrence local or metastatic; unable        to have standard surgical resection; abbreviated chemotherapy regimen secondary to        toxicity.|May 2014|May 13, 2014|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00631631||159523|
NCT00627211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHF Gastro BS1|Carbon Dioxide Versus Air Insufflation in Oesophago-Gastro-Duodenoscopy (OGD)|A Double-Blinded, Randomized Trial Comparing Carbondioxide(CO2)and Air Insufflation in Oesophago-Gastro-Duodenoscopy (OGD)||Norwegian Department of Health and Social Affairs|No|Enrolling by invitation|February 2008|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2008|February 28, 2008|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00627211||159856|
NCT00637793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGX267XSS2001|Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome|A Double-Blind, Placebo-Controlled, Cross Over Study Using a Latin Square Design to Evaluate the Safety, Tolerability, and Efficacy of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjogren's Syndrome||TorreyPines Therapeutics|No|Completed|February 2008|November 2008|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|24|||Both|21 Years|55 Years|No|||January 2009|January 28, 2009|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637793||159057|
NCT00637806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100.2.C.005|Treatment of Cancer-Associated Anorexia Using Megestrol Acetate Concentrated Suspension|A Randomized, Double-Blind, Placebo-Controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-Associated Anorexia in Subjects With Cancer of Multiple Types||Par Pharmaceutical, Inc.|No|Terminated|June 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|N/A|No|||March 2008|March 11, 2008|March 11, 2008|Yes|Yes|Difficulty finding the required patient population|No||https://clinicaltrials.gov/show/NCT00637806||159056|
NCT00637741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-004|DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions|Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions||Flanders Medical Research Program|No|Completed|March 2008|November 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 30, 2010|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00637741||159061|
NCT00637754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608001730|Safety of Sports for Patients With Implantable Cardioverter-Defibrillators|Safety of Sports for Patients With Implantable Cardioverter-Defibrillators: A Multi-Center Registry||Yale University|Yes|Completed|September 2006|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|10 Years|60 Years|No|Non-Probability Sample|Individuals between the ages of 10 and 60 years who have defibrillators who participate in        competitive (organized sports at any level) or dangerous sports.|June 2015|June 10, 2015|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00637754||159060|
NCT00638053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENGHD-0018-078|A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury|Head Trauma With Traumatic Brain Injury (TBI): A Multicenter, Phase IV Study to Evaluate the Effects of Genotropin in Adult Patients With Growth Hormone Deficiency (GHD) Caused by Trauma and/or Head Injury|GHD|Pfizer|No|Terminated|November 2002|November 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|March 11, 2008|Yes|Yes|See reason for termination in detailed description.|No||https://clinicaltrials.gov/show/NCT00638053||159037|
NCT00638352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 5334|False/Negative Rate of Lung Percutaneous Needle Biopsy|Determination of the False Negative Rate of Percutaneous Needle Biopsies That Include Core Tissue Samples||State University of New York - Upstate Medical University|No|Completed|June 2006|April 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|We will review medical records to identify patients who underwent percutaneous needle        biopsy of a lung mass between 5/1/01 and 10/30/04. If the pathology report indicates that        the the biopsy showed no evidence of malignancy, we will examine the medical record for a        "gold standard" diagnosis of the lesion in question, including the pathology result from a        surgical resection or a repeat biopsy, or imaging follow-up demonstrating regression of        the lesion (or size stability for at least 2 years), or clinical follow-up for at least 2        years.|May 2015|May 12, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638352||159015|
NCT00638573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA04034|The Incretin Effect in Patients With Chronic Pancreatitis|The Incretin Effect in Patients With Chronic Pancreatitis With and Without Secondary Diabetes Mellitus||University Hospital, Gentofte, Copenhagen|No|Completed|January 2006|July 2006||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|32|Samples With DNA|Blood samples|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with chronic pancreatitis with and without secondary diabetes mellitus|March 2008|January 12, 2010|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638573||158998|
NCT00638586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY/102008|Comparison of Patients Undergoing Radial or Femoral Arterial Access for Percutaneous Catheterization-Nursing Aspects|||Hillel Yaffe Medical Center||Not yet recruiting|April 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|All hospitalized patients that are candidates for undergoing PTCA.|March 2008|March 12, 2008|March 12, 2008||||No||https://clinicaltrials.gov/show/NCT00638586||158997|
NCT00638807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191082|Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen|A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen||Pfizer|No|Completed|December 2003|July 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|388|||Both|40 Years|N/A|No|||March 2009|March 12, 2009|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638807||158980|
NCT00639093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAP-CRC-cyberpsychologie|A Virtual Arm to Stop Smoking|A Virtual Arm to Stop Smoking. A Comparative Study||Universite du Quebec en Outaouais|No|Completed|March 2008|June 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|March 12, 2008||No||No|July 30, 2009|https://clinicaltrials.gov/show/NCT00639093||158958|
NCT00639327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JACCRO GC-05|Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer|Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer||Japan Clinical Cancer Research Organization|Yes|Completed|March 2008|June 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||June 2011|June 27, 2011|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00639327||158940|
NCT00639574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0030|Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi|Interest of Néfopam in the Treatment of Pain During the Intense Ureteral Calculi Uncomplicated in Adults in Emergencies Unit.||University Hospital, Clermont-Ferrand||Completed|March 2008|September 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|50 Years|No|||March 2010|March 26, 2010|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639574||158921|
NCT00637000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-07-0002|Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone|Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone||Indivior Inc.|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||February 2014|April 9, 2014|March 10, 2008|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00637000||159118|
NCT00628342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961AC00001|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)||AstraZeneca||Completed|April 2003|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|85 Years|No|||March 2009|March 11, 2009|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628342||159772|
NCT00629213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Canadian: ACRI02; Bay g 5421|Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial|Metabolic Syndrome and Its Single Traits as Risk Factors of Diabetes in People With Impaired Glucose Tolerance: The STOP-NIDDM Trial||GWT-TUD GmbH|Yes|Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2|||1429|||Both|40 Years|70 Years|No|||March 2008|March 5, 2008|February 22, 2008||||No||https://clinicaltrials.gov/show/NCT00629213||159708|
NCT00629226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080071, CDR0000588196|Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer|Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer||National Institutes of Health Clinical Center (CC)||Completed|October 2007|||December 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|March 1, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00629226||159707|
NCT00630084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960044|Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma|The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|August 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00630084||159642|
NCT00630097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27.140|A Dose Ranging Study of Modafinil for Methamphetamine Dependence|A Dose Ranging Study of Modafinil for Methamphetamine Dependence||California Pacific Medical Center Research Institute|Yes|Active, not recruiting|December 2009|June 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|50 Years|No|||June 2010|June 21, 2011|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630097||159641|
NCT00630344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-316|RAD001 and Bicalutamide for Androgen Independent Prostate Cancer|A Phase II Trial of RAD001 and Bicalutamide for Androgen Independent Prostate Cancer||Dana-Farber Cancer Institute|Yes|Terminated|February 2008|January 2016|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|February 28, 2008|No|Yes|Low overall response rate|No|January 20, 2014|https://clinicaltrials.gov/show/NCT00630344||159622|
NCT00630643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0401-01|NI-0401 in Active Crohn's Disease|A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn´s Disease||NovImmune SA|Yes|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||February 2008|March 6, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630643||159599|
NCT00630656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-0801|Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis|A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis||Agennix|Yes|Completed|April 2008|February 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630656||159598|
NCT00630981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-111/Psy 07-016|Psychotherapy and Pharmacotherapy in Dissociative Disorders|The Interest of a Specific Combined Treatment (Psychotherapy and Pharmacotherapy) in Patients With Dissociative Disorders||Espace Hogan|Yes|Active, not recruiting|February 2008|July 2009|Anticipated|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|No|Probability Sample|This will be an open single arm "pilot" clinical trial on patients with dissociative        disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan        Psychotherapeutic Center in Montreux. Patients will be interviewed according to the        Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured        Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered and, if        the outcome on SCID is positive, the patient can be included in the study.        The patients will be treated by a psychiatrist who has experience with the use of the        specific combined treatment for dissociative disorders (Damsa et al., 2005).|April 2009|April 16, 2009|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630981||159573|
NCT00630578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH074937-01A2|Improving Effectiveness: Treatment Outcome Research|Improving Effectiveness: Treatment Outcome Research||Center for Trauma Recovery, St Louis|No|Completed|August 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2011|April 6, 2011|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630578||159604|
NCT00630591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0756|DAMES: Daughters And MothErS Against Breast Cancer|DAMES: Daughters And MothErS Against Breast Cancer||M.D. Anderson Cancer Center|Yes|Completed|February 2008|July 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|482|||Female|21 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 27, 2012|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630591||159603|
NCT00630604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 94-2314-B-037-020|Quantitative Ultrasonography (US) Evaluation on Femoral Condyle Cartilage|Quantitative Evaluation by Ultrasonography for Severity of Knee Osteoarthritis|US|Kaohsiung Medical University||Completed||||||N/A|Observational|N/A|||||||Both|40 Years|90 Years|No|Probability Sample|patients with knee OA who were going to receive total knee arthroplasty|February 2008|March 6, 2008|February 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630604||159602|
NCT00630617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-06-14|Childhood Obesity Prevention|Project FAMILIA Giya Marianas: Childhood Obesity Prevention Program||Western Michigan University|Yes|Completed|July 2004|July 2007|Actual|July 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|900|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2008|February 28, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630617||159601|
NCT00627796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-9|Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly|A Multicenter, Open, Prospective, Observational Study to Investigate the Effect of Lanreotide Autogel 120 mg on Control of GH and IGF-I Excess and Tumor Shrinkage in Newly Diagnosed Patients With Acromegaly|ATG1line|Federico II University|No|Completed|January 2003|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|80 Years|No|||December 2007|February 22, 2008|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627796||159813|
NCT00638378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-254|Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer|A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer||Incyte Corporation|No|Terminated|February 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|N/A|No|||January 2012|January 20, 2012|March 12, 2008|Yes|Yes|According to the protocol, the sponsor terminated the study after it was determined that less    than 2 of the first 22 patients showed a PSA50 response.|No|December 15, 2011|https://clinicaltrials.gov/show/NCT00638378||159013|
NCT00638391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ax-003|Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer|Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis|Ax-003|AstraZeneca|No|Completed|May 2005|March 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1600|||Female|N/A|N/A|No|Probability Sample||March 2008|March 19, 2008|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00638391||159012|
NCT00637767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588063|High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant|A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myeloma||National Cancer Institute (NCI)||Recruiting|December 2007|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00637767||159059|
NCT00637780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0031005|Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis|An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis||Pfizer|No|Suspended|June 2010|November 2024|Anticipated|November 2024|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|6 Years|17 Years|No|||February 2016|February 23, 2016|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637780||159058|
NCT00638066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130/6/6081|Botulinum Toxin Injection for Treatment of Vaginismus|Comparison of Efficacy of 250 Units Versus 500 Units of Botulinum Toxin in the Treatment of Refractory Vaginismus||Tehran University of Medical Sciences|No|Active, not recruiting|October 2007|April 2008|Anticipated|April 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||March 2008|March 17, 2008|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00638066||159036|
NCT00638612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaTK01|AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)|AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer|PaTK01|Advantagene, Inc.|Yes|Completed|August 2008|June 2015|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|March 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00638612||158995|
NCT00638599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2579-7FW|Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer|Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube for Airway Management in Modified Radical Mastectomy on Breast Cancer|LMATBBC|Nanjing Medical University|Yes|Completed|January 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|200|||Female|18 Years|70 Years|No|||July 2009|July 14, 2009|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00638599||158996|
NCT00638833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11495A|Memantine Therapy for Multiple Sclerosis|Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis|Memantine-MS|Clinica Universidad de Navarra, Universidad de Navarra|No|Terminated|September 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||June 2012|June 7, 2012|March 12, 2008||No|Unexpected side-effects: reversible and mild to moderate neurological impairment|No||https://clinicaltrials.gov/show/NCT00638833||158978|
NCT00638846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0801|Performance of Two Silicone Hydrogel Toric Contact Lenses|Multi-Center Evaluation Of Two Silicone Hydrogel Toric Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|March 10, 2008|Yes|Yes||No|June 18, 2010|https://clinicaltrials.gov/show/NCT00638846||158977|
NCT00638820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704M06581|Reduced Intensity AlloTransplant For Osteopetrosis|Reduced Intensity Allogeneic Transplantation For Severe Osteopetrosis Incorporating A Second Cd34 Selected Graft||Masonic Cancer Center, University of Minnesota|Yes|Terminated|September 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|45 Years|No|||February 2011|February 22, 2011|March 11, 2008|Yes|Yes|Excess toxicity|No|August 26, 2009|https://clinicaltrials.gov/show/NCT00638820||158979|Only 3 participants were treated in this study; all died by Day 100. Data for both treatment arms were combined due to low number. (Arm 1 utilized mobilized peripheral blood or marrow (related or unrelated). Arm 2 received cord blood transplants).
NCT00640588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AES01|Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine|Prospective Exploratory Study to Describe in CHB naïve and Non-naïve Patients, Hepatitis B Virus (HBV) Kinetics During the First 24 Weeks of Treatment With Telbivudine|EBEREST|Novartis||Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640588||158844|
NCT00640601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00025|Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia|A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia|SPECTRUM|AstraZeneca|No|Completed|March 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|331|||Both|18 Years|65 Years|No|||June 2012|June 22, 2012|March 17, 2008|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00640601||158843|The open-label design and lack of a placebo group constitute potential limitations. In addition, the small sample size of some of the subgroups may limit conclusions drawn from subgroup analyses.
NCT00639314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP-0502|Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy|Randomized Controlled Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy||Wakayama Medical University|Yes|Completed|October 2005|March 2011|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|N/A|No|||January 2010|June 23, 2011|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639314||158941|
NCT00637598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013552|Early Detection of Breast Cancer Using Tomosynthesis Imaging|Early Detection of Breast Cancer Using Tomosynthesis Imaging||Duke University|Yes|Completed|November 2004|October 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|385|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 31, 2014|March 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637598||159072|
NCT00637611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455A_4149|Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit|Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit (Study I)||Sanofi||Completed|February 2003|April 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|1010|||Both|15 Years|N/A|No|||January 2011|January 11, 2011|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637611||159071|
NCT00629486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-950181|Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma|Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 17, 2013|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629486||159688|
NCT00629785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960129|The Analysis of BMI, Asthma Prevalence, and Lung Functions of Schoolchildren in Southern Taiwan|||Kaohsiung Medical University Chung-Ho Memorial Hospital||Completed||||||N/A|Observational|Time Perspective: Retrospective|||||||Both|13 Years|16 Years||||March 2007|February 26, 2008|February 26, 2008||||No||https://clinicaltrials.gov/show/NCT00629785||159665|
NCT00629798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008|Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)|A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2008|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|N/A|65 Years|No|||December 2015|December 15, 2015|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629798||159664|
NCT00630669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-10-009-03|Comparison Between Two Endoscopic Treatments of Bleeding Internal Hemorrhoids:Band Ligation and Electrocoagulation Probe|Randomized Study Of Endoscopic Band Ligation Versus Bipolar Probe Electrocoagulation Of Bleeding Internal Hemorrhoids||University of California, Los Angeles|No|Completed|December 1997|May 2001|Actual|May 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||May 2001|March 6, 2008|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00630669||159597|
NCT00630682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25.139|A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence|A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence|1D|California Pacific Medical Center Research Institute|Yes|Completed|September 2006|August 2011|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|50 Years|No|||May 2013|May 30, 2013|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630682||159596|
NCT00630994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588839|Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis|Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis||Mayo Clinic|Yes|Terminated|March 2008|April 2012|Actual|August 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|120 Years|No|||November 2012|November 25, 2015|March 6, 2008|Yes|Yes|Stopped due to slow accrual|No|January 9, 2012|https://clinicaltrials.gov/show/NCT00630994||159572|Study terminated early. Most analyses were not performed.
NCT00631293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/103|Study of the Effect of Lactisole on the Intestinal Glucose Uptake|Study on the Effect of Lactisole on the Intestinal Glucose Uptake||University Ghent|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 6, 2009|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00631293||159549|
NCT00630955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0602001068|Family History Study of Alcohol Consumption Using Memantine|NMDA Antagonist Efficacy in Reducing Human Alcohol Consumption: Impact of Family History||Yale University|Yes|Completed|June 2006|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|111|||Both|21 Years|50 Years|No|||August 2013|January 17, 2014|February 27, 2008||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00630955||159575|
NCT00630968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01031|S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy|Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy||UCB Pharma|No|Completed|August 2000|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1541|||Both|16 Years|N/A|No|||September 2009|November 14, 2013|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00630968||159574|
NCT00637156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESTIGE LP Two Level Study|Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels|A Prospective, Randomized, Controlled, Multicenter Pivotal Clinical Trial of the Artificial Cervical Disc-LP at Two Levels for Symptomatic Cervical Disc Disease||Medtronic Spinal and Biologics|Yes|Active, not recruiting|June 2006|March 2018|Anticipated|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637156||159106|
NCT00638885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-008-07S|Memory and the Hippocampus in Twins|Memory and the Hippocampus in Vietnam Twins With PTSD||VA Office of Research and Development|Yes|Completed|April 2010|June 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|142|Samples With DNA|blood for genetic testing, blood samples and urine and saliva collections|Male|50 Years|70 Years|No|Non-Probability Sample|Twins with history of military service during Vietnam era with and without PTSD|January 2015|January 8, 2015|March 12, 2008||No||No|January 8, 2015|https://clinicaltrials.gov/show/NCT00638885||158974|
NCT00638079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR 100.1.C.003|Evaluating the Effect of Food on Absorption of Megace ES|Single-center, Randomized, Open-label, 2-way Crossover Bioavailability Study, Evaluating the Effect of Food on Megace ES (Megestrol Acetate 625 mg/5 mL Oral Suspension) Following a 625 mg Dose in Healthy Subjects||Par Pharmaceutical, Inc.|No|Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|March 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00638079||159035|
NCT00638365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB001-03|Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa|A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa||KaloBios Pharmaceuticals|Yes|Completed|March 2008|April 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|12 Years|N/A|No|||June 2014|June 4, 2014|March 12, 2008|Yes|Yes||No|July 12, 2011|https://clinicaltrials.gov/show/NCT00638365||159014|
NCT00639626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-00218|Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)|Use of Levemir® Improves Metabolic and Clinical Status in CFRD||Nationwide Children's Hospital|No|Terminated|August 2008|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|16 Years|45 Years|No|||May 2015|May 14, 2015|March 14, 2008|Yes|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT00639626||158917|
NCT00638859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6369|Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia|Evaluation of the Safety, Pharmacokinetics, Efficacy, and Acceptability of HMR3647 20 mg/kg qd for 5-7 Days With Community-Acquired Pneumonia (CAP) in Children (Multicenter, Open Label, Noncomparative Study)||Sanofi||Completed|March 2004|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|6 Months|16 Years|No|||October 2009|October 1, 2009|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638859||158976|
NCT00639119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERPME01|Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type|Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type||University of Turku|No|Enrolling by invitation|August 2007|||August 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|70 Years|No|||February 2008|March 18, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00639119||158956|
NCT00639613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2007-031|The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia|Exspression of Prohormone Convertase 1 and 2 in Small Intestinal Endocrine Mucosa Cells in Patients With Type 2 Diabetes|T2DM-PC1-2|University Hospital, Gentofte, Copenhagen|Yes|Completed|March 2008|||June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples With DNA|Buffy coat|Both|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with type 2 diabetes|June 2015|June 25, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639613||158918|
NCT00637923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-2026|Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients|Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C|STEALTHC-3|Romark Laboratories L.C.|Yes|Completed|March 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|March 11, 2008|Yes|Yes||No|November 18, 2013|https://clinicaltrials.gov/show/NCT00637923||159047|
NCT00638222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSC-08|Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease|Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease||University of Toledo Health Science Campus|Yes|Terminated|May 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|6|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|March 5, 2008|Yes|Yes|Poor enrollment|No|July 8, 2014|https://clinicaltrials.gov/show/NCT00638222||159025|Early termination due to poor enrollment leading to small number of subjects to be analyzed.
NCT00628927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0031A|An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.|An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association With Treatment Outcomes in Methamphetamine and Cocaine Abusers||University of Cincinnati|Yes|Completed|February 2008|March 2010|Actual|October 2009|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|217|Samples With DNA|Blood sample for the oxidative stress/damage analysis|Both|18 Years|99 Years|No|Non-Probability Sample|Persons randomized into the National Drug Abuse Treatment Clinical Trials Network STAGE-12        Study (CTN-0031- NCT00573183)|December 2015|December 1, 2015|March 3, 2008||No||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00628927||159728|
NCT00628940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/085|PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?|PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?||University Ghent|No|Recruiting|January 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628940||159727|
NCT00628953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-NEE-0003|Adult Asthmatics and Acid Reflux|A Randomized, Double-Blind, Parallel Group Multicenter Efficacy and Safety Phase IIB Pilot Study of Esomeprazole 40mg Bid Versus Placebo Bid in Adult Asthmatics Treated for 4 Months||AstraZeneca|No|Completed|October 2002|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|70 Years|No|||March 2009|March 12, 2009|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628953||159726|
NCT00629499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 116|Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer|Phase II Trial of Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients)||SCRI Development Innovations, LLC|No|Completed|April 2008|September 2010|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|February 26, 2008|No|Yes||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00629499||159687|
NCT00630357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01037|Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy|A Phase IV, Open-label, Multi-center Trial to Evaluate the Safety and Efficacy of Keppra® After Conversion to Mono-therapy in Adult Subjects With Partial Epilepsy||UCB Pharma|No|Completed|March 2003|July 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|16 Years|N/A|No|||September 2009|November 14, 2013|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00630357||159621|
NCT00631007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT131-007|A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator|A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes||InteKrin Therapeutics, Inc.|No|Completed|February 2008|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|367|||Both|30 Years|75 Years|No|||August 2010|August 18, 2010|February 27, 2008|Yes|Yes||No|August 18, 2010|https://clinicaltrials.gov/show/NCT00631007||159571|
NCT00631020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM 20063287|Youth Smoking Cessation: Therapy +/- "The Patch"|Determining the Efficacy of Cognitive-behavioral Motivational Enhancement +/- Nicotine Replacement Therapy for Adolescents||University of California, Los Angeles|Yes|Completed|December 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||April 2015|April 18, 2015|February 27, 2008|Yes|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00631020||159570|
NCT00631306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003443|Effects of Cranberry Juice on Risk Factors for Cardiovascular Disease|Effects of Cranberry Juice on Risk Factors for Cardiovascular Disease||Mayo Clinic|No|Completed|February 2008|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mayo Clinic Patients|August 2011|August 10, 2011|February 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631306||159548|
NCT00631267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-502-141207|CoNCReTe-trial: Colles Fractures, Determining the Norm in Closed Reduction Techniques|Colles Fractures, Determining the Norm in Closed Reduction Techniques|CoNCReTe|Rijnstate Hospital|No|Terminated|July 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|16 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 5, 2014|February 27, 2008||No|Due to poor patient accrual|No||https://clinicaltrials.gov/show/NCT00631267||159551|
NCT00631280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-12-16|Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD|Response Variability in Children With ADHD||Children's Hospital Medical Center, Cincinnati|No|Completed|September 2007|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|7 Years|11 Years|No|||March 2015|March 3, 2015|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631280||159550|
NCT00637169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTG-2006-COT|Canadian Oxygen Trial (COT)|Efficacy and Safety of Targeting Lower Arterial Oxygen Saturations to Reduce Oxygen Toxicity and Oxidative Stress in Very Preterm Infants: The Canadian Oxygen Trial (COT)|COT|McMaster University|Yes|Completed|December 2006|December 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1201|||Both|N/A|24 Hours|No|||December 2014|December 4, 2014|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00637169||159105|
NCT00637182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033US/0016|Gynecomastia Extension Study|An OptioExtension of Trial 1033US/0006 to Assess Safety, Tolerability, Efficacy of Anastrozole (ZD1033, Arimidex™) in Treatment of Gynecomastia in Pubertal Boys Given Placebo and to Conduct a Long-Term Safety Follow-Up of Non-Responding Subjects Given Anastrozole in the Previous Trial||AstraZeneca|No|Completed|January 2001|October 2002|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Male|11 Years|18 Years|No|||March 2008|March 10, 2008|March 7, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00637182||159104|
NCT00638638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3233|Myocardial Infarction With ST-Elevation|Myocardial Infarction With ST-elevation Treated by Primary Percutaneous Intervention Facilitated by Early Reopro Administration in Alsace.|MISTRAL|University Hospital, Strasbourg, France|No|Active, not recruiting|January 2005|January 2010|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|N/A|No|||September 2009|September 16, 2009|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00638638||158993|
NCT00638872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA/01/06|Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers|Diabetic Foot Ulcers and Use of PDRN (Polydeoxyribonucleotide -Placentex Mastelli) as a Treatment for Wound Healing.||University of Messina|Yes|Completed|October 2007|December 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|45 Years|80 Years|No|||September 2012|September 10, 2012|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638872||158975|
NCT00639132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-US|The Natural History of Metachromatic Leukodystrophy|The Natural History of Metachromatic Leukodystrophy|NH-US|University of Pittsburgh|No|Active, not recruiting|January 2012|January 2025|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|blood, CSF and urine|Both|N/A|6 Years|No|Non-Probability Sample|Patients with biochemical evidence of MLD including low levels of arylsulphatase A white        cell activity and increased amounts of urinary sulphatide excretion are eligible for the        study. A total of 10 patients representing various ranges of disease severity are expected        to enroll.|February 2016|February 12, 2016|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00639132||158955|
NCT00639145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGPAF-001|Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol|Maternal Events and Pregnancy Outcomes in a Cohort of Human Immunodeficiency Virus‐Infected Women Receiving Antiretroviral Therapy in Sub‐ Saharan Africa|MEP Project|Elizabeth Glaser Pediatric AIDS Foundation|No|Completed|September 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Female|15 Years|45 Years|No|Probability Sample|HIV positive pregnant women attending ART clinics|August 2013|August 13, 2013|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639145||158954|
NCT00639340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP00-006|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2001|||||N/A|N/A|N/A||||||||||||||February 22, 2010|March 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00639340||158939|
NCT00639353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0804|Silicone Hydrogel Contact Lenses on Low Astigmatism in Japan|The Clinical Performance of the Silicone Hydrogel Contact Lens on Low to Moderate Astigmatism in Japan||Johnson & Johnson Vision Care, Inc.|No|Terminated|February 2008|||June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|39 Years|No|||October 2014|October 28, 2014|March 14, 2008|Yes|Yes|English to Japanese translation issues caused enrollment of incorrect and unqualified    subjects; error applied to all subjects enrolled prior to termination.|No||https://clinicaltrials.gov/show/NCT00639353||158938|
NCT00639639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003877|Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia|ATTAC|Duke University|Yes|Active, not recruiting|January 2006|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|16|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|March 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00639639||158916|
NCT00639860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01|Clinical and Histological Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia|Clinical and Histological Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia|OSSIX|University of Michigan|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2009|May 20, 2009|March 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00639860||158899|
NCT00640302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPET A|A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza|A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza Infection|PIPET A|Kirby Institute|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Patients will be asked to provide a blood sample and an appropriate respiratory tract      sample. As a minimum, we will collect a combined nose and throat sample.      A further respiratory tract swab will be collected on day 5 (range 5-10) and stored for      future use. Index case follow-up will include an assessment and respiratory tract specimen      and blood sample 14 days after informed consent. A final assessment for outcomes (including      a blood sample) will occur approximately one month after enrolment.|Both|N/A|N/A|No|Non-Probability Sample|Patients presenting at study sites with the recognised clinical case definition for        pandemic influenza (to be distributed by State and Commonwealth Departments of Health when        first clinical case occurs).|April 2012|April 22, 2012|March 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00640302||158866|
NCT00640094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000821-49|The Melatonin Adjunct in the Acute myocaRdial Infarction Treated With Angioplasty|A Unicentric, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Melatonin as an Adjunct in Patients With Acute myocaRdial Infarction Undergoing Primary Angioplasty|MARIA|Fundación Canaria Rafael Clavijo para la Investigación Biomédica|Yes|Recruiting|May 2013|November 2015|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|272|||Both|18 Years|75 Years|No|||September 2014|September 26, 2014|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640094||158882|
NCT00637910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM6F5JER|Tarceva Italian Lung Optimization tRial|Optimization of Erlotinib for the Treatment of Patients With Advanced Non Small Cell Lung Cancer: an Italian Randomized Trial|TAILOR|Fatebenefratelli and Ophthalmic Hospital|Yes|Recruiting|November 2007|February 2013|Anticipated|February 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|850|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00637910||159048|
NCT00638235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004|Pelvic Floor Repair Systems for Prolapse Repair|A Prospective, Multi-Center Study to Assess the AMS Pelvic Floor Repair System Devices for Prolapse Repair|PROPEL|American Medical Systems|No|Active, not recruiting|May 2006|March 2012|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|750|||Female|21 Years|N/A|No|||January 2011|January 27, 2011|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638235||159024|
NCT00638716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM200-101|A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy|DM200-101|ConjuChem|Yes|Completed|February 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|25 Years|N/A|No|||November 2008|November 18, 2008|March 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00638716||158987|
NCT00638729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 157/01|Clonidine Versus Midazolam for Premedication|Effects of Clonidine and Midazolam Premedication on Bispectral Index and Recovery After Elective Surgery||University of Schleswig-Holstein|No|Completed|August 2005|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|60|||Both|18 Years|75 Years|No|||February 2008|March 18, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638729||158986|
NCT00629239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3540C00005|Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 4-week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|TOP|AstraZeneca|No|Completed|January 2008|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|40 Years|N/A|No|||November 2010|November 4, 2010|February 25, 2008|Yes|Yes||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00629239||159706|
NCT00629252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98_PPI-P50|The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients|||University of Zurich|No|Terminated|February 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|January 21, 2008||No|Not enough subjects have been recruited in the expected period.|No||https://clinicaltrials.gov/show/NCT00629252||159705|
NCT00630110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI-2358-101|Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer|Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer||Nereus Pharmaceuticals, Inc.|Yes|Completed|February 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|N/A|No|||August 2011|August 15, 2011|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630110||159640|
NCT00630695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003576-19|Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer|Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer||University Hospital, Limoges|No|Completed|March 2008|December 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|148|||Female|18 Years|80 Years|No|||January 2012|January 13, 2012|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00630695||159595|
NCT00636558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSX-X04|Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers|A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours||Viralytics|Yes|Completed|March 2008|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636558||159152|
NCT00627250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02-06A|Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability|Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial||Carolinas Healthcare System|Yes|Completed|March 2003|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|16 Years|65 Years|No|||February 2008|March 23, 2010|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00627250||159854|
NCT00627497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05-05 and P07-03|DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion|A Prospective, Randomized, Controlled Pivotal Clinical Investigation of DIAM™ Spinal Stabilization System in Patients With Degenerative Lumbar Spinal Stenosis.||Medtronic Spinal and Biologics|Yes|Terminated|February 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|35 Years|N/A|No|||April 2012|April 24, 2012|February 21, 2008|Yes|Yes|slow patient recruitment|No|November 29, 2011|https://clinicaltrials.gov/show/NCT00627497||159835|Studies terminated before full cohort of participants were enrolled. Data and adverse events presented are through 24 months of follow-up.
NCT00637520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006742|Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study|Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study||Duke University|No|Recruiting|July 2007|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|80|Samples With DNA|Frozen tissue, serum, whole blood, urine|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Liver Clinic, Liver Transplant Clinic, Weight Loss Surgery Clinic|March 2016|March 2, 2016|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00637520||159078|
NCT00638131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOS-ND-2007|Bosentan Use in Patients With Diabetic Nephropathy|Effect of Bosentan on Systemic and Renal Inflammatory Markers in Patients With Diabetic Nephropathy on Angiotensin II Receptor Blockers||Centre hospitalier de l'Université de Montréal (CHUM)|No|Terminated|January 2009|June 2010|Actual|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|80 Years|No|||June 2010|June 14, 2010|March 12, 2008|Yes|Yes|problem of recruitment|No||https://clinicaltrials.gov/show/NCT00638131||159032|
NCT00629967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-94045|A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients|A Randomized, Open Labeled, Active-Controlled Trial of 24-Week Versus 48-Week Courses of Peg-Interferon Alpha Plus Ribavirin for Genotype-1 Infected Chronic Hepatitis C Patients||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|April 2005|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||January 2008|February 26, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629967||159651|
NCT00639158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-275|Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 in Combination With Atorvastatin and Ezetimibe to Atorvastatin in Combination With Ezetimibe in Subjects With Combined (Atherogenic) Dyslipidemia||Abbott|No|Completed|February 2008|||October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|543|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|March 14, 2008|Yes|Yes||No|October 2, 2009|https://clinicaltrials.gov/show/NCT00639158||158953|
NCT00639366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCOG-HER-PCI|Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer|Prospective Randomised Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated With Trastuzumab (Herceptin®) for Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|February 2007|October 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Anticipated|390|||Female|18 Years|N/A|No|||December 2008|August 6, 2013|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00639366||158937|
NCT00639379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0802|Comparison of Two Toric Contact Lenses on Current Toric Wearers|A Multi-Center, Subject Masked, Randomized, Two Week Crossover Design, Investigation of the Acuvue Cypress Toric Silicone Hydrogel Lens Compared to the Bausch & Lomb SofLens66® Toric Hydrophilic Lens||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|March 13, 2008|Yes|Yes||No|June 18, 2010|https://clinicaltrials.gov/show/NCT00639379||158936|
NCT00639392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU-PT101439|Phase 1 Study of Zoledronic Acid in Sickle Cell Disease|Phase 1 Study of Zoledronic Acid in Sickle Cell Disease||Virginia Commonwealth University|Yes|Withdrawn|June 2007|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|0|||Both|18 Years|70 Years|No|||November 2011|November 10, 2011|March 14, 2008|Yes|Yes|Ended early due to inability to identify eligible subjects|No||https://clinicaltrials.gov/show/NCT00639392||158935|
NCT00639873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW # 83/2008|Artemisinin Resistance in Bangladesh|Artemisinin Resistance in Bangladesh||Medical University of Vienna|No|Completed|June 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|126|||Both|8 Years|65 Years|No|||August 2013|August 22, 2013|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639873||158898|
NCT00639899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVS-001-IL|The Effect of Spermatic Vein Embolization on Prostatic Hypertrophy|Selective Retrograde Venography and Sclerotherapy of Internal Spermatic Veins and Associated Venous Bypasses and Retro-Peritoneal Collateral in Patients With Varicocele and Hypertrophy of Prostate||Maaynei Hayesha Medical Center|No|Completed|September 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|45 Years|80 Years|No|||March 2008|March 19, 2008|March 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00639899||158897|
NCT00640107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 5431|The Purpose of This Study is to Evaluate New Commercially Available MRI Sequence and/or Hardware|Evaluation and Optimization of New MRI Hardware and Software in Existing SUNY MRI Units and Newly Installed Commercially Available Units.||State University of New York - Upstate Medical University|No|Active, not recruiting|October 2006|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|any subjects willing to undergo an MRI|May 2015|May 12, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00640107||158881|
NCT00638495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820HPC01|Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease —|Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease —||Toray Industries, Inc|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||January 2010|January 28, 2010|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638495||159004|
NCT00638742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111139|A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.|A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%.||Pfizer|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|47|||Both|N/A|N/A|No|||December 2010|December 29, 2010|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638742||158985|
NCT00639236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017/04|Effectiveness and Safety of Inhaling Hypertonic Saline in Patients With Chronic Obstructive Pulmonary Disease|Effectiveness and Safety of Inhaling Hypertonic Saline in the Functional Exercise Capacity of Patients With Chronic Obstructive Pulmonary Disease: a Randomized Trial||Federal University of São Paulo|Yes|Completed|May 2004|November 2006|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|68|||Both|40 Years|75 Years|No|||March 2008|March 19, 2008|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639236||158947|
NCT00629265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26283|Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients|Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients||Boston Medical Center|Yes|Completed|March 2008|May 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|21 Years|N/A|No|||October 2014|October 29, 2014|January 30, 2008|Yes|Yes||No|August 28, 2013|https://clinicaltrials.gov/show/NCT00629265||159704|Because of funding limitations research assistants could not be hired at most sites, and so 170 (instead of 240) subjects were enrolled. However, the results suggest additional patients would not have changed the outcome.
NCT00629278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOUMODENA-SHORT-HER|Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer|SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS||National Cancer Institute (NCI)||Recruiting|December 2007|||December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2500|||Female|18 Years|75 Years|No|||July 2009|August 6, 2013|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00629278||159703|
NCT00630370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007033|A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome|A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-Controlled, 58 Day, Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome||Procter and Gamble|No|Terminated|February 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|75 Years|No|||December 2008|June 16, 2009|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630370||159620|
NCT00630383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08025|Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.|Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.|WIRMS-1|University of Nottingham|Yes|Withdrawn|February 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||June 2012|June 13, 2012|February 27, 2008||No|superceded by another similar study|No||https://clinicaltrials.gov/show/NCT00630383||159619|
NCT00631644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080085|Eating Behavior in Adolescents|Eating Behavior in Adolescents||National Institutes of Health Clinical Center (CC)||Completed|March 2008|September 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|301|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00631644||159522|
NCT00636571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005438|Feasibility of Exercise With Post-Op Lung Cancer Patients|Determining the Feasibility of Post-Operative Training for Patients Diagnosed With Non-Small Cell Lung Cancer||Duke University|No|Completed|March 2006|March 2008|Actual|September 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|21|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00636571||159151|
NCT00636909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P002293|Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders|Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders|MINI HEME|Beth Israel Deaconess Medical Center|Yes|Completed|July 1999|||March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|65 Years|No|||February 2016|February 5, 2016|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00636909||159125|
NCT00636896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID-US-X297|Effects of Modafinil on Olanzapine Weight Gain|A Comparison of the Effects of Modafinil on Olanzapine Associated Eating Behaviors in Normal Human Subjects||Neuropsychiatric Research Institute, Fargo, North Dakota|No|Completed|July 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2008|March 10, 2008|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636896||159126|
NCT00629980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-105|Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis|A Multi-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone in Subjects With Blepharitis||Merck Sharp & Dohme Corp.||Completed|February 2008|||September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629980||159650|
NCT00630266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47-1389|Confirmation Trial of the Acorn CorCap Cardiac Support Device (CSD) at the Same Time as Mitral Valve Repair|Clinical Evaluation of Acorn CorCap Cardiac Support Device Concomitant to MVR - A Confirmatory Trial|MVR + CorCap|Acorn Cardiovascular, Inc.|No|Recruiting|January 2008|||December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|80 Years|No|||June 2009|June 16, 2009|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630266||159628|
NCT00638898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03112|Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor|Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors||City of Hope Medical Center|Yes|Active, not recruiting|December 2006|||April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|6 Months|40 Years|No|||November 2015|November 4, 2015|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00638898||158973|
NCT00639171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 4909|Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant|Clinical Implementation and Evaluation of MR Spectroscopy for Breast Cancer Detection||State University of New York - Upstate Medical University|No|Completed|November 2005|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|13|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from two ongoing clinical studies of the breast at SUNY Upstate        Medical University.|December 2015|December 2, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639171||158952|
NCT00630500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEMPDD-130206|Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)|A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies|MEMPDD|Helse Stavanger HF|Yes|Completed|February 2006|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|N/A|N/A|No|||February 2009|July 27, 2015|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00630500||159610|
NCT00630825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12068|A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus|The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus|EGO|Eli Lilly and Company|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|262|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|February 28, 2008|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00630825||159585|
NCT00639652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16/2008BO2|Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970|Observational Study: Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970||University Hospital Tuebingen|No|Enrolling by invitation|December 2007|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|Samples Without DNA|Paraffinized histology blocks and sections.|Both|N/A|N/A|No|Probability Sample|BCCs excluded from the randomized trial NCT00515970|March 2008|March 14, 2008|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639652||158915|
NCT00631137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584274|Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men Receiving Glucocorticoids for Newly Diagnosed High-Grade Glioma|A Randomized, Controlled Comparative Trial to Determine if Testosterone Gel Prevents Steroid Related Weakness in Brain Cancer Patients||National Cancer Institute (NCI)||Terminated|January 2008|||September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|60|||Male|18 Years|N/A|No|||March 2008|September 29, 2008|March 6, 2008|||Study terminated due to low accrual.|No||https://clinicaltrials.gov/show/NCT00631137||159561|
NCT00631150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01035|A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy|A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy||UCB Pharma|No|Completed|March 2003|July 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|16 Years|N/A|No|||September 2009|November 14, 2013|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631150||159560|
NCT00631449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H52899-31393-03|Raltegravir Intensification in HIV-infected Patients|Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response||University of California, San Francisco|Yes|Completed|February 2008|March 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|February 28, 2008|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00631449||159537|
NCT00639015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1282|Phenylephrine in Septic Shock|Phenylephrine Versus Norepinephrine in Septic Shock: Effects on Systemic and Regional Hemodynamics. A Randomized, Controlled, Trial||University of Roma La Sapienza|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2008|August 15, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00639015||158964|
NCT00639249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME1-2|Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke|A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Phase IIa Study of Safety and Motor Function Restoration in Subjects Treated With SA4503 Following Acute Ischemic Stroke||M's Science Corporation|Yes|Completed|February 2008|||June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||July 2009|July 28, 2009|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639249||158946|
NCT00636545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPK109|Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors|A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of Genasense Administered as a 2-hour Intravenous Infusion to Subjects With Solid Tumors||Genta Incorporated|No|Completed|May 2007|March 2010|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|N/A|No|||January 2009|April 4, 2012|October 11, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00636545||159153|
NCT00629811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0036|Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women|A Double-Blind, Placebo-Controlled, Randomised Dose Ranging Trial to Investigate the Efficacy of Two Different Dosing Regimens of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers.||Renovo|No|Completed|September 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|78|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2008|February 26, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629811||159663|
NCT00631319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMT 1077-302|A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic OA Pain|A Phase III, Flexible Dose Titration Followed by a Randomized Double-Blind Study of Controlled Release OROS Hydromorphone HCL Compared to Placebo in Patients With Chronic OA Pain|OA Pain|Mallinckrodt|No|Completed|February 2008|June 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|200|||Both|30 Years|80 Years|No|||March 2012|March 20, 2012|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631319||159547|
NCT00631332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO1-AG-9-2115|Women's Health Initiative Study of Cognitive Aging|Effects of Hormone Replacement Therapy on Cognitive Aging: Women's Health Initiative Study of Cognitive Aging (WHISCA)|WHISCA|Wake Forest School of Medicine|Yes|Active, not recruiting|July 1999|June 2008|Anticipated|September 2007|Actual|N/A|Observational|N/A|||Actual|2303|||Female|65 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|A subset of women who were enrolled in the Women's Health Initiative Memory Study (WHIMS),        who are at least 65 years old and not diagnosed with any type of dementia.|February 2008|February 28, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631332||159546|
NCT00640250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mekos 07 2P3.2 201|Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response|Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study||Allerderm|No|Completed|April 2008|September 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|18 Years|N/A|No|||May 2010|February 19, 2013|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640250||158870|
NCT00640263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12174 PROMISE-PEP|Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding|A Randomised Controlled Trial Comparing the Efficacy of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir (LPV/r) Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|December 2009|February 2014|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1500|||Both|N/A|9 Days|No|||April 2014|April 11, 2014|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00640263||158869|
NCT00640549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581040|Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus|Impact of Atorvastatin on the Distribution, Composition, and Metabolism of LDL and HDL Subfractions: A Double-Blind Placebo-Controlled Phase IV Study With Patients Suffering From Combined Hyperlipidemia and Diabetes. Atorvastatin and LDL Profile in NIDDM (ALPIN Study)|ALPIN|Pfizer|No|Terminated|March 2003|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|35 Years|75 Years|No|||March 2008|March 28, 2008|March 14, 2008|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00640549||158847|
NCT00636935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARPCP001|Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)|Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of >70 at Presentation.||George Washington University|No|Withdrawn|February 2008|August 2013|Actual|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|February 28, 2008||No|No patient completed protocol|No||https://clinicaltrials.gov/show/NCT00636935||159123|
NCT00636922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C24112|Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia|A Phase I Dose Finding Study of Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia (AML) Unfit for Intensive Induction Chemotherapy||Bayside Health|No|Active, not recruiting|February 2010|January 2014|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00636922||159124|
NCT00637195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111567|Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)|Evaluation of the Immunogenicity and Safety of a Commercially Available Vaccine When Co-administered With GlaxoSmithKline Biologicals' HPV Vaccine (580299) in Healthy Female Subjects.||GlaxoSmithKline||Completed|March 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|152|||Female|20 Years|25 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|February 28, 2008|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00637195||159103|
NCT00638625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 5376|Correlation of X-ray and Pathology With Needle Biopsy of Lung Tumors|Pilot Study of Radiologic-Pathologic Correlation in Lung Tumors Based on Core Needle Biopsy||State University of New York - Upstate Medical University|No|Withdrawn|January 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Study subjects will be recruited among patients who are referred for percutaneous needle        biopsy of a suspected malignant lesion in the lung. Consecutive patients who meet the        eligibility criteria will be offered enrollment until the study accrual target has been        met.|May 2015|May 12, 2015|March 12, 2008||No|Due to specimen collection difficulties; this study has been terminated|No||https://clinicaltrials.gov/show/NCT00638625||158994|
NCT00638157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-010|Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)|A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis||Cubist Pharmaceuticals LLC|No|Terminated|March 2008|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|March 12, 2008|No|Yes|commitment completed|No|March 4, 2013|https://clinicaltrials.gov/show/NCT00638157||159030|As the study was terminated prematurely, conclusions that can be drawn from the efficacy results are limited.
NCT00638417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4..2005.1527a|Treatment and Rehabilitation of Patients With Hip Arthroplasty to Regain Walk and Work Efficiency and Quality of Life|Treatment and Rehabilitation of Patients With Hip Arthroplasty to Regain Walk and Work Efficiency and Quality of Life||Norwegian University of Science and Technology|No|Completed|January 2006|November 2007|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||October 2008|October 1, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00638417||159010|
NCT00630279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S339.2.001|Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis|A Multi-center, Single-blind, Parallel-design, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate Oral Recombinant Microbial Lipase Efficacy in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis||Solvay Pharmaceuticals|No|Terminated|February 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|N/A|No|||August 2009|August 4, 2009|February 22, 2008||No|This trial discontinued March 7,2009 due to high screen failure rate.|No||https://clinicaltrials.gov/show/NCT00630279||159627|
NCT00630240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960297|Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation by Transcatheter Arterial Chemoembolization|Investigation the Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation in Patients With Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|February 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|53|Samples Without DNA|plasma|Both|20 Years|80 Years|No|Non-Probability Sample|hepatocellular carcinoma caused by hepatitis B or C|July 2009|August 30, 2009|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00630240||159630|
NCT00630838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL-N007177|Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)|Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)||University of Michigan|Yes|Completed|September 2006|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|105|||Both|1 Month|12 Months|No|||February 2008|July 12, 2011|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630838||159584|
NCT00630851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2501017|A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes|A Six-month, Multicenter, Double-blind, Parallel, Placebo-controlled Study of the Effect on Global/Behavioural/ADL Functions and Tolerability of Aricept in Patients Wtih Severe Alzheimer's Disease Living in an Assisted Care Facility||Pfizer|Yes|Completed|October 2002|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|249|||Both|50 Years|N/A|No|||March 2015|March 4, 2015|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630851||159583|
NCT00630786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060332|Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study|A Phase 1b/2 Trial of AMG 655 in Combination With Panitumumab in Subjects With Metastatic Colorectal Cancer||Amgen|No|Completed|January 2008|November 2010|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|February 28, 2008|No|Yes||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00630786||159588|
NCT00630799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP/C/04/PRO|Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients|Efficacy and Safety of a New Leuprolide Acetate 17 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients||GP-Pharm|No|Terminated|May 2008|July 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Male|18 Years|N/A|No|||September 2010|September 7, 2010|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630799||159587|
NCT00630812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-CF-302|Long Term Administration of Inhaled Mannitol in Cystic Fibrosis|Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study||Pharmaxis|Yes|Completed|September 2008|November 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|318|||Both|6 Years|N/A|No|||August 2012|August 6, 2012|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630812||159586|
NCT00631462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-TG101348-001|A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis|A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis||TargeGen|No|Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||October 2009|October 22, 2009|January 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631462||159536|
NCT00631475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-322|Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443|Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)|BUILD OL|Actelion|No|Completed|April 2008|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||March 2015|September 9, 2015|February 12, 2008|No|Yes||No|June 19, 2012|https://clinicaltrials.gov/show/NCT00631475||159535|
NCT00631748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA1 42|Quetiapine for the Reduction of Cocaine Use|A Double-Blind, Placebo-Controlled Trial of the Efficacy of Quetiapine for the Reduction of Cocaine Use|AZC|Seattle Institute for Biomedical and Clinical Research|Yes|Completed|February 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||March 2014|March 3, 2014|March 3, 2008|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00631748||159514|1) High number of drop-outs (68%) means that analyses are limited by a lack of power. 2) More males than females included-may reflect differences in cocaine drug usage between the sexes.
NCT00639028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 07 02|Comparative Study of Two Radiological Modalities, Ultrasonography Versus Stress Radiography, in the Urgent Care and Prognosis of Lateral Ankle Sprain (TALOS)|Comparative Study of Two Radiological Modalities, Ultrasonography Versus Stress Radiography, in the Urgent Care and Prognosis of Lateral Ankle Sprains.|TALOS|University Hospital, Grenoble|Yes|Completed|November 2007|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|390|||Both|18 Years|55 Years|No|||January 2014|January 22, 2014|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00639028||158963|
NCT00636870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455_4124|Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine|A Randomized, Double-blind, Repeat-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Desloratadine (Clarinex®) Compared to Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine.||Sanofi||Completed|February 2003|January 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|220|||Both|18 Years|55 Years|No|||January 2011|January 10, 2011|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636870||159128|
NCT00636883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC07/031|Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer|Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer|GEMOX-T|National Guard Health Affairs|Yes|Terminated|January 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||January 2014|January 19, 2014|March 8, 2008||No|slow accrual rate|No||https://clinicaltrials.gov/show/NCT00636883||159127|
NCT00630123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-252-06|Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation(TMS) on Brain Derived Neurotrophic Factor (BDNF) in Depressed Patients.|Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) on Serum Levels of Brain Derived Neurotrophic Factor in Depressed Patients.||Queen's University|No|Completed|November 2006|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|36|Samples Without DNA|serum frozen|Both|18 Years|65 Years|No|Non-Probability Sample|Adults patients with current major depressive disorder or bipolar depression who are to        receive either ECT or TMS.|December 2015|December 14, 2015|February 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00630123||159639|
NCT00631033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-511-230108|DZX Mediated Insulin Suppression in Obese Men|Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III||Rijnstate Hospital||Completed|July 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|51|||Male|25 Years|50 Years|No|||November 2014|November 5, 2014|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631033||159569|
NCT00640276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP_PTV_706|Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome|A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome|ProPit|JW Pharmaceutical|Yes|Completed|April 2008|June 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|75 Years|No|||March 2012|March 28, 2012|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00640276||158868|
NCT00640562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00031|Quetiapine Extended Release Depression Symptoms|Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study|ExAttitude|AstraZeneca|No|Completed|February 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|65 Years|No|||May 2012|May 17, 2012|March 17, 2008|Yes|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00640562||158846|Multicentre, randomized, open-label, flexible dose, parallel group, non inferiority
NCT00636584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0048|Clinical Study Investigating the Effect of Sodium Nitroprusside Infusion on Thyroidal Function|Does Sodium Nitroprusside Infusion Affect Thyroidal Function in Patients Undergoing Coronary Artery Bypass Grafting, a Prospective Randomized Clinical Trial.||Kavaklıdere Umut Hospital|No|Recruiting|February 2008|March 2008|Anticipated|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|106|||Both|30 Years|85 Years|No|||March 2008|March 7, 2008|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636584||159150|
NCT00636597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Buff VAMC 001|A Prospective Evaluation of Same Day Bidirectional Endoscopy for Occult Bleeding|Prospective Evaluation of Same Day Bidirectional Endoscopy for Occult Bleeding||VA Office of Research and Development|No|Terminated|April 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Outpatients referred for GI consult due to occult bleeding (iron deficiency or FOBT        positivity)|October 2011|October 19, 2011|March 7, 2008||No|Not able to find enough eligible patients (200) in last 4 years.|No||https://clinicaltrials.gov/show/NCT00636597||159149|
NCT00637234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC-SCZ CTRI476BDE06|Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia|Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia|OXC-SCZ|University of Cologne|Yes|Completed|July 2004|July 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||July 2008|July 23, 2008|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00637234||159100|
NCT00637247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-019|A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer|A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)||AmpliMed Corporation|Yes|Completed|April 2008|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|March 10, 2008|Yes|Yes||No|September 17, 2010|https://clinicaltrials.gov/show/NCT00637247||159099|
NCT00637208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVS-002-IL|Sclerotherapy of Internal Spermatic Veins in Patients With Varicocele and Localized Prostate Cancer|Selective Retrograde Venography and Sclerotherapy of Internal Spermatic Veins and Associated Venous Bypasses and Retro-Peritoneal Collateral in Patients With Bilateral Varicocele and Localized Prostate Cancer||Maaynei Hayesha Medical Center|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|45 Years|75 Years|No|||March 2008|March 14, 2008|March 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637208||159102|
NCT00637221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPL-2009-2-FEN-001|Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome|An Open Label Exploratory Study to Investigate the Safety and Effects of NPL-2009 ( 50 mg - 150 mg Single Dose) on Prepulse Inhibition Tests and Continuous Performance Tasks, in Adults With Fragile X Syndrome||Neuropharm|Yes|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|45 Years|No|||April 2012|April 26, 2012|March 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637221||159101|
NCT00637819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWA486_6014|Leflunomide in Systemic Lupus Erythematosus|A Randomized, Double-Blind, Placebo Controlled Clinical Trial of Leflunomide in Systemic Lupus Erythematosus (SLE)||Sanofi||Completed|January 2003|July 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||March 2008|March 27, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00637819||159055|
NCT00629954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFA-001|Abuja Heart Study: Prospective Epidemiological Investigation of Cardiovascular Diseases|Abuja Heart Study (AHS) is a Multi-site Prospective Epidemiological Investigation of Cardiovascular Disease (CVD) .|AHS|Healthsystem Plus|Yes|Recruiting|November 2009|November 2016|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Abuja residents from the rural and metropolitan area.|August 2012|September 25, 2013|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629954||159652|
NCT00627159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA3840015|ICA-CHAMP: Indo-Central Asian Cardiovascular Health Assessment and Management Program|ICA-CHAMP: Indo-Central Asian Cardiovascular Health Assessment and Management Program|ICA-CHAMP|University of Calgary|No|Active, not recruiting|May 2007|June 2008|Anticipated|April 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|375|||Both|45 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 20, 2008|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00627159||159860|
NCT00627419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP159|A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma|A Phase 2, Open-Label, Single-Arm, Multicenter Study Evaluating the Safety and Antitumor Activity of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90 (HSP90), in Patients With Metastatic Melanoma||Infinity Pharmaceuticals, Inc.|No|Terminated|February 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|February 21, 2008|Yes|Yes|Study closed & recruitment will not recommence|No||https://clinicaltrials.gov/show/NCT00627419||159841|
NCT00630227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-C07-002|Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study|Phase 2 Study of the 20 mL Biologic Lung Volume Reduction (BLVR) System in Patients With Homogeneous or Upper Lobe Predominant Emphysema||Aeris Therapeutics|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|40 Years|N/A|No|||October 2011|October 21, 2011|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630227||159631|
NCT00630513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T.E.A. Study|T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam|A Prospective, Double-blind, Multi Center, Randomized Clinical Study to Compare the Efficacy and Safety of Ertapenem 3 Days Versus Ampicillin-Sulbactam 3 Days in the Treatment of Localized Community Acquired Intra-abdominal Infection (IAI). (T.E.A. Study Three Days Ertapenem vs Three Days Ampicillin- Sulbactam)|TEA|University of Bologna|No|Completed|January 2008|December 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||September 2008|August 17, 2011|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00630513||159609|
NCT00631189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00068|Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients|Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Subjects With Type IIa and IIb Hypercholesterolaemia|CAP-Chol|AstraZeneca|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|668|||Both|18 Years|N/A|No|||June 2011|November 25, 2013|February 28, 2008|Yes|Yes||No|March 11, 2010|https://clinicaltrials.gov/show/NCT00631189||159557|As the recruitment target was not reached at the date initially planned, and in view of the recruitment difficulties, AstraZeneca decided not to extend the patient recruitment period and to perform only a descriptive analysis of the data.
NCT00631163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2204|Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis|A Multi-Center, Open-label, Non Comparative, Phase II Trial on Efficacy and Safety of ICL670 Given for 1 Year With Dose Adjustments Based on Serum Ferritin in Patients With Chronic Anemia and Transfusional Hemosiderosis Including an Additional 1 Year Extension.||Novartis|No|Completed|October 2007|February 2012|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|2 Years|N/A|No|||January 2016|January 29, 2016|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631163||159559|
NCT00631176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-8-4931|"Just-In-Time Training" in Pediatric Airway Management|Effectiveness of "Just-In-Time" Training With/Without a High Fidelity Simulation on Patient Safety in Airway Management in Pediatric Intensive Care Unit|JIT|Children's Hospital of Philadelphia|No|Completed|June 2007|December 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Both|N/A|N/A|No|||January 2010|January 7, 2010|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631176||159558|
NCT00627107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RW-002|A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit|Study of the ReWalk Motorized Exoskeleton Suit That Enables Individuals With Lower Limbs Impairment to Walk and to Perform Other Basic Mobility Functions.|RW|Argo Medical Technologies Ltd.|Yes|Completed|February 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|6|||Both|18 Years|55 Years|No|||November 2010|November 27, 2010|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00627107||159864|
NCT00627120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT001|Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects|A Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety and Pharmacokinetics of VGX-1027 in Healthy Subjects||VGX Pharmaceuticals, LLC|No|Completed|February 2008|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 8, 2009|January 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00627120||159863|
NCT00627380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003083|Yoga for the Management of HIV-Metabolic Syndromes|Yoga for the Management of HIV-Metabolic Syndromes||Washington University School of Medicine|Yes|Completed|November 2005|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||July 2010|July 23, 2010|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00627380||159844|
NCT00640029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060409|Evaluation of the Prosthetic Disc Replacement|Medico-economic Evaluation of the Prosthetic Replacement of the Lumbar and Cervical Intervertebral Disc|EVA|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|February 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|301|||Both|20 Years|65 Years|No|||March 2015|March 6, 2015|February 15, 2008||No|Insuffisent recruitment|No||https://clinicaltrials.gov/show/NCT00640029||158887|
NCT00640510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9622|A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia|A Placebo-Controlled, Double-Blind Confirmatory Study of Rapid-Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia||Eli Lilly and Company|No|Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|20 Years|64 Years|No|||August 2009|August 26, 2009|March 18, 2008|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00640510||158850|
NCT00640523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-210|Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)|Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)||BioCryst Pharmaceuticals|Yes|Completed|March 2008|November 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640523||158849|
NCT00639834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1342-01|Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Phase 1, Multicenter, Single-dose, Dose-escalation, Safety and Tolerability Study of MDX-1342 (Anti-CD19 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis|MDX1342-01|Bristol-Myers Squibb|Yes|Completed|February 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|January 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00639834||158901|
NCT00631046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2007-0088|Essential Fatty Acids During Complementary Feeding|The Importance of Increasing Intake of Essential Fatty Acids During Complementary Feeding on Infant Growth and Body Composition, Intestinal Health, Immune Function and Risk Markers for Later Metabolic Complications.|EFiON|University of Copenhagen||Completed|February 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|8 Months|19 Months|Accepts Healthy Volunteers|||July 2009|July 14, 2009|February 28, 2008||||No||https://clinicaltrials.gov/show/NCT00631046||159568|
NCT00640055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP03|Verbal Autopsy to Assess Early Neonatal Death and Stillbirth|Using Verbal Autopsy to Determine Cause of Stillbirths and Early Neonatal Deaths Within the NICHD Global Network|VA|NICHD Global Network for Women's and Children's Health|Yes|Completed|July 2007|July 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|7 Days|Accepts Healthy Volunteers|||July 2014|July 29, 2014|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00640055||158885|
NCT00640289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND5986|Clinical Trial of Factor XIII (FXIII) Concentrate|Clinical Research Study of Factor XIII Concentrate From Human Plasma Fibrogammin P in Patients With Factor XIII Deficiency||Children’s Hospital of Orange County|No|Completed|January 2000|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|N/A|N/A|No|||March 2008|February 9, 2015|March 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00640289||158867|
NCT00640575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sais-201204|Subacromial Ultrasound-guided or Systemic Steroid Injection for Rotator Cuff Disease, a Randomized Double Blinded Study|Subacromial Ultrasound-guided or Systemic Steroid Injection for Rotator Cuff Disease, a Randomized Double Blinded Study||Oslo University Hospital|Yes|Completed|March 2005|December 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||March 2005|July 3, 2011|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00640575||158845|
NCT00636610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4429g|A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer|A Randomized, Placebo-Controlled Phase II Study of Vismodegib (GDC-0449, Systemic Hedgehog Antagonist) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer||Genentech, Inc.||Completed|May 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|199|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|March 5, 2008|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00636610||159148|
NCT00636948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 99039|Rectal Cancer Trial On Defunctioning Stoma|Rectal Cancer Trial On Defunctioning Stoma|RECTODES|Rectal Cancer Trial on Defunctioning Stoma Study Group|Yes|Completed|December 1999|||June 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|234|||Both|18 Years|N/A|No|Probability Sample|Patients operated for rectal cancer in whom low anteriror resection with or without        preoperative adjuvant treatment was the planned treatment, who did not have any        intraoperative adverse events and who had accepted participation.|March 2008|March 10, 2008|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636948||159122|
NCT00638404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain Prediction|Severity Postoperative Pain Prediction|Predicting Severity of Postoperative Pain After Surgery||Wake Forest School of Medicine|Yes|Terminated|August 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|300|||Female|18 Years|N/A|No|Non-Probability Sample|scheduled for elective cesarean section, non-pregnant subjects scheduled for inpatient        gynecological surgeries|September 2009|February 1, 2010|March 12, 2008||No|Further evaluation determined it was not feasible to enroll the post-partum tubal ligation    group at our facility|No||https://clinicaltrials.gov/show/NCT00638404||159011|
NCT00638092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/S0501/31|A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years|A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants With Follow-up at 2 Years|I2S2|University of Oxford|Yes|Completed|March 2010|May 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1275|||Both|N/A|42 Hours|No|||May 2015|May 15, 2015|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00638092||159034|
NCT00638118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455A_4146|Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen|A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen||Sanofi||Completed|February 2003|May 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|48|||Both|15 Years|55 Years|No|||January 2011|January 10, 2011|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00638118||159033|
NCT00629707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS048610|Cerebral Edema in Pediatric Diabetic Ketoacidosis|Cerebral Edema in Pediatric Diabetic Ketoacidosis||University of California, Davis|Yes|Completed|June 2008|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|18 Years|No|||September 2012|September 12, 2012|March 4, 2008||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00629707||159671|Study terminated after enrollment of 20 subjects. Review of data from these subjects showed minimal difference between groups and substantial variability suggesting that a larger sample would be very unlikely to show significant differences.
NCT00630253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2000-09|Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia|A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|February 2000|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|59 Years|No|||January 2016|January 21, 2016|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630253||159629|
NCT00630526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-00696|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2008|||||N/A|N/A|N/A||||||||||||||April 29, 2008|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630526||159608|
NCT00630539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-50717|A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women|Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A Phase II Dose Ranging, 12-Week, Randomized , Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 5 mg, 15 mg and 30 mg Daily Doses With Placebo||Shionogi Inc.||Completed|August 2007|February 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|126|||Female|40 Years|80 Years|No|||March 2013|May 21, 2013|February 28, 2008|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00630539||159607|
NCT00630877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-229|Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin|A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan® Plus Acetylsalicylic Acid (ASA), Niaspan® Plus ASA Placebo or Niaspan® Placebo Plus ASA Placebo Daily for Six Weeks||Abbott|No|Completed|February 2008|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|276|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|February 29, 2008|Yes|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00630877||159581|
NCT00631202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA_EPO_3|Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia|Single-Center, Open-Label, Sequential Trial to Test the Efficacy, Safety and Tolerability of Epoetin Alfa in Patients With Friedreich's Ataxia||Federico II University|No|Completed|February 2008|June 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|50 Years|No|||May 2010|May 26, 2010|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631202||159556|
NCT00631488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0893-015|A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)|A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK0893 in Combination With Sitagliptin or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|146|||Both|21 Years|65 Years|No|||February 2015|February 4, 2015|February 21, 2008|Yes|Yes||No|October 7, 2011|https://clinicaltrials.gov/show/NCT00631488||159534|
NCT00631501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-47|Doxycycline for Lateral Epicondylalgia - RCT|||Kaunas University of Medicine||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|65 Years|No|||February 2008|February 27, 2008|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631501||159533|
NCT00627133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K17644|Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study|A Pilot Study Examining the Efficacy of Keppra in Acute Alcohol Related Seizure Control in the Emergency Department Setting||Medical University of South Carolina|No|Not yet recruiting|February 2008|||July 2008|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|64 Years|No|||February 2008|October 23, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00627133||159862|
NCT00627146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK-AntiCD3-02|Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients|Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients||AZ-VUB|No|Completed|June 2000|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|12 Years|45 Years|No|||September 2008|September 25, 2008|February 22, 2008||||No||https://clinicaltrials.gov/show/NCT00627146||159861|
NCT00627393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|557|Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)|High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes)|RING|New England Research Institutes|Yes|Completed|April 2008|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|114|||Both|N/A|N/A|No|||April 2014|April 16, 2015|February 28, 2008||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00627393||159843|
NCT00627406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-VN-2002-0046MCH|Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles|A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl)||Regionshospitalet Viborg, Skive|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|384|||Female|20 Years|39 Years|No|||September 2013|September 25, 2013|February 22, 2008||No||No|September 25, 2013|https://clinicaltrials.gov/show/NCT00627406||159842|
NCT00636519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT002|Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle|Botulism Antitoxin Effects on Paralysis Induced by Type A and Type B Botulinum Neurotoxins in the Extensor Digitorum Brevis Muscle||Cangene Corporation|No|Completed|February 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 22, 2011|March 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00636519||159154|
NCT00637715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8758|Once Daily Given Alfuzosin in the Treatment of BPH|Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms||Sanofi|No|Completed|October 2003|December 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Male|40 Years|N/A|No|||April 2008|April 1, 2008|March 11, 2008||||No||https://clinicaltrials.gov/show/NCT00637715||159063|
NCT00639847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|989-0030-090|This Study Compared an in Home Asthma Management Program Provided by Nurses or Respiratory Therapist|A Randomized Controlled Study to Evaluate the Role of an In Home Asthma Disease Management Program Provided by Respiratory Therapists in Improving Outcomes and Reducing the Cost of the Care||The University of Texas Health Science Center at San Antonio|No|Completed|October 1998|December 2002|Actual|December 2002|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2008|March 21, 2008|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00639847||158900|
NCT00640068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-236|Advanced Cardiovascular Imaging Consortium|Advanced Cardiovascular Imaging Consortium: A Collaborative Quality Improvement Project|ACIC|William Beaumont Hospitals|No|Completed|July 2007|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42926|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Referral from other healthcare provider or support staff (e.g. physician office, clinics),        Emergency Room, self referral with prescription|April 2014|April 2, 2014|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00640068||158884|
NCT00637832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588042|Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma|Short Chemo Radiotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab Tiuxetan (ZevalinTM) as Therapy for First and Second Relapse in Follicular Lymphoma||National Cancer Institute (NCI)||Recruiting|April 2008|||March 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||July 2009|October 6, 2009|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00637832||159054|
NCT00638144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4109|Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C|Prevention of Graft Reinfection After Liver Transplantation for HCV Related End-stage Liver Disease . Study of Humoral Anti-HCV Response||University Hospital, Strasbourg, France|No|Recruiting|February 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|blood|Both|18 Years|75 Years|No|Probability Sample|patients with resolved infection chronically infected patients|September 2015|September 29, 2015|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00638144||159031|
NCT00637546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-305|Gait and Balance of Diabetes Type 2 Patients|Efficacy of a Specific Physiotherapy Group Treatment on Gait and Balance in Patients With Diabetic Neuropathy||University Hospital, Geneva|No|Completed|September 2007|March 2009|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|N/A|N/A|No|||March 2009|January 13, 2010|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00637546||159076|
NCT00637845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311|Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)|A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy||AstraZeneca||Completed|June 2002|February 2003|Actual|February 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637845||159053|
NCT00629681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081031|A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia|Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia||Pfizer||Completed|November 2004|February 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|217|||Both|18 Years|N/A|No|||April 2011|April 22, 2011|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629681||159673|
NCT00629434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMU IRB # 4510F|A Comparison of Diabetes Group Education as Administered Through Telemedicine Versus as Administered in Person|A Comparison of Diabetes Group Education as Administered Through Telemedicine Versus as Administered in Person||State University of New York - Upstate Medical University|No|Active, not recruiting|June 2001|August 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|85 Years|No|||February 2008|March 4, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629434||159692|
NCT00629720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKM6270|Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology|Four-week, Open-label, Multicenter, Randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety, Tolerability and the Effects on Leak Point Pressure of Two Oral Doses of Alfuzosin (0.1 mg/kg/Day; 0.2 mg/kg/Day) in Children and Adolescents 2 to 16 Years-of-age With Elevated Detrusor Leak-point Pressure of Neuropathic Etiology|ALFACHIP|Sanofi||Completed|July 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|2 Years|16 Years|No|||December 2009|December 11, 2009|February 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00629720||159670|
NCT00631215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.11.0005|Effects of Hyperbaric Oxygen Therapy on Cognitive Function on Autistic Spectrum Disordered Children|Effects of Hyperbaric Oxygen Therapy on Cognitive Function on Autistic Spectrum Disordered Children||Pediatric Partners of Ponte Vedra|No|Recruiting|January 2008|October 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|6 Years|75 Years|Accepts Healthy Volunteers|||January 2008|March 6, 2008|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631215||159555|
NCT00631228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-378|XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study|XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study|XIENCE V India|Abbott Vascular|Yes|Completed|June 2008|August 2012|Actual|April 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|N/A|N/A|No|Non-Probability Sample|The group will be all consecutively enrolled patients in India treated by a broad group of        physicians at a variety of health care facilities, who consent to participate and receive        the XIENCE V® EECSS, which is expected to represent the range of clinical use during        commercialization.|August 2012|August 13, 2012|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631228||159554|
NCT00630864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX1A-201|The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis|The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis||Pfizer|No|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||January 2013|January 9, 2013|February 27, 2008|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00630864||159582|
NCT00630552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060323|A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer|A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer||Amgen||Completed|June 2007|April 2012|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|138|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630552||159606|
NCT00630890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07455|Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)|Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)||University of California, San Francisco|No|Terminated|October 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|February 28, 2008||No|investigator left UCSF and study was closed prematurely in 2008. No results to report.|No||https://clinicaltrials.gov/show/NCT00630890||159580|
NCT00631514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Pavlicevic|Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)|Relevance of the Interaction Between Antihypertensive and Antirheumatic Drugs in a Family Practice||University of Split|No|Completed|January 2005|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|88|||Both|55 Years|78 Years|No|||February 2008|March 7, 2008|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631514||159532|
NCT00631527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0684|Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer|Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|February 2008|||January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||January 2015|January 28, 2015|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631527||159531|
NCT00631540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-581|REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent|||Cook|Yes|Completed|February 2008|May 2012|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|February 28, 2008|No|Yes||No|February 11, 2011|https://clinicaltrials.gov/show/NCT00631540||159530|
NCT00628355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP10272/2007|Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment|Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial.||University of Sao Paulo|Yes|Terminated|February 2008|March 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|45 Years|No|||May 2014|May 23, 2014|February 25, 2008|No|Yes|Lidocaine injection group showed significant improvement in pain|No|September 15, 2010|https://clinicaltrials.gov/show/NCT00628355||159771|Early termination leading to small numbers of subjects analyzed.
NCT00628719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA KAMRC|Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis|A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis||Banaras Hindu University|No|Completed|February 2008|March 2009|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|2 Years|65 Years|No|||April 2009|April 2, 2009|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00628719||159744|
NCT00637728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100.2.C.006|Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients|A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects With Lung or Pancreatic Cancer||Endo Pharmaceuticals|No|Terminated|June 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|March 11, 2008|Yes|Yes|Difficulty finding the required patient population|No|January 29, 2016|https://clinicaltrials.gov/show/NCT00637728||159062|
NCT00604864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|trial_EU-0053/endometriosis|Effect of Anti TNFa Upon Deep Endometriosis Associated Pain|Anti TNFa Treatment for Deep Endometriosis Associated Pain : a Randomised Placebo Controlled Trial.|Infliximab|Katholieke Universiteit Leuven|Yes|Completed|February 2004|November 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|20 Years|45 Years|No|||January 2008|January 29, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604864||161529|
NCT00636961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2318|An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)|An Exploratory, Double Blind, Randomized, Placebo-controlled, 2-way Cross-over Study to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With COPD||Novartis|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|27|||Both|40 Years|80 Years|No|||July 2011|July 29, 2011|March 10, 2008||No||No|July 29, 2011|https://clinicaltrials.gov/show/NCT00636961||159121|
NCT00636974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR/05-025|A Randomised Comparison on the Dose Requirement Between, Levobupivacaine, Ropivacaine and Bupivacaine in Intrathecal Anaesthesia|Minimum Local Anaesthetic Dose for Intrathecal Anaesthesia: a Randomised Comparison Between Levobupivacaine, Ropivacaine and Bupivacaine||Hospital Authority, Hong Kong||Completed|January 2006|July 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|75|||Both|18 Years|N/A||||October 2013|October 22, 2013|December 19, 2007||||No||https://clinicaltrials.gov/show/NCT00636974||159120|
NCT00640081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589635|Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer|A Two-arm Phase II Randomised Trial of Intermittent Chemotherapy Plus Continuous Cetuximab and of Intermittent Chemotherapy Plus Intermittent Cetuximab in First Line Treatment of Patients With K-ras-normal (Wild-type) Metastatic Colorectal Cancer||Medical Research Council|Yes|Completed|July 2007|September 2015|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|100 Years|No|||March 2016|March 22, 2016|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00640081||158883|
NCT00636636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0062|Safety and Efficacy of Gabapentin in Postherpetic Neuralgia|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia||Depomed|No|Completed|March 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|452|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|February 21, 2008|Yes|Yes||No|October 13, 2011|https://clinicaltrials.gov/show/NCT00636636||159146|
NCT00637533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03102008-1034|A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.|A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.||Stanford University||Completed|May 2004|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|10|||Both|21 Years|80 Years|No|||January 2011|January 18, 2011|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00637533||159077|
NCT00636987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505|Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra|Post-Approval Study Protocol of the St. Jude Medical Biocor and Biocor Supra Valves||St. Jude Medical|No|Completed|April 2007|March 2016|Actual|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|N/A|No|||September 2015|March 9, 2016|March 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00636987||159119|
NCT00628875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-5022|Feasibility of Ventilation Detection Via Standard Defibrillator Pads in Mechanically Ventilated Pediatric Patients|"Feasibility of Ventilation Detection Using Thoracic Impedence Acquired Via Standard Defibrillator Electrode Pads in Mechanically Ventilated Pediatric Patients"|Vent Detection|Children's Hospital of Philadelphia|No|Completed|January 2007|December 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|||Both|6 Months|17 Years|No|Non-Probability Sample|Pediatric patients admitted to the Pediatric Intensive care Unit, Progressive Care Unit or        Operating Room at the Children's Hospital of Philadelphia|April 2010|April 12, 2010|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628875||159732|
NCT00628628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0918|Rasburicase in Patients at Risk for Tumor Lysis Syndrome|Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome||M.D. Anderson Cancer Center|Yes|Completed|January 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|N/A|N/A|No|||May 2013|May 31, 2013|February 25, 2008||No||No|May 31, 2013|https://clinicaltrials.gov/show/NCT00628628||159750|
NCT00629395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001502|Computerized Cognitive Training for Childhood Cancer Survivors|Computerized Cognitive Training for Childhood Cancer Survivors: A Pilot Study||Duke University|No|Terminated|June 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|9 Years|17 Years|No|||May 2013|May 31, 2013|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00629395||159694|
NCT00629694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01-07|Adenoidectomy, Myringotomy and Tubes' Insertion vs Adenoidectomy and Myringotomy Alone in Children With Otitis Media With Effusion and Adenoid Hypertrophy|Adenoidectomy, Myringotomy and Tubes' Insertion vs Adenoidectomy and Myringotomy Alone in Children With Otitis Media With Effusion and Adenoid Hypertrophy||Aghia Sophia Children's Hospital of Athens||Completed|September 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|3 Years|12 Years|No|||January 2012|January 20, 2012|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00629694||159672|
NCT00629421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960012|Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study|Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|January 2001|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1300|||Both|N/A|N/A|No|Non-Probability Sample|Well-dignosed patients with cirrhosis|April 2013|April 17, 2013|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629421||159693|
NCT00629993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA9722|Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities|Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities||Columbia University|Yes|Terminated|January 2004|August 2010|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Screening|1||Actual|282|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||February 2011|February 28, 2011|February 26, 2008||No|Principal Investigator left the institution|No||https://clinicaltrials.gov/show/NCT00629993||159649|
NCT00630006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-950182|Genetic Polymorphisms of Interleukin-10 and TNF-α on Outcome of HCV-Related Chronic Liver Disease|||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|January 2007|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2007|March 5, 2008|February 26, 2008||||No||https://clinicaltrials.gov/show/NCT00630006||159648|
NCT00631605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705061R|Studies of Neuroendocrine and Energy Metabolism in Patients With Eating Disorders|Studies of Neuroendocrine and Energy Metabolism in Patients With Eating Disorders||National Taiwan University Hospital|Yes|Completed|May 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|112|Samples Without DNA|serum|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with eating disorders and normal controls|March 2009|March 1, 2009|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00631605||159525|
NCT00627185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X030814016|Dental Tobacco Control.Net:Improving Practice|Dental Tobacco Control.Net:Improving Practice|DTC|University of Alabama at Birmingham|Yes|Completed|September 2003|August 2008|Actual|June 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Both|19 Years|N/A|Accepts Healthy Volunteers|||August 2010|March 5, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00627185||159858|
NCT00627432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574179|Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer|Phase 2 Randomized Study Evaluating the Efficacy of Gemcitabine With or Without Oxaliplatin in Patients With Advanced Urothelial Cancer That Cannot be Treated With Cisplatin-based Chemotherapy||National Cancer Institute (NCI)||Suspended|July 2004|||March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|100|||Both|18 Years|N/A|No|||July 2009|October 6, 2010|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00627432||159840|
NCT00627172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15559|Combined Use of Coronary MDCTA, Coronary Doppler Ultrasonography and PET Perfusion in Diagnosing Coronary Artery Disease|Combined Use of Coronary MDCTA, Coronary Doppler Ultrasonography and PET Perfusion in Diagnosis of Coronary Artery Disease|PECTUS|University of Turku|No|Completed|January 2007|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|Samples With DNA|serum|Both|40 Years|80 Years|No|Probability Sample|Patients with chest pain|August 2008|August 8, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00627172||159859|
NCT00627692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-26|Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility|A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Oral Once-Daily Prucalopride (R108512) Solution in Constipated Elderly Subjects Living in a Nursing Facility||Movetis|No|Completed|February 1999|May 2000|Actual|May 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|100|||Both|65 Years|N/A|No|||January 2008|May 28, 2008|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627692||159821|
NCT00627705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02012008-995|A Study of N-Acetyl Cysteine in Children With Autism|Double-blind , Randomized, Placebo Controlled Study of N-Acetyl Cysteine in Autism.||Stanford University||Completed|February 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Years|12 Years|No|||July 2011|July 20, 2011|February 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627705||159820|
NCT00628043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO316 JP|Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients|A Phase Ⅲ Randomized Double-Blind Placebo-Controlled Study of Epoetin Beta for the Treatment of Chemotherapy-Induced Anemia (CIA) in Cancer Patients||Chugai Pharmaceutical||Completed|May 2008|September 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|79 Years|No|||September 2009|September 17, 2009|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00628043||159795|
NCT00628056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3159|Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes|Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes|DDCM|University Hospital Birmingham|No|Recruiting|October 2006|April 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|75|||Both|16 Years|80 Years|No|||February 2008|February 24, 2008|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00628056||159794|
NCT00628069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-43|The Effect of Bench-model Training in Cognitive Learning in the Operating Room|The Effect of Bench-model Training in Cognitive Learning in the Operating Room||The Physicians' Services Incorporated Foundation||Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents enrolled in first or second year from a variety of divisions.|September 2012|September 4, 2012|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628069||159793|
NCT00628082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK 2996|Energetic Abnormalities in Heart Failure With Preserved Ejection Fraction|Energetic Abnormalities in Heart Failure With Preserved Ejection Fraction||University Hospital Birmingham|No|Recruiting|March 2006|April 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|50|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Heart Failure Clinic|February 2008|February 24, 2008|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00628082||159792|
NCT00628368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574175|Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer|Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of the EGFR in Response to Treatment With Neoadjuvant Chemoradiotherapy in Patients With Cancer of the Esophagus or Rectum||National Cancer Institute (NCI)||Recruiting|November 2005|||September 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Diagnostic|||Anticipated|160|||Both|18 Years|N/A|No|||July 2009|December 13, 2009|March 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00628368||159770|
NCT00609037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050298|Wound Repair and Body Contouring Surgery After Gastric Bypass|A Pilot/Feasibility Study on Wound Repair and Body Contouring Surgery After Gastric By-pass||Vanderbilt University|No|Completed|January 2006|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|34|||Both|18 Years|65 Years|No|Non-Probability Sample|All potential subjects presenting to the plastic surgery practice ages 18-65 will be        approached for participation|December 2015|December 10, 2015|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00609037||161222|
NCT00640614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mekos 07 7P3.2 301|Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy|Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol||Allerderm|No|Completed|April 2008|October 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|235|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 18, 2015|March 3, 2008|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT00640614||158842|
NCT00636649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007133|Escitalopram Treatment of Night Eating Syndrome|Escitalopram Treatment of Night Eating Syndrome: a Randomized Controlled Trial||Duke University|No|Completed|October 2008|July 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||February 2016|February 11, 2016|February 3, 2008|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00636649||159145|
NCT00636662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP012|FLU A+B Nasal Swab Clinical Study|Evaluation of the RAMP FLU A+B Test Versus Viral Culture Using Clinical Nasal Swab Samples From Patients With Suspected Influenza Infections|FLUA+B|Response Biomedical Corp.|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|800|Samples With DNA|mucous|Both|N/A|N/A|No|Non-Probability Sample|Nasal swab samples will be collected from subjects suspected of having influenza        infections and onset has occurred within 3 days of examination. Across the sites these        samples will be drawn from an approximately 60% pediatric patients (<21 years), and 40%        adult patients (>21 years) and it is expected that the population will be divided        approximately equally between males and females.|January 2009|January 8, 2009|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636662||159144|
NCT00628602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT8|BION Active Seating for Pressure Ulcer Prevention|BION Active Seating for Pressure Ulcer Prevention||University of Southern California|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|70 Years|No|||June 2015|June 1, 2015|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00628602||159752|
NCT00628615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-029|Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase|Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase||Maastricht University Medical Center|No|Active, not recruiting|April 2008|June 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male patients with lower urinary tract symptoms Female patients with overactive bladder        syndrome|December 2008|December 15, 2008|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00628615||159751|
NCT00628654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583063|Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants|Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer||University of California, Davis|No|Recruiting|October 2005|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|Blood samples|Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|volunteers and patients with ovarian, peritoneal, and fallopian tube cancers|January 2016|January 20, 2016|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00628654||159749|
NCT00628303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP169|A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Motavizumab Prophylaxis on Reduction of the Incidence of Serious Early Childhood Wheezing in Preterm Infants||MedImmune LLC||Withdrawn|October 2010|December 2011|Anticipated|February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|6 Months|Accepts Healthy Volunteers|||July 2012|July 30, 2012|February 20, 2008|Yes|Yes|Study never officially opened for enrollment|No||https://clinicaltrials.gov/show/NCT00628303||159775|
NCT00637260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820117|Motor Cortex Stimulation for Parkinson's Disease|Motor Cortex Stimulation for Parkinson's Disease. A Prospective Double Blind Randomized Study With Cross-over||Catholic University, Italy|Yes|Completed|December 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|13|||Both|N/A|N/A|No|||September 2015|September 1, 2015|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00637260||159098|
NCT00637273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB106 (DURATION - 2)|A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)|A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin||AstraZeneca|No|Completed|January 2008|July 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|514|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|March 6, 2008|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00637273||159097|
NCT00629148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007SSVC|Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)|Randomized Multicenter Phase II Study of Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine as First Line Chemotherapy for Patients With Metastatic Breast Cancer||Fudan University|No|Completed|August 2007|December 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|70 Years|No|||June 2011|July 6, 2011|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629148||159713|
NCT00629161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A11-3|Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease|||Fudan University||Recruiting|November 2008|||August 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|50 Years|N/A|No|||September 2009|May 26, 2010|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629161||159712|
NCT00631553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12014|Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound|Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound||University of Virginia|No|Recruiting|June 2006|December 2009|Anticipated|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 6, 2008|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631553||159529|
NCT00631566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-003-RV210|Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons|Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons|MRSA|Uniformed Services University of the Health Sciences|Yes|Active, not recruiting|May 2007|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631566||159528|
NCT00627198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTK787/ZK222584|The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors|An Open Label Phase II Study Evaluating the Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors That Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms|CPTK787|University of Iowa|Yes|Completed|December 2006|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2010|December 1, 2010|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627198||159857|
NCT00631579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD5290|Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma|Open-label, Multicenter Study of Repeated Doses of SR29142 (Rasburicase) as a Uricolytic Therapy for Hyperuricemia in Adult Patients With Leukemia or Lymphoma.||Sanofi||Completed|April 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|74 Years|No|||October 2009|October 1, 2009|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00631579||159527|
NCT00631592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ING111322|GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study|See Detailed Description||GlaxoSmithKline||Completed|February 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|February 27, 2008||||||https://clinicaltrials.gov/show/NCT00631592||159526|
NCT00627744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEGAMI|Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction|Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes.|BEGAMI|Karolinska Institutet|Yes|Completed|May 2008|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627744||159817|
NCT00627445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1858|Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Insulin Aspart 30 Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|441|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|February 22, 2008|Yes|Yes||No|March 11, 2010|https://clinicaltrials.gov/show/NCT00627445||159839|
NCT00627458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111344|Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine|Immunogenicity and Reactogenicity of GSK Bio's DTPa-HBV-IPV/Hib Vaccine When Given as a Booster Dose.||GlaxoSmithKline||Completed|February 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|219|||Both|16 Months|20 Months|Accepts Healthy Volunteers|||September 2009|September 29, 2009|February 20, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00627458||159838|
NCT00627718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMB 06-029|Assessment of Macular Edema Using HRT Technique|Assessment of Macular Edema Using HRT Technique||McGill University Health Center|No|Not yet recruiting|April 2008|July 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 29, 2008|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627718||159819|
NCT00627731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hamamatsu-18-68|Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients|Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients||Hamamatsu University|No|Completed|June 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|16 Years|80 Years|No|||October 2009|September 5, 2011|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627731||159818|
NCT00629005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5033-W|Strength Training and Stroke|Should We Train Strength or Skill in Post-Stroke Rehabilitation?||VA Office of Research and Development|No|Completed|February 2008|September 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||January 2013|January 28, 2013|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00629005||159723|
NCT00604604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-66874|Postpartum Depression Prevention Trial|An RCT to Evaluate the Effectiveness of Peer (Mother-to-Mother) Support for the Prevention of Postpartum Depression||University of Toronto|Yes|Completed|August 2004|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|702|||Female|N/A|N/A|No|||January 2008|June 2, 2015|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604604||161549|
NCT00640627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191069|Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen|A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen||Pfizer|No|Completed|December 2003|September 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|380|||Both|40 Years|N/A|No|||March 2008|April 2, 2008|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640627||158841|
NCT00636675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018745|CONNECT for Quality: A Study to Reduce Falls in Nursing Homes|Outcomes of Nursing Management Practice in Nursing Homes|CONNECT|Duke University|Yes|Recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1136|||Both|65 Years|N/A|No|||January 2016|January 25, 2016|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00636675||159143|
NCT00627965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sildenafil1|Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness|Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness||Altitude Physiology Expeditions|No|Completed|March 2003|February 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|62|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2008|February 24, 2008|February 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627965||159801|
NCT00628264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP214-CS004|Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery||Action Pharma A/S|Yes|Terminated|March 2008|June 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|75|||Both|18 Years|N/A|No|||May 2009|May 29, 2009|February 25, 2008|Yes|Yes|The study was terminated due to a considerably lower recruitment rate than anticipated|No||https://clinicaltrials.gov/show/NCT00628264||159778|
NCT00628277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-049|Methods of Weight Loss in Overweight Coronary Patients|Methods of Weight Loss in Overweight Coronary Patients||University of Vermont|Yes|Completed|October 2002|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|21 Years|90 Years|No|||February 2008|February 26, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628277||159777|
NCT00628667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-NEE-0002|Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux|A Multicenter, Double -Blind, Placebo-controlled Study to Evaluate the Effects of Esomeprazole 40mg Bid on the Signs and Symptoms of Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux||AstraZeneca||Completed|February 2002|March 2003|Actual|March 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|February 26, 2008||||||https://clinicaltrials.gov/show/NCT00628667||159748|
NCT00629135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-MW-01|Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses|Single Centre, Prospective, Comparative, Open-label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses|MEMO|Hannover Medical School|Yes|Recruiting|November 2005|August 2012|Anticipated|February 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||May 2010|June 21, 2011|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629135||159714|
NCT00628901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M9011|A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)|A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)||Boston Scientific Corporation|No|Completed|January 2006|January 2011|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||July 2012|July 2, 2012|February 25, 2008|No|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00628901||159730|
NCT00629733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-RO14-2006-01|Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers|||Rovi Pharmaceuticals Laboratories|No|Completed|December 2007|December 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00629733||159669|
NCT00629746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-EMG-01|Intraoperative Electromyographic Monitoring of the Recurrent Laryngeal Nerve in Thyroid Surgery|Intraoperative Electromyographic Monitoring of the Recurrent Laryngeal Nerve in Thyroid Surgery||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|June 2006|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|N/A|N/A|No|||May 2010|September 6, 2010|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629746||159668|
NCT00631241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0153|Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer|Histopathologic Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer Undergoing Radical Hysterectomy or Radical Trachelectomy and Pelvic Lymph Node Dissection: A Feasibility Study||M.D. Anderson Cancer Center|No|Completed|February 2008|||September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|N/A|N/A|No|||September 2012|September 26, 2012|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631241||159553|
NCT00627471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_02936|Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)|A 24 Weeks, Randomized, 2 Arms, Controlled, Multi-centre, National, Open-labeled, Parallel Study in Insulin naïve Patients With Type 2 Diabetes to Compare a Lantus Titration Algorithm vs. Physician's Standard Practice|Malbec|Sanofi|Yes|Terminated|January 2008|||March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|74 Years|No|||June 2010|June 1, 2010|February 22, 2008||No|Low recruitment in spite of strategies implemented|No||https://clinicaltrials.gov/show/NCT00627471||159837|
NCT00628121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9575A402|Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer|Clinical Pharmacological Study of NS75A for Healthy Adult Women||Nippon Kayaku Co.,Ltd.|No|Completed|April 2006|February 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|31|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||February 2008|February 25, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628121||159789|
NCT00628095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6341009|Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CE-224,535, An Antagonist Of The P2x7 Receptor, In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate||Pfizer|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2009|October 7, 2009|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628095||159791|
NCT00628108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00423|Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria.|BALL|UCB Pharma|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|6 Months|11 Months|No|||February 2015|February 18, 2015|February 22, 2008|Yes|Yes||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00628108||159790|
NCT00628381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-08|L-citrulline Supplementation During Sepsis|Arginine and Nitric Oxide (NO) Metabolism in Sepsis; L-citrulline Enteral Supplementation for the Normalisation of the Arginine-NO Metabolism||Maastricht University Medical Center|Yes|Not yet recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||September 2010|September 2, 2010|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628381||159769|
NCT00629304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 07 08|Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients|Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients With Chronic Failure of Intensive Insulin Therapy and Conventional Care. The TELEDIAB-1 STUDY|TELEDIAB-1|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|September 2007|August 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|180|||Both|18 Years|N/A|No|||August 2009|February 8, 2012|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629304||159701|
NCT00628732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012005004|A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors|A Pharmacokinetic and Phase II Study of Oral Cyclophosphamide and Oral Topotecan in Children With Recurrent and or Refractory Solid Tumors||Children's Medical Center Dallas|No|Completed|January 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|21 Years|No|||January 2009|January 27, 2009|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628732||159743|
NCT00628745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461001|Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)|Transthyretin-associated Amyloidosis Outcomes Survey (Thaos): A Global, Multi-center, Longitudinal, Observational Survey Of Patients With Documented Transthyretin (Ttr) Mutations Or Wild-type Ttr Amyloidosis|THAOS|Pfizer|No|Recruiting|July 2007|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Participants with transthyretin-associated amyloidoses (ATTR), including ATTR-PN        (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM.|March 2016|March 23, 2016|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00628745||159742|
NCT00604916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-402|Oral Care Protocol for Preventing Ventilator- Associated Pneumonia|The Effectiveness of an Oral Care Protocol in Preventing Ventilator- Associated Pneumonia for Intensive Care Unit Patient|VAP|Mackay Memorial Hospital|Yes|Completed|March 2007|January 2008|Actual|November 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|N/A|No|||January 2008|January 16, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00604916||161525|
NCT00604929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 83017|Effect of Nutrition on Muscle Protein Synthesis|The Effect of Carbohydrate and Protein Intake on Muscle Protein Synthesis During Endurance Exercise||Maastricht University Medical Center|No|Completed|August 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604929||161524|
NCT00605189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACP2005-009|A Trial Examining Cellular Energetics Related to Various Wound Treatment Therapies|A Randomized, Controlled Trial Examining Cellular Energetics Related To Various Wound Treatment Therapies||KCI USA, Inc.|No|Terminated|July 2007|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|December 20, 2007|Yes|Yes|Study no longer met business objectives|No||https://clinicaltrials.gov/show/NCT00605189||161504|
NCT00627640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27919|Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa|A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine|SETTLE|Newron||Completed|February 2009|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|549|||Both|30 Years|80 Years|No|||June 2012|March 27, 2013|February 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627640||159825|
NCT00627978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707009284|Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons|Phase II Study of Ixabepilone in Patients With Metastatic Breast Cancer and a Prospective Evaluation of Its Effects on the Ultrastructure of Neurons||Weill Medical College of Cornell University|No|Recruiting|November 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|February 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627978||159800|
NCT00627991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01282008-990|Blood Pressure Lowering in Acute Stroke Trial (BLAST)|The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Effects on Cerebral Blood Flow.||Stanford University||Withdrawn|August 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||20|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|February 22, 2008||||No||https://clinicaltrials.gov/show/NCT00627991||159799|
NCT00628004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK144WS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2008|||||N/A|N/A|N/A||||||||||||||September 3, 2015|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628004||159798|
NCT00628290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBD-CT1|Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis|Evaluation of the Antipsychotic Efficacy of the Phytocannabinoid Cannabidiol in Treating Acute Schizophrenic Psychosis. A Double-Blind, Controlled Clinical Trial|CBD-CT1|University of Cologne|No|Completed|October 2002|March 2008|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|65 Years|No|||January 2008|March 17, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628290||159776|
NCT00628914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESRC973|Brain Mechanisms and Targeting Insomnia in Major Depression|Brain Mechanisms and Targeting Insomnia in Major Depression||University of California, Los Angeles|No|Active, not recruiting|May 2008|February 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|64 Years|No|||July 2010|August 19, 2010|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628914||159729|
NCT00628888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH073946|A Waitlist-Controlled Trial of the Unified Protocol for the Treatment of Emotional Disorders in Adolescents|Treatment of Emotional Disorders in Adolescence||University of Miami|No|Completed|July 2006|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|12 Years|18 Years|No|||December 2014|December 18, 2014|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00628888||159731|
NCT00629447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008486|Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients|A Pilot Trial of Innohep (Tinzaparin) Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients||Duke University|No|Completed|February 2004|October 2009|Actual|March 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00629447||159691|
NCT00630565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2006-13|Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia|Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|July 2006|December 2018|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|70 Years|No|||January 2016|January 22, 2016|March 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630565||159605|
NCT00630903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF99|PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides|Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa.|MF99|Madrilenian Group of Cutaneous Lymphomas|No|Terminated|January 2000|||January 2003|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|70 Years|No|||February 2008|March 6, 2008|February 28, 2008||No|Insufficient accrual|No||https://clinicaltrials.gov/show/NCT00630903||159579|
NCT00631618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA6181DN|Clinical Trial of Sutent to Treat Metastatic Melanoma|A Phase II Trial of Sutent in Metastatic Melanoma Patients With KIT Aberrations.||California Pacific Medical Center Research Institute||Completed|September 2007|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2014|February 22, 2014|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00631618||159524|
NCT00627237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-0939|Improving Executive Functioning After Traumatic Brain Injury (TBI): A Trial of the "Short Term Executive Plus" Program|Short-Term Executive Plus (STEP): A Randomized Controlled Trial of Short Term Intensive Cognitive Rehabilitation.|STEP|Icahn School of Medicine at Mount Sinai|No|Completed|January 2008|July 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00627237||159855|
NCT00627484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2401|Changes in Insulin Sensitivity After Weight Loss|Changes in Insulin Sensitivity After Weight Loss Induced by Diet or Bariatric Surgery||Columbia University|Yes|Recruiting|March 2005|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|110|Samples With DNA|The researchers may want to retain your blood and/or tissue sample(s) so that additional      research studies can be done now or in the future.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited by physician referral and from outpatient obesity, bariatric        surgical clinics and endocrinology clinics at Columbia University Medical Center as well        as from the Medical Center Community and metropolitan area via IRB-approved flyers and        internet postings. Subjects will also be recruited from the following website:        www.craigslist.com using the same posting format of the IRB-approved flyers.|October 2015|October 13, 2015|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00627484||159836|
NCT00627770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HECVSante01|Lower Leg Edema Evaluation After Total Knee Arthroplasty Using Bioimpedance|Validation of a Procedure Using Bioimpedance to Measure the Edema of Lower Leg of Patients After Total Knee Surgery||Haute Ecole Cantonale Vaudoise de Santé|No|Completed|January 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|34|||Both|16 Years|N/A|No|||January 2009|January 28, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00627770||159815|
NCT00627757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-2007-0069|Antipsychotic Medicine and Metabolic Syndrome|Changes in Enteroendocrine and Neuroendocrine Axes in Patients With Weight Gain After Treatment With Antipsychotics|AMMS1|Glostrup University Hospital, Copenhagen|Yes|Recruiting|February 2008|December 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples Without DNA|whole blood, serum, plasma|Male|18 Years|45 Years|No|Probability Sample|50 patients and 100 control persons. Patients should be treated with minimum one        antipsychotic drug and hospitalized or treated as out-patients at Glostrup, Ballerup or        Gentofte hospitals.        Controls will be chosen from the database at Institute of Health and Prevention, Glostrup.|July 2010|July 29, 2010|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627757||159816|
NCT00628407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-5023|Effects of Sternal Wall Pressure in Children|Effect of Gentle Sternal Chest Wall Pressure on Intrathoracic Pressure During Mechanical Ventilation in Children.|SWP|Children's Hospital of Philadelphia|No|Completed|January 2007|December 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|6 Months|7 Years|No|Non-Probability Sample|Any patient in the Pediatric Intensive Care Unit (PICU), Progressive Care Unit (PCU) and        Operating Room (OR) settings involving stable, mechanically ventilated children in the        Children's Hospital of Philadelphia.|March 2011|March 9, 2011|February 26, 2008||No||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00628407||159767|
NCT00628420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082004-051|Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics|A Randomized, Double Blind, Placebo Controlled, Single Oral Dose Study to Demonstrate the Safety, Tolerability, and Pharmacokinetics of ACP-104 (N-desmethylclozapine) in Schizophrenia, or Other Psychotic Disorders.|ACP-104|University of Texas Southwestern Medical Center|Yes|Completed|January 2005|October 2007|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|45|||Both|20 Years|50 Years|No|||February 2008|June 27, 2011|February 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00628420||159766|
NCT00628394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803-476|Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation|Cognitive Treatments in Schizophrenia||University of Texas Southwestern Medical Center|No|Completed|September 2003|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|119|||Both|18 Years|60 Years|No|||June 2012|June 21, 2012|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00628394||159768|
NCT00628771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074399|Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women|Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study||Yale University|Yes|Completed|August 2008|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1233|||Female|14 Years|21 Years|No|||February 2014|February 4, 2014|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00628771||159740|
NCT00628758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00016|A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma|A Comparison of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5mg, 1 Inhalation Two Times a Day (b.i.d.) Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults a -26-week, Randomized, Open-label, Parallel-group, Multicentre Study|PASSION|AstraZeneca|No|Completed|December 2005|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|430|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|January 10, 2008|Yes|Yes||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00628758||159741|
NCT00629850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TexasState 2008-29541|Respiratory Resistance Training on Sleep Quality in Persons With Spinal Cord Injury|Concurrent Respiratory Resistance Training and Changes in Respiratory Muscle Strength and Sleep Quality in Persons With Spinal Cord Injury||Texas State University, San Marcos|No|Terminated|February 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|February 25, 2008||No|unable to recruit participants.|No|July 19, 2011|https://clinicaltrials.gov/show/NCT00629850||159660|Unable to recruit subjects for the study
NCT00629863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWORTH-COGNATE|Endoscopic Ultrasound in Diagnosing Cancer in Patients With Localized Stomach Cancer or Esophageal Cancer|Cancer of the Oesophagus or Gastricus: New Assessment of the Technology of Endosonography COGNATE||National Cancer Institute (NCI)||Completed|September 2004|January 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|||Anticipated|700|||Both|18 Years|N/A|No|||January 2009|August 6, 2013|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00629863||159659|
NCT00629291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4859-OG-CTIL|MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions.|Evaluation of Iron Overload in the Heart, Liver and Pancreas: Patients With Sickle β Thalassemia and Sickle Cell Anemia.||Sheba Medical Center|No|Completed|January 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|None Retained|No biosepcimens retained|Both|18 Years|35 Years|No|Non-Probability Sample|Sickle cell anemia and Sickle cell β thalassemia patients from dedicated outpatient        hospital clinic.|May 2010|May 9, 2010|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629291||159702|
NCT00604942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0802/73|vMII for Measurement of Oesophageal Bolus Transport and Reflux|Volume Sensitive Multichannel Intraluminal Impedance (vMII) for the Measurement of Oesophageal Bolus Transport and Reflux|vMII|Guy's and St Thomas' NHS Foundation Trust|No|Terminated|November 2007|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|4||Anticipated|140|||Both|18 Years|80 Years|No|||July 2009|July 31, 2009|January 15, 2008||No|prototype catheter never delivered|No||https://clinicaltrials.gov/show/NCT00604942||161523|
NCT00627653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0093|Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function|PET (Positron Emission Tomography) Detection of the Effects of Aging on the Human Heart (Aim #2 Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function)|PPAR|National Institute on Aging (NIA)|No|Active, not recruiting|October 2005|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627653||159824|
NCT00628693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-6-4839|Quantitative Measurement of Cardiopulmonary Resuscitation (CPR) During In Hospital Cardiac Arrest|Quantitative Measurement of Cardiopulmonary Resuscitation During In Hospital Cardiac Arrest|Q-CPR|Children's Hospital of Philadelphia|No|Completed|June 2006|November 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|89|||Both|8 Years|N/A|No|Non-Probability Sample|Cardiac arrests occurring in the Pediatric Intensive Care Unit or Emergency Department at        The Children's Hospital of Philadelphia equipped with the MRx/Q-CPR|January 2016|January 26, 2016|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628693||159746|
NCT00629187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-306|Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy|Phase I Dose Escalation Study of Temozolomide With Autologous Stem Cell Rescue for Patients With Relapsed/Refractory CNS Malignancy Including Isolated Metastatic Disease|CN-306|Tufts Medical Center|No|Terminated|April 2004|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|70 Years|No|||April 2012|April 26, 2012|February 25, 2008||No|The study was stopped due to lack of adequate enrollment.|No||https://clinicaltrials.gov/show/NCT00629187||159710|
NCT00629460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETPUL|A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors|A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors||St. Jude Children's Research Hospital|No|Completed|February 2008|April 2012|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|27|||Both|N/A|21 Years|No|Probability Sample|Pediatric patients with known or suspected malignant solid tumors found by CT to have at        least one pulmonary nodule measuring> or equal to 0.5 cm and < or equal to 3.0 cm in size        will be eligible for enrollment.|October 2012|October 16, 2012|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629460||159690|
NCT00628680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AATML2003-A|A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis|Pivotal/Phase III Multicentered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 Solution (Zuragen), and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis||Ash Access Technology|No|Active, not recruiting|July 2006|||July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|415|||Both|18 Years|N/A|No|||February 2008|March 4, 2008|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628680||159747|
NCT00629174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28_12_2005|Prevention of the Age-Related Cognitive Impairment by Exercise and Mental Activity - Berlin Bleibt Fit|Randomized, Controlled Study About the Effects of an Exercise Program and Mental Activity on the Age-Associated Impairment of Cognitive Function|BBF|Charite University, Berlin, Germany|No|Recruiting|June 2006|||December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|252|||Female|70 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 11, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629174||159711|
NCT00630045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALIC|Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis|A Phase III Study of Surgery in Combination With Neoadjuvant Chemotherapy of Oxaliplatin Plus Capecitabine in Colorectal Cancer With Respectable Liver Metastasis||Peking University People's Hospital|Yes|Recruiting|January 2008|June 2015|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|392|||Both|18 Years|75 Years|No|||February 2008|March 5, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00630045||159645|
NCT00630292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0718|Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors|Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors||University of North Carolina, Chapel Hill|No|Terminated|March 2008|December 2009|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Female|18 Years|N/A|No|||May 2010|May 10, 2010|February 28, 2008||No|Existing vessel analysis software could not be applied to breast MRI data.|No|February 3, 2010|https://clinicaltrials.gov/show/NCT00630292||159626|The software used to perform breast vessel analysis failed to detect any vessels in the breast due to the limited spatial resolution possible for breast imaging with the 1.5T Magnetic Resonance Imaging System used in the study.
NCT00630916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNPCR-01|Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve|Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve||Sorin Group USA, Inc.|Yes|Completed|November 2003|December 2007|Actual|December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|756|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|February 28, 2008|Yes|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00630916||159578|
NCT00637481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00859|A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer|A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer||National Cancer Institute (NCI)||Completed|March 2008|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|66|||Female|18 Years|72 Years|Accepts Healthy Volunteers|||May 2013|September 11, 2014|March 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00637481||159081|
NCT00627783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000.217|Do You Need to Assess Myocardial Ischemia in Type 2 Diabetes|Randomized Strategy Trial Comparing Detection of Silent Ischemia With no Detection of Silent Ischemia in Asymptomatic Patients With Type 2 Diabetes Mellitus. Effects on Cardiovascular Events.|DYNAMIT|Hospices Civils de Lyon|No|Terminated|December 2000|July 2005||July 2005||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|642|||Both|55 Years|75 Years|No|||February 2008|February 29, 2008|February 22, 2008|No|Yes|Poor recruiting status|No||https://clinicaltrials.gov/show/NCT00627783||159814|
NCT00628433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE3286-0301|Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis|A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis||Harbor Therapeutics|No|Completed|February 2008|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|27|||Both|18 Years|65 Years|No|||June 2011|June 11, 2011|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628433||159765|
NCT00628797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-200|Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis|Multizenter-Studie Zur UVA-1 Therapie für Die Hautbeteiligung Bei Systemischer Sklerodermie||University of Cologne|No|Recruiting|February 2008|November 2010|Anticipated|July 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2010|January 27, 2010|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628797||159738|
NCT00628784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-14034|Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer|Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer||Walter Reed Army Medical Center|Yes|Recruiting|March 2007|March 2012|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2008|July 22, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628784||159739|
NCT00629018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCM-SCT1|Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy|The Effects of Autologous Intracoronary Stem Cell Transplantation In Patients With End-Stage Dilated Cardiomyopathy||University Medical Centre Ljubljana|Yes|Completed|May 2006|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|80 Years|No|||April 2015|April 23, 2015|February 25, 2008||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT00629018||159722|
NCT00639301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-019|Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life|Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2008|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|473|||Both|18 Years|N/A|No|Non-Probability Sample|Adult survivors of retinoblastoma will be identified via the NCI and New York        (MSKCC)databases and offered participation in the study.|October 2015|October 26, 2015|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00639301||158942|
NCT00629538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMUHIRB20070304|Therapeutic Thoracentesis for Patients With Congestive Heart Failure and Large Pleural Effusion|Effect of Therapeutic Thoracentesis on Cardiopulmonary Function in Patients With Congestive Heart Failure Complicated With Large to Massive Pleural Effusion||Taipei Medical University Hospital|Yes|Completed|March 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2010|December 28, 2010|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629538||159684|
NCT00629551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10438|An Eight-Week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder|An Eight-Week, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Saredutant (100 mg and 30 mg) Once Daily in Combination With Paroxetine 20 mg Once Daily Compared to Saredutant Placebo in Combination With Paroxetine 20 mg Once Daily in Patients With Major Depressive Disorder|COMPASS|Sanofi|Yes|Completed|February 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|820|||Both|18 Years|65 Years|No|||March 2009|March 19, 2009|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629551||159683|
NCT00604955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLPM03|Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis|A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis||PATH|Yes|Completed|October 2007|January 2010|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2000|||Both|2 Years|55 Years|No|||October 2014|October 2, 2014|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604955||161522|
NCT00604968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05059|Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)|Caelyx(R) in Breast Cancer in the Elderly. Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer.||Merck Sharp & Dohme Corp.|No|Terminated|February 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|65 Years|N/A|No|||April 2015|April 29, 2015|January 21, 2008||No||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00604968||161521|
NCT00627354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574184|Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|Phase 2 Randomized Study Evaluating 3 Chemotherapy Regimens as Second-line Treatment in Patients With Hormone-refractory Metastatic Prostate Cancer||National Cancer Institute (NCI)||Completed|September 2006|||May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|90|||Male|18 Years|N/A|No|||July 2009|May 13, 2011|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00627354||159846|
NCT00627367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 0710359|Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain|A Randomized Controlled Trial Comparing Protocolized Versus Non-protocolized Treatment of Adult ED Patients With Acute Severe Pain||Montefiore Medical Center|No|Completed|October 2007|||October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627367||159845|
NCT00628316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMV 001 2008|Effects of Caffeine in Tinnitus|Effects of Caffeine Consumption on Tinnitus Perception||Faculdade de Medicina de Valenca|No|Completed|January 2008|December 2008|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2008|March 21, 2011|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628316||159774|
NCT00628329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11213|Vitamin A, Its Receptors and Asthma|Vitamin A, Its Receptors and Asthma: Vitamin A Levels in Serum and Expression and Responsiveness of Vitamin A Receptors in Circulating Mononuclear Cells of Asthmatics||University of Kansas Medical Center|No|Withdrawn|May 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|0|Samples With DNA|Serum without DNA, cells with DNA|Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male or female Age 18-64|May 2012|May 3, 2012|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00628329||159773|
NCT00629200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0354|Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Completed|September 2006|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629200||159709|
NCT00629772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6003|Safety and Efficacy of Infliximab in Palmoplantar Psoriasis|A Double-Blind Study on the Safety and Efficacy of Infliximab in Palmoplantar Psoriasis||Innovaderm Research Inc.|No|Completed|March 2007|July 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|February 27, 2008||No||No|April 14, 2010|https://clinicaltrials.gov/show/NCT00629772||159666|The lack of validated scales to specifically assess severity of palmoplantar psoriasis. The study was powered to detect a difference of 55 percentage points.
NCT00629759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-IT-HEP001|A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma|Phase 1 Clinical Study for Evaluating the Safety and Efficacy of a Transdermal Injection of JX-594 (Thymidine Kinase (-)/GM-CSF(+) Vaccinia Virus) Within the Tumor of Patients With Hepatic Carcinoma||Jennerex Biotherapeutics|Yes|Completed|January 2006|August 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|N/A|No|||February 2008|January 3, 2013|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629759||159667|
NCT00630019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPH0107|Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator|||Santen Inc.|No|Completed|February 2008|||October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|96|||Both|18 Years|N/A|No|||February 2009|February 4, 2009|February 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630019||159647|
NCT00630032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACS08 - UC-0140/0610|Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer|Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.|TavIx|UNICANCER|Yes|Active, not recruiting|September 2007|September 2017|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|762|||Female|18 Years|70 Years|No|||December 2014|December 14, 2014|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630032||159646|
NCT00630305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0726|Endothelial Bleb Response With Toric Lenses|Evaluation of the Short-Term Corneal Endothelial Response to Wear of Toric Soft Contact Lenses in Asian Eyes||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 19, 2008|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630305||159625|
NCT00630929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191062|Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)|A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee||Pfizer|No|Completed|January 2003|February 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|388|||Both|40 Years|N/A|No|||September 2008|September 10, 2008|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630929||159577|
NCT00630942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1559-02|Minocycline in Primary Sclerosing Cholangitis (PSC)|Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC)||Mayo Clinic|No|Completed|February 2003|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|75 Years|No|||December 2010|December 3, 2010|February 27, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00630942||159576|
NCT00635102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12449|Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects|Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects||Yale University|No|Completed|October 1997|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|40|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||March 2008|March 12, 2008|March 6, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00635102||159262|
NCT00635375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8828882|Comparative Study of Phototherapy for Hyperbilirubinemia|A Comparative Study Between BiliSoft Blue LED Fiberoptic Blanket Phototherapy, Giraffe Spot PT Phototherapy, Natus Blue LED Bank Light Phototherapy, and BiliSoft + Giraffe Spot PT Combination Therapy||GE Healthcare|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|82|||Both|N/A|1 Month|No|||January 2009|January 9, 2009|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635375||159241|
NCT00628485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT9|BION Treatment of Dysphagia After Radical Head-Neck Surgery|BION Stimulation to Improve Swallowing Function After Radical Head-neck Surgery and Follow-up Chemoradiation Therapy||University of Southern California|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|70 Years|No|||June 2015|June 1, 2015|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00628485||159761|
NCT00628498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2006-05|Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study|Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study|Treatment IND|Jazz Pharmaceuticals|No|Recruiting|December 2007|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|N/A|N/A|No|||October 2015|March 18, 2016|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628498||159760|
NCT00628810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564065|Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study||National Cancer Institute (NCI)||Recruiting|January 2007|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|108|||Both|18 Years|74 Years|No|||March 2008|February 6, 2009|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00628810||159737|
NCT00628511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6902256|Validation of Portable Monitoring Device for Diagnosing Sleep Apnea|A Validation Study of A New Diagnostic Device for Screening of Obstructive Sleep Apnea in High Risk Patient Population||Chinese University of Hong Kong|No|Completed|January 2007|February 2008|Actual|December 2007|Actual|N/A|Observational|N/A||1|Actual|175|||Both|N/A|N/A|No|Probability Sample|patients suspected of sleep apnea|February 2008|February 8, 2016|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00628511||159759|
NCT00629057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNIT-PR-001|A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer|An Open-Label, Phase I Dose Escalation Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer|BNIT-PR-001|Bavarian Nordic, Inc.|No|Completed|March 2008|September 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|75 Years|No|||June 2011|May 6, 2013|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00629057||159719|
NCT00629590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-106|Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis|A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Two Weeks in Subjects With Posterior Blepharitis||Merck Sharp & Dohme Corp.||Completed|March 2008|||July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629590||159680|
NCT00629330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6313|Dissemination of Prostate Cancer Screening to PCP's in African American Communities|Dissemination of Prostate Cancer Screening to Primary Care Physicians in African American Communities||Columbia University|Yes|Terminated|January 2004|November 2010|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Screening|1||Actual|86|||Male|45 Years|75 Years|Accepts Healthy Volunteers|||February 2011|October 12, 2015|February 26, 2008||No|Principal Investigator left the institution.|No||https://clinicaltrials.gov/show/NCT00629330||159699|
NCT00630448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708009371|Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)|Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)||Weill Medical College of Cornell University|Yes|Withdrawn|November 2008|October 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|0|Samples With DNA|Blood|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Source of subjects will be the population of individuals with known Von Willebrand Disease        and the normal population from protocol #0005004439 entitled "Evaluation of the Lungs of        Normal (Smokers, Ex-smokers, Non-smokers) Individuals with Segmental Bronchopulmonary Lung        Lavage, Bronchial Brushing, and Bronchial Wall Biopsy"|August 2010|December 9, 2015|February 27, 2008||No|Prinicipal Investigator initiated study closure.|No||https://clinicaltrials.gov/show/NCT00630448||159614|
NCT00630188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-0845|Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial|Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial||University of North Carolina, Chapel Hill|No|Completed|March 2005|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|128|||Male|40 Years|80 Years|Accepts Healthy Volunteers|||February 2008|March 5, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630188||159634|
NCT00639587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00275|Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis|A Double-blind, Parallel, Active Comparator Controlled, Randomized Trial; Comparison of the Efficacy and Safety in Children With Perennial Allergic Rhinitis of Cetirizine Tablets Versus Ketotifen Dry Syrup||UCB Pharma|No|Completed|August 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|||Actual|149|||Both|7 Years|14 Years|No|||September 2009|September 3, 2009|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639587||158920|
NCT00639600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95/CHUG/10/C2|Transplantation of Pancreatic Islets in Patients With Type 1 Diabetes Mellitus and Functional Kidney Graft|Transplantation d'îlots pancréatiques allogéniques Adultes Pour le Traitement du diabète insulinodépendant. Etude GRAGIL 1|GRAGIL1|University Hospital, Grenoble|Yes|Terminated|June 2008|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||May 2010|May 28, 2010|March 14, 2008||No|a new study has began recently|No||https://clinicaltrials.gov/show/NCT00639600||158919|
NCT00632996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM10320|Exercise and Manual Therapy for Shoulder Subacromial Impingement Syndrome|Effectiveness of Rehabilitation for Subacromial Impingement Syndrome||Virginia Commonwealth University|No|Completed|January 2008|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|75 Years|No|||December 2015|December 18, 2015|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632996||159422|
NCT00633295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107DIL02|Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor|An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor||Novartis||Completed|June 2008|||May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633295||159400|
NCT00633945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806259|Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)|Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus||University of Pennsylvania|Yes|Completed|November 2007|October 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||March 2009|February 18, 2011|March 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00633945||159350|
NCT00634283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-10-051|Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects|Physiologic Monitoring of Antidepressant Medication Effects in Normal Healthy Subjects II||University of California, Los Angeles|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver)|1||Actual|7|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2009|August 6, 2009|March 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634283||159325|
NCT00634556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0832|Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)|Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)|TSfMRI|Washington University School of Medicine|No|Completed|February 2006|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|March 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00634556||159304|
NCT00634543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012967|A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy|Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study||Janssen Korea, Ltd., Korea|No|Completed|December 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|75 Years|No|||July 2013|July 26, 2013|March 6, 2008|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00634543||159305|The study was a non-inferiority study to demonstrate that tramadol/acetaminophen did not have poorer ffectiveness as compared to gabapentin. However this could not be demonstrated because of error in the minimum significant difference set-up.
NCT00634842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3502|Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily|Effect of Two Different Fasting Blood Glucose Titration Targets in Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily in Combination With 1-3 Oral Agents|TITRATE™|Novo Nordisk A/S|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|March 6, 2008|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00634842||159282|
NCT00627809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-337|Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction|Phase 4 Study of Application of Intracoronary Low Dose Streptokinase Complementary to Standard Percutaneous Coronary Intervention in Patients With ST Elevation Acute Myocardial Infarction: Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction||Istanbul University|No|Completed|January 2007|February 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|20 Years|75 Years|No|||June 2009|June 22, 2009|February 22, 2008||||No||https://clinicaltrials.gov/show/NCT00627809||159812|
NCT00627822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL-EN|Medical Education in a Private Hospital|Patient and Companion Perspectives on Medical Education in a Non-Teaching Private Hospital||Instituto do Cerebro de Brasilia|No|Completed|March 2005|April 2006|Actual|April 2006|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|209|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Private hospital: Patient and family members|February 2008|February 22, 2008|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627822||159811|
NCT00628160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-SS-JFDEZ-1|Terlipressin in Septic Shock in Cirrhosis|Effects on Survival of Terlipressin Administration in Cirrhotic Patients With Severe Sepsis or Septic Shock. A Randomized, Open Labelled Controlled Trial||Hospital Clinic of Barcelona|No|Completed|October 2006|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00628160||159786|
NCT00629070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS 087657|Quadriceps Muscle Plasticity in Children With Cerebral Palsy|In Vivo Assessment of Quadriceps Muscle Plasticity in Children With Cerebral Palsy||Medical University of South Carolina|No|Recruiting|January 2009|May 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|7 Years|17 Years|No|||July 2010|July 30, 2010|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629070||159718|
NCT00628823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-115376|Treatment of Mild Enteropathy Celiac Disease|Treatment of Mild Enteropathy Celiac Disease|TMCD|University of Tampere|No|Completed|March 2003|December 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|16 Years|N/A|No|||December 2008|December 3, 2008|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00628823||159736|
NCT00629616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARMINA02|Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer|A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.|NIMFEA|UNICANCER|Yes|Active, not recruiting|August 2007|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Female|N/A|N/A|No|||August 2014|August 5, 2014|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00629616||159678|
NCT00629902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-1974|Heart Valve Prosthesis-Patient Mismatch|Impact of Prosthesis-Patient Mismatch on Clinical Outcomes After Mitral Valve Replacement||Florence Nightingale Hospital, Istanbul|Yes|Completed|February 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|80 Years|No|Probability Sample|Tertiary care clinic|May 2008|May 9, 2008|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00629902||159656|
NCT00629603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-950347|Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease|Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|January 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 17, 2013|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629603||159679|
NCT00630461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2026 GCRC 2627|Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma|Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma||University of North Carolina, Chapel Hill|No|Terminated|May 2008|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|50 Years|No|||October 2012|October 5, 2012|February 28, 2008|No|Yes|Data collected under different protocol; funding exhuasted|No||https://clinicaltrials.gov/show/NCT00630461||159613|
NCT00631436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074550|The Effects of Explosive Blast as Compared to Post-Traumatic Stress Disorder on Brain Function and Structure|The Effects of Explosive Blast as Compared to Post-Traumatic Stress Disorder on Brain Function and Structure||Minnesota Veterans Research Institute|Yes|Recruiting|April 2008|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|180|Samples With DNA|Whole blood samples and isolated DNA and serum|Both|20 Years|50 Years|No|Non-Probability Sample|National Guard Soldiers|February 2008|July 20, 2011|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631436||159538|
NCT00630734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0272|Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin|Genetic Predictors of Pharmacokinetic Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin: the Role of SLCO1B1 Polymorphisms.||University of Colorado, Denver|Yes|Completed|February 2008|September 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|February 28, 2008|Yes|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00630734||159592|The study included only heterozygous carriers of the SLCO1B1 *15 and *17 haplotypes. Pravastatin urine concentrations were not measured; therefore the impact of darunavir/ritonavir on pravastatin renal clearance was not assessed in this population.
NCT00633607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-112|Hereditary Colorectal and Associated Tumor Registry Study|Hereditary Colorectal and Associated Tumor Registry Study||University of Pittsburgh|Yes|Recruiting|April 2012|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|1000|Samples With DNA|Serum, plasma, and extracted DNA are stored for potential future studies.|Both|8 Years|100 Years|No|Non-Probability Sample|Potential research subjects are recruited from our Hereditary GI clinic.|January 2016|January 14, 2016|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00633607||159376|
NCT00633893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-057|Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism|A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism||Bristol-Myers Squibb|Yes|Completed|May 2008|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2711|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|March 5, 2008|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00633893||159354|
NCT00633906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045957|HORIZONS HIV Intervention|Reducing HIV Risk in Female Teens: A Tailored Approach|HORIZONS|Emory University|No|Completed|April 2002|October 2005|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|715|||Female|15 Years|21 Years|Accepts Healthy Volunteers|||June 2008|November 18, 2013|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00633906||159353|
NCT00633919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E02/04/SLIT1-M|Efficacy of SLITone in House Dust Mite Allergic Patients|A Randomised, Double-blind, Placebo-controlled Trial Assessing the Efficacy of SLITone in House Dust Mite Allergic Patients||ALK-Abelló A/S|No|Completed|July 2006|February 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|65 Years|No|||June 2011|June 7, 2011|March 4, 2008||No||No|November 11, 2010|https://clinicaltrials.gov/show/NCT00633919||159352|Retrospectively, trial design (medication use did not reflect the asthma status of subjects), and subject number (low power) and characteristics (mild, well-controlled asthma; low medication use needed) were not optimal for this trial purpose.
NCT00634257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0678|Spirituality/Religiosity in Patients and Caregivers|A Preliminary Study of Spirituality/Religiosity, Symptom Distress and Quality of Life Among Palliative Care Patients and Their Primary Caregivers||M.D. Anderson Cancer Center|No|Completed|February 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|193|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with advanced cancer receiving palliative care and their primary caregivers.|September 2011|September 12, 2011|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00634257||159327|
NCT00634270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F071019012|A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas|A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas|Protocol 102|University of Alabama at Birmingham|Yes|Active, not recruiting|April 2008|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|3 Years|75 Years|No|||February 2014|March 14, 2014|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634270||159326|
NCT00627263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|530|Stress Reduction Program to Reduce Abnormal Heart Rhythms Treated With Implantable Cardioverter Defibrillators (The RISTA Study)|Reducing Vulnerability to ICD Shock Treated Ventricular Arrhythmias|RISTA|Yale University|Yes|Recruiting|January 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|304|||Both|21 Years|N/A|No|||March 2012|March 30, 2012|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00627263||159853|
NCT00627510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMUPSY20050001|Routine Plasma Level Determination to Compare Actual vs Expected Plasma Levels at Psychiatric Inpatient Admission|Routine Plasma Level Determination to Compare Actual vs Expected Plasma Levels at Psychiatric Inpatient Admission for Determination of Compliance and/or Speed of Drug Metabolism||Medical University Innsbruck|Yes|Completed|June 2005|December 2007|Actual|July 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|161|||Both|N/A|N/A|No|Probability Sample|patients consecutively admitted for routine psychiatric inpatient treatment|February 2008|February 22, 2008|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627510||159834|
NCT00627523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281287|Genotropin Treatment In Very Young Children Born Small For Gestational Age|A Two Year Multicentre, Randomized Two Arm Study Of Genotropin Treatment In Very Young Children Born Small For Gestational Age: Early Growth And Neurodevelopment(Egn)|EGN|Pfizer|No|Completed|February 2008|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|19 Months|29 Months|No|||October 2014|October 27, 2014|February 22, 2008|Yes|Yes||No|September 10, 2014|https://clinicaltrials.gov/show/NCT00627523||159833|
NCT00627536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0050|Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions|A Double-Blind, Placebo-Controlled, Randomised Dose-Ranging Trial to Investigate the Efficacy of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers||Renovo|No|Completed|July 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|39|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2008|March 3, 2008|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627536||159832|
NCT00627835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-003|Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)|A Phase I Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)||British Columbia Cancer Agency|No|Withdrawn||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Anticipated|30|||Both|18 Years|N/A|No|||November 2010|November 3, 2010|February 14, 2008||No|Site decided not to open this study|No||https://clinicaltrials.gov/show/NCT00627835||159810|
NCT00627848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5772749|Rivastigmine in Mild Alzheimer's Disease, FMRI Study|Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease|ADFRMI|Kuopio University Hospital|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Both|55 Years|85 Years|No|||October 2011|October 27, 2011|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627848||159809|
NCT00629083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONSUI-US01|Bulking Agents for the Treatment of Stress Urinary Incontinence in Females|A Single-Masked, Randomized, Multi-Center, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Bulkamid® and Contigen® as Bulking Agents for the Treatment of Stress Urinary Incontinence in Females||Contura|Yes|Completed|April 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|345|||Female|18 Years|N/A|No|||February 2015|February 6, 2015|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629083||159717|
NCT00629122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710009492|Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation|Pharmacokinetic Evaluation of Sublingual Versus Oral Tacrolimus Administration in Patients Awaiting Kidney Transplantation||Weill Medical College of Cornell University|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2010|November 4, 2010|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629122||159715|
NCT00629356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960195|Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection|Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Withdrawn|July 2007|July 2008|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The patients who are suspicious of dengue infection.|May 2010|March 31, 2015|February 26, 2008||No|The study had been revised and made a new application.|No||https://clinicaltrials.gov/show/NCT00629356||159697|
NCT00629629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitolo2|Impacts of the 10 Steps for Healthy Feeding in Infants: a Randomized Field Trial|Impacts of the 10 Steps for Healthy Feeding in Infants: a Randomized Field Trial||Federal University of Health Science of Porto Alegre|No|Completed|October 2001|June 2003|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|1||Actual|500|||Both|N/A|N/A|No|||March 2008|March 5, 2008|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00629629||159677|
NCT00629642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-005|Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis|A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity|SONIC|Astellas Pharma Inc|No|Completed|March 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|249|||Both|18 Years|65 Years|No|||September 2012|March 4, 2013|February 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00629642||159676|
NCT00629915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS051631|The Role of Cerebral Hemodynamics in Moyamoya Disease|The Role of Cerebral Hemodynamics in Moyamoya Disease||Washington University School of Medicine|No|Active, not recruiting|October 2006|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|Persons with moyamoya disease will be recruited without restriction in regards to gender,        race, age, and socioeconomic status. At Washington University, persons will be identified        and recruited from the Neurosurgery service, the Stroke service of the Department of        Neurology, and the Interventional Neuroradiology service.        We have invited several established stroke investigators at large tertiary care facilities        in the Midwest to form a cooperative study group. All these investigators have        large-volume clinical practices and see several people with moya moya disease each year.|June 2015|June 1, 2015|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00629915||159655|
NCT00630474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-825|Nasal Decongestion and Obstructive Sleep Apnea|Does Nasal Decongestion Improve Obstructive Sleep Apnea ?||University of Zurich|No|Completed|January 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|75 Years|No|||December 2009|December 21, 2009|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00630474||159612|
NCT00630201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-807|Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence|An Open-Label, Multi-Center Extension Study Of Probuphine in Patients With Opioid Dependence|PRO-807|Titan Pharmaceuticals|Yes|Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|65 Years|No|||October 2012|October 6, 2014|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630201||159633|
NCT00631111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-07-02|Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain|Ibuprofen 400 mg Effervescent Tablet Dental Pain Study II||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|270|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631111||159563|
NCT00631124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91697|A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles|A Double-blind, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Oral Estradiol / Drospirenone Regimens in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles||Bayer|No|Completed|February 2008|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|103|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631124||159562|
NCT00635765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2L-OCT-01 PR-302|Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients|Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients||Ambrilia Biopharma, Inc.|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|65 Years|No|||June 2009|June 3, 2009|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635765||159211|
NCT00636077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gambro 1461|Comparative Effects Of Dialysate Flow Rate And Membrane Packing On The Performance Of Dialyzers Used For Hemodialysis|Effect Of Dialysate Flow Rate On Mass Transfer Coefficient - Area (KoA) In Dialyzers With Different Membrane Packing Densities||Gambro Renal Products, Inc.|No|Completed|February 2008|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|19 Years|N/A|No|||June 2011|June 6, 2011|February 20, 2008||No||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00636077||159188|
NCT00633321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-NIC/04|Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation||Celtic Pharma Development Services|No|Completed|May 2007|February 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|522|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 7, 2011|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633321||159398|
NCT00633620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charite-CVK-Endo-1|Narrow Band Versus Conventional Endoscopic Imaging for Screening Colonoscopy|Narrow Band Versus Conventional Endoscopic Imaging for Screening Colonoscopy in a Private Practice Setting - A Large Prospective Randomized Trial|BECOP-2|Charite University, Berlin, Germany|No|Completed|March 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1250|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||March 2008|March 11, 2008|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00633620||159375|
NCT00633932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00002|Reflux Esophagitis Phase III Study (Initial Treatment)|A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis||AstraZeneca|No|Completed|December 2007|December 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|602|||Both|20 Years|N/A|No|||December 2010|December 2, 2010|March 4, 2008|Yes|Yes||No|December 10, 2009|https://clinicaltrials.gov/show/NCT00633932||159351|
NCT00630708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nanfang200803|Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency|Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency|SDBRAS|Nanfang Hospital of Southern Medical University|Yes|Recruiting|February 2008|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|309|||Both|18 Years|70 Years|No|||October 2013|October 29, 2013|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630708||159594|
NCT00630721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0941|Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells|Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells||University of North Carolina, Chapel Hill|No|Completed|September 2007|March 2011|Actual|May 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630721||159593|
NCT00631059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 07-46|Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients|Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients||University of California, Irvine|Yes|Terminated|March 2008|June 2010|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2010|October 11, 2010|February 27, 2008||No|Haluted due to slow accrual|No||https://clinicaltrials.gov/show/NCT00631059||159567|
NCT00634569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG-0705|Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects|Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases.||Grifols Biologicals Inc.|No|Completed|May 2008|May 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|2 Years|16 Years|No|||March 2013|March 18, 2013|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634569||159303|
NCT00634855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 17821|Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR|Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR||Medical University of South Carolina|No|Not yet recruiting|March 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Whole blood|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women who are between 30 and 40 weeks gestation and are admitted to MUSC.|March 2008|March 12, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00634855||159281|
NCT00634868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|or003121107|Treatment of Wounds Utilizing Light|||QRay Ltd.|Yes|Terminated|August 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2011|June 9, 2011|February 7, 2008||No|Slow patients recruitment|No||https://clinicaltrials.gov/show/NCT00634868||159280|
NCT00631657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05701|A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)|A 6-Month, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Outpatient Trial, Investigating the Efficacy and Safety of Org 50081 in Adult Patients With Chronic Primary Insomnia||Merck Sharp & Dohme Corp.|No|Completed|March 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|65 Years|No|||July 2015|July 21, 2015|February 29, 2008|Yes|Yes||No|May 15, 2014|https://clinicaltrials.gov/show/NCT00631657||159521|
NCT00627276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581419|Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia|Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach||OHSU Knight Cancer Institute|Yes|Completed|December 2007|November 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Female|21 Years|N/A|No|||July 2015|July 17, 2015|February 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00627276||159852|
NCT00628524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCS Study|Homburg Cream & Sugar Study|Prospective Investigation of the Influence of Triglyceride Tolerance on Cardiovascular Outcomes in Patients With Coronary Artery Disease|HCS|University Hospital, Saarland|No|Completed|February 2008|August 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|514|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|> 500 consecutive patients with stable coronary artery disease being treated in the        cardiology department of the university hospital.|December 2013|December 6, 2013|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628524||159758|
NCT00628537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT4|Prevention of Post-Stroke Hand/Wrist Flexion Deformity|BION Implantable Microstimulator||University of Southern California|No|Completed|April 2004|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|85 Years|No|||June 2015|June 1, 2015|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00628537||159757|
NCT00628836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT3|Treatment of Shoulder Subluxation in Chronic Stroke Patients|BION Implantable Microstimulation System||University of Southern California|No|Completed|June 2001|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|85 Years|No|||June 2015|June 1, 2015|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00628836||159735|
NCT00629382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM05|Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis|Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico|EUPHAS|St. Bortolo Hospital|No|Completed|December 2004|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||April 2008|December 1, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629382||159695|
NCT00629369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC2007-39|Duration of Second Stage of Labor Wearing a Dental Occlusion Device|Duration of Second Stage of Labor Wearing a Dental Occlusion Device: a Randomized Controlled Trial||Mercy Medical Center|Yes|Completed|October 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Female|16 Years|45 Years|No|||March 2008|March 7, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629369||159696|
NCT00629928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-NEN-0014|Ulcer Prevention II|A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk||AstraZeneca||Completed|February 2001|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|800|||Both|18 Years|60 Years|No|||January 2011|January 24, 2011|February 27, 2008||||||https://clinicaltrials.gov/show/NCT00629928||159654|
NCT00629941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-104|Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis|A Multi-Center, Open-Label Study Evaluating the Cytokine and Eyelid Margin Bacterial Load Levels of Subjects Diagnosed With Chronic Blepharitis Following Dosing With AzaSite® (Azithromycin Ophthalmic Solution) 1%||Merck Sharp & Dohme Corp.||Completed|March 2008|||August 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00629941||159653|
NCT00630487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281282|Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency|Prospective, Randomized, Double Blind Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Adult Patients With Isolated Growth Hormone Deficiency (PRO ISO-GHD Study)|IGHD|Pfizer|No|Terminated|May 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||February 2013|February 26, 2013|February 28, 2008|Yes|Yes|See termination reason in detailed description.|No|August 3, 2010|https://clinicaltrials.gov/show/NCT00630487||159611|
NCT00630214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-03-01|Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection|Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients||Asan Medical Center|Yes|Completed|May 2004|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|200|||Both|15 Years|85 Years|No|||February 2008|March 5, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00630214||159632|
NCT00635479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1096320|Role of Vacuum Assisted Closure (VAC) Device in Postoperative Management of Pelvic and Acetabular Fractures|Role of Vacuum Assisted Closure (VAC) Device in Postoperative Management of Pelvic and Acetabular Fractures||University of Missouri-Columbia|No|Completed|March 2008|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|March 6, 2008||No||No|January 1, 2014|https://clinicaltrials.gov/show/NCT00635479||159233|
NCT00635492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-EW-B005|CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy|CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months||AstraZeneca|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2515|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consisted of patients aged 18 or above, with type 2 diabetes starting        any of the available initial injectable treatment options (any insulin, or exenatide BID)        for the treatment of type 2 diabetes as part of routine clinical care.|March 2015|March 20, 2015|February 20, 2008||No||No|July 31, 2013|https://clinicaltrials.gov/show/NCT00635492||159232|Serious adverse events (SAEs) and adverse events (AEs) were not collected as part of this observational studyFactors associated with treatment choice : this analysis was done on baseline lock( april 2009) where all others are from final lock.
NCT00636402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTCU_pkk2008_01|Study of Efficacy and Adverse Effects: Vessel Sealing System Tonsillectomy Versus Cold Knife Tonsillectomy|Vessel Sealing System Tonsillectomy vs Cold Knife Tonsillectomy: A Randomized, Paired Control Study of Efficacy and Adverse Effects||Chulalongkorn University|Yes|Enrolling by invitation|March 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||December 2008|December 10, 2008|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636402||159163|
NCT00632047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586791|Early Detection of Breast Cancer and Cervical Cancer in Women in India|Early Detection of Common Cancers in Women in India||National Cancer Institute (NCI)||Recruiting|May 1998|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Screening|||Anticipated|151538|||Female|35 Years|64 Years|No|||July 2009|August 23, 2013|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00632047||159493|
NCT00631072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-432|In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer|A Phase I Trial of in Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2008|||February 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631072||159566|
NCT00631085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 2678 IRB 08-0082|Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adults|Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adults|GammaTox|University of North Carolina, Chapel Hill|No|Completed|May 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|February 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631085||159565|
NCT00630422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|monteiro|Functional Abilities in Rett Syndrome|Functional Abilities in Rett Syndrome||Faculdades Metropolitanas Unidas|No|Completed|February 2006|December 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|64|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|This study investigated only patients with Rett syndrome that matched the criteria for the        classic form of the disease|January 2008|March 6, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00630422||159616|
NCT00631358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORE 14351|Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention|||Alcon Research|No|Completed|February 2008|||February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|17 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 29, 2010|February 29, 2008||No||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00631358||159544|
NCT00631670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 404-2005|Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord|Stereotactic Body Radiation Therapy for Tumors Near the Spinal Cord||University of Florida|No|Completed|October 2005|November 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|N/A|N/A|No|||June 2010|February 1, 2012|February 29, 2008|No|Yes||No|November 28, 2011|https://clinicaltrials.gov/show/NCT00631670||159520|
NCT00627289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 11 320499.|Selective Neurectomy and Mesh Removal for Chronic Postherniotomy Pain|The Effect of Selective Neurectomy and Mesh Removal on Chronic Postherniotomy Pain||Rigshospitalet, Denmark|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic pain occuring after groin hernia repair. Patients must experience        moderate/severe pain related impairment of everyday activities. Patients have to be able        to localize a maximum point of pain.|October 2012|April 4, 2014|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00627289||159851|
NCT00627302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5353|Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision|||Bp Consulting, Inc||Completed|February 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 20, 2008|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00627302||159850|
NCT00631345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK069901|Healthy Living Partnership to Prevent Diabetes|Translating Research Into the Prevention of Diabetes Mellitus (TRIP DM)|HELPPD|Wake Forest Baptist Health|No|Active, not recruiting|August 2007|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|301|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 8, 2014|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00631345||159545|
NCT00627861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712009564|Combined Renin Inhibition/Beta-blockade|Renin System Responses to Combined Renin Inhibition and Beta Adrenergic Blockade||The Rogosin Institute|No|Terminated|November 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||October 2015|October 26, 2015|February 24, 2008||No|The renin laboratory used in the study is no longer available.|No|August 19, 2011|https://clinicaltrials.gov/show/NCT00627861||159808|
NCT00628186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP-0501|Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy|Prospective, Randomized, and Controlled Trial That Lost Stent Versus External Stent of Pancreaticojejunostomy After Pancreaticoduodenectomy||Wakayama Medical University|Yes|Completed|April 2005|February 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|N/A|No|||January 2010|January 15, 2010|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00628186||159784|
NCT00628550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082007-065|Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation|A Prospective, Randomized, Controlled Trial of Combination Vasopressin and Epinephrine to Epinephrine Only for In-Intensive Care Unit Pediatric Cardiopulmonary Resuscitation|Vasopressin|University of Texas Southwestern Medical Center|Yes|Recruiting|April 2008|December 2011|Anticipated|April 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|18 Years|No|||June 2010|June 24, 2010|February 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628550||159756|
NCT00628849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000444|Champy Versus AO for Mandible Fractures|A Comparison of 2mm Plates and Screws With Larger Plates Ans Screws in the Treatment of Mandibular Fractures|Mand|Emory University|No|Completed|February 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|126|||Both|11 Years|89 Years|No|Non-Probability Sample|All patients who present with a fractured mandible|November 2013|November 19, 2013|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00628849||159734|
NCT00634036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLITZ 001|Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics|A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics|GLITZ Asthma|University of Pittsburgh|Yes|Completed|October 2009|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|60 Years|No|||January 2016|January 8, 2016|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634036||159343|
NCT00634049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0103|Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi|Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi|VITAL|Astellas Pharma Inc|Yes|Active, not recruiting|April 2008|January 2016|Anticipated|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|March 5, 2008|Yes|Yes||No|December 2, 2015|https://clinicaltrials.gov/show/NCT00634049||159342|Enrollment in the clinical study was suspended in January 2009 pending further characterization of newly identified impurities. After successful study completion resumption of enrollment started in April 2011 for the 9766-CL-0103/WSA-CS-003 study.
NCT00629655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007CZ-4|A Spinal Functional Magnetic Resonance Imagine (fMRI) Study of Resting-State, Motor Task and Acupoint Stimulation|A Spinal fMRI Study of Resting-State, Motor Task and Acupoint Stimulation||China Rehabilitation Research Center|Yes|Completed|February 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|group 1: male residents of Beijing group 2: male stroke patients of Beijing Boai hospital|June 2009|June 4, 2009|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00629655||159675|
NCT00629668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-940189|Genetic Polymorphisms of TNF-α Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease|||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|January 2007|December 2007|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||||||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2007|March 5, 2008|February 26, 2008||||No||https://clinicaltrials.gov/show/NCT00629668||159674|
NCT00634647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080074|Satraplatin and Prednisone to Treat Prostate Cancer|A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2008|April 2013|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|N/A|No|||September 2015|September 30, 2015|March 12, 2008|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00634647||159297|
NCT00634972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-156|Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity|Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity|ROP|University of South Alabama|No|Enrolling by invitation|November 2005|December 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|15 Days|Accepts Healthy Volunteers|||March 2008|March 12, 2008|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00634972||159272|
NCT00630773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-12-5077|Q-CPR Compression Sensor Size Qualification in Children|Feasibility of CPR Adjuncts in Children: Q-CPR Compression Sensor Size Qualification|PUCK|Children's Hospital of Philadelphia|No|Completed|March 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Both|6 Months|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|Emergency Department (ED), Pediatric Intensive Care Unit (PICU), Operating Room (OR) and        Regular Inpatient Care Area (RIPCA) settings at the Children's Hospital of Philadelphia.|December 2008|December 2, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00630773||159589|
NCT00636090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000346|Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001|Molecular, Genetic, and Genomic Assessments of MTOR Inhibition in Metastatic Hormone-Refractory Prostate Cancer Tissue From Patients Treated With RAD001||Duke University|No|Completed|January 2007|January 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples With DNA|This study involves the retention of tissue sample from tumor biopsies as well as blood      samples.|Male|18 Years|N/A|No|Non-Probability Sample|Adult men enrolled in the study entitled: A Single Arm, Phase II Study of RAD001 in        Patients with Metastatic, Hormone-Refractory Prostate Cancer.|December 2013|December 3, 2013|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00636090||159187|
NCT00636389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gambro 1460|Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers|Urea, Phosphate and b2-Microglobulin Removal and Ease of Use: Comparing the Polyflux HD-C4 With the Polyflux 210H||Gambro Renal Products, Inc.|No|Completed|February 2008|March 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|February 13, 2008||No||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00636389||159164|
NCT00636623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ekici - 2|Comparison of Exercise and Massage in Fibromyalgia|Comparison of Pilates Exercises and Connective Tissue Massage in Females With Fibromyalgia|FM|Pamukkale University|No|Completed|November 2006|August 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Female|25 Years|60 Years|No|||March 2008|March 7, 2008|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636623||159147|
NCT00631371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-3311|Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects|Phase 3b, Randomized, Open-label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-alfa As First-line Treatment In Subjects With Advanced Renal Cell Carcinoma|INTORACT|Pfizer|Yes|Completed|April 2008|April 2015|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|791|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|February 28, 2008|Yes|Yes||No|April 18, 2013|https://clinicaltrials.gov/show/NCT00631371||159543|
NCT00631384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.32.02.05.29|Experimental Design of Couple Counseling and Testing in Antenatal Clinics in Dar es Salaam, Tanzania|Experimental Design of Couple Counseling and Testing in Antenatal Clinics in Dar es Salaam, Tanzania|CVCT|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|March 2003|September 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1521|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2008|March 6, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00631384||159542|
NCT00631683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0368|Assessment of Hemodynamic Changes During Weaning From Mechanical Ventilation With Flo-Trac Vigileo (TM) Monitor.|Use of Flo-Trac/Vigileo (TM) for Hemodynamic Monitoring During Discontinuation From Mechanical Ventilation||The University of Texas Health Science Center, Houston|No|Withdrawn|February 2008|February 2008|Anticipated|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanically ventilated patients at Memorial Hermann Hospital MICU.|May 2009|May 14, 2009|February 22, 2008||No|Terms for legal agreements between institution and Sponsor could not be made.|No||https://clinicaltrials.gov/show/NCT00631683||159519|
NCT00627315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB0528|Prospective Study of Hormone Levels After Bariatric Surgery|Prospective Study of Hormone Levels and Appetite After Bariatric Surgery||Columbia University|Yes|Recruiting|March 2015|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|Samples With DNA|blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the outpatient obesity and surgical clinics at        Columbia-Presbyterian Medical Center after they have chosen to undergo a surgical        procedure.|October 2015|October 13, 2015|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00627315||159849|
NCT00627549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avaulta 17431|Avaulta Versus Anterior Repair|The Use of Avaulta Plus for Anterior Repair. A Multicenter Randomised Prospective Controlled Study||Roskilde County Hospital||Not yet recruiting||||||N/A|Interventional|N/A|2||||||Female|18 Years|N/A|No|||February 2008|February 29, 2008|February 22, 2008||||No||https://clinicaltrials.gov/show/NCT00627549||159831|
NCT00627874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLS2008|Trial of Myopia Prevention Using +3D Lenses|A Randomised, Controlled Trial of Prevention of Juvenile-Onset Myopia in Chinese Children|PLS|Sun Yat-sen University||Not yet recruiting|April 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|N/A|N/A|No|||February 2009|February 20, 2009|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00627874||159807|
NCT00627887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN40355220|Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression|Randomised Controlled Trial of Electroconvulsive Therapy (ECT) With Pharmacotherapy or Pharmacotherapy Alone in Relapse Prevention of Depression||Örebro County Council|No|Completed|January 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00627887||159806|
NCT00628199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12202007-950|Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability|Derivation of Primary Donor Cell Lines for Human Cell Reprogramming||Stanford University||Enrolling by invitation|September 2007|||January 2010|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|1 Year|75 Years|Accepts Healthy Volunteers|||February 2009|February 20, 2009|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00628199||159783|
NCT00628212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A4|Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes|A Phase II, Double-Blind, Placebo-Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus -Confirmative Study-||Mitsubishi Tanabe Pharma Corporation|No|Completed|January 2008|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|324|||Both|20 Years|75 Years|No|||April 2013|April 12, 2013|February 24, 2008||No||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00628212||159782|
NCT00628563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP501RGD0685|REALL: A Retrospective Observational Study to Compare the Effectiveness and Cost-Effectiveness Between Different Step-3 Asthma Treatment Strategies|REALL STUDY: A Retrospective Observational Study to Compare the Effectiveness and Cost-effectiveness Between Different Step-3 Asthma Treatment Strategies in Real Life Patients in Primary Care|REALL|University of Aberdeen|Yes|Completed|September 2007|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|50000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|1. Patients with a physician diagnosis of asthma who have stepped-up to any option of             step-3 asthma treatment (trial therapy), and;          2. Patients with the trial therapy who have data in their records for at least one year             for the baseline period and at least one year for the outcome period.|February 2016|February 26, 2016|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00628563||159755|
NCT00628862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5122C00001|Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU|A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-national, Phase III, Efficacy and Safety Study of Inhaled Formoterol 4.5 μg and 9 μg Twice Daily in Japanese and European Patients With Chronic Obstructive Pulmonary Disease (COPD)|OCEAN|AstraZeneca|No|Completed|December 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|613|||Both|40 Years|N/A|No|||September 2012|September 25, 2012|January 24, 2008||No||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00628862||159733|
NCT00629096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCMR0007/2006|Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy|Effects of Intracoronary Infusion of Bone Marrow-derived Progenitor Cells on Myocardial Regeneration in Patients With Non-ischemic Dilated Cardiomyopathy.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|February 2008|December 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|80 Years|No|||May 2013|December 4, 2014|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629096||159716|
NCT00634400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-AHS-0003|Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)|Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function||AstraZeneca|No|Completed|March 1999|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|6268|||Both|18 Years|N/A||||January 2011|January 24, 2011|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634400||159316|
NCT00634413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC_4022_CLIN_02P|Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD|A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 on Markers of Pulmonary Inflammation in Subjects With Moderate to Severe COPD||Pulmagen Therapeutics|No|Completed|February 2008|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|40 Years|75 Years|No|||February 2009|February 27, 2009|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00634413||159315|
NCT00634660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-001|Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria|A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Subcutaneous Doses of rAvPAL-PEG in Subjects With Phenylketonuria||BioMarin Pharmaceutical|Yes|Completed|May 2008|October 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|25|||Both|16 Years|50 Years|No|||July 2015|July 23, 2015|March 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00634660||159296|
NCT00634374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09090405|Administration of a Bitter-Tasting Medication: Comparison Between the Rx Medibottle and the Oral Syringe|Efficacy of the Rx Medibottle Compared to the Oral Syringe in Delivering Infant-Acceptable Liquid Medication Completely and Accurately: a Controlled Clinical Trial||Bronx-Lebanon Hospital Center Health Care System|No|Completed|January 2005|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|81|||Both|N/A|24 Months|No|||March 2008|April 11, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00634374||159318|
NCT00635219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11984A|Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder|A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder||H. Lundbeck A/S|No|Completed|February 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|766|||Both|18 Years|75 Years|No|||December 2013|December 23, 2013|March 3, 2008||No||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00635219||159253|
NCT00635232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCO-C-006|A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension|A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension||Ligand Pharmaceuticals|No|Completed|March 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|261|||Both|18 Years|70 Years|No|||September 2011|September 12, 2011|March 6, 2008|No|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00635232||159252|The 800mg dose level was discontinued from further enrollment per protocol amendment due to findings from another PS433540 trial that suggested clinical benefit beyond 500mg was expected to be limited.
NCT00635505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A004-CLN-C|Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients|Randomized, Placebo-Controlled, Parallel, Multi-Center, 12-Week Study to Evaluate the Efficacy and Safety of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Adult and Adolescent Asthmatic Patients||Amphastar Pharmaceuticals, Inc.|No|Terminated|September 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|12 Years|75 Years|No|||July 2012|July 11, 2013|March 7, 2008|Yes|Yes|IND voluntarily withdrawn, without prejudice|No||https://clinicaltrials.gov/show/NCT00635505||159231|
NCT00635518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitolo1|Randomized Controlled Trial of Dietary Advice in Primary Care to Promote Healthy Feeding of Infants|Randomized Controlled Trial of Dietary Advice in Primary Care to Promote Healthy Feeding of Infants||Federal University of Health Science of Porto Alegre|No|Withdrawn|March 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|1||Anticipated|329|||Female|N/A|N/A|No|||May 2011|June 22, 2011|March 5, 2008||No|Funding was canceled and no resources are available.|No||https://clinicaltrials.gov/show/NCT00635518||159230|
NCT00635206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIPAP Rescue|Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter|Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter|BIPAP|Clayton Sleep Insititute|Yes|Completed|September 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|21 Years|75 Years|No|||July 2009|July 13, 2009|March 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00635206||159254|
NCT00631761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cystoscopy Project|Standardized Criteria to Judge Diagnostic Urethrocystoscopy Skills|Standardized Criteria to Judge Diagnostic Urethrocystoscopy Skills||University of Cincinnati|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|20 Years|50 Years|No|||August 2008|August 18, 2008|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631761||159513|
NCT00631774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSR Version 2|A Study to Evaluate the Postprandial Metabolic Response After Use of Glucerna SR in Obese Type 2 Diabetes|An Open Label, Randomized, and Parallel Study to Evaluate the Postprandial Metabolic Response After 24-Week Use of Glucerna SR in Obese Asian Subjects With Type 2 Diabetes||Taipei Veterans General Hospital, Taiwan|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|20 Years|75 Years|No|||December 2011|December 5, 2011|March 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00631774||159512|
NCT00640315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12915|Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.|Proof of Concept Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics, Gas Exchange and Lung Function Parameters of a Single-dose of BAY63-2521 IR-tablet in Patients With COPD Associated Pulmonary Hypertension in an Non-randomized, Non-blinded Design||Bayer|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|February 29, 2008||No||No|November 7, 2013|https://clinicaltrials.gov/show/NCT00640315||158865|
NCT00630747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKT024EXT|Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase|An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy||Shire|Yes|Completed|September 2004|January 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Male|5 Years|N/A|No|||May 2014|July 16, 2015|February 28, 2008|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00630747||159591|This study design was open-label, and the lack of a concurrently followed placebo group limits the strength of the observations, because the progression of the disease is variable and has not been well described.
NCT00630760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-07-6|Oral NRX 194204 in Patients With Refractory Malignancies|A Multiple-Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Refractory Malignancies||University of Southern California|No|Terminated|February 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||May 2014|May 19, 2014|February 28, 2008|Yes|Yes|Sponsor withdrew study. Accrual not completed|No||https://clinicaltrials.gov/show/NCT00630760||159590|
NCT00631397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5974|A Preliminary Study of Bone Density in Neonates|A Preliminary Study of Bone Density Measurements in Neonates Using the Sunlight Omnisense 7000P Ultrasound Bone Sonometer||University of South Florida|Yes|Completed|March 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|Measuring proteins in the blood plasma|Both|24 Weeks|33 Weeks|Accepts Healthy Volunteers|Probability Sample|Premature Infants In the Neonatal Intensive Care Unit|March 2007|June 14, 2012|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631397||159541|
NCT00631098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070198|Cannulation for Resuscitation|The Feasibility of Cannulating External Jugular Vein Compared With Cubital Vein (by Paramedics and Emergency Department Interns)|CARE|Kuopio University Hospital|No|Completed|March 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631098||159564|
NCT00631423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E 102/7|Evaluation of Patients With Vena Cava Inferior Thrombosis|Clinical Course and Prognosis of Patients With Vena Cava Inferior Thrombosis||Johann Wolfgang Goethe University Hospitals|No|Completed|July 2007|August 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Whole blood, serum|Both|18 Years|90 Years|No|Non-Probability Sample|patients with venous thrombosis involving the inferior cava inferior obtained from the        Main-Isar-Thrombosis registry in which all patients seen for venous thromboembolism in our        department are registered|April 2015|April 14, 2015|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00631423||159539|
NCT00631696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081104|Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo|Prospective Randomized Double-Blind Study Of Sperm Production In Healthy Volunteers Receiving Pregabalin Or Placebo||Pfizer|No|Completed|February 2008|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|222|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|February 15, 2008|Yes|Yes||No|September 24, 2012|https://clinicaltrials.gov/show/NCT00631696||159518|
NCT00627328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163|The Atrial High Rate Episodes in Pacemaker Patients|The Atrial High Rate Episodes (A-HIRATE) in Pacemaker Patients||Medtronic Cardiac Rhythm Disease Management|No|Completed|July 2000|September 2004|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|427|||Both|50 Years|N/A|No|Non-Probability Sample|Prospective study with patients undergoing a Medtronic Kappa DR 700 or Medtronic Kappa 900        DR implant, for approved indications.|February 2008|February 22, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00627328||159848|
NCT00627575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEP108937|AED/Statin Interaction Study|An Open-label, Two-cohort Study to Assess the Effect of Lamotrigine and Phenytoin on the Pharmacokinetics of Atorvastatin in Healthy Subjects||GlaxoSmithKline|No|Completed|February 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|May 31, 2012|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627575||159829|
NCT00627562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-03-080|A Pilot Study of the Use of the DaVinci Robotic System for Otorhinolaryngology-Head and Neck Surgery|A Pilot Study of the Use of the DaVinci Robotic System for Otorhinolaryngology-Head and Neck Surgery||Montefiore Medical Center|Yes|Active, not recruiting|July 2007|December 2017|Anticipated|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00627562||159830|
NCT00627913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27170|Retrobulbar Injection of Anesthesia Versus Healon 5 in the Management of Intraoperative Floppy Iris Syndrome|Retrobulbar Injection of Anesthesia Versus Injection of Healon 5 Viscoelastic Into the Anterior Chamber in the Management of Intraoperative Floppy Iris Syndrome||Penn State University|Yes|Terminated|February 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||January 2008|April 22, 2010|February 25, 2008||No|Study terminated due to insufficient subject participation|No||https://clinicaltrials.gov/show/NCT00627913||159804|
NCT00628589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-301|Staccato® Loxapine Treatment of Schizophrenic Patients With Agitation|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation||Alexza Pharmaceuticals, Inc.|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||June 2008|June 10, 2008|February 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628589||159753|
NCT00628225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zonmw22000039|Smoking Cessation in Patients With COPD (SMOCC) in General Practice|Smoking Cessation in Patients With COPD (SMOCC) in General Practice|SMOCC|Radboud University|Yes|Completed|March 2000|December 2003|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|667|||Both|35 Years|N/A|No|||February 2008|October 16, 2008|February 25, 2008||||No||https://clinicaltrials.gov/show/NCT00628225||159781|
NCT00633412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-NEN-0005|A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only|||AstraZeneca||Completed|February 2001|March 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|N/A|No|||June 2009|June 9, 2009|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633412||159391|
NCT00633425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE490B_4001|Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride|||Sanofi||Completed|October 2002|October 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|35 Years|70 Years|No|||March 2008|March 26, 2008|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633425||159390|
NCT00633685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR064845|Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure|Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure||TEMPVA Research Group, Inc.|No|Recruiting|March 2010|August 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2010|May 24, 2010|March 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633685||159370|
NCT00634998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10046-001|Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy|Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy||Washington State University|No|Completed|November 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|10|||Both|50 Years|70 Years|No|||July 2008|September 6, 2012|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00634998||159270|
NCT00634673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA05060|Postprandial Fatty Acids and FABP2 in Type 2 Diabetes Mellitus (DM)|FABP2 Ala54Thr Genotype Influences the Postprandial Serum Fatty Acids Profile in Type 2 Diabetic Patients||Hospital de Clinicas de Porto Alegre|No|Completed|June 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|26|||Both|40 Weeks|75 Years|No|||February 2008|March 12, 2008|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00634673||159295|
NCT00634985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1601085|Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs|A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS||Pfizer|No|Completed|November 2002|December 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|55 Years|No|||April 2011|April 22, 2011|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634985||159271|
NCT00635531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131002|A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder||Pfizer|Yes|Terminated|April 2004|September 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|13 Years|17 Years|No|||April 2008|April 7, 2008|March 5, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00635531||159229|
NCT00635791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0537.cc|Phase I Study of Vorinostat and Sorafenib in Advanced Cancer|A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-type Specific Expanded Cohorts at the Recommended Phase 2 Dose||University of Colorado, Denver|Yes|Completed|March 2008|March 2012|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|March 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00635791||159209|
NCT00635778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-002|Infusion of MK-0646 in Subjects With Advanced Solid Tumors (MK-0646-002)(COMPLETED)|An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers||Merck Sharp & Dohme Corp.|No|Completed|August 2006|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|February 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00635778||159210|
NCT00640328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115102|Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients|A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients|OMS115102|GlaxoSmithKline|Yes|Completed|May 2008|October 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|38|||Both|18 Years|55 Years|No|||November 2012|June 19, 2014|March 18, 2008|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00640328||158864|
NCT00640341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552|Comparative Performance of PureVision, Acuvue Oasys and O2Optix|Product Performance of Bausch & Lomb PureVision® Contact Lens When Compared to Johnson & Johnson Acuvue Oasys Contact Lens and the Ciba Vision O2Optix Contact Lens Worn Daily.||Bausch & Lomb Incorporated|No|Completed|February 2008|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|510|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|February 20, 2008|Yes|Yes||No|February 3, 2011|https://clinicaltrials.gov/show/NCT00640341||158863|
NCT00640354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H - 18876|Time to Defibrillation Using Automated External Defibrillators by Pediatric Residents in Simulated Cardiac Arrests|Defibrillation by Automated External Defibrillators Versus Manual Defibrillators in Simulated Pediatric In-Hospital Cardiac Arrests: A Prospective Randomized Controlled Trial of Pediatric Residents||Baylor College of Medicine|No|Completed|December 2006|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||March 2008|March 18, 2008|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00640354||158862|
NCT00631709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMOTE-IPG 2008|REmote MOnitoring Transmission Evaluation of IPGs|REmote MOnitoring Transmission Evaluation of IPGs|REMOTE-IPG|Medtronic|No|Completed|March 2008|February 2010|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|N/A|N/A|No|||April 2015|April 7, 2015|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00631709||159517|
NCT00631410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181148|Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer|Phase I Study Of Sunitinib In Combination With Oxaliplatin, L-Leucovorin, And 5-Fluorouracil In Patients With Metastatic Colorectal Cancer||Pfizer|Yes|Completed|January 2008|March 2010|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|N/A|No|||March 2011|March 11, 2011|January 2, 2008|No|Yes||No|July 21, 2010|https://clinicaltrials.gov/show/NCT00631410||159540|
NCT00627341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5593|A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa|Addressing Fear of Food in Anorexia Nervosa||New York State Psychiatric Institute|No|Completed|December 2007|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|16 Years|45 Years|No|||May 2012|May 10, 2012|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00627341||159847|
NCT00627627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP153|A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer|A Phase 2, Open-Label, Single-Arm, Multicenter, Multinational Study to Evaluate the Antitumor Activity and Safety of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90(HSP90), in Patients With Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive(HER2+) Breast Cancer That Has Progressed Despite Prior Her2=Targeted Therapy||MedImmune LLC|Yes|Withdrawn|April 2008|||February 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Female|18 Years|80 Years|No|||February 2010|February 1, 2010|February 21, 2008|Yes|Yes|Redirect focus of the indication|No||https://clinicaltrials.gov/show/NCT00627627||159826|
NCT00627926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX07-950-108|A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)|A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C||Vertex Pharmaceuticals Incorporated|Yes|Completed|March 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1095|||Both|18 Years|70 Years|No|||July 2014|July 16, 2014|February 22, 2008|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00627926||159803|
NCT00627952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006350-10|A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients|Double Blind, Randomized, Parallel Group, Multicentre Study to Evaluate the Effects of Manidipine 20 MG Vs. Amlodipine 10 MG and the Combination of Manidipine 10 MG Plus Delapril 30 MG Vs. Amlodipine 5 MG Plus Delapril 30 MG on Intraglomerular Pressure in Hypertensive Patients||University of Erlangen-Nürnberg Medical School|Yes|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||January 2013|January 18, 2013|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00627952||159802|
NCT00628238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC014|Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)|A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)||Chronic Lymphocytic Leukemia Research Consortium|Yes|Recruiting|February 2008|July 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||September 2010|September 8, 2010|February 26, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00628238||159780|
NCT00627588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-001-07|Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease|A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.||Oxford BioMedica|Yes|Completed|January 2008|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|48 Years|65 Years|No|||May 2013|May 9, 2013|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00627588||159828|
NCT00627900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-Vorgang: Verschiedenes|Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents|Model Project for the Reduction of Coronary Restenosis|GERSHWIN|Charite University, Berlin, Germany|No|Completed|April 2003|||September 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized|2||Actual|958|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 24, 2008|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00627900||159805|
NCT00633152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-19|Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections|A Phase 2, Multicenter, Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Intramuscular Ceftaroline Versus Intravenous Linezolid in Adult Subjects With Complicated Skin and Skin Structure Infections||Forest Laboratories|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|March 3, 2008|No|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00633152||159411|
NCT00633165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-BRS-202|Brostallicin Clinical Trial for Myxoid Liposarcoma|A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation|SMI-BRS-202|Systems Medicine LLC|No|Active, not recruiting|August 2007|June 2010|Anticipated|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2010|February 24, 2010|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633165||159410|
NCT00633139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-MLD-048|Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)|A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Efficacy and Long Term Safety of HGT-1111 (Recombinant Human Arylsulfatase A [rhASA, Metazym]) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)||Shire|Yes|Completed|August 2007|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|1 Year|5 Years|No|||February 2014|July 14, 2015|February 29, 2008||No||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00633139||159412|
NCT00633711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNR-IBIM-001|Effects of Obstructive Sleep Apnea Treatment by Fixed CPAP and by Auto-CPAP (Somnosmart2)|Differential Effects of Chronic Treatment of OSAS by CPAP and SOMNOsmart2 on Norepinephrine and Blood Pressure||Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|No|Completed|March 2007|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|25 Years|60 Years|No|||April 2010|June 15, 2011|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633711||159368|
NCT00634062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-002640|Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder|Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder||Mclean Hospital|Yes|Completed|December 2004|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|64 Years|No|||March 2008|March 11, 2008|March 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634062||159341|
NCT00634387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2008|Effects of Anthocyans on Cardiovascular and Sympathetic Function|Effects of Anthocyans on Cardiovascular and Sympathetic Function||Oslo University Hospital|No|Completed|March 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Male|35 Years|50 Years|No|||February 2010|July 3, 2011|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00634387||159317|
NCT00635544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3|Cross-Over Multicentre Study in Adolescents|Healthy Life Style in Europe by Nutrition in Adolescence: Cross-Over Multicentre Study|HELENA-COMS|Federico II University|Yes|Completed|January 2007|April 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Female|13 Years|16 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00635544||159228|
NCT00635245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021012|CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery|A Phase 1 Pharmacodynamic Study Of CP-751,871 As Neoadjuvant Treatment For Early Breast Cancer||Pfizer||Withdrawn||||||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Female|18 Years|N/A|No|||March 2015|March 10, 2015|March 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00635245||159251|
NCT00636116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-07/02|Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.|A Comparison of Anavip® and CroFab® in the Treatment of Patients With Crotalinae Envenomation: A Randomized, Prospective, Blinded, Controlled, Comparative, Multicenter Study||Instituto Bioclon S.A. de C.V.|No|Completed|May 2008|January 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|121|||Both|2 Years|80 Years|No|||January 2012|January 9, 2012|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636116||159185|
NCT00631787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080084|Evaluation of Toxicity From Stem Cell Transplant|||National Institutes of Health Clinical Center (CC)||Completed|February 2008|December 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|61|||Both|10 Years|80 Years|No|||December 2015|December 11, 2015|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00631787||159511|
NCT00636103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM/CTS/002|Efficacy Study of Herbal Formula CUF2 to Treat Childhood Asthma|A Randomized Double-Blind Placebo-Controlled Study of the Effect of Traditional Chinese Medicines in the Treatment of Childhood Asthma||Chinese University of Hong Kong|No|Completed|July 2002|August 2003|Actual|August 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|7 Years|15 Years|No|||March 2008|March 11, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636103||159186|
NCT00632060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 EA-0000055|Manual and Manipulative Therapy for Low Back Pain|The Efficacy of Manual and Manipulative Therapy for Low Back Pain in Military Active Duty Personnel: A Feasibility Study||Samueli Institute for Information Biology||Recruiting|February 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|35 Years|No|||February 2008|March 7, 2008|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632060||159492|
NCT00631800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB-N003|Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110|Phase II Randomized, Double Blind, Placebo Controlled, Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110, for the Prevention of Staphylococcal Infection|N003|Biosynexus Incorporated|Yes|Completed|May 2003|November 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|88|||Both|N/A|120 Hours|Accepts Healthy Volunteers|||February 2008|February 29, 2008|February 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631800||159510|
NCT00631722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00011|Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia|||Peking University|No|Completed|May 2007|May 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|No|||February 2008|August 21, 2012|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00631722||159516|
NCT00631735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5452|Perceptions of Touch in People With Cancer|Perceptions of Touch in People With Cancer||State University of New York - Upstate Medical University|No|Completed|February 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|N/A||1|Anticipated|12|||Both|18 Years|89 Years|No|Non-Probability Sample|adults, at least 18 years old, who have been diagnosed with cancer (any form) and are in        active treatment. Treatment must include intravenous chemotherapy (either as an outpatient        or an inpatient) with or without surgery and/or radiation. Each participant will be fluent        in English, able to hear and speak, fully alert and oriented, able to verbalize both        concrete and abstract ideas, and able to comprehend and sign consent for participation.|June 2009|June 16, 2009|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00631735||159515|
NCT00636363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|554|Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution|||Bausch & Lomb Incorporated|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|541|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|March 7, 2008|Yes|Yes||No|February 3, 2011|https://clinicaltrials.gov/show/NCT00636363||159166|
NCT00636376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-1-2721|Effects of Head Elevation on Intracranial Pressure in Children|Effect of Head Elevation on Intracranial Pressure and Cerebral Venous Outflow in Children||Children's Hospital of Philadelphia|No|Completed|January 2002|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|N/A|18 Years|No|||October 2008|October 20, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636376||159165|
NCT00627614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|284-06|Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer|Identification and Differentiation of Breast Masses by Vibro-Acoustography||Mayo Clinic|Yes|Completed|March 2006|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|147|||Female|21 Years|N/A|No|||June 2015|June 1, 2015|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00627614||159827|
NCT00632307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lkhemer1-2008|Breath Analysis by Ion Mobility Spectrometry|Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry||Lung Clinic Hemer|No|Recruiting|July 2006|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||8|Anticipated|1000|Samples Without DNA|breath, pleural fluid (only in patients with therapeutic pleurocentesis)|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients of the lung clinic hemer with pulmonary diseases.|August 2015|September 1, 2015|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632307||159475|
NCT00632320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB No.:93-09-02A|Continuous Positive Airway Pressure and Oxygen Concentration on Measurement of Rapid Shallow Breathing Index|Effect of Continuous Positive Airway Pressure and Oxygen Concentration on Measurement of Rapid Shallow Breathing Index||Taipei Veterans General Hospital, Taiwan|No|Completed|October 2004|August 2005|Actual|December 2004|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|98|||Both|N/A|N/A|No|Non-Probability Sample|respiratory therapy intensive Care unit in a medical center|March 2008|March 7, 2008|March 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00632320||159474|
NCT00632567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060246|EPIC :Anal Incontinence After Delivery. Secondary Prevention With Caesarean Section.|Anal Incontinence After Delivery. Secondary Prevention With Caesarean Section.|EPIC|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|March 2008|April 2016|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|554|||Female|18 Years|N/A|No|||March 2016|March 18, 2016|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00632567||159455|
NCT00628251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00012|Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer|A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy|ICEBERG 3|AstraZeneca|Yes|Active, not recruiting|July 2008|December 2015|Anticipated|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|125|||Female|18 Years|N/A|No|||November 2014|November 5, 2014|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00628251||159779|
NCT00628576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN 2003/15 (2-16-4 - 0001- 03)|Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities|Deep Venous Thrombosis. Long-Term Results After Treatment With Either Low-Molecular -Weight Heparin or Unfractionated Heparin. Examinations of the Venous System.||Aalborg Universitetshospital|No|Completed|October 1993|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||February 2008|February 26, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628576||159754|
NCT00633724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVT-L0701|Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer|Phase I Study of Multiple-vaccine Therapy Including Antiangiogenic Vaccine Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Unresectable or Recurrent Non-small Cell Lung Cancer||Fukushima Medical University|Yes|Completed|May 2007|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|N/A|No|||August 2013|August 13, 2013|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00633724||159367|
NCT00633438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191067|Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery|A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery||Pfizer|No|Completed|January 2004|June 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|204|||Both|18 Years|65 Years|No|||March 2009|March 12, 2009|March 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633438||159389|
NCT00633698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ep_Li 001_2006|Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)|Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)|NICOLa|Charite University, Berlin, Germany|No|Active, not recruiting|January 2008|March 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||August 2009|August 3, 2009|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00633698||159369|
NCT00634426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011|Surgical Versus Nonoperative Treatment of Metastatic Epidural Spinal Cord Compression|Surgical Versus Nonoperative Treatment of Metastatic Epidural Spinal Cord Compression. Quality of Life and Cost-effectiveness Outcomes|MESCC|AOSpine North America Research Network|No|Completed|March 2008|March 2013|Actual|March 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|163|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who present for the treatment of new (cohorts 1 & 3) or old (cohort 2) metastatic        epidural spinal cord compression at the participating sites.|March 2015|May 19, 2015|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00634426||159314|
NCT00634686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0096|Effects of Omega-3 Fatty Acids on Bone and Frailty|Effects of Omega-3 Fatty Acids on Bone and Frailty||National Institute on Aging (NIA)|No|Active, not recruiting|January 2007|June 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|65 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 29, 2009|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00634686||159294|
NCT00635024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589032|Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma|A Phase II Trial of Thymoglobulin and Melphalan in Patients With Relapsed Multiple Myeloma||Mayo Clinic||Terminated|May 2008|November 2010|Actual|July 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2011|August 19, 2011|March 12, 2008|Yes|Yes|Due to competing trials, this study is permanenlty closed to patient acrrual.|No|August 27, 2010|https://clinicaltrials.gov/show/NCT00635024||159268|After 1 patient was recruited, this trial temporarily closed to allow the first dose of Anti-thymocyte Globulin to be split over two days. Before the modification was written, it was decided to permanently close this study due to competing trials.
NCT00635804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3281-002|Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK3281 in Healthy and Hepatitis C Infected Male Patients (MK-3281-002)(TERMINATED)|A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Rising Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK3281 in Healthy Male Subjects and Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3281 in Hepatitis C Infected Male Patients||Merck Sharp & Dohme Corp.||Terminated|February 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|February 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00635804||159208|
NCT00635557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-6827-07-004|Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme|Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme With MPC-6827 in Combination With Carboplatin||Myrexis Inc.|No|Active, not recruiting|March 2008|August 2011|Anticipated|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|March 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635557||159227|
NCT00635817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-CP07-167|A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty|A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty||Abbott|No|Completed|June 2008|June 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|2 Years|11 Years|No|||October 2011|October 25, 2011|March 7, 2008|Yes|Yes||No|January 20, 2011|https://clinicaltrials.gov/show/NCT00635817||159207|
NCT00635830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-035|An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)|An Open-Label, Single-Dose, Safety and Tolerability Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years||Merck Sharp & Dohme Corp.||Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Female|9 Years|26 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|March 3, 2008|No|Yes||No|March 17, 2009|https://clinicaltrials.gov/show/NCT00635830||159206|
NCT00636129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIT COUHES 577|Biochemical and Physiological Changes Associated With Differing Durations of Relaxation Response Training|Biochemical and Physiological Changes Associated With Differing Durations of Relaxation Response Training||Massachusetts General Hospital|No|Completed|December 2006|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Whole blood Serum Plasma|Both|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects ages 18-49.|September 2011|September 16, 2011|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636129||159184|
NCT00631813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-INT-2|Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation|A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation||Movetis|No|Completed|November 1995|April 1997|Actual|April 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|253|||Both|18 Years|70 Years|No|||February 2008|May 28, 2008|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00631813||159509|
NCT00627666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583220|Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer|Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies||National Cancer Institute (NCI)||Completed|January 2003|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|52|||Both|15 Years|65 Years|No|||July 2009|March 25, 2013|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00627666||159823|
NCT00627679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0010-CL-P101|Safety and Blood Level Study of Unit Dose Budesonide|A Randomized, Double Blind, Active Controlled, Single Dose, 4 Arm, 4 Period Crossover, Phase 1 Study Investigating the Tolerability and Pharmacokinetics of MAP0010|UDB P101|Allergan|No|Completed|December 2005|May 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|February 22, 2008||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00627679||159822|
NCT00632333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR07-079|Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer|Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer||Teikyo University|Yes|Recruiting|February 2008|March 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|80 Years|No|||September 2009|July 20, 2011|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632333||159473|
NCT00632034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSC/010|Stem Cells and Tibial Fractures|A Phase I Safety Study Following the Infusion of Expanded Autologous Progeny of an Adult CD34+ Stem Cell Subset to Patients With Recent Tibial Fractures|STIF|Imperial College London|Yes|Completed|May 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|17 Years|75 Years|No|||May 2010|February 19, 2016|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632034||159494|
NCT00632580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0079|Intra- Versus Extraarticular Injection of Ropivacaine in Total Knee Arthroplasty|Intraartikulær Versus ekstraartikulær Bolus Injektion Med Ropivacain Ved Total knæalloplastik: et Prospektivt, Randomiseret, Dobbeltblindet, Kontrolleret Studie||Hvidovre University Hospital|No|Recruiting|January 2008|July 2008|Anticipated|July 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2009|March 17, 2009|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00632580||159454|
NCT00632879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96011|The Study of Metabolic Syndrome in Hemodialysis Patients|The Study of Metabolic Syndrome in Hemodialysis Patients||Far Eastern Memorial Hospital||Recruiting|March 2007|March 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood samples are collected for analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients who receive maintenance hemodialysis in our HD center|July 2008|July 7, 2008|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632879||159431|
NCT00633178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH072838, #4914|Effectiveness of Group Interpersonal Psychotherapy in Treating Women With Prenatal Depression|Therapy for Prenatal Depression: Maternal & Fetal Effects||New York State Psychiatric Institute|Yes|Completed|January 2005|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|116|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|August 31, 2015|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00633178||159409|
NCT00632853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-30610|Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide|Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide||Alliance for Clinical Trials in Oncology|Yes|Recruiting|March 2008|||June 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|729|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00632853||159433|
NCT00632866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070125-AOM 07065|Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome|Randomized, Double-blind, Placebo-controlled Trial of Hydroxychloroquine in Primary Sjögren's Syndrome|JOQUER|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2008|May 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||July 2012|July 1, 2012|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632866||159432|
NCT00634439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12414|Safety Study of Atomoxetine and Cerebrovascular Outcomes|Atomoxetine and Cerebrovascular Outcomes in Adults||Eli Lilly and Company|No|Completed|January 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|72000|||Both|18 Years|N/A|No|Probability Sample|The source population is derived from the proprietary Ingenix RDM, with a cross-sectional        population of approximately 12 million current health plan members across the US at the        beginning of 2007 who have both medical and prescription benefit coverage.|September 2009|September 14, 2009|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00634439||159313|
NCT00634075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-08-01|Clinical Assessment of Fish Oil-based Lipid Emulsion Infusions in Critical Patients With Severe Sepsis|Clinical Assessment of Fish Oil-based Lipid Emulsion Infusions in Critical Patients With Severe Sepsis||Li Shin Hospital|Yes|Completed|March 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|N/A|No|||August 2009|August 12, 2009|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00634075||159340|
NCT00635011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16280|Pre- and Postoperative Cognitive Behavior Therapy for Patients Accepted for Bariatric Surgery|Pre- and Postoperative Cognitive Behavior Therapy for Patients Accepted for Bariatric Surgery||Helse Fonna|Yes|Active, not recruiting|February 2008|December 2016|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||March 2015|March 18, 2015|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00635011||159269|
NCT00635258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GnRH-ant.Ovodon|Administration of GnRH Antagonist to Oocyte Donation Recipients|Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.|GnRH-Ovodon|Centro Ginecologia y Obstetricia.|Yes|Completed|January 2004|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Female|18 Years|34 Years|Accepts Healthy Volunteers|Probability Sample|Patients with an indication for oocyte donation with functioning ovaries.|March 2008|March 6, 2008|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00635258||159250|
NCT00635570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14067B|Acceptability of the NuvaRing Among Students|Acceptability of the NuvaRing Among College and Graduate Students|ACCEPT|University of Chicago|No|Completed|July 2008|July 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|273|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 24, 2013|March 5, 2008|Yes|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT00635570||159226|This study is an randomized controlled trial offering internal but not necessarily external validity. Thus, we do not know whether these findings would be replicable in other populations.
NCT00635271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080081|Biomarkers in Exhaled Breath From Asthmatic Patients|Identification of Biomarkers in Exhaled Breath Condensates From Asthmatic Patients||National Institutes of Health Clinical Center (CC)||Terminated|February 2008|November 2012||||Phase 1|Observational|Time Perspective: Prospective|||Actual|19|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|February 19, 2014|March 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00635271||159249|
NCT00636142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000181-39|Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity|A Prospective Trial of Anti-TNF-Alpha Chimeric Monoclonal Antibody (Infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity||Medical University of Graz|Yes|Completed|September 2005|September 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Male|20 Years|50 Years|No|||March 2008|March 13, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636142||159183|
NCT00631826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-2007|Shoulder Rotational Flexibility and Throwing Arm Injuries of Baseball Pitchers|Shoulder Internal/External Rotational Flexibility is Related to Throwing Arm Injuries in Professional Baseball Players||University of Florida|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Male|18 Years|40 Years|No|Non-Probability Sample|Collegiate level baseball pitchers|April 2012|April 4, 2012|February 29, 2008||||No||https://clinicaltrials.gov/show/NCT00631826||159508|
NCT00632086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA32540-104|Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers|A Phase 1, Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Aspirin Administered as PA32540 (Aspirin/Omeprazole) or as the Aspirin Component of PA32540 or as Ecotrin® 325 mg in Healthy Volunteers||POZEN|No|Completed|February 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2008|March 7, 2008|February 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00632086||159490|
NCT00632411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|524|Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)|Efficacy of a Smoking Quit Line in the Military|AFIII|University of Tennessee|Yes|Completed|April 2008|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1298|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 18, 2014|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00632411||159467|
NCT00632424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-149|Phase 1 Trial of Oral Ixabepilone|A Phase 1 Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects With Advanced Cancer||R-Pharm|No|Terminated|May 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 3, 2008|No|Yes|Business Objectives Changed|No|September 15, 2010|https://clinicaltrials.gov/show/NCT00632424||159466|The MTD of oral ixabepilone at the scheduled doses used in this study was not determined due to early study discontinuation.
NCT00632437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0102|Intraoperative Optical Imaging of Brain Function|Intraoperative Optical Imaging of Brain Function||M.D. Anderson Cancer Center|No|Withdrawn|February 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients having a brain tumor which is scheduled to be surgically removed.|July 2012|July 27, 2012|February 13, 2008||No|Terminated due to poor enrollment.|No||https://clinicaltrials.gov/show/NCT00632437||159465|
NCT00632125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-66-INJ-14|Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.|Post-authorization Safety Study to Prospectively Monitor the Incidence of Relevant Drug-related Adverse Events and EPO-related Lack of Efficacy Among CKD Subjects Receiving HX575 Recombinant Human Erythropoietin Alfa i.v.|EPO-PASS|Sandoz|Yes|Completed|July 2008|September 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1706|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632125||159487|
NCT00628030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT101376|NOURISH: Nourishing Our Understanding of Role Modeling to Improve Support and Health|Parent Skills Training to Enhance Weight Loss in Overweight Children|NOURISH|Virginia Commonwealth University|Yes|Completed|April 2008|July 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 9, 2015|February 22, 2008||No||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00628030||159796|
NCT00632892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96013|The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity|The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity||Far Eastern Memorial Hospital|Yes|Completed|December 2007|||January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||80|Samples Without DNA|The urine samples are collected just before and 30 minutes after IVP.The samples are      immediately frozen at -80'C until analyzed.|Both|18 Years|N/A|No|Non-Probability Sample|1. Adult patients (> 18 years old)          2. Undergoing IVP with an appropriate medical indication          3. Signing informed consent|February 2008|March 10, 2008|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632892||159430|
NCT00632593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPGlap1|Trial Comparing Early Complications of Two Techniques in the Laparoscopic Gastric Bypass|Prospective Randomized Trial Comparing Early Complications of Hand-Sewn Versus Circular Stapled Gastro-Jejunal Anastomosis in Laparoscopic Gastric Bypass||Hospital Universitari de Bellvitge|No|Completed|March 2005|May 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|102|||Both|21 Years|50 Years|No|||February 2008|March 7, 2008|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00632593||159453|
NCT00633191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pseud-IgY-1|Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis|Post Marketing Study of Anti-pseudomonas IgY in Prevention of Recurrence of Pseudomonas Aeruginosa Infections Infections in Cystic Fibrosis (CF) Patients|PseudIgY|Immunsystem AB|Yes|Active, not recruiting|November 2003|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|N/A|N/A|No|||September 2014|September 3, 2014|March 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00633191||159408|
NCT00633477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-242_301|Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis-Induced Cardiovascular and Respiratory Failure||Takeda|Yes|Terminated|February 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|March 4, 2008|Yes|Yes|Business Decision; No Safety Or Efficacy Concerns.|No|December 5, 2012|https://clinicaltrials.gov/show/NCT00633477||159386|
NCT00633737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wound healing study|The Effects of Stress Reduction on Surgical Wound Healing|The Effects of Stress Reduction on Surgical Wound Healing: A Randomised Controlled Trial||University of Auckland, New Zealand|No|Completed|March 2008|December 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|80 Years|No|||December 2013|December 19, 2013|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633737||159366|
NCT00633451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-173|Randomized Clinical Trial of Rehabilitation for Subacromial Impingement Syndrome|Randomized Clinical Trial of Rehabilitation for Subacromial Impingement Syndrome: A Comparison of Manual Therapy + Exercise to Exercise Only||Proaxis Therapy|No|Completed|February 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|75 Years|No|||March 2013|March 26, 2013|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633451||159388|
NCT00633750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0222|Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery|Phase II Trial of OSI-774 (Tarceva), a Human Epidermal Growth Factor (HER) (erbB, Also Known as Epidermal Growth Factor Receptor, EGFR) Tyrosine Kinase Inhibitor, in Treatment-Naïve Operable Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|August 2002|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2012|August 2, 2012|March 11, 2008|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00633750||159365|
NCT00633763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5785|PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus|PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus||University of California, Irvine|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Joslin Diabetes Clinic at the University of California Irvine, age-matched controls will        be obtained from Orange County California.|May 2009|May 27, 2009|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633763||159364|
NCT00634699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Éthic Committee, UQTR|The Treatment of Carpal Tunnel Syndrome Using Thumb Pressure Along the Median Nerve|Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome: a Preliminary Study.||Guy Hains Chiropractor|Yes|Completed|September 2006|September 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 25, 2011|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00634699||159293|
NCT00634712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-AHS-0007|Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)|Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function||AstraZeneca|No|Completed|June 1999|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|734|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634712||159292|
NCT00634452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1401-01|Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma|A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma|MDX1401-01|Bristol-Myers Squibb|No|Completed|February 2008|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|12 Years|N/A|No|||December 2012|December 5, 2012|February 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00634452||159312|
NCT00634725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589283|Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery|Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study||Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Yes|Completed|February 2008|September 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|820|||Both|18 Years|120 Years|No|||November 2012|December 10, 2015|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00634725||159291|
NCT00634738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cer-06-115-06.03|The Treatment of the Median Nerve for the Elimination of the Symptoms Associated With the Carpal Tunnel Syndrome|Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study||Guy Hains Chiropractor|No|Completed|January 2007|September 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|60 Years|No|||June 2010|June 25, 2011|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00634738||159290|
NCT00635297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|889 VP|Percutaneous Vertebroplasty: Prophylactic Treatment of Adjacent Vertebra|Percutaneous Vertebroplasty.Study of Refracture Rates After Prophylactic Vertebroplasty of Adjacent Vertebrae||Ullevaal University Hospital|Yes|Suspended|April 2008|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||January 2008|March 2, 2010|March 5, 2008||No|Problems with patient recruitement|No||https://clinicaltrials.gov/show/NCT00635297||159247|
NCT00635583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1482|The Effect of Dairy on Bone Mass and Body Composition in 4th-8th Grade Boys and Girls|Influence of Dairy on Bone Accrual and Bone Size and Fat and Lean Mass in Early Pubertal Overweight vs. Healthy-weight Boys and Girls|B3|Purdue University|No|Active, not recruiting|March 2008|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00635583||159225|
NCT00635843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-08|MAVERICK™ Total Disc Replacement- Pivotal Study|"A Prospective, Randomized Controlled Clinical Investigation of MAVERICK™ Total Disc Replacement in Patients With Degenerative Disc Disease"||Medtronic Spinal and Biologics|Yes|Completed|April 2003|November 2010|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|577|||Both|18 Years|70 Years|No|||October 2011|August 1, 2013|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635843||159205|
NCT00635856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839US/0040|Open Label Trial to Assess Iressa in Prostate Cancer Patients|Phase II, Open-Label Trial to Assess the Activity of ZD1839 (IRESSA TM) in Patients With Recurrent Prostate Cancer Who Have Rising Serum PSA Levels Despite Serum Testosterone < 50mg/dl||AstraZeneca|No|Completed|May 2001|February 2003|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|March 7, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00635856||159204|
NCT00635869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5199|Advancing Research and Clinical Practice Through Close Collaboration (ARCC): A Pilot Test of an Intervention to Improve Evidence-Based Care and Patient Outcomes|Advancing Research and Clinical Practice Through Close Collaboration (ARCC): A Pilot Test of an Intervention to Improve Evidence-Based Care and Patient Outcomes||State University of New York - Upstate Medical University|No|Completed|September 2005|August 2006|Actual|August 2006|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Registered Nurse staff working on inpatient study units (medicine, surgery, surgical        intensive care)|March 2008|March 13, 2008|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00635869||159203|
NCT00636155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001363|EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of EL625 in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Duke University|No|Terminated|February 2008|May 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|January 22, 2008|Yes|Yes|funding|No|May 29, 2012|https://clinicaltrials.gov/show/NCT00636155||159182|
NCT00636168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-029|Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma|Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group||Bristol-Myers Squibb|Yes|Active, not recruiting|June 2008|April 2016|Anticipated|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1211|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|March 7, 2008|Yes|Yes||No|July 25, 2014|https://clinicaltrials.gov/show/NCT00636168||159181|
NCT00632099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5568|Progesterone Treatment for Cocaine-dependent Women: A Pilot Study|Progesterone Treatment for Cocaine-dependent Women: A Pilot Study|PROG|New York State Psychiatric Institute|Yes|Completed|February 2008|September 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|60 Years|No|||April 2014|April 9, 2014|March 6, 2008||No||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00632099||159489|Given the limited sample size, it was not possible to adequately determine whether OM-PROG may be an effective treatment for cocaine-dependence in women, but it was well tolerated.
NCT00632450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40004879|EnSite Real-Time Cardiac Performance Measurements (RT CPM) Study|EnSite Real-Time Cardiac Performance Measurements Study, a Non-significant Risk Study|EnSite RT CPM|St. Jude Medical|No|Completed|December 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Probability Sample|Patients indicated for implantation of a CRT pulse generator|March 2010|March 25, 2010|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632450||159464|
NCT00632632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0411007625|Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)|Combined Exposure Therapy and D-Cycloserine vs. Placebo for Posttraumatic Stress Disorder|VR-DCS|Weill Medical College of Cornell University|Yes|Completed|January 2005|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|70 Years|No|||July 2015|July 29, 2015|February 29, 2008|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT00632632||159450|
NCT00632931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-070|A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)|A Randomized, Partially-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Effects of a Single Dose of Vorinostat on the QTc Interval in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.||Completed|July 2007|April 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|February 29, 2008|Yes|Yes||No|January 18, 2010|https://clinicaltrials.gov/show/NCT00632931||159427|
NCT00628979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC004|Addressing Help-Seeking Barriers in Developing an Intensive Treatment for Veterans With Panic Disorder|Addressing Help-Seeking Barriers in Developing an Intensive Treatment for Veterans With Panic Disorder||VA Office of Research and Development|No|Completed|March 2008|July 2009|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|74 Years|No|||July 2009|July 1, 2009|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628979||159725|
NCT00633464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-139|Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer|Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative (ER, PR, Her2 Negative) Locally Advanced Non-resectable and/or Metastatic Breast Cancer||R-Pharm|No|Completed|June 2008|May 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|March 5, 2008|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00633464||159387|
NCT00632905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-CMX-03|Bone Health Observational Study|A Prospective Study to Evaluate the Incidence of Skeletal Related Events In Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT).|BHOS|CMX Research|No|Active, not recruiting|September 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Male|18 Years|N/A|No|Non-Probability Sample|primary care clinics|May 2011|May 30, 2011|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00632905||159429|
NCT00633204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMU-H18-59-P2|Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer|Phase II Study of Bladder Cancer Using Novel Tumor Antigens for Prevention of the Recurrence for Bladder Cancer After TUR-Bt||Iwate Medical University|Yes|Active, not recruiting|February 2008|November 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|150|||Both|20 Years|80 Years|No|||January 2009|June 22, 2011|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633204||159407|
NCT00634088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-144|Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer||R-Pharm|No|Terminated|June 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|March 5, 2008|No|Yes|Slow Accrual|No|April 1, 2011|https://clinicaltrials.gov/show/NCT00634088||159339|
NCT00634114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00006|Reflux Esophagitis Phase III Study (Maintenance Treatment)|A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis||AstraZeneca|No|Completed|January 2008|May 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|540|||Both|20 Years|N/A|No|||May 2010|May 18, 2010|March 4, 2008|Yes|Yes||No|May 18, 2010|https://clinicaltrials.gov/show/NCT00634114||159337|
NCT00634140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710-24|The Influence of Ezetimibe on Gallbladder Function|Te Influence of Ezetimibe on Gallbladder Function||Indiana University|Yes|Withdrawn|August 2009|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|90 Years|No|||March 2015|March 27, 2015|March 3, 2008|Yes|Yes|Study was never initiated due to lack of funding support.|No||https://clinicaltrials.gov/show/NCT00634140||159336|
NCT00634101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0716|A Comparison of Two Daily Disposable Contact Lenses|The Comparative Clinical Performance of Narafilcon A and the FOCUS DAILIES AquaComfort Plus Lens||Johnson & Johnson Vision Care, Inc.|No|Terminated|January 2008|||March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|60 Years|No|||August 2011|August 30, 2011|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634101||159338|
NCT00635037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP myofascial|Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine|Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine on Pain Relief of Patients With Myofascial Pain: Randomized Clinical Study|ACP|Federal University of São Paulo|Yes|Completed|June 2004|November 2006|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||March 2008|March 12, 2008|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635037||159267|
NCT00635284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA401|ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies|A Phase I Trial of ABI-009 (Nab-rapamycin) Administered Weekly in Patients With Advanced Non-hematologic Malignancies||Celgene Corporation|No|Completed|December 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||June 2010|September 14, 2011|March 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00635284||159248|
NCT00635310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940211|Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin|Safety Profiles of Percutaneous Liver Biopsy in Hemodialysis Patients With Chronic Hepatitis C Pre-treated With 1-Deamino-8- D-Arginine Vasopressin||National Taiwan University Hospital|Yes|Recruiting|January 2005|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|3520|||Both|N/A|N/A|No|||December 2012|December 19, 2012|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00635310||159246|
NCT00635323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP4174/2501|Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma|A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable Hepatocellular Carcinoma||Pfizer|No|Completed|November 2002|May 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|65 Years|No|||April 2008|April 2, 2008|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00635323||159245|
NCT00635895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ekici - 3|Comparison of Lymph Drainage and Connective Tissue Massage in Fibromyalgia Patients|Comparison of Manual Lymph Drainage Therapy and Connective Tissue Massage in Females With Fibromyalgia: A Randomized Controlled Trial|FM|Pamukkale University|No|Completed|June 2006|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|25 Years|60 Years|No|||March 2008|March 7, 2008|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00635895||159201|
NCT00635882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05122|Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)|A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma||Merck Sharp & Dohme Corp.|No|Completed|February 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|93|||Both|12 Years|N/A|No|||September 2015|September 18, 2015|January 21, 2008|Yes|Yes||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00635882||159202|
NCT00636181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTG3|Positive Pressure Treatment of Obstructive Sleep Apnea|Positive Airway Pressure Initiation: Impact of Therapy Mode and Titration Process on Adherence and Outcomes||Philips Respironics|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||June 2009|June 9, 2009|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636181||159180|
NCT00636220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-HIV-01|Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid|Evaluation of the DPP HIV Test With Reader and the HIV 1/2 Stat-Pak Test Using Oral Fluids|HIVOF|Chembio Diagnostic Systems, Inc.|Yes|Completed|March 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|101|Samples Without DNA|oral fluid samples and venous blood|Both|12 Years|N/A|No|Non-Probability Sample|The study population consists of 100 participants with known (clinically or serologically)        confirmed HIV infection. The participants, recruited by the staff of the Laboratory of        Vial Diagnostics from the Evelyn Jordan Center, may be males or females (including        pregnant women) at least 12 years of age from any ethnic and racial background.|July 2015|July 27, 2015|March 10, 2008||No||No|January 8, 2009|https://clinicaltrials.gov/show/NCT00636220||159177|
NCT00636233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016517|Genetics of Spina Bifida and Anencephaly|The Hereditary Basis of Neural Tube Defects||Duke University|No|Recruiting|May 1993|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|10000|Samples With DNA|Whole blood, serum, saliva, cord blood, fetal tissue, cultured fetal cells|Both|N/A|N/A|No|Probability Sample|Any current pregnancy affected by anencephaly or acrania.|August 2015|August 26, 2015|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00636233||159176|
NCT00632138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABROIN-MAPS|Pelvic Floor Muscle Training and Biofeedback or Standard Therapy in Men Who Have Undergone Radical Prostatectomy or Transurethral Resection of the Prostate|MAPS (Men After Prostate Surgery) : Conservative Treatment for Men With Urinary Incontinence After Prostate Surgery; Multicentre Randomised Controlled Trial of Pelvic Floor Muscle Training and Biofeedback [MAPS]||National Cancer Institute (NCI)||Completed|January 2005|July 2011|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|800|||Male|N/A|N/A|No|||December 2008|August 6, 2013|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00632138||159486|
NCT00632164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Welch|Sympathetic and Parasympathetic Responses to Specific Chiropractic Adjustments|Sympathetic and Parasympathetic Responses to Specific Chiropractic Adjustments of Subluxation of the Cervical and Thoracic Spine||Sherman College of Straight Chiropractic|No|Completed|January 2005|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|40|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Random ages 25-55 asymptomatic|February 2008|February 29, 2008|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632164||159485|
NCT00632645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060211|Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride|Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study.|NEUROHD|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|April 2009|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632645||159449|
NCT00628992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3912|Early Rehabilitation of COPD Patients in ICU|Effects of Early Rehabilitation in Chronic Obstructive Pulmonary Disease Patients Under Mechanical Ventilation for Acute Respiratory Failure in Intensive Care Unit.||University Hospital, Strasbourg, France||Terminated|February 2008|September 2011|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00628992||159724|
NCT00632346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2007.160|Relationship of Adverse Childhood Experiences to Overweight and Obesity|Relationship of Adverse Childhood Experiences (Childhood Abuse, Neglect, and Household Dysfunction) to the Severity of Overweight and Obesity in Young Adults in a Military Dependent Population.||Brooke Army Medical Center|Yes|Active, not recruiting|September 2007|February 2008|Anticipated|February 2008|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|200|||Both|18 Years|23 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patients between the ages of 18 and 23 years of age who present to the        Brooke Army Medical Center Adolescent Medicine Clinic(regardless of their gender, height,        weight, blood pressure, reason for appointment, or health status)|February 2008|March 7, 2008|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632346||159472|
NCT00632359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0213|Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease|A Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy - RV-CLL-PI-0270||M.D. Anderson Cancer Center|Yes|Completed|February 2008|||October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00632359||159471|
NCT00632372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60015786|Cardiac Resynchronization Therapy (CRT) Based Heart Failure Monitoring Study|CRT-D Based Heart Failure Monitoring Study|zLAP|St. Jude Medical|Yes|Completed|January 2008|December 2015|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|February 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00632372||159470|
NCT00632619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080791|Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood|A Novel Multimodal Intervention for Children With ADHD and Impaired Mood||Florida International University|Yes|Completed|March 2009|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|7 Years|11 Years|No|||April 2013|April 12, 2013|March 7, 2008|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT00632619||159451|relatively small sample size, the lack of a gold standard measurement for mood dysregulation in children, run at a specialty mental health research center and therapy subjects had more contact with study staff which may have impacted results.
NCT00633217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111117|Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)|A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg Twice-daily With Fluticasone Propionate/Salmeterol DISKUS 250/50mcg Twice-daily in Subjects With COPD||GlaxoSmithKline||Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|40 Years|N/A|No|||October 2012|October 17, 2012|February 19, 2008|Yes|Yes||No|October 22, 2009|https://clinicaltrials.gov/show/NCT00633217||159406|
NCT00633230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGT006|Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C|Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C||University of Virginia|No|Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||June 2015|June 24, 2015|March 3, 2008|No|Yes|No funding secured|No||https://clinicaltrials.gov/show/NCT00633230||159405|
NCT00633503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5891|Monitoring of Tissue Transfer Flaps by Modulated Imaging (MI) Spectroscopy|Monitoring of Tissue Transfer Flaps by Modulated Imaging (MI) Spectroscopy||University of California, Irvine|No|Recruiting|January 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|The subjects will be recruited from the pool of the patients seen in the Aesthetic and        Plastic Surgery Institute clinics, as well as patients initially seen as in-patient        consultations by the Plastic Surgery Service. Patients requiring reconstructive surgery        using either a pedicle or free tissue transfer flap(s) will be identified. Patients        requiring emergency reconstructive surgery after acute trauma will be excluded from the        study as a matter of patient safety. The location and type of tissue transfer flaps        enrolled will be dependent on the patient mix that presents during the study enrolment        period. After explaining the nature, rationale, objectives, benefits, and risks of the        study to the patients, they will be asked to consent to the study.|November 2012|November 11, 2012|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633503||159384|
NCT00633490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007APA|Study of Apatinib as an Inhibitor of Tumor Angiogenesis|Phase 1 Study of Apatinib as an Inhibitor of Angiogenesis||Fudan University|No|Recruiting|July 2007|June 2008|Anticipated|June 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||March 2008|July 21, 2008|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00633490||159385|
NCT00634751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0248|CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma|A Phase I/II STudy of Oxaliplatin, Oral Capecitabine and Sorafenib in Patients With Advanced Pancreatic and Biliary Carcinoma"||University of Wisconsin, Madison|Yes|Completed|February 2008|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634751||159289|
NCT00635050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070824009|Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin|Phase II Trial of Primary Systemic Therapy for Locally Advanced Breast Cancer Using Sequential Doxil, Paclitaxel, and Cyclophosphamide With Concurrent Avastin||University of Alabama at Birmingham|Yes|Active, not recruiting|March 2008|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|19 Years|N/A|No|||July 2014|July 1, 2014|March 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635050||159266|
NCT00635596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT110-101|Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer|An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE) MT110 in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment|MT110-101|Amgen Research (Munich) GmbH|Yes|Completed|March 2008|January 2015|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00635596||159224|
NCT00635609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-08607|Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate|Randomized, Open-label Study to Evaluate the Efficacy and Safety of Doryx Tablets Compared to Doxycycline Hyclate in the Treatment of Acne Vulgaris.||Warner Chilcott|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|12 Years|N/A|No|||April 2012|April 18, 2012|March 7, 2008|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00635609||159223|
NCT00635622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV-006|Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis|A Phase IIa Study of the Colonization Efficiency, Safety and Acceptability of LACTIN-V Administered Vaginally to Women With Bacterial Vaginosis||Osel, Inc.|Yes|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Female|18 Years|40 Years|No|||March 2009|July 9, 2009|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635622||159222|
NCT00636194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|562|Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon OptiFree Replenish Multipurpose Solution|Product Performance of Bausch & Lomb Multi-Purpose Solution Compared to Alcon Opti-Free Replenish Multi-Purpose Solution When Used With Silicone Hydrogel Contact Lenses Worn on a Daily Wear Basis||Bausch & Lomb Incorporated|No|Completed|February 2008|April 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|361|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|March 7, 2008|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00636194||159179|
NCT00636207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-380|A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)|A Sequential, 3-Part, Double-Blind, Randomized, Placebo-Controlled, Single-Rising-Dose and Rising-Multiple-Dose Study in Healthy Subjects and Mild or Moderate Asthmatic Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled MK-0476||Merck Sharp & Dohme Corp.||Completed|August 2007|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|46|||Both|18 Years|65 Years|No|||February 2015|February 6, 2015|March 3, 2008|No|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00636207||159178|
NCT00632190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581311|Spectroscopy in Diagnosing Dysplasia and Neoplasia in the Cervix in Women Undergoing Colposcopy|Measurement of Fluorescence EEM of Cervical Intraepithelial Neoplasia||National Cancer Institute (NCI)||Completed|January 2000|||March 2003|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|1800|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 27, 2010|March 7, 2008||||No||https://clinicaltrials.gov/show/NCT00632190||159484|
NCT00631839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDCA002|Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury|Prospect Study to Evaluate Clinical, Dosimetrical, Functional, Biological and Genetic Factors in Predicting Chemo-Radiotherapy Induced Lung and Esophagus Injury||Shanghai Cancer Hospital, China|Yes|Active, not recruiting|January 2002|October 2008|Anticipated|January 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|140|Samples With DNA|Patients' blood samples will be retained for the purpose of cytokine and MnSOD assay and DNA      detection. The samples will be left till the study ends. Paitents will have their vein blood      drawn from left arm 6am every Monday during RT. All above is stated in informed consent      form.|Both|18 Years|75 Years|No|Probability Sample|Patients enrolled are Chinese with thoracic neoplasms, no distant metastasis and initially        treated.|October 2008|October 6, 2008|March 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00631839||159507|
NCT00631852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER-SCCI 07-001.1|A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer|A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer||Southern Illinois University|Yes|Active, not recruiting|February 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||December 2014|December 11, 2014|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631852||159506|
NCT00632112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98551|A Real Life Evaluation of the Performance of a Large Volume Nebulizer|A Real Life Evaluation of the Performance of a Large Volume Nebulizer||Arkansas Children's Hospital Research Institute|No|Recruiting|March 2008|||July 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|21 Years|No|Non-Probability Sample|Pediatric patients admitted to the Pediatric Intensive Care Unit due to status        asthmaticus, requiring continuous albuterol nebulization.|June 2009|June 3, 2009|February 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00632112||159488|
NCT00632697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LETS|Pentoxifylline and Endometriosis|Combined Laparoscopic Surgery and Pentoxifylline Therapy for Treatment of Endometriosis-Associated Infertility: A Preliminary Study|LETS1|Hospital Clinic of Barcelona|No|Completed|October 2001|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|40 Years|No|||March 2008|March 10, 2008|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00632697||159445|
NCT00632710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0829/04|Assessment of the Effectiveness of Low-Level Laser Therapy on the Hands of Patients With Rheumatoid Arthritis|Assessment of the Effectiveness of Low-Level Laser Therapy on the Hands of Patients With Rheumatoid Arthritis: a Randomized Double-Blind Controlled Trial||Federal University of São Paulo|Yes|Completed|July 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||March 2008|March 4, 2008|February 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00632710||159444|
NCT00632463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADMA-001|RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness|RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness||ADMA Biologics, Inc.|Yes|Completed|February 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|21|||Both|2 Years|65 Years|No|||March 2013|March 12, 2013|March 3, 2008|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00632463||159463|Unfortunately enrollment in this study was suspended early due to slow accrual rates.
NCT00632476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|546|Evaluating the Effects of Supplemental Vitamin C on Infant Lung Function in Pregnant Smoking Women|In-Utero Smoke, Vitamin C, and Newborn Lung Function||Oregon Health and Science University|Yes|Completed|March 2007|July 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|282|||Female|15 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 31, 2013|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00632476||159462|
NCT00629512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-NEN-0013|Prevention of Gastric Ulcers|A Comparative Efficacy and Safety Study of Nexium (Esomeprazole Magnesium) Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated With Daily NSAID Use in Patients at Risk||AstraZeneca||Completed|March 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|504|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|February 27, 2008||Yes||||https://clinicaltrials.gov/show/NCT00629512||159686|
NCT00629525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009495|RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer|A Single Arm, Two Center, Phase II Study of RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer||Duke University|No|Completed|August 2005|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|N/A|No|||February 2015|February 12, 2015|February 27, 2008|Yes|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00629525||159685|
NCT00632385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1601092|Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy|An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy||Pfizer|No|Completed|January 2003|August 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|18 Years|65 Years|No|||April 2011|April 22, 2011|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00632385||159469|
NCT00632398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587451|Multimedia Training for Family Caregivers in Use of Touch and Massage in Supportive Cancer Care|Couples and Cancer: Building Partner Efficacy in Caring||Collinge and Associates, Inc.|No|Completed|March 2008|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|228|||Both|21 Years|120 Years|No|||December 2015|December 12, 2015|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00632398||159468|
NCT00632918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96064|Effects of Heart Rates and Variability of Heart Rates on Image Quality of Dual-Source CT Coronary Angiography|A Retrospective Study of Effects of Heart Rates and Variability of Heart Rates on Image Quality of Dual-Source CT Coronary Angiography With Regard to Motion Artifact.|DSCT|Far Eastern Memorial Hospital|Yes|Completed|October 2007|December 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|149|None Retained|No biospecimens|Both|21 Years|78 Years|Accepts Healthy Volunteers|Probability Sample|The patients or examined persons from Taiwan.|December 2008|December 25, 2008|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00632918||159428|
NCT00633802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-089|Low-Dose Risperidone Treatment for Subjects Suffering From Borderline Personality Disorder|||Tel-Aviv Sourasky Medical Center||Recruiting|April 2004|||April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|No|||March 2008|March 11, 2008|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633802||159361|
NCT00634153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-145|The Surgical Gastrointestinal Diseases Registry Protocol|The Surgical Gastrointestinal Diseases Registry Protocol||University of Pittsburgh|Yes|Active, not recruiting|January 2004|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with gastrointestinal diseases.|January 2016|January 14, 2016|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00634153||159335|
NCT00634166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS-401|Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group|Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group||Mylan Bertek Pharmaceuticals|No|Completed|September 2007|April 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|3 Months|N/A|No|||April 2013|September 26, 2014|February 11, 2008|Yes|Yes||No|September 22, 2014|https://clinicaltrials.gov/show/NCT00634166||159334|The study was terminated on 17 June 2013 due to the recommendation and request by the FDA to design a superiority clinical study to satisfy the sponsor’s post marketing study commitment for SS5%.
NCT00633776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perforomist CT Study|Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)|Perforomist Versus Foradil Evaluated by Inspiratory Capacity and HRCT||University of California, Los Angeles|No|Withdrawn|March 2008|January 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|N/A|No|||September 2008|September 24, 2008|March 4, 2008||No|Sponsor withdrew funding prior to study initiation|No||https://clinicaltrials.gov/show/NCT00633776||159363|
NCT00633789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-026|Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types|A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors||Bristol-Myers Squibb|No|Completed|June 2008|December 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|597|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633789||159362|
NCT00634465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stabilimax Bar|A Biomechanical Assessment of the AST Stabilimax BAR Using Radiostereometric Analysis (RSA)|A Biomechanical Assessment of the AST Stabilimax BAR Using Radiostereometric Analysis (RSA)||State University of New York - Upstate Medical University|No|Withdrawn|October 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|75 Years|No|Non-Probability Sample|This is a single-center, non-randomized study. 10 Subjects who are identified to receive        the AST Stabilimax BAR device will be approached to participate in this study. All        subjects will receive 10 RSA tantalum beads (5 in each vertebra) at the time of their        lumbar surgery. After surgery, subjects will have the biplanar xrays taken. The biplanar        xrays will be taken from 5 standing positions: neutral, flexion (bending forward),        extension (bending backwards), left side bending, and right side bending. RSA analysis        will be completed to determine the amount of motion on sagittal and coronal planes.|May 2015|May 22, 2015|March 4, 2008||No|low enrollment|No||https://clinicaltrials.gov/show/NCT00634465||159311|
NCT00634764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 16751|Predictors of Maternal Weight Gain and Neonatal Body Composition|Resting Metabolic Rate, Insulin Resistance, and Attitude Towards Weight Gain During Pregnancy to Predict Maternal Weight Gain and Neonatal Body Composition.||Medical University of South Carolina|No|Recruiting|November 2006|October 2008|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|The study population will consist of pregnant women who present for prenatal care at        MUSC's Cannon Place clinic or Prenatal Wellness Center prior to 16 weeks gestational age.|July 2008|July 18, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00634764||159288|
NCT00635336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMU-H18-59-P1|Novel Peptide Vaccination for Patients With Advanced Bladder Cancer|Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer||Iwate Medical University|Yes|Completed|February 2007|February 2010|Actual|February 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|80 Years|No|||January 2009|October 20, 2010|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00635336||159244|
NCT00635349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012964|A Comparative Study of Tramadol Hydrochloride Plus Acetaminophen Tablets Maintenance Versus Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Maintenance in Participants With Knee Osteoarthritis|A Comparison of Tramadol/Acetaminophen Tablets Maintenance Versus NSAID Maintenance After Tramadol/Acetaminophen and NSAID Combination Therapy in Knee Osteoarthritis Patients: Multicenter, Randomized, Open Comparative Study||Janssen Korea, Ltd., Korea|No|Completed|May 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|40 Years|75 Years|No|||July 2013|July 16, 2013|March 6, 2008|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00635349||159243|There was no wash-out period after Day 28 to show drug efficacy in participants whose pain was already relieved and results were not meet the objective by setting inappropriate non-inferiority limit by applying WOMAC total score in hypothesis.
NCT00636246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501075|A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.|Sertraline/[S,S]-Reboxetine Combination Versus Sertraline And [S,S]-Reboxetine Monotherapy In Major Depressive Disorder (MDD) In A Double-Blind, Placebo-Controlled, Eight Week Study.||Pfizer|No|Completed|June 2004|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|510|||Both|18 Years|65 Years|No|||April 2008|April 3, 2008|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636246||159175|
NCT00636259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7054US/0014|Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer|A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer||AstraZeneca||No longer available||||||N/A|Expanded Access|N/A|||||||Male|18 Years|N/A||||June 2008|June 10, 2008|March 7, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00636259||159174|
NCT00635921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSP-2003-002|Ziprasidone in the Treatment of Borderline Personality Disorder|Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|March 2004|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|45 Years|No|||March 2008|March 11, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00635921||159200|
NCT00636272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-011608-T|Longitudinal Surveillance Registry|Longitudinal Surveillance Registry|LSR|Boston Scientific Corporation|Yes|Terminated|March 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|N/A|N/A|No|Non-Probability Sample|Patient who are or will be implanted with a LATITUDE-enabled pulse generator (ICD or        CRT-D).|August 2008|August 14, 2008|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636272||159173|
NCT00631865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-skin-001|Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin|Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin||Royan Institute|Yes|Completed|February 2009|June 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|12 Years|65 Years|No|||February 2009|June 13, 2011|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00631865||159505|
NCT00632203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05146|Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)|A Randomized Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients||Merck Sharp & Dohme Corp.|No|Terminated|March 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|February 29, 2008|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00632203||159483|The interpretation of the study results should be taken with caution because of the small sample size due to early termination.
NCT00632216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISED_L_01054|A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis|Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis|ROSPA-CTx|Sanofi|No|Completed|May 2004|May 2006|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|464|||Female|55 Years|70 Years|No|||March 2008|March 10, 2008|March 3, 2008||||No||https://clinicaltrials.gov/show/NCT00632216||159482|
NCT00633009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LtSTA-08|Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen|A Blinded, Placebo Controlled Study Evaluating Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen (LtSTA)||Nielsen BioSciences, Inc.|No|Completed|August 2008|January 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|3||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|March 3, 2008|Yes|Yes||No|July 19, 2012|https://clinicaltrials.gov/show/NCT00633009||159421|
NCT00629824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB- 960047|Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C|Efficacy and Safety of Pegylated Interferon Plus Ribavirin Combination Therapy in Treating Older Patients With Chronic Hepatitis C||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|February 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|250|||Both|50 Years|80 Years|No|||February 2007|September 6, 2010|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629824||159662|
NCT00629837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11876|Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980|A Randomized, Double-blind, Cross-over Study to Determine the Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 in Previously Treated Patients With Severe Hemophilia A||Bayer|No|Completed|September 2005|March 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|27|||Male|12 Years|60 Years|No|||November 2014|November 17, 2014|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00629837||159661|
NCT00633243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702002306|Effective Treatment of Hepatitis C in Substance Users|Effective Treatment of Hepatitis C in Substance Users||Yale University|No|Completed|April 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|21|||Both|18 Years|N/A|No|||January 2013|January 1, 2013|February 29, 2008||No||No|October 19, 2012|https://clinicaltrials.gov/show/NCT00633243||159404|This trial contains a small sample size of patients with considerable comorbidity and is drawn from one specialized treatment setting. Our conclusions will need empiric testing within carefully conducted RCTs.
NCT00633516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2088-6099|A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions|A Pilot Study to Evaluate the Correlation Between Modified Two Layer Diffuse Optical Spectroscopy With the Clinical and Histological Examinations of Pigmented Skin Lesions Based on Physiological Parameters||University of California, Irvine|No|Completed|July 2008|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|August 2015|August 5, 2015|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633516||159383|
NCT00633529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200068-200|Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC|Open-Label Phase 1b Study of Erlotinib Plus Bevacizumab and IMO-2055 in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Chemotherapy for Advanced or Metastatic Disease||EMD Serono|No|Completed|November 2007|March 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|March 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00633529||159382|
NCT00633815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00007190|Upright Versus Supine Exercise Testing in Fontan-palliated Patients|Study of Upright Versus Supine Exercise Testing in Fontan-palliated Patients, Compared With Healthy Controls, to Evaluate for Postural Effects on Exercise Parameters||University of Michigan|No|Completed|January 2008|November 2008||November 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|45|||Both|8 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Fontan-palliated patients aged 8-30 will be recruited for this study. Eligible patients        will be identified from the cardiology and surgery database here. Patients will be        contacted by phone and/or formal letter informing them of the study. If their primary        cardiologist is not in our group, a courtesy call will be made or letter sent. Age and        gender matched healthy controls will be sought as well through local recruitment (schools,        university campus, local community postings).|September 2009|September 9, 2009|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633815||159360|
NCT00633828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKOISR10002|Influence of External Factors on Skeletal Growth in Youth|Determinants for Peak Bone Mass, Skeletal Architecture, Fractures, Adipositas and Cardiovascular Risk Factors During Growth and Adulthood||Region Skane|No|Active, not recruiting|August 1999|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|500|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633828||159359|
NCT00634179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002996|A Phase I/II Trial of VR-CHOP in Lymphoma Patients|A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas||Emory University|Yes|Completed|February 2008|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 11, 2008|Yes|Yes||No|February 17, 2016|https://clinicaltrials.gov/show/NCT00634179||159333|
NCT00634192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100DDE01|Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin|A Multicenter, Open Label, 2 Period Cross-over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects||Novartis||Completed|February 2008|August 2009|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|N/A||||August 2010|August 31, 2010|March 4, 2008||||No||https://clinicaltrials.gov/show/NCT00634192||159332|
NCT00634205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELCWP-01062|Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma|A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma||European Lung Cancer Working Party|Yes|Completed|July 2006|June 2010|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00634205||159331|
NCT00634478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00008047|Pre-lemniscal Radiation Deep Brain Stimulation for ET|Pre-lemniscal Radiation Deep Brain Stimulation for ET||Medical College of Wisconsin|No|Terminated|October 2008|September 2021|Anticipated|March 2021|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|21 Years|75 Years|No|||August 2015|August 21, 2015|January 9, 2008|Yes|Yes|Difficulty in recruitment. Funding issues.|No||https://clinicaltrials.gov/show/NCT00634478||159310|
NCT00634218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRDRP 15RT-0165|Reaching and Treating Lesbian, Gay, Bisexual, and Transgender (LGBT) Cigarette Smokers|REaching and Treating LGBT Smokers: The Internet||University of California, San Francisco|Yes|Completed|February 2008|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|363|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 25, 2012|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00634218||159330|
NCT00634777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET N GETTEC|Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma|Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma|pet|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|January 2007|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|239|||Both|18 Years|80 Years|No|||July 2011|July 19, 2011|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00634777||159287|
NCT00634491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2438|Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy|Effect of Acetazolamide in Prevention of Contrast Nephropathy||Shiraz University of Medical Sciences|Yes|Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|240|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2008|March 4, 2008|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634491||159309|
NCT00635063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-AD923-005|A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects|A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects With Malignancies||Sosei|No|Terminated|February 2008|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||June 2008|June 5, 2008|March 4, 2008||No|Termination is due to a combination of a device defect potentially impacting the quality of    the AD 923 IMP and a major change in corporate strategy.|No||https://clinicaltrials.gov/show/NCT00635063||159265|
NCT00635076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131007|A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder||Pfizer|Yes|Terminated|July 2004|September 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|13 Years|17 Years|No|||April 2008|April 7, 2008|March 5, 2008|Yes|Yes|Please see Detailed Description for the termination reason.|No||https://clinicaltrials.gov/show/NCT00635076||159264|
NCT00635947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-08|Study of Maternal Hydration on the Increase of Amniotic Fluid Index|Randomized Trial of Maternal Hydration on the Increase of Amniotic Fluid Index||UPECLIN HC FM Botucatu Unesp|Yes|Completed|July 1998|January 2005|Actual|July 1999|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|99|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2008|March 13, 2008|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00635947||159198|
NCT00628459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIENKO2|Effect of Iron Versus Multiple Micronutrient Supplementation on Anemia in Preschool Children of Malaria-Endemic Area|||Centre National de la Recherche Scientifique et Technologique|No|Completed|August 2006|February 2008|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|297|||Both|6 Months|23 Months|No|||February 2008|March 4, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628459||159763|
NCT00631878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB-N002|Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110|Phase I/II Randomized, Double Blind, Placebo Controlled, Dose Escalation, Safety and Pharmacokinetics Study in VLBW Neonates, a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for the Prevention of S. Epidermidis Infection|N002|Biosynexus Incorporated|Yes|Completed|November 2001|August 2003|Actual|May 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|53|||Both|N/A|7 Days|No|||February 2008|February 29, 2008|February 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631878||159504|
NCT00632489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 119|LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients|A Phase I Study of LBH589 in Combination With Capecitabine ± Lapatinib||SCRI Development Innovations, LLC|No|Completed|May 2008|July 2011|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|March 3, 2008|No|Yes||No|May 18, 2015|https://clinicaltrials.gov/show/NCT00632489||159461|
NCT00629577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581308|Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples|Ex Vivo Gene Expression Profiling of Cervical Cancer Progression in Biopsies And Tissue Samples From Patients With Cervical Lesions|SAGE|British Columbia Cancer Agency|No|Suspended|September 2006|December 2011|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|19 Years|N/A|No|||November 2010|November 3, 2010|March 5, 2008||No|Awaiting funding renewal|No||https://clinicaltrials.gov/show/NCT00629577||159681|
NCT00632502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05365|Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)|Safety of SCH 527123 in Subjects With Neutrophilic Asthma||Merck Sharp & Dohme Corp.|Yes|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|70 Years|No|||October 2015|October 28, 2015|February 29, 2008|Yes|Yes||No|October 14, 2014|https://clinicaltrials.gov/show/NCT00632502||159460|
NCT00632723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0057|IRESSA™ (Gefitinib) in Breast Cancer Patients|A Phase II Trial to Assess the Efficacy of IRESSA™ (Gefitinib) 500 mg/Day in Patients With Breast Cancer Who Have Failed Tamoxifen or Have an Oestrogen Receptor Negative Tumour and Would be Considered for Systemic Therapy||AstraZeneca||Completed|April 2001|October 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|54|||Female|18 Years|N/A|No|||April 2009|April 21, 2009|January 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00632723||159443|
NCT00630396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 NS055728-01A1|Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke|Minocycline to Improve Neurologic Outcome in Stroke (MINOS)|MINOS|Georgia Regents University|Yes|Completed|May 2008|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|19 Years|N/A|No|||December 2011|December 9, 2011|February 28, 2008|Yes|Yes||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00630396||159618|Some statistical tests could not be performed due to small sample size in the 4.5 and 6mg/kg dose tiers.The modified continual reassessment method (CRM) failed to identify the maximum tolerated dose of intravenous minocycline.
NCT00633256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601001031|The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers|The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers.||Yale University|Yes|Completed|December 2006|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|No|||March 2012|March 14, 2012|February 29, 2008||No||No|March 14, 2012|https://clinicaltrials.gov/show/NCT00633256||159403|
NCT00633542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO 02/02 MM|Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)|Thalidomide-Dexamethasone vs Alpha-Interferon-Dexamethasone as Maintenance Therapy After Thalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin Combination for||Università Politecnica delle Marche|No|Completed|June 2003|October 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||March 2008|March 4, 2008|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00633542||159381|
NCT00633555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-198-2|A Comparison of the Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Women Who Are or Who Are Predicted to be Low Responders|A Randomized Controlled Trial of Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Predicted Low Responders|LR|University of Connecticut Health Center|No|Completed|July 2006|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|54|||Female|21 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women ages 21-44 who are currently undergoing In Vitro Fertilization treatment at our        center.|February 2011|February 9, 2011|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633555||159380|
NCT00633568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELCWP 01063|Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer|A Phase III Randomised Study Comparing Concomitant Radiochemotherapy With Cisplatin and Docetaxel as Induction Versus Consolidation Treatment in Patients With Locally Advanced Unresectable Non-small Cell Lung Cancer.||European Lung Cancer Working Party|Yes|Terminated|January 2007|February 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|March 5, 2008||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00633568||159379|
NCT00633841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Affiris 002|Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease|Randomized, Controlled, Parallel Group, Patient-Blinded, Single-Center Phase I Pilot Study to Assess Tolerability and Safety of Repeated s.c. Administration of a Single-Dose of AFFITOPE AD02 Applied With or Without Adjuvant to Patients With Mild to Moderate Alzheimer's Disease||Affiris AG|Yes|Completed|February 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|50 Years|80 Years|No|||October 2010|October 18, 2010|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00633841||159358|
NCT00633854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB008606|High-Frequency-Ultrasound Annular Arrays for Ophthalmic Imaging|High-Frequency-Ultrasound Annular Arrays for Small Animal and Ophthalmic Imaging||Weill Medical College of Cornell University|Yes|Enrolling by invitation|February 2008|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ophthalmology practice|February 2008|March 4, 2008|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633854||159357|
NCT00634231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-098|A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors|A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors||Advantagene, Inc.|Yes|Active, not recruiting|April 2010|December 2020|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|3 Years|21 Years|No|||October 2015|October 28, 2015|March 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00634231||159329|
NCT00634244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00520|Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)||National Cancer Institute (NCI)|No|Completed|October 2008|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|65 Years|No|||April 2015|July 2, 2015|March 11, 2008|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT00634244||159328|
NCT00634504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR001-CLN-pro017|Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze|An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, With or Without Voraxaze Treatment|LVPK|BTG International Inc.|No|Completed|May 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||June 2014|June 4, 2014|March 6, 2008|No|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00634504||159308|
NCT00634517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A004-CLN-E|4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma|A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, 4-Week Study to Evaluate the Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Patients With Asthma in Pediatric Patients With Asthma||Amphastar Pharmaceuticals, Inc.|No|Terminated|March 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|4 Years|11 Years|No|||July 2013|July 11, 2013|March 7, 2008|Yes|Yes|IND voluntarily withdrawn, without prejudice|No||https://clinicaltrials.gov/show/NCT00634517||159307|
NCT00634790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131004|A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks|An Open-Label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks||Pfizer|Yes|Terminated|May 2004|October 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|13 Years|17 Years|No|||April 2008|April 7, 2008|March 5, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00634790||159286|
NCT00635362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15148A|Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion|Immediate Post-placental Insertion of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean Delivery vs. 4-8 Week Post-delivery Interval Insertion: A Randomized Controlled Trial||University of Chicago|No|Terminated|May 2007|February 2013|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 1, 2013|March 5, 2008|Yes|Yes|Low recruitment|No|February 22, 2013|https://clinicaltrials.gov/show/NCT00635362||159242|
NCT00635934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04-05|A-MAV™ Anterior Motion Segment Replacement|A Prospective, Non-Randomized Pilot Clinical Investigation of the A-MAV™ Anterior Motion Segment Replacement in Patients With Lumbar Degenerative Disc Disease||Medtronic Spinal and Biologics|Yes|Completed|December 2005|May 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|70 Years|No|||October 2011|April 24, 2012|March 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00635934||159199|
NCT00628472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4300|Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort|Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort||Henry Ford Health System|No|Completed|January 2007|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|21|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||May 2007|March 4, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628472||159762|
NCT00628173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8417|Results of Different Location of Ahmed Glaucoma Valve Implantation in Refractory Glaucoma, Superior Versus Inferior|||hahid Beheshti University of Medical Sciences||Completed|January 2005|December 2007||May 2007||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|106|||Both|N/A|N/A|No|||February 2008|October 16, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00628173||159785|
NCT00635635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001282|Guided Imagery for Military Sexual Trauma-Related Posttraumatic Stress Disorder (PTSD)|Guided Imagery for Military Sexual Trauma-Related PTSD||Duke University|No|Completed|October 2007|May 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|40|||Female|18 Years|65 Years|No|||May 2010|May 25, 2010|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00635635||159221|
NCT00635648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-066|A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)|A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults||Merck Sharp & Dohme Corp.||Completed|January 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|February 29, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00635648||159220|This was an open-label non-comparative study with a relatively small sample size.
NCT00635960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLA_GH_1|Growth Hormone in Amyotrophic Lateral Sclerosis|Efficacy, Safety and Tolerability of Growth Hormone in Patients With Amyotrophic Lateral Sclerosis as add-on Therapy to Riluzole||Federico II University|Yes|Completed|March 2007|May 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|85 Years|No|||May 2010|May 25, 2010|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00635960||159197|
NCT00629031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAMRC PSD|An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis|An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL)||Banaras Hindu University|No|Completed|February 2008|August 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|329|||Both|5 Years|55 Years|No|||September 2008|September 11, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00629031||159721|
NCT00629044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC IR 2006|Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD|Etude du Polymorphysme génétique de la cholestérol 24S Hydroxylase et Des Teneurs en 24S hydroxycholestérol Chez Des Patients Atteints de Glaucome ou de dégénérescence Maculaire liée à l'âge.||Centre Hospitalier Universitaire Dijon|Yes|Completed|November 2007|January 2011|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|320|||Both|40 Years|N/A|Accepts Healthy Volunteers|||August 2009|March 25, 2011|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00629044||159720|
NCT00629343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC3255|Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide|A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma||Columbia University|Yes|Active, not recruiting|October 2007|August 2014|Anticipated|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00629343||159698|
NCT00631904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010503|St. Mary's Duluth Clinic (SMDC) Pacemaker Magnetic Resonance Imaging (MRI) Study|SMDC Pacemaker-MRI Cohort Study||Essentia Health|No|Completed|January 2005|July 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Permanent pacemaker or implantable cardioverter-defibrillator (ICD) implanted for at least        6 weeks.|August 2011|August 31, 2011|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00631904||159503|
NCT00629889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586523|Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors|Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study.||Centre Hospitalier Universitaire Vaudois|No|Completed|February 2008|May 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00629889||159657|
NCT00629876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM_101|A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.|A Phase 1, Multicenter, Open-Label Dose Escalation Study Evaluating the Safety and Tolerability of Multiple Hematide Injections in Subjects With Refractory Non-Small Cell Lung Cancer, Breast Cancer, or Prostate Cancer Who Are Anemic and Receiving Cytotoxic Chemotherapy||Takeda|No|Terminated|January 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|80 Years|No|||November 2011|November 29, 2011|February 26, 2008|Yes|Yes|Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology    indications.|No||https://clinicaltrials.gov/show/NCT00629876||159658|
NCT00630162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QM094008|Intestinal Protozoal Infections and Sexual Transmitted Diseases Among Targeted Cohorts|Survey of Intestinal Protozoal Infections and Sexual Transmitted Diseases Among Targeted Cohorts||Kaohsiung Medical University Chung-Ho Memorial Hospital||Completed|March 2007|July 2008|Actual|||N/A|Observational|N/A|||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2008|February 2, 2009|February 26, 2008||||No||https://clinicaltrials.gov/show/NCT00630162||159636|
NCT00639821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Array study IBD 1|Mucosal Gene Expression Defects in IBD|Mucosal Gene Expression Defects in Patients With Inflammatory Bowel Disease Before and After First Infliximab Therapy||Katholieke Universiteit Leuven|No|Completed|July 2004|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|Samples Without DNA|Ileal/colonic mucosal biopsies from patiens with inflammatory bowel disease refractory to      corticosteroids and/or immunosuppression and from 12 control individuals|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Colonic mucosal biopsies from patients with refractory inflammatory bowel disease who had        never been treated with biological therapy.|October 2012|October 19, 2012|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00639821||158902|
NCT00632983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584897|Active Surveillance, Radical Prostatectomy, or Radiation Therapy in Treating Patients With Localized Prostate Cancer|Acitve Monitoring, Radical Prostatectomy, or Radiation Therapy in Treating Patients With Localized Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|June 2001|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|2050|||Male|50 Years|69 Years|No|||October 2011|April 13, 2012|March 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00632983||159423|
NCT00633269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00010|Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours|Open, Non-Randomized, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]-AZD2281 (KU-0059436) in Patients With Advanced or Metastatic Solid Tumours Refractory to Standard Treatments||AstraZeneca|No|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633269||159402|
NCT00633282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07JC14011|Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease|Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus||Fudan University|Yes|Completed|March 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|184|||Both|18 Years|65 Years|No|||June 2012|June 3, 2012|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00633282||159401|
NCT00633581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUIH 2008-1-1|Efficacy of Vitamin C Injection on Fatigue in Workers After Work|Efficacy of High Dose Vitamin C Parenteral Supplement on Amelioration of Fatigue in Company Workers After Work: A Double-Blind, Randomized Controlled Trial||DongGuk University|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|150|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||April 2009|April 8, 2009|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633581||159378|
NCT00633594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 58|Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma|Phase I/II Study Evaluating Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients With Mantle Cell Lymphoma||SCRI Development Innovations, LLC|No|Active, not recruiting|June 2008|November 2016|Anticipated|April 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633594||159377|
NCT00633867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-so802-4|Randomised Controlled Trial of Intubation With the McGrath Series 5 Video Laryngoscope vs the Macintosh Laryngoscope|Randomised Controlled Trial of Intubation With the McGrath Series 5 Video Laryngoscope vs the Macintosh Laryngoscope||NHS Grampian|Yes|Completed|February 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||March 2008|July 29, 2011|March 4, 2008||No||No|February 25, 2010|https://clinicaltrials.gov/show/NCT00633867||159356|
NCT00633880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa NOH302|Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)|Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH|NOH302|Chelsea Therapeutics|Yes|Completed|January 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|March 5, 2008|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT00633880||159355|
NCT00634530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitolo4|Impact of a Nutritional Intervention Program for Weight Control During Pregnancy|Impact of a Nutritional Intervention Program for Weight Control During Pregnancy||Federal University of Health Science of Porto Alegre|No|Completed|September 2007|January 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|318|||Female|N/A|35 Years|No|||February 2009|February 3, 2009|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00634530||159306|
NCT00634803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0608001776|Clinical Trial of Integrated Treatment for Pain and Opioid Dependence|Clinical Trial of Integrated Treatment for Pain and Opioid Dependence|POD|Yale University|No|Recruiting|September 2009|August 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|91|||Both|18 Years|65 Years|No|||September 2014|September 29, 2014|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00634803||159285|
NCT00634829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A004-CLN-D|Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction|Randomized, Double-Blind, Controlled, Single-Dose, Three-Treatment, Cross-Over Study of The Protective Effects Of Albuterol-HFA In Preventing Exercise-Induced Bronchoconstriction In Adolescent And Adult Asthmatic Patients||Amphastar Pharmaceuticals, Inc.|No|Terminated|February 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|24|||Both|12 Years|50 Years|No|||July 2013|July 11, 2013|March 7, 2008|Yes|Yes|IND voluntarily withdrawn, without prejudice|No||https://clinicaltrials.gov/show/NCT00634829||159283|
NCT00634816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cross Sectional|Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers|Cross-sectional Study of Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers||State University of New York - Upstate Medical University|No|Completed|April 2003|April 2006|Actual|April 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|38|||Both|16 Years|40 Years|No|Non-Probability Sample|Subjects will be recruited from the Oncology Clinic by one of the sub-investigators.|May 2013|May 29, 2013|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00634816||159284|
NCT00635089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Res-5-0004|Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis|An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002||Teva Pharmaceutical Industries|No|Completed|May 2008|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|5 Years|N/A|No|||August 2013|August 16, 2013|March 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635089||159263|
NCT00590408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-13642|Efficacy and Safety of Coenzyme Q10 in the Treatment of Statin-Associated Myalgia|||Creighton University||Terminated|March 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|19 Years|79 Years|No|||November 2009|November 27, 2009|December 28, 2007|Yes|Yes|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00590408||162613|
NCT00586430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|929-05|The Impact of Lorazepam on Cognition in APOE e4 Carriers|The Impact of Lorazepam on Cognition in APOE e4 Carriers||Mayo Clinic|Yes|Completed|December 2005|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Actual|36|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||December 2007|December 21, 2007|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586430||162907|
NCT00587574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|488/2007|Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic HSCT|Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic Hematopoietic Stem Cell Transplantation and Immunomodulatory Consequences of Chronic Graft-Versus-Host Disease and Therapy||Medical University of Vienna|No|Recruiting|October 2007|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|peripheral blood mononuclear cells as cell pellets and DNA, plasma and serum samples, tissue      biopsy samples, urine|Both|18 Years|80 Years|No|Probability Sample|all consecutive patients after allogeneic hematopoietic cell transplantation|October 2007|January 4, 2008|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587574||162821|
NCT00587587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-KEL-001-AG|A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids|A Prospective, Randomized, Controlled Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids||Organogenesis|No|Completed|December 2007|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||August 2011|August 16, 2011|December 21, 2007|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00587587||162820|
NCT00587886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-119|Estrogen, Diet, Genetics and Endometrial Cancer|Estrogen, Diet, Genetics and Endometrial Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2001|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1315|Samples With DNA|Buccal specimen|Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|In collaboration with the New Jersey Department of Health and Senior Services NJDHSS), we        will use rapid case ascertainment to identify patients as they are diagnosed.For controls        aged 65 and over, we will obtain lists from CMS of a sample of women in the 6 counties. As        an alternative way of reaching controls, we will conduct area sampling.|February 2016|February 1, 2016|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00587886||162799|
NCT00587275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST013|Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI|A Double-Blind, Randomized, Placebo-Controlled Crossover Study to Assess the Efficacy of AST-120 in Patients With Gastroesophageal Reflux Disease (GERD) Who Continue to be Symptomatic on a Standard Dose of Proton Pump Inhibitor (PPI)||Ocera Therapeutics|No|Terminated|October 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|80 Years|No|||June 2014|June 2, 2014|December 21, 2007|Yes|Yes|Terminated for lack of enrollment|No||https://clinicaltrials.gov/show/NCT00587275||162843|
NCT00587288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Res-5-0010|Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma|An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation||Teva Pharmaceutical Industries|Yes|Completed|November 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|75 Years|No|||August 2013|August 16, 2013|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587288||162842|
NCT00598988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6866|Acupuncture for Infectious Mononucleosis Trial|Acupuncture for Infectious Mononucleosis Trial|AIM|University of Alberta|Yes|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|15 Years|25 Years|No|||January 2009|January 8, 2009|December 4, 2007||No||No||https://clinicaltrials.gov/show/NCT00598988||161969|
NCT00599001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV3-HNV-01|Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males|A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Male Volunteers||Dynavax Technologies Corporation|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|February 26, 2016|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599001||161968|
NCT00599339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0854|Transdermal Rotigotine User Surveillance Study|A Naturalistic, Multisite, Observational Study of Rotigotine Transdermal Patch and Other Currently Prescribed Therapies in Patients With Idiopathic Parkinson's Disease|TRUST|UCB Pharma|No|Completed|June 2006|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|2195|||Both|N/A|N/A|No|Probability Sample|Primary Care|July 2015|July 27, 2015|January 10, 2008|No|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT00599339||161944|
NCT00595751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-1.6|NeuroLex EEG-Based ADHD Assessment Aid, Pivotal Study|Best Estimate Diagnosis Used to Evaluate EEG in Association With ADHD in a Multi-Site, Clinical Sample of Children and Adolescents|NEBA|Lexicor Medical Technology, LLC|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|6 Years|18 Years|No|Non-Probability Sample|The study focuses on individuals who have consecutively presented to participating clinics        with suspected attention and/or behavior concerns and would receive a clinician's        comprehensive evaluation for ADHD. The study population includes male and female        participants aged 6-17.99 years regardless of race, ethnicity, and socioeconomic origin.        Because of inclusion of patients with consecutive presentation to provide a representative        clinical sample, the exact numbers for sub-groups will not be controlled. The study        population will include patients with comorbid conditions. The non-ADHD subgroup will        include patients with other causes of attentional concerns, which may include other common        psychiatric disorders, organic causes of attention problems (such as poor hearing, vision        disturbances, remote head injury, substance abuse), and/or no diagnosis.|July 2008|July 29, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595751||162211|
NCT00611351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122-05|Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin||University of Nebraska|Yes|Completed|June 2005|September 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|65 Years|No|||February 2011|February 3, 2011|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00611351||161050|
NCT00611052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL423-0|Prevention of Adolescent Major Depression|"Adolescents Coping With Stress": Prevention of Adolescent Major Depression in School Health Care|CWSA-Fin|National Institute for Health and Welfare, Finland|No|Active, not recruiting|March 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|1000|||Both|14 Years|16 Years|No|||September 2011|September 30, 2011|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611052||161072|
NCT00611065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI-HS-2007-5671|Imaging of Prostate Cancer Using Two-Dimensional MR Spectroscopy and Diffusion Tensor Imaging|Imaging of Prostate Cancer Using Two-Dimensional MR Spectroscopy and Diffusion Tensor Imaging||University of California, Irvine|No|Withdrawn|June 2007|||June 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Male|21 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|January 12, 2008||No|There is no funding to proceed.|No||https://clinicaltrials.gov/show/NCT00611065||161071|
NCT00589017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581181|Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy|Phase II Study of Tamoxifen for Progressive Metastatic Bladder Cancer Following Previous Platinum-Based Chemotherapy||National Cancer Institute (NCI)||Recruiting|July 2005|||July 2010|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589017||162715|
NCT00589030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06057|Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol||City of Hope Medical Center|Yes|Completed|April 2007|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|January 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589030||162714|
NCT00589043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA at present|Computed Tomography Laser Mammography Breast Imaging Device|Computed Tomography Laser Mammography Breast Imaging Device Model 1020|CTLM|Imaging Diagnostic Systems|No|Not yet recruiting|October 2015|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|600|||Female|21 Years|N/A|No|Non-Probability Sample|Heterogeneous or extremely dense breast patient population scheduled for biopsy|August 2015|August 24, 2015|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00589043||162713|
NCT00589329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB01-00012|Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam|Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam||MetroHealth Medical Center|Yes|Terminated|December 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|December 27, 2007||No|published data suggest potential harm in other investigations.|No||https://clinicaltrials.gov/show/NCT00589329||162692|
NCT00589355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12110|C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance|C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance||Yale University|No|Active, not recruiting|January 2002|October 2008|Anticipated|June 2003|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|46|||Female|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups of healthy postmenopausal women who do not smoke. One group includes women with        either pre-diabetes or diet-controlled diabetes. The control group includes women with        normal glucose tolerance|December 2007|December 27, 2007|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00589355||162691|
NCT00589927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0003|Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent|Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions|DECLARELONG|CardioVascular Research Foundation, Korea|Yes|Completed|December 2007|February 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|486|||Both|18 Years|75 Years|No|||July 2009|March 17, 2010|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00589927||162648|
NCT00590187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC682-06|Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients|A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes||Cyclacel Pharmaceuticals, Inc.|No|Recruiting|December 2007|||November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|300|||Both|60 Years|N/A|No|||November 2011|November 7, 2011|December 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590187||162630|
NCT00589914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012289|Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia|A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1221|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|December 21, 2007|Yes|Yes||No|August 30, 2011|https://clinicaltrials.gov/show/NCT00589914||162649|Of 1221 patients randomized, one patient was enrolled twice and assigned 2 patient numbers. Only the first patient number is included in the results reported for 1220 randomized patients.
NCT00596310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCP-Lung|Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning|Early Detection of Lung Cancer in a High-Risk Population Defined by Pulmonary Function Testing, Biomarkers, and Computerized Tomography Scanning||University of Kentucky|No|Active, not recruiting|November 2004|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596310||162169|
NCT00586729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-012|Vashe Wound Therapy Study|Pilot Study to Evaluate Effectiveness of Vashe™ Wound Therapy as an Antimicrobial Irrigant in Burn Wound Management||Maricopa Integrated Health System|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|December 21, 2007||No||No|August 9, 2012|https://clinicaltrials.gov/show/NCT00586729||162884|
NCT00587015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-8015-1003|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)||MedImmune LLC|No|Terminated|August 2007|October 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||November 2011|November 21, 2011|December 21, 2007|No|Yes|Due to a lack of IP supply and then terminated because they were combined into one new study    with the new IP formulation.|No||https://clinicaltrials.gov/show/NCT00587015||162863|
NCT00587301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H# 11876|Lap-Band Surgery on Adolescents for Safety and Efficacy|A Prospective, Open-label Study to Evaluate the Safety and Efficacy of Lap-Band® Adjustable Gastric Band (LAGB®) Operations in the Treatment of Morbidly Obese Adolescents (Ages 14-17)|ALAGB|New York University School of Medicine|Yes|Recruiting|June 2005|December 2019|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|14 Years|17 Years|No|||March 2016|March 8, 2016|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00587301||162841|
NCT00587314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258-04|The Effect of Ablation Therapy on Barrett's Esophagus|The Effect of Ablation Therapy on Barrett's Esophagus|ablation IN BE|Mayo Clinic|No|Enrolling by invitation|January 2004|January 2022|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Esophageal Biopsy|Both|18 Years|90 Years|No|Non-Probability Sample|Patients who have had or qualify for ablation therapy for treatment of their barrett's        esophagus|December 2015|December 15, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587314||162840|
NCT00596843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA013763|Chronic Hepatitis Intervention Project for Drug Users|Chronic Hepatitis Intervention Project for Drug Users||National Institute on Drug Abuse (NIDA)|No|Active, not recruiting|September 2003|February 2008|Anticipated|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|851|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 13, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00596843||162128|
NCT00597129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hPAM4-01|Safety and Efficacy Study of 90Y-hPAM4 at Different Doses|A Phase I, Dose-Escalating Study to Investigate the Safety, Tolerability, Pharmacokinetics and Dosimetry of a Single Dose of 90YHumanized PAM4 IgG in Patients With Locally Advanced/Metastatic Pancreatic Cancer||Immunomedics, Inc.|No|Completed|August 2004|October 2007|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2008|January 8, 2008|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597129||162107|
NCT00597142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2006|A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.|A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.|RENAISSANCE|Boston Scientific Corporation|Yes|Completed|January 2004|October 2009|Actual|July 2005|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597142||162106|
NCT00597168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NBE-SER-2006/1|Quality of Life in Schizophrenic Patients|QUALITY: A Non-interventional Study Evaluating Quality Of Life in Schizophrenic Patients Treated With Atypical Antipsychotics, in the Ambulatory Setting. A 9-month, Observational, Multicentric Prospective Study.|Quality|AstraZeneca|No|Completed|October 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|124|||Both|18 Years|65 Years|No|Non-Probability Sample|Ambulatory patients|June 2010|June 8, 2010|November 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00597168||162105|
NCT00597402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000458|Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas|Avastin in Combination With Radiation and Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma Multiformes and Gliosarcomas||Duke University|Yes|Completed|July 2007|May 2013|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|January 10, 2008|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00597402||162087|
NCT00588107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-032|A Web Site and Print Materials Intervention for Smoking Intervention for Childhood and Young Adult Cancer Survivors|Partnership for Health: A Web-Based Smoking Intervention For Cancer Survivors|PFH2|Dana-Farber Cancer Institute|No|Completed|September 2005|December 2013|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|374|||Both|18 Years|55 Years|No|||December 2014|December 30, 2014|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588107||162783|
NCT00598429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0037|Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure|Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network|IPGE1|NICHD Neonatal Research Network|Yes|Withdrawn|May 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|N/A|7 Days|No|||July 2015|July 27, 2015|January 10, 2008|Yes|Yes|Withdrawn due to lack of recruitment|No||https://clinicaltrials.gov/show/NCT00598429||162010|
NCT00598442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-13|Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis|AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment|PEARL 2|Affymax|Yes|Completed|November 2007|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|493|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|January 10, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00598442||162009|
NCT00599014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005380|Heart Failure Study: The Atlanta Cardiomyopathy Consortium|The Atlanta Cardiomyopathy Consortium|TACC|Emory University|No|Completed|November 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|335|Samples With DNA|Blood for DNA/RNA/Proteomics analysis and Urine for proteomic analysis|Both|18 Years|N/A|No|Non-Probability Sample|Cardiology and general medicine clinics; Inpatients from cardiology services|August 2015|October 4, 2015|January 11, 2008||No||No|November 13, 2013|https://clinicaltrials.gov/show/NCT00599014||161967|Long baseline visit with several questionnaires to be completed made more difficult for the patients to be enrolled. Adverse Events data was not collected as part of this observational registry.
NCT00596089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0274|Use of Jumping Mechanography as a Method to Assess Musculoskeletal Status in Older Adults|Use of Jumping Mechanography as a Method to Assess Musculoskeletal Status in Older Adults: A Pilot Study||University of Wisconsin, Madison|No|Completed|October 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women 60 years and older and men and women 20-30 years of age|January 2008|October 1, 2015|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00596089||162186|
NCT00596102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-303|Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51|Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51. An Uncontrolled Phase 3 Follow-up Study||Valneva Austria GmbH||Completed|October 2005|||March 2011|Actual|Phase 3|Observational|Observational Model: Cohort||1|Actual|3258|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 3,300 subjects having completed IC51, JE-VAX or placebo treatment in studies        IC51-301 or IC51-302 will take part in the safety follow up, up to month 6 after 1st        vaccination in the study IC51-301 (NCT00604708) or IC51-302 (NCT00605085).        Only ~160 subjects, who have been treated with IC51 will take part in the immunogenicity        and long-term analysis up to month 60.|June 2014|June 27, 2014|January 4, 2008|No|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00596102||162185|
NCT00595764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA019511|Counseling for Primary Care Office-based Buprenorphine|Counseling for Primary Care Office-based Buprenorphine||Yale University|No|Completed|August 2005|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|65 Years|No|||September 2014|September 30, 2014|October 3, 2007|Yes|Yes||No|July 18, 2013|https://clinicaltrials.gov/show/NCT00595764||162210|
NCT00611884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1836|Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes|A 16 Week Randomised, Open-labelled, Four-armed, Treat-to-target, Parallel-group Trial Comparing SIBA D Once Daily, SIBA E Once Daily, SIBA D Monday, Wednesday and Friday and Insulin Glargine Once Daily, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment||Novo Nordisk A/S|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|245|||Both|18 Years|75 Years|No|||October 2015|October 16, 2015|January 29, 2008|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT00611884||161009|
NCT00611611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060217005|BLYS and IFN in SLE|BLyS and IFN Responses to Antigen Challenge in Human SLE||University of Alabama at Birmingham|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|39|||Both|19 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|lupus and healthy controls|April 2011|April 27, 2011|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00611611||161030|
NCT00611624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601000957|Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma|A Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I and II Breast Carcinoma|Mammosite|Yale University|Yes|Completed|May 2006|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|50 Years|N/A|No|||April 2014|April 5, 2014|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00611624||161029|
NCT00611637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4138-07-10R5|CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease|A Pilot Clinical Trial of CMV pp65 Specific T Cell Adoptive Immunotherapy in Patients Who Have Undergone Allogeneic Stem Cell Transplantation for Malignant Disease|CMV-BMT|Duke University|No|Terminated|August 2005|June 2008|Actual|February 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|January 29, 2008|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00611637||161028|
NCT00611650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000578224|Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia|Phase II Trial of Polyphenon E in Current and Former Smokers With Bronchial Dysplasia||British Columbia Cancer Agency|Yes|Terminated|October 2006|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|23|||Both|45 Years|74 Years|No|||March 2012|March 7, 2012|February 8, 2008|Yes|Yes|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00611650||161027|
NCT00589056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582319|Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase I/II Trial of Protease Inhibitor, Nelfinavir, Given With Concurrent Thoracic Chemoradiotherapy in Patients With Locally-Advanced Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|June 2007|||December 2009|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|December 25, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589056||162712|
NCT00589069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORP5010|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2003|||||N/A|N/A|N/A||||||||||||||May 15, 2015|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589069||162711|
NCT00589368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0585|Transfer of Grasp Control Across Hands After Stroke|Interhemispheric Transfer of Grasp Control After Stroke||New York University School of Medicine|No|Completed|May 2006|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|58|||Both|21 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with stroke will be recruited from the inpatient and outpatient Rehabilitation        units at the Mount Sinai Medical Center and from referrals by community rehabilitation        physicians and neurologists. Control subjects will be recruited by public advertisement in        the New York City area. There are no exclusions based on gender or ethnic groups.|October 2012|October 5, 2012|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00589368||162690|
NCT00590421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Car&RAD05|Carotid Atherosclerotic Disease Following Childhood Scalp Irradiation|Carotid Atherosclerotic Disease Following Childhood Scalp Irradiation||Assaf-Harofeh Medical Center|No|Completed|July 2004|November 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|295|Samples Without DNA|Blood samples, 10 ml, were procured for assessment of creatinine, total cholesterol, high      density lipoproteins (HDL), triglycerides (TG), calculated low density lipoproteins (LDL)      and homocysteine.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study was designed to include 150 persons who were treated as children for Tinea        Capitis by scalp irradiation in the 1950's and 150 subjects who were not exposed to        radiation. This sample size was determined under the following assumption: power of ≥95%,        alpha error level of 5%, 10% prevalence of carotid stenosis in the non exposed group and        minimal OR of 2.5.|December 2007|October 16, 2008|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00590421||162612|
NCT00586443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001082|BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)|A Phase I Study of Bevacizumab, Everolimus, and Panitumumab for Patients With Advanced Solid Tumors|BEP|Duke University|No|Completed|November 2007|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|56|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00586443||162906|
NCT00586456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2007|||||N/A|N/A|N/A||||||||||||||June 14, 2013|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586456||162905|
NCT00596882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806910|Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study|Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study||University of Pennsylvania|No|Completed|February 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 1, 2009|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596882||162126|
NCT00597181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710-28|A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy|A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open-Angle Glaucoma|Optonol|Indiana University|No|Terminated|November 2007|August 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2010|September 16, 2010|January 7, 2008|Yes|Yes|Patient population limited|No||https://clinicaltrials.gov/show/NCT00597181||162104|
NCT00596570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12007|Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting|Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: A Multicenter, Prospective Registry|AFCAS|University of Turku|No|Completed|January 2007|February 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|996|Samples Without DNA|Anticoagulation samples|Both|N/A|N/A|No|Probability Sample|Patients with atrial fibrillation undergoing PCI-S.|December 2007|June 29, 2010|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596570||162149|
NCT00596856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1942|Development and Dissemination of Oral Health Risk Assessment and Referral Guidelines|Development and Dissemination of Oral Health Risk Assessment and Referral Guidelines - PORRT|PORRT|University of North Carolina, Chapel Hill|No|Withdrawn|April 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|0|||Both|N/A|N/A|No|||March 2013|March 15, 2013|January 8, 2008||No|Published study provided evidence that intervention would provide little effect; study not    approved by provider community.|No||https://clinicaltrials.gov/show/NCT00596856||162127|
NCT00597922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1407|Examining Heart Attacks in Young Women|Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction (AMI) Patients (VIRGO)|VIRGO|Yale University|No|Completed|September 2007|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2985|Samples With DNA|Blood specimens for biomarker analysis and storage for future genetic studies|Both|18 Years|55 Years|No|Non-Probability Sample|2,000 women and 1,000 men between the ages of 18 and 55 years who are hospitalized with a        heart attack|June 2014|June 26, 2014|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597922||162047|
NCT00598143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-141|Biomarkers of Molecular Risk in Smokers|Biomarkers of Molecular Risk in Smokers||Memorial Sloan Kettering Cancer Center||Completed|February 2005|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|45|Samples With DNA|Saliva Samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MSKCC clinics|May 2015|May 27, 2015|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598143||162031|
NCT00597675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000163|Mucosal Immunotherapy for Peanut Allergy|Mucosal Immunotherapy for Peanut Allergy|MIT|University of North Carolina, Chapel Hill|Yes|Completed|March 2007|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|1 Year|7 Years|No|||June 2015|June 6, 2015|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597675||162066|
NCT00595478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85846|Family Based Contingency Management for Adolescent Alcohol Abuse|Family Based Contingency Management for Adolescent Alcohol Abuse||Dartmouth-Hitchcock Medical Center|Yes|Completed|August 2007|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595478||162232|
NCT00596050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16271|Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions|Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions||Drexel University|No|Completed|August 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||September 2013|August 13, 2014|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596050||162189|
NCT00595790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-304|Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51|Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis||Valneva Austria GmbH|No|Completed|September 2005|November 2007|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|374|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|January 4, 2008||Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00595790||162208|
NCT00595816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKK VASTE|Injury Prevention Among Conscripts|Prevention of Musculoskeletal Injuries in Finnish Conscripts. A Cluster Randomized Controlled Trial.|VASTE|UKK Institute|Yes|Completed|July 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|800|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2008|January 4, 2008|January 4, 2008||||No||https://clinicaltrials.gov/show/NCT00595816||162207|
NCT00596362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-040|Treatment With Intravitreal Avastin for Large Uveal Melanomas|Neoadjuvant Treatment With Intravitreal Avastin for Large Uveal Melanomas||Memorial Sloan Kettering Cancer Center||Completed|April 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|January 8, 2008|No|Yes||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00596362||162165|
NCT00596375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06693|Lidocaine Lubricant in Pediatric Urethral Catheterization|Lidocaine Lubricant Use as an Anesthetic Agent in Emergency Room Urethral Catheterization||Children's Healthcare of Atlanta|No|Completed|August 2006|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|47|||Both|2 Months|2 Years|No|||December 2007|January 16, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596375||162164|
NCT00611676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2664-B01|A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain|A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain||University of Washington|No|Completed|September 2004|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|18|||Both|50 Years|80 Years|No|||January 2008|January 25, 2008|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00611676||161025|
NCT00596037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPLG-005-RO|Treatment of Adults With Growth Hormone Deficiency|A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency||LG Life Sciences|Yes|Completed|August 2006|May 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|23 Years|70 Years|No|||October 2012|October 4, 2012|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596037||162190|
NCT00589381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080030|Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma|Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|August 2007|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|December 20, 2007|No|Yes||||https://clinicaltrials.gov/show/NCT00589381||162689|
NCT00589641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006806|Relapse Prevention for Suicidal Dually Diagnosed Youths|Relapse Prevention for Suicidal Dually Diagnosed Youths|CBT-RP|Duke University|Yes|Completed|July 2005|October 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|13 Years|19 Years|No|||June 2010|July 9, 2014|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00589641||162670|
NCT00590200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 P50 HL077107-03|GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Disease|Molecular Determinants of Coronary Artery Disease|GATC|The Cleveland Clinic|Yes|Enrolling by invitation|January 2001|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15000|Samples With DNA|Approximately 70 mls of blood will be dispensed as follows (Approximately 80 mls if cell      lines are drawn or if the patient is having a cardiac CT scan):      4 x 10 mls EDTA Tube (DNA will be amplified in order to preserve quantity)        1. x 10ml Lithium Heparin Tube (drawn on selected patient populations at CCF only- See           Appendix E. for cell line protocol)        2. x 5 mls Serum Tube      1 x 7 mls Serum Tube      1 x 2.7 mls Sodium Citrate Tube (CCF Only. See Appendix D)      1 x 4.5 mls CTAD tube (platelet release inhibited)      1 x 4.5 mls SCAT-1 tube (coagulation activation inhibited) (Blood may be dispensed in the      above tubes in different quantities if functional studies are needed on a subset of samples)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All Cleveland Clinic patients undergoing cardiac catheterization or have had a heart        catheterization within one year, coming in for outpatient appointments, or have scheduled        cardiac CT scans or CT scans performed within one year of scheduled blood draw, will be        eligible to be enrolled.|January 2012|January 23, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590200||162629|
NCT00590434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0002|Yield and Safety of Colonoscopy in Patients Older Than 80 Years|The Yield and Safety of Screening and Surveillance Colonoscopy in Elderly Patients (> 80 Years)||Midwest Biomedical Research Foundation|No|Completed|August 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|169|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is a Veteran population presenting to a VA Hospital upper endoscopy        unit|October 2012|October 25, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590434||162611|
NCT00598156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19033|Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva|Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.|ACT|Lund University Hospital|Yes|Completed|June 2007|August 2012|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|249|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598156||162030|
NCT00597415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer walking model|Efficacy of Celecoxib 200mg in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee|A Double-Blind, Placebo-Controlled, Randomized, Crossover Pilot Study of the Efficacy of Celecoxib 200 mg QD in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee.||University Hospital Case Medical Center|Yes|Recruiting|December 2004|March 2008|Anticipated|February 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|45 Years|N/A|No|||December 2007|January 9, 2008|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597415||162086|
NCT00597428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBD0632|Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone|A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)|OPAL|Sucampo Pharma Americas, LLC|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 9, 2008|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT00597428||162085|Post-study, it was determined that lubiprostone efficacy was dose-dependently decreased with concomitant methadone use (30% higher morphine equivalent daily dose (MEDD) than parallel pivotal study NCT00595946).
NCT00597688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meghna|Role of Oral Chlorhexidine Gel in Prevention of Ventilator Associated Pneumonia|Oral Mucosal Decontamination With Chlorhexidine for Prevention of Ventilator Associated Pneumonia in Children - A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|86|||Both|3 Months|15 Years|No|||February 2009|March 22, 2011|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00597688||162065|
NCT00599352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11152|Hypovitaminosis D and an Inadequate PTH Response in Chronic Liver Disease Patients|Hypovitaminosis D and an Inadequate PTH Response in Chronic Liver Disease Patients||University of Kansas Medical Center|No|Terminated|January 2008|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599352||161943|
NCT00595127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-062|Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine|A Pilot Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine||Memorial Sloan Kettering Cancer Center|Yes|Completed|June 2001|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 9, 2013|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00595127||162256|
NCT00595140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-Nr. 2007-005585-12|Acute Application of Pegvisomant and Octreotide in Acromegaly|The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment||Ludwig-Maximilians - University of Munich|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|No|||January 2008|March 31, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595140||162255|
NCT00599378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11018|Implementation Intentions to Promote Colon Cancer Screening in Rural Primary Care Practice|Implementation Intentions to Promote Colon Cancer Screening in Rural Primary Care Practice||University of Kansas Medical Center|Yes|Completed|September 2007|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|373|||Both|50 Years|N/A|No|||September 2013|September 6, 2013|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00599378||161941|
NCT00595153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CHR# H6788-30617|Study of the Mechanisms of Asthma|Determining Mechanisms of Asthma Through Detailed Analysis of Airway Secretions and Tissues|MAST|University of California, San Francisco|Yes|Completed|April 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|127|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|January 2, 2008|No|Yes||No|September 25, 2013|https://clinicaltrials.gov/show/NCT00595153||162254|
NCT00595491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001050|Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation|Inflammatory Cellular Trafficking in Asthma in Response to Segmental Allergen Challenge||Massachusetts General Hospital|Yes|Recruiting|January 2008|January 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|178|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00595491||162231|
NCT00596154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-129|Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma|Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)|PCNSL|Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2004|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|72 Years|No|||August 2015|August 14, 2015|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00596154||162181|
NCT00596115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12316|Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day|Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day||Bennett, James P., Jr., M.D., Ph.D.||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|30 Years|80 Years||||July 2012|July 24, 2012|January 5, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00596115||162184|
NCT00596128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK-SH_Hanss_2008/01|Standard Operating Procedures in Daily Clinical Routine|Does Implementation of a Standard Operating Procedure for Blood Sugar Control Into Daily Clinical Routine Improve Care of Patients||University of Schleswig-Holstein|Yes|Completed|December 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|800|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00596128||162183|
NCT00596141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORO_PG_LSU_1_08|Pilot Study to Evaluate the Use of OroScience Topical Oral Wound Emulsion in Post Operative Wound Healing|Pilot Study to Evaluate the Use of OroScience Topical Oral Wound Emulsion in Post Operative Wound Healing||OroScience, Inc.|No|Completed|February 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|21 Years|N/A|No|||May 2013|May 6, 2013|January 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00596141||162182|
NCT00612924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-006|The Vascutek AnacondaTM Stent Graft System Phase II IDE Study|The Anaconda Endovascular Graft US FDA Phase II Clinical Study||Terumo CVS|Yes|Active, not recruiting|April 2009|July 2017|Anticipated|July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|195|||Both|18 Years|85 Years|No|||February 2016|February 10, 2016|January 22, 2008|Yes|Yes||No|February 10, 2016|https://clinicaltrials.gov/show/NCT00612924||160929|
NCT00596908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSE-A-01|123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor|123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor (AIM)|AIM|Alseres Pharmaceuticals, Inc|No|Completed|December 2007|March 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|54|Samples Without DNA|2 blood draws and 2 urine collections per subject.|Both|40 Years|N/A|No|Non-Probability Sample|Patients with tremor referred to a Movement Disorder Specialist for evaluation|May 2009|May 28, 2009|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596908||162124|
NCT00589953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-04-004|High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study|High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study||Atlantic Health System|Yes|Terminated|July 2007|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||July 2013|July 29, 2013|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589953||162647|
NCT00596011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15008|Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia|Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia (HGPIN) or Atypical Small Acinar Proliferation (ASAP)||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|December 2007|August 2016|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|97|||Male|30 Years|80 Years|No|||January 2016|January 12, 2016|January 7, 2008|Yes|Yes||No|August 15, 2014|https://clinicaltrials.gov/show/NCT00596011||162192|Primary Endpoint: Progression to PCa. Recent evidence demonstrates ASAP is a stronger diagnostic predictor associated with PCa compared to HGPIN. Due to this evidence and recruitment challenges, we revised inclusion criteria to include men with ASAP.
NCT00596024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAD|Lutein and Alzheimer's Disease Study|Lutein and Oxidative Stress in Alzheimer's Disease - A Pilot Study|LAD|Oregon Health and Science University|No|Recruiting|December 2007|||December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|55 Years|N/A|No|||January 2008|January 4, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00596024||162191|
NCT00596323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X070207013|Implantable Antenna Sensors for Continuous Glucose Monitoring|Implantable Antenna Sensors for Continuous Glucose Monitoring||University of Alabama at Birmingham|No|Completed|June 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults|December 2009|December 1, 2009|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00596323||162168|
NCT00596583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQNA-DY001|DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery|AQNA-DY001: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery||Aqumen Biopharmaceuticals, N.A.|No|Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2009|February 27, 2009|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596583||162148|
NCT00598455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS0500008|Tuberous Sclerosis Complex Natural History Study: Renal Manifestations|Tuberous Sclerosis Complex Natural History Study: Renal Manifestations||Children's Hospital Medical Center, Cincinnati|No|Recruiting|February 2008|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|7 Years|65 Years|No|Probability Sample|a. The target population for this study will be patients with tuberous sclerosis who        attend a tuberous sclerosis clinic that is part of the consortium. The data collected will        include routine imaging data, age, gender, and if know, the genotype. Approximately 855        patients throughout the United States will be asked to participate in this natural history        study and 450 of those are anticipated to consent and have complete data on 3 years of CT        and MR Imaging Scans to measure angiomyolipoma growth and adiposity.|August 2012|August 1, 2012|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00598455||162008|
NCT00598169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-053|Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma|Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma||AIDS Malignancy Consortium|No|Completed|November 2007|November 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|120 Years|No|||February 2016|February 8, 2016|January 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00598169||162029|
NCT00598182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709022R|Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study|From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD||National Taiwan University Hospital|Yes|Completed|September 2007|September 2009|Actual|||N/A|Observational|Observational Model: Case-Only||1|Actual|64|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who were diagnosed as DSM-IV ADHD and participated in the randomized clinical        trial for CONCERTA at NTUH Taiwan will be enrolled into this study.|April 2012|May 16, 2012|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598182||162028|
NCT00598741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-083|Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors|Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors||Memorial Sloan Kettering Cancer Center|Yes|Completed|July 2004|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|N/A|N/A|No|||April 2014|April 9, 2014|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598741||161988|
NCT00599027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05277|An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma|An Exploratory Study of Mometasone Furoate Nasal Spray in Patients With Moderate-severe Persistent Allergic Rhinitis and Intermittent Asthma: Effects on the Quality of Life Evaluated With the Rhinasthma Questionnaire||Merck Sharp & Dohme Corp.|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|75 Years|No|||March 2015|March 27, 2015|January 10, 2008|Yes|Yes||No|April 8, 2010|https://clinicaltrials.gov/show/NCT00599027||161966|
NCT00598754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSBRI NCC9-59-172 #1|Diagnostic Three Dimensional Echocardiography Study Protocol|Diagnostic Two and Three Dimensional Echocardiography Study Protocol|NSBRI 4401|The Cleveland Clinic|No|Enrolling by invitation|June 2001|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients coming to Cleveland Clinic to have surgery for aortic stenosis or aortic        insufficiency.|January 2008|January 21, 2008|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00598754||161987|
NCT00599053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061228003|Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates|Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates||University of Alabama at Birmingham|Yes|Terminated|May 2007|August 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|7|||Both|N/A|3 Days|No|||August 2012|November 28, 2012|January 10, 2008|Yes|Yes|Enrollment was terminated early due to a change in practice on the obstetrical side that    included administering azithromycin to women with preterm labor.|No|May 30, 2012|https://clinicaltrials.gov/show/NCT00599053||161964|Early termination due to small number enrolled.
NCT00599365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H45161-31657-01|Impact of CAMP in an Ambulatory Renal Clinic|Impact of a Pharmacist's Collaborative Management, Adherence,and Medication Education Program (CAMP) in an Ambulatory Renal Clinic|CAMP|San Francisco Veterans Administration Medical Center|Yes|Recruiting|December 2007|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2007|February 14, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00599365||161942|
NCT00595504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-001929|Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia|Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia||Massachusetts General Hospital|Yes|Completed|January 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||August 2012|August 14, 2012|January 7, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00595504||162230|The limitations of this study include the relatively small sample size and short intervention period (8 weeks).
NCT00595777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/MRE10/84|Edinburgh Pain Assessment Tool (EPAT©) Study|Does the Institutionalisation of Pain Assessment Using the EPAT© Package Reduce the Pain in Cancer In-patients More Than Usual Care; a Cluster Randomised Trial.|EPAT©|University of Edinburgh|Yes|Completed|December 2007|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1928|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595777||162209|
NCT00596167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609-18|Intradialytic Drug Removal by Short-daily Hemodialysis|Intradialytic Drug Removal by Short-daily Hemodialysis||Indiana University|Yes|Completed|September 2007|September 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 7, 2008|Yes|Yes||No|April 3, 2013|https://clinicaltrials.gov/show/NCT00596167||162180|Overall limitation is the relatively small sample size.
NCT00612690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH073749|School-Based Mental Health Services for Urban Children|Mental Health Services & Predictors of Learning in Urban Schools||University of Illinois at Chicago|No|Completed|June 2005|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|482|||Both|5 Years|12 Years|No|||May 2014|May 15, 2014|January 22, 2008||No||No|August 16, 2013|https://clinicaltrials.gov/show/NCT00612690||160947|This study was conducted in high poverty urban communities and therefore there were many impediments to recruitment and retention such as school closings and family migration.
NCT00612443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0.243|Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy|Healing Touch and Health-Related Quality of Life in Women With Breast Cancer in Women With Breast Cancer Receiving Radiation Therapy||University of Wisconsin, Milwaukee|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|N/A|No|||January 2008|January 20, 2009|January 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00612443||160966|
NCT00612703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-111|A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors||ArQule|No|Completed|February 2008|||September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00612703||160946|
NCT00596349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-131|Women Surviving Ovarian Cancer|Quality of Life in Women Surviving Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Completed|November 2004|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|62|||Female|N/A|N/A|No|Non-Probability Sample|Memorial Sloan-Kettering Cancer Center (MSKCC) clinic The Queens Cancer Center        Hospital(QCC)clinic|February 2009|February 25, 2009|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596349||162166|
NCT00595725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-127|Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma|Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma||Memorial Sloan Kettering Cancer Center|Yes|Completed|February 2003|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|151|||Both|N/A|N/A|No|||September 2011|September 7, 2011|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595725||162213|
NCT00596895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ2003-113|Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer|Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy.||University of Florida|No|Completed|November 2003|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|45 Years|80 Years|No|||January 2008|September 16, 2011|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596895||162125|
NCT00597194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216L2002|Day Case Inguinal Hernia Repair in Children. Is Laparoscopic Approach Justified?|Day Case Inguinal Hernia Repair in Children. Is Laparoscopic Approach Justified?||Hospital for Children and Adolescents, Finland|No|Completed|October 2002|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|89|||Both|4 Months|16 Years|No|||December 2007|January 16, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597194||162103|
NCT00597935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16P01|Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial|Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial: A Randomized Trial of Sacrospinous Ligament Fixation (SSLF) Versus Uterosacral Ligament Suspension (ULS) With and Without Perioperative Behavioral Therapy/Pelvic Muscle Training|OPTIMAL|NICHD Pelvic Floor Disorders Network|Yes|Completed|February 2008|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|439|||Female|18 Years|N/A|No|||September 2013|September 27, 2013|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597935||162046|
NCT00597701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090403|Treating Alcohol Withdrawal With Oral Baclofen|Treating Alcohol Withdrawal With Oral Baclofen: a Randomized, Double Blind, Placebo Controlled Trial||Essentia Health|No|Completed|April 2003|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|79|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|January 9, 2008|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00597701||162064|
NCT00597961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-088|Health Communication in Families|Health Communication in Families||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2003|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|Concentrating on two distinct tumor types, lung cancer and melanoma, because of the        prominence of risk behaviors in the etiology of both of these cancers. With regard to lung        cancer, we have identified high concordance of smoking among the spouses, siblings and        children of recently diagnosed patients. In the context of melanoma, patients report a        desire to use focused family discussions to encourage family members to reduce their skin        cancer risk and increase early detection behaviors.        "Family" defined as a group consisting of blood relatives, domestic partners, & on-blood        relatives as defined by cancer patient. During interviews with melanoma-affected families        we will be gathering data from a melanoma patient & ne of their adult sons or daughters.        During the interviews with lung cancer-affected families we will be gathering data from a        lung cancer patient and either one of their adult children, or one of their siblings, or        their spouse.|September 2015|September 17, 2015|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597961||162044|
NCT00597948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD055189-01|Healthy Lifestyles for People With Intellectual Disabilities|Efficacy of a Health Intervention for People With Intellectual Disabilities|HLID|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|April 2007|March 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|131|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597948||162045|
NCT00598494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSBRI NCC9-59-172 #4|Effect of Bedrest With and Without Exercise on the Heart|Effect of Bedrest With and Without Exercise on Cardiac Atrophy: Synergistic Supplemental Testing With the Cleveland Clinic Bedrest Study|NSBRI #4|The Cleveland Clinic|No|Recruiting|February 2007|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal volunteers|January 2008|January 21, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00598494||162006|
NCT00599040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040719005|The DINE Study-Diet Intervention to Negate Diabetes Study (Improving Weight Loss Outcomes for African Americans)|The DINE Study-Diet Intervention to Negate Diabetes Study (Improving Weight Loss Outcomes for African Americans)|DINE|University of Alabama at Birmingham|Yes|Completed|September 2005|December 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|113|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 15, 2013|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599040||161965|
NCT00599066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB No: 13577|Intraoperative M-Entropy Measurements|Same-patient Reproducibility of Intraoperative M-Entropy Measurements||University of Oklahoma|Yes|Completed|September 2007|April 2009|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|18 Years|90 Years|No|||October 2013|October 29, 2013|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00599066||161963|
NCT00599391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-RF-CTP1|Far Infrared Treatment for Kidney Diseases|Phase 1 Study to Examine the Use of Far Infrared Radiation for Renal Failure.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|February 2008|February 2009|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2009|January 2, 2009|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599391||161940|
NCT00599404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-111|PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400|An Open-Label, 2-Period Pharmacokinetic Study to Evaluate the Intra-Subject Variability in Esomeprazole Plasma Levels in Healthy Subjects Following Oral Administration of PN 400 Tablets||POZEN|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2008|April 23, 2008|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599404||161939|
NCT00595166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpecSheath|Using a Sheathed Speculum to Visualize and Access the Cervix in Women With Excessive Vaginal Tissue|Using a Sheathed Speculum to Visualize and Access the Cervix in Women With Excessive Vaginal Tissue||University of South Florida|No|Terminated|June 2007|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|5|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 4, 2008||No|Design changed to observational, not RCT. PI left USF; study closed.|No||https://clinicaltrials.gov/show/NCT00595166||162253|
NCT00595179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908042|Intraperative Assessment of Renal Perfusion Using Infrared Imaging|Intraoperative Assessment of Renal Perfusion Using Infrared Imaging||National Institutes of Health Clinical Center (CC)||Completed|December 2007|January 2012|Actual|||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||April 2012|April 4, 2012|January 3, 2008||||No||https://clinicaltrials.gov/show/NCT00595179||162252|
NCT00595517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00005|Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer|A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use||AstraZeneca|No|Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|395|||Both|20 Years|N/A|No|||August 2012|August 20, 2012|January 7, 2008||No||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00595517||162229|
NCT00595868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR GA3051DO|Efficacy of Varenicline in Ambivalent Smokers|Efficacy of Varenicline in Ambivalent Smokers||University of Vermont Medical Center|No|Completed|March 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 22, 2011|January 4, 2008|No|Yes||No|September 7, 2011|https://clinicaltrials.gov/show/NCT00595868||162203|
NCT00596180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU IRB #6626|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Carbon Monoxide Poisoning|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Carbon Monoxide Poisoning||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|January 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||January 2015|January 1, 2015|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00596180||162179|
NCT00612456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD7108240|To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD|A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.||GlaxoSmithKline|No|Completed|March 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|70|||Both|50 Years|N/A|No|||February 2013|February 28, 2013|January 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612456||160965|
NCT00612729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ye-Or 2008|Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.|Influence of Light-filters in IOLs on Color Perception and Contrast Acuity. A Randomized, Double-masked Study With Intraindividual Comparison.||Hospital Hietzing|No|Completed|May 2008|June 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|32|||Both|55 Years|80 Years|No|||December 2008|August 16, 2010|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00612729||160944|
NCT00596596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-3|Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation|A Double-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Efficacy and Safety of Prucalopride (R093877) in Subjects With Chronic Idiopathic Constipation||Movetis|No|Completed|September 1996|June 1997|Actual|June 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|313|||Both|18 Years|70 Years|No|||January 2008|May 28, 2008|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596596||162147|
NCT00597220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORWARD|Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation|Randomized, Prospective, Placebo-controlled, Multi-center Study to Test the Efficacy of n-3 PUFA for the Maintenance of Normal Sinus Rhythm in Patients With Persistent Atrial Fibrillation|FORWARD|Fundacion GESICA|Yes|Active, not recruiting|January 2008|August 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1600|||Both|21 Years|N/A|No|||June 2011|June 21, 2011|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597220||162101|
NCT00597714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003567|Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant|Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplantation||Duke University|Yes|Completed|February 2008|November 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|264|||Both|18 Years|N/A|No|||February 2014|May 2, 2014|January 14, 2008|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00597714||162063|
NCT00597974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA2389|Neurological Outcome With Carotid Artery Stenting|Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty|CAS|Columbia University|No|Completed|September 2003|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|108|Samples With DNA|plasma serum DNA (obtained via buccal samples using a buccal cell collection swab)|Both|18 Years|N/A|No|Non-Probability Sample|Columbia University/NY Presbyterian Hospital|June 2015|June 2, 2015|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597974||162043|
NCT00598208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06055|A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)|A Phase 2, Open Label, Randomized Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or ICSI.||Merck Sharp & Dohme Corp.|No|Completed|May 2003|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|325|||Female|18 Years|39 Years|No|||June 2015|June 1, 2015|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598208||162026|
NCT00598234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950704|Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty|Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty||National Taiwan University Hospital|No|Completed|September 2006|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|60 Years|N/A|No|||June 2010|June 20, 2010|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598234||162025|
NCT00598195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57839|Ketamine Pharmacokinetics in Children Having Heart Surgery|Ketamine Pharmacokinetics in Children Undergoing Cardiac Surgery||Arkansas Children's Hospital Research Institute|No|Completed|June 2006|December 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|N/A|6 Years|No|||February 2013|February 26, 2013|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00598195||162027|
NCT00598507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14965|Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma|Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|May 2007|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||August 2013|November 15, 2013|January 10, 2008|Yes|Yes||No|September 12, 2013|https://clinicaltrials.gov/show/NCT00598507||162005|
NCT00598481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115611|ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID|ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID|Gene-ADA|GlaxoSmithKline|No|Active, not recruiting|October 2002|June 2019|Anticipated|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|17 Years|No|||March 2015|March 26, 2015|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598481||162007|
NCT00599079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|340|Azithromycin in the Treatment of M. Avium Complex Lung Disease|Open, Noncomparative Trial of Azithromycin in the Treatment of M.Avium Complex (MAC) Lung Disease||The University of Texas Health Science Center at Tyler|No|Active, not recruiting|February 1993|||August 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||January 2008|January 11, 2008|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00599079||161962|
NCT00599092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2873|Pituitary Tumor Surveillance: Pathogenic Correlation|Pituitary Tumor Surveillance: Pathogenetic Correlation||Cedars-Sinai Medical Center|No|Recruiting|January 1997|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1250|Samples With DNA|whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|tertiary referral center|July 2009|July 8, 2009|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599092||161961|
NCT00599417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACLY_L_03329|PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections|Prospective, Pivotal Unicentre, Randomized Double-bind, Placebo-controlled Study, to Evaluate Efficacy and Safety of Bacterial Lysates (Pulmonarom) in the Prevention of Respiratory Tract Infections||Sanofi||Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|6 Months|6 Years|No|||September 2009|September 18, 2009|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599417||161938|
NCT00599430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danisco - Mao|Evaluation of Probiotics on Symptoms of Upper Respiratory Tract Infections|Probiotics and Effects on Illness-Related Symptoms for Pre-School Age Children||Danisco|No|Completed|November 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|326|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||January 2008|January 11, 2008|January 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00599430||161937|
NCT00595530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-101|Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain|Use of Low-Dose Ketamine Infusion in Acute Painful Episodes of Sickle Cell Disease: A Pilot Study||Connecticut Children's Medical Center|Yes|Completed|January 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|7 Years|N/A|No|||July 2013|July 29, 2013|December 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00595530||162228|
NCT00595829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL019-002|A Phase 1 Study of XL019 in Adults With Polycythemia Vera|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera||Exelixis||Terminated|December 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00595829||162206|
NCT00596466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081160|Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures|An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures||Pfizer|No|Completed|April 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|January 8, 2008|Yes|Yes||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00596466||162157|
NCT00596479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/04|Filgrastim for the Promotion of Collateral Growth in Patients With CAD|Subcutaneous Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease||University Hospital Inselspital, Berne||Completed|November 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|90 Years|No|||June 2015|June 15, 2015|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596479||162156|
NCT00612963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070023H|Novel Rinse to Treat in Oral Candidiasis in Cancer Patients|Novel Rinse to Treat Oral Candidiasis in Cancer Patients "Evaluate Iocide Oral Rinse in Any Patient With Thrush, Including But Not Limited to Patients Currently Receiving or Post Radiation Therapy for Head and Neck Cancer or Patients Positive for HIV/AIDS or Transplant Patients"||Biomedical Development Corporation|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Probability Sample|Male or female volunteers who are currently receiving or post radiation therapy for head        and neck cancer and currently having signs and/or symptoms of oral candidiasis|August 2009|March 4, 2010|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00612963||160926|
NCT00612937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908069|Streptococcal Infection and Respiratory Distress in Newborns|Respiratory Distress of the Newborn and Its Relationship to Group B Streptococcal Colonization||National Institutes of Health Clinical Center (CC)||Completed|February 2008|June 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|16000|||Both|N/A|N/A|No|||June 2015|June 20, 2015|February 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00612937||160928|
NCT00612950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 03005|Beta-Cell Function After Near-Normalisation of Blood Glucose|Four Weeks of Near Normalisation of Blood Glucose Improves the Insulin Response to GLP-1 and GIP in Patients With Type 2 Diabetes||Hvidovre University Hospital|No|Completed|October 2006|May 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|8|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2008|February 11, 2008|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00612950||160927|
NCT00596635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606001581|Cranberry for UTI Prevention in Residents of Long Term Care Facilities|Cranberry for UTI Prevention in Residents of Long Term Care Facilities|PACS|Yale University|No|Completed|January 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|56|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 19, 2013|January 8, 2008||No||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00596635||162144|The inability to follow all participants for the full six months reflects the vulnerability of the population.
NCT00596648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-202|A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer|A Phase 1b/2 Study of XL184 With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer||Exelixis||Completed|December 2007|||August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596648||162143|
NCT00596661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD 640-0051-01|The TRIMAXX Coronary Stent Trial|A Prospective, Multi-Center, Non-Randomized, Single-Arm Trial to Evaluate the Safety and Feasibility of the TriMaxx Coronary Stent in de Novo Coronary Artery Lesions.||Abbott Vascular|Yes|Completed|May 2004|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||October 2008|October 10, 2008|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596661||162142|
NCT00597207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zoll-0100|Circulation Improving Resuscitation Care (CIRC)|A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest|CIRC|Zoll Medical Corporation|Yes|Completed|January 2008|December 2013|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4231|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|January 8, 2008||No||No|March 8, 2014|https://clinicaltrials.gov/show/NCT00597207||162102|
NCT00597233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1529|Human Insulin NPH and Insulin Aspart in Type 1 Diabetes|Comparative Evaluation of Human NPH Insulin + Insulin Aspart and Human NPH Insulin + Human Soluble Insulin in Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|October 2002|December 2002|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|91|||Both|18 Years|N/A|No|||January 2013|April 12, 2013|January 9, 2008||||No||https://clinicaltrials.gov/show/NCT00597233||162100|
NCT00597246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-028|Imaging Brain Tumors With FACBC and Methionine|Imaging Brain Tumors With FACBC and Methionine||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|May 2003|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|N/A|N/A|No|||June 2015|June 15, 2015|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597246||162099|
NCT00597441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007995|Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation|Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation||Duke University|Yes|Terminated|November 2005|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|60 Years|No|||November 2012|November 13, 2012|December 27, 2007|No|Yes|accrual of evaluable subjects too low|No||https://clinicaltrials.gov/show/NCT00597441||162084|
NCT00597454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-067|An Access Delivery Model That Eliminates Barriers to Breast Cancer Care Delivery|An Access Delivery Model That Eliminates Barriers to Breast Cancer Care Delivery With Emphasis on the Coordination of Care Within and Between an Outpatient Screening Facility and a Diagnostic and Treatment Center||Memorial Sloan Kettering Cancer Center|Yes|Completed|July 2004|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|150|||Female|N/A|N/A|No|||July 2012|July 25, 2012|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00597454||162083|
NCT00597467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVI060105|Study of Soft Contact Lens Use With 7 Day Extended Wear|An Open-Labeled, Multi-Center, Randomized Investigation of the VISA (Comfilcon A) Silicone Hydrogel Soft (Hydrophilic) Contact Lens for Use in a 7 Day Extended Wear Regimen||Coopervision, Inc.|No|Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|455|||Both|18 Years|N/A|No|||December 2008|December 19, 2008|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597467||162082|
NCT00597727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2296|A Study of Sublingual Immunotherapy in Peanut-allergic Children|A Double-blinded, Placebo-controlled Study of Peanut Sublingual Immunotherapy in Children - DBPC Peanut SLIT|SLB|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|January 2008|October 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|1 Year|11 Years|No|||October 2015|October 10, 2015|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597727||162062|
NCT00598260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(H)N-2957|Active Management Of Risk In Pregnancy At Term to Reduce Rate of Cesarean Deliveries|Active Management Of Risk In Pregnancy At Term - a Prospective Study||Albert Einstein Healthcare Network|Yes|Terminated|June 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|222|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 9, 2011|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598260||162023|
NCT00598273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-11|Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis|AFX01-11: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment|PEARL 1|Affymax|Yes|Completed|October 2007|February 2010|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|490|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|January 10, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00598273||162022|
NCT00598247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-07-3|A Pilot Study of PPX in Women With Metastatic Colorectal Cancer|A Pilot Study of PPX (Paclitaxel Poliglumex, CT-2103) in Women With Metastatic Colorectal Cancer||University of Southern California|No|Completed|January 2008|July 2011|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||February 2014|February 5, 2014|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598247||162024|
NCT00598819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5593|A Prospective Study of a New Device for Monitoring Cerebral Oxygenation on Healthy Volunteers|A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Healthy Volunteers||University of California, Irvine|Yes|Completed|October 2007|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 15, 2011|December 19, 2007||No||No|January 15, 2010|https://clinicaltrials.gov/show/NCT00598819||161982|No Adverse Events (AE's) or Serious Adverse Events (SAE's) were reported in this study.
NCT00599105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI-HS-2000-1141|Angiogenesis in Early Breast Cancer for Prognosis Prediction|Angiogenesis in Early Breast Cancer for Prognosis Prediction||University of California, Irvine|No|Completed|November 2000|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|700|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599105||161960|
NCT00598767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSBRI NCC9-59-172 #2|Three Dimensional Imaging and Wireless Technologies to Enhance Medical Care in Space|Multimodality 3D Imaging and Wireless Technologies To Enhance Medical Care in Space|NSBRI #2|The Cleveland Clinic|No|Recruiting|June 2003|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at the Cleveland Clinic undergoing aortic valve repair or replacement|January 2008|January 21, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00598767||161986|
NCT00598780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00421|Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study|Long-term Evaluation of Safety and Treatment Satisfaction With Levocetirizine in Routine Clinical Practice in the Czech and Slovak Republics - Non-interventional Study||UCB Pharma|No|Completed|September 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7870|||Both|2 Years|N/A|No|Probability Sample|Patients with newly diagnosed persistent allergic rhinitis, within the approved age        limits.        Age ≥ 2 years|October 2008|May 25, 2012|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00598780||161985|
NCT00599456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27103|Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.|A Placebo Controlled Double Blinded Prospective Study to Investigate the Usefulness of Omega 3 Fatty Acids in the Relief of Vasomotor Symptoms of Menopausal Women||Christiana Care Health Services|No|Completed|September 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|N/A|65 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599456||161935|
NCT00599469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-AD-CTP1|Far Infrared Treatment for Alzheimer's Disease|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|February 2008|April 2009|Anticipated|March 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|No|||August 2009|August 14, 2009|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599469||161934|
NCT00595205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104435|Intussusception Surveillance After Rotarix Introduction in Mexico|Post-Authorization Safety Study (PASS) of Post-Marketing Surveillance for Intussusception Following Rotarix™ Introduction Into the Instituto Mexicano Del Seguro Social (IMSS) in Mexico||GlaxoSmithKline||Completed|January 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|786|||Both|N/A|364 Days|No|Non-Probability Sample|All eligible children < 1 year of age (children ineligible on day of first birthday) who        are/have been treated at one of the study hospitals/medical facilities with definite        intussusception.|February 2011|March 15, 2012|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00595205||162251|
NCT00595556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-113-1|Zonisamide vs. Placebo in the Treatment of Alcohol Dependence|Zonisamide vs. Placebo in the Treatment of Alcohol Dependence||University of Connecticut Health Center|No|Completed|July 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||September 2010|September 28, 2010|January 6, 2008|Yes|Yes||No|May 15, 2010|https://clinicaltrials.gov/show/NCT00595556||162226|The small sample size and the short duration of treatment are limitations. High rates of retention in the treatment and adherence to the medication regimen are strengths. The concomitant psychotherapy may have caused a ceiling effect on medication.
NCT00595842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070204|Artificial Root-End Barriers|Clinical Success of Artificial Root-End Barriers With Mineral Trioxide Aggregate in Teeth With Immature Apices||The University of Texas Health Science Center at San Antonio|No|Completed|February 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|10|||Both|5 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients between 5-40 years old who have been treated with MTA|March 2012|March 7, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595842||162205|
NCT00595569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120/04|Flexible, Intensive Insulin Therapy in Patients With Type 1 Diabetes|Flexible, Intensive Insulin Management in Patients With Type 1 Diabetes and Changes in Metabolic Control, Quality of Life, Locus of Control and Diabetes Knowledge||University of Lausanne Hospitals|No|Completed|April 2002|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with type 1 diabetes followed at the Division of Endocrinology and        Diabetology, University of Basel are strongly encouraged to attend the course 6 to 12        months after having been diagnosed. The population that participates in those FIT courses        includes patients from the University of Basel Hospital, but also patients that are        referred from out of hospital physicians/diabetologists.|December 2007|January 15, 2008|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00595569||162225|
NCT00588029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-030|Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer|Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer||Memorial Sloan Kettering Cancer Center|No|Active, not recruiting|July 1999|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|7000|Samples With DNA|Blood, Cerebro-Spinal Fluid and Saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer patients seen at Memorial Sloan-Kettering Cancer Center|October 2015|October 1, 2015|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588029||162788|
NCT00588042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005081|Remote Myocardial Ischemic Preconditioning in Humans|Remote Myocardial Ischemic Preconditioning in Humans|RemoteMIPH|Mayo Clinic|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00588042||162787|
NCT00617812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL/DTPwHB-Hib/PMS/2007/0100|Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine|An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants.||Shantha Biotechnics Limited|No|Completed|March 2008|May 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|160|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||June 2009|June 24, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617812||160566|
NCT00612976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312006001|Symbicort in Chronic Obstruktive Pulmonary Disease|Symbicort in Chronic Obstruktive Pulmonary Disease|SYMBIOSE|AstraZeneca|No|Completed|February 2006|||September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18014|||Both|N/A|N/A|No|Probability Sample|general practitioners and internists|January 2008|February 11, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00612976||160925|
NCT00613561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0707|Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases|Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases|SIDS|Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|December 2007|December 2017|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|11 Years|No|||May 2009|May 26, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613561||160882|
NCT00596674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-08-0043|Health Promotion for Women With Fibromyalgia|Health Promotion for Women With Fibromyalgia||University of Texas at Austin|No|Completed|July 2003|May 2008|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Female|18 Years|75 Years|No|||April 2012|April 24, 2012|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596674||162141|
NCT00596921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2008.029|Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure|Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure||Brooke Army Medical Center|No|Not yet recruiting||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients with central venous monitoring in place.|January 2008|January 16, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596921||162123|
NCT00596934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03DK074488|Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)|Nonalcoholic Steatohepatitis: is Leptin an Etiological Factor (Phase 2).||University of Michigan|No|Completed|February 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|65 Years|No|||April 2013|April 24, 2013|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596934||162122|
NCT00597259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710028M|Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B|Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B||National Taiwan University Hospital|No|Recruiting|January 2008|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|294|||Both|18 Years|70 Years|No|||June 2010|June 28, 2010|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597259||162098|
NCT00597480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070303|Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)|Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH) by Comparison of Two Regimens of rhGH Administration to SGA Children. Pharmacogenetics of Metabolic Responses to rhGH|SGA|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|January 2008|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|4 Years|10 Years|No|||April 2014|April 20, 2015|January 7, 2008||No|no more inclusions|No||https://clinicaltrials.gov/show/NCT00597480||162081|
NCT00597740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-106|Propofol Sedation Study|Clinical Utility of Propofol Sedations Without and With a Formal "ICU Sedation Protocol" in Intubated Neurotrauma Patients|SPIN|Scottsdale Healthcare|No|Completed|December 2007|December 2013|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|57|||Both|18 Years|80 Years|No|Probability Sample|Neurotrauma ICU patients brought to our level one trauma facility requiring intubation.|December 2013|December 2, 2013|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597740||162061|
NCT00597753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-12|Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis|AFX01-12: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin Alfa|EMERALD 1|Affymax|Yes|Completed|September 2007|January 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|803|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|January 10, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00597753||162060|
NCT00598286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080049|PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2|Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2||National Institutes of Health Clinical Center (CC)||Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598286||162021|
NCT00598533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S02907|Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis|Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis|ISAR-TEST-5|Deutsches Herzzentrum Muenchen|Yes|Completed|February 2008|September 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3002|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598533||162004|
NCT00598832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18113|Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%|A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris||Galderma|No|Completed|November 2007|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1075|||Both|12 Years|N/A|No|||March 2011|March 21, 2011|January 11, 2008|Yes|Yes||No|April 16, 2010|https://clinicaltrials.gov/show/NCT00598832||161981|
NCT00598793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-2163|Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy|Biphasic Insulin Aspart 70/30 + Metformin Compared to Insulin Glargine + Metformin in Type 2 Diabetes Failing OAD Therapy|INITIATE|Novo Nordisk A/S|No|Completed|November 2002|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|242|||Both|18 Years|75 Years|No|||June 2012|June 5, 2012|January 11, 2008||||No||https://clinicaltrials.gov/show/NCT00598793||161984|
NCT00598806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-612|Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer||Spectrum Pharmaceuticals, Inc|No|Completed|September 2007|March 2012|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|813|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598806||161983|
NCT00599482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-SCC-CTP1|Far Infrared Radiation for Sickle Cell Pain Management|Phase 1 Study to Examine the Use of Far Infrared Radiation for Pain Management During Sickle Cell Crisis||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|January 2008|January 2009|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|N/A|N/A|No|||January 2009|January 2, 2009|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599482||161933|
NCT00599183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC IRB PRO00009246|Diffusion Tensor (Magnetic Resonance) Imaging and Tractography in Herniation of the Cervical Spine|Diffusion Tensor (Magnetic Resonance) Imaging and Tractography in Herniation of the Cervical Spine: An Investigator-Initiated Pilot Study||Cedars-Sinai Medical Center|No|Completed|August 2006|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|N/A|N/A|No|||July 2013|July 29, 2013|January 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599183||161955|
NCT00595257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriCell/CT/IND-001|Feasability Study of Autologous Bone Marrow Aspirate Concentrate for Treatment of CLI|Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Non Reconstructable Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease||Harvest Technologies|No|Completed|December 2007|April 2010|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00595257||162247|
NCT00595218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PittRadOnc|Patient Preference Survey for Radiation Oncologists|How Can Radiation Oncologists Better Serve Their Patients? A Randomized Study to Determine Whether Radiation Oncologists Can Improve Patient Satisfaction by Attempting to Meet Their Patients' Preferences||University of Pittsburgh||Completed|April 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|500|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00595218||162250|
NCT00595543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5349|Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%|||Bp Consulting, Inc||Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|166|||Both|18 Years|N/A|No|||March 2009|March 17, 2009|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595543||162227|
NCT00595231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN111-CL03|Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)|A Multi-Center,Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients With Moderate to Severe Generalized Anxiety Disorder||Biotie Therapies Inc.|No|Completed|March 2008|||October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|65 Years|No|||February 2014|January 13, 2016|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595231||162249|
NCT00595244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-006|Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease|CSP 127-006 A Phase 3 Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive Technology Using PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Arter Disease||Point Biomedical|Yes|Completed|July 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|456|||Both|18 Years|N/A|No|||July 2008|July 1, 2008|January 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00595244||162248|
NCT00595855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARMASURG001|A Comparison Between Deep Sclerectomy and Trabeculectomy|Deep Sclerectomy Versus Trabeculectomy. A 7 Year Prospective Randomised Clinical Trial||University of Parma|No|Completed|October 1997|December 2006|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|65 Years|N/A|No|||January 2008|January 7, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595855||162204|
NCT00588471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2026-02|Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention|The Effect of Acute Statin Treatment on Inflammation and Peripheral Arterial Tone in Patients Undergoing Percutaneous Coronary Intervention.||Mayo Clinic|No|Terminated|November 2002|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|December 22, 2007|Yes|Yes|The study was terminated because not enough subjects could be recruited.|No|October 9, 2012|https://clinicaltrials.gov/show/NCT00588471||162755|The study was terminated early because not enough subjects could be recruited.
NCT00618111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAN-T1-PVFD-1|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|March 2005|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 15, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00618111||160543|
NCT00618124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181044|A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together|A Phase 1 Safety And Pharmacokinetic Study Of SU011248 And Capecitabine In Patients With Advanced Solid Tumors||Pfizer|No|Completed|May 2005|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||April 2010|April 29, 2010|February 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00618124||160542|
NCT00618085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0605/84NOC|Motor Imagery Practice in Neurological Rehabilitation|An Integrated Motor Imagery Program in Rehabilitation - a RCT||Nuffield Orthopaedic Centre NHS Trust|No|Completed|February 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2009|May 1, 2009|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00618085||160545|
NCT00618098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEX-205|Study of OCTAPLEX and FFP in Patients Under Vit K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures|A Randomized, Open Label, Efficacy and Safety Study of OCTAPLEX and Fresh Frozen Plasma (FFP) in Patients Under Vitamin k Antagonist Therapy With the Need for Urgent Surgery or Invasive Procedures||Octapharma|Yes|Completed|April 2008|August 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|February 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00618098||160544|
NCT00597272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-086|Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma|Pilot Trials With a KLH Conjugated Bivalent GangliosideVaccine Mixed With Immunological Adjuvants QS-DG or OPT-821in Patients With Disease Free AJCC Stage III or IV||Memorial Sloan Kettering Cancer Center||Completed|December 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|21 Years|N/A|No|||November 2012|November 19, 2012|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597272||162097|
NCT00596947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803242|Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant|Randomized, Prospective Single-center Study Comparing a Rapid Discontinuation of Corticosteroids (Steroid Withdrawal) With Corticosteroid Therapy in Kidney Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy||University of Pennsylvania|No|Terminated|October 2005|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|19 Years|74 Years|No|||February 2011|February 18, 2011|January 8, 2008|Yes|Yes|due to low study enrollment|No|February 18, 2011|https://clinicaltrials.gov/show/NCT00596947||162121|The trial was terminated early due to low enrollment. Therefore no results beyond basic results section are reported due to uninterpretable data.
NCT00597766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24HD054600|Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain|Clinical Trials in Stroke Rehabilitation||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|December 2007|February 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597766||162059|
NCT00597493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000464|Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM|Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme||Duke University|Yes|Completed|September 2007|December 2010|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|January 9, 2008|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00597493||162080|
NCT00598000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-006|Quality of Life and Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) Anatomic Lung Resection Versus Thoracotomy and Anatomic Lung Resection|Quality of Life and Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) Anatomic Lung Resection Versus Thoracotomy and Anatomic Lung Resection||Memorial Sloan Kettering Cancer Center||Completed|February 2005|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|216|||Both|N/A|N/A|No|Non-Probability Sample|MSKCC Clinics|April 2015|April 22, 2015|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598000||162041|
NCT00598546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-112|Quality of Life Among Long-Term Survivors of Resected Gastric Cancer|Quality of Life Among Long-Term Survivors of Resected Gastric Cancer||Memorial Sloan Kettering Cancer Center|Yes|Completed|September 2004|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|212|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have had curative resection at MSKCC for gastric cancer and are at least        three years NED.|July 2009|July 9, 2009|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598546||162003|
NCT00598559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APA-351|Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients|A Phase III, Multi-Center, Open-Label, Prospective, Repeated Dose, Randomized, Controlled, Multi-Day Study of the Safety and Efficacy of Intravenous Acetaminophen in Adult Inpatients||Mallinckrodt|No|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|213|||Both|18 Years|85 Years|No|||May 2015|May 14, 2015|January 8, 2008|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00598559||162002|No separate efficacy analyses were performed for the fever because only 1 subject in each active group had fever as an indication, and no subject had both pain and fever as indications for treatment with IV acetaminophen.
NCT00598572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000288/1|Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage|Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage|DFO In ICH|Beth Israel Deaconess Medical Center|Yes|Completed|July 2008|April 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||February 2011|February 16, 2011|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598572||162001|
NCT00598585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-04-378-07|Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS|Phase 4 Study of the Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic Fatigue Syndrome.||Charles Drew University of Medicine and Science|Yes|Recruiting|July 2002|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2009|February 23, 2009|August 31, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598585||162000|
NCT00599118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8271|Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation|Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation||The Cleveland Clinic|Yes|Active, not recruiting|August 2005|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1300|Samples With DNA|plasma, serum, buffy coat, DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with atrial fibrillation|June 2010|June 1, 2010|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599118||161959|
NCT00599443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S203.1.001|Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.||Solvay Pharmaceuticals|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2008|June 27, 2008|January 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00599443||161936|
NCT00595270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-305|Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51|Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51||Valneva Austria GmbH|No|Completed|October 2005|April 2009|Actual|September 2007|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|349|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 5, 2014|January 4, 2008|No|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00595270||162246|
NCT00595283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080163|Effectiveness of Parent-Child Interaction and Emotion Development Therapy in Treating Preschool Children With Depression|Early Intervention in Depression: Dyadic Emotion Development Therapy for Preschool Children||Washington University School of Medicine|No|Completed|October 2007|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|3 Years|6 Years|No|||March 2013|March 20, 2013|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00595283||162245|
NCT00599495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBMT MUDRIC-MM|Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT|Allogeneic Stem Cell Transplantation From Unrelated Donors After Dose-reduced Intensity Conditioning Regimen for Patients With Multiple Myeloma and Relapse After Autologous Stem Cell Transplantation: A Phase II-study||Universitätsklinikum Hamburg-Eppendorf|No|Completed|November 2002|December 2009|Actual|August 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599495||161932|
NCT00599508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-03-20-08|Nutritional Supplementation in Cognitive Aging|Nutritional Supplementation in Cognitive Aging||University of Cincinnati|No|Completed|June 2006|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|69|||Both|66 Years|N/A|No|||January 2015|January 14, 2015|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599508||161931|
NCT00595881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-6-5388|Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections|Emergency Bedside Ultrasound for the Evaluation of Soft Tissue Infections in the Pediatric Emergency Department||Children's Hospital of Philadelphia|No|Completed|July 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|420|||Both|2 Months|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from the emergency department at a tertiary care children's        hospital with annual census of 78,000 patients per year.|February 2012|December 27, 2012|January 7, 2008||No||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00595881||162202|Potential misclassification of lesions based on reference standard. Biased lesion outcome, as ultrasound results were not incorporated into patient care.Single institution
NCT00595894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|028-03-ET|Rheumatoid Arthritis Comorbidity: Bone Health in Men and African Americans|RA Comorbidity: Bone Health in Men and African Americans||University of Nebraska|Yes|Completed|July 2004|January 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1745|Samples With DNA|Baseline sera and DNA collected|Both|19 Years|N/A|No|Non-Probability Sample|CLEAR enroll African American RA patients from 4 core academic centers in the Southeast        U.S. VARA enroll RA patientss from participating VA medical centers.|March 2011|June 18, 2013|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595894||162201|
NCT00596219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-147|Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma|Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma||Memorial Sloan Kettering Cancer Center|Yes|Completed|December 2003|October 2010|Actual|October 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|January 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00596219||162176|
NCT00588289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-068|Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA|CCG-LTFI: A Groupwide Protocol for Collecting Follow- up Data||Memorial Sloan Kettering Cancer Center||Completed|September 1999|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|102|||Both|N/A|N/A|No|Non-Probability Sample|The patient must have completed anti-cancer treatment according to a CCG protocol, or must        have been declared off protocol therapy, but not off study.|October 2013|October 8, 2013|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588289||162769|
NCT00613925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU RES 4145|Endometrial Biopsy Instrument Comparison Study|Comparison of Pain Experienced by Patients Undergoing Endometrial Biopsy by Pipelle and Explora Curette||Oregon Health and Science University|No|Completed|January 2008|January 2011|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|73|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|January 31, 2008|Yes|Yes||No|June 4, 2012|https://clinicaltrials.gov/show/NCT00613925||160856|Providers not blinded
NCT00613912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUFF-2005-740-004|Advanced MRI in Major Depression|Advanced MRI at 3T for the Evaluation of Ambulant Patients With Major Depression||University of Aarhus|Yes|Completed|March 2008|June 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ambulant patients with major depression, selected from the Department of Psychatry,        Aalborg hospital-Århus University Hospital.|November 2011|November 18, 2011|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613912||160857|
NCT00596960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-009-07S|Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients|Motivating Chronic Hepatitis C Patients to Reduce Alcohol Use||VA Office of Research and Development|Yes|Completed|November 2008|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|January 8, 2008||No||No|November 12, 2014|https://clinicaltrials.gov/show/NCT00596960||162120|
NCT00597285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080027|Relationship of HHV-6B Virus to Seizures and Brain Injury|HHV6B in Epilepsy Imaging and CSF Studies||National Institutes of Health Clinical Center (CC)||Terminated|January 2008|November 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|January 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00597285||162096|
NCT00597506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001574|Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus|Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus|BEV/EV|Duke University|Yes|Completed|October 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2012|December 21, 2012|December 26, 2007|Yes|Yes||No|July 10, 2012|https://clinicaltrials.gov/show/NCT00597506||162079|
NCT00597987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-045|BRCA1 Haploinsufficiency and Gene Expression|BRCA1 Haploinsufficiency and Gene Expression||Memorial Sloan Kettering Cancer Center||Completed|September 2004|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|120|Samples With DNA|Blood samples from cases will be collected from patients who have previously undergone      genetic counseling through the Clinical Genetics Service at MSKCC and tested positive for a      germline mutation in BRCA1. Blood samples from controls will be obtained from two sources.      First from specimens already collected under IRB Protocol #99-030, entitled "Collection of      Tissue, Blood, and Cells to be Used for Studying the Causes, Prevention, Diagnosis, and      Treatment of Breast Cancer (T. King, PI). Controls will also be collected from patients who      have previously undergone genetic counseling through the Clinical Genetics Service at MSKCC      and tested negative for germline mutations in BRCA1. Isolation of total RNA from blood will      be performed using the PAXgene™ Blood RNA System. This study will use lymphocyte RNA samples      from 50 individuals with BRCA1 mutations and 50 age-matched controls. Gene expression      profiling will be performed in the Genomics Core Laboratory of MSKCC.|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will be performed using lymphocyte RNA samples from 50 women with BRCA1        mutations and 50 age-matched controls without BRCA1 mutations. Class comparison analysis        will be performed on the gene expression data.|September 2012|September 12, 2012|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597987||162042|
NCT00598013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2004-0082|Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes|A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes||Yonsei University|Yes|Completed|November 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|83|||Both|18 Years|N/A|No|||January 2008|January 17, 2008|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598013||162040|
NCT00598312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OL-01110|Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer|A Phase 3, Open-Label, Multi-Center, Safety And Efficacy Study of Oakwood Laboratories' Leuprolide Acetate For Injectable Suspension 22.5 mg In Patients With Prostate Cancer||Oakwood Laboratories, LLC|No|Completed|April 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Male|45 Years|N/A|No|||September 2010|September 2, 2010|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598312||162019|
NCT00598299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20072037R|Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Auto-Serum and Cord Blood Serum|Department of Ophthalmology, National Taiwan University Hospital||National Taiwan University Hospital|Yes|Completed|April 2007|April 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|heahty adult volunteers and donated cord blood|October 2008|November 2, 2008|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598299||162020|
NCT00598858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 07-14|Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate|Phase II Study to Determine the Effects of Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate in Patients Who Are Scheduled for Radical Prostatectomy With Genomic Correlates of Pathological Response|2007-5904|University of California, Irvine|Yes|Withdrawn|January 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||April 2013|April 3, 2013|January 10, 2008|No|Yes|Halted due to zero accrual and lack of funding|No||https://clinicaltrials.gov/show/NCT00598858||161979|
NCT00599196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0716|An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease|An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease||UCB Pharma|No|Completed|August 2002|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|381|||Both|30 Years|N/A|No|||September 2010|September 24, 2014|December 24, 2007|Yes|Yes||No|December 11, 2009|https://clinicaltrials.gov/show/NCT00599196||161954|
NCT00599131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.029|Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)|A Phase II Organ Preservation Trial Using Cetuximab and Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to One Cycle of Induction Chemotherapy With Taxotere, Cisplatin, 5-Fluorouracil (TPF), and Cetuximab||University of Michigan Cancer Center|Yes|Terminated|August 2007|October 2010|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|December 12, 2007|Yes|Yes|The study was discontinued prematurely due to early stopping rules.|No|April 16, 2014|https://clinicaltrials.gov/show/NCT00599131||161958|The study was discontinued prematurely due to an early stopping rule.
NCT00599144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|usl8|Effectiveness of Bupivacaine After Laparoscopic Cholecystectomy|Effectiveness for Postoperative Pain After Laparoscopic Cholecystectomy of 0,5% Bupivacaine-Soaked Tabotamp Placed in the Gallbladder Bed||Santa Maria alla Gruccia Hospital|Yes|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||January 2008|January 22, 2008|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599144||161957|
NCT00595296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeneSearch BLN Assay PPC Study|GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study|GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study||Janssen Diagnostics, LLC|No|Terminated|December 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|461|Samples With DNA|Samples of the lymph node tissue homogenate and RNA extract are collected if the subject      gives permission via the informed consent form.|Both|18 Years|N/A|No|Probability Sample|Patients must have been diagnosed with carcinoma of the breast and be a candidate for        lymph node surgery as per each site's standard of care. The patients may be female or        male, at least 18 years old, and must meet study inclusion criteria described later in        this protocol. Patients receiving pre-operative therapy for breast cancer, such as        neoadjuvant therapy and/or hormonal intervention are not eligible to participate in this        study.|January 2016|January 11, 2016|January 4, 2008|Yes|Yes|GeneSearch™ BLN Assay has been voluntarily withdrawn from the US market.|No||https://clinicaltrials.gov/show/NCT00595296||162244|
NCT00595582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU#H05-168|Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine|Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine||Louisiana State University Health Sciences Center Shreveport|No|Terminated|May 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 25, 2012|January 4, 2008|Yes|Yes|For various reasons.|No|October 11, 2011|https://clinicaltrials.gov/show/NCT00595582||162224|2 patients withdrew due to Dyspepsia (intolerance to supplement).
NCT00595907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Janssens1/2008|Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis|Observational Study of Production of IFN-Gamma by Peripheral Lymphocytes in Response to Specific Antigens Before and After Treatment for Tuberculosis||University Hospital, Geneva|Yes|Completed|October 2004|July 2006|Actual|July 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|89|Samples Without DNA|Peripheral blood lymphocytes cultured over-night; ELISPOT for detection of interferon-gamma      production|Both|18 Years|N/A|No|Non-Probability Sample|Patients either at diagnosis of tuberculosis, under treatment for tuberculosis, or within        6 months after treatment completion|January 2008|January 7, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595907||162200|
NCT00596492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQNA-DY002|DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery|AQNA-DY002: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery|AQNA-DY002|Aqumen Biopharmaceuticals, N.A.|No|Terminated|May 2008|December 2008|Anticipated|September 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2009|February 27, 2009|January 9, 2008|Yes|Yes|Terminated due to reasons unrelated to safety|No||https://clinicaltrials.gov/show/NCT00596492||162155|
NCT00588497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|628-04|Characterization of the Essure System Tubal Sterilization Using Ultrasound and X-Ray|Characterization of the Essure System Tubal Sterilization Using Ultrasound and X-Ray||Mayo Clinic||Completed|February 2004|March 2006|Actual|March 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|25|||Female|18 Years|50 Years|No|Non-Probability Sample|Twenty-five subjects for this study will be recruited from patients who have requested a        form of permanent sterilization, and who, after considering all the options, choose the        trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed        suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert        system, Conceptus Incorporated, Mountain View, California) placement will be offered the        opportunity to participate in the study. Consent will be documented on a Mayo Clinic        patient consent form at the time the decision is made to schedule the procedure.|May 2011|May 20, 2011|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00588497||162753|
NCT00613938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014116|A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|901|||Both|18 Years|80 Years|No|||April 2014|April 24, 2014|January 31, 2008|Yes|Yes||No|October 2, 2009|https://clinicaltrials.gov/show/NCT00613938||160855|
NCT00614198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 0503g|ScanBrit Dietary Intervention in Autism|The ScanBrit Randomised Controlled Study of Gluten- and Casein-free Dietary Intervention for Children With Autism Spectrum Disorders|ScanBrit|Center for Autisme, Denmark|No|Completed|April 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|4 Years|11 Years|No|||May 2010|August 31, 2010|January 31, 2008||No||No|May 17, 2010|https://clinicaltrials.gov/show/NCT00614198||160837|Single-blind trial, no placebo condition, analysis based on per protocol (not intention to treat), socio-economic status not recorded, independent screening for underlying somatic conditions potentially associated with results not undertaken
NCT00596687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005062|Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery|RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)|RABBIT 2-SX|Emory University|Yes|Completed|December 2007|July 2013|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|80 Years|No|||February 2014|February 7, 2014|January 8, 2008|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00596687||162140|
NCT00596700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECDAI-2006|Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study|Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study||Rabin Medical Center|Yes|Completed|January 2007|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596700||162139|
NCT00596713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0593/06|Epidemiology of Sleep Disturbances Among the Adult Population of the Sao Paulo City|Epidemiology of Sleep Disturbances Among the Adult Population of the Sao Paulo City||Associação Fundo de Incentivo à Pesquisa|Yes|Completed|June 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1100|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|General population of Sao Paulo city|July 2012|July 11, 2012|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00596713||162138|
NCT00597519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-014|A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy|A Myeloablative Conditioning Regimen Consisting of Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients With Hematological Malignancy.||Memorial Sloan Kettering Cancer Center||Completed|March 2006|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|4 Years|50 Years|No|||January 2016|January 14, 2016|December 26, 2007|No|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT00597519||162078|
NCT00596986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUK-B2.1|Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression|Impact of Therapeutical Strategies on Emotional Processing in Depression: Neurofunctional and Clinical Issues in the Context of Affective Bias|GETTY|Charite University, Berlin, Germany||Active, not recruiting|October 2008|||September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|55 Years|No|||July 2009|July 31, 2009|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596986||162118|
NCT00597298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCPN-01-08|Diaphragm Training Post-Cardiac Surgery|Randomized Controlled Trial on the Diaphragm Training With Threshold for Patient With Post-Cardiac Surgery Diaphragmatic Paralysis|DIATRACS|Ospedali Riuniti Trieste|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|48|||Both|18 Years|90 Years|No|||February 2009|February 3, 2009|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597298||162095|
NCT00597311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-48|Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer|Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer||Kaunas University of Medicine|No|Recruiting|January 2007|January 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||January 2008|January 9, 2008|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597311||162094|
NCT00597532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-062|Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study|Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2002|August 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|140|||Female|N/A|N/A|No|||August 2015|August 11, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597532||162077|
NCT00597545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC3837|Effect of Raised CBF During CEA on Cognition in DM Patients|Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients||Columbia University|No|Terminated|March 2007|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|January 9, 2008||No|Half of DM patients had EEG changes and therefore were excluded.|No|June 2, 2015|https://clinicaltrials.gov/show/NCT00597545||162076|
NCT00597779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN #07-065|Randomized Comparison of 2 Fixation Techniques for Unstable Intertrochanteric Hip Fractures|Extramedullary vs. Intramedullary Devices in the Treatment of Unstable Intertrochanteric Hip Fractures|EMvsIM|McGill University Health Center|No|Completed|February 2007|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|55 Years|N/A|No|||August 2014|August 14, 2014|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597779||162058|
NCT00598598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSBRI NCC9-59-172 #3|Echocardiographic Assessment of Cardiovascular Changes in Long Term Space Flight|Echocardiographic Assessment of Cardiovascular Adaptation and Counter Measures n Microgravity|NSBRI#3|The Cleveland Clinic|No|Recruiting|October 2003|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients coming to the Cleveland Clinic with aortic valve insufficiency or aortic valve        stenosis, undering going repair or replacement, or patient undergoing coronary bypass        surgery.|January 2008|January 21, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00598598||161999|
NCT00598325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-4513|Antibody and Safety Study of 6 Doses of NicVAX in Smokers|Phase 2 Single Center, Open-label Study to Assess Immunogenicity and Safety of 6 Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®)in Smokers||Nabi Biopharmaceuticals|No|Completed|January 2008|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|74|||Both|18 Years|65 Years|No|||May 2012|May 8, 2012|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598325||162018|
NCT00599222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUTA001|The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study|A Prospective, Randomized, Controlled Study on Intravitreal Ranibizumab (Lucentis) Combined With Transpupillary Thermotherapy (TTT) for Neovascular Age-related Macular Degeneration (AMD)||St. Erik Eye Hospital|No|Completed|February 2008|February 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|N/A|No|||November 2011|November 21, 2011|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00599222||161952|
NCT00598845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD 15501|Molecular Markers in Treatment in Endometrial Cancer|Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.|MoMaTEC|University of Bergen|No|Recruiting|April 2001|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Tumor specimens from endometrial carcinoma, from curettage and hysterectomy specimens,      formalin-fixed and paraffin-embedded and fresh frozen, stored at minus 80 °C, corresponding      blood samples with normal DNA|Female|N/A|N/A|No|Non-Probability Sample|Women with endometrial carcinoma that undergo an endometrial biopsy before treatment with        hysterectomy with bilateral salpingoophorectomy with or without pelvic lymph node staging.|December 2014|December 22, 2014|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00598845||161980|
NCT00599170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13nhl-07-3|Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma|Rituximab Plus CHOP Given Every Two Weeks With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma||University of Southern California|No|Active, not recruiting|January 2008|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|N/A|No|||January 2016|January 31, 2016|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599170||161956|
NCT00586651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0701/2030/ON/US|Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis|An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation||Teva Pharmaceutical Industries||Completed|December 2007|September 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|99 Years|No|||September 2015|September 22, 2015|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00586651||162890|
NCT00586664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-S&E-0409071-P|Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis|||Bausch & Lomb Incorporated|No|Completed|October 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|130|||Both|10 Years|N/A|No|||February 2013|February 4, 2013|December 21, 2007|Yes|Yes||No|October 8, 2009|https://clinicaltrials.gov/show/NCT00586664||162889|
NCT00595595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070149H|Development of a Model to Evaluate Regenerative Endodontic Techniques Using Extract Human Teeth|Development of a Model to Evaluate Regenerative Endodontic Techniques||The University of Texas Health Science Center at San Antonio|No|Completed|February 2007|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1080|Samples With DNA|extracted teeth 10ml of blood for DNA banking|Both|16 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting for surgical removal of impacted teeth|September 2012|September 14, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595595||162223|
NCT00587210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381-04|Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel|Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel||Mayo Clinic|No|Completed|June 2004|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Gastroenteroloy Clinic; Inflammatory Bowel Disease Clinic|January 2016|January 20, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587210||162848|
NCT00587522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135-00274|Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease|Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease||NDO Surgical, Inc.|No|Completed|August 2001|May 2003|Actual|May 2003|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||December 2007|December 21, 2007|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587522||162825|
NCT00587821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003|Peptide Profiles of Women Undergoing Breast Biopsy|Peptide Profiles of Women Undergoing Breast Biopsy||Memorial Sloan Kettering Cancer Center||Completed|January 2006|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|571|||Female|18 Years|N/A|No|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment        team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer        Center (MSKCC). If the investigator is a member of the treatment team, s/he will screen        their patient's medical records for suitable research study participants and discuss the        study and their potential for enrolling in the research study. Other potential subjects        will be informed of the study by her treating professional at the time she is told of the        need for a biopsy. Lists of patients scheduled for biopsy will be reviewed by study        personnel on a weekly basis.|December 2013|December 18, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587821||162804|
NCT00588809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00250|Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia|A Phase 2 Study of AZD6244 in Relapsed or Refractory AML||National Cancer Institute (NCI)||Completed|December 2007|December 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||February 2013|July 6, 2015|December 21, 2007|Yes|Yes||No|July 6, 2015|https://clinicaltrials.gov/show/NCT00588809||162730|
NCT00589095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0606001531|Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities|Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities||Yale University|No|Terminated|November 2006|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients referred to the Yale Brain Tumor Center for management of glioblastome multiforme|July 2014|July 1, 2014|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00589095||162709|
NCT00613951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1792|Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes|A 16 Week Randomised, Open Labelled, 3-armed, Parallel Group, Treat-to-target Trial Comparing Twice Daily (BID) Injections of SIAC 30 (B), SIAC 45 (B) and NovoMix®30, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment||Novo Nordisk A/S|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|75 Years|No|||November 2015|November 27, 2015|January 30, 2008|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT00613951||160854|
NCT00614211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACC001|Laparoscopic Approach to Cervical Cancer|A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer|LACC|Queensland Centre for Gynaecological Cancer|Yes|Recruiting|January 2008|July 2022|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|740|||Female|18 Years|N/A|No|||April 2015|April 20, 2015|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614211||160836|
NCT00596726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G030202|RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study|RECOVER I: IMPELLA® RECOVER® LP/LD 5.0 Support System: A Clinical Safety & Feasibility Study|RECOVER I|Abiomed Inc.|No|Completed|August 2006|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|75 Years|No|||May 2010|May 25, 2010|January 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00596726||162137|
NCT00597012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR055557|Comparing Knee Cartilage Surgery Versus Standard Physical Therapy in Treating People With a Meniscal Tear and Osteoarthritis|Partial Meniscectomy Versus Nonoperative Management in Meniscal Tear With OA: A Randomized Controlled Trial (MeTeOR)||Brigham and Women's Hospital|Yes|Active, not recruiting|May 2008|August 2016|Anticipated|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|351|||Both|45 Years|N/A|No|||January 2016|January 11, 2016|January 8, 2008||No||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00597012||162116|Surgical randomized controlled trials present methodological challenges, including crossover from one group to the other.
NCT00596999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-HPDSC-001|A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders|A Single-Arm Study to Assess the Safety of Transplantation With Umbilical Cord Blood Augmented With Human Placental-Derived Stem Cells From Partially Matched Related Donors in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders|HPDSC|Celgene|Yes|Enrolling by invitation|May 2007|December 2013|Anticipated|July 2013|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6|||Both|N/A|55 Years|No|Non-Probability Sample|subjects requiring cord blood transplantation|November 2007|April 9, 2012|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596999||162117|
NCT00598026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2007-A00888-45|Evaluation of the " Tele-follow-up " for the Follow-up of Implantable Defibrillators|Evaluation of the " Tele-follow-up " for the Follow-up of Implantable Defibrillators|EVATEL|Rennes University Hospital|Yes|Completed|January 2008|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1501|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00598026||162039|
NCT00597558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2299|Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)|Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)|EggOIT|University of North Carolina, Chapel Hill|Yes|Completed|February 2003|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|1 Year|16 Years|No|||June 2015|June 26, 2015|January 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597558||162075|
NCT00597571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11382-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2003|||||N/A|N/A|N/A||||||||||||||April 27, 2015|January 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00597571||162074|
NCT00597792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135-01762|Registry Study of the NDO Surgical Plicator for the Treatment of GERD|Registry Study of the NDO Surgical Plicator for the Treatment of GERD||NDO Surgical, Inc.|No|Terminated|August 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||May 2008|May 29, 2008|January 9, 2008|Yes|Yes|Sponsoring company ceased business operations|No||https://clinicaltrials.gov/show/NCT00597792||162057|
NCT00598611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04805-V2.0|Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)|An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)|AUD2OCU|Charite University, Berlin, Germany|Yes|Completed|September 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||May 2012|May 30, 2012|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598611||161998|
NCT00598624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005182-11|Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)|Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies|AlloTreo|IRCCS San Raffaele|No|Recruiting|September 2005|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|175|||Both|18 Years|69 Years|No|||August 2009|August 10, 2009|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598624||161997|
NCT00598871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-DV-201|A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds|A Randomized, Double-Mask, Placebo-Controlled, Dose Response, Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Diabetic Patients' Corneal Wounds Resulting From Epithelial Debridement During Vitrectomy||ReGenTree, LLC|No|Terminated|December 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2012|June 10, 2015|December 19, 2007|Yes|Yes|slow recruitment|No|February 22, 2010|https://clinicaltrials.gov/show/NCT00598871||161978|
NCT00590356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070208|Star-Close Versus Angio-Seal for Femoral Artery Hemostasis|A Randomized Comparison of Percutaneous CLip-based Vascular Occluder (Star-Close) Versus Bio-absorble Hemostatic Device (Angio-SEal) for Femoral Artery Hemostasis After Percutaneous Coronary Intervention|CLOSE|CardioVascular Research Foundation, Korea|Yes|Withdrawn|March 2007|June 2008|Anticipated|June 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|532|||Both|18 Years|N/A|No|||December 2007|August 18, 2010|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00590356||162617|
NCT00599209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11390|Health Information Technology in the Nursing Home|Health Information Technology in the Nursing Home||University of Massachusetts, Worcester|No|Completed|September 2004|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|23|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2011|August 2, 2011|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00599209||161953|
NCT00599521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18114|Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%|A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris||Galderma|No|Completed|November 2007|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1067|||Both|12 Years|N/A|No|||March 2011|March 21, 2011|January 11, 2008|Yes|Yes||No|April 16, 2010|https://clinicaltrials.gov/show/NCT00599521||161930|
NCT00587223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-EB-001-AG|Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)|A Prospective, Multicenter, Within Subject Controlled Study to Evaluate the Effect of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa||Organogenesis|Yes|Terminated|December 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|2 Years|65 Years|No|||June 2010|June 25, 2010|December 21, 2007|Yes|Yes|Insufficient patient enrollment|No|March 29, 2010|https://clinicaltrials.gov/show/NCT00587223||162847|Study terminated early, the 1 enrolled subject subsequently discontinued study at Day 7.
NCT00587847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.10.030|Campath Maintenance in Chronic Lymphocytic Leukemia|Maintenance Alemtuzumab in Refractory Chronic Lymphocytic Leukemia||Northwell Health|No|Terminated|August 2005|November 2009|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|December 21, 2007|Yes|Yes|Insufficient recruitment.|No|May 29, 2013|https://clinicaltrials.gov/show/NCT00587847||162802|Trial was terminated early due to poor accrual.
NCT00588068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-109|Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome|Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome||Memorial Sloan Kettering Cancer Center|No|Recruiting|September 2000|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Tumor, marrow and blood samples|Both|N/A|N/A|No|Non-Probability Sample|Patients will be offered participation in this study by their attending oncologist in the        Department of Pediatrics at Memorial Sloan Kettering Cancer Center.|February 2016|February 25, 2016|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588068||162786|
NCT00587860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132-06|A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome|A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome||Mayo Clinic|No|Completed|February 2006|March 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|70 Years|No|||March 2010|March 2, 2010|December 27, 2007|No|Yes||No|October 26, 2009|https://clinicaltrials.gov/show/NCT00587860||162801|A majority of the participants were local females with mild symptomsThe number of participants limits power of conclusionsWe evaluated the efficacy of SJW in all subtypes of IBS not allowing specific conclusions regarding subtypes
NCT00588276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-023|Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors|Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors||Memorial Sloan Kettering Cancer Center||Completed|June 2005|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 22, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588276||162770|
NCT00599326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A US17|Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda|Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda||University of Texas Southwestern Medical Center|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|January 10, 2008|Yes|Yes||No|August 21, 2013|https://clinicaltrials.gov/show/NCT00599326||161945|10 patients were enrolled, of which 8 were compliant with therapy and had evaluable data. Of the 2 patients dropped from the study, one patient was lost to follow-up after 2 months and another was noncompliant with medication dosing.
NCT00614250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT6796|Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea|A Double-blind, Randomized, Placebo-controlled, Study of the Safety and Activity of Four Escalating Single Doses of AVE0657 in Patients Suffering From Obstructive Sleep Apnea Hypopnea Syndrome||Sanofi|Yes|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|38|||Both|18 Years|75 Years|No|||July 2009|July 17, 2009|January 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614250||160834|
NCT00614263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB 006-005|A Study to Examine Levels of Sedation During Outpatient Colonoscopies|A Prospective, Blinded Study Examining Sedation Levels During Outpatient Colonoscopies||Baylor Research Institute|No|Completed|March 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|N/A||2|Actual|100|||Both|18 Years|N/A|No||Outpatient GI clinic|September 2013|September 10, 2013|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614263||160833|
NCT00614224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOSCH-TAEX-001|Structural Neuroplasticity Associated With Aerobic Treadmill Training in Geriatric Chronic Stroke Survivors|Structural Neuroplasticity Associated With Aerobic Treadmill Training in Geriatric Chronic Stroke Survivors||University Hospital Tuebingen|No|Completed|January 2008|April 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|60 Years|N/A|No|||January 2008|May 27, 2015|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614224||160835|
NCT00597324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-1-MV|Predictive Value of Allen's Test Result in Elective Patients Undergoing Coronary Catheterization Through Radial Approach|Should Intervention Through RADial Approach be Denied to Patients With Negative Allen's Test Results?|RADAR|Università degli Studi di Ferrara|Yes|Completed|October 2007|August 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|203|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00597324||162093|
NCT00597584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-14|Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis|AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin|EMERALD 2|Affymax|Yes|Completed|October 2007|January 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|823|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|January 10, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00597584||162073|
NCT00597025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR017PB|Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin|Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin||Satellite Healthcare|No|Recruiting|December 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|375|||Both|18 Years|N/A|No|||December 2007|January 8, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00597025||162115|
NCT00588692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002008|Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure|Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure|SACAR|Mayo Clinic|No|Completed|July 2007|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|December 21, 2007||No||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00588692||162738|
NCT00598338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-28|Efficacy and Safety Study of Prucalopride for the Re-Treatment of Chronic Constipation|A Two-Period, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of re-Treatment of Prucalopride on Efficacy and Safety in Subjects With Chronic Constipation.||Movetis|No|Completed|April 1999|February 2000|Actual|February 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|516|||Both|18 Years|N/A|No|||January 2008|May 28, 2008|January 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00598338||162017|
NCT00598351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080044|Natural History Study of Patients With Neurofibromatosis Type 2|A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2008|||||N/A|Observational|Time Perspective: Prospective|||Actual|169|||Both|8 Years|75 Years|No|||August 2015|August 28, 2015|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598351||162016|
NCT00589303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004554|AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study|Pacing and AV Node Ablation Compared to Drug Therapy in Symptomatic Elderly Patients With Atrial Fibrillation Clinical Trial (PACIFIC) - Pilot Study|PACIFIC|Mayo Clinic|Yes|Terminated|December 2007|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|65 Years|N/A|No|||February 2013|February 25, 2013|December 21, 2007|Yes|Yes|Lack of funding|No|February 25, 2013|https://clinicaltrials.gov/show/NCT00589303||162694|The study was terminated when about half of the subjects were enrolled due to lack of funding.
NCT00589563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06141|Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer|A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation||City of Hope Medical Center|Yes|Completed|May 2007|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|32|||Both|2 Years|N/A|No|||September 2014|September 3, 2014|December 21, 2007|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT00589563||162675|
NCT00589875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrTK02|Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)|A Phase 2a Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Glioma|BrTK02|Advantagene, Inc.|Yes|Active, not recruiting|March 2007|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 27, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589875||162652|
NCT00590655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231410|Maintenance Programme After Weight Loss|Effect of Maintenance Programme on the Long Term Weight Reduction in Severely Obese Patients. A Randomized Controlled Trial||Helsinki University|No|Completed|August 2002|May 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|65 Years|No|||December 2007|January 9, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590655||162595|
NCT00586677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016431|Evaluation of Parenting Interventions to Decrease Family Risk for Child Maltreatment|Evaluation of Parenting Interventions to Decrease Family Risk for Child||Duke University|No|Completed|May 2005|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|123|||Both|N/A|N/A|No|||September 2014|September 19, 2014|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586677||162888|
NCT00599534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 07.0135|Controlled Trial on Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome|A Randomized Double Blind Controlled Trial on the Effect of Treatment in Children With Obstructive Sleep Apnea Syndrome.||University of Louisville|No|Terminated|December 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|2 Years|9 Years|No|||August 2009|August 6, 2009|January 11, 2008|Yes|Yes|Principal Investigator has transferred to another Institution|No||https://clinicaltrials.gov/show/NCT00599534||161929|
NCT00586976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107-05|A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery|A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery||Mayo Clinic|Yes|Terminated|July 2005|June 2008|Actual|June 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 21, 2007||No|Stopped by DSMB due to increased wound infection rate.|No||https://clinicaltrials.gov/show/NCT00586976||162866|
NCT00587535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1478-03|Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration|Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration||Mayo Clinic|No|Completed|August 2003|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Gastroenterology Clinic; Liver Transplant Center; Surgery Clinic|January 2016|January 20, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587535||162824|
NCT00587834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-PER-002-CTX|Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration|A Clinical Trial to Evaluate Gintuit (TM) (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen) as an Alternative to Tissue From the Palate to Enhance Oral Soft Tissue Regeneration and Wound Healing||Organogenesis|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|70 Years|No|||October 2012|October 9, 2012|December 21, 2007|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00587834||162803|Secondary outcome measures were tested with a closed testing strategy; therefore pain was not tested (no p-value) because previous endpoint (site sensitivity) failed.
NCT00587548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79-06|Intraoperative Gamma Probe Localization of the Ureter|Intraoperative Gamma Probe Localization of the Ureter||Mayo Clinic|Yes|Terminated|January 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 27, 2010|December 21, 2007|Yes|Yes|Decided not pursue the study|No||https://clinicaltrials.gov/show/NCT00587548||162823|
NCT00587873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-030|Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)|Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)||Memorial Sloan Kettering Cancer Center||Completed|March 1994|June 2009|Actual|December 2003|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|N/A|No|||June 2009|June 10, 2009|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00587873||162800|
NCT00588081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-044|Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function|Immediate Vaginal Reconstruction Following Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|May 2001|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|N/A|N/A|No|||June 2015|June 1, 2015|December 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00588081||162785|
NCT00595114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1421|Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease|Ancillary Study of Oxidative Stress and Anti-Inflammatory Lipids in Airway Disease in the MIA (ACRN) and LEUKO (CCRN) Trials||Brigham and Women's Hospital|Yes|Completed|December 2007|August 2009|Actual|August 2009|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|52|Samples With DNA|Blood and sputum samples with DNA|Both|18 Years|N/A|No|Non-Probability Sample|This ancillary study will use data and specimens previously collected in the Macrolides in        Asthma (MIA) and the Antileukotriene Therapy for COPD Exacerbations (LEUKO) trials.|May 2012|May 14, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00595114||162257|
NCT00613691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1620|A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma|A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma||Spectrum Pharmaceuticals, Inc|No|Completed|January 2008|December 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|January 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613691||160873|
NCT00614575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.635|Survey on PD Patients With Depressive Symptoms|BI_Sifrol Tablets Special Drug Use Surveillance(Survey on the Safety and Efficacy in Parkinson's Disease Patients With Depressive Symptoms)||Boehringer Ingelheim||Completed|January 2007|||August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1089|||Both|20 Years|N/A|No|Non-Probability Sample|PD patients with depressive symptoms|August 2014|August 1, 2014|January 31, 2008||||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00614575||160810|
NCT00614588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-986|Temperature Measurement in Post-Anesthesia Care Units|Accuracy of Temperature Measurement in Post-Anesthesia Care Units||Outcomes Research Consortium|No|Completed|January 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder        catheter.|September 2008|October 22, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614588||160809|
NCT00588250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|876-04|Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates|Prospective Randomized Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates||Mayo Clinic|No|Terminated|May 2003|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|December 22, 2007||No|Implantation rate significantly lower in treatment group than Controls.|No||https://clinicaltrials.gov/show/NCT00588250||162772|
NCT00597805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-001|Quality of Life in Patients Undergoing Total Pelvic Exenteration|A Prospective Study of Quality of Life in Patients Undergoing Pelvic Exenteration||Memorial Sloan Kettering Cancer Center||Recruiting|January 2005|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|136|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC's Clinics and Moffitt Cancer Center, Tampa, Florida|February 2016|February 9, 2016|January 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00597805||162056|
NCT00589589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-07-040|Computer Decision Support to Achieve Glycemic Control in the ICU|Computer Decision Support to Achieve Glycemic Control in the ICU|EndoTool|United States Army Institute of Surgical Research|No|Completed|January 2008|January 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|80 Years|No|||September 2015|September 1, 2015|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00589589||162674|
NCT00588991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00259|Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders|A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders||National Cancer Institute (NCI)||Active, not recruiting|November 2007|||February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2015|December 7, 2015|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588991||162716|
NCT00590395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC IRB Pro00007311|FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis|The Utility of FDG-PET and PET/CT in the Evaluation of Patients With Suspected Cholecystitis||Cedars-Sinai Medical Center|No|Completed|July 2007|July 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||December 2007|August 24, 2010|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00590395||162614|
NCT00590369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8309-c|Negative Pressure Wound Therapy: Are All Systems Alike?|Negative Pressure Wound Therapy: Are All Systems Alike?||The Cleveland Clinic|No|Terminated|January 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|December 26, 2007|No|Yes|Recruitment challenges|No|June 22, 2011|https://clinicaltrials.gov/show/NCT00590369||162616|small sample size; early termination; did not reach expected sample size. Single center
NCT00590382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-005 - E/C|Emergency/Compassionate Use - Muscular VSD Occluder|||St. Jude Medical||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||August 2009|January 28, 2015|December 20, 2007|Yes|Yes||||https://clinicaltrials.gov/show/NCT00590382||162615|
NCT00586989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003997|Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus|Endoscopic Tri-Modal Imaging for the Detection of High-Grade Dysplasia and Early Adenocarcinoma in Patients With Barrett's Esophagus: A Randomized Crossover Multi-center Study|ETMI|Mayo Clinic|No|Completed|December 2007|September 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|esophageal biopsies|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|patients with barrett's esophagus or esophageal cancer referred for endoscopy|September 2010|January 5, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586989||162865|
NCT00590642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-MD-14|Augmentation in Tx-resistant OCD: an Open Label Trial|Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial||Creighton University|No|Completed|April 2006|October 2009|Actual|October 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|19 Years|55 Years|No|Probability Sample|Psychiatry clinic|November 2009|November 27, 2009|December 11, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00590642||162596|
NCT00587236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-06|Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis|A Blinded Comparison of Conventional Colonoscopy to Endoscopic AFI and NBI for Dysplasia Detection in Patients With Ulcerative Colitis and Sclerosing Cholangitis or Known Colorectal Dysplasia or Cancer- A Pilot Clinical Study||Mayo Clinic|No|Completed|March 2006|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|65|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients presenting with chronic ulcerative colitis and Primary sclerosing cholangitis        and/or patients with chronic ulcerative colitis and known colorectal dysplasia or cancer        needing a surveillance colonoscopy.|January 2016|January 13, 2016|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587236||162846|
NCT00587561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMF0005|Efficacy of Social Cognition Training in Schizophrenia|Efficacy of Social Cognition Training in Schizophrenia||VA Connecticut Healthcare System|No|Active, not recruiting|January 2008|December 2016|Anticipated|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587561||162822|
NCT00588094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-075|Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL|A Phase II Study of Dose Augmented Rituximab and Ice for Patients With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell Non-Hodgkin's Lymphoma Undergoing Second-Line Therapy Prior to Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center|Yes|Completed|October 2003|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|72 Years|No|||October 2015|October 27, 2015|December 26, 2007|Yes|Yes||No|October 27, 2015|https://clinicaltrials.gov/show/NCT00588094||162784|
NCT00614913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSR #48095|Proton Beam Therapy for Treatment of Hepatocellular Carcinoma|Phase I/II Study of Proton Beam Therapy for Hepatocellular Carcinoma||Loma Linda University|Yes|Completed|May 1998|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|December 26, 2007||No||No|June 29, 2011|https://clinicaltrials.gov/show/NCT00614913||160786|
NCT00614276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0340|Female Sexual Dysfunction Intervention|TENDRILS: A Multimedia Intervention for Women's Sexual Dysfunction After Cancer||M.D. Anderson Cancer Center|Yes|Completed|October 2007|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|91|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women, over 18 years old, with cancer-related sexual dysfunction.|October 2013|January 7, 2015|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00614276||160832|
NCT00588705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-063|The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer|The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|27|||Female|12 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Memorial Sloan-Kettering Cancer Center (MSK) breast cancer patients seen by the clinical        genetics service (CGS)and their daughters|October 2015|October 18, 2015|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588705||162737|
NCT00588445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-071|Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene|Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene in Patients With NSCLC||Memorial Sloan Kettering Cancer Center||Completed|June 2004|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|December 26, 2007|No|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00588445||162757|
NCT00589602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF-6501|T-Cell Depletion, Donor HSCT, and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases|Phase II Feasibility Study of T-Cell Depletion in Allogeneic Unrelated Bone Marrow Transplantation (MUD ALLO BMT) Followed by Delayed T-Cell Infusions||The Cleveland Clinic|Yes|Active, not recruiting|January 2004|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|January 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00589602||162673|
NCT00589615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|325/E05/01|Effectiveness of an Educational Program in the Prevention of Osteoporosis and Fractures|Effectiveness of an Educational Program in the Prevention of Osteoporosis and Fractures||Helsinki University|No|Completed|January 1996|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2181|||Female|60 Years|70 Years|Accepts Healthy Volunteers|||December 2007|January 9, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00589615||162672|
NCT00589888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00041116|FFA-Induced Hypertension and Endothelial Dysfunction|Free Fatty Acids-Induced Hypertension and Endothelial Dysfunction in Obese Subjects||Emory University|Yes|Completed|August 2006|August 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|June 6, 2014|December 28, 2007|Yes|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT00589888||162651|
NCT00590174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070043|Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation|Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events|ZEST-LATE|CardioVascular Research Foundation, Korea|Yes|Completed|October 2007|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1175|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT00590174||162631|
NCT00590135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 3516|The Effect of Lipitor on Aortic Stenosis|The Effect of Statin Therapy (Atorvastatin) on the Progression of Calcific Valvular Aortic Stenosis||The Cleveland Clinic|No|Active, not recruiting|August 2000|June 2008|Anticipated|June 2008|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||May 2007|January 9, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00590135||162634|
NCT00590148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-163|Assessing Function in Pediatric Patients With Sickle Cell Disease|Assessing Function in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain Using the FIM Instrument||Connecticut Children's Medical Center|No|Completed|January 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|7 Years|21 Years|No|Non-Probability Sample|Children and adolescents with sickle cell disease|July 2013|July 29, 2013|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00590148||162633|
NCT00586690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005124|Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT|Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions(DLI) From 6/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)||Duke University|Yes|Completed|May 2005|November 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||January 2014|May 2, 2014|December 21, 2007|No|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00586690||162887|
NCT00586703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005123|Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT|Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions (DLI) From 3-5/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)||Duke University|Yes|Completed|April 2005|November 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||May 2014|June 6, 2014|December 21, 2007|No|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00586703||162886|
NCT00587002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001023|Differences in Epicardial Plaque and Microvascular Function in Women With an Acute Myocardial Infarction|Differences in Epicardial Plaque and Microvascular Function in Women With an Acute Myocardial Infarction||Mayo Clinic|No|Completed|March 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|65|||Both|18 Years|N/A|No|||April 2011|April 13, 2011|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587002||162864|
NCT00587249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-416|ICC-1132 - Candidate Vaccine Against P Falciparum Malaria|Phase I Trial of ICC-1132, a Candidate Vaccine Against Plasmodium Falciparum Malaria Based on a Viral-like Particle Comprising Recombinant Hepatitis B Core Antigen and Circumsporozoite Epitopes, to Assess Vaccine Safety and Immunogenicity in Healthy Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2002|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|75|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|April 11, 2013|January 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00587249||162845|
NCT00587262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004832|Scalar Localization Cochlear Electrode Array Using 64 Slice CT|Scalar Localization of Cochlear Implant Electrode Array in Hearing Preservation Patients Using 64 Slice CT||Mayo Clinic|No|Completed|October 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|5|||Both|8 Years|100 Years|No|Non-Probability Sample|Either part of the existing Cochlear Implant data base, or those persons who have had a        Cochlear implant with either short or long electrode array who have had a high frequency        hear loss.|September 2009|December 30, 2015|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00587262||162844|
NCT00597909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYP1203-004|Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Terminated|December 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|75 Years|No|||October 2015|October 7, 2015|January 9, 2008|Yes|Yes|Study was terminated due to lack of enrollment and business decisions.|No||https://clinicaltrials.gov/show/NCT00597909||162048|
NCT00598130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL-PN-002-IS|Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy|A Prospective, Randomized, Single-Blind, Standard Care Controlled, Multi-Center, Phase II Study Evaluating the Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy|Fleece|OMRIX Biopharmaceuticals|Yes|Completed|February 2008|February 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||November 2009|November 5, 2009|December 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00598130||162032|
NCT00588302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1032-03|Moexipril for Primary Biliary Cirrhosis|Open-Label Pilot Investigation of Moexipril for the Treatment of Primary Biliary Cirrhosis (PBC)||Mayo Clinic|Yes|Completed|June 2003|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|85 Years|No|||May 2011|May 20, 2011|December 22, 2007||||No||https://clinicaltrials.gov/show/NCT00588302||162768|
NCT00588315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-099|In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin|In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin||Memorial Sloan Kettering Cancer Center|No|Recruiting|November 1999|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1500|||Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of the Dermatology, Clinical Immunology Services, Pediatrics and Radiology        Oncology departments that are determined to have a skin lesion with anticipated epidermal        and superficial dermal histologic alterations amenable to visualization by surface        confocal microscopy will be offered the opportunity to participate in the study.|March 2016|March 7, 2016|December 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00588315||162767|
NCT00598728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-041|Quality of Life Among Survivors of Hodgkin Lymphoma|A Global Assessment of Medical Morbidities and Quality of Life Among Survivors of Hodgkin Lymphoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2005|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|255|||Both|N/A|N/A|No|Non-Probability Sample|The study population will be recruited from over 800 patients who were enrolled on IRB        approved protocols for the firstline treatment of HL between 1975-2000.|January 2016|January 13, 2016|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00598728||161989|
NCT00588510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-120|Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction|Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction||Memorial Sloan Kettering Cancer Center|No|Completed|January 2000|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|||Both|3 Years|N/A|No|Non-Probability Sample|Osteosarcoma patients seen in the Pediatrics Department or the Orthopedic Division of the        Surgery Department at Memorial Sloan-Kettering Cancer Center|September 2011|September 1, 2011|December 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00588510||162752|
NCT00596336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract number: 2006-004902-16|Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients|A Randomized Phase II Trial to Determine Whether the Application of Imiquimod Cream to the Vaccination Site Can Improve the Immune Responsiveness to Influenza Vaccination in Patients With Untreated Chronic Lymphocytic Leukemia|CLLIFVAC|The Royal Bournemouth Hospital|No|Active, not recruiting|October 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|102|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2012|November 29, 2012|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00596336||162167|
NCT00610779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emc070166ctil|Treatment of Acute Rhino-Sinusitis With Essential Oils of Aromatic Plants|Treatment of Acute Rhino-Sinusitis With Essential Oils of Some Aromatic Medical Plants.||HaEmek Medical Center, Israel|Yes|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|January 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00610779||161093|
NCT00615173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGLN-001|Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis|||Sun Yat-sen University|Yes|Completed|July 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|14 Years|65 Years|No|||October 2008|October 27, 2008|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615173||160766|
NCT00615186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAD-301|Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy|A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Glass-Art|Bradmer Pharmaceuticals Inc.|Yes|Terminated|June 2008|December 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||February 2011|February 8, 2011|February 1, 2008|Yes|Yes|Due to delay in site initiation and funding considerations|No||https://clinicaltrials.gov/show/NCT00615186||160765|
NCT00589316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2186.00|Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome|Hematopoietic Bone Marrow Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation||Fred Hutchinson Cancer Research Center|No|Recruiting|October 2007|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|January 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00589316||162693|
NCT00589628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000057|Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis|Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis||Duke University|Yes|Completed|September 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|4 Years|18 Years|No|||August 2013|August 22, 2013|December 27, 2007|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT00589628||162671|Study recruitment was difficult and slow. Optimal number not achieved in this descriptive study.
NCT00589901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200507CX|An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)|Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer||Fudan University|No|Recruiting|August 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|70 Years|No|||April 2008|April 17, 2008|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00589901||162650|
NCT00590161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-1196 CWRU CRU|Pentoxifylline in Patients With Nonalcoholic Steatohepatitis|Treatment Efficacy of Pentoxifylline in Patients With Nonalcoholic Steatohepatitis: A Double-blind Randomized Placebo Controlled Trial||Case Western Reserve University|Yes|Completed|December 2006|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|70 Years|No|||August 2013|August 5, 2013|December 26, 2007|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00590161||162632|
NCT00586469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111258|A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk|Observer-blind, Post-Marketing Study to Compare the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007-2008 Season) Made With New vs. Aged Bulk Material, in Adults Ranging in Age From 18 to 60 Years||GlaxoSmithKline||Completed|December 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1000|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|July 11, 2013|December 21, 2007|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00586469||162904|
NCT00586716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54298|Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients|IVIG Treatment for Live-donor Renal Transplant Patients With a Positive Crossmatch and in Patients With High PRA||Loma Linda University|No|Terminated|November 2004|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|12 Years|80 Years|No|||October 2009|October 8, 2009|December 21, 2007|Yes|Yes|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00586716||162885|
NCT00586417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012830|A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments|A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments.||Duke University|No|Terminated|January 2007|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 2, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00586417||162908|
NCT00659373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000594003|Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02|Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers|Co-SOFT|International Breast Cancer Study Group|Yes|Active, not recruiting|December 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|357|||Female|N/A|N/A|No|||November 2013|November 1, 2013|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00659373||157412|
NCT00626483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000581|Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia|REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme|REGULATe|Duke University|Yes|Active, not recruiting|March 2007|September 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|120 Years|No|||October 2015|October 15, 2015|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626483||159912|
NCT00626496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|489-04|Family Study of Lymphoproliferative Disorders|Genetic Epidemiology of Lymphoproliferative Disorders||Mayo Clinic|No|Recruiting|April 2004|||July 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|We will collect blood samples from patients and their relatives for DNA and cytogenetic      studies. A one time blood draw of 50 cc will be done.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults over the age of 18 who have a family history of a blood or lymph node disorder.|April 2015|April 14, 2015|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626496||159911|
NCT00626990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26053-22054|Phase III Trial of Anaplastic Glioma Without 1p/19q LOH|Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.|CATNON|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Active, not recruiting|December 2007|||January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|751|||Both|18 Years|120 Years|No|||February 2016|February 9, 2016|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00626990||159873|
NCT00627003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAS-0067-033|A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS|A Double-blind, Randomized, Placebo-controlled Multicenter Efficacy Study for the Treatment of Patients With Restless Legs Syndrome (RLS)||Pfizer|No|Completed|November 2002|May 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|75 Years|No|||April 2011|April 22, 2011|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627003||159872|
NCT00623090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC051100|Internet-Based Education for Prostate Cancer Screening|Internet-Based Education for Prostate Cancer Screening|PCSEd|Georgetown University|No|Completed|October 2007|August 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|1893|||Male|45 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623090||160166|
NCT00623376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4940|Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons|Randomized Double Blind Cross Over Study Assessing the Effect of Cannabiniods on Spasticity in Spinal Cord Injured Persons :A Pilot Study||University of Manitoba||Completed|July 2007|December 2007|Actual|November 2007|Actual|Phase 2|Interventional|N/A|2||||||Both|18 Years|N/A|No|||June 2007|February 25, 2008|February 14, 2008||||No||https://clinicaltrials.gov/show/NCT00623376||160145|
NCT00656630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA012602|Medication Development in Alcoholism: Acamprosate Versus Naltrexone|Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone||The Scripps Research Institute|No|Completed|December 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|62|||Both|18 Years|55 Years|No|||July 2012|July 19, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656630||157621|
NCT00623883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNMC.1997.0091|Colonoscopic Removal of Aberrant Crypt Foci: a Prospective, Randomized, Blinded Trial|Colonoscopic Biomarkers for Cancer Risk Assessment and Prevention||National Naval Medical Center|Yes|Completed|January 1999|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|February 15, 2008|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00623883||160106|
NCT00624221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-10|Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty|A Prospective, Randomized, Single Center Study Evaluating Use of Surgeon- and Eye Bank-prepared Donor Tissue for Descemet's Stripping and Endothelial Keratoplasty, a Type of Cornea Transplant||Cornea Research Foundation of America|No|Completed|January 2006|November 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|No|||October 2010|October 21, 2010|February 19, 2008||No||No|February 2, 2010|https://clinicaltrials.gov/show/NCT00624221||160080|
NCT00646256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG Ja 680 / 4-2, 4-3|Cognitive Determinants of Psychoeducation and Information in Psychoses|Psychoeducation in Patients With Schizophrenia: Neuropsychological Performance and Cognitive Training as Determinants of Outcome|COGPIP|German Research Foundation|No|Recruiting|February 2006|||December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||March 2008|March 25, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646256||158411|
NCT00657696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-063|Learning and Relationships in Primary Care|Learning and Relationships in Primary Care Clinical Microsystems|Learn & Relate|VA Office of Research and Development|No|Completed|January 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|7905|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|clinicians and staff in VA primary care outpatient clinics in VISN 17|December 2014|January 5, 2015|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00657696||157540|
NCT00657709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P13|Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants|A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants||Novartis|Yes|Completed|March 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|3630|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||April 2015|April 13, 2015|April 2, 2008|Yes|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT00657709||157539|
NCT00658541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04065|Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets|A Randomized, Two-way Crossover, Single-dose, Open-label Study to Evaluate the Relative Bioequivalence of a Test Tablet Formulation of Zolpidem Tartrate 10mg, Compared to an Equivalent Dose of Ambien® in Fed, Healthy, Adult Subjects||Mutual Pharmaceutical Company, Inc.|No|Completed|May 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 29, 2011|April 9, 2008|No|Yes||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00658541||157476|
NCT00659087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-3224|Effectiveness of a Femoral Block Following Total Knee Arthroplasty (TKA)|A Pilot Study of the Feasibility of Early Discharge After Total Knee Arthroplasty Using a Femoral Nerve Block||Edmonton Civic Employees Research Fund|No|Completed|April 2008|December 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||February 2008|June 21, 2011|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00659087||157434|
NCT00659100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451159|A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment|A 3-Month, Open-Label, Pharmacy-Based, Actual-Use Trial in a Simulated Over-The-Counter (OTC) Environment to Assess Self-Selection and Consumer Use Patterns of Gabapentin 250 mg for Occasional Sleeplessness||Pfizer|No|Completed|August 2006|January 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1254|||Both|18 Years|N/A|No|||April 2011|April 22, 2011|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659100||157433|
NCT00625313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSO 2003-A101|Clinical Study of a UV-Absorbing Acrylic Posterior Chamber Intraocular Lens|A Prospective, Multi-center, Single-phase, Non-randomized, Open-label Study to Assess the Safety and Efficacy of the HMY Model YA-60BB Intraocular Lens (IOL) for the Correction of Aphakia Following Phacoemulsification Cataract Extraction|HMY|Hoya Surgical Optics, Inc.|No|Completed|March 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|617|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 17, 2015|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625313||160000|
NCT00625326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-121-PSOR-201|Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis|A Phase II Study of the Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis||Deltanoid Pharmaceuticals|No|Completed|January 2008|June 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|321|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625326||159999|
NCT00625001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1994/2424|Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome|Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome||University of Aarhus|No|Active, not recruiting|November 1994|June 2010|Anticipated|October 1996|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|54|Samples Without DNA|Blood samples|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with Turner syndrome|February 2008|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625001||160022|
NCT00625261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243/2002|Effectiveness of Early Parent-Based Language Intervention|Effectiveness of a Parent-Based Language Intervention Group Program for Two-Year-Old Children With Language Delay||Heidelberg University|Yes|Active, not recruiting|October 2003|October 2011|Anticipated|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|24 Months|27 Months|No|||August 2007|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625261||160003|
NCT00658528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-G000-301|Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)||Eisai Inc.||Completed|February 2008|January 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1061|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|April 9, 2008|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00658528||157477|
NCT00659984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593357|N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma|A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma||New Approaches to Neuroblastoma Therapy Consortium|Yes|Completed|March 2008|November 2010|Actual|August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|1 Year|30 Years|No|||August 2012|August 1, 2012|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659984||157365|
NCT00627016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-GD07-170|A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn|A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)||Takeda|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|65 Years|No|||April 2011|April 25, 2011|February 21, 2008|Yes|Yes||No|March 18, 2010|https://clinicaltrials.gov/show/NCT00627016||159871|
NCT00627029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR 8756|Evaluation of Programs of Coordinated Care and Disease Management|Evaluation of Programs of Coordinated Care and Disease Management|Coca|Mathematica Policy Research, Inc.|No|Active, not recruiting|September 2000|December 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|18277|||Both|N/A|N/A|No|||September 2015|September 29, 2015|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00627029||159870|
NCT00622804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCHC06OT049|Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy|Phase III Study on Comparison for Bile Reflux and Gastric Stasis in Patients With Gastric Cancer After Distal Gastrectomy||The Catholic University of Korea|No|Withdrawn|July 2007|||July 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|75 Years|No|||July 2009|July 31, 2009|February 14, 2008||No|It was very difficult to enroll patients in this study.|No||https://clinicaltrials.gov/show/NCT00622804||160188|
NCT00622817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2848|The Influence of Inhaled Adrenalin Versus Decongestant as a Local Nasal Treatment in Bronchiolitis|Double Blinded Controled Study:Treatment With Adrenaline Inhalation Versus Nasal Decongestant Drops for Bronchiolitis||Schneider Children's Medical Center, Israel|No|Completed|October 2004|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|1 Month|12 Months|No|||February 2002|February 25, 2008|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622817||160187|
NCT00623103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713B2315|Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)|A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)||Novartis||Completed|January 2008|||November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|583|||Both|50 Years|85 Years|No|||October 2011|October 19, 2011|February 14, 2008|Yes|Yes||No|October 19, 2011|https://clinicaltrials.gov/show/NCT00623103||160165|
NCT00656643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-002|Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema|A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy||Santen Inc.|No|Completed|June 2008|May 2012|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|131|||Both|18 Years|N/A|No|||July 2010|January 8, 2013|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656643||157620|
NCT00656942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P 000110|Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain|Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain||Massachusetts General Hospital|Yes|Active, not recruiting|July 2006|December 2014|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|164|||Both|18 Years|65 Years|No|Non-Probability Sample|The groups of subjects on chronic opioid and non-opioid treatment for chronic pain will be        recruited from the MGH Pain Center's patients. We want to emphasize that our MGH Pain        Center patient population comprehends a significant number of patients on stable dose of        non-opioid and opioid pain medication for chronic pain. The investigators and study staff        will search daily the MGH Pain Center clinic list and will approach the patients who might        qualify for the study. The group of opioid naive subjects will be recruited by advertising        in local newspapers and by using e-mail announcements through Partners HealthCare system.|September 2014|September 3, 2014|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00656942||157597|
NCT00623662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-07-075|Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection|Metabolic Preconditioning Using Intravenous Dextrose: a Novel Strategy to Improve Hepatic Function After Liver Resection||McGill University Health Center|No|Recruiting|February 2008|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00623662||160123|
NCT00656916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0390|Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status|Randomized Study of Early Treatment With Inhaled Corticosteroids Versus Observation for Patients Who Have Decreased Lung Function Status Post Allogeneic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Terminated|March 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|April 7, 2008||No|Terminated due to slow accrual.|No|February 7, 2012|https://clinicaltrials.gov/show/NCT00656916||157599|
NCT00623896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174/07|3 Nehb Precordial Leads Anterior, Dorsalis and Inferior Allow Accurate Diagnostics of Different Heart Conditions|Nehb 3-Lead Bipolar Leads for Rapid Diagnosis & Treatment of STEMI|Nehb-STEMI|Assaf-Harofeh Medical Center|No|Recruiting|June 2007|August 2008|Anticipated|May 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|All STEMI Patients admitted to ICCU during the study period with ST elevations presenting        on first 12 lead ECG performed on admition.|June 2007|February 25, 2008|February 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00623896||160105|
NCT00646269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/17|Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease|Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease|ETNA3|University Hospital, Bordeaux|Yes|Completed|March 2008|December 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|640|||Both|50 Years|N/A|No|||July 2013|July 31, 2013|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646269||158410|
NCT00624182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUGIS-001|Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer|Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer||Akita University Hospital|Yes|Suspended|February 2008|December 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|80 Years|No|||June 2015|June 22, 2015|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624182||160083|
NCT00624429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-053|A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children|A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children||Phoenix Children's Hospital|No|Recruiting|March 2008|January 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Months|36 Months|No|||February 2009|September 17, 2009|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624429||160064|
NCT00624442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 1121|A Study of CK-1827452 Infusion in Stable Heart Failure|A Phase II, Multi Center, Double-Blind, Randomized, Placebo Controlled, Dose-Escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CK-1827452 in Patients With Stable Heart Failure||Cytokinetics||Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|45|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|December 21, 2007|Yes|Yes||No|February 28, 2010|https://clinicaltrials.gov/show/NCT00624442||160063|Other Adverse Event table shows treatment emergent adverse events that occurred in two or more patients. Total for Other Adverse Events is the number of patients affected by an adverse event where an adverse event occurred in two or more patients.
NCT00624741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-001|Compassionate Use Study of Pergolide in Patients With Parkinson's Disease|Compassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's Disease||Valeant Pharmaceuticals International, Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||June 2012|June 20, 2012|February 15, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00624741||160041|
NCT00625014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05.009|Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans|Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans||Leiden University Medical Center|No|Completed|March 2005|July 2005|Actual|July 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||February 2008|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625014||160021|
NCT00625651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060464|Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer|A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer||Amgen||Completed|October 2007|September 2011|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|202|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625651||159975|
NCT00625950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-AP-10208-208-1|Endometriosis Patients Undergoing Quinagolide Treatment|Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|February 2008|May 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|5|||Female|18 Years|37 Years|No|||January 2009|January 9, 2009|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00625950||159953|
NCT00625924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-009|Sensory Morbidity Following Breast Surgery|Sensory Morbidity Following Breast Surgery||Memorial Sloan Kettering Cancer Center||Completed|February 2008|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||3|Actual|290|||Female|21 Years|N/A|No|Non-Probability Sample|MSKCC clinics|January 2014|January 14, 2014|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00625924||159955|
NCT00625963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.060|The Study Of CT Scans and Echo Parameters in Patients With PAH|The Study of CT Scan and Echocardiogram Parameters in Patients With Pulmonary Hypertension With Regards to Hemodynamics, Sleep Studies, and Various Laboratory Markers.||Northwell Health|No|Completed|April 2007|July 2011|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|71|||Both|18 Years|80 Years|No|Non-Probability Sample|Pulmonary Arterial Hypertension; Idiopathic Lung Disease|July 2013|July 29, 2013|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00625963||159952|
NCT00625625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586464|Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer|Ultrastaging of Early Cancer of the Large Bowel Using Intraoperative Lymphatic Mapping, Sentinel Node Analysis and Blood Testing||National Cancer Institute (NCI)||Active, not recruiting|March 2004|||November 2007|Anticipated|Phase 2|Interventional|Primary Purpose: Diagnostic|||Anticipated|225|||Both|18 Years|N/A|No|||February 2008|September 16, 2013|February 27, 2008||||No||https://clinicaltrials.gov/show/NCT00625625||159977|
NCT00625638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0591|Interactive Voice Response System in Advanced Cancer Patients|Symptom Assessment in Advanced Cancer Patients Using an Interactive Voice Response (IVR) System||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2008|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|136|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 24, 2015|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625638||159976|
NCT00625911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-01-AW-114-CTIL|Ketamine Improves Post-Thoracotomy Analgesia|Ketamine Improves Post-Thoracotomy Analgesia||Tel-Aviv Sourasky Medical Center|Yes|Completed|September 2001|March 2002|Actual|March 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|N/A|N/A|No|||February 2008|February 28, 2008|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00625911||159956|
NCT00626184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV003-0811|A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease|A Phase 1, Two Stage, Single Dose, Single-Blind, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease||Alvine Pharmaceuticals Inc.|No|Completed|February 2008|July 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 17, 2009|February 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00626184||159935|
NCT00626197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT4072g|A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)|A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus|BELONG|Genentech, Inc.||Active, not recruiting|February 2008|June 2016|Anticipated|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|369|||Both|16 Years|N/A|No|||March 2016|March 16, 2016|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626197||159934|
NCT00626730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22042-26042|Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma|Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study||European Organisation for Research and Treatment of Cancer - EORTC||Completed|December 2007|||February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Actual|78|||Both|18 Years|70 Years|No|||July 2014|July 16, 2014|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00626730||159893|
NCT00626743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK3530_AMD_I_2007|Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine|Clinical Trial to Investigate the Influence of SK3530 on the Blood Pressure of Patients With Hypertension Taking Amlodipine||SK Chemicals Co.,Ltd.||Completed|May 2008|July 2011|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Male|19 Years|65 Years|No|||March 2014|March 13, 2014|February 21, 2008||No||No|March 13, 2014|https://clinicaltrials.gov/show/NCT00626743||159892|
NCT00626756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LigaStudy|Lithium Dilution Method in Guiding Fluid Therapy in Critically Ill Patients|LIGA Trial-Lithium Dilution Method in Guiding Fluid Therapy in Critically Ill Patients|LIGA|ASQA a.s.|No|Recruiting|January 2008|||December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|15|||Both|18 Years|70 Years|No|||February 2008|February 28, 2008|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626756||159891|
NCT00626769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-07|Third Year Evaluation on Genistein Efficacy and Safety|Safety Profile and Bone Efficacy of the Phytoestrogen Genistein in a Cohort of Osteopenic, Postmenopausal Women After Three Years of Treatment: a Follow-up Study||University of Messina|No|Completed|July 2005|September 2006|Actual|July 2006|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|138|Samples With DNA|whole blood, serum, plasma, urine.|Female|49 Years|67 Years|No|Non-Probability Sample|Postmenopausal women (age 49-67 yrs)|May 2009|May 18, 2009|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00626769||159890|
NCT00660725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-025|Study of GemOx and Vandetanib in Advanced Solid Malignancy|An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025)||University of Pittsburgh|Yes|Completed|February 2009|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|April 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660725||157308|
NCT00623116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231408|A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland|Kallmann Syndrome in Finland||Hospital for Children and Adolescents, Finland|No|Enrolling by invitation|December 2007|December 2025|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|15 Years|N/A|Accepts Healthy Volunteers|||January 2008|February 13, 2008|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00623116||160164|
NCT00656357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN117-CL01|Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers|A Human Laboratory Assessment of the Safety and Potential Efficacy of SYN117 (Nepicastat) in Cocaine-dependent Volunteers Receiving Cocaine||Biotie Therapies Inc.|Yes|Completed|June 2008|||May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|No|||February 2014|February 9, 2016|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656357||157642|
NCT00657254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10922|Extension Program for Bay 43-9006|Extension Program for Bay 43-9006||Bayer|No|Completed|December 2002|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|April 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657254||157574|
NCT00657267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-013|Dose-Intense Temozolomide in Recurrent Glioblastoma|Phase 2 Study of Dose-Intense Temozolomide in Recurrent Glioblastoma||Dana-Farber Cancer Institute|Yes|Completed|May 2008|October 2013|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|April 8, 2008|Yes|Yes||No|June 16, 2013|https://clinicaltrials.gov/show/NCT00657267||157573|
NCT00656929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUH06034|Randomized Controlled Trial of Vitamin D3 Supplementation for Viral Upper Respiratory Tract Infections (URI) Prevention|A Randomized Controlled Trial of Vitamin D3 Supplementation for the Prevention of Viral Upper Respiratory Tract Infections||Winthrop University Hospital|No|Completed|December 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|167|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2008|April 10, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656929||157598|
NCT00657228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-58|Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department|Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic/Anaphylactoid Reactions in the Emergency Department||Truman Medical Center|Yes|Withdrawn|December 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|April 9, 2008|Yes|Yes|Study did not start.|No||https://clinicaltrials.gov/show/NCT00657228||157576|
NCT00646880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETAOD-0084-055|A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring|Double-Blind Crossover Comparative Ambulatory Urodynamic Monitoring (AUM) Study of Tolterodine PR and Propiverine in Korean Patients With Overactive Bladder (OAB)||Pfizer||Completed|March 2003|August 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|N/A|No|||March 2008|March 28, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646880||158363|
NCT00624455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00265|How Does Gabapentin Affects Post-operative Tonsillectomy Pain?|Does a Single Preoperative Dose of Gabapentin Reduce Postoperative Tonsillectomy Pain and Subsequent Morphine Requirement in Children?||University of British Columbia|No|Completed|July 2007|August 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|28|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||August 2009|August 17, 2009|February 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00624455||160062|
NCT00624468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28156|Atacicept in Subjects With Optic Neuritis|A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course||EMD Serono|Yes|Terminated|June 2008|January 2011|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||January 2016|January 19, 2016|February 15, 2008|Yes|Yes|EMD Serono voluntarily decided to terminate this trial after observing increased MS disease    activity in trial 28063 ATAMS [Please refer to ATAMS]|No|January 19, 2016|https://clinicaltrials.gov/show/NCT00624468||160061|The Sponsor voluntarily terminated this trial after observing increased Multiple Sclerosis (MS) disease activity in trial 28063 (ATAMS).
NCT00624754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070116|Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT|recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients|Alloforb|Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|16 Years|N/A|No|||January 2009|May 3, 2013|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624754||160040|
NCT00625027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000004841|The Effect of Telehealth Ontario on Non-urgent Emergency Department Use at The Hospital for Sick Children|The Effect of Telehealth Ontario on Non-urgent Emergency Department Use at The Hospital for Sick Children||The Hospital for Sick Children|No|Completed|March 2004|September 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|115|||Both|N/A|18 Years|No|Probability Sample|All children presenting to the ED between 0600 and 2400 during the study period|July 2013|July 31, 2013|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625027||160020|
NCT00658619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-032D|Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)|Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to AMD||Allergan|No|Completed|May 2008|April 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|119|||Both|50 Years|N/A|No|||March 2013|March 13, 2013|April 11, 2008|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00658619||157470|
NCT00658905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVT.BSSL-020|Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants|A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Infant Formula Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age||Swedish Orphan Biovitrum|Yes|Completed|April 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|N/A|32 Weeks|No|||October 2014|October 31, 2014|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00658905||157448|
NCT00658918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-405|To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Clinical Trial Designed to Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, 200µg, 100µg or 25µg Once Daily for Six Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age.||Takeda||Completed|September 2004|November 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|2 Years|5 Years|No|||April 2008|May 4, 2012|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658918||157447|
NCT00626249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-T-017|Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function|A Phase 1b, Single-Dose, Open Label, Parallel Design, Controlled Pharmacology Trial of Fumaryl Diketopiperazine Administered as Technosphere Inhalation Power in Subjects With Either Mild or Moderate Chronic Kidney Disease vs. Matched Subjects Without Chronic Kidney Disease||Mannkind Corporation||Completed|August 2007|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|80 Years|No|||December 2013|December 13, 2013|February 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00626249||159930|
NCT00626509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GICR-GIR-1|Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer|Sunitinib Either Before or After Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Recruiting|February 2008|||January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|110|||Both|18 Years|N/A|No|||June 2009|August 9, 2013|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00626509||159910|
NCT00626236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810P201|Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems|A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems||Supernus Pharmaceuticals, Inc.|Yes|Completed|September 2008|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|78|||Both|6 Years|12 Years|No|||January 2013|January 18, 2013|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626236||159931|
NCT00626522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT001148|Aclidinium/Formoterol Fixed Combination Dose Finding Study|A Randomised, 4-week, Placebo-controlled, Double-blind, 6 Arm Parallel Group, Dose-finding Clinical Trial, to Assess the Efficacy, Safety and Pharmacokinetics of Three Different Doses of Formoterol Combined With the Inhaled Anticholinergic Aclidinium Bromide, Aclidinium Bromide Monotherapy and Formoterol Monotherapy All Administrated Once Daily by Inhalation Via Almirall Inhaler in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease.||Almirall, S.A.|No|Completed|January 2008|||November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|513|||Both|40 Years|80 Years|No|||May 2015|May 28, 2015|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626522||159909|
NCT00626535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9619C00001|A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)|A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)||AstraZeneca||Completed|March 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||March 2009|March 11, 2009|February 21, 2008||||No||https://clinicaltrials.gov/show/NCT00626535||159908|
NCT00660413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG-MMG D-R|Comparison of Acceleromyography (AMG) and Mechanomyography (MMG) for Establishing Potency of Neuromuscular Blocking Agents|Comparison of Acceleromyography and Mechanomyography for Establishing Potency of Neuromuscular Blocking Agents, A Randomized Controlled Study||Rigshospitalet, Denmark|No|Completed|December 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||April 2008|April 15, 2008|April 15, 2008||||No||https://clinicaltrials.gov/show/NCT00660413||157332|
NCT00660426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1213|Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors|Phase I Study Of Oxaliplatin, Gemcitabine And Capecitabine In Advanced Gastrointestinal Malignancies And Other Solid Tumors||Washington University School of Medicine|Yes|Completed|March 2005|April 2008|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660426||157331|
NCT00656370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-07-03|Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)|The INcreased Flow Utilizing Subcutaneously-Enabled Normal Saline and Lactated Ringer's (INFUSE-NSLR) Study: A Phase IV, Double-Blind, Randomized Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) in Volunteer Subjects|INFUSE-NSLR|Halozyme Therapeutics|No|Completed|December 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2010|April 27, 2010|April 3, 2008|Yes|Yes||No|February 18, 2010|https://clinicaltrials.gov/show/NCT00656370||157641|
NCT00656617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0835|Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)|Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML||M.D. Anderson Cancer Center|No|Completed|April 2008|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|15 Years|65 Years|No|||February 2015|February 26, 2015|April 7, 2008||No||No|February 26, 2015|https://clinicaltrials.gov/show/NCT00656617||157622|
NCT00656656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pemphigus-Luebeck|Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus|Combined Treatment of Autoimmune Bullous Diseases With Protein A Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab||University of Luebeck|Yes|Active, not recruiting|January 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656656||157619|
NCT00657553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100241|Preemptive Strike With Bortezomib in Multiple Myeloma Patients|Preemptive Strike With Bortezomib (VELCADE) in Participants With Multiple Myeloma Still Event-free on Total Therapy 2 (UARK 98-026)|2007-77|University of Arkansas|Yes|Terminated|February 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|April 9, 2008||No|Due to poor accrual|No|April 14, 2011|https://clinicaltrials.gov/show/NCT00657553||157551|Early termination leading to small numbers of subjects analyzed
NCT00657241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111704|Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril|Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril||State University of New York at Buffalo|Yes|Completed|April 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||June 2010|June 30, 2010|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657241||157575|
NCT00657501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESTW008|Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|BLOOM|BioSante Pharmaceuticals|No|Completed|March 2008|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|575|||Female|30 Years|65 Years|No|||January 2013|January 4, 2013|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657501||157555|
NCT00657514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-PAD-01|Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease|Evaluation of Ranolazine on Skeletal Muscle Endpoints During Exercise In Subjects With Chronic Angina and Peripheral Arterial Disease||Colorado Prevention Center|Yes|Withdrawn|May 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Male|40 Years|N/A|No|||August 2014|August 13, 2014|April 8, 2008|Yes|Yes|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00657514||157554|
NCT00657527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0043|Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease|An 8-Week Randomized Double Blind Placebo Controlled Multicenter Trial to Evaluate the Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease.||AstraZeneca|No|Completed|December 2001|December 2002|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657527||157553|
NCT00646893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reprogenetics-01|Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age|Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART||Reprogenetics|Yes|Suspended|June 2008|April 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|1200|||Female|37 Years|42 Years|No|||February 2010|February 21, 2010|March 26, 2008||No|lack of appropriate funding|No||https://clinicaltrials.gov/show/NCT00646893||158362|
NCT00647231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKT-500-US12|HKT-500-US12 In Adult Patients With OA Knee Pain|Protocol HKT-500-US12: A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee||Hisamitsu Pharmaceutical Co., Inc.|Yes|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|300|||Both|45 Years|N/A|No|||May 2015|May 12, 2015|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647231||158338|
NCT00624767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-002|A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients|A Phase 2, Randomized, Crossover Study to Evaluate the Effect of Intranasal Insulin and NovoLog on Postprandial Glycemic Control in Type 2 Diabetic Patients||Nastech Pharmaceutical Company, Inc.|No|Completed|March 2008|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||May 2008|May 16, 2008|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624767||160039|
NCT00624780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081147|Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder|Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder||Pfizer|Yes|Completed|May 2009|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|615|||Both|18 Years|65 Years|No|||September 2012|March 5, 2013|February 15, 2008|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00624780||160038|
NCT00625040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB-INK|Incretin Physiology and Beta-cell Function Before and After Weight-loss|Incretin Physiology and Beta-cell Function Before and After Weight-loss - Effects of Long-term Weight Loss Following Laparoscopic Adjustable Gastric Banding||Glostrup University Hospital, Copenhagen|Yes|Terminated|January 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|p-glucose, p-glucagon, p-GLP1, p-GIP, p-cpeptid, p-insulin, p-paracetamol, buffy coat,      urine, whole blood sampels|Both|18 Years|N/A|No|Non-Probability Sample|The cases and controls are recruited from The Bariatric Clinic at Glostrup Hospital|October 2014|October 8, 2014|February 19, 2008||No|Not enough patients in the follow-up period|No||https://clinicaltrials.gov/show/NCT00625040||160019|
NCT00625339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0367|Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA|Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA||Yonsei University|Yes|Completed|February 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|70 Years|No|||May 2012|May 7, 2012|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625339||159998|
NCT00658931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIJ-US-X047|Cymbalta for Depression as a Complication of Bereavement|Cymbalta for Depression as a Complication of Bereavement||Jefferson Clinic, P.C.|No|Active, not recruiting|April 2008|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||February 2010|February 10, 2010|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00658931||157446|
NCT00659230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-06|Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans|A Randomized, Placebo-Controlled Trial of the Dopamine-B-Hydroxylase (DBH) Inhibitor, Nepicastat, for the Treatment of PTSD in OIF/OEF Veterans|Nepicastat|Tuscaloosa Research & Education Advancement Corporation|Yes|Completed|April 2009|June 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 2, 2014|March 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659230||157423|
NCT00659217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fuzhough0713|Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis|Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis||Organ Transplant Institute, China|Yes|Not yet recruiting|May 2008|May 2010|Anticipated|May 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659217||157424|
NCT00625937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582621|Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer||National Cancer Institute (NCI)||Recruiting|November 2006|||November 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|46|||Both|18 Years|N/A|No|||February 2011|February 25, 2011|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00625937||159954|
NCT00626782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#07-819|Lucentis Versus Mitomycin C During Glaucoma Surgery|Lucentis Versus Mitomycin C as Adjunctive Agent During Trabeculectomy Surgery||Wills Eye|No|Completed|January 2008|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|February 20, 2008|Yes|Yes||No|February 11, 2015|https://clinicaltrials.gov/show/NCT00626782||159889|
NCT00659815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|549|Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a New Packaging Configuration|Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a Clear Polyethylene Terephthalate (PET) Bottle.||Bausch & Lomb Incorporated|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|312|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|April 12, 2008|Yes|Yes||No|September 7, 2010|https://clinicaltrials.gov/show/NCT00659815||157378|
NCT00627055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 079|Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens|The HIV Second-line Therapy AntiRetroviral Study in Patients Who Failed NNRTI-based Regimens||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|May 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2011|February 3, 2011|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00627055||159868|
NCT00660738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074/2007|Functional Tests in Individuals With Chronic Obstructive Pulmonary Disease (COPD)|Comparison of Different Functional Tests and Relation With Functional State and Quality of Life in Individuals With Chronic Obstructive Pulmonary Disease (COPD)||Universidade Federal de Sao Carlos|Yes|Completed|January 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|11|||Male|55 Years|81 Years|No|Non-Probability Sample|chronic obstructive pulmonary disease.|January 2012|January 22, 2012|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00660738||157307|
NCT00656682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK079855|Primary Care Community Partnerships to Prevent Diabetes|Primary Care Community Partnerships to Prevent Diabetes|RAPID|Northwestern University|Yes|Completed|April 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|509|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00656682||157617|
NCT00656669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0802-15/1011003564; IUCRO-0215|Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer|An Exploratory Study of the Biological and Clinical Activity of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer||Indiana University|Yes|Completed|April 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|April 7, 2008|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT00656669||157618|
NCT00656955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908107|Follow-Up Study of Kidney Cancer Patients|Follow-up of Kidney Cancer Patients From the Central European Multicenter Case-Control Study||National Institutes of Health Clinical Center (CC)||Completed|April 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1002|||Both|29 Years|N/A|No|||August 2015|September 16, 2015|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00656955||157596|
NCT00657566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13447|SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection|SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection||National Institute of General Medical Sciences (NIGMS)|Yes|Completed|September 2008|August 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|518|||Both|16 Years|N/A|No|||December 2013|October 5, 2015|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00657566||157550|
NCT00657579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01040702|Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Double-Masked, Parallel-Group, Dose-Response Trial of DE-104 Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Santen Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|N/A|4||||||Both|20 Years|74 Years|No|||March 2009|March 12, 2009|April 7, 2008||||No||https://clinicaltrials.gov/show/NCT00657579||157549|
NCT00657540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XF-07/03|Black Widow Spider Antivenin for Patients With Systemic Latrodectism|A Phase III Multicenter Clinical Trial of Analatro® [Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2] in Patients With Systemic Latrodectism|BWSP3|Instituto Bioclon S.A. de C.V.|Yes|Completed|August 2009|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|10 Years|N/A|No|||December 2015|December 15, 2015|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657540||157552|
NCT00657826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001 Rev. E|ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm|ATS 3f(r) Aortic Bioprosthesis Model 1000||Medtronic Cardiovascular|Yes|Terminated|October 2001|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|21 Years|N/A|No|||October 2015|October 9, 2015|April 4, 2008|Yes|Yes|Business decision to end study due to limited enrollment and study population|No||https://clinicaltrials.gov/show/NCT00657826||157530|
NCT00624195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060154|Clinical Trial of CNS-targeted HAART (CIT2)|HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART||University of California, San Diego|Yes|Completed|March 2007|June 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|February 15, 2008||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00624195||160082|
NCT00624208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00615|The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats|The Effects of Droperidol and Ondansetron on Dispersion of Myocardial Repolarization in Children||University of British Columbia|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||August 2009|August 17, 2009|February 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00624208||160081|
NCT00657774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-1-003|A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group, 6-Week Study to Evaluate the Effect of Multiple Doses of FlutiForm™ 250/10 Microgram HFA pMDI Twice Daily, FlutiForm™ 100/10 Microgram HFA pMDI Twice Daily, Prednisone and Placebo on the Hypothalmic-Pituitary-Adrenal Axis in Adult Subjects With Mild to Moderate Asthma.||SkyePharma AG|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|65 Years|No|||November 2008|November 28, 2008|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657774||157534|
NCT00657787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075235|Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans|Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans||Boston VA Research Institute, Inc.|No|Active, not recruiting|September 2008|September 2017|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1600|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|US Military Veterans|January 2016|January 20, 2016|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657787||157533|
NCT00658073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-K-2|Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Recipients of Living Kidney Allografts||Fuzhou General Hospital|Yes|Completed|March 2008|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|60 Years|No|||February 2011|March 7, 2011|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658073||157511|
NCT00658086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-RSV01-106|Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)||Alnylam Pharmaceuticals|No|Completed|April 2008|June 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2009|June 15, 2009|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658086||157510|
NCT00658346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12168 DYNA M-O|Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon|Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|June 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|171|Samples With DNA|plasma and mononucleus cells|Both|18 Years|N/A|No|Non-Probability Sample|HIV-1 infected patients coming for medical care in four treatment centers in Yaounde.|August 2015|August 3, 2015|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658346||157490|
NCT00658359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921050|Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients|A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients||Pfizer|Yes|Completed|August 2008|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|178|||Both|18 Years|70 Years|No|||August 2015|August 18, 2015|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658359||157489|
NCT00658944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_ML_002|Predictive Objective Parameters for Outcome of the Treatment of Stress Urinary Incontinence|Preoperative MUCP and VLPP Failed to Predict Long Term (4-Years) Outcome in Patients Who Underwent Transobturator Mid-Urethral Slings. a Prospective Observational Descriptive Study||University Of Perugia|No|Completed|May 2002|February 2008|Actual|December 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|65|||Female|18 Years|80 Years|No|Non-Probability Sample|Stress or mixed urinary incontinence (stress component clinically predominant), defined        according to ICS guidelines, associated or not with urethral hypermobility|April 2008|April 15, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00658944||157445|
NCT00659243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVT.BSSL-021|Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Pasteurized Breast Milk for Preterm Infants|A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Pasteurized Breast Milk Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age||Swedish Orphan Biovitrum|Yes|Completed|March 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|N/A|32 Weeks|No|||October 2014|October 31, 2014|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659243||157422|
NCT00659542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5204518|Glubran Mesh Fixation in Lichtenstein Hernioplasty|Randomized Study of Mesh Fixation With Absorbable Sutures or Glubran Tissue Sealant in Lichtenstein Hernioplasty|Cyanoacr|Kuopio University Hospital|No|Completed|October 2007|December 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2010|March 10, 2010|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00659542||157399|
NCT00659516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123|Smart Capnography Respiratory Index in Post Anesthesia Patients|Smart Capnography Respiratory Index: Clinical Evaluation||Shaare Zedek Medical Center|No|Not yet recruiting|May 2008|December 2008|Anticipated|August 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|the respiratory index evaluation will be performed on 40 patients (adult and pediatric) of        which 30 will be non intubated|April 2008|April 15, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659516||157401|
NCT00659529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|851R14-8510M3|Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease|The Role of Phosphodiesterase Inhibitors in CF Lung Disease||National Jewish Health|Yes|Completed|August 2008|December 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|14 Years|N/A|No|||April 2014|April 1, 2014|April 14, 2008|No|Yes||No|April 1, 2014|https://clinicaltrials.gov/show/NCT00659529||157400|
NCT00659555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD7110861|Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops|An Open-label, Two-period, Fixed-sequence Study in Healthy Volunteers to Evaluate the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Dose of Pazopanib (GW786034) Administered as Eye Drops||GlaxoSmithKline|No|Completed|April 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|March 15, 2012|April 10, 2008||||||https://clinicaltrials.gov/show/NCT00659555||157398|
NCT00626548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00015|A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer|A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients|ENTHUSE M0|AstraZeneca|Yes|Terminated|January 2008|May 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2577|||Male|18 Years|N/A|No|||April 2012|August 29, 2012|January 24, 2008|Yes|Yes|early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely    to meet its primary efficacy endpoints|No|April 26, 2012|https://clinicaltrials.gov/show/NCT00626548||159907|
NCT00660114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RCN-PUL-2008/1|Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients|A Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Patient Aged 5-Year Old or Younger in Outpatient Department|PUL NIS|AstraZeneca|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|914|||Both|N/A|5 Years|No|Non-Probability Sample|Patient aged 5-year old or younger who has been diagnosed as cough variant asthma and        decided by physician to use Pulmicort® Respules® inhalation.|May 2009|May 27, 2009|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660114||157355|
NCT00660127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002112|The Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients|The Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients||Wake Forest School of Medicine|No|Completed|October 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|general community population|April 2008|August 8, 2012|April 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660127||157354|
NCT00660088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-08-004|Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly|Tolerability, Safety, And Pharmacokinetics Of Three Formulations Of Oral Ketasyn™ (Ac-1202) Administered For Fourteen Days, With Or Without Titration, In Healthy Elderly Volunteers||Accera, Inc.|No|Completed|April 2008|August 2008|Actual|June 2008|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|60|Samples Without DNA|plasma beta-hydroxybutyrate|Both|55 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy elderly male and female subjects 55 - 85 years of age|October 2008|October 7, 2008|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00660088||157357|
NCT00660101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/100/0501|Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer|OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse:||AVAX Technologies|No|Active, not recruiting|June 2008|January 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|34|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660101||157356|
NCT00656383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-42497|Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population|Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population||Queen's University|No|Completed|October 2000|March 2005|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|90 Years|No|||November 2015|November 18, 2015|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656383||157640|
NCT00656695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iminoral|Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation|The Comparison Between Clinical and Paraclinical Effect of Iminoral Vs Neoral in Prevention of Acute Rejection in the First Year Afer Transplantation in De Novo Renal Transplant Patients||Imam Khomeini Hospital|Yes|Completed|April 2008|October 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656695||157616|
NCT00656968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-IRB00003151|Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection|Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection|960025|Kaohsiung Veterans General Hospital.|No|Completed|May 2007|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|75 Years|No|||September 2015|September 14, 2015|January 3, 2008||No||No|August 17, 2010|https://clinicaltrials.gov/show/NCT00656968||157595|The trial was performed in a single country
NCT00657280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04082008-1088|Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure|Effect of Sitagliptin on Insulin Resistance and Myocardial Metabolism in Heart Failure|S-001|Stanford University|Yes|Completed|April 2008|February 2012|Actual|February 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|April 9, 2008|No|Yes||No|May 13, 2014|https://clinicaltrials.gov/show/NCT00657280||157572|
NCT00657605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060282|Effects of Human Leptin Replacement|Effects of Human Leptin Replacement||University of Miami|Yes|Active, not recruiting|June 2001|December 2010|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|80 Years|No|||April 2008|April 14, 2008|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657605||157547|
NCT00657839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11863|Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia|A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Assess the Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia||Bayer|No|Completed|October 2005|June 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|222|||Male|45 Years|64 Years|No|||October 2014|October 27, 2014|April 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657839||157529|
NCT00657852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-NV001|Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Disodium Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant||Hospital Clinic of Barcelona|No|Completed|December 2000|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||April 2008|April 8, 2008|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657852||157528|
NCT00658138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-07-020|Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults|Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults||3M|No|Completed|December 2008|December 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|April 8, 2008||No||No|December 29, 2011|https://clinicaltrials.gov/show/NCT00658138||157506|Main limitation of study was small sample size and short duratrion. Study was a pilot of one year's duration.
NCT00658151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|avital.ctil|Ultrasound Diagnosis of Antibiotic Associated Diarrhea|||Shaare Zedek Medical Center||Not yet recruiting|April 2008|||January 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in internal and geriatrics departments who developed diarrhea in a period of 72        hours since the beginning of admission and received antibiotics.|April 2008|April 11, 2008|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658151||157505|
NCT00624481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-008|Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD|A Phase 2, 24-Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study To Evaluate The Effect Of Teriparatide Nasal Spray On Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density||Nastech Pharmaceutical Company, Inc.|No|Withdrawn|March 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|350|||Female|N/A|89 Years|No|||March 2008|March 11, 2008|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624481||160060|
NCT00657800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030238|The Effect of a Coordinated Inpatient Diabetes Education Program in the Outpatient Setting|The Effect of a Coordinated Inpatient Diabetes Education Program on Glycemic Control, Diabetes Self-Management, Patient Satisfaction, and Quality of Life in the Outpatient Setting||University of Pittsburgh|Yes|Completed|December 2007|September 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657800||157532|
NCT00658099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1976|Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®|Change in Weight on Insulin Detemir (Levemir®) or Isophane (NPH) Insulin (Insulatard®) in Patients With Type 2 Diabetes Mellitus|EVIDENCE|Novo Nordisk A/S|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|699|||Both|6 Years|80 Years|No|Non-Probability Sample|Type 2 diabetes patiens failing on oral anti-diabetic agents|March 2016|March 2, 2016|April 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00658099||157509|
NCT00658372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361018|A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder||Pfizer|No|Terminated|May 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|360|||Both|18 Years|65 Years|No|||November 2012|November 9, 2012|April 9, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00658372||157488|
NCT00658385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-030|Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major|A Pilot Trial to Assess the Feasibility and Safety of GCSF Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major||Memorial Sloan Kettering Cancer Center||Completed|April 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2011|February 11, 2011|April 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658385||157487|
NCT00658632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-G000-303|Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)||Eisai Inc.||Completed|February 2008|September 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1397|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|April 9, 2008|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00658632||157469|
NCT00659256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080106|Hepatitis C Treatment and Atherosclerosis|Hepatitis C Eradication and Progression of Atherosclerosis||National Institutes of Health Clinical Center (CC)||Completed|April 2008|March 2015||||N/A|Observational|N/A|||Actual|70|||Both|30 Years|N/A|No|||March 2015|March 25, 2015|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00659256||157421|
NCT00659568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-LRCC-UWOREB13877|Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma|A Phase I Study of Temsirolimus in Combination With Metformin in Advanced Solid Tumours||National Cancer Institute (NCI)||Completed|March 2008|August 2010||February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||August 2010|May 29, 2013|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659568||157397|
NCT00659581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.511|J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation|Special Survey (Survey on Cerebrovascular and Cardiovascular Events Under Long-term Use) of Micardis Tablets (Telmisartan)||Boehringer Ingelheim||Completed|April 2006|||June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21471|||Both|20 Years|N/A|No|Probability Sample|Japanese hypertension patients|March 2014|May 8, 2014|April 11, 2008||||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00659581||157396|This study is prospective observational study with no limitation of other antihypertensive treatment in compliance with Japanese Pharmaceutical Affairs Law (JPAL) and Good Post-marketing Study Practice (GPSP).
NCT00659841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-401|To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200µg Once Daily) in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 12 Years and Older||Takeda||Completed|December 2003|February 2005|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|302|||Both|12 Years|N/A|No|||April 2008|May 4, 2012|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659841||157376|
NCT00659854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR467908CTIL|Cow's Milk Allergy in Infants With Obstructive Sleep Apnea (OSA)|Cow's Milk Allergy in Infants With Obstructive Sleep Apnea||Soroka University Medical Center|Yes|Not yet recruiting|April 2008|||April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Months|24 Months|No|||April 2008|May 5, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00659854||157375|
NCT00659490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3120C00006|Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940|A Randomised, Double Blind, Placebo-Controlled Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940, in Patients Undergoing Impacted Mandibular Third Molar Extraction||AstraZeneca|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|June 5, 2012|April 10, 2008|Yes|Yes||No|May 4, 2010|https://clinicaltrials.gov/show/NCT00659490||157403|
NCT00659503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-407|Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older||Takeda||Completed|February 2005|November 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|N/A|No|||April 2008|May 4, 2012|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659503||157402|
NCT00659802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMPL-004-US-02|Phase II Study of HMPL-004 in Patients With Ulcerative Colitis|A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis With or Without Mesalamine||Hutchison Medipharma Limited|No|Completed|March 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|224|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659802||157379|
NCT00660452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO55.06 CHIN|A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites|A Randomised, Double-blind, Placebo-controlled, Multi-centre, Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-dust Mites||Stallergenes|No|Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|484|||Both|16 Years|50 Years|No|||October 2011|October 10, 2011|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660452||157329|
NCT00660439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET 40|Treatment Effects of Narrative Exposure Therapy|Treatment Effects of Narrative Exposure Therapy on Psychiatric Symptoms and Cortisol Levels in Patients With Posttraumatic Stress Disorder||University of Bergen|No|Recruiting|May 2007|November 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2008|April 15, 2008|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00660439||157330|
NCT00656708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|359.22|Kerlix Gauze Study in a Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients|Kerlix AMD Gauze Study In A Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients||University of Iowa|Yes|Active, not recruiting|August 2008|January 2011|Anticipated|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|432|||Both|1 Year|N/A|No|||August 2009|August 18, 2009|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656708||157615|
NCT00656981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91231|Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women With Moderate Acne Vulgaris||Bayer||Completed|January 2003|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|541|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|April 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00656981||157594|
NCT00657293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goldstein_Arm1207|Arm Training in Patients With Chronic Obstructive Pulmonary Disease|Arm Training in COPD: Short and Medium Term Effects on Dyspnoea, Health-related Quality of Life, Arm Function and Arm Exercise Capacity.||West Park Healthcare Centre|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|N/A|N/A|No|||February 2010|February 19, 2010|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657293||157571|
NCT00657319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1939|Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins|Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins||Novo Nordisk A/S|No|Completed|October 2007|April 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3495|||Both|18 Years|N/A|No|Probability Sample|Adult with type 2 diabetes mellitus on premix insulin treatment.|February 2016|February 18, 2016|April 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657319||157569|
NCT00657618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-12631|Use of Sodium Stibogluconate as a Treatment for Leishmaniasis|Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis||U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|October 2004|December 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|N/A|N/A|No|||October 2015|October 28, 2015|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657618||157546|
NCT00657865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ram_Gep_1|Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril|Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril||Medical University of Vienna|No|Completed|March 2008|August 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 19, 2011|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657865||157527|
NCT00658164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111.2007|Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores|||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||Recruiting|October 2007|||March 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|65 Years|No|||July 2007|April 11, 2008|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658164||157504|
NCT00658177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100497|Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects||Bayer||Completed|June 2003|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|463|||Male|18 Years|N/A|No|||December 2014|December 1, 2014|April 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00658177||157503|
NCT00657462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAMLTIPS|Efficacy of the Pre-Admission Medication List (PAML) Builder Reminder Prompts|Effect of Reminder Prompts on Utilization of the PAML Builder Application Features|PAMLTIPS|Brigham and Women's Hospital|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2000|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 2, 2009|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00657462||157558|
NCT00658112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000027|Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne|Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne||Wake Forest School of Medicine|No|Completed|July 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|13 Years|18 Years|No|||June 2013|June 19, 2013|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658112||157508|
NCT00658398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060252|The BREVALCO Study, Effect of an Interactive Computer Program to Prevent Alcohol Misuse|Effect of an Interactive Computer Program to Prevent Alcohol Misuse. A Multicentre Randomized Controlled Trial. The BREVALCO Study.|BREVALCO|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2008|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|601|||Both|18 Years|N/A|No|||August 2013|May 19, 2015|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658398||157486|
NCT00658645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11915A|Efficacy of Bifeprunox in Patients With Schizophrenia|A Multinational, Randomised, Double-blind, Fixed-dose, Bifeprunox Study Combining a 12-Week Placebo-controlled, Quetiapine-referenced Phase With a 12-month Quetiapine-controlled Phase in Patients With Schizophrenia||H. Lundbeck A/S|No|Terminated|March 2008|November 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|227|||Both|18 Years|65 Years|No|||September 2010|September 24, 2010|April 9, 2008||No|Interim analysis showed inadequate efficacy of bifeprunox|No||https://clinicaltrials.gov/show/NCT00658645||157468|
NCT00659594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-406|Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older||Takeda||Completed|November 2004|September 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||April 2008|May 4, 2012|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659594||157395|
NCT00659607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.475|Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension|PMS Study of MicardisPlus Tablet||Boehringer Ingelheim||Completed|September 2003|||July 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6901|||Both|18 Years|N/A|No|Probability Sample|Hospitals and clinics in Korea|May 2014|May 8, 2014|April 10, 2008||||No|July 29, 2009|https://clinicaltrials.gov/show/NCT00659607||157394|
NCT00659880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioMen|Clinical Application of BioCleanse Meniscus|Clinical Application of BioCleanse Meniscus Registry|Meniscus|RTI Surgical|No|Completed|April 2008|July 2015|Actual|July 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|55 Years|No|Non-Probability Sample|All patients, between the ages of 18 and 55 years, who have selected meniscal allograft        transplantation (MAT) using BioCleanse allografts will be eligible to participate in the        MAT registry.|July 2015|July 17, 2015|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659880||157373|
NCT00659893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-022|Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2|A Multi-center, Open Label, Dose-area Escalation, Cohort Study to Evaluate the Safety and Tolerability of 0.05% PEP005 Topical Gel Applied for Two Consecutive Days to Treatment Area(s) of up to a Total of 100 cm2 in Patients With Actinic Keratoses on the Extensor (Dorsal Aspect) Forearm(s)||Peplin|No|Completed|April 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|64|||Male|18 Years|N/A|No|||November 2008|September 11, 2015|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659893||157372|
NCT00659867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-09|Endomicroscopy in Ulcerative Colitis|Chromoscopy-guided Endomicroscopy With the PENTAX EC-3870CIFK / EC-3870CILK Confocal Colonoscopes for the Detection of Intraepithelial Neoplasias in Subjects With Long Standing Ulcerative Colitis||PENTAX Europe GmbH|No|Terminated|December 2008|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|182|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|April 14, 2008||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT00659867||157374|
NCT00659828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060295|Effects of Leptin Replacement in Children|Effects of Leptin Replacement in Children||University of Miami|Yes|Active, not recruiting|June 2005|December 2010|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|5 Years|18 Years|No|||April 2008|April 14, 2008|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659828||157377|
NCT00660465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR467608CTIL|Exploring the Relationship Between Varying CO2 Levels and the Regional BOLD Signal, by Using Breathing Exercises|Exploring the Relationship Between Varying CO2 Levels and the Regional BOLD Signal, by Using Breathing Exercises .||Soroka University Medical Center|No|Not yet recruiting|May 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|6|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|residents|February 2008|November 9, 2014|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660465||157328|
NCT00660478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050194|Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris Patients|Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris Patients|SORT-OUTIII|Aarhus University Hospital Skejby|Yes|Completed|January 2006|October 2009|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2342|||Both|18 Years|N/A|No|||September 2008|August 28, 2013|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00660478||157327|
NCT00656123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589230|Vaccine Therapy and Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer|A Phase I Clinical Trial of an Allogeneic Colon Cancer Cell Vaccine Administered With a GM-CSF Producing Bystander Cell Line in Patients With Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Recruiting|March 2008|||February 2009|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||July 2009|December 17, 2013|April 9, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00656123||157660|
NCT00656721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002434-UFRJ|Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients|Flutter Valve Improves Respiratory Mechanics and Sputum Production in Bronchiectasis Patients||Universidade Federal do Rio de Janeiro|No|Completed|September 2004|June 2006|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|8|||Both|28 Years|92 Years|No|||June 2015|June 18, 2015|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656721||157614|
NCT00656994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-032|Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia|A Phase III Safety Study to Evaluate the Long-term Effects of TAK-375 on Endocrine Function in Adult Subjects With Chronic Insomnia||Takeda|No|Completed|January 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|45 Years|No|||February 2012|February 27, 2012|March 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656994||157593|
NCT00657306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AILD|Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function|Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Stress Doses of Hydrocortisone on Renal Function and on Liver and Systemic Haemodynamics|AILD|University of Turin, Italy|Yes|Not yet recruiting|May 2008|May 2009|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||April 2008|April 11, 2008|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00657306||157570|
NCT00657592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12027|Treatment of Major Depressive Disorder (MDD) With Ziprasidone|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder||Cedars-Sinai Medical Center|No|Completed|March 2008|December 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|65 Years|No|||March 2012|March 26, 2012|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657592||157548|
NCT00657332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12102007-931|Clinical and Pathologic Studies in Neuroendocrine Tumors|Clinical and Pathologic Studies in Neuroendocrine Tumors||Stanford University||Terminated|July 2007|June 2008|Anticipated|June 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|biopsy of tumor, blood sample and/or urine samples.|Both|18 Years|N/A|No|Non-Probability Sample|neuroendocrine tumor patients|February 2010|February 26, 2010|April 9, 2008||No|not known|No||https://clinicaltrials.gov/show/NCT00657332||157568|
NCT00657917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13225|Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396|Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396||U.S. Army Medical Research and Materiel Command|No|Completed|November 2004|November 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||November 2011|November 29, 2011|February 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657917||157523|
NCT00658229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK - 08/212b|The Physical Exercise and Prostate Cancer Study|Physical Exercise for Patients With Prostate Cancer During Androgen Deprivation Therapy - A Randomized Trial|PEPC|Oslo University Hospital|Yes|Completed|November 2008|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Male|N/A|75 Years|No|||October 2012|October 12, 2012|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658229||157499|
NCT00657878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-8|Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval|Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy.|MITO-8|National Cancer Institute, Naples|No|Active, not recruiting|November 2008|June 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Female|N/A|N/A|No|||October 2015|October 28, 2015|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657878||157526|
NCT00658190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P-001658|Internet-Based Cervical Cytology Screening Program|Internet-Based Cervical Cytology Screening Program|IBCCSP|Massachusetts General Hospital|No|Completed|October 2003|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|175|||Female|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Females presenting to clinics at MGH or WRAMC for a Pap test|April 2012|April 6, 2015|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658190||157502|
NCT00657475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/19|Coronary Bypass and Artotic Leaflet Surgery : Heparin Low Dose vs Full Dose|A Prospective Study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement With Conventional Versus Half Heparin Dose Under Closed and Coated Extra Corporeal Circulation System (MECC) - APPACHES Study.|APPACHES|University Hospital, Bordeaux|No|Completed|June 2008|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|238|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657475||157557|
NCT00657488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LATH0102/IFM0102|Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma|Multicenter, Randomized Study Comparing the Efficacy and Safety of Two Doses of Thalidomide (100 mg/Day Versus 400 mg/Day) in the Treatment of Subjects With Refractory or Relapsed Multiple Myeloma.||Celgene|No|Completed|December 2001|April 2006|Actual|October 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||September 2008|September 22, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00657488||157556|
NCT00658411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-411|Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation|A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload||Dana-Farber Cancer Institute|Yes|Terminated|August 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|5|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|March 31, 2008|Yes|Yes|Closed due to slow patient accrual|No|December 4, 2012|https://clinicaltrials.gov/show/NCT00658411||157485|The number of patients enrolled on this study is far too small to draw reliable conclusions.
NCT00658658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050252|Panitumumab Pediatric Study|A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors||Amgen||Completed|March 2008|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|1 Year|17 Years|No|||September 2015|October 7, 2015|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00658658||157467|
NCT00658671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-CL-001|A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer|An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer||CASI Pharmaceuticals, Inc.|No|Completed|April 2008|June 2012|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|67|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00658671||157466|
NCT00658996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|559|Product Performance of a Toric Contact Lens|A Study to Evaluate the Product Performance of a Prism-Ballasted Toric Contact Lens When Worn by Currently Adapted Soft Contact Lens Wearers.||Bausch & Lomb Incorporated|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|220|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|April 12, 2008|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00658996||157441|
NCT00658957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-TOP-002|Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer|A Phase II, Randomized, Parallel, Double-blind, Placebo-controlled Study to Assess Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With Uninfected Lower Extremity Skin Ulcers||Innocoll|No|Terminated|April 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|49|||Both|18 Years|80 Years|No|||March 2012|March 22, 2012|April 10, 2008|Yes|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT00658957||157444|
NCT00658970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KX01-01-07|Evaluation of KX2-391 in Patients With Advanced Malignancies|A Combined Rising Single-dose (RSD) and Rising Multiple-dose (RMD)Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies||Kinex Pharmaceuticals Inc|No|Completed|November 2007|May 2011|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|January 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00658970||157443|
NCT00659620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fuzhough0712|Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy|Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy||Organ Transplant Institute, China|Yes|Not yet recruiting|May 2008|May 2010|Anticipated|May 2008|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||April 2008|April 14, 2008|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659620||157393|
NCT00659906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|621|Optimizing Body Composition & Health After Breast Cancer|Optimizing Body Composition & Health After Breast Cancer||OHSU Knight Cancer Institute|Yes|Completed|January 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|71|||Female|N/A|N/A|No|||May 2015|May 26, 2015|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00659906||157371|
NCT00660166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allogeneic NKCell post ABMT|Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions|HLA Class I Haplotype Mismatched Natural Killer Cell Infusions After Autologous Stem Cell Transplant for Hematological Malignancies||Tufts Medical Center|Yes|Completed|April 2006|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|13 Years|70 Years|No|||June 2012|June 25, 2012|April 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660166||157351|
NCT00660140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0925|Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer|A Phase II Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer||Washington University School of Medicine|Yes|Completed|March 2002|April 2009|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|April 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660140||157353|
NCT00656149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-IHT|In-home Telerehabilitation for Quadriplegic Hand Function|Outcome Evaluation of Exercise and Electrical Therapy for Quadriplegic Hand Function|SCI-IHT|University of Alberta|No|Active, not recruiting|May 2007|January 2012|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00656149||157658|
NCT00656136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.23|BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)|Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)||Boehringer Ingelheim||Completed|April 2008|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|585|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|April 4, 2008||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00656136||157659|
NCT00656396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 232_06|Point of Care Coagulation Testing in Patients Undergoing Major Surgery|Does Point of Care Coagulation Testing Reduce the Transfusion of Non-erythrocyte Blood Products in Patients Undergoing Major Surgery? A Randomized-Controlled Trial|POC-OP|University of Bern|No|Completed|May 2008|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|228|||Both|18 Years|90 Years|No|||September 2015|September 7, 2015|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656396||157639|
NCT00656734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1411-01|Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.|A Phase 1, Open-Label, Multicenter Dose-escalation, Multidose Study of MDX1411 Administered Every 14 Days in Subjects With Advanced or Recurrent Clear Cell Renal Cell Carcinoma|MDX1411-01|Bristol-Myers Squibb|No|Completed|April 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|April 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00656734||157613|
NCT00656747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11980|Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis|MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations of Chronic Bronchitis.||Bayer|Yes|Completed|March 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1372|||Both|60 Years|N/A|No|||November 2014|November 27, 2014|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656747||157612|
NCT00657007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBSL01|Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 1, Multi-Center, Double-Blind, Single and Double Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus||Human Genome Sciences Inc.|No|Completed|February 2002|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|70|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657007||157592|
NCT00657020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S3250493|Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms|Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated With Nicotine Withdrawal||GlaxoSmithKline|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|February 12, 2015|April 2, 2008|Yes|Yes||No|October 12, 2009|https://clinicaltrials.gov/show/NCT00657020||157591|
NCT00657930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3526|Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)|Evaluation on Glycaemic Control and Weight Change of Once Daily Levemir® (Insulin Detemir) in Type 2 Diabetes Mellitus Treated by an Intensive Insulin Treatment (ICT)|LEONCET2|Novo Nordisk A/S|No|Completed|March 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2289|||Both|18 Years|N/A|No|Probability Sample|Adult Type 2 Diabetes Mellitus patients on intensive insulin treatment|March 2016|March 2, 2016|April 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657930||157522|
NCT00657943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-006665-33|The Copenhagen Insulin and Metformin Therapy Trial|The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial|CIMT|Steno Diabetes Center|Yes|Completed|April 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|415|||Both|30 Years|N/A|No|||February 2014|February 2, 2014|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657943||157521|
NCT00657891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgE 025 US22|The Effect of Xolair (Omalizumab) on Allergy Blood Cells|The Effect of Xolair (Omalizumab) on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils||Creighton University|No|Completed|March 2007|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|49|||Both|16 Years|50 Years|No|||September 2013|September 30, 2013|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657891||157525|
NCT00657904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6876C00023|Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer|A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.||AstraZeneca|No|Completed|August 1995|August 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3618|||Male|18 Years|N/A|No|||June 2012|June 5, 2012|April 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657904||157524|
NCT00658203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEAR - IPEA01|Clinical Evaluation on Advanced Resynchronization|Clinical Evaluation on Advanced Resynchronization||LivaNova|Yes|Completed|November 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||April 2008|April 7, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00658203||157501|
NCT00658216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCR 06 007|Brain Natriuretic Peptide (BNP) Usefulness In Elderly Dyspneic Patients (BED)|Usefulness of Measuring Plasma Brain Natriuretic Peptide for Diagnosis and Prognosis in Very Elderly Patients.|BED|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2007|February 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|390|Samples Without DNA|Blood sample for brain natriuretic peptide measurement|Both|80 Years|N/A|No|Non-Probability Sample|Defined population|July 2013|August 2, 2013|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658216||157500|
NCT00657813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-330-01|Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition|Evaluation of [123I] MNI-330 and Single Photon Emission Computed Tomography (SPECT) as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Institute for Neurodegenerative Disorders|No|Terminated|March 2008|July 2008|Actual|June 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 7, 2010|April 8, 2008|No|Yes|Data did not evidence [123I]MNI-330 as a useful tool in the detection of AD.|No||https://clinicaltrials.gov/show/NCT00657813||157531|
NCT00658684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221006|Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.|An Open-Label, Multicenter, Long Term Study to Evaluate the Safety, Tolerability and Efficacy of Fesoterodine in Patients With Overactive Bladder.||Pfizer|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Both|20 Years|N/A|No|||October 2010|October 5, 2010|April 9, 2008|Yes|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00658684||157465|
NCT00658697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004|Docetaxel, Bevacizumab and Androgen Deprivation Therapy for BCR After Definitive Local Therapy for Prostate Cancer|A Phase II Trial of Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising Prostate Specific Antigen (PSA) After Local Therapy||Dana-Farber Cancer Institute|Yes|Completed|June 2008|June 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|18 Years|N/A|No|||January 2016|January 29, 2016|April 9, 2008|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT00658697||157464|
NCT00658983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/049|Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers|Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers||University Hospital, Ghent|No|Recruiting|April 2008|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2014|December 4, 2014|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00658983||157442|
NCT00659009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boeing-003|Effects of Mild Hypobaric Hypoxia on Oxygen Saturation During Sleep|The Effects of Mild Hypobaric Hypoxia on Oxygen Saturation During Sleep: An Investigation of the Physiologic Mechanisms and Significance||The Boeing Company|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|16|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||February 2010|August 14, 2012|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659009||157440|
NCT00659269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0553C|A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients|A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.||New Mexico Cancer Care Alliance|Yes|Completed|July 2006|June 2015|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|319|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 14, 2008|Yes|Yes||No|June 18, 2015|https://clinicaltrials.gov/show/NCT00659269||157420|The number of completed surveys decreased as time went on for each group of patients. This resulted in small numbers of patients to analyze, especially in Group 3 (Vinca Alkaloids), since there weren't many patients in this group to begin with.
NCT00659633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061204014|The Effect of Intravenous Lidocaine on Allodynia|The Effect of Intravenous Lidocaine on Allodynia (Carl Koller Grant)||University of Alabama at Birmingham|No|Active, not recruiting|December 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|N/A|No|||August 2015|August 4, 2015|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659633||157392|
NCT00659919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trazodone-60CTIL|Treatment of Neuroleptic Induced Acute Akathisia With Trazodone|||BeerYaakov Mental Health Center||Completed|November 2000|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|70 Years|No|||June 2008|June 15, 2008|April 16, 2008||||No||https://clinicaltrials.gov/show/NCT00659919||157370|
NCT00659932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/03/13/3.18|Dealing With Anxiety: A Cognitive Behavioural Program for Diabetes|Dealing With Anxiety: A Pilot Cognitive Behavioural Program for Diabetic Clinic Outpatient Attendees||Hunter and New England Health|No|Completed|May 2002|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|64|||Both|N/A|N/A|No|||December 2007|April 14, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659932||157369|
NCT00660179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-302|Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension|SERAPHIN|Actelion|Yes|Completed|May 2008|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|742|||Both|12 Years|N/A|No|||August 2015|September 10, 2015|April 14, 2008|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT00660179||157350|
NCT00660192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709003056|Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches|Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches||Yale University|Yes|Completed|January 2008|July 2015|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|April 10, 2008|Yes|Yes||No|August 18, 2014|https://clinicaltrials.gov/show/NCT00660192||157349|Small study- results could have been different if numbers were larger Technique of injection different from PREEMPT study. Larger doses were injected into temporal and posterior neck muscles. No trapezius injection.
NCT00660153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-103|Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers|A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers||AVEO Pharmaceuticals, Inc.|No|Completed|June 2008|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660153||157352|
NCT00660491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exercise, Food and Endothelium|Endothelial Dysfunction Induced by Postprandial Lipemia|Endothelial Dysfunction Induced by Postprandial Lipemia: Complete Protection Afforded by High Intensity Aerobic Interval Exercise||Norwegian University of Science and Technology|No|Completed|January 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|8|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 5, 2012|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660491||157326|
NCT00656162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM005-HMO-CTILL|Ultrasound Detection of Radiographically Negative Fractures of Elbow in Children|||Hadassah Medical Organization||Completed|January 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|15 Years|No|Non-Probability Sample|children with clinically suspected but x-ray negative elbow trauma|October 2010|November 4, 2010|April 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00656162||157657|
NCT00656175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP-Raltegravir|Raltegravir Therapy for Women With HIV and Fat Accumulation|Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation||University of California, Los Angeles|No|Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Female|18 Years|N/A|No|||December 2012|December 17, 2012|April 2, 2008|Yes|Yes||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00656175||157656|High prevalence of generalized obesity; small sample size; short follow-up; not designed to assess the potential contribution of NRTIs to lipohypertrophy, nor could we exclude the NRTI backbone as a confounding factor.
NCT00656409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04MI07|Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)|Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)||Institute of Child Health|No|Completed|June 2006|March 2008|Actual|||Phase 3|Interventional|Primary Purpose: Basic Science|||Actual|30|||Both|2 Years|N/A|No|||April 2008|April 10, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656409||157638|
NCT00656422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-ISP-1|Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine|Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine||University Hospital Tuebingen|No|Terminated|November 2007|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|66|||Both|18 Years|80 Years|No|||October 2012|October 31, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656422||157637|
NCT00656760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCENT0001|PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer|The Clinical Utility of PET-CT in the Management of Squamous Cell Carcinoma of Neck Nodes With an Unknown Primary Malignancy.||University of Calgary|No|Completed|July 2007|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Anticipated|36|||Both|18 Years|N/A|No|||April 2008|August 22, 2011|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656760||157611|
NCT00656773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 139 03|A Randomized, Double-blind Comparison of Morphine and Sufentanil for Prehospital Traumatic Severe Acute Pain|A Randomized, Double-blind Comparison of Morphine and Sufentanil for Treatment of Prehospital Traumatic Severe Acute Pain.||University Hospital, Toulouse|Yes|Completed|January 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||February 2010|February 25, 2010|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656773||157610|
NCT00657345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM200801|IRS Proteins and Trastuzumab Resistance|IRS Proteins and Trastuzumab Resistance||University of Massachusetts, Worcester|No|Completed|March 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Female|18 Years|70 Years|No|Non-Probability Sample|Women age 18-70 with breast cancer|November 2013|November 4, 2013|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657345||157567|
NCT00658502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH97006|Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment|Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment||Far Eastern Memorial Hospital||Recruiting|March 2008|August 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|6 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|age under 25 year old with or without myopia|March 2008|April 14, 2008|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658502||157479|
NCT00658775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-G000-302|Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)||Eisai Inc.||Completed|February 2008|January 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1069|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|April 9, 2008|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00658775||157458|
NCT00658125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0095-B|Deep Brain Stimulation (DBS) for Alzheimer's Disease|Modulation of Cognitive Function Using Electrical Brain Stimulation in Patients With Early Alzheimer Disease||University Health Network, Toronto|Yes|Active, not recruiting|March 2007|June 2010|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|40 Years|80 Years|No|||January 2010|April 7, 2010|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658125||157507|
NCT00658437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY503C1|CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy|A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure||Cytavis Biopharma GmbH|No|Completed|April 2008|May 2010|Actual|August 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|90 Years|No|||August 2009|June 7, 2011|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658437||157484|
NCT00658710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701040|Impact of Prolonged Physical Therapy on Gait Performance of Chronic Phase Stroke Patients|Impact of Prolonged Physical Therapy on Gait Performance of Chronic Phase Stroke Patients|HEMIMARCHE|Centre Hospitalier Universitaire de Saint Etienne|Yes|Terminated|June 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|70|||Both|18 Years|75 Years|No|||November 2013|November 6, 2013|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658710||157463|
NCT00659022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILENT|Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth|Accelerated Growth of Synchronous Colorectal Liver Metastases: Effects of Neo-adjuvant Therapy||Radboud University|Yes|Recruiting|July 2008|April 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|80 Years|No|||February 2009|September 9, 2011|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00659022||157439|
NCT00659282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1766|Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes|Observational Study of Safety and Effectiveness of NovoMix® 30 (Biphasic Insulin Aspart) for the Treatment of Diabetes Mellitus|IMPROVE™|Novo Nordisk A/S|No|Completed|September 2006|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57610|||Both|N/A|N/A|No|Non-Probability Sample|Patients from both general and speciality practice settings who have been deemed        appropriate to receive NovoMix® 30 as new treatment and as part of routine out-patient        care by the prescribing physician.|August 2014|August 11, 2014|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659282||157419|
NCT00659646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-TOP-003|The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers|A Randomized, Controlled, Open Label Study of the Safety and Efficacy of a Topical Gentamicin Collagen Sponge Combined With An Antibiotic Compared to Antibiotic Therapy Alone in Diabetic Patients With Moderately Infected Foot Ulcers||Innocoll|No|Completed|April 2008|February 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|80 Years|No|||April 2013|April 29, 2013|April 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659646||157391|
NCT00659659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP166|A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma|A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma||MedImmune LLC|No|Completed|January 2008|March 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|April 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659659||157390|
NCT00659945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07070325|Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery|Efficacy of Pre-operative Aprepitant Plus Ondansetron vs Ondansetron Plus Placebo in Patients at Moderate-to-High Risk Post-operative Nausea (PONV) Undergoing Ambulatory Plastic Surgery||University of Pittsburgh|Yes|Completed|June 2008|June 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 1, 2013|April 15, 2008|Yes|Yes||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00659945||157368|
NCT00660231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/06/009|Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|A Phase II Study of Gemcitabine and Bexarotene (Gembex) in the Treatment of Cutaneous T-cell Lymphoma|GemBex|University College, London|Yes|Completed|March 2008|January 2014|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00660231||157346|
NCT00660205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20080002|Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer|Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer|GIVTE|University of Aarhus|No|Completed|February 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|285|Samples Without DNA|Blood samples with seperation in plasma and serum. Urin samples. tumour tissue samples.|Both|15 Years|85 Years|No|Non-Probability Sample|From February 2008 to December 2009 all patients admitted to The Department of Surgical        Gastroenterology with upper GI cancer or pancreatic cancer will be included.        Depending on the disease nature and progression, the patients will be followed as        palliation or surgery cohorts.|March 2012|March 23, 2012|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00660205||157348|
NCT00660218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X90003|A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer|A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer||State University of New York - Upstate Medical University|Yes|Recruiting|March 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|April 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660218||157347|
NCT00660504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0750018|Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer|Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC||Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|No|Completed|April 2008|August 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|April 10, 2008||No||No|November 21, 2013|https://clinicaltrials.gov/show/NCT00660504||157325|
NCT00660517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP4001|A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|December 2007|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|607|||Both|12 Years|N/A|No|||July 2012|July 23, 2012|April 14, 2008|Yes|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00660517||157324|
NCT00656188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10898|Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects||Bayer||Completed|October 2002|May 2003|Actual|May 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|463|||Male|18 Years|N/A|No|||October 2013|October 9, 2013|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00656188||157655|
NCT00656201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH 2003p000075|Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)|Comparison of Crinone 8% Intravaginal Gel or Intramuscular Progesterone Supplementation for In Vitro Fertilization (IVF) and Embryo Transfer (ET) Cycles in Women Under Age 40 Years Old||Brigham and Women's Hospital|No|Completed|July 2003|July 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|468|||Female|21 Years|39 Years|No|||September 2011|September 20, 2011|April 4, 2008||No||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00656201||157654|
NCT00656435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709051M|Bevacizumab and Long Acting Gas in Diabetic Vitrectomy|Bevacizumab Pretreatment and Long Acting Gas Infusion on the Vitreous Clear-up After Diabetic Vitrectomy||National Taiwan University Hospital|Yes|Completed|December 2006|February 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|85 Years|No|||February 2008|April 7, 2008|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00656435||157636|
NCT00656448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0890|A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS|Randomized Study of Procrit vs no Procrit in Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Undergoing Frontline Myelosuppressive Induction/Consolidation Chemotherapy||M.D. Anderson Cancer Center|Yes|Completed|March 2008|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|51|||Both|N/A|N/A|No|||November 2013|November 4, 2013|April 7, 2008||No||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00656448||157635|
NCT00657046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa IDH201|Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension|A Phase II, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit and Safety of Droxidopa in Patients With Intradialytic Hypotension|IDH201|Chelsea Therapeutics|No|Completed|December 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|80 Years|No|||May 2014|May 27, 2014|April 8, 2008|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT00657046||157589|
NCT00657631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801009613|Acceptance and Commitment Therapy for Delusions|Acceptance and Commitment Therapy for Delusions|ACT|Weill Medical College of Cornell University|No|Completed|April 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||October 2009|October 9, 2009|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657631||157545|
NCT00657644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11182|Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction|Open-label Multi-centre Non Randomised Study of Efficacy and Safety of Vardenafil (BAY 38-9456; SB-782528) Administered in Flexible-dose Regimen in Males With Erectile Dysfunction of Broad Aetiology.||Bayer|No|Completed|August 2003|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Male|18 Years|N/A|No|||December 2014|December 23, 2014|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657644||157544|
NCT00657657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110071|Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine|Immune Response to a Hepatitis B Vaccine Challenge Dose in Healthy Subjects Who Received Primary Vaccination of GlaxoSmithKline Biologicals' Hepatitis B Vaccine, Approximately 20 Years Ago.||GlaxoSmithKline||Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2009|August 6, 2009|April 8, 2008|Yes|Yes||No|August 6, 2009|https://clinicaltrials.gov/show/NCT00657657||157543|
NCT00659113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593402|S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery|A Phase II Trial of a TS-1/Cisplatin Based Definitive Chemoradiotherapy for Resectable Esophageal Cancer||National Cancer Institute (NCI)||Recruiting|March 2008|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|32|||Both|18 Years|75 Years|No|||December 2008|December 3, 2011|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00659113||157432|
NCT00658242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-3-5842|Craniofacial Surgery Perioperative Registry|Craniofacial Surgery Perioperative Registry||Children's Hospital of Philadelphia|No|Completed|March 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|249|||Both|N/A|18 Years|No|Non-Probability Sample|Subjects presenting for craniofacial surgery|August 2013|August 7, 2013|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658242||157498|
NCT00658515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC20971|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome|A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome||Hoffmann-La Roche||Completed|April 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15865|||Both|45 Years|N/A|No|||March 2016|March 1, 2016|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658515||157478|
NCT00658788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10085|Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis|A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of a Consecutive Treatment Regimen of Clobetasol Propionate 0.05% Spray, Followed by Calcitriol Ointment 3µg/g, in the Management of Moderate to Severe Plaque Psoriasis||Galderma Laboratories, L.P.|No|Completed|March 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|305|||Both|18 Years|80 Years|No|||September 2012|August 12, 2014|March 4, 2008|Yes|Yes||No|August 12, 2014|https://clinicaltrials.gov/show/NCT00658788||157457|
NCT00658450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/HD11/4748U|Rehabilitation Program for Cognitive Deficits in Ugandan Children After Cerebral Malaria|A Randomised Trial to Investigate the Effect of a Rehabilitation Program for Cognitive Deficits in Ugandan Children After Cerebral Malaria.||Makerere University|Yes|Completed|February 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|5 Years|15 Years|Accepts Healthy Volunteers|||December 2012|December 5, 2012|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00658450||157483|
NCT00658723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-07-002|The Fibrin Patch Soft Tissue Study|A Prospective, Randomized, Controlled, Superiority Evaluation of Fibrin Patch as an Adjunct to Control Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery||Ethicon, Inc.|Yes|Completed|March 2008|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|April 11, 2008|Yes|Yes||No|March 29, 2014|https://clinicaltrials.gov/show/NCT00658723||157462|
NCT00658736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF IRB 07-729|Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis|A RANDOMIZED, TRIPLE-BLINDED STUDY OF ENDOSCOPIC ULTRASOUND GUIDED CELIAC PLEXUS BLOCKADE (EUS-CPB) WITH BUPIVICAINE AND TRIAMCINOLONE VS. BUPIVICAINE ALONE FOR TREATMENT OF PAIN IN CHRONIC PANCREATITIS||The Cleveland Clinic|Yes|Completed|March 2008|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658736||157461|
NCT00659035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABuv111407|Use of Driving Tests to Evaluate Patient Performance on Oral Opioids|Use of Driving Tests to Evaluate Patient Performance on Oral Opioids|OpDrive|Rush University Medical Center|No|Active, not recruiting|April 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Anticipated|450|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Pain Clinic population|November 2015|November 13, 2015|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00659035||157438|
NCT00659048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-408|Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)|Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)||Takeda||Completed|December 2004|December 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|60 Years|No|||April 2008|May 4, 2012|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659048||157437|
NCT00659295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1677|Observational Study to Evaluate the Safety of Levemir® in Diabetes|A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study: Predictable Results and Experience in Diabetes Through Intensification and Control to Target: an International Variability Evaluation|PREDICTIVE™|Novo Nordisk A/S|No|Completed|June 2004|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|51170|||Both|N/A|N/A|No|Non-Probability Sample|Patients from both general and speciality practice settings who have been deemed        appropriate to receive Levemir® (insulin detemir) as new treatment and as part of routine        out-patient care by the prescribing physician.|August 2014|August 15, 2014|April 10, 2008|No|Yes||No|June 16, 2011|https://clinicaltrials.gov/show/NCT00659295||157418|
NCT00659308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cep0728/02|Amniotic Membrane and Anterior Stromal Puncture to the Treatment of Symptomatic Bullous Keratopathy|Amniotic Membrane and Anterior Stromal Puncture: a Comparative Study in the Treatment of Symptomatic Bullous Keratopathy||Federal University of São Paulo|No|Completed|June 2005|June 2007|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||January 2008|April 14, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659308||157417|
NCT00660595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00042|Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose|A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose||AstraZeneca|No|Terminated|September 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||August 2010|August 24, 2010|April 14, 2008|Yes|Yes|To difficult to recruit patients in the acute setting|No|December 4, 2009|https://clinicaltrials.gov/show/NCT00660595||157318|
NCT00659698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGC-AP-02|Effect of an Artificial Pancreas in Patients Undergoing Hepatic Resection|Prevention for Surgical Site Infection After Hepatic Resection||Kochi University|Yes|Completed|April 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|N/A|N/A|No|||April 2008|April 15, 2008|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00659698||157387|
NCT00659971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBC002-01|Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis|A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113||Pacgen Biopharmaceuticals Corporation|Yes|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|223|||Both|18 Years|65 Years|No|||June 2008|June 25, 2008|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659971||157366|
NCT00660244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OAT-ARI-2007/1|Breast Cancer Tumor Care Observational Programme|Breast Cancer Tumor Care Patient Observation Programme||AstraZeneca|No|Completed|February 2008|December 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women|June 2012|June 5, 2012|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660244||157345|
NCT00660257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PanFlu-1002|Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine|Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza (H5N1)Vaccine in Two-Dose Primed Healthy Adults: A Single Center, Non-Randomized Clinical Trial||Sinovac Biotech Co., Ltd|Yes|Completed|January 2007|March 2008|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|57|||Both|19 Years|61 Years|Accepts Healthy Volunteers|||April 2008|April 16, 2008|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660257||157344|
NCT00660569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RES-PUL-2007/1|Utilization Patterns of Pulmicort in Real Life Practice|Utilization Patterns of Pulmicort HFA in Real Life Practice||AstraZeneca|No|Completed|January 2008|February 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|260|||Both|N/A|N/A|No|Non-Probability Sample|Population treated by General Practitioner, Pneumologists or Paediatricians|November 2010|November 30, 2010|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660569||157320|
NCT00660530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0588|Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients|An Evaluation of Chewed vs. Crushed Lanthanum Carbonate in the Efficacy of Phosphate Binding in Hemodialysis Patients||University of Illinois at Chicago|No|Completed|January 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660530||157323|
NCT00656474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLYC-101-1a|Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation|Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.||Glycotex, Inc.||Completed|March 2008|August 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|April 7, 2008|Yes|Yes||No|June 23, 2011|https://clinicaltrials.gov/show/NCT00656474||157633|
NCT00656461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-106|Phase 1 Study of MKC-1 in Patients With Advanced Cancer|Phase 1 Study of MKC-1 in Patients With Advanced or Metastatic Solid Malignancies||CASI Pharmaceuticals, Inc.|No|Completed|March 2008|November 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2009|November 23, 2009|April 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656461||157634|
NCT00657358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061204013|The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers|The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers (Carl Koller Grant) (The Effect of Intravenous Lidocaine on Allodynia)||University of Alabama at Birmingham|No|Completed|April 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 24, 2013|April 9, 2008|Yes|Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00657358||157566|
NCT00657371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0246|Efficacy of the Third Eye Retroscope Auxiliary Imaging System|A Prospective Efficacy Evaluation of the Third Eye Retroscope Auxiliary Imaging System||M.D. Anderson Cancer Center|No|Completed|March 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|288|||Both|50 Years|80 Years|No|||October 2013|October 11, 2013|April 8, 2008||No||No|October 11, 2013|https://clinicaltrials.gov/show/NCT00657371||157565|
NCT00657384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3959|Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy|Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy : a Prospective Randomized Double-blinding Study||University Hospital, Strasbourg, France|No|Recruiting|October 2008|November 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657384||157564|
NCT00657969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADISP|Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections|Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections|CADISP|Cervical Artery Dissections and Ischemic Stroke Patients - Consortium||Active, not recruiting|July 2005|September 2009|Anticipated|January 2009|Actual|N/A|Observational|Observational Model: Case Control||3|Actual|4169|Samples With DNA|DNA, plasma, serum|Both|18 Years|N/A|No|Non-Probability Sample|groups 1 and 2: hospital-based, neurology departments group 3: community samples|October 2009|October 20, 2009|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657969||157519|
NCT00659126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002864|Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors|A Phase II Study of Ferumoxytol and Gadolinium Magnetic Resonance Imaging at 3T and 7T in Subjects With Primary or Metastatic Brain Tumors Either Before or After Therapy||OHSU Knight Cancer Institute|Yes|Recruiting|November 2006|May 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|April 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659126||157431|
NCT00659997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMDEWORMING|Efficacy Albendazole and Levamisole Against STH on Unguja|Longitudinal Study of Efficacy of Standard Albendazole Treatment Versus Levamisole/Pyrantel Pamoate on Soil Transmitted Helminth Infections|ALBvLEV|Natural History Museum, United Kingdom|No|Completed|June 2006|September 2007|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Female|1 Year|45 Years|No|||April 2008|April 15, 2008|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00659997||157364|
NCT00656552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPE100|Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation|Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study||Cairo University|Yes|Not yet recruiting|May 2008|||December 2008|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Male|20 Years|59 Years|Accepts Healthy Volunteers|||April 2008|April 10, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656552||157627|
NCT00656565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-OSM-402|Inspiratory Flow and Volumes in Bronchiectatics|Inspiratory Flow Rates and Volumes in Subjects With Bronchiectasis Using Low and High Resistance Dry Powder Inhaler Devices||Pharmaxis|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|N/A||1|Anticipated|15|||Both|18 Years|80 Years|No|Non-Probability Sample|subjects aged 18-80 years, with bronchiectasis and FEV1 greater or equal to 50% predicted        and greater or equal to 1L|August 2008|August 5, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656565||157626|
NCT00658463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS 041348|Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients|Effects of Rosuvastatin on the, in Vivo, Kinetic of VLDL apoB, IDL apoB, LDL apoB and HDL apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients||Centre Hospitalier Universitaire Dijon|Yes|Completed|January 2006|September 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|30 Years|75 Years|No|||March 2008|April 14, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00658463||157482|
NCT00658749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR645-CS1|A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma|AIR645-CS1|Altair Therapeutics, Inc.|No|Completed|April 2008|May 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 24, 2009|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658749||157460|
NCT00658762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361020|A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder||Pfizer|No|Terminated|May 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|286|||Both|18 Years|65 Years|No|||November 2012|November 9, 2012|April 9, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00658762||157459|
NCT00659958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-407|ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs|Post-authorization, Observational and Prospective Follow up Study to Evaluate Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs||Eisai Inc.|No|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|No|||March 2010|May 9, 2013|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00659958||157367|
NCT00659321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIASPAN-DD-2005|Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome|Placebokontrollierte Untersuchung Zur Wirkung Von Nikotinsäure Auf Die Dyslipidämie Bei Metabolischem Syndrom Und Das Arterioskleroserisiko (Placebo Controlled Investigation of Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome and the Risk of Atherosclerosis)||GWT-TUD GmbH||Completed|January 2007|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|30 Years|75 Years|No|||January 2012|January 10, 2012|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00659321||157416|
NCT00660010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M90-516|Study of Lupron Depot In The Treatment of Central Precocious Puberty|Study of Lupron Depot In The Treatment of Central Precocious Puberty||Abbott|No|Completed|January 1991|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|10 Years|No|||April 2011|April 8, 2011|April 15, 2008|Yes|Yes||No|April 22, 2010|https://clinicaltrials.gov/show/NCT00660010||157363|Study drug was discontinued usually at the initiation of puberty (12 years for males and 11 years for females) with the concurrence of the investigator, or at the discretion of the investigator. Adverse events are coded with the COSTART dictionary.
NCT00656240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01040703|To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Double-Masked, Parallel-Group Trial of DE-104 Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Santen Pharmaceutical Co., Ltd.||Completed||||||Phase 2|Interventional|N/A|2||||||Both|20 Years|74 Years|No|||March 2009|March 12, 2009|April 7, 2008||||No||https://clinicaltrials.gov/show/NCT00656240||157651|
NCT00656500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004330|Quitline Use in Surgical Patients|Increasing QUITPLAN Helpline Utilization in Surgical Patients||Mayo Clinic|No|Completed|July 2007|June 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656500||157631|
NCT00660543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2753|MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy|Early Assessment of Tumor Response to Therapy Using Ferumoxytol (Code 7228) as an MR Contrast Agent in Patients With Glioblastoma Multiforme (MedDRA Code 10018337)||OHSU Knight Cancer Institute|Yes|Completed|December 2006|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|April 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660543||157322|
NCT00660556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDS-US02-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2003|||||N/A|N/A|N/A||||||||||||||February 8, 2016|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660556||157321|
NCT00656799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05773|Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)|A Single Center, Open-Label Trial in Subjects With Severe Renal Impairment Evaluating the Dialysability of the Sugammadex-Rocuronium Complex||Merck Sharp & Dohme Corp.|No|Completed|April 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|April 7, 2008|No|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00656799||157608|
NCT00656786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS701|Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash|A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash||Spectrum Pharmaceuticals, Inc|Yes|Active, not recruiting|April 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00656786||157609|
NCT00657033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100519|Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction|A Randomized, Double Blind, Parallel Group, Multi-center Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction, and Their Female Partners' Sexual Quality of Life.||Bayer||Completed|October 2003|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|229|||Male|18 Years|N/A|No|||October 2013|October 10, 2013|April 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657033||157590|
NCT00656825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFB001-SS-01|Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers|Multicentre, Placebo-Controlled, Multi-Dosis, Phase I Clinical Trial to Evaluate the Tolerability and Bioavailability of TGF β1 Inhibitor Peptide 144 After Topical Administration in Healthy Volunteers.||ISDIN|No|Completed|March 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 4, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656825||157606|
NCT00659386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-4-010|IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load|Intravenous Immunoglobulin Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load||Maastricht University Medical Center|No|Recruiting|February 2009|August 2010|Anticipated|February 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00659386||157411|
NCT00659399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-742|Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression|07-742 Phase I/ Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression||New York University School of Medicine|Yes|Withdrawn|January 2008|November 2010|Anticipated|September 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|75 Years|No|||March 2015|March 16, 2015|April 10, 2008|No|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00659399||157410|
NCT00659724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gambro 1462|Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer|The Gambro Polyflux HD-C4 Big Ease Of Use And Thrombogenicity Study||Gambro Renal Products, Inc.|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Assessment of dialyzer ease of use and thrombogenicity assessments following routine        dialysis therapy of 33 adult patients (18 years of age or older)|May 2011|May 27, 2011|April 14, 2008||No||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00659724||157385|
NCT00660335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG1068-16|Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas|Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)- Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects With a History of Acute or Acute Recurrent Pancreatitis||Repligen Corporation|No|Completed|March 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|258|||Both|18 Years|N/A|No|||December 2009|December 2, 2009|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660335||157338|
NCT00660647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK-20070008|Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)|Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis|OPERA|University of Aarhus|Yes|Completed|September 2007|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00660647||157314|
NCT00656266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-15138|Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation|A Prospective Randomized Trial of Prednisone and Tacrolimus Versus Prednisone, Tacrolimus and Mycophenolate Mofetil in Pediatric Liver Transplantation||Baylor College of Medicine|No|Terminated|November 2004|July 2008|Anticipated|April 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|N/A|16 Years|No|||April 2008|April 22, 2008|April 7, 2008||No|insufficient funding|No||https://clinicaltrials.gov/show/NCT00656266||157649|
NCT00660387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S187.3.002|Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects|A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations||AbbVie|Yes|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|30 Years|N/A|No|||January 2015|January 12, 2015|April 15, 2008|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00660387||157334|
NCT00658476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9407|Omega-3 Fatty Acids for Treatment of Depression in Adolescents|Treating Adolescent Depression With Fish Oils|PUFA|Cedars-Sinai Medical Center|No|Completed|November 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|13 Years|21 Years|No|||March 2012|March 26, 2012|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658476||157481|
NCT00659672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-384|Effect of Whey Protein on Blood Pressure|Effect of Whey Protein on Blood Pressure||USDA Beltsville Human Nutrition Research Center|Yes|Completed|September 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|35|||Both|28 Years|70 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659672||157389|
NCT00659685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODO-P3-265|Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 16 mg ODT With That of GlaxoSmithKine's Zofran 16 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|November 2003|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|April 15, 2008|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659685||157388|
NCT00658281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0132|Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients|A Pilot Study of Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients Using On-Board Imaging System With Linear Accelerator||M.D. Anderson Cancer Center|No|Completed|March 2008|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with breast cancer.|October 2015|October 5, 2015|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658281||157495|
NCT00658294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1351|Analysis of the Potentially Parasitocidal Effect of a Long Term Chemotherapy With Benzimidazoles|Analysis of the Potentially Parasitocidal Effect of a Long Term Chemotherapy With Benzimidazoles in Patients With Inoperable Alveolar Echinococcosis Using PET-CT and EmII/3-10 Serology||University of Zurich|No|Recruiting|January 2008|January 2009|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No||Patients with inoperable alveolar echinococchosis|April 2008|April 11, 2008|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658294||157494|
NCT00660270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0307|Chemotherapy and Radiation Following Pancreatic Surgery|A Phase II Trial Of Adjuvant Chemoradiation Following Pancreatic Resection For Adenocarcinomas Of The Pancreas Using 3-D Conformal Radiation With Cisplatin, 5FU, And Alpha-Interferon As Radiosensitizing Agents Followed By Gemcitabine||Washington University School of Medicine|No|Completed|May 2002|February 2009|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660270||157343|
NCT00660283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KARE003|A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma|A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma|KARE003|Kentuckiana Cancer Institute|Yes|Active, not recruiting|January 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||January 2010|January 18, 2010|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00660283||157342|
NCT00659425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-8015-1004|CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL)||MedImmune LLC|No|Completed|September 2008|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|6 Months|25 Years|No|||May 2015|May 19, 2015|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659425||157408|
NCT00657098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/203|Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy|Mabtornib Protocol.Vascular, Metabolic and Hormonal Effects of Angiogenesis Inhibitors and Epidermal Growth Factor Receptor Inhibitors|Mabtornib|University Medical Center Groningen|No|Terminated|March 2008|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|Samples With DNA|Serum Plasma Urine DNA|Both|18 Years|N/A|No|Non-Probability Sample|Patients who will be treated with angiogenesis inhibitors or EGFR inhibitors|October 2015|October 5, 2015|April 8, 2008||No|slow inclusion rate|No||https://clinicaltrials.gov/show/NCT00657098||157585|
NCT00657111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0064|CS-8958 Single Inhaled Dose in Elderly|CS-8958 - A Phase I, Double-Blind, Placebo Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Elderly Subjects||Biota Scientific Management Pty Ltd|Yes|Completed|April 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|38|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 11, 2009|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00657111||157584|
NCT00656214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|olplycopene|Treatmant of Oral Lichen Planus With Lycopene|Efficacy of Oral Lycopene in the Management of Oral Lichen Planus||College of Dental Sciences, India||Completed|December 2004|July 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||November 2004|April 9, 2008|April 4, 2008||||No||https://clinicaltrials.gov/show/NCT00656214||157653|
NCT00656227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1008|A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision|A Double Blind, Placebo Controlled Randomised Trial to Investigate the Scar Improvement Efficacy of a Single Intradermal Application of RN1001 (Avotermin) in Subjects Undergoing Excision of Benign Head and Neck Naevi.||Renovo|No|Active, not recruiting|April 2004|July 2012|Anticipated|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|||Actual|239|||Both|18 Years|85 Years|No|||April 2008|April 10, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656227||157652|
NCT00660582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nordic 7.5|FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor|FLOX + Cetuximab (Erbitux®): First Line Treatment for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor, A Phase II Study||Odense University Hospital|Yes|Completed|April 2008|February 2013|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|152|||Both|18 Years|75 Years|No|||January 2015|January 20, 2015|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00660582||157319|
NCT00659711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1931 Januvia|The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects|The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects|1928|Kaleida Health|No|Active, not recruiting|March 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|75 Years|No|||December 2012|December 17, 2012|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659711||157386|
NCT00657059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGIgAN-001|Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)|A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)||Sun Yat-sen University|Yes|Recruiting|September 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|14 Years|60 Years|No|||May 2015|May 18, 2015|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657059||157588|
NCT00657072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4840|Biomechanical Evaluation of Wrist Ligament Injuries: Diagnostic Tool to Detect Wrist Instability|Biomechanical Evaluation of Wrist Ligament Injuries: Diagnostic Tool to Detect Wrist Instability||State University of New York - Upstate Medical University|No|Completed|May 2003|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|16 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have suffered ligamentous injuries to their wrists will be recruited for this        study|November 2015|November 20, 2015|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657072||157587|
NCT00657085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-ABU-HSET-0607-02|Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction|Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction||Lumenis Ltd.|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|Samples With DNA|Biopsied hair follicles retained and analzed through horizontal sectioning and viability      staining|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|5 Adult male subjects that have sought laser back hair removal|December 2008|December 10, 2008|April 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00657085||157586|
NCT00622765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011362|A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|November 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|321|||Both|18 Years|65 Years|No|||April 2014|April 24, 2014|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00622765||160191|
NCT00622778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-Wolf|Immunemodulation in Patients With Minor Head Injury|Diagnostic Algorithm in Minor Head Injury|MHI|Medical University of Vienna|No|Completed|October 2007|July 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|Samples Without DNA|Serum from peripheral blood|Both|1 Year|N/A|No|Non-Probability Sample|Patients from daily practice|July 2011|April 10, 2012|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622778||160190|
NCT00657670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00013454|Evaluation of Effectiveness of Correcting Refractive Error With Ready-made Spectacles|Evaluation of the Feasibility of Correcting Refractive Error From a Limited Inventory of Ready-made Spectacles: Wearer Retention, Vision Function, Quality of Life and Cost|RECS|Johns Hopkins University|No|Completed|April 2008|September 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|11 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 8, 2009|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00657670||157542|
NCT00657683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98P1|A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age|A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age||Novartis||Completed|December 2007|May 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|65|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00657683||157541|
NCT00623324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aplindore-201|The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease|A Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease||Ligand Pharmaceuticals|No|Completed|January 2008|||July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|N/A|No|||September 2011|September 29, 2011|February 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00623324||160149|
NCT00623337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Newhints|Ghana Newborn Home Visits Neonatal Mortality Trial|Cluster Randomised Trial to Evaluate the Impact of Routine Home Visits to Provide a Package of Essential Newborn Care Interventions in the Third Trimester of Pregnancy and the 1st Week of Life on Neonatal Mortality in Rural Ghana|Newhints|London School of Hygiene and Tropical Medicine|Yes|Active, not recruiting|January 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|15000|||Both|N/A|12 Months|No|||February 2010|February 17, 2010|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00623337||160148|
NCT00660348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0724 CDR0000593173|Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer|A Randomized Study of Optimal Pain Management: Standard Pain Control Versus Early Intervention With Intrathecal Therapy in Patients With Advanced Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center||Terminated|March 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|N/A|No|||October 2014|October 7, 2014|April 16, 2008|No|Yes|Low enrollment|No|May 21, 2014|https://clinicaltrials.gov/show/NCT00660348||157337|Subject started study 7/14/2010, but withdrew her consent on 7/24/2010 due to increased upper quadrant pain. One subject enrolled. She withdrew consent before study team could collect any follow-up data. We do not have any participants to analyze.
NCT00623597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV20911|A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.|A Phase I/II Study of Invirase® Boosted With Ritonavir in HIV Infected Infants and Children 4 Months to Less Than 6 Years Old||Hoffmann-La Roche|No|Completed|June 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|4 Months|6 Years|No|||February 2016|February 4, 2016|February 18, 2008|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT00623597||160128|
NCT00657397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS Methaville|Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices|Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville|Methaville|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|197|||Both|18 Years|70 Years|No|||July 2012|July 23, 2012|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657397||157563|
NCT00660075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITA001|Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Effects of Sitagliptin on Postprandial Plasma Lipoprotein Concentrations in Men With Type 2 Diabetes||Laval University|Yes|Completed|February 2008|April 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|65 Years|No|||November 2012|November 13, 2012|April 14, 2008||No||No|May 18, 2011|https://clinicaltrials.gov/show/NCT00660075||157358|
NCT00645892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-596|Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Abbott|No|Completed|November 2003|||September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2008|March 25, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645892||158439|
NCT00658489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27092|Implementation and Evaluation of Bright Futures Curriculum Within CORNET Continuity Practice|Implementation and Evaluation of Bright Futures Curriculum Within CORNET Continuity Practice||Christiana Care Health Services|No|Completed|January 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Both|12 Months|35 Months|Accepts Healthy Volunteers|||November 2011|November 9, 2011|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658489||157480|
NCT00657137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP2001-202|APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)|A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane|APRiCOT-B|Tragara Pharmaceuticals, Inc.|Yes|Terminated|April 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Female|18 Years|N/A|No|||March 2012|March 13, 2012|March 31, 2008|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00657137||157582|
NCT00657150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.64|Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty|A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)||Boehringer Ingelheim||Completed|March 2008|||September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|2055|||Both|18 Years|N/A|No|||December 2013|June 23, 2014|March 27, 2008||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00657150||157581|
NCT00660361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALF-50/08|A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients|A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir (TDF) in HIV-HBV co-Infected Patients||Bayside Health|No|Recruiting|April 2008|September 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|92|Samples Without DNA|Stored serum samples|Both|18 Years|N/A|No|Non-Probability Sample|Individuals co-infected with HIV-HBV and currently receiving tenofovir as part of their        HAART regimen|April 2008|April 16, 2008|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00660361||157336|
NCT00659737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071433|Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting|A Randomized, Double-blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting||Drexel University|No|Completed|April 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|115|||Both|18 Years|65 Years|No|||September 2013|May 1, 2014|April 8, 2008||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00659737||157384|
NCT00659334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-1127|Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation|Multi-disciplinary Study: MR, Histologic and EM Imaging of Intravenous Superparamagnetic Crystalline Particles (Combidex) to Brain, Intra-cerebral Tumors and in CNS Inflammation||OHSU Knight Cancer Institute|Yes|Terminated|August 2000|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|7||Actual|116|||Both|5 Years|75 Years|No|||October 2012|October 10, 2012|April 10, 2008|Yes|Yes|AMAG not continuing with Combidex, the study drug|No|May 15, 2012|https://clinicaltrials.gov/show/NCT00659334||157415|Early trial termination due to study drug Combidex no longer manufactured.
NCT00659347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOV 947-010|Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DOV 21,947 in Patients With Major Depressive Disorder||DOV Pharmaceutical, Inc.|No|Terminated|March 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||December 2008|December 4, 2008|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659347||157414|
NCT00659360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01054|AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma|A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma||National Cancer Institute (NCI)|Yes|Completed|February 2008|November 2012|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2014|July 2, 2015|April 15, 2008|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00659360||157413|
NCT00625274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00063|A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients|||AstraZeneca||Completed|June 2004|November 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|60 Years|No|||February 2008|February 27, 2008|February 20, 2008||||No||https://clinicaltrials.gov/show/NCT00625274||160002|
NCT00625612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08640|Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease|A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease and FEV1 Greater Than or Equal to 75% Predicted But Less Than or Equal to 110% Predicted||Merck Sharp & Dohme Corp.|Yes|Completed|February 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|466|||Both|5 Years|N/A|No|||October 2015|October 8, 2015|February 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625612||159978|
NCT00656513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0537|Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer|A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia||Radiation Therapy Oncology Group|Yes|Completed|September 2008|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|196|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|April 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656513||157630|
NCT00656812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_MALT|Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma|Phase II Trial of Rituximab Plus 2CdA in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Completed|May 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00656812||157607|
NCT00656487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA024194|Neurobiology of Cannabis Dependence|Neurobiology of Cannabis Dependence|SCCAN|The Scripps Research Institute|No|Completed|April 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|60|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|April 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00656487||157632|
NCT00660322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS015378|Using the Telephone to Improve Care in Childhood Asthma|Using the Telephone to Improve Care in Childhood Asthma||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|January 2004|June 2007|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|362|||Both|5 Years|12 Years|No|||April 2008|April 15, 2008|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660322||157339|
NCT00660621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KARE004|A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma|A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma|KARE004|Kentuckiana Cancer Institute|Yes|Recruiting|April 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||January 2010|January 18, 2010|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00660621||157316|
NCT00660634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85/2004|Angioplasty in Peripheral Arterial Disease and Endothelial Function|The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function|PTA-PAD-FMD|University Hospital Inselspital, Berne|Yes|Completed|December 2004|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|40 Years|90 Years|No|||April 2008|April 25, 2008|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00660634||157315|
NCT00656526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012|Preemptive Analgesia for Postlaminectomy|Intraoperative Perineural Injection of Lidocaine for Postlaminectomy Pain||Harran University|No|Completed|September 2007|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|50 Years|No|||April 2008|April 10, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656526||157629|
NCT00622791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-01|Propofol Pharmacokinetics and Pharmacodynamics During Cardiopulmonary Bypass|Effects of Cardiopulmonary Bypass on Plasma Propofol Concentrations and Bis Values During Coronary Surgery||University of Sao Paulo|Yes|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|Samples Without DNA|Blood samples|Both|18 Years|80 Years|No|Probability Sample|Twenty patients undergoing elective coronary artery bypass graft surgery|February 2008|February 13, 2008|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622791||160189|
NCT00623077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS023|MT2004-30: Tomotherapy for Solid Tumors|Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors||Masonic Cancer Center, University of Minnesota|Yes|Terminated|August 2005|December 2015|Anticipated|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|70 Years|No|||April 2015|April 10, 2015|February 22, 2008|No|Yes|Replaced by another study|No||https://clinicaltrials.gov/show/NCT00623077||160167|
NCT00658268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKOISR10001|Bisphosphonates and Impaction Grafting in Hip Revision|Bisphosphonates and Impaction Grafting in Hip Revision Evaluated With Radiostereophotogrametri. A Randomized, Double-blind Study in Patients Operated for Aseptic Loosening and Osteolysis.||Region Skane|No|Recruiting|March 2008|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|45 Years|80 Years|No|||January 2012|January 26, 2012|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658268||157496|
NCT00623350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005731|Stroke DOC Arizona TIME - Stroke Team Remote Evaluation Using a Digital Observation Camera|Stroke Team Remote Evaluation Using a Digital Observation Camera Arizona - The Initial Mayo Clinic Experience||Mayo Clinic|Yes|Completed|December 2007|January 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2011|May 11, 2011|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00623350||160147|
NCT00623610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK-Tx-04|Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes|Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes||AZ-VUB|No|Completed|September 2000|October 2005|Actual|October 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|No|||February 2008|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00623610||160127|
NCT00623857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAO 93-442|Micronutrients and Child Health Study|Effects of Supplementation With Zinc and Other Micronutrients on the Health and Development of African Children|MACH|Wageningen University|Yes|Completed|March 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|612|||Both|6 Months|60 Months|Accepts Healthy Volunteers|||November 2014|November 14, 2014|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623857||160108|
NCT00645905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-538|Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Abbott|No|Completed|June 2003|||March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645905||158438|
NCT00659061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|754-Ped/ERC-07|Monitoring and Evaluation of Micronutrients (Sprinkles) Project|Monitoring and Evaluation of Micronutrients (Sprinkles) Project|Sprinkles|Aga Khan University|No|Completed|August 2007|May 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|610|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||May 2009|May 28, 2009|April 14, 2008||No||No|December 15, 2008|https://clinicaltrials.gov/show/NCT00659061||157436|The attrition rate was high (6.8% in intervention group and 5.0% in the control group) due to unforeseen migration because of political unrest in the region.
NCT00659074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODO-P3-266|Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 24 mg ODT With That of GlaxoSmithKine's Zofran 24 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|October 2003|February 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|April 15, 2008|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659074||157435|
NCT00657982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4616-RB-CTIL|Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer|Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer||Sheba Medical Center|No|Recruiting|April 2008|||March 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|N/A|No|||January 2009|January 19, 2009|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657982||157518|
NCT00657995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGC-AP-01|Tight Glycemic Control by Artificial Pancreas|Continuous Postoperative Blood Glucose Monitoring and Control by an Artificial Pancreas in Patients Undergoing Pancreatic Resection: A Prospective Randomized Clinical Trial||Kochi University|Yes|Completed|April 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||April 2008|April 8, 2008|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00657995||157517|
NCT00660296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 07-238-VK|Randomized Controlled Trial Comparing Co2 vs. Air in Colonoscopy in Sedated Patients|Randomized Controlled Trial Comparing Co2 vs. Air in Colonoscopy in Sedated Patients||Medical University of Vienna|No|Recruiting|February 2008|October 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|90 Years|No|||April 2008|April 16, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00660296||157341|
NCT00660309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2329|A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus|An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus||Novartis|No|Completed|April 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|45|||Both|18 Years|75 Years|No|||August 2012|August 27, 2012|April 11, 2008|No|Yes||No|July 20, 2012|https://clinicaltrials.gov/show/NCT00660309||157340|
NCT00660608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVA 100|Conservation of Red Cell Mass , Oxygen Supply and Demand in Cardiac Surgery|Conservation of Red Cell Mass, Oxygen Supply and Demand in Cardiac Surgery||Virginia Commonwealth University|Yes|Completed|April 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Pre-OP, surgery clinics, inpatients|July 2010|July 2, 2010|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00660608||157317|
NCT00626210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8564|Modafinil Treatment for Sleep/Wake Disturbances in Older Adults|Modafinil Treatment for Sleep/Wake Disturbances in Older Adults||VA Palo Alto Health Care System|No|Terminated|February 2008|October 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|50 Years|N/A|No|||October 2014|October 28, 2014|February 20, 2008|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00626210||159933|Early termination leading to small numbers of subjects analyzed
NCT00626223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCRB 2007/0234|5-Methyltetrahydrofolate Survival and Inflammation in ESRD Patients|5-Methyltetrahydrofolate Survival and Inflammation in ESRD Patients||St. Orsola Hospital|No|Completed|January 1998|July 2007|Actual|July 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|341|||Both|18 Years|N/A|No|||February 2008|February 28, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00626223||159932|
NCT00657956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dal07-02|Roentgen Stereophotogrammetric Analysis (RSA) to Evaluate Fixation of Biofoam Advance Total Knee Arthroplasty Components|Prospective RCT Using Roentgen Stereophotogrammetric Analysis (RSA) to Evaluate Fixation of the Biofoam Advance Total Knee Arthroplasty Components With and Without Screw Augmentation||Dalhousie University|No|Completed|April 2008|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|50|||Both|21 Years|80 Years|No|||March 2014|March 28, 2014|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657956||157520|
NCT00658255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0729|Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler|A Randomized, Multicenter, Open-label, Active-controlled, Single-dose, 5-period, Incomplete Block, Cross-over Study to Evaluate the Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort pMDI or Oxis Turbuhaler to Adults With Stable Asthma||AstraZeneca|No|Completed|October 2002|May 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658255||157497|
NCT00658814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00790|Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia||National Cancer Institute (NCI)||Active, not recruiting|December 2008|||June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|133|||Both|60 Years|N/A|No|||February 2016|February 5, 2016|April 12, 2008|Yes|Yes||No|July 22, 2013|https://clinicaltrials.gov/show/NCT00658814||157455|
NCT00656253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A11|Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease|||Fudan University|Yes|Completed|August 2008|February 2011|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|50 Years|N/A|No|||September 2009|March 21, 2011|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656253||157650|
NCT00656539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-107|Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis|A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Four Weeks in Subjects With Posterior Blepharitis||Merck Sharp & Dohme Corp.|No|Completed|April 2008|||November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|April 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656539||157628|
NCT00657124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEA-AP-01|Effect of Preoperative Supplementation in Insulin Resistance|Preoperative Oral Supplementation of Carbohydrate and Branched-Chain Amino Acids-Enriched Nutrient Improves Insulin Resistance in Patients With Hepatectomy; Prospective Randomized Clinical Trial by Using Artificial Pancreas||Kochi University|Yes|Completed|April 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|26|||Both|N/A|N/A|No|||April 2008|April 11, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00657124||157583|
NCT00627042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13922|Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy|An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B as First Line Monotherapy in Patients With Unresectable Hepatocellular Cancer||Eli Lilly and Company|No|Completed|February 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|February 18, 2008|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00627042||159869|The duration of response results should be interpreted with caution since the sample size for this analysis was very small (2 participants).
NCT00623064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30061|Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer|Phase I Study of Cisplatin, Gemcitabine and Lapatinib as First Line Treatment in Advanced/Metastatic Urothelial Cancer||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 2007|August 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00623064||160168|
NCT00623363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBI-501|Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease|||Daiichi Sankyo Inc.|No|Completed|April 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|85 Years|No|||November 2015|November 6, 2015|January 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00623363||160146|
NCT00623636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0004 CL P301|Phase 3 Study of MAP0004 in Adult Migraineurs|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extension.|FREEDOM301|Allergan|Yes|Completed|July 2008|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|902|||Both|18 Years|65 Years|No|||December 2013|December 9, 2013|February 7, 2008|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00623636||160125|
NCT00623623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123.28|STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction|STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms||Boehringer Ingelheim||Completed|March 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1891|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|February 15, 2008||||No||https://clinicaltrials.gov/show/NCT00623623||160126|
NCT00623649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCH 916-103|Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection|A Phase 1B, Multicentre, Randomized, Double-Blinded, and PLacebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and PK of Multiple Ascending Doses of VCH-916 in the Treatment Naive or Experienced Subjects With Chronic Hep C-Infection.||Vertex Pharmaceuticals Incorporated|Yes|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|60 Years|No|||February 2014|April 2, 2014|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00623649||160124|
NCT00623870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21279|A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.|An Open Label Study to Investigate the Maximum Tolerated Dose of RO5045337 in Patients With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL / SCLL)||Hoffmann-La Roche||Completed|May 2008|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00623870||160107|
NCT00646243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPROVE|Echo Assessment of Intraventricular Dyssynchrony|Italian Multicenter PROject on Echo Assessment of Left VEntricular (IMPROVE) Dyssynchrony Study|IMPROVE|Italian Society of Cardiology|No|Not yet recruiting|March 2008|March 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|336|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive consenting patients candidate to cardiac resynchronization therapy by clinical        and electrocardiographic criteria.|March 2008|March 27, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646243||158412|
NCT00658801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-226|Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma|A Phase II Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma||National Cancer Center, Korea||Terminated|January 2007|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2011|July 7, 2011|March 24, 2008||No|difficult to register|No||https://clinicaltrials.gov/show/NCT00658801||157456|
NCT00656838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA132709-01|Focusing Implementation to Bring Effective Reminders (FIBER)|Focusing Implementation to Bring Effective Reminders (FIBER)|FIBER|Kaiser Permanente|No|Completed|April 2008|February 2013|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|85289|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||October 2011|February 19, 2014|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656838||157605|
NCT00658827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013141|Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis|Exposure to Remicade (Infliximab) During Pregnancy in Patients With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: a Review and Analysis of Birth Outcomes From the Swedish, Danish and Finnish Medical Birth Registers||Janssen Biotech, Inc.|No|Active, not recruiting|January 2007|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|370|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female patients of child bearing age with one of the diseases of interest and infants        delivered by such patients.|March 2016|March 8, 2016|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658827||157454|
NCT00659139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82/02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2008|||||N/A|N/A|N/A||||||||||||||April 10, 2008|April 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659139||157430|
NCT00659152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21.02.2008.411|Morphofunctional Lung Analysis by Positron Emission Tomography|Morphofunctional Lung Analysis by Positron Emission Tomography in ALI-ARDS Patients||Policlinico Hospital|No|Completed|February 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|ALI/ARDS ICU patients|April 2015|April 27, 2015|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00659152||157429|
NCT00659412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-737|A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Alefacept When Given in Combination With Methotrexate in Subjects With Psoriatic Arthritis With an Open-label Retreatment Course||Astellas Pharma Inc|No|Completed|September 2003|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|185|||Both|18 Years|70 Years|No|||September 2014|September 17, 2014|April 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00659412||157409|
NCT00625300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-4726-OC-CTIL|Repetitive Transcranial Stimulation (r-TMS) Treatment for Patients With Parkinson's Disease|Efficacy and Safety Study:The Influence of Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease|r-TMS|Sheba Medical Center|No|Completed|April 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|N/A|No|||October 2009|October 19, 2009|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00625300||160001|
NCT00649350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METF-0364|Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg|Single-Dose Food In Vivo Bioequivalence Study Metformin Hydrochloride ER Tablets (750 mg; Mylan) and Glucophage XR (750 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649350||158177|
NCT00649363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONDA-04102|Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ondansetron Orally Disintegrating Tablets (8 mg; Mylan) to Zofran ODT® Tablets (8 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649363||158176|
NCT00649831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661045|A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis|Azithromycin (Zithromax®) 5 Days Versus Amoxicillin-Clavulanic Acid (Augmentin®): Multicentre, Randomised, Open-Label Study To Compare The Clinical Efficacy And Safety Of Azithromycin With Those Of Amoxicillin-Clavulanic Acid In Patients Presenting With An Exacerbation Of Chronic Bronchitis||Pfizer|No|Completed|October 2002|June 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|36 Years|74 Years|No|||October 2008|October 20, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649831||158140|
NCT00651027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121004|Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554|An Open Label Study, To Evaluate The Pharmacokinetics, Safety And Toleration Of A Single Oral Dose Of Pf-00868554 In Subjects With Hepatic Impairment To Subjects With Normal Hepatic Function||Pfizer|No|Completed|February 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||January 2014|January 2, 2014|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651027||158048|
NCT00651040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3401|Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis|A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis.|Prometheus|Institute of Rheumatology, Prague|No|Active, not recruiting|May 2008|January 2015|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||October 2013|October 21, 2013|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651040||158047|
NCT00645424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581123|A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol|A Randomized, 12-Week, Open Labeled Study To Evaluate The Efficacy And Safety Of Once Daily Atorvastatin In Diabetes Mellitus Type 2 With Hyperlipidemia||Pfizer|No|Completed|December 2003|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|80 Years|No|||April 2008|April 28, 2008|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645424||158475|
NCT00645437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004174|A Study to Evaluate the Pharmacokinetics and Safety of Levofloxacin in Patients With Varying Degrees of Renal Function.|An Open-Label Randomized Multiple-Dose Study to Evaluate Levofloxacin Steady-State Pharmacokinetics and Safety in Subjects With Varying Degrees of Renal Function||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2004|April 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|59|||Both|18 Years|65 Years|No|||April 2010|June 6, 2011|March 24, 2008||||||https://clinicaltrials.gov/show/NCT00645437||158474|
NCT00645450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-013-07S|PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation|PTSD Symptom Reduction by Propranolol Given After Memory Activation||VA Office of Research and Development|Yes|Terminated|April 2008|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||November 2013|November 19, 2013|March 19, 2008||No|Difficulty recruiting subjects and unable to replace study physician who changed jobs|No||https://clinicaltrials.gov/show/NCT00645450||158473|
NCT00646308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB9681|Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas|Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas||Columbia University|No|Terminated|March 2008|March 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|None Retained|Serum samples|Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients with a history of nonsecreting pituitary tumor.|April 2011|April 22, 2011|March 25, 2008||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00646308||158407|
NCT00646321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0725|Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT|A 12 Week, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study of SYMBICORT pMDI Administered Once Daily in Children and Adolescents 6 to 15 Years of Age With Asthma - SPROUT||AstraZeneca|No|Completed|April 2003|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|540|||Both|6 Years|15 Years|No|||January 2011|January 21, 2011|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646321||158406|
NCT00646009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0733|Symbicort Onset of Action 2|A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.||AstraZeneca|No|Completed|March 2003|August 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646009||158430|
NCT00646022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080098|Natural History of Familial Carcinoid Tumor|Natural History of Familial Carcinoid Tumor||National Institutes of Health Clinical Center (CC)||Recruiting|March 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|18 Years|N/A|No|||August 2015|September 10, 2015|March 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00646022||158429|
NCT00646035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-015|A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis|A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis||Abbott||Completed|January 2002|||November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646035||158428|
NCT00646048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2106|A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms|A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms|AAA IDE|Boston Scientific Corporation|No|Completed|February 2003|March 2010|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2011|January 26, 2011|March 26, 2008|Yes|Yes||No|June 29, 2010|https://clinicaltrials.gov/show/NCT00646048||158427|
NCT00648596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481161|A Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion|An International, Multicentre, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfunction Treated With Sildenafil Citrate||Pfizer|No|Completed|May 2003|May 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|780|||Male|18 Years|N/A|No|||April 2015|April 21, 2015|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648596||158234|
NCT00646581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2006|Effect of Single Dose Intranasal Insulin On Cognitive Function|Effect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia||University of Massachusetts, Worcester|Yes|Completed|October 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|January 31, 2008||No||No|August 17, 2012|https://clinicaltrials.gov/show/NCT00646581||158386|
NCT00646919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY56/2007|Preoperative Nasal Swabs From Pediatric Patients|Double-Blind Prospective Study Concerning the Connection Between Positive Nasal Culture for Staphyloccoci in Pediatric Patients Undergoing Any Elective Surgery in the Out-Patient Clinic in the Hillel Yaffe Medical Center, Over a Period of One Year||Hillel Yaffe Medical Center|Yes|Not yet recruiting||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|N/A|16 Years|No|Probability Sample|All pediatric patients attending our outpatient surgery clinic|March 2008|March 26, 2008|March 26, 2008||||No||https://clinicaltrials.gov/show/NCT00646919||158360|
NCT00647556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10067|Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage|A Comparative Study of Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream, for the Treatment of Photodamage||Galderma Laboratories, L.P.|No|Completed|April 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|N/A|No|||September 2012|September 21, 2012|March 26, 2008|Yes|Yes||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00647556||158313|
NCT00652366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21128|A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer.||Hoffmann-La Roche||Completed|May 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|467|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|April 1, 2008||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT00652366||157945|
NCT00652704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99062|Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions|Randomized, Open-Label, 3-Way Crossover, Comparative Bioavailability Study of Par's and Oclassen's (Monodox) Doxycycline Monohydrate Capsules Administered as 1 x 100 mg Capsule in Healthy Adult Males Under Fasting and Fed Conditions||Par Pharmaceutical, Inc.|No|Completed|July 1999|September 1999|Actual|September 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652704||157920|
NCT00646516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5896C00001|Gemini Symbicort pMDI|A Rand, Doubleblind, Activecontrolled, Parallel-grp,Singledummy, Multicenter,12 wk Study to Assess the Effic.&Safety of Symbicort pMDI 2x160/4.5mcg QD Compared to Symb. pMDI 2x80/4.5mcg QD, Symb. pMDI 2x80/4.5mcg Bid and to Budesonide pMDI 2x160 Mcg QD in Asthmatic Sub's12yrs and Over||AstraZeneca|No|Completed|October 2003|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|615|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646516||158391|
NCT00646529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0719|Long-Term Safety of Symbicort in Asthmatic Children - SAPLING|A Six Month, Randomized, Open-Label, Safety Study of Symbicort (160/4.5mcg) Compared to Pulmicort Turbuhaler in Asthmatic Children Aged Six to Eleven Years - SAPLING||AstraZeneca|No|Completed|July 2002|October 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|6 Years|11 Years|No|||March 2009|March 27, 2009|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646529||158390|
NCT00646841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0351051|Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients|The Effects of Doxazosin Gastrointestinal Therapeutic System (GITS) on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensives on Drug Therapy||Pfizer|No|Completed|February 2003|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||August 2008|August 7, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646841||158366|
NCT00647153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04085|Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer|Pre-Surgical Detection of Colorectal Carcinomas Using 123Iodine-Labeled cT84.66 Diabody Antibody Fragments to Carcinoembryonic Antigen (CEA)||City of Hope Medical Center|Yes|Completed|May 2006|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|March 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00647153||158344|
NCT00647478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060224|System-IGF-1 Pathway and Alzheimer's Disease|A Multicenter Study to Assess Differences Between Circulating Levels of IGF-I and IGFBP-3 in Patients With Sporadic Late-onset Alzheimer's Disease and Control Elderly Subjects.|SIGAL|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2007|July 2012|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|693|Samples With DNA|Blood for plasma levels and polymorphisms in IGF1 system components|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ambulatory Elderly subjects|June 2013|June 5, 2013|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647478||158319|
NCT00647920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-573|Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate|Study of the Human Anti-TNF-Antibody Adalimumab||Abbott|No|Completed|July 2003|||April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00647920||158286|
NCT00647959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOXY-0612|Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mg|Single-Dose Fasting Bioequivalence Study of Doxycycline Monohydrate Tablets (150 mg; Mylan) and Adoxa Tablets (150 mg; Par) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|March 2006|April 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647959||158283|
NCT00648362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIM-0447|Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Glimepiride Tablets (1 mg; Mylan) to Amaryl® Tablets (1 mg; Aventis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2004|December 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648362||158252|
NCT00648375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH058911-01|Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder|Efficacy of Propanolol for Treatment of Posttraumatic Stress Disorder||Weill Medical College of Cornell University|No|Terminated|December 2003|September 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|50 Years|No|||June 2012|June 27, 2012|March 28, 2008|Yes|Yes|inadequate recruitment|No||https://clinicaltrials.gov/show/NCT00648375||158251|
NCT00648388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO-0395|Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Cilostazol Tablets (100 mg; Mylan) and Pletal® Tablets(100 mg; Otsuka) in Healthy Volunteers||Mylan Pharmaceuticals|No|Completed|March 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648388||158250|
NCT00648869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|generex-HMO-CTIL|Open-label Crossover Metformin Gum Versus Tablet in Healthy Volunteers|Open-label,Randomized, Crossover Study Comparing Metformin Gum and Immediate Release Tablet in Healthy Volunteers||Hadassah Medical Organization|Yes|Withdrawn|June 2008|November 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2008|October 25, 2009|March 27, 2008|Yes|Yes|Drug was not sent|No||https://clinicaltrials.gov/show/NCT00648869||158214|
NCT00648882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVO-0711|Fasting Study of Levothyroxine Sodium Tablets 300 Mcg to Synthroid® Tablets 300 Mcg|Single-Dose Fasting Bioequivalence Study of Levothyroxine Sodium Tablets (300 Mcg; Mylan) to Synthroid® Tablets (300 Mcg; Abbott)||Mylan Pharmaceuticals||Completed|March 2007|May 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|33|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648882||158213|
NCT00648856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERT-0225|Food Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Sertraline Hydrochloride Tablets (100 mg; Mylan) and Zoloft® Tablets (100 mg; Pfizer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648856||158215|
NCT00649337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC0001|Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons|Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Screening Mammography, Including Cost Comparisons||SonoCine, Inc.|Yes|Recruiting|January 2003|January 2010|Anticipated|July 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|4650|||Female|35 Years|90 Years|Accepts Healthy Volunteers|||March 2008|March 27, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00649337||158178|
NCT00649376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEXO-0351|Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra® Tablets (180 mg; Aventis) in Healthy Adult Volunteers||Mylan Pharmaceuticals||Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649376||158175|
NCT00650299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPR-0467|Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg|Single-Dose Food In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (3 mg; Mylan) to Xanax XR® Tablets (3 mg; Pharmacia & Upjohn) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650299||158104|
NCT00650312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METF-0282|Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR Tablets (500 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2002|November 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650312||158103|
NCT00650325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERT-0224|Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Sertraline Hydrochloride Tablets (100 mg; Mylan) and Zoloft® Tablets (100 mg; Pfizer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|49|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650325||158102|
NCT00650728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esophagus imaging|Esophagus Imaging for Radiofrequency Ablation of Atrial Fibrillation|Esophagus Imaging for Radiofrequency Ablation of Atrial Fibrillation: Comparison of Two Methods||Luzerner Kantonsspital|Yes|Completed|March 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||||||Both|18 Years|N/A|No|||June 2011|June 22, 2011|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00650728||158071|
NCT00650754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR2008 1.0|Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility|A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Normal Hysterosalpingogram and Normal Semen Analysis and Evidence of Premature Ovarian Aging (POA).|DHEAFert|Center for Human Reproduction|No|Terminated|March 2008|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Female|21 Years|37 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|March 31, 2008||No|Failure to recruit designed nuimebrt of subjects|No||https://clinicaltrials.gov/show/NCT00650754||158069|
NCT00651053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 2005-01|Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis|Validation of Endoscopic Ultrasound Criteria for Diagnosis of Chronic Pancreatitis Using Dual Secretin and Cholecystokinin Pancreatic Function Testing as Reference Standard||The Cleveland Clinic|No|Completed|May 2005|December 2007|Actual|||N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|N/A|No|||March 2008|February 2, 2016|March 30, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00651053||158046|
NCT00645697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1955AM|Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization|Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization: Multicenter Collaborative Study|AVA-ION|Rafic Hariri University Hospital|No|Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|Retrospective review of INO treated by the 25 collaborators from the 5 continents.|March 2008|March 25, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645697||158454|
NCT00646061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0705/045-005|Pain Control in Renal Colic|||Seoul National University Hospital||Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|16 Years|45 Years|No|||September 2009|September 20, 2009|March 25, 2008||||No||https://clinicaltrials.gov/show/NCT00646061||158426|
NCT00646971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P041012|Oxidative Stress and Endothelial Dysfunction in Obstructive Sleep Apnea|Exhaled Markers of Oxidative Stress and Endothelium-dependent Vascular Relaxation in Obstructive Sleep Apnea. Effect of Continuous Positive Airway Pressure Therapy.|SOREVAS|Assistance Publique - Hôpitaux de Paris|No|Terminated|January 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|30 Years|70 Years|No|||May 2010|July 9, 2010|March 17, 2008||No|Insuffisent recrutment|No||https://clinicaltrials.gov/show/NCT00646971||158356|
NCT00646594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5896C00005|Atlantis Symbicort|A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.||AstraZeneca|No|Completed|November 2003|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|12 Years|N/A|No|||March 2009|March 26, 2009|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646594||158385|
NCT00646607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000354-31|FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer|A Randomized Trial Investigating the Role of FOLFOX-4 Regimen Duration (3 Versus 6 Months) and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer|TOSCA|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|Yes|Completed|June 2007|November 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3756|||Both|18 Years|75 Years|No|||December 2009|November 25, 2014|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00646607||158384|
NCT00648102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1307-02|Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer|A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian Cancer|CDX1307-02|Celldex Therapeutics|No|Completed|January 2006|December 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||July 2010|July 23, 2010|March 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00648102||158272|
NCT00647270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-261|Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing|A Multi-center, Randomized, Double-blind,Placebo-controlled Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing||Abbott|No|Completed|December 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|420|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|March 27, 2008|Yes|Yes||No|April 14, 2010|https://clinicaltrials.gov/show/NCT00647270||158335|Abbott identified Investigator non-compliance with the protocol requirements at one site and made the decision to exclude the data from this site from all efficacy analyses. Sample size was too small to demonstrate superiority and non-inferiority.
NCT00647569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRAM M-20070240|Trial of Collagen Mesh for Prevention of Ventral Hernia After Surgery for Advanced Pelvic Cancer|Randomized Controlled Trial of Collagen Mesh for Prevention of Ventral Hernia in Patients With Vertical Rectus Abdominis Musculocutaneus Flap for Advanced Pelvic Malignancy|VRAM|University of Aarhus|No|Completed|April 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|59|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647569||158312|
NCT00648986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5735|Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails|Single Center, Open-Label, Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails||Columbia University|No|Completed|August 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|76 Years|No|||June 2014|June 30, 2014|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00648986||158205|
NCT00652379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-2007-228|Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients|Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics||University of Aarhus|Yes|Completed|June 2008|May 2011|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00652379||157944|
NCT00652392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0726|Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM|A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active-controlled Study of Symbicort pMDI Administered Once Daily in Adults and Adolescents With Asthma - STEM||AstraZeneca|No|Completed|April 2003|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|750|||Both|16 Years|N/A|No|||January 2011|January 21, 2011|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652392||157943|
NCT00647205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS EP 40 QUANTI SPOT|Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT|Evaluation of 2 Interferon γ Assays (QuantiFERON TB Gold In-Tube® and T-SPOT.TB®) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT||French National Agency for Research on AIDS and Viral Hepatitis|No|Completed|January 2008|November 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Anticipated|240|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647205||158340|
NCT00647218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC BRE 9936|Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer|A Pilot Study of Neoadjuvant Paclitaxel and Concurrent Radiation With Correlative Molecular Studies in Stage II/III Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|February 2000|November 2004|Actual|November 2004|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647218||158339|
NCT00646854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006130-17|Alemtuzumab and CHOP in T-cell Lymphoma|A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas|ACT-1|University of Aarhus|Yes|Active, not recruiting|June 2008|December 2016|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|308|||Both|18 Years|60 Years|No|||November 2012|January 8, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00646854||158365|
NCT00646867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805 806 09 004|Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis|An Open Label Study of the Therapeutic Effects of Tetrix Cream in Allergic Contact and Irritant Contact Dermatitis||Coria Laboratories, Ltd.|No|Completed|February 2008|March 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 19, 2008|March 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00646867||158364|
NCT00647166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 060243|Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)|Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors|CHUSPAN2|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2008|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647166||158343|
NCT00647179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-ISA-20070130|Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment|Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment||University of Aarhus|No|Recruiting|February 2008|January 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Whole blood, serum, muscle samples, fat samples|Both|18 Years|70 Years|No|Non-Probability Sample|Patiens recently diagnoses with acromegaly, recruited from the clinic|December 2014|December 2, 2014|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647179||158342|
NCT00647192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPLERAF-01|EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion|EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion|EPLERAF|University Hospital, Saarland|Yes|Terminated|March 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|March 26, 2008||No|Inclusion rate too low. Recruitment of further study centers too costly.|No||https://clinicaltrials.gov/show/NCT00647192||158341|
NCT00647491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-575|A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|||Abbott|No|Completed|February 2004|August 2005|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|352|||Both|20 Years|N/A|No|||March 2008|March 27, 2008|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00647491||158318|
NCT00647946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-UK-104-1008|Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue|A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART)|RAVE|Gilead Sciences|No|Completed|February 2003|February 2006|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||June 2008|June 27, 2008|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00647946||158284|
NCT00648895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-08|A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients|Effect of Nebivolol on Forearm Vasodilation, Nitric Oxide Bioavailability, and Oxidative Stress in Patients With Stage 1/2 Hypertension||Forest Laboratories|No|Completed|November 2007|||July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|79 Years|No|||August 2010|August 30, 2010|March 28, 2008|Yes|Yes||No|July 21, 2010|https://clinicaltrials.gov/show/NCT00648895||158212|The study was terminated early because of difficulties with enrollment. Only 12 of 30 planned patients were enrolled.
NCT00649415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0513-137|A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea|A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg BID, PRN In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea||Pfizer|No|Completed|January 2003|July 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|154|||Female|18 Years|44 Years|No|||March 2008|April 7, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649415||158172|
NCT00649883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P6|Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months|A Phase II, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Investigational Vaccine and Active Influenza Vaccine in Healthy Children Aged 6 to <60 Months||Novartis||Completed|January 2008|October 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|360|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||December 2011|December 7, 2011|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00649883||158136|
NCT00649896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTR-0334|Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day|Comparative Evaluation of the Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System (0.025 mg/Day; Mylan) and Climara® Transdermal System (0.025 mg/Day; Berlex) in Healthy Postmenopausal Female Volunteers||Mylan Pharmaceuticals||Completed|August 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|76|||Female|40 Years|69 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649896||158135|
NCT00649389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8635-A-U301|Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension|A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension||Daiichi Sankyo Inc.|No|Completed|May 2008|December 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|2500|||Both|18 Years|80 Years|No|||August 2010|August 31, 2010|March 28, 2008|Yes|Yes||No|August 9, 2010|https://clinicaltrials.gov/show/NCT00649389||158174|
NCT00649402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBE-0309|Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg|Single-Dose Food in Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649402||158173|
NCT00649870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0405|Food Study of Valacyclovir Hydrochloride Tablets 1000 mg to Valtrex® Tablets 1000 mg|Single-Dose Food In Vivo Bioequivalence Study of Valacyclovir Hydrochloride Tablets (1000 mg; Mylan) to Valtrex® Tablets (1000 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2005|June 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649870||158137|
NCT00650741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC0001|Evaluation of a New Non-Invasive Device for Detection of Endothelial Dysfunction|Evaluation of a New Non-Invasive Device for Detection of Endothelial Dysfunction||Lavi Cardiatec|No|Enrolling by invitation|February 2008|||||N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who visited a clinic where FMD is performed and community sample|March 2008|March 30, 2008|March 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00650741||158070|
NCT00650390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-532|Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab|Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab|PROWD|Abbott||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2008|March 28, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00650390||158097|
NCT00645463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351043|Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics|A Phase 1, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Modified Release Diltiazem On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects||Pfizer|No|Completed|March 2007|June 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|September 16, 2009|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645463||158472|
NCT00646633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-08-010|Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors|Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors||University of California, Los Angeles|Yes|Recruiting|March 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|65 Years|No|||March 2008|March 25, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646633||158382|
NCT00646958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-1741-202|Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections|A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection||Melinta Therapeutics, Inc.|No|Completed|December 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|March 26, 2008|Yes|Yes||No|March 24, 2009|https://clinicaltrials.gov/show/NCT00646958||158357|This was an unblinded study, which raises the possibility of bias.
NCT00647595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03 DK74683 (completed)|Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome|Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|April 21, 2015|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00647595||158310|
NCT00647608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRPL-05116|Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg|Single-Dose Fed Bioequivalence Study of Propranolol Hydrochloride Extended-Release Capsules (160 mg; Mylan) and Inderal® LA Capsules (160 mg; Wyeth) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647608||158309|
NCT00647582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588774|Radiation Therapy During and After Lumpectomy in Treating Women With Stage I or Stage II Breast Cancer|Phase II Study of Intra-operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With Stage T1N0M0 or T2N0M0 Breast Cancer||Mayo Clinic|Yes|Active, not recruiting|October 2002|||June 2005|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Female|18 Years|N/A|No|||March 2015|March 31, 2015|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647582||158311|
NCT00649090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991077|A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer|A Phase 4, Open-Label Exemestane Adjuvant Safety Surveillance Program: Adjuvant Exemestane (Aromasin) Treatment Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer (IES Inclusion Criteria)||Pfizer|No|Completed|March 2005|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1549|||Female|N/A|N/A|No|||September 2008|September 25, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649090||158197|
NCT00649103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUIN-0290|Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Quinapril Hydrochloride Tablets (40 mg; Mylan) and Accupril® Tablets (40 mg; Parke-Davis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649103||158196|
NCT00649116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METP-02128|Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Metoprolol Tartrate Tablets (100 mg; Mylan) and Lopressor® (100 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649116||158195|
NCT00648557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVO-02144|Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (200 mg; Mylan) to Synthroid Tablets (200 mg; Abbott) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648557||158237|
NCT00648570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCI-0427|Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg|The Objective of This Study Was to Investigate the Bioequivalence of Mylan's Escitalopram Oxalate 20 mg Tablets to Forest's Lexapro® 20 mg Tablets Following a Single, Oral 20 mg (1 x 20 mg) Dose Administered Under Fasting Conditions.||Mylan Pharmaceuticals||Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648570||158236|
NCT00648583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONDA-0314|Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg|Single-Dose Food In Vivo Bioequivalence Study of Ondansetron Tablets (24 mg; Mylan) and Zofran® Tablets (24 mg; GSK) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648583||158235|
NCT00648999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEXI-P01-02|Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients|Phase IV, Non Randomized Study in ARV Experienced Patients Under Switch Therapy With Kaletra||AbbVie|No|Completed|November 2003|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|17 Years|N/A|No|||January 2013|March 14, 2013|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00648999||158204|
NCT00649012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIOG-02140|Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg|Single-Dose Food In Vivo Bioequivalence Study of Pioglitazone HCl Tablets (45 mg; Mylan) to Actos® Tablets (45 mg; Takeda) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|March 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649012||158203|
NCT00652743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111443|Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules|Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules||GlaxoSmithKline||Completed|March 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|516|||Both|19 Years|61 Years|Accepts Healthy Volunteers|||September 2011|July 23, 2012|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652743||157917|
NCT00652756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7299|Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation|Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation|iVent|Tufts Medical Center|No|Terminated|August 2007|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652756||157916|
NCT00647244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS-HIV-002|Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients|Efficacy and Safety of Switching From AZT to Tenofovir|SWAP|University of Aarhus|Yes|Completed|June 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2010|December 17, 2010|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647244||158337|
NCT00647530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCTU-FOXTROT-001|Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery|FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer||National Cancer Institute (NCI)||Completed|January 2008|November 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|1050|||Both|N/A|N/A|No|||November 2008|August 6, 2013|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00647530||158315|
NCT00647504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R07054|Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis|Nordic IVUS Study: Prospective Clinical Observational Registry Study Including Consecutive Patients With Clinical Signs or Symptoms Due to In-stent Restenosis (ISR) or Definite (ARC Criteria) Stent Thrombosis (ST)|NIVUS|University of Tampere|Yes|Completed|October 2007|March 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|450|||Both|18 Years|N/A|No|Probability Sample|10-15 Nordic high volume PCI centers with experience in IVUS.|September 2011|September 9, 2011|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647504||158317|
NCT00647972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLAN-02136|Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Olanzapine Tablets (20 mg; Mylan) and Zyprexa® Tablets (20 mg; Eli Lilly) in Healthy Volunteers||Mylan Pharmaceuticals||Terminated|May 2003|||May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 19, 2009|March 30, 2008|Yes|Yes|during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced    to 5 mg due to safety concerns.|No||https://clinicaltrials.gov/show/NCT00647972||158282|
NCT00647985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEXO-0352|Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg|Single-Dose Food In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra® Tablets (180 mg; Aventis) in Healthy Adult Volunteers||Mylan Pharmaceuticals||Completed|November 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647985||158281|
NCT00648401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERA-05135|Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fed Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) and Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2006|February 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648401||158249|
NCT00648414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENT-06104|Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr|Investigational Study of the Effect of Clinical Procedures on Drug Delivery of the Fentanyl Transdermal System (25 µg/hr; Mylan) and Duragesic® (25 µg/hr; Janssen) in Healthy Volunteers||Mylan Pharmaceuticals||Terminated|October 2006|||October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label|6||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes|due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr|No||https://clinicaltrials.gov/show/NCT00648414||158248|
NCT00648427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARO-0509|Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Paroxetine Hydrochloride Controlled-Release Tablets (25 mg; Mylan) to Paxil CR™ Tablets (25 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|April 2005|May 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648427||158247|
NCT00648440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDO-0299|Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Midodrine HCl Tablets (5 mg; Mylan) and ProAmatine® Tablets (5 mg; Roberts) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648440||158246|
NCT00648908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-F203EXT|Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial|Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial||Acorda Therapeutics|Yes|Completed|June 2006|April 2011|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|269|||Both|18 Years|70 Years|No|||January 2012|February 24, 2012|March 28, 2008|Yes|Yes||No|January 25, 2012|https://clinicaltrials.gov/show/NCT00648908||158211|
NCT00648921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLAN-0332|Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Olanzapine Tablets (5 mg; Mylan) and Zyprexa® Tablets (5 mg; Eli Lilly) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|June 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648921||158210|
NCT00649428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-R-005|Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles|||Fibrocell Technologies, Inc.|No|Completed|October 2006|May 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|March 27, 2008|Yes|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00649428||158171|
NCT00649441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUTZ-0311|Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Quinapril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Accuretic™ Tablets (20 mg/25 mg; Parke-Davis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649441||158170|
NCT00650338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-002|Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension|A Randomized, Double-masked, Placebo- and Active- Controlled, Parallel-group, Multi-center, Dose-response Trial of DE-104 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension||Santen Inc.||Completed|March 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|165|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650338||158101|
NCT00650351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPR-04106|Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg|Single-Dose Food In Vivo Bioequivalence Study of Ciprofloxacin Extended-Release Tablets (1000 mg; Mylan) and Cipro® XR Tablets (1000 mg; Bayer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650351||158100|
NCT00650364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDO-0276|Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Midodrine HCl Tablets (5 mg; Mylan) and ProAmatine® Tablets (5 mg; Roberts) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2002|September 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650364||158099|
NCT00650403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARO-0679|Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg|Single-Dose Fed Bioequivalence Study of Paroxetine Hydrochloride Tablets (40 mg; Mylan) and Paxil® Tablets (40 mg; GSK) in Healthy Adult Volunteers||Mylan Pharmaceuticals||Completed|December 2006|January 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650403||158096|
NCT00651066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12150b|Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam|Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in Vietnam : A Phase II Trial||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|June 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||July 2013|July 16, 2013|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00651066||158045|
NCT00651079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGZ111452|GSK1247303 First Time in Human Study|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1247303 in Healthy Male and Female Subjects||GlaxoSmithKline||Terminated|February 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|March 31, 2008||||||https://clinicaltrials.gov/show/NCT00651079||158044|
NCT00646334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0505|Comparative Study of AESCULAP Optilene® Mesh Elastic Versus Ethicon Ultrapro® Mesh in Incisional Hernia Repair|A Randomised, Multi-center, Prospective, Observer and Patient Blind Study to Evaluate AESCULAP Optilene® Mesh Elastic Versus Ethicon Ultrapro® Mesh in Incisional Hernia Repair|Optilene|Aesculap AG|No|Completed|June 2006|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00646334||158405|
NCT00646620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0732|Symbicort Onset of Action 1|A Randomized, Multicenter, Placebo and Active-Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.||AstraZeneca|No|Completed|April 2003|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||April 2009|April 3, 2009|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646620||158383|
NCT00647296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNS-760704-CL201|Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)|A 2-Part, Randomized, Double-Blind, Safety and Tolerability Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS)|CL201|Knopp Biosciences|No|Completed|March 2008|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|102|||Both|21 Years|80 Years|No|||August 2013|August 8, 2013|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647296||158333|
NCT00648089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2007-03|EPOMI Study: ErythroPOietin in Myocardial Infarction|ErythroPOietin in Myocardial Infarction|EPOMI|University Hospital, Angers|Yes|Completed|April 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||January 2011|January 28, 2011|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00648089||158273|
NCT00648661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESCI-0428|Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg|Single-Dose Food In Vivo Bioequivalence Study of Escitalopram Oxalate Tablets (20 mg; Mylan) to Lexapro® Tablets (20 mg; Forest) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648661||158229|
NCT00648674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-MOA-001-AG|A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers|A Prospective, Single-Site Study to Identify and Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers||Organogenesis|No|Withdrawn|July 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||August 2015|August 18, 2015|March 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00648674||158228|
NCT00648687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA 07437|Pain Response During Examination for Retinopathy of Prematurity|Evaluation of the Pain Response During Examination for Retinopathy of Prematurity in Very Low Birth Weight Infants|ROP|National Bioethics Commission of Brazil|No|Completed|March 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|5 Weeks|6 Months|No|||September 2009|July 21, 2010|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00648687||158227|
NCT00649129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYB-0262|Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride ER Tablets (10 mg; Mylan) and Ditropan XL® Tablets (10 mg; ALZA) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649129||158194|
NCT00649025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-3-005|A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults|A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10ug Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (250ug Twice Daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients With Moderate to Severe Asthma||SkyePharma AG|Yes|Completed|March 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|438|||Both|12 Years|N/A|No|||August 2010|August 24, 2010|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649025||158202|
NCT00649038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEHZ-0211|Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg|Single-Dose Food in Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649038||158201|
NCT00649545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-574|Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis|A Multi-Center Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Active Rheumatoid Arthritis|CanAct|Abbott||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2008|March 31, 2008|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00649545||158162|
NCT00649558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIOG-02139|Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Pioglitazone HCl Tablets (45 mg; Mylan) and Actos® Tablets (45 mg; Takeda) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|February 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649558||158161|
NCT00653159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15498A|Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial|Intrauterine Contraception for Adolescents Aged 14 to 18: A Multi-center Randomized Controlled Feasibility Trial of Levonorgestrel-releasing Intrauterine System Compared to the Copper T 380A|MINT|University of Chicago|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|April 1, 2008|Yes|Yes||No|September 18, 2012|https://clinicaltrials.gov/show/NCT00653159||157886|
NCT00653172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXL103/2001|Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia|A Double-Blind, Multicenter, Randomized, Double Dummy, Three-Arm Parallel-Group Comparative Study of the Efficacy, Safety and Tolerance of Oral NXL 103 Versus Oral Comparator in the Treatment of Community-Acquired Pneumonia in Adults||Novexel Inc|No|Completed|October 2007|November 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|70 Years|No|||January 2009|January 8, 2009|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653172||157885|
NCT00647543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581111|Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand|A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, And 40 Mg||Pfizer|No|Completed|August 2003|April 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|242|||Both|18 Years|80 Years|No|||April 2008|April 28, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647543||158314|
NCT00648011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUTZ-0312|Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg|Single-Dose Food In Vivo Bioequivalence Study of Quinapril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Accuretic™ Tablets (20 mg/25 mg; Parke-Davis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2003|September 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648011||158279|
NCT00648518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METF-0363|Fasting Study of Metformin Hydrochloride ER Tablets 750 mg and Glucophage® XR Tablets 750 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metformin Hydrochloride ER Tablets (750 mg; Mylan) and Glucophage® XR Tablets (750 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648518||158240|
NCT00648531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BALS-0431|Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Balsalazide Disodium Capsules (750 mg; Mylan) and Colazal® Capsules (750 mg; Salix) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648531||158239|
NCT00647517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSH-CMCTC-96-013|Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis|Chung Shan Medical University Hospital, Taiwan|CS07102|Chung Shan Medical University|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|65 Years|No|||January 2008|March 31, 2010|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647517||158316|
NCT00648024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAG-02129|Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Anagrelide Hydrochloride Capsules (1 mg; Mylan) to Agrylin® Capsules (1 mg; Shire US) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2003|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648024||158278|
NCT00647998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISC-001|The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial|Phase 2 Dose Finding Trial of Prophylactic Darbepoetin Alfa to Improve Outcomes From Ischemic Complications of Surgery|DISC|University of Pennsylvania|No|Completed|January 2008|October 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00647998||158280|
NCT00648453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8564|Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function|Effect of Plavix Treatment on NO Production Measured by Laser Doppler Method Referring to Endothelial Function in Patients With Severe Coronary Heart Disease||Sanofi||Completed|December 2002|April 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|30 Years|70 Years|No|||April 2008|April 1, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00648453||158245|
NCT00648466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMA-0358|Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Sumatriptan Succinate Tablets (100 mg; Mylan) to Imitrex® Tablets (100 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 30, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648466||158244|
NCT00649922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-600|Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis|Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis||Abbott|No|Completed|October 2003|February 2005|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|20 Years|N/A|No|||March 2008|March 31, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649922||158133|
NCT00649935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZIT-04101|Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg|Single-Dose Fed In Vivo Bioequivalence Study of Azithromycin Tablets (600 mg; Mylan) to Zithromax® Tablets (600 mg; Pfizer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2005|June 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649935||158132|
NCT00650416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARV-0369|Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Carvedilol Tablets (12.5 mg; Mylan) to Coreg® Tablets (12.5 mg; GSK) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|March 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650416||158095|
NCT00650429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281056|A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder|Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study||Pfizer|No|Completed|October 2003|May 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|No|||April 2008|April 7, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650429||158094|
NCT00651105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2347|Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects|A Double-blind, Placebo-controlled, Randomized, Cross-over Study to Evaluate the GLP-1-mediated and Non-GLP-1-mediated Effects of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects||Novartis|No|Completed|February 2008|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||November 2009|November 5, 2009|March 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651105||158042|
NCT00649909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-08-HMO-CTIL|Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients|Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients||Hadassah Medical Organization|No|Recruiting|November 2008|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetic patients that take aspirin, from the diabetology clinic.|February 2009|February 8, 2009|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00649909||158134|
NCT00650377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-0461|Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Finasteride Tablets (5 mg; Mylan) to Proscar® Tablets (5 mg; Merck) in Healthy Male Volunteers||Mylan Pharmaceuticals||Completed|October 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650377||158098|
NCT00646087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-07-04|Ketamine Frequency Treatment for Major Depressive Disorder|Ketamine Frequency Treatment for Major Depressive Disorder||Essentia Health|No|Withdrawn|March 2008|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 3, 2011|March 25, 2008|Yes|Yes|Pilot study determined that this study would not be feasible.|No||https://clinicaltrials.gov/show/NCT00646087||158424|
NCT00646672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080095|Aneurysms and Carotid Artery Block in Newborns|Assessment of Cerebral Circulation and Perfusion in Adults After Neonatal Carotid Occlusion||National Institutes of Health Clinical Center (CC)||Completed|March 2008|April 2010||||N/A|Observational|Time Perspective: Retrospective|||Actual|6|||Both|18 Years|25 Years|No|||April 2010|April 17, 2010|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00646672||158379|
NCT00647283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-2005-CE512090-O|Assessment Of the Safety and Benefit of Prospective Immunosuppressive Drug Withdrawal in Liver Transplantation and Prediction of Operational Tolerance|ASSESSMENT OF THE SAFETY AND BENEFIT OF PROSPECTIVE IMMUNOSUPPRESSIVE DRUG WITHDRAWAL IN LIVER TRANSPLANTATION AND PREDICTION OF OPERATIONAL TOLERANCE||Hospital Clinic of Barcelona|Yes|Active, not recruiting|November 2005|December 2012|Anticipated|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|75 Years|No|||April 2011|April 19, 2011|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647283||158334|
NCT00648115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6192-R|Evaluating Vocational Materials for Incarcerated Veterans With Mental Illness or Substance Abuse|Evaluating Vocational Materials for Incarcerated Veterans With Mental Illness||VA Office of Research and Development|No|Active, not recruiting|June 2009|April 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|111|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|March 27, 2008||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00648115||158271|
NCT00648128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAI-P2-316|Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fed State|Single Dose Crossover Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Healthy Male and Female Volunteers / Fed State||Mylan Pharmaceuticals|Yes|Completed|March 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2003|March 31, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648128||158270|
NCT00647621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHEN-0529|Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg|Steady-State Bioequivalence Study of Extended Phenytoin Sodium Capsules (100 mg; Mylan) and Dilantin® Kapseals® (100 mg; Pfizer) in Healthy Adult Volunteers||Mylan Pharmaceuticals||Completed|October 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647621||158308|
NCT00647634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPR-0466|Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (3 mg; Mylan) to Xanax XR® Tablets (3 mg; Pharmacia & Upjohn) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647634||158307|
NCT00647647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERB-0392|Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Terbinafine Hydrochloride Tablets (250 mg; Mylan) to Lamisil® Tablets (250 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647647||158306|
NCT00647660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABE-0626|Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg|Single-Dose Fasting Bioequivalence Study of Nadolol/Bendroflumethiazide Tablets (80 mg/5 mg; Mylan) to Corzide® Tablets (80 mg/5 mg; King) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647660||158305|
NCT00658840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-199|Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma|A Phase II Study of Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma||National Cancer Center, Korea||Recruiting|June 2006|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00658840||157453|
NCT00648609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080801|Community Based Self Management of COPD Facilitated by a Palliative Care Team:Impact on Health Care Utilization and QOL|Community Based Self Management of COPD Facilitated by a Palliative Care Team:Impact on Health Care Utilization and QOL||Essentia Health|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|23|||Both|60 Years|N/A|No|Non-Probability Sample|Patients with advanced COPD from St. Mary's Duluth Clinic Health Systrem population in        Duluth Minnesota|June 2011|June 16, 2011|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00648609||158233|
NCT00648622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARV-0370|Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg|Single-Dose Food In Vivo Bioequivalence Study of Carvedilol Tablets (12.5 mg; Mylan) to Coreg® Tablets (12.5 mg; GSK) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|April 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648622||158232|
NCT00649051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METO-02110|Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (2.5 mg; Mylan) and Zaroloxyn® Tablets (2.5 mg; Celltech) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649051||158200|
NCT00649064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281120|A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs|A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder||Pfizer|No|Completed|December 2003|September 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|65 Years|No|||April 2008|April 7, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649064||158199|
NCT00649077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELO-0443|Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Meloxicam Tablets (15 mg; Mylan) and Mobic® Tablets (15 mg; Boehringer Ingelheim) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649077||158198|
NCT00647257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COZ-002-00-28SEP2007|The Effect of Losartan on Atrial Fibrillation (AF) Burden and Pacemaker Dependence in Patients With Sick Sinus Syndrome|The Effect of Losartan on Atrial Fibrillation and Pacemaker Dependence in Sick Sinus Syndrome (SSS) Patients Receiving Physiological Pacemaker - A Prospective, Randomized, Multicenter Study in Taiwan||Chung Shan Medical University|Yes|Recruiting|April 2008|December 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|220|||Both|20 Years|80 Years|No|||March 2010|March 31, 2010|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647257||158336|
NCT00648544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2722|Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Non-Smoking Male and Female Subjects||Mylan Pharmaceuticals|Yes|Completed|July 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648544||158238|
NCT00648479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKL-001-HMO-CTIL|New Method for Distal Interlocking of Cannulated Intramedullary Nails|New Method for Distal Interlocking of Cannulated Intramedullary Nails||Hadassah Medical Organization||Terminated||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|10|||Both|18 Years|65 Years|No|||December 2011|December 25, 2011|March 17, 2008||No|the company does not want to proceed yet with the study|No||https://clinicaltrials.gov/show/NCT00648479||158243|
NCT00648492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METF-0284|Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg|Single-Dose Food In Vivo Bioequivalence Study Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR (500 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648492||158242|
NCT00648505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEGL-0494|Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg|Single-Dose Food In Vivo Bioequivalence Study of Glipizide and Metformin HCl Tablets (5 mg/500 mg; Mylan) to Metaglip® Tablets (5 mg/500 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|June 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648505||158241|
NCT00648934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPR-0584|Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg|Single-Dose Fed Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648934||158209|
NCT00648947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOP-0402|Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Clopidogrel Bisulfate Tablets (75 mg; Mylan) to Plavix® Tablets (75 mg; Bristol-Myers Squibb/Sanofi) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648947||158208|
NCT00648960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAI-P3-134|Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting State|Single Dose Crossover Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Healthy Male and Female Volunteers / Fasting State||Mylan Pharmaceuticals|Yes|Completed|July 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648960||158207|
NCT00649454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEGL-0493|Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Glipizide and Metformin HCl Tablets (5 mg/500 mg; Mylan) to Metaglip® Tablets (5 mg/500 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|June 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649454||158169|
NCT00649467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPR-0585|Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg|Single-Dose Fasting Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers Dosed With Applesauce||Mylan Pharmaceuticals||Completed|November 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649467||158168|
NCT00650780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton4|Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment|Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment|Gc|Creighton University|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|29|||Both|19 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will include thirty males and females who took part in a previous study of a        single oral dose of vitamin D.|March 2008|April 1, 2008|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00650780||158067|
NCT00651092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor466208ctil|Inferior Submucosal Turbinectomy Versus Blunt Turbinectomy for Inferior Turbinate Hypertrophy|to Compare Two Well Popularized Methods of Inferior Nasal Turbinectomy||Soroka University Medical Center|No|Not yet recruiting|March 2008|January 2010|Anticipated|May 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2008|April 1, 2008|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00651092||158043|
NCT00645476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-31C|Memantine and Cognitive Dysfunction in Bipolar Disorder|This is a Placebo-controlled Study. It Will Compare the Effects of Memantine With Placebo on Cognitive Dysfunction|Memantine|Cedars-Sinai Medical Center|No|Completed|February 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||March 2012|March 26, 2012|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645476||158471|
NCT00645489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC002|A Family Intervention for Improving Self-Care of Patients With Heart Failure|A Family Intervention for Improving Self-Care of Patients With Heart Failure||VA Office of Research and Development|No|Completed|March 2008|December 2009|Actual|March 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|50 Years|N/A|No|||December 2008|January 4, 2010|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00645489||158470|
NCT00650767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-162-201|A Study of ARRY-438162 in Patients With Rheumatoid Arthritis|||Array BioPharma|Yes|Completed|March 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|201|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650767||158068|
NCT00646984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARV-DEM-LD|Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy|Comparison of Strategies of Interruption/Reinitiation of Antiretroviral Therapy in Response to Immunologic/Virologic Changes in HIV-Infected Patients With Lipodystrophy.||Hospital Clinic of Barcelona|Yes|Completed|January 2002|April 2006|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|147|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00646984||158355|
NCT00647309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5096-MA-CTIL|Troponin Elevation in the Elderly Patient With Hip Fracture|Correlation Between Troponin Level and Rehabilitation Outcome in Elderly Patient With Hip Fracture||Sheba Medical Center|No|Recruiting|April 2008|June 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|whole blood|Both|65 Years|N/A|No|Probability Sample|patients aged 65 years and over with hip fracture|June 2012|June 11, 2012|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647309||158332|
NCT00647322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07NR07|The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy|The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy||Institute of Child Health||Not yet recruiting|September 2008|||September 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Anticipated|64|||Both|6 Years|21 Years|No|||March 2008|March 26, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647322||158331|
NCT00646997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YT1977/2|Impact of Left Atrial Function on Postoperative Atrial Fibrillation|Impact Of Velocity Vector Imaging, Tissue Doppler Imaging, Conventional Echocardiography And P Wave Dispertion In Evaluating Post-Operative Atrial Fibrillation After Coronary Bypass Graft Surgery||Florence Nightingale Hospital, Istanbul|Yes|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|80|||Both|30 Years|80 Years|No|Probability Sample|Tertiary care clinic|June 2008|June 27, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00646997||158354|
NCT00647673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERA-05134|Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fasting Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) to Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers Dosed in the Evening||Mylan Pharmaceuticals||Completed|January 2006|February 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647673||158304|
NCT00647712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVA-0380|Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Divalproex Sodium Extended-Release Tablets (500 mg; Mylan) to Depakote ER® Tablets (500 mg; Abbott) in Healthy, Adult Male Volunteers||Mylan Pharmaceuticals||Completed|December 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 24, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647712||158301|
NCT00647725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-69714-14XS|Labor Analgesia in the Latent Phrase|Labor Analgesia in the Latent Phrase of the First-stage of Spontaneous Delivery|LALP|Nanjing Medical University|Yes|Completed|January 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15000|||Female|18 Years|45 Years|No|||September 2009|September 30, 2009|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00647725||158300|
NCT00647738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCE-P3-022|Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State|Single Dose Crossover Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State||Mylan Pharmaceuticals|Yes|Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647738||158299|
NCT00648635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0322|Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations|A Pilot Study for Prospective Discovery of Possible Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations in Patients Undergoing Treatment for Locally Recurrent Rectal Adenocarcinoma||M.D. Anderson Cancer Center|No|Recruiting|March 2008|||March 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|164|||Both|N/A|N/A|No|Non-Probability Sample|Patients with recurrent rectal cancer.|March 2016|March 8, 2016|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00648635||158231|
NCT00648648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1775-001|A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)|A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|February 2008|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|203|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|March 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00648648||158230|
NCT00659451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPV002DIM2008|Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular|Effects Of Losartan On Myocardial Structure And Function And On Epicardial Fat Deposition In Diabetic Hypertensive Patients With Left Ventricular: Qualitative And Quantitative Alteration||University of Pavia|No|Recruiting|April 2008|April 2009|Anticipated|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|80 Years|No|||April 2008|April 14, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00659451||157406|
NCT00649610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471012|Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain|Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily vs. Diclofenac 75 mg Twice Daily in Subjects With Acute Low Back Pain||Pfizer|No|Completed|November 2002|May 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|65 Years|No|||March 2008|April 7, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649610||158157|
NCT00649623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLME-0574|Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649623||158156|
NCT00650065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETI-0286|Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Cetirizine HCl Tablets (10 mg; Mylan) and Zyrtec® Tablets (10 mg; Pfizer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650065||158122|
NCT00650078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP01-007|Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis|A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients With Rheumatoid Arthritis|CAPRA-2|Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|80 Years|No|||April 2013|April 23, 2013|March 28, 2008|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00650078||158121|
NCT00648037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-118|Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT|Pilot Trial of Rituximab (Rituxan) for the Prevention of EBV-LPD Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT||Memorial Sloan Kettering Cancer Center||Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||December 2015|December 29, 2015|March 27, 2008|No|Yes||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00648037||158277|
NCT00649961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0970 (MIND)|Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study|Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study|MIND|Imperial College London|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|23 Weeks|31 Weeks|No|||January 2011|January 13, 2014|March 27, 2008||No||No|January 13, 2014|https://clinicaltrials.gov/show/NCT00649961||158130|
NCT00648973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2341002|To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses|Evaluation of Nasal Congestion Clinical Efficacy for Diphenhydramine 25 mg and Diphenhydramine 50 mg in Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo and Pseudoephedrine Controlled Study||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1021|||Both|12 Years|65 Years|No|||August 2011|August 19, 2011|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00648973||158206|
NCT00649480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BALS-06128|Fed Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg|Single-Dose Fed Bioequivalence Study of Balsalazide Disodium Capsules (750 mg; Mylan) and Colazal® Capsules (750 mg; Salix) in Healthy Volunteers||Mylan Pharmaceuticals|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2006|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649480||158167|
NCT00649493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RABE-0326|Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg|Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Tablets (20 mg; Mylan) and Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|8 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649493||158166|
NCT00649948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METF-0413|Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mg|Single-Dose Food In Vivo Bioequivalence Study Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR (500 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|February 2004|June 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649948||158131|
NCT00650442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTR-02133|Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System|Evaluation of the Adhesion Quality and Primary Dermal Irritation Potential of an Alternate Second Generation Estradiol Transdermal Systems in Normal Healthy Female Volunteers||Mylan Pharmaceuticals||Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|39|||Female|40 Years|66 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650442||158093|
NCT00645723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL\VAP|Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii|Phase 3b Randomized Double Blind Controled Placebo Comparative Trial of Intravenous Colistin vs Intravenous Colistin Plus Nebulized Colistin in Patients With Ventilator-associated Pneumonia (VAP) Due Multiresistant Acinetobacter Baumanii||Hospitales Universitarios Virgen del Rocío|Yes|Recruiting|April 2008|April 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|67|||Both|18 Years|N/A|No|||August 2009|August 3, 2009|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645723||158452|
NCT00646100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACE1|Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|TACEHCC|Sun Yat-sen University|Yes|Completed|July 2007|February 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|75 Years|No|||June 2012|June 5, 2012|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646100||158423|
NCT00646347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|slhdoc02|A Pilot Study of Neuro Hand Orthosis Program In Stroke Upper Limb Rehabilitation|A Pilot Study of Neuro Hand Orthosis Program: A Promising Restorative Therapy Treatment for the Severe Paralytic Arm in Subacute Stroke Rehabilitation|NHOP|St Luke's Hospital, Singapore|Yes|Recruiting|March 2008|July 2010|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|89 Years|No|||February 2009|February 4, 2009|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00646347||158404|
NCT00646646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F050721005|The Effect of Sedation on Eye Movements|The Effect of Sedation on Eye Movements|Eye Movement|University of Alabama at Birmingham|No|Completed|April 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|65|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|March 25, 2008|Yes|Yes||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00646646||158381|
NCT00645710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04122|Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery|A Phase I/II Trial of Radioimmunotherapy (Y-90 cT84.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver||City of Hope Medical Center|Yes|Active, not recruiting|February 2005|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|70 Years|No|||November 2015|November 4, 2015|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645710||158453|
NCT00646360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024976|Effects of Prenatal DHA Supplements on Infant Development|Effects of Prenatal DHA Supplements on Infant Development||Emory University|Yes|Active, not recruiting|February 2005|December 2018|Anticipated|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1094|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646360||158403|
NCT00647023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Incretins and PCOS|Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)|||Hvidovre University Hospital|No|Terminated|February 2004|May 2006|Actual|May 2006|Actual|N/A|Interventional|Primary Purpose: Basic Science|1||Actual|66|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647023||158353|
NCT00647049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZNS-00465|Freiburg ZNS-NHL Study|Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation||University Hospital Freiburg|No|Recruiting|January 2007|August 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|65 Years|No|||November 2009|November 16, 2009|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647049||158351|
NCT00657410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP0207|Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura|Randomized Study of the Treatment of Primary Immune Thrombocytopenic Purpura (ITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone Versus High-dose Dexamethasone.|ITP0207|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|April 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||April 2015|April 21, 2015|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00657410||157562|
NCT00647686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENT-0623|Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System With Askina Derm Overlay|Single-Dose In Vivo Bioequivalence and Wear Study of Fentanyl Transdermal System (25 µg/h; Mylan) and Fentanyl Transdermal System With Overlay (25 µg/h; Mylan) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647686||158303|
NCT00647699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVX-002|Corneal Collagen Cross-linking for Progressive Keratoconus|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus|CXL|Avedro, Inc.|No|Completed|December 2007|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|14 Years|N/A|No|||June 2015|June 22, 2015|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647699||158302|
NCT00658008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361019|A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder||Pfizer|No|Terminated|April 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|501|||Both|18 Years|65 Years|No|||November 2012|November 9, 2012|April 8, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00658008||157516|
NCT00658021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5550C00002|Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes|Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes.||AstraZeneca|Yes|Recruiting|May 2008|May 2020|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|195|||Both|10 Years|17 Years|No|||February 2016|February 29, 2016|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658021||157515|
NCT00658853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149-03|Effective High Aerobic Intensity Endurance Training Regimes in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effective High Aerobic Intensity Interval Training to Improve Maximal Oxygen Uptake in COPD Patients||Norwegian University of Science and Technology|Yes|Completed|January 2004|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|20 Years|85 Years|No|||April 2008|April 14, 2008|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00658853||157452|
NCT00648141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COXA-0508-243|Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis|A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis||Pfizer|No|Completed|January 2003|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|458|||Both|18 Years|75 Years|No|||March 2008|April 7, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648141||158269|
NCT00648154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LETR-05123|Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg|Single-Dose Fed Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers||Mylan Pharmaceuticals||Completed|November 2005|January 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Female|40 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 30, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648154||158268|
NCT00648167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-201|A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)|A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)||Keryx Biopharmaceuticals|Yes|Completed|March 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|19 Years|N/A|No|||October 2014|October 10, 2014|March 27, 2008|Yes|Yes||No|October 4, 2014|https://clinicaltrials.gov/show/NCT00648167||158267|
NCT00659464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/22|Multi-Site Near Infrared Spectroscopy (NIRS) Monitoring of Children During Tilt Table Testing|Use of Multi-site Near Infrared Spectroscopy (NIRS) Monitoring for Hemodynamic Assessment During Tilt Table Testing in Children|NIRS & Tilt|Medical College of Wisconsin|No|Completed|January 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|7 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children ages 7 through 21 years who present to exercise stress lab for investigation of        syncope.|February 2012|February 9, 2012|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00659464||157405|
NCT00659477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_02673|Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)|Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With OADs in Patients With DMT2, Assessed by Continuous Glucose Monitoring System (CGMS). Multicentre, Prospective, Open- Label, Single Arm, Comparative Study in Patients Switched From NPH Insulin to Insulin Lantus®.|COBIN 2|Sanofi||Completed|March 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|80 Years|No|||July 2010|July 29, 2010|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00659477||157404|
NCT00649142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01 294867|Predisposing Factors for Chronic Postherniotomy Pain|Prospective Study of Predisposing Factors for Chronic Postherniotomy Pain||Rigshospitalet, Denmark|No|Completed|January 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|455|||Male|18 Years|80 Years|No|||September 2008|January 20, 2009|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00649142||158193|
NCT00649155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPR-04114|Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ciprofloxacin Extended-Release Tablets (500 mg; Mylan) and Cipro® XR Tablets (500 mg; Bayer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649155||158192|
NCT00649168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BROM-0733|Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg|Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg Bromocriptine Mesylate Capsules Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions||Mylan Pharmaceuticals||Completed|April 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649168||158191|
NCT00649636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUO-0603|Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg|Single-Dose Fasting Bioequivalence Study of Fluoxetine Capsules (40 mg; Mylan) and Prozac Pulvules (40 mg; Dista) in Healthy Adult Volunteers||Mylan Pharmaceuticals||Completed|February 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649636||158155|
NCT00649649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUIN-0291|Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg|Single-Dose Food In Vivo Bioequivalence Study of Quinapril Hydrochloride Tablets (40 mg; Mylan) and Accupril® Tablets (40 mg; Parke-Davis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649649||158154|
NCT00649662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPR-04105|Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ciprofloxacin Extended-Release Tablets (1000 mg; Mylan) and Cipro® XR Tablets (1000 mg; Bayer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649662||158153|
NCT00649675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MELO-0444|Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg|Single-Dose Food In Vivo Bioequivalence Study of Meloxicam Tablets (15 mg; Mylan) and Mobic® Tablets (15 mg; Boehringer Ingelheim) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649675||158152|
NCT00649506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NITF-0324|Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg|Single-Dose Food In Relative Bioavailability Study of Mylan Nitrofurantoin Macrocrystals 100 mg Capsules and Procter & Gamble Macrodantin® 100 mg Capsules in Healthy Volunteers||Mylan Pharmaceuticals||Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649506||158165|
NCT00649519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBE-0308|Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649519||158164|
NCT00649532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONDA-0313|Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ondansetron Tablets (24 mg; Mylan) and Zofran® Tablets (24 mg; GSK) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649532||158163|
NCT00649974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0404|Fasting Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Valacyclovir Hydrochloride Tablets (1000 mg; Mylan) to Valtrex® Tablets (1000 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649974||158129|
NCT00650481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYB-02116|Fasting Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (5 mg; Mylan) and Ditropan XL® Tablets (5 mg; ALZA) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650481||158090|
NCT00650494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-05112|Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg|Single-Dose Food in Vivo Bioequivalence Study of Valacyclovir Hydrochloride Tablets (1000 mg; Mylan) to Valtrex® Tablets (1000 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2005|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 11, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650494||158089|
NCT00650026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-583|Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis|Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis|ReAct|Abbott||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||April 2008|April 10, 2008|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00650026||158125|
NCT00650455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471018|Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients|Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population||Pfizer|No|Completed|February 2003|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|489|||Both|18 Years|N/A|No|||July 2008|July 18, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650455||158092|
NCT00650468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-99-001|A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients|A Prospective, Randomized, Multi-Center Double-Blind Study of Early Corticosteroid Cessation vs. Long Term Corticosteroid Therapy With Prograf and CellCept in Primary Renal Transplant Patients||Astellas Pharma Inc|Yes|Completed|November 1999|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|70 Years|No|||March 2009|November 15, 2011|March 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00650468||158091|
NCT00650793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003376|A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia|A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS� Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia - Open Label Phase||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|February 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|473|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|March 31, 2008||||||https://clinicaltrials.gov/show/NCT00650793||158066|
NCT00651118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP4002|A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|March 2008|July 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|832|||Both|12 Years|N/A|No|||August 2012|August 27, 2012|March 28, 2008|Yes|Yes||No|May 10, 2012|https://clinicaltrials.gov/show/NCT00651118||158041|
NCT00645762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1156-001|Balloon REmodeling Antrostomy THErapy Study|Balloon REmodeling Antrostomy THErapy Study (BREATHE I)|BREATHE I|Entellus Medical, Inc.|No|Completed|September 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|March 20, 2008||No||No|March 15, 2013|https://clinicaltrials.gov/show/NCT00645762||158449|
NCT00645736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-AU-103-0185|CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study|Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy|CHARM|Gilead Sciences|No|Completed|February 2008|November 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|788|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with a diagnosis of chronic hepatitis B who have been prescribed antihepadnaviral        therapy for at least 6 months.|November 2011|November 21, 2011|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645736||158451|
NCT00645749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0484, 2007-0390|Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis|Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis|HINT|University of Wisconsin, Madison|Yes|Active, not recruiting|July 2008|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|50 Years|No|||October 2015|October 9, 2015|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645749||158450|
NCT00646659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-24061|Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery|Randomized Phase II Feasibility Study of Cetuximab Combined With 4 Cycles of TPF Followed by Platinum Based Chemo-radiation Strategies||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|February 2008|April 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|75 Years|No|||January 2013|January 7, 2013|March 27, 2008||No|Recruitment was suspended prematurely for safety concerns and closed after IDMC review|No||https://clinicaltrials.gov/show/NCT00646659||158380|
NCT00647036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07SG10|Microbial Invasion During Parenteral Nutrition in Surgical Infants Receiving Glutamine|Microbial Invasion During Parenteral Nutrition in Surgical Infants Receiving Glutamine.||Institute of Child Health|No|Not yet recruiting|July 2008|||July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|N/A|3 Months|No|||March 2008|March 28, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647036||158352|
NCT00646711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-461|Pediatric Switch Study for Children and Adolescent Patients With Epilepsy|A 14 Day Randomized, Open-Label, Cross-Over, Single Center, Outpatient Study of Depakote Delayed-Release or Depakote Sprinkle vs. Divalproex Sodium Extended-Release in Child and Adolescent Patients With Epilepsy||Abbott|No|Completed|February 2003|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|6 Years|17 Years|No|||March 2008|March 25, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646711||158376|
NCT00647335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807101|Genetics of Polycystic Ovary Syndrome|Population Genetics of Polycystic Ovary Syndrome||University of Pennsylvania|No|Completed|February 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|189|Samples With DNA|Saliva|Female|N/A|N/A|No|Non-Probability Sample|Women with a diagnosis of PCOS undergoing treatment at University of Pennsylvania and        University of Iowa.|November 2011|May 8, 2013|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647335||158330|
NCT00647348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSTC-001|Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis|A Phase II Randomised, Placebo-controlled Clinical Trial of Simvastatin in Patients With Secondary Progressive Multiple Sclerosis.|MS-STAT|Imperial College London|Yes|Completed|January 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|65 Years|No|||November 2012|November 26, 2012|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647348||158329|
NCT00658866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erta_MD_1|Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection|Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection|2007-005020-33|Medical University of Vienna|No|Completed|February 2008|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|85 Years|No|||March 2011|August 8, 2011|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00658866||157451|
NCT00658879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6291023|Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan|Special Investigation Of Somavert -Long Term Use||Pfizer|No|Active, not recruiting|August 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6291023 prescribes the Pegvisomant.|March 2016|March 23, 2016|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00658879||157450|
NCT00658554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-113|Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers|Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers||ArQule|No|Completed|April 2008|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|June 18, 2008|April 11, 2008|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00658554||157475|
NCT00658567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-014|A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis|||ACADIA Pharmaceuticals Inc.||Completed|March 2008|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|123|||Both|40 Years|N/A|No|||August 2014|August 29, 2014|April 10, 2008|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT00658567||157474|
NCT00650936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-014|Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study|||St. Jude Medical|No|Active, not recruiting|August 2007|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|N/A|N/A|No|||January 2015|January 30, 2015|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650936||158055|
NCT00651274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03476|Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)|A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Simvastatin 20 Mg In Subjects With Primary Hypercholesterolemia And Coronary Heart Disease||Merck Sharp & Dohme Corp.|No|Completed|April 2003|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651274||158029|
NCT00659165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM HRRC # 08-043|Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes|Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes||University of New Mexico|No|Completed|April 2008|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|10|||Both|18 Years|60 Years|No|||January 2011|September 6, 2011|April 14, 2008||No||No|January 19, 2011|https://clinicaltrials.gov/show/NCT00659165||157428|
NCT00659438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00080|Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer|A Randomized, Double-blind Phase II Trial to Assess the Efficacy and Safety of Bicalutamide (Casodex® ) Associated to ZD6474 (Zactima™ ) or to Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression||AstraZeneca|Yes|Completed|February 2008|July 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Male|18 Years|N/A|No|||June 2012|June 14, 2012|April 10, 2008|Yes|Yes||No|November 14, 2011|https://clinicaltrials.gov/show/NCT00659438||157407|
NCT00649987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALBU-0517|Fed Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg|Single-Dose Fed Bioequivalence Study of Albuterol Sulfate Extended-Release Tablets (8 mg; Mylan) and VoSpire® ER Tablets (8 mg; Pliva) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649987||158128|
NCT00650000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODA-0278|Fasting Study of Modafinil Tablets 200 mg and Provigil® Tablets 200 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Modafinil Tablets (200 mg; Mylan) and Provigil® Tablets (200 mg; Cephalon) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650000||158127|
NCT00650013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDO-0277|Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Midodrine HCl Tablets (5 mg; Mylan) and ProAmatine® Tablets (5 mg; Roberts) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650013||158126|
NCT00649571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOXY-0536|Fasting Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Doxycycline Monohydrate Tablets (100 mg; Mylan) and Adoxa Tablets (100 mg; Par) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649571||158160|
NCT00650039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471109|Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction|A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg QD And Valdecoxib 20 Mg BID Compared To Placebo Over Multiple Days For Management Of Acute Postsurgical Pain In Patients Undergoing Anterior Cruciate Ligament Reconstruction||Pfizer|No|Completed|March 2004|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|488|||Both|18 Years|75 Years|No|||March 2008|June 3, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650039||158124|
NCT00650052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZONI-0374|Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Zonisamide Capsules (100 mg; Mylan) to Zonegran® Capsules (100 mg; Elan) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|107|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650052||158123|
NCT00650806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014578|A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|376|||Both|18 Years|65 Years|No|||April 2013|April 1, 2013|March 31, 2008|Yes|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT00650806||158065|
NCT00650819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03757|Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)|A Multicenter, Double-blind, Randomized, Active-controlled Parallel Groups Study Comparing The Efficacy and Safety of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg Vs Simvastatin Or Ezetimibe Alone in Subjects With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|June 2004|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00650819||158064|
NCT00651131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-4PSW-03-03|Cubicin(R) for Complicated Post-Surgical Wound Infections|Cubicin(R) for Complicated Post-Surgical Wound Infections|PSW|Cubist Pharmaceuticals LLC|No|Terminated|June 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||June 2009|June 24, 2009|March 31, 2008|No|Yes|terminated due to slow enrollment|No||https://clinicaltrials.gov/show/NCT00651131||158040|
NCT00651144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03317|Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)|SCH 058235: Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Rosuvastatin in Healthy Hypercholesterolemic Subjects||Merck Sharp & Dohme Corp.|No|Completed|March 2003|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|55 Years|No|||April 2015|April 15, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651144||158039|
NCT00645775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHAIGOB131CT|Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome|The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.||Gateway Health Alliance|Yes|Completed|November 2006|April 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|102|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2006|March 25, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645775||158448|
NCT00645788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12429|Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis|Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects With Cystic Fibrosis||Bayer|Yes|Completed|May 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|288|||Both|12 Years|N/A|No|||May 2014|May 30, 2014|March 26, 2008|Yes|Yes||No|January 21, 2012|https://clinicaltrials.gov/show/NCT00645788||158447|
NCT00645502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002617|Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.|A Bioequivalence Study Comparing a Single Oral Intake of a 4mg Orally-disintegrating Tablet With a 4mg Conventional Risperdal Tablet in Patients With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2003|July 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|65 Years|No|||April 2010|April 22, 2010|March 24, 2008||||||https://clinicaltrials.gov/show/NCT00645502||158469|
NCT00645515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281065|A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia|Ziprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study||Pfizer|No|Terminated|June 2003|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||April 2008|April 25, 2008|March 20, 2008|Yes|Yes|This study was terminated on November 20, 2003 because of poor recruitment. This study was not    terminated due to safety/efficacy.|No||https://clinicaltrials.gov/show/NCT00645515||158468|
NCT00646126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUD 6/025|Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission|Validation of the Use of Istope-Based Molecular Techniques for Malaria Control||Tropical Medicine Research Institute|Yes|Completed|August 2005|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|1 Year|N/A|Accepts Healthy Volunteers|||August 2005|March 27, 2008|March 25, 2008||||No||https://clinicaltrials.gov/show/NCT00646126||158421|
NCT00646373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB#06-0012-B|Effect of Decreased Pump Prime Volume on Blood Transfusions and Postoperative Complications of Patients Undergoing High Risk Cardiac Surgical Procedures|Effect of Decreased Pump Prime Volume on Blood Transfusions and Postoperative Complications of Patients Undergoing High Risk Cardiac Surgical Procedures: A Pilot Study||University Health Network, Toronto||Terminated|December 2006|||December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|No|||December 2006|April 19, 2011|March 25, 2008||No|Protocol was comparing to standard of practice, which has changed over the course of slow    recruitment and no longer can be used as a comparator.|No||https://clinicaltrials.gov/show/NCT00646373||158402|
NCT00646386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-518|Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis|Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis||Abbott||Completed|March 2003|||April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646386||158401|
NCT00646113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-NAR-0001|Study Evaluating OsseoSpeed™ Narrow Implant in the Upper and Lower Anterior Jaw|An Open, Prospective, Single Arm, Multi-centre Study Evaluating Osseospeed™ Implant 3 mm Diameter Replacing a Central or Lateral Mandibular Incisor or Lateral Maxillary Incisor. A 5-year Follow-up Study.||Dentsply Implants|No|Completed|March 2008|||August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|70 Years|No|||March 2016|March 21, 2016|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646113||158422|
NCT00646724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fuzhough0712|Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients|Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients||Fuzhou General Hospital|Yes|Recruiting|January 2008|January 2014|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||June 2011|June 15, 2011|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646724||158375|
NCT00658307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009/2008|The Effects of Repetitive Transcranial Magnetic Stimulation in Healthy Human Subjects|The Effects of Repetitive Transcranial Magnetic Stimulation in Healthy Human Subjects||Centre for Addiction and Mental Health|No|Completed|April 2008|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658307||157493|
NCT00658320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A1202|Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids|A 12-month, Multicenter, Randomized, Open-label Study to Investigate Efficacy and Safety of Concentration Controlled Everolimus With Reduced Dose Cyclosporine A Versus Mycophenolate Mofetil With Standard Dose Cyclosporine A in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids||Novartis||Completed|February 2008|May 2012|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|122|||Both|18 Years|65 Years|No|||May 2013|May 13, 2013|April 10, 2008||No||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00658320||157492|
NCT00657722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K060205|Identification of Criteria of the Success of the Endarterectomy in Chronic Pulmonary Post Embolic Hypertension|Identification Of The Predictive Angiographic And Computed Tomographic (CT) Criteria Of The Success Of The Thromboendarterectomy In Chronic Pulmonary Hypertension|ETHAPE|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2008|November 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|249|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00657722||157538|
NCT00658892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593085|Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma|B7-DC Xab Plasma Therapy for the Treatment of Metastatic Melanoma. A Feasibility/Pilot Study||Mayo Clinic||Active, not recruiting|April 2008|||February 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|April 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00658892||157449|
NCT00659178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI108621|Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer|A Phase I, Dose Escalation Study to Assess the Safety & Biological Activity of Interleukin 18 (SB-485232) Administered by IV Infusion in Combination With Pegylated Liposomal Doxorubicin (Doxil) in Advanced Stage Epithelial Ovarian Cancer||GlaxoSmithKline|No|Completed|June 2008|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||March 2011|March 15, 2012|April 10, 2008||||No||https://clinicaltrials.gov/show/NCT00659178||157427|
NCT00659191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111451|A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1265744 in Healthy Male and Female Subjects and Subjects Infected With HIV||GlaxoSmithKline||Completed|February 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|April 10, 2008||||||https://clinicaltrials.gov/show/NCT00659191||157426|
NCT00645619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022007-022|Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children|Use of a Novel Protein (sTREM-1) to Differentiate Pure Viral Lung Infection From Viral With co-Existing Bacterial Lung Infection||University of Texas Southwestern Medical Center|No|Recruiting|November 2007|June 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|60|Samples Without DNA|Bronchoalveolar lavage fluid and Serum.|Both|N/A|18 Years|No|Non-Probability Sample|Intubated patients in the intensive care unit with respiratory failure. Intubated patients        patients in the OR undergoing video-assisted thoracic surgery for empyema.        Intubated patients undergoing cardiopulmonary bypass.|March 2008|March 26, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00645619||158460|
NCT00659776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-1562|MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation|Multi-Disciplinary Study: MR, Histologic And EM Imaging Of Intravenous Superparamagnetic Crystalline Particles (Ferumoxytol) In CNS Inflammation||Oregon Health and Science University|Yes|Recruiting|July 2004|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|120|||Both|18 Years|80 Years|No|||November 2012|November 28, 2012|April 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659776||157381|
NCT00660049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02252008-1026|Feasibility Study of a Novel Device for Chronic Wounds|Feasibility Study of a Novel Device for Chronic Wounds||Stanford University|Yes|Completed|March 2008|August 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660049||157360|
NCT00660062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUAG-7|Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)|Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study|DUAG-7|Hillerod Hospital, Denmark|No|Terminated|August 2009|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|N/A|No|||April 2011|December 7, 2014|April 14, 2008||No|Slow inclusion|No||https://clinicaltrials.gov/show/NCT00660062||157359|
NCT00650585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-DR-FX-001|An Effectiveness Trial of Project ALERT|Promising Programs for Substance Abuse Prevention: Replication and Evaluation Initiative||Pacific Institute for Research and Evaluation|No|Completed|May 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|8338|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 5, 2013|March 31, 2008||No||No|July 27, 2009|https://clinicaltrials.gov/show/NCT00650585||158082|
NCT00649584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG035-0002|A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies|A Phase I Dose Escalation Study of Weekly SGN-35 Monotherapy and in Combination With Gemcitabine in Patients With Relapsed/Refractory CD30-positive Hematologic Malignancies||Seattle Genetics, Inc.|No|Terminated|March 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|12 Years|N/A|No|||December 2014|December 17, 2014|March 27, 2008|No|Yes|Sponsor decision not to enroll cohorts of combined SGN-35 and gemcitabine therapy.|No||https://clinicaltrials.gov/show/NCT00649584||158159|
NCT00649597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEHZ-0210|Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649597||158158|
NCT00650832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006775|TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.|A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Subjects, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.||Tibotec Pharmaceuticals, Ireland||Completed|October 2003|July 2007|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Actual|334|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|March 28, 2008||||||https://clinicaltrials.gov/show/NCT00650832||158063|
NCT00651157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00233|Viral Therapy in Treating Patients With Metastatic Melanoma|A Phase II Trial of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin®) in Patients With Metastatic Melanoma||National Cancer Institute (NCI)|Yes|Completed|April 2008|October 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2014|March 21, 2014|April 1, 2008|Yes|Yes||No|August 5, 2013|https://clinicaltrials.gov/show/NCT00651157||158038|
NCT00651170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/01|Diffusion of Local Anesthetic After Median Nerve Block|Can Ultrasound Predict Success of Median Nerve Block? Relationship Between Diffusion of Local Anesthetic and Effectiveness of a Nerve Block|Echoalr|Hopital Foch|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|August 2009|August 28, 2009|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00651170||158037|
NCT00645528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-198|Do Group Insulin Education Visits Reduce Barriers to Insulin Initiation?|Do Group Insulin Education Visits Reduce Barriers to Insulin Initiation?||VA Office of Research and Development|No|Completed|April 2008|September 2008|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|39|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|March 21, 2008||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT00645528||158467|This was a pilot study. Limitations include the small sample size and lack of a control group.
NCT00645541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0951|Axillary Reverse Mapping for Invasive Carcinoma of the Breast|Axillary Reverse Mapping for Invasive Carcinoma of the Breast||M.D. Anderson Cancer Center|No|Completed|March 2008|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645541||158466|
NCT00646139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589972|KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment|A Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies||Roswell Park Cancer Institute|Yes|Completed|October 2007|March 2009|Actual|August 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2011|March 1, 2011|March 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00646139||158420|
NCT00645801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-024L|Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation|Amitiza® (Lubiprostone) Plus GoLYTELY® (Polyethylene Glycol-electrolyte Solution) vs. Placebo Plus GoLYTELY® (Polyethylene Glycol-electrolyte Solution) for Outpatient Colonoscopy Preparation: A Randomized, Double-blind, Placebo-controlled Trial||Henry Ford Health System|No|Completed|March 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645801||158446|
NCT00646152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080093|Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study|A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC||National Institutes of Health Clinical Center (CC)||Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|70 Years|No|||July 2014|July 2, 2014|March 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00646152||158419|
NCT00646685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0498-B|Duct-to-duct vs Roux-en-y Hepaticojejunostomy for Biliary Reconstruction in Adult Living Donor Liver Transplantation|Prospective Randomized Trial for Comparison of Duct-to-duct and Roux-en-y Hepaticojejunostomy for Biliary Reconstruction in Adult Living Donor Liver Transplantation||University Health Network, Toronto|No|Enrolling by invitation|February 2008|July 2016|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|90 Years|No|||June 2012|July 24, 2014|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646685||158378|
NCT00646698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0217|Body Composition and Very-Low-Density-Lipoprotein-Triglycerides (VLDL-TG) Kinetics|Impact of Body Composition on Very-Low-Density-Lipoprotein-Triglycerides Kinetics||University of Aarhus|No|Completed|April 2006|June 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|30|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|March 2008|March 27, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00646698||158377|
NCT00657163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0300501|Fluoxetine on Motor Rehabilitation After Ischemic Stroke|Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial|FLAME|University Hospital, Toulouse|No|Completed|March 2005|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||July 2009|September 15, 2011|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657163||157580|
NCT00658333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AUS67|A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms|A Multicenter, Randomized, Double Blind, Double Dummy Controlled Study to Assess the Tolerability of an Increased Dose of Enteric Coated MPA After Conversion From MMF in Renal Transplant Recipients Who Required MMF Dose Reductions Due to Gastrointestinal Symptoms||Novartis||Terminated|March 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||July 2012|July 31, 2012|January 23, 2008|No|Yes||No|December 2, 2010|https://clinicaltrials.gov/show/NCT00658333||157491|Due to the insufficient number of patients enrolled in the study, no conclusions can be made from the data.
NCT00649246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63865 - PANDA|Prospective Assessment in Newborns for Diabetes Autoimmunity|1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D|PANDA|Georgia Regents University|Yes|Recruiting|July 1997|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50000|Samples With DNA|whole blood, DNA, serum, RNA, urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|newborns, young children, adults with or without type 1 diabetes|May 2011|May 12, 2011|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00649246||158185|
NCT00658580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELCWP 01994|Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer|A Phase III Randomized Study Comparing A Chemotherapy With Cisplatin And Etoposide To A Etoposide Regimen Without Cisplatin For Patients With Extensive Small-Cell Lung Cancer||European Lung Cancer Working Party|Yes|Completed|April 2000|February 2015|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|361|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00658580||157473|
NCT00658593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI1|Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer|A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer||Canadian Cancer Trials Group||Terminated|March 2008|January 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|April 12, 2008||No|due to poor accrual|No||https://clinicaltrials.gov/show/NCT00658593||157472|
NCT00650169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOP-0403|Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg|Single-Dose Food In Vivo Bioequivalence Study of Clopidogrel Bisulfate Tablets (75 mg; Mylan) to Plavix® Tablets (75 mg; Bristol-Myers Squibb/Sanofi) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2004|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650169||158114|
NCT00650598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471039|A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction|A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy Procedure for Anterior Cruciate Ligament Reconstruction||Pfizer|No|Completed|March 2004|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|N/A|No|||October 2008|October 6, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650598||158081|
NCT00659204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208035|Efficacy of Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel|A Randomized Controlled Trial of the Efficacy of a Novel Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel Against Bacterial Hand Flora||Madigan Army Medical Center|No|Recruiting|April 2008|August 2008|Anticipated|August 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|40|||Both|19 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 15, 2008|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00659204||157425|
NCT00659789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-BI Vacc-4x 2007/1|Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV|A Phase II, Randomized, Double-blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART||Bionor Immuno AS|Yes|Completed|August 2008|June 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|55 Years|No|||August 2010|January 27, 2015|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659789||157380|
NCT00655005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0723|Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer|Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|May 2007|May 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|21 Years|N/A|No|Non-Probability Sample|Newly diagnosed HNC patients.|September 2012|September 7, 2012|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00655005||157745|
NCT00655291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP20B-301|Efficacy of XP20B Following Bunionectomy Surgery|Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Analgesic Efficacy of XP20B in Subjects With Pain Following Bunionectomy Surgery||Xanodyne Pharmaceuticals|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 7, 2008|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655291||157723|
NCT00650091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020066|Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF|Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF|PANTHER-IPF|Duke University|Yes|Completed|October 2009|January 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|35 Years|85 Years|No|||February 2015|May 27, 2015|March 28, 2008|Yes|Yes||No|July 31, 2014|https://clinicaltrials.gov/show/NCT00650091||158120|
NCT00650507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011898|Clinical and Genomic Responses to Open Heart Surgery|Clinical and Genomic Responses to Open Heart Surgery: A Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning||The Hospital for Sick Children|No|Completed|March 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|300|||Both|N/A|17 Years|No|||August 2013|August 25, 2013|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00650507||158088|
NCT00650520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BROM-0734|Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets|Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions||Mylan Pharmaceuticals||Completed|May 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|119|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650520||158087|
NCT00650533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIM-0448|Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg|Single-Dose Food In Vivo Bioequivalence Study of Glimepiride Tablets (1 mg; Mylan) to Amaryl® Tablets (1 mg; Aventis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650533||158086|
NCT00650546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61737|Role of Exenatide in NASH-a Pilot Study|Role of Exenatide in Treatment of NASH-a Pilot Study|NAFLD|Indiana University|No|Completed|August 2006|August 2010|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650546||158085|
NCT00650845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-044|Renal Safety Evaluation After Dotarem®-Enhanced MRI|Renal Safety Evaluation After Dotarem®-Enhanced MRI Compared With Non-enhanced MRI in Patients at High Risk of Developing Contrast Medium Induced Nephropathy|RESCUE|Guerbet|Yes|Completed|January 2008|August 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|135|||Both|18 Years|N/A|No|||March 2015|May 21, 2015|March 4, 2008||No||No|March 11, 2015|https://clinicaltrials.gov/show/NCT00650845||158062|
NCT00651183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.649|Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment|Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment||Boehringer Ingelheim||Completed||April 2008|Actual|April 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|286|||Both|18 Years|N/A|No|Non-Probability Sample|PD patients|May 2014|May 9, 2014|March 31, 2008|||||December 14, 2009|https://clinicaltrials.gov/show/NCT00651183||158036|
NCT00660660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00122|Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)||AstraZeneca|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|85 Years|No|||February 2015|February 19, 2015|April 15, 2008|Yes|Yes||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00660660||157313|
NCT00656591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04PC01|Community-Based Interventions for Infant Health in Nepal|An Evaluation of the Cost-Effectiveness of Community-Based Participatory Interventions for Pregnant Women in Nepal to Reduce Fetal and Infant Mortality, and to Improve Fetal Growth and Cognitive Development in Infancy.||Institute of Child Health||Recruiting|March 2005|December 2008|Anticipated|December 2008|Anticipated|Phase 1|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|192000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|48 village development committee areas|April 2008|April 7, 2008|December 22, 2006||No||No||https://clinicaltrials.gov/show/NCT00656591||157624|
NCT00645814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-528|Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Abbott|No|Completed|March 2003|||September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645814||158445|
NCT00656578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-08P|Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy and Safety of a Single Intraoperative Administration of 4975 in Patients Undergoing Unilateral Transpositional First Metatarsal Osteotomy for the Correction of Hallux Valgus Deformity||Anesiva, Inc.|No|Completed|March 2008|September 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2009|May 1, 2009|April 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656578||157625|
NCT00646399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB-N007|Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis|A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis||Biosynexus Incorporated|Yes|Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1579|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||October 2011|October 20, 2011|March 26, 2008|Yes|Yes||No|August 22, 2011|https://clinicaltrials.gov/show/NCT00646399||158400|
NCT00658060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4632-IE-CTIL|Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients|Exertional Muscle Fatigue In FMF Patients Evaluated By MRI And MR Spectroscopy Of The Thigh||Sheba Medical Center|No|Recruiting|September 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with FMF, fulfilling the Tel Hashomer criteria for the diagnosis of FMF,        suffering from episodes of exertional leg pain and or exertional ankle edema, 18-45 years        old, on a stable (≥ 2 weeks) dose of oral colchicine therapy, Non-smokers|April 2008|April 11, 2008|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658060||157512|
NCT00649259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYB-02109|Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg|Single-Dose Food In Vivo Bioequivalence Study of Oxybutynin Chloride ER Tablets (10 mg; Mylan) and Ditropan XL® Tablets (10 mg; ALZA) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649259||158184|
NCT00649272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYB-05129|Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg|Single-Dose Fasting Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (15 mg; Mylan)and Ditropan XL® Tablets (15 mg; ALZA) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2006|February 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649272||158183|
NCT00650182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006715|A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant|Safety Evaluation of D-TRANS Fentanyl With Naltrexone HCL in Opioid Tolerant Patients (ALZA C-2002-022)||Alza Corporation, DE, USA||Completed|January 2003|July 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|406|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|May 18, 2011|March 28, 2008||||||https://clinicaltrials.gov/show/NCT00650182||158113|
NCT00658606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AME-001|Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects|Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Astellas Pharma Inc|Yes|Completed|October 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|April 10, 2008|Yes|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00658606||157471|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00650949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCL08001|Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma|A Phase Ib/II Study of CYT997 in Combination With Carboplatin in Relapsed Glioblastoma Multiforme||Gilead Sciences|Yes|Terminated|November 2009|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|March 27, 2008|Yes|Yes|Strategic|No||https://clinicaltrials.gov/show/NCT00650949||158054|
NCT00650962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710019R|Pre-shock Cardiopulmonary Resuscitation to Patients With Out-of-hospital Resuscitation, A Randomised Clinical Trial|Does Longer Pre-shock Cardiopulmonary Resuscitation Improve the Outcome of Patients With Out-of-hospital Cardiac Arrest? A Randomized Control Trial.|CPR|National Taiwan University Hospital|Yes|Completed|February 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1666|||Both|18 Years|N/A|No|||December 2011|January 2, 2012|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00650962||158053|
NCT00650611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281123|A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders|A 27-Week Open-Label Trial To Characterize The Safety And Tolerability Of Orally Administered Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed), Schizophrenia Or Schizoaffective Disorder||Pfizer|No|Completed|December 2003|March 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|10 Years|17 Years|No|||April 2008|April 7, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650611||158080|
NCT00650910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF110557|Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer|An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally Administered Digoxin in Subjects With Metastatic ErbB2 Positive Breast Cancer||GlaxoSmithKline|No|Completed|April 2008|December 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||August 2011|May 31, 2012|March 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00650910||158057|
NCT00650923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00678|Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma|Phase I Trial of Aflibercept (VEGF Trap) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Glioma||National Cancer Institute (NCI)||Completed|July 2008|December 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||April 2014|May 29, 2014|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00650923||158056|
NCT00645333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.119|Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer|Phase I/II Trial of MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer: A Study by the Stem Cell Clinical Consortium||University of Michigan Cancer Center|Yes|Completed|March 2008|October 2012|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|March 24, 2008|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00645333||158482|
NCT00645346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98P2|A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age|A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age||Novartis||Completed|February 2008|July 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|130|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00645346||158481|
NCT00651287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9061007|A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension|A 12-Week Open-Label, Uncontrolled Multicenter Study to Assess the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Subjects With Mild to Moderate Hypertension||Pfizer|No|Completed|December 2002|June 2004|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|200|||Both|19 Years|65 Years|No|||March 2008|April 7, 2008|March 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651287||158028|
NCT00645606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589684|Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Older Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia|Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients Older Than 65 Years With Previously Untreated B-cell Chronic Lymphocytic Leukemia (B-CLL): a Phase III Intergroup Trial of the GOELAMS and the FCGCLL/WM Groups|LLC2007SA|University Hospital, Tours|Yes|Completed|December 2007|October 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|542|||Both|66 Years|N/A|No|||October 2015|October 16, 2015|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00645606||158461|
NCT00655551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0925|Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures|A Multicenter, Open-label Trial to Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Lacosamide Maintenance as Adjunctive Therapy in Subjects With Partial-onset Seizures||UCB Pharma|Yes|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|16 Years|60 Years|No|||March 2015|March 10, 2015|March 26, 2008|Yes|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00655551||157703|
NCT00659750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-402|To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200 mg Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older||Takeda||Completed|December 2003|April 2005|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|418|||Both|12 Years|N/A|No|||April 2008|May 4, 2012|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00659750||157383|
NCT00659763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-40|Diagnostic Strategies in Patients Suspected of Irritable Bowel Syndrome|Diagnostic Strategies in Patients Suspected of Irritable Bowel Syndrome and the Prevalence of Intestinal Parasites in Patients Suspected of Irritable Bowel Syndrome||University Hospital Koge|No|Completed|February 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|149|Samples With DNA|Blood and fecal sample|Both|18 Years|50 Years|No|Non-Probability Sample|Patients are recruited from primary care.|February 2012|February 17, 2012|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00659763||157382|
NCT00650559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TE-001|Thorax Enlarging Surgery: a Novel Surgical Approach to Emphysema|Chest Wall Enlargement by Widening Sternotomy in Patients With Severe Emphysema: a Feasibility Trial.|TE|Katholieke Universiteit Leuven|No|Terminated|June 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|50 Years|70 Years|No|||March 2008|March 28, 2008|March 28, 2008||No|post-surgical complications in the last 2 patients|No||https://clinicaltrials.gov/show/NCT00650559||158084|
NCT00650858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVH05|Clinical Trial on Treatment of Intraventricular Hemorrhage|Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (IVH)|CLEAR IVH|Johns Hopkins University|Yes|Completed|February 2004|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|75 Years|No|||June 2012|June 13, 2012|December 26, 2007|Yes|Yes||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00650858||158061|
NCT00650871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW679769/903|A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia||GlaxoSmithKline||Completed|July 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|1||Actual|48|||Both|18 Years|64 Years|No|||May 2009|May 15, 2009|March 31, 2008||||||https://clinicaltrials.gov/show/NCT00650871||158060|
NCT00651196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton5|Bone Health in Type 1 Diabetes|Pilot Study - Type 1 Diabetes and Bone Health|DMB|Creighton University|No|Completed|January 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|Samples Without DNA|Transilial bone specimens are retained for measurements|Both|19 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|males or females who are greater than 19 years of age and less than age 50 who have been        diagnosed with type 1 diabetes for over 3 years.|March 2013|March 14, 2013|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00651196||158035|
NCT00651209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2410|A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)|A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of lead-in Telbivudine for 24 Weeks With or Without Tenofovir Treatment Intensification in Adult Patients With HBeAg-positive Chronic Hepatitis B.||Novartis||Completed|February 2008|||December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00651209||158034|
NCT00656877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6077|Incidence of Fat Embolism With Computer Assisted Total Knee Arthroplasty|Incidence of Fat Embolism With Computer Assisted Total Knee Arthroplasty|Fat Embolism|Marshall University|No|Completed|January 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are deemed candidates for Computer Assisted Total Knee Arthroplasty|April 2008|April 4, 2008|December 27, 2007||No||No||https://clinicaltrials.gov/show/NCT00656877||157602|
NCT00656279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH07-377|Intensive Dietary Education to Lower Serum Phosphorus in Patients With Chronic Kidney Disease|Intensive Patient Education Using the Phosphorus Point System© Tool to Improve Serum Phosphorus Levels in Patients With Chronic Kidney Disease||St. Michael's Hospital, Toronto|No|Completed|April 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|24|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656279||157648|
NCT00657748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070803|Lithium and Acetate for Canavan Disease|Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease||Assistance Publique - Hôpitaux de Paris|Yes|Withdrawn|September 2009|January 2011|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|15 Years|No|||April 2015|April 20, 2015|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00657748||157536|
NCT00656851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK59531 (completed)|Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome|Myocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic Syndrome|WU197|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|September 2005|August 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|24|||Both|28 Years|50 Years|No|||August 2013|August 19, 2013|April 10, 2008||No||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00656851||157604|We did not perform the myocardial metabolic measurements under insulin-stimulated conditions (i.e. hyperinsulinemic clamps). Small number of participants and high measurement variability, efficacy was not found. Study ended to minimize risk/benefit.
NCT00656864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-107|Pioglitazone Incretin Study|Effects of Pioglitazone on the Regulation of Insulin Secretion in Patients With Type 2 Diabetes||University of Vermont|No|Completed|May 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|75 Years|No|||January 2010|February 1, 2011|April 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656864||157603|
NCT00648739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-003|Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM|A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma||Alexion Pharmaceuticals|No|Completed|June 2008|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||November 2012|November 5, 2012|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648739||158223|
NCT00648765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAG-02130|Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg|Single-Dose Food In Vivo Bioequivalence Study of Anagrelide Hydrochloride Capsules (1 mg; Mylan) to Agrylin® Capsules (1 mg; Shire US) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2003|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648765||158222|
NCT00648778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOXA-0280|Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Loxapine Succinate Capsules (25 mg; Mylan) and Loxitane® Capsules (25 mg; Watson) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648778||158221|
NCT00650195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METO-0409|Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (10 mg; Mylan) and Zaroloxyn® Tablets (10 mg; Celltech) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|February 2004|March 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650195||158112|
NCT00650208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMO-0445|Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Lamotrigine Tablets (25 mg; Mylan) to Lamictal® Tablets (25 mg; GSK) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650208||158111|
NCT00650221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2721|Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Non-Smoking Male and Female Subjects||Mylan Pharmaceuticals|Yes|Completed|June 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650221||158110|
NCT00650234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METF-0412|Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR Tablets (500 mg; Bristol-Myers Squibb) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650234||158109|
NCT00649753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0225080125|Algometer and Category II Pelvic Blocking and Cranial Protocol|An Investigation of Algometer Readings for DeJarnette Category II Indicators After Category II Blocking and Cranial Protocol|Algometer|Logan College of Chiropractic||Completed|March 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2008|July 22, 2009|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00649753||158146|
NCT00650156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-017|Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis|A Randomized, Parallel-group, Open-Label, Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis.||Abbott|No|Completed|June 2007|||October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||September 2010|November 11, 2010|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00650156||158115|
NCT00650975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D001747-01|ThromboAblation in Acute Myocardial Infarction|ThromboAblation in Acute Myocardial Infarction|TAAMI|KCRI|Yes|Terminated|March 2008|January 2010|Actual|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||January 2011|January 19, 2011|March 26, 2008||No|Slow enrollment rate.|No||https://clinicaltrials.gov/show/NCT00650975||158052|
NCT00651300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARA-0505-086|A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery|A Multicentre, Double-Blind, Placebo-Controlled Study of the Recovery Benefits Following Treatment With a Cox-2 Regimen in Patients Undergoing Elective Laparoscopic Intra-Peritoneal Abdominal Surgery||Pfizer|No|Terminated|April 2003|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|65 Years|No|||June 2009|June 8, 2009|March 31, 2008||No|See Detailed Description field.|No||https://clinicaltrials.gov/show/NCT00651300||158027|
NCT00651313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-1077-04|Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)|A Phase II, Double-Blind, Crossover Study to Assess the Efficacy and Safety of 10% (150mg) Lidocaine Vaginal Gel Administered to Women With Recurrent Dysmenorrhea|Lidocaine 04|Juniper Pharmaceuticals, Inc.|No|Completed|August 2007|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|81|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|March 28, 2008|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00651313||158026|
NCT00645918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P95082|GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety|GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety|GRAVITAS|Accumetrics, Inc.|Yes|Completed|June 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|2800|||Both|18 Years|N/A|No|||June 2011|June 15, 2011|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645918||158437|
NCT00645931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-105|Psychological Effects of Bone Marrow Transplants in Children|Proposal for a Bone Marrow Transplant Pre, Post, and Long Term Psychological Evaluation Study.||Spectrum Health Hospitals|No|Completed|June 2004|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|18 Years|No|Non-Probability Sample|patients under the age of 18|December 2009|December 29, 2009|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645931||158436|
NCT00655564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004816|Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis|Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis||Wake Forest School of Medicine|No|Completed|May 2008|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|April 4, 2008|Yes|Yes||No|June 27, 2012|https://clinicaltrials.gov/show/NCT00655564||157702|
NCT00655577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K78751|Exercise and Prevention of Hip Fractures|Role of Exercise in Prevention of Osteoporotic Fractures in Elderly Women||University of Oulu|No|Completed|August 1998|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Female|71 Years|74 Years|No|||April 2008|April 4, 2008|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655577||157701|
NCT00660686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|387|Exercise for Physical Health in Men With Prostate Cancer|Exercise for Physical Health in Men With Prostate Cancer||OHSU Knight Cancer Institute|Yes|Completed|January 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|56|||Male|18 Years|100 Years|No|||October 2015|October 20, 2015|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00660686||157311|
NCT00660023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20752|A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis|A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|August 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|April 16, 2008|No|Yes||No|February 16, 2016|https://clinicaltrials.gov/show/NCT00660023||157362|
NCT00660036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-154|Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia|Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)||University of Pittsburgh|Yes|Terminated|September 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||January 2016|January 14, 2016|April 11, 2008|No|Yes|due to new safety information|No||https://clinicaltrials.gov/show/NCT00660036||157361|
NCT00660374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX1000-1865|Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes|Assessment of Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation on Glycaemic Control in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660374||157335|
NCT00660673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S187.3.005|Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD|Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies||AbbVie|No|Active, not recruiting|November 2009|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|261|||Both|30 Years|99 Years|No|||January 2016|January 8, 2016|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660673||157312|
NCT00656292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002881|Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery|Perioperative HMG-CoA-Reductase-Inhibitors: A Pilot Study Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery||Mayo Clinic|Yes|Recruiting|April 2008|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||June 2014|June 3, 2014|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656292||157647|
NCT00656305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM004|ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic and Multiple Myeloma Bone Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation Therapy||InSightec||Completed|March 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656305||157646|
NCT00657202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-332|Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1|Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1||Massachusetts General Hospital|Yes|Active, not recruiting|March 2008|December 2013|Anticipated|October 2009|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657202||157577|
NCT00647101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111002|A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma|Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-Line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg||Pfizer|No|Completed|December 2003|February 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|600|||Both|18 Years|N/A|No|||March 2008|March 28, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647101||158348|
NCT00657176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252-KOA-0701|An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Non-Randomized Study of OPB-31121 in Patients With Advanced Solid Tumors||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Recruiting|March 2008|June 2009|Anticipated|March 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|N/A|No|||April 2008|April 17, 2008|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00657176||157579|
NCT00657189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP179|A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus|A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Subjects With Systemic Lupus Erythematosus||MedImmune LLC|No|Completed|August 2008|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|87|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00657189||157578|
NCT00657735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-BIP-02|Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression|A Prospective Double Blind Randomized Controlled Trial To Explore The Tolerability, Safety And Efficacy Of The H1-Coil Deep Transcranial Magnetic Stimulation (TMS) In Subjects With Bipolar Depression||Shalvata Mental Health Center|Yes|Recruiting|January 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|68 Years|No|||January 2012|January 4, 2012|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657735||157537|
NCT00658034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-IM-01|Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue|Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: a Randomized Phase III Trial||Alta Bates Summit Medical Center|No|Recruiting|April 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|64 Years|No|||October 2011|October 25, 2011|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00658034||157514|
NCT00649766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01EY015899|Tailored Messages to Increase Eye Examination Behavior|Tailored Messages to Increase Eye Examination Behavior||National Eye Institute (NEI)|No|Active, not recruiting|June 2006|May 2008|Anticipated|May 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|330|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 28, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00649766||158145|
NCT00649779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALBU-0516|Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg|Single-Dose Fasting Bioequivalence Study of Albuterol Sulfate Extended-Release Tablets (8 mg; Mylan) and VoSpire® ER Tablets (8 mg; Pliva) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649779||158144|
NCT00650247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMA-0359|Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Sumatriptan Succinate Tablets (100 mg; Mylan) to Imitrex® Tablets (100 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2004|December 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|57|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 30, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650247||158108|
NCT00650273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZIT-04100|Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Azithromycin Tablets (600 mg; Mylan) to Zithromax® Tablets (600 mg; Pfizer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650273||158106|
NCT00650286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODA-0279|Food Study of Modafinil Tablets 200 mg to Provigil® Tablets 200 mg|Single-Dose Food In Vivo Bioequivalence Study of Modafinil Tablets (200 mg; Mylan) to Provigil® Tablets (200 mg; Cephalon) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|September 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650286||158105|
NCT00650624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALAJP-8274-156|A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)|A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg QD Versus Placebo In Patients With OA Of The Knee||Pfizer|No|Completed|June 2003|January 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|416|||Both|20 Years|N/A|No|||March 2008|April 7, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650624||158079|
NCT00650637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4301004|A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea|A Randomized, Open-Label, Third-Party Blinded Study for the Prophylaxis and Treatment of Nelfinavir-associated Diarrhea||Pfizer|Yes|Terminated|January 2003|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|N/A|No|||June 2011|June 3, 2011|March 31, 2008|Yes|Yes|The study was prematurely discontinued due to administrative reasons on August 18, 2003. There    were no safety concerns that led to the decision to terminate.|No||https://clinicaltrials.gov/show/NCT00650637||158078|
NCT00650988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5205|Cryotherapy for Barrett's Esophagus and Early Esophageal Cancers|A Pilot Study of Cryotherapy for Barrett's Esophagus With High-Grade Dysplasia and Early Esophageal Cancers||Case Comprehensive Cancer Center|Yes|Completed|September 2005|December 2008|Actual|May 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||December 2012|December 21, 2012|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650988||158051|
NCT00645658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12112007-932|Testosterone Replacement Therapy in Advanced Chronic Kidney Disease|Testosterone Replacement Therapy in Advanced Chronic Kidney Disease||Stanford University||Completed|August 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|45 Years|80 Years|No|||May 2012|May 3, 2012|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645658||158457|
NCT00645632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582263|Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma|Treatment of Newly Diagnosed Untreated Osteosarcoma: A Pilot Study of a New Chemotherapeutic Regimen Including Ifosfamide||Mayo Clinic||Completed|November 1990|January 2008|Actual|January 1995|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|60|||Both|N/A|N/A|No|||May 2011|May 13, 2011|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645632||158459|
NCT00645645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980249|A Study of the Genetic Analysis of Brain Disorders|Genetic Analysis of Brain Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|October 1998|||||N/A|Observational|N/A|||Anticipated|6000|||Both|N/A|N/A|No|||July 2015|July 29, 2015|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00645645||158458|
NCT00645944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702002331|Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia|Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia||Yale University|No|Completed|April 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|64 Years|No|||June 2015|June 22, 2015|March 25, 2008|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT00645944||158435|
NCT00645957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006249|A Comparison of Redrubber Versus Penrose Drains|A Comparison of Redrubber Versus Penrose Drains in the Management of Odontogenic (Dental) Infections|redrubber|Emory University|No|Completed|February 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|16 Years|N/A|No|||November 2013|November 19, 2013|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00645957||158434|
NCT00655863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322_301|Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.|Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes||Takeda|No|Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|70 Years|No|||May 2013|May 23, 2013|April 4, 2008|Yes|Yes||No|February 17, 2013|https://clinicaltrials.gov/show/NCT00655863||157680|
NCT00651352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S3010567|A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges|A Single Dose Bioequivalence Study of 2mg and 4mg Nicotine Lozenges||GlaxoSmithKline|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651352||158023|
NCT00660400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15158|Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant|A Pilot Study Of Pre-Transplant 5-Azacitidine (Vidaza) In Patients With High-Risk Myelodysplastic Syndrome (MDS) Who Are Candidates For Allogeneic Hematopoietic Cell Transplantation||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|March 2008|June 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|68 Years|No|||September 2014|September 11, 2014|April 16, 2008|No|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00660400||157333|Limitation: Small single center pilot study to show the use of pre-treatment 5-Azacitidine and successfully proceeding to transplant.
NCT00656318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701002178|Impact of Oral Contraceptives on GABA and Neurosteroids|Impact of Oral Contraceptives on GABA and Neurosteroids||Yale University|No|Terminated|August 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|6|||Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women between the ages of 18 and 42 with regular menstrual cycles of 28-32 days will be        invited to participate in a brain imaging study examining the effects of two different        oral contraceptives on cortical GABA levels.|August 2009|August 24, 2009|April 7, 2008||No|Funding withdrawn from study sponsor.|No||https://clinicaltrials.gov/show/NCT00656318||157645|
NCT00656604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0358|Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics|Evaluation of Patients With Breast Cancer Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, and Proteomics||Vanderbilt-Ingram Cancer Center|Yes|Completed|November 2003|January 2008|Actual|October 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 4, 2013|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00656604||157623|
NCT00656890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1100-06|A Study of MDX-1100 in Subjects With Active Ulcerative Colitis|A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis|MDX1100-06|Bristol-Myers Squibb|Yes|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656890||157601|
NCT00656903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080103|High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration|High Speed Indocyanine Green Angiography Findings in Induction/PRN Regimen of Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Completed|April 2008|August 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|75|||Both|50 Years|N/A|No|||August 2014|August 20, 2014|April 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00656903||157600|
NCT00647114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V930-003|A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)|A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients With Cancer Expressing HER-2 and/or CEA||Merck Sharp & Dohme Corp.||Completed|August 2007|April 2009|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|March 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00647114||158347|
NCT00647855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVO-0323|Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg|Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (300 μg; Mylan) to Synthroid® Tablets (300 μg; Abbott) in Healthy Volunteers.||Mylan Pharmaceuticals||Completed|May 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647855||158291|
NCT00647413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Krebshilfe-107539|Prevent Exposure to Tobacco Smoke at Home [Gesunde Atemluft zu Hause]|Cancer Prevention by Reducing Exposure to Environmental Tobacco Smoke at Home|GESA|University Medicine Greifswald|No|Not yet recruiting|May 2008|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Both|N/A|3 Years|Accepts Healthy Volunteers|||March 2008|March 28, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647413||158324|
NCT00657423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-EnXS0802|Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)|Study of Endostar Combined With Docetaxel and Cisplatin on the Angiogenesis of Advanced Non-small Cell Lung Cancer||Xijing Hospital|Yes|Recruiting|April 2008|April 2009|Anticipated|December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2008|September 15, 2010|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00657423||157561|
NCT00657436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyRiAD|Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement|Study of Myeloid-related Protein 8/14 and Additional Biomarkers (Multi Marker Approach) for Early Diagnosis and Risk Stratification in Patients Presenting With Acute Chest Pain at the Emergency Department|MyRiAD|University of Zurich|No|Completed|March 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|403|||Both|18 Years|90 Years|No|Probability Sample|Consecutive patients - systematic sampling - presenting with acute chest pain at the        emergency room in which determination of cardiac biomarkers is indicated for clinical        diagnostics|May 2012|May 30, 2012|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657436||157560|
NCT00657449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471007|A Double-Blind, Double-Dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain|A Double-Blind, Double-Dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg vs. Rofecoxib 50 mg in the Symptomatic Treatment of Patients With Ankle Sprain||Pfizer|No|Terminated|June 2003|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|N/A|N/A|No|||March 2008|April 8, 2008|March 31, 2008|Yes|Yes|See Detailed Description|No||https://clinicaltrials.gov/show/NCT00657449||157559|
NCT00657761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENF/01FD-05/UF1|Metabolic Effects of Enfuvirtide in Healthy Volunteers|Effect of Enfuvirtide on Lipid and Glucose Metabolism and Mitochondrial Function in Healthy Volunteers||Hospital Clinic of Barcelona|No|Completed|September 2005|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 8, 2008|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00657761||157535|
NCT00658047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-1504-201|A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis|A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis|CH-1504-201|Chelsea Therapeutics|Yes|Completed|April 2008|June 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|201|||Both|18 Years|80 Years|No|||April 2013|April 9, 2013|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00658047||157513|
NCT00649792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-F204 EXT|Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial|Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial||Acorda Therapeutics|Yes|Completed|August 2007|April 2011|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|214|||Both|18 Years|70 Years|No|||January 2012|February 24, 2012|March 28, 2008|Yes|Yes||No|January 25, 2012|https://clinicaltrials.gov/show/NCT00649792||158143|
NCT00649805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERA-05136|Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fasting Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg;Mylan) and Verelan® PM Extended-Release Capsules (300 mg; Schwarz) Sprinkled on Applesauce in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2006|February 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649805||158142|
NCT00649818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LORZ-02102|Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Lorazepam Tablets (2 mg; Mylan) and Ativan Tablets (2 mg; Wyeth) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649818||158141|
NCT00650676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor464308ctil|The Effect of Somatosensory Cue on Postural Stability in Blinded Persons|The Effect of Somatosensory Cue on Postural Stability in Blinded Persons||Soroka University Medical Center|Yes|Completed|January 2008|June 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|30 blind persons and 30 control|September 2010|September 19, 2010|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00650676||158075|
NCT00651001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IbSalut-M-002|Metabolic Syndrome and Leptin Level Associated With Fructose Consumption in Spain|Prevalence of Cardiovascular Risk Factors in Minorca - Spain||Hospital Mateo Orfila|No|Completed|June 2008|June 2009||January 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|800|Samples Without DNA|Serum and urine collections.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|800 Adults, age 18 to 70|August 2009|August 3, 2009|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00651001||158050|
NCT00650650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF-US-XR-05|Comparison of Ultrasound Versus Radiography for Diagnosis of Nasal Fractures|Comparison of Ultrasound Versus Radiography for Diagnosis of Nasal Fractures||Klinikum der Universitaet Muenchen, Grosshadern|No|Completed|March 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Patients with suspected nasal fracture.|April 2009|April 20, 2009|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00650650||158077|
NCT00650663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03377|Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)|A Multicenter, Double-Blind, Randomized Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of Ezetimibe Coadministered With Simvastatin Versus Simvastatin Monotherapy in African-American Subjects With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|October 2003|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650663||158076|
NCT00645359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.063|Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma|Pilot Study of Diffusion MRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B Cell Lymphoma|dMRI|University of Michigan Cancer Center|Yes|Terminated|November 2006|||July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lymphoma of any stage or subtype (including all Hodgkin's and non-Hodgkin's        lymphomas), previously untreated or in relapse, who are starting on a new line of therapy        with intent to induce a remission.|October 2014|October 3, 2014|March 24, 2008||No|Insufficient resources to evaluate pilot, second to shift in research priorities|No|October 3, 2014|https://clinicaltrials.gov/show/NCT00645359||158480|This study was not completed due to insufficient resources to evaluate the pilot phase of the study, secondary to shifting research priorities.
NCT00646295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5058-ER-CTIL|Pascal Pascal Dynamic Contour Tonometer (DCT) Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on CT Scan|Pascal Dynamic Contour Tonometer Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on Orbital CT Scan||Sheba Medical Center|No|Recruiting|June 2008|September 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2008|June 18, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646295||158408|
NCT00645983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT001916|Chamomile Therapy for Generalized Anxiety|Chamomile Therapy for Generalized Anxiety Disorder||University of Pennsylvania|Yes|Completed|October 2005|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||December 2009|December 1, 2009|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00645983||158432|
NCT00645970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 07-047|Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma|Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma||VA Office of Research and Development|No|Completed|July 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|359|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Two non-stratified samples of participants will be recruited at each study site. A        polytrauma injury group (PTR) will be comprised of between 150 and 200 inpatients or        former inpatients returning for additional rehabilitation care to the Minneapolis and        Tampa PRCs (ns = 75-100 at each site). PTR subjects will be subdivided into those with        combat polytrauma (60% based on current data) and those with non-combat polytrauma (40%)        for selected subsequent analyses. A comparison group of between 300 and 400 non-polytrauma        OEF/OIF service members (NPTR) will be sampled randomly from the pool of all veterans on        the Minneapolis and Tampa OEF/OIF patient registries (ns = 150-200 at each site). This        latter group will be dichotomized into those with pain (NPTR-P; approximately 42 - 50%        based on our previous research) and those without (NPTR-NP) for later analyses.|May 2015|May 14, 2015|March 24, 2008||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT00645970||158433|
NCT00646542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23137|Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency|A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency||Novartis|Yes|Completed|March 2005|||October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|525|||Both|18 Years|85 Years|No|||January 2013|January 3, 2013|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646542||158389|
NCT00651378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03708|Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)|An Open-Label, Randomized, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of "Switching" to Rosuvastatin 10 mg Daily Versus Atorvastatin 10 mg Daily With Ezetimibe 10 mg Daily Versus Doubling the Dose of Atorvastatin to 20 mg Daily in Subjects With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease or Diabetes Mellitus Who Have Not Achieved Study Target LDL-C Goal While Dosing With Atorvastatin 10 mg Daily||Merck Sharp & Dohme Corp.|No|Terminated|September 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|87|||Both|18 Years|75 Years|No|||April 2015|April 28, 2015|March 31, 2008|Yes|Yes|Slow enrollment [HIGH SCREEN FAILURE RATE]|No||https://clinicaltrials.gov/show/NCT00651378||158021|
NCT00651391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03336|Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Ezetimibe Plus Simvastatin Compared With Simvastatin Alone on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (The EFFECTS Trial)||Merck Sharp & Dohme Corp.|No|Terminated|October 2003|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|28|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|March 31, 2008|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00651391||158020|
NCT00651404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03406|Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)|A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 mg In Subjects With Primary Hypercholesterolemia And Coronary Heart Disease.||Merck Sharp & Dohme Corp.|No|Completed|January 2004|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|75 Years|No|||April 2015|April 7, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651404||158019|
NCT00646230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584267|N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma|A Phase I Study of Intravenous (Emulsion) Fenretinide in Children With Recurrent or Resistant Neuroblastoma|IV Fenretinide|Children's Hospital Los Angeles|Yes|Active, not recruiting|December 2006|June 2016|Anticipated|March 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|30 Years|No|||March 2016|March 23, 2016|March 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00646230||158413|
NCT00660699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0580 / 201101866|A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers|A Feasibility Phase II Study of Gemcitabine With Docetaxel With Concurrent 3-D Conformal Radiation Plus Continuous Infusion 5-Fluorouracil in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers||Washington University School of Medicine|Yes|Completed|September 2002|September 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 11, 2008|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT00660699||157310|
NCT00660712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NTR-DUM-2007/1|Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey|Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey||AstraZeneca|No|Completed|March 2008|March 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1018|||Both|18 Years|N/A|No|Probability Sample|Speciality care outpatient clinic (Psychiatry outpatient clinic)|May 2009|May 22, 2009|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660712||157309|
NCT00656331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-106|The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.|The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications: A Comparison of Amlodipine and Hydrochlorothiazide||University of New Mexico|Yes|Terminated|August 2005|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||April 2012|April 11, 2012|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656331||157644|
NCT00656344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9603000551|Cognitive Behavioral Treatment of Posttraumatic Stress Disorder Enhanced by Virtual Reality for Individuals With PTSD and Substance Abuse|Cognitive Behavioral Treatment of Posttraumatic Stress Disorder Enhanced by Virtual Reality for Individuals With PTSD and Substance Abuse||Weill Medical College of Cornell University|Yes|Completed|October 2006|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||December 2013|December 6, 2013|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00656344||157643|
NCT00646802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMISE|Vaginal PROgesterone as Maintenance Treatment After an epISode of prEterm Labor (PROMISE Study)|Vaginal Progesterone as a Maintenance Treatment in Women With Previous Preterm Labor. Randomized, Double Blinded, Placebo-controlled Trial|PROMISE|Hospital Clinic of Barcelona|Yes|Completed|June 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|265|||Female|18 Years|45 Years|No|||May 2012|May 23, 2012|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00646802||158369|
NCT00647868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasobol 01/2008|NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers|A Multiple Dose, Pharmacokinetic Study Comparing Different Regimens of Testosterone Given as Intranasal NASOBOL® in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers||M et P Pharma|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647868||158290|
NCT00647881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARO-0510|Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg|Single-Dose Food In Vivo Bioequivalence Study of Paroxetine Hydrochloride Controlled-Release Tablets (25 mg; Mylan) to Paxil CR™ Tablets (25 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647881||158289|
NCT00648258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0513-141|A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan|A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg QD And Naproxen 500mg BID In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan||Pfizer|No|Completed|July 2003|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||March 2008|April 7, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648258||158260|
NCT00648271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METP-02138|Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg|Single-Dose Food In Vivo Bioequivalence Study of Metoprolol Tartrate Tablets (25 mg; Mylan) and Lopressor® (50 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648271||158259|
NCT00647829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471026|A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat|Clinical Protocol For A Double-Blind, Randomized, Placebo-Controlled Comparison Of The Efficacy, Safety, And Tolerability Of Bextra® (Valdecoxib) 20 Mg Twice Daily, Bextra® 40 Mg Once Daily, And Placebo In The Symptomatic Treatment Of Subjects With Pharyngitis||Pfizer|No|Completed|February 2003|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|197|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647829||158293|
NCT00647842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENT-05128|Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System|Single-Dose In Vivo Bioequivalence and Wear Study of Fentanyl Transdermal System (25 µg/h; Mylan) and Fentanyl Transdermal System With Overlay (25 µg/h; Mylan) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2005|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647842||158292|
NCT00648245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIM-CL-003|Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD|A Phase 2a, Double Blind, Placebo Controlled, Multicenter, Dose Escalation Study to Evaluate the Safety and Efficacy of BIO 11006 Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease|BREATH-1|BioMarck Pharmaceuticals, Ltd.|Yes|Completed|June 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|172|||Both|45 Years|N/A|No|||February 2011|February 9, 2011|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648245||158261|
NCT00649844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281039|A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs|Double Blind, Double-Dummy Multicenter, Parallel Group Comparison Of The Efficacy And The Tolerability Of Ziprasidone Vs. Clozapine In Schizophrenic Patients Who Are Refractory And/Or Intolerant To Antipsychotic Therapy|MOZART|Pfizer|Yes|Completed|January 2003|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649844||158139|
NCT00649857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETI-0287|Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg|Single-Dose Food In Vivo Bioequivalence Study of Cetirizine HCl Tablets (10 mg; Mylan) and Zyrtec® (10 mg; Pfizer) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649857||158138|
NCT00650260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 106411c|Intraoperative Warming Comparison of Devices|Intraoperative Warming : Comparison of Performance of the Dynatherm Medical vitalHEAT™ Temperature Management System (vH2) and the Arizant Bair Hugger System||University of South Florida|No|Completed|February 2009|August 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|March 27, 2008|Yes|Yes||No|August 5, 2010|https://clinicaltrials.gov/show/NCT00650260||158107|
NCT00651014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03405|Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease and/or Type II Diabetes||Merck Sharp & Dohme Corp.|Yes|Terminated|January 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|March 31, 2008||No|slow subject recruitment and lack of medical and scientific merit due to change in new    standard of therapy during that same period.|No||https://clinicaltrials.gov/show/NCT00651014||158049|
NCT00650689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03396|Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)|A Multicenter, Randomized, Parallel Groups, Placebo-controlled Study Comparing the Efficacy, Safety, and Tolerability of the Daily Coadministration of Ezetimibe 10 mg With Atorvastatin 10 mg in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease for Whom Diet and Exercise Have Failed.||Merck Sharp & Dohme Corp.|No|Completed|May 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|75 Years|No|||July 2015|July 3, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00650689||158074|
NCT00645671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|525|Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery|A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|March 13, 2008|Yes|Yes||No|June 28, 2010|https://clinicaltrials.gov/show/NCT00645671||158456|
NCT00645372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281115|A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients|A Six Week, Multicenter, Double Blind, Double-Dummy, Parallel, Comparative Study To Compare The Efficacy, Safety And Tolerability Of Ziprasidone With Risperidone In The Treatment Of Chinese Subjects With Acute Exacerbation Of Schizophrenia||Pfizer|No|Completed|July 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|65 Years|No|||April 2015|April 21, 2015|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645372||158479|
NCT00645385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07090991|Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.|Treatment Of Newly Diagnosed, High-Grade, Malignant Glioma With Polifeprosan 20 Containing Carmustine Implant (Gliadel® Wafer) Using MR Spectroscopy Data As A Primary Indicator Of Therapeutic Response.|Gliadel-MRS|Weill Medical College of Cornell University|No|Terminated|June 2007|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|85 Years|No|||August 2009|August 26, 2009|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00645385||158478|
NCT00646932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-ZEM-05-002|Paricalcitol Injection Phase II Trial|A Phase 2, Open-Label, Multicenter, Multi-Dose Study to Evaluate the Pharmacokinetics and Tolerability of Paricalcitol Injection in Chronic Kidney Disease Stage 5 Subjects With Secondary Hyperparathyroidism Undergoing Hemodialysis||Abbott|No|Completed|November 2005|||February 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|25|||Both|20 Years|74 Years|No|||March 2008|March 26, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00646932||158359|
NCT00646945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003226-29|Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology|International, Randomized, Controled, Double-Blind Study Assessing Efficacy of Kalinox® 170 Bar During the Realization of Invasive Gestures in Adult Oncology||Air Liquide Santé International|No|Completed|September 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|286|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00646945||158358|
NCT00646555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904051|Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis|Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens||National Institutes of Health Clinical Center (CC)||Completed|November 2003|April 2012||||N/A|Observational|N/A|||Anticipated|300|||Both|18 Years|N/A|No|||April 2012|September 26, 2015|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00646555||158388|
NCT00651755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1033|Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients|Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients With Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|Yes|Completed|March 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|March 31, 2008||No||No|February 8, 2013|https://clinicaltrials.gov/show/NCT00651755||157992|
NCT00646477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 1|ISIS 1 Therapeutic Effectiveness|Therapeutic Efficacy Evaluation of the CPAP/autoCPAP Sandman in the Treatment of New Patients With Obstructive Sleep Apnoea Syndrome||Tyco Healthcare Group|No|Recruiting|October 2007|May 2008|Anticipated|May 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|75 Years|No|||March 2008|March 25, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646477||158394|
NCT00646464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0052-08-HMO-CTIL|New Continuous Performance Tests (CPT) for the Diagnosis of Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)|New Computerized Continuous Performance Test (CPT) for Diagnosing Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)|CPT|Hadassah Medical Organization|No|Recruiting|February 2008|December 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|6-12 year old children suspected as ADHD otherwise healthy|August 2009|August 10, 2009|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646464||158395|
NCT00646815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM2008|Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency|Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency||University of Aarhus|No|Completed|March 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00646815||158368|
NCT00647127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-004524-21|Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain|Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain||University of Aarhus|Yes|Completed|February 2008|January 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|22|||Male|18 Years|65 Years|No|||September 2012|September 13, 2012|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647127||158346|
NCT00647426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12506|Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Phase II Study of Sorafenib in Combination With Carboplatin and Docetaxel in the First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer||University of Pennsylvania|No|Completed|November 2007|December 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2011|January 31, 2013|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647426||158323|
NCT00647439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080099|Genetics and Markers of Degenerative and Inflammatory Eye Diseases|Epigenetics, Molecular Genetics, and Biomarkers of Degenerative and Inflammatory Ocular Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|March 2008|||||N/A|Observational|N/A|||Anticipated|1000|||Both|4 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00647439||158322|
NCT00647894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPR-04118|Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (1 mg; Mylan) to Xanax XR Tablets (1 mg; Pharmacia & Upjohn) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2005|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647894||158288|
NCT00647907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501018|A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections|An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection||Pfizer|No|Completed|April 2003|May 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|12 Years|N/A|No|||May 2011|May 12, 2011|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00647907||158287|
NCT00648284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104243|Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects|An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece||GlaxoSmithKline||Completed|March 2004|||||N/A|Observational|Time Perspective: Prospective||||1100|||Both|40 Years|80 Years|No|||October 2008|October 13, 2008|March 27, 2008||||No||https://clinicaltrials.gov/show/NCT00648284||158258|
NCT00648297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABE-0627|Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg|Single-Dose Fed Bioequivalence Study of Nadolol/Bendroflumethiazide Tablets (80 mg/5 mg; Mylan) and Corzide® Tablets (80 mg/5 mg; King) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648297||158257|
NCT00648310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|local oestrogens 9/2003|Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity|Is There A Synergic Effect Of Topical Oestrogens When Associated To Antimuscarinics In The Treatment Of Symptomatic Detrusor Overactivity||Università degli Studi dell'Insubria|No|Completed|January 2004|December 2007|Actual|||Phase 2/Phase 3|Interventional|N/A|2||||||Female|N/A|N/A|No|||March 2008|March 27, 2008|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00648310||158256|
NCT00648791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-0460|Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Finasteride Tablets (5 mg; Mylan) and Proscar Tablets (5 mg; Merck) in Healthy Male Volunteers||Mylan Pharmaceuticals||Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|29|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648791||158220|
NCT00648804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONDA-04115|Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg|Single-Dose Food In Vivo Bioequivalence Study of Ondansetron Orally Disintegrating Tablets (8 mg; Mylan) to Zofran ODT® Tablets (8 mg; GlaxoSmithKline) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648804||158219|
NCT00649285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NITF-02103|Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules (100 mg; Mylan) and Macrobid® Capsules (100 mg; Procter & Gamble) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|71|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649285||158182|
NCT00649298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-R-A001- 09|A Clinical Trial of IntensiVE Dialysis|ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease.|ACTIVE|The George Institute|Yes|Completed|May 2008|October 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||June 2013|June 23, 2015|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649298||158181|
NCT00650702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 02|Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Phase II, Randomized, Masked, Parallel-Group Study of Safety and Preliminary Efficacy of the Punctum Plug Delivery System in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension|CORE|Mati Therapeutics Inc.|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||March 2011|September 16, 2013|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650702||158073|
NCT00650715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBVIGF1FM|Effects of Whole-Body Vibration Exercise on Serum IGF-1 in Fibromyalgia|Effect of Acute and Chronic Whole-Body Vibration Exercise on Serum Insulin-Like Growth Factor-1 Levels in Women With Fibromyalgia||Institut Nacional d'Educacio Fisica de Catalunya||Completed|December 2004|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Female|35 Years|69 Years|No|||March 2008|March 31, 2008|March 31, 2008||||No||https://clinicaltrials.gov/show/NCT00650715||158072|
NCT00645398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081056|A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia|A 13-Week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of Pregabalin (BID) in Patients With Fibromyalgia||Pfizer|Yes|Completed|September 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|751|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645398||158477|
NCT00645411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58P12|Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents|A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Children and Adolescents||Novartis|Yes|Completed|October 2007|July 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|3604|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|March 21, 2008|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00645411||158476|
NCT00645684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBS-WV-H-0219|Clinical Use of an Absorbable Coated Suture Material in Surgery (Safil)|Clinical Use of an Absorbable Coated Suture Material in Surgery (Safil) One Layer Running(A) vs. Two-Layer Suture Technique (B)||Aesculap AG|No|Completed|April 1998|May 2002|Actual|September 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|80 Years|No|||March 2008|March 25, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645684||158455|
NCT00646074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NR009560|Self- Care TALK Study - Promoting Alzheimer's Disease (AD) Spousal Caregiver Health|Self Care TALK to Promote AD Spousal Caregiver Health||University of Kansas Medical Center|No|Completed|July 2006|August 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|46|||Both|60 Years|N/A|No|||March 2012|March 5, 2012|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646074||158425|
NCT00645996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070567(101/07)|The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants|||Assaf-Harofeh Medical Center|No|Recruiting|March 2008|October 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|9 Months|14 Months|Accepts Healthy Volunteers|||March 2008|March 26, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00645996||158431|
NCT00648050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERA-0613|Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fasting Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) to Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers Dosed in the Evening||Mylan Pharmaceuticals||Completed|March 2006|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648050||158276|
NCT00648063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LETR-05122|Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg|Single-Dose Fasting Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers||Mylan Pharmaceuticals||Completed|November 2005|January 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Female|40 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 30, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648063||158275|
NCT00648076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVA-0381|Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg|Single-Dose Food In Vivo Bioequivalence Study of Divalproex Sodium Extended-Release Tablets (500 mg; Mylan) to Depakote ER® Tablets (500 mg; Abbott) in Healthy, Adult Male Volunteers||Mylan Pharmaceuticals||Completed|December 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 24, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648076||158274|
NCT00646282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006614|Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients|Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney|PAD|Emory University|No|Terminated|April 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|March 25, 2008|Yes|Yes|slow enrollment and discontinued once original principal investigator left Emory|No|January 14, 2015|https://clinicaltrials.gov/show/NCT00646282||158409|Due to slow enrollment and primary investigator leaving institution, the study was terminated. Subjects were notified and those on active drug returned to their physicians to be treated according to standard of care.
NCT00646568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hcgstimtest-HMO-CTIL|Human Chorionic Gonadotropin (hCG) Test: A Novel Method to Evaluate the Ovarian Reserve|hCG Stimulating Test of the Thecal Cells to Evaluate the Ovarian Reserve||Hadassah Medical Organization||Completed|June 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|45 Years|No|||June 2011|June 22, 2011|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00646568||158387|
NCT00646906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708270|Mechanisms of Action of Acetaminophen|A Randomized, Double-Blind, Crossover Study to Evaluate the Mechanism of Action of Acetaminophen||University of Pennsylvania|No|Completed|May 2004|February 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|May 14, 2013|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00646906||158361|
NCT00652002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0717|Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5|A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5||AstraZeneca|No|Completed|July 2002|January 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652002||157973|
NCT00652015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 039/08|Molecular and Cellular Mechanisms of the In-stent-thrombosis|Molecular and Cellular Mechanisms of the In-stent-thrombosis. Is it Possible to Predict a In-stent-thrombosis Using Biomarkers?||RWTH Aachen University|No|Withdrawn|May 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|1 sample of approximately 30 mL blood will be taken from each patient of both study group.      CD39 and CD73 activity as well as EPC-number and function will be analyzed.|Both|18 Years|N/A|No|Non-Probability Sample|patients having developed an SAT or LT after stent implantation using PTCA|September 2015|September 22, 2015|March 31, 2008||No|Recruitment numbers could not at all been achieved in an acceptable period of time|No||https://clinicaltrials.gov/show/NCT00652015||157972|
NCT00646490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG840401|Pleural Fluid and Serum Procalcitonin in Patients With Parapneumonic Pleural Effusion|Diagnostic and Prognostic Values of Pleural Fluid Procalcitonin in Parapneumonic Pleural Effusion||Chang Gung Memorial Hospital|No|Completed|July 2005|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|Samples Without DNA|serum,pleural fluid|Both|17 Years|80 Years|No|Probability Sample|Patients from the out-patient-department in division of pulmonary and critical care        medicine and the department of emergency medicine at Chang Gung Memorial Hospital,        Kaohsiung.|March 2008|February 27, 2013|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646490||158393|
NCT00646503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600ACN04|Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B|A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End of Year 4 Treatment||Novartis||Completed|March 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||June 2011|June 16, 2011|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00646503||158392|
NCT00646828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070139|Cardiovascular Evaluation of Adult PHA 1 Patients|Cardiovascular Evaluation of a Rare Condition With Hyperaldosteronism Without Hypertension: PHA 1|PHACARV|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patient with Pseudohypoaldosteronism type 1 and the family of these patient who dont have        mineralocorticoid receptor mutation|July 2010|January 18, 2012|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00646828||158367|
NCT00647140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051081|Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer|Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer.|DOPMET|Assistance Publique - Hôpitaux de Paris|No|Terminated|August 2007|February 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|29|||Both|18 Years|N/A|No|||May 2010|July 6, 2010|March 26, 2008||No|Insuffisent recruitment|No||https://clinicaltrials.gov/show/NCT00647140||158345|
NCT00647452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-0002|Very Low Density Lipoprotein (VLDL) Triglyceride Metabolism in Exercise|Very Low Density Lipoprotein (VLDL) Triglyceride Metabolism in Exercise||University of Aarhus|Yes|Completed|April 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647452||158321|
NCT00647465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050601|Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer|Randomized Double-Blind Placebo Controlled Study Evaluating the Effect of Sublingual Administration of IFNa on the Immune Response to Influenza Vaccination in Subjects Aged 75 or More.|GP-INFA|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|October 2005|March 2008|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|140|||Both|75 Years|N/A|Accepts Healthy Volunteers|||November 2005|March 28, 2008|March 26, 2008||No|End of the study|No||https://clinicaltrials.gov/show/NCT00647465||158320|
NCT00647933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07004|An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)|An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 After a Single Subcutaneous Dose in Healthy Female Volunteers Whose Pituitary Function is Suppressed by Lyndiol®.||Merck Sharp & Dohme Corp.|No|Completed|June 2000|December 2000|Actual|December 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00647933||158285|
NCT00648323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0351063|Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement|A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia||Pfizer|No|Completed|November 2003|January 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Male|50 Years|80 Years|No|||March 2008|April 2, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648323||158255|
NCT00648336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERC-0360|Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Mercaptopurine (50 mg; Mylan) and Purinethol® Tablets (50 mg; Gate) in Healthy Male Volunteers||Mylan Pharmaceuticals||Completed|November 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648336||158254|
NCT00648349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RABE-0325|Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Rabeprazole Sodium Delayed-Release Tablets (20 mg; Mylan) to Aciphex® Delayed-Release Tablets (20 mg; Eisia) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|May 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648349||158253|
NCT00648830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAI-P4-057|Comparative Bioavailability Study of Clarithromycin 250 mg Tablets|Randomized Single Dose Crossover Replicate Comparative Bioavailability Study of Clarithromycin 250 mg Tablets in Healthy Male and Female Volunteers Under Fasted Conditions||Mylan Pharmaceuticals|Yes|Completed|May 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648830||158217|
NCT00648817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-104-0318|Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers|A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV-1 Seronegative Healthy Adult Males||Gilead Sciences|No|Completed|July 2006|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648817||158218|
NCT00648843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYB-02117|Food Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (5 mg; Mylan) and Ditropan XL® Tablets (5 mg; ALZA) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2002|January 2003|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648843||158216|
NCT00649311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPLA-0501-072|A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension|Clinical Protocol For A Double-Blind, Randomized, Active- Controlled Comparison Study Of The Antihypertensive Effect Of Eplerenone Versus Losartan In Patients With Mild To Moderate Hypertension||Pfizer|No|Terminated|April 2003|September 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|N/A|No|||November 2009|November 30, 2009|March 27, 2008|Yes|Yes|Poor enrollment; termination not due to safety reasons.|No||https://clinicaltrials.gov/show/NCT00649311||158180|
NCT00649324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCTZ-0588|Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg|Single-Dose Fasting In-Vivo Bioequivalence Study of Hydrochlorothiazide Tablets (50 mg; Mylan) to Hydrochlorothiazide Tablets (50 mg; Ivax) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2005|October 2005|Actual|October 2005|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649324||158179|
NCT00655434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-001-RT0920G Rev:03/07/08|HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population|HerpeSelect® Express Rapid Test Study Protocol Sexually Active Adult Population||Focus Diagnostics, Inc.|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community based research clinic|January 2009|January 8, 2009|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00655434||157712|
NCT00655707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSC/001|A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency|A Phase I/II Safety and Tolerability Dose Escalation Study Following the Autologous Infusion of Expanded Adult Haematopoietic Stem Cells to Patients With Liver Insufficiency||Imperial College London|Yes|Completed|January 2006|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|65 Years|No|||June 2015|June 4, 2015|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655707||157691|
NCT00655720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3369-5|The Effects on Growth of a Non-Routine Infant Formula|The Effects on Growth and Tolerance of Hydrolyzed Formulas Fed to Term Infants||Mead Johnson Nutrition|No|Completed|March 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|293|||Both|N/A|16 Days|Accepts Healthy Volunteers|||April 2008|April 10, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00655720||157690|
NCT00655967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC# 06-318|Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)|Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study|SAFADIE|University of New Mexico|No|Recruiting|December 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|60 Years|N/A|No|||April 2008|July 24, 2009|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655967||157672|
NCT00655980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 07-0592|Vitamins in Nitrous Oxide Study|Pharmacogenetics of Adverse Outcomes After Nitrous Oxide Anesthesia|VINO|Washington University School of Medicine|Yes|Active, not recruiting|February 2008|July 2012|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|625|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655980||157671|
NCT00655746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-249|The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects|The Effect of Omeprazole on the Pharmacokinetics of Dasatinib (BMS-354825) in Healthy Subjects||Bristol-Myers Squibb|No|Completed|April 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2009|December 8, 2009|April 3, 2008|No|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00655746||157688|
NCT00651573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-064|Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery|Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery||The Cleveland Clinic|Yes|Recruiting|March 2007|July 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|1300|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651573||158006|
NCT00651846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91270|Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women|Single Center, Double Blind, Randomized, Crossover Study to Investigate the Impact of the Oral Contraceptive Yasmin (30 µg EE / 3 mg DRSP) Compared to Microgynon (30 µg / 150 LNG) on Hemostasis Parameters in 40 Female Volunteers||Bayer|No|Completed|June 2003|February 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00651846||157985|
NCT00651859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-024|Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension|||Allergan||Completed|November 2002|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|111|||Both|20 Years|N/A|No|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651859||157984|
NCT00652834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001911|Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®|Gastrointestinal Mucosal Findings in Patients Receiving Mycophenolic Acid (MPA) as Demonstrated by Small Bowel Capsule Endoscopy (SBCE)||University of California, Los Angeles|No|Completed|April 2009|May 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|No|||December 2014|February 5, 2016|April 1, 2008|Yes|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00652834||157910|We did not enroll asymptomatic patients and in the extension of the trial the number of patients re-examined were few and the data obtained from them are not enough to provide definitive information.
NCT00652847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-152|Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)|Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|May 2005|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652847||157909|
NCT00653237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|igellma-1|Laryngeal Mask Supreme™ Versus the I-gel™|A Comparison of The Laryngeal Mask Supreme™ and the I-gel™ in a Simulated Difficult Airway Scenario in Anesthetized and Ventilated Patients||University Hospital Inselspital, Berne|No|Completed|March 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 11, 2014|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653237||157880|
NCT00653549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01169|Bioavailability Study of Torsemide Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|April 2001|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 16, 2011|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653549||157857|
NCT00653562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6199-JC-0002|Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography|Single Blind, Multi-center, Post Marketing Clinical Study of Zolpidem (Myslee) in Adolescent Patients With Insomnia - Evaluation With Polysomnography||Astellas Pharma Inc|No|Completed|November 2006|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|11|||Both|12 Years|18 Years|No|||April 2010|April 6, 2010|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653562||157856|
NCT00653575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH083502|Adult Sexual Risk Behavior Among Women With a History of Childhood Sexual Abuse|HIV Risk Among Women With a History of Childhood Sexual Abuse||Syracuse University|No|Completed|August 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|481|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will include women seeking treatment at the Monroe County Health Department STD        Clinic.|April 2013|April 12, 2013|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00653575||157855|
NCT00650104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/196|Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164|101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164||GlaxoSmithKline|No|Completed|May 2002|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|30 Years|N/A|No|||April 2013|May 2, 2013|March 27, 2008|Yes|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00650104||158119|
NCT00624143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|antifungal prophylaxis|Antifungal Prophylaxis in Pediatric Acute Leukemia|Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial.||All India Institute of Medical Sciences, New Delhi|No|Recruiting|February 2008|||December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|15 Years|No|||January 2008|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624143||160086|
NCT00624156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-011|Expressive Writing and Adjustment to Metastatic Breast Cancer|Expressive Writing and Adjustment to Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|February 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|98|||Female|18 Years|N/A|No|Probability Sample|MSKCC clinics|October 2015|October 28, 2015|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624156||160085|
NCT00652717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-150|Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)|A Multicenter, Open Study To Evaluate The Efficacy Of Ezetimibe 10 Mg Added On Statin Therapy, In Reducing LDL Cholesterol To Target Levels In Patients After Acute Coronary Syndrome||Merck Sharp & Dohme Corp.||Completed|February 2005|August 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652717||157919|
NCT00653107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FO2007/45|Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only|Palliation of Dysphagia in Patients With Advanced Cancer of the Oesophagus by Comparing Stent Followed by 3 Courses of Brachytherapy With 3 Courses of Brachytherapy Only. A Randomised Phase III Study (PACO)|PACO|Oslo University Hospital|No|Terminated|June 2008|May 2020|Anticipated|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||April 2012|April 12, 2012|April 1, 2008||No|The study was closed prematurely due to slow recruitment|No||https://clinicaltrials.gov/show/NCT00653107||157890|
NCT00653133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iflocpnb2007|Multicenter Continuous Peripheral Nerve Block Surveillance Study|Multicenter Continuous Peripheral Nerve Block Surveillance Study Comparing Ultrasound Guided Catheter Placement to Non Ultrasound Guided Catheter Placement Techniques|cpnb|Halyard Health|No|Completed|May 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1821|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|March 28, 2008|Yes|Yes||No|May 19, 2011|https://clinicaltrials.gov/show/NCT00653133||157888|
NCT00653770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB017|A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A|A Phase I Study to Assess the Safety and Immunogenicity of New TB Vaccine Candidates FP85A and MVA85A, in Healthy Adults Who Have Previously Been Immunized With BCG, Using a Prime-boost Delivery Schedule||University of Oxford|Yes|Completed|September 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|31|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2010|February 8, 2010|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653770||157840|
NCT00653471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capnography|Micro-Stream Capnography in Non-Intubated Lean and Obese Patients With and Without Obstructive Sleep Apnea|The Accuracy of End-Tidal PCO2 Measurements With Main-Stream and Micro-Stream Capnography in Non-Intubated Lean and Obese Patients With and Without Obstructive Sleep Apnea||Outcomes Research Consortium|No|Completed|June 2006|September 2008|Actual|August 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|February 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653471||157863|
NCT00654394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0044|Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects|Randomized, Double-Blind, Multicenter, Trial to Assess the Effect of High & Low Doses of ZD4522 on Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects With Asymptomatic Carotid Stenosis After 24 Months of Dosing.||AstraZeneca|No|Completed|January 2000|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|April 3, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00654394||157792|
NCT00654407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0068|Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia|An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.||AstraZeneca|No|Completed|November 2001|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|4875|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|April 3, 2008||||||https://clinicaltrials.gov/show/NCT00654407||157791|
NCT00654693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080021|NTX Wireless Patient Monitoring System|A Pilot Study to Evaluate the Performance of Nihon Kohden's NTX Wireless Patient Monitoring System||Vanderbilt University|Yes|Completed|March 2008|June 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be recruited in the Vanderbilt University Medical Center pre-operative        clinic or in the Round Wing, after the effects of anesthesia have worn off. Before        performing any trial-related procedures, written Informed Consent and HIPAA authorization        will be obtained.|September 2012|September 6, 2012|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654693||157769|
NCT00654667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI - SOS|Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome|Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome.|RSV|University of California, San Francisco|No|Withdrawn|May 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||March 2015|March 3, 2015|April 3, 2008||No|no participant enrollment|No||https://clinicaltrials.gov/show/NCT00654667||157771|
NCT00654680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10473|Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury|A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Subjects With ED Solely Secondary to Traumatic Spinal Cord Injury||Bayer||Completed|October 2002|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|418|||Male|18 Years|N/A|No|||September 2013|September 26, 2013|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00654680||157770|
NCT00655174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019990290|Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?|A Double-Blind Placebo-Controlled Randomized Clinical Trial of Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?||The Hospital for Sick Children|Yes|Completed|June 1999|January 2007|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|108|||Both|3 Years|10 Years|No|||April 2008|April 4, 2008|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655174||157732|
NCT00655187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110467|Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants|Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children < 5 Years of Age in KK Hospital, Singapore||GlaxoSmithKline||Completed|April 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1270|Samples With DNA|Stool samples|Both|N/A|5 Years|No|Probability Sample|Children less than 5 years of age, hospitalised with acute GE, living in Singapore served        by the hospital participating in the study (KK Hospital) and whose parents/ guardians are        willing to provide informed consent, will be considered as cases.        Cases will be limited to those subjects who are born after 1 November 2005, aged at least        16 weeks and whose stool samples have been tested positive for rotavirus (RV).        For each case, two controls hospitalised for acute disease with non-GE causes in the same        hospital during the same period, will be included in the study after matching them by date        of birth.|November 2011|November 25, 2011|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655187||157731|
NCT00655200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3525|Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus|Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|February 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2286|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Type 1 and Type 2 Diabetes|November 2012|August 13, 2014|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655200||157730|
NCT00655213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGXD02 - SAVER|Spontaneous Atrio Ventricular Conduction Preservation|Spontaneous Atrio Ventricular Conduction Preservation|SAVER|LivaNova|Yes|Completed|November 2003|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|622|||Both|18 Years|N/A|No|||April 2008|April 3, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00655213||157729|
NCT00655447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARW-OVCONS-0307|Examining the Long-Term Risks of Oophorectomy|Ovarian Conservation: Long-Term Health Outcomes From the Nurse's Health Study.||Parker, William H., M.D.|No|Completed|January 1980|June 2004|Actual|June 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32175|||Female|30 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nurses' Health Study I, which included 122,701 married registered nurses living in 11 U.S.        states and who were ages 30 to 55 in 1976|April 2008|April 8, 2008|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655447||157711|
NCT00655733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200500401|Phase II Study of HMPL-004 in Subjects With Crohn's Disease|||Hutchison Medipharma Limited|No|Completed|April 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||November 2012|November 4, 2012|April 6, 2008|Yes|Yes||No|April 18, 2011|https://clinicaltrials.gov/show/NCT00655733||157689|
NCT00655993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00746|Effect of Statin Therapy on C-Reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)|Effect of Statin Therapy on C-Reactive Protein Levels in Patients With COPD||VA Loma Linda Health Care System|No|Recruiting|April 2008|December 2009|Anticipated|March 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|79 Years|No|||April 2008|April 9, 2008|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655993||157670|
NCT00652145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24DK078228|Dose Escalation and Remission (DEAR)|Test Treat Strategy to Prevent Ulcerative Colitis Relapse|DEAR|University of Pennsylvania|No|Completed|September 2008|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|119|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|April 1, 2008|Yes|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT00652145||157962|
NCT00652158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10002|A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies|A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies||Millennium Pharmaceuticals, Inc.|No|Terminated|April 2006|April 2008|Actual|March 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652158||157961|
NCT00651872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074941|Development and Validation of a PTSD-Related Functional Impairment Scale|Development and Validation of a PTSD-Related Functional Impairment Scale||Boston VA Research Institute, Inc.|No|Completed|June 2008|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|740|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Veterans and Active Duty Military Personnel|August 2013|March 5, 2014|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00651872||157983|
NCT00652483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-021|Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|May 2003|September 2004|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|433|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652483||157936|
NCT00649207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-128|A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases|A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases||AbbVie|No|Completed|March 2008|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|March 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00649207||158188|
NCT00649688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METZ-0292|Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets (100/50 mg; Mylan) and Lopressor HCT® Tablets (100/50 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649688||158151|
NCT00649701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-URS PS000415|Novel Internet-Based Interventions to Reduce Sexual Risk Among Men Who Have Sex With Men|Phase 1 Online Intervention to Reduce Sexual Risk Among Men Who Have Sex With Men|5Part|Public Health Solutions|Yes|Active, not recruiting|April 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|3097|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 19, 2008|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00649701||158150|
NCT00649714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZONI-0375|Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Zonisamide Capsules (100 mg; Mylan) to Zonegran® Capsules (100 mg; Elan) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2003|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|110|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649714||158149|
NCT00650117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FENT-06102|Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System|Single-Dose In Vivo Bioequivalence and Wear Study of Fentanyl Transdermal System (25 µg/h; Mylan) and Fentanyl Transdermal System With Overlay (25 µg/h; Mylan) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00650117||158118|
NCT00650130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL 417-7|Whole Blood-plasma-oral Fluid Ratios of Psychoactive Drugs and Medicines|DRUID Sub-study: Substance Concentration Ratio/Impairment||National Institute for Health and Welfare, Finland|No|Completed|May 2008|October 2011|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|300|Samples With DNA|Blood samples and oral fluid are collected for the study. However no DNA detection is done      at any stage. The laboratory where samples are analysed do not analyse DNA. DNA is not      relevant to this study.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|drivers of motorised vehicles in general road traffic|November 2013|November 1, 2013|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00650130||158117|
NCT00623584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKC001SFM08|Comparison of Corneal Grafts Cultured in Serum-free Versus Corneal Grafts Cultured in Serum Supplemented Culture Media|In Vitro and Clinical Comparison of Corneal Grafts Cultured in Serum Free Medium or Standard Serum Supplemented Medium in Patients With Degeneration of the Corneal Endothelium|SFM|Klinikum Chemnitz gGmbH|Yes|Not yet recruiting|April 2011|October 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||December 2010|December 7, 2010|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00623584||160129|
NCT00652730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980564|Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions|Comparative, Randomized, 3-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar)15 mg Buspirone HCl Tablets Following Administration of a 30 mg Dose in Healthy Adult Males Under Fed and Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|July 1998|September 1998|Actual|September 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|21|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652730||157918|
NCT00653484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592809|Energy Balance Interventions for Colorectal Cancer Prevention|Energy Balance Interventions for Colorectal Cancer Prevention||Vanderbilt University|Yes|Completed|March 2008|June 2013|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|40|||Both|50 Years|N/A|No|||December 2013|December 16, 2013|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00653484||157862|
NCT00653796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03434|Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)|SCH 58235: A Multicentre, Randomised, Parallel Group, Placebo-Controlled Study Comparing the Efficacy, Safety, And Tolerability of the Daily Co-Administration of Ezetimibe 10 mg With Atorvastatin 10 mg vs. Ezetimibe Placebo With Atorvastatin 10 mg in Untreated Subjects With Primary Hypercholesterolaemia and Coronary Heart Disease||Merck Sharp & Dohme Corp.|No|Completed|September 2003|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653796||157838|
NCT00653809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0065|Racial Differences: Nitric Oxide(NO) and Endothelin-1(ET-1) in Preeclampsia (PreE)|Elucidating the Role of Nitric Oxide and Endothelin-1 Activation in Endothelial Cells Co-cultured With Placental Explants From African-american and Caucasian High Risk Pregnancies||University of Mississippi Medical Center|No|Completed|June 2007|September 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||8|Actual|52|Samples With DNA|Placental Tissue|Female|18 Years|40 Years|No|Non-Probability Sample|Women delivering babies at the University of MS Medical Center|April 2012|April 5, 2012|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653809||157837|
NCT00654056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKO-M20070267|Severe Insulin Resistance in Patients With Type 2 Diabetes|Severe Insulin Resistance in Patients With Type 2 Diabetes: Mechanisms Behind Insulin Resistance.||University of Aarhus|No|Completed|March 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|8|||Both|25 Years|75 Years|No|||March 2013|March 8, 2013|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00654056||157818|
NCT00654420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-007|A Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (0646-007)|An Open Label, Randomized Phase I/IIa Trial Evaluating MK0646 in Combination With Erlotinib for Patients With Recurrent Non-Small Cell Lung Cancer||Merck Sharp & Dohme Corp.||Completed|March 2008|February 2012|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654420||157790|
NCT00654706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11723A|Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia|A Randomised, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of Sertindole Versus Comparator in Patients With Schizophrenia Using the MATRICS Consensus Cognitive Battery (MCCB)||H. Lundbeck A/S|No|Completed|March 2008|March 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|55 Years|No|||May 2014|May 14, 2014|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654706||157768|
NCT00654940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081187|A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients|Methodology Study To Assess The Ability Of A Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover Study To Detect The Effect Of Pregabalin In Post-Traumatic Neuropathic Pain Patients||Pfizer|No|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|25|||Both|18 Years|80 Years|No|||February 2010|February 8, 2010|April 3, 2008|No|Yes||No|January 5, 2010|https://clinicaltrials.gov/show/NCT00654940||157750|
NCT00654927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-F202 EXT|Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis|Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis||Acorda Therapeutics|Yes|Completed|November 2003|April 2011|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|177|||Both|18 Years|70 Years|No|||January 2012|March 1, 2012|April 4, 2008|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT00654927||157751|
NCT00655460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-45210-1|Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 1|Clinical Process Improvement With A Bedside Computerized Insulin Therapy Protocol For Blood Glucose Control (eProtocol-insulin) in Adult And Pediatric ICU Patients:Further Refinement and Validation of eProtocol-insulin||Intermountain Health Care, Inc.|Yes|Recruiting|February 2006|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|1 Month|N/A|No|||January 2008|February 24, 2015|April 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655460||157710|
NCT00655772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1_Shinada|A Clinical Trial to Assess the Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor|A Randomized, Double Blind, Crossover, Placebo-Controlled Clinical Trial to Assess the Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor||Tokyo Medical and Dental University|No|Completed|February 2007|April 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|15|||Male|19 Years|38 Years|Accepts Healthy Volunteers|||March 2008|April 4, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00655772||157687|
NCT00656006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1008-C1052 (ALFR-HC-06)|A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3|A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3||Human Genome Sciences Inc.|Yes|Completed|November 2005|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|43|||Both|18 Years|65 Years|No|||August 2013|August 1, 2013|December 20, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656006||157669|
NCT00656019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0026|Development of Vitamin D as a Therapy for Breast Cancer - Phase II|Development of Vitamin D as a Therapy for Breast Cancer - Phase II||Stanford University|Yes|Completed|April 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|56|||Female|18 Years|N/A|No|||July 2013|July 24, 2013|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656019||157668|
NCT00648193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARO-0678|Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg|Single-Dose Fasting Bioequivalence Study of Paroxetine Hydrochloride Tablets (40 mg; Mylan) and Paxil® Tablets (40 mg; GSK) in Healthy Adult Volunteers||Mylan Pharmaceuticals||Completed|December 2006|January 2007|Actual|December 2006|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648193||158265|
NCT00648206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL 419-9|Testing Alcohol Only Samples for Drugs and Drugs Only Samples for Alcohol|Retrospective Study of Unrequested Analytical Data in DUID-cases From a 2 Week Period||National Institute for Health and Welfare, Finland|No|Completed|September 2008|October 2011|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Crossover||2|Actual|250|Samples With DNA|Whole blood samples are collected for the study. However no DNA detection is done at any      point in the study. The laboratory where the samples are analysed does not analyse DNA. DNA      is not relevant for this study|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|drivers of motorised vehicles in general road traffic|November 2013|November 1, 2013|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00648206||158264|
NCT00652496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-030|Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|January 2005|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|249|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652496||157935|
NCT00652509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_510|Journey for Control of Diabetes Study (0431-111)|Journey for Control of Diabetes Study||Merck Sharp & Dohme Corp.||Completed|May 2008|July 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|621|||Both|18 Years|80 Years|No|||August 2012|August 29, 2012|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652509||157934|
NCT00648700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVO-0573|Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg|Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (300 μg; Mylan) to Levothroid® Tablets (300 μg; Llyod) in Healthy Volunteers.||Mylan Pharmaceuticals||Completed|August 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648700||158226|
NCT00648713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERB-0393|Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg|Single-Dose Food In Vivo Bioequivalence Study of Terbinafine Hydrochloride Tablets (250 mg; Mylan) and Lamisil® (250 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648713||158225|
NCT00649220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90001-0716/1|Memantine and Antipsychotics Use|Prospective, Single-arm, Multi-centre, Open-label Study to Investigate the Potential to Reduce Concomitant Antipsychotics Use in Patients With Moderate to Severe Dementia of Alzheimer's Type (DAT) Treated With Memantine|MemAP|Merz Pharmaceuticals GmbH|No|Terminated|July 2008|June 2009|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|50 Years|85 Years|No|||September 2011|September 22, 2011|March 27, 2008||No|Study terminated due to too slow enrollment|No|August 9, 2011|https://clinicaltrials.gov/show/NCT00649220||158187|Early termination due to too slow enrollment lead to a small sample size, limiting the ability for confirmatory analysis. All analysis of the primary efficacy endpoint were treated as exploratory.
NCT00649233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METZ-0293|Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg|Single-Dose Food In Vivo Bioequivalence Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets (100/50 mg; Mylan) to Lopressor HCT® Tablets (100/50 mg; Novartis) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649233||158186|
NCT00649727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYB-0263|Fed Study of Oxybutynin Chloride Extended-Release Tablets 10 mg and Ditropan XL® Tablets 10 mg|Single-Dose Food In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (10 mg; Mylan) and Ditropan XL® Tablets(10 mg; ALZA) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2002|August 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649727||158148|
NCT00649740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPR-0583|Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg|Single-Dose Fasting Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649740||158147|
NCT00650143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22021980|Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction|Safety and Efficacy of Sitagliptin Plus Granulocyte-colony Stimulating Factor in Patients Suffering From Acute Myocardial Infarction|SITAGRAMI|Ludwig-Maximilians - University of Munich|Yes|Recruiting|March 2008|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|174|||Both|18 Years|N/A|No|||July 2011|July 7, 2011|March 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00650143||158116|
NCT00634309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-AHS-0006|Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)|Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function||AstraZeneca|No|Completed|June 1999|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|597|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634309||159323|
NCT00634322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR001-CLN-pro012|High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma|Randomized, Blinded, Placebo-Controlled Trial of High Dose Methotrexate With Leucovorin Rescue (HDMTX-LV) With or Without Glucarpidase in Osteosarcoma||BTG International Inc.|No|Terminated|October 2008|April 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|7|||Both|8 Years|50 Years|No|||September 2014|September 9, 2014|March 6, 2008|Yes|Yes|Lack of enrollment|No|November 30, 2012|https://clinicaltrials.gov/show/NCT00634322||159322|No efficacy endpoints were reported due to early termination (insufficient enrollment).
NCT00634582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583657|Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases|Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Terminated|January 2009|June 2015|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|18 Years|120 Years|No|||November 2013|September 22, 2015|March 12, 2008|Yes|Yes|slow accrual|No|November 22, 2013|https://clinicaltrials.gov/show/NCT00634582||159302|
NCT00653146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000590603|The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia|Effects of Mindfulness-Based Stress Reduction (MBSR) on Immune Response to HPV||Fox Chase Cancer Center|No|Completed|September 2007|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|186|||Female|18 Years|N/A|No|||September 2015|September 2, 2015|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00653146||157887|
NCT00653822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0485-CL-J101|A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Dose Study to Assess the Tolerability, Safety, and Pharmacokinetics of Alefacept in Caucasian and Japanese Healthy Volunteers||Astellas Pharma Inc|No|Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|75|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2008|February 26, 2013|April 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653822||157836|
NCT00653835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03435|Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)|SCH 58235: A Multicenter, Randomised, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, and Tolerability Of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg vs Ezetimibe Placebo With Simvastatin 20 mg in Untreated Subjects With Primary Hypercholesterolaemia And Coronary Heart Disease (Protocol P03435)||Merck Sharp & Dohme Corp.||Completed|September 2003|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653835||157835|
NCT00654069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-ADF-105|Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Repeat-Dose Study of the Safety and Efficacy of OxyADF (Oxycodone HCl and Niacin) Tablets for the Treatment of Acute, Moderate to Severe Postoperative Pain Following Bunionectomy Surgery in Adult Patients||Acura Pharmaceuticals Inc.|No|Completed|September 2007|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|405|||Both|18 Years|N/A|No|||April 2008|April 2, 2008|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654069||157817|
NCT00654082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481103|A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction|A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction||Pfizer|No|Completed|September 2002|August 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Male|19 Years|N/A|No|||April 2008|April 2, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654082||157816|
NCT00654095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05456|Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)|Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors||Merck Sharp & Dohme Corp.|No|Completed|December 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|146|||Both|20 Years|N/A|No|||June 2015|June 9, 2015|April 1, 2008|No|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00654095||157815|
NCT00654433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBT-002|ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases|A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism|UCBT-002|Aldagen|Yes|Terminated|March 2008|November 2011|Actual|July 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|16 Years|No|||July 2014|July 7, 2014|April 3, 2008|Yes|Yes|Terminated - Sponsor Decision|No||https://clinicaltrials.gov/show/NCT00654433||157789|
NCT00645827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006564|Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients|Use of an Insulin Infusion Conversion Equation (IICE) to Improve Inpatient Glycemic Control: A Randomized Controlled Trial|IICE|Emory University|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 12, 2014|March 25, 2008||No||No|September 3, 2014|https://clinicaltrials.gov/show/NCT00645827||158444|
NCT00655239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH081051|Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis|Neuroscience-Guided Cognitive Remediation in Adolescents at Risk for Psychosis||University of California, San Francisco|No|Recruiting|June 2008|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|100|||Both|12 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00655239||157727|
NCT00655252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001L2401|Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy|An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy||Novartis||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2011|August 18, 2011|April 7, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00655252||157726|
NCT00655226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 05-0961|Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients|Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients||Icahn School of Medicine at Mount Sinai|Yes|Terminated|March 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|N/A|No|||August 2011|August 5, 2011|April 3, 2008||No|low enrollment|No||https://clinicaltrials.gov/show/NCT00655226||157728|
NCT00655785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPCR1R2-2|Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)|Phase Ｉ/Ⅱ Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer||Fukushima Medical University|No|Completed|September 2007|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|80 Years|No|||March 2013|March 13, 2013|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655785||157686|
NCT00656032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080074|Vitamin D, Insulin Resistance and Inflammation in ESRD|Vitamin D, Insulin Resistance and Inflammation in ESRD||Vanderbilt University|No|Completed|April 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656032||157667|
NCT00651586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198782-002|Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers|||Allergan||Completed|October 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|8 Years|N/A|No|||July 2008|July 25, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651586||158005|
NCT00651599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91354|Treatment of Vasomotor Symptoms in Korean Post Menopausal Women|A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq(drospirenon2mg and Estradiol 1mg) in Postmenopausal Korean Women With Vasomotor Symptoms Over 3, 28 Day Treatment Cycle||Bayer|No|Completed|July 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|45 Years|65 Years|No|||December 2014|December 30, 2014|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00651599||158004|
NCT00651612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-024T|Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients|||Allergan||Completed|November 2005|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|604|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651612||158003|
NCT00647751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMO-0446|Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg|Single-Dose Food In Vivo Bioequivalence Study of Lamotrigine Tablets (25 mg; Mylan) to Lamictal® Tablets (25 mg; GSK) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647751||158298|
NCT00648219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLME-0575|Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg|Single-Dose Fed In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|December 2005|January 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648219||158263|
NCT00648232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077512|HIV Counseling and Testing and Linkage to Care in Uganda|HIV Counseling and Testing and Linkage to Care in Uganda||University of California, Los Angeles|Yes|Completed|May 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|3415|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00648232||158262|
NCT00649181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METO-0361|Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (5 mg; Mylan) and Zaroloxyn® Tablets (5 mg; Celltech) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649181||158190|
NCT00649194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RABE-0340|Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg|Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Delayed-Release Tablets (20 mg; Mylan) to Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|August 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00649194||158189|
NCT00654511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3502|Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy|Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy.|DexT&A|Children's Research Institute|Yes|Completed|January 2005|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|101|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||March 2011|March 28, 2011|April 3, 2008||No||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00654511||157783|
NCT00654758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M200-1211|A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of Volociximab (M200) in Combination With Carboplatin and Paclitaxel in Subjects With Previously Untreated Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)||Abbott|Yes|Completed|December 2007|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654758||157764|
NCT00634608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN276200700263P|Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow|Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow||University of Missouri-Columbia|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 1, 2011|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00634608||159300|
NCT00634595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG0717E10A|Trial of E10A in Head and Neck Cancer|A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer||Sun Yat-sen University|Yes|Recruiting|March 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|65 Years|No|||July 2010|July 26, 2010|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00634595||159301|
NCT00634894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0689|Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II, Double-Blinded, Randomized Evaluation of Femara (Letrozole) Versus Placebo for Adjuvant Treatment After Completion of First-Line Chemotherapy for Patients With Optimally Debulked and Chemoresponsive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||M.D. Anderson Cancer Center|Yes|Terminated|March 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|N/A|N/A|No|||September 2009|October 15, 2009|March 6, 2008||No|The drug company sponsor has withdrawn support.|No|September 16, 2009|https://clinicaltrials.gov/show/NCT00634894||159278|
NCT00653497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28-0502-B/C|Effectiveness and Cost-Efficiency of Aquatic Exercise for Management of Osteoarthritis|Effectiveness and Cost-Efficiency of Aquatic Exercise for Management of Osteoarthritis||University of Washington||Completed|March 1997|June 1998|Actual|June 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|249|||Both|55 Years|75 Years|No|||April 2008|April 1, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653497||157861|
NCT00653848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPCG-13|Treatment of Prostate Cancer With Docetaxel + Hormonal Treatment Versus Hormonal Treatment in Patients Treated With Radical Radiotherapy|Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-risk Prostate Cancer Treated With Radical Radiotherapy|AdRad|Scandinavian Prostate Cancer Group|Yes|Active, not recruiting|May 2007|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|378|||Male|18 Years|75 Years|No|||April 2008|November 18, 2014|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653848||157834|
NCT00654108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0052|Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled Dose Escalation, Inpatient Phase I Study to Determine the Safety and Immunogenicity of a Single Oral Dose of a Combined Live, Attenuated, Enterotoxigenic Escherichia Coli (ETEC)-Cholera Vaccine (Peru-15 pCTB) in Healthy Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2008|December 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|62|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 3, 2011|April 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00654108||157814|
NCT00654121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVDM IT 001|Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives|Prevention of Clinical Onset of Type 1 Diabetes by Daily Administration of Metabolically Active Insulin in High Risk First Degree Relatives.||AZ-VUB|No|Completed|February 2000|November 2007|Actual|April 2004|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|112|||Both|5 Years|39 Years|Accepts Healthy Volunteers|||April 2008|April 4, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654121||157813|
NCT00654446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0099|IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin|A 6-wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study, Which Describes the Renal Effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the Treatment of Sub's With Fredrickson Type IIa & Type IIb Dyslipidaemia, Inc. Heterozygous Familial Hypercholesterolaemia||AstraZeneca||Completed|September 2002|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||442|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654446||157788|
NCT00654459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARM 02-07|Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function|Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function||Federico II University|Yes|Completed|July 2007|April 2008|Actual|January 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|70 Years|No|Probability Sample|males and females aged between 18 and 70 with hypercholesterolemya|April 2008|April 14, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654459||157787|
NCT00646191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-529|Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Multicenter Extension Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis||Abbott|No|Completed|March 2003|||June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|137|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646191||158416|
NCT00646165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-110|Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia|Phase 1, Multicentre, Open-label, Dose Finding Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia||Mundipharma Research Limited||Terminated|July 2008|May 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|N/A|No|||March 2010|March 30, 2010|March 26, 2008||No|Poor recruitment and change in development strategy|No||https://clinicaltrials.gov/show/NCT00646165||158418|
NCT00655473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC21153|A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease|A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors||Hoffmann-La Roche||Completed|March 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655473||157709|
NCT00655486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0926|Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures|A Multicenter, Open-label Extension Trial to Assess the Long-term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects With Partial-onset Seizures||UCB Pharma|No|Completed|April 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|16 Years|60 Years|No|||March 2015|March 10, 2015|March 26, 2008|Yes|Yes||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00655486||157708|
NCT00646737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ABR02|Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant|Phase IV Study of Enteric-coated Mycophenolate Sodium in Combination With Tacrolimus in Renal Transplant Patient||Novartis||Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||May 2012|May 7, 2012|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00646737||158374|
NCT00646750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELTAMO-Z-BEAM LDGGB|Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom|Autologous Transplantation of Haematopoietic Stem Cells With Conditioning Including Zevalin + BEAM to Patients Suffering From Refractory Large B-cell Diffuse Lymphom|Z-BEAM LDGGB|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Completed|January 2008|June 2012|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00646750||158373|
NCT00647075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YUNZHI-BC|Yunzhi as Dietary Supplement in Breast Cancer|A Randomized, Parallel, Double-blind, Placebo-controlled, Pilot Clinical Study on the Effects of Yunzhi as Dietary Supplement in 60 Adult Patients Undergoing Adjuvant/Neoadjuvant Chemotherapy for Breast Cancer.|YUNZHI-BC|Hospital Clinic of Barcelona|No|Recruiting|November 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||March 2010|December 14, 2010|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647075||158350|
NCT00647361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK BE 217-06|Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects on Cardiac Performance|Short Term Effects of Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation on Cardiac Performance||University Hospital Inselspital, Berne|No|Completed|March 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|85 Years|No|||July 2011|July 18, 2011|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00647361||158328|
NCT00647374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETTA001-HMO-CTIL|Assessment of Cortical Plasticity Following Short Term Limb Immobility|Assessment of Cortical Plasticity Following Short Term Limb Immobility||Hadassah Medical Organization||Suspended|May 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|75 Years|No|Non-Probability Sample|patients with wristfracture|February 2010|March 1, 2010|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647374||158327|
NCT00647764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1311003|Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas|Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas||Esanex Inc.|No|Completed|March 2008|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647764||158297|
NCT00647777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLAN-0333|Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Olanzapine Tablets (5 mg; Mylan) and Zyprexa® Tablets (5 mg; Eli Lilly) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|June 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647777||158296|
NCT00648180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOXY-0537|Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Doxycycline Monohydrate Tablets (100 mg; Mylan) and Adoxa Tablets (100 mg; Par) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|July 2005|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648180||158266|
NCT00654173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522US/0003|Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)|A 12-Week, Randomized, Open-Label, 3 Arm Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin Achieving NCEP ATP III LDL-C Goals in High Risk Subjects With Hypercholesterolaemia in the Managed Care Setting.|SOLAR|AstraZeneca|No|Completed|June 2002|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4444|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654173||157809|
NCT00654186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-PCA-PI-327|Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients|A Phase II Study Evaluating the Toxicity and Efficacy of Single Agent Lenalidomide (Revlimid®) in Chemotherapy-Naïve Androgen-Independent Prostate Cancer Patients||Oncology Specialists, S.C.|No|Completed|February 2008|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Male|18 Years|N/A|No|||February 2014|February 28, 2014|April 2, 2008|No|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT00654186||157808|
NCT00648726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661104|An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia|An Open, Prospective, Randomized, Multi-Center Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin vs. Cefuroxime Monotherapy or Plus Oral Erythromycin for the Treatment of Chinese Hospitalized Patients With Community- Acquired Pneumonia||Pfizer|No|Completed|January 2003|August 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|139|||Both|18 Years|70 Years|No|||March 2008|March 27, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00648726||158224|
NCT00654199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507007970|Ventricular Asynchrony in Cardiac Surgery Patients|Ventricular Asynchrony in Cardiac Surgery Patients||Weill Medical College of Cornell University|No|Completed|May 2006|October 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatient population|March 2012|March 7, 2012|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00654199||157807|
NCT00655018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITENAFLD|Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)|Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial|VITENAFLD|Bambino Gesù Hospital and Research Institute|Yes|Completed|January 2003|October 2006|Actual|October 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|3 Years|20 Years|No|||March 2008|April 8, 2008|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655018||157744|
NCT00655031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A004|Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection|A Placebo Controlled, Randomized, Double Blind Pilot Study to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection in Human Subjects||POM Wonderful LLC|No|Completed|April 2008|July 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 14, 2008|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655031||157743|
NCT00655304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFPROM-001|The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure|The Effect of Prometheus (R) Liver Support Dialysis on Intracranial Pressure, Cerebral Oxidative Metabolism and Hemodynamics in Patients With Acute Liver Failure||Rigshospitalet, Denmark|No|Completed|March 2007|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||July 2010|July 26, 2011|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655304||157722|
NCT00634634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040706|Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer|Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer||Rutgers, The State University of New Jersey|No|Active, not recruiting|August 2008|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||November 2015|November 5, 2015|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634634||159298|
NCT00634946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6603/1021|SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation|A Multicenter, Randomized, Double-blind Recommended Dose-finding Study of SI-6603 in Patients With Lumbar Disc Herniation (Phase II/III Study)||Seikagaku Corporation||Completed|January 2008|August 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|195|||Both|20 Years|70 Years|No|||March 2011|March 29, 2011|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00634946||159274|
NCT00653185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-SYR-472-007|Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes||Takeda|No|Completed|May 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|369|||Both|18 Years|80 Years|No|||May 2012|May 18, 2012|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653185||157884|
NCT00653198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104676|Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama|Hospital-based, Case-control Study to Assess the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 March 2006 and at Least 12 Weeks of Age, in Panama||GlaxoSmithKline||Completed|March 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|885|Samples With DNA|Stool samples|Both|12 Weeks|N/A|No|Probability Sample|Cases will include those children born after 1 March 2006, at least 12 weeks of age and        hospitalised for RV SGE in the study hospital, during the designated study period. For        each case, three hospital controls and three neighbourhood controls will be included in        the study, after matching by date of birth. Hospital controls will be children        hospitalised for non-GE causes in the study hospital during the same time period as the        case. Neighbourhood controls will be children without any symptoms of GE or SGE, and        residing in the same area as the case at least for three consecutive months.|March 2011|March 17, 2011|March 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653198||157883|
NCT00653211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2008|||||N/A|N/A|N/A||||||||||||||April 14, 2015|March 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653211||157882|
NCT00653510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK-M20070267|The Metabolic Effects of Acute Hyperglycemia in Patients With Type 2 Diabetes|The Effect of Acute Hyperglycemia on Cardiac Output, Amino Acid, Lipid and Glucose Metabolism in Patients With Type 2 Diabetes||University of Aarhus|No|Completed|March 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00653510||157860|
NCT00653523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05457|Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)|Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors||Merck Sharp & Dohme Corp.|No|Completed|December 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|20 Years|N/A|No|||June 2015|June 9, 2015|April 1, 2008|No|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00653523||157859|
NCT00653861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JULIDO-001|Safety and Effectiveness of JUVÉDERM™ Injectable Gel With Lidocaine|||Allergan|Yes|Completed|April 2008|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|October 6, 2014|April 2, 2008|Yes|Yes||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00653861||157833|
NCT00654134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2844 GCRC 2311|Inhalation of 20,000 Endotoxin Units(EU) of Clinical Center Reference Endotoxin in Healthy Volunteers|Inhalation of 20,000 EU of Clinical Center Reference Endotoxin in Healthy Volunteers|Entox|University of North Carolina, Chapel Hill|No|Completed|October 2005|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00654134||157812|
NCT00654719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|372/2000|Enteral Nutrition in Congestive Heart Failure and Cardiac Cachexia|The Influence of Enteral Nutrition on Functional Status and Inflammatory Activation in Patients With Congestive Heart Failure and Cardiac Cachexia.||National Heart and Lung Institute|Yes|Completed|April 2001|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||April 2008|April 3, 2008|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654719||157767|
NCT00645554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002848|A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers|A Bioequivalent Study to Compare Galantamine Oral Solution With Marketed Galantamine Capsule After Single Oral Administration of 10 mg.||Xian-Janssen Pharmaceutical Ltd.||Completed||September 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|2|||Male|18 Years|48 Years|Accepts Healthy Volunteers|||March 2010|May 18, 2011|March 24, 2008||||No||https://clinicaltrials.gov/show/NCT00645554||158465|
NCT00646451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-19086|Pregabalin in the Treatment of Essential Tremor|A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor||Baylor College of Medicine|No|Completed|June 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||November 2015|November 4, 2015|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646451||158396|
NCT00646438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USCDP|United States Coronary Artery Bypass Surgery (CABG) Diabetes Project (USCDP) Pilot Study|United States CABG Diabetes Project (USCDP) Pilot Study|USCDP|Providence Heart & Vascular Institute|No|Not yet recruiting|March 2009|December 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2008|February 3, 2009|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646438||158397|
NCT00646412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0602|A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group|A Prospective, Randomised, Controlled, Single-blind Phase I-II Clinical Trial on the Safety of A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group|A-PART|Aesculap AG|No|Completed|July 2008|August 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646412||158399|
NCT00646425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSX-003|The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis|Randomized, Double-Masked, Placebo-controlled Evaluation of the Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis Who Undergo Tapering of Concomitant Immunosuppressive Medications|BSX-003|Cerimon Pharmaceuticals|No|Terminated|May 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|12 Years|80 Years|No|||August 2010|August 17, 2010|March 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00646425||158398|
NCT00647088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070141|Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications|Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications|GENERAC|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2200|Samples With DNA|blood samples DNA Tissue valve|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|case control study Case = patients with aortic valve stenosis Controls = participants free        of aortic valve stenosis|February 2016|February 24, 2016|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00647088||158349|
NCT00647387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGA-016|Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study||VPA|St. Jude Medical|Yes|Recruiting|March 2008|September 2023|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||February 2016|February 11, 2016|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647387||158326|
NCT00647400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-702|Adalimumab in Adult Japanese Subjects With Psoriasis|A Multicenter Open-Label Continuation Study of the Long-term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis||Abbott||Completed|April 2006|April 2010|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|20 Years|N/A|No|||April 2011|April 1, 2011|March 27, 2008||No||No|December 4, 2009|https://clinicaltrials.gov/show/NCT00647400||158325|
NCT00647790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-088|Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer|PET Using Hormone Receptor Ligands in Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|November 2006|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|79|Samples Without DNA|Serum blood sample postimaging, Serum Estradiol (female only)|Both|18 Years|N/A|No|Non-Probability Sample|Breast Clinic|August 2015|August 12, 2015|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00647790||158295|
NCT00647816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRPL-05115|Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg|Single-Dose Fasting Bioequivalence Study of Propranolol Hydrochloride Extended-Release Capsules (160 mg; Mylan) and Inderal® LA Capsules (160 mg; Wyeth) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|September 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00647816||158294|
NCT00654524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8664L0001|Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis|A Randomized Study Comparing Goserelin or Expectant Management Following Laparoscopic Surgery for Advanced Endometriosis||Zhejiang University|Yes|Recruiting|March 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|40 Years|No|||September 2008|March 14, 2011|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654524||157782|
NCT00654550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEX-OCU-001|A Study to Assess the Safety, Tolerability and Effect of Nexagon™ Applied to the Eye After PRK Laser Eye Surgery for Nearsightedness|A Phase 1 Randomized, Prospective, Double-Masked, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Subjects Following Bilateral Photorefractive Keratectomy (PRK) for the Correction of Mild to Moderate Myopia.||CoDa Therapeutics Inc.|No|Completed|April 2008|December 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|50 Years|No|||January 2009|January 6, 2009|April 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00654550||157780|
NCT00654771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502110|Comparison of Catheterized and Clean Catch Urine Specimens for Protein/Creatinine Ratio in Preeclampsia Evaluation|Prospective Comparison of Catheterized and Clean Catch Urine Specimens for Determination of Protein/Creatinine Ratio in Evaluation of Preeclampsia|UPREE|University of Pittsburgh|No|Completed|July 2005|June 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|76|||Female|14 Years|50 Years|No|Non-Probability Sample|Any pregnant woman between the ages of 14 - 50 who is being evaluated for preeclampsia is        eligible for this study.|August 2012|August 14, 2012|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654771||157763|
NCT00655044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3514|Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes|Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus|PREDICTIVE™|Novo Nordisk A/S|No|Completed|May 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|3637|||Both|18 Years|N/A|No|Non-Probability Sample|Type 1 and type 2 diabetes patients|November 2012|August 13, 2014|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655044||157742|
NCT00655057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH070753|Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression|SPECT Brain Imaging as a Bio-Marker of Major Depression||University of Pennsylvania|Yes|Completed|October 2005|December 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|April 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655057||157741|
NCT00655070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1644-31803-02|Effect of Timi3 Ultrasound on Myocardial Blow Flow in the Hibernating Myocardium|Evaluation of the Effect of T3US on Myocardial Blow Flow in the Hibernating||University of California, San Francisco|No|Terminated|April 2008|December 2010|Actual|April 2010|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655070||157740|
NCT00655317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009410|Acupuncture and Post-Operative Ileus|Acupuncture and Post-Operative Ileus: A Prospective Randomized Study to Evaluate the Effects of Electrostimulated Acupuncture on Recovery From Ileus Following Standard Elective Colon Surgery||Mayo Clinic|No|Completed|August 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|107|||Both|18 Years|89 Years|No|||March 2011|March 10, 2011|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655317||157721|
NCT00625664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6668|Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer|Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer|CILAB|Sanofi||Completed|February 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|337|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625664||159974|
NCT00625677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sched2|Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life|A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life|Sched2|Public Health England|No|Completed|February 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|130|||Both|7 Weeks|12 Weeks|Accepts Healthy Volunteers|||September 2010|September 1, 2010|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625677||159973|
NCT00653224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00431|A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis||UCB Pharma|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|580|||Both|18 Years|65 Years|No|||December 2009|August 29, 2011|April 1, 2008|Yes|Yes||No|July 28, 2009|https://clinicaltrials.gov/show/NCT00653224||157881|
NCT00653536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08-010|A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke|Feasibility and Safety of NeuroFlo™ in Patients With Persistent Arterial Occlusion (PAO) After Failed Mechanical Revascularization|PAO|University of California, Los Angeles|Yes|Withdrawn|March 2008|June 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|April 2, 2008|No|Yes|No Patients enrolled; sponsor not providing devices anymore|No||https://clinicaltrials.gov/show/NCT00653536||157858|
NCT00654472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OY1975|Mitral Valve Area Assessment: Comparison With Transthoracic Echocardiography and Magnetic Resonance Imaging|Quantification of Rheumatic Mitral Stenosis With Cardiac Magnetic Resonance Imaging and Comparison With Transthoracic Echocardiography||Florence Nightingale Hospital, Istanbul|Yes|Recruiting|April 2008|June 2008|Anticipated|June 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|||Both|20 Years|65 Years|No|Non-Probability Sample|tertiary care clinic|April 2008|April 7, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654472||157786|
NCT00645567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6103-R|Biomechanics of Wheelchair Transfers|Evaluation of Transfer Technologies to Preserve Shoulder Function in SCI||VA Office of Research and Development|No|Completed|January 2010|December 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|5|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|A sample of 58 veterans with paraplegia who use a rigid manual wheelchair will be        recruited to participate in this study.|December 2014|December 17, 2014|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00645567||158464|
NCT00645840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW 112007-037|Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes|An Exploratory, Open Label Study of Anti-inflammatory Therapy With Anakinra in Children With Newly Diagnosed Type 1 Diabetes Mellitus||University of Texas Southwestern Medical Center|No|Completed|March 2008|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|6 Years|18 Years|No|||June 2010|June 12, 2012|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645840||158443|
NCT00645853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1250C00042|Long-term Safety in Atrial Fibrillation Patients|Long-term Treatment With the Oral Direct Thrombin Inhibitor AZD0837, Compared to Vitamin-K Antagonists, as Stroke Prevention in Patients With Non-valvular Atrial Fibrillation and One or More Risk Factors for Stroke and Systemic Embolic Events. A 5-year Follow-up Study||AstraZeneca|Yes|Completed|October 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|523|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|March 19, 2008|Yes|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00645853||158442|
NCT00646178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-570|Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy|Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy||Abbott||Completed|June 2003|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00646178||158417|
NCT00646776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-360|Drug Interaction Study|Study to Evaluate the Exposure of Rifabutin Administered in an Alternate Regimen in Combination With Atazanavir and Ritonavir Healthy Subjects||Bristol-Myers Squibb|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|March 26, 2008|No|Yes||No|September 3, 2010|https://clinicaltrials.gov/show/NCT00646776||158371|
NCT00646789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0633-019|A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)|A Multicenter, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years||Merck Sharp & Dohme Corp.||Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|March 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00646789||158370|
NCT00646763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007445|A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation|A Phase II Single Institution Randomized Study Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplant||Emory University|Yes|Terminated|April 2008|February 2011|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|March 25, 2008||No|Accrual goal met|No|March 14, 2012|https://clinicaltrials.gov/show/NCT00646763||158372|
NCT00653263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alcohol & Substance Dependence|Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study|Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study||University of Arkansas|Yes|Completed|August 2006|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|65 Years|No|Non-Probability Sample|We will enroll 20 methamphetamine dependent individuals ages 18-65 recruited from those        admitted to the Recovery Centers of Arkansas in North Little Rock.|February 2010|February 22, 2010|April 1, 2008||No||No|October 22, 2009|https://clinicaltrials.gov/show/NCT00653263||157878|The small sample size (N=6) is a significant limitation of the current study.
NCT00653601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014008|Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery|Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery||Cedars-Sinai Medical Center|No|Recruiting|April 2008|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|2 mL of blood for testing X 5 per patient|Both|18 Years|N/A|No|Non-Probability Sample|Patients' with BMS/DES on plavix prior to surgery who are in need of an elective        procedures|September 2009|September 3, 2009|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653601||157853|
NCT00653913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03962|Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)|Evaluation of Potential for Pharmacokinetic Drug Interaction Between SCH 58235 and Pitavastatin||Merck Sharp & Dohme Corp.|No|Completed|March 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00653913||157829|
NCT00654563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12126|Memory Disorders Registry|Memory Disorders Registry||Cedars-Sinai Medical Center|No|Completed|August 2007|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|The main Memory Disorders Registry only involves records-keeping to follow subjects' care,      and does not involve any biospecimen collection. The optional postmortem exam (brain-only      autopsy) obtains brain tissue, and it would be performed after death, so that no risks will      impact the subject involved in the postmortem examination. With regard to cosmetic concerns,      the incision is made from ear to ear through the neck region, leaving no disfiguration. The      postmortem exam is not a genetic screen, but in rare instances it might find brain atrophy,      although no specific inclusions. If found, the subject's family would be informed of this      finding.|Both|18 Years|N/A|No|Non-Probability Sample|The Registry's study population will consist of private patients of Dr. Robert Cohen who        have been diagnosed with a Memory Disorder or who are referred to him due to subjective        reports of having a memory problem.|March 2012|March 26, 2012|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654563||157779|
NCT00654784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-II-001|Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy|A Phase IIa Double Blind, Randomised, Placebo Controlled, Single Centre Study at the University of Leuven to Assess the Efficacy and Tolerability of Idebenone in 8 - 16 Year Old Males With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy|DELPHI|Santhera Pharmaceuticals|No|Completed|October 2005|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Male|8 Years|16 Years|No|||July 2011|July 29, 2011|April 3, 2008||||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00654784||157762|
NCT00655330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPH200603 -1|Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy|A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy||Guangdong General Hospital|Yes|Recruiting|May 2008|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|30 Years|70 Years|No|||February 2016|February 18, 2016|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00655330||157720|
NCT00655343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-AS-21-DE|Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)|GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S||Neovii Biotech|Yes|Completed|February 2003|March 2009|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|202|||Both|18 Years|60 Years|No|||December 2011|December 9, 2011|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655343||157719|
NCT00655590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11520|Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function|A Randomized, Double-blind, Placebo Controlled, Parallel Arm, Multicenter Trial Assessing the Effect of Daily Treatment of Vardenafil 20 mg or Sildenafil 100 mg Compared to Placebo on Spermatogenesis||Bayer||Completed|January 2005|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|200|||Male|25 Years|64 Years|Accepts Healthy Volunteers|||December 2014|December 26, 2014|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655590||157700|
NCT00655603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2007-0072|Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus|Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of GLP-1 in Patients With Type 2 Diabetes Mellitus.||University Hospital, Gentofte, Copenhagen|No|Enrolling by invitation|March 2008|September 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2009|April 3, 2009|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655603||157699|
NCT00626288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS|Mesalazine Therapy in Patients With Irritable Bowel Syndrome|A Randomised Controlled Multicenter Trial Assessing the Efficacy and Safety of Mesalazine Therapy in Patients With Irritable Bowel Syndrome.|IBS-02/07|SOFAR S.p.A.|No|Completed|December 2007|July 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|65 Years|No|||July 2013|July 25, 2013|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626288||159927|
NCT00626301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 077|Lopinavir/Ritonavir Monotherapy in Children|Simplifying Antiretroviral Treatment in Virally Suppressed Children by Switching From Double Boosted Protease Inhibitors to Lopinavir/Ritonavir Monotherapy||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|2 Years|18 Years|No|||March 2015|March 25, 2015|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626301||159926|
NCT00653874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|neoaiims2007|Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates|Routine Use of Transcutaneous Bilirubinometry Reduces the Need for Blood Sampling in Neonates With Jaundice||All India Institute of Medical Sciences, New Delhi|No|Completed|November 2006|August 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|617|||Both|N/A|168 Hours|No|||April 2008|April 4, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653874||157832|
NCT00654147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A009|Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects|A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects|HIV|University of Miami|Yes|Completed|April 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||July 2015|July 11, 2015|April 2, 2008||No||No|January 20, 2015|https://clinicaltrials.gov/show/NCT00654147||157811|Pilot study with 44 subjects and generalization f results is limited by the small sample size.
NCT00651235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200610030M|A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome|A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome|MFS|National Taiwan University Hospital|Yes|Recruiting|February 2007|June 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Both|1 Year|N/A|No|||June 2010|June 8, 2010|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651235||158032|
NCT00645866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582618|Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer|A Neo-Adjuvant Study of Sequential Epirubicin and Docetaxel in Combination With Capecitabine in Patients With Locally Advanced Breast Cancer||Mayo Clinic|Yes|Completed|April 2003|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|47|||Female|18 Years|N/A|No|||May 2011|May 13, 2011|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645866||158441|
NCT00645879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24806|Anaplerotic Therapy in Propionic Acidemia|Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia.||University of Utah|Yes|Completed|July 2008|February 2010|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|5 Years|12 Years|No|||January 2015|January 17, 2015|March 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00645879||158440|
NCT00651664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14002|A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies|A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies||Millennium Pharmaceuticals, Inc.|No|Completed|October 2007|January 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651664||157999|
NCT00646204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18912|Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease|A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE||Baylor College of Medicine|No|Completed|April 2006|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||April 2009|April 30, 2009|December 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00646204||158415|
NCT00646217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05555585Z|Self Care TALK Study - Promoting Stroke Caregiver Health|Promoting Stroke Caregiver Health Vis Self Care TALK: Education and Support Telephone Partnerships With Nurses||University of Kansas Medical Center|No|Completed|July 2005|February 2010|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39|||Both|55 Years|N/A|No|||March 2012|March 5, 2012|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00646217||158414|
NCT00652184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARYS-0701|Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)|Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older||aRigen Pharmaceuticals, Inc.|No|Active, not recruiting|March 2008|September 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||October 2008|October 3, 2008|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652184||157959|
NCT00652197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-HYDRO-1A-H|Monitoring Patient Cerebro-Spinal Fluid Drainage With an Ultrasonic Flow Sensor|A Flow Monitor for Pediatric Hydrocephalic Shunts - Flow Sensor Study||Transonic Systems Inc.|No|Enrolling by invitation|March 2009|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|15|||Both|N/A|20 Years|No|Non-Probability Sample|Pediatric hydrocephalus patients under the care of the Children's Hospital of Wisconsin.|June 2012|June 4, 2012|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652197||157958|
NCT00652210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506007919|Use of Multiphoton Microscopy in the Diagnosis of Cancer|Use of Multiphoton Microscopy in the Diagnosis of Cancer|MPM|Weill Medical College of Cornell University|No|Completed|June 2005|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|344|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652210||157957|
NCT00652561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1203|Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer|An Open-Label, Non-Randomized, Multicenter, Three Stage, Phase 2 Study of S-1 as 2nd Line Therapy for Patients With Advanced Non-Small Cell Lung Cancer (Stage IIIB/Stage IV)||Taiho Oncology, Inc.|No|Completed|February 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652561||157931|
NCT00652574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0935|Dasatinib in Resectable Malignant Pleural Mesothelioma|Phase I Trial of Induction Dasatinib Therapy in Patients With Resectable Malignant Pleural Mesothelioma||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2008|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|March 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652574||157930|
NCT00652899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS138|Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer|MT2007-19R: WCC #53 Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer||Masonic Cancer Center, University of Minnesota|Yes|Terminated|March 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|April 3, 2008|Yes|Yes|Withdrawn due to toxicity|No|August 20, 2010|https://clinicaltrials.gov/show/NCT00652899||157905|Endpoint for association of clinical benefit response with donor/recipient KIR ligand matching status is not evaluable due to 0 complete responders.Correlative laboratory objectives are irrelevant due to ineffectiveness of study regimen.
NCT00652912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B043204|Bioavailability Study of Clonazepam ODT Under Fasting Conditions|Comparative, Randomized, Single-Dose, Bioavailability Study of Kali's Clonazepam ODT 1 mg With That of Klonopin Wafers 1 mg ODT in Healthy Adult Subjects Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|March 2004|May 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652912||157904|
NCT00652925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N49-01-02-195|A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA|Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA||Pfizer|Yes|Completed|October 2002|April 2005|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|2 Years|18 Years|No|||April 2008|May 29, 2008|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652925||157903|
NCT00653276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-057|MD Ezetimibe Cyclosporine Interaction (0653-057)|An Open-Label, 2-Period, Crossover Study to Determine the Effect of Multiple Oral Doses of Ezetimibe 20 mg on the Pharmacokinetics of a Single Oral Dose of Cyclosporine in Young, Healthy, Normal, Male and Female Subjects||Merck Sharp & Dohme Corp.||Completed|November 2003|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653276||157877|
NCT00653614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91765|Cycle Control and Safety of E2-DRSP|A Multi-center, Double-blind, Randomized, Parallel-group Study to Evaluate Cycle Control and Safety of 6 Different Regimens of an Oral Contraceptive Containing Estradiol and Drospirenone in Healthy Female Volunteers Aged Between 18 and 35 Years Over 7 Cycles||Bayer|No|Completed|March 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|635|||Female|18 Years|35 Years|No|||April 2015|April 21, 2015|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653614||157852|
NCT00653627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB015|A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination|A Human Pilot Study to Quantify BCG From the BCG Vaccination Site, and to More Fully Characterise the Immune Response to BCG||University of Oxford|Yes|Completed|August 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 30, 2010|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653627||157851|
NCT00653640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-367|Physical Work Capacity After Traumatic Brain Injury|Physical Work Capacity After Traumatic Brain Injury||The University of Texas Medical Branch, Galveston|No|Completed|May 2006|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|60 Years|No|||June 2012|June 19, 2012|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653640||157850|
NCT00653926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAK-mini|Local Infiltration Analgesia Following Unicompartmental Knee Arthroplasty|Local Infiltration Analgesia (LIA) With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Unicompartmental Knee Arthroplasty||University Hospital Orebro|Yes|Completed|September 2005|September 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||April 2008|April 4, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653926||157828|
NCT00654212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shan|Endo-Laparoscopic Approach Versus Conventional Open Surgery in Obstructing Left-sided Colon Cancer: RCT|Endo-Laparoscopic Approach Versus Conventional Open Surgery in the Management of Obstructing Left-sided Colon Cancer: A Randomized Trial||Pamela Youde Nethersole Eastern Hospital|Yes|Completed|January 2002|December 2007|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||May 2015|May 3, 2015|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654212||157806|
NCT00654225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522US/0006|Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)|A 6-Week, Randomized,Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in South Asian Subjects.|IRIS|AstraZeneca||Completed|October 2002|March 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2340|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654225||157805|
NCT00655083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIC 02|A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants|Pilot Study to Evaluate the Oral Absorption, Safety, and Tolerability of Nepadutant Administered as Single Oral Doses to Infants With Colic and Other Functional Gastrointestinal Disorders||Menarini Group|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|6 Weeks|24 Weeks|No|||October 2011|October 11, 2011|April 3, 2008|No|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00655083||157739|No infants aged 18-24 weeks were dosed at 0.5 mg/kg dose when the trial was stopped because of slow recruitment and drug expiration.
NCT00655356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-R-006|Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles|||Fibrocell Technologies, Inc.|No|Completed|November 2006|May 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|March 31, 2008|Yes|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00655356||157718|
NCT00655616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sm2006msd01|Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics|A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype||University of Dundee|Yes|Completed|August 2007|December 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|5 Years|18 Years|No|||February 2009|March 23, 2011|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655616||157698|
NCT00655876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0436|Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer|A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery||Radiation Therapy Oncology Group|Yes|Active, not recruiting|June 2008|||August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|74 Years|No|||March 2015|March 31, 2015|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655876||157679|
NCT00626314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDAM06-5|Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Trial to Assess the Efficacy, Safety and Tolerability of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Myocardium, Using an Endomyocardial Delivery System|CAuSMIc II|Mytogen, Inc.||Not yet recruiting|March 2008|August 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|165|||Both|21 Years|75 Years|No|||February 2008|February 28, 2008|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626314||159925|
NCT00626327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P21|Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers|A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers||Novartis||Completed|February 2008|October 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1630|||Both|7 Months|1 Year|Accepts Healthy Volunteers|||April 2013|April 12, 2013|February 20, 2008|Yes|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT00626327||159924|
NCT00650572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-380-101|A Study of ARRY-380 in Patients With Advanced HER2+ Cancer|||Array BioPharma|No|Completed|May 2008|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00650572||158083|
NCT00650884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dynasplint, DYN1-08-022|Plantar Fasciitis Treated With Dynamic Splinting|Plantar Fasciopathy Treated With Dynamic Splinting: A Randomized, Controlled, Cross-Over Study||Dynasplint Systems, Inc.|Yes|Completed|February 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00650884||158059|
NCT00651222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-PB|Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy|Influence of Androgen Suppression Therapy for Prostate Cancer on the Timing and Onset of Fatal Myocardial Infarctions in Men Undergoing Prostate Brachytherapy||Prostate Cancer Foundation of Chicago|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Male|N/A|N/A|No|Non-Probability Sample|Prostate cancer patients treated with prostate brachytherapy at an ambulatory surgery        center|March 2008|March 31, 2008|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651222||158033|
NCT00645580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-3-08|Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function|Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function||Sha’ar Menashe Mental Health Center|No|Active, not recruiting|April 2008|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||March 2008|February 18, 2009|March 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645580||158463|
NCT00645593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.097|Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer|Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma||University of Michigan Cancer Center|Yes|Completed|March 2008|June 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|March 24, 2008|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT00645593||158462|
NCT00651911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8637|Fasturtec TLS Treatment / Prophylysis|A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome||Sanofi||Completed|July 2003|July 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|45|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00651911||157980|
NCT00652223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT005-AllQbG10 01|Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy|Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (AllQbG10) in Subjects With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy||Cytos Biotechnology AG|No|Completed|March 2005|November 2005|Actual|||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|55 Years|No|||April 2008|April 4, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652223||157956|
NCT00652236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405340-111500|Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain|Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain. Three-Year Follow up of a Randomized Trial||Klinik Valens|No|Terminated|January 2006|February 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|174|||Both|20 Years|55 Years|No|Non-Probability Sample|Tertiary rehabilitaton centre|March 2008|March 31, 2008|March 27, 2008||No|Study was terminated according the study protocol end of 2007|No||https://clinicaltrials.gov/show/NCT00652236||157955|
NCT00652587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC_001|Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma|A Randomized Controlled Trial of Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Hepatectomy Alone for Stage IIIA Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Completed|January 2002|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|70 Years|No|||March 2008|March 31, 2008|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652587||157929|
NCT00652600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50233|Bioavailability Study of Propranolol Under Fed Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fed Conditions.||Par Pharmaceutical, Inc.|No|Completed|September 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652600||157928|
NCT00652964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801064R|PHOX2B Mutation-Confirmed Congenital Central Hypoventilation Syndrome in A Chinese Family: Presentations From Newborn to Adulthood|PHOX2B Mutation-Confirmed Congenital Central Hypoventilation Syndrome in A Chinese Family: Presentations From Newborn to Adulthood||National Taiwan University Hospital|Yes|Recruiting|September 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|N/A|N/A|No|Probability Sample|A Chinese family of CCHS with presentations from newborn to adulthood and genetic analysis        confirming the PHOX2B mutation was analyzed. After identifying central hypoventilation in        an adult male (index case), clinical evaluation was performed on the complete family,        which consisted of the parents, five siblings, and five offsprings. In addition, pulmonary        function test, overnight polysomnography, arterial blood gas, and hypercapnia ventilatory        response, and genetic screening for PHOX2B gene mutations were performed on living family        members.|November 2012|November 6, 2012|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652964||157900|
NCT00652977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lu1-99|Ritgens Maneuver for the Prevention of Anal Sphincter Tears at Delivery: A Randomized Controlled Trial|Modified Ritgens Maneuver for Perineal Protection at Delivery||Lund University Hospital|No|Completed|December 1999|July 2001|Actual|July 2001|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1623|||Female|16 Years|44 Years|No|||April 2008|April 4, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652977||157899|
NCT00652938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111507|Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine (580299) Co-administrated With a Commercially Available Vaccine in Healthy Female Adolescents||GlaxoSmithKline||Completed|April 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|744|||Female|9 Years|15 Years|Accepts Healthy Volunteers|||April 2013|December 19, 2013|March 27, 2008|Yes|Yes||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00652938||157902|
NCT00652951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110142|Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib|Non-inferiority of Co-administration of GSK Biologicals'Pneumococcal Conjugate Vaccine GSK1024850A With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib.||GlaxoSmithKline||Completed|April 2008|December 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|780|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||October 2011|November 17, 2011|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652951||157901|
NCT00653653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AW_SH_08|Medication Optimisation for Reducing Events in a Private Practice Setting|Observational Study of the Pharmaco-Economic and Medical Effects of Optimising Medication Using Pharmacokinetic Pharmacogenomics and Medication Interaction Analysis in Private Practice.|MORE|Awenydd GmbH|Yes|Active, not recruiting|August 2008|October 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample.|April 2009|April 7, 2009|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653653||157849|
NCT00653666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC1029 (completed)|Metabolic Consequences of CPT-1 Deficiency|Metabolic Consequences of CPT1A Deficiency in Alaska Native Children||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|October 2007|February 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|3 Years|5 Years|No|||February 2010|February 24, 2010|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00653666||157848|
NCT00653939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC401-216|A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer|A Phase II Study to Assess the Safety and Efficacy of the Combination of Carboplatin, Paclitaxel, and Bevacizumab ± Combretastatin A4 Phosphate (CA4P) Followed by Bevacizumab ± CA4P in Subjects With Chemotherapy Naïve Stage IIIB/IV Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC)|FALCON|OXiGENE|Yes|Completed|March 2008|October 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|March 18, 2008|Yes|Yes||No|January 14, 2015|https://clinicaltrials.gov/show/NCT00653939||157827|
NCT00654238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802861|Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer|Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer||University of Pennsylvania|Yes|Completed|February 2006|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654238||157804|
NCT00654251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0228|Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias|Utility Of Home Based Gait Monitoring, Performance Scores And Functional Visual Assessment In Spinocerebellar Ataxias (SCA)||University of Mississippi Medical Center|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients attending the Ataxia Clinic|April 2009|April 28, 2009|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00654251||157803|
NCT00654537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0065|STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges|A 6 Week Open Label, Dose Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Subjects With Hypercholesterolemia.|STELLAR|AstraZeneca|No|Completed|April 2001|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|5625|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|April 3, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00654537||157781|
NCT00654797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HC-45210-2|Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2|Clinical Process Improvement With A Bedside Computerized Insulin Therapy Protocol For Blood Glucose Control (eProtocol-insulin) in Adult And Pediatric Intensive Care Unit Patients-Second Phase (Phase-2): Distribution and Implementation of Validated eProtocol-insulin in Naïve ICUs||Intermountain Health Care, Inc.|Yes|Recruiting|September 2007|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|1 Month|N/A|No|||February 2015|February 24, 2015|April 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654797||157761|
NCT00654810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0097|Exercise Rehabilitation of Younger and Older People With Claudication|Exercise Rehabilitation of Younger and Older People With Claudication||National Institute on Aging (NIA)|No|Completed|February 1994|January 2000|Actual|January 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|45 Years|90 Years|No|||April 2008|April 7, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00654810||157760|
NCT00655096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080102|Screening for Research Participants|Screening Study for the Evaluation and Diagnosis of Potential Research Participants||National Institutes of Health Clinical Center (CC)||Recruiting|April 2008|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|10000|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|December 2, 2015|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00655096||157738|
NCT00655889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-G-003|Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency|||Fibrocell Technologies, Inc.|No|Completed|January 2006|July 2008|Actual|April 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|70 Years|No|||June 2013|June 4, 2013|April 4, 2008|Yes|Yes||No|June 4, 2013|https://clinicaltrials.gov/show/NCT00655889||157678|This was a small, open-label study without a placebo control, and was not powered to provide statistically significant demonstrations of product efficacy.
NCT00651417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Germanium|Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue|A Phase II, Pilot, Randomized, Double-blind Study Comparing the Effectiveness Organic Germanium to Placebo in Decreasing the Severity of Fatigue in Patients Undergoing Radiation Therapy for Prostae and Bbreast Cancers||Arizona Oncology Services|Yes|Recruiting|April 2005|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|101|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651417||158018|
NCT00651430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor462807ctil|Physical Functioning Following Total Hip Arthroplasty|Step Execution, Stability, Quality of Life, Fear of Falling and Their Association Following Total Hip Arthroplasty||Soroka University Medical Center|No|Completed|March 2008|May 2010|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|None Retained|no biospecimens are to be retained|Both|40 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|30 adults suffer from Hip OA prior THA|December 2007|June 10, 2010|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00651430||158017|
NCT00622635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2340|A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, 3-period, 14-day Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol (300 µg Once Daily [od]) in Patients With Moderate-to-severe COPD, Using Open-label Salmeterol (50 µg Twice Daily [Bis in Die, Bid]) as Active Control||Novartis||Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|68|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 4, 2008|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00622635||160201|
NCT00650897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-06-4426-RG-CTIL|Efficacy Study of Escitalopram for Depression in Patients With Diabetes|Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label|EFDID|Sheba Medical Center|No|Not yet recruiting|April 2008|October 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2008|March 30, 2008|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00650897||158058|
NCT00651248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|renatago|Evaluation of Salivary Flow and Buffer Capacity Associated to Aged People's Oral Health|Evaluation of Salivary Flow and Buffer Capacity Associated to Aged People's Oral Health||Academia Cearense de Odontologia|Yes|Completed|September 2006|August 2007|Actual|||N/A|Observational|Observational Model: Cohort||1|Actual|68|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|68 aged, average 70.4 years, SD ± 7.27 represented institution's residents of long        permanence.|March 2008|March 31, 2008|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651248||158031|
NCT00651261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-10603|Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|April 2008|||October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|59 Years|No|||September 2015|September 15, 2015|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651261||158030|
NCT00656097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-M-A003|A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects|A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects||Crucell Holland BV|No|Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|140|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 15, 2011|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656097||157662|
NCT00651651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0716|Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5|A 12 Week Randomized, Double-blind, Double-Dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Children (at Least 6years of Age) and Adults With Asthma-SPRUCE 80/4.5||AstraZeneca|No|Completed|August 2002|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|6 Years|N/A|No|||January 2011|January 21, 2011|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651651||158000|
NCT00651924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-147|Piloting IVR (Interactive Voice Response) for Chronic Pain Treatment|Piloting Interactive Voice Response Modules for Chronic Pain Treatment||VA Office of Research and Development|No|Completed|December 2008|April 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|27|||Both|18 Years|N/A|No|||June 2014|April 6, 2015|March 31, 2008||No||No|September 17, 2014|https://clinicaltrials.gov/show/NCT00651924||157979|Difficulty recruiting for phase 2 lead to a small number of subjects analyzed.
NCT00652249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-HYDRO-1B-H|Diagnosing Malfunctioning Hydrocephalic Shunt Valves With a Flow Sensor|A Flow Monitor for Pediatric Hydrocephalic Shunts - Study of Flow Sensor With the Shunt Valve||Transonic Systems Inc.|No|Withdrawn|March 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|N/A|20 Years|No|Non-Probability Sample|Pediatric hydrocephalus patients under the care of the Children's Hospital of Wisconsin,        who have had an external ventriculostomy and are instrumented with an Extra-Ventricular        Drainage system.|June 2012|June 4, 2012|March 31, 2008|No|Yes|Due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00652249||157954|
NCT00652626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA PH US 2007 PK006|Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function|A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function|RENAL|Celgene|No|Completed|November 2008|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|31|||Both|18 Years|N/A|No|||August 2013|August 2, 2013|April 1, 2008|No|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00652626||157926|
NCT00652613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&N_3DCRT_IMRT07|Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase II Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) vs Intensity Modulated Radiotherapy (IMRT) for Squamous Cell Carcinoma of the Head and Neck (HNSCC)||Tata Memorial Hospital|Yes|Active, not recruiting|August 2005|August 2009|Anticipated|March 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||April 2008|April 9, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652613||157927|
NCT00653003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-704|Bioavailability Study of Leflunomide Tablets Under Fed Conditions|To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fed Conditions||Par Pharmaceutical, Inc.|No|Completed|December 2003|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|62|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653003||157898|
NCT00653016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002908|An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method|An Open Label Multicentre Study to Evaluate Patient Satisfaction and Preference for the EVRA Transdermal Contraceptive System Compared to Previously Used Contraceptive Method.||Janssen-Ortho Inc., Canada||Completed|October 2002|August 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|405|||Female|18 Years|45 Years|No|||March 2010|March 25, 2010|April 1, 2008||||No||https://clinicaltrials.gov/show/NCT00653016||157897|
NCT00653302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4043|Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)|Assessment of the Phenotype of the Type 2 Diabetic Responders to the First Insulinisation Using Lantus (Insulin Glargine) Plus Glucophage (Metformin) Combination After Failure in OADs Treatment|GALATEE|Sanofi||Completed|April 2003|October 2005|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|30 Years|69 Years|No|||December 2008|December 2, 2008|April 1, 2008||||No||https://clinicaltrials.gov/show/NCT00653302||157876|
NCT00653315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-121|Bioavailability Study of Tramadol/APAP Tablets Under Fasting Conditions|To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|May 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 9, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653315||157875|
NCT00653679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC0001|Exercise and Muscle Protein Signalling|The Impact of Resistance Versus Endurance Exercise on the Muscle Protein Signalling Response||Maastricht University Medical Center|No|Withdrawn|September 2008|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|April 1, 2008||No|A paper on the same topic came out just before we wanted to start our study.|No||https://clinicaltrials.gov/show/NCT00653679||157847|
NCT00653692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9811|Fetal Neurobehavior in Poly-drug Dependent Women|Methadone, Buprenorphine and Fetal Neurobehavior||Johns Hopkins University|No|Completed|May 2007|August 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29|||Female|18 Years|41 Years|No|Non-Probability Sample|Poly drug dependent pregnant women|February 2013|February 20, 2013|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00653692||157846|
NCT00653952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004369|CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|A Phase 3, Randomized, Open-Label, Comparative Study of CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|May 1997|April 2000|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Female|18 Years|N/A|No|||April 2010|April 23, 2010|April 1, 2008|Yes|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00653952||157826|
NCT00654264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29283|Water Immersion in Right-Sided Heart Failure: A Pilot Study|Water Immersion in Right-Sided Heart Failure: A Pilot Study||University of Maryland|Yes|Completed|December 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|13|||Both|18 Years|N/A|No|||October 2011|October 27, 2011|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00654264||157802|
NCT00654277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODO-P2-158|Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 8 mg ODT With That of GlaxoSmithKine's Zofran 8 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|August 2002|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 10, 2008|April 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00654277||157801|
NCT00655369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4251033|A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep|PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of PD 0200390 in Adults With Nonrestorative Sleep||Pfizer|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|306|||Both|18 Years|64 Years|No|||July 2012|July 17, 2012|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655369||157717|
NCT00655629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12094|Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.|Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-dose, Double-blind, Randomized Multi-center Trial||Bayer|No|Completed|April 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|339|||Male|18 Years|N/A|No|||July 2014|July 29, 2014|April 4, 2008|Yes|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00655629||157697|
NCT00651443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-NH-103|Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma|A Phase I, Open Label Study to Evaluate the Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma||Biogen|No|Terminated|August 2008|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2011|January 6, 2011|March 31, 2008|No|Yes|A company's strategic decision to focus on areas whereit believes it can be competitive and    decided to exit Oncology|No||https://clinicaltrials.gov/show/NCT00651443||158016|
NCT00651768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0728|Titratable Dosing in Moderate to Severe Asthmatics|A 52 wk Randomized, Doubleblind, Single Dummy, Parallel Group Multicenter Phase 3 Study Comparing the Long Term Safety of Symbicort pMDI 4x160/4.5mcg Bid to SymbicortpMDI 2x160/4.5mcg Bid & Budesonide HFA pMDI 4x160mcg Bid in Adult and Adolescent Subjects With Asthma||AstraZeneca|No|Completed|August 2003|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|570|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651768||157991|
NCT00651781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nº EudraCT: 2005-004370-24|Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia|A Phase I/II National, Open-label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).||PETHEMA Foundation|Yes|Completed|April 2008|February 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651781||157990|
NCT00626613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REM-TWN-MA5|The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)|Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN)||Jinan Mental Hospital||Active, not recruiting||||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver)|||||||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 29, 2008|February 19, 2008||||No||https://clinicaltrials.gov/show/NCT00626613||159902|
NCT00655538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC21144|A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients|A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents.||Hoffmann-La Roche||Completed|February 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|476|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00655538||157704|
NCT00655824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111752|Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403|An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo||GlaxoSmithKline|No|Terminated|January 2008|March 2013|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|April 4, 2008|Yes|Yes|The clinical development of intravenously administered ofatumumab in RA will no longer be    pursued, so this study was prematurely terminated by the Sponsor.|No|March 26, 2012|https://clinicaltrials.gov/show/NCT00655824||157683|Development of the IV route of ofatumumab (OFA) administration in RA will no longer be pursued. This study was prematurely terminated; OFA treatment was discontinued. Participants could complete only <=7 treatment courses and a follow-up evaluation.
NCT00651677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITT02|Hand Assisted Versus "Pure" Laparoscopic Assisted Proctectomy for Rectal Cancer|A Multicenter Prospective Randomized Study Comparing Hand Assisted Versus "Pure" Laparoscopic Assisted Proctectomy for Rectal Cancer||Weill Medical College of Cornell University|No|Recruiting|April 2011|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651677||157998|
NCT00651690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-065|Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment|||Allergan||Completed|March 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||May 2008|May 23, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651690||157997|
NCT00651937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0601|Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden|Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis||M.D. Anderson Cancer Center|Yes|Completed|March 2008|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|60 Years|N/A|No|||January 2016|January 21, 2016|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651937||157978|
NCT00652639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B043201|Bioavailability Study of Clonazepam Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Kali's Clonazepam Tablets 1 mg With That of Klonopin Tablets 1 mg in Healthy Adult Subjects Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|February 2004|April 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652639||157925|
NCT00653380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99061|Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Comparative Bioavailability Study of Par's and Oclassen's (Monodox) Doxycycline Monohydrate Capsules Administered as 1 x 100 mg Capsule in Healthy Adult Males Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|September 1999|October 1999|Actual|October 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653380||157870|
NCT00653393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0413-001|Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions|To Compare Bioavailability of Kali Tranylcypromine 10mg Tablets to That of Parnate 10 mg Tablets Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|October 2004|December 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653393||157869|
NCT00653029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5406|An fMRI Study of Attention and Effort After Concussion|An fMRI Study of Selective Attention, Working Memory, and Effort After Mild Traumatic Brain Injury||State University of New York - Upstate Medical University|No|Active, not recruiting|October 2006|December 2009|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|20|None Retained|No biospecimens|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Community sample|December 2008|December 1, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653029||157896|
NCT00653354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0513-149|Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Assessment Of The Analgesic Efficacy Of The Dosing Regimen Of Valdecoxib Compared To Placebo Patients In Pain Following Bunionectomy||Pfizer|No|Completed|December 2002|March 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|360|||Both|18 Years|N/A|No|||April 2008|April 7, 2008|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653354||157872|
NCT00653367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-EKPF-2008-01|Evaluation of Chronic Pain After Nerve Section During Thoracotomy|Post Thoracotomy Pain After Nerve Section||Rigshospitalet, Denmark|No|Withdrawn|December 2011|December 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|75 Years|No|||August 2011|February 23, 2012|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653367||157871|
NCT00653328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GYN 0288|Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma|A Phase II Study of Atrasentan (ABT-627) Plus DOXIL in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Serous Papillary Adenocarcinoma Following Platinum + Taxane Therapy||Vanderbilt-Ingram Cancer Center|Yes|Terminated|May 2003|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||May 2012|May 16, 2012|April 3, 2008|Yes|Yes|Abbott (drug manufacturer) discontinued manufacture of ABT-627|No|September 30, 2010|https://clinicaltrials.gov/show/NCT00653328||157874|
NCT00653341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901/4002|Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)|Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or NPH Human Insulin.||Sanofi||Completed|January 2000|October 2001|Actual|October 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|764|||Both|30 Years|70 Years|No|||April 2009|April 17, 2009|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653341||157873|
NCT00654290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55318|Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft|Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft, A Prospective Double-Blind Randomized Study||Shiraz University of Medical Sciences|Yes|Completed|March 2007|February 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|240|||Both|45 Years|70 Years|No|||April 2008|April 4, 2008|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654290||157800|
NCT00654303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0034|OLE Study to Evaluate Safety / Efficacy of ZD4522|ZD4522 Long Term Extension Trial||AstraZeneca||Completed|August 1999|February 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3500|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654303||157799|
NCT00654576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA720A22|Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia|Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia:One-Year Follow up.|ACPIOS|Central South University|Yes|Completed|February 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|16 Years|50 Years|No|||April 2008|April 7, 2008|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654576||157778|
NCT00655109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003-04|A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis|A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis||Greiner, Jack V., OD DO PhD|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||April 2008|April 2, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00655109||157737|
NCT00655122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGMAEI-0042-046|Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study|Double-Blind, Placebo-Controlled, Pilot Study, In Medical Patients With Prophylaxis Of Venous Thromboembolism in Primary Care||Pfizer|No|Terminated|April 2003|December 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|8|||Both|65 Years|N/A|No|||September 2008|September 25, 2008|April 4, 2008||No|See Detailed Description.|No||https://clinicaltrials.gov/show/NCT00655122||157736|
NCT00655642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC 0612369|Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED|A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department.||Vanderbilt University|No|Terminated|March 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|171|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|April 4, 2008|Yes|Yes|Conditional analysis showed observed differences were significantly less than power    calculations|No|March 21, 2011|https://clinicaltrials.gov/show/NCT00655642||157696|Early termination resulted in failure to meet our predetermined sample size.
NCT00655655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0414|Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors|A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors||Mayo Clinic|No|Active, not recruiting|December 2004|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655655||157695|
NCT00655902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B237|Copenhagen Obesity Risk Assessment Study|Copenhagen Obesity Risk Assessment Study - A Double Blind Randomized Dietary Intervention Study Examining the Effect of a High Intake of Trans Fatty Acids on Abdominal Obesity and Risk Markers of Type 2 Diabetes and Cardiovascular Disease.|COBRA|University of Copenhagen|No|Completed|April 2008|March 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||April 2009|April 28, 2011|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655902||157677|
NCT00651794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR024148-01|Improving Teamwork for Neonatal Resuscitation|Improving Teamwork for Neonatal Resuscitation||The University of Texas Health Science Center, Houston|No|Active, not recruiting|June 2007|January 2010|Anticipated|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|104|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|January 7, 2011|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651794||157989|
NCT00652028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-08-01|Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects|A Phase II, Open-Label, Multicenter, Escalating Dose, Study to Determine Pharmacokinetic and Pharmacodynamic Profile of Dexmedetomidine in Pediatric Subjects Ages ≥ 2 Through < 17 Years Old||Hospira, Inc.|Yes|Completed|November 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|69|||Both|2 Years|16 Years|No|||August 2015|August 7, 2015|April 1, 2008|Yes|Yes||No|March 11, 2015|https://clinicaltrials.gov/show/NCT00652028||157971|
NCT00652353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-55-66-PM|Mnemonic for the Ottawa Ankle Rule|Efficacy of a Mnemonic to Improve Knowledge of the Ottawa Ankle and Foot Rules Among Medical Students and Residents; a Randomized Controlled Trial.||St. Justine's Hospital|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|191|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2013|March 18, 2013|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652353||157946|
NCT00622661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS 2059.00|Carbohydrates and Related Biomarkers|A Feeding Study to Examine the Effect of Glycemic Load and Obesity on Cancer Biomarkers|CARB|Fred Hutchinson Cancer Research Center|Yes|Completed|June 2006|July 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|89|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622661||160199|
NCT00655837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG040-0008|Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL|A Phase Ib Study of SGN-40 in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Seattle Genetics, Inc.|No|Completed|April 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655837||157682|
NCT00656110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LID-RLS-RCT-01|Neuroma Injections to Treat Restless Legs Syndrome - RCT|Randomized, Placebo-Controlled Trial of Bilateral 3rd/4th Common Digital Foot Nerve Injections to Treat Restless Legs Syndrome||Lowcountry Infectious Diseases|No|Recruiting|April 2008|December 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2009|March 9, 2009|April 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00656110||157661|
NCT00651326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR12|Androgen Suppression Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With High-Risk Localized Prostate Cancer|A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate (DART)||Canadian Cancer Trials Group|Yes|Terminated|March 2008|January 2011|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|N/A|No|||December 2012|December 17, 2012|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00651326||158025|
NCT00651703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT004-MelQbG10 04|Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients|Safety, Tolerability, and Immunogenicity of CYT004-MelQbG10 Vaccine With or Without Immunostimulating Adjuvant in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma||Cytos Biotechnology AG|No|Completed|April 2008|July 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Both|18 Years|N/A|No|||November 2010|November 11, 2010|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00651703||157996|
NCT00652262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100608|BAY38-9456 - Supportive Trial for Spinal Injury|An Open, Multi-centre, Flexible Dose Uptitration Study to Investigate the Efficacy and Safety of Vardenafil 10 mg and 20 mg in Males With Spinal Cord Injury Suffering From Erectile Dysfunction||Bayer|No|Completed|March 2004|November 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Male|20 Years|64 Years|No|||December 2014|December 18, 2014|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652262||157953|
NCT00652275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSP3_ML_0304|Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine|Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali.||African Malaria Network Trust|Yes|Recruiting|May 2008|December 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|378|||Both|12 Months|48 Months|Accepts Healthy Volunteers|||April 2008|May 6, 2008|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00652275||157952|
NCT00653718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5390L00068|Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study|Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study|AIMS|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|May 2008|December 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|N/A|No|Non-Probability Sample|Early breast cancer patients|September 2008|July 30, 2009|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653718||157844|
NCT00653731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PfVMS-T6|Effective Strategies for Dementia Care|Testing Three Interventions for Clinical Effectiveness in Long Term Care Residents With Dementia: Snoezelen, Structured Reminiscence Therapy, 10-minutes Activation. A Cluster-randomized Controlled Trial.|WISDE|Martin-Luther-Universität Halle-Wittenberg|No|Completed|February 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|327|||Both|55 Years|N/A|No|||August 2011|August 30, 2011|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653731||157843|
NCT00653978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Changhai-080129|Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures|Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial||Changhai Hospital|Yes|Recruiting|May 2008|December 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||July 2009|June 21, 2011|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653978||157824|
NCT00653705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0901|The Effect of Yogurt Containing BB12 on Children's Health and Child Care Absenteeism|The Effect of Daily Consumption of Yogurt Containing Bifidobacterium Lactis (BB12) on Children's' Health and Child Care Absenteeism||University of North Carolina, Chapel Hill|No|Completed|January 2007|April 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|181|||Both|12 Months|48 Months|Accepts Healthy Volunteers|||May 2013|May 30, 2013|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653705||157845|
NCT00653965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522US/0007|Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)|A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in Hispanic Subjects.|STARSHIP|AstraZeneca|No|Completed|May 2003|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|March 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653965||157825|
NCT00654589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ADE02|Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload|A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present||Novartis||Completed|February 2008|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654589||157777|
NCT00654823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-XX-XXXX-EG-CTIL|Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial|Prospective Study Comparing Between the Commonly-Used and Pharmacogenetically-Guided Warfarin Administration Protocols|PGxWarfarin|Sheba Medical Center|No|Not yet recruiting|June 2008|June 2011|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|community sample|April 2008|April 4, 2008|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00654823||157759|
NCT00655135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L299-016|Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients|Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients With Mildly to Moderately Active Crohn's Disease||Millennium Pharmaceuticals, Inc.|No|Completed|February 2000|||June 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|185|||Both|18 Years|80 Years|No|||April 2008|April 8, 2008|April 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655135||157735|
NCT00655382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004724|Dynamic MRI Evaluation Post Operative Stapled Trans Anal Rectal Resection (STARR) Procedure|Dynamic MRI Evaluation Post op STARR Procedure||Mayo Clinic|Yes|Completed|October 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Female|18 Years|90 Years|No|Non-Probability Sample|Patients who had STARR procedure performed at Mayo Clinic - Jacksonville|May 2010|May 20, 2010|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655382||157716|
NCT00655668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-TCL-001|A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma|EXPECT|Celgene|Yes|Terminated|March 2008|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|April 4, 2008|Yes|Yes|Decision not to pursue as single agent in the study population.|No|November 30, 2011|https://clinicaltrials.gov/show/NCT00655668||157694|
NCT00651456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-GFPC-0701|Mesothelioma Avastin Plus Pemetrexed-cisplatin Study|A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)|MAPS|Intergroupe Francophone de Cancerologie Thoracique|Yes|Active, not recruiting|February 2008|December 2016|Anticipated|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|448|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|March 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00651456||158015|
NCT00651807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05806|A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)|Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH)||Merck Sharp & Dohme Corp.|No|Terminated|March 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Male|50 Years|80 Years|No|||February 2015|February 3, 2015|March 31, 2008|No|Yes|Business Reasons|No||https://clinicaltrials.gov/show/NCT00651807||157988|
NCT00652041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaCyDexVMP7|Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma|Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma|TaCyDexVMP7|PETHEMA Foundation|Yes|Completed|January 2007|June 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652041||157970|
NCT00623207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0139 EMC|Use of Atropine in Tredmill Stress Testing|Safety and Feasibility of Atropine Added During Treadmill Stress Testing in Patients With Chronotropic Incompetence or Poor Exercise Capacity.||HaEmek Medical Center, Israel|No|Completed|December 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|103|||Female|18 Years|N/A|No|||July 2015|July 24, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623207||160157|
NCT00623220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-008-PED|Inhaled Nitrous Oxide for Pain Relief During Eye Exam in the Pre-term Infant|A Randomized Controlled Trial on the Effectiveness of Inhaled Nitrous Oxide for Pain Relief During ROP Screening Exam in the Pre-term Infant||McGill University Health Center|No|Completed|March 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|32 Weeks|N/A|No|||October 2013|October 28, 2013|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00623220||160156|
NCT00655850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070727010|Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer|Pilot Phase II Study of Metronomic Chemotherapy in Combination With Avastin in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer||University of Alabama at Birmingham|Yes|Active, not recruiting|March 2008|September 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|19 Years|N/A|No|||February 2016|February 22, 2016|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655850||157681|
NCT00651339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor465708ctil|The Effect of Botox Injection on Postural Stability of Cerebral Palsy (CP) Children|||Soroka University Medical Center|Yes|Terminated|February 2008|June 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|3 Years|7 Years|No|Probability Sample|30 children suffer from Cerbral Palsy|February 2008|April 12, 2010|March 30, 2008||No|recruiting or enrolling participants has halted prematurely and will not resume|No||https://clinicaltrials.gov/show/NCT00651339||158024|
NCT00651950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-HYDRO-1C-H|Bench Study of Transcutaneous Hydrocephalic Shunt Flow Sensor Alignment Accuracy and Repeatability|A Flow Monitor for Pediatric Hydrocephalic Shunts - Bench Study of Sensor Alignment Accuracy and Repeatability||Transonic Systems Inc.|No|Withdrawn|March 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Three neurosurgeons and six nurses|June 2012|June 4, 2012|March 31, 2008||No|Withdrawn due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00651950||157977|
NCT00653042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003352|Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA|A Pilot, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Nesiritide Infusion, Initiated Post-Induction of Anesthesia, in the Management of Coronary Artery Bypass Graft (CABG) Patients Requiring CardioPulmonary Bypass (CPB)||Scios, Inc.||Completed|March 2004|June 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|305|||Both|18 Years|N/A|No|||March 2010|May 18, 2011|April 1, 2008||||||https://clinicaltrials.gov/show/NCT00653042||157895|
NCT00653055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01210|Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions|Randomized, 4-Way Replicate Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|August 2001|December 2001|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653055||157894|
NCT00653068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0333|Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System|Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation||Children's Oncology Group|Yes|Active, not recruiting|December 2008|||April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|N/A|21 Years|No|||May 2015|May 12, 2015|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653068||157893|
NCT00653081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT|Supervised Exercises Compared With Radial Extracorporal Shock Wave Therapy (rESWT) in Patients With SIS|Supervised Exercises Compared With Radial Extracorporal Shock Wave Therapy (rESWT) in Patients With Subacromial Impingement Syndrome: A Single Blind Clinical Randomized Study||Ullevaal University Hospital|Yes|Active, not recruiting|July 2006|December 2008|Anticipated|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|70 Years|No|||January 2007|April 3, 2008|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00653081||157892|
NCT00653406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003262|A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients|Multiple-dosing Study of Long Acting Injectable of Risperidone in Schizophrenic Patients||Janssen Pharmaceutical K.K.||Completed|November 2002|October 2003|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|20 Years|64 Years|No|||March 2010|May 16, 2011|April 1, 2008||||No||https://clinicaltrials.gov/show/NCT00653406||157868|
NCT00653744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522US/0002|Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)|A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects. (ARIES)|ARIES|AstraZeneca|No|Completed|March 2002|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1700|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|March 26, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00653744||157842|
NCT00653991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH082671|Effectiveness of Interactive Virtual Environment Games in Reducing Risky Sexual Behavior Among Men Who Have Sex With Men (The SOLVE-IT Study)|SOLVE IT: Real Risk Reduction for MSM|SOLVE-IT|National Institute of Mental Health (NIMH)|No|Not yet recruiting|October 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4000|||Male|18 Years|24 Years|No|||March 2009|March 10, 2009|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00653991||157823|
NCT00654316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB006|Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine|A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG.||University of Oxford|Yes|Completed|February 2004|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|April 4, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654316||157798|
NCT00654602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0091|48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety|A 48 Week, Open Label, Non-Comparative, Multicentre, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects With Fredrickson Type IIa and Type IIb Dyslipidaemia, Including Heterozygous Familial Hypercholesterolaemia.||AstraZeneca||Completed|February 2002|November 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Both|18 Years|N/A|No|||May 2009|May 27, 2009|April 3, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00654602||157776|
NCT00654836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200027|Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|A Phase II Study of Carboplatin, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Avastin as the First Line Therapy in Metastatic Breast Cancer.||Loyola University|No|Completed|October 2007|September 2015|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654836||157758|
NCT00655395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702009008|Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine|A Phase I/Phase II Evaluation of Laromustine (VNP40101M), A Sulfonylhydrazine Alkylating Agent, Combined With Infusional Cytarabine in Elderly Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome||Weill Medical College of Cornell University||Active, not recruiting|March 2008|October 2010|Anticipated|April 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|52|||Both|60 Years|N/A|No|||March 2010|March 8, 2010|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655395||157715|
NCT00651469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91209|Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women With Moderate Acne Vulgaris.||Bayer||Completed|January 2003|July 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|534|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|March 31, 2008|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00651469||158014|
NCT00651482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-11789|Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)|Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)||Stanford University|Yes|Terminated|August 2008|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|March 28, 2008|No|Yes|slow accrual|No|June 30, 2014|https://clinicaltrials.gov/show/NCT00651482||158013|
NCT00652054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1201|Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer|An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase 2 Study of S-1 as 2nd Line Therapy for Patients With Metastatic Pancreatic Cancer Who Have Previously Received 1st Line Treatment With a Gemcitabine Regimen||Taiho Oncology, Inc.|No|Completed|June 2005|October 2007|Actual|June 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652054||157969|
NCT00652067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604001371|Clofazamine for the Treatment of Mycobacterium Avium Intracellulare(MAI)|IND for One Patient to Receive Clofazamine for Treatment of MAI||Yale University|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|N/A|Observational|N/A||1|Actual|1|||Female|N/A|N/A|No|Non-Probability Sample|Single patient|March 2008|April 2, 2008|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652067||157968|
NCT00652080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTL0408|An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)|||Berg, LLC|Yes|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2010|July 24, 2012|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652080||157967|
NCT00652405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P8009|Effect of Alcohol on Cephalic Phase Reflex and Gene Expression|Effect of Moderate Alcohol Consumption on Cephalic Phase Reflex and Gene Expression of Adipose Tissue in Postmenopausal Women|AR22|TNO|Yes|Completed|May 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Female|N/A|65 Years|Accepts Healthy Volunteers|||May 2008|August 10, 2010|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652405||157942|
NCT00652418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91396|Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography|Evaluation of a Single Intravenous Injection of Magnevist (SH L 451 A) at 0.1 mmol/kg and 0.2 mmol/kg in Contrast-enhanced 3D-Magnetic Resonance Angiography in Patients With Arterial Disease in the Abdominal to Leg Regions in the Ability of Detecting of Vessel Abnormalities||Bayer|No|Completed|July 2004|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|12|||Both|20 Years|N/A|No|||October 2013|October 10, 2013|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652418||157941|
NCT00652431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04955|Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)|SCH 465981: Assessment of Bi-Directional Interaction Between Components of Vytorin® (Ezetimibe and Simvastatin) and Niaspan® (Niacin Extended-Release Tablets) in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|May 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652431||157940|
NCT00651365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014644|A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of the Selective Met Inhibitor JNJ-38877605 in Subjects With Advanced or Refractory Solid Tumors||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|February 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|March 31, 2008||No|Early termination due to increase in serum creatinine levels and minimal PD activity.|No||https://clinicaltrials.gov/show/NCT00651365||158022|
NCT00651716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 0653|T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant|Regulatory T Cells at Engraftment as Predictors of Acute Graft-Versus-Host Disease Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation||Vanderbilt-Ingram Cancer Center|No|Active, not recruiting|December 2006|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood|Both|18 Years|N/A|No|Probability Sample|People with a disease which is being treated with a bone marrow and/or a stem cell        transplant.|June 2015|June 12, 2015|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00651716||157995|
NCT00651729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-056|Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity|||Allergan||Completed|April 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|279|||Both|21 Years|N/A|No|||May 2008|May 23, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651729||157994|
NCT00652652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003319|Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS|Evaluation of Synergy Between Natrecor and Furosemide on Renal and Neurohormone Responses in Chronic Heart Failure: A Phase-IV Study||Scios, Inc.||Completed|March 2003|January 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||March 2010|May 18, 2011|April 1, 2008||||||https://clinicaltrials.gov/show/NCT00652652||157924|
NCT00652665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B033201|Bioavailability Study of Leflunomide Tablets Under Fasting Conditions|To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|June 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|April 3, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652665||157923|
NCT00652678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project # 1050425|Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients|Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients||State University of New York - Upstate Medical University|No|Recruiting|August 2006|August 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|45|Samples With DNA|peripheral blood mononuclear cells|Female|48 Years|N/A|No|Non-Probability Sample|Potential study subjects will be drawn from patients with a history of treatment for        breast cancer with lumpectomy followed by radiation therapy.|July 2011|July 8, 2011|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652678||157922|
NCT00653757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588847|Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer|Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer||Mayo Clinic|Yes|Completed|March 2002|December 2007|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|100|||Male|19 Years|N/A|No|||March 2012|March 15, 2012|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653757||157841|
NCT00654004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71869|Fatty Acid Oxidation Disorders & Body Weight Regulation Grant|Fatty Acid Oxidation Disorders & Body Weight Regulation||Oregon Health and Science University|No|Completed|April 2006|January 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|26|Samples Without DNA|Blood and urine samples. Body composition and energy expenditure data. MRI/MRS images.|Both|7 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were patients with a diagnosis of mitochondrial trifunctional protein, long-chain        3-hydroxyacylCoA dehydrogenase, very long-chain acylCoA dehydrogenase or carnitine        palmitoyltransferase 2 deficency. They were recruited through advertisements on the FAO        support website, or physician referral. Control subjects were from the greater Portland        area. They were recruited via adverstisements at OHSU.|April 2013|April 18, 2013|April 3, 2008||No||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00654004||157822|Trial included small number of subjects with a rare disorder of long-chain fatty acid oxidation. Subjects were predominately children and adolescents. There were some technical difficulties with recruitment and collection of all the outcomes.
NCT00654342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|caugs_01|Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer|Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer||Chung-Ang University|No|Recruiting|October 2007|||February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|18 Years|80 Years|No|||April 2008|April 2, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654342||157796|
NCT00654329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3641|Dexmedetomidine vs Fentanyl for BMT|Dexmedetomidine for Peri-operative Sedation and Analgesia in Children Undergoing Bilateral Myringotomy With Tube Placement (BMT)|DexBMT|Children's Research Institute|Yes|Completed|August 2005|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|101|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||March 2011|March 28, 2011|April 3, 2008||No||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00654329||157797|
NCT00654849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKHTA2007|Electrosurgical Bipolar Plasmakinetic Vessel Sealing During Abdominal Hysterectomy: A Randomized Controlled Trial|Electrosurgical Bipolar Plasmakinetic Vessel Sealing During Abdominal Hysterectomy: A Randomized Controlled Trial|PKAHRCT|Hospital de Concentracion Norte de Petroleos|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Female|N/A|N/A|No|||April 2008|April 21, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654849||157757|
NCT00654862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECA-02-006|Acute Hemodynamic Effects of Cocoa Polyphenols in Subjects With Hypertension and Optimal Blood Pressure|Randomized Controlled, Double-Blind, Sample Size-Calculated, Three-Period Crossover, Phase 1 Study to Investigate the Efficacy of a Single Oral Dose of Cocoa Phenols on Blood, Pressure, Heart Rate and Plasma Levels of Phenols, Bioactive Nitric Oxide and Oxidation Markers in Subjects With Stage 1 Essential Hypertension and Optimal Blood Pressure||University of Cologne|No|Completed|October 2007|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654862||157756|
NCT00655148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIPV-03|Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination Vaccine|Clinical Trial Comparing the Safety and Immunogenicity of Two Combined Diphtheria, Tetanus, Acellular Pertussis, and Inactivated Poliovirus (DTaP-IPV) Vaccines Administered to Healthy Children at 2, 3½, and 16 Months of Age||Statens Serum Institut|No|Completed|September 2003|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|817|||Both|N/A|49 Days|No|||January 2013|January 18, 2013|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655148||157734|
NCT00655941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2007-088|Influence of Weight Loss or Exercise on Cartilage in Obese Knee Osteoarthritis Patients|Influence of Weight Loss or Exercise on CARtilage in Obese Knee Osteoarthritis Patients: a Randomized Controlled Trial (CAROT).|CAROT|Frederiksberg University Hospital|No|Completed|April 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|50 Years|N/A|No|||January 2012|January 5, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655941||157674|
NCT00655915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071107|Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release|Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release||Vanderbilt University|No|Terminated|December 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who present to Vanderbilt Hand Center with carpal tunnel syndrome|March 2011|March 8, 2011|March 28, 2008||No|Study was terminated by principal investigator|No||https://clinicaltrials.gov/show/NCT00655915||157676|
NCT00655928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro524|Modulation of Lung Injury Complicating Lung Resection|Modulation of Lung Injury Complicating Lung Resection||Imperial College London|No|Completed|August 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|47|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655928||157675|
NCT00651820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017 101 09 001|Effect of Collagenase on Healing and Scarring|A Randomized, Double-blind, Paired-Comparison of the Effect of Collagenase Santyl® Ointment on Healing and Scarring Characteristics of 600μm Dermatome Wounds||Healthpoint|No|Completed|April 2008|March 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|March 20, 2008|No|Yes||No|June 4, 2010|https://clinicaltrials.gov/show/NCT00651820||157987|
NCT00652093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20957|Lumbar Stenosis Outcomes Research II|Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial|LUSTORII|University of Rochester|Yes|Terminated|March 2008|August 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|24|||Both|50 Years|N/A|No|||February 2016|February 24, 2016|March 11, 2008||No|Removal of Darvocet from US market|No|July 10, 2012|https://clinicaltrials.gov/show/NCT00652093||157966|This study terminated early (leading to small number of subjects analyzed) due to US Food and Drug Administration (FDA) removing active control (Darvocet) from the U.S. market.
NCT00652444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-151|Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)|Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial||Merck Sharp & Dohme Corp.||Completed|September 2003|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652444||157939|
NCT00652769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/0156|A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)|A Randomized Controlled Trial of Endobronchial or Endoscopic Ultrasound as a First Test in the Diagnosis and Staging of Lung Cancer|BOOST|University College London Hospitals|Yes|Active, not recruiting|March 2008|July 2012|Anticipated|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|168|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652769||157915|
NCT00622960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA 1-04-CR-05|Effect of High Monounsaturated Fat Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes|Comparison of High Monounsaturated Fat and High Carbohydrate Diets on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes||University of Cincinnati|No|Completed|April 2004|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|30 Years|75 Years|No|||February 2008|February 22, 2008|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622960||160176|
NCT00622973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF320000-113512/1|USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases|Noninvasive Detection of Clinically Occult Lymph Node Metastases in Prostate and Bladder Cancer Evaluated by USPIO-Enhanced MRI and Diffusion-Weighted MRI: A Histopathological Correlation||University Hospital Inselspital, Berne|Yes|Completed|September 2007|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|130|||Both|18 Years|90 Years|No|||October 2011|October 7, 2011|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622973||160175|
NCT00651742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1204|Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer|An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase 2 Study of S-1 in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Pancreatic Cancer||Taiho Oncology, Inc.|No|Completed|February 2006|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651742||157993|
NCT00651963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-141|Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)|Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia||Merck Sharp & Dohme Corp.||Completed|September 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651963||157976|
NCT00651976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0776|Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery|Pre-Surgical Trial of Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer (Spore)||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|March 2008|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|April 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651976||157975|
NCT00653419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980563|Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets in Healthy Adult Males Under Fasting Conditions Following Administration of a 30 mg Dose||Par Pharmaceutical, Inc.|No|Completed|June 1998|September 1998|Actual|September 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653419||157867|
NCT00653432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-0702|Safety and Effectiveness Study of Hyaluronic Acid for Osteoarthritis of the Knee|||Anika Therapeutics, Inc.|No|Completed|January 2008|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|350|||Both|35 Years|75 Years|No|||June 2010|June 21, 2010|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653432||157866|
NCT00654355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002300|Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit|Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit||Wake Forest School of Medicine|No|Recruiting|April 2008|||September 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|15 Years|No|||January 2009|January 9, 2009|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654355||157795|
NCT00654628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-172|Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)|Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients|BRAVO|Merck Sharp & Dohme Corp.||Completed|August 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|173|||Both|20 Years|79 Years|No|||August 2015|August 11, 2015|April 2, 2008|Yes|Yes||No|July 30, 2010|https://clinicaltrials.gov/show/NCT00654628||157774|
NCT00654641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20292|Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy|Prevention of Abdominal Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy||West Virginia University|No|Terminated|September 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Female|18 Years|N/A|No|||December 2012|December 18, 2012|April 2, 2008||No|Poor enrollment. No apparent treatment effect.|No|February 3, 2010|https://clinicaltrials.gov/show/NCT00654641||157773|Slow enrollment caused the closure of the trial prior to meeting enrollment target.
NCT00654875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2403|Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.|A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.||Novartis|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|April 3, 2008|No|Yes||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00654875||157755|
NCT00654615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003715|Fixation of Unstable Distal Radius Fractures|The Fixation of Unstable Metaphyseal Distal Radius Fractures: A Randomized, Controlled Trial||Wake Forest School of Medicine|Yes|Completed|May 2008|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|80 Years|No|||December 2014|June 8, 2015|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00654615||157775|
NCT00655408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMERP-001|Iron-Deficiency Anemia in Infants in Two Weekly Programs|Iron-Deficiency Anemia in Infants: Comparative Study of Two Weekly Supplement Programs|IDA|Sao Jose do Rio Preto University|No|Completed|April 2003|January 2004|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|130|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655408||157714|
NCT00655681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-213|Prevention of Post Operative Bone Loss in Children|Prevention of Post Operative Bone Loss in Children||University of New Mexico|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|4 Years|18 Years|No|||February 2012|February 29, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655681||157693|
NCT00651521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWW-0002|Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients|Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients||Chang Gung Memorial Hospital|Yes|Recruiting|April 2009|December 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Anticipated|1000|||Both|18 Years|85 Years|No|Non-Probability Sample|All CKD patients admitted for coronary angiography from 1992 to 2004. The patients were        further categorized into five stages of CKD.|December 2013|December 24, 2013|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00651521||158010|
NCT00651534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR9106341|To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females|An Open-Label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400 mg Ronacaleret (a Calcium-Sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females.||GlaxoSmithKline||Completed|February 2008|||||N/A|Observational|Time Perspective: Prospective||1||32|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2009|June 4, 2009|March 28, 2008||||||https://clinicaltrials.gov/show/NCT00651534||158009|
NCT00651495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G07-09-025|Activating Seniors to Improve Chronic Disease Care|Activating Seniors to Improve Chronic Disease Care||University of California, Los Angeles|No|Completed|April 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|116|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 3, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00651495||158012|
NCT00651508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA202-002|Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|Open Label, Multi-center, Phase 2 Study of KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Previously Treated With First-Line Chemotherapy||Bristol-Myers Squibb||Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||April 2009|January 24, 2011|March 26, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00651508||158011|
NCT00652106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-019T|Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension|||Allergan||Completed|June 2003|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|432|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652106||157965|
NCT00652119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0223|Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin|Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Treatment of Women With Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2008|||February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|N/A|No|||August 2015|August 20, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652119||157964|
NCT00652457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-HD|Study of Memantine to Treat Huntington's Disease|A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease"||University of California, San Diego|Yes|Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1|||60|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|March 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652457||157938|
NCT00652782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_806|Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients|A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of The Effects of MK7418, Both as Monotherapy and in Combination With Furosemide, On Diuresis and Renal Function in Patients With Congestive Heart Failure (CHF) And Renal Impairment Treated With Oral Loop Diuretics Who Require Hospitalization For Fluid Overload||NovaCardia, Inc.||Completed|December 2004|||August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|160|||Both|18 Years|N/A|No|||April 2008|April 1, 2008|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652782||157914|
NCT00652795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40074|Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Doxycycline 150 mg Tablet and Monodox 50 mg Capsule Administered as 1 x 150 mg Tablet or 3 x 50 mg Capsules in Healthy Subjects Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|July 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652795||157913|
NCT00623246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|560|Evaluating Behavioral Treatments to Improve Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in People With Obstructive Sleep Apnea (The BREATHE Study)|Motivating Adherence to CPAP in Obstructive Sleep Apnea|BREATHE|National Jewish Health|Yes|Active, not recruiting|December 2007|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|30 Years|80 Years|No|||December 2014|December 8, 2014|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00623246||160154|
NCT00623259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-MAG-001|Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects|Phase I Vaccination Study Testing the Safety and Reactogenicity of a Recombinant MVA HIV Multiantigen Vaccine (MVA-mBN120B) in HIV-infected Subjects With CD4 Count > 350/µL||Bavarian Nordic|Yes|Completed|May 2008|April 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|55 Years|No|||May 2010|May 19, 2010|February 19, 2008||Yes||||https://clinicaltrials.gov/show/NCT00623259||160153|
NCT00651989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ud'A-Ophtha-001|Agreement Between Spectral Domain and Time Domain Optical Coherence Tomography (OCT)|Agreement in Foveal Thickness Measurements Between Spectralis® and Stratus® Optical Coherence Tomography||G. d'Annunzio University|Yes|Not yet recruiting|April 2008|May 2008|Anticipated|May 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|19 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|volounteer students and employers from the Clinic staff|March 2008|April 2, 2008|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00651989||157974|
NCT00652691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|976101|Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer|A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer||Mayo Clinic|Yes|Active, not recruiting|August 1998|||December 2015|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Female|18 Years|70 Years|No|||March 2015|March 31, 2015|April 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652691||157921|
NCT00653120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40451|Bioavailability Study of Propranolol Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|May 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653120||157889|
NCT00652288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403026582|Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs|Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Given as a Bolus by Continuous Subcutaneous Insulin Infusion (CSII) and in MDI Basal-Bolus Therapy in Pediatric Subjects With Type 1 Diabetes (TID)|PK/PD|Yale University|No|Enrolling by invitation|April 2007|January 2012|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|8 Years|17 Years|No|||March 2008|March 31, 2008|March 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652288||157951|
NCT00652301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-050|A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled,4-Period, Crossover Study to Evaluate the Effects of Ezetimibe and Simvastatin, Coadministered and Alone, on Intestinal Absorption of Cholesterol||Merck Sharp & Dohme Corp.||Completed|July 2003|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 16, 2015|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652301||157950|
NCT00652314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0307|Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin|Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin|Control|Vascular Solutions, Inc|No|Completed|March 2008|January 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|97|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 28, 2008|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT00652314||157949|
NCT00654017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481076|A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis|Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Flexible, Titration Dose Administered on an As Needed Basis (PRN) to Evaluate the Efficacy and the Safety of Sildenafil for the Treatment of Erectile Dysfunction in Male Patients on Hemodialysis||Pfizer|No|Completed|October 2002|April 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|19 Years|N/A|No|||April 2008|April 2, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654017||157821|
NCT00654030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-0505|Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer|Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)||University of Kentucky|Yes|Completed|October 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|April 2, 2008|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00654030||157820|
NCT00654043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01170|Bioavailability Study of Torsemide Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fed Conditions.||Par Pharmaceutical, Inc.|No|Completed|April 2001|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 10, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00654043||157819|
NCT00654368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070301|CAMEO: Canadian Methotrexate and Etanercept Outcome Study|Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)||Amgen|No|Completed|June 2008|February 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|April 3, 2008||No||No|February 10, 2014|https://clinicaltrials.gov/show/NCT00654368||157794|
NCT00654381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.23|Japanese P III vs Voglibose and Placebo|A Double-blind Phase III Study to Evaluate the Efficacy of BI 1356 5 mg and 10 mg vs. Placebo for 12 Weeks and vs. Voglibose 0.6 mg for 26 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control, Followed by an Extension Study to 52 Weeks to Evaluate Long-term Safety||Boehringer Ingelheim||Completed|April 2008|||January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|561|||Both|20 Years|80 Years|No|||December 2013|December 11, 2013|April 3, 2008||||No|May 18, 2011|https://clinicaltrials.gov/show/NCT00654381||157793|
NCT00654654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-R-007|Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases|||Fibrocell Technologies, Inc.|No|Completed|March 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|April 3, 2008|Yes|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00654654||157772|
NCT00655161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-4000-03|A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation|A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation||GlobeImmune|Yes|Completed|April 2008|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|April 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00655161||157733|
NCT00654888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0068/05|Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy|Study of Automated Lamellar Keratectomy With a New Option in Treatment in Symptomatic Patients With Bullous Keratopathy.|ALKSBK|Federal University of São Paulo|Yes|Completed|March 2005|February 2008|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|10 Years|N/A|No|||April 2008|April 10, 2008|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654888||157754|
NCT00655421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391|Oral Cancer Screening in Mumbai, India by Primary Health Care Workers|Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India.||Tata Memorial Hospital|Yes|Active, not recruiting|April 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|3||Actual|329|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 2, 2009|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655421||157713|
NCT00655694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0410/97|Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)|A Non Interventional Study to Asses the Utility of Genomic/ Proteomic/ Metabonomic Profiling Approaches to the Classification and Pathological Basis of Inflammatory Lung Disease in Smokers, and Ex-smokers vs. Non-smokers and Asthmatics||Imperial College London||Completed||September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective|||||||Both|35 Years|N/A||||April 2008|June 3, 2015|April 4, 2008||||No||https://clinicaltrials.gov/show/NCT00655694||157692|
NCT00655954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-Q0407-91|Osteoprotegerin (OPG) in Induced Chronic Obstructive Pulmonary Disease (COPD) Sputum|Osteoprotegerin (OPG) in Induced Sputum as a Novel Biomarker for COPD||Imperial College London||Completed||March 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Prospective|||||||Both|35 Years|N/A||||April 2008|April 9, 2008|April 4, 2008||||No||https://clinicaltrials.gov/show/NCT00655954||157673|
NCT00651547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-039-0718|Symbicort in Asthmatic Children - SEEDLING|A 12 Week Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort TM (40/4.5 Mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Asthmatic Children Aged Six to Eleven Years - SEEDLING 40/4.5||AstraZeneca|No|Completed|July 2002|October 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|405|||Both|6 Years|11 Years|No|||March 2009|March 27, 2009|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651547||158008|
NCT00651560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-148|Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)(COMPLETED)|Vytorin As Strategy To Reduce Dislipidemia In Adults||Merck Sharp & Dohme Corp.||Completed|November 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651560||158007|
NCT00651833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1202|Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer|An Open-Label, Non-Randomized, Multicenter, Three-Stage, Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy for Patients With Advanced Non-Small Cell Lung Cancer (Stage IIIB/Stage IV)||Taiho Oncology, Inc.|No|Completed|February 2005|July 2007|Actual|October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651833||157986|
NCT00652132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-LT-2007-03|Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer|A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma||National Cancer Institute (NCI)||Recruiting|December 2007|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|115|||Both|N/A|18 Years|No|||June 2009|August 9, 2013|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00652132||157963|
NCT00652470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007601|A Study Comparing Two Treatments for Infants With Hydrocephalus|International Infant Hydrocephalus Study: A Multicentre, Prospective Study||The Hospital for Sick Children|Yes|Active, not recruiting|September 2005|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|N/A|24 Months|No|||December 2015|December 15, 2015|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00652470||157937|
NCT00652808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471045|Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee|Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg QD and Naproxen 500 mg BID in Treating the Signs and Symptoms of Osteoarthritis of the Knee||Pfizer|No|Completed|May 2004|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||April 2008|April 7, 2008|April 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652808||157912|
NCT00652821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-122|Bioavailability Study of Tramadol/APAP Tablets Under Fed Conditions|To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fed Conditions.||Par Pharmaceutical, Inc.|No|Completed|May 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 9, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652821||157911|
NCT00623818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080052|Mirror Therapy for Phantom Limb Pain|fMRI Investigation of Cortical Reorganization and Phantom Limb Pain Following Amputation||National Institutes of Health Clinical Center (CC)||Recruiting|February 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|90|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|February 4, 2016|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00623818||160111|
NCT00652327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04355|Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)|A Multicenter, Randomized, Open-labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety and Tolerability of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Ongoing Statin in the Treatment of Hypercholesterolemia.||Merck Sharp & Dohme Corp.|No|Completed|December 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|80 Years|No|||June 2015|June 23, 2015|March 31, 2008||Yes||No|May 12, 2010|https://clinicaltrials.gov/show/NCT00652327||157948|
NCT00652340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP2001-201|APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer|APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients|TP2001-201|Tragara Pharmaceuticals, Inc.|Yes|Completed|April 2008|March 2012|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||March 2012|March 13, 2012|March 31, 2008|Yes|Yes||No|March 13, 2012|https://clinicaltrials.gov/show/NCT00652340||157947|
NCT00653445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3569C00006|Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg|A 6wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel Group Study to Compare the Safety & Efficacy of Rosuvastatin 40mg in Comb.With Ezetimibe 10mg in Subjects With Hypercholesterolaemia & CHD or Atherosclerosis or a CHD Risk Equiv. (10 yr Risk Score >20%).|EXPLORER|AstraZeneca|No|Completed|June 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||March 2009|March 25, 2009|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653445||157865|
NCT00653458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODO-P2-159|Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability Study of Kali's Ondansetron ODT 8 mg With That of GlaxoSmithKine's Zofran ODT 8 mg in Healthy Adult Subjects Under Fed Conditions||Par Pharmaceutical, Inc.|No|Completed|August 2002|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 10, 2008|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00653458||157864|
NCT00653094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.K.prot.02-03-08|An Open Label, Prospective, One Arm, Feasibility, Study for The Use of Halevy Kit for the Treatment of Perianal Fistulas in Patients With Crohn's Disease|An Open Label, Prospective, One Arm, Feasibility, Study for The Use of Halevy Kit for the Treatment of Perianal Fistulas in Patients With Crohn's Disease||ResQ Medical Ltd|Yes|Not yet recruiting|June 2008|August 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2008|April 3, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00653094||157891|
NCT00653783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS050095-02_PROBE|Diagnostic and Prognostic Biomarkers in Parkinson Disease|Blood Alpha-Synuclein, Gene Expression, and Smell Testing as Diagnostic and Prognostic Biomarkers in Parkinson's Disease|PROBE|The Parkinson Study Group|No|Active, not recruiting|August 2007|||July 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|Samples With DNA|Whole Blood, serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic, spouses, PD patients from another trial|December 2008|December 30, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653783||157839|
NCT00654914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10781|A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction|A National, Multicentre, Open Label, Flexible Dose, Twelve Week Treatment to Assess the Efficacy and Safety of 5mg, 10mg and 20mg Bay 38-9456, a Phosphodiesterase Type V Inhibitor, in the Treatment of Male Patients With Erectile Dysfunction|VIS|Bayer|No|Completed|May 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|527|||Male|18 Years|N/A|No|||December 2014|December 18, 2014|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00654914||157752|
NCT00654901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L21|Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™|Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants||Sanofi|No|Completed|March 2008|July 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|881|||Both|15 Months|18 Months|Accepts Healthy Volunteers|||May 2013|May 6, 2013|April 3, 2008||No||No|May 6, 2013|https://clinicaltrials.gov/show/NCT00654901||157753|
NCT00605969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-552|Dynamic Imaging of the Hip for Pre-operative Planning|Hip Reconstruction and Modeling for Surgical Pre-Operative Planning||Ottawa Hospital Research Institute|No|Completed|May 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00605969||161447|
NCT00606255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AKR19T|Compliance of Antihypertensive Treatment Study (CAT Study)|Compliance of Antihypertensive Treatment Study|CAT|The Catholic University of Korea|Yes|Active, not recruiting|January 2008|January 2009|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1062|||Both|18 Years|N/A|No|Probability Sample|① Patient diagnosed as hypertension.        ② Hypertension patients diagnosed and treated but not meeting the target blood pressure.        (Target blood pressure: SBP<140mmHg and DBP<90mmHg. In case having concomitant disease        JNC-VII guideline is followed)|January 2008|January 31, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00606255||161425|
NCT00606268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-CL-2103|A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant|A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin as an Antifungal Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplant||Astellas Pharma Inc|No|Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|42|||Both|4 Months|16 Years|No|||August 2014|August 19, 2014|January 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606268||161424|
NCT00606281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-06-003|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|65 Years|No|||January 2014|January 16, 2014|January 19, 2008||No||No|November 28, 2013|https://clinicaltrials.gov/show/NCT00606281||161423|
NCT00606606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3843|Reducing Adverse Drug Events in the Nursing Home|Reducing Adverse Drug Events in the Nursing Home||University of Massachusetts, Worcester|No|Withdrawn|July 2000|June 2006|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 27, 2015|January 11, 2008||No|This is not a human subject's study. Protocol registered in error. This protocol studied    nursing homes as a unit.|No||https://clinicaltrials.gov/show/NCT00606606||161398|
NCT00606658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCU-07-VINJ002|Usefulness of Shirodhara for Insomnia|Usefulness of Shirodhara (Oil Dripping Treatment in Ayurveda) for Insomnia - A Case Series||Southern California University of Health Sciences|No|Completed|January 2008|September 2008|Actual|September 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||September 2012|September 18, 2012|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606658||161394|
NCT00607867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-010-07F|LoBAG30 Diet in Patients on Metformin|Metabolic Response to a LoBAG30 Diet in Diabetic Patients on Metformin|LoBAG Diet|VA Office of Research and Development|No|Terminated|April 2008|March 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|70 Years|No|||December 2014|December 10, 2014|January 31, 2008||No|The funding ended before the study was completed.|No|November 17, 2014|https://clinicaltrials.gov/show/NCT00607867||161303|Funding ended with only 14 subjects studied. With a parallel arm design, we were not able to draw any conclusions from the study. Funds were unavailable for a more sophisticated statistical analysis.
NCT00608088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA 0006088|Evaluation of a Community Health Nurse/Peer Counselor Program to Help Low-Income Women Breastfeed Longer|Support for Low-Income Breastfeeding: Cost and Outcomes||National Institute of Nursing Research (NINR)|Yes|Completed|March 2003|August 2006|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|328|||Female|12 Years|44 Years|Accepts Healthy Volunteers|||January 2008|January 24, 2008|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00608088||161286|
NCT00608101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #040907-HAAF in T1DM, Q1|Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 1||Vanderbilt University|No|Withdrawn|September 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608101||161285|
NCT00607529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-023|Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device|Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device||Memorial Sloan Kettering Cancer Center||Completed|August 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|MSKCC patients|June 2010|June 3, 2010|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607529||161328|
NCT00607542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-2005-13-2|Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity|Pediatric Pharmacokinetic and Pharmacodynamic Study of Oral Baclofen for the Treatment of Spasticity Associated With Cerebral Palsy|Best PK/PD|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|November 2008|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|2 Years|16 Years|No|||February 2011|December 2, 2011|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607542||161327|
NCT00607854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/11|Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)|Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.|ZEVALLO|University Hospital, Bordeaux|Yes|Completed|February 2008|November 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||February 2013|February 28, 2013|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00607854||161304|
NCT00608400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-08-02|Effect of Dietary Conjugated Linoleic Acid (CLA) on Parathyroid Hormone in Men|Does Dietary Cis-9, Trans-11 Conjugated Linoleic Acid Reduce Parathyroid Hormone in Men?||McGill University|No|Completed|December 2008|December 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|55|||Male|19 Years|53 Years|Accepts Healthy Volunteers|||March 2012|March 1, 2012|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608400||161267|
NCT00608049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481|Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes|Optimal Macronutrient Intake - Carbohydrate||Brigham and Women's Hospital|Yes|Completed|February 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|189|||Both|30 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608049||161289|
NCT00608374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581143|Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma|A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes||National Cancer Institute (NCI)||Completed|June 2006|January 2013|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|400|||Both|18 Years|N/A|No|||June 2009|August 23, 2013|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT00608374||161269|
NCT00608699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMA111316|A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers|A Study to Evaluate the Ability of the HM74A Agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|December 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00608699||161247|
NCT00608712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00097|Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)|Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)||AstraZeneca|No|Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|140|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608712||161246|
NCT00608959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-226-301|Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects|A Single- Center, Open-Label, Study of the Persistence of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects||Mallinckrodt|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 22, 2010|January 23, 2008|Yes|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00608959||161227|FDA reviewer noted that there were multiple endpoints that required multiplicity adjustments to control for the overall type I error rate.Based on feedback the 72 hour endpoint was selected for Part 2 as the primary efficacy endpoint.
NCT00604812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-083|Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years||Merck Sharp & Dohme Corp.|No|Completed|December 2007|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|31|||Both|6 Years|17 Years|No|||November 2015|November 9, 2015|October 17, 2007|No|Yes||No|June 3, 2009|https://clinicaltrials.gov/show/NCT00604812||161533|Pharmacokinetic data presented are preliminary data.
NCT00615862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11399|Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis|Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis||Virginia Commonwealth University|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|1. Diagnosis of alcohol use disorders will be made through the use of a validated           questionnaire.        2. Blood collected as part of routine patient care (and that is destined to be discarded)           will be evaluated for a number of immune markers. Cortisol levels measured as part of           routine care will be recorded.        3. Delirium will be assessed through the use of a validated instrument.|Both|18 Years|N/A|No|Probability Sample|All patients admitted to the medical intensive care unit at Virginia Commonwealth        University Medical Center (also known as Medical College of Virginia Hospitals) will be        eligible for study participation unless they meet study exclusion criteria.|June 2009|February 21, 2012|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615862||160714|
NCT00616460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0124-07-EMC|ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding||ACRIPAB|HaEmek Medical Center, Israel|No|Completed|February 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616460||160668|
NCT00607126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-04-064-02|Locomotor Training in Persons With Multiple Sclerosis|Robotic Locomotor Training in Persons With Multiple Sclerosis||University of California, Los Angeles|No|Completed|July 2006|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||January 2013|January 15, 2013|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607126||161358|
NCT00604461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14896|Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)|Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|October 2007|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2011|November 21, 2013|January 17, 2008|Yes|Yes|Slow Accrual|No|November 17, 2011|https://clinicaltrials.gov/show/NCT00604461||161560|This trial was closed early due to slow patient accrual. The planned accrual had been 44.
NCT00608595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0174|Celecoxib in Treating Patients With Early-Stage Rectal Cancer|Pilot COX-2 Activity in Early Stage Rectal Cancer -Short Term Administration of Celecoxib (SPORE)||Vanderbilt-Ingram Cancer Center|Yes|Terminated|July 2002|April 2008|Actual|May 2004|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2013|March 2, 2013|January 30, 2008||No|low accrual|No||https://clinicaltrials.gov/show/NCT00608595||161254|
NCT00605059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV94|Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|AV94|Institute for Neurodegenerative Disorders|No|Terminated|August 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 5, 2010|January 16, 2008||No|Scans showed no visual difference between affected subjects & healthy volunteers|No||https://clinicaltrials.gov/show/NCT00605059||161514|
NCT00609180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|549|Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)|Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) and Prospective, Randomized, Blinded, Placebo-Controlled, Multi-Center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)|EDEN-Omega|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|December 2007|April 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|272|||Both|13 Years|N/A|No|||February 2012|February 9, 2012|January 31, 2008||No|The Omega arm of this study was stopped for futility. The EDEN arm continues to recruit    patients as a separate independent study.|No||https://clinicaltrials.gov/show/NCT00609180||161212|
NCT00604695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N3770S|A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks|A Randomized Trial Evaluating Low-Dose IntraCoronary AdjunctivE Tenecteplase During Primary PCI for ST-Elevation Myocardial Infarction (ICE T)|ICE T-TIMI 49|Brigham and Women's Hospital|Yes|Completed|July 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|74 Years|No|||August 2012|August 6, 2012|January 7, 2008|Yes|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT00604695||161542|This pilot study was not adequately powered to exclude a modest increase in bleeding events. Study drug could not be administered to 4 patients and 7 patients were excluded for not meeting the inclusion criteria of TIMI Flow Grade 0/1 at enrollment.
NCT00606671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS|Metabolic Disturbances in Polycystic Ovary Syndrome (PCOS)|Insulin Resistance in Polycystic Ovary Syndrome (PCOS)||Hvidovre University Hospital|Yes|Completed|February 2004|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||8|Actual|65|Samples With DNA|Fat and muscle biopsies|Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|lean and obese women with and without PCOS|January 2008|February 1, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00606671||161393|
NCT00606684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C111045|A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Study B2C111045, A Dose-Finding Study of GW642444 Versus Placebo in Patients With COPD||GlaxoSmithKline|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|602|||Both|40 Years|80 Years|No|||June 2013|July 11, 2013|January 18, 2008|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00606684||161392|
NCT00606697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKI110334|A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of GW597599 and GR205171 on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment and Daytime Cognitive Function in Subjects With Primary Insomnia||GlaxoSmithKline|No|Completed|December 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|64 Years|No|||February 2011|May 31, 2012|January 22, 2008||||No||https://clinicaltrials.gov/show/NCT00606697||161391|
NCT00605943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080061|Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab|Pilot Study for the Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab Avastin or Ranibizumab Lucentis||National Institutes of Health Clinical Center (CC)||Completed|January 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||||30|||Both|18 Years|N/A|No|||August 2009|September 26, 2015|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00605943||161449|
NCT00613743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-165/psy06-033|Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis|Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis||University Hospital, Geneva|Yes|Completed|December 2007|December 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2008|January 12, 2010|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613743||160870|
NCT00613756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.548|Special Survey on PD Patients With Renal Dysfunction|Post Marketing Surveillance of BI-Sifrol® (Pramipexole). Special Survey on Patients With Parkinson's Disease and Renal Dysfunction||Boehringer Ingelheim||Completed|February 2004|||September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with idiopathic PD with renal dysfunction from Primary Care setting.|November 2013|November 12, 2013|January 31, 2008||||No||https://clinicaltrials.gov/show/NCT00613756||160869|
NCT00608426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAB 05-303|Proactive Tobacco Treatment for Veterans|Proactive Tobacco Treatment for Diverse Veteran Smokers||VA Office of Research and Development|Yes|Completed|October 2009|December 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|6400|||Both|18 Years|80 Years|No|||March 2014|April 6, 2015|January 31, 2008||No||No|June 6, 2014|https://clinicaltrials.gov/show/NCT00608426||161266|Smoking abstinence rates were not biochemically verified
NCT00608387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|453|Evaluating a Web-Based Cardiovascular Disease Risk Factor Reduction Program Among American Indians|Web-based, Patient-centered Approach to CVD Risk-factor Management and Reduction||Black Hills Center for American Indian Health|Yes|Completed|February 2009|June 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|149|||Both|18 Years|75 Years|No|||June 2014|June 3, 2014|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00608387||161268|
NCT00604526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-122|High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy|Pilot Study of High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy||Memorial Sloan Kettering Cancer Center||Completed|September 2006|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|18 Years|85 Years|No|||January 2016|January 4, 2016|January 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00604526||161555|
NCT00604825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105106|Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)|A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms||GlaxoSmithKline|No|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|359|||Female|40 Years|65 Years|No|||August 2015|August 27, 2015|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604825||161532|
NCT00604838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlSense-Pivot101|Pivotal Study of the Al-Sense Study Protocol|Pivotal Study of the Al-ASense Study Protocol||Western Galilee Hospital-Nahariya|Yes|Completed|May 2006|November 2006|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|330|||Female|18 Years|45 Years|No|||January 2008|January 29, 2008|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604838||161531|
NCT00604851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001316|Study of Acid Reflux Therapy for Children With Asthma|Study of Acid Reflux Therapy for Children With Asthma|SARCA|Emory University|Yes|Completed|September 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|306|||Both|6 Years|16 Years|No|||January 2014|January 14, 2014|December 27, 2007||No||No|July 10, 2013|https://clinicaltrials.gov/show/NCT00604851||161530|
NCT00615875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2936|Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial|Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial|NAPS|McMaster University|No|Not yet recruiting|March 2008|June 2008|Anticipated|May 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2008|February 1, 2008|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615875||160713|
NCT00607750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG003-203|Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF|A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab)||CoMentis|No|Completed|May 2008|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|56 Years|N/A|No|||October 2010|October 26, 2010|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607750||161312|
NCT00607763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-CL-2102|Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug|A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Infants And Toddlers (≥4 Months TO < 24 Months Of Age) With Esophageal Candidiasis Or Other Invasive Candidiasis||Astellas Pharma Inc|No|Completed|October 2007|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|4 Months|23 Months|No|||August 2014|August 19, 2014|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607763||161311|
NCT00604474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07030750|Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants|Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants||University of California, San Francisco|No|Withdrawn|October 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Months|36 Months|No|||February 2012|February 2, 2012|January 17, 2008||No|Not sufficient enrollment|No||https://clinicaltrials.gov/show/NCT00604474||161559|
NCT00604708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-301|Immunogenicity Study of the Japanese Encephalitis Vaccine IC51|Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of IC51 vs. JE-VAX as Vaccines for Japanese Encephalitis in Healthy Subjects||Valneva Austria GmbH|Yes|Completed|September 2005|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|867|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 31, 2012|January 4, 2008||Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00604708||161541|
NCT00604721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00247|Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer|A Phase 2 Study of AZD6244 in Advanced or Metastatic Hepatocellular Carcinoma||National Cancer Institute (NCI)||Completed|November 2007|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2013|May 12, 2014|January 17, 2008|Yes|Yes||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00604721||161540|The study was stopped at the interim analysis due to lack of radiographic response.
NCT00605072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0127|The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial|The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)|AVEC|University of Southern California|No|Completed|January 2008|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|53|||Both|60 Years|N/A|No|||January 2013|January 14, 2013|January 11, 2008||No||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00605072||161513|The main limitation is the small sample size. The validity of TCD measurements as an index of cerebral blood flow is based on the assumption that cerebral vessel diameters are constant but we didn't have brain imaging to validate this assumption.
NCT00605345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21058|A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Recipients.|An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera Versus Darboepoetin Alfa for the Maintenance of Haemoglobin Levels in Renal Transplant Recipients With Chronic Renal Anaemia.||Hoffmann-La Roche||Completed|December 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|65 Years|No|||May 2015|May 5, 2015|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605345||161492|
NCT00605644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200A3-2202|Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain||Valeant Pharmaceuticals International, Inc.|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|120|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605644||161472|
NCT00605670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-058|Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery|Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument||Memorial Sloan Kettering Cancer Center||Completed|June 2005|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|722|||Both|18 Years|85 Years|No|Non-Probability Sample|Clinics at the various sites|November 2013|November 13, 2013|January 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00605670||161470|
NCT00605683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27918|MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist|A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|MOTION|Newron||Completed|November 2007|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|679|||Both|30 Years|80 Years|No|||March 2013|October 28, 2013|December 19, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605683||161469|
NCT00606970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seigen Safety Trial: Cancer|Safety Assessment of Lactobacillus Fermented Extract in Cancer Patients Undergoing Chemotherapy|Assessment of the Safety of Dietary Supplement Lactobacillus Fermented Extract in Cancer Patients Undergoing Chemotherapy||New Hope Medical Center|No|Withdrawn|January 2007|December 2009|Actual|January 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|75 Years|No|||May 2013|May 5, 2013|January 22, 2008|Yes|Yes|FDA sent letter to IRB stating it should be done under new drug application|No||https://clinicaltrials.gov/show/NCT00606970||161370|
NCT00606307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/07/2357/28|Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases|A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases||Italfarmaco|No|Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||April 2009|May 23, 2013|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606307||161421|
NCT00606320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-06-005|A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|65 Years|No|||January 2014|January 16, 2014|January 19, 2008||No||No|November 28, 2013|https://clinicaltrials.gov/show/NCT00606320||161420|
NCT00606944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0706-046-008|Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection|Randomized Controlled Trial of Fast-Track Rehabilitation After Elective Colorectal and Small Bowel Resection||Seoul National University Hospital|Yes|Completed|June 2007|September 2011|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|20 Years|80 Years|No|||July 2012|July 19, 2012|January 22, 2008||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT00606944||161372|
NCT00606957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUH IRB# AGR-0623|The Effect of Vitamin D Repletion on Insulin Resistance|The Effect of Vitamin D Repletion on Insulin Resistance||Rockefeller University||Completed|January 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606957||161371|
NCT00613769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSM|Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery|A Prospective, Randomized, Blind, Multicenter Trial Comparing Orally Administered Trimethoprim-sulfamethoxazole With Intravenously Administered Cefuroxime and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery||Halmstad County Hospital|Yes|Completed|September 2007|May 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1073|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613769||160868|
NCT00613782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reandron 1000 (ZK 5488) 321399|Reandron in Diabetic Men Witn Low Testosterone Level|Testosterone Replacement Therapy in Men With Type 2 Diabetes Mellitus and Low Testosterone Levels||Austin Health|Yes|Completed|January 2009|April 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Male|18 Years|65 Years|No|||June 2012|June 30, 2014|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613782||160867|
NCT00608062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0537|Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women|Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency|SHAPE|University of Colorado, Denver|No|Completed|March 2007|||June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Actual|92|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608062||161288|
NCT00608075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adler #1|Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder|Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder|LAMBS/LADS|University of Cincinnati|No|Active, not recruiting|April 2007|July 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|260|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608075||161287|
NCT00608738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS 03CC1|Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment|Developing a Nested Whole-Person-Care Guide: Screening and Evaluation Steps (American Cancer Society) ACS||Northwestern University||Completed|July 2001|January 2005|Actual|January 2005|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Health Services Research|||Anticipated|750|||Both|21 Years|N/A|No|||July 2012|July 9, 2012|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00608738||161244|
NCT00608725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8398|Pathophysiology of Orthostatic Intolerance|Pathophysiology of Orthostatic Intolerance||Vanderbilt University|No|Recruiting|December 1996|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00608725||161245|
NCT00608972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040702|Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer|A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer||Rutgers, The State University of New Jersey|No|Completed|May 2008|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||November 2015|November 5, 2015|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608972||161226|
NCT00604539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/IV-SIN-01|Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee|Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee||Bioiberica|No|Completed|February 2008|||November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|40 Years|N/A|No|||December 2011|December 16, 2011|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604539||161554|
NCT00604552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS01000010|AneuRx Post Market Study in the Treatment of AAA|AneuRx Post Market Surveillance Registry||Medtronic Endovascular|No|Terminated|July 2003|February 2009|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|349|||Both|18 Years|N/A|No|||January 2013|June 24, 2013|December 21, 2007|Yes|Yes|Mutual agreement between FDA closed the 522 postmarket surveillance Registry.|No|February 21, 2013|https://clinicaltrials.gov/show/NCT00604552||161553|Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.
NCT00615199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921043|A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Safety And Efficacy Of CP-690,550 In Subjects With Moderate To Severe Crohn's Disease.||Pfizer|No|Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|139|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|January 14, 2008|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT00615199||160764|
NCT00615212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIX110825|Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects|A Single Center, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK376501 on Hepatic Cytochrome P450 Activity in Healthy Adult Subjects||GlaxoSmithKline||Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|February 1, 2008||||||https://clinicaltrials.gov/show/NCT00615212||160763|
NCT00615225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPPRB/114-02|Brain Death: Inflammatory Response, Apoptosis, and Endotoxin Tolerance|Observational Study on the Systemic Inflammatory Response During Brain Death.||Delafontaine Hospital|No|Completed|January 2000|December 2007|Actual|November 2007|Actual|N/A|Observational|N/A||3|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any brain dead patients diagnosed in three different ICUs|February 2008|February 13, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00615225||160762|
NCT00606866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12977A|MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma|Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma|MRI|University of Chicago|Yes|Completed|July 2004|June 2008|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|January 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606866||161378|
NCT00606879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGX523-1A-002|Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors|A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer||SGX Pharmaceuticals, Inc.|No|Terminated|January 2008|June 2009|Anticipated|January 2009|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||July 2008|July 22, 2008|January 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606879||161377|
NCT00608894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro Study 2016|LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis|A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis||Veloxis Pharmaceuticals|No|Completed|December 2007|July 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2009|December 18, 2014|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608894||161232|
NCT00608907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-CAN-1006|An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)|An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)||Millennium Pharmaceuticals, Inc.||Completed|September 2007|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||January 2012|January 26, 2012|January 23, 2008|No|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00608907||161231|
NCT00608933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0198|Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine|CAM USE and Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2008|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|1360|||Both|N/A|N/A|No|||September 2015|September 1, 2015|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00608933||161229|
NCT00604487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|inductionCTIL|Induction of Labor in Patients With Unfavorable Cervical Conditions|||Hillel Yaffe Medical Center|No|Completed|January 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604487||161558|
NCT00604734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-8|A Prospective Clinical Study On A Total Hip Resurfacing System|A Prospective Clinical Study On A Total Hip Resurfacing System||Biomet, Inc.|No|Active, not recruiting|October 2004|October 2017|Anticipated|October 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|N/A|N/A|No|||January 2016|January 8, 2016|December 23, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604734||161539|
NCT00605046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV151|Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects|Evaluation of [123I] AV151 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease (AD) in Comparison to Healthy Subjects|AV151|Institute for Neurodegenerative Disorders|No|Terminated|August 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 5, 2010|January 16, 2008|No|Yes|Scans showed no visual difference between affected subjects & healthy volunteers|No||https://clinicaltrials.gov/show/NCT00605046||161515|
NCT00605696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|542|Evaluating the Effectiveness of Early Insulin Therapy in People at Risk for Developing Acute Lung Injury/Acute Respiratory Distress Syndrome|Early Insulin Therapy and Development of Acute Respiratory Distress Syndrome||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|April 2008|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605696||161468|
NCT00605709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTL0208|Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma|||Berg, LLC|Yes|Withdrawn|March 2008|||July 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605709||161467|
NCT00605358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079265-01A1|Increasing Use of Mental Health Services|Increasing Use of Mental Health Services by Community Dwelling Adults With Depression|Open Door|Weill Medical College of Cornell University|Yes|Active, not recruiting|August 2007|January 2016|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|60 Years|90 Years|No|||January 2011|December 16, 2014|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605358||161491|
NCT00606333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-06|Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions|A Randomized, Multi-Center, Single-Blind Comparison of the Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Versus the TAXUS Liberte Paclitaxel-eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|NEVO RES-I|Cordis Corporation|Yes|Terminated|March 2008|October 2012|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|394|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|January 17, 2008||No|The NEVO™ stent will not be commercialized. Cordis have decided to close the study after 3    years. This decision took the absence of safety signals into account.|No||https://clinicaltrials.gov/show/NCT00606333||161419|
NCT00607282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0610-038-004|Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer|Efficacy of Udenafil in Treatment of Erectile Dysfunction After Radical Resection for Sigmoid Colon and Rectal Cancer : a Randomized Controlled Trial||Seoul National University Hospital|Yes|Completed|March 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Male|19 Years|70 Years|No|||September 2012|September 2, 2012|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607282||161347|
NCT00607269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA 015990|Voucher-Based Incentives in a Prevention Setting|Voucher-Based Incentives in a Prevention Setting|VIPS|Friends Research Institute, Inc.|No|Completed|April 2005|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|131|||Male|18 Years|65 Years|No|||July 2013|July 30, 2013|January 22, 2008||No||No|April 19, 2013|https://clinicaltrials.gov/show/NCT00607269||161348|
NCT00607555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268-2007|A Study on the Effects of Feeding and Feeding Methods on Breathing Pattern in Very Low Birth Weight Preterm Infants|Observational Study on the Effects of Enteral Feeding and Feeding Methods on Respiratory Pattern as Assessed by Diaphragm Electrical Activity (EAdi) in Very Low Birth Weight Preterm Infants||Sunnybrook Health Sciences Centre|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|12 Months|No|Non-Probability Sample|Premature infants admitted to the Neonatal Intensive Care Unit of Sunnybrook Health        Sciences Centre|September 2008|October 30, 2009|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00607555||161326|
NCT00614068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 00-0996|Effectiveness of Trauma-Focused Cognitive Behavioral Therapy in Treating Children With Post-Traumatic Stress Disorder|Creating a Collaborative Field Research Organization||Icahn School of Medicine at Mount Sinai|No|Completed|January 2007|February 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|8 Years|18 Years|No|||April 2015|April 3, 2015|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00614068||160846|
NCT00608439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003668|Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy|Centella Asiatica Triterpene Extract for Diabetic Neuropathy -- a Pilot Study|CAST|Oregon Health and Science University|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|85 Years|No|||November 2012|November 9, 2012|January 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00608439||161265|
NCT00614328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2988 GCRC 2497|Combination of Naltrexone and Baclofen for Alcohol Dependence:A Pilot Study.|Feasibility and Tolerability of a Combination of Naltrexone and Baclofen for Alcohol Dependence: A Pilot Study.||University of North Carolina, Chapel Hill|No|Completed|July 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|25 Years|60 Years|No|||May 2011|May 5, 2011|January 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614328||160828|
NCT00608985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-057A301|Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia|Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group Polysomnography Study to Assess the Efficacy and Safety of a 16-day Oral Administration of ACT-078573 in Adult Subjects With Chronic Primary Insomnia|RESTORA 1|Midnight Pharma, LLC|No|Completed|March 2008|November 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|709|||Both|18 Years|64 Years|No|||February 2016|February 11, 2016|January 11, 2008||No||No|December 21, 2012|https://clinicaltrials.gov/show/NCT00608985||161225|
NCT00608998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 7853|Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression|Vascular Risk Factors and Coronary Calcifications in Chronic Renal Failure Patients: Identification of Specific Factors Linked to Renal Failure Progression|Pre-HD|University Hospital, Montpellier|Yes|Recruiting|July 2007|June 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|120|Samples With DNA|whole blood white cells serum plasma urine|Both|18 Years|90 Years|No|Non-Probability Sample|primary care clinic|January 2008|March 28, 2011|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608998||161224|
NCT00614926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5178|Modafinil for Treatment of Fatigue in ALS Patients|Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study||New York State Psychiatric Institute|Yes|Completed|June 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|No|||February 2012|February 17, 2012|December 28, 2007||No||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00614926||160785|
NCT00615238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK53907 (completed 2004)|PHYSICAL ACTIVITY IN THE TREATMENT OF OBESITY|Physical Activity in the Treatment of Obesity: A Randomized Trial|CHANGE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|April 2000|May 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|177|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00615238||160761|
NCT00615537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX-07-003|Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses|Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses||BioTex, Inc.|Yes|Completed|February 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||April 2011|April 4, 2011|February 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00615537||160738|
NCT00607451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PoC_12001|Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia|A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced Dyskinesia||Neurim Pharmaceuticals Ltd.|Yes|Terminated|March 2008|November 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|8|||Both|30 Years|80 Years|No|||September 2014|October 8, 2014|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607451||161334|
NCT00608920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0772|Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping|SPECT Lymph Node Mapping to Define Nodal Clinical Target Volume in Patients With Prostate Cancer|SPECT|Washington University School of Medicine|No|Completed|March 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Male|18 Years|N/A|No|||May 2013|May 22, 2013|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00608920||161230|
NCT00605085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-302|Safety and Tolerability of the Japanese Encephalitis Vaccine IC51|Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study||Valneva Austria GmbH||Completed|October 2005|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2675|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 19, 2012|January 4, 2008||Yes||No|June 1, 2012|https://clinicaltrials.gov/show/NCT00605085||161512|
NCT00604747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0038.0.254.000-05|Practice Structure on Motor Learning in Post-Stroke Patients|The Effects of Practice Structure on Motor Learning in Post-Stroke Patients||University of Sao Paulo|Yes|Completed|August 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|40 Years|62 Years|Accepts Healthy Volunteers|||January 2008|January 29, 2008|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604747||161538|
NCT00605735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM119-015|PoC in Rheumatoid Arthritis With Methotrexate|A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate||Bristol-Myers Squibb|Yes|Completed|March 2008|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605735||161465|
NCT00606008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14916|A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma|A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|March 2007|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2012|November 13, 2012|January 21, 2008|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT00606008||161444|No definitive conclusions can be made regarding outcome differences between bevacizumab vs. bevacizumab-naive study patients, due to not enough patients who received bevacizumab prior to study enrollment (2 AA, 3 GB).
NCT00605371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEP111102|Bioequivalence and Food Effect of 250mg of Lamotrigine XR|A Pivotal Single-dose, Randomised, Parallel-group, Open-label Study to Demonstrate Bioequivalence of 250mg Lamotrigine XR Relative to 200mg + 50mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 250mg Lamotrigine XR in Healthy Male and Female Volunteers||GlaxoSmithKline|No|Completed|January 2008|March 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|226|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|January 18, 2008||||||https://clinicaltrials.gov/show/NCT00605371||161490|
NCT00605384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-137|A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection|A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Versus Adefovir Added to Continuing Lamivudine in Adults With Lamivudine- Resistant Chronic Hepatitis B Virus Infection||Bristol-Myers Squibb|No|Terminated|August 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||November 2010|November 15, 2010|January 18, 2008|Yes|Yes|Business Objectives Have Changed|No|July 13, 2010|https://clinicaltrials.gov/show/NCT00605384||161489|Following review of business priorities, BMS decided to terminate this study at an early stage. This was a strategic decision, not based on clinical or safety concerns. Due to limited data, no conclusions on safety and efficacy can be made.
NCT00606710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cogent-4 0806|Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following|Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following|Cogent-4|Guidant Corporation|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with risk of developing life threatening ventricular arrhythmias with and without        heart failure|November 2008|November 21, 2008|January 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606710||161390|
NCT00607568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC HIC 0605001441|Atomoxetine Effects in Humans|Atomoxetine Effects in Humans||Yale University|Yes|Completed|June 2006|September 2009|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 9, 2011|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00607568||161325|
NCT00617929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS072|Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant|Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2008|January 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|N/A|No|||April 2015|April 10, 2015|February 15, 2008|Yes|Yes|Replaced by another protocol|No||https://clinicaltrials.gov/show/NCT00617929||160557|
NCT00614042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16007|Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma|A Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma||Emergent Product Development Seattle LLC|Yes|Completed|January 2008|March 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||January 2015|April 3, 2015|January 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614042||160848|
NCT00614341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600-001|Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study|A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study|DPN|MedRelief|No|Completed|May 2006|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|No|||January 2008|February 12, 2008|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614341||160827|
NCT00614666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCFE-2007-001|Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment|Phase I/II Evaluation of the Safety, Pharmacokinetics, and Preliminary Effectiveness of Nikkomycin Z in the Treatment of Patients With Uncomplicated Coccidioides Pneumonia||University of Arizona|Yes|Terminated|September 2007|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|50 Years|No|||August 2009|February 12, 2013|January 31, 2008|Yes|Yes|Recruitment challenges and lack of funding caused an early end to this study|No||https://clinicaltrials.gov/show/NCT00614666||160804|
NCT00615251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-PGN-302|A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization|A Phase 3, Single-Blind, Randomized Study to Compare DR-2011 to a Progesterone Gel for Luteal Phase Supplementation for In Vitro Fertilization||Teva Pharmaceutical Industries|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1297|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00615251||160760|
NCT00615550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-1620-302|PREGNANT Short Cervix Trial|The Effect of Vaginal Progesterone Administration in the Prevention of Preterm Birth in Women With a Short Cervix [Vaginal Progesterone Bioadhesive Gel (Prochieve)® Extending Gestation A New Therapy for Short Cervix - Trial (PREGNANT Short Cervix - Trial)]||Juniper Pharmaceuticals, Inc.|Yes|Completed|March 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|465|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|January 18, 2008|Yes|Yes||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00615550||160737|Trial not powered for subgroup analysis.
NCT00632606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#08-0006|MgSO4 vs Metoclopramide for Headache in Pregnant Women|Magnesium Sulfate vs Metoclopramide for Headache in Pregnant Women|MagHead|Women and Infants Hospital of Rhode Island|No|Withdrawn|August 2008|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|75 Years|No|||December 2012|December 21, 2012|February 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00632606||159452|
NCT00608621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA06103|Influence of Physostigmine on Patient-Controlled Analgesia (PCA) in Postoperative Intensive Care Patients|Influence of Physostigmine on Patient-Controlled Analgesia (PCA) in Postoperative Intensive Care Patients, Considering Pain Score, Opioid Consumption, Hemodynamics and Cognitive Function|ANA06103|Klinikum Ludwigshafen|No|Completed|January 2007|October 2007|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|60|||Both|18 Years|80 Years|No|Probability Sample|Elective major surgery, postoperative ICU patients|December 2007|February 5, 2008|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608621||161253|
NCT00608660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI12B03|Randomized Controlled Trial of Acupuncture to Treat Bell's Palsy According to Different Stages|Studying of Acupuncture for Bell's Palsy According to Different Stages||Chengdu University of Traditional Chinese Medicine|Yes|Completed|October 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|900|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 15, 2009|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00608660||161250|
NCT00605098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-LPV 01|Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy|Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy in HIV-infected Women||Oswaldo Cruz Foundation|No|Completed|February 2008|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|N/A|No|||October 2013|October 25, 2013|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00605098||161511|
NCT00605397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-134|PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer|Pilot Trial of PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer|Cu-64 HER2+|Memorial Sloan Kettering Cancer Center||Completed|January 2007|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|11|||Female|18 Years|N/A|No|||December 2015|December 23, 2015|January 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00605397||161488|
NCT00605410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO 07-161|Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness|Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness||University of Saskatchewan|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|12|||Both|19 Years|N/A|No|||July 2008|January 6, 2009|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605410||161487|
NCT00605982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-124|Breast MRI as a Preoperative Tool for DCIS|Breast MRI as a Preoperative Tool for DCIS||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2006|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|115|||Both|21 Years|59 Years|No|||January 2016|January 12, 2016|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00605982||161446|
NCT00605995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5207|Add-on Simvastatin in Schizophrenia Trial|Add-on Simvastatin in Schizophrenia Trial|ASSIST|New York State Psychiatric Institute|No|Terminated|February 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||April 2012|April 27, 2012|January 21, 2008||No|Study was stopped because enrollment was slower than anticipated by the investigators and the    foundation funding the study.|No||https://clinicaltrials.gov/show/NCT00605995||161445|
NCT00606983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0702-042-006|Prevention of Acute Voiding Difficulty After Radical Proctectomy|Prevention of Acute Voiding Difficulty After Radical Proctectomy for Rectal Cancer With Tamsulosin||Seoul National University Hospital|Yes|Completed|May 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||July 2011|July 18, 2011|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606983||161369|
NCT00617396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET0448|Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder|An Open Label Study of Seroquel SR® (Quetiapine) for the Treatment of Refractory and Treatment Resistant Functional Bowel Disorders||University of North Carolina, Chapel Hill|No|Completed|February 2008|May 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|60 Years|No|||February 2014|February 4, 2014|February 5, 2008|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00617396||160597|Uncontrolled open label study and is vulnerable to biases favoring a treatment response.Sample size is small.
NCT00617409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15206|To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid|A Randomized Phase II Trial Using Dendritic Cells Transduced With an Adenoviral Vector Containing the p53 Gene to Immunize Patients With Extensive Stage Small Cell Lung Cancer in Combination With Chemotherapy With or Without All Trans Retinoic Acid||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|October 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617409||160596|
NCT00617695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1221C00005|Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study With Single-Blind, Placebo-Challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the Treatment of Acute Migraine Headache in Adolescents.||AstraZeneca||Completed|September 2003|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|247|||Both|12 Years|17 Years|No|||April 2009|April 3, 2009|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617695||160575|
NCT00617942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-BR-211B|Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer|BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer||Brown University|Yes|Active, not recruiting|February 2008|December 2014|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||July 2014|July 15, 2014|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617942||160556|
NCT00614354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTTI ACS 201|Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.|Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.||Molecular Targeting Technologies, Inc.|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|18 Years|N/A|No|||October 2012|October 23, 2013|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614354||160826|
NCT00614367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML4102005|Chromosomal Analysis of Single Cells in Human Embryos|Chromosomal Analysis of Single Cells in Human Embryos||Katholieke Universiteit Leuven|No|Active, not recruiting|October 2005|June 2008|Anticipated|March 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|30|Samples With DNA|Single blastomeres of human embryos|Both|N/A|4 Days|Accepts Healthy Volunteers|Probability Sample|3-4 day old human IVF embryos|January 2008|February 11, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00614367||160825|
NCT00614380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.7|Open Label Study Telmisartan and Amlodipine in Hypertension|An Open Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Combination of Telmisartan 40mg + Amlodipine 5mg or the Combination of Telmisartan 80mg + Amlodipine 5mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.||Boehringer Ingelheim||Completed|January 2008|||March 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|976|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|January 28, 2008||||No|December 14, 2009|https://clinicaltrials.gov/show/NCT00614380||160824|
NCT00614055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1791|Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes|A 16 Week Randomised, Open Labelled, 3 Armed, Parallel Group, Treat-to-target Trial Comparing Once Daily Injection of SIAC 30 (B), SIAC 45 (B) and Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment||Novo Nordisk A/S|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|178|||Both|18 Years|75 Years|No|||December 2015|December 10, 2015|January 30, 2008|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT00614055||160847|
NCT00614952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 050444|Cost/Effectiveness Analysis of the Respiratory Poligraphy at Home|Diagnostic Validity Study and Cost Analysis of Domiciliary Respiratory|Telesleep|Sociedad Española de Neumología y Cirugía Torácica|No|Recruiting|January 2006|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|320|||Both|18 Years|70 Years|No|||December 2012|June 3, 2015|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00614952||160783|
NCT00614679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17624|A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia|A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|October 2006|||December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2008|February 11, 2008|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00614679||160803|
NCT00614939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00007|Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment|A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin Compared With Placebo in Adult Patients With Type 2 Diabetes and Renal Impairment (Moderate, Severe, and End-Stage) With an Additional 40-week, Randomized, Double-blind, Placebo-controlled Long-term Observational Period.||AstraZeneca|Yes|Completed|January 2008|March 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|572|||Both|18 Years|N/A|No|||May 2011|May 16, 2011|January 31, 2008||No||No|June 7, 2010|https://clinicaltrials.gov/show/NCT00614939||160784|
NCT00615563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.116|Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)|Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)||Boehringer Ingelheim||Completed|March 2007|January 2008||January 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|246|||Both|18 Years|18 Years|No|Probability Sample|Primary care clinic|November 2013|November 20, 2013|January 31, 2008||||No||https://clinicaltrials.gov/show/NCT00615563||160736|
NCT00615576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR2111256|Repeat Dose Study in Male Healthy Volunteer Smokers|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SB-656933 Following 14 Days Repeat Dosing in Healthy Male Smokers.||GlaxoSmithKline||Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|February 1, 2008||||No||https://clinicaltrials.gov/show/NCT00615576||160735|
NCT00632073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05241|Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)|Effect of Vicriviroc on HIV RNA Levels in Cerebrospinal Fluid||Merck Sharp & Dohme Corp.|No|Completed|March 2008|March 2010|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00632073||159491|
NCT00608634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582634|Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses|Phase 2a Randomized, Placebo-Controlled, Double-Blind Trial of Topical Perillyl Alcohol in Sun Damaged Skin||University of Arizona|Yes|Completed|May 2004|June 2009|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|89|||Both|18 Years|N/A|No|||March 2014|March 27, 2015|February 5, 2008|Yes|Yes||No|April 15, 2011|https://clinicaltrials.gov/show/NCT00608634||161252|
NCT00608647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rap-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2006|||||N/A|N/A|N/A||||||||||||||May 18, 2015|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608647||161251|
NCT00604760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM 3454-101|Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia|A Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia||Memory Pharmaceuticals|No|Active, not recruiting|December 2007|||February 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|55 Years|No|||December 2008|December 5, 2008|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604760||161537|
NCT00604773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radboud 2007/283|Incidence of Delirium in Critically Ill Patients in a Dutch University Hospital|Incidence of Delirium in Critically Ill Patients in a Dutch University Hospital||Radboud University|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|blood, urine|Both|18 Years|N/A|No|Non-Probability Sample|tertiary care clinic|February 2009|August 30, 2010|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00604773||161536|
NCT00606034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-500R|U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod|A Prospective Trial of U500 Regular Insulin by Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes and Severe Insulin Resistance Who Have Failed Previous Insulin Regimens||Mountain Diabetes and Endocrine Center|No|Completed|December 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||January 2014|January 7, 2014|January 19, 2008||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT00606034||161442|Small sample size. Also an uncontrolled pilot study.
NCT00606047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-813|Prevalence of Femoroacetabular Impingement in Asymptomatic Patients|Prevalence of Femoroacetabular Impingement in Asymptomatic Patients||Ottawa Hospital Research Institute|No|Active, not recruiting|August 2007|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|May 2014|May 28, 2014|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606047||161441|
NCT00605423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 00012714|The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot|A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur™ in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis™|MAP|Johns Hopkins University|Yes|Completed|January 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|6|||Both|50 Years|N/A|No|||March 2014|March 10, 2014|January 17, 2008|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT00605423||161486|
NCT00605722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21213|A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.|A Single Arm, Open Label Study of First Line Treatment With Tarceva Plus Avastin on Progression-free Survival in Patients With Advanced or Metastatic Liver Cancer||Hoffmann-La Roche||Completed|March 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|January 18, 2008||No||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00605722||161466|
NCT00606346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013912|A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease|A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease|DEVELOP|Janssen Biotech, Inc.|Yes|Recruiting|May 2007|December 2039|Anticipated|December 2035|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|5000|||Both|1 Month|17 Years|No|||December 2015|December 9, 2015|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606346||161418|
NCT00606359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID26|Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects|Immunogenicity of the Inactivated Split-Virion Influenza Vaccine Administered by the Intradermal Route in Renal Transplant Subjects||Sanofi|Yes|Completed|November 2007|June 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|62|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606359||161417|
NCT00606372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240376|On-Pump vs. Off-Pump CABG in High-Risk Patients (EuroSCORE 6+)|Aortocoronary Bypasses in High-Risk Patients (EuroSCORE 6+) With or Without Use of the Cardio-Pulmonary Bypass.|PRAGUE 6+|Charles University, Czech Republic|Yes|Enrolling by invitation|June 2006|December 2009|Anticipated|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|220|||Both|18 Years|N/A|No|Probability Sample|People indicated for surgical myocardial revascularisation with high surgical risk|January 2008|January 22, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606372||161416|
NCT00606021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11839|A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer||Eli Lilly and Company||Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|January 17, 2008|Yes|Yes||No|October 3, 2011|https://clinicaltrials.gov/show/NCT00606021||161443|Due to a mistake in the randomization parameters form, the randomization was actually implemented in the ratio of 1:1 instead of the planned ratio of 2:1.
NCT00617188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582821|Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer|Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma||Masonic Cancer Center, University of Minnesota|Yes|Completed|June 2007|July 2008|Actual|April 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|February 14, 2008|Yes|Yes||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00617188||160613|
NCT00617435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-A00397-44|Impact of Trans Fatty Acids From Natural and Industrial Origin in the Induction of Insulin Resistance Development||Trans-Insulin|Institut National de la Recherche Agronomique||Completed|October 2007|January 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|66|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 13, 2009|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617435||160595|
NCT00617448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/0008|Ligasure Versus Diathermy Haemorrhoidectomy Under Local Anesthesia|Ligasure™ Versus Diathermy Haemorrhoidectomy Under Spinal or Local Anaesthesia With Ropivacaine. A Randomized Study With One Year Follow-up|LDHLA|Hospital de Viladecans|Yes|Completed|May 2005|June 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|81|||Both|20 Years|90 Years|No|||February 2008|February 15, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617448||160594|
NCT00617708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00797|S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients With Metastatic Pancreatic Cancer||National Cancer Institute (NCI)|Yes|Completed|March 2008|February 2014|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||October 2013|July 25, 2014|February 15, 2008|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00617708||160574|
NCT00613795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-13013|Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia|Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia: A Prospective, Randomized, Placebo-controlled, Double-blind Study||Creighton University|No|Completed|August 2004|November 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|125|||Both|19 Years|N/A|No|||March 2010|March 17, 2010|January 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00613795||160866|
NCT00615316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|365/2006|Guaraná for Radiation Related Fatigue in Breast Cancer Patients|Guaraná ("Paullinia Cupana") for Radiation Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study||Faculdade de Medicina do ABC|Yes|Completed|December 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|N/A|No|||February 2008|February 13, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00615316||160755|
NCT00614705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631013|PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia|A Four Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2A Study Of PH-797804 In The Treatment Of Post-Herpetic Neuralgia||Pfizer||Completed|April 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|January 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614705||160802|
NCT00614965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.16|Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV|A Multicenter Randomized Phase II Study of the Combination of Irinotecan/Cisplatin Versus Pemetrexed/Cisplatin as Second-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)||Hellenic Oncology Research Group|No|Completed|November 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|75 Years|No|||May 2011|May 20, 2011|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00614965||160782|
NCT00615290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.127|Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy|Pharmaco-epidemiological Description of the Patient Population Treated With Aptivus Under Market Conditions, Safety & Efficacy||Boehringer Ingelheim||Completed|June 2007|||May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|No|Probability Sample|HIV-infected patients|August 2014|August 6, 2014|January 31, 2008||||No|February 3, 2010|https://clinicaltrials.gov/show/NCT00615290||160757|
NCT00615264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901|Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients|A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277® in Newly Diagnosed Type 1 Diabetes Patients|DIA-AID|Andromeda Biotech Ltd.|Yes|Completed|September 2005|January 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|457|||Both|16 Years|45 Years|No|||July 2013|July 10, 2013|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00615264||160759|
NCT00615277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213/2005|The Effect of Long-Chain Polyunsaturated Fatty Acids on Cognitive Performance and Mood|The Effect of Long-Chain Polyunsaturated Fatty Acids on Cognitive Performance and Mood of Healthy Young Adults||University of Ulm|No|Completed|October 2006|||January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|82|||Both|16 Years|24 Years|Accepts Healthy Volunteers|||February 2008|February 13, 2008|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615277||160758|
NCT00615589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umcc 2007.074|Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen|Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen||University of Michigan Cancer Center|Yes|Terminated|February 2008|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|70 Years|No|||August 2015|August 11, 2015|January 22, 2008|Yes|Yes|Low accrual|No|December 3, 2014|https://clinicaltrials.gov/show/NCT00615589||160734|
NCT00632944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5529|Effects of Nursing Rounds on Patients Fall Rates|Effects of Nursing Rounds on Patients Fall Rates, Satisfaction, and Call Light Use in an In-patient Medical Surgical Unit||State University of New York - Upstate Medical University|No|Completed|January 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|N/A||1|Anticipated|300|||Both|18 Years|89 Years|No|Non-Probability Sample|In patients on 2 units: an Oncology/OBGYN unit and an Orthopedic/Neurology unit.|March 2008|June 4, 2015|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632944||159426|
NCT00632957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK IRB # 04-0339-F1V|Oral Infections: Dietary Regulation of Local and Systemic Inflammatory Responses|Center for the Biologic Basis of Oral/Systemic Diseases Project 5: Oral Infections: Dietary Regulation of Local and Systemic Inflammatory Responses.||University of Kentucky|No|Completed|September 2004|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 11, 2011|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632957||159425|
NCT00608361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00792|Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery|Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction||National Cancer Institute (NCI)|No|Completed|October 2008|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00608361||161270|
NCT00604786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00007520|The Effect of Omalizumab on Responses to Cat Allergen Challenge|Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge||Johns Hopkins University|Yes|Completed|July 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|50 Years|No|||October 2009|October 27, 2009|January 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604786||161535|
NCT00604799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigational Plan #031|VALOR: The Talent Thoracic Stent Graft System Clinical Study|Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms|VALOR|Medtronic Endovascular|Yes|Completed|July 2003|June 2011|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|379|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|December 21, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604799||161534|
NCT00606060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11486|BAY14-2222 Continuous Infusion in Surgeries|Safety and Efficacy of Continuous Infusion of Recombinant Factor VIII - Sucrose-formulated (BAY 14 2222) Concentrate in Patients With Hemophilia A Undergoing Major Elective Surgery.||Bayer|No|Completed|July 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|12 Years|65 Years|No|||April 2010|April 12, 2010|January 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606060||161440|
NCT00606073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC IRB#31/2007|The Influence of Different Concentrations of Glucose in Culture Media on Fertilization and Embryo Quality|The Influence of Different Concentrations of Glucose in Culture Media(i.e: ISM1 vs. IVF) on Fertilization and Embryo Quality||Hillel Yaffe Medical Center|Yes|Not yet recruiting|February 2008|||August 2009|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2008|January 21, 2008|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606073||161439|
NCT00616889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-206-05|Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder|Effects of Seroquel on Sleep Architecture in Patients With Bipolar Depression or Major Depressive Disorder - An Open Label Study||Queen's University|No|Completed|May 2006|January 2009|Actual|January 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|65 Years|No|Non-Probability Sample|Adults with current Major Depressive Disorder or Bipolar Depression|December 2015|December 14, 2015|September 9, 2005|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616889||160636|
NCT00616902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-221|The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5|Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5|PRIMO II|Abbott|Yes|Terminated|January 2009|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|February 5, 2008|Yes|Yes|This study was prematurely terminated due to low enrollment|No|May 21, 2010|https://clinicaltrials.gov/show/NCT00616902||160635|This study was prematurely terminated due to low enrollment. Only 12 subjects were randomized at 10 investigative sites with none of the subjects completing the study.
NCT00606723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML SCT-BFM 2007|Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML|Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML; Multi Center Therapy Concept||Hannover Clinical Trial Center GmbH|Yes|Recruiting|April 2010|January 2021|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|153|||Both|N/A|21 Years|No|||February 2016|February 23, 2016|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606723||161389|
NCT00617461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110527|A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment|Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.||XenoPort, Inc.|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||January 2013|July 15, 2013|February 6, 2008|Yes|Yes||No|April 26, 2011|https://clinicaltrials.gov/show/NCT00617461||160593|
NCT00617994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-202|Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis|An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of INCB018424 When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).||Incyte Corporation|No|Completed|August 2007|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|65 Years|No|||March 2012|March 13, 2012|January 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617994||160552|
NCT00617721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3930|Markers of Defective Membrane Remodelling in Scott-like Syndromes|Defect in Cell Stimulation and Unexplained hemorrhagesMarkers Related to Membrane Remodelling in the Prognosis Scott-like Syndormes||University Hospital, Strasbourg, France|No|Recruiting|June 2008|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|125|Samples With DNA|plasma, white cells, DNA (when the family is informative)|Both|2 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with unexplained bleeding disorder|November 2015|November 4, 2015|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617721||160573|
NCT00617955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aprotinin|Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates|Systemic Effects of Aprotinin During Cardiac Surgery/ Long Term Death Rates||State University of New York - Upstate Medical University|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|462|||Both|18 Years|N/A|No|Probability Sample|Cardiac Surgery patients|December 2009|December 29, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617955||160555|
NCT00617968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976D_2502|GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer|A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-positive Breast Tumor.||Sanofi||Completed|October 2003|June 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Female|60 Years|N/A|No|||September 2009|September 1, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617968||160554|
NCT00614393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-004|Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004 AM9)|A Phase II III Study of MK0646 Treatment in Combination With Cetuximab and Irinotecan For Patients With Metastatic Colorectal Cancer||Merck Sharp & Dohme Corp.|Yes|Completed|December 2007|March 2012|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|560|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00614393||160823|
NCT00614718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USB01|Failure of Chronically Implanted Defibrillator Leads -Incidence and Management|Failure of Chronically Implanted Defibrillator Leads -Incidence and Management A Retrospective Multicenter Study||University Hospital, Basel, Switzerland|No|Completed|January 1993|January 2007|Actual|January 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|1317|||Both|N/A|N/A|No|Non-Probability Sample|1317 consecutive patients with an ICD implanted at three European centers between 1993 and        2004|January 2008|February 12, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00614718||160801|
NCT00615849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPT|Efficacy of the Additional Mechanical Pleurodesis for Surgical Management of Primary Spontaneous Pneumothorax|Phase III Study of Evaluation of the Efficacy of Additional Mechanical Pleurodesis After Thoracoscopic Wedge Resection for the Management of Primary Spontaneous Pneumothorax||Seoul National University Bundang Hospital|Yes|Completed|November 2006|July 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1440|||Both|16 Years|35 Years|No|||September 2011|September 28, 2011|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615849||160715|
NCT00615303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID12-49-23|The Effectiveness of Simethicone In Improving Visibility During Colonoscopy|The Effectiveness of Simethicone In Improving Visibility During Colonoscopy: A Randomized, Placebo-controlled Study||Ramathibodi Hospital|No|Completed|December 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|70 Years|No|||February 2013|February 21, 2013|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615303||160756|
NCT00616421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P20|Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children|A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age||Novartis|Yes|Completed|March 2008|October 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|2907|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 31, 2008|Yes|Yes||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00616421||160671|
NCT00616434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108UC201|A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Avonex® in Subjects With Moderate to Severe Ulcerative Colitis||Biogen|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|65 Years|No|||July 2014|July 23, 2014|February 5, 2008|Yes|Yes||No|July 23, 2014|https://clinicaltrials.gov/show/NCT00616434||160670|
NCT00632970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS001|Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals|A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy||George Washington University|Yes|Completed|February 2008|June 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2009|July 7, 2011|February 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00632970||159424|
NCT00604500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04703|A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)|An Open-Label, Multi-Center, Patient Handling Study of Mometasone Furoate/Formoterol Fumarate MDI With an Integrated Dose Counter in Adolescent and Adult Subjects and Adult With Asthma or COPD||Merck Sharp & Dohme Corp.|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|272|||Both|12 Years|N/A|No|||September 2015|September 10, 2015|January 21, 2008|No|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00604500||161557|
NCT00605748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. C00807|Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins|PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins|PAVAV|Deutsches Herzzentrum Muenchen|Yes|Recruiting|December 2007|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|80 Years|No|||August 2008|August 26, 2008|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605748||161464|
NCT00605761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF2110398|SD Cystic Fibrosis Study|An Open Label Dose Ascending, Single Dose Study to Investigate the Pharmacokinetics of SB-656933 in Subjects With Cystic Fibrosis.||GlaxoSmithKline||Completed|February 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|9|||Both|16 Years|N/A|No|||April 2011|March 15, 2012|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605761||161463|
NCT00605436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9377-29543-02|Yoga for the Treatment of Metabolic Syndrome|Restorative Yoga for Therapy of the Metabolic Syndrome: A Pilot Trial||University of California, San Francisco|No|Completed|October 2006|June 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2008|January 30, 2008|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00605436||161485|
NCT00616057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/21/NOV/300|Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome|Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome|FRUCTOB|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|February 2008|June 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|65 Years|No|||July 2012|July 4, 2012|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616057||160699|
NCT00616070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-601-003|Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)|||Sirion Therapeutics, Inc.||Completed|December 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Years|N/A|No|||June 2011|June 29, 2011|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616070||160698|
NCT00616356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUH IRB # CRI-0618|Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults|Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults||Rockefeller University|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Rockefeller University Personnel|November 2011|November 7, 2011|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00616356||160676|
NCT00617175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANCE III|Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III|ADVANCE III: Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III|ADVANCEIII|Medtronic Bakken Research Center|Yes|Completed|March 2008|February 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1902|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 4, 2008||No||No|August 30, 2012|https://clinicaltrials.gov/show/NCT00617175||160614|
NCT00618007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7941006|Effect of PF-00734200 in Subjects With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of 12-Week Administration Of PF-00734200 To Subjects With Type 2 Diabetes Mellitus And Insufficient Glycemic Control On Metformin Treatment||Pfizer|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|289|||Both|18 Years|80 Years|No|||June 2011|June 9, 2011|February 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00618007||160551|
NCT00618020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-b No. OVC-C01|Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries|A Feasibility Study to Evaluate the Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusion in Coronary Arteries||Ovalum|Yes|Completed|August 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|80 Years|No|||July 2008|July 17, 2008|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00618020||160550|
NCT00613808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP 3|Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers|An Investigation of Topical Application of Gaseous Nitric Oxide on Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremities||Nitric BioTherapeutics, Inc|Yes|Terminated|February 2008|May 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00613808||160865|
NCT00614081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7825|GFR Measurement With Contrast-enhanced Dynamic MRI|Measurement of Glomerular Filtration Rate With Contrast-enhanced Dynamic MR Imaging in Renal Transplant Recipients: Evaluation of the Agreement With the Cr51 -EDTA Method and of Reproducibility|IREN|University Hospital, Bordeaux|No|Completed|January 2008|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|71|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00614081||160845|
NCT00614133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-64456|Effect of Intravenous Nutrition and Epidural Analgesia on Protein Loss After Surgery|Hypocaloric Isonitrogenous Nutrition and Epidural Analgesia: a Novel Strategy to Induce Anabolism After Surgery||McGill University Health Center|No|Completed|June 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||January 2008|January 30, 2008|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00614133||160841|
NCT00614731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN KLH 07|Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route|Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|February 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614731||160800|
NCT00614744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0038|Late Hypothermia for Hypoxic-Ischemic Encephalopathy|Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network||NICHD Neonatal Research Network|Yes|Active, not recruiting|April 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|N/A|24 Hours|No|||July 2015|July 24, 2015|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00614744||160799|
NCT00615602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/04.23|Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer|A Multicenter Randomized Phase III Study Comparing 6 Versus 12 Months of Trastuzumab in Combination With Dose Dense Docetaxel Following FE75C as Adjuvant Treatment of Women With Axillary Lymph Node Positive Breast Cancer Over-expressing HER2||Hellenic Oncology Research Group|No|Completed|October 2004|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|489|||Female|18 Years|75 Years|No|||March 2015|March 3, 2015|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615602||160733|
NCT00616174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01490|Does Warming Mothers During Cesarean Delivery Help Keep Babies Warm When Delivered?|The Effect of Maternal Warming During Cesarean Delivery on Neonatal Temperature||University of British Columbia|Yes|Completed|February 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|70|||Female|19 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 14, 2014|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616174||160690|
NCT00615615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N159|Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures|Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial||UCB Pharma|No|Completed|September 1999|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|216|||Both|4 Years|16 Years|No|||September 2009|September 16, 2013|January 27, 2008||||No||https://clinicaltrials.gov/show/NCT00615615||160732|
NCT00632658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0208B|Development and Validation of a Symptom Scale for Children With Chronic Graft-Versus-Host Disease|Development and Validation of a Symptoms Scale for Children With Chronic Graft-Versus-Host Disease|cGVHD|Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|January 2008|July 2010|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|5 Years|18 Years|No|Non-Probability Sample|Patients with cGVHD will be identified by their local physican and asked to participate in        this research study. A total of 24 children will be asked to participate in this study.        The parents of all of the 24 children will also be asked to participate and give us their        feed-back on what it is like to cope with a child with cGVHD.|January 2009|January 27, 2009|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00632658||159448|
NCT00604513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 DK72972 (completed)|Ready. Set. ACTION! A Theater-Based Obesity Prevention Program for Children|A Theater-Based Obesity Prevention Program for Children|RSA|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2006|May 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|181|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|December 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00604513||161556|
NCT00605449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIX109980|A Drug Interaction Study Between Simvastatin and GSK376501|Phase I, Randomized, Open-Label, 3 Period Crossover Drug Interaction Study Between Simvastatin and GSK376501 in Healthy Subjects||GlaxoSmithKline||Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|January 18, 2008||||||https://clinicaltrials.gov/show/NCT00605449||161484|
NCT00615784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04407|Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia|A Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia|UPCC 04407|University of Pennsylvania|No|Completed|January 2008|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|February 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00615784||160720|
NCT00617227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maimid|Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin|Measurement of Serum Vancomycin in Patients Receiving Enteral ( Oral/Intracolonic) Vancomycin.||Maimonides Medical Center|Yes|Completed|October 2007|February 2010|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Clostridium difficile associated colitis on enteral vancomycin therapy|February 2010|February 9, 2010|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00617227||160610|
NCT00616603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57164|The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks|The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks||Loma Linda University|No|Terminated|August 2007|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|80 Years|No|||June 2014|June 10, 2014|February 4, 2008||No|PI is no longer here.|No|May 17, 2013|https://clinicaltrials.gov/show/NCT00616603||160658|PI left the institution and data analysis cannot be summarized due to poor data integrity.
NCT00613834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 3343|Intrauterine Lidocaine Infusion for Essure Sterilization Procedures|Intrauterine Lidocaine Infusion for Pain Management During Outpatient Essure Transcervical Tubal Sterilization Procedures||Oregon Health and Science University|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|58|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 9, 2012|January 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00613834||160863|
NCT00613821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU RES 2173|Lidocaine and Pain Management in First Trimester Abortions|A Comparison of Intrauterine Lidocaine Infusion and Paracervical Block for Pain Management in First Trimester Abortions||Oregon Health and Science University|Yes|Completed|September 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|January 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00613821||160864|
NCT00614094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007043|Maternal Hypoglycemia and Placental Pathology|Maternal Hypoglycemia During One Hour Glucose Tolerance Test as a Risk for Decreased Placental Weight and Placental Pathology||Oklahoma State University Center for Health Sciences|Yes|Completed|December 2007|July 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|350|||Female|N/A|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women younger than 35, who delivered a term infant either by vaginal delivery or cesarean        section at Tulsa Regional Medical Center between July 1, 2005 and July 31, 2007|July 2008|July 8, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614094||160844|
NCT00614432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 3861|Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women|Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women||University of Hawaii|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Whole blood|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women will be approached about this study after they have made a decision to terminate the        pregnancy and have completed the preoperative history and physical examination and        surgical consenting process. We will recruit women who continue on anticoagulant therapy        (heparin, low molecular weight heparin, or warfarin) without interruption for the surgical        procedure. Our control group will consist of women who are not on anticoagulant treatment.|December 2010|December 16, 2010|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614432||160820|
NCT00614419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81/2002/O|Prospective Randomized Trial Comparing Lichtenstein's Repair of Inguinal Hernia With Polypropylene Mesh Versus Surgisis|Prospective Randomized, Double-Blind, Controlled Trial Comparing Lichtenstein's Repair of Inguinal Hernia With Polypropylene Mesh Versus Surgisis ES Soft Tissue Graft||St. Orsola Hospital|No|Completed|January 2003|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|N/A|No|||December 2007|February 12, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614419||160821|
NCT00614757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKP0003|Insulin Resistance Study|The Prevalence of Insulin Resistance and the Potential Modulation of Insulin Resistance by N-acetylcysteine (NAC) in Patients Chronically Infected by the Hepatitis C Virus|IR|Midwest Biomedical Research Foundation|Yes|Suspended|May 2005|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 25, 2012|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614757||160798|
NCT00614978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAP111172|Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer|Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer|LAPTEM|Jules Bordet Institute|No|Completed|January 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|70 Years|No|||June 2011|September 18, 2012|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00614978||160781|
NCT00615329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Huntsman Cancer Institute|Huntsman Biopsy Study|The Huntsman Cancer Institute - The Use of Microarray Analysis in Characterizing Mesenchymal Tissue Tumors: Differentiation of Normal, Benign, and Malignant Conditions||State University of New York - Upstate Medical University|No|Terminated|April 2003|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|142|Samples With DNA|cDNA microarrays facilitate the systematic and comprehensive analysis of transcriptional      alterations occurring in diseased tissues.|Both|N/A|N/A|No|Non-Probability Sample|All patients who present to Doctor Damron for care relating to a bone or soft tissue tumor        that has been established to be or is suspected to possibly be a sarcoma AND who will        require a diagnostic or therapeutic surgical procedure which will result in procurement of        tissue for histologic review will be approached in the consent process.|November 2014|November 24, 2014|February 1, 2008||No|Huntmans Cancer Institute terminated study|No||https://clinicaltrials.gov/show/NCT00615329||160754|
NCT00615342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-04-03|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2005|||||N/A|N/A|N/A||||||||||||||February 17, 2015|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00615342||160753|
NCT00615628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osteosarcoma & Paget's Disease|Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:|Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: Examination of Osteosarcoma Tissue Samples From Two Family Members for Loss of Heterozygosity in the Chromosome 18 Region, Genetically Linked With Paget's Disease of Bone||State University of New York - Upstate Medical University|No|Terminated|April 2002|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|8|Samples With DNA|Once a specimen is obtained DNA will be isolated for paraffin-embedded tissue and peripheral      blood. Osteosarcoma samples from paraffin embedded, formalin-fixed post-surgical tissue      samples will be obtained for the proband and father. Matched normal spamples will be      obtained from these individuals as adjacent normal tissue from the post-surgical specimens|Both|N/A|N/A|No|Non-Probability Sample|This is a familial study therefore the only inclusion/exclusion criteria would be that        subjects must be a blood relative and over the age of 18. The subjects are proband and        father along with unaffected blood relatives. Their peripheral blood will act as a control        and provide information to delineate the inheritance from the father, as seen in the son.|May 2013|May 29, 2013|February 1, 2008||No|low enrollment low enrollment|No||https://clinicaltrials.gov/show/NCT00615628||160731|
NCT00615641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72850|Diet, Exercise and Body Fat in 3-5 Year Olds|Relationship of Dietary Factors and Physical Activity to Body Fat in 3-5 Year Old Children||Arkansas Children's Hospital Research Institute|No|Completed|June 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|65|Samples Without DNA|Urine|Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are seeking healthy 3-5 year old children in the greater Little Rock area.|February 2010|February 12, 2010|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615641||160730|
NCT00632671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040807|COLOMBES Project:Constitution of a Population-based Cohort of Obese Subjects With Longitudinal Long-term Follow-up|Constitution of a Population-based Cohort of Obese Subjects With Longitudinal Long-term Follow-up.|COLOMBES|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|March 2005|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|311|Samples With DNA|plasma, serum, DNA, RNA, cell blood, for persons undergoing bariatric surgery (specific      consentment): samples of liver and adipocytes|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Morbidly obese subjects|December 2013|December 31, 2013|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632671||159447|
NCT00632684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH073559|Effectiveness of an Adaptive Treatment Model for At-risk Family Caregivers|Adaptive Intervention for At-risk Family Caregivers||Penn State University|No|Completed|July 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|November 22, 2011|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00632684||159446|
NCT00605111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3021|Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes|Efficacy and Safety of Initiation of Biphasic Insulin Aspart 30 Treatment in Subjects With Type 2 Diabetes Mellitus Failing OAD Therapy||Novo Nordisk A/S|No|Completed|December 2003|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|193|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|January 18, 2008||||No||https://clinicaltrials.gov/show/NCT00605111||161510|
NCT00605124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSHP Dnro6/2007|Progressive Exercise After Total Knee Arthroplasty (TKA)|Progressive Exercise After Total Knee Arthroplasty: A Randomised Controlled Trial||Jyväskylä Central Hospital|No|Completed|January 2008|December 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00605124||161509|
NCT00615498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000064|Study to Evaluate the Effects of Weight Loss on Airway Inflammation and Mechanics in Subjects With Asthma (Asthma-Bariatric Surgery Study)|Study to Evaluate the Effects of Weight Loss on Airway Inflammation and Mechanics in Subjects With Asthma||Emory University|No|Completed|July 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Blood and exhaled breath condensate samples will obtained at all time points (baseline, 1      month, 6 months, and 1 year.|Both|18 Years|70 Years|No|Non-Probability Sample|Obese asthmatics|July 2013|July 30, 2013|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00615498||160741|
NCT00615511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE0504007841|Efficacy of Pregnenolone in Patients With Schizophrenia|Efficacy of Pregnenolone in Patients With Schizophrenia||Weill Medical College of Cornell University|No|Completed|June 2007|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615511||160740|
NCT00615524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG108843|Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer||GlaxoSmithKline||Terminated|April 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Female|18 Years|N/A|No|||March 2013|March 1, 2013|February 1, 2008|||Cancelled Before Enrollment|No||https://clinicaltrials.gov/show/NCT00615524||160739|
NCT00616616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071271|Single Incision Laparoscopy|Single Incision Laparoscopy|SIL|University of California, San Diego|No|Completed|September 2007|February 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||August 2010|August 27, 2010|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616616||160657|
NCT00616629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00005|Cardiac Electrophysiological Study|A Multi-centre, Double-blind, Randomised, Placebo-controlled, Singledose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure||AstraZeneca|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|55|||Both|20 Years|80 Years|No|||August 2011|August 17, 2011|February 5, 2008|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00616629||160656|
NCT00616967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0785, CDR0000586335|Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer|A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Completed|May 2008|February 2014|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Female|18 Years|N/A|No|||June 2014|June 16, 2014|February 14, 2008|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT00616967||160630|A proportion of women received additional preoperative chemotherapy after study treatment,complicating the evaluation of primary endpoint and role of FDG-PET in predicting response. Limited matched samples for Ki67 analysis.
NCT00616980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00009937/STU00001469|Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia|Injection of Autologous CD34-Positive Cells for Improved Symptomatic Relief and Ischemic Wound Healing in Subjects With Moderate or High-Risk Critical Limb Ischemia|ACT34-CLI|Losordo, Douglas, M.D.|Yes|Completed|December 2007|August 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|28|||Both|21 Years|80 Years|No|||July 2011|July 21, 2011|January 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616980||160629|
NCT00616915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-219-05|Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?|Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?||Queen's University|No|Completed|January 2007|January 2010|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616915||160634|
NCT00616928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110464|Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years|A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged ≥18 Years||GlaxoSmithKline||Completed|January 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|10||Actual|4561|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 13, 2014|January 28, 2008|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00616928||160633|
NCT00616941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2006-001|A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission|A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) With or Without Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission||Ludwig Institute for Cancer Research|Yes|Completed|August 2008|June 2011|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|26|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|February 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00616941||160632|
NCT00617201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#07-0041|Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial|Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial||University of Kentucky|Yes|Completed|July 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 13, 2012|February 5, 2008|Yes|Yes||No|November 13, 2012|https://clinicaltrials.gov/show/NCT00617201||160612|
NCT00617214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NDE-SER-2007/1|Schizophrenic Patients Taking Part in Integrated Care Program|Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Non-interventional Study|CARE I|AstraZeneca|No|Terminated|January 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Probability Sample|outpatient department from clinics or private practices|October 2008|December 8, 2010|February 5, 2008||No|Difficulty finding eligible sites/patients:current situation in health policy cause negative    effects on existing/planned contracts for integrated care programs|No||https://clinicaltrials.gov/show/NCT00617214||160611|
NCT00617786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-176|CPT Testing for Sacral Neuromodulation Outcomes|Current Perception Threshold Testing for Sacral Neuuromodulation Outcomes||William Beaumont Hospitals|No|Completed|October 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 22, 2011|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617786||160568|
NCT00618046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXCA-T600-PVFD-2|Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|November 2004|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|45 Years||||February 2008|February 15, 2008|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00618046||160548|
NCT00614107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5301UMU|Organization in Acute Atrial Fibrillation Post Open Heart Surgery|Organization in Acute Atrial Fibrillation Post Open Heart Surgery|A-Fib|State University of New York - Upstate Medical University|No|Enrolling by invitation|January 2008|January 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples With DNA|Tissue sample for the right and left sid eof the heart.|Both|18 Years|79 Years|No|Non-Probability Sample|Any person over 18 years having an elective valve, CABG or combination procedure|January 2008|February 12, 2008|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00614107||160843|
NCT00614120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1796|Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|January 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|929|||Both|18 Years|80 Years|No|||October 2014|October 29, 2014|January 15, 2008|Yes|Yes||No|February 23, 2010|https://clinicaltrials.gov/show/NCT00614120||160842|
NCT00614406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 3854|The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle|The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle.||Oregon Health and Science University|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|11|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|January 31, 2008|Yes|Yes||No|July 15, 2011|https://clinicaltrials.gov/show/NCT00614406||160822|
NCT00605293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21060|A Study of Intravenous Mircera for the Maintenance Treatment of Hemodialysis Patients With Chronic Renal Anemia|An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. Versus Epoetin Alfa for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|December 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605293||161496|
NCT00606580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14134|Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)|A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)||U.S. Army Medical Research and Materiel Command|No|Completed|January 2008|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|375|||Both|5 Years|65 Years|No|||June 2014|June 11, 2014|January 21, 2008|Yes|Yes||No|May 12, 2014|https://clinicaltrials.gov/show/NCT00606580||161400|
NCT00614770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR0003|Narrow Band Imaging Colon Polyp Study|A Multicenter, Prospective, Randomized Controlled Trial for the Detection of Colon Polyps and Predicting Histology||Kansas City Veteran Affairs Medical Center|No|Completed|February 2008|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|630|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 16, 2010|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614770||160797|
NCT00615004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-7|Cardiovascular Outcome After Surgery or Somatostatin Analogues|An Observational, Retrospective, Comparative Study to Investigate Differential Outcome on Cardiomyopathy Following Control of Acromegaly After Surgery or Somatostatin Analogues Given as First-Line Therapy|CVAcro|Federico II University|No|Completed|January 1997|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|215|Samples Without DNA|Sera from most patients on a yearly bases are stored in our freezed at minus 80° for      eventual further studies. No experimental parameters are included in the current study.|Both|18 Years|85 Years|No|Probability Sample|We will review all files from consecutive patients with active acromegaly coming to the        Units of Endocrinology or Neurosurgery of the "Federico II" University of Naples from Jan        1st 1997 to December 31st 2006, primarily treated with either surgery or depot SSA, i.e.        lanreotide (LAN) or slow-release octreotide (LAR), and with an available follow-up of at        least 12 months. Due to the study design, this is a non ran-domized study. However, our        routine procedure generally considers first-line treatment with SSA for 6-12 months,        unless the tumors are clearly non invasive on Magnetic Resonance Imaging (MRI) and/or the        patients who do not present any surgical or anesthesiological risk.|December 2007|February 13, 2008|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615004||160779|
NCT00614991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL111242|An Interaction Study to Assess Drug Levels in Healthy Adult Subjects|Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics After Fosamprenavir (FPV) and Raltegravir (RTG) Are Each Administered Alone Versus in Combination With or Without Ritonavir (RTV) Boosting in Healthy Adult Subjects||Garden State Infectious Disease Associates, PA|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label|6||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 1, 2008|No|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00614991||160780|Data for primary outcomes are not available per intervention . Values reported as means are uncertain measure type (data no longer available).
NCT00615355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-262 ex 06/07|Epidermal Cell Transplantation in Vitiligo Skin With and Without Narrow-band Ultraviolet B (UVB) Treatment|Efficacy of Narrow-band UVB Treatment After Transplantation of Harvested Epidermal Cells in Vitiligo||Medical University of Graz|No|Active, not recruiting|February 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|11|||Both|18 Years|70 Years|No|||July 2014|July 22, 2014|February 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00615355||160752|
NCT00606203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-0083|Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke?|||Chang Gung Memorial Hospital|No|Recruiting|September 2007|September 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606203||161429|
NCT00606541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002146|An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)|An Open Label, Double-blind Discontinuation Study of Quetiapine (Extended Release) XR in Social Anxiety Disorder||Duke University|Yes|Terminated|January 2008|November 2012|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|65 Years|No|||December 2012|July 31, 2014|January 22, 2008|No|Yes|The study was terminated by the sponsor due to budgetary issues|No||https://clinicaltrials.gov/show/NCT00606541||161403|
NCT00606554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26906|Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation|A Randomized Controlled Trial of Computer-Driven Weaning Compared With Standard of Care Weaning in Medical Patients Requiring Mechanical Ventilation||Boston Medical Center|No|Terminated|January 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||June 2011|July 24, 2013|January 3, 2008||No|Slow recruitment of subjects|No|February 7, 2011|https://clinicaltrials.gov/show/NCT00606554||161402|This trial was terminated early due to slow recruitment. It did not reach the target N of 220.
NCT00633308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NxStage LongHD|Phosphorus and Calcium Removal During Long Hemodialysis Treatment Sessions|Phosphorus and Calcium Removal During Long Hemodialysis Treatment Sessions|hemodialysis|Indiana University|No|Withdrawn|March 2008|February 2011|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 21, 2008|No|Yes|No coordinator available to work on study.|No||https://clinicaltrials.gov/show/NCT00633308||159399|
NCT00632736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101468/248|An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease|An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169||GlaxoSmithKline|No|Completed|February 2004|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|419|||Both|30 Years|N/A|No|||March 2011|April 13, 2015|March 4, 2008|Yes|Yes||No|December 2, 2010|https://clinicaltrials.gov/show/NCT00632736||159442|
NCT00633022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1111138|A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging|A Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Two Regimens of GW856553, Over a Period of 3 Month, on In-vivo Macrophage Activity, as Assessed by FDG-PET/CT Imaging, in the Carotid Arteries and Aorta of Subjects With Established Atherosclerosis||GlaxoSmithKline|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|102|||Both|50 Years|80 Years|No|||July 2012|August 2, 2012|February 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633022||159420|
NCT00605137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1604|Safety of Insulin Detemir in Children With Type 1 Diabetes|Safety of Insulin Detemir and Insulin NPH in Children With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|May 2004|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|83|||Both|7 Years|18 Years|No|||June 2012|June 19, 2012|January 17, 2008||||No||https://clinicaltrials.gov/show/NCT00605137||161508|
NCT00616083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56991|Percent Body Fat in Breast Fed Infants|Developing Normative Body Composition Data in Early Infancy|PeaPod|Arkansas Children's Hospital Research Institute|No|Completed|April 2006|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|190|||Both|N/A|2 Weeks|No|Non-Probability Sample|Helathy breast fed infats, less than a week old living in the Little Rock area.|August 2009|August 19, 2009|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616083||160697|
NCT00616369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X070116004|Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)|Identification of Genetic Markers for Cardiopulmonary Diseases|Genotype|University of Alabama at Birmingham|No|Completed|January 2008|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|255|Samples With DNA|The following genetic tests will be performed on these specimens:      Endothelin1, Endothelin receptors A&B, Prostaglandin, Prostaglandin receptors,      CytochromeP450, NPR, A, B and C, Transforming Growth Factor (B), Pai-1 HindIII, Toll-like      receptor4, Pai-1 4g5g, Xho-1, P22, Tissue Plasminogin Activators, Urokinase Plasminogen      Activators, Fibrinogen, Nitric Oxide Synthase, BMPRs, SMADs, VEGFs, FGFs, Rho Kinase,      Elastins, Angiopoietin, PDE5, Serotonin receptor, Angiotensin, Alk 1, and Cell Culture (DNA      immortalization)      There is a possibility that other genetic testing could arise as the study progresses. In      this case, the IRB would be notified prior to testing.|Both|15 Years|N/A|No|Non-Probability Sample|Participants with the diagnosis of any of the previously listed Cardiopulmonary Diseases        who are ≥15 years of age will be approached and offered the opportunity to participate in        this study.|January 2016|January 7, 2016|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616369||160675|
NCT00616382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHPDA2|Treating the Resistant Patent Ductus Arteriosus (PDA)|New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates||Shaare Zedek Medical Center|Yes|Not yet recruiting|March 2008|||March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||January 2008|February 14, 2008|January 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00616382||160674|
NCT00616642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586480|Rosiglitazone in Treating Patients With Pituitary Tumors|Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors||Jonsson Comprehensive Cancer Center|Yes|Terminated|October 2006|||November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|65 Years|No|||March 2013|March 4, 2013|February 14, 2008|Yes|Yes|low patient recruitment|No|March 4, 2013|https://clinicaltrials.gov/show/NCT00616642||160655|Recruitment was the main limitation. Patients were available but were not interested in the study due to possible side effects of the study drug.
NCT00616954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-06-HMO-CTIL|A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT|An Investigator Initiated, Prospective, Randomized, Controlled Study in Order to Evaluate the Effect of Anti-thymocyte Globulin (Fresenius ATG) on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical Allogeneic Hematopoietic Stem-cell Transplantation||Hadassah Medical Organization||Terminated|May 2008|September 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|3 Years|70 Years|No|||August 2009|April 19, 2015|January 22, 2008||No|low recruitment|No||https://clinicaltrials.gov/show/NCT00616954||160631|
NCT00617513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-INT-1|Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation|A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation||Movetis|No|Completed|March 1995|March 1996|Actual|March 1996|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|174|||Both|18 Years|70 Years|No|||February 2008|May 28, 2008|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617513||160589|
NCT00617526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA806-201|Naïve HIV POC Monotherapy Trial|A Multicenter Phase 2a, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Determine the Antiviral Activity, Pharmacokinetics, Tolerability and Safety of RDEA806 in HIV-1 Positive, Antiretroviral naïve Subjects||Ardea Biosciences, Inc.|No|Completed|January 2008|August 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Male|18 Years|65 Years|No|||December 2013|December 20, 2013|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617526||160588|
NCT00617474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L1386|The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group|The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group||Labbafinejhad Hospital||Not yet recruiting|March 2008|March 2009|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|March 27, 2008|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617474||160592|
NCT00617487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EchostressSSc|Pulmonary Arterial Hypertension in Systemic Sclerosis|Stress Echocardiography in the Early Identification of Pulmonary Arterial Hypertension in Systemic Sclerosis||IRCCS Policlinico S. Matteo|Yes|Recruiting|December 2007|January 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|patients with systemic sclerosis|August 2009|August 3, 2009|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617487||160591|
NCT00617734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13913|Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck|A Randomized Phase 2 Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy||ImClone LLC|No|Completed|March 2008|July 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|January 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617734||160572|
NCT00617981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-06-301|Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)|A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma||Celsion|Yes|Active, not recruiting|February 2008|December 2015|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|700|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617981||160553|
NCT00618072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK-109157|EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance|EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrome W)|EMPOWIR|New York Medical College|Yes|Completed|January 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Female|35 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|February 5, 2008||No||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00618072||160546|Widespread media coverage of cardiovascular risks of rosiglitazone led to an unanticipated high drop out rate of subjects just prior to their randomization; 22 of 68 eligible subjects did not undergo randomization due to concerns about the drug.
NCT00618059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILO-04|Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Sequence Crossover Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|August 2004|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 15, 2008|January 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00618059||160547|
NCT00613847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-090|Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab|Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab||Memorial Sloan Kettering Cancer Center||Completed|October 2006|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|17|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|January 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00613847||160862|
NCT00613860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/08|Sequential Endoscopic Lung Volume Reduction|Sequential Endoscopic Lung Volume Reduction in Patients With Heterogeneous Lung Emphysema||Heidelberg University|Yes|Recruiting|January 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|40 Years|80 Years|No|||January 2008|April 26, 2011|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613860||160861|
NCT00614146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1438|Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure|Therapeutic Impact of Albumin Dialysis With the Molecular Adsorbents Recirculating System (MARS®) in Severely Decompensated Chronic Liver Disease|RELIEF|Gambro Lundia AB|Yes|Completed|April 2003|April 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|No|||June 2009|June 15, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00614146||160840|
NCT00606593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-057A201|Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia|Multicenter, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Dose-finding Study to Evaluate the Efficacy and Safety of Oral Administration of ACT-078573 in Elderly Subjects With Chronic Primary Insomnia||Midnight Pharma, LLC|No|Completed|December 2007|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|112|||Both|65 Years|N/A|No|||February 2016|February 11, 2016|January 4, 2008|Yes|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT00606593||161399|
NCT00606918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA-4343|Validation of a New Device to Measure Neuromuscular Disease Progression|Validation of a New Device to Measure Neuromuscular Disease Progression|ATLIS|Massachusetts General Hospital|No|Completed|January 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with ALS|May 2011|May 11, 2011|January 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606918||161374|
NCT00605605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-93-28|Vascular Endothelial Protection Effects of Dextromethorphan|Anti-Inflammation & Vascular Endothelial Protection Effects of Dextromethorphan on Heavy Smoker||National Cheng-Kung University Hospital|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Male|30 Years|60 Years|No|||January 2008|January 30, 2008|January 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00605605||161475|
NCT00605891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/PR/033009/001/05|Dose Finding Study of CHF 4226 for Treating Patients With COPD|A Randomized, Controlled,14-Treatment Day, Multicenter Study to Determine the Optimal Efficacious and Safe Dose of CHF 4226 in a Metered Dose Inhaler in Treating Patients With Chronic Obstructive Pulmonary Disease||Chiesi Farmaceutici S.p.A.|No|Completed|October 2006|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|278|||Both|40 Years|75 Years|No|||August 2010|August 24, 2010|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605891||161453|
NCT00605904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080058|Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics|Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics||National Institutes of Health Clinical Center (CC)|No|Completed|January 2008|March 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|21 Years|65 Years|No|||May 2012|May 23, 2012|January 30, 2008|No|Yes||No|September 21, 2011|https://clinicaltrials.gov/show/NCT00605904||161452|
NCT00605917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501092|Special Investigation Of J Zoloft For Panic Disorder Patients|Special Investigation Of J Zoloft For Panic Disorder Patients||Pfizer|No|Completed|April 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|997|||Both|N/A|N/A|No|Probability Sample|The patients to whom an investigator involved in A0501092 prescribes sertraline        hydrochloride.|August 2012|August 20, 2012|January 18, 2008|No|Yes||No|August 20, 2012|https://clinicaltrials.gov/show/NCT00605917||161451|
NCT00606229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-07-001|A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|65 Years|No|||February 2014|February 11, 2014|January 19, 2008||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00606229||161427|
NCT00606242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL6788-15958-08|Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma|A Randomized Double Blind Study of the Dose Response Effects of Fluticasone Propionate on Hypertonic-saline Induced Bronchoconstriction in Asthmatic Subjects|FluSAL|University of California, San Francisco|No|Completed|January 2000|December 2007|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|44|||Both|18 Years|75 Years|No|||March 2014|March 6, 2014|January 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00606242||161426|
NCT00605878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080059|Studies of Skin Microbes in Healthy People and in People With Skin Conditions|Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients||National Institutes of Health Clinical Center (CC)||Recruiting|January 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|2 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00605878||161454|
NCT00606216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-162|Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy|Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy||Memorial Sloan Kettering Cancer Center||Completed|January 2007|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|66|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be identified and recruited to participate in the study by Memorial        Sloan-Kettering Cancer Center (MSKCC) and Weill Cornell Medical Center (WCMC).|December 2015|December 9, 2015|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00606216||161428|
NCT00607139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 009|Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors|Evaluation of Counter-Regulatory Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors in Children With T1DM||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|December 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|Samples Without DNA|Serum|Both|3 Years|17 Years|No|Non-Probability Sample|Approximately 30-50 subjects will be enrolled in this study at five clinical centers with        approximately 6-10 enrolled at each center.|January 2008|January 22, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607139||161357|
NCT00607438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-06-025|A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer|A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer||Veeda Oncology|No|Terminated|September 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|January 22, 2008|Yes|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00607438||161335|
NCT00630175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5202|Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia|Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia. A Double-Blind, Randomized, Placebo-Controlled,Three Way Cross-Over Study||Sanofi||Completed|September 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|113|||Both|18 Years|64 Years|No|||May 2009|May 15, 2009|February 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00630175||159635|
NCT00630409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-033|Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma|Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma||University of Pittsburgh|Yes|Completed|September 2004|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|February 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00630409||159617|
NCT00616096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAD01|Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels|Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels||University of Luebeck|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2010|January 27, 2010|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616096||160696|
NCT00616395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07130|Study of Early Infant Diet on Growth and Development|Effects of Diet on Metabolism, Body Composition, Brain Function in Infants/Children|Beginnings|Arkansas Children's Hospital Research Institute|No|Active, not recruiting|September 2002|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Plasma, urine, and stool may be collected from some study participants.|Both|1 Month|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy infants|September 2015|September 9, 2015|December 31, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00616395||160673|
NCT00616408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-8|Prediction of Tumor Shrinkage in Acromegaly|Predictive Value of 3 Months Results on 12 Months Tumor Shrinkage After First-Line Octreotide-LAR Therapy in Patients With Acromegaly||Federico II University|No|Completed|January 1997|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|61|||Both|18 Years|85 Years|No|Probability Sample|Newly diagnosed patients with acromegaly treated first-line with octreotide-LAR|December 2007|February 5, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616408||160672|
NCT00616655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194-027|Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects|A Double Blind, Randomized, Placebo Controlled, Multicenter Study Examining the Efficacy and Safety of SEP-225441 in Subjects With Generalized Anxiety Disorder.||Sunovion|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|456|||Both|18 Years|50 Years|No|||July 2015|July 27, 2015|February 4, 2008|Yes|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT00616655||160654|
NCT00617019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.619|Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)|A Cross-sectional, Retrospective Screening and Case-control Study Examining the Frequency of, and Risk Factors Associated With, Impulse Control Disorders in Parkinson's Disease Patients Treated With MIRAPEX® (Pramipexole) and Other Anti-parkinson Agents (DOMINION Study)||Boehringer Ingelheim||Completed|September 2006|||January 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|3234|||Both|30 Years|75 Years|No|Non-Probability Sample|Parkinson's patients treated with various medications|November 2013|November 11, 2013|February 5, 2008||||No||https://clinicaltrials.gov/show/NCT00617019||160626|
NCT00617032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13E04|Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94|A Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis||Targeted Genetics Corporation|Yes|Completed|February 2004|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||February 2008|February 5, 2008|February 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617032||160625|
NCT00617500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHS 18/07|Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement|Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement||Sociedade Hospital Samaritano|Yes|Active, not recruiting|July 2008|November 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|278|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617500||160590|
NCT00617747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311CUS/0022|Efficacy and Tolerability of Zolmitriptan Nasal Spray|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG) Nasal Spray in the Acute Treatment of Adult Subjects With Migraine.||AstraZeneca|No|Completed|September 2002|June 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2114|||Both|18 Years|65 Years|No|||April 2009|April 3, 2009|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617747||160571|
NCT00617760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|670701|Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)|Open-label, Randomized, 3-arm, Phase 3B Clinical Study to Investigate the Safety and Immunogenicity of a Concomitant Administration of Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate (MenC-TT) Vaccine and 7-valent Pneumococcal CRM197-conjugate Vaccine (PCV7) in Toddlers Previously Immunized During Infancy With PCV7||Pfizer|Yes|Completed|March 2008|December 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|330|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||May 2015|May 20, 2015|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617760||160570|
NCT00608855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC03C3|Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases|Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study||Mayo Clinic||Active, not recruiting|November 2003|||December 2015|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|February 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00608855||161235|
NCT00608868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00067|SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients|A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients|SELINE|AstraZeneca||Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|19 Years|80 Years|No|||August 2012|August 29, 2012|January 23, 2008||No||No|February 8, 2010|https://clinicaltrials.gov/show/NCT00608868||161234|
NCT00613873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-066|Use of Screening Colonoscopy Among Minority Women and Men|A Model Program for Increasing Use of Screening Colonoscopy Among Minority Women and Men||Memorial Sloan Kettering Cancer Center||Completed|July 2003|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|611|||Both|50 Years|N/A|No|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment        team, the protocol investigators or research team at Memorial Sloan-Kettering Cancer        Center(MSKCC). The study will be offered to all eligible women who come for breast or        cervical cancer screening at The Breast Examination Center of Harlem during the study        period|January 2009|January 14, 2009|January 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00613873||160860|
NCT00604994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEGS|Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer|Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer|LEGS|Queensland Centre for Gynaecological Cancer|No|Completed|June 2008|April 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|761|||Female|18 Years|N/A|No|Non-Probability Sample|Women with gynaecological conditons requiring treatment|August 2013|August 18, 2013|January 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00604994||161519|
NCT00606632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX/20-001|Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody|A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)||Wilex|No|Completed|March 2008|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|226|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|January 21, 2008|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00606632||161396|
NCT00606645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XmAb2513-01|Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma|A Phase 1 Study of Every Other Week XmAb®2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma||Xencor, Inc.|No|Completed|December 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|January 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00606645||161395|
NCT00606905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13157A|Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage|Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial||University of Chicago|No|Completed|November 1999|January 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|45 Years|No|||August 2010|October 3, 2012|January 23, 2008|Yes|Yes||No|August 3, 2010|https://clinicaltrials.gov/show/NCT00606905||161375|
NCT00607152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASBU_L_00351|Rasburicase (Fasturtec) Registration Trial|A Multi-center, Randomized, Open-label, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Patients With Hematological Malignancies||Sanofi|No|Terminated|October 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|50 Years|No|||May 2014|May 7, 2014|January 22, 2008||No|the patient enrollment is too difficult|No||https://clinicaltrials.gov/show/NCT00607152||161356|
NCT00607464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-71137|Multicentre Randomised Controlled Trial of HELP (Heat Loss Prevention) in the Delivery Room|Multicentre Randomised Controlled Trial of HELP (Heat Loss Prevention) in the Delivery Room|HeLP|Sunnybrook Health Sciences Centre|Yes|Terminated|September 2004|October 2012|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1685|||Both|24 Weeks|28 Weeks|No|||August 2011|August 11, 2011|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607464||161333|
NCT00606567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010068|A Randomized Trial of Remote Monitoring of Implantable Cardioverter Defibrillators Versus Quarterly Device Interrogations in Clinic|A Randomized Trial of Remote Monitoring of Implantable Cardioverter Defibrillators Versus Quarterly Device Interrogations in Clinic|Medusa SAK|Duke University|No|Completed|December 2006|May 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||December 2012|July 11, 2014|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606567||161401|
NCT00607776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGT-104-9582|Artificial Tears Study in Mild to Moderate Dry Eye Patients|Artificial Tears Study in Mild to Moderate Dry Eye Patients||Abbott Medical Optics|Yes|Completed|January 2007|April 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|February 5, 2008|December 19, 2007||No||No||https://clinicaltrials.gov/show/NCT00607776||161310|
NCT00606892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 0702002338|Varenicline and Nicotine Interactions in Humans (VA)|Varenicline Attenuates Some of the Subjective and Physiological Effects of Intravenous Nicotine in Humans.||Yale University|Yes|Completed|August 2007|November 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|January 23, 2008||No||No|March 14, 2012|https://clinicaltrials.gov/show/NCT00606892||161376|
NCT00608335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-CL-2101|Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug|A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis||Astellas Pharma Inc|No|Completed|October 2007|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|84|||Both|2 Years|16 Years|No|||September 2011|March 12, 2013|January 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00608335||161272|
NCT00630435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0713E1-1137|Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of 3 New Formulations of Premarin® /MPA 0.625 mg/2.5 mg Compared With Reference Formulation of Premarin®/MPA in Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|76|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||February 2009|February 3, 2009|February 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00630435||159615|
NCT00615797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTXO1-2002|Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea|Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea||University of Cape Town|No|Completed|May 2002|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|4 Years|16 Years|No|||December 2014|December 3, 2014|February 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00615797||160719|
NCT00616109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.034|Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC|Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer||University of Michigan Cancer Center|Yes|Completed|September 2007|January 2011|Actual|December 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|February 4, 2008|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT00616109||160695|The trial was to be terminated at stage 1 if less than, or equal to, 8 patients were progression free at 4 months. The PFS rate did not reach the threshold required for study continuation and, therefore, the study was discontinued early.
NCT00616122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583268|Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer|Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer||University of California, San Francisco|Yes|Completed|March 2006|December 2012|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|February 14, 2008|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00616122||160694|Based on published literature indicating significant toxicity and low response rate for combination sunitinib in the treatment of advanced breast cancer, the PI and Breast Oncology Site Committee closed enrollment after accrual of 32 participants.
NCT00616447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-270-07|rTMS Treatment in Patients With General Anxiety Disorder|A 12-week, Double-blind, Randomized, Placebo-controlled Multicentered Study Evaluating Efficacy and Safety of High-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment in Patients With Generalized Anxiety Disorder (GAD)||Queen's University|No|Completed|January 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616447||160669|
NCT00616694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_4027|Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy|A Randomized Multicenter Parallel Group Study to Determine if Knowledge of Baseline Vertebral Fracture Prevalence (as Determined by Hologic IVA) and Bone Turnover Marker Determinations Improves Persistence With Actonel 5mg Daily Therapy in Subjects Receiving Chronic Glucocorticoid Therapy|ACTIVATE|Sanofi||Completed|July 2002|December 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|248|||Both|30 Years|85 Years|No|||February 2008|February 20, 2008|February 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616694||160651|
NCT00617279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPT 07-05|GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft|Comparison of Primary Patency Between GORE PROPATEN Vascular Graft and Disadvantaged Autologous Vein Graft For Below-Knee Arterial Bypass (PRODIGY Study)|PRODIGY|W.L.Gore & Associates|No|Terminated|December 2007|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|21 Years|N/A|No|||December 2011|December 8, 2011|December 18, 2007|Yes|Yes|Study terminated due to low enrollment|No|February 7, 2011|https://clinicaltrials.gov/show/NCT00617279||160606|The study was terminated prior to completion of enrollment. The primary patency and secondary endpoints were not calculated due to the paucity of data.
NCT00617773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCPOv01-06|Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A PHASE II TRIAL OF Hu3S193 THERAPY FOR PATIENTS WITH PLATINUM REFRACTORY OR PLATINUM RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER||Recepta Biopharma|No|Completed|May 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||November 2013|November 1, 2013|February 15, 2008|Yes|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00617773||160569|
NCT00618033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169-07|Comparison of Different Glucose Concentrations in Dialysate of Hemodialysis Patients|Short-Term Study of Physiologic Dialysate Glucose Concentration in Chronic Hemodialysis Patients|Dextrose|Renal Research Institute|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00618033||160549|
NCT00605007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001392|Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD|The Impact of Corticosteroid-induced Hyperglycemia on Clinical Outcome (Length of Stay, Disposition, APACHE Score, Need for Ventilatory Support and ICU Admission, Mortality) in Patients With COPD Exacerbation||Emory University|No|Completed|February 2006|December 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|450|||Both|18 Years|80 Years|No|Probability Sample|Patients admitted with COPD exacerbation at Atlanta Medical Center and Grady Memorial        Hospital|April 2010|November 20, 2013|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00605007||161518|
NCT00609167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583225|Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Trial of Cyclophosphamide, Bortezomib and Dexamethasone (CYBOR-D) in Patients With Newly Diagnosed Active Multiple Myeloma||Mayo Clinic|Yes|Completed|December 2006|November 2010|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|January 31, 2008|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00609167||161213|
NCT00604682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-001|Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis|Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis|PSOR-001|Celgene|No|Completed|January 2005|December 2005|Actual|October 2005|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||January 2008|October 9, 2012|January 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00604682||161543|
NCT00605618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA192-002|Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors|A Phase I/II Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2009|January 24, 2011|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605618||161474|
NCT00605631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MENDMI|The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study|The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study||Boston Scientific Corporation|Yes|Completed|May 2005|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00605631||161473|
NCT00607217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMU- 86-03-105-5433B|The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases|Controlled Trial of Serologic and Clinical Efficacy of Influenza Vaccine in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2008|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|360|||Both|25 Years|N/A|Accepts Healthy Volunteers|||September 2008|January 20, 2009|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00607217||161352|
NCT00607178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMU- 86-03-105-5433A|The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases|Randomized, Single-Blind, Placebo-Controlled Study of Influenza Vaccine in Preventing Cardiovascular Events in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris|IVCAD|hahid Beheshti University of Medical Sciences|Yes|Completed|January 2008|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Both|25 Years|N/A|No|||September 2008|January 20, 2009|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00607178||161355|
NCT00607477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15386B|Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension|A Pilot Study of the Treatment of VEGF-Signaling Pathway Inhibitor-Induced Hypertension With Direct Vasodilators, Minoxidil and Hydralazine||University of Chicago|No|Terminated|January 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|January 22, 2008|Yes|Yes|Study has been terminated due to poor accrual.|No|November 22, 2010|https://clinicaltrials.gov/show/NCT00607477||161332|This study enrolled only 2 subjects and due to poor accrual, enrollment was stopped early. Due to the limited number of subjects available results cannot be assessed.
NCT00607789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nelson #2|Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression|A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder.||University of Cincinnati|Yes|Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||September 2012|October 12, 2012|January 23, 2008||No||No|March 8, 2011|https://clinicaltrials.gov/show/NCT00607789||161309|
NCT00607984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3990|Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors|High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors||Rabin Medical Center|No|Recruiting|June 2006|||December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|21 Years|No|||January 2008|February 5, 2008|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00607984||161294|
NCT00608010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-ART-06/13|Day 3 Embryo Cryopreservation: Metabolic and Viability Analysis|Day 3 Embryo Cryopreservation: Metabolic and Viability Analysis||V.K.V. American Hospital, Istanbul||Completed|October 2006|||January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Female|18 Years|N/A|No|||January 2008|February 5, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00608010||161292|
NCT00608348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#020777-SNA during hypo/ex|Sympathetic Nerve Activity During Hypoglycemia and Exercise|Sympathetic Nerve Activity During Hypoglycemia and Exercise||Vanderbilt University|No|Completed|April 2002|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00608348||161271|
NCT00615810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-UK-177-0109|ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial|A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching From a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raised Cholesterol|ROCKET I|Gilead Sciences|No|Completed|March 2008|January 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|N/A|No|||July 2010|July 30, 2010|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00615810||160718|
NCT00615823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1152|Atorvastatin in Pulmonary Hypertension|Clinical Effect and Tolerability of Atorvastatin Versus Placebo in Patients With Pulmonary Hypertension: Double-blinded, Randomised, Prospective Phase II Study for 6 Months With Adjusted Doses of Atorvastatin|APATH|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Completed|February 2007|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|65 Years|No|||February 2012|February 22, 2012|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00615823||160717|
NCT00616135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESTORE-2|Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy|A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study.|RESTORE-2|Cytori Therapeutics|No|Completed|June 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Female|18 Years|75 Years|No|||May 2011|May 13, 2011|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616135||160693|
NCT00616148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA40616|Efficacy of YKP3089 in Patients With Photosensitive Epilepsy|Pharmacodynamic Evaluation of YKP3089 in Epilepsy Patients With a Photo-induced Paroxysmal EEG-Response: Proof of Principle||SK Life Science|Yes|Completed|August 2007|January 2010|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|16 Years|60 Years|No|||December 2013|December 26, 2013|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616148||160692|
NCT00616161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PST2744-DM-04-012|A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function|A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function|HORIZON-HF|sigma-tau i.f.r. S.p.A.|Yes|Completed|August 2006|August 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|85 Years|No|||February 2008|February 5, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616161||160691|
NCT00616733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0777-A-U102|12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients|An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis||Daiichi Sankyo Inc.|Yes|Completed|March 2008|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|65 Years|No|||March 2011|March 9, 2011|February 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00616733||160648|
NCT00616746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607001614|Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans|Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans||Yale University|No|Completed|January 2007|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|18|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|February 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00616746||160647|
NCT00617240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2992 GCRC-2501|Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth|Metformin Mitigation of Atypical Antipsychotic-Induced Metabolic Dysregulation in Adolescent Youth|PREVENT|University of North Carolina, Chapel Hill|No|Completed|January 2007|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|9|||Both|10 Years|17 Years|No|||February 2014|February 7, 2014|February 5, 2008|Yes|Yes||No|September 2, 2013|https://clinicaltrials.gov/show/NCT00617240||160609|Small number of subjects analyzed and recruited, however, based on preliminary data, a larger, multi-site trial was developed.
NCT00617253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN028-1642|Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients|An Open Label, Dose Escalation Safety and Tolerability Trial of the Combination of s.c. Recombinant Human IL-21 (rIL-21) and Sunitinib (Phase 1) Followed by an Open Label Stratified Randomized 2-arm Trial of rIL-21 Plus Sunitinib Versus Sunitinib Alone (Phase 2a) in Subjects With Stage IV Renal Cell Carcinoma||Novo Nordisk A/S|No|Completed|July 2007|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|9|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617253||160608|
NCT00616707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614513-2|Analysis of Microalbuminuria and Markers of Inflammation and Oxidative Stress in Adolescents of Different Ethnic Backgrounds|Analysis of Microalbuminuria and Markers of Inflammation and Oxidative Stress in Adolescents of Different Ethnic Backgrounds|IM|University of California, Davis|No|Completed|August 2006|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|68|Samples Without DNA|Aliquots from the citrate vial & Serum seperator vial are being retained|Both|12 Years|18 Years|No|Non-Probability Sample|pediatric out-patient at UCDavis Medical Center clinic|November 2012|November 22, 2012|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616707||160650|
NCT00607958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPVRTV_500100_IQ|Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours|Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours||Germans Trias i Pujol Hospital|No|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2009|July 14, 2009|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00607958||161296|
NCT00617266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|351|Tobacco Control Among Business Process Outsourcing (BPO) Employees|Tobacco Control Among Business Process Outsourcing (BPO) Employees||Tata Memorial Hospital|Yes|Recruiting|August 2007|February 2009|Anticipated|April 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 14, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00617266||160607|
NCT00617539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583265|Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases|A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation||University of California, San Francisco|Yes|Completed|February 2005|January 2014|Actual|January 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|February 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617539||160587|
NCT00617552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-101-CL-P005|Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess Efficacy and Safety of TZP-101 When Administered as 30 Minute i.v. Infusion for POI to Subjects Undergoing Major Open Abdominal Surgery||Tranzyme, Inc.|Yes|Completed|July 2007|August 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|267|||Both|18 Years|80 Years|No|||December 2012|December 5, 2012|February 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00617552||160586|
NCT00605306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149A2203|Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Tolerability of 14-days Treatment With an Inhaled Dose of QMF149 (500/800) in Mild to Moderate Asthmatic Patients||Novartis|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||March 2013|March 11, 2013|January 18, 2008|Yes|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT00605306||161495|
NCT00605319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506007934|An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia|An Open Label Study to Measure the Efficacy of Fesoterodine (Toviaz) on Continued Detrusor Overactivity in Patients That Have Undergone Treatment for Bladder Outlet Obstruction|Toviaz|Weill Medical College of Cornell University|No|Recruiting|January 2010|||January 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|40 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 12, 2010|January 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605319||161494|
NCT00605332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETRIEVE I|Crux Biomedical IVC Filter - Evaluation of the Crux Inferior Vena Cava Filter System (Retrieve)|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System - ("Retrieve")|Retrieve|Crux Biomedical|Yes|Completed|October 2007|July 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|88|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00605332||161493|
NCT00606619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMC07OT135|Effects of Early Oral Feeding After Resection of Gastric Cancer|Phase III Clinical Trial for Effect Early Oral Feeding on Recovery After Resection of Gastric Cancer||The Catholic University of Korea|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|20 Years|75 Years|No|||February 2009|May 27, 2010|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00606619||161397|
NCT00607230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-001347|Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics|Determination of Dosing and Frequency of BCG Administration Necessary to Alter T-Lymphocyte Profiles in Type I Diabetics||Massachusetts General Hospital|Yes|Completed|November 2007|February 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 4, 2013|January 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607230||161351|
NCT00607243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_SPX_301|Safety and Efficacy of CJ-50300 in Healthy Volunteers|Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers||Seoul National University Hospital|Yes|Completed|January 2008|December 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|123|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 7, 2013|January 31, 2008||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00607243||161350|the study was limited to vaccinia-naïve adults, thus yielding no data concerning the efﬁcacy of CJ-50300 in non-naïve adults or in children.
NCT00607256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061046|Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia|A Multi-center, Long-term, Open-label Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia||Pfizer|Yes|Terminated|October 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||February 2011|February 15, 2011|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607256||161349|
NCT00606931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEM-07-02|Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities|Pilot Clinical Study to Evaluate High Resolution PET Imaging- Guidance for Sampling of Breast Abnormalities in Patients With Known or Suspected Breast Cancer|PEM-BX|Naviscan PET Systems|Yes|Completed|January 2008|August 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|22|||Female|25 Years|N/A|No|||May 2009|May 20, 2009|January 22, 2008|Yes|Yes||No|March 27, 2009|https://clinicaltrials.gov/show/NCT00606931||161373|
NCT00607191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW 122007-004|Clubfoot DNA Repository|Clubfoot DNA Repository||Texas Scottish Rite Hospital for Children|Yes|Recruiting|January 2008|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Each of the study participants (affected and non-affected individuals) will be asked to      provide DNA from a blood sample. A 10cc sample of blood will be removed on 1 or 2 occasions      by drawing blood from the arm or by finger stick by research staff. If the participant is a      child who will be undergoing surgery, the blood sample will be collected at that time to      eliminate additional stick. If collecting a blood sample is not possible we can also obtain      DNA by collecting a saliva sample. This second technique does not give us as much DNA as we      would get from blood. Therefore, if we get saliva samples, we might require more than one      saliva sample over the course of the study.|Both|N/A|75 Years|No|Non-Probability Sample|Patients being treated at the participating facilities with a diagnosis of clubfoot, and        their affected family members.|July 2010|July 27, 2010|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607191||161354|
NCT00607204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|559|Examining the Biological Factors That Affect Sleep Duration|Neurobiology of Individual Differences in Sleep Duration||Brigham and Women's Hospital|No|Completed|October 2005|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|119|Samples Without DNA|Plasma samples|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will include healthy people who are catagorized as either short sleepers or        long sleepers.|July 2013|July 30, 2013|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00607204||161353|
NCT00607802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-99107|Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer|White Cell Transfer as Cancer Therapy||Comprehensive Cancer Center of Wake Forest University||Withdrawn||||||N/A|Interventional|Primary Purpose: Treatment|||Actual|0|||Both|N/A|N/A|No|||June 2013|June 4, 2013|January 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607802||161308|
NCT00607997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-0014|Study of Voreloxin in Older Patients With Untreated Acute Myeloid Leukemia|A Phase 2, Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Voreloxin Injection in Patients Equal to or Greater Than 60 Years of Age With Previously Untreated Acute Myeloid Leukemia||Sunesis Pharmaceuticals|No|Completed|April 2008|May 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|60 Years|N/A|No|||June 2012|June 5, 2012|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607997||161293|
NCT00607815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-007-07F|A Comparison of Cognitive Processing Therapy (CPT) Versus Present Centered Therapy (PCT) for Veterans|A Comparison of CPT vs PCT for Veterans||VA Office of Research and Development|No|Active, not recruiting|June 2009|December 2016|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Male|18 Years|75 Years|No|||February 2016|February 29, 2016|February 4, 2008||No||No|February 27, 2015|https://clinicaltrials.gov/show/NCT00607815||161307|Significant amounts of missing data from patients not attending assessment. Drop out rate from treatment was higher than other clinical trials of CPT and PCT in civilian samples, but in keeping with other studies of Veterans.
NCT00608023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH9507-CTR-1012|TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy|A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Subjects With Excess Abdominal Fat Accumulation||Theratechnologies||Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|263|||Both|18 Years|65 Years|No|||March 2014|March 27, 2014|January 23, 2008|No|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00608023||161291|
NCT00608036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527|Evaluating the Relationship Between Physical Activity, Diet, Weight, and the Neighborhood Environment for Adolescents|Ecological Analysis of Activity, Eating, and Weight in Adolescents||University of California, San Diego|No|Completed|May 2008|May 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|954|||Both|12 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|Participants will be selected from identified neighboorhoods in the Seattle-King County,        WA and Baltimore-Washington, DC areas.|December 2015|December 7, 2015|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00608036||161290|
NCT00615836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS31|An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults|A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults||Ferring Pharmaceuticals|Yes|Completed|December 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|554|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|January 18, 2008|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT00615836||160716|
NCT00616993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-601-004|Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)|||Sirion Therapeutics, Inc.||Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Years|N/A|No|||June 2011|June 29, 2011|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616993||160628|
NCT00617006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS# 20655|Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice|Before and After Study Evaluating Deployment of the Sprixx GJ Personal Hand Hygiene Device in the Intra-Operative Environment||Dartmouth-Hitchcock Medical Center|No|Completed|July 2007|October 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|114|Samples Without DNA|Environmental Bacterial Samples of Workspace|Both|N/A|N/A|No|Probability Sample|Operating Rooms were randomized and patients in these rooms were enrolled for the study.|February 2008|February 14, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00617006||160627|
NCT00607425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-094|Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening|Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening|SPIT-LC|Scottsdale Healthcare|No|Terminated|August 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|40|Samples With DNA|Saliva|Both|40 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Untreated, clinical stage I and II non-small cell lung cancer (NSCLC) patients and        matching healthy control subjects will be recruited to participate in this study.        Untreated patients have not yet had either complete surgical removal of their lung cancer,        any chemotherapy, or any radiation therapy to treat their lung cancer.|July 2008|July 15, 2008|January 22, 2008||No|Change in isolation method|No||https://clinicaltrials.gov/show/NCT00607425||161336|
NCT00607711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC1001|Study of Oral Palifosfamide Tris in Solid Tumors|A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors||Ziopharm|No|Suspended|March 2008|November 2009|Anticipated|November 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2008|April 30, 2008|January 24, 2008|Yes|Yes|IND was withdrawn|No||https://clinicaltrials.gov/show/NCT00607711||161315|
NCT00616720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582566|Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma|Randomized Phase II Trial of Dendritic Cell-Based Idiotype Vaccination With Adjuvant Cytokines for Plateau Phase and Post-Transplant Multiple Myeloma||Mayo Clinic||Completed|August 2001|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00616720||160649|
NCT00617045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0609001827-Lilly-Duloxetine|Duloxetine for the Treatment of Postpartum Depression|Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder|DuloxPPD|Yale University|No|Withdrawn|July 2007|May 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|February 4, 2008|Yes|Yes|poor patient recruitment|No||https://clinicaltrials.gov/show/NCT00617045||160624|
NCT00608881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2CARE 01.00|Coenzyme Q10 in Huntington's Disease (HD)|Coenzyme Q10 in Huntington's Disease (HD)|2CARE|Massachusetts General Hospital|Yes|Active, not recruiting|March 2008|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|608|||Both|16 Years|N/A|No|||November 2014|November 25, 2014|February 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608881||161233|
NCT00617565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1536|Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes|A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficacy and Safety Profile of Biphasic Insulin Aspart 30 (BIAsp 30) and Biphasic Human Insulin 30/70 (BHI 30/70) in Chinese Type 1 and 2 Diabetics||Novo Nordisk A/S|No|Completed|July 2003|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|219|||Both|18 Years|70 Years|No|||May 2012|May 24, 2012|February 6, 2008||||No||https://clinicaltrials.gov/show/NCT00617565||160585|
NCT00617578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA080|Fast VT Episodes Are Terminated by ATP One Shot|Fast VT Episodes Are Terminated by ATP One Shot|FavoriteATP|Biotronik SE & Co. KG|No|Completed|November 2007|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|No|||May 2012|December 18, 2013|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00617578||160584|
NCT00617799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582909|Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma|Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2||National Cancer Institute (NCI)||Active, not recruiting|October 2007|||December 2012|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|15|||Both|19 Years|N/A|No|||June 2009|June 16, 2009|February 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00617799||160567|
NCT00605930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|083.03|A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.|Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.||University of Louisville|No|Completed|April 2004|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||April 2014|April 2, 2014|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00605930||161450|
NCT00606294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-070|Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients|A Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|June 2004|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|January 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00606294||161422|
NCT00607503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 010|A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes|A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Both|12 Years|18 Years|No|||January 2008|January 29, 2012|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607503||161330|
NCT00607516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMI-RSA-DEXA|Radiostereometric Analysis of Acetabular Wear and Periprosthetic Bone Mineral Density Changes in Hemiarthroplasties|Radiostereometric Analysis of Acetabular Wear and Periprosthetic Bone Mineral Density Changes in Cemented and Uncemented Hemiarthroplasties for Femoral Neck Fractures|HEMI-RSADEXA|Ullevaal University Hospital|No|Active, not recruiting|March 2006|January 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|65 Years|N/A|No|||February 2007|June 23, 2009|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607516||161329|
NCT00607828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|337-07|Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer|Feasibility of Hypofractionated Stereotactic Radiotherapy in Patients With Hepatocellular Carcinoma||University of Nebraska|Yes|Recruiting|November 2007|||October 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|19 Years|N/A|No|||March 2010|March 23, 2010|February 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00607828||161306|
NCT00607841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 3121|A Study of Ispinesib in Metastatic Breast Cancer|A Phase I/II Non-Randomized, Open-Label, Dose-Finding Study of Ispinesib (SB-715992) Followed By a Fixed-Dose Study in Chemotherapy-Naïve Patients With Metastatic Breast Cancer (MBC).||Cytokinetics|No|Completed|December 2007|||November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||January 2010|January 14, 2010|January 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00607841||161305|
NCT00607490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD038493|A Randomized Clinical Trial for Women With Vulvodynia|Cognitive-Behavioral Therapy for Vulvodynia: a Clinical Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|September 2000|March 2005|Actual|March 2005||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|21 Years|60 Years|No|||January 2008|February 4, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00607490||161331|
NCT00608673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77|Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus|Pimecrolimus 1% Cream vs. Betamethasone Valerate 0.1% Cream in the Treatment of Facial Discoid Lupus Erythematosus: a Double-Blind Randomized, Pilot Study.||hahid Beheshti University of Medical Sciences|Yes|Completed|April 2006|November 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|No|||January 2008|February 6, 2008|January 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00608673||161249|
NCT00608686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-WOLKOWITZ-AA013929|Neurosteroids and Acute Alcohol Intoxication in Humans|Neurosteroids and Acute Alcohol Intoxication in Humans||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Active, not recruiting|May 2004|March 2009|Anticipated|January 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|92|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|January 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00608686||161248|
NCT00608946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKS-PSY-DEM-01|Treatment With Copper in Patients With Mild Alzheimer´s Dementia|||University Hospital, Saarland|Yes|Completed|March 2004|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|50 Years|80 Years|No|||January 2008|February 5, 2008|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608946||161228|
NCT00616668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-2718-AK-CTIL|Early Postoperative Fitting of the Air- Limb Prosthesis for Transtibial Amputees|Early Postoperative Fitting of the Air- Limb Prosthesis for Transtibial Amputees||Sheba Medical Center|No|Completed|January 2003|December 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||February 2008|February 14, 2008|February 4, 2008||||No||https://clinicaltrials.gov/show/NCT00616668||160653|
NCT00616681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXCA-01|Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions|A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|June 2004|July 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2008|February 14, 2008|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00616681||160652|
NCT00616187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1931/Si.270 am 8.5.03|Atorvastatin in Relapsing-Remitting Multiple Sclerosis|Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis||Charite University, Berlin, Germany|Yes|Completed|October 2003|||June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|55 Years|No|||February 2008|February 14, 2008|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00616187||160689|
NCT00607971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL1251/052/CL|Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)||Alizyme|Yes|Terminated|April 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|939|||Female|18 Years|N/A|No|||July 2008|July 4, 2008|January 23, 2008|Yes|Yes|Terminated due to insufficient efficacy over placebo in Study ATL1251/038/CL.|No||https://clinicaltrials.gov/show/NCT00607971||161295|
NCT00608322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23GM083211|Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis|Randomized Double-blind Placebo-controlled Trial of Inhaled Nitric Oxide for the Treatment of Microcirculatory Dysfunction and Organ Failure in Sepsis||National Institute of General Medical Sciences (NIGMS)|Yes|Completed|August 2009|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|14 Years|N/A|No|||June 2013|June 3, 2013|January 23, 2008|Yes|Yes||No|April 16, 2013|https://clinicaltrials.gov/show/NCT00608322||161273|
NCT00617058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-3110 GCRC-2529|Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine|Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine|ZAC|University of North Carolina, Chapel Hill|Yes|Terminated|March 2007|September 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1|||Both|10 Years|17 Years|No|||November 2012|November 28, 2012|February 5, 2008|Yes|Yes|Terminated in lieu of similar,competing large, multi-site study.|No|October 29, 2012|https://clinicaltrials.gov/show/NCT00617058||160623|In terms of study limitations, this research study was only able to enroll a single study participant before the trial was terminated prematurely due to study start-up for a larger, multisite effort examining similar outcome measures.
NCT00607724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000585468|GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists||Genentech, Inc.||Completed|April 2007|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|68|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|January 31, 2008|No|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT00607724||161314|
NCT00607737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPLY|Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes|Doubleblind, Randomised, Single Centre Investigator Sponsored Study of Applications Site Reactions After Deep and Superficial Subcutaneous and Intradermal Injection of Insulin Detemir and Saline in Subjects With Diabetes Mellitus|APPLY|Steno Diabetes Center|No|Completed|January 2008|July 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|60 Years|No|||August 2012|August 31, 2012|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00607737||161313|
NCT00605020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1558|Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus|PreFER|Novo Nordisk A/S|No|Completed|December 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|719|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|January 17, 2008||||No||https://clinicaltrials.gov/show/NCT00605020||161517|
NCT00605033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04843|A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)|A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects||Indivior Inc.|No|Completed|March 2008|May 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|241|||Both|15 Years|N/A|No|||September 2010|April 14, 2011|January 17, 2008||Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00605033||161516|
NCT00608296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BITREC - Project II|Functional and Neurochemical Brain Changes Bipolar Depression|Functional and Neurochemical Brain Changes Following Successful Treatment of Early Course Bipolar Depression||University of Cincinnati|No|Completed|January 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|12 Years|35 Years|No|Probability Sample|You are being asked to take part in this research study because you have been diagnosed        with bipolar disorder and are currently experiencing a depressive episode. Bipolar        disorder is an illness characterized by recurrent mood swings including mania, (periods of        elation, excessive excitement, irritability, high energy, racing thoughts, poor sleep,        poor judgment, reckless behavior) and clinical depression (periods of depressed mood, loss        of interest in activities and disruption of sleep, appetite and energy). To participate in        this study you must be at least 12 years old, and no older than 35.|December 2014|December 22, 2014|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00608296||161274|
NCT00608582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-DC05672|Transcranial Magnetic Stimulation to Improve Speech in Aphasia|Transcranial Magnetic Stimulation to Improve Speech||Boston University|No|Completed|July 2002|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|63|||Both|45 Years|80 Years|No|||January 2015|January 29, 2015|January 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00608582||161255|
NCT00605657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080053|Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)|Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)||National Institutes of Health Clinical Center (CC)|No|Completed|January 2008|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|70 Years|No|||February 2013|February 14, 2013|January 15, 2008||No||No|February 14, 2013|https://clinicaltrials.gov/show/NCT00605657||161471|
NCT00605956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-108-08|NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers|An Evaluation of the Photoallergy Potential of NatrOVA Creme Rinse - 1% in Healthy Volunteers||ParaPRO LLC|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|65|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2008|July 31, 2008|January 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00605956||161448|
NCT00644384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582327|Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer|Chemoprevention Trial of Acitretin Versus Placebo in Patients at High Risk for Basal Cell Carcinoma or Squamous Cell Carcinoma||Mayo Clinic|Yes|Completed|February 2003|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|||Anticipated|130|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|March 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644384||158554|
NCT00675389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000748|Impact of Peer Health Workers and Mobile Phones on HIV Care|Impact of Peer Health Workers and Mobile Phones on HIV Care||Johns Hopkins University|No|Completed|March 2006|January 2012|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1200|||Both|N/A|N/A|No|||March 2012|March 28, 2012|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675389||156188|
NCT00644644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061241|Validation of the NTX Wireless Patient Monitoring System|A Validation of the NTX Wireless Patient Monitoring System in Combination With Novel Computer Interface to Generate Proactive Medical Responses to Patient Specific Events|TATRC|Vanderbilt University|Yes|Enrolling by invitation|March 2008|June 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1200|||Both|18 Years|N/A|No|Probability Sample|Post-op orthopedic and GI patients who will be admitted for a minimum of 24 hours to the        Round Wing area of Vanderbilt University Medical Center.|March 2008|March 25, 2008|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00644644||158534|
NCT00644956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481183|A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil|A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra (Sildenafil Citrate) And Cialis (Tadalafil)||Pfizer|No|Completed|June 2003|November 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|N/A|No|||March 2008|March 26, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644956||158511|
NCT00645307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003289|A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS® Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia - Open Label Phase||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|August 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|235|||Both|18 Years|N/A|No|||April 2010|June 6, 2011|March 24, 2008||||||https://clinicaltrials.gov/show/NCT00645307||158484|
NCT00679029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|412-07|Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer|Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express HER-2/Neu||University of Nebraska|Yes|Active, not recruiting|May 2008|||December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Female|19 Years|N/A|No|||August 2011|August 8, 2011|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679029||155912|
NCT00641199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAAD-07-112|Probiotics for Prevention of Antibiotic-associated Diarrhea|The Effect of Jarro-Dophilus EPS Probiotics on the Prevention of Diarrhea, Quality of Life and Symptoms in Adults Receiving Antibiotic Therapy.||University of Saskatchewan|No|Completed|March 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|204|||Both|18 Years|75 Years|No|||January 2010|January 14, 2010|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641199||158797|
NCT00674908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL/DTPwHB-Hib/INT/2007/0200|Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine|A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants.||Shantha Biotechnics Limited|No|Completed|March 2008|May 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|144|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||June 2009|June 24, 2009|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674908||156225|
NCT00667758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1/05|Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis|Antagonist to Gonadotropin-Releasing Hormone in Rheumatoid Arthritis (AGRA): A Double-blind, Randomized, Placebo Controlled Trial|AGRA|Betanien Hospital|Yes|Completed|May 2008|October 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667758||156768|
NCT00667771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080125|The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion|Effect of Naltrexone on Craving and Ethanol-Induced Brain Activity||National Institutes of Health Clinical Center (CC)||Completed|April 2008|April 2011|Actual|December 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|70|||Both|21 Years|50 Years|No|||April 2011|April 5, 2011|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00667771||156767|
NCT00668044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10627|Ciprofloxacin on Burned Patients|A Population Pharmacokinetics Study of Plasma Levels of Ciprofloxacin Following a Regimen of Repeated Dose I.V. Administration (400 mg TID) on Burn Patients||Bayer|No|Completed|November 2002|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||October 2009|October 26, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668044||156746|
NCT00668122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11454|Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections|Efficacy and Safety of Ciprofloxacin Extended-Release 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.|EMERON|Bayer|No|Completed|March 2004|January 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668122||156740|
NCT00675883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-CAN-0703|COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS|COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS|COMPASS|Biogen|No|Completed|May 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|N/A||2|Actual|1000|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients enrolled in the MS AllianceTM program|January 2012|January 26, 2012|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00675883||156151|
NCT00677274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJFY-02028M03|Epidural Analgesia in Different Cervix Diameter and the Rate of Cesarean Delivery|Epidural Labor Analgesia in Different Cervical Dilation Diameter and the Risk of Cesarean Delivery|EACDRCD|Nanjing Medical University|Yes|Completed|May 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|780|||Female|18 Years|45 Years|No|||February 2009|February 11, 2009|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677274||156044|
NCT00677833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661157|Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa|Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa||Pfizer|Yes|Completed|June 2008|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|361|||Both|6 Months|12 Years|No|||May 2014|May 27, 2014|May 12, 2008|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00677833||156001|Cohort 1 was a screening cohort, meant for safety evaluation, but not included in the efficacy assessments.
NCT00678106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8841004|Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections|A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Adolescents, Aged 12 Through 17 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections||Pfizer|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|12 Years|17 Years|No|||October 2009|October 9, 2009|May 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678106||155980|
NCT00677196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01887|The StoneBreakerTM Trial|The Canadian StoneBreakerTM Trial: A Randomized, Multicentre Trial Comparing The LMA StoneBreakerTM and the Swiss LithoClastR During Percutaneous Nephrolithotripsy.||University of British Columbia|No|Completed|February 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 23, 2010|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677196||156050|
NCT00677209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVH-2004/1|The Effect of Autologous Autovaccine in Patients With Allergy on House-dust-mite|Frankfurt Investigator-initiated Autovaccine-study|FIAVS|Johann Wolfgang Goethe University Hospitals|Yes|Completed|July 2006|December 2010|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|35 Years|No|||May 2008|December 28, 2010|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677209||156049|
NCT00644111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN 07-0736-A|Post-operative Epidural Analgesia After Minimally Invasive Lumbar Decompression and Fusion|Post-operative Epidural Analgesia After Minimally Invasive Lumbar Decompression and Fusion||University Health Network, Toronto|Yes|Completed|February 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|No|||February 2013|February 11, 2013|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644111||158575|
NCT00677755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taizhou2004-08|Medical Abortion for Emergency Contraception Failure|Medical Termination of Pregnancy Due to Emergency Contraception Failure: A Randomized Trial Comparing Mifepristone Combined Misoprostol and Misoprostol Alone.||Taizhou Hospital|No|Completed|October 2004|November 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|394|||Female|16 Years|40 Years|No|||May 2008|May 15, 2008|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00677755||156007|
NCT00644657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13291|The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization|The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization||University of Oklahoma|No|Completed|March 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|27|||Both|18 Years|65 Years|No|||September 2011|September 7, 2011|March 24, 2008|No|Yes||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00644657||158533|Limited to primarily Male VA population.
NCT00678418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-013|ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence|Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence||Alkermes, Inc.|No|Completed|June 2008|November 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||January 2012|January 11, 2012|May 14, 2008|Yes|Yes||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00678418||155957|
NCT00678717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071179|Autonomic Function Testing and Spinal Cord Stimulation in Chronic Visceral Pain|Autonomic Function Testing and Spinal Cord Stimulation: Implications for Successful Therapy in Chronic Visceral Pain|AFTSCSCVP|Vanderbilt University|No|Terminated|February 2008|February 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|May 8, 2008||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00678717||155934|
NCT00678730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0706002754|Pharmacogenetics of Cannabinoid Response|Pharmacogenetics of Cannabinoid Response||Yale University||Recruiting|July 2007|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|162|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|May 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678730||155933|
NCT00678743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-06009X|An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin|An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia||Provident Clinical Research|No|Active, not recruiting|August 2007|September 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|79 Years|No|||May 2008|May 14, 2008|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678743||155932|
NCT00678756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-VITAKET|Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol|Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol|VITAKET|Technische Universität Dresden|Yes|Active, not recruiting|March 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|80 Years|No|||June 2010|June 7, 2010|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678756||155931|
NCT00674895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-PD-CTP1|Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control and Treatment of Parkinson's Disease.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2008|June 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2009|January 2, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674895||156226|
NCT00679042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND11807-2007-0330|Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol|Islet Transplantation in Type 1 Diabetic Patients Using the UIC Protocol, Phase 3||University of Illinois at Chicago|Yes|Recruiting|June 2007|December 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||August 2014|August 21, 2014|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679042||155911|
NCT00667784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0571|Long Term Minor Sibling Donor Well-Being|Long Term Minor Sibling Donor Well-Being||M.D. Anderson Cancer Center|No|Terminated|April 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2|||Both|5 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parent, legal guardian, or sibling of a patient that will have a bone marrow or stem cell        transplant.|March 2012|March 29, 2012|April 24, 2008||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00667784||156766|
NCT00668733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW01-0803|Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year|Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705||Graceway Pharmaceuticals, LLC|No|Completed|April 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|179|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consisted of subjects who have been treated with imiquimod or with        placebo in one of the aformentioned studies and who demonstrated complete clearance of all        clinically visible or palpable AK lesions in the selected treatment area at the        end-of-study visit.|July 2010|July 13, 2010|April 24, 2008|Yes|Yes||No|June 15, 2010|https://clinicaltrials.gov/show/NCT00668733||156693|
NCT00675649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014980|A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Parallel-group Study Evaluating the Efficacy and Safety of Golimumab Administered Subcutaneously in Symptomatic Subjects With Severe, Persistent Asthma||Centocor, Inc.|Yes|Withdrawn|May 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 9, 2015|May 8, 2008||||No||https://clinicaltrials.gov/show/NCT00675649||156169|
NCT00677287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-A24-I, II|Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Combination With Tegafur/Uracil/Folinate in Treating Patients With Refractory Colorectal Cancer||Tokyo University|Yes|Terminated|May 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||May 2008|December 28, 2009|May 12, 2008||No|Lack of financial support|No||https://clinicaltrials.gov/show/NCT00677287||156043|
NCT00677521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011557|A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)|A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)||The Hospital for Sick Children|No|Terminated|January 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|10 Years|18 Years|No|||August 2013|August 16, 2013|May 12, 2008||No|poor recruitment and no student currently interested in working on this project.|No||https://clinicaltrials.gov/show/NCT00677521||156025|
NCT00677807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2335SE|Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Extension to a 26-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease||Novartis|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|415|||Both|40 Years|N/A|No|||August 2011|August 18, 2011|May 13, 2008|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00677807||156003|
NCT00677846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314/03|Venous Thrombus Investigation With Contrast Enhanced Ultrasound Imaging|Venous Thrombus Investigation With Contrast Enhanced Ultrasound Imaging, a Follow up Study||University Hospital Freiburg|No|Recruiting|April 2007|August 2008|Anticipated|July 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|31|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a newly diagnosed occluding venous thrombus with duplexsonography and        symptoms of deep venous thrombosis less than for 2 weeks.|May 2008|May 13, 2008|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00677846||156000|
NCT00678080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0015|Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes|A Randomized, Controlled Trial of Metformin Versus Insulin in Women With Type 2 Diabetes Mellitus During Pregnancy in a Population With Severe Health Disparities||The University of Texas Health Science Center, Houston|No|Recruiting|September 2008|August 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00678080||155982|
NCT00678093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mulligan|Effects of a Mulligan Mobilisation in the Lumbar Flexion Range of Asymptomatic Subjects|The Effects of the Mulligan Mobilisation Sustained Natural Apophyseal Glide (SNAG) in the Lumbar Flexion Range of Asymptomatic Subjects as Measured by the Zebris CMS20 3-D Motion Analysis System|Mulligan|University of Manchester|No|Completed|January 2005|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2008|May 13, 2008|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00678093||155981|
NCT00676988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP0701|Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients|A Cross Sectional Study To Determine The Relationship Between Serum Infliximab Concentration And Efficacy In Patients With Luminal Crohn's Disease|X-Sectional|University of Western Ontario, Canada|Yes|Completed|May 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|327|Samples Without DNA|Serum infliximab concentrations and CRP levels.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with Luminal Crohn's disease receiving infliximab at Canadian Infusion Centres|June 2012|June 13, 2012|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676988||156066|
NCT00677482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7304|Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates|Cytomegalovirus (CMV) microRNA Expression in Vivo and Immune Evasion Correlates||University of Alberta|No|Active, not recruiting|April 2008|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Solid organ tranplant recipients with both asymptomatic CMV viremia and symptomatic CMV        disease are eligible for inclusion in the study. This include liver, kidney, heart,        pancreas, lung, intestinal and combined transplant recipients.|May 2015|May 26, 2015|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677482||156028|
NCT00677495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 25/07|Gluten-free Diet in Gluten-genetically Predisposed Subjects|Usefulness of Gluten-free Diet in Gluten-genetically Predisposed Subjects Positive to Intestinal-mucosa Anti-transglutaminase Antibodies||IRCCS Burlo Garofolo|No|Active, not recruiting|May 2007|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|No|||April 2014|April 24, 2014|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677495||156027|
NCT00677508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 05/154|Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling|Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling||Medical College of Wisconsin|No|Active, not recruiting|September 2005|December 2015|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|800|||Both|2 Years|18 Years|No|Non-Probability Sample|Children will be recruited from the Constipation Clinic at Children's Hospital of        Wisconsin, as well as four coolaborating sites.|October 2015|October 21, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677508||156026|
NCT00674635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104972|Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Bayesian Adaptive Dose Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Intravenous Infusions GSK315234A in Patients With Active Rheumatoid Arthritis (RA)||GlaxoSmithKline|No|Completed|April 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|75 Years|No|||November 2012|November 15, 2012|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674635||156246|
NCT00678041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SutkinAppic|Nitrofurantoin and Urinary Tract Infections (UTIs)|A Randomized, Double-blind, Placebo-controlled Trial Examining the Effect of Nitrofurantoin Prophylaxis in Women Performing Clean Intermittent Self-catheterization After Surgery for Urinary Incontinence and/or Pelvic Organ Prolapse|APPIC|University of Pittsburgh|No|Terminated|May 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|May 10, 2008||No|Inadequate patient recruitment|No||https://clinicaltrials.gov/show/NCT00678041||155985|
NCT00678067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHA-RICH1|Effects of Docosahexaenoic and Eicosapentaenoic Acids in Hypercholesterolemic Children Plus Diet on Docosahexaenoic Acid (DHA) Status|Effects of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid(EPA)Supplementation on DHA Plasmatic Status and Blood Lipid Profile in Hypercholesterolemic Children in Addition to National Cholesterol Education Program Step I Diet|DHA-RICHOIL|University of Milan|No|Completed|June 2005|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|3 Years|13 Years|No|||May 2008|May 16, 2008|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00678067||155983|
NCT00678431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0553-06-071|Randomized Trial of a Nutritional Supplement in Alzheimer's Disease|A Single Center, Multi-site, Randomized, Double-blind, Placebo-controlled Trial of Resveratrol With Glucose and Malate (RGM) to Slow the Progression of Alzheimer's Disease||VA Office of Research and Development|No|Completed|January 2008|June 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|50 Years|90 Years|No|||November 2012|November 13, 2012|January 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678431||155956|
NCT00679055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0736-006|A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)|An Exploratory Double-Blind, Placebo Controlled, Randomized, 12-Week Oral Dose Study to Evaluate the Effects of MK0736 on Atherosclerotic Disease Biomarkers in Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease||Merck Sharp & Dohme Corp.|No|Terminated|May 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|85 Years|No|||January 2015|January 30, 2015|May 14, 2008|Yes|Yes|Lack of recruitment|No|January 30, 2015|https://clinicaltrials.gov/show/NCT00679055||155910|Study terminated due to lack of recruitment.
NCT00676221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-20097|Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)|Patient Reported Outcomes in Renal Transplant Patients Tolerating GI Symptoms Converted to Myfortic (EC-MPS).||Foothills Medical Centre|No|Active, not recruiting|July 2006|September 2008|Anticipated|August 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2008|May 14, 2008|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676221||156125|
NCT00668096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11334|A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.|A Randomized, Double Blind, Placebo Controlled, Flexible Dose, Multicentre Study of Levitra in a Broad Population of Men With Erectile Dysfunction and Previously Untreated With PDE5 Inhibitors.|FINDER|Bayer|No|Completed|May 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|260|||Male|18 Years|64 Years|No|||December 2014|December 23, 2014|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668096||156742|
NCT00668109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10893|Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia|A Randomized, Open-label, Multi-center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabetes, Hypertension or Hyperlipidemia|LUTECIA|Bayer|No|Completed|December 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|614|||Male|18 Years|N/A|No|||December 2014|December 18, 2014|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668109||156741|
NCT00668746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-P-5756-1|Long-term Safety of Minocycline in Patients With Gum Disease|Long-term Safety Evaluation of Minocycline Resistance After Treatment With Minocycline HCl Microspheres, 1 mg in Subjects With Chronic Periodontitis||OraPharma|No|Completed|December 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|25 Years|N/A|No|||December 2011|December 6, 2011|April 24, 2008|Yes|Yes||No|February 26, 2010|https://clinicaltrials.gov/show/NCT00668746||156692|
NCT00677261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|378-2007|Comparing Postoperative Functional Recovery and Analgesic Efficacy of a Single Shot Sciatic Nerve Block Versus Posterior Capsule/Fat Pad Infiltration of Local Anesthetic for Total Knee Arthroplasty|A Prospective, Unicenter, Randomized, Placebo Controlled, Clinical Interventional Trial, Comparing the Postoperative Functional Recovery as Well as Analgesic Efficacy of a Single Shot Sciatic Nerve Block Versus Posterior Capsule/Fat Pad Infiltration of Local Anesthetic for Total Knee Arthroplasty.||Sunnybrook Health Sciences Centre|Yes|Completed|June 2008|November 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|75 Years|No|||July 2011|November 19, 2014|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677261||156045|
NCT00677313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB002-002|An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy|An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy||Bristol-Myers Squibb||Completed|March 2009|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|5 Years|N/A|No|||February 2015|April 8, 2015|May 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677313||156041|
NCT00677560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0709/2|Impulse Oscillometry and Airway Inflammation in Chronic Obstructive Pulmonary Disease|Impulse Oscillometry and Airway Inflammation in Chronic Obstructive Pulmonary Disease||Imperial College London|Yes|Not yet recruiting|August 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|105|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients will be recruited from outpatient clinics|May 2008|May 13, 2008|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677560||156022|
NCT00677534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11225|Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease|Exploring the Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease||University of Kansas Medical Center|No|Completed|May 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|21 Years|88 Years|No|||April 2014|April 10, 2014|May 12, 2008||No||No|June 11, 2012|https://clinicaltrials.gov/show/NCT00677534||156024|This was a pilot study using a small number of patients. Further studies are needed to validate these findings in larger groups of patients.
NCT00678158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-101|Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone|Phase I Dose Escalation Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone||Memorial Sloan Kettering Cancer Center||Completed|August 2006|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|85 Years|No|||November 2015|November 16, 2015|May 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678158||155976|
NCT00678119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-003-006|Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment|A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib||Argos Therapeutics|Yes|Completed|January 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2013|July 11, 2013|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678119||155979|
NCT00678132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080128|AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers|A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|April 2008|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||September 2012|September 24, 2015|May 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678132||155978|
NCT00677794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|small bowel cleansing and VCE|Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination|Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination: a Randomized, Blinded, Controlled Trial||Queen's University|No|Completed|March 2008|June 2015|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|198|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00677794||156004|
NCT00678444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07070018|Patient Satisfaction Regarding Timing of Clean Intermittent Self-Catheterization Teaching After Prolapse or Incontinence Surgery|||University of Pittsburgh|Yes|Completed|April 2008|January 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|199|||Female|18 Years|100 Years|No|||January 2016|January 27, 2016|May 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00678444||155955|
NCT00677222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMI-07-001|Safety Study of AMI MultiStem® to Treat Heart Attacks|A Phase I, Multicenter, Dose-Escalation Trial Evaluating the Safety of Allogeneic AMI MultiStem® in Patients With Acute Myocardial Infarction||Athersys, Inc|Yes|Completed|May 2008|February 2012|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||May 2012|May 10, 2012|May 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677222||156048|
NCT00677235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-07-002|Post-Approval Study for the FLAIR Endovascular Stent Graft|A Prospective, Randomized, Concurrently-Controlled Post-Approval Study of the FLAIR Endovascular Stent Graft|RENOVA|C. R. Bard|No|Completed|December 2008|March 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|270|||Both|21 Years|N/A|No|||August 2014|August 6, 2014|May 12, 2008|Yes|Yes||No|January 20, 2014|https://clinicaltrials.gov/show/NCT00677235||156047|
NCT00674648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-065|Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants|A Phase I Dose Escalation Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2007|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674648||156245|
NCT00677768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO_ALS-01|Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)|A Multicenter Study for the Validation of ALS Biomarkers|BIO_ALS-01|Massachusetts General Hospital|No|Completed|April 2008|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|475|Samples With DNA|650 blood samples (plasma and serum)will be collected from four groups: ALS volunteers      diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases,      volunteers with other neurological diseases and healthy control volunteers.      300 cerebrospinal fluid (CSF) samples will be collected from all four groups: ALS volunteers      diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases,      volunteers with other neurological diseases and healthy control volunteers.      Up to 600 DNA samples will also be collected from all 4 groups: ALS volunteers diagnosed      with ALS, volunteers with pure lower or pure upper motor neuron diseases, volunteers with      other neurological diseases and healthy control volunteers.|Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers will be invited to participate in this study by their neurologists either in        clinic or at a regular scheduled appointment visit.|November 2015|November 20, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677768||156006|
NCT00678054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF99551|Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)|A Phase II Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Patients With Evidence of Serologic (PSA) Progression After Definitive Therapy for Localized Prostate Cancer||University of California, San Francisco|Yes|Active, not recruiting|April 1999|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|N/A|N/A|No|||October 2015|October 2, 2015|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678054||155984|
NCT00675441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0321|Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)|A Phase II Study of Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Versus-Host Disease (GVHD)||M.D. Anderson Cancer Center|No|Terminated|April 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|May 7, 2008||No|Terminated due to slow accrual.|No|October 21, 2013|https://clinicaltrials.gov/show/NCT00675441||156184|The study did not meet all primary and secondary objectives due to slow patient accrual.
NCT00675662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07NT14|Trim Tots Pre-school Obesity Prevention Programme|TrimTots Pre-school Obesity Prevention Programme|TrimTots|Institute of Child Health|No|Completed|April 2008|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|173|||Both|12 Months|72 Months|Accepts Healthy Volunteers|||September 2015|January 12, 2016|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00675662||156168|
NCT00675675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLAP500772484|Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders|TRECC: Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders||University of California, Los Angeles|Yes|Completed|July 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|53|||Both|9 Years|14 Years|No|||August 2015|August 19, 2015|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675675||156167|
NCT00675896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00007|A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome|A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Quetiapine Fumarate Sustained Release(Seroquel SRTM) in the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome.||Dr Alexander McIntyre Inc.|No|Completed|April 2007|July 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||July 2011|July 3, 2011|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00675896||156150|
NCT00675909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0260A|Improving Sedation of Children Undergoing Procedures in the Emergency Department|Improving Sedation of Children Undergoing Procedures in the Emergency Department: Evaluation of Different Dosages and Routes of Administration of the Sedative Midazolam||Seattle Children's Hospital|Yes|Completed|November 2006|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|180|||Both|6 Months|7 Years|No|||June 2012|June 11, 2012|May 8, 2008|Yes|Yes||No|July 29, 2011|https://clinicaltrials.gov/show/NCT00675909||156149|
NCT00676468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11765|Comparative Effects of Fish Oil Supplementation and a Montelukast on EIB and Airway Inflammation in Asthma|Comparative Effects of Fish Oil Supplementation and a Leukotriene Receptor Antagonist on EIB and Airway Inflammation in Asthma||Indiana University|No|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|40 Years|No|||October 2009|October 8, 2009|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676468||156106|
NCT00676234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-11021991|Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure|Recombinant Human Erythropoietin Use in ICU Patients: Does it Prevent Acute Renal Failure?||University Hospital, Geneva|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2009|June 26, 2009|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00676234||156124|
NCT00667810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133K1-3000|Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers||Pfizer|Yes|Terminated|June 2008|August 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|901|||Both|50 Years|89 Years|No|||December 2015|December 4, 2015|April 24, 2008|Yes|Yes|The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical    benefit. This decision was not based on any new safety concerns.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT00667810||156764|The impact of study termination, the shorter observational periods and the resulting small sample size coupled with not having enough participants with post baseline assessments for various reasons were limiting factors for data interpretation.
NCT00669032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM-ME3710/304|Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee|Random, Phase IV, Multicentre, Double Blind, Placebo Controlled, Parallel Study to Assess Long-term Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid (ADANT®) in Patients With Knee OA of the Knee||Tedec-Meiji Farma, S.A.|No|Completed|October 2003|December 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|446|||Both|45 Years|N/A|No|||January 2016|January 19, 2016|April 25, 2008||No||No|November 19, 2015|https://clinicaltrials.gov/show/NCT00669032||156670|Control of rescue medication: patients were asked at every assessment visit about the frequency and doses of consumption, but it was not delivered in hand.
NCT00669305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR|Bone Marrow for Hemoglobinopathy Research|Bone Marrow for Hemoglobinopathy Research||St. Jude Children's Research Hospital|No|Recruiting|July 2007|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|28|Samples With DNA|Stem Cells through Bone Marrow Aspiration|Both|N/A|N/A|No|Probability Sample|Patients with Sickle Cell Anemia or Thalassemia|February 2016|February 2, 2016|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669305||156649|
NCT00677027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2006.3622 (REK)|Dose Escalation Safety Study of MM-10-001 in Healthy Subjects|Dose Escalation Safety Study of MM-10-001||GlycaNova Norge AS|Yes|Active, not recruiting|February 2008|June 2008|Anticipated|June 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|45 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 12, 2008|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677027||156063|
NCT00678184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2006.03.LP|The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake|The Effect of Acute HMG-CoA-Reductase Inhibition (Atorvastatin) on Renal Sodium Excretion, Renal Hemodynamics, Tubular Function and Vasoactive Hormones in Healthy Subjects During Normal and High Sodium Intake||Regional Hospital Holstebro|Yes|Completed|January 2007|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|23|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 14, 2008|May 13, 2008||||No||https://clinicaltrials.gov/show/NCT00678184||155974|
NCT00678197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD042117|Philippine Child Health and Policy Experiment|Philippine Child Health and Policy Experiment||University of California, San Francisco||Completed|April 2003|September 2007||September 2007|Actual|N/A|Interventional|Primary Purpose: Health Services Research|3||||||Both|6 Months|5 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00678197||155973|
NCT00677547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7061|Cell-mediated Immune Response to Influenza Vaccine|Humoral and Cell-mediated Immune Response to Influenza Vaccine in Kidney Tranpslant Recipients.||University of Alberta|No|Completed|November 2007|June 2010|Actual|January 2010|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult kidney transplant recipients and healthy volunteers (enrolled among hospital staff)|September 2011|September 13, 2011|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677547||156023|
NCT00678873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8843|Single Incision Laparoscopic Cholecystectomy|Single Incision Laparoscopic Cholecystectomy|SILC|North Texas Veterans Healthcare System|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2008|December 14, 2009|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678873||155922|
NCT00678145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-202|Mechanisms Responsible for Hypoglycemia Associated Autonomic Failure|Mechanisms of Hypoglycemia Associated Autonomic Failure|HAAF|Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|March 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|116|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||July 2013|July 24, 2013|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678145||155977|
NCT00678470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOO-AMEVIVE-2008|Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis|A Single Arm, Open Label Study to Explore if Response to Intralesional Alefacept Injections Prior to the Standard Course of Intramuscular Treatment Can Predict Clinical Outcomes in Patients With Moderate to Severe Chronic Plaque Psoriasis||University of California, San Francisco|Yes|Completed|September 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 19, 2013|May 13, 2008|No|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00678470||155953|
NCT00678795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS0208|A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis|A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis.||GW Pharmaceuticals Ltd.|No|Completed|August 2002|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|135|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 14, 2008||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT00678795||155928|
NCT00678808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORP5164|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2008|||||N/A|N/A|N/A||||||||||||||August 11, 2015|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678808||155927|
NCT00678457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO45228|Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial|Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial||University of Virginia|Yes|Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|May 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678457||155954|
NCT00678769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00282|Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer|Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers||National Cancer Institute (NCI)||Completed|May 2008|October 2015|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|16 Years|N/A|No|||November 2015|November 3, 2015|May 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678769||155930|
NCT00678782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-IA-02|Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis|Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence||University of Padova|Yes|Completed|April 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||May 2008|May 15, 2008|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678782||155929|
NCT00674934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-MS-CTP1|Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Multiple Sclerosis.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2008|June 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||January 2009|January 2, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674934||156223|
NCT00674921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009/ESR/NDA/DID-01/2008|Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda|Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda|CCS|MRC/UVRI Uganda Research Unit on Aids|No|Not yet recruiting|June 2008|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1650|||Both|16 Years|59 Years|No|||May 2008|June 4, 2008|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674921||156224|
NCT00675220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1884|Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™|A Prospective, Open-Labelled, Non-Controlled, Observational Study to Assess the Efficacy and Safety of NovoRapid™ FlexPen™ in the Treatment of Acute Hyperglycemia: A Post-Marketing Surveillance Study||Novo Nordisk A/S|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|373|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Diabetes|May 2012|May 24, 2012|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00675220||156201|
NCT00675454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|565|Evaluating the Effects of Surgical and Non-Surgical Treatment Options in People With Emphysema|Emphysema: Outcomes and Technology Assessment||Washington University School of Medicine|No|Enrolling by invitation|January 2000|||November 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|35 Years|90 Years|No|Non-Probability Sample|Participants with moderate to severe emphysema who are undergoing pulmonary        rehabilitation, lung volume reduction surgery, or lung transplantation.|August 2013|August 19, 2013|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675454||156183|
NCT00675467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0054|Palliative Care and Symptom Management for the Pediatric Oncology Patient|Palliative Care and Symptom Management for the Pediatric Oncology Patient||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2008|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|56|||Both|10 Years|18 Years|No|Probability Sample|Study participants 10-18 years of age with cancer and their parent(s) or caregiver(s).|March 2016|March 7, 2016|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675467||156182|
NCT00675688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-303|Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women|A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2002|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3544|||Female|40 Years|75 Years|No|||May 2008|May 9, 2008|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675688||156166|
NCT00675922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-096|Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks|Comparing the Use of Sulfamylon 5%, Dakins 0.025%, Cerium, Silver Nitrate 5% and/or Other Topical Antimicrobial Products for the Treatment of Excised and/or Grafted Burn Wounds|Soaks|The University of Texas Medical Branch, Galveston|Yes|Terminated|July 1995|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|N/A|90 Years|No|||December 2012|December 10, 2012|December 26, 2007||No|Data inconclusive.|No|August 6, 2012|https://clinicaltrials.gov/show/NCT00675922||156148|
NCT00675935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62572|Falls - Tailoring Interventions for Patient Safety|Translating Fall Risk Status Into Interventions to Prevent Patient Falls: Falls TIPS (Tailoring Interventions for Patient Safety)|Falls TIPS|Brigham and Women's Hospital|No|Completed|September 2007|August 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2010|July 22, 2010|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00675935||156147|
NCT00675961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-002539|Effectiveness of Alcohol Interventions Among Tuberculosis (TB) Patients in Tomsk Oblast, Russia|Effectiveness of Alcohol Interventions Among TB Patients in Tomsk Oblast, Russia|IMPACT|Brigham and Women's Hospital|Yes|Completed|January 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|400|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|May 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00675961||156145|
NCT00675974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-126|Use of Pressure Garments for Burn Scars|Prospective Randomized Study of the Effectiveness of Prospective Randomized Study on the Effectiveness of Pressure Garment Therapy for the Prevention of Hypertrophic Scarring in Burned Children|Jobst|The University of Texas Medical Branch, Galveston|Yes|Withdrawn|August 2005|December 2014|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|17 Years|No|||November 2012|November 13, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00675974||156144|
NCT00676247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802011R|Cerebral Blood Flow Parameters and Neurobehavioral Development in Infants at Term Age|Cerebral Blood Flow Parameters and Neurobehavioral Development in Full-Term Infants and Very Low Birth Weight Preterm Infants at Term Age||National Taiwan University Hospital|Yes|Completed|April 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|1|||Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Newborns in the primary care clinic|January 2009|January 19, 2009|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00676247||156123|
NCT00668473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00011196|Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis|Endostatin and Other Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis||University of Michigan|No|Completed|May 2007|January 2012|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|Samples Without DNA|skin serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Attendees of a tertiary care clinic|June 2015|June 5, 2015|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668473||156713|
NCT00676793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-179|A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression|Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression||Louisiana State University Health Sciences Center Shreveport|Yes|Active, not recruiting|May 2004|July 2013|Anticipated|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Female|21 Years|75 Years|No|||September 2012|September 25, 2012|May 9, 2008|No|Yes||No|September 2, 2011|https://clinicaltrials.gov/show/NCT00676793||156081|
NCT00677040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030804|Normal Tissue Oxygenation Following Radiotherapy|Normal Tissue Oxygenation Following Radiotherapy||Essentia Health|No|Completed|April 2008|August 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have undergone breast conserving therapy consisting of lumpectomy and        pPatients with breast cancer who received postoperative radiotherapy for breast        conservation will be identified from tumor registry data and recruited into the study if        they have completed radiotherapy less than one year ostoperative radiotherapy.|September 2011|September 19, 2011|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677040||156062|
NCT00678210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921047|Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 2B, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Evaluating The Efficacy And Safety Of Dose Regimens With Oral CP-690,550 In The Treatment Of Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|No|Completed|July 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|197|||Both|18 Years|N/A|No|||November 2012|November 19, 2012|May 13, 2008|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00678210||155972|
NCT00678236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070237|A Migration and Bone Density Study Comparing 2 Types of Bone Cement in the OptiPac Bone Cement Mixing System|A Migration and Bone Density Study Comparing Refobacin Bone Cement R vs. Refobacin Plus Bone Cement in the OptiPac Bone Cement Mixing System. A Prospective Randomized Study on Primary Total Knee Arthroplasty||University of Aarhus|Yes|Completed|June 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|54|||Both|70 Years|N/A|No|||August 2013|August 19, 2013|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00678236||155971|
NCT00677573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ughno1|Efficacy of Urinary Follicle-Stimulating Hormone (FSH) Among Poor Responders|Comparison of Urinary Purified Follicle-Stimulating Hormone (FSH) and Rec-FSH Among Poor Responders Undergoing Ovarian Stimulation With GnRH Antagonist||German Hospital, Istanbul|No|Not yet recruiting|May 2008|November 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Female|20 Years|44 Years|Accepts Healthy Volunteers|||May 2008|May 9, 2008|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677573||156021|
NCT00677859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVHD-2007-001|Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia|A Phase I, Multicenter, Dose-Escalation Trial Evaluating Maximum-Tolerated Dose of Single and Repeated Administration of Allogeneic MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia||Athersys, Inc|Yes|Completed|July 2008|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|65 Years|No|||January 2012|January 3, 2012|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677859||155999|
NCT00677872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX-08066-202|An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease|||Epix Pharmaceuticals, Inc.||Terminated|May 2008|||December 2008|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|40 Years|N/A|No|||July 2009|July 28, 2009|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677872||155998|
NCT00678886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115495|Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1|Durable-Response Therapy Evaluation ForEarly or New-Onset Type 1 Diabetes - DEFEND|DEFEND-1|GlaxoSmithKline|Yes|Completed|July 2008|January 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|272|||Both|12 Years|45 Years|No|||February 2013|February 7, 2013|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678886||155921|
NCT00678509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast-A24-I, II|Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Breast Cancer||Tokyo University|Yes|Terminated|May 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||March 2009|December 28, 2009|May 12, 2008||No|Lack of financial support|No||https://clinicaltrials.gov/show/NCT00678509||155950|
NCT00678483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10139|Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients|A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overweight or Obese Patients|MODERATO|Sanofi|Yes|Terminated|April 2008|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|N/A|No|||June 2009|June 16, 2009|May 13, 2008|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00678483||155952|
NCT00678821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080133|Aerobic Exercise in Patients With Pulmonary Hypertension|The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Pulmonary Hypertension: Initial Studies for Establishing Guidelines||National Institutes of Health Clinical Center (CC)||Completed|May 2008|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|97|||Both|21 Years|82 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678821||155926|
NCT00674661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVX-003|Corneal Collagen Cross-Linking for Ectasia (CXL)|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery|CXL|Avedro, Inc.|No|Completed|December 2007|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|14 Years|N/A|No|||June 2015|June 22, 2015|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674661||156244|
NCT00674674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17990|Phase 1 Intrathecal Topotecan for Neoplastic Meningitis|A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children With Neoplastic Meningitis|PBTC-019|Baylor College of Medicine|Yes|Completed|October 2005|December 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|3 Years|21 Years|No|||May 2012|May 11, 2012|December 21, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00674674||156243|
NCT00675233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595166|Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx|Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Larynx||Roswell Park Cancer Institute|Yes|Active, not recruiting|January 2008|||June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00675233||156200|
NCT00675246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORTICOID001|Antenatal Corticoid Therapy for Late Preterm Babies|Antenatal Corticoid Therapy for Fetal Lung Maturation in Late Preterm Pregnancies: a Randomized Controlled Trial|ACTLPT|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|May 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|320|||Female|18 Years|49 Years|No|||June 2010|June 8, 2010|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675246||156199|
NCT00675480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PO5C00527|Thrombectomy in Acute Myocardial Infarction|Aspiration Thrombectomy as an Adjunctive Therapy to Primary Angioplasty in Patients With ST Segment Elevation Myocardial Infarction|TAMI|Institute of Cardiology, Warsaw, Poland|No|Completed|November 2004|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|N/A|No|||January 2009|January 28, 2009|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675480||156181|
NCT00675701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-LX1403|A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study|A Double Blind, Randomized, Repeat-Dose, Parallel Group Study to Define the ECG Effects of Lixivaptan Using a Clinical and a Supratherapeutic Dose, Compared to Placebo and Moxifloxacin (a Positive Control), in Healthy Adult Men and Women: A Thorough ECG Study||CardioKine Inc.|Yes|Completed|May 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|298|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|June 20, 2011|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675701||156165|
NCT00675948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEXT0101|Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain|An Open-label, Extension Study, to Investigate the Long-term Safety and Tolerability of Cannabis Based Medicine Extracts in Patients With Cancer-related Pain.||GW Pharmaceuticals Ltd.|No|Completed|April 2002|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|43|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 8, 2008||No||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00675948||156146|
NCT00675987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000490|A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients|Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose||Brigham and Women's Hospital|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|53|||Both|18 Years|75 Years|No|||February 2013|February 4, 2013|May 8, 2008||No||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00675987||156143|
NCT00676832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08CP01|Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis||Prometheus Laboratories|No|Completed|May 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|190|||Both|18 Years|75 Years|No|||September 2010|September 27, 2010|May 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676832||156078|
NCT00677066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP 1405|Safety Study of Home Oxygen Therapy for Children With Acute Bronchiolitis|A Randomised Controlled Trial: Home Oxygen Therapy Versus Hospital Oxygen Therapy for Children With Acute Bronchiolitis||Princess Margaret Hospital for Children|Yes|Completed|August 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|44|||Both|3 Months|24 Months|No|||May 2008|May 12, 2008|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00677066||156060|
NCT00668486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03748|Dermacyd Delicata Breeze - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Breeze.||Sanofi|No|Completed|January 2008|||February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|28|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 9, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668486||156712|
NCT00676819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1416|Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes|Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Soluble Insulin in Geriatric Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2002|July 2002|Actual|July 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|19|||Both|65 Years|N/A|No|||September 2011|June 5, 2012|May 9, 2008||||No||https://clinicaltrials.gov/show/NCT00676819||156079|
NCT00677053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-442_202|Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes|A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes||Takeda|Yes|Completed|March 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|2753|||Both|30 Years|80 Years|No|||February 2012|February 1, 2012|May 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677053||156061|
NCT00677300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck 072-00|Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients|Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients|RADAR|Dallas VA Medical Center|Yes|Completed|January 2009|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00677300||156042|
NCT00678899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORP5180|Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System|Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant||Cochlear|No|Completed|April 2008|July 2014|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|May 14, 2008|Yes|Yes||No|September 10, 2014|https://clinicaltrials.gov/show/NCT00678899||155920|
NCT00678522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2006.04.LP|The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes|The Acute Effect of Atorvastatin on Renal Sodium Excretion, Glomerular Filtration Rate, Tubular Function and Vasoactive Hormones in Patients With Non-Insulin Dependent Type II Diabetes.||Regional Hospital Holstebro|Yes|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|25|||Both|40 Years|70 Years|No|||May 2008|May 14, 2008|May 13, 2008||||No||https://clinicaltrials.gov/show/NCT00678522||155949|
NCT00678535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200048-052|Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer|Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction|EXPAND|Merck KGaA|Yes|Completed|June 2008|February 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|904|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|May 13, 2008|No|Yes||No|March 30, 2013|https://clinicaltrials.gov/show/NCT00678535||155948|
NCT00675051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H47369-31390|Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension|Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension||University of California, San Francisco|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Precapillary Pulmonary Hypertension|March 2008|April 12, 2011|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00675051||156214|
NCT00675064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO105774|Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects|Single-blind, Placebo-controlled, Randomized Study Testing Single Ascending Doses of GSK369796 in Healthy Subjects||GlaxoSmithKline|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|41|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|March 15, 2012|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00675064||156213|
NCT00674739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW01-0801|Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts||Graceway Pharmaceuticals, LLC|No|Completed|May 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|470|||Both|12 Years|N/A|No|||May 2011|May 19, 2011|May 7, 2008|Yes|Yes||No|April 24, 2011|https://clinicaltrials.gov/show/NCT00674739||156238|
NCT00678496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112276|Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis|Computerised Cognitive Behavioural Therapy for Treatment of Depression in MS (CoSMoS): Clinical Trial Pilot Study|CoSMoS|University of Sheffield|No|Completed|October 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678496||155951|
NCT00678834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005C0034|Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol|Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol||Ohio State University|Yes|Completed|March 2006|June 2012|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|80|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2014|September 8, 2014|May 14, 2008||No||No|July 2, 2014|https://clinicaltrials.gov/show/NCT00678834||155925|
NCT00674687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451138|A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing|A Randomized Double-Blind, Placebo-Controlled, Crossover Study To Assess The Reproducibility And The Effect Of Gabapentin On Quantitative Sensory Testing In Neuropathic Pain Patients||Pfizer|No|Completed|July 2004|June 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||May 2008|May 8, 2008|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674687||156242|
NCT00674700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO57.07|Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis|A Randomized, DBPC, Multi-national Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis||Stallergenes|No|Completed|October 2007|February 2010|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|509|||Both|18 Years|50 Years|No|||December 2011|December 20, 2011|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674700||156241|
NCT00674947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207ST101|A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors|A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors||Biogen||Completed|June 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||September 2011|September 12, 2013|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674947||156222|
NCT00674960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-FD-CTP1|Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2008|October 2009|Anticipated|May 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||August 2009|August 14, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674960||156221|
NCT00675259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07074|Phase II NCT w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer|Phase II Trial of Neoadjuvant Chemotherapy [NCT] With Weekly Nanoparticle Albumin-bound Paclitaxel [Nab-paclitaxel; Abraxane®] in Combination With Carboplatin and Bevacizumab in Women With Clinical Stages I-III Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|July 2008|March 2014|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Female|18 Years|N/A|No|||March 2014|March 11, 2014|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675259||156198|
NCT00676000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p002015|Randomized Trial of Interrupted Versus Continuous Vaginal Closure of Anterior Repair With Mesh|Randomized Trial of Interrupted Versus Continuous Vaginal Closure of Anterior Repair With Mesh||Brigham and Women's Hospital|Yes|Withdrawn|April 2008|||December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|N/A|No|||March 2009|March 17, 2009|May 8, 2008||No|Due to decrease in Avaulta mesh kit usage & inability to recruit study subjects.|No||https://clinicaltrials.gov/show/NCT00676000||156142|
NCT00676260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD4833/EC412|Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin|Effect of Pioglitazone 15 mg or 30 mg on Microcirculation in Type 2 Diabetes Patients Treated With Insulin||Takeda|No|Completed|December 2002|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|40 Years|80 Years|No|||February 2012|February 27, 2012|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676260||156122|
NCT00676533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100544|Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections|Cipro® XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections||Bayer|No|Completed|June 2003|January 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|276|||Female|18 Years|65 Years|No|||October 2013|October 10, 2013|May 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676533||156101|
NCT00675714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-157|Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation|Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation||The University of Texas Medical Branch, Galveston|Yes|Recruiting|January 2004|September 2017|Anticipated|September 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Anticipated|1100|||Both|N/A|80 Years|No|||November 2015|November 30, 2015|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00675714||156164|
NCT00675727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-60/4051|Safety Study of CADI-05 in Patients With Advanced Stage Melanoma|Open Label, Single Arm, Phase I/II Study of CADI-05 in Patients With Advanced Stage III or Stage IV Melanoma||Cadila Pharnmaceuticals|Yes|Terminated|December 2006|||December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2009|June 10, 2009|May 8, 2008|Yes|Yes|DSMB reviewed data of 1st 10 subjects; determined no safety concerns. Efficacy as a single    agent in this patient population was unlikely. Voluntary Termination|No||https://clinicaltrials.gov/show/NCT00675727||156163|
NCT00676546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|741-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||May 9, 2008|May 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676546||156100|
NCT00676845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSE-866/47|Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection|Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome|ArtStiff|Daiichi Sankyo Inc.|No|Completed|August 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|133|||Both|18 Years|75 Years|No|||April 2012|April 26, 2012|May 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676845||156077|
NCT00677079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD11489|Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase 2, Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Sanofi|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||September 2013|September 23, 2013|May 9, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00677079||156059|
NCT00668499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18M-07-2|A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma|A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma||University of Southern California|No|Withdrawn|April 2008|April 2011|Anticipated|April 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|90 Years|No|||May 2014|May 19, 2014|April 25, 2008|Yes|Yes|Sponsor withdrew support|No||https://clinicaltrials.gov/show/NCT00668499||156711|
NCT00669019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00193|Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase 2 Study of AZD0530 in Metastatic Melanoma||National Cancer Institute (NCI)|Yes|Completed|July 2006|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2014|May 6, 2014|April 26, 2008|Yes|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT00669019||156671|Trial was designed with a maximum target accrual of 37 patients. Per protocol, the trial was stopped after the first stage based on an interim analysis of the response rate among the first 23 patients.
NCT00677586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080507|I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer|||Fudan University|Yes|Completed|January 2000|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||March 2009|March 24, 2009|May 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677586||156020|
NCT00677599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15098|The FLAVO Trial: Dietary Flavonoids and Cardiovascular Disease Risk Reduction in Postmenopausal Women With Type 2 Diabetes|Reducing Cardiovascular Risk With Dietary Flavonoids in Post Menopausal Women With Type 2 Diabetes|FLAVO|University of East Anglia|No|Completed|May 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|152|||Female|N/A|70 Years|No|||May 2011|May 12, 2011|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677599||156019|
NCT00677885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080124|P-glycoprotein Function in Brain Diseases|Measurement of P-Glycoprotein Function in Alzheimer Disease, Parkinson Disease, and Frontotemporal Dementia Using Positron Emission Tomography||National Institutes of Health Clinical Center (CC)||Completed|May 2008|August 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|20|||Both|35 Years|N/A|No|||August 2014|August 26, 2014|May 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00677885||155997|
NCT00678171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-TLF-001|A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System|A Pilot Study to Evaluate an OP-1 Putty Spinal System and an Autograft Spinal System in Patients Requiring Transforaminal Lumbar Interbody Fusion of the Spine||Olympus Biotech Corporation|No|Completed|February 2007|March 2010|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||January 2014|January 3, 2014|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678171||155975|
NCT00678912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ-2239|Weaning Children From Mechanical Ventilation:Computer-driven System Versus Usual Care|Single Center Randomized Clinical Trial Comparing Weaning From Mechanical Ventilation With Computer-driven System vs Usual Care in Children||St. Justine's Hospital|Yes|Completed|September 2007|July 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|2 Years|18 Years|No|||September 2012|September 18, 2012|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678912||155919|
NCT00678548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2007.1943|Effect of Guided Imagery on Patients With Chronic Pain Related to Spinal Cord Injury|Effect of Positive Guided Imagery on Patients With in or Below-level Chronic Pain Related to Spinal Cord Injury||Norwegian University of Science and Technology|No|Withdrawn|October 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||April 2015|April 7, 2015|May 13, 2008||No|Due to other projects priority|No||https://clinicaltrials.gov/show/NCT00678548||155947|
NCT00678561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921038|Topical CP-690,550 For Chronic Plaque Psoriasis|Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics And Pilot Efficacy Of 4 Weeks Treatment With Topical CP-690,550 In Chronic Plaque Psoriasis||Pfizer|No|Completed|October 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|81|||Both|18 Years|N/A|No|||November 2010|November 12, 2010|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678561||155946|
NCT00675324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/104-31/3|Bowel Preparation Before Colonoscopy|Bowel Preparation With Nutritional Drinks Instead of Traditional Bowel Preparation||Karolinska Institutet|No|Terminated|April 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|90 Years|No|||September 2012|September 17, 2012|May 7, 2008||No|The bowel was not clean when the colonoscopy was performed|No||https://clinicaltrials.gov/show/NCT00675324||156193|
NCT00675337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wghjmd1|Effect of Infant Placement on Iron Stores in Infancy: A Pilot Study|The Effect of Infant Placement at Delivery on Iron Stores in Early Infancy: A Pilot Study||Davison, James, D.O.|Yes|Active, not recruiting|June 2008|April 2009|Anticipated|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|30|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2008|December 30, 2008|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675337||156192|
NCT00674752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451157|A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study Of Gabapentin 250 mg And 500 mg In Transient Insomnia Induced By A Sleep Phase Advance||Pfizer|No|Completed|March 2006|August 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|377|||Both|18 Years|N/A|No|||April 2011|April 22, 2011|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674752||156237|
NCT00674765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807057 - Kampan_AA016553|Seroquel for Frequent, Heavy Drinkers|A Phase II Double-blind, Placebo-controlled Trial of Quetiapine for Frequent, Heavy Drinkers (Seroquel2)||University of Pennsylvania|Yes|Completed|January 2008|January 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|70 Years|No|||September 2014|September 16, 2014|May 6, 2008|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT00674765||156236|
NCT00674778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/6/2006|Prospective Registry on Vascular Access in Interventions in Lazio Region|Prospective Registry on Vascular Access in Interventions in Lazio Region|PREVAIL|San Filippo Neri General Hospital|No|Completed|June 2006|June 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1052|||Both|N/A|N/A|No|||May 2008|May 7, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674778||156235|
NCT00678860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080135|Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires|Pilot Validation Study of Computer Administration of Vision Targeted Quality of Life Instruments||National Institutes of Health Clinical Center (CC)||Completed|May 2008|October 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|147|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|September 26, 2015|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678860||155923|
NCT00674713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1014/05|Effect of Acupuncture on Postoperative Nausea and Vomiting|||Catholic University of the Sacred Heart||Completed|January 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|140|||Both|18 Years|70 Years|No|||May 2008|May 7, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674713||156240|
NCT00678847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULTRA-BEST|Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy|Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy||Kingfisher Healthcare|No|Recruiting|March 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2008|May 15, 2008|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678847||155924|
NCT00675272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070197|Organ Donation and Hydrocortisone Treatment|Organ Donation and Vasopressor Use: Effects of Hydrocortisone Treatment|HYDRO|Kuopio University Hospital|No|Terminated|May 2008|December 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|May 7, 2008|Yes|Yes|Routine use of corticoids became standard therapy|No||https://clinicaltrials.gov/show/NCT00675272||156197|
NCT00675493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3567|Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Type 1 and Type 2 Diabetes Mellitus in Romania||Novo Nordisk A/S|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|942|||Both|10 Years|75 Years|No|Non-Probability Sample|Type 1 and type 2 diabetes patients inadequately controlled on human premixes|February 2016|February 18, 2016|May 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00675493||156180|
NCT00674973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21129|A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer|A Randomized, Double Blind Study of Biomarkers Predictive of Improvement in Progression Free Survival in Patients With Advanced Pancreatic Cancer Treated With Tarceva.||Hoffmann-La Roche||Completed|June 2008|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00674973||156220|
NCT00674986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000590|A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes|A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes||Hoffmann-La Roche||Completed|March 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|522|||Both|25 Years|N/A|No|||August 2013|August 19, 2013|May 7, 2008||No||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00674986||156219|
NCT00676013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-286|Skin Substitutes in Burn Care|The Use of Alloderm and Other Skin Substitutes in Acute Burn Treatment and Burn Scar Reconstruction|Quad|The University of Texas Medical Branch, Galveston|Yes|Terminated|December 1997|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|158|||Both|N/A|90 Years|No|||September 2011|September 6, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00676013||156141|
NCT00676273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28142|TVT-Secur Versus TVT-Obturator: A Randomized Trial of Suburethral Sling Operative Procedures|TVT-Secur Versus TVT-Obturator: A Randomized Trial of Suburethral Sling Operative Procedures||Boston Urogynecology Associates|No|Recruiting|March 2007|December 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 12, 2008|November 16, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676273||156121|
NCT00676559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 00015499|Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study|Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study|CAPTURE|Johns Hopkins University|Yes|Withdrawn|April 2008|April 2010|Anticipated|April 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|No|||January 2009|January 30, 2009|May 8, 2008|Yes|Yes|Unrelated serious adverse events involving one of the proposed medications|No||https://clinicaltrials.gov/show/NCT00676559||156099|
NCT00677092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001945|Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis|An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis|GENESYF|Massachusetts General Hospital|No|Active, not recruiting|May 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677092||156058|
NCT00677352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501088|A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder|A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder||Pfizer|No|Completed|May 2008|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|321|||Both|20 Years|64 Years|No|||May 2011|May 17, 2011|May 9, 2008|Yes|Yes||No|January 19, 2011|https://clinicaltrials.gov/show/NCT00677352||156038|
NCT00677625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 03/64 HRRC 188-03|Pediatric Liver Database|Pediatric Liver Disease and Liver Transplant Database||Medical College of Wisconsin|No|Recruiting|June 2003|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|18 Years|No|Non-Probability Sample|All child subjects will be recruited from the Hepatology Clinic at Children's Hospital of        Wisconsin|December 2015|December 1, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677625||156017|
NCT00677638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN004|Transapical Implantation of Ventor Embracer™ Valve in Patients With Severe Aortic Valve Disease|Catheter-Based Transapical Implantation of the Ventor Embracer™ Heart Valve Prosthesis in Patients With Severe Aortic Valve Disease||Ventor Technologies|No|Active, not recruiting|June 2008|December 2014|Anticipated|January 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|75 Years|N/A|No|||December 2009|December 2, 2009|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677638||156016|
NCT00668538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-373|Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans|Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans||University of Southern Denmark|Yes|Completed|April 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668538||156708|
NCT00677612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-A02-I, II|Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Combination With Tegafur/Uracil/Folinate in Treating Patients With Refractory Colorectal Cancer||Tokyo University|Yes|Terminated|May 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||January 2009|December 28, 2009|May 12, 2008||No|Lack of financial support|No||https://clinicaltrials.gov/show/NCT00677612||156018|
NCT00677898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-256|A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)|A Patient-Centered Approach to Improve Screening for Side Effects of SGAs||VA Office of Research and Development|No|Completed|March 2010|June 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|239|||Both|18 Years|70 Years|No|||August 2014|April 6, 2015|May 9, 2008||No||No|September 5, 2014|https://clinicaltrials.gov/show/NCT00677898||155996|
NCT00677911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTRI975|Immunologic Response to Negative Cognition in Persons With Chronic Pain|Immunologic Response to Negative Cognition in Persons With Chronic Pain||Oregon Health and Science University|Yes|Completed|February 2007|December 2007|Actual|December 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment|1||Actual|47|||Both|18 Years|65 Years|No|||May 2008|May 13, 2008|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00677911||155995|
NCT00674791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000902|Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease|A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA 51) Following Completion of Prescribed Chemotherapy or Trastuzumab for TXN2-3M0 or Metastatic Breast Cancer With No Evidence of Disease||Duke University|No|Completed|June 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2011|June 18, 2013|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674791||156234|
NCT00675363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85487|Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol|A Randomized Trial of Daily Sedative Interruption in Critically Ill, Mechanically Ventilated Patients Being Managed With a Sedation Protocol|SLEAP|Mount Sinai Hospital, Canada|Yes|Active, not recruiting|January 2008|November 2011|Anticipated|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|410|||Both|18 Years|N/A|No|||September 2011|September 23, 2011|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675363||156190|
NCT00675311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7021|Remote Monitoring in Diabetes Disease Management|A Randomized Study of the Clinical and Economic Impact of Remote Monitoring Program With Disease Management Compared to Conventional Diabetes Disease Management Interventions||LifeScan|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|64 Years|No|||December 2009|December 17, 2009|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675311||156194|
NCT00675025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-220|Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial|An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial||Eisai Inc.||Terminated|April 2008|||February 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|10 Years|17 Years|No|||December 2008|December 10, 2008|May 7, 2008|Yes|Yes|Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.|No||https://clinicaltrials.gov/show/NCT00675025||156216|
NCT00674726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-002-05-08|Study on the Difference of Axilo-rectal Temperature in Appendicitis|Prospective Study on the Difference of Axilar-rectal Temperature in Acute Appendicitis||Cirujanos la Serena|No|Withdrawn|May 2008|July 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|15 Years|N/A|No|Non-Probability Sample|Patients consulting in the emergency unit with acute appendicitis or acute gastroenteritis|October 2012|October 29, 2012|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674726||156239|
NCT00674999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-040|Use of Amnion on Partial Thickness Burns|Project Title The Treatment of Partial Thickness Burns: Treated Amnion Versus Currently in Use Topical Medications|Amnion|The University of Texas Medical Branch, Galveston|No|Withdrawn|June 2005|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|N/A|N/A|No|||November 2012|November 13, 2012|December 26, 2007||No|Hurricane- terminated study due to skin bank being destroyed|No||https://clinicaltrials.gov/show/NCT00674999||156218|
NCT00675012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR005|NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer|NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer||MolMed S.p.A.|No|Completed|December 2007|May 2013|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00675012||156217|
NCT00675519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH93-TD-1050|An Evaluation of the Brief Interventional for Problem Drinkers Among Medical Inpatients|Effects of Brief Intervention for General Hospital Inpatients With Unhealthy Alcohol Use in Taiwan: A Randomized, Controlled Trial|BI|Mackay Memorial Hospital|Yes|Completed|January 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00675519||156178|
NCT00675506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574|Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese|Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity||Massachusetts General Hospital|Yes|Completed|July 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|No|||December 2012|December 3, 2012|May 7, 2008|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00675506||156179|
NCT00675740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leipzig 03|Physical Exercise Versus Rosiglitazone in CAD and Prediabetes|Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes||University of Leipzig|No|Completed|January 2004|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|35 Years|70 Years|No|||January 2010|February 1, 2010|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675740||156162|
NCT00676026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505027759|Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women|The Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women||Yale University|No|Completed|May 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|3||Actual|8|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00676026||156140|
NCT00676286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-24152|Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers|Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19||AHS Cancer Control Alberta|Yes|Active, not recruiting|November 2008|August 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Male|18 Years|N/A|No|||March 2014|March 31, 2014|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00676286||156120|
NCT00676572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0708/29|p38 Mitogen−Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma|p38 MAPK Activation as the Basis for Corticosteroid Insensitivity in Severe Asthma||Imperial College London|No|Active, not recruiting|May 2008|April 2016|Anticipated|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|sputum cell pellets and supernatant; BAL supernatant; endobronchial biopsies; smooth muscle      cell culture from biopsies|Both|18 Years|60 Years|No|Non-Probability Sample|Asthmatic subjects will be recruited from asthma clinics at the Royal Brompton Hospital        and from primary care clinics.|February 2016|February 23, 2016|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676572||156098|
NCT00677365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpex-204|Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients|Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients||Forest Laboratories|Yes|Completed|June 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|151|||Both|16 Years|N/A|No|||May 2012|May 8, 2012|May 12, 2008|No|Yes||No|September 4, 2011|https://clinicaltrials.gov/show/NCT00677365||156037|
NCT00677651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070668|Sex Differences in Gene Expression in Human Adipose Tissue|Sex Differences in Gene Expression in Human Adipose Tissue||University of California, San Diego|Yes|Completed|April 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|10|Samples With DNA|Blood, Fat tissue from abdomen and buttock|Both|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|General Population|August 2009|August 17, 2009|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677651||156015|
NCT00677664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COP 001|Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation|Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial.||Federal University of São Paulo|No|Active, not recruiting|July 2006|September 2008|Anticipated|July 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||May 2008|May 13, 2008|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677664||156014|
NCT00669097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2106|Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies|An Open-Label, Non-Randomized, Single-Center, Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion (ADME) of TKI258 After a Single Oral Administration of TKI258 500mg and to Assess the Preliminary Safety of TK258 400mg Once Daily in Patients With Advanced Solid Malignancies||Novartis||Completed|April 2008|||January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00669097||156665|
NCT00678249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP-9809|Pivotal Study for the FLAIR Endovascular Stent Graft|A Prospective, Multi-Center, Randomized Evaluation of an IMPRA/Bard ePTFE Encapsulated Carbon Lined Nitinol Endoluminal Device for AV Access Graft Stenoses||C. R. Bard|Yes|Completed|January 2001|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|227|||Both|18 Years|90 Years|No|||May 2011|May 10, 2011|May 13, 2008|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00678249||155970|
NCT00678262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR470008CTIL|Changes in Heart Rate in Response to Cold Pressor Test|Changes in Heart Rate in Response to Cold Pressor Test|HRVW1|Soroka University Medical Center|No|Completed|May 2008|October 2008||October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|September 2010|September 19, 2010|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00678262||155969|
NCT00678574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9803010098|The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder|The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder||Yale University|No|Completed|March 1998|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00678574||155945|
NCT00678587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPL104054|Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures|Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures|ELEVATE|GlaxoSmithKline|Yes|Terminated|June 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|292|||Both|18 Years|N/A|No|||January 2013|February 7, 2013|May 13, 2008|||GSK decision|No|October 10, 2010|https://clinicaltrials.gov/show/NCT00678587||155944|
NCT00678600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01AI062435|Study of Provider Computer Alerts Designed to Improve Delivery of HIV Care|Optimizing HIV Disease-Specific Provider Alerts: A Randomized Controlled Informatics Trial Comparing Electronic Health Record (EHR) vs. Non-EHR Provider Alerts||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|September 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|1011|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00678600||155943|
NCT00674804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080127|Communicating a Cancer Diagnosis-Current Methods and Their Effects|Communicating a Cancer Diagnosis: Current Methods and Their Effects||National Institutes of Health Clinical Center (CC)||Completed|April 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|N/A||||1100|||Both|18 Years|N/A|No|||July 2009|August 27, 2009|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00674804||156233|
NCT00674817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB110123|An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.|A Randomized, Double-blind, Crossover Study to Investigate the Bronchodilatation Post-inhalation of GSK961081 Alone and With the Addition of Cumulative Doses of Short Acting Bronchodilators (Salbutamol and Ipratropium Bromide) in Patients With COPD||GlaxoSmithKline|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|45|||Both|40 Years|75 Years|No|||October 2012|October 25, 2012|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00674817||156232|
NCT00675077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-HD-CTP1|Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2008|June 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||January 2009|January 2, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675077||156212|
NCT00675090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3B109689|Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease|A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist||GlaxoSmithKline||Completed|February 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|50 Years|N/A|No|||November 2011|May 31, 2012|April 24, 2008||||No||https://clinicaltrials.gov/show/NCT00675090||156211|
NCT00676143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133K1-3001|Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Trial Of Bapineuzumab In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Carriers||Pfizer|Yes|Terminated|May 2008|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1099|||Both|50 Years|88 Years|No|||December 2012|December 20, 2012|May 2, 2008|Yes|Yes|The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical    benefit. This decision was not based on any new safety concerns.|No||https://clinicaltrials.gov/show/NCT00676143||156131|
NCT00676650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181120|Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy|A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen|SUN 1120|Pfizer|Yes|Terminated|July 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|873|||Male|18 Years|N/A|No|||February 2013|February 5, 2013|May 8, 2008|Yes|Yes|Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or    unexpected safety issues were identified.|No|December 20, 2012|https://clinicaltrials.gov/show/NCT00676650||156092|A complete analysis was not performed due to the sponsors early termination of the clinical trial.
NCT00675792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05774|Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)|A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety-assessor Blinded, Anesthesiologist-TOF-Watch® SX Blinded Trial Comparing T4/T1 Ratio at Time of Tracheal Extubation Using 4 mg/kg Sugammadex Administered at 1-2 PTCs or Better After the Last Dose of Rocuronium Bromide to 50 µg/kg Neostigmine Administered as Per Standard of Care in Adult Subjects Undergoing Elective Open Abdominal Procedures Requiring Neuromuscular Blockade Reversal||Merck Sharp & Dohme Corp.|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||February 2015|February 24, 2015|May 7, 2008|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00675792||156158|
NCT00676091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-012|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Brazil||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|354|||Both|N/A|54 Days|Accepts Healthy Volunteers|||August 2011|August 4, 2011|April 8, 2008|Yes|Yes||No|September 22, 2010|https://clinicaltrials.gov/show/NCT00676091||156135|
NCT00675038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRIRON|Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload|Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* MRI In Patients With Iron Overload||St. Jude Children's Research Hospital|No|Completed|October 2005|June 2008|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|7 Years|N/A|No|Probability Sample|Clinic|September 2011|September 14, 2011|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00675038||156215|
NCT00675285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/1064/2004|Effects of Montelukast in Children With Asthma|Effects of Oral Montelukast on Airway Inflammation in Children With Mild Asthma||Catholic University of the Sacred Heart|Yes|Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|6 Years|14 Years|No|||May 2008|May 8, 2008|May 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00675285||156196|
NCT00675532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yale HIC #0708002942|Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).|Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).||Yale University|Yes|Withdrawn|May 2011|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||July 2013|July 19, 2013|May 7, 2008|Yes|Yes|Resources|No||https://clinicaltrials.gov/show/NCT00675532||156177|
NCT00675753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070609|Three Interacting Single Nucleotide Polymorphisms (SNPs) and the Risk of Preterm Birth in Black Families|Genetic Variations in Three Interacting Single Nucleotide Polymorphisms and the Risk of Preterm Birth in Black Families||University of Miami|Yes|Terminated|September 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|258|Samples With DNA|Blood spot specimens were collected from the mother and her infant.|Both|N/A|28 Days|Accepts Healthy Volunteers|Non-Probability Sample|The study populations were preterm mothers and their infants, born prior to 37 weeks        gestation, and term mothers and their infants.|December 2015|December 16, 2015|May 7, 2008||No|Study site did not have sufficient subjects for the case group|No||https://clinicaltrials.gov/show/NCT00675753||156161|
NCT00676039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-2007024|Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations|Examination of the Pharmacokinetic Properties of Two Generic Antidepressants and Their Respective Brand Preparations in Healthy Male Volunteers||University of Ottawa|No|Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 10, 2009|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00676039||156139|
NCT00676052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC2110664|Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Dose-Ranging Study for GSK233705B Delivered Once Daily in Subjects With COPD||GlaxoSmithKline|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|576|||Both|40 Years|80 Years|No|||October 2012|October 25, 2012|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676052||156138|
NCT00676871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP155|A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)|A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 In Adults With B-Cell Chronic Lymphocytic Leukemia(CLL)Who Have Residual Disease Following Previous Therapy for CLL||MedImmune LLC|No|Withdrawn|June 2008|June 2011|Anticipated|March 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|30|||Both|18 Years|80 Years|No|||September 2008|September 4, 2008|May 8, 2008|Yes|Yes|Replacing this trial with a new trial.|No||https://clinicaltrials.gov/show/NCT00676871||156075|
NCT00676585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000227|Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest|Corticosteroids Therapy in Refractory Shock Following Cardiac Arrest||Beth Israel Deaconess Medical Center|Yes|Completed|October 2007|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2014|September 16, 2014|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676585||156097|
NCT00676858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-000124|Gas Embolism With Use of Argon Plasma Coagulation|Gas Embolism With Use of Argon Plasma Coagulation||Beth Israel Deaconess Medical Center|Yes|Recruiting|July 2008|||June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|patients referred to tertiary care center|April 2010|April 21, 2010|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676858||156076|
NCT00677963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-019|Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation|Contrast-enhanced Ultrasound and Magnetic Resonance Imaging for the Evaluation of Neovascularisation in Carotid Artery Plaques||Maastricht University Medical Center|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00677963||155991|
NCT00678288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12782|A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.|A Phase II, Randomized, Open-label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma||Bayer|No|Terminated|April 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|May 14, 2008||No||No|September 10, 2010|https://clinicaltrials.gov/show/NCT00678288||155967|The study was terminated early by the Sponsor due to low accrual. No efficacy analyses were performed.
NCT00673634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07122|Efficiency of Preoxygenation in Obese Patients: Pressure Assisted Versus Traditional Method|Efficiency of Preoxygenation in Obese Patients: Evaluation of Traditional Method Versus Pressure Assisted Preoxygenation.||Maisonneuve-Rosemont Hospital|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|75 Years|No|||May 2008|June 10, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673634||156323|
NCT00673647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIA5-2507DSM407|CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS|Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II)|CANDIS-II|Technische Universität Dresden|Yes|Active, not recruiting|May 2008|October 2009|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|16 Years|N/A|No|||August 2009|August 25, 2009|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00673647||156322|
NCT00678275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATGFamilyStudy|Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia|Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study||Universitätsklinikum Hamburg-Eppendorf|No|Completed|October 2006|March 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|65 Years|No|||May 2015|May 12, 2015|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00678275||155968|
NCT00678613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBP-Probiotics rct|Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial|||All India Institute of Medical Sciences, New Delhi||Recruiting|July 2007|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|250|||Both|13 Years|65 Years|No|||May 2008|May 14, 2008|May 13, 2008||||No||https://clinicaltrials.gov/show/NCT00678613||155942|
NCT00676390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708046|Estimated Physical Activity of Congestive Heart Failure Patients by a Physical Activity Questionnaire|Estimated Physical Activity of Congestive Heart Failure Patients by a Physical Activity Questionnaire : Concordance Study.|H2OBis|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2008|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|20 Years|80 Years|No|||October 2013|October 25, 2013|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676390||156112|
NCT00676403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081183|Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients|Randomized, Double-Blind, 6-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome||Pfizer|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|137|||Both|18 Years|65 Years|No|||June 2010|June 28, 2010|May 8, 2008|Yes|Yes||No|January 8, 2010|https://clinicaltrials.gov/show/NCT00676403||156111|
NCT00678392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061032|Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer|Axitinib (AG-013736) As Second Line Therapy For Metastatic Renal Cell Cancer: AXIS Trial||Pfizer|Yes|Active, not recruiting|September 2008|February 2016|Anticipated|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|723|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|May 12, 2008|Yes|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00678392||155959|
NCT00678405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0107-11134|Trial of a Breathlessness Intervention Service for Intractable Breathlessness|Phase III Randomized Controlled Trial of a Breathlessness Intervention Service for Intractable Breathlessness.||Cambridge University Hospitals NHS Foundation Trust|Yes|Recruiting|August 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2010|June 24, 2010|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678405||155958|
NCT00675103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0409|Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients|Multicenter, Open-Label, 24 Week Regimen of 8 mg Pegloticase i.v. in Symptomatic Gout Subjects Who Participated in Previous Studies of Pegloticase i.v.||Savient Pharmaceuticals|No|Completed|May 2008|April 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|May 6, 2008|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00675103||156210|
NCT00675116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110371|GW823296 Repeat Dose Study In Healthy Male And Female Subjects|A Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 After Once-Daily Repeated Oral Doses in Healthy Male and Female Subjects||GlaxoSmithKline||Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|April 24, 2008||||No||https://clinicaltrials.gov/show/NCT00675116||156209|
NCT00675350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGX-635-205|Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors|A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors||Teva Pharmaceutical Industries|Yes|Completed|April 2008|January 2009|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|May 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00675350||156191|
NCT00676663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0301|Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer|A Ph 2, Randomized, Double-Blind, Multicenter Study of Exemestane +/- Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer, Progressing on Treatment With a Non-Steroidal AI|ENCORE301|Syndax Pharmaceuticals|Yes|Completed|May 2008|October 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|130|||Female|18 Years|N/A|No|||March 2014|March 19, 2014|May 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676663||156091|
NCT00675545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR01/30/06|A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients|A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients||National University Hospital, Singapore|No|Completed|May 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|30 Years|N/A|No|||March 2012|March 30, 2012|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675545||156176|
NCT00675298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK081647|Linkage Analysis in Interstitial Cystitis|Genetic Studies of Urologic Chronic Pelvic Pain Syndrome|IC|Beth Israel Deaconess Medical Center|No|Completed|January 2006|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||5|Anticipated|300|Samples With DNA|Saliva and urine|Both|3 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Self-referred patients and subjects from a Bulgarian high-prevalence CPPS population|February 2014|February 5, 2014|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675298||156195|
NCT00676065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2006_03|Long-term Active Surveillance Study for Oral Contraceptives (LASS)|Long-term Active Surveillance Study for Oral Contraceptives (LASS)||Center for Epidemiology and Health Research, Germany|Yes|Completed|February 2001|December 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|58303|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women attending offices of oral contraceptives prescribing physicians|November 2014|November 13, 2014|May 8, 2008||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT00676065||156137|In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.
NCT00676078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-050|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2005|||||N/A|N/A|N/A||||||||||||||September 29, 2014|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676078||156136|
NCT00675766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-012-04F|Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences|Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences||VA Office of Research and Development|Yes|Completed|September 2005|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|223|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|To be enrolled in the study, participants must be between the ages of 18-40 years (younger        groups) or 50 years old and older (older groups). The study population will consist of an        ethnically diverse sample of approximately 1/3 Caucasian, 1/3 African American and 1/3        Hispanic. Approximately, 25% of participants will be female. The population will consist        of veterans with additional recruitment from the community in order to meet project goals.|April 2015|April 29, 2015|May 7, 2008||No||No|February 13, 2015|https://clinicaltrials.gov/show/NCT00675766||156160|Large number of subjects who were lost to follow up (i.e moved from community, did not answer follow up calls to schedule visits) resulted in a reduced sample size of subjects who completed the study.
NCT00676598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHCIRB 4305|A Prospective Analysis of the Effect of Therapeutic Hypothermia After Cardiac Arrest|A Prospective Analysis of the Effect of Therapeutic Hypothermia After Cardiac Arrest||Advocate Hospital System|No|Completed|January 2007|December 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|Any adult non-pregnant patient who is unresponsive after resuscitation from cardiac arrest        regardless of presenting rhythm and who survives to hospital admission.|January 2012|January 4, 2012|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00676598||156096|
NCT00677378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/34|Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain|Capsaicin-sensitive Transient Receptor Potential Vanilloid One (TRPV1) and Tyrosine Kinase (TrkA) Receptor Expression in Children With Retrosternal Pain|TRPV1|Medical College of Wisconsin|No|Completed|December 2006|October 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|77|Samples Without DNA|We are collecting a single mucosal biopsy during an endoscopy procedure.|Both|5 Years|17 Years|No|Non-Probability Sample|Children undergoing an endoscopy procedure for gastrointestinal symptoms and chest pain or        reasons other than those listed in the exclusion criteria.|October 2015|October 21, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677378||156036|
NCT00677391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLAY-02-001|Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population|Randomized Trial of Obese Non-Diabetic Malaysians Using Sibutramine: A Randomized Double-Blind Placebo-Controlled Study of Sibutramine in the Management of Obese Subjects in Malaysia||Abbott||Completed|December 2002|||November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|65 Years|No|||May 2008|May 13, 2008|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677391||156035|
NCT00677404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-PVD-001|Autologous Transplantation of Bone Marrow Mononuclear Cell (BM-MNC) With and Without Granulocyte-Colony Stimulation Factor (G-CSF) for Treatment of Chronic Lower Limb Ischemic Patients|Evaluation of Clinical Outcome in Advanced Chronic Lower Limb Ischemia by Stem Cell Transplantation With or Without (Granulocyte-colony Stimulation Factor) G-CSF Injection||Royan Institute|Yes|Completed|January 2008|January 2010|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2010|July 27, 2011|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677404||156034|
NCT00677105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013924|A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.|An Open-Label Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-26481585 in Subjects With Advanced Stage and/or Refractory Solid Malignancies and Lymphomas||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|August 2007|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|92|||Both|18 Years|N/A|No|||September 2012|September 14, 2012|May 8, 2008||||No||https://clinicaltrials.gov/show/NCT00677105||156057|
NCT00677690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2008|Neuromuscular Electrical Stimulation in Chronic Obstructive Pulmonary Disease (COPD)|Combination of Pulmonary Rehabilitation and Neuromuscular Electrical Stimulation and in COPD Patients: a Randomized Clinical Trial of Efficacy||Fondazione Salvatore Maugeri|No|Completed|January 2007|January 2009|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|60 Years|80 Years|No|||November 2011|November 4, 2011|May 8, 2008||No||No|January 5, 2009|https://clinicaltrials.gov/show/NCT00677690||156012|
NCT00677703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1600|Txt Now 2 Decrease Pregnancies L8r: A Study to Evaluate the Effect of Daily Text Message Reminders on Pill Continuation|The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial||Columbia University|No|Completed|January 2008|July 2012|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|968|||Female|N/A|24 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677703||156011|
NCT00677976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/163|Use of Functional Magnetic Resonance Imaging (fMRI) to Study Brain Activation in Children With Irritable Bowel Syndrome|Use of Functional Magnetic Resonance Imaging (fMRI) to Study Brain Activation Following Rectal Stimulation in Children With Irritable Bowel Syndrome|fMRI|Medical College of Wisconsin|No|Active, not recruiting|June 2007|December 2015|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|17|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children will be selected from the Gastroenterology Clinic at Children's Hospital of        Wisconsin.|October 2015|October 21, 2015|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677976||155990|
NCT00678301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110521|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Zilbrix™ Hib and Polio Sabin™||GlaxoSmithKline||Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|365|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||December 2015|December 10, 2015|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678301||155966|
NCT00666302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-02-004|A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis|A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis||Astellas Pharma Inc|No|Completed|October 2002|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|413|||Both|16 Years|N/A|No|||September 2014|September 17, 2014|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00666302||156880|
NCT00678925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1752 (completed)|Supplemental Choline and Brain Development in Humans|Supplemental Choline and Neurodevelopment in Humans||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|December 2004|May 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 16, 2010|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678925||155918|
NCT00676715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT4422g|A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis|Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS||Genentech, Inc.||Active, not recruiting|January 2008|||September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|221|||Both|18 Years|55 Years|No|||February 2016|February 1, 2016|May 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676715||156087|
NCT00674882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTFU|Protocol For Collecting Long-Term Follow-Up Data On Recipients of Bone Marrow and Blood Stem Cell Transplant|Protocol For Collecting Long-Term Follow-Up Data On Recipients of Hematopoietic Stem Cell Transplant||St. Jude Children's Research Hospital|No|Recruiting|January 2002|December 2045|Anticipated|December 2040|Anticipated|N/A|Observational|N/A||1|Anticipated|600|||Both|N/A|N/A|No|Probability Sample|St. Jude patient at least one year post receipt of an autologous or allogeneic transplant        for a malignant or non-malignant condition|September 2015|September 21, 2015|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674882||156227|
NCT00678691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArmoFibro-001|An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue|||State University of New York - Upstate Medical University|No|Completed|August 2007|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|May 13, 2008|Yes|Yes||No|September 6, 2012|https://clinicaltrials.gov/show/NCT00678691||155936|
NCT00678704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100607|BAY38-9456 - Pivotal Trial for Diabetes Patient|A Randomized, Placebo-controlled, Double-blind, Multi-centre, Parallel Group Study to Investigate the Efficacy and Safety of BAY 38-9456 in Males With Diabetes Suffering From Erectile Dysfunction||Bayer|No|Completed|January 2004|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|790|||Male|20 Years|64 Years|No|||December 2014|December 18, 2014|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00678704||155935|
NCT00679003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMC12395|Managing Inflammatory Bowel Disease|Psychosocial Intervention for Children With IBD|Managing IBD|University of Washington|No|Completed|September 2007|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|190|||Both|8 Years|17 Years|No|||April 2015|April 14, 2015|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679003||155913|
NCT00643487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infrapatellar Plica|In Vivo Arthroscopic Behavior of the Infrapatellar Plica of the Knee|In Vivo Arthroscopic Behavior of the Infrapatellar Plica of the Knee||State University of New York - Upstate Medical University|No|Completed|February 2006|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|80 Years|No|Non-Probability Sample|Inclusion:        Healthy subject >18 years of age, skeletally mature Pending knee joint arthroscopy.        Exclusion:        Active infection|November 2014|November 24, 2014|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00643487||158623|
NCT00675558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC0355|Bariatric Surgery for Morbid Obesity|Bariatric Surgery for Morbid Obesity: Clinical and Pathophysiologic Consequences||Columbia University|No|Completed|November 2006|March 2012|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|50|Samples With DNA|Blood samples and biopsies of omental and subcutaneous fat.|Both|18 Years|75 Years|No|Non-Probability Sample|The subject population will be drawn from adults referred for bariatric surgery at New        York Presbyterian Hospital.|July 2013|July 14, 2013|May 7, 2008||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00675558||156175|
NCT00675584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|581|Childhood Asthma Research and Education (CARE) Network Trial - Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)|Childhood Asthma Research and Education (CARE) Network Trial - Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)|MIST|Milton S. Hershey Medical Center|Yes|Completed|August 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|278|||Both|12 Months|53 Months|No|||February 2013|February 24, 2013|May 7, 2008|Yes|Yes||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00675584||156174|May not be applicable to young children whose asthma is more severe than that of the children in the study. Daily or intermittent use of inhaled glucocorticoids may not be efficacious in preschool-age children with transient or infrequent wheezing.
NCT00676104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0584-2005|Discrete Hypothermia in the Management of Traumatic Brain Injury|Discrete Hypothermia in the Management of Traumatic Brain Injury||Emory University|Yes|Completed|July 2006|October 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676104||156134|
NCT00676312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTH134A2101|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects|A Partially-Blinded, Randomized, Placebo and Active Controlled, Ascending Single-Dose Crossover Phase I Study to Explore the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of PTH134 Formulated With Different Concentrations of 5-CNAC in Healthy Postmenopausal Women||Novartis||Completed|May 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|32|||Female|40 Years|70 Years||||December 2008|December 10, 2008|May 8, 2008||||No||https://clinicaltrials.gov/show/NCT00676312||156118|
NCT00675779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204-08|Efficacy Study of Atorvastatin in Pelvic Pain Relief in Women With Endometriosis|Comparison of Pain Relief and Inflammatory Status in Women With Surgically Confirmed Endometriosis Treated With Atorvastatin, Oral Contraceptive or Combined Oral Contraceptives and Atorvastatin: Open Randomized Controlled Trial|EndoStatin|Poznan University of Medical Sciences|No|Active, not recruiting|April 2008|March 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Female|18 Years|45 Years|No|||May 2008|May 9, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00675779||156159|
NCT00676611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCG001|Acetabular Fractures of Both Columns|Both Column Acetabular Fractures With Associated Posterior Deformity Patterns: Implications for Surgical Treatment and Prognosis||Penn State University|No|Enrolling by invitation|May 2008|September 2008|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|The study will include 10 patients who have had column fractures with an associated        posterior wall fracture or significantly displaced posterior column fracture that required        a separate approach for reduction and/or fixation of the hip performed at Hershey Medical        Center by two surgeons, Drs. David Goodspeed and J. Spence Reid over a 12 month period        (June 2006 - May 2007). There is no control population.|May 2008|May 12, 2008|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676611||156095|
NCT00676299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011881|A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.|An Open-label, Phase I Study to Determine the Safety and Pharmacokinetics of JNJ-26483327, a Multi-targeted Kinase Inhibitor, Administered to Subjects With Advanced Stage and/or Refractory Solid Malignancies||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2006|July 2008|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|19|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|May 8, 2008||||No||https://clinicaltrials.gov/show/NCT00676299||156119|
NCT00676884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QGUY/2005/AER 001/-02|A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema|A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema||Aerovance, Inc.|No|Completed|February 2006|August 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||May 2008|May 9, 2008|May 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676884||156074|
NCT00677118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YP2008004|Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Active, not recruiting|June 2006|March 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|506|||Both|18 Years|69 Years|No|||March 2010|July 11, 2013|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677118||156056|
NCT00677131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803049R|Study of the Evaluation of Patient Education Efficacy in Pharmacy of National Taiwan University Hospital|Study of the Evaluation of Patient Education Efficacy: Reconstitution, Storage, and Administration of Oral Antibiotic Suspension From Powder Dosage Form at Pharmacy of National Taiwan University Hospital||National Taiwan University Hospital|Yes|Completed|April 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|December 2, 2009|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00677131||156055|
NCT00677677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7350|Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients|Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients.||University of Alberta|No|Completed|May 2008|December 2012|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|35 Years|No|||December 2014|December 30, 2014|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677677||156013|
NCT00678366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-001|Evaluation of Adding Small Amounts of Oxygen to the CO2 Pneumoperitoneum Upon Pain and Inflammation|Evaluation of Adding Small Amounts of Oxygen to the CO2 Pneumoperitoneum Upon Pain and Inflammation||University Hospital, Gasthuisberg|No|Completed|May 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 25, 2011|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00678366||155961|
NCT00678379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080127|Pediatric Tonsillectomy Pain Reduction Study|Pediatric Tonsillectomy Pain Reduction Study, a Randomized, Placebo Controlled, Double-Blind Clinical Trial Using Clonidine and Local Anesthetics||Vanderbilt University|Yes|Completed|April 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|3 Years|17 Years|No|||December 2009|December 10, 2009|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678379||155960|
NCT00674869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-APR-12|Effectiveness of Pit and Fissure Sealants in the Prevention of Dental Caries|Effectiveness of Pit and Fissure Sealants in the Prevention of Dental Caries||Centre Hospitalier Universitaire de Nice|No|Completed|December 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|6 Years|15 Years|No|||June 2009|February 20, 2012|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00674869||156228|
NCT00666601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-102|Microdialysis and Pharmacokinetic Study of TR-701|An Open Label, Single Dose, Microdialysis and Pharmacokinetic Study of TR-701 in Normal Healthy Adults||Trius Therapeutics LLC|No|Completed|April 2008|March 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666601||156857|
NCT00667732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 75,235|How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics|Metformin, Exenatide, and Glargine Insulin in Combination for Treatment of Patients With Type 2 Diabetes|MEXELIN|Oregon Health and Science University|Yes|Completed|March 2007|April 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|April 24, 2008|Yes|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT00667732||156770|
NCT00675402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-032|Micro- and Macrovascular Adaptations in Patients With Peripheral Arterial Disease During Supervised Exercise Therapy|Micro- and Macrovascular Adaptations in Patients With Peripheral Arterial Disease During Supervised Exercise Therapy: a MRI Study|VAPAV|Maastricht University Medical Center|No|Recruiting|January 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|117|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to the vascular surgeon with complaints of claudication for their first        time, will be asked to participate with the study, with respect toward the in- and        exclusion criteria.|March 2011|March 21, 2011|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00675402||156187|
NCT00678015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075511|Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer|A Phase II Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non-Metastatic Recurrent Prostate Cancer||University of California, San Francisco|Yes|Terminated|May 2008|June 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||March 2014|March 11, 2014|May 12, 2008|Yes|Yes|Per protocol - interim analysis showed no significant PSA declines among the first 12 patients    after 3 cycles of treatment|No|January 28, 2014|https://clinicaltrials.gov/show/NCT00678015||155987|Per protocol - accrual was stopped early after a pre-planned interim analysis showed no significant PSA declines after 3 cycles of treatment among the first 12 patients enrolled.
NCT00678028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0080-07-EMC|Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection|Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection||HaEmek Medical Center, Israel|No|Completed|February 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|whole blood for genetic test and serum for MBL test|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|young women with recurrent UTI - study group and young women witout recurrent UTI - a        control group|April 2009|April 22, 2009|February 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00678028||155986|
NCT00674830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017738|Self-help Treatment for Insomnia in Breast Cancer Patients|Self-help Treatment for Insomnia in Breast Cancer Patients||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|April 2008|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|240|||Female|18 Years|75 Years|No|||August 2013|August 14, 2013|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00674830||156231|
NCT00674843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-MD-CTP1|The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2008|June 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|No|||August 2009|August 14, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674843||156230|
NCT00675129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDIR-04-627|Treatment for Adolescents With Deliberate Self Harm|A Randomized Controlled Trial for Repetitive Deliberate Self-harm and Suicidal Behaviours Among Norwegian Adolescents: a Comparison Between Dialectical Behaviour Therapy Adapted for Adolescents (DBT-A) and Enhanced Usual Care (EUC)||Oslo University Hospital|Yes|Completed|May 2008|December 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|12 Years|18 Years|No|||October 2014|October 22, 2014|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00675129||156208|
NCT00676962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22908|Facilitating Implementation of Cognitive Behavioral Therapy in Primary Care and Community Clinics|Facilitating Implementation of Cognitive Behavioral Therapy in Primary Care and Community Clinics||South Central VA Mental Illness Research, Education & Clinical Center|No|Completed|May 2008|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|23|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 21, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676962||156068|
NCT00676975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM-IBS|The Efficacy of Tradition Chinese Medicine in Patients With Irritable Bowel Syndrome|Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome(TCM- IBS)|TCM-IBS|Chinese University of Hong Kong|No|Active, not recruiting|May 2008|December 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676975||156067|
NCT00676364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-20030313|Randomized Control Trial of a Topical Anesthetic to Evaluate Pain and Anxiety During Venipuncture|A Randomized, Placebo-Controlled Trial to Evaluate Pain and Anxiety During Venipuncture in Pediatric Patients With or Without Pre-treatment by a Topical Anesthetic||Lehigh Valley Hospital|Yes|Completed|March 2003|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|May 9, 2008||No||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00676364||156114|Convenience sample at one hospital site during dayshift hours Monday through Friday. Variable ages may increase the variance among pain measurements. Analyzed IV cannulation and lab draw together. We did not conduct interrater reliability testing.
NCT00675805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIG-001|Preventing Intravenous Immunoglobulin-associated Adverse Reactions|Prospective Assessment of 0.2 um Pore-sized Filters in Preventing Intravenous Immunoglobulin-associated Adverse Reactions||University Hospital, Basel, Switzerland|No|Completed|May 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675805||156157|
NCT00676325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unifespcep 1790/06|Surgical Treatment To Greater Anterior Vaginal Prolapse|A Randomized Controlled Trial Study, To Compare Colporrhaphy Versus NAZCA TC™ ,Macroporous Polypropylene Mesh, In Surgical Treatment To Greater Anterior Vaginal Prolapse .|Nazcatc™|Federal University of São Paulo|Yes|Enrolling by invitation|January 2007|December 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|50 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 12, 2008|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00676325||156117|
NCT00676351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-PHRC-05|Follow up of Ventilatory Function in Infant After Bronchiolitis During the First Year of Life|Follow up of Ventilatory Function in Infant After One (or More) Bronchiolitis During the First Year of Life. Course Towards Asthma||Centre Hospitalier Universitaire de Nice|No|Completed|January 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|29|||Both|3 Months|32 Months|No|||May 2008|May 12, 2008|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00676351||156115|
NCT00676897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000257|Statin Therapy in the Treatment of Sepsis|Study of Statin Therapy in the Treatment of Sepsis||Beth Israel Deaconess Medical Center|Yes|Completed|February 2008|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676897||156073|
NCT00676624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2007-097|Infectious Causes of Uveitis|Infectious Causes of Uveitis, With Special Focus on Infection With Leptospira||Statens Serum Institut|Yes|Completed|April 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Corpus vitreum (vitreus body) Aqua from the anterior champer Whole blood in dry container      Whole blood in container containing EDTA Whole blood in QuantiFERON test KIT for      tuberculosis Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patient at a referal hospital eye clinic with uveitis were vitrectomy will be performed        for diagnostic reasons|May 2014|May 14, 2014|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676624||156094|
NCT00676910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012745|A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.|A Phase I Study to Determine the Safety, Pharmacology, and Pharmacodynamics of JNJ26854165 in Subjects With Advanced Stage and/or Refractory Solid Tumors||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2006|February 2010|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|71|||Both|18 Years|N/A|No|||March 2010|March 24, 2010|May 8, 2008||||No||https://clinicaltrials.gov/show/NCT00676910||156072|
NCT00676676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p000348|Effects of Testosterone in Women With Depression|Effects of Testosterone in Women With Depression: A Pilot Study||Massachusetts General Hospital|Yes|Completed|March 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|75 Years|No|||November 2012|November 1, 2012|May 8, 2008|No|Yes||No|May 10, 2012|https://clinicaltrials.gov/show/NCT00676676||156090|
NCT00676689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-09|COMPASSION: COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV|Implantation of the SAPIEN Transcatheter Heart Valve (THV) in the Pulmonic Position||Edwards Lifesciences|Yes|Active, not recruiting|April 2008|November 2019|Anticipated|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|N/A|No|||February 2016|February 1, 2016|May 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676689||156089|
NCT00676702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014716|A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)|A Single-Dose, Open-Label, Randomized, Crossover Study to Evaluate Intraduodenal Enzyme Delivery of PANCREASE MT in Subjects With Severe Exocrine Pancreatic Insufficiency||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment|2||Actual|13|||Both|18 Years|85 Years|No|||February 2010|May 18, 2011|May 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676702||156088|
NCT00677417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Diagnostic Value of Hyperbilirubinaemia as a Predictive Factor for Appendiceal Perforation in Acute Appendicitis|A Retrospective Study Investigating the Diagnostic Value of Hyperbilirubinaemia as a Predictive Factor for Appendiceal Perforation in Acute Appendicitis||Ruhr University of Bochum|No|Completed|May 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|538|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are appendectomied and who received preoperative Liver function test        (bilirubin, liver transaminases GOT and GPT)|October 2012|October 15, 2012|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677417||156033|
NCT00678990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL-01|Heparinized Islets in Clinical Islet Transplantation|Open Study to Evaluate Safety and Efficacy of Allogenic Islet Transplantation Using Islets Coated With Immobilised Heparin||Corline Biomedical AB|Yes|Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678990||155914|
NCT00666315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME-07-001|Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease|Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease -A Prospective, Comparative, Multicenter, Observational Study||Ethicon Endo-Surgery (Europe) GmbH|No|Completed|December 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|18 Years|80 Years|No|Non-Probability Sample|Consecutive euthyroid patients with multinodular goiter for whom a total Thyroidectomy        under general anesthesia is indicated.|May 2008|May 21, 2008|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666315||156879|
NCT00668005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100539|Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension|A Randomized, Double-blind, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administration for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Men With Arterial Hypertension and Erectile Dysfunction||Bayer|No|Completed|February 2003|September 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|388|||Male|18 Years|N/A|No|||December 2014|December 15, 2014|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668005||156749|
NCT00668018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10678|Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours|An Open-label, Multicenter Study to Assess Safety, Tolerability, Efficacy and Impact on Quality of Life of Vardenafil 10mg in Patients With Erectile Dysfunction Within a Time Window of up to 6 Hours After Intake of Study Drug||Bayer|No|Completed|January 2003|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|887|||Male|18 Years|N/A|No|||December 2014|December 18, 2014|April 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668018||156748|
NCT00676169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC002|The EPIC Observational Study|Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF|EPIC OBS|CF Therapeutics Development Network Coordinating Center|No|Active, not recruiting|October 2004|March 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1700|Samples With DNA|For study purposes, OP swabs or expectorated sputum for bacterial culture will be obtained      annually beginning in the calendar year of first isolation of Pa from a respiratory culture      at the local site laboratory. A serum sample for serology assessment and banking will be      obtained annually in conjunction with a scheduled clinical blood draw whenever possible.      Under a separate consent, additional blood (6 ml) will be collected for DNA use and banking      for studies of genetic factors that may be associated with CF pathogenesis, disease      progression, and clinical outcomes. These studies will test for association between gene      variants and various CF-related phenotypes using either a targeted (i.e., candidate gene)      approach or by performing a whole-genome scan.|Both|N/A|12 Years|No|Non-Probability Sample|Children with Cystic Fibrosis who are Pa negative or concurrently enrolled in the EPIC        Clinical Trial|February 2015|February 23, 2015|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676169||156129|
NCT00678938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2_P5, 01EB0420|Smoking Interventions in the General Population|General Population Based Interventions for Smokers Not Ready to Quit: Testing Smoking Reduction vs. Abstinence Oriented Computer Expert Systems||University Medicine Greifswald|Yes|Active, not recruiting|October 2004|October 2008|Anticipated|October 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1462|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 14, 2008|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678938||155917|
NCT00675597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-178|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer|A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|May 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|May 7, 2008|No|Yes||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00675597||156173|
NCT00675818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07097|The Optimal Mode of Renal Replacement Therapy in Acute Kidney Injury (OMAKI) Study|The Optimal Mode of Renal Replacement Therapy in Acute Kidney Injury (OMAKI) Study: A Pilot Randomized Controlled Trial of Convective Versus Diffusive Clearance|OMAKI|St. Michael's Hospital, Toronto|Yes|Completed|May 2008|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|16 Years|N/A|No|||March 2012|March 9, 2012|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675818||156156|
NCT00676923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK6657_3b|Improving Diabetes After Bariatric Surgery|LABS-3 Diabetes: Mechanisms for Improvement of Type 2 Diabetes Following Bariatric Surgery|LABS-3|University of Pittsburgh|Yes|Completed|March 2008|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|Samples Without DNA|serum, plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will be selected from the LABS-2 cohort at participating LABS clinical        centers.|November 2012|November 12, 2012|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676923||156071|
NCT00677144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-0712|Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer|A Randomized Phase II Study of Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Advanced or Recurrent Colorectal Cancer||Hallym University Medical Center|No|Completed|April 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|75 Years|No|||October 2012|October 4, 2012|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00677144||156054|
NCT00676117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00007|Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males|A Single-Centre, Open, Randomised, Three-Way Cross-Over Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Healthy Male Subjects||AstraZeneca|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 11, 2009|May 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676117||156133|
NCT00676130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P000414|Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients|Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Placebo Added to Standard Treatment of Uncomplicated Cellulitis in Emergency Department Patients||Brigham and Women's Hospital|No|Completed|May 2007|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|153|||Both|12 Months|N/A|No|||August 2012|August 12, 2012|December 28, 2007||No||No|July 3, 2012|https://clinicaltrials.gov/show/NCT00676130||156132|
NCT00676338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWCH (DURATION - 4)|Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)|Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes||AstraZeneca|No|Completed|November 2008|January 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|820|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|May 9, 2008|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00676338||156116|
NCT00676637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD-07-01|Glaucoma Adherence Study|A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening|GAS|Alcon Research|No|Completed|May 2008|February 2010|Actual|February 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Patients were selected from five study sites in the European Union.|May 2012|May 29, 2012|May 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676637||156093|
NCT00675142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-08EMC.CTIL|Optimal Timing of Intrauterine Insemination (IUI) When Utilizing Superovulation Combined With GnRH Antagonists|A Randomized Open Three Arm Prospective Trial To Determine The Optimal Timing for Intrauterine Insemination After Superovulation With Recombinant Gonadotropins Utilizing GnRH Antagonists||HaEmek Medical Center, Israel||Completed|May 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|107|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 21, 2015|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675142||156207|
NCT00675831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-193|Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies|Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies After Matched Allogeneic Hematopoietic Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Completed|December 2007|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675831||156155|
NCT00677157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080132|Evaluation and Diagnosis of People With Pain and Fatigue Syndromes|Evaluation and Diagnosis of Potential Research Subjects With Pain and Fatigue Syndromes||National Institutes of Health Clinical Center (CC)||Recruiting|May 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677157||156053|
NCT00677443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-03-012|Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer|A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer||Samsung Medical Center|No|Completed|June 2008|January 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|344|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677443||156031|
NCT00675623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONNECTION|A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease|A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)|CONNECTION|Medivation, Inc.|Yes|Completed|May 2008|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|598|||Both|50 Years|N/A|No|||August 2012|August 27, 2012|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675623||156171|
NCT00666627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH 14463|Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects|A 2-year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care.||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Active, not recruiting|April 2007|December 2014|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|410|||Female|35 Years|85 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666627||156855|
NCT00668031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11694|Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement Surgery||Bayer|No|Completed|February 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|359|||Both|18 Years|N/A|No|||December 2014|December 26, 2014|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668031||156747|
NCT00677183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/36|Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children|Development of a Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children|NASH|Medical College of Wisconsin|No|Withdrawn|May 2008|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Actual|0|Samples With DNA|10mL of blood will be retained from each participant and their parents. 5mL of this blood      will undergo DNA extraction and genotyping for several known NASH related genes. The other      5mL of blood will be saved as serum for future analysis.|Both|2 Years|18 Years|No|Non-Probability Sample|The child subjects will be recruited from the Hepatology Clinic at Children's Hospital of        Wisconsin.|August 2015|August 21, 2015|May 9, 2008||No|PI did not receive funding for this PI-initiated study. PI subsequently left the institution.|No||https://clinicaltrials.gov/show/NCT00677183||156051|
NCT00677456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDH00431|Evaluation of Four Reconstructions After Total Gastrectomy|Postoperative Life Quality Evaluation of Four Reconstructions After Total Gastrectomy||Tang-Du Hospital|Yes|Recruiting|January 2008|January 2013|Anticipated|February 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|80|||Both|30 Years|80 Years|No|||January 2008|May 12, 2008|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677456||156030|
NCT00675870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195183-202|Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia|Phase II Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia||NuRx Pharmaceuticals, Inc.|No|Recruiting|April 2008|||April 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||May 2008|May 9, 2008|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675870||156152|
NCT00676182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 08-267|Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury|Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury||VA Office of Research and Development|No|Completed|July 2008|August 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|55 Years|No|Non-Probability Sample|Convenience sample of OIF/OEF Veterans discharged from the James A. Haley Veterans'        Hospital in Tampa, FL with a diagnosis of mild/moderate TBI with or without comorbid PTSD.|March 2016|March 24, 2016|May 7, 2008||No||No|March 24, 2016|https://clinicaltrials.gov/show/NCT00676182||156128|
NCT00643201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-056|Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism|A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism||Bristol-Myers Squibb|Yes|Completed|July 2008|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5614|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|March 20, 2008|Yes|Yes||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00643201||158645|
NCT00643214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806 805 09 003|Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis|A Study to Determine if Tetrix Cream Impedes the Resolution of Experimentally Induced Allergic Contact Dermatitis||Coria Laboratories, Ltd.|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 19, 2008|March 20, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00643214||158644|
NCT00676728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013960|A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome|A Phase 1 Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Subjects With Advanced or Refractory Leukemia or Myelodysplastic Syndrome||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|December 2008|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|May 8, 2008|No|Yes|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT00676728||156086|
NCT00676741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3516|Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin|Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart) or Levemir® (Insulin Detemir) - for Treatment of Diabetes Mellitus|COMMIT|Novo Nordisk A/S|No|Completed|February 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3809|||Both|18 Years|75 Years|No|Non-Probability Sample|Diabetes type 2|June 2012|June 5, 2012|May 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676741||156085|
NCT00677430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0899|Quantitative Analysis of Outcomes in Breast Reconstruction|Multimodality Anthropometric Analysis for Quantitative Assessment of Outcomes in Breast Reconstructive Surgery||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2008|||May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Female|21 Years|N/A|No|Non-Probability Sample|Study participants with breast cancer that have had or are about to have breast        reconstructive surgery.|February 2016|February 15, 2016|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00677430||156032|
NCT00677716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0503|Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse|Open-label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse||Peregrine Pharmaceuticals|No|Completed|July 2007|November 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|75 Years|No|||April 2014|April 23, 2014|May 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00677716||156010|
NCT00677989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH No. 96044|Study on Laparoscopic Operation for Perforated Appendicitis|The Role of Oxidized Proteins and Free Radicals on Laparoscopic Operation for Perforated Appendicitis||Far Eastern Memorial Hospital|No|Recruiting|May 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|serum|Both|12 Years|80 Years|No|Probability Sample|Patients with perforated appendicitis treated at the Far-Eastern Memorial Hospital,        Taipei,Taiwan|January 2009|February 6, 2009|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00677989||155989|
NCT00678639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004120|Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain|Randomized Cost Comparison of Cardiac MRI Use in ED Patients With Chest Pain||Wake Forest Baptist Health|No|Completed|January 2008|||March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|110|||Both|18 Years|N/A|No|||April 2010|April 28, 2010|May 8, 2008||No||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00678639||155940|
NCT00675610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECHO-01|Enhancing Communication and HIV Outcomes|Enhancing Communication and HIV Outcomes|ECHO|Johns Hopkins University|No|Completed|May 2008|May 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|186|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675610||156172|
NCT00676377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8771148z|A New Approach of Neostigmine in Unavoidable Post Operative Ileus|A New Approach of Neostigmine in Unavoidable Post Operative Ileus After Surgery||Baqiyatallah Medical Sciences University|Yes|Completed|August 2007|February 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|3|||Both|18 Years|76 Years|No|||May 2008|May 12, 2008|May 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676377||156113|
NCT00677729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSERFLA|Hypertonic Saline to Reduce Hospital Admissions in Bronchiolitis|Inhaled Hypertonic Saline to Reduce Hospital Admissions in Infants With Viral Bronchiolitis (HS in ER Study)||Queen's University|Yes|Completed|November 2008|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|N/A|24 Months|No|||November 2015|November 12, 2015|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00677729||156009|
NCT00678002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/157|Quality of Life in Pediatric Transplant Patients|Quality of Life and Vulnerability in Pediatric Solid Organ Transplant Recipients||Medical College of Wisconsin|No|Enrolling by invitation|October 2008|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|21 Years|No|Non-Probability Sample|Children's Hospital of Wisconsin in the Hepatology Clinic, Cardiology Clinic, and Kidney        Clinic.|April 2015|April 9, 2015|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00678002||155988|
NCT00641459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014665|A Study on Behavioral and Psychological Symptoms of Dementia|Behavioral and Psychological Symptoms of Dementia (BPSD) in Taiwan - An Observational Study||Johnson & Johnson Taiwan Ltd||Completed|September 2007|September 2008|Actual|September 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|359|||Both|N/A|N/A|No|Probability Sample|Males or females with diagnosis of dementia according to DSM-IV criteria|May 2014|May 22, 2014|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641459||158777|
NCT00667524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK031_08|Eosinophilic Esophagitis: Influence of Dilation on Dysphagia and Inflammation|Eosinophilic Esophagitis: Influence of Esophageal Dilation on the Underlying Inflammation and Efficacy/Safety of the Procedure||University of Bern|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|207|Samples Without DNA|formalin-fixed esophageal biopsies (blinded review of histology slides)|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Eosinophilic Esophagitis referred to gastroenterologists in whole        Switzerland working in private practice and in secondary and tertiary referral centers        (Departments of Gastroenterology in hospitals)|December 2009|December 24, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667524||156786|
NCT00668057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10690|BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.|Randomized, Double-blind, Multi-centre, Parallel-goup Study to Investigate the Efficacy and Safety of Three Doses of BAY38-9456 (5 mg, 10 mg and 20 mg) Versus Placebo in the Treatment of Patients With Erectile Dysfunction||Bayer|No|Completed|December 2002|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|624|||Male|22 Years|N/A|No|||March 2015|March 5, 2015|April 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668057||156745|
NCT00668070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9831-CL-0301|A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831|Protocol for a Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week Treatment, Adaptive Proof-of-principle Study of Twice Daily Oral Dosing of a Novel PDE4 Inhibitor (ASP9831) in Subjects With Non-alcoholic Steatohepatitis (NASH)|ASTER|Astellas Pharma Inc|Yes|Completed|April 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|N/A|No|||November 2010|March 19, 2013|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668070||156744|
NCT00677469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2590|Low Doses of Cholestyramine in the Treatment of Hyperthyroidism|Low Doses of Cholestyramine in the Treatment of Hyperthyroidism||Shiraz University of Medical Sciences|No|Completed|July 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|20 Years|60 Years|No|||May 2008|May 13, 2008|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677469||156029|
NCT00677742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1723|The Impact of Pack Supply on Birth Control Pill Continuation|Impact of Pack Supply on Oral Contraception Continuation|SixPack|Columbia University|No|Completed|June 2007|November 2012|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|700|||Female|N/A|35 Years|No|||December 2012|December 11, 2012|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677742||156008|
NCT00676195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05062008-1139|An Open-Label Study of N-Acetyl Cysteine in Children With Autism|An Open-Label Study of N-Acetyl Cysteine in Autism||Stanford University|Yes|Completed|June 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|3 Years|12 Years|No|||December 2015|December 2, 2015|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676195||156127|
NCT00676429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA1280023|Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders|Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial||University Hospital Freiburg|No|Completed|July 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|7 Years|17 Years|No|||November 2008|November 17, 2008|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676429||156109|
NCT00676442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-103|Study Evaluating the Effect of Food on the Bioavailability of PN400 Components|An Open-Label, Randomized, Four-Way Crossover Study to Evaluate the Effect of Food on the Bioavailability of Naproxen and Esomeprazole From a PN 400 Tablet in Healthy Subjects||POZEN|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 4, 2008|May 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00676442||156108|
NCT00676416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCHCH-0288-323|Influence of Propofol on Alveolar Macrophage in Asthmatic Patients|Influence of Propofol on Alveolar Macrophage Immunity in Asthmatic Patients Undergoing General Anesthesia|PAMAP|Nanjing Medical University|Yes|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Female|18 Years|45 Years|No|Probability Sample|Patients with or without asthma undergoing general anesthesia|March 2009|March 30, 2009|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676416||156110|
NCT00677248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-007831-24|LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe|A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia||Karo Bio AB|Yes|Completed|April 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|75 Years|No|||May 2008|November 27, 2008|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677248||156046|
NCT00677781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK251_07|Impact of Microparticles on Postoperative Complications in Surgical Patients|The Impact of Microparticles on Inflammatory Responses During Visceral and Cardiac Surgery||University of Bern|No|Completed|February 2008|January 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac or hepatobiliary or colorectal surgery. Setting: university        hospital.|September 2011|September 5, 2011|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00677781||156005|
NCT00643825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 06-004|Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients|Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or "Stop and Go" in Glioblastoma Patients: The PATSGO Study|PATSGO|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|January 2008|January 2012|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||July 2010|July 22, 2010|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643825||158597|
NCT00678340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCH 07/0094|Randomized Trial of Two Ablation Catheters in Paroxysmal Atrial Fibrillation|A Single Centre, Randomized, Single Blinded Trial of Wide Area Circumferential Ablation With Pulmonary Vein Isolation Compared to a Multipolar, Circular Ablation Catheter in Patients With Paroxysmal Atrial Fibrillation||University College London Hospitals|Yes|Completed|September 2007|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678340||155963|
NCT00678353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-UPLF-01|Study of OP-1 Putty in Uninstrumented Posterolateral Fusions|Prospective Data Collection From the Stryker Biotech Pivotal IDE Study of OP-1 Putty in Uninstrumented Posterolateral Fusions||Olympus Biotech Corporation|No|Completed|May 2007|August 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|202|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients treated in clinical protocol S01-01US|June 2011|June 9, 2011|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678353||155962|
NCT00678964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-005827-32|Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Multicentre Randomised Phase II Trial of Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients (=/> 70 Years) With Advanced Non-Small Cell Lung Cancer|TIE|LungenClinic Grosshansdorf|Yes|Recruiting|June 2006|||November 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|70 Years|N/A|No|||May 2008|May 15, 2008|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678964||155916|
NCT00678977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG109599|A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors|A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors.||GlaxoSmithKline|No|Completed|April 2008|March 2011|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00678977||155915|
NCT00674856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT 3012-X-106|A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function|A Phase 1 Repeated Dose Open Label Study to Investigate the Pharmacokinetics and Safety of Naproxcinod 750mg Bid Administered to Patients With Impaired Renal Function Compared to Matching Healthy Subjects|HCT3012-X-106|NicOx|Yes|Completed|May 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674856||156229|
NCT00675376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|564|Evaluating Quality of Life for Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation|Lung Transplant for COPD: Outcomes/Technology||Washington University School of Medicine|No|Enrolling by invitation|January 2006|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|21 Years|67 Years|No|Non-Probability Sample|All study participants will undergo evaluation in the lung transplant clinic at Washington        University Medical Center and Barnes-Jewish Hospital. They must have the diagnosis of COPD        predominantly due to emphysema.|August 2013|August 19, 2013|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00675376||156189|
NCT00676156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00001305|A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis|A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis||Oregon Health and Science University|No|Completed|December 2005|November 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|80 Years|No|||November 2012|November 2, 2012|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676156||156130|
NCT00676936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI 07-005|Corticosteroids for Cancer Pain|Corticosteroids for Cancer Pain||Norwegian University of Science and Technology|No|Completed|April 2008|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676936||156070|
NCT00640900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20073396|Food, Activity and Behavior Trial|A Multi-Site Randomized Trial of a Commercial Weight Loss Program|FAB|Jenny Craig, Inc.|Yes|Active, not recruiting|July 2007|July 2010|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|440|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 31, 2008|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00640900||158820|
NCT00678652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1395|Group B Meningococcal Vaccine|A Phase 1 Dose-Escalation Study of the Safety and Immunogenicity of Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 10, 25, 50, or 75 μg With Adjuvant|HOPS|Walter Reed Army Institute of Research (WRAIR)|No|Completed|April 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2010|May 8, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00678652||155939|
NCT00678665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR469908CTIL|Changes in Heart Rate in Response to Heat Pressure and Neural Stimulation|Initial Study for the Definition in Heart Rate Changes in Response to Heat Pressure and Neural Stimulation||Soroka University Medical Center|Yes|Not yet recruiting|May 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|May 2008|May 14, 2008|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00678665||155938|
NCT00678678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/07|Chest Physiotherapy After Bariatric Aurgery - A Comparison Between Incentive Spirometry and Expiratory Positive Airway Pressure (Epap)|Chest Physiotherapy After Bariatric Surgery - a Comparison Between Incentive Spirometry and Epap||Universidade Metodista de Piracicaba||Completed||||||N/A|Interventional|N/A|2||||||Female|18 Years|65 Years|No|||April 2008|May 13, 2008|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00678678||155937|
NCT00675181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-KRK-2008-002|Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow|Effects of Melatonin on Oxygen Consumption and Choroidal Blood Flow in Women With Vasospastic Syndrome in Comparison to Controls|MelO2|University Hospital, Basel, Switzerland|No|Completed|May 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Female|20 Years|30 Years|Accepts Healthy Volunteers|||September 2012|September 10, 2012|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00675181||156204|
NCT00667745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH080001-01|Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder|Lithium Use for Bipolar Disorder (LiTMUS): A Randomized Controlled Effectiveness Trial|LiTMUS|National Institute of Mental Health (NIMH)|Yes|Completed|April 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|80 Years|No|||July 2010|April 30, 2013|April 24, 2008||No||No|October 25, 2012|https://clinicaltrials.gov/show/NCT00667745||156769|
NCT00668083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OIT-CAS-2007/1|Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer|Observational Retrospective Trial on Sequential Hormonal Therapy in Patients|Sorse|AstraZeneca|No|Completed|September 2007|July 2008|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|214|||Male|N/A|N/A|No|Non-Probability Sample|THIS IS A RETROSPECTIVE TRIAL THEREFORE CLINICAL DATA ARE FROM ARCHIVED CLINICAL RECORD OF        PATIENTS WHO WERE ADMITTED IN THE HOSPITAL.|December 2010|December 9, 2010|April 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668083||156743|
NCT00668434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR053960|Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica|A Corticosteroid Taper for Acute Sciatica Treatment (The ACT FAST Study)|ACT FAST|Kaiser Permanente|Yes|Completed|November 2008|September 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|70 Years|No|||April 2015|April 9, 2015|April 25, 2008|Yes|Yes||No|October 20, 2014|https://clinicaltrials.gov/show/NCT00668434||156716|
NCT00642018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10461|A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer|A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer||Eli Lilly and Company|No|Completed|March 2008|April 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Male|18 Years|75 Years|No|||May 2012|May 24, 2012|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642018||158736|
NCT00642031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0249|Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies|A Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies||M.D. Anderson Cancer Center|No|Completed|August 2006|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||February 2013|February 12, 2013|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00642031||158735|
NCT00676208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-141|Improving Medical Training for the Care of Chronic Conditions|Improving Medical Training for the Care of Chronic Conditions||VA Office of Research and Development|No|Completed|April 2008|February 2012|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|33|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2014|April 6, 2015|May 7, 2008||No||No|September 29, 2014|https://clinicaltrials.gov/show/NCT00676208||156126|The small sample sizes and the reliance on one site for the data. This was a pilot study, both limitations were recognized from the outset and indeed seen as an advantage given the focus on trying to identify measures to include in a larger study.
NCT00676455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-017|Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions|Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions||Lahey Clinic|No|Terminated|February 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects to be recruited from the practice of the Oncology Department. All subjects with        hepatic or pulmonary metastatic lesions will be offered the opportunity to participate|May 2013|May 9, 2013|May 8, 2008|No|Yes|Low participant enrollment, Insufficient findings for data analysis|No|August 26, 2009|https://clinicaltrials.gov/show/NCT00676455||156107|
NCT00677001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010630|A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.|A Phase I Study to Evaluate the Safety and Pharmacokinetics of R306465 in Subjects With Advanced Solid Malignancies||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2005|October 2006|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|April 24, 2008||||No||https://clinicaltrials.gov/show/NCT00677001||156065|
NCT00677820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA182|A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Trivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|MI-MA182|MedImmune LLC|No|Completed|June 2008|December 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2010|October 12, 2010|May 13, 2008|Yes|Yes||No|August 20, 2010|https://clinicaltrials.gov/show/NCT00677820||156002|
NCT00666471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCENT0002|Minimally Invasive Control of Epistaxis (MICE)|Minimally Invasive Control of Epistaxis: Efficacy and Economic Analysis|MICE|University of Calgary|No|Terminated|June 2008|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||June 2009|June 10, 2009|April 23, 2008||No|one PI (BM) no longer felt he had clinical equipoise regarding the intervention. No adverse    events.|No||https://clinicaltrials.gov/show/NCT00666471||156867|
NCT00666783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006L01595|An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients|A Phase II, Multicenter,Double-Blind, Randomized Trial of Palonosetron Compared With Granisetron in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in the Chinese Cancer Patients||Xijing Hospital||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|208|||Both|18 Years|70 Years|No|||August 2006|April 24, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666783||156843|
NCT00667082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI-0052-103|Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma|NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma||Triphase Research and Development I Corporation|No|Completed|March 2008|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667082||156820|
NCT00667355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-239|A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis|A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis||Abbott|No|Completed|February 2008|January 2011|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|15 Years|N/A|No|||January 2012|January 24, 2012|April 24, 2008||No||No|May 28, 2010|https://clinicaltrials.gov/show/NCT00667355||156799|
NCT00667875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTON-1R21AA017525-01|An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence|An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence|NALAPZ|Medical University of South Carolina|Yes|Completed|April 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||December 2009|August 4, 2011|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667875||156759|
NCT00667888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-381|A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation|A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2001|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Male|N/A|N/A|No|||December 2015|December 31, 2015|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667888||156758|
NCT00667901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592958|Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery|A Phase 0 Trial of Riluzole in Patients With Resectable Stage III and IV Melanoma||Rutgers, The State University of New Jersey|Yes|Terminated|February 2007|November 2008|Actual|October 2008|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||December 2009|December 10, 2009|April 25, 2008|Yes|Yes|All enrollment, treatment, follow-up & data analysis completed|No||https://clinicaltrials.gov/show/NCT00667901||156757|
NCT00668525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT-MD-49|Escitalopram in Adult Patients With Major Depressive Disorder|A Double-blind, Fixed-dose Study of Escitalopram in Adult Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|April 2008|||February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|877|||Both|18 Years|65 Years|No|||May 2010|May 7, 2010|April 28, 2008|No|Yes||No|March 22, 2010|https://clinicaltrials.gov/show/NCT00668525||156709|
NCT00668226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03745|Dermacyd Delicata Pocket BR - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Delicata Pocket BR.||Sanofi|No|Completed|December 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668226||156732|
NCT00671047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL105|The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study|The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study|SAGE|XDx|No|Active, not recruiting|December 2007|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Whole blood, plasma, serum|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|December 2008|December 29, 2008|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671047||156517|
NCT00671970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000220|Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)|Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma||Duke University|No|Completed|February 2007|April 2010|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|January 29, 2008|Yes|Yes||No|December 28, 2012|https://clinicaltrials.gov/show/NCT00671970||156449|
NCT00668408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM6YHYW4|LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure|Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF)||Azienda Ospedaliero-Universitaria Careggi|Yes|Recruiting|May 2008|October 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|40 Years|80 Years|No|||August 2009|August 27, 2009|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00668408||156718|
NCT00668421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0548-00104|CEP-701 (Lestaurtinib) in Myelofibrosis|A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|April 2008|January 2015|Anticipated|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|April 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00668421||156717|
NCT00668720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS_tinnitus_Utrecht|Repetitive Transcranial Magnetic Stimulation (rTMS) for Tinnitus|Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment in Patients With Chronic Tinnitus||UMC Utrecht|No|Completed|April 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||June 2011|June 29, 2011|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668720||156694|
NCT00668967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6661003|Bioequivalence Study Of Verapamil|Bioequivalence Study Of Verapamil (Covera HS) 240 Mg Extended Release Tablets Produced By Alza Corporation, Vacaville And Pfizer Inc, Puerto Rico: A Two Sequence, Four-Way Crossover Design, Single Dose, Open-Label, Randomized Study In Healthy Volunteers||Pfizer|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 7, 2009|April 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00668967||156675|
NCT00668980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/50842-4|Symbolic Representation in Young Children With Down Syndrome|The Constitution of Symbolic Representation in Young Children With Down Syndrome||University of Sao Paulo|Yes|Completed|July 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study Group - children with Down syndrome that attend speech-language therapy at the        Speech Language Pathology Laboratory in Syndromes and Sensorimotor Deficits of the School        of Medicine of the University of São Paulo or from the Association of Parents and Friends        of Exceptional children of São José dos Campos.        Control Group        - typically developing children followed up in the Pediatrics Ambulatory of the        University's Hospital and/or being assisted in the University' Hospital Nursery School.|January 2010|January 13, 2010|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668980||156674|
NCT00669266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wue-Adrenal-Tumors-92/2002|Adrenal Tumors - Pathogenesis and Therapy|Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen||University of Wuerzburg|No|Recruiting|September 2002|December 2024|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|500|Samples With DNA|Germline DNA Tumor samples Serum Plasma Urine|Both|N/A|N/A|No|Non-Probability Sample|Patients with adrenal tumors|September 2015|September 6, 2015|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669266||156652|
NCT00669500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU eIRB3694|Body Worlds 3 Nutrition Display|Body Worlds 3 - Nutrition and College of Pharmacy Weeks Exhibit and Lifestyle Intervention||Oregon Health and Science University|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3188|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 27, 2011|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669500||156634|
NCT00669513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSP-CV|Cardiovascular Effects of Partial Sleep Deprivation|Cardiovascular Effects of Partial Sleep Deprivation in Healthy Volunteers||University of Sao Paulo|No|Completed|January 2006|April 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||April 2008|April 29, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669513||156633|
NCT00665535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R011NR009680-01A1|Pressure Ulcer Prevention: Turning for Ulcer Reduction|Preventing Pressure Ulcers: A Multi-site RCT in Nursing Facilities|TURN|The University of Texas Health Science Center, Houston|Yes|Completed|March 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|967|||Both|65 Years|N/A|No|||March 2012|March 20, 2012|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665535||156939|
NCT00665847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002746|TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents|A Phase II, Open-label Trial, to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents||Tibotec Pharmaceuticals, Ireland|Yes|Completed|November 2008|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|6 Years|17 Years|No|||April 2015|April 2, 2015|April 22, 2008|No|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00665847||156915|
NCT00666211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0424|Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain|Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain.||Vanderbilt-Ingram Cancer Center|No|Completed|May 2005|May 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|98|||Both|21 Years|N/A|No|||August 2012|August 4, 2012|April 23, 2008||No||No|October 21, 2011|https://clinicaltrials.gov/show/NCT00666211||156887|
NCT00666484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593560|Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma|Phase II Study Evaluating the Toxicity and Efficacy of a Modified German Paediatric Hodgkin's Lymphoma Protocol (HD95) in Young Adults (Aged 18-30 Years) With Hodgkin's Lymphoma||University College, London|Yes|Completed|March 2008|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|30 Years|No|||December 2014|December 3, 2014|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00666484||156866|
NCT00666497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103 PH GL 2007 CL003|Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML or Intermediate-2 or High-Risk MDS||Mirati Therapeutics Inc.|Yes|Terminated|June 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|60 Years|N/A|No|||April 2015|April 22, 2015|April 23, 2008|Yes|Yes|Celgene terminated its collaboration agreement with MethylGene for the development of    MGCD0103. All Celgene-sponsored trials with MGCD0103 with be closed.|No||https://clinicaltrials.gov/show/NCT00666497||156865|
NCT00667095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007399|Over Active Bladder Instillation Study - Botox|Evaluation of the Efficacy of Botulinum-A Toxin/DMSO Instillation in the Treatment of Women With Over Active Bladder (OAB) Syndrome and/or Urinary Urge Incontinence||Mayo Clinic|Yes|Terminated|April 2008|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|N/A|No|||July 2014|July 10, 2014|April 23, 2008|Yes|Yes|Study terminated early due to PI's extended medical leave.|No|May 9, 2014|https://clinicaltrials.gov/show/NCT00667095||156819|
NCT00667108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451140|A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance||Pfizer|No|Completed|October 2004|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|784|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667108||156818|
NCT00667368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0131|Bacterial Vaginosis Home Screening to Prevent STDs|Home Screening for Bacterial Vaginosis to Prevent STDs||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2008|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1370|||Female|15 Years|25 Years|No|||August 2015|November 5, 2015|April 24, 2008|Yes|Yes||No|September 24, 2015|https://clinicaltrials.gov/show/NCT00667368||156798|
NCT00667381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS# 2007-5989|Femoral Arterial Access With Ultrasound Trial|Femoral Arterial Access With Ultrasound Trial|FAUST|University of California, Irvine|No|Completed|April 2008|March 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1014|||Both|18 Years|N/A|No|||October 2010|October 19, 2010|April 24, 2008||No||No|September 27, 2010|https://clinicaltrials.gov/show/NCT00667381||156797|
NCT00667641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592905|Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors|Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway||Rutgers, The State University of New Jersey|Yes|Completed|March 2007|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|April 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667641||156777|
NCT00667654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-02P|Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)|A Phase 2, Open-Label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis||Anesiva, Inc.|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|40 Years|N/A|No|||May 2009|May 1, 2009|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667654||156776|
NCT00668551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00022923|Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population|Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population|Tele-PD|University of Rochester|No|Completed|April 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Study participants will be recruited from the Presbyterian Home Parkinson disease nursing        home, assisted living, independent living, and adult day care populations, as well as the        local PD support group that meets monthly at the Presbyterian Home.|April 2009|April 10, 2009|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668551||156707|
NCT00668239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA-04288|Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser|Treatment of Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone and Laser Photocoagulation: Randomized Clinical Trial With Morphological and Functional Evaluation||Hospital de Clinicas de Porto Alegre|No|Completed|September 2004|June 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|30 Years|N/A|No|||April 2008|April 28, 2008|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668239||156731|
NCT00668798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV/MM0105/FFM|Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms|Incidence and Clinical Outcome of Human Cytomegalovirus Transmission Via Thawed Frozen Breast Milk in Preterm Infants <31 Weeks. A Prospective Trial.||Johann Wolfgang Goethe University Hospitals|No|Suspended|January 2005|March 2008|Anticipated|January 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|58|Samples With DNA|thawed frozen breast milk of lactating mothers|Both|24 Weeks|31 Weeks|No|Non-Probability Sample|preterm infants of less than 32 weeks of gestation|April 2008|April 28, 2008|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668798||156688|
NCT00671684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001577|Endoscopic Mucosal Resection (EMR) for Diagnosis of Hirschsprung's Disease|Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial|EDGE|Massachusetts General Hospital|No|Enrolling by invitation|October 2007|April 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|10 Years|N/A|No|||May 2008|May 2, 2008|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00671684||156469|
NCT00671697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0916 / 201011797|Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia|A Phase I Study of Intravenous Decitabine in Combination With Arsenic Trioxide and Ascorbic Acid in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia||Washington University School of Medicine|Yes|Completed|May 2008|May 2011|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|May 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671697||156468|
NCT00671710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4079|Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|A Phase 1 and 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain||Advocate Hospital System|No|Completed|April 2008|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|26|||Both|N/A|N/A|No|||June 2010|January 13, 2011|April 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671710||156467|
NCT00668707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007077-01H|Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality|Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial|AMPLCaRe|The Canadian College of Naturopathic Medicine|Yes|Active, not recruiting|September 2007|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|711|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|April 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00668707||156695|
NCT00668447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0102|Soy and Isoflavones Effect on Bone|Soy Proteins and Isoflavones Impact Bone Mineral Density in Older Women||National Institute on Aging (NIA)|No|Completed|November 2001|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|97|||Female|65 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 25, 2008|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668447||156715|
NCT00669279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8COG11059|Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure|Non-Invasive Determination of Central Aortic Blood Pressure in Hypertensive Patients Treated With Controlled-Release Carvedilol or Atenolol||University of Florida|No|Completed|April 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||September 2011|February 17, 2012|April 28, 2008|Yes|Yes||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00669279||156651|Small sample size, short duration.
NCT00669526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051653|Clinical and Cost Effectiveness of Brief Cognitive-Behavioral Therapy (CBT) for Pediatric Internalizing Disorders|Clinical and Cost Effectiveness of Brief CBT for Pediatric Internalizing Disorders||Robert Wood Johnson Foundation|No|Completed|October 2004|April 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|7 Years|17 Years|No|||April 2008|April 29, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669526||156632|
NCT00669539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-139|Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old|An Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old|ATS13|Jaeb Center for Health Research|No|Completed|May 2008|December 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|156|||Both|3 Years|6 Years|No|Non-Probability Sample|Community Sample|May 2012|May 31, 2012|April 28, 2008||No||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00669539||156631|
NCT00669786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-EB-0103-0408-1|Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles|Highly Purified Human Menopausal Gonadotropin Versus Recombinant Follicle Stimulating Hormone in Ovarian Hyperstimulation With Gonadotropin Releasing Hormone Antagonists. A Randomized Study.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed||||||Phase 3|Interventional|N/A|2||||||Female|18 Years|37 Years|Accepts Healthy Volunteers|||April 2008|April 30, 2008|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00669786||156612|
NCT00669799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEIGS|Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study|Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study||University of South Florida|No|Withdrawn|March 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||May 2015|May 27, 2015|April 29, 2008|No|Yes|UNABLE TO PROCEED WITH STUDY DUE TO STAFFING OF COLLABORATIVE INVESTIGATORS|No||https://clinicaltrials.gov/show/NCT00669799||156611|
NCT00665548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer West|Weight-Bearing Magnetic Resonance Imaging (MRI) for Analysis of Knee Osteoarthritis (OA)|Weight-Bearing MRI for Analysis of Knee OA||University of California, San Francisco||Completed|March 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|33|||Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female, 40 years and older, community sample|March 2008|April 16, 2009|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665548||156938|
NCT00665860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEXW-2001-04550|Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss|Safety, Efficacy, and Optimal Dosage of Soy Isoflavones to Prevent Osteoporosis|OPUS|Baylor College of Medicine|Yes|Completed|April 2001|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|403|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665860||156914|
NCT00666510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP125-01|Bronchospasm Associated With High Nitric Oxide|Higher Exhaled Nitric Oxide (NO) is Associated With Intraoperative Bronchospasm||University of Sao Paulo|No|Completed|January 1999|December 2004|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|31|Samples Without DNA|Sputum|Both|16 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hospital, late post-anesthesia cared patients|April 2008|April 23, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666510||156864|
NCT00666523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhytalgicOA|Effect of Phytalgic in Osteoarthritis (OA)|Randomized Double-Blind Study of Food Supplement Phytalgic on Symptoms of Osteoarthritis||Université Victor Segalen Bordeaux 2|No|Completed|January 2007|April 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|20 Years|N/A|No|||April 2008|April 23, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666523||156863|
NCT00666796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451149|A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects|A Randomized, Double-Blind, 4-Way Crossover, Placebo-Controlled, Single Center Trial to Evaluate the Potential Pharmacodynamic Interaction Between Gabapentin 500 mg and Ethanol in Healthy Volunteers||Pfizer|No|Completed|April 2005|May 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|20|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 23, 2008|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666796||156842|
NCT00666809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12049|Vardenafil in Tinnitus|Evaluation of Vardenafil for the Treatment of Subjective Tinnitus: A Controlled Pilot Study||Bayer|No|Completed|October 2006|May 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|64 Years|No|||December 2014|December 8, 2014|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666809||156841|
NCT00667121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000585065|Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline|The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study||Mayo Clinic|Yes|Active, not recruiting|March 2008|||May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|85|||Both|18 Years|120 Years|No|Probability Sample|PATIENT CHARACTERISTICS:          -  Menopausal status not specified          -  Life expectancy ≥ 16 weeks          -  No contraindication for venlafaxine, citalopram hydrobromide, escitalopram oxalate,             gabapentin, or sertraline hydrochloride        PRIOR CONCURRENT THERAPY:          -  See Disease Characteristics          -  More than 4 weeks since prior and no concurrent medications that are known to inhibit             the CYP2D6 system|January 2016|January 11, 2016|April 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667121||156817|
NCT00667134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00009559|Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis|Stimulatory Autoantibodies to the PDGFR and Phosphorylation of the PDGFR in Patients With Systemic Sclerosis||University of Michigan|No|Completed|March 2008|February 2012|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|26|Samples Without DNA|skin serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects from a tertiary care clinic specializing in scleroderma. Controls recruited by        subjects being biopsied.|June 2015|June 5, 2015|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00667134||156816|
NCT00667407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-915|Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma|A Randomized, Double-Blind Study to Determine the Efficacy of Levalbuterol Versus Racemic Albuterol in the Treatment of Acute Asthma||Sunovion|No|Completed|November 2000|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|627|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667407||156795|
NCT00667394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080101|Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors|A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas||National Institutes of Health Clinical Center (CC)|No|Completed|April 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|April 25, 2008|Yes|Yes||No|July 30, 2012|https://clinicaltrials.gov/show/NCT00667394||156796|
NCT00668252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050904|Circulating Endothelium Progenitor Cells and Endogenous Oestrogen in Healthy Subjects|Impact of Endogenous Sexual Hormones (Oestrogens and Testosterone) on the Endothelium Circulatory on Rolling at the Young and Old Healthy Volunteer.|Oestropec|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|48|None Retained|whole peripheral blood (150 ml)|Both|18 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|March 2006|April 28, 2008|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00668252||156730|
NCT00673140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-ALS-CTP1|Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2008|June 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||August 2009|August 14, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00673140||156361|
NCT00665652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-PN-PI-235|Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance|A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)|MGUS|Dartmouth-Hitchcock Medical Center|Yes|Suspended|April 2008|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|April 22, 2008|Yes|Yes|The study has been suspended for slower than anticipated enrollment to date.|No||https://clinicaltrials.gov/show/NCT00665652||156930|
NCT00668811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCI-2007-214|Sutent Adjunctive Treatment of Differentiated Thyroid Cancer|Sutent Adjunctive Treatment of Differentiated Thyroid Cancer|IIT Sutent|Washington Hospital Center|Yes|Completed|April 2008|December 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|April 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668811||156687|
NCT00671398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-023|Efficacy of Ramelteon on Transient Insomnia in Healthy Adults|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia||Takeda|No|Completed|December 2002|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|289|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671398||156491|
NCT00662519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF IRB 280-2006|Neulasta in Type 1 Diabetes|Short Course of Pegylated GCSF (Neulasta®) as Immunomodulatory Therapy for Type 1 Diabetes||University of Florida|Yes|Completed|April 2008|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|April 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00662519||157170|
NCT00668460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03744|Dermatological Evaluation of Topic Compatibility-Dermacyd Delicata Pocket BR|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Delicata Pocket BR.||Sanofi|No|Completed|November 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|52|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668460||156714|
NCT00668993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-GU-42708|Randomized Clinical Trial Investigating Efficacy of EFT (Emotional Freedom Technique) for Food Cravings|The Emotional Freedom Technique (EFT) Versus a Waitlist for Food Cravings: A Randomized Clinical Trial||Soul Medicine Institute|No|Completed|April 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2009|September 19, 2009|April 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00668993||156673|
NCT00669292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEUTC|PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer|Phase I/II Study of URLC10-177 and TTK-567, Novel Tumor Specific Epitope Peptides Restricted to HLA-A*2402 Derived From Tumor Associated Antigens, Combined With CpG7909, a TLR9 Agonist, in Patients With Advanced or Recurrent Esophageal Cancer.||Wakayama Medical University|Yes|Recruiting|November 2006|||November 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|20 Years|80 Years|No|||September 2010|September 8, 2010|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669292||156650|
NCT00669552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6715|Intracardiac T-wave Alternans and Ischemia|Intracardiac T-wave Alternans and Ischemia During Percutaneous Coronary Interventions||Columbia University|No|Completed|August 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary artery disease (CAD) undergoing PCI that also have an appropriate        Medtronic implantable defibrillator.|April 2013|April 11, 2013|April 28, 2008||No||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00669552||156630|
NCT00669825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV003-0812|Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal|A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal|FED|Alvine Pharmaceuticals Inc.|No|Completed|March 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 17, 2010|April 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00669825||156609|
NCT00669812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593564|High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma|A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas||National Cancer Institute (NCI)||Recruiting|February 2008|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|N/A|No|||November 2008|August 23, 2013|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00669812||156610|
NCT00665886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCSC-DIRENF-0802|Compact Closed System Versus Mounted Open System (COSMOS)|Randomized Study of Closed Peripheral Intravenous Systems Versus Mounted Open Systems|COSMOS|Hospital San Carlos, Madrid|Yes|Completed|March 2008|April 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1200|||Both|18 Years|N/A|No|||April 2009|April 10, 2009|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665886||156912|
NCT00665873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-28064152|Antibiotic Therapy is Not Necessary to Implant Totally Implantable Venous Access Devices: Randomized Prospective Study|Antibiotic Therapy is Not Necessary to Implant Totally Implantable Venous Access Devices: Randomized Prospective Study|TIVAD|Universita degli Studi di Catania|Yes|Completed|January 2004|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2008|May 7, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00665873||156913|
NCT00666237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071037|Primary Tube Versus Trabeculectomy Study|Primary Tube Versus Trabeculectomy Study||Bascom Palmer Eye Institute|Yes|Recruiting|April 2008|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|85 Years|No|||August 2014|August 7, 2014|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666237||156885|
NCT00666250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xocai01|Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors|Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors||University of Utah|No|Completed|January 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|10|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||April 2008|February 4, 2016|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666250||156884|
NCT00666263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160604|Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy|A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy||Baxalta US Inc.|Yes|Completed|August 2008|September 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2013|June 26, 2015|April 23, 2008|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT00666263||156883|
NCT00666536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489AUS02|The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy|A Multicenter, Randomized, Double Blind, Parallel Design Trial to Evaluate the Blood Pressure Lowering Efficacy Comparing Moderate Versus Aggressive Treatment Regimen of Valsartan + Amlodipine in Patients Uncontrolled on ARB Monotherapy|EXTRA|Novartis|No|Completed|March 2008|||January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|728|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|April 23, 2008||No||No|November 16, 2010|https://clinicaltrials.gov/show/NCT00666536||156862|
NCT00667160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-02-006|Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis|A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis||Astellas Pharma Inc|No|Completed|December 2002|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|426|||Both|2 Years|16 Years|No|||September 2014|September 17, 2014|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667160||156814|
NCT00667420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07326|Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma|A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma|EOXP|Massachusetts General Hospital|No|Terminated|April 2008|June 2014|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 3, 2014|April 24, 2008|Yes|Yes|Closed due to slow accrual|No|June 27, 2014|https://clinicaltrials.gov/show/NCT00667420||156794|This study was stopped early due to poor tolerability. We will not further study this regimen in this patient population.
NCT00667433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 0706|Raltegravir as Early Therapy in African-Americans Living With HIV Study|CID 0706 - Safety, Tolerability, Pharmacokinetic, and Metabolic Features of Raltegravir Among African-American Men and Women With HIV Infection|REAL|University of North Carolina, Chapel Hill|No|Completed|June 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00667433||156793|
NCT00667667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFZ-Elvis-II|Effects of Whole Body Vibration on Postmenopausal Risk-factors in Elderly Women|Effect of Whole Body Vibration Training on Two Different Devices on Osteoporotic Risk Factors in Postmenopausal Women. A Randomized Controlled Trial.||University of Erlangen-Nürnberg Medical School|No|Terminated|April 2008|November 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|108|||Female|60 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667667||156775|
NCT00667914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.335 (REC)|A New Clinical Pathway for Patients With Fractured Neck of Femur|A New Clinical Pathway for Patients With Fractured Neck of Femur - The Orthopedics Operate, the Geriatricians Manage the Medical Work-up||Norwegian University of Science and Technology|Yes|Completed|April 2008|May 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|397|||Both|70 Years|N/A|No|||February 2015|February 11, 2015|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00667914||156756|
NCT00672828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUSN-0604-01B|Interactive Computer Program or Brochure in Increasing Colorectal Cancer Screening Among African Americans|Promoting Colon Cancer Screening Among African Americans|PACT|Indiana University|Yes|Completed|January 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|693|||Both|51 Years|80 Years|No|||August 2013|August 16, 2013|May 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00672828||156385|
NCT00665665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9112-1846|Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers|Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Healthy Male and Female Volunteers||Novo Nordisk A/S|No|Terminated|November 2007|October 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|101|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|April 23, 2008|Yes|Yes|The trial is terminated due to re-evaluation of the compound|No||https://clinicaltrials.gov/show/NCT00665665||156929|
NCT00673374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004904|Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients|Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients||Duke University|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|N/A|N/A|No|Non-Probability Sample|All consecutive emergency department patients undergoing abdominal CT for non-traumatic        abdominal pain and tenderness will be prospectively enrolled, with the following        exceptions. For study purposes, "abdominal pain and tenderness" is defined as pain and        tenderness to direct palpation in the region anterior to the mid-axillary line        bilaterally, and extending from the costal margins to the inguinal ligaments.        Consequently, patients undergoing CT for indications such as isolated vomiting, fever        without source, staging of malignancies, isolated flank pain or suspected renal colic, or        other indications that do not meet the above definition will not be enrolled.|February 2014|February 23, 2014|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00673374||156343|
NCT00662233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582271|Combination Chemotherapy in Treating Patients With Sarcoma|A Pilot Study for Soft Tissue Sarcoma||Mayo Clinic|Yes|Active, not recruiting|October 1991|||September 2015|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|120|||Both|N/A|21 Years|No|||March 2015|March 31, 2015|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00662233||157192|
NCT00669006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-835|Neuropathic Pain Database|National Neuropathic Pain Database Study|NePDatabase|Lawson Health Research Institute|Yes|Active, not recruiting|April 2008|January 2017|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|900|||Both|N/A|N/A|No|Probability Sample|New patients referred to the outpatient pain clinic with a diagnosis of Neuropathic Pain.|March 2016|March 19, 2016|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669006||156672|
NCT00669565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0702|Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer|A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Locally Advanced or Metastatic Breast Cancer||Peregrine Pharmaceuticals|No|Completed|July 2008|August 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|18 Years|N/A|No|||March 2011|March 23, 2011|April 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00669565||156629|
NCT00669838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP432-03|Anesthesia for Dental Treatment in Cardiac Patients: Lidocaine Comparative Study|Loco Regional Anesthesia for Dental Treatment in Cardiac Patients: Comparative Study Between Plain Lidocaine 2% and Lidocaine 2% With Epinephrine 1:100.000||University of Sao Paulo|No|Completed|January 2003|July 2005|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|59|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with acquired valvular diseases participated in this study, aging between 18-65        years in need of dental surgery (extractions) or restorative dentistry in mandible|April 2008|April 30, 2008|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00669838||156608|
NCT00665561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001067|Prospective Observational Epidemiologic Study of Maraviroc's Safety|An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients|POEM|ViiV Healthcare|No|Active, not recruiting|March 2008|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Treatment experienced, HIV-1 infected patients in routine clinical practice.|March 2016|March 7, 2016|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665561||156937|
NCT00665574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIM 1.0|ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee|A Prospective, Multi-center, Randomized, Double-blind Feasibility Study to Evaluate the Safety and Performance of ActaVisc and ActaVisc Mx Intra-articular Injection for Management of Pain Associated With Osteoarthritis in the Knee.||Carbylan Therapeutics, Inc.|No|Terminated|March 2008|June 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|23|||Both|40 Years|85 Years|No|||July 2009|July 13, 2009|April 22, 2008||No|Business decision|No||https://clinicaltrials.gov/show/NCT00665574||156936|
NCT00665587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121402|AMAZING PRAGUE (PRAGUE-12)|Surgical Treatment of Atrial Fibrillation - Prospective Randomized Study|AmP|Charles University, Czech Republic|Yes|Enrolling by invitation|June 2007|June 2012|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|220|||Both|18 Years|N/A|No|Probability Sample|Patients who suffer from atrial fibrillation (documented AF in 6 month before the surgery)        but are indicated to a cardiac surgery for other predominant cardiac diagnosis (heart        valve surgery, coronary revascularization or combined surgery)|April 2008|April 23, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00665587||156935|
NCT00665925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-010|Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate|Taski-2|AstraZeneca|Yes|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|420|||Both|18 Years|N/A|No|||May 2011|May 5, 2011|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665925||156909|
NCT00665938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3369-6|Followup of Infants Fed Non-routine Infant Formula|||Mead Johnson Nutrition|No|Completed|October 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|183|||Both|4 Months|4 Months|Accepts Healthy Volunteers|||January 2012|January 27, 2012|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00665938||156908|
NCT00666224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA 9010|Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome|A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With Clinically Isolated Syndrome (CIS)|PreCISe|Teva Pharmaceutical Industries|Yes|Completed|January 2004|June 2010|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|481|||Both|18 Years|45 Years|No|||June 2012|June 19, 2012|April 22, 2008|Yes|Yes||No|May 3, 2012|https://clinicaltrials.gov/show/NCT00666224||156886|
NCT00666549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0548-00106|Research Tissue Bank|Research Tissue Bank||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2007|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|N/A||1|Anticipated|400|Samples With DNA|Blood, bone marrow, bone marrow biopsy, toenail clippings, phlebotomized blood, spleen cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Philadelphia chromosome negative myeloproliferative disorders        (MPD) polycythemia vera (PV), idiopathic myelofibrosis (IM), and essential thrombocythemia        (ET) are eligible and not currently participating in any MPD-RC treatment studies.|January 2016|January 29, 2016|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666549||156861|
NCT00666822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6107|Compliance to a Hormone Therapy Regimen in Breast Cancer|Adherence to Endocrine Therapy in Women With Breast Cancer in Clinical Practice Settings||Case Comprehensive Cancer Center|No|Completed|December 2007|December 2015|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|178|||Female|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|February 2016|February 4, 2016|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00666822||156840|
NCT00667147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-07-3|Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib|Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination With Vandetanib||University of Southern California|No|Completed|March 2008|June 2014|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667147||156815|
NCT00671996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP 01-07|Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C|A Local Feasibility Study on Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Patients Operated Upon Colon Cancer Stage Dukes' C|MANFOL|PledPharma AB|No|Completed|June 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00671996||156447|
NCT00672308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002—034|Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults|Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults|ORS|International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|May 2003|August 2006|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|195|||Male|18 Years|55 Years|No|||December 2004|May 5, 2008|May 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00672308||156424|
NCT00672568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-04P|Safety and Tolerability of 4975 in Patients Undergoing Arthroscopic Surgery to Repair the Rotator Cuff of the Shoulder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Stage Exploratory Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of Intraoperative Subacromial Injection With 4975 in Patients Undergoing Arthroscopic Rotator Cuff Repair of the Shoulder||Anesiva, Inc.|No|Terminated|July 2008|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|75 Years|No|||May 2009|May 1, 2009|May 2, 2008||No|Study has been halted after completing Stage 1, for corporate reasons. No future patients will    be enrolled or treated.|No||https://clinicaltrials.gov/show/NCT00672568||156405|
NCT00669916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2102|A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis|Phase 2a Single-Dose, Randomized, Double Blind, Multi-Center, Parallel-Group, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety, Tolerability, and Population Pharmacokinetics of AIN457 in Patients With Stable Plaque-type Psoriasis||Novartis|No|Completed|February 2007|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|75 Years|No|||April 2015|April 9, 2015|April 29, 2008|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00669916||156602|
NCT00669929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rota-001|Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea|Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea||Yonsei University|No|Recruiting|May 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|200|||Both|N/A|5 Years|No|Probability Sample|patients to visit assigned hospital|February 2009|February 18, 2009|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00669929||156601|
NCT00665678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDMRP PT074585|Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)|Neural Correlates of Early Intervention for PTSD||Atlanta Research and Education Foundation|Yes|Terminated|April 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|50 Years|No|||July 2012|July 10, 2012|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665678||156928|
NCT00665977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F & P 07-004|Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure|Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure|Thermosmart|Clayton Sleep Insititute|No|Completed|September 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|44|||Both|16 Years|65 Years|No|||July 2010|July 6, 2010|February 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665977||156905|
NCT00674284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802022R|Adrenal Exhaustion Syndrome in Critically Ill Patients Without Improvement|Change of Serum Cortisol Levels in Patients Without Improvement in Intensive Care Unit||National Taiwan University Hospital|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|All of the adult patients (age >18 years) admitted to the intensive care units of the        National Taiwan University Hospital between January 2005 and December 2006 were surveyed.|November 2009|November 23, 2009|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674284||156273|
NCT00674596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATARAM2008|The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria|||Gulhane School of Medicine||Completed|January 2006|March 2008||March 2008||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2008|May 7, 2008|May 6, 2008||Yes||||https://clinicaltrials.gov/show/NCT00674596||156249|
NCT00669318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS0881|Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Pentostatin, Alemtuzumab, and Low Dose Rituximab: A Phase II Clinical Trial||Mayo Clinic|Yes|Completed|July 2008|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|April 29, 2008|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00669318||156648|
NCT00669058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03736|Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Tangerina Mix|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Tina Gel Tangerina Mix.||Sanofi|No|Completed|December 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|52|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00669058||156668|
NCT00669331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-B-305|Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis|: A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis.||Pharmaxis|Yes|Completed|November 2009|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|485|||Both|18 Years|85 Years|No|||January 2014|January 12, 2014|April 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669331||156647|
NCT00669344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713BSG01|RIVastigmine In Vascular cognitivE Impairment|A 24-Week Prospective, Double Blind, Randomized, Placebo-Controlled Pilot Study of 9 mg/Day Rivastigmine in Patients With Vascular Cognitive Impairment Not Dementia to Evaluate Efficacy, Safety and Tolerability in Asian Patients|RIVIVE|Singapore General Hospital|No|Completed|February 2006|February 2008|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|55 Years|85 Years|No|||April 2008|April 29, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669344||156646|
NCT00669578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC078B|CC-4047 in Treating Patients With Myelofibrosis|A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis®||Mayo Clinic|Yes|Completed|May 2008|May 2014|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|120 Years|No|||October 2015|October 29, 2015|April 29, 2008|Yes|Yes||No|November 7, 2012|https://clinicaltrials.gov/show/NCT00669578||156628|
NCT00669851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-700-34|Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study|A Phase 3, International, Exploratory, Open-Label, Multicenter, Dual-Injection, Echocardiographic Imaging Settings and Safety Study of AI-700 in Normal Volunteers and Stable Cardiac Patients||Acusphere||Completed|November 2006|March 2007|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|39|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2008|April 29, 2008|April 29, 2008||||||https://clinicaltrials.gov/show/NCT00669851||156607|
NCT00665951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 07.04|Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)|The Pharmacokinetics of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children: a Pilot Study of Lopimune vs. the Branded Product (SURF Study).|SURF|Radboud University|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|February 24, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00665951||156907|
NCT00665899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0977|A Couples Approach to Enhance Breast Cancer Survivorship|A Couples Approach to Enhance Breast Cancer Survivorship|CanThrive|University of North Carolina, Chapel Hill|Yes|Completed|July 2004|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|163|||Both|N/A|N/A|No|||February 2011|February 21, 2011|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665899||156911|
NCT00665912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI-004|Platelet-Rich and Concentrated Platelet-Poor Plasma to Reduce Air Leak Post-Lobectomy: A Randomized Controlled Trial|Platelet-Rich and Concentrated Platelet Poor Plasma to Reduce Air Leak Post Lobectomy: A Randomized Controlled Trial||Biomet, Inc.|No|Completed|January 2008|November 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||June 2011|December 5, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665912||156910|
NCT00666848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070977|Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome|Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome||Vanderbilt University|No|Completed|March 2008|January 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|70 Years|No|||April 2012|April 12, 2012|April 23, 2008|Yes|Yes||No|September 4, 2011|https://clinicaltrials.gov/show/NCT00666848||156838|
NCT00671437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0285 / 201107108|Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer|Determination of Tumor SUV by FDG-PET/CT Before and After Cetuximab in Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck|SCCHN|Washington University School of Medicine|No|Completed|June 2008|August 2015|Actual|December 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|May 1, 2008|Yes|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT00671437||156488|
NCT00671723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12783|Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients|Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis||University of Oklahoma|Yes|Completed|October 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|90 Years|No|||January 2014|January 6, 2014|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671723||156466|
NCT00669110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A6-2001|Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder|6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|7 Years|18 Years|No|||April 2011|April 21, 2011|April 25, 2008|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00669110||156664|
NCT00669123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/IV/PSO/ART|Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis|Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis||Bioiberica|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|40 Years|N/A|No|||April 2008|April 28, 2008|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00669123||156663|
NCT00669383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU eRIB#1845|Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants|Rescue Antenatal Steroids and Lung Volumes in Preterm Infants||Oregon Health and Science University|Yes|Active, not recruiting|June 2001|||July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Female|15 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 17, 2012|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669383||156643|
NCT00669617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2307|Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 μg) in Patients With Moderate to Severe COPD Using Salbutamol (200 μg) and Salmeterol/Fluticasone (50/500 μg) as Active Controls||Novartis|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|89|||Both|40 Years|N/A|No|||September 2011|September 7, 2011|April 28, 2008|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00669617||156625|
NCT00669630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL087768|The GoodNEWS Lifestyle Enhancement Program|The GoodNEWS (Genes, Nutrition, Exercise, Wellness, and Spiritual Growth) Trial|GoodNEWS|University of Texas Southwestern Medical Center|No|Recruiting|September 2008|June 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 11, 2010|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669630||156624|
NCT00669942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2101|Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients|A Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients With Pharmacodynamics Assessed in an Expanded Cohort at the Maximum Tolerated Dose||Novartis|No|Completed|December 2005|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|12||Actual|104|||Both|18 Years|75 Years|No|||March 2015|March 27, 2015|April 29, 2008|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00669942||156600|
NCT00666341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0701rP|Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens|A Double-blind Placebo-controlled Dose-response Study for Evaluation of Safety and Efficacy of Immunotherapy With a Cocktail of Recombinant Major Allergens of Timothy Grass Pollen (Phleum Pratense) Adsorbed to Aluminium Hydroxide in Patients With IgE-mediated Allergic Rhinitis/Rhinoconjunctivitis With or Without Bronchial Asthma||Allergopharma GmbH & Co. KG|Yes|Completed|September 2007|May 2010|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|50 Years|No|||November 2013|November 7, 2013|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00666341||156877|
NCT00666614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTSLEP|A Pilot Study to Examine Sleep and Fatigue in Pediatric Brain Tumor Patients Hospitalized for High Dose Chemotherapy|A Pilot Study to Examine Sleep and Fatigue in Pediatric Brain Tumor Patients Hospitalized for High Dose Chemotherapy||St. Jude Children's Research Hospital|No|Completed|April 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|43|||Both|4 Years|21 Years|No|||January 2012|January 3, 2012|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666614||156856|
NCT00665990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGIO1|Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia|Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia||St. Jude Children's Research Hospital|No|Completed|November 2007|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|N/A|21 Years|No|||January 2015|January 8, 2015|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665990||156904|
NCT00670332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-700-36|Prognostic Assessment of Contrast Echocardiography (PACE Study)|Prognostic Assessment of Contrast Echocardiography (PACE Study): An Observational Follow-up Study of Patients With Chest Pain Evaluated With AI-700 Contrast Echocardiography|PACE|Acusphere||Terminated|July 2007|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|773|||Both|18 Years|80 Years|No|Non-Probability Sample|This observational study will enroll up to 773 patients who participated in either        AI-700-32 or AI-700-33 and who were evaluated with AI-700 contrast ECHO at rest and at        pharmacologic-induced stress. Approximately 28 international study centers will        participate. At the time of AI-700 contrast ECHO (defined as the index date), the patients        were to have had a recent history of chest pain and were to meet all eligibility criteria.        Chest pain (angina) was defined as either:          -  typical chest pain: 1) substernal chest discomfort with a characteristic quality and             duration that is 2) provoked by exertion or emotional stress and 3) relieved by rest             or nitroglycerin, or          -  atypical chest pain (angina) that meets 2 of the 3 typical chest pain             characteristics.|April 2008|April 29, 2008|April 29, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00670332||156572|
NCT00668759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERI-305-AMIO|A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation|A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation|AVRO|Cardiome Pharma|No|Completed|April 2008|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|85 Years|No|||December 2009|December 12, 2009|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668759||156691|
NCT00668772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.15|Tiotropium/Salmeterol Inhalation Powder in COPD|1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)||Boehringer Ingelheim||Terminated|April 2008|||October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|207|||Both|40 Years|N/A|No|||April 2014|April 30, 2014|April 17, 2008||||No||https://clinicaltrials.gov/show/NCT00668772||156690|
NCT00669045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2224n|An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)|A Phase IV, Prospective, Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)||Genentech, Inc.||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|||April 2008|July 1, 2015|April 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00669045||156669|
NCT00669071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10081|Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma|Split-Face, Randomized, Open-Label Study of Sequential Treatment With Tri-Luma® Cream With Intense Pulsed Light (IPL) vs. a Mild Inactive Control Cream With Intense Pulsed Light (IPL) in Subjects With Melasma||Galderma Laboratories, L.P.|No|Terminated|January 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|74 Years|No|||September 2012|September 21, 2012|April 24, 2008||No|Enrollment closed|No|September 25, 2009|https://clinicaltrials.gov/show/NCT00669071||156667|
NCT00669084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908120|Innate and Acquired Resistance to Plasmodium Falciparum Malaria in Mali|Studies of Innate and Acquired Resistance to P. Falciparum Malaria in Mali||National Institutes of Health Clinical Center (CC)||Completed|April 2008|November 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2100|||Both|6 Months|65 Years|Accepts Healthy Volunteers|||November 2013|February 19, 2014|April 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00669084||156666|
NCT00669357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H040006|AbioCor Implantable Replacement Heart|AbioCor Implantable Replacement Heart||Abiomed Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|75 Years||||May 2013|May 1, 2013|April 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669357||156645|
NCT00669591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0704|A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer|A Phase II Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Breast Cancer||Peregrine Pharmaceuticals|No|Completed|January 2008|August 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|18 Years|N/A|No|||August 2010|August 26, 2010|April 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00669591||156627|
NCT00669864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1960|Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin|Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin||Novo Nordisk A/S|No|Completed|November 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|293|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|April 29, 2008|Yes|Yes||No|April 29, 2010|https://clinicaltrials.gov/show/NCT00669864||156606|This single-armed trial does not permit a comprehensive comparison between BIAsp30 and basal insulin. Otherwise, this could have proffered greater clarity on the putative benefits that BIAsp30 brings to subjects with type 2 diabetes.
NCT00669877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-229|Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma|Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma||M.D. Anderson Cancer Center|No|Completed|August 2002|||October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|N/A|N/A|No|||October 2015|October 8, 2015|April 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669877||156605|
NCT00665600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-914|Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)|A Double-Blind, Randomized, Multicenter, Parallel-Group Study of Levalbuterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease||Sunovion|No|Completed|February 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|257|||Both|35 Years|N/A|No|||February 2012|February 21, 2012|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665600||156934|
NCT00666289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0548-00105|Familial Myeloproliferative Disorders|Molecular Biology of Familial Myeloproliferative Disorders||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|March 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|200|Samples With DNA|Blood samples from subjects and family members with myeloproliferative disease.|Both|7 Years|N/A|No|Non-Probability Sample|families with multiple member diagnosed with myeloproliferative disease|February 2016|February 10, 2016|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666289||156881|
NCT00666562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00906|Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer|A Phase II Randomized, Placebo-Controlled Trial of Polyphenon E to Evaluate Bladder Tissue Levels of EGCG||National Cancer Institute (NCI)||Terminated|July 2008|||April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|33|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666562||156860|
NCT00666276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951142|Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|February 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1004|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A5951142 prescribes the Linezolid.|May 2012|May 29, 2012|April 22, 2008|No|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00666276||156882|
NCT00666575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451146|A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Actual Use Study of the Safety and Tolerability of Gabapentin 500 mg in a Potential OTC Population||Pfizer|No|Completed|December 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2105|||Both|12 Years|N/A|No|||April 2008|April 23, 2008|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666575||156859|
NCT00666835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-29-INJ-9|Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients|Randomized, Double-Blind, Multicenter, Parallel-Group, Equivalence Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients||Novartis|No|Completed|April 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|462|||Both|18 Years|N/A|No|||April 2008|April 24, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666835||156839|
NCT00668564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2008-02|Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism|Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Terminated|March 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|21 Years|No|||November 2012|November 6, 2012|April 25, 2008|Yes|Yes|Replaced by another study|No|June 14, 2011|https://clinicaltrials.gov/show/NCT00668564||156706|Other secondary objectives outlined in study protocol were not analyzed; number of patients were too few to be relevant.
NCT00668577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03747|Dermatological Evaluation of Topic Compatibility - Dermacyd Breeze|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Breeze.||Sanofi|No|Completed|December 2007|||February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|52|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 9, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668577||156705|
NCT00668824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q0704/2|Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist|Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist|CHD Vasovist|Guy's Hospital|No|Recruiting|March 2007|December 2009|Anticipated|July 2008|Anticipated|Phase 4|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||July 2009|July 31, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668824||156686|
NCT00668590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G08-01-038-01|Improving Diabetes Care With Patient Decision Aids - A Trial in Community-based Primary Care|Improving Diabetes Care With Patient Decision Aids - A Randomized Controlled Trial in Community-based Primary Care||University of California, Los Angeles|No|Completed|August 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|201|||Both|40 Years|N/A|No|||April 2011|April 8, 2011|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668590||156704|
NCT00668837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002944|A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.|Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2004|June 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|407|||Both|18 Years|65 Years|No|||March 2010|June 6, 2011|April 24, 2008||||||https://clinicaltrials.gov/show/NCT00668837||156685|
NCT00669136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-101|Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma|A Phase I/II Trial Testing Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma||University of Pittsburgh|Yes|Terminated|June 2009|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|April 25, 2008|No|Yes|Poor accrual and limited target patient population for future accrual. Did not complete the    Phase 1 portion of the trial.|No||https://clinicaltrials.gov/show/NCT00669136||156662|
NCT00669396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23111|Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception|A Pilot Study of Copper T380A IUDs Versus Oral Levonorgestrel for Emergency Contraception||University of Utah|Yes|Completed|April 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|57|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 25, 2008|Yes|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00669396||156642|
NCT00669643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq / DECIT 403293/2005-7|Uniform Multidrug Therapy Regimen for Leprosy Patients|Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients|U-MDT|University of Brasilia|Yes|Active, not recruiting|February 2007|October 2016|Anticipated|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2122|||Both|6 Years|65 Years|No|||April 2013|April 2, 2013|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00669643||156623|
NCT00666003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-120|Hemodynamic Assessment APCO Monitor vs Crit Line for Renal Replacement Rx|Hemodynamic Assessment Comparison Between Arterial Pressure Cardiac Output Monitor and Crit Line Utilized During Renal Replacement Therapy|APCOvC-Line|Baystate Medical Center|No|Completed|April 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Renal Failure Patients in the ICU|February 2011|February 7, 2011|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666003||156903|
NCT00666016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO19622 CL E Q 1159-1|Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)|Double-Blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients With Non-Alcoholic Steatohepatitis (NASH)||Trophos|No|Completed|April 2008|April 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2008|January 26, 2011|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666016||156902|
NCT00666328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-07-02|Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)|The Evaluation of Patients With Acute Hypertension and Intracerebral Hemorrhage With Intravenous Clevidipine Treatment (ACCELERATE)|ACCELERATE|The Medicines Company|No|Completed|June 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|April 22, 2008|Yes|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00666328||156878|
NCT00667225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 07-1330|Efficacy of Cantharidin in Molluscum Contagiosum|Efficacy of Cantharidin in Molluscum Contagiosum: A Randomized, Blinded, Placebo-Controlled Prospective Study||University of North Carolina, Chapel Hill|No|Completed|January 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|5 Years|10 Years|No|||June 2011|June 16, 2011|April 24, 2008|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00667225||156809|Small sample size and random disproportionate assignment to the vehicle group. Other limitations include short duration of follow up and interval between treatments. Finally, matching subjects in each group with comparable lesion counts.
NCT00667238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04082008-1086|Chronic Pediatric Pain|Functional Impact of Chronic Pediatric Pain||Stanford University||Recruiting|November 2006|||||N/A|Observational|Time Perspective: Retrospective||||300|||Both|6 Years|17 Years|No|||April 2008|April 25, 2008|April 24, 2008||||No||https://clinicaltrials.gov/show/NCT00667238||156808|
NCT00669955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYLHp07-01|Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy|Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days||Axcan Pharma|No|Completed|June 2008|August 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|N/A|No|||August 2010|August 3, 2010|April 29, 2008|Yes|Yes||No|June 21, 2010|https://clinicaltrials.gov/show/NCT00669955||156599|
NCT00670345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO/URC/ER/mm 139/DG|Tranexamic Acid in Urologic Surgery|Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study.|TRANEX-URO|Università Vita-Salute San Raffaele||Completed|April 2008|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||||||Male|18 Years|N/A|No|||July 2010|April 4, 2014|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670345||156571|
NCT00670358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC078E|Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma|Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma||Mayo Clinic|Yes|Recruiting|August 2008|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|120 Years|No|||January 2016|January 7, 2016|April 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670358||156570|
NCT00668785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3848s|Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)|Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)||Jumper, J. Michael, M.D.|No|Terminated|March 2007|March 2012|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|21 Years|N/A|No|||April 2015|April 7, 2015|April 25, 2008|Yes|Yes|Study was terminated due to low enrollment|No|September 6, 2013|https://clinicaltrials.gov/show/NCT00668785||156689|Study was terminated by Sponsor and Investigator due to low enrollment. Data not analyzed. Technical problems with measurement leading to unreliable or uninterpretable data.
NCT00669604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3RF-1|HIV Vertical Transmission in Vietnam|Counseling on Formula Feeding and Antiretroviral Prophylaxis Successfully Reduced Transmission of HIV-1 From Mother to Child in Northern Vietnam||National Institute of Hygiene and Epidemiology, Vietnam|No|Completed|March 2004|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|Samples With DNA|Peripheral EDTA blood samples were collected from the child at birth (1-2 days), at 1, 3, 6,      12, and 18 months of age and processed at the Molecular Laboratory in the Hanoi Obstetric      and Gynaecology hospital. The maternal blood samples were taken at the same day as the first      sample of their child. Three ml EDTA blood was taken from the mother and 2 ml from the      child. The blood was processed within 8 hours. Cells and plasma were stored separately at -      20 Celcius degree.|Both|N/A|N/A|No|Probability Sample|HIV-1 infected pregnant women were identified in the Obstetric and Gynaecology hospitals        in Hanoi (2004-2007) and Haiphong (2006-2007).        They were encouraged to participate in a prospective study with regular clinical follow up        of their children from birth to 12-18 months of age. All participants signed an informed        consent.|April 2008|April 29, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669604||156626|
NCT00669890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA2533|Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML|Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamid and Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia|High Risk|New York Medical College|Yes|Terminated|May 2004|December 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|30 Years|No|||April 2015|April 20, 2015|April 29, 2008||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00669890||156604|
NCT00669903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0190C00007|Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Oral Multiple Ascending Doses of AZD0328 in Patients With Schizophrenia||AstraZeneca||Terminated|April 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|55 Years|No|||July 2010|July 9, 2010|April 29, 2008|Yes|Yes|Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to    stop further development of AZD0328|No|February 4, 2010|https://clinicaltrials.gov/show/NCT00669903||156603|
NCT00665613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-054|The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin|The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin||Northwell Health|Yes|Completed|October 2004|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|300|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|patients on warfarintherapy in the SIUH coumadin center|October 2015|October 13, 2015|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665613||156933|
NCT00665626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-011|Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic|Taski-3|Rigel Pharmaceuticals|Yes|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|195|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665626||156932|
NCT00665639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-7-008|Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis|A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis||Astellas Pharma Inc||Completed|June 2004|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|454|||Both|16 Years|N/A|No|||August 2014|August 19, 2014|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665639||156931|
NCT00665964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2007-249|Comparing X-3 To N2vac Polyethylene With the Triathlon Total Knee System|A Prospective, Randomized, Multi-center Study Comparing the Ten-Year Survival for X-3 Polyethylene to N2vac Polyethylene When Used With the Triathlon Posterior Stabilized (PS) Total Knee System||Dalhousie University|No|Withdrawn|May 2008|May 2020|Anticipated|May 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|384|||Both|21 Years|75 Years|No|||August 2009|August 10, 2009|April 22, 2008|Yes|Yes|Not funded at this time.|No||https://clinicaltrials.gov/show/NCT00665964||156906|
NCT00667927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLREM|Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission|Autologous Bone Marrow Transplant for Children With AML in First Complete Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse||St. Jude Children's Research Hospital|No|Completed|March 1991|January 2008|Actual|January 1995|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|1 Year|18 Years|No|||April 2008|April 25, 2008|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667927||156755|
NCT00668265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # (112-07)|Anxiety in Recovering Opiate Dependence|A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence||Beth Israel Medical Center|No|Terminated|January 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|65 Years|No|||February 2013|February 15, 2013|April 28, 2008|No|Yes|The study was not completed, the funding sponsor lost interest.|No|October 19, 2012|https://clinicaltrials.gov/show/NCT00668265||156729|
NCT00668278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/NIR01/124|I-Gel Versus Disposable Laryngeal Mask (LMA) for General Anesthesia (GA) With Controlled Ventilation|I-Gel Versus Disposable Laryngeal Mask Airway for General Anesthesia With Controlled Ventilation|IGE(L)MA|Northern Health and Social Care Trust|No|Completed|February 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668278||156728|
NCT00668291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060251|Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)|Assessment of the Clinical Symptoms of the Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC).|EVACARNEY|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|January 2008|November 2015|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|133|Samples With DNA|2 tubes EDTA 5 mL each (DNA) and 2 tubes heparine 5 mL each (cellular biology)|Both|N/A|N/A|No|Non-Probability Sample|Consultations|August 2015|August 28, 2015|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668291||156727|
NCT00668304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100569|Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox|Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD|SPEED|Bayer|No|Completed|June 2004|January 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|April 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668304||156726|
NCT00669409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091022|A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee|A Phase 1/2A, Randomized, Placebo-Controlled, Double Blind, Dose-Escalation, Multicenter Study Of The Safety, Tolerability, Efficacy And Pharmacokinetics, Of A Single Intravenous Dose Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee||Pfizer|Yes|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|83|||Both|35 Years|75 Years|No|||January 2011|January 10, 2011|April 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669409||156641|
NCT00669656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-07-3|Herbal Therapy for Treatment of Recurrent Prostate Cancer|A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy||University of Southern California|Yes|Completed|November 2008|October 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Male|18 Years|N/A|No|||October 2015|October 24, 2015|April 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669656||156622|
NCT00669669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000.00|O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas|Benzylguanine-Mediated Tumor Sensitization With Chemo-Protected Autologous Stem Cells for Patients With Malignant Gliomas||Fred Hutchinson Cancer Research Center|Yes|Recruiting|February 2009|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00669669||156621|
NCT00665379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS1NL|Comparative Trial in Compression Therapy in Leg Lymphedema|Prospective, Randomized Controlled Trial Comparing the Effect of 3M Coban 2 Layer Compression System Versus Trico Bandages in the Treatment of Leg Lymphedema.||Nij Smellinghe Hosptial|No|Completed|April 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2012|May 19, 2012|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00665379||156951|
NCT00665691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSGA|Pilot Test for a Newly Developed Nutrition Screening Method: Pediatric Subjective Global Assessment|Pilot Test for a Newly Developed Nutrition Screening Method: Pediatric Subjective Global Assessment||St. Jude Children's Research Hospital|No|Completed|September 2003|||July 2010|Actual|N/A|Observational|N/A||1|Anticipated|132|||Both|2 Years|16 Years|No|Probability Sample|Participant is between 2 and 16 years of age and receiving treatment for a hematologic or        solid malignancy at St. Jude Children's Research Hospital.|June 2011|June 1, 2011|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665691||156927|
NCT00665704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-197|Tobacco Tactics Website for Veteran Smokers|Tobacco Tactics Website for Veteran Smokers||VA Office of Research and Development|No|Completed|March 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|9|||Both|18 Years|N/A|No|||June 2014|April 6, 2015|April 22, 2008||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00665704||156926|
NCT00666913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3107|Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial|Menopausal Symptoms in Women With Breast Cancer||Case Comprehensive Cancer Center|No|Completed|October 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|183|||Female|18 Years|N/A|No|Probability Sample|Data from an archived database of a closed clinical trial is retrieved.|September 2015|September 28, 2015|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00666913||156833|
NCT00667537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15302|PK in Pts With HRPC & Skeletal Metastes|A Phase I, Open-label, Dosimetry, Biodistribution and Pharmacokinetic Study of Alpharadin™ in Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases||Bayer|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667537||156785|
NCT00669968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-034|Study of Value of Cardiac PET Scans With or Without CT Angiography and/or Measurement of Coronary Flow Reserve|PET Myocardial Perfusion Imaging With CT Angiography and Measurement of Coronary Flow Reserve: A Prospective Study of Effectiveness, Impact on Patient Management, Prognostic Value, and Downstream Costs||Kettering Health Network|No|Completed|February 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who undergo Rubidium PET adenosine stress test with or without CT angiography of        coronary arteries and/or coronary flow reserve measurment at Kettering Medical Medical        Center.|May 2012|May 30, 2012|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00669968||156598|
NCT00669981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH076813|Effectiveness of Cognitive Behavioral Couples Therapy for Post-traumatic Stress Disorder|Cognitive-Behavioral Couples Therapy for Posttraumatic Stress Disorder||Ryerson University|No|Completed|August 2008|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||November 2013|November 22, 2013|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00669981||156597|
NCT00670371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NSE-DUM-2007/1|Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study|Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study||AstraZeneca|No|Completed|March 2008|November 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Psychiatric patients and informal caregivers. Selected from outpatient wards|November 2009|November 24, 2009|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670371||156569|
NCT00670384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALI001-08|Phase 2 Study in Adults Sensitized to Short Ragweed|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy in Adults Sensitized to the Standardized Allergenic Extract, Short Ragweed (Ambrosia Artemisiifolia)||Antigen Laboratories, Inc.|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||January 2014|January 8, 2014|April 29, 2008|Yes|Yes|No funding.|No||https://clinicaltrials.gov/show/NCT00670384||156568|
NCT00669370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002484-87|Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer|Biweekly Docetaxel (Taxotere®)in Combination With Capecitabine (Xeloda®)as First-Line Treatment in Patients With Advanced Gastric Cancer|GAST-TaxXel|University of Turku|No|Recruiting|June 2006|||March 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2008|April 29, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669370||156644|
NCT00674271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080059|Immune Profile and Complication Risk in Type 2 Diabetes|Immune Profile and Complications Risk in Type 2 Diabetes|IMPACT|University of Aarhus|No|Active, not recruiting|May 2008|May 2018|Anticipated|March 2011|Actual|N/A|Observational|N/A||2|Anticipated|200|Samples With DNA|Whole blood, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 patients with newly diagnosed (<5 years since diagnosis) type 2 diabetes referred from        general practitioners to Medical Department M, Aarhus University Hospital, Denmark.        100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects        matched for age and gender.|November 2011|November 3, 2011|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674271||156274|
NCT00674570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H841-31915-01A|Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder|Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder||VA Office of Research and Development|No|Recruiting|July 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|140|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674570||156251|
NCT00674583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111414|Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children|Non-inferiority of GSK Biologicals' Meningococcal Vaccine (GSK134612) Compared to Licensed MenC-CRM197 Conjugate Vaccine in Healthy Children||GlaxoSmithKline||Completed|May 2008|January 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|414|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674583||156250|
NCT00670293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5700|Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa|Imaging of Dopamine Systems in Anorexia Nervosa||New York State Psychiatric Institute|No|Active, not recruiting|July 2008|December 2015|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|51|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include people with anorexia nervosa seeking inpatient treatment        or already receiving inpatient treatment and people who will act as healthy control        participants.|August 2015|August 31, 2015|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670293||156575|
NCT00666861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290/07|Type 2 Diabetes and Exercise - A Pilot Study|Understanding the Acute Effects of Prolonged Sedentary Behaviour (Sitting) on Post-meal Glucose and Lipids - A Pilot Study||Bayside Health|No|Terminated|April 2008|November 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2|Samples Without DNA|Plasma samples|Both|45 Years|65 Years|No|Non-Probability Sample|Patients with Type 2 Diabetes|July 2009|July 28, 2009|April 23, 2008||No|Pilot study superseded by a larger NHMRC funded trial|No||https://clinicaltrials.gov/show/NCT00666861||156837|
NCT00667173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-IDP-115-P2-01|A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea|A Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-115 in the Treatment of Rosacea||Dow Pharmaceutical Sciences|No|Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|140|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667173||156813|
NCT00667446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-CP07-177|Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty|A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty||AbbVie|No|Completed|December 2008|January 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|N/A|N/A|No|||January 2014|January 8, 2014|April 24, 2008|Yes|Yes||No|October 16, 2013|https://clinicaltrials.gov/show/NCT00667446||156792|
NCT00667459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESTIGE® LP Protocol, #P03-03|Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD|A Prospective, Multicenter, Controlled Clinical Trial of an Artificial Cervical Disc LP at a Single Level for Symptomatic Cervical Disc Disease||Medtronic Spinal and Biologics|Yes|Completed|January 2005|June 2014|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|April 24, 2008|Yes|Yes||No|August 22, 2014|https://clinicaltrials.gov/show/NCT00667459||156791|
NCT00667940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002730|Faculty Development to Improve Mini-CEX Ratings|Effect of Faculty Development on Mini-CEX Score Reliability and Accuracy: A Randomized, Controlled Trial||Mayo Clinic|No|Completed|March 2006|June 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2008|April 25, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00667940||156754|
NCT00669149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHPAU 2007/01|Anticoagulant Treatments and Percutaneous Coronary Angioplasty|Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients|TACA|Centre Hospitalier de PAU|Yes|Recruiting|June 2008|December 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|480|||Both|18 Years|N/A|No|||July 2011|July 1, 2011|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00669149||156661|
NCT00665717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 07.05|The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)|The Influence of Raltegravir on Pravastatin Pharmacokinetics in Healthy Volunteers (GRAPPA)|GRAPPA|Radboud University|No|Completed|May 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|June 6, 2011|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00665717||156925|
NCT00666029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2-65 (Version 4. 2007-07-03)|Implications for Treatment of the Metabolic Syndrome|Implications for Treatment of the Metabolic Syndrome||University Hospital Southampton NHS Foundation Trust.|Yes|Completed|February 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666029||156901|
NCT00666042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eye drops vs. spray|Bioequivalence of Eye Drops and Spray Administration of Vigamox|Laboratory-masked, Randomized Parallel, Comparative, Pilot Study on the Bioavailability of Vigamox in the Aqueous Humor When Administered Either as Commercially Available Eye Drops or in a Spray Form||Advanced Ophthalmic Pharma|No|Completed|February 2009|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|16|||Both|21 Years|N/A|No|||August 2009|January 18, 2012|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666042||156900|
NCT00666354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003|Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis|Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the Treatment of Fingernail Psoriasis||MediQuest Therapeutics|Yes|Active, not recruiting|October 2007|January 2009|Anticipated|September 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|83|||Both|18 Years|75 Years|No|||February 2009|February 9, 2009|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666354||156876|
NCT00666640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14748|3D Imaging of the Hip Using DXA|Parameters Derived From DXA-based Structural Engineering Models of the Proximal Femur as a Biomarker for Hip Fracture Prediction.|3DScans|Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|May 2008|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Female|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample Subjects recruited from A+E attendances/fracture clinics at Sheffield        hospitals|September 2014|September 18, 2014|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666640||156854|
NCT00667251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108919|Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer|A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/Neu Positive Metastatic Breast Cancer||GlaxoSmithKline|Yes|Active, not recruiting|October 2008|October 2016|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|652|||Female|18 Years|N/A|No|||February 2015|February 23, 2015|April 25, 2008|Yes|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00667251||156807|
NCT00667550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5995|Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders|Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders||University of California, Irvine|Yes|Completed|March 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients with a diagnosis of a colorectal disorder requiring surgery. Patients must        be able to complete the questionnaires in English as the questionnaires are only available        and valid in English.|July 2010|July 13, 2010|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667550||156784|
NCT00670007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1226_3001|Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.|An Open-label, Non-controlled, Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Zemaira® Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency Who Completed Clinical Study CE1226_4001||CSL Behring||Completed|April 2008|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670007||156595|
NCT00670683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1914|Observational Study of Patients With Diabetes Using Levemir® FlexPen®|Safety and Efficacy of Insulin Detemir (Levemir® FlexPen®) in Patients With Diabetes Mellitus||Novo Nordisk A/S|No|Completed|July 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|797|||Both|N/A|N/A|No|Non-Probability Sample|Diabetic patients|March 2016|March 2, 2016|April 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670683||156545|
NCT00670696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 305/24674|A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel|A Randomised, Controlled, Single-blinded, Cross Over Comparison Study to Compare the Efficacy of the Rapydan Medicated Plaster Versus Tetracaine Gel||Jazz Pharmaceuticals|No|Withdrawn|April 2008|||December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 24, 2012|April 29, 2008||No|No longer sponsor of trial|No||https://clinicaltrials.gov/show/NCT00670696||156544|
NCT00673972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705051M|Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome|A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment||National Taiwan University Hospital|Yes|Withdrawn|April 2008|December 2009|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|20 Years|N/A|No|||March 2010|March 8, 2010|May 5, 2008||No|difficulty in recruiting patients|No||https://clinicaltrials.gov/show/NCT00673972||156297|
NCT00666874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGGM/02/1999|Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women|Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women||Second University of Naples|No|Completed|February 1999|February 2002|Actual|December 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|20 Years|46 Years|Accepts Healthy Volunteers|||April 2008|April 23, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666874||156836|
NCT00667186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AI068453|HIV Screening in the Emergency Department Setting|HIV Screening in the Emergency Department Setting||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|9572|||Both|18 Years|64 Years|No|||January 2013|January 30, 2013|April 3, 2008||No||No|October 29, 2012|https://clinicaltrials.gov/show/NCT00667186||156812|
NCT00667472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-NIBIB-LAMMP-2007-6098|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks||University of California, Irvine|Yes|Withdrawn|March 2008|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|April 24, 2008|No|Yes|No participants enrolled|No||https://clinicaltrials.gov/show/NCT00667472||156790|
NCT00667485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15878B|Rapamycin Plus Bevacizumab in Advanced Cancers|A Phase I Study of Rapamycin (Sirolimus) With Bevacizumab in Patients With Advanced Malignancies||University of Chicago|Yes|Completed|April 2008|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|April 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667485||156789|
NCT00668317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004102-13|Bronchial Hyper-responsiveness in Reflux Cough|An 8 Week Non-selected Cohort Study to Investigate Whether the Treatment of Reflux Induced Cough Alters Associated Bronchial Hyper-responsiveness||Hull and East Yorkshire Hospitals NHS Trust|Yes|Terminated|September 2006|January 2010|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5|||Both|18 Years|75 Years|No|||October 2012|October 16, 2012|April 24, 2008||No|Primary care physicians began prescribing antacid therapy for chronic cough|No|March 16, 2012|https://clinicaltrials.gov/show/NCT00668317||156725|
NCT00667680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2007|Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression|Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression - Effect on Clinical and Neurophysiological Parameters||Ludwig-Maximilians - University of Munich|Yes|Completed|March 2007|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||November 2009|November 13, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667680||156774|
NCT00667693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-046|Pentax Airway Scope (AWS) Intubation|Pentax AWS Intubation Study||Outcomes Research Consortium|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|100|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667693||156773|
NCT00668850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-084-OL|Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin|A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus||Generex Biotechnology Corp.|No|Active, not recruiting|April 2008|September 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||June 2011|June 6, 2011|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00668850||156684|
NCT00668863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181151|Study Of Sunitinib With FOLFIRI In Colorectal Cancer|A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer||Pfizer|No|Completed|May 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|20 Years|N/A|No|||October 2011|October 11, 2011|April 25, 2008|Yes|Yes||No|September 2, 2011|https://clinicaltrials.gov/show/NCT00668863||156683|
NCT00669422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-206 ChemoFx® PRO Study|ChemoFx® PRO - A Post-Market Data Collection Study|ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes||Precision Therapeutics|No|Terminated|October 2006|October 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2756|Samples With DNA|Leftover tumor cells from the test and pathology slides will be collected and stored to look      for potential genetic variations related to drug pathway genes to identify patterns      associated with clinical outcome.|Female|18 Years|N/A|No|Non-Probability Sample|Approximately 3,000 patients from 150 academic and community based physicians in the        United States.        Patients have a confirmed solid tumor malignancy and their tissue specimen has been        submitted to Precision Therapeutics, Inc. as part of the patient's medical care|October 2012|October 4, 2012|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00669422||156640|
NCT00669682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC5529|T-wave Alternans and Intrathoracic Impedance Measurements|T-wave Alternans and Intrathoracic Impedance Measurements||Columbia University|No|Completed|August 2008|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Class III or IV heart failure patients|April 2013|April 11, 2013|April 28, 2008||No||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00669682||156620|
NCT00665743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-102|Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations|An Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Naproxen 500 mg Administered as PN 400 (Naproxen / Esomeprazole), as the [Active Comparator 1], or as [Active Comparator 2] in Healthy Volunteers||POZEN|No|Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2008|June 9, 2008|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665743||156923|
NCT00666055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 0708|Sex, Aging and Antiretroviral Pharmacokinetics|CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics||University of North Carolina, Chapel Hill|No|Completed|March 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|11|Samples With DNA|blood; genital secretions; genital tissue|Female|19 Years|N/A|No|Non-Probability Sample|Subjects will primarily be recruited from the UNC Infectious Disease Clinic and the Wake        County HIV Clinic.|September 2012|September 18, 2012|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666055||156899|
NCT00666367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-004755-11|Vitamin D as Treatment for Chronic Obstructive Pulmonary Disease (COPD)|High Dosis of Vitamin D as Treatment for COPD.||Katholieke Universiteit Leuven|No|Completed|January 2008|August 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|N/A|N/A|No|||October 2009|December 23, 2010|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666367||156875|
NCT00666653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|697|Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease|Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease: a Double-Blind Placebo Controlled Crossover Study|DALI|Oregon Health and Science University|Yes|Completed|July 2003|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|30 Years|80 Years|No|||April 2008|April 24, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666653||156853|
NCT00666666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00264|R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer|A Phase II Study of AT101, to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients With Newly Diagnosed Stage D2 Prostate Cancer||National Cancer Institute (NCI)|No|Completed|July 2009|June 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Male|18 Years|N/A|No|||August 2014|December 17, 2014|April 24, 2008|Yes|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00666666||156852|
NCT00666926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8031001|Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms|A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies||Verastem, Inc.|No|Completed|December 2005|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|March 26, 2008|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00666926||156832|PET and RECIST Response Analysis Sets as defined in Protocol Amendment 3 dated 20Mar2007 are reported in Basic Results per the revised definitions in Statistical Analysis Plan version 2 dated 11Apr2008.
NCT00666939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451141|A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study Of Gabapentin 100 mg and 250 mg in Transient Insomnia Induced By A Sleep Phase Advance||Pfizer|No|Completed|October 2004|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|773|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666939||156831|
NCT00667264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD Phantom Pilot|Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain|Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain||University of California, San Diego|No|Completed|October 2008|December 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667264||156806|
NCT00667563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-054|Vaccine Therapy in Preventing HPV in HIV-Positive Women in India|A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India||AIDS Malignancy Consortium|No|Completed|August 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Female|18 Years|120 Years|No|||February 2016|February 1, 2016|April 25, 2008||No||No|January 23, 2014|https://clinicaltrials.gov/show/NCT00667563||156783|
NCT00670397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 109307|Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer|Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and Stage I Carcinoma of the Oral Cavity||Roswell Park Cancer Institute|Yes|Terminated|June 2010|July 2015|Actual|November 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|120 Years|No|||March 2016|March 14, 2016|April 30, 2008|No|Yes|safety issues|No||https://clinicaltrials.gov/show/NCT00670397||156567|
NCT00670956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03705|Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)|Investigation of Prenatal Steroids for Treatment of Prenatally Diagnosed CCAMs|CCAM Steroids|University of California, San Francisco|Yes|Terminated|April 2008|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|April 30, 2008||No|Recruitment has been poor. Study drug is being offered as part of standard care of women    carrying a pregnancy diagnosed with CCAM|No|March 18, 2015|https://clinicaltrials.gov/show/NCT00670956||156524|
NCT00666588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00323|Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia|A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia||National Cancer Institute (NCI)|Yes|Completed|April 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Both|1 Year|21 Years|No|||December 2013|May 13, 2014|April 24, 2008|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00666588||156858|
NCT00667498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311026134|Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance|Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance||Yale University|No|Completed|March 2004|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||February 2009|February 16, 2009|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667498||156788|
NCT00667706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBVSSG-HMO-CTIL|Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy|Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy||Hadassah Medical Organization|No|Not yet recruiting|April 2008|||April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||April 2008|April 25, 2008|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00667706||156772|
NCT00667953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02602|Study of Temzolomide and Gleevec in Advanced Melanoma|Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma||University of Pennsylvania|No|Completed|January 2003|March 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667953||156753|
NCT00667966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11861|Assess Efficacy in Subjects With Traumatic Spinal Cord Injury|Double-blind, Cross-over, Placebo Controlled Pilot Study to Characterize the Profile of Those Patients With Spinal Cord Injury Diagnosed by Electrophysiological, Urodynamic and Clinical (ASIA Group) Assessment Who May Respond to Vardenafil Treatment. (LEMDE)|LEMDE|Bayer|No|Completed|July 2005|February 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Male|18 Years|64 Years|No|||May 2015|May 5, 2015|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667966||156752|
NCT00668330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLE-2007-007|Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus|Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment||Chinese University of Hong Kong|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|80 Years|No|||February 2012|February 10, 2012|April 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668330||156724|
NCT00668603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1030N1016|Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)|Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy: A Randomized, Placebo-controlled Prospective Study|SYMPTOM|Helsinki University|Yes|Completed|August 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Female|48 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668603||156703|
NCT00668876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|furukawa2008|Effects of Immunonutrition in Patients Undergoing Pancreaticoduodenectomy|Effects of Immunonutrition on Surgical Site Infection and Th1/Th2/Th17 Differentiation in Patients Undergoing Pancreaticoduodenectomy||Chiba University|No|Completed|May 2006|September 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Both|18 Years|75 Years|No|||October 2008|December 2, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00668876||156682|
NCT00669162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12313|Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer|A Phase I/II Trial of Post-Prostatectomy Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3NO Prostate Cancer||University of Kansas Medical Center|Yes|Active, not recruiting|August 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|85 Years|No|||September 2014|March 31, 2015|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669162||156660|
NCT00666068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L2/2003A|Effects of Corticotropin Releasing Hormone (CRH) on the Sleep in Patients With Hypopituitarism|Effects of CRH on the Sleep in Patients With Hypopituitarism||Max-Planck-Institute of Psychiatry|No|Completed|February 2008|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2011|May 11, 2011|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666068||156898|
NCT00666081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKT108169|Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies|A Phase I Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Potential Anti-cancer Activity of the AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies||GlaxoSmithKline||Withdrawn|April 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|April 22, 2008|No|Yes|Study Cancelled before enrollment|No||https://clinicaltrials.gov/show/NCT00666081||156897|
NCT00666380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14620.a|A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya|Phase 1a Open-label Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B in Healthy Malaria-Naïve Adults||U.S. Army Medical Research and Materiel Command|Yes|Completed|April 2008|June 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00666380||156874|
NCT00666679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-386|Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)|Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma||Merck Sharp & Dohme Corp.||Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|15 Years|85 Years|No|||April 2015|April 23, 2015|April 23, 2008|Yes|Yes||No|January 7, 2010|https://clinicaltrials.gov/show/NCT00666679||156851|
NCT00666952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIMDM IIG Grant 0094-1|Study Testing Patient Decision Tools Related to the Risks and Benefits of Weight Loss Surgery|Randomized Trial of a Patient Decision Aid for Bariatric Surgery|POINT of View|Group Health Cooperative|No|Completed|May 2008|January 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|20 Years|65 Years|No|||September 2009|September 10, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666952||156830|
NCT00666965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-07-003|A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients|A Placebo-Controlled Study for SPM 962 in RLS Patients||Otsuka Pharmaceutical Co., Ltd.|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|230|||Both|20 Years|79 Years|No|||March 2014|March 26, 2014|April 23, 2008||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00666965||156829|
NCT00666978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10332|Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking|Enhancing Tobacco Use Treatment for African American Light Smokers||University of Kansas Medical Center|No|Completed|December 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Actual|540|||Both|18 Years|N/A|No|Probability Sample|African Americans Smokers|October 2012|October 8, 2012|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00666978||156828|
NCT00667277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0548-00103|Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis|Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis||Icahn School of Medicine at Mount Sinai|Yes|Terminated|March 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|April 24, 2008|Yes|Yes|lack of response activity in the setting of an unacceptable toxicity profile|No|April 11, 2014|https://clinicaltrials.gov/show/NCT00667277||156805|The study was terminated due to lack of response activity in the setting of an unacceptable toxicity profile at the completion of the first stage.
NCT00667797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-921|Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects|Pharmacoeconomic Outcomes of Levalbuterol and Racemic Albuterol in Inpatients Requiring Nebulization (POLARIS)|POLARIS|Sunovion|No|Completed|March 2003|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|486|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667797||156765|
NCT00670709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QEEG and HD|Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease|Examination of Quantitative Electroencephalographic Biomarkers in Huntington's Disease: A Pilot Project|HD|University of California, Los Angeles|No|Completed|September 2006|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|42|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|30 subjects with mild or moderate Huntington's Disease and 15 healthy normal controls|February 2013|February 4, 2013|April 30, 2008||No||No|June 16, 2009|https://clinicaltrials.gov/show/NCT00670709||156543|
NCT00670722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3517|Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin|Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|6500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Type 2 diabetes|June 2012|June 26, 2012|April 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670722||156542|
NCT00670735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27896|HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)|HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)||University of Utah|No|Recruiting|April 2008|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1400|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric Hydrocephalus patients.|January 2016|January 7, 2016|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670735||156541|
NCT00667199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15305|BAY88-8223, Does Response Study in HRPC Patients|A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin®) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients||Bayer|No|Completed|May 2005|October 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Male|40 Years|N/A|No|||June 2014|June 24, 2014|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667199||156811|
NCT00667511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0010|Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™|Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™||NxStage Medical|Yes|Completed|April 2008|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|April 24, 2008|Yes|Yes||No|December 22, 2014|https://clinicaltrials.gov/show/NCT00667511||156787|
NCT00667719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAH100A2301|A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension|A 28 to 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension||Novartis|No|Completed|June 2008|||October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|564|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|April 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667719||156771|
NCT00667979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11586|Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse|A Pilot, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Vardenafil Versus Placebo Administered 12, 18 and 24 Hours Prior to Initiation of Sexual Intercourse in Subjects With ED||Bayer|No|Completed|September 2004|December 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|264|||Male|18 Years|64 Years|No|||June 2009|June 29, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667979||156751|
NCT00667992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5252C00008|Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma|A Phase 3, Randomised, Open-label, Crossover Study to Compare HFA vs CFC pMDI Formulations of Budesonide on Methacholine Hyper-reactivity in Patients With Stable, Persistent, Mild to Moderate Asthma||AstraZeneca|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|65 Years|No|||October 2012|October 9, 2012|April 23, 2008|Yes|Yes||No|May 12, 2010|https://clinicaltrials.gov/show/NCT00667992||156750|
NCT00669435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPV003DIM2008|Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis|Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients||University of Pavia|No|Recruiting|April 2008|April 2009|Anticipated|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|40 Years|80 Years|No|||April 2008|April 28, 2008|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00669435||156639|
NCT00668616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170200|Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes|Cyclophosphamid + Farmorubicin® With Subsequent Administration of Taxol® (q3w) Versus Intensified Administration of Farmorubicin® Followed by Taxol® (q2w) in the Adjuvant Treatment of Breast Cancer in Patients With 1-3 Afflicted Lymph Nodes (1-3 LK+)||North Eastern Germany Society of Gynaecologic Oncology||Completed|March 2000|July 2009|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1034|||Female|18 Years|75 Years|No|||July 2010|July 28, 2010|April 25, 2008||||No||https://clinicaltrials.gov/show/NCT00668616||156702|
NCT00665418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIBAS_UKBB_ANE_LR4|Sevoflurane and Laryngeal Reflex Responses in Pediatric Patients|Impact of High Concentrations of Sevoflurane on Laryngeal Reflex Responses in Pediatric Patients||University Hospital, Basel, Switzerland|No|Terminated|February 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|25 Months|84 Months|No|||March 2009|March 11, 2009|January 23, 2008||No|Recruitment finished earlier, because all 40 patients enrolled|No||https://clinicaltrials.gov/show/NCT00665418||156948|
NCT00665431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-309|Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis|Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee||POZEN|No|Completed|April 2008|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|610|||Both|50 Years|N/A|No|||November 2011|November 1, 2011|April 18, 2008|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00665431||156947|
NCT00665392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593027|Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery|Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV||Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Completed|February 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|75 Years|No|||August 2012|August 21, 2012|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665392||156950|
NCT00665405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP649-05|Atelectasis During Delivery - Comparing Cesarian (c) -Section and Labor|CT Study of Atelectasis After Delivery - Comparison Between Cesarian Section and Labor||University of Sao Paulo|No|Completed|July 2006|November 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hospital, obstetric division|January 2008|April 21, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665405||156949|
NCT00665730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSPRAY00406|Evaluation of the Safety and Effectiveness of Sepraspray™ in Reducing Post-surgical Adhesions|Evaluation of the Safety and Effectiveness of Sepraspray™ in Limiting the Formation of Postoperative Adhesions to Serosal Tissue (Abdominal Surgery)||Sanofi|Yes|Terminated|July 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 23, 2008|No|Yes|Study terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00665730||156924|
NCT00666094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|520073168|A Randomized Controlled Trial of Exercise Training Among Men With Type 2-diabetes|A Randomized Controlled Trial of Strength Versus Aerobic Exercise Training to Improve Glycemic Control in Men With Type 2-diabetes||Norwegian University of Science and Technology|No|Completed|August 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|35 Years|71 Years|No|||November 2014|November 25, 2014|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666094||156896|
NCT00666393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013048|An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients|An Open-Label Evaluation of Safety of the IONSYS System [Fentanyl Iontophoretic Transdermal System (40ug) for Management of Acute Post-Operative Pain in Pediatric Patients||Alza Corporation, DE, USA|No|Withdrawn|October 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Years|17 Years|No|||February 2014|February 28, 2014|April 22, 2008||No|Program Cancelled.|No||https://clinicaltrials.gov/show/NCT00666393||156873|
NCT00666692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M200-1212|A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)|Phase 1b Trial Evaluating the Safety of Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Subjects With Previously Untreated Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)||Abbott|Yes|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666692||156850|
NCT00666705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001082|A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects|An Open Label Phase 4 Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects||ViiV Healthcare|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|April 23, 2008|Yes|Yes||No|March 5, 2009|https://clinicaltrials.gov/show/NCT00666705||156849|
NCT00666991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC#11140|Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers|A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies||CritiTech, Inc.|Yes|Completed|July 2008|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|22|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00666991||156827|
NCT00667017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000594170|RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Phase II Study of IMTOX25 in Relapsed/Refractory Cutaneous T-Cell Lymphoma||National Cancer Institute (NCI)||Completed|July 2008|||February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|April 24, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00667017||156825|
NCT00667290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0098|Exercise for Elderly Peripheral Revascularized Patients|Exercise for Elderly Peripheral Revascularized Patients||National Institute on Aging (NIA)|Yes|Completed|July 2000|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|80|||Both|40 Years|90 Years|No|||April 2008|April 24, 2008|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667290||156804|
NCT00670436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPCAD-CTO V 2.3|The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions|The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions|PEPCAD-CTO|University of Ulm|No|Completed|February 2008|March 2014|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|90 Years|No|||June 2014|June 7, 2014|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670436||156564|
NCT00670449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D1201E1|An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis|An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis||Novartis||Completed|April 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|143|||Both|18 Years|60 Years|No|||June 2013|June 26, 2013|April 28, 2008||No||No|March 8, 2013|https://clinicaltrials.gov/show/NCT00670449||156563|
NCT00670761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2.1|Misoprostol for the Treatment of Incomplete Abortion|Misoprostol for the Treatment of Incomplete Abortion: Comparison of Treatment Options||Gynuity Health Projects|No|Completed|July 2004|December 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|720|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 20, 2012|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670761||156539|
NCT00668629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03734|Dermacyd Tina Gel Sweet Flower - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Tina Gel Sweet Flower.||Sanofi|No|Completed|November 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668629||156701|
NCT00668889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03737|Dermacyd Tina Gel Tangerina Mix - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Tina Gel Tangerina Mix.||Sanofi|No|Completed|November 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668889||156681|
NCT00668902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611-07|Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole|Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole||Indiana University|Yes|Completed|March 2007|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|25|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|January 17, 2008||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT00668902||156680|
NCT00669175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 01-003|Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients|Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients||Children's Mercy Hospital Kansas City|No|Completed|February 2008|June 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|30 Days|No|Probability Sample|Neonates admitted to the NICU within the first five days of life with an anticipated need        for opiate infusion for at least four days|July 2011|July 19, 2011|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00669175||156659|
NCT00669448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID H-C-2007-0088|A Pilot Trial on Effect of Mindfulness-based Cognitive Therapy for Individuals With Multiple Chemical Sensitivities (MCS)|A Pilot Trial on the Effect of Mindfulness-based Cognitive Therapy Versus "Treatment as Usual" for Individuals With Multiple Chemical Sensitivities||University Hospital, Gentofte, Copenhagen|No|Completed|April 2008|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|70 Years|No|||April 2008|August 18, 2011|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669448||156638|
NCT00669695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0721|Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin|Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin|StatinflaSAS|University Hospital, Grenoble|Yes|Terminated|May 2008|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|54|||Both|18 Years|65 Years|No|||September 2013|September 23, 2013|April 21, 2008||No|Interim analysis performed without efficient results|No||https://clinicaltrials.gov/show/NCT00669695||156619|
NCT00665444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS.WPIC.I#0008449|Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder|Reducing Medical Risks in Individuals With Bipolar Disorder: Enhancing Outcomes With Aripiprazole||University of Pittsburgh|No|Terminated|April 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||January 2016|January 14, 2016|April 21, 2008||No|The study was terminated by the sponser due to low study enrollment.|No|January 14, 2016|https://clinicaltrials.gov/show/NCT00665444||156946|
NCT00665457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|085-04|Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery|Neoadjuvant Therapy and Biomarker Analysis of Stage II and III Breast Cancer With Docetaxel/Capecitabine and Celecoxib Followed by Doxorubicin/Cyclophosphamide and Celecoxib||University of Nebraska|Yes|Completed|April 2004|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|19 Years|N/A|No|||June 2013|June 17, 2013|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665457||156945|
NCT00665470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080104|Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma|Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin||National Institutes of Health Clinical Center (CC)|Yes|Completed|April 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|April 23, 2008|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00665470||156944|
NCT00665756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLAU0037|Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves and Second Trabeculectomy in Glaucoma Patients|Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves and Second Trabeculectomy in Glaucoma Patients||Federal University of São Paulo|No|Active, not recruiting|January 2006|July 2008|Anticipated|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||April 2008|April 23, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00665756||156922|
NCT00666107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#33245|Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men|Pilot Study to Evaluate the Immunogenicity and Safety of the HPV Quadrivalent Vaccine (Gardasil) in HIV-infected Men|MIRB #862|Southern California Institute for Research and Education|No|Active, not recruiting|June 2008|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Male|18 Years|N/A|No|||November 2010|March 12, 2012|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666107||156895|
NCT00666120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3370-6|Assessment of Feeding Tolerance in Infants Fed Cow Milk Formula|Assessment of Feeding Tolerance in Infants Fed Cow Milk Formula||Mead Johnson Nutrition|No|Completed|June 2005|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|333|||Both|N/A|18 Days|Accepts Healthy Volunteers|||April 2008|April 23, 2008|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666120||156894|
NCT00666406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060601|Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A|Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A: a Phase IV, Prospective, Randomized, Controlled, Cross-over, Single Center Study||Baxalta US Inc.|No|Completed|March 2008|September 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|15 Years|60 Years|No|||February 2013|June 26, 2015|April 22, 2008||No||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00666406||156872|
NCT00666419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-UIB-23|Prevalence of Back Pain and Associated Risk Factors in 10-12 Year Old Schoolchildren|Prevalence of Back Pain and Associated Risk Factors in 10-12 Year Old Schoolchildren||Kovacs Foundation|Yes|Withdrawn|September 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|8000|||Both|10 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|All 10-12 year old schoolchildren on the island of Mallorca, Spain|June 2011|June 26, 2011|April 23, 2008||No|Recruiting at schools was slower than planned. Missing data higher than acceptable.|No||https://clinicaltrials.gov/show/NCT00666419||156871|
NCT00666718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12047|A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients|A Prospective Randomized Trial to Compare Basal Bolus Therapies That Use Either Insulin Lispro Protamine Suspension or Insulin Glargine Together With Lispro Insulin in Patients With Type 2 Diabetes||Eli Lilly and Company|No|Completed|April 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|374|||Both|18 Years|N/A|No|||May 2011|May 11, 2011|April 23, 2008|Yes|Yes||No|February 18, 2011|https://clinicaltrials.gov/show/NCT00666718||156848|
NCT00667004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-S&E-1107071-P|Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease|||Bausch & Lomb Incorporated|No|Completed|April 2008|||December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667004||156826|
NCT00667303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTRV|Prospective Surveillance For Respiratory Virus Infections In Children Undergoing Hematopoietic Stem Cell Transplantation|Prospective Surveillance For Respiratory Virus Infections In Children Undergoing Hematopoietic Stem Cell Transplantation||St. Jude Children's Research Hospital|No|Completed|December 2007|August 2012|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|51|Samples Without DNA|Nasopharyngeal washes Fluorescent antibody detection Respiratory viral culture|Both|N/A|18 Years|No|Probability Sample|Children, birth to 18 years old, within the first 100 days of a hematopoietic stem cell        transplant who are either asymptomatic, or symptomatic with an upper respiratory tract        infection (URTI) or a lower respiratory tract infection (LRTI).|September 2012|September 6, 2012|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667303||156803|
NCT00667316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-I-25|The Influence of Different Factors on Workers' Disability Due to Low Back Pain|Study to Identify the Influence of Different Factors on Workers' Disability Due to Low Back Pain||Kovacs Foundation|Yes|Recruiting|February 2008|September 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|7200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Workers from companies and workers' health care organizations who are currently active.|March 2014|March 11, 2014|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667316||156802|
NCT00667823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-303|Long-term Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension|Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension|SERAPHIN OL|Actelion|Yes|Active, not recruiting|October 2008|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|550|||Both|12 Years|N/A|No|||October 2015|October 27, 2015|April 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667823||156763|
NCT00668135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10657|Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia|Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia||Bayer|No|Completed|March 2003|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|348|||Male|20 Years|65 Years|No|||December 2014|December 15, 2014|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668135||156739|
NCT00667576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-309|Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis|Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose)||Abbott|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|153|||Both|20 Years|N/A|No|||January 2012|January 18, 2012|April 24, 2008||No||No|March 18, 2010|https://clinicaltrials.gov/show/NCT00667576||156782|Different PTH thresholds were applied for suspending study drug: paricalcitol groups <60 pg/mL, maxacalcitol group ≤150 pg/mL. This study was not statistically powered to compare treatments.
NCT00667589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU2149|Sorafenib-induced Hand- Foot Skin Reaction Treatment|Four-arm Study to Evaluate Urea 40% Cream, Fluocinonide 0.05% Cream, Tazarotene 0.1% Cream, and an Emollient Cream for the Treatment of Hand-foot Skin Reaction Related to the Use of Multi-targeted Tyrosine Kinase Inhibitor Sorafenib.||Northwestern University|No|Terminated|June 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|April 24, 2008|Yes|Yes|Study was halted due to poor subject accrual.|No|February 26, 2013|https://clinicaltrials.gov/show/NCT00667589||156781|
NCT00670462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0402S56276|Maintenance-Tailored Obesity Treatment|Maintenance-Tailored Obesity Treatment|LIFE|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|October 2004|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 12, 2014|April 30, 2008||No||No|November 12, 2014|https://clinicaltrials.gov/show/NCT00670462||156562|
NCT00670748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080121|Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer|Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 2008|September 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|66 Years|No|||July 2015|August 12, 2015|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670748||156540|
NCT00670774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007208|Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant|A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in Positive Crossmatch Living Donor Kidney Transplantation||Mayo Clinic|Yes|Active, not recruiting|March 2008|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|April 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670774||156538|
NCT00666887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant ID # 21569|Minocycline in Clinically Isolated Syndromes (CIS)|A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)|MinoCIS|University of Calgary|Yes|Completed|January 2009|July 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|142|||Both|18 Years|60 Years|No|||July 2015|July 13, 2015|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666887||156835|
NCT00666900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-IDP-107-P2-01|A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris|A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules||Dow Pharmaceutical Sciences|No|Completed|January 2008|September 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|366|||Both|12 Years|N/A|No|||February 2012|February 16, 2012|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666900||156834|
NCT00667212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15143A|Psychotherapy for Intermittent Explosive Disorder|Individual Cognitive Behavioral Psychotherapy for Intermittent Explosive Disorder||University of Chicago|Yes|Completed|August 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|No|||December 2010|June 11, 2013|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667212||156810|
NCT00668642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH07-109|Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer|Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer||NorthShore University HealthSystem Research Institute|Yes|Completed|March 2007|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|N/A|No|||February 2014|February 13, 2014|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00668642||156700|
NCT00668915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rehabtjr-HMO-CTIL|Arthroplasty Rehabilitation Score - Can we Predict the Short Term Postoperative Outcome?|Arthroplasty Rehabilitation Score - Can we Predict the Short Term Postoperative Outcome?||Hadassah Medical Organization|No|Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing primary arthroplasty|April 2008|April 28, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00668915||156679|
NCT00669188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080122|Patient Provider Communication and Interaction in a Virtual Clinical Setting|Patient-Provider Communication and Interaction in a Virtual Clinical Setting||National Institutes of Health Clinical Center (CC)||Completed|April 2008|December 2013|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|1||Actual|208|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00669188||156658|
NCT00669461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78055|Lubiprostone as a Treatment for Constipation in Parkinson's Disease|Lubiprostone as a Treatment for Constipation in Parkinson's Disease||University of Arkansas|No|Terminated|June 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|50 Years|85 Years|No|||April 2012|April 16, 2012|April 28, 2008||No|Lack of recruitment|No|October 25, 2011|https://clinicaltrials.gov/show/NCT00669461||156637|Early termination leading to small numbers of subjects analyzed
NCT00669708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST-Pr-12-2007|Topical Therapy With Cooling Effect in Dry Itchy Skin|kühlender Effekt Der Eucerin pH5 Lotion Und Der Eucerin pH5 Lotion Mit Cooling Compound Bei Trockener, Juckender Haut||University Hospital Muenster|No|Completed|April 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00669708||156618|
NCT00665483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0205PR|Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.|Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a 6-grass Pollen Mixture, House Dust Mite (Dermatophagoides Pteronyssinus), Birch Pollen, and Mugwort Pollen||Allergopharma GmbH & Co. KG|No|Completed|March 2007|November 2010|Actual|September 2007|Actual|Phase 4|Interventional|N/A|1||||||Both|18 Years|60 Years|No|||November 2013|November 7, 2013|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665483||156943|
NCT00665496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100492|A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction|A Randomized, Double Blind, Double Dummy, Parallel Group, Multi-center Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction.||Bayer|No|Completed|June 2003|November 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|732|||Male|18 Years|N/A|No|||December 2014|December 15, 2014|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665496||156942|
NCT00665769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31475|Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage|Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage|PhysDis|Baylor University|Yes|Terminated|June 2008|September 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|N/A|7 Days|No|||January 2016|January 12, 2016|April 22, 2008|Yes|Yes|Recruitment was proceeding too slowly|No||https://clinicaltrials.gov/show/NCT00665769||156921|
NCT00665782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97307|Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast|Stress Measures in Women With Newly Diagnosed Breast Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|March 2008|||July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|24|||Female|18 Years|120 Years|No|Non-Probability Sample|Those diagnosed with stage I-III invasive breast cancer or ductal carcinoma in situ of the        breast within the past 2 weeks|October 2015|October 22, 2015|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00665782||156920|
NCT00666432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043960|Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes|Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes||University of Maryland|Yes|Active, not recruiting|May 2008|September 2016|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Family-Based||3|Anticipated|3500|Samples With DNA|Blood or saliva will be stored for future genetic analysis.|Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the University of Maryland, Community Mental Health Center        and Private Psychiatrists.|November 2015|November 30, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00666432||156870|
NCT00666445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADG-08-01|Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test|Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test: AD Template Development Study||Orasi Medical, Inc.|No|Completed|April 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be referred from dementia/Alzheimer's Disease clinical patients at study        sites.|August 2010|August 12, 2010|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666445||156869|
NCT00666731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311-06|A Breast Cancer Information Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer|Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)|BCCR|University of Nebraska|No|Recruiting|October 2006|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|999999|Samples With DNA|Tissue, blood|Both|19 Years|120 Years|No|Non-Probability Sample|1. Adult individuals (male and female) who have a personal diagnosis/history of breast             cancer, atypical hyperplasia, ductal carcinoma in situ (DCIS) or lobular carcinoma in             situ (LCIS) (as stated in the NCCN Breast and/or Ovarian Genetic Assessment             Guidelines v.1.2006 (Appendix A)          2. Adult individuals who have characteristics of hereditary breast cancer, as defined in             the NCCN Breast and/or Ovarian Genetic Assessment Guidelines v.1.2006 (Appendix A) or             who have a breast cancer risk of > 1.67% over 5 years as estimated by GAIL Model             (Appendix C )          3. Age 19 or greater          4. Able to provide informed consent|November 2015|November 30, 2015|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00666731||156847|
NCT00667030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041199|Aging, Lifestyle and Inflammation in Veterans Exercising|Aging, Lifestyle and Inflammation in Veterans Exercising|ALIVE|University of Maryland|Yes|Active, not recruiting|July 2005|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 15, 2013|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00667030||156824|
NCT00667602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P22|Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers|A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers||Novartis||Completed|March 2008|October 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|662|||Both|6 Months|8 Months|Accepts Healthy Volunteers|||September 2013|September 3, 2013|April 24, 2008|Yes|Yes||No|February 18, 2013|https://clinicaltrials.gov/show/NCT00667602||156780|GCP compliance issues were identified at one site, data collected for this site were not used in this data posting.
NCT00667836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00023261|Multi-Center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients|Multi-Center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients||Shriners Hospitals for Children|No|Recruiting|March 2006|September 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|3 Years|18 Years|No|Probability Sample|All NF1 patients|April 2008|April 24, 2008|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667836||156762|
NCT00668148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13925|A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma|A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET||ImClone LLC|No|Completed|July 2008|February 2012|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|12 Years|N/A|No|||September 2011|May 8, 2012|April 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00668148||156738|
NCT00670475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/86010|Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee|Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee||Ardabil University of Medical Sciences|Yes|Completed|April 2008|April 2010|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|85 Years|No|||April 2010|April 28, 2010|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670475||156561|
NCT00670787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 19041|Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial|A Randomized Trial to Establish the Effects of Combination Pill of Losartan Potassium and Hydrochlorothiazide on Medication Compliance Among Patients With High Blood Pressure.|COMFORT|Kyushu University|Yes|Completed|June 2008|February 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|20 Years|N/A|No|||March 2011|March 4, 2011|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670787||156537|
NCT00671008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1964|Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes|Efficacy of Glycaemic Control of Biphasic Insulin Aspart (NovoMix® 30) or Insulin Detemir (Levemir®) in Patients With Type 1 or 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|December 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|N/A|N/A|No|Non-Probability Sample|Type 1 and Type 2 Diabetes Mellitus|March 2016|March 2, 2016|April 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671008||156520|
NCT00668343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/9388|Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo||irmsrct|Tehran University of Medical Sciences|Yes|Completed|April 2005|March 2009|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|15 Years|60 Years|No|||July 2010|July 29, 2010|April 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00668343||156723|
NCT00668356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080101|Bioequivalence Study of Didanosine in Children Treated for HIV|PKPOP Study of Didanosine in HIV Treated Children, at Fasting Period and During the Meal|ddI|Assistance Publique - Hôpitaux de Paris|No|Suspended|September 2009|December 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|6 Years|15 Years|No|||January 2009|February 6, 2009|April 25, 2008||No|questions of the benefit efficacy/risks of ddI during the meal not resolved|No||https://clinicaltrials.gov/show/NCT00668356||156722|
NCT00668655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10086|An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%|An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%||Galderma Laboratories, L.P.|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Female|20 Years|75 Years|No|Non-Probability Sample|Community Sample|September 2012|September 11, 2012|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668655||156699|
NCT00668668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03733|Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Sweet Flower|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Tina Gel Sweet Flower.||Sanofi|No|Completed|December 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|52|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668668||156698|
NCT00668928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-252|Effect of Dietary Polyphenols on Insulin Sensitivity|Effect of Dietary Polyphenols on Insulin Sensitivity||USDA Beltsville Human Nutrition Research Center|Yes|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 28, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00668928||156678|
NCT00669201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-4912-IE-CTIL|Wrist Cartilage - High Resolution in Vivo MR T2 Mapping- a Feasibility Study|Wrist Cartilage - High Resolution in Vivo MR T2 Mapping- a Feasibility Study||Sheba Medical Center|No|Recruiting|December 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers, volunteers with known osteoarthritis, routine MR population for wrist        investigation|April 2008|April 29, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669201||156657|
NCT00669214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD4412n|A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp|A Phase IV Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp|SCALP|Genentech, Inc.||Completed|February 2008|||January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|April 28, 2008|Yes|Yes||No|August 24, 2010|https://clinicaltrials.gov/show/NCT00669214||156656|Since the completion of this study, efalizumab has been voluntarily withdrawn from the U.S. market because of a safety issue.
NCT00669474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/219|Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.|Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.||University Hospital, Ghent|No|Terminated|June 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|75 Years|No|||June 2015|June 3, 2015|April 28, 2008||No|Study never started|No||https://clinicaltrials.gov/show/NCT00669474||156636|
NCT00669721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LWH-INT-79|OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis|Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients||St. Orsola Hospital|Yes|Recruiting|March 2008|June 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2008|April 28, 2008|April 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669721||156617|
NCT00669734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03111|Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery|Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)||National Cancer Institute (NCI)||Active, not recruiting|February 2010|||November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||October 2015|December 7, 2015|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00669734||156616|
NCT00665821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-S-24|The Effect of Two Short Education Programs for Nonspecific Low Back Pain in a Workers' Health Care Organization|Study of the Effect of Two Short Education Programs for the Treatment of Nonspecific Low Back Pain in Patients Seen at a Workers' Health Care Organization||Kovacs Foundation|Yes|Terminated|September 2008|February 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Anticipated|657|||Both|18 Years|65 Years|No|||May 2009|May 14, 2009|April 23, 2008||No|From Sept./08 to April/09 only 30 subjects were recruited. It has proved extremely difficult    to recruit subjects.|No||https://clinicaltrials.gov/show/NCT00665821||156917|
NCT00665834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED 938-06|Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome|Comparison of the Effect Noted in The Apo/Apo-1 Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome CENTAURUS Study||Queen's University|Yes|Completed|April 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|75 Years|No|||April 2008|April 23, 2008|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665834||156916|
NCT00665795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1152/05|Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy|Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.||University of Sao Paulo|No|Completed|July 2005|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|80|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with Graves´ orbitopathy|November 2013|November 17, 2013|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00665795||156919|
NCT00665808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1951|Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany|Insulin Detemir (Levemir®) Versus Isophane (NPH) Insulin (Protaphane®) in Combination With Oral Antidiabetic Agents (OAD) in Patients With Diabetes Mellitus Type 2 Comparing Treatment Satisfaction, Diabetes-related and General Health-related Quality of Life, as Well as Diabetes-control||Novo Nordisk A/S|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|8125|||Both|N/A|N/A|No|Non-Probability Sample|Patients willing and able to give signed informed consent; Patients with Type 2 diabetes        mellitus; Patients, who should intensify treatment with long acting insulin in addition to        their treatment with oral antidiabetic agents, due to insufficient blood glucose control;        Patients with no regular use of short acting insulin (occasional use for correction is        allowed); Patients with no contraindication for use of Protaphane® or Levemir®|June 2012|June 26, 2012|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665808||156918|
NCT00666744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/19|A Randomised Controlled Trial of Family Mediated Exercises (FAME) Following Stroke|A Randomised Controlled Trial of Family Mediated Exercises (FAME) Following Stroke|FAME|University of Dublin, Trinity College|No|Recruiting|April 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2008|October 28, 2008|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666744||156846|
NCT00667043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPI 07 001|Remifentanil and Propofol Versus Fentanyl and Midazolam for Sedation During Therapeutic Hypothermia. A Randomised, Controlled Trial|Remifentanil and Propofol Versus Fentanyl and Midazolam for Sedation During Therapeutic Hypothermia. A Randomised, Controlled Trial|Cool Sedation|Norwegian University of Science and Technology|No|Completed|April 2008|June 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00667043||156823|
NCT00667056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-04-001|Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis||Astellas Pharma Inc|No|Completed|July 2004|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|17 Years|N/A|No|||September 2014|September 17, 2014|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667056||156822|
NCT00667329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM99-070|Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab|Primary Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab||M.D. Anderson Cancer Center|No|Active, not recruiting|July 1999|||July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||September 2015|September 8, 2015|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667329||156801|
NCT00667615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-045|Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)|A Multi-Center Phase I/II Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2008|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|60 Years|N/A|No|||March 2016|March 7, 2016|April 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00667615||156779|
NCT00667862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589C2208|Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer|A Phase II, Open Label, Single Arm Study of i.v. Panobinostat (LBH589) in Patients With Metastatic Hormone Refractory Prostate Cancer||Novartis||Completed|April 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Male|18 Years|N/A|No|||May 2013|May 10, 2013|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00667862||156760|
NCT00668174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATH - CA/AG69334-01A2,|Effect of Exercise on Sex Hormones in Postmenopausal Women|Physical Activity and Total Health Trial||Fred Hutchinson Cancer Research Center|Yes|Completed|January 1997|December 2004|Actual|December 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|173|||Female|50 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668174||156736|
NCT00668161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPEAL CA77572-01|Effect of Exercise on Biomarkers of Colon Cancer Risk|Exercise Intervention Trial for Colorectal Polyp Patients|APPEAL|Fred Hutchinson Cancer Research Center|Yes|Completed|January 2001|February 2005|Actual|December 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|202|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668161||156737|
NCT00670488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206-002|Dose Escalation Study With MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors (2206-002)|A Phase I Dose Escalation Study of Oral MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|April 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670488||156560|
NCT00670501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|547|Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis|Effects of LY333334 in the Treatment of Postmenopausal Women With Osteoporosis||Eli Lilly and Company|Yes|Completed|August 1996|April 1999|Actual|April 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1637|||Female|30 Years|85 Years|No|||April 2008|April 29, 2008|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670501||156559|
NCT00671333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-060|PRCT: Ligament Reconstruction & Tendon Interposition With a Joint Spacer for Trapeziometacarpal OA|A Randomized Prospective Study Comparing Ligament Reconstruction and Tendon Interposition (LRTI) With a Joint Spacer (Ascension PyroDisk) for Trapeziometacarpal Osteoarthritis.|TMC/PyroDisk|Simon Fraser Orthopaedic Fund|No|Recruiting|April 2008|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|50 Years|N/A|No|||May 2015|May 19, 2015|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671333||156496|
NCT00668369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Weaning_HCV|Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation|Effect of Immunosuppression Drug Weaning on Hepatitis C Virus Induced Liver Damage After Liver Transplantation.||Hospital Clinic of Barcelona|No|Completed|April 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|75 Years|No|||December 2013|December 19, 2013|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668369||156721|
NCT00668681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo060234|Evaluation of EndoRefix Endovascular Delivery System and Staple|Safety Data Collection for Delivery System and Use of Staple in Endovascular Procedures|EndoRefix|Lombard Medical|No|Withdrawn|April 2008|February 2009|Anticipated|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|N/A|No|||October 2012|October 15, 2012|April 25, 2008|Yes|Yes|Company business decision, IDE closed, no commercialization planned|No||https://clinicaltrials.gov/show/NCT00668681||156697|
NCT00668694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-040|Iron Deficiency Anemia and Psychosocial Stimulation|Effect of Psychosocial Stimulation on Development of Iron-deficient Anemic Infants: A Randomized Controlled Trial|IDA|International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|October 2007|September 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|424|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||April 2008|July 11, 2011|April 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00668694||156696|
NCT00668941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AR056651-01A2, 5RO1 ARO5|Cyclic Versus Daily Teriparatide on Bone Mass|Cyclic Versus Daily Teriparatide on Bone Mass||Helen Hayes Hospital|No|Active, not recruiting|September 2005|November 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|140|||Female|45 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|April 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00668941||156677|
NCT00669227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAMI 01-04|Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction (SCAMI)|Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction - A Randomized, Double-blind, Placebo Controlled Trial (SCAMI)|SCAMI|University of Ulm|No|Completed|October 2005|||January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|35 Years|75 Years|No|||June 2014|June 7, 2014|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669227||156655|
NCT00669760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muko e.V. S05/07|Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients|Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients, a Non-interventional, Prospective, Longitudinal Multicenter Study.|StaphCI|University Hospital Muenster|No|Completed|July 2008|January 2015|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|195|None Retained|Sera|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|CF-patients with persistent S. aureus culture in their airway specimens|January 2015|January 6, 2015|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00669760||156614|
NCT00669747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIS-WHM-703M|Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)|A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ||Windy Hill Medical, Inc.|No|Recruiting|May 2008|December 2009|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Female|18 Years|N/A|No|||October 2008|October 1, 2008|April 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00669747||156615|
NCT00666159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-02-005|Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis|A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis||Astellas Pharma Inc|No|Completed|December 2002|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|226|||Both|2 Years|16 Years|No|||September 2014|September 17, 2014|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00666159||156891|
NCT00666172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080108|Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women|Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women||National Institutes of Health Clinical Center (CC)||Completed|April 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|270|||Female|18 Years|N/A|No|||August 2015|August 19, 2015|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00666172||156890|
NCT00666133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2.1|Treatment Approaches for Preeclampsia in Low-Resource Settings|Treatment Approaches for Preeclampsia in Low-Resource Settings||Gynuity Health Projects|No|Completed|April 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|304|||Female|18 Years|N/A|No|||December 2009|December 8, 2009|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00666133||156893|
NCT00666146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042566|Familial Schizophrenia and Spectrum Personality Disorders|Familial Schizophrenia and Spectrum Personality Disorders||University of Maryland|Yes|Active, not recruiting|July 2004|December 2015|Anticipated|July 2010|Actual|N/A|Observational|Observational Model: Family-Based||3|Actual|539|Samples With DNA|Blood sample for DNA extraction|Both|16 Years|58 Years|Accepts Healthy Volunteers|Non-Probability Sample|University of Maryland, Baltimore: Enrolling by Invitation|March 2015|March 3, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00666146||156892|
NCT00666757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11715|A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression|TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode|TRY FIRST|Eli Lilly and Company|No|Completed|May 2008|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|750|||Both|18 Years|N/A|No|||May 2010|May 12, 2010|April 23, 2008|Yes|Yes||No|February 16, 2010|https://clinicaltrials.gov/show/NCT00666757||156845|
NCT00666770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451139|A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance||Pfizer|No|Completed|October 2004|November 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|309|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|April 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00666770||156844|
NCT00667069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577485|Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer|Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk.||National Cancer Institute (NCI)||Recruiting|December 2007|||December 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|718|||Male|18 Years|N/A|No|||April 2008|February 6, 2009|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00667069||156821|
NCT00667342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS2008|A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma|A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma||St. Jude Children's Research Hospital|Yes|Active, not recruiting|May 2008|April 2018|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Both|N/A|30 Years|No|||September 2015|September 11, 2015|April 24, 2008|Yes|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT00667342||156800|Accrual to this study was stopped early after 4.5 years due to slow accrual of participants. No eligible participants were enrolled on Stratum B. All enrolled participants continue on study and results will be reported when available.
NCT00667628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC101-203|Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma||Taiho Oncology, Inc.|No|Terminated|April 2008|April 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|20 Years|N/A|No|||June 2013|June 4, 2013|April 24, 2008|Yes|Yes|Terminated due to safety concerns.|No||https://clinicaltrials.gov/show/NCT00667628||156778|
NCT00667849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-TIB-0907|Trial to Evaluate UltraSound in the Treatment of Tibial Fractures|Trial to Evaluate UltraSound in the Treatment of Tibial Fractures|TRUST|Bioventus LLC|Yes|Terminated|September 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|501|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|April 21, 2008|Yes|Yes|Study was terminated due to futility|No|September 24, 2015|https://clinicaltrials.gov/show/NCT00667849||156761|Poor Compliance: Protocol defined compliance as ≥18 minutes use per day. Devices have a treatment monitor that showed average compliance of 42.3% (sham) and 44.6% (active) in 80% of treatment days. Poor treatment adherence confounds results.
NCT00668200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446K2401|Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®|Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation||Novartis||Completed|May 2008|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|N/A|N/A|No|||February 2015|February 17, 2015|April 22, 2008|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00668200||156734|
NCT00668213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060471|Antioxidant Systems and Age-Related Macular Degeneration|Antioxidant Systems and Age-Related Macular Degeneration||Vanderbilt University|No|Completed|June 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|143|Samples Without DNA|Blood serum|Both|55 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Subjects at risk of macular degeneration|January 2014|January 8, 2014|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00668213||156733|
NCT00668187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801M24964|A Natural History Study of the Gangliosidoses|A Natural History Study of the Gangliosidoses||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2010|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|52|||Both|N/A|N/A|No|Non-Probability Sample|Any infant or juvenile with Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis;        and any adult with a late-onset gangliosidosis disease|March 2016|March 4, 2016|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668187||156735|
NCT00668512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM200701|Intratumoral Injection Of Alpha-Gal Glycosphingolipids|Phase I Study To Evaluate The Toxicity And Feasibility Of Intratumoral Injection Of Alpha-Gal (Beta-galactosidase ) Glycosphingolipids In Patients With Advanced Melanoma||University of Massachusetts, Worcester|Yes|Completed|March 2007|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|75 Years|No|||March 2015|March 17, 2015|April 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00668512||156710|
NCT00671034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL07P4|Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia|A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase, IND# 100594) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|Yes|Active, not recruiting|July 2008|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|2 Years|30 Years|No|||March 2015|March 3, 2015|May 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671034||156518|
NCT00671346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD-17895|NORVIT and WENBIT - Long-term Follow-up|Combined Analyses and Long-term Follow-up in the Two Norwegian Homocysteine-Lowering B-Vitamin Trials NORVIT and WENBIT|NORVITWENBIT|Haukeland University Hospital|No|Active, not recruiting|December 1998|January 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|6839|||Both|27 Years|86 Years|No|Probability Sample|The study population for combined analyses consists of the of 3 749 + 3 090 = 6 839 men        and women aged 27 - 86 years when randomised in the NORVIT and WENBIT trials between        December 1998 and April 2004. All patients in NORVIT were randomised following an acute        myocardial infarction, whereas patients in WENBIT were randomised following coronary        angiography, of which 85% had stable angina pectoris, 10% had acute myocardial infarction        and 5% had unstable angina pectoris at baseline.|November 2015|November 4, 2015|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00671346||156495|
NCT00668382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM200702|Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection|Phase I Study To Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection Of Alpha-Gal Glycosphingolipids In Patients With Advanced Or Refractory Solid Tumors||University of Massachusetts, Worcester|Yes|Completed|July 2007|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|75 Years|No|||May 2013|May 10, 2013|April 25, 2008|No|Yes||No|October 25, 2012|https://clinicaltrials.gov/show/NCT00668382||156720|No allergic/immune toxicity. The single toxicity/AE was bacterial infection with UGI flora at injection site following EUS (endoscopic ultra-sound) guided injection of pancreatic cancer. Added injections covered with antibiotic prophylaxis.
NCT00668395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010002585 / 0704-14|Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics|Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics, Autoinduction and Drug Interactions in Healthy Volunteers.||Indiana University|Yes|Completed|May 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|73|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|November 27, 2007||No||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00668395||156719|
NCT00668954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0878|Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus|Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus Following a Glucose Load||University of Colorado, Denver|No|Completed|April 2008|November 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|26|||Both|35 Years|70 Years|No|||July 2015|July 29, 2015|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00668954||156676|
NCT00669240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051085|Varenicline Observational Investigation In The Cessation of Smoking|Champix Observational Investigation In The Cessation of Smoking|CHOICES|Pfizer|No|Completed|November 2007|August 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|567|||Both|18 Years|N/A|No|Non-Probability Sample|The patients enrolled should be of legal adult age who regularly smoke and of which the        main tobacco product is cigarettes. The patients must be willing to make an attempt to        stop smoking.        All patients enrolled should meet the usual prescribing criteria for varenicline as per        SmPC and should be entered into the trial at the Investigators discretion.|June 2015|June 30, 2015|April 25, 2008|No|Yes||No|June 7, 2010|https://clinicaltrials.gov/show/NCT00669240||156654|
NCT00669253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/189|Treatment of Periodontitis Using Er:YAG Laser vs. Conventional Treatment Modalities|Randomized Controlled Trial to Evaluate the Efficacy of Er:YAG Laser and Surgical Therapy in Treatment of Chronic Periodontitis||University Hospital, Ghent|No|Completed|June 2008|December 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Both|35 Years|N/A|No|||December 2014|December 4, 2014|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00669253||156653|
NCT00669487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH003|A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP|||South East Asia Research Collaboration with Hawaii|Yes|Completed|April 2008|April 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|April 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00669487||156635|
NCT00669773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR08/34/06|Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient|Phase 2 Randomized Study of Adriamycin & Docetaxel in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor to Validate Gene Expression & Proteomic Signatures Predictive of Treatment Response||National University Hospital, Singapore||Active, not recruiting|February 2007|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Female|18 Years|N/A|No|||December 2013|December 8, 2013|April 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00669773||156613|
NCT00665522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013201|A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)|A Prospective Safety Surveillance Study of IONSYS (Fentanyl HCl)||Alza Corporation, DE, USA|No|Terminated|December 2007|September 2008|Actual|September 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|218|||Both|18 Years|N/A|No|Probability Sample|Approximately 3,000 patients who have scheduled surgery and need treatment of acute        moderate to severe post-operative pain and are treated with fentanyl HCl 40 mcg system in        the hospital setting will be evaluated. In addition, a group of approximately 1,500        patients treated with opioid intravenous patient-controlled analgesia (IV PCA) will be        matched to fentanyl HCl 40 mcg system patients with respect to (1) country (match will        first be sought within the same research center, and extended to patients in the same        country if no match is found), (2) pre-surgical physical condition and (3) surgery risk        (high risk versus low risk). Patients at multiple research centers in multiple countries        will be included.|April 2015|April 9, 2015|April 22, 2008||No|Study was terminated at the request of the company due to the recall of marketed product in    Europe.|No||https://clinicaltrials.gov/show/NCT00665522||156940|
NCT00665509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201.3.127|Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2008/2009. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects||Solvay Pharmaceuticals|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 12, 2008|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00665509||156941|
NCT00666185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-7-005|Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis|A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis||Astellas Pharma Inc||Completed|August 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|523|||Both|16 Years|N/A|No|||September 2014|September 17, 2014|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00666185||156889|
NCT00666198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481263|Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)|Special Investigation For Long-term Use Of Revatio (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|May 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3337|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A1481263 prescribes the SILDENAFIL(Revatio).|August 2015|August 3, 2015|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00666198||156888|
NCT00666458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00002|18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)|18-wk, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Comparison With Sitagliptin in Combination With Metformin in Adult Patients With T2D Who Have Inadequate Glycaemic Control on Metformin Alone||AstraZeneca|Yes|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|822|||Both|18 Years|N/A|No|||March 2010|March 5, 2010|April 23, 2008||No||No|March 5, 2010|https://clinicaltrials.gov/show/NCT00666458||156868|
NCT00665340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11561|Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)|A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction.||Bayer||Completed|July 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Male|18 Years|64 Years|No|||October 2013|October 10, 2013|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665340||156954|
NCT00661024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN/501/ZKL/L|Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves in Thyroid Surgery|Randomized Clinical Trial Evaluating Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves in Thyroid Surgery||Jagiellonian University|Yes|Completed|January 2006|April 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1000|||Both|18 Years|80 Years|No|||April 2008|April 17, 2008|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661024||157285|
NCT00672854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007587|Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in Intensive Care Unit Patients|StudyComparing a Soybean Oil-Based vs Olive Oil-Based Lipid Emulsion: Effects on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function,Insulin Sensitivity and Carb Metabolism Intensive Care Unit Patients|TPN 2|Emory University|Yes|Completed|November 2008|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||July 2014|July 2, 2014|April 18, 2008|Yes|Yes||No|July 2, 2014|https://clinicaltrials.gov/show/NCT00672854||156383|
NCT00672841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003161|β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients|Randomized Comparison of β-D-Glucan Surveillance With Preemptive Anidulafungin Versus Standard Care for the Management of Invasive Candidiasis in Surgical Intensive Care Unit Patients||Duke University|Yes|Completed|June 2008|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2012|January 20, 2015|May 4, 2008|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00672841||156384|This study represents a 1st attempt at preemptive antifungal therapy based on the fungal biomarker 1,3-Beta-D-Glucan in the intensive care unit. Main limitation: the small number of subjects with proven/probable invasive candidiasis.
NCT00672867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-FMAU-309|A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B|A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B||Bukwang Pharmaceutical||Completed|December 2007|September 2014|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||July 2012|December 17, 2014|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672867||156382|
NCT00673413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X12605|The Perception of the Estomy-Individual Regarding of Its Situation|The Perception of the Estomy-Individual Regarding of Its Situation||Universidade da Regiao da Campanha|No|Completed|September 2006|September 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|18 Years|80 Years|No|Non-Probability Sample|Patients Estomizados of a group of visitors to estomizados support from the Center for        Pharmaceutical Assistance at the University of the Region Campaign.|May 2008|May 5, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673413||156340|
NCT00673686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91377|Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D|Single Center, Double-blind, Randomized Study to Compare the Effect of SH T 00186 D on Follicular Development in a 24-day Regimen Versus a 21-day Regimen in Healthy Female Volunteers||Bayer|No|Completed|May 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673686||156319|
NCT00673699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY-07/2008|The Role of Narrow-Band Imaging Endoscopy in Diagnosing Gastric Intestinal Metaplasia|Observational: Studies in Human Beings Health Outcomes||Hillel Yaffe Medical Center|Yes|Not yet recruiting|May 2008|February 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Gastric mucosal biopsy during upper gastrointestinal endoscopy|Both|18 Years|75 Years|No|Non-Probability Sample|Hundred consecutive dyspeptic patients|May 2008|May 5, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673699||156318|
NCT00674011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-149|Hypertension in Breast Cancer Patients Receiving Bevacizumab|A Pilot Study of Hypertension in Breast Cancer Patients Receiving Bevacizumab||Dana-Farber Cancer Institute|No|Terminated|January 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically or cytologically confirmed breast cancer who will be starting        treatment with bevacizumab and chemotherapy.|May 2014|May 5, 2014|May 6, 2008||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00674011||156294|
NCT00674297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 28005|Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients|Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients||Hospital for Special Surgery, New York|Yes|Active, not recruiting|May 2008|||July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|65 Years|No|||February 2013|February 3, 2013|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674297||156272|
NCT00653588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0106|Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks|A 26-Week, Double Blind, Randomised, Multi-Centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin (40 mg) With Atorvastatin (80 mg) in Subjects With Hypercholesterolaemia and Coronary Heart Disease or CHD Risk Equivalents|POLARIS|AstraZeneca|No|Completed|April 2003|September 2004|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|45 Years|75 Years|No|||March 2009|March 13, 2009|April 2, 2008||||No||https://clinicaltrials.gov/show/NCT00653588||157854|
NCT00653887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/054/HP|Biofeedback and Cortical Excitability|Modifications of the Anal Muscle Cortical Excitability Area After Biofeedback Training|Biofeedback|University Hospital, Rouen|Yes|Terminated|January 2008|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|April 2, 2008||No|Procedure needs to be changed|No||https://clinicaltrials.gov/show/NCT00653887||157831|
NCT00653900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013820|Platelet Function Testing Help and Intraoperative Bleeding Risk for Patients Who Are on Plavix Prior to Surgery|Does Platelet Function Testing Help us Assess Intraoperative Bleeding Risk in Cardiac and Vascular Surgery for Patients Who Are on Plavix Prior to Admission?||Cedars-Sinai Medical Center|No|Recruiting|April 2008|April 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|1 drop of blood for the "verify now" test, which is done before the procedure.|Both|18 Years|N/A|No|Non-Probability Sample|Participants will be those patients who are taking plavix and are undergoing vascular or        cardiac surgery.|April 2008|April 2, 2008|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00653900||157830|
NCT00672269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-451|Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors|A Pilot Study to Investigate Germ-Line MEN1 and SDHD Gene Mutation in Familial Cases of Carcinoid Cancer||Rutgers University|No|Recruiting|April 2008|June 2010|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Blood: a small sample of 2 tubes (2 - 4 teaspoons, or 20 ml). One tube will be used to      prepare the DNA (your genetic material) for the test. The other would be used for further      gene evaluation. The DNA will be stored with Rutgers University Cell and DNA Repository      (RUCDR).|Both|12 Years|N/A|No|Probability Sample|Individuals with carcinoid cancer that report to have a first-degree family member also        with carcinoid tumor|February 2009|February 3, 2009|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672269||156427|
NCT00672282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6876C00025|Casodex vs Placebo in Non-Metastatic Early Prostate Cancer|A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.|SPCG6|AstraZeneca|No|Completed|October 1995|August 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1218|||Male|18 Years|N/A|No|||March 2009|May 26, 2009|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672282||156426|
NCT00672555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 07/050/2B|Limberg-flap: Prospective Data Collection|Prospective Evaluation of Feasibility and Results of the Treatment of Pilonidal Sinus by Excision and Covering of the Defect With a Limberg-flap.||Cantonal Hospital of St. Gallen|Yes|Completed|August 2006|September 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|16 Years|N/A|No|||June 2011|June 3, 2011|May 1, 2008||No||No|April 28, 2010|https://clinicaltrials.gov/show/NCT00672555||156406|Study was conducted as planned. A long time was needed to get the follow-up information.
NCT00672815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-06-0155|The Impact of Texas Senate Bill 42 on Middle School Children's Level of Physical Activity|The Impact of Texas Senate Bill 42 on Middle School Children's Level of Physical Activity|TXSB42|The University of Texas Health Science Center, Houston|No|Completed|April 2006|June 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|141|||Both|18 Years|75 Years|No|Probability Sample|There are 1,224 school districts and 1,159 public middle schools in the state of Texas. Of        all Texas students, 43% are Hispanic, 14% are African American, 40% are White, and 3% are        other. Additionally, 51.8% are considered economically disadvantaged. PHR 11 covers a        large area of the LRGV (along the Texas/Mexico border), and including 50 school districts        and 485 public schools. Within PHR 11, 84.5% of children are considered economically        disadvantage and more than 90% are Latino).|January 2010|January 20, 2010|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672815||156386|
NCT00673127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-414|Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer|A Phase II Trial of Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer|KHAD|Dana-Farber Cancer Institute|Yes|Completed|February 2005|December 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Male|18 Years|N/A|No|||April 2015|April 20, 2015|May 5, 2008|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00673127||156362|
NCT00671112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2407|Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma|A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma||Case Comprehensive Cancer Center|Yes|Terminated|June 2008|||October 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|May 2, 2008|No|Yes|Treatment ineffective|No||https://clinicaltrials.gov/show/NCT00671112||156512|
NCT00671450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-142|Visual Dysfunction in Mild Traumatic Brain Injury (MTBI): A Comparison Group Study|Visual Dysfunction in MTBI: A Comparison Group Study|VDMTBI|VA Office of Research and Development|No|Completed|October 2008|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|75|||Both|19 Years|39 Years|No|Non-Probability Sample|Participants will be drawn from the patient population of the VAPAHCS PTSD Center and        Clinics.|August 2009|January 24, 2013|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671450||156487|
NCT00664989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006867-01H|Resurfacing Hemiarthoplasty Versus Conventional Stemmed Arthroplasty|Resurfacing Hemiarthroplasty Versus Conventional Stemmed Hemiarthroplasty||Ottawa Hospital Research Institute|No|Completed|August 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|recent humeral resurfacing|August 2010|October 21, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664989||156980|
NCT00665002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15025|Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms|Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|June 2008|February 2015|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|April 18, 2008|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00665002||156979|
NCT00665327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10872|Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia|A Study of Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia||Bayer||Completed|November 2002|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|65 Years|N/A|No|||November 2014|November 17, 2014|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665327||156955|
NCT00672321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-MREC-07-H1010-66|Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma|Melanoma Lifestyle Study||National Cancer Institute (NCI)||Recruiting|December 2007|||September 2010|Anticipated|N/A|Observational|N/A|||Anticipated|2774|||Both|N/A|N/A|No|||July 2009|August 9, 2013|May 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00672321||156423|
NCT00673179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0404|Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy|Outpatient Chemotherapy in Pediatric Osteosarcoma: Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy||M.D. Anderson Cancer Center|No|Terminated|May 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|5 Years|40 Years|No|||September 2014|September 3, 2014|May 6, 2008||No|Low accrual.|No|June 12, 2013|https://clinicaltrials.gov/show/NCT00673179||156358|Study could not meet accrual goal due to logistical considerations, terminated early.
NCT00673192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710041R|Evaluation of ELISA Assay on Human Papilloma Viruses (HPV) Infection Population|Evaluation of ELISA Assay on HPV Infection Population||National Taiwan University Hospital|No|Recruiting|January 2008|December 2008|Anticipated|January 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||January 2008|May 6, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673192||156357|
NCT00673166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMTV|Evaluation of Local Mechanisms for Staff Motivation to Reduce Hospital Mortality|Evaluation of Local Mechanisms for Staff Motivation to Improve Treatment and Reduce Mortality Due to Malaria at the Paediatric Ward||Gates Malaria Partnership|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|900|||Both|N/A|59 Months|No|||March 2009|March 5, 2009|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00673166||156359|
NCT00673712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iflocv2008|Multicenter Infection Surveillance Study Following Open Heart Surgery|Phase 4 Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures||Halyard Health|No|Completed|April 2008|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|646|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|May 6, 2008|Yes|Yes||No|April 3, 2015|https://clinicaltrials.gov/show/NCT00673712||156317|
NCT00673725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP-EC-001|Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis|A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment||Astellas Pharma Inc|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Months|16 Years|No|||August 2014|August 22, 2014|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673725||156316|
NCT00674024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090003|Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function|A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction||National Institutes of Health Clinical Center (CC)||Completed|October 2008|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||January 2013|October 9, 2014|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674024||156293|
NCT00674037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051042|Efficacy of Monetary Incentives for Primary Care Physicians on Patients|Efficacy of Monetary Incentives for Primary Care Physicians on Patients' Recruitment|COFRASAanc|Assistance Publique - Hôpitaux de Paris|No|Terminated|September 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|170|||Both|18 Years|N/A|No|||December 2013|October 31, 2014|April 9, 2008||No|default inclusion|No||https://clinicaltrials.gov/show/NCT00674037||156292|
NCT00674310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROPI-T25-PVFD-1|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|February 2004|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2008|May 20, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674310||156271|
NCT00674323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952A2209|Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy|A Multicentre, Randomized, Double Masked, Exploratory, Indocyanine Green Angiography (ICGA) Guided Study of 6 Months Duration to Compare the Safety and Effect on Polyp Regression of Verteporfin Photodynamic Therapy (PDT) Alone or Added to Ranibizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy|PCV|Novartis|No|Completed|April 2008|||May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||April 2011|April 15, 2011|May 5, 2008||No||No|December 21, 2010|https://clinicaltrials.gov/show/NCT00674323||156270|
NCT00642629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5326-09|A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes|||Synta Pharmaceuticals Corp.|No|Completed|December 2005|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00642629||158689|
NCT00643227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661075|A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Clarithromycin Extended Release for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults||Pfizer|No|Completed|January 2003|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|504|||Both|16 Years|N/A|No|||March 2008|March 19, 2008|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643227||158643|
NCT00643500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01033|Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy|Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy||UCB Pharma|No|Completed|January 2002|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|342|||Both|16 Years|N/A|No|||September 2009|November 14, 2013|February 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643500||158622|
NCT00643513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORU-FAS-2007/1|Quality Of Life While Receiving Faslodex|Quality Of Life And Symptoms In Postmenopausal Women With Hormone Receptor Positive Disseminated Breast Cancer While Receiving Faslodex.||AstraZeneca||Completed|June 2007|January 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643513||158621|
NCT00643838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT : 2006-005691-40|Use of 50% Nitrous Oxide / 50% Oxygen Premix in Primary Care Dental Centers|Sedation Faisability by Inhalation of Kalinox 170 Bar During Therapeutic Cares in Primary Care Dental Centers||Air Liquide Santé International|No|Completed|December 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|480|||Both|1 Year|N/A|No|||January 2009|January 9, 2009|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643838||158596|
NCT00671983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04282008-1124|The Effect of Obstructive Sleep Apnea on Medical Outcomes After Gastric Bypass Surgery|The Effect of Obstructive Sleep Apnea on Medical and Neurobehavioral Outcomes After Gastric Bypass Surgery - An Exploratory Investigation||Stanford University||Withdrawn|March 2010|July 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|50|||Both|30 Years|65 Years|No|||July 2011|July 20, 2011|May 2, 2008||No|not adequate resources|No||https://clinicaltrials.gov/show/NCT00671983||156448|
NCT00672295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012282|PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer|A Phase I Trial of A SRC Kinase Inhibitor, Dasatinib,in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer||Duke University|Yes|Completed|August 2007|November 2012|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||December 2012|December 27, 2012|May 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00672295||156425|
NCT00663585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00016428|Intensive Meditation and Migraines: Effects on Health and Well Being|Intensive Meditation and Migraines: Effects on Health and Well Being||Johns Hopkins University|Yes|Recruiting|April 2008|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||October 2008|February 11, 2010|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663585||157088|
NCT00663845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12165|Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia.||Bayer|No|Completed|May 2006|April 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|395|||Male|18 Years|65 Years|No|||October 2013|October 10, 2013|April 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00663845||157068|
NCT00664079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-10-4547|Thyroid Hormones in Critically Ill Children|Thyroid Hormone Deficiency in Critically Ill Children|Thyroid|Children's Hospital of Philadelphia|No|Terminated|October 2005|December 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|Samples Without DNA|Whole blood and serum|Both|12 Months|18 Years|No|Non-Probability Sample|Patients who are admitted to the Pediatric Intensive Care Unit at the Children's Hospital        of Philadelphia will be approached if they meet inclusion criteria.|July 2008|March 11, 2015|April 18, 2008||No|Sluggish enrollment.|No||https://clinicaltrials.gov/show/NCT00664079||157050|
NCT00671463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P000965|Pancreatic Stent to Prevent Leak After Distal Pancreatectomy|Leak Elimination After Pancreatic Stenting, a Randomized Controlled Trial|LEAPS|Massachusetts General Hospital|Yes|Withdrawn|April 2008|||April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|May 1, 2008||No|Anticipated high risk of pancreatitis|No||https://clinicaltrials.gov/show/NCT00671463||156486|
NCT00671749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10066|Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris|A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris||Galderma Laboratories, L.P.|No|Completed|December 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|12 Years|35 Years|No|||February 2016|February 16, 2016|April 30, 2008||No||No|August 12, 2014|https://clinicaltrials.gov/show/NCT00671749||156464|
NCT00672022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3445|Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses|Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset GM2 Gangliosidosis: Single and Steady State Oral Doses||Children's Research Institute||Completed|July 2004|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|6 Months|5 Years|No|||July 2005|May 5, 2008|May 2, 2008||||No||https://clinicaltrials.gov/show/NCT00672022||156445|
NCT00671736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moli1901-010B|Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis|A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults With Cystic Fibrosis||AOP Orphan Pharmaceuticals AG|Yes|Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|12 Years|N/A|No|||August 2009|August 26, 2009|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671736||156465|
NCT00672009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13963|A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer|A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer||Cedars-Sinai Medical Center|No|Terminated|April 2008|August 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|N/A|N/A|No|||September 2014|September 3, 2014|May 1, 2008|Yes|Yes|The sponsor terminated funding for the study.|No||https://clinicaltrials.gov/show/NCT00672009||156446|
NCT00672594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007396|Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy|Investigator-Initiated Pilot Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy||Duke University|No|Completed|July 2006|September 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||May 2014|July 31, 2014|May 4, 2008|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00672594||156403|
NCT00672880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006455|Self System Therapy and Chronic Low Back Pain Trial|The Use of Self-System Therapy to Alter Self-Discrepancies in Chronic Low Back Pain Patients|Low Back Pain|Duke University|Yes|Completed|October 2003|December 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|137|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00672880||156381|
NCT00673205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6876C00024|(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer|A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer|Capri|AstraZeneca|No|Completed|September 1995|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3588|||Male|18 Years|N/A|No|||December 2010|December 9, 2010|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00673205||156356|
NCT00673218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AUS22|The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils|The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils||Creighton University|No|Active, not recruiting|June 2007|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|25|||Both|19 Years|50 Years|No|||July 2012|July 3, 2012|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00673218||156355|
NCT00673426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOBLA0108|Safety Evaluation of Use Sodic Enoxaparin|Safety Evaluation of Use Sodic Enoxaparin Produced by the Laboratory Blausiegel When Compared With Product Clexane of Sanofi-Aventis Ltda in Chronic Renal Desease Patients.|Enoxaparin|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|January 2008|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|60|||Female|18 Years|80 Years|No|||January 2008|May 6, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673426||156339|
NCT00673738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15294|Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)|Safety and Efficacy (Phase II) Study of Concurrent Cetuximab Plus Conformal Thoracic Radiotherapy in (Poor Prognosis) Patients With Inoperable or Unresectable, Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|April 2008|August 2015|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|May 5, 2008|No|Yes||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00673738||156315|Accrual, and therefore treatment ended earlier than planned due to pulmonary toxicity. Three participants remain on follow-up.
NCT00674050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-114|A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy Volunteers|A Phase 1, Open-Label Study to Investigate the Effect of Albuterol (Salbutamol) and Fluticasone on the Pharmacokinetics of Inhaled Technosphere® Insulin Inhalation Powder in Healthy Subjects||Mannkind Corporation||Completed|May 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674050||156291|
NCT00674336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0551-2006|Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study|Norwalk Virus Inactivation by High Hydrostatic Pressure Processing: A Comprehensive and Integrated Program for Research and Outreach|Shellfish|Emory University|Yes|Completed|September 2007|March 2010|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|51|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674336||156269|
NCT00669994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100546|Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections|Prospective, Open Label Non-comparative, Multi-center Trial to Evaluate the Efficacy and Safety of Cipro® XR 500 mg Once Daily for 3 Days in Treating Female Patients With Acute, Uncomplicated, Symptomatic Lower Urinary Tract Infections||Bayer||Completed|July 2003|October 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Female|18 Years|44 Years|No|||December 2014|December 18, 2014|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00669994||156596|
NCT00643240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006LS057|Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia|Phase I Open Label, Single Arm Escalation Trial to Evaluate the Biodistribution and Safety of BU-12 in Patients With Advanced Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|12 Years|N/A|No|||November 2012|November 6, 2012|March 25, 2008|No|Yes|Due to slow accrual|No||https://clinicaltrials.gov/show/NCT00643240||158642|
NCT00643253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-490-000|Provider Approaches to Improved Rates of Infant Nutrition and Growth Study|Provider Approaches to Improved Rates of Infant Nutrition and Growth Study|PAIRINGS|Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|March 2008|July 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|299|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 9, 2013|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643253||158641|
NCT00643526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014914|A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector|An Open-Label, Randomized, Validation Study to Establish That the Design, Functionality, and Ergonomic Features of the Autoinjector Conform to Defined User Needs and Intended Use for Self-Administration by Subjects With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Psoriasis||Centocor, Inc.|No|Completed|December 2007|January 2008|Actual|January 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|February 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643526||158620|
NCT00643864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-05-14B|Mirror-Box Training in Adults With Chronic Hemiparesis Secondary to Stroke|Mirror-Box Training in Adults With Chronic Hemiparesis Secondary to Stroke: A Descriptive Case Series and Pilot Study||Carolinas Healthcare System|Yes|Terminated|February 2006|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|30 Years|80 Years|No|||February 2012|February 9, 2012|March 20, 2008||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00643864||158594|
NCT00662779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASRC948|Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)|Evaluation of the Bronchoprotective Effect of Arformoterol in Children With Exercise Induced Bronchospasm|EIB|University of New Mexico|Yes|Withdrawn|April 2008|July 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|12 Years|17 Years|No|||December 2015|December 9, 2015|April 16, 2008|Yes|Yes|High number of screen failures-couldn't find qualified subjects in timely manner|No||https://clinicaltrials.gov/show/NCT00662779||157150|
NCT00663572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD07/12-L|Food Habit Programming: Influence of Genetics and Early Nutrition in a Population of Preterm Infants|Food Habit Programming: Influence of Genetics and Early Nutrition in a Population of Preterm Infants|Polynuca|Nantes University Hospital||Terminated|March 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|234|||Both|2 Years|25 Months|No|Non-Probability Sample|Preterm infants < 33 SA who stayed at least 2 weeks after birth in Nantes hospital,        included in the " Grandir ensemble " network, 2 years old in 2008 and 2009|September 2013|September 2, 2013|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663572||157089|
NCT00670605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584244|Cancer Occurrence and Outcome in Young Patients Undergoing Cancer Treatment at the Vanderbilt-Ingram Cancer Center|VICC Adolescent and Young Adult Oncology Review||Vanderbilt University||Terminated|June 2007|||December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|15 Years|30 Years|No|Probability Sample|Newly diagnosed|March 2011|March 23, 2011|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00670605||156551|
NCT00670878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUCCESS-B|Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer|Prospectively Randomized Phase III Trial, Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer||Ludwig-Maximilians - University of Munich|Yes|Completed|June 2008|||October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|799|||Female|18 Years|N/A|No|||March 2012|March 31, 2012|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670878||156530|
NCT00672035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELT202|Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study|Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging Study to Assess the Immunogenicity and Safety of LT Application in Healthy Adults||Intercell USA, Inc.|No|Completed|October 2006|July 2008|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Actual|406|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672035||156444|
NCT00672048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002593|Partnership for Glaucoma|Expanding Quality Care for Glaucoma Through a Provider-Patient Partnership||Duke University|No|Completed|October 2007|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|721|||Both|N/A|N/A|No|||December 2013|January 3, 2014|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00672048||156443|
NCT00672360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20959|Folate Rechallenge|Folate Rechallenge: A Pilot Study||Baylor College of Medicine|No|Completed|May 2007|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|N/A|N/A|No|||September 2015|September 10, 2015|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00672360||156420|
NCT00672334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-002223-32|Sodium Bicarbonate in Cardiac Surgery Study|A Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Sodium Bicarbonate on Postoperative Renal Function in Patients Undergoing Elective Cardiopulmonary Bypass|Bic-MC|Austin Health|Yes|Terminated|May 2008|January 2012|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|350|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00672334||156422|
NCT00672347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210665|Clonidine and Morphine in Caudal Anesthesia|Comparison of Clonidine and Morphine Plus Bupivacaine in Caudal Peridural Anesthesia for Postoperative Analgesia After Pediatric Urogenital Surgery||Federal University of Minas Gerais|Yes|Completed|July 2008|September 2009|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|1 Year|10 Years|No|||March 2010|March 18, 2010|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672347||156421|
NCT00672893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB035-Multi-site|Vibration Response Imaging (VRI) in Patients That Are Undergoing Pulmonary Interventional Procedure|Vibration Response Imaging (VRI) in Patients That Are Undergoing Pulmonary Interventional Procedure||Deep Breeze|No|Completed|February 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients in the age range of 18-85 and consisting of both male and females, who present to        the clinic with airway obstruction and who are designated to undergo intervention.|June 2009|June 15, 2009|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00672893||156380|
NCT00673231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00006|Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin|A 24-week International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Patients With Type 2 Diabetes With Inadequate Glycaemic Control on Insulin||AstraZeneca|No|Completed|April 2008|January 2011|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1240|||Both|18 Years|80 Years|No|||September 2013|September 25, 2013|May 6, 2008|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT00673231||156354|For participants who did not complete 24 weeks LOCF (last observation carried forward) was used. Only values prior to insulin up-titration were used for outcome measures except for mean daily insulin dose which was evaluated regardless of.
NCT00673452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12220|A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia|Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia||Eli Lilly and Company|No|Completed|June 2008|July 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|530|||Both|18 Years|N/A|No|||May 2010|May 28, 2010|May 5, 2008|Yes|Yes||No|April 14, 2010|https://clinicaltrials.gov/show/NCT00673452||156337|
NCT00673439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0100|Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)|A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)||James Graham Brown Cancer Center|Yes|Terminated|November 2007|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||May 2013|May 3, 2013|May 5, 2008|Yes|Yes|study terminated due to low accrual|No|May 3, 2013|https://clinicaltrials.gov/show/NCT00673439||156338|Study terminated, results data not available
NCT00673751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-032|Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome|GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome||Glostrup University Hospital, Copenhagen|No|Enrolling by invitation||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|8|||Both|18 Years|70 Years|No|||May 2008|May 6, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673751||156314|
NCT00674076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802028R|Clinical Application of Ultrasound in Obstructive Sleep Apnea|Clinical Application of Ultrasound in Obstructive Sleep Apnea||National Taiwan University Hospital|Yes|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients who are arranged to recived polysomography|June 2012|July 8, 2012|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674076||156289|
NCT00674349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706001R|Screening of Biomarkers on Endometrial Cancers|Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Endometrial Cancers||National Taiwan University Hospital|No|Recruiting|January 2006|December 2011|Anticipated|January 2007|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|250|||Female|15 Years|80 Years|No|||January 2006|July 21, 2008|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00674349||156268|
NCT00670020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18821|Supplemental Perioperative Oxygen to Reduce the Incidence of Post-Cesarean Endometritis and Wound Infection|Supplemental Perioperative Oxygen to Reduce the Incidence of Post-Cesarean Endometritis and Wound Infection||University of Washington|No|Completed|January 2001|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|143|||Female|16 Years|N/A|No|||April 2008|April 30, 2008|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670020||156594|
NCT00643539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661037|Multicenter, Open, Randomized Comparative Trial To Compare The Efficacy Of Azithromycin Versus Amoxicillin In Children With Strep Throat|Multicenter, Open, Randomized Comparative Trial To Compare Bacteriological And Clinical Efficacy Of Azithromycin Versus Amoxicillin In Children With Streptococcus Tonsillitis||Pfizer|No|Completed|December 2002|July 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|3 Years|15 Years|No|||March 2008|March 19, 2008|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643539||158619|
NCT00643552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4973|Muscle Strength, Physical Work Capacity and Functional Performance in Individuals With Down Syndrome|Muscle Strength, Physical Work Capacity and Functional Performance in Individuals With Down Syndrome||State University of New York - Upstate Medical University|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|18|||Both|17 Years|N/A|No|Non-Probability Sample|community sample|March 2008|March 25, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643552||158618|
NCT00643877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008－46|Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer|A Prospective,Multi-Center,Randomized Control Trial of Preoperative Hepatic and Regional Arterial Chemotherapy(PHRAC) Using Oxaliplatin, Fluorodeoxyuridine(FUDR) and Mitomycin C(MMC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer|PHRAC|Fudan University|Yes|Recruiting|December 2008|December 2014|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|74 Years|No|||March 2009|March 24, 2009|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643877||158593|
NCT00644150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH075639|Effectiveness of HIV/Sexually Transmitted Infection Training for Physicians in China|Project Ai Shi Zi: Integrating HIV/STI Prevention and Treatment in China||University of California, Los Angeles|Yes|Completed|April 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|1373|||Both|18 Years|45 Years|No|||December 2013|December 11, 2013|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644150||158572|
NCT00644163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10MH078819|Effectiveness of a Risk Reduction Program in Preventing the Transmission of HIV and Sexually Transmitted Diseases in African-American Couples|NIMH Multisite HIV/STD Prevention Trial for African American Couples||University of Pennsylvania|Yes|Completed|November 2003|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||Actual|1070|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|January 23, 2014|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644163||158571|
NCT00670306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS-102-Z041|Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)|Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: an Open-Labeled Safety and Efficacy Assessment Study|AEZS-102-Z041|AEterna Zentaris|No|Completed|March 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|528|||Male|50 Years|N/A|No|||April 2011|April 1, 2011|April 22, 2008|Yes|Yes||No|October 18, 2010|https://clinicaltrials.gov/show/NCT00670306||156574|
NCT00670319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1363|Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis|Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis|MORE|Eli Lilly and Company|Yes|Completed|November 1994|September 1999|Actual|September 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|7705|||Female|N/A|80 Years|No|||April 2008|April 30, 2008|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670319||156573|
NCT00663312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0031|Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's Disease|Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's Disease||University Hospital, Clermont-Ferrand||Terminated|April 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|8|||Both|18 Years|70 Years|No|||October 2008|October 7, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00663312||157109|
NCT00663325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03735|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Tangerina Mix||Sanofi|No|Completed|December 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Female|10 Years|20 Years|Accepts Healthy Volunteers|||January 2009|January 7, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663325||157108|
NCT00670891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP 000001|A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children|A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children|VPH|Vachira Phuket Hospital|Yes|Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|5 Years|9 Years|No|||April 2008|May 26, 2008|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670891||156529|
NCT00671125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-021|Study of Efficacy of Ramelteon in Adults With Chronic Insomnia|A Phase III, Randomized, Double-Blind Placebo-Controlled, PSG Plus Outpatient Study to Determine the Safety and Efficacy of TAK-375 in Adults With Chronic Insomnia||Takeda|No|Completed|January 2003|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|405|||Both|18 Years|64 Years|No|||November 2012|November 8, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671125||156511|
NCT00672061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-375-039|Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea|A Phase II Safety Study of TAK-375 in Subjects With Mild to Moderate Obstructive Sleep Apnea||Takeda|No|Completed|July 2003|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|26|||Both|21 Years|64 Years|No|||February 2012|February 27, 2012|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672061||156442|
NCT00672074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-IPAM-201|Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus|A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients||Helsinn Therapeutics (U.S.), Inc|No|Completed|April 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|85 Years|No|||June 2011|June 8, 2011|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672074||156441|
NCT00672373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGB-ZWF-01|Extract of Ginkgo Biloba and Tardive Dyskinesia|A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia|EGBTD|Beijing HuiLongGuan Hospital|Yes|Completed|December 2006|August 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|60 Years|No|||May 2008|May 5, 2008|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672373||156419|
NCT00672607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schwabe-Wenex|a Clinical Trial to Evaluate the Efficacy and Safety of Agnucaston Tablets in the Treatment of Premenstrual Syndrome (PMS)||ACT-RCT-C 01|Schwabe-Wenex International Ltd|Yes|Completed|February 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Female|18 Years|45 Years|No|||September 2009|September 30, 2009|May 4, 2008||||No||https://clinicaltrials.gov/show/NCT00672607||156402|
NCT00672906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010889|Group Parent Training for Adolescent Eating Disorders|Group Parent Training for Adolescent Eating Disorders|GPT-AN|Duke University|Yes|Completed|July 2005|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Female|11 Years|18 Years|No|||May 2014|September 12, 2014|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00672906||156379|
NCT00672919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-OPI-523|Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.|A Single-Arm, Open-Label, Multicenter Study Evaluating the Triglyceride Changes in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia Following Treatment Conversion From Rosiglitazone to Pioglitazone HCl in Combination With Stable Statin Therapy|COMPLEMENT|Takeda|No|Completed|November 2003|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|305|||Both|18 Years|70 Years|No|||February 2012|February 27, 2012|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672919||156378|
NCT00673777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-NSCLC02|Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Non-Small Cell Lung Cancer||Tokyo University|Yes|Recruiting|May 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||May 2008|May 12, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673777||156312|
NCT00673764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-24|The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance|||Alcon Research|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Months|N/A|No|||January 2012|January 31, 2012|May 2, 2008||No||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00673764||156313|
NCT00674063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-738|A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis|A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Weekly Intravenous Administration of 7.5mg and 0.075mg/kg Alefacept in Subjects Weighing Between 100kg and 150kg, With Moderate to Severe Chronic Plaque Psoriasis||Astellas Pharma Inc|No|Completed|July 2003|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674063||156290|
NCT00674362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87076|Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study|A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis|CERTAIN|UCB Pharma|No|Completed|June 2008|December 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|No|||December 2011|December 9, 2011|May 5, 2008|Yes|Yes||No|December 9, 2011|https://clinicaltrials.gov/show/NCT00674362||156267|
NCT00670033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-46|Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension|Comparison of Safety and IOP-Lowering Efficacy of Three Alternative Travoprost Formulations to Vehicle and TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|158|||Both|18 Years|N/A|No|||June 2014|July 9, 2014|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670033||156593|
NCT00670410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA7937|Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma|A Pilot Study of Sequential Autologous Stem Cell Transplantation and Immunotherapy With Reduced Intensity Allogeneic Stem Cell Transplant for High Risk Neuroblastoma||Columbia University|Yes|Terminated|December 2002|December 2011|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|N/A|30 Years|No|||May 2009|January 12, 2011|April 29, 2008||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00670410||156566|
NCT00670423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803-17; IUCRO-0204|A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation|A Phase I Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation||Indiana University|Yes|Completed|May 2008|October 2013|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670423||156565|
NCT00643890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRGX-GAD-02|Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease|Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease||Neurologix, Inc.|Yes|Terminated|August 2008|||December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|44|||Both|30 Years|75 Years|No|||February 2012|February 20, 2012|March 24, 2008|Yes|Yes|Due to financial reasons|No||https://clinicaltrials.gov/show/NCT00643890||158592|
NCT00643903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068208|Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project)|The Balance Project - RCT of an HIV Treatment Side Effects Coping Intervention||University of California, San Francisco|No|Completed|April 2004|February 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|250|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643903||158591|
NCT00644176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661145|A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery|A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin in Serum, Bronchial Washings and Lung Tissue Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Resection||Pfizer|No|Completed|November 2004|April 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|66|||Both|18 Years|N/A|No|||June 2011|June 3, 2011|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644176||158570|
NCT00644449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661102|A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB)||Pfizer||Completed|January 2003|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|551|||Both|35 Years|N/A|No|||May 2011|May 12, 2011|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644449||158549|
NCT00663039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043595|Effects of Oxytocin Nasal Spray on Social Affiliation|Effects of Oxytocin Nasal Spray on Social Affiliation||University of Maryland|Yes|Active, not recruiting|October 2009|August 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|24|||Both|18 Years|64 Years|No|||November 2015|November 30, 2015|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663039||157130|
NCT00674609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA0101|A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy|A Double Blind, Randomized, Parallel Group, Placebo Controlled, Comparative Study of the Efficacy, Safety and Tolerability of Cannabis Based Medicine (CBM) Extracts in Patients With Cancer-related Pain.|SPRAY|GW Pharmaceuticals Ltd.|No|Completed|February 2002|March 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|177|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|April 28, 2008||No||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00674609||156248|
NCT00670904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M29670|Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation|Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation||University of Montana|No|Completed|October 2005|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2008|January 11, 2010|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670904||156528|
NCT00670618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/187 - Part 2|A Prospective, Randomized Clinical Study on the Effects of Casein Phosphopeptide-amorphous Calcium Phosphate (CPP-ACP) Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 2|A Prospective, Randomized Clinical Study on the Effects of CPP-ACP Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 2||University Hospital, Ghent|No|Recruiting|June 2008|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|400|||Both|10 Years|60 Years|No|||December 2014|December 4, 2014|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670618||156550|
NCT00671138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/115|Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity|A Phase 2a, Randomized, Double Blinded, Placebo Controlled, Study Evaluating Immunity and Gluten-sensitivity by Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus.||Princess Alexandra Hospital, Brisbane, Australia|Yes|Completed|October 2007|September 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00671138||156510|
NCT00671476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000594671|Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery|Intraductal Therapy of DCIS: A Presurgery Study||National Cancer Institute (NCI)||Recruiting|February 2008|||February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Female|18 Years|N/A|No|||June 2009|January 9, 2014|May 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671476||156485|
NCT00671775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK75119|Cognitive Effects of Bariatric Surgery|Cognitive Effects of Bariatric Surgery||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Active, not recruiting|September 2005|||March 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|||Both|25 Years|70 Years|No|Non-Probability Sample|Participants will be recruited from the bariatric and weight loss programs of affiliated        clinical centers.|March 2011|March 15, 2011|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00671775||156463|
NCT00672087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK65990|Diagnostic Challenges in IC (and Male CPPS)|Diagnostic Challenges in IC (and Male CPPS)||Beth Israel Deaconess Medical Center|No|Completed|September 2003|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|Samples With DNA|saliva, whole blood, serum, white cells, urine, prostatic fluid, prostate/bladder tissue|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Tertiary university medical centers and primary care clinic|February 2014|February 5, 2014|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672087||156440|
NCT00672386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013051|A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes|A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110 (R256918)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|352|||Both|18 Years|70 Years|No|||July 2014|July 10, 2014|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672386||156418|
NCT00672399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-EW-GWCI|Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects|A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects||AstraZeneca|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|February 23, 2015|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00672399||156417|
NCT00672620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_304|Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder||Takeda|No|Completed|April 2008|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|611|||Both|18 Years|75 Years|No|||October 2013|October 25, 2013|May 2, 2008|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00672620||156401|
NCT00673465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05338|Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338AM1)(COMPLETED)|A Randomized, Placebo-controlled, Three-Way Crossover Study to Evaluate the Effect of SCH 497079 on Metabolic Parameters and to Determine the Influence of Race/Ethnic Origin on Therapeutic Response||Merck Sharp & Dohme Corp.|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00673465||156336|
NCT00673478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.24|Tiotropium and Salmeterol PK Study in COPD Patients|A Randomised, Open-label, 4-way Crossover Study to Characterize the Pharmacokinetics, Safety and Efficacy of FDC Tiotropium/Salmeterol, Tiotropium, Salmeterol and a Free Combination of Tiotropium Plus Salmeterol Following 4-week Treatment Periods in Patients With COPD.||Boehringer Ingelheim||Completed|May 2008|||June 2009|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||Actual|50|||Both|40 Years|N/A|No|||April 2014|April 30, 2014|May 6, 2008||||No||https://clinicaltrials.gov/show/NCT00673478||156335|
NCT00673491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCPIEAC-EXART12MARCHE|Clinical Pathways for Effective and Appropriate Care|Diffusion of Clinical Pathways for the Implementation of Effective and Appropriate Care||Agenzia Regionale Sanitaria delle Marche|Yes|Completed|July 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|448|||Both|18 Years|N/A|No|||May 2008|May 6, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673491||156334|
NCT00673504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-II-004 / 2007-005022-71|First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer|Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer||Central European Society for Anticancer Drug Research|No|Completed|April 2008|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||November 2011|November 30, 2011|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673504||156333|
NCT00674089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|586-Ped/ERC-06|Newborn Vitamin A (VA) Supplementation Pilot Project, Pakistan|Evaluation of the Effectiveness of Vitamin A Supplementation (VAS) as Part of a Neonatal Post Partum Care Package in Rural Pakistan|VA|Aga Khan University|Yes|Completed|January 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|7400|||Both|N/A|15 Days|Accepts Healthy Volunteers|||October 2010|August 9, 2011|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674089||156288|
NCT00674102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A1101|An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With NSCLC||Novartis||Completed|April 2008|||March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||August 2011|August 31, 2011|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674102||156287|
NCT00674115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18133|A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)|Randomized, Crossover Pharmacodynamic Study Comparing the Effects of Zegerid® (20 mg Omeprazole/Sodium Bicarbonate) and Prilosec OTC® (20 Mg-equivalent Omeprazole)||Bayer|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|May 2, 2008|Yes|Yes||No|September 17, 2009|https://clinicaltrials.gov/show/NCT00674115||156286|
NCT00674375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS017075-01|Risk Score Alerts for Chest Pain Care|Can Risk Score Alerts Improve Office Care for Chest Pain?||Harvard Vanguard Medical Associates|Yes|Completed|November 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|8000|||Both|30 Years|N/A|No|||March 2015|March 17, 2015|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674375||156266|
NCT00674388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wake up Safe|The Pediatric Anesthesia Quality Improvement Project|The Pediatric Anesthesia Quality Improvement Project|WUS|The Society for Pediatric Anesthesia|No|Recruiting|February 2008|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|3000000|||Both|N/A|21 Years|No|Non-Probability Sample|All Children undergoing anesthesia at the participating hospitals|May 2015|May 21, 2015|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674388|2 Weeks|156265|
NCT00670046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595004|Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer|Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer||National Cancer Institute (NCI)||Recruiting|May 2008|||April 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|85 Years|No|||July 2009|February 18, 2011|April 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670046||156592|
NCT00670059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SET study|Pre-Implantation Genetic Screening in Women Under the Age of 36 Years With Single Embryo Transfer|Pre-Implantation Genetic Screening in Women Under the Age of 36 With Single-Embryo Transfer||Vrije Universiteit Brussel|No|Terminated|October 2004|February 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|240|||Female|18 Years|35 Years|No|||April 2008|April 30, 2008|April 29, 2008||No|At the first prespecified interim analysis|No||https://clinicaltrials.gov/show/NCT00670059||156591|
NCT00644748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451004|A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy|An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy||Pfizer|No|Completed|May 2003|August 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|51 Years|N/A|No|||October 2008|October 9, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644748||158526|
NCT00644761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-02-531|PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients|A Multi-Center Phase 2, Open-Label Study to Evaluate the Pharmacokinetics of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil 10 mg to Patients Post-Liver Transplantation||Gilead Sciences|No|Completed|February 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||April 2008|April 7, 2008|March 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644761||158525|
NCT00645047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHI 07-054|Veterans Telemedicine Outreach for PTSD Services|Veterans Telemedicine Outreach for PTSD Services|VTOPS|VA Office of Research and Development|No|Completed|February 2009|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|207|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00645047||158504|
NCT00674622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT003969-01A1|Prolotherapy for the Treatment of Chronic Lateral Epicondylitis|Prolotherapy for the Treatment of Chronic Lateral Epicondylitis||University of Pittsburgh|Yes|Completed|September 2007|October 2011|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|65 Years|No|||June 2012|June 14, 2012|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674622||156247|
NCT00670631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25009|Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment|Tandem Autotransplantation for Multiple Myeloma Patients With Less Than 12 Months of Preceding Therapy, Incorporating Bortezomib With the Transplant Chemotherapy and During Maintenance||University of Iowa|Yes|Active, not recruiting|February 2008|April 2014|Anticipated|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|204|||Both|18 Years|75 Years|No|||November 2013|November 26, 2013|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670631||156549|
NCT00670917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000594676|Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy|A Randomized Controlled Trial Assessing the Effect of Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy||National Cancer Institute (NCI)||Recruiting|April 2008|||April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|||Anticipated|80|||Both|18 Years|N/A|No|||July 2009|April 9, 2010|May 1, 2008||||No||https://clinicaltrials.gov/show/NCT00670917||156527|
NCT00671151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS042146|Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline||Hospital Universitari Son Dureta|No|Completed|June 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Male|40 Years|75 Years|Accepts Healthy Volunteers|||April 2008|May 2, 2008|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671151||156509|
NCT00671489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDMC-TPOP-01|Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study|Phase 2 Study of Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study||Japan Science and Technology Agency|Yes|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|N/A|No|||May 2009|July 2, 2012|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00671489||156484|
NCT00671788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0170M|A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|A Phase II Evaluation of Dasatinib (SprycelÂ®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|June 2008|||December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|May 2, 2008|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00671788||156462|
NCT00671801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0472|Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I|Phase I Trial of Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Terminated|April 2008|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|April 30, 2008|No|Yes|Poor accrual.|No||https://clinicaltrials.gov/show/NCT00671801||156461|
NCT00672646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00010|Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386|A Double-blind, Randomized, Placebo and Naproxen Controlled Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386, in Patients Undergoing Impacted Mandibular Third Molar Extraction||AstraZeneca||Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 7, 2012|May 1, 2008|Yes|Yes||No|August 31, 2011|https://clinicaltrials.gov/show/NCT00672646||156399|
NCT00672659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNB/CPS 02 2007|Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)|Phase IIa Proof of Concept Study of Pipamperone/Citalopram (PipCit) Versus Citalopram in the Treatment of Major Depressive Disorder (MDD)||PharmaNeuroBoost N.V.|Yes|Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|65 Years|No|||April 2011|April 29, 2011|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672659||156398|
NCT00672932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRC5004|Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients|Pilot Study of Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients||University of California, San Francisco|No|Completed|April 2008|February 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|April 29, 2008||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00672932||156377|The underlying hypothesis might not have actually been addressed because of the particular makeup of the subject group with minimal CNS infection and immunoactivation that left little room to discern a therapeutic effect.
NCT00672945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 01340-202|A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil|Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil||Epix Pharmaceuticals, Inc.||Terminated|April 2008|||January 2010|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|2||Anticipated|420|||Both|50 Years|90 Years|No|||July 2009|July 28, 2009|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672945||156376|
NCT00672633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08010028|Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides|A Double Blind Randomized Controlled Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides.||Children's Hospital Boston|Yes|Terminated|April 2008|March 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|10 Years|19 Years|No|||May 2013|May 24, 2013|April 30, 2008||No|Very slow recruitment.|No|March 8, 2013|https://clinicaltrials.gov/show/NCT00672633||156400|Early termination leading to small numbers of subjects analyzed
NCT00673257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTR06C1|Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer|Pharmacokinetics of Daunomycin in Children||Children's Oncology Group|Yes|Active, not recruiting|January 2007|||July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|N/A|21 Years|No|||September 2015|September 1, 2015|May 6, 2008|No|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00673257||156352|
NCT00673517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSCILLATE Biomarkers Substudy|The Effect of High Frequency Oscillation on Biological Markers of Lung Injury|The Effect of High Frequency Oscillation on Biological Markers of Ventilator Induced Lung Injury (VILI): Nested Translational Biology Sub-Study of the OSCILLATE Pilot Study||St. Michael's Hospital, Toronto|No|Completed|November 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Known biomarkers: IL6, IL8, IL10, IL-1Beta, ICAM-1, TGFBeta, Chemokine ligand 10, FGFBeta,      VEGF, and INFGamma Novel biomarkers: ACE, surfactant protein D, clara cell protetin, von      Willerbrand Facotr, Ang1, Ang2, and TF, PCIII, neuropeptide Y, PBEF, APCRc, and PAI-1|Both|18 Years|N/A|No|Non-Probability Sample|Subset of patients enrolled in the parent study (OSCILLATE- #NCT00474656) Patients        enrolled in the parent study have early severe acute respiratory syndrome and will be        recruited from a critical care environment|November 2008|November 14, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673517||156332|
NCT00673790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-04|The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose|Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose||Forest Laboratories|No|Completed|May 2008|||July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|543|||Both|18 Years|80 Years|No|||September 2010|September 22, 2010|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00673790||156311|
NCT00674141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS089-HMO-CTIL|Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment|Nasal Administration of Dexamethasone for MS Treatment||Hadassah Medical Organization|No|Withdrawn|July 2008|January 2009|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2008|June 2, 2010|May 6, 2008|No|Yes|was not approved by the ministry of health|No||https://clinicaltrials.gov/show/NCT00674141||156284|
NCT00674154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT-20080011|Effect of Vitamin D Treatment in Primary Hyperparathyroidism|Effect of Vitamin D Treatment in Primary Hyperparathyroidism||University of Aarhus|Yes|Completed|May 2008|August 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||August 2013|October 23, 2013|May 5, 2008||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT00674154||156283|
NCT00674401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIC-13|Radiofrequency Ablation of Drivers of Atrial Fibrillation|RADAR-AF: Radiofrequency Ablation of Drivers of Atrial Fibrillation|RADAR-AF|Hospital General Universitario Gregorio Marañon|Yes|Completed|January 2009|May 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|No|||September 2013|September 21, 2013|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674401||156264|
NCT00670098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72452|Changes in Sexual Function Following Bariatric Surgery|Psychosocial Changes Associated With Weight Loss||University of Pennsylvania|No|Completed|August 2005|September 2013|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|207|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|October 20, 2015|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670098||156590|
NCT00670111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESET|Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction|Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction|RESET|Boston Scientific Corporation|Yes|Terminated|July 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|April 23, 2008|Yes|Yes|Difficulty in enrollment|No||https://clinicaltrials.gov/show/NCT00670111||156589|
NCT00645060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05198|Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors|A Phase I Study of Yttrium-90 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced Malignancies||City of Hope Medical Center|Yes|Active, not recruiting|October 2006|||November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|120 Years|No|||December 2015|December 9, 2015|March 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00645060||158503|
NCT00645073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-628|Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis|A Phase IV Comparative Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis||Abbott||Completed|November 2003|||March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|N/A|No|||March 2008|March 22, 2008|March 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645073||158502|
NCT00640705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCF-002|Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Pain Due to Mild to Moderate Ankle Sprain.||Cerimon Pharmaceuticals|No|Terminated|January 2008|October 2008|Anticipated|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|75 Years|No|||September 2008|September 3, 2008|March 18, 2008|No|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00640705||158835|
NCT00670644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587714|Self-Care for Lymphedema in Patients With Breast Cancer|Breast Cancer Treatment Related Lymphedema Self Care Practices||Vanderbilt University|No|Completed|May 2006|March 2011|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Female|18 Years|120 Years|No|Non-Probability Sample|Breast Cancer patients|December 2015|December 7, 2015|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00670644||156548|
NCT00670930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2432|Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists|A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Trial to Explore the Effects of 78 Weeks Omalizumab Treatment Given as Add on Therapy on Markers of Airway Inflammation and Remodeling in Patients With Moderate to Severe Persistent Allergic Asthma Receiving Inhaled Corticosteroids and Long Acting Beta-agonists|eXplore|Novartis||Completed|April 2008|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||November 2012|December 12, 2012|April 30, 2008|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00670930||156526|
NCT00671177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol10642|Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique|Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique||VA Palo Alto Health Care System|Yes|Completed|September 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|229|||Male|18 Years|N/A|No|||January 2009|January 28, 2009|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00671177||156508|
NCT00671190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-018|Safety and Efficacy of Ramelteon in Healthy Subjects|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Phase-Shifting Effects of Repeated Daily Dosing of Ramelteon in Healthy Subjects||Takeda|No|Completed|March 2005|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|75|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671190||156507|
NCT00671203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-002|Prevention of Colon Ischemia During Aortic Aneurysm (AAA) Repair|Prevention of Colon Ischemia During Aortic Aneurysm (AAA) Repair||Spectros Corporation|Yes|Completed|June 2007|January 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|January 30, 2011|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671203||156506|
NCT00671502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP510|A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back|Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back||Meda Pharmaceuticals|No|Completed|April 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|840|||Both|18 Years|70 Years|No|||October 2011|October 4, 2011|May 1, 2008|Yes|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00671502||156483|
NCT00671814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-101|Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults|A Double-Blind, Placebo and Active Controlled, Single and Multiple Rising Dose, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults|SAD/MAD|Trius Therapeutics LLC|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|June 1, 2012|May 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671814||156460|
NCT00672672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065-08|Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients|Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients||University of Nebraska|Yes|Terminated|February 2009|||July 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Both|19 Years|90 Years|No|||August 2011|August 2, 2011|May 2, 2008||No|Study closed with no subjects accrued. PI decided to stop study.|No||https://clinicaltrials.gov/show/NCT00672672||156397|
NCT00672685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 116 03|Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline|Assessment of the Efficacy of Omega-3 Fatty Acids Supplementation, Multi-domain Intervention or Their Combination on the Change of Cognitive Functions in Frail Elderly Subjects|MAPT|University Hospital, Toulouse|No|Completed|May 2008|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1680|||Both|70 Years|N/A|No|||April 2015|April 16, 2015|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672685||156396|
NCT00673244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 010835|Protocol to Assess the Severity of Acute Kidney Injury|Protocol to Assess the Severity of Acute Kidney Injury|AKI|George Washington University|No|Completed|April 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|44|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00673244||156353|
NCT00672997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-64|A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|301|||Both|20 Years|N/A|No|||July 2014|July 14, 2014|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672997||156372|
NCT00673270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-0077969-20|Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression|Hemodynamic and Biological Effects of Fludrocortisone and Hydrocortisone, in Healthy Volunteers With Aldosterone Induced Suppression|AFLUCO2|Rennes University Hospital|No|Terminated|May 2008|March 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|13|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||March 2012|March 1, 2012|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673270||156351|
NCT00673530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRICORE|Clinical Nutrition Concept for Hospitalized Patients With Malnutrition|Effect of an Evidence Based Clinical Nutrition Concept on Clinical Outcomes in Hospitalized Patients With Malnutrition When Severity of Disease is Taken Into Consideration|NUTRICORE|Charite University, Berlin, Germany|Yes|Completed|July 2006|March 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10242|||Both|18 Years|N/A|No|||February 2009|March 7, 2016|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00673530||156331|
NCT00673803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|preloaded 2008|Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification|Influence of Two Sharp-edged Hydrophobic Acrylic Micro-incision-IOLs on Posterior Capsule Opacification. A Randomized, Double-masked Study With Intraindividual Comparison.||Hospital Hietzing|No|Completed|December 2008|June 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|80 Years|No|||December 2008|August 16, 2010|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673803||156310|
NCT00674128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001566|Comparison of Cyanoacrylate Tissue Adhesive and Suture for Closure of Cardiac Device Pockets|Prospective Comparison of Cyanoacrylate Tissue Adhesive (Dermabond) and Suture (Vicryl) for Closure of Cardiac Device Pockets||Mayo Clinic|No|Terminated|May 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|21 Years|N/A|No|||December 2010|December 1, 2010|May 5, 2008|Yes|Yes|Slow accrual.|No|October 5, 2010|https://clinicaltrials.gov/show/NCT00674128||156285|
NCT00674167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA02/33/06|The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma|The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.||National University Hospital, Singapore|Yes|Active, not recruiting|May 2007|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674167||156282|
NCT00674414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595159|Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery|A Phase II, Randomized, Multi-center Study, Assessing Value of Adding Everolimus (RAD001) to Trastuzumab as Preoperative Therapy of HER-2 Positive Primary Breast Cancer Amenable to Surgery.||UNICANCER||Terminated|April 2008|||January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|N/A|No|||January 2013|January 17, 2013|May 6, 2008||No|IDMC decision due to accrual issue (82 pts accrued / 120 expected)|No||https://clinicaltrials.gov/show/NCT00674414||156263|
NCT00670124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFHypothermia01|Hypothermia to Prevent High Intracranial Pressure in Patients With Acute Liver Failure|Pilot Trial on the Effect of Mild Hypothermia on Intracranial Pressure in Patients With Hyperacute Liver Failure||Rigshospitalet, Denmark|No|Completed|January 2005|June 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670124||156588|
NCT00670137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAL0001-OA|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2008|||||N/A|N/A|N/A||||||||||||||April 30, 2008|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670137||156587|
NCT00670150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9L-07-12|New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia|Phase II Study of NRX 195183 Induction and NRX 195183 Combined With Arsenic Trioxide (As2o3) as Initial Consolidation Therapy Followed by Continuous NRX 195183 Maintenance Therapy for Patients With Untreated Acute Promyelocytic Leukemia||University of Southern California|No|Withdrawn|May 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|April 28, 2008|Yes|Yes|sponsor withdrew support|No||https://clinicaltrials.gov/show/NCT00670150||156586|
NCT00670163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078752|Effectiveness of Community-Level Behavioral and Biomedical Interventions for Reducing HIV/STIs in Men in Peru|Comunidades Positivas and Enhanced Partner Therapy in Peru||University of California, Los Angeles|Yes|Completed|April 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|718|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670163||156585|
NCT00640731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-US-001|Safety and Efficacy Study of OmniWave Endovascular System to Treat Deep Vein Thrombosis|Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study|SONIC I|OmniSonics Medical Technologies, Inc.|Yes|Enrolling by invitation|March 2008|July 2008|Anticipated|July 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||March 2008|March 20, 2008|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640731||158833|
NCT00641043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.15|Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone|A Randomised, Double-blind, Placebo Controlled, Parallel Group 24 Week Study to Assess the Efficacy and Safety of BI 1356 (5 mg) in Combination With 30 mg Pioglitazone (Both Administered Orally Once Daily), Compared to 30 mg Pioglitazone Plus Placebo in Drug Naive or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control.||Boehringer Ingelheim||Completed|March 2008|||June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|389|||Both|18 Years|80 Years|No|||January 2014|January 22, 2014|February 29, 2008||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00641043||158809|
NCT00641056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWBR (DURATION - 3)|Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)|Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea||AstraZeneca|No|Completed|April 2008|November 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|467|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|March 17, 2008|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00641056||158808|
NCT00641316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F071006001|An Assessment of Bone Augmentation in Post-Extraction Sockets|A Prospective Study of Bone Augmentation Techniques in Extraction Sockets and Implant Surface Textures|FMD-007|University of Alabama at Birmingham|Yes|Completed|April 2008|November 2012|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|102|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 27, 2013|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641316||158788|
NCT00670657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-IT-131-0177|CRITIC - Treatment of Candidemia and Invasive Candidiasis|CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients|CRITIC|Gilead Sciences|No|Completed|May 2007|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|14 Years|N/A|No|||March 2009|March 26, 2009|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670657||156547|
NCT00670670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/187 - Part 1|A Prospective, Randomized Clinical Study on the Effects of Casein Phosphopeptide-amorphous Calcium Phosphate (CPP-ACP) Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 1|A Prospective, Randomized Clinical Study on the Effects of CPP-ACP Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 1||University Hospital, Ghent|No|Recruiting|July 2008|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|10 Years|60 Years|No|||December 2014|December 4, 2014|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670670||156546|
NCT00671216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB1111509|A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.|A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705 and GW642444 as Monotherapies and in Combination in Healthy Subjects.||GlaxoSmithKline||Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1|||16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|April 30, 2008||||No||https://clinicaltrials.gov/show/NCT00671216||156505|
NCT00671229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12496-CP-006A|Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1|Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|May 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|420|Samples With DNA|Serum samples, DNA, Exhaled Breah Condensate|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|April 2015|April 13, 2015|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00671229||156504|
NCT00671515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-07-20|Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome|Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome||University Hospital Case Medical Center|Yes|Completed|April 2008|November 2011|Actual|August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|70 Years|No|||October 2014|October 9, 2014|May 1, 2008|Yes|Yes||No|October 31, 2013|https://clinicaltrials.gov/show/NCT00671515||156482|
NCT00671827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0122|Evaluation of Robot-Assisted Surgery in Gynecologic Oncology|Prospective Evaluation of Robot-Assisted Surgery in Gynecologic Oncology||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2008|||April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|1000|||Female|N/A|N/A|No|Non-Probability Sample|Women who have undergone or will undergo a robotic-assisted gynecologic procedure at M. D.        Anderson Cancer Center and St. Luke's Episcopal Hospital.|November 2015|November 6, 2015|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671827||156459|
NCT00672100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2007-198|Initial Local Anesthetic Dose With Continuous Interscalene Analgesia|The Effect Of Initial Local Anesthetic Dose With Continuous Interscalene Analgesia On Postoperative Pain And Diaphragmatic Function In Arthroscopic Shoulder Surgery Patients: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study||William Beaumont Hospitals|No|Completed|January 2009|August 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|80 Years|No|||May 2013|May 22, 2013|May 2, 2008||No||No|July 12, 2011|https://clinicaltrials.gov/show/NCT00672100||156439|
NCT00672113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100128|Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension|Effects of Adalat LA 30 mg and Coracten 30 mg on Nifedipine Plasma Concentration , Plasma Catecholamines, Blood Pressure Response and Heart Rate in Fed Mild to Moderate Hypertensive Patients.||Bayer|No|Completed|December 2003|August 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|43|||Both|18 Years|75 Years|No|||December 2014|December 18, 2014|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00672113||156438|
NCT00672412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1069|Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand|A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), and Nevirapine (NVP) as GPO-Vir Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children Greater Than or Equal to Five Months and Less Than 13 Years of Age in Thailand||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2008|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|5 Months|12 Years|No|||September 2012|September 11, 2012|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672412||156416|
NCT00672438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04212008-1119|Heritability of Opioid Effects: A Twin Study|Heritability of Opioid Effects: A Twin Study||Stanford University||Completed|May 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|242|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672438||156415|
NCT00672451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT002367-01A2|Rhubarb and Angiotensin Converting Enzyme Inhibitor|Rhubarb and Angiotensin Converting Enzyme Inhibitor|RACE II|Wake Forest School of Medicine|Yes|Terminated|January 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||May 2009|August 18, 2011|May 2, 2008||No|unable to meet recruitment goal|No||https://clinicaltrials.gov/show/NCT00672451||156414|
NCT00672698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15042008/001|Evaluation of Surgical Risk in Elderly Patients Submitted to Elective Surgery|Evaluation of Surgical Risk in Elderly Patients Submitted to Elective Surgery: Comparative Study of Elective Vascular, Digestive and Biliary Surgery||Cirujanos la Serena|No|Withdrawn|November 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|0|||Both|15 Years|N/A|No|Non-Probability Sample|All patients older than 65 years of age submitted to elective surgery at our institution|October 2012|October 29, 2012|May 2, 2008||No|NOT ENOUGH DATA AVAILABLE|No||https://clinicaltrials.gov/show/NCT00672698||156395|
NCT00672958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_303|Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults With Major Depressive Disorder||Takeda|No|Completed|April 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|75 Years|No|||October 2013|October 24, 2013|May 2, 2008|Yes|Yes||No|April 19, 2013|https://clinicaltrials.gov/show/NCT00672958||156375|
NCT00672971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OYS001-07|Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice|An Open Label Randomized Study to Compare the Safety and Efficacy of Silcap Plus (Approximately 4% Dimeticone) Against Nix Cream Rinse.||Oystershell NV|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|4 Years|85 Years|No|||May 2008|May 5, 2008|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672971||156374|
NCT00673283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008644|Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging|Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging||Duke University|No|Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|86|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|July 31, 2014|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00673283||156350|
NCT00673543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0074|Corticosteroid Therapy on Glucose Control in Pregnant Women With Diabetes|The Effects of Corticosteroid Therapy on Glucose Control in Pregnant Women With Insulin Requiring Diabetes Mellitus||The University of Texas Health Science Center, Houston|No|Completed|May 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|16|||Female|18 Years|52 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women who will receive corticosteroid therapy.|January 2011|January 3, 2011|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673543||156330|
NCT00673842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21721|Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction|Risk Estimation Following Infarction Noninvasive Evaluation - ICD Efficacy|REFINE-ICD|University of Calgary|Yes|Suspended|March 2011|December 2018|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|80 Years|No|||January 2016|January 23, 2016|April 29, 2008|Yes|Yes|Funding withdrawn by partner due to low enrollment|No||https://clinicaltrials.gov/show/NCT00673842||156307|
NCT00673816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080129|Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome|Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome|VHL3|National Institutes of Health Clinical Center (CC)|Yes|Terminated|May 2008|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|May 6, 2008|Yes|Yes|Inability to recruit and adequate number of participants|No|September 27, 2011|https://clinicaltrials.gov/show/NCT00673816||156309|Early termination of the trial resulted in a small number of participants being analyzed, and Microperimetry (MP-1) results were not accurate for either participant due to fixation issues.
NCT00673829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-04|Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer|Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer||Roger Williams Medical Center|Yes|Active, not recruiting|May 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|May 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00673829||156308|
NCT00674180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-833|Data Analysis of a Managed Care Weight Reduction Trial|Data Analysis of a Managed Care Weight Reduction Trial||Albert Einstein College of Medicine of Yeshiva University|No|Active, not recruiting|April 2008|||April 2008|Actual|N/A|Observational|N/A||3|Actual|588|||Both|N/A|N/A|No|Non-Probability Sample|Participants were recruited from an HMO's patient population and from New Hyde Park, NY.|May 2008|May 6, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674180||156281|
NCT00674427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805534 UPCC 20406|Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant|A Phase I/II Trial Of DLI And Activated DLI (ADLI) Followed By Either Repetitive Dosing Of ADLI Or Dose Escalated ADLI For Patients With Relapse After Allogeneic Stem Cell Transplantation||University of Pennsylvania|No|Terminated|January 2008|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|May 5, 2008|Yes|Yes|Insufficient funds|No||https://clinicaltrials.gov/show/NCT00674427||156262|
NCT00670514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smoking cessation project|Smoking Cessation in a Dentistry Setting|A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri||Uppsala University|No|Completed|April 2003|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|2|||300|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 30, 2008|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00670514||156558|
NCT00670176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICSC01|Pre- and Postoperative Cardiopulmonary Rehabilitation Reduces Complications After Coronary Artery Bypass Surgery: A Randomized Trial|Pre- and Postoperative Cardiopulmonary Rehabilitation Reduces Complications After Coronary Artery Bypass Surgery: A Randomized Trial||Universidade do Sul de Santa Catarina|Yes|Completed||June 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||56|||Both|N/A|N/A|No|||April 2008|April 30, 2008|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670176||156584|
NCT00640744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18077|Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions|Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis|DCAT|Baylor College of Medicine|No|Recruiting|February 2006|February 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|85 Years|No|||December 2010|December 2, 2010|January 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00640744||158832|
NCT00641069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAND V6|Automated Chest Compression in Cardiac Arrest|Effect on Hemodynamics of Automated Band Chest Compression Device in Cardiac Arrest Resuscitation||Beaujon Hospital|No|Completed|February 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients aged > 18 with out-of-hospital cardiac arrest|July 2009|July 14, 2009|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641069||158807|
NCT00641082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-401|A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function|A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function||Bukwang Pharmaceutical||Completed|February 2008|||March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|60 Years|No|||April 2012|April 24, 2012|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00641082||158806|
NCT00670943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.E. 2007-05-41|Effect of Abrupt Plavix® Discontinuation on Platelet Function|Effect of Abrupt Plavix® Discontinuation on Platelet Function||Université de Montréal|Yes|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|52|||Both|18 Years|90 Years|No|Probability Sample|Patients with stable coronary artery disease|March 2009|March 24, 2009|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670943||156525|
NCT00671528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05134|Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)|Double-blind Evaluation of the Safety and Efficacy of Quadriderme® (Betamethasone Diproprionate, Clotrimazole and Gentamicin) Compared With Betamethasone Diproprionate Combined With Gentamicin Sulfate and With Betamethasone Diproprionate in the Treatment of Impetiginous Eczema||Merck Sharp & Dohme Corp.|No|Terminated|July 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3|||Both|12 Years|N/A|No|||December 2014|December 29, 2014|May 1, 2008||No|terminated early due to lack of recruitment [only 3 of 207 subjects were enrolled]|No|May 19, 2011|https://clinicaltrials.gov/show/NCT00671528||156481|This study was terminated early due to lack of recruitment (only 3 of 201 participants were enrolled). Statistical analyses were not performed.
NCT00671853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-06-19|Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)|Quetiapine XR in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression With or Without Substance Use Disorder||University Hospital Case Medical Center|Yes|Completed|April 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||January 2013|September 30, 2013|May 1, 2008|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00671853||156458|
NCT00671866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|y.finkelstein.ctil.|Neurotoxic Health Hazards of Long-Term Low-Level Exposure to Organophosphate (OP) Compounds in in Hula Valley|||Shaare Zedek Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|||||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Kibbutzim|April 2008|May 4, 2008|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671866||156457|
NCT00672139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200K1-4001|Study Evaluating The Safety Of Subcutaneous Methylnaltrexone In Treatment Of Opioid-Induced Constipation|Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation||Valeant Pharmaceuticals International, Inc.|No|Recruiting|July 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|168|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672139||156437|
NCT00672152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001360|A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation|A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies|WT-1|Duke University|No|Terminated|June 2007|October 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||December 2013|December 7, 2013|May 4, 2008|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00672152||156436|
NCT00671879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP511|Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back|Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back||Meda Pharmaceuticals|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|830|||Both|18 Years|70 Years|No|||October 2012|October 22, 2012|May 1, 2008|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00671879||156456|
NCT00672191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-004-001|Phase II Study of AGS‑004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV|A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption||Argos Therapeutics|Yes|Completed|February 2008|November 2011|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|60 Years|No|||January 2013|January 22, 2013|May 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672191||156433|
NCT00672165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-017|Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies|Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies||Memorial Sloan Kettering Cancer Center||Completed|July 2005|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|N/A|No|||February 2015|February 24, 2015|May 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00672165||156435|
NCT00672178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001398|Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)|Phase I/II Trial Evaluating Toxicity and Efficacy of Adding Stereotactic Body Radiotherapy to Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer||Duke University|No|Terminated|March 2008|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||January 2011|January 9, 2011|May 4, 2008|Yes|Yes|Slow accrual|No|September 21, 2010|https://clinicaltrials.gov/show/NCT00672178||156434|Early termination due to low accrual, only one subject enrolled.
NCT00672724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-375-041|Efficacy of Ramelteon in Adults With Chronic Insomnia|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment With Ramelteon in Adult Subjects With Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data||Takeda|No|Terminated|February 2005|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1081|||Both|18 Years|64 Years|No|||February 2012|February 27, 2012|May 2, 2008|Yes|Yes|Issues with data collection tool|No||https://clinicaltrials.gov/show/NCT00672724||156393|
NCT00672711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2007-200|Susceptibility to Chronic Post-Traumatic Extremity Pain|Susceptibility to Chronic Post-Traumatic Extremity Pain||William Beaumont Hospitals|No|Completed|April 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|250|Samples With DNA|Whole blood serum|Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing shoulder surgery|September 2012|September 18, 2012|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672711||156394|
NCT00672984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-112|Guanfacine Immediate-release Electrocardiogram Results (QTc) Study|A Phase I, Randomized, Gender Stratified, Double-Blind, Placebo- and Positive-Controlled, Three Period Crossover Trial to Assess the Effect of Guanfacine Hydrochloride on QT/QTc Interval in Healthy Men and Women||Shire||Completed|April 2008|August 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|83|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 22, 2009|May 2, 2008|No|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00672984||156373|
NCT00673296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200711050R|Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation|Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation||National Taiwan University Hospital|Yes|Active, not recruiting|January 2007|December 2008|Anticipated|April 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||April 2008|May 5, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673296||156349|
NCT00674193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL06B1|Evaluating Dactinomycin and Vincristine in Young Patients With Cancer|A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children With Cancer||Children's Oncology Group|No|Active, not recruiting|February 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|Samples With DNA|blood and urine|Both|N/A|16 Years|No|Probability Sample|Patients with a diagnosis of cancer, including, but not limited to, any of the following:        Acute lymphoblastic leukemia, Ewing sarcoma, Rhabdomyosarcoma, Soft tissue sarcoma, Wilms        tumor who are due to receive or receiving dactinomycin and/or vincristine as a component        of cancer treatment on another clinical trial|August 2015|August 26, 2015|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674193||156280|
NCT00673855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-17|Acute Comfort of Lubricant Eye Drops FID 112903|||Alcon Research|No|Completed|May 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|May 2, 2008||No||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00673855||156306|
NCT00674440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-003683|Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism|Localization of Focal Forms of Hyperinsulinism of Infancy With 18F-labeled L-fluoro-DOPA PET Scan||Children's Hospital of Philadelphia|Yes|Active, not recruiting|December 2004|December 2016|Anticipated|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|105|||Both|N/A|18 Years|No|||February 2016|February 18, 2016|May 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674440||156261|
NCT00674453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2181042|The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation|The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis|LACE|Ligand Pharmaceuticals|No|Completed|September 2004|September 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|51|||Female|50 Years|N/A|No|||August 2011|August 8, 2011|April 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674453||156260|
NCT00670189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA194-002|A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer|A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|July 2008|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670189||156583|
NCT00670202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-002369|Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis|The Effect of Fasudil on Rho Kinase Activity in Patients Scheduled for Elective Carotid Endarterectomy||Brigham and Women's Hospital|No|Recruiting|April 2008|April 2011|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670202||156582|
NCT00670527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPET, Project nr. 104.|[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases|Evaluation of [18F] Fluorocholine PET/CT for Detection of Regional Lymph Node Metastases From Prostate Cancer|PROPET|Odense University Hospital|Yes|Recruiting|January 2008|April 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Anticipated|205|||Male|N/A|N/A|No|||October 2012|October 5, 2012|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670527||156557|
NCT00670800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2276|Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome|Influence of Insulin Resistance on Cognitive, Emotional and Opioid System Functioning in Women With Polycystic Ovary Syndrome||University of Michigan|No|Completed|January 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|April 30, 2008||No||No|January 2, 2013|https://clinicaltrials.gov/show/NCT00670800||156536|
NCT00640757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 26009|Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome|Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome||Pennington Biomedical Research Center|No|Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00640757||158831|
NCT00640770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE06-02|Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease|A Prospective, Randomized, Multicenter Comparison of Balloon Angioplasty and the Cypher Selecttm + Coronary and Infrapopliteal Stent in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease|ACHILLES|Cordis Corporation|Yes|Completed|March 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|85 Years|No|||March 2011|March 14, 2011|March 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640770||158830|
NCT00641355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 26-2007|Acute Phase Proteins as Early Markers in Sepsis|Acute Phase Proteins as Early Markers in Sepsis||University of Zurich|No|Not yet recruiting|April 2008|September 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with severe trauma|March 2008|March 21, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641355||158785|
NCT00641602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|322|A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis|A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis.||AstraZeneca||Completed|December 2002|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|75 Years|No|||March 2009|March 25, 2009|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00641602||158767|
NCT00671242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kkaira1970|Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake|Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer|angiogenesis|Gunma University|Yes|Completed||||||N/A|Observational|N/A||2|||||Both|N/A|N/A|No|||January 2008|May 2, 2008|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671242||156503|
NCT00671255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-025|Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Elderly Subjects With Chronic Insomnia||Takeda|No|Completed|December 2002|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|829|||Both|65 Years|N/A|No|||February 2012|February 27, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671255||156502|
NCT00671268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0704rP|Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma|Multicentre, Multinational Randomised DBPC Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma|AMETHYST|Allergopharma GmbH & Co. KG|No|Completed|March 2008|March 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|60 Years|No|||November 2013|November 7, 2013|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00671268||156501|
NCT00671541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCID 2006-026|Nasospore Stent For Use in Enodscopic Sinus Surgery|Nasospore Stent For The Use in Endoscopic Sinus Surgery||Lahey Clinic|No|Withdrawn|March 2006|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|May 1, 2008|No|Yes|Principal Investigator left the institution requested study terminated.|No||https://clinicaltrials.gov/show/NCT00671541||156480|
NCT00671567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-020|Ramelteon in Adults With Chronic Insomnia|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Adults With Chronic Insomnia||Takeda|No|Completed|December 2002|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|848|||Both|18 Years|64 Years|No|||November 2012|November 16, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671567||156478|
NCT00671554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC/ORI 07-02|Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma|Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG||Greenville Health System|No|Terminated|April 2008|March 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|April 30, 2008|Yes|Yes|Due to business considerations; not due to toxicities or adverse events.|No|April 3, 2012|https://clinicaltrials.gov/show/NCT00671554||156479|
NCT00672204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612M98726|Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes|Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients|RAPTIVA|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2007|August 2012|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||February 2013|February 20, 2013|May 2, 2008|Yes|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT00672204||156432|Early termination due to Raptiva being withdrawn from market
NCT00672217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0924|Cognitive-Behavioral Therapy for Chronic Insomnia After Breast Cancer Treatment|Cognitive-Behavioral Therapy for Chronic Insomnia After Breast Cancer Treatment|REST|University of Colorado, Denver|No|Completed|July 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|64|||Female|21 Years|65 Years|No|||January 2013|May 26, 2015|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672217||156431|
NCT00672464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006916|Cardio Risk of Acute Schizophrenia Olanzapine Duke|Combined Treatment of Cardiovascular Risk Factors In Newly Admitted Patients With Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine And Matched Controls|CRASOD|Duke University|No|Withdrawn|April 2008|February 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|May 4, 2008|Yes|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT00672464||156413|
NCT00672737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01222008-985|Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea|Experimental Pain Processing and Autonomic Function in Subjects Suffering From Obstructive Sleep Apnea||Stanford University||Active, not recruiting|February 2008|December 2010|Anticipated|August 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|50|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 7, 2010|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672737||156392|
NCT00673023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8641|Study the Role of Genetic Variation in the Determining Lipid Profile Response to Dietary Change|Study the Role of Polymorphism at the CETP Gene Locuse in the Determining Lipid Profile Response to Dietary Change||Tabriz University|Yes|Completed|October 2007|||December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|102|||Both|18 Years|35 Years|No|||May 2008|May 4, 2008|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00673023||156370|
NCT00673010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-116|Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma|Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2005|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00673010||156371|
NCT00673556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-740|A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate|A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study Examining the Efficacy and Safety of Weekly Intramuscular Administration of 15mg Alefacept Over 12 Weeks in a Population of Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate||Astellas Pharma Inc|No|Completed|October 2003|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|195|||Both|16 Years|N/A|No|||August 2014|August 25, 2014|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00673556||156329|
NCT00674505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G070189/S002|Safety & Performance Study of Lumen Biomedical's FiberNet Distal Protection System for the Treatment of Renal Artery Stenosis|FiberNet Renal Artery Embolic Protection Study: A Prospective, Single-arm Feasibility Trial of Renal Artery Distal Protection Using the Lumen Biomedical FiberNet Embolic Protection System|FORTRESS|VIVA Physicians|Yes|Active, not recruiting|January 2008|||June 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|85 Years|No|||February 2010|February 16, 2010|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674505||156256|
NCT00674206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007792|A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer|A Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2NEU- (Triple Negative) Metastatic Breast Cancer||Emory University|Yes|Terminated|October 2008|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|May 6, 2008|Yes|Yes|Sponsor funding stopped|No|March 30, 2012|https://clinicaltrials.gov/show/NCT00674206||156279|Early termination of the study due to slow accrual
NCT00674466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM200-102|A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-Week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy||ConjuChem|Yes|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|25 Years|N/A|No|||November 2008|November 18, 2008|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674466||156259|
NCT00674479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0925|INCB018424 in Patients With Advanced Hematologic Malignancies|Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2008|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00674479||156258|
NCT00674492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-193|Hepatitis C Virus (HCV) Treatment Completion or Withdrawal|Patients' View of Hepatitis C Treatment Completion or Withdrawal||VA Office of Research and Development|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|VHA patients who ever initiated antiviral treatment for hepatitis C.|April 2015|April 27, 2015|May 6, 2008||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00674492||156257|
NCT00670215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100588|BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis|Prospective, Randomized, Double-blind, Comparison of Ciprofloxacin Extended-release 1000 mg Tablets Given as Two Different Prophylactic Dosing Regimens (Regimen I - Single-dose Ciprofloxacin MR 1000 mg or Regimen II - Multiple-dose Ciprofloxacin MR 1000 mg Once Daily for 3 Days) for the Prevention of Post-operative Infectious Complications in Patients Undergoing Transrectal Needle Biopsy of the Prostate||Bayer||Completed|April 2004|October 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|497|||Male|18 Years|N/A|No|||December 2014|December 18, 2014|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670215||156581|
NCT00670540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC-04-02|Epidemiology of Thromboembolism Disease: A Cohort Study|A Prospective Epidemiological Multicenter Cohort Study on Patients Clinically Suspected of Deep Vein Thrombosis or Pulmonary Embolism|OPTIMEV|University Hospital, Grenoble|No|Completed|November 2004|February 2010|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8256|||Both|18 Years|N/A|No|Non-Probability Sample|All male or female inpatients and outpatients hospital and office-based. 18 years old with        clinical suspicion of deep vein thrombosis (DVT) or pulmonary embolism (PE).        Patients with cognitive disorders or language impairment preventing collection of risk        factor data by history-taking were excluded.|May 2012|May 4, 2012|April 30, 2008||No||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00670540||156556|
NCT00670813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE03|Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil|Verstärkung Der Therapeutischen Wirkung Von Schlafentzug Durch Modafinil - Eine Doppelblinde, Randomisierte, Placebokontrollierte Monozentrische Studie Der Phase II (Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil - a Double Blind, Placebo-controlled Monocentric Phase II Study)||Technische Universität München|Yes|Withdrawn|May 2008|November 2009|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|70 Years|No|||April 2008|July 19, 2011|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670813||156535|
NCT00641368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08-003|R4Power: An Online Resilience Program for Adolescents|R4Power: An Online Resilience Program for Adolescents|R4Power|Swarthmore College||Recruiting|October 2007|October 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||March 2008|March 17, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641368||158784|
NCT00641615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWMU1035|Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer|Phase I Study of Peptide Vaccine and S-1 Plus CPT-11 Chemotherapy in Patients With Unresectable Recurrent or Metastatic Colorectal Cancer||Tokyo Women's Medical University|Yes|Completed|May 2007|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|N/A|No|||May 2015|May 11, 2015|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641615||158766|
NCT00641628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC01|Nipple Areola Complex Conservation|Subcutaneous Mastectomy With Conservation of the Nipple Areola Complex: Broadening the Indications||Technische Universität München|No|Completed|July 2003|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|||Samples Without DNA|Breast Carcinoma Tissue|Female|N/A|N/A|No|||March 2008|March 19, 2008|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00641628||158765|
NCT00670969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27265|Validation of Hand Held Indirect Calorimeter in Overweight and Obese Patients|Validation of Handheld Indirect Calorimeter in Overweight and Obese Patients||Penn State University|No|Not yet recruiting|May 2008|May 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Major Inclusion & Exclusion Criteria: Age at least 18 years (no upper limit). Able to fast        overnight. Have a BMI no less than 25 kg/m2.        Method of Identification of Subjects/Samples/Medical Records: Participants will be        recruited with a flyer. Interested individuals will contact the investigators who will ask        basic eligibility questions. If eligible, pre-test requirements will be explained to the        participant (12 hour fast, avoidance of physical activity and smoking for the same time        period.)|April 2008|May 1, 2008|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670969||156523|
NCT00671281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tranexamic Acid in FESS|The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery|The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery: A Randomized, Prospective, Double-Blinded Study||University of Calgary|No|Withdrawn|October 2008|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|65 Years|No|||September 2010|September 2, 2010|April 30, 2008||No|Study was cancelled|No||https://clinicaltrials.gov/show/NCT00671281||156500|
NCT00671294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-017|Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety and Efficacy of TAK-375 in Elderly Subjects With Chronic Insomnia.||Takeda|No|Completed|October 2002|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|100|||Both|65 Years|N/A|No|||February 2012|February 27, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671294||156499|
NCT00671580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PZ-601-02|Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection|A Phase II Randomized, Observer-Blind, Multi-Center Study to Evaluate the Safety, Potential Efficacy, and Pharmacokinetics of Two Dosing Regimens of Intravenous PZ-601 and Standard of Care in the Treatment of Complicated Skin and Skin Structure Infections||Protez Pharmaceuticals, Inc.|No|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671580||156477|
NCT00671892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3030-07-8R5|Role of TLR4 in Environmental Asthma|Role of TLR4 in Environmental Asthma||Duke University|No|Completed|September 2001|April 2008|Actual|August 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|855|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|May 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671892||156455|
NCT00672230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSUeirb00000403|Dietary Lutein and the Retinopathy of Prematurity|The Placental and Mammary Transfer of Lutein and Zeaxanthin Into the Fetus and the Breast-Fed Infant||Oregon Health and Science University|No|Recruiting|August 2005|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 5, 2008|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672230||156430|
NCT00672477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200K1-4000|Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness|A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2008|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|254|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672477||156412|
NCT00672490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00023|Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder|An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder|MANIA|AstraZeneca|No|Completed|April 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|376|||Both|18 Years|60 Years|No|||June 2012|June 11, 2012|May 2, 2008|Yes|Yes||No|June 24, 2010|https://clinicaltrials.gov/show/NCT00672490||156411|
NCT00672750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23597|A Retrospective Review Of Outcomes Following Laparoscopic Myomectomy|A Retrospective Review Of Outcomes Following Laparoscopic Myomectomy|retromyo|The Advanced Gynecologic Surgery Institute|No|Active, not recruiting|February 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Anticipated|900|||Female|16 Years|70 Years|No|Probability Sample|Private patients of Dr Charles Miller who have undergone laparoscopic myomectomy since        1999|June 2015|June 22, 2015|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00672750||156391|
NCT00673049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021018|Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer|Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology|NSCLC|Pfizer|Yes|Terminated|May 2008|April 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|583|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|May 5, 2008|Yes|Yes|See termination reason in detailed description.|No|April 26, 2013|https://clinicaltrials.gov/show/NCT00673049||156368|
NCT00673036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1244|French Registry of Acute Coronary Syndrome|French Registry of Acute Coronary Syndrome With or Without ST Elevation|Fast-MI|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2005|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3750|Samples With DNA|Whole blood, serum and DNA|Both|18 Years|N/A|No|Non-Probability Sample|Admitted patients in a Unit of Coronary Intensive Care (USIC) for a acute coronary        syndrome|October 2015|October 13, 2015|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673036||156369|
NCT00673062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05031|Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)|Study of the Decongestant Effect of SCH 900538 Compared With Placebo and Pseudoephedrine as Active Control in Subjects With Seasonal Allergic Rhinitis (SAR) Exposed to Pollen in an Environmental Exposure Unit||Merck Sharp & Dohme Corp.|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|265|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|May 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00673062||156367|
NCT00674518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23RR017554-01A2|Changing Healthy Outcomes In Clinic Environments|Health Promotion Intervention: Sedentary Primary Care Patients|CHOICE|Oregon Health and Science University|Yes|Active, not recruiting|January 2005|March 2009|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|100|||Both|30 Years|65 Years|No|||May 2008|May 6, 2008|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674518||156255|
NCT00673868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26769|Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants|A Phase I-II Randomized Trial to Examine the Clinical, Immunologic and Virologic Effects of CMV Specific CTL When Used for Prophylaxis Against CMV Disease in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants||Penn State University|Yes|Completed|October 2007|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Both|2 Years|65 Years|No|||April 2008|January 22, 2009|May 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00673868||156305|
NCT00673881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-335-001|ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study|ABT-335 (Choline Fenofibrate)Reverse Cholesterol Transport (RCT) Study||Radiant Research|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|May 5, 2008|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00673881||156304|
NCT00670553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589CBE01|A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer|A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer||Novartis||Completed|September 2008|||January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670553||156555|
NCT00670566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBEH_L_03170|Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients|Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients||Sanofi|No|Completed|April 2008|||March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|503|||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670566||156554|
NCT00670826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M100 IRB07-003313|Comparison Study of Intraoperative Patient Warming Systems|Intraoperative Warming: Comparison of Performance of the Dynatherm Medical vitalHEAT Temperature Management System(vH2)With the Arizant Bair Hugger System||Dynatherm Medical Inc.|No|Not yet recruiting|July 2008|November 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2008|May 1, 2008|April 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670826||156534|
NCT00670839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005023-15|Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)|Open-label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of Double-dose (40 µg at S0, S4 and S24), Versus Standard Dose Vaccination (20 µg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost|B-BOOST|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|May 2008|February 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|178|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670839||156533|
NCT00671060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.3|Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy|Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy, Inclusive, Not Accompanied by Complete Expulsion of the Contents of the Uterus||Gynuity Health Projects|Yes|Completed|October 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|153|||Female|N/A|N/A|No|||May 2013|May 6, 2013|April 29, 2008|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00671060||156516|
NCT00671359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-103|Food Effects of Single Oral Dose of 600mg TR-701|An Open-Label, Single-Dose, Two-Treatment, Randomized, Two-Way Crossover, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults in the Fed and Fasted State||Trius Therapeutics LLC|No|Completed|April 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|May 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671359||156494|
NCT00671372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APO3583g|A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Multiple Doses of Dulanermin Administered Intravenously in Combination With Camptosar®/Erbitux® Chemotherapy or the Folfiri Regimen With or Without Bevacizumab in Subjects With Previously Treated Metastatic Colorectal Cancer||Genentech, Inc.||Completed|July 2006|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671372||156493|
NCT00641641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINT01|The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection|An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection|PINT|Kirby Institute|Yes|Completed|March 2008|June 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2013|May 23, 2013|February 28, 2008||No||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00641641||158764|Limited cohort (n=16) of exclusively male participants treated with a licensed regimen of combination antiretroviral therapy with the primary focus being a detailed examination of virus decay characteristics
NCT00641654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudractCT 2006-003409-18|Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin|An Open-label Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 Weeks Pegylated Interferon Alfa-2a 40 kD (PEGASYS) Combination Therapy With Ribavirin (Copegus) in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy With Pegylated Interferon and Ribavirin|RelapC|Göteborg University|No|Terminated|January 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||March 2012|August 29, 2012|March 17, 2008||No|Recruitment problems in Denmark and Norway|No||https://clinicaltrials.gov/show/NCT00641654||158763|
NCT00641901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070117004|A Study to Evaluate Associations Between Gingivitis and Pregnancy Outcomes|A Study of Oral Health Care Education and Therapy to Reduce Gingivitis During Pregnancy|TRIUMPH|University of Alabama at Birmingham|No|Completed|January 2007|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|Samples Without DNA|Samples of venous blood and gingivial crevicular fluid (GCF)will be collected at baseline      and at week-8.      GCF samples will be harvested from two non-adjacent oral sites, flash-frozen in liquid      nitrogen and stored at -70 degrees F. until batched testing. GCF samples will be analyzed      for TNFalpha, IL1beta and IL 6 by Lumidex methodology.      Blood samples will be analyzed for Serum Inflammatory markers, C-Reative Protein and      inflammatory cytokines.|Female|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Center for Women's Reproductive Heath at UAB|February 2013|February 27, 2013|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641901||158744|
NCT00670982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-214|Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer|Phase 2 Study of Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|May 2008|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|April 29, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00670982||156522|
NCT00671307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBC101|Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels|Phase 1b Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Infusion Trial of the Pharmacokinetics of Rhu-pGelsolin in Patients With Decreased Natural Gelsolin Levels||Critical Biologics Corporation|Yes|Completed|March 2008|May 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||April 2010|September 27, 2010|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671307||156498|
NCT00671593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008369|Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge|Genetics of Environmental Asthma: Differential Gene Expression in the Lung and Peripheral Blood After Inhaled Allergen Challenge||Duke University|Yes|Terminated|October 2006|April 2009|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|May 2, 2008|No|Yes|funding terminated|No||https://clinicaltrials.gov/show/NCT00671593||156476|
NCT00671905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1. 25/4/08|Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)|Circumferential vs Ganglionated Plexi Ablation in Patients With Paroxysmal Atrial Fibrillation: A Randomized Study||Cardiovascular Research Society, Greece|Yes|Completed|May 2008|August 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||April 2013|April 10, 2013|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671905||156454|
NCT00671918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO3-05|Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma|A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping||Navidea Biopharmaceuticals|No|Completed|April 2008|July 2009|Actual|June 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|186|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|April 30, 2008|Yes|Yes||No|April 13, 2013|https://clinicaltrials.gov/show/NCT00671918||156453|
NCT00672763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITDIBD1|Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease|The Immunomodulatory Role of Vitamin D in Inflammatory Bowel Disease (The IBDVit Study): Double-Blind, Placebo-Controlled Trial of Adjuvant Vitamin D (Colecalciferol) With Corticosteroids in Active Crohn's Disease|IBDVit1|Imperial College London|Yes|Withdrawn|May 2008|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2011|June 3, 2015|May 2, 2008||No|Unable to recruit adequate trial participants|No||https://clinicaltrials.gov/show/NCT00672763||156390|
NCT00672503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 04-065E|Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit|"Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit||Children's Mercy Hospital Kansas City|No|Completed|May 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|321|||Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Patients who acquired a CA-UTI while hospitalized in the PICU between 2004-2007.          2. Patients who had an indwelling urinary catheter while hospitalized in the PICU             between 2004-2007 but did not acquire a CA-UTI.          3. Nurses currently employed in the PICU at Children's Mercy Hospital.          4. All Patient's who acquired a CA-UTI during 2009|October 2011|October 7, 2011|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672503||156410|
NCT00673322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|298-04|Trial of Second Generation Designer T Cells in Colorectal Carcinoma|Phase II/Pilot Trial of Second Generation Designer T Cells in Colorectal Cancer||Roger Williams Medical Center|Yes|Terminated|May 2008|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|May 5, 2008|Yes|Yes|This study will be incorporated into another study.|No||https://clinicaltrials.gov/show/NCT00673322||156347|
NCT00673309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-454|Assessment of Mechanisms of Improved Wound Healing|Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients||The University of Texas Medical Branch, Galveston|Yes|Completed|July 2002|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|13||Actual|644|||Both|N/A|90 Years|No|||May 2012|May 4, 2012|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00673309||156348|
NCT00673569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0655, CDR0000512886|Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment|A Phase II Single-Arm Trial Assessing the Use of an Ex Vivo Sensitivity Assay to Predict Response of Relapsed Metastatic Non-Small Cell Lung Cancer Patients to Erlotinib||Sidney Kimmel Comprehensive Cancer Center||Completed|September 2006|||July 2007|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673569||156328|
NCT00674232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2.0|Treatment of Incomplete Abortion With 600 Mcg Oral Misoprostol Compared to Standard Surgical Treatment|Misoprostol for Treatment of Incomplete Abortion||Gynuity Health Projects|No|Completed|May 2006|October 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|311|||Female|14 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 5, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00674232||156277|
NCT00674245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0001-01 & R&D#00-77|Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.|The Effect Of Pantoprazole 40 mg Once Daily Versus Placebo On The Power Spectral Analysis Of The Sleep Electroencephalogram (EEG) Of Patients With Gastroesophageal Reflux Disease (GERD)||Southern Arizona VA Health Care System|No|Completed|April 2008|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2010|August 18, 2010|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674245||156276|
NCT00670228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_01687|Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction|A Multi-center, Phase 3b, Stratified, Randomized, Open-label Clinical Trial to Evaluate the Efficacy of Intensive Apidra®/Lantus® Therapy vs Sliding Scale Insulin on Infarct Size in Hyperglycemic Subjects With Anterior STEMI (ST Elevation Myocardial Infarction) Undergoing PCI (Percutaneous Coronary Intervention)|INTENSIVE|Sanofi|Yes|Terminated|April 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|35 Years|80 Years|No|||January 2011|January 14, 2011|April 29, 2008|Yes|Yes|Due to Negative feasibility assessment of recruiting the planned number of subjects within the    study timelines|No|November 16, 2010|https://clinicaltrials.gov/show/NCT00670228||156580|Early termination leading to small numbers of subjects analyzed. Only descriptive statistics were presented for primary and key secondary efficacy endpoints. The analysis focused on a review of safety Adverse Events (AEs) data.
NCT00670241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 80185-G21|Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris|A Phase 3 Study Comparing a Gel Containing Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) With Tacalcitol Ointment (4 mcg/g) and Gel Vehicle, Used Once Daily in the Treatment of Psoriasis Vulgaris||LEO Pharma|No|Completed|April 2008|April 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|458|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|April 29, 2008||No||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00670241||156579|
NCT00670254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPRESS|Hydrocortisone for Prevention of Septic Shock|Placebo-controlled, Randomised, Double-blind Study to Investigate the Efficacy and Safety of Low Dose Hydrocortisone to Prevent the Development of Septic Shock in Patients With Severe Sepsis|HYPRESS|Charite University, Berlin, Germany|Yes|Completed|January 2009|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670254||156578|
NCT00670267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAND1002|Oral Nadolol for the Treatment of Adults With Mild Asthma|An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma||Invion, Inc.|No|Completed|January 2007|June 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||February 2010|February 2, 2010|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00670267||156577|
NCT00670579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFC#30/2008|Study About Complications of Totally Implanted Venous Access Devices (TIVADs) in People With Cystic Fibrosis (CF)|A Prospective Study About Complications of Totally Implantable Central Venous Access Ports in People With CF||University of Florence||Completed|May 2008|September 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|N/A|N/A|No|Non-Probability Sample|People with CF and with a TIVAD implanted|August 2011|August 22, 2011|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670579||156553|
NCT00670852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391-07-FB|Followup of Glenoid Fix Utilizing Auto Bone Graft in Shoulder Replacement|Computed Tomographic and Functional Follow-up of Glenoid Anchor Peg Component Fixation Utilizing Autologous Bone Graft in Total Shoulder Arthroplasty|Glenoid|University of Nebraska|No|Recruiting|April 2008|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|70|||Both|19 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Maximum number will be 70. Patients who received a total shoulder replacement with an        anchor peg glenoid and autologous bone grafting from the investigator of this study will        be recruited for this study.|April 2011|April 25, 2011|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00670852||156532|
NCT00671073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC-MD-50|Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD||Forest Laboratories|No|Completed|April 2008|||May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|427|||Both|40 Years|80 Years|No|||March 2012|March 1, 2012|April 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671073||156515|
NCT00671086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-022|Efficacy of Ramelteon in Subjects With Chronic Insomnia|A Phase 3, Open-label, Fixed-dose Study to Determine the Safety of Long-term Administration of TAK-375 in Subjects With Chronic Insomnia||Takeda|No|Completed|February 2003|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1213|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671086||156514|
NCT00671385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA-003|Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning|Early Screening of Breast Cancer Using Radiation-Free Pressure-Free Optical Scanning||Spectros Corporation|Yes|Recruiting|April 2008|April 2011|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Female|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women 18-50 with who EITHER (a) have a region of interest but without a diagnosis, or (b)        are healthy volunteers without breast cancer.|January 2011|January 30, 2011|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671385||156492|
NCT00642265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/573|The Treatment of Clavicular Fractures|The Treatment of Displaced, Midshaft Clavicular Fractures: Operative vs Conservative. A Prospected, Randomized Study||University Hospital, Ghent|No|Recruiting|April 2008|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00642265||158717|
NCT00642278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014587|An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|451|||Both|18 Years|65 Years|No|||July 2013|July 15, 2013|March 21, 2008|Yes|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT00642278||158716|
NCT00642551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-3-074|Beneficial Effects of Long Term Menaquinone-7|Clinical Trial on Beneficial Effects of Long Term Menaquinone-7 (Vitamin K2) Intake by Postmenopausal Women||Maastricht University Medical Center|No|Completed|March 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Female|55 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642551||158695|
NCT00670995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103623B|Tobacco Zero: Interactive Tobacco Education for Teens|Tobacco World: Interactive Tobacco Education for Teens||Deschutes Research, Inc.|No|Completed|November 2009|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|1864|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670995||156521|
NCT00671320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0513-146|A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle|A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib Vs. Diclofenac In Ankle Sprain||Pfizer|No|Completed|December 2002|October 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||April 2008|April 30, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671320||156497|
NCT00671606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0206|Hysteroscopic Lymphatic Mapping for Endometrial Cancer|Hysteroscopic Injection of Tracers for Sentinel Node Identification in Women With Endometrial Cancer||M.D. Anderson Cancer Center|No|Terminated|April 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Female|N/A|N/A|No|||April 2012|April 16, 2012|April 29, 2008||No|Slow accrual.|No|June 30, 2011|https://clinicaltrials.gov/show/NCT00671606||156475|Early termination due to low detection rate of sentinel lymph nodes in the five participants.
NCT00671619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESBA105CRD01|Study of ESBA105 Eye Drops in Healthy Subjects|A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects||ESBATech AG|No|Completed|April 2008|August 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2008|August 22, 2008|April 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00671619||156474|
NCT00671931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-09-12|Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine|Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine||Children's Hospital Medical Center, Cincinnati|Yes|Completed|April 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label|5||Actual|44|||Both|10 Years|25 Years|No|||August 2013|August 22, 2013|April 30, 2008|No|Yes||No|June 24, 2011|https://clinicaltrials.gov/show/NCT00671931||156452|
NCT00672776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024970|Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD)|Effects of Paxil CR on Neural Circuits in PTSD||Emory University|Yes|Completed|May 2003|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|50 Years|No|||January 2015|January 16, 2015|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672776||156389|
NCT00672789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000118|Adherence to Hydroxyurea in Children With Sickle Cell Anemia|Adherence to Hydroxyurea in Children With Sickle Cell Anemia||Duke University|No|Completed|April 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|31|||Both|2 Years|17 Years|No|||November 2012|May 24, 2013|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00672789||156388|
NCT00673075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-06|The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease|Efficacy and Tolerability of Nebivolol Compared With Carvedilol in Patients With Coronary Artery Disease and Stage I or II Hypertension||Forest Laboratories|No|Completed|May 2008|||September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||September 2010|September 2, 2010|April 29, 2008|Yes|Yes||No|September 2, 2010|https://clinicaltrials.gov/show/NCT00673075||156366|The study was terminated early because of difficulties with enrollment. Only 39 out of 160 planned patients were randomized.
NCT00673088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROPI-T25-PVFS-1|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions||Roxane Laboratories|No|Completed|February 2004|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2008|May 21, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673088||156365|
NCT00673894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07/059|Effects of Glutamine on GLP-1 and Insulin Secretion in Man|Study of the Effects of Glutamine on GLP-1, Insulin Secretion and Glycaemia in Man||Garvan Institute of Medical Research|No|Recruiting|April 2008|June 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2008|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673894||156303|
NCT00673907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2104-05-0003|HIPWOODS - Health Effects Related to Exposure to Particle Pollution From Woodburning Stoves|Health Effects Related to Exposure to Particle Pollution From Woodburning|HIPWOODS|University of Aarhus|No|Completed|January 2007|November 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2012|February 1, 2012|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673907||156302|
NCT00673582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00213|Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients|Randomized, Multicentre, Double- Blind, Placebo Controlled Trial of Rosuvastatin 10 mg for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Ultrasound in HIV-positive Patients Treated With Antiretrovirals||University of British Columbia|Yes|Terminated|April 2008|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|35 Years|N/A|No|||August 2009|August 24, 2009|April 30, 2008||No|Sponsor has withdrawn the funding|No||https://clinicaltrials.gov/show/NCT00673582||156327|
NCT00674544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200BO-116837|Influence of a Lifestyle Intervention in Preschool Children on Physiological and Psychological Parameters|Influence of a Lifestyle Intervention in Preschool Children on Physiological and Psychological Parameters (Ballabeina)|Ballabeina|University of Lausanne Hospitals|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|650|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||April 2009|January 27, 2011|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00674544||156253|
NCT00674557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-CR0207-22|Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer|A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer||National Cancer Institute (NCI)||Terminated|June 2008|March 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|111|||Female|18 Years|N/A|No|||March 2009|July 9, 2013|May 7, 2008|||Withdrawn as the clinical development of ATN-224 was terminated by the drug company who was    providing ATN-224 for the study|No||https://clinicaltrials.gov/show/NCT00674557||156252|
NCT00674531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608071|Detection of Enterovirus RNA in Atheromatous Lesions|Detection of Enterovirus RNA by RT-PCR in Atheromatous Lesions|ATH-ENTE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|January 2008|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|100|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00674531||156254|
NCT00670592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHCD122A2103|Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies|A Phase IA/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (CHIR-12.12-LYM-01)||Novartis||Completed|March 2008|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|April 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00670592||156552|
NCT00670865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-364|Automated Versus Conventional Hospital Discharge Summaries and Prescriptions|Automated Versus Conventional Hospital Discharge Summaries and Prescriptions: A Randomized Controlled Trial||St. Michael's Hospital, Toronto|No|Completed|May 2008|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|209|||Both|N/A|N/A|No|||April 2010|April 15, 2010|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00670865||156531|
NCT00671099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDMC-TPOP-02|Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study|Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study||Japan Science and Technology Agency|Yes|Completed|December 2008|December 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00671099||156513|
NCT00671411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-165|Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast|Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast||Memorial Sloan Kettering Cancer Center||Completed|March 2008|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Both|21 Years|99 Years|No|||December 2015|December 23, 2015|May 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00671411||156490|
NCT00671424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2105251|A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide|An Evaluation of the Safety, Tolerability, and Pharmacodynamic Effects of GSK189075 When Administered With Furosemide or Hydrochlorothiazide||GlaxoSmithKline|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|April 30, 2008||||||https://clinicaltrials.gov/show/NCT00671424||156489|
NCT00642291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTC-211|An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects|An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects||Gilead Sciences|No|Completed|November 2002|July 2004|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|3 Months|17 Years|No|||April 2008|April 7, 2008|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642291||158715|
NCT00642304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20937|A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not on Dialysis.|A Single Arm Open Label Study to Assess Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneously Mircera for the Maintenance of Hemoglobin Levels in Patients With Chronic Renal Anemia Not on Dialysis||Hoffmann-La Roche||Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642304||158714|
NCT00641940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803680|Girls in Transition Study: Helping Girls Enter the Teenage Years|Girls in Transition Study: Helping Girls Enter the Teenage Years|GT|Swarthmore College||Active, not recruiting|October 2005|June 2008|Anticipated|June 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2008|March 17, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641940||158741|
NCT00642564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014668|Study on Migraine and Headache in Epileptic Patients|MIGRAINE AND HEADACHE IN EPILEPTIC PATIENTS||Johnson & Johnson Taiwan Ltd||Completed|February 2008|March 2009|Actual|March 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|955|||Both|7 Years|N/A|No|Probability Sample|This study will enroll patients with diagnosis of epilepsy and age should be equal or more        than 7 years old.|May 2014|May 22, 2014|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642564||158694|
NCT00642577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20696|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.|A Randomized, Open Label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Irinotecan + 5-fluorouracil/Folinic Acid, and Irinotecan + 5-fluorouracil/Folinic Acid Alone, on Progression-free Survival in Chinese Patients With Metastatic Colorectal Cancer.||Hoffmann-La Roche||Completed|July 2007|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642577||158693|
NCT00671021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.E. 2007-05-42|Duration of Platelet Inhibition by Aspirin|Evaluation of Duration of Platelet Inhibition by Aspirin in a Standard 24-hour Interval Dosing Regimen||Hopital du Sacre-Coeur de Montreal|Yes|Completed|July 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|90 Years|No|Probability Sample|Patients suffering from stable CAD, on chronic ASA therapy|March 2009|August 20, 2012|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671021||156519|
NCT00671944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-35200-9579|Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism|Long-term Impact of Protein on Calcium Kinetics||Yale University|No|Completed|May 2003|April 2010|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||June 2010|June 30, 2010|May 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00671944||156451|
NCT00672243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000345|Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme|Phase II Trial of Erlotinib Plus Sirolimus for Patients With Recurrent Malignant Glioma Multiforme||Duke University|Yes|Completed|April 2007|December 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2013|August 2, 2013|January 29, 2008|Yes|Yes||No|March 30, 2011|https://clinicaltrials.gov/show/NCT00672243||156429|
NCT00672516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604M85353|Management of Bleeding Following Cardiopulmonary Bypass|Management of Excessive Bleeding Following Cardiopulmonary Bypass: A Pilot Feasibility Study||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|43|||Both|N/A|75 Years|No|Non-Probability Sample|Study populations includes male and female patients over 18 kg in weight and less than 75        years old who are undergoing cardiopulmonary bypass and are theoretically at risk for        significant bleeding in the peri-operative period|May 2015|May 26, 2015|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00672516||156409|
NCT00673348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCZ_TDM_Korea|Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations|A Prospective Observational Study of Plasma Voriconazole Concentration Measurement and Its Correlation With CYP2C19 Genotype in Korean Patients||The Catholic University of Korea|No|Recruiting|May 2008|April 2010|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|-  Two times of venous blood sampling will be carried out at steady state. Three ml of           venous blood is sampled right before the morning dose (trough sampling). The second           sampling is carried out at any time point within 2-4 hours after the morning dose (peak           sampling). To obtain the exact dose and sampling history, at least three dosing times           around the trough and peak sampling will be recorded to the minute. Sampling time will           also be recorded as clock time.        -  Genotyping of CYP2C19 will also be performed using 3 ml of peripheral blood sampled           into EDTA tubes.|Both|15 Years|65 Years|No|Non-Probability Sample|Patients suspected of invasive fungal infection (proven or probable cases) with        immunocompromised state (for example, during neutropenia, receiving HSCT) in Catholic        Hematopoietic Stem Cell Transplantation [HSCT] Center in Seoul, Korea.|June 2008|July 22, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673348||156345|
NCT00673101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-07|Prospective Evaluation of FibroScan in Patients Treated With Methotrexate|Evaluation of Liver Fibrosis Using FibroScan and Non-invasive Biochemical Markers in Patients Treated With Methotrexate|Methoscan|Association HGE CHU Bordeaux Sud|No|Recruiting|January 2006|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated by Methotrexate|January 2016|January 7, 2016|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673101||156364|
NCT00673335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0104/0701 - ONCO03|Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation|Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation|LIBER|UNICANCER|No|Active, not recruiting|May 2008|February 2022|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|386|||Female|40 Years|69 Years|No|||August 2014|August 5, 2014|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00673335||156346|
NCT00674219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-08-063-03|Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder|Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial||University of California, Los Angeles|Yes|Completed|May 2005|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00674219||156278|
NCT00661349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-174 (KANELA)|Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients|Prospective, Open Label and Randomized Clinical Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients||Germans Trias i Pujol Hospital|No|Terminated|February 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|60 Years|No|||April 2009|April 22, 2009|April 10, 2008||No|It has been impossible to achieve the number of patients defined by protocol|No||https://clinicaltrials.gov/show/NCT00661349||157260|
NCT00670280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40 MC 08962-01|Reducing Environmental Tobacco Smoke in Neonatal Intensive Care Unit (NICU) Infants' Homes|Reducing Environmental Tobacco Smoke in NICU Infants' Homes||The University of Texas Health Science Center, Houston|Yes|Completed|May 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|3||Actual|144|||Both|12 Years|N/A|No|||January 2016|January 5, 2016|April 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00670280||156576|
NCT00661960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715792|CCRC: A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy|CCRC: A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy||University of California, Davis|No|Completed|March 2008|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661960||157213|
NCT00662246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-225|Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma|A Phase I Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma||National Cancer Center, Korea||Completed|January 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2012|April 2, 2012|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00662246||157191|
NCT00662259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP21030|Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder|Randomized, Double-Blind, Placebo-Controlled Study of a Benzodiazepine vs Placebo on Functional Magnetic Resonance Imaging (fMRI) of the Brain, and on Behavioral/Clinical Measures in Patients With Generalized Anxiety Disorder||University of California, San Diego|No|Recruiting|April 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||May 2009|May 21, 2009|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662259||157190|
NCT00662532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-P-5265-1|Antibiotic Study for Dental Implants|Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects With Peri-Implantitis||OraPharma|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|21 Years|N/A|No|||December 2011|December 6, 2011|April 17, 2008|Yes|Yes||No|April 27, 2010|https://clinicaltrials.gov/show/NCT00662532||157169|
NCT00662792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.13|Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD|A Randomised, Double-blind Clinical Efficacy and Safety Comparison of Tiotropium/Salmeterol 7.5/25 Inhalation Powder in the Morning Via Tiotropium/Salmeterol HandiHaler, Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler, Salmeterol 50 Mcg MDPI in the Morning and Evening and the Free Combination Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler Plus Salmeterol 50 Mcg MDPI in the Morning and Evening Following Chronic Administration (6-week Treatment Periods) in Patients With COPD||Boehringer Ingelheim||Completed|April 2008|||August 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||Actual|147|||Both|40 Years|N/A|No|||April 2014|April 30, 2014|April 17, 2008||||No||https://clinicaltrials.gov/show/NCT00662792||157149|
NCT00662805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104246|Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)|A 2-year Observational Study to Evaluate Safety of Seretide 50/500μg Twice Daily Administered by DISKUS, in Patients With COPD||GlaxoSmithKline|No|Completed|June 2004|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|762|Samples Without DNA|Participants will undergo physical examination and blood pressure measurement. A complete      medical history will be taken, as well as blood and urine samples.|Both|N/A|N/A|No|Non-Probability Sample|Planned: 1000 / Recruited: 771 / Analyzed: 771 A target enrolment of approximately 1000        subjects is planned, at outpatient sites. Any subject with COPD who has an indication to        receive Salmeterol + Fluticasone 50/500mcg twice daily at the discretion of the        investigator and has met all the inclusion criteria, may take part in the study.        Inclusion criteria          -  Outpatient diagnosed with COPD (Criteria of the British Thoracic Society or NHLBI/WHO             Global initiative for Chronic Obstructive Lung Disease)          -  FEV1 < 50% of the one predicted at treatment start and/or          -  History of repetitive COPD exacerbations and/or          -  Patient remains symptomatic despite regular bronchodilator therapy|January 2014|January 16, 2014|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00662805||157148|
NCT00641953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-004A|IMX-150 Cream for Diabetic Neuropathy|A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of Pain in Diabetic Peripheral Neuropathy of the Feet||Procris Pharmaceuticals|No|Completed|August 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|75 Years|No|||June 2008|June 13, 2008|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641953||158740|
NCT00641979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-005-0698|New Nasal Applicator / New Formulation - User Study|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Functionality of a New Nasal Device With Reformulated Rhinocort Aqua (Budesonide) Versus the Current Product and Versus Placebo in Subjects With Seasonal Allergic Rhinitis (SAR).||AstraZeneca||Completed|April 2002|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|200|||Both|6 Years|N/A|No|||January 2011|January 21, 2011|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00641979||158739|
NCT00642317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0901|Asian Youth and Tobacco Control Survey|Asian Youth and Tobacco Control Survey||M.D. Anderson Cancer Center|No|Completed|March 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|617|||Both|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants self-identified as having Chinese or Vietnamese descent.|July 2012|July 31, 2012|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642317||158713|
NCT00671632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-375-015|Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse|A Randomized, Single Center, Double-Blind, Multiple-Dose, Placebo-Controlled, Crossover, Double-Dummy Study of The Acute Behavioral and Subjective Effects of Ramelteon in Subjects With a History of Polydrug Abuse.||Takeda|No|Completed|June 2003|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|60 Years|No|||February 2012|February 27, 2012|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00671632||156473|
NCT00671645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG R04/TAKO 08|Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy|Preoperative Combined RadioChemo-MolecularTargetTherapy of the Locally Advanced Rectum Carcinoma (cT3NxM0) - a Phase II Pilot Study With Preoperative Application of Capecitabine, Bevacizumab and Radiotherapy (RTx)||Austrian Breast & Colorectal Cancer Study Group|No|Terminated|July 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||March 2009|March 12, 2009|April 30, 2008||No|reaching of step 1 (recruitment of 8 patients) per protocol -> risk assessment -> termination    because of occurance of toxicity Grade 3 and 4|No||https://clinicaltrials.gov/show/NCT00671645||156472|
NCT00671957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002212|Energy Expenditure and Gastric Bypass Surgery Study|Energy Expenditure and Gastric Bypass Surgery Study|Energy|Oregon Health and Science University|Yes|Active, not recruiting|February 2006|September 2016|Anticipated|July 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Morbidly obese patients undergoing Bariatric surgery.|October 2015|October 14, 2015|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00671957||156450|
NCT00672256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011917|Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence|Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence|SmokeAtt02|Duke University|No|Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|62|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|July 14, 2014|May 4, 2008||No||No|March 30, 2009|https://clinicaltrials.gov/show/NCT00672256||156428|
NCT00672529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18376|Orthomolecular Therapy and Asthma in Children|Orthomolecular Treatment as add-on Therapy for Childhood Asthma||Canadian Institute of Natural and Integrative Medicine|No|Recruiting|February 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|7 Years|18 Years|No|||February 2011|February 2, 2011|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00672529||156408|
NCT00673361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9361|Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma|Phase II Pilot Trial of "Chemo-Switch" Regimen of Biochemotherapy Followed by Daily Low-Dose Temozolomide Plus Sorafenib in Advanced Melanoma||Duke University|No|Terminated|March 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||December 2012|January 11, 2016|May 4, 2008|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00673361||156344|
NCT00673621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-113|A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics|A Phase 1, Open-Label, Controlled Clinical Trial to Evaluate Pharmacokinetics After Administration of Technosphere® Insulin Inhalation Powder Alone and With Salbutamol (Albuterol) and/or After Methacholine Challenge Testing in Subjects With Asthma Versus Matched Healthy Subjects Without Asthma||Mannkind Corporation||Completed|May 2008|December 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00673621||156324|
NCT00673595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007194|Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo|Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo||Mayo Clinic|Yes|Terminated|March 2007|February 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|19|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|May 5, 2008||No|Difficulty with recruiting sujects and subjects complying with the protocol|No|February 21, 2012|https://clinicaltrials.gov/show/NCT00673595||156326|This study was terminated early due to difficulty with recruiting subjects and with subjects complying with the protocol.
NCT00673608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AAU01|Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload|A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study)||Novartis||Completed|November 2007|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|118|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673608||156325|
NCT00673920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT4394g|A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy|A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy|FEATURE|Genentech, Inc.||Terminated|April 2008|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|314|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|May 5, 2008|Yes|Yes|Based on analysis of results and consideration of available treatments, the overall benefit to    risk profile of ocrelizumab was not favorable in RA.|No||https://clinicaltrials.gov/show/NCT00673920||156301|
NCT00673933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC TA203/08|Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris|A Blinded, Randomized, Intra-individual, Vehicle-controlled and Multi-centre Study of Photodynamic Therapy With MAL Cream in Patients With Skin Type V or VI With Acne Vulgaris||Photocure|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|15 Years|40 Years|No|||July 2013|July 11, 2013|May 5, 2008|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT00673933||156300|
NCT00672581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00025|Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment|An Open-label Comparative Study of the Pharmacokinetics, Safety and Tolerability of ZD4054 (Zibotentan) Following a 10 mg Single Oral Dose of ZD4054(Zibotentan) to Healthy Subjects and to Subjects With Mild, Moderate and Severe Hepatic Impairment||AstraZeneca|No|Completed|April 2008|March 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2010|September 27, 2010|May 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00672581||156404|
NCT00661648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGC-AP-03|Effect of an Artificial Pancreas in Patients Undergoing Pancreatic Resection|Prevention for Surgical Site Infection After Pancreatic Resection||Kochi University|Yes|Recruiting|April 2007|June 2009|Anticipated|April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|N/A|No|||January 2009|January 28, 2009|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00661648||157237|
NCT00661661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921041|Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan|A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis||Pfizer|No|Completed|April 2008|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|487|||Both|20 Years|N/A|No|||April 2015|April 23, 2015|February 7, 2008||No||No|February 17, 2015|https://clinicaltrials.gov/show/NCT00661661||157236|
NCT00673153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2200.00|Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia||Fred Hutchinson Cancer Research Center|No|Terminated|March 2008|||August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|107|||Both|60 Years|N/A|No|||November 2011|November 3, 2011|May 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00673153||156360|
NCT00673387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA102|Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects.||AstraZeneca|No|Completed|April 2008|October 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|636|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|May 6, 2008|Yes|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT00673387||156342|Drug Randomization stratified:sex,3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total:8 treatment groups).
NCT00673400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARR|Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM|Morbidity and Functional Outcome of Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM in Obstructed Defecation|STARR|Cantonal Hospital of St. Gallen|No|Completed|January 2008|November 2009|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|N/A|N/A|No|||October 2012|October 1, 2012|May 5, 2008||No||No|July 16, 2012|https://clinicaltrials.gov/show/NCT00673400||156341|
NCT00673660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581156|Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels|Assessment Of Statin Treatment Compliance In Dyslipidemia Patients: An Observational Study||Pfizer|No|Completed|October 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|375|None Retained|No biospecimen is retained|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with dyslipidemia and taking or planning to take statin treatment.        Patients living in the same city of the study center. Patients aged 18 years old and over.|December 2009|November 5, 2010|May 1, 2008|No|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00673660||156321|The registered endpoint - observing reasons of compliance or non-compliance to statin treatment - was separated into outcome measure 6 and 7 because observing reasons for compliance with statin treatment were not collected or analyzed.
NCT00673673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710003118|FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer|Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer||Yale University|No|Completed|May 2008|July 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|May 5, 2008|Yes|Yes||No|May 13, 2014|https://clinicaltrials.gov/show/NCT00673673||156320|
NCT00673985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-12|Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study|A Randomized Study Comparing the Edwards Self-ExpandIng LifeStent Versus Angioplasty-alone In LEsions INvolving The SFA and/or Proximal Popliteal Arter|RESILIENT|C. R. Bard|Yes|Completed|July 2004|October 2010|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|246|||Both|18 Years|N/A|No|||October 2010|October 21, 2010|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00673985||156296|
NCT00673998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB-072/2004|Isokinetic Testing Protocol in Elderly and Young Men|The Effects of Rest Interval on Quadriceps Torque During an Isokinetic Testing Protocol in Elderly and Young Men||University of Brasilia|No|Completed|February 2005|November 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|38|||Male|20 Years|75 Years|Accepts Healthy Volunteers|||May 2008|May 6, 2008|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00673998||156295|
NCT00641992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFP-ALA|Prognosis of Failure Treatment of Amebic Liver Abscess|Prognosis Factors of the Response After Medical Treatment of Amebic Liver Abscess||Universidad Autonoma de San Luis Potosí|No|Completed|May 1999|April 2000|Actual|April 2000|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|16 Years|80 Years|No|Non-Probability Sample|sequential patients with clinical, ultrasonographic and serologic diagnosis (ELISA) of        amebic liver abscess|March 2008|March 17, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00641992||158738|
NCT00642005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laphumid|Humidification in Laparoscopic Colonic Surgery|Humidification in Laparoscopic Colonic Surgery - A Double Blinded, Randomised Controlled Trial.||University of Auckland, New Zealand|No|Completed|April 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|15 Years|N/A|No|||March 2014|March 10, 2014|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00642005||158737|
NCT00642330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBU-001|Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants|Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus||Hopital La Rabta|Yes|Completed|January 2007|December 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|N/A|96 Hours|No|||March 2008|March 24, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00642330||158712|
NCT00671658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-230|Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia|Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia||M.D. Anderson Cancer Center|No|Completed|November 2002|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|220|||Both|N/A|N/A|No|||August 2013|August 23, 2013|April 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00671658||156471|
NCT00671671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121006|Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.|A Phase 1, Non- Randomized, Open Label, Sequential Group, Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.||Pfizer|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||November 2013|November 25, 2013|April 25, 2008|No|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00671671||156470|
NCT00672542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000806|Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells|Phase I Study of Active Immunotherapy of Metastatic Melanoma With Mature Autologous Dendritic Cells Transfected With Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing||Duke University|No|Completed|January 2008|July 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|February 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00672542||156407|
NCT00672802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-375-038|Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease|A Phase II Safety Study of TAK-375 in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease||Takeda|No|Completed|August 2003|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|26|||Both|21 Years|N/A|No|||February 2012|February 27, 2012|May 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00672802||156387|
NCT00673114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008292|Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies|A Prospective, Phase I/II Trial Determining the Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Banked Unrelated Umbilical Cord Blood Supplemented With Related, Haplo-Identical T-Cell Depleted Stem Cells in Subjects With High Risk Malignancies||Duke University|Yes|Completed|August 2007|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|55 Years|No|||March 2015|March 16, 2015|December 27, 2007|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00673114||156363|
NCT00664326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11726|A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC|A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer (RCC)||Bayer|Yes|Active, not recruiting|April 2008|January 2017|Anticipated|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|April 17, 2008|No|Yes||No|October 28, 2012|https://clinicaltrials.gov/show/NCT00664326||157031|
NCT00664664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD125-007|Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia|A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of APD125 in Patients With Primary Insomnia Characterized by Difficulty Maintaining Sleep||Arena Pharmaceuticals|No|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|675|||Both|18 Years|65 Years|No|||December 2008|December 29, 2008|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664664||157005|
NCT00664677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-1421 #105|Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia|Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia||Erimos Pharmaceuticals|No|Terminated|August 2007|June 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|April 21, 2008|No|Yes|Funding constraints|No||https://clinicaltrials.gov/show/NCT00664677||157004|
NCT00673946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011675|Impact of Oximetry on Hospitalization in Acute Bronchiolitis|Impact of Oximetry on Hospitalization||The Hospital for Sick Children|Yes|Completed|March 2008|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|213|||Both|6 Weeks|12 Months|No|||December 2013|December 6, 2013|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00673946||156299|
NCT00673959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-08|Acute Comfort of Lubricant Eye Drop FID 111421|||Alcon Research|No|Completed|December 2007|||February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|May 2, 2008||No||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00673959||156298|
NCT00674258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-NSCLC24|Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Non-Small Cell Lung Cancer||Tokyo University|Yes|Recruiting|May 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||May 2008|May 12, 2008|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00674258||156275|
NCT00632554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hamamatsu-18-67|The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia|Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia||Hamamatsu University|No|Completed|June 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|80 Years|No|||September 2014|September 18, 2014|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00632554||159456|
NCT00632840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWA_DC012008|Pharmacological Regulation of Fat Transport in Metabolic Syndrome|Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome||The University of Western Australia|No|Completed|June 2001|December 2007|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|11|||Male|25 Years|70 Years|No|||February 2008|February 29, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00632840||159434|
NCT00632515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0316|Screening for Familial Colorectal Cancer (CRC) Patients|Screening and Risk Communication for First Degree Relatives of Colorectal Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2008|||January 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|325|||Both|N/A|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with diagnosis of Colorectal Cancer at or before age 60 years, and their First        Degree Relatives (FDRs) who are age 40 years or older.|February 2016|February 4, 2016|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632515||159459|
NCT00633074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111454|Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations|Non-inferiority Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A Using Different Formulations.||GlaxoSmithKline||Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|720|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 26, 2012|February 29, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00633074||159416|
NCT00633087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080402|A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer|A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer|2-Deoxyglucose|Rutgers, The State University of New Jersey|No|Terminated|November 2006|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|March 3, 2008|Yes|Yes|Slow accrual|No|November 15, 2013|https://clinicaltrials.gov/show/NCT00633087||159415|
NCT00624806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 07-292|Developing a Home Telehealth Program to Manage Pressure Ulcers in SCI/D|Developing a Home Telehealth Program to Manage Pressure Ulcers in SCI/D||VA Office of Research and Development|No|Completed|February 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|18|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|April 6, 2015|February 14, 2008||No||No|July 25, 2014|https://clinicaltrials.gov/show/NCT00624806||160036|The study duration was short and the sample was small. Because we only studied subjects who received the DMP, it is unknown how many would have had skin breakdown in a comparable period without the DMP.
NCT00633659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6034|Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia|A Phase II Study of Hemospan® Versus Voluven® to Evaluate Vascular Resistance and Forearm Blood Flow, and to Assess Local Skin Blood Flow and Tissue Oxygenation in the Ischemic Foot of Patients With Chronic Critical Limb Ischemia||Sangart|No|Completed|September 2007|December 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|6|||Both|N/A|N/A|No|||August 2013|August 15, 2013|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633659||159372|
NCT00634023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00113|Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD|A Cross-Sectional, Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With Gastroesophageal Reflux Disease (GERD) RANGE: Retrospective ANalysis of GErd|RANGE|AstraZeneca|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects attending PC offices with reflux symptoms. Subjects must not have participated in        any other clinical study in the time window between the Index Visit and Visit 1.|March 2009|March 10, 2009|March 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00634023||159344|
NCT00634335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor465808ctil|Echocardiographic Characteristics of High Endurance Israeli Athletes|Echocardiographic Characteristics of High Endurance Israeli Athletes||Soroka University Medical Center|Yes|Recruiting|March 2008|June 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|81|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|professional bicyclists in Israel|February 2008|December 29, 2008|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00634335||159321|
NCT00634348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281110|A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients|A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care||Pfizer|No|Completed|April 2004|March 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|70 Years|No|||June 2008|June 17, 2008|March 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00634348||159320|
NCT00675194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-ICE-2003|Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer|A Prospective, Open, Comparative Multicentre Phase II Study for the Evaluation of Irinotecan and Capecitabine Versus Cisplatin and Capecitabine in Advanced Gastric Adenocarcinoma or Gastric-Oesophagal Junction||Johannes Gutenberg University Mainz|Yes|Completed|October 2003|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|120|||Both|18 Years|75 Years|No|||May 2008|May 16, 2008|May 6, 2008||||No||https://clinicaltrials.gov/show/NCT00675194||156203|
NCT00675207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWOIADJ 2006|Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs|Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs||Northwestern Ophthalmic Institute S.C.|Yes|Completed|January 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|41 Years|N/A|No|||May 2008|May 6, 2008|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675207||156202|
NCT00675636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587344|Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer|Vanderbilt Hereditary Colorectal Cancer Registry||Vanderbilt University|No|Recruiting|January 2007|||April 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Anyone with known or suspected hereditary colorectal cancer syndrome, early age o onset of        colorectal cancer (see below).|April 2011|April 1, 2011|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00675636||156170|
NCT00623844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF 01EL0606|Prevention Through Activity in Kindergarten Trial|Prevention Through Acitivity in Kindergarten Trial|PAKT|University of Wuerzburg|No|Completed|May 2007|November 2008|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|718|||Both|43 Months|67 Months|Accepts Healthy Volunteers|||December 2014|March 30, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623844||160109|
NCT00624169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0044|Peptic Ulcer Perforation Study|Peptic Ulcer Perforation Study - an Optimized Perioperative Course for Patients Surgically Treated for Peptic Ulcer Perforation|PULP|Copenhagen University Hospital at Herlev|No|Completed|November 2007|May 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||May 2010|May 26, 2010|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624169||160084|
NCT00624416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27015|Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas|A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas||Pennington Biomedical Research Center|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|February 15, 2008|Yes|Yes||No|February 10, 2011|https://clinicaltrials.gov/show/NCT00624416||160065|The single case that did not have an increase in lipoma volume showed variability which may have been because of a small lipoma making accurate measurement difficult.
NCT00635414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-NEP-0011|Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously|An Open, Randomized, Two-way Crossover Study Comparing the Effect of 40mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD).||AstraZeneca||Completed|August 2002|October 2002|Actual|October 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2011|January 24, 2011|March 6, 2008||||||https://clinicaltrials.gov/show/NCT00635414||159238|
NCT00635674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAMSCPAP|Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome|Effects of CPAP on Cardiovascular Risk Profile in Patients With Severe Obstructive Sleep Apnea and Metabolic Syndrome||Pavol Jozef Safarik University|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|35 Years|75 Years|No|||March 2008|March 13, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00635674||159218|
NCT00636025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-CBED07-04|Cellulite and Magnetic Resonance Imaging|Anatomy of Subcutaneous Structures in Areas With and Without Cellulite Depressions by Magnetic Resonance Imaging||Brazilan Center for Studies in Dermatology|No|Completed|July 2008|December 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|None Retained|None retained|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Females patients with cellulite on the buttocks.|February 2015|February 24, 2015|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636025||159192|
NCT00636051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5166|Evidence-Based Practice (EBP) Awareness Project: Peer-to-Peer Dissemination|Evidence-Based Practice (EBP) Awareness Project: Peer-to-Peer Dissemination||State University of New York - Upstate Medical University|No|Completed|February 2005|November 2006|Actual|November 2006|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|91|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All RN staff & RN patient service leaders (PSLs) who are over 18 years of age, employed by        Upstate and working full or parttime on direct care units within service lines represented        on the Nursing Research Council (NRC) will be invited to participate. This target        population includes approximately 551 staff RNs & PSLs. We expect to enroll a minimum of 5        and as many as 15 RNs on the 29 nursing units over the course of the study for a sample        size between 145 and 435|June 2009|June 8, 2009|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636051||159190|
NCT00636337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003249|Inattention in Childhood Cancer Survivors|TRICCS: Targeting Inattention in Childhood Cancer Survivors|TRICCS|Duke University|No|Completed|December 2007|November 2012|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|23|||Both|8 Years|16 Years|No|||February 2013|February 15, 2013|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00636337||159168|
NCT00631969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12093|Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction|Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-dose, Double-blind, Randomized Multi-center Trial - POTENT I||Bayer|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|362|||Male|18 Years|N/A|No|||December 2014|December 8, 2014|February 29, 2008|Yes|Yes||No|October 5, 2010|https://clinicaltrials.gov/show/NCT00631969||159499|
NCT00631982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/08|Invitro Maturation of Oocytes for Patients With Polycystic Ovaries|In Vitro Maturation of Oocytes for Patients With Polycystic Ovaries||Assaf-Harofeh Medical Center||Not yet recruiting|April 2008|||October 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|39 Years|No|||March 2008|March 7, 2008|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631982||159498|
NCT00632281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 502-2005|Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors|Stereotactic Body Radiation Therapy for Tumors in the Thorax||University of Florida|No|Completed|January 2006|November 2008|Actual|October 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|N/A|N/A|No|||June 2010|January 17, 2012|February 29, 2008|Yes|Yes||No|December 1, 2011|https://clinicaltrials.gov/show/NCT00632281||159477|
NCT00623922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2007.2472|Effect of Patient Education in Rheumatic Diseases|The Effect of Patient Education on Coping and Well Being in Patients With Arthritis.||Norwegian University of Science and Technology|No|Completed|February 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|141|||Both|18 Years|80 Years|No|||April 2015|April 7, 2015|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00623922||160103|
NCT00632788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97005|The Influence of Acute Myocardial Infarction Checklist on the Door-to-Balloon Time|The Influence of Acute Myocardial Infarction Checklist on the Door-to-Balloon Time in Patients Suffering From Acute ST-Elevation Myocardial Infarction||Far Eastern Memorial Hospital|No|Completed|April 2006|December 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|213|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with diagnostic criteria of acute ST-elevation myocardial infarction who were        preparing for emergency cardiac catheterization|January 2008|March 3, 2008|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632788||159438|
NCT00632801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5579|Does Chewing Gum After Elective Laparoscopic Colectomy Surgery Decrease Ileus?|Does Chewing Gum After Elective Laparoscopic Colectomy Surgery Decrease Ileus?||State University of New York - Upstate Medical University|No|Terminated|December 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|89 Years|No|||December 2014|December 7, 2014|March 3, 2008||No|Change in procedure nd medication used instead of gum|No||https://clinicaltrials.gov/show/NCT00632801||159437|
NCT00633113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIKRO|Minimally Invasive Knee Replacement Outcomes (MIKRO) Study|A Randomized, Prospective, Blinded Clinical Trial Comparing Two Total Knee Replacement Techniques|MIKRO|Dartmouth-Hitchcock Medical Center|Yes|Completed|November 2007|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|131|||Both|35 Years|85 Years|No|||April 2013|April 25, 2013|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633113||159414|
NCT00624819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111345 (Mth 12)|Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine|Long-term Follow-up Study to Assess Antibody Persistence in Children Previously Vaccinated With Four Doses of Pneumococcal Conjugate Vaccine in Primary Vaccination Study (105553) and Booster Vaccination Study (107046)||GlaxoSmithKline||Completed|March 2008|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|524|||Both|28 Months|32 Months|Accepts Healthy Volunteers|||July 2012|October 2, 2014|February 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624819||160035|
NCT00633672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-NEN-0006|A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued|A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued||AstraZeneca||Completed|February 2001|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|February 27, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00633672||159371|
NCT00634010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0477|Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain|Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain||M.D. Anderson Cancer Center|Yes|Terminated|February 2008|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|March 5, 2008||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00634010||159345|
NCT00625053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-293|Functional Outcome After Incisional Hernia Repair: Open Versus Laparoscopic Repair|Abdominal Midline Incisional Hernia Repair and Functional Outcome: Randomized Controlled Trial to Compare Open and Laparoscopic Surgical|GINCISHERNIA|University Hospital, Geneva|No|Recruiting|April 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||April 2008|April 10, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625053||160018|
NCT00625378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12311|Sorafenib Long Term Extension Program (STEP)|Sorafenib Long Term Extension Program|STEP|Bayer|No|Recruiting|December 2007|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|16 Years|N/A|No|||March 2016|March 7, 2016|February 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00625378||159995|
NCT00634361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA01.03.0011|Ethyl-EPA Treatment of Prodromal Patients|Ethyl-EPA Treatment of Prodromal Patients||Yale University|No|Completed|September 2001|August 2005|Actual|August 2005|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|14 Years|35 Years|No|||May 2014|May 21, 2014|March 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00634361||159319|
NCT00634621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEH-HEX-2007-01|Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer|A Post-authorization, Observational Study to Assess the Impact of Blue Light Cystoscopy After Administration of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer.||GE Healthcare|No|Completed|February 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|283|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with documented or suspected bladder cancer.|August 2014|August 12, 2014|February 26, 2008||No||No|July 9, 2014|https://clinicaltrials.gov/show/NCT00634621||159299|
NCT00675428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MY201|Study of Natalizumab in Relapsed/Refractory Multiple Myeloma|A Phase 1/2, Two-Arm, Dose-Finding Study of Natalizumab for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma||Biogen|Yes|Terminated|September 2008|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|May 6, 2008|Yes|Yes|Sponsor decision due to low enrollment and not safety concerns.|No|September 15, 2014|https://clinicaltrials.gov/show/NCT00675428||156185|
NCT00634881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587746|Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia|Consolidation Therapy With Alemtuzumab (MabCampath®) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study||National Cancer Institute (NCI)||Recruiting|November 2003|||December 2011|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|36|||Both|18 Years|N/A|No|||March 2008|August 23, 2013|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00634881||159279|
NCT00635141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011193|The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis|The Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic Fibrosis||The Hospital for Sick Children|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|6 Years|18 Years|No|||August 2013|August 30, 2013|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00635141||159259|
NCT00635700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801003386|Ziprasidone in the Psychosis Prodrome|Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk|ZIP|Yale University|Yes|Completed|March 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|16 Years|40 Years|No|||May 2014|May 14, 2014|March 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635700||159216|
NCT00635713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238IL/0021|Second Line Breast Cancer Trial|A Double-Blind, Randomized, Multi-Center Trial Comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long Acting ICI 182,780) With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.||AstraZeneca||Completed|May 1997|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|588|||Female|18 Years|N/A|No|||April 2009|April 9, 2009|March 7, 2008||||No||https://clinicaltrials.gov/show/NCT00635713||159215|
NCT00636038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-E6|Bioavailability of Yellow Maize Carotenoids in Humans|||Tufts University|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|8|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||March 2008|March 13, 2008|March 7, 2008||||No||https://clinicaltrials.gov/show/NCT00636038||159191|
NCT00636350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58-1950-7-707|Bioavailability of Pepper Carotenoids in Humans|||Tufts University|No|Active, not recruiting|September 2007|May 2009|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|5|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00636350||159167|
NCT00622843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV150 Prevnar|Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting|An Open-Label, Phase III, Randomized Study of Pneumococcal Conjugate Vaccination in HIV, in Comparison to Polysaccharide Vaccine Boosting in Previously Vaccinated Patients||Uniformed Services University of the Health Sciences|Yes|Completed|December 2002|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|275|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|February 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622843||160185|
NCT00631995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET32|Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers|Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) in Toddlers||Sanofi|Yes|Completed|April 2008|April 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|373|||Both|12 Months|12 Months|Accepts Healthy Volunteers|||March 2016|March 22, 2016|February 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00631995||159497|
NCT00632008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBG-1-12|Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers|A Randomised, Double-blind, Placebo-controlled Study to Determine the Efficacy of Soluble Beta-1,3/1,6-glucan in Chronic Foot Ulcers in Diabetes||Biotec Pharmacon ASA|No|Completed|March 2007|October 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||January 2010|January 25, 2010|February 29, 2008||||No||https://clinicaltrials.gov/show/NCT00632008||159496|
NCT00632294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0689|Retrospective Study of the Biomechanical Properties of Large Allografts|Retrieved Allograft Study: Retrospective Study of the Biomechanical Properties of Large Allografts||M.D. Anderson Cancer Center|No|Terminated|December 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|2|Samples With DNA|A leftover sample of the removed allograft bone will be collected and used to learn about      the properties (such as bone strength, bone density, and new bone formation) of the removed      transplant tissue.|Both|N/A|N/A|No|Non-Probability Sample|Patients that require the retrieval of a bone allograft (transplant).|July 2012|July 31, 2012|February 4, 2008||No|Low accrual.|No||https://clinicaltrials.gov/show/NCT00632294||159476|
NCT00623935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.065|Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia|Hematopoietic Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia||University of Michigan Cancer Center|Yes|Active, not recruiting|March 2007|January 2016|Anticipated|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|55 Years|70 Years|No|||June 2015|June 12, 2015|February 14, 2008|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT00623935||160102|
NCT00632814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12684|Russian Kogenate Pediatric Study|A Prospective Study to Evaluate the Effect of rFVIII-FS in Different Prophylactic Regimens on Bleeding Events Frequency and Development of Arthropathy in Previously Treated and Minimally Treated Hemophilia A Pediatric Population.||Bayer|No|Completed|June 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Male|1 Year|12 Years|No|||June 2015|June 4, 2015|March 4, 2008|Yes|Yes||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00632814||159436|Protocol deviations were not excluded: e.g. a previously untreated patient developed the transitory inhibitor; change to a higher group did not always occur according protocol; there was temporary lack of smaller vial sizes at the centers.
NCT00632827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-PTCL-ONTAK|Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)|Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for In-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial||University of California, San Francisco|Yes|Active, not recruiting|June 2008|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|70 Years|No|||October 2014|October 3, 2014|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00632827||159435|
NCT00624234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS049096|Neurobiology and Treatment of Reading Disability in NF-1|Neurobiology and Treatment of Reading Disability in Neurofibromatosis Type 1 (NF-1)||Vanderbilt University|No|Active, not recruiting|February 2006|December 2014|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|180|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00624234||160079|
NCT00624247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705002664|Early Versus Delayed Routine HIV Testing in Connecticut Jails|Early Versus Delayed Routine HIV Testing in Connecticut Jails|SWAB|Yale University|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|621|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|October 16, 2014|February 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624247||160078|
NCT00624793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0339|Acupuncture for Nausea in HIV|Acupuncture for Chronic Nausea in HIV: A Randomized Clinical Trial|AcuN|New York University School of Medicine|No|Completed|May 2005|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|70 Years|No|||June 2012|June 21, 2012|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624793||160037|
NCT00625690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064-05|CT Scans in Screening for Lung Cancer in Current and Former Smokers|Development of a Lung Cancer-Screening Program at the University of Nebraska Medical Center: A Feasibility Study||University of Nebraska|Yes|Active, not recruiting|May 2005|||December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Collection of blood sample: At the time of the initial CT scan, every subject will be asked      to donate a small blood sample, approximately 10 ml in a yellow EDTA tube (less than 1      tablespoon) from their arm by standard blood drawing techniques, for storage for use in      future studies. The blood sample will be number coded, and serum from the blood sample will      be stored frozen and held at UNMC for future studies. All studies will be proposed in future      IRB submissions.|Both|19 Years|N/A|No|Non-Probability Sample|Normal subjects with at least a 30 pack-year history of cigarette smoking.|February 2011|February 3, 2011|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00625690||159972|
NCT00625352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUH-ONC-0019|Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma|Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma||Ulsan University Hospital|No|Recruiting|February 2008|||December 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|70 Years|N/A|No|||February 2008|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625352||159997|
NCT00625365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMP 115-415|A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice|CARES (Contrast EchocArdiography REgistry for Safety Surveillance): A Prospective, Phase IV, Open-Label, Nonrandomized, Multicenter, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice||Lantheus Medical Imaging|No|Completed|February 2008|July 2009|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1060|||Both|18 Years|N/A|No|||August 2011|December 31, 2015|February 20, 2008|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00625365||159996|
NCT00676754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0002|Epidemiology of MDR-TB in Peru|Epidemiology of Multidrug-Resistant Tuberculosis in Peru|Estudio Epi|Harvard University Faculty of Medicine|No|Active, not recruiting|September 2009|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18544|Samples With DNA|whole blood, sputum|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population includes two categories of subjects: (1) the 4,000 TB index subjects        and (2) their approximately 18,000 household members. All of these individuals live in        Lima, Peru, in the catchment area of the participating public health centers.        Approximately 50% of study participants will be female. According to the ethnic and racial        categories used by NIH, all of the study population would be classified as "Hispanic or        Latino" (Mestizo). None of these participants live within a tribal indigenous culture; all        speak Spanish while some also speak the indigenous (Quechua) language of their birthplace        in Peru. At least 75% of this population has some "Amerindian" heritage. Less than 1% of        individuals are either Asian-Peruvian or Afro-Peruvian in descent.        Apart from the age restriction (at least 16 years old) for the TB index subjects only,        there are no other restrictions on participant selection|March 2013|March 27, 2013|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676754||156084|
NCT00676767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSU-HML-RSt1|Resistant Starch on Glycemic Response in Older Adults|Resistant Starch Type 4 on the Glycemic Response in Older Adults||Kansas State University|No|Completed|August 2006|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|9|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 22, 2008|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00676767||156083|
NCT00677014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-050508-H|Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)|SMARTDELAY Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy|SMART-AV|Boston Scientific Corporation|No|Completed|May 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1060|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|May 9, 2008|No|Yes||No|July 27, 2012|https://clinicaltrials.gov/show/NCT00677014||156064|
NCT00634907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00019469|Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)|Prospective CYP2C9 And VKORC1 Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)For Anticoagulation||University of Utah|Yes|Completed|October 2006|August 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00634907||159277|
NCT00635154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583300|Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma|A Phase II Study of Anakinra (IL-1 Receptor Antagonist) in Patients With Smoldering/Indolent Multiple Myeloma||Mayo Clinic||Completed|December 2002|November 2010|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||December 2010|December 17, 2010|March 12, 2008|Yes|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00635154||159258|
NCT00635427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-GCB-044|An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease|An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease||Shire|No|Completed|May 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|95|||Both|2 Years|N/A|No|||March 2014|May 15, 2015|March 6, 2008|Yes|Yes||No|December 11, 2013|https://clinicaltrials.gov/show/NCT00635427||159237|
NCT00635440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Muscle-2446|Randomized, Controlled Study to Investigate the Effect of Neuromuscular Electrical Stimulation (NMES) on Muscle Metabolism of Abdominal Surgical Patients|The Effect of Neuromuscular Electrical Stimulation on Muscle Metabolism of Major Abdominal Surgical Patients||Medical University of Vienna|No|Completed|December 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|N/A|No|||March 2008|March 12, 2008|February 25, 2008||||No||https://clinicaltrials.gov/show/NCT00635440||159236|
NCT00635726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.16|Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer|Sequential High Dose MVAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin), Followed by Gemcitabine Plus Cisplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer||Hellenic Oncology Research Group|No|Terminated|February 2008|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|75 Years|No|||October 2015|October 7, 2015|March 11, 2008||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00635726||159214|
NCT00636064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARA-0505-071|A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery|A Double-Blind Multicenter Study of the Safety and Efficacy of Parecoxib Sodium/Valdecoxib and Placebo/Valdecoxib Compared to Placebo for Treatment of Post-Surgical Pain in Patients Who Have Coronary Bypass Graft Via Median Sternotomy||Pfizer|Yes|Completed|January 2003|January 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1671|||Both|18 Years|80 Years|No|||March 2008|October 9, 2008|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636064||159189|
NCT00622856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc004377ctil|The Cost-efficacy of Psychological Intervention for Strengthening Parental Authority Among Parents of Diabetic Adolescents With Poor Glycemic Control|The Cost-efficacy of Psychological Intervention for Strengthening Parental Authority Among Parents of Diabetic Adolescents With Poor Glycemic Control||Rabin Medical Center|No|Recruiting|February 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|10 Years|18 Years|No|||November 2015|November 26, 2015|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622856||160184|
NCT00632021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539|Pharmacist Intervention to Decrease Medication Errors in Heart Disease Patients (The PILL-CVD Study)|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|PILL-CVD|Vanderbilt University|No|Completed|May 2008|March 2012|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|862|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00632021||159495|
NCT00623675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEO-002|Heavy Metal Urine Analysis in 20 Healthy Persons Taking Mineralox|Heavy Metal Urine Analysis in 20 Healthy Persons Taking Mineralox||CreoMed, Inc.|No|Suspended|February 2008|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2009|July 6, 2009|February 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00623675||160122|
NCT00624832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2210|A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels|A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations||Novartis|No|Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||April 2011|April 12, 2011|February 18, 2008||No||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00624832||160034|
NCT00624845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-004|Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy|Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP|C07-004|Omeros Corporation|No|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||June 2011|June 17, 2011|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624845||160033|
NCT00633126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-15|Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age|Pharmacokinetics of a Single Dose of Ceftaroline in Subjects 12 to 17 Years of Age Receiving Antibiotic Therapy||Forest Laboratories|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|12 Years|17 Years|No|||February 2013|February 11, 2013|March 3, 2008|No|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00633126||159413|
NCT00623909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709009417|Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study|Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study.||Weill Medical College of Cornell University|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|25 Years|65 Years|No|||June 2013|June 13, 2013|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623909||160104|
NCT00624520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-008-07F|Mental Stress Reduction in Defibrillator Patients|Effectiveness of Mental Stress Reduction in Defibrillator Patients||VA Office of Research and Development|Yes|Terminated|September 2008|July 2014|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|21 Years|85 Years|No|||December 2014|December 15, 2014|February 14, 2008||No|Exhaustion of subject population pool, greater than expected drop-out rates . Data analysis    approved by DMC for study completions|No|November 19, 2014|https://clinicaltrials.gov/show/NCT00624520||160058|Early termination of study after 12 month study extension and interim data analysis, due to high drop-out rate and exhaustion of population pool, 9 subjects short of revised target enrollment.
NCT00625391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003735-01A1|Green Tea and Tai Chi for Bone Health|GTP and Tai Chi for Bone Health: a Pilot Study|GTP-TC-Bone|Texas Tech University Health Sciences Center|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|171|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2014|August 1, 2014|February 26, 2008|Yes|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00625391||159994|Limitation of this study included: (1) the number of subjects in each group at the baseline was not equal. (2) The amount of dietary calcium intake for each subject was not available.
NCT00625404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10015|FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women|Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women||FHI 360|Yes|Completed|May 2009|January 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2120|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 22, 2014|February 19, 2008|Yes|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00625404||159993|
NCT00625066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583154|Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy|Tennessee Colorectal Polyp Study||National Cancer Institute (NCI)||Recruiting|January 2003|||January 2011|Anticipated|N/A|Observational|N/A|||Anticipated|7000|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||October 2008|January 27, 2010|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00625066||160017|
NCT00625703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB File # 112007-010|Pharmacokinetics of Linezolid in Children With Cystic Fibrosis|Pharmacokinetics of Linezolid in Children With Cystic Fibrosis||University of Texas Southwestern Medical Center|No|Recruiting|May 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|14|||Both|N/A|18 Years|No|||December 2008|January 21, 2009|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625703||159971|
NCT00625989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sputdend08|The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics|The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics||McMaster University|No|Completed|February 2008|December 2008|Actual|November 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|January 23, 2008||No||No|April 14, 2015|https://clinicaltrials.gov/show/NCT00625989||159950|
NCT00676481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 A1060363|Rapid HIV Testing for Emergency Department Patients|Rapid HIV Testing for Emergency Department Patients||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|July 2004|June 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|570|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2008|March 5, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00676481||156105|
NCT00676780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-176|Green Tea Extract and Prostate Cancer|Green Tea Extract and Prostate Cancer||Louisiana State University Health Sciences Center Shreveport|Yes|Completed|May 2004|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|33|||Male|18 Years|75 Years|No|||June 2012|June 29, 2012|May 9, 2008|Yes|Yes||No|August 29, 2011|https://clinicaltrials.gov/show/NCT00676780||156082|Patient compliance was an issue.
NCT00635167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27012|Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)|Contrast Enhanced Transrectal Ultrasound (TRUS) to Assess Prostatic Vascularity as a Measure of Treatment Response and Early Prediction of Treatment Failure After XRT||Thomas Jefferson University|Yes|Recruiting|January 2008|June 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Male|40 Years|80 Years|No|||April 2008|April 9, 2008|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635167||159257|
NCT00635453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitolo3|Impact of the "Ten Steps for Healthy Feeding of Children Younger Than Two Years" in Health Centers|Impact of the "Ten Steps for Healthy Feeding of Children Younger Than Two Years" in Health Centers||Federal University of Health Science of Porto Alegre|No|Completed|March 2008|June 2012|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|1||Actual|474|||Female|N/A|N/A|No|||July 2012|July 17, 2012|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00635453||159235|
NCT00635739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1493|Effect of Whey Protein Supplementation and Resistance Exercise on Muscle Parameters in Older Adults|Efficacy of Whey Protein Supplementation on Resistance Exercise-Induced Changes in Muscle Strength, Fat Free Mass, and Function in Mobility-Limited Older Adults||Tufts University|No|Completed|April 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|70 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|March 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00635739||159213|
NCT00635752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-07442a(REK)|Trauma-focused Cognitive-behavioural Therapy(TF-CBT) for Children: A Study of Process and Outcome.|Trauma-focused Cognitive-behavioural Therapy for Children: A Study of Process and Outcome.||Norwegian Center for Violence and Traumatic Stress Studies|No|Completed|April 2008|August 2013|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|10 Years|18 Years|No|||April 2015|April 22, 2015|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00635752||159212|
NCT00627068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL086917|The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function|The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function||University of California, San Francisco|Yes|Completed|July 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|60|Samples Without DNA|whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Population in both low and high risk groups should represent the general population.|September 2011|September 16, 2011|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00627068||159867|
NCT00622830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPL110736|Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-|Phase I Study of SB-480848 (Darapladib) -A Double Blind, Randomised, Placebo-controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-480848 in Healthy Japanese Male Subjects-||GlaxoSmithKline|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|18|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|February 13, 2008||||No||https://clinicaltrials.gov/show/NCT00622830||160186|
NCT00623389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-001889|Evaluation of an Advanced Lower Extremity Neuroprostheses|Evaluation of Advanced Lower Extremity Neuroprostheses|LE-IST|Case Western Reserve University|Yes|Recruiting|May 2005|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|January 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00623389||160144|
NCT00623688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070908|Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital|Effectiveness and Costs of Albuterol Delivered by MDI With Spacer Versus Nebulizer in Children Hospitalized With Moderate and Severe Asthma Exacerbations||Akron Children's Hospital|Yes|Completed|February 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|12 Months|18 Years|No|||January 2015|January 13, 2015|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00623688||160121|
NCT00624858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-402|A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression|An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) in Overweight or Obese Subjects With Major Depression||Orexigen Therapeutics, Inc|No|Completed|January 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||October 2012|October 23, 2012|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624858||160032|
NCT00624260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070142|Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study|Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study|ITEP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2008|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|240|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624260||160077|
NCT00624533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI051650|Efficiency of GDS Method for Lumbar Stabilization for Non-Specific Low Back Pain in Primary Care|Evaluation of the Efficiency of Physiotherapeutic Treatment of Non-Specific Low Back Pain in Primary Care Centers Through GDS Techniques for Articular and Muscular Chains|GDS|Carlos III Health Institute|Yes|Completed|January 2006|October 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|65 Years|No|||February 2008|February 26, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624533||160057|
NCT00625742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0739|Multimodal Treatment Strategy for Cancer Cachexia|An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia||M.D. Anderson Cancer Center|No|Terminated|February 2008|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|February 19, 2008||No|Low Accrual|No|December 4, 2015|https://clinicaltrials.gov/show/NCT00625742||159969|The sample size of the available data is too small to detect any significant differences.
NCT00625079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPF/PH|Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil|Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study||University of California, Los Angeles|Yes|Recruiting|February 2007|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|N/A|N/A|No|||February 2008|February 19, 2008|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625079||160016|
NCT00625092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS068|Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies|Phase I Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies||Masonic Cancer Center, University of Minnesota|Yes|Completed|October 2007|September 2011|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00625092||160015|
NCT00626600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXI3001|A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion|An Open, Multi-centre, Non-comparative Observational Study to Assess the Safety and Tolerability of Oxycodone Injection 50 mg/mL as a Subcutaneous Infusion in Patients With Severe Cancer Pain.||Mundipharma Research Limited||Terminated|May 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|February 20, 2008||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00626600||159903|
NCT00626002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-016|Open Label Continuation Study in Moderate to Severe Psoriasis|A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Preceding Psoriasis Study With ABT-874||AbbVie|No|Completed|February 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2301|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|February 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626002||159949|
NCT00626015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000947|Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery|Zenapax®-Activated Peptide ImmunoTherapy [ZAP IT]|ZAP IT|Duke University|Yes|Completed|March 2007|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|120 Years|No|||January 2016|January 20, 2016|February 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00626015||159948|
NCT00676494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC 05003|The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions|A Prospective, Single Arm, Multi-Center Study to Assess Performance of the Pathway PV Atherectomy System During Percutaneous Peripheral Vascular (PV) Interventions||Pathway Medical Technologies Inc.|Yes|Completed|February 2006|February 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|N/A|No|||May 2009|May 18, 2009|May 8, 2008|Yes|Yes||No|February 23, 2009|https://clinicaltrials.gov/show/NCT00676494||156104|
NCT00676507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR001-03|Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy|Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy|STOP|NovaRx Corporation|Yes|Completed|July 2008|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|532|||Both|18 Years|75 Years|No|||May 2015|May 6, 2015|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676507||156103|
NCT00634920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ASE01|Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients|A Controlled Randomized Open-label Multicenter Study Evaluating if Early Conversion to Everolimus (Certican) From Cyclosporine (Neoral) in de Novo Renal Transplant Recipients Can Improve Long-term Renal Function and Slow Down the Progression of Chronic Allograft Nephropathy||Novartis|Yes|Completed|March 2008|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|March 6, 2008|Yes|Yes||No|May 6, 2014|https://clinicaltrials.gov/show/NCT00634920||159276|
NCT00634933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3206K1-2203|Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis|A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate||Pfizer|No|Terminated|March 2008|October 2012|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|222|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|March 5, 2008|Yes|Yes|The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No    safety reasons contributed to the termination of the study.|No|December 27, 2012|https://clinicaltrials.gov/show/NCT00634933||159275|As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.
NCT00635193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206OC202|Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)|A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer That Have Relapsed After Prior Therapy With a Platinum/Taxane-Based Chemotherapy||AbbVie|No|Completed|July 2007|October 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|138|||Female|18 Years|N/A|No|||January 2013|January 10, 2013|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635193||159255|
NCT00635466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lap RC|Phase II Trial to Evaluate Laparoscopic Surgery for Stage 0/I Rectal Carcinoma|Phase II Trial to Evaluate Laparoscopic Surgery for Stage 0/I Rectal Carcinoma|Lap RC|Japan Society of Laparoscopic Colorectal Surgery|Yes|Active, not recruiting|February 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|495|||Both|20 Years|75 Years|No|||June 2011|June 15, 2011|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00635466||159234|
NCT00626795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD1414-C21|Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)|Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)||LEO Pharma|Yes|Completed|February 2008|June 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|682|||Both|2 Years|N/A|No|||November 2013|November 22, 2013|February 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00626795||159888|
NCT00623155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10828|Seasonal Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine in Children in Mali|Evaluation of a Malaria Transmission Target Strategy Based on the Periodic Treatment With Sulfadoxine-Pyrimethamine vs. Early Case Management||University of Bamako|No|Completed|July 2002|January 2004|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|262|||Both|6 Months|10 Years|Accepts Healthy Volunteers|||September 2002|February 22, 2008|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623155||160161|
NCT00623129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583031|Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer|Electroacupuncture for Xerostomia in Head and Neck Patients||Mayo Clinic|Yes|Terminated|February 2006|||November 2010|Actual|N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Supportive Care|||Anticipated|30|||Both|21 Years|89 Years|No|||August 2011|February 23, 2016|February 22, 2008|No|Yes|Slow accrual; did not meet accrual goal|No||https://clinicaltrials.gov/show/NCT00623129||160163|
NCT00623142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0047|The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery|The Effects of Hyperbaric Oxygen Preconditioning On Cardiovascular Protection & Ischemic Reperfusion Injury||Hull and East Yorkshire Hospitals NHS Trust|Yes|Completed|January 2005|January 2008|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|81|||Both|20 Years|85 Years|No|||January 2008|February 22, 2008|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623142||160162|
NCT00623402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeCOG SoraPeg 2007|Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma|Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma: a Prospective Non-randomized, Multicenter Phase II Study|SoraPeg|University of Schleswig-Holstein|Yes|Completed|January 2008|||October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||February 2008|January 11, 2011|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00623402||160143|
NCT00623714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-065|Induced Sputum Study (0000-065)|A Randomized, Placebo-Controlled, Crossover Study to Assess the Effects of Inhaled Fluticasone on Markers of Inflammation After Allergen Challenge in Patients With Allergic Asthma||Merck Sharp & Dohme Corp.||Completed|January 2008|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|55 Years|No|||April 2015|April 15, 2015|February 11, 2008|No|Yes||No|May 24, 2010|https://clinicaltrials.gov/show/NCT00623714||160119|
NCT00623961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0425|Validation Study of Neuropathic Pain|Validation Study of Positive Phenomena in Neuropathic Pain||University of Wisconsin, Madison|No|Completed|April 2007|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with neuropathic pain from the following diagnosis groups: post-herperic        neuralgia, painful diabetic neuropathy, and spinal cord injury will be included in the        study if their pain is of at least 6 months duration.|June 2010|January 12, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623961||160100|
NCT00624286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2346|Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease||Novartis|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|416|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 15, 2008|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00624286||160075|
NCT00625131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-007-07F|Nicotine Patch Pretreatment for Smoking Cessation in PTSD|Nicotine Patch Pre-treatment for Smoking Cessation in PTSD||VA Office of Research and Development|Yes|Completed|May 2008|March 2013|Actual|March 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|February 19, 2008||No||No|October 28, 2014|https://clinicaltrials.gov/show/NCT00625131||160012|
NCT00625157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASF1096-203|Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)|Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study (2)||Astion Pharma A/S|No|Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|70 Years|No|||February 2008|February 28, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00625157||160011|
NCT00624273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDN-D-002G|Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis|Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis|Sildenafil|Charite University, Berlin, Germany|Yes|Completed|February 2004|February 2007|Actual|November 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||July 2003|January 6, 2009|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00624273||160076|
NCT00625417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587230|Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors|Breast Tumor Detection Using Optical Spectroscopy||Vanderbilt University||Recruiting|August 2006|||August 2013|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|No|||January 2012|January 9, 2012|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00625417||159992|
NCT00626067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #06-762E|Study of Patient Use and Perception of the Travatan Dosing Aid|Pilot Study of Patient Acceptance and Impact of the New Travatan™ Compliance Monitoring Dispenser (Travatan™ Dosing Aid)||Wills Eye|No|Completed|September 2006|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2008|February 29, 2008|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00626067||159944|
NCT00625729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS064|Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia|MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2008|April 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|February 26, 2008|Yes|Yes|No patients exhibited natural killer cell expansion (primary endpoint).|No|July 2, 2010|https://clinicaltrials.gov/show/NCT00625729||159970|Study was terminated early due to lack of NK expansion and failure to meet primary outcome.
NCT00626340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9907010780|Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder|Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen||Yale University|No|Completed|July 1999|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626340||159923|
NCT00626834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OV-1014|Vigabatrin Ph 2a Cocaine Interaction Study|A Phase 2A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study||National Institute on Drug Abuse (NIDA)|Yes|Completed|February 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|24|||Both|18 Years|45 Years|No|||November 2010|November 3, 2010|February 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626834||159885|
NCT00676520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-374|XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study|XVU-Phase 1|Abbott Vascular|Yes|Completed|July 2008|March 2011|Actual|March 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8053|||Both|N/A|N/A|No|Non-Probability Sample|Patients who agree to participate by signing the Institutional Review Board (IRB) approved        informed consent form, and who recieve only XIENCE V® EECSS during the index procedure.|October 2012|October 10, 2012|October 16, 2007|Yes|Yes||No|June 7, 2012|https://clinicaltrials.gov/show/NCT00676520||156102|
NCT00676806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBT001|A Phase II Study of Umbilical Cord Blood Transplantation|A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning||Tufts Medical Center|Yes|Completed|July 2005|July 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|N/A|70 Years|No|||December 2014|December 8, 2014|May 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00676806||156080|
NCT00634959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001015|Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus|An Investigation Into The Effects Of Food And Dose Regimen On Viral Load Response In HIV Infected Patients On Short-Term Monotherapy With UK-427,857 (Maraviroc)||ViiV Healthcare|No|Completed|July 2003|December 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|37|||Both|18 Years|55 Years|No|||November 2010|November 9, 2010|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00634959||159273|
NCT00635180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUS-IOP-07|Intraocular Pressure (IOP) and Isometric Exercise|Changes in Intraocular Pressure and Pulsatile Ocular Blood Flow Measured Continuously During Isometric Exercise||Oslo University Hospital|No|Completed|January 2007|February 2008|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||February 2008|July 3, 2011|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00635180||159256|
NCT00626262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9615C00014|Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv|An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)||AstraZeneca|No|Completed|July 2002|October 2002|Actual|October 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2011|January 21, 2011|February 21, 2008||||No||https://clinicaltrials.gov/show/NCT00626262||159929|
NCT00626275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33CL232|Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis|A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Subjects With Rheumatoid Arthritis||Cubist Pharmaceuticals LLC|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|46|||Both|18 Years|75 Years|No|||June 2015|June 4, 2015|February 22, 2008|No|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT00626275||159928|
NCT00626561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0324|Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix|A Phase II Evaluation of Bevacizumab and Paclitaxel in Patients With Recurrent Small Cell, Large Cell, and Neuroendocrine Tumors of the Cervix and Uterus||M.D. Anderson Cancer Center|No|Terminated|February 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|N/A|N/A|No|||June 2014|June 5, 2014|February 20, 2008||No|Due to slow accrual.|No|June 5, 2014|https://clinicaltrials.gov/show/NCT00626561||159906|
NCT00622869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001H2304|Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients|A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients|RAD|Novartis||Completed|January 2008|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|719|||Both|18 Years|70 Years|No|||May 2013|May 17, 2013|February 13, 2008|No|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT00622869||160183|
NCT00623974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0562|Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia|A Phase II Study of Short-Term Use of Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia||M.D. Anderson Cancer Center|Yes|Terminated|May 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|7|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|February 14, 2008|Yes|Yes|Terminated due to slow accrual.|No|August 13, 2010|https://clinicaltrials.gov/show/NCT00623974||160099|
NCT00623987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036/99|Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants|Absence of Residual Vein Thrombosis After an Episode of Unprovoked Deep Vein Thrombosis: Short-Term Anticoagulation is Safe.|Exten-DACUS|Azienda Ospedaliera Universitaria Policlinico|Yes|Completed|June 1999|January 2008|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||March 2008|March 24, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00623987||160098|
NCT00623415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005262-39|Flupirtine as Oral Treatment in Multiple Sclerosis|Multicentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-β1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis|FLORIMS|Charite University, Berlin, Germany|Yes|Terminated|December 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||January 2016|January 27, 2016|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00623415||160142|
NCT00623701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0703st|Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation|A Multicentre, Multinational, Placebo-controlled, Double-blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen|ALLEGRA6|Allergopharma GmbH & Co. KG|No|Completed|March 2008|October 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|65 Years|No|||November 2013|November 7, 2013|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00623701||160120|
NCT00623948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4664-R|Implanted Gluteal Stimulation System for Pressure Sore Prevention|Implanted Gluteal Stimulation System for Pressure Sore Prevention||VA Office of Research and Development|No|Withdrawn|September 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|February 11, 2008|No|Yes|Suitable implanted technolgy was not available|No||https://clinicaltrials.gov/show/NCT00623948||160101|
NCT00625170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03.136|Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans|Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans||Leiden University Medical Center|No|Completed|May 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|11|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2004|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625170||160010|
NCT00625456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-IV-011|Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors|A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors||SillaJen, Inc.|Yes|Completed|June 2008|June 2014|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2012|November 30, 2015|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625456||159989|
NCT00625105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPG001|Using Heart Rate Variability Biofeedback to Improve Attention and Memory in PTSD+ Combat Veterans|Using Heart Rate Variability Biofeedback to Improve Attention and Memory in PTSD+ Combat Veterans|HRVB|William Jennings Bryan Dorn VA Medical Center|Yes|Active, not recruiting|January 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 5, 2014|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625105||160014|
NCT00625755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001539/4|A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma|A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma||Beth Israel Deaconess Medical Center|Yes|Completed|December 2002|February 2008|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2008|March 10, 2008|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625755||159968|
NCT00625768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1409-101|Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma|A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma||Antisoma Research|Yes|Completed|January 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2009|August 24, 2009|February 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00625768||159967|
NCT00626405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0775|Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Trial of Temozolomide (TMZ) and Bevacizumab or ABI-007 (ABX)/Carboplatin (CBDCA) and Bevacizumab in Patients With Unresectable Stage IV Malignant Melanoma||Alliance for Clinical Trials in Oncology|No|Completed|August 2008|November 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626405||159918|
NCT00626366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|498-07-FB|Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison|Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison||University of Nebraska|Yes|Not yet recruiting|March 2008|June 2008|Anticipated|April 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|8|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2008|February 20, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626366||159921|
NCT00626379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1379|Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])|Low CV Risk, Ages 25-44 & CV/Non-CV Outcomes, Ages 65+|CHAS|Northwestern University|No|Active, not recruiting|November 2007|December 2016|Anticipated|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1395|Samples With DNA|Whole blood, serum, white cells, and urine|Both|65 Years|84 Years|No|Probability Sample|Original participants in the Chicago Heart Association (CHA) Detection in Industry study        (1967 to 1973) who still reside in the Greater Chicagoland area.|February 2015|February 27, 2015|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00626379||159920|
NCT00626392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-241|Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia|Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia|ASA EFFECTS|Abbott|No|Completed|February 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|277|||Both|18 Years|N/A|No|||August 2009|August 26, 2009|February 21, 2008|Yes|Yes||No|April 16, 2009|https://clinicaltrials.gov/show/NCT00626392||159919|
NCT00626028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT 22|Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing|Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing||INO Therapeutics|No|Completed|September 2004|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|136|||Both|N/A|18 Years|No|||October 2010|October 18, 2010|February 20, 2008|Yes|Yes||No|September 21, 2009|https://clinicaltrials.gov/show/NCT00626028||159947|Although the first and last treatments were randomly assigned, the second treatment was always the iNO/O2 combination. Without randomization of all 3 treatments, we cannot exclude an interaction of time with treatment.
NCT00626041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 71550000144|U-CHAMP: Urban Cardiovascular Health Assessment and Management Program|U-CHAMP: Urban Cardiovascular Health Assessment and Management Program|U-CHAMP|University of Calgary|No|Recruiting|February 2008|June 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|110|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2010|January 25, 2010|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00626041||159946|
NCT00626054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004907|Comparison of Two Methods of Administration of a PEG Solution|Comparison of Two Methods of Administration of a PEG Solution During Bowel Preparation for Colonoscopy in Hospitalized Patients|PEG|Rabin Medical Center|Yes|Recruiting|March 2009|March 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||July 2010|July 22, 2010|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626054||159945|
NCT00626353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2007-0027|Interdisciplinary Home Rehabilitation of Patients With Stroke. A Randomised Controlled Intervention Trial.|Interdisciplinary Home Rehabilitation of Patients With Stroke. A Randomised Controlled Intervention Trial.||University Hospital, Gentofte, Copenhagen|Yes|Completed|July 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|71|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626353||159922|
NCT00677326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast-A02-I, II|Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Breast Cancer||Tokyo University|Yes|Terminated|May 2008|May 2009|Actual|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|20 Years|85 Years|No|||May 2009|December 28, 2009|May 12, 2008||No|Difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT00677326||156040|
NCT00625976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-004|Graded Exposure (GEXP) in Vivo Versus Physiotherapy in Complex Regional Pain Syndrome Type I (CRPS-I)|The Effectivity of Graded Exposure in Vivo Versus Standardized Physiotherapy in Complex Regional Pain Syndrome Type I (CRPS-I) Patients With Pain Related Fear: a Randomized Clinical Trial||Maastricht University Medical Center|No|Completed|May 2008|September 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||September 2014|September 18, 2014|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00625976||159951|
NCT00626808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA175|A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children|A Post Marketing Evaluation of the Effectiveness of the Risk Minimization Plan For Use of FluMist Among Children Less Than 5 Years of Age||MedImmune LLC|No|Completed|October 2007|March 2010|Actual|March 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|321697|||Both|N/A|N/A|No|Non-Probability Sample|Children < 60 months of age.|July 2014|July 21, 2014|February 20, 2008|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT00626808||159887|
NCT00627081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/11|Effect of Thoracic Epidural Analgesia on Intravenous Closed-Loop Anesthesia|Intravenous Opioid-sparing Effect of Thoracic Epidural Administration of Chirocaine (5 mg/ml) During Thoracotomy|Drone-APDT|Hopital Foch|No|Completed|February 2008|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2011|January 22, 2011|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00627081||159866|
NCT00627094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK143WS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||May 30, 2008|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00627094||159865|
NCT00622882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-B/06/274|Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia|Early Infectious Disease Consultation for Better Outcomes From Staphylococcus Aureus Bacteremia||National University Hospital, Singapore|Yes|Recruiting|October 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|1 Month|N/A|No|||January 2014|January 6, 2014|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622882||160182|
NCT00623740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 060250|PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates|Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial|PREMILOC|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|April 2008|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|523|||Both|N/A|24 Hours|No|||September 2013|December 3, 2014|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00623740||160117|
NCT00624299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-07-006|Botox Clinical Trial|Botulinum Toxin: an Adjunct in Limb Reconstruction - Can it Reduce Pain and Joint Complications in the Lengthening Phase?||Sheffield Children's NHS Foundation Trust|No|Withdrawn|March 2008|May 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|16 Years|No|||March 2015|March 17, 2015|February 15, 2008||No|A similar study had already been conducted, therefore pursuing this trial would have been    unethical|No||https://clinicaltrials.gov/show/NCT00624299||160074|
NCT00624312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.0048|Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations|A Prospective, Randomized, Double-Blinded Control Study of Procrit Versus Placebo to Determine Efficacy in Pre-Operative Patients Undergoing Major Surgical Oncology Operations||University of Louisville|Yes|Withdrawn|February 2008|January 2010|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|February 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624312||160073|
NCT00624325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV 06-01|Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders|Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders|SCIN-C|Foundation for Liver Research|Yes|Completed|July 2007|December 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|60 Years|No|||March 2011|March 10, 2011|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00624325||160072|
NCT00624572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHX0784|Efficacy of Chlorexidine as Intracanal Medicament in Primary Teeth|Efficacy of 1% Chlorexidine Gel as Intracanal Medicament in Primary Molar Teeth - a Clinical and Microbiological Study||Universidade Federal do Ceara||Active, not recruiting|October 2007|February 2009|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|8 Years|No|||February 2008|February 25, 2008|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624572||160054|
NCT00624546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB18199|Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD|Effect of Antireflux Therapy on the Expression of Genes Known to be Important in Inflammation, Metaplasia and Neoplasia in Patients With GERD||University of Rochester|Yes|Terminated|January 2009|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|24|Samples With DNA|Esophageal mucosal biopsies|Both|18 Years|74 Years|No|Non-Probability Sample|Subjects: (a) 20 patients with GERD and (b) 20 non-GERD controls.|October 2015|October 23, 2015|December 28, 2007||No|Expected recruitment numbers have not been achieved.|No||https://clinicaltrials.gov/show/NCT00624546||160056|
NCT00624559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134024-1|The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure|COX-2 Regulation of Renal Sodium Handling in Blood Pressure Maintenance||University of Delaware|Yes|Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|12|||Both|22 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|February 15, 2008||No||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00624559||160055|
NCT00624585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15276|Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts|A Pilot Study of Oral Dasatinib in Subjects With MDS and Excess Marrow Blasts||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|February 2008|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||May 2012|November 21, 2013|February 15, 2008|Yes|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00624585||160053|
NCT00625807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003425-01A2|Comparison of Two Behavioral Treatments for Stress Reduction|Exploratory Analysis of RR and MBSR for Stress Reduction||Massachusetts General Hospital|No|Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 3, 2009|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00625807||159964|
NCT00625820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00016705|Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria|Safety and Efficacy of Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria: An Open-Label Pilot Study||University of Michigan|No|Active, not recruiting|May 2008|April 2013|Anticipated|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||January 2013|January 7, 2013|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625820||159963|
NCT00625118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPS|A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years|A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years|DIPS|Public Health England|No|Completed|December 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|42 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|Children in receipt of pre-school booster vaccinations (age 3.5-6 years)|January 2009|November 2, 2010|February 19, 2008||||No||https://clinicaltrials.gov/show/NCT00625118||160013|
NCT00625794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23RR018471|Nicotine Replacement and Counseling In Adolescents|A Randomized Trial of the Nicotine Nasal Spray in Adolescent Smokers||University of California, San Francisco|No|Completed|September 2005|July 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||May 2007|February 27, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625794||159965|
NCT00626080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2007Det001|Insulin Detemir Action in Cerebro|Effects of INsulin dEtemiR and Neutral protaminE Hagedorn (NPH) Insulin on BRain glucOse Metabolism: a Study in Persons With Type 1 Diabetes|INcEREBRO|VU University Medical Center|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|40|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 29, 2011|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00626080||159943|
NCT00626652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJI-201|Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Effects of K201 Injection, 2 mg/mL on the Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation|RESTORATION|Sequel Pharmaceuticals, Inc|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|153|||Both|18 Years|N/A|No|||January 2010|January 7, 2010|February 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00626652||159899|
NCT00626639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040124|A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy|A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy With Concurrent Chemotherapy||Swedish Orphan Biovitrum|Yes|Active, not recruiting|July 2005|December 2015|Anticipated|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|5|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|February 21, 2008|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT00626639||159900|
NCT00626626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25223|Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation|Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation||Milton S. Hershey Medical Center|Yes|Terminated|May 2007|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||January 2013|January 8, 2013|February 20, 2008||No|Investigator decision|No||https://clinicaltrials.gov/show/NCT00626626||159901|
NCT00626873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584233|Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary|Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer||National Cancer Institute (NCI)||Recruiting|January 2007|||January 2013|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|100|||Female|21 Years|N/A|No|||October 2008|August 11, 2009|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00626873||159882|
NCT00677339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVDAPT 1|L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)|Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia.|AVDAPT|Menzies School of Health Research|Yes|Completed|June 2008|May 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|15 Years|N/A|No|||January 2012|January 17, 2012|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00677339||156039|
NCT00626574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105838c|Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa|A Double Blinded, Placebo Controlled, Pilot Study to Evaluate the Safety of Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa|EPO|University of South Florida|Yes|Terminated|July 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|30 Years|75 Years|No|||September 2012|September 25, 2012|February 7, 2008|Yes|Yes|This study is terminated as a result of data from a study that showed increased mortality in    stroke patients.|No|September 8, 2011|https://clinicaltrials.gov/show/NCT00626574||159905|In late October 2008, we received a letter from the sponsor requesting that we terminate any further work on this study.
NCT00626821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK175OS|Coloplast DialogueStudy|An Open Label, Non-comparative, Multi-national Post-Market Study to Document Real Life Experience on SenSura With Focus on Skin Condition and Quality of Life||Coloplast A/S|No|Completed|February 2008|December 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3017|||Both|18 Years|N/A|No|||January 2012|February 9, 2012|February 21, 2008||No||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00626821||159886|
NCT00623168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14474|Ribavirin for Hemorrhagic Fever With Renal Syndrome|A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in the 121st Combat Support Hospital (Seoul, Korea)||U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|February 2008|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|17 Years|65 Years|No|||October 2015|October 28, 2015|February 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00623168||160160|
NCT00622622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WPR2-0710|Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer|Phase I Study of Gemcitabine With Antiangiogenic Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 Derived From VEGFR2 in Patients With Unresectable, Locally Advanced, Recurrent or Metastatic Pancreatic Cancer||Wakayama Medical University|Yes|Completed|November 2006|February 2009|Actual|December 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|80 Years|No|||February 2009|February 17, 2009|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622622||160202|
NCT00623727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12781|BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A|Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A||Bayer|Yes|Terminated|June 2008|October 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Male|12 Years|70 Years|No|||July 2013|July 8, 2013|January 9, 2008|Yes|Yes||No|June 10, 2011|https://clinicaltrials.gov/show/NCT00623727||160118|The recruitment and double-blind study phase were prematurely terminated after a scheduled interim analysis confirmed overt failure regarding the primary endpoint as judged by the independent Data and Safety Monitoring Board.
NCT00624026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90001-0608/1|Memantine - Communication Study|Prospective, Single-arm, Multicenter, Open-label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment||Merz Pharmaceuticals GmbH|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|50 Years|90 Years|No|||October 2011|October 31, 2011|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00624026||160095|
NCT00624000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND # 11364|IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion|IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion||University of North Carolina, Chapel Hill||Completed|March 2004|December 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|19 Years|N/A|No|||November 2011|November 4, 2011|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624000||160097|
NCT00624013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 U54 RR01616-07|Diabetes and Depression in Hispanics and African Americans: Treatment of Depression With Sertraline and Its Effect on A1c and Quality of Life|The Effects of Pharmacologic Treatment of Depression on Glycated Hemoglobin, Lipids and Quality of Life in Underserved Hispanics and African Americans With Diabetes: A Randomized, Placebo Controlled Trial|DandD|Charles Drew University of Medicine and Science|Yes|Active, not recruiting|September 2006|October 2008|Anticipated|October 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|21 Years|N/A|No|||February 2008|February 15, 2008|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624013||160096|
NCT00624598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41 # 001|The Short-Term Effect of a Technology Driven Weight Control (SMART) Program for Obese Adults|Phase I Study of Integrating RMR Technology and Email Counseling in a PCP Office.|WCPC|Colorado Center for Chronic Care Innovations, Inc.|No|Completed|January 2008|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 15, 2008|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624598||160052|
NCT00624871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-MD-thesis-ahmed|Ascorbic Acid and Ibuprofen in Infants With Hypoxic Ischemic Encephalopathy|Ascorbic Acid Combined With Ibuprofen in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial.||Al-Azhar University|Yes|Completed|April 2004|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|2 Hours|No|||February 2008|February 27, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00624871||160031|
NCT00625534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-122|Functional Outcome After Groin Hernia Mesh Repair: Open Versus Laparoscopy|Chronic Significant Pain and Functional Outcome After Laparoscopic Versus Open Groin Hernia Mesh Repair: Design of a Randomized Controlled Clinical Trial|GENINGHERNIA|University Hospital, Geneva|No|Recruiting|April 2008|April 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Male|21 Years|70 Years|No|||April 2008|April 10, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625534||159984|
NCT00625833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061037|A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.|A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.||Pfizer|No|Terminated|December 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||February 2009|February 16, 2009|February 14, 2008|Yes|Yes|Study was terminated for futility following the planned interim analysis.|No||https://clinicaltrials.gov/show/NCT00625833||159962|
NCT00625430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253/001|A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer|A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate|FP253-GDEPT|Biotech Equity Partners Pty Ltd|Yes|Recruiting|March 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||July 2011|July 8, 2011|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00625430||159991|
NCT00625443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKR-501-CL-004|Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic ITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003|A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003||Eisai Inc.|No|Completed|May 2007|October 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625443||159990|
NCT00626418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aplindore-101|The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome|A Single-blind, Placebo Controlled Sleep Laboratory Study of the Acute Effects of Aplindore in Restless Legs Syndrome||Ligand Pharmaceuticals|No|Completed|February 2008|||October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|February 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00626418||159917|
NCT00626119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|729-01-0|Vibro-Acoustography Imaging in Finding Breast Microcalcifications and Lesions in Women|In Vivo Breast Imaging by Vibro-acoustography||Mayo Clinic|Yes|Completed|June 2001|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|34|||Female|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with and without breast masses|June 2012|June 19, 2012|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00626119||159940|
NCT00626431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-PC07-169|A Study of Leuprolide to Treat Prostate Cancer|A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma||Abbott|No|Completed|February 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|310|||Male|18 Years|N/A|No|||July 2011|July 15, 2011|February 20, 2008|Yes|Yes||No|August 20, 2010|https://clinicaltrials.gov/show/NCT00626431||159916|Treatment with Formulation B was prematurely discontinued as testosterone was not adequately suppressed to <= 50 ng/dL or escapes from suppression occurred. Subjects who had not received dose 2 of Formulation B were discontinued after Week 24.
NCT00626899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM-Vig/Vig|Comparison Performance Vigileo vs. Continuous CCO (Vigilance) in Patients With Induced Therapeutic Hypothermia|Comparison of the Performance of a New Pulse-contour Analysis Cardiac Output Measurement (Vigileo) With the Traditional Method in Patients With Induced Therapeutic Hypothermia After Cardiac Arrest||University Hospital Inselspital, Berne|No|Completed|March 2007|May 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Patients after cardiac arrest who are treated with therapeutic hypothermia and require a        PAC for hemodynamic monitoring|January 2010|January 13, 2010|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626899||159880|
NCT00626886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-003|Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy|A Phase II, Randomized, Single Dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx® Bupivacaine Implant in Men After Open Mesh Herniorrhaphy||Innocoll|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|53|||Male|18 Years|N/A|No|||April 2013|April 29, 2013|February 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626886||159881|
NCT00622674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000586671|Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors|Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR||Masonic Cancer Center, University of Minnesota|Yes|Completed|November 2005|February 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|February 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622674||160198|
NCT00677924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN206|Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer|A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy|GEN206|Genmab|Yes|Terminated|April 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|May 13, 2008||No|Due to changes in portfolio review|No|September 12, 2011|https://clinicaltrials.gov/show/NCT00677924||155994|The trial was prematurely closed when 9 out of 97 patients were enrolled. The trial design was originally divided in two parts. Patient allocation was terminated before Part 2 was started.
NCT00677937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL10564|A Diabetes Prevention Study Targeting High Risk Individuals With Education and Ongoing Support|A Randomised Controlled Trial to Investigate an Educational Programme and Continuous Monitoring to Prevent Diabetes in Individuals With Screen Detected Pre-diabetes in a Multi-ethnic Population|PREVENTION|University Hospitals, Leicester|Yes|Completed|May 2009|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|748|||Both|18 Years|75 Years|No|||December 2014|December 4, 2014|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00677937||155993|
NCT00626587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-94-0101A|EBUS-Guided TBNA Increases the Diagnostic Yield of Peripheral Pulmonary Lesions|Endobronchial Ultrasonography-Guided Transbronchial Needle Aspiration Increases the Diagnostic Yield of Peripheral Pulmonary Lesions : A Randomized Trial||Chang Gung Memorial Hospital|Yes|Completed|January 2005|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|182|||Both|N/A|N/A|No|||January 2005|February 28, 2008|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626587||159904|
NCT00622648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXA_C_01249|Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin|International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings|LIFENOX|Sanofi||Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8329|||Both|40 Years|N/A|No|||December 2010|December 27, 2010|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622648||160200|
NCT00622934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|425/195 13/4/86|Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients|Relationship Between Clinical Recovery and Oxidative Stress and Inflammation Following Usage of Erythropoietin in Admitted Traumatic Patient In Intensive Care Unit|EPREX|Tehran University of Medical Sciences|Yes|Recruiting|July 2007|May 2008|Anticipated|May 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|65 Years|No|||November 2010|November 17, 2010|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622934||160178|
NCT00623428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV21371|A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response|A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response||Hoffmann-La Roche||Completed|June 2008|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|235|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|February 18, 2008|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00623428||160141|
NCT00623441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Final version1.1|E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent|E-Five Registry: To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor ABT-578 Eluting Coronary Stent System; A Prospective, Multicenter Registry|eFive|Medtronic Cardiovascular|Yes|Completed|September 2005|February 2009|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8314|||Both|18 Years|N/A|No|Non-Probability Sample|Real-world patients requiring drug eluting stent implantation|October 2015|October 26, 2015|February 18, 2008||No||No|September 1, 2009|https://clinicaltrials.gov/show/NCT00623441||160140|Data collection in this large global registry was limited to MACE (major adverse cardiac events) defined as the composite endpoint of death, myocardial infarction (Q- and non-Q-wave), emergent cardiac bypass surgery and TLR.
NCT00623454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.1110 (REK)|Non Cardiac Chest Pain and Benign Palpitations|A Randomized Controlled Trial of Cognitive Behavioural Therapy for Non-cardiac Chest Pain and Palpitations.||Norwegian University of Science and Technology|No|Completed|March 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||August 2011|August 25, 2011|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623454||160139|
NCT00624611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01444|The Effect of Washing Red Blood Cells on Post Heart Surgery Blood Loss|Post Cardiac Surgery Blood Loss: Effect of Washing Residual Cardiopulmonary Bypass Circuit Blood Red Cells Prior to Re-infusion. A Proof of Concept Study||University of British Columbia|No|Completed|February 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|2 Years|10 Years|No|||April 2011|April 12, 2011|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00624611||160051|
NCT00624624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-472-120607|Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism|Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism||Rijnstate Hospital|No|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|24|Samples Without DNA|serum|Male|20 Years|55 Years|No|Non-Probability Sample|Men with planned bariatric surgery|November 2014|November 5, 2014|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624624||160050|
NCT00624338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27646|Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)|A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)|APRIL-SLE|EMD Serono||Completed|January 2008|October 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|461|||Both|16 Years|N/A|No|||March 2016|March 11, 2016|February 15, 2008|Yes|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT00624338||160071|Atacicept 150 mg group was discontinued on 2 February 2011 based on the recommendation from the Independent Data Monitoring Committee.
NCT00625183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 113607|Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma|A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma||Roswell Park Cancer Institute||Terminated|March 2008|December 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|February 26, 2008|Yes|Yes|Withdrawn due to poor/low accrual|No|September 19, 2014|https://clinicaltrials.gov/show/NCT00625183||160009|Due to the study's early termination, as a result of low accrual, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.
NCT00624884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YT1977|Velocity Vector Imaging in Patients With Moderate-to-Severe Aortic Regurgitation|Velocity Vector Imaging in Patients With Moderate-to-Severe Aortic Regurgitation||Florence Nightingale Hospital, Istanbul|Yes|Completed|March 2008|May 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Tertiary care clinic|June 2008|June 27, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624884||160030|
NCT00626678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87- 01-30 - 6907|Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone|A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Adjuvant Azathioprine Therapy in New Cases of Pemphigus Vulgaris Receiving Prednisone||Tehran University of Medical Sciences|Yes|Completed|January 2008|September 2010|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|10 Years|75 Years|No|||November 2010|November 26, 2010|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626678||159897|
NCT00625469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPF/PAH|Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan|Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study||University of California, Los Angeles|Yes|Recruiting|October 2007|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|N/A|N/A|No|||February 2008|February 19, 2008|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625469||159988|
NCT00625781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061018-237|Treatment of Impaired Glucose Tolerance in Pregnancy|Randomized Controlled, Multicenter Study Evaluating Treatment of Glucose Intolerance in Pregnancy|TIP|University Hospital Orebro|No|Recruiting|February 2008|January 2013|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 24, 2010|February 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00625781||159966|
NCT00622726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0036|Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity|Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial|BEAT-ROP|The University of Texas Health Science Center, Houston|Yes|Active, not recruiting|March 2008|August 2020|Anticipated|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|N/A|22 Weeks|No|||February 2016|February 22, 2016|February 13, 2008|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00622726||160194|Limitations:number of patients is too small to determine efficacy of bevacizumab in posterior zone II ROP.number of patients is too small to determine safety of bevacizumab systemically.
NCT00626665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15;PGI/DM/EC/40/7/11/07|Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma|Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Completed|December 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|No|||March 2013|March 21, 2013|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626665||159898|
NCT00622687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILO-1998|Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis|Comparision Between Maximally Tolerated Intravenous Iloprost Doses Versus Low-Dosed Iloprost for a 21-Day Treatment Course|ILODOSE|Charite University, Berlin, Germany|No|Terminated|September 1997|December 2007|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||December 2007|February 22, 2008|February 14, 2008||No|sufficient number to reach the primary endpoint and as planned|No||https://clinicaltrials.gov/show/NCT00622687||160197|
NCT00622986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XMT-5Cs-002-2007|China Cimicifuga Trial of Climacteric Complaint Control|A Multicentered RCT Study of the Efficacy and Safety of an Extract of Cimicifuga Foetida L. for the Treatment of Climacteric Symptoms of Chinese Women|CCCCC|Shandong Luye Pharmaceutical Co., Ltd.|No|Recruiting|February 2008|February 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|288|||Female|40 Years|60 Years|No|||February 2008|February 22, 2008|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622986||160174|
NCT00677950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S01-01US|OP-1 Putty for Posterolateral Fusions|OP-1 Putty for Posterolateral Fusions||Olympus Biotech Corporation|No|Completed|October 2001|November 2005|Actual|November 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|336|||Both|18 Years|85 Years|No|||June 2011|June 9, 2011|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00677950||155992|
NCT00622895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2067.00|Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis|Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis||Fred Hutchinson Cancer Research Center|Yes|Recruiting|September 2006|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|70 Years|No|||March 2016|March 10, 2016|February 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00622895||160181|
NCT00622908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|373|Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis||Bausch & Lomb Incorporated|No|Completed|December 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|270|||Both|1 Year|N/A|No|||March 2015|March 4, 2015|February 14, 2008|Yes|Yes||No|June 29, 2009|https://clinicaltrials.gov/show/NCT00622908||160180|
NCT00622921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP0031|Couples-based Behavioral Psychotherapy for Male Patients With Posttraumatic Stress Disorder and Alcohol Dependence|Couples-based Behavioral Psychotherapy for Male Patients With Posttraumatic Stress Disorder and Alcohol Dependence||Yale University|No|Withdrawn|February 2008|February 2012|Anticipated|February 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|21 Years|65 Years|No|||January 2012|January 26, 2012|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622921||160179|
NCT00623194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1690|Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689|A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 Years With Type 1 Diabetes on a Basal-Bolus Regimen With Insulin Aspart as Bolus Insulin||Novo Nordisk A/S|No|Completed|February 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|146|||Both|3 Years|17 Years|No|||November 2014|November 20, 2014|February 14, 2008|Yes|Yes||No|September 5, 2010|https://clinicaltrials.gov/show/NCT00623194||160158|
NCT00623467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91682|Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging|A Multicenter, Open-label, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS).||Bayer|No|Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|343|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|February 18, 2008|No|Yes||No|June 20, 2011|https://clinicaltrials.gov/show/NCT00623467||160138|
NCT00623181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID30|Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults|Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age||Sanofi|Yes|Completed|January 2008|June 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|February 6, 2008|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00623181||160159|
NCT00623753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVP-I|Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults|Evaluate Tolerability and Safety of Multi-Envelope, Prime-boost HIV Vaccine (DVP) in Healthy Adults||St. Jude Children's Research Hospital|Yes|Terminated|May 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2011|September 14, 2011|February 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00623753||160116|
NCT00623766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-042|Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases|A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases||Bristol-Myers Squibb|No|Completed|July 2008|October 2012|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|16 Years|N/A|No|||May 2014|May 27, 2014|February 19, 2008|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00623766||160115|
NCT00624364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1579|Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes|Comparison of Efficacy and Safety of Biphasic Insulin Aspart Plus Metformin to Biphasic Insulin Aspart Monotherapy in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|May 2004|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|140|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|February 15, 2008||||No||https://clinicaltrials.gov/show/NCT00624364||160069|
NCT00624910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-002|Efficacy and Safety of A Collagen Bupivacaine Implant in Women Following Abdominal Hysterectomy|A Phase II, Single Dose, Blinded, Prospective Study to Investigate the Efficacy and Safety of the CollaRx® Bupivacaine Implant in Women Following Abdominal Hysterectomy or Other Nonlaparoscopic Benign Gynecological Procedure||Innocoll|No|Completed|December 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|54|||Female|18 Years|75 Years|No|||March 2012|March 22, 2012|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624910||160029|
NCT00624923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 06-13|Targeting Inflammation Using Salsalate in CardioVascular Disease|Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)|TINSAL-CVD|Joslin Diabetes Center|Yes|Active, not recruiting|September 2008|||January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|278|||Both|21 Years|75 Years|No|||March 2015|March 30, 2015|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624923||160028|
NCT00624936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588051|Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes|Phase I Study of Vidaza and Velcade (Bortezomib) in Acute Myeloid Leukemia||National Cancer Institute (NCI)||Recruiting|April 2008|||March 2011|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||June 2009|April 9, 2010|February 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00624936||160027|
NCT00625482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-7041-121|Sex-Differential Health Interventions In Low-Birth-Weight Infants|Sex-Differential Health Interventions In Low-Birth-Weight Infants||Bandim Health Project||Active, not recruiting|February 2008|||||N/A|Interventional|Primary Purpose: Prevention|4||||||Both|N/A|1 Month||||October 2013|October 22, 2013|February 18, 2008||||No||https://clinicaltrials.gov/show/NCT00625482||159987|
NCT00625495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9615C00013|Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)|An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)||AstraZeneca|No|Completed|September 2002|November 2002|Actual|November 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||January 2011|January 21, 2011|February 20, 2008||||No||https://clinicaltrials.gov/show/NCT00625495||159986|
NCT00626145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00200301|Long Term Follow-up of Autologous Bone Marrow Mononuclear Cells Therapy in STEMI|Long Term Functional Evaluation After Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells in Patients With ST-Elevation Myocardial Infarction||Xijing Hospital|Yes|Active, not recruiting|March 2003|March 2008|Anticipated|March 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|45 Years|65 Years|No|||February 2008|February 28, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626145||159938|
NCT00626093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 388|'Effect of CRT on Defibrillation Threshold Estimates' Study|Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates||St. Jude Medical|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|February 7, 2008||No||No|July 21, 2011|https://clinicaltrials.gov/show/NCT00626093||159942|
NCT00622700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6260|Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis|An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period|TOPIC|Sanofi|Yes|Completed|February 2008|February 2016|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|618|||Both|18 Years|55 Years|No|||February 2016|February 25, 2016|February 14, 2008|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT00622700||160196|
NCT00622713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DFR08|A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)|A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26)|EXTRA|Novartis||Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|50 Years|N/A||||June 2011|June 27, 2011|February 14, 2008||||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00622713||160195|
NCT00622999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Malnutr_Colon_CH_2007|Effects of Malnutrition on Colon Cancer Patients With Abdominal Surgery|Effects of Malnutrition on Colon Cancer Patients With Abdominal Surgery||University Hospital Inselspital, Berne|No|Completed|January 2003|January 2005|Actual|January 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|186|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing colorectal surgery with diagnosed malignity.|March 2011|March 10, 2011|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00622999||160173|
NCT00623012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702002350|Rapamycin for Prevention of Chronic Graft-Versus-Host Disease|Rapamycin for Prevention of Chronic Graft-Versus-Host Disease||Yale University|No|Terminated|February 2008|August 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|February 13, 2008|Yes|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00623012||160172|
NCT00626912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND07.001|PRET: Patients Prone to Recurrence After Endovascular Treatment|PRET: Patients Prone to Recurrence After Endovascular Treatment. A Randomized Trial Comparing Platinum and Hydrogel-coated Coils|PRET|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Completed|June 2007|December 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626912||159879|
NCT00626925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-052-2|Topiramate Treatment of Problem Drinkers|Topiramate Treatment of Problem Drinkers||University of Connecticut Health Center|No|Active, not recruiting|February 2008|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||June 2013|June 18, 2013|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626925||159878|
NCT00623545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0235|Bioenergetic Alterations After Exenatide Administration|Bioenergetic Alterations After Exenatide Administration||University of Wisconsin, Madison|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 5, 2015|February 14, 2008|No|Yes||No|July 22, 2013|https://clinicaltrials.gov/show/NCT00623545||160132|study was limited by the number of subjects who did not complete the study as a result of nausea. The nausea was short-lived and mild in all subjects that completed the study.
NCT00678626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021008|Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer|A Randomized Phase 2, Open-Label Study Of CP-751,871 In Combination With Docetaxel And Docetaxel Alone As A First Line Treatment Of Patients With Advanced Breast Cancer||Pfizer|No|Withdrawn|April 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||April 2015|April 30, 2015|May 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00678626||155941|
NCT00678314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMV 151:2003/9759|Patient Controlled Regional Analgesia Following Carpal Tunnel Release: A Double-Blind Study Using Distal Perineural Catheters|Patient Controlled Regional Analgesia Following Carpal Tunnel Release: A Double-Blind Study Using Distal Perineural Catheters||University Hospital Orebro|Yes|Completed|January 2004|February 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|88|||Both|18 Years|75 Years|No|||May 2008|May 13, 2008|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00678314||155965|
NCT00626847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#07-826|How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?|Nuclear Genetic and Mitochondrial Influences in Glaucoma||Wills Eye|No|Completed|March 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|97|Samples With DNA|whole blood|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|glaucoma clinic|December 2012|December 31, 2012|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626847||159884|
NCT00626860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-01112/1|The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma|The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|July 2000|November 2008|Anticipated|January 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2008|February 21, 2008|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626860||159883|
NCT00623779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1250C00051|Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)|A Controlled, Randomized, Parallel , Multi-centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA Therapy||AstraZeneca|Yes|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|128|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|February 15, 2008|Yes|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00623779||160114|
NCT00624039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB2006|The Effect of Cataract Extraction on the Contractility of Ciliary Muscle|The Effect of Cataract Extraction on the Contractility of Ciliary Muscle||Samsung Medical Center|No|Enrolling by invitation|May 2006|March 2008|Anticipated|March 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|15|||Both|55 Years|N/A|No|||May 2006|February 18, 2008|February 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00624039||160094|
NCT00623480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12800|Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment|Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment|SPINART|Bayer|Yes|Completed|March 2008|November 2013|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Male|12 Years|50 Years|No|||November 2014|November 5, 2014|February 4, 2008|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00623480||160137|
NCT00624052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.8|26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension|An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension||Boehringer Ingelheim||Completed|March 2008|||June 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|838|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|February 5, 2008||||No|December 28, 2009|https://clinicaltrials.gov/show/NCT00624052||160093|
NCT00624351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0007|Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease|A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease||UCB Pharma|Yes|Completed|January 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|227|||Both|18 Years|N/A|No|||July 2011|September 2, 2011|February 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624351||160070|
NCT00625209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070128|Activated Protein C and Corticosteroids for Human Septic Shock|Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock|APROCCHS|University of Versailles|Yes|Completed|March 2008|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1241|||Both|18 Years|N/A|No|||August 2015|August 2, 2015|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625209||160007|
NCT00624637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-253|Does Massage With or Without Aromatherapy Reduce Infant's Distress?|Does Massage With or Without Aromatherapy Reduce Infant's Distress After Craniofacial Surgery? A Randomized Controlled Trial|aromatherapy|Erasmus Medical Center|No|Recruiting|January 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|110|||Both|6 Months|3 Years|No|||February 2008|February 25, 2008|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624637||160049|
NCT00625872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281283|Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy|Neuromuscular Changes In Small For Gestational Age (SGA) Children During Somatropin Therapy - A Prospective Randomized, Controlled, Open-Label Multicenter Trial|SGA-POWER|Pfizer|No|Terminated|July 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|6 Years|10 Years|No|||January 2012|January 27, 2012|February 19, 2008|Yes|Yes|The study terminated on 19-Jan-2011 due to insufficient recruitment of patients. No safety    reasons contributed to the termination of the study.|No|January 27, 2012|https://clinicaltrials.gov/show/NCT00625872||159959|The study was prematurely discontinued, therefore not all data was powered.
NCT00625196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZA102940|Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects|A Randomised, Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Pharmacodynamics and Pharmacokinetics of GW685698X and GW642444M When Administered Separately and in Combination as a Single Dose From a Novel Dry Powder Device in Healthy Japanese Subjects||GlaxoSmithKline|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|16|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|February 19, 2008||||No||https://clinicaltrials.gov/show/NCT00625196||160008|
NCT00625521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASF1096-201|Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions|Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study||Astion Pharma A/S|No|Completed|November 2006|July 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|70 Years|No|||February 2008|February 28, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00625521||159985|
NCT00625846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00198|Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer|A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2008|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|188|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625846||159961|
NCT00626106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060362|A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer|An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer||Amgen||Completed|March 2008|August 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|156|||Female|18 Years|N/A|No|||January 2015|January 16, 2015|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626106||159941|
NCT00626691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV2707|The Effects of Walnuts on Antioxidant Capacity and Nutritional Status in Humans|The Effects of Walnuts on Antioxidant Capacity and Nutritional Status in Humans||Tufts University|Yes|Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|24|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 18, 2009|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626691||159896|
NCT00626704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060324|Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma|A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma||Amgen|No|Completed|November 2007|March 2011|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||April 2015|May 7, 2015|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00626704||159895|
NCT00626717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-03-CCL|Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus|Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus|CCL|University Hospital Freiburg|No|Completed|August 2007|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|N/A|No|||January 2013|January 16, 2013|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626717||159894|
NCT00623025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.3.125|Creon in HIV Patients With Steatorrhea|Double-blind, Cross-over, Randomized, Placebo-controlled, Multi-center Study to Investigate the Effect of Creon®25 000 on the Coefficient of Fat Absorption of HIV-infected Patients||Abbott|No|Terminated|January 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|80 Years|No|||July 2011|July 28, 2011|February 14, 2008||No|Discontinued prematurely due to low enrollment|No||https://clinicaltrials.gov/show/NCT00623025||160171|
NCT00623038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEST-APGAR|Trial to Evaluate a Specified Type of APGAR|Trial to Evaluate a Specified Type of APGAR|TEST-APGAR|Technische Universität Dresden|No|Completed|March 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1855|||Both|N/A|10 Minutes|No|Probability Sample|Very preterm infants born prior to 32 completed weeks of gestation|April 2011|April 21, 2011|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623038||160170|
NCT00623285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG2007|The Effects of Peri-operative Pregabalin Administration on Post-operative Analgesia in Patients Undergoing Coronary Bypass Grafting|The Effects of Peri-operative Pregabalin Administration on Post-operative Analgesia in Patients Undergoing Coronary Bypass Grafting||University of Manitoba|Yes|Recruiting|April 2008|June 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||March 2011|March 14, 2011|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623285||160151|
NCT00623272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007 28|Left Ventricular Function Assessment After Acute Myocardial Infarction: Comparison Between Bi-, Three-dimensional and Cardiac Magnetic Resonance|Left Ventricular Function Assessment After Acute Myocardial Infarction: Comparison Between bi-, Three-dimensional and Cardiac Magnetic Resonance||Assistance Publique Hopitaux De Marseille|Yes|Completed|November 2008|July 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|120|||Both|18 Years|N/A|No|||June 2008|August 21, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623272||160152|
NCT00623831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2005-003|A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen|A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.||Ludwig Institute for Cancer Research|No|Completed|May 2007|May 2013|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|February 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00623831||160110|
NCT00678327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593562|Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma|A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma||National Cancer Institute (NCI)||Recruiting|August 2008|||September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1200|||Both|18 Years|N/A|No|||June 2009|August 23, 2013|May 9, 2008||||No||https://clinicaltrials.gov/show/NCT00678327||155964|
NCT00675155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAAD-SR-CTP1|Far Infrared Irradiation for Stroke Rehabilitation|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation||GAAD Medical Research Institute Inc.|Yes|Active, not recruiting|May 2008|June 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2009|January 2, 2009|May 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675155||156206|
NCT00622947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20070144|The Antidepressant Effect of Right Temporal Low Frequency rTMS Compared to Sham|The Antidepressant Effect of Right Temporal Kow Frequency rTMS Compared to Sham. A Clinical Controlled, Randomized, Blinded Study.||University of Aarhus|No|Terminated|February 2008|February 2010|Actual|February 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||June 2010|June 25, 2010|January 24, 2008||No|to few included patients|No||https://clinicaltrials.gov/show/NCT00622947||160177|
NCT00623506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA IRB# 01209|Adjunctive Pregnenolone in Veterans With Mild TBI|Adjunctive Pregnenolone in Veterans With Mild TBI||Durham VA Medical Center||Completed|January 2008|November 2012|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|No|||May 2013|May 13, 2013|February 15, 2008|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00623506||160135|
NCT00623792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK077102-01A1|Study on Impact of Lifestyle Change and Weight Loss Before Bariatric Surgery|Preoperative Lifestyle Intervention in Bariatric Surgery|PREP|Duquesne University|No|Completed|March 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00623792||160113|
NCT00624065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR111096|Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure|COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either Carvedilol CR + Lisinopril or Lisinopril Monotherapy||GlaxoSmithKline||Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|348|||Both|18 Years|80 Years|No|||February 2013|February 7, 2013|February 14, 2008|Yes|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00624065||160092|
NCT00624078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-03/07|Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation|Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation||Instituto Bioclon S.A. de C.V.|No|Completed|May 2005|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1426|||Both|N/A|N/A|No|||February 2011|February 19, 2011|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00624078||160091|
NCT00624962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583517|Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors|Pilot Study of Early Enteral Tube Feedings in Children Receiving Chemotherapy for Newly Diagnosed AML/MDS and High Risk Solid Tumors||Vanderbilt University|Yes|Withdrawn|March 2006|January 2008|Anticipated|January 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|1 Year|21 Years|No|||November 2010|December 10, 2014|February 27, 2008||No|no participants enrolled|No||https://clinicaltrials.gov/show/NCT00624962||160025|
NCT00625547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAS-0067-031|A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS|A Double-Blind, Randomized, Active-Controlled Multicenter Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)||Pfizer|No|Completed|January 2003|December 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|361|||Both|18 Years|75 Years|No|||October 2008|October 28, 2008|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625547||159983|
NCT00625859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGW111083|A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects|A Double-blind, Randomized, 6-sequence, 3-period Crossover Drug-drug Interaction Study to Evaluate the Pharmacokinetics of WELLBUTRIN SR (Bupropion) and GSK189075 When Co-administered or Administered Alone in Healthy Male Volunteers||GlaxoSmithKline|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|March 15, 2012|February 19, 2008||Yes||||https://clinicaltrials.gov/show/NCT00625859||159960|
NCT00625560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0351|Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA|Randomized, Open-Labelled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B With Detectable HBV DNA||Yonsei University|Yes|Completed|February 2008|November 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|70 Years|No|||May 2012|May 7, 2012|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00625560||159982|
NCT00625573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-01|Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)|Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)|ABX067|Mt. Sinai Medical Center, Miami|Yes|Completed|September 2007|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|90 Years|No|||September 2009|September 17, 2009|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625573||159981|
NCT00626132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 25036|Standardized Eucommia Extract in the Treatment of Hypertension|Evaluation of the Safety and Efficacy of a Standardized Eucommia Extract in the Treatment of Hypertension||Pennington Biomedical Research Center|No|Completed|May 2007|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00626132||159939|
NCT00626444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07U.21|Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)|Phase II Trial of High Dose Intravenous Vitamin C in Patients With Refractory Non-Hodgkin Lymphoma||Thomas Jefferson University|Yes|Terminated|February 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|February 21, 2008|No|Yes|Slow accrual|No|November 24, 2014|https://clinicaltrials.gov/show/NCT00626444||159915|Study was terminated due to poor accrual. No reportable data has been collected for any of the specified outcome measures.
NCT00626457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02142008-1018|Promoting Healthy Weight With 'Stability Skills First'|Promoting Healthy Weight With 'Stability Skills First' (Fresh Start Weight Loss Study)||Stanford University|Yes|Completed|February 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|267|||Female|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00626457||159914|
NCT00626938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 04-145.11|Role of Proteomics in Diagnosing Sarcoidosis|Proteomics as a Tool for Biomarker Detection in Sarcoidosis||Maastricht University Medical Center|No|Completed|March 2005|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1000|Samples With DNA|Blood will be collected from all participants, but all samples will be stored anonymously.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients visiting the out-patient clinic of the university hospital Maastricht.|November 2012|November 5, 2012|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00626938||159877|
NCT00632762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 008 01|Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)|Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.|AMANDYSK|University Hospital, Toulouse|No|Completed|November 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|80 Years|No|||April 2011|April 7, 2011|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00632762||159440|
NCT00626964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-0517|Prevention of Coronary Heart Disease in Morbidly Obese Patients|Prevention of Coronary Heart Disease in Morbidly Obese Patients. Lifestyle Intervention, Low Energy Diet or Bariatric Surgery.|SphCor|The Hospital of Vestfold|No|Recruiting|February 2008|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood samples to biobank.|Both|18 Years|70 Years|No|Non-Probability Sample|Morbidly Obese patients with BMI > 40, or BMI > 35 with comorbidity such as Hypertension,        Obstructive Sleep Apnea, Weight Related Osteoarthrosis, Type 2 DM.|February 2008|February 28, 2008|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626964||159875|
NCT00626977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-07|Labor Analgesia With Ropivacaine and Clonidine|Labor Analgesia With Ropivacaine Added to Clonidine. A Randomized Clinical Trial|LA|UPECLIN HC FM Botucatu Unesp|Yes|Completed|May 2000|December 2001|Actual|May 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women having requested epidural analgesia for labor and hers newborns|February 2008|July 7, 2015|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626977||159874|
NCT00622739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SaxenaZiprasidone|Ziprasidone in Pediatric Bipolar Disorder|Ziprasidone in Pediatric Bipolar Disorder: a 6-week, Open-label Comparison of Rapid vs. Slow Dose Titration||University of Texas Southwestern Medical Center|Yes|Completed|February 2007|November 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|10 Years|17 Years|No|||June 2014|June 25, 2014|February 13, 2008|No|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT00622739||160193|
NCT00622752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVT 302/3011|Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes|A Double-Blind, Randomized, Placebo- and NRT -Controlled Phase II Study to Assess the Effects of EVT 302 Alone and in Combination With NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes||Evotec Neurosciences GmbH|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|90|||Male|18 Years|55 Years|No|||June 2008|June 16, 2008|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00622752||160192|
NCT00623558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCST-L0002|Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)|A Randomized, Multicenter, Open Phase II Study of Cetuximab With Docetaxel, Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)||Seoul National University Hospital|No|Completed|April 2008|August 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||April 2013|December 3, 2013|February 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00623558||160131|
NCT00623571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|516|Hospitalization at Home of Elderly Patients With Heart Failure|Acute Exacerbation of Chronic Heart Failure: "Hospital at Home" Versus Inpatient Care for Elderly Patients. A Randomized, Controlled Trial.||Azienda Ospedaliera San Giovanni Battista|No|Completed|April 2004|October 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|101|||Both|75 Years|N/A|No|||January 2004|February 25, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00623571||160130|
NCT00623298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fogr SOSS|Narrative Exposure Therapy Versus Group Interpersonal Psychotherapy|Narrative Exposure Therapy Versus Group Interpersonal Psychotherapy -A Controlled Clinical Trial With Orphaned Survivors of the Rwandan Genocide||University of Konstanz|No|Terminated|January 2005|March 2006|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|13 Years|29 Years|Accepts Healthy Volunteers|||February 2008|February 25, 2008|February 14, 2008||||No||https://clinicaltrials.gov/show/NCT00623298||160150|
NCT00675168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROLOG|Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice|PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice|PROLOG|Odense University Hospital|Yes|Recruiting|May 2008|June 2012|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|1700|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00675168||156205|
NCT00623493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908070|Detecting Risk of Suicide in a Pediatric Emergency Department|Detecting Risk of Suicide in a Pediatric Emergency Department||National Institutes of Health Clinical Center (CC)||Completed|February 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|10 Years|21 Years|No|||September 2015|October 6, 2015|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00623493||160136|
NCT00623805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21440|A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer|A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma||Hoffmann-La Roche||Completed|March 2008|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|February 18, 2008||No||No|June 6, 2014|https://clinicaltrials.gov/show/NCT00623805||160112|
NCT00624377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.399|Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice|Safety and Effectiveness of Spiriva® in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice||Boehringer Ingelheim||Completed|December 2007|||March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2031|||Both|40 Years|80 Years|No|Probability Sample|COPD|February 2014|February 27, 2014|February 19, 2008||||No|February 23, 2012|https://clinicaltrials.gov/show/NCT00624377||160068|
NCT00624650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003491|Hemodynamics and Extravascular Lung Water in Acute Lung Injury|Hemodynamics and Extravascular Lung Water in Acute Lung Injury: A Prospective Randomized Controlled Multicentered Trial of Goal Directed Treatment of EVLW Versus Standard Management for the Treatment of Acute Lung Injury|HEAL|Oregon Health and Science University|Yes|Completed|February 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||July 2010|May 27, 2011|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624650||160048|
NCT00624663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-JA-234-CTIL|A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers|A Double-Blind, Placebo-controlled Crossover Study to Assess the Pharmacokinetic Profile and the Physiological and Behavioral Effects of Repeat Rivastigmine (Exelon®) Administration in Young Healthy Male Volunteers|RIVA-1|Tel-Aviv Sourasky Medical Center|Yes|Completed|January 2009|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2008|March 26, 2014|October 30, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00624663||160047|
NCT00624949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010248|Aortic Dimensions in Turner Syndrome|Aortic Dimensions, 24hour Ambulatory Blood Pressure and Sympathovagal Tone in Turner Syndrome. In Relation to Aortic Dilatation and Dissection.||University of Aarhus|No|Active, not recruiting|August 2003|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|102|Samples With DNA|Blood samples|Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recrutted from hospital clinics and through the patient organisation|February 2008|February 27, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624949||160026|
NCT00625586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587562|Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer|A Phase 2 Evaluation of the Monoclonal Antibody, RAV12, in Combination With Standard Gemcitabine in the Treatment of Patients With Metastatic Pancreatic Cancer Who Have Not Been Previously Treated for Metastatic Disease||MacroGenics|No|Terminated|March 2008|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|February 26, 2008|Yes|Yes|Corporate decision|No|August 20, 2012|https://clinicaltrials.gov/show/NCT00625586||159980|Only 2 patients enrolled in the trial. Both were evaluable for safety and only one was evaluable for efficacy. No statistical analyses were performed.
NCT00625599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evcom-13|Fractures in the Elderly Population of El Salvador at Hospital Zacamil: Exploring Knowledge, Causes, Risk Factors, and Outcomes|Fractures in the Elderly Population of El Salvador at Hospital Zacamil: Exploring Knowledge, Causes, Risk Factors, and Outcomes||Edward Via Virginia College of Osteopathic Medicine|Yes|Recruiting|January 2008|||April 2008|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There will be two populations for this study. Hospital patients, females and males, over        the age of 45 that are admitted to the department of orthopedics at the Hospital Zacamil        in San Salvador, El Salvador from January 2008 to April 2008 will represent one of the        populations. All patients over the age of 45 presenting to the hospital due to an acute        fracture will be invited to join the study. The individual's care will not be changed        negatively or positively based on whether or not the individual decides to participate in        this study.        The second population group will be the university students, females and males, over the        age of 18 participating in non-medical studies at the Evangelical University in February        2009. No student will be negatively affected by not participating in this study. There        will be no positive or negative influence on the student's grade or course assessment from        participating or choosing not to participate in this study.|January 2008|February 28, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625599||159979|
NCT00625222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS-VNS001|Transcranial Direct Current Stimulation (tDCS) As A Tool For Prospective Responder Identification Before Vagus Nerve Stimulation (VNS) Implantation|||University of Luebeck|Yes|Recruiting|September 2007|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|12 Years|N/A|No|||January 2010|January 27, 2010|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00625222||160006|
NCT00626171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMsmsp|Role of Cigarette Smoking in Regulating Allergen-induced Early and Late Responses in Mild Asthmatics|A Study Evaluating the Role of Cigarette Smoking in Regulating Allergen-induced Early and Late Responses in Mild Asthmatics.||McMaster University|No|Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|65 Years|No|||April 2013|April 23, 2013|February 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00626171||159936|
NCT00625885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070110|Multicenter ACL Revision Study (MARS)|Multicenter ACL Revision Study (MARS)|MARS|Vanderbilt University|No|Active, not recruiting|February 2007|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1250|||Both|12 Years|65 Years|No|Non-Probability Sample|All ACL-deficient candidates scheduled for a revision ACL reconstruction at one of the        participating MARS sites.|December 2015|December 7, 2015|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625885||159958|
NCT00626470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSP Study|Prospective Trial on Trochanteric Femur Fractures Treated With or Without a Trochanter Support Plate|A Prospective Randomised Study of Unstable Trochanteric Femur Fractures Treated With Dynamic Hip Screw With and Without a Trochanter Support Plate|TSP|St. Olavs Hospital|No|Completed|December 2008|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|N/A|No|||March 2015|March 17, 2015|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00626470||159913|
NCT00626951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07208763-1|Crossover Study With the ProSeal and Supreme Laryngeal Mask Airway|The Supreme Laryngeal Mask Airway. A Randomized, Crossover Study With the ProSeal Laryngeal Mask Airway in Paralyzed, Anesthetized Patients|Supreme|Medical University Innsbruck|No|Completed|December 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|94|||Female|18 Years|80 Years|No|||June 2008|June 25, 2008|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00626951||159876|
NCT00633373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS004|Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients|An Open-label Treatment Use Protocol of Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients||APT Pharmaceuticals, Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||September 2012|September 13, 2012|March 5, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00633373||159394|
NCT00633386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191066|Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery|A Double-Blind, Placebo-Controlled, Randomized, Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery||Pfizer|No|Completed|February 2003|August 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|65 Years|No|||March 2009|March 12, 2009|March 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00633386||159393|
NCT00633334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-077|Development of Early Detection Signs for Gastrointestinal Cancer|Investigation of the Immune Response to Gastrointestinal Tumors and Development of Novel Biomarkers for the Presence of Gastrointestinal Cancer||University of Pittsburgh|Yes|Recruiting|September 2003|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples With DNA|peripheral blood portions of tumor tumor draining lymph nodes|Both|18 Years|N/A|No|Non-Probability Sample|Potential research subjects are first identified by their primary doctor/clinical team.        The research project will be discussed and mutually agreed upon between the subject and        his/her caregiver before the research team will contact the subject. Other subjects are        referred in specifically for possible participation in a particular study which they or        their physician are aware of based on publications which list clinical trials at UPMCHS.|December 2015|December 1, 2015|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00633334||159397|
NCT00633633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0822|Lifestyle Intervention for Heart Failure|Take Heart: Exercise & Diet Intervention for Heart Failure in Cancer Survivors||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2008|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|85|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00633633||159374|
NCT00623051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12126 ORANGE FARM 2|Evaluation of the Extension at Community Level of Safe Male Circumcision (ANRS 12126 ORANGE FARM 2)|Evaluation of the Extension at Community Level of Safe Male Circumcision (ANRS 12126 ORANGE FARM 2)|ORANGE FARM 2|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|January 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|27000|||Male|N/A|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00623051||160169|
NCT00634296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA2004-302|The Effects of the Inspiratory Muscle Plus Aerobic Training Compare to Aerobic Training Alone in Heart Failure Patients.|The Effects of the Inspiratory Muscle Training Plus Aerobic Training Compare to Aerobic Training Alone in Heart Failure Patients With Inspiratory Muscle Weakness.||Hospital de Clinicas de Porto Alegre|No|Recruiting|March 2005|March 2010|Anticipated|March 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|25 Years|75 Years|No|||March 2008|March 6, 2008|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00634296||159324|
NCT00675844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH443-904|An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment|An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48-Weeks in Subjects Who Have Completed 96 -Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018||Achillion Pharmaceuticals|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|65 Years|No|||January 2014|January 20, 2014|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00675844||156154|
NCT00675857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-503011|A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes|A Phase IIa Study of the Safety and Clinical Proof-of-concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome||Bellus Health Inc||Completed|April 2008|May 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|30 Years|95 Years|No|||August 2010|August 23, 2010|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00675857||156153|
NCT00623233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11649|Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer|A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes||Eli Lilly and Company|No|Completed|March 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|N/A|No|||December 2011|December 2, 2011|February 13, 2008|Yes|Yes||No|December 2, 2011|https://clinicaltrials.gov/show/NCT00623233||160155|
NCT00623519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST-ANA-2004-01|Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole|Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole.||AstraZeneca||Completed|June 2004|February 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|165|||Female|18 Years|N/A|No|Non-Probability Sample|Medical Oncology|March 2009|March 6, 2009|February 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00623519||160134|
NCT00624390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSPRAY00306|Sepraspray™ Laparoscopic Myomectomy Study|A Randomized, Masked Patient, Independent Reviewer, Multi-Center Pilot Study to Evaluate the Feasibility of Sepraspray™ Adhesion Barrier in Laparoscopic Myomectomy||Sanofi|Yes|Completed|November 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|41|||Female|18 Years|50 Years|No|||May 2015|May 7, 2015|February 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00624390||160067|
NCT00624975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHPR-01|Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants|A Multi-site, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Trehalose-reformulated Peru-15 (Choleragarde)Vaccine Given Simultaneously With Measles Vaccine in Healthy Indian and Bangladeshi Infants||International Vaccine Institute|Yes|Terminated|November 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|9 Months|12 Months|Accepts Healthy Volunteers|||July 2012|July 30, 2012|February 19, 2008||No|one of site was not able to get an approval from the national regulatory authority.|No||https://clinicaltrials.gov/show/NCT00624975||160024|
NCT00624676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRP05021|Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne Vulgaris|Randomized Study Comparing the Efficacy and Tolerance of a Lipophilic Hydroxy Acid Derivative of Salicylic Acid and 5% Benzoyl Peroxide in the Treatment of Facial Acne Vulgaris||Cosmetique Active International|No|Completed|January 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||September 2011|September 18, 2011|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624676||160046|
NCT00625235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 2003.046|A High Protein Diet and Weight Maintenance|The Use of a High Protein Diet in Achieving Long-Term Weight Loss and Improved Cardiovascular Risk Factors||University of Melbourne|No|Completed|July 2003|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2|||180|||Both|18 Years|75 Years|No|||June 2003|February 19, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625235||160005|
NCT00635388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007149|A Study of the Effects of Probiotics in Children Grades 1-3|A Double-blind, Randomized, Placebo-controlled Study of the Effects of Probiotics in Children Grades 1-3||Procter and Gamble|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|360|||Both|5 Years|9 Years|Accepts Healthy Volunteers|||October 2009|October 15, 2009|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00635388||159240|
NCT00635401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051043|A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking|A Multicenter, Open-Label Study Exploring the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking||Pfizer|No|Completed|May 2004|August 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|75 Years|No|||April 2008|April 7, 2008|March 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635401||159239|
NCT00625898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-44-I|BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab|A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab|BETH|NSABP Foundation Inc|Yes|Terminated|April 2008|July 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3509|||Female|18 Years|N/A|No|||July 2014|July 7, 2014|February 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00625898||159957|
NCT00626158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#074510|Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers|A Phase I Study, With Expanded Cohort, of Biweekly Fixed-dose Rate Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic and Biliary Carcinomas||University of California, San Francisco|Yes|Completed|February 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|February 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00626158||159937|
NCT00635986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fentanyl|Analgesic Effect and Plasma Concentration of Epidural Versus Intravenous Fentanyl|Analgesic Effect and Plasma Concentration of Epidural Versus Intravenous Fentanyl|FTN|Federal University of São Paulo|Yes|Completed|May 2004|November 2006|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||March 2008|March 11, 2008|January 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635986||159195|
NCT00636285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB-A001|Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants|Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetics Study in Adults of BSYX-A110, a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants||Biosynexus Incorporated|No|Completed|April 2001|November 2001|Actual|September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 8, 2008|February 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00636285||159172|
NCT00631917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2404|A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension|A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension||Novartis|No|Completed|February 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|774|||Both|50 Years|N/A|No|||June 2011|June 30, 2011|March 3, 2008|Yes|Yes||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00631917||159502|
NCT00631943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081068|A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain|An Open Label, Non-comparative, Multicentre Study to Evaluate the Efficacy and Tolerability of Pregabalin in Peripheral Neuropathic Pain||Pfizer|No|Completed|November 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||April 2011|April 22, 2011|March 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00631943||159501|
NCT00632229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF 08-0100|Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder|Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder||University of South Florida|No|Completed|October 2007|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|No|||October 2013|December 19, 2013|February 29, 2008||No||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00632229||159481|Modest sample and analyses were potentially underpowered to detect between-group differences on OCD measures.It was not possible to determine response from participants' current medication.Little racial/ethnic and socioeconomic variability
NCT00632749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1247.3|BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment|An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Efficacy and Pharmacokinetics of BI 811283 in Combination With Cytarabine in Patients With Previously Untreated Acute Myeloid Leukaemia Ineligible for Intensive Treatment||Boehringer Ingelheim||Completed|May 2008|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|March 4, 2008||||No|March 27, 2015|https://clinicaltrials.gov/show/NCT00632749||159441|
NCT00633399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002361|Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs|A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.||Massachusetts General Hospital|Yes|Completed|July 2008|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|458|||Both|18 Years|65 Years|No|||June 2014|June 24, 2014|March 4, 2008|No|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT00633399||159392|
NCT00633347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-CV-1006-02|Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation|||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|January 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|570|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00633347||159396|
NCT00633360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002057|The Oral Contraceptive Pill for Premenstrual Worsening of Depression|The Oral Contraceptive Pill for Premenstrual Worsening of Depression.||Massachusetts General Hospital|No|Completed|February 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|99|||Female|18 Years|45 Years|No|||July 2014|July 9, 2014|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633360||159395|
NCT00633958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI 05-303|A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors|A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors|FLT|Dana-Farber Cancer Institute|No|Terminated|March 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5|||Both|N/A|21 Years|No|||April 2011|July 6, 2011|March 5, 2008||No|Large phase II opened to accue same patients|No||https://clinicaltrials.gov/show/NCT00633958||159349|
NCT00633971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 08-065|Treatment Trial for Post-Thrombotic Syndrome|A Randomized Trial to Determine the Impact of Lymphedema Therapy on Quality of Life and Disease Severity in Patients With Post-Thrombotic Syndrome||University of Vermont|No|Active, not recruiting|March 2008|September 2011|Anticipated|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00633971||159348|
NCT00676949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KU-CY5peptides|Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors|Phase I Study of Tumor Specific Potentiated Vaccine Therapy Using Cyclophosphamide Combined Epitope Peptide Cocktail for Progressive/Relapsed Solid Tumors(GI/Lung/Cervical Cancer)|peptidevac|Kyushu University|Yes|Completed|November 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|80 Years|No|||April 2011|June 22, 2011|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00676949||156069|
NCT00677170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15001|Study of MLN4924 in Adult Patients With Nonhematologic Malignancies|An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.||Completed|April 2008|December 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|May 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00677170||156052|
NCT00623532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGR-2006-01-Etude MARGE|Intervention Study of Mind-Body Physical Activity in Frail Institutionalized Elderly|A Randomized Interventional Study of a Cognition-Action Physical Activity and Adapted Tai-Chi in Frail Institutionalized Elderly||Association de Recherche Gerontologique|Yes|Completed|May 2006|February 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|160|||Both|65 Years|N/A|No|||May 2009|May 18, 2009|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00623532||160133|
NCT00624091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOVAL-1|Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study (ENDOVAL)|Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis|ENDOVAL|Instituto de Ciencias del Corazon|Yes|Recruiting|September 2007|September 2010|Anticipated|November 2007|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||February 2008|February 18, 2008|February 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00624091||160090|
NCT00624104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-0001|VLDL-triglyceride Under Acute Hyperinsulinaemia|VLDL-triglyceride Under Acute Hyperinsulinaemia||University of Aarhus|Yes|Completed|March 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|N/A||2|Actual|16|Samples With DNA|specimen of muscle specimen of adipose tissue|Male|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males with diabetes from departments out-patient clinic. Control group of healthyt        volunteers|November 2011|November 4, 2011|February 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00624104||160089|
NCT00624117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnro46/2005|Progressive Exercise After Operation of Rotator Cuff Rupture and Anterior Labrum Rupture|Progressive Exercise After Operation of Rotator Cuff Rupture and Anterior Labrum Rupture: Randomized Controlled Trial||Jyväskylä Central Hospital|No|Completed|May 2006|February 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|65 Years|No|||May 2010|May 25, 2010|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624117||160088|
NCT00624130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91352|Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers|Open, Randomized, Parallel Multi-center Comparison of Cycle Control and Safety of the Oral Contraceptive Yasmin 20 in a 24-day Regimen vs. Mercilon for 7 Cycles in 440 Healthy Female Volunteers||Bayer|No|Completed|March 2004|June 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|453|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|February 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00624130||160087|
NCT00624988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0723070100|The Effect of Vibration Therapy on the Bone Density of the Tiba in Patients With Spinal Cord Injury|The Effect of Vibration Therapy on the Bone Density of the Tiba in Patients With Spinal Cord Injury|SCI|Logan College of Chiropractic|Yes|Recruiting|July 2008|February 2009|Anticipated|February 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2008|October 16, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00624988||160023|
NCT00624715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707002888|Cannabinoid Receptor Function & Alcoholism|Cannabinoid Receptor Function & Alcoholism: Effects of Δ-9-THC||Yale University||Active, not recruiting|July 2007|December 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00624715||160043|
NCT00625248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 18|Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy|A Prospective Evaluation of Bleeding Risk of Anticoagulant and Antiplatelet Therapy for Interventional Techniques||Pain Management Center of Paducah|Yes|Completed|February 2008|January 2010|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|12000|||Both|18 Years|N/A|No|Probability Sample|ambulatory surgery center patients|June 2013|June 20, 2013|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00625248||160004|
NCT00635115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFSA-2005-01|The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia|The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia|VEPRO|Santéclair|No|Completed|February 2006|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|43 Years|60 Years|No|||March 2008|March 12, 2008|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00635115||159261|
NCT00636012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSW-08|Stimulation of Gastric Slow Waves With Acupuncture at St36 and Pe6 - a Randomized Single-blind Controlled Trial|Stimulation of Gastric Slow Waves by Acupuncture of St36 and Pe6 - a Randomized Single-blind Controlled Trial|GSW|Charite University, Berlin, Germany|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|65|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636012||159193|
NCT00636298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006037|Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy|Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy||Emory University|Yes|Withdrawn|October 2008|March 2012|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|March 11, 2008|Yes|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT00636298||159171|
NCT00635661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBPHS-5535|Assessment of the Stroke Rehabilitation Assessment of Movement as a Clinical Tool|A Comparison of the Stroke Rehabilitation Assessment of Movement, the Functional Independence Measure and the Stroke Impact Scale||State University of New York - Upstate Medical University|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Adults who have sustained an ischemic stroke|January 2012|January 31, 2012|March 7, 2008||No||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00635661||159219|
NCT00635973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0026|Open-Label Extension of Other SZ1839 (Iressa) Trials|Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.||AstraZeneca|No|Completed|February 2000|October 2003|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|March 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635973||159196|
NCT00632242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC1779-004|ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders|A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders||Archemix Corp.|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|28|||Both|18 Years|75 Years|No|||March 2008|January 8, 2009|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632242||159480|
NCT00632528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061007|MEOPA to Improve Physical Therapy Results After Multilevel Surgery|Evaluation of the Efficacy of "MEOPA" Used to Obtain Better ROM Immediately After Multilevel Surgery in Children With Spastic Diplegia, Quadriplegia or Hemiplegia.|KINOPA|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|6 Years|20 Years|No|||February 2008|January 9, 2012|February 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00632528||159458|
NCT00632775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011114|0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Hospitalized Children|Randomized, Double Blind, Controlled Trial of 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Hospitalized Children||The Hospital for Sick Children|Yes|Completed|December 2007|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|1 Month|18 Years|No|||August 2013|August 23, 2013|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632775||159439|
NCT00624494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4347.07.2006|Single Transpulmonary Thermodilution and Continuous Monitoring of Central Venous Oxygen Saturation During Off-pump Coronary Surgery|Single Transpulmonary Thermodilution and Continuous Monitoring of Central Venous Oxygen Saturation During Off-pump Coronary Surgery|OPCAB|Northern State Medical University|No|Completed|May 2005|September 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||January 2011|January 4, 2011|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00624494||160059|
NCT00633035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-94-C-016|Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit|Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit||Far Eastern Memorial Hospital|Yes|Completed|September 2007|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|90 Years|No|||October 2013|October 12, 2013|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00633035||159419|
NCT00633048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3230A1-1000|Study Evaluating the Safety and Tolerability of NSA-789|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 16, 2009|February 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00633048||159418|
NCT00633061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL084097|Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer|Phase II Study on the Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer|DVT|University of Texas Southwestern Medical Center|Yes|Completed|March 2008|December 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|N/A|18 Years|No|||February 2013|February 6, 2013|February 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00633061||159417|
NCT00633984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000386|D-Cycloserine Enhancement of Exposure in Social Phobia|D-Cycloserine Enhancement of Exposure in Social Phobia||Massachusetts General Hospital|Yes|Completed|March 2007|September 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|March 4, 2008||No||No|January 2, 2014|https://clinicaltrials.gov/show/NCT00633984||159347|
NCT00633997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2224|Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes|An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes||Novartis|No|Terminated|February 2008|||December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 9, 2016|March 4, 2008|No|Yes|After analysis of the existing data, it was determined that additional skin biopsy samples    would not be required to determine study outcome.|No||https://clinicaltrials.gov/show/NCT00633997||159346|
NCT00633646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05PJ14057(Shanghai, China)|Effect of Protein-Restricted Diet on Nitrogen Balance and Residual Renal Function in Peritoneal Dialysis (PD) Patients|Effect of Protein-Restricted Diet on Nitrogen Balance and Residual Renal Function in PD Patients||Shanghai Jiao Tong University School of Medicine|No|Completed|January 2006|February 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|80 Years|No|||March 2008|April 24, 2008|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00633646||159373|
NCT00675415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#06-681|Does Capnography Prevent Hypoxemia During Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound?|Does Capnography Prevent Hypoxemia During ERCP and EUS? A Randomized, Controlled Trial||The Cleveland Clinic|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|263|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|February 22, 2014|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00675415||156186|
NCT00641745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050237|Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia|Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial||Sunovion|Yes|Completed|March 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|629|||Both|18 Years|75 Years|No|||June 2015|June 16, 2015|March 18, 2008|Yes|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00641745||158756|
NCT00624403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/22|Comparison of Two Type of Laryngeal Mask : I-Gel & LMA ProSeal|LMA ProSeal & I-Gel : a Prospective Controlled Trial|I-Gel|University Hospital, Bordeaux|No|Completed|March 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|700|||Both|N/A|N/A|No|||January 2014|March 9, 2015|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624403||160066|
NCT00624689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUMME|Effects of Milk Fat Globule Membrane (MFGM) - Enriched Formula With Reduced Energy and Protein Content on Growth and Development|Double-blinded Interventional Study on the Effects of MFGM-enriched Formula With Reduced Energy and Protein Content on Growth and Development|TUMME|Umeå University|No|Active, not recruiting|March 2008|March 2018|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|240|||Both|N/A|2 Months|Accepts Healthy Volunteers|||December 2014|December 19, 2014|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624689||160045|
NCT00624702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2102|Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma|A Multi-center, Randomized, Single-dose, Double-blind, 4-way Cross-over Study to Evaluate Tolerability Following Treatment With Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma||Novartis|No|Completed|February 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|98|||Both|18 Years|65 Years||||August 2010|August 26, 2010|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624702||160044|
NCT00624728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9420-04|Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)|Assessment of 18Fluoro-thymidine PET-CT for the Volume Definition of High-grade Gliomas (GLIO-TEP) : Correlation With Histopathology|GLIO-TEP|University Hospital, Bordeaux|Yes|Completed|February 2008|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||May 2012|May 3, 2012|February 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00624728||160042|
NCT00635128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110947|Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine|Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting.||GlaxoSmithKline||Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|415|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|March 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00635128||159260|
NCT00635687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/102/HP|Transient Elastography and Variceal Bleeding|Can Liver Stiffness Values Predict Early Rebleeding in Variceal Rupture|PROME|University Hospital, Rouen|No|Terminated|March 2008|May 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|29|||Both|18 Years|75 Years|No|||March 2013|March 4, 2013|March 7, 2008||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT00635687||159217|
NCT00635999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH039172-01|A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder|Desensitization and Cognitive Therapy in General Anxiety||National Institute of Mental Health (NIMH)|No|Completed|October 1991|October 1998|Actual|October 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|76|||Both|18 Years|85 Years|No|||August 2009|October 22, 2010|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00635999||159194|
NCT00636324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB project # 07-047|Level of Continuous Positive Airway Pressure (CPAP) in Preterm Infants After Extubation (L-CPAP Study)|Nasal Continuous Positive Airway Pressure in Preterm Infants After Extubation: Comparison of Different Levels of Pressure|L-CPAP|McMaster University|Yes|Terminated|July 2007|June 2010|Anticipated|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|N/A|14 Days|No|||February 2009|February 9, 2009|March 7, 2008||No|Difficulties in recruitment - will require longer time to achieve sample size|No||https://clinicaltrials.gov/show/NCT00636324||159169|
NCT00636311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2006-005|A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma|IGEV +/- Bortezomib (Velcade) as Induction Before High Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma After First Line Treatment: a Randomized Phase II Trial. On Behalf of Intergruppo Italiano Linfomi||Istituto Clinico Humanitas|No|Completed|February 2008|February 2010|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|No|||September 2010|September 1, 2010|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00636311||159170|
NCT00631956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC0950806|SAPPHIRe III in Taiwan－Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families|Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families－A Follow-up Genetic Study of Taiwan SAPPHIRe Cohort||National Health Research Institutes, Taiwan||Recruiting|October 2006|December 2010|Anticipated|||N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Anticipated|1200|Samples With DNA|Plasma, serum, urine, and buffy coat|Both|40 Years|70 Years|No|Non-Probability Sample|A follow-up genetic study of Taiwan SAPPHIRe Cohort|August 2009|August 12, 2009|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00631956||159500|
NCT00632255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADA1012|Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment|Compliance to Long Term Imatinib Therapy in Newly Diagnosed Patients With Chronic Myeloid Leukaemia.||Imperial College London|No|Completed|January 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CML who have been treated with imatinib (Glivec®) within 6 months of        diagnosis as first line therapy.|October 2009|June 2, 2015|February 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00632255||159479|
NCT00632268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612015M|Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer|Phase II Study of Low-dose RAD001(Everolimus) Plus Cisplatin and HDFL (Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin) Chemotherapy for First-line Treatment of Unresectable, Recurrent or Metastatic Gastric Cancer||National Taiwan University Hospital|Yes|Completed|February 2008|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|75 Years|No|||August 2013|August 19, 2013|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00632268||159478|
NCT00632541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE06-109|A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer|A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109||Hoosier Cancer Research Network|Yes|Terminated|October 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 28, 2008||No|Significant Toxicities Experienced|No|December 2, 2015|https://clinicaltrials.gov/show/NCT00632541||159457|The study was terminated early due to a poor safety profile as well as the lack of significant efficacy of this combination over bevacizumab alone in the short followup period where it was evaluated. Therefore, secondary objectives were not analyzed.
NCT00694837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09-04/07|Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma|Phase I/II Study for Patients With Newly Diagnosed Glioblastoma Testing Nelfinavir in Combination With Concomitant Temozolomide and Radiotherapy.||Maastricht Radiation Oncology|Yes|Completed|March 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||April 2015|April 9, 2015|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00694837||154708|
NCT00687206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Val25/08|Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage|Efficacy and Safety of Valsartan 160 mg Plus Hydrochlorothiazide 25 mg Once a Day in Patients With Slight Hypertension and Target Organ Damage||Federico II University|Yes|Completed|March 2008|December 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|65 Years|No|||January 2009|January 28, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00687206||155290|
NCT00688116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-01|Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients With Solid Tumors||Synta Pharmaceuticals Corp.|No|Active, not recruiting|October 2007|November 2014|Anticipated|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|25 Years|N/A|No|||September 2014|September 17, 2014|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688116||155222|
NCT00688129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA021424|KITS: School Readiness in Foster Care Efficacy Trial|KITS: School Readiness in Foster Care Efficacy Trial|KITS|Oregon Social Learning Center|No|Active, not recruiting|September 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|4 Years|6 Years|No|||October 2015|October 13, 2015|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688129||155221|
NCT00695981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B07103-2|Operative Versus Non-operative Management of Rotator Cuff Tear|The Effectiveness and Cost-Effectiveness of Operative and Non-operative Management of Rotator Cuff Tear||Central Finland Hospital District|Yes|Active, not recruiting|June 2008|October 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|35 Years|N/A|No|||January 2016|January 27, 2016|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00695981||154622|
NCT00696566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14468|Healthy Volunteer Study of Clopidogrel and Rifampicin|Study of the Potentiation of the Effects of Clopidogrel by Rifampicin in Healthy Volunteers||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00696566||154578|
NCT00696826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-017|A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)|An Open-Label, Single Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK0431||Merck Sharp & Dohme Corp.||Completed|April 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||August 2015|August 18, 2015|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696826||154559|
NCT00684801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6Y07|Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers|Improving the Quality of Advanced Cancer Care With Disease Management||Case Comprehensive Cancer Center|Yes|Completed|August 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|605|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|October 2015|October 8, 2015|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00684801||155474|
NCT00685620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPR010213-01|Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers|Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers|CASA|National Institute on Drug Abuse (NIDA)|No|Completed|August 2002|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|463|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2008|May 23, 2008|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685620||155411|
NCT00686257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-6060|Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure|Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure||Tufts Medical Center|No|Completed|January 2003|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|May 27, 2008|Yes|Yes||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00686257||155363|Could not blind subjects or investigators
NCT00686270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-303|A Long Term Safety Study of Apricitabine in HIV-infected Patients|A Phase 3, Open Label 96-week Extension Study of the Safety of Apricitabine in Treatment-experienced HIV-1 Infected Patients Who Have Completed Protocol AVX-301 or AVX-302 or Who Have Met the Criteria for Open-label Access to ATC Because of Virological Failure/Lack of Response||Avexa|No|Withdrawn|May 2008|May 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|May 27, 2008|Yes|Yes|Study was withdrawn owing to Sponsor decision|No||https://clinicaltrials.gov/show/NCT00686270||155362|
NCT00686582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-023|An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees|An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees||Bavarian Nordic|Yes|Completed|August 2008|October 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|304|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 21, 2010|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686582||155338|
NCT00686595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05133|A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)|swiTching From etAnercept to iNfliximab in the Treatment of Moderate to Severe Psoriasis; a Multi-center, Open Label Trial evaluatinG the Efficacy, tOlerance and Safety (TANGO)|TANGO|Merck Sharp & Dohme Corp.|Yes|Completed|October 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|May 27, 2008|No|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00686595||155337|
NCT00686933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-425|Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Study M10-346||AbbVie|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|60 Years|No|||January 2013|January 11, 2013|May 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00686933||155311|
NCT00686946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/04|The National Register of Antipsychotic Medication in Pregnancy (NRAMP)|The National Register of Antipsychotic Medication in Pregnancy (NRAMP)|NRAMP|The Alfred|No|Recruiting|January 2005|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|16 Years|45 Years|No|Non-Probability Sample|Women from across Australia who are taking, or have taken, antipsychotic medication during        pregnancy|January 2016|January 21, 2016|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00686946||155310|
NCT00687336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR2007/058|Helicobacter Pylori Empiric Treatment in Ulcer Bleeding|Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding|HETUB|Hospital de Sabadell|No|Recruiting|March 2008|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|178|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687336||155280|
NCT00693498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24518|Washed Versus Standard Blood Cell Transfusions in Pediatric Open Heart Surgery|Standard vs. Washed Blood Cell Transfusions in Pediatric Cardiac Surgery: Impact on Post-operative Inflammation as Evidenced by the IL-6 to IL-10 Ratio.||University of Rochester|No|Completed|July 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|N/A|17 Years|No|||November 2012|November 28, 2012|June 5, 2008||No||No|November 30, 2011|https://clinicaltrials.gov/show/NCT00693498||154810|
NCT00693511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01DK078858|Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth|Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|October 2007|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|45|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693511||154809|
NCT00697684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-384|Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant|A Reduced Intensity Conditioning With Clofarabine Antithymocyte Globulin and Total Lymphoid Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Active, not recruiting|June 2008|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697684||154493|
NCT00697697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0010-CL-P301X|A Study of 2 Doses of MAP0010 in Asthmatic Children|A Randomized, Double-blind, Active-controlled, Phase 3 Extension Study Investigating the Safety and Efficacy Over 40 Weeks of 2 Doses of MAP0010 in Asthmatic Children (12 Months to 8 Years Old at the Time of Enrollment Into the MAP0010-CL-P301 Study)||Allergan|No|Terminated|April 2008|December 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|192|||Both|12 Months|8 Years|No|||December 2013|December 9, 2013|June 12, 2008|Yes|Yes|Corporate decision|No|August 19, 2013|https://clinicaltrials.gov/show/NCT00697697||154492|The study was terminated due to a corporate decision before all subjects had completed the study.
NCT00693758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18798|Assessment of Oxygen Changes in the Heart With Cardio-vascular Magnetic Resonance Imaging|Magnetic Resonance Imaging for the Detection of Oxygen Changes in the Heart||University of Calgary|Yes|Completed|January 2006|September 2011|Actual|September 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|7||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 2, 2011|December 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00693758||154790|
NCT00693524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-01-IT-01|Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX|An Open, Randomized, Multicentre Clinical Study to Compare the Safety and Efficacy of a Combination of Sequential Therapy of Tacrolimus (FK506) With Monoclonal Anti-IL2R Antibodies and Mycophenolate Mofetil Versus Tacrolimus (FK506) With Steroids in Liver Allograft Transplantation|TAST|Astellas Pharma Inc|No|Completed|November 2002|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693524||154808|
NCT00687167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-1377|Fed Bioavailability Study of Zonisamide Capsules|A Relative Bioavailability Study of 100 mg Zonisamide Capsules Under Non-Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|January 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|May 24, 2008|No|Yes||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00687167||155293|
NCT00687180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMF vs Imurel|Mycophenolate vs Azathioprin in Autoimmune Hepatitis|||Rigshospitalet, Denmark||Completed||||||Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||May 2008|May 29, 2008|May 28, 2008||||No||https://clinicaltrials.gov/show/NCT00687180||155292|
NCT00694018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-177|Veterans Walk to Beat Back Pain|Veterans Walk to Beat Back Pain||VA Office of Research and Development|No|Completed|May 2009|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|229|||Both|18 Years|N/A|No|||September 2014|April 6, 2015|May 28, 2008||No||No|October 6, 2014|https://clinicaltrials.gov/show/NCT00694018||154771|
NCT00694031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESHOL|Survival Study in Patients Undergoing On-line Hemodiafiltration|A Randomized Study to Evaluate Survival in Patients Undergoing Hemodialysis or On-line Hemodiafiltration|ESHOL|Hospital Clinic of Barcelona|Yes|Completed|May 2007|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|906|||Both|18 Years|N/A|No|||June 2012|February 27, 2014|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694031||154770|
NCT00684359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRACTICE I|Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I|Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I|PRACTICE I|Medstar Research Institute|Yes|Completed|June 2007|February 2010|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, male or female, > 18 years of age; who are scheduled for an elective PCI with a        drug eluting stent; willing to return for all required follow up visit and live/work        within a 60 mile radius of the Washington Hospital Center.|May 2010|May 28, 2010|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684359||155508|
NCT00685269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-028|Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)|The Safety and Efficacy of Eszopiclone in Subjects With Mild to Moderate Obstructive Sleep Apnea Syndrome||Sunovion|No|Completed|August 2003|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|35 Years|64 Years|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685269||155438|
NCT00686140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03T-459; SCH-A01|A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia|Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in First-Episode and Drug-naive Patients With Schizophrenia||Beijing HuiLongGuan Hospital|Yes|Completed|June 2006|March 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 10, 2013|June 10, 2006||No||No||https://clinicaltrials.gov/show/NCT00686140||155371|
NCT00687869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GX0711|Participative Rehabilitation in Stroke Patients|Participative Rehabilitation Process Management "Stroke in Saxony-Anhalt"|PaReSiS|Martin-Luther-Universität Halle-Wittenberg|No|Completed|June 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|322|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687869||155241|
NCT00688376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-G000-333|Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment|Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment||Eisai Inc.|No|Completed|August 2008|September 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|6 Years|17 Years|No|||September 2009|September 22, 2009|May 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688376||155202|
NCT00688688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-049|Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder|TAURUS|Astellas Pharma Inc|Yes|Completed|April 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2792|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 29, 2008|Yes|Yes||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00688688||155178|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00688701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6018|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents|GETGOAL-MONO|Sanofi|Yes|Completed|May 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|361|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688701||155177|
NCT00696280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0981 / 201104043|Observational Study of Delayed Nausea and Vomiting|Observational Study of Delayed Nausea and Vomiting Following Administration of Carboplatin Containing Regimens for Treatment of Cancer|DelayedNaus|Washington University School of Medicine|No|Completed|November 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have received one treatment of carboplatin|June 2013|June 11, 2013|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696280||154600|
NCT00684749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801E25711|A Pilot Study to Evaluate the BodyLogic TM System (Mentor) in Augmentation Mammaplasty|Pilot Study to Investigate The BodyLogic TM System (Mentor) in Breast Augmentation.||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2008|December 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|142|||Female|22 Years|N/A|No|Probability Sample|Female patients having cosmetic breast augmentation.|February 2015|February 19, 2015|May 22, 2008||No||No|February 20, 2013|https://clinicaltrials.gov/show/NCT00684749||155478|snap shot view, responder bias
NCT00685633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000596077|Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer|Phase II, Randomized Study of Patients With Rising PSA at High-Risk of Progression After Primary Therapy to Assess the Clinical and Molecular Efficacy of the Enzastaurin - Bicalutamide Combination to Suppress the Androgen Receptor Without Testosterone Ablation||Eastern Cooperative Oncology Group||Withdrawn|December 2008|||June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||November 2008|August 16, 2013|May 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685633||155410|
NCT00685945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAAS & Fibrinolysis|Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3|Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3||Vanderbilt University|Yes|Completed|December 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 21, 2013|May 27, 2008|No|Yes||No|August 25, 2011|https://clinicaltrials.gov/show/NCT00685945||155386|
NCT00685958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY6771|Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery|Multicenter, Non-comparative, Open-label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery||Sanofi||Completed|July 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|20 Years|N/A|No|||October 2009|October 1, 2009|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00685958||155385|
NCT00686283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNR009267B|Personalized Exercise for Adolescents With Diabetes|Personalized Exercise for Adolescents With Diabetes||University of Arizona|No|Completed|August 2007|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|12 Years|19 Years|No|||May 2014|May 19, 2014|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00686283||155361|
NCT00686296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-2007-0709-H|Pilot Study Comparing Taliderm™ Dressing Versus Standard of Care for Open Incision and Drainage of Wounds|Pilot Study Comparing Taliderm™ Dressing Versus Standard of Care for Open Incision and Drainage of Wounds||The University of Texas Health Science Center at San Antonio|Yes|Completed|December 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|May 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686296||155360|
NCT00686608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB #938|Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients|Hypothalamic fMRI Response to Nutrients||Oregon Health and Science University|No|Recruiting|October 2006|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 4, 2012|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00686608||155336|
NCT00686959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11514|Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer|Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology|PROCLAIM|Eli Lilly and Company|Yes|Completed|September 2008|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|598|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|May 28, 2008|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00686959||155309|
NCT00686972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00004876|The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition|The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition||Johns Hopkins University|No|Active, not recruiting|May 2007|May 2012|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|21 Years|65 Years|No|||March 2010|March 25, 2010|May 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00686972||155308|
NCT00697411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM Aicardi H12791|Study of Selected X-Linked Disorders: Aicardi Syndrome|Pathogenesis of Selected X-Linked Dominant Disorders and New Strategies to Identify the Gene Mutated in Aicardi Syndrome||Baylor College of Medicine|No|Recruiting|October 2002|January 2017|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|lymphoblast DNA; tissue|Both|N/A|N/A|No|Non-Probability Sample|Girls with Aicardi syndrome and their unaffected parents. Sometimes additional family        members are also enrolled.|October 2014|October 31, 2014|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697411||154514|
NCT00697671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKHEM|Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies|Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies||St. Jude Children's Research Hospital|No|Completed|March 2007|May 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|N/A|18 Years|No|||July 2013|July 15, 2013|April 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697671||154494|
NCT00685308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1122837|Wingspan Stenting for Symptomatic Severe Stenosis of Intracranial Atherosclerosis Registry in China|Wingspan Stenting for Symptomatic Severe Stenosis of Intracranial Atherosclerosis Registry in China|WingspanSSIR|Ministry of Health, China|Yes|Recruiting|December 2007|October 2010|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|75 Years|No|Non-Probability Sample|Chinese population with symptomatic severe stenosis of intracranial atherosclerosis|May 2008|May 27, 2008|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685308||155435|
NCT00685815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0117|Intravenous Iron Metabolism in Restless Legs Syndrome|Intravenous Iron Metabolism in Restless Legs Syndrome||Luitpold Pharmaceuticals|Yes|Completed|November 2006|December 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685815||155396|
NCT00687856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|585|Identifying and Facilitating Ventricular Recovery on Mechanical Support|Identifying and Facilitating Ventricular Recovery on Mechanical Support|RECOVER|University of Pittsburgh|Yes|Completed|April 2008|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|211|||Both|18 Years|N/A|No|Non-Probability Sample|This study will include participants who have undergone or are about to undergo LVAD        implantation at one of the three participating clinical centers.|January 2016|January 13, 2016|May 29, 2008||No||No|January 13, 2016|https://clinicaltrials.gov/show/NCT00687856||155242|
NCT00688103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etanercept-01|Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan|Efficacy and Safety of Etanercept in Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan|JESMR|Japan Biological Agent Study Integrated Consortium|Yes|Completed|June 2005|October 2010|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|May 25, 2008||No||No|March 29, 2012|https://clinicaltrials.gov/show/NCT00688103||155223|
NCT00684996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01099|Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850)||National Cancer Institute (NCI)||Terminated|June 2008|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|N/A|N/A|No|||April 2013|April 28, 2014|May 24, 2008|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00684996||155459|
NCT00685555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMF-1300-05|Healthy Futures Project: A Community Based Obesity Prevention Program|SWITCH: Rationale, Design, and Implementation of a Community, School, and Family-based Intervention to Modify Behaviors Related to Childhood Obesity|SWITCH|National Institute on Media and the Family|No|Completed|October 2005|December 2006|Actual|December 2006|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1300|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||May 2008|June 22, 2011|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685555||155416|
NCT00685828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62005|Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor|Phase III Randomized, Intergroup, International Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117)||European Organisation for Research and Treatment of Cancer - EORTC||Active, not recruiting|January 2001|||February 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|946|||Both|18 Years|N/A|No|||July 2014|July 3, 2014|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685828||155395|
NCT00686803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL3994-003|Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension|A Single-Center, Single-Dose, Placebo-Controlled, Randomized, Double-Blind, Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension||Palatin Technologies|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|21|||Both|18 Years|65 Years|No|||July 2013|July 8, 2013|May 27, 2008|Yes|Yes||No|August 24, 2011|https://clinicaltrials.gov/show/NCT00686803||155321|
NCT00687193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921040|Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD||Pfizer|Yes|Completed|March 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|318|||Both|20 Years|70 Years|No|||March 2013|March 19, 2013|May 22, 2008|Yes|Yes||No|November 26, 2012|https://clinicaltrials.gov/show/NCT00687193||155291|
NCT00688389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960195_1|Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection|Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|July 2007|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The samples are obtained from the Kaohsiung Medical University Chung-Ho Memorial Hospital        in Kaohsiung, Taiwan.|January 2014|February 9, 2014|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688389||155201|
NCT00684385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0052|An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck|An International Expanded Access Clinical Programme With ZD1839 (IRESSA) for Patients With Advanced Non-small Cell Lung Cancer(NSCLC) and Patients With Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck (H&NC)||AstraZeneca||Active, not recruiting|August 2001|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|130 Years|No|||February 2016|February 1, 2016|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684385||155506|
NCT00685282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR469308CTIL|The Effect of Stress on DNA Integrity and the Effect of Cognitive Behavioral Therapy on Stress and Infertility in Women|The Effect of Stress on DNA Integrity and the Effect of Cognitive Behavioral Therapy on Stress and Infertility in Women Undergoing IVF Treatment.||Soroka University Medical Center|Yes|Completed|November 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|70|||Female|18 Years|35 Years|No|||February 2013|February 11, 2013|May 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00685282||155437|
NCT00685295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAIRTOP|Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain|Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain in the ED|FAIRTOP|Massachusetts General Hospital|Yes|Recruiting|November 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||February 2009|February 9, 2009|May 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00685295||155436|
NCT00685971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH 07-036|Cholecalciferol for Vitamin D in Adult Cystic Fibrosis (CF) Patients|Randomized Placebo-Controlled Trial of Cholecalciferol for Vitamin D Deficiency in Adults With Cystic Fibrosis||St. Michael's Hospital, Toronto|No|Completed|December 2008|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2011|November 20, 2014|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00685971||155384|
NCT00685984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070403|Peripheral Endothelial Function and Coronary Status in Asymptomatic Diabetic Patients|Peripheral Endothelial Function and Coronary Status in Asymptomatic Type 2 Diabetic Patients: Relations With Coronary Microcirculation Assessed With Trans-thoracic Echo-doppler|PEFDIA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2008|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|173|Samples Without DNA|whole blood, serum|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  type 2 diabetes          -  overweight free of diabetes          -  control|May 2011|October 27, 2011|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00685984||155383|
NCT00686309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP8-295-R|Comparison of On-line and Off-line Measurements of Exhaled Nitric Oxide (NO)|Comparison of On-line and Off-line Measurements of Exhaled NO||Ziv Hospital|No|Not yet recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General population bth healthy and with respiratory illness such as asthma, COPD, PCD,        Rhinitis|August 2009|August 15, 2009|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00686309||155359|
NCT00686322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-02-12|Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)|Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer||Taipei Veterans General Hospital, Taiwan|Yes|Completed|April 2008|October 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2010|September 13, 2011|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686322||155358|
NCT00686335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP01-201|A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma|A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma|MONA|Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|June 2008|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|May 26, 2008||No||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00686335||155357|This was an explorative study to collect data for a subsequent controlled trial and therefore no hypothesis testing was performed. The size of the efficacy population (N=7) is too small to detect any statistically significant changes.
NCT00686621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05113|Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)|Single Patient Emergency Treatment Use of Posaconazole in Invasive Fungal Infections||Merck Sharp & Dohme Corp.|No|Completed|January 2007|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|2 Years|N/A|No|||September 2015|September 7, 2015|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686621||155335|
NCT00686634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-06-002|Sitagliptin in Combination With Metformin and Sulfonylurea|Sitagliptin in Combination Oral Agent Therapy for Type 2 Diabetes||Charles Drew University of Medicine and Science|Yes|Completed|January 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|75 Years|No|||November 2014|November 25, 2014|May 27, 2008|Yes|Yes||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00686634||155334|
NCT00686985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCAR study|Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer|A Phase II Study of Docetaxel - Carboplatin as Second Line Treatment in Patients With Refractory or Relapsed Small Cell Lung Cancer|DOCAR|Jeroen Bosch Ziekenhuis|No|Recruiting|September 2007|July 2010|Anticipated|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2008|May 29, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686985||155307|
NCT00684398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908144|Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I|Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I||National Institutes of Health Clinical Center (CC)||Completed|May 2008|November 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|645|||Both|18 Years|N/A|No|||November 2015|November 28, 2015|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684398||155505|
NCT00685542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-081-043-232|Effect of Diacerein on Hand Osteoarthritis|Phase IV Study of Diacerein in Human Hand Osteoarthritis||Seoul National University Hospital|Yes|Completed|June 2008|December 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|40 Years|N/A|No|||December 2010|December 2, 2010|May 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00685542||155417|
NCT00686764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSUIRB#3862|Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above-Knee Amputees|Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above Knee Amputees||Oregon Health and Science University|No|Completed|May 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|7|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will consist of 25 trans-femoral amputees meeting the inclusion and exclusion        criteria. We will recruit participants from the OHSU clinics, Primary Care Clinics, and        specialty clinics including orthopaedic surgery, general surgery, pain centers, neurology,        and orthotics and prosthesis clinics and offices. We anticipate that the majority of        subjects will be recruited from the Department of Orthopaedics and Rehabilitation's        clinical practice. Potential subjects will be identified from the investigators' clinic        and medical records. Recruiting outside of the Department of Orthopaedics and        Rehabilitation will be done using recruiting posters and letters addressed to the primary        care physicians, specialists and at prosthetic clinics. Recruitment notices will be posted        on the OHSU and Department of Orthopaedics and Rehabilitation's Web sites and the OHSU        Study Participation Web site. We intend to enroll 30 subjects.|December 2015|December 10, 2015|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686764||155324|
NCT00686777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05172|Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)|Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight||Merck Sharp & Dohme Corp.|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|20 Years|N/A|No|||September 2015|September 24, 2015|May 27, 2008|Yes|Yes||No|December 12, 2011|https://clinicaltrials.gov/show/NCT00686777||155323|
NCT00687544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04469|Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)|Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon||Merck Sharp & Dohme Corp.|No|Terminated|December 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||September 2015|September 11, 2015|May 27, 2008|No|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00687544||155264|The study was terminated early due to low enrollment. The primary and secondary outcomes were not evaluated. A formal safety analysis was not performed for the 11 participants enrolled in the study.
NCT00688363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS 2003-Nauck-01|Blood Glucose Self Monitoring and HbA1c Effects on Glucose Control|The Benefit of the Blood Glucose Self Monitoring and a Regular Three-monthly Hemoglobin A1c Profile in Patients With Type 2-diabetes and Conventional Insulin Therapy||Deutsche Diabetes Gesellschaft|No|Completed|February 2003|December 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|300|||Both|40 Years|80 Years|No|||July 2011|July 29, 2011|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00688363||155203|
NCT00688662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK074739|Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction|A Phase III Randomized Multicenter Clinical Trial of Sphincterotomy for the Treatment of SOD III Patients|EPISOD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|July 2008|August 2016|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|214|||Both|18 Years|65 Years|No|||November 2014|November 6, 2014|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688662||155180|
NCT00688675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GCH-NEX-2007/1|Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments|GERD Segmentation: Document How Swiss GPs Allocate Their GERD Patients to the Three GERD Patient Segments||AstraZeneca|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|2912|||Both|12 Years|N/A|No|Non-Probability Sample|Previously diagnosed GERD patients on treatment for at least 2 weeks; in Switzerland|December 2010|December 6, 2010|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688675||155179|
NCT00696605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swiss AVP-Copeptin Trial|Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion|Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion||Hospital Centre Biel/Bienne|No|Recruiting|July 2008|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers; patients with chronic renal failure|June 2011|June 22, 2011|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00696605||154575|
NCT00696618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010972|Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men|A Randomized, Blinded, Comparative Study of the Mucosal Toxicity, Colorectal Distribution, and Participant Acceptability of Three Different Preparatory Enemas (Hypo-, Iso-, and Hyper-osmolar)||Johns Hopkins University|Yes|Completed|July 2007|March 2012|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|9|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|March 30, 2015|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00696618||154574|
NCT00686478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN - 1598|Intron A for the Treatment of Hypertrophic Scar|A Double-blind Placebo Controlled Trial Using Subcutaneous Injections of Intron A for the Treatment of Hypertrophic Scar||University of Alberta|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||January 2014|January 28, 2014|May 26, 2008||No|The trial is not being done at this time|No||https://clinicaltrials.gov/show/NCT00686478||155346|
NCT00686790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04603|Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)|An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron in naïve Patients With Chronic Hepatitis B and D Co-infection||Merck Sharp & Dohme Corp.|No|Completed|December 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|May 27, 2008|No|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT00686790||155322|
NCT00687583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010579|Head Movement Effect on Different Tracheal Tubes|Effect of Head Movement on the Position of Different Tracheal Tubes Determined Radiologically||The Hospital for Sick Children|No|Recruiting|April 2007|January 2009|Anticipated|December 2008|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|6 Years|No|Probability Sample|Fifty children undergoing any procedure in the Image Guided Therapy (IGT) department        requiring tracheal intubation and chest X-ray, will be recruited and will be evenly        distributed in three different age groups (0 to 6 months, 6 to 24 months, 24 months to 6        years).|May 2008|May 28, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687583||155262|
NCT00697463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6871|Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women|Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women|IOPForteo|Columbia University|No|Active, not recruiting|August 2008|September 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697463||154510|
NCT00684099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/05.18|Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Study Of The Docetaxel/Pemetrexed Combination As First Line Treatment In Patients With Advanced/Metastatic NSCLC||Hellenic Oncology Research Group|No|Completed|May 2006|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|80 Years|No|||December 2009|December 14, 2009|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684099||155528|
NCT00684372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK study|BK Viremia After Renal Transplantation|BK Viremia After Renal Transplantation: Screening, Early Diagnosis, Early Reduction in Immunosuppression and Treatment With Leflunomide (Arava)||Karolinska University Hospital|Yes|Active, not recruiting|May 2007|May 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2009|February 5, 2009|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00684372||155507|
NCT00685009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|548|The Women's Health Initiative Memory Study (The WHIMS Study)|Women's Health Initiative Memory Study||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|January 1996|March 2008|Actual|September 1997|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|7525|||Female|65 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will include participants from the hormone therapy trial of the WHI study.|October 2015|October 16, 2015|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685009||155458|
NCT00685022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-309|Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma|A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Subjects Twelve Years of Age and Older With Asthma||Sunovion|No|Completed|June 2003|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|12 Years|N/A|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685022||155457|
NCT00686491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 20141|Respiratory Health of Elite Athletes|Center of Excellence in CardioRespiratory Health of High-level Athletes: Evaluation of Long-term Effects of Training.|cold air|Laval University|No|Completed|June 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|133|Samples With DNA|Serum - plasma - sputum|Both|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Athletes training in the province of Quebec. Controls from Quebec schools and        universities.|February 2011|February 21, 2011|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00686491||155345|
NCT00685685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVI-P4-125|Fasting Bioavailability Study of Lovastatin Tablets and Mevacor Tablets|A Single Dose Crossover Comparative Bioavailability Study of Lovastatin 40mg Tablets in Healthy Male Volunteers/Fasting State||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|54|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|May 24, 2008|No|Yes||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00685685||155406|
NCT00685698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-04|Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections|An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens||TaiGen Biotechnology Co., Ltd.|No|Completed|June 2008|June 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 25, 2014|May 22, 2008|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00685698||155405|
NCT00685997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82310-98-08012|Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas|Whole-body MR Imaging for Staging Malignant Lymphomas||UMC Utrecht|No|Completed|June 2008|June 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|135|||Both|8 Years|N/A|No|Non-Probability Sample|Patients, aged 8 years and older, with newly diagnosed Hodgkin's disease or non-Hodgkin's        lymphoma, who will undergo computed tomography (CT) for staging|July 2013|July 2, 2013|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00685997||155382|
NCT00686010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAY2-1|Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia|A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia||Japan Tobacco Inc.|No|Completed|May 2000|June 2001|Actual|January 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|198|||Both|22 Years|65 Years|No|||May 2008|May 28, 2008|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00686010||155381|
NCT00686348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-TL-52030-225 (MS319)|Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study|Somatuline® Depot (Lanreotide) Injection for Acromegaly (SODA): A Post-marketing Observational Study|SODA|Ipsen|No|Active, not recruiting|May 2008|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|260|Samples Without DNA|Routine clinical laboratory assessments will be performed: GH and IGF-1|Both|N/A|N/A|No|Non-Probability Sample|Patients with a clinical diagnosis of acromegaly|November 2015|November 30, 2015|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686348||155356|
NCT00686647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-ST1210|AngioSculpt® Coronary Bifurcation Study|AngioSculpt® Scoring Balloon Catheter Multi-Center Coronary Bifurcation Study|AGILITY|AngioScore, Inc.|No|Completed|April 2008|January 2011|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|May 28, 2008|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00686647||155333|
NCT00684762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11788|Fasted Bioavailability Study of Cilostazol Tablets, 100 mg|A Comparative Bioavailability Study of Cilostazol Tablets, 100mg Under Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|March 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|May 24, 2008|No|Yes||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00684762||155477|
NCT00686465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2007-PETREC|Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study|Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study. PET in Recurrent Cancer(PETREC)|PETREC|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|March 2009|July 2012|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00686465||155347|
NCT00687570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/332-31|Bowel Preparation Before Rectal Cancer Surgery|Bowel Preparation With Nutritional Drinks Instead of Traditional Bowel Preparation Before Rectal Cancer Surgery||Karolinska Institutet|No|Completed|July 2008|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|90 Years|No|||February 2015|February 19, 2015|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687570||155263|
NCT00695734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJanssens 4|Detection of Latent Tuberculosis in Hemodialysis Patients|Interferon-Gamma Release Assays (IGRA) Versus Tuberculin Skin Testing for Detection of Latent Tuberculosis Infection (TB) in Chronic Hemodialysis Patients||University Hospital, Geneva|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|Adults aged over 18 Under hemodialysis for > 3 months End stage renal failure|June 2008|June 10, 2008|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695734||154640|
NCT00696046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB01-139|Intra Bone Marrow Injection Of Unrelated Cord Blood Cells|Direct Intra Bone Marrow Injection Of Unrelated Cord Blood Cells To Improve Engraftment And Reduce Acute Graft-Versus-Host Disease|CB01|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Recruiting|March 2006|June 2009|Anticipated|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|16 Years|70 Years|No|||June 2008|June 9, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696046||154617|
NCT00684723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVI-P4-126|Fed Bioavailability Study of Lovastatin Tablets and Mevacor Tablets|A Single Dose Crossover Comparative Bioavailability Study of Lovastatin 40mg Tablets in Healthy Male Volunteers/Fed State||Mutual Pharmaceutical Company, Inc.|No|Completed|July 2004|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|54|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|May 24, 2008|No|Yes||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00684723||155480|
NCT00684736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSK Sepsis|Tryptophan, Serotonin and Kynurenine in Septic Shock|Tryptophan, Serotonin and Kynurenine in Septic Shock|TSK|Central Hospital, Versailles|No|Completed|June 2004|April 2008|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Patients who were 18 years of age or older and had been hospitalized in our ICU were        prospectively enrolled in the study if they met all eligibility criteria. Inclusion        criteria were clinical evidence of infection, evidence of a systemic response to        infection, and the onset of shock within the previous 3 hours.|May 2008|August 7, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684736||155479|
NCT00684983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00665|Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer|Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane||National Cancer Institute (NCI)|Yes|Active, not recruiting|July 2008|||January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||December 2015|January 29, 2016|May 22, 2008|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00684983||155460|
NCT00696631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4966|European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure|Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease|ANDROMEDA|Sanofi|Yes|Terminated|June 2002|August 2003|Actual|January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|653|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|June 12, 2008|No|Yes|Terminated as the active treatment was associated with an increased hazard|No||https://clinicaltrials.gov/show/NCT00696631||154573|
NCT00696865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0970C00006|AZD2624 Multiple Ascending Dose Study in Japan|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2624 When Given in Multiple Ascending Oral Doses in Young Healthy Male Japanese Subjects|JMAD|AstraZeneca||Completed|May 2008|August 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 15, 2009|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696865||154556|
NCT00696878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05714|Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)|A Phase III, Uncontrolled Trial to Assess the Non-immunogenicity and Safety of Org 36286 in Patients Undergoing Repeated Controlled Ovarian Stimulation Cycles Using a Multiple Dose GnRH Antagonist Protocol|Trust|Merck Sharp & Dohme Corp.|No|Completed|September 2006|May 2009|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|682|||Female|18 Years|39 Years|No|||May 2015|May 20, 2015|June 11, 2008|No|Yes||No|April 6, 2015|https://clinicaltrials.gov/show/NCT00696878||154555|
NCT00697203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC18589|A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)|A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels||Hoffmann-La Roche||Completed|July 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|292|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697203||154530|
NCT00697476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2007-002|Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC|Phase I-II Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With Topotecan in Patients With Chemosensitive Recurrent Small Cell Lung Cancer (SCLC)||Istituto Clinico Humanitas|No|Terminated|January 2009|January 2010|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2013|May 27, 2013|June 11, 2008||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00697476||154509|
NCT00693316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098001|Safety and Tolerability Study With Single Ascending Doses of ORM-12741|Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Single Ascending Doses of ORM-12741||Orion Corporation, Orion Pharma|Yes|Completed|July 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 10, 2010|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00693316||154822|
NCT00693576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2519|The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates|The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates||Shiraz University of Medical Sciences|Yes|Completed|April 2007|May 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|75 Years|No|||June 2008|June 5, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693576||154804|
NCT00693823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-179, Viabahn #1|Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusive Disease|A Prospective Randomized Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Superficial Femoral Artery Occlusion||Texas Vascular Associates|Yes|Completed|September 2003|January 2008|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||June 2008|June 6, 2008|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693823||154786|
NCT00685711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP001|Safety of Cat-PAD in Cat Allergic Subjects|An Escalating Single Intradermal or Subcutaneous Dose Study in Cat Allergic Subjects to Assess the Safety of Cat-PAD.||Circassia Limited|Yes|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|88|||Both|18 Years|65 Years|No|||August 2008|August 5, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00685711||155404|
NCT00685724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-259|A Pilot SMART Design for Pathological Gamblers|A Pilot SMART Design for Pathological Gamblers|SMART|University of Connecticut Health Center|No|Completed|January 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685724||155403|
NCT00686660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD rehabilitation CYH 2007|A Multi-Center Study of Rehabilitation to Stable Chronic Obstructive Pulmonary Disease (COPD) Patients|||Beijing Chao Yang Hospital|Yes|Recruiting|September 2007|September 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|40 Years|75 Years|No|||May 2008|June 13, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686660||155332|
NCT00687050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goethe-Uni-FFM-328-07|Peroral Supplemental Nutrition in End-stage Renal Disease With and Without HIV Comorbidity|MRT-based Pilot Study to Evaluate Peroral Supplemental Nutrition for Prevention of Cachexia in End-stage Renal Disease With and Without HIV Comorbidity||Johann Wolfgang Goethe University Hospitals|No|Completed|May 2008|May 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|75 Years|No|||May 2010|May 25, 2010|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687050||155302|
NCT00684112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010379|Analgesic Effects of Gabapentin After Scoliosis Surgery in Children|Analgesic Effects of Gabapentin After Scoliosis Surgery in Children||The Hospital for Sick Children|No|Completed|May 2008|February 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|10 Years|17 Years|No|||August 2013|August 15, 2013|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684112||155527|
NCT00685256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592726|Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children|Parent Communication Study II - Randomized Controlled Trial of Decision Support vs. Education for Parent Communication of BRCA 1/2 Cancer Genetic Test Results to Children||Georgetown University|No|Recruiting|March 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|400|||Female|8 Years|N/A|No|||August 2015|August 24, 2015|May 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00685256||155439|
NCT00686114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shixiu - 1|Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer|Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial.||Wenzhou Medical University|Yes|Recruiting|May 2008|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|344|||Both|18 Years|70 Years|No|||April 2014|April 28, 2014|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686114||155373|
NCT00695422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-058|Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials|A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials||AIDS Malignancy Consortium|No|Active, not recruiting|May 2008|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|Blood specimens, anal cytology and biopsy of any lesions observed, cervical cytology and      biopsy of any lesions observed.|Both|18 Years|N/A|No|Non-Probability Sample|This study will enroll patients who are study participants on interventional AMC protocols        for diseases other than HPV-associated neoplasia with an accrual goal of 15 patients or        more.|November 2015|November 17, 2015|June 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00695422||154663|
NCT00695747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-067|Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy|Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy||Lahey Clinic|No|Completed|January 1998|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|N/A|N/A|No|||January 2009|January 21, 2009|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695747||154639|
NCT00695786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0042|Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma|A Phase II Study of Revlimid in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Hodgkin's Lymphoma (NHL)||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2008|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|155|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695786||154637|
NCT00696059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 04-20|Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?|Can Bone Erosions Heal in Adalimumab (Humira) Treated Rheumatoid Arthritis Patients. An Imaging Study Using Computed Tomography and Magnetic Resonance Imaging.|HURRAH|Hvidovre University Hospital|No|Completed|August 2004|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|90 Years|No|||June 2008|June 11, 2008|June 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696059||154616|
NCT00696072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-185|Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic|Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic||Bristol-Myers Squibb|Yes|Completed|August 2008|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Female|18 Years|N/A|No|||May 2015|May 6, 2015|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696072||154615|
NCT00696319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2008-NAR|Dynamic Stability of the Anterior Cruciate Ligament (ACL) Deficient Knee|Dynamic Stability of the ACL Deficient Knee - a Prospective Cohort Study||Oslo University Hospital|No|Suspended|January 2007|June 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|13 Years|55 Years|No|||June 2011|June 30, 2011|June 9, 2008||No|Study was suspended due to lack of resources.|No||https://clinicaltrials.gov/show/NCT00696319||154597|
NCT00696332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-TAL-201 (ALSTAR)|Talampanel for Amyotrophic Lateral Sclerosis (ALS)|A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of Talampanel in Subjects With Amyotrophic Lateral Sclerosis (ALS)|ALS|Teva Pharmaceutical Industries|Yes|Completed|September 2008|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|559|||Both|18 Years|80 Years|No|||October 2011|October 20, 2011|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696332||154596|
NCT00696904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-351|Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects|||Abbott||Completed|June 2008|||February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|133|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|October 19, 2010|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696904||154553|
NCT00696917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/031|Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y|Safety and Immunogenicity of 3 Lots of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine, Administered According to a 2 Dose Schedule, and Engerix™-B Administered According to a 3 Dose Schedule to Healthy Volunteers ≥ 15 Years of Age||GlaxoSmithKline||Completed|April 1999|||February 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|1303|||Both|15 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696917||154552|
NCT00696891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/022|Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults|Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine With That of Engerix™-B When Both Are Injected According to 3 Dose Schedule (0, 1, 6 Months) in an Adult Population Aged Between 50 and 70 Years||GlaxoSmithKline||Completed|June 1997|||May 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|380|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696891||154554|
NCT00697216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/027|Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).|Study Comparing the Immunogenicity and Reactogenicity of GSK Biologicals' HBV-MPL Vaccine Injected According to a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in a Healthy Adult Population (15-40 Years)||GlaxoSmithKline||Completed|March 1997|||March 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|340|||Both|15 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697216||154529|
NCT00693602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERWASE|Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma|Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma||St. Jude Children's Research Hospital|No|Completed|June 2006|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|87|||Both|N/A|N/A|No|||December 2011|January 3, 2012|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693602||154802|
NCT00693615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/004|Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females|Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, When Formulated With Aluminum Hydroxide, AS04, or Without Adjuvant, in Healthy Adult Female Volunteers||GlaxoSmithKline||Completed|October 2000|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||June 2008|June 5, 2008|June 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693615||154801|
NCT00693329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0406|Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy|Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy|ENCINO|Biosite|Yes|Completed|March 2008|December 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|260|Samples Without DNA|Blood sample taken at 8 timepoints over 2 days.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing intra-arterial angiography involving administration of iodinated        contrast agent(s).|December 2009|December 17, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693329||154821|
NCT00693589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-Nr. 115/03|Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-Dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease|Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-Dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease||University Hospital Inselspital, Berne|No|Completed|January 2005|April 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||June 2008|June 6, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693589||154803|
NCT00693836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-WPH-USMS-ReSoLuCENT|Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) Region|Resource for the Study of Lung Cancer Epidemiology in North Trent||National Cancer Institute (NCI)||Recruiting|January 2006|||October 2010|Anticipated|N/A|Observational|N/A|||Anticipated|2000|||Both|18 Years|N/A|No|||December 2008|August 9, 2013|June 6, 2008||||No||https://clinicaltrials.gov/show/NCT00693836||154785|
NCT00686361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-70444|Choline Nutrition in Children With Cystic Fibrosis (CF)|To Investigate Whether Choline Supplementation in Children With CF Will Correct Biochemical Markers of Choline Deficiency and Improve Plasma Indices of Methylation Capacity and Redox Status and Result in Decreased Pro-inflammatory Cytokines||University of British Columbia|No|Completed|October 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|34|||Both|5 Years|17 Years|No|||June 2011|June 6, 2011|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00686361||155355|
NCT00686673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nccncs-08-142|Effect of a Decision Aid on Decision Making for Family Member's Disclosure of Terminal Illness|Effect of a Decision Aid on Decision Making for Family Member's Disclosure of Terminal Illness to Patient With Terminal Cancer||National Cancer Center, Korea|Yes|Completed|June 2008|March 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|440|||Both|18 Years|N/A|No|||March 2009|February 14, 2011|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686673||155331|
NCT00686686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04555|Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)|A Multi Center, Open Label, Single-Arm Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP), Including the Pustular Form (PsPPP)|TIPS|Merck Sharp & Dohme Corp.|No|Completed|December 2007|April 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|70 Years|No|||September 2015|September 2, 2015|May 27, 2008|No|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00686686||155330|
NCT00687063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3530|Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes|An Observational, Safety and Efficacy Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus.|DIABESITY|Novo Nordisk A/S|No|Completed|April 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10008|||Both|6 Years|N/A|No|Non-Probability Sample|Type 2 diabetics|November 2012|August 13, 2014|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687063||155301|
NCT00687076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1400|Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)|Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ("The ELIMIT Trial")||Baylor College of Medicine|Yes|Completed|April 2004|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|102|||Both|40 Years|80 Years|No|||August 2014|August 7, 2014|May 28, 2008|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT00687076||155300|MRI was performed in the distal SFA. Ethnicity which was not part of the randomization protocol differed significantly between mono- and triple-therapy groups. The attrition rate was high in ELIMIT. ELIMIT was not powered to assess clinical outcomes.
NCT00697723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMGIABPrecruit|Arterial Versus Venous Graft Recruitment by Intra-Aortic Balloon Pump|||University Magna Graecia||Completed|January 2005|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|138|||Both|N/A|N/A|No|||June 2008|June 13, 2008|June 11, 2008||||No||https://clinicaltrials.gov/show/NCT00697723||154490|
NCT00693537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UISM-2-2008|Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease|Long- But Not Short-Term Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease||Paracelsus Medical University||Completed||||||Phase 4|Interventional|Allocation: Randomized|2||||||Both|50 Years|80 Years|No|||June 2008|June 6, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00693537||154807|
NCT00686127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast Pain|Symptom Management After Breast Cancer Surgery|A Randomized, Double-Blind, Placebo-Controlled Trial (RDBPCT) of the Effectiveness of the Lidocaine Patch in the Management of Neuropathic Pain After Breast Cancer Surgery||University of California, San Francisco|Yes|Completed|September 2003|December 2013|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|21|||Female|18 Years|N/A|No|||April 2014|April 2, 2014|May 27, 2008|No|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00686127||155372|
NCT00695435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-33|Tobramycin Tear Concentrations|Evaluation of Tobramycin Tear Concentrations of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Versus TOBREX® Ophthalmic Solution in Normal Volunteers||Alcon Research|No|Completed|June 2008|||June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 23, 2010|June 9, 2008|Yes|Yes||No|April 27, 2009|https://clinicaltrials.gov/show/NCT00695435||154662|
NCT00695448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIK111051|Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma|A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma||GlaxoSmithKline|No|Terminated|June 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2011|March 15, 2012|June 9, 2008|No|Yes|This study was terminated prematurely due to lack of sufficient exposure following single- and    repeat-dosing.|No||https://clinicaltrials.gov/show/NCT00695448||154661|
NCT00696085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-008236/21|Fetal Alcohol Damage Prevention Study|Prevention of Fetal Alcohol Damage Using Maternal Blood Markers||Massachusetts General Hospital|No|Completed|March 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|612|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00696085||154614|
NCT00696358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICE-VIT1|Excimer Lamp Versus Excimer Laser in Vitiligo Treatment|Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo||Centre Hospitalier Universitaire de Nice||Completed||||||Phase 3|Interventional|N/A|2||||||Both|18 Years|N/A|No|||October 2008|October 30, 2008|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00696358||154594|
NCT00696345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Septin-9-2006|Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay|Feasibility Study for Performance of Septin 9 in Plasma From Cases With Colorectal Cancer and Controls With Non-Diseased, Non-Colorectal Disease and Non-Colorectal Cancers||Epigenomics, Inc|No|Completed|January 2005|February 2007|Actual|October 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|700|Samples With DNA|Residual plasma samples retained according to protocol.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are identified at colonoscopy as having or not having colorectal cancer. Blood        from all subjects was drawn either before or more than 2 days and up to 6 months after        colonoscopy and prior to starting any cancer specific treatment. Cancer diagnosis was        confirmed histologically from the surgical specimen and only adenocarcinomas were included        in this study.|June 2008|June 13, 2008|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00696345||154595|
NCT00697242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/009|Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults|Study to Compare the Immunogenicity, Safety and Reactogenicity of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccines With and Without Adjuvant in Healthy Older Adult Volunteers||GlaxoSmithKline||Completed|January 1994|November 1995|Actual|November 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|362|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697242||154527|
NCT00697528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352/06|Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy|Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy||University of Sao Paulo|Yes|Completed|January 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|66|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Grave's disease within the orbital service of HCFMUSP at the Ophthalmology        Department|June 2008|December 18, 2013|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697528||154505|
NCT00697229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/004|Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules|Study to Evaluate the Immunogenicity and Reactogenicity of GSK Biologicals' MPL-Adjuvanted Recombinant Hepatitis B Vaccine in Comparison With Those of Engerix™-B in Healthy Adult Volunteers Following 2 Different Schedules||GlaxoSmithKline||Completed|September 1992|December 1998|Actual|May 1996|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|8||Actual|99|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697229||154528|
NCT00697489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2008|Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse|Pelvic Organ Prolapse Correction Plus Preventive Treatment of Urinary Stress Incontinence vs. Correction of Pelvic Organ Prolapse Followed by Treatment of Urinary Stress Incontinence||University Magna Graecia|Yes|Withdrawn|June 2008|||August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|80 Years|No|||April 2013|April 5, 2013|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00697489||154508|
NCT00693849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iSPOT-D|International Study to Predict Optimised Treatment - in Depression|International Study to Predict Optimised Treatment - in Depression|iSPOT-D|BRC Operations Pty. Ltd.|No|Recruiting|September 2008|February 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|2688|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00693849||154784|
NCT00693862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939115|Pharmacokinetic Study With Repeated Doses of Stalevo|Levodopa Concentration Profile After Repeated Doses of Stalevo||Orion Corporation, Orion Pharma|No|Completed|December 2006|May 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|30 Years|72 Years|No|||June 2008|June 6, 2008|June 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693862||154783|
NCT00694096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI21897|Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response|Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response||University of Utah|Yes|Completed|September 2007|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|June 6, 2008|Yes|Yes||No|October 28, 2015|https://clinicaltrials.gov/show/NCT00694096||154765|
NCT00694109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012-CS6|An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia|An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia||Sanofi|No|Completed|April 2008|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|12 Years|N/A|No|||November 2015|November 17, 2015|June 5, 2008|Yes|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT00694109||154764|
NCT00694382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6521|Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy|A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy|SAVE-ONCO|Sanofi|Yes|Completed|June 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3212|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694382||154743|
NCT00686374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-807|Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806|A Multi-center, Open-label Study of the Human Anti−TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Crohn's Disease Who Have Demonstrated a Clinical Response in the M06-806 Study||AbbVie|Yes|Active, not recruiting|May 2008|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|7 Years|18 Years|No|||January 2016|January 20, 2016|May 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00686374||155354|
NCT00686387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008WFCRC-01|Establishment of a Brain and Spinal Tumor Tissue Bank|Establishment of a Brain and Spinal Tumor Tissue Bank and Clinical Data Repository for Identifying Molecular Markers of Clinical Outcome||Taipei Medical University WanFang Hospital|No|Recruiting|May 2008|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Whole blood, Fresh tissue|Both|20 Years|N/A|No|Non-Probability Sample|Neurosurgery clinic or oncology clinic in Wan Fang Hospital|April 2011|April 11, 2011|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00686387||155353|
NCT00687479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-013|Insulin Action During Pregnancy in Woman at High Risk for Gestational Diabetes|Clinically Useful Methods for Assessment of Insulin Sensitivity and Beta Cell Function in Women at High Risk for Gestational Diabetes: Does Race Matter?|DRM|Woman's|No|Completed|January 2006|December 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|175|Samples Without DNA|Blood samples for insulin measurements|Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, nondiabetic pregnant African-American and Caucasian women who have been scheduled        for a standard 3-hour glucose tolerance test at 24-28 weeks in the Woman's Hospital        Pathology laboratory.|December 2014|December 17, 2014|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687479||155269|
NCT00687804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002D2301|A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study|A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema|RESTORE|Novartis||Completed|May 2008|January 2012|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|345|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|May 27, 2008||No||No|January 19, 2011|https://clinicaltrials.gov/show/NCT00687804||155246|
NCT00687817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0701|Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer|A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Peregrine Pharmaceuticals|No|Completed|June 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687817||155245|
NCT00694902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP2107882|Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677|A Single-centre, Randomized, Double-blind , Placebo Controlled, Dose Escalating Cross-over Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Inhaled Doses of GSK610677 and Placebo in Healthy Male Subjects||GlaxoSmithKline|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|March 15, 2012|June 9, 2008||||No||https://clinicaltrials.gov/show/NCT00694902||154703|
NCT00694915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-60/9150|Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder|Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence|STCC|Cadila Pharnmaceuticals|Yes|Active, not recruiting|August 2008|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||May 2012|May 3, 2012|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694915||154702|
NCT00695188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMTX2007_01|Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis|Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis A Multicenter, Randomized, Double-blind, Controlled Phase IV Trial||Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation|Yes|Completed|May 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||August 2009|February 15, 2011|June 9, 2008||No||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00695188||154681|
NCT00695461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO NAT 004|Lactobacillus Plantarum 299v in Colon Surgery|L Plantarum 299v to Patients Undergoing Colon Resection - a Randomized Placebo-Controlled Study|Lp 299v|Skane University Hospital|No|Completed|January 2001|August 2006|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|72|||Both|N/A|N/A|No|||June 2008|June 10, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695461||154660|
NCT00695773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-014|Laparoscopic Vs. Open Prostatectomy Outcomes|Laparoscopic Vs. Open Prostatectomy Outcomes||Lahey Clinic|No|Terminated|February 2006|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|158|||Male|N/A|N/A|No|Non-Probability Sample|A Lahey Clinic IRB approved database and current clinic population of patients having a        laparascopic or open prostatectomy|November 2008|November 28, 2008|June 10, 2008||No|Insufficient findings for data analysis|No||https://clinicaltrials.gov/show/NCT00695773||154638|
NCT00696371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080158|PET Imaging of Peripheral Benzodiazepine Receptors|PET Imaging of Peripheral Benzodiazepine Receptors Using [11C](R)-PK 11195 and [11C]PBR28||National Institutes of Health Clinical Center (CC)||Completed|June 2008|August 2014||||Phase 1|Observational|Time Perspective: Prospective|||Actual|15|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696371||154593|
NCT00696657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-1821|A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide|Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial||Novo Nordisk A/S|No|Completed|June 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|14||Actual|415|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696657||154571|
NCT00696644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12456|A Study for Teriparatide in Severe Osteoporosis|An Italian Observational Study to Evaluate Fracture Outcomes, Compliance to Treatment, Back Pain, Health-related Quality of Life in Patients With Severe Osteoporosis Treated According to Common Clinical Practice|ISSO|Eli Lilly and Company|No|Completed|June 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|794|||Both|21 Years|N/A|No|Non-Probability Sample|Primary care clinic|May 2011|May 5, 2011|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696644||154572|
NCT00697541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-118-ROSE-202|Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%|A Phase II, Single-Center, Two-Way Crossover Relative Systemic Bioavailability Study of Col-118 Administered Topically as a 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2% Administered to the Eye in Subjects With Moderate to Severe Erythematous Rosacea||Galderma|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|June 12, 2008|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT00697541||154504|
NCT00697502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG03/32/06|Study of Capecitabine In Patients With Solid Tumors|A Phase I Study of Capecitabine In Patients With Solid Tumors||National University Hospital, Singapore|No|Completed|May 2007|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697502||154507|
NCT00697515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-316|Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)||Shire|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|55 Years|No|||December 2011|December 6, 2011|June 11, 2008|Yes|Yes||No|November 20, 2009|https://clinicaltrials.gov/show/NCT00697515||154506|
NCT00693641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-02-12-1 (UIO, BIOLOGEN)|Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief|Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief||University of Oslo|No|Completed|July 2008|June 2011|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 3, 2011|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693641||154799|
NCT00693342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597674|Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission|A Randomized Phase III Trial in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer With a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821||Gynecologic Oncology Group||Withdrawn|August 2008|||January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||July 2008|April 8, 2013|June 6, 2008|Yes|Yes|Never opened to accrual, a GOG working number, not developed into a clinical trial.|No||https://clinicaltrials.gov/show/NCT00693342||154820|
NCT00693628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13310|Effects of Shrinker Use on Healing and Volume|Effects of Shrinker Use on Healing and Volume for Transtibial Amputees||University of Oklahoma|No|Completed|March 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 20, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00693628||154800|
NCT00693875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAOYANG HOSPITAL|The Incidence of Intra-Operative Awareness in China and Analysis of Relevant Factors: a Multicentre Study|The Incidence of Intra-Operative Awareness in China and Analysis of Relevant Factors: a Multicentre Study||Capital Medical University|Yes|Completed|April 2007|June 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11197|||Both|12 Years|N/A|No|Probability Sample|The subjects would be selected from the patients of the 24 hospitals who would undergo        general anesthesia during different kinds of operations in different areas around China        after the written informed consents obtained. Each hospital would continuously provide        500～600 subjects for the investigation.|January 2009|January 27, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693875||154782|
NCT00694122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002515/24|Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon|Comparison of Lantus and NPH Insulin in the Dawn Phenomenon|DAWN|Massachusetts General Hospital|Yes|Completed|June 2005|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|June 6, 2008||No||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00694122||154763|Limitation: delayed and slow participant recruitment due to expansive use of insulin pumps and participants unwilling to cross over to alternate insulin.
NCT00694135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-001|Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis|A Prospective, Multi-Center, Randomized, Double-Masked, Safety, Tolerability and Efficacy Study of Four Iontophoretic Doses of Dexamethasone Phosphate Ophthalmic Solution in Patients With Non-Infectious Anterior Segment Uveitis||Eyegate Pharmaceuticals, Inc.|No|Completed|June 2008|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|12 Years|85 Years|No|||August 2010|August 27, 2010|June 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694135||154762|
NCT00694395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95013|A Qualitative Study of Delays in Hospital Admission in Patient With Acute Stroke|Decision Making Process in Patients With Symptoms of Acute Ischemic Stroke Why do They Delay in Seeking Medical Help? A Qualitative Study||Far Eastern Memorial Hospital|No|Completed|August 2006|July 2007|Actual|May 2007|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|20 patients admitted to hospital due to acute ischemic stroke and were delayed to receive        thrombolytic therapy. Family or caregivers who had involved in the process of decision        making were also invited to the interview.|July 2006|June 9, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694395||154742|
NCT00694408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPT/OL|A Pilot Trial of Pediatric Liver Transplantation Without Steroids|A Randomized Pilot Trial of a Steroid-Free Immunosuppressant Regimen in Pediatric Liver Transplantation||Birmingham Children's Hospital NHS Foundation Trust|Yes|Not yet recruiting|June 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|18 Years|No|||June 2008|June 9, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694408||154741|
NCT00687089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Subutex-214CTIL|Examination of Cognitive Function in Patients Treated With Subutex|Examination of Cognitive Function, Weight, Sexual Function in Patients Receiving Treatment With Subutex at 3 Months Without Using Opiates||BeerYaakov Mental Health Center|Yes|Completed|June 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|70 Years|No|Probability Sample|People who suffer from addiction problems (opiates) and willing to start Buprenorphine        treatment|January 2009|January 25, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687089||155299|
NCT00688064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29074|Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris|Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With Doxycycline Hyclate 100 mg Tablets Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel Associated With Doxycycline Hyclate 100 mg Tablets in the Treatment of Severe Acne Vulgaris.|ACCESS I|Galderma|No|Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|459|||Both|12 Years|35 Years|No|||March 2010|March 31, 2010|May 28, 2008|No|Yes||No|February 23, 2010|https://clinicaltrials.gov/show/NCT00688064||155226|
NCT00688077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-524/030408|FGF-23 Suppressibility by Calcitonin|Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study||Rijnstate Hospital||Recruiting|May 2008|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|12|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 8, 2011|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688077||155225|
NCT00688090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC1106-MT-001|Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.|A Phase 1/2, Open Label, Non-Randomized Dose Escalation Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma||Mannkind Corporation|No|Completed|June 2008|May 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||August 2010|August 2, 2010|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688090||155224|
NCT00694928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBC-303-603-622467|Vaginal Infection Study 2|||Lumara Health, Inc.||Completed|May 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|843|||Female|16 Years|N/A|No|||February 2012|February 29, 2012|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694928||154701|
NCT00694941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2506POE015|A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)|A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)||Ono Pharmaceutical Co. Ltd|No|Completed|June 2008|||December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694941||154700|
NCT00695201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-011|Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer|A Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer.||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2000|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00695201||154680|
NCT00696098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-3-067|Effects of Butyrate on Colonic Health of Patients With Diarrhoea Predominant IBS and UC in Remission|Effects of Butyrate on Colonic Health of Patients With Diarrhoea Predominant||Maastricht University Medical Center|No|Completed|May 2007|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|65 Years|No|||October 2009|October 6, 2009|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696098||154613|
NCT00696384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-491-016|A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension|An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension||Takeda|No|Completed|June 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|418|||Both|18 Years|N/A|No|||November 2011|November 29, 2011|June 10, 2008|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00696384||154592|
NCT00696683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-03/06|Establishment of Natural History of Scorpion Envenomation|Establishment of Natural History of Scorpion Envenomation in the Absence of Antivenom Treatment in Pediatric Patients||Instituto Bioclon S.A. de C.V.|No|Completed|August 2004|July 2005|Actual|August 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|97|||Both|6 Months|18 Years|No|Non-Probability Sample|Male and female patients 6 months to 18 years of age who presented for emergency treatment        of scorpion sting and who had clinically important systemic signs of envenomation were        included.|June 2008|June 11, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696683||154570|
NCT00696943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST-CA005CTIL|18F ML-10 for Early Detection of Response of Brain Metastases to SRS|An Open-label, Multi-center Study to Evaluate [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Stereotactic Radio Surgery (SRS)||Aposense Ltd.|Yes|Terminated|July 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|18 Years|N/A|No|||November 2008|February 13, 2013|June 11, 2008||No|Replaced by a global study protocol NST-CA004|No||https://clinicaltrials.gov/show/NCT00696943||154550|
NCT00696956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pac-3|Drug Coated Balloons for Prevention of Restenosis|Paclitaxel Coated Balloons for Prevention of Restenosis in Small Arteries Below the Knee Compared to Angioplasty Using Uncoated Balloons|Piccolo|University Hospital Tuebingen|No|Recruiting|April 2008|April 2011|Anticipated|April 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|95 Years|No|||May 2008|June 12, 2008|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696956||154549|
NCT00696930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMT 487A 2202|Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors|A Phase II Open-label Multi-center Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors||Molecular Insight Pharmaceuticals, Inc.||Withdrawn|June 2008|||June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 11, 2008||Yes||||https://clinicaltrials.gov/show/NCT00696930||154551|
NCT00697554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/036|Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-Liver Transplant Patients 18 Years of Age|Study to Compare the Immunogenicity and Safety of GSK Biologicals' Novel Adjuvanted HBV Vaccine (0, 21-Day Schedule) to a Double Dose of Engerix™ -B (0, 7, 21-Day Schedule), in Pre-Liver Transplant Patients ≥ 18 y, Boosted at Month 6-12||GlaxoSmithKline||Completed|January 2000|||May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|93|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697554||154503|
NCT00697567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208141/002|Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant|Study in Healthy HSV Positive and HSV Negative Adults to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Herpes Simplex (gD) Candidate Vaccine With or Without Adjuvant||GlaxoSmithKline||Completed|September 1992|December 1997|Actual|December 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697567||154502|
NCT00693355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 05-137|Effects of Butyrate Enemas on Colonic Health|Effects of Butyrate Enemas on Colonic Health||Maastricht University Medical Center|No|Completed|December 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2008|June 6, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693355||154819|
NCT00693654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000656|Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients|A Controlled Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Pruritus in Adult Hemodialysis Patients||Wake Forest School of Medicine|No|Active, not recruiting|November 2006|October 2008|Anticipated|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||June 2008|June 11, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693654||154798|
NCT00693888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTDemenz-44-052|Lighthouse Project on Dementia, Ulm, Germany|Lighthouse Project on Dementia, Ulm, Germany - Improvement of Advice and Diagnostics for People Suffering From Dementia After the Classification of Their Level of Care (ULTDEM Study).|ULTDEM|University of Ulm|Yes|Recruiting|June 2008|September 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|60 Years|N/A|No|||March 2009|August 16, 2010|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693888||154781|
NCT00694148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201 GL_3001|Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines|NT 201 is a Botulinum Toxin Type A Preparation Free of Complexing Proteins. Injected Into the Muscle, NT 201 Causes a Reversible Local Relaxation of the Injected Muscle. Botulinum Toxin Type A is Widely Used for Aesthetic Treatment of Mimic Wrinkles. This Study Will Investigate the Safety and Efficacy of NT 201 in the Treatment of Glabellar Frown Lines.||Merz Pharmaceuticals GmbH|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00694148||154761|
NCT00694161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX1B-201|The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy|The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy||Pfizer|No|Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|40 Years|N/A|No|||January 2013|January 4, 2013|June 6, 2008|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00694161||154760|Results for Holter monitoring parameters, increased interstitial markings, pleural effusions, PtGA and cardiothoracic ratio are presented as absolute values at specified time points and not as change from baseline as planned.
NCT00694421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0605007|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 2|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 2||University of Pittsburgh|No|Completed|January 2008|May 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|139|||Both|2 Years|54 Years|Accepts Healthy Volunteers|Non-Probability Sample|Membership in one of the two identified source populations|May 2015|May 26, 2015|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694421||154740|
NCT00694694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG50|Azithromycin + Artesunate v Artemether-Lumefantrine in Uncomplicated Malaria.|A Randomized Trial of Azithromycin + Artesunate v Artemether-Lumefantrine in Uncomplicated Malaria in Tanzanian Children.|CAZAMS|Gates Malaria Partnership|Yes|Completed|June 2008|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|261|||Both|6 Months|5 Years|No|||March 2009|March 5, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694694||154719|
NCT00687830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFL-8964|Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.|A Randomized Endoscopist-blinded Clinical Trial Comparing the Bowel Cleansing Effect and Patient Tolerability of Same Day Polyethylene Glycol Bowel Preparation Regimen v Regimen Given on the Day Before Colonoscopy|CCF|Cleveland Clinic Florida|No|Completed|February 2008|November 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|192|||Both|N/A|N/A|No|||February 2012|February 8, 2012|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687830||155244|
NCT00687518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2006/0416|Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers|Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers|HEPEPO|Rennes University Hospital|No|Recruiting|March 2008|February 2009|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2008|May 29, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687518||155266|
NCT00687843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMOG-GC01|Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients|Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients|TMOG-GC01|Tokyo Metropolitan Oncology Group|Yes|Active, not recruiting|June 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|20 Years|80 Years|No|||March 2012|March 20, 2012|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687843||155243|
NCT00692991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|566|Using Magnetic Resonance Imaging to Evaluate Heart Vessel Function After Angioplasty or Stent Placement Procedures|Microvascular Obstruction by Contrast-enhanced MRI Following Percutaneous Coronary Interventions||Johns Hopkins University|No|Completed|October 1999|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|||Both|21 Years|N/A|No|Non-Probability Sample|Patients listed on the cardiac catheterization schedule who are undergoing percutaneous        coronary interventions.|February 2013|February 22, 2016|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692991||154847|
NCT00693004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 03140-203|Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease||Epix Pharmaceuticals, Inc.||Terminated|May 2008|||January 2010|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|3||Anticipated|236|||Both|50 Years|90 Years|No|||July 2009|July 28, 2009|May 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693004||154846|
NCT00693017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-317|Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy|A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy||Eisai Inc.||Terminated|June 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|12 Years|65 Years|No|||November 2015|December 21, 2015|June 3, 2008||No|Sponsor's decision|No|August 13, 2012|https://clinicaltrials.gov/show/NCT00693017||154845|Due to early termination of the study by the Sponsor. No formal analyses were conducted.
NCT00695474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080061|Vitamin D and Type 2 Diabetes - a Cross Sectional Study|Vitamin D and Type 2 Diabetes - a Cross Sectional Study||University of Aarhus|No|Completed|June 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|150|Samples With DNA|Blood samples, urine.|Both|18 Years|90 Years|No|Non-Probability Sample|The study population consists of Danish type 2 diabetics from the outpatient clinic at        Silkeborg Hospital.|July 2009|July 10, 2009|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695474||154659|
NCT00695500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080137|Varenicline to Reduce Alcohol Consumption in Heavy Drinkers|A Randomized, Double-blind, Placebo Controlled Trial (RCT) of Varenicline to Reduce Alcohol Consumption in Heavy Drinkers||National Institutes of Health Clinical Center (CC)||Completed|June 2008|June 2015|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|50|||Both|21 Years|60 Years|No|||June 2015|June 4, 2015|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695500||154657|
NCT00695513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3534|Inulin and Protein Fermentation in Hemodialysis Patients|A Phase 1/2 Study on the Effects of BENEO synergy1 on the Generation Rate and Serum Concentration of P-cresol and Related Protein-fermentation Endproducts in Haemodialysis Patients||Universitaire Ziekenhuizen Leuven|No|Completed|March 2006|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695513||154656|
NCT00695799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120080063|Propofol Concentration In The Ambient Air Of The Operating Room And In The Blood Of Anesthesia Care Providers|Measurement Of Propofol Concentration In The Ambient Air Of The Operating Room And In The Blood Of Anesthesia Care Providers During Propofol -Based General Anesthesia||Rutgers, The State University of New Jersey|No|Completed|June 2008|December 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Standard blood draw|Both|18 Years|64 Years|No|Non-Probability Sample|Anesthesia care providers|December 2013|December 10, 2013|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695799||154636|
NCT00696397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000046|Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology|Sleep Disturbance in Atopic Dermatitis: A Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology||Wake Forest School of Medicine|No|Completed|March 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|31|Samples With DNA|Blood, dermal microdialysate|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|adult men and women between 18 and 50 years of age with atopic dermatitis|August 2012|August 8, 2012|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696397||154591|
NCT00696410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM0001911|The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy|Pilot Study to Assess the Impact of Zinc Supplementation on Left Ventricular Remodeling, Function, and Oxidative Stress in Nonischemic Cardiomyopathy||University of Michigan|Yes|Completed|June 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|21 Years|N/A|No|||December 2012|December 17, 2012|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696410||154590|
NCT00696696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 06-882|Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer|A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer||New York University School of Medicine|Yes|Completed|September 2007|June 2013|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|June 11, 2008|Yes|Yes||No|November 18, 2011|https://clinicaltrials.gov/show/NCT00696696||154569|
NCT00696969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL Combo 07|Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis|Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL).||Drugs for Neglected Diseases|Yes|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|634|||Both|18 Years|60 Years|No|||February 2010|February 10, 2010|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00696969||154548|
NCT00696982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shlomit9|The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation|The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation||Assaf-Harofeh Medical Center|No|Recruiting|June 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2008|June 12, 2008|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00696982||154547|
NCT00696995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1917|An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment|An Observational, Prospective Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix® 30 (Biphasic Insulin Aspart) Treatment|Start|Novo Nordisk A/S|No|Completed|January 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|509|None Retained|Venous blood samples drawn as part of routine clinical evaluation|Both|18 Years|N/A|No|Probability Sample|Patients with type 2 diabetes.|June 2012|June 15, 2012|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696995||154546|
NCT00697255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05693|A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)|A Phase II, Randomized, Controlled, Open-label, Feasibility Trial to Evaluate if a Single or Repeated Dose of Org 36286 (Corifollitropin Alfa) Followed by a Low Daily Dose of Either hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility||Merck Sharp & Dohme Corp.|No|Terminated|May 2007|May 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Female|18 Years|39 Years|No|||May 2015|May 29, 2015|June 11, 2008|No|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00697255||154526|
NCT00693433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00157|Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma|A Phase 1 Study of CCI-779 in Combination With Dexamethasone in Multiple Myeloma||National Cancer Institute (NCI)||Completed|December 2008|||August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2013|December 3, 2015|June 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693433||154815|
NCT00693381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-02-CEE-01|Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation|An Open, Multicentre, Randomised, Parallel Group Pilot-Study to Compare Safety and Efficacy of Discontinuation of Mycophenolate Mofetil From a Tacrolimus/MMF/Steroid Triple Regimen Following Kidney Transplantation|DISTAMP|Astellas Pharma Inc|No|Completed|February 2003|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693381||154818|
NCT00693667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP011|Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women|A Phase II, Double-Blind, Randomized, Placebo-controlled, Clinical Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women|PH3|PhytoHealth Corporation|No|Completed|February 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|92|||Female|40 Years|60 Years|No|||November 2011|November 3, 2011|February 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693667||154797|
NCT00693901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499|Influence of Public Parks on Physical Activity Levels of Diverse Communities|Parks and Physical Activity in Diverse Communities||RAND|Yes|Completed|October 2007|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|50|||Both|N/A|N/A|No|||December 2012|December 13, 2012|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693901||154780|
NCT00694174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|027505MP4F|Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants|Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants||Children's Hospital of Michigan|Yes|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|N/A|7 Days|No|||June 2008|June 9, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00694174||154759|
NCT00694434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Fisch|Graduated Embryo Score (GES) in the Fresh Cycle Predicts Outcome From Frozen Embryo Transfer|Graduated Embryo Score (GES) Int he Fresh Cycle Predicts Outcome From Frozen Embryo Transfer|GES/FET|Sher Institute for Reproductive Medicine, Las Vegas|No|Completed|January 2002|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|183|||Female|21 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|All IVF patients at our center between 2002 and 2007 with at least 2 frozen blastocysts        undergoing frozen embryo transfer.|June 2008|June 9, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694434||154739|
NCT00694447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000143|Acupuncture for Pain and Sleep Disturbance in Knee Osteoarthritis|Exploring Outcomes and Mechanisms of Acupuncture in Treating Pain and Sleep Disturbance in Knee Osteoarthritis||Emory University|No|Completed|February 2007|||April 2008|Actual|N/A|Interventional|N/A|2||||||Both|55 Years|N/A|No|||November 2013|November 19, 2013|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694447||154738|
NCT00694707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-16|Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia|Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia||Forest Laboratories|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|732|||Both|18 Years|60 Years|No|||March 2012|March 2, 2012|June 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694707||154718|
NCT00694720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT6795|Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients|A Double-Blind, Randomized, Placebo-Controlled, Study Evaluating the Safety and Activity of Four Escalating Single Doses of AVE0657 in Congestive Heart Failure Patients Presenting as Cheyne-Stokes Breathing Syndrome||Sanofi|Yes|Terminated|June 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|8|||Both|18 Years|75 Years|No|||April 2009|April 30, 2009|May 7, 2008|Yes|Yes|Termination following reassessment of the potential benefit-risk of AVE0657|No||https://clinicaltrials.gov/show/NCT00694720||154717|
NCT00695006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5388642|Manual Therapy, Exercise and Traction for Patients With Cervical Radiculopathy: A RCT|Manual Therapy, Exercise and Traction for Patients With Cervical Radiculopathy: A RCT||Rocky Mountain University of Health Professions||Active, not recruiting|September 2006|July 2008|Anticipated|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|70 Years|No|||June 2008|June 24, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695006||154695|
NCT00687531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04879|Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)|Open Label, 12-week Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate Dry Powder 400 mcg Once-daily in Persistent Mild-moderate Asthmatic Patients at Least 12 Years Old|APEGO|Merck Sharp & Dohme Corp.|No|Terminated|November 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|385|||Both|12 Years|N/A|No|||October 2015|October 19, 2015|May 27, 2008|No|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00687531||155265|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.
NCT00692419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-190|Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients|Pain, Sexual Dysfunction and Depression in Hemodialysis Patients|SMILE|VA Office of Research and Development|Yes|Completed|November 2008|January 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|N/A|No|||September 2014|April 6, 2015|June 4, 2008||No||No|October 30, 2014|https://clinicaltrials.gov/show/NCT00692419||154891|Individual providers were overseeing the care of patients from both study arms. The sample size was relatively small. Single geographic area. No control arm. Symptoms assessed during dialysis. No formal assessment of treatment compliance.
NCT00692731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-06001|Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss|A Randomized, Double-Blind, Controlled Study to Assess the Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss||Provident Clinical Research|No|Completed|June 2006|August 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|132|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Subjects included generally healthy, normally sedentary men and women. Eligible        participants were required to be 21 to 65 years of age, have a waist circumference ≥ 87 cm        (women) or ≥ 90 cm (men), and total cholesterol ≥ 200 mg/dL at screening.|June 2008|June 4, 2008|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00692731||154867|
NCT00693290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/NIR03/40|Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy|Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy||University of Ulster|Yes|Not yet recruiting|June 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|16 Years|80 Years|No|||June 2008|June 6, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693290||154824|
NCT00693303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1125|Examining the Effectiveness of My Scrivener on Handwriting Legibility|Examining the Effectiveness of My Scrivener on Handwriting Legibility||Shenandoah University|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|5 Years|13 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|June 5, 2008||No||No|July 10, 2009|https://clinicaltrials.gov/show/NCT00693303||154823|
NCT00695812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siblings Autism.ctil|The Development of Younger Siblings of Children With Autism Now at 10 Years of Age|The Development of Younger Siblings of Children With Autism Now at 10 Years of Age||Shaare Zedek Medical Center|No|Not yet recruiting|September 2008|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|104|||Both|10 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants in the SIBS-A and SIBS-TD groups, who are now reaching the age of 10        years, participated in the longitudinal study and were seen at the ages of 4, 14, 24, 36,        54 months and 7 years. The SIBS-A group (n = 42) comprises children who have an older        sibling with autism. All probands were diagnosed using the Autism Diagnostic Observation        Schedule (Lord, Rutter, DiLavore & Risi, 2002) and/or the Autism Diagnostic Interview -        Revised (ADI-R; Lord, Rutter, & Le Couteur, 1994). Families were recruited through        treatment centers, special schools, the national organization for children with autism in        Israel, and through families of children with autism.        The SIBS-TD group (n = 62) comprises children who have an older sibling with typical        development and who participated in the longitudinal study. Families were recruited from        maternity wards in Jerusalem. (more information is available in Yirmiya et al., 2006).|June 2008|June 11, 2008|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695812||154635|
NCT00695825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|073101|Effects the Glycemic Index on Metabolic Risk Markers|Postprandial Effects of a Low vs. a High Glycemic Index Food Product on Metabolic Risk Markers in Lean and Obese Subjects||Maastricht University Medical Center|Yes|Active, not recruiting|February 2008|December 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2008|December 11, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00695825||154634|
NCT00696111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15872B|Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea|PCOS, Sleep Apnea and Metabolic Risk in Women||University of Chicago|Yes|Active, not recruiting|December 2007|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Female|18 Years|40 Years|No|||December 2014|December 2, 2014|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696111||154612|
NCT00696423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111535|Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children|Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children||GlaxoSmithKline||Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|467|||Both|18 Months|24 Months|Accepts Healthy Volunteers|||November 2012|November 21, 2012|June 5, 2008|Yes|Yes||No|July 17, 2009|https://clinicaltrials.gov/show/NCT00696423||154589|
NCT00696709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-004|A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)|A Phase I, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults||Merck Sharp & Dohme Corp.|Yes|Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|160|||Both|50 Years|59 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696709||154568|
NCT00696722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM2ATV|Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction|Influence of Atazanavir Treatment on Endothelial Dysfunction, Vascular Inflammation and Heme Oxygenase Activity in Type 2 Diabetes Mellitus|DM2ATV|Radboud University||Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|70 Years|No|||January 2009|January 24, 2010|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00696722||154567|
NCT00697008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GES-DUM-2007/3|Asociación Española de Gastroenterologia (Spanish Gastroenterology Association) Gastroesophageal Reflux Disease Guideline - Prospective Study|Symptomatic Assessment and Therapeutic Outcomes in Typical GERD Patients Following a New CP Guideline in the Clinical Practice|Prospect|AstraZeneca|No|Completed|December 2007|||January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|17 Years|N/A|No|Probability Sample|Patients with typical GERD symptoms consulting in specialized care setting and are managed        following the new local GERD guidelines|February 2009|February 9, 2009|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00697008||154545|
NCT00697294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22293|Impact of Vitamin D Status on Bones in Breastfed Infants|Vitamin D Status and Impact on Bone Mineralization in Human Milk Fed Hispanic and Caucasian Infants||Baylor College of Medicine|No|Completed|July 2008|November 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|N/A|2 Hours|Accepts Healthy Volunteers|||December 2011|December 2, 2011|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00697294||154523|
NCT00697268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080150|p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram|An Investigation to Determine Whether Levels of P11 Protein in Peripheral Blood Cells Correlate With Treatment Response to Citalopram in Patients With Major Depressive Disorder||National Institutes of Health Clinical Center (CC)||Completed|June 2008|||||N/A|Observational|N/A|||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|November 21, 2015|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00697268||154525|
NCT00693953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-06-278|Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism|Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism||Yellen & Associates, Inc.|No|Withdrawn|January 2010|December 2012|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|200|||Both|5 Years|25 Years|No|Non-Probability Sample|The study population includes individuals with Autism without exclusion on the basis of        sex, gender, race or ethnicity. There will be 100 research subjects, with a ratio of four        males to one female, and those being approximately sixty-five children and thirty-five        adults.|October 2009|October 1, 2009|June 5, 2008||No|grant was not approved.|No||https://clinicaltrials.gov/show/NCT00693953||154776|
NCT00693407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/07/088|Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation|Activation of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation in Functional Dyspepsia Patients and Healthy Controls||National University Hospital, Singapore|Yes|Completed|September 2008|September 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693407||154817|
NCT00693420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-032|Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence|||Allergan||Completed|April 2007|December 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 26, 2013|June 5, 2008|Yes|Yes||No|January 14, 2009|https://clinicaltrials.gov/show/NCT00693420||154816|
NCT00693927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minitransplant - random|Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC)|Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Phase II Trial||University Hospital of Liege|No|Completed|March 2002|May 2008|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|N/A|70 Years|No|||September 2011|September 1, 2011|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00693927||154778|
NCT00693940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|586|Effectiveness of Group Walking Sessions for Increasing Activity in People With Peripheral Arterial Disease (The Group Oriented Arterial Leg Study [GOALS])|Increasing Activity in Peripheral Arterial Disease||Northwestern University|Yes|Completed|June 2008|May 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|25 Years|N/A|No|||October 2015|October 27, 2015|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693940||154777|
NCT00693914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXFXN1|Working Memory Performance Among Childhood Brain Tumor Survivors|Working Memory Performance Among Childhood Brain Tumor Survivors Treated With Conformal Radiation Therapy: A Pilot Study||St. Jude Children's Research Hospital|No|Completed|April 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|130|||Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Both the patient group and sibling group will be accrued using a broad stratification        process for gender (Male, Female) and age (8-12 years of age, 13-18 years of age).|October 2011|October 3, 2011|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693914||154779|
NCT00694187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZALE-01|Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions.||Roxane Laboratories|No|Completed|January 2004|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 9, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694187||154758|
NCT00694473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-002178|Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery|Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery||Massachusetts General Hospital|No|Completed|June 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|65|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|June 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694473||154736|
NCT00694460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M49P2|Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers|A Phase II, Pilot, Randomized, Open-Label, Single-Center Study to Evaluate Immunogenicity, Safety and Booster Response of 3 Full Intramuscular Doses Versus 3 Half Intramuscular Doses Versus 3 Intradermal Doses Versus 2 Intradermal Doses of PCEC Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine as a Pre-Exposure Regimen in 12 to 18 Months Old Toddlers in Thailand.||Novartis||Completed|August 2002|September 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|200|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||June 2008|June 9, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00694460||154737|
NCT00694733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB #937|Regulation of Cortisol Metabolism and Fat Patterning|Regulation of Cortisol Metabolism and Fat Patterning||Oregon Health and Science University|No|Completed|May 2005|September 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|140|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||June 2012|June 4, 2012|June 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694733||154716|
NCT00695604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15322B|Repeated High-dose Inhaled Corticosteroids for Asthma|Repeated High-dose Inhaled Corticosteroids for Asthma|ReHICS|Johns Hopkins University|Yes|Completed|May 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|No|||May 2013|May 9, 2013|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695604||154649|
NCT00692432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901-475|Macrophage Inhibitory Factor (MIF) and High-Mobility Group-1 Protein (HMG-1) in Children Undergoing Cardiopulmonary Bypass|Macrophage Inhibitory Factor (MIF) and High-Mobility Group-1 Protein (HMG-1) in Children Undergoing Cardiopulmonary Bypass||University of Texas Southwestern Medical Center|No|Active, not recruiting|September 2001|December 2008|Anticipated|September 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|cardiac tissue serum|Both|N/A|5 Years|No|Non-Probability Sample|Children at Children's Medical Center Dallas who are having cardiac surgery that requires        CPB and an expectation of cardiac tissue removal.|August 2007|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692432||154890|
NCT00692744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/042/HP|Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH)|Study of Quality of Life After Aneurysmal Subarachnoid Hemorrhage in Patients Aged 70 Years or Older.|FASHE|University Hospital, Rouen|Yes|Completed|October 2008|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|353|None Retained|2 randomized arms (clipping and coiling) and 3 prospective observational arms (clipping,      coiling, conservative) For the randomized arms, we anticipated 20 patients in each arm.|Both|70 Years|90 Years|No|Probability Sample|Primary cara clinic in differents countries of France|September 2014|September 1, 2014|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692744||154866|
NCT00688714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1700C00001|Study to Investigate Safety and Tolerability of a Single Dose of AZD6482|A Randomised, Double-Blind, Placebo-Controlled Phase I Study to Assess the Tolerability, Safety, Pharmacokinetic, and Pharmacodynamic Properties of AZD6482, Alone and co-Administered With ASA, After Single Ascending Intravenous Doses to Healthy Male Subjects||AstraZeneca|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2008|May 30, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688714||155176|
NCT00695838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GFR-DUM-2007/3|National Survey on Gastroesophageal Reflux Disease (GERD) Patients|Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice|LINEA|AstraZeneca|No|Completed|January 2008|December 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5084|||Both|18 Years|N/A|No|Probability Sample|First three consecutive patients with GERD symptoms seen by GP|August 2009|August 4, 2009|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695838||154633|
NCT00695851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-019|Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.|A Phase I Randomized Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.||Memorial Sloan Kettering Cancer Center||Completed|March 2005|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||March 2009|March 27, 2009|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00695851||154632|
NCT00696124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US 06-1-001|Safety Study of Gene Therapy in Treating Lower Leg Ischemia|Phase 1, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Critical Limb Ischemia||ViroMed Co., Ltd. dba VM BioPharma|Yes|Completed|March 2007|May 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|15|||Both|20 Years|90 Years|No|||July 2010|July 21, 2010|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696124||154611|
NCT00696137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEN-290|Long-term Extension Study of BEMA™ Fentanyl|Open-label, Long-term Extension Study for Treatment of Breakthrough Cancer Pain With BEMA™ Fentanyl||BioDelivery Sciences International|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696137||154610|
NCT00696436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-491-019|An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.|A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension||Takeda|No|Completed|April 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1291|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|June 10, 2008|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00696436||154588|
NCT00696449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000406|Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris|An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris||Wake Forest School of Medicine|No|Active, not recruiting|June 2006|October 2008|Anticipated|May 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|13 Years|18 Years|No|||June 2008|June 10, 2008|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696449||154587|
NCT00697021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57/08|Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance|Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI|TEG|Assaf-Harofeh Medical Center|Yes|Recruiting|June 2008|October 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2008|June 12, 2008|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00697021||154544|
NCT00697307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002626|Bioequivalence Study of Patches With Different Release Profiles|A Bioequivalence Study Of A Low Cumulative Release Lot Of Norelgestromin (NGMN)/Ethinyl Estradiol (EE) Transdermal Contraceptive Systems Compared With Currently Marketed Ortho-Evra In Healthy Female Volunteers||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2003|July 2003|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|43|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|June 5, 2008||||||https://clinicaltrials.gov/show/NCT00697307||154522|
NCT00697281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/010/07|OC000459 Dose Finding Study in Hay Fever Sufferers.|A Dose Finding Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis.||Oxagen Ltd|No|Completed|May 2008|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|120|||Both|18 Years|50 Years|No|||February 2009|February 23, 2009|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697281||154524|
NCT00693732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/06/264|Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS)|Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS)||National University Hospital, Singapore||Completed|February 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693732||154792|
NCT00693966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/005|Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females|A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers||GlaxoSmithKline||Completed|October 1999|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|210|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||June 2008|June 5, 2008|June 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693966||154775|
NCT00693680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZnIMI/2004|Zinc Supplementation of Imipramine Therapy|The Role of Zinc in Therapy of Unipolar Depression||Polish Academy of Sciences|Yes|Completed|January 2005|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2008|June 9, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693680||154796|
NCT00693693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000702|Adherence to Topical Hydrocortisone 17-Butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis|Adherence to Topical Hydrocortisone 17-Butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis||Wake Forest School of Medicine|No|Active, not recruiting|November 2006|September 2008|Anticipated|September 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||June 2008|June 11, 2008|June 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693693||154795|
NCT00694486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07070157|Eustachian Tube Testing in a Pressure Chamber -- Validation Study|Eustachian Tube Testing in a Pressure Chamber -- Validation||Children's Hospital of Pittsburgh|No|Completed|January 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy adults|September 2010|September 8, 2010|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694486||154735|
NCT00694499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 29_04_2008|Non-Operative Management of High Grade Blunt Hepatic Injury: Clinical Complications and the Role of Collateral Damage|Retrospective Single Centre Study Which Investigates the Safety of the Non-Operative Management of Patients With High Grade Blunt Liver Injuries (NOMLI) and the Impact of to the LI Collateral Intra- and Extra-Abdominal Damage on Interventions and Outcome|NOMLI|University of Bern|No|Completed|January 2000|December 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|183|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with blunt liver injury treated at Bern University Hospital from 2000-2006|June 2008|June 9, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694499||154734|
NCT00694200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.03|Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer|Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Patients With Metastatic Breast Cancer. A Multicenter Phase II Study||Hellenic Oncology Research Group|No|Terminated|April 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|75 Years|No|||May 2015|May 27, 2015|June 6, 2008||No|Not reached the statistical hypothesis at the interim analysis|No||https://clinicaltrials.gov/show/NCT00694200||154757|
NCT00695045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Intrathecal Morphine in Knee Arthroplasty|Determination of the Efficacy and Side-Effect Profile of Lower Doses of Intrathecal Morphine in Patients Undergoing Total Knee Arthroplasty||University College Hospital Galway|No|Completed|July 2003|April 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||June 2008|June 9, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695045||154692|
NCT00695292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 156|Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer|Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|June 2008|September 2012|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|June 9, 2008|No|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00695292||154673|
NCT00695305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP2105521|An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks|A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis||GlaxoSmithKline|No|Completed|November 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|50 Years|80 Years|No|||November 2012|November 15, 2012|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695305||154672|
NCT00695591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS01|Home Sleep Testing in Neuromuscular Disease Patients|Home Sleep Testing in Neuromuscular Disease Patients|HSTNMD|Landon Pediatric Foundation|No|Completed|July 2008|July 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|9|||Both|8 Years|50 Years|No|Non-Probability Sample|Study Population Description Patients from the Neuromuscular Disease Clinic at Ventura        County Medical Center        Non-Probability Sample: invitation to volunteer        Neuromuscular Disease|August 2014|August 12, 2014|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00695591||154650|
NCT00695318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-08-004|Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy|A Randomized, Double-Masked, Fellow-Eye Comparison Of The Safety And Efficacy Of 0.2 And 0.5 µg/Day Fluocinolone Acetonide Intravitreal Insert To Sham Injection In Subjects With Bilateral Geographic Atrophy Due To AMD||Alimera Sciences|No|Terminated|December 2008|||October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|55 Years|N/A|No|||May 2015|May 11, 2015|June 9, 2008|Yes|Yes||No|April 17, 2015|https://clinicaltrials.gov/show/NCT00695318||154671|
NCT00692120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0013|Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy|Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy|D2/D3|University of Wisconsin, Madison|No|Completed|February 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2010|October 1, 2015|January 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00692120||154914|
NCT00688727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R000726|Cognitive Behavioural Therapy in Dissociative Seizures|Cognitive Behavioural Therapy in Dissociative Seizures: A Randomised Controlled Trial||South London and Maudsley NHS Foundation Trust|No|Active, not recruiting|March 2001|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|70 Years|No|||January 2009|January 21, 2009|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688727||155175|
NCT00695864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05222008-1180|Effect of Ondansetron for Withdrawal Symptoms|Effect of Ondansetron for Withdrawal Symptoms||Stanford University||Completed|May 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695864||154631|
NCT00695877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ad5HVR48.ENVA.01/IPCAVD-002|Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults|A Phase I Randomized, Double-blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 5 HVR48 HIV-1 Vaccine (Ad5HVR48.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad5HVR48.ENVA.01 (rAd5HVR48) HIV-1/IPCAVD-002 Vaccine Study)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|February 2009|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00695877||154630|
NCT00696150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ultrasound for hip # study-1|Can the Femoral Nerve Block be Improved by Ultrasound Guidance?|Can the Use of Ultrasound to Guide the Insertion of a Needle for an Anterior Psoas Compartment Nerve Block Increase Its Efficacy in Comparison to Traditional Techniques Utilising Loss of Resistance and Nerve Stimulation?||NHS Greater Glasgow and Clyde|No|Not yet recruiting|July 2008|August 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|269|||Both|35 Years|90 Years|No|||June 2008|June 11, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696150||154609|
NCT00696735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS 064|High-Dose Therapy Treatment in Patients With Follicular Lymphoma|Randomized Phase III Study Comparison Between Conventional Chemotherapy and High-Dose Therapy Followed by Autologous Purged Stem-Cell Transplantation in Patients With Follicular Lymphoma Stage III,IV First-Line Treatment for Patients Younger Than 60 Years Old With a High Tumor Burden||French Innovative Leukemia Organisation|Yes|Completed|June 1994|May 2006|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|60 Years|No|||September 2006|October 23, 2008|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00696735||154566|
NCT00697606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study #08-032|Seprafilm® for Prevention of Adhesions at Repeat Cesarean|Randomized Double-Blind Controlled Study to Determine if Seprafilm® Reduces Adhesions After Primary Cesarean Section|SPARC|Abington Memorial Hospital|Yes|Terminated|July 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|450|||Female|18 Years|50 Years|No|||December 2015|December 29, 2015|June 12, 2008||No|lack of funding|No||https://clinicaltrials.gov/show/NCT00697606||154499|
NCT00693446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/04/2-D|A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids|An Open-Label, Comparative, Randomized, Prospective Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids||Nantes University Hospital|No|Active, not recruiting|April 2004|April 2017|Anticipated|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|60 Years|No|||May 2015|May 11, 2015|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693446||154814|
NCT00693706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110127|Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix|Safety and Immunogenicity Study of GSK Biologicals' Cell Culture-based Influenza Virus Vaccine 1388442A Compared With US Licensed TIV in Healthy Adults||GlaxoSmithKline|No|Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|June 2, 2008|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00693706||154794|
NCT00697580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD033064-13|Strength and Nutrition Outcomes for Latino Adolescents|Intra-Abdominal Fat and Risk of Disease in Adolescents|SANO LA|University of Southern California|Yes|Completed|May 2005|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|104|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||July 2011|July 20, 2011|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697580||154501|
NCT00697593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27809|ChangE From Any Systemic psoriasiS therapY to Raptiva|A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or Psoralen-Ultraviolet Light A (PUVA), Narrow-Band Ultraviolet Light B (NBUVB) to Raptiva 1mg/kg/ Week Therapy.|EASY|Merck KGaA||Terminated|January 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|June 11, 2008||No|The study was terminated after the European Medicines Agency recommended to suspend the    marketing authorisation of Raptiva in the European Union|No|June 29, 2010|https://clinicaltrials.gov/show/NCT00697593||154500|
NCT00695097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNE Rituxin|The Effect of Rituximab on the Development of Anti-Donor Antibodies|The Effect of Rituximab on the Development of Anti-Donor Antibodies and Resolution of B Cell Infiltration in the Renal Allograft of Patients Undergoing Rejection||University of California, San Francisco|No|Completed|August 2004|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||February 2014|February 7, 2014|June 9, 2008|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT00695097||154688|The limitations were small number of participants and short follow up time of only 12 months.
NCT00694213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPT1-102|Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)|A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines Administered With the Biojector® 2000 Needle-Free System||Vical|Yes|Completed|August 2007|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|47|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 11, 2009|June 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694213||154756|
NCT00694226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1719/2003|Brief Intervention in Substance Use in Adolescent Psychiatric Patients|Brief Intervention in Substance Use Among Adolescent Psychiatric Patients: A Randomized Controlled Trial||Hospital Clinic of Barcelona|No|Completed|March 2004|||September 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|12 Years|17 Years|No|||June 2008|June 9, 2008|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00694226||154755|
NCT00694512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 3224|Ghrelin Regulation and Structure: Effect of Diet Composition on Ghrelin|Ghrelin Regulation and Structure: Effect of Diet Composition on Ghrelin||Oregon Health and Science University|No|Completed|February 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 14, 2012|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694512||154733|
NCT00694772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-21417|Coblation-Tonsillotomy vs Electrocautery-Tonsillectomy for the Treatment of Obstructive Sleep Apnea (OSA) in Children|Coblation-Tonsillotomy Versus Electrocautery-Tonsillectomy for Treatment of Moderate and Severe Obstructive Sleep Apnea in Children: A Randomized, Prospective, Single-Blinded Study||University of Calgary|No|Recruiting|June 2008|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|8 Years|No|||June 2008|June 9, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694772||154713|
NCT00694785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC1779-010|A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B|A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B||Archemix Corp.||Withdrawn|October 2008|||June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2|||Both|16 Years|75 Years|No|||August 2009|August 20, 2009|June 6, 2008|Yes|Yes|Sponsor decided not to go forward with the study.|No||https://clinicaltrials.gov/show/NCT00694785||154712|
NCT00695058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2007-047|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence|TMNS|Copenhagen University Hospital at Herlev|Yes|Withdrawn|August 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 23, 2012|June 9, 2008|Yes|Yes|Failure to include|No||https://clinicaltrials.gov/show/NCT00695058||154691|
NCT00695630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30779|Flumazenil Reversal of Oral Triazolam|Flumazenil Rescue Strategy||University of Washington|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695630||154647|
NCT00692783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ2008-19|Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility|Incidence of Oral Candidiasis, Prevalence of Candida Dubliniensis in HIV Patients and In-vitro Azole Susceptibility. (I.C.O.N.I.C.)|ICONIC|University of Florida|No|Terminated|May 2008|January 2009|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|65 Years|No|Non-Probability Sample|HIV with or without AIDS defining illnesses at the Boulevard Comprehensive Care Center|May 2015|May 7, 2015|May 28, 2008||No|Dr. Vindas completed his fellowship + low enrollment|No||https://clinicaltrials.gov/show/NCT00692783||154863|
NCT00693030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0106|Optical Coherence Tomography for Drug Eluting Stent Safety|In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography|ODESSA|A.O. Ospedale Papa Giovanni XXIII|Yes|Recruiting|August 2006|December 2008|Anticipated|June 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|77|||Both|18 Years|N/A|No|||June 2008|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00693030||154844|
NCT00693043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCID 2008-007|Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy|A Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy||Lahey Clinic|No|Withdrawn|February 2008|||March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|85 Years|No|||March 2014|March 26, 2014|June 2, 2008|Yes|Yes|Principal Investigator left the institution requested termination|No||https://clinicaltrials.gov/show/NCT00693043||154843|
NCT00693056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-10100-P2A-001|Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)|A Double-Blinded, Randomized, Placebo-Controlled, Dose-Exploring Study of RX-10100 for Eight Weeks of On-Demand Administration in Subjects With Erectile Dysfunction (ED)||Rexahn Pharmaceuticals, Inc.|No|Completed|June 2008|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Male|18 Years|65 Years|No|||May 2009|May 4, 2009|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693056||154842|
NCT00695890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012007070222|Effects of Sevoflurane and Propofol on Light Flash Evoked Pupillometry|Effects of Sevoflurane and Propofol on Light Flash Evoked Pupillometry.||Rutgers, The State University of New Jersey|No|Completed|September 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|December 2014|December 17, 2014|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695890||154629|
NCT00696163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3555|Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes|A Multicentre, Open Label, Nonrandomised, Non- Interventional, A Multicentre, Open Label, Nonrandomised, Non- Interventional, Observational Study to Evaluate the Quality of Life and Clinical Outcomes in Subjects Using Biphasic Insulin Aspart 30 (NovoMix® 30) for the Treatment of Diabetes Mellitus|IMPROVE Life|Novo Nordisk A/S|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24975|||Both|N/A|N/A|No|Probability Sample|Type 2 diabetes|August 2014|August 11, 2014|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696163||154608|
NCT00696462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70346|The Effect of Forced Air Warming During Cesarean Section on Postoperative Infectious Morbidity|The Effect of Forced Air Warming During Cesarean Section on Postoperative Infectious Morbidity||Vanderbilt University|Yes|Withdrawn|March 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 11, 2012|June 2, 2008||No|Study terminated for lack of funds to initiate study|No||https://clinicaltrials.gov/show/NCT00696462||154586|
NCT00697320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1921|Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany|Efficacy of NovoSeven® (Activated Recombinant Human Factor VII): Non-interventional Study in Patients With Congenital Haemophilia With Inhibitors, Acquired Haemophilia, Factor FVII Deficiency, and Glanzmann's Thrombasthenia|WIRK|Novo Nordisk A/S|No|Completed|June 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|64|||Both|N/A|N/A|No|Non-Probability Sample|Patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX,        acquired haemophilia, congenital FVII deficiency, or Glanzmann's thrombasthenia who have        received at least one dose of NovoSeven®.|August 2014|August 8, 2014|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697320||154521|
NCT00697060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP024|A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer|A Multicenter, Phase II Trial of the Safety and Efficacy of Amplimexon® (Imexon for Injection) in Combination With Taxotere® (Docetaxel) for Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)||AmpliMed Corporation||Withdrawn|August 2010|August 2012|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|June 11, 2008|Yes|Yes|Study cancelled prior to start due to change in company priorities.|No||https://clinicaltrials.gov/show/NCT00697060||154541|
NCT00697333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG NUK/RT 2006-1|Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC|Optimisation of Radiotherapy-Planning in Patients With Inoperable Locally Advanced Non-Small-Cell Lung Cancer by FDG-PET|PET-Plan|Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN|Yes|Recruiting|May 2009|May 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697333||154520|
NCT00697346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14003|Study of MLN8237 in Patients With Advanced Hematological Malignancies|An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|July 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2015|December 17, 2015|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697346||154519|
NCT00697619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446ECN02|To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer|A Prospective, Open-label, Randomized Phase III Study to Evaluate the Efficacy of ZOMETA® (Zoledronic Acid) in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer||Sun Yat-sen University|No|Completed|September 2005|September 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||December 2011|March 4, 2012|June 11, 2008||No||No|December 19, 2011|https://clinicaltrials.gov/show/NCT00697619||154498|
NCT00697632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-101|Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies|Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies||Mirati Therapeutics Inc.|No|Recruiting|June 2008|May 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|May 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697632||154497|
NCT00693719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0327-04|Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer|A Phase II Study: Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer||University of Arizona|Yes|Completed|August 2007|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|120 Years|No|||August 2013|October 15, 2015|June 6, 2008|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00693719||154793|
NCT00693979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taxus Perseus|A Prospective Evaluation in a Randomized Trial of TAXUS in the Treatment of De Novo Coronary Artey Lesions|A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions||National University Hospital, Singapore|No|Not yet recruiting||||||Phase 1|Interventional|N/A|||||||Both|18 Years|80 Years|No|||June 2008|June 5, 2008|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693979||154774|
NCT00694239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-053|Risk Assessment and Treat Compliance in Hypertension Education Trial|Evaluation of the Effect of Cardiovascular Risk Assessment in Treatment Compliance in Hypertension|RATCHET|Lawson Health Research Institute|Yes|Completed|May 2007|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|84 Years|No|||June 2011|June 29, 2011|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694239||154754|
NCT00694252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.15|Lapatinib and Circulating Tumor Cells in Breast Cancer|A Pilot Feasibility Study to Evaluate the Efficacy of Lapatinib in Eliminating Cytokeratin-positive Tumour Cells Circulating in the Blood of Women With Breast Cancer||University Hospital of Crete|No|Completed|July 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||September 2015|September 25, 2015|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694252||154753|
NCT00695643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-37/DIV|Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis|Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis||Dr. Falk Pharma GmbH|Yes|Terminated|January 2008|January 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|345|||Both|40 Years|80 Years|No|||May 2014|May 16, 2014|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695643||154646|
NCT00695656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2007/7|National Survey on Hypertension in General Practitioner (GP) Consultation|Profile of Hypertensive Patients Seen in General Practitioner Consultation|Prophyl GP|AstraZeneca|No|Completed|April 2008|November 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2853|||Both|18 Years|N/A|No|Probability Sample|First three consecutive patients with hypertension seen by general practitioner|August 2009|August 4, 2009|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695656||154645|
NCT00695955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-491-006|One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension|A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension||Takeda|No|Completed|June 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|669|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|June 10, 2008|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00695955||154624|
NCT00695968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0024|Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI|A Prospective Study Evaluating Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography, and Magnetic Resonance Imaging in the Detection of Breast Cancer||Stanford University||Terminated|April 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Female|18 Years|80 Years|No|Non-Probability Sample|Patients must have a suspicious breast lesion|July 2012|July 10, 2012|June 10, 2008||No|low accrual|No||https://clinicaltrials.gov/show/NCT00695968||154623|
NCT00694746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT40|Study of Fish Oil to Reduce ALT Levels in Adolescents|Randomized Trial of Fish Oil Versus Placebo to Reduce ALT Levels in Overweight Adolescents||Boston University|No|Terminated|June 2008|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|13 Years|17 Years|No|||January 2016|January 28, 2016|June 6, 2008|No|Yes|Study closed for slow recruitment|No||https://clinicaltrials.gov/show/NCT00694746||154715|
NCT00694759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSUIRB00002532|Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)|Cortisol Regulation in Polycystic Ovary Syndrome||Oregon Health and Science University|No|Recruiting|October 2006|July 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|107|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 3, 2010|June 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694759||154714|
NCT00695331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUBH R96007|Efficacy and Safety Study of Titrated Oral Misoprostol Solution for Labor Augmentation|A Comparison of Titrated Oral Misoprostol Solution to Intravenous Oxytocin for Labor Augmentation: A Randomized Controlled Trial||China Medical University Hospital|Yes|Recruiting|February 2008|January 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|143|||Female|18 Years|45 Years|No|||July 2008|July 8, 2008|June 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00695331||154670|
NCT00696800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05787|A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)|A Phase III, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as Reference||Merck Sharp & Dohme Corp.|Yes|Completed|June 2006|January 2008|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1509|||Female|18 Years|36 Years|No|||July 2015|July 13, 2015|June 11, 2008|Yes|Yes||No|August 6, 2014|https://clinicaltrials.gov/show/NCT00696800||154561|
NCT00696553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080219|Nutrition and Resistance Training in Head and Neck Cancer|Randomized Trial of Specialized Nutrition Therapy (SNT) Versus SNT Plus Resistance Training (RT) in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation Therapy (CCR)|ELAF|Vanderbilt University|No|Completed|March 2006|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|21 Years|N/A|No|||July 2011|July 25, 2011|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00696553||154579|
NCT00684775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19497-2|Employment-Based Depot Naltrexone Clinical Trial II|||National Institute on Drug Abuse (NIDA)|Yes|Not yet recruiting|May 2008|||May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||May 2008|May 23, 2008|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684775||155476|
NCT00684788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19497-1|Employment-Based Depot Naltrexone Clinical Trial|Employment-Based Depot Naltrexone Clinical Trial||National Institute on Drug Abuse (NIDA)||Recruiting|May 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|80|||Both|18 Years|65 Years|No|||May 2008|May 23, 2008|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684788||155475|
NCT00693069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.E.2004-06-24A|Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function|Effect of Different Dosing Regimens of Clopidogrel Given Before Elective Percutaneous Coronary Intervention on Platelet Function||Hopital du Sacre-Coeur de Montreal|No|Completed|September 2004|April 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|90 Years|No|||June 2008|August 20, 2012|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00693069||154841|
NCT00685347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-312|Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects|A Dose Response Study of Levalbuterol and Racemic Albuterol HFA MDI in Pediatric Subjects With Asthma||Sunovion|No|Completed|January 2003|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|6 Years|11 Years|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685347||155432|
NCT00685035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0802M26441|Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings|Comparison of Sine Waveform High Frequency Chest Wall Oscillation Using Different Settings in Cystic Fibrosis||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|May 2008|October 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685035||155456|
NCT00685048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-108-2|Brief Therapies for Problem Gambling Substance Abusers|Brief Therapies for Problem Gambling Substance Abusers||University of Connecticut Health Center|No|Completed|July 2007|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|220|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685048||155455|
NCT00685061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#20020213|Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation|Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Cadaver Donor Renal Transplantation: A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy||University of Miami|Yes|Completed|November 2002|September 2005|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|16 Years|N/A|No|||May 2008|May 27, 2008|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685061||155454|
NCT00696748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U00006KO|The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men|A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men|NePlaM3|Russian Academy of Medical Sciences|No|Recruiting|October 2005|December 2010|Anticipated|January 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Male|35 Years|70 Years|No|||June 2008|June 11, 2008|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00696748||154565|
NCT00697034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-467|Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin|Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin||Wake Forest School of Medicine|No|Terminated|June 2006|December 2008|Actual|August 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|June 9, 2008||No|Lack of qualified and willing volunteers.|No||https://clinicaltrials.gov/show/NCT00697034||154543|
NCT00697047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1CA121125|Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up|Systems of Support to Increase Colon Cancer Screening and Follow-up|SOS|Group Health Cooperative|No|Active, not recruiting|July 2008|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|4||Anticipated|6200|||Both|50 Years|73 Years|No|||August 2015|August 10, 2015|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697047||154542|
NCT00697073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-III-002-E|Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|IONIA-E|Santhera Pharmaceuticals|Yes|Completed|July 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|8 Years|18 Years|No|||May 2013|May 24, 2013|June 11, 2008|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00697073||154540|
NCT00697645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tmstroke Hadassah|Use of Deep Transcranial Magnetic Stimulation After Stroke|Phase 2 Double Blind Randomized Clinical Trial of Deep Transcranial Magnetic Stimulation After Stroke|tmstroke|Hadassah Medical Organization|Yes|Not yet recruiting|March 2009|||December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||June 2008|February 8, 2009|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00697645||154496|
NCT00693992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00469|Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy|Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511) as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-small Cell Lung Cancer||National Cancer Institute (NCI)|Yes|Completed|June 2008|May 2015|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|N/A|No|||June 2015|February 5, 2016|June 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693992||154773|
NCT00694265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTU_CTS|Sonographic Follow-up of Patients With Carpal Tunnel Syndrome Undergoing Surgical or Conservative Treatment|Sonographic Follow-up of Patients With Carpal Tunnel Syndrome Undergoing Surgical or Conservative Treatment: Prospective Cohort Study.|CTS|University of Bern|No|Completed|January 2002|December 2003|Actual|June 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected CTS|August 2008|August 25, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694265||154752|
NCT00694798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-80/8230|Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder|Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium w (Mw) in BCG Refractory Superficial Transitional Cell Carcinoma|STCC|Cadila Pharnmaceuticals|Yes|Completed|October 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694798||154711|
NCT00693459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-07-06|Study of a New Circular Anal Dilator|Feasibility Study of a New Circular Anal Dilator for Transanal Hemorrhoidectomy||University Hospital Case Medical Center|No|Completed|May 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||January 2013|January 16, 2013|February 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00693459||154813|
NCT00693472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05145|Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145AM1)(COMPLETE)|Efficacy of SCH 420814 to Reduce the Frequency or Severity of Neuroleptic Induced Akathisia||Merck Sharp & Dohme Corp.|No|Completed|August 2007|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|46|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|May 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00693472||154812|
NCT00694811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG-1942|Effects of Re-Feeding Duration on Weight Maintenance After Weight Loss With Very-Low-Energy Diets (VLEDs)|Liquid Very-Low-Energy Diets (VLEDs) in Obesity Treatment. Effects of Re-Feeding Duration On Weight Maintenance, Eating Behaviour and Health-Related Quality of Life||Göteborg University|No|Completed|August 2004|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|60 Years|No|||June 2008|June 10, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00694811||154710|
NCT00694525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5611|Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia|Potential Modulatory Role of Osteoprotegerin in Bone Metabolism of Patients With 21-Hydroxylase Deficiency||Office of Rare Diseases (ORD)|No|Recruiting|April 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples With DNA|With participant's permission, 5 mL of blood will be stored for potential new blood markers      in the future.|Female|20 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Premenopausal women between the ages of 20 and 35 who have 21-OHD CAH or do not have        21-OHD CAH.|June 2009|June 1, 2009|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694525||154732|
NCT00694538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI070046|Efficacy of Interferential Laser Therapy in Shoulder Pain|Efficacy of Interferential Laser Therapy in Pain Reduction in Shoulder Musculoskeletal Pathologies.|PI070046|Hospital Universitario Ramon y Cajal|Yes|Completed|January 2008|November 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||November 2009|November 12, 2009|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694538||154731|
NCT00695344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVEROSTAT|Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant|Prospective and Randomized Study to Evaluate the Effect of Everolimus in the Clinical and Intra-Cardiac Ecography Progression of Heart Graft Vascular Illness.|EVEROSTAT|Fundacion Investigacion y Desarrollo|Yes|Active, not recruiting|January 2006|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695344||154669|
NCT00695357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RGR-DUM-2008/1|Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006|Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006|EPAGGELIA|AstraZeneca|No|Completed|April 2008|June 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|832|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care|April 2009|April 29, 2009|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695357||154668|
NCT00695370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0035|Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children|Hematopoietic Progenitor Cell Mobilization in Children With Malignancies: Evaluation of Pegfilgrastim at 300µg/kg in Hematological Steady State||University Hospital, Clermont-Ferrand||Terminated|January 2006|January 2008|Anticipated|December 2007|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|18 Years|No|||June 2008|June 12, 2008|June 9, 2008||No|Recruiting or enrolling participants has halted and will not resume|No||https://clinicaltrials.gov/show/NCT00695370||154667|
NCT00695669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111626|A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64|A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64.||GlaxoSmithKline|No|Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|312|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|June 10, 2008|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00695669||154644|
NCT00695071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT0300-108-USA|Study to Assess Blood Levels of Itraconazole During a Two-Week Period|Assessment of the Steady State Pharmacokinetics of Itraconazole and Hydroxy-Itraconazole in Healthy Subjects After Administration of a New Itraconazole 200 mg Film Coated Tablet Once Daily for Fourteen Days in Fed Condition||GlaxoSmithKline|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 23, 2011|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695071||154690|
NCT00695084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMSTrial|Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)|Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis||National Multiple Sclerosis Society|No|Completed|March 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|21 Years|80 Years|No|||June 2008|June 10, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695084||154689|
NCT00696514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw 6130.0031|Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People|Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People|B-PROOF|Wageningen University|Yes|Active, not recruiting|September 2008|March 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 24, 2011|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696514||154582|
NCT00696527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OFR-DUM-2007/1|National Survey on Infiltrative Breast Cancer|National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer|CSI|AstraZeneca|No|Completed|June 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Female|18 Years|N/A|No|Probability Sample|First ten consecutive women with infiltrative breast cancer seen by oncologists, and        fulfilling eligibility criteria.|December 2010|December 9, 2010|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00696527||154581|
NCT00697125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/005|Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants|Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine With Different Adjuvants in Healthy Adult Volunteers||GlaxoSmithKline||Completed|June 1993|July 1994|Actual|July 1994|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 11, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697125||154536|
NCT00685074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MES-III|Computer-based Brief Intervention for Perinatal Substance Abuse|Computer-based Brief Intervention for Perinatal Drug, Alcohol, and Tobacco Abuse||Wayne State University|Yes|Completed|September 2007|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685074||155453|
NCT00685334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4696 (MH069868-01)|Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa|Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa||New York State Psychiatric Institute|Yes|Completed|November 2003|September 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|16 Years|N/A|No|||September 2013|September 25, 2013|May 23, 2008|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00685334||155433|
NCT00685607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOPDIR4003|Study to Determine the Best Way to Measure How Quickly the Drug Can Give Relief From Sudden Diarrhea|A Placebo-Controlled, Double-Blind, Randomized Pilot Study to Evaluate the Appropriateness of Multiple Endpoints in Measuring the Onset of Clinical Efficacy of Loperamide-Simethicone Caplets in the Treatment of Acute Non-specific Diarrhea||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||October 2011|October 4, 2011|May 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00685607||155412|
NCT00685906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00042|AZD6140 Oral Contraceptive Interaction Study|A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers||AstraZeneca|No|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2010|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00685906||155389|
NCT00686556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS024|Total Marrow Irradiation for Refractory Acute Leukemia|Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord BloodTransplantation In Patients With Refractory Acute Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|August 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|20|||Both|N/A|55 Years|No|||January 2016|January 21, 2016|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00686556||155340|
NCT00696488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000156|Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population|Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population||Wake Forest School of Medicine|No|Completed|April 2007|October 2008|Actual|August 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|N/A|No|||February 2009|February 12, 2009|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696488||154584|
NCT00696787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A4-2003|A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of DVS SR in Adult Female Outpatients With Fibromyalgia Syndrome||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|June 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|125|||Female|18 Years|N/A|No|||February 2013|February 20, 2013|June 11, 2008|Yes|Yes||No|January 29, 2010|https://clinicaltrials.gov/show/NCT00696787||154562|
NCT00696761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L9990|The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients|The Long Term Effects of Alfuzosin(Xatral XL) in LUTS/BPH Patients: Evaluation of Voiding and Storage Function According to Bladder Outlet Obstruction Grade and Bladder Contractility||Asan Medical Center|No|Completed|May 2006|August 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|232|||Male|50 Years|N/A|No|||January 2014|January 15, 2014|June 11, 2008||No||No|July 22, 2013|https://clinicaltrials.gov/show/NCT00696761||154564|Patients were not divided into three groups according to the ICS nomogram (obstructed [BOOI <40], equivocally obstructed (20 <BOOI <40), and unobstructed [BOOI <20]).
NCT00693485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-030D|Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy|||Allergan|Yes|Completed|September 2008|August 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|June 5, 2008|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00693485||154811|
NCT00694005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0185|Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch|Phase IV Study of the Choice of Optimal Strategy for Bifurcation Lesions With Normal Side Branch|CROSS|CardioVascular Research Foundation, Korea|Yes|Completed|January 2008|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|504|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694005||154772|
NCT00694278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMC95|Clinical Evaluation of the Effect of Duodenal-Jejunal Bypass on Type 2 Diabetes|Clinical Evaluation of the Effect of Duodenal-Jejunal Bypass on Type 2 Diabetes in Adults||Ferzli, George S., M.D. F.A.C.S.||Recruiting|June 2008|||||Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|15|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|primary care office|June 2008|June 5, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694278||154751|
NCT00694291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC 07-038|Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer|Phase II Double Blind Randomized Placebo Controlled Study of Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer||Fox Chase Cancer Center|Yes|Withdrawn|June 2008|||June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||March 2015|March 4, 2015|June 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694291||154750|
NCT00694304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11984B|Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults|A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|May 2008|April 2010|Actual|March 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|535|||Both|18 Years|75 Years|No|||February 2014|February 17, 2014|June 6, 2008||No||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00694304||154749|
NCT00694317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZALE-02|Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions.||Roxane Laboratories|No|Completed|February 2004|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 9, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694317||154748|
NCT00694551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15262|PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment|Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|October 2008|August 2016|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Male|18 Years|N/A|No|||January 2016|January 12, 2016|June 4, 2008|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00694551||154730|
NCT00694824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAS-INT-02|Vascular Calcification's Risk Factors in Haemodialysis Patients|Traditional and Not Traditional Risk Factors in Appearance and Progression of Vascular Calcification in Haemodialysis Patients.||St. Orsola Hospital|No|Completed|November 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|253|Samples Without DNA|For each patient a blood sample was drawn to check the basal values of hemoglobin,      hematocrit, folates, vitamin B12, C reactive protein, PTH, calcium, phosphorus, albumin,      alkaline phosphatase, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,      uric acid, fibrinogen, homocysteine. To better understand the mineral methabolism TGFb1,      fetuin A, OPG, FGF 23, OPN and MGP will be checked. The values for each patient will be the      median of 4 determinations, each sample was drawn before the midweek dialysis session.|Both|18 Years|80 Years|No|Probability Sample|253 chronic hemodialysis patients were selected among those undergoing hemodialysis at the        Nephrology Dialysis and Renal Transplantation Unit, S.Orsola University Hospital, Bologna,        Italy between April 2003 and March 2008. All the patients have started dialysis from at        least 6 months at the beginning of the study.|June 2008|June 10, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00694824||154709|
NCT00695110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-08005|Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men|Phase II, Repeat Dose, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men||Clarus Therapeutics, Inc.|No|Completed|June 2008|August 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Male|18 Years|68 Years|No|||August 2010|August 23, 2010|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695110||154687|
NCT00695383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G 0523.06|Early Exercise Training in Critically Ill Patients|Early Exercise in Critically Ill Patients Enhances Short-Term Functional Recovery||Katholieke Universiteit Leuven|No|Completed|December 2005|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Both|N/A|N/A|No|||June 2008|June 10, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695383||154666|
NCT00695994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRG-PG02/26/06|The Effect of Docetaxel or Gemcitabine-based Chemotherapy in East Asian and Caucasian Patients|The Effect of Pharmacogenetics on Treatment Toxicities and Outcomes in East Asian and Caucasian Patients Undergoing Docetaxel or Gemcitabine-based Chemotherapy||National University Hospital, Singapore||Completed|October 2006|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695994||154621|
NCT00696228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071325|High Fat Diet: Oxidative and Cardiovascular Effects|High Fat Diet: Oxidative Effects and Cardiovascular Risk|AFN|Vanderbilt University|No|Completed|August 2008|December 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|144|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696228||154603|
NCT00696241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-491-008|Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension||Takeda|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1275|||Both|18 Years|N/A|No|||July 2011|July 27, 2011|June 10, 2008|Yes|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00696241||154602|
NCT00696254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-2008|Impact of General Anaesthetics on Excitability of the Peripheral Sensory Nerve|||University of Zurich||Completed|March 2008|December 2008||||Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|18 Years|75 Years|No|Non-Probability Sample|Inclusion criteria: German speaking patients scheduled for surgery under general        anaesthesia|June 2009|June 2, 2009|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00696254||154601|
NCT00696540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDP-CT1-08|Hypertonic Saline for Outpatient Bronchiolitis|Safety and Efficacy of Hypertonic Vrs. Normal Saline as Diluent of Salbutamol to Reduce Respiratory Distress in Outpatients With the Clinical Diagnosis of Bronchiolitis During the RSV Epidemic.|Hypertonic|University Diego Portales|Yes|Recruiting|June 2008|October 2008|Anticipated|September 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|1 Month|24 Months|No|||June 2008|June 9, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696540||154580|
NCT00685568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-090|Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis|Phase I Pilot Toxicity/Methods Validation Study of Celecoxib in Genotype-Positive Children With Familial Adenomatous Polyposis||M.D. Anderson Cancer Center|Yes|Completed|December 2002|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|22|||Both|10 Years|14 Years|No|||November 2012|November 16, 2012|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685568||155415|
NCT00685919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101499|Peripheral Dopamine in Postural Tachycardia Syndrome|Kidney Dopamine Effects on Urinary Sodium Excretion in Postural Tachycardia Syndrome||Vanderbilt University|No|Active, not recruiting|May 2008|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685919||155388|
NCT00686244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKZ01FD0609|IT-Based Training in Metabolic Syndrome|Effect of Personal and IT Based Training to Performance, Metabolic Profil and Quality of Life by Patients With Metabolic Syndrome|SPRINT|Technische Universität München|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|125|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 11, 2009|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00686244||155364|
NCT00686569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20070062|Mediastinal Microdialysis in Patients With Oesophageal or Cardia Cancer Treated by Resection|Mediastinal Microdialysis in Early Diagnosis of Anastomotic Leakage After Resection for Esophageal Cancer: Preliminary Results||Odense University Hospital|No|Completed|April 2007|February 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoin oesophageal resection for cancer|August 2014|August 3, 2014|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686569||155339|
NCT00697086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4508|European Study of Dronedarone in Atrial Fibrillation|Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO)|ERATO|Sanofi||Completed|August 2002|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|174|||Both|21 Years|N/A|No|||July 2009|July 28, 2009|June 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697086||154539|
NCT00697359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-ABL-R-001|Implantable Loop Recorder Versus Conventional Ambulatory Monitoring in Detecting Atrial Fibrillation After Pulmonary Vein Isolation|An Observational Study to Assess the Efficacy of Continuous Subcutaneous Arrhythmia Monitoring Versus Conventional Ambulatory ECG-monitoring in Detecting Atrial Fibrillation in Patients After Pulmonary Vein Isolation||Odense University Hospital|No|Active, not recruiting|June 2008|January 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|30 Years|70 Years|No|||November 2013|November 28, 2013|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697359||154518|
NCT00697372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P648|SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|SEA-SIDE|Catholic University of the Sacred Heart|No|Completed|September 2007|April 2010|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|85 Years|No|||June 2010|June 14, 2010|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697372||154517|
NCT00693745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0405|Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF|NGAL Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF|GALLANT|Biosite|No|Completed|September 2008|July 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|231|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department/hospital with symptoms of new or        decompensated heart failure and who will be treated with at least one dose of diuretic.|October 2010|October 21, 2010|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693745||154791|
NCT00693771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_02756|Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin|A Prospective Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin|OPTIMIZATION|Sanofi|No|Completed|April 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|313|||Both|35 Years|75 Years|No|||January 2011|January 24, 2011|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693771||154789|
NCT00684229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-933|Regional Anesthesia in Colon Rectal Surgery|Regional Anesthesia in Patients Undergoing Colon-Rectal Surgery||Outcomes Research Consortium|Yes|Recruiting|December 2007|December 2022|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|2500|||Both|18 Years|85 Years|No|||May 2012|May 8, 2012|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684229||155518|
NCT00684879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908143|Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia|Illness Perceptions and the Health Belief Model: Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia||National Institutes of Health Clinical Center (CC)||Completed|May 2008|January 2016||||N/A|Observational|Time Perspective: Prospective|||Anticipated|320|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00684879||155468|
NCT00686413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00018|Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects|An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (Non Nicotine Users)|PET|AstraZeneca|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Male|20 Years|80 Years|Accepts Healthy Volunteers|||September 2008|December 8, 2010|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686413||155351|
NCT00687102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0132|Cognition in the Study of Tamoxifen and Raloxifene|Effects of Selective Estrogen Receptor Modulators on Cognitive Aging: Cognition in the Study of Tamoxifen and Raloxifene|Co-STAR|Wake Forest School of Medicine|Yes|Completed|October 2001|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1498|||Female|65 Years|N/A|Accepts Healthy Volunteers|||May 2008|August 3, 2011|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687102||155298|
NCT00686699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04628|Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Subjects With Schizophrenia (Study P04628)(TERMINATED)|A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders||Merck Sharp & Dohme Corp.|No|Terminated|July 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||August 2015|August 4, 2015|May 27, 2008|Yes|Yes|Study terminated after 9 subjects completed due to lack of enrollment for 6 months|No||https://clinicaltrials.gov/show/NCT00686699||155329|
NCT00686712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-02-524|Insulin Glargine at Bedtime or in AM Versus NPH|The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy||Charles Drew University of Medicine and Science|Yes|Completed|February 2003|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|75 Years|No|||March 2013|March 25, 2013|May 27, 2008|Yes|Yes||No|September 15, 2010|https://clinicaltrials.gov/show/NCT00686712||155328|Early termination leading to smaller than anticipated enrollment.
NCT00686725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05572|Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)|A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)||Merck Sharp & Dohme Corp.|No|Completed|June 2008|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|70 Years|No|||December 2015|December 11, 2015|May 27, 2008|Yes|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT00686725||155327|
NCT00690274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BF2.649|Study to Demonstrate Cognitive Enhancing Effects of BF2.649|A Randomized, Double Blind, Placebo Controlled, Study to Demonstrate the Cognitive Enhancing Effects of BF2.649 in People With Schizophrenia and Schizoaffective Disorder||University of Texas Southwestern Medical Center|Yes|Completed|June 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|55 Years|No|||June 2010|August 15, 2012|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690274||155056|
NCT00690287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0280C00014|A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients|A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D and Q.I.D Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study||AstraZeneca|No|Completed|February 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|24|||Both|30 Years|65 Years|No|||January 2012|January 10, 2012|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690287||155055|
NCT00690300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I1-GOA-1|Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer|Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer||University of Ulm|Yes|Recruiting|January 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2010|March 2, 2010|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690300||155054|
NCT00690248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2007/5|Depressive Symptoms in Acute Manic Episode|Prevalence of Depressive Symptoms in Manic Episodes of Bipolar Patients: an Observational Study|MM1|AstraZeneca|No|Completed|November 2007|December 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|65 Years|No|Non-Probability Sample|bipolar patients admitted to a psychiatric Unit due to an acute mania episode.|December 2010|December 7, 2010|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690248||155058|
NCT00690560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589530|Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma|International Phase II Study Evaluating the Association of CHOP-rituximab With Consolidation by Early Ibritumomab Tiuxetan-Y90 in Patients Aged 65 to 80 Years With CD20+ Large Cell Malignant Lymphoma and no Prior Therapy||Centre Antoine Lacassagne||Completed|May 2007|October 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|65 Years|80 Years|No|||February 2015|February 8, 2015|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690560||155034|
NCT00690573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-240|Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis|A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis||Abbott|No|Completed|May 2008|September 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|4 Years|17 Years|No|||September 2012|September 5, 2012|June 2, 2008||No||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00690573||155033|
NCT00691184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-060-1001|Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis|A Double-Blind, Randomized, Parallel Design Study To Assess the Safety and Pharmacokinetics of Terbinafine Hydrogen Cloride (HCl) Nail Lacquer Applied for 28 Days in Patients With Onychomycosis||NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)||Completed|February 2005|December 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|70 Years|No|||June 2008|June 3, 2008|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691184||154986|
NCT00691197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9689-002|Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear|Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear||Allergan|No|Completed|March 2008|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|246|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 26, 2015|March 4, 2008|No|Yes||No|November 6, 2009|https://clinicaltrials.gov/show/NCT00691197||154985|
NCT00686231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56438-31921|Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter|The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter||University of California, San Francisco|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|19|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 17, 2013|May 19, 2008|No|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00686231||155365|a
NCT00686530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011050|Comparison of Abnormal Cortical Development in Brain Malformations on Postmortem Imaging With Autopsy|Comparison of Abnormal Cortical Development in Brain Malformations on Postmortem Imaging With Autopsy||The Hospital for Sick Children|No|Withdrawn|August 2007|February 2010|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Macroscopic examination of the fetus will be performed initially follwed by organ removal      for tissue fixation for a period of two weeks.|Both|N/A|N/A|No|Non-Probability Sample|40 fetal post mortem brains, with suspected diagnosis of brain malformation|May 2008|December 2, 2013|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00686530||155342|
NCT00686543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05115|Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)|A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection||Merck Sharp & Dohme Corp.|No|Completed|December 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|75|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|May 27, 2008|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00686543||155341|
NCT00686881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04773|Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)|A Clinical Study of SCH 54031 as Monotherapy in IFN-treated Patients With Chronic Hepatitis C||Merck Sharp & Dohme Corp.|Yes|Terminated|December 2006|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|20 Years|N/A|No|||September 2015|September 4, 2015|May 27, 2008|No|Yes|This study was terminated due to low enrollment|No|February 3, 2012|https://clinicaltrials.gov/show/NCT00686881||155315|This study was prematurely discontinued because of low enrollment.
NCT00686894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04440|Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)|Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab|EUSpA|Merck Sharp & Dohme Corp.|No|Terminated|January 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 27, 2008|No|Yes|Poor Enrollment|No|November 24, 2009|https://clinicaltrials.gov/show/NCT00686894||155314|
NCT00687960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSU-HML-RSt2|Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults|Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults||Kansas State University|No|Completed|November 2006|December 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|13|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2008|May 28, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00687960||155234|
NCT00688220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#887|Effect of Celliant Materials on Pain and Blood Oxygenation in Subjects With Chronic Elbow and Wrist Pain|Effect of Celliant Materials on Pain and Blood Oxygenation in Subjects With Chronic Elbow and Wrist Pain||Southern California Institute for Research and Education|No|Terminated|July 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Participating subjects will be recruited who have chronic elbow or wrist pain from        epidondylitis, carpal tunnel syndrom or other chronic disease - 40 with chronic elbow and        40 will chronic wrist pain.|June 2010|June 2, 2010|May 28, 2008||No|PI closed study due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT00688220||155214|
NCT00688506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 292/07|Combined Sono-electro-magnetic Therapy for Treatment of Refractory Chronic Pelvic Pain Syndrome|Combined Sono-electro-magnetic Therapy for Treatment of Refractory Chronic Pelvic Pain Syndrome: A Prospective, Randomized, Double-blind, Placebo-controlled Trial||University Hospital Inselspital, Berne|No|Completed|November 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|N/A|No|||July 2012|July 2, 2012|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688506||155192|
NCT00688519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114741|Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies|A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, Versus Vehicle in Subjects With Plaque-type Psoriasis||GlaxoSmithKline|No|Completed|March 2008|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|336|||Both|12 Years|N/A|No|||April 2012|April 12, 2012|May 29, 2008|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00688519||155191|
NCT00684606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5164-OM-CTIL|Transcervical Foley Catheter With or Without Oxytocin for Induction of Labor|Transcervical Foley Catheter With or Without IV Oxytocin Infusion for Induction of Labor: a Randomized Controlled Trial||Sheba Medical Center|No|Recruiting|May 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 18, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684606||155489|
NCT00684619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LN_GMALLE_2004_55|506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)|Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7)||Johann Wolfgang Goethe University Hospitals|No|Completed|June 2003|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||May 2008|August 20, 2010|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00684619||155488|
NCT00683956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05062008-1141|Evaluation of a Closed-Loop Control System for Administering Patient-Specific Anesthesia|Evaluation of a Closed-Loop Control System for Patient-Specific Induction and Maintenance of Propofol Hypnosis||Stanford University||Completed|May 2008|September 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|1||Anticipated|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00683956||155539|
NCT00684554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5600|Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial|Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial of At-Home Versus In-Office Buprenorphine Induction||New York State Psychiatric Institute|No|Completed|December 2007|April 2010|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|May 22, 2008||No||No|May 19, 2015|https://clinicaltrials.gov/show/NCT00684554||155493|The primary pilot study limitations are sample size and treatment setting, which restricts statistical comparison of outcomes and generalizability.
NCT00684567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04661|Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)|SCH 52365 Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme||Merck Sharp & Dohme Corp.|Yes|Completed|September 2005|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||January 2015|January 19, 2015|May 22, 2008|No|Yes||No|October 31, 2008|https://clinicaltrials.gov/show/NCT00684567||155492|
NCT00685165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04090|Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Primidone 50 mg, Compared to an Equivalent Dose of Primidone (Mysoline®) in Healthy Adult Subjects||Mutual Pharmaceutical Company, Inc.|No|Completed|May 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|December 16, 2009|May 24, 2008|No|Yes||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00685165||155446|
NCT00685178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA021808|Clinical Trial of Topiramate for Cocaine Addiction|Clinical Trial of Topiramate for Cocaine Addiction||Johns Hopkins University|Yes|Completed|February 2007|September 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|250|||Both|18 Years|55 Years|No|||June 2014|June 13, 2014|May 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00685178||155445|
NCT00685464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHGentofte|Intravenous Versus Intracoronary Use of Abciximab|Intravenous vs. Intracoronary Use of Abciximab||University Hospital, Gentofte, Copenhagen|Yes|Completed|January 2006|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|90 Years|No|||February 2009|August 9, 2011|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685464||155423|
NCT00687115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908140|Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting|Predicting Adaptive Thermogenesis||National Institutes of Health Clinical Center (CC)||Recruiting|May 2008|March 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00687115||155297|
NCT00687128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-10-788|Exercise Dose-Response on Features of the Metabolic Syndrome|Dose-Response Effects of Aerobic Exercise on Insulin Sensitivity and the Metabolic Syndrome||Charles Drew University of Medicine and Science|Yes|Completed|October 2004|April 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|60 Years|No|||February 2012|February 24, 2012|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687128||155296|
NCT00687492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAP-DUM-2008/1|Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia|Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia|CEPHEUS|AstraZeneca|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8000|||Both|18 Years|N/A|No|Probability Sample|Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose        change for a minimum of 6 weeks.|December 2010|December 1, 2010|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687492||155268|
NCT00687505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP1039-001|Safety Study of FP-1039 To Treat Cancer|A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors||Five Prime Therapeutics, Inc.|No|Completed|July 2008|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687505||155267|
NCT00690313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vig508|Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections|To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection||Illinois Retina Associates||Not yet recruiting|July 2008|September 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|No|||May 2008|June 3, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00690313||155053|
NCT00690586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nsdk07-09|Fluid Balance, Hormones and Urine Proteomics in Nephrotic Syndrome in Childhood|Fluid Balance, Hormones and Urine Proteomics in Nephrotic Syndrome in Childhood||Aarhus University Hospital|No|Completed|December 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|Samples With DNA|Whole blood samples for hormone analyzes Urine samples for urine protomis, AQP II and ENaC|Both|1 Year|15 Years|No|Probability Sample|Patients with nephrotic syndrome will be included from 5 pediatric centrs in Denmark.|June 2008|June 7, 2010|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690586||155032|
NCT00690599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-125|Socioeconomic Profile and Patient Satisfaction Assessment|Socioeconomic Profile and Patient Satisfaction Assessment in an Academic Dental General Clinic|Satisfaction|Fortaleza University|Yes|Completed|April 2006|June 2006|Actual|May 2006|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|80|||Both|18 Years|70 Years|No|Probability Sample|Patients assisted in the general dental practice clinic at UNIFOR Ceará - Brazil.|May 2008|June 3, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00690599||155031|
NCT00690872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577971|Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer|Phase II Trial Evaluating Efficacy of a Strategy Employing Combination Gemcitabine and Carboplatin Chemotherapy Followed by EBV-Specific Cytotoxic T-Lymphocytes in Patients With Metastatic or Locally Recurrent EBV-Positive Nasopharyngeal Carcinoma||National Cancer Institute (NCI)||Recruiting|July 2008|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|21 Years|N/A|No|||June 2009|June 26, 2009|June 4, 2008||||No||https://clinicaltrials.gov/show/NCT00690872||155010|
NCT00681343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#20010704|Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation|Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy||University of Miami|Yes|Completed|September 2002|October 2007|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|16 Years|N/A|No|||May 2008|May 23, 2008|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681343||155735|
NCT00681356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-01P|Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement|A Phase 3, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, Safety, and Pharmacokinetics of 4975 in Patients Undergoing Primary Unilateral Total Knee Arthroplasty||Anesiva, Inc.|Yes|Completed|September 2007|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|214|||Both|18 Years|85 Years|No|||May 2009|May 1, 2009|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681356||155734|
NCT00681369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OFR-FAS-2007/1|Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France|Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France||AstraZeneca|No|Completed|May 2007|June 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|217|||Female|N/A|N/A|No|Probability Sample|Hospital sample|January 2011|January 21, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00681369||155733|
NCT00686907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 1029|Blind Adult Melatonin Treatment Study|Melatonin for Circadian Sleep Disorders in the Blind||National Eye Institute (NEI)|Yes|Active, not recruiting|March 2007|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|55 Years|No|||October 2012|October 23, 2012|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686907||155313|
NCT00686920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFHE3002|Safety Study for Patients With a History of Hepatic Encephalopathy|||Valeant Pharmaceuticals International, Inc.|No|Completed|March 2007|||December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|No|||February 2011|February 2, 2011|May 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00686920||155312|
NCT00687310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00018|Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial|Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial||AstraZeneca|No|Completed|December 2005|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|160|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|May 28, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00687310||155282|
NCT00687323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05052|Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)|Phase II Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Subjects Unsuitable for Standard Induction Therapy Exhibiting Low MGMT Expression|TALL|Merck Sharp & Dohme Corp.|Yes|Completed|July 2007|December 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|May 27, 2008|No|Yes||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00687323||155281|
NCT00687726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056/2547|Simple Home-Based Exercise for Knee Osteoarthritis|The Relationship of Knee Joint Osteoarthritis to Balance and Walking Ability.||Srinakharinwirot University|No|Completed|May 2006|February 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|50 Years|80 Years|No|||May 2008|May 28, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687726||155252|
NCT00687973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489AFR02|Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg|Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg|EXPLOR|Novartis|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|393|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|March 20, 2008||No||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00687973||155233|
NCT00687986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSEL|Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer|A Randomized Clinical Trial of Surgery Versus Radiosurgery (Stereotactic Radiotherapy) in Patients With Stage IA NSCLC Who Are Fit to Undergo Primary Resection|ROSEL|VU University Medical Center|Yes|Terminated|October 2008|December 2015|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|960|||Both|18 Years|N/A|No|||January 2011|June 2, 2015|May 28, 2008||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00687986||155232|
NCT00688233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234567|Effect of the Innovated Seifi's Functional Appliance on Skeletal and Dentoalveolar Changes of Class II/ 1, Deep Bite|Phase 1 Effect of the Innovated Seifi's Functional Appliance on the Skeletal and Dentoalveolar Changes of Class II/Division 1, Deep Bite Cases|Seifi-Fx|hahid Beheshti University of Medical Sciences||Recruiting|December 2007|May 2009|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||May 2008|May 28, 2008|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00688233||155213|
NCT00688532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6874C00008|Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not|A Pharmacoepidemiological Study on the Association Between Bicalutamide Treated Prostate Cancer and Risk of Coronary Heart Disease (CHD) and Heart Failure (HF) in the General Practice Research Database (GPRD)||AstraZeneca|No|Completed|December 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|5103|||Male|50 Years|84 Years|No|Probability Sample|GPRD containing computerized information entered by general practitioners in the UK|January 2013|January 30, 2013|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688532||155190|
NCT00685516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000596162|Green Tea or Water in Treating Patients With Prostate Cancer Undergoing Surgery|A Phase II Randomized, Open-Label, Two-Arm Study of Green Tea and a Water Control in Men Scheduled for Prostatectomy||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|September 2007|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Male|40 Years|75 Years|No|||September 2015|September 3, 2015|May 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685516||155419|
NCT00683969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX17798|A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis||Hoffmann-La Roche||Completed|August 2004|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|80 Years|No|||May 2008|May 23, 2008|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683969||155538|
NCT00683982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT261179|Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to Rotavirus|Nitazoxanide vs Probiotics in the Treatment of Acute Rotavirus Diarrhea in Children: A Randomized Single Blind Controlled Trial in Bolivian Children||Centro Pediatrico Albina de Patino|No|Completed|August 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|75|||Both|N/A|24 Months|No|||May 2008|May 23, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00683982||155537|
NCT00685191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITHACA|HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain|HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain||Germans Trias i Pujol Hospital|No|Completed|June 2008|October 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2009|November 6, 2009|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685191||155444|
NCT00685204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL139204|An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma|A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma|TL139|Taxolog Inc.|Yes|Recruiting|March 2008|||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||May 2008|May 22, 2008|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685204||155443|
NCT00685490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KK-R-207-430R1|Vitrectomy for Branch Retinal Vein Occlusion|Vitrectomy for Persistent Macular Edema in Branch Retinal Vein Occlusion||Shinjo Ophthalmologic Institute|Yes|Completed|July 1995|November 2006|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|70|||Both|45 Years|86 Years|No|Probability Sample|70 consecutive patients who underwent PPV, with and without OLM peeling, for persistent        macular edema associted with BRVO|May 2008|May 23, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685490||155421|
NCT00685503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080146|Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization (MACTEL 1)||National Institutes of Health Clinical Center (CC)||Completed|May 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||April 2011|September 26, 2015|May 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00685503||155420|
NCT00686426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMI-993|Role of Dairy Products in Weight Maintenance|Role of Dairy Products in Weight Maintenance: Prevention of Weight Regain Following Weight Loss||University of Tennessee|No|Completed|November 2003|July 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|338|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 28, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686426||155350|
NCT00685477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCK-2008|Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying|Dose Response of Intravenous Sincalide (CCK-8) for Gallbladder Emptying||Temple University|No|Recruiting|May 2008|||May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685477||155422|
NCT00686751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223-04|Immune Effects of Vitamin D in Hemodialysis Patients|Immunomodulatory Effects of Vitamin D in Chronic Hemodialysis Patients||Renal Research Institute|Yes|Completed|December 2004|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|75 Years|No|||May 2009|May 12, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686751||155325|
NCT00687141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0190C00006|Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects|A Phase I, Randomized, Double-blind (with-in Panel), Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Healthy Elderly Volunteers After Oral Multiple Ascending Doses of AZD0328||AstraZeneca|Yes|Completed|November 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|112|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||July 2008|December 8, 2010|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687141||155295|
NCT00687154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-127|Observational Study of DME Following Scatter Laser Photocoagulation|An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation|PRP|Diabetic Retinopathy Clinical Research Network|Yes|Completed|September 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|155|||Both|18 Years|N/A|No|||March 2011|March 18, 2011|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687154||155294|
NCT00690326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physical activity RCT|Behavioral Change Communication (BCC) to Promote Physical Activity Among Females With Type 2 Diabetes Mellitus Attending Diabetic Clinic|Behavioral Change Communication to Promote Physical Activity Among Females With Type 2 Diabetes Mellitus Attending Diabetic Clinic.|BCC|Thiruvananthapuram Medical College|Yes|Completed|May 2006|October 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|86|||Female|30 Years|65 Years|No|||June 2008|June 3, 2008|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690326||155052|
NCT00690612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2451C00006|Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)|An Open-label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: a Long Term Study|HIP|AstraZeneca|Yes|Completed|September 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|1 Year|10 Years|No|||July 2011|July 7, 2011|June 2, 2008|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00690612||155030|
NCT00690885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07HUCO01|Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis|Evaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF)||Amarillo Biosciences, Inc.|No|Terminated|June 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|40 Years|N/A|No|||April 2012|April 20, 2012|June 3, 2008|Yes|Yes|Insufficient patient accrual|No||https://clinicaltrials.gov/show/NCT00690885||155009|
NCT00681655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O'CONNOR_AA007611-18|GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)|GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)|GPRA|Indiana University|Yes|Active, not recruiting|May 2008|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|141|||Both|21 Years|27 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681655||155711|
NCT00682006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|683-Ped/ERC-06|Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan|Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan: A Community-based Randomized Control Trial|Chlorhexidine|Aga Khan University|No|Completed|January 2008|December 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|9800|||Both|N/A|28 Days|No|||July 2009|July 7, 2011|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00682006||155684|
NCT00687349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31466-G|Improving Clinician Communication Skills (ICCS)|Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses|ICCS|University of Washington|Yes|Completed|April 2007|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|6086|||Both|18 Years|N/A|No|||September 2014|September 13, 2014|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687349||155279|
NCT00687362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04528|A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)|A Multicenter, Multinational, Open Label Study on the Efficacy and Safety of Infliximab Monotherapy in Moderate-to-severe Chronic Plaque Psoriasis in Middle Eastern Population||Merck Sharp & Dohme Corp.|No|Completed|May 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|May 27, 2008|No|Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00687362||155278|
NCT00687713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS Bupropion Meth 0001|Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence|Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence||National Institute on Drug Abuse (NIDA)|Yes|Completed|May 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||May 2011|June 29, 2015|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00687713||155253|
NCT00687947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHM-CGRP-MA-2008|Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)|CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls|CGRP-2008|Danish Headache Center|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2009|July 31, 2009|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687947||155235|
NCT00687752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27052008|Sonographic Assessment of Fetal Deglutition Associated With Hydramnion:Its Absence is Indicative of Central Nervous System (CNS) Pathology|Sonographic Assessment of Fetal Deglutition Associated With Hydramnion:Its Absence is Indicative of CNS Pathology? a Report on Two Cases.|FD|Hippocration General Hospital|Yes|Enrolling by invitation|May 2007|May 2009|Anticipated|April 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|310|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|May 2008|May 30, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687752||155250|
NCT00687999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-940055|NIDDM and IR in Combination Therapy for CHC|Non-insulin-dependent Diabetes Mellitus and Insulin Resistance in Chronic Hepatitis C Patients Treated With Combination Therapy With Pegylated Interferon and Ribavirin in Taiwan||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|December 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|18 Years|70 Years|No|||May 2008|August 3, 2009|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687999||155231|
NCT00688246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP3B|Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3|The Influence of Five Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer||Canadian Cancer Trials Group|Yes|Completed|January 2008|January 2013|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|238|Samples With DNA|Serum|Female|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Eligible women consenting to be randomized to the core MAP.3 trial will be approached for        participation in this companion study. They must have an acceptable quality BMD scan by        DEXA taken within 12 months prior to randomization to MAP.3. A BMD T-score > -2.0 SD (i.e.        2.0 standard deviations below the average peak BMD of a young adult woman) has been        established as the study population cut-off because postmenopausal women who have BMD        T-scores as low as or lower than - 2.0 SD are currently recommended to consider        pharmacological therapies for their bones|July 2012|November 11, 2013|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688246||155212|
NCT00685230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-02/03|Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients|Prospective, Randomized, Double-Blind, Controlled Study of Alacramyn® vs. Placebo in Pediatric Patients With Systemic Signs of Scorpion Sting Envenomation||Instituto Bioclon S.A. de C.V.|No|Completed|May 2004|October 2005|Actual|August 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|6 Months|18 Years|No|||June 2011|June 1, 2011|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685230||155441|
NCT00684242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0750|Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain|A Pilot Clinical Trial of Lenalidomide (Revlimid®) for the Treatment of Refractory Cancer Pain||M.D. Anderson Cancer Center|No|Terminated|May 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|May 22, 2008|No|Yes|Low accrual.|No|December 20, 2012|https://clinicaltrials.gov/show/NCT00684242||155517|
NCT00684255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1324|Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)|Reduced Intensity Conditioning And Allogeneic Stem Cell Transplantation in Patients With Medically Refractory Systemic Lupus Erythematosus and Medically Refractory Systemic Sclerosis (SSc)||New York Medical College|Yes|Terminated|August 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|7 Years|50 Years|No|||February 2014|February 6, 2014|May 22, 2008|No|Yes|inactive|No|December 22, 2008|https://clinicaltrials.gov/show/NCT00684255||155516|Study closed due to low accrual. Did not meet enrollment goals.
NCT00686439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 06-087|Adalimumab for Inflammatory Osteoarthritis|HUM 06-087: Proof of Concept Study : Adalimumab for the Treatment of Osteoarthritis||University of Alberta|No|Completed|June 2008|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|N/A|No|||June 2012|June 12, 2012|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00686439||155349|
NCT00686062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8937-16337|Evaluation of a Decision Assisting Tool for Prenatal Testing|Adaptation and Implementation of a Prenatal Genetic Testing Decision-Assisting Tool for Clinical Use||University of California, San Francisco|No|Completed|April 2001|April 2004|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2|||494|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 28, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686062||155377|
NCT00686075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP178|A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants|A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-old Children and in 2 Month-old Infants||MedImmune LLC|No|Completed|June 2008|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|1338|||Both|2 Months|23 Months|Accepts Healthy Volunteers|||September 2014|September 22, 2014|May 23, 2008|No|Yes||No|September 22, 2014|https://clinicaltrials.gov/show/NCT00686075||155376|
NCT00691808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX6171.1-201-AAMI|Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment|A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI)||Lexicon Pharmaceuticals|No|Completed|February 2008|||October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|103|||Both|60 Years|80 Years|No|||February 2010|February 17, 2010|June 2, 2008||No||No|November 17, 2009|https://clinicaltrials.gov/show/NCT00691808||154938|
NCT00691509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589004|Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer|The Role of Diet, Complementary Treatment and Lifestyle in Breast Cancer Survival||National Cancer Institute (NCI)||Recruiting|January 2005|||December 2010|Anticipated|N/A|Observational|N/A|||Anticipated|2300|||Female|N/A|75 Years|No|||June 2008|August 23, 2013|June 4, 2008||||No||https://clinicaltrials.gov/show/NCT00691509||154961|
NCT00692107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKVO 96-10|Radiotherapy for Prostate Cancer: Conventional Dose Versus High Dose|Phase III Study for Prostate Cancer, Randomizing Between Two Radiation Dose Levels (68 Gy vs. 78 Gy) and Utilizing Three Dimensional Conformal Radiotherapy||The Netherlands Cancer Institute|Yes|Completed|June 1997|December 2007|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|669|||Male|N/A|N/A|No|||June 2008|June 5, 2008|August 25, 2005||No||No||https://clinicaltrials.gov/show/NCT00692107||154915|
NCT00680511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA021695|Development of a Family-Based Treatment for Adolescent Methamphetamine Use|Development of a Family-Based Treatment for Adolescent Methamphetamine Use|AIMS|Oregon Research Institute|No|Completed|September 2007|December 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|15 Years|19 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680511||155798|
NCT00680745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00005|Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients|A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone||AstraZeneca|No|Completed|April 2008|May 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|597|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|May 16, 2008|Yes|Yes||No|April 13, 2011|https://clinicaltrials.gov/show/NCT00680745||155780|For participants who did not complete 24 weeks LOCF (last observation carried forward) was used. Only values prior to rescue medication were used.
NCT00680758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0770|Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer|A Phase I Study of Cisplatin, Paclitaxel, and RAD001 Patients With Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|May 2008|December 2010|Actual|August 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|May 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680758||155779|
NCT00681044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595782|HD Melphalan and SCT in Patients With IGDD or LCDD|High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD)||Boston Medical Center|Yes|Terminated|October 2006|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|120 Years|No|||January 2016|January 14, 2016|May 18, 2008|Yes|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00681044||155758|
NCT00681057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2008|||||N/A|N/A|N/A||||||||||||||August 13, 2009|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681057||155757|
NCT00682019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100493|Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Duration of Efficacy and Safety of Vardenafil Administered for 10 Weeks in a Flexible-Dose Regimen Compared to Placebo in Subjects With Erectile Dysfunction||Bayer||Completed|December 2003|August 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|383|||Male|18 Years|N/A|No|||October 2013|October 10, 2013|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00682019||155683|
NCT00682032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.0041|The Effect of Beta-glucan in Non-Small Cell Lung Cancer|Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer||James Graham Brown Cancer Center|Yes|Recruiting|April 2008|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00682032||155682|
NCT00682383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN 07|Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)|Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC||Mt. Sinai Medical Center, Miami|Yes|Completed|September 2003|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|26|||Both|18 Years|90 Years|No|||October 2012|October 29, 2012|May 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682383||155656|
NCT00687375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-24/2006|Laparoscopic Inguinal Hernia Repair- Transabdominal Preperitoneal (TAPP) Versus Totally Extra Peritoneal (TEP)|A Randomized Controlled Trial of Laparoscopic Inguinal Hernia Repair- Transabdominal Preperitoneal (TAPP) Versus Totally Extra Peritoneal (TEP) Approach||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|April 2007|March 2009|Anticipated|May 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||May 2008|May 29, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687375||155277|
NCT00687388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-07-084|The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia|The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia: A Prospective Randomized Multicenter Trial||Samsung Medical Center|Yes|Withdrawn|May 2008|||March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Male|50 Years|80 Years|No|||June 2013|June 7, 2013|May 27, 2008||No|in order to prepare a new clinical trial to evaluate with pathological change|No||https://clinicaltrials.gov/show/NCT00687388||155276|
NCT00687739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0512|Prevention of Obesity in Women Via Estradiol Regulation|Estrogen Deficiency and Mechanisms of Fat Accumulation|POWER|University of Colorado, Denver|Yes|Completed|May 2008|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|150|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00687739||155251|
NCT00687765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11616|Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma|Phase I/II Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma||Sanofi|No|Completed|July 2008|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|May 28, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00687765||155249|
NCT00688012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC3649-201|Safety Study of SPC3649 in Healthy Men|A Placebo-controlled, Double-blind, Randomized, Single Dose, Dose Escalating Trial in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649||Santaris Pharma A/S|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment||||64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00688012||155230|
NCT00688259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-016-07S|Cognitive-Behavioral Therapy in Veterans With Schizophrenia|Cognitive-Behavioral Therapy in Veterans With Schizophrenia||VA Office of Research and Development|Yes|Active, not recruiting|April 2009|June 2015|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|70 Years|No|||May 2015|May 5, 2015|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688259||155211|
NCT00688272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA106914|Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag|A Phase I, Double-blind, Placebo and Observer-blind Positive Controlled, Randomized, Parallel Group Study in Healthy Subjects to Investigate the Photoirritant Potential of Eltrombopag||GlaxoSmithKline||Completed|June 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|March 15, 2012|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688272||155210|
NCT00685243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4812|Treatment of Surgical Scars With Fractional Photothemolysis Versus Pulse Dye Laser|Treatment of Surgical Scars With Fractional Photothemolysis Versus Pulse Dye Laser||Henry Ford Health System|No|Active, not recruiting|January 2008|July 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||May 2008|May 27, 2008|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685243||155440|
NCT00690339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00201|Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study|||Allergan||Completed|February 2001|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|941|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|October 6, 2014|June 2, 2008|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00690339||155051|
NCT00684905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-00|Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy|Phase II Interstitial Brachytherapy Combined With Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Prior External Beam Irradiation||Mayo Clinic|Yes|Completed|April 2000|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Male|N/A|N/A|No|||November 2012|November 9, 2012|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684905||155466|
NCT00685776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-019|Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)|A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease|DEFINE|Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|March 2008|November 2017|Anticipated|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|80 Years|No|||January 2016|February 15, 2016|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685776||155399|
NCT00685789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006CB504502|Acupuncture With Deqi And Psychological Effects in Treatment of Bell's Palsy|Study of Effects of Deqi and Neuropsychological Factors on Acupuncture Effects in Treatment of Bell's Palsy|ADAPT|Huazhong University of Science and Technology|Yes|Completed|October 2008|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|65 Years|No|||June 2008|September 28, 2011|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685789||155398|
NCT00686088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX302-1-02|An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy|An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy||Sophiris Bio Corp|No|Completed|February 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||September 2009|October 27, 2009|May 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00686088||155375|
NCT00686101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042643|Knowledge and Perception of Smoking Risks/Consequences|Knowledge and Perception of Smoking Risks/Consequences, Smoking Habits and Motivators for Smoking Cessation Among People With Schizophrenia|SmokCess|University of Maryland|No|Completed|December 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patient volunteers will be recruited from the MPRC Outpatient and Inpatient Programs and        through NIDA. Control subjects will be recruited by MPRC and NIDA via newspaper        advertisements from the Baltimore metropolitan area. We anticipate recruiting up to 110        schizophrenia patients for a total of 100 completers and up to 110 normal controls for a        total of 100 completers. All participants will be 18-65 years old, will smoke cigarettes        daily, and must not be interested in reducing or quitting tobacco use. Nicotine dependence        appears to be about equally represented among ethnic and racial backgrounds and gender.|October 2009|October 8, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686101||155374|
NCT00686738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-256|Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients|Validity Verification of Indices Utilizing TGF-b1, NF-kB, PET/CT, and MRS Predicting Response to Neoadjuvant Chemotherapy in Osteosarcoma Patients||National Cancer Center, Korea|Yes|Completed|February 2007|December 2015|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|NF-kB expression status will be determined on initial biopsy and surgically removed tumor      specimen.|Both|5 Years|40 Years|No|Probability Sample|osteosarcoma patients hospitalized to National Cancer Center, Korea|March 2016|March 22, 2016|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686738||155326|
NCT00691522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDS 0701|Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)|Open-Label, Imaging Study of Human Corticotropin-Releasing Factor (hCRF) for The Reduction of Peritumoral Brain Edema (PBE) in Patients With Primary Malignant or Metastatic Brain Tumors||PharmaNet|No|Terminated|November 2008|October 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||January 2009|January 8, 2009|June 2, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00691522||154960|
NCT00691821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA012-0801-01|Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds|A 12-week, Prospective, Open-label, Randomized, Controlled Clinical Trial Comparing Negative Pressure Wound Therapy (NPWT) to Standard Wound Care for the Treatment of Chronic Pressure Wounds of the Pelvic Region|NPWT|St. Joseph's Healthcare Hamilton|No|Terminated|April 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|May 27, 2008||No|Patients not meeting inclusion criteria, therefore recruitment rate low, terminated due to the    lack of feasibility to complete the study in a timely manner.|No||https://clinicaltrials.gov/show/NCT00691821||154937|
NCT00691834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003467|Safety and Efficacy on Cell-based Therapy in Patients With Recent Large Acute Myocardial Infarction|ReNEW: A Phase 2, Randomized, Placebo-Controlled, Double-Blinded Study of the Efficacy and Safety of Autologous Bone Marrow Mononuclear Cell Transfer for Myocardial Salvage in Acute Myocardial Infarction|ReNeW|Duke University|Yes|Withdrawn|August 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||November 2012|August 12, 2013|June 3, 2008|No|Yes|Study never received IRB approval. Study was never pursued.|No||https://clinicaltrials.gov/show/NCT00691834||154936|
NCT00680537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW IRB # 082006-080|Physical Therapy Program for Prevention of Shoulder Pain After Device Implant|Physical Therapy Program for Prevention of Shoulder Pain After Device Implant||University of Texas Southwestern Medical Center|No|Recruiting|April 2008|April 2011|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2008|February 17, 2010|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680537||155796|
NCT00680771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB # 19132|The Psychoneuroimmunology of Insomnia|The Psychoneuroimmunology of Insomnia: Response to a Vaccine Challenge||University of Rochester|No|Completed|March 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|28|||Female|30 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Community Sample|September 2012|September 14, 2012|May 15, 2008||No||No|September 26, 2011|https://clinicaltrials.gov/show/NCT00680771||155778|Sample size limited by much higher than expected number of otherwise eligible participants having alrady been exposed to Hep B vaccine or virus.
NCT00681070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11020|Cosmetic Outcomes of Absorbable Versus Non-absorbable Sutures in Pediatric Facial Lacerations|Cosmetic Outcomes of Absorbable Versus Non-absorbable Sutures in Pediatric Facial Lacerations, Part 2|Catgut|Temple University|No|Completed|April 2008|September 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681070||155756|
NCT00681382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RFI-SYM-2006/1|Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland|INSPIRE Asthma Patient Survey to Clarify the Use of Asthma Medication and Effects of Asthma in Everyday Life in Finland||AstraZeneca|No|Completed|October 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|142|||Both|18 Years|70 Years|No|Non-Probability Sample|Primary care clinic|January 2011|January 21, 2011|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681382||155732|
NCT00681395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-360|Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium|||AstraZeneca|No|Completed|May 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681395||155731|
NCT00681642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200702037R|Corneal Epithelial Wound Healing Difference Between Human Autoserum and Cord Blood Serum|Phase 1 Study of Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Autoserum and Cord Blood Serum—in Vitro Cell Culture Experiment||National Taiwan University Hospital|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|7|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy pregnant women underwent smooth cesarean section during labor Healthy blood donor|December 2010|January 6, 2011|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681642||155712|
NCT00687453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-02-519|Insulin Glargine Versus Twice-Daily NPH|The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy||Charles Drew University of Medicine and Science|Yes|Completed|February 2003|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|75 Years|No|||February 2014|February 7, 2014|May 27, 2008|Yes|Yes||No|September 15, 2010|https://clinicaltrials.gov/show/NCT00687453||155271|Early termination leading to smaller than anticipated enrollment.
NCT00687778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-EE-109-CTIL|11C-Acetate PET/CT Non-FDG-Avid Tumors|||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|May 2008|June 2010|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low        intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer,        well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine        tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and        lobular breast carcinoma.|May 2008|May 30, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687778||155248|
NCT00686998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0970C00004|Phase IIA Study in Patients With Schizophrenia|A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD2624 in Adult Schizophrenia Patients||AstraZeneca|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|65 Years|No|||March 2013|March 20, 2013|May 28, 2008|Yes|Yes||No|April 28, 2010|https://clinicaltrials.gov/show/NCT00686998||155306|
NCT00687011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04594|Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)|Open-label Clinical Trial to Assess the Efficacy, Tolerability and Safety of a Single IV Dose of Palonosetron 0.25 mg + Dexamethasone IV in the Prevention of Moderately Emetogenic Chemotherapy-induced Nausea and Vomit (CINV).||Merck Sharp & Dohme Corp.|No|Completed|October 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|118|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687011||155305|
NCT00687401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04612|A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)|A Multi-center, Open Label Trial Evaluating the Efficacy , SAfety and the Impact on QUAlity of Life of Infliximab TherapY in Patients With Moderate-to-severe Psoriasis Not Responding to Standard or Biologic Therapy|ESAQUALITY|Merck Sharp & Dohme Corp.|Yes|Completed|June 2006|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|215|||Both|18 Years|75 Years|No|||October 2015|October 19, 2015|May 27, 2008|No|Yes||No|December 2, 2010|https://clinicaltrials.gov/show/NCT00687401||155275|
NCT00687414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-054 Protocol # 080311 AA|Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders|Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders||Spectrum Health Hospitals|No|Completed|April 2008|January 2010|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|peripheral blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community sample|January 2010|January 8, 2010|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687414||155274|
NCT00688571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-CS-PMSS|Melody Transcatheter Pulmonary Valve (TPV) Post-Market Surveillance Study|Melody TPV Post-Market Surveillance Study||Medtronic Cardiovascular|No|Completed|October 2007|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|5 Years|N/A|No|||October 2015|October 28, 2015|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688571||155187|
NCT00684008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-08|Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant|A Phase I Study of CYT107 (Recombinant Glycosylated Human IL-7) in Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant||Cytheris, Inc.|Yes|Completed|March 2008|April 2011|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|15 Years|N/A|No|||July 2012|July 25, 2012|May 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00684008||155535|
NCT00684268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRSili|Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders|Multicenter Study To Evaluate The Efficacy Of Silymarin In Addition To Combination-Therapy With Pegylated Interferon Alfa 2a (Peg-Ifn Alfa 2a) And Ribavirin In Patients With Chronic Hepatitis C|NRSily|Medical University of Vienna|No|Completed|October 2007|June 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|70 Years|No|||October 2012|October 24, 2012|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00684268||155515|
NCT00684281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00851-52|Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment|Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment||Assistance Publique Hopitaux De Marseille|No|Completed|July 2008|December 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|50 Years|90 Years|No|||August 2014|August 27, 2014|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00684281||155514|
NCT00684918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM016|Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)|A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered For Three Consecutive Days Every 2 Weeks to Older Patients With Previously Untreated Acute Myeloid Leukemia (AML)||Teva Pharmaceutical Industries|No|Completed|April 2008|December 2009|Actual|August 2009|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|70 Years|N/A|No|||August 2013|August 16, 2013|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684918||155465|
NCT00684931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/21|Cerebellar Loops and Attention Deficit Hyperactivity Disorder (ADHD)|Alterations of Fronto-Cerebello-Frontal Loops in Attention Deficit Hyperactivity Disorder (ADHD) : A Study Using Magnetic Resonance Imaging (MRI)|TDA/H|University Hospital, Bordeaux|No|Terminated|February 2008|July 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2009|June 22, 2009|May 22, 2008||No|Difficulties in the organisation|No||https://clinicaltrials.gov/show/NCT00684931||155464|
NCT00685802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11801|Fasted Bioavailability Study of Cilostazol Tablets, 50mg|A Comparative Bioavailability Study of Cilostazol Tablets, 50mg, Under Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|June 2004|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|May 24, 2008|No|Yes||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00685802||155397|
NCT00691210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ3001|Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies|Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies|SAHA|Columbia University|Yes|Completed|June 2008|March 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|38|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|June 3, 2008|Yes|Yes||No|March 7, 2014|https://clinicaltrials.gov/show/NCT00691210||154984|
NCT00691483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051095|Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date|A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date||Pfizer|Yes|Completed|September 2008|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|659|||Both|18 Years|75 Years|No|||October 2015|October 16, 2015|June 3, 2008|Yes|Yes||No|September 9, 2010|https://clinicaltrials.gov/show/NCT00691483||154963|
NCT00686452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER20159|Airway Dysfunction and Remodelling in Athletes Following Swimming Training in Chlorinated Pools|Airway Dysfunction and Remodelling in Athletes Following Swimming Training in Chlorinated Pools|proto nage|Laval University|No|Recruiting|March 2007|May 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||7|Anticipated|100|Samples With DNA|Serum, plasma, bronchial biopsies|Both|14 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Swimmers from Quebec swimming school and universities Control from université Laval or        secondary School|May 2008|December 18, 2008|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00686452||155348|
NCT00691496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5157|A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men|A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men||Centers for Disease Control and Prevention|No|Completed|May 2008|November 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|326|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 12, 2012|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691496||154962|
NCT00692445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5214-23-CRD-001|TC-5214 as add-on the Treatment of Major Depressive Disorder|A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of TC-5214 in the Treatment of MDD With Subjects Who Are Partial Responders or Non-Responders to Citalopram Therapy||Targacept Inc.|No|Completed|June 2008|July 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|574|||Both|18 Years|70 Years|No|||June 2013|June 13, 2013|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00692445||154889|
NCT00692757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-07-9|Wound Antiseptic Study With Hypochlorous Acid & Iodopovidone|Comparative Study of Two Antiseptics Solutions for the Prevention of Surgical Site Infection|WASH|Universidad Tecnológica de Pereira|Yes|Recruiting|July 2008|March 2009|Anticipated|January 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|432|||Both|18 Years|N/A|No|||October 2008|October 20, 2008|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692757||154865|
NCT00692770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12414|Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)|A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.|STORM|Bayer|Yes|Completed|August 2008|November 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1114|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 5, 2008|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT00692770||154864|
NCT00681083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPHC SDC 2008|Titration Pressures in Sleep Apnea Patients Using ThermoSmart® Versus Conventional Humidification|Titrations Pressures in Sleep Apnea Patients Using ThermoSmart® Versus Conventional Humidification||Fisher and Paykel Healthcare|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2011|July 10, 2011|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681083||155755|
NCT00681408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12442|Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)|Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)||University of Virginia|Yes|Completed|March 2007|August 2010|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|21 Years|N/A|No|||May 2015|May 27, 2015|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681408||155730|
NCT00681668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449L00023|Quetiapine in Postpartum Depression|The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorder With Psychotic Symptoms||AstraZeneca|No|Terminated|August 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|39 Years|No|||December 2010|December 7, 2010|May 20, 2008|Yes|Yes|Recruitment behind plan, no increase expected|No|October 29, 2009|https://clinicaltrials.gov/show/NCT00681668||155710|Study termination (the study could not finalised in the planned,nor in an acceptable time).
NCT00681681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K02NS058760|Sex Differences in Vascular Markers of Stroke Risk|Sex Differences in Vascular Markers of Stroke Risk|SAVVY|Wake Forest School of Medicine|No|Completed|February 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|117|Samples With DNA|RNA and DNA samples collected|Both|45 Years|65 Years|No|Non-Probability Sample|Participants will be recruited from primary care clinics, which may include internal        medicine, family practice, and obstetrics/gynecology within the Wake Forest University        health system.|December 2014|December 10, 2014|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681681||155709|
NCT00687466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFC #21/2006|Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay|Phase 3 Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay||Fondazione per la ricerca sulla Fibrosi Cistica|Yes|Active, not recruiting|August 2005|October 2009|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|10 Years|70 Years|No|||August 2009|August 3, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687466||155270|
NCT00687024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010634|Determining the Extent of Diffusion Tensor Abnormalities in Focal Cortical Dysplasia|Determining the Extent of Diffusion Tensor Abnormalities in Focal Cortical Dysplasia|FCP|The Hospital for Sick Children|No|Completed|May 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|N/A|18 Years|No|Non-Probability Sample|Children with suspected FCD presenting with intractable epilepsy for MRI & MEG. The        children will be identified from referral for clinical MRI scans.|September 2013|September 4, 2013|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00687024||155304|
NCT00687037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPYRY_L_03930|Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power|Uni Centric Study, Phase III, for Safety Oral Mucosa Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Canela Power||Sanofi|No|Completed|January 2008|||February 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687037||155303|
NCT00687427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor470708ctil|Return to Work After Hand Injury: the Role of Medical, Demographic and Psycho-Social Factors|Return to Work After Hand Injury: The Role of Medical, Demographic and Psychosocial Factors||Soroka University Medical Center||Not yet recruiting|June 2008|December 2008|Anticipated|||N/A|Observational|Observational Model: Cohort||3|Anticipated|75|||Both|18 Years|60 Years|No|Non-Probability Sample|Individuals will be recruited from those referred to occupational therapy department at        Soroka Medical Center.|May 2008|May 29, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00687427||155273|
NCT00687440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03679|A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)|Pegylated Liposomal Doxorubicin (Caelyx) in Combination With Herceptin and Taxotere as First-line Chemotherapy in Metastatic Breast Cancer Patients: A 2 Stage Phase II, Open Label, Multicenter Study.||Merck Sharp & Dohme Corp.|No|Completed|May 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|70 Years|No|||October 2014|October 29, 2014|May 27, 2008|No|Yes||No|January 21, 2010|https://clinicaltrials.gov/show/NCT00687440||155272|
NCT00688298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U0299|Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence|A Prospective, Single-Arm, Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence||Boston Scientific Corporation||Completed|May 2004|March 2008|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|18 Years|N/A|No|||May 2008|May 30, 2008|May 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688298||155208|
NCT00688311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715524-1|Pilot Trial of a Synbiotic in HIV+ Patients|Pilot Trial of a Synbiotic in HIV+ Patients||University of California, Davis|No|Completed|May 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|34|||Female|18 Years|N/A|No|||November 2009|November 19, 2009|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00688311||155207|
NCT00688584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301/2006|Ultra-brief Intervention for Problem Drinkers|Ultra-brief Intervention for Problem Drinkers||Centre for Addiction and Mental Health|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1767|||Both|19 Years|N/A|No|||April 2013|April 8, 2013|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688584||155186|
NCT00684021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|579|Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)|Transplantation in Myocardial Infarction Evaluation (TIME) Protocol: A Phase II, Randomized, Controlled, Double-Blind Trial Evaluating the Effect of Timing on the Administration of Bone Marrow Mononuclear Cells (BMMNCs) Versus Placebo in Patients With Acute Myocardial Infarction||The University of Texas Health Science Center, Houston|Yes|Completed|July 2008|November 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|21 Years|N/A|No|||June 2015|June 2, 2015|May 22, 2008|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00684021||155534|The choice of Day 3 or Day 7 as randomization points while based on the literature were nevertheless somewhat arbitrary. cMR-baseed ejection fractions tended to be high.
NCT00684294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCMRC #08-08|Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer|Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer|Auto TAG|Mary Crowley Medical Research Center|Yes|Active, not recruiting|May 2008|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00684294||155513|
NCT00684307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1250C00008|Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation|A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation||AstraZeneca|Yes|Completed|February 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|1084|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|May 22, 2008|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00684307||155512|
NCT00690066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901|PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for Recently Diagnosed Type 1 Diabetes Mellitus||Mesoblast, Ltd.|Yes|Completed|June 2008|December 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|12 Years|35 Years|No|||December 2014|December 2, 2014|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690066||155072|
NCT00685529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-019|Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)|An Open-Label, Randomized, Multiple Dose, 3-Way Crossover Study of Arformoterol Tartrate Inhalation Solution and Foradil® (Racemic Formoterol) in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)||Sunovion|No|Completed|April 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|35 Years|N/A|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685529||155418|
NCT00690898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-79-52030-207|Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma|Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma|PRIMARYS|Ipsen|Yes|Completed|May 2008|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|75 Years|No|||February 2014|February 27, 2014|June 3, 2008|No|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00690898||155008|
NCT00690911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002161|Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis|A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36)||Wake Forest School of Medicine|No|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 2, 2008|Yes|Yes|Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the    study started.|No||https://clinicaltrials.gov/show/NCT00690911||155007|
NCT00690924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000596506|Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer|A Pilot Study of Oral Calcitriol in Patients at High Risk for Lung Cancer||Roswell Park Cancer Institute|Yes|Recruiting|July 2008|||December 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|40 Years|79 Years|No|||December 2015|December 4, 2015|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690924||155006|
NCT00690937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECS00107|A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia|A Multicenter, Single-blind, Active and Placebo-controlled, Parallel-group, Randomized Study of Two Dosing Regimens of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesterolemia|Sevelamer ECS|Sanofi|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|120|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690937||155005|
NCT00690950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110895|A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart|Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride?||Urologic Consultants of Southeastern PA|Yes|Enrolling by invitation|May 2008|||July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|50 Years|80 Years|No|||June 2008|June 4, 2008|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690950||155004|
NCT00691795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC9826|Epidural Fentanyl-bupivacaine Versus Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor|Comparison of Fentanyl-bupivacaine and Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor in Patients With Continuous Epidural Analgesia||Columbia University|No|Withdrawn||December 2011|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||February 2012|February 13, 2012|June 3, 2008||No|Study was recently terminated due to poor enrollment - never enrolled.|No||https://clinicaltrials.gov/show/NCT00691795||154939|
NCT00691223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM Goltz H21291|Study of Selected X-linked Disorders: Goltz Syndrome|Pathogenesis of Focal Dermal Hypoplasia or Goltz Syndrome and Related Disorders||Baylor College of Medicine|No|Recruiting|June 2007|January 2018|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|lymphoblast DNA; tissue|Both|N/A|N/A|No|Non-Probability Sample|Individuals with Goltz syndrome and their parents. Sometimes additional family members are        also enrolled.|June 2011|June 23, 2011|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691223||154983|
NCT00692159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102ST101|Study of TRC102 in Combination With Pemetrexed in Cancer Patients|Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable||Tracon Pharmaceuticals Inc.|No|Completed|June 2008|September 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||September 2010|September 8, 2010|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692159||154911|
NCT00692458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-029|A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)|A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Reducing the Risk of Bone Metastasis in Women With Breast Cancer||Merck Sharp & Dohme Corp.||Withdrawn||August 2008|Anticipated|August 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|No|||November 2014|November 7, 2014|June 4, 2008|Yes|Yes|Withdrawn for administrative reasons|No||https://clinicaltrials.gov/show/NCT00692458||154888|
NCT00692471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080233|Sleep Actigraphy in Postural Tachycardia Syndrome (POTS)|Assessment of Objective Sleep Disturbances in Orthostatic Intolerance Using Actigraphy||Vanderbilt University|No|Active, not recruiting|June 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with the Postural Tachycardia Syndrome. The criteria include:          -  an increase in heart rate on standing (from supine) of >30 bpm          -  in the setting of symptoms of cerebral hypoperfusion that are worse with standing and             better when recumbent          -  the symptoms are daily or almost daily          -  the symptoms are chronic (lasting greater than 6 motnsh)|December 2014|December 18, 2014|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00692471||154887|
NCT00684411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-063|Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma|A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma||Dana-Farber Cancer Institute|Yes|Completed|June 2008|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|May 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684411||155504|
NCT00681096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25/2008|Causes of Low Back Pain in Nurses in Israeli Hospitals|||Hillel Yaffe Medical Center||Not yet recruiting|June 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nurses working in 4 Israeli hospitals|May 2008|May 20, 2008|May 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00681096||155754|
NCT00681109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-07-047|Topical IL-1-Ra for Treatment of Posterior Blepharitis|Safety and Efficacy of Topical Interleukin-1-Receptor Antagonist in the Treatment of Signs and Symptoms of Posterior Blepharitis||Massachusetts Eye and Ear Infirmary|No|Completed|January 2008|October 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|May 19, 2008|Yes|Yes||No|December 19, 2011|https://clinicaltrials.gov/show/NCT00681109||155753|
NCT00681421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-OKA0201|Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Esophageal Cancer||Tokyo University|Yes|Completed|May 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||November 2009|November 18, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681421||155729|
NCT00681694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-264|Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer|Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer||Massachusetts General Hospital|Yes|Recruiting|March 2002|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|414|||Male|18 Years|N/A|No|Non-Probability Sample|Patients who have indicated their intention to receive brachytherapy at one of the four        accrual sites.|April 2010|April 27, 2010|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681694||155708|
NCT00681707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2008/1|Retrospective Treatment Pattern Survey for the Patients With Hypertension and Stroke|A Retrospective, Multi Centre, Non-Interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Post Stroke Patients With Hypertension.|SAPPHIRE|AstraZeneca|No|Completed|May 2008|July 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with history of stroke, receiving hypertension medication during at least 1 year.|July 2009|July 8, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681707||155707|
NCT00688051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 06-091E|Changes in Adherence After Playing "My Life With CF" Game|Changes in Adherence to Diet, Treatment and Medication in the Cystic Fibrosis Patient as a Result of Participation in a Simulation Game.||Children's Mercy Hospital Kansas City|Yes|Completed|May 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688051||155227|
NCT00688025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-033R|Magnetoencephalographic (MEG) Localization of Ramelteon's Effects on Brain Function and Cortical Arousal in Insomnia|Magnetoencephalographic Localization of Ramelteon's Effects on Brain Function and Cortical Arousal in Insomnia||Henry Ford Health System|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Insomniacs, individuals with difficulty falling asleep or staying asleep.|March 2010|March 30, 2010|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688025||155229|
NCT00688285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07110299|Automated Clinical Reminders in the Care of Chronic Kidney Disease Patients|Automated Clinical Reminders in the Care of Chronic Kidney Disease Patients|ACRinCKD|University of Pittsburgh|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|248|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688285||155209|
NCT00684320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH073004-03|Attention Disengagement Training for Social Phobia|Attention Disengagement Training for Social Phobia|SPAttn|San Diego State University|Yes|Completed|September 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||April 2014|April 2, 2014|May 22, 2008||No||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00684320||155511|
NCT00684632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2246-0702|A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients|A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients||Kyowa Hakko Kirin Company, Limited|No|Completed|March 2008|||April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|51|||Both|20 Years|80 Years|No|||August 2012|August 30, 2012|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684632||155487|
NCT00684645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181171|Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®|Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®||Pfizer|No|Completed|June 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|186|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic and/or advanced renal cell carcinoma after failure of cytokines        therapy.|July 2012|July 17, 2012|May 22, 2008|No|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT00684645||155486|
NCT00684658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR004009|TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes|An Internet Coping Skills Training Program for Teens With Type 1 Diabetes||Yale University|Yes|Completed|May 2008|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|320|||Both|11 Years|14 Years|No|||October 2012|October 16, 2012|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00684658||155485|
NCT00684944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-014-009|Open Label Study of TRx0014 in Alzheimer's Disease|An Open Label Continuation Study of the Effects of TRx0014 30 mg TID and 60 mg TID in Patients With Alzheimer's Disease||TauRx Therapeutics Ltd|No|Completed|July 2007|December 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|N/A|N/A|No|||February 2012|February 1, 2012|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684944||155463|
NCT00685217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21528|Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT)|Tension-free Vaginal Tape Management of Stress Incontinence in Women: Randomized Trial of TVT Secur Versus TVT||University of Calgary|Yes|Terminated|May 2008|April 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Female|N/A|N/A|No|||January 2015|January 7, 2015|May 22, 2008|Yes|Yes|poor recruitment|No||https://clinicaltrials.gov/show/NCT00685217||155442|
NCT00690963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-24123|Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating|A Phase I/II Dose Escalation Trial Using Hypofractionation With Individualized Differential Boosting With Respiratory Gated Intensity-modulated Radiation Therapy (IMRT) in the Treatment of Non-small Cell Lung Cancer.||AHS Cancer Control Alberta|Yes|Active, not recruiting|September 2008|October 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||March 2014|March 4, 2014|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690963||155003|
NCT00690625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-9505-B 01|Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream|Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream; Randomized Double Blind Clinical Trial||University of Washington|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|70 Years|No|||December 2008|December 8, 2008|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690625||155029|
NCT00690638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-PROT301|Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects With Type 2 Diabetes Mellitus||Phenomix|No|Completed|July 2008|April 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|85 Years|No|||January 2010|April 12, 2010|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690638||155028|
NCT00690651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166/08|Rest Easy: Is Bed Rest Really Necessary After Surgical Repair of an Ankle Fracture?|Randomized Controlled Study Into Early Mobilization Following Internal Fixation of Isolated Ankle Fractures.||The Alfred|Yes|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|80 Years|No|||January 2010|June 8, 2010|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690651||155027|
NCT00690664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002509|Evaluation of Scalp and Hair Shaft With Biologic Markers in African American and Caucasian Hair|Evaluation of Scalp and Hair Shaft With Biologic Markers in African American and Caucasian Hair||Wake Forest School of Medicine|No|Active, not recruiting|April 2007|June 2016|Anticipated|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Hair, both broken strands and those that release from the scalp with bulb intact.|Female|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy female subjects between the ages of 21-60 will be enrolled in this study. These        subjects will be recruited from Wake Forest University Health Sciences Dermatology clinic        and our Institutional Review Board (IRB) approved advertising. Half of the participants        will be African American and the other half will be Caucasian.|December 2015|December 9, 2015|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690664||155026|
NCT00691847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0163|Reducing Edema Following Refractive Surgery|Reducing Edema Following Refractive Surgery||FORSIGHT Vision3|Yes|Completed|June 2008|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|60 Years|No|Probability Sample|At least 10 subjects following laser refractive procedure|June 2009|June 2, 2009|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00691847||154935|
NCT00692133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2007/2|Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment|Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment|TOOL|AstraZeneca|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patient aged 18-year old or older who has been diagnosed as schizophrenia or bipolar        disorder|December 2010|December 8, 2010|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00692133||154913|
NCT00692146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00009|Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)|A Double-Blind, Randomized, Single-Centre, Placebo-Controlled, Crossover Study to Investigate the Effects of a Single Oral Dose of AZD1386 on Intradermal Capsaicin Evoked Pain Symptoms and Heat Sensitivity in Healthy Volunteers||AstraZeneca|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 5, 2008|June 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692146||154912|
NCT00691860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPT-SerraA-01|Use of a Mesh to Prevent Parastomal Hernia|Randomized, Controlled, Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia||Corporacion Parc Tauli|No|Completed|April 2006|February 2008|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|N/A|No|||June 2008|September 14, 2015|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00691860||154934|
NCT00684125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM 07-934|Evaluation of Different Strategies of Pericardial Drainage After Aortic Valvular Surgery|Evaluation of Different Strategies of Pericardial Drainage After Aortic Valvular Surgery: A Prospective Randomized Trial|Blake|Montreal Heart Institute|No|Completed|June 2008|July 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||July 2011|July 21, 2011|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00684125||155526|
NCT00684138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-40|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)||Alcon Research|No|Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|300|||Both|21 Years|N/A|No|||July 2010|July 6, 2010|May 22, 2008|Yes|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00684138||155525|Data from one investigator, who implanted 20 subjects, were excluded from analysis due to non compliance with data collection and documentation. This resulted in 280 implanted subjects that were considered evaluable.
NCT00684424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081213|Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency|Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency||Pfizer|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|199|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients|May 2010|May 27, 2010|May 22, 2008||No||No|March 9, 2010|https://clinicaltrials.gov/show/NCT00684424||155503|
NCT00684437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0699|Literacy and Smoking Risk Communications|Literacy and Smoking Risk Communications||M.D. Anderson Cancer Center|Yes|Active, not recruiting|May 2008|||May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|495|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684437||155502|
NCT00681122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OEU-ARI-2007/1|CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)|An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman|CARIATIDE|AstraZeneca|No|Completed|May 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2600|||Female|18 Years|N/A|No|Probability Sample|Postmenopausal women with hormone sensitive early breast cancer that have been prescribed        adjuvant AI medication (aromatase inhibitors; anastrozole or letrozole) according to the        current product SmPC. The adjuvant AI medication must not have exceeded thirteen weeks of        treatment duration.|October 2011|January 15, 2016|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00681122||155752|
NCT00681135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKL-08-MHW|Mechanical Plaque Control and Gingivitis Reduction in Fixed Appliance Patients|Mechanical Plaque Control and Gingivitis Reduction in Fixed Appliance Patients: Comparison of Different Toothbrushing Protocols||University of Jena|No|Completed|April 2008|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|118|||Both|11 Years|15 Years|No|||February 2012|February 21, 2012|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00681135||155751|
NCT00681434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0234|Bilateral Training Versus Unilateral Training in Stroke|Bilateral Training for Upper Extremity Hemiparesis in Stroke||University of Illinois at Chicago|No|Completed|May 2005|||August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681434||155728|
NCT00681447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 15|Treatment of Chronic Low Back and Lower Extremity Pain|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Lumbar Interlaminar Epidural Injections in Lumbar Disc Herniation, and Discogenic Pain||Pain Management Center of Paducah|No|Completed|February 2008|December 2014|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00681447||155727|
NCT00681720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00007|Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325|An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 After Oral Administration to Healthy Volunteers|PET|AstraZeneca|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 20, 2008|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681720||155706|
NCT00681733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|drakchaudhary|Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)|A Study Of Metabolic Factors And Efficacy Of Pentoxifylline Versus Pioglitazone In Lean And Obese Nash (Non-Alcoholic Steatohepatitis) Patients.|NASH|Govind Ballabh Pant Hospital|Yes|Recruiting|January 2007|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||May 2008|May 20, 2008|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681733||155705|
NCT00687791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mediking 0706|Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study|Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study||Pro Top & Mediking Company Limited|Yes|Recruiting|December 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2008|June 17, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687791||155247|
NCT00688038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0393|Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy|A Study to Determine Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Therapy of Metastases to Bone||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2008|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688038||155228|
NCT00684333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRC 015/10062|Safety and Efficacy of EZ-Ject Injector a Pain-Free Subcutaneous Automatic Injection in Healthy Volunteers|Assessment of Safety and Efficacy of EZ-Ject Injector a Novel Device for Pain-Free Subcutaneous Automatic Injection in Healthy Volunteers||Sindolor|No|Suspended|June 2009|February 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|January 10, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00684333||155510|
NCT00684671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111572|Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination|Challenge Dose Administration of Twinrix™ or Comparator 4 Years After Primary Vaccination.||GlaxoSmithKline||Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|506|||Both|41 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 14, 2012|May 23, 2008|Yes|Yes||No|October 29, 2009|https://clinicaltrials.gov/show/NCT00684671||155484|
NCT00684684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT01028|Safety and Feasibility Study of the Chartis System|A Safety and Feasibility Study of the Chartis System During Diagnostic Bronchoscopy||Pulmonx, Inc.|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00684684||155483|
NCT00684957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC2883|Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors|Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors in Adult Patients With Growth Hormone Deficiency||Columbia University|No|Terminated|January 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|5|||Male|25 Years|65 Years|No|||November 2012|November 2, 2012|May 23, 2008|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00684957||155462|
NCT00690703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-00|Radiofrequency Ablation of Pulmonary Tumors Response Evaluation|Radiofrequency Ablation of Pulmonary Tumors Response Evaluation: a Prospective, Intention-to-Treat, Multicenter Clinical Trial|RAPTURE|Angiodynamics, Inc.|No|Completed|July 2001|December 2007|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690703||155023|
NCT00690352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066-08-FB|Specialized Substance Abuse Supervision (SSAS) Versus Non-SSAS Recidivism Rates Among Nebraska Felony Drug Offenders|Comparing Recidivism Rates of Felony Drug Offenders in Nebraska Who Were Sentenced to, and/or Participated in, Specialized Substance Abuse Supervision (SSAS) to Those Without SSAS|SSAS|University of Nebraska|No|Completed|March 2008|August 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|344|||Both|17 Years|N/A|No|Non-Probability Sample|Probationers and parolees who participated in SSAS starting anytime between March 1, 2006        and February 28, 2007 at any of the five participating SSAS sites in Nebraska, plus        matched sets of probationers and parolees who did not participated in SSAS at any of the        probation/parole sites in the state of Nebraska.|May 2014|May 30, 2014|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00690352||155050|
NCT00691535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05132008-1160|Genetics of Symptomatology and Treatment Response in Psychotic Major Depression|Association of BDNF, COMT, MDRI, CRH, CRF, and GC Receptor Genetic Polymorphisms With Symptomatology and Treatment Response in Psychotic Major Depression||Stanford University||Recruiting|October 2003|||||N/A|Observational|N/A||||500|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2008|June 4, 2008|June 3, 2008||||No||https://clinicaltrials.gov/show/NCT00691535||154959|
NCT00691262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-IT-02|Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis|A Long Term, Non-comparative, Multi-centre Study to Further Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis.||Astellas Pharma Inc|No|Completed|October 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|2 Years|15 Years|No|||August 2014|August 29, 2014|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691262||154980|
NCT00691548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cetuximab-Zr.89 fase I|Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients|Non Invasive Imaging of Cetuximab-Zirconium-89 Uptake With PET: a Phase I Trial in Stage IV Cancer|Cetuximab Zr89|Maastricht Radiation Oncology|Yes|Completed|June 2009|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00691548||154958|
NCT00683865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10995|Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.|Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID)|MAIDEN|Bayer|No|Completed|April 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|749|||Female|18 Years|N/A|No|||October 2014|October 12, 2014|May 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00683865||155546|
NCT00683878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-030|Add-on to Thiazolidinedione (TZD) Failures|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone||AstraZeneca|No|Completed|July 2008|June 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|420|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|May 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683878||155545|
NCT00684151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CTH-DUM-2007/1|Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand|Lipid-lowering Therapy in Patients With High Cardiovascular Risk and Their 3-year Mortality Rate in General Practice in Thailand||AstraZeneca|No|Completed|April 2008|November 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1240|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at        least 3 months|December 2011|December 9, 2011|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684151||155524|
NCT00684450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM 07-997|Cardiac Surgery: In Vivo Titration of Protamine|Cardiac Surgery : In Vivo Titration of Protamine|Protamine|Montreal Heart Institute|Yes|Completed|June 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|N/A|No|||August 2011|August 24, 2011|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00684450||155501|
NCT00692796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMRC HS 1603 substudy|Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis|Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis||National Jewish Health|No|Completed|April 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|60|||Both|40 Years|90 Years|No|||July 2008|April 16, 2010|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692796||154862|
NCT00688766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-06|Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib||Infinity Pharmaceuticals, Inc.|Yes|Terminated|August 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|May 29, 2008|Yes|Yes|Based on Independent Data Monitoring Committee (IDMC) recommendation.|No||https://clinicaltrials.gov/show/NCT00688766||155172|
NCT00693082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000854|Polycystic Ovarian Syndrome: Impact of Flaxseed Supplementation|Polycystic Ovarian Syndrome: Impact of Flaxseed Supplementation||Duke University|Yes|Terminated|August 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|June 3, 2008||No|recruitment and pilot funding issues|No||https://clinicaltrials.gov/show/NCT00693082||154840|
NCT00688740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6041|Docetaxel in Node Positive Adjuvant Breast Cancer|A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.|TAX316|Sanofi|Yes|Completed|June 1997|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1491|||Female|18 Years|70 Years|No|||February 2011|February 14, 2011|May 29, 2008|Yes|Yes||No|January 25, 2011|https://clinicaltrials.gov/show/NCT00688740||155174|
NCT00688753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001LFR08|RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe|A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer|MACS0460|Novartis||Completed|July 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|May 30, 2008|No|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT00688753||155173|
NCT00688324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043248|Biomarker Study of Acamprosate in Schizophrenia|Biomarker Study of Acamprosate in Schizophrenia||University of Maryland|Yes|Completed|June 2008|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|55 Years|No|||September 2012|September 10, 2012|May 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688324||155206|
NCT00688597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM-CL-201|Study to Evaluate the Safety of AT2220 in Pompe Disease|An Open-Label, Multicenter, Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Three Dosing Regimens of Oral AT2220 in Patients With Pompe Disease||Amicus Therapeutics|No|Terminated|November 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|74 Years|No|||May 2011|May 16, 2011|May 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688597||155185|
NCT00684034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01179-44|Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality|Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality||Assistance Publique Hopitaux De Marseille|No|Completed|June 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|131|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00684034||155533|
NCT00684047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG402|Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis|A Prospective, Single-blind, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Peripheral Vascular Surgery||Grifols Biologicals Inc.|No|Completed|February 2008|May 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|239|||Both|3 Years|N/A|No|||December 2015|December 17, 2015|May 20, 2008||No||No|September 25, 2015|https://clinicaltrials.gov/show/NCT00684047||155532|
NCT00684346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011762|18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients|A Pilot Study of 18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients After Treatment for a Pulmonary Exacerbation||The Hospital for Sick Children|No|Completed|April 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|6 Years|18 Years|No|||August 2013|August 30, 2013|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00684346||155509|
NCT00684697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Piron Trial|Iron Status and Myelination in Premature Infants|Double Blind Randomized Placebo Controlled Trial of Iron Supplementation in Premature Infants|Piron|University of Rochester|Yes|Recruiting|May 2008|May 2017|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|100|||Both|N/A|32 Weeks|No|||January 2016|January 19, 2016|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684697||155482|
NCT00684710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3186A1-101|Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Male|20 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 28, 2009|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00684710||155481|
NCT00684970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLH-202|Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)|A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)|TLH-202|Tiltan Pharma Ltd.|Yes|Recruiting|March 2009|||February 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|N/A|No|||December 2013|December 4, 2013|May 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684970||155461|
NCT00687609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12382|Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE|An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse.|PEACE|Eli Lilly and Company|No|Terminated|September 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|13 Years|17 Years|No|||August 2010|August 18, 2010|May 28, 2008|Yes|Yes|The study was discontinued early, owing to difficulties in recruiting the target sample after    seven patients had been recruited.|No|July 22, 2010|https://clinicaltrials.gov/show/NCT00687609||155260|The study was discontinued early, owing to difficulties in recruiting the target sample after seven patients had been recruited. Therefore, only disposition, demographic, and safety data are reported.
NCT00687622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEK111054|Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma|An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma||GlaxoSmithKline||Completed|July 2008|November 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687622||155259|
NCT00691236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382|Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma|Evaluation of Zoledronic Acid as a Single Agent and as an Adjuvant to Chemotherapy in the Management of High Grade Osteosarcoma|ZOL|Tata Memorial Hospital|Yes|Recruiting|May 2008|August 2013|Anticipated|May 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||June 2011|June 22, 2011|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00691236||154982|
NCT00691249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSU-HML-RSt3|Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes|Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes||Kansas State University|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|10|||Both|N/A|N/A|No|||May 2008|June 30, 2009|May 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691249||154981|
NCT00688155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0133|Seniors Health and Activity Research Program-Pilot|Seniors Health and Activity Research Program-Pilot|SHARP-P|National Institute on Aging (NIA)|Yes|Recruiting|May 2008|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|100|||Both|70 Years|85 Years|Accepts Healthy Volunteers|||November 2008|November 13, 2008|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688155||155219|
NCT00688428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00002|Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination|A Phase I, Open-Label, Randomized, Single-Center, 2-Stage Group Sequential Design, 2-Way Crossover Bioequivalence Study Comparing a Fixed-Dose Combination Capsule of Esomeprazole 40mg and Low-Dose Acetylsalicylic Acid (ASA) 325mg With a Free Combination of Esomeprazole Capsule 40mg and Low-Dose ASA||AstraZeneca|No|Completed|April 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|84|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 11, 2009|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688428||155198|
NCT00683852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS - 2008A053242|A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy|A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT||Massachusetts General Hospital|No|Completed|July 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|224|||Both|18 Years|65 Years|No|||August 2010|August 11, 2010|May 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683852||155547|
NCT00683891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOCUS|FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey|FazaClo Outcomes in the Control of Schizophrenia (FOCUS)|FOCUS|Azur Pharma, Inc||Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|The enrolled population consists of male and female patients with treatment-resistant        schizophrenia of 18 years of age or older, already taking Clozaril (clozapine) or generic        clozapine, or patients with treatment-resistant schizophrenia who have failed on other        atypical antipsychotic drugs.|June 2008|June 18, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00683891||155544|
NCT00685087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Wiggins|A Prospective Study of Natural History of Pancreatitis|A Prospective Study of Natural History of Pancreatitis||Virginia Commonwealth University|No|Completed|September 2004|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|65 Years|No|Probability Sample|Subjects presenting to the Pancreatitis clinic with diagnosis of pancreatitis|May 2008|May 17, 2013|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685087||155452|
NCT00685360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-07-204|A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)|A Multi Center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC 67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-resistant Tuberculosis||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|April 2008|October 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|481|||Both|18 Years|64 Years|No|||August 2015|August 13, 2015|May 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685360||155431|
NCT00693095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000580|Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer|Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer|ERaDICATe|Duke University|Yes|Completed|September 2008|April 2015|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693095||154839|
NCT00693108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVFANDROGENS|Androgens for Poor Responders in In Vitro Fertilization|Transdermal Testosterone to Improve Ovarian Response to Gonadotropins in Poor Responder IVF Patients With Normal Basal Concentrations of FSH||Hospital Clinic of Barcelona||Completed|September 2006|||||Phase 3|Interventional|N/A|2||||||Female|19 Years|39 Years|No|||June 2008|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00693108||154838|
NCT00688779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0540C00001|Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season|A Double Blind, Placebo Controlled, Randomised, First Time In Man. Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD8848 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out Of Season|SAD|AstraZeneca|No|Completed|January 2008|April 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688779||155171|
NCT00688792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|asthma1-HMO-CTIL|Maternal Variables Associated With Adherence in Children With Asthma|Reasons for Poor Adherence for Long-Term Preventing Therapy in Children With Asthma|asthma|Hadassah Medical Organization|No|Not yet recruiting|July 2008|June 2011|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|2 Years|12 Years|No|Probability Sample|Parents to children aged 2 - 12 years with moderate to severe asthma.|May 2008|June 2, 2008|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688792||155170|
NCT00688805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908433|Effects of Propranolol on Responses to Drug-Related Imagery Scripts|Effects of Propranolol on Responses to Drug-Related Imagery Scripts||National Institutes of Health Clinical Center (CC)||Terminated|December 2007|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|55 Years|No|||December 2013|December 20, 2013|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688805||155169|
NCT00689026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCG 08-02-186|Efficacy of Lubiprostone in Combination With Standard PEG Preparation|Efficacy of Lubiprostone Used With Polyethylene Glycol to Enhance Colonoscopy Preparation Quality in Diabetic Patients: A Randomized Single-Blind Controlled Trial||Georgia Regents University|No|Terminated|May 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Both|50 Years|N/A|No|||October 2014|October 17, 2014|May 29, 2008|Yes|Yes||No|September 30, 2014|https://clinicaltrials.gov/show/NCT00689026||155152|
NCT00689312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012122|Palatability of Oral Rehydration Solutions|Palatability of Oral Rehydration Solutions||The Hospital for Sick Children|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|66|||Both|5 Years|10 Years|No|||December 2013|December 10, 2013|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689312||155130|
NCT00688337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-EE-108-CTIL|Correlation Between Fluorodeoxyglucose (FDG) and FLT Uptake and Gene-Expression Oncotype Assay in Patients With Breast Cancer|||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|June 2008|June 2010|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|None Retained|not relevant|Female|18 Years|86 Years|No|Non-Probability Sample|Newly diagnosed patients with breast cancer, clinically nodal negative, prior to surgery        and/or treatment|May 2008|May 30, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688337||155205|
NCT00688610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HannoverPro II|Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter|Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter||Hannover Medical School|No|Completed|November 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|571|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00688610||155184|
NCT00688623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CDE16|RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe|A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors|RAMSETE/CDE16|Novartis||Active, not recruiting|June 2009|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||January 2016|January 10, 2016|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688623||155183|
NCT00688636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0168X75|Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery|||University of Pittsburgh|Yes|Active, not recruiting|January 2005|December 2008|Anticipated|August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|72 Years|No|||May 2008|June 2, 2008|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688636||155182|
NCT00684060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|578|Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)|A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction||The University of Texas Health Science Center, Houston|Yes|Completed|July 2008|February 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|21 Years|N/A|No|||July 2015|July 7, 2015|May 22, 2008|Yes|Yes||No|April 9, 2012|https://clinicaltrials.gov/show/NCT00684060||155531|Lack of in-vivo testing of cell product. While there are several different approaches to measure myocardial strain (myocardial tagging, DENSE, etc.), these were not employed in this study due to the need for specialized expertise at each site.
NCT00684073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05094|Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)|Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy||Indivior Inc.|No|Completed|July 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2009|April 14, 2011|May 22, 2008|No|Yes||No|December 17, 2008|https://clinicaltrials.gov/show/NCT00684073||155530|
NCT00689494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BnaiZionMC-08-BP-003-CTIL|Cervical Device Contraception-2 (Nanopaz)|Cervical Device Contraception|NANOPAZ|Bnai Zion Medical Center|Yes|Not yet recruiting|June 2008|May 2010|Anticipated|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Female|1 Month|2 Months|Accepts Healthy Volunteers|||June 2008|June 2, 2008|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00689494||155116|
NCT00689806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15427A|Evaluation of Lovastatin in Severe Persistent Asthma|Evaluation of Lovastatin in Severe Persistent Asthma||University of Chicago|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||June 2013|June 20, 2013|May 23, 2008||No|Study never opened|No||https://clinicaltrials.gov/show/NCT00689806||155092|
NCT00690079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00008|Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386|A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Caucasian Young and Elderly Subjects After Oral Multiple Doses.|MAD|AstraZeneca|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|69|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2009|December 8, 2010|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690079||155071|
NCT00689793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iron-0508-PMU|Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors|Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors : a Randomized Controlled Trial|ferdon|University of Lausanne|Yes|Completed|November 2008|April 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|May 28, 2008||No||No|May 18, 2012|https://clinicaltrials.gov/show/NCT00689793||155093|
NCT00690690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5142|No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks|No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks||Centers for Disease Control and Prevention|No|Completed|June 2008|November 2009|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|370|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||March 2010|March 8, 2010|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690690||155024|
NCT00690391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS2008|Analysis of Palliative Surgery in View of Quality of Life and Prognosis|Analysis of Palliative Surgery in View of Quality of Life and Prognosis||Johann Wolfgang Goethe University Hospitals|No|Recruiting|May 2008|May 2013|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|Patients with plannes surgery and cancer in he University hospital Frankfurt|May 2008|May 30, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00690391||155047|
NCT00687258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vit E-Rif01-1|Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients|Evaluation Of The Impact Of A New Synthetic Vitamin E-Bonded Membrane On The Anemia And Oxidative Stress In End-Stage Renal Disease (ESRD) Patients|Vi-E|A. Manzoni Hospital|Yes|Completed|July 2006|July 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00687258||155286|
NCT00687271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6213-006|A Study of MK6213 Co-Administered With Atorvastatin in Patients With Hypercholesterolemia (MK-6213-006)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy, and Tolerability of MK6213 Co-Administered With Atorvastatin in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|330|||Both|18 Years|75 Years|No|||September 2015|September 25, 2015|May 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00687271||155285|
NCT00690976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5123|Proyecto SOL: A Risk Reduction Intervention for Hispanic Men Who Have Sex With Men (MSM)|Proyecto SOL: A Risk Reduction Intervention for Hispanic MSM||Centers for Disease Control and Prevention|No|Completed|July 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||March 2010|March 10, 2010|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690976||155002|
NCT00690989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0974 IISP #35151|Retrospective Evaluation of Patient Failure to Follow-up at a Community Based Headache Clinic|If You Build it, They Will Come; But Will They Return for Follow-up? A Retrospective Assessment of Potential Risk Factors for Patient Failure to Follow-up at a Community Based Headache Clinic||Kilgo Headache Clinic|No|Completed|July 2005|June 2009|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Community based headache clinic population|March 2015|March 31, 2015|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690989||155001|
NCT00688168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0612|Inflammatory Cytokines in Symptom Production in Multiple Myeloma|Identifying the Role of Inflammatory Cytokines in Symptom Production in Multiple Myeloma||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2008|||May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|625|Samples With DNA|Tissue sample by inserting a swab into mouth and rubbing firmly against the inside of cheeck      or underneath lower or upper lip for about a minute during a regularly schedule clinic      visit.|Both|18 Years|N/A|No|Non-Probability Sample|Patients, 18 years or older, diagnosed with multiple myeloma (MM).|February 2016|February 18, 2016|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688168||155218|
NCT00688181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U8043|The Prefyx PPS™ System eRegistry|The Prefyx PPS™ System eRegistry||Boston Scientific Corporation||Active, not recruiting|December 2006|April 2009|Anticipated|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|44|||Female|18 Years|N/A|No|Non-Probability Sample|All patients presenting to the institution for treatment of female Urinary Stress        Incontinence (SUI) should be eligible for enrollment in the PPS eRegistry. However, any        patient meeting any of the contraindications should NOT be included as noted in the        Directions For Use. Minors are excluded from the registry per contraindications in which        mesh implants are contraindicated in 'patients with the potential for future growth'.|March 2009|March 30, 2009|May 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688181||155217|
NCT00688441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C215|The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis||Capnia, Inc.|No|Completed|July 2008|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|453|||Both|18 Years|65 Years|No|||August 2010|August 18, 2010|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688441||155197|
NCT00685100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone|||Medical University of Vienna||Completed|January 2004|January 2007|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||40|||Both|50 Years|85 Years|No|||May 2008|April 14, 2015|May 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00685100||155451|
NCT00685373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2306|Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease|An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease||Novartis||Completed|May 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|3 Years|N/A|No|||July 2012|July 24, 2012|May 27, 2008|Yes|Yes||No|April 25, 2011|https://clinicaltrials.gov/show/NCT00685373||155430|
NCT00685646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGU0705|Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases|A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease|ZAPCA|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Completed|May 2008|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|227|||Male|20 Years|N/A|No|||October 2015|October 15, 2015|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685646||155409|
NCT00685932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21107|Mobius® Post-cesarean Pain Randomized Control Trial|Mobius Pain Study: A Randomized Controlled Trial of Standard Versus Mobius® Retraction at Cesarean Delivery||Dartmouth-Hitchcock Medical Center|Yes|Completed|July 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|125|||Female|18 Years|N/A|No|||October 2011|October 19, 2011|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00685932||155387|
NCT00692822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08011|Antimicrobial Susceptibility Patterns of N. Gonorrhea Isolates in an Era of Quinolone Resistance|Antimicrobial Susceptibility Patterns of Neisseria Gonorrhea Isolates in an Era of Quinolone Resistance||University of Florida|No|Completed|June 2008|March 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|Urethral discharge for Neisseria gonorrheae culture|Male|18 Years|80 Years|No|Non-Probability Sample|Male patients seen in the Duval County Sexually Transmitted Diseases Clinic with smears        positive for gram negative diplococci or unexplained pyuria|February 2009|March 6, 2012|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692822||154860|
NCT00689039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00004|Study of an Extended Release (ER) Tablet, Single and Repeated Dosing|A Two-part, Single-centre, Open (Part A) Single Blind (Part B), Randomised, Placebo-controlled Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Doses With and Without Food and Multiple Ascending Oral Doses of AZD1305 Extended-release Tablet in Healthy & Elderly Subj||AstraZeneca|No|Completed|April 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|94|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2010|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689039||155151|
NCT00689052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.637|Pramipexole ER vs. Placebo in Fibromyalgia|A Randomized, Double-blind, Placebo-controlled, Dose Titration Efficacy and Safety Study of Pramipexole ER (0.75 to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients Diagnosed With Fibromyalgia, as Assessed by the American College of Rheumatology (ACR) Criteria Followed by a 24-week Open-label Extension Phase||Boehringer Ingelheim||Terminated|July 2008|||November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||May 2014|June 3, 2014|May 29, 2008|Yes|Yes||No|October 23, 2009|https://clinicaltrials.gov/show/NCT00689052||155150|Early termination leading to no number of subjects analysed for any outcome measure
NCT00689325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NNL-SER-2008/1|Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics|A Non-interventional Study Evaluating Well-being/Quality of Life in Schizophrenic Patients Treated With Seroquel XR® (Quetiapine) and Other Atypical Antipsychotics.A 9-month, Observational, Multicentric Prospective Study.|Xperience|AstraZeneca||Completed|April 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|158|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with schizophrenia treated with atypical antipsychotics (AAPs) to stay in        remission|October 2010|October 26, 2010|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689325||155129|
NCT00689624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.21|Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer|A Triplet Combination With Irinotecan Plus Oxaliplatin,Continuous Infusion 5-Fluorouracil And Leucovorin Plus Cetuximab As First Line Treatment In Metastatic Colorectal Cancer. A Pilot Phase II Trial||University Hospital of Crete|No|Completed|July 2007|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||September 2015|September 25, 2015|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689624||155106|
NCT00688350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC1114797|Medication Adherence in Hypertension Study|Interventions to Improve Medication-Taking Behavior in Older Adults With Hypertension: An Exploratory Study||University of Missouri-Columbia|No|Completed|July 2008|June 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|60 Years|N/A|No|||August 2009|August 3, 2009|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688350||155204|
NCT00688649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC200|Nutritional Supplement Compliance Study|An Investigation of the Effects of Different Modes of Delivery of Oral Nutritional Supplements in Participants at Risk of Malnutrition - A Pilot Study|NSCS|Nutricia UK Ltd|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00688649||155181|
NCT00684086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96943|English Diabetes Self-Management Program|English Diabetes Self-Management Program||Stanford University||Completed|April 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label||||350|||Both|18 Years|N/A|No|||May 2008|May 23, 2008|May 22, 2008||||No||https://clinicaltrials.gov/show/NCT00684086||155529|
NCT00689819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803305872|Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients|Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients in an Urban Emergency Department: Is a Program Focused on Early Detection and Blood Pressure Control Clinically and Cost Effective?||Wayne State University|Yes|Completed|October 2008|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|123|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|June 2, 2008||No||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00689819||155091|Despite our best efforts, study retention was hindered by a higher than expected drop-out rate (26.0% overall; 27.7% control and 24.1% intervention).
NCT00690365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NGR-SER-2007/1|Safety and Efficacy of Switching to Quetiapine in Outpatients With Schizophrenia|A Non-interventional, Open Label, Phase IV Observational Study for the Safety and Efficacy of Switching to Quetiapine (Seroquel) in Outpatients With Schizophrenia Who Have Been Unsuccessfully Treated With Other Antipsychotics|Q-chase|AstraZeneca|No|Completed|June 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|576|||Both|18 Years|65 Years|No|Non-Probability Sample|Primary Care|December 2010|December 8, 2010|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690365||155049|
NCT00690378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXL104/2001|Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections|Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults||AstraZeneca|No|Completed|November 2008|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|No|||August 2011|August 18, 2011|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690378||155048|
NCT00690677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BUS19T|Phase II Trial of LBH589 in Refractory Colorectal Cancer|Phase II Trial of LBH589 in Refractory Colorectal Cancer||Swedish Medical Center|No|Completed|June 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690677||155025|
NCT00690404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00005|AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers|A Phase 1, Single-center, Randomized, Open-label, Two-way Crossover, Formulation and Food Effect Study in Healthy Volunteers, to Assess the Pharmacokinetics of AZD 2066 After Single Doses of a New Oral Solid Formulation and an Oral Solution||AstraZeneca|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690404||155046|
NCT00687245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9614C00007|Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)|A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)||AstraZeneca|No|Completed|August 2006|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|40|||Both|1 Year|11 Years|No|||June 2008|June 10, 2008|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687245||155287|
NCT00688454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CCH-CRE-2007/1|C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients|C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients||AstraZeneca|No|Completed|February 2007|January 2008|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|3392|||Both|N/A|N/A|No|Non-Probability Sample|Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins        patients|April 2009|April 8, 2009|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688454||155196|
NCT00688467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05363|Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of SCH 527123 in Subjects With Allergen-Induced Asthma||Merck Sharp & Dohme Corp.|No|Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|May 29, 2008|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00688467||155195|
NCT00683904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-160|Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer|A Phase I Study of Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer as First-line Treatment||R-Pharm|Yes|Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|N/A|No|||February 2016|February 9, 2016|May 22, 2008|No|Yes||No|February 8, 2011|https://clinicaltrials.gov/show/NCT00683904||155543|
NCT00687895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF2003|Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania|Quality Malaria Case Management In Under- Fives In Primary Health Care (Phc) Institutions In Bagamoyo And Kibaha Districts Of Coastal Tanzania:a Multicomponent Controlled Intervention Study||Muhimbili University of Health and Allied Sciences|Yes|Completed|July 2003|March 2004|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|3131|||Both|6 Months|59 Months|No|||May 2008|May 28, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687895||155239|
NCT00684164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6833|Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients|Safety and Efficacy of Conivaptan for the Correction of Euvolemic and Hypervolemic Hyponatremia in Critically Ill Neurological Patients||Columbia University|Yes|Withdrawn|May 2008|June 2010|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|May 22, 2008|No|Yes|Unable to complete a contract with the Sponsor|No||https://clinicaltrials.gov/show/NCT00684164||155523|
NCT00684463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04935|Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)|Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia||Merck Sharp & Dohme Corp.|No|Completed|April 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|59|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|May 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00684463||155500|
NCT00684476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130504|Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings|||Meir Medical Center||Completed|June 2004|May 2006||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||60|||Both|6 Years|75 Years|No|||March 2004|May 23, 2008|May 21, 2008||||No||https://clinicaltrials.gov/show/NCT00684476||155499|
NCT00685386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1404|A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP)|A Randomized, Controlled, Double-blind Trial of CO2 Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography||University of North Carolina, Chapel Hill|No|Completed|June 2008|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|74|||Both|18 Years|N/A|No|||April 2011|January 22, 2013|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685386||155429|
NCT00685412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV001|Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3|Phase I Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Post Surgical or Ablative Treatment of Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN)||Inovio Pharmaceuticals|No|Completed|May 2008|March 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Female|18 Years|45 Years|No|||December 2011|December 8, 2011|May 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00685412||155427|
NCT00685659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020623|Effectiveness of Extended Treatments for Drug Dependence||ETDD|National Institute on Drug Abuse (NIDA)|No|Recruiting|May 2007|May 2011|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|340|||Both|18 Years|75 Years|No|||May 2008|May 23, 2008|May 23, 2008||||No||https://clinicaltrials.gov/show/NCT00685659||155408|
NCT00685672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|edaadr-07|Safety of Epidural Fentanyl and Adrenalin During Childbirth|Pharmacokinetic Interaction Effects of Combined Fentanyl and Adrenalin in Epidural Analgesia During Child Birth||Oslo University Hospital|No|Recruiting|August 2008|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|40 Years|No|||April 2015|April 22, 2015|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00685672||155407|
NCT00689065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALAA-01-ST-001|Safety Study of CALAA-01 to Treat Solid Tumor Cancers|A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies||Calando Pharmaceuticals|Yes|Terminated|May 2008|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00689065||155149|
NCT00689338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851019|Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study|Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations|ICE|Pfizer|No|Completed|July 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|18 Years|N/A|No|||May 2011|May 25, 2011|May 29, 2008|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00689338||155128|In a change to the protocol, time to first negative blood/tissue culture will only concern time to first negative blood culture. Lack of regular tissue sampling meant that analysis of time to first tissue culture could not be meaningfully performed.
NCT00690794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-03|Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension|An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution||Alcon Research|No|Completed|July 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|726|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|June 3, 2008|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00690794||155016|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)
NCT00690534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-090|Insulin and Sarcopenia in the Elderly|Insulin and Sarcopenia in the Elderly||The University of Texas Medical Branch, Galveston|No|Terminated|September 2005|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|11||Actual|88|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2015|September 8, 2015|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690534||155036|
NCT00693277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0186|Assessing Novel Methods of Improving Patient Education of Nutrition|Assessing Novel Methods of Improving Patient Education of Nutrition: eHealth, Health Literacy and Chronic Kidney Disease||University of Wisconsin, Madison||Withdrawn|September 2006|September 2008|Anticipated|||N/A|Interventional|N/A|||Actual|0|||Both|N/A|N/A||||October 2015|October 6, 2015|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00693277||154825|
NCT00688961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSH-001|Effects of Omacor and Aspirin on Platelet Function|A Pilot Study of the Effects of Omacor (Alone and With Aspirin) on Platelet Function in Healthy Subjects||Sanford Research|Yes|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||May 2008|June 2, 2008|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688961||155157|
NCT00689208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4411M00007|Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity|Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity - a Concept Study in Mani||AstraZeneca|No|Completed|May 2007|November 2008|Actual|October 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|March 12, 2009|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689208||155138|
NCT00689221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 121974-011|Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status|Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)|CENTRIC|EMD Serono|Yes|Completed|September 2008|August 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|545|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|May 29, 2008|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00689221||155137|
NCT00689481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114742|Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies|A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267 , Versus Vehicle Foam in Subjects With Plaque-type Psoriasis||GlaxoSmithKline|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|12 Years|N/A|No|||April 2012|April 5, 2012|May 29, 2008|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00689481||155117|
NCT00686205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7B5-02-05R05|Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay|||Abbott Diagnostics Division|No|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|24111|||Both|17 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 16, 2011|May 21, 2008|Yes|Yes||No|January 13, 2010|https://clinicaltrials.gov/show/NCT00686205||155367|
NCT00686504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00013|Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066|An Open Label, Non-randomized Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 After Oral Administration to Healthy Subjects|PET|AstraZeneca|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||August 2008|December 8, 2010|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686504||155344|
NCT00690092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S104-1, S104-2, S104-3|A Multi-center Study of Spherule-Derived Coccidioidin|Safety, Sensitivity and Specificity of Spherule-derived Coccidioidin in Naive Adults, in Adults With a History of Pulmonary Coccidioidomycosis and in Adults With a History of Pulmonary Histoplasmosis||Nielsen BioSciences, Inc.|No|Completed|May 2005|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Actual|113|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690092||155070|
NCT00686855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-027|Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease|An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease||Dana-Farber Cancer Institute|Yes|Completed|August 2008|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|4 Years|N/A|No|||February 2014|February 24, 2014|May 27, 2008|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT00686855||155317|
NCT00686868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFA110867|Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients|Clinical Phase I/IIA Study of Subcutaneously Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate||GlaxoSmithKline||Completed|June 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|35|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686868||155316|
NCT00683930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX17796|A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)|A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel Group, Mult-center, 52-week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Achieve Remission With Reduced Corticosteroid in Subjects With Pemphigus Vulgaris||Hoffmann-La Roche||Completed|May 2004|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|70 Years|No|||May 2011|May 25, 2011|May 19, 2008|Yes|Yes||No|November 18, 2009|https://clinicaltrials.gov/show/NCT00683930||155541|
NCT00687648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595712|Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer|Randomised Phase II Study of Metronomic Chemotherapy Plus the Same Aromatase Inhibitor Compared to Metronomic Chemotherapy Alone in Women With Hormone Receptor Positive, Her-2 Non-Overexpressing Advanced Breast Cancer Whose Disease Has Progressed While Receiving an Aromatase Inhibitor, Correlating Response With Circulating Endothelial Progenitor Cells, VEGF and VEGFR||National Cancer Institute (NCI)||Recruiting|May 2008|||April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||June 2009|June 16, 2009|May 30, 2008||||No||https://clinicaltrials.gov/show/NCT00687648||155258|
NCT00687908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29075|Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance|Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Vehicle Gel as a 6-month Acne Maintenance Treatment|ACCESS II|Galderma|No|Completed|November 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|243|||Both|12 Years|35 Years|No|||September 2010|September 30, 2010|May 28, 2008|No|Yes||No|July 16, 2010|https://clinicaltrials.gov/show/NCT00687908||155238|
NCT00684840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-15462-4|Effects of Stress and Other Factors on Opiate Drug Choice.|Biobehavioral Study of Opioid Drug Seeking Behavior: Study 4|DSS|Wayne State University|Yes|Completed|March 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|Samples With DNA|Whole Blood|Both|18 Years|55 Years|No|Non-Probability Sample|Heroin dependent research volunteers|June 2012|June 1, 2012|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00684840||155471|
NCT00685139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-1376|Fasting Bioavailability Study of Zonisamide Capsules|A Relative Bioavailability Study of 100 mg Zonisamide Capsules Under Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|January 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|May 24, 2008|No|Yes||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00685139||155448|
NCT00685425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-308|Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol|A Dose Response and PharmacoDynamic Study of Levalbuterol and Racemic Albuterol HFA MDI in Subjects Twelve Years of Age and Older With Asthma||Sunovion|No|Completed|October 2002|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|12 Years|N/A|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685425||155426|
NCT00693121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MethodistRC Project 1|Amantadine for Treatment of Symptoms of the Post-Traumatic Confusional State|Amantadine Hydrochloride for Treatment of Symptoms of the Post-Traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial||Methodist Rehabilitation Center|No|Active, not recruiting|April 2003|June 2008|Anticipated|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|N/A|N/A|No|||June 2008|June 5, 2008|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00693121||154837|
NCT00688818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183/2007|Quetiapine in Co-Morbid Depressive and Anxiety Disorders|Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Co-Morbid Depressive and Anxiety Disorders||Centre for Addiction and Mental Health|Yes|Completed|June 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||August 2014|August 20, 2014|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688818||155168|
NCT00688831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00002|Single Ascending Dose Study (SAD) iv Formulation|A Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Ascending Intravenous Doses of AZD1305 in Helahty Male Volunteers|2006-006253-27|AstraZeneca|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2010|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688831||155167|
NCT00690209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0034|By Pass Surgery With Stem Cell Therapy in Chronic Ischemic Cardiopathy|Efficacy of Surgical Coronary Revascularization Associated With Stem Cells Injection in Patients With Severe Chronic Ischemic Heart Disease With Residual Viability. A Prospective, Controlled Pilot Trial.||University Hospital, Clermont-Ferrand||Completed|May 2008|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|12|||Both|18 Years|75 Years|No|||July 2014|July 4, 2014|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00690209||155061|
NCT00690820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.3.127|Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)|A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis||Solvay Pharmaceuticals|Yes|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|7 Years|11 Years|No|||February 2010|May 26, 2010|June 3, 2008|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00690820||155014|
NCT00688974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2004/0123|Comparison of 2 Prospective Surgical Techniques in the Treatment of Obesity in Type 2 Diabetes|Comparison of 2 Prospective Surgical Techniques (Gastric Bypass and Adjustable Gastric Banding) in the Treatment of Obesity in Type 2 Diabetes|OBEDIAB|University Hospital, Lille|Yes|Completed|May 2004|September 2012|Actual|November 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|70 Years|No|||May 2008|October 22, 2012|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688974||155156|
NCT00689234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220083458 (no sponsor)|Diaphragm Plication in Adults With Phrenic Nerve Paralysis|Diaphragm Plication in Adults With Phrenic Nerve Paralysis: a Randomised Controlled Study||Katholieke Universiteit Leuven|No|Recruiting|April 2008|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689234||155136|
NCT00689247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00008|To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305|A Phase I, Open, Randomised, Single-Centre, Crossover Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) After Oral and Intravenous Administration of 14C-labelled and Non-labelled AZD1305 to Healthy Male Volunteers||AstraZeneca|No|Completed|April 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689247||155135|
NCT00689507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9S-MC-JDCF|A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib|A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma||Applied Molecular Evolution|No|Completed|March 2008|May 2014|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||May 2015|June 25, 2015|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689507||155115|
NCT00689520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV1/01|Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis|Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis||Hospital Universitari de Bellvitge|No|Completed|January 2002|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||May 2008|June 2, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00689520||155114|
NCT00686218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07203|Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia|A Phase I Dose Escalation Study of LBH589 in Combination With Imatinib Mesylate for Patients With Chronic Myeloid Leukemia in Cytogenetic Remission With Residual Disease Detectable by Q-PCR||City of Hope Medical Center|Yes|Completed|May 2008|August 2014|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686218||155366|
NCT00686829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04100|Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Study P04100AM4)(COMPLETED)|Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Protocol No. P04100)||Merck Sharp & Dohme Corp.|No|Completed|June 2005|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686829||155319|
NCT00686842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-059|PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma|A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma||AIDS Malignancy Consortium|No|Terminated|September 2008|December 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|May 29, 2008|Yes|Yes|Drug supply unavailable.|No|January 30, 2012|https://clinicaltrials.gov/show/NCT00686842||155318|
NCT00688194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000596572|Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy|Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy||National Cancer Institute (NCI)||Recruiting|May 2008|||May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|4||Anticipated|396|||Female|18 Years|N/A|No|||May 2008|August 23, 2013|May 30, 2008||||No||https://clinicaltrials.gov/show/NCT00688194||155216|
NCT00683917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-202|Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids|A Multi-center, Active Controlled, Pharmacokinetic, Safety and Efficacy Study of Proellex in Pre-Menopausal Women With Symptomatic Uterine Fibroids to Assess Persistence of Response||Repros Therapeutics Inc.|Yes|Terminated|May 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|10|||Female|18 Years|45 Years|No|||August 2014|August 5, 2014|May 22, 2008|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00683917||155542|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00684528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jfr_il0801|A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin|||Meir Medical Center|Yes|Recruiting|June 2008|December 2012|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|May 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00684528||155495|
NCT00684814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04064|Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Under Fasting Conditions|A Randomized, Two-way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioequivalence of a Test Tablet Formulation of Zolpidem Tartrate 10 mg, Compared to an Equivalent Dose of Ambien® in Healthy Adult Subjects.||Mutual Pharmaceutical Company, Inc.|No|Completed|May 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 18, 2012|May 24, 2008|No|Yes||No|December 4, 2009|https://clinicaltrials.gov/show/NCT00684814||155473|
NCT00684827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-310|A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma|A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Subjects Twelve Years of Age and Older With Asthma||Sunovion|No|Completed|October 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|12 Years|N/A|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684827||155472|
NCT00685113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-OXY-301|A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder|A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Doses of DR-3001 Versus Placebo in Women With Overactive Bladder||Teva Pharmaceutical Industries|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1104|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 30, 2013|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685113||155450|
NCT00685152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|psiy-267-07|High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)|High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)||Queen's University|No|Completed|January 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|May 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685152||155447|
NCT00685438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-2007|Ultraviolet Exposure, Antioxidant Use and Skin Erythema at Extreme High Altitude|Observational Study of Skin Erythema by Spectrophotometer, and UV Exposure With Viospore Ultraviolet Monitors at Extreme Altitude (Mt. Everest, North Side)||Sunnybrook Health Sciences Centre|No|Completed|April 2007|June 2007|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|25|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|9 Mountaineers with intention to summit Everest (1 American, 1 British, 1 German, 5        Australians, 1 Asian-Australian) 4 Trekkers with intention to go to 7000m (2 Americans, 1        Asian, 1 British) 12 climbing sherpas (11 Nepali and 1 Tibetan)|May 2008|May 27, 2008|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00685438||155425|
NCT00689663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YC11|Laparoscopic Cholecystectomy - Fundus First and Harmonic Ace Compared With Conventional Technique|Randomized Multicentre Trial: Comparison of Harmonic Ace and Eletrocautery; Comparison of Fundus First and Conventional Dissection||Sundsvall Hospital|No|Completed|May 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|233|||Both|18 Years|65 Years|No|||May 2008|May 29, 2008|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00689663||155103|
NCT00690196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 CA119 159|Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms|Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanism||University of California, Los Angeles|Yes|Completed|March 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Female|30 Years|70 Years|No|||July 2012|July 9, 2012|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00690196||155062|
NCT00690521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 03-477|A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients|A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients||University of New Mexico|Yes|Recruiting|January 2003|January 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|13|||Both|18 Years|N/A|No|||June 2008|June 3, 2008|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690521||155037|
NCT00690547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG27112007|Force Enhancement of Musculus Quadriceps Femoris During and After Excentric Muscle Activity in Vivo|Force Enhancement of m. Quadriceps Femoris During and After Excentric Muscle Activity in Vivo by Maximal and Sub-maximal Deliberately Activation.||German Research Foundation|No|Active, not recruiting|October 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Male|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|males without previous muscular or neurophysiological diseases at an age between 20 and 40        years|November 2009|November 27, 2009|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00690547||155035|
NCT00691119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003439|Relaxation and Visualization Therapy for Breast Cancer Patients|A Feasibility Study of Relaxation and Visualization Therapy for Breast Cancer Patients||National College of Natural Medicine|No|Terminated|December 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|9|||Female|45 Years|70 Years|No|||May 2013|May 8, 2013|June 3, 2008||No|Inadequate recruitment|No||https://clinicaltrials.gov/show/NCT00691119||154991|
NCT00691132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007NT127|Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers|Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|February 2009|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|120|||Both|21 Years|70 Years|No|||August 2012|August 29, 2012|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691132||154990|
NCT00688987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 545|The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation|Cortisol, Central Obesity, and Insulin Resistance: Long Term Studies in Addison's Patients||Oregon Health and Science University|No|Completed|August 2000|August 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688987||155155|
NCT00689260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28358|Easypod United States User Trial|A Randomized, Multicenter, 3 Month Phase IV Study to Evaluate the Effect on Subject Adherence With Injection Schedule by Using the Easypod™ rhGH Delivery Device||EMD Serono|No|Completed|March 2008|October 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|42|||Both|10 Years|18 Years|No|||April 2015|April 27, 2015|May 22, 2008||No||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00689260||155134|Enrollment ended early due to slow enrollment. Only 44 enrolled of the 100 subjects needed. Of the 44 enrolled, only 35 subjects had valid device data for analysis.
NCT00689533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWSD0003|VEPTR Implantation to Treat Children With Early Onset Scoliosis Without Rib Abnormalities|VEPTR Implantation to Treat Children With Early Onset Scoliosis Without Rib Abnormalities: a Prospective Multicenter Study||Shriners Hospitals for Children|No|Recruiting|January 2008|January 2016|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Months|10 Years|No|Non-Probability Sample|The study population will be selected from participating children's hospitals, most likely        during spine clinic.|May 2008|May 29, 2008|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689533||155113|
NCT00687284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3515|Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus|Observational Study on Evaluation of Glycaemic Control in Patients Using Levemir® (Insulin Detemir) as Initiation Insulin Therapy by Levemir® (Insulin Detemir) Administered Once Daily as the Treatment for Type 2 Diabetes Mellitus.|START|Novo Nordisk A/S|No|Completed|February 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2188|||Both|6 Years|75 Years|No|Non-Probability Sample|Diabetes mellitus type 2|June 2012|June 26, 2012|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687284||155284|
NCT00687297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE0501|Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer|A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)||PrECOG, LLC.|Yes|Completed|April 2008|April 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|May 27, 2008|Yes|Yes||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00687297||155283|
NCT00686517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03552|Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)|An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-week Course of PEG-Interferon Alpha-2b Versus a 12-week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C||Merck Sharp & Dohme Corp.|No|Completed|December 2003|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|130|||Both|18 Years|65 Years|No|||July 2015|July 6, 2015|May 27, 2008|No|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00686517||155343|
NCT00688480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK001|Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?|Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?||University of Dundee|Yes|Completed|January 2008|February 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|June 24, 2010|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688480||155194|
NCT00688493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00001|Effects of Single Oral Dose Dapagliflozin QT Study|A Double-blind, Randomized, Four-period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years||AstraZeneca|No|Completed|July 2007|April 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688493||155193|
NCT00684177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC110977|Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)|A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL||GlaxoSmithKline|No|Completed|May 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|508|||Both|2 Months|N/A|No|||August 2012|August 23, 2012|May 22, 2008|Yes|Yes||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00684177||155522|
NCT00684190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00016|Drug Interaction Study Between AZD3355 and Nexium|An Open, Randomised, Three Period Cross, Single Centre, Phase 1 Pharmacokinetic Interaction Study of the Reflux Inhibitor AZD3355 150 mg Bid and Esomeprazole 40 mg od After 7 Days of Treatment in Healthy Volunteers||AstraZeneca|No|Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|May 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00684190||155521|
NCT00684203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04772|Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)|Phase II Study of SCH 530348 in Subjects With Acute Coronary Syndrome||Merck Sharp & Dohme Corp.|Yes|Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|120|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 22, 2008|Yes|Yes||No|May 9, 2014|https://clinicaltrials.gov/show/NCT00684203||155520|
NCT00684489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11023|Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension|Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled or Complicated Hypertension|Renin|Medical University of South Carolina|No|Completed|September 2003|September 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 22, 2008|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00684489||155498|
NCT00684541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Amir|Interpretation Modification Program for Social Phobia|Interpretation Modification Program for Social Phobia|SP Interp|San Diego State University|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|65 Years|No|||April 2014|April 2, 2014|May 22, 2008||No||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00684541||155494|
NCT00684866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-311|Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma|A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatric Subjects With Asthma||Sunovion|No|Completed|January 2003|July 2003|Actual|July 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|4 Years|11 Years|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00684866||155469|
NCT00685126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-033|Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)|A Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects Birth to 48 Months Old With Reactive Airways Disease in an Acute Setting||Sunovion|No|Completed|February 2001|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|117|||Both|N/A|48 Months|No|||February 2012|February 21, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685126||155449|
NCT00685399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2208|Safety and Efficacy of AIN457 in Noninfectious Uveitis|An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis||Novartis|No|Completed|June 2008|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|79|||Both|18 Years|75 Years|No|||November 2013|November 18, 2013|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685399||155428|
NCT00685737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNAI-002|Safety of a Hypolipidemic Agent in Healthy Normal Volunteers|A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of 1-MNA, (A Hypolipidemic Agent) in Healthy Volunteers|PNAI-002|Pharmena North America|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 25, 2008|May 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00685737||155402|
NCT00685750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109752|Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma|Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma||GlaxoSmithKline||Terminated|April 2008|December 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|7||Actual|219|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|May 23, 2008||No|Slow enrolment over the last 2 years with none in the past 1 year. No increase in the number    of completed subjects for 1 year and no more ongoing study subjects|No||https://clinicaltrials.gov/show/NCT00685750||155401|
NCT00686023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-ES-0054|Comparing Surgical Techniques for CRIF of Pertrochanteric Fractures|Comparing Surgical Techniques for CRIF of Pertrochanteric Fractures||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2008|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||May 2008|May 28, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686023||155380|
NCT00686036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200L00010|Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy|A Randomized, Double-blind, Multicentre, Phase II Controlled Trial Assessing ZACTIMATM (Vandetanib) Against Placebo in Prolonging the Off-treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy|ZENITH|AstraZeneca|No|Terminated|May 2008|October 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|N/A|No|||April 2011|April 27, 2011|May 27, 2008|Yes|Yes|Slow recruitment|No|April 27, 2011|https://clinicaltrials.gov/show/NCT00686036||155379|It was planned that approx 100 patients would be recruited over a period of approx 2 years, due to slow recruitment the study was terminated early. No statistical analyses was done and no conclusion can be drawn about the outcomes in this study.
NCT00689962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lisfranc 1|A Comparison of Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|A Randomized, Prospective Comparison of Stainless Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|Lisfranc|Rothman Institute Orthopaedics|Yes|Recruiting|July 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|May 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00689962||155080|
NCT00689949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144-08|Validation of Urinary Biomarkers of Folate Status|Determination of the Suitability of Urinary Total P-aminobenzoylglutamate (p-ABG)and Formiminoglutamate (FIGLU) as a Markers for Folate Status||Ludwig-Maximilians - University of Munich|No|Completed|June 2008|December 2012|Actual|October 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|53|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689949||155081|
NCT00690833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002928|Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis|Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis||Wake Forest School of Medicine|No|Completed|August 2007|November 2009|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|3 Months|N/A|No|||June 2008|March 24, 2010|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690833||155013|
NCT00690846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002156|Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum|A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)||Wake Forest School of Medicine|No|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 2, 2008|Yes|Yes|Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the    study started.|No||https://clinicaltrials.gov/show/NCT00690846||155012|
NCT00690859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2007/1|Predictors of Recurrence in Bipolar Disorder in Spain|Evaluation of Predictor Factors of Recurrence in Bipolar Disorder in Spain|PREBIS|AstraZeneca|No|Completed|June 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|595|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months        prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic        or mixed) within the year prior to recruitment.|May 2009|May 28, 2009|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690859||155011|
NCT00691145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-IT-01|Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis|A Long-term, Non-comparative, Multi-centre Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus (FK506) Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis FG-506-06-IT-01||Astellas Pharma Inc|No|Completed|October 2002|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|350|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691145||154989|
NCT00689000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-2797-002|Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)|A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma||Chroma Therapeutics|Yes|Completed|May 2006|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||October 2010|October 21, 2010|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689000||155154|
NCT00685880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006348|Prolotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis|Randomized, Double Blind Comparison Trial of Prolotherapy (Dextrose) Compared to Corticosteroid Injection for the Treatment of Symptomatic Thumb Carpo-metacarpal Joint Arthritis||Mayo Clinic|No|Terminated|May 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|45 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 27, 2012|May 26, 2008||No|Unable to recruit adequate numbers of patients|No|July 27, 2012|https://clinicaltrials.gov/show/NCT00685880||155391|Early termination due to low enrollment; no subject data was analyzed.
NCT00686192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC001|Calcium and Lipid Metabolism|The Effects of Calcium Supplementation on Adipocyte Metabolism in Overweight Women||USDA, Western Human Nutrition Research Center|No|Completed|September 2001|July 2002|Actual|July 2002|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||May 2008|July 21, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686192||155368|
NCT00687921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-EE-118-CTIL|F18-Flouride PET/CT in Acute Knee Injury|F18-Flouride PET/CT in Acute Knee Injury. A Prospective Study||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|June 2008|June 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|None Retained|not relevant|Both|18 Years|85 Years|No|Probability Sample|patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are        scheduled for arthroscopy|May 2008|May 30, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00687921||155237|
NCT00688545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191344|Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis|SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs|SINCERE|Pfizer|No|Terminated|April 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|275|||Both|2 Years|17 Years|No|Non-Probability Sample|Juvenile Idiopathic Arthritis (JIA) subtypes that correspond to the former Juvenile        Rheumatoid Arthritis (JRA) classification system who are treated by a participating        pediatric rheumatologist and treated with either celecoxib or an nsNSAID; celecoxib or        nsNSAID must be new treatment or recent initiation (within last 6 months).|July 2013|July 22, 2013|May 29, 2008|Yes|Yes|See termination reason in detailed description.|No|May 7, 2013|https://clinicaltrials.gov/show/NCT00688545||155189|Study terminated prematurely: Sponsor released by FDA from post-marketing commitment. As a result, only a small number of participants/analyses could be performed, data must be interpreted with caution. Endpoints arbitrarily assigned as primary.
NCT00688558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT705-X-03-003|Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels|A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels||Akros Pharma Inc.|No|Completed|February 2004|March 2006|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|70 Years|No|||May 2008|June 2, 2008|May 29, 2008||||No||https://clinicaltrials.gov/show/NCT00688558||155188|
NCT00684502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00002|Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects|A Phase I, Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects After Oral Multiple Ascending Doses||AstraZeneca|Yes|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|110|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2008|December 8, 2010|May 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00684502||155497|
NCT00684515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05005|Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)|Phase II Study of SCH 530348 in Subjects With Cerebral Infarction||Merck Sharp & Dohme Corp.|Yes|Completed|September 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|May 22, 2008|Yes|Yes||No|May 9, 2014|https://clinicaltrials.gov/show/NCT00684515||155496|
NCT00684892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT01029|Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)|A Safety and Feasibility Study of the Chartis System in Subjects With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)||Pulmonx, Inc.|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00684892||155467|
NCT00685451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA016574|Cognitive Therapy for PTSD in Addiction Treatment|Cognitive Therapy for PTSD in Addiction Treatment||Dartmouth-Hitchcock Medical Center|No|Completed|November 2004|November 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685451||155424|
NCT00684853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pep1|Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD|Intravitreal Bevacizumab Combined With PDT (Full Fluence) Versus Bevacizumab to Treat Exudative Age-Related Macular Degeneration||Federal University of São Paulo|Yes|Recruiting|November 2007|||May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|N/A|No|||May 2008|May 27, 2008|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00684853||155470|
NCT00685763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0609-PC01|Proton Therapy for Unresectable Cancer (CA) of Pancreas|A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas|PC01|University of Florida|Yes|Active, not recruiting|March 2008|December 2020|Anticipated|October 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|100 Years|No|||January 2016|January 22, 2016|May 22, 2008|Yes|Yes||No|May 23, 2014|https://clinicaltrials.gov/show/NCT00685763||155400|
NCT00686400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07R-1815, SMRI|A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia|A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia||Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|May 2008|May 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|360|Samples With DNA|serum, CSF if patients agree to lumbar puncture all frozen and stored at -80 degree Celsius      until analysis|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients who are admitted to inpatient treatment due to a first episode of psychotic        symptoms, diagnoses of schizophrenia, schizophreniform and schizoaffective disorder age-        and gender-matched control subjects|May 2008|January 22, 2010|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686400||155352|
NCT00686049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 065|HIV Treatment-Readiness Measure (HTRM) Validation|Validation of the HIV Treatment Readiness Measure (HTRM)||Westat|Yes|Completed|May 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|13 Years|24 Years|No|Non-Probability Sample|HIV-infected, English speaking youth between 13 and 24 years of age who are enrolled in        care at an AMTU or collaborating site, not currently on HAART but planning to initiate        HAART within the next two months.|February 2016|February 29, 2016|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686049||155378|
NCT00689975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588427|Diet and Exercise or Normal Care in Overweight or Obese Women Who Have Undergone Treatment for Stage I, Stage II, or Stage III Breast Cancer|The Effects of a Combined Diet and Exercise Intervention on Biomarkers Associated With Disease Recurrence After Breast Cancer Treatment: The Sheffield DEBRA Trial||National Cancer Institute (NCI)||Completed|February 2006|||October 2008|Actual|N/A|Interventional|Allocation: Randomized|1||Anticipated|100|||Female|N/A|N/A|No|||December 2009|August 23, 2013|June 3, 2008||||No||https://clinicaltrials.gov/show/NCT00689975||155079|
NCT00690261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709004R|The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction|The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction||National Taiwan University Hospital|Yes|Recruiting|September 2007|August 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Pleural effusions and lung cancer tissue|Both|18 Years|90 Years|No|Probability Sample|patients diagnosed of lung cancer with malignant pleural effusions|May 2008|June 3, 2008|June 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00690261||155057|
NCT00690222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDA-RS/2008-024|Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery|A Comparison of Intracameral Phenylephrine 2% and Tropicamide 0.2% With Topical Phenylephrine 2.5% and Tropicamide 1% for Pupillary Dilation During Cataract Surgery on Patients With and Without Pseudoexfoliation Syndrome.||Nova Scotia Health Authority|No|Terminated|March 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|N/A|No|||May 2008|March 24, 2015|May 30, 2008||No|Funding|No||https://clinicaltrials.gov/show/NCT00690222||155060|
NCT00690235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092007-025|Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Effects of Pramlintide on Weight Reduction in Clozapine- and Olanzapine-Induced Weight Gain in Obese People Diagnosed With Schizophrenia||University of Texas Southwestern Medical Center|Yes|Completed|November 2007|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|33|||Both|18 Years|65 Years|No|||June 2012|June 21, 2012|January 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690235||155059|
NCT00691171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GUS-DUM-2007/1|Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use|Using an Electronic Health Record-based Intervention and Broad Education Reach Strategies to Improve Quality of Care for GERD and Gastroprotection for Patients on NSAIDs: a Randomized Controlled Trial||AstraZeneca|No|Completed|January 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|5234|||Both|18 Years|N/A|No|Non-Probability Sample|Primarily primary care practices of physicians participating in the Medical Quality        Improvement Consortium (MQIC)|April 2015|April 14, 2015|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00691171||154987|
NCT00685321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0024-07-SHA|Tolerability, Safety and Efficacy of the H1-coil Deep Transcranial Magnetic Stimulation in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia|A Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia||Shalvata Mental Health Center|Yes|Recruiting|June 2008|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|65 Years|No|||January 2012|January 4, 2012|May 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00685321||155434|
NCT00685594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2008-1|Vitamin D for the Prevention of Diabetes Type 2|Prevention of Type 2 Diabetes With Vitamin D Supplementation in Subjects With Reduced Glucose Tolerance Detected in the Tromso Study 2007/2008||University of Tromso|Yes|Completed|March 2008|September 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|511|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|May 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00685594||155413|
NCT00685893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23503-G|Integrating Palliative and Critical Care (IPACC) Study|An ICU Intervention to Improve End-of-Life Care|IPACC|University of Washington|Yes|Completed|June 2003|October 2010|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|3498|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00685893||155390|
NCT00687661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUICK Study|Queen's University Investigation of Calcification in Chronic Kidney Disease|The Use of Bisphosphonates to Prevent or Delay the Progression of Vascular Calcification in End-Stage Renal Disease: A Randomized Controlled Trial|QUICK|Queen's University|Yes|Completed|October 2008|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|May 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00687661||155257|
NCT00687674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597065|Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase I/II Study of Sorafenib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma||Mayo Clinic|Yes|Terminated|August 2008|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|May 30, 2008|Yes|Yes|Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II    portion.|No|November 23, 2011|https://clinicaltrials.gov/show/NCT00687674||155256|
NCT00687687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11615|Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma|A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma||Sanofi|No|Completed|May 2008|December 2011|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||August 2012|August 1, 2012|May 28, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00687687||155255|
NCT00687700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAB110553|A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers|A Study to Investigate the Relative Pharmacological Activity of Aninhaled B2-agonist/Anticholinergic Dual Pharmacophore Inhealthy Volunteers||GlaxoSmithKline|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|23|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|May 28, 2008||||No||https://clinicaltrials.gov/show/NCT00687700||155254|
NCT00687934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-02|Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors||Synta Pharmaceuticals Corp.|No|Completed|October 2007|October 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|25 Years|N/A|No|||September 2014|September 17, 2014|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687934||155236|
NCT00688207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA109941|Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)|An Open Label, Single Oral Dose Study in Patients With Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population||GlaxoSmithKline||Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|50 Years|90 Years|No|||October 2010|October 14, 2010|May 28, 2008||||No||https://clinicaltrials.gov/show/NCT00688207||155215|
NCT00683995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2246-0703|A Phase III Clinical Study of KW-2246|A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients||Kyowa Hakko Kirin Company, Limited|No|Completed|March 2008|||July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|20 Years|80 Years|No|||August 2012|August 23, 2012|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00683995||155536|
NCT00684580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJLTFU|Protocol For Collecting Data On Patients With Childhood Cancer|Protocol For Collecting Data On Patients With Childhood Cancer||St. Jude Children's Research Hospital|No|Recruiting|May 2000|May 2025|Anticipated|May 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|All patients actively being treated and previously treated at St. Jude Children's Research        Hospital for childhood cancer.|December 2015|December 18, 2015|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00684580||155491|
NCT00684593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04481|A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)|A Study to Assess the Clinical Effects of SCH 527123 in Psoriasis||Merck Sharp & Dohme Corp.|No|Completed|June 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|May 22, 2008|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00684593||155490|
NCT00683943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080134|Lithium Treatment for Patients With Spinocerebellar Ataxia Type I|Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1)||National Institutes of Health Clinical Center (CC)||Completed|May 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||February 2014|February 28, 2014|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00683943||155540|
NCT00684216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N07MAN|Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer|Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer||The Netherlands Cancer Institute|No|Terminated|April 2008|May 2013|Anticipated|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Female|N/A|N/A|No|||May 2012|May 10, 2012|May 22, 2008||No|acrual too slow|No||https://clinicaltrials.gov/show/NCT00684216||155519|
NCT00688948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2007-035|Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)|A Pilot Study Looking At The Use Of Alfuzosin In The Treatment Of Bladder Dysfunction In Patients With Multiple Sclerosis||Nova Scotia Health Authority|No|Terminated|November 2007|November 2009|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2009|June 23, 2011|May 30, 2008||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00688948||155158|
NCT00679991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-201-101|A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients|A Phase 1-2, Multi-Center, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease||Proteon Therapeutics|Yes|Completed|November 2008|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679991||155838|
NCT00680004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dCTA-2006-YH|Dynamic Computed Tomography Angiography (CTA) Follow-up for EndoVascular Aortic Replacement (EVAR)|The Value of Dynamic CTA During the Follow-up of EndoVascular Aortic Replacement (EVAR): a Pilot Study||Radboud University|Yes|Recruiting|January 2007|December 2009|Anticipated|September 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|patients undergoing either a preoperative CT procedure or with an implanted aortic        endoprothesis (-graft) presenting to the department of radiology for a scheduled follow-up        CTA procedure.|May 2008|May 16, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680004||155837|
NCT00689468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arizona HSC #98-83|Echinacea Purpurea and Osteopathy in Children With Recurrent Otitis Media|Echinacea Purpurea and Cranial Osteopathic Manipulative Treatment in Children With Recurrent Otitis Media: a Randomized Controlled Trial.||University of Arizona|Yes|Completed|July 1999|October 2002|Actual|September 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|90|||Both|12 Months|60 Months|Accepts Healthy Volunteers|||May 2008|May 30, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689468||155118|
NCT00689767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801|COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)|COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms|CONFIRM 1|Atrium Medical Corporation|Yes|Terminated|June 2008|July 2012|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|June 2, 2008||No|Terminated ahead of schedule after completion of the 3-year follow-up time point due to    Sponsor decision.|No||https://clinicaltrials.gov/show/NCT00689767||155095|
NCT00679978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SaitamaVFOFH|Vertebral Fracture and Osteonecrosis Associated With High-dose Glucocorticoid|Vertebral Fracture and Osteonecrosis of the Femoral Head Associated With High-dose Glucocorticoid Therapy||Saitama Medical University|No|Completed|January 2001|October 2007|Actual|October 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|20 Years|N/A|No|Probability Sample|Patients admitted to our hospital for the treatment of active systemic rheumatic diseases        taking at least 0.5 mg/kg/day for PSL equivalent|September 2009|September 17, 2009|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679978||155839|
NCT00680277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV2270|Vitamin A Value of Spirulina Carotenoids in Humans|Vitamin A Value of Spirulina Carotenoids in Humans||Tufts University|No|Active, not recruiting|April 2004|May 2009|Anticipated|March 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680277||155816|
NCT00680524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-184|Telephone-based Care for OEF/OIF Veterans With PTSD|Telephone Based Care for OIF/OEF Veterans With PTSD||VA Office of Research and Development|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|April 6, 2015|May 16, 2008||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00680524||155797|
NCT00694590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ00207|Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Sanofi|No|Completed|June 2008|September 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||March 2015|March 19, 2015|June 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694590||154727|
NCT00694876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Health Literacy|Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India|Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India||Robin, Alan L., M.D.|No|Completed|June 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|250|||Both|18 Years|69 Years|No|Probability Sample|Glaucoma Patients from Aravind Eye Hospital at Madurai, Tamil Nadu, India|November 2012|November 29, 2012|June 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00694876||154705|
NCT00661622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04F.445|Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF|Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)||Thomas Jefferson University|Yes|Completed|October 2004|June 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|April 16, 2008|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00661622||157239|
NCT00661921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070212|A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus|A Mutiple Dose, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous AMG 108 in Patients With Type 2 Diabetes Mellitus||Amgen||Withdrawn|June 2008|October 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|200|||Both|18 Years|N/A|No|||February 2009|February 5, 2009|April 17, 2008|||Program Development discontinued|No||https://clinicaltrials.gov/show/NCT00661921||157216|
NCT00661934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR-R-01|Recording of Heart Signals From the Chest Wall|Recording of Heart Signals From the Chest Wall||Hillel Yaffe Medical Center|Yes|Recruiting|May 2008|May 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|80 Years|No|Probability Sample|The study will be conducted on a maximum of 200 adult subjects (age above 18), from 2        groups:        Group 1: Dialysis Patients Group 2: Patients after Myocardial Infarction,Patients        suffering from CHF, patients in ICCU and patients hospitalized in Cardiology Unit.|July 2008|July 30, 2008|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00661934||157215|
NCT00662181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-053|Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone|Follow-up on the HIGH: Low Study - the Longterm Effect of Growth Hormone||Hvidovre University Hospital|Yes|Not yet recruiting|May 2008|January 2009|Anticipated|October 2008|Anticipated|N/A|Observational|N/A||1|Anticipated|46|||Male|18 Years|N/A|No|Non-Probability Sample|Participants from the HIGH: low study|April 2008|April 18, 2008|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00662181||157196|
NCT00695396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013651|A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion|A Randomized, Double Blind, Placebo Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes at Risk For Transfusion||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|June 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|June 5, 2008|Yes|Yes|The study was stopped due to low subject enrollment. No safety issue or other concern factored    into this decision.|No|February 8, 2011|https://clinicaltrials.gov/show/NCT00695396||154665|Because this study was terminated prematurely due to slow enrollment, only limited data were collected. No formal statistical testing was performed. Only descriptive statistics were provided.
NCT00695409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07076|Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, and High-Dose Combination Chemotherapy Followed By Peripheral Blood Stem Cell Transplant in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma|A Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody in Combination With High-Dose Beam (BCNU, Etoposide, Cytarabine and Melphalan) Followed by Autologous Stem Cell Transplantation for Patients With Poor Risk/Relapsed B-Cell Lymphoma||City of Hope Medical Center|Yes|Active, not recruiting|March 2008|||March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|118|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695409||154664|
NCT00695695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908142|The Experience of Caregivers of Children With Down Syndrome|The Role of Hope in Adaptation to Uncertainty: The Experience of Caregivers of Children With Down Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 2008|February 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00695695||154642|
NCT00691158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB #2168|A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide|A Pilot Study of the fMRI Response to Leptin and Pramlintide||Oregon Health and Science University|Yes|Active, not recruiting|January 2006|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 4, 2012|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691158||154988|
NCT00691743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GGR-DUM-2008/1|Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2|Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2|NSAIDS II|AstraZeneca||Completed|March 2008|December 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|850|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care|January 2009|January 9, 2009|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691743||154943|
NCT00691756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-9764|A Comparison of Renal Perfusion in Thoracoabdominal Aortic Aneurysm (TAAA) Repair|A Comparison of Cold Blood Versus Cold Crystalloid Renal Perfusion for Prevention of Acute Renal Failure Following Thoracoabdominal Aortic Aneurysm Repair: A Randomized Study||Baylor College of Medicine|No|Completed|January 2002|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|N/A|No|||June 2008|June 4, 2008|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691756||154942|
NCT00691730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHL-064|Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer|The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure||University Health Network, Toronto||Active, not recruiting|February 2008|||June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00691730||154944|
NCT00692393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/103/HP|Primary vs. Secondary Anastomosis for Hinchey Stage III-IV Diverticulitis a Prospective Randomized Trial|Primary vs. Secondary Anastomosis After Sigmoid Colon Resection for Perforated Diverticulitis (Hinchey Stage III and IV): a Prospective Multicentric Randomized Trial|DIVERTI|University Hospital, Rouen|No|Completed|June 2008|November 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692393||154893|
NCT00692679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1261|FMRI of Cholinergic Mechanisms in Schizophrenia|FMRI of Cholinergic Mechanisms in Schizophrenia||VA Eastern Colorado Health Care System|No|Not yet recruiting|May 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with schizophrenia|July 2012|July 25, 2012|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692679||154871|
NCT00692692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070416|Use of Dermal Matrix in Breast Reconstruction|The Use of An Acellular Dermal Matrix Sling in a Two-stage Breast REconstruciton After Mastectomy: A Double-blinded Randomized Trial||Vanderbilt University|No|Terminated|June 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|75 Years|No|||July 2013|August 3, 2013|June 4, 2008||No|higher rate of post-operative infectin in the Dermal Matrix arm of the study|No|August 3, 2013|https://clinicaltrials.gov/show/NCT00692692||154870|Study was terminated early due to more infections recorded in the dermal matrix group; I currently do not have the exact number
NCT00692705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0180C00018|Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid|Open Label Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease|PET|AstraZeneca|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|13|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||January 2009|January 22, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00692705||154869|
NCT00692718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFAHeft|N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure|N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure||Osaka General Medical Center||Not yet recruiting|July 2008|||June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|160|||Both|20 Years|N/A|No|||June 2008|June 18, 2008|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00692718||154868|
NCT00692978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0712/63|Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate|The Pharmacokinetics of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols||Imperial College London|No|Completed|August 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|April 5, 2013|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692978||154848|
NCT00693264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0005|Effects of Hoodia on Blood Pressure and Heart Function|The Hemodynamic and Electrocardiographic Effects of Hoodia Gordonii in Healthy Volunteers||University of Mississippi Medical Center|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2009|March 27, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693264||154826|
NCT00683787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000596150|Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer|Multicenter Randomized Phase II Trial of Docetaxel With/Without VANDETANIB for Advanced Gastroesophageal Cancer||Roswell Park Cancer Institute|Yes|Terminated|May 2008|March 2011|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|75 Years|No|||December 2014|December 29, 2014|May 21, 2008|Yes|Yes|low accrual|No|May 12, 2014|https://clinicaltrials.gov/show/NCT00683787||155552|Due to the study's early termination and inadequate number of patients no statistical inference of the primary and secondary aims were carried forth.
NCT00680017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-313|30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease|A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease||AstraZeneca||Completed|June 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|May 15, 2008|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00680017||155836|
NCT00679692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-950123|Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease|Insulin-Like Growth Factor-1,Insulin-Like Growth Factor Binding Protein-3 and Human Growth Hormone in Serum of Patients With Chronic Liver Disease and Possible Clinical Applications.||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|September 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|210|Samples Without DNA|serum|Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Acute hepatitis liver cirrhosis hepatocellular carcinoma|January 2006|May 16, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679692||155861|
NCT00680550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 466|INSIGHT (R)XT. Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT|Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT.||Medtronic BRC|No|Completed|April 2008|April 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1003|||Both|18 Years|N/A|No|Probability Sample|Patients currently implanted with, or who will be implanted with a Reveal XT Insertable        Cardiac Monitor for arrhythmia diagnosis or monitoring.|October 2013|October 15, 2013|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680550||155795|
NCT00680784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKT-500-US10|HKT-500 in Adult Patients With Ankle Sprain|Protocol HKT-500-US10: A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Grade I or Grade II Ankle Sprain||Hisamitsu Pharmaceutical Co., Inc.|Yes|Completed|April 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|260|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680784||155777|
NCT00694564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD060705|Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children|A Pilot Open-labeled Trial of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children||Huang, Jeannie, M.D.|Yes|Completed|June 2007|July 2012|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|8 Years|22 Years|No|||January 2016|January 27, 2016|June 6, 2008|No|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00694564||154729|
NCT00694577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-179|Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer|Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer: A Phase I Feasibility/Pilot Study||Massachusetts General Hospital|Yes|Active, not recruiting|September 2003|September 2019|Anticipated|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|330|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|June 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694577||154728|
NCT00694850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12916|Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)|A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension.||Bayer|No|Active, not recruiting|August 2008|October 2018|Anticipated|October 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00694850||154707|
NCT00694863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.1|Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy|Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study|ACTHiMeN|Radboud University|No|Completed|July 2008|December 2012|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|95 Years|No|||December 2010|January 4, 2013|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00694863||154706|
NCT00695149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHA_SCI0401|Treatment for Acute Spinal Cord Injury|Clinical Study of Treatment for Acute Spinal Cord Injury Using Cultured Bone Marrow Stromal Cells||Translational Research Informatics Center, Kobe, Hyogo, Japan||Terminated|July 2005|March 2010|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|15 Years|60 Years|No|||June 2011|June 1, 2011|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695149||154684|
NCT00695162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#11-3307|Speech Intelligibility and Cognition: Are Inpatients Impaired by Noise?|Speech Intelligibility and Cognition: Are Inpatients Impaired by Noise?||Portland VA Medical Center|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|84|||Both|18 Years|88 Years|No|||February 2011|February 15, 2011|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695162||154683|
NCT00695175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2007/6|National Survey on Hypertension in Cardiologic Private Practice|Profile of Hypertensive Patients Seen in Private Cardiology Consultation|Prophyl C|AstraZeneca|No|Completed|February 2008|September 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1800|||Both|18 Years|N/A|No|Probability Sample|First three consecutive patients with hypertension seen by Cardiologists|August 2009|August 4, 2009|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695175||154682|
NCT00691444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 1251|Blind Child Melatonin Treatment Study|Melatonin Studies of Blind Children||Oregon Health and Science University|Yes|Recruiting|September 2002|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|26|||Both|5 Years|20 Years|No|||November 2014|November 4, 2014|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691444||154966|
NCT00691769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000301|Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia|Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia||Wake Forest School of Medicine|No|Active, not recruiting|April 2006|December 2015|Anticipated|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|25|Samples With DNA|Two, 4mm punch biopsies will be obtained of skin tissue.|Female|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Wake Forest University Health Sciences Dermatology Clinic.|December 2015|December 9, 2015|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00691769||154941|
NCT00691782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003923|The Impact of African American Women's Hair Care Practices and Hair Attitudes on Exercise Habits|The Impact of African American Women's Hair Care Practices and Hair Attitudes on Exercise Habits||Wake Forest School of Medicine|No|Active, not recruiting|September 2007|March 2016|Anticipated|October 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Female|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|African American females between the ages of 21 and 60.These subjects will be recruited        from Wake Forest University Health Sciences Dermatology clinic and our Institutional        Review Board (IRB) approved advertising.|December 2015|December 9, 2015|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00691782||154940|
NCT00692081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVULM|Social Competence Training for Adolescents With Borderline Intellectual Functioning|A Randomized Controlled Trial of a Social Competence Group Training for Adolescents With Borderline Intellectual Functioning|SCT-ABI|University of Ulm|No|Completed||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|16 Years|23 Years|No|||June 2008|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692081||154917|
NCT00692380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-10274|Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable NSCLC|A Phase I Dose Intensification Study Using Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Patients With Inoperable, Non-Small Cell Lung Cancer||Virginia Commonwealth University|Yes|Terminated|June 2006|June 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|N/A|N/A|No|||April 2013|April 23, 2013|June 3, 2008|No|Yes|insufficient accrual|No||https://clinicaltrials.gov/show/NCT00692380||154894|
NCT00692406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007082|Neuroimaging Attentional Impairment During Abstinence|Neuroimaging Attentional Impairment During Abstinence|SmokeAtt01|Duke University|No|Completed|June 2005|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|June 3, 2008||No||No|February 22, 2009|https://clinicaltrials.gov/show/NCT00692406||154892|
NCT00682929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200311404|Cannabis for Spasticity in Multiple Sclerosis|Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study||University of California, Davis|Yes|Recruiting|March 2003|June 2013|Anticipated|January 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|N/A|No|||July 2012|July 5, 2012|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682929||155616|
NCT00683241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 11807|A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer|A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine Leaded With Autologous Tumor Cell Lysate for Recurrent Ovarian or Primary Peritoneal Cancer||Abramson Cancer Center of the University of Pennsylvania|No|Completed|November 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||February 2013|February 25, 2013|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683241||155593|
NCT00683254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sanostec-200701751|Analysis of Impact on Nasal Obstruction by Commercially Available Internal Nasal Stents|Analysis of Impact on Nasal Obstruction by Commercially Available Internal Nasal Stents||University of Iowa|No|Not yet recruiting|May 2008|August 2008|Anticipated|August 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|35|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Our subject pool will be comprised of healthy volunteers, at least 18 years of age, who        have not had nasal surgery, are not currently using a topical decongestant, topical nasal        steroid spray, or over the counter decongestant, and have no history of recurrent        epistaxis or a running nosebleed within 2 weeks prior to data collection.|May 2008|May 22, 2008|May 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00683254||155592|
NCT00683527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-34/2006|Timing of Iron Supplementation in Very Low Birth Weight Infants|New Versus Standard Enteral Iron Supplementation Regime in Very Low Birth Weight Infants - A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|No|Completed|May 2006|January 2007|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|N/A|60 Days|No|||May 2008|May 21, 2008|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683527||155571|
NCT00679705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/110|Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself|Pilot Study: A Dose-Response Finding Study of Ritodrine (Pre-Par®) to Find the Highest Well Tolerated Dose in Young, Healthy, Female Volunteers. To Find the Size-Order of the Hemodynamical Effects of Ritodrine (PrePar®) and Atosiban (Tractocile®) to Determine the Relevance of a PK/PD-Modelling in the Final Study. Final Study: Investigating the Influence of Tocolytical Medications: Ritodrine (PrePar®) and Atosiban (Tractocile®) at the Clinical Dose on the Hemodynamics and Arterial Function in Healthy Female Volunteers, Compared to Placebo During Continuous Intravenous Infusion.||University Hospital, Ghent|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|23|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2009|April 17, 2009|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679705||155860|
NCT00680030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 06/91|Reversibility of Dysmotility After Gastric Banding|Reversibility of Esophageal Dysmotilities Associated With Gastric Banding After Conversion to Gastric Bypass||Cantonal Hospital of St. Gallen|Yes|Enrolling by invitation|September 2007|December 2008|Anticipated|September 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|70 Years|No|Non-Probability Sample|Morbidly obese patients in whom a conversion from gastric band to gastric bypass is planed|May 2008|May 15, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680030||155835|
NCT00680290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW IRB 072004-047|The Effect of Low Intensity Exercise on Quality of Life and Hemodynamics in Patients With Permanent Atrial Fibrillation|The Effect of Low Intensity Exercise on Quality of Life and Hemodynamics in Patients With Permanent Atrial Fibrillation||University of Texas Southwestern Medical Center|No|Recruiting|July 2007|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||May 2008|May 19, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680290||155815|
NCT00680303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402763-17|Spacing Lidcombe Program Clinic Visits|The Effect of Spacing of Lidcombe Program Clinic Visits||University of Sydney|Yes|Recruiting|January 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|120|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||April 2008|May 15, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680303||155814|
NCT00680563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21467|A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.|An Open Label Study of the Safety, Tolerability and Effect on Hemoglobin Levels of Once-monthly Subcutaneous Mircera in Predialysis Patients With Chronic Renal Anemia Not Currently Treated With ESA.||Hoffmann-La Roche||Terminated|April 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680563||155794|
NCT00680797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCD-034-04F|Metabolic Effects of Androgenicity in Aging Men and Women|Metabolic Effects of Androgenicity in Aging Men and Women||VA Office of Research and Development|Yes|Active, not recruiting|January 2005|July 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|33|||Male|60 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|May 8, 2008||No||No|July 24, 2014|https://clinicaltrials.gov/show/NCT00680797||155776|Small sample size may limit generalizability of these results. Follow-up studies are being conducted to further evaluate these results.
NCT00694330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-349|Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor|A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor||Massachusetts General Hospital|Yes|Recruiting|June 2008|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|June 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694330||154747|
NCT00695136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080154|The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism|An Investigation of the Relationship Between Donepezil Enhanced REM Sleep, Sleep Architecture and Behavior in the Prepubertal Child With Autism||National Institutes of Health Clinical Center (CC)|No|Completed|June 2008|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|2 Years|10 Years|No|||April 2013|April 22, 2013|June 10, 2008|No|Yes||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00695136||154685|No controls and small number of patients.
NCT00694889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06TAF-972|Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia|Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia||University of California, San Francisco|No|Completed|August 2007|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|144|||Both|12 Years|35 Years|No|||May 2015|May 15, 2015|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00694889||154704|
NCT00663351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMA 030022|Safety and Effectiveness Study of the Reflection Ceramic Acetabular System|Post Approval Study: Reflection Ceramic Acetabular System|RCH|Smith & Nephew, Inc.||Completed|December 2004|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|456|||Both|21 Years|80 Years|No|||March 2015|March 18, 2015|February 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663351||157106|
NCT00691457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-09|Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina|Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina||Alcon Research|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||June 2009|September 28, 2012|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691457||154965|
NCT00691470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-505|Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation|A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation|EmbraceAC|ARYx Therapeutics|Yes|Active, not recruiting|May 2008|June 2009|Anticipated|June 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||October 2008|February 1, 2010|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691470||154964|
NCT00681993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-0805|Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens|"A Feasibility Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens (PBIC)"|PBIC|Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|April 2008|July 2017|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Female|18 Years|N/A|No|||November 2012|November 15, 2012|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681993||155685|
NCT00692094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 0194|Blind Elderly Melatonin Treatment Study|Melatonin Entrainment of Elderly Blind Free-runners||Oregon Health and Science University|Yes|Completed|August 2004|December 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|12|||Both|55 Years|N/A|No|||April 2014|April 8, 2014|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692094||154916|
NCT00682682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030091D|Reducing Brief Thermal and Electrical Pain (Four Study Days)|Reducing Brief Thermal and Electrical Pain (Four Study Days)|4DO|University of Washington|No|Completed|December 2007|December 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682682||155634|
NCT00683540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-156|Formative Evaluation in Implementation Research: Guideline Development|Formative Evaluation in Implementation Research: Guideline Development||VA Office of Research and Development|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|VA health services investigators|August 2014|April 6, 2015|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00683540||155570|
NCT00683800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A2-3353|Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women|A Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety And Efficacy Of DVS SR For The Treatment Of Vasomotor Symptoms Associated With Menopause||Pfizer|Yes|Completed|June 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2186|||Female|45 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 21, 2011|May 21, 2008|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00683800||155551|GCS scales were analyzed only for main study efficacy population.
NCT00683813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38390|Trial of a Cardiac Rehabilitation Program Delivered Remotely Through the Internet|Randomized Trial of a Cardiac Rehabilitation Program Delivered Remotely Through the Internet|vCRP|Simon Fraser University|No|Completed|November 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683813||155550|
NCT00679393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17526|Comparative Study of Fixation or Fusion of Calcaneal Fractures|A Prospective Randomized Multicentre Clinical Trial Comparing Open Reduction Internal Fixation With Primary Subtalar Fusion in Patients With Severely Comminuted (Sanders IV), Displaced, Intra-articular Fractures of the Calcaneus|Sanders IV|University of Calgary|No|Completed|February 2004|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|16 Years|59 Years|No|||February 2015|February 10, 2015|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679393||155884|
NCT00679718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-103|A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Patients With Moderate to Severe Dry Eye Disease||Merck Sharp & Dohme Corp.||Completed|January 2000|July 2000|Actual|July 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|N/A|N/A||||August 2015|August 26, 2015|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679718||155859|
NCT00679731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-255|A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis||AbbVie|Yes|Completed|April 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679731||155858|
NCT00691561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5394|Culturally-Tailored HIV Risk Reduction for African-American MSM|Culturally-Tailored HIV Risk Reduction for African-American MSM (Project ABLE: African-Americans Building Life Empowerment|Project ABLE|Centers for Disease Control and Prevention|No|Completed|June 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 10, 2010|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691561||154957|
NCT00680316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z4240g|A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis|A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme® in 3- to 5-Year-Old Patients With Cystic Fibrosis||Genentech, Inc.||Terminated|June 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|3 Years|5 Years|No|||May 2011|May 18, 2011|May 16, 2008|Yes|Yes|Most patients were unable to perform the test being used to measure lung function, thus it    became clear the study would not yield clinically meaningful data|No|August 31, 2010|https://clinicaltrials.gov/show/NCT00680316||155813|Children were unable to perform forced oscillometry (FOT) or did not remain stable during the study. No efficacy analyses were performed because no patients had complete (pre- or post-treatment) data for pulmonary function tests, including FOT.
NCT00680329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD-07-02|Glaucoma Adherence Study, Spain|A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening|GAS|Alcon Research|No|Completed|May 2008|July 2009|Actual|July 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Patients were selected from one study site in Spain.|May 2012|May 29, 2012|May 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680329||155812|
NCT00680576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA023568|Adolescent Substance Abuse: Progressive Treatment||ADAPT|Oregon Research Institute|No|Completed|March 2008|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680576||155793|
NCT00680823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08030283|Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache|Is Paraspinal Intramuscular Ropivacaine Injection an Effective Treatment for Headache in a Pediatric Emergency Department?||Children's Hospital of Pittsburgh|Yes|Recruiting|January 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680823||155775|
NCT00662545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A109324|Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection|Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection||University of California, San Francisco|Yes|Completed|April 2008|May 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|April 16, 2008||No||No|May 14, 2013|https://clinicaltrials.gov/show/NCT00662545||157168|
NCT00662558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191338|A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain|A Six Week Double-Blind, Randomized, Multicenter Comparison Study Of The Analgesic Effectiveness Of Celecoxib 200 Mg BID Compared To Tramadol Hydrochloride 50 Mg QID In Subjects With Chronic Low Back Pain||Pfizer|No|Completed|January 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|802|||Both|18 Years|N/A|No|||October 2009|October 21, 2009|December 6, 2007|Yes|Yes||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00662558||157167|
NCT00694603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-026|Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy|A Phase II Trial of Cetuximab (c225) as Therapy for Recurrent Non-Small Cell Lung Cancer in Patients Who Have Received Prior Therapy With Tyrosine Kinase Inhibitor Directed Against the EGFR Pathway||Massachusetts General Hospital|Yes|Terminated|September 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|December 28, 2007|Yes|Yes|Slow accrual|No|April 28, 2012|https://clinicaltrials.gov/show/NCT00694603||154726|
NCT00663052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-4425|Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis|A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis|PRISTINE|Pfizer|No|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|April 17, 2008||No||No|January 18, 2011|https://clinicaltrials.gov/show/NCT00663052||157129|
NCT00663338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/06/162|Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke|A Multi-centre Exploratory Study to Evaluate the Efficacy of the Dopamine Receptor Agonist Rotigotine in the Treatment of Hemispatial Neglect and Motor Deficits Following Stroke||University College, London|Yes|Completed|January 2010|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2010|February 18, 2011|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663338||157107|
NCT00681629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00048|Schizophrenic Patients in Integrated Care|CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Phase IV Study|CARE II|AstraZeneca|No|Terminated|July 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||June 2012|June 22, 2012|May 20, 2008|Yes|Yes|Difficulty finding eligible sites/patients; current situation in health policy cause negative    effect on existing/planned contracts for integrated care program|No|April 7, 2010|https://clinicaltrials.gov/show/NCT00681629||155713|The study was stopped due to poor enrollment and no data analysis was performed.
NCT00682695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS036695|Genetic and Environmental Risk Factors for Hemorrhagic Stroke|Genetic and Environmental Risk Factors for Hemorrhagic Stroke|GERFHS|University of Cincinnati|No|Completed|September 1997|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|3187|Samples With DNA|whole blood or buccal DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will be limited to physician-reviewed cases of people who have had a        hemorrhagic stroke and who live within a 50-mile radius of Cincinnati, Ohio.|May 2009|May 6, 2009|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682695||155633|
NCT00682708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07056|Sentinel Surveillance of Malnutrition, Niger|Sentinel Surveillance of Acute Malnutrition in the Region of Maradi, Niger, Children Under 5: Impact of a Preventive Intervention||Epicentre|No|Completed|August 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Primary Purpose: Prevention|||||||Both|6 Months|59 Months|Accepts Healthy Volunteers|||May 2008|May 21, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00682708||155632|
NCT00682344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000796-42|Pharmacokinetic of levobupivacaïne After Sciatic Nerve Block in Children|Pharmacokinetic of levobupivacaïne After Sciatic Nerve Block in Children||Assistance Publique Hopitaux De Marseille|No|Terminated|January 2008|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|6 Months|12 Years|No|||August 2014|August 27, 2014|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682344||155659|
NCT00682942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16500|How to Predict Lung Recruitment at the Bedside in Patients Affected by Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)|How to Predict Lung Recruitment at the Bedside in Patients Affected by Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)||Policlinico Hospital|No|Completed|May 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|patients affected by acute lung injury/acute respiratory distress syndrome who are        mechanically ventilated|November 2011|November 30, 2011|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00682942||155615|
NCT00683267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-03P|Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Intraoperative Localized Instillation of 4975 in Patients Undergoing Primary Unilateral Total Hip Arthroplasty||Anesiva, Inc.|No|Terminated|September 2007|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|85 Years|No|||May 2009|May 1, 2009|May 21, 2008|Yes|Yes|Enrollment of patients has halted prematurely and will not resume. No future patients will be    enrolled or treated.|No||https://clinicaltrials.gov/show/NCT00683267||155591|
NCT00683553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK.004|A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)|A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients at High Risk of Acute Kidney Injury Undergoing Major Cardiovascular Surgery||Quark Pharmaceuticals|Yes|Terminated|May 2008|September 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|3|||Both|21 Years|85 Years|No|||November 2010|November 12, 2010|May 21, 2008|Yes|Yes|Lack of an available patient population|No||https://clinicaltrials.gov/show/NCT00683553||155569|
NCT00679068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|525FSM|Effects of Bosentan on Respiratory Mechanics|Effects of 12 Weeks Treatment With Bosentan on Respiratory Mechanics in Patients With Pulmonary Hypertension||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Terminated|May 2008|June 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Both|18 Years|80 Years|No|||August 2015|August 19, 2015|May 14, 2008||No|lack of recruitment of patients|No||https://clinicaltrials.gov/show/NCT00679068||155909|
NCT00679081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-PER-004-CTX|A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage|A Prospective, Randomized, Controlled Pilot Study of CelTx(TM) (Apligraf®) as an Alternative to Tissue From the Palate in the Treatment of Gingival Recession Requiring Root Coverage||Organogenesis|No|Terminated|May 2008|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||January 2012|January 9, 2012|May 14, 2008|Yes|Yes||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00679081||155908|This study was terminated early due to suboptimal clinical outcomes. Due to two study design changes, the data could not be combined and analyzed for effectiveness (ie, no secondary effectiveness endpoints were tested).
NCT00679406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07110063|Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 1|Treatment of Insomnia in Military Veterans:Phase 1|BBTIMV1|University of Pittsburgh|Yes|Completed|June 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679406||155883|
NCT00679744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3448|A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis|A Dose-Escalated, Double-Blind, Placebo-Controlled, Randomized Phase I Clinical Trial of Pyrimethamine in Patients Affected With Chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff Variants)||Exsar Corporation|No|Withdrawn|May 2008|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|May 15, 2008|Yes|Yes|Due to lack of funding|No||https://clinicaltrials.gov/show/NCT00679744||155857|
NCT00679757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0242|The Prevalence and Implications of Obstructive Sleep Apnea in the Population of a Wound Center|The Prevalence and Implications of Obstructive Sleep Apnea in the Population of a Wound Center||Ohio State University|No|Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of the OSU Wound Center|June 2010|June 9, 2010|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679757||155856|
NCT00691886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-011|Safety and Efficacy of Intravenous (IV) Dexmedetomidine During Flexible Bronchoscopy and Endobronchial Ultrasound|Safety and Efficacy of Intravenous Dexmedetomidine Infusion During Flexible Bronchoscoy and Endobronchical Ultrasound||Lahey Clinic|No|Withdrawn|April 2008|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|85 Years|No|||May 2012|May 9, 2012|June 4, 2008|Yes|Yes|PI left institution prior to enrollment|No||https://clinicaltrials.gov/show/NCT00691886||154932|
NCT00691899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-030|A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)|A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer||Merck Sharp & Dohme Corp.||Withdrawn||August 2008|Anticipated|August 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Male|18 Years|N/A|No|||November 2014|November 7, 2014|June 4, 2008|Yes|Yes|Withdrawn for administrative reasons|No||https://clinicaltrials.gov/show/NCT00691899||154931|
NCT00680342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT003566|Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment|A Multicenter, Randomized, Double-masked, Placebo-controlled Phase II Study to Assess the Safety and Efficacy of a Standardized Orally Administered Silymarin Preparation (Legalon) for the Treatment of Patients With Chronic Hepatitis C Who Failed Conventional Antiviral Therapy|SyNCH|National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|April 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|N/A|No|||March 2013|March 11, 2013|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680342||155811|
NCT00692172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-728|Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis|An Open-Label, Multi-center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis Who Have Completed Studies C99-717 or C99-712||Astellas Pharma Inc|No|Completed|December 2001|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|175|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692172||154910|
NCT00692484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060629|Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics|Pilot Evaluation of the Effect of Application Procedure on the Antimicrobial Effects of an Aqueous CHG and a Traditional Iodophor Scrub Paint||CareFusion|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 21, 2013|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00692484||154886|
NCT00663364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST-Pr-5-2006|Care of the Dry Skin With Physiogel AI Lotion® (W0156)|Klinische Untersuchung Zur Pflege Trockener Haut Mit Physiogel AI Lotion Und Physiogel Lotion||University Hospital Muenster|Yes|Completed|April 2008|November 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||February 2009|July 6, 2010|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00663364||157105|
NCT00662818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-034|Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)|A Multicenter, Randomized, Double-Blind, Placebo- and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stable Vascular Disease||Merck Sharp & Dohme Corp.|Yes|Completed|March 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|April 17, 2008|Yes|Yes||No|September 5, 2014|https://clinicaltrials.gov/show/NCT00662818||157147|
NCT00662831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301083|Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients|A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients|FEENICS|Pfizer|Yes|Completed|April 2008|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|April 16, 2008|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00662831||157146|Study enrollment was terminated before planned number of participants was obtained. Although randomized participants were allowed to complete entire course of therapy according to protocol and study status was therefore designated as completed.
NCT00663650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control|A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control||Queen's University|No|Recruiting|August 2008|June 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||July 2011|July 11, 2011|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663650||157083|
NCT00682045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-20080169|Latent Tuberculosis Infection in Renal Transplant Recipients|A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Renal Transplant Recipients||Asan Medical Center|Yes|Completed|June 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|Samples With DNA|peripheral blood mononuclear cells|Both|16 Years|N/A|No|Non-Probability Sample|renal transplant recipients|March 2009|June 1, 2010|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682045||155681|
NCT00682058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72507|Body Composition & REE Responses to Bariatric Surgery|Body Composition & REE Responses to Bariatric Surgery||St. Luke's-Roosevelt Hospital Center|Yes|Active, not recruiting|October 2006|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|Consenting, eligible LABS patients from Weill Cornell and the University of Pittsburgh,        prior to bariatric surgery|March 2014|March 28, 2014|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682058||155680|
NCT00682357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11199|Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis|Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis||University of Kansas Medical Center|No|Enrolling by invitation|May 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|25|||Both|40 Years|N/A|No|||September 2008|September 15, 2008|May 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682357||155658|
NCT00682370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT - 2007-003790-11|Effects of Heme Arginate in Healthy Male Subjects|Dose Escalation, Randomized, Placebo Controlled Study to Investigate the Effects of Intravenous Heme Arginate on Heme Oxygenase-1 (HO-1) and Heme Metabolism in Association With HO-1 Gene GTn Promoter Polymorphism in Healthy Male Subjects|HEMAHS|Medical University of Vienna|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 13, 2013|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682370||155657|
NCT00682734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetoclopramideDFS|Metoclopramide for Migraine: A Dose Finding Study|Metoclopramide for Acute Migraine: A Dose Finding Study|MDFS|Montefiore Medical Center|Yes|Completed|April 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|349|||Both|18 Years|69 Years|No|||November 2012|November 28, 2012|May 19, 2008|Yes|Yes||No|July 24, 2011|https://clinicaltrials.gov/show/NCT00682734||155630|
NCT00682968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-187|Evidence Synthesis: Hypertension Medication Adherence & Intensification|Evidence Synthesis: Hypertension Medication Adherence & Intensification||VA Office of Research and Development|No|Completed|July 2008|October 2008|Actual|September 2008|Actual|N/A|Observational|N/A||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|VA clinicians, hospital administrators and PIs/authors of above studies|July 2014|April 6, 2015|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682968||155613|
NCT00682955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|857-PED/ERC-07|Comparing the Efficacy of Different Zinc Formulations in the Treatment of Diarrhea|Comparing the Efficacy of Different Zinc Formulations in the Treatment of Acute Diarrhea Among Young Children at Hospital Based Setting in Pakistan|Zinc|Aga Khan University|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|6 Months|5 Years|No|||May 2008|May 21, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682955||155614|
NCT00682981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM017|A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)|A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients With Extensive- Stage Small Cell Lung Cancer (ES-SCLC)||Teva Pharmaceutical Industries|No|Completed|May 2008|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|218|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|May 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682981||155612|
NCT00683280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-035-3|Contingency Management and Pharmacotherapy for Smoking Cessation|Contingency Management and Pharmacotherapy for Smoking Cessation|Donaghue|University of Connecticut Health Center|No|Completed|May 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||November 2011|June 12, 2012|May 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00683280||155590|
NCT00683566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01178-45|State Dependent Resonance in the BG-cortical Loops|State Dependent Resonance in the BG-cortical Loops||Assistance Publique Hopitaux De Marseille|No|Completed|February 2008|December 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|80 Years|No|||August 2014|August 27, 2014|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00683566||155568|
NCT00679094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00865|Bowman-Birk Inhibitor Concentrate in Healthy Men|Phase I Single Dose Safety and Pharmacokinetic Study of a New Formulation of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age||National Cancer Institute (NCI)||Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|October 7, 2014|May 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679094||155907|
NCT00679419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-071812|Coronary Artery Disease and Renal Failure Registry|Coronary Artery Disease and Renal Failure Registry|CAD-REF|Institut für Klinisch-Kardiovaskuläre Forschung GmbH||Active, not recruiting|December 2007|May 2013|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|3352||Urine, whole blood, serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosed coronary artery disease were consecutively enrolled and classified        into six groups according to their kidney function|October 2012|November 1, 2012|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679419||155882|
NCT00691275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801-012|Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration|Ondansetron vs. Placebo in the Management of Children With Dehydration Due to Acute Gastroenteritis||Children's Hospitals and Clinics of Minnesota|No|Withdrawn|September 2008|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|5 Years|No|||July 2015|July 13, 2015|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691275||154979|
NCT00691912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4102000|Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin|Extended Dose Frequency 1st-line Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (Myocet®)|MyoPac|University of Magdeburg|No|Terminated|December 2006|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||September 2014|September 1, 2014|June 4, 2008||No|Study was stopped due because recrutation.was much slower as anticipated.|No||https://clinicaltrials.gov/show/NCT00691912||154930|
NCT00691873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marshall, Gailen 6 3 08|Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids|A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab) on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids||University of Mississippi Medical Center|Yes|Completed|May 2006|October 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|No|||January 2007|June 5, 2008|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691873||154933|
NCT00692497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P REK NORD 122/2006|Electronic Referral and Booking of Outpatient Day Case Surgery Compared With Traditional Referral Routines.|Costs-effectiveness and Waiting Time for Direct Electronic Referral and Booking of Outpatient Day Case Surgery Compared With Traditional Referral Routines. A Randomised Controlled Trial|one-stop|University Hospital of North Norway|No|Completed|October 2010|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|120|||Both|N/A|N/A|No|||January 2016|January 26, 2016|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692497||154885|
NCT00692510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00016|Drug Interaction Study Between AZD3480 and Cytochrome P450|A Phase I, Double Blind, Randomized, Two-Way Cross Over, Single- Centre Study in Healthy CYP2D6 Extensive Metabolizers and Poor Metabolizers to Investigate the Potential of AZD3480 to Inhibit Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 Activity|Cocktail|AstraZeneca|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2008|November 25, 2008|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692510||154884|
NCT00692809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/LTBI/07|Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection|Impact of HIV Infection on Latent TB Among Patients With HIV-TB Co-infection|HIV-TB|Ministry of Science and Technology, India|No|Recruiting|July 2008|March 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|180|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV+ve+LTBI HIV+ve+clinical TB HIV-ve+clinical TB Normal control|June 2008|September 14, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00692809||154861|
NCT00663078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0107/60|Group Cognitive Behavioral Therapy (CBT) Intervention for Women With Mild to Moderate Depression|A Pilot Study to Develop a Brief Group Intervention for Women With Mild and Moderate Depression|BackonTrack|University of Bristol|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Female|30 Years|54 Years|No|||February 2009|January 13, 2010|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663078||157127|
NCT00663091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-001|A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers|A Prospective, Randomized Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers|WPP-201|Southwest Regional Wound Care Center|Yes|Completed|September 2006|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663091||157126|
NCT00663104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFZ-Trace|Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause|Effect of Exercise and Exercise + Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause||University of Erlangen-Nürnberg Medical School|No|Terminated|April 2008|November 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|126|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663104||157125|
NCT00663637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-0801|Removal of Endotracheal Tube Secretions Comprehensively Until Extubation|Evaluation of the Safety and Efficacy of CAM (Complete Airway Management) Catheters: Phase II Study|RESCUE|O. M. Neotech, Inc.|No|Recruiting|April 2008|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||April 2008|May 28, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663637||157084|
NCT00664144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC4983|Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma|Study of Efficacy and Safety of Rasburicase for the Treatment/Prevention of Hyperuricemia Related to Tumor Lysis Syndrome in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma, Previously Treated or Not With Urate Oxidase Presenting With Hyperuricemia and/or Bulky Disease|GRAAL2|Sanofi||Terminated|July 2002|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Actual|33|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|April 18, 2008|No|Yes|due to poor enrollment|No||https://clinicaltrials.gov/show/NCT00664144||157045|
NCT00682071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-311|Ultrasound Guided Embryo Transfer: Abdominal Versus Transvaginal, a RCT|Abdominal Versus Transvaginal Ultrasound Guided Embryo Transfer: Results of a Randomized Clinical Trial||University of Wisconsin, Madison|No|Completed|August 2003|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|224|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing assisted reproductive cycles at the University of Wisconsin REI        Program|May 2008|October 1, 2015|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682071||155679|
NCT00682084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-ISC-20070131|Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome|Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome Before and After Surgical Treatment||University of Aarhus|No|Recruiting|April 2008|January 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Whole blood, serum, muscle samples, fat samples|Both|18 Years|70 Years|No|Non-Probability Sample|Patients recently diagnosed with Cushing's syndrome, recruited from the clinic.|December 2014|December 2, 2014|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682084||155678|
NCT00682097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP21549|A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.|A Randomized, Double-Blind, Multiple-Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4998452 Following Oral Administrations in Patients With Type 2 Diabetes Mellitus||Hoffmann-La Roche||Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|55|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|May 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682097||155677|
NCT00682409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00743-50|Magnetic Resonance (MR) Imaging in the Post Operative Follow-up of Cholesteatoma in Children|||Assistance Publique Hopitaux De Marseille|No|Completed|January 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|37|||Both|5 Years|18 Years|No|||August 2014|August 27, 2014|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682409||155655|
NCT00682721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 08090230|Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women|Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women||University of Pittsburgh|No|Withdrawn|February 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|40 Years|No|||February 2012|February 29, 2012|May 16, 2008|Yes|Yes|Sponsor has withdrawn support for this study and it will not be performed|No||https://clinicaltrials.gov/show/NCT00682721||155631|
NCT00682747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKSH-037|Hyperbaric Oxygen for the Treatment of a Dry Mouth Which Occurred After Radiotherapy|Randomized Phase II Trial of Hyperbaric Oxygen for the Treatment of Radiation-Induced Xerostomia||Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|May 2008|October 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2008|May 16, 2008|May 16, 2008||||No||https://clinicaltrials.gov/show/NCT00682747||155629|
NCT00682994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0667|Patient and Family Decision Making in the Palliative Care Setting|Patient and Family Decision Making and Information Disclosure Preferences in the Palliative Care Setting: a Multi-Center Survey in Chile, Guatemala, and U.S.||M.D. Anderson Cancer Center|No|Completed|March 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|780|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|February 17, 2016|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00682994||155611|
NCT00683293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSA-RobHyst|Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy|Laparoscopic Hysterectomy: a Clinical Randomized Trial Comparing Conventional and Robot-assisted(Da Vinci®)Techniques||Kantonsspital Aarau|No|Completed|November 2008|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 11, 2014|May 21, 2008|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00683293||155589|
NCT00690105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-FR-04|Protopic Ointment in Adult Atopic Eczema of the Face|Comparative, Multicentre, Randomized, Double-blind Study to Assess the Efficacy of Tacrolimus 0.1% Ointment Versus Fluticasone 0.005% Ointment in Adult Patients Suffering From Moderate to Severe Atopic Dermatitis and Presenting With So-called 'Red Face' Lesions of the Head and Neck.||Astellas Pharma Inc|No|Completed|February 2004|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|577|||Both|16 Years|N/A|No|||August 2014|August 28, 2014|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690105||155069|
NCT00690417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0211|Vitamin D Inadequacy in Rural Populations, Evaluation of Correction by Food Supplementation|Vitamin D Inadequacy: Documentation in Rural Populations and Evaluation of Correction by Food Supplementation (Phase III; Manitowoc Prevalence Study)||University of Wisconsin, Madison|No|Completed|August 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Female|55 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 23, 2011|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00690417||155045|
NCT00690430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230C2303|Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease|A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues.||Novartis|Yes|Completed|April 2008|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|May 15, 2008|Yes|Yes||No|April 5, 2013|https://clinicaltrials.gov/show/NCT00690430||155044|
NCT00690716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C112|The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Nasal Carbon Dioxide in the Treatment of Mild Headache in Migraineurs||Capnia, Inc.|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|292|||Both|18 Years|65 Years|No|||August 2012|August 6, 2012|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690716||155022|
NCT00691002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 80190-O21|Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds|Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas||LEO Pharma|No|Completed|May 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1245|||Both|18 Years|N/A|No|||January 2010|November 8, 2013|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691002||155000|
NCT00691015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597130|Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant|A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|May 2008|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Actual|48|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691015||154999|
NCT00691574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 0668|Melatonin Levels in Smith Magenis Syndrome (SMS)|Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot Study||Oregon Health and Science University|Yes|Completed|September 1998|May 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|5|||Both|3 Years|85 Years|Accepts Healthy Volunteers|||November 2013|November 9, 2013|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691574||154956|
NCT00692562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIK2005|Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease|Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease||Fuzhou General Hospital|Yes|Completed|June 2005|December 2007|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|60 Years|No|||June 2008|September 15, 2011|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692562||154880|
NCT00692185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5116 (MH069868-02)|Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa|Atypical Antipsychotic Medication in Anorexia Nervosa||New York State Psychiatric Institute|Yes|Completed|October 2005|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|16 Years|N/A|No|||September 2013|September 20, 2013|June 4, 2008|Yes|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00692185||154909|
NCT00692536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Um dnr 07-034M|Diet Composition - Metabolic Regulation and Long-term Compliance|Diet Composition - Metabolic Regulation and Long-term Compliance|KNOTA|Umeå University|No|Completed|September 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|70|||Female|N/A|70 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692536||154882|
NCT00692549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RandomizedIVUS|Ultrasound Guidance for Intravenous Cannulation in Emergency Department Patients.|Ultrasound-Guided Peripheral Intravenous Cannulation in Emergency Department Patients With Difficult IV Access: a Randomized Trial.||University of California, San Francisco|No|Completed|June 2005|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2008|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692549||154881|
NCT00662857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-116|A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro|A Phase 2, Open-Label, Randomized, 2-Way Crossover, Clinical Trial to Compare the Pharmacokinetics of 2 Formulations of "Intended Commercial Product" Technosphere® Insulin Inhalation Powder and to Determine the Bioavailability of a 30 Unit Cartridge of "Intended Commercial Product" Technosphere® Insulin Inhalation Powder Versus a 10 Unit Subcutaneous Injection of Insulin Lispro in Subjects With Type 1 Diabetes Mellitus||Mannkind Corporation||Completed|April 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|60 Years|No|||October 2014|October 9, 2014|April 16, 2008|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00662857||157144|
NCT00663390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03743|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR||Sanofi|No|Completed|December 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 28, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663390||157103|
NCT00663663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33597-G|Telephone Intervention for Pain Study (TIPS)|Efficacy of Telephone-Delivered Cognitive Behavioral Therapy for Chronic Pain|TIPS|University of Washington|No|Completed|September 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663663||157082|
NCT00663377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#656|Effects of Losartan on Insulin Resistance in Patients With Heart Failure|Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors||Tottori University Hospital|No|Completed|April 2006|March 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Anticipated|16|||Both|N/A|N/A|No|||April 2008|April 18, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663377||157104|
NCT00661128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1433|Evaluating the Genetic Factors That May Lead to Sudden Cardiac Arrest (The GenSCA Study)|Genomics of Sudden Cardiac Arrest|GenSCA|University of Washington|Yes|Enrolling by invitation|September 2007|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|8750|Samples With DNA|De-identified white blood cells, red blood cells, plasma, and DNA|Both|18 Years|N/A|No|Non-Probability Sample|The group of people who have experienced SCA will be selected from participants in the        Cardiac Arrest Blood Study (CABS), participants in the Cardiovascular Health Study (CHS),        and residents of Seattle and King County, WA who experience SCA.        The control group of people who have not experienced SCA will be selected from        participants in CABS, participants in the Heart and Vascular Health Study, participants in        CHS, and residents of Seattle and King County, WA who have not experienced SCA.|December 2012|December 18, 2012|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661128||157277|
NCT00689013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8750|The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting|The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting||University of Tennessee|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|205|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 22, 2009|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00689013||155153|
NCT00682422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2007-1471|Kid STRIDE: Exploring Participation in a Family-based Intervention|Kid STRIDE: Exploring Participation in a Family-based Intervention||University of Wisconsin, Madison|No|Completed|February 2008|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Actual|10|||Both|9 Years|16 Years|No|Non-Probability Sample|Participants in the current Kid STRIDE behavioral intervention study.|June 2010|October 1, 2015|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682422||155654|
NCT00682435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC0702028|Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients|Safety and Speed of Onsent of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg in the Treatment of Adult ED Patients With Moderate to Severe Pain||Montefiore Medical Center|No|Active, not recruiting|June 2007|||November 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|21 Years|64 Years|No|||May 2008|May 21, 2008|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682435||155653|
NCT00689273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9421006|Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee|A 2-Week, Randomized, Double Blind, Placebo Controlled, Parallel-Group, Phase 2, Multicenter Study Of Pf-04136309 In Subjects With Osteoarthritic Pain Of The Knee||Pfizer|Yes|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|75 Years|No|||September 2012|September 25, 2012|May 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00689273||155133|
NCT00689559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3691C00001|Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects|A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)||AstraZeneca|No|Completed|March 2008|April 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|52|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 30, 2009|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689559||155111|
NCT00689832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-FR-05|Protopic Ointment in Children Atopic Eczema|Comparative, Multicentre, Randomised, Double-blind Study to Assess the Efficacy of Tacrolimus 0.03% Ointment Versus Fluticasone 0.005% Ointment in Children Aged 2 Years or Over Suffering From Moderate to Severe Atopic Dermatitis.||Astellas Pharma Inc|No|Completed|February 2004|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|487|||Both|2 Years|15 Years|No|||August 2014|August 28, 2014|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689832||155090|
NCT00690118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERP ALS|Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis|Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)||University of Ulm|Yes|Terminated|May 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|June 2, 2008||No|The interim analysis showed no tendency in favour of the verum group. Therefore it was decided    to stop the study prematurely.|No||https://clinicaltrials.gov/show/NCT00690118||155068|
NCT00690729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-170|Cognitive-Behavioral Bibliotherapy for the Treatment of Obsessive Compulsive Disorder in Children and Adolescents|Cognitive-Behavioral Treatment of Obsessive Compulsive Disorder in Children and Adolescents||University of Connecticut Health Center|No|Completed|July 2005|August 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|8 Years|18 Years|No|||August 2010|August 26, 2010|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690729||155021|
NCT00690742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC010608|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2008|||||N/A|N/A|N/A||||||||||||||June 4, 2008|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690742||155020|
NCT00691028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-650-13|Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis|Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis||Mitsubishi Tanabe Pharma Corporation|No|Completed|September 2005|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|327|||Both|20 Years|75 Years|No|||January 2014|January 30, 2014|June 3, 2008||No||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00691028||154998|
NCT00691041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5221|A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)|A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)|UDP|Centers for Disease Control and Prevention|No|Completed|August 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|233|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 12, 2012|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691041||154997|
NCT00691288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011295|Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children|Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children Taking Highly Active Antiretroviral Therapy (HAART): a Randomized Cross-over Study||The Hospital for Sick Children|No|Terminated|June 2008|December 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|5 Years|18 Years|No|||June 2014|June 10, 2014|May 27, 2008||No|Unable to enroll sufficient patients|No||https://clinicaltrials.gov/show/NCT00691288||154978|
NCT00691587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB001-04|Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa|A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa||KaloBios Pharmaceuticals|No|Completed|April 2008|April 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|36|||Both|18 Years|N/A|No|||July 2009|July 29, 2009|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691587||154955|
NCT00689637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00014|Drug Interaction Study Between AZD3480 and Warfarin|A Single-Centre, Double Blind, Randomized, Two-Way Cross-Over Study of Repeated Doses of AZD3480 and Single Dose of Warfarin to Evaluate the Pharmacokinetic Interaction of AZD3480 and Warfarin and the Effect of AZD3480 Pharmacodynamic in Healthy Male Subjects (Phase I|DDI|AstraZeneca|No|Completed|September 2007|February 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 30, 2009|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689637||155105|
NCT00689650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0094|Fractional Nonablative 1540 nm Laser Resurfacing for Burn Scars- A Randomised Controlled Trial|Fractional Nonablative 1540 nm Laser Resurfacing for Burn Scars- A Randomised Controlled Trial||Bispebjerg Hospital||Active, not recruiting|November 2007|||||N/A|Interventional|N/A|2||||||Both|18 Years|60 Years|No|||May 2008|May 30, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689650||155104|
NCT00692198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|583|Long-term Oxygen Treatment Trial|Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease|LOTT|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|January 2009|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|738|||Both|40 Years|N/A|No|||October 2015|October 6, 2015|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692198||154908|
NCT00692523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH - GS - 001|Effectiveness of Virtual Reality Exercises in STroke Rehabilitation (EVREST)|A Pilot Randomised, Two Parallel Group Study Comparing Wii Gaming Versus Recreational Activity in Patients Receiving Standard Rehabilitation After Stroke|EVREST|St. Michael's Hospital, Toronto|No|Completed|November 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||October 2009|October 1, 2009|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692523||154883|
NCT00689910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK of Ral in Pregnant Women|Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum|Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum||University of California, San Francisco||Withdrawn|February 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Plasma Cervicovaginal lavage fluid Endocervical canal fluid|Female|16 Years|N/A|No|Probability Sample|Preliminary eligibility will be determined by the study investigators, research staff, and        the patient's primary pregnancy healthcare provider. During a dedicated visit to the        primary investigator's office, potential participants will undergo a screening examination        including review of physical exam and blood work obtained by their primary pregnancy        provider within two weeks of study enrollment. Those that qualify will then provide        written consent and be able to continue in the study.|March 2012|March 28, 2012|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689910||155084|
NCT00663117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK073614 l|The Effects of Naltrexone on Active Crohn's Disease|The Effects of Naltrexone in Active Crohn's Disease|LDN|Penn State University|Yes|Completed|September 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||May 2013|May 16, 2013|April 18, 2008|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00663117||157124|
NCT00665132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-STMR07-001-Rev A.1|Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves|Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves|StimRouter|Bioness Inc|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665132||156970|
NCT00663910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE-9Z07-CC417|Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer|Evaluation of Protoporphyrin Formation in Non-Melanoma Skin Cancers After Topical Application of 5-Aminolevulinic Acid: A Pilot Study||The Cleveland Clinic|Yes|Completed|March 2008|October 2009|Actual|October 2009|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|April 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00663910||157063|
NCT00661141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP1-01-01|Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism|Phase IIa, Prospective, Randomized, Blinded, Intra-Subject Controlled, Dose Escalation Study of Fomepizole for Mitigation of Acetaldehyde Related Toxicity in Human Subjects With Altered Ethanol Metabolism With Concomitant Ethanol Exposure||Raptor Pharmaceuticals Inc.|No|Completed|April 2008|July 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||November 2009|September 25, 2012|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661141||157276|
NCT00661154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIIMG0001|Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project|Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project||Stanford University|Yes|Completed|February 2008|July 2010|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with metastatic (stage IV) colorectal cancer|August 2012|August 8, 2012|April 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661154||157275|
NCT00689546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-AVH-2008|Acute Viral Hepatitis and Diabetes Mellitus|Natural Course of Acute Icteric Viral Hepatitis in Type II Diabetes Mellitus Patients and Non-Diabetic Patients:A Pilot Cohort Study||All India Institute of Medical Sciences, New Delhi|No|Recruiting|February 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|250|||Both|18 Years|70 Years|No|Non-Probability Sample|All consecutive patients of acute viral hepatitis attending the OPD of Department of        Gastroenterology and Endocrinology, All India Institute of Medical Sciences (AIIMS) will        be candidates for the inclusion in the study.|January 2007|May 30, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689546||155112|
NCT00689845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588011|Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma|A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26)||National Cancer Institute (NCI)||Recruiting|June 2007|||||N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|5||Anticipated|120|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|June 3, 2008||||No||https://clinicaltrials.gov/show/NCT00689845||155089|
NCT00690131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29891|An Integrated Approach to Smoking Cessation in Severe Mental Illness (SMI)|An Integrated Approach to Smoking Cessation in SMI||University of Maryland|Yes|Active, not recruiting|April 2008|March 2011|Anticipated|March 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||June 2008|June 3, 2008|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690131||155067|
NCT00690144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803078R|High-fidelity Simulation in Health Care Education|Prospective Study Focusing on Impact of High-fidelity Simulation in Health Care Education||National Taiwan University Hospital|Yes|Recruiting|July 2007|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2010|June 28, 2010|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00690144||155066|
NCT00690443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEGR 733-006|Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia|A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia||Aegerion Pharmaceuticals, Inc.|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|May 20, 2008|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00690443||155043|
NCT00690755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-037-04F|Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome|Defective Atypical PKC Activation in Diabetes and Metabolic Syndrome||VA Office of Research and Development|Yes|Completed|October 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|8|None Retained|Muscle biopsies taken before and after insulin stimulation in euglycemic clamp studies|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|type 2 diabetes controlled by diet or oral agents and comparable non-diabetic control        subjects|December 2014|December 3, 2014|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690755||155019|
NCT00691054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20080055|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Did Not Respond to First-Line Therapy With Gemcitabine|Phase II Trial of Abraxane® in the Treatment of Patients With Pancreatic Cancer Who Have Failed First-Line Treatment With Gemcitabine-Based Therapy||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|June 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2013|July 25, 2014|June 4, 2008|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT00691054||154996|
NCT00691301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0076GG|Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix||Gynecologic Oncology Group|Yes|Completed|September 2008|||July 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|N/A|N/A|No|||May 2015|May 27, 2015|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691301||154977|
NCT00691314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A10-2|Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis|Safety and Efficacy of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis|ESSCAS|Peking Union Medical College Hospital|No|Completed|June 2008|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|40 Years|75 Years|No|||February 2011|February 23, 2011|April 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00691314||154976|
NCT00692211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-177|Interventions to Improve Colorectal Cancer Screening|Interventions to Improve Colorectal Cancer Screening Rates and Adherence||VA Office of Research and Development|No|Completed|June 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|404|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|June 3, 2008||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT00692211||154907|
NCT00692835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333/12-5-2008|Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT)|Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT)||Aristotle University Of Thessaloniki|Yes|Completed|May 2008|September 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2012|September 29, 2012|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00692835||154859|
NCT00692848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URG73|Impact of Procalcitonin on the Management of Children Aged 1 to 36 Month Presenting With a Fever Without a Source|The Impact of Procalcitonin on the Management of Children Aged 1 to 36 Month Presenting With a Fever Without a Source||St. Justine's Hospital|No|Completed|November 2006|June 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|384|||Both|1 Month|36 Months|No|||June 2008|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692848||154858|
NCT00689923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710029R|Vertebroplasty Using Real-Time, Fluoroscopy-Controlled, Catheter-Assisted, Low-Viscosity Cement Injection|Vertebroplasty Using Real-Time, Fluoroscopy-Controlled, Catheter-Assisted, Low-Viscosity Cement Injection||National Taiwan University Hospital|No|Active, not recruiting|November 2007|||October 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|45 Years|N/A|No|Non-Probability Sample|painful vertebral compression fracture|May 2008|June 3, 2008|June 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00689923||155083|
NCT00689936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-020|Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma|A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.|FIRST|Celgene|Yes|Active, not recruiting|August 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1623|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00689936||155082|
NCT00664794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005883-01H|Rotator Cuff Repair With Arthroscopic Acromioplasty (Shaving the Acromion Bone) Versus Repair Without Acromioplasty|Arthroscopic Rotator Cuff Repair With and Without Arthroscopic Acromioplasty in the Treatment of Full Thickness Rotator Cuff Tears||Ottawa Hospital Research Institute|No|Completed|October 2006|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|January 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664794||156995|
NCT00660842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-7|Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer|Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study|MITO-7|National Cancer Institute, Naples|No|Active, not recruiting|November 2008|December 2016|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660842||157299|
NCT00660881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0008|Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease|A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007||UCB Pharma|No|Completed|May 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660881||157296|
NCT00661167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taiho10041040|Phase II Study of ABI-007 for Gastric Cancer|Phase II Study of ABI-007 by Tri-weekly Schedule for Patients With Unresectable or Recurrent Gastric Cancer Refractory to 5-FU Containing Regimen.||Taiho Pharmaceutical Co., Ltd.|Yes|Completed|April 2008|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|20 Years|74 Years|No|||January 2012|January 16, 2012|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661167||157274|
NCT00689286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT5|BION Treatment of Knee Osteoarthritis|BION Implantable Microstimulator System||University of Southern California|No|Withdrawn|April 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||June 2015|June 1, 2015|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689286||155132|
NCT00689299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALI002-08|Phase 2 Study in Adults Sensitized to Cat|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (Felis Domesticus)||Antigen Laboratories, Inc.|No|Completed|October 2008|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|167|||Both|18 Years|55 Years|No|||April 2014|April 14, 2014|May 30, 2008|Yes|Yes||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00689299||155131|Adverse events: 41%, 58%, and 45% > 5% in Group A, B, and C, respectively.
NCT00689572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13419|New Medication Treatment for Stimulant Dependence|New Medication Treatment for Stimulant Dependence||University of Virginia|Yes|Active, not recruiting|July 2008|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00689572||155110|
NCT00689858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETC_DDI_I_2008|Study to Assess the Effect of Pharmacokinetics/Pharmacodynamics (PK/PD) Interaction After co-Administration of Cilostazol With Ginkgo Biloba or Placebo|Clinical Trial to Assessment the PK/PD Characteristics and Safety After co-Administration of Cilostazol With Ginkgo Biloba or Placebo in Healthy Subject.||SK Chemicals Co.,Ltd.||Completed|May 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||June 2008|January 12, 2009|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00689858||155088|
NCT00689871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020056|Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants|||Allergan||Completed|January 1999|August 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|715|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|October 6, 2014|June 2, 2008|Yes|Yes||No|December 19, 2011|https://clinicaltrials.gov/show/NCT00689871||155087|The Revision-reconstruction arm only had 15 patients enrolled, which makes the data for that arm difficult to interpret.
NCT00689884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0546|Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies|A Prospective Feasibility and Cost Analysis of Peripheral Blood Stem Cell Mobilization Using Pegfilgrastim in Patients With Hematologic Malignancies||Dartmouth-Hitchcock Medical Center|Yes|Terminated|January 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2011|July 31, 2012|May 30, 2008|Yes|Yes|Lack of enrollment.|No|January 16, 2012|https://clinicaltrials.gov/show/NCT00689884||155086|Outcome was not reported. The study was terminated for lack of enrollment. Data collection was terminated. No data analysis was performed.
NCT00690157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLKARD 1304/IK-AG-K-283/03|Registry of Patients Referred for Heart Transplantation|National Polish Registry of Patients Referred for Heart Transplantation. POLKARD HF|POLKARD HF|Institute of Cardiology, Warsaw, Poland|No|Completed|October 2003|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|999|Samples With DNA|whole blood|Both|10 Years|N/A|No|Non-Probability Sample|Patients with advanced heart failure referred for orthotropic heart transplantation (OHT)|September 2009|September 14, 2009|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00690157||155065|
NCT00690170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18014|Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects|Nicotinic Modulation of (NMDA) Receptor Antagonist Schizophrenia-like Information Processing Deficits in Humans||Yale University|Yes|Completed|December 2002|September 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 8, 2012|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00690170||155064|
NCT00690469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEPI05N1|Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers|Carcinogen Metabolism, DNA Repair, Parental Exposures and Retinoblastoma||Children's Oncology Group|No|Active, not recruiting|June 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|245|Samples With DNA|saliva samples, blood and tumor samples if enrolled on ARET0332|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Diagnosed with sporadic retinoblastoma (RB) on or after 07/01/2006|March 2015|March 26, 2015|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690469||155041|
NCT00690456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10518|Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Glycemic Effect of Rimonabant Added to Metformin in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy|TOCCATA|Sanofi|Yes|Terminated|May 2008|February 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||June 2009|June 12, 2009|May 7, 2008|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00690456||155042|
NCT00691327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910044|Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants|Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants||Allergan|No|Completed|December 1997|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|84329|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2013|October 6, 2014|June 3, 2008|Yes|Yes||No|December 30, 2013|https://clinicaltrials.gov/show/NCT00691327||154975|
NCT00691600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-18758|Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage|Phase 3 Study Comparing Bactrim to Placebo in the Management of Abscesses < 5cm and 23 hr Observation Unit to Inpatient Treatment in the Management of Abscesses 5-10cm in the Pediatric Population.||Baylor College of Medicine|Yes|Completed|December 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|472|||Both|90 Days|18 Years|No|||December 2010|December 2, 2010|December 28, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00691600||154954|
NCT00691925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0164|Mitigating Pain Following Refractive Surgery|Contact Lens for Mitigating Pain Following Refractive Procedure||FORSIGHT Vision3|Yes|Completed|June 2008|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|60 Years|No|Probability Sample|at least 10 subjects following refractive surgery|June 2009|June 2, 2009|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00691925||154929|
NCT00689078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003-05|Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model|A Single-Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model||ORA, Inc.|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689078||155148|
NCT00689351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-010|Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea|Phase 2, Randomized, Active-Controlled, Double-Blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine Pediatric Vaccinations In Korea||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|180|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||June 2011|June 24, 2011|May 29, 2008||No||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00689351||155127|
NCT00688844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007828|Nutritional and Neurotransmitter Changes in PKU Subjects on BH4|Baseline Evaluation and Long-term Follow-up of Nutritional Status and Neurotransmitter Concentrations in Phenylketonuria Patients Initiating Treatment With Sapropterin Dihydrochloride (KuvanTM), a Tetrahydrobiopterin Analog.|BH4&PKU|Emory University|No|Completed|October 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|Samples With DNA|Blood plasma Blood platelets Whole blood Urine|Both|4 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Phenylketonuria (PKU) subjects ages 4 through adulthood who plan to start BH4 therapy but        are not currently on BH4.|May 2015|May 13, 2015|May 29, 2008||No||No|August 5, 2013|https://clinicaltrials.gov/show/NCT00688844||155166|
NCT00689091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00013626|Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study|A Prospective, Randomized, Controlled Trial Comparing Bispectral Index Monitoring to Electronic Alerts for Prevention of Awareness During Anesthesia in the General Population|MACS|University of Michigan|Yes|Completed|May 2008|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|22185|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|May 29, 2008||No||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00689091||155147|
NCT00689104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-046|Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder|SCORPIO|Astellas Pharma Inc|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|2336|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 29, 2008|Yes|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT00689104||155146|
NCT00689364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJB730603|Comprehensive Therapy to Relieving the Risk of Recurrence and Metastasis for Colorectal Cancer|Retrospective-Prospective Cohort Study Effectiveness of Comprehensive Therapy of TCM to Relieving the Risk of Recurrence and Metastasis for Stage II & III Colorectal Cancer Based on Conventional Western Medicine Therapy||Ministry of Science and Technology of the People´s Republic of China|Yes|Active, not recruiting|April 2007|March 2014|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|480|||Both|18 Years|75 Years|No|Non-Probability Sample|CTTCT plus CWMT cohort in China:160 CWMT cohort in China:160 CWMT cohort in Norway:300|June 2011|July 20, 2011|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00689364||155126|
NCT00664846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A10-1|Standard Medical Management in Secondary Prevention of Ischemic Stroke in China|Standard Medical Management in Secondary Prevention of Ischemic Stroke in China.|SMART|Peking Union Medical College Hospital|No|Completed|April 2008|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4000|||Both|18 Years|N/A|No|||February 2011|April 8, 2011|April 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00664846||156991|
NCT00664859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-AtorFen-2001-1X|12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia|A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia||Veloxis Pharmaceuticals|No|Completed|October 2007|February 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|220|||Both|18 Years|N/A|No|||October 2009|December 18, 2014|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664859||156990|
NCT00664456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIGU05-01|Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer|A Phase III, Multicenter, Randomized, Controlled Study of Neoadjuvant LHRH-agonist Therapy and Permanent I-125 Implantation With vs. Without Adjuvant LHRH-agonist Therapy in Patients With Untreated Intermediate-risk Prostate Cancer.|SHIP0804|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Active, not recruiting|April 2008|May 2021|Anticipated|May 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|421|||Male|20 Years|75 Years|No|||September 2015|September 11, 2015|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00664456||157021|
NCT00664469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_006|INdians Followed for INtensive Lipid Lowering Treatment and Its safetY|INdians Followed for INtensive Lipid Lowering Treatment and Its safetY: To Assess The Safety And Effectiveness Of Ezetimibe Co-Administered With Any Statin Compared To Doubling Of Current Statin Daily Dose In South Asian Canadians|INFINITY|Sunnybrook Health Sciences Centre|No|Terminated|August 2007|November 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||July 2011|July 27, 2011|April 1, 2008|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00664469||157020|
NCT00665145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-509-0703|Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509|A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509||Sangamo Biosciences|No|Completed|January 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|70 Years|No|||October 2012|October 30, 2012|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665145||156969|
NCT00660855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3471107|A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain|A Multicenter, Open Label Trial To Evaluate Analgesic Effect Of Intravenous And Subsequent Oral Therapy With Parecoxib/Valdecoxib (Bextra® IM/IV And Bextra®) 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain||Pfizer|No|Terminated|June 2004|July 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|21 Years|65 Years|No|||April 2008|April 21, 2008|April 1, 2008|Yes|Yes|See Detailed Description.|No||https://clinicaltrials.gov/show/NCT00660855||157298|
NCT00660868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK157072007|Is Pentoxifylline Able to Improve Olfactory Sensitivity?|Agapurin Retard Used in Patients With Smell Disorder- A Post-marketing Observational Study||Technische Universität Dresden|No|Completed|November 2009|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|7|||Both|18 Years|50 Years|No|Non-Probability Sample|hyposmic or functionally anosmic patients TDI-score <31; age: 18-50 years; odor threshold:        better than 1; cause of smell loss: post traumatic, postinflammatory, idiopathic|February 2016|February 4, 2016|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00660868||157297|
NCT00661193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593575|S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)||Southwest Oncology Group|No|Active, not recruiting|December 2008|||February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661193||157272|
NCT00689598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07061|Spironolactone for Paroxysmal Atrial Fibrillation|Use of Spironolactone to Treat Patients With Paroxysmal Atrial Fibrillation- A Multi-Center, Prospective, Randomized, Placebo-Controlled, Double Blind Study||Taichung Veterans General Hospital|Yes|Recruiting|March 2008|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2008|June 4, 2008|March 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689598||155108|
NCT00689611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZESCA 9197|Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial|Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial|ZESCA|McGill University|Yes|Completed|December 2005|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|392|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|May 30, 2008||No||No|December 11, 2013|https://clinicaltrials.gov/show/NCT00689611||155107|Relatively high number who withdrew or were lost to follow-up (22.2%), but within expectations for smoking cessation trials; Relatively small numbers of serious adverse events occurred, limiting power to examine secondary safety end points.
NCT00689585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN#07-062|Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)|A Single Centre. Parallel-Group, Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial on Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)||McGill University Health Center|No|Terminated|September 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||May 2011|May 11, 2011|May 29, 2008||No|Recruitment difficult and enrolment low: decision was made to stop the study.|No||https://clinicaltrials.gov/show/NCT00689585||155109|
NCT00690183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226-08-EP|Relationship Between Physical Activity and Stem Cells in Older Adults|Relationship Between Physical Activity and Stem Cells in Older Adults||University of Nebraska|No|Completed|June 2008|October 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|39|Samples Without DNA|Plasma will be retained for cytokine analysis.|Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample of Omaha, NE metro area|January 2013|January 16, 2013|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690183||155063|
NCT00690482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9831C00001|Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 4 Week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Columbus|AstraZeneca|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|40 Years|N/A|No|||December 2013|December 13, 2013|May 30, 2008|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00690482||155040|
NCT00691938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0172 / 201012979|LBH589 Plus Decitabine for Myelodysplastic Syndromes or Acute Myeloid Leukemia|A Phase I/II Study of LBH589 Plus Decitabine for Patients Age ≥ 60 Years With High Risk MDS or AML||Washington University School of Medicine|Yes|Active, not recruiting|June 2008|September 2015|Anticipated|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|51|||Both|60 Years|N/A|No|||March 2015|March 18, 2015|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691938||154928|
NCT00690768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBETRA|Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)|Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study)|IBETRA|University of Sao Paulo|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||May 2008|June 3, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00690768||155018|
NCT00691067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW060048|A Controlled Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness|A Randomized, Double-blind Placebo-controlled Crossover Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness||Bronx Veterans Medical Research Foundation, Inc|Yes|Recruiting|May 2008|August 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|35 Years|N/A|No|||September 2011|September 9, 2011|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691067||154995|
NCT00692575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33690-J|Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury|Modular Scheduled Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury: A Randomized Controlled Trial||University of Washington|No|Completed|June 2008|April 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|153|||Both|16 Years|N/A|No|||April 2014|April 10, 2014|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692575||154879|
NCT00692861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080153|Autoimmunity in Neurologic Complications of Celiac Disease|The Role of Autoimmunity in Neurologic Complications of Celiac Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2008|January 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|14|||Both|18 Years|N/A|No|||January 2014|October 9, 2014|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00692861||154857|
NCT00693134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012004-072|Role of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Children With Myocarditis|The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Children With Acute Inflammatory Cardiomyopathy||University of Texas Southwestern Medical Center|No|Completed|March 2004|July 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|Samples Without DNA|Biopsy tissue, if available.|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inpatients of the Cardiac Service at Children's Medical Center.|February 2008|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00693134||154836|
NCT00693160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002457|Effect of Spinal Ketorolac After Acute Opioid Exposure|Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity Following Acute Opioid Exposure||Wake Forest School of Medicine|Yes|Terminated|December 2007|January 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|February 15, 2008|Yes|Yes|the manufacturing of preservative free ketorolac (Acular-PF) was discontinued|No|May 15, 2013|https://clinicaltrials.gov/show/NCT00693160||154834|
NCT00688857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK008|Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations|A Randomized, Open-label, Multi-dose Crossover Study Assessing the Pharmacokinetic Profiles of Diazoxide Choline Coated Versus Uncoated Formulations in Healthy Volunteers||Essentialis, Inc.|No|Completed|May 2008|July 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2010|November 4, 2010|May 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688857||155165|
NCT00688870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3004|Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine Pediatric Vaccinations In Taiwan||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2008|November 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|168|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||October 2011|October 31, 2011|May 29, 2008||No||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00688870||155164|Geometric Mean Concentration Outcome Measures were identified as secondary analysis in the study protocol, but are included to maintain consistency with other postings for this program.
NCT00689117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114681|A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel|A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of CT Gel in Subjects With Acne Vulgaris||GlaxoSmithKline|No|Completed|April 2008|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1649|||Both|12 Years|N/A|No|||August 2011|September 22, 2011|May 24, 2008|Yes|Yes||No|November 2, 2010|https://clinicaltrials.gov/show/NCT00689117||155145|
NCT00689377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CEU-DUM-2006/1|Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention|Prevalence of Peripheral Arterial Disease in Subjects With a Moderate CVD Risk, With No Overt Vascular Diseases nOR diAbetes Mellitus|PANDORA|AstraZeneca|No|Completed|May 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|9000|||Both|45 Years|N/A|No|Non-Probability Sample|Subjects of either sex, any race, with at least two CVD risk factors, with no overt        cardiovascular diseases nor diabetes mellitus|March 2012|March 19, 2012|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689377||155125|
NCT00689676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280674|Expressive Language and Cognitive Early Development in Very Low Birth-Weight Preterm Toddlers|Expressive Language and Cognitive Early Development in Very Low Birth-Weight Preterm Toddlers||University of Sao Paulo|Yes|Completed|January 2006|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Both|1 Month|18 Months|Accepts Healthy Volunteers|Non-Probability Sample|Study Group:        Very-Low Birth weight preterm newborns (mean weight: 1073g, mean gestational age: 29        3/7w), born in the Hospital of the University of São Paulo between March 2005 and February        2006, assisted in the High Risk Newborns Follow up Ambulatory of the University's        Hospital.        Control Group:        Full-term newborns (mean weight: 3291g, mean gestational age: 39 1/7w), followed up in the        Pediatrics Ambulatory of the University's Hospital and/or being assisted in the        University' Hospital Nursery School.|February 2009|February 13, 2009|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689676||155102|
NCT00664547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross 1997|Reduction in Cardiovascular Risk Factors and Visceral Adipose Tissue in Men: Separate Effects of Diet- and Exercise-Induced Weight Loss|Reduction in Cardiovascular Risk Factors and Visceral Adipose Tissue in Men: Separate Effects of Diet- and Exercise-Induced Weight Loss||Queen's University|No|Completed|September 1997|December 1999|Actual|December 1999|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|4||||||Male|20 Years|60 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664547||157014|
NCT00664872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC96-2314-B195-011|Effect of Psychosocial Treatment by the Case Manager in Patients After a Suicide Attempt|Effect of Proactive Psychosocial Treatment by the Case Manager in Patients After a Suicide Attempt: a Randomised Controlled Trial||Mackay Memorial Hospital|Yes|Completed|August 2007|July 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664872||156989|
NCT00665158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross2006|Prevention and Reduction of Obesity Through Active Living|Prevention and Reduction of Obesity Through Active Living|PROACTIVE|Queen's University|Yes|Completed|September 2003|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 27, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665158||156968|
NCT00660907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00004|Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients|A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.||AstraZeneca|No|Completed|March 2008|January 2013|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1217|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|April 15, 2008|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT00660907||157294|For participants who did not complete 52 weeks LOCF (last observation carried forward) was used.
NCT00660920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-07-101|Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies|A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies||Ariad Pharmaceuticals|No|Active, not recruiting|May 2008|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|April 15, 2008|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00660920||157293|
NCT00690495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0705|Use of a Modified Propofol Emulsion in Adults|Prospective, Monocentric Controlled, Randomized, Double-blind Study to Compare the Two Different Propofol Emulsions Regarding Tolerability and Injection Pain During the Induction of Anesthesia in Adults||B. Braun Melsungen AG|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|80 Years|No|||January 2012|January 2, 2012|June 2, 2008||No||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00690495||155039|
NCT00690508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/35X|Validation of Supra-Sternal Tube-Tip Palpation|Validation of Supra-Sternal Tube-Tip Palpation (SSTTP): A Method to Identify Correct Depth of Intubation in Infants and Children|SSTTP|University of Ottawa|No|Recruiting|June 2008|January 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|150|||Both|1 Month|8 Years|No|||June 2008|June 2, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00690508||155038|
NCT00689897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006CB504502-2|Psychological Outcomes From a Study of Acupuncture Treatment on Experimentally Primary Dysmenorrhea|Psychological Outcomes From a Study of Acupuncture Treatment on Experimentally Primary Dysmenorrhea||Huazhong University of Science and Technology|Yes|Recruiting|June 2008|July 2011|Anticipated|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|30 Years|No|||April 2009|June 22, 2011|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689897||155085|
NCT00691613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTR-ECG-3|Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model|Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model - A Randomised Cross-over Study to Evaluate if Infusion of a Single Dose of EPO Protects Against Ischemia-reperfusion Injury in Man|IPIIR|University Medical Center Groningen|No|Not yet recruiting|July 2010|December 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691613||154953|
NCT00692224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-68:12/08/2005|Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial|Effect of Oral Zinc Given Daily Between Days 2 and 7 of Life to Term or Near Term Neonates With Serum Bilirubin Levels of More Than 6 mg/dL at 24 ± 6 Hours of Life on Hyperbilirubinemia and Phototherapy||All India Institute of Medical Sciences, New Delhi|Yes|Completed|October 2005|October 2006|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|294|||Both|N/A|30 Hours|No|||June 2008|June 5, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00692224||154906|
NCT00692237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|746/07|Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes|Cardiovascular Effects of Chronic Sildenafil (Viagra) Treatment in Diabetic Subjects With Endothelial Dysfunction.|CECSID|University of Roma La Sapienza|Yes|Completed|January 2008|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Male|35 Years|75 Years|No|||May 2013|May 5, 2013|June 4, 2008|Yes|Yes||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00692237||154905|
NCT00692263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-372|The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects|The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects||University of Southern Denmark|Yes|Completed|February 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2008|September 9, 2008|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692263||154903|
NCT00692276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-VISS-01|Investigating Superion™ In Spinal Stenosis|A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis||VertiFlex, Incorporated|Yes|Active, not recruiting|June 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|45 Years|N/A|No|||January 2015|July 2, 2015|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00692276||154902|
NCT00692588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.P. #07-2949|MRI to Measure Treatment With Antibiotics in Alzheimer's Disease|Magnetic Resonance Imaging to Measure Treatment Effects of Doxycycline and Rifampicin in Alzheimer's Disease|DARAD-MRI|St. Joseph's Healthcare Hamilton|No|Completed|June 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|58|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants in the DARAD Trial (Doxycycline and Rifampicin for Alzheimer's disease).|April 2011|April 5, 2011|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692588||154878|
NCT00692601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 07-410|The Acute Effects of Capsiate During Exercise|Effect of Differing Doses of A Sweet Pepper Extract - Capsiate (A Capsaicin Analogue) - On Energy Expenditure and Blood Parameters in Humans During Exercise||McMaster University|No|Completed|April 2008|September 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2008|September 15, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692601||154877|
NCT00692874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OHU-ZOL-2007/1|Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy|Quality of Life Analysis of Prostate Cancer Patient's Therapy|AZTEK EXT|AstraZeneca|No|Completed|June 2008|September 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1646|||Male|N/A|N/A|No|Non-Probability Sample|Early or locally-advanced prostate cancer patients on androgen deprivation therapy|December 2010|December 9, 2010|June 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692874||154856|
NCT00693147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|334/12-05-2008|Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T)|Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T)||Aristotle University Of Thessaloniki|Yes|Completed|May 2008|September 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2012|September 29, 2012|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693147||154835|
NCT00688883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305621|Fludara (Oral) Phase II Study for Indolent Lymphoma|A Multicenter, Open Study to Assess the Antitumor Effect and Safety of Oral Fludarabine Phosphate (Fludara (SH T 586): 40 mg/m2/Day) Administered in 3 - 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by a Observation Period of 23 Days) in Patients With Indolent Lymphoma||Sanofi||Completed|February 2003|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|20 Years|74 Years|No|||December 2013|December 2, 2013|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00688883||155163|
NCT00689130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251|ADVANCE: Assessment for Defining Variability in Anesthesia Through Novel Clinical EEG|"Advance": Assessment for Defining Variability in Anesthesia|CVI|Medtronic - MITG|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients, aged 18-80, under general anesthesia for a moderately painful elective surgical        procedure.|November 2008|March 6, 2012|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689130||155144|
NCT00689390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05063|Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)|Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C||Merck Sharp & Dohme Corp.|Yes|Terminated|February 2007|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1954|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 27, 2008|No|Yes|The study was terminated due to satisfaction of post-marketing commitments|No|September 1, 2015|https://clinicaltrials.gov/show/NCT00689390||155124|
NCT00689403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00014|Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305|A Phase I, Two-part, Randomised, Open, Single-centre, Crossover Study to Evaluate Different Extended-release Formulations of AZD1305 When Given as Single Oral Doses to Healthy Male Volunteers|2007-005765-38|AstraZeneca|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2010|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689403||155123|
NCT00689689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RL-005|A Randomized Clinical Study Comparing a Fully-Coated Cementless Stem Versus a Cemented Stem for Total Hip Replacements|A Randomized Clinical Study Comparing a Fully-Coated Cementless Stem Versus a Cemented Stem for Total Hip Replacements||Nova Scotia Health Authority|No|Completed|July 1998|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|72 Years|N/A|No|||May 2008|February 15, 2012|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689689||155101|
NCT00689988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/1149|Augmentative and Alternative Communication (AAC) and Lexical Gain in Children With Down Syndrome|Augmentative and Alternative Communication and Lexical Gain in Children With Down Syndrome: Pilot Study||University of Sao Paulo|Yes|Completed|July 2005|June 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|5 Years|11 Years|Accepts Healthy Volunteers|||June 2008|June 3, 2008|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00689988||155078|
NCT00660933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSTPARTFEEV|Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia|Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia Randomized Trial||Hospital Clinic of Barcelona|No|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|N/A|No|||September 2005|March 7, 2016|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00660933||157292|
NCT00660946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|618-05|Comparison of Point of Care to Lab INR in Dialysis Patients on Warfarin|Correlation of Point of Care INR to Laboratory INR in Hemodialysis Patients Taking Warfarin||Mayo Clinic|No|Completed|June 2005|December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|21 Years|N/A|No|Non-Probability Sample|Dialysis patients who undergo INR testing in the management their chronic warfarin        therapy.|April 2008|April 16, 2008|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00660946||157291|
NCT00664807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-CTNV-001|Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)|Medtronic Genetic Arrhythmia Markers for Early Detection|GAME|Medtronic Corporate Technologies and New Ventures|No|Completed|April 2008|May 2009|Actual|April 2009|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1023|||Both|40 Years|N/A|No|Non-Probability Sample|Primary Care Clinic, Hospitals|August 2009|August 24, 2009|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664807||156994|
NCT00664820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-140|Effects of Probiotics on Rheumatoid Arthritis Patients|Effects of Probiotics on Rheumatoid Arthritis Patients||Lawson Health Research Institute|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 2, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664820||156993|
NCT00664833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100537|Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction|An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes.||Bayer|No|Completed|May 2004|October 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|1029|||Male|18 Years|N/A|No|||December 2014|December 8, 2014|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664833||156992|
NCT00660894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593164|Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery|Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression||Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Active, not recruiting|April 2008|||June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1535|||Both|20 Years|80 Years|No|||July 2014|July 14, 2014|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00660894||157295|
NCT00661882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405-02|Computer Tools for Improving Early Diagnosis and Treatment in Healthy Volunteers or Patients With Pancreatic Cancer or Who Are At Risk For Pancreatic Cancer or Who Have a Noncancer Pancreatic Disorder|1) Development of the Pancreatic Cancer Collaborative Registry and Risk Assessment Models; 2) Pancreatic Cancer Pre-Validation Reference Set for Serum/Plasma Biomarkers; 3) Effects of Tobacco and Alcohol on Pancreatic Cancer; 4) Enhancing the Biomedical Computing Platform for Pancreatic Cancer Research||University of Nebraska|No|Recruiting|February 2003|||December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|240|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will be asked to voluntarily participate in this project because they        have been diagnosed with PC, have a family history of PC, or fulfill the criteria to be        one of the three different control groups meaning they will either have a diagnosis of        chronic pancreatitis, acute biliary obstruction, or they are a healthy unaffected        individual.|June 2011|June 30, 2011|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00661882||157219|
NCT00690781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU 724|Protein Nutrition During Weight Loss|Effect of Milk Proteins and Protein Feeding Pattern on Body Composition and Protein Metabolism in Energy Restricted Obese Subjects|SURPROL-CF-H|Institut National de la Recherche Agronomique|No|Completed|May 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|48|||Both|18 Years|40 Years|No|||January 2011|January 26, 2011|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00690781||155017|
NCT00691626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074364|Cognitive Behavioral Therapy (CBT) for Nightmares in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans|CBT for Nightmares in OEF/OIF Veterans||VA Office of Research and Development|Yes|Active, not recruiting|April 2009|September 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|60 Years|No|||January 2016|January 15, 2016|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00691626||154952|
NCT00691639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-27|Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)|Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)||Alcon Research|No|Completed|March 2008|||August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients who received anecortave acetate treatment|September 2009|September 30, 2009|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00691639||154951|
NCT00691951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Symbicort smokers AZ|Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects|Comparative Effects of Budesonide and Budesonide/Formoterol (Symbicort) on Asthma Control in Smoking Asthmatic Subjects: A Pilot Study|D5890L00013|Laval University||Completed||||||Phase 3|Interventional|N/A|||||||Both|18 Years|45 Years|No|||June 2008|October 17, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00691951||154927|
NCT00691964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-114|Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis||AbbVie|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|347|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691964||154926|
NCT00692250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOL00207|A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers|A Phase I Open Label, Randomised, Single Dose, 2-way Crossover, 2-Sequence Pharmacokinetic Study on the Interaction of Colesevelam and Ciclosporin in Healthy Volunteers||Sanofi|No|Completed|September 2007|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692250||154904|
NCT00692289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OHU-ARI-2007/1|Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer|Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer|RADAR II E|AstraZeneca|No|Completed|June 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1510|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal, hormonreceptor positive patients with early breast cancer treated with        Arimidex (in accordance with the local SmPC).|June 2012|June 5, 2012|June 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692289||154901|
NCT00692302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078082|Effectiveness of a Family-Based Intervention for Adolescent Suicide Attempters (The SAFETY Study)|Family Based Intervention for Adolescent Suicide Attempters||University of California, Los Angeles|No|Recruiting|March 2006|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|12 Years|19 Years|No|||June 2013|June 5, 2013|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692302||154900|
NCT00692614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0140-001|A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)|A Phase IIb, Randomized, Masked, Sham-Controlled, Clinical Trial to Study the Efficacy and Safety of the Helical Triamcinolone Acetonide Implant (MK0140) in Diabetic Patients With Clinically Significant Macular Edema||Merck Sharp & Dohme Corp.||Terminated|June 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00692614||154876|
NCT00692887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP-POST-01|Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)|Correlation Between Visual Field Defects on Foresee PHP and OCT in Patients With CNV Before and After Treatment|PHP|Notal Vision Ltd|Yes|Completed|June 2008|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|15|||Both|50 Years|N/A|No|Non-Probability Sample|-  Subjects diagnosed as new CNV or treated CNV          -  Age >50 years          -  VA with habitual correction <20/160 in the study eye|January 2009|January 27, 2009|May 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00692887||154855|
NCT00689143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPPIS-0604|A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva|A Phase I, Open-Label, Single Center, Safety/Tolerability and Pharmacokinetic Study of Leukine® Administrated in the Gingiva as Three Single Doses on Separate Days||Innoventus Project AB|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689143||155143|
NCT00689416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4411M00010|Effects of Crestor on Inflammation of Atherosclerotic Plaques|Exploratory Study of New Imaging Biomarkers for Measurement of Carotid Plaque Inflammation||AstraZeneca|No|Completed|December 2007|June 2009|Actual|||Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|74|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00689416||155122|
NCT00689702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-688|Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer|Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study|XERT|Institute of Oncology Ljubljana|Yes|Active, not recruiting|February 2007|May 2013|Anticipated|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|80 Years|No|||March 2012|March 23, 2012|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689702||155100|
NCT00689715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC0183|Efficacy Study of EUS-guided Ethanol Lavage With Paclitaxel Injection for Cystic Tumors of the Pancreas|Phase 2/3 Study of EUS-guided Ethanol Lavage With Paclitaxel Injection for Cystic Tumors of the Pancreas|EUS-EP|Asan Medical Center|Yes|Recruiting|June 2006|February 2012|Anticipated|February 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|85 Years|No|||February 2012|February 2, 2012|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00689715||155099|
NCT00690001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803084R|The Detection of Drug-Resistant HIV-1 in Taiwan|The Detection of Drug-Resistant HIV-1 in Taiwan||National Taiwan University Hospital|No|Recruiting|April 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|20 Years|60 Years|No|Non-Probability Sample|HIV-1-infected patients under antiretroviral therapy with clinical suspicion of emergence        of virus resistance|April 2008|July 7, 2008|June 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00690001||155077|
NCT00660959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-LX3405|Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia||CardioKine Inc.|Yes|Completed|April 2008|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||November 2010|June 20, 2011|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660959||157290|
NCT00661258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25495|China Adherence for Life|Adherence for Life Pilot Study: Phases II and III|AFL|Boston University|No|Completed|June 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||April 2008|May 8, 2008|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00661258||157267|
NCT00665171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pcodsnp|Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome|Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome - a Study on Multigenerational Families||Maaynei Hayesha Medical Center|No|Not yet recruiting|June 2008|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|The study aims to perform a whole genome analysis for the detection of genes, associated      with the polycystic ovary syndrome. Therefore, the main clinical effort is the diagnosis of      index cases and recruitment of family members to give DNA samples.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Multigenerational families with at least one woman affected with the polycystic ovary        syndrome.|April 2008|April 22, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00665171||156967|
NCT00665184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 11900|Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease|High Force Resistance Training and Dopamine Replacement Effects on Hypokinesia in Parkinson Disease||University of Utah|Yes|Completed|August 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|40 Years|90 Years|No|||September 2011|September 20, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665184||156966|
NCT00661895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-13859|Black Education and Treatment of Hypertension (BEAT HTN)|Black Education and Treatment of Hypertension (BEAT HTN)|BEAT|Creighton University|No|Completed|August 2005|November 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|25 Years|80 Years|No|||November 2012|November 6, 2012|December 28, 2007|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00661895||157218|
NCT00691080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003|Understanding Sleep Problems in Children With Autism Spectrum Disorder|Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.|REST|Baylor College of Medicine|Yes|Completed|September 2007|November 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|58|None Retained|SAMPLE: Saliva What is the purpose of the sample collection? Determination of dim light      melatonin onset (DMLO), as measured by salivary melatonin secretion.      SAMPLE: Urine What is the purpose of the sample collection? Measurement of secreted      6-suplhatoxymaltonin, a metabolite of melatonin.|Both|4 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with the diagnosis of ASD and that are not diagnosised with ASD (controls).|January 2016|January 12, 2016|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691080||154994|
NCT00691093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221059|Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy|Observational Study In Patients With Overactive Bladder (OAB) Treated With Toviaz® After Failure Of Previous Antimuscarinic Therapy Due To Ineffectivity Or Intolerance.||Pfizer|No|Completed|July 2008|June 2009|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|823|||Both|18 Years|N/A|No|Non-Probability Sample|patients older than 18 years with overactive bladder after failure of previous        antimuscarinic therapy (due to lack of efficacy or intolerance)|February 2011|February 16, 2011|June 3, 2008||No||No|March 15, 2010|https://clinicaltrials.gov/show/NCT00691093||154993|
NCT00691340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-WUK-2008-002|Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease|Systematic Characterization of the Cellular Proteome From Human Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease||University Hospital, Basel, Switzerland|No|Withdrawn|June 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|0|None Retained|plasma|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Glaucoma patients Alzheimer's patients|March 2015|March 9, 2015|June 3, 2008||No|was replaced by another study. Problems with recruitment.|No||https://clinicaltrials.gov/show/NCT00691340||154974|
NCT00691652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597410|Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma|Phase I/II Study of Oral Clofarabine + Rituximab in Relapsed B Cell NHL||OHSU Knight Cancer Institute||Terminated|May 2008|April 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|89 Years|No|||September 2011|September 22, 2011|June 4, 2008|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00691652||154950|
NCT00691665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-06|Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial|A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial||Alcon Research|No|Completed|May 2008|||January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|12 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 23, 2010|June 3, 2008||No||No|January 26, 2010|https://clinicaltrials.gov/show/NCT00691665||154949|
NCT00691977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duke-10571|Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate|A Phase I Dose-Escalation Study of Preoperative Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk, Localized Carcinoma of the Prostate||Virginia Commonwealth University|No|Withdrawn|September 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|N/A|69 Years|No|||April 2013|April 23, 2013|June 3, 2008|No|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00691977||154925|
NCT00692627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKMAL0804|Evaluation of Volume Status, Haemodynamics and Microcirculatory Flow in Adult Patients With Severe Falciparum Malaria|Evaluation of Volume Status, Haemodynamics and Microcirculatory Flow in Adult Patients With Severe Falciparum Malaria|PRiSM|University of Oxford|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|16 Years|N/A|No|Non-Probability Sample|Severe Falciparum Malaria|January 2010|January 21, 2015|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692627||154875|
NCT00692900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-06-009|Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer|Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer||University of Pittsburgh|Yes|Completed|December 2008|October 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|N/A|No|||January 2016|January 31, 2016|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692900||154854|
NCT00692913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-262|A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)|A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women||Merck Sharp & Dohme Corp.||Completed|June 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|515|||Female|65 Years|N/A|No|||July 2015|July 21, 2015|June 4, 2008|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00692913||154853|
NCT00693173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-049|Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients|Genital Drop Technique With Intensity-Modulated Radiation Therapy (IMRT) in Male Anal and Distal Rectal Cancer Patients: A Dosimetric Comparison||The University of Texas Medical Branch, Galveston|No|Completed|July 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|14|||Male|18 Years|80 Years|No|Non-Probability Sample|Male anal cancer and distal rectal cancer patients 18 years or older.|February 2013|February 11, 2013|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00693173||154833|
NCT00693186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HXV01C|A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA|An Open-label, Randomised, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Booster Dose of Two Different Hepatitis B Vaccines to Explore the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children Previously Vaccinated at About 3, 5 and 11 to 13 Months of Age With Either HEXAVAC® or INFANRIX®-HEXA||Sanofi Pasteur MSD|No|Completed|October 2008|March 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|410|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00693186||154832|
NCT00688922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRACTIC080703|Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study|Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl|PRACTIC|Osaka Acute Coronary Insufficiency Study Group|Yes|Recruiting|July 2008|June 2011|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|20 Years|N/A|No|||November 2008|November 28, 2008|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00688922||155160|
NCT00689156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBCG 07-READ|Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer|Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer|READ|Danish Breast Cancer Cooperative Group|No|Completed|June 2008|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2015|||Female|18 Years|75 Years|No|||January 2013|January 3, 2013|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689156||155142|
NCT00689728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11351|A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy|A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy||Eli Lilly and Company|No|Completed|June 2008|May 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|75 Years|No|||December 2010|December 9, 2010|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00689728||155098|
NCT00689741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580299/001|Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women|A Double-Blind, Placebo-Controlled, Randomised Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil.||GlaxoSmithKline||Completed|January 2001|April 2003|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1113|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||May 2008|May 30, 2008|May 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00689741||155097|
NCT00690014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26129|Evaluation of Renal Drug Transport in Healthy Volunteers|Evaluation of Renal Drug Transport in Healthy Volunteers||University of Maryland|Yes|Completed|August 2007|June 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 3, 2008|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690014||155076|
NCT00661908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274/03|Diabetes-Related Discrimination at Workplace and by Insurances|Discrimination of Insulin-Treated Diabetic Subjects at the Workplace and by Insurances||University Hospital, Basel, Switzerland|No|Completed|March 2004|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|509|||Both|16 Years|N/A|No|Non-Probability Sample|Within a time period of two month we recruited all insulin-treated diabetic patients from        the outpatient clinic of the University Hospital of Basel (n=203), from 5 regional        hospitals (n=135) in the North-western part of Switzerland and from 13 specialist        practices (n=107) as well as from 15 randomly selected general practioner practices        (n=64)in the mentioned area.|April 2008|April 16, 2008|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661908||157217|
NCT00664885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRI-EX97-9706PI|Effectiveness of Cultural Sensitive Collaborative Treatment of Depressed Chinese|Effectiveness of Cultural Sensitive Collaborative Treatment of Depressed Chinese in Primary Care||Mackay Memorial Hospital||Completed|January 2008|December 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|280|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664885||156988|
NCT00661232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102-02-777|Multicenter Myocardial Viability Trial|An International, Multicenter Trial Assessing Myocardial Viability With Contrast - Enhanced Magnetic Resonance Imaging||CHI St. Luke's Health, Texas|No|Active, not recruiting|August 2003|||October 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|235|||Both|21 Years|85 Years|No|Probability Sample|Patients were recruited from 9 institutions on 3 different continent. All patients        recruited for the study had a history of angiographically documented chronic coronary        artery disease and resting wall motion abnormalities, and were scheduled for cardiac        revascularization (coronary artery bypass surgery or percutaneous intervention).|February 2006|April 16, 2008|April 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661232||157269|
NCT00661557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107408|Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects|Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 Administered in Healthy Subjects Either Previously Primed With Mencevax™ ACWY or naïve to Meningococcal Vaccination.||GlaxoSmithKline||Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|272|||Both|4 Years|34 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|April 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661557||157244|
NCT00661570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD736|Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis|Amendment on Phase I Trial NO7VEG 'Assessment of a Next Generation Indwelling Provox Voice Rehabilitation System (Vega)||Atos Medical AB|No|Terminated|March 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||October 2010|October 13, 2010|April 9, 2008|Yes|Yes|Primary endpoint reached, slow accrual, leakage around|No|August 2, 2010|https://clinicaltrials.gov/show/NCT00661570||157243|
NCT00662740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1184.14|Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol PE Capsule) in COPD|1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)||Boehringer Ingelheim||Terminated|April 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|220|||Both|40 Years|N/A|No|||April 2014|April 30, 2014|April 17, 2008||||No||https://clinicaltrials.gov/show/NCT00662740||157153|
NCT00662753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP01|A Study in the Use of Home Blood Pressure Monitoring and Telephone Follow-up to Control Blood Pressure|A Structured Program for Hypertension Control in Community Clinics: A Randomized Trial||George Washington University|No|Completed|April 2008|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|80 Years|No|||April 2008|February 23, 2016|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00662753||157152|
NCT00690807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-10-AD-21|A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis|A Phase 2 Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Atopic Dermatitis||Provectus Pharmaceuticals|No|Completed|June 2008|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00690807||155015|
NCT00691379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.02|Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer|Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negative (ER-,PR-,HER2-) Metastatic Breast Cancer. A Multicenter Phase I-II Study||Hellenic Oncology Research Group|No|Recruiting|April 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|75 Years|No|||October 2015|October 6, 2015|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00691379||154971|
NCT00691353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NGR-DUM-2008/1|Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers|Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers|DIDAXI|AstraZeneca|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|540|||Both|18 Years|65 Years|No|Non-Probability Sample|Target Group:Patients that suffer from Bipolar Disorder Type 1 who are treated with        atypical antipsychotics as monotherapy or cotherapy with mood stabilizers|December 2008|December 2, 2008|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691353||154973|
NCT00691366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002115|Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis|Autonomic Nervous System Physiology and Chronic Pruritus: A Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis||Wake Forest School of Medicine|No|Completed|March 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Wake Forest University Health Sciences Dermatology Clinic population and from appropriate        IRB-approved advertising in the community.|June 2008|August 8, 2012|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00691366||154972|
NCT00691990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332/12_05_2008|Classic Total Thyroidectomy With or Without Drains|Classic Total Thyroidectomy With or Without Drains||Aristotle University Of Thessaloniki|Yes|Completed|May 2008|July 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2009|August 3, 2011|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00691990||154924|
NCT00692003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-315|Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures|A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures||Eisai Inc.||Terminated|August 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|6 Years|65 Years|No|||September 2012|September 11, 2012|June 3, 2008||No|Sponsor's decision|No|August 13, 2012|https://clinicaltrials.gov/show/NCT00692003||154923|This study was terminated early at the Sponsor’s discretion. When this study was discontinued, only 6 subjects had been treated. Data from the 5 subjects treated with zonisamide were insufficient to draw firm conclusions regarding efficacy.
NCT00692315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28839|Treating Oxidative Stress in Children With Autism|Efficacy of Methylcobalamin and Folinic Acid Treatment on Glutathione Redox Status and Core Behavior in Children With Autism||Arkansas Children's Hospital Research Institute|Yes|Completed|September 2006|December 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|3 Years|7 Years|No|||June 2008|June 5, 2008|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692315||154899|
NCT00692640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11434|Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of XL147 (SAR245408) in Combination With Erlotinib in Subjects With Solid Tumors||Sanofi||Completed|May 2008|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692640||154874|
NCT00692926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008970|Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells|A Pilot Trial of Unrelated Umbilical Cord Blood Transplantation Augmented With Ex Vivo CytokinePrimed ALDHbr Umbilical Cord Blood Cells||Duke University|Yes|Completed|October 2005|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Both|N/A|55 Years|No|||February 2016|February 4, 2016|June 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692926||154852|
NCT00693199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMI-AT-02|Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension|||Anhui Medical University|Yes|Completed|July 2006|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Male|50 Years|N/A|No|||June 2008|August 7, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693199||154831|
NCT00693212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1491|Further Studies of Attention Deficit Disorder - Residual Type (RT)|Further Studies of Attention Deficit Disorder - Residual Type||University of Utah|No|Completed|February 1986|November 1994|Actual|November 1994|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|116|||Both|21 Years|55 Years|No|||June 2008|June 5, 2008|June 3, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00693212||154830|
NCT00688896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT705-X-02-001|Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia|A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia||Akros Pharma Inc.|No|Completed|June 2002|March 2004|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|65 Years|No|||May 2008|June 2, 2008|May 29, 2008||||No||https://clinicaltrials.gov/show/NCT00688896||155162|
NCT00688909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345DUS59|Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer|Open-label, Single-arm, Multicenter Study to Evaluate the Rheumatological Tolerability of Letrozole as an Adjuvant Breast Cancer Treatment in Postmenopausal Women Who Are Intolerant and Discontinue Anastrozole Due to Grade 2-3 Arthralgia-myalgia|REAL|Novartis|No|Completed|March 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|261|||Female|50 Years|N/A|No|||November 2012|November 15, 2012|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688909||155161|
NCT00689195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381|Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma|Evaluation of Curcumin Formulation, and Ashwagandha Root Powder Extract in the Management of Advanced High Grade Osteosarcoma"|OSCAT|Tata Memorial Hospital|Yes|Recruiting|May 2008|June 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|8 Years|65 Years|No|||June 2011|June 22, 2011|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00689195||155139|
NCT00689754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102007-022|Efficacy and Safety Study on Nasogastric (NG) Tube in Patients With Upper Gastrointestinal Bleed|The Role of Routine Placement of Nasogastric Tube in Patients With Suspected Upper Gastrointestinal Hemorrhage|NG|University of Texas Southwestern Medical Center|No|Completed|January 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|282|||Both|21 Years|N/A|No|||November 2011|November 16, 2011|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00689754||155096|
NCT00690027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTVEPCS|San Diego Bleeding Esophageal Varices Study|San Diego Bleeding Esophageal Varices Study||University of California, San Diego|Yes|Completed|April 1988|December 2005|Actual|August 1996|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|211|||Both|N/A|N/A|No|||June 2008|June 3, 2008|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00690027||155075|
NCT00690040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0007-08-EMC|Single Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable Cervix|Single Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable Cervix||HaEmek Medical Center, Israel|No|Completed|June 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Female|18 Years|48 Years|No|||May 2011|May 18, 2011|May 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00690040||155074|
NCT00661323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|561|Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function|Left Ventricular Strain Quantification From 4D Echocardiography||Yale University|No|Recruiting|July 2010|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will consist of two groups:          1. Normal volunteers will be recruited through the use of an approved study recruitment             flyer.          2. Chemotherapy patients will be approached at the time of their nuclear scan to rule             out cardiac disease prior to chemotherapy. These patients will be referred to the             study by their doctor for the assessment of heart function.|July 2009|January 29, 2013|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661323||157262|
NCT00661245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S107|Transoral Gastroplasty for the Treatment of Morbid Obesity||TOGA®|Satiety, Inc.|Yes|Active, not recruiting|July 2008|||October 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|275|||Both|18 Years|60 Years|No|||May 2009|May 4, 2009|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661245||157268|
NCT00661271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00002064|Mindfulness-based Stress Reduction for Urban Youth|Mindfulness-based Stress Reduction for Urban Youth||Johns Hopkins University|Yes|Completed|September 2007|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|14 Years|22 Years|Accepts Healthy Volunteers|||March 2011|July 18, 2012|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661271||157266|
NCT00661284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA226JP|A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)|A Study to Investigate the Duration of Maintained Efficacy in Patients With Rheumatoid Arthritis Who Had Treated With MRA||Chugai Pharmaceutical||Completed|April 2008|May 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|189|||Both|20 Years|N/A|No|Non-Probability Sample|Subject who have participated in previous studies|July 2012|July 31, 2012|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661284||157265|
NCT00661583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0921|Use of Ranibizumab With Mitomycin C During Trabeculectomy|Occlusion Prevention for TrabeculectOmy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study)|OCTOPUS|University of Colorado, Denver|No|Completed|April 2008|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|N/A|No|||May 2015|May 27, 2015|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661583||157242|
NCT00661596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11139|Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction|Multi-centre, Randomised, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy of Vardenafil and Its Influence on Self-esteem and Self-confidence in Patients With Erectile Dysfunction||Bayer|No|Completed|May 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Male|18 Years|N/A|No|||December 2014|December 28, 2014|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661596||157241|
NCT00662194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALF-55/08|Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)|A Study of Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C or Hepatitis B||Bayside Health|No|Recruiting|April 2008|October 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||8|Anticipated|40|Samples Without DNA|Serum samples|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinics|March 2014|March 6, 2014|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662194||157195|
NCT00662506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00267|Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma|A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs||National Cancer Institute (NCI)||Active, not recruiting|April 2008|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662506||157171|
NCT00691106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000002|A Multi-center Study to Evaluate the Safety of Etanercept in the Treatment of Lichen Planus|A Double-blind, Randomized, Multi-center Study to Evaluate the Safety and Efficacy of Etanercept 50 mg Twice Weekly Versus Etanercept 25 mg Twice Weekly Versus Placebo in the Treatment of Lichen Planus||Wake Forest School of Medicine|No|Active, not recruiting|March 2007|September 2009|Anticipated|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2008|March 24, 2010|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691106||154992|
NCT00691704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002869|Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy|Lenalidomide and Low Dose Dexamethasone Induction Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy for Newly Diagnosed High-risk Multiple Myeloma||Duke University|No|Completed|August 2008|May 2014|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|June 3, 2008|Yes|Yes||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00691704||154946|
NCT00691717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-36|Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|201|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691717||154945|
NCT00691678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC8748|Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer|Pase II Study of Glucosamine With Chondroitin on Joint Symptoms Induced By Aromatase Inhibitors in Breast Cancer Patients||Columbia University|Yes|Completed|May 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|53|||Female|21 Years|N/A|No|||February 2013|February 19, 2013|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691678||154948|
NCT00691691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18740|Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors|A Phase II Study of Fractionated Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors||AHS Cancer Control Alberta|No|Recruiting|November 2007|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||August 2011|January 18, 2012|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00691691||154947|
NCT00692328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19AT002656-02|Expectation and Response to Levodopa and Acupuncture in Parkinson's Disease|Expectation and Response to Levodopa & Acupuncture in Parkinson's Disease||Oregon Health and Science University|Yes|Completed|August 2005|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|63|||Both|18 Years|80 Years|No|||May 2015|May 4, 2015|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692328||154898|
NCT00692341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061036|Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics|A Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Subjects With Impaired Hepatic Function||Pfizer|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 5, 2012|June 4, 2008|No|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00692341||154897|
NCT00692354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-2797-001|Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours|A Phase I Study to Evaluate the Safety and Tolerability, of the Aminopeptidase Inhibitor, CHR-2797, in Patients With Advanced Tumours||Chroma Therapeutics|Yes|Completed|October 2004|March 2008|Actual|November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||June 2008|August 5, 2010|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692354||154896|
NCT00692367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO007090041|Physical Activity Following Surgery Induced Weight Loss|Physical Activity Following Surgery Induced Weight Loss||University of Pittsburgh|Yes|Completed|December 2007|November 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 2, 2014|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00692367||154895|
NCT00692653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR009692|Personal Patient Profile Prostate (P4) Randomized, Multisite Trial|Personal Patient Profile Prostate (P4) Randomized, Multisite Trial|P4|Dana-Farber Cancer Institute|No|Completed|February 2007|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|498|||Male|21 Years|N/A|No|||April 2015|April 30, 2015|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692653||154873|
NCT00692666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Letigen|Letigen® and Cardiovascular Morbidity|Letigen® and Cardiovascular Morbidity. A Register-Based Epidemiological Study||University of Southern Denmark|No|Completed|May 2006|August 2007|Actual|May 2006|Actual|Phase 4|Observational|Time Perspective: Retrospective||||300000|||Both|18 Years|70 Years|No|||June 2008|June 5, 2008|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00692666||154872|
NCT00692939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7049|Autologous Stem Cell Transplantation for Crohn's Disease|Autologous Stem Cell Transplantation With CD34 Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Young Adult Patients With Severe Crohn's Disease||University of Pittsburgh|No|Recruiting|October 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|25 Years|No|||February 2016|February 12, 2016|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00692939||154851|
NCT00692952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|China FDA 2003L02778|Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial|Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial|BZK|Shanghai Institute of Planned Parenthood Research|Yes|Completed|March 2004|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|240|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||June 2008|July 9, 2009|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692952||154850|
NCT00693225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-008503|Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study|Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis||Mayo Clinic|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|June 4, 2008|No|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT00693225||154829|Our methods relied upon pill counting as a proxy for adherence to medical therapy. Now that PPIs are available over the counter, few patients present de novo with LA C and LA D esophagitis. We didn't control for other factors that can affect GERD.
NCT00693238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0702-PR04|Proton Therapy for Low and Intermediate Risk Prostate Cancer|A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate|PR04|University of Florida|Yes|Active, not recruiting|April 2008|December 2033|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Male|18 Years|N/A|No|||September 2015|September 29, 2015|June 4, 2008|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00693238||154828|
NCT00679380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-01-02/02|(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis|Efficacy and Safety of Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablets in Patients With Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Double-Dummy, Comparative Study Versus Placebo With an Additional Reference Arm Evaluating Entocort®EC||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2008|April 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|514|||Both|18 Years|75 Years|No|||July 2014|July 3, 2014|May 14, 2008|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00679380||155885|
NCT00689429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCG002|Operatively Treated Open Pilon Fractures|Natural History and Functional Outcome of Operatively Treated Open Pilon Fractures||Penn State University|No|Enrolling by invitation|May 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Adult (18 years and older) patients treated with definitive open reduction and fixation of        open pilon fractures between 2000 - 2007 at Hershey Medical Center.|May 2008|May 30, 2008|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689429||155121|
NCT00689442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT705-X-03-002|Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels|A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels||Akros Pharma Inc.|No|Completed|January 2004|March 2006|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|70 Years|No|||May 2008|June 2, 2008|May 29, 2008||||No||https://clinicaltrials.gov/show/NCT00689442||155120|
NCT00689455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIT-DUM-2008/2|Regional Observatory on Metabolic Syndrome- LAZIO|Regional Observatory on Metabolic Syndrome in Italy- LAZIO|ORSA|AstraZeneca|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1574|||Both|18 Years|75 Years|No|Non-Probability Sample|Primary care clinic|December 2010|December 2, 2010|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689455||155119|
NCT00689780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3120C00003|Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940|A Phase I, Multi-Centre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study, After Administration of Oral Multiple Ascending Doses in Adult Subjects With Chronic Low Back Pain||AstraZeneca|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||December 2010|December 8, 2010|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689780||155094|
NCT00690053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-040|Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET)|Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PAT): A Phase I Study|HX-4|Maastricht Radiation Oncology|Yes|Completed|August 2008|||February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2009|June 29, 2009|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00690053||155073|
NCT00662207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6176-R|Two Devices for Reflex Voiding Following Spinal Cord Injury|Two Devices for Reflex Voiding Following SCI: Urodynamic Evaluation||VA Office of Research and Development|No|Completed|October 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|3|||Male|18 Years|70 Years|No|||November 2014|November 4, 2014|April 1, 2008||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00662207||157194|
NCT00662220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV07-01|High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4|High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4|VIRID|Foundation for Liver Research|Yes|Terminated|April 2008|November 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|70 Years|No|||July 2014|July 11, 2014|April 17, 2008|Yes|Yes|Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study    had to be terminated.|No||https://clinicaltrials.gov/show/NCT00662220||157193|
NCT00662168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-151|An Investigation of Small Intestinal Carcinoid Carcinoma in Families|An Investigation of Eight Reported Cases of Small Intestinal Carcinoid Carcinoma in Multiple Family Members||Rutgers University|No|Recruiting|January 2008|November 2008|Anticipated|November 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|8|||Both|12 Years|N/A|No|Probability Sample|Individuals with carcinoid cancer that report to have a family member also with carcinoid        tumor|April 2008|April 17, 2008|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662168||157197|
NCT00662480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080028|Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark|Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark||Central Jutland Regional Hospital|Yes|Recruiting|September 2008|December 2023|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Anticipated|40000|||Male|65 Years|74 Years|No|||February 2009|February 24, 2016|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00662480||157173|
NCT00662493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020077|A Comparison of Two Exercise Programs on Knee Motor Control|The Effect of Specific Versus Generalised Quadriceps Exercise on Neural Control of the Vasti||University of Melbourne|No|Completed|March 2003|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||April 2008|April 18, 2008|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00662493||157172|
NCT00691392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBTC Study 30PK|Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)|Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis|S30PK|Centers for Disease Control and Prevention|Yes|Completed|April 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||August 2012|August 15, 2012|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691392||154970|
NCT00691405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-026|A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Double-blind, Randomized, Multicenter, Two-part Parallel-group, Dose-ranging Study of Twice-daily and Once-daily (R,R) Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Sunovion|No|Completed|October 2003|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|215|||Both|35 Years|N/A|No|||February 2012|February 21, 2012|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00691405||154969|
NCT00691418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-Martek01|Docosahexaenoic Acid (DHA) Administration and Length of Gestation: a Feasibility Study|DHA Administration and Length of Gestation: a Feasibility Study||Kaiser Permanente|No|Withdrawn|July 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|N/A|N/A|No|||March 2015|March 4, 2015|June 3, 2008||No|decision made not to proceed -- no subjects were ever enrolled|No||https://clinicaltrials.gov/show/NCT00691418||154968|
NCT00691431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05302008-1190|IntraLase vs Hansatome Flaps in LASIK|Comparison of the IntraLaser Femtosecond Laser and Hansatome Mechanical Keratome for Laser In Situ Keratomileusis||Stanford University||Completed|May 2004|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment||||51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 1, 2011|June 3, 2008||||No||https://clinicaltrials.gov/show/NCT00691431||154967|
NCT00692016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13080|Fast & Fed Pharmacokinetic (PK) Study|An Open Label, Randomized, Two-Way Crossover Study to Determine the Bioavailability of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet Under Fasting and Fed Conditions|Keifer|Bayer|No|Completed|January 2008|March 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|June 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692016||154922|
NCT00692029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0300-F1V|Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles|Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles|ATV|University of Kentucky|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|12 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|PreTeen and Teenage children|February 2011|February 18, 2011|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692029||154921|
NCT00692042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0980C00001|Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704|A Phase I, First Time in Man, Single-Centre, Randomised, Double-Blind (Within Panels), Placebo-Controller Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1704 After Administration of Oral Single Ascending Doses in Healthy Volunteers||AstraZeneca|No|Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|80|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 23, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00692042||154920|
NCT00692055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-105|Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations|Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations||POZEN|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|September 4, 2008|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00692055||154919|
NCT00692068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICHKC-2008-1|Relations Between Residual Renal Function and Oxidative and Carbonyl Stress in Peritoneal Dialysis Patients|Relations Between Residual Renal Function and Oxidative and Carbonyl Stress in Peritoneal Dialysis Patients||Iwata City Hospital||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|10 Years|90 Years|No|Probability Sample|single dialysis center|June 2008|June 5, 2008|June 4, 2008||||No||https://clinicaltrials.gov/show/NCT00692068||154918|
NCT00692965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-51-2008|Sleep Quality and Presence of Sleep Disordered Breathing|Sleep Quality and Presence of Sleep Disordered Breathing In An Inner City African American HIV Infected Population Aged 50 Years and Older||University of Florida|No|Completed|June 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|74|||Both|50 Years|N/A|No|Non-Probability Sample|HIV infected, inner city ambulatory African-American population,aged 50 years and older|August 2012|August 23, 2012|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00692965||154849|
NCT00693251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0714|Optimal Stenting Strategy For True Bifurcation Lesions|Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions|PERFECT|CardioVascular Research Foundation, Korea|Yes|Completed|January 2008|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|75 Years|No|||November 2015|November 16, 2015|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693251||154827|
NCT00688935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 0714|Young Blind Child Melatonin Treatment Study|Identification of Free-Running Rhythms in Blind Children||Oregon Health and Science University|Yes|Active, not recruiting|January 2005|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|25|||Both|1 Year|20 Years|No|||November 2013|November 9, 2013|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688935||155159|
NCT00689169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZBEAM2|Targeted Intensification Utilizing ZBEAM Followed by Autologous Stem Cell Transplantation (ASCT) in Patients With High-grade B-Cell Lymphoma|Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transplantation (ASCT)|ZBEAM2|Lymphoma Study Association|Yes|Completed|August 2007|January 2014|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|65 Years|No|||March 2015|March 24, 2015|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00689169||155141|
NCT00689182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA017|Safety and Efficacy of Iron Reduction by Phlebotomy|A Phase II Trial of the Safety and Efficacy of Iron Reduction by Phlebotomy in Recipients of Hematopoietic Stem Cell Transplants||Nova Scotia Health Authority|No|Completed|May 2007|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|65 Years|No|||February 2013|February 19, 2013|May 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00689182||155140|
NCT00643344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7429-31882-01|Craving and Lifestyle Management Through Mindfulness Pilot Study|Craving and Lifestyle Management Through Mindfulness Pilot Study|CALMM|University of California, San Francisco|Yes|Completed|January 2008|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 25, 2014|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643344||158634|
NCT00644241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus|SCT|Postgraduate Institute of Medical Education and Research|No|Completed|January 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|30 Years|75 Years|No|||October 2015|October 19, 2015|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644241||158565|
NCT00644254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECLNI DPAC|The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma|The Prognostic Impact of Extracapsular Lymph Node Involvement (ECLNI) in Ductal Pancreatic Adenocarcinoma (DPAC).|ECLNI DPAC|Katholieke Universiteit Leuven|No|Completed|October 2007|March 2008|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|145|||Both|N/A|N/A|No|Probability Sample|Resected ductal pancreatic adenocarcinoma|July 2009|July 6, 2009|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644254||158564|
NCT00644514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001166|Genetics of Asthma - Bronchoscopy Studies|The Genetics of Environmental Asthma: LPS Inhalation and Bronchoscopy in Normal Subjects and Subjects With Mild Atopic Asthma||Duke University|No|Terminated|September 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|March 24, 2008|No|Yes|grant funding no longer available|No||https://clinicaltrials.gov/show/NCT00644514||158544|
NCT00640783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGMM/06/2000|Mediterranean Diet and the Metabolic Syndrome|Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome||Second University of Naples|No|Completed|June 2001|January 2004|Actual|October 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||March 2008|March 19, 2008|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00640783||158829|
NCT00640796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKEXP|Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors|Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors||St. Jude Children's Research Hospital|No|Completed|September 2008|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|18 Years|No|||April 2014|April 23, 2014|March 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00640796||158828|
NCT00641394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-CORT-32008|The Effect of Psychotherapy on Stress Biochemistry: An RCT of Psychotherapy and Emotional Freedom Techniques (EFT)|The Effect of Psychotherapy on Stress Biochemistry: A Randomized Blind Controlled Trial of Psychotherapy and Emotional Freedom Techniques (EFT)||Soul Medicine Institute|Yes|Completed|April 2008|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|83|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 9, 2012|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641394||158782|
NCT00641680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5360C00005|Rhinocort Aqua Versus Placebo and Fluticasone Propionate|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IIIb Study to Assess the Efficacy, Safety & Product Attributes of Rhinocort Aqua(Budesonide) Versus Placebo and FluticasonePropionate as an Active Comparator in Patients 12yrs Age &Older With SeasonalAllergicRhinitis||AstraZeneca||Completed|April 2003|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|750|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00641680||158761|
NCT00641095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-UCL-MCLIII|Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma|Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma||National Cancer Institute (NCI)||Recruiting|December 2006|||September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|550|||Both|18 Years|N/A|No|||November 2008|August 9, 2013|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00641095||158805|
NCT00641108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077580|Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression|Effect of Psychotherapy on Brain Serotonin Activity||University of Pennsylvania|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|March 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641108||158804|
NCT00695942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708115|Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease|Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease: Role of Angiogenic Factors, Hemostasis and Uterine Artery Doppler|AngioPred|Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|June 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|plasma and serum samples|Female|16 Years|50 Years|No|Non-Probability Sample|community sample|May 2012|May 16, 2012|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00695942||154625|
NCT00697112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H-102385|Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)|Surveillance Registry Of Sirolimus Use In Recipients Of Kidney Allograft From Expanded Criteria Donors (ECD)||Pfizer|No|Completed|May 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|Kidney allograft recipients|December 2013|December 3, 2013|June 10, 2008|No|Yes||No|December 3, 2013|https://clinicaltrials.gov/show/NCT00697112||154537|
NCT00686166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0713|S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer|A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer||Southwest Oncology Group|Yes|Active, not recruiting|February 2009|July 2017|Anticipated|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 28, 2008|Yes|Yes||No|January 26, 2016|https://clinicaltrials.gov/show/NCT00686166||155370|
NCT00697658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014788|INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia|INVega Is Studied In an Observational Design in the Netherlands||Janssen-Cilag B.V.|No|Completed|March 2008|November 2009|Actual|November 2009|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|27|||Both|18 Years|65 Years|No|Non-Probability Sample|Schizophrenia patients meeting DSM-IV criteria receiving paliperidone ER, as part of the        common practice of participating physicians. Patients may enter the study as soon as their        paliperidone ER treatment starts or when it has been less than 14 days after their        treatment start.|April 2014|April 24, 2014|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697658||154495|
NCT00643851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-021|An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets|A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control||AstraZeneca|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|600|||Both|18 Years|77 Years|No|||March 2015|March 20, 2015|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643851||158595|
NCT00644124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD10173|Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma|A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non Hodgkin's B-cell Lymphoma||Sanofi|No|Completed|March 2008|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|March 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644124||158574|
NCT00644683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.081|A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy|A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy||University of Michigan Cancer Center|Yes|Completed|September 2007|September 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|28|Samples Without DNA|Serum|Female|25 Years|50 Years|No|Non-Probability Sample|premenopausal women with invasive adenocarcinoma of the breast between the ages of 25 and        50.|June 2014|June 5, 2014|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00644683||158531|
NCT00644969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051072|Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder|A Phase 3B 12-Week, Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder.||Pfizer|Yes|Completed|May 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|128|||Both|18 Years|75 Years|No|||March 2011|March 23, 2011|March 21, 2008|Yes|Yes||No|March 23, 2011|https://clinicaltrials.gov/show/NCT00644969||158510|
NCT00644982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501066|A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression|A Multicenter Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder||Pfizer|No|Completed|October 2002|September 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||April 2008|April 7, 2008|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644982||158509|
NCT00640952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-19781|Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease|Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease||Baylor College of Medicine|No|Withdrawn|August 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|December 28, 2007||No|PI left site|No||https://clinicaltrials.gov/show/NCT00640952||158816|
NCT00640965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ptcl-01325|DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Two-Arm, Multi-Center Phase II Trial to Assess the Safety, Tolerability, and Efficacy of DP-VPA (up to 900 mg) Once Daily for 10 Weeks in Adult Subjects With Migraine||D-Pharm Ltd.|No|Withdrawn|July 2008|August 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||May 2009|May 4, 2009|March 17, 2008|No|Yes|STUDY WAS NOT STARTED|No||https://clinicaltrials.gov/show/NCT00640965||158815|
NCT00642720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|*P05.1649L|Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients|The Effects of Weekly Administration of 40 mg Pegvisomant or Placebo on Quality of Life and Insulin Sensitivity in Acromegalic Patients With Normal IGF-I Concentrations During Long-Term Treatment With Long-Acting Somatostatin Analogs|mec-2005-290|Erasmus Medical Center|No|Completed|October 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||March 2008|March 24, 2008|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642720||158682|
NCT00643019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2004415H|Project Sexual Awareness for Everyone (SAFE)|Preventing Recurrent Sexually Transmitted Infections in Minority Women|SAFE|The University of Texas Health Science Center at San Antonio|No|Completed|January 1993|December 2012|Actual|January 1994|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00643019||158659|
NCT00643032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/2007|Preoperative Anxiety and Postoperative Pain in Children|Comparison of 2 Methods to Reduce Postoperative Pain in Children and a Comparison of 3 Methods of Preoperative Education Intervention to Reduce Anxiety in Children and Their Family||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2008|||January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|2||Anticipated|250|||Both|3 Months|12 Years|No|||March 2008|March 19, 2008|March 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643032||158658|
NCT00643994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCP001.3|CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution||Accuray Incorporated|Yes|Active, not recruiting|December 2007|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|298|||Male|18 Years|N/A|No|||June 2014|June 23, 2014|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643994||158584|
NCT00644007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK3530_HTN_III|Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension|A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction Taking Antihypertensive Medication||SK Chemicals Co.,Ltd.|Yes|Completed|December 2007|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Male|19 Years|N/A|No|||April 2013|April 16, 2013|March 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00644007||158583|
NCT00644826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PfVMS-T5|Growing Old at Home|Growing Old at Home - Effectiveness and Cost-effectiveness of Preventive Home Visits to Reduce Nursing Home Admissions in the Elderly||Martin-Luther-Universität Halle-Wittenberg|No|Completed|September 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|336|||Both|80 Years|N/A|No|||January 2010|June 1, 2010|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00644826||158520|
NCT00644267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ (DHHS)-1R18HS017202|Using a Telemedicine System to Promote Patient Care Among Underserved Individuals|Using a Telemedicine System to Promote Patient Care Among Underserved Individuals|AHRQ|Temple University|Yes|Active, not recruiting|April 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|85 Years|No|||September 2010|September 30, 2010|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644267||158563|
NCT00640809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191071|Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole|Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD)||Pfizer|No|Completed|October 2003|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|408|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2008|April 2, 2008|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640809||158827|
NCT00640822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 80190-O22|Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds|A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intertriginous Areas||LEO Pharma|No|Completed|February 2008|July 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|782|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 18, 2008||No||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00640822||158826|
NCT00641381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99067|Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma|High Dose Chemotherapy and Combination Anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma||City of Hope Medical Center|Yes|Active, not recruiting|May 2000|||October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|10 Years|60 Years|No|||January 2016|January 28, 2016|March 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641381||158783|
NCT00697099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10342|Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery|SAVE-HIP1|Sanofi|Yes|Completed|June 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2326|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697099||154538|
NCT00686179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00004|Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days|A Double-Blind, Randomised, Multicentre, Placebo-Controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days, Using Moxifloxacin as a Positive Control, in Healthy Male Volunteers, CYP2D6 Extensive and Poor Metabolisers.|TQT|AstraZeneca|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|75|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||September 2008|September 24, 2008|May 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00686179||155369|
NCT00697398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00084-51|Repetitive Trans-cranial Magnetic Stimulation of the Motor Cortex in Fibromyalgia: A Study Evaluating the Clinical Efficiency and the Metabolic Correlate in 18FDG-PET|Repetitive Trans-cranial Magnetic Stimulation of the Motor Cortex in Fibromyalgia: A Prospective Randomized Blinded Placebo-controlled Study Evaluating the Clinical Efficiency and the Metabolic Correlate in 18FDG-PET||Assistance Publique Hopitaux De Marseille|No|Completed|October 2008|October 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||January 2010|August 27, 2014|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00697398||154515|
NCT00644137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020752|GABA (Gamma Amino Butyric Acid) Medication for Tobacco|Pregabalin Given to Tobacco Users to Study Addiction||Yale University|Yes|Completed|August 2007|February 2010|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 7, 2015|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644137||158573|
NCT00644410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC heart failure|Autologous Mesenchymal Stromal Cell Therapy in Heart Failure|A Single Centre, Randomised Controlled Study of the Effect of NOGA-guided Direct Intramyocardial Injection of Mesenchymal Stromal Cells on the Development of New Myocardium and Blood Vessels in Patients With Heart Failure||Rigshospitalet, Denmark|No|Completed|September 2008|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|30 Years|80 Years|No|||March 2015|March 16, 2015|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644410||158552|
NCT00645008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801009626|Identification of Dominate Stressors in the Intensive Care Unit (ICU)|Stressors Associated With Cardiac Surgery Intensive Care Treatment||Weill Medical College of Cornell University|No|Recruiting|April 2008|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|This study involves patients both male and female who are admitted to the intensive care        unit immediately following cardiopulmonary bypass for either myocardial revascularization        or valvular surgery.|March 2012|March 16, 2012|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00645008||158507|
NCT00645021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351029|Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug|A Phase 1, Open-Label, Parallel Group, Multiple-Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of CP-945,598 Administered To Subjects With Impaired And Normal Hepatic Function||Pfizer|No|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|August 26, 2009|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645021||158506|
NCT00644995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080658|Effectiveness of The Step Up Wellness Program for People With Depression|Step Up Wellness Program for Depression, Physical Inactivity, and Smoking||Group Health Cooperative|No|Completed|November 2008|September 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||July 2014|July 23, 2014|March 25, 2008||No||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00644995||158508|This was a pilot feasibility trial and was not powered to detect statistically significant outcomes.Point prevalent abstinence outcomes imputed missing values as smokers.
NCT00640978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0666|Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer|Phase II Study of Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Terminated|March 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|March 17, 2008|Yes|Yes|Significant Adverse Effects - Futility|No|July 22, 2011|https://clinicaltrials.gov/show/NCT00640978||158814|
NCT00641797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-2006123IRB#|The Vertigo Study: Comparison Between Convention Therapy and Vestibular Rehabilitation for Benign Paroxysmal Positional Vertigo (BPPV) in Emergency Department (ED) Patients|A Randomized Trial to Evaluate Resolution of Symptoms Using Vestibular Rehab Versus Conventional Therapy in Patients Presenting to the Emergency Department (ED) With Diagnosis of Benign Paroxysmal Positional Vertigo (BPPV)||Lehigh Valley Hospital|Yes|Enrolling by invitation|November 2006|December 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00641797||158752|
NCT00642733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21285|A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer|An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer||Hoffmann-La Roche||Terminated||May 2010|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2008|June 17, 2008|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642733||158681|
NCT00642746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3753|Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)|Phase II Study of Erlotinib (Tarceva) Alternating With Chemotherapy for Second-line Treatment of Metastatic Colorectal Cancer With Molecular Correlates for p53 Pathway||OHSU Knight Cancer Institute|Yes|Terminated|March 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|No|||September 2014|September 24, 2014|March 24, 2008|Yes|Yes|Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.|No|February 12, 2014|https://clinicaltrials.gov/show/NCT00642746||158680|Study terminated before target enrollment was reached due to excessive toxicities and limited enrollment.
NCT00643045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW 1015/015/III/2003|Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50 100 mg/Day) and High (150 200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist||Newron|Yes|Completed|December 2004|July 2007|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|269|||Both|30 Years|80 Years|No|||March 2008|March 24, 2008|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00643045||158657|
NCT00643669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-65|24 Hour IOP Lowering Efficacy of AL-3789|||Alcon Research|No|Completed|February 2008|||April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643669||158609|
NCT00643682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC-GI-1|Improving Bowel Preparation for Colonoscopy With a Simple Educational Card|Improving Bowel Preparation for Colonoscopy With a Simple Educational Card||Boston Medical Center|No|Completed|February 2006|October 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2000|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|March 20, 2008||No||No|July 9, 2012|https://clinicaltrials.gov/show/NCT00643682||158608|
NCT00644540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P2E1|Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study|A Phase II, Observer-Blind, Parallel Groups, Single Center, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine in the Previous V70P2 Study.||Novartis||Completed|November 2007|June 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|89|||Both|16 Months|48 Months|Accepts Healthy Volunteers|||January 2014|January 23, 2014|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00644540||158542|
NCT00644839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351042|Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug|A Phase 1, Open-Label, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Omeprazole On The Single Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects||Pfizer|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|August 11, 2009|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644839||158519|
NCT00645177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-265|Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic Breast Cancer||AbbVie||Completed|July 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|N/A|No|||January 2013|January 23, 2013|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645177||158494|
NCT00645190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005803|A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease|A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation.||Xian-Janssen Pharmaceutical Ltd.||Completed|March 2004|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|215|||Both|40 Years|N/A|No|||March 2010|May 18, 2011|March 24, 2008||||No||https://clinicaltrials.gov/show/NCT00645190||158493|
NCT00641134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93/2007|Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active Follow-up CR-AGE-EXTRA Trial|Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active Follow-up, a Randomised Controlled Trial. CR-AGE EXTRA Trial|CR-AGE-EXTRA|University of Florence|No|Recruiting|April 2008|November 2010|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|75 Years|N/A|No|||February 2009|February 5, 2009|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641134||158802|
NCT00641407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGMM-01/2006|Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes|Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial||Second University of Naples|No|Completed|January 2007|March 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|70 Years|No|||March 2008|March 28, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641407||158781|
NCT00641420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HenryFord4447|Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin|Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin||Henry Ford Health System|No|Active, not recruiting|September 2007|September 2008|Anticipated|August 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||March 2008|March 21, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641420||158780|
NCT00641667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014896|An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain|A Phase III Study of JNS020QD in Cancer Pain Patients - Evaluation of the Efficacy and Safety of JNS020QD Switched From Opioid Analgesics||Janssen Pharmaceutical K.K.|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|20 Years|N/A|No|||May 2013|May 31, 2013|March 17, 2008|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00641667||158762|
NCT00641914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004-0111|Inhaled Steroid Treatment as Regular Therapy in Early Asthma|Inhaled Steroid Treatment As Regular Therapy in Early Asthma. A Study on the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort Turbuhaler ® ) in Newly Diagnosed Asthma.|START|AstraZeneca||Completed|October 1996|February 2003|Actual|February 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|6800|||Both|6 Years|60 Years|No|||March 2009|March 24, 2009|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00641914||158743|
NCT00696813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014707|Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics|PILAR: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry|PILAR|Janssen-Cilag International NV|No|Completed|June 2008|January 2011|Actual|January 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3064|||Both|18 Years|N/A|No|Probability Sample|Patients of medical health professionals with a diagnosis of schizophrenia|February 2013|February 4, 2013|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00696813||154560|
NCT00687596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC101-202|Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy|A Phase 2, Double-blind, Placebo-controlled, Randomized, International, Multicenter Study of Oral TAC 101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy||Taiho Oncology, Inc.|No|Terminated|June 2008|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|May 28, 2008|Yes|Yes|Terminated due to safety concerns|No||https://clinicaltrials.gov/show/NCT00687596||155261|
NCT00687882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0585|Evaluation of the Duration of Therapy for Thrombosis in Children|Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children|Kids-DOTT|All Children’s Hospital Johns Hopkins Medicine|Yes|Recruiting|March 2008|December 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|750|||Both|N/A|20 Years|No|||December 2015|December 29, 2015|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00687882||155240|
NCT00644423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA IRB# 01210|Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)|Omega-3 Fatty Acids and PTSD||Durham VA Medical Center|No|Active, not recruiting|September 2008|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644423||158551|
NCT00644436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806 805 09 001|Study to Determine if Tetrix Cream is Removed From the Hands by Gentle Washing With Soap and Water|A Study of the Substantivity of Tetrix Cream||Coria Laboratories, Ltd.|No|Completed|November 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 26, 2008|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644436||158550|
NCT00644696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.084|Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma|A Phase One Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma||University of Michigan Cancer Center|Yes|Active, not recruiting|April 2008|August 2016|Anticipated|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|1 Year|25 Years|No|||May 2015|May 18, 2015|March 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644696||158530|
NCT00644709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581112|A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)|A Multicenter, Open-Label Extension Study Of High-Risk Hyperlipidemic Patients Treated With An Atorvastatin Starting Dose Adapted To Their Baseline LDL-C Level||Pfizer|No|Completed|September 2003|March 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|196|||Both|30 Years|80 Years|No|||March 2008|March 27, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644709||158529|
NCT00641264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|294|Quality of Life Validation in Laryngitis|Laryngopharyngeal Reflux Health Related Quality of Life (LPR-HRQL) Questionnaire Development and Psychometric Testing in Patients Receiving Omeprazole 20 mg Bid as Treatment for Laryngopharyngeal Reflux.||AstraZeneca|No|Completed|May 2001|June 2003|Actual|June 2003|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Both|18 Years|70 Years|No|||June 2009|June 10, 2009|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641264||158792|
NCT00641277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W040218006|Longitudinal Efficacy of Dental Implants in Anterior Areas|A Study to Evaluate the Efficacy of the 3mm Maximus Dental Implant in Areas of Limited Tooth-to-tooth Spacing|Maximus|University of Alabama at Birmingham|No|Completed|March 2004|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|||Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Dental clinic|February 2013|February 27, 2013|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641277||158791|
NCT00640666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROG-SIU.003|Changes in Cancer-related Cytokines After Participation in a Physical Activity Behavior Change Intervention (CICK Study)|Changes in Cancer-related Cytokines After Participation in a Physical Activity Behavior Change Intervention (CICK Study)|CICK|University of Alabama at Birmingham|No|Completed|March 2008|March 2015|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Female|18 Years|70 Years|No|||May 2015|May 9, 2015|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00640666||158838|
NCT00642122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004-0764|Adults With Moderate to Severe Asthma|A Randomized, Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of Pulmicort Respules at 0.5mg QD, 1.0mg QD, 1.0mg Bid, 2.0mg Bid and Pulmicort Turbuhaler at 4.00mcg Bid on Adolescents (12 Yrs of Age and Older) With Adults With Moderate to Severe Asthma.||AstraZeneca|No|Completed|April 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|900|||Both|12 Years|N/A|No|||January 2011|January 21, 2011|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642122||158728|
NCT00642421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2L-OCT-01 PR-303|Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients|Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2l-OCT-01 PR, Administered Intra Muscularly Every 4, 5 or 6 Weeks in Acromegalic Patients||Ambrilia Biopharma, Inc.|No|Terminated|February 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2010|February 7, 2010|March 21, 2008|Yes|Yes|Commercial reasons|No||https://clinicaltrials.gov/show/NCT00642421||158705|
NCT00642434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM04094|Comparison of Blood Pressure Medications on Metabolism|Carvedilol vs.Metoprolol: A Comparison of Effects on Endothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients With Type 2 Diabetes and Hypertension||University of New Mexico|Yes|Completed|January 2004|July 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|21|||Both|45 Years|85 Years|No|||August 2011|August 24, 2011|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642434||158704|
NCT00643357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002698-38|Study of the Efficacy and Safety of Kalinox® 170 Bar for the Performance of Care Procedures in Children With Burns|Study of the Efficacy and Safety of KALINOX® 170 Bar for the Performance of Care Procedures in Children With Burns|Burns|Air Liquide Santé International|No|Withdrawn|March 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|4 Years|15 Years|No|||January 2012|January 18, 2012|March 19, 2008||No|No patient recruited due to current guidelines for the pain related to burn|No||https://clinicaltrials.gov/show/NCT00643357||158633|
NCT00643370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-23980|Quantifying Lung Tumor Movement Under Deep Inspiration Breath Holds|Quantifying Lung Tumor Movement Under Dep Inspiration Breath Holds||AHS Cancer Control Alberta||Completed|April 2008|||January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|patients with any primary lung cancer who are undergoing radiotherapy or chemoradiotherapy|August 2011|February 12, 2016|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643370||158632|
NCT00644553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-524|Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis|A Phase IIIB/IV Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets vs. Amoxicillin-Clavulanate for the Treatment of Subjects With Acute Bacterial Sinusitis||Abbott||Completed|May 2003|||March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|437|||Both|12 Years|N/A|No|||March 2008|March 26, 2008|March 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644553||158541|
NCT00644852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013993|Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone|Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone||Johnson & Johnson Taiwan Ltd||Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|342|||Both|N/A|N/A|No|Probability Sample|This study will enroll patients with diagnosis of Schizophrenia or Schizoaffective        disorder by DSM-IV-TR criteria and who have ever been treated with risperidone long-acting        injectable for more than 3 months.|May 2014|May 22, 2014|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644852||158518|
NCT00645242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0561017|A Study Of Diflucan In Children With Ringworm Of The Scalp|An Open Label, Multicenter Trial Of Diflucan (Fluconazole) For 6 Weeks Given Once Daily To Pediatric Patients With Tinea Capitis||Pfizer|No|Completed|November 2002|March 2003|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|185|||Both|3 Years|12 Years|No|||March 2008|March 25, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645242||158489|
NCT00645203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01-352|Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media|An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media||Abbott||Completed|July 2002|||April 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|447|||Both|6 Months|4 Years|No|||March 2008|March 20, 2008|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645203||158492|
NCT00645216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351047|Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety|A Phase 1, Open Label, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Grapefruit Juice On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects||Pfizer|No|Completed|June 2007|October 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|August 6, 2009|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645216||158491|
NCT00641147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00536|Curcumin in Treating Patients With Familial Adenomatous Polyposis|Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)||National Cancer Institute (NCI)|Yes|Active, not recruiting|October 2010|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||March 2016|March 1, 2016|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641147||158801|
NCT00641433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORT 014|Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails|Topical Collagen-Silver Versus Standard Care Following Phenol Ablation of Ingrown Nails: A Randomized Controlled Trial||Rosalind Franklin University of Medicine and Science|No|Recruiting|November 2005|May 2008|Anticipated|May 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2008|March 18, 2008|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641433||158779|
NCT00641446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004-0758|Varicella Vaccination With Pulmicort|Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children Between the Ages of One and Eight Years Treated With Pulmicort Respules® Versus Non-Steroidal Conventional Asthma Therapy||AstraZeneca|No|Completed|October 2001|October 2003|Actual|October 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|10 Months|8 Years|No|||March 2009|March 24, 2009|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641446||158778|
NCT00641927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-005|Antidepressant Therapy for Bipolar II Major Depression|Acute Antidepressant Therapy in Bipolar II Major Depression||Stanley Medical Research Institute|Yes|Completed|April 2002|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||March 2008|March 18, 2008|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641927||158742|
NCT00697424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPHHC254a|Comparison of Breathing Events Detected by the SleepStyle 200 Auto Continuous Positive Airway Pressure (CPAP) Device to Attended Polysomnography|Investigation of Methods to Detect Respiratory Irregularities in Obstructive Sleep Apnea (OSA)||Fisher and Paykel Healthcare|Yes|Completed|May 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2008|December 7, 2008|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697424||154513|
NCT00697710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710D1416|A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis|A Phase Ib/IIa, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Mild to Moderate Atopic Dermatitis||Shionogi Inc.|No|Completed|July 2007|September 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|65 Years|No|||July 2011|September 13, 2011|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697710||154491|
NCT00688415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRXP-A101|Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer|A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma||VentiRx Pharmaceuticals Inc.||Completed|November 2008|November 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|18 Years|N/A|No|||December 2010|December 21, 2010|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00688415||155199|
NCT00685581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU684|Impact of Vaccenic Acid Consumption on the Metabolism of Saturated Fatty Acids: Relationship With Cardiovascular Risk Factors|Rationale, Study Design and Baseline Data of the TRANSQUAL Clinical Trial: A Study to Evaluate the Impact of Different Milk Fatty Acid Profiles on Cardiovascular Risk Factors in Healthy Volunteers; Focus on Trans Fatty Acids|TRANSQUAL WPC|Institut National de la Recherche Agronomique|Yes|Completed|April 2007|May 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|107|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 13, 2009|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00685581||155414|
NCT00645034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481163|A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin|A Double-Blind, Placebo-Controlled, Randomized, 2-Way Crossover Study to Investigate the Hemodynamic Effects of a Single Dose of Sildenafil (100mg) in Subjects With Benign Prostatic Hyperplasia Being Treated With Doxazosin||Pfizer|No|Completed|November 2002|July 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Male|35 Years|75 Years|No|||March 2008|March 26, 2008|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645034||158505|
NCT00640679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01308|Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation|Prospective, Randomized, Double-Blind Trial of Abrupt and Tapered Interruption of Long-term Clopidogrel Therapy After Implantation of a Drug-Eluting Stent|ISAR-CAUTION|Deutsches Herzzentrum Muenchen|Yes|Active, not recruiting|April 2008|July 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||June 2012|June 11, 2012|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640679||158837|
NCT00640991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECREATE Pilot|REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)|An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study|RECREATE Pilot|Population Health Research Institute|Yes|Completed|April 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|N/A|N/A|No|||June 2009|June 15, 2010|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00640991||158813|
NCT00641810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-123|The Effect of Caffeine Reduction on Snoring and Quality of Life|The Effect of Caffeine Reduction on Snoring and Quality of Life||University of Vermont|No|Completed|March 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 29, 2013|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641810||158751|
NCT00641524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beatonclf|Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease|Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease||University of Western Ontario, Canada|No|Recruiting|January 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|75 Years|No|||August 2011|August 15, 2011|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641524||158773|
NCT00641537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27820|CLARITY Extension Study|A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)||EMD Serono||Completed|February 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|867|||Both|18 Years|65 Years|No|||January 2014|January 10, 2014|March 13, 2008|No|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT00641537||158772|
NCT00642447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B12406|Helium:Oxygen Noninvasive Positive Pressure Ventilation in Patients Exposed to Sulfur Mustard|Helium:Oxygen Versus Air:Oxygen Nonivasive Positive Pressure Ventilation in Patients Exposed to Sulfur Mustard||Baqiyatallah Medical Sciences University||Completed|April 2007|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1|||23|||Male|38 Years|59 Years|No|||March 2008|March 24, 2008|March 19, 2008||||No||https://clinicaltrials.gov/show/NCT00642447||158703|
NCT00643071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-1108|Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients|Tacrolimus (FK506) P-III, Open-label Study in Severe Refractory Ulcerative Colitis Patients or Patients Who Attended and Received Placebo in F506-CL-1107 Study||Astellas Pharma Inc|Yes|Completed|September 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|16 Years|64 Years|No|||August 2014|August 25, 2014|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643071||158655|
NCT00644280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LinLucentis|Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery|Evaluation of Safety and Efficacy of Ranibizumab in Glaucoma Patients Treated With Filtration Tubes"||University of California, San Francisco|Yes|Terminated|April 2008|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|21 Years|N/A|No|||July 2013|July 25, 2013|March 24, 2008|Yes|Yes|low recruitment|No|May 29, 2013|https://clinicaltrials.gov/show/NCT00644280||158562|IOP reduction may be attributable to cataract surgery instead of or in addition to ranibizumab use. Further studies, with larger sample size and longer follow-up, are needed to evaluate safety and potential efficacy of intravitreal ranibizumab.
NCT00644566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604008460|Pilot Study of Shared Care of ADHD in a Pediatric Clinic:Colocation of a Psychologist as an ADHD Care Manager|Pilot Study of Shared Care of ADHD in a Pediatric Clinic:Colocation of a Psychologist as an ADHD Care Manager|shared care|Weill Medical College of Cornell University||Recruiting|August 2006|June 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|140|||Both|6 Years|17 Years|No|||November 2010|November 4, 2010|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00644566||158540|
NCT00645255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB118|Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Examine the Longer-Term Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Obese Subjects||Abbott|No|Terminated|September 1998|||January 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|466|||Both|18 Years|N/A|No|||March 2008|March 24, 2008|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645255||158488|
NCT00645268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481146|A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes|A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes||Pfizer|No|Completed|December 2002|January 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Male|35 Years|70 Years|No|||March 2008|March 20, 2008|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645268||158487|
NCT00640848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-057-103|Almorexant in Primary Insomnia|Multi-center, Multiple-stage, Double-blind, Randomized, Placebo-controlled, Two-way Crossover, Single-dose Study to Investigate the Effects of ACT-078573 on Sleep Measured by Polysomnography in Patients With Primary Insomnia|Insomnia|Midnight Pharma, LLC|Yes|Completed|May 2006|September 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|161|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00640848||158824|
NCT00640835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-US-07-0001|Safety and Tolerability of Buprenorphine/Naloxone Film Strips|A Phase 2 Multi-Center Open-label Study to Assess the Safety and Tolerability of a Buprenorphine/Naloxone Film Strip Administered by the Sublingual and Buccal Routes||Indivior Inc.|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|382|||Both|18 Years|65 Years|No|||October 2008|November 6, 2012|March 14, 2008|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00640835||158825|
NCT00641173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-009-06F|Early Intervention for Post Traumatic Stress Disorder (PTSD)|Early Intervention for PTSD in Iraqi Veterans||VA Office of Research and Development|Yes|Withdrawn|September 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|No|||June 2015|June 25, 2015|March 17, 2008|Yes|Yes|Withdrawn by funding source|No||https://clinicaltrials.gov/show/NCT00641173||158799|
NCT00641186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16378|Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)|A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease|Xyrem|Baylor College of Medicine|No|Completed|September 2004|November 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|30 Years|75 Years|No|||April 2009|April 30, 2009|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641186||158798|
NCT00652860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582297|Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery|Chemotherapy, Irradiation, and Surgery for Function-Preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and GM-CSF; Aerosol GM-CSF During Preoperative Irradiation and Postoperatively||Mayo Clinic|Yes|Completed|August 2001|||November 2006|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|39|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00652860||157908|
NCT00641693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5360C00703|Assess the Efficacy and Safety of Rhinocort Aqua|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT AQUA (Budesonide) Nasal Spray 16mg, 32mg and 64mg Per Day Versus Placebo in Paediatric Subjects Ages 2-5 Years Old With Allergic Rhinitis.||AstraZeneca|No|Completed|April 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|650|||Both|2 Years|5 Years|No|||January 2011|January 21, 2011|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00641693||158760|
NCT00641706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00668|Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme|Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|July 2008|November 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||October 2011|April 28, 2014|March 21, 2008|Yes|Yes||No|March 6, 2013|https://clinicaltrials.gov/show/NCT00641706||158759|
NCT00685841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-050|A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease||Sunovion|Yes|Completed|February 2002|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|717|||Both|35 Years|N/A|No|||November 2012|November 1, 2012|May 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00685841||155394|
NCT00685854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080147|Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization (MACTEL 2)||National Institutes of Health Clinical Center (CC)||Completed|May 2008|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2011|September 26, 2015|May 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00685854||155393|
NCT00685867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHP-CT-037940|Two Strategies for Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Prevention in Surgical Patients|An Interventional Study to Evaluate the Impact of Two Innovative Strategies in Preventing Nosocomial MRSA Infection in Surgical Patients|MOSAR-04|University Hospital, Geneva|No|Completed|May 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|126750|||Both|N/A|N/A|No|||August 2012|August 20, 2012|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00685867||155392|
NCT00683826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6762|The Effects of Leucine on Body Weight|Effects of Leucine Supplement on Body Weight and Cardiometabolic Changes||Columbia University|Yes|Completed|May 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|May 22, 2008|No|Yes||No|March 1, 2011|https://clinicaltrials.gov/show/NCT00683826||155549|
NCT00683839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA107442-3|Tobacco Cessation Via Public Health Dental Clinics|Tobacco Cessation Via Public Health Dental Clinics (PHD2)|PHD2|Oregon Research Institute|Yes|Completed|January 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2637|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 24, 2011|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00683839||155548|
NCT00644722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N° 2007-A00350-53|Out-of-Hospital Intubation With Metal Single Use Laryngoscope Blades|Out-of-Hospital Intubation in Emergency Conditions With Either Metal Single Use or Reusable Laryngoscope Blades : Impact on Intubation Difficulties|LAMETA|Henri Mondor University Hospital|Yes|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644722||158528|
NCT00644735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|325|Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed|Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed.||AstraZeneca||Completed|December 2002|January 2004|Actual|January 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|75 Years|No|||March 2009|March 25, 2009|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644735||158527|
NCT00641004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-PPB-0701i|Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy|Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy||Otsuka Pharmaceutical, Inc., Philippines|No|Completed|April 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|August 23, 2011|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641004||158812|
NCT00641290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR ID 08-645-1800|Vigileo FloTrac vs Pulmonary Artery Catheter|Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study||Hospital Sultanah Aminah Johor Bahru|Yes|Not yet recruiting|April 2008|August 2008|Anticipated|August 2008|Anticipated|N/A|Observational|N/A|||Anticipated|60|||Both|N/A|N/A|No|||April 2008|April 4, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641290||158790|
NCT00641550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXERC01|Exercise and Pregnancy: Randomized Clinical Trial|Effects of Physical Exercise During Pregnancy on the Maternal and Perinatal Outcomes: A Randomized Clinical Trial||Universidade Estadual da Paraiba|No|Recruiting|April 2008|December 2011|Anticipated|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|188|||Female|10 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 12, 2011|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641550||158771|
NCT00641836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPAH-EPC-2|Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension|One-Year Follow-Up of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension||Zhejiang University||Completed|July 2005|December 2007|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|98|||Both|18 Years|60 Years|No|||March 2008|March 18, 2008|March 18, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00641836||158749|
NCT00642148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKI102428|A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week, Randomised, Double-blind, Placebo-controlled Study to Assess the Anti-inflammatory Activity, Efficacy and Safety of GW856553 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|February 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|306|||Both|40 Years|N/A|No|||March 2011|March 10, 2011|March 17, 2008||||No||https://clinicaltrials.gov/show/NCT00642148||158726|
NCT00642135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050308|CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment|Efficacy and Tolerance of Ophthalmic Insert Mydriasert® Versus Reference Treatment (Phenylephrine and Tropicamide Eyedrops) in Premature Newborns, Neonates and Infants Justifying a Mydriasis for a Bilateral Diagnosis Fundus||Assistance Publique - Hôpitaux de Paris|Yes|Terminated|January 2006|June 2008|Anticipated|February 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|18 Months|No|||January 2006|April 9, 2008|March 17, 2008||No|The total number of patients has been reached.|No||https://clinicaltrials.gov/show/NCT00642135||158727|
NCT00642460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA18221|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)|A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab||Hoffmann-La Roche||Completed|May 2008|August 2014|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|2 Years|17 Years|No|||January 2016|January 14, 2016|March 19, 2008|Yes|Yes||No|September 16, 2011|https://clinicaltrials.gov/show/NCT00642460||158702|This study consists of 3 parts:Part I: a 12 week double-blind placebo controlled study is complete.Part II: a 92 week single arm open-label extension study- CSR completed Dec. 2011.Part III: a 3 year open label continuation study is ongoing.
NCT00643695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02101|Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C|Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C||Portland VA Medical Center|No|Enrolling by invitation|March 2008|||June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||March 2008|March 20, 2008|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643695||158607|
NCT00644878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AUS09|Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib|A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib|MACS0254|Novartis|No|Completed|October 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|March 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644878||158517|
NCT00645229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281055|A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder|Efficacy And Safety Of Ziprasidone In Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder, Including Patients With A Diagnosis Of Recent Onset||Pfizer|No|Terminated|September 2004|March 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|60 Years|No|||April 2008|April 7, 2008|March 25, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00645229||158490|
NCT00640874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPET C|A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza|A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza.|PIPET C|Kirby Institute|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Contact group members of people with diagnosed influenza who are recommended to receive NA        inhibitor prophylaxis for short periods of time will be enrolled following provision of        informed consent. Each episode of short-term prophylaxis will be recorded separately.|April 2012|April 22, 2012|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640874||158822|
NCT00640861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589446|Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer|MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines for Breast Adenocarcinomas||Mayo Clinic|Yes|Active, not recruiting|August 2008|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00640861||158823|
NCT00641160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-CL002|Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies|A Phase 1 Study of the Safety, Pharmacokinetics, and Biological Activity of Metronomic Dosing With Orally Administered Vinorelbine Tablets in Subjects With Non-Hematologic Malignancies For Which There Are No Currently Accepted Therapies||Metronome Therapeutics|No|Active, not recruiting|March 2008|November 2008|Anticipated|November 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||September 2008|September 24, 2008|March 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641160||158800|
NCT00652522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF06003AF|Atrial Fibrillation Management in Congestive Heart Failure With Ablation|Atrial Fibrillation Management in Congestive Heart Failure With Ablation|AMICA|St. Jude Medical|Yes|Recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|75 Years|No|||August 2015|August 6, 2015|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00652522||157933|
NCT00642044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/07-CEP|Corneal Collagen Crosslinking With Riboflavin for Keratoconus Treatment: A Brazilian Study|Corneal Collagen Crosslinking With Riboflavin for Keratoconus Treatment: A Brazilian Study||Universidade Federal do Rio de Janeiro|No|Recruiting|February 2007|December 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|35 Years|No|||March 2008|April 22, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00642044||158734|
NCT00642057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-721|Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements|Compassionate Use of Tetrabenazine in the Treatment of Hyperkinesias|TBZ|Baylor College of Medicine||Available|June 1989|February 2013|Actual|December 2009|Actual|N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||February 2016|February 10, 2016|December 28, 2007|No|Yes|Commercial availability of Xenazine|||https://clinicaltrials.gov/show/NCT00642057||158733|
NCT00641719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12194|A Long-term Study for the Treatment of Painful Diabetic Neuropathy|A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain - Extension Phase||Eli Lilly and Company|Yes|Completed|March 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|20 Years|80 Years|No|||March 2011|March 3, 2011|March 19, 2008|Yes|Yes||No|March 3, 2011|https://clinicaltrials.gov/show/NCT00641719||158758|
NCT00641732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-442_201|Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement|A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement||Takeda|Yes|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|1045|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641732||158757|
NCT00686816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008030|Weight Loss in Pre-diabetic, Obese Women|A Study Among Pre-diabetic, Obese Women to Evaluate the Weight Loss Effects of a Non-Digestible Fat Substitute||Procter and Gamble|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|21 Years|55 Years|No|||October 2009|October 15, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00686816||155320|
NCT00687219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05116|Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)|Treatment of Patients With Compensated Liver Cirrhosis With SCH 54031 + Ribavirin||Merck Sharp & Dohme Corp.|No|Completed|June 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|20 Years|70 Years|No|||September 2015|September 18, 2015|May 27, 2008|Yes|Yes||No|October 27, 2011|https://clinicaltrials.gov/show/NCT00687219||155289|
NCT00687232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3540C00010|Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers|A Randomised, Placebo-controlled Single-blind, Single-centre Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers||AstraZeneca|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|May 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00687232||155288|
NCT00694343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-HE06-03|Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section|Evaluation of the Efficacy of 6% Hydroxyethyl Starch (HES, 130/0.4) in Normal Saline Compared to Ringer's Lactate Solution for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section|CAESAR|Fresenius Kabi|No|Completed|June 2008|June 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|167|||Female|18 Years|N/A|No|||May 2012|May 30, 2012|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00694343||154746|
NCT00694356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-009|Study of MK0646 in Patients With Solid Tumors (0646-009)(COMPLETED)|A Phase I Study of MK0646 in Patients With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors||Merck Sharp & Dohme Corp.||Completed|August 2008|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|N/A|No|||February 2015|February 4, 2015|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694356||154745|
NCT00640692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer GIST Genotyping Study|Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial|Kinase Genotyping of Gastrointestinal Stromal Tumors (GIST) From Patients Enrolled in the A6181112 Phase IIIb Trial at Participating U.S. and Ex-U.S. Medical Centers||Oregon Health and Science University|No|Terminated|December 2007|April 2011|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Genomic DNA from tumor samples|Both|18 Years|80 Years|No|Non-Probability Sample|Patients enrolled in Pfizer A6181112|September 2009|September 18, 2009|March 18, 2008||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00640692||158836|
NCT00641303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043225|Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer|A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors||University of Maryland|Yes|Completed|May 2008|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|51|||Female|18 Years|N/A|No|||January 2012|January 26, 2012|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641303||158789|
NCT00641563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM-NMP3|Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)|The Effects of Dexmedetomidine/Remifentanil and Midazolam/Remifentanil on Auditory-evoked Potentials and Electroencephalogram at Light-to-moderate Sedation Levels in Healthy Subjects||University Hospital Inselspital, Berne|No|Completed|March 2004|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 13, 2011|February 25, 2008||No||No|April 27, 2009|https://clinicaltrials.gov/show/NCT00641563||158770|
NCT00641823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARZ-002HMO-CTIL|Objective Functional Outcome Measures in Orthopedic Surgery Using Advanced Tracking Technologies|Objective Functional Outcome Measures in Orthopedic Surgery Using Advanced Tracking Technologies||Hadassah Medical Organization||Recruiting|March 2008|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|patients suffering from osteoarthritis of the hips and knees, patient suffering from        spinal claudication, and unimpaired controls|March 2013|March 21, 2013|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641823||158750|
NCT00642473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21308|MATER Study: A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash|MATER An Open Label Study to Assess the Effect of Metronidazole Actavis 1% Topical Cream in the Prevention and Treatment of Tarceva-associated Rash in Patients With Non-small Cell Lung Cancer||Hoffmann-La Roche||Completed|February 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642473||158701|
NCT00642161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004-0726|New Version Pulmicort Turbuhaler USA Children|A Placebo-controlled Comparison of the Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Children and Adolescents.||AstraZeneca|No|Completed|November 2002|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|430|||Both|6 Years|17 Years|No|||January 2011|January 21, 2011|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00642161||158725|
NCT00643058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005035|Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II|Nitric Oxide, LPS and the Pathogenesis of Asthma - Phase II||Duke University|No|Terminated|April 2003|December 2009|Actual|July 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|70|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|March 24, 2008|No|Yes|Funding period completed.|No||https://clinicaltrials.gov/show/NCT00643058||158656|
NCT00644319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000590072|Ibuprofen or Morphine in Treating Pain in Patients Undergoing Pleurodesis for Malignant Pleural Effusion|A 2 x 2 Factorial Trial to Assess Whether Non-Steroidal Anti-Inflammatory Analgesics and Small Bore Chest Tubes Are Less Painful Than Opiate Analgesics and a Large Bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion [TIME1]||National Cancer Institute (NCI)||Recruiting|March 2007|||September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|||Anticipated|320|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00644319||158559|
NCT00644020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYS-CN-1.1PUMPⅡPartA|Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients|A Randomized, Double Blind, Placebo Controled, Multicenter Phase ⅡStudy to Evaluate the Safety and Efficacy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients||Shenzhen Kangzhe Pharmaceutical Co., Ltd.|Yes|Recruiting|December 2007|August 2008|Anticipated|August 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|Samples With DNA|collection of blood sample before the operation and ahead of the third and the sixth period.      collection of the tumor tissue during the operation|Both|18 Years|75 Years|No|Probability Sample|HCC complicating branch cork after resection|December 2007|March 25, 2008|March 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00644020||158582|
NCT00644293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661119|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Three-Day Azithromycin for the Treatment of Group A β-Hemolytic Streptococcal Pharyngitis/Tonsillitis in Adolescents and Adults||Pfizer|No|Completed|January 2003|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|598|||Both|13 Years|N/A|No|||June 2011|June 3, 2011|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644293||158561|
NCT00644306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Hospital, Nancy|Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma|Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma|IFM 01/01|Central Hospital, Nancy, France|Yes|Terminated|April 2002|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|232|||Both|75 Years|N/A|No|||March 2008|March 20, 2008|March 20, 2008||No|survival advantage demonstrated|No||https://clinicaltrials.gov/show/NCT00644306||158560|
NCT00644891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-569|Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications|A Comparative, Multi-Center, Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications||Abbott||Completed|January 2003|||January 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|158|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|March 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644891||158516|
NCT00645294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-02-517|Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV|A Phase 1-2 Open-Label Study of the Pharmacokinetics and Safety of a Single Dose of Adefovir Dipivoxil in Children and Adolescents (Aged 2-17) With Chronic Hepatitis B||Gilead Sciences|No|Completed|February 2003|August 2003|Actual|August 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|47|||Both|2 Years|17 Years|No|||March 2008|March 21, 2008|March 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00645294||158485|
NCT00640887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12150a|Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa|Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|65 Years|No|||June 2011|June 17, 2011|February 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00640887||158821|
NCT00652886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B053205|Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions|Compare the Relative Bioavailability of Oxandrolone 10mg Tablets With That of OXANDRIN 10 mg Tablets Following a Single Oral Dose(1*10 mg Tablet) in Healthy, Adult Subjects Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|March 2005|June 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 3, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652886||157906|
NCT00653250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0055|Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|COX-2 Activity in Early and Advanced NSCLC and The Effect of Short-Term Administration of Specific COX-2 Inhibitors (Celecoxib)||Vanderbilt-Ingram Cancer Center|Yes|Completed|December 2000|January 2008|Actual|March 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|N/A|No|||May 2013|May 20, 2013|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00653250||157879|
NCT00688142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/6079/ES/US|Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder|Magnetoencephalographic Imaging of Sleepiness: The Effect of Armodafinil in Shift Work Sleep Disorder||Henry Ford Health System|No|Completed|February 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Study population must be healthy night shift workers with a diagnosis of shift work sleep        disorder.|March 2010|March 30, 2010|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00688142||155220|
NCT00688402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00031|Study to Compare Different Formulations of AZD3355|A Double-blind, Randomized, Cross-over Design, Phase 1 Pharmacodynamic Study to Investigate the Effect of Different Formulations of AZD3355 for the Development of Paresthesiae After Dosing in Healthy Subjects||AstraZeneca|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|May 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00688402||155200|
NCT00641017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 248|Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2008|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|7||Actual|87|||Both|6 Months|49 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|March 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641017||158811|
NCT00641030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06114|Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes|A Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation||City of Hope Medical Center|Yes|Completed|July 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|1 Year|N/A|No|||July 2012|July 16, 2012|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641030||158810|
NCT00641849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103057|Physical Activity and Dietary Behaviors of Adults 18 to 80 Years of Age|Physical Activity and Dietary Behaviors of Adults 18 to 80 Years of Age|Compliance|University of Missouri-Columbia|No|Terminated|July 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|54|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2010|June 21, 2010|March 18, 2008||No|Terminated by PI r/t lack of funding and retirement of study personel.|No||https://clinicaltrials.gov/show/NCT00641849||158748|
NCT00642174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11241|Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)|A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.|OPTIMUS-3|Eli Lilly and Company|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|74 Years|No|||February 2010|February 19, 2010|March 21, 2008|Yes|Yes||No|January 18, 2010|https://clinicaltrials.gov/show/NCT00642174||158724|
NCT00642187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-004-0620|New Version Pulmicort Turbuhaler USA Adults|A Placebo-controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated With Inhaled Steroids.||AstraZeneca|No|Completed|July 2002|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|525|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|March 18, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00642187||158723|
NCT00642200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-surg-001|Recurrent Inguinal Hernia Treatment - Lichtenstein Versus Laparoscopic Totally Extraperitoneal Preperitoneal Hernioplasty|Lichtenstein Hernioplasty Versus Totally Extraperitoneal Laparoscopic Hernioplasty in Treatment of Recurrent Inguinal Hernia - A Prospective Randomized Trial||North Karelia Central Hospital|No|Completed|January 1997|April 2007|Actual|February 2002|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2008|May 20, 2008|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00642200||158722|
NCT00642759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-339|Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Trial of Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer||Massachusetts General Hospital|Yes|Completed|April 2008|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642759||158679|
NCT00642772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-180|Group Physical Therapy for Knee Osteoarthritis|Pilot Study of Group Physical Therapy for Knee Osteoarthritis||VA Office of Research and Development|No|Completed|March 2008|December 2009|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|March 19, 2008||No||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00642772||158678|
NCT00642785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071/081|Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections|A Research Study Examining the Effectiveness of Distant Activation of ACE Pigments Associated With Recurrent Human Herpes Simplex Virus-Induced Skin Lesions.||Institute of Progressive Medicine|Yes|Completed|January 2008|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|500|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|HSV and HZV infected patients|May 2008|May 30, 2008|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642785||158677|
NCT00642798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-108|An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)|An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects||Merck Sharp & Dohme Corp.||Completed|March 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|March 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00642798||158676|
NCT00644332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 3041|An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)|An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women's Ischemia Symptom Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)||Gilead Sciences|No|Completed|November 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|172|||Female|18 Years|N/A|No|||May 2012|May 29, 2012|March 24, 2008|Yes|Yes||No|May 29, 2012|https://clinicaltrials.gov/show/NCT00644332||158558|The study was terminated early at 86% of targeted enrollment (172 of approximately 200 subjects).
NCT00644579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-1205|bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients|bLAC - A Phase II Double-Blind, Placebo Controlled, Clinical Proof of Concept Trial of the Efficacy of 8 Weeks Treatment of Cutaneous Warts With bLAC in Immune Suppressed, Kidney Transplanted Patients||NatImmune A/S|No|Recruiting|March 2008|February 2009|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00644579||158539|
NCT00644592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302-2007|LXRA Gene Polymorphisms and Response to Fenofibrate|LXRA Gene Polymorphisms and Response to Fenofibrate||University of Florida|No|Terminated|March 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 24, 2012|March 21, 2008|Yes|Yes|supply issues with the formulation of fenofibrate that was used.|No|March 12, 2012|https://clinicaltrials.gov/show/NCT00644592||158538|
NCT00645281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121001|A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.|Symptom Specific Effectiveness of Tolterodine ER 4 mg in Patients With Symptoms of Overactive Bladder (OAB) in a Primary Care Setting. A Phase IV, Open-Label, Single-Arm, Non-Randomized, Trial in Adult Patients With OAB.||Pfizer||Completed|March 2004|January 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|896|||Both|18 Years|N/A|No|||March 2008|March 25, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645281||158486|
NCT00652171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP: 093/03|Efficacy and Safety of Antidepressant Augmentation With Lamotrigine|Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression||Institute of Social Security of the Civil Servants of Minas Gerais|Yes|Completed|January 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||April 2008|April 3, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00652171||157960|
NCT00642967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21146|A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis|A Single Arm, Open Label, French Multi-centre Study to Assess the Maintenance of Hemoglobin Levels With Once Monthly Subcutaneous Administration of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease Not on Dialysis||Hoffmann-La Roche||Completed|May 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642967||158663|
NCT00643292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661073|A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Amoxicillin/Clavulanate Potassium (Augmentin ES-600 Trademark) for the Treatment of Acute Otitis Media in Children Undergoing Diagnostic Tympanocentesis||Pfizer|No|Completed|January 2003|May 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|902|||Both|3 Months|48 Months|No|||May 2011|May 16, 2011|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643292||158638|
NCT00642928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-02 / BF 2.649|Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients|Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD)||Bioprojet|Yes|Completed|October 2007|June 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|108|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642928||158666|
NCT00642941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21157|A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.|A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.||Hoffmann-La Roche||Completed|November 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|2 Years|N/A|No|||March 2016|March 1, 2016|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642941||158665|
NCT00642954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-074|Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)|A Phase I Study of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Merck Sharp & Dohme Corp.||Completed|February 2008|August 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|March 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00642954||158664|
NCT00642343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BALANCE W/COCHLEAR_BERRYHILL|Balance in Children With Cochlear Implants|Balance in Children With Cochlear Implants||University of Oklahoma|No|Completed|March 2008|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|66|||Both|4 Years|18 Years|No|||June 2010|June 14, 2010|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642343||158711|
NCT00642356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELC200AUS14|Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off|An 8-week, Prospective, Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center Comparison Study of the Effects of Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off||Novartis||Terminated|March 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|30 Years|85 Years|No|||February 2011|February 16, 2011|March 19, 2008|Yes|Yes|slow enrollment|No|December 14, 2010|https://clinicaltrials.gov/show/NCT00642356||158710|
NCT00694070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2008-11|Evaluation of a Diabetes Data Management System|Evaluation of a Diabetes Data Management System In a Clinical Setting||Ascensia Diabetes Care|No|Completed|July 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|51|||Both|18 Years|N/A|No|Probability Sample|Lay users males or females and health care professionals.|January 2016|January 29, 2016|June 6, 2008|No|Yes||No|July 1, 2009|https://clinicaltrials.gov/show/NCT00694070||154767|
NCT00694616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/OSA/CPAP/2008|Prevalence of Metabolic Syndrome in Obstructive Sleep Apnea (OSA) and Effect of Treatment With Continuous Positive Airway Pressure (Auto-CPAP) on Metabolic Syndrome|Prevalence of Metabolic Syndrome in Obstructive Sleep Apnea and the Effect of Treatment With Auto-titrating Continuous Positive Airway Pressure (Auto-CPAP) on Metabolic Syndrome||All India Institute of Medical Sciences, New Delhi|No|Completed|July 2008|December 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|30 Years|65 Years|No|||June 2013|June 22, 2013|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694616||154725|
NCT00694629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHSTP-5399|TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment|TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis||Centers for Disease Control and Prevention|Yes|Completed|December 2008|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|865|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|June 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694629||154724|
NCT00694642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|progenitorCD133|Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis|Safety and Efficacy of Transendocardial Injection of Autologous Endothelial Progenitor Cell CD 133 for Therapeutics Angiogenesis|PROGENITOR|Hospital San Carlos, Madrid|Yes|Completed|May 2008|February 2012|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||May 2008|August 4, 2013|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694642||154723|
NCT00641576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W050404001|Evaluation of the ACE Dental Implant|A Study to Evaluate the Morse Taper Lock and Connection of the ACE Implant Internal-Connection and Its Effect of the Biological Gap|ACE-2005|University of Alabama at Birmingham|No|Completed|April 2005|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|19 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Dental school periodontology clinic|July 2013|July 18, 2013|March 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641576||158769|
NCT00641589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002299|A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease|An Open-Label, Randomized Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Subjects With Chronic Kidney Disease||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2006|November 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|N/A|No|||April 2010|May 17, 2011|March 17, 2008||||||https://clinicaltrials.gov/show/NCT00641589||158768|
NCT00641862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD052143|Randomized Trial of Vitamin B12 in Pregnant Indian Women|Randomized Trial of Vitamin B12 in Pregnant Indian Women|B12|Harvard School of Public Health|Yes|Active, not recruiting|December 2008|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|366|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641862||158747|
NCT00642811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00030|A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders|A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND]|RESPOND|AstraZeneca|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|March 19, 2008|Yes|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00642811||158675|
NCT00642486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMF 38-PM-07|Portable Monitoring for Diagnosis and Management of Sleep Apnea|Portable Monitoring in the Diagnosis and Management of Obstructive Sleep Apnea|HomePAP|Case Western Reserve University|Yes|Completed|February 2008|March 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|373|||Both|18 Years|N/A|No|||March 2008|May 25, 2010|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00642486||158700|
NCT00643383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06CCL3-001|A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain|||Labopharm Inc.||Completed|March 2008|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|277|||Both|18 Years|80 Years|No|||April 2012|April 30, 2012|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643383||158631|
NCT00644618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Union Hospital|Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy|Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy Versus Gemcitabine Alone in Patients With Locally Advanced Pancreatic Cancer||Huazhong University of Science and Technology|Yes|Completed|January 2003|January 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||March 2008|March 24, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644618||158536|
NCT00644605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481140|A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension|A Multinational, Multi-centre, Randomised, Double-blind, Double-dummy, Placebo-controlled Study to Assess the Efficacy and Safety of 20, 40, and 80mg TID Sildenafil in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over||Pfizer|No|Completed|October 2002|November 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|275|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644605||158537|
NCT00644930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN73824458|Non-Invasive Positive Pressure Ventilation and Adult Respiratory Distress Syndrome (ARDS)|The Efficacy of Non-Invasive Positive Pressure Ventilation in ARDS: A Controlled Cohort Study|NPPV|Eskisehir Osmangazi University|Yes|Completed|August 2003|December 2007|Actual|September 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2008|March 26, 2008|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00644930||158513|
NCT00644943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-541|A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media|A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media||Abbott||Completed|February 2003|||April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|425|||Both|6 Months|6 Years|No|||March 2008|March 21, 2008|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644943||158512|
NCT00651885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.219.B|Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure|A Randomized, Single-Center, Placebo Controlled Study To Assess the Safety of UT-15C (Treprostinil Diethanolamine) Sustained Release (SR) in Patients Undergoing an Infra-Popliteal Endovascular Intervention for the Treatment of Critical Limb Ischemia||Ochsner Health System|No|Completed|March 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2008|May 13, 2011|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00651885||157982|
NCT00652548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0007|Use of Ultrasound to Evaluate Clavicle Fractures in Pediatric Patients|Utility of Bedside Ultrasound to Diagnose Clavicle Fractures in the Pediatric Emergency Department||University of Louisville|No|Completed|March 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|1 Year|18 Years|No|Non-Probability Sample|Children age 1-18 years presenting to a tertiary center pediatric emergency department        complaining of recent traumatic shoulder injury.|March 2008|January 12, 2010|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00652548||157932|
NCT00652873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01211|Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fed Conditions||Par Pharmaceutical, Inc.|No|Completed|July 2001|December 2001|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 1, 2008|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00652873||157907|
NCT00643305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project HELP|HIV Prevention With the Mentally Ill|HIV Prevention With the Mentally Ill: Motivation-Skills||Boston Medical Center|Yes|Completed|February 2006|January 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|53|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2008|May 2, 2013|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643305||158637|
NCT00643266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RecollectionTraining|Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment|Memory Interventions for Older Adults||Baycrest|No|Recruiting|February 2008|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00643266||158640|
NCT00643279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPASS-HF|Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)|Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)||Medtronic Cardiac Rhythm Disease Management|Yes|Active, not recruiting|March 2003|||June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|274|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|February 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643279||158639|
NCT00694083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-003|Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)|A Phase I Study of MK-8669 in Patients With Metastatic or Locally Advanced Solid Tumors||Merck Sharp & Dohme Corp.||Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|N/A|No|||February 2015|February 12, 2015|May 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694083||154766|
NCT00694369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-092|A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)|A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Multiple-Dose Clinical Trial to Study the Efficacy and Safety of MK0663/Etoricoxib 90 and 120 mg, Ibuprofen 600 mg, and Acetaminophen 600 mg/Codeine 60 mg in the Treatment of Patients With Postoperative Dental Pain||Merck Sharp & Dohme Corp.|No|Completed|June 2008|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|588|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 6, 2008|Yes|Yes||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00694369||154744|
NCT00694954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E20270|Capsule Endoscopy vs Standard of Care for Obscure Intestinal Bleeding|A Randomized Controlled Trial of Capsule Endoscopy vs Standard Care in Patients With Iron Deficiency Anemia With Suspected Obscure / Occult Gastrointestinal Bleeding||University of Calgary|No|Recruiting|February 2007|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2011|December 16, 2011|December 14, 2007||No||No||https://clinicaltrials.gov/show/NCT00694954||154699|
NCT00695214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-00379|Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea|Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea||University of Southern California|No|Recruiting|February 2004|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00695214||154679|
NCT00641329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLON-302|CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD|Phase III Evaluation of the Safety and Efficacy of CLONICEL (Clonidine HCl Sustained Release) as Add-on to Psychostimulant Medication vs. Psychostimulant Medication Alone in Children and Adolescents With ADHD||Addrenex Pharmaceuticals, Inc.|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|6 Years|17 Years|No|||March 2009|April 8, 2010|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00641329||158787|
NCT00641342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMPC|Prevention of Parastomal Hernia by Primary Mesh Insertion|Prevention of Parastomal Hernia by Primary Mesh Insertion: a Randomized Double-blinded Controlled Multi-centre Study.||University Hospital, Gentofte, Copenhagen|No|Terminated|March 2007|February 2015|Anticipated|February 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|198|||Both|18 Years|N/A|No|||March 2008|February 6, 2014|March 18, 2008||No|Lack of recruitment from different study sites and due to structural changes in the included    centers|No||https://clinicaltrials.gov/show/NCT00641342||158786|
NCT00642213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS30678|A Comparison of Hemorrhagic and Ischemic Strokes Among Blacks and Whites|A Comparison of Hemorrhagic and Ischemic Strokes Among Blacks and Whites: A Population-Based Study in Cincinnati, Ohio|GCNKSS|University of Cincinnati|No|Active, not recruiting|July 1993|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1200|Samples With DNA|We have collected blood and/or buccal samples from an interviewed cohort during years      1999,2005, and 2010.|Both|18 Years|N/A|No|Non-Probability Sample|Prospective cohort:Ischemic stroke patient in 1999/2005/2010 that resides in the GCNK        area.        Retrospective cohorts: All stroke and TIA events occurring during the following study        periods: 1993-94, 1999, 2005, 2010, and 2015. This group is ALL stroke patients of any age        that resides in our 5 county region.|May 2015|May 27, 2015|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642213||158721|
NCT00642499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S175.2.101|Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting|A Double-Blind, Randomized, Parallel-Group, Pilot Study of Oral Dronabinol Versus Placebo in the Treatment or Prevention of Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting||Solvay Pharmaceuticals|No|Completed|August 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|70 Years|No|||March 2008|April 1, 2008|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642499||158699|
NCT00642824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21150|A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.|Local Substudy Associated to the International Study MO19390 to Determine the BRCA1 Gene mRNA Expression as a Predictive Marker of Response to Chemotherapy||Hoffmann-La Roche||Terminated|May 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 19, 2008||No|Terminated due to low enrollment. No statistical analyses were performed.|No||https://clinicaltrials.gov/show/NCT00642824||158674|
NCT00643110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rendell 01|Milk as Treatment for Hypoglycemia|Milk as Treatment for Hypoglycemia||Creighton University|No|Withdrawn|April 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 24, 2015|March 20, 2008|Yes|Yes|Not funded|No||https://clinicaltrials.gov/show/NCT00643110||158652|
NCT00643123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB8981|Allopurinol Add-on Treatment for Refractory Mania|A Double-Blind, Placebo Controlled Augmentation Study With Allopurinol for Treatment Resistant Mania||Cedars-Sinai Medical Center|No|Completed|September 2007|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||March 2012|March 26, 2012|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643123||158651|
NCT00643422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cirrus_OCT_0308|Reproducibility of Cirrus Optical Coherence Tomography Measurements|Reproducibility of Retinal Thickness and Volume Measurements Determined With the Cirrus Spectral Domain OCT||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|attendants of health care center|July 2008|July 21, 2008|March 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00643422||158628|
NCT00643084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bowel Prep|Bowel Prep vs Non-Bowel Prep for Laparoscopic Colorectal Surgery|A Randomized Controlled Trial of Bowel-Prepped vs Non-Bowel-Prepped Laparoscopic Colorectal Surgery||McMaster University|No|Not yet recruiting|May 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||March 2008|March 24, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643084||158654|
NCT00643708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200602070|Ovarian Laser Treatment in Women With Polycystic Ovarian Syndrome: A Randomized Study on the Laser Dose|Transvaginal Ultrasound-Guided Ovarian Interstitial Laser Treatment in Anovulatory Women With Polycystic Ovarian Syndrome: A Randomized Prospective Study on the Effect of Laser Dose Used on the Outcome||Shen-Zhen City Maternity and Child Healthcare Hospital|Yes|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|56|||Female|23 Years|34 Years|Accepts Healthy Volunteers|Probability Sample|Fifty-six patients with anovulatory infertility due to PCOS were included in the study        between January 2005 and December 2007. All women presented with oligo-/amenorrhea and        anovulation for at least 2 years and were seeking pregnancy. The mean (± SD) age was 29.1        ± 3.1 years and the mean duration of infertility 3.3 ± 2.0 years. The mean body mass index        (BMI) was 22.9 ± 3.5 kg/m2. All subjects had polycystic ovaries on transvaginal ultrasound        scan (TVS) (Aloka-1000, UST-985, 5 MHz transvaginal probe, Aloka Co. Ltd, Tokyo, Japan),        and the diagnosis of PCOS was made according to criteria of The Rotterdam (The Rotterdam        ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2003).|March 2008|March 25, 2008|March 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00643708||158606|
NCT00644371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELTAMO-Z-RIC-Allo|Allogenic Stem Cell Transplantation (SCT) With Non-Myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)|Allogeneic Transplantation of Haematopoietic Stem Cells Following Non-Myeloablative Conditioning With Melphalan, Fludarabine, Thiotepa, Rituximab and Ibritumomab Tiuxetan (Zevalin) in Patients With Aggressive Non-Hodgkin's B-Cell Lymphoma|Z-RIC-Allo|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Recruiting|November 2007|||September 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||March 2008|March 27, 2008|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644371||158555|
NCT00644904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB05-147|Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis|A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis|VitD4MS|University of Toronto|No|Completed|July 2006|February 2008|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2008|March 27, 2008|March 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644904||158515|
NCT00644917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011 101 09 001|Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment|Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment||Healthpoint|No|Completed|February 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|March 24, 2008|No|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00644917||158514|
NCT00651638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-112|A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype|A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype||ArQule|No|Completed|March 2008|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|June 18, 2008|March 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00651638||158001|
NCT00651898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-597|Circulating-water Garment With Forced-air Warming and Circulating-water Mattress During Abdominal Surgery|Comparison of a Circulating-water Garment With a Combination of Forced-air Warming and Circulating-water Mattress Warming During Major Abdominal Surgery||The Cleveland Clinic|No|Completed|August 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|50|||Both|18 Years|85 Years|No|Probability Sample|Male or female patients between 18-85 years of age who are undergoing major abdominal        surgery who do not have a contradiction to forced-air or circulating water warming.        Patient's undergoing combined procedures are not eligible to participate. Patient can not        have a core temperature over 38°C, be pregnant or|February 2016|February 27, 2016|March 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00651898||157981|
NCT00642642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-A-008|Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring|A Phase II/III Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Isolagen Therapy in the Treatment of Moderate to Sever Facial Acne Scarring||Fibrocell Technologies, Inc.|No|Completed|November 2007|March 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|65 Years|No|||July 2013|July 19, 2013|March 19, 2008|Yes|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00642642||158688|
NCT00644189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-401|Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma|A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma||Massachusetts General Hospital|Yes|Completed|June 2008|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644189||158569|
NCT00643565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20924|A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.|An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma||Hoffmann-La Roche||Active, not recruiting|July 2008|May 2019|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|6 Months|18 Years|No|||January 2016|January 15, 2016|March 20, 2008||No||No|December 7, 2015|https://clinicaltrials.gov/show/NCT00643565||158617|Reported results represent the interim results up to approximately 6.75 years (data cut-off date 31 May 2015).
NCT00643578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ivax-65307|Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay|A Pilot Study to Evaluate the Dose-response of Inhaled Formoterol to Inhibit Airway Responsiveness to Methacholine in Patients With Mild Asthma||University of Florida|No|Completed|March 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|60 Years|No|||November 2011|November 29, 2011|March 20, 2008|Yes|Yes||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00643578||158616|
NCT00694655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009560|Human Immune Responses to The Yellow Fever Virus Vaccine|Human Immune Responses to Yellow Fever Vaccination||Emory University|No|Recruiting|May 2008|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694655||154722|
NCT00694668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120610008|The (Cost-) Effectiveness of Mindfulness-training and Cognitive Behavioural Therapy in Adolescents and Young Adults With Deliberate Self Harm|The (Cost-) Effectiveness of Mindfulness-training and Cognitive Behavioural Therapy in Adolescents and Young Adults With Deliberate Self Harm|DSH|Leiden University Medical Center|No|Recruiting|May 2008|October 2012|Anticipated|November 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|15 Years|35 Years|No|||November 2009|November 5, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694668||154721|
NCT00694967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003103|A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix|Histologic Evaluation of the Cervix at Risk for Preterm Birth Trial:Medical Versus Surgical Therapy||Lehigh Valley Hospital|No|Terminated|November 2003|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2008|June 7, 2008|June 7, 2008|Yes|Yes|Interim analysis showed no difference in outcome between treatment groups.|No||https://clinicaltrials.gov/show/NCT00694967||154698|
NCT00695240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-310|Post-Operative Pain Control Using Direct Continuous Bupivacaine Infusion After Pelvic Organ Prolapse Repair|Post-Operative Pain Control Using Direct Continuous Bupivacaine Infusion After Pelvic Organ Prolapse Repair||St. Luke's Hospital, Kansas City, Missouri|No|Recruiting|April 2007|July 2009|Anticipated|July 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 10, 2008|June 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00695240||154677|
NCT00695227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 DK66165 (completed)|Screening for Barrett's Esophagus in Otolaryngology Patients|Screening for Barrett's Esophagus in Otolaryngology Patients|SCE|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|May 2004|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2011|May 2, 2011|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00695227||154678|
NCT00695487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK240_07|Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?|Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?|THC|University Hospital Inselspital, Berne|No|Terminated|July 2008|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|70 Years|No|||March 2014|March 11, 2014|June 10, 2008||No|In the intermediate analysis, no effect could be shown, not even a tendency.|No||https://clinicaltrials.gov/show/NCT00695487||154658|
NCT00641875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.050|The Effect of Nocturnal Haemodialysis on Arterial Stiffness|The Effect of Nocturnal Haemodialysis on Arterial Stiffness||Melbourne Health|No|Completed|December 2005|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|80 Years|No|Probability Sample|All participants are adult patients who are receiving maintenance dialysis at the North        West Dialysis Service. Consecutive patients enrolled in the Nocturnal Haemodialysis        program are invited to participate in the study|April 2015|April 23, 2015|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641875||158746|
NCT00642226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.2006.1159(REK)|Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)|A Randomized Study Comparing Combined Vitrectomy and Triamcinolone to Laser Grid in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)||Helse Stavanger HF|No|Terminated|November 2006|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|March 19, 2008|Yes|Yes|Due to recruiting problems and the introduction of new treatment strategies (ranibizumab and    dexamethasone implant).|No||https://clinicaltrials.gov/show/NCT00642226||158720|
NCT00642512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S175.3.102|Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Efficacy Study of Oral Dronabinol Alone and in Combination With Ondansetron Versus Ondansetron Alone in Subjects With Delayed Chemotherapy-Induced Nausea and Vomiting||Solvay Pharmaceuticals|No|Completed|July 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|64|||Both|18 Years|N/A|No|||March 2008|March 31, 2008|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642512||158698|
NCT00643097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004040|Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII|ACTIVATe|Duke University|Yes|Active, not recruiting|September 2007|December 2016|Anticipated|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|March 25, 2008|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00643097||158653|
NCT00643149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661071|A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of Azithromycin SR Versus Amoxicillin For The Treatment Of Strep Throat In Children|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial Of Azithromycin SR Versus Amoxicillin For The Treatment Of Group A Β-Hemolytic Streptococcal Pharyngitis/Tonsillitis In Children||Pfizer|No|Completed|May 2003|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|693|||Both|2 Years|12 Years|No|||May 2011|May 16, 2011|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643149||158649|
NCT00643721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5408|Body Water Content Sensor|Body Water Content Sensor||State University of New York - Upstate Medical University|No|Active, not recruiting|September 2007|April 2008|Anticipated|April 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young healthy athletes|March 2008|March 25, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643721||158605|
NCT00643448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00019|Explorative Study of AZD1305 in Atrial Fibrillation Patients|A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placebo When Given to Patients With Documented AF||AstraZeneca|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|65|||Both|20 Years|80 Years|No|||December 2011|December 21, 2011|March 20, 2008|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00643448||158626|
NCT00643396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-23929/23929|Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer|Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer||AHS Cancer Control Alberta||Completed|February 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|No|||April 2012|February 24, 2016|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643396||158630|
NCT00644033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VML 251 00/02|A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine|||Endo Pharmaceuticals||Completed|June 2001|June 2002|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|579|||Female|18 Years|N/A|No|||June 2011|June 13, 2011|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644033||158581|
NCT00656045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAN E01-1703-011|Leisure Time Activity and Nutrition Program|The Effects of Two Different Leisure-Time Activity Prescriptions on Eating and Activity Behaviors During Behavioral Weight Loss Treatment|LEAN|University of Tennessee|Yes|Completed|March 2008|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 26, 2008|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656045||157666|
NCT00656058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080097|Montelukast to Treat Bronchiolitis Obliterans|Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2008|May 2018|Anticipated|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|6 Years|80 Years|No|||March 2015|December 2, 2015|April 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00656058||157665|
NCT00644631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481177|A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate|A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) In The United States||Pfizer|No|Completed|June 2003|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||March 2008|March 26, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644631||158535|
NCT00642070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31467-D|Host Response to Urinary Tract Infection in Women|Host Response to Urinary Tract Infection in Women||University of Washington|No|Completed|February 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|326|Samples With DNA|whole blood,serum, urine|Female|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women between the ages of 18-49 with symptoms of a urinary tract infection for fewer than        7 days|June 2014|June 3, 2014|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00642070||158732|
NCT00642083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-499-301107|Stenting of Haemodialysis Acces Trial|Stenting of Haemodialysis Acces Re-stenosis Trial (SHARE Trial)|SHARE|Rijnstate Hospital||Terminated||August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2011|December 14, 2011|March 19, 2008|||slow inclusion|No||https://clinicaltrials.gov/show/NCT00642083||158731|
NCT00642369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00053|A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia|Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia||Guang Dong Provincial Mental Health Institute|No|Completed|March 2008|October 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||March 2014|March 21, 2014|March 18, 2008||No||No|December 14, 2009|https://clinicaltrials.gov/show/NCT00642369||158709|the present study lasted for only 4 weeks. it might be too short to investigate the effect of quetiapine fumarate and haloperidol on sleep and clinical parameters.
NCT00642655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3176s|Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation|A Phase I/II Trial to Investigate the Safety and Efficacy of Rituximab and IVIG as Agents to Desensitize Highly-HLA Sensitized Dialysis Patients Awaiting Kidney Transplantation||Cedars-Sinai Medical Center|No|Completed|September 2005|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|75 Years|No|||March 2008|March 24, 2008|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642655||158687|
NCT00642668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21348|A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.|An Open Label Study of the Safety, Tolerability and Effect on Hemoglobin Levels of Monthly Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Treated With ESA or Dialysis.||Hoffmann-La Roche||Completed|April 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642668||158686|
NCT00644475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPV001DIM2008|Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension|Randomized, Controlled, Parallel Arm, PROBE Study to Evaluate Different Effects of Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension||University of Pavia|No|Recruiting|March 2008|March 2009|Anticipated|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2008|March 25, 2008|March 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00644475||158547|
NCT00644488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA185-005|A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer|A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer||Bristol-Myers Squibb|Yes|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|20 Years|N/A|No|||May 2009|January 24, 2011|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644488||158546|
NCT00644462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSI-WZA-01|Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording|Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording||KarmelSonix Ltd.|No|Not yet recruiting|June 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|asthmatic subjects or healthy subjects|January 2009|January 10, 2009|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644462||158548|
NCT00694681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS-233-01-0012-RI|Working Toward Wellness|Enhanced Services for the Hard to Employ Demonstration: Telephonic Care Management for Depressed Medicaid Recipients|WtW|MDRC|No|Completed|October 2004|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|499|||Both|18 Years|65 Years|No|||March 2012|March 23, 2012|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00694681||154720|
NCT00695253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10807-01|Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA)|Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With AAA||Los Angeles Biomedical Research Institute|Yes|Completed|January 2002|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 28, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695253||154676|
NCT00695266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2007/5|National Survey on Hypertension at Hospital|Profile of Hypertensive Patients Seen in Hospital Outpatient's Department|PROPHYL HO|AstraZeneca|No|Completed|December 2007|September 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|655|||Both|18 Years|N/A|No|Probability Sample|First five consecutive patients with hypertension seen by Cardiologists|August 2009|August 4, 2009|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695266||154675|
NCT00695526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06066|Effects of Cranberry Extractive on the Lipid Profiles in Subjects With Type 2 Diabetes|Phase 3 Study of Cranberry on Lipid Profiles in Type 2 Diabetes||Taichung Veterans General Hospital|No|Completed|May 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|50 Years|75 Years|No|||June 2008|June 14, 2008|April 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00695526||154655|
NCT00641888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715922-1|Impact of Antiretroviral Therapy on Cardiac Biomarkers|Impact of Antiretroviral Therapy on Biomarkers of Inflammation Associated With Cardiovascular Risk||University of California, Davis|No|Recruiting|March 2008|December 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|69 Years|No|Probability Sample|Patients presenting to an HIV clinic and an infectious diseases clinic affiliated with a        tertiary care hospital|January 2010|January 19, 2010|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00641888||158745|
NCT00642525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endoray|Detection of Anastomotic Leakage After Esophageal Surgery|Radiologic vs. Endoscopic Evaluation of the Conduit After Esophageal Resection: a Prospective, Blinded, Intraindividual Controlled Diagnostic Study.||Heidelberg University|No|Completed|January 2006|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|55|||Both|18 Years|N/A|No|||March 2008|March 19, 2008|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642525||158697|
NCT00642538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-253-002|A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus|A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus||Mannkind Corporation||Completed|February 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00642538||158696|
NCT00643136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-000-167|A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures|Pregabalin BID Add-on Trial: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Single-Center Sleep EEG Study in Patients With Partial Seizures and Sleep Disturbance Part B: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Pregabalin Add-on Treatment||Pfizer||Completed|November 2002|June 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||April 2008|April 23, 2008|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643136||158650|
NCT00643409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661078|A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Acute Bacterial Maxillary Sinusitis in Adults Undergoing Diagnostic Sinus Aspiration||Pfizer|No|Completed|January 2003|February 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|541|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643409||158629|
NCT00643747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/061|Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis|An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (AAV2/2-hRPE65p-hRPE65) for Gene Therapy of Severe Early-onset Retinal Degeneration||University College, London|Yes|Completed|January 2007|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|5 Years|30 Years|No|||December 2013|December 4, 2015|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643747||158603|
NCT00643786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT : 031003|Interest of Re-oxygenation After Inhalation of 50% Nitrous Oxide / 50% Oxygen Premix in Dental Cares|Validation of a Kalinox's Administration Protocol for Dental Cares : Interest of Re-oxygenation and Pollution Control||Air Liquide Santé International|No|Terminated|February 2004|June 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|128|||Both|1 Year|N/A|No|||June 2014|June 23, 2014|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643786||158600|
NCT00643734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661103|A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults||Pfizer|No|Completed|April 2003|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|468|||Both|18 Years|N/A|No|||March 2008|March 19, 2008|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643734||158604|
NCT00643760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110448|A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)|Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)||XenoPort, Inc.|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|421|||Both|18 Years|N/A|No|||January 2013|July 15, 2013|February 19, 2008|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00643760||158602|
NCT00644046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWW-0001|Chronic Kidney Disease Prevention of An-Lo District, Keelung|Chronic Kidney Disease Prevention of An-Lo District, Keelung.||Chang Gung Memorial Hospital|Yes|Completed|July 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1500|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2012|September 5, 2012|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644046||158580|
NCT00655811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003739|Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects|Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects||Wake Forest School of Medicine|No|Completed|February 2008|October 2009|Actual|August 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|April 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00655811||157684|
NCT00651625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 04-347|Reciprocating Medical Devices - a Study of a New Safety Device|Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures|RPD|University of New Mexico|Yes|Completed|November 2004|August 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 21, 2008||No||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00651625||158002|no adverse events
NCT00656071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHughes-PGY2|Retrospective Postoperative ARDS Study at Vanderbilt University|Intraoperative Anesthetic Characteristics and the Development of ARDS||Vanderbilt University|No|Completed|October 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|89|||Both|11 Years|N/A|No|Non-Probability Sample|The surgical and post-op patients at VUMC. The collection dates will be from October 1,        2001 until August 31, 2007.|September 2012|September 5, 2012|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00656071||157664|
NCT00642096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4026C00001|Factorial Study of Metoprolol Succinate TOPROL-XL (324A)|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Factorial Study of Metoprolol Succinate Extended Release Tablets (TOPROL-XL) Hydrochlorothiazide and Their Combination in Patients With Essential Hypertension.||AstraZeneca|No|Completed|June 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Anticipated|1900|||Both|18 Years|80 Years|No|||March 2009|March 24, 2009|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00642096||158730|
NCT00642382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMI-CP-Ankle-001|Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis|Randomized, Double Blind,Saline-Controlled, Multi-Center, Prospective Study to Evaluate the Safety and Effectiveness of Carticept's Agilus Device for the Treatment of Ankle Osteoarthritis||Cartiva, Inc.|No|Terminated|April 2008|December 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|95 Years|No|||February 2013|February 13, 2013|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642382||158708|
NCT00642681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-112|Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge|Evaluation of the Effect of Symptomatic Upper Respiratory Infections on Pharmacological Characteristics of Technosphere®/Insulin in Subjects With Diabetes Mellitus After a Meal Challenge||Mannkind Corporation||Completed|December 2007|August 2008|Actual|July 2008|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects who developed symptoms of URI at any point during the MKC-TI-030 trial and were        randomized to study treatment of TI|December 2014|December 1, 2014|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642681||158685|
NCT00642980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060216|Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis|Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy|PREMEVA|University Hospital, Lille|Yes|Completed|April 2006|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3105|||Female|18 Years|N/A|No|||January 2008|January 22, 2014|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642980||158662|
NCT00643916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA26|Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age|Safety and Immunogenicity of a Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine (TetraMenD) In Toddlers 9 to 18 Months of Age||Sanofi|Yes|Completed|December 2004|October 2007|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|378|||Both|9 Months|5 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|March 24, 2008|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00643916||158590|
NCT00644501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|910|Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes|Open Label Study to Evaluate Long Term Treatment Effect of DiaPep277® in Patients Who Have Completed Studies 461* (Phase II) or 901** (Pase III)||Andromeda Biotech Ltd.|Yes|Completed|September 2008|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|48 Years|No|||July 2013|July 10, 2013|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644501||158545|
NCT00645086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-472|Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis|A Phase III Comparative Efficacy Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Subjects With Acute Bacterial Exacerbation of Chronic Bronchitis.||Abbott||Completed|December 2002|||April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|465|||Both|40 Years|N/A|No|||March 2008|March 26, 2008|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645086||158501|
NCT00645099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013189|A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia|A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia||Janssen-Cilag International NV|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|462|||Both|18 Years|65 Years|No|||April 2014|April 24, 2014|March 24, 2008||No||No|April 7, 2010|https://clinicaltrials.gov/show/NCT00645099||158500|Open-label design
NCT00644774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-568|A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications|A Comparative, Multi-Center, Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications||Abbott||Completed|January 2003|||January 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|157|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|March 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644774||158524|
NCT00645112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-630|A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media|A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media||Abbott||Completed|November 2003|||January 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|357|||Both|6 Months|6 Years|No|||March 2008|March 22, 2008|March 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645112||158499|
NCT00694980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS4262g|A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis|A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta7 Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Ulcerative Colitis||Genentech, Inc.||Completed|September 2008|September 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|70 Years|No|||February 2016|February 1, 2016|June 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694980||154697|
NCT00694993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHI110157|Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects|See Detailed Description||GlaxoSmithKline|No|Completed|December 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|June 9, 2008||||No||https://clinicaltrials.gov/show/NCT00694993||154696|
NCT00695279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENEFU|Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products|Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products at St. Jude Children's Research Hospital||St. Jude Children's Research Hospital|No|Recruiting|December 2006|December 2036|Anticipated|December 2036|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood samples|Both|N/A|N/A|No|Non-Probability Sample|Gene therapy recipient patients|December 2015|January 4, 2016|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695279||154674|
NCT00695539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CGR-CRE-2007/1|Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients|A Multi-centre, Open Label, Non-randomised, Non Interventional, 24 Weeks Study for the Efficacy and Safety of Rosuvastatin Following Its Administration in Real Life Clinical Practice in Greek Hypercholesterolaemic Patients|RESEARCH|AstraZeneca|No|Completed|December 2007|December 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|810|||Both|18 Years|80 Years|No|Non-Probability Sample|Primary Care|October 2009|October 2, 2009|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00695539||154654|
NCT00695552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEMOII|The Effect of Exercise on Depressive Symptoms in Unmedicated Patients|DEMO II: A Randomized, Parallel-group, Observer-blinded Clinical Trial of Aerobic Exercise Versus Stretching Exercise for Patients With Light to Moderate Depression|DEMOII|University of Copenhagen|No|Recruiting|September 2008|April 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2008|March 17, 2010|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695552||154653|
NCT00642239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMNa-ESO-01-2007|A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma|A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma||Shandong Luye Pharmaceutical Co., Ltd.|No|Recruiting|April 2008|December 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||May 2008|May 13, 2008|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642239||158719|
NCT00642252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nanotech Phase II April 2008|Development and Validation of a Multi-Mineral Fluoride Mouthrinse|Development and Validation of a Multi-Mineral Fluoride Mouthrinse||Indiana Nanotech, LLC|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|13 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00642252||158718|
NCT00643162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8648|Depression in Older Adults|Combination Lexapro and Massage for Treatment in Depression in Older Subjects||Cedars-Sinai Medical Center|No|Completed|June 2006|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|60 Years|N/A|No|||March 2012|March 26, 2012|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643162||158648|
NCT00643435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715598-1|Self-Efficacy Enhancing Interviewing Techniques Study|Self-Efficacy Enhancing Interviewing Techniques Study|SEE-IT|University of California, Davis|No|Completed|February 2006|March 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|64|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2008|March 25, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643435||158627|
NCT00644059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P5|Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines|A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months||Novartis|Yes|Completed|November 2007|August 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|4902|||Both|6 Months|71 Months|Accepts Healthy Volunteers|||August 2015|August 31, 2015|March 20, 2008||No||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00644059||158579|
NCT00644072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080091|SNX-5422 to Treat Solid Tumor Cancers and Lymphomas|Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|March 2008|June 2011|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2011|September 26, 2015|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00644072||158578|
NCT00644085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99/191|Does Low-Dose Aspirin Improve Outcome in In Vitro Fertilisation/Intra Cytoplasmatic Sperm Injection (IVF/ICSI)?|Does Low-Dose Aspirin Improve Outcome in IVF/ICSI? A Prospective, Randomized, Double Blind Placebo Controlled Trial||University Hospital, Ghent|No|Completed|April 2000|December 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|201|||Female|N/A|N/A|No|||March 2008|March 26, 2008|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644085||158577|
NCT00644345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-08|T-Wave Alternans (TWA) Reproducibility in CAD Patients|Reproducibility of T Wave Alternans Testing in Patients With Ischemic Heart Disease.||Assaf-Harofeh Medical Center|No|Not yet recruiting|May 2008|May 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with coronary artery disease enrolled in a cardiac rehabilitation program.|March 2008|March 25, 2008|March 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00644345||158557|
NCT00644358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDA-07-DP-04|A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)|A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|616|||Both|18 Years|70 Years|No|||September 2011|September 15, 2011|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00644358||158556|
NCT00644098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Effect of a Soluble Fibre Blend and Medium Chain Triglycerides on Body Composition and Cardiometabolic Risk Factors|The Effect and Dose-response of Soluble Fibre Blend and Medium Chain Triglycerides (MCT) on Body Composition and Cardiometabolic Risk Factors in Overweight and Obese Adults: a Double-blind, Placebo-controlled Study.||Canadian Center for Functional Medicine||Completed|September 2008|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|20 Years|45 Years|No|||September 2015|September 30, 2015|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644098||158576|
NCT00641212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-005-0414|Children, Perennial Allergic Rhinitis (PAR), l-t Growth|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis.||AstraZeneca||Completed|January 2000|April 2003|Actual|April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|209|||Both|4 Years|10 Years|No|||March 2009|March 24, 2009|March 18, 2008||Yes||||https://clinicaltrials.gov/show/NCT00641212||158796|
NCT00641225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3227K1-1000|Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis|An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Subjects With Rheumatoid Arthritis||Pfizer|No|Completed|March 2008|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|70 Years|No|||February 2013|February 21, 2013|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641225||158795|
NCT00656084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-026|Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell|A Phase II Study of Gemzar, Novantrone and Rituxan in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (B9E-US-X436)||US Oncology Research|No|Completed|December 2004|January 2008|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2010|April 5, 2010|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00656084||157663|
NCT00641472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-RES-2103|Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children|An Evaluation of the Effectiveness of Pulmicort Respules (Budesonide Inhalation Suspension) Versus SINGULAIR (Montelukast Sodium) in Children 2-8 Years Old With Asthma Requiring Controller Therapy.||AstraZeneca|No|Completed|October 2002|February 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|2 Years|8 Years|No|||March 2009|March 24, 2009|March 18, 2008||||No||https://clinicaltrials.gov/show/NCT00641472||158776|
NCT00641758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pycno2007-003|Pycnogenol and Endothelial Function in Coronary Artery Disease|A Double-blind, Randomized, Placebo-controlled, Cross - Over Design, Single Center Study to Evaluate the Effects of Treatment With Pycnogenol® on Endothelial Function in Subjects With Stable Coronary Artery Disease (Pycno2007-003)||University of Zurich|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641758||158755|
NCT00642109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|slingrnd06|A Comparison of the Retropubic (TVT) With the Transobturator Sling Operation in the Treatment of Female Stress Urinary Incontinence or Stress Dominated Mixed Urinary Incontinence|A Prospective Randomized Clinical Trial: Comparison of the Retropubic (TVT) With the Transobturator (outside-in T.O.T. Monarc or Inside-out TVT-O) Sling Operation in the Treatment of Female Stress Urinary Incontinence or Stress Dominated Mixed Urinary Incontinence||University of Zurich|No|Terminated|January 2006|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|160|||Female|N/A|N/A|No|||July 2015|July 25, 2015|March 17, 2008||No|higher incidence of pain related sexual dysfunction in the TO arm|No||https://clinicaltrials.gov/show/NCT00642109||158729|
NCT00642694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-031R|Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon|Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon|TAKEDA|University of Texas Southwestern Medical Center|No|Terminated|May 2007|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|70 Years|No|||March 2012|October 24, 2012|March 19, 2008|Yes|Yes|Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor|No|March 29, 2012|https://clinicaltrials.gov/show/NCT00642694||158684|
NCT00643318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL001.0|CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer|A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)||Accuray Incorporated|No|Active, not recruiting|April 2006|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643318||158636|
NCT00643929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA108132|LENS - Long-term Eltrombopag Observational Study|LENS - Long-term Eltrombopag Observational Study - A Long Term Observational Ocular Safety Follow-up Study in Adults Who Have Received Study Medication (SB-497115-GR / Eltrombopag Olamine or Placebo) in a Phase II or III Clinical Study Evaluating Eltrombopag|LENS|GlaxoSmithKline|No|Completed|February 2007|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|164|||Both|N/A|N/A|No|Probability Sample|Subjects who participated in a prior eltrombopag study, regardless of indication, and have        received either placebo or eltrombopag.|June 2013|April 16, 2015|March 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00643929||158589|
NCT00640718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-MRK-PROT1.1|Evaluation of EverOn™ System in Medical / Surgical Ward|Evaluation of EarlySense EverOn™ System in Medical / Surgical Ward||EarlySense Ltd.|Yes|Recruiting|March 2008|May 2010|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|85 Years|No|Probability Sample|Adults hospitalized in medical surgical units and are willing to sign consent form|March 2008|March 20, 2008|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00640718||158834|
NCT00695019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07HWHC09|Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Low-Dose Human Interferon-alpha by the Oral Mucosal Route During the 6-Month Follow-up Period of Standard Combination Therapy for Hepatitis C Virus Infection||Amarillo Biosciences, Inc.|No|Completed|June 2009|February 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|169|||Both|21 Years|N/A|No|||August 2013|August 27, 2013|June 9, 2008|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT00695019||154694|
NCT00696176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-022|STAT3 DECOY in Head and Neck Cancer|Preliminary Assessment of the Safety and Biological Activity of Intratumoral STAT3 DECOY in Surgically Resectable Head and Neck Squamous Cell Carcinoma||University of Pittsburgh|Yes|Completed|August 2008|August 2011|Actual|August 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|18 Years|N/A|No|||September 2012|July 22, 2015|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696176||154607|
NCT00695565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-027|Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy|||Arcion Therapeutics Inc|Yes|Completed|May 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||January 2010|January 22, 2010|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695565||154652|
NCT00695578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00000341|Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy|A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy||Wake Forest School of Medicine|No|Completed|October 2006|February 2008|Actual|June 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|N/A|No|||February 2009|February 12, 2009|June 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695578||154651|
NCT00642863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P01HD039386-06A1|Brain and Behavior Depending on Timing of Iron Deficiency in Human Infants|Brain and Behavior Depending on Timing of Iron Deficiency in Human Infants||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|April 2008|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|1614|||Both|N/A|5 Days|No|||March 2014|October 28, 2014|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642863||158671|
NCT00642876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESTIGE®|PRESTIGE® Cervical Disc Study|Investigation of the PRESTIGE® Cervical Disc Device at a Single Level for Symptomatic Cervical Disc Disease||Medtronic Spinal and Biologics|Yes|Completed|October 2002|May 2013|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|541|||Both|18 Years|N/A|No|||February 2013|July 31, 2013|March 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00642876||158670|
NCT00642837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014803|A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets|Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets ; Multicenter, Open-label, Prospective, Observational Study||Janssen Korea, Ltd., Korea||Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||9|Actual|982|||Both|12 Years|N/A|No|Probability Sample|Patients with rheumatism who have moderate-to-severe pain|April 2014|April 24, 2014|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642837||158673|
NCT00642850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21040|STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients|MIRCEA in ESRD A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|187|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642850||158672|
NCT00643461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-07-009|Clinical Evaluation of Three Dental Adhesive Systems in Class V Restorations|Clinical Evaluation of Three Dental Adhesive Systems in Class V Restorations||3M|No|Completed|April 2008|June 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|46|||Both|19 Years|N/A|No|Non-Probability Sample|Class V cavities|April 2013|April 16, 2013|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643461||158625|
NCT00643773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-07-1111|The Effect of Leucine on Body Composition and Muscle Characteristics in Elderly, Type 2 Diabetes Patients|The Influence of Leucine Supplementation on Body Composition and Muscle Characteristics in Elderly, Type 2 Diabetes Patients.||Maastricht University Medical Center|Yes|Completed|May 2008|June 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|60|||Male|65 Years|N/A|No|||August 2011|August 25, 2011|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643773||158601|
NCT00643474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000577|PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)|PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)||Hoffmann-La Roche||Completed|March 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1000|||Both|35 Years|75 Years||||May 2010|March 1, 2016|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643474||158624|
NCT00643799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191152|Safety and Efficacy of Celecoxib Versus Naproxen in the 6-Month Treatment of Knee Osteoarthritis|A Randomized, Multicenter, Double-Blind, Double-Dummy Study Comparing the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Naproxen 500 mg Twice Daily in the 6-Month Treatment of Subjects With Osteoarthritis of the Knee|CLOAK|Pfizer|No|Completed|March 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|586|||Both|40 Years|N/A|No|||April 2008|April 22, 2008|March 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643799||158599|
NCT00643812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-7504-E/G 03|Improving Firearm Storage in Alaska Native Villages|Improving Firearm Storage in Alaska Native Villages||University of Washington|No|Completed|November 2004|December 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|266|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2008|March 25, 2008|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00643812||158598|
NCT00655798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P6957|Effect of Nutritional Interventions on Inflammatory Status in Healthy Overweight Men|Effect of Nutritional Interventions on Inflammatory Status in Healthy Overweight Men||TNO||Completed|December 2006|June 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|42|||Male|18 Years|59 Years|Accepts Healthy Volunteers|||April 2008|April 4, 2008|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655798||157685|
NCT00641498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601401|Effectiveness of Standard Emergency Department Psychiatric Treatment Associated With Treatment Delivery by a Suicide Prevention Center|Effectiveness of Standard Emergency Department Psychiatric Treatment Compared With Effectiveness of Standard Emergency Department Psychiatric Treatment Associated With Treatment Delivery by a Suicide Prevention Center.||University Hospital, Toulouse|No|Completed|March 2007|October 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|607|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641498||158775|
NCT00641771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-230|4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter 4-Week Study to Assess the Effect of Alendronate 70 mg and Vitamin D3 2800 IU Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women||Merck Sharp & Dohme Corp.||Completed|May 2004|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Female|50 Years|80 Years|No|||December 2014|December 24, 2014|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641771||158754|
NCT00642993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05483|Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects (Study P05483)(COMPLETED)|A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects||Merck Sharp & Dohme Corp.|No|Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00642993||158661|
NCT00643006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAU2|Physical Exercise and Its Impact on Signs of Inflammation in Fibromyalgia|Physical Exercise and Its Impact on Signs of Inflammation in Women With Fibromyalgia||Göteborg University|No|Completed|January 2008|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Female|18 Years|60 Years|No|||September 2012|September 28, 2012|March 19, 2008||No||No|May 3, 2012|https://clinicaltrials.gov/show/NCT00643006||158660|
NCT00643591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAASTRO 07-12-12/09|Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma|Pilot Study on the Determination of Therapy Resistant Areas Within the Tumor in Patients With High-grade Glioma by Repeated 18F-FDG-PET-CT Scans||Maastricht Radiation Oncology|Yes|Terminated|June 2008|June 2010|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|EDTA blood, serum|Both|19 Years|N/A|No|Non-Probability Sample|Patients treated with radical radiotherapy for a high grade glioma.|April 2015|April 9, 2015|March 20, 2008||No|Patient compliance was low.|No||https://clinicaltrials.gov/show/NCT00643591||158615|
NCT00643604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-PH-413|Rapid Switch From Flolan to Remodulin in the Outpatient Clinic|Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension in the Outpatient Clinic: Safety, Efficacy and Treatment Satisfaction||United Therapeutics|No|Terminated|March 2008|February 2012|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||June 2013|June 19, 2013|March 20, 2008|Yes|Yes|Due to availability of eligible subjects at center and enrollment competition with other    studies.|No|March 28, 2013|https://clinicaltrials.gov/show/NCT00643604||158614|The main limitations of this study are the small sample size, open-label design and relatively short duration of follow-up.
NCT00643942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-06-23|Staining in a Healthy, Non-Dry Eye Population|||Alcon Research|No|Completed|June 2007|||January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with normal healthy eyes|March 2008|May 8, 2015|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643942||158588|
NCT00644202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007|A Pilot Weight Control Intervention at HPHC|A Pilot Weight Control Intervention at Harvard Pilgrim Health Care (HPHC)||Dana-Farber Cancer Institute|Yes|Completed|May 2006|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|101|||Both|25 Years|65 Years|No|||March 2008|March 20, 2008|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644202||158568|
NCT00644787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014899|A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain|A Phase II/III Study of JNS020QD in Cancer Pain Patients - A Dose-Finding, Double-Blind Study of JNS020QD Compared With JNS005 in Patients Previously Untreated With Opioid Analgesics||Janssen Pharmaceutical K.K.|No|Completed|December 2007|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|156|||Both|20 Years|N/A|No|||June 2013|June 6, 2013|March 24, 2008|Yes|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT00644787||158523|
NCT00644800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281074|A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis|An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis||Pfizer|No|Completed|July 2003|May 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|55 Years|No|||April 2008|April 7, 2008|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644800||158522|
NCT00645125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-567|A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications|A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications||Abbott||Completed|January 2003|||February 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|154|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||March 2008|March 26, 2008|March 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645125||158498|
NCT00695032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07GENE03|Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors|Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)||Institut Claudius Regaud|No|Suspended|October 2007|||September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|June 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00695032||154693|
NCT00695916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12102007-930|MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery|Randomized Trial of Breast MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery||Stanford University||Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic||||180|||Female|18 Years|N/A|No|||December 2008|December 12, 2008|June 10, 2008||||No||https://clinicaltrials.gov/show/NCT00695916||154627|
NCT00695929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levosimendan|Levosimendan in Congenital Cardiac Surgery|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|July 2008|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|5 Years|No|||January 2010|January 25, 2010|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695929||154626|
NCT00696475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC007|Diazoxide Choline in Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects||Essentialis, Inc.|No|Completed|June 2008|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|75 Years|No|||November 2010|November 4, 2010|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696475||154585|
NCT00642590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD049762|Lifestyle and Fertility Study|Antioxidant Status, Diet and Early Pregnancy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Active, not recruiting|March 2008|November 2017|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|266|Samples With DNA|Whole blood, plasma, serum, urine|Both|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are looking for couples who are planning a pregnancy. This must be a first pregnancy        for women, ages 18 to 39, and both partners must be in good general health with no history        of infertility.|April 2015|May 18, 2015|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642590||158692|
NCT00643175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|osteoporotic hip fracture|Effectiveness of Automated Inpatient Endocrinology Consultation for Osteoporotic Hip Fracture|||State University of New York - Upstate Medical University||Terminated|June 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|55 Years|N/A|No|Non-Probability Sample|Using the existing WebCAIS order system, an automated endocrinology consult and        appropriate laboratory studies will be drawn on all non-traumatic hip fractures. Data from        these patients will be collected in a prospective study, and the patients will be followed        up over time to check adherence to osteoporotic medical therapy and future incidence of        re-fracture.|December 2009|December 29, 2009|March 24, 2008||No|Dr. Grose has left this practice, this study is terminated|No||https://clinicaltrials.gov/show/NCT00643175||158647|
NCT00643188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP020|Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF|Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation|CASTLE-AF|Biotronik SE & Co. KG|Yes|Active, not recruiting|January 2008|September 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||February 2016|March 1, 2016|February 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00643188||158646|
NCT00655499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593012|Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|An Open-label Phase II Clinical Trial of Panitumumab in Combination With Irinotecan for Patients With Advanced Metastatic Colorectal Cancer Without KRAS Mutation (Wild Type) in Third Line Chemotherapy (Patients Pretreated With FOLFOX or XELOX ± Bevacizumab and Irinotecan Alone or FOLFIRI or CAPIRI ± Bevacizumab) [PIMABI]||Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Completed|June 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|68|||Both|18 Years|80 Years|No|||August 2012|August 22, 2012|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00655499||157707|
NCT00655512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-OCT011-023|Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound|Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream (Elidel® 1% Cream), Hydrocortisonacetat 1% Cream (Hydrogalen® Cream), Betamethasonvalerat 0,1% Cream (Betagalen® Cream) and Clobetasol-17-propionat 0,05% Cream (Clobegalen® Cream) Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound - a Single Blind, Placebo-controlled, Randomized, Monocenter Clinical Trial|OCT|Technische Universität Dresden|No|Completed|January 2008|October 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655512||157706|
NCT00655525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080191|Omega-3 Fatty Acid Administration in Dialysis Patients|Omega-3 Fatty Acid Administration in Dialysis Patients||Vanderbilt University|Yes|Completed|April 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00655525||157705|
NCT00641511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H22601|Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)|Pharmacogenetic Clinical Trial of Nepicastat for PTSD||Michael Debakey Veterans Affairs Medical Center|Yes|Completed|June 2008|November 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||December 2009|June 8, 2011|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00641511||158774|
NCT00641784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|464-07|Tocolytics Trial: Intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population|A Randomized Trial of Oral Nifedipine Versus Intravenous Magnesium Sulfate in the Acute Management of Preterm Labor in Women With Singleton Gestations, Intact Fetal Membranes, and Positive Vaginal Fetal Fibronectin||MemorialCare|No|Terminated|March 2008|March 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|55 Years|No|||September 2009|September 17, 2009|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00641784||158753|
NCT00643617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCP002.2|CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry||Accuray Incorporated|Yes|Active, not recruiting|November 2007|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|253|||Male|18 Years|N/A|No|||June 2014|June 23, 2014|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643617||158613|
NCT00643630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806 805 09 002|Evaluation of Tetrix Cream as a Protective Barrier Against Injurious Materials|A Study to Determine the Skin Barrier Effect of Tetrix Cream||Coria Laboratories, Ltd.|No|Completed|October 2007|November 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2008|May 19, 2008|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643630||158612|
NCT00643955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5495|Neuromuscular Characteristics of Individuals With Down Syndrome (DS)|Neuromuscular Characteristics of Individuals With Down Syndrome||State University of New York - Upstate Medical University|No|Recruiting|March 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with Down Snydrome and control subjects without DS|March 2008|March 25, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643955||158587|
NCT00643968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-FR-104-1016|Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial|Randomized Multicenter Open-Label, Pilot Trial to Evaluate the Efficacy and Safety of Switching HIV-1 Stable Infected Patients Under HAART to a New Once Daily Triple Therapy Combination Including EFV+3TC+TDF Versus a Dual QD Therapy Containing EFV+TDF|COOL|Gilead Sciences|Yes|Completed|March 2003|September 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|140|||Both|18 Years|70 Years|No|||June 2008|June 27, 2008|March 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643968||158586|
NCT00644215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8662|Comparison of Subconjunctival 5-Fluorouracil (FU) Injection and Mitomycin C for Treatment of Early Bleb Failure|Comparison of Subconjunctival 5-FU Injection and Mitomycin C for Treatment of Early Bleb Failure, a Randomized Clinical Trial||hahid Beheshti University of Medical Sciences|Yes|Recruiting|June 2007|||February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|N/A|No|||June 2008|June 16, 2008|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644215||158567|
NCT00644228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00798|Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma|A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant.||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2008|||August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|525|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|March 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644228||158566|
NCT00644813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26863|Clinical Outcomes Following Glenoid Neck Fracture as Correlated With Quantitative Assessment of Osseous Injury|Clinical Outcomes Following Glenoid Neck Fracture as Correlated With Quantitative Assessment of Osseous Injury||Boston Medical Center|Yes|Recruiting|March 2008|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Gender: Both Age: Adult (18-64 yrs), Geriatric (65+ yrs) Ethnicity: All Ethnic Groups        Languages: English Groups to be recruited will include: Patients only|November 2015|November 16, 2015|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644813||158521|
NCT00645138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801009584|Comparison of Paravertebral Block With General Anesthesia in Patients Undergoing Breast Cancer Surgery|A Comparison of Ultrasound-assisted Paravertebral Block and General Anesthesia for Outpatient Breast Cancer Surgery, a Prospective Randomized Trial||Weill Medical College of Cornell University|No|Completed|April 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||August 2011|August 4, 2011|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00645138||158497|
NCT00645151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581104|A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol|A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study)|LA ATGOAL|Pfizer|No|Completed|April 2004|February 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|512|||Both|18 Years|80 Years|No|||April 2008|April 8, 2008|March 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645151||158496|
NCT00645164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011 101 09 002|Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment|Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment||Healthpoint|No|Completed|March 2008|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 1, 2010|March 24, 2008|No|Yes||No|October 8, 2008|https://clinicaltrials.gov/show/NCT00645164||158495|Interpretation of frequency distribution of skin irritation scores was based on long term experience with this type of testing.
NCT00695903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-013|Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia|A Phase 2 Multicenter, Randomized, Double-blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia|HDSAB|Cubist Pharmaceuticals LLC|Yes|Terminated|September 2008|October 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 10, 2008|Yes|Yes|terminated due to lack of enrollment|No|August 23, 2011|https://clinicaltrials.gov/show/NCT00695903||154628|Because the study was terminated early due to lack of enrollment, there were not sufficient patients to provide meaningful analysis for the following secondary outcomes: persistent/recurrent bacteremia and time to defervescence/clearance.
NCT00696215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11719A|The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease|The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months||Istanbul University|Yes|Recruiting|June 2007|October 2008|Anticipated|June 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||June 2008|June 11, 2008|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00696215||154604|
NCT00696189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120060249|Effects of Nitrous Oxide on Intraocular Pressure|The Effects of Nitrous Oxide on Intraocular Pressure and Ocular Perfusion||Rutgers, The State University of New Jersey|No|Terminated|September 2006|September 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|No|Probability Sample|Ages of 18 and 65 years of age and mentally capable of giving consent. Scheduled for        gynecological surgery and will be placed in the Trendelenburg position (head lower than my        waist) on the operating room table.|April 2015|April 23, 2015|June 9, 2008||No|PI is no longer at this institution|No||https://clinicaltrials.gov/show/NCT00696189||154606|
NCT00696202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91295|Mirena Efficiency and Tolerability During the First Year of Use|A Multicentre, Open Label, Uncontrolled Study of the Tolerance, Acceptability and Contraceptive Efficacy of Mirena 52 mg®, an Intra-uterine Levonorgestrel Device, During the First Year After Insertion Post-partum||Bayer|No|Completed|September 2003|March 2005|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|199|||Female|25 Years|39 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00696202||154605|
NCT00642603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21567|A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer|A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Terminated|May 2008|September 2012|Anticipated|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|March 19, 2008|Yes|Yes||No|June 10, 2010|https://clinicaltrials.gov/show/NCT00642603||158691|This study was terminated early because interim data from a predecessor study invalidated the scientific rationale that provided justification for the conduct of this study. Efficacy analyses were not performed.
NCT00642616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-134|Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease|A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up||Sanofi|Yes|Terminated|March 2009|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|March 21, 2008|Yes|Yes|Terminated upon recommendation of the Data Safety Monitoring Board (DSMB)|No|November 23, 2015|https://clinicaltrials.gov/show/NCT00642616||158690|- Early termination of trial leading to small numbers of subjects analyzed
NCT00642889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-1015/017/III/2003|Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)|A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.||Newron|Yes|Completed|June 2005|July 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|227|||Both|30 Years|80 Years|No|||March 2008|March 21, 2008|March 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00642889||158669|
NCT00642902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28063|Atacicept in Multiple Sclerosis, Phase II|A Randomised, Double-blind, Placebo-controlled, Multicentre Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of Three Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS)||EMD Serono||Terminated|March 2008|February 2011|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|292|||Both|18 Years|60 Years|No|||April 2011|April 22, 2011|March 21, 2008|Yes|Yes|EMD Serono voluntarily decided to terminate this trial after observing increased MS disease    activity in the atacicept treatment groups compared to placebo|No||https://clinicaltrials.gov/show/NCT00642902||158668|
NCT00654732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0144|Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma|A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|March 2008|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|16 Years|N/A|No|||September 2015|September 28, 2015|April 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654732||157766|
NCT00654745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-8663-403|18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics|A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects||Daiichi Sankyo Inc.|No|Completed|May 2008|June 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|207|||Both|18 Years|80 Years|No|||July 2010|July 9, 2010|April 4, 2008|Yes|Yes||No|April 21, 2010|https://clinicaltrials.gov/show/NCT00654745||157765|
NCT00654953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA018197|Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans|Sertraline Augmented With GABA Agents for Cocaine Dependence||University of Arkansas|Yes|Completed|January 2006|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|65 Years|No|||March 2011|March 28, 2011|April 4, 2008|Yes|Yes||No|March 28, 2011|https://clinicaltrials.gov/show/NCT00654953||157749|
NCT00654966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-02/08|Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers|Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers.||Monash University|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00654966||157748|
NCT00654979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFF-104|A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter|A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter||RMT Medical Technologies, Ltd.|No|Completed|July 2003|March 2008|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|117|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|March 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00654979||157747|
NCT00655265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOL00107|A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication|A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCentre Study of Colesevelam as Add-on Therapy in Patients With Familial Hypercholesterolaemia||Sanofi|No|Completed|August 2007|October 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|75 Years|No|||February 2014|February 10, 2014|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655265||157725|
NCT00655278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2000-0639|T2000 in Essential Tremor - Open Label Continuation|Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study||Taro Pharmaceuticals USA|Yes|Terminated|August 2007|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|75 Years|No|||November 2013|December 19, 2013|April 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00655278||157724|
NCT00640913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ö 109-07|Early Reversal of Defunctioning Stoma Trial|Early Reversal of Defunctioning Stoma Trial|ELSOR|Rectal Cancer Trial on Defunctioning Stoma Study Group|Yes|Recruiting|February 2008|November 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Analysis of serum C-Reactive Protein (CRP) and Procalcitonin (PCT).|Both|18 Years|85 Years|No|Non-Probability Sample|Twenty patients operated on with low anterior resection of the rectum for cancer and a        defunctioning loop stoma.|March 2008|March 19, 2008|March 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00640913||158819|
NCT00640926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-1741-201|Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia|A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP)||Melinta Therapeutics, Inc.|No|Completed|October 2007|April 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|158|||Both|18 Years|65 Years|No|||February 2010|January 16, 2015|March 18, 2008|Yes|Yes||No|January 8, 2010|https://clinicaltrials.gov/show/NCT00640926||158818|The yield of typical bacterial pathogens, most importantly S. pneumoniae, was quite low. The presence of atypical pathogens was assessed only by paired serologies, not by culture or polymerase chain reaction (PCR).
NCT00641238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 4886|Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)|Clinical Follow-up of Patients Treated With Radiofrequency Ablation of Lung Masses.||State University of New York - Upstate Medical University|No|Completed|March 2004|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with clinical stage I NSCLC that are treated with Radiofrequency ablation.|May 2015|May 12, 2015|March 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00641238||158794|
NCT00642707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 140 2101|Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection|A Phase 2a, Randomized, Double-blind, Placebo Controlled Study of PRO 140 by Subcutaneous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection||CytoDyn, Inc.|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|March 21, 2008|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00642707||158683|
NCT00643643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001007|Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus|A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.||ViiV Healthcare|No|Completed|October 2002|June 2003|Actual|June 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|41|||Both|18 Years|55 Years|No|||November 2010|November 9, 2010|March 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00643643||158611|
NCT00643656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT : 2006-004203-19|Use of 50% Nitrous Oxide / 50% Oxygen Premix During Liver Biopsy of Focal Lesion|Study of the Efficiency of Kalinox 170 Bar During Liver Biospy of Focal Lesion||Air Liquide Santé International|No|Completed|October 2007|December 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00643656||158610|
NCT00643981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-03-I|Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia|Phase I Study to See if a of A Combination Stem Cell Therapy is Safe and Feasible for the Treatment of Severe Coronary Ischemia|CI|TCA Cellular Therapy||Completed|February 2008|February 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||December 2008|April 27, 2011|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00643981||158585|
NCT00644527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPH-2008-MT-1|Receptive Music Therapy for the Treatment of Depression|"Rezeptive Musiktherapie Bei Depression - Eine Randomisierte, Placebokontrollierte Studie" / Receptive Music Therapy in Depression: A Randomized Placebo-Controlled Trial||Heidelberg University|Yes|Completed|March 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|203|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2008|November 17, 2008|March 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00644527||158543|
NCT00641121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7689|Bethaherpesviruses in Children Who Are Immune Suppressed|Bethaherpesviruses in Children Who Are Immune Suppressed||The Cleveland Clinic|No|Recruiting|November 2005|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|11 Years|No|Non-Probability Sample|Chilren that are Immune suppressed|March 2008|March 20, 2008|March 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00641121||158803|
NCT00695617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML4960|Citrate Anticoagulation During MARS Treatment|Citrate Anticoagulation During MARS Treatment||Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||March 2009|March 4, 2009|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00695617||154648|
NCT00697385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|758-A-03-1|The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders|Open Label Continuation Study for the Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders||Mary M. Gooley Hemophilia Center|No|Completed|April 2003|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|8 Years|60 Years|No|||September 2008|September 18, 2008|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697385||154516|
NCT00696501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-039|Direct Stimulation Of Spinal Nerve Roots To Determine Sensory And Motor Innervation Patterns|Direct Stimulation Of Spinal Nerve Roots To Determine Sensory And Motor Innervation Patterns||Lahey Clinic|No|Recruiting|May 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|85 Years|No|Non-Probability Sample|All neurosurgical patients will be screened for potential eligibility from the        Neurosurgery Department's Clinical and operative schedules.|March 2016|March 15, 2016|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00696501||154583|
NCT00696774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12349|Switching to Duloxetine in Patients With Depression|Attributes of Response in Depressed Patients Switched to Treatment With Duloxetine (ARDENT Study)|ARDENT|Eli Lilly and Company|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|242|||Both|18 Years|N/A|No|||September 2010|September 2, 2010|June 11, 2008|Yes|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00696774||154563|
NCT00654160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592931|Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer|A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer||Mayo Clinic|Yes|Active, not recruiting|June 2008|||June 2015|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00654160||157810|
NCT00642915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4039|Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)|A 24 Week, Open-Label, Single Arm, Multi-Center Clinical Study to Document the Benefits of the Combination of Lantus and Amaryl in Ethnic Japanese Type 2 Diabetic Patients Living Outside of Japan (in US or Brazil), Who Failed Good Metabolic Control With Oral Antidiabetic Drugs (OADs)||Sanofi||Completed|June 2003|July 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|100|||Both|20 Years|70 Years|No|||August 2008|August 22, 2008|March 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00642915||158667|
NCT00654485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4522IL/0069|COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects|A 12 Week Randomized, Double-Blind, Force-Titration, Parallel Group, Multi Centre, Phase IIIb Study to Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects With Raised LDL-C and a 10 Year Risk of CHD >10%||AstraZeneca||Completed|May 2002|February 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|940|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|April 3, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00654485||157785|
NCT00654498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.630|Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)|A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks||Boehringer Ingelheim||Completed|April 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|80 Years|No|||March 2014|June 3, 2014|March 27, 2008|Yes|Yes||No|December 18, 2009|https://clinicaltrials.gov/show/NCT00654498||157784|
NCT00644397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB06-00029|Plate Fixation of Distal Femur Fractures: A Protocol for a Study of Two Plate Options|Plate Fixation of Distal Femur Fractures: a Protocol for a Randomized, Prospective Study of Two Plate Options||MetroHealth Medical Center|No|Recruiting|May 2006|||May 2026|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|16 Years|N/A|No|Probability Sample|Participating research centers will evaluate for enrollment all patients presenting with        distal femur fractures. The number of patients to be recruited is based on previously        reported malunion rates. Assuming a 15% incidence of malunion in the locked plating group,        a difference of +/- 5% would be statistically significant. In order for the study to have        power of 80% to detect a difference at the 0.05 level, 49 patients will be required in        each group.|March 2016|March 15, 2016|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00644397||158553|
NCT00644670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581099|A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol|A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving LDL Cholesterol Targets With Atorvastatin Starting Doses Of 10 Mg, 20 Mg And 40 Mg.||Pfizer|No|Completed|June 2003|March 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|232|||Both|30 Years|80 Years|No|||March 2008|March 26, 2008|March 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00644670||158532|
NCT00654992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH B-0608/036-004|Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery|Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial|EPO-CABG|Seoul National University Bundang Hospital|No|Completed|September 2006|February 2009|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|71|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 28, 2009|April 4, 2008||No||No|March 17, 2009|https://clinicaltrials.gov/show/NCT00654992||157746|
NCT00645320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281114|A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study|An Open Label, Extension Study To Assess The Efficacy And Tolerability Of Oral Ziprasidone In Patients Successfully Completing A Previous Study With Ziprasidone||Pfizer|No|Completed|August 2003|August 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|55 Years|No|||April 2008|April 7, 2008|March 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00645320||158483|
NCT00640939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCF-003|Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Pain Due to Mild to Moderate Tendonitis or Bursitis||Cerimon Pharmaceuticals|No|Completed|December 2007|June 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|75 Years|No|||August 2008|August 5, 2008|March 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00640939||158817|
NCT00641251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS07008|DSS: Diabetes Surgery Study - Intensive Medical Management of Type 2 Diabetes, With and Without Gastric Bypass Surgery|Global Randomized Prospective Study of Intensive Medical Management of Type 2 Diabetes, With and Without Gastric Bypass Surgery|DSS|Medtronic - MITG|Yes|Active, not recruiting|February 2008|March 2017|Anticipated|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|30 Years|67 Years|No|||February 2015|February 27, 2015|February 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00641251||158793|
NCT00642395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603603|Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)|Velcade®-Melphalan Association as Conditioning Regimen Before Autologous Stem-cell Transplantation in Multiple Myeloma Patients Under 65 Years||University Hospital, Toulouse|No|Completed|July 2007|July 2011|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|65 Years|No|||October 2011|October 10, 2011|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00642395||158707|
NCT00642408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUGR|Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso|Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso||Institute of Tropical Medicine, Belgium|Yes|Completed|June 2003|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1370|||Female|15 Years|44 Years|No|||September 2010|September 12, 2010|March 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00642408||158706|
NCT00643331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001.075|The Effect of Exercise in Postmenopausal Women With Low Bone Density|The Effect of Exercise in Postmenopausal Women With Low Bone Density||University of Melbourne|No|Completed|February 2001|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Female|50 Years|N/A|Accepts Healthy Volunteers|||March 2008|June 2, 2015|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00643331||158635|
NCT00712361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-CL-R-007|A Comparative Study of the SoftTouch Non-Invasive Finger-Mounted Device|A Comparative Clinical Trial to Assess the Accuracy of the SoftTouch. A Novel Non-invasive Device for Measuring Peripheral Blood Glucose, Carbon Dioxide, pH, Hemoglobin, Hematocrit, SpO2, Peripheral Pulse and Blood Pressure.||Cnoga Medical Ltd.|Yes|Completed|July 2008|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Actual|70|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2014|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712361||153387|
NCT00712075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E4876-R|Functional Rehabilitation for Older Patients With Schizophrenia|Functional Rehabilitation for Older Patients With Schizophrenia (FROPS)|FROPS|VA Office of Research and Development|Yes|Terminated|July 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|107|||Both|45 Years|N/A|No|||May 2015|May 12, 2015|July 3, 2008||No|Loss of funding|No|April 15, 2015|https://clinicaltrials.gov/show/NCT00712075||153409|Early termination leading to small sample size and loss of follow-up data.No 50% CBSST comparison group without mobile computer to test efficacy of shorter treatment alone.
NCT00712088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5159|Project ICARE: Intervening for Community Awareness, Respect, & Empowerment|Project ICARE: Intervening for Community Awareness, Respect, & Empowerment - Behavioral Intervention to Reduce Sexual Risk Behavior of African American Men Who Have Sex With Men||Centers for Disease Control and Prevention||Completed|July 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|275|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 10, 2010|June 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00712088||153408|
NCT00712348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-06-002|Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase|A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase in Patients With Gaucher Disease Treated With Imiglucerase||Protalix|Yes|Completed|December 2008|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|2 Years|N/A|No|||May 2014|May 30, 2014|July 7, 2008|Yes|Yes||No|April 30, 2014|https://clinicaltrials.gov/show/NCT00712348||153388|
NCT00712621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-QOLII0608|Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination|Phase II Two Arm Randomized Controlled Clinical Trial to Study Quality of Life and Survival of Breast Cancer Patients After Completion of Chemotherapy or Radiation Therapy or Surgery or Any Combination Therapy in Stage I to IV Carcinoma||American Scitech International|No|Withdrawn|February 2010|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|460|||Female|25 Years|85 Years|No|||November 2009|November 20, 2009|June 18, 2008|No|Yes|Study is withdrawn due to unavailability of eligible subject population. We will request the    sponsors to extend the time for enrollment.|No||https://clinicaltrials.gov/show/NCT00712621||153367|
NCT00703508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB HM11153|Pharmacogenetics of Metformin Action in PCOS|Pharmacogenetics of Metformin Action in PCOS||Virginia Commonwealth University|Yes|Completed|July 2008|March 2014|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|18 Years|45 Years|No|||May 2014|May 27, 2014|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703508||154054|
NCT00703846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114568|STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%|A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS||GlaxoSmithKline|No|Completed|June 2008|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|498|||Both|12 Years|N/A|No|||January 2012|January 19, 2012|June 20, 2008|Yes|Yes||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00703846||154028|
NCT00709189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002200|Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.|A Pivotal Bioequivalence Study of 250 Mcg NGM/35 Mcg EE With or Without Folic Acid in Healthy Female Subjects.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2005|August 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|53|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|June 6, 2011|June 30, 2008||||||https://clinicaltrials.gov/show/NCT00709189||153628|
NCT00709449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-011007|An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects|An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects||Medical University of Vienna|Yes|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 30, 2009|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00709449||153608|
NCT00704730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-301|Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer|An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer|EXAM|Exelixis|Yes|Active, not recruiting|June 2008|December 2015|Anticipated|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|June 23, 2008|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT00704730||153960|
NCT00709696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702M02324|Human Laboratory Study Of Varenicline in Smokers|Human Laboratory Study Of Varenicline in Smokers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|6|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 9, 2015|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709696||153589|
NCT00710281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-020|Analysis Of Intracranial Artery Lesions Using 2-D/3D Phase Contrast MR|Hemodynamic Analysis Of Intracranial Artery And Associated Lesions Using 2-D/3D Phase Contrast MR Angiography Focused On Wall Shear Stress Measurement||Lahey Clinic|No|Withdrawn|March 2008|December 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|July 1, 2008|Yes|Yes|Investigator is no longer at study site|No||https://clinicaltrials.gov/show/NCT00710281||153545|
NCT00713908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20430|Voiding Dysfunction in the Postoperative Period Following Placement of the TVT|Voiding Dysfunction in the Postoperative Period Following Placement of the TVT||University of Rochester|No|Terminated|November 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Urogynecology clinic|December 2009|December 15, 2009|July 8, 2008||No|The Co-Principal Investigator has moved and is no longer interested in continuing this study    at this site.|No||https://clinicaltrials.gov/show/NCT00713908||153269|
NCT00713921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051008|Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients|Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients||Saint Thomas Health Services|Yes|Recruiting|February 2008|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|21 Years|85 Years|No|||December 2012|December 11, 2012|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713921||153268|
NCT00713375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803013R|Time Frequency Analysis of Electrocardiogram and Blood Pressure in Intracranial Hemorrhage Patients|Multiscale Entropy and Time-Frequency Analysis of Electrocardiogram and Blood Pressure in Patients With Spontaneous Intracranial Hemorrhage||National Taiwan University Hospital|Yes|Recruiting|April 2008|||April 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood. Cerebral spinal fluids|Both|N/A|N/A|No|Non-Probability Sample|Patients with spontaneous intracranial hemorrhage|July 2008|July 10, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713375||153309|
NCT00713934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Liver-001|Autologous Bone Marrow Stem Cells in Cirrhosis Patients|Autologous Transplantation of Bone Marrow Derived CD 133 Positive Stem Cell and Mono Nuclear Cell (MNC) Transplantation in Patients With Decompensate Cirrhosis: Randomized Clinical Trial||Royan Institute|Yes|Completed|January 2008|February 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|75 Years|No|||March 2010|October 1, 2011|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713934||153267|
NCT00714233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB # 09354|Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)|Treatment of Polycystic Ovary Syndrome (POS) in Overweight Adolescents||University of Rochester|No|Completed|August 2002|December 2007|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|43|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||May 2011|April 29, 2015|July 8, 2008|Yes|Yes||No|April 8, 2011|https://clinicaltrials.gov/show/NCT00714233||153244|
NCT00715858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R07-63|A Pilot Study of Inflammatory Markers in Alzheimer's Disease|A Pilot Study Comparing Inflammatory Biomarkers in Blood and CSF in Patients With Alzheimer's Disease and Age-Matched Controls||McMaster University|No|Recruiting|May 2008|October 2009|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|21|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 3, 2009|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715858||153119|
NCT00711841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIFernando Figueira|Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome|Postpartum Dexamethasone for Women With Class I HELLP Syndrome: a Double-blind, Placebo-controled, Randomized Clinical Trial|COHELLP|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Active, not recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|13 Years|49 Years|No|||March 2016|March 16, 2016|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711841||153427|
NCT00711815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W061101002 (UAB 0626)|A Study to Identify Markers in Blood and Tissue of HPV Clearance|Biomarkers of HPV Clearance: A Prospective Study||University of Alabama at Birmingham|Yes|Completed|January 2007|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|Samples With DNA|Whole blood, cervical cells|Female|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HPV-positive women with biopsy-confirmed CIN 1 or negative biopsies or normal colposcopic        findings|August 2011|August 4, 2011|July 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00711815||153429|
NCT00712101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Final version 1.1|Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction|Prospective Randomized Controlled Clinical Study to Compare Abciximab-bolus i.v. Versus i.c. in Primary PCI in Patients With Acute ST-elevation Myocardial Infarction|AIDA STEMI|University of Leipzig|Yes|Completed|July 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1912|||Both|18 Years|N/A|No|||August 2009|April 19, 2011|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00712101||153407|
NCT00712114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE3286-0201|Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis|A Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate||Harbor Therapeutics|No|Completed|July 2008|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|75 Years|No|||June 2011|June 11, 2011|July 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712114||153406|
NCT00712374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSP01|Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal|Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal||London School of Hygiene and Tropical Medicine|Yes|Enrolling by invitation|September 2008|July 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100000|||Both|3 Months|119 Months|Accepts Healthy Volunteers|||September 2009|September 21, 2009|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712374||153386|
NCT00712387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSI2|Trial of Proficiency- Based Simulation Training for General Surgical Trainees|A National, Prospective,Randomised, Single Blinded Controlled Trial of Proficiency- Based Simulation Training for General Surgical Trainees||Royal College of Surgeons, Ireland|No|Active, not recruiting|July 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|24|||Both|27 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 23, 2009|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712387||153385|
NCT00712634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599675|Cytomegalovirus Vaccine in Healthy Participants|A Phase I Dose Escalation Study of Lipopeptide Vaccines With Activity Against Human Cytomegalovirus||City of Hope Medical Center||Completed|November 1997|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 18, 2009|July 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712634||153366|
NCT00712855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1012-C1077|A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma|A Phase 1B, Multi-center, Open Label, Dose Escalation Study of Mapatumumab ([HGS1012], a Fully-human Monoclonal Antibody to TRAIL-R1) in Combination With Sorafenib as a First Line Therapy in Subjects With Advanced Hepatocellular Carcinoma|HCC|GlaxoSmithKline|No|Completed|June 2008|August 2012|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712855||153349|
NCT00712868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03447|Acceptability of Lactacyd Femina|Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up Lactacyd Femina|LACTAFEM|Sanofi||Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|559|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2009|July 17, 2009|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712868||153348|
NCT00713154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mito 02-02|Safety and Preliminary Efficacy Study of MTS-01 for the Prevention of Alopecia Induced by WHole Brain Radiotherapy|A Phase II, Double-Blind Placebo-Controlled, Parallel Group Study of the Safety and Preliminary Efficacy of MTS-01, for the Prevention of Alopecia Induced by Whole Brain Radiotherapy||Mitos Pharmaceuticals|No|Terminated|April 2007|September 2008|Anticipated|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|N/A|No|||July 2008|July 10, 2008|July 9, 2008|Yes|Yes|Major planned study protocol modifications|No||https://clinicaltrials.gov/show/NCT00713154||153326|
NCT00708916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP016|Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients|Clinical and Immune-modulating Effects of CC-10004 in Discoid Lupus Erythematosus||New York University School of Medicine|Yes|Completed|June 2008|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||December 2012|December 10, 2012|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708916||153649|
NCT00708929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-040607|Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid?|Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid?||Medical University of Vienna|Yes|Completed|June 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 15, 2013|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00708929||153648|
NCT00709462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX-1307-01|A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)|A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX-1307-01)||Celldex Therapeutics|No|Completed|March 2004|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||July 2010|July 23, 2010|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709462||153607|
NCT00709475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3551|Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus|Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus|LevSafeQD|Novo Nordisk A/S|No|Completed|May 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|747|||Both|N/A|N/A|No|Probability Sample|Type 2 diabetic patients|March 2012|June 28, 2012|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709475||153606|
NCT00709709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060105|Medical Evaluation of Scanner in Coronary Syndrome|Medical and Economic Medical Evaluation of Scan Multislice of Coronary Artery in Exploration of Stable Coronary Syndrome. Comparison With Quantitative Coronarography|EVASCAN|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2006|December 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1500|||Both|18 Years|N/A|No|||July 2008|November 13, 2014|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00709709||153588|
NCT00710008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00481598|Effect of Short-Term Exercise Training on ATP Synthesis in Relatives of Type 2 Diabetic Humans|Effect of Short-Term Exercise Training on ATP Synthesis in Relatives of Type 2 Diabetic Humans|RECO1|Landsteiner Institut|No|Completed|February 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2008|August 19, 2008|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00710008||153566|
NCT00710541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-Study|Non-invasive Ventilation in Severe Chronic Obstructive Pulmonary Disease(COPD)|Non-invasive Ventilation in Patients With Severe Chronic Obstructive Pulmonary Disease and Lung Emphysema (COPD)||Deutsche Lungenstiftung e.V.|Yes|Terminated|October 2004|December 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|January 22, 2008||No|The publication of a national guideline on NPPV precluded further recruitment.|No||https://clinicaltrials.gov/show/NCT00710541||153525|
NCT00713674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJMRSA-01|Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx|Comparison of Decolonization of MRSA Using Theraworx|SJMRSA|St. John's Health System, Missouri|No|Withdrawn|March 2008|February 2009|Anticipated|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|January 11, 2010|July 7, 2008||No|Lack of patient recruitment.|No||https://clinicaltrials.gov/show/NCT00713674||153287|
NCT00713947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051021|Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control|Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course|Aspylori|Assistance Publique - Hôpitaux de Paris|Yes|Withdrawn|April 2008|March 2010|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|June 18, 2008||No|no inclusion|No||https://clinicaltrials.gov/show/NCT00713947||153266|
NCT00714246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU 26983|Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer|Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer||Milton S. Hershey Medical Center|Yes|Active, not recruiting|August 2008|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|90 Years|No|||September 2015|September 21, 2015|July 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00714246||153243|
NCT00714571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6366-W|Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)|Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI||VA Office of Research and Development|No|Completed|July 2008|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714571||153218|
NCT00715299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3983-R|Locomotor Training (Walking Therapy) Post Stroke|Mechanisms of Response to Locomotor Training After Stroke||VA Office of Research and Development|No|Completed|June 2005|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|85 Years|No|||February 2015|February 17, 2015|July 10, 2008||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00715299||153162|
NCT00715520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046953|Neurobiological Principles Applied to the Rehabilitation of Stroke Patients|Neurobiological Principles Applied to the Rehabilitation of Stroke Patients||Emory University|No|Recruiting|April 2007|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|26|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715520||153145|
NCT00715533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBF-1000+|3 Tesla (3T) Stroke Medical Radiologic Technology (MRT) for Examining Mismatch in 1000+|3T Stroke MRT for Examining Mismatch in the CSB of the Charité Universitätsmedizin Berlin (3Tesla in 1000+)|1000Plus|Charite University, Berlin, Germany|No|Completed|July 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic. Patients presenting with acute (< 24 h) transient ischemic attack or        stroke at the emergency ward, Campus Benjamin Franklin|June 2014|June 23, 2014|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715533||153144|
NCT00711854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-059|Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection|Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole (TMP-SMX) Plus Rifampicin With a Regimen of Linezolid in the Treatment of Infections Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)||University Hospital, Geneva|No|Completed|January 2009|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711854||153426|
NCT00712413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYLHp08-01|Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori|Pilot Study Assessing the Safety, Tolerability, Compliance and Efficacy of Twice Daily Dosed Pylera Plus Omeprazole as a First Line Treatment of Helicobacter Pylori Infection||Axcan Pharma|No|Withdrawn|August 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2008|December 17, 2008|July 8, 2008|Yes|Yes|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT00712413||153383|
NCT00711828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0883|Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma|A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma||Mayo Clinic|Yes|Active, not recruiting|August 2008|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|July 8, 2008|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00711828||153428|
NCT00712127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608088|Re-energize With Nutrition, Exercise and Weight Loss|Preventing Adverse Effects In Class II and Class III Obesity|RENEW|University of Pittsburgh|Yes|Completed|June 2006|May 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|310|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 18, 2011|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00712127||153405|
NCT00712140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598391|Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer|Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve||National Cancer Institute (NCI)||Recruiting|October 2007|||October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|4000|||Female|18 Years|N/A|No|||November 2008|September 1, 2011|July 8, 2008||||No||https://clinicaltrials.gov/show/NCT00712140||153404|
NCT00712660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITA-04-2008|Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia|ITAREPS Trial: A Prospective Randomized Double-blind Controlled Study in IT-aided Mobile Phone-based Relapse Prevention Program in Schizophrenia.||Prague Psychiatric Center|No|Completed|November 2008|March 2012|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|146|||Both|18 Years|60 Years|No|||March 2013|March 31, 2013|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00712660||153364|
NCT00713492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080178|Computer-Assisted Self-Administration of Ethanol|Computer-Assisted Self-Administration of Ethanol (CASE) in Humans||National Institutes of Health Clinical Center (CC)||Recruiting|July 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2015|December 24, 2015|July 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00713492||153301|
NCT00712647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IR-4239A|Carotene and Retinol Efficacy Trial|Caret and Retinol Efficacy Trial: The Caret Coordinating Center|CARET|Fred Hutchinson Cancer Research Center|Yes|Completed|May 1985|June 2005|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18314|||Both|45 Years|69 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|July 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712647||153365|
NCT00712881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C19562/2037|Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer|Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer||Teva Pharmaceutical Industries||Completed|October 2008|December 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Female|18 Years|70 Years|No|||February 2016|February 5, 2016|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712881||153347|
NCT00712894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhongshan 2006-70|Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction|Reversal of No-reflow/Slow-flow During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction--a Prospective Randomized Study Comparing Intracoronary Infusion of Diltiazem, Verapamil and Nitroglycerin|EDUCATE-AMI|Fudan University|Yes|Completed|December 2006|August 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|80 Years|No|||September 2012|September 20, 2012|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712894||153346|
NCT00713479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18185-PI-EDL-V|An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers|A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline in Methamphetamine-dependent Volunteers Receiving Methamphetamine||University of California, Los Angeles|Yes|Completed|July 2008|September 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|55 Years|No|||December 2013|December 19, 2013|July 10, 2008|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00713479||153302|Small sample size
NCT00709202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07TGF-1112|Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain in Adolescents and Young Adults|The Attenuation of Second Generation Antipsychotic Induced Weight Gain in Adolescents and Young Adults Using Betahistine: A Double-Blind, Placebo-Controlled Trial||Nathan Kline Institute for Psychiatric Research|No|Recruiting|July 2008|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|39 Years|No|||June 2011|June 7, 2011|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709202||153627|
NCT00709722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLE01-ENK|Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis|Safety and Efficacy Study on Deoxyspergualin (NKT-01) in Patients With Uncontrolled Lupus Nephritis Receiving Oral Corticosteroids and Prior Treatment of Standard Immunosuppressive Therapy||Nippon Kayaku Co.,Ltd.|No|Completed|October 2003|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|70 Years|No|||July 2008|May 21, 2009|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00709722||153587|
NCT00710021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ALE02|Vitamin D3 in Systemic Lupus Erythematosus|Effect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|November 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|July 1, 2008|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT00710021||153565|
NCT00710554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCL0405|A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex® in the Treatment of Subjects With Peripheral Neuropathic Pain, Associated With Allodynia||GW Pharmaceuticals Ltd.|No|Completed|August 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|246|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|July 3, 2008||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00710554||153524|
NCT00710294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360007-001|Device Based Therapy in Hypertension Extension Trial|DEBuT - HET: Device Based Therapy in Hypertension Extension Trial: Long-Term Follow-Up Trial for Patients Who Completed the DEBuT-HT Study|DEBuT-HET|CVRx, Inc.|No|Completed|August 2005|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|N/A|No|||October 2011|October 28, 2011|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710294||153544|
NCT00710307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-79-52800-001|Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)|Descriptive, Cross-sectional and Prospective Epidemiology Study, on the Identification of Insulin-like Growth Factor-1 Status in Idiopathic Short Stature Children (EPIGROW Study)|EPIGROW|Ipsen||Completed|October 2008|January 2010|Actual|January 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|275|Samples With DNA|Whole blood will be collected. The blood sample will be kept as long as necessary and for a      maximum of 5 years.|Both|2 Years|N/A|No|Non-Probability Sample|Idiopathic Short Stature children|September 2010|September 9, 2010|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710307||153543|
NCT00711451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-056|Manual and Expressed Placental Removal at Cesarean Delivery and Its Effects on Various Cardiac Indices|Manual and Expressed Placental Removal at Planned Cesarean Delivery and Its Effects on Various Cardiac Indices as Measured By Continuous Wave Doppler Ultrasonography||William Beaumont Hospitals|No|Terminated|July 2008|January 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|July 2, 2008||No|unable to recruit patients|No||https://clinicaltrials.gov/show/NCT00711451||153457|
NCT00707083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POWH-CRE-2008.077-T|Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia|A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008.||Prince of Wales Hospital, Shatin, Hong Kong|No|Active, not recruiting|May 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2500|||Both|N/A|17 Years|No|||May 2015|May 31, 2015|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707083||153785|
NCT00707122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALBIOS|Volume Replacement With Albumin in Severe Sepsis|Efficacy of Albumin Administration for Volume Replacement in Patients With Severe Sepsis or Septic Shock - the ALBumin Italian Outcome Sepsis (ALBIOS) Study|ALBIOS|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Completed|July 2008|October 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1818|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707122||153784|
NCT00713960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CDK-DUM-2008/1|CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.|CARE - Quality Development in Cardiovascular Disease in General Practice||AstraZeneca|No|Completed|April 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2193|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2012|January 13, 2012|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00713960||153265|
NCT00715039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001141|Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder|A 4-Week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients With Generalized Anxiety Disorder: Assessment of a New Instrument Intended to Capture Rapid Onset||Pfizer|No|Completed|October 2003|May 2004|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|169|||Both|18 Years|65 Years|No|||October 2008|October 1, 2008|July 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715039||153182|
NCT00715286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I473|Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study|Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|November 2001|June 2009|Anticipated|April 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Female|20 Years|65 Years|No|||July 2008|July 14, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00715286||153163|
NCT00715312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|625.9|Effect of Oleic Acid on Inflammation Markers and Blood Lipid Metabolites: A Randomised, Double-Blind, Crossover Study|Effect of Oleic Acid on Inflammation Markers and Blood Lipid Metabolites: A Randomised, Double-Blind, Crossover Study.||Malaysia Palm Oil Board|No|Completed|February 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|43|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2008|July 14, 2008|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715312||153161|
NCT00715546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCMPA 1642/07|Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy|Phase 1 Study of Autologous-Derived Stem Cell Transplantation in Patients With Lipodystrophy|AADSCTPL|Irmandade Santa Casa de Misericórdia de Porto Alegre|Yes|Active, not recruiting|October 2007|November 2011|Anticipated|August 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|N/A|No|||March 2009|June 21, 2011|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715546||153143|
NCT00715559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 07-0478|Cysteamine Therapy for Major Depressive Disorder|An Open-Label Study of Cysteamine Bitartrate in Treatment-Resistant Major Depression||Murrough, James, M.D.|No|Terminated|July 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||June 2011|June 23, 2011|July 11, 2008|Yes|Yes|Change in resources available for study procedures.|No|April 18, 2011|https://clinicaltrials.gov/show/NCT00715559||153142|
NCT00715845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO200|Carbon Dioxide Insufflation on Cerebral Microemboli|Effects of Carbon Dioxide Insufflation on Cerebral Microemboli During Cardiopulmonary Bypass: A Randomised Trial Correlating Embolic Load & Neurologic Outcomes.||University Health Network, Toronto|No|Terminated|April 2008|October 2011|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A|No|||October 2011|October 25, 2011|June 17, 2008||No|ran out of funding|No||https://clinicaltrials.gov/show/NCT00715845||153120|
NCT00712686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-003|Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia|A Multicenter, Double-Blind, Randomized, Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|June 2000|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|690|||Both|18 Years|65 Years|No|||June 2010|November 7, 2013|July 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712686||153362|
NCT00712699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32MH078388|Effectiveness of an Extended Release Stimulant Medication in Treating Preschool Children With ADHD|Placebo vs. Extended Release Stimulant Crossover Trial in Preschoolers With ADHD||Baystate Medical Center|No|Completed|June 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|36 Months|66 Months|No|||August 2013|August 10, 2013|July 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712699||153361|
NCT00712153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95023|Follow-up of Coronary Artery Bypass Graft Patency by Multislice Computed Tomography|Follow-up of Coronary Artery Bypass Graft Patency by Multislice Computed Tomography||Far Eastern Memorial Hospital|Yes|Completed|November 2006|||November 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|N/A|N/A|No|Probability Sample|Patients underwent CABG and performed MSCT after the surgeries|July 2008|August 5, 2010|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712153||153403|
NCT00712400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-070703|Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects|Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects||Medical University of Vienna|Yes|Completed|June 2005|January 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|24|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712400||153384|
NCT00713505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598114|Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction|A Behavioral Intervention Trial for Parents of Childhood Cancer Survivors With Neurobehavioral Late Effects||City of Hope Medical Center|Yes|Completed|May 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized|2||Anticipated|56|||Both|6 Years|16 Years|No|||October 2010|October 11, 2010|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00713505||153300|
NCT00713518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0451001|Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).|Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study).|MONET|Quark Pharmaceuticals|No|Completed|November 2009|July 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|152|||Both|50 Years|N/A|No|||October 2012|October 10, 2012|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713518||153299|
NCT00712907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-161202|Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow|Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow||Medical University of Vienna|Yes|Completed|February 2003|May 2003|Actual|May 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|12|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||July 2008|July 9, 2008|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712907||153345|
NCT00712920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP434|A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 in Patients With Perennial Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|January 2007|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|581|||Both|12 Years|N/A|No|||June 2011|June 6, 2011|July 8, 2008|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00712920||153344|Standard deviations for primary endpoint are not available.
NCT00713167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMU 87-01-106-5694|The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL)|Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia|GSE|hahid Beheshti University of Medical Sciences|Yes|Completed|July 2008|February 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|21 Years|64 Years|No|||May 2009|May 20, 2009|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00713167||153325|
NCT00714337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00007|Formulation and Food Effect Study of AZD1386 in Healthy Volunteers|A Phase I, Single-Centre, Randomised, Open-Label, Five-Way Cross-Over Formulation- and Food-Effect Study in Healthy Volunteers to Assess the Pharmacokinetics of AZD1386 After Single Doses of Two Oral Solid Formulations and an Oral Solution||AstraZeneca|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|12|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714337||153236|
NCT00714350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23126|Evaluation of Information Displays A Paper & Pencil, Computer, Simulator, and ICU Based Study|Evaluation of Information Displays A Paper & Pencil, Computer, Simulator, and ICU Based Study||University of Utah|Yes|Completed|July 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ICU nurses|December 2014|December 11, 2014|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714350||153235|
NCT00709501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28160|Disseminating Effective Habits for Long-Term Weight Loss|Disseminating Effective Habits for Long-Term Weight Loss||Penn State University|No|Completed|July 2009|December 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|65 Years|No|||October 2015|October 19, 2015|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709501||153604|
NCT00709735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-07-1-0440|A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol|A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol||Massachusetts General Hospital|No|Recruiting|May 2007|April 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||April 2010|April 27, 2010|June 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709735||153586|
NCT00710320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB No 14004|Temperature Changes During Induction of General Anesthesia in Pediatric Patients|Temperature Changes During Induction of General Anesthesia in Pediatric Patients||University of Oklahoma|Yes|Completed|July 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|6 Months|3 Years|Accepts Healthy Volunteers|Probability Sample|Children in an academic center|February 2010|February 3, 2010|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00710320||153542|
NCT00710827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91579|Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks|A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH)||Bayer|No|Withdrawn|October 2008|October 2008|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Male|50 Years|N/A|No|||November 2012|November 22, 2012|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710827||153503|
NCT00711126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C106180|A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection|A Single-centre, Open-label, Sequential, Dose-ascending Study to Examine Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Intravenous, Inhaled and Oral Doses of GW642444 in Healthy Male Subjects||GlaxoSmithKline|No|Completed|October 2008|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|9|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711126||153481|
NCT00711139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Affiris 003|Long-term Safety and Tolerability of AFFITOPE AD01|Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD01 Applied During AFFiRiS 001||Affiris AG|Yes|Completed|June 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|22|Samples Without DNA|Serum|Both|50 Years|N/A|No|Non-Probability Sample|Subjects having participated in AFFiRiS 001, as AFFiRiS 003 is a follow-up trial.|December 2009|May 26, 2010|July 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00711139||153480|
NCT00707447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIDAM 006-04|Evaluation of a Primary Type 2 Diabetes Prevention Programme|Evaluation of a Teaching and Treatment Programme for Primary Prevention of Type 2 Diabetes|PREDIAS|Forschungsinstitut der Diabetes Akademie Mergentheim|No|Completed|April 2004|May 2008|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|182|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|June 26, 2008||No||No|September 3, 2012|https://clinicaltrials.gov/show/NCT00707447||153760|
NCT00714584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003256|Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers|Pharmacokinetics of Naltrexone Hydrochloride (HCl) Following Intravenous (i.v.) and Oral Routes of Administration in Healthy Subjects||Alza Corporation, DE, USA||Completed|May 2003|June 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|May 18, 2011|July 10, 2008||||||https://clinicaltrials.gov/show/NCT00714584||153217|
NCT00715572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3T42008|Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone|Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone in the Treatment of Primary Hypothyroidism||I.M. Sechenov First Moscow State Medical University|No|Completed|March 2002|May 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|48 Years|No|||July 2008|July 14, 2008|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715572||153141|
NCT00715884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-6330|Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems|A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE).|ELITE|Cordis Corporation|Yes|Active, not recruiting|July 2008|September 2014|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|678|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|July 11, 2008|Yes|Yes||No|February 25, 2011|https://clinicaltrials.gov/show/NCT00715884||153117|The study was terminated early by the Sponsor for business reasons. Hence the data was under powered for hypothesis testing. No definitive conclusions can be made from this data.
NCT00715871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB07211|Clinical Study of Smoke-Break Liquid Cigarettes|Phase II Study to Measure Effectiveness and to Monitor Side Effects of Smoke-Break Nicotine Delivery Device||Smoke-Break, Inc.|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|70 Years|No|||November 2014|November 17, 2014|July 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715871||153118|
NCT00704743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P98-0172|A Trial Comparing Circumferential Casting Versus Splinting in Displaced Colles' Fractures|A Prospective Randomized Controlled Trial Comparing Circumferential Casting Versus Splinting in Displaced Colles' Fractures||University of British Columbia|No|Completed|November 1998|January 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||June 2008|June 24, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704743||153959|
NCT00712673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6014|GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin|GETGOAL-M|Sanofi|Yes|Completed|June 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|680|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712673||153363|
NCT00712933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112234|A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057|A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057||GlaxoSmithKline|Yes|Active, not recruiting|June 2008|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|733|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712933||153343|
NCT00712946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M1155457|Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages|Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages|Barosleep|GE Healthcare|Yes|Completed|March 2006|December 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|103|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ASO patients admitted to electrive vascualr surgery in Turku University Hospital|March 2010|April 27, 2011|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712946||153342|
NCT00713180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Research laboratory|Determinants of Pterygium Occurrence and Recurrence in a Rural African Population|Determinants of Pterygium Occurrence and Recurrence in a Rural African Population||Anguria, Peter, M.D.|Yes|Completed|August 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|355|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2008|June 24, 2015|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713180||153324|
NCT00713791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00029|Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.|A Phase I, Randomised, Single-blind, Single-centre, Incomplete-block Crossover, Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets||AstraZeneca||Completed|June 2008|August 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 10, 2010|July 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00713791||153278|
NCT00705900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-LCDPOP|LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis|A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis||NeoStrata Company, Inc.|Yes|Completed|January 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2008|November 17, 2008|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705900||153874|
NCT00713778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH-CL-030408|The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst|The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Exc||Shandong Provincial Hospital|Yes|Completed|November 2003|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|192|||Female|18 Years|40 Years|No|||July 2008|August 15, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713778||153279|
NCT00714051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E4955-R|Fall Prevention Program for Older Adults|Fall Prevention Program for Older Adults||VA Office of Research and Development|No|Completed|October 2008|October 2014|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|65 Years|80 Years|No|||October 2014|October 2, 2014|July 8, 2008||No||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00714051||153258|
NCT00714363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25514|Comparison of LASIK and SBK|Comparison of Laser-Assisted in Situ Keratomeleusis (LASIK) vs Sub-Bowman's Keratomileusis (SBK): Assessment of Visual Function and Patient Satisfaction||University of Utah|No|Completed|October 2007|January 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|80 Years|No|||October 2010|October 15, 2010|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714363||153234|
NCT00706771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNH 18/08|Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study|A Randomized Double-blind Controlled Pilot Feasibility and Safety Trial of NGAL-directed Sodium Bicarbonate to Protect Renal Function in Patients With the Systemic Inflammatory Response Syndrome, Oliguria and Elevated Lipocalin Levels|BLISS|Austin Health|No|Completed|February 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706771||153809|
NCT00709748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Empi 07-1-02|E-STIM Trial: Comparing the Efficacy of the Empi Select TENS to a Control for the Treatment of Chronic Lower Back Pain|The E-STIM Trial: A Randomized, Double-Blind, Multicenter Trial Comparing the Efficacy of the Empi Select Transcutaneous Electrical Nerve Stimulation (TENS) to a Control for the Treatment of Chronic Lower Back Pain|E-STIM|Empi, A DJO Company|No|Recruiting|February 2008|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||July 2008|July 2, 2008|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709748||153585|
NCT00710840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0183|Effectiveness of Minimally Invasive Total Knee Replacement in Improving Rehabilitation and Function|Functional Outcomes Following Minimally Invasive Total Knee Arthroplasty||University of Colorado, Denver||Completed|June 2008|January 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|85 Years|No|||March 2015|May 14, 2015|June 27, 2008|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT00710840||153502|Small sample size; Relatively short follow-up time
NCT00710853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC23B11|Effects of Qigong, Tai Chi and Yoga Practice in Older Adults|Effects of Qigong, Tai Chi and Yog Practice on Indicators of Health and Quality of Life in Older Adults||Bastyr University|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|50|||Both|70 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 9, 2009|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710853||153501|
NCT00711464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715868-1|A Dose-response Study of Modafinil Effects on Cognition in Healthy Adults and in Schizophrenia Patients|A Dose-response Study of Modafinil Effects on Cognition in Healthy Adults and in Schizophrenia Patients.|InO|University of California, Davis|No|Completed|May 2008|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||August 2011|July 5, 2012|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00711464||153456|
NCT00711477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-431|A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects|Naltrexone Sustained Release (SR) 32 mg and Bupropion Sustained Release (SR) 360 mg Combination Therapy in Functional Magnetic Resonance Imaging (fMRI) Changes in Overweight or Obese Subjects||Orexigen Therapeutics, Inc|No|Completed|September 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|46|||Female|18 Years|45 Years|No|||December 2014|January 5, 2015|July 3, 2008|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT00711477||153455|
NCT00707148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0048|Pertussis Vaccine in Healthy Pregnant Women|Safety and Immunogenicity of Tdap Vaccine in Healthy Pregnant Women, Safety in Their Neonates, and Effect of Maternal Immunization on Infant Immune Responses to DTaP Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2009|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|80|||Both|N/A|45 Years|Accepts Healthy Volunteers|||August 2012|July 24, 2014|June 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00707148||153782|
NCT00707434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0616|Continuous Glucose Monitoring in Critically Ill|Continuous Glucose Monitoring Device Compared With Point-of-care Glucose Testing in the ICU||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2008|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707434||153761|
NCT00714818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02706|Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness|Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness: Impact on Knowledge, Risk Perception, Perceived Control and Internalized Stigma.||University of British Columbia|No|Completed|August 2008|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|13|||Female|19 Years|N/A|No|||November 2011|November 21, 2011|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714818||153199|
NCT00715065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080608|fMRI in Blood Phobia Syncope|Neuroimaging in Blood Phobia Syncope||Vanderbilt University|No|Withdrawn|June 2010|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Patients with at least 1 prior syncopal episode in response to viewing blood          2. Healthy subjects without a history of syncope|January 2013|January 7, 2013|July 10, 2008||No|Could not get funding for fMRI studies at this time.|No||https://clinicaltrials.gov/show/NCT00715065||153180|
NCT00715078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-2|To Evaluate Sipuleucel-T Manufactured With Different Concentrations of Prostate Adenocarcinoma (PA2024) Antigen|A Randomized, Multicenter, Single Blind Study in Men With Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen|ProACT|Dendreon|Yes|Completed|August 2008|April 2015|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|122|||Male|18 Years|N/A|No|||October 2015|October 5, 2015|July 11, 2008|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT00715078||153179|
NCT00714805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-16637|Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)|Non-Invasive Measurement of GI Motility in Patients With ALS|GIDysmotility|Drexel University|No|Recruiting|January 2007|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope.|May 2014|September 18, 2015|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714805||153200|
NCT00715052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBOtbi1|The Effect of Hyperbaric Oxygen Therapy on Patients Suffering From Neurologic Deficiency Due Traumatic Brain Injury|||Assaf-Harofeh Medical Center|No|Completed|August 2008|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||October 2008|May 6, 2013|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00715052||153181|
NCT00711867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003313|Comparison of Intraoperative Warming Devices|Intraoperative Warming: Comparison of Performance of the Dynatherm Medical vitalHeat™ Temperature Management System (vH2) and the Arizant Bair Hugger System||Mayo Clinic|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|N/A|No|||December 2009|December 9, 2009|July 7, 2008|Yes|Yes||No|October 28, 2009|https://clinicaltrials.gov/show/NCT00711867||153425|
NCT00712179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6365-R|Understanding Different Parameters in Locomotor Training (a Type of Walking Training) for Person After a Stroke|Developing Evidence-based Parameter Selection for Locomotor Training||VA Office of Research and Development|No|Completed|July 2008|December 2013|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Controls and persons who have sustained a stroke|October 2014|October 9, 2014|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00712179||153401|
NCT00711880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWNP0101|A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.|A Double Blind, Randomised, Placebo Controlled Parallel Group Study of Cannabis Based Medicine Extract (CBME), in the Treatment of Peripheral Neuropathic Pain Characterised by Allodynia.||GW Pharmaceuticals Ltd.|No|Completed|May 2002|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|125|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|July 7, 2008||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT00711880||153424|
NCT00712166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-205-0117|Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa|A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine For Inhalation in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)|AIR-CF4|Gilead Sciences|Yes|Completed|May 2008|August 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|6 Years|N/A|No|||November 2010|November 19, 2010|July 7, 2008|Yes|Yes||No|September 10, 2010|https://clinicaltrials.gov/show/NCT00712166||153402|
NCT00705016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200052-013|Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Open-label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck|ADVANTAGE|Merck KGaA|Yes|Completed|October 2008|June 2013|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|184|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|June 24, 2008||No||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00705016||153939|
NCT00712959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD526|Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose|Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose||Sanofi|No|Completed|June 2008|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|769|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 1, 2014|July 7, 2008|Yes|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT00712959||153341|
NCT00713193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0194|Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)|A Multi-Center, Randomized Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in the Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP)||Ohio State University|Yes|Active, not recruiting|November 2007|November 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713193||153323|
NCT00713531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 008/RV233|Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, Thailand|||South East Asia Research Collaboration with Hawaii|No|Completed|July 2008|June 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|992|Samples Without DNA|Plasma, CD4, HIV-RNA|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population in Thailand who are seeking HIV counseling and testing at TRCARC|May 2015|May 27, 2015|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713531||153298|
NCT00705913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRVSS-02|Randomized Sizing and Hemodynamic Study Mitroflow vs. Magna|A Randomized Study to Compare Sizing, Implant Techniques and Hemodynamic Performance Between the Mitroflow and the Carpentier-Edwards Magna Pericardial Tissue Valves in the Aortic Position||Sorin Group USA, Inc.|No|Terminated|June 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|368|||Both|18 Years|N/A|No|||November 2011|January 6, 2012|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00705913||153873|
NCT00714064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC 490320|PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers|PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease|PneuMum|Menzies School of Health Research|Yes|Completed|June 2006|July 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|227|||Female|17 Years|39 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714064||153257|
NCT00714376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 5.2.08.02|Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients|Phase II Single Center Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients With an Early Rising PSA Following Radical Prostatectomy|TAX1|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Terminated|May 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|75 Years|No|||October 2012|October 30, 2012|July 10, 2008||No|Prematurely terminated due to financial considerations|No||https://clinicaltrials.gov/show/NCT00714376||153233|
NCT00707044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 01-039|Short-Stay Intensive Care for Coronary Artery Bypass Patients|Short-Stay Intensive Care for Coronary Artery Bypass Patients,Development of a Guideline for Giving Adequate Care on the Cardiosurgical Intensive Care||Maastricht University Medical Center|Yes|Completed|January 2001|May 2004|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|597|||Both|18 Years|78 Years|No|||June 2008|June 27, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707044||153788|
NCT00710567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH003|Evaluation of the Safety and Effectiveness of the DuraHeart™ LVAS|Evaluation of the Safety and Effectiveness of the DuraHeart™ Left Ventricular Assist System in Patients Awaiting Transplantation||Terumo Heart Inc.|Yes|Terminated|July 2008|January 2017|Anticipated|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 2, 2008|Yes|Yes|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00710567||153523|
NCT00707460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22419|The Effect of a Traditional Dietary Intervention on Diabetes Mellitus and Cardiovascular Disease Risk Factors in a First Nation Community: A Pilot Study|Objective 3: Pilot Dietary Trial; The Sandy Lake Health & Diabetes Project (SLHDP): Understanding and Addressing Metabolic Syndrome, Diabetes and Associated Complications in Aboriginal Canadians|SLHDP|University of Toronto|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 18, 2010|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707460||153759|
NCT00707473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0433|Induction Therapy-Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses|Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses||M.D. Anderson Cancer Center|No|Recruiting|June 2008|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|17 Years|N/A|No|||November 2015|November 2, 2015|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707473||153758|
NCT00707785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.22.05.12.20.A2|Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis|Effect of Vitamin A in the Treatment of Sepsis and Necrotizing Enterocolitis in Hospitalized Neonates||Johns Hopkins University|Yes|Completed|December 2006|June 2012|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|424|||Both|N/A|28 Days|No|||September 2013|September 24, 2013|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707785||153735|
NCT00714610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21498|Serum Metal Ion Concentrations Following Primary Hip Arthroplasty|Serum Metal Ion Concentrations Following Unilateral Versus Bilateral Large Head Metal on Metal Primary Hip Arthroplasty||University of Utah|Yes|Completed|August 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|39|Samples Without DNA|Blood will be drawn for analysis.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Two groups were identified: the first group having undergone unilateral large-head (≥38        mm) primary MOM THA and the second having undergone bilateral large-head primary MOM THA.        Patients were at least 18 years old, were at least 1 year out from their index procedure,        and had well-positioned components.        Patients in both cohorts had cementless modular titanium alloy proximally porous-coated,        tapered femoral stems (Biomet Taperloc or Bi-Metric; Biomet, Warsaw, Ind).        All surgeries were done between the years of 2003 and 2009.|February 2014|February 3, 2014|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714610||153215|
NCT00715338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70808|Effects of Oxygen on Lung Tissue During Anesthesia|Effects of Oxygen on Lung Tissue During Anesthesia||Vanderbilt University|Yes|Active, not recruiting|June 2008|August 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|None Retained|serum|Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for a routine surgical procedure|January 2009|January 27, 2009|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00715338||153159|
NCT00715325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-IL-LIT-0703_S_01|ProtectiScope CS Intended for Diagnostic and Therapeutic Colonoscopy|Evaluation of Safety and Efficacy of a New Colonoscope, ProtectiScope CS, to Diagnose Large Bowel Diseases||Stryker GI Ltd.|No|Not yet recruiting|October 2008|January 2009|Anticipated|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2008|September 17, 2008|July 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00715325||153160|
NCT00704132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-059|Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)|A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Completed|February 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|30 Years|70 Years|No|||August 2015|August 13, 2015|June 23, 2008|No|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00704132||154006|
NCT00704444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05244|A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)|Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy||Merck Sharp & Dohme Corp.|No|Completed|June 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|11332|||Both|N/A|N/A|No|Non-Probability Sample|The population will be selected from 2,000 institutions in Japan.|February 2015|February 24, 2015|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704444||153982|
NCT00712426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P000827|Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)|Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)|CREST-E|Massachusetts General Hospital|Yes|Terminated|September 2009|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|553|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 8, 2008|Yes|Yes|Results of an interim analysis showed that it was unlikely that creatine was effective in    slowing loss of function in early symptomatic Huntington's Disease.|No||https://clinicaltrials.gov/show/NCT00712426||153382|
NCT00712439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0046|Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy||Depomed|No|Completed|April 2006|December 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|July 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712439||153381|
NCT00705367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-217|Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg|A Single Center, Randomized, Placebo-Controlled, Double Blind, Parallel Group Study to Evaluate the Tolerability of a Single Dose of Abatacept 30 mg/kg Via Intravenous Infusion in Chinese SLE Subjects With Lupus Nephritis||Bristol-Myers Squibb|No|Completed|August 2008|July 2011|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|June 24, 2008|Yes|Yes||No|May 4, 2010|https://clinicaltrials.gov/show/NCT00705367||153914|
NCT00705380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29MH058641|Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder|Cognitive-Behavioral Treatment of Panic in Adolescence||Boston University|Yes|Completed|July 1998|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|12 Years|17 Years|No|||March 2015|March 4, 2015|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705380||153913|
NCT00705003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBM-IT-01|Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)|A Double-Blind, Placebo-Controlled Study of a Combination Product (BCI-024 and BCI-049) in Patients With Major Depressive Disorder (MDD)||Massachusetts General Hospital|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|142|||Both|18 Years|65 Years|No|||June 2014|June 17, 2014|June 23, 2008||No||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00705003||153940|
NCT00705341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAACRC07|MethaCholine Bronchoprovocation Study (MeCIS)|MethaCholine Bronchoprovocation - Influence of High Potency Inhaled corticoSteroids in Asthma (MeCIS) Study|MeCIS|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|January 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|219|||Both|12 Years|69 Years|Accepts Healthy Volunteers|||February 2013|February 11, 2013|June 24, 2008|Yes|Yes||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00705341||153916|
NCT00705627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007047|A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|A Multicenter Trial Comparing Neoadjuvant Chemotherapy Followed by CCRT v.s. CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Recruiting|June 2008|June 2017|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|60 Years|No|||May 2014|May 26, 2014|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705627||153895|
NCT00706160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080161|Language Mapping in Patients With Epilepsy|Noninvasive Language Mapping in Patients With Localization-Related Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|June 2008|April 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|153|||Both|7 Years|55 Years|Accepts Healthy Volunteers|||April 2013|February 19, 2014|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706160||153854|
NCT00706134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2405|Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study|An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal||Novartis|No|Completed|May 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|756|||Both|65 Years|N/A|No|||June 2011|June 24, 2011|June 25, 2008||No||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00706134||153856|
NCT00706147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arimoclomol in SOD1 fALS|Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis|Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS)||University of Miami|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|June 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00706147||153855|
NCT00706446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000285|Study of the Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations|Genotype Stratified Treatment With Anticholinergic vs. Beta-agonist (Long Acting) and Exacerbations (GABLE)|GABLE|Brigham and Women's Hospital|No|Terminated|June 2008|September 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|355|||Both|18 Years|75 Years|No|||July 2014|July 16, 2014|June 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706446||153832|
NCT00706810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI25089|Combination of Hydroxyurea and Verapamil for Refractory Meningiomas|Combination of Hydroxyurea and Verapamil for Refractory Meningiomas||University of Utah|Yes|Completed|December 2007|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706810||153806|
NCT00711152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2007-339|Community Health Worker Reduces Care Utilization|Inclusion Of a Community Health Worker in a Collaborative Diabetes Care Program Reduces Health Care Utilization (JADE)|JADE-MOS|Chinese University of Hong Kong|Yes|Completed|February 2008|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|661|||Both|18 Years|N/A|No|||September 2015|September 5, 2015|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711152||153479|
NCT00711165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mometasone TBC|Mometasone and Markers of Airway Inflammation|The Effects of Mometasone on Markers of Airway Inflammation||Creighton University|No|Completed|August 2005|August 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|19 Years|50 Years|No|||July 2008|July 3, 2008|July 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00711165||153478|
NCT00711178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicenter Sun-PDT|A Randomized Multicenter Study of Daylight Mediated Photodynamic Therapy (PDT)|||Bispebjerg Hospital|Yes|Completed|June 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2008|November 1, 2010|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711178||153477|
NCT00711490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080175|Sirolimus to Treat Diabetic Macular Edema|Pilot Study of the Evaluation of Sirolimus in the Treatment of Diabetic Macular Edema|SDME|National Institutes of Health Clinical Center (CC)|Yes|Completed|July 2008|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|July 8, 2008|No|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00711490||153454|
NCT00707798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111651|Evaluation of Pneumococcal Vaccine Formulations in Young Adults|A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189242A) in Young Adults.||GlaxoSmithKline||Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|157|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00707798||153734|
NCT00708110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111521|Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults|A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults (ING111521)||ViiV Healthcare||Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|65 Years|No|||August 2013|November 7, 2013|June 30, 2008|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00708110||153710|
NCT00708123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3157503|In Situ Caries of Fluoride Toothpastes|Comparison of the Clinical Efficacy From the Retention Phase of Fluoride Delivery of Fluoride Toothpastes Using an in Situ Caries Model||GlaxoSmithKline|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||March 2013|April 18, 2013|July 1, 2008|Yes|Yes||No|September 14, 2010|https://clinicaltrials.gov/show/NCT00708123||153709|
NCT00714831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI081304|Referral From Primary Health Care Centers to a Physical Activity Program. A Randomized Controlled Trial|Referral From Primary Health Care Centers to a Physical Activity Program: Establishing Long-Term Adherence? A Randomized Controlled Trial||Jordi Gol i Gurina Foundation|Yes|Not yet recruiting|September 2008|December 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|424|||Both|18 Years|N/A|No|||July 2008|July 11, 2008|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00714831||153198|
NCT00714844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolUmbI-DptSClin-Det1|Insulin Detemir and Waist Circumference|Waist Circumference Reduction After Insulin Detemir Treatment in Type 2 Diabetes Patients Previously Treated With NPH Insulin||University of Roma La Sapienza|No|Completed|January 2007|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|Type 2 diabetic patients accessing the Diabetologic Centre|April 2008|July 7, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00714844||153197|
NCT00715897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBOcva1|Hyperbaric Oxygen Therapy Induced Neuroplasticity in Post Stroke Patients Suffering Chronic Neurological Deficiencies|||Assaf-Harofeh Medical Center||Completed|August 2008|November 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||December 2011|December 23, 2011|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00715897||153116|
NCT00715585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08335|Addressing The Role of Nutrition Education & Health Literacy in Diabetes Care|Addressing The Role of Nutrition Education & Health Literacy in Diabetes Care|DiNES|Vanderbilt University|Yes|Completed|June 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00715585||153140|
NCT00715598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33066-G|Cognitive Testing for the Pain Quality Assessment Scale (PQAS)|Cognitive Testing for the Pain Quality Assessment Scale (PQAS)|PQAS|University of Washington|No|Completed|June 2008|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|213|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will consist of individuals from the general community who have participated in a        survey study for SCI or multiple sclerosis(MS), experience chronic pain and indicated a        willingness to be contacted for further studies. Subjects from the general population may        learn about the study through UW-affiliated websites and newsletters.|May 2012|May 7, 2012|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715598||153139|
NCT00704470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK261122004|Performance and Stress During Full Scale Simulator Training|Excellence in Performance and Stress Reduction During Two Different Full Scale Simulator Training Courses: A Pilot Study||Technische Universität Dresden|No|Completed|April 2005|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|32|||Both|N/A|N/A|No|||June 2008|June 25, 2008|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00704470||153980|
NCT00704483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBR759A2201|Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis|A 12-week, Open Label, Multicenter, Titration Study, With a 9-month Maintenance Treatment Extension, to Demonstrate Efficacy of SBR759 Compared to Sevelamer HCl in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis|SBR759|Novartis||Completed|July 2008|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|321|||Both|18 Years|N/A|No|||November 2011|November 3, 2011|June 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00704483||153979|
NCT00704457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-024|Impact Of Sacral Neuromodulation On Urine Markers For Interstitial Cystitis (IC)|Impact Of Sacral Neuromodulation On Urine Markers For IC||William Beaumont Hospitals|No|Completed|February 2004|December 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|11|Samples Without DNA|Urines were collected and sent for urine marker analysis.|Female|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone sacral nerve stimulation.|August 2013|August 1, 2013|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00704457||153981|
NCT00704756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05494|An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)|An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT|PEGIMPACT|Merck Sharp & Dohme Corp.|No|Withdrawn|January 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice        in Belgium.|August 2014|August 8, 2014|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704756||153958|
NCT00702806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07015|Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)|A Phase II, Open Label, Prospective, Randomized, Comparative Clinical Trial to Investigate the Appropriate Dose of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI.||Merck Sharp & Dohme Corp.|Yes|Completed|July 2001|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|99|||Female|18 Years|39 Years|No|||June 2015|June 26, 2015|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702806||154108|
NCT00705354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-119|Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery|Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following||Lahey Clinic|No|Withdrawn|January 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 12, 2012|June 24, 2008|Yes|Yes|Principal Investigator left the institution requested termination.|No||https://clinicaltrials.gov/show/NCT00705354||153915|
NCT00705640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13498|Vaccine Therapy in Treating Patients With Advanced Melanoma|A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment||University of Virginia|Yes|Completed|May 2008|||June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|45|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|June 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705640||153894|
NCT00705653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47-01-001|Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors|A Phase I Study of CGC-11047 in Subjects With Advanced Refractory Solid Tumors||Progen Pharmaceuticals|No|Completed|March 2005|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|June 23, 2008|No|Yes||No|November 6, 2011|https://clinicaltrials.gov/show/NCT00705653||153893|
NCT00704522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04281|Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)|Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program.||Merck Sharp & Dohme Corp.|No|Completed|March 2005|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|601|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients receiving a patient assistance program during therapy for hepatitis C at        sites in Austria.|October 2015|October 5, 2015|June 23, 2008|No|Yes||No|April 21, 2010|https://clinicaltrials.gov/show/NCT00704522||153976|
NCT00706459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpineMRI|Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study|Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study||University of California, San Francisco|No|Terminated|March 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|53|Samples Without DNA|Disc specimens are taken out during back surgery and will be studied using techniques for      tissue analysis to explain the properties and characteristics of disc tissue from patients      with back pain.|Both|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potential subjects are patients seen by surgeons in the UCSF ACC Orthopedic Clinic. If a        patient meets all inclusion and exclusion criteria, the orthopedic surgeon will talk to        the patient about the new dedicated examinations using 3 Tesla MRI that can identify        painful degenerated discs. When patient is comfortable with participating and has made a        decision to go ahead with the MRI, patient can let the orthopedic surgeon's assistant know        about his/her decision, the assistant will make sure that patient still meets the        inclusion and exclusion criteria and will call the coordinator at the Imaging Center to        set up an MRI appointment.        Flyers will be posted at different UCSF campuses to recruit for normal age-matched and        young normal volunteers.|November 2012|November 13, 2012|June 24, 2008||No|Due to funding issue, study has been terminated.|No||https://clinicaltrials.gov/show/NCT00706459||153831|
NCT00706784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-001343|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System Study|Inducing a Medical Castration With a GnRH Agonist While Simultaneously Replacing Physiologic Levels and Patterns of Human Sex Steroid Hormones Using an Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|VaginalRing|Massachusetts General Hospital|Yes|Terminated|June 2008|June 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|June 25, 2008|No|Yes|Sponsor making changes to manufacturing of vaginal ring.|No|April 16, 2014|https://clinicaltrials.gov/show/NCT00706784||153808|Early termination leading to small numbers of subjects analyzed.
NCT00706797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4437|Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects|An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) Added to Methotrexate in Comparison With Usual Treatment in Subjects With Moderate Rheumatoid Arthritis Disease Activity||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|September 2008|May 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||June 2011|June 16, 2011|June 25, 2008|Yes|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00706797||153807|Following early termination of the study, only disposition of randomized participants, description of demographic data on safety population, and safety analyses were performed.
NCT00703365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12849|Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)|A Multicenter, Open Label, Single Arm, Phase II Study to Investigate the Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Patients With Advanced Hepatocellular Carcinoma (HCC)||Mahidol University|No|Completed|February 2008|August 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703365||154065|
NCT00703378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK01/06/05|Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle|Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle||National University Hospital, Singapore||Completed|May 2006|February 2012|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|No|||March 2012|March 27, 2012|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703378||154064|
NCT00707161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI15461|Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma|A Prospective Phase II Study of Radiation Therapy and Concurrent Cisplatin Chemotherapy in the Treatment of Locally Advanced or Metastatic Malignant Melanoma||University of Utah|Yes|Terminated|September 2005|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|June 26, 2008||No|discontinued due to low enrollment|No|April 20, 2011|https://clinicaltrials.gov/show/NCT00707161||153781|Early termination due to low enrollment.
NCT00707174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI13361|Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna|Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna||University of Utah|Yes|Completed|March 2005|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|June 25, 2008||No||No|June 4, 2012|https://clinicaltrials.gov/show/NCT00707174||153780|
NCT00707486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-I-D-1|A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing|A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing||HemCon Medical Technologies, Inc|No|Completed|June 2008|July 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|14 Years|N/A|No|||December 2012|December 6, 2012|June 27, 2008|Yes|Yes||No|April 2, 2010|https://clinicaltrials.gov/show/NCT00707486||153757|
NCT00707499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS747158-101|A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158|A Single-Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial of BMS 747158 in Healthy Subjects||Lantheus Medical Imaging|Yes|Completed|September 2007|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|13|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707499||153756|
NCT00703677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPTUNE_PSP_CBD|A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration|A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration||Westat|No|Completed|September 2008|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|40 Years|80 Years|No|||June 2015|June 9, 2015|June 20, 2008||No||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00703677||154041|The majority of subjects did not tolerate study drug, therefore, evaluations of subjects on study drug are limited in number.
NCT00703989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI#: 2004-582|Reactive Oxygen Species in the Pathogenesis of Diabetic Complications|The Role of the Glucosamine Pathway and Reactive Oxygen Species in the Pathogenesis of Diabetic Complications||Albert Einstein College of Medicine of Yeshiva University|No|Completed|February 2005|February 2008|Actual|October 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 23, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00703989||154017|
NCT00715624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6016|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin|GETGOAL-L|Sanofi|Yes|Completed|July 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|496|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715624||153137|
NCT00711906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMP0108|Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy|The Role of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria And Its Effects in Pregnancy||Institute of Tropical Medicine, Belgium|No|Terminated|February 2009|September 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|352|||Female|N/A|N/A|No|||January 2016|January 15, 2016|July 8, 2008||No|Malaria prev. fell in the study area, so we cannot evaluate the primary endpoint|No||https://clinicaltrials.gov/show/NCT00711906||153422|
NCT00711893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASt-IBP 0408|Feature Assessment Study for Indications Based Programming|Feature Assessment Study for Indications Based Programming|FASt-IBP|Guidant Corporation|No|Completed|June 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|18 Years|N/A|No|Probability Sample|Patients indicated for the implant of an cardioverter defibrillator or cardiac        resynchronization defibrillator defibrillator.|March 2013|March 11, 2013|July 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00711893||153423|
NCT00704769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04299|Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)|Observational Study Evaluating the Safety and Efficacy of Desloratadine Syrup for Perennial Allergic Rhinitis in Indonesian Pediatric Patients||Merck Sharp & Dohme Corp.|No|Completed|May 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|591|||Both|2 Years|11 Years|No|Non-Probability Sample|Children, ages 2-11, with a history of perennial allergic rhinitis|May 2015|May 27, 2015|June 23, 2008||No||No|March 12, 2009|https://clinicaltrials.gov/show/NCT00704769||153957|
NCT00704782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM13|Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease|An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease||Medivation, Inc.||Terminated|April 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|50 Years|N/A|No|||November 2015|November 13, 2015|June 23, 2008|Yes|Yes|The study was halted after a Phase 3 study of dimebon failed to show efficacy.|No||https://clinicaltrials.gov/show/NCT00704782||153956|
NCT00705042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-1110|Study Evaluating Enbrel Drug Levels in Healthy Male Chinese Subjects|A Randomized, Open-Label, Single-Dose Administration, Parallel-Group, Multisite Study of the Pharmacokinetics of Etanercept, 25 or 50 mg, Administered Subcutaneously to Healthy Chinese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|July 2008|November 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 27, 2009|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00705042||153938|
NCT00705055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-07-0018-CTIL|Face Anthropometric Pattern Recognition Technology for Computer Aided Diagnosis of Human Genetic Disorders.|Face Anthropometric Pattern Recognition Technology, Based on 3D Reconstruction Technology, for Computer Aided Diagnosis of Human Genetic Disorders. Multicenter Collaborative Study.|DW 6/2007|Carmel Medical Center|Yes|Recruiting|November 2007|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|800|||Both|N/A|2 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Newborn infants born at Carmel Medical Center or at Soroka Medical Center|November 2013|November 19, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00705055||153937|
NCT00703352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2007-002605-53|Eplerenone in Systemic Right Ventricle|Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial.|EVEDES|Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|July 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||November 2011|November 30, 2011|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703352||154066|
NCT00703625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0444|Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies|Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies||Washington University School of Medicine|Yes|Completed|March 2008|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703625||154045|
NCT00705666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04437|Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)|Real Situation Observational Study of VIRAFERONPEG® in Patients With Chronic Hepatitis C|ADEQUATION|Merck Sharp & Dohme Corp.|No|Completed|February 2006|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|789|||Both|18 Years|N/A|No|Probability Sample|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in        combination with ribavirin at academic centers, clinics, and private practices in France.|October 2015|October 1, 2015|June 23, 2008|No|Yes||No|March 30, 2010|https://clinicaltrials.gov/show/NCT00705666||153892|
NCT00704535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04748|Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)|Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Ezetimibe Among Filipino Patients||Merck Sharp & Dohme Corp.|No|Completed|March 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4105|||Both|18 Years|N/A|No|Probability Sample|Filipino subjects with hypercholesterolemia|April 2015|April 9, 2015|June 23, 2008||No||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00704535||153975|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.
NCT00705107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04247|Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)|Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C||Merck Sharp & Dohme Corp.|No|Terminated|November 2004|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|267|||Both|N/A|N/A|No|Probability Sample|Treatment-naïve adult patients with hepatitis C treated with PegIntron pen and Rebetol        receiving a patient assistance program at approximately 40 sites in Romania. Patient        assistance program can consist of prophylactic treatment (eg, with growth factors,        psychiatric medications) or other interventions (eg, psychotherapy, patient support        groups, visiting nurse, nurse telephone calls, educational literature).|June 2015|June 3, 2015|June 23, 2008||No||No|February 11, 2009|https://clinicaltrials.gov/show/NCT00705107||153934|
NCT00705926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI071915|Effectiveness of Antiretroviral Therapy During Acute HIV Infection|A Phase 1 Clinical Trial to Evaluate the Initiation of Treatment Versus no Treatment During Acute HIV-1 Infection||Massachusetts General Hospital||Active, not recruiting|October 2008|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|65 Years|No|||April 2013|April 2, 2013|June 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705926||153872|
NCT00706173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071982|Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD)|A Randomized Double-blind Placebo-controlled Cross-over Trial of Hydrocortisone for Post-traumatic Stress Disorder||University of California, San Diego|No|Withdrawn|August 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|65 Years|No|||August 2011|June 2, 2015|June 25, 2008||No|Unable to recruit eligible subjects for the trial.|No||https://clinicaltrials.gov/show/NCT00706173||153853|
NCT00706485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007|Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators|Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators||Massachusetts General Hospital|Yes|Completed|July 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|June 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00706485||153830|
NCT00702884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07121|Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer|A Mechanistic Radiographic and Biologic Phase 2 Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastroesophageal Cancers||Ohio State University Comprehensive Cancer Center|Yes|Completed|June 2008|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|June 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00702884||154102|
NCT00703131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-012|Surgisis Anal Fistula Plug Study: An Experience in Saudi Arabia|A Single-center Single Arm Prospective Study Evaluating the Surgisis Biodesign Anal Fistula Plug|SurgiSIS AFP|Cook||Completed|April 2009|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|N/A|N/A|No|Non-Probability Sample|Residents of Saudi Arabia with chronic anal fistula|February 2015|February 10, 2015|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703131||154083|
NCT00703690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-016|MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)|A Multicenter, Double-Blind, Randomized, Placebo and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of MK0767 in Patients With Metabolic Syndrome and Dyslipidemia||Merck Sharp & Dohme Corp.||Terminated|January 2002|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|436|||Both|21 Years|65 Years|No|||June 2015|June 11, 2015|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703690||154040|
NCT00703703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328A2414|Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects|A 3-way Cross-over, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess Pharmacologic Effects of a 7-day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older||Novartis||Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|117|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 1, 2012|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703703||154039|
NCT00715910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111670|The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults|Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra® in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination||GlaxoSmithKline||Completed|July 2008|October 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|818|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||September 2014|November 20, 2014|July 11, 2008|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00715910||153115|
NCT00703885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB 060407 - A|PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)|PharmacofMRI of Anxiolytic Medications (Alprazolam)||University of California, San Diego|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|16|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 20, 2008||No||No|June 19, 2013|https://clinicaltrials.gov/show/NCT00703885||154025|This is a single dose cross-over study in 16 healthy subjects.BOLD fMRI analyses for this study were not completed by the investigators.
NCT00703872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 01-2006-01|HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients|An Evaluation of Two Dose Routes of HDV-Interferon Administered With Ribavarin in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients||Hepasome Pharmaceuticals|No|Active, not recruiting|May 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2009|January 8, 2009|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00703872||154026|
NCT00705679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-003 (VOICE)|Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women|Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|5029|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|June 24, 2008|Yes|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT00705679||153891|In September 2011, the oral TDF arm was discontinued for futility; in November 2011, the TFV gel and gel placebo arms were discontinued for futility. The TDF-FTC and oral placebo arms continued follow-up until the end of study in August 2012.
NCT00706511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15870|Metabolic Study of Sleep Apnea in Men and Women|Sleep and Metabolism in Obesity: Impact of Gender||University of Chicago|Yes|Active, not recruiting|December 2007|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|No|||May 2014|May 16, 2014|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706511||153828|
NCT00702520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05783|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38833 for Org 36286 (Corifollitropin Alfa)|Care|Merck Sharp & Dohme Corp.|No|Completed|April 2006|January 2008|Actual|November 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|15|||Female|18 Years|39 Years|No|Non-Probability Sample|Women with an ongoing pregnancy at least 10 weeks after embryo transfer in Trial 38833        were enrolled in this trial.|December 2014|December 3, 2014|June 18, 2008|No|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00702520||154130|
NCT00703950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0288.0.008.000-05|Sucking Pattern of Preterm Infants Using Cup or Bottle Before Breastfeeding|Effects of the Use of a Bottle and a Cup on Breast Sucking Patterns of Premature Infants: Safety and Efficacy||Instituto Fernandes Figueira|No|Terminated|January 2008|December 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|56|||Both|29 Weeks|33 Weeks|No|||August 2015|August 10, 2015|April 2, 2008||No|Sample size was re- calculated considering sucking pattern parameters|No||https://clinicaltrials.gov/show/NCT00703950||154020|
NCT00703638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS086|Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.||Masonic Cancer Center, University of Minnesota|Yes|Completed|May 2008|November 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703638||154044|
NCT00705120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOIT|Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation|Treatment of Severe (Types II and III) Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation||St. Jude Children's Research Hospital|No|Completed|November 1995|October 2007|Actual|July 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|3 Years|N/A|No|||June 2008|June 23, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00705120||153933|
NCT00705432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05216|Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)|A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1|SPRINT-2|Merck Sharp & Dohme Corp.|Yes|Completed|August 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1472|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|June 24, 2008|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00705432||153910|
NCT00706212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-PET-2008|The Accuracy of CHOLINE PET CT in the Diagnosis of Urological Malignancies|A Comparative Study to Examine the Accuracy of CHOLINE PET CT in the Diagnosis|GS-PET-2008|Rabin Medical Center||Recruiting|June 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Rabin Medical center Urological oncology patients|May 2008|June 26, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706212||153850|
NCT00706537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5351053|Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH|A Multiple Dose, Randomized, Double-Blind (3rd Party Open), Placebo-Controlled Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of CP-945598 In Subjects With Nonalcoholic Steatohepatitis (NASH)||Pfizer|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|65 Years|No|||November 2008|August 11, 2009|June 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706537||153827|
NCT00702533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080138|A New Method for Determining Gastric Acid Output Using a Wireless Capsule|A New Method for Determining Gastric Acid Output Using a Wireless Capsule||National Institutes of Health Clinical Center (CC)||Recruiting|June 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|December 2, 2015|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00702533||154129|
NCT00703144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 300 02|Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy|Pharmacokinetics of Piperacillin and Tazobactam in Anuric Septic Patients Treated by Continuous Veno Venous Hemodiafiltration|PTCRRT|University Hospital, Toulouse|No|Completed|June 2008|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703144||154082|
NCT00703430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-IIT-12292|Memantine on Aggression and Agitation of Alzheimer's Disease (AD)|The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study||Peking University|Yes|Recruiting|March 2008|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|N/A|No|||January 2013|January 24, 2013|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703430||154060|
NCT00703105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200541|Ovarian Dendritic Cell Vaccine Trial|Defining the Role of CD4+CD25+ Immunoregulatory T-cells in the Treatment of Patients With Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies||Loyola University|No|Recruiting|October 2008|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Female|18 Years|N/A|No|||June 2014|June 5, 2014|June 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703105||154085|
NCT00703118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014842|A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment|A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Infection Who Failed Prior Standard Treatment||Tibotec BVBA|Yes|Completed|October 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|663|||Both|18 Years|70 Years|No|||December 2013|December 5, 2013|June 19, 2008|Yes|Yes||No|July 18, 2011|https://clinicaltrials.gov/show/NCT00703118||154084|
NCT00703404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908160|Response to Standard HIV Treatment in Bamako, Mali|A Cohort Observational Study to Assess the Virologic Response to Standard HIV Treatment in Bamako, Mali||National Institutes of Health Clinical Center (CC)||Completed|June 2008|February 2016||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703404||154062|
NCT00703417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes|Does Bone Structure Explain the Increased Fracture Risk in Type II Diabetes Patients? A Pilot Study|Does Bone Structure Explain the Increased Fracture Risk in Type II Diabetes Patients? A Pilot Study||University of California, San Francisco|No|Completed|May 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|40|||Female|55 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|10 healthy postmenopausal women 10 postmenopausal women with Type II Diabetes and without        fracture 10 postmenopausal women with Type II Diabetes and with fracture of the long bone        of the upper arm, hip, ankle, or foot 10 postmenopausal women with Type II Diabetes with        and without fracture|June 2011|June 6, 2011|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703417||154061|
NCT00704301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-DEL/009|Rivastigmine for Intensive Care Unit (ICU) Delirium|Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial||UMC Utrecht|Yes|Terminated|November 2008|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||October 2009|August 12, 2010|June 20, 2008||No|The study is prematurely terminated due to a safety issue|No||https://clinicaltrials.gov/show/NCT00704301||153993|
NCT00703534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00027|Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms|Validation of Patient-reported Outcomes Measures for the Assessment of GERD Symptoms and Their Subsequent Impact on Patients With Partial Response to Proton Pump Inhibitor (PPI) Treatment in a Two Part Multi-center Phase IIa Study Including a Four Week Randomised, Double-blind, Placebo-controlled, Parallel-group Treatment Period|C27|AstraZeneca|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|478|||Both|18 Years|70 Years|No|||May 2011|May 20, 2011|June 19, 2008|Yes|Yes||No|February 4, 2011|https://clinicaltrials.gov/show/NCT00703534||154052|
NCT00703547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRZ107432|A First Time in Human Study of GSK586529 in Healthy Volunteers|A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers||GlaxoSmithKline||Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|April 14, 2008||||No||https://clinicaltrials.gov/show/NCT00703547||154051|
NCT00704158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011-CLN-20|Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer|A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer||Celldex Therapeutics|No|Completed|June 2008|June 2011|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Female|18 Years|N/A|No|||February 2015|February 2, 2015|June 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00704158||154004|
NCT00704145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1087/2007|Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease|A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease|OCTAXUS|A.O. Ospedale Papa Giovanni XXIII|Yes|Completed|November 2007|November 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2010|February 5, 2010|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00704145||154005|
NCT00706186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD Xyrem|Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients|Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.|ALD|Clayton Sleep Insititute|Yes|Terminated||||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|50 Years|65 Years|No|||July 2010|July 6, 2010|June 24, 2008|No|Yes|Withdrawn by Investigator, protocol in revision|No||https://clinicaltrials.gov/show/NCT00706186||153852|
NCT00706199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111684|The Expression of Antigens in Bone Marrow Samples From Volunteering Donors.|Analysis of Expression of Antigens in Bone Marrow Samples From Volunteering Donors.||GlaxoSmithKline||Completed|July 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 1, 2009|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706199||153851|
NCT00706498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.19|Phase II Study of BI 2536 in Prostate Cancer|A Single Arm Phase II Study to Investigate the Efficacy, Safety and Pharmacokinetics of a Single Dose of 200 mg of i.v. BI 2536, Administered Once Every 3 Weeks in Patients With Advanced Metastatic Hormone-refractory Prostate Cancer.||Boehringer Ingelheim||Completed|September 2006|||February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|20|||Male|18 Years|N/A|No|||April 2014|April 30, 2014|June 24, 2008||||No||https://clinicaltrials.gov/show/NCT00706498||153829|
NCT00703079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-10|Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly|Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly: Results of a 5 Years Observational, Open, Prospective Study|GLUSSA|Federico II University|No|Completed|January 1997|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|100|Samples Without DNA|Sera from most patients on a yearly bases are stored in our freezed at minus 80° for      eventual further studies. No experimental parameters are included in the current study.|Both|18 Years|80 Years|No|Probability Sample|We will review all files from consecutive patients with active acromegaly coming to the        Units of Endocrinology or Neurosurgery of the "Federico II" University of Naples from Jan        1st 1997 to June 1st 2008, primarily treated with either surgery or depot SSA, i.e.        lanreotide (LAN) or slow-release octreotide (LAR), and with an available follow-up of at        least 60 months. Due to the study design, this is a non ran-domized study. However, our        routine procedure generally considers first-line treatment with SSA for 6-12 months,        unless the tumors are clearly non invasive on Magnetic Resonance Imaging (MRI) and/or the        patients who do not present any surgical or anesthesiological risk.|June 2008|June 20, 2008|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703079||154087|
NCT00704197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27010|"ISIS" Study of Sex Differences in Characteristics of Adiposity and Metabolism|Study of Sex Differences in Characteristics of Adiposity and Metabolism|ISIS|Pennington Biomedical Research Center|Yes|Active, not recruiting|August 2007|August 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|23|Samples With DNA|whole blood, urine, adipose tissue|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Baton Rouge|January 2016|January 22, 2016|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00704197||154001|
NCT00705692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86_3893|Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients|Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients: A Randomized Double-Blind Placebo-Controlled Trial||Shiraz University of Medical Sciences|Yes|Completed|March 2008|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|80 Years|No|||July 2013|July 24, 2013|June 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00705692||153890|
NCT00705705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070316|Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks|Targeted Social Network HIV Prevention Intervention||Medical College of Wisconsin|No|Completed|July 2004|September 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|852|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 10, 2011|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705705||153889|
NCT00705965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKSK-371|Effects of a Psychotherapy Intervention in Depressed Patients With Coronary Artery Disease|A Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease - a Randomised Controlled Trial (SPIRR-CAD)|SPIRR-CAD|University of Göttingen|Yes|Completed|November 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|570|||Both|18 Years|75 Years|No|||June 2014|June 19, 2014|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705965||153869|
NCT00706836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB 060407 - B|PharmacofMRI of Anxiolytic Medications (Pregabalin)|PharmacofMRI of Anxiolytic Medications (Pregabalin)||University of California, San Diego|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|16|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 26, 2008||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00706836||153804|
NCT00703092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB HM11246|Pilot Study:Role of Dietary Fiber in PCOS Anovulation|Pilot Study: Role of Dietary Fiber in PCOS Anovulation||Virginia Commonwealth University|Yes|Terminated|February 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|June 20, 2008||No|P.I. left University. Study terminated|No|May 27, 2014|https://clinicaltrials.gov/show/NCT00703092||154086|
NCT00702923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO07808|CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer|Phase I Dose Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer||University of Wisconsin, Madison|Yes|Terminated|July 2008|March 2013|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||April 2014|April 7, 2014|June 18, 2008|No|Yes|Enrollment was halted prematurely due to slow accrual.|No|February 24, 2014|https://clinicaltrials.gov/show/NCT00702923||154099|
NCT00703157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-CS|Surgical or Catheter Ablation of Lone Atrial Fibrillation (AF) Patients|The SCALAF Success Trial|SCALAF|Medtronic Cardiovascular|No|Active, not recruiting|November 2007|April 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703157||154081|
NCT00703170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0447|Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies|Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Resistant Solid Malignancies||Washington University School of Medicine|Yes|Completed|March 2008|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703170||154080|
NCT00703716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-06|Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX|Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX|TRAUMAX|Integra LifeSciences Services|No|Completed|May 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|190|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with a trochanteric fracture whom surgeon advised the use of a screw-plate TRAUMAX|September 2014|September 10, 2014|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703716||154038|
NCT00704015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-215|Smoking Cessation Intervention in Acute Orthopedic Surgery|Smoking Cessation Intervention in Acute Orthopedic Surgery - A Randomized Controlled Trial||Karolinska Institutet|No|Active, not recruiting|February 2004|June 2008|Anticipated|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|105|||Both|18 Years|90 Years|No|||June 2008|June 23, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704015||154015|
NCT00704028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT08020|Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia|A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in Treating Iron Deficiency Anemia||Luitpold Pharmaceuticals|Yes|Completed|June 2008|March 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|June 20, 2008|No|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00704028||154014|
NCT00704041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-41372|Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck|A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously|MAGE|University of Maryland|Yes|Recruiting|July 2009|June 2012|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||July 2009|July 8, 2009|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704041||154013|
NCT00703898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0327/3619|Durability of Nevirapine-Based Antiretroviral Regimen|Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study||Bamrasnaradura Infectious Diseases Institute|Yes|Completed|November 2004|April 2010||December 2009||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|15 Years|N/A|No|||June 2008|July 7, 2008|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703898||154024|
NCT00703911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3507|Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors|A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors|ONE|Novo Nordisk A/S|No|Completed|March 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|102|||Male|N/A|N/A|No|Non-Probability Sample|Patients with haemophilia A or B with inhibitors, using activated recombinant human factor        VII as on-demand treatment|August 2014|August 6, 2014|June 19, 2008|No|Yes||No|July 29, 2011|https://clinicaltrials.gov/show/NCT00703911||154023|
NCT00703612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adis-002|Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Type 2 Diabetics|Phase I/II Study of Intravenous Administration of Activated Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Type 2 Diabetes||Adistem Ltd|No|Active, not recruiting|November 2007|January 2009|Anticipated|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|40 Years|70 Years|No|||June 2008|June 28, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703612||154046|
NCT00703924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-9768.1|Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World|Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: a Phase 2 Study in the Old World||U.S. Army Medical Research and Materiel Command|No|Completed|March 2003|January 2005|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|5 Years|75 Years|No|||June 2015|June 5, 2015|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703924||154022|
NCT00704496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25325|The Effect of Pseudoephedrine on Rhinitis and Sleep|||Penn State University|No|Recruiting|June 2007|||September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||June 2008|June 24, 2008|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00704496||153978|
NCT00706823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0004|Comparison of I-gel to the Laryngeal Mask Airway|A Randomized Clinical Comparison of the Intersurgical I-gel and the Laryngeal Mask Airway Unique in Non-Obese Adult Patients During General Surgery|I-gel|The University of Texas Health Science Center, Houston|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2011|March 8, 2011|June 24, 2008||No||No|March 8, 2011|https://clinicaltrials.gov/show/NCT00706823||153805|
NCT00713895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA000468|Treating Chinese Smokers With Interactive Expert System|Treating Chinese Smokers With Interactive Expert System||University of California, San Francisco||Completed|August 2001|August 2005|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|363|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|July 9, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713895||153270|
NCT00714480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMG 617|Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment|Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment||Swedish Medical Center|Yes|Completed|July 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|3|||Both|18 Years|N/A|No|||August 2011|August 2, 2011|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714480||153225|
NCT00714493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013879|RESTART C0168Z05 Rheumatoid Arthritis Study|A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).||Centocor Ortho Biotech Services, L.L.C.|No|Completed|July 2008|June 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|203|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|July 10, 2008|Yes|Yes||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00714493||153224|
NCT00704808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04739|Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)|Post Marketing Surveillance of Radiotherapy With Concomitant and Adjuvant Chemotherapy With Temozolomide for Patients With Newly Diagnosed and Operated Glioblastoma Multiforme||Merck Sharp & Dohme Corp.|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed glioblastoma multiforme.|September 2015|September 8, 2015|June 23, 2008|No|Yes||No|March 17, 2010|https://clinicaltrials.gov/show/NCT00704808||153954|
NCT00714714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-5893|Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.|An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using a Split-Face Model||Valeant Pharmaceuticals International, Inc.|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|July 10, 2008|Yes|Yes||No|April 1, 2009|https://clinicaltrials.gov/show/NCT00714714||153207|
NCT00714974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU7643|A Prospective, Randomized, Blinded Study of BIS Analysis in ICU Patients Requiring Neuromuscular Blocking Agents|A Prospective, Randomized, Blinded Study of BIS Analysis in ICU Patients Requiring Neuromuscular Blocking Agents||University of Utah|No|Completed|February 2000|October 2007|Actual|February 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2008|July 8, 2008|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00714974||153187|
NCT00706550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDA-002-08S|Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects|Immune Responses to Pneumococcal Vaccination Among HIV-Infected Subjects||VA Office of Research and Development|No|Completed|October 2008|September 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|107|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|June 24, 2008||No||No|September 26, 2013|https://clinicaltrials.gov/show/NCT00706550||153826|
NCT00702819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND # 100,633|Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity|Phase 1 Trial of Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity|BLOCK-ROP|Vision Research Foundation|Yes|Terminated|June 2008|July 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|30 Weeks|36 Weeks|No|||June 2008|January 26, 2010|June 19, 2008|Yes|Yes|Low enrollment due to the stringent enrollment criteria. Unable to answer study questions|No||https://clinicaltrials.gov/show/NCT00702819||154107|
NCT00702832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 4.2007.1802|Effect of Vestibular Rehabilitation - a Randomized Controlled Trial|Effects of Vestibular Rehabilitation in the Treatment of Patients With Acute Vestibular Loss. - A Randomized Controlled Trial||Norwegian University of Science and Technology|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|70 Years|No|||April 2012|April 10, 2012|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702832||154106|
NCT00704210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBPHS 5379|Effectiveness of Mechanical Decompression for Low Back Pain Relief|Effectiveness of Mechanical Decompression for Low Back Pain Relief|SpiDERS|State University of New York - Upstate Medical University|No|Withdrawn|August 2006|July 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||October 2010|November 20, 2015|June 20, 2008||No|Study withdrawn by sponsor|No||https://clinicaltrials.gov/show/NCT00704210||154000|
NCT00703456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10866|The Effect of Balance Training on Unloading Reaction in Individuals With Functional Ankle Instability|The Effect of Balance Training on Unloading Reaction in Individuals With Functional Ankle Instability||University of Kansas Medical Center|No|Recruiting|June 2008|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|70|||Both|18 Years|45 Years|No|||February 2013|February 14, 2013|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703456||154058|
NCT00703742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kunming MC|A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression|A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression||Kunming Medical University|Yes|Completed|June 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 24, 2011|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703742||154036|
NCT00703755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEN0203|A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.|A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.||Solvay Pharmaceuticals|No|Completed|March 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|2288|||Both|18 Years|75 Years|No|||June 2008|June 24, 2008|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703755||154035|
NCT00703443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS# 2007-5577|The Genetics of Cardiomyopathy and Heart Failure|The Genetics of Cardiomyopathy and Heart Failure||University of California, Irvine|No|Active, not recruiting|April 2007|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Whole blood, Saliva, Buccal cells|Both|N/A|N/A|No|Non-Probability Sample|We are recruiting both local participants (who have been evaluated at UCI) and remote        participants (who have been referred from outside UCI) with familial and simplex cases of        hypertrophic, dilated, noncompaction, restrictive, and mitochondrial cardiomyopathies. As        a control group, we are also recruiting patients with nuclear mutations known to increase        the risk of cardiomyopathy, but who have not themselves developed cardiomyopathy.|April 2009|February 1, 2010|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703443||154059|
NCT00704054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-028|A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)|A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.||Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|1 Year|17 Years|No|||February 2015|February 12, 2015|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704054||154012|
NCT00703729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0403|Compression and Cold Therapy on the Post-Operative Shoulder|The Effectiveness of Simultaneous Intermittent Compression and Continuous Cold Therapy on the Post-Operative Shoulder: A Randomized Controlled Trial||University of Colorado, Denver|No|Completed|June 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|75 Years|No|||August 2015|August 10, 2015|June 19, 2008||No||No|July 15, 2015|https://clinicaltrials.gov/show/NCT00703729||154037|Some patients were removed from the trial due to non-compliance, most commonly for failing to complete the pain diaries.There is also some inherent recall bias in asking a patient to fill out a diary.
NCT00704340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRS-05-002|DuraSeal Sealant Post Market Study|DuraSeal Sealant Post Market Study||Integra LifeSciences Corporation|No|Completed|September 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|75 Years|No|||September 2014|September 4, 2014|June 23, 2008|Yes|Yes||No|April 26, 2010|https://clinicaltrials.gov/show/NCT00704340||153990|
NCT00704353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT08021|Safety and Tolerability of a Single Dose of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia|A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent||Luitpold Pharmaceuticals|Yes|Completed|June 2008|March 2011|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|735|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|June 20, 2008|No|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00704353||153989|
NCT00702546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05711|Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)|Follow-up Protocol to Collect the Outcome of Frozen-thawed Embryo Transfer Cycles After Cryopreservation of Embryos in Clinical Trial 107012||Merck Sharp & Dohme Corp.|No|Completed|December 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|102|||Female|18 Years|36 Years|No|Non-Probability Sample|Women from whom embryos have been cryopreserved in base study P05690|May 2015|May 4, 2015|June 18, 2008|No|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00702546||154128|
NCT00702845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05690|To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)|A Phase III, Randomized, Double-blind, Active-controlled, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 µg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference|Ensure|Merck Sharp & Dohme Corp.|No|Completed|January 2007|December 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|397|||Female|18 Years|36 Years|No|||April 2015|April 10, 2015|June 18, 2008|No|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT00702845||154105|
NCT00704509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11916A|Efficacy of Bifeprunox in Patients With Schizophrenia|A Multinational, Randomised, Double-Blind, Fixed-Dose, Bifeprunox Study Combining a 12-Week Placebo-Controlled, Quetiapine-Referenced Phase With a 12-Month Quetiapine-Controlled Phase in Patients With Schizophrenia||H. Lundbeck A/S|No|Terminated|June 2008|November 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|346|||Both|18 Years|65 Years|No|||September 2010|September 24, 2010|June 24, 2008||No|Interim analysis showed inadequate efficacy of bifeprunox|No||https://clinicaltrials.gov/show/NCT00704509||153977|
NCT00704795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-037|Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes|Glucagon Responses Following Oral Glucose and Isoglycemic iv Glucose in Patients With Type 1 Diabetes - a Role for the Gastrointestinal Tract in Diabetic Hyperglucagonemia?||University Hospital, Gentofte, Copenhagen|No|Active, not recruiting|June 2008|October 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case Control||2|Actual|20|Samples Without DNA|Plasma|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with type 1 diabetes mellitus and no residual beta-cell function (C-peptide        negative)|June 2008|June 25, 2008|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00704795||153955|
NCT00705406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-212|A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza|A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza||BioCryst Pharmaceuticals|Yes|Completed|July 2008|October 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|June 24, 2008|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00705406||153912|The majority of the subjects enrolled in this study with a laboratory confirmed influenza infection were infected with an influenza A/H1N1 virus containing an H275Y mutation associated with reduced susecptibility to peramivir and oseltamivir.
NCT00714168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|584|Evaluating the Effectiveness of a Stepped-Care Approach to Long-Term Weight Loss (The Step-Up Study)|The Effect of a Stepped-care Approach to Long-term Weight Loss|Step-Up|University of Pittsburgh|Yes|Completed|March 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|363|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|July 10, 2008||No||No|January 6, 2013|https://clinicaltrials.gov/show/NCT00714168||153249|This study was not designed to test for weight loss equivalency between conditions. This study is unable to determined if an alternative intensity or frequency of intervention steps would be more or less effective for weight loss.
NCT00714181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600329|Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Hydroxychloroquine in Combination With Temozolomide in Patients With Advanced Solid Tumors||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|June 2008|June 2013|Actual|July 2011|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|120 Years|No|||February 2016|February 17, 2016|July 11, 2008||||No||https://clinicaltrials.gov/show/NCT00714181||153248|
NCT00715000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060208|Oral Versus Intravenous Rehydration for Prevention of Dehydration in Premature Babies, During the First Days of Life.|Prevention of Dehydration in Premature Babies Between 32 and 34+6 Gestational Age, Weighing Between 1700 and 2200 g, During the First Days of Life, Using Oral Rehydration Solution in Alternative to Intravenous Infusion|SROPREMA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2008|August 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|32 Weeks|34 Weeks|No|||April 2013|April 24, 2013|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715000||153185|
NCT00714194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H41297-32404-01|Effect of Daily Interruption of Continuous Sedation on Delirium, Sleep Perception in Intensive Care Unit (ICU) Patients|The Effect of Daily Interruption of Continuous Sedation on the Occurrence of Delirium and Perception of Sleep in ICU Patients|ICUDelirium|University of California, San Francisco|Yes|Completed|July 2008|September 2009|Actual|September 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|21 Years|N/A|No|||May 2015|May 6, 2015|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00714194||153247|
NCT00714207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.32.01.12.04.A1|Evaluation of Adolescent Smoking Cessation Programs|Evaluation of Adolescent Smoking Cessation Programs||Johns Hopkins University|No|Completed|July 2002|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|407|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||July 2008|July 10, 2008|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714207||153246|
NCT00714506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07040024|Effects of a Weight Reduction and Lifestyle Program in Older Adults|Effects of a Weight Reduction and Lifestyle Program in Older Adults||University of Pittsburgh|Yes|Completed|March 2008|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|65 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714506||153223|
NCT00714519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-101-09-032|Feasibility Study of the Execution of an Efficacy Trial in the Nursing Home Setting|A Phase II Feasibility Study of Xenaderm® Ointment Exploring Design Issues for Phase III Efficacy in Partial-Thickness Wounds||Healthpoint|No|Withdrawn|July 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|July 10, 2008|Yes|Yes|The study was terminated due to the inability to enroll subjects. No subjects were or ever    will be enrolled into this study.|No||https://clinicaltrials.gov/show/NCT00714519||153222|
NCT00714532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14RT-0160H|Smoking Reduction and Cessation Interventions for Chinese|A Stage-Based Scheduled Smoking Intervention for Chinese||University of California, San Francisco|Yes|Completed|April 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 9, 2013|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714532||153221|
NCT00714727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 07-12|Set Point Acupuncture for Migraines Using a Digital Assistant|Set Point Acupuncture for Migraines Using a Digital Assistant|SPAMDA|Memorial Medical Center|No|Completed|July 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2009|July 11, 2013|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714727||153206|
NCT00715221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 07080301|Multi-Tracer Pet Quantitation of Insulin Action|Multi-Tracer Pet Quantitation of Insulin Action||University of Pittsburgh|No|Recruiting|July 2007|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Aliquotted blood samples|Both|30 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Normal volunteer sample|April 2010|April 2, 2010|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00715221||153168|
NCT00715468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ACA07|Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*|Prospective, 6 Month, Open Label, Conversion Study From MMF to MYFORTIC* Evaluating the Severity of GI Symptoms and MPA Metabolite as a Surrogate Marker of MYFORTIC||Maisonneuve-Rosemont Hospital|No|Completed|August 2007|April 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|N/A|No|Non-Probability Sample|renal transplant patients who have received a transplant at least 3 months and        experiencing Gastrointestinal symptoms|December 2014|December 11, 2014|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715468||153149|
NCT00715741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29830|Does High Intraoperative Inspired Oxygen Reduce Postoperative Arterial Oxygen Saturation?|Does High Intraoperative Inspired Oxygen Reduce Postoperative Arterial Oxygen Saturation?||University of Utah|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|100|||Both|18 Years|70 Years|No|||February 2010|February 2, 2010|July 10, 2008||No||No|August 11, 2009|https://clinicaltrials.gov/show/NCT00715741||153128|This data for this outcome measure is identical
NCT00715754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18858|Antecedents of Obesity: Fetal Measures of Adiposity|Antecedents of Obesity: Fetal Measures of Adiposity, "A Plan for Obesity Disaster Management"|FEMA|University of Utah|No|Completed|September 2006|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Both|N/A|72 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Children born at the University of Utah Hospital, whose mothers received prenatal care        also at the University of Utah Hospital.|November 2009|May 1, 2015|July 10, 2008||No||No|July 21, 2009|https://clinicaltrials.gov/show/NCT00715754||153127|
NCT00703209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW-001|Study on the Role of Decompression of Lower Extremity Nerves for the Treatment of Patients With Symptomatic Diabetic Neuropathy With Chronic Nerve Compression|Controlled, Randomized, Double-Blinded, Prospective Study On the Role of Decompression of Lower Extremity Nerves for the Treatment of Patients With Symptomatic Diabetic Neuropathy With Chronic Nerve Compression|DNND|University of Texas Southwestern Medical Center|No|Completed|January 2008|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703209||154077|
NCT00703469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1106-02|A Study of MDX-1106 to Treat Patients With Hepatitis C Infection|A Phase I, Double-blind,Multicenter,Randomized,Placebo-controlled,Safety and Pharmacokinetic Dose-escalation Study of a Single Intravenous Administration of MDX-1106, a Fully Human Monoclonal Antibody to PD-1, in Subjects With Active Hepatitis C Genotype 1 Infection|MDX1106-02|Bristol-Myers Squibb|No|Completed|October 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703469||154057|
NCT00703482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEN0205|A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes|A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes||Solvay Pharmaceuticals|No|Completed|May 2003|September 2004|Actual|September 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|278|||Both|40 Years|79 Years|No|||June 2008|June 24, 2008|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703482||154056|
NCT00704067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075291|Improving Work Outcomes for Veterans With Traumatic Brain Injury|Improving Work Outcomes for Veterans With Traumatic Brain Injury||United States Department of Defense|No|Completed|September 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00704067||154011|
NCT00703768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8664L00006|Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year|An Open-Label, Phase ll Trial Comparing FACT-P Scores For Subjects Who Are Indicated To Receive Androgen Deprivation Therapy And Have A Doubling In PSA Post Curative Therapy Of Either Less Than Or Greater Than One Year||Urology South Shore Research Inc.|No|Recruiting|June 2006|July 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|Male subjects aged 18 years or older with histologically-confirmed prostate cancer,        showing biochemical failure (defined as a rising PSA) following definitive therapy        (surgery or radiation) and indicated to receive hormone therapy.|February 2009|February 13, 2009|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703768||154034|
NCT00704327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-029|Evaluating the Impact of Cerebral Ischemic And Degenerative Changes On Cognition|Evaluating the Impact of Cerebral Ischemic And Degenerative Changes On Cognition||Lahey Clinic|No|Recruiting|February 2008|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|50 Years|N/A|No|Non-Probability Sample|Subjects identified from Neurology Department who have already undergone Cognitive Testing        and have been referred for an MRI exam|March 2016|March 15, 2016|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00704327||153991|
NCT00704366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8180C00021|AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours|A Phase I, Open-label, Dose-escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignancies||AstraZeneca|Yes|Completed|June 2008|May 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|N/A|No|||May 2011|May 13, 2011|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704366||153988|
NCT00704379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS055827|Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury|Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury||Baylor College of Medicine|No|Completed|June 2008|April 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|94|||Both|18 Years|85 Years|No|||August 2015|August 10, 2015|June 20, 2008||No||No|April 24, 2015|https://clinicaltrials.gov/show/NCT00704379||153987|
NCT00703339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREINH-IPF-201|Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|A Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis||Lung Biotechnology PBC|Yes|Terminated|June 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|35 Years|80 Years|No|||May 2012|May 10, 2012|June 19, 2008|No|Yes|Lack of enrollment to the trial. Very difficult population to recruit.|No|February 25, 2011|https://clinicaltrials.gov/show/NCT00703339||154067|Study was closed on December 31, 2009 and enrolled a total of 1 patient with complete assessment and 4 screened failures. The reason for the closure was lack of enrollment. No data will be analyzed.
NCT00703599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ad-003|Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes|Phase I/II Study of Intravenous Administration of Activated Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Type 1 Diabetes||Adistem Ltd|No|Recruiting|November 2007|December 2009|Anticipated|November 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|60 Years|No|||June 2008|June 28, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703599||154047|
NCT00705081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04276|Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)|Observational Study Evaluating the LDL-C Lowering Effects of Ezetimibe With a Statin as Prescribed in Daily Routine Practice in an Indonesian Population||Merck Sharp & Dohme Corp.|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|453|||Both|N/A|N/A|No|Non-Probability Sample|subjects with hypercholesterolemia|June 2015|June 8, 2015|June 23, 2008||No||No|March 26, 2009|https://clinicaltrials.gov/show/NCT00705081||153936|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.
NCT00705094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-24167|Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients|Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients||AHS Cancer Control Alberta|No|Completed|September 2008|July 2012|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Male|18 Years|N/A|No|Probability Sample|testicular cancer patients who have recieved surgery and are scheduled for either        chemotherapy or surveillance|September 2014|September 29, 2014|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00705094||153935|
NCT00705419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04999|Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)|COVER - Continuing Observation After Vicriviroc (VCV) Exposure Registry|COVER|Merck Sharp & Dohme Corp.|Yes|Completed|July 2007|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|180|||Both|18 Years|N/A|No|Non-Probability Sample|The registry will enroll subjects who received vicriviroc or control in a Phase 2 or 3        clinical trial (with the exception of P03802 and ACTG A5211 [and its rollover P04100]),        and are no longer receiving study medication.|February 2015|February 4, 2015|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705419||153911|
NCT00705939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-06-003|Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial|A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease||Protalix|Yes|Completed|June 2008|August 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|June 25, 2008|Yes|Yes||Yes|April 30, 2014|https://clinicaltrials.gov/show/NCT00705939||153871|
NCT00713648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13CD-1725|Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency|A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency||Novo Nordisk A/S|No|Completed|August 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|41|||Both|6 Years|N/A|No|||November 2015|November 25, 2015|July 7, 2008|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT00713648||153289|
NCT00714753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600446|Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer|Pilot Evaluation of High Dose-Rate Brachytherapy ± Image-Guided Intensity Modulated Hypofractionated External Radiotherapy for Localized Prostate Cancer||Mayo Clinic|Yes|Active, not recruiting|August 2008|||September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|142|||Male|18 Years|120 Years|No|||February 2016|February 15, 2016|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00714753||153204|
NCT00714766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heat stress RH08|Heat Stress and Volume Administration|Heat Stress and Volume Administration||Rigshospitalet, Denmark|Yes|Completed|July 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2009|February 13, 2009|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714766||153203|
NCT00715247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17793|Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes|Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes||University of Utah|No|Recruiting|July 2006|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|Whole blood and bone marrow aspirate|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients suspected to have one of the following blood disorders: polycythemia vera,        myelofibrosis or essential thrombocythemia.|March 2016|March 17, 2016|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715247||153166|
NCT00715494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070971|A Pilot Study of Rehabilitation Among Intensive Care Unit (ICU) Survivors: the RETURN Trial|Returning to Everyday Tasks Utilizing Rehabilitation Networks (RETURN)|RETURN|Vanderbilt University|Yes|Active, not recruiting|July 2008|December 2016|Anticipated|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00715494||153147|
NCT00715780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3615|Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents|Observational Safety and Efficacy Study in Subjects Using Insulin for the Treatment of Type 2 Diabetes Mellitus Failing on Oral Anti-diabetic Agents||Novo Nordisk A/S|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1667|||Both|18 Years|N/A|No|Probability Sample|Type 2 diabetic patients|August 2014|August 12, 2014|July 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715780||153125|
NCT00714987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3800|The EVLW for Set the Positive End Expiratory Pressure (PEEP) in the Acute Respiratory Distress Syndrome (ARDS)|Predictive Value of the Extra-Vascular Lung Water (EVLW) for the Alveolar Recruitment in the Acute Respiratory Distress Syndrome ( ARDS ).||University Hospital, Strasbourg, France|No|Withdrawn|January 2009|February 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|All patients mechanically ventilated, monitored with the Picco® system, hospitalized in a        medical critical care unit of an university hospital|September 2009|September 16, 2009|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00714987||153186|
NCT00715234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0763|Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients|Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients||University of Colorado, Denver|No|Completed|October 2007|September 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|4807|||Both|11 Years|18 Years|No|||June 2013|June 21, 2013|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00715234||153167|
NCT00715481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNSG-SID 0601|Renal Insufficiency And Cardiovascular Events|Reduced Estimated Glomerular Filtration Rate (eGFR)and Prediction of Cardiovascular Disease and Renal Outcome in Subjects With Type 2 Diabetes: Italian Multicenter Study|RIACE|Diabetic Nephropathy Study Group|No|Completed|June 2008|February 2015|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15628|||Both|40 Years|80 Years|No|Probability Sample|Outpatients clinics|February 2015|February 9, 2015|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00715481||153148|
NCT00712036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA R01 13636|Entry Into Comprehensive Methadone Treatment Via Interim Maintenance|Entry Into Comprehensive Methadone Treatment Via Interim Maintenance||Friends Research Institute, Inc.|Yes|Completed|June 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|230|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00712036||153412|
NCT00715767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1-5700|Basic Life Support (BLS) and Barriers to Cross-Cultural Education|Correlation of Cognitive and Technical Skills Assessment for Basic Life Support and Identification of Barriers to Cross-Cultural Education|BLSinBotswana|Children's Hospital of Philadelphia|No|Completed|January 2009|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|215|||Both|N/A|N/A|No|||October 2010|October 13, 2010|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00715767||153126|
NCT00703222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22053-CHESAT|A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells|A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma|CHESAT|Baylor College of Medicine|Yes|Active, not recruiting|June 2008|May 2024|Anticipated|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||August 2015|August 26, 2015|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703222||154076|
NCT00703495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 06/2008|Invasive and Non-Invasive Assessment of Cerebral Oxygenation in Patients With Severe Traumatic Brain Injury (TBI)|Validation of Non- Invasive Regional Transcranial Oxygen Saturation (rSO2) by Comparison With Invasive Brain Tissue Oxygenation (PbtO 2) Measurement in Patients With Severe Traumatic Brain Injury||Hospitales Universitarios Virgen del Rocío|Yes|Completed|July 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Stable patients with severe traumatic brain injury (Glasgow Coma Scale < 9) monitored        through intracranial pressure (ICP) and brain tissue partial pressure of oxygen (PbtO2)        probe, inserted for indications other than inclusion in this study|April 2009|April 3, 2009|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703495||154055|
NCT00703781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-S&E-0415081-P-ER|Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery|||Bausch & Lomb Incorporated|No|Completed|June 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|June 20, 2008|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00703781||154033|
NCT00703794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ev3-FD1942-CR00045|Researching AXIUM Coiling Experience and Recanalization (RACER)|ev3 Researching AXIUM Coiling Experience and Recanalization (RACER)|RACER|ev3|Yes|Completed|June 2008|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|N/A|No|||June 2011|March 8, 2012|June 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703794||154032|
NCT00704080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11441|A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas|A Phase 1 Dose-Escalation Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Subjects With Malignant Gliomas||Sanofi||Completed|August 2008|February 2013|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704080||154010|
NCT00704977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor471508ctil|Alcohol 20% for Separation of Pterygium and Comparison of Different Wound Closure Methods|Evaluation of Alcohol 20% for Separation of Pterygium Tissue During Pterygium Surgery and Comparison of Three Different Methods of Wound Closure in Pterygium Surgery: Bare Sclera, Sliding Flap, Amniotic Membrane With Biological Glue||Soroka University Medical Center|No|Recruiting|June 2008|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||June 2008|June 24, 2008|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00704977||153942|
NCT00704184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-007|Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)|A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Hepatitis C Infection||Merck Sharp & Dohme Corp.|Yes|Completed|July 2008|April 2010|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|95|||Both|18 Years|65 Years|No|||December 2015|December 23, 2015|June 23, 2008|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00704184||154002|
NCT00713310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007017|Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis|Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis||Warner Chilcott|No|Completed|December 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|5 Years|17 Years|No|||April 2012|April 3, 2012|July 9, 2008|Yes|Yes||No|March 6, 2012|https://clinicaltrials.gov/show/NCT00713310||153314|
NCT00705952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP4Health ("GLP-1")|Group Lifestyle Intervention for People With New Onset Type 2 Diabetes.|Effect of Intensive Lifestyle Intervention on Hormonal Factors Regulating Food Intake and Blood Glucose Control in Patients With New Onset Type 2 Diabetes.|GLP4Health|The Royal Bournemouth Hospital|No|Completed|January 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705952||153870|
NCT00713635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD1879|Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome|The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome|D1879|Columbia University|No|Active, not recruiting|December 2010|January 2016|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|51|||Both|N/A|50 Years|No|Non-Probability Sample|Study subjects will consist of mothers and infants referred to the MSCHONY for evaluation        of complex congenital heart disease consisting of: 1) single ventricle variant, such as        hypoplastic left heart (HLHS); 2) Tetralogy of Fallot; 3) Transposition of the Great        Vessels, and 4)Lung anomalies. We anticipate that 24 mothers and 24 fetuses/infants will        be enrolled during the period of study. This will give us a total of 24 women-fetus/infant        dyads or 48 subjects total (if one counts the mother and the fetus/infant separately).|February 2015|February 2, 2015|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713635||153290|
NCT00714740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1522|Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude|Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude||University of Zurich|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|49|||Both|20 Years|70 Years|No|||May 2014|May 18, 2014|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714740||153205|
NCT00715026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-300|Trilogy AB Acetabular Hip System Post Approval Study|Multicenter Post Approval Study of the Trilogy AB(R) Acetabular System||Zimmer, Inc.|No|Terminated|April 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|80 Years|No|||November 2014|November 25, 2014|July 8, 2008|Yes|Yes|Sponsor business decision unrelated to clinical performance.|No|November 13, 2013|https://clinicaltrials.gov/show/NCT00715026||153183|A business decision unrelated to device performance led to the early termination of the study and withdrawal of the study device(s) from the US market. Early termination of the study limits the usefulness of the available data.
NCT00715013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2401|Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma|Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-label Phase I/II Trial.||University of Zurich|No|Completed|July 2008|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||August 2011|September 14, 2011|November 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00715013||153184|
NCT00715260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC120-8002|An Observational Study of Pruritus Amongst Hemodialysis Patients|A Multicenter, Prospective, Observational Study of Pruritus Amongst Hemodialysis Patients: The ITCH National Registry|ITCH Registry|Acologix, Inc.|No|Active, not recruiting|December 2007|July 2008|Anticipated|July 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients on thrice-weekly (or more frequent) maintenance hemodialysis who have Uremic        Pruritus|July 2008|July 14, 2008|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00715260||153165|
NCT00715507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10599|Evaluation of Drug Display in Critical Care Setting|Evaluation of Drug Display in Critical Care Setting||University of Utah|Yes|Active, not recruiting|July 2003|January 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Board certified attending anesthesiologists at the University of Utah Health Sciences        Center and supervised anesthesiology residents|June 2012|June 18, 2012|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715507||153146|
NCT00715793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 07-008|Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma|Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma|UPCI-07-008|University of Pittsburgh|Yes|Completed|June 2008|August 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|June 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715793||153124|
NCT00711763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-048|Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants|Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants||Louisiana State University Health Sciences Center Shreveport|No|Suspended|July 2008|September 2011|Anticipated|April 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|9 Months|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited from the NICU at (LSUHSC) after obtaining parental consent.|April 2011|May 4, 2011|July 3, 2008||No|failure to recruit more patients and lack of supporting personnel.|No||https://clinicaltrials.gov/show/NCT00711763||153433|
NCT00711776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZVC111449|Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers|Bioequivalence Study of Aciclovir 5% Cream - Bioequivalence Study of Aciclovir Cream Between Current and New Formulation in Japanese Healthy Volunteers -||GlaxoSmithKline|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711776||153432|
NCT00712049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0-2007|Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)|Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial|NASCIT|Medical University of Vienna|No|Recruiting|June 2008|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00712049||153411|
NCT00712309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAP Protocol 2.0|Endovascular Treatment of Popliteal Artery - Balloon Angioplasty Versus Primary Stenting|Endovascular Treatment of Atherosclerotic Popliteal Artery Lesions - Balloon Angioplasty Versus Primary Stenting|ETAP|Herz-Zentrums Bad Krozingen|Yes|Recruiting|February 2007|||June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|80 Years|No|||February 2009|February 9, 2009|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712309||153391|
NCT00712322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDAR328B2201|2 Week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Yrs) With Neurogenic Detrusor Overactivity|A 14-day, Open-label, Multicenter, Dose-escalating, Sequential Cohort Study to Evaluate Pharmacodynamics (Urodynamics) and Pharmacokinetics, Clinical Efficacy, Tolerability and Safety, Following Multiple Doses (mg/kg/Day) of Darifenacin Liquid Oral Suspension Given b.i.d. (Twice Daily) in Children, Ages 2 - 15 Years, With Neurogenic Detrusor Overactivity||Warner Chilcott|Yes|Suspended|October 2008|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|9|||Both|2 Years|15 Years|No|||January 2015|January 22, 2015|July 3, 2008|Yes|Yes|Due to extremely difficult enrollment.|No||https://clinicaltrials.gov/show/NCT00712322||153390|
NCT00703807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804003747|Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers|A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers||Yale University|No|Completed|December 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||January 2014|January 13, 2014|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703807||154031|
NCT00703820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML08|Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia|AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia||St. Jude Children's Research Hospital|Yes|Recruiting|August 2008|August 2019|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|N/A|21 Years|No|||October 2015|October 30, 2015|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703820||154030|
NCT00703833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0777-019|A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)|A Double-Blind, Multicenter, Placebo-Controlled Study of MK0777 Gel Extrusion Module (GEM) 1.5 mg b.i.d. in the Treatment of Outpatients With Generalized Anxiety Disorder||Merck Sharp & Dohme Corp.||Completed|September 2002|February 2003|Actual|February 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|June 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703833||154029|
NCT00704106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHF008|Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders|HBV Viral Suppression by Entecavir in Adefovir Partial Responders|ADVPR|Pacific Health Foundation|No|Active, not recruiting|May 2008|December 2013|Anticipated|||N/A|Observational|Observational Model: Cohort||4|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|-  Age 18 years or older          -  All genders and ethnicity          -  Positive HBsAg          -  HBeAg positive and negative          -  Pretreatment HBV DNA of 10,000 copies/mL or higher (for purposes of this study, both             copies and equivalent IU measurements will be recorded and analyzed)          -  Patients who are switched to, or prescribed, entecavir after treatment with adefovir             for at least 12 weeks by the providing physician          -  Patients with and without prior lamivudine exposure will be enrolled but enrollment             of lamivudine experienced cases will be limited to no more than 30 patients total|May 2012|May 8, 2012|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00704106||154008|
NCT00704392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL647-003|Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors||Exelixis||Withdrawn|June 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|June 20, 2008|No|Yes|Study not initiated|No||https://clinicaltrials.gov/show/NCT00704392||153986|
NCT00704405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-009|Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)|A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Experienced Patients With Chronic Genotype 1 Hepatitis C Virus Infection||Merck Sharp & Dohme Corp.|Yes|Completed|March 2009|September 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|285|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|June 23, 2008|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00704405||153985|
NCT00704093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2442007§149|The Effect of Right Ventricular Pacing on Myocardial Oxidative Metabolism and Efficiency|The Effect of Right Ventricular Pacing on Myocardial Oxidative Metabolism and Efficiency||University of Turku|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||July 2008|July 3, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704093||154009|
NCT00704990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCNM-083-ADHD|Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD)|The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder: A Pilot Study||The Canadian College of Naturopathic Medicine|Yes|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|6 Years|12 Years|No|||October 2015|October 15, 2015|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00704990||153941|
NCT00713063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603-01|Behavioral Exercise Intervention for Smoking Cessation|Behavioral Exercise Intervention for Smoking Cessation||Butler Hospital|No|Completed|April 2006|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||January 2015|January 29, 2015|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713063||153333|
NCT00713076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-18|Wettability of Contact Lenses With a Multi-Purpose Solution|||Alcon Research|No|Completed|October 2007|||March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|August 18, 2014|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00713076||153332|
NCT00713323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCL0404 Part A|A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.|A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex® in the Treatment of Subjects With Neuropathic Pain. This Will be Followed by a Randomised-withdrawal Phase (Part B) for a Subset of Patients.||GW Pharmaceuticals Ltd.|No|Completed|October 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|380|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|July 10, 2008||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00713323||153313|
NCT00713882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0802009649|Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors|Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors||Weill Medical College of Cornell University|No|Completed|April 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be identified via physician referral at Weill Cornell Medical College,        Hematology-Oncology outpatient clinic, or self-referral.|March 2009|March 10, 2009|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713882||153271|
NCT00713336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00017|Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval|A Phase I, Double-blind, Double-dummy, Placebo-controlled, Randomised, Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years.||AstraZeneca|No|Completed|June 2008|November 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 27, 2010|July 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00713336||153312|
NCT00714558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003253|Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers|Pharmacokinetics of Fentanyl Citrate Following Intravenous (i.v.) and Oral Routes of Administration in Healthy Subjects||Alza Corporation, DE, USA||Completed|April 2003|May 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|May 18, 2011|July 10, 2008||||||https://clinicaltrials.gov/show/NCT00714558||153219|
NCT00715832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QI-Breast Vaccine 1|A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer|A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer||Southern Cancer Center|Yes|Recruiting|May 2008|February 2015|Anticipated|February 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|85 Years|No|||August 2009|August 25, 2009|July 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715832||153121|
NCT00715273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|587|Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication|Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy|CPC|University of Washington|Yes|Active, not recruiting|June 2001|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|217|||Both|21 Years|70 Years|No|||December 2015|December 1, 2015|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715273||153164|
NCT00715806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/020/08|Claustrophobia and Magnetic Resonance Imaging|Reduction of Claustrophobia During Magnetic Resonance Imaging: Randomized, Controlled Trial|CLAUSTRO|Charite University, Berlin, Germany|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|174|||Both|18 Years|N/A|No|||November 2009|June 21, 2011|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00715806||153123|
NCT00715819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07092008-1245|Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma|Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma||Stanford University||Recruiting|April 2008|||December 2009|Anticipated|N/A|Observational|Time Perspective: Prospective|||Anticipated|30|||Both|N/A|N/A|No|||February 2009|February 17, 2009|July 11, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00715819||153122|
NCT00711802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-017|Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections|An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens||Cubist Pharmaceuticals LLC|No|Completed|July 2008|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|396|||Both|1 Year|17 Years|No|||January 2016|January 5, 2016|July 7, 2008|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00711802||153430|
NCT00711789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNH 23/08|Angiotensin in Septic Kidney Injury Trial|A Pilot Crossover Randomised Controlled Trial of Angiotensin II in Critically Ill Patients With Severe Sepsis and Acute Renal Failure|ASK-IT|Austin Health|No|Recruiting|February 2010|||February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2009|June 22, 2011|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711789||153431|
NCT00712062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCNSL-001|Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma|Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria||University of Florida|Yes|Withdrawn|February 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|July 3, 2008|Yes|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00712062||153410|
NCT00712335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MASK2008|The Effects of Montelukast on Smokers With Asthma|The Effects of Montelukast on Sputum Cells and Inflammatory Markers in Smokers With Asthma||Inje University|Yes|Completed|February 2007|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|5||Actual|105|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|July 7, 2008|Yes|Yes||No|November 16, 2011|https://clinicaltrials.gov/show/NCT00712335||153389|It is difficult attaining representative gender ratios (i.e., representative of the general population) when conducting a smoking study in Korea, as smoking by females is still considered culturally taboo.
NCT00704119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 5002|Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation|CT 5002 An Open-label, Non-randomized, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® Using a Tablet Formulation||MediGene|Yes|Terminated|May 2008|August 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2010|March 23, 2010|June 23, 2008||No|Following an SAE, study was put on hold. After performing preclinical follow-up studies,    volunteers were no longer available for continuation.|No||https://clinicaltrials.gov/show/NCT00704119||154007|
NCT00704418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-S&E-0415081-P-WR|Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery|||Bausch & Lomb Incorporated|No|Completed|June 2008|December 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|June 20, 2008|Yes|Yes||No|November 15, 2010|https://clinicaltrials.gov/show/NCT00704418||153984|
NCT00704431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPL111814|A Study With Darapladib to Collect Tolerability Information|An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00704431||153983|
NCT00704717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04301|Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)|Evaluation of Satisfaction in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C||Merck Sharp & Dohme Corp.|No|Completed|September 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|185|||Both|N/A|N/A|No|Probability Sample|Patients with hepatitis C under treatment with PegIntron Pen plus Rebetol therapy at        approximately 70 sites in Romania.|April 2015|April 8, 2015|June 23, 2008||No||No|February 11, 2009|https://clinicaltrials.gov/show/NCT00704717||153961|
NCT00704691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F071108004|Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas|Open-Label, One Arm Pilot Investigation of Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas||University of Alabama at Birmingham|Yes|Terminated|June 2008|December 2009|Actual|July 2009|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|19 Years|N/A|No|||April 2012|April 18, 2012|June 21, 2008|No|Yes|Closed due to futility with only 1 patient accrued|No||https://clinicaltrials.gov/show/NCT00704691||153963|
NCT00704704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-MM-TLV-0069-08-CTIL|Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)|A Phase 2, Single Arm Study to Determine the Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk Myelodysplastic Syndrome|IMDS001|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2008|April 2011|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2008|June 24, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704704||153962|
NCT00709982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002380|A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) /Ethinyl Estradiol (EE) in Healthy Women.|An Open-label Pharmacokinetic Drug Interaction Study of Folic Acid and 250 Mcg NGM/35 Mcg EE (ORTHO-CYCLEN) in Healthy Women..||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2005|July 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|47|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|June 6, 2011|June 30, 2008||||||https://clinicaltrials.gov/show/NCT00709982||153568|
NCT00709995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11531|A Study for Participants With Metastatic Renal Cell Carcinoma|Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma||Eli Lilly and Company|No|Active, not recruiting|June 2008|December 2015|Anticipated|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709995||153567|
NCT00712777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-230408|Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism|Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism||Medical University of Vienna|Yes|Withdrawn|March 2008|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712777||153355|
NCT00714220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-16684|Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)|Quantitative Measurement of Nutritional Substrate Utilization in Patients With ALS||Drexel University|No|Terminated|November 2006|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|107|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope.|October 2015|October 28, 2015|July 10, 2008||No|Lack of funding and support staff.|No||https://clinicaltrials.gov/show/NCT00714220||153245|
NCT00714545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004408|SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents|Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V||Scripps Health|Yes|Recruiting|April 2006|December 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714545||153220|
NCT00714779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK123|Fluoxetine vs. Brief Psychotherapy for Major Depression|Fluoxetine vs. Brief Psychotherapy in the Treatment of Major Depression - a Randomized Comparative Study||University of Turku|No|Completed|January 2000|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|20 Years|60 Years|No|||July 2008|July 7, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00714779||153202|
NCT00714792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23123|Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?|Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?||University of Rochester|No|Recruiting|June 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Urine specimen|Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Urogynecology clinic|June 2009|June 10, 2009|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714792||153201|
NCT00709761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT111111|Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC|LPT 111111- A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE®) and Lapatinib (TYKERB®) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer||GlaxoSmithKline|No|Active, not recruiting|July 2008|June 2016|Anticipated|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||January 2016|February 1, 2016|July 1, 2008|Yes|Yes||No|October 13, 2011|https://clinicaltrials.gov/show/NCT00709761||153584|
NCT00709774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPaS-SvA|Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block|Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block||Osaka General Medical Center||Not yet recruiting|July 2008|||June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|N/A|No|||June 2008|July 2, 2008|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709774||153583|
NCT00708617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OST07008|FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease|Non Invasive Diagnostic Methods for Fibrosis in Alcoholic Liver Disease : FIBROSCAN Validation and Comparison of Fibrotest - FIBROSCAN Association With FIBROSCAN Alone|FIBROMAF|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|227|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with Alcoholic Liver Disease|January 2014|January 22, 2014|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00708617||153671|
NCT00708630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPKF001|The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination|The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination||University of Auckland, New Zealand|No|Completed|June 2008|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 26, 2012|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708630||153670|
NCT00710333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0093|Safety of Juvista When Administered Following Excision of Ear Lobe Keloids|A Single-centre, Double Blind, Randomised, Tolerance Study to Investigate the Safety of Juvista 500ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids.|RN1001-0093|Renovo|No|Completed|July 2008|December 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|85 Years|No|||March 2010|March 8, 2010|July 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00710333||153541|
NCT00700557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|changeme-12332111|Probiotics at the Treatment of Antibiotic Associated Diarrhea|Lactobacillus Casei e Bifidobacterium Breve as Probiotics at the Treatment of Antibiotic Associated Diarrhea: a Randomized Double Blind Study||Federal University of Uberlandia|Yes|Completed|October 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2009|August 24, 2009|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00700557||154279|
NCT00700869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070204|Evaluation of a New Mechanical Ventilation Weaning Strategy for Patients With Altered Level of Consciousness|Phase 2 Study of a New Mechanical Ventilation Weaning Strategy Governs by a Respiratory Behaviour Status Assessment for Patients With Altered Level of Consciousness|ORGAR|Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2008|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||September 2011|October 4, 2011|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00700869||154255|
NCT00701129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03807|An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease|An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme®-Naive, CRIM(-) Patients With Infantile-onset Pompe Disease||Sanofi|Yes|Completed|October 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|No|||April 2014|April 9, 2014|June 17, 2008|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT00701129||154236|Due to the small number of patients assessed in this study the results must be interpreted with caution.
NCT00701155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1953|Observational Study to Evaluate the Safety While Using Levemir®|Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3593|||Both|N/A|N/A|No|Non-Probability Sample|Type 1 or 2 diabetes patients|February 2016|February 18, 2016|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701155||154234|
NCT00701415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL06207|A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms|A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms|FIELD|Sanofi|Yes|Completed|September 2008|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Male|5 Years|18 Years|No|||October 2015|October 16, 2015|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00701415||154214|
NCT00708747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2340|Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients|Biseko Versus Albumin in the Treatment of High Risk Patients With Systemic Inflammatory Response Syndrome - a Randomized Controlled Trial||Medical University of Vienna|No|Completed|July 1996|September 2003|Actual|June 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||July 2008|July 1, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00708747||153661|
NCT00710268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00022|Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours|A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin®) In Patients With Advanced Solid Tumours||AstraZeneca|Yes|Completed|June 2008|November 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00710268||153546|
NCT00710515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00020|Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies|A Phase I, Open-Label Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|July 2008|June 2010|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|July 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00710515||153527|
NCT00707759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fondecyt1080166|Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection|Multicenter, Open-Label, Randomized Study on Steroid-Free Immunosuppression, in Comparison With Daily Steroid Therapy, in Pediatric Renal Transplant : Impact on Growth, Bone Metabolism and Acute Rejection||Fondo Nacional de Desarrollo Científico y Tecnológico, Chile|Yes|Completed|June 2008|December 2014|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|1 Year|16 Years|No|||October 2015|October 13, 2015|June 26, 2008||No||No|October 13, 2015|https://clinicaltrials.gov/show/NCT00707759||153737|
NCT00708045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI21946|A Multi-modality Imaging Assessment of Chemobrain|A Multi-modality Imaging Assessment of Chemobrain|Chemobrain|University of Utah|Yes|Active, not recruiting|May 2007|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708045||153715|
NCT00708331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EyeKon SC25-FOLD|Hydrophilic Acrylic Intraocular Lens|SC25-FOLD Hydrophilic Acrylic Intraocular Lens||EyeKon Medical, Inc.|Yes|Active, not recruiting|August 2002|||May 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|354|||Both|18 Years|N/A|No|||July 2008|July 1, 2008|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708331||153693|
NCT00708344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBEH_R_02931|ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination|Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination: A Comparison of Active and Usual Titration Regimen in the Treatment of Hypertensive Patients Insufficiently Controlled by Monotherapy|ACTUAL|Sanofi|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|832|||Both|18 Years|N/A|No|||July 2010|July 15, 2010|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708344||153692|
NCT00707070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gisondi 2|Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis|Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis|CobAcE|Universita di Verona|No|Not yet recruiting|September 2008|October 2009|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2008|June 27, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707070||153786|
NCT00707382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0056|Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment|A Three-armed Randomised Controled Trial on the Effect of Genotyping for CYP450 Polymorphisms and Intense Clinical Monitoring on Antipsychotic Drug Treatment.||Bispebjerg Hospital|No|Completed|February 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|311|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707382||153764|
NCT00707408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 03/3-B|High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)|A Phase II Trial Evaluating the Safety and the Efficacy of High-Dose Imatinib in Relapsed/Refractory c-Kit Positive and BCR-Abl Negative AML Patients||Nantes University Hospital|No|Completed|February 2004|January 2009|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|90 Years|No|||January 2009|January 30, 2009|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707408||153763|
NCT00707746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012-CS19|Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects|A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of ISIS 301012 Administration in High Risk Statin Intolerant Subjects|ASSIST|Sanofi|No|Completed|October 2008|January 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|June 27, 2008|Yes|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT00707746||153738|
NCT00708032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0806|Clinical Performance of a New Daily Disposable Contact Lens Worn in a Neophyte Population.|Clinical Performance of a New Daily Disposable Contact Lens Worn in a Neophyte Population.||Johnson & Johnson Vision Care, Inc.|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|June 27, 2008|Yes|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00708032||153716|
NCT00708305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3508570|Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes|Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes||GlaxoSmithKline|No|Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|65|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|July 1, 2008|Yes|Yes||No|September 14, 2010|https://clinicaltrials.gov/show/NCT00708305||153695|
NCT00708318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEF-2494|Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects|A Pilot, Phase I, 2-Period, Fasting, Bioavailability, Safety and PK Study Evaluating A Single Dose Intravenous Fentanyl 200 µg) and Single Doses of 2 or 3 mL AeroLEF (Liposome-Encapsulated Fentanyl 500 µg/mL) in Normal Healthy Non Subjects||YM BioSciences|No|Completed|October 2001|June 2002|Actual|November 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 1, 2008|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00708318||153694|
NCT00710073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK99_06|Sono-Electro-Magnetic Therapy for Refractory Chronic Pelvic Pain Syndrome|Sono-Electro-Magnetic Therapy for the Treatment of Chronic Pelvic Pain Syndrome: A Pilot Study||University Hospital Inselspital, Berne|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||July 2008|July 2, 2008|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710073||153561|
NCT00710086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJFY-08021MZ|Intravenous Remifentanil for Labor Analgesia|Remifentanil Intravenous Patient-controlled Labor Analgesia for Nulliparous Women|IRELAN|Nanjing Medical University|Yes|Completed|July 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1000|||Female|18 Years|45 Years|No|||September 2009|September 17, 2009|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710086||153560|
NCT00710346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080170|Establishment of Fibroid Tissue Bank|Establishment of a Fibroid Tissue Bank||National Institutes of Health Clinical Center (CC)||Completed|June 2008|||||N/A|Observational|Time Perspective: Prospective|||Actual|43|||Female|21 Years|80 Years|No|||November 2015|November 24, 2015|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00710346||153540|
NCT00710034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01 CA135884-2|Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine|Oral Tobacco as a Harm Reduction Product: Study 2 - Efficacy of Oral Tobacco Products Compared to Medicinal Nicotine for Smoking Cessation and Among Non-abstainers, for Reduction in Cigarette Smoking||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|April 2010|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|390|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710034||153564|
NCT00710047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00028|Food Effect Study of a Single Dose of ZD4054 (Zibotentan)|A Randomised, Open-label, Single-centre, Crossover Study in Healthy Male Volunteers to Assess the Effect of Food on the Pharmacokinetics of a 10 mg Single Oral Dose of ZD4054 (Zibotentan)||AstraZeneca|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 10, 2010|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00710047||153563|
NCT00710060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10MH061537|Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations|NIMH Collaborative HIV/STD Prevention Trial||RTI International|Yes|Completed|September 2002|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18147|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2008|November 1, 2013|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00710060||153562|
NCT00710866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAC 6273-15-2008/4160872|Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity||TITRE|British Columbia Centre for Disease Control|Yes|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|262|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||July 2011|July 11, 2011|July 7, 2008||No||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00710866||153500|
NCT00699998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11058|A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects|A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed|TRILOGY ACS|Eli Lilly and Company|Yes|Completed|June 2008|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9326|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|June 16, 2008|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00699998||154322|
NCT00700271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489AFR01|Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day|Efficacy of a Combination of Amlodipine / Valsartan on Blood Pressure Control, With One Nocturnal or Diurnal Intake a Day, in Ambulatory Blood Pressure Monitoring Setting, in Essential Uncontrolled Hypertensive Patients With Amlodipine 5mg ; The ExPERT Study||Novartis|No|Completed|October 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|478|||Both|18 Years|N/A|No|||May 2011|May 16, 2011|December 11, 2007||No||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00700271||154301|
NCT00700570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21209|A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer|An Open Label Study to Assess the Resection Rate of Liver Metastases Following Neoadjuvant Therapy With Avastin in Combination With Oxaliplatin and Capecitabine (XELOX) in Patients With Metastatic Colorectal Cancer With Unresectable Liver Metastasis||Hoffmann-La Roche||Completed|August 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|N/A|75 Years|No|||February 2016|February 1, 2016|June 17, 2008||No||No|August 19, 2015|https://clinicaltrials.gov/show/NCT00700570||154278|
NCT00700882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598300|Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery|A Phase II Trial of Dasatinib in Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas||Eastern Cooperative Oncology Group|No|Recruiting|May 2009|||March 2017|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|87|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|June 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00700882||154254|
NCT00701142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1470|Haemocomplettan® P During Aortic Replacement|Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery||CSL Behring|No|Completed|June 2008|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2011|September 18, 2013|June 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701142||154235|
NCT00701428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGSKAS-12916|Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment|Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment|LosartanPAP|Skaraborg Hospital|Yes|Completed|June 2008|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|50 Years|69 Years|No|||November 2014|November 17, 2014|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00701428||154213|
NCT00709332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002206|A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) in Healthy Women.|An Open-label Pharmacokinetic Drug Interaction Study of Folic Acid and 250 Mcg NGM/35 Mcg E E (ORTHO-CYCLEN) in Healthy Women.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2005|February 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|47|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|June 6, 2011|June 30, 2008||||||https://clinicaltrials.gov/show/NCT00709332||153617|
NCT00710528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-02|Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies|A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies||Gilead Sciences|No|Completed|June 2008|August 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00710528||153526|
NCT00708058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0089|Use of Defibrillator Information in the Emergency Department|Can Pacemakers, Defibrillators, and Internal Heart Failure Devices Be Used to Evaluate and Guide Management in the Emergency Department?||Ohio State University|No|Completed|August 2007|March 2010|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|All patients aged 18 or older who present to The Ohio State University Medical Center        Emergency Department for any reason, and who have an implanted Medtronic cardiac        defibrillator present|March 2012|March 19, 2012|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708058||153714|
NCT00708071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550703|Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures|An Exploratory Phase 2 Clinical Study to Evaluate Efficacy and Safety of the Adjuvant Use of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) in Subjects Undergoing Rhytidectomy||Baxter Healthcare Corporation|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|June 30, 2008|Yes|Yes||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00708071||153713|
NCT00708357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-311004|Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?|Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?||Medical University of Vienna||Terminated|May 2005|January 2013|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|12|||Male|19 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00708357||153691|
NCT00708370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581162|A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.|An Outcome Research on the Impact of a Disease Management Program (COACH) on the Attainment of Better Cardiovascular Risk Control in Dyslipidemic Patients at Primary Care Centers (DISSEMINATE).|DISSEMINATE|Pfizer|No|Completed|August 2008|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|297|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708370||153690|
NCT00708643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0803|Clinical Performance of a New Daily Disposable Contact Lens Worn in an Established Contact Lens Wearing Population|||Johnson & Johnson Vision Care, Inc.||Completed|June 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|17 Years|N/A|No|||May 2015|May 5, 2015|June 27, 2008|Yes|Yes||No|November 1, 2010|https://clinicaltrials.gov/show/NCT00708643||153669|
NCT00708656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAW0105|The Colitis Once Daily Asacol Study|A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.|CODA|Cardiff and Vale University Health Board|Yes|Completed|October 2006|September 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|No|||September 2010|September 16, 2010|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00708656||153668|
NCT00708981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metabolism IST|Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)|Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)||John H. Stroger Hospital|Yes|Completed|May 2007|December 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||September 2014|September 30, 2014|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708981||153644|
NCT00708994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803003638|Cannabinoids, Neural Synchrony, and Information Processing|Cannabinoids, Psychosis, Neural Synchrony, and Information Processing|THC-Gamma|Yale University||Recruiting|April 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|July 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708994||153643|
NCT00709241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051044|Psychosocial Patterns and Prognosis in Patients With Heart Failure|Prognostic Value of Negative Affectivity in Patients With Heart Failure|PANIC|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|325|Samples Without DNA|serum, urine.|Both|18 Years|N/A|No|Non-Probability Sample|heart failure patients|October 2014|October 22, 2014|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00709241||153624|
NCT00709254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEF-2495|Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects|Phase I, 3-Period, Fasting, Bioavailability, Safety Assessment and PK Study Evaluating Single Dose Administration of i.v. Fentanyl (200 µg) and Single and Multiple Doses of 3 mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 µg/mL) Administered in Normal Healthy Subjects|LEF-2495|YM BioSciences|No|Completed|December 2001|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 2, 2008|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709254||153623|
NCT00709527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH2000|ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration|A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability AND Pharmacokinetic Profile Of Multiple Intravitreous Injections Of ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Multiple Doses Of Lucentis® 0.5 mg/Eye, Or With One Induction Dose Of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration||Ophthotech Corporation||Completed|July 2008|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|50 Years|N/A|No|||June 2012|June 14, 2012|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709527||153602|
NCT00709540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A011-02|A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women||Acceleron Pharma, Inc.|Yes|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Female|45 Years|85 Years|No|||December 2008|December 8, 2008|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709540||153601|
NCT00710619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1965|Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX|Dosing Observational Study in Hemophilia Subjects With Inhibitors: A Phase IV Diary Study in Subjects Prescribed NovoSeven® as First Line on Demand Therapy for Acute Bleeding Episodes|DOSE|Novo Nordisk A/S|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Male|N/A|N/A|No|Non-Probability Sample|Male subjects with congenital haemophilia A or B with inhibitors with spontaneous bleeds        requiring on-demand treatment|August 2012|August 30, 2012|July 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00710619||153519|
NCT00710879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|568|Evaluation of a Multi-Purpose Solution|A Study to Evaluate the Clinical Performance of a Multi-Purpose Solution.||Bausch & Lomb Incorporated|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|June 30, 2008|Yes|Yes||No|January 14, 2011|https://clinicaltrials.gov/show/NCT00710879||153499|
NCT00710892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21580-CASPALLO|CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene|CASPALLO: A Phase I Study Evaluating the Use of Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation|CASPALLO|Baylor College of Medicine|Yes|Active, not recruiting|December 2008|July 2026|Anticipated|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|65 Years|No|||February 2016|February 1, 2016|July 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00710892||153498|
NCT00711191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5021005|A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas|A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer||Hoffmann-La Roche|No|Completed|June 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|June 26, 2008|No|Yes||No|May 3, 2012|https://clinicaltrials.gov/show/NCT00711191||153476|
NCT00711204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-417|Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease|A 12-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease||Eisai Inc.||Withdrawn|January 2008|||June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||December 2012|December 6, 2012|January 21, 2008|Yes|Yes|No patients were enrolled in the study.|No||https://clinicaltrials.gov/show/NCT00711204||153475|
NCT00710580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-315|Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis||AbbVie|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|350|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|July 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00710580||153522|
NCT00710593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 064|Impact of an HPV Vaccine in HIV-Infected Young Women|Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|99|||Female|16 Years|23 Years|No|||October 2012|October 26, 2012|July 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00710593||153521|
NCT00710606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC8127|Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®|Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®||Columbia University|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|July 1, 2008||No||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00710606||153520|
NCT00702871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403(7)/04MC(ACA)/Protocol/3499|A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia|A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study||Maulana Azad Medical College|No|Completed|March 2005|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|13 Years|N/A|No|||June 2008|June 19, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702871||154103|
NCT00700583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mccho|Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men|Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men With LUTS: a Pilot Study||Seoul National University Hospital||Completed|May 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Male|N/A|N/A|No|||May 2011|May 9, 2011|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00700583||154277|
NCT00700895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG01/11/06|Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose|A Randomized Controlled Trial to Assess the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regimen for Calculating Warfarin Maintenance Dose||National University Hospital, Singapore|Yes|Recruiting|August 2006|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00700895||154253|
NCT00701168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJCC 07-04|Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer|A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006||Leo W. Jenkins Cancer Center||No longer available||||||N/A|Expanded Access|N/A|||||||Both|19 Years|N/A||||October 2010|October 4, 2010|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00701168||154233|
NCT00708435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE1116_3002|Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy|An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Coumarin Derivatives in Subjects With Acute Major Bleeding||CSL Behring||Completed|June 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||September 2013|January 1, 2014|July 1, 2008|Yes|Yes||No|June 7, 2013|https://clinicaltrials.gov/show/NCT00708435||153685|
NCT00709072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10483|Follow-up of Children After Stuttering Treatment|Relapse Following the Lidcombe Program for Preschool Children Who Stutter||University of Sydney|No|Recruiting|February 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|3 Years|7 Years|No|||June 2009|April 22, 2010|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709072||153637|
NCT00709319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-125|Evaluation of Vitrectomy for Diabetic Macular Edema|Evaluation of Vitrectomy for Diabetic Macular Edema Study|Vitrectomy-D|Diabetic Retinopathy Clinical Research Network|No|Completed|July 2005|February 2009|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|N/A|No|Non-Probability Sample|adults with diabetic macular edema|February 2012|February 16, 2012|July 1, 2008||No||No|July 27, 2011|https://clinicaltrials.gov/show/NCT00709319||153618|
NCT00709865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160HF301|Phase 2b Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Tolerability of Intravenous Tonapofylline in Subjects With Acute Decompensated Heart Failure and Renal Insufficiency|TRIDENT-1|Biogen|Yes|Completed|July 2008|December 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|420|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709865||153576|
NCT00710177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/92, GC 49|PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn|Prostaglandin G/H Synthase-1 (PTGS1) Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN)|PPHN|Medical College of Wisconsin|No|Recruiting|January 2006|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|whole blood, meconium|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and        normal, healthy infants born greater than or equal to 34 weeks gestational age.|September 2015|September 1, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710177||153553|
NCT00710814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6692|Trial of Leptin Administration After Roux-en-Y Gastric Bypass|Effects of Leptin on Body Weight and Neuroendocrine Axes After Gastric Bypass||Columbia University|Yes|Completed|April 2008|July 2014|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Female|25 Years|65 Years|No|||October 2015|October 16, 2015|July 1, 2008|Yes|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT00710814||153504|
NCT00708695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0616|Age-17 Follow-up of Home Visiting Intervention|Age-17 Follow-up of Home Visiting Intervention|MemphisY17|University of Colorado, Denver|Yes|Completed|May 2008|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1138|Samples With DNA|Spit samples will be taken.|Both|17 Years|65 Years|No|Probability Sample|The Memphis trial was designed to test the effects of the program with a large sample of        very low-income African-Americans living in a major urban area, when the program was        administered through a local health department, and the program developers had limited        involvement in its implementation. In this trial, 1,139 low-income pregnant women (98%        unmarried, 67% <19 years old, 92% African-American) were randomly assigned to experimental        or comparison services; 743 were followed after delivery. The sample has resided in        extraordinarily stressful neighborhoods and has endured extreme poverty. At registration,        the mean level of neighborhood disorganization (assessed by census tract data at the block        group and using the Lauritsen scale) was 3.43 SD above the national mean, i.e., the        average level of adversity in the sample neighborhoods was among the worst in the nation        (in the top 1000th). 85% of the sample had incomes below the federal poverty guidelines.|March 2016|March 1, 2016|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708695||153665|
NCT00709033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22899-ATECRAB|T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL|Phase I Study Of The Administration Of Peripheral Activated T-Cells and EBV Specific CTLs Expressing CD19 Chimeric Receptors For Advanced B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia (ATECRAB)|ATECRAB|Baylor College of Medicine|Yes|Active, not recruiting|July 2009|April 2027|Anticipated|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||December 2015|January 12, 2016|July 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709033||153640|
NCT00708669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-DESsERT®, version 1.6|Japan-Drug Eluting Stents Evaluation; a Randomized Trial|A Japanese Prospective, Randomized, Multi-center Trial Comparing the TAXUS Stent and the CYPHER Stent in Patients With Coronary Artery Disease Eligible for PCI.|J-DESsERT®|Associations for Establishment of Evidence in Interventions|Yes|Completed|March 2008|||September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3500|||Both|20 Years|N/A|No|||April 2012|November 4, 2014|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00708669||153667|
NCT00708682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3009|Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico|A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|July 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|225|||Both|42 Days|98 Days|Accepts Healthy Volunteers|||October 2011|October 24, 2011|June 27, 2008||No||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00708682||153666|
NCT00709007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018577-03S1|Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India|Evaluating the Role of Directly Administered Antiretroviral Therapy (DAART) in Conjunction With Opiate Substitution in Delivery of Highly Active Antiretroviral Therapy to HIV-1-infected Injecting Drug Users (IDUs) in Chennai, India|DAART+|Johns Hopkins University|No|Withdrawn|July 2008|July 2011|Anticipated|July 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2009|April 14, 2015|July 1, 2008||No|No participants satisfied eligibility criteria and were enrolled into the study since July    2008.|No||https://clinicaltrials.gov/show/NCT00709007||153642|
NCT00709020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07213|White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors|A Translational Breast Cancer Prevention Trial of Mushroom Powder in Postmenopausal Breast Cancer Survivors||City of Hope Medical Center|Yes|Completed|June 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|21 Years|N/A|No|||June 2015|June 3, 2015|July 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709020||153641|
NCT00709267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002386|Bioavailability Study of Folic Acid in Healthy Women|A Randomized, Open Label Absolute Bioavailability Study of Folic Acid.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2004|December 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|12|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|June 6, 2011|June 30, 2008||||||https://clinicaltrials.gov/show/NCT00709267||153622|
NCT00709553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00010|Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)|A Randomised, Open-label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 (Zibotentan) on the Pharmacokinetics of a CYP450 3A Probe (Midazolam) in Healthy Male Subjects||AstraZeneca|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 27, 2010|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709553||153600|
NCT00709787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841059|Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management|Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management||Pfizer|No|Completed|June 2008|February 2009|Actual|February 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|899|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult Hypertensive Patients managed in primary care|March 2009|November 9, 2010|July 1, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00709787||153582|
NCT00709800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPT1-101|Pandemic Influenza Plasmid DNA Vaccines (Needle)|A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines||Vical|Yes|Completed|August 2007|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 11, 2009|July 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709800||153581|
NCT00706589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-KOA-0703|Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder|A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder||Korea Otsuka Pharmaceutical Co.,Ltd.|Yes|Completed|October 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|6 Years|18 Years|No|||June 2013|June 19, 2013|June 25, 2008||No||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00706589||153823|
NCT00706875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-040|A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors|A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Female|18 Years|60 Years|No|Non-Probability Sample|GTD survivors treated at Memorial Sloan-Kettering Cancer Center (MSKCC).|April 2015|April 28, 2015|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706875||153801|
NCT00706888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etude 9108|Study on Effects of a Dairy Product Based on Polyphenols and Enriched With Vitamins B6, B9 and B12 on Some Cardiovascular Factor of Risk|||Elvir SAS||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|64|||Both|18 Years|74 Years|No|||July 2009|July 3, 2009|June 26, 2008||||No||https://clinicaltrials.gov/show/NCT00706888||153800|
NCT00711503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-007146-34|Anti-Interleukin-1 in Diabetes Action|A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes|AIDA|Steno Diabetes Center|Yes|Completed|January 2009|June 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|35 Years|No|||August 2012|August 31, 2012|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711503||153453|
NCT00702572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-004|Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer|Phase I Study of Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||Milton S. Hershey Medical Center|Yes|Active, not recruiting|April 2008|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00702572||154126|
NCT00707512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101CD401|CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring|INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring|INFORM|Biogen|No|Terminated|June 2008|August 2050|Anticipated|August 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|N/A|No|Non-Probability Sample||June 2015|July 16, 2015|June 27, 2008|No|Yes|Sponsor's decision.|No||https://clinicaltrials.gov/show/NCT00707512||153755|
NCT00707525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607-C-M09-EL|Embryo Aneuploidies and Ovarian Stimulation|Incidence of EmbyoO Aneuploidies in Natural Versus Stimulated Cycles in the Same Women.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|February 2008|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||||||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00707525||153754|
NCT00707811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCED08043|Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing|Evaluation of ST2 and IL-33 for Risk Stratification and Diagnosis in Patients Presenting to the Emergency Department With Dyspnea||The Cleveland Clinic|No|Recruiting|April 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the Cleveland Clinic Emergency Department with signs and/or        symptoms of dyspnea (trouble breathing)|June 2008|June 27, 2008|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707811||153733|
NCT00708136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor404605ctil|Effect of Water-Exercise on Balance Function of Healthy Elderly Individuals|Effect of Water-Exercise on Balance Function of Healthy Elderly Individuals - A Randomized Control Study|EWEB|Soroka University Medical Center|Yes|Completed|January 2006|June 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|||Actual|37|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2005|July 1, 2008|June 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00708136||153708|
NCT00708409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross-01|Long-Term Follow-up After the Autograft Aortic Valve Procedure (Ross Operation)|Long-Term Follow-up After the Autograft Aortic Valve Procedure (Ross Operation)-the German-Dutch- Ross Registry||University of Luebeck|No|Enrolling by invitation|January 2001|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|1800|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|January 2009|February 12, 2009|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708409||153687|
NCT00708422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-07|Effects of Travatan Z and Xalatan on Ocular Surface Health|Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan®||Alcon Research|No|Completed|July 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|June 30, 2008|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00708422||153686|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge (Pflugfelder and Baudoin, 2011).
NCT00709592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11561|Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT|Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation||Virginia Commonwealth University|Yes|Active, not recruiting|July 2008|September 2020|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|40 Years|70 Years|No|||November 2015|November 19, 2015|July 1, 2008|Yes|Yes||No|February 1, 2015|https://clinicaltrials.gov/show/NCT00709592||153597|
NCT00710437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513433|Effects of Dexmedetomidine on the Intraoperative Electroencephalogram During Endarterectomy Surgery|Effects of Dexmedetomidine on the Intraoperative Electroencephalogram During Endarterectomy Surgery||University of California, Davis|No|Completed|April 2005|November 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|22|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing elective carotid endarterectomy|July 2012|July 6, 2012|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710437||153533|
NCT00707135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13142A|Rapamycin in Advanced Cancers|A Phase Ib Study of Rapamycin (Sirolimus) in Patients With Advanced Malignancies||University of Chicago|Yes|Completed|June 2005|December 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|June 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00707135||153783|
NCT00707421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRO Pre-op Med Trab|Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes|A Randomized Clinical Trial Comparing Preoperative Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Compared to Placebo With Regard to Clinical Outcomes Following Trabeculectomy.||Universitaire Ziekenhuizen Leuven||Completed|July 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|62|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00707421||153762|
NCT00704561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|457/2008|Six-month Coverage and Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography|Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).|OCTAMI|A.O. Ospedale Papa Giovanni XXIII|Yes|Completed|April 2008|October 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2009|February 9, 2010|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00704561||153973|
NCT00705159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550|Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis|Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis||Bausch & Lomb Incorporated|No|Completed|June 2008|May 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|137|||Both|N/A|6 Years|No|||March 2015|March 4, 2015|June 20, 2008|Yes|Yes||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00705159||153930|
NCT00705172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1961|Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome|Efficacy and Safety of Norditropin® (Somatropin) in Children With Prader-Willi Syndrome (PWS)||Novo Nordisk A/S|No|Completed|November 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|41|||Both|N/A|15 Years|No|Non-Probability Sample|Children with Prader-Willi Syndrome|December 2014|December 19, 2014|June 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705172||153929|
NCT00709280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS002|Infant Study of Inhaled Saline in Cystic Fibrosis|Infant Study of Inhaled Saline in Cystic Fibrosis|ISIS|CF Therapeutics Development Network Coordinating Center|Yes|Completed|April 2009|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|321|||Both|4 Months|59 Months|No|||February 2013|February 11, 2013|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709280||153621|
NCT00709813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCN 154739/320|Study to Test a Computer-assisted Support System to Improve Patient-centered Care and Symptom Relief in Cancer Patients|Including Patient Preferences in Symptom Management of Cancer Patients: A Randomized Clinical Trial||Oslo University Hospital|No|Completed|December 2003|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|145|||Both|18 Years|N/A|No|||March 2009|July 3, 2011|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00709813||153580|
NCT00710099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC/08/08|Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers|Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate on Cutaneous Blood Flow in Healthy Volunteers|INFLUX-VS|University Hospital, Grenoble|No|Completed|July 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 5, 2011|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710099||153559|
NCT00710112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/92, GC151|Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants|Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants|CLD|Medical College of Wisconsin|No|Recruiting|June 2006|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|whole blood|Both|N/A|N/A|No|Probability Sample|Infants born weighing less than 1500 grams|September 2015|September 2, 2015|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00710112||153558|
NCT00710125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPX-150-001|Safety Study of GPX-150 in Patients With Solid Tumors|Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors||Gem Pharmaceuticals|No|Completed|January 2008|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|July 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00710125||153557|
NCT00710359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19157|Cobalamin Status in Young Children With Gastrointestinal Symptoms or Feeding Problems|Cobalamin Status in Young Children With Gastrointestinal Symptoms or Feeding Problems||Haukeland University Hospital|No|Completed|April 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|8 Months|No|||August 2010|August 13, 2010|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710359||153539|
NCT00710372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT006-AngQb 03|Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension|A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension||Cytos Biotechnology AG|No|Completed|June 2008|November 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|69 Years|No|||November 2010|November 11, 2010|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00710372||153538|
NCT00706264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECEP-TRIAL|Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix|Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP)|PECEP|Maternal-Infantil Vall d´Hebron Hospital|Yes|Completed|June 2007|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2780|||Female|18 Years|45 Years|No|||July 2014|July 25, 2014|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00706264||153846|
NCT00706277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-007161-25|Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function|Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function||Medical University Innsbruck||Completed|June 2008|December 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2009|February 9, 2009|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706277||153845|
NCT00706602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3233B0-115216|Predicting the Course of Chronic Obstructive Pulmonary Disease (COPD) in Primary Care|International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts|ICECOLDERIC|University of Zurich|No|Active, not recruiting|May 2008|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|||Both|40 Years|N/A|No|Non-Probability Sample|COPD patients from primary care. Patients are identified through electronic or paper-based        patient charts and by participating general practitioners.|June 2010|June 24, 2010|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706602||153822|
NCT00706615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599060|Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer|A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer||Jonsson Comprehensive Cancer Center|Yes|Withdrawn|July 2008|||April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||July 2012|October 28, 2015|June 26, 2008|No|Yes|no accrual|No||https://clinicaltrials.gov/show/NCT00706615||153821|
NCT00702559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96040|Design the Home Care Platform for the Monitoring of A Hemodialysis Arteriovenous Graft by Intelligent Physiological Signal|||Far Eastern Memorial Hospital||Recruiting|January 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|16 Years|N/A|No|Probability Sample|50 prosthetic dialysis accesses on upper extremities|June 2008|June 19, 2008|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702559||154127|
NCT00707824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110/2000|Epidural Nalbuphine for Postcesarean Epidural Morphine Induced Pruritus|Study of Epidural Nalbuphine for Prevention of Epidural Morphine Induced Pruritus||Mahidol University|No|Completed|June 2000|February 2006|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|165|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2006|July 7, 2008|June 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00707824||153732|
NCT00707837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK15|Nutritional Study in Preterm Infants|Effect of Supplemental Infant Formula on Blood Levels in Preterm Infants||Abbott Nutrition|Yes|Completed|May 2005|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|N/A|21 Days|No|||September 2008|April 24, 2009|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707837||153731|
NCT00708149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLin|Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial|Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial||Far Eastern Memorial Hospital|No|Completed|June 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||January 2013|January 6, 2013|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00708149||153707|
NCT00708448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI26198|Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients|Development of an Integrated Molecular Biomarker ofEarly Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients Using Imaging Assessments and Genomic Modeling||University of Utah|Yes|Active, not recruiting|January 2008|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|June 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708448||153684|
NCT00708461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK067362|Environmental Intervention for Weight Gain Prevention|Environmental Intervention for Weight Gain Prevention|HealthWorks|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2006|March 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1747|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|June 27, 2008||No||No|December 13, 2011|https://clinicaltrials.gov/show/NCT00708461||153683|The recruitment goal of 6 sites represents only 3% of those initially contacted for participation, or 16% of eligible and interested sites. The design limits power due to the small sample size at the group level.
NCT00708760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23011|Moderate Sedation Educational Software|Moderate Sedation Education Software||University of Utah|Yes|Active, not recruiting|April 2007|September 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|nurses providing moderate sedation|March 2012|March 6, 2012|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00708760||153660|
NCT00708773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13934B|Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors|A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors||University of Chicago|Yes|Active, not recruiting|February 2006|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|June 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708773||153659|
NCT00710190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360004-001|Device Based Therapy in Hypertension Trial|A Study of Baroreflex Hypertension Therapy in Refractory Hypertension|DEBuT-HT|CVRx, Inc.|No|Completed|July 2003|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|21 Years|N/A|No|||October 2011|October 28, 2011|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00710190||153552|
NCT00708084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-M-A004|Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents|A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents||Crucell Holland BV|Yes|Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||March 2012|March 19, 2012|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708084||153712|
NCT00708097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3508565|In Situ Caries Efficacy of Fluoride Toothpastes|Clinical Efficacy of Fluoride Toothpastes Using an in Situ Caries Model||GlaxoSmithKline|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|57|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|July 1, 2008|Yes|Yes||No|September 15, 2011|https://clinicaltrials.gov/show/NCT00708097||153711|
NCT00707772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRCGL-07-03|Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection|A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection||Baqiyatallah Medical Sciences University|Yes|Completed|March 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|12 Years|N/A|No|||September 2009|September 16, 2009|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707772||153736|
NCT00704600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-03-026|Nelfinavir, a Phase I/Phase II Rectal Cancer Study|A Phase I/II Trial Testing Nelfinavir, an Inhibitor of Akt Signaling, in Combination With Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer|Nelfinavir|Maastricht Radiation Oncology|Yes|Completed|September 2008|July 2013|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704600||153970|
NCT00705458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-07-07-197|Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain|A Randomized Trial Comparing Multi-Detector Coronary CT Angiography and Stress Myocardial Perfusion Imaging as the Initial Test for the Diagnosis of Coronary Artery Disease in Intermediate Risk Patients Admitted for Chest Pain|PROSPECT|Montefiore Medical Center|Yes|Completed|July 2008|December 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|400|||Both|21 Years|N/A|No|||August 2015|August 21, 2015|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705458||153908|
NCT00705471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04204|Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)|Infliximab Use in Fistulizing Crohn's Disease: Impact on Health Care Resources||Merck Sharp & Dohme Corp.|No|Terminated|April 2005|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|The charts of subjects with fistulizing CD to be recorded for the time period for up to        three years before and for one year after their initial infliximab infusion for comparison        of health care costs and utilization prior to infliximab and post infliximab use.|April 2015|April 7, 2015|June 23, 2008||No|Study stopped prematurely due to enrolment challenges.|No||https://clinicaltrials.gov/show/NCT00705471||153907|
NCT00705744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03982|Dermacyd Femina (Lactic Acid) - Photo Dermatological Evaluation of the Irritation and Sensitivity Potential.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Femina.||Sanofi|No|Completed|April 2008|||May 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705744||153886|
NCT00705757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer GA6111AX|The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye|The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation||Summa Health System|No|Completed|March 2008|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|89|||Both|30 Years|N/A|No|||December 2015|December 14, 2015|June 24, 2008||No||No|December 25, 2014|https://clinicaltrials.gov/show/NCT00705757||153885|
NCT00705991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 27-2007|Validation of Thrombelastometry (ROTEM®)|||University of Zurich|No|Completed|January 2008|October 2008||||Phase 4|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Healthy Patients|November 2012|January 22, 2013|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00705991||153867|
NCT00705770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-58|A Multi-Dose Study With a Treatment for Open-Angle Glaucoma|||Alcon Research|No|Withdrawn|May 2008|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||July 2008|May 29, 2012|June 24, 2008|Yes|Yes|Change in study design|No||https://clinicaltrials.gov/show/NCT00705770||153884|
NCT00706251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTFNIAME|Follow up of Nasolacrimal Intubation in Adults|Long Term Follow up of Nasolacrimal Intubation in Adults With Mild Epiphora||Shaare Zedek Medical Center|No|Completed|January 2000|||December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|180|||Both|18 Years|75 Years|No|Non-Probability Sample|Patient who underwent nasolacrimal intubation in Maccabi Healthcare, due to mild epiphora,        during the years 2000-2007.|June 2008|June 26, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706251||153847|
NCT00706914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-MD-24|Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 4-Week Pilot Study to Assess Symptoms in Stable, Moderate to Severe COPD Patients Taking Aclidinium Bromide 200 Mcg Once Daily in Combination With Formoterol Fumarate Once or Twice Daily Versus Formoterol Fumarate Twice Daily||Forest Laboratories|No|Completed|June 2008|||November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|156|||Both|40 Years|80 Years|No|||September 2011|September 30, 2011|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706914||153798|
NCT00702585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07016|Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)|A Phase II, Randomized, Double-blind, Placebo-controlled, Comparative Trial to Investigate the Optimal Dose of a Single Administration of Org 36286 (Corifollitropin Alfa) to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility||Merck Sharp & Dohme Corp.|Yes|Completed|August 2001|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|55|||Female|18 Years|39 Years|No|||June 2015|June 26, 2015|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702585||154125|
NCT00706901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-016-08S|Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans|Impact of Group Motivational Interviewing for Dually Diagnosed Veterans|GMI-IHMDs|VA Office of Research and Development|No|Active, not recruiting|May 2010|February 2016|Anticipated|June 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|70 Years|No|||September 2015|September 14, 2015|June 26, 2008||No||No|October 30, 2014|https://clinicaltrials.gov/show/NCT00706901||153799|
NCT00708162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-183-0145|Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir|A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults||Gilead Sciences|Yes|Completed|July 2008|April 2015|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|724|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|June 30, 2008|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT00708162||153706|10 participants from a single study site were excluded from Intent-to-Treat (ITT) Analysis Set due to critical and multiple protocol violations (elvitegravir arm: n = 3; raltegravir arm: n = 7).
NCT00708474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSM2008001|OsseoFit™ Prospective Data Collection|OsseoFit™ Porous Tissue Matrix™ Prospective Data Collection||Biomet, Inc.|No|Withdrawn|June 2008|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|45 Years|No|||February 2012|February 29, 2012|June 25, 2008|Yes|Yes|Planning new study protocol|No||https://clinicaltrials.gov/show/NCT00708474||153682|
NCT00708786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITAC01-VISION|Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in Implantable Cardioverter-Defibrillator (ICD) Patients|Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in ICD Patients||LivaNova|Yes|Completed|April 2004|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|755|||Both|18 Years|N/A|No|||June 2008|June 30, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00708786||153658|
NCT00709085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803038R|To Study the Effects of Host Genetic Factors on Liver Cirrhosis and Hepatocellular Carcinoma (HCC)|Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4)||National Taiwan University Hospital|No|Recruiting|April 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|320|Samples With DNA|liver tissue (non-tumor part)|Both|50 Years|70 Years|No|Probability Sample|A total of 596 patients with histologically proven HCC were collected by Dr. Po-Huang        Lee's Lab. (The Department of Surgery, National Taiwan University Hospital, Taipei,        Taiwan)|November 2009|November 23, 2009|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00709085||153636|
NCT00709605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080171|Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection|A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP In Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection||National Institutes of Health Clinical Center (CC)||Completed|June 2008|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|18 Years|55 Years|No|||May 2014|October 9, 2014|June 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709605||153596|
NCT00709345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078576|Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks|Effectiveness of a Cognitive Behavioral Treatment for Reducing Atypical Antipsychotic Medication Health Risks in People With Serious Mental Illness||Medical College of Wisconsin|No|Completed|July 2006|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|333|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00709345||153616|
NCT00709878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK-Lapatinib|Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors|Histological Characterization and Differentiation of Rash From Other EGFR Inhibitors||Northwestern University|No|Completed|April 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|32|Samples With DNA|Skin tissue biopsies.|Both|N/A|N/A|No|Non-Probability Sample|Patients selected for this study were treated with lapatinib, erlotinib, panitumumab or        cetuximab, developed skin toxicities and were biopsied as standard of care for skin rash        at the Department of Dermatology, Northwestern University.|February 2015|February 24, 2015|July 1, 2008||No||No|August 27, 2010|https://clinicaltrials.gov/show/NCT00709878||153575|Small sample size
NCT00710723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dwille1|Vitrification Versus Slow Freezing of Human Day 3 Embryos|Vitrification Versus Slow Freezing of Human Day 3 Embryos||University Hospital, Gasthuisberg||Active, not recruiting|October 2005|December 2008|Anticipated|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|901|||Both|18 Years|43 Years|Accepts Healthy Volunteers|||January 2008|July 3, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00710723||153511|
NCT00710996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-023|Blue Light Intraocular Lenses (IOLs) and Photostress|Blue Light Intraocular Lenses (IOLs) and Photostress||Alcon Research|No|Completed|January 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with existing bilateral Intraocular Lenses (IOLs) of given type, age-matched        patients with normal vision and no cataract surgery.|January 2010|January 29, 2010|July 3, 2008||No||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00710996||153491|
NCT00711009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-336|Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)|A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects|PROGRESS|Abbott||Completed|July 2008|October 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|July 3, 2008|Yes|Yes||No|November 16, 2010|https://clinicaltrials.gov/show/NCT00711009||153490|
NCT00703664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00275|Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma|Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas||National Cancer Institute (NCI)||Active, not recruiting|July 2008|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|116|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703664||154042|
NCT00703976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 07-021|Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer|Phase II Randomized Trial of Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer||University of Pittsburgh|Yes|Completed|October 2008|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703976||154018|
NCT00708383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PresbyterianHDallasARTS-SSS|in Vitro Fertilization (IVF) Media Protein and Live Birth Rates|A Randomized Controlled Study of Human Serum Albumin and Serum Substitute Supplement as Protein Supplements for IVF Culture and the Effect on Live Birth Rates|SSS|Texas Health Resources|Yes|Completed|September 2001|November 2003|Actual|November 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|538|||Female|20 Years|40 Years|No|||June 2008|July 1, 2008|June 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00708383||153689|
NCT00704223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3576|Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes|Observational Study on Safety and Efficacy in Subjects Using NovoMix® 70 (Biphasic Insulin Aspart) for Treatment of Type 2 Diabetes Mellitus|INTENSIV|Novo Nordisk A/S|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|619|Samples With DNA|Blood sample|Both|18 Years|N/A|No|Probability Sample|Male and female above 18 years with type 2 diabetes|June 2014|June 23, 2014|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704223||153999|
NCT00704834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614150|Gene Expression Profiles in Multiple Sclerosis (MS)|Gene Expression Profiles in Patients With Multiple Sclerosis||University of California, Davis|No|Active, not recruiting|March 2006|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|Samples With DNA|35cc of peripheral blood will be obtained from each subject via venipuncture.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult subjects aged 18 to 70 will be enrolled. There will be four study groups: patients        with a clinically isolated syndrome (CIS), patients with untreated relapsing-remitting MS        (RR-MS), patients with chronic, progressive MS (CPMS), and age- and gender-matched control        subjects without MS. Patients of both sexes and all races will be recruited into the study        without bias.|November 2012|November 29, 2012|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704834||153952|
NCT00704847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC021C2302|Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis||Nordic Bioscience A/S|Yes|Terminated|June 2008|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1030|||Both|51 Years|80 Years|No|||September 2012|October 22, 2012|June 24, 2008|Yes|Yes|Male subjects were terminated due to an imbalance in prostate cancer events|No|August 13, 2012|https://clinicaltrials.gov/show/NCT00704847||153951|The study showed an underexposure to calcitonin compared to what was expected from phase I trials.
NCT00705185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002525|Exploring a Potential Blood Test to Diagnose Major Depressive Disorder|Exploring Potential Serum/Plasma-Based Biomarkers as a Test for Major Depressive Disorder Diagnostics ("Bio-Test MDD")|Bio-TestMDD|Massachusetts General Hospital|No|Completed|April 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|serum, plasma|Both|18 Years|65 Years|No|Non-Probability Sample|Adults with Major Depressive Disorder (DSM-IV)|June 2010|June 7, 2010|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00705185||153928|
NCT00705484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04808|European Safety Registry in Ulcerative Colitis (Study P04808AM3)|Ulcerative Colitis European Registry: A Prospective, Observational, Non-interventional, Post-Marketing Safety Surveillance Program||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|June 2007|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects, ages 18 years and older, with a diagnosis of moderate-to-severe active UC        will be eligible to enroll in the registry.|January 2016|January 20, 2016|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705484||153906|
NCT00705783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-07-246|Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|ASPIRE|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|July 2008|February 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|843|||Both|18 Years|60 Years|No|||June 2013|June 16, 2013|June 24, 2008|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00705783||153883|
NCT00706004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|76992|Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis|Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis||University of Arkansas|No|Completed|July 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2011|March 14, 2011|June 25, 2008||No||No|February 16, 2011|https://clinicaltrials.gov/show/NCT00706004||153866|
NCT00706654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-07-247|Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia|ASPIRE|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|September 2008|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|937|||Both|18 Years|60 Years|No|||July 2013|July 12, 2013|June 25, 2008|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00706654||153818|
NCT00706927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-241005|Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|A Double-masked Randomized Cross-over Study Comparing of the Effect of Xalacom® (Latanoprost/Timolol)and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension||Medical University of Vienna||Completed|January 2006|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706927||153797|
NCT00702897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96041|Ambulatory Surgery of Lower Extremity Varicose Vein|||Far Eastern Memorial Hospital|Yes|Recruiting|January 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|All patients with varicose veins who underwent endovenous laser treatment for GSV reflux        in our hospital were reviewed.|June 2008|June 19, 2008|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702897||154101|
NCT00702910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2C111401|A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients|A Randomised, Single-dose, Dose-ascending, Double-blind, Placebo-controlled, 5-way Crossover Study to Investigate the Efficacy, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M in Asthmatic Patients||GlaxoSmithKline||Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||May 2011|March 15, 2012|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702910||154100|
NCT00708799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISN 17-001|Efficacy of Macrolide Immunomodulation in Severe Sepsis.|Efficacy of Macrolide Immunomodulation in Severe Sepsis||VA Office of Research and Development|No|Terminated|November 2007|November 2015|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|June 27, 2008|Yes|Yes|Safety evaluation due to recent publications.|No||https://clinicaltrials.gov/show/NCT00708799||153657|
NCT00709098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-063A302|Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Randomized Study Comparing the Safety and Tolerability of Iloprost Inhalation Solution Delivered by I-neb Utilizing Power Disc-15 and Power Disc-6 in Patients With Symptomatic Pulmonary Arterial Hypertension|PROWESS 15 Ext|Actelion|No|Completed|September 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||March 2015|September 10, 2015|July 1, 2008|Yes|Yes||No|September 27, 2012|https://clinicaltrials.gov/show/NCT00709098||153635|
NCT00709618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT111110|Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects|A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer||GlaxoSmithKline|No|Terminated|June 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Female|18 Years|N/A|No|||June 2014|June 30, 2014|July 2, 2008|No|Yes|Evolving standard of care practices in this disease setting was limiting enrolment and leading    to a delay in delivering this study information to the public.|No|December 13, 2012|https://clinicaltrials.gov/show/NCT00709618||153595|The study was terminated due to low screening and a low enrollment rate after 3 years.
NCT00710203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715981|Dermatosis Papulosa Nigra|Efficacy of a 585 nm Pulsed Dye Laser (PDL) for the Treatment of Dermatosis Papulosa Nigra, and Compare it to Therapy With Curettage and Electrodesiccation.|DPN|University of California, Davis|No|Completed|July 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|July 2, 2008||No||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00710203||153551|
NCT00710450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Townley Merck|Effect of Montelukast on Basophils, In-vitro|The Effect of Montelukast In-vitro on Basophil Histamine and Leukotriene, IL-4 Adn IL-13 Release in Subjects With Allergic Rhinitis or Allergic Asthma||Creighton University|No|Active, not recruiting|May 2008|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|15|Samples Without DNA|Supernatents from stimulation assays will be kept for batch assay.|Both|12 Years|N/A|No|Probability Sample|Allergic rhinitis or allergic asthma, age 13+|September 2011|September 22, 2011|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00710450||153532|
NCT00710463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV and Rehabilitation|Evaluation of the Role of Nocturnal Non-Invasive Ventilation in Pulmonary Rehabilitation|Evaluation of the Role of Nocturnal Non-Invasive Ventilation in Pulmonary Rehabilitation||Deutsche Lungenstiftung e.V.|No|Completed|May 2003|November 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|All patients were recruited at a single center, the rehabilitation hospital "Klinikum        Berchtesgadener Land" at Germany.        Patients entering the well defined, hospital based pulmonary rehabilitation programme        after Januar 1, 2005 were additionally treated with nocturnal non invasive ventilation.        The results of these patients were compared with a group of patients who underwent the        same rehabilitation programme in the years 2003 to 2005, when non invasive ventilation was        not availabe.|July 2008|July 3, 2008|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710463||153531|
NCT00704249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA-4905|VENICE Study Nevirapine Full Dose/Dose Escalation|Randomized Multicenter Study to Compare Starting Nevirapine at the Full Dose With Dose Escalation in Patients Who Require Efavirenz to be Withdrawn Due to Adverse Reactions|VENICE|Clinical Trial Agency of HIV Study Group||Completed|July 2006|February 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2009|February 10, 2009|June 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00704249||153997|
NCT00704236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD003|Improvement of Insulin Resistance With Traditional Chinese Treatment in Patients With Type 2 Diabetes|Phase 4 Study on the Effect of Insulin Resistance With Traditional Chinese Treatment in Type 2 Diabetes||Shanghai Jiao Tong University School of Medicine|Yes|Completed|September 2006|February 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|70 Years|No|||December 2008|December 10, 2008|June 16, 2008||||No||https://clinicaltrials.gov/show/NCT00704236||153998|
NCT00704574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1920|Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes|Safety of Levemir® (Insulin Detemir) Treatment in Children and Adolescents With Type 1 Diabetes (PREDICTIVE™ - Youth)|PREDICTIVE™|Novo Nordisk A/S|No|Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|159|||Both|6 Years|18 Years|No|Non-Probability Sample|Children Age 6 - 18 with type 1 diabetes|April 2013|August 12, 2014|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704574||153972|
NCT00704860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB- 200506|Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism|Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism||University of Ottawa|No|Completed|February 2005|December 2010|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|January 18, 2011|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00704860||153950|
NCT00704886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p001264|A Randomized Controlled Trial of Using Video Images in Dementia|A Randomized Controlled Trial of Using Video Images in Dementia||Massachusetts General Hospital|No|Completed|September 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 22, 2009|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704886||153949|
NCT00705198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05062|Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)|Temodal Capsule All-Case-Registered Surveillance (Designated Drug Use Investigation) - Evaluation of The Safety and Efficacy of Temodal in Patients With Newly Diagnosed Malignant Glioma (Concomitant With Radiotherapy and Then as Monotherapy) and Relapsed Malignant Glioma (as Monotherapy)||Merck Sharp & Dohme Corp.|No|Active, not recruiting|September 2006|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with temozolomide for newly diagnosed malignant glioma (concomitant with        radiotherapy and then as monotherapy) and relapsed malignant glioma (as monotherapy). In        addition, up to 450 patients with newly diagnosed anaplastic astrocytoma will be        registered to investigate survival time.|February 2016|February 3, 2016|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705198||153927|
NCT00705497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA|Radiofrequency Ablation of Tumors|Radiofrequency Ablation of Tumors (RFA) A Phase I Study||St. Jude Children's Research Hospital|No|Completed|January 2003|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|N/A|No|||June 2011|June 1, 2011|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705497||153905|
NCT00705796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasobol 02/2008|Influence of Administration Route of Testosterone on Male Fertility|Influence on Human Male Fertility of Testosterone After Intranasal (MPP10) or Transdermal (AndroGel™) Application||M et P Pharma|No|Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|50 Years|80 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|June 25, 2008||No|financial constraints|No||https://clinicaltrials.gov/show/NCT00705796||153882|
NCT00706017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3518|Observational Study to Evaluate the Safety of Levemir® in Diabetes|Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|PREDICTIVE™|Novo Nordisk A/S|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2282|||Both|N/A|N/A|No|Non-Probability Sample|Patients from both general and speciality practice settings deemed appropraite to receive        Levemir® as new treatment and as part of routine out-patient care by the prescribing        physician|November 2012|August 13, 2014|June 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00706017||153865|
NCT00706290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597438|Brief CBT for Anxiety and Advanced Cancer|Brief CBT for Anxiety and Advanced Cancer||Massachusetts General Hospital|No|Completed|April 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706290||153844|
NCT00706303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/246|Glasgow Supported Self Management Trial (GSuST)|Glasgow Supported Self-Management Randomised Controlled Trial for Patients With Moderate/ Severe COPD - GSuST|GSuST|NHS Greater Glasgow and Clyde|No|Recruiting|June 2007|December 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|N/A|N/A|No|||June 2008|June 26, 2008|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706303||153843|
NCT00706628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1239.3|A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer|A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer||Boehringer Ingelheim||Completed|March 2006|||December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|87|||Male|18 Years|N/A|No|||January 2015|January 14, 2015|June 24, 2008||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00706628||153820|Data from the ComBI 70 group were not included in analyses of efficacy, data was available for one patient for this group for the primary outcome however is not reported to avoid reporting patient level data.
NCT00706641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU07-122|Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder|A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder||Hoosier Cancer Research Network|Yes|Completed|June 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|June 25, 2008|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT00706641||153819|
NCT00706940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080340|Tear Dynamics After Restasis Treatment in Dry Eye Patients|Tear Dynamics After Restasis Treatment in Dry Eye Patients Phase II Clinical Trial and Phase IIb 6-month Follow-up After Discontinuation of Study Treatment||University of Miami|No|Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|90 Years|No|Non-Probability Sample|dry eye patients more than 18 yrs old|March 2016|March 8, 2016|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706940||153796|
NCT00702624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05710|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 107012 for the Development of Org 36286 (Corifollitropin Alfa)|Care|Merck Sharp & Dohme Corp.|No|Completed|April 2007|June 2008|Actual|April 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|113|||Female|18 Years|36 Years|No|Non-Probability Sample|Women with an ongoing pregnancy at least 10 weeks after embryo transfer in base study        P05690 (NCT00702845) were enrolled in this trial.|December 2015|December 11, 2015|June 18, 2008|No|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00702624||154122|
NCT00702936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILG-1|Telmisartan Versus Ramipril After Acute Coronary Syndrome|Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome|TERACS|Catholic University of the Sacred Heart|Yes|Recruiting|November 2007|November 2008|Anticipated|August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|80 Years|No|||June 2008|June 19, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702936||154098|
NCT00702598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-03029|The WORKER Study: Escitalopram and Telephone-based Cognitive Behaviour Therapy (CBT) for Depressed Working People|The WORKER Study: A Randomized Controlled Trial of Escitalopram and Telephone-based Cognitive Behaviour Therapy in Working Patients With Major Depressive Disorder||University of British Columbia|Yes|Completed|June 2008|December 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|19 Years|65 Years|No|||May 2012|May 7, 2012|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702598||154124|
NCT00702611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ada-UC-07-102|Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis|An Open Randomized Multicenter Clinical Investigation to Compare the Efficacy and Safety of Prednisone Plus Adacolumn® GMA Apheresis vs Prednisone Alone in the Treatment of Patients With Mild or Moderately Active Steroid Dependent Ulcerative Colitis|ATICCA|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa|Yes|Terminated|June 2008|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|75 Years|No|||September 2015|September 4, 2015|June 19, 2008||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00702611||154123|
NCT00703183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4429-0001|Safety and Tolerability of ACU-4429|A Single Center, Randomized, Double-Masked, Dose-Escalating, Placebo-Controlled Study of the Safety and Tolerability ACU-4429 in Healthy Volunteers||Acucela Inc.|Yes|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703183||154079|
NCT00709358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070308|Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections|Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units|EVAMICA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2000|||Both|18 Years|N/A|No|||May 2011|December 26, 2011|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00709358||153615|
NCT00709631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006477|Interest of a Systematic Biopsy for Hard-to-heal Leg Ulcers|Prospective Evaluation of the Interest of a Systematic Biopsy for Hard-to-heal Leg Ulcers|ULCERE|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2006|May 2010|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with one or more leg ulcers, diagnosed as related to venous insufficiency,        associated or not with concomitant arterial insufficiency.|June 2010|February 24, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00709631||153594|
NCT00709891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000649|Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease|Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease in Women Undergoing Routine Cervical Cancer Screening||Hoffmann-La Roche||Completed|May 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|47208|||Female|21 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 5, 2015|June 30, 2008||No||No|January 20, 2015|https://clinicaltrials.gov/show/NCT00709891||153574|
NCT00710216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVD-001|Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B|Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study)|EVD|University of Ulm|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||April 2009|April 16, 2009|July 2, 2008||No|Sponsor withdraw|No||https://clinicaltrials.gov/show/NCT00710216||153550|
NCT00710476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dwille2|Effect of the Number of Inseminated Spermatozoa on Subsequent Human Embryonic Development in Vitro|Effect of the Number of Inseminated Spermatozoa on Subsequent Human Embryonic Development in Vitro||University Hospital, Gasthuisberg|No|Completed|August 2006|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|43 Years|Accepts Healthy Volunteers|||January 2008|July 2, 2008|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00710476||153530|
NCT00704002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONFraM|Conservative Versus Operative Treatment of Displaced Neck Fractures of the Fifth Metacarpal|Conservative Versus Operative Treatment of Displaced Neck Fractures of the Fifth Metacarpal|CONFraM|Heinrich-Heine University, Duesseldorf|Yes|Terminated|December 2006|June 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|75 Years|No|||March 2013|March 27, 2013|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704002||154016|
NCT00704262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 80190-O23|Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds|Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and on the Intertriginous Areas||LEO Pharma|No|Completed|May 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704262||153996|
NCT00704587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProFaCo|Prognostic Factors for All Types of Cancer Combined|Flow Cytometrical Analysis of the Human Immune System to Assess Tumor-related Material Piling up in Activated Macrophages in All Relevant Cancer Types.|ProFaCo|Atrium Medical Center|No|Active, not recruiting|November 2006|July 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|520|Samples With DNA|white cells      tissue      plasma      serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|all patients diagnosed or suspected of cancerous conditions in the broadest sense of the        word|December 2014|December 2, 2014|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704587||153971|
NCT00704275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391/48|Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes|Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes||Chulalongkorn University|No|Recruiting|June 2007|October 2008|Anticipated|July 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||June 2008|June 23, 2008|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00704275||153995|
NCT00704288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-201|Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme|A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse||Exelixis||Completed|May 2008|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|222|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704288||153994|
NCT00705224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05562|Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)|Observational Multicenter Study to Evaluate Influence of Insulin Resistance on the Safety and Efficacy (as Measured by Sustained Virological Response) of Treatment With Any Pegylated Interferon and Ribavirin (Standard of Care) in Different Populations of HCV Patients in Russia.||Merck Sharp & Dohme Corp.|No|Completed|May 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|65 Years|No|Probability Sample|The study will include naïve patients with chronic hepatitis C (CHC) of any genotype who        will be treated with a standard treatment regimen (pegylated interferon and ribavirin)        according to routine clinical practice in Russia.|June 2015|June 4, 2015|June 23, 2008|No|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00705224||153925|
NCT00705211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05245|A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)|Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy||Merck Sharp & Dohme Corp.|No|Completed|June 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1794|||Both|N/A|N/A|No|Non-Probability Sample|The population will be selected from 200 institutions in Japan.|February 2015|February 24, 2015|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705211||153926|
NCT00705510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154/2551(EC1)|Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction|Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction||Mahidol University|Yes|Completed|May 2008|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||November 2010|November 8, 2010|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705510||153904|
NCT00705809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908163|T-Cell Project: Epidemiologic Component|T-Cell Project: Epidemiologic Component||National Institutes of Health Clinical Center (CC)||Completed|June 2008|July 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|800|||Both|18 Years|N/A|No|||July 2011|September 26, 2015|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705809||153881|
NCT00706030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-2204|Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer|A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer||Puma Biotechnology, Inc.|No|Active, not recruiting|April 2008|December 2017|Anticipated|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|June 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706030||153864|
NCT00706316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-CTL|Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer|A Phase I Trial Evaluating the Administration of Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) to Patients With Recurrent or Metastatic EBV-Positive Nasopharygneal Cancer (NPC)|NPC-CTL|University Health Network, Toronto|Yes|Completed|December 2007|November 2012|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706316||153842|
NCT00706953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015091|A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib|A Phase II Single Arm Study of VELCADE and DOXIL (PLD) in Patients With Relapsed Multiple Myeloma Previously Treated With VELCADE||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Withdrawn|July 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|June 26, 2008||||No||https://clinicaltrials.gov/show/NCT00706953||153795|
NCT00702637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A020510; R01|Study of Modafinil to Treat Fatigue in Persons With Traumatic Brain Injury|Modafinil for the Treatment of Fatigue and Excessive Daytime Sleepiness in Individuals With Traumatic Brain Injury||Craig Hospital||Completed|October 2002|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||60|||Both|18 Years|65 Years||||June 2010|June 10, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702637||154121|
NCT00703196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579360|Folic Acid Clinical Trial for the Prevention of Cervical Cancer|HPV Clearance by Folic Acid Supplementation (FACT for HPV)||University of Alabama at Birmingham|Yes|Completed|March 2007|||May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|368|||Female|19 Years|120 Years|No|||January 2014|October 6, 2015|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703196||154078|
NCT00709371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZB-202|Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity|A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity||Orexigen Therapeutics, Inc|No|Completed|July 2008|July 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|729|||Both|18 Years|65 Years|No|||November 2012|November 27, 2012|June 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709371||153614|
NCT00709384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030198B|Prevention of Atrial Tachycardia After a Right Atriotomy II|Prevention of Atrial Tachycardia After a Right Atriotomy II||Aarhus University Hospital Skejby|No|Completed|January 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2009|September 18, 2009|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709384||153613|
NCT00709644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002203|Bioequivalence Study of the Oral Contraceptive (OC) Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.|A Pivotal Bioequivalence Study of 250 Mcg NGM/25 Mcg EE With or Without Folic Acid in Healthy Female Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2005|August 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|54|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|July 1, 2008||||||https://clinicaltrials.gov/show/NCT00709644||153593|
NCT00709904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10636|Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery|SAVE-HIP3|Sanofi|Yes|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|469|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709904||153573|
NCT00710229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 07-192-1007|Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration|A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age-related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA)|MANTA|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Recruiting|July 2008|||December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|50 Years|N/A|No|||June 2010|June 8, 2010|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00710229||153549|
NCT00710489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200815981|Potential Research Study Participant Registry|Potential Research Study Participant Registry||University of California, Davis|No|Recruiting|May 2008|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|N/A||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult community members with an interest in one or more of the following dermatologic        conditions: Acne, Actinic Keratosis, Blistering Diseases, Dysplastic Nevi (mole), Eczema,        Psoriasis, Vitaligo, Skin Cancer Prevention, Skin Cancer Treatment, Phototherapy Treatment        Options, Rosacea, Leg or Foot Ulcers, Lichen Planus, Atopic Dermatosis, Canker        Sores,others as indicated.|April 2015|April 15, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710489||153529|
NCT00704613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTMRG1|Planning Margin Requirements for Pediatric Radiation Oncology|Planning Margin Requirements for Pediatric Radiation Oncology||St. Jude Children's Research Hospital|No|Completed|March 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|375|||Both|N/A|N/A|No|Non-Probability Sample|All patients receiving external beam radiation therapy at St. Jude Children's Research        Hospital will be screened for participation on this research protocol based on the        Inclusion Criteria.|November 2011|November 29, 2011|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704613||153969|
NCT00704899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGIMS-001|Anti-Depressants vs Physiotherapy in Management of Fibromyalgia|Effect of Anti-Depressants vs Physiotherapy in Management of Fibromyalgia Syndrome: What Predicts a Clinical Benefit?||Mahatma Gandhi Institute of Medical Sciences|No|Completed|March 2006|April 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|60 Years|No|||June 2008|June 25, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704899||153948|
NCT00705237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCID 2007-118|Study of the Use of LUMA Lightwire|LUMA Lightwire Study||Lahey Clinic|No|Terminated|March 2008|February 2009|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|75 Years|No|||February 2009|February 17, 2009|June 23, 2008|No|Yes|Insufficient findings for data analysis|No||https://clinicaltrials.gov/show/NCT00705237||153924|
NCT00705250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-041|Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma|A Phase II Study of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma.||Memorial Sloan Kettering Cancer Center||Completed|June 2008|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|June 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00705250||153923|
NCT00705523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChA - 807226|Varenicline (Chantix™) for the Treatment of Alcohol Dependence|A Phase II, Randomized, Double-Blind Pilot Trial of Varenicline (Chantix™) for the Treatment of Alcohol Dependence|ChA|University of Pennsylvania|Yes|Completed|June 2008|December 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||June 2015|June 1, 2015|June 24, 2008|Yes|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00705523||153903|
NCT00705536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-07-04|Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20|A Phase I, Randomized, Double-Blind Crossover Pharmacokinetic, Pharmacodynamic, and Safety Study of Subcutaneously Administered Humalog® (Insulin Lispro Injection; Rapid-Acting Insulin) With and Without Recombinant Human Hyaluronidase (rHuPH20) Versus Subcutaneously Administered Humulin R® (Regular Insulin Injection) With and Without rHuPH20||Halozyme Therapeutics|No|Completed|December 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|4||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|June 24, 2008|No|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00705536||153902|
NCT00705822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976J_3502|Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer|Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage|PROSTATA|Sanofi||Terminated|August 2006|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|75 Years|No|||November 2010|November 29, 2010|June 24, 2008||No|low recruitment rate|No||https://clinicaltrials.gov/show/NCT00705822||153880|
NCT00706043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA001|French Validation Orebro Musculoskeletal Pain Screening Questionnaire (OMPSQ) Questionnaire|Validation of a French Translation of the Orebro Musculoskeletal Pain Screening Questionnaire (OMPSQ): A Prospective One-Year Follow-up Study||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Not yet recruiting|June 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|20 Years|55 Years|No|Non-Probability Sample|Males and females 20-55 years old suffering from acute low back pain|May 2008|June 26, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706043||153863|
NCT00706329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSH ID 07-003|Minimally Invasive Closure of Umbilical Hernias|Study of Minimally Invasive Closure of Umbilical Hernias|MIC|South Shore Hospital|No|Terminated|April 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|June 25, 2008|Yes|Yes|The study was terminated prematurely by the IRB due to data integrity and protocol compliance    issues|No|June 5, 2013|https://clinicaltrials.gov/show/NCT00706329||153841|The study was terminated prematurely by the IRB due to data integrity and compliance concerns. Results are not shared due to data integrity concerns. These concerns are outlined in an FDA warning letter.
NCT00706667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 07-2008|Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery|Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin for the Correction of Preoperative Anaemia in Patients Undergoing Orthopaedic Surgery||University of Zurich|No|Terminated|May 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|June 25, 2008||No|Not being able to recuit sufficient patients due to a lack of complience|No||https://clinicaltrials.gov/show/NCT00706667||153817|
NCT00706966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000596822|MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer|A Pilot Study of MRI and Spectroscopy Imaging Changes With 6-months of Dutasteride in Patients With Symptomatic Benign Prostatic Hypertrophy and Low-risk Prostate Cancer on Watchful Waiting or Requiring Neoadjuvant Androgen Suppression Prior to Prostate Brachytherapy||University of California, San Francisco|Yes|Completed|June 2005|August 2011|Actual|December 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Male|N/A|N/A|No|||December 2013|December 2, 2013|June 27, 2008|No|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00706966||153794|The inclusion of only men with low volume disease may have limited our ability to accurately assess response rates after dutasteride due to the background effects on normal prostate metabolism.
NCT00702650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14272|A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations|A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion® (Cutaneous Solution) in Hypogonadal Men||Eli Lilly and Company|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Male|18 Years|N/A|No|||July 2011|July 21, 2011|June 19, 2008|Yes|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00702650||154120|
NCT00702663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96035|Seroprevalence of Hepatitis B Infection and Effect of Booster Response Amongst Taiwanese Young Adults|Seroprevalence of Hepatitis B Infection, Effect of Booster Response, and Significance of Anti-HBc Positivity Amongst Taiwanese Young Adults||Far Eastern Memorial Hospital|Yes|Recruiting|October 2007|October 2008|Anticipated|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1800|Samples With DNA|Hepatitis B DNA|Both|18 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|18-20 year- old freshmen from a private university from northern Taiwan|June 2008|June 19, 2008|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702663||154119|
NCT00702988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06056|Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 for the Development of Org 36286 (Corifollitropin Alfa).||Merck Sharp & Dohme Corp.|No|Completed|October 2003|February 2005|Actual|February 2005|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|44|||Female|18 Years|39 Years|No|Non-Probability Sample|Women with an ongoing pregnancy at least 10 weeks after embryo transfer in Trial 38826        were enrolled in this trial.|August 2015|August 28, 2015|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702988||154094|
NCT00702949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N07C1|Pregabalin in Treating Women With Hot Flashes|A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes||Alliance for Clinical Trials in Oncology||Completed|June 2008|March 2015|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|207|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|June 19, 2008|Yes|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT00702949||154097|
NCT00709397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002410/1|HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy|HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy||Brigham and Women's Hospital|No|Terminated|June 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples With DNA|Peripheral blood mononuclear cells will be tested for HIV-1 DNA levels. The cell pellets      obtained from each of the samples will be tested for 1) total HIV-1 DNA and 2-LTR circles      using real-time quantitative PCR and 2) integrated proviral DNA using Alu real-time nested      PCR.|Both|18 Years|N/A|No|Non-Probability Sample|Eligible subjects are antiretroviral-experienced patients requiring raltegravir to        construct an adequately potent antiretroviral regimen.|July 2010|July 29, 2010|July 1, 2008||No|lack of accrual|No||https://clinicaltrials.gov/show/NCT00709397||153612|
NCT00709410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK - 02|Mass Oral Cholera Vaccination in Zanzibar|Mass Oral Cholera Vaccination in High-risk Populations in Zanzibar: Assessment of Effectiveness and Herd Protection||International Vaccine Institute|No|Completed|January 2009|December 2011|Actual|February 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51151|||Both|2 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 29, 2012|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709410||153611|
NCT00709657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-060707|The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion|The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion||Medical University of Vienna|Yes|Terminated|March 2008|November 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|50 Years|N/A|No|||November 2014|November 13, 2014|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709657||153592|
NCT00709917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1857|Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes|Observational Study Investigating the Efficacy of Switching From Metformin Monotherapy to a Dual Therapy of Metformin and Repaglinide on Glycaemic Control in Type 2 Diabetes|REPAMET|Novo Nordisk A/S|No|Completed|March 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2171|||Both|18 Years|N/A|No|Non-Probability Sample|Type 2 diabetic patients having failed on metformin monotherapy|March 2016|March 2, 2016|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709917||153572|
NCT00709930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-II-01|Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension|Randomized Placebo-Controlled Trial of Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Field in Mild and Moderate Essential Hypertension||Kyoto University|Yes|Completed|December 2007|December 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Both|20 Years|74 Years|No|||March 2009|March 30, 2009|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00709930||153571|
NCT00710255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 08-023|Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm|Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm Determined by Dynamic Analysis of Exhaled Breath Condensate.||University of Vermont|No|Completed|October 2007|July 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|12 Years|75 Years|No|Non-Probability Sample|Asthmatics with exercise induced bronchospasm|July 2008|January 12, 2010|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710255||153547|
NCT00700791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0001|Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars|Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars||Ohio State University|No|Active, not recruiting|July 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|9||Anticipated|168|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700791||154261|
NCT00704314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK: 258/2002|Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?|Effects of High Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Non-Obese Type 2 Diabetic Patients||Medical University of Vienna|Yes|Completed|October 2002|July 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|21 Years|70 Years|No|||June 2008|June 23, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704314||153992|
NCT00704912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27184|Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women|Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women|OWL-PCOS|Milton S. Hershey Medical Center|Yes|Completed|September 2008|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|217|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|June 23, 2008|Yes|Yes||No|November 13, 2015|https://clinicaltrials.gov/show/NCT00704912||153947|
NCT00705263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04244|Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)|Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Slovenia||Schering-Plough|No|Completed|October 2005|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|113|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic hepatitis C treated with the PegIntron pen plus Rebetol at sites in        Slovenia.|August 2009|August 20, 2009|June 23, 2008|No|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00705263||153922|
NCT00705276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03983|Dermacyd Femina Delicata (Lactic Acid)- Photo Dermatological Evaluation of the Irritation and Sensitivity Potential|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Femina Delicata||Sanofi|No|Completed|April 2008|||May 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705276||153921|
NCT00705549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.23|Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer|Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer||Hellenic Oncology Research Group|No|Terminated|February 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Actual|88|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|June 25, 2008||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00705549||153901|
NCT00705562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK62|Tolerance of Healthy Term Infants Fed Infant Formulas|Tolerance of Healthy Term Infants Fed Infant Formulas||Abbott Nutrition|Yes|Completed|June 2008|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|190|||Both|N/A|8 Days|Accepts Healthy Volunteers|||January 2009|January 2, 2009|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705562||153900|
NCT00705835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-072|Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel|Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel: A Trial Studying RsPMSA Doses||Memorial Sloan Kettering Cancer Center||Completed|January 2003|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|N/A|No|||January 2012|January 6, 2012|June 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00705835||153879|
NCT00706056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712009565|A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure|A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure||Weill Medical College of Cornell University|No|Recruiting|September 2008|January 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|85|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with Normal Tension Glaucoma|January 2011|January 3, 2011|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706056||153862|
NCT00706342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00022|Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)|A Phase II, Open-Label, Efficacy and Safety, Ascending Dose, Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura||AstraZeneca|Yes|Completed|January 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|75 Years|No|||August 2014|August 19, 2014|June 25, 2008|No|Yes||No|July 23, 2014|https://clinicaltrials.gov/show/NCT00706342||153840|
NCT00706355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0331002|A Study of PF-04217903 in Patients With Advanced Cancer|Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-4217903 in Patients With Advanced Cancer||Pfizer|No|Terminated|August 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|June 25, 2008|No|Yes|See termination reason in detailed description.|No|April 26, 2012|https://clinicaltrials.gov/show/NCT00706355||153839|Insufficient number of participants had been enrolled in the study due to a strategic development decision; therefore some of the objectives for this study were either not investigated or not fully investigated.
NCT00706680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0619-A|Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol|The Use of Thymoglobulin in a Calcineurin Inhibitor and Steroid Minimization Protocol||University Health Network, Toronto|No|Recruiting|February 2008|June 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2008|June 25, 2008|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00706680||153816|
NCT00702676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00033|Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison|A Double-blind, Double-dummy, Randomized, Crossover Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) During Initial Dose Escalation in Healthy Volunteers||AstraZeneca|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 15, 2009|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00702676||154118|
NCT00702689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080148|Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease|A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease||National Institutes of Health Clinical Center (CC)|No|Completed|May 2008|July 2013|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|4 Years|N/A|No|||September 2015|September 29, 2015|June 19, 2008|Yes|Yes||No|September 5, 2012|https://clinicaltrials.gov/show/NCT00702689||154117|
NCT00702702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-301|Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids|A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy||Repros Therapeutics Inc.|Yes|Terminated|June 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|56|||Female|18 Years|45 Years|No|||August 2014|August 5, 2014|June 18, 2008|Yes|Yes|Repros stopped study for safety and FDA put study on hold because of safety.|No|June 23, 2014|https://clinicaltrials.gov/show/NCT00702702||154116|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00703001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007I-45|Waukesha Smiles: Dental Outreach to Low-income Waukesha Children|Waukesha Smiles: Dental Outreach to Low-income Waukesha Children||Medical College of Wisconsin|No|Completed|April 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2010|September 3, 2010|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703001||154093|
NCT00702962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-005|Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer|Phase I/II Study of Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer||Milton S. Hershey Medical Center|Yes|Active, not recruiting|September 2008|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00702962||154096|
NCT00702975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULCN0107|Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy|A Phase II Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy||Radboud University|No|Completed|September 2008|June 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2012|July 12, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702975||154095|
NCT00709423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-161106|Effects of Moxaverine and Placebo on Ocular Blood Flow|A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow||Medical University of Vienna|Yes|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2008|July 2, 2008|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709423||153610|
NCT00709683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3572|Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®|An Observational Study Evaluating the Safety and Efficacy of the Treatment With Biphasic Insulin Aspart (NovoMix® 30 FlexPen®) in the Treatment of Type 2 Diabetics After Failing on Basal/ Intermediate Mono or Combination Therapy||Novo Nordisk A/S|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|216|||Both|N/A|N/A|No|Probability Sample|Type 2 diabetic patients|March 2016|March 4, 2016|July 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709683||153590|
NCT00709956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-063A301|Iloprost Power 15 in Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension|PROWESS 15|Actelion|No|Completed|July 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||March 2015|September 10, 2015|July 1, 2008|Yes|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00709956||153570|
NCT00709969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566A2403|Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria|Open Label, Multicenter Study for Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets (6-Dose Regimen) in African Infants and Children in the Treatment of Acute Uncomplicated Falciparum Malaria||Novartis||Completed|July 2002|February 2003|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|310|||Both|N/A|N/A||||July 2008|July 2, 2008|July 2, 2008||||No||https://clinicaltrials.gov/show/NCT00709969||153569|
NCT00710242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL02|Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Assess the Safety and Efficacy or Pre-Treatment With DF01 During Late Pregnancy in Reducing Prolonged Labor||Dilafor AB|No|Completed|April 2007|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Female|18 Years|40 Years|No|||May 2009|May 18, 2009|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00710242||153548|
NCT00700453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804-07|Video Game-Brain Functioning Reversibility Study|Video Game-Brain Functioning Reversibility Study||Indiana University|Yes|Active, not recruiting|July 2008|December 2018|Anticipated|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|60|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||April 2012|May 2, 2012|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00700453||154287|
NCT00701636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12903-01|Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery|Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery||Los Angeles Biomedical Research Institute|Yes|Completed|July 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|19 Years|74 Years|No|||January 2011|January 4, 2011|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00701636||154197|
NCT00701649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT006-AngQb 02|Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension|A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension||Cytos Biotechnology AG|No|Completed|March 2008|November 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|69 Years|No|||December 2009|December 1, 2009|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701649||154196|
NCT00704925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200311036|Treatment of Lambert-Eaton Syndrome With 3,4 DAP|Treatment of Lambert-Eaton Syndrome With 3, 4-Diaminopyridine||University of California, Davis|Yes|Available|January 2000|June 2011|Anticipated|June 2010|Anticipated|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 23, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00704925||153946|
NCT00704938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080155|Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer|Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination||National Institutes of Health Clinical Center (CC)|Yes|Terminated|June 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|June 24, 2008|Yes|Yes|Terminated due to withdrawal of support from our collaborator.|No|July 10, 2012|https://clinicaltrials.gov/show/NCT00704938||153945|This study was terminated prior to completing accrual due to the withdrawal of support from our collaborator.
NCT00705289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04250|A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)|Epidemiology, Correlation and Predictive Value of Disease Activity and Biomarkers in RA Patients Initiated on Infliximab in Clinical Practice|REMARK|Merck Sharp & Dohme Corp.|No|Completed|December 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|728|Samples Without DNA|Blood and Urine samples|Both|N/A|N/A|No|Non-Probability Sample|Subjects will be patients with rheumatoid arthritis in whom treatment with infliximab is        started for the first time, in line with current clinical practice (and thus consistent        with the European SPC of Remicade®).        Subjects will be recruited from approximately 12 countries, including: Austria, Belgium,        Denmark, France, Greece, the Netherlands, Norway, Poland, Portugal, Sweden, Switzerland        and Turkey.|July 2015|July 29, 2015|June 23, 2008|No|Yes||No|September 3, 2009|https://clinicaltrials.gov/show/NCT00705289||153920|
NCT00705302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10307300|Patient Education in Patients With Chronic Obstructive Pulmonary Disease (COPD) - Effect and Costs|A Randomised Controlled Trial of the Effect of a Patient Education Program for Patients With Chronic Obstructive Pulmonary Disease (COPD)||Norwegian University of Science and Technology|Yes|Completed|September 2007|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|88|||Both|18 Years|N/A|No|||February 2012|February 3, 2012|June 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00705302||153919|
NCT00705575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2353|Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension|A 12 Week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension|ACQUIRE|Novartis|No|Completed|June 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|688|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|June 23, 2008|No|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00705575||153899|
NCT00705848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000336|Matrix Biology of Tracheobronchomalacia and Tracheal Stenosis|Matrix Biology of Tracheobronchomalacia and Tracheal Stenosis||Beth Israel Deaconess Medical Center|Yes|Completed|July 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples With DNA|Airway biopsies and brushings are to be used for staining and culture, respectively|Both|18 Years|N/A|No|Non-Probability Sample|patients with tracheobronchomalacia or tracheal stenosis referred to this tertiary care        facility|June 2011|June 13, 2011|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705848||153878|
NCT00706069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.06|Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer|A Phase I Study Of Vinorelbine Oral Plus Capecitabine Combination In Patients With Metastatic Breast Cancer||Hellenic Oncology Research Group|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|75 Years|No|||December 2009|December 14, 2009|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706069||153861|
NCT00706381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080165|Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)|Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)||National Institutes of Health Clinical Center (CC)||Completed|June 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|1||Actual|39|||Both|18 Years|N/A|No|||August 2015|December 11, 2015|June 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00706381||153837|
NCT00706368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AI063182|Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females|Taking Charge of my Health: A Trial to Investigate the Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|April 2006|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Female|14 Years|35 Years|Accepts Healthy Volunteers|||May 2008|June 25, 2008|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706368||153838|
NCT00706693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17089-AH|Skittles(TM) Effective for Treating Hypoglycemia in Children With Type 1 Diabetes|The Effectiveness of Glucose, Sucrose and Fructose in Treating Hypoglycemia in Children With Type 1 Diabetes||University of Calgary|No|Completed|August 2003|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|3 Years|18 Years|No|||July 2008|July 7, 2008|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706693||153815|
NCT00706706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181132|Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma|A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study)|MRCC RCC|Pfizer|No|Completed|July 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|June 25, 2008|No|Yes||No|August 24, 2012|https://clinicaltrials.gov/show/NCT00706706||153814|
NCT00703014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05712|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38819 for Org 36286 (Corifollitropin Alfa)||Merck Sharp & Dohme Corp.|No|Completed|August 2006|March 2009|Actual|April 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|541|||Female|18 Years|36 Years|No|Non-Probability Sample|Women with an ongoing pregnancy at least 10 weeks after ET in Base Trial P05787        (NCT00696800) were enrolled in this trial.|June 2015|June 24, 2015|June 18, 2008|No|Yes||No|November 18, 2014|https://clinicaltrials.gov/show/NCT00703014||154092|
NCT00703274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54NS057405|Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia|Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia|PROTECT DC|Georgetown University|No|Completed|April 2008|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|230|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703274||154072|
NCT00703235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUI - clinical - 185290|Intravitreal Bevacizumab for Diabetic Macular Edema|||Isfahan Ophthalmology Research Center||Enrolling by invitation||||||Phase 2/Phase 3|Interventional|N/A|||||||Both|N/A|N/A|No|||June 2008|June 20, 2008|June 20, 2008||||No||https://clinicaltrials.gov/show/NCT00703235||154075|
NCT00703248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPD-OST10030701|The Human Immunodeficiency Virus and Osteopathic Manipulation Evaluation Study||HOME|Nova Southeastern University||Completed|October 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Primary Purpose: Supportive Care|2||||||Male|18 Years|65 Years|No|||June 2008|July 7, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703248||154074|
NCT00703261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-081|Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)|A Randomized, Double-Blind, Parallel Group Study to Evaluate the Effects of High Dose Statin Therapy on 18Fluorine Fluorodeoxyglucose (18FDG) Uptake in Arteries of Patients With Atherosclerotic Vascular Disease||Merck Sharp & Dohme Corp.||Completed|August 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|30 Years|80 Years|No|||October 2015|October 8, 2015|June 19, 2008|No|Yes||No|October 25, 2011|https://clinicaltrials.gov/show/NCT00703261||154073|
NCT00709436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-017|Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery|Randomized, Multiple-center, Double-blind, Placebo-controlled Study of the Safety and Analgesic Efficacy of Repeated Dosing of PMI-150 (Intranasal Ketamine) to Treat Acute Post-operative Pain Following Orthopedic Trauma, Injury, or Surgery.||Hospira, Inc.|No|Completed|June 2008|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|85 Years|No|||January 2012|January 10, 2012|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709436||153609|
NCT00709670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070607|ComParative Diagnostic Study Between Multislice Computed Tomography (MSCT) and Stress Echography in Coronarin Patients.|ComParative Diagnostic Study Between MSCT and Stress Echography in Patients Presenting With Suspected Acute Coronary Syndrome Without ST Segment Elevation.|PEPSI|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2008|March 2012|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|217|||Both|18 Years|N/A|No|||July 2008|September 17, 2013|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00709670||153591|
NCT00700154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IICVS_00|Insulin Infusion Diabetes Ulcer|The Effect of Insulin Infusion on Metabolic Control and Inflammation in Diabetic Patients During Cardio-vascular Intervention and/or Treatment for Acute Foot Ulcer Infection.|IINDU|Karolinska Institutet|Yes|Enrolling by invitation|November 2011|November 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2011|April 8, 2015|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00700154||154310|
NCT00701324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1247.1|BI 811283 in Various Solid Tumours|An Open Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 811283 Administered Intravenously Over 24 h Continuous Infusion in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|June 2007|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|June 18, 2008||||No||https://clinicaltrials.gov/show/NCT00701324||154221|
NCT00701337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507402|Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route|Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route: Pilot Study||University Hospital, Toulouse|No|Completed|September 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|45 Years|60 Years|No|||June 2010|June 29, 2010|February 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00701337||154220|
NCT00700817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1860|The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus|The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension||Novo Nordisk A/S|No|Completed|June 2008|June 2010|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|665|||Both|18 Years|80 Years|No|||August 2014|August 8, 2014|June 18, 2008|Yes|Yes||No|June 11, 2010|https://clinicaltrials.gov/show/NCT00700817||154259|
NCT00704626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200210314|Serum Auto-Antibodies|CCRC: Serum Auto-Antibodies in Neurological Disease|SAA|University of California, Davis|No|Active, not recruiting|January 2002|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|5cc of serum will be obtained from patients with multiple sclerosis and other autoimmune and      inflammatory diseases of the nervous system. Samples may be processed immediately or at a      later time. Samples will be stored frozen in the freezer located in the Neuroscience      building at Research Park in Davis, CA. Samples are identified with initials only.|Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years and older with multiple sclerosis, myasthenia gravis and other        autoimmune or inflammatory neurological illnesses will be selected for participation in        this study.|November 2012|November 20, 2012|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704626||153968|
NCT00704639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 07.04|Chemoradiation Treatment for Head and Neck Cancer|A Phase II Study of Cetuximab, Carboplatin and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma||Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|April 2008|December 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|June 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00704639||153967|
NCT00704951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05532|Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)|P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.||Merck Sharp & Dohme Corp.|No|Withdrawn|July 2008|June 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections|August 2015|August 24, 2015|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704951||153944|
NCT00704964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04413|Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)|Impact of Patient Support From Medical Staff on the Adherence to Therapy With PegIntron Plus Rebetol|@dhere|Merck Sharp & Dohme Corp.|No|Completed|May 2005|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|746|||Both|N/A|N/A|No|Non-Probability Sample|Participants with chronic hepatitis C treated in 44 non-university centers in Germany.|October 2015|October 5, 2015|June 23, 2008||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00704964||153943|
NCT00705874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47-01-002|Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma|A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma||Progen Pharmaceuticals|No|Completed|May 2006|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|172|||Both|18 Years|N/A|No|||January 2012|January 22, 2012|June 23, 2008|No|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT00705874||153876|
NCT00705588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC084936CTIL|Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.|||Rabin Medical Center|No|Not yet recruiting|August 2008|||January 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2008|June 25, 2008|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705588||153898|
NCT00705861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK3530_DM_III|Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus|A 12 Week, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus||SK Chemicals Co.,Ltd.|Yes|Completed|November 2007|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|112|||Male|19 Years|N/A|No|||April 2013|April 16, 2013|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705861||153877|
NCT00706082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-510|Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)|A Two-stage Prospective Observational Cohort Study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension and Pulmonary Hypertension|DETECT|Actelion|No|Terminated|October 2008|March 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|490|Samples Without DNA|Serum and plasma samples will be stored at a central laboratory for at least two additional      years after official study termination.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with scleroderma in USA, Canada, UK, Germany, Switzerland, Austria, The        Netherlands, Belgium, Sweden, Slovakia, and Turkey.|June 2012|June 21, 2012|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706082||153860|
NCT00706095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-E044-108|Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System|An Open-label, Parallel Group Study to Explore the Pharmacokinetics of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors and Normal or Reduced Hepatic Function According to the Child-Pugh System||Eisai Inc.|No|Completed|February 2008|April 2010|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|February 4, 2008||No||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00706095||153859|
NCT00706394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP03-023|34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms|Prospective, Multicenter, Single Arm Phase II Study of the Powerlink 34mm Cuff for the Endovascular Repair of Abdominal Aortic Aneurysms||Endologix|Yes|Active, not recruiting|September 2005|September 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|May 2, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00706394||153836|
NCT00706719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-201|To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone|A Randomized, Open-Label, Fixed Dose, Active-Control, Multi-Center Phase IIB Study to Evaluate Fertility in Men With Secondary Hypogonadism, Comparing Androxal® to a Topical Testosterone in Men Previously Treated With Topical Testosterone.||Repros Therapeutics Inc.|No|Completed|June 2008|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Male|21 Years|60 Years|No|||July 2015|July 22, 2015|June 25, 2008|Yes|Yes||No|August 25, 2010|https://clinicaltrials.gov/show/NCT00706719||153813|
NCT00706732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX502-003|A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza|A Single-Site, Phase I/II, Double Blinded, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Adult Volunteers 65 Years of Age or Older|AVX502-003|AlphaVax, Inc.|No|Completed|June 2008|March 2009|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|28|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 11, 2012|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706732||153812|
NCT00706979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA021619-01A1|A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers|A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers||Medical University of South Carolina|No|Completed|September 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|849|||Both|18 Years|N/A|No|||October 2010|November 7, 2011|June 26, 2008||No||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00706979||153793|
NCT00706992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080162|Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients|Transfer of Autologous T Cells Transduced With the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma||National Institutes of Health Clinical Center (CC)|Yes|Terminated|June 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|50|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 27, 2008|Yes|Yes|<11 subjects were enrolled to each Arm|No|December 18, 2012|https://clinicaltrials.gov/show/NCT00706992||153792|
NCT00703521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M49P2|Rabies Immunization Concomitant With JEV in Children|A Three-Year Clinical Study on Immunogenicity, Safety and Booster Response of Purified Chick Embryo Cell Rabies Vaccine (Pcecv) Administered Intramuscularly or Intradermally to 12- to 18-Month-Old Thai Children Concomitantly With Japanese Encephalitis Vaccine||Mahidol University|No|Completed|August 2002|September 2005|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||June 2008|October 23, 2008|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703521||154053|
NCT00703859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-24139|Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma|A Phase I Single Arm Trial Combining Radiotherapy and Temozolomide With Dichloroacetate (DCA) in Patients With Newly Diagnosed Glioblastoma Multiform Tumours||AHS Cancer Control Alberta|Yes|Withdrawn|July 2008|||January 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2011|February 18, 2016|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00703859||154027|
NCT00708578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_02670|Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)|Insulin Glargine Combined With Sulfonylurea Versus Metformin in Patients With Type 2 Diabetes: A Randomized, Controlled Trial.||Sanofi|No|Completed|May 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|75 Years|No|||January 2011|January 24, 2011|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708578||153674|
NCT00708591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13274B|Study of Rapamycin Plus Ketoconazole in Advanced Cancers|A Phase Ib Study Administering Rapamycin (Sirolimus) With Ketoconazole in Patients With Advanced Malignancies||University of Chicago|Yes|Completed|October 2004|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|June 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708591||153673|
NCT00700466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hanss_EA 162/07|Intravenous Beta-blockade for Improvement of Autonomic Activity|Beta-adrenoceptor Blockade Prior to Induction of Anesthesia for Improvement of Depressed Autonomic Regulation||University of Schleswig-Holstein|Yes|Completed|March 2008|November 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for coronary artery bypass surgery|February 2009|January 15, 2010|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700466||154286|
NCT00700479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602001143|Studies on Aldosterone and Vascular Function|Studies on Aldosterone and Vascular Function||Yale University|No|Completed|January 2006|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 17, 2008|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00700479||154285|
NCT00700128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060714|Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals|Prevention of Menstrual Migraines: Effects of Continuous Oral Contraceptives to Combination With Prophylactic Frovatriptan Use During Hormone Free Intervals|MAM|Scott and White Hospital & Clinic|No|Completed|June 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700128||154312|
NCT00700141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-031-DE|Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®|Non-Interventional Study on the Use of TachoSil® During Thyroid Surgery||Nycomed|No|Completed|September 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|482|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatients|April 2010|May 4, 2012|June 17, 2008||No||No|March 11, 2010|https://clinicaltrials.gov/show/NCT00700141||154311|
NCT00700804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC064|Meat Protein and Calcium: Do They Interact Synergistically or Antagonistically?|Meat Protein and Calcium: Do They Interact Synergistically or Antagonistically?||USDA Grand Forks Human Nutrition Research Center|No|Completed|June 2003|January 2005|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Female|50 Years|80 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|June 18, 2008|No|Yes||No|December 30, 2008|https://clinicaltrials.gov/show/NCT00700804||154260|
NCT00701051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-039-08S|Exercise Training and Glucose Metabolism in Aging|Aging, Angiogenesis and Metabolic Responses to Aerobic Exercise||VA Office of Research and Development|Yes|Completed|October 2006|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|June 18, 2008||No||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00701051||154241|
NCT00700505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR-DM-001|A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy|A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy||ThermaRx, Inc.|Yes|Completed|April 2008|December 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|25 Years|80 Years|No|||August 2012|August 13, 2012|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00700505||154283|
NCT00701077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060802|DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome|DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome|DAPREB|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|July 2008|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||June 2008|July 1, 2008|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701077||154239|
NCT00704652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|394/2007|Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus|Evaluation of Functional and Morphological Retinal Changes in the Course of Systemic Aranesp Treatment in Patients With Diabetes Mellitus|EPOinDR|Medical University of Vienna|No|Terminated|May 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|5|||Both|18 Years|80 Years|No|Probability Sample|Diabetic patients with min. Grade 2 renal insufficiency, and in Group B with anemia that        is to be treated with systemic ESA therapy.|April 2015|April 6, 2015|June 23, 2008||No|Patient recruitment was not sufficient to achieve the needed patient numbers.|No||https://clinicaltrials.gov/show/NCT00704652||153966|
NCT00705601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001380|Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study|Refinement Of Patient Reported Outcomes Instruments In Subjects With Insomnia Characterized By Nonrestorative Sleep||Pfizer|No|Terminated|August 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|64|||Both|18 Years|64 Years|No|||February 2011|February 1, 2011|June 24, 2008|No|Yes|See Detailed Description|No||https://clinicaltrials.gov/show/NCT00705601||153897|
NCT00705887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002996|A Motivational Enhancement Approach to Skin Cancer Prevention|The Feasibility of a Motivational Enhancement Approach to Skin Cancer Prevention in a Sample of Young Adult Patients||Oregon Health and Science University|No|Completed|September 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|82|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2008|June 25, 2008|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705887||153875|
NCT00706108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 100013-116673 /|Adaptive Coordination in Anaesthesia Teams and Its Relationship to Clinical Performance.|Adaptive Coordination in Anaesthesia Teams and Its Relationship to Clinical Performance. (Cooperative Project ETHZ, OAT, Prof. G. Grote, and IfA/USZ; Founding by Swiss National Science Foundation to Both Institutions)|RACoP|University of Zurich|No|Completed|January 2005|March 2010|Actual|||N/A|Observational|N/A||3|Actual|161|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Anesthesia personnel (nurse anesthetists, anesthesia residents, staff anesthetists, OR        attendants, other members of anesthesia / perioperative team)and patients as seen on        video; all if informed consent was obtained|January 2011|January 10, 2011|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706108||153858|
NCT00706407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709009413|Uro-NIRS Clinical Study|Uro-NIRS Clinical Study|Uro-NIRS|Weill Medical College of Cornell University|No|Completed|April 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 12, 2010|June 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706407||153835|
NCT00706745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLA362|Conjugated Linoleic Acid and Atherosclerosis|Possible Effects of Supplementation With Cis-9, Trans-11 Conjugated Linoleic Acid on Markers of Atherosclerosis||UMC Utrecht|Yes|Completed|June 2007|December 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00706745||153811|
NCT00707005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0164|Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients|Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients||Yonsei University|No|Recruiting|May 2008|September 2008|Anticipated|July 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|110|Samples Without DNA|Conjunctival swab samples|Both|N/A|N/A|No|Non-Probability Sample|Myopia patients scheduled for refractive surgery|June 2008|June 26, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707005||153791|
NCT00702715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05769|Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)|A Multi-center, Parallel-group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of 4.0 mg/kg Sugammadex Administered at 1-2 PTC in Subjects With Normal or Severely Impaired Renal Function||Merck Sharp & Dohme Corp.|No|Completed|September 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|June 19, 2008|Yes|Yes||No|March 15, 2011|https://clinicaltrials.gov/show/NCT00702715||154115|
NCT00707980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_301|Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder||Takeda|No|Completed|June 2008|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|836|||Both|18 Years|76 Years|No|||October 2013|October 24, 2013|June 27, 2008|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00707980||153720|
NCT00707993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322_303|Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics|A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes||Takeda|No|Completed|June 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|441|||Both|65 Years|90 Years|No|||May 2013|May 22, 2013|June 27, 2008|Yes|Yes||No|February 17, 2013|https://clinicaltrials.gov/show/NCT00707993||153719|
NCT00708279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-07-04 SOMMA|Study of Osteopathic Manipulation in the Management of Angina|Study of Osteopathic Manipulation in the Management of Angina|SOMMA|University of New England|No|Completed|August 2007|July 2008|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|81 Years|No|||June 2010|April 13, 2011|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00708279||153697|
NCT00708604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04033|Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes|Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes Using a Sirolimus/Tacrolimus/MMF-Based Immunosuppressive Regimen||City of Hope Medical Center|Yes|Completed|August 2005|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||July 2014|July 2, 2014|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708604||153672|
NCT00708942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC CE201/08|Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1|A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-grade Cervical Intraepithelial Neoplasia (CIN1)||Photocure|No|Terminated|January 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|83|||Female|18 Years|N/A|No|||April 2013|April 17, 2013|July 1, 2008||No|Slow recruitment, study stopped with only 13 of 70 patients included in second part of the    study|No|March 4, 2013|https://clinicaltrials.gov/show/NCT00708942||153647|Slow recruitment lead to early terminaiton of the second part of the trial, including arms 4 and 5, after enrolment of 13 patients. No formal statistical analysis conducted on this part of the data.
NCT00699582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-305|To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures||Eisai Inc.||Completed|May 2008|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|389|||Both|12 Years|N/A|No|||October 2012|June 26, 2014|June 17, 2008|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00699582||154353|
NCT00699595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070721003|Hormonal Effects on Pain Perception|Hormonal Effects on Pain Perception|HEPP|University of Alabama at Birmingham|No|Completed|September 2008|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|None Retained|Plasma for progesterone levels|Female|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy term pregnant women|November 2014|November 8, 2014|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699595||154352|
NCT00699907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0707-04|Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer|A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer||University of Arizona|Yes|Completed|January 2005|November 2014|Actual|November 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|127|||Female|18 Years|N/A|No|||April 2014|December 11, 2014|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699907||154329|
NCT00700193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-FLU-04-05|A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population|An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (= or >6 Months to < 9 Years of Age).||CSL Limited|No|Completed|March 2005|||June 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|298|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||November 2008|November 6, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700193||154307|
NCT00700206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.2101|Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)|Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)||Telik|No|Completed|May 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||August 2011|October 10, 2011|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700206||154306|
NCT00700492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2437-30/12/2003|Does Hormonal Luteal Support After Intra-uterine Insemination (IUI) Increase the Pregnancy Rate?|Luteal Support With Vaginal Progesterone Capsules Following Ovulation Induction With Human Menopausal Gonadotropins (hMG) for Intra Uterine Insemination: A Comparative Study||University Hospital, Gasthuisberg|No|Terminated|May 2004|June 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|June 17, 2008||No|Change in Belgian law on the use of hMG in IUI|No||https://clinicaltrials.gov/show/NCT00700492||154284|
NCT00700518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P150-005|Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon|A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon||Procris Pharmaceuticals|No|Completed|June 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|10|||Both|18 Years|50 Years|No|||December 2008|December 29, 2008|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00700518||154282|
NCT00700830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3571|Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes|Assessment of Safety and Efficacy of Levemir® (Insulin Detemir) Treatment for Insulin Naive Patients With Type 2 Diabetes Mellitus|IDEALS|Novo Nordisk A/S|No|Completed|January 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1976|||Both|18 Years|N/A|No|Non-Probability Sample|Type 2 diabetes insulin naive patients|December 2013|August 13, 2014|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700830||154258|
NCT00700843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0008|Long-Term Follow-up of Ohio State University Medical Center (OSUMC) Bariatric Patients|Long-Term Follow-up of Ohio State University Medical Center (OSUMC) Bariatric Patients||Ohio State University|No|Terminated|April 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|89 Years|No|Non-Probability Sample|Adults who participated in the bariatric program at OSUMC ten or more years ago, including        bariatric surgery.|May 2015|May 13, 2015|June 17, 2008||No|Difficulty recruiting|No||https://clinicaltrials.gov/show/NCT00700843||154257|
NCT00701103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-001|Phase I Dose Escalation Trial of MK-0646 in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)(COMPLETED)|An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a Weekly, Every Other Week, or Every Three Week Infusion in Patients With Advanced Solid Tumors and Multiple Myeloma||Merck Sharp & Dohme Corp.|No|Completed|January 2006|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|98|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|June 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701103||154237|
NCT00701714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-22-INJ-17|Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients|Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients||Sandoz|No|Terminated|September 2007|January 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|337|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|June 17, 2008||No|investigation of adverse events|No||https://clinicaltrials.gov/show/NCT00701714||154191|
NCT00704665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2773|Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma|A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Scleroderma||Rutgers, The State University of New Jersey|No|Completed|December 1998|December 2001|Actual|December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|70 Years|No|||June 2008|June 24, 2008|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704665||153965|
NCT00704678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBR759A2202|Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis|A 12-week, Open Label, Multicenter, Titration Study, With a 12 Month Extension, to Determine the Optimal Titration Regimen for SBR759, Compared to Sevelamer HCl, in Lowering Serum Phosphate Levels in Asian Patients With Chronic Kidney Disease on Hemodialysis|SBR759|Novartis||Completed|August 2008|||June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|203|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|June 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00704678||153964|
NCT00705614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03164|Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)|Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy|ENCORE|Merck Sharp & Dohme Corp.|Yes|Completed|July 2003|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2662|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects, ages 18 years and older, with a diagnosis of active or fistulizing CD with        no previous exposure to Remicade will be eligible to enroll into the registry.|February 2015|February 9, 2015|June 23, 2008|No|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT00705614||153896|
NCT00710502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05626|Transvaginal NOTES Cholecystectomy: Phase I/II Mexico Clinical Trial|Transvaginal Natural Orifice Translumenal and Endoscopic Surgery (NOTES) Cholecystectomy vs. Laparoscopic Cholecystectomy: Phase I/II Clinical Trial||North Texas Veterans Healthcare System|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Female|18 Years|65 Years|No|||December 2009|December 14, 2009|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710502||153528|
NCT00710788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.1|Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis|Interventional, Multicenter, Prospective, Randomized Trial to Slow Down the Progression of Cardiovascular Calcifications to Reduce QTd in Incident Dialysis Patients|Independent|Azienda Sanitaria ASL Avellino 2|Yes|Completed|January 2007|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|75 Years|No|||February 2013|February 9, 2013|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710788||153506|
NCT00706121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593329|S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000|S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT|ACP|Southwest Oncology Group|Yes|Completed|June 2008|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|8097|||Male|50 Years|120 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706121||153857|
NCT00706420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01083|Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen|Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen||City of Hope Medical Center|Yes|Active, not recruiting|January 2002|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||March 2015|March 18, 2015|June 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00706420||153834|
NCT00706433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUSA-CP0103|Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne|A Randomized, Evaluator-blinded, Parallel Group Light Dose Ranging Study of Photodynamic Therapy With Levulan Topical Solution + Blue Light Versus Levulan Topical Solution Vehicle + Blue Light on Moderate to Severe Facial Acne Vulgaris||DUSA Pharmaceuticals, Inc.|No|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|266|||Both|12 Years|N/A|No|||October 2011|October 20, 2011|June 24, 2008|Yes|Yes||No|July 9, 2009|https://clinicaltrials.gov/show/NCT00706433||153833|
NCT00706758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S487-02|Structured Patient Education Versus Written Information for Patients With Irritable Bowel Syndrome|Structured Patient Education Versus Written Information for Patients With Irritable Bowel Syndrome||Sahlgrenska University Hospital, Sweden|No|Completed|August 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|70 Years|No|||June 2008|July 19, 2011|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00706758||153810|
NCT00707018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0088|Immobilization in External Rotation After First Time Anterior Shoulder Dislocation|Immobilization in External Rotation After First Time Anterior Shoulder Dislocation: A Prospective Randomized Study||University of Colorado, Denver|No|Completed|September 2004|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|14 Years|30 Years|No|||January 2013|December 11, 2013|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707018||153790|
NCT00702728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R100-CCFM S103/208|Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention|A Study to Evaluate the Effectiveness of Induced Diuresis With Matched Hydration Therapy Compared to Standard Overnight Hydration in the Prevention of Contrast Induced Nephropathy -MYTHOS Study|MYTHOS|Centro Cardiologico Monzino|No|Recruiting|June 2008|December 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2008|October 9, 2009|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00702728||154114|
NCT00702741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|551|Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy|A Long-Term Follow-up Study of Chondrogen - Adult Human Stem Cells Delivered by Intra-articular Injection Following Meniscectomy in Subjects 18-60 Years||Mesoblast, Ltd.|No|Completed|June 2008|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|60 Years|No|||December 2014|December 2, 2014|June 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00702741||154113|
NCT00703027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96027|Diabetes Mellitus Care Decision Making Model Through Data Mining|Diabetes Mellitus Care Decision Making Model Through Data Mining||Far Eastern Memorial Hospital|Yes|Completed|October 2002|September 2007|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|2000|||Both|18 Years|90 Years|No|Non-Probability Sample|This retrospective cohort study included 2,000 patients who visited our Division of        Endocrinology and Metabolism outpatient department in this hospital with the diagnosis        diabetes mellitus who had been enrolled into the Diabetes Care Program from year 2002        until 2007.|June 2009|March 26, 2012|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00703027||154091|
NCT00703287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN07NE039|Specialized Physiotherapy Program for Cervical Dystonia|Randomized Trial of a Specialized Physiotherapy Program Versus Standard Physiotherapy Advice in Patients With Cervical Dystonia (Spasmodic Torticollis).||South Glasgow University Hospitals NHS Trust|No|Completed|January 2008|December 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 1, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703287||154071|
NCT00708292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2103|A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.|An Open-label, Multi-center, Phase I-Ib/II Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma.||Novartis||Completed|July 2008|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708292||153696|
NCT00708955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080169|Evaluation and Treatment of People With Eye Diseases|Evaluation and Treatment Protocol for Potential Research Participants With Ocular Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|June 2008|||||N/A|Observational|N/A|||Anticipated|5000|||Both|N/A|N/A|No|||September 2015|September 18, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00708955||153646|
NCT00709215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OV06-001|Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia|A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia||OncoVista, Inc.|Yes|Recruiting|June 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2009|January 8, 2009|June 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709215||153626|
NCT00709488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSO-OL008|Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|A Phase 1 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy||Light Sciences Oncology|No|Completed|June 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||November 2012|November 14, 2012|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00709488||153605|
NCT00699920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAMF_L_02661|Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks|A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During the 2 Years of Follow-up, in Children in Uganda.|SMART-CURE|Sanofi||Completed|June 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|413|||Both|6 Months|59 Months|No|||June 2010|June 28, 2010|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00699920||154328|
NCT00699933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/008|Diagnostic and Interventional Therapy in Acute Pancreatitis|Diagnostic and Interventional Therapy in Acute Pancreatitis||University of Regensburg|No|Recruiting|May 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Bacterial DNA|Both|18 Years|N/A|No|Non-Probability Sample|50 patients with acute pancreatitis|June 2010|August 8, 2011|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699933||154327|
NCT00700219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX01-OBX0006|Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes|Development of a Non-invasive Test to Detect Intra-amniotic Infection and Predict Preterm Birth in Women Presenting With Preterm Labor and and Intact Amniotic Membranes|IAI|ProteoGenix, Inc.|No|Recruiting|June 2008|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|900|Samples Without DNA|Cervical-vaginal Fluid, Amniotic Fluid, Maternal Serum, Neonatal Cord Blood, Maternal Urine,      Placental and Umbilical Cord Tissues|Female|18 Years|N/A|No|Non-Probability Sample|Women presenting to labor and delivery with signs and symptoms of preterm labor and        documented intact amntiotic membranes|July 2010|July 19, 2010|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700219||154305|
NCT00700531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-003968-22|European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy|European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy|EuLITE|University Hospital Birmingham|Yes|Recruiting|June 2008|June 2012|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2009|July 6, 2010|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700531||154281|
NCT00700856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM6T9CET|Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial|Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.|TOSCA IT|Italian Society of Diabetology|Yes|Active, not recruiting|September 2008|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3371|||Both|50 Years|75 Years|No|||August 2015|August 26, 2015|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00700856||154256|
NCT00701090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-803|A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)|A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin||Merck Sharp & Dohme Corp.||Completed|May 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1035|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|June 17, 2008|Yes|Yes||No|September 13, 2010|https://clinicaltrials.gov/show/NCT00701090||154238|
NCT00701727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ezetimibe RCT-001|Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study|Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study||Radiant Research|No|Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||March 2011|March 14, 2011|June 17, 2008|Yes|Yes||No|January 10, 2011|https://clinicaltrials.gov/show/NCT00701727||154190|
NCT00705315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.21|Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer|Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study||Hellenic Oncology Research Group|No|Completed|May 2008|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|75 Years|No|||August 2010|August 18, 2010|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705315||153918|
NCT00710801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400A2427|Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation|Randomized, Open-label Study to Evaluate the Hepatitis C Virus (HCV) Burden in Patients Receiving Cyclosporine (Neoral or CSA) Versus Tacrolimus (Prograf) in de Novo Liver Recipients Receiving Mycophenolate Sodium (Myfortic): Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation||University of Alberta||Completed|May 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Serum Tissue|Both|18 Years|75 Years|No|Non-Probability Sample|HCV positive patients undergoing orthotopic liver transplantation|September 2011|September 14, 2011|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710801||153505|
NCT00711100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA135884|Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers|Study 1: Preference, Health Effects and Efficacy of Four Oral Tobacco Products for Smoking Cessation||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|August 2008|December 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|104|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 14, 2015|July 2, 2008||No||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00711100||153483|
NCT00711074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00010|Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers|An Open-Label, Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of [14C]AZD5672 in Healthy Male Volunteers||AstraZeneca|No|Completed|June 2008|July 2008|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|4|||Male|50 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 8, 2009|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711074||153485|
NCT00711087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20344|Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)|Botulinum Toxin A Treatment of Detrusor External Sphincter Dyssynergia During Early Spinal Cord Injury (Protocol #H-20344)||Baylor College of Medicine|No|Terminated|July 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|50 Years|No|||September 2015|September 11, 2015|July 7, 2008|Yes|Yes|Funds no longer available|No|September 11, 2015|https://clinicaltrials.gov/show/NCT00711087||153484|
NCT00711412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05I2|Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer|A Phase II Study of Capecitabine and Oxaliplatin With Radiation for Esophageal and Gastroesophageal Junction Adenocarcinoma||Northwestern University|Yes|Active, not recruiting|October 2005|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|July 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00711412||153460|
NCT00711659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00006933|Standardizing Educational Opportunities on the Complete Pediatric Physical Exam|Standardizing Educational Opportunities on the Complete Pediatric Physical Exam|Head to Toe|Medical College of Wisconsin|No|Completed|June 2007|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|519|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All third year medical students starting their pediatric clerkship at the Medical College        of Wisconsin|November 2013|November 25, 2013|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00711659||153441|
NCT00707356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN801 PCM201|Study of WST11 in Patients With Localized Prostate Cancer|Vascular-Targeted Photodynamic Therapy Using WST 11 in Patients With Localized Prostate Cancer||Steba Biotech S.A.|Yes|Completed|September 2008|July 2012|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||April 2015|April 27, 2015|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707356||153766|
NCT00707707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00011|Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer|Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Given in Combination With Paclitaxel in the 1st or 2nd Line Treatment of Patients With Metastatic Triple Negative Breast Cancer||AstraZeneca|No|Active, not recruiting|September 2008|December 2016|Anticipated|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|130 Years|No|||January 2016|January 14, 2016|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707707||153740|
NCT00708968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA090739|Prostate Cancer: Family Care for Patients and Spouses|Prostate Cancer: Family Care for Patients and Spouses||University of Michigan|Yes|Completed|September 2001|December 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|263|||Both|21 Years|N/A|No|||July 2008|June 15, 2015|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00708968||153645|
NCT00709228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04793|Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)|PREDICT - Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24||Merck Sharp & Dohme Corp.|No|Completed|May 2006|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|496|Samples With DNA|Blood sample for PCR|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|January 2015|January 14, 2015|June 23, 2008|No|Yes||No|November 9, 2009|https://clinicaltrials.gov/show/NCT00709228||153625|
NCT00709514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCB-WH1-CP001|Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers|A Phase II, Double-blind, Placebo-controlled Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers||Oneness Biotech Co., Ltd.|No|Completed|December 2008|March 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|N/A|No|||July 2013|July 8, 2013|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709514||153603|
NCT00699946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7381*KELLY|Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery|A Double-Blind, Randomized, Placebo-Controlled Study of Perioperative Administration of Olanzapine to Prevent Postoperative Delirium in Joint Replacement Patients||The New England Baptist Hospital|No|Completed|January 2005|October 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|495|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 19, 2009|June 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699946||154326|
NCT00699959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2007/8|National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups|Comparison and Description of Coronary Patients Management With or Without Heart Failure in Cardiology Consulting|COMPAR|AstraZeneca|No|Completed|June 2008|January 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|1650|||Both|18 Years|N/A|No|Probability Sample|First two consecutive Coronary patients with or without heart failure|August 2009|August 4, 2009|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00699959||154325|
NCT00699972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-304|Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures||Eisai Inc.|No|Completed|June 2008|November 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|390|||Both|12 Years|99 Years|No|||October 2015|October 30, 2015|June 17, 2008|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00699972||154324|
NCT00700232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOHP06-YB GEN CIG|ABCB4 Gene Mutations in Intrahepatic Cholestasis of Pregnancy and Controls|Mutations and Polymorphisms of Gene ABCB4 Among Women Suffering From Intrahepatic Cholestasis of Pregnancy. A Study With a Control Group.||University Hospital, Tours|No|Completed|July 2006|July 2009|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|blood samples|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|multiparous normal pregnant women (control group)from a single University center|June 2010|June 16, 2010|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700232||154304|
NCT00700544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM SA 2002|Treatment Outcome in Elderly Patients|Adjonction of Androgenotheapy for Post-Remission Treatment of Elderly Patients With Acute Myeloid Leukemia - Results of the Multicenter Goelams SA-2002 Trial.||University Hospital, Grenoble|Yes|Completed|June 2002|May 2008|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|330|||Both|60 Years|N/A|No|||June 2008|June 13, 2008|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700544||154280|
NCT00701389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-026|Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)|A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Single Dose Crossover Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 in Migraine Patients||Merck Sharp & Dohme Corp.||Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|June 17, 2008|No|Yes||No|August 27, 2014|https://clinicaltrials.gov/show/NCT00701389||154216|
NCT00701402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2007/9|National Survey on Dyslipidemic Patients|Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.|PRYSME|AstraZeneca|No|Completed|June 2008|January 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|3655|||Both|18 Years|N/A|No|Probability Sample|First three consecutive dyslipidemic patients seen by GP|August 2009|August 4, 2009|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701402||154215|
NCT00708396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Escitalopram -199CTIL|Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study|||BeerYaakov Mental Health Center|Yes|Recruiting|July 2008|July 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2009|January 26, 2009|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00708396||153688|
NCT00705328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137444|Families First Edmonton (FFE)|Families First Edmonton: The Comparative Effects and Expense of Four Models of Augmenting Services for Low-income Families|FFE|University of Alberta|No|Completed|December 2005|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|4||Anticipated|2400|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 7, 2011|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705328||153917|
NCT00711113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OSS-0001|Study on OsseoSpeed™ Implants Replacing 2-5 Teeth in the Posterior Upper Jaw, Restored With Provisional Teeth Attached 6-7 Weeks Later|An Open, Prospective Study to Evaluate Implant Stability, Marginal Bone Adaptation and the Survival Rate of Astra Tech Dental Implant System, Fixture Osseospeed™, in Patients With Tooth Loss in the Posterior Maxilla in an Early Loading Protocol.||Dentsply Implants|No|Completed|December 2003|||September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|July 7, 2008|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00711113||153482|
NCT00711438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIS PhIInm v3 26/10/06|Pilot Randomized Controlled Trial of a Breathlessness Intervention Service for Chronic Obstructive Pulmonary Disease|Phase II Pilot Pragmatic Single-Blinded Fast Track Randomised Controlled Trial of the Breathlessness Intervention Service Versus Standard Care for Patients With Chronic Obstructive Pulmonary Disease|BIS-PhIInm|Cambridge University Hospitals NHS Foundation Trust|No|Completed|April 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|13|||Both|18 Years|N/A|No|||October 2006|July 7, 2008|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711438||153458|
NCT00707057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO-0001|Ibuprofen Extended-Release Dental Pain Study|Ibuprofen 600 mg Extended-Release (ER) Multiple-Dose Dental Pain Study||SCOLR Pharma, Inc.|No|Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|256|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|June 26, 2008|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00707057||153787|Of the 12 subjects who prematurely discontinued all 4 doses of the study drug, 6 subjects received 1 dose of study drug, 2 subjects received 2 doses, and 4 subjects received 3 doses.
NCT00711425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OSS-0002|Study on OsseoSpeed™ Implants in Patients Missing 2-5 Teeth in the Posterior Lower Jaw, Restored With Permanent Teeth Attached 6-7 Weeks Later|An Open, Prospective Study to Evaluate Implant Stability, Marginal Bone Adaptation and the Survival Rate of Astra Tech Dental Implant System, Fixture Osseospeed™, in Patients With Tooth Loss in the Posterior Mandible in an Early Loading Protocol.||Dentsply Implants|No|Completed|February 2004|||January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|July 7, 2008|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00711425||153459|
NCT00711672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808231|Study of the Therapeutic Use of Language in Patients With Metastatic Colorectal Cancer|Critical Negotiations: Narrative Agreement, Negotiation, and Register Use in Encounters Between Patients With Metastatic Colorectal Carcinoma and Their Oncologists||Hematology and Oncology Associates of NE Pennsylvania|Yes|Completed|July 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic colorectal carcinoma and their physicians at a large community        cancer center in Northeastern Pennsylvania.|June 2011|June 2, 2015|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711672||153440|
NCT00707369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH 365/1-1|Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization|Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization|ABPARO-Studie|University Hospital Muenster|Yes|Completed|October 2008|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|540|||Both|18 Years|75 Years|No|||March 2015|March 2, 2015|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00707369||153765|
NCT00707720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSI 07-01|Multi-Center Feasibility Study of Trans-oral Endoscopic Restrictive Implant System (TERIS) for Treatment of Obesity|Multi-center Feasibility Study to Evaluate the Safety of the Trans-oral Endoscopic Restrictive Implant System (TERIS) for the Treatment of Obesity||BaroSense Inc.|No|Completed|June 2008|December 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|50 Years|No|||April 2013|April 9, 2013|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707720||153739|
NCT00708006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1029-C1078|A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors|A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors||Human Genome Sciences Inc.|No|Completed|May 2008|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708006||153718|
NCT00708019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cancer Pain Management|Improving Cancer Pain Management Through Self-Care|Improving Cancer Pain Management Through Self-Care||University of California, San Francisco|No|Active, not recruiting|December 2007|April 2014|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|222|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00708019||153717|
NCT00707876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-PAD-001|Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)|A Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA Versus Ferumoxytol Vascular Enhanced MRI (VE-MRI) for the Detection of Clinically Significant Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in Subjects With Peripheral Arterial Disease Scheduled for Digital Subtraction Angiography (DSA)||AMAG Pharmaceuticals, Inc.|No|Active, not recruiting|September 2008|December 2014|Anticipated|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|108|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707876||153728|
NCT00708812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XYL014|Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer|Paclitaxel Plus Carboplatin (TC) Versus TC Plus Endostar in Patients With Advanced Non-small Cell Lung Cancer(NSCLC): a Randomized, Double-blind, Placebo-controlled, Multicentre Study||Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd|No|Completed|July 2007|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|75 Years|No|||July 2011|July 20, 2011|June 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00708812||153656|
NCT00709111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5256|Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression|A Pilot Trial of Maraviroc for Treatment of Subjects on Antiretroviral Therapy With Suboptimal CD4 T-cell Count Recovery Despite Sustained Virologic Suppression||AIDS Clinical Trials Group|Yes|Completed|January 2009|April 2010|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|16 Years|N/A|No|||January 2016|January 4, 2016|July 1, 2008|No|Yes||No|July 26, 2011|https://clinicaltrials.gov/show/NCT00709111||153634|
NCT00708487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PresbyterianHDallasARTSO2|Live Births With Low Oxygen Blastocyst Culture|A Controlled Randomized Trial Evaluating the Effect of Lowered Incubator Oxygen Tension on Live Births in a Predominantly Blastocyst Transfer Program|Oxygen|Texas Health Resources|Yes|Completed|August 1999|August 2001|Actual|August 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Female|20 Years|40 Years|No|||June 2008|July 1, 2008|June 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00708487||153681|
NCT00681811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-MLD-049|Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD|A Multi-center, Open-Label Extension Study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) Treatment in Patients With Late Infantile Metachromatic Leukodystrophy (MLD)||Shire|No|Terminated|February 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|3 Years|6 Years|No|||February 2014|August 4, 2015|May 19, 2008|Yes|Yes|Terminated prior to planned completion date due to lack of efficacy.|No|September 26, 2012|https://clinicaltrials.gov/show/NCT00681811||155699|Early termination due to lack of efficacy.
NCT00681824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550701|Fibrin Sealant for the Sealing of Dura Sutures|An Exploratory Phase 2 Study Evaluating the Efficacy and Safety of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated (FS VH S/D) 500 S-APR for the Sealing of Dura Defect Sutures in Posterior Fossa Surgery||Baxter Healthcare Corporation|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|3 Years|N/A|No|||May 2013|May 21, 2013|May 19, 2008|Yes|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00681824||155698|
NCT00682188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD053371|A School Nurse-Delivered Intervention for Overweight and At Risk Adolescents|A School Nurse-Delivered Intervention for Overweight and At Risk Adolescents||University of Massachusetts, Worcester|Yes|Completed|September 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|84|||Both|13 Years|18 Years|No|||March 2014|March 12, 2014|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682188||155670|
NCT00683111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC-2007-176|Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease|Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction||Ruttonjee Hospital|Yes|Completed|July 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683111||155602|
NCT00683384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-102300|Study Evaluating the Safety of Enbrel (Etanercept)|A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Etanercept (Enbrel) 25 mg by Subcutaneous Injection||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|93|||Both|N/A|N/A|No|Non-Probability Sample|Primary Care|October 2010|October 15, 2010|May 21, 2008||No||No|October 15, 2010|https://clinicaltrials.gov/show/NCT00683384||155582|
NCT00683410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-102339|Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)|A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) 0.5 mL by Intramuscular Injection||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3366|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care|October 2010|October 15, 2010|May 21, 2008||No||No|October 15, 2010|https://clinicaltrials.gov/show/NCT00683410||155580|
NCT00683436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG2-73-205|Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs|A Multi-Center, Randomized, Blinded, Active and Placebo-Controlled, Crossover Study of the Efficacy and Safety of Two Doses of Adipiplon Bilayer Tablets in Primary Insomniacs||Neurogen Corporation|No|Terminated|May 2008|November 2008|Anticipated|October 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|84|||Both|21 Years|64 Years|No|||July 2008|July 21, 2008|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683436||155578|
NCT00683449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-221-CL-006|Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma|A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma||MediciNova|No|Terminated|June 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|55 Years|No|||October 2011|October 5, 2011|May 21, 2008|Yes|Yes|Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more    appropriate dosing scheme for MN-221 in subjects with asthma.|No|February 16, 2011|https://clinicaltrials.gov/show/NCT00683449||155577|
NCT00683709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2726|Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder|Metabolic Side Effects, Diet and Exercise Counseling and Brain Function in a Naturalistic Clinical Trial of Clozapine for Treatment Resistant Bipolar and Schizoaffective Disorder||St. Joseph's Healthcare Hamilton|No|Completed|January 2007|July 2011|Actual|July 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|N/A|No|Non-Probability Sample|Psychiatric outpatients from within the catchment area of the hospitalwho suffer from        chizoaffective disorder and respond poorly to treatment offered to participate in research|August 2011|August 2, 2011|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683709||155558|
NCT00679263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-221-CL-005|Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma|A Randomized, Single-blind, Parallel Group, Placebo-controlled, Dose Rate Escalation Study Evaluating the Safety and Effects of MN-221 in Subjects Diagnosed With Moderate to Severe Asthma||MediciNova|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|50 Years|No|||November 2011|December 14, 2011|May 14, 2008|Yes|Yes||No|February 16, 2011|https://clinicaltrials.gov/show/NCT00679263||155894|
NCT00679588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6520|Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery|A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery|SAVE-ABDO|Sanofi|Yes|Completed|April 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4413|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679588||155869|
NCT00709059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04243|Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)|A Non-interventional Phase IV Survey to Assess the Antiviral Effectiveness of PegIntron® and Rebetol® Treatment According to the Stage of Liver Fibrosis in Previously Untreated Patients With Genotype 1/4/5/6 Chronic Hepatitis C (CHC) (PRACTICE)|PRACTICE|Merck Sharp & Dohme Corp.|No|Completed|December 2004|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|538|||Both|18 Years|N/A|No|Probability Sample|Previously untreated patients with chronic hepatitis C, infected with HCV genotype 1, 4,        5, or 6, receiving treatment with PegIntron and Rebetol.|November 2015|November 3, 2015|June 23, 2008|No|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00709059||153638|
NCT00709306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K07CA108685|The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention|The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention||Fox Chase Cancer Center|No|Completed|March 2006|June 2010|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|200|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709306||153619|
NCT00709293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thymoglobulin - Alejos|Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients|Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients||University of California, Los Angeles|No|Withdrawn|July 2008|||May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|N/A|21 Years|No|||June 2013|June 17, 2013|July 1, 2008|No|Yes|Insufficient funding|No||https://clinicaltrials.gov/show/NCT00709293||153620|
NCT00707603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04/126|Chronic Hepatitis C and Insulin Resistance|Understanding the Relationship Between Insulin Resistance and Chronic Hepatitis C Infection||Garvan Institute of Medical Research|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|Samples Without DNA|serum|Male|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hepatitis C patients|July 2015|July 13, 2015|June 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00707603||153748|
NCT00707616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|348-05|Common Genetic Variation and Type 2 Diabetes|The Effect of Diabetes-associated Gene Variation on Glucose Metabolism in Humans||Mayo Clinic|No|Completed|March 2006|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|190|Samples With DNA|Samples for hormone measurement and DNA extraction|Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, non-diabetic|January 2013|January 18, 2013|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707616||153747|
NCT00711555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0363|Emend for Multiple-day Emetogenic Chemotherapy|An Open Label Phase II Study of Aprepitant for Multi-day Moderately-high to Highly Emetogenic Chemotherapy Regimens||University of Illinois at Chicago|No|Completed|November 2005|January 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|18 Years|N/A|No|||August 2009|August 6, 2009|July 3, 2008|Yes|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00711555||153449|
NCT00711568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBS-014-01S|A Clinical Trial of Magnetic Stimulation in Depression|A Clinical Trial of Magnetic Stimulation in Depression||VA Office of Research and Development|No|Completed|October 2001|December 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|65 Years|No|||March 2013|March 29, 2013|July 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00711568||153448|
NCT00711581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endograb-HMO-CTIL|Evaluation of Laparoscopic Internal Retractor Device|Evaluation of the Efficacy and Safety of the Endograb: A Laparoscopic Internal Retractor Device||Hadassah Medical Organization|No|Completed|August 2008|August 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||June 2008|April 9, 2014|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00711581||153447|
NCT00707226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-171000|Circadian Variations in Ocular Blood Flow in Glaucomatous and Normal Eyes|Circadian Variations in Ocular Blood Flow in Glaucomatous and Normal Eyes||Medical University of Vienna||Completed|November 2000|December 2001|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Male|N/A|N/A|Accepts Healthy Volunteers|||June 2008|June 27, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707226||153776|
NCT00711243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04I2|Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor|A Phase I/II Study of Taxotere, Oxaliplatin, and 5- Fluorouracil||Northwestern University|Yes|Active, not recruiting|March 2005|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|58|||Both|18 Years|120 Years|No|||September 2015|September 29, 2015|July 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00711243||153472|
NCT00708825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH 97018|Reverse-Loop Upper Arm Arteriovenous Graft|Reverse-Loop Upper Arm Arteriovenous Graft for Chronic Hemodialysis||Far Eastern Memorial Hospital|Yes|Suspended|January 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|7|Samples Without DNA|prosthetic vascular graft (ePTFE)|Both|16 Years|N/A|No|Non-Probability Sample|uremic patient, compromized forarm and elbow options|June 2008|June 30, 2008|June 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708825||153655|
NCT00708513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cell Saver 704.03|Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.|Phase I/II Evaluation of Intraoperative Autotransfusion Filtration for Major Surgical Oncology Operations|Cellsaver|University of Louisville|Yes|Completed|December 2003|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|Surgical Oncology Clinic|October 2013|October 18, 2013|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708513||153679|
NCT00708838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-02-2707-AA-CTIL|Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors|VLA-1 Receptors on Peripheral T Cells in Ischemic Heart Disease Patients||Sheba Medical Center|No|Completed|January 2002|February 2007|Actual|January 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Actual|151|None Retained|Blood samples isolated from patients included in the study and anallysed by FACS|Both|18 Years|80 Years|No|Probability Sample||July 2008|July 1, 2008|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00708838||153654|
NCT00709124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00017423|Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness|Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness|NMES|Johns Hopkins University|No|Completed|June 2008|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 1, 2008|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT00709124||153633|
NCT00682578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKMAL0701|A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan|Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan||University of Oxford|Yes|Recruiting|July 2007|December 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|3 Months|N/A|No|||January 2010|January 21, 2010|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00682578||155642|
NCT00682825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1253|Study Evaluating Whether the Bispectral Index Prevents Patients at Higher Risk From Being Awake During Surgery and Anesthesia|BAG-RECALL Study: BIS or Anesthesia Gas to Reduce Explicit Recall|BAG-RECALL|Washington University School of Medicine|Yes|Completed|March 2008|||December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6000|||Both|18 Years|N/A|No|||January 2011|January 3, 2011|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682825||155623|
NCT00683098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEP Clara|Long-Term Results After Endoscopic Total Extraperitoneal Repair of Recurrent Inguinal Hernia|Long-Term Results After Endoscopic Total Extraperitoneal Repair of Recurrent Inguinal Hernia||St. Claraspital AG|No|Enrolling by invitation|June 2008|December 2008|Anticipated|August 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|patients, who had endoscopic total extraperitoneal repair of recurrent inguinal hernia at        our institution between 1995 and 2008|June 2008|June 12, 2008|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683098||155603|
NCT00682838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-163|Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring|Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring||VA Office of Research and Development|No|Completed|July 2009|June 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|300|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00682838||155622|
NCT00683423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB114-006|BMS-741672 for Diabetic Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial to Evaluate the Efficacy and Safety of BMS-741672 in Patients With Diabetic Neuropathic Pain||Bristol-Myers Squibb|No|Completed|July 2008|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683423||155579|
NCT00683462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-1734-226-CRD-005|An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)|An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)||AstraZeneca||Completed|May 2008|July 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|No|||October 2009|October 29, 2009|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683462||155576|
NCT00679289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2007-001|Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma|Phase II Study of the Anti-Ganglioside GD3 Mouse/Human Chimeric Antibody KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma||Ludwig Institute for Cancer Research|Yes|Active, not recruiting|March 2008|October 2015|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679289||155892|
NCT00679601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-205|Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)|An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis||Anacor Pharmaceuticals, Inc.|No|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||May 2008|May 15, 2008|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679601||155868|
NCT00679614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-427|Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery|The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in Elderly Patients Having Joint Replacement Surgery: a Randomized Controlled Study.||Lawson Health Research Institute|No|Recruiting|September 2008|November 2009|Anticipated|November 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|51|||Both|70 Years|N/A|No|||September 2009|September 2, 2009|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679614||155867|
NCT00710424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCL0305|A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy||GW Pharmaceuticals Ltd.|No|Completed|July 2005|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|297|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|July 2, 2008||No||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00710424||153534|
NCT00710684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ3110866|A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease|Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease||GlaxoSmithKline|No|Completed|July 2008|August 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|684|||Both|50 Years|85 Years|No|||September 2011|March 15, 2012|June 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00710684||153514|
NCT00709839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSIGT_Hydrocortisone_01|Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans|Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans||Medical University of Vienna|No|Completed|June 2008|December 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2009|May 31, 2011|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709839||153578|
NCT00710164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSCR capsule-1|Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke|||Fudan University|Yes|Recruiting|September 2008|||July 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||September 2009|May 27, 2010|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00710164||153554|
NCT00707902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920'073|Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray Compared to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats|Multicentric Randomized Double Blind Double Dummy Placebo Controlled Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray in Comparison to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats||Bioforce AG|Yes|Completed|February 2006|August 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|154|||Both|12 Years|75 Years|No|||June 2008|June 30, 2008|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707902||153726|
NCT00708188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.431/24|Multidetector Raw CT as a Single Tool in the Setting of Ischemic Stroke|Evaluation of Multidetector Raw Computerized Tomography in the Etiological Analysis of Acute Ischemic Stroke: the "COCASE" Protocol.|COCASE|Hospices Civils de Lyon|No|Completed|March 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|49|||Both|18 Years|90 Years|No|||July 2013|July 25, 2013|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00708188||153704|
NCT00708201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3753-002|A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy|A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy.||Cubist Pharmaceuticals LLC|Yes|Completed|March 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|June 27, 2008|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00708201||153703|
NCT00707577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p001384|A Maintenance Program for the Be Fit Employee Wellness Program|A Randomized Controlled Trial of a Maintenance Program for the Be Fit Employee Wellness Program at Massachusetts General Hospital||Massachusetts General Hospital|No|Completed|February 2008|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|330|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707577||153750|
NCT00707590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB116-001|Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)|Randomized, Double-Blind, Placebo-Controlled Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus||Bristol-Myers Squibb|No|Terminated|August 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 9, 2009|June 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00707590||153749|
NCT00708526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26111|Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea|Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea||University of Utah|Yes|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|22|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|June 30, 2008||No||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00708526||153678|
NCT00708851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-LCDUVB|NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study|A Clinical Evaluation of Safety & Efficacy of Adding an At-home Topical LCD Solution Regimen to Standard Narrowband UVB Phototherapy Administered 3 Times Weekly to Adults With Generalized Plaque Psoriasis.||NeoStrata Company, Inc.|No|Completed|April 2007|March 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|June 27, 2008||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT00708851||153653|This is a bilateral pilot study including 12 subjects. Subjects will apply the liquor carbonis distillate (LCD) solution to one half of their body, while receiving narrow-band ultraviolet B (NB-UVB) light therapy across their whole body.
NCT00708877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI18450|Liver Transplantation for Cholangiocarcinoma|Liver Transplantation for Cholangiocarcinoma||University of Utah|Yes|Terminated|March 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|16 Years|N/A|No|||July 2013|July 23, 2013|June 27, 2008||No|study procedures have become standard of care as patients seeking Model for End-Stage Liver    Disease (MELD) exception points for cholangiocarcinoma|No|December 13, 2011|https://clinicaltrials.gov/show/NCT00708877||153652|
NCT00709137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00027466|Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension|Randomized Trial of Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension||VA Salt Lake City Health Care System|Yes|Withdrawn|October 2008|November 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|July 1, 2008||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00709137||153632|
NCT00709150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068468|Collaborative Depression Care Management in Treating Depressed Low-income Hispanics With Diabetes|Multifaceted Depression Diabetes Program for Hispanics|MDDP|University of Southern California|Yes|Completed|March 2005|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|387|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00709150||153631|
NCT00682214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-78/24.03.2008|Cholecalciferol Supplementation, Muscle Strength|Skeletal Muscle Strength Including Its Energy Metabolism, Bone Mineral Homeostasis and Th1/Th2 Cytokines Expression in Asian Indians With Chronic Hypovitaminosis D Before and After Oral Cholecalciferol Supplementation|MRVD|Indian Council of Medical Research|No|Completed|May 2008|June 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2008|June 14, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682214||155668|
NCT00682591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05595|Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy|Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients (Methadone, Buprenorphine, Suboxone) Under Hepatitis C Therapy (Peginterferon Alfa and Ribavirin)||University of Wuerzburg|Yes|Withdrawn|July 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|190|||Both|18 Years|65 Years|No|Non-Probability Sample|Outpatients with chronic hepatitis C infection and drug substitution therapy (methadone,        burpenorphine, suboxone)|February 2009|February 3, 2009|May 20, 2008||No|Study had to be withdrawn because financial support was cancelled.|No||https://clinicaltrials.gov/show/NCT00682591||155641|
NCT00679302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14415|Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management|A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics||St. Louis University|Yes|Completed|July 2006|May 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|3 Months|18 Years|No|||March 2014|March 28, 2014|May 14, 2008||No||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00679302||155891|Small sample size with large number of loss to follow up at the 3 month mark.
NCT00679315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-07-073|Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female|Efficacy and Safety of Alfuzosin for the Treatment of Non-neurogenic Voiding Dysfunction in Female: An 8 Week Prospective, Randomized Double Blind, Placebo-Controlled, Parallel Group Study (Phase Ⅱ)||Samsung Medical Center|No|Completed|June 2008|December 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Female|18 Years|N/A|No|||June 2013|June 7, 2013|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679315||155890|
NCT00680485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPS108221|Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416|See Detailed Description||GlaxoSmithKline|No|Terminated|June 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment||||96|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|April 14, 2008||||No||https://clinicaltrials.gov/show/NCT00680485||155800|
NCT00710697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701|Cardiac Safety Assessment Study of Picoplatin in Solid Tumors|A Phase 1 Study of Picoplatin in Subjects With Advanced Non-Hematological Malignancies With Emphasis on Cardiac Repolarization||Poniard Pharmaceuticals|No|Active, not recruiting|June 2008|July 2009|Anticipated|March 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|July 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00710697||153513|
NCT00710710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.10|Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer|An Open, Randomised, Clinical Phase II Trial in Patients With Unresectable Advanced Pancreatic Cancer Investigating the Efficacy, Safety, and Pharmacokinetics of BI 2536 Administered in Repeated 3-week Cycles as a Single i.v. Dose of 200 mg on Day 1 or as 60 mg Doses on Days 1, 2, and 3||Boehringer Ingelheim||Completed|August 2006|||October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|89|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|July 3, 2008||||No||https://clinicaltrials.gov/show/NCT00710710||153512|
NCT00709579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODULCORTICOATROPHIE|Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids|Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids||Pierre Fabre Dermo Cosmetique|Yes|Active, not recruiting|June 2008|August 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|50 Years|N/A|No|||July 2008|July 3, 2008|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00709579||153598|
NCT00709852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91681|Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging|A Multicenter, Randomized, Double-blind, Crossover, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)||Bayer|No|Completed|June 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|402|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|July 1, 2008|Yes|Yes||No|August 19, 2011|https://clinicaltrials.gov/show/NCT00709852||153577|
NCT00711256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2007-120|Sunscreen: Persistence of Sun Protection Factor and the Influence on Vitamin D|Sunscreen Removal by Clothing Meassured in Vivo. Sun Protection Factor Persistence During a Day Indoor Without Physical Activity. Does Sunscreen Reduce Vitamin D?|sunscreen|Bispebjerg Hospital|No|Recruiting|July 2008|November 2008|Anticipated|August 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2008|July 7, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711256||153471|
NCT00711269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1001002|Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia|Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase III Study>||Sumitomo Dainippon Pharma Co., Ltd.||Completed|July 2008|||||Phase 3|Interventional|Primary Purpose: Treatment|4||Anticipated|440|||Both|18 Years|74 Years|No|||June 2012|June 11, 2012|June 11, 2008||||No||https://clinicaltrials.gov/show/NCT00711269||153470|
NCT00707239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074K6-2000|Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia|A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study Of The Safety And Efficacy of 2 Doses Of Tigecycline Versus Imipenem/Cilastatin For The Treatment Of Subjects With Hospital-Acquired Pneumonia||Pfizer|Yes|Terminated|December 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|June 26, 2008|Yes|Yes|See termination reason in detailed description.|No|June 5, 2012|https://clinicaltrials.gov/show/NCT00707239||153775|Formal statistical conclusions could not be made due to premature termination of study, because of enrollment difficulties, and small number of enrolled participants.
NCT00707252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-128|Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer|Phase I/II Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer||Louisiana State University Health Sciences Center Shreveport|Yes|Terminated|January 2008|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|June 26, 2008|Yes|Yes|Phase II not initiated due to cancellation of supply of Poly E by collaborator.|No||https://clinicaltrials.gov/show/NCT00707252||153774|
NCT00707265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-05|rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study|A Prospective, Randomized Clinical Investigation of rhBMP-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease|CRM|Medtronic Spinal and Biologics|Yes|Completed|March 2002|February 2010|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|N/A|No|||September 2011|August 1, 2013|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707265||153773|
NCT00707629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507-18|Long Term Effects of Diabetes of Very Young Children|Long Term Effects of Diabetes of Very Young Children||Indiana University|No|Completed|August 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|25|||Both|6 Years|10 Years|No|Non-Probability Sample|Children between ages 6 and 10. Diagnosed with type 1 diabetes prior to the age of 5        years.|February 2016|February 29, 2016|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00707629||153746|
NCT00707915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH0001|Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons|Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons: a Pilot Study||Minamihanno Hospital|No|Completed|January 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|50 Years|N/A|No|||March 2012|March 24, 2012|June 27, 2008||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00707915||153725|
NCT00708500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05101|Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)|A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin||Merck Sharp & Dohme Corp.|Yes|Completed|August 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|404|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|June 27, 2008|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00708500||153680|
NCT00708539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25921|A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.|A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.||Nordica Fertility Clinic|Yes|Recruiting|April 2006|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2686|||Female|18 Years|40 Years|No|||July 2008|July 1, 2008|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708539||153677|
NCT00708552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ3110865|Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease|Study AZ3110865, a Study Comparing SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease||GlaxoSmithKline||Completed|July 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|576|||Both|50 Years|85 Years|No|||February 2012|May 31, 2012|June 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708552||153676|
NCT00708890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF_815357|Twelve Step Based Self-help Groups for Substance Related Disorders|Twelve Step Based Self-help Groups for Substance Related Disorders - A Randomized Controlled Trial on a Detoxification Center|TSF_Norway|Sorlandet Hospital HF|No|Completed|September 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|70 Years|No|||April 2014|April 15, 2014|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708890||153651|
NCT00708903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-105|Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)|A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects||Puma Biotechnology, Inc.|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|June 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00708903||153650|
NCT00709163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A026|Nesiritide - Dilated Cardiomyopathy|Nesiritide as an Adjunctive Therapy for Children With Dilated Cardiomyopathy Admitted to the Intensive Care Unit||University of California, Los Angeles|No|Completed|December 2003|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|21 Years|No|||June 2008|July 2, 2008|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00709163||153630|
NCT00709176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA107383|Outcomes of Triaged Family Care in Advanced Cancer|Outcomes of Triaged Family Care in Advanced Cancer|FOCUS-Triage|University of Michigan|Yes|Completed|June 2005|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|484|||Both|18 Years|N/A|No|||October 2013|February 10, 2014|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709176||153629|
NCT00682604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UItaquera|The Nutritional Status and Food Intake of Community Health Agents|Community Health Agents From East Zone of Sao Paulo City, Brazil: A Look at Their Nutritional Status and Food Intake||Unidade Itaquera|No|Completed|September 2006|October 2006|Actual|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|88|||Both|18 Years|N/A|No|Non-Probability Sample|Community health agents from East Zone of Sao Paulo City, Brazil.|May 2008|May 20, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682604||155640|
NCT00682851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08020012|A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test|A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test||University of Pittsburgh|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|519|||Female|15 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 25, 2011|May 16, 2008|Yes|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00682851||155621|A major limitation of this study was that in the first 122 women, 24% of the cohort, the vaginal swabs used for the diagnostic tests were collected in random order, which resulted in decreased sensitivity of the OSOM Rapid and BVBLue tests.
NCT00683475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13924|A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer|A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy||Eli Lilly and Company|Yes|Completed|August 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Male|18 Years|N/A|No|||October 2014|October 7, 2014|May 19, 2008|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00683475||155575|
NCT00683124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM7KP2PX|Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients|Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.|MaNeLo|IRCCS Policlinico S. Matteo|Yes|Recruiting|July 2008|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|291|||Both|12 Months|55 Years|No|||July 2011|July 20, 2011|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683124||155601|
NCT00683137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0513-144|Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery|Clinical Protocol for a Multiple Dose Randomized, Double-Blind, Placebo Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Bunionectomy Surgery||Pfizer|No|Completed|October 2002|February 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|450|||Both|18 Years|N/A|No|||May 2008|May 22, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683137||155600|
NCT00683722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801|PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Mesoblast, Ltd.||Completed|April 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|40 Years|80 Years|No|||December 2014|December 3, 2014|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683722||155557|
NCT00683735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZBL 2008-Nauck-01|Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis|Quantification of the DPP-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis||Diabeteszentrum Bad Lauterberg im Harz|Yes|Completed|February 2009|December 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|20|||Both|30 Years|75 Years|No|||December 2015|December 17, 2015|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683735||155556|
NCT00680212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8458|Vitamin A Equivalence of Plant Carotenoids in Children|Phase 2 Study of VITAMIN A EQUIVALENCE OF PLANT CAROTENOIDS IN CHILDREN||Tufts University|Yes|Completed|July 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|72|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680212||155821|
NCT00680498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clover 1|Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment|Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment|CLOVER|Illinois Retina Associates||Completed|February 2007|October 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|50 Years|N/A|No|||March 2012|March 27, 2012|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680498||155799|
NCT00711321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Affiris 004|Long-term Safety and Tolerability of AFFITOPE AD02|Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD02 Applied During AFFiRiS 002||Affiris AG|Yes|Completed|November 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|23|Samples Without DNA|serum|Both|50 Years|N/A|No|Non-Probability Sample|Subjects having participated in AFFiRiS 002|May 2010|May 26, 2010|July 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00711321||153466|
NCT00710957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck - 33500|Vitamin D and Physical Function in Older Adults|Role of Vitamin D Status on Physical Function and Falls in Adults of Advanced Age||Wake Forest School of Medicine|No|Completed|April 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1100|||Both|79 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiovascular Health Study (CHS), is a longitudinal, observational, population-based        study of the onset, progression, and course of heart disease and stroke in the elderly        which began in 1988. We are only examining those that participated in the the CHS All        Stars which is from the same cohort of people who were still alive in 2005 when enrollment        began. We approached everyone who was in the CHS study and asked them to participate in        the CHS All Stars study. Blood samples were collected at the year 18 visit and analyzed        for serum 25(OH)D.|November 2013|November 14, 2013|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710957||153494|
NCT00711282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OSS-0009|Study of Bone Preservation When OsseoSpeed™ Implants Are Placed Immediately Following Tooth Extraction|A Prospective, Randomized, Controlled Study to Evaluate Buccal Bone Preservation Using Fixture MicroThread™ OsseoSpeed™ Placed in Fresh Extraction Sockets the Maxilla.||Dentsply Implants|No|Completed|December 2005|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00711282||153469|
NCT00711295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810705|Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups|An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups||Nanotherapeutics, Inc.|Yes|Completed|August 2008|October 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|3583|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|October 7, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00711295||153468|
NCT00711594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.33|LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib|Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.||Boehringer Ingelheim||Completed|April 2008|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|20 Years|N/A|No|||January 2015|January 13, 2015|July 8, 2008||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00711594||153446|
NCT00707278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI13633|Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma|A Prospective Phase I Study of Radiation Therapy and Concurrent Capecitabine and Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma||University of Utah|Yes|Completed|September 2005|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|June 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00707278||153772|
NCT00707642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV-002-C-101|Safety Study of HBV-002 West Nile Vaccine in Healthy Adults|Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults||Hawaii Biotech, Inc.|Yes|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 13, 2009|June 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00707642||153745|
NCT00707928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si249/2007|Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study|Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study||Mahidol University|No|Completed|February 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|March 6, 2011|June 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00707928||153724|
NCT00708227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82211|Pharmacogenetics of b2-Agonists in Asthma.|Pharmacogenetics of b2-Agonists in Asthma.||Nemours Children's Clinic|No|Completed|September 2007|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|10 Years|N/A|No|||April 2015|April 13, 2015|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708227||153701|
NCT00708214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.5|BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer|A Phase II Study of BIBW 2992 Administration in Patients With Hormone Refractory Metastatic Breast Cancer||Boehringer Ingelheim||Completed|January 2007|||February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|N/A|No|||October 2013|December 5, 2013|June 30, 2008||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00708214||153702|
NCT00699270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomet 12380-76|A Clinical Investigation of the Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems|A Prospective, Non-Controlled, Clinical Investigation of the Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems||Biomet, Inc.|No|Withdrawn|August 2007|December 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients that have already made the decision to undergo shoulder replacement surgery and        will receive a Biomet humeral stem.|January 2012|January 25, 2012|June 13, 2008|No|Yes|Business need changed.|No||https://clinicaltrials.gov/show/NCT00699270||154377|
NCT00699283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01306|A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures|An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.||UCB Pharma|No|Terminated|August 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|16 Years|75 Years|No|||September 2012|August 26, 2014|June 12, 2008|Yes|Yes|An interim analysis revealed the study was unlikely to attain a positive outcome for the    efficacy analysis. No safety concerns were detected|No||https://clinicaltrials.gov/show/NCT00699283||154376|
NCT00699530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-ISP-20070132|Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment|Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment||University of Aarhus|No|Recruiting|May 2008|January 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Whole blood, serum, muscle samples, fat samples|Both|18 Years|70 Years|No|Non-Probability Sample|Patients recently diagnosed with hyperprolactinemia|December 2014|December 2, 2014|May 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00699530||154357|
NCT00699543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECO-PLEASANT|The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention|The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention: Comparison or Efficacy Between COroflex PLEASe ANd TaxusTM Stent||Seoul National University Hospital|Yes|Active, not recruiting|July 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|915|||Both|18 Years|N/A|No|||December 2013|December 15, 2013|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00699543||154356|
NCT00699855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28614|Long Term Follow up Study of Predictive Markers in GHD and TS Children|Observational Long-term Follow-up of the Phase IV Open-label Trial of Predictive Markers in GHD and TS Pre-pubertal Children Treated With Saizen|PREDICT LT FUP|Merck KGaA||Completed|September 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|N/A||1|Actual|182|||Both|N/A|N/A|No|Non-Probability Sample|Subjects initially enrolled in PREDICT (NCT 00256126) clinical study and continuing a        growth hormone treatment.|February 2014|February 17, 2014|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699855||154333|
NCT00699868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01197-46|Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients|Cellular Immunity, Cytomegalovirus Infection and Septic Shock in ICU Patients|2006/25|Assistance Publique Hopitaux De Marseille|No|Completed|March 2008|August 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|29|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699868||154332|
NCT00683150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0126|Perioperative Kinetics of Reactive Hyperemia Using Noninvasive Digital Thermal Monitoring|Characterizing the Perioperative Kinetics of Reactive Hyperemia Using Noninvasive Digital Thermal Monitoring: an Observational Study of a Surrogate Marker of Endothelial Function||M.D. Anderson Cancer Center|No|Completed|May 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|59|||Both|18 Years|N/A|No|Non-Probability Sample|Study participants scheduled to have major abdominal or thoracic surgery.|July 2012|July 27, 2012|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683150||155599|
NCT00683163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICS001|PTH & Ibandronate Combination Study (PICS)|PTH & Ibandronate Combination Study (PICS): Optimizing the Use of PTH With Boniva (Pilot Randomized Controlled Trial)|PICS|University of California, San Francisco|Yes|Completed|May 2008|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Female|55 Years|75 Years|No|||August 2013|August 29, 2013|May 20, 2008|Yes|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT00683163||155598|
NCT00679328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-01|OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions|Study #91-01 - A Randomized Study of the Stryker OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions||Olympus Biotech Corporation|No|Completed|February 1992|December 1999|Actual|August 1996|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|85 Years|No|||June 2011|June 9, 2011|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679328||155889|
NCT00679341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21976|A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease|A Randomized, Multicenter, Phase ii Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease||Hoffmann-La Roche||Completed|September 2008|May 2012|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|May 14, 2008|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00679341||155888|
NCT00679627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012463|A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease||Janssen Research & Development, LLC||Terminated|June 2008|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2051|||Both|45 Years|90 Years|No|||September 2013|September 10, 2013|May 15, 2008|Yes|Yes|Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended    early termination of the trial|No|April 23, 2013|https://clinicaltrials.gov/show/NCT00679627||155866|
NCT00679640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-ATA-2007/1|Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France|Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France|SISTOLA|AstraZeneca|Yes|Completed|January 2008|July 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Both|N/A|N/A|No|Probability Sample|Patients seen in outpatient care (private consultation or outpatient hospital        consultation) at the baseline visit|July 2010|December 1, 2010|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679640||155865|
NCT00679913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0509-513-157|Standardization of Surgery on the Pancreatic Cancer|Randomized Controlled Study: Comparison Between Extended and Standard Pancreatoduodenectomy||Seoul National University Hospital|Yes|Completed|November 2005|December 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|244|||Both|20 Years|85 Years|No|||May 2014|May 8, 2014|May 15, 2008|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00679913||155844|
NCT00679926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baker - 001|Kaletra and Viread in Antiretroviral Naïve Patients|A Phase IV Open Label Investigation of the Efficacy and Durability of Once Daily Antiretroviral Therapy With Kaletra and Viread in Antiretroviral Naïve Patients.||Oklahoma State University Center for Health Sciences|No|Terminated|May 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||October 2012|October 9, 2012|May 15, 2008||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00679926||155843|
NCT00680225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4290s|Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma|Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma||New England Retina Associates|No|Completed|September 2007|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680225||155820|
NCT00680238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKotze|Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)|Pregnancy and Implantation Rates When Embryos Are Selected Based on a Single Day 3 Score (Day 3)vs Graduated Embryo Score(GES) Plus Soluble Human Leukocyte Antigen-G Expression.||University of Stellenbosch|Yes|Completed|June 2004|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|214|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||May 2008|May 19, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680238||155819|
NCT00711308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX0401ES|Tinzaparin in the Treatment of the Acute Pulmonary Embolism|Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism||Complejo Hospitalario Xeral-Calde|No|Completed|April 2005|February 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711308||153467|
NCT00711022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OSS-0008|Study on ASTRA TECH Implant System, OsseoSpeed™ Implants in Patients Missing All Teeth in the Upper Jaw, Restored With Provisional Teeth Within 24 Hours|An Open, Prospective, Multicenter Study to Evaluate the Outcome of ASTRA TECH Implant System, OsseoSpeed™ Implants, in Patients With Totally Edentulous Maxillas and Poor Bone Quality and Quantity in an Immediate Loading Protocol.||Dentsply Implants|No|Completed|May 2005|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|N/A|No|||May 2014|July 4, 2014|July 7, 2008|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT00711022||153489|
NCT00711347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-013|Intraoperative Floppy Iris Syndrome|||Alcon Research|No|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||August 2010|August 4, 2010|July 3, 2008||No||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00711347||153465|
NCT00710970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16848|Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment|H-16848 - Phase II Pilot Study With Correlative Markers of Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy||Baylor College of Medicine|Yes|Completed|January 2007|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|July 7, 2008||No||No|December 27, 2012|https://clinicaltrials.gov/show/NCT00710970||153493|
NCT00710983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-7041-122|Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth|Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth||Bandim Health Project|No|Active, not recruiting|July 2008|January 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||||||Both|N/A|1 Month|No|||November 2013|November 14, 2013|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00710983||153492|
NCT00711620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007015|Efficacy of Thymosin alpha1 for Severe Sepsis|Multicenter, Randomized, Controlled Study to Evaluate the Efficacy of Thymosin alpha1 in Patients With Severe Sepsis|ETASS|Sun Yat-sen University|Yes|Completed|May 2008|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|366|||Both|18 Years|85 Years|No|||October 2009|June 13, 2011|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00711620||153444|
NCT00707291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMOCT9010_Vis_Edge|Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface|Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface||University of Miami|No|Completed|July 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|61|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|normal healthy subjects|July 2014|July 4, 2014|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707291||153771|
NCT00707304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-0207|Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer|FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens|FORTIS-M|Agennix|Yes|Completed|November 2008|August 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|742|||Both|18 Years|N/A|No|||August 2012|August 13, 2012|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707304||153770|
NCT00707317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBNET-TIGRA|T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals|Prospective Head-to-head Comparison of the Two Commercially Available Approved TIGRA (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) With the Established Mendel-Mantoux Skin-test in Immunocompromized Patients|TBNET-TIPS|Tuberculosis Network European Trialsgroup|No|Completed|June 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|1843|Samples Without DNA|Plasma supernatants of stimulated samples for cytokine analysis.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|immunocompetent and immunocompromised patients|December 2015|December 15, 2015|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00707317||153769|
NCT00707655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN207|Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy|An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy||Genmab|Yes|Terminated|September 2008|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|June 27, 2008||No|The decision is based on company re-evaluation of indications to be pursued within SCCHN|No|October 7, 2011|https://clinicaltrials.gov/show/NCT00707655||153744|All adverse events were collected during the 8 week treatment period and for 4 additional weeks. Serious adverse events were collected for the extended follow-up period of 2 years.
NCT00707941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007|Oseltamivir Randomised Controlled Efficacy Trial|Efficacy of Oseltamivir in Reducing the Duration of Clinical Illness, Viral Shedding, and Transmissibility Reduction Within Households Among Participants in an Influenza Disease Burden Surveillance Cohort in Urban Dhaka, Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|May 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|700|||Both|1 Year|N/A|No|||June 2008|July 11, 2011|June 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707941||153723|
NCT00708240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMHR-REB-2006-14|Treatment Youth With Obsessive-Compulsive Disorder|Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations.||University of Ottawa|Yes|Recruiting|January 2007|December 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||June 2008|June 30, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00708240||153700|
NCT00699556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0508000486|Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy|Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy||Yale University|Yes|Active, not recruiting|January 2006|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|21 Years|N/A|No|||February 2016|February 10, 2016|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00699556||154355|
NCT00699569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-NV-248|Hyperimmune Colostrum and Oral Mucositis|The Effect of Hyperimmune Colostrum on Radiation-Induce Oral Mucositis of Patients With Head and Neck Cancer|Mucositis|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2008|July 22, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00699569||154354|
NCT00699881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202- 806|Study of Cetuximab to Treat Gastric Cancer|Phase II Study of Cetuximab (Erbitux®) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-line Chemotherapy|STAGE|Fudan University|No|Completed|May 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|70 Years|No|||June 2008|December 21, 2009|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00699881||154331|
NCT00699894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07118|Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting|Comparison of Aprepitant PO and Ondansetron IV for Prevention of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Orthognathic Surgery and General Anesthesia.||Northwell Health|Yes|Withdrawn|June 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Male|15 Years|25 Years|No|||August 2013|August 8, 2013|June 16, 2008||No|Logistical difficulties running the study|No||https://clinicaltrials.gov/show/NCT00699894||154330|
NCT00700167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-098|Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy|Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy - A Phase I Trial in Melanoma||Memorial Sloan Kettering Cancer Center||Completed|September 2001|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00700167||154309|
NCT00700180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21015|A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.|A Randomized, Open-label Study to Explore the Correlation of Biomarkers With Response Rate in Chemo-naive Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Who Receive Treatment With Avastin in Addition to Carboplatin-based Chemotherapy||Hoffmann-La Roche||Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|June 17, 2008||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT00700180||154308|
NCT00683748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T cell study|Monitoring Cellular Immunity After Kidney and Liver Transplantation|Monitoring Cellular Immunity After Kidney and Liver Transplantation||Karolinska University Hospital|No|Active, not recruiting|March 2007|March 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Serum, whole blood|Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing kidney or liver transplantation at the Karolinska University        Hospital|February 2009|February 4, 2009|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683748||155555|
NCT00683761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM601-008|A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma|A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma||TransMolecular|No|Active, not recruiting|August 2008|April 2010|Anticipated|February 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||July 2009|July 16, 2009|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683761||155554|
NCT00679354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00339|Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy|Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma||National Cancer Institute (NCI)||Completed|June 2008|July 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|21 Years|No|||October 2011|May 5, 2014|May 14, 2008|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00679354||155887|
NCT00679653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD200010|Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives|Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives|HOS|Abbott|No|Completed|February 2002|||December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|171|||Both|20 Years|65 Years|No|||May 2008|May 16, 2008|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00679653||155864|
NCT00679666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0050,2008H0049|Corneal Crosslinking in Keratoconus and Corneal Ectasia|Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia|CXL|Ohio State University|No|Withdrawn|April 2008|October 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|207|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 29, 2011|April 2, 2008|Yes|Yes|Investigator no longer at university|No||https://clinicaltrials.gov/show/NCT00679666||155863|
NCT00679939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD111179|Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health|A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|April 2008|September 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|226|||Female|55 Years|80 Years|No|||April 2013|April 5, 2013|May 15, 2008|Yes|Yes||No|January 7, 2011|https://clinicaltrials.gov/show/NCT00679939||155842|
NCT00679952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0612-018-191|Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy|Randomised Prospective Study of Clinical Outcomes After Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy After Pancreatoduodenectomy||Seoul National University Hospital|Yes|Completed|March 2007|March 2010|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|168|||Both|15 Years|85 Years|No|||May 2014|May 8, 2014|May 15, 2008|Yes|Yes||No|March 13, 2011|https://clinicaltrials.gov/show/NCT00679952||155841|
NCT00680264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007HSG021|Prospective Study of Scoliosis in Children With Cerebral Palsy|Prospective Study of Scoliosis in Children With Cerebral Palsy|PCPS|Setting Scoliosis Straight Foundation|No|Recruiting|June 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|402|||Both|8 Years|21 Years|No|Non-Probability Sample|Patients who present to the investigator's clinic, who meet the inclusion criteria will be        offered enrollment in the study|December 2013|December 20, 2013|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680264||155817|
NCT00710736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-543-204|A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer|||Array BioPharma|No|Completed|June 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|July 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00710736||153510|
NCT00711035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22994-CHALLAH|Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)|Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)|CHALLAH|Baylor College of Medicine|Yes|Completed|November 2008|August 2013|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||March 2014|March 3, 2014|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00711035||153488|
NCT00711048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9127C00001|Esophageal Hypersensitivity Study in Healthy Volunteers|A Phase I, Two Centre, Double-blind, Randomized, Cross-over Study to Evaluate AZD1386 in Single Doses of 30 mg and 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity and Development of Sensitization in Healthy Male Volunteers||AstraZeneca|No|Completed|June 2008|July 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|45|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711048||153487|
NCT00711607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05822|A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)|A Combined Multiple Dose and Single Dose Trial to Assess the Pharmacokinetic Profile of NOMAC, E2 and E1 After Oral Administration of NOMAC-E2 in Healthy Female Volunteers||Merck Sharp & Dohme Corp.|No|Completed|May 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|25|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|July 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00711607||153445|
NCT00711633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1977/06-05-02|Evaluation of Safety, Tolerance and Effects on the Intestinal Flora of a New Fermented Milk for Preterm Infants|Evaluation of a Fermented Formula Without Live Bacteria for Preterm Infants: Effects on Microbiota Species and Intestinal Inflammatory Markers||Assistance Publique - Hôpitaux de Paris|No|Completed|December 2002|June 2007|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|58|||Both|N/A|15 Days|No|||June 2008|July 4, 2008|July 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00711633||153443|
NCT00707668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCMC07OT076|Chung-ju Metabolic Disease Cohort (CMC) Study|Chung-ju Metabolic Disease Cohort (CMC) Study||The Catholic University of Korea|No|Recruiting|May 2007|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Plasma Serum Whole blood Urine|Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults over 30 years of age living in Chung-ju city|July 2014|July 25, 2014|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707668||153743|
NCT00707681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCRA06001A|Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)|A Phase II Randomized, Controlled Study to Evaluate the Quality of Life, Survival and Therapeutic Benefits of MS-20 in Patient With Advanced Hepatocellular Carcinoma||Microbio Co Ltd|Yes|Recruiting|March 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|80 Years|No|||February 2010|February 24, 2010|June 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707681||153742|
NCT00707694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998-125|The Longevity Genes in Founder Populations Project|Searching for Longevity Genes in the Historically Unique Ashkenazi Jewish Population||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|July 1998|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1500|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ashkenazi Jews:        Ages 95 and older, their offspring and control group with no family history of longevity.|January 2009|January 29, 2009|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707694||153741|
NCT00707954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-02|Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients|A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|June 2008|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|25 Years|65 Years|No|||March 2014|March 26, 2014|June 27, 2008||No||No|March 26, 2014|https://clinicaltrials.gov/show/NCT00707954||153722|
NCT00707967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111517|Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.|Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) in HIV-positive Adults.||GlaxoSmithKline||Completed|June 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|37|||Both|18 Years|50 Years|No|||April 2011|April 14, 2011|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707967||153721|
NCT00708266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNF4|The Influence of Fatty-Acids on Systemic and Subcutaneous Cytokines|A Mono-Centre Randomized Study to Investigate the Effect of Elevated Plasma Fatty Acid Concentrations on Cytokines in Interstitial Fluid of Subcutaneous Adipose Tissue|TNF4|Medical University of Graz|No|Completed|February 2007|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 27, 2008|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00708266||153698|
NCT00708253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBE-DBE_2008|Single- Versus Double-balloon Enteroscopy in Small Bowel Diagnostics|Single- vs. Double-balloon Enteroscopy in Small Bowel Diagnostics: A Randomized Controlled Single-blind Multicenter Trial|SBE_vs_DBE|University Hospital Muenster|Yes|Completed|June 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||April 2010|April 9, 2010|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00708253||153699|
NCT00699010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-ADF-111|Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse|A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse||Acura Pharmaceuticals Inc.|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699010||154395|
NCT00699322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCMC08MI081|Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress|The Comparative Study of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on the Effect of Improving Glucose Variability and Oxidative Stress in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin||The Catholic University of Korea|Yes|Recruiting|June 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|80 Years|No|||October 2009|October 28, 2009|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00699322||154373|
NCT00699335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Matrix LQ, FT-1300-028|Matrifen® for Therapy of Severe Chronic Pain®|Efficacy of Matrifen® in Patients Older Than 18 Years With Severe, Chronic Pain Including Quality of Life Questionnaire|Matrix LQ|Nycomed||Completed|June 2008|||July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5308|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients|May 2012|May 4, 2012|June 17, 2008||No||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00699335||154372|
NCT00683501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNB-001-CT001|Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure|A Phase II Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in Previously Untreated Patients With Elevated Intraocular Hypertension|DNB-001|Danube Pharmaceuticals, Inc.|Yes|Completed|October 2007|October 2008|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|54|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683501||155573|
NCT00679367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595759|Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis|A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis|MRD|Boston Medical Center|Yes|Completed|May 2008|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679367||155886|
NCT00679679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fux-1|Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome|Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial||Hospital Privado de Cordoba, Argentina|No|Completed|January 2003|December 2005|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|35 Years|No|||May 2008|May 16, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679679||155862|
NCT00679965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-200|Study of Different Doses of a Novel Treatment for Onychomycosis|A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 2.5%, 5.0%, and 7.5% Solutions vs. Vehicle for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail||Anacor Pharmaceuticals, Inc.|No|Completed|February 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|159|||Both|18 Years|65 Years|No|||July 2012|July 26, 2012|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679965||155840|
NCT00680251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.K015|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2008|||||N/A|N/A|N/A||||||||||||||March 22, 2016|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680251||155818|
NCT00712192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95016|Endoscopic Saphenous Vein Harvest for Coronary Artery Bypass Grafting|The Impact on Endothelial Function and Integrity by Endoscopic Saphenous Vein Harvest for Coronary Artery Bypass Grafting||Far Eastern Memorial Hospital|Yes|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|N/A|N/A|No|||July 2008|July 8, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712192||153400|
NCT00710749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-FLO-0001|The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects|An Open Prospective Multicenter Study Comparing the Urine Flow Measurements of Standard Clinic Flow Measurements vs Comercially Available Portable Digital Flow Meters and a Disposable Flow Meter in a Crossover and Randomized Order on Male BPH Subjects||Wellspect HealthCare|No|Completed|July 2008|||April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Male|45 Years|85 Years|No|||September 2012|September 27, 2012|July 3, 2008|Yes|Yes||No|March 18, 2011|https://clinicaltrials.gov/show/NCT00710749||153509|
NCT00710762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.9|A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer|A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer||Boehringer Ingelheim||Completed|March 2006|March 2014|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|||Actual|89|||Female|18 Years|N/A|No|||March 2015|March 16, 2015|July 3, 2008||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00710762||153508|Data from all randomised patients collected upto NOV’08 were included in all above sections,unless stated otherwise.5 patients continued on BIBF1120 after database lock(DBL)-NOV’08 upto Mar’14,but due to limited data no further analyses were done.
NCT00711061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-07-119E|Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy|Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy.||Children's Mercy Hospital Kansas City|No|Completed|June 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Male|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Endocrine clinic and community sample|February 2009|February 9, 2009|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711061||153486|
NCT00711386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRR111382|GSK706769 Repeat Dose Study|A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects||GlaxoSmithKline|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|July 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00711386||153462|
NCT00711360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA083|Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement (HomeCARE II)|Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement|HomeCARE II|Biotronik SE & Co. KG|No|Completed|July 2008|September 2012|Actual|January 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|303|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711360||153464|
NCT00707330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-12-1-18-15-23|Study of the Ability of Clarithromycin to Induce Oxidative Stress|A Randomized, Single Blinded, Open-Label Crossover-Study of the Possible Induction of Oxidative Stress by Clarithromycin in Healthy Subjects|CLAROX|Rigshospitalet, Denmark|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|26|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2008|August 8, 2008|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707330||153768|
NCT00707343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI20112|[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors|Preliminary Evaluation of the Efficacy of [F-18] Fluorothymidine (FLT) to Differentiate Radiation Necrosis From Tumor Recurrence and as a Marker of Proliferation in Patients With Primary Brain Tumors||University of Utah|Yes|Completed|May 2007|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 26, 2008|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT00707343||153767|
NCT00702468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWSP0702|Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis|A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex®.||GW Pharmaceuticals Ltd.|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|June 19, 2008||No||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00702468||154134|
NCT00698061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/033|Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y|A Study to Compare the Immunogenicity and Safety of GSK Biologicals Adjuvanted HBV Vaccine to Engerix™-B, in a Non-responder Population ≥ 15 Years of Age, When Administered Intramuscularly, According to a 0, 1, 2, 12 Month Schedule||GlaxoSmithKline|No|Completed|November 1999|May 2001|Actual|September 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|145|||Both|15 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 17, 2011|June 11, 2008||||No||https://clinicaltrials.gov/show/NCT00698061||154464|
NCT00698074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q2709/64|Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy|Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy||University Hospital Birmingham||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||June 2008|June 13, 2008|June 11, 2008||||No||https://clinicaltrials.gov/show/NCT00698074||154463|
NCT00698373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Molecular FMT imaging|Evaluation of Thoracic Tumors With 18F-FMT and 18F-FDG PET-CT A Clinicopathological Study|Evaluation of Thoracic Tumors With 18F-FMT and 8F-FDG PET-CT: A Clinicopathological Study||Gunma University|No|Completed||||||N/A|Observational|Time Perspective: Prospective||1|||||Both|20 Years|N/A|No|Non-Probability Sample|Patients with indeterminate pulmonary nodule suspicious of lung cancer were eligible for        this prospective study.|June 2008|June 16, 2008|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00698373||154442|
NCT00698698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tear proteins|Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics|Tear Proteins and Diabetic Retinopathy||Dow University of Health Sciences|Yes|Active, not recruiting|January 2009|June 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Anticipated|350|||Both|30 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|diabetic population|January 2009|January 30, 2009|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698698||154418|
NCT00698711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-122|Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21|Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Comparing MUC-2-KLH Doses||Memorial Sloan Kettering Cancer Center||Completed|November 1997|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|No|||January 2012|January 27, 2012|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698711||154417|
NCT00708565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00769|Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude|Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude||VA Loma Linda Health Care System|No|Recruiting|July 2008|October 2008|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|||Anticipated|50|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||June 2008|July 1, 2008|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00708565||153675|
NCT00698997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816233-1|Intensive Intervention for Toddlers With Autism (EARLY STEPS)|Intensive Intervention for Toddlers With Autism||University of California, Davis|Yes|Recruiting|April 2008|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|12 Months|24 Months|No|||June 2008|June 12, 2008|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00698997||154396|
NCT00699621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-1 EUDRACT 2007-006206-24|Platelet Transfusion in Acute Intracerebral Hemorrhage|Platelet Transfusion in Acute Primary Intracerebral Hemorrhage for Patients on Platelet Inhibitors||University of Oulu|Yes|Recruiting|January 2009|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00699621||154350|
NCT00683774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB 4479|Insulin and Polycystic Ovary Syndrome|Determination if Direct Inhibition of Insulin Release With Diazoxide Decreases Renal Clearance of D-Chiroinositol (DCI) and Increases Circulating DCI in Obese Women With Polycystic Ovary Syndrome (PCOS)||Virginia Commonwealth University|Yes|Completed|November 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|May 21, 2008|Yes|Yes||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00683774||155553|
NCT00715663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPEN3-1891|Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix® 30 FlexPen® as Monotherapy, or in Combination With OHA, in Treatment of Type 2 Diabetic Patients in Routine Clinical Practice: A Post-Marketing Surveillance Study||Novo Nordisk A/S|No|Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1584|||Both|N/A|N/A|No|Non-Probability Sample|All patients with type 2 diabetes, inadequately controlled on their current therapy, who        are prescribed NovoMix® 30 FlexPen® as monotherapy, or in combination with OHA, in        accordance with the approved labelling.|May 2012|May 23, 2012|July 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715663||153134|
NCT00715923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715802|Modified Consent Form Utility|CTSA Utility of Modified Consent Forms in Clinical Research: Fraga Tea Study||University of California, Davis|No|Terminated|November 2007|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 11, 2008||No|funding|No||https://clinicaltrials.gov/show/NCT00715923||153114|
NCT00715936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|993-PEDS/ERC-08|The Pakistan Early Childhood Development Scale Up Trial|Phase 1 Study on the Integration of Early Childhood Interventions in a Primary Care Health Service in Sindh, Pakistan|PEDS|Aga Khan University|Yes|Recruiting|July 2009|April 2012|Anticipated|March 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1500|||Both|N/A|24 Months|Accepts Healthy Volunteers|||December 2010|July 6, 2011|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00715936||153113|
NCT00711919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-255|Pitavastatin on Carotid Intima-media Thickness|Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-Lowering Therapy|PEACE|Kyoto Prefectural University of Medicine|No|Active, not recruiting|July 2007|||December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|80 Years|No|||September 2009|September 9, 2009|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711919||153421|
NCT00711932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080328006/UAB0802|The Effect of TRA-8 on Ovarian Cancer Tissue|Death Receptor-Mediated Apoptosis and Therapy Strategies in Ovarian Cancer||University of Alabama at Birmingham|Yes|Completed|August 2008|January 2013|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|478|||Female|19 Years|N/A|No|Non-Probability Sample|Patients with histologically confirmed epithelial carcinoma of the ovary or of        extra-ovarian origin, any histologic subtype or stage 19 years of age or older.|June 2013|September 10, 2013|July 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00711932||153420|
NCT00712478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1866|Observational Study Describing Conditions for Intensification of Insulin Therapy in Type 2 Diabetes|Observational Study on Efficacy of Intensification of Insulin Therapy to at Least 3 Daily Injections in Type 2 Diabetes|INTENSE3MIX|Novo Nordisk A/S|No|Completed|September 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|114|||Both|40 Years|N/A|No|Non-Probability Sample|Men and women aged 40 years old and more with type 2 diabetes|March 2016|March 3, 2016|June 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712478||153378|
NCT00713024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712022R|Patterns of Cerebral Activation to Innocuous and Noxious Heat Stimulations in Neuropathic Pain|Patterns of Cerebral Activation to Innocuous and Noxious Heat Stimulations in Neuropathic Pain||National Taiwan University Hospital|Yes|Recruiting|January 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|150|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit healthy control subjects and patients having neuropathic pain in the        current study.|June 2010|June 28, 2010|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713024||153336|
NCT00710775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R78- CCM S80/507|Heart Leaflet Technologies Valve Study|Temporary Intra-operative Placement of HLT Percutaneous Aortic Valve|HLT|Centro Cardiologico Monzino|No|Recruiting|November 2007|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|7|||Both|75 Years|80 Years|No|||May 2008|October 9, 2009|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00710775||153507|
NCT00701298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00295|Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors|Inhibition of DNA Methylation by 1-Hr Infusion of 5-aza-2'-Deoxycitidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alpha 2B (PEG-Intron): A Phase I Study With Molecular Correlates||National Cancer Institute (NCI)||Terminated|April 2009|||October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2011|February 21, 2014|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701298||154223|
NCT00701311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-135|An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome|An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome||William Beaumont Hospitals|Yes|Completed|June 2008|March 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||September 2014|September 25, 2014|June 18, 2008|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00701311||154222|The limitation of this study is that only 9 of 17 participants completed full 12 weeks of treatment and there was no placebo arm.
NCT00711373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192.98|Allogeneic Hand Transplantation Composite Tissue Allotransplantation|Composite Tissue Allotransplantation of the Hand|HandCTA|Christine M. Kleinert Institute for Hand and Microsurgery|Yes|Recruiting|June 1998|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||January 2013|January 30, 2013|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711373||153463|
NCT00702143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A05|A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)|An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-45 in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)||Avid Radiopharmaceuticals|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|184|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 8, 2012|June 19, 2008|Yes|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT00702143||154158|
NCT00702455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A06-025|Keep It Off: A Weight Loss Maintenance Study|Novel Approaches to Weight Loss Maintenance|KIO|HealthPartners Institute|Yes|Completed|September 2006|July 2012|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|419|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702455||154135|
NCT00698087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/016|Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B|Study to Compare the Safety, Immunogenicity and Reactogenicity of Different Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B||GlaxoSmithKline||Completed|January 1995|February 1996|Actual|February 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698087||154462|
NCT00697788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001264/1;MGH|Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients|Cardiovascular Safety of Dexmedetomidine in Pediatric Burn Patients.||Massachusetts General Hospital|No|Completed|January 2006|December 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|2 Years|18 Years|No|||December 2011|December 11, 2011|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697788||154485|
NCT00698100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-122|Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines|Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines: A Phase I Trial to Assess Safety and Immune Response||Memorial Sloan Kettering Cancer Center||Completed|June 2002|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2011|September 15, 2011|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698100||154461|
NCT00699296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B1201|Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma|A Phase II Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma||Novartis|No|Terminated|May 2008|||December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|20 Years|N/A|No|||November 2012|November 26, 2012|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699296||154375|
NCT00699309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomet 13594-115|A Clinical Investigation of the Taperloc® Microplasty™ Hip System|A Prospective, Non-controlled, Clinical Investigation of the Taperloc® Microplasty™ Hip System||Biomet, Inc.|No|Completed|August 2005|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring relief from painful or disabling joint disease.|March 2013|March 19, 2013|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699309||154374|
NCT00698737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA 022243-2|Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)|Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)|ARC|Wayne State University|Yes|Completed|April 2008|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|55 Years|No|Non-Probability Sample|Heroin dependent and Cocaine abuse or dependent research volunteers.|November 2012|November 20, 2012|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698737||154415|
NCT00698750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomet 12381-30|A Clinical Investigation of the Copeland™ Humeral Resurfacing Head|A Prospective, Non-controlled, Clinical Investigation of the Copeland™ Humeral Resurfacing Head||Biomet, Inc.|No|Terminated|April 2004|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring humeral resurfacing.|August 2012|August 14, 2012|June 13, 2008|No|Yes|Sponsor terminated study early due to limited enrollment and follow-up.|No||https://clinicaltrials.gov/show/NCT00698750||154414|
NCT00699023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239/07|Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes|Effects of Ezetimibe in Association With Statins on Postprandial Lipemia in Type 2 Diabetic Patients|EZE|Federico II University|No|Completed|June 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|13|||Both|40 Years|65 Years|No|||November 2009|November 3, 2009|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699023||154394|
NCT00699348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21438|CARISMA Study: A Study of Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|July 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|351|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00699348||154371|
NCT00699608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESZ111503|An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.|A Randomised, Double-blind, Double-dummy, Placebo-controlled, 3-way Crossover Study to Evaluate Potential Next-day Residual Effects of a Single Evening Dose of 3mg Eszopiclone and 7.5mg Zopiclone in Healthy Adult Subjects.||GlaxoSmithKline||Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|91|||Both|25 Years|40 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|June 17, 2008|Yes|Yes||No|October 6, 2009|https://clinicaltrials.gov/show/NCT00699608||154351|
NCT00699634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1975|Nabilone for the Treatment of Phantom Limb Pain|A Randomized Double-blind Placebo Controlled Trial Assessing the Effect of the Oral Cannabinoid Nabilone on Pain and Quality of Life in Patients With Phantom Limb Pain||University of Manitoba|Yes|Completed|January 2009|April 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||April 2011|April 28, 2011|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00699634||154349|
NCT00715390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-10-3923|Dysrhythmias During General Anesthesia in Children|Dysrhythmias During General Anesthesia in Children||Children's Hospital of Philadelphia|No|Completed|October 2004|August 2006|Actual|August 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|234|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All patients who have undergone anesthesia at the Children's Hospital of Philadelphia or        at one of CHOP's satellite surgicenters, and whose anesthetic record was recorded        electronically into the Compurecord system will be screened.|December 2012|December 13, 2012|July 11, 2008||No||No|April 3, 2009|https://clinicaltrials.gov/show/NCT00715390||153155|
NCT00715403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.16|A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120|Extension Study to Establish Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Patients With Previous Clinical Benefit From BIBF 1120||Boehringer Ingelheim||Completed|October 2004|||September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|41|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|July 11, 2008||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00715403||153154|
NCT00711945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GROWTH1|Growth Relapse and Outcomes With Therapy 1|Growth Relapse and Outcomes With Therapy 1:Factors Determining Poor Outcomes in Pediatric Crohn"s Disease|GROWTH1|European Society of Pediatric Gastroenterology, Hepatology and Nutrition|Yes|Recruiting|March 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Serum for antiglycan antibodies stool for calprotectin|Both|N/A|18 Years|No|Non-Probability Sample|New onset pediatric Crohn's disease until and including age 18|July 2008|July 8, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711945||153419|
NCT00711958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-31-INJ-11|Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients|Double-Blind, Randomized, Multicenter, Clinical Phase III Study to Evaluate the Efficacy and Safety of HX575 for the Treatment of Chemotherapy Associated Anemia in Cancer Patients||Novartis|No|Completed|November 2004|December 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||July 2008|July 8, 2008|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711958||153418|
NCT00712205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSBH-336-06|Vitamin D for the Treatment of Severe Asthma|Asthma and Vitamin D (a Clinical Pilot Study)||Kantonsspital Baselland Bruderholz|No|Enrolling by invitation|August 2008|August 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2009|August 12, 2009|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00712205||153399|
NCT00712491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-002|Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration|A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration||Santen Inc.|No|Terminated|September 2008|March 2010|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|N/A|No|||July 2010|January 8, 2013|July 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712491||153377|
NCT00712725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3207-005|MK3207 for Treatment of Acute Migraines (3207-005)|A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-finding Study of MK3207 in the Treatment of Acute Migraine||Merck Sharp & Dohme Corp.||Completed|July 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|676|||Both|18 Years|65 Years|No|||January 2015|January 23, 2015|July 8, 2008|Yes|Yes||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00712725||153359|
NCT00712751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-073|The Sexual Health of Rectal Cancer Patients|The Sexual Health of Rectal Cancer Patients: A Pilot Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|192|||Both|21 Years|N/A|No|Probability Sample|Colorectal patients|October 2015|October 18, 2015|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712751||153357|
NCT00701038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0186|Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure|The Role of Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure||Ohio State University|No|Completed|August 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|21 Years|80 Years|No|||January 2013|January 29, 2013|June 17, 2008||No||No|August 12, 2011|https://clinicaltrials.gov/show/NCT00701038||154242|
NCT00711399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC 07-0063|Assessment of Cough and Wheeze With Breath Sound Documenting Device|Use of Objective Cough Counting and Breath Sounds Documenting Device, to Assess the Severity and Duration of Cough and Wheeze in Children and Adults Suffer From Acute or Chronic Respiratory Disease.||Carmel Medical Center|Yes|Completed|September 2008|September 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|55|||Both|1 Year|45 Years|No|Non-Probability Sample|The study population will consist of children with respiratory infection, asthmatic        children and CF patients who suffer from respiratory symptoms such as cough and and/or        shortness of breath.|September 2010|September 13, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00711399||153461|
NCT00711646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS0106|A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.|A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.||GW Pharmaceuticals Ltd.|No|Completed|June 2002|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|189|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|July 8, 2008||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00711646||153442|
NCT00702481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB/NCCS-01|Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer|Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)||National Cancer Centre, Singapore|No|Active, not recruiting|April 2008|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|21 Years|70 Years|No|||March 2016|March 21, 2016|June 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00702481||154133|
NCT00702494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-TB-403-02|Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours|An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.||BioInvent International AB|Yes|Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||December 2009|December 3, 2009|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702494||154132|
NCT00702169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neo- 01/2006|Continuous Monitoring of the Lungs Ventilation Dynamics During Mechanical Ventilation|Continuous Monitoring of the Lungs Ventilation Dynamics During Mechanical Ventilation by Small Surface Patches That Include Safe Motion Sensors||Carmel Medical Center|Yes|Completed|December 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|15|||Both|N/A|3 Months|No|Probability Sample|Babies receiving respiratory support, born at 26 weeks and over & birth weight 700 grams.|March 2009|March 29, 2009|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702169||154156|
NCT00697775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/028|Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents|Study to Assess the Feasibility of GSK Bio's Candidate HBV / MPL Vaccines Following Different Schedules and Formulations and to Compare Their Safety and Immunogenicity to That of Engerix™-B in Healthy Adolescents Aged 11 to 15||GlaxoSmithKline||Completed|March 1998|||May 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|200|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697775||154486|
NCT00698126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1897|Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes|A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Aspart (NovoRapid® ) or Soluble Human Insulin for the Treatment of Diabetes Mellitus the UPGRADE Study|UPGRADE|Novo Nordisk A/S|No|Completed|October 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|4099|||Both|18 Years|N/A|No|Probability Sample|Any subject with type 2 diabetes who is already in treatment with insulin aspart or        soluble human insulin will be included in the study|August 2014|August 8, 2014|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00698126||154459|
NCT00698412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP-102/2004|Effectiveness of Cane in Osteoarthritis (OA) Patients|The Impact of Daily Cane Use on Pain, Function, Quality of Life and Energy Consumption During the Gait in Patients With Knee Osteoarthritis||Federal University of São Paulo|Yes|Completed|January 2005|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|40 Years|N/A|No|||May 2008|June 13, 2008|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698412||154439|
NCT00698386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTPR7885/Med/141166/06|Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients|Efficacy of Oral Zinc Administration as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters (Double-blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial||Ministry of Science and Technology, India|Yes|Recruiting|February 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|150|||Both|18 Years|60 Years|No|||June 2008|September 14, 2009|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698386||154441|
NCT00698724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5359|Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care|A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care||Bp Consulting, Inc||Completed|June 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 8, 2009|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698724||154416|
NCT00699660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 06-331|Enhancing Equitable and Effective (E-3) Post Traumatic Stress Disorder (PTSD) Disability Assessment|Enhancing Equitable and Effective PTSD Disability Assessment|E-3PTSD|VA Office of Research and Development|Yes|Completed|May 2009|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|406|||Both|18 Years|N/A|No|||September 2014|April 6, 2015|June 12, 2008||No||No|September 23, 2014|https://clinicaltrials.gov/show/NCT00699660||154348|Information external to interview such as psychological testing or charts were not available to the expert reviewers. Another limitation is that Veterans in our study did not undergo a concurrent, independent evaluation for assessment of PTSD.
NCT00699361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|panto001|Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure|Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure||Johann Wolfgang Goethe University Hospitals|Yes|Withdrawn|August 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||June 2008|February 10, 2014|June 13, 2008||No|Study withdrawn for financial issues|No||https://clinicaltrials.gov/show/NCT00699361||154370|
NCT00700245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060053|The Effect of Acute and Chronic Exercise at the Metabolic Syndrome and Markers of Inflammation in Obese Subjects|The Effect of Acute and Chronic Exercise at the Metabolic Syndrome and Markers of Inflammation in Obese Subjects||Aarhus University Hospital|No|Recruiting|September 2006|March 2009|Anticipated|June 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 17, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700245||154303|
NCT00700258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-4407|Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]|Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitinib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (MRCC), Mantle Cell Lymphoma (MCL), And Gastro-intestinal Stroma Tumor (GIST)|STAR-TOR|Pfizer|No|Recruiting|January 2013|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1600|||Both|18 Years|99 Years|No|Non-Probability Sample|Tumor patients with renal cell carcinoma (RCC), mantle cell lymphoma (MCL) or        gastro-intestinal stroma tumor (GIST)        Gastro-Intestinal Stroma Tumor|February 2016|February 5, 2016|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700258||154302|
NCT00715949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-11-4572|Neurocognitive Evaluation of Mild Traumatic Brain Injury in the Hospitalized Pediatric Population|Neurocognitive Evaluation of Minor Traumatic Brain Injury in the Hospitalized Pediatric Population||Children's Hospital of Philadelphia|No|Completed|December 2005|June 2014|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|11 Years|19 Years|No|Non-Probability Sample|Pediatric blunt trauma patients (age 11-19 years) admitted to The Children's Hospital of        Philadelphia for treatment of mild traumatic brain injury|April 2015|April 14, 2015|July 14, 2008||No||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00715949||153112|
NCT00712218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR OP.3|Lymphadenectomy In Ovarian Neoplasms|Randomized, Multicentre Trial for Lymphadenectomy In Ovarian Neoplasms|LION|Philipps University Marburg Medical Center|Yes|Active, not recruiting|December 2008|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Female|18 Years|75 Years|No|||February 2012|February 1, 2012|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00712218||153398|
NCT00712504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181035|Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer|A Phase 1 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Solid Tumors||Pfizer|No|Completed|July 2004|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||November 2008|November 7, 2008|July 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712504||153376|
NCT00712517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42908|Propofol Versus Volatile Anesthesia in Post Operative Pain Management|Do Patients Anesthetized With Propofol Have Less Pain Than Those Anesthetized With Volatile?||The Cleveland Clinic|No|Suspended|December 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|July 7, 2008||No|Enrolling of participants has halted and the results are being gathered|No||https://clinicaltrials.gov/show/NCT00712517||153375|
NCT00712738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080157|Oral Nifedipine to Treat Iron Overload|A Trial of Oral Nifedipine for the Treatment of Iron Overload||National Institutes of Health Clinical Center (CC)||Completed|June 2008|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2010|September 26, 2015|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00712738||153358|
NCT00682448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06122201|Metformin for the Prevention of the Metabolic Side-effects of Zyprexa|Metformin to Prevent the Metabolic Complications of Olanzapine||Rush University Medical Center|No|Completed|August 2007|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|May 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682448||155652|
NCT00682461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2110367|Oral Tolerability Of Two Nicotine Dosage Forms|A Randomized, Open Label Study to Evaluate the Oral Tolerability of a Nicotine Prototype||GlaxoSmithKline|No|Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 24, 2013|May 20, 2008|Yes|Yes||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00682461||155651|
NCT00682474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA114556|School Nurse-Delivered Smoking Cessation Intervention|School Nurse-Delivered Smoking Cessation Intervention||University of Massachusetts, Worcester|Yes|Completed|September 2006|February 2010|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1058|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||August 2011|August 18, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682474||155650|
NCT00701064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-008-08S|Bright Light: An Adjunct Treatment for Combat Posttraumatic Stress Disorder (PTSD)|Bright Light: An Adjunct Treatment for Combat PTSD||VA Office of Research and Development|No|Active, not recruiting|January 2009|December 2015|Anticipated|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|60 Years|No|||October 2015|October 23, 2015|June 17, 2008||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT00701064||154240|
NCT00701883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70,961|Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol|Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin"|MBX-8025|CymaBay Therapeutics, Inc.|Yes|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|183|||Both|18 Years|75 Years|No|||May 2015|May 19, 2015|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00701883||154178|
NCT00701623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPCRI0208|Sodic Heparin Effectiveness of the Treatment of Burns|Clinical Efficacy of Product Alimax ® (Sodic Heparin) in Treatment of Burns: Comparative Study of Raw Materials Between Two Suppliers|SODIC HEPARIN|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Withdrawn|June 2008|||June 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|84|||Both|12 Years|N/A|Accepts Healthy Volunteers|||February 2008|October 26, 2010|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701623||154198|
NCT00701896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0173|Smoking Cessation Using Motivational Therapy and Varenicline|Smoking Cessation and the Natural History of HIV-Associated Emphysema||Ohio State University|Yes|Active, not recruiting|June 2008|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|365|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00701896||154177|
NCT00697801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0010-CL-P201|Study of MAP0010 in Asthmatic Children and Adolescents|A Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group, Phase 2 Study Investigating the Efficacy, Tolerability and Pharmacokinetics of MAP0010 in Asthmatic Children and Adolescents Over 6 Weeks||Allergan|No|Completed|July 2006|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|208|||Both|1 Year|18 Years|No|||December 2013|December 9, 2013|June 12, 2008|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00697801||154484|
NCT00698763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001088|Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables|Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables and Cerebrovascular Reactivity in Patients With Recent Stroke or TIA.|Electro|Orion Corporation, Orion Pharma|No|Completed|August 2008|September 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|50 Years|80 Years|No|||November 2009|November 23, 2009|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698763||154413|
NCT00698113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENT-SK-CAM07-323R|Parent-Delivered Massage in Paediatric Cancer|Parent-Delivered Massage in Paediatric Cancer||Centennial College|Yes|Recruiting|April 2007|June 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|6 Years|18 Years|No|||June 2008|June 17, 2009|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00698113||154460|
NCT00698399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80237|Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients|Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients, Phase II||Vanderbilt University|No|Enrolling by invitation|March 2008|April 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|serum of patients who are undergoing liver transplantation surgery|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from those on the list awaiting liver transplantation at        Vanderbilt University Medical Center (VUMC). They will be recruited by the investigators        prior to the time of their transplantation surgery|June 2008|June 12, 2008|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00698399||154440|
NCT00699049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMK-1|A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Comparison of the Efficacy and Safety of Any Alpha Blocker Monotherapy and Any Alpha Blocker Plus Solifenacin in Men With Residual Overactive Bladder Symptoms of Urinary Frequency and Urgency With/Without Urgency Incontinence After Previous Monotherapy With Any Alpha Blocker||Samsung Medical Center|No|Completed|June 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Male|50 Years|N/A|No|||January 2016|January 6, 2016|June 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699049||154392|
NCT00699985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/11872|Psychological Symptoms in Patients With Behcet's Disease by SCL90-R|Comparison of Psychological Symptoms in Patients With Behcet's Disease and Control Patients by Symptom Check List 90-Revised (SCL-90-R)|SCL90-R|Tehran University of Medical Sciences|Yes|Completed|September 2006|December 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|400|||Both|14 Years|N/A|No|Non-Probability Sample|BD and Non-BD patients who attended the clinic for their routine follow-up.|August 2010|August 13, 2010|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00699985||154323|
NCT00699673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3910|Evaluation of the Brain Natriuretic Peptide as a Predictor of Morbidity and Mortality in Cardiac Surgery|Evaluation of the Brain Natriuretic Peptide as a Predictor of Morbidity and Mortality in Cardiac Surgery||University Hospital, Strasbourg, France|No|Active, not recruiting|June 2008|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patient who need cardiac surgery and age > 18 years|August 2015|August 6, 2015|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00699673||154347|
NCT00711971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT004166-01A1|Does Fish Oil Prevent Depression in Pregnancy and Postpartum?|Does EPA or DHA Prevent Depressive Symptoms in Pregnancy and Postpartum?||University of Michigan|Yes|Completed|September 2008|January 2013|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|126|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 22, 2013|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00711971||153417|
NCT00711984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0-2003|Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Trial in Patients With Advanced Atherosclerosis|Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis.||Medical University of Vienna|No|Recruiting|February 2004|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711984||153416|
NCT00712231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH97007|Limitations of Using a Sheimpflug Image-Based Device for Measuring Anterior Chamber Depth in Pseudophakic Eyes|To Assess the Degree of Agreement of Anterior Chamber Depth Measurements by 2 Optical Devices (Pentacam and IOLMaster) and Compare Them With Contact Ultrasound A-Scan in Phakic and Pseudophakic Eyes.||Far Eastern Memorial Hospital|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|184|None Retained|no specimen|Both|40 Years|80 Years|No|Probability Sample|Ninety phakic eyes were randomly selected for study from the outpatient clinic.        Ninety-four pseudophakic eyes that had a standard clear cornea phacoemulsification with        one of three acrylic IOLs (MA60BM, SA60AT, SN60AT) implanted into the capsular bag by the        same surgeon were also studied.|July 2008|July 8, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712231||153397|
NCT00712530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHU004|Single DermaVir Immunization in HIV-1 Infected Patients on HAART|A Phase I Study to Evaluate the Tolerability and Safety of LC002, a DermaVir Vaccine, in HIV-1-infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)|GIHU004|Genetic Immunity|Yes|Completed|January 2005|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|50 Years|No|||February 2013|February 19, 2013|July 4, 2008|No|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00712530||153374|This is a Phase I small sample study that was not powered for the secondary efficacy endpoints.
NCT00712543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KR-001|A Preference Study Comparing Kristalose® and Liquid Lactulose|A Preference Study Comparing Kristalose® and Liquid Lactulose in the Treatment of Constipation||Cumberland Pharmaceuticals|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||August 2011|August 19, 2011|July 8, 2008||No||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00712543||153373|
NCT00682786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0561|Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma|Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma||Washington University School of Medicine|Yes|Completed|October 2002|August 2010|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|April 11, 2008|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT00682786||155626|
NCT00701363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52030-214|Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects|A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg|LEAD|Ipsen||Completed|October 2008|May 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|June 18, 2008|No|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT00701363||154218|
NCT00701350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX03-OBX0009|Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes|Identification of Proteomic Markers of Intra-amniotic Infection (IAI) in Patients With Preterm Premature Rupture of Amniotic Membranes (PPROM)|PPROM|ProteoGenix, Inc.|No|Completed|June 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|79|Samples Without DNA|Cervical-vaginal Fluid, Amniotic Fluid, Maternal Serum, Neonatal Cord Blood, Placental and      Umbilical Cord Tissues|Female|18 Years|N/A|No|Non-Probability Sample|Women within the target gestational age range presenting to labor and delivery wards with        documented rupture of amniotic membranes no greater than 24 hours duration.|July 2010|July 19, 2010|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00701350||154219|
NCT00702156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN05CA013|Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease|Cardioselective Beta-Blockade Using Bisoprolol in Patients With Chronic Heart Failure (CHF) and Coexistent Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) With or Without Significant Reversibility.||NHS Greater Glasgow and Clyde|Yes|Terminated|March 2005|July 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|90 Years|No|||August 2008|September 2, 2008|June 19, 2008||No|Inadequate patient recruitment|No||https://clinicaltrials.gov/show/NCT00702156||154157|
NCT00702182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPCTG-VEP1|Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer|Phase 1 Study of Oral Vinorelbine in Combination With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules||National Cancer Centre, Singapore|No|Completed|April 2008|October 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|21 Years|N/A|No|||October 2012|October 17, 2012|June 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00702182||154155|
NCT00698438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XVT-USF|Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study|Prospective, Randomized Clinical Trial,to Compare Standard Trabeculectomy to the Ex-PRESS Mini Glaucoma Shunt Implantation Under a Scleral Flap in Eyes With Open-Angle Glaucoma|XVT-USF|University of Witwatersrand, South Africa|Yes|Completed|March 2005|||August 2007||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2|||30|||Both|18 Years|N/A|No|||June 2008|June 12, 2008|March 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00698438||154437|
NCT00698425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/Eyegate/01|Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System|Single Center, Single-masked, Randomized, Dose Escalation Study to Evaluate Safety and Tolerability of Transscleral Iontophoresis Using Citrate Buffer Delivered by the EyeGate® II Drug Delivery Device System in Healthy Adult Volunteers||Eyegate Pharmaceuticals, Inc.|No|Completed|March 2008|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|19||Actual|105|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 20, 2010|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698425||154438|
NCT00699374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181170|Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer|A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma||Pfizer|Yes|Terminated|July 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1075|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|June 16, 2008|Yes|Yes|See termination reason in detailed description.|No|December 7, 2012|https://clinicaltrials.gov/show/NCT00699374||154369|Study terminated early due to futility. Subsequently, EQ-5D data were not collected or analyzed.
NCT00698776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712003357|Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma|Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-Galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma||Yale University|No|Recruiting|April 2009|May 2011|Anticipated|May 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||May 2009|May 5, 2009|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698776||154412|
NCT00699686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBRA|Endothelial Effects of Basal Insulin: Detemir Versus Glargine|Effects of Optimized Glycemic Control Achieved With add-on Basal Insulin Therapy on Indexes of Endothelial Damage and Regeneration in Type 2 Diabetic Patients With Macroangiopathy. A Randomized Cross-over Trial Comparing Detemir vs Glargine||University of Padova|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|35 Years|80 Years|No|||August 2010|August 16, 2010|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00699686||154346|
NCT00699387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAGAS-CHILDREN-POPPK|Population Pharmacokinetics of Benznidazole in Children With Chagas Disease|Population Pharmacokinetics Study of Benznidazole in Children With Chagas Disease||Hospital de Niños R. Gutierrez de Buenos Aires|Yes|Completed|April 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|37|||Both|2 Years|12 Years|No|||July 2011|July 29, 2011|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00699387||154368|
NCT00700284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 001, TMC120-C130|Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)|Phase I Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine) as a Vaginal Microbicide||International Partnership for Microbicides, Inc.|No|Completed|October 2004|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|June 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700284||154300|
NCT00711516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/4026/AP/US|Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance|Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea||Teva Pharmaceutical Industries||Completed|September 2008|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||July 2013|July 12, 2013|July 8, 2008|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00711516||153452|
NCT00711698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001163|Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)|PCA for Pain Control in Adults With Sickle Cell Disease in the ED Decreases Admission Rates Over Standard Bolus Therapy||Johns Hopkins University|No|Withdrawn|September 2007|||September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2009|August 4, 2009|July 7, 2008||No|technical difficulties coordinating study|No||https://clinicaltrials.gov/show/NCT00711698||153438|
NCT00712244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-014|DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus|DisCoVisc Versus Competitor||Alcon Research|No|Completed|October 2007|||April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|112|||Both|50 Years|N/A|No|||September 2010|September 10, 2010|July 7, 2008|Yes|Yes||No|April 27, 2009|https://clinicaltrials.gov/show/NCT00712244||153396|
NCT00712556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 0828|PET Study in Patients With Non-Hodgkin Lymphoma|Positron Emission Tomography Study in Patients With Non-Hodgkin Lymphoma||Vanderbilt-Ingram Cancer Center|Yes|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|55|||Both|N/A|N/A|No|Non-Probability Sample|Patients with non-Hodgkin lymphoma|February 2013|February 25, 2013|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00712556||153372|
NCT00712764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-011206|Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure.|Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure.||Medical University of Vienna|Yes|Completed|January 2005|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2006|July 8, 2008|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712764||153356|
NCT00713050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13785A|Speech and Language Therapy After Stroke|Neurophysiological Measurement in Aphasia Treatment||University of Chicago|No|Terminated|August 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|N/A|N/A|No|||June 2013|June 10, 2013|July 9, 2008||No|Protocol expired; PI retired|No||https://clinicaltrials.gov/show/NCT00713050||153334|
NCT00682487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0246-07-MMC|Hair Cortisol and the Risk of Acute Myocardial Infarction|Hair Cortisol and the Risk of Acute Myocardial Infarction||Meir Medical Center|Yes|Completed|June 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Male|N/A|N/A|No|Probability Sample|Cases: Patients admitted to the cardiology department due to acute myocardial infarction        Controls: Patiens admitted ro an Internal Medicine department due to non-thrombotic        disease.|April 2009|June 18, 2009|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682487||155649|
NCT00683072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKUH-9703023|Patient-Ventilator Dyssynchrony: How is the Effect of Management?|Patient-Ventilator Dyssynchrony: How is the Effect of Management?||National Cheng-Kung University Hospital||Recruiting|March 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Between March 2008 through December 2008, patients admitted to our respiratory intensive        care unit for the management of acute respiratory failure were daily screened for the        presence of patient-ventilator asynchrony.|May 2008|May 22, 2008|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683072||155605|
NCT00701376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-877|Hepatic Effects of Gastric Bypass Surgery|Long Term Hepatic Effects of Gastric Bypass Surgery||Outcomes Research Consortium|No|Active, not recruiting|June 2008|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701376||154217|
NCT00701675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-005-04F|Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly|Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly|Sert-GAD|VA Office of Research and Development|Yes|Completed|October 2005|September 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Both|60 Years|N/A|No|||November 2013|November 7, 2013|June 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701675||154194|
NCT00701662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1464|A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)|A Multicentre Study of Subcutaneous Immunoglobulin (SCIG) in Patients With Multifocal Motor Neuropathy (MMN)||CSL Behring|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||June 2013|June 2, 2013|June 18, 2008|Yes|Yes||No|June 2, 2013|https://clinicaltrials.gov/show/NCT00701662||154195|
NCT00697814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1374/04|Clomiphene in Males With Prolactinomas and Persistent Hypogonadism|Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism||Federal University of São Paulo|No|Completed|June 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|70 Years|No|||June 2008|June 13, 2008|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00697814||154483|
NCT00697827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSP01|A Study of the In-Space Device for Treatment of Moderate Spinal Stenosis|A Multi-Center Randomized Controlled Trial of the In-Space Compared to X STOP® for Treatment of Moderate Degenerative Lumbar Spinal Stenosis|In-Space|Synthes USA HQ, Inc.|No|Terminated|June 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|N/A|No|||June 2012|June 5, 2012|June 11, 2008|Yes|Yes|Study terminated due to low enrollment.|No|May 3, 2012|https://clinicaltrials.gov/show/NCT00697827||154482|Study terminated early secondary to low enrollment leading to small number of subjects available for analyses.
NCT00698477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR04/19/07|Chemotherapy on Methylation Patterns in Breast Tumor Tissue Correlating With Clinical Response and Outcomes|Study of the Effect of Chemotherapy on Methylation Patterns in Breast Tumor Tissue and Paired Plasma Samples and Correlation With Clinical Response and Outcomes||National University Hospital, Singapore||Recruiting|October 2007|||||N/A|Observational|N/A|||||||Female|21 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 15, 2008|June 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00698477||154434|
NCT00698139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6786|Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate|Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate for Six Hours in Patients With Congestive Heart Failure, Heart Rate <70 Beats Per Minute and Fluid Overload.||Columbia University|No|Terminated|April 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|90 Years|No|||July 2014|July 11, 2014|June 11, 2008||No|Closed by Sponsor|No|January 28, 2014|https://clinicaltrials.gov/show/NCT00698139||154458|Early termination leading to small numbers of subjects analyzed
NCT00698802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX1000-1919|Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes|Assessment of Safety and Efficacy of Biphasic Human Insulin IU 100 to EX1000 on Glycaemic Control in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|June 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698802||154410|
NCT00699036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2007.066|Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)|Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial||Brooke Army Medical Center|Yes|Recruiting|April 2007|August 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||June 2009|June 18, 2009|June 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699036||154393|
NCT00698789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 19602-201|Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes|A Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety and Tolerability of INCB019602 Plus Metformin Compared to Metformin Alone in Type 2 Diabetic Subjects||Incyte Corporation|No|Terminated|May 2008|June 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|70 Years|No|||October 2012|October 25, 2012|June 13, 2008|Yes|Yes|Study ended after diabetes development plan review. .|No||https://clinicaltrials.gov/show/NCT00698789||154411|
NCT00710632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000590278|Screening to Predict Weight Loss in Patients With Cancer|Predicting Weight Loss in People With Cancer: Development of a Screening Tool||National Cancer Institute (NCI)||Active, not recruiting|September 2007|||August 2008|Anticipated|N/A|Interventional|Primary Purpose: Supportive Care|1||Anticipated|220|||Both|18 Years|N/A|No|||July 2009|September 16, 2013|July 3, 2008||||No||https://clinicaltrials.gov/show/NCT00710632||153518|
NCT00700011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCLO111|Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)|A Pilot Study of IV Clofarabine for Patients With Myelodysplastic Syndrome Who Have Failed 5-azacytidine||Texas Oncology Cancer Center|Yes|Terminated|March 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|June 17, 2008||No|poor accrual|No|December 6, 2012|https://clinicaltrials.gov/show/NCT00700011||154321|
NCT00711529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0057|Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.|Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.||Women and Infants Hospital of Rhode Island|Yes|Completed|July 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|27|||Female|18 Years|N/A|No|||May 2013|May 14, 2013|July 3, 2008|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT00711529||153451|We were unable to meet recruitment goals because of 1) lower-than-anticipated rate of referrals, and 2) subjects' unwillingness to randomization. This resulted in small numbers that limit interpretation of results.
NCT00707187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220013701|Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction|Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis||Rutgers, The State University of New Jersey|No|Completed|July 2001|July 2002||July 2002||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|N/A|No|||June 2008|June 27, 2008|June 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707187||153779|
NCT00707538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS747158-102|A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress|A Phase I Dosimetry, Biodistribution and Safety Study of BMS747158 in Healthy Subjects Undergoing 2-Day Rest/Stress Positron Emission Tomography||Lantheus Medical Imaging|Yes|Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2011|August 17, 2011|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707538||153753|
NCT00712257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALVAGE - 00106-661|Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis|A Prospective, Multicenter Trial to Evaluate the Safety and Performance of Spectranetics Laser With Adjunct PTA and GORE VIABAHN Endoprosthesis for the Treatment of SFA Instent Restenosis.|SALVAGE|VIVA Physicians|Yes|Terminated|November 2007|August 2009|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|89 Years|No|||June 2014|June 2, 2014|July 3, 2008|Yes|Yes|Due to safety concerns|No||https://clinicaltrials.gov/show/NCT00712257||153395|
NCT00681746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0850C00011|Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280|An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers|PET|AstraZeneca|No|Completed|February 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2008|December 8, 2010|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00681746||155704|
NCT00681759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00004|An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients|A Prospective Descriptive, Multi-National, Multi-Centre Observational Study of Burden of Upper GI-Symptoms in Subjects With Cardiovascular Risk or Disease Receiving Treatment With Low-Dose Aspirin||AstraZeneca|No|Completed|January 2008|September 2008|Actual|||N/A|Observational|Time Perspective: Prospective||3|Actual|1836|||Both|18 Years|N/A|No|Probability Sample|Patients with cardiovascular risk or disease receiving LDA treatment in specialist and        primary care clinics.|October 2008|October 30, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00681759||155703|
NCT00682110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0042|Hemodynamic Measurements During Liver Transplantation|Comparing Different Methods For Measurement of Cardiac Output During Orthotopic Liver Transplantation|OLT|Washington University School of Medicine|No|Completed|July 2007|March 2010|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|20 subjects will be enrolled in this observational study in the Liver Transplant Group; 10        patients in the Other Surgery Control Group for a total of 30 subjects. Patients will be        recruited from the Operating Room schedule. Written, informed consent will be obtained        from each subject prior to surgery. All participants will be informed that they may        decline to participate in, or withdraw from, the study at any time.|March 2010|March 31, 2010|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682110||155676|
NCT00682123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-P39|Risk of Positive Doping Tests Following Ingestion of Supplements Contaminated With Trace Quantities of Nandrolone Metabolites|Supplement Contamination: Detection of Nandrolone Metabolites in Urine After Administration of Small Doses of a Nandrolone Precursor||Loughborough University|No|Completed|March 2006|September 2006|Actual|September 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2008|May 20, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682123||155675|
NCT00682500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pneuma AR-06|Calfactant for Direct Acute Respiratory Distress Syndrome|Calfactant Therapy for Direct Acute Respiratory Distress Syndrome & Direct Acute Lung Injury in Adults and Children|CARDS|Pneuma Pharmaceuticals Incorporated|Yes|Terminated|May 2008|February 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|332|||Both|12 Years|85 Years|No|||July 2012|July 23, 2012|May 20, 2008|Yes|Yes|Expected mortality rates in placebo and treatment groups lower than predicted|No||https://clinicaltrials.gov/show/NCT00682500||155648|
NCT00683371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H43796-31316-03|Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis|Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis||University of California, San Francisco|No|Recruiting|October 2007|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 10, 2014|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683371||155583|
NCT00701922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4015|Surveillance Study of Viral Infections Following Lung Transplantation|Season Surveillance Study of Viral Infections in Lung Transplant Recipients||Hannover Medical School|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|388|Samples Without DNA|Nasopharyngeal and oropharyngeal swabs      bronchoalveolar lavage      blood samples|Both|18 Years|70 Years|No|Non-Probability Sample|lung transplant recipients in in a single-centre outpatient clinic|December 2008|October 27, 2011|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701922||154175|
NCT00701935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-CA-GWCE|Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin|Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin||AstraZeneca|No|Terminated|August 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|85 Years|No|||March 2015|March 23, 2015|June 17, 2008|Yes|Yes|Enrollment was much slower than anticipated, leading to a decision to terminate the study    early for enrollment futility.|No|January 11, 2013|https://clinicaltrials.gov/show/NCT00701935||154174|The dropout rate in the study was higher than anticipated (of 80 patients randomized, only 53 completed Study Period II), and enrollment was much slower than anticipated, leading to a decision to terminate the study early for enrollment futility.
NCT00701909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2280-32187-01|Pain Medicine for Wound Care Procedures|The Effectiveness of Small Doses of Ketamine With Morphine on Decreasing Pain Responses During Open Wound Care||University of California, San Francisco|No|Completed|June 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|65 Years|No|||January 2014|January 14, 2014|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701909||154176|
NCT00702195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06054|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials for the Development of Org 36286 (Corifollitropin Alfa).||Merck Sharp & Dohme Corp.|No|Completed|January 2002|September 2003|Actual|September 2003|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|29|||Female|18 Years|39 Years|No|Non-Probability Sample|All women who became pregnant during Trials 38805 or 38807 were enrolled in Trial 38817|August 2015|August 28, 2015|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702195||154154|
NCT00697840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/019|Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B|Study to Assess the Safety, Immunogenicity and Reactogenicity of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Adjuvanted Recombinant Hepatitis B Vaccine, Recombinant Hepatitis B Vaccine New Formulation and Engerix™-B||GlaxoSmithKline||Completed|June 1995|January 1996|Actual|January 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|150|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697840||154481|
NCT00697853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/030|Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults|Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine Administered According to a 0, 6 Month Schedule and of Engerix™-B Administered According to a 0, 1, 6 Month Schedule in Healthy Adults||GlaxoSmithKline||Completed|November 1998|||July 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|200|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697853||154480|
NCT00698815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00471|Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2008|||December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|130|||Both|18 Years|N/A|No|||January 2015|March 5, 2015|June 14, 2008|Yes|Yes||No|February 17, 2015|https://clinicaltrials.gov/show/NCT00698815||154409|
NCT00698451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015094|A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers|A Phase II Single Arm Study of Carboplatin and DOXIL (PLD) Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||August 2013|August 20, 2013|June 12, 2008|Yes|Yes||No|December 10, 2011|https://clinicaltrials.gov/show/NCT00698451||154436|
NCT00698464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2114|Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function|A Phase I, Open-label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function||Novartis||Completed|July 2008|||April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|34|||Both|18 Years|75 Years|No|||May 2012|May 29, 2012|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00698464||154435|
NCT00699400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28599|Oocyte Cryopreservation Registry (HOPE Registry)|A Phase IV, Prospective, Multicenter, Observational Oocyte Cryopreservation Registry||EMD Serono||Completed|June 2008|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|204|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women of reproductive age who, in order to achieve a pregnancy, will have embryos created        from thawed autologously or heterologously implanted oocytes that were either:          -  cryopreserved at the time of or following the Registry's launch, or          -  cryopreserved prior to the Registry's launch, but will undergo             thaw/fertilization/transfer procedures while the subject is enrolled in the Registry.|December 2013|December 9, 2013|June 13, 2008||No||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00699400||154367|
NCT00711542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-08-16 REPAIR-ACS|Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI|Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome: REPAIR - ACS|REPAIR-ACS|Johann Wolfgang Goethe University Hospitals|No|Terminated|September 2008|December 2015|Anticipated|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|July 8, 2008||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00711542||153450|
NCT00710905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCONsur002.08|Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3|Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3||Alcon Research|No|Terminated|October 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|21 Years|N/A|No|||November 2011|November 21, 2011|July 3, 2008||No|Postmarket study terminated as the SN6AD3 is no longer promoted.|No|October 4, 2011|https://clinicaltrials.gov/show/NCT00710905||153497|
NCT00711217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK15|Evaluation of a Medical Food for Chronic Wounds|Evaluation of a Medical Food for Chronic Wounds||Abbott Nutrition|Yes|Completed|June 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|N/A|No|||May 2011|November 1, 2011|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00711217||153474|
NCT00707551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00009|An Interaction Study of Ketoconazole/Verapamil Versus AZD1305|A Phase I, Single-centre, Randomised, Open, Three-way Crossover Study to Evaluate the Effect of Ketoconazole and Verapamil, Respectively, on the Pharmacokinetics of AZD1305 After Repeated Oral Adm of Ketoconazole and Verapamil and Single Oral Dosing of AZD1305 to Young Healthy Male Volunteers||AstraZeneca|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|27|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|June 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00707551||153752|
NCT00681460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUMS 705/07|Metformin in Gestational Diabetes Mellitus|Effects of Insulin and/or Metformin Treatment on Perinatal Outcome and Metabolic Parameters in Women With Gestational Diabetes Mellitus: Prospective Randomized Trial.|MetGDM|K. Marcinkowski University of Medical Sciences|No|Completed|May 2008|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 23, 2015|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681460||155726|
NCT00681772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100541|Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction|Open-label, Multi-centre, Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in Males With Erectile Dysfunction||Bayer|No|Completed|March 2003|November 2003|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|333|||Male|18 Years|N/A|No|||December 2014|December 10, 2014|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00681772||155702|
NCT00681785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269/05|Thrombophylaxis in Transurethral Surgery With Dalteparine|Thromboseprophylaxe Mit Niedermolekularem Heparin Bei Transurethralen Eingriffen||University Hospital, Basel, Switzerland|No|Completed|June 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|250|||Both|N/A|N/A|No|||May 2008|May 19, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00681785||155701|
NCT00682136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAPTRIAL|Analgesic Efficacy of Local Anesthetic Transversus Abdominis Plane (TAP) Blocks in Abdominal Surgery|Efficacy of Local Anesthetic TAP Blocks in Providing Pain Relief Following Laparoscopic and Open Abdominal Surgery||Hunter Colorectal Research|No|Completed|April 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|206|||Both|18 Years|N/A|No|||June 2010|June 2, 2010|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682136||155674|
NCT00682149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM2-AOC|Effects of Polyphenol Containing Antioxidants on Oxidative Stress in Diabetic Patients|Effects Polyphenol Containing Antioxidants on Oxidative Stress in Diabetic Patients||Yeditepe University Hospital|No|Recruiting|May 2008|October 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|65 Years|No|||May 2008|May 20, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682149||155673|
NCT00682513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NS058949-04|Identification, Prevalence, and Lifespan of Rapid-Onset Dystonia-Parkinsonism|Clinical, Genetic, and Cellular Consequences of Mutations in the NA,K-ATPase ATP1A3||Wake Forest School of Medicine|No|Recruiting|April 2008|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|whole blood, tissue (saliva samples)|Both|2 Years|N/A|No|Non-Probability Sample|Selection will take place predominantly via primary care clinics, i.e., physician        referrals when patients present with a movement disorder suspicious for RDP.|December 2014|December 8, 2014|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682513||155647|
NCT00701688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALSCT|Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Phase I Study Of The Use Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation||St. Jude Children's Research Hospital|No|Completed|September 2007|February 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|2 Years|18 Years|No|||March 2012|March 22, 2012|June 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701688||154193|
NCT00701701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU03707|Immune Tolerance Induction Study|An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme||Sanofi|Yes|Recruiting|December 2008|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|9|||Both|1 Month|N/A|No|||March 2016|March 8, 2016|June 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701701||154192|
NCT00701948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4108|New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn|Interest of New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn|NOSODIAG|University Hospital, Strasbourg, France|No|Recruiting|July 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|240|Samples Without DNA|Serum|Both|N/A|90 Days|No|Non-Probability Sample|Newborn hospitalized in neonatal intensive care unit with a clinical suspicion of        nosocomial bacterial infection|April 2010|April 27, 2010|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701948||154173|
NCT00702221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR002-CLN-pro008|Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension|A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension||BTG International Inc.|Yes|Terminated|June 2008|September 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|35 Years|70 Years|No|||October 2010|October 12, 2010|June 19, 2008|Yes|Yes|Dose limiting adverse effects|No||https://clinicaltrials.gov/show/NCT00702221||154152|
NCT00702208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD1382|Feasibility of Delphi Screener for Cervical Cytology|The Feasibility and Acceptability of Using the Delphi Screener for Cervical Cytology Testing Among Low Income Women in New York City||Columbia University|No|Completed|September 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|198|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|December 12, 2013|May 30, 2008|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00702208||154153|
NCT00698152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.H012|A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement|A Prospective, Non-controlled, Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement||Biomet, Inc.|No|Active, not recruiting|January 2006|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|149|||Both|N/A|N/A|No|Non-Probability Sample|Patients that have already made the decision to undergo Total Hip Replacement and will        recieve ArComXL® polyethylene|June 2015|June 17, 2015|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00698152||154457|
NCT00709566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoyalCSI|EMPART - Exercise and Manual Physiotherapy Arthritis Research Trial|The Effectiveness of Exercise Therapy and Manual Therapy in Hip Osteoarthritis - A Multicentre Randomised Controlled Trial|EMPART|Royal College of Surgeons, Ireland|No|Active, not recruiting|April 2008|December 2010|Anticipated|September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|40 Years|80 Years|No|||July 2010|July 22, 2010|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00709566||153599|
NCT00710398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 07-409|"Improving Diet, Exercise And Lifestyle (IDEAL) for Women" Study|The Impact of Higher Dairy and Dietary Protein on the "Quality" of Hypoenergetic diet-and Exercise-induced Weight Loss in Pre-menopausal, Overweight and Obese Young Women||McMaster University|No|Completed|July 2008|January 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|19 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00710398||153536|
NCT00710658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCS 06067/001|Internet Support for Cancer Patients|A Randomized Clincial Trial to Evaluate the Effects of an Internett-based Support System for Cancer Patients on Symptom Distress, Depression, and Quality of Life.|WebChoice|Oslo University Hospital|No|Completed|May 2006|November 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|325|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00710658||153516|
NCT00709826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP2001-203|APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer|APRiCOT-P (Apricoxib in Combination Oncology Treatment - Pancreas): Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Gemcitabine and Erlotinib in the Treatment of Patients With Advanced Pancreatic Cancer||Tragara Pharmaceuticals, Inc.|Yes|Completed|August 2008|May 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|July 1, 2008|Yes|Yes||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00709826||153579|
NCT00699062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGao001|Effect of Montelukast on the Airway Remodeling|Effect of Montelukast on the Airway Remodeling in Asthma Patients: Physiological-radiological Correlation||Chinese Academy of Medical Sciences|Yes|Completed|January 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|65 Years|No|||January 2012|January 3, 2012|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00699062||154391|
NCT00710385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5518|Abuse Liability of Suboxone Versus Subutex|Reinforcing Effects of Intravenous Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intravenous Drug Users (P05207)||Columbia University|No|Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|12|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00710385||153537|
NCT00707564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-I-D-2|Study of Hemostatic Efficacy of the HemCon Dental Dressing in a Population Treated With Anticoagulant Medications|A Randomized, Self-Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing in a Population Treated With Anticoagulant Medications||HemCon Medical Technologies, Inc|No|Withdrawn|July 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|14 Years|N/A|No|||September 2012|September 20, 2012|June 27, 2008|Yes|Yes|unable to enroll patient population|No||https://clinicaltrials.gov/show/NCT00707564||153751|
NCT00707889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-300|Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer|An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer||AbbVie|No|Completed|October 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707889||153727|
NCT00707200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0548-AE|The Cytoadherence in Pediatric Malaria (CPM) Study|Clinical Outcomes in Pediatric Plasmodium Falciparum Malaria According to Host Cytoadherence Factors|CPM|University Health Network, Toronto|No|Completed|October 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|Freshly frozen citrated plasma aliquots, frozen spun red cell pellets, and whole blood blots      onto nucleic acid storage cards (Whatman FTA).|Both|6 Months|12 Years|No|Non-Probability Sample|Children, age 6 months to 12 years, with symptomatic malaria and (asexual) Plasmodium        falciparum parasitemia.|July 2009|January 22, 2010|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00707200||153778|
NCT00681174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEST-TOR-01|Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery|Preoperative Controlled-Release Oxycodone or Intraoperative Morphine As Transition Opioid After Intravenous Anesthesia For Video-Assisted Thoracic Surgery: a Randomized, Double-blind, Controlled Trial.||University of Parma|Yes|Terminated|July 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||January 2012|January 5, 2012|May 19, 2008||No|Failure to enroll sufficient patients by expected deadline.|No||https://clinicaltrials.gov/show/NCT00681174||155748|
NCT00681473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-195|Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma|Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma||Massachusetts General Hospital|Yes|Active, not recruiting|July 2007|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681473||155725|
NCT00682162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-UM-0001-DI|Impact of Acupuncture on Vasomotor Rhinitis|Impact of Acupuncture on Vasomotor Rhinitis: a Randomised Placebo Controlled Pilot Study||Ludwig-Maximilians - University of Munich|No|Completed|January 1998|June 1999|Actual|January 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||May 2008|January 12, 2015|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682162||155672|
NCT00682175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-169|Metabolic Derangements in Acute Heart Failure Syndrome|Metabolic Derangements in Acute Heart Failure Syndrome||The Cleveland Clinic|No|Terminated|May 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|serum, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22) with        Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery catheter for        hemodynamically guided therapy.|March 2009|March 25, 2009|May 20, 2008||No|Project not initiated|No||https://clinicaltrials.gov/show/NCT00682175||155671|
NCT00682526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIME Multicenter Study|Pre-Hospital Wireless Transmission of Electrocardiograms to a Cardiologist Via a Hand-Held Device|Pre-hospital Wireless Transmission of Electrocardiograms to a Cardiologist Via a Hand-held Device: The TIME Multicenter Study||Welch Allyn|No|Completed|June 2003|May 2010|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control||3|Actual|527|||Both|18 Years|N/A|No|Non-Probability Sample|EMS transported patients age 18 or over who have their ECG attempted to be wirelessly        transmitted and with the intention to treat with coronary reperfusion therapy (PCI or        thrombolytics) based on their initial presentation All self transported and EMS        transported patients age 18 or over with the intention to undergo reperfusion therapy (PCI        or thrombolytics)based on their initial presentation who do not qualify for the        intervention group.|February 2012|February 21, 2012|May 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682526||155646|
NCT00682799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWOG MDS SCT RC RIC-06|Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC)|Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC) EWOG MDS SCT RC RIC-06||University Hospital Freiburg|No|Completed|April 2007|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|112|Samples With DNA|Hematopoietic chimerism will be investigated from PB samples. Prior to transplant 5 ml EDTA      PB from patient and donor are required and will be sent to the laboratory of the      Coordinating Investigator (P.B.). Post transplant PB samples (5 -10 ml EDTA blood) from day      +30 (4 days), +60(4 days), +100 (7 days) and +180 (7 days) will also being sent to the      laboratory of the Coordinating Investigator (P.B.) From EDTA PB cell subpopulations will be      isolated and DNA will be extracted and stored for further investigations.|Both|N/A|215 Months|No|Non-Probability Sample|Patients will only be allowed to enter the trial if they or their caretakers provide        written informed consent about their participation (following full explanation of the        trial) and if the physician has verified that the patient meets all of the Inclusion        Criteria and none of the Exclusion Criteria.|January 2015|January 14, 2015|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682799||155625|
NCT00683670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0652 / 201103308|Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma|Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma||Washington University School of Medicine|Yes|Recruiting|August 2008|August 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00683670||155561|
NCT00683683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARC (Morrison 038-2008)|The Strategies for Post Arrest Resuscitation and Care Network|The Strategies for Post Arrest Resuscitation and Care Network|SPARC|St. Michael's Hospital, Toronto|Yes|Completed|April 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||May 2014|May 25, 2015|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00683683||155560|
NCT00683696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EchoCRT|Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)|Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)|EchoCRT|Biotronik, Inc.|Yes|Terminated|August 2008|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1680|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|August 30, 2007|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT00683696||155559|Endpoint results should be interpreted with caution and take into consideration the early study closure and subsequent reduction in sample size (809 vs. 1258) and events (218 vs. 381). These changes impact the statistical power of the findings.
NCT00679276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-102|Treatment Outcomes of Vaginal Prolapse Repair|Treatment Outcomes of Vaginal Prolapse Repair||William Beaumont Hospitals|No|Completed|May 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|291|||Female|18 Years|N/A|No|Non-Probability Sample|Patients having prolift surgery at William Beaumont Hospital by Dr. Lary Sirls, Dr.        Predeep Nagaraju, and Dr. Kenneth Peters.|June 2010|June 4, 2010|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679276||155893|
NCT00701961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMP0208|Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy|The Pharmacokinetic of the Fixed-dose Combination of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnant Women||Institute of Tropical Medicine, Belgium|Yes|Completed|October 2008|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|49 Years|No|||September 2010|September 12, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701961||154172|
NCT00702247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00019702/3174|Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)|Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Two Step Approach to Reduce Toxicity Involving High-Dose Melphalan and Autologous Stem Cell Transplant Followed by PBSC Allografting After Low-Dose TBI||Azienda Ospedaliera San Giovanni Battista||Recruiting|July 1999|||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Both|18 Years|65 Years|No|||June 2008|June 19, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702247||154150|
NCT00702260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMI-C10-PVFD-1|Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions||Roxane Laboratories|No|Completed|January 2005|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702260||154149|
NCT00702234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05715|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38825 for Org 36286 (Corifollitropin Alfa)|Care|Merck Sharp & Dohme Corp.|No|Completed|February 2007|January 2010|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|268|||Female|18 Years|39 Years|No|Non-Probability Sample|Women with an ongoing pregnancy at least 10 weeks after fresh embryo transfer in base        study P05714 (NCT00696878) were enrolled in this trial.|April 2015|April 9, 2015|June 18, 2008|No|Yes||No|April 9, 2015|https://clinicaltrials.gov/show/NCT00702234||154151|
NCT00697866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/037|Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-Blind Safety Evaluation Using Engerix™-B as Control|Evaluating the Consistency of 3 Consecutive Lots of GSK Bio's Novel Adjuvanted HBV Vaccine With Single-Blind Safety Evaluation Using Engerix™-B as a Control, Administered According to a 0, 1, 2-Mth Schedule in Healthy Volunteers (15-50y).||GlaxoSmithKline||Completed|August 2000|||February 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|951|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697866||154479|
NCT00710151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-3805|Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors|Neurotoxicity in Primary Central Nervous System Lymphoma: An International, Collaborative, Observational Study of Cognition in Long-Term Survivors||OHSU Knight Cancer Institute|Yes|Terminated|July 2008|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|75 Years|No|Non-Probability Sample|Individuals who have had PCNSL and have survived disease-free for 2 years or more.|April 2015|April 22, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710151||153555|
NCT00710671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 070|Psychosocial Needs of YMSM|Psychosocial Needs of HIV+ Young Men Who Have Sex With Men (YMSM)||Westat|Yes|Completed|March 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|254|||Male|16 Years|24 Years|No|Non-Probability Sample|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past        year and accquired HIV behaviorally.|February 2016|February 29, 2016|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710671||153515|
NCT00710645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200310977|Lido Workset Study|Assessment of Spasticity in MS Patients Using a Lido Workset||University of California, Davis|No|Completed|April 2003|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 20, 2012|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710645||153517|
NCT00710138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19072|Cobalamin Status in Young Children With Developmental Delay|Cobalamin Status in Young Children With Developmental Delay and Regression||Haukeland University Hospital|No|Completed|June 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|8 Months|No|||August 2010|August 13, 2010|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710138||153556|
NCT00711230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermaVir Phase II|Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients|A Phase II Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antiretroviral Activity of DermaVir Patch (LC002) in Treatment-Naïve HIV-1-Infected Patients|GIEU006|Genetic Immunity|Yes|Active, not recruiting|April 2008|January 2015|Anticipated|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|50 Years|No|||February 2013|February 19, 2013|July 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00711230||153473|
NCT00708175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-4833_402|Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.|A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment||Takeda|No|Completed|May 2008|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Female|N/A|70 Years|No|||January 2012|January 3, 2012|June 27, 2008|Yes|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT00708175||153705|
NCT00707850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRCGL-08-06|Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection|A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Thalassemic Patients With Chronic Hepatitis C Infection||Baqiyatallah Medical Sciences University|Yes|Completed|May 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|12 Years|N/A|No|||September 2009|August 30, 2010|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707850||153730|
NCT00681187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-99-52030-216|Somatuline Autogel Preference and Health Economy Study|A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.|SAPHE|Ipsen|No|Completed|June 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|May 19, 2008|No|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00681187||155747|
NCT00681486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kl4501123|Ghrelin - A Possible Opportunity to Improve Appetite|Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss|Phase 3|Göteborg University||Completed|October 2003|July 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|No|||August 2009|August 20, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681486||155724|
NCT00681499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 18/08|Quality of Life After Liver Resection|Long-term Evaluation of the Quality of Life After Major Hepatic Resection for Malignant and Benign Diseases.||University of Bern|No|Completed|February 2008|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|198|||Both|18 Years|N/A|No|Non-Probability Sample|All patients requiring liver resection for any benign or malignant liver diseases,        including secondary tumours|November 2015|November 12, 2015|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681499||155723|
NCT00681798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200L00003|Dose Escalation Study With Zactima and Chemotherapy in Metastastic Pancreas Carcinoma|Dose Escalation Study of the Combination of ZD6474, Gemicitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma||AstraZeneca|No|Completed|July 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|8|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00681798||155700|
NCT00682539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIASTIN Study|Intraocular Bevacizumab Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema|A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema|TRIASTIN|Medical University of Vienna|Yes|Recruiting|October 2007|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682539||155645|
NCT00682552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01336-48|Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence|Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence||Assistance Publique Hopitaux De Marseille|No|Terminated|May 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Female|18 Years|65 Years|No|||August 2014|August 27, 2014|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00682552||155644|
NCT00682812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01335-48|Significance of the High-risk Hpv Viral Load|Significance of the High-risk Hpv Viral Load||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|June 2008|December 2014|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|149|||Female|18 Years|N/A|No|||January 2010|August 27, 2014|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682812||155624|
NCT00683397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 93/08|Frankfurt Thrombophilia Registry|Frankfurt Thrombophilia Registry - Evaluation of Patients With Venous Thromboembolism||Johann Wolfgang Goethe University Hospitals||Recruiting|May 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|whole blood, serum|Both|18 Years|N/A|No|Non-Probability Sample|consecutive patients with acute or previous VTE >18 years of age|August 2012|August 13, 2012|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683397||155581|
NCT00683085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMSUT-PPKVEGFR10201|Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer|Phase I/II Trial of Human Leukocyte Antigen (HLA)-A*02:01-restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination Combined With Conventional Dose of Gemcitabine for Advanced Pancreatic Cancer||Tokyo University|Yes|Terminated|May 2008|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|20 Years|85 Years|No|||July 2011|July 20, 2011|May 16, 2008||No|Lack of eligible patient|No|June 9, 2009|https://clinicaltrials.gov/show/NCT00683085||155604|Early termination leading to small numbers of subjects analyzed
NCT00679562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03648|Lactacyd Radiance (Lactic Acid) Prophetic Patch Test|Skin Irritation : Prophetic Patch Test of Lactacyd Radiance||Sanofi|No|Completed|March 2008|||April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 5, 2009|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679562||155871|
NCT00708708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4499|Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings|A Prospective Non-interventional Study (Nis) Of The Routine Use Of Etanercept In The Long-term Treatment Of Patients With Plaque-type Psoriasis In Everyday Practice: An Efficacy, Safety, And Health Economic Evaluation||Pfizer|No|Completed|June 2008|December 2013|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|926|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with moderate to severe plaque psoriasis|July 2015|July 24, 2015|June 30, 2008||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00708708||153664|
NCT00708721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI26135|Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia|Phase I/II Study of Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (Dysplastic Type) Patients Who Have Failed Hypomethylating Therapy||University of Utah|Yes|Completed|March 2008|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|June 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00708721||153663|
NCT00708734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F5070-R|Exercise Intervention to Reduce Postural Instability in Osteoarthritis|Exercise Intervention to Reduce Postural Instability in Osteoarthritis||VA Office of Research and Development|No|Completed|July 2008|November 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|50 Years|N/A|No|||October 2014|October 21, 2014|June 27, 2008||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00708734||153662|
NCT00709046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710033M|High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment|High Dose Versus Standard Dose Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Hemostasis: A Prospective Randomized Comparative Study||National Taiwan University Hospital|Yes|Recruiting|January 2008|||January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|N/A|No|||January 2010|January 11, 2010|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00709046||153639|
NCT00697879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-3996-001|Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours|A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours||Chroma Therapeutics|No|Completed|February 2008|November 2011|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||November 2011|November 25, 2011|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00697879||154478|
NCT00710411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG KFO-200|Inflammatory Response After Muscle and Skeleton Trauma|Inflammatory Response in Polytraumatized Patients|IRAMST|University of Ulm|No|Completed|April 2009|December 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|48|Samples With DNA|Whole blood, serum, white cells, and tissues will be retained.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Polytraumatized patients with an ISS > 18 Controls: healthy volunteers|December 2015|December 16, 2015|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00710411||153535|
NCT00710944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OSS-0006|Study to Compare Survival for ASTRA TECH Implant System, OsseoSpeed™ Implants Following Immediate Loading in Extraction Sockets Versus Immediate Loading in Healed Ridges|An Open, Prospective, Controlled Study in the Maxilla to Evaluate Clinical Outcome of ASTRA TECH Implant System, OsseoSpeed™ Implants in Single Tooth Replacement Using an Immediate Loading Protocol in Extraction Sockets and Healed Ridges.||Dentsply Implants|No|Completed|April 2005|November 2012|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|132|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|July 7, 2008|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT00710944||153495|
NCT00710931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCONsur001.08|Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1|Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1||Alcon Research|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|21 Years|N/A|No|||December 2011|December 5, 2011|July 3, 2008|Yes|Yes||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00710931||153496|
NCT00707213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI22418|FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients|FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients||University of Utah|Yes|Terminated|August 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|N/A|N/A|No|||August 2015|August 4, 2015|June 25, 2008||No|Funding from the NIH ended and not all patients had been accrued|No||https://clinicaltrials.gov/show/NCT00707213||153777|
NCT00707863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0711-14|Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram|fMRI and Genotype Markers of Antidepressant Side Effects and Response in Young Adults Compare to Older Adults||Indiana University|No|Completed|May 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|50 Years|No|||October 2011|March 5, 2013|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00707863||153729|
NCT00661752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|quarter-time cardiac SPECT|Protocol for Evaluation of Quarter-Time Cardiac Imaging: 5-Minutes Rest and 3-Minutes Stress Wide Beam Reconstruction (WBR) Versus Full-Time Filtered Back Projection (FBP)|Quarter-Time Myocardial Perfusion SPECT||St. Luke's-Roosevelt Hospital Center|Yes|Completed|May 2007|January 2008|Actual|August 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|134|||Both|18 Years|N/A|No|Non-Probability Sample|Adult male and female patients referred to St. Luke's NM lab. for clinically indicated        myocardial perfusion SPECT|August 2008|August 25, 2008|April 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661752||157229|
NCT00662012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-10950|Sodium Stibogluconate Treatment of Leishmaniasis|Sodium Stibogluconate Treatment of Leishmaniasis||U.S. Army Medical Research and Materiel Command|No|Completed|June 2002|December 2007|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|418|||Both|N/A|N/A|No|||April 2015|April 7, 2015|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662012||157209|
NCT00662610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT3012-X-111|A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure|A 12-Week, Phase 1, Multicenter, Double-Blind, Randomized, Dose Ranging, Forced Titration, Naproxen-Controlled, Parallel-Group, Pharmacodynamic Study, to Assess the Effects Different Doses of Naproxcinod and Naproxen on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension|HCT3012-X-111|NicOx|Yes|Completed|March 2008|November 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|N/A|No|||June 2011|June 16, 2011|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662610||157163|
NCT00663923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-43|Comparison of Cross-cylinder and Conventional Photorefractive Keratectomy(PRK) in Correcting Medium-high Astigmatism|Comparison of Cross-cylinder and Conventional PRK for Laser Correction of Astigmatism: A Randomized Clinical Trial.|PRK|Tabriz University|Yes|Completed|November 2007|December 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 10, 2012|April 18, 2008||No||No|December 30, 2009|https://clinicaltrials.gov/show/NCT00663923||157062|
NCT00712595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mife_Fibroids_01|Mifepristone for Treatment of Uterine Fibroids|Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial.|Mifemyo|Mediterranea Medica S. L.|Yes|Completed|January 2007|March 2009|Actual|January 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|50 Years|No|||April 2009|April 22, 2009|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712595||153369|
NCT00712023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 196/2007|Effect of Forced-air Warming and Circulating-water Mattress in Preventing Heat Loss During Vascular Surgery|Effect of Forced-air Warming and Circulating-water Mattress in Preventing Heat Loss During Vascular Surgery||Mahidol University|No|Completed|July 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||April 2008|September 27, 2009|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00712023||153413|
NCT00712803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 252|Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults|A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3-3'Ddelta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712803||153353|
NCT00712790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC - AHCC05|Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)|Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma||Singapore Clinical Research Institute|No|Completed|June 2008|April 2014|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712790||153354|
NCT00713349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-101-09-004|Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing|A Randomized, Evaluator Blinded, Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing of Induced Thermal Wounds||Healthpoint|No|Completed|June 2008|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 9, 2013|July 9, 2008|No|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00713349||153311|
NCT00713362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801030R|Chest Tube Drainage or Thoracoscopic Surgery for Failed Aspiration of Spontaneous Pneumothorax|Comparison of Chest Tube Drainage Versus Thoracoscopic Surgery for Unsuccessful Aspiration of Primary Spontaneous Pneumothorax: a Prospective Randomized Trial||National Taiwan University Hospital|No|Recruiting|April 2008|September 2013|Anticipated|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|50 Years|No|||November 2012|December 13, 2012|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713362||153310|
NCT00713089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNB01|Study of Stool Microbiota in Two Diverse Cohorts of Asian and Its Influence on Allergy Development|A 2 Year Prospective Study of Stool Microbiota in Two Diverse Cohorts of Asian (Singaporean and Indonesian) Newborns and Its Influence on Allergy Development||National University Hospital, Singapore|No|Completed|March 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|74|Samples With DNA|Stools samples will be collected between 72 to 120 hours (or 3 to 5 days) and at 1, 3 and 12      months of age.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|75 subjects randomised into the placebo arm of an ongoing randomised double-blind placebo        controlled clinical trial at National University Hospital, Singapore.        For Indonesia Cohort, the expecting mothers visiting at the well mother clinics at Gadjah        Mada University Hospital were invited to participate in the study.|January 2014|January 7, 2014|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713089||153331|
NCT00713102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Surgical and Medical Emergencies on Board of European Aircraft Carriers|Surgical and Medical Emergencies on Board of European Aircraft Carriers||Ruhr University of Bochum|Yes|Completed|January 2008|August 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|10189|||Both|N/A|N/A|No|Non-Probability Sample|Men, women, adolescent, children and babies who have suffered from an emergency on board        an European airline.|October 2012|October 15, 2012|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00713102||153330|
NCT00695123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080156|Screening for Subjects to Participate in Studies of Blood Disorders|Screening of Subjects to Determine Eligibility to Safely Participate in Blood Disorders Studies||National Institutes of Health Clinical Center (CC)||Recruiting|June 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|June 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00695123||154686|
NCT00695708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO 805/14|Training-induced Cerebral Reorganization in Schizophrenia|Training-induced Cerebral Reorganization in Schizophrenia||University of Konstanz|Yes|Completed|January 2008|January 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|60|||Both|N/A|60 Years|Accepts Healthy Volunteers|||June 2008|April 12, 2010|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00695708||154641|
NCT00696033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3777|Exploring the Effects of Diazepam and Lorazepam|Exploring the Effects of Diazepam and Lorazepam on the Neural Correlates of Perceptual Priming and Explicit Memory in Healthy Volunteers|ibid|University Hospital, Strasbourg, France|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|22|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696033||154618|
NCT00696306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007WFCRC-002|MRI-SWI as a Predictor of Functional Outcome in Acute Ischemic Stroke|Diffusion Tensor Imaging (DTI) and Susceptibility Weighted Imaging (SWI) as a Predictor of Functional Outcome in Acute Ischemic Stroke||Taipei Medical University WanFang Hospital|No|Completed|February 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|N/A|No|Non-Probability Sample|Acute Ischemic Stroke|April 2011|April 11, 2011|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00696306||154598|
NCT00696592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-01-ARMAST-2007|Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-Related Macular Degeneration|A Randomized, Controlled, Open Label, Phase II Study of Visudyne® Photodynamic Therapy (PDT) Combined With Bevacizumab (Avastin) vs Avastin Alone in Patients With Neovascular Age-Related Macular Degeneration (AMD)|ARMAST|University of Padova|Yes|Recruiting|January 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|55 Years|80 Years|No|||April 2007|June 10, 2008|June 10, 2008||||No||https://clinicaltrials.gov/show/NCT00696592||154576|
NCT00664690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-04-309|Effect of Celecoxib on Transitional Pain After Outpatient Surgery|Effect of Celecoxib on Transitional Pain After Outpatient Surgery||Lawson Health Research Institute|No|Recruiting|July 2004|||December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||April 2008|April 22, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664690||157003|
NCT00664703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43MH081553|Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients|A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients||Yaupon Therapeutics|Yes|Completed|July 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|13|||Both|21 Years|45 Years|No|||June 2013|June 19, 2013|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664703||157002|
NCT00665015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEFCS-summer 07|Pleural Effusion Following Cardiac Surgery: Prevalence, Risk Factors and Clinical Features|Pleural Effusions Following Cardiac Surgery: Prevalence, Risk Factors and Clinical Features.||Laval University|No|Completed|January 2004|October 2006|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2892|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing coronary artery bypass grafting surgery, heart valve replacement        surgery or both procedures.|April 2008|April 21, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665015||156978|
NCT00660751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNIC01CTIL|The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control|The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control||Rambam Health Care Campus||Active, not recruiting|August 2007|||August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2008|April 16, 2008|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660751||157306|
NCT00661414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1009-Onc-001|Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors|A Multi-Center, Open-Label, Single-Arm, Phase 1, Dose Escalation Study of ASONEP (Sonepcizumab/LT1009) Administered as a Single Agent Weekly to Subjects With Refractory Advanced Solid Tumors|ASONEP|Lpath, Inc.|No|Completed|April 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|N/A|No|||January 2012|January 27, 2012|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661414||157255|
NCT00661427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-039|Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer|A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer.||Memorial Sloan Kettering Cancer Center|Yes|Completed|November 2007|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 7, 2008|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00661427||157254|
NCT00661778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20081|A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer|An Open Label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Docetaxel and Cisplatin on Progression-free Survival in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer||Hoffmann-La Roche||Completed|July 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|April 17, 2008||No||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00661778||157227|
NCT00662025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181163|Study Of Sunitinib With Capecitabine In Breast Cancer|A Phase II Study Of Sunitinib Malate In Combination With Capecitabine In Patients With Advanced Or Metastatic Breast Cancer||Pfizer|Yes|Completed|April 2008|May 2012|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Female|20 Years|N/A|No|||May 2013|May 22, 2013|April 17, 2008||No||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00662025||157208|
NCT00662324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-042|Development of a Clinical Trial Specific Question Prompt List|Development of a Clinical Trial Specific Question Prompt List||Memorial Sloan Kettering Cancer Center||Completed|April 2008|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|treatment at MSKCC of lung, prostate or breast cancer A current health care professional        at MSKCC current involvement in recruiting patients with lung, prostate or breast cancer        to Phase I,II, or III clinical trials at MSKCC|May 2013|May 29, 2013|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662324||157185|
NCT00663676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0100|Growth Hormone Administration and the Human Immune System - I|Growth Hormone Administration and the Human Immune System - I||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|September 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663676||157081|
NCT00663689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cslc0803|Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer|A Phase II Study of Erlotinib in Benefitted Patients With Asymptomatic Brain Metastases Advanced Non-Small Cell Lung Cancer By Chemotherapy.||Guangdong Provincial People's Hospital|Yes|Active, not recruiting|March 2008|January 2012|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||April 2008|April 21, 2008|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663689||157080|
NCT00712608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3378-2|The Evaluation of Cow's Milk Formula - Study B|The Evaluation of Cow's Milk Formula - Study B||Mead Johnson Nutrition|No|Completed|August 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|399|||Both|N/A|16 Days|Accepts Healthy Volunteers|||April 2009|January 26, 2010|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712608||153368|
NCT00712816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-02|Use of Cold and Compression Therapy With Total Knee Replacement Patients|Investigating the Use of a Cryopneumatic Therapy Device in Primary Total Knee Arthroplasty Patients||CoolSystems, Inc.|No|Active, not recruiting|July 2008|May 2012|Anticipated|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|85 Years|No|||March 2012|March 19, 2012|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712816||153352|
NCT00712829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX-P101|Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents|A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for 123-I-MIP-1072 and 123-I-MIP-1095||Molecular Insight Pharmaceuticals, Inc.|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|12|||Male|18 Years|N/A|No|||October 2011|October 7, 2011|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712829||153351|
NCT00713115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803040R|Prospective Randonmized Comparison of Needlescopic Versus Conventional Laparoscopic Adrenalectomy|Prospective Randonmized Comparison of Needlescopic Versus Conventional Laparoscopic Adrenalectomy for Benign Adrenal Tumors Less Than 5 cm in Diameter||National Taiwan University Hospital|No|Recruiting|June 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|3 Years|80 Years|No|||June 2008|July 9, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713115||153329|
NCT00713401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 4129|Safety Study of Tecadenoson to Treat Atrial Fibrillation|An Open-Label, Sequential-Group, Dose-Escalation Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Tecadenoson Alone and in Combination With a Beta-Blocker in Adults With Rapid Atrial Fibrillation (CVT 4129)||Gilead Sciences|No|Completed|February 2008|July 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|21|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713401||153308|
NCT00713414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080181|Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia|Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia and Other Focal Dystonias||National Institutes of Health Clinical Center (CC)||Recruiting|July 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|45|||Both|21 Years|80 Years|No|||November 2015|November 24, 2015|July 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00713414||153307|
NCT00713687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM-658-EBE-0024-I|Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma|Sequential Combination of Chemotherapy With Gemcitabine/Oxaliplatin and Photodynamic Therapy in Advanced Cholangiocarcinoma|GemOx-PDT|Technische Universität München|No|Withdrawn|August 2008|December 2011||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|90 Years|No|||July 2008|August 9, 2012|July 7, 2008|||recruiting failed|No||https://clinicaltrials.gov/show/NCT00713687||153286|
NCT00713700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL00233|AMPLATZER Duct Occluder II Clinical Study|Closure of Patent Ductus Arteriosus With the AMPLATZER DUCT Occluder II|ADO II|St. Jude Medical|Yes|Active, not recruiting|August 2008|January 2017|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|6 Months|18 Years|No|||April 2015|April 2, 2015|July 9, 2008|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00713700||153285|
NCT00696020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.4|Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)|Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD||Boehringer Ingelheim||Completed|June 2008|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|360|||Both|40 Years|N/A|No|||July 2015|July 20, 2015|June 10, 2008||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT00696020||154619|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information".
NCT00663598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100477|Levitra® - Real Life Safety and Efficacy of Levitra|REALISE Levitra® - Real Life Safety and Efficacy of Levitra|REALISE|Bayer|No|Completed|October 2003|September 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30825|||Male|18 Years|N/A|No|||December 2014|December 18, 2014|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00663598||157087|
NCT00663858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS-102-036|Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)|Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: a Double-blind Placebo-controlled Efficacy Study||AEterna Zentaris|Yes|Completed|March 2008|January 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|420|||Male|50 Years|N/A|No|||December 2010|December 15, 2010|April 17, 2008||No||No|November 11, 2010|https://clinicaltrials.gov/show/NCT00663858||157067|
NCT00664092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJ070306PSY-C1|Evaluating Alternative Aftercare Models for Ex-Offenders|Evaluating Alternative Aftercare Models for Ex-Offenders||DePaul University|Yes|Completed|October 2007|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Actual|300|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664092||157049|
NCT00664365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPE111154|FTIH Study With GSK958108|A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK958108 in Healthy Male Subjects||GlaxoSmithKline|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|April 10, 2008||||No||https://clinicaltrials.gov/show/NCT00664365||157028|
NCT00664339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDI (976) 407|Flu Vaccination in Congestive Heart Failure|Influenza Vaccine Pilot Study in Severe Congestive Heart Failure Patients. The Flu Vaccination Heart Failure (FLUVACS II) Study|FLUVACS-IC|La Fundacion Favaloro para la Investigacion y la Docencia Medica|Yes|Completed|May 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|117|||Both|21 Years|90 Years|No|||April 2008|April 17, 2008|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664339||157030|
NCT00664352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1004-0082|Juvidex (Mannose-6-Phosphate) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites|A Double Blind, Placebo Controlled Trial to Investigate the Efficacy and Safety of Two Concentrations of Juvidex (Mannose-6-Phosphate) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites Using Different Dosing Regimes||Renovo|No|Completed|February 2008|November 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|195|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2009|January 5, 2009|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664352||157029|
NCT00665028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007246-01H|Perioperative Ischemia Reduction Study (PROSE) Pilot|Perioperative Ischemia Reduction Study (PROSE) Pilot||Ottawa Hospital Research Institute|No|Completed|November 2007|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|55 Years|N/A|No|Non-Probability Sample|Elective non-cardiac surgical procedure|January 2015|January 6, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665028||156977|
NCT00665041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-CB-090108-001|Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome|A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|May 2008|October 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|21 Years|34 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00665041||156976|
NCT00660764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25V07|Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)|Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)|HEROS|AstraZeneca||Completed|May 2003|April 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|75 Years|No|Non-Probability Sample|patients of practices of General Practioners|March 2009|March 13, 2009|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660764||157305|
NCT00661440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579-0707/1|Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus|Efficacy and Safety of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus: a Randomized, Double-blind, Placebo-controlled, Single Center, Proof of Concept Study Using a Two-period Cross-over Design||Merz Pharmaceuticals GmbH|No|Completed|May 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|80 Years|No|||November 2009|November 25, 2009|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661440||157253|
NCT00661765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051071|A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.|A Phase I, Open-Label, Randomized, Single Dose, Cross Over Study to Estimate the Relative Bioavailability of a Varenicline (CP-526,555) Transdermal Delivery System to the Chantix Immediate Release Tablet Formulation in Adult Smokers||Pfizer|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 22, 2009|April 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661765||157228|
NCT00662883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET-PK-009|Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)|A Randomized, Open Label Study to Assess the Effects of a Nasal Corticosteroid on the Pharmacokinetics, Safety, and Tolerability of PMI-150 (Intranasal Ketamine Hydrochloride) 30 mg||Javelin Pharmaceuticals|No|Completed|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 21, 2008|April 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00662883||157142|
NCT00663130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11333|Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)|A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction||Bayer||Completed|April 2004|July 2004|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|759|||Male|18 Years|64 Years|No|||October 2013|October 9, 2013|April 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00663130||157123|
NCT00663416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTx™-265-CP-201-IS (CA)|REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)|REGENESIS|Stem Cell Therapeutics Corp.|Yes|Terminated|March 2008|January 2009|Anticipated|October 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|85 Years|No|||August 2009|August 10, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663416||157101|
NCT00663403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063940|Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)|Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)||University of Michigan|No|Completed|February 2007|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||May 2009|December 1, 2015|April 18, 2008|Yes|Yes||No|April 29, 2010|https://clinicaltrials.gov/show/NCT00663403||157102|Transmembrane and total body clearance results limited to continuous venovenous hemodialysis run at ~2 L/h dialysate flow. Clinical outcomes (such as infection cure rate, length of hospital stay, mortality rate) of subjects was not assessed.
NCT00664196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|595-04|Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning|Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning||Roger Williams Medical Center|Yes|Active, not recruiting|April 2008|July 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||May 2013|October 14, 2014|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664196||157041|
NCT00664157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0033|Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus|Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus .||University Hospital, Clermont-Ferrand||Completed|September 2007|October 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||January 2011|January 18, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664157||157044|
NCT00664170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANX 514-01|A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer|A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer||Mast Therapeutics, Inc.|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||May 2009|May 27, 2009|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664170||157043|
NCT00664183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVD-301|A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects|A Phase 3 Safety and Efficacy Study of Vitreosolve® for Ophthalmic Intravitreal Injection in Retinopathy Subjects||Vitreoretinal Technologies, Inc.|No|Terminated|March 2008|||December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|400|||Both|30 Years|N/A|No|||October 2009|October 19, 2009|April 18, 2008|Yes|Yes|slow enrollment , interim analysis conducted.|No||https://clinicaltrials.gov/show/NCT00664183||157042|
NCT00712842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-221203|Neurovascular Coupling in Patients With Early Stage Diabetes Retinopathy|Neurovascular Coupling in Patients With Early Stage Diabetes Retinopathy||Medical University of Vienna|Yes|Completed|January 2007|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 Patients with Diabetes Type 1 50 Healthy Control Subjects|July 2012|July 19, 2012|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712842||153350|
NCT00713427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO-WALLFLEX-BIL-PALL-002|Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction|A Multi-Center, Single Arm, Prospective Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction||Boston Scientific Corporation|Yes|Completed|July 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||August 2009|August 31, 2009|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713427||153306|
NCT00713713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-TIP-02|Effect of Different Ventilatory Strategies on Cardiac Function in Patients With Acute Respiratory Failure|Hemodynamic Impact of Low and High Tidal Volume Mechanical Ventilation in Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) Patients|VITALI|Fondazione Poliambulanza Istituto Ospedaliero|No|Completed|July 2008|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|16|||Both|18 Years|N/A|No|||July 2009|July 31, 2009|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713713||153284|
NCT00713726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1386/06|Tramadol Versus Fentanyl for Post-Operative Analgesia in Newborn Infants|Post-Operatory Analgesia in Newborn Infants: a Comparative Study of Fentanyl Versus Tramadol||Federal University of São Paulo|Yes|Completed|January 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|N/A|28 Days|No|||July 2008|July 10, 2008|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713726||153283|
NCT00713973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-09|Comparative Study Between Thrombosis Prophylaxis Protocols|Comparative Study Between American and Brazilian Protocols for Deep Venous Thrombosis Prophylaxis: a New Proposal||UPECLIN HC FM Botucatu Unesp|Yes|Completed|June 2007|June 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|212|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who underwent plastic surgery in the Hospital of the Medical School of Botucatu,        in the period of one year.|July 2008|October 17, 2008|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00713973||153264|
NCT00713986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID: AGC 1107|Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B|Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B: a Comparison Between Skin-to-Skin Contact, Glucose 25% and Both of Them||Federal University of São Paulo|No|Completed|March 2006|July 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|640|||Both|N/A|72 Hours|No|||July 2008|July 11, 2008|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00713986||153263|
NCT00714259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080429003|Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies|UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies||University of Alabama at Birmingham|Yes|Terminated|July 2008|February 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|70 Years|No|||June 2013|June 18, 2013|July 10, 2008||No|Accrual goals could not be met within a timely manner|No||https://clinicaltrials.gov/show/NCT00714259||153242|
NCT00714272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSGA0801|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2008|||||N/A|N/A|N/A||||||||||||||July 11, 2008|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00714272||153241|
NCT00663611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907260|Growth Hormone Administration and the Human Immune System|Growth Hormone Administration and the Human Immune System||National Institutes of Health Clinical Center (CC)||Completed|October 2006|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Male|20 Years|50 Years|No|||December 2015|December 15, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663611||157086|
NCT00664105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0319|Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)|PhII Study of Concurrent Chemoradiotherapy With Weekly Docetaxel, Carboplatin and Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC)||Vanderbilt-Ingram Cancer Center|Yes|Terminated|February 2004|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|April 19, 2008|Yes|Yes|Treatment became standard.|No|September 30, 2010|https://clinicaltrials.gov/show/NCT00664105||157048|Outcome measure #4, "Number of participants with AEs by grade", will not match the total number of participants in this study. Some participants have multiple events in one or more grade designations or some participants have no events at all.
NCT00664378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCL07001|Efficacy Study of CYT997 in Multiple Myeloma|A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma||Gilead Sciences|Yes|Terminated|January 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|April 18, 2008|Yes|Yes|Difficulty enrolling patients|No||https://clinicaltrials.gov/show/NCT00664378||157027|
NCT00664391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03746|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze||Sanofi|No|Completed|January 2008|||February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|32|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 9, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664391||157026|
NCT00664716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104RA202|Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants|Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.|RESPOND|Biogen|Yes|Completed|July 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|391|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664716||157001|
NCT00665054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11382|BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction|Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction.||Bayer|No|Completed|August 2004|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Male|18 Years|64 Years|No|||December 2014|December 23, 2014|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00665054||156975|
NCT00660777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPE-OSA|Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea|Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea: A Randomized, Controlled Study||University of Sao Paulo|No|Completed|February 2004|April 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|25 Years|65 Years|No|||April 2008|April 15, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00660777||157304|
NCT00661076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20622|ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B|A Randomized, Open Label Study to Compare the Effect of Combination Treatment With PEGASYS + Adefovir Dipivoxil Versus PEGASYS Monotherapy on HBV-DNA and ALT Levels in Patients With HBeAg-negative, Chronic Hepatitis B.'||Hoffmann-La Roche||Completed|August 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661076||157281|
NCT00662623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-17246-01|Enabling Sleep Apnea Patient-Centered Care Via an Internet Intervention|Enabling Sleep Apnea Patient-Centered Care Via an Internet Intervention||Veterans Medical Research Foundation|No|Active, not recruiting|April 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2010|July 6, 2010|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00662623||157162|
NCT00663702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-185|Phase IIIB Switching From Intravenous to Subcutaneous Study|A Phase 3B Multi-center Open-Label Study to Evaluate the Safety of Abatacept in Subjects Who Switch From Intravenous to Subcutaneous Abatacept Therapy||Bristol-Myers Squibb|No|Completed|May 2008|January 2012|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|April 18, 2008|Yes|Yes||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00663702||157079|
NCT00663936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA4437420|Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease|A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease||Toyama Chemical Co., Ltd.|Yes|Completed|April 2008|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|373|||Both|50 Years|90 Years|No|||December 2012|October 9, 2013|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663936||157061|
NCT00664209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJJF Clinical Discovery 2007|Treating H. Pylori in Parkinson's Patients With Motor Fluctuations|Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease||University of California, Los Angeles|No|Recruiting|January 2008|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|N/A|N/A|No|||April 2008|April 21, 2008|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664209||157040|
NCT00664482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-006-001|A Single-Patient Study Using AGS 006|A Single-Patient Study Using AGS 006 as an Immunotherapeutic in a Subject With Newly Diagnosed Resectable Pancreatic Cancer||Argos Therapeutics|No|Completed|May 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|N/A|No|||January 2013|January 22, 2013|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664482||157019|
NCT00713440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-INK|Incretin Physiology Associated With Steroid Hormone Treatment|Incretin Physiology and Beta-Cell Function Before and After Treatment With Steroid Hormone in Healthy Individuals||Glostrup University Hospital, Copenhagen|Yes|Completed|July 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2009|August 5, 2009|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713440||153305|
NCT00713453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200704066R|Muscle Response to Enzyme Replacement Therapy in Pompe Disease|Muscle Response to Enzyme Replacement Therapy in Pompe Disease||National Taiwan University Hospital|No|Recruiting|January 2007|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|16|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with Pompe disease, prepare or on enzyme replacement therapy|March 2015|March 21, 2015|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713453||153304|
NCT00713739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD CID 06-050|Alfuzosin for Medical Expulsion Therapy of Ureteral Stones|Evaluation of Alfuzosin as Medical Expulsion Therapy for Ureteral Stones|MET|United States Naval Medical Center, San Diego|Yes|Recruiting|January 2008|December 2012|Anticipated|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 25, 2012|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713739||153282|
NCT00713999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM/DBL 01|Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar|Study of Reproductive Health in Rural Madagascar With Emphasis on Urogenital Schistosomiasis and Sexually Transmitted Infections|FGS/MGS/STI|University of Aarhus|Yes|Completed|August 2001|September 2003|Actual|April 2002|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|680|||Both|15 Years|49 Years|Accepts Healthy Volunteers|||July 2008|July 11, 2008|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00713999||153262|
NCT00714285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111295|Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.|Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults.||GlaxoSmithKline||Completed|July 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|420|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|July 11, 2008|Yes|Yes||No|July 11, 2013|https://clinicaltrials.gov/show/NCT00714285||153240|
NCT00714597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10572|Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility|SAVE-VEMED|Sanofi|Yes|Terminated|July 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|421|||Both|40 Years|N/A|No|||January 2013|January 14, 2013|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00714597||153216|
NCT00663624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008143|Management of Hyperglycemia in the ER: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care|Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care|NOVO ER|Emory University|Yes|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||November 2013|November 20, 2013|April 18, 2008|Yes|Yes|Lack of funding for the study at the Emory site|No||https://clinicaltrials.gov/show/NCT00663624||157085|
NCT00664404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0829|Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal|Pharmacogenetics, Emotional Reactivity and Smoking Cessation: Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal||M.D. Anderson Cancer Center|Yes|Completed|April 2008|||October 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 23, 2012|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664404||157025|
NCT00664729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG020583|Diet, Exercise, Metabolism, and Obesity in Older Women|Diet, Exercise, Metabolism, and Obesity in Older Women:DEMO|DEMO|Wake Forest School of Medicine|Yes|Completed|November 2002|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|112|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||April 2008|January 12, 2010|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664729||157000|
NCT00665067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0548-00107|Correlative Biomarker Study in Patients With Myeloproliferative Disorders|Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|April 2007|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|N/A||1|Anticipated|860|Samples With DNA|Leftover tissue will be asked for to be stored in the MPD-RC Tissue Bank|Both|18 Years|N/A|No|Non-Probability Sample|Subjects enrolled in MPD-RC treatment protocols.|January 2016|January 29, 2016|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665067||156974|
NCT00660790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCW 02/07|Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders|Multifactorial Treatment of Cardiovascular Risk in Patients With Diabetes Mellitus Type-2: Identification of Treatment Non-Responders (The CARDIONOR Study)|CARDIONOR|Medical University of Graz|No|Completed|April 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|Samples Without DNA|plasma, serum|Both|45 Years|75 Years|No|Probability Sample|120 Type-2 diabetic patients with no history of vascular events and need for therapy        intensification.|October 2012|October 30, 2012|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00660790||157303|
NCT00660803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OBR-FAS-2007/1|Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer|Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer||AstraZeneca|No|Completed|May 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|hospitals and primary care clinics|January 2010|January 20, 2010|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00660803||157302|
NCT00661089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0335-006|Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity|"A Randomized Double-Blind Placebo-Controlled Trial of Botulinum Toxin Type A (BOTOX ) in the Treatment of Hemiplegic Shoulder Pain and Spasticity"||Rehabilitation Institute of Chicago|No|Completed|September 2003|February 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||October 2012|November 29, 2012|April 16, 2008|Yes|Yes||No|October 1, 2011|https://clinicaltrials.gov/show/NCT00661089||157280|Best and Worst pain collected, which may have limited the ability to detect overall pain. At the time of enrollment, subjects were on average very impaired by the Fugl-Meyer Scale measure, and pain on average had been present for several years.
NCT00663143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006692|Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation|Thiazolidinedione-Induced Bone Loss: Effects on Bone Marrow Stromal Cell Differentiation Capacity and Osteoblast Formation|TZDBONE|Emory University|Yes|Completed|July 2009|December 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|Bone Marrow|Both|18 Years|80 Years|No|Non-Probability Sample|Subjects with 1) traumatic mandibular (jaw) fracture who will undergo bone grafting or 2)        trauma patients who will undergo intra-medullary rod placement for traumatic limb        fractures will be considered as potential candidates in the study|March 2015|March 30, 2015|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663143||157122|
NCT00663715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-02-5808|Ultrasound Description of the Sciatic Nerve|Anatomical Description of the Sciatic Nerve Via a Lateral Mid-Thigh Approach Using Ultrasound||Children's Hospital of Philadelphia|No|Withdrawn|April 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|11 Years|17 Years|No|Non-Probability Sample|Pediatric patients|April 2010|March 11, 2015|April 18, 2008|No|Yes|No subjects were enrolled. Sciatic blocks infrequently used for pain control.|No||https://clinicaltrials.gov/show/NCT00663715||157078|
NCT00663949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3079|Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy|Phase 2 Trial of Effect of Combine Pentoxifylline and Captopril on Proteinuria in Diabetic Nephropathy||Shiraz University of Medical Sciences|No|Completed|February 2006|January 2008|Actual|December 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|30 Years|70 Years|No|||March 2008|April 21, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663949||157060|
NCT00664495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross 1999|Reduction of Abdominal Obesity and Insulin Resistance in Women|Reduction of Abdominal Obesity and Insulin Resistance in Women||Queen's University|No|Completed|April 1999|December 2003|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|4||||||Female|20 Years|50 Years|Accepts Healthy Volunteers|||April 2008|April 22, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664495||157018|
NCT00664508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-390|Mobility Assessment of Patients With Total Hip Arthroplasty|Mobility Assessment of Patients With Total Hip Arthroplasty: Joint Mechanics and Rehabilitation||Ottawa Hospital Research Institute|No|Active, not recruiting|November 2007|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2015|May 21, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664508||157017|
NCT00664521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28155|Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo Controlled, Multi-centre, Exploratory, Pilot, Phase II Trial of 150mg Atacicept Given Subcutaneously in Combination With Rituximab in Subjects With Rheumatoid Arthritis.|August III|Merck KGaA||Completed|March 2008|January 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||April 2012|April 4, 2012|April 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00664521||157016|
NCT00713128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00455|Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy|Prospective Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy||Steward St. Elizabeth's Medical Center of Boston, Inc.|No|Completed|April 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colorectal cancer receiving Irinotecan based therapy|February 2009|April 11, 2011|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713128||153328|
NCT00713141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR03/09/04|Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer|Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer||National University Hospital, Singapore||Completed|November 2004|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1||30|||Female|18 Years|N/A|No|Probability Sample|A pilot study involving 30 women who have been diagnosed with breast cancer and will        undergo standard adjuvant chemotherapy will be conducted first. This is to allow (1) the        establishment of the acceptability of the procedure to patients and (2) documentation of        the various effect sizes associated with (a) cognitive changes (b) changes in the level of        the various biochemical markers following chemotherapy (c) the relationship between extent        of cognitive decline and extent of DNA damage. It is estimated that up to approximately        100 patients can be recruited to participate in the main study.|August 2010|August 30, 2010|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00713141||153327|
NCT00713752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH002|Establishing Normal Values for Neuropsychological Testing in HIV-negative Thais|||South East Asia Research Collaboration with Hawaii|Yes|Completed|February 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|494|||Both|20 Years|69 Years|Accepts Healthy Volunteers|Probability Sample|HIV-negative Thais|September 2014|September 25, 2014|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00713752||153281|
NCT00714012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12002|Evaluation of Information Displays-A Paper, Computer and Simulator Based Study|Evaluation of Information Displays-A Paper, Computer and Simulator Based Study||University of Utah|Yes|Active, not recruiting|October 2004|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|projected end users of the domain specific visualizations. experts and novice users of the        domain specific information.|November 2011|November 14, 2011|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714012||153261|
NCT00714298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0503408|Diagnostic Value of Heart-Fatty Acid Binding Protein and Ischemia Modified Albumin as Biochemical Markers on Non ST Segment Elevation Acute Coronary Syndrome at the Emergency Room.|Analyse en médecine d'Urgence d'Une stratégie d'Utilisation combinée de Deux Marqueurs Biologiques Dans le Diagnostic de Syndrome Coronaire Aigu Non ST+: étude Des Performances de la Heart-Fatty Acid Binding Protein et de l' Ischemia Modified Albumin dès la première Heure de Prise en Charge||University Hospital, Toulouse|No|Completed|May 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|700|||Both|18 Years|N/A|No|||July 2008|July 11, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00714298||153239|
NCT00663871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|567|Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior|BioBehavioral Studies of Cardiovascular Disease||University of Pittsburgh|No|Completed|June 2008|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|275|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663871||157066|
NCT00663884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-KAD-402|Glufast On Insulin Glargine Trial in Type 2 DM|A Prospective, Randomized and Multi-center Clinical Study to Evaluate Efficacy and Safety of Combination Therapy of Mitiglinide or Voglibose With Long-acting Insulin in Type 2 Diabetic Patients|GLORIA|JW Pharmaceutical|Yes|Completed|February 2008|September 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|30 Years|70 Years|No|||March 2012|March 28, 2012|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663884||157065|
NCT00664118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCHCH-0121-236|Doula Combined Latent Phrase Epidural Analgesia in Primiparous Women|In Combination of Doula and Epidural Analgesia in the Latent Phrase of Labor in Primiparous Women|DCLEAP|Nanjing Medical University|Yes|Completed|April 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Female|18 Years|45 Years|No|||May 2009|May 26, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664118||157047|
NCT00664417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUF04|Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine|Safety and Immunogenicity of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine in Healthy Adults||Sanofi|Yes|Completed|April 2008|August 2010|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|9||Actual|375|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664417||157024|
NCT00664430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W10-131|Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects|Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects||Abbott|No|Terminated|January 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|April 21, 2008||No|Low enrollment rate|No|June 3, 2010|https://clinicaltrials.gov/show/NCT00664430||157023|Early termination leading to no efficacy evaluation. All adverse events occurred during calcitriol challenge phase.
NCT00664742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BTR03|The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome|The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome||Novartis|No|Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|614|||Both|20 Years|90 Years|No|||April 2011|April 19, 2011|April 21, 2008||No||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00664742||156999|
NCT00664755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA016511|Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity|Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity||Medical University of South Carolina|Yes|Recruiting|July 2007|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|214|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|August 4, 2011|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664755||156998|
NCT00661791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB120206|Effects of Massage Therapy and Kinesthetic Stimulation on Pre-Term Infants|Effects of Massage Therapy and Kinesthetic Stimulation on Pre-Term Infants||George Washington University|No|Completed|February 2003|October 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|28 Weeks|32 Weeks|No|||April 2008|April 17, 2008|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661791||157226|
NCT00662350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT-DK-TMW08|Temperature Mapping of the Prostate With the Wallterm™ System|Temperature Mapping of the Prostate With the Wallterm™ System|WT-DK-TMW08|Pnn Medical A/S|No|Completed|June 2008|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|||Male|50 Years|N/A|No|Non-Probability Sample|Men with BPH|February 2010|February 3, 2010|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00662350||157183|
NCT00662038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPF-012|Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|PIPF-012|InterMune|No|Active, not recruiting|August 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3000|||Both|40 Years|84 Years|No|||January 2012|January 30, 2012|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662038||157207|
NCT00662337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2341003|Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride|A Randomized, Two-Way Crossover Evaluation of the Bioequivalence Between Two Oral Formulations of Diphenhydramine: ULTRATAB Tablet Versus KAPSEALS Capsule||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 7, 2011|March 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00662337||157184|
NCT00663429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-AT202-07|Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma|A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma||Callisto Pharmaceuticals|No|Completed|November 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2009|August 30, 2011|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663429||157100|
NCT00663442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24-MHO1823|Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)|Dose Response Pharmacogenetic Study of ADHD||University of Illinois at Chicago|No|Completed|December 1999|November 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|48|||Both|6 Years|17 Years|No|||April 2008|April 21, 2008|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663442||157099|
NCT00663728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11575|Assessment of Duration of Erection With Vardenafil 10 mg|A Randomized, Double-blind, Crossover Study to Evaluate the Duration of Erection Following Vardenafil (10mg) Administration for Four Weeks in a Fixed Dose Regimen Compared to Placebo in Males With ED||Bayer||Completed|September 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|201|||Male|18 Years|64 Years|No|||December 2014|December 26, 2014|April 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00663728||157077|
NCT00663741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12931|Sorafenib Gastric Cancer Asian Phase I Study|Phase I Study to Investigate Safety, Pharmacokinetics and Preliminary Efficacy Profile of Sorafenib (BAY 43-9006) in Combination With S-1 Plus CDDP in Asian Patients With Unresectable / Recurrent Gastric Cancer||Bayer|Yes|Completed|May 2008|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|74 Years|No|||June 2013|June 9, 2013|April 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00663741||157076|
NCT00664560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-307|Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis|Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee||POZEN|No|Completed|April 2008|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|614|||Both|50 Years|N/A|No|||January 2012|January 20, 2012|April 18, 2008|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00664560||157013|
NCT00663962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-139-08|Pregabalin and Post-thoracotomy Pain|A Prospective, Randomized, Double Blinded, Placebo Controlled Pilot Study Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome||Queen's University|Yes|Completed|April 2008|May 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|April 18, 2008||No||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00663962||157059|
NCT00663975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI 07-001|Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients|An Open-Label, Multi-Center Safety and Efficacy Study of DCI-1020 in Pediatric Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency||Digestive Care, Inc.|Yes|Withdrawn|February 2009|November 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|2 Years|No|||May 2010|May 12, 2010|April 17, 2008|No|Yes|Study not being conducted|No||https://clinicaltrials.gov/show/NCT00663975||157058|
NCT00664898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACF4375g|A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma|An Open-Label, Phase Ib, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Bortezomib (Velcade®, PS-341) in Patients With Relapsed or Refractory Multiple Myeloma||Genentech, Inc.||Completed|May 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2011|November 11, 2011|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664898||156987|
NCT00664222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#344.1|Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)|Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure||Tottori University Hospital||Completed|January 2004|December 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|16|||Both|N/A|N/A||||April 2008|April 21, 2008|April 18, 2008||||No||https://clinicaltrials.gov/show/NCT00664222||157039|
NCT00664534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11806|Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast|Comparison of Premixed Insulin Lispro Low-Mixture and Mid-Mixture Regimens With Separate Basal and Bolus Insulin Injections in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Oral Therapy Who Consume Light Breakfast||Eli Lilly and Company|No|Completed|April 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|344|||Both|30 Years|74 Years|No|||November 2011|November 9, 2011|April 21, 2008|Yes|Yes||No|November 9, 2011|https://clinicaltrials.gov/show/NCT00664534||157015|
NCT00713466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00006980|The Use of Computer-Assisted Learning Pediatrics Program (CLIPP) in the Pediatric Clerkship|The Use of Computer-Assisted Learning Pediatrics Program (CLIPP) in the Pediatric Clerkship|CLIPP|Medical College of Wisconsin|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|198|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All third year medical students entering their pediatric clerkship at the Medical College        of Wisconsin|July 2008|July 30, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713466||153303|
NCT00714025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 08-002|A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy|A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma After Failure of Platinum-based Chemotherapy||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|November 2008|January 2012|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2012|January 23, 2012|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714025||153260|
NCT00714038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RDK-DUM-2008/1|CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.|CARE - Quality Development in Asthma in General Practice||AstraZeneca|No|Completed|May 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2122|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|March 2011|March 8, 2011|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714038||153259|
NCT00714311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106/04|Efficacy of Transference-Focused Psychotherapy for Borderline Personality Disorder|A Randomized-Controlled Trial of Transference-Focused Psychotherapy vs. Treatment by Experienced Community Psychotherapists for Borderline Personality Disorder||University Hospital Muenster|No|Completed|October 2004|February 2015|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|45 Years|No|||February 2015|February 4, 2015|July 9, 2008||No||No|February 4, 2015|https://clinicaltrials.gov/show/NCT00714311||153238|
NCT00714324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELIA003|Simplified Nutritional Screening for Patient Use|Validation of Nutritional Screening for Patient Use||University of Southampton|No|Recruiting|July 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Observational|N/A||2|Anticipated|2200|||Both|18 Years|N/A|No|Probability Sample|Patients attending general outpatient clinics|January 2009|January 2, 2009|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00714324||153237|
NCT00715351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1896|Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes|Efficacy and Safety of Glycaemic Control of Levemir® or Insulatard® in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|May 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|342|||Both|6 Years|N/A|No|Non-Probability Sample|Insulin naïve patients with type 2 diabetes treated with oral antidiabetics|June 2012|June 26, 2012|July 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715351||153158|
NCT00715364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTx™-265-CP-201-IS (US)|REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|REGENESIS|Stem Cell Therapeutics Corp.|Yes|Withdrawn|August 2009|September 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||September 2011|September 2, 2011|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715364||153157|
NCT00715611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-053|Pleurectomy/Decortication Followed By Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma|Phase II Toxicity Study of Pleurectomy/Decortication Followed By Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma||Memorial Sloan Kettering Cancer Center||Recruiting|July 2008|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715611||153138|
NCT00663897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMCP-97-007|Lansoprazole Versus Mosapride for Functional Dyspepsia|A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome||Lotung Poh-Ai Hospital|Yes|Completed|May 2008|September 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|329|||Both|20 Years|90 Years|No|||October 2009|October 8, 2009|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663897||157064|
NCT00664131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLNOQ|Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors|Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors||St. Jude Children's Research Hospital|No|Completed|August 2005|October 2008|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|165|||Both|6 Years|28 Years|No|Non-Probability Sample|Survivors of ALL who are currently 6-28 years of age, 5 years from ALL diagnosis, and 1        year off therapy who were treated on institutional protocols at St. Jude Children's        Research Hospital. Survivors will be recruited in the Leukemia and ACT clinics at St. Jude        Children's Research Hospital. We anticipate that 494 survivors are available. We plan to        enroll every survivor who is eligible and visits Leukemia or/ and ACT clinic at St. Jude        Children's Research Hospital|September 2011|September 22, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664131||157046|
NCT00664781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593558|Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer|A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer||Cancer Research UK||Completed|December 2007|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|78|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00664781||156996|
NCT00665119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-TIP-01|Effects of Remifentanil on Respiratory Function in Mechanically Ventilated Patients|Effects of Remifentanil on Breathing Pattern, Respiratory Effort and Gas Exchange in Mechanically Ventilated Patients.||Fondazione Poliambulanza Istituto Ospedaliero|No|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2008|December 17, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00665119||156971|
NCT00660816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2507|Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|January 2008|July 2015|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|April 16, 2008|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00660816||157301|
NCT00660829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP440|A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Subjects With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|December 2007|April 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|536|||Both|12 Years|N/A|No|||April 2015|April 9, 2015|April 14, 2008|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00660829||157300|
NCT00661102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21419|A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).|A Randomized, Open Label Study Comparing the Efficacy of Topical Corticosteroids or Bepantol in the Prophylaxis of Hand-foot Syndrome in Patients Receiving Oral Xeloda for Treatment of Metastatic Breast Cancer or Colorectal Cancer.||Hoffmann-La Roche||Completed|December 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|598|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661102||157279|
NCT00661115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10695|To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.|A Randomised, Double Blind, Placebo Controlled, Multi-center, Fixed Dose, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil (BAY 38-9456) in Men With Erectile Dysfunction .||Bayer|Yes|Completed|May 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|173|||Male|21 Years|N/A|No|||December 2014|December 15, 2014|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661115||157278|
NCT00662363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00001168|Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation|Lubiprostone (Amitiza®) Compared to Standard Care in the Treatment of Postoperative Opioid-induced Constipation in Inpatient Rehabilitation Patients Following Orthopedic Procedures||Rehabilitation Institute of Chicago|No|Completed|April 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|April 16, 2008|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00662363||157182|Additional laxatives were frequently required for symptom control
NCT00662636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0616|Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery|Phase I Trial of the Combination of Dasatinib and Lapatinib||Mayo Clinic|No|Active, not recruiting|August 2008|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00662636||157161|
NCT00662649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2301E1|Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis||Novartis||Completed|February 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|920|||Both|20 Years|58 Years|No|||June 2012|June 9, 2012|April 17, 2008||No||No|June 9, 2012|https://clinicaltrials.gov/show/NCT00662649||157160|
NCT00662896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT 3012-X-112|To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension|A 16-week, Phase 1, Multicenter, Double-Blind, Randomized, Naproxen and Ibuprofen-controlled, Parallel-Group Pharmacological Study, to Assess the Effect of Naproxcinod (375mg and750mg, Bid) Compared to Doses of Naproxen (250mg and 500mg, Bid) and to Ibuprofen (600mg, Tid) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension.|HCT3012-X-112|NicOx|Yes|Completed|March 2008|December 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|300|||Both|40 Years|N/A|No|||June 2011|June 16, 2011|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662896||157141|
NCT00662909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-047|Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder|ARIES|Astellas Pharma Inc|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2149|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|April 17, 2008|Yes|Yes||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00662909||157140|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00663182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Entecavir-01|Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis|Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial||Shanghai Changzheng Hospital|Yes|Enrolling by invitation|January 2008|December 2012|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|N/A|No|||April 2008|April 22, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663182||157119|
NCT00663767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-222|A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction|||Array BioPharma||Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|250|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 29, 2011|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663767||157074|
NCT00664573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104RA204|104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants|Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.|RESPOND-EXT|Biogen|Yes|Terminated|November 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|339|||Both|18 Years|75 Years|No|||December 2015|December 17, 2015|April 21, 2008|Yes|Yes|Analysis of data from 104RA202 failed to meet primary endpoint|No||https://clinicaltrials.gov/show/NCT00664573||157012|
NCT00664586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-1421 #104|A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors|A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors.||Erimos Pharmaceuticals|No|Terminated|May 2007|June 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|April 21, 2008|No|Yes|Funding constraints|No||https://clinicaltrials.gov/show/NCT00664586||157011|
NCT00664911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593133|Combination Chemotherapy in Treating Older Patients With Solid Tumour,|Study of a Scale Predicting the Feasibility of Chemotherapy in Patients Aged 75 Years or Older With Solid Tumour|OLD|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Completed|March 2008|October 2013|Actual|April 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|516|||Both|75 Years|N/A|No|||October 2013|October 15, 2013|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00664911||156986|
NCT00665197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3.30.27|Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia|Improving Outcomes in Radiotherapy Using New Strategies of Treatment Delivery With Focus on Oesophageal Cancer.||International Atomic Energy Agency|No|Completed|February 2007|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|81 Years|No|||October 2011|October 12, 2011|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665197||156965|
NCT00665210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-511|Digital Sizing for Orthopaedic Hip Implants|Photo-manipulation of Digital Radiographs and Digitized Templates as a Method for Preoperative Sizing of Total Hip Arthroplasties||Ottawa Hospital Research Institute|No|Recruiting|October 2007|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients booked for primary total hip arthroplasty with non-cemented prosthesis|October 2011|October 24, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665210||156964|
NCT00713765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00005|Pharmacokinetic Interaction Between AZD3480 and Donepezil|A Double-blind, Randomised, Cross-over, Placebo-controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6||AstraZeneca|No|Terminated|December 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|1||Actual|33|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|July 9, 2008||No|Ended prematurely - The trial never commenced.|No||https://clinicaltrials.gov/show/NCT00713765||153280|
NCT00714857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dex-Pop-PK|Population Pharmacokinetics of Dexmedetomidine in ICU Patients|Population Pharmacokinetics of Dexmedetomidine in ICU Patients|Dex-Pop-PK|University of Turku|No|Completed|October 2007|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00714857||153196|
NCT00714870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00446|Pediatric Quality of Life Among Population With Body Mass Index (BMI) Greater Than or Equal to 85%|Pediatric Quality of Life Among Population With BMI Greater Than or Equal to 85%: Impact of a Behavioral Intervention Program||Steward St. Elizabeth's Medical Center of Boston, Inc.|Yes|Completed|February 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|10 Years|20 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|July 9, 2008||No||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00714870||153195|
NCT00715650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6432-R|Benefits Counseling to Preserve Function Among Disability Applicants|Benefits Counseling to Preserve Function Among Disability Applicants||VA Office of Research and Development|No|Completed|December 2008|December 2015|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|92|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|July 11, 2008||No||No|October 6, 2014|https://clinicaltrials.gov/show/NCT00715650||153135|
NCT00664443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007233-01H|Effectiveness of Dispatch-Assisted Cardiopulmonary Resuscitation (CPR) Instructions|Effectiveness of Dispatch-Assisted Cardiopulmonary Resuscitation (CPR) Instructions: An Evaluation of 9-1-1 Calls.||Ottawa Hospital Research Institute|No|Completed|July 2007|December 2010|Actual|June 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8357|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with out-of-hospital cardiac arrest|January 2012|October 21, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664443||157022|
NCT00664768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT0131|A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy|A Prospective, Randomized, Double-Blind Controlled Study to Evaluate the Nutritional Safety (Growth) of an Amino Acid Based Formula With Prebiotics and Probiotics in Infants Diagnosed With Cow Milk Allergy, With or Without Other Food Allergies.|CMA|Nutricia North America|No|Completed|March 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|N/A|8 Months|No|||October 2012|March 5, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664768||156997|
NCT00665093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1894|Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia||Novo Nordisk A/S|No|Completed|May 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1569|||Both|N/A|N/A|No|Non-Probability Sample|Type 1 and Type 2 diabetes mellitus|March 2016|March 3, 2016|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665093||156973|
NCT00665106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVG07D108|Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy|A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of NOVA63035 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy||Novagali Pharma||Completed|April 2008|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|20|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|April 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665106||156972|
NCT00661804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|568|Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study|A Longitudinal Cohort Study of Patients With Thalassemia in the Thalassemia Clinical Research Network||New England Research Institutes|Yes|Completed|May 2007|June 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|416|Samples With DNA|DNA and frozen plasma genetic biorepository|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients with thalassemia, as documented by clinical diagnosis, seen at sites funded        by the Thalassemia Clinical Research Network (TCRN) and their satellites.|June 2011|November 9, 2011|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661804||157225|
NCT00662051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0589-F6A|Oral Contraceptives and Asthma Control|Oral Contraceptives and Asthma Control||University of Kentucky|No|Withdrawn|April 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Female|18 Years|45 Years|No|Non-Probability Sample|Subjects will be recruited from University of Kentucky clincis and the surrounding        community.|August 2013|August 7, 2013|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00662051||157206|
NCT00662064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00/0039|Pharmacology and Physiology of the Lower Urinary Tract|Pharmacology and Physiology of the Lower Urinary Tract||University College London Hospitals|No|Recruiting|February 2002|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|bladder biopsies from patients with lower urinary tract dysfunction and from healthy      controls|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with lower urinary tract dysfunction and controls with normal lower urinary tract        function|June 2008|June 19, 2008|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00662064||157205|
NCT00662662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0485|Sexual Behavior in Head and Neck Cancer Patients|Sexual Behavior in Head and Neck Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2008|||April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Approximately 600 oropharynx study participants and 900 non-oropharynx study participants.|February 2016|February 18, 2016|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662662||157159|
NCT00662922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-AnIt-07|Consequences of Hypoglycemia on Intensive Care Unit (ICU) Patients|Does Hypoglycemia Under Intensive Insulin Therapy During Critical Illness Lead to Neurocognitive Dysfunction||University Hospital Muenster|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|74|||Both|18 Years|80 Years|No|Probability Sample|All patients who were admitted to the hospital ICU after 2003 are screened for        hypoglycemia|January 2010|January 8, 2010|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00662922||157139|
NCT00663156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4359-617|A Prospective Study of Autologous Fat Grafting for Breast Augmentation|||Georgetown University||Completed|March 2008|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|13|||Female|20 Years|50 Years|No|||February 2013|February 14, 2013|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00663156||157121|
NCT00663169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885A2212|Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout|A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of a Single Dose of ACZ885 in Hospitalized Patients With Acute Gout||Novartis|No|Completed|April 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|80 Years|No|||December 2012|December 4, 2012|April 18, 2008|Yes|Yes||No|August 30, 2012|https://clinicaltrials.gov/show/NCT00663169||157120|
NCT00663455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Recaltox-1|Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant Recipients|A Multicenter, Randomized, Parallel-group, Trial to Reduce Toxicity of Calcineurininhibitor-therapy in Steroid-free Longterm Immunosuppression in Pediatric and Adolescent Kidney Transplant Recipients|Recaltox|University of Erlangen-Nürnberg Medical School|Yes|Terminated|December 2008|June 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|3 Years|16 Years|No|||June 2015|June 3, 2015|April 21, 2008||No|Recruitment goals were not achieved. Extension of the trial concept had to be abjected due to    methodological reasons.|No||https://clinicaltrials.gov/show/NCT00663455||157098|
NCT00663754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH070699|Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II)|Eating Disorder Prevention Program Effectiveness Trial||Oregon Research Institute|Yes|Completed|March 2005|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|306|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663754||157075|
NCT00664235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003228|The Analysis of Skin Temperature by Long Wave Infrared Imaging to Determine Its Effectiveness as a Predictor of Tissue Injury|Study of Thermal Imaging as an Objective RISK Indicator; The Evaluation of Skin Blood Flow and Temperature by Long Wave Infra-Red Imaging to Determine Effectiveness as a Predictor of Pressure Ulcer or Non-Visible Deep Tissue Damage||Trillennium Medical Imaging, Inc.|No|Recruiting|February 2008|June 2008|Anticipated|April 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from Duke North inpatient unit 8100 or 8300. All patients        admitted to the above floor will be evaluated for willingness to participate.|April 2008|April 21, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664235||157038|
NCT00664599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/12487|Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease|Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)||Tehran University of Medical Sciences|Yes|Completed|April 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|N/A|No|||April 2008|April 27, 2008|April 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00664599||157010|
NCT00664924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRY-C-01-06-RPM|Comparative in Patient, Non-intervention Study of the Remote Physiological Monitoring System (RPM�) vs Standard Physiological Monitoring Devices|Comparative In-patient, Non-intervention Study of the Remote Physiological Monitoring System (RPM�), a Non-invasive, Remote, Ambulatory Vital Signs Monitoring Device, Versus Standard Physiological Monitoring Devices by Simultaneous Monitoring of Heart Rate, ECG, SpO2, Blood Pressure, Body Temperature, and Respiration Rate in a 24 hr Monitoring Period (BRYTECH #BRY-C-01-06-RPM)||Ottawa Hospital Research Institute|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort 1 (Exercise): patients who are scheduled to undergo a minimum of 20 minutes of        exercise testing.        Cohort 2 (ICU): patients admitted to the Intensive Care Unit (ICU) Cohort 3 (Post-op):        patients in Post-Operative care Cohort 4 (ER): patients admitted to the Emergency Room        (e.g., high risk medical admissions) These cohorts are considered representative of a        broad spectrum of the general patient population. Patients participating in the study will        be assigned to one of these 4 cohorts, with a minimum of 10 patients assigned to Cohort 1        (Exercise) and a minimum of 5 patients in each of the other cohorts.|August 2010|August 25, 2010|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664924||156985|
NCT00664937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-359|Exercise Induced Bronchoconstriction (0476-359)|A 3 Period, Double-Blind, Randomized Crossover Study to Evaluate the Effects of a Single Dose of Montelukast Compared With Placebo on Exercise-Induced Bronchoconstriction as Assessed by Hyperpolarized Gas Magnetic Resonance Imaging.||Merck Sharp & Dohme Corp.||Completed|May 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|24|||Both|18 Years|55 Years|No|||June 2015|June 24, 2015|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664937||156984|
NCT00665223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACR16 C008|A Study of Treatment With ACR16 in Patients With Huntington's Disease|A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease|MermaiHD|Teva Pharmaceutical Industries|Yes|Completed|April 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|437|||Both|30 Years|N/A|No|||March 2013|March 28, 2013|April 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00665223||156963|
NCT00665236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002750-01A2|Craniosacral Therapy in Migraine: A Feasibility Study|Craniosacral Therapy in Migraine: A Feasibility Study||University of North Carolina, Chapel Hill|Yes|Completed|September 2006|September 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|12 Years|80 Years|No|||November 2012|November 30, 2012|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665236||156962|
NCT00661310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uppsala80|Optimizing Drug-Therapy in Patients 80 Years and Older|Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial||Uppsala University Hospital|No|Completed|September 2005|June 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|400|||Both|80 Years|N/A|No|||October 2008|December 4, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00661310||157263|
NCT00714623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-048|The SCRIPPS DES REAL WORLD Registry|A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic||Scripps Health|Yes|Completed|March 2005|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|859|||Both|18 Years|N/A|No|Probability Sample|Patients 18 years of age or older undergoing PCI and requiring the placement of at least        one drug-eluting stent will be included to this study. For this registry, consecutive        patients, that will have coronary percutaneous intervention with the CypherTM at the Green        Hospital of Scripps Clinic, will be enrolled. It is estimated that up to 1000 patients        will be included in the registry enrolled over a four year period. It is expected that        enrollment will conclude in March 2009.|December 2012|December 20, 2012|July 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00714623||153214|
NCT00702754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401CDNA|An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia|An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia||Solstice Neurosciences|No|Completed|June 2001|September 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|502|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|June 12, 2008||||No|May 12, 2009|https://clinicaltrials.gov/show/NCT00702754||154112|
NCT00702767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-060|Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants|Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants During the First Week of Life||OSF Healthcare System|No|Completed|July 2005|April 2007|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|110|||Both|N/A|1 Day|No|||June 2008|June 23, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702767||154111|
NCT00715091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENRADAS-01|Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis|Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial|ENRADAS|Charite University, Berlin, Germany|Yes|Completed|September 2008|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|65 Years|No|||August 2014|August 22, 2014|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00715091||153178|
NCT00715104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-1|Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer|An Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge®) as Neoadjuvant Treatment in Men With Localized Prostate Cancer|NeoACT|Dendreon|Yes|Completed|July 2008|December 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Male|18 Years|N/A|No|||April 2015|April 14, 2015|July 11, 2008|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT00715104||153177|
NCT00703300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00263|Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia|Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia||National Cancer Institute (NCI)||Completed|June 2008|October 2014|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||September 2014|November 6, 2014|June 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703300||154070|
NCT00703313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPH0108|Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators|||Santen Inc.|No|Completed|May 2008|||June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 4, 2009|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703313||154069|
NCT00661479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-028D|An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa|||Allergan|Yes|Completed|July 2008|May 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|21|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|October 29, 2007|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00661479||157250|
NCT00661492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-118|Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)|A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy||US Oncology Research|No|Active, not recruiting|May 2008|May 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Male|18 Years|N/A|No|||April 2010|April 6, 2010|April 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661492||157249|
NCT00662077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIH-IBAN|Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort|Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort||Germans Trias i Pujol Hospital|No|Suspended||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||July 2008|July 31, 2008|April 17, 2008||No|Financial difficulties|No||https://clinicaltrials.gov/show/NCT00662077||157204|
NCT00662376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-POB-01-UK|Study on Safety, Tolerance and Metabolic Effects of a Nutritional Supplement, Given as a Drink Before Gallbladder Surgery|Safety, Tolerance and Metabolic Effects of Using a Preoperative Oral Nutritional Supplement (PreOP Booster) in Gastrointestinal Surgery||Fresenius Kabi||Completed|April 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|80 Years|No|||November 2008|December 5, 2008|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662376||157181|
NCT00662389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEIRB08-090|Application of the Apsara Thermal Wand System|TP-1013 Pilot 1: Application of the Apsara Thermal Wand System||Apsara Medical Corporation||Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 22, 2009|April 17, 2008||No||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00662389||157180|
NCT00662402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-Trial|Impact of Extensive Consultation on Career Development Grant Outcomes|Impact of Extensive Consultation on Career Development Grant Outcomes||University of California, San Francisco|No|Active, not recruiting|April 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|132|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662402||157179|
NCT00662675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014719|A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency|A Randomized Double-blind (Withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrelipase MT Capsules Compared With Placebo in the Treatment of Subjects With Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|7 Years|60 Years|No|||April 2014|April 24, 2014|April 17, 2008|Yes|Yes||No|February 5, 2010|https://clinicaltrials.gov/show/NCT00662675||157158|
NCT00662935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04 -APN -03|Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)|Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)||Centre Hospitalier Universitaire de Nice|No|Completed|May 2005|March 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||April 2008|April 17, 2008|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662935||157138|
NCT00663988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-GuoSZ0709|Human Partial Facial Allotransplantation|Human Partial Facial Allotransplantation||Xijing Hospital|Yes|Completed|April 2006|||April 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|40 Years|No|||February 2006|April 20, 2008|April 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00663988||157057|
NCT00664001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anti-oxidant|Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness|Randomized Double-Blind Placebo-Controlled Trial of Oral Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness.||Altitude Physiology Expeditions|No|Completed|March 2003|December 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|83|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2008|April 21, 2008|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00664001||157056|
NCT00664261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584270|Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking|Addressing Parental Smoking by Changing Pediatric Office Systems||National Cancer Institute (NCI)||Completed|September 2007|July 2013|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|3000|||Both|N/A|N/A|No|||June 2011|December 17, 2013|April 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00664261||157036|
NCT00664950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-002|InterTAN IM Nail Versus Sliding Hip Screw in Geriatric Fractures|A Multi-centre Randomized Control Trail Comparing a Novel Intramedullary Device (InterTAN) Versus Conventional Treatment (Sliding Hip Screw) of Geriatric Fractures.||Lawson Health Research Institute|Yes|Completed|November 2007|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|55 Years|N/A|No|||September 2015|September 1, 2015|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664950||156983|
NCT00665249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AA017135-01|Project Motion, A Study of Motivational Interviewing to Reduce Heavy or Problematic Drinking|Component Analysis of Motivational Interviewing||Northwell Health|Yes|Completed|April 2008|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|89|||Both|18 Years|65 Years|No|||April 2015|April 27, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665249||156961|
NCT00665262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-159|The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in the Elderly|The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in Elderly Patients Having Joint Replacement Surgery: a Prospective Feasibility Study||Lawson Health Research Institute|No|Completed|March 2006|December 2008||September 2007|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|70 Years|N/A|No|||April 2008|April 18, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00665262||156960|
NCT00661297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100536|Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil|A Randomised, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy, Safety, and Reliability of 10mg Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction||Bayer||Completed|June 2003|January 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|523|||Male|18 Years|N/A|No|||December 2014|December 1, 2014|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661297||157264|
NCT00661609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2782C00010|A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer|A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer||AstraZeneca||Completed|May 2008|December 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||December 2010|December 13, 2010|April 16, 2008|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00661609||157240|
NCT00714636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-16262|Cerebrospinal Fluid Repository|Cerebrospinal Fluid Repository|CSF|Drexel University|No|Completed|October 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples With DNA|Cerebrospinal Fluid from Lumbar Puncture.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Those undergoing a lumbar puncture for reasons unrelated to this study.|June 2010|June 15, 2010|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714636||153213|
NCT00703053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0019|H5N1 Priming and Boosting Strategies|A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2008|November 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|9||Actual|505|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2009|August 15, 2013|June 19, 2008|Yes|Yes||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00703053||154089|
NCT00715377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/2007|Anticholinergic Burden in Schizophrenia|Anticholinergic Burden in Schizophrenia||Centre for Addiction and Mental Health|No|Terminated|June 2007|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|50 Years|N/A|No|||August 2015|August 21, 2015|July 11, 2008||No|Insufficient subject accrual|No||https://clinicaltrials.gov/show/NCT00715377||153156|
NCT00715637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|509912|Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study|Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study||Antisoma Research|Yes|Active, not recruiting|June 2007|||June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||October 2010|October 12, 2010|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715637||153136|
NCT00703560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102005-009|Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients|Molecular Basis of Interferon Response in HCV|VK|University of Texas Southwestern Medical Center|No|Completed|September 2005|January 2013|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|72|Samples With DNA|serum, peripheral blood mononuclear cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients with HCV genotype 1 with or without HIV-infection of any race.|January 2013|January 18, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703560||154050|
NCT00703573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0721D1424|A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of S-777469 (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis||Shionogi Inc.|No|Completed|May 2008|December 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|209|||Both|18 Years|65 Years|No|||July 2011|September 13, 2011|June 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00703573||154049|
NCT00703586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMA-0612|Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc|A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02)||Rockefeller University|No|Completed|September 2007|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00703586||154048|
NCT00661180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10941|Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec|Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib)|ORACLE|Bayer||Completed|January 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|April 15, 2008|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00661180||157273|
NCT00661505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21096|A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia|A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Haemodialysis Patients With Chronic Renal Anaemia.||Hoffmann-La Roche||Completed|May 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661505||157248|
NCT00661453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25409|CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I|Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)||University of Utah|Yes|Completed|April 2008|June 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|12 Months|No|||June 2015|June 1, 2015|April 14, 2008|No|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT00661453||157252|
NCT00661466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-004|Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery|A Phase II, Randomized, Single-dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx Bupivacaine Implant in Patients After Gastrointestinal Surgery||Innocoll|No|Terminated|April 2008|February 2010|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|75 Years|No|||February 2011|September 12, 2012|April 15, 2008|Yes|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT00661466||157251|
NCT00661817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|448|Evaluating a Blood Pressure Reduction and Weight Loss Program in a Low Income, Ethnically Diverse Population (The Be Fit, Be Well [BFBW] Study)|Integrated Weight Loss Technologies for Weight and Blood Pressure Control in Urban Clinics|BFBW|Washington University School of Medicine|Yes|Completed|November 2006|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|365|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 3, 2012|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661817||157224|
NCT00661843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZMCSL0001|A Study of Yoga for Treating Geriatric Insomnia|A Mixed Design, With Wait List Control Crossover to Intervention, Clinical Trial of Integrated Yoga Style Practice Intervention for Improving Sleep and Quality of Life in the Elderly Population||Shaare Zedek Medical Center|Yes|Completed|May 2008|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|74|||Both|60 Years|N/A|No|||August 2010|October 4, 2010|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661843||157222|
NCT00662090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWOG MDS 2006|Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood|Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood|EWOG MDS 2006|University Hospital Freiburg|No|Recruiting|January 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|260|Samples With DNA|At diagnosis, prior to HSCT and at relapse material form peripheral blood and bone marrow      will be retrieved and stored for research purposes. If there are other diagnostic bone      marrow examinations at other time points (prior to HSCT), the material will be handled the      same way.      The following material will be retrieved:        -  8 smears from PB        -  8 smears from BM        -  at least 5 ml of heparinized PB        -  at least 5 ml of heparinized BM|Both|N/A|215 Months|No|Non-Probability Sample|MDS and JMML diagnosted|December 2015|December 2, 2015|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662090||157203|
NCT00662688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593019|Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer|Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas|PAM07|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Terminated|October 2007|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|80 Years|No|||March 2013|March 12, 2013|April 18, 2008||No|recruitment prematurely stopped due to a lack of eligible patients.|No||https://clinicaltrials.gov/show/NCT00662688||157157|
NCT00662948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAR2007|ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)|Open Study in Phase II to Evaluate Efficacy of Initial R-CHOP Combination in Folicular Lymphoma no Treated Previously. Consolidation w Ith One Dose of 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)||PETHEMA Foundation|Yes|Suspended|December 2008|October 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||April 2015|January 16, 2016|April 8, 2008||No|No inclusion|No||https://clinicaltrials.gov/show/NCT00662948||157137|
NCT00662961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Patrocinio|Forehead Lift Fixation|Periosteum Versus Bone for the Fixation of Forehead Lift: A Prospective, Randomized, Controlled, Split-Face Trial.|Forehead|Federal University of Uberlandia|No|Completed|January 2007|August 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||April 2008|April 17, 2008|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00662961||157136|
NCT00663195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#344|Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure|Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure||Tottori University Hospital||Completed|January 2004|December 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|16|||Both|N/A|N/A||||April 2008|April 18, 2008|April 18, 2008||||No||https://clinicaltrials.gov/show/NCT00663195||157118|
NCT00663208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-004|A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects|Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of Daclatasvir in Subjects Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|167|||Both|18 Years|60 Years|No|||September 2015|September 16, 2015|April 18, 2008|Yes|Yes||No|August 14, 2015|https://clinicaltrials.gov/show/NCT00663208||157117|
NCT00664014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-07-802-01|A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia|Randomized, Double-blind, Multicenter, Placebo-controlled (Standard Therapy + Placebo), Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia||Otsuka Beijing Research Institute|No|Completed|May 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||March 2010|March 5, 2010|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00664014||157055|
NCT00664248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-06-22-2006-012|A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris|||Dow Pharmaceutical Sciences||Completed|October 2006|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1414|||Both|12 Years|70 Years|No|||April 2008|April 18, 2008|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664248||157037|
NCT00664612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-337|Comparison of AirTraq Laryngoscope to Macintosh Laryngoscope for Intubation of Patients With Potential Cervical Spine Injury|Comparison of AirTraq Laryngoscope to Macintosh Laryngoscope for Intubation of Patients With Potential Cervical Spine Injury||Lawson Health Research Institute|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664612||157009|
NCT00665275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG-8462|Complementary and Alternative Medicine Among Outpatients With Inflammatory Rheumatic Diseases in Western Sweden|The Use of Complementary and Alternative Medicine Among Outpatients With Inflammatory Rheumatic Diseases in Western Sweden.||Göteborg University|No|Completed|March 2007|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|200|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Probability Sample|Lists of outpatients who were scheduled for appointments at the rheumatology clinic were        sent to an external randomizer, to randomly elect patients who were asked to participate.        Patients were eligible for inclusion if they were attending the rheumatology clinic and        had had an appointment there before. Patients were excluded if they were on their first        visit to the practice, had dementia or had difficulties understanding Swedish.|April 2008|April 18, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00665275||156959|
NCT00665288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007751-01H|Survey of Attitudes and Factors Associated With CPR in an Older Population|A Survey of Attitudes and Factors Associated With Successful Cardiopulmonary Resuscitation (CPR) Knowledge Transfer in an Older Population Most Likely to Witness Cardiac Arrest||Ottawa Hospital Research Institute|No|Completed|January 2008|August 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|413|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Independent-living individuals aged 55 years or older|March 2012|March 26, 2012|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665288||156958|
NCT00661635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-0513-145|A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain|A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Laparoscopic Cholecystectomy Surgery||Pfizer|No|Completed|November 2002|July 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|490|||Both|18 Years|75 Years|No|||March 2008|April 21, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00661635||157238|
NCT00707031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6019|GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin|A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin|GETGOAL-X|Sanofi|Yes|Completed|June 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|639|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00707031||153789|
NCT00703963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001398|Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care|Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care: A Randomized Controlled Trial||Mayo Clinic|No|Completed|March 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 18, 2014|June 10, 2008|Yes|Yes||No|August 18, 2014|https://clinicaltrials.gov/show/NCT00703963||154019|
NCT00703040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 066a|Linkage to Care - Part I|HIV-Related Care Engagement: Linkage to Care and Care-Seeking for HIV-Infected Adolescents, Phase I||Westat|Yes|Completed|March 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|35|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Component 1: The object of study is a collection of documents on existing linkage-to-care        protocols and does not constitute a population. Component 2: Ideally, a minimum of two        clinical staff and/or case managers from each of 15 AMTU and a minimum of one staff member        representing the AMTU's community partners/sites where linkage to care activities occur.        Component 3- Structured Observations: Clinical site staff providing linkage to care        counseling. Please note that patients are not part of this study population. See Section        5.3 and Section 10.0 for additional details.|February 2016|February 29, 2016|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703040||154090|
NCT00706563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111631|A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in People Aged 18 Years or Above||GlaxoSmithKline||Completed|July 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 8, 2009|June 25, 2008|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00706563||153825|
NCT00706576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26336|Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor|Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study||Penn State University|Yes|Recruiting|June 2008|July 2011|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||June 2008|July 13, 2010|June 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00706576||153824|
NCT00661531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-BR-030|Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy|A Single Arm Phase II Study of Pharmacologic Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies||Georgetown University|Yes|Terminated|April 2008|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||November 2015|November 28, 2015|April 17, 2008|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00661531||157246|
NCT00661830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-GEMSO-2007|Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)|A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract||Johannes Gutenberg University Mainz|No|Completed|May 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|April 15, 2008||No||No|August 27, 2012|https://clinicaltrials.gov/show/NCT00661830||157223|
NCT00661518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASAP|PET/CT Imaging of Aneurysm Wall Inflammation|Imaging of Aneurysm Wall Inflammation Using Positron Emission Tomography.|ASAP|Radboud University|No|Recruiting|October 2007|December 2008|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|35|||Both|N/A|N/A|No|Non-Probability Sample|Population: At the Radboud University Nijmegen Medical Centre, approximately 80 patients        undergo prophylactic aneurysm repair each year. 10-15 patients are scheduled for        conventional ('open') repair the remaining 65-70 patients undergo endovascular aneurysm.        We therefore expect to finish including patients for both studies by the end of august        2008. The study population will be comprised both male (± 80%) and female patients with an        abdominal aortic aneurysm.        Inclusion criteria        Exclusion criteria        -Diabetes Mellitus type 1 en 2|April 2008|April 14, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00661518||157247|
NCT00662103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593410|Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors|Comparison of Aerobic and Resistance Exercise in Older Breast Cancer Survivors||OHSU Knight Cancer Institute||Completed|March 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|115|||Female|65 Years|120 Years|No|||October 2015|October 13, 2015|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00662103||157202|
NCT00662415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI-0771043|Examining Brain Changes Using Functional Magnetic Resonance Imaging (fMRI) in Amputees With Phantom Limb Pain Following Mirror Therapy|Study Using Functional MRI to Examine Changes in the Brain in Unilateral Lower Limb Amputees Treated With Mirror Therapy for Phantom Limb Pain.||Walter Reed Army Medical Center|No|Recruiting|February 2008|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|42|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2008|April 14, 2008|March 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00662415||157178|
NCT00662428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BÄK 06-69|Increasing Cost-effectiveness of Inpatient Treatment of Affective Disorders|Evaluation of a Guideline-based Net Care Intervention to Reduce the Duration of Inpatient Depression Treatment|INCA|University Hospital Freiburg||Completed|May 2008|August 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|202|||Both|18 Years|65 Years|No|||June 2012|June 20, 2012|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00662428||157177|
NCT00662701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06.30A/FAST|Ablation or Surgery for Atrial Fibrillation (AF) Treatment|Atrial Fibrillation: Ablation or Surgical Treatment; A Randomized Study Comparing Non-pharmacologic Therapy in Patients With Drug-refractory Atrial Fibrillation|FAST|St. Antonius Hospital|Yes|Completed|May 2007|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|30 Years|70 Years|No|||November 2015|November 18, 2015|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00662701||157156|
NCT00662974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor468908ctil|Searching for the Perfect Oil to Protect the Perineum: A Randomized-Controlled, Double-Blind Trial|A Randomised Double Blind Clinical Trial to Verify if Perineal Massage Increases the Chances of Delivering With an Intact Perineum Comparing the Two Oils. As Secondary Objective, we Will Evaluate the Effects of Perineal Massage on Specific Tear Location, the Severity of Perineal Tears and the Amount of Suture Material Required for Repair||Soroka University Medical Center|No|Not yet recruiting|May 2008|March 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|300|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2008|April 18, 2008|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662974||157135|
NCT00663221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC2 Atlas|Study of the Osteoprotector Effects of a Milk Product Based on Anthocyans and Enriched in Calcium and Vitamin D|||Elvir SAS||Completed|March 2008|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|56|||Female|50 Years|65 Years|No|||July 2009|July 3, 2009|April 14, 2008||||No||https://clinicaltrials.gov/show/NCT00663221||157116|
NCT00663468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLV-0021-08|Treatment of Sub-capital Fractures of Hip Joint by Using TriboFit™ Acetabular Buffer|||Active Implants||Active, not recruiting|April 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|September 2012|September 21, 2012|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00663468||157097|
NCT00663780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1004-0084|Pharmacogenomic Analysis of Samples From Subjects in Study RN1004-0082|Pharmacogenomic Analysis of Blood Samples to Identify Polymorphisms That Segregate Responders From Non-Responders Following Treatment With Juvidex of Split Skin Donor Sites in Renovo's Clinical Study RN1004-0082||Renovo|No|Completed|February 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|195|Samples With DNA|Plasma retained until samples analysed then destroyed|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will analyse samples from subjects participating in clinical study RN1004-0082,        a double blind, placebo controlled trial to investigate the efficacy and safety of two        concentrations of Juvidex in accelerating the healing of split thickness skin graft donor        sites using different dosing regimes.|January 2009|January 5, 2009|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663780||157073|
NCT00664274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061/C39-0|Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia|COMT Genotype and Response to Cognitive Remediation in Schizophrenia|COMT|Manhattan Psychiatric Center|Yes|Active, not recruiting|April 2007|October 2016|Anticipated|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|142|||Both|18 Years|55 Years|No|||April 2015|April 16, 2015|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00664274||157035|
NCT00664963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YUKON-BTK v3.0|YUKON-drug-eluting Stent Below The Knee - Randomised Double-blind Study|YUKON-drug-eluting Stent Below The Knee - Prospective Randomized Double-blind Multicenter Study|YUKON-BTK|Herz-Zentrums Bad Krozingen|No|Completed|April 2006|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|21 Years|N/A|No|||December 2014|December 16, 2014|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664963||156982|
NCT00661336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001793|A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma|An Open-Label, Multicenter, Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic Buthionine Sulfoximine (BSO) in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma||Duke University||Withdrawn|April 2008|||December 2009|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||April 2010|March 12, 2015|April 17, 2008|No|Yes|The study was withdrawn due to lack of patients.|||https://clinicaltrials.gov/show/NCT00661336||157261|
NCT00697736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.392|Cardiac Repercussion of Systemic Sclerodermias|Cardiac Repercussion of Systemic Sclerodermias : Detection of Infra-clinical Abnormalities by Analysis of the Myocardic Regional Function Using Myocardial Tissular Doppler Mode.|HTAP-SCLERO|Hospices Civils de Lyon|Yes|Completed|March 2007|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|148|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00697736||154489|
NCT00693550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|497-00|Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer|Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma?||Mayo Clinic||Completed|August 2000|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|otorhinolaryngology departments of Mayo Clinic Rochester and Mayo Clinic Arizona|June 2011|June 6, 2011|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00693550||154806|
NCT00660972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5248|Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)|First-Phase Viral Decay Rates in Treatment-Naive Subjects Initiating Treatment With Raltegravir (RAL) and Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF): A Pilot Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2008|April 2010|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|April 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00660972||157289|
NCT00660985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18115|Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%|A Pharmacokinetic Study to Compare the Systemic Exposure to Adapalene During Dermal Application of Either Differin® Gel, 0.3% (Adapalene 0.3%) or Differin® Gel, 0.1% (Adapalene 0.1%) for 30 Days in Subjects With Acne Vulgaris||Galderma||Completed|May 2008|November 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|35 Years|No|||January 2011|January 19, 2011|April 15, 2008|Yes|Yes||No|October 15, 2009|https://clinicaltrials.gov/show/NCT00660985||157288|
NCT00660998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100540|Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes|A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction||Bayer|No|Completed|February 2003|January 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|318|||Male|18 Years|N/A|No|||December 2014|December 10, 2014|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00660998||157287|
NCT00702780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUDC001|Progression Delaying Effect of Escitalopram in Alzheimer's Disease|Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease|ESAD|Seoul National University Hospital|Yes|Completed|November 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|40 Years|90 Years|No|||May 2014|May 13, 2014|June 15, 2008||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT00702780||154110|
NCT00704821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC299-ONC-004-AST|PTC299 for Treatment of Advanced Cancer|A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer||PTC Therapeutics|No|Suspended|June 2008|June 2014|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||April 2012|April 6, 2012|June 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00704821||153953|
NCT00703326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13892|Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer|A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer||Eli Lilly and Company|Yes|Active, not recruiting|August 2008|May 2016|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1144|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|June 20, 2008|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00703326||154068|One participant assigned to placebo + docetaxel (doc) treatment and was given ramucirumab (ram) in Cycle 1. Considered ram + doc treatment arm for safety population, for ITT population the participant was analyzed according to assigned treatment.
NCT00705133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11-087-01|Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension|Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease||University of California, Los Angeles|No|Recruiting|January 2008|February 2009|Anticipated|October 2008|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||June 2008|June 24, 2008|June 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00705133||153932|
NCT00706849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012-CS7|Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects With Coronary Artery Disease|RADICHOL II|Sanofi|Yes|Completed|July 2008|May 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|June 26, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00706849||153803|
NCT00706862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-0208|Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer|FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|FORTIS-C|Agennix|Yes|Recruiting|February 2009|March 2016|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|N/A|No|||March 2012|March 13, 2012|June 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00706862||153802|
NCT00661206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01207|Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting|Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent|ISAR-SAFE|Deutsches Herzzentrum Muenchen|Yes|Active, not recruiting|September 2008|November 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4005|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661206||157271|
NCT00661219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10621|Depression Related Improvement With Vardenafil for Erectile Response|A Randomized Double-blind Multi-center Parallel Group Three Month Study to Compare the Tolerability and Efficacy of Flexible Dose Vardenafil Versus Placebo in Men With Depression and Erectile Dysfunction.|DRIVER|Bayer||Completed|December 2002|November 2003|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|280|||Male|18 Years|N/A|No|||December 2014|December 18, 2014|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661219||157270|
NCT00661856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012254|Effect of Soy Isoflavones on Bone Mineral Density and Physical Performance Indices|The Effect of Increased Soy Protein Intake on Bone Metabolism|SoyPTI|Creighton University|Yes|Completed|January 2001|January 2004|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|203|||Female|55 Years|72 Years|Accepts Healthy Volunteers|||April 2008|April 17, 2008|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00661856||157221|
NCT00661869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05I/C51-3|Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness|Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness|Wellness|Manhattan Psychiatric Center|Yes|Completed|September 2006|January 2008|Actual|September 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|295|||Both|18 Years|65 Years|No|||August 2010|August 6, 2010|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661869||157220|
NCT00662116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0530|Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure|BREAK-DHF-I|Synvista Therapeutics, Inc|Yes|Terminated|March 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|50 Years|N/A|No|||January 2009|January 29, 2009|April 17, 2008|Yes|Yes|Study has been terminated early due to financial constraints.|No||https://clinicaltrials.gov/show/NCT00662116||157201|
NCT00662441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100578|Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction|Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals||Bayer|No|Completed|September 2003|June 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Male|18 Years|N/A|No|||June 2009|June 19, 2009|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00662441||157176|
NCT00663234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1063|IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia|Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Completed|August 2009|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|10 Years|18 Years|No|||March 2014|March 23, 2015|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663234||157115|
NCT00663481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoFactor 510-20|A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.|A Single Dose, Within Subject, 3 Period, Pharmacokinetic Bridging Study of CoFactor Formulations and of Leucovorin Administered Intravenously in Healthy, Adult Subjects.||Mast Therapeutics, Inc.|No|Completed|April 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 27, 2009|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663481||157096|
NCT00663494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#244|Matrix Metalloproteinase (MMP) in Heart Failure|MMP is Produced in Failing Hearts||Tottori University Hospital||Completed|February 2003|July 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|22|||Both|N/A|N/A||Non-Probability Sample|chronic heart failure|April 2008|July 20, 2011|April 18, 2008||||No||https://clinicaltrials.gov/show/NCT00663494||157095|
NCT00663793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33738-B|ORAL T-6: Oral Androgens in Man-6|Oral Androgens in Man-6: Pharmacokinetics of Slow and Fast Release, External Matrix Oral Testosterone Formulations in Normal Men With Experimental Hypogonadism|ORAL-T-6|University of Washington|No|Completed|October 2008|June 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 27, 2010|April 18, 2008|Yes|Yes||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00663793||157072|
NCT00664040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404|Heredity and Phenotype Intervention (HAPI) Heart Study|Heredity and Phenotype Intervention (HAPI) Heart Study|HAPI|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|May 2003|August 2006|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|868|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 18, 2008|April 18, 2008||||No||https://clinicaltrials.gov/show/NCT00664040||157053|
NCT00664638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-037|Renal Denervation in Patients With Refractory Hypertension|Renal Denervation in Patients With Refractory Hypertension|HTN-1|Medtronic Vascular|No|Completed|April 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|April 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00664638||157007|
NCT00661011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELCWP 01061|Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy|A Phase II Study Assessing the Curative Effect of the Combination of Lobectomy Followed by Mediastinal Concomitant Radiochemotherapy in Patients With Locally Advanced Unresectable Stage III Non-small Cell Lung Cancer Responding to Induction Chemotherapy||European Lung Cancer Working Party|Yes|Terminated|January 2007|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|April 15, 2008||No|The study was terminated due to too slow recruitment|No||https://clinicaltrials.gov/show/NCT00661011||157286|
NCT00697749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/034|Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype|Study to Compare the Immunogenicity and Safety of GSK Biologicals' Novel Adjuvanted HBV Vaccine (0, 6 Month Schedule) to Engerix™-B (0, 1, 6 Month Schedule) in Healthy (≥ 15 Years) Volunteers Positive for the HLA-DQ2 Genotype||GlaxoSmithKline||Completed|April 1999|||January 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|230|||Both|15 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697749||154488|
NCT00694057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE3286-0401|Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus|A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerance and Activity of HE3286 When Administered Orally for 12 Weeks to Adult Patients With Type 2 Diabetes Mellitus||Harbor Therapeutics|No|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|65 Years|No|||June 2011|June 11, 2011|June 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00694057||154768|
NCT00661947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|682-2007|Pharmacokinetics and Pharmacodynamics of Fructose|Pharmacokinetics and Pharmacodynamics of Fructose Following Soft Drink Consumption: Sucrose vs High Fructose Corn Syrup||University of Florida|Yes|Completed|March 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|Samples With DNA|DNA, whole blood, serum, plasma, and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General population from Gainesville, FL area.|October 2011|February 14, 2012|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661947||157214|
NCT00702507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114678|Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants|Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis||GlaxoSmithKline|No|Completed|May 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|15 Months|No|||March 2012|March 22, 2012|June 18, 2008|No|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00702507||154131|
NCT00705731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A105658|Adherence and the Economics of Colon Cancer Screening|Adherence and the Economics of Colon Cancer Screening||University of California, San Francisco|No|Completed|March 2007|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|50 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|General population of users of outpatient primary care clinics at San Francisco General        Hospital at average risk for development of colorectal cancer (CRC). Outpatient clinics        include the General Medical Clinic, the Family Health Center, and the Positive Health        Program (HIV primary care clinic).|June 2012|June 11, 2012|June 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00705731||153887|
NCT00705146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-03133|CMC (Carpometacarpal) OA (Osteoarthritis) Thumb Splint Study|Comparison of Two Carpometacarpal Stabilizing Splints for People With Thumb Osteoarthritis||University of British Columbia|No|Completed|April 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|45 Years|N/A|No|||December 2014|December 9, 2014|June 23, 2008||No||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00705146||153931|The main limitation of this cross-over trial was that the therapists who collected the data were not blinded to the splinting intervention, as they were required to fabricate and fit each splint.
NCT00702858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blue Citrus BC-AIT-001|Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer|Pilot, Single Center Randomized Controlled, Double-Blind, Cross Over, Intent to Treat Trial of Blue Citrus to Placebo in Those Breast Cancer Patients Receiving Aromatase Inhibitor Therapy||Legacy Health System|Yes|Completed|April 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Female|18 Years|N/A|No|||August 2013|August 27, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702858||154104|
NCT00703066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMZ2_3_08|Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years|A Phase I, Randomized, Controlled, Double-Blind, Single Centre Trial to Evaluate the Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years||African Malaria Network Trust|Yes|Active, not recruiting|June 2008|August 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|30|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||November 2008|November 23, 2008|June 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00703066||154088|
NCT00662129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0735|Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Albumin-Bound Paclitaxel in Combination With Gemcitabine and Bevacizumab in Patients With Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|November 2008|||August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662129||157200|
NCT00661544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0603|Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients|Phase I/II Study of the Combination of Arsenic Trioxide With Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma||M.D. Anderson Cancer Center|No|Completed|March 2004|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|N/A|70 Years|No|||February 2013|February 26, 2013|April 15, 2008||No||No|March 13, 2009|https://clinicaltrials.gov/show/NCT00661544||157245|
NCT00662714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F01/01 CF-RD|Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis|Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus||Mukoviszidose Institut gGmbH|No|Completed|September 2001|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|10 Years|N/A|No|||July 2012|July 6, 2012|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662714||157155|
NCT00662987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCMC0506007924|Effect of Duration of Antibiotic Therapy on Recovery Following Tonsillectomy|Effect of Duration of Antibiotic Therapy on Recovery Following Tonsillectomy||Weill Medical College of Cornell University|No|Completed|September 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|18 Years|Accepts Healthy Volunteers|||April 2008|April 17, 2008|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662987||157134|
NCT00663000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-7538|Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance|Observational, Cross-sectional, Longitudinal, Multi-center, Diagnostic Study to Evaluate the Influence of Acromegaly on Glucose Tolerance and to Evaluate the Changes of Impaired Glucose Tolerance During Standard Treatment of Acromegaly.||University Hospital Tuebingen|Yes|Completed|April 2008|December 2012|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|138|Samples Without DNA|serum|Both|18 Years|75 Years|No|Non-Probability Sample|1. Acromegaly in adult subjects (≥ 18 years) either controlled or uncontrolled             (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of             suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose,             OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).          2. Written informed consent|September 2014|September 13, 2014|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00663000||157133|
NCT00663247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07057|Mechanistic Randomized Controlled Trial (RCT) of Mesalazine in Symptomatic Diverticular Disease|Mechanistic Randomized Controlled Trial of Mesalazine in Symptomatic Diverticular Disease||University of Nottingham|Yes|Completed|April 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||June 2012|June 13, 2012|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663247||157114|
NCT00663806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100534|A Phase IV Study of Cipro XR in Uncomplicated UTI|EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction|EXPRESS|Bayer|No|Completed|February 2003|July 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|7614|||Female|18 Years|65 Years|No|||December 2014|December 1, 2014|April 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00663806||157071|
NCT00664027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-C-0801|Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy|An Open-Label, Randomized, Dose-ranging Phase IIa Trial to Determine the Effects of RTA 402 (Bardoxolone Methyl) on Renal Function in Patients With Diabetic Nephropathy||Reata Pharmaceuticals, Inc.||Completed|April 2008|||May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664027||157054|
NCT00664287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-082|Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients Deemed Appropriate for Further Lipid Modification.||Merck Sharp & Dohme Corp.||Withdrawn|September 2008|||November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664287||157034|
NCT00664625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-002|A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects|Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|60 Years|No|||September 2015|September 23, 2015|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664625||157008|
NCT00665301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFW-019|Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000|Validation Study Comparing the Cardiac Output Pulmonary Arterial Catheter (Swan Ganz) to the FloWave™ 1000 Device||Woolsthorpe Technologies, LLC|No|Completed|March 2008|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|95 Years|No|Non-Probability Sample|Any patient that has a Swan Ganz PAC catheter in place.|July 2008|July 7, 2008|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00665301||156957|
NCT00665314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD3100-EU23|Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).|A Multicenter, Randomized, Comparative, Patient-blinded Study to Evaluate the Safety and Efficacy of G-CSF Alone Versus AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Adult Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkins Disease (HD) or Multiple Myeloma (MM) Who Have Previously Failed Stem Cell Collections or Collection Attempts||Sanofi|No|Completed|November 2007|June 2009|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|78 Years|No|||February 2014|February 10, 2014|April 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00665314||156956|
NCT00697437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK01/01/06|Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel|Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel||National University Hospital, Singapore|Yes|Completed|October 2006|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697437||154512|
NCT00693797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR/9022-3|Clinical Significance of Collagen Metabolism Changes in Left Cardiac Ventricle|Clinical Significance of Collagen Metabolism Changes in Patients With Failing and Pressure Overloaded Left Cardiac Ventricle.||Charles University, Czech Republic|No|Completed|January 2006|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|frozen serum for collagen metabolism detection|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with aortic stenosis and left ventricular hypertrophy|April 2009|April 27, 2009|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693797||154787|
NCT00661973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-006664-29|Inhaled Corticosteroids on Airway Smooth Muscle in Asthma|The Effect of Inhaled Corticosteroids (ICS) on Airway Smooth Muscle in Asthma||Imperial College London|No|Withdrawn|April 2008|March 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|60 Years|No|||June 2011|June 3, 2015|April 16, 2008||No|The study was withdrawn for administrative reasons|No||https://clinicaltrials.gov/show/NCT00661973||157212|
NCT00661986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leipzig chocolate|Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients|Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients||University of Leipzig|No|Completed|February 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||January 2010|February 1, 2010|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00661986||157211|
NCT00693784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-BX01P-2007|Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System: A Pilot Study|A Multicenter Pilot Study of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System||Spinal Restoration, Inc.|Yes|Completed|June 2008|January 2011|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|June 4, 2008|No|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00693784||154788|
NCT00694044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051106|Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects|A Randomized, Investigator and Subject Blind, Sponsor Open Parallel Group Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pro-Cognitive Effects of Varenicline, Under Various Titration Schemes, in Healthy Elderly Non-Smoking Subjects||Pfizer|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|50|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||June 2009|June 1, 2009|June 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00694044||154769|
NCT00703651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID02|Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults|Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Vaxigrip® in Adults||Sanofi|No|Completed|September 2003|July 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1150|||Both|18 Years|57 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00703651||154043|
NCT00705978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.4.009|Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis|A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension||Abbott|No|Completed|June 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||August 2011|August 16, 2011|June 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00705978||153868|
NCT00703391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00002|A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 2-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Tolerability and Pharmacokinetics of Orally Administered AZD9668 in Patients With COPD||AstraZeneca|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Both|40 Years|80 Years|No|||January 2012|January 24, 2012|June 19, 2008|Yes|Yes||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00703391||154063|
NCT00703937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT08019|Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia|A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia||Luitpold Pharmaceuticals|Yes|Completed|July 2008|March 2011|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|708|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|June 20, 2008|No|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT00703937||154021|
NCT00704171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN-06-002|PleuraSeal Post Market Study (Europe)|Prospective Multi-Center Randomized Post Market Study to Evaluate the PleuraSeal Sealant System as Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy||Integra LifeSciences Corporation|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|June 23, 2008||No||No|December 21, 2009|https://clinicaltrials.gov/show/NCT00704171||154003|
NCT00662142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-12-13-03 (MARTEK)|Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function|Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function||University of Cincinnati||Completed|January 2006|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|30|||Male|8 Years|10 Years|No|||May 2013|May 15, 2013|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00662142||157199|
NCT00662155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB # 14533|The Role of Partial Reinforcement in the Long Term Management of Insomnia|The Role of Partial Reinforcement in the Long Term Management of Insomnia|ADER|University of Pennsylvania|Yes|Completed|July 2006|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|318|||Both|21 Years|55 Years|No|||February 2011|October 9, 2015|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662155||157198|
NCT00662454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 0411|Oral Contraceptive Efficacy and Body Weight|Oral Contraceptive Efficacy and Body Weight: Does Obesity Affect the Risk of Contraceptive Failure?||Oregon Health and Science University|Yes|Completed|January 2006|May 2006|Actual|May 2006|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|120|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2011|August 3, 2011|April 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662454||157175|
NCT00662727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR-RCT-IL|Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris|Randomized, Placebo Controlled, Double Blind Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device||Medispec|No|Completed|January 2007|November 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||February 2013|February 17, 2013|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00662727||157154|
NCT00663819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-109|Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses|Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal, Coloanal and Ileoanal Anastomoses: A Prospective Randomized Study||W.L.Gore & Associates|No|Terminated|April 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|April 18, 2008|Yes|Yes|Per SAP|No|August 21, 2014|https://clinicaltrials.gov/show/NCT00663819||157070|
NCT00664053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0099|Effects of DHEA/Exercise on Bone, Muscle and Balance|Effects of DHEA/Exercise on Bone, Muscle and Balance||National Institute on Aging (NIA)|No|Completed|October 2004|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|99|||Female|65 Years|N/A|Accepts Healthy Volunteers|||April 2008|April 25, 2008|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00664053||157052|
NCT00664976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECT-0408|Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy|Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy||Norwegian University of Science and Technology|No|Completed|April 2008|September 2013|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00664976||156981|
NCT00697138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA021155|Agonist Replacement Therapy for Cocaine Dependence|Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications||University of Kentucky|Yes|Completed|June 2006|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|1||Actual|46|||Both|18 Years|50 Years|No|||February 2012|February 29, 2012|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697138||154535|
NCT00697151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6372|Patent Foramen Ovale in Cryptogenic Stroke Study|Patent Foramen Ovale in Cryptogenic Stroke Study|PICSS|Columbia University|Yes|Completed|June 1993|June 2000|Actual|June 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|630|||Both|30 Years|85 Years|No|||September 2011|September 14, 2011|June 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697151||154534|
NCT00697164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2516114389|Randomized Trial of Erythropoietin During Cerebral Malaria|Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria|EPOMAL|Claude Bernard University|Yes|Recruiting|October 2007|March 2009|Anticipated|December 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Months|15 Years|No|||June 2008|June 12, 2008|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697164||154533|
NCT00693563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32148-G|Scheduled Telephone Intervention for Individuals With Spinal Cord Injury and Their Families|Scheduled Telephone Intervention for Individuals With Spinal Cord Injury and Their Families: A Randomized Controlled Trial|SCILink|University of Washington|No|Completed|August 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|168|||Both|16 Years|N/A|No|||January 2013|January 10, 2013|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00693563||154805|
NCT00661674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04152008-1099|POWS: Palonosetron/Ondansetron Opioid Withdrawal Study|POWS: Palonosetron/Ondansetron Opioid Withdrawal Study||Stanford University||Completed|April 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661674||157235|
NCT00661687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|544|Comparative Performance of PureVision Lens Designs|A Study to Evaluate the Product Performance of the Redesigned Bausch & Lomb PureVision® Contact Lens (Test) Compared to the Currently Marketed Bausch & Lomb PureVision® Contact Lens (Control) When Worn on an Extended Wear Basis.||Bausch & Lomb Incorporated|No|Completed|December 2007|June 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|April 16, 2008|Yes|Yes||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00661687||157234|2 participants discontinued due to adverse events, not classified as serious. One subject in the test group developed corneal ulcer, one subject in the control group developed a central epithelial defect, both conditions resolved following treatment.
NCT00662571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007204|Acamprosate: Genes Associated With Response|A Probe Study of Acamprosate: Genes Associated With Response|ACAM|Mayo Clinic|Yes|Completed|May 2008|February 2013|Actual|February 2013|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|485|Samples With DNA|Samples obtained from study "Developing a DNA Repository for Genomic Studies of Addiction: A      Pilot Study"|Both|18 Years|80 Years|No|Non-Probability Sample|Subjects selected from Mayo Clinics Addiction programs.|March 2013|March 20, 2013|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00662571||157166|
NCT00662272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-100-001|Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant|Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With Ascending Doses of JVRS-100 Adjuvant|H-100-001|Colby Pharmaceutical Company|Yes|Completed|June 2008|December 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|128|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2010|March 15, 2010|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662272||157189|
NCT00662285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16225|Description of Iron Status in Blood Donors|Description of Iron Status in Blood Donors||Haukeland University Hospital|Yes|Enrolling by invitation|April 2008|April 2009|Anticipated|April 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|400|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||April 2008|April 18, 2008|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00662285||157188|
NCT00662844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR065013|Vitamin D Supplementation in Younger Women|Optimum Vitamin D Nutrition in Young Women|VITADAS|Creighton University|Yes|Completed|April 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|5||Actual|198|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00662844||157145|
NCT00704548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08014|Antihypertensive Effect of Simvastatin in Hypertensive Patients|Antihypertensive Effect of Simvastatin in Hypertensive Patients: a Randomized Clinical Trial With Ambulatory Blood Pressure Monitoring||Hospital de Clinicas de Porto Alegre||Recruiting|June 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|70 Years|No|||June 2009|June 25, 2009|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00704548||153974|
NCT00712010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.26.MET|Metabolic Effect of High-protein Meals in Men|Acute Metabolic Effect of the Protein Quality of a High-protein Meal Replacement in Healthy Men|OPTI-PROT|Nestlé|No|Completed|July 2008|April 2011|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Actual|25|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|July 3, 2008||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT00712010||153414|
NCT00706225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1134|Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women|An Open-Label, Single/Multiple Dose, Non-Randomized, 3-Period, Crossover Study To Determine The Potential Drug Interaction Of Bazedoxifene On Conjugated Estrogens (CE) In Healthy Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||September 2010|September 21, 2010|June 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00706225||153849|
NCT00706238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110551|MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma|Study of GSK1203486A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma||GlaxoSmithKline||Terminated|September 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|June 25, 2008|Yes|Yes|The study was terminated early due to difficulties in recruiting subjects, not following    concerns for the safety or absence of clinical activity in patients.|No||https://clinicaltrials.gov/show/NCT00706238||153848|
NCT00712569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-079|Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety|Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety||Memorial Sloan Kettering Cancer Center||Completed|June 2008|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|85|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|physicians at the Breast Service and their patients will be recruited to participate in        this study.|February 2015|February 5, 2015|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00712569||153371|
NCT00663013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701008961|Virtual Reality for Burn Wound Care Pain Control|Virtual Reality for Burn Wound Care Pain Control||Weill Medical College of Cornell University|No|Recruiting|October 2007|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|12 Years|N/A|No|||January 2011|January 3, 2011|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00663013||157132|
NCT00662467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-281|Warfarin After Anterior ST-Elevation Myocardial Infarction|Warfarin After Anterior ST-Elevation Myocardial Infarction||McMaster University|No|Completed|November 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||April 2008|April 18, 2008|April 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00662467||157174|
NCT00663533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32431-B|VAS-2 Vasectomy With the Vax-X|Vasectomy With the Vas-X, a Simple, Minimally Invasive Device for Male Sterilization: A Pilot Study|VAS-2|University of Washington|No|Completed|April 2008|July 2013|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663533||157092|
NCT00663546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908094|Malaria Studies in Cambodia|Studies of P. Vivax and P. Falciparum Malaria in Cambodia||National Institutes of Health Clinical Center (CC)||Completed|March 2008|December 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2765|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|November 4, 2014|April 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00663546||157091|
NCT00663559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOGUG/0107|Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy|Study Phase II to Determinate the Efficacy of Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy|SOGUG/0107|Spanish Oncology Genito-Urinary Group|Yes|Completed|February 2008|February 2010|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||November 2007|December 17, 2014|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00663559||157090|
NCT00663507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004914|Kidney Transplantation in Patients With Sickle Cell Disease|Kidney Transplantation in Patients With Sickle Cell Disease||Emory University|Yes|Terminated|March 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2|Samples With DNA|100 mLs of whole blood will be collected at designated time points. Baseline, and at      1,3,6,9,12,18 and 24 months post-transplant|Both|18 Years|65 Years|No|Non-Probability Sample|Diagnosis of sickle cell disease (SS type) with end stage renal disease|February 2013|February 25, 2013|April 18, 2008||No|Only 1 patient was enrolled. No funding, small number of eligible patients so would not    achieve statistical power.|No||https://clinicaltrials.gov/show/NCT00663507||157094|
NCT00663520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study #3631|Elucidating the Role of Microvascular Dysfunction in Heart Disease in Women|Elucidating the Role of Microvascular Dysfunction in Heart Disease in Women|MVD|Oregon Health and Science University|Yes|Recruiting|January 2008|||June 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Fifty non-smoking women, between 45 and 75 years of age, with chest pain will be referred        to this study by clinicians at OHSU. The control group will be fifty non-smoking women        with no cardiac symptoms, matched with the study group by age and risk factors. Flyers and        other advertisements may be used to recruit both the study group and the control group.        Criteria for exclusion from the study are pregnancy, allergy to any component in the drugs        used in the study, severe asthma, known disease of the heart vessels or heart valves,        active infection, cancer, uncontrolled hypertension, kidney disease and current smoking        status.|April 2008|July 22, 2011|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663520||157093|
NCT00664300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0032|Facial Expression Recognition of Emotion and Categorization of Emotional Words in Gilles de la Tourette's Syndrome|Facial Expression Recognition of Emotion and Categorization of Emotional Words in Gilles de la Tourette's Syndrome||University Hospital, Clermont-Ferrand||Completed|August 2007|October 2009|Actual|October 2008|Actual|N/A|Observational|N/A||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|30 patients with Gilles de la Tourette's Syndrome and 30 healthy paired volunteers        (control group)|January 2011|January 18, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664300||157033|
NCT00664313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5356|TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB|TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis|LiMiT|Centers for Disease Control and Prevention|Yes|Completed|April 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||October 2012|October 1, 2012|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00664313||157032|
NCT00664651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006541|Joint Stiffness Following Knee Replacement Surgery|Capsular Changes in Joint Contractures Post-Knee Arthroplasty:A Case-Control Study||Ottawa Hospital Research Institute|No|Withdrawn|December 2006|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|joint contractures following knee surgery|April 2015|April 22, 2015|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00664651||157006|
NCT00696839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#08-17|Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects|Clinical Trial Of Cognitive-behavioral Therapy To Reduce Antiretroviral Side Effects In HIV Patients||Duquesne University|Yes|Completed|September 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|29|||Both|18 Years|N/A|No|||March 2010|March 1, 2010|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00696839||154558|
NCT00697762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014284|Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures|A Double-Blind Study to Evaluate the Effectiveness and Safety of RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures||SK Life Science|No|Terminated|October 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|56|||Both|16 Years|N/A|No|||January 2013|January 14, 2013|June 12, 2008|Yes|Yes|The trial was stopped based on information from the global phase 3 studies.|No||https://clinicaltrials.gov/show/NCT00697762||154487|
NCT00661362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00006|Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes|A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy||AstraZeneca|Yes|Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|570|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|April 17, 2008|Yes|Yes||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00661362||157259|
NCT00661375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11515|BAY43-9006 Phase II Study for Renal Cell Carcinoma|Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma||Bayer|Yes|Completed|November 2004|March 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|April 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00661375||157258|
NCT00661700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10940|A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction|A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction||Bayer|No|Completed|April 2003|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|611|||Male|18 Years|N/A|No|||November 2014|November 17, 2014|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661700||157233|
NCT00661739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 38|A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer|A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer|RiTa|German Breast Group|Yes|Completed|July 2005|May 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Female|18 Years|N/A|No|||September 2010|August 31, 2011|April 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00661739||157230|
NCT00661999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000593480|Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer|A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia||Mayo Clinic|Yes|Completed|January 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|502|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|April 18, 2008|Yes|Yes||No|February 14, 2011|https://clinicaltrials.gov/show/NCT00661999||157210|
NCT00662298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-002084-27|Prednisolone Pharmacokinetics in Severe Asthma|The Pharmacokinetics and Anti-inflammatory Effects of Prednisolone in Severe Asthma||Imperial College London|No|Completed|June 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|70 Years|No|||June 2011|March 25, 2015|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00662298||157187|
NCT00662584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-05-045-01|Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD)|The Efficacy of Functional Magnetic Resonance Imaging (fMRI) Guided Low Frequency Repetitive Magnetic Transcranial Stimulation (rTMS) Therapy on Symptoms of Generalized Anxiety Disorder (GAD)||University of California, Los Angeles|Yes|Completed|August 2006|April 2007|Actual|March 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||April 2008|April 17, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00662584||157165|
NCT00662597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2301|ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer|A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC)|ATRACT-1|Novartis||Terminated|April 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1285|||Both|18 Years|N/A|No|||May 2012|May 3, 2012|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662597||157164|
NCT00663065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3186A1-1102|A Study of the Safety of PAZ-417 in Healthy Elderly Adults|An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PAZ-417 Administered Orally to Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|April 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 3, 2009|April 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00663065||157128|
NCT00705445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|752-Peds/ERC-07|Evaluation of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Children of Pakistan|Prospective Cluster Randomized Controlled Evaluation of the Impact of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Cohorts of Children in Pakistan||Aga Khan University|Yes|Completed|November 2008|July 2012|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2745|||Both|N/A|6 Months|Accepts Healthy Volunteers|||August 2012|August 27, 2012|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00705445||153909|
NCT00705718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medtronic - 089|Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System|Endurant Stent Graft System US Clinical Study||Medtronic Endovascular|Yes|Active, not recruiting|June 2008|November 2016|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 24, 2008|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00705718||153888|Adverse Events and Serious Adverse Events listed in ClinicalTrials.gov were re-coded, using MeDRA codes. To do so, events were reclassified. As a result, data in listings may not match those in Clinical Update reports, SSEDs, or Instructions for Use.
NCT00712296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01 AT002647-2|Effectiveness of Chinese Herbal Therapy for Asthma|Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase II||Icahn School of Medicine at Mount Sinai|Yes|Suspended|August 2008|July 2010|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|55 Years|No|||December 2009|December 29, 2009|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00712296||153392|
NCT00712582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-026|Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma|Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|101|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712582||153370|
NCT00702793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02939|Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)|Safety and Tolerability of Varenicline When Used for Smoking Cessation/Reduction in Individuals With Severe and Persistent Mental Illness: An Open Label Pilot Trial||University of British Columbia|No|Withdrawn|April 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|65 Years|No|||May 2012|May 7, 2012|June 18, 2008||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT00702793||154109|
NCT00713661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-029-IM|Evaluation of TachoSil® Application on a Colorectal Anastomosis (TC-029-IM)|Non-randomised, Open, Multi-center Trial Evaluating Feasibility and Safety of TachoSil® Application on a Colorectal Anastomosis.||Nycomed|Yes|Completed|June 2008|July 2010|Actual|June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2012|May 4, 2012|July 7, 2008||No||No|December 20, 2011|https://clinicaltrials.gov/show/NCT00713661||153288|
NCT00662766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H22-05|Intervention With Black Currant Seed Press Residues in Healthy Subjects|Intervention Study on the Health Beneficial Effects of Bread Enriched With Black Currant Seed Press Residues in Healthy Subjects||University of Jena|Yes|Completed|September 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|36|||Female|18 Years|35 Years|No|||April 2008|April 16, 2008|April 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00662766||157151|
NCT00663026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133L1-2203|Study Evaluating Bapineuzumab In Alzheimer Disease Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD||Pfizer|Yes|Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|79|||Both|50 Years|89 Years|No|||September 2013|September 11, 2013|April 17, 2008|Yes|Yes||No|September 11, 2013|https://clinicaltrials.gov/show/NCT00663026||157131|Designation of outcomes as primary, secondary was based on study team’s input as study did not specify them as primary or secondary.
NCT00663260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-029|Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control||AstraZeneca|Yes|Completed|June 2008|June 2011|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|202|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|April 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663260||157113|
NCT00663273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_03732|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower||Sanofi|No|Completed|December 2007|||January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Female|10 Years|20 Years|Accepts Healthy Volunteers|||January 2009|January 7, 2009|April 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00663273||157112|
NCT00663832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589C2205|A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer|An Open Label, Single Arm, Phase Ib Dose Finding Study of i.v. Panobinostat (LBH589) With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer||Novartis||Completed|February 2008|||December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Male|18 Years|N/A|No|||May 2012|May 15, 2012|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00663832||157069|
NCT00664066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD490-404|DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)|A Non-Interventional, Post-Authorisation Study to Assess Adverse Events and Drug Utilisation Among Chronic Kidney Disease Patients Treated With DYNEPO|DELFT|Shire||Terminated|April 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients with established Chronic Kidney Disease|September 2009|September 28, 2009|April 21, 2008||No|The termination of the study is not linked to a product recall or result of any safety signal.    Rather it was sponsor's commercial decision to withdraw the MA|No|August 18, 2009|https://clinicaltrials.gov/show/NCT00664066||157051|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.
NCT00696293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2RR024154|Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults|Optimizing Outcomes in Older Adults With Low Back Pain and Depression|ACHIEVE2|University of Pittsburgh|No|Completed|May 2007|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|60 Years|N/A|No|||February 2012|February 2, 2012|June 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00696293||154599|
NCT00696579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_ML_003|Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer|BCG vs. Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer: A Randomized Prospective Study||University Of Perugia|No|Completed|January 2004|||March 2008||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|No|||June 2008|June 10, 2008|June 10, 2008||||No||https://clinicaltrials.gov/show/NCT00696579||154577|
NCT00697450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3560|Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics|Observational Study Evaluating the Body Weight Progress During the Treatment With Insulin Detemir (Levemir®) in Type 2 Patients, Previously Treated With Other Basal Insulins||Novo Nordisk A/S|No|Completed|July 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|206|||Both|18 Years|N/A|No|Non-Probability Sample|Type 2 diabetics|January 2013|January 18, 2013|June 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697450||154511|
NCT00665353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5239|Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance|A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy||AIDS Clinical Trials Group|Yes|Completed|March 2009|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|April 22, 2008|No|Yes||No|June 7, 2012|https://clinicaltrials.gov/show/NCT00665353||156953|The study did not fully enroll and the small sample size precluded subgroup analysis.
NCT00665366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-502|Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder|A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated on Valproate or Lithium and in Need of Further Clinical Improvement||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|June 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|493|||Both|18 Years|N/A|No|||February 2013|November 7, 2013|April 18, 2008|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00665366||156952|
NCT00661037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_SI|SAFEty of Two Strategies of ICD Management at Implantation|SAFEty of Two Strategies of ICD Management at Implantation|SAFE-ICD|Guidant Corporation|Yes|Completed|March 2008|September 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2130|||Both|18 Years|N/A|No|Non-Probability Sample|All patients having the risk of life threatening arrhythmias and indicated for the implant        of an implantable cardioverter defibrillator.|August 2012|August 31, 2012|April 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661037||157284|
NCT00661713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P10|Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules|A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged 11-17 Years According to Different Vaccination Schedules||Novartis||Completed|June 2008|December 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|1631|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|April 16, 2008|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT00661713||157232|
NCT00661726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|569|Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia|A Phase IIA Study of Subcutaneous 5-aza-2'- Deoxycytidine (Decitabine) in Patients With Thalassemia Intermedia||New England Research Institutes|Yes|Completed|January 2008|September 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2014|April 9, 2014|April 16, 2008|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00661726||157231|
NCT00662311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6600|Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery|Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined With Paclitaxel and Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin||University of Washington|No|Terminated|March 2008|September 2011|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|April 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00662311||157186|
NCT00662870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3T06|Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine|Safety, Immunogenicity and Lot Comparability of DAPTACEL™ (Aventis Pasteur Classic Five-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) When Administered With Other Recommended Vaccines at 2, 4, 6, and 15 to 16 Months of Age.||Sanofi|No|Completed|May 2001|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1941|||Both|42 Days|84 Days|Accepts Healthy Volunteers|||January 2012|January 26, 2012|April 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00662870||157143|
NCT00711750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96042|Immediate Maintained Cannulation of a Newly Implanted Prosthetic Arteriovenous Access for Acute Hemodialysis|||Far Eastern Memorial Hospital||Recruiting|January 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|39|||Both|N/A|N/A|No|Probability Sample|Patients with end-stage renal disease underwent the specific prosthetic arteriovenous        access creation in our hospital from November 2003 to October 2005 were retrospectively        reviewed.|July 2008|July 8, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711750||153434|
NCT00711737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.06|Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months|Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months||Changi General Hospital|No|Completed|September 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|21 Years|N/A|No|Non-Probability Sample|Outpatients in psychiatric clinic in a general hosptial|June 2011|June 15, 2011|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00711737||153435|
NCT00712270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-009|Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia|A Randomized Double-blind Trial of Aripiprazole and Risperidone in Schizophrenia: An Evaluation of Neuroimaging, Neuropsychological, and Pharmacogenomic Markers of Differential Treatment Response|BEST|Kettering Health Network|No|Terminated|April 2005|November 2010|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|55 Years|No|||February 2016|February 25, 2016|July 7, 2008|No|Yes|Study terminated due to failure to meet sufficient enrollment for valid analysis|No||https://clinicaltrials.gov/show/NCT00712270||153394|
NCT00712283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579-0628/1|Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers|A Single Center, Randomized, Double-blind, Placebo-controlled, Parallel Group Design Study to Investigate the Effect of 12,5 mg, 25 mg, 50 mg and 75 mg Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers||Merz Pharmaceuticals GmbH||Completed|July 2008|June 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Anticipated|64|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00712283||153393|
NCT00663286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-06-22-2006-017|A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris|||Dow Pharmaceutical Sciences||Completed|October 2006|||August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1399|||Both|12 Years|70 Years|No|||April 2008|April 18, 2008|April 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00663286||157111|
NCT00663299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2004|COMPLEX Post Market Surveillance Electronic Registry|COMPLEX Post Market Surveillance Electronic Registry|COMPLEX|Codman & Shurtleff|No|Completed|June 2004|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|299|||Both|N/A|N/A|No|||May 2012|May 15, 2012|April 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00663299||157110|
NCT00695682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101606|Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)|The Safety and Tolerability of Intravitreal Infliximab (Remicade) in Patients With Refractory Diabetic Macular Edema or Choroidal Neovascularization Secondary to Age Related Macular Degeneration- A Pilot Study|ITVR|Retina Research Foundation|No|Recruiting|June 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|N/A|N/A|No|||June 2008|June 11, 2008|June 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00695682||154643|
NCT00696007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-039|Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer|Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer||Lahey Clinic|No|Withdrawn|April 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|June 10, 2008|Yes|Yes|Study was unable to recruit subjects meeting the study requirements.|No||https://clinicaltrials.gov/show/NCT00696007||154620|
NCT00696852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHBI-1201|Mindfulness, Yoga, and Cardiovascular Disease|Effects of Mindfulness and Yoga on Heart Rate Variability and Immune Markers||The Cleveland Clinic|No|Completed|June 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00696852||154557|
NCT00697177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/05|The Prevalence of Gastro-oesophageal Reflux in Chronic Lung Disease|The Prevalence of Gastro-oesophageal Reflux in Chronic Obstructive Pulmonary Disease and Bronchiectasis and the Effects of Medications, Physiotherapy Airway Clearance Techniques and Exercise on Gastro-oesophageal Function.||Bayside Health||Completed|July 2005|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults with COPD and bronchiectasis|September 2005|February 12, 2013|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT00697177||154532|
NCT00697190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-4523|Clinical Performance of Atypical Contact Lens Powers on Subjects With Astigmatism|||Johnson & Johnson Vision Care, Inc.|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|June 10, 2008|Yes|Yes||No|September 9, 2010|https://clinicaltrials.gov/show/NCT00697190||154531|
NCT00661050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03132008-1041|Treatment of Interstitial Cystitis/Painful Bladder Syndrome Using Alternative Techniques: Exercise, Meditation, Tai Chi|Exercise and Meditation: A Pilot Study of Alternative Techniques in the Treatment of Chronic Pelvic Pain Related to Painful Bladder Syndrome (PBS)/Interstitial Cystitis (IC) PI: Dr. Christopher Payne||Stanford University|No|Terminated|April 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|IC Patients from Stanford University Urology Clinic's patient population.|March 2011|March 18, 2011|April 4, 2008||No|Terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00661050||157283|
NCT00661063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042/2007|Diabetic Neuropathy Topical Treatment|Diabetic Neuropathic Pain Topical Treatment- Comparative Study||Irmandade da Santa Casa de Misericordia de Sao Paulo|Yes|Not yet recruiting|April 2008|June 2009|Anticipated|April 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||April 2008|April 17, 2008|April 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00661063||157282|
NCT00661388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21524|A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.|An Open Label Study of the Safety, Tolerability and Effect on Hemoglobin Levels of Monthly Subcutaneous Mircera in Predialysis Patients With Chronic Renal Anemia Not Currently Treated With ESA.||Hoffmann-La Roche||Completed|August 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00661388||157257|
NCT00661401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310570|Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin|Serum IgG Antibody to Streptococcus Pneumoniae, Haemophilus Influenzae Type b and Tetanus Toxoid in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin Infusions||Federal University of São Paulo|Yes|Completed|January 2002|November 2002|Actual|November 2002|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|75 Years|No|||April 2008|April 15, 2008|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00661401||157256|
NCT00720668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA006|The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma|The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma|HBV-HCC|Sun Yat-sen University|Yes|Recruiting|June 2006|May 2010|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|75 Years|No|Probability Sample|patients with hepatocellular carcinoma (HCC) after percutaneous radiofrequency ablation.|February 2009|February 6, 2009|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720668||152753|
NCT00721552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2008Pred002|Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome|Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-controlled, Double-blind Intervention Study With a 2x2 Factorial Design|SPHINX|VU University Medical Center|No|Completed|October 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|6||Actual|82|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 28, 2012|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721552||152688|
NCT00720759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6346-R|Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine|Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine||VA Office of Research and Development|No|Completed|July 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|20 Years|80 Years|No|||January 2014|January 21, 2014|July 21, 2008|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00720759||152747|
NCT00721019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16079A-S3|Sleep Loss and Glucose Metabolism in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk.||University of Chicago|No|Completed|July 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721019||152728|
NCT00721305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLCIENCIAS 111540820508|Lovastatin: Immunomodulatory Value Evaluation|Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy (HAART): A Phase-II Randomized Clinical Trial (RCT)|LIVE|Universidad de Antioquia|Yes|Completed|August 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||September 2011|September 30, 2011|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721305||152707|
NCT00721877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00895|Resveratrol in Healthy Adult Participants|Clinical Study of Resveratrol on Drug and Carcinogen Metabolizing Enzymes||National Cancer Institute (NCI)||Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|October 7, 2014|July 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00721877||152663|
NCT00722553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-011|Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder|A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder||Spectrum Pharmaceuticals, Inc||Completed|July 2008|September 2011|Actual|April 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|July 23, 2008|Yes|Yes||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00722553||152613|
NCT00722956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00025|Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin|A Phase I, Single Centre, Open-label Study to Assess the Pharmacokinetics of Both AZD5672 (Steady-state) and Atorvastatin (Single Dose) When Co Administered in Healthy Volunteers||AstraZeneca|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722956||152583|
NCT00722969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/203|Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Phase II Study of Erlotinib and Sorafenib in Patients With Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy||Free University Medical Center|No|Active, not recruiting|November 2007|April 2009|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|N/A|N/A|No|||March 2009|March 2, 2009|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722969||152582|
NCT00723567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27669|A Novel Mutation of the Spectrin Gene|Case Report: A Novel Mutation of the Spectrin Gene in a Family of Northern European Descent Is Associated With Three Different Phenotypes||University of Utah|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Members from a family of northern European descent in which members had different        erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.|February 2009|February 18, 2009|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723567||152539|
NCT00723580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Act1|Actigraphic Analysis of Treatment Response|Actigraphic Analysis of Treatment Response in a Six Year Old Girl With Kabuki Syndrome||Child Psychopharmacology Institute|No|Completed|May 2008|August 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1|||Female|2 Years|10 Years|No|||July 2015|July 28, 2015|July 24, 2008||No||No|September 22, 2010|https://clinicaltrials.gov/show/NCT00723580||152538|This single case study has limited generalizability in that these results may not apply to others. The methods explored, however, may apply to others and Single-subject repeated measurements can provide valuable clinical and scientific data.
NCT00724178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63666 (completed)|The Effect of Vitamin D and Calcium on Bone in Pediatric HIV|The Effect of Vitamin D and Calcium on Bone in Pediatric HIV||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|July 2003|December 2006|Actual|August 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|6 Years|16 Years|No|||January 2010|January 14, 2010|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724178||152492|
NCT00721812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111406|A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686|A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 After Single and Repeated Oral Dosing in Healthy Volunteers Using a Dose-Escalating, Randomized, Placebo-Controlled Study Design||GlaxoSmithKline||Completed|September 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|87|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|July 22, 2008||||No||https://clinicaltrials.gov/show/NCT00721812||152668|
NCT00722111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4796-R|Exercise for Swallowing Problems After Stroke|Rehabilitation Exercise for Dysphagia Subsequent to Stroke||VA Office of Research and Development|No|Completed|February 2011|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Both|45 Years|N/A|No|||September 2013|September 27, 2013|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722111||152646|
NCT00722124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006365|S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence|S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence||Mayo Clinic|No|Completed|September 2008|June 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 5, 2011|July 23, 2008||No||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00722124||152645|
NCT00722423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-101|An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes|An Integrated Care Model for Improving HCV Patient Outcomes|HCV|VA Office of Research and Development|No|Completed|May 2009|May 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|364|||Both|18 Years|75 Years|No|||September 2015|September 16, 2015|July 23, 2008||No||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00722423||152622|
NCT00722982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-stem AMT|Migration Pattern of C-stem AMT Versus Exeter in Total Hip Arthroplasty|Migration Pattern of C-stem AMT Versus Exeter in Total Hip Arthroplasty||Oslo University Hospital|No|Active, not recruiting|July 2008|July 2015|Anticipated|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|70|||Both|30 Years|80 Years|No|Probability Sample|70 patients admitted to orthopedic clinic Ringerike hospital for coxarthrosis are planned        to be included in stydy. The all should agree in a written form to participate in study.        They are randomized to be operated THA with Exeter- or C-stem AMT femur prostesis.        Marathon acetabular prosthesis will be used for all patients included.|November 2014|November 21, 2014|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00722982||152581|
NCT00723593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080187|Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease|Natural History and Pathophysiology of Gastrointestinal Graft Versus Host Disease||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2008|February 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 19, 2014|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723593||152537|
NCT00723606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281152|A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation|A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia||Pfizer|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|376|||Both|18 Years|65 Years|No|||June 2015|June 30, 2015|July 25, 2008|Yes|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT00723606||152536|
NCT00721214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11328|5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome|A Phase II Study of the Use of 5-Azacytidine as Pre-Transplant Cytoreduction Prior to Allogeneic Stem Cell Transplantation for High Risk Myelodysplastic Syndromes||Virginia Commonwealth University|Yes|Completed|July 2008|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|70 Years|No|||February 2016|February 3, 2016|July 22, 2008|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT00721214||152713|
NCT00722150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1396|Artemisinin Resistance in Cambodia II|Artemisinin Resistance in Cambodia II|ARC II|Armed Forces Research Institute of Medical Sciences, Thailand|Yes|Completed|July 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|143|||Both|18 Years|65 Years|No|||January 2011|January 24, 2011|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722150||152643|
NCT00721617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009277|FFA Hypertension and Inflammation in Lean and Obese Subjects|Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects|FFAADA|Emory University|Yes|Completed|April 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 23, 2015|June 26, 2008|Yes|Yes||No|May 11, 2015|https://clinicaltrials.gov/show/NCT00721617||152683|A larger sample size and inclusion of subjects from different ethnicities would be required to generalize the results of this study. Study used healthy volunteers--outcomes cannot be applied to patients with diabetes mellitus or insulin resistance
NCT00721890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-126639|Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma|Phase II Study: Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma|DBGT-OC-CR|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Completed|June 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Female|N/A|N/A|No|||October 2013|October 22, 2013|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721890||152662|
NCT00721318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck35016|A Prevalence Study of Chronic Widespread Pain (CWP) Among Patients With Rheumatoid Arthritis (RA) and Control Population in Tallinn and Harjumaa County|A Prevalence Study of Chronic Widespread Pain (CWP) Among Patients With Rheumatoid Arthritis (RA) and Control Population Matched by Gender, Age and Place of Residence in Tallinn and Harjumaa County||Estonian Society for Rheumatology|No|Active, not recruiting|May 2008|May 2010|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|6000|||Both|16 Years|N/A|No|Non-Probability Sample|Study population: Tallinn and Harju County (Estonia), population 552,000. The residents of        both Tallinn and Harju County receive national health care services.|July 2008|July 23, 2008|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721318||152706|
NCT00721331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-197-001|A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers|A Phase I, Single-Center, Randomized, Vehicle-Controlled Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers||Zalicus|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2008|September 24, 2008|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721331||152705|
NCT00722215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/WCRC/02|Endothelin Receptor Antagonism in Proteinuric Nephropathy|The Systemic & Renal Effects of Endothelin Receptor Antagonism in Proteinuric Nephropathy||University of Edinburgh|No|Completed|May 2006|December 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|22|||Both|18 Years|70 Years|No|||August 2006|July 23, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722215||152638|
NCT00722228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0359-08-HMO-CTIL|Allogeneic Whole Cell Cancer Vaccine for Metastatic Epithelial Tumors|||Hadassah Medical Organization||Not yet recruiting||||||Phase 1/Phase 2|Interventional|N/A|||||||Both|18 Years|N/A|No|||July 2008|July 24, 2008|July 23, 2008||||No||https://clinicaltrials.gov/show/NCT00722228||152637|
NCT00722241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-300012, Rev01|Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System|Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System||DexCom, Inc.|No|Completed|May 2008|July 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory (non-hospitalized) individuals with type 1 diabetes or insulin-treated type 2        diabetes selected from endocrinology clinics within the United States|July 2008|July 24, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722241||152636|
NCT00722254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17806|Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder|Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder||University of Utah|No|Terminated|June 2006|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|Samples With DNA|Whole Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from primary pulmonary hypertension or myelofibrosis (primary or        secondary)|March 2016|March 17, 2016|July 23, 2008||No|This study was stopped due to poor enrollment numbers|No||https://clinicaltrials.gov/show/NCT00722254||152635|
NCT00722566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138 MMY 3021|A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma|An Open-Label Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma||Millennium Pharmaceuticals, Inc.|No|Completed|July 2008|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|July 23, 2008|Yes|Yes||No|August 30, 2011|https://clinicaltrials.gov/show/NCT00722566||152612|
NCT00722800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080p-000843|A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS|A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of YAZ Compared With Placebo In The Treatment Of Hidradenitis Suppurativa||Massachusetts General Hospital|No|Terminated|October 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Female|14 Years|45 Years|No|||January 2014|January 16, 2014|July 24, 2008|Yes|Yes|Poor recruitment|No|May 6, 2013|https://clinicaltrials.gov/show/NCT00722800||152595|Very small sample size.
NCT00723398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26970|Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention|Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer||Milton S. Hershey Medical Center|No|Active, not recruiting|March 2009|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|372|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723398||152552|
NCT00723411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/P3/07/4|A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)|A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (EU)||Diamyd Therapeutics AB|Yes|Terminated|July 2008|August 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|334|||Both|10 Years|20 Years|No|||October 2011|October 7, 2011|July 24, 2008||No|The primary endpoint at 15 months was not met.|No||https://clinicaltrials.gov/show/NCT00723411||152551|
NCT00723255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00598|Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|September 2008|||July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|18 Years|N/A|No|||September 2014|July 6, 2015|July 25, 2008|Yes|Yes||No|May 11, 2015|https://clinicaltrials.gov/show/NCT00723255||152562|
NCT00723554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-063A402|Iloprost Power Disc-15 in Pulmonary Arterial Hypertension|A Phase IIIb, Multicenter, Open-label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 (PD-6) to Power Disc-15 (PD-15) With the I-neb® AAD®|INHALE-15|Actelion|No|Terminated|July 2008|April 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|85 Years|No|||March 2013|March 27, 2013|July 24, 2008|No|Yes|sponsor's decision|No|January 14, 2013|https://clinicaltrials.gov/show/NCT00723554||152540|
NCT00724477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05103|Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)|PRAGMATIC (This is the True Official Title of the Protocol for This Study)||Merck Sharp & Dohme Corp.|No|Completed|October 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1663|||Both|18 Years|N/A|No|Probability Sample|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as        a monotherapy, and are treated with INEGY|September 2015|September 28, 2015|July 25, 2008||No||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00724477||152469|
NCT00720642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intact 06-06|Percutaneous Excision Trial|Percutaneous Excision Trial (I-Pet): A Multi-Center Clinical Study Of The Intact Breast Lesion Excision System (Bles) To Demonstrate That A Definitive Diagnosis Can Be Made From The Tissue Sample Collected With The Intact Bles.|I-PET|Intact Medical Corporation|No|Completed|July 2006|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1170|Samples Without DNA|Breast lesion tissue|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with an imaged breast abnormality found with mammography or sonography whose        initial biopsy will be taken with the Intact BLES.|September 2012|September 11, 2012|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720642||152755|
NCT00733161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20795203|Effect of Passive Exercise on Systemic Endothelial Function in Elderly Patients With Chronic Heart Failure|Effect of Passive Exercise on Systemic Endothelial Function in Elderly Patients With Chronic Heart Failure||Kyoto University||Completed|August 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|65 Years|N/A|No|||July 2010|July 6, 2010|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733161||151807|
NCT00733174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101797|Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance|Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance||Denver Research Institute|Yes|Recruiting|March 2004|||January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|75 Years|No|||August 2008|August 11, 2008|August 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733174||151806|
NCT00722709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAstudy|Intraperitoneal Local Anaesthetic in Colonic Surgery|Randomised Double Blind Trial to Investigate the Effects of Intraperitoneal Local Anaesthetic Following Colonic Surgery.||University of Auckland, New Zealand|Yes|Completed|September 2008|January 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|July 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722709||152601|
NCT00723268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286293|Evaluation of Therapeutic Effect of 0.5 mg Colchicine and 5 mg Prednisolone on Oral Aphthae|Evaluation of Therapeutic Effect of 0.5 mg Colchicine and 5 mg Prednisolone on Oral Aphthae||Mashhad University of Medical Sciences|Yes|Active, not recruiting|May 2007|||August 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||July 2008|July 28, 2008|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723268||152561|
NCT00723931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04123|PegIntron Injection Surveillance Plan (Study P04123)|PegIntron Injection Surveillance Plan||Merck Sharp & Dohme Corp.|No|Completed|June 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1267|||Both|N/A|N/A|No|Probability Sample|Surveillance will be conducted at digestive departments of internal medicine in university        or general hospitals where participants with chronic hepatitis C are generally treated.|November 2015|November 2, 2015|July 25, 2008|No|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00723931||152511|
NCT00724191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00051052|Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)|Quantitation of Human Brain Tumor Therapy Response by MR||University of Michigan|No|Active, not recruiting|September 1999|December 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|190|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00724191||152491|
NCT00725062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004LS034|Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant|Phase I-II Dose Escalation Study of CD4+CD25+ Cells in Adult Patients Undergoing HLA-Identical Sibling Donor Peripheral Blood Progenitor Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Terminated|June 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||November 2012|November 6, 2012|July 29, 2008|Yes|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00725062||152424|
NCT00720967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-058 (NAC 08018)|Preop Hemodialysis or Intraop Ultrafiltration for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery|Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial|SeRenaD-CPB|University Hospital, Geneva|No|Not yet recruiting|November 2008|November 2012|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|95 Years|No|||July 2008|July 22, 2008|July 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720967||152732|
NCT00734474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11422|A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin|A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin||Eli Lilly and Company|Yes|Completed|August 2008|July 2012|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|1202|||Both|18 Years|75 Years|No|||March 2015|March 31, 2015|August 12, 2008|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00734474||151706|
NCT00721825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moleac|Study of NeuroAid In Enhancing Recovery After Stroke|A Double-Blinded, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of a Traditional Chinese Medicine NeuroAid In Enhancing Recovery After Stroke (TIERS)|TIERS|Moleac Pte Ltd.|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|80 Years|No|||July 2008|July 23, 2008|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721825||152667|
NCT00722137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-LYM-3002|Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma|A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant||Millennium Pharmaceuticals, Inc.||Active, not recruiting|May 2008|June 2017|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|487|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|July 23, 2008|Yes|Yes||No|November 8, 2014|https://clinicaltrials.gov/show/NCT00722137||152644|
NCT00722995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K060213|Surgical Treatment for Morbid Obesity by Sleeve Gastrectomy Versus Gastric Bypass|Surgical Treatment for Morbid Obesity by Sleeve Gastrectomy Versus Gastric Bypass. Study Comparing Complications, Efficacy and Quality of Life.|SLEEVE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|January 2008|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|June 1, 2015|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00722995||152580|
NCT00721357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6341-W|Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke|Skeletal Muscle Properties and the Metabolic Cost of Walking Post-Stroke||VA Office of Research and Development|No|Completed|August 2008|September 2013|Actual|July 2012|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|30|None Retained|None retained|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|community sample|July 2015|July 29, 2015|July 21, 2008||No||No|January 8, 2015|https://clinicaltrials.gov/show/NCT00721357||152703|
NCT00721630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-025|Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer|Phase II Study of a Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|July 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721630||152682|
NCT00721903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-0124|Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies|3D Breast Ultrasound In Predicting Response to Breast Cancer Therapies||University of Michigan|Yes|Completed|March 2000|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|88|||Female|25 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721903||152661|
NCT00721916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taiho10020390|Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer|Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus 5-FU, l-LV and Oxaliplatin Combination Therapy (mFOLFOX6) in Patients With Untreated Metastatic Colorectal Cancer||Taiho Pharmaceutical Co., Ltd.|Yes|Completed|July 2008|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|20 Years|N/A|No|||October 2012|October 31, 2012|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721916||152660|
NCT00722267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-REU-DUM-2007/1|European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients|Patient Perception of Symptom Variability. A Cross-sectional Study of Patients With Severe COPD.||AstraZeneca|No|Completed|July 2008|February 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|7400|||Both|45 Years|N/A|No|Probability Sample|Participating physicians (GPs and Respiratory physicians) will be asked to recruit 4        patients (on average). The first patients presenting for a consultation for any reason,        who meet eligibility criteria, and give informed consent, should be enrolled.|July 2009|July 24, 2009|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722267||152634|
NCT00722579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC08-01|A Study of the Presillion Stent in de Novo Coronary Lesions|A Non-Randomized, Multi-Center, Single-Arm Safety Study of the Presillion Stent in de Novo Native Coronary Artery Lesions|PRESILLION|Cordis Corporation|Yes|Completed|July 2008|March 2010|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||June 2010|June 11, 2010|July 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722579||152611|
NCT00722813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00003409|Cost Effectiveness and Utility of Computed Tomography Angiography (CTA) and Cardiac Cath|Cost Effectiveness and Utility of Coronary Artery Computed Tomography Angiography (CTA) in Screening for Coronary Artery Disease||University of Michigan|Yes|Completed|October 2006|November 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|N/A|No|Probability Sample|Subjects who have had both CTA and Cardiac catherizations|November 2013|November 20, 2013|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722813||152594|
NCT00723099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2239.00|Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer|Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen||Fred Hutchinson Cancer Research Center|Yes|Recruiting|June 2008|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|N/A|69 Years|No|||November 2015|November 13, 2015|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00723099||152573|
NCT00728364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFD-CKD-Austria-2008|Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy|A Case Finding Study for Anderson-Fabry Disease Among Patients With Chronic Kidney Disease Not on Renal Replacement Therapy||Klinikum Wels-Grieskirchen|No|Completed|October 2008|December 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|4353|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with chronic kidney disease KDOQI stage 1-5 attending outpatient nephrology        clinics in Austria and willing to participate|April 2012|April 10, 2012|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728364||152172|
NCT00723918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS32228_NARC011|Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy|NARC 011: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Methadone and Combination of Methadone and SAB378 in HIV-associated Painful Peripheral Neuropathy||Washington University School of Medicine|Yes|Terminated|April 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||January 2011|January 11, 2011|July 28, 2008|Yes|Yes|Withdrawal of pharmaceutical support from Novartis - no participants randomized|No||https://clinicaltrials.gov/show/NCT00723918||152512|
NCT00720655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISH6417|Effects of Fatty and Lean Fish Intake on Cardiovascular Risk Factors in Subjects With Coronary Heart Disease|Effects of Fatty and Lean Fish Intake on Cardiovascular Risk Factors in Subjects With Coronary Heart Disease||University of Eastern Finland|No|Completed|August 2005|||December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|N/A|70 Years|No|||January 2014|January 21, 2014|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720655||152754|
NCT00732940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1006-1070|Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)||Human Genome Sciences Inc.|Yes|Terminated|October 2008|March 2012|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||March 2013|August 1, 2013|August 8, 2008|Yes|Yes|Sponsor terminated study for business reasons.|No|April 7, 2011|https://clinicaltrials.gov/show/NCT00732940||151824|
NCT00733187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-384|Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869|A Pharmacokinetic Study to Evaluate the Effect of Food on the Oral Bioavailability and Effect of Diurnal Variation on the Pharmacokinetics of ABT-869||AbbVie|No|Completed|February 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|18 Years|N/A|No|||January 2013|February 7, 2013|August 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733187||151805|
NCT00733486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 02/41|A Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS®) Complete Anterior-Posterior Glide (APG) Mobile Bearing Knee|A Prospective, Non-Comparative Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS®) Complete Anterior-Posterior Glide (AP Glide) Mobile Bearing Knee System in Primary Knee Arthroplasty||DePuy International|No|Terminated|August 2005|February 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|233|||Both|45 Years|85 Years|No|||June 2015|June 8, 2015|August 11, 2008|No|Yes|The study was terminated at 2 years as investigators were unable to continue participation in    the study.|No||https://clinicaltrials.gov/show/NCT00733486||151782|
NCT00733824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0897 / 201105349|Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma|A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Autologous Peripheral Blood Stem Cells Collected From Patients With Lymphoma||Washington University School of Medicine|No|Completed|November 2008|September 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|61|||Both|18 Years|75 Years|No|||February 2014|February 13, 2014|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733824||151756|
NCT00734123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDETMA_08|Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.|Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases.|PRIMARIA|Hospital Arnau de Vilanova|Yes|Recruiting|April 2008|May 2013|Anticipated|April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2948|||Both|40 Years|74 Years|Accepts Healthy Volunteers|||August 2008|August 13, 2008|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00734123||151733|
NCT00734136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-040|Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome|Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome||Lahey Clinic|No|Terminated|May 2005|February 2009|Actual|July 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|N/A|No|||February 2009|February 17, 2009|August 12, 2008||No|Insufficient findings for data analysis|No||https://clinicaltrials.gov/show/NCT00734136||151732|
NCT00734487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001749|AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study|Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study|A2ASDOCT|Duke University|No|Completed|June 2008|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|470|||Both|50 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|The A2A SDOCT study will recruit AMD subjects from the AREDS 2 study population at 4 AREDS        2 Study Centers. Controls will be recruited from Duke University Eye Center and Emory        University.|February 2015|October 20, 2015|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734487||151705|
NCT00734149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008089|Bortezomib With Melphalan and Prednisone for Multiple Myeloma|A Prospective Study of Bortezomib in Combination With Melphalan and Prednisone for Patients With Previously Untreated Multiple Myeloma|MVP|Duke University|No|Completed|July 2004|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|December 26, 2007|Yes|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00734149||151731|
NCT00729963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER911|Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients|Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea||Laval University|Yes|Completed|January 2004|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||April 2013|April 9, 2013|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00729963||152051|
NCT00729976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091/08|Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.|Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.||Assaf-Harofeh Medical Center|No|Recruiting|September 2008|June 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Months|5 Years|No|||March 2010|April 4, 2011|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00729976||152050|
NCT00730275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-081|A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)|A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents||Merck Sharp & Dohme Corp.|No|Completed|July 2008|February 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|35|||Both|10 Years|17 Years|No|||August 2015|August 7, 2015|August 6, 2008|No|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00730275||152027|
NCT00730288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD10|Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects|Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine||Sanofi|No|Completed|August 2006|January 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|35|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730288||152026|
NCT00721929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0148|Lipid-poor Adrenal Masses: Evaluation With Chemical Shift MRI|Lipid-poor Adrenal Masses: Evaluation With Chemical Shift MRI||University of Michigan||Completed|October 2003|July 2012|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721929||152659|
NCT00721955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-302|Staccato® Loxapine Treatment of Agitation in Bipolar Disorder Patients|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation|AMDC-004-302|Alexza Pharmaceuticals, Inc.|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||October 2008|October 22, 2008|July 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721955||152658|
NCT00722280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030180|Human Upper Extremity (Hand and Forearm) Allotransplantation|The Pittsburgh Protocol in Human Upper Extremity Allotransplantation||University of Pittsburgh|Yes|Enrolling by invitation|December 2008|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722280||152633|
NCT00722293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG109603|A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors|A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics Dose Escalation of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors||GlaxoSmithKline|No|Completed|July 2008|February 2014|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|111|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722293||152632|
NCT00722592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-009|Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)|A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination, Versus PLD Alone, in Subjects With Platinum-Resistant Ovarian Cancer|PRECEDENT|Endocyte|Yes|Completed|September 2008|December 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Female|18 Years|N/A|No|||December 2014|December 18, 2014|July 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722592||152610|
NCT00722826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H627-29142-02|Tetralogy of Fallot Seed Grant|MRI Assessment of Right Ventricular Function in Patients After Repair of Tetralogy of Fallot||University of California, San Francisco|Yes|Completed|June 2007|||June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|82|||Both|13 Years|N/A|No|Non-Probability Sample|This is a cross sectional study. Patients with pulmonary regurgitation after repair of        tetralogy of Fallot assisted in the adult or pediatric congenital heart disease clinic or        referred for clinical MRI studies at our institution will be invited to participate in the        study.|May 2015|May 29, 2015|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722826||152593|
NCT00723112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20716|The Role of Erythropoietin in Myelodysplastic Syndrome|The Role of Erythropoietin in Myelodysplastic Syndrome||University of Utah|No|Completed|February 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects diagnosed with myelodysplastic syndrome|November 2010|November 22, 2010|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723112||152572|
NCT00728104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090|The Use of L-Carnitine And CoQ10 Supplements In the Treatment of Cyclic Vomiting Syndrome (CVS)|Co-Enzyme Q10, L-Carnitine and Amitriptyline Usage in Cyclic Vomiting Syndrome (CVS): A Research Study||Medical College of Wisconsin|No|Enrolling by invitation|October 2007|December 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||4|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|Cyclic Vomiting Syndrome (CVS) is a condition where children and adults have repeated        attacks of severe vomiting, nausea, abdominal pain, headaches, and tiredness. These        episodes can last from several hours to several days.|September 2015|September 3, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728104||152192|
NCT00728351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237A2309|Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)|A Multicenter, Double-blind, Randomized Study to Compare the Efficacy of 24 Weeks Treatment With Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) Versus Metformin Monotherapy (1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.||Novartis|Yes|Completed|June 2008|||February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|78 Years|No|||January 2013|January 2, 2013|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00728351||152173|
NCT00728650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAB11119|A Retrospective Review of Malignant Liver Tumors|A Retrospective Review of Malignant Liver Tumors||University of Oklahoma|No|Completed|October 2003|June 2011|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|228|||Both|20 Years|90 Years|No|Non-Probability Sample|Primary care clinic and patients treated at St. John Medical Center in Tulsa, OK|February 2012|February 6, 2012|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728650||152150|
NCT00732602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0058|The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes|The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes||University Hospital, Gentofte, Copenhagen|No|Completed|January 2008|||August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|8|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00732602||151849|
NCT00732615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1-11-040|Use of NPSP558 in the Treatment of Hypoparathyroidism|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism|REPLACE|Shire|Yes|Completed|December 2008|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|85 Years|No|||March 2015|November 10, 2015|August 8, 2008|Yes|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT00732615||151848|
NCT00732927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU/OVR/001/2001|Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion|Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study|PARVO|Università degli Studi dell'Insubria|No|Terminated|July 2002|September 2007|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|85 Years|No|||August 2008|August 7, 2008|August 7, 2008||No|slow recruitment rate|No||https://clinicaltrials.gov/show/NCT00732927||151825|
NCT00734175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 251|Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine|Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H6N1 (6-2) AA ca Recombinant (A/Teal/Hong Kong/W312/1997 (H6N1) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H6N1 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|September 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2008|August 5, 2009|August 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00734175||151729|
NCT00734188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-6D2-B|Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma|A Multi-Center, Open-Label, Phase I, Dose-Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma||Pain Therapeutics|No|Completed|January 2009|June 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734188||151728|
NCT00733200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chenxp002|Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?|Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?||Huazhong University of Science and Technology|Yes|Completed||||||N/A|Interventional|N/A|1||||||Both|26 Years|72 Years|No|||August 2008|December 10, 2009|August 8, 2008||||No||https://clinicaltrials.gov/show/NCT00733200||151804|
NCT00733499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 05/28|A Study to Determine the Difference in Low Contact Stress (LCS) Duofix Versus Low Contact Stress (LCS) Porocoat Knee Systems|A Prospective, Randomised, Single Blinded Study Comparing the Pain, Biological Fixation and Outcomes of Patients With LCS Complete Duofix or LCS Porocoat Knee Systems||DePuy International|No|Active, not recruiting|September 2006|November 2020|Anticipated|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|90 Years|No|||September 2015|September 23, 2015|August 11, 2008|Yes|Yes||No|March 22, 2014|https://clinicaltrials.gov/show/NCT00733499||151781|
NCT00733837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0627080141|Cervical Multifidus Muscle Function|||Logan College of Chiropractic|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2008|December 17, 2008|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733837||151755|
NCT00733850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLT-PANC-001|Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer|A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer||KangLaiTe USA|Yes|Completed|August 2008|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733850||151754|
NCT00734162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0115|Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection|A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection||Gilead Sciences|Yes|Completed|December 2008|December 2015|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|12 Years|17 Years|No|||February 2016|February 2, 2016|August 13, 2008|Yes|Yes||No|October 8, 2012|https://clinicaltrials.gov/show/NCT00734162||151730|
NCT00734500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000637|Anidulafungin PK in Infants and Toddlers|Anidulafungin PK in Infants and Toddlers||Duke University||Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|24 Months|No|||November 2012|November 16, 2012|August 13, 2008|No|Yes||No|August 31, 2011|https://clinicaltrials.gov/show/NCT00734500||151704|
NCT00729989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804774|Efficacy and Safety of Gastric Suctioning During Neonatal Resuscitation|Efficacy and Safety of Gastric Suctioning During Neonatal Resuscitation- A Randomized Clinical Trial||University of Iowa|Yes|Not yet recruiting|August 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5000|||Both|N/A|7 Days|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00729989||152049|
NCT00730002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00000714|Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus|Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus||University of Michigan|No|Completed|March 2008|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|66|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00730002||152048|
NCT00730301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUROPT 07-074-0507|EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema|A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema|EUROPT|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|Yes|Recruiting|July 2007|||September 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|75 Years|No|||August 2008|August 5, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730301||152025|
NCT00721682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/6-K|Evaluation of Acute Pain in Maltreated Children|Evaluation of Acute Pain in Maltreated Children : a Prospective, Multicentric and Controlled Study|ANTALPED|Nantes University Hospital|No|Completed|November 2008|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|78|||Both|N/A|6 Years|No|Non-Probability Sample|maltreated children who consult in paediatric emergencies for recent fracture or burn|October 2013|October 23, 2013|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721682||152678|
NCT00721695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-005|Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.|Randomized, Controlled, Double-Masked, Multicenter, Exploratory Study of the Clinical Benefit and Safety of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR) Using a Coaxial Phacoemulsification Process||Omeros Corporation|No|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|50 Years|N/A|No|||July 2014|July 16, 2014|July 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721695||152677|
NCT00721968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-005|Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract|A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Clinical Investigation Of The Trabecular Micro-Bypass Stent Model GTS400 In Conjunction With Cataract Surgery||Glaukos Corporation|Yes|Completed|March 2007|August 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|July 23, 2008|Yes|Yes||No|April 18, 2013|https://clinicaltrials.gov/show/NCT00721968||152657|There are no limitations and caveats to report
NCT00726687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBL1005|Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors|Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors||Ziopharm|No|Active, not recruiting|June 2008|June 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726687||152301|
NCT00727194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-001|Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients With Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment With Immunosuppressants||Alexion Pharmaceuticals|Yes|Completed|October 2008|July 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|80 Years|No|||July 2010|November 17, 2011|July 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00727194||152262|
NCT00727207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597004|Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy|Phase II Trial on Efficacy of mTOR Inhibitor RAD001 as Maintenance Therapy for Patients Above 60 Years in Mantle Cell Lymphoma After First and Second Line Chemotherapy||Technische Universität München||Terminated|May 2008|September 2014|Anticipated|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|35|||Both|40 Years|N/A|No|||December 2012|December 13, 2012|July 31, 2008||No|Lack of participations (8 of 25)|No||https://clinicaltrials.gov/show/NCT00727207||152261|
NCT00727545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRJ-1|Effect of Rice Fortification With Iron on Anemia Among Children|Effect of Weekly Rice Fortification With Iron on Frequency of Anemia and Hemoglobin Concentration Among Children Attending Public Day Care Centers From Rio de Janeiro||Universidade Federal do Rio de Janeiro|Yes|Completed|March 2006|December 2006|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|385|||Both|12 Months|60 Months|Accepts Healthy Volunteers|||July 2008|August 4, 2008|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727545||152235|
NCT00727831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599206|Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|Phase I Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients With Primary Central Nervous Lymphoma (PCNSL)||University College, London|Yes|Completed|July 2008|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|August 1, 2008||||No||https://clinicaltrials.gov/show/NCT00727831||152213|
NCT00727844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-I-N167|Linezolid to Treat Extensively-Drug Resistant Tuberculosis|A Phase 2a, Randomized, 2-Arm, Open-Label, Clinical Trial of the Efficacy of Linezolid Combined With Antituberculous Therapy in Subjects With Extensively Drug-Resistant (XDR) Pulmonary Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2008|November 2014|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|N/A|No|||May 2014|February 12, 2016|August 1, 2008|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT00727844||152212|Small sample size
NCT00728377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK74876|An Exercise Intervention to Prevent Gestational Diabetes|An Exercise Intervention to Prevent Recurrent GDM||University of Massachusetts, Amherst|Yes|Completed|July 2007|November 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|488|||Female|18 Years|40 Years|No|||January 2015|January 9, 2015|August 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00728377||152171|
NCT00732316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600347|Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome|HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY||Asan Medical Center|No|Completed|April 2008|May 2011|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|N/A|75 Years|No|||July 2012|July 16, 2012|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732316||151871|
NCT00732329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-DEMENZ-44-074|Effectiveness of Home Based Occupational Therapy for Dementia.|Effectiveness of an Optimized Home Based Occupational Therapy for Patients With Dementia.|ERGODEM|Technische Universität Dresden|No|Completed|August 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|55 Years|N/A|No|||February 2015|February 10, 2015|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732329||151870|
NCT00733512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-019|Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL)|Surgeon Experience ReSTOR Aspheric +4 Intraocular Lens (IOL)||Alcon Research||Completed|June 2007|||March 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|146|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects were selected from primary care clinics.|April 2010|April 14, 2010|August 8, 2008||No||No|March 24, 2010|https://clinicaltrials.gov/show/NCT00733512||151780|
NCT00732628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM13883|Evaluating Outcomes in the Placement of Boomerang Percutaneous Device|Technical and Clinical Outcomes Following Placement of Boomerang Percutaneous Closure Device After Cerebral Angiography or Neurointerventional Procedures||University of Michigan|No|Terminated|January 2008|September 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|patients having a neurointerventional procedure, such as a cerebral angiography|February 2009|February 20, 2009|July 25, 2008||No|Physician is no longer associated with the Univ. of Michigan Medical Center|No||https://clinicaltrials.gov/show/NCT00732628||151847|
NCT00732641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01972|Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)|Phase III Randomized, Prospective Multi-center Trial of PEG-Interferon α-2b as a Maintenance Therapy, Compared to Observation, in Patients With Multiple Myeloma Who Responded to Induction Therapy (Protocol No P01972)||Merck Sharp & Dohme Corp.|Yes|Completed|December 2000|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|85 Years|No|||October 2015|October 8, 2015|August 8, 2008|Yes|Yes||No|October 27, 2011|https://clinicaltrials.gov/show/NCT00732641||151846|
NCT00734201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V24343-1Ob-03|Safety and Efficacy of Low Doses of V24343 in Obese Subjects|A Double-blind, Placebo-controlled, Parallel Group Study of the Effect of V24343 on Blood Pressure and Weight in Obese Subjects||Vernalis (R&D) Ltd|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|32|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00734201||151727|
NCT00734526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0059|Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma|A Phase I Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma||M.D. Anderson Cancer Center|No|Completed|December 2008|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734526||151702|
NCT00734513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011905|Partner-Assisted Emotional Disclosure for GI Cancer|Partner Assisted Emotional Disclosure for GI Cancer||Duke University|No|Completed|January 2003|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||August 2008|April 9, 2013|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734513||151703|
NCT00730015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-303|Trial of Linaclotide in Patients With Chronic Constipation|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Chronic Constipation||Ironwood Pharmaceuticals, Inc.||Completed|August 2008|October 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|643|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|August 5, 2008|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00730015||152047|
NCT00730314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI #07-00119|Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells|Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor||Children's Hospital Los Angeles|Yes|Recruiting|August 2008|||August 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|N/A|21 Years|No|||June 2011|June 22, 2011|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730314||152024|
NCT00730327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-005|A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects|Safety and Effectiveness of the BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects||Apollo Endosurgery, Inc.|No|Completed|June 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|448|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|August 6, 2008|Yes|Yes||No|August 27, 2015|https://clinicaltrials.gov/show/NCT00730327||152023|
NCT00730626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-119|Dose Response Study of a Fermented Yogurt on the Immune System and Gut Health|Dose Response Study of the Impact of a Yogurt Containing Bifidobacterium Lactis BB-12 and Lactobacillus Acidophilus LA-5 on the Immune System and Gut Health.|PRO|Laval University|No|Completed|August 2008|May 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 19, 2009|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730626||152000|
NCT00730951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107460|The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation|The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation||St. Michael's Hospital, Toronto|No|Completed|June 2007|March 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|18|||Both|18 Years|70 Years|No|||July 2015|July 30, 2015|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730951||151975|
NCT00730964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-191-003|A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.|A Post-marketing Surveillance Study of the Occurrence of Serious Adverse Reactions Among Patients Who Receive Optison in Routine Medical Practice|OSSAR|GE Healthcare|Yes|Completed|May 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1039|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|August 5, 2008|No|Yes||No|April 5, 2012|https://clinicaltrials.gov/show/NCT00730964||151974|
NCT00730977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-DEV-101b|A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device|A Pilot Study to Investigate the Tolerability of Inhaled Dry Powder Mannitol (IDPM) Administered Via a Novel Dry Powder Inhaler Device in Healthy Individuals and Subjects With Bronchiectasis.||Pharmaxis|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730977||151973|
NCT00731211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GU 56|Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma|A Phase II Trial of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Sunitinib or Bevacizumab||SCRI Development Innovations, LLC|No|Completed|September 2008|September 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|August 5, 2008|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00731211||151955|
NCT00731224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DAU01|Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.|A 24-week, Multi-center, Open-label Evaluation of Compliance and Tolerability of the Once-daily 10 cm² Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.|CARE|Novartis||Completed|July 2008|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|380|||Both|50 Years|N/A|No|||March 2013|March 28, 2013|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731224||151954|
NCT00727220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0312-13|Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes|A Prospective Study of the Impact of CSII Therapy in Young Children With Type 1 DM||Indiana University|No|Active, not recruiting|January 2004|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|2 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children diagnosed with type 1 diabetes for at least one year at the time of study. In        addition, children must be under the age of 5 years|April 2012|April 1, 2012|July 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00727220||152260|
NCT00727233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080180|Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas|Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas||National Institutes of Health Clinical Center (CC)||Completed|July 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|3 Years|18 Years|No|||May 2012|October 9, 2014|July 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00727233||152259|
NCT00727558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0808|A Comparison of Daily Disposable Contact Lenses.|||Johnson & Johnson Vision Care, Inc.||Completed|July 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|60 Years|No|||May 2015|May 5, 2015|July 30, 2008|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00727558||152234|
NCT00727857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-OPIMET-008|Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.|A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 Diabetes||Takeda|No|Completed|June 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|600|||Both|18 Years|N/A|No|||July 2011|July 27, 2011|July 30, 2008|Yes|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00727857||152211|
NCT00728117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC3|Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants|Should Very Low Birth Weight Infants Receive Enteral Nutrition During Indomethacin or Ibuprofen Treatment of a Patent Ductus Arteriosus? A Multi-Center Randomized Controlled Trial||University of California, San Francisco|Yes|Completed|July 2008|September 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|177|||Both|23 Weeks|33 Weeks|No|||November 2012|November 8, 2012|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728117||152191|
NCT00728130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RON-SCCI 08-003-1|Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients|Prospective Study to Assess the Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Patients With Carcinoma of the Upper Aerodigestive Tract||Southern Illinois University|No|Completed|May 2008|June 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|July 31, 2008|No|Yes||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00728130||152190|
NCT00732043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUP-0205-1XX|Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer|A 48-Month Extension to the Randomized, Double-blind, Placebo-Controlled Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer||Roll International Corporation|Yes|Active, not recruiting|December 2007|January 2015|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|200|||Male|18 Years|N/A|No|||March 2012|March 15, 2012|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732043||151892|
NCT00732056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRN163L CP14A010|A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer|A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer||Geron Corporation|No|Completed|July 2008|March 2012|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732056||151891|
NCT00733525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059304|Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa|Stepped Care vs Best Available Care for Bulimia Nervosa||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2000|August 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|293|||Female|18 Years|N/A|No|||May 2014|May 23, 2014|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733525||151779|
NCT00733538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFM-04-01|Stage I Multiple Myeloma Treatment|Stage I Multiple Myeloma Treatment|IFM-01-04|Centre Hospitalier Universitaire de Nice|No|Active, not recruiting|December 2004|November 2012|Anticipated|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||February 2009|March 23, 2012|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733538||151778|
NCT00733551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOT109681|Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.|A Randomized, Double-blind, Ascending Dose Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Repeat Doses of Motilin Receptor Agonist GSK962040 in Male and Female Healthy Volunteers||GlaxoSmithKline|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|August 12, 2008||||No||https://clinicaltrials.gov/show/NCT00733551||151777|
NCT00733863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAD106A2201|Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.|A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106||Novartis||Completed|July 2008|||February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|85 Years|No|||May 2010|May 10, 2010|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00733863||151753|
NCT00734552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-KAPDRRF|Study to Evaluate the Protective Effect of α-Keto Acid With Low-protein Diet on Renal Function in PD Patients|Randomized, Open-Label, Prospective Study to Evaluate the Protective Effect of α-Keto Acid With Low-protein Diet on Residual Renal Function (RRF) in Peritoneal Dialysis Patients||Sun Yat-sen University|Yes|Completed|October 2007|May 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|75 Years|No|||May 2015|May 20, 2015|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734552||151700|
NCT00734565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M37P1|Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b|A Phase I, Single-arm, Single-center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months||Novartis||Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|2 Months|20 Months|Accepts Healthy Volunteers|||February 2012|February 6, 2012|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734565||151699|
NCT00734539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001538|Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight|Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants < 750 Grams Birth||Duke University|Yes|Completed|November 2008|April 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|362|||Both|N/A|5 Days|No|||July 2014|July 27, 2014|August 13, 2008|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT00734539||151701|
NCT00730028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0051|Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus|Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2009|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1310|||Both|6 Months|85 Years|No|||April 2015|February 18, 2016|August 7, 2008|Yes|Yes||No|February 18, 2016|https://clinicaltrials.gov/show/NCT00730028||152046|
NCT00730041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|845|Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea|Randomized Placebo-Controlled Study of the Pillar® Palatal Implant System With CPAP|Pillar-CPAP|Medtronic Xomed, Inc.|No|Terminated|November 2007|March 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|August 6, 2008||No|Medtronic acquisition of Restore Medical, business decision|No|August 7, 2009|https://clinicaltrials.gov/show/NCT00730041||152045|The study was underpowered for this comparison as only half the planned enrollment occurred. Also, changes occurred with the sleep stage and position as well as the masks used between the two PSGs, which may have affected some of the results.
NCT00730340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tonsillar Closure_Berryhill|Closure Method Study Following Tonsillectomy in Children|Decreased Morbidity With Closure of the Tonsillar Fossae||University of Oklahoma|No|Completed|August 2008|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|5 Years|10 Years|No|||June 2010|June 14, 2010|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730340||152022|
NCT00730639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-003|A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies|A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of MDX-1106 in Subjects With Selected Advanced or Recurrent Malignancies|MDX1106-03|Bristol-Myers Squibb|Yes|Active, not recruiting|January 2009|November 2016|Anticipated|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|311|||Both|18 Years|N/A|No|||May 2015|November 4, 2015|August 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730639||151999|
NCT00730652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1411-02|Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma|A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1411 Administered Every 7 Days in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma|MDX1411-02|Bristol-Myers Squibb|No|Withdrawn|May 2009|March 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||April 2010|April 21, 2010|August 4, 2008|No|Yes|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT00730652||151998|
NCT00730990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8801007|A Phase I, Healthy Volunteer Positron Emission Tomography Study|A8801007 A Phase I, Healthy Volunteer Qualification Of Ligand [C 11] PF 04621053 And Randomized Determination Of H3 Receptor Occupancy Of PF 03654746, Using PET||Pfizer|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2008|December 2, 2008|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730990||151972|
NCT00731003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-070|The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients|The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and IBS Patients||Maastricht University Medical Center|Yes|Completed|April 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00731003||151971|
NCT00731237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-382|XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery|EXCEED|Abbott Vascular|No|Completed|October 2008|October 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2517|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing planned or possible PCI should be invited to participate in the        study.|October 2009|October 15, 2009|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731237||151953|
NCT00731250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111611|A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model|A Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Oral, Single Dose SB-705498 in a Validated Intranasal Capsaicin Challenge Model in Healthy Volunteers||GlaxoSmithKline|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|May 19, 2011|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731250||151952|
NCT00731458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15606B|Prospective Comparison of Cirrus Versus Stratus Ocular Coherence Tomography for Different Retinal Pathology.|Prospective Comparison of Cirrus and Stratus Optical Coherence Tomography for Quantifying Retinal Thickness||University of Chicago|No|Completed|May 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00731458||151937|
NCT00731471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB019|A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV||University of Oxford|Yes|Completed|August 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|50 Years|No|||March 2011|March 25, 2011|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00731471||151936|
NCT00726934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-08-367|The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients|The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients||Indiana University|Yes|Recruiting|September 2007|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|170|||Both|1 Year|30 Years|No|||November 2015|November 13, 2015|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726934||152282|
NCT00726947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 0040239|Ultrasound Elasticity Imaging of Venous Thrombi|Aging Venous Thrombi With Ultrasound Elasticity Imaging||University of Michigan|No|Active, not recruiting|December 2002|||||Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|86|||Both|N/A|N/A|No|||September 2010|September 23, 2010|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726947||152281|
NCT00726960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aprepitant 1|Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers|Modulation of Opiate Reward by NK1 Antagonism: A Laboratory-Based Proof of Concept Study||Karolinska University Hospital|No|Active, not recruiting|January 2008|June 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||July 2008|July 30, 2008|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726960||152280|
NCT00727246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07020121|CDP-Choline and Working Memory After TBI: A Neuroimaging Study|CDP-Choline and Working Memory After TBI: A Neuroimaging Study.||University of Pittsburgh|Yes|Completed|March 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00727246||152258|
NCT00727259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04067|Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)|Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C|SATISFACTION|Merck Sharp & Dohme Corp.|No|Completed|October 2004|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1995|||Both|18 Years|N/A|No|Probability Sample|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol at sites in        France.|April 2015|April 7, 2015|July 30, 2008|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00727259||152257|
NCT00727571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050239|LEARN-6™: A Prospective, Observational Nursing Home Study|Prospective Observational Study to Evaluate Physical Performance and Quality of Life in Older Long Stay Nursing Home Residents With Chronic Kidney Disease With and Without Anemia||Amgen||Completed|September 2006|July 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|815|None Retained|N/A (None Retained)|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Older, long-term stay Nursing Home (NH) residents with CKD, with and without anemia|July 2014|July 18, 2014|July 31, 2008||||No|October 29, 2009|https://clinicaltrials.gov/show/NCT00727571||152233|21 subjects could not be classified into the defined groups because of missing lab values at enrollment
NCT00727870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolyMem001|Evaluation of Preferences of Consumers and Clinicians for the Management of Shave Biopsy Sites With a PolyMem Formulation Dressing or Current Standard of Care.|A Single Site, Three Arm, Open Label Comparative Preference Study to Evaluate the Preference of Consumers and Health Care Professionals for the Use of Shapes by PolyMem Wound Dressings and Shapes by PolyMem Silver Wound Dressings, Each Compared to Antibiotic Ointment Covered With a Band-aid Type Dressing (Current Standard of Practice) and to Each Other in the Post-biopsy Management of Shave Biopsies. Each Participant Serves as Own Control. A Blinded Third Party Physician Will Evaluate and Compare the Wounds Based on Photos Taken at the Various Follow-up Points..||Ferris Mfg. Corp.|No|Active, not recruiting|July 2008|June 2012|Anticipated|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 1, 2012|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727870||152210|
NCT00727883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OIT-DUM-2006/1|Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients|Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients|SOSTA|AstraZeneca|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|190|||Female|N/A|N/A|No|Non-Probability Sample|Post menopausal women treated with adjuvant TAM for breast cancer|December 2010|December 9, 2010|July 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00727883||152209|
NCT00728416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05583|Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)||Merck Sharp & Dohme Corp.|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|333|||Both|12 Years|N/A|No|||May 2015|May 28, 2015|July 31, 2008|Yes|Yes||No|October 9, 2009|https://clinicaltrials.gov/show/NCT00728416||152168|
NCT00729014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804062R|A Study of Drug-Induced Kidney Disease|A Study of Drug-Induced Kidney Disease||National Taiwan University Hospital|Yes|Recruiting|May 2008|||September 2008|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|a medical center|May 2008|August 1, 2008|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00729014||152122|
NCT00732953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UULM-JW-GP|Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries|Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries - a Randomized Clinical Trial.||University of Ulm|No|Completed|February 2009|February 2014|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2014|June 7, 2014|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732953||151823|
NCT00733213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OGR-DUM-2007/1|Depiction of Prostate Cancer Treatment Alternatives in Greece|Depiction of Prostate Cancer Treatment Alternatives in Greece||AstraZeneca|No|Completed|January 2008|March 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|310|||Male|18 Years|N/A|No|Probability Sample|Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer|October 2009|October 13, 2009|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00733213||151803|
NCT00733564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2008-209|Evaluation of Different Anesthesia for Uterine Curettage|Evaluation of the Anesthetic Efficacy of Propofol,Sevoflurane and Paracervical Block for Uterine Curettage|EDAUC|Nanjing Medical University|Yes|Completed|August 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Female|19 Years|45 Years|No|||March 2009|March 30, 2009|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733564||151776|
NCT00733577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111829|A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.|A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral SB756050 Administered for 6 Days to Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|60 Years|No|||December 2012|December 6, 2012|August 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733577||151775|
NCT00733876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG-IMC001|Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery|Phase I Clinical Trial, Dose-escalating Intra-aortic Infusion of Allogeneic , Bone Marrow-derived Multipotent Stromal Cells to Prevent and Treat Post-operative Acute Kidney Injury in Patients Who Require On-pump Cardiac Surgery||AlloCure Inc.|Yes|Completed|August 2008|October 2013|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733876||151752|
NCT00733889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-06-02|A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma|Phase II, Multicentre, Uncontrolled Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Chemotherapy (Docetaxel, Cisplatin, 5-fluorouracil) as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy (Cisplatin) Plus Cetuximab in Patients With a Locoregional Esophageal Carcinoma||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|December 2006|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|70 Years|No|||February 2013|February 19, 2013|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733889||151751|
NCT00730054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03025|Clonidine-Remifentanil. Effect of the Combination on Acute Pain and Respiration in Healthy Volunteers|Clonidine-Remifentanil. Effect of the Combination on Acute Pain and Respiration in Healthy Volunteers|Remiclon|Oslo University Hospital|No|Completed|February 2005|May 2005|Actual|May 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2008|July 3, 2011|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730054||152044|
NCT00734578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-313|Efficacy and Safety of SPD503 in Combination With Psychostimulants|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 Years With a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|461|||Both|6 Years|17 Years|No|||February 2012|February 10, 2012|August 12, 2008|Yes|Yes||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00734578||151698|
NCT00730353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GI06-112|Sutent + Taxol for Advanced Esophageal Cancer|A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer||Hoosier Cancer Research Network|Yes|Completed|August 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|August 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730353||152021|
NCT00730665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8311003|Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)|A Parallel-Group, Randomized, Double-Blind, Multi-Center Dose Response Study To Evaluate The Efficacy And Safety Of PF-00885706, A 5-HT4 Receptor Partial Agonist, As Add-On Therapy To Esomeprazole For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD) Who Have A Poor Response To Proton Pump Inhibitor (PPI) Treatment||Pfizer|Yes|Terminated|January 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|81|||Both|18 Years|65 Years|No|||July 2011|July 12, 2011|August 6, 2008|Yes|Yes|This study has been placed on clinical hold by the sponsor due to operational reasons.|No||https://clinicaltrials.gov/show/NCT00730665||151997|
NCT00731016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002471-27|Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid|Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid||Assistance Publique Hopitaux De Marseille|No|Completed|October 2008|July 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|3 Years|N/A|No|||July 2013|July 4, 2013|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00731016||151970|
NCT00731263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1600C00001|A Study of Tor Kinase Inhibitor in Advanced Tumors|A Phase I/II, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients With Advanced Solid Tumours.||AstraZeneca|No|Completed|July 2008|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|August 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00731263||151951|
NCT00731484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP00004|Validation of TearLab Osmometer|Validation of TearLab Osmometer||TearLab Corporation|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|233|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Ophthalmic and optometric clinics.|April 2011|April 6, 2011|August 7, 2008|Yes|Yes||No|April 6, 2011|https://clinicaltrials.gov/show/NCT00731484||151935|As recruitment came from the general clinical population, only 19 subjects were classified as having Sjögren's Syndrome, and few of the subjects had severe dry eye. Therefore, the upper range is lower than we have observed in subsequent studies.
NCT00727272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA3-085|A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions|A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|July 30, 2008|No|Yes||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00727272||152256|
NCT00727584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599886|Radiation Therapy in Treating Patients With Metastatic Spinal Cord Compression|SCORAD: A Randomised Feasibility Study of Single Fraction Radiotherapy Compared to Multi-fraction Radiotherapy in Patients With Metastatic Spinal Cord Compression||National Cancer Institute (NCI)||Completed|November 2007|August 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2009|August 23, 2013|August 1, 2008||||No||https://clinicaltrials.gov/show/NCT00727584||152232|
NCT00727896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS001IDRF|"Information Technology Methodology for Patient Motivation in Diabetes Management."|"Reinforcement of Adherence to Prescription Recommendations in Diabetic Patients Using Short Message Service (SMS)- A Pilot Study"||India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals|Yes|Completed|August 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|30 Years|65 Years|No|||March 2011|June 24, 2011|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727896||152208|
NCT00728143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1_Jenkins|Blood Glucose Response to Highly Viscous Polysaccharide Enriched Biscuits in Healthy and Diabetic Subjects|Therapeutic Trials of Low Glycemic Index Foods and Dietary Fiber in the Management of Diabetes, Hyperlipidemia and Renal Disease||St. Michael's Hospital, Toronto|No|Completed|August 1989|November 1989|Actual|November 1989|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|19|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2008|August 4, 2008|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728143||152189|
NCT00729313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-54-52030-053|Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae|A Phase III Multicentre Randomised Double-blind Comparative Study of Efficacy and Safety of Lanreotide 30 mg Versus Placebo for Treatment of Patients With Digestive Fistulae||Ipsen|No|Completed|April 2000|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|80 Years|No|||June 2012|June 18, 2012|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729313||152101|
NCT00733226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B100İEG0110001 - 2860|Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing|Phase IV Study of Effect of OM-85 BV (Broncho-Vaxom) on Wheezing Related Morbidity in Children With Recurrent Wheezing||Kecioren Education and Training Hospital|No|Completed|August 2007|October 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|6 Months|6 Years|No|||July 2014|July 4, 2014|August 11, 2008||No||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00733226||151802|Main shortcoming of our study is the small sample size. This might have hampered the appearance of some statistically meaningful differences such as wheezing attacks that require steroid treatment, rate and duration of hospitalizations.
NCT00733590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00045142|Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention|Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention (PROSe-ICD)|PROSe-ICD|Johns Hopkins University|No|Recruiting|June 2003|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Whole blood drawn at 6-12 month intervals|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with ischemic or non-ischemic cardiomyopathy undergoing their first ICD generator        replacement for primary prevention.|March 2016|March 14, 2016|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733590||151774|
NCT00733902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091011|Tanezumab in Osteoarthritis of the Knee|A Phase 3 Randomized, Double Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee||Pfizer|Yes|Completed|September 2008|November 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|697|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733902||151750|
NCT00734240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 353512 CS1|Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers|Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers||Ionis Pharmaceuticals, Inc.|No|Completed|July 2008|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|16||Actual|103|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 28, 2010|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734240||151724|
NCT00734214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-265|Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial|Hypotonic Versus Isotonic Parenteral Fluids in Children - a Randomized Controlled Trial||McMaster University|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|258|||Both|6 Months|16 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|August 12, 2008||No||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00734214||151726|
NCT00734227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TvSSTUDY|TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis|TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis||University of California, San Diego|Yes|Completed|July 1996|July 2006|Actual|October 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|153|||Both|N/A|N/A|No|||July 2008|August 13, 2008|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734227||151725|
NCT00734591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2171121|Follow-Up Study for Exubera|An Observational Follow-Up Study Of Patients Previously Enrolled In Exubera Controlled Clinical Trials|FUSE|Pfizer|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|7439|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects who participated in a controlled trial of Exubera active within the last five        years (17 protocols total)|September 2012|September 24, 2012|August 12, 2008|No|Yes||No|September 24, 2012|https://clinicaltrials.gov/show/NCT00734591||151697|Detection and/or reporting bias possible in continuous analysis (presented here) of lung cancer mortality and lung cancer incidence endpoints. Study had insufficient power to draw clear statistical conclusions due to small number of events.
NCT00730067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002237-73|Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension|Sildenafil for COPD-associated Pulmonary Hypertension. A Randomized Double Blinded Placebo Controlled Study.||University of Aarhus|Yes|Withdrawn|June 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||August 2012|August 22, 2012|August 4, 2008|Yes|Yes|As a single center, it was not possible to recruit enough patients with pulmonary hypertension|No||https://clinicaltrials.gov/show/NCT00730067||152043|
NCT00730366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DELIMAL|New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa|New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa.||Institute of Tropical Medicine, Belgium|No|Completed|March 2004|December 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2766|||Female|N/A|N/A|No|||September 2010|September 12, 2010|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730366||152020|
NCT00730678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGEN5|Pharmacogenetic Determinants Of Treatment Response In Children|Pharmacogenetic Determinants Of Treatment Response In Children||St. Jude Children's Research Hospital|No|Recruiting|July 1998|March 2034|Anticipated|December 2033|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8800|Samples With DNA|DNA or RNA for genetic testing will typically be obtained simultaneously with blood that is      drawn for clinical reasons.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients at St. Jude Children's Research Hospital who are being treated for a        malignancy are eligible to participate in this study.|February 2016|February 9, 2016|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730678||151996|
NCT00731029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218352/053|Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03|Comparative Vaccination Study of the Reactogenicity and Immunogenicity of a Thiomersal-Free Formulation of Influsplit SSW® 2002/2003 Versus the Standard Formulation of Influsplit SSW® 2002/2003 in Individuals Over 18 Years||GlaxoSmithKline||Completed|September 2002|||April 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|239|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00731029||151969|
NCT00731276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000601207|Irinotecan in Treating Asian Patients With Solid Tumors|Phase I Study to Investigate Genotype-based Dose Individualization of Irinotecan in Asian Cancer Patients||National Cancer Centre, Singapore|No|Active, not recruiting|June 2008|||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|120 Years|No|||March 2016|March 22, 2016|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731276||151950|
NCT00726700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL-2003-2|Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma|Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab||National Cancer Institute (NCI)||Completed|May 2004|February 2012|Actual|||Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|109|||Both|61 Years|80 Years|No|||July 2012|August 1, 2013|July 31, 2008||||No||https://clinicaltrials.gov/show/NCT00726700||152300|
NCT00726713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-001|Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)|A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)||Pamlab, Inc.|No|Completed|June 2008|June 2011|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|25 Years|80 Years|No|||July 2013|July 26, 2013|July 30, 2008||No||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00726713||152299|Adverse Event reporting detailed in the “Other Adverse Events” section was provided only with specificity to the affected Organ System. Additional detail for the “Other Adverse Events” was not available at the time of reporting.
NCT00726726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-005|Drug Interaction Study With a Potential Alzheimer's Disease Compound|Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail||Bristol-Myers Squibb|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 4, 2008|July 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726726||152298|
NCT00727597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL 110408|A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT|A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT|SUPPoRT|Georgetown University|Yes|Completed|July 2008|July 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|July 31, 2008|Yes|Yes||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00727597||152231|
NCT00727909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6288-R|Evaluation of Open-canal Behind-the-Ear Hearing Aids and Traditional In-the-ear Hearing Aids.|Evaluation of Open-Ear Canal and Traditional Custom-Fit Hearing Aids||VA Office of Research and Development|No|Completed|May 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|290|||Both|21 Years|85 Years|No|||June 2014|June 4, 2014|July 30, 2008||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT00727909||152207|No limitations or caveats to report.
NCT00728156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3639a|Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)|Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|August 2009|April 2012|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||October 2015|October 7, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728156||152188|
NCT00728429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000601334|Aerobic Exercise in Patients Receiving Chemotherapy for Cancer|CCCWFU 99108 - Effect of Exercise Training in Patients Receiving Anthracycline Drugs - A Pilot Study||Comprehensive Cancer Center of Wake Forest University|No|Terminated|June 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|80 Years|No|||July 2012|July 12, 2012|August 2, 2008|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00728429||152167|
NCT00728715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGR-0000013|Efficacy of Budesonide-Formoterol in Bronchiectasis|Clinical Efficacy and Safety of Budesonide and Formoterol in the Management of Non-Cystic Fibrosis Bronchiectasis||Hospital General de Requena|No|Completed|January 2004|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||July 2008|July 31, 2008|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728715||152145|
NCT00728728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-012-07F|Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia|Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia||VA Office of Research and Development|Yes|Active, not recruiting|December 2009|December 2015|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|21 Years|65 Years|No|||October 2015|October 13, 2015|August 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728728||152144|
NCT00725556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ana Carina Tamanaha|The Development of Autistic Children Based on Mothers´Response in Autism Behavior Checklist|The Development of Autistic Children Based on Mother´s Response in Autism Behavior Checklist||Federal University of São Paulo|Yes|Completed|March 2006|December 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|11|||Both|3 Years|12 Years|No|||July 2008|July 31, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725556||152386|
NCT00725569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POR2008|Homeopathy for Post-operative (C. Section) Recovery|Effect of Homeopathic Drugs Bellis Perennis ו- Staphysagria on the Post-operative Recovery, of Women Undergoing Cesarean Section- (an Exploratory) Double Blind, Placebo Controlled Study||Shaare Zedek Medical Center|No|Completed|August 2008|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 18, 2009|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00725569||152385|
NCT00733252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1508|Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease|Optical Coherence Tomography of Human Airways||Case Comprehensive Cancer Center|Yes|Withdrawn|April 2008|February 2011|Actual|January 2011|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|Samples Without DNA|Fresh Bronchi from 10 subjects undergoing pneumonectomy or lobectomy for malignant and      benign processes will be obtained from the UHCMC Pathology Department as discarded tissue      from fresh specimens|Both|N/A|N/A|No|Probability Sample|primary care clinic|October 2015|October 1, 2015|August 12, 2008||No|Low interest|No||https://clinicaltrials.gov/show/NCT00733252||151800|
NCT00733915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 01/13|Long-term Study of the DePuy Low Contact Stress (LCS) Complete Total Knee System|A Prospective, Non-Comparative Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS) Complete Mobile-bearing Total Knee System.||DePuy International|No|Completed|January 2002|October 2012|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|N/A|N/A|No|||January 2015|January 21, 2015|August 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733915||151749|
NCT00734253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PYR-210|Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2b Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Nephropathy Due to Type 2 Diabetes||NephroGenex, Inc.|Yes|Completed|August 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|317|||Both|25 Years|N/A|No|||May 2014|October 6, 2015|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734253||151723|
NCT00734604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12313|A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.|A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.||Eli Lilly and Company|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|378|||Male|18 Years|N/A|No|||October 2010|October 21, 2010|August 12, 2008|Yes|Yes||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00734604||151696|
NCT00730093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH12008|The Absorption of Vitamin B12 Among Healthy Pregnant Women|The Absorption of Vitamin B12 Among Healthy Pregnant Women||University of Aarhus|No|Completed|August 2008|August 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|27|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||August 2009|August 5, 2009|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00730093||152041|
NCT00734617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001223|Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II|Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II|CON NIC II|Duke University|Yes|Completed|August 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|479|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|July 2, 2014|August 13, 2008|Yes|Yes||No|February 3, 2011|https://clinicaltrials.gov/show/NCT00734617||151695|
NCT00730080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU/Kuvan/White|Sapropterin in Individuals With Phenylketonuria|Effects of Sapropterin on Brain and Cognition in Individuals With Phenylketonuria||Washington University School of Medicine|No|Active, not recruiting|July 2008|July 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|6 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic for phenylketonuria. St. Louis community for control.|December 2014|December 8, 2014|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00730080||152042|
NCT00730379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-004|A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)|A Phase I Study of Ridaforolimus (MK8669) and MK0646 in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.||Completed|July 2008|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|August 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730379||152019|
NCT00730691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_308|Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder||Takeda|No|Completed|June 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|781|||Both|18 Years|65 Years|No|||October 2013|October 25, 2013|August 6, 2008|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00730691||151995|
NCT00731042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I2MS05-010877|A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects|A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects||3M|No|Completed|March 2008|July 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|33|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|August 6, 2008|No|Yes||No|January 23, 2009|https://clinicaltrials.gov/show/NCT00731042||151968|
NCT00731289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3II Fuchs|Gait Patterns After Intraarticular Treatment of Patients With Osteoarthritis of the Knee|Efficacy and Safety of Intra-Articular Injections of Durolane® in the Treatment of Osteoarthritis in the Knee||Philipps University Marburg Medical Center|No|Completed|July 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|35 Years|80 Years|No|||August 2008|August 7, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731289||151949|
NCT00731523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2108|Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.|An Open-label, Single-dose, Parallel-group Study to Compare the Pharmacokinetics of FTY720 and Metabolites in Subjects With Severe Renal Impairment With That in Matched Healthy Control Subjects||Novartis|No|Completed|July 2008|||August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731523||151932|
NCT00723801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-001762|Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome|Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome||Brigham and Women's Hospital|Yes|Completed|October 2007|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|25 Years|N/A|No|||September 2014|September 8, 2014|July 25, 2008||No||No|August 15, 2014|https://clinicaltrials.gov/show/NCT00723801||152521|
NCT00723814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|andonhealth|Blood Pressure Monitor Clinical Test|||Andon Health Co., Ltd||Completed||||||N/A|Observational|N/A|||||||Both|N/A|N/A||||July 2008|July 28, 2008|July 27, 2008||||No||https://clinicaltrials.gov/show/NCT00723814||152520|
NCT00726973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-085|Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)|A Pilot Study With Reduced Fluence Photodynamic Therapy With Visudyne Ranibizumab VS. Ranibizumab Only to Treat Exudative AMD||Lahey Clinic|No|Withdrawn|December 2006|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||May 2012|May 9, 2012|July 30, 2008|Yes|Yes|Unable to recruit study participants|No||https://clinicaltrials.gov/show/NCT00726973||152279|
NCT00728442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K 070603|Impact of OncoDoc2 on Guideline Compliance in the Management of Breast Cancer|Impact of the OncoDoc2 Decision Support System on Compliance of Multidisciplinary Staff Meeting Decisions With Clinical Practice Guidelines in the Management of Non-metastatic Breast Cancer.|OncoDoc2|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2008|April 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|816|||Female|N/A|N/A|No|||September 2013|September 2, 2013|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728442||152166|
NCT00728455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9112-1905|Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers|Single Subcutaneous Dose Rising Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0349 in Overweight/Obese Male Subjects||Novo Nordisk A/S|No|Withdrawn|July 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|0|||Male|18 Years|45 Years|No|||October 2014|October 16, 2014|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00728455||152165|
NCT00729027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6910|Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia|A Multicenter, Double-blind, Randomized, 12-month, Placebo-controlled Study to Evaluate the Lipid-lowering Effect, Safety and Tolerability of AVE5530 25 mg/Day and 50mg/Day When Added to Ongoing Stable Statin Therapy (HMG-CoA Reductase Inhibitors) in Patients With Primary Hypercholesterolemia||Sanofi|No|Terminated|July 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1015|||Both|18 Years|N/A|No|||November 2009|November 10, 2009|August 1, 2008|Yes|Yes|AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|No||https://clinicaltrials.gov/show/NCT00729027||152121|
NCT00729339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMCP-97-011|Role of Mosapride in Patients With Gastroesophageal Reflux Disease|Role of Mosapride in Patients With Gastroesophageal Reflux Disease||Lotung Poh-Ai Hospital|Yes|Completed|June 2008|May 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|90 Years|No|||May 2009|May 12, 2009|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00729339||152099|
NCT00729625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD045514|Air Muscle and Task Practice in Upper Limb Stroke Rehab|Air Muscle and Task Practice in Upper Limb Stroke Rehab||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|April 2005|March 2007|Actual|March 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|24|||Both|18 Years|75 Years|No|||April 2005|August 5, 2008|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729625||152077|
NCT00725595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092801|Treatment of Cheyne Stocks Respiration With Adaptive Servo Ventilation and Bilevel Ventilators in Patients With Chronic Heart Failure|||Nanjing Medical University|Yes|Recruiting|August 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 4|Observational|Observational Model: Case-Only||1|Anticipated|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients with both CSR and heart failure|August 2008|August 25, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725595||152383|
NCT00733603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICCRN RCT#3 (IND)|Physical Therapy in Women With Interstitial Cystitis|A Single-Blinded Randomized Multi-Center Trial to Evaluate the Efficacy and Durability of Myofascial Tissue Manipulation in Women With Interstitial Cystitis/Painful Bladder Syndrome|IC03|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|June 2008|May 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|No|||January 2010|January 12, 2010|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733603||151773|
NCT00733616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-08-02|Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status|Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|November 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733616||151772|
NCT00733928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 99/26|The Press Fit Condylar (P.F.C.) Sigma Metal-backed Versus All-poly|Randomised Prospective Comparison of P.F.C All-polyethylene Versus Metal-backed Tibial Component. A Clinical, Radiological and Roentgen Stereophotogrammetric Analysis (RSA) Study.||DePuy International|No|Completed|October 1999|January 2006|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|65 Years|N/A|No|||February 2010|February 15, 2010|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733928||151748|
NCT00722332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-009|Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients|Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients||Cangene Corporation|No|Completed|February 2008|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Both|N/A|N/A|No|||October 2013|October 30, 2013|July 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722332||152629|
NCT00722345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2162|Exercise Consultation in Obese Youth|Can Exercise Consultation Increase Activity Levels and Improve Metabolic Markers in Obese Adolescents? A Pilot Study.||St. Justine's Hospital|No|Completed|June 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|14 Years|18 Years|No|||June 2005|July 24, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722345||152628|
NCT00721981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ODE-DUM-2008/1|An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy|A Non-interventional Study for Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy. With Special Focus on Patients Who Are in Transition From First Line to Second Line Treatment||AstraZeneca|No|Terminated|April 2009|October 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from non-small cell lung cancer (NSCLC) (stage IIIb and IV) undergoing        chemotherapy, who are in transition from 1st to 2nd line treatment.|December 2010|December 9, 2010|July 23, 2008||No|Low Recruitment|No||https://clinicaltrials.gov/show/NCT00721981||152656|
NCT00721994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAS: IDE subjects|Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects|Cormet Resurfacing Hip System Post PMA Approval Study (PMA #P050016)Pre-market (IDE) Study Group 10 Year Follow-Up With Metal Ion and Renal Function Data Collection Clinical Investigation Plan|PAS:IDE|Corin|Yes|Enrolling by invitation|May 2008|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|blood specimens for metal ion testing and renal function testing|Both|N/A|N/A|No|Non-Probability Sample|IDE study subjects at 5 IDE study sites|October 2015|October 6, 2015|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721994||152655|
NCT00722306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4251072|A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers||Pfizer|No|Completed|May 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|July 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722306||152631|
NCT00722319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS-1|Ongoing WARfarin and Coronary STENTing|Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.|WAR-STENT|War-Stent Investigators|No|Active, not recruiting|March 2009|October 2011|Anticipated|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Patients treated with warfarin who are hospitalized at tertiary centers all over the        country to undergo percutaneous coronary intervention with stent implantation|January 2010|August 11, 2011|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722319||152630|
NCT00722605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-080|Multiple Respiration-Correlated Cone Beam Computed Tomography (CT) Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer|The Use of Multiple Respiration-Correlated Cone Beam CT Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer.||Memorial Sloan Kettering Cancer Center||Completed|July 2008|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722605||152609|
NCT00722839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|City of Hope 03121|Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants|A Phase I Dose Escalation Study of Peptide Vaccines With Activity Against Human Cytomegalovirus||City of Hope Medical Center|Yes|Completed|December 2006|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722839||152592|
NCT00722852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-III-06|Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee|Multicentre, Randomized, Double-blind, Placebo-controlled Study of Safety and Efficacy of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee||IDEA AG|No|Completed|June 2008|April 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|555|||Both|46 Years|N/A|No|||October 2009|October 2, 2009|July 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722852||152591|
NCT00723125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-BR-211A|Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer|Q3week Carboplatin With Weekly Abraxaneä And Avastin + Subsequent Dose-Dense Ac With Avastin As Neoadjuvant Therapy In Resectable And Unresectable (Stage Iia-Iiib) Her2-Negative Breast Cancer||Brown University|Yes|Completed|September 2008|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|19 Years|N/A|No|||October 2014|October 14, 2014|July 15, 2008||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT00723125||152571|
NCT00723424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00021|Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin|An Open-label Study to Assess the Effect of AZD5672 at Steady State on the Pharmacokinetics of Digoxin Following Single Dose Administration in Healthy Volunteers||AstraZeneca|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723424||152550|
NCT00724100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMRI-564-101|A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors|A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors||Albany Molecular Research, Inc.|No|Terminated|September 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||September 2011|August 26, 2014|July 25, 2008|No|Yes|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT00724100||152498|
NCT00724373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05269|Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)|Retrospective Data Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol||Merck Sharp & Dohme Corp.|No|Completed|November 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|442|||Both|18 Years|N/A|No|Probability Sample|Participants with genotype 1 HCV infection who have been treated with pegylated interferon        alfa-2b and ribavirin in the preceding 48 months at sites in the UK.|September 2015|September 24, 2015|July 25, 2008|No|Yes||No|May 6, 2010|https://clinicaltrials.gov/show/NCT00724373||152477|
NCT00727285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICK07A0|Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies|CF Leukocyte Genes as Biomarkers for Novel Therapies||National Jewish Health|Yes|Completed|February 2008|October 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|CF patients followed by the Adult CF Program at National Jewish Health, who are ≥ 18 years        and present with signs and symptoms of an acute pulmonary exacerbation. All subjects will        be treated with at least two pathogen specific I.V. antibiotics for a minimum of 10 days,        along with standard guidelines for other aspects of care for an acute pulmonary        exacerbation. Concomitant use of inhaled antibiotics and systemic steroids will be        allowed, and typical co-infections or co-morbidities will not result in exclusion.|August 2013|August 16, 2013|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00727285||152255|
NCT00729040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57408|Enhancing Adherence by Building Online Communities|Enhancing Adherence to an Internet-Mediated Walking Program by Building Online Communities||Robert Wood Johnson Foundation|No|Completed|January 2008|January 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00729040||152120|
NCT00729352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16347-CP-001|Lung Mucus Hypersecretion and NQO1|Dependency of O3-Induced Lung Mucus Hypersecretion on NQO1||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|August 2008|June 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|60|Samples With DNA|Bronchoalveolar lavage specimens.|Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be healthy adults, non-smokers, recruited from the University campus and        local community. Fifty% will be female. Recruitment of minority ethnic groups will be        consistent with census population for central NC. Subjects will have a clinical history        and lung function screening at protocol entry. Female subjects of childbearing age will        have pregnancy testing. Equal numbers of NQO1 sufficient and deficient subjects, based        upon genoytypic pre-screening and stratified by racial background will be studied.        Subjects will also be genotyped for GSTM1 wild type or null genotype. As individuals with        an increased BMI may respond strongly to O3 we will only recruit subjects with body        habitus within normal range for gender, age, and racial group.|September 2014|September 25, 2014|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00729352||152098|
NCT00729365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01DK071733-01A1|PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)|Nocturnal Hypertension and Prevention of Microalbuminuria in Type 1 Diabetes|PREVENTKD|Northwestern University|Yes|Terminated|July 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|65|||Both|13 Years|50 Years|No|||February 2015|February 24, 2015|August 4, 2008||No|Data from other studies showed that study could not be completef successfully|No|December 30, 2014|https://clinicaltrials.gov/show/NCT00729365||152097|The study was terminated prematurely because of new information from the literature from other studies showing that this study could not be successful.Only 59 patients were screened and consented and 46 were found acceptable who were randomized.
NCT00729638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-288|RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma|An Open-Label Phase I Study of the Safety of and Efficacy of RAD001 in Combination With Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma||Massachusetts General Hospital|Yes|Completed|June 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729638||152076|
NCT00725933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121ST101|Administration of BIIB028 to Subjects With Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB028 Administered to Subjects With Advanced Solid Tumors||Biogen|No|Completed|June 2008|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||December 2011|September 12, 2013|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725933||152357|
NCT00733629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS4|Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia|In Vitro Studies pf Endothelial Cells Derived From HHT Patients||Imperial College London||Active, not recruiting||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|N/A|N/A|No|||August 2008|August 12, 2008|August 12, 2008||||No||https://clinicaltrials.gov/show/NCT00733629||151771|
NCT00733642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951008|Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease|An Open Label, Single Dose Escalation Study Of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease||Pfizer|No|Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|15|||Both|50 Years|N/A|No|||July 2009|July 24, 2009|August 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733642||151770|
NCT00734266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000164/7|Changes in Leukotrienes During Cardiac Surgery in Patients With Chronic Obstructive Pulmonary Disease|Changes in Leukotrienes During Cardiac Surgery in Patients With Chronic Obstructive Pulmonary Disease||Massachusetts General Hospital|Yes|Completed|April 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients schedules to undergo cardiac surgery with use of CPB.|March 2013|March 5, 2013|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734266||151722|
NCT00734630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-11|Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension.||Forest Laboratories|No|Completed|August 2008|May 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|491|||Both|18 Years|85 Years|No|||March 2011|March 31, 2011|August 13, 2008|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00734630||151694|
NCT00722358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-004|A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects|Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of BMS-650032 in Subjects Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|60 Years|No|||June 2011|June 15, 2011|July 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722358||152627|
NCT00722618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220060957|Communication With in Vitro Fertilization (IVF) Patients About Risks|Improving Communication With IVF Patients About Risks Such as Multiple Births||University of Kansas Medical Center|No|Active, not recruiting|September 2007|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|260|||Both|18 Years|N/A|No|||April 2010|April 14, 2010|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722618||152608|
NCT00722865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-388|Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma|Avastin (Bevacizumab) in Combination With ABVD for the Treatment of Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma||Massachusetts General Hospital|Yes|Active, not recruiting|September 2008|December 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722865||152590|
NCT00723151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC007660|Effects of Intensity of Early Communication Intervention|Effects of Intensity of Early Communication Intervention||University of Kansas Medical Center|No|Completed|July 2005|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Months|27 Months|Accepts Healthy Volunteers|||October 2010|October 29, 2010|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723151||152570|
NCT00723437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAIL1|Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis|Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin||Istituti Fisioterapici Ospitalieri|No|Completed|January 2005|July 2008|Actual|January 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|70 Years|No|||July 2008|July 25, 2008|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723437||152549|
NCT00723450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA102833|Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients|The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age||GlaxoSmithKline|No|Completed|July 2008|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|301|||Both|10 Years|17 Years|No|||March 2014|May 8, 2014|July 24, 2008|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00723450||152548|
NCT00723827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05557|Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)|Temodal (Temozolomide) Post Marketing Surveillance Protocol||Merck Sharp & Dohme Corp.|No|Completed|March 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|682|||Both|N/A|N/A|No|Probability Sample|Participants with newly diagnosed glioblastoma multiforme.        Participants with malignant glioma, such as glioblastoma multiforme or anaplastic        astrocytoma, showing recurrence or progression after standard therapy.|January 2015|January 19, 2015|July 25, 2008|No|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00723827||152519|
NCT00723840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04560|Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560)|Assessment of the Social Cost of Crohn's Disease (COsto Sociale Della Malattia di CrOhn - COSMO): Economic and Quality of Life Aspects|COSMO|Merck Sharp & Dohme Corp.|No|Completed|September 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|245|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with Crohn's Disease for at least 6 months who have active disease despite drug        therapy and are seen at one of 25 gastroenterology centers spread across Italy.|July 2015|July 29, 2015|July 25, 2008|No|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00723840||152518|
NCT00724113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051039|ARTHRO Distension Plus Intensive Mobilisation in Shoulder Capsulitis|Evaluation of the Effectiveness of ARTHRO -Distension Plus Intensive Mobilisation in Shoulder Capsulitis|CAPSULITE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|February 2009|July 2014|Anticipated|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|April 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00724113||152497|
NCT00724126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFIB3008|Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome|TARGET 2|Valeant Pharmaceuticals International, Inc.|No|Completed|July 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|637|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|July 26, 2008|Yes|Yes||No|June 30, 2014|https://clinicaltrials.gov/show/NCT00724126||152496|
NCT00724399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00010173|Preventive Health Practices in Women|Preventive Health Practices in Women||University of Michigan|No|Active, not recruiting|January 2006|July 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1418|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prospective survey study on women who attend screening mammography and routine/annual        gynecology visits to assess baseline knowledge regarding CVD.|June 2015|June 1, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00724399||152475|
NCT00728169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020715JEM13314|Developing Asthma Interventions Using Community Based Research|Feasibility of Developing an Effective Asthma Intervention Using CBPR Methods||Meharry Medical College|Yes|Completed|July 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|African-American, 18 years and older|September 2009|September 17, 2009|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728169||152187|
NCT00728741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080192|Brain Activity During Strategic Planning|Functional Neuro-Imaging of Strategy Use During Human Behavior||National Institutes of Health Clinical Center (CC)||Completed|August 2008|May 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 27, 2010|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00728741||152143|
NCT00728754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2301|A Study of Certain Prevail Implants Used for the Preservation of Crestal Bone in Short Fixed Bridge Cases.|A Prospective, Randomized-controlled Multicenter Study of the Osseotite Certain Lateralized Implant in Short-span Fixed Bridge Cases for Preservation of Crestal Bone|Cliffhanger|Biomet, Inc.|Yes|Completed|March 2005|April 2011|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|August 1, 2008|Yes|Yes||No|June 26, 2009|https://clinicaltrials.gov/show/NCT00728754||152142|
NCT00729378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD050775|Jump-In - Building Better Bones|Exercise and Bone Development in Young Girls||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|April 2007|August 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|400|||Female|9 Years|16 Years|Accepts Healthy Volunteers|||February 2012|February 24, 2012|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00729378||152096|
NCT00729651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-263|Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)|A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women||Merck Sharp & Dohme Corp.|No|Completed|March 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|343|||Female|18 Years|N/A|No|||July 2015|July 21, 2015|August 5, 2008|No|Yes||No|February 5, 2010|https://clinicaltrials.gov/show/NCT00729651||152075|
NCT00729664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA210-001|Multiple Ascending Dose (MDX1105-01)|A Phase 1, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors|Anti-PDL1|Bristol-Myers Squibb|No|Completed|February 2009|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|281|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729664||152074|
NCT00725322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01072008-965|Subcutaneous Botulinum Toxin for Cutaneous Allodynia|Subcutaneous Botulinum Toxin for Cutaneous Allodynia||Stanford University||Active, not recruiting|December 2007|January 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725322||152404|
NCT00721838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK072493|Dietary Intake and Eating Behaviors in Adolescents Who Undergo Bariatric Surgery|Dietary Intake and Eating Behaviors in Adolescents Who Undergo Bariatric Surgery|Teen LABS|University of Pennsylvania|No|Active, not recruiting|February 2009|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Both|14 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will assess changes in dietary intake and eating behavior in 110 extremely        obese adolescents who undergo bariatric surgery as part of the main Teen-LABS study. These        individuals will be recruited from one of 4 Teen-LABS sites: Baylor College of Medicine,        Cincinnati Children's Hospital Medical Center, University of Alabama at Birmingham, and        the University of Pittsburgh Medical Center. Changes in bariatric surgery patients will be        compared to those of 110 obese adolescents treated with a lifestyle modification program        designed to produce an 8% weight loss. These individuals will be recruited from a study at        the Children's Hospital of Philadelphia (PI: Robert Berkowitz, M.D.) which will be ongoing        at the same time and will include the same measures as those proposed in this application.|December 2013|December 10, 2013|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721838||152666|
NCT00733941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.1755|Interval Training in Young Healthy Individuals|Interval Training: Training, Detraining and Retraining; an Interventional Study||Norwegian University of Science and Technology|No|Completed|September 2008|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|27 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733941||151747|
NCT00721734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-005|Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function|Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function||Onyx Pharmaceuticals|No|Completed|November 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 22, 2008|No|Yes||No|November 2, 2015|https://clinicaltrials.gov/show/NCT00721734||152674|
NCT00722007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cormet (P050016) New Enroll|Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)|Cormet Resurfacing Hip System Post PMA-Approval Study Post-approval Study Group (New Enrollment)|PASNew|Corin|Yes|Active, not recruiting|April 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|July 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722007||152654|
NCT00722371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-102|MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)|A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|September 2008|March 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|1615|||Both|18 Years|78 Years|No|||March 2015|March 23, 2015|July 22, 2008|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT00722371||152626|
NCT00722631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIO 2007|Anti-Inflammatory Effects of Pioglitazone|Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT||Kurume University|Yes|Completed|May 2007|April 2012|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|35 Years|85 Years|No|||September 2012|September 26, 2012|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00722631||152607|
NCT00722878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5903|Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease|Early Onset and Progression of Primary Ciliary Dyskinesia Lung Disease Prior to 10 Years of Age||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|July 2008|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|48|Samples With DNA|Approximately 2 teaspoons of blood and a small amount of urine (if the child is able to      urinate in a cup) will be collected and held at the specimen bank located at Denver      Children's Hospital. These samples will be used to help identify markers that may predict      the clinical course of PCD.|Both|N/A|4 Years|No|Non-Probability Sample|Participants in this study will be children younger than 5 years of age who have been        diagnosed with PCD as based on electron microscopy and/or presence of two known        disease-causing gene mutations or for whom a diagnosis of PCD has been determined probable        as based on clinical features and very low nasal nitric oxide (less than 60 nl/minute).|March 2016|March 4, 2016|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722878||152589|
NCT00722891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/289/07/B|Ocular Responses to Short and Long-term Lens Wear|Ocular Responses to Acute and Chronic Lens Wear||Bausch & Lomb Incorporated|No|Completed|July 2008|September 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|17 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 12, 2010|July 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722891||152588|
NCT00723164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05041|Premedication on Sevoflurane Induction|Low Dose Fentanyl/Midazolam Improves Sevoflurane Induction in Adults||Maisonneuve-Rosemont Hospital|No|Completed|October 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||July 2008|July 25, 2008|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723164||152569|
NCT00723463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 5527|Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue|Retrospective - Prospective - Study to Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissues at 3T MRI||University of Michigan|No|Active, not recruiting|June 2006|December 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723463||152547|
NCT00723476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH072541|Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families|Family Centered Advanced Care Planning (FCACP)||Children's Research Institute|Yes|Completed|September 2005|September 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|12 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723476||152546|
NCT00723853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11113B|REACH-OUT: Chicago Children's Diabetes Prevention Program|REACH-OUT: Chicago Children's Diabetes Prevention Program|REACH-OUT|University of Chicago|No|Completed|April 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|131|||Both|9 Years|65 Years|No|||September 2013|September 4, 2013|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723853||152517|
NCT00724386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIRB 9849|Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer|A Phase I Study of Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine With Filgrastim Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer||University of Chicago|No|Completed|June 1999|November 2012|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00724386||152476|
NCT00724412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-07-15|Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye|||Alcon Research|No|Completed|April 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724412||152474|
NCT00724425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-493-01|A Phase 1 Dose Escalation Study of IPI-493|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients With Advanced Malignancies||Infinity Pharmaceuticals, Inc.|No|Terminated|July 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|July 25, 2008|No|Yes|Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus exclusively on    retaspimycin|No||https://clinicaltrials.gov/show/NCT00724425||152473|
NCT00728767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPH - 1948|Brief Intervention for Heavy Drinkers|Brief Intervention for Heavy Drinkers - a Randomized Controlled Trial||University of Southern Denmark|Yes|Completed|January 2008|December 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|772|||Both|18 Years|N/A|No|||August 2009|April 13, 2011|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728767||152141|
NCT00729053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2055-003|Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma|A Phase 2, Multi-Center, Randomized, Open-Label Study of Two Dose Levels of IMOxine® (IMO-2055 for Injection) in Patients With Metastatic or Locally Recurrent Clear Cell Renal Carcinoma||Idera Pharmaceuticals, Inc.|No|Completed|June 2004|November 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|224|||Both|18 Years|N/A|No|||January 2009|January 8, 2009|August 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729053||152119|
NCT00729079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24895|Diabetes Prevention Program Pilot Study|Virtual Translation of Diabetes Prevention to Primary Care: A Pilot Study|DPP|University of Rochester|No|Completed|December 2008|October 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2013|October 8, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00729079||152118|
NCT00729677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237-04|Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin|Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer||Beth Israel Medical Center|No|Completed|June 2005|December 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|64|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiveing chemotherapy including oxaliplatin at the ambulatory care center|October 2015|October 5, 2015|August 6, 2008||No||No|September 15, 2009|https://clinicaltrials.gov/show/NCT00729677||152073|This was a convenience sample of patients seen at 2 medical centers. Subjects were restricted to those who could complete Quality of Life forms in Spanish or English.
NCT00725335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHB001|Effect of I/R Injuries by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative Hepatectomy|The Effect of Ischemia/Reperfusion Injuries Elicited by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative Excision:A Multicenter Prospective Randomized Controlled Trial||Southwest Hospital, China|Yes|Completed|September 2008|November 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|498|||Both|18 Years|65 Years|No|||November 2012|November 23, 2012|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00725335||152403|
NCT00725608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05444|Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)|Evaluation of Transfer From Subutex or Other Treatment for Opioid Drug Dependence to Suboxone: Acceptability, Safety and Impact on Medication Dispensing||Indivior Inc.|No|Completed|May 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|339|||Both|15 Years|N/A|No|Non-Probability Sample|All patients on substitution therapy for opioid dependence willing to switch to Suboxone|April 2012|April 26, 2012|July 25, 2008||No||No|October 18, 2011|https://clinicaltrials.gov/show/NCT00725608||152382|
NCT00725621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03756|Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)|Real Life Dosing Regimen of Remicade in Austria, Monitored Over 9 Consecutive Infusions in Rheumatoid Arthritis Therapy||Merck Sharp & Dohme Corp.|No|Completed|March 2004|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|516|||Both|N/A|N/A|No|Non-Probability Sample|Patients with severe RA being treated at specialized centers.|September 2015|September 2, 2015|July 25, 2008|No|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00725621||152381|
NCT00722176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-1020 IIb (Extension)|Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020|A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone||BioLineRx, Ltd.|Yes|Completed|June 2008|December 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|220|||Both|18 Years|65 Years|No|||June 2010|June 27, 2010|July 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722176||152641|
NCT00722189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/01850|Observational Study of Efficacy and Safety of Travogen Cream and Travocort Cream in the Treatment of Mycoses|Observational Study of the Efficacy, Safety and Tolerance of Travogen Cream (Isoconazole) and Travocort Cream (Isoconazole, Diflurcortolone) in the Treatment of Patients With Local Skin Mycosis of Various Etiology and Localization||Bayer|No|Completed|July 2008|February 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|900|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diagnosed skin mycoses|March 2015|March 18, 2015|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00722189||152640|
NCT00721435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00045519 (2002-0584)|Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions|Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions||University of Michigan|No|Active, not recruiting|April 2002|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|260|||Female|25 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721435||152697|
NCT00721448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00054|An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers|A Two-Cohort, Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Chinese Volunteers Living in China||AstraZeneca|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721448||152696|
NCT00721747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG/2007-01|Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer|Phase II, Open, Not Randomized Clinical Trial, to Evaluate the Sequential Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in her2 Negative Breast Cancer Patients||Grupo Oncológico Gallego|Yes|Active, not recruiting|January 2008|January 2015|Anticipated|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|83|||Female|18 Years|70 Years|No|||March 2012|March 15, 2012|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721747||152673|
NCT00722020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0078|HFCWO in Hospitalized Asthmatic Children|High Frequency Chest Wall Oscillation in Hospital Management of Asthmatic Children||Hill-Rom|No|Completed|July 2008|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Months|18 Years|No|||October 2015|October 22, 2015|July 23, 2008||No||No|August 25, 2015|https://clinicaltrials.gov/show/NCT00722020||152653|
NCT00722917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-379_201|Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus|A Phase II, Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-center Study to Determine the Efficacy and Safety of TAK-379 in Subjects With Type 2 Diabetes||Takeda|No|Terminated|July 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|323|||Both|18 Years|80 Years|No|||October 2011|October 12, 2011|July 24, 2008|Yes|Yes|Animal Toxicity Findings|No||https://clinicaltrials.gov/show/NCT00722917||152586|
NCT00722930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOTEL-FL1LC-0701|Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma|Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy|GOTEL-FL1LC|Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas|No|Recruiting|April 2008|April 2013|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||July 2008|July 25, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00722930||152585|
NCT00722644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA13802|Cognitive Behavioral Stress Management for HIV+ Drug Abusers|Cognitive Behavioral Treatment of HIV+ Drug Abusers||National Institute on Drug Abuse (NIDA)||Completed|September 1999|August 2007||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment||||450|||Both|18 Years|60 Years|No|||July 2008|July 23, 2008|July 23, 2008||||No||https://clinicaltrials.gov/show/NCT00722644||152606|
NCT00722904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H627-30777|Evaluation of Vascular Pathology With 3D, Time-Resolved Phase Contrast Magnetic Resonance Imaging (MRI)|Evaluation of Vascular Pathology With 3D, Time-Resolved Phase Contrast MRI||University of California, San Francisco|Yes|Completed|June 2007|September 2010|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients: primarily status post intervention for repair of aortic coarctation and        undergoing routine MRI follow up, but also adult patients with other vascular pathologies        undergoing routine MRI evaluation, who may be good candidates for 4D Flow blood flow        analysis.        Healthy subjects: healthy members of the radiology residency program and staff at UCSF.|October 2013|October 4, 2013|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722904||152587|
NCT00723177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5725|Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal|The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal|AV411|New York State Psychiatric Institute|No|Active, not recruiting|October 2008|December 2013|Anticipated|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|July 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00723177||152568|
NCT00723190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLON-303|Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-Label, Chronic Exposure Evaluation of the Safety of CLONICEL (Clonidine HCl Sustained Release) in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)||Shionogi Inc.|No|Completed|January 2008|June 2010|Actual|March 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|303|||Both|6 Years|17 Years|No|||September 2011|January 24, 2012|July 24, 2008|Yes|Yes||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00723190||152567|Efficacy results need to be reviewed in the context that the study is an open-label/non-placebo controlled study. No formal statistical testing of efficacy results has been done. No adjustments have been made to account for drop-outs or missing data.
NCT00723489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN YF08|Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis|A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2008|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|82|||Both|27 Years|43 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|July 25, 2008|No|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT00723489||152545|
NCT00723502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-002|Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients|An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection|FLASH|MerLion Pharmaceuticals GmbH|Yes|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||October 2008|June 15, 2009|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723502||152544|
NCT00723866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS94-087|Botulinum Toxin Type A and Modified Constraint-Induced Movement Therapy for Poststroke Upper Extremity Spasticity|Combined Botulinum Toxin Type A With Modified Constraint-Induced Movement Therapy for Chronic Stroke Patients With Upper Extremity Spasticity||Kaohsiung Veterans General Hospital.|Yes|Completed|December 2005|June 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|45 Years|75 Years|No|||July 2008|July 29, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723866||152516|
NCT00724139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol # 078|The Effect of Training With Custom-Made Biomechanical Perturbation Platform on Kinetics, Kinematics and Electromyography in Knee Osteoarthritis Patients|||HaEmek Medical Center, Israel||Recruiting|January 2008|May 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|50 Years|75 Years|No|||July 2008|July 28, 2008|July 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00724139||152495|
NCT00725036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1998-1496|Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes|A 24-month Multicentre, Open-label, Randomised, Parallel Group, Long Term Safety Trial Comparing Intensive Treatment of Pulmonary Inhaled Human Insulin With Insulin Aspart Administered s.c., Both in Combination With NPH, in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|September 2002|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|305|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|July 29, 2008||||No||https://clinicaltrials.gov/show/NCT00725036||152426|
NCT00728793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-101-101|A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors|A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced and Refractory Solid Tumors||Curis, Inc.|No|Completed|August 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|August 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728793||152139|
NCT00729092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08042105|Additional Positron Emission Tomography (PET) Scan of Brain in Patients Undergoing PET Scan for Diseases Unrelated to Brain|Additional (Positron Emission Tomography)PET Scan of Brain in Patients Undergoing PET Scan for Diseases Unrelated to Brain||Rush University Medical Center|No|Active, not recruiting|May 2008|December 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Between 18-80 years of age|May 2013|May 28, 2013|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729092||152117|
NCT00729118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08001|Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|September 2008|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|August 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729118||152116|
NCT00729391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD058320|Women-Focused HIV Prevention in the Western Cape|Women-Focused HIV Prevention in the Western Cape|WC-WHC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Active, not recruiting|September 2008|March 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|720|||Female|18 Years|33 Years|No|||April 2011|May 12, 2011|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00729391||152095|
NCT00729690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08021105|Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement|Effects of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Total Knee Replacement (TKA)||Rush University Medical Center|No|Completed|August 2008|July 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|48|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|August 5, 2008|Yes|Yes||No|October 18, 2012|https://clinicaltrials.gov/show/NCT00729690||152072|
NCT00720993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGS-08-001|Colorectal Cancer Screening Validation Study|Altered Gene Expression in Colorectal "Smears" of Individuals With Colon Cancer|CRC screening|IntelliGeneScan, Inc.|No|Enrolling by invitation|August 2008|May 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|165|Samples Without DNA|Rectal smears ("cytology brush") samples and RNA recovered from such materials.|Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing routine colonoscopy screening or patients scheduled for colorectal        cancer surgery.|February 2009|April 22, 2009|July 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720993||152730|
NCT00725348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT0700NED001|An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis|An Open-Label, Multi-Center Pilot Trial to Assess the Efficacy and Safety of Oral R115866 in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis||GlaxoSmithKline|No|Completed|April 2004|December 2006|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||July 2008|September 23, 2011|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00725348||152402|
NCT00725634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05538|A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma|A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors|P05538|AVEO Pharmaceuticals, Inc.|No|Completed|September 2008|December 2013|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|July 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725634||152380|
NCT00721565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROG-SCCI 08-001-1|An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial; Pilot Study)|An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial)|BEAT|University of Alabama at Birmingham|Yes|Completed|April 2006|August 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Female|18 Years|70 Years|No|||May 2015|May 9, 2015|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721565||152687|
NCT00721578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501089|A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections|An Observational Study Of Patients Receiving Therapy For Systemic Fungal Infections||Pfizer|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|23|||Both|18 Years|75 Years|No|Probability Sample|A database of outcomes in patients with proven or probable Systemic Fungal Infections        (SFI) treated with antifungals in 5 centers across India.|January 2011|January 6, 2011|July 22, 2008|Yes|Yes||No|July 28, 2010|https://clinicaltrials.gov/show/NCT00721578||152686|Primary and Secondary outcome measured were arbitrarily defined as they were not defined in the protocol.This study was terminated prematurely due to slow recruitment rate leading to a small (23) number of subjects analyzed.
NCT00722527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17665|Molecular Biology of Polycythemia and Thrombocytosis|Molecular Biology of Polycythemia and Thrombocytosis||University of Utah|No|Recruiting|July 2006|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|Subjects who have polycythemia and thrombocytosis will be included in the study.|March 2016|March 17, 2016|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722527||152615|
NCT00721760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10343|Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery|SAVE-HIP2|Sanofi|Yes|Completed|July 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1003|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|July 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721760||152672|
NCT00722033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PontificiauCC|Common Neonatal Procedures Could Affect the aEEG in <30 Weeks of Gestational Age Preterms|Effect of Common Neonatal Procedures Over the Amplitude- Integrated Electroencephalography Register in <30 Weeks Preterms.|ELECTROPREM|Pontificia Universidad Catolica de Chile|No|Not yet recruiting|August 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|N/A|30 Minutes|No|||July 2008|August 13, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722033||152652|
NCT00722046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951002|Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease|A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|December 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|198|||Both|50 Years|N/A|No|||October 2012|October 8, 2012|July 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00722046||152651|
NCT00722670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020852|Pregnant Women's CoOp|Woman-Focused HIV Prevention With Pregnant African-Americans||RTI International|No|Completed|June 2007|August 2010|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|N/A|No|||May 2013|May 7, 2013|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722670||152604|
NCT00723203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07174|Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60||City of Hope Medical Center|Yes|Terminated|April 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|July 25, 2008|Yes|Yes|Terminated early due to a lack of efficacy|No|June 12, 2014|https://clinicaltrials.gov/show/NCT00723203||152566|There were no responses observed in the first 12 evaluable patients accrued to the first stage of the two-stage Optimum design of Simon. As a result the study was terminated due to a lack of efficacy.
NCT00723515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPE 260/08|Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study|Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study||University of Pernambuco|No|Completed|February 2007|October 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Both|7 Years|12 Years|No|||July 2008|July 24, 2008|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723515||152543|
NCT00723879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04206|Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)|Evaluation of Adherence Rate in Patients Receiving PegIntron / Rebetol (Weight Based) for Hepatitis C in Conjunction With a Patient Assistance Program.||Merck Sharp & Dohme Corp.|No|Terminated|October 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|No|Probability Sample|Patients receiving a patient assistance program during therapy for Hepatitis C will be        enrolled into this study. All patients will receive PegIntron and Rebetol (according to        the label) and the patient assistance program, which includes (1) medications used for        treatment (psychiatric medications); (2) other interventions (nurse support); and (3)        educational literature.|November 2015|November 2, 2015|July 25, 2008|No|Yes|Because of slow recruitment; Despite the study was started long time ago (Oct 2004), we have    not reached the projected number of patients (150 patients)|No||https://clinicaltrials.gov/show/NCT00723879||152515|
NCT00723892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04252|Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)|Observatory on Treatment Adhesion in Patients Suffering From Hepatitis C Chronic Treated With ViraferonPeg® Injected / Rebetol® in Conjunction With a Psychotherapeutic Assistance Program||Merck Sharp & Dohme Corp.|No|Completed|July 2005|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|614|||Both|18 Years|N/A|No|Probability Sample|Participants at sites in France who are receiving a psychotherapy support program during        therapy for hepatitis C and a control group without a psychotherapy support program.|October 2015|October 29, 2015|July 25, 2008|No|Yes||No|August 25, 2010|https://clinicaltrials.gov/show/NCT00723892||152514|
NCT00724152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6324-P|Cognitive Behavioral Therapy (CBT) for Tinnitus|Cognitive-behavioral Therapy for Tinnitus||VA Office of Research and Development|No|Completed|February 2009|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|July 23, 2008||No||No|January 6, 2015|https://clinicaltrials.gov/show/NCT00724152||152494|During Period 2 only two participants (one completer) were randomized to "standard care" and only four participants (3 completers) were randomized "Cognitive Behavioral Therapy."
NCT00724438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15956A|Pharmacokinetics of Implanon in Obese Women|Pharmacokinetics of Implanon in Obese Women||University of Chicago|No|Completed|July 2008|December 2011|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|Samples With DNA|whole blood, serum, plasma|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from resident and faculty practices at the University of        Chicago outpatient facilities and from the University of Chicago clinical trails database        of past study participants.|September 2013|September 4, 2013|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724438||152472|
NCT00724724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A10-3|The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial|The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial|ESCAPE|Peking Union Medical College Hospital|Yes|Recruiting|August 2008|August 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|40 Years|75 Years|No|||February 2011|February 23, 2011|July 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00724724||152450|
NCT00724737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-0643|Presurgical Planning With Functional MRI (fMRI) Mapping of Motor Cortex in Patients With Cerebral Tumors|Presurgical Planning With Motion Corrected fMRI Mapping of Motor Cortex in Patients With Cerebral Tumors||University of Michigan|No|Completed|July 2006|August 2011|Actual|July 2011|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2011|August 4, 2011|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724737||152449|
NCT00729131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00008547|Functional Implications of TNF|Functional Implications of TNF||National Institute of Environmental Health Sciences (NIEHS)|No|Completed|August 2008|February 2012|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10|Samples With DNA|Bronchoalveolar lavage specimens.|Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy non-smokers (18-35 yr) will be recruited from the Duke campus and local community;        50% will be women. Subjects will have a clinical history and lung function screening at        protocol entry. Female subjects of childbearing age will have pregnancy testing. We will        only recruit subjects with a normal body habitus as an increased BMI may modify        sensitivity to O3. Subjects will have lung volumes within predicted normal, and FEV1, and        FEF25-75, within range of predicted, and methacholine response less than the mean Mch PC20        dose for non-asthmatic population in our human inhalation laboratory. Atopic status of        study subjects will be determined by lack of positive skin test by prick technique (using        panel of antigens common to central NC) and without seasonal or perennial allergic        symptoms.|September 2014|September 25, 2014|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00729131||152115|
NCT00725088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A02-10|Study of Rehabilitation Therapy on Patients After Acute Myocardial Infarction|Study of Rehabilitation Therapy on Patients After Acute Myocardial Infarction||Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|December 2006|December 2010|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|35 Years|74 Years|No|||July 2008|August 22, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725088||152422|
NCT00729404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91558|Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene|Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles||Bayer|No|Terminated|August 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729404||152094|
NCT00729417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0208|Obstetrical Risk Factors for the Development of Urinary and/or Fecal Incontinence|Obstetrical Risk Factors for the Development of Urinary and/or Fecal Incontinence||Maaynei Hayesha Medical Center|No|Not yet recruiting|August 2008|||August 2010|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|women of age 18 or above|August 2008|August 6, 2008|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729417||152093|
NCT00721591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13677B|Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy|Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy||University of Chicago|No|Active, not recruiting|March 2005|July 2014|Anticipated|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|14|Samples Without DNA|Plasma from subjects to obtain concentrations of heparin will be retained|Female|18 Years|44 Years|No|Non-Probability Sample|The study population will consist of 15 subjects prescribed dalteparin and 15 subjects        prescribed unfractionated heparin, who are identified through the University of Chicago        Recurrent Pregnancy Loss Program.|March 2014|March 27, 2014|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721591||152685|
NCT00721266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21495|A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.|An Open Label, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Tumor Growth Control Rate of RO5083945, a Glycoengineered Antibody Against EGFR, in Patients With Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.||Hoffmann-La Roche||Completed|June 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00721266||152709|
NCT00721851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/140/07|320-slice Coronary Computed Tomography (CT) Angiography|Coronary Artery Imaging With 320-slice Computed Tomography||Charite University, Berlin, Germany|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|40 Years|N/A|No|Probability Sample|Consecutive eligible patients referred to the Charité and scheduled to undergo        conventional coronary angiography.|February 2009|June 21, 2011|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721851||152665|
NCT00722202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3252K1-1001|Study Evaluating the Safety and Pharmacokinetics (PK) of Ascending Single IV Doses of ERB-257 in Healthy Japanese Males|Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 24, 2009|July 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722202||152639|
NCT00722774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 247|Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine|Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H2N2 (A/Ann Arbor/6/60 ca Recombinant), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N2 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed||||September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2008|November 7, 2008|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722774||152596|
NCT00722059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 13236|Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography|Assessment of Emerging Technology: Comparison of Breast Tomosynthesis and Digital Mammography in the Evaluation of Heterogeneously Dense and Extremely Dense Breasts||University of Michigan|No|Completed|April 2006|October 2013|Actual|October 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Female|30 Years|N/A|No|||January 2014|January 31, 2014|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722059||152650|
NCT00722384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU101|Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5|An Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 by Single Intravitreal Injection in Patients With Wet Age-Related Macular Degeneration||OPKO Health, Inc.|No|Completed|August 2004|December 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Both|55 Years|N/A|No|||July 2008|July 24, 2008|July 23, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00722384||152625|
NCT00722657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004|Social-Economics Profile of the Asthmatic Patients Attended at Nucleus of Integrated Medical Care|Social-Economics Profile of the Asthmatic Patients Attended at Nucleus of Integrated Medical Care||Fortaleza University|Yes|Completed|April 2006|June 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|40|None Retained|None Retained - no samples retained|Both|N/A|80 Years|No|Probability Sample|community sample|May 2008|July 23, 2008|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00722657||152605|
NCT00724750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14817A|Comparison of Two Methods of Negative Pressure Wound Therapy|Prospective Randomized Control Trial Comparing Two Methods of Negative Pressure Wound Therapy: Gauze Suction Versus Vacuum Assisted Closure Device||University of Chicago|Yes|Completed|July 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|July 25, 2008|No|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT00724750||152448|
NCT00724763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0609080136|The Effect of Acupuncture on Blood Pressure and Heart Rate Variability (HRV)|The Effect of Acupuncture on Blood Pressure and HRV|Acupuncture|Logan College of Chiropractic|No|Recruiting|July 2008|||July 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||July 2008|July 29, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724763||152447|
NCT00722943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28032|Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study|Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study|DMT|University of Utah|Yes|Completed|July 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|46|||Both|N/A|14 Days|No|||February 2013|February 6, 2013|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722943||152584|
NCT00723216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10094|Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery|Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates.||Sanofi|No|Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|151|||Both|40 Years|N/A|No|||April 2010|April 2, 2010|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723216||152565|
NCT00723229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34187-B|A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation|A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults||University of Washington|No|Active, not recruiting|August 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2010|July 20, 2010|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00723229||152564|
NCT00723528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015166|An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis|A Placebo-Controlled Double-Blind Comparative Study of CNTO1275 in Patients With Plaque Type Psoriasis||Janssen Pharmaceutical K.K.|No|Completed|March 2008|March 2010|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|158|||Both|20 Years|N/A|No|||April 2014|April 22, 2014|July 24, 2008|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00723528||152542|
NCT00723541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00003483|Breast Lesion Analysis for Tomosynthesis Mammography|Tomosynthesis Mammography: Computer-Aided Analysis of Breast Lesions||University of Michigan|No|Recruiting|January 2008|December 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|800|||Female|21 Years|N/A|No|||December 2015|December 8, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723541||152541|
NCT00723905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100746|Remicade Infusion Management Program|Remicade Infusion Management Program|RemiTRAC|Janssen Inc.|No|Completed|August 2005|October 2012|Actual|October 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1630|||Both|N/A|N/A|No|Non-Probability Sample|The data captured and reported in this registry will reflect a "real world" approach to        the treatment of Rheumatoid Arthritis and Crohn's Disease with infliximab.|January 2013|January 14, 2013|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00723905||152513|
NCT00724776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABF656A1202|Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients|A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Single Dose of Albinterferon Alfa 2b (Alb-IFN), Recombinant Human Albumin-interferon Alfa Fusion Protein in Japanese Chronic Hepatitis C Patients.||Novartis|No|Completed|July 2008|||July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|69 Years|No|||August 2010|August 10, 2010|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724776||152446|
NCT00724165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR009864|Seamos Activas: Increasing Physical Activity Among Latinas|Seamos Activas: Increasing Physical Activity Among Latinas||University of California, San Diego|No|Completed|September 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|106|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724165||152493|
NCT00724451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05488|Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)|Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice||Merck Sharp & Dohme Corp.|No|Completed|July 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1128|||Both|18 Years|N/A|No|Probability Sample|Consecutive adult patients with chronic hepatitis C seen in common clinical practice at        approximately 54 sites in Italy. Treatment for hepatitis C is determined at the local site        (pegylated interferon a or b/ribavirin).|September 2015|September 24, 2015|July 25, 2008|No|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT00724451||152471|
NCT00724464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05209|Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)|A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice||Merck Sharp & Dohme Corp.|No|Completed|December 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|332|||Both|18 Years|N/A|No|Probability Sample|Treatment-naïve participants with chronic hepatitis C treated with PegIntron and Rebetol        in accordance with approved labeling in clinical practice in Greece prior to enrollment in        the current study. Data from patients treated at approximately 28 sites will be        retrospectively analyzed.|October 2015|October 16, 2015|July 25, 2008||No||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00724464||152470|
NCT00720733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMH084723A|Intervention for (Those) Recently Informed of Seropositive Status (IRISS)|A Positive Affect Intervention for Those Recently Diagnosed With HIV|IRISS|University of California, San Francisco|No|Completed|September 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720733||152748|
NCT00721006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01-II|Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia|Phase II Safety/Efficacy Study of A Combination Stem Cell Therapy That Develops Mature Stable Vessel Formation in Ischemic Limbs|MESENDO|TCA Cellular Therapy|Yes|Completed|June 2008|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|35|||Both|19 Years|N/A|No|||September 2010|May 7, 2014|July 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721006||152729|
NCT00721279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.655|Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome|Sifrol Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary RLS||Boehringer Ingelheim||Completed|September 2007|||October 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|549|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with idiopathic RLS|May 2014|May 19, 2014|July 23, 2008||||No|October 22, 2009|https://clinicaltrials.gov/show/NCT00721279||152708|
NCT00720707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|841|Coronally Advanced Flap in Combination With Acellular Dermal Matrix and Enamel Matrix Derivatives for Root Coverage|Coronally Advanced Flap in Combination With Acellular Dermal Matrix With or Without Enamel Matrix Derivatives for Root Coverage||Tabriz University|Yes|Completed|April 2006|March 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|65 Years|No|||July 2008|July 22, 2008|July 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720707||152750|
NCT00720720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-03|Effect of Phytosterols Enriched Products Consumption on Carotid Artery Artherosclerotic Plaque|Effect of Phytosterols Enriched Products Consumption on Carotid Artery Artherosclerotic Plaque|PHYTOPLAQUES|French Cardiology Society|Yes|Terminated||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|0|||Both|40 Years|75 Years|No|||July 2008|April 2, 2010|July 21, 2008||No|Recruitment and organizational difficulties|No||https://clinicaltrials.gov/show/NCT00720720||152749|
NCT00721604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-TIP-03|Fluid Responsiveness Prediction at the Bedside|Prediction of Volume Expansion Effectiveness in Hypotensive Critically Ill Patients.||Fondazione Poliambulanza Istituto Ospedaliero|No|Completed|July 2008|May 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Hypotensive patients in a General Intensive Care Unit of a University-affiliated hospital.        Patients can be recruited only if they have both arterial and central venous catheters|July 2009|July 31, 2009|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721604||152684|
NCT00721864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17790|The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)|The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)||University of Utah|No|Completed|May 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Whole Blood|Both|7 Years|N/A|No|Non-Probability Sample|Patients with paroxysmal nocturnal hemoglobinuria (PNH)|August 2011|August 5, 2011|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00721864||152664|
NCT00722514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0110599604|Evaluation of a Patient Education Program for Ankylosing Spondylitis|Evaluation of a Patient Education Program for Ankylosing Spondylitis||Rehazentrum Bad Eilsen||Completed|July 1998|July 2001||February 2001||N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||July 2008|August 14, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722514||152616|
NCT00722540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8630-1958|Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083|Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NCC126-0083 in Healthy Male Japanese Subjects.||Novo Nordisk A/S|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|July 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722540||152614|
NCT00723736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04446|Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)|Non-Interventional Study of the Safe Use of Aerius in Pediatric Patients With Allergic Rhinitis or Chronic Idiopathic Urticaria.||Merck Sharp & Dohme Corp.|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|1 Year|5 Years|No|Non-Probability Sample|Pediatric clinics around Hungary.|April 2015|April 9, 2015|July 25, 2008||No||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00723736||152526|
NCT00723749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05603|Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)|Post-marketing Surveillance Study (Paper-AWB) for GPs and Clinics: Treatment of Opioid-dependent Patients With SUBOXONE® 2 mg / 8 mg Sublingual Tablets - Acceptability and Safety Data From a Real Life Scenario.||Indivior Inc.|Yes|Completed|March 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|384|||Both|15 Years|N/A|No|Non-Probability Sample|Opioid-dependent patients for whom a drug dependence therapy with SUBOXONE® is planned and        indicated, and who have already been pre-treated with SUBUTEX®, or another maintenance        drug for at least 6 months.|April 2012|April 26, 2012|July 25, 2008||No||No|January 11, 2012|https://clinicaltrials.gov/show/NCT00723749||152525|
NCT00722072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000601002|Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy|A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment||OHSU Knight Cancer Institute||Terminated|July 2008|July 2012|Actual|July 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|120 Years|No|||October 2015|October 20, 2015|July 24, 2008|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00722072||152649|
NCT00722397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND - DK61230-GENETICS|TODAY Genetics Study|Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Genetics Study||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|August 2008|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|2654|Samples With DNA|Collect 27 mL of blood to send (1) for extraction of DNA to the NIDDK Central Repository and      (2) for measurement of glucose, C-peptide, and autoantibody analysis to a central blood      laboratory.|Both|N/A|N/A|No|Probability Sample|Recruitment is conducted within a 'catchment' area that includes (a) the patient pools of        the 15 TODAY clinical centers and (b) collaborating clinics and physicians who either        refer subjects to a TODAY site or obtain IRB approval to conduct the protocol at their own        locale.|June 2015|June 3, 2015|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722397||152624|
NCT00720954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.11.008|Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy|Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy For Diagnosis of Patients With Pleural Effusions: A Randomized Control Trial||Eskisehir Osmangazi University||Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Diagnostic|2||Actual|124|||Both|18 Years|85 Years|No|||July 2008|July 22, 2008|July 21, 2008||||No||https://clinicaltrials.gov/show/NCT00720954||152733|
NCT00721201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14791|Glucocorticoid Receptor Antagonism in Subclinical Cushings|A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|November 2008|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||July 2010|May 26, 2011|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721201||152714|
NCT00721539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0026|Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract|A Pilot Study Assessing Transoral Robotic Surgery (TORS) For Oral And Laryngopharyngeal Benign And Malignant Lesions Using The da Vinci® Robotic Surgical System||Stanford University|Yes|Terminated|September 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|9|||Male|18 Years|N/A|No|||September 2012|September 30, 2012|July 22, 2008||No|Low Accrual|No||https://clinicaltrials.gov/show/NCT00721539||152689|
NCT00721370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000431|Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer|Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer||Beth Israel Deaconess Medical Center|No|Completed|July 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|21 Years|N/A|No|||February 2013|February 14, 2013|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00721370||152702|
NCT00721383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04092307|Telephone Resources and Assistance for Caregivers (TRAC)|Clinical Trial to Enhance Caregiver Physical Activity|TRAC|Rush University Medical Center|Yes|Completed|May 2007|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|211|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 30, 2014|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721383||152701|
NCT00721396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P12|Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules|A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.||Novartis|Yes|Completed|August 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1885|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||March 2015|March 17, 2015|July 22, 2008|Yes|Yes||No|February 18, 2015|https://clinicaltrials.gov/show/NCT00721396||152700|
NCT00717340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-08-104|A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer|A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer||AVEO Pharmaceuticals, Inc.|No|Completed|February 2009|February 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||June 2012|June 27, 2012|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717340||153005|
NCT00717912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRODEX 9708|Determination of the Glycemic Index and the Insulinemic Index of a Sweetener Syrup|Determination of the Glycemic Index and the Insulinemic Index of a Sweetener||Routin SA|Yes|Recruiting|July 2008|September 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2008|July 17, 2008|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717912||152961|
NCT00718276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-09-13-HyD|Pharmacokinetic Study: Effect of 25(OH)D and Vitamin D3 on Serum 25(OH)D|Pharmacokinetic Study in Healthy Postmenopausal Women to Compare Supplementation of Vitamin D3 to 25(OH)D||University of Zurich|Yes|Completed|March 2008|September 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Female|50 Years|75 Years|Accepts Healthy Volunteers|||December 2011|December 22, 2011|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718276||152934|
NCT00718575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0587-AE|The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation|A Prospective, Randomized Trial to Investigate the Effects of Glucose/ Ischemic Preconditioning Donor Pre-treatment on Reperfusion Injury in Deceased-Donor Liver Transplantation||University Health Network, Toronto|No|Terminated|August 2008|March 2012|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||June 2012|July 24, 2014|July 16, 2008||No|too few patients meeting current eligibility criteria|No||https://clinicaltrials.gov/show/NCT00718575||152911|
NCT00719485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yee_1|A Study on the Use of Educational Programs Prior to Lumbar Spinal Surgery|A Prospective Randomized Control Trial Assessing the Effect of Two Different Educational Programs on Functional Outcome and Quality of Life Scores for Patients Having Posterior Decompressive Lumbar Spinal Surgery for Degenerative Conditions of the Lumbar Spine||Sunnybrook Health Sciences Centre|No|Not yet recruiting|April 2009|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|80 Years|No|||July 2008|February 5, 2009|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719485||152842|
NCT00719719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080184|Cause of Unexplained Anaphylaxis|Studies in the Pathogenesis of Idiopathic Anaphylaxis||National Institutes of Health Clinical Center (CC)||Recruiting|July 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|13 Years|60 Years|No|||December 2015|December 15, 2015|July 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00719719||152824|
NCT00720031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 98/9-C|Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones|Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones||Nantes University Hospital|No|Completed|November 2000|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2008|July 22, 2008|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720031||152800|
NCT00724321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58205|Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude|Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction With Exercise at High Altitude||Loma Linda University|No|Withdrawn|July 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|July 25, 2008||No|PI has left the institution. We are unable to locate any study records to determine if    subjects were enrolled.|No||https://clinicaltrials.gov/show/NCT00724321||152481|
NCT00723710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04600|Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)|Guidelines to the Intron A® Health Management Program II: A Nursing Support Program for Patients With High-Risk Melanoma Receiving High Dose Intron A Therapy||Merck Sharp & Dohme Corp.|No|Completed|April 2006|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|299|||Both|18 Years|N/A|No|Probability Sample|Approximately 300 patients with malignant melanoma who are free of disease but at high        risk for systemic recurrence. The study is conducted in Canada.|August 2015|August 24, 2015|July 25, 2008|No|Yes||No|August 21, 2013|https://clinicaltrials.gov/show/NCT00723710||152528|
NCT00723723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05467|Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)|Compliance With LDL-Lowering Therapy For Secondary Prevention of Coronary Heart Disease in Real Life Practice||Merck Sharp & Dohme Corp.|No|Completed|January 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|555|||Both|18 Years|N/A|No|Probability Sample|Patients being treated with a statin for secondary prevention of coronary heart disease|August 2015|August 11, 2015|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723723||152527|
NCT00724906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSE-A-02a, ALSE-A-02b|Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor|Evaluation of the Diagnostic Accuracy and Safety of 123 I-ALTROPANE® as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes (POET-2)|POET-2|Alseres Pharmaceuticals, Inc|No|Not yet recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|240|||Both|40 Years|80 Years|No|||February 2010|February 2, 2010|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00724906||152436|
NCT00724607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-167|Brain Injury Outcomes (BIO) Study|Validation of Brief Objective Neurobehavioral Detectors of Mild TBI|BIO|VA Office of Research and Development|No|Recruiting|May 2008|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Tissue samples are requested for 1.) current laboratory measures, 2.) current genomic,      immunologic, angiogenic and endocrine measures, and 3.) future unknown measures.|Both|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|OEF/OIF/OND veterans with and without mTBI and/or PTSD|September 2015|September 23, 2015|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00724607||152459|
NCT00725192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT004079-01A1|Sleep-directed Hypnosis As A Complement To Cognitive Processing Therapy (CPT) In Treating Posttraumatic Stress Disorder (PTSD)|Sleep-directed Hypnosis As A Complement To CPT In Treating PTSD|Hypnosis|Center for Trauma Recovery, St Louis|No|Active, not recruiting|July 2008|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||April 2011|April 6, 2011|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725192||152414|
NCT00724919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910X-101440|A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli|Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2003|April 2004|Actual|April 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|256|||Both|18 Years|N/A|No|Non-Probability Sample|patients admitted to ICU/burn unit|August 2008|August 7, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00724919||152435|
NCT00720811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A60487|Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs|Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs||Mbarara University of Science and Technology|Yes|Completed|October 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6456|||Both|4 Months|59 Months|No|||March 2012|March 15, 2012|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720811||152743|
NCT00721071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009154|Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis|Diagnostic Utility of Induced Sputum Using Hypertonic Saline to Evaluate Airway Infection and Inflammation in Cystic Fibrosis||The Hospital for Sick Children|No|Completed|December 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|95|||Both|6 Years|18 Years|No|||August 2013|August 30, 2013|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721071||152724|
NCT00721084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16079A-S1|Fitness and Sleep in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk||University of Chicago|No|Completed|July 2008|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|||Both|21 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy non-obese community-living men and women with a parent, sibling or grandparent who        has type 2 diabetes|September 2013|September 4, 2013|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721084||152723|
NCT00726739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006LS046|Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma||Masonic Cancer Center, University of Minnesota|Yes|Terminated|June 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|July 31, 2008|Yes|Yes|Pre-planned analysis established it unlikely study would meet primary objective.|No|August 29, 2012|https://clinicaltrials.gov/show/NCT00726739||152297|
NCT00726752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061044|A Study In Patients With Advanced Solid Tumor|A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 At Single Doses Of 5 mg, 7 mg And 10 mg, And At Multiple Doses||Pfizer|No|Completed|July 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||May 2012|May 17, 2012|July 30, 2008|No|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00726752||152296|
NCT00717925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K1-103|Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)|A Phase 1 Study Of CMC-544 Administered As A Single Agent In Subjects With B-Cell Non-Hodgkin's Lymphoma||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|74 Years|No|||December 2015|December 7, 2015|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717925||152960|
NCT00718289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012008|Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes|Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes||Ospedale Regionale di Locarno|No|Completed|March 2007|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||July 2008|July 17, 2008|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718289||152933|
NCT00718302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27190|A Multicenter Randomized Trial Comparing Antiglide and Lateral Plate Fixation in Ankle Fractures|Ankle Fracture Plating: A Multicenter Randomized Trial Comparing Lateral and Antiglide Plating in Displaced Lateral Malleolus Fractures||Boston Medical Center|Yes|Completed|June 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|249|||Both|18 Years|85 Years|No|||March 2013|March 5, 2013|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718302||152932|
NCT00719160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408026977|The Effect of Protein on Calcium Absorption and Gastric Acid Production|Dietary Protein's Effect on Gastric pH and Calcium Absorption||Yale University|No|Completed|January 2005|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|July 17, 2008|No|Yes||No|January 26, 2012|https://clinicaltrials.gov/show/NCT00719160||152867|
NCT00719173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0514|Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer|Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|August 2005|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00719173||152866|
NCT00720057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13130|Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet in Postsurgical Dental Pain||Bayer|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|312|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|July 1, 2008|Yes|Yes||No|January 3, 2011|https://clinicaltrials.gov/show/NCT00720057||152799|
NCT00719771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05071|Global® AP™ Total Shoulder Arthroplasty|A Multi-center Clinical Study of the Global® AP™ Shoulder in Total Shoulder Arthroplasty||DePuy Orthopaedics|No|Completed|January 2008|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|70 Years|No|||December 2013|May 20, 2014|July 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00719771||152820|
NCT00720356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07C3|Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation||Northwestern University|Yes|Active, not recruiting|March 2009|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|July 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720356||152777|
NCT00723073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000605/1; BWH|Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia|Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis||Brigham and Women's Hospital|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|323|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients who are persistently febrile and neutropenic after receiving broad        spectrum antibiotics and receive empiric antifungal therapy with either caspofungin or        micafungin|August 2010|August 25, 2010|July 24, 2008||No||No|June 7, 2010|https://clinicaltrials.gov/show/NCT00723073||152575|Retrospective, observational, sequential cohort study conducted at a single center. Only adult patients were treated at our institution, so these results cannot be extrapolated to a pediatric population.
NCT00723086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD6563|Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer|An Extension Multicenter Phase II Open Label Non-comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer.||Sanofi|No|Completed|May 2005|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|N/A|N/A|No|||September 2009|September 30, 2009|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723086||152574|
NCT00724074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|garnett|The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty|The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty||Capital Health, Canada|Yes|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|69 Years|No|||July 2008|July 25, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724074||152500|
NCT00724594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS052448|Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)|Safety of N-acetylcysteine in Maternal Chorioamnionitis||Medical University of South Carolina|Yes|Completed|August 2008|August 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|13 Years|N/A|No|||May 2015|May 8, 2015|July 28, 2008|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00724594||152460|
NCT00724620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04511|PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)|Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response and Tolerability, in These Patients.||Schering-Plough|No|Completed|June 2005|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|65 Years|No|||July 2008|July 25, 2008|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00724620||152458|
NCT00724633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-252|Effect of Lowering the Dialysate Sodium on Blood Pressure in Hemodialysis Patients|Effect of Lowering the Dialysate Sodium on Blood Pressure in Hemodialysis Patients: a Randomized Controlled Trial.||Lawson Health Research Institute|Yes|Recruiting|November 2011|November 2014|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724633||152457|
NCT00725205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04690|Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)|Patient Compliance During PegIntron (Injection Pen) and Rebetol Combination Therapy in Chronic Hepatitis C||Merck Sharp & Dohme Corp.|No|Completed|March 2006|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|294|||Both|18 Years|N/A|No|Non-Probability Sample|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection        pen) and Ribavirin combination therapy as their usual medical treatment according to the        approved dosage/regimen were selected for this study.|October 2015|October 7, 2015|July 25, 2008||No||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00725205||152413|
NCT00729794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSE-226-2008|Vasopressin, Epinephrine, and Steroids for Cardiac Arrest|Vasopressin, Epinephrine, and Corticosteroids for Inhospital Cardiac Arrest: A Multicenter Randomized Controlled Trial|VSE-2|University of Athens|Yes|Completed|September 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00729794||152064|
NCT00725218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-MZ203|Flurbiprofen Axetil for Uterine Contraction Pain|Phase IV Study of Flurbiprofen Axetil for Uterine Contraction Pain After Abortion|FAUCOP|Nanjing Medical University|Yes|Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Female|19 Years|45 Years|No|||May 2008|August 5, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725218||152412|
NCT00720824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Berberich|Reduction of Immunization Discomfort in Children|Reduction of Immunization Discomfort in 4-6 Year Old Children: A Randomized Clinical Trial.||Berberich, F. Ralph, M.D.|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||July 2008|July 22, 2008|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720824||152742|
NCT00720837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0610|Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors|Pilot Study Evaluating the Feasibility of Real-Time, Magnetic Resonance Thermal Imaging (MRTI) and Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors||M.D. Anderson Cancer Center|No|Terminated|July 2008|||October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||October 2012|October 10, 2012|July 21, 2008|Yes|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00720837||152741|
NCT00726388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-010|An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain|An Open-Label, Multiple-Dose, Multiple-Day, Non-Randomized, Single-Arm Safety Study Of Repeat-Doses Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain||Javelin Pharmaceuticals|No|Active, not recruiting|September 2008|May 2009|Anticipated|April 2009|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|850|||Both|18 Years|85 Years|No|||April 2009|April 17, 2009|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726388||152323|
NCT00726401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-E002-2007-2|A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis||Afexa Life Sciences Inc|No|Completed|May 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||October 2010|October 7, 2010|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726401||152322|
NCT00726986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8507|Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Sorafenib in Conjunction With Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Terminated|July 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|July 31, 2008|Yes|Yes|Extreme toxicity|No|July 8, 2014|https://clinicaltrials.gov/show/NCT00726986||152278|This study was terminated after enrolling 18 patients on the basis of excessive toxicity observed and preliminary efficacy data showing that study was unlikely to meet primary end point.
NCT00717938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2007-006033-14|A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer|A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer|RASTEN|Lund University Hospital|No|Recruiting|June 2008|April 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717938||152959|
NCT00717951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAX625|A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer|A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer||Academy Military Medical Science, China|Yes|Active, not recruiting|May 2008|May 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|N/A|No|||May 2008|July 24, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717951||152958|
NCT00719186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMN-PPCOSII|Pregnancy in Polycystic Ovary Syndrome II|A 20 Week Double-Blind Randomized Trial of Clomiphene Citrate and Letrozole for the Treatment of Infertility in Women With Polycystic Ovary Syndrome|PPCOSII|Yale University|Yes|Completed|February 2009|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|750|||Female|18 Years|40 Years|No|||May 2014|May 12, 2014|July 17, 2008|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT00719186||152865|
NCT00719199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMO-2055-210|Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer|Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease||EMD Serono|No|Terminated|January 2009|August 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|July 17, 2008|No|Yes|Sponsor will discontinue further development of EMD 1201081|No||https://clinicaltrials.gov/show/NCT00719199||152864|
NCT00719472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U4391g|A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)|A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma|RATE|Genentech, Inc.||Completed|July 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|451|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|July 18, 2008|Yes|Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00719472||152843|
NCT00719732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-001|Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3|Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3||Alcon Research|No|Completed|September 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|218|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2010|March 4, 2010|July 21, 2008||No||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00719732||152823|
NCT00720070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597895|PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer|A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer||National Cancer Institute (NCI)||Recruiting|September 2007|||August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|2||Anticipated|560|||Both|18 Years|N/A|No|||December 2008|August 23, 2013|July 19, 2008||||No||https://clinicaltrials.gov/show/NCT00720070||152798|
NCT00720083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0619|Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer|A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck||Radiation Therapy Oncology Group|Yes|Terminated|November 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|July 19, 2008|Yes|Yes|Withdrawal of drug supply.|No|March 22, 2013|https://clinicaltrials.gov/show/NCT00720083||152797|This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed.
NCT00719784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147/2008|Vibration Response Imaging in the Diagnosis of Pulmonary Disease|Vibration Response Imaging in the Diagnosis of Pulmonary Disease - an Exploratory Study||Singapore General Hospital|No|Completed|July 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|21 Years|N/A|No|||June 2009|June 23, 2009|July 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00719784||152819|
NCT00720369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000738/1|CoQ10 in Geriatric Bipolar Depression|Oral Administration of CoQ10 and Phosphorus-31 Magnetization Transfer Magnetic Resonance Spectroscopy in Geriatric Bipolar Disorder and Healthy Older Adults|CoQ10|Mclean Hospital|Yes|Completed|July 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|42|||Both|55 Years|89 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|July 18, 2008|Yes|Yes||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00720369||152776|
NCT00720382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP436|A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis|Active Controlled Trial of the Safety and Tolerability of MP 03-036 (Astepro 0.15%) in Patients With Perennial Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|March 2007|July 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|703|||Both|12 Years|N/A|No|||May 2015|May 4, 2015|July 21, 2008|Yes|Yes||No|November 6, 2009|https://clinicaltrials.gov/show/NCT00720382||152775|
NCT00724061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07H4|Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL|Pilot Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy in Cutaneous T-Cell Lymphoma||Northwestern University|Yes|Terminated|September 2008|December 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|July 26, 2008|No|Yes|Closed early due to poor accrual.|No|November 25, 2013|https://clinicaltrials.gov/show/NCT00724061||152501|Only 7 patients were enrolled before the study was terminated by the Data Monitoring Committee due to poor accrual. Accrual was limited by a worldwide psoralen shortage and well as the exclusion of patients with prior UV light exposure.
NCT00723762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valproic Acid-Albumin|Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients|Valproic Acid-associated Hypoalbuminemia in Medically Fragile Pediatric and Young Adult Patients in a Long Term Care Facility Part 1: Potential Mechanism for Decreased Albumin Synthesis||Akron Children's Hospital|No|Completed|February 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control||3|Anticipated|90|Samples Without DNA|Serum and urine samples from patients receiving VPA.|Both|N/A|N/A|No|Non-Probability Sample|Medically fragile residents of the Hattie Larlham Long Term Care Facilit.|March 2011|March 8, 2011|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723762||152524|
NCT00728910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807965 CNTR|Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study|Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study|CENTAUR|University of Pennsylvania|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|August 4, 2008|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00728910||152130|
NCT00728923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5707|Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)|Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)||New York State Psychiatric Institute|Yes|Completed|August 2008|July 2011|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|No|||March 2012|March 30, 2012|July 31, 2008||No||No|August 29, 2011|https://clinicaltrials.gov/show/NCT00728923||152129|
NCT00724334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED12015|A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis|An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis||Sanofi|No|Completed|July 2008|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00724334||152480|
NCT00724347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4739-R|PC-Based Rehabilitation of Auditory Function|PC-based Rehabilitation of Auditory Function|CINT|VA Office of Research and Development|No|Completed|July 2008|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|July 24, 2008||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT00724347||152479|Five publications describing the new tests that we developed have appeared.
NCT00729547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRF-2005-079-HS0012|The Therapeutic Efficacy of Neurofeedback in Depression|The Therapeutic Efficacy of Frontal EEG Asymmetry Neurofeedback in Depression|neurofeedback|Korea University|No|Completed|September 2006|January 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|60 Years|No|||September 2006|August 4, 2008|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729547||152083|
NCT00729781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|925|Study of Polyester Implants for the Treatment of External Nasal Valve Collapse (NVC)|Open Label, Baseline Controlled Study to Evaluate the Use of Polyethylene Terephthalate (PET) Implants for the Treatment of External Nasal Valve Collapse and Cosmetic Contour Deformity|NVC|Medtronic Xomed, Inc.|No|Terminated|April 2008|January 2011|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|August 5, 2008|Yes|Yes|Strategic Business Decision|No|August 23, 2011|https://clinicaltrials.gov/show/NCT00729781||152065|
NCT00725478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIR-001/K|SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease|Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.|PIR-001/K|Desitin Arzneimittel GmbH|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Morbus Parkinson who require therapy with dopamine agonists.|July 2008|March 30, 2010|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725478||152392|
NCT00725803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-227-0102|Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV|A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects With Chronic Hepatitis C (GS-US-227-0102)||Gilead Sciences|No|Completed|April 2008|March 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|65 Years|No|||June 2014|June 11, 2014|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725803||152367|
NCT00725816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2006|||||N/A|N/A|N/A||||||||||||||March 14, 2016|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725816||152366|
NCT00726076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006628|Managing Epilepsy Well- WebEase Project|Managing Epilepsy Well: Self-Management Intervention Research-Coordinating Center||Emory University|No|Completed|July 2008|November 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|194|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726076||152346|
NCT00726414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-1613|A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg|A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg Under Fasting and Fed Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|December 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 13, 2010|July 30, 2008|No|Yes||No|December 4, 2009|https://clinicaltrials.gov/show/NCT00726414||152321|
NCT00727922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071203|Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity|Evaluation of Mangafodipir Protective Activity Against Oxaliplatin Neurotoxicity|MnDPDP-K04|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2008|April 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2011|December 15, 2011|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727922||152206|
NCT00717665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESA 5970|Self-monitoring of Blood Pressure in Primary Care|Self-monitoring of Blood Pressure in Primary Care in Older Diabetic Patients With Uncontrolled Systolic Hypertension||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|June 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|30 Years|N/A|No|||June 2011|June 24, 2011|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717665||152980|
NCT00717678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGXLKTx-0701-TW|A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients|A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF in de Novo Kidney Transplant Recipients||Astellas Pharma Inc|No|Completed|December 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|12 Years|N/A|No|||December 2015|December 16, 2015|July 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00717678||152979|
NCT00718848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186223|Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease|Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease||St. Michael's Hospital, Toronto|No|Completed|July 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|67|Samples Without DNA|Serum and plasma.|Both|18 Years|N/A|No|Non-Probability Sample|The patients who convert to in-centre nocturnal hemodialysis and their matched controls        will be drawn from a population of prevalent chronic hemodialysis patients.|October 2015|October 13, 2015|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00718848||152890|
NCT00718861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2301E2|3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs|A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis||Novartis|Yes|Completed|May 2008|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Female|65 Years|N/A|No|||September 2014|October 2, 2014|July 18, 2008|Yes|Yes||No|November 8, 2013|https://clinicaltrials.gov/show/NCT00718861||152889|
NCT00718887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-171|Suboptimal Responders to Adefovir Switching to Entecavir|A Comparative Study of the Week 12 Antiviral Efficacy and Safety of Switching to Entecavir vs. Continuing Adefovir Treatment in Adults With Chronic Hepatitis B and Suboptimal Response to Adefovir||Bristol-Myers Squibb|No|Completed|July 2008|January 2011|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Both|16 Years|N/A|No|||January 2013|January 4, 2013|July 17, 2008|Yes|Yes||No|October 17, 2012|https://clinicaltrials.gov/show/NCT00718887||152887|
NCT00718926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C244|The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients|The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients||Meiji University of Oriental Medicine|Yes|Not yet recruiting|August 2008|March 2010|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|50|Samples Without DNA|After application of anethesia eyedrops, nitrocel membrane is put ocular surface. Then,      removed the membrane. This method is commonly used clinically.|Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The dry eye patients at the clinic of Kyoto Prefectural University of Medicine hospital|May 2008|July 18, 2008|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00718926||152885|
NCT00718939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360014|Rheos® Diastolic Heart Failure Trial|Rheos® Diastolic Heart Failure Trial||CVRx, Inc.|No|Completed|July 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|21 Years|N/A|No|||May 2013|May 1, 2013|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718939||152884|
NCT00719212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO 015|Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer|A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer||Translational Research in Oncology|Yes|Completed|January 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|July 18, 2008|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00719212||152863|
NCT00719225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-056|A Belatacept Compassionate Use Study for Patients With a Kidney Transplant|Belatacept for Renal Allograft Recipients: A Compassionate Use Program||Bristol-Myers Squibb|No|Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||July 2011|July 13, 2011|July 17, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00719225||152862|
NCT00716079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC-571281|The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial|An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage.|INTERACT2|The George Institute|Yes|Completed|September 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2839|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|July 14, 2008||No||No|August 21, 2013|https://clinicaltrials.gov/show/NCT00716079||153102|
NCT00720395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH085026|Identifying Predictors of Bipolar Disorder Relapse During Pregnancy and the Postpartum Period|Predictors of Postpartum Relapse in Women With Bipolar Disorder||National Institute of Mental Health (NIMH)|Yes|Withdrawn|August 2005|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Plasma, serum, and urine samples are processed and stored at each study visit.|Female|18 Years|45 Years|No|Non-Probability Sample|This study will include women who are pregnant or recently gave birth and who meet DSM-IV        criteria for any subtype of bipolar disorder.|March 2009|May 6, 2015|July 18, 2008||No|Withdrawn [Funding was never granted for this study. No participants were ever enrolled.]|No||https://clinicaltrials.gov/show/NCT00720395||152774|
NCT00720408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGXLLTx-0702-TW|A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.|A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF and Steroid Withdraw in de Novo Liver Transplant Recipients.||Astellas Pharma Inc|No|Completed|December 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|70 Years|No|||September 2009|September 14, 2009|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720408||152773|
NCT00720421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00003|A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.|A Phase 1, Single Centre, Single Dose, Double-blind, Double-dummy, Four-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effects of AZD7325 on Sedation, Cognition and Electroencephalogram (EEG) in Comparison With Lorazepam in Healthy Male Volunteers.||AstraZeneca|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2008|December 8, 2010|July 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720421||152772|
NCT00716066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2260.00|Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy|High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases||Fred Hutchinson Cancer Research Center|No|Recruiting|June 2008|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|70 Years|No|||September 2015|September 11, 2015|July 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00716066||153103|
NCT00723775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRR110744|GSK706769/KALETRA Drug-drug Interaction Study|Phase I, Open Label Drug-drug Interaction Study in Healthy Volunteers to Evaluate the Effect of KALETRA (Lopinavir-ritonavir) on GSK706769 Pharmacokinetics and to Evaluate the Pharmacokinetics of a New Oral Formulation of GSK706769||GlaxoSmithKline||Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|July 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00723775||152523|
NCT00723788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC4024|Magnetic Resonance Imaging (MRI) of Appendicitis in Children|Magnetic Resonance Evaluation of Appendicitis in Children Aged 8-18||Children's Research Institute|No|Completed|August 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|21|||Both|8 Years|18 Years|No|||November 2014|November 14, 2014|July 25, 2008|Yes|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT00723788||152522|
NCT00729261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210-04|A Prospective Trial of Elective Extubation in Brain Injured Patients.|A Prospective Trial of Elective Extubation in Brain Injured Patients Meeting Extubation Criteria for Ventilatory Support.||Mayo Clinic|No|Completed|August 2004|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||August 2008|April 27, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00729261||152105|
NCT00729248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KV-08-001|The Differential Effects of 3 Different Immunosuppressive|The Differential Effects of 3 Different Immunosuppressive Agents, Tacrolimus Mycophenolate Mofetil and Sirolimus on the Generation of Tregs and DCregs in in Vitro MLR and T Cell Activation Assays||Northwestern University|Yes|Completed|July 2008|January 2010|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|12|Samples With DNA|White Cells.|Both|18 Years|N/A|No|Non-Probability Sample|Six to Twelve preoperative renal transplant living donor pairs.|May 2013|May 23, 2013|August 4, 2008||No||No|August 25, 2010|https://clinicaltrials.gov/show/NCT00729248||152106|
NCT00729807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000602047|Pentamidine in Treating Patients With Relapsed or Refractory Melanoma|Treatment of Melanoma With Wild-type p53 and Detectable S100B Using Pentamidine: a Phase II Trial With Correlative Biomarker Endpoints||National Cancer Institute (NCI)||Recruiting|July 2008|||July 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2008|December 16, 2009|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729807||152063|
NCT00729820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cognitive performance-221CTIL|The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.|The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.||BeerYaakov Mental Health Center||Not yet recruiting|August 2008|||||N/A|Observational|N/A||1|Anticipated|30|||Both|20 Years|50 Years|No|Non-Probability Sample|1. Men and women at age - 20-50 years          2. The following demographic and anamnesis' data should be readily available:        Age, ethnicity, marital and educational status. History of physical disorders and        pharmacological treatments.|June 2008|August 7, 2008|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00729820||152062|
NCT00725491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05703|A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)|A Phase III, Multi-center, Open-label, Randomized Study to Assess the Efficacy and Safety of Org 37462 Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for IVF or ICSI, Using a Long Protocol of Triptorelin as a Reference Treatment.||Merck Sharp & Dohme Corp.|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|259|||Female|18 Years|35 Years|No|||November 2014|November 18, 2014|July 28, 2008||No||No|December 17, 2009|https://clinicaltrials.gov/show/NCT00725491||152391|
NCT00725829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot. 116|Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects|Effects of Simvastatin Versus Simvastatin Combined With Ezetimibe on Blood Coagulation in Patients With Acute Coronary Events: Relationship With Cholesterol-Lowering and Anti-Inflammatory Properties||Jagiellonian University|No|Recruiting|June 2008|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|75 Years|No|||February 2009|February 9, 2009|July 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725829||152365|
NCT00726102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0768|Development and Health of Rural Chinese Children Fed Meat as a Daily Complementary Food From 6-18 Mos of Age|Development and Health of Rural Chinese Children Fed Meat as a Daily Complementary Food From 6-18 Mos of Age||University of Colorado, Denver|No|Completed|November 2008|December 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1488|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||December 2013|May 26, 2015|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00726102||152345|
NCT00726115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-1111|Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531|Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 29, 2009|July 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726115||152344|
NCT00726128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-005|Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System|A Multi-Center Prospective Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System|VueLock|Biomet, Inc.|No|Completed|August 1998|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|371|||Both|N/A|N/A|No|Non-Probability Sample|Subjects from multiple centers with disease of the cervical spine|February 2012|March 14, 2016|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726128||152343|
NCT00726427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00001|A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers|A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD1656 in Healthy Male Subjects||AstraZeneca|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726427||152320|
NCT00728468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471014|A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients|A Phase 1, Open Label, Single Arm Trial To Evaluate The Effect Of PF- 00299804 On The Pharmacokinetics Of Dextromethorphan In Patients With Advanced Malignant Solid Tumors||Pfizer|No|Completed|September 2008|July 2014|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|July 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728468||152164|
NCT00718315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21450|A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.|A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer.||Hoffmann-La Roche||Completed|April 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|July 16, 2008||No||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00718315||152931|
NCT00718614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-300505-2|Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With Insulin-dependent Diabetes Mellitus (IDDM)|Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With IDDM||Medical University of Vienna|Yes|Terminated|June 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|80|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 24, 2014|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00718614||152908|
NCT00718913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.07|Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer|A Phase II Trial of Postoperative Chemotherapy and Chemo-radiotherapy for Resected Adenocarcinoma of the Stomach and Gastro-esophageal Junction||Hellenic Oncology Research Group|No|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00718913||152886|
NCT00718640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015082|An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function|Safety and Efficacy of Velcade in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function||Janssen-Ortho Inc., Canada|No|Terminated|October 2007|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|July 17, 2008|Yes|Yes|Study stopped due to lagging enrolment.|No|June 21, 2013|https://clinicaltrials.gov/show/NCT00718640||152906|Participants’ recruitment was limited due to pre-defined criteria of renal disease and requirement of repeated evaluation of creatinine clearance. Due to insufficient number of participants the outcome measure data was not analyzed.
NCT00719797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598582|Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER|TRIBE|Gruppo Oncologico del Nord-Ovest|Yes|Completed|July 2008|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|509|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|July 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00719797||152818|
NCT00719810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-3341-201|Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections|A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX 3341 Compared With Tigecycline for the Treatment of Complicated Skin and Skin Structure Infections||Melinta Therapeutics, Inc.|No|Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|July 18, 2008|Yes|Yes||No|January 7, 2010|https://clinicaltrials.gov/show/NCT00719810||152817|
NCT00720434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121007|A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study To Evaluate Peginterferon Alfa 2a (Pegasys®) And Ribavirin (Copegus®) With And Without PF-00868554 In Subjects Chronically Infected With Hepatitis C Virus||Pfizer|No|Completed|August 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|65 Years|No|||June 2013|June 18, 2013|July 18, 2008|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT00720434||152771|
NCT00716625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181176|Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)|Special Investigation For Rcc Of Sutent (Regulatory Post Marketing Commitment Plan).||Pfizer|No|Completed|June 2008|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1700|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6181176 prescribes the sunitinib malate        (Sutent).|October 2015|October 6, 2015|July 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00716625||153060|
NCT00725647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0803/98|Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies|A Study of the Value of Plasma N-terminal proBNP Concentrations for Diagnosing Patent Ductus Arteriosus in Preterm Babies.||St George's, University of London|No|Completed|May 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|N/A|N/A|No|Non-Probability Sample|Preterm infants in a tertiary level neonatal intensive care unit|September 2009|September 17, 2009|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725647||152379|
NCT00725660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0153-08-HMO.CTIL|Pre-Eclampsia Prediction By Doppler Screening Of Uterine Arteries And Angiogenic Factors In Second Trimester Of Pregnancy|||Shaare Zedek Medical Center||Not yet recruiting|September 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women in second trimester that took the routine triple test, and are having an        early routine detailed ultrasound examination, in Jerusalem, Israel.|July 2008|July 29, 2008|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00725660||152378|
NCT00725946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0001|Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT|A Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT||Stanford University||Terminated|February 2008|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Female|18 Years|N/A|No|||May 2013|May 30, 2013|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00725946||152356|
NCT00716326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8589 (REK)|The Use of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Pain of Predominantly Peripheral Neuropathic Origin|The Use of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Pain of Predominantly Peripheral Neuropathic Origin||Norwegian Fund for Postgraduate Training in Physiotherapy|No|Completed|January 2007|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|80 Years|No|||December 2008|December 17, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00716326||153083|
NCT00728390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471004|A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks|Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors||Pfizer|No|Completed|July 2008|January 2013|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|July 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728390||152170|
NCT00728403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122380|Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes|Long Term Metabolic and Therapeutic Effects of Combined Treatment of American Ginseng (Panax Quinquefolius L.) Extract and Korean Red Ginseng (Steamed Panax C.A. Meyer) Extract in the Treatment of Type 2 Diabetes||St. Michael's Hospital, Toronto|No|Active, not recruiting|September 2008|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|40 Years|75 Years|No|||July 2015|July 30, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728403||152169|
NCT00728637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5856|Evaluating the Effectiveness of a Family Heart Health Educational Program (The FIT-Heart Study)|Effectiveness of a Family Heart Health Intervention Trial (FIT Heart I)|FIT-Heart|Columbia University|Yes|Completed|January 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|501|||Both|20 Years|79 Years|Accepts Healthy Volunteers|||May 2013|May 14, 2013|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00728637||152151|
NCT00728962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2208|A Study of Osseotite Certain Prevail Implants Used to Support Short Fixed Bridges With Immediate Occlusal Loading.|A Prospective, Observational Study of Osseotite Certain IOL (Immediate Occlusal Loading) Implants in Immediate Occlusal Loading of Short Span Fixed Restorations|Fireball|Biomet, Inc.|Yes|Completed|March 2005|October 2009|Actual|May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Non-Probability Sample|These will be patients who are otherwise seeking dental implant therapy and belong to the        study centers' standard patient population.|January 2015|January 13, 2015|August 1, 2008|No|Yes||No|June 26, 2009|https://clinicaltrials.gov/show/NCT00728962||152126|
NCT00728975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01321|The Bowel Research Collaborative Data Tracking System Implementation Study|The Bowel Research Collaborative Data Tracking System Implementation Study||British Columbia Cancer Agency|No|Completed|June 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||13|Anticipated|390|||Both|N/A|N/A|No|Probability Sample|Patients receiving palliative care|February 2010|May 26, 2010|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728975||152125|
NCT00729560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04487VCUIRB|Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome|Determination if Pharmacologic Blockade of Androgen Action Decreases Renal Clearance of D-Chiro-Inositol (DCI), Increases the Circulating Concentration of DCI, and Enhances Insulin-Stimulated Release of the D-chiro-inositol-containing Inositolphosphoglycan (DCI-IPG) Mediator in Obese Women With Polycystic Ovary Syndrome (PCOS)|PCOS|Virginia Commonwealth University|No|Terminated|July 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|8|||Female|18 Years|40 Years|No|||September 2014|September 5, 2014|August 5, 2008|Yes|Yes|Lack of recruitment|No|May 27, 2014|https://clinicaltrials.gov/show/NCT00729560||152082|
NCT00729573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-003B|Bone Mineral Density Substudy - An Ancillary Study to MTN-003|Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|518|Samples With DNA|Urine and blood samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Sexually active, HIV-uninfected women who are currently enrolled in MTN-003|March 2016|March 8, 2016|August 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729573||152081|
NCT00725257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGMM/4/2004|Dietary Control of Type 2 Diabetes: Low-Carbohydrate Mediterranean Diet Versus Low-Fat Diet|Effect of a Low-Carbohydrate Mediterranean Diet or Low-Fat Diet in Newly-Diagnosed Type 2 Diabetic Patients||Second University of Naples|No|Completed|June 2004|December 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|30 Years|75 Years|No|||July 2008|July 28, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725257||152409|
NCT00725504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07072008-1232|Effect of IV Lidocaine Infusions on Pain|Effect of IV Lidocaine Infusions on Pain||Stanford University||Completed|September 2008|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|July 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725504||152390|
NCT00725842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05484|Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)|Relapse Rate and Predictive Factors in the Treatment of Hepatitis C in Common Clinical Practice|RE-CHUT|Merck Sharp & Dohme Corp.|No|Terminated|January 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with hepatitis C previously treated with Peg-IFN alfa-2b + ribavirin in common        clinical practice at approximately 60 centers in France.|September 2015|September 18, 2015|July 28, 2008|No|Yes|Low enrollment|No|June 13, 2012|https://clinicaltrials.gov/show/NCT00725842||152364|Due to low enrollment some planned analyses were not performed.
NCT00726765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05320|Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain (Study P05320)(COMPLETED)|Observational Trial on the Value of Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain||Merck Sharp & Dohme Corp.|No|Completed|June 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1090|||Both|18 Years|N/A|No|Non-Probability Sample|Each of several participating national centers of excellence will establish a network with        local primary care physicians or their equivalent who will work with the center of        excellence and will provide referrals of suitable patients.|January 2016|January 20, 2016|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726765||152295|
NCT00728195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014737|An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|November 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|498|||Both|18 Years|65 Years|No|||March 2014|March 25, 2014|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728195||152185|
NCT00728208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105467|GSK372475 PK Study in Healthy Volunteers|A Placebo-controlled, Single-blind, Randomised, Parallel Group, 28-day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 in Healthy Young and Elderly, Male and Female Subjects||GlaxoSmithKline|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 9, 2011|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728208||152184|
NCT00718627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD02|Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders|Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children With Urea Cycle Disorders (UCDs)||Cytonet GmbH & Co. KG|Yes|Completed|July 2008|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|5 Years|No|||February 2016|February 5, 2016|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718627||152907|
NCT00718874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080605012|A Specialized Diet for the Unique Metabolic Characteristics of Peripubertal African American Girls|Dietary Intervention to Improve Insulin Dynamics During the Pubertal Transition|PRIMO|University of Alabama at Birmingham|Yes|Completed|June 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Female|9 Years|15 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00718874||152888|
NCT00719251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102-04-12916|Effects of High Voltage Pulsed Current (HVPC) and Low Level Laser Therapy (LLLT) on Wound Healing in Diabetic Ulcers|Effects of High Voltage Pulsed Current and Low Level Laser Therapy on Wound Healing in Diabetic Ulcers.||Universidad Industrial de Santander|Yes|Completed|March 2004|December 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|30 Years|75 Years|No|||March 2009|March 4, 2009|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00719251||152860|
NCT00719498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005008|Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)|Early High-dose Erythropoietin Therapy and Hypothermia After Out-of-hospital Cardiac Arrest: A Matched Control Study||Janssen Cilag S.A.S.||Completed|November 2003|July 2004|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|75 Years|No|||April 2010|May 16, 2011|July 17, 2008||||No||https://clinicaltrials.gov/show/NCT00719498||152841|
NCT00720096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15042|Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan|A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|July 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||December 2013|December 13, 2013|July 21, 2008|No|Yes|Funds for this project have been spent, and it is thereby terminated.|No|October 15, 2010|https://clinicaltrials.gov/show/NCT00720096||152796|Due to limited sample size, we were unable to make definitive conclusions in this trial.
NCT00725673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-1752|Case Control Study: Determinants of Osteoporosis in GOLD II COPD Patients.|Determination of Risk Factors for Developing Osteoporosis in COPD GOLD II Patients. A Case Control Study to Identify Possible Risk Factors for Developing Osteoporosis in COPD GOLD II Patients.||Catharina Ziekenhuis Eindhoven|Yes|Completed|September 2007|June 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|106|Samples Without DNA|Whole blood|Both|40 Years|N/A|No|Probability Sample|GOLD II COPD patients (ATS and GOLD guidelines) visiting the outpatient clinic of        pulmonary medicine of the Catharina Hospital Eindhoven.|November 2009|November 9, 2009|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725673||152377|
NCT00726284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-006|Spine Patient Outcomes Registry for Biomet/EBI|BIOMET/EBI Spine Patient Outcomes Registry|SPO|Biomet, Inc.|No|Completed|April 2004|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|651|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is an open cohort prospective patient registry conducted at multiple clinical centers|February 2012|March 14, 2016|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726284||152331|
NCT00726297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-03-21|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2005|||||N/A|N/A|N/A||||||||||||||December 18, 2012|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726297||152330|
NCT00725972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goal Directed Therapy|Pre-emptive Hemodynamic Optimization of High Risk Patients Undergoing Elective Major Surgical Procedures|Pre-emptive Hemodynamic Optimization of High Risk Patients Undergoing Elective Major Surgical Procedures.||University of Pittsburgh|Yes|Recruiting|July 2008|||May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|80 Years|No|||March 2010|March 9, 2010|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00725972||152354|
NCT00725959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 07-0459|Online Social Networking for HIV Prevention|Online Social Networking for HIV Prevention||Colorado School of Public Health|No|Recruiting|September 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6204|||Both|16 Years|20 Years|Accepts Healthy Volunteers|||July 2009|January 26, 2012|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00725959||152355|
NCT00726245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000|Plasma Rich in Growth Factors (PRGF) Treatment for Muscle Tear|PRP as a Treatment for Acute Muscle Tears - Randomized-double-blind-placebo Control Trail.||Meir Medical Center|Yes|Completed|January 2008|March 2011|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|40 Years|No|||July 2011|July 10, 2011|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726245||152334|
NCT00728689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIGA-246-005|Phase I Trial of an Investigational Small Pox Medication|A Phase I Randomized, Double-Blind, Crossover, Exploratory Study of the Pharmacokinetics of a Single Oral Dose of Form I Versus Form V Capsules of the Anti-Orthopoxvirus Compound ST-246® in Fed Normal Healthy Volunteers||SIGA Technologies|Yes|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|June 22, 2015|August 1, 2008|No|Yes||No|June 10, 2009|https://clinicaltrials.gov/show/NCT00728689||152147|
NCT00728702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAL0002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2008|||||N/A|N/A|N/A||||||||||||||August 5, 2008|August 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00728702||152146|
NCT00728988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581161|Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome|A Prospective Randomized, Open-Label, Parallel-Group Comparative Study: Atorvastatin Pre-Treatment Versus Usual Care In Asian Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention|ALPACS|Pfizer|No|Completed|September 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|499|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|July 31, 2008|Yes|Yes||No|April 25, 2011|https://clinicaltrials.gov/show/NCT00728988||152124|Defective high-sensitivity C reactive protein reagents showed instability and 20% average positive bias in results, affecting only change from baseline in CRP. Analyses were performed on all samples; results include affected and unaffected samples.
NCT00728936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMO-2125-001|Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients|A Phase 1, Multi-center, Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin||Idera Pharmaceuticals, Inc.|Yes|Completed|September 2007|May 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||May 2012|May 15, 2012|August 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728936||152128|
NCT00728949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13935|A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer|Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy||Eli Lilly and Company|No|Completed|August 2008|February 2015|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00728949||152127|
NCT00729586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01085|Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer|A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2008|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Female|N/A|N/A|No|||January 2016|March 18, 2016|August 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729586||152080|
NCT00729599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPYRY_L_04020|Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.|Single Site Study, Phase III, for Safety Dermatological Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Teen.|Cepacol Teen|Sanofi|No|Completed|July 2008|||August 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 3, 2009|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729599||152079|
NCT00729274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222207|HYPERTONIC SALINE IN ACUTE VIRAL BRONCHIOLITIS: A RANDOMIZED CLINICAL TRIAL|HYPERTONIC SALINE IN ACUTE VIRAL BRONCHIOLITIS: A RANDOMIZED CLINICAL TRIAL||Laval University|No|Withdrawn|November 2011|April 2014|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Weeks|12 Months|No|||September 2015|September 4, 2015|August 5, 2008||No|Was not approved by funding organization|No||https://clinicaltrials.gov/show/NCT00729274||152104|
NCT00729287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000602239|Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer|Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer||National Cancer Institute (NCI)||Recruiting|June 2008|||October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||June 2009|November 10, 2009|August 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729287||152103|
NCT00725517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-R-001|Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange|Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange in Continuous Ambulatory Peritoneal Dialysis Patients, Compare to 2.5% Dianeal Peritoneal Dialysis Solution.||Shanghai Jiao Tong University School of Medicine|Yes|Completed|December 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|80 Years|No|||July 2008|July 31, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725517||152389|
NCT00725855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM 3454-102|A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients|A Single-Center, Double-Blind, Placebo-Controlled, Randomized Blocks Study Investigating the Effect of 4 Dosages (1 mg, 5 mg, 15 mg, 50 mg) of MEM 3454 on P50 Sensory Gating and Mismatch Negativity (MMN) in Patients With Schizophrenia|P50|Memory Pharmaceuticals|No|Not yet recruiting|August 2008|April 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|12|||Both|18 Years|55 Years|No|||July 2008|July 30, 2008|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725855||152363|
NCT00726141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01EB0421|Brief Interventions on Smoking for Hormonal Contraceptive Users|Brief Interventions on Smoking for Hormonal Contraceptive Users|BRISC|University of Luebeck|No|Completed|October 2004|October 2007|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|699|||Female|14 Years|25 Years|No|||July 2008|July 30, 2008|July 28, 2008||||No||https://clinicaltrials.gov/show/NCT00726141||152342|
NCT00726440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01022-51|Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients?|Are the Continous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients With Poor Metabolic Control?||Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|February 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|180|||Both|8 Years|60 Years|No|||April 2011|February 8, 2012|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00726440||152319|
NCT00727610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-00510|Development of a Screening Strategy for Community-based Adverse Drug Related Events in the Emergency Department|Development of a Screening Strategy for Community-based Adverse Drug Related Events in the Emergency Department||University of British Columbia|No|Completed|May 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1588|||Both|19 Years|N/A|No|Probability Sample|Adults presenting to the emergency departments of participating institutions who have used        at least one prescription or over-the-counter medication in the 2 weeks prior to        presentation.|February 2011|February 15, 2011|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727610||152230|
NCT00718341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2204|Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients|A Multi-centre, Randomized, Double-blind, Placebo Controlled, Two-period, Crossover Proof-of-concept Study in Male Patients With Fragile X Syndrome to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of AFQ056||Novartis|No|Completed|June 2008|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|35 Years|No|||May 2010|May 5, 2010|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718341||152929|
NCT00718354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI0702|Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT|Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer|GASTRANOX|Thrombosis Research Institute|Yes|Completed|July 2008|August 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|740|||Both|18 Years|75 Years|No|||May 2015|May 12, 2015|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718354||152928|
NCT00719823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001068|Maraviroc Compassionate Use|Maraviroc Compassionate Use||ViiV Healthcare|No|Withdrawn|August 2008|May 2010|Anticipated|May 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|N/A|No|||November 2010|November 10, 2010|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719823||152816|
NCT00719836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB1518-2007-001|A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies|A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies||S*BIO|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|July 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00719836||152815|
NCT00716339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 481/2004|Pseudophakic Accommodation|||Medical University of Vienna||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2|||40|||Both|50 Years|75 Years|No|||July 2008|July 14, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00716339||153082|
NCT00716612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Solgar-080|Does Coenzyme Q 10 Supplementation Reduce Muscle Pain Caused by Statins? (Cholesterol Lowering Medications)|Effect of Coenzyme Q 10 Supplementation on Myalgia Induced by HMG-CoA Reductase Inhibitors|COSMIC|Hadassah Medical Organization|Yes|Completed|January 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|20 Years|90 Years|No|||January 2013|January 24, 2013|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716612||153061|
NCT00726310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-044|Evaluation Of Spinelink® Fixation In The Treatment Of Degenerative Spondylolisthesis And Spinal Instability|A Multicenter Prospective Patient Outcome Evaluation Of Spinelink® Fixation In The Treatment Of Degenerative Spondylolisthesis And Spinal Instability||Biomet, Inc.|No|Completed|May 2000|November 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|205|||Both|N/A|N/A|No|Non-Probability Sample|Multiple site around the US|February 2012|March 14, 2016|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726310||152329|
NCT00726609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04641|Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)|Post-marketing Surveillance (PMS) Management of Invasive Mycosis With Posaconazole||Merck Sharp & Dohme Corp.|No|Completed|January 2006|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|214|||Both|18 Years|N/A|No|Probability Sample|Subjects with invasive fungal infection refractory to first-line treatment or unable to        tolerate it were selected at hospitals in Germany.        Following the enlargement of the marketing authorization for posaconazole, subjects at        risk for invasive fungal infection were also enrolled.|February 2015|February 16, 2015|July 30, 2008|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00726609||152307|
NCT00726271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5653|Pilot Study of Dietary Modification of Appetite Set Point in Obesity|A Pilot 6 Week Study of the Feasibility and Acceptability of Dietary Modification With the Goal of Changing the Appetite Set Point in People Taking Medications That Cause Weight Gain Through Increased Appetite.||State University of New York - Upstate Medical University|No|Enrolling by invitation|June 2008|September 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2008|July 30, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00726271||152332|
NCT00729326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-US-GWCV|Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione|Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione||AstraZeneca|No|Completed|August 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|70 Years|No|||March 2015|March 20, 2015|August 4, 2008||No||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00729326||152100|
NCT00729612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08059|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|August 2008|||December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|August 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729612||152078|
NCT00728663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/07|Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer|Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Completed|June 2008|April 2010|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|N/A|No|||April 2013|April 9, 2013|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00728663||152149|
NCT00728676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioMarin-300|Study to Evaluate the Effects of Kuvan on Individuals With Phenylketonuria (PKU) With Maladaptive Behaviors|Pilot Study to Evaluate the Effects of Kuvan on Adult Individuals With Phenylketonuria With Measurable Maladaptive Behaviors||University of Southern California|No|Completed|August 2008|May 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with PKU followed at our clinic|January 2013|January 17, 2013|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00728676||152148|
NCT00725530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-007|Evaluation of Deposits on Contact Lenses Worn Extended Wear|||Alcon Research|No|Completed|March 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|54|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|July 28, 2008|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00725530||152388|
NCT00725543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04044|Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)|Remicade Therapy in Ankylosing Spondylitis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions||Merck Sharp & Dohme Corp.|No|Completed|June 2004|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|358|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with AS will receive Remicade induction therapy at specialized centers.|September 2015|September 28, 2015|July 25, 2008|No|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00725543||152387|
NCT00725270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06012008-1191|Treatment of Schizoaffective Disorder Using Mifepristone|Treatment of Schizoaffective Disorder Using Mifepristone||Stanford University||Terminated|April 1998|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|75 Years|No|||March 2014|March 12, 2014|July 28, 2008|No|Yes|Lack of funding.|No||https://clinicaltrials.gov/show/NCT00725270||152408|
NCT00726453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP102|The Medtronic RESOLUTE US Clinical Trial|A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm|R-US|Medtronic Vascular|Yes|Active, not recruiting|July 2008|June 2016|Anticipated|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1516|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|July 30, 2008|No|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT00726453||152318|
NCT00726466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4385s|Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration|A Phase I Study of the Inhibition of LFA-1 to Intercellular Adhesion Molecule-1 (ICAM-1) Using Subcutaneous Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)|SEIRA|Vitreous -Retina- Macula Consultants of New York|No|Withdrawn|March 2008|||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|N/A|No|||July 2015|July 6, 2015|July 29, 2008||Yes|Lack of recruitment|||https://clinicaltrials.gov/show/NCT00726466||152317|
NCT00726778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040109007|Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes|Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes|AMERICO|University of Alabama at Birmingham|No|Completed|May 2004|December 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|360|Samples With DNA|Three 5-ml blood samples will be obtained from each subject and sent to the Laboratory Core      of the General Clinical Research Center to establish EBV lymphoblastoid cell lines and for      DNA extraction. EBV lines will be kept at UAB for future genetic analysis. Extracted DNA      will be sent to Dr. Mark Shriver at the Pennsylvania State University for genotyping of the      ancestry informative markers (AIMs).|Both|7 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|120 African Americans, 120 European Americans and 120 Hispanic Americans (60 males and 60        females per group). To minimize the influence of puberty on SI and AIRg, recruitment will        be limited to individuals between ages 7-12, a range that based on previous observations        from our team, categorize children from Tanner stage 1 and 2.|March 2011|March 15, 2011|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726778||152294|
NCT00726999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/71,GC 138|Perioperative Use of Gabapentin To Decrease Narcotic Requirements in Spinal Fusion|Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients||Medical College of Wisconsin|Yes|Completed|June 2006|May 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|9 Years|18 Years|No|||January 2011|January 3, 2011|July 30, 2008|Yes|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00726999||152277|
NCT00727298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04840|Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)|Post Marketing Surveillance Study of the Labeled Use of Remicade® (Infliximab) in Patients With Chronic Inflammatory Diseases|REMission|Merck Sharp & Dohme Corp.|No|Completed|February 2006|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4485|||Both|18 Years|N/A|No|Non-Probability Sample|Participants treated with infliximab by rheumatologists, gastroenterologists, and        dermatologists for chronic inflammatory diseases, such as rheumatoid arthritis, ankylosing        spondylitis, psoriatic arthritis, psoriasis, or Crohn's disease.|November 2015|November 30, 2015|July 30, 2008|No|Yes||No|August 10, 2012|https://clinicaltrials.gov/show/NCT00727298||152254|
NCT00727311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04538|Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)|Treatment of Chronic Hepatitis C With PegIntron Injector and Rebetol (Post Marketing Surveillance Study)||Merck Sharp & Dohme Corp.|No|Completed|August 2005|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2302|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with chronic hepatitis C, who are either treatment-naïve or previous        relapsers after interferon monotherapy, from 500 sites in Germany|October 2015|October 8, 2015|July 30, 2008|No|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00727311||152253|
NCT00727623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIWAC-01|Mortality Analysis of ST Elevation Myocardial Infarction (STEMI) Patients in Belgium|Prospective Observational Study to Assess Predictors of in Hospital Mortality in STEMI Patients Admitted in Belgian Hospitals||Universiteit Antwerpen|No|Recruiting|July 2007|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Probability Sample|Patients with acute ST elevation myocardial infarction admitted in Belgian hospitals.|July 2015|July 19, 2015|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00727623||152229|
NCT00727636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09-0344|Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy|Pilot Study of Immunogenicity and Tolerability to the Quadrivalent Human Papillomavirus Virus-like Particle (VLP) Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy Compared to Healthy Children and Youth Adult Females|HPV|Children's Hospital Boston|Yes|Completed|July 2008|April 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Female|9 Years|26 Years|No|||May 2011|May 3, 2011|July 31, 2008|Yes|Yes||No|May 3, 2011|https://clinicaltrials.gov/show/NCT00727636||152228|
NCT00727935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU P 2006-03|Comparison Of The Analgesia Obtained By Infiltration For The Joinings Of Episiotomies (Liropep)|Comparison Of The Analgesia Obtained By Infiltration Of Lidocaïne 1% And Ropivacaïne 0,75% Versus Placebo For The Joinings Of Episiotomies Among Parturients Under Epidural Analgesia|LiRoPep|University Hospital, Angers|Yes|Completed|October 2006|||July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|165|||Female|18 Years|50 Years||||August 2008|August 4, 2008|July 30, 2008||||No||https://clinicaltrials.gov/show/NCT00727935||152205|
NCT00728182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3302 (NA-1-002)|Evaluating Neuroprotection in Aneurysm Coiling Therapy|A Phase II, Multicenter, Randomized, Fasting, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Male and Female Patients Undergoing Endovascular Repair of Brain Aneurysms|ENACT|NoNO Inc.|Yes|Completed|August 2008|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|August 1, 2008|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00728182||152186|
NCT00728481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006685|The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis|The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis||Mayo Clinic|Yes|Completed|May 2008|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|July 15, 2008|Yes|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT00728481||152163|The index endoscopy was obtained solely for clinical reasons and could have been done as long as 18 months prior to study enrollment.A single question on the dysphagia questionnaire was used to assess dysphagia symptom response.
NCT00728494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04671|Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)|Evaluation of Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron / Rebetol in Conjunction With a Patient Assistance Program - Non Interventional Observational Study.||Merck Sharp & Dohme Corp.|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|99|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic HCV.|July 2015|July 20, 2015|July 31, 2008||No||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00728494||152162|
NCT00728780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-586|Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.|||AstraZeneca|No|Completed|August 2008|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|August 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728780||152140|
NCT00718952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVALUATION-01|The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension|Multi-centre, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Treatment of Pulmonary Arterial Hypertension With Vardenafil in China|EVALUATION|Tongji University|Yes|Completed|July 2008|February 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|65 Years|No|||February 2010|February 11, 2010|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00718952||152883|
NCT00719238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-093-02|A Pilot Study to Promote Maternal and Infant Oral Health|A Pilot Study to Promote Maternal and Infant Oral Health||University of Connecticut Health Center|No|Completed|January 2007|July 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 18, 2008|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719238||152861|
NCT00716092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.37|The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients|A 4-week, Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group Study Comparing the Influence of BI 1356 (5 mg) and Sitagliptin (100 mg) Administered Orally Once Daily on Various Biomarkers in Type 2 Diabetic Patients||Boehringer Ingelheim||Completed|July 2008|||November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|80 Years|No|||January 2014|June 18, 2014|July 15, 2008||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00716092||153101|
NCT00716105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.29.INF|Effect of the Level of Dietary Protein on Infant Growth|Effect of the Level of Dietary Protein on Infant Growth and Body Composition in the First Year of Life||Nestlé|No|Completed|August 2008|February 2015|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|405|||Both|3 Months|12 Months|Accepts Healthy Volunteers|||October 2014|May 18, 2015|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00716105||153100|
NCT00725361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07222008-1265|A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).|A Pilot Study to Evaluate the Efficacy of Ambrisentan in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis.||Stanford University||Completed|June 2008|||December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2011|March 11, 2011|July 28, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00725361||152401|
NCT00725374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06469|A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)|A Exploratory, Double-blind, Randomized, Placebo-controlled Trial to Investigate the Tissue Specific Effects of 2.5 mg Tibolone on Breast Cancer in Postmenopausal Women, in Particular on Breast Tissue Proliferation.|STEM|Merck Sharp & Dohme Corp.|No|Completed|December 2002|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Female|N/A|N/A|No|||May 2014|May 22, 2014|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725374||152400|
NCT00727116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U49CE001274|Pennsylvania Abusive Head Trauma Prevention Program|Pennsylvania Abusive Head Trauma Prevention Program||Centers for Disease Control and Prevention|No|Completed|January 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|949609|||Both|N/A|N/A|No|||February 2015|February 6, 2015|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727116||152268|
NCT00727493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPOZAHN|Osteoporosis and Dental Implant|Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis|OPOZAHN|Charite University, Berlin, Germany|No|Recruiting|January 2004|April 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Female|60 Years|75 Years|Accepts Healthy Volunteers|||August 2008|August 1, 2008|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727493||152239|
NCT00727506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.36|BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma|Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme||Boehringer Ingelheim||Active, not recruiting|July 2008|March 2016|Anticipated|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 31, 2008||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00727506||152238|
NCT00726882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-459|A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies|A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-333 Clinical Studies||AbbVie||Completed|August 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|65 Years|No|||December 2014|December 29, 2014|July 30, 2008|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT00726882||152286|
NCT00727103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNY UMU IRBPHS #5656|Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia|Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double Blind, Placebo Controlled Trial||State University of New York - Upstate Medical University|Yes|Terminated|July 2008|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|69 Years|No|||June 2011|June 2, 2011|July 28, 2008|No|Yes|Slow recruitment, high drop-out rate in both arms|No||https://clinicaltrials.gov/show/NCT00727103||152269|
NCT00725881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP100-301|Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication|A Randomized, Double-Blinded, Placebo-Controlled Phase 1/2 Dose-Range-Finding Study to Evaluate the Safety, Efficacy and PK of Multiple Once Daily Intravenous Doses of TSC in Patients With Intermittent Claudication||Diffusion Pharmaceuticals LLC|Yes|Completed|August 2008|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|48|||Both|40 Years|N/A|No|||July 2011|July 1, 2011|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725881||152361|
NCT00729001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/005|Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.|Study of Two Doses of GlaxoSmithKline Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Two Different Formulations) in Healthy Infants Following a 0, 2 Month Schedule and Previously Uninfected With Human Rotavirus.||GlaxoSmithKline||Completed|November 2000|||September 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|529|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||August 2008|August 6, 2008|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729001||152123|
NCT00729300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-08-071-02A|A Study of the Relationship Between Disulfiram and Cocaine Self-Administration.|Laboratory Models of Cocaine Self-Administration||National Institute on Drug Abuse (NIDA)|Yes|Suspended|April 2006|June 2009|Anticipated|June 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|55 Years|No|||August 2008|April 7, 2009|August 6, 2008|Yes|Yes|Project moved to new university|No||https://clinicaltrials.gov/show/NCT00729300||152102|
NCT00725868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00533-50|Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention|Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention.||Assistance Publique Hopitaux De Marseille|No|Completed|September 2007|December 2010|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|170|||Both|18 Years|90 Years|No|||August 2011|August 25, 2011|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00725868||152362|
NCT00726791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2008-02-071|Efficacy of rTMS (Repetitive Transcranial Magnetic Stimulation) on Patients With Somatoform Pain Disorder|Efficacy of rTMS (Repetitive Transcranial Magnetic Stimulation) on Patients With Somatoform Pain Disorder||Samsung Medical Center|Yes|Withdrawn|April 2008|June 2009|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|July 30, 2008||No|patient did not enroll|No||https://clinicaltrials.gov/show/NCT00726791||152293|
NCT00727012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS06003RG|Multicenter International Trial Ring AnnulopLasty|Multicenter International Trial Ring AnnulopLasty|MITRAL|St. Jude Medical|No|Completed|June 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00727012||152276|
NCT00727324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP IBD 02-02|Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis|A Pilot, Open-label, Multi-center Clinical Trial to Investigate the Safety and Efficacy of Bovine-Calf Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis.||AM-Pharma|Yes|Completed|May 2006|December 2006|Actual|November 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727324||152252|
NCT00727337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6303-R|Supplementing Hearing Aids With Computerized Auditory Training|Supplementing Hearing Aids With Computerized Auditory Training|LACE|VA Office of Research and Development|No|Completed|January 2009|December 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|279|||Both|55 Years|85 Years|No|||January 2015|January 12, 2015|July 30, 2008||No||No|October 22, 2014|https://clinicaltrials.gov/show/NCT00727337||152251|
NCT00727649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6126-W|Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence|Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence|FIRM|VA Office of Research and Development|No|Completed|July 2008|December 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|July 29, 2008|Yes|Yes||No|January 23, 2015|https://clinicaltrials.gov/show/NCT00727649||152227|Please note that the data on those lost to follow-up limits our ability to conclude differences between the two interventions.
NCT00727948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0801|The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy|The Impact of the Anti-Platelet Agent Aspirin on Angiogenesis Proteins in Women With Breast Cancer||University of Vermont|Yes|Active, not recruiting|July 2008|December 2011|Anticipated|December 2010|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|95 Years|No|||June 2010|April 21, 2011|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727948||152204|
NCT00727961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04072|A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)|Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy.||Merck Sharp & Dohme Corp.|No|Completed|November 2004|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Female|18 Years|N/A|No|||April 2015|April 29, 2015|June 23, 2008|No|Yes||No|January 29, 2009|https://clinicaltrials.gov/show/NCT00727961||152203|
NCT00728806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PROPDBM|Biomarker for Peritoneal Ultrafiltration Failure|Biomarker for Early Detection and Intervention of Peritoneal Ultrafiltration Failure||Sun Yat-sen University|Yes|Completed|October 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|40|Samples Without DNA|peritoneal tissue will be collected at the time of peritoneal dialysis catheter insertion or      extubation. Serum and dialysate samples will be collected for protein analysis.|Both|20 Years|65 Years|No|Non-Probability Sample|Inpatients and outpatients in the peritoneal dialysis center of 1st Affiliated Hospital,        Sun Yat-Sen University|May 2015|May 21, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728806||152138|
NCT00719277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-005|Feasibility Study: Sleuth Monitoring System|Pilot Clinical Study of the Sleuth Implantable ECG Monitoring System|PULSE|Transoma Medical|No|Active, not recruiting|December 2006|September 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2009|May 4, 2009|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719277||152858|
NCT00719511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-SkinSIT-002|Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration|Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind, Dose-response Study to Assess the Optimal Dose as Well as Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration||University of Zurich|No|Completed|February 2008|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|65 Years|No|||February 2011|February 16, 2011|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719511||152840|
NCT00729703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTION - ITAC03|Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications|Optimal Antitachycardia Therapy in ICD Patients Without Pacing Indications|OPTION|LivaNova|Yes|Completed|June 2006|October 2013|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|462|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729703||152071|
NCT00725985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28821|Oral Cladribine in Early Multiple Sclerosis (MS)|A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS|ORACLE MS|EMD Serono|Yes|Completed|December 2008|April 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|617|||Both|18 Years|55 Years|No|||August 2013|August 2, 2013|July 30, 2008|Yes|Yes||No|June 11, 2013|https://clinicaltrials.gov/show/NCT00725985||152353|Due to early termination of trial, efficacy data presented from core double blind ITP only. Due to low number of participants entering OLMP and LTFU period and the reduced duration, only descriptive safety data from OLMP and LTFU are presented.
NCT00727519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJHD-23-7-08CTIL|The Effect of Pomegranate Juice on Oxidative Stress in Hemodialysis Patients|A Randomized Clinical Trial for Estimating the Effects of Pomegranate Juice Consumption by Hemodialysis Patients on Oxidative Stress, Infections, Cardiovascular Events and Mortality||Western Galilee Hospital-Nahariya|No|Completed|July 2008|January 2010|Actual|||Phase 3|Interventional|Primary Purpose: Prevention|2||||||Both|18 Years|N/A|No|||March 2010|March 22, 2010|July 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00727519||152237|
NCT00727792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00041512|Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams|Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams||University of Michigan|No|Enrolling by invitation|January 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00727792||152216|
NCT00727805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-40|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2003|||||N/A|N/A|N/A||||||||||||||October 4, 2011|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00727805||152215|
NCT00727766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0853 / 201108049|Oral Clofarabine for Acute Myeloid Leukemia|Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia||Washington University School of Medicine|Yes|Completed|January 2009|November 2014|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|25|||Both|60 Years|N/A|No|||November 2014|November 10, 2014|July 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00727766||152218|
NCT00727779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15DK080488|Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome|Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome||East Tennessee State University|Yes|Completed|January 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 13, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727779||152217|
NCT00725283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111444|Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)|Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients With Acute Myeloid Leukemia||GlaxoSmithKline|Yes|Active, not recruiting|October 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||August 2015|March 3, 2016|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725283||152407|
NCT00725296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04264|Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)|Remicade Therapy in Psoriatic Arthritis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions||Merck Sharp & Dohme Corp.|No|Completed|December 2004|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|178|||Both|N/A|N/A|No|Non-Probability Sample|Participants will receive Remicade induction therapy consisting of 3 infusions in weeks 0,        2, and 6 given in specialized centers. Maintenance therapy will consist of a maximum of 6        infusions given in doses and intervals due to the discretion of physicians.|October 2015|October 13, 2015|July 25, 2008|No|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00725296||152406|
NCT00726154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08020410|Pilot Study of the Effects of Circadian Rhythms on the Treatment of Bipolar I Depression.|Rhythmicity as a Moderator of Treatment Outcomes of Bipolar I Depression -Pilot Study|Rhythms|University of Pittsburgh|No|Withdrawn|June 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|60 Years|No|||January 2012|January 10, 2012|July 28, 2008|No|Yes|This study did not receive funding|No||https://clinicaltrials.gov/show/NCT00726154||152341|
NCT00726167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106537|Serum Procalcitonin Study in the Management of Ventilated Patients|Clinical Utility of Serum Procalcitonin in the Management of Ventilator-Associated Pneumonia||University of Missouri-Columbia|No|Recruiting|September 2008|August 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|mechanically ventilated surgical intensive care unit patients|December 2008|December 8, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00726167||152340|
NCT00726479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1219.4|Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis|A Phase II, Randomised, Double-blind, Placebo-controlled and Parallel Group Study to Evaluate the Safety and Efficacy of Four Weeks Treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) in Patients With COPD Associated With Chronic Bronchitis.||Boehringer Ingelheim||Withdrawn|August 2008|||September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|0|||Both|40 Years|N/A|No|||March 2014|March 26, 2014|July 30, 2008||||No||https://clinicaltrials.gov/show/NCT00726479||152316|
NCT00726492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/378/664|An Examination of the Value of Shortwave Diathermy and Hydrotherapy for Patients With Osteoarthritis of Their Knees|A Randomised Controlled Trial Evaluating the Effects of Shortwave Diathermy and Hydrotherapy for Patients With Osteoarthritis of Their Knees||University College Dublin|No|Completed|June 2001|April 2003|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|77|||Both|50 Years|70 Years|No|||July 2008|July 29, 2008|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726492||152315|
NCT00726505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-020|Renal Mechanism of Action/Splay vs. TmG|Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|MOA|AstraZeneca|No|Terminated|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|1|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|July 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726505||152314|
NCT00726804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARTA|Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis|Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares|SPARTA|Glostrup University Hospital, Copenhagen|Yes|Terminated|March 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||August 2015|August 18, 2015|July 30, 2008||No|It was not possible to recruit patients|No||https://clinicaltrials.gov/show/NCT00726804||152292|
NCT00727025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS 20069|Randomized Controlled Trial of Subcuticular Skin Closure Versus Steri-strip S Closure|Closing Linear Incisions in Plastic Surgery: A Randomized Clinical Trial Comparing a New Coaptive Film Device Versus Standard Subcuticular Sutures for Scar Quality, Patient Comfort, and Closure Time||Dartmouth-Hitchcock Medical Center|Yes|Completed|July 2005|March 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|July 30, 2008||No||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00727025||152275|patients not blindedsurgeons rated photographs of scars, while the patients were rating their actual scars.All patients were caucasian
NCT00727350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBRT-NSCLC|Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.|Phase II Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.||AZ-VUB|No|Recruiting|March 2007|December 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||August 2008|August 1, 2008|July 31, 2008||||No||https://clinicaltrials.gov/show/NCT00727350||152250|
NCT00727662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT003682|A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue|Iyengar Yoga for Breast Cancer Survivors With Persistent Fatigue||National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|June 2008|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|40 Years|65 Years|No|||April 2015|April 13, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727662||152226|
NCT00728507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0018|Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis|A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis||Johns Hopkins University|Yes|Active, not recruiting|November 2009|December 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|July 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728507||152161|
NCT00724815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-15-NP101-007|The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine|The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study|NP101-007|Teva Pharmaceutical Industries|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|530|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|July 28, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00724815||152443|
NCT00724828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X-101959|Study Evaluating Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Filipino Children|An Evaluation of Streptococcus Pneumoniae Serotype Carriage Rate For Nasopharyngeal Carriage in Filipino Children Attending Well Baby Clinic in Hospitals and Primary Care Centers||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|May 2005|November 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|2 Months|5 Years|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|July 2008|July 29, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724828||152442|
NCT00720447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-BRD-07-137|Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma|Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma||National Cancer Institute (NCI)||Not yet recruiting|November 2008|||November 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2011|August 1, 2013|July 19, 2008||||No||https://clinicaltrials.gov/show/NCT00720447||152770|
NCT00725686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0451008|Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)|A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").||Quark Pharmaceuticals|Yes|Completed|February 2007|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|50 Years|N/A|No|||October 2012|October 5, 2012|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725686||152376|
NCT00725699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSRPAMD01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2008|||||N/A|N/A|N/A||||||||||||||March 5, 2011|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725699||152375|
NCT00725712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET111643|Study of GSK1363089 in Metastatic Gastric Cancer|A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer||GlaxoSmithKline|No|Completed|March 2007|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725712||152374|
NCT00726895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-0376|A Dose Proportionality Study of Quinine Sulfate Capsules Under Fasting Conditions|A Randomized, Two-way Crossover Design Used to Compare the Dose Proportionality of Quinine Sulfate Capsules, 324 mg Following a Single Oral Dose of 1 x 324 mg Capsule Versus 2 x 324 mg Capsules in Healthy Adult Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|May 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|July 30, 2008|No|Yes||No|November 24, 2009|https://clinicaltrials.gov/show/NCT00726895||152285|
NCT00728091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10102|A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia|A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)|AQUARIST1|Sanofi|Yes|Terminated|July 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|N/A|No|||March 2009|March 16, 2009|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00728091||152193|
NCT00728338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC002|Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides|Effect of Docosahexenoic Acid (22:6n-3, DHA) Supplementation on Risk Factors for Cardiovascular Disease in Hyperlipidemic Men||USDA, Western Human Nutrition Research Center|No|Completed|June 2003|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|39 Years|66 Years|Accepts Healthy Volunteers|||August 2008|August 7, 2008|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728338||152174|
NCT00728065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-121|The Effects of Salvia Hispanica-Enriched Foods on Glycemic and Insulinemic Responses and Subjective Satiety|The Effects of Salvia Hispanica-Enriched Foods on Glycemic and Insulinemic Responses and Subjective Satiety||St. Michael's Hospital, Toronto|No|Completed|December 2007|February 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728065||152195|
NCT00728078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA005|Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|LDT-RFA|Sun Yat-sen University|Yes|Recruiting|July 2008|July 2011|Anticipated|July 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||February 2009|February 6, 2009|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728078||152194|
NCT00725309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|576|Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease|Specialized Center of Clinically Oriented Research: Alveolar and Airway Mechanisms for COPD: Genetic Determinants: Elastin Quality and Quantity (Project 2)||Washington University School of Medicine|Yes|Active, not recruiting|November 2007|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|255|Samples With DNA|Plasma, serum, isolated RNA and DNA, lung tissue (obtained from other substudies)|Both|18 Years|N/A|No|Non-Probability Sample|This study will enroll people who undergo evaluation or follow-up at Barnes-Jewish        Hospital for lung volume reduction surgery (LVRS). Researchers will also enroll eligible        COPD patients from other Washington University Medical Center pulmonary clinics.|September 2012|September 14, 2012|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00725309||152405|
NCT00725582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3192K1-1002|Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma|The Effects of IMA-026 on Allergen-Induced Airway Responses and Airway Inflammation in Subjects With Mild Atopic Asthma||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|60 Years|No|||June 2009|June 1, 2009|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725582||152384|
NCT00725894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-010|Pediatric Locking Nail for the Treatment of Femoral Fractures in Children|A Prospective Multi-Center Clinical Outcomes Study To Assess The Safety and Effectiveness Of The Pediatric Locking Nail For Treatment Of Femoral Fractures In Children|PLN|Biomet, Inc.|No|Completed|November 2007|November 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|8 Years|16 Years|No|Non-Probability Sample|Pediatric femoral fractures in patients 8-16 years of age where a nail is preferred|November 2013|November 15, 2013|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725894||152360|
NCT00725907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6000|Treatment of ATFL Tears With PRP|Treatment of ATFL Tears After Ankle Sprains With PRP||Meir Medical Center||Completed|January 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2011|July 10, 2011|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00725907||152359|
NCT00726180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.130|Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer|Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer||University of Michigan Cancer Center|Yes|Terminated|July 2008|October 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|N/A|No|||August 2013|August 9, 2013|July 28, 2008|Yes|Yes|Due to low enrollment|No|March 8, 2013|https://clinicaltrials.gov/show/NCT00726180||152339|
NCT00726193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-012|Study to Analyze the Effects of EBI OsteoGen™ on the Surgical Reconstruction of Tibia Non-unions|A Prospective Randomized Multi - Center Clinical Outcomes Collection Study To Analyze The Effect Of Ebi Osteogen™ Direct Current Stimulator On The Surgical Reconstruction Of Tibia Nonunions||Biomet, Inc.|No|Terminated|June 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|4|||Both|18 Years|75 Years|No|Non-Probability Sample|private practice patients|May 2012|March 14, 2016|July 29, 2008||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00726193||152338|
NCT00727038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4143S|Lucentis for New Onset Neovascular Glaucoma|Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma|NVG|University of Illinois at Chicago|No|Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||July 2008|July 26, 2010|July 29, 2008|Yes|Yes|Company withdrew funding/sponsorship|No||https://clinicaltrials.gov/show/NCT00727038||152274|
NCT00727363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNRNProbiotics|Prophylactic Probiotics in Premature Infants|Prophylactic Probiotics for the Prevention of Sepsis and NEC in Premature Infants in Colombia. A Randomized Double-Blind, Multicenter Trial|C3P|Colombian Neonatal Research Network|Yes|Terminated|August 2008|August 2011|Anticipated|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|751|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||June 2011|June 21, 2011|July 31, 2008||No|We are underpowered to find a difference in the primary outcome.|No||https://clinicaltrials.gov/show/NCT00727363||152249|
NCT00727376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0132|Evaluation of Polyflex Stenting in Esophageal Cancer Patients|Clinical Evaluation of Polyflex Stenting in Esophageal Cancer Patients Undergoing Chemotherapy and/or Radiation Therapy||University of Louisville|No|Completed|March 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|26|||Both|18 Years|N/A|No|Non-Probability Sample|Esophageal cancer patients who have elected to have a stent placed.|January 2010|August 4, 2011|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727376||152248|
NCT00727675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DA024050-01A1|Chronic Pain and Opioid Dependence Assessment and Treatment|Chronic Pain and Opioid Dependence Assessment and Treatment|CPODAT|Yale University|No|Active, not recruiting|August 2008|July 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||January 2014|January 13, 2014|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727675||152225|
NCT00727688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-57|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2006|||||N/A|N/A|N/A||||||||||||||December 19, 2012|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00727688||152224|
NCT00727974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/24|Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines|Genetic Analysis of Children With Cyclic Vomiting Syndrome and Migraines||Medical College of Wisconsin|Yes|Recruiting|January 2008|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|880|Samples With DNA|5 ml of blood will be drawn through venipucture from the study subjects, their biological      parents and siblings when available. In addition, 4 ml of blood will be drawn for serologic      testing.|Both|N/A|21 Years|No|Probability Sample|Cyclic vomiting syndrome (CVS) may be the most severe recurrent vomiting disorder in        humans. CVS is characterized by a sudden onset of rapid-fire vomiting, usually beginning        in the early morning hours or upon wakening. It has a peak vomiting intensity of every        5-10 minutes (6-12 emeses) and episodes last between 2 hours and 10 days. These episodes        of acute vomiting occur on average once every 2 to 4 weeks. The child returns to        completely normal health between vomiting episodes. Children are diagnosed based on their        specific vomiting pattern and a lack of positive findings on laboratory testing.|September 2015|September 3, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727974||152202|
NCT00728221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118328|Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation|Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation|ESGC|St. Michael's Hospital, Toronto|No|Completed|November 2007|||April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|17|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2008|August 1, 2008|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728221||152183|
NCT00724516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00013441|Evaluation Of A Novel Breast Compression Paddle For Wire Localization In Mammography|Evaluation Of A Novel Breast Compression Paddle For Wire Localization In Mammography||University of Michigan||Completed|June 2007|December 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Female|18 Years|N/A|No|||May 2012|May 18, 2012|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00724516||152466|
NCT00725101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11540|Fibromyalgia Health Outcome Study on Cost of Treatments|Real World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments (The REFLECTIONS Study)|REFLECTIONS|Eli Lilly and Company|No|Completed|June 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1700|||Both|18 Years|N/A|No|Probability Sample|Multiple care centers|April 2012|November 29, 2012|July 28, 2008|No|Yes||No|April 27, 2012|https://clinicaltrials.gov/show/NCT00725101||152421|
NCT00729430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|591|Evaluating a Heart Magnetic Resonance Imaging (MRI) Procedure and the Effect of Fish Oil Supplementation in People Who Have Recently Had a Heart Attack (The PROSPECT-CMR Study)|Prognostic, Anti-arrhythmic, and Ventricular Remodeling Effects of High Dose Fish Oil in Patients With a Recent Myocardial Infarction|Omega-REMODEL|Brigham and Women's Hospital|Yes|Completed|August 2008|July 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|374|||Both|21 Years|N/A|No|||January 2015|January 26, 2015|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729430||152092|
NCT00729443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0490C00012|Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers|A Single-Centre, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 Following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers|SAD|AstraZeneca|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|64|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2008|November 10, 2008|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729443||152091|
NCT00726622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z6051|Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer|A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|August 2008|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|486|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00726622||152306|
NCT00727129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04-001|Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms|Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients||Upsher-Smith Laboratories||Completed|July 2004|August 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|495|||Female|18 Years|N/A|No|||September 2008|September 25, 2008|July 29, 2008||||||https://clinicaltrials.gov/show/NCT00727129||152267|
NCT00727142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/0149|Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus (INPH)|Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus||University College London Hospitals|No|Terminated|July 2008|July 2012|Anticipated|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|40 Years|N/A|No|||July 2008|August 8, 2011|July 29, 2008||No|observed benefit of treatment larger than expected|No||https://clinicaltrials.gov/show/NCT00727142||152266|
NCT00727155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H23264|Adjusting to Chronic Conditions Using Education Support and Skills|Improving Quality Of Life For Chronically Ill Patients Using Education Support And Skills; A Randomized Controlled Mental Trial|ACCESS|VA Office of Research and Development|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2009|July 9, 2009|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00727155||152265|
NCT00718224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10571|Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery|A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of Semuloparin (AVE5026) With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery|SAVE-KNEE|Sanofi|Yes|Completed|July 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1150|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718224||152938|
NCT00718237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-029|Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)|A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of V260 in Healthy Infants in Japan||Merck Sharp & Dohme Corp.||Completed|August 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|762|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||May 2015|May 13, 2015|July 16, 2008|Yes|Yes||No|June 23, 2010|https://clinicaltrials.gov/show/NCT00718237||152937|
NCT00718536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALqd-ATV|Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy|Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy||Germans Trias i Pujol Hospital|No|Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||April 2009|April 8, 2009|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718536||152914|
NCT00728611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000|Preparation Rich in Growth Factors (PRGF) Treatment for Osteoarthritis of the Knee|PRP as a Treatment for Knee Osteoarthritis - Randomized-double-blind-placebo Control Trail.||Meir Medical Center|Yes|Completed|January 2008|March 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|40 Years|75 Years|No|||July 2011|July 10, 2011|August 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00728611||152153|
NCT00728624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1891005|Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns|Expert Group On Antibiotic Susceptibility Testing [EGAST] 2008: A Non-Interventional, Multicenter In-Vitro Study To Evaluate The Prevalence Of Beta-Lactamase Producing Strains Among Clinical Isolates Obtained From Hospital In-Patients And Comparison Of Antimicrobial Susceptibility Using Disc-Diffusion Method|EGAST 2008|Pfizer|No|Completed|November 2008|September 2009|Actual|September 2009|Actual|Phase 0|Observational|Time Perspective: Prospective||1|Actual|2039|||Both|N/A|N/A|No|Non-Probability Sample|Isolates from hospitalised patients|August 2010|August 26, 2010|August 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728624||152152|
NCT00725920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TopirPTSD|Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.|Randomized Clinical Trial to Study the Topiramate Efficacy for Posttraumatic Disorder Treatment||Federal University of São Paulo|Yes|Completed|January 2007|December 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||August 2014|August 5, 2014|July 28, 2008||No||No|June 1, 2010|https://clinicaltrials.gov/show/NCT00725920||152358|
NCT00726206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00062 53|Correlation Between the Analysis of the Rapid Cortical Oscillations, the General Movements of the Preterm's and the Cerebral Palsy|Correlation Between the Analysis of the Rapid Cortical Oscillations, the General Movements of the Preterm's and the Cerebral Palsy||Assistance Publique Hopitaux De Marseille|No|Completed|July 2008|September 2010|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|44|||Both|N/A|23 Months|No|||August 2014|August 27, 2014|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726206||152337|
NCT00726219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD07.052|Insertion Distance of Femoral Perineural Catheters in the Context of Major Knee Surgery.|Influence of the Insertion Distance on Loss of Sensation Produced by Femoral Perineural Catheters in the Context of Major Knee Surgery.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|December 2008|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||June 2010|February 9, 2011|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726219||152336|
NCT00726817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-3-020|The Effects of Butyrate Enemas on Visceral Perception|The Effects of Butyrate Enemas on Visceral Perception||Maastricht University Medical Center|No|Completed|December 2007|||February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2008|July 31, 2008|July 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726817||152291|
NCT00726830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0791|Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer|A Randomized Comparison of Oral Methadone as a "First-Switch" Opioid Versus Opioid Switching Between Sustained-Release Morphine and Oxycodone for Oncology-Hematology Outpatients With Pain Management Problems: The "Simply Rotate" Study||M.D. Anderson Cancer Center|Yes|Terminated|March 2009|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|July 31, 2008||No|Low Accrual.|No|November 9, 2012|https://clinicaltrials.gov/show/NCT00726830||152290|
NCT00726843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85067-3|Evaluation of Yoga for the Treatment of Pediatric Headaches|Evaluation of Yoga for the Treatment of Pediatric Headaches||Medical College of Wisconsin|No|Terminated|July 2008|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|13 Years|17 Years|No|||April 2015|April 6, 2015|July 30, 2008||No|Enrollment proceeded too slowly to conduct study as RCT.|No||https://clinicaltrials.gov/show/NCT00726843||152289|
NCT00727051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9730-30837|Comparison of Coronary CT Angiography With Conventional Coronary Angiography in Liver and Lung Transplant Candidates|Comparison of Coronary CT Angiography With Conventional Coronary Angiography in Liver and Lung Transplant Candidates.||University of California, San Francisco|Yes|Suspended|June 2007|||July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Liver and lung transplant candidates referred for coronary angiography.|August 2014|August 15, 2014|July 29, 2008||No|No funding|No||https://clinicaltrials.gov/show/NCT00727051||152273|
NCT00727389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lnunes|Prevention of Functional Decline of Aged Women|The Influence of the Support Group on the Functional Incapacity in the Prevention of Functional Decline of Aged Women.|Incapacity|Academia Cearense de Odontologia|Yes|Completed|April 2007|November 2007|Actual|October 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Female|60 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 31, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00727389||152247|
NCT00727402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23EY015270-01|Longitudinal Evaluation of Silicone Hydrogel (LASH) Study|The Longitudinal Evaluation of Silicone Hydrogel (LASH) Contact Lens Study|LASH|National Eye Institute (NEI)|No|Completed|October 2006|October 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|205|Samples Without DNA|tear samples contact lenses bacteria isolated from contact lenses|Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|study volunteers from academic community willing to wear extended wear contact lenses|February 2012|February 13, 2012|July 31, 2008||No||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00727402||152246|
NCT00727701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-246|Study of Individualized Wound Prevention Instruction to Prevent Venous Ulcer Development|Does Use of a Wound After-care Summary for Patients With a History of Venous Ulcers Lower Recurrence Rate?||VA Office of Research and Development|No|Terminated|July 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|72|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|July 30, 2008||No|Study delayed for over a year by research shutdown at Seattle VA and other issues. Study    designer moved to Ann Arbor in the interim, so the study was closed.|No||https://clinicaltrials.gov/show/NCT00727701||152223|
NCT00727987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015340|A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Study of Golimumab (CNTO 148) Administered in Combination With Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis||Janssen Pharmaceutical K.K.|No|Completed|May 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|269|||Both|20 Years|74 Years|No|||May 2013|May 22, 2013|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727987||152201|
NCT00728234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klebermass_01|Analysis of Correlation of Amplitude-Integrated EEG and Neurodevelopmental Outcome in Preterm Infants|Analysis of Amplitude-Integrated Electroencephalography and Its Predictive Value for Neurodevelopmental Outcome in Preterm Infants Born Below 30 Weeks Gestational Age||Medical University of Vienna|No|Completed|January 2000|July 2006|Actual|December 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|284|||Both|23 Weeks|29 Weeks|No|Non-Probability Sample|inclusion of all preterm infants born below 30 weeks gestational age within the study        period at medical university vienna|July 2008|August 6, 2008|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728234||152182|
NCT00724841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM303|A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma|A Multi-Center, Open-Label, Phase I/II Study of GEM1777 in Combination With Temozolomide Administered Every 4 Weeks to Patients With Metastatic Melanoma||Teva Pharmaceutical Industries|No|Terminated|June 2008|August 2010|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|1|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|July 28, 2008|Yes|Yes|Study terminated prematurely due to financial contraints.|No||https://clinicaltrials.gov/show/NCT00724841||152441|
NCT00729716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioCart™II 005-06|Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle|Phase II Study to Investigate the Efficacy and Safety of BioCart™II in the Treatment of Symptomatic Cartilage Defects of the Femoral Condyle in Comparison With Microfracture||ProChon Biotech Ltd|No|Active, not recruiting|May 2008|May 2015|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|60 Years|No|||March 2012|April 16, 2012|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729716||152070|
NCT00725998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 039/2004|Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users|Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users|ECAP|University of Sao Paulo||Completed||||||N/A|Observational|N/A||1|||||Both|N/A|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|The ECAP characteristics have been analyzed in 13 children implanted younger than three        years old.|July 2008|October 17, 2008|July 28, 2008||||No||https://clinicaltrials.gov/show/NCT00725998||152352|
NCT00725387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0024|Combined F18 and F18 FDG PET/CT for Evaluation of Malignancy|Combined F18 and F18 FDG PET/CT for Evaluation of Malignancy||Stanford University|Yes|Recruiting|August 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must be referred for evaluation of bone metastases.|January 2015|January 30, 2015|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725387||152399|
NCT00726323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET111644|A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)|A Phase 2 Study of the c-Met RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Papillary Renal-Cell Carcinoma||GlaxoSmithKline|No|Completed|June 2006|July 2012|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726323||152328|
NCT00726648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C32325|CDP323 Biomarker Study|Double-blind, Placebo-controlled, Randomized, Parallel-group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.||UCB Pharma|Yes|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|71|||Both|18 Years|65 Years|No|||August 2009|September 2, 2011|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726648||152304|
NCT00726908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070322005|Intramuscular Lipid and Insulin Action:Ethnic Aspects|Intramuscular Lipid and Insulin Action:Ethnic Aspects|QuEST|University of Alabama at Birmingham|No|Completed|April 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|69|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726908||152284|
NCT00727818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R304 - 002|A Split-Blind Clinical Investigation to Compare the Performance and Safety of Inion GTR™ Biodegradable Membrane System to Resorbable Bilayer Bio-Gide®-Membrane of Geistlich Biomaterials in Enhancing Bone Regeneration After Removal of Wisdom Teeth.|||University of Zurich||Completed|May 2006|February 2007||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|30 Years|No|||July 2008|July 31, 2008|July 31, 2008||||No||https://clinicaltrials.gov/show/NCT00727818||152214|
NCT00718549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21283|A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia|A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With MabThera vs no Treatment, After Induction With MabThera, Cladribine and Cyclophosphamide on Progression-free Survival in Previously Untreated Patients With Progressive B-CLL. The Trial Conducted With PALG Sites||Hoffmann-La Roche||Completed|July 2009|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718549||152913|
NCT00718783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARB|Molecular Analysis of Retinoblastoma|Molecular Analysis of Retinoblastoma||St. Jude Children's Research Hospital|No|Recruiting|April 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|-  Each tumor sample will be immediately transferred to a sterile cryovial and flash           frozen in liquid nitrogen.        -  White blood cells will be isolated from the blood sample as a source of genomic DNA.|Both|N/A|N/A|No|Non-Probability Sample|Patients with retinoblastoma|January 2016|January 27, 2016|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718783||152895|
NCT00719108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WosulinR/PK-PD/HV/EMEA/2008/v2|Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.|Randomized,Single Center,Double Blind,Two-period,Crossover Glucose Clamp Trial to Test Bioequivalence Between Two Recombinant Human Soluble Insulins - Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects||Wockhardt|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 26, 2012|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719108||152871|
NCT00718770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0727.cc|A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression|Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression||University of Colorado, Denver|Yes|Completed|November 2008|February 2013|Actual|January 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|July 17, 2008|No|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00718770||152896|Small numbers of participants with higher than expected numbers of patients not eligible and who could not complete trial due to lack of efficacy or drug side effects
NCT00726232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-256|Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia|An Open-Label Study to Determine the Safety and Efficacy of INCB018424 in Patients With Advanced Polycythemia Vera or Essential Thrombocythemia Refractory to Hydroxyurea||Incyte Corporation|No|Active, not recruiting|July 2008|December 2018|Anticipated|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|73|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|July 29, 2008|Yes|Yes||No|January 20, 2012|https://clinicaltrials.gov/show/NCT00726232||152335|
NCT00722475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IvIg for recurrent miscarriage|Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage|A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Immunoglobulin for Women With Unexplained Secondary Recurrent Miscarriage||Rigshospitalet, Denmark|Yes|Completed|August 2008|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|40 Years|No|||November 2014|November 5, 2014|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722475||152619|
NCT00723008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-07-024|Cranial Electrotherapy Stimulation in Burned Patients|Effect of Cranial Electrotherapy Stimulation on PTSD in Burned Outpatients|CES|United States Army Institute of Surgical Research|No|Completed|May 2007|December 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||February 2013|February 19, 2013|December 25, 2007|Yes|Yes||No|October 9, 2012|https://clinicaltrials.gov/show/NCT00723008||152579|This study had a high study turn-over rate, which led to small data group analysis. All subjects enrolled were active military service men. This made civilian and female comparison impossible. The PI also changed during study course.
NCT00723021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0041002|PF-04191834 Single Dose Bronchodilatory Study In Asthma.|A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patients.||Pfizer|No|Completed|July 2008|July 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|15|||Both|18 Years|60 Years|No|||December 2012|December 27, 2012|July 24, 2008|Yes|Yes||No|December 27, 2012|https://clinicaltrials.gov/show/NCT00723021||152578|
NCT00723294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z1072|Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer|A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|September 2008|||September 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|July 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00723294||152559|
NCT00723658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0629|S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia|S0629, Observational Study of Asymptomatic Waldenstrom's Macroglobulinemia and Phase II Study of Tandem Autologous Transplant and Maintenance Treatment for Patients With Symptomatic Disease||Southwest Oncology Group|Yes|Withdrawn|September 2008|||May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 26, 2008|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00723658||152532|
NCT00723645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05181|Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)|Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-life Clinical Practice in Spanish Hospitals (FAST-4)|FAST-4|Merck Sharp & Dohme Corp.|No|Completed|April 2008|February 2011|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|279|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with chronic hepatitis C who were treated for the first time with pegylated        interferon alfa-2b plus ribavirin and achieved end-of-treatment response.|November 2015|November 26, 2015|July 25, 2008|No|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT00723645||152533|
NCT00723957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-163|A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer|A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-small Cell Lung Cancer||R-Pharm|No|Completed|December 2008|August 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 25, 2008|Yes|Yes||No|June 20, 2011|https://clinicaltrials.gov/show/NCT00723957||152509|
NCT00724230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04841|Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)|PegIntron/REBETOL Combination Therapy Designated Drug Use Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C Excluding Those With "IFN Naive Low Viral Load and Genotype 1 and High Viral Load"-||Merck Sharp & Dohme Corp.|No|Completed|February 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|505|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic hepatitis C excluding subjects with HCV genotype 1 and high viral        load, and interferon-naïve subjects with low viral load. Patients undergoing treatment        with PegIntron and Rebetol in clinical practice at approximately 50 to 100 sites in Japan.|February 2015|February 2, 2015|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00724230||152488|
NCT00725114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC-006|Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain|A Multicentre , Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Inadequately Controlled Cancer-related Pain|TEC-006|Wex Pharmaceuticals Inc.|No|Completed|April 2008|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||August 2012|July 7, 2014|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725114||152420|
NCT00725127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARING-2008/1|Chronotherapy With Low-dose Aspirin for Primary Prevention|Chronotherapy With Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Subjects With Impaired Fasting Glucose or Diabetes (CARING Study).|CARING|University of Vigo|Yes|Recruiting|October 2008|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3200|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725127||152419|
NCT00726011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC-006OL|Tetrodotoxin Open-label Efficacy and Safety Continuation Study|A Multicentre, Open-label, Long-term Efficacy and Safety Continuation Study of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Cancer-related Pain|TEC-006OL|Wex Pharmaceuticals Inc.|No|Completed|July 2008|July 2012|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00726011||152351|
NCT00726336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111604|GSK1349572 Drug Interaction With Tenofovir|A Phase I, Open Label, Single Sequence,Drug Interaction Study Evaluating Plasma GSK1349572 and Tenofovir Pharmacokinetics in Healthy Adult Subjects (ING111604)||GlaxoSmithKline||Completed|August 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|July 29, 2008||||||https://clinicaltrials.gov/show/NCT00726336||152327|
NCT00726349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD 06.084|Transfusion Requirements in Orthopedic Surgery (PHASE 2)|Transfusion Requirements in Orthopedic Surgery (Phase 2): A Prospective Observational Evaluation of the Optimal Transfusion Trigger.|TRIOS|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|May 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|305|||Both|60 Years|N/A|No|Probability Sample|Patients undergoing isolated elective total hip or knee arthroplasty (primary or revision        surgery for a non-malignant condition), aged 60 years or older and able to walk prior to        surgery.|May 2011|May 4, 2011|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726349||152326|
NCT00726635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0014-08-RMC|The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies|Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial||Rabin Medical Center|No|Recruiting|August 2008|August 2009|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Female|18 Years|70 Years|No|||July 2008|February 15, 2009|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726635||152305|
NCT00727532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07U1|Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer|Correlation of Pathologic Findings After Neo-adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma||Northwestern University|Yes|Terminated|July 2008|June 2015|Anticipated|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|August 1, 2008|No|Yes|Low Accrual|No||https://clinicaltrials.gov/show/NCT00727532||152236|
NCT00717886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-051|Upper Extremity Lymphatic Mapping for Breast Cancer Patients|Upper Extremity Lymphatic Mapping for Breast Cancer Patients: A Pilot Study||Memorial Sloan Kettering Cancer Center||Completed|June 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Female|21 Years|N/A|No|||October 2015|October 19, 2015|July 16, 2008||No||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00717886||152963|
NCT00718250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O5CC14|Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2|A Phase I Study of Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) Expressing B7.1 (CD80) and IL-2 for the Potential Enhancement of Graft Versus Leukaemia(GvL) Effect in Poor Prognosis AML|RFUSIN2-AML1|King's College Hospital NHS Trust|Yes|Recruiting|May 2008|February 2012|Anticipated|May 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||July 2008|July 16, 2008|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00718250||152936|
NCT00719407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9299-32566-01|Neonatal Erythropoietin in Asphyxiated Term Newborns|Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial|NEAT|University of California, San Francisco|Yes|Completed|January 2010|November 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|24 Hours|No|||November 2012|November 7, 2012|July 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00719407||152848|
NCT00719654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 17495|Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia|Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia||Medical University of South Carolina|No|Recruiting|August 2007|August 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Blood plasma and a portion of placenta is retained|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The study population will consist of women who present to MUSC's Women's Health Clinic        prior to their 34th week of pregnancy.|July 2008|July 18, 2008|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00719654||152829|
NCT00719121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT0700-107-BEL|Study on Anti-inflammatory Effects of Topical R115866 Gel|Placebo-Controlled, Investigator Blinded, Explorative Trial to Evaluate the Anti-inflammatory Effect of Multiple Topical Applications of R115866 Gel (0.35%) in Two Models of Cutaneous Inflammation in Healthy Male Subjects||GlaxoSmithKline|No|Completed|November 2006|March 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|4||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|September 23, 2011|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719121||152870|
NCT00722163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195/2006|A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis|A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis|PSTEP|Ontario Mental Health Foundation|No|Recruiting|September 2007|March 2013|Anticipated|May 2009|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|330|||Both|16 Years|35 Years|No|||July 2008|July 23, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722163||152642|
NCT00722748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC004714|Genomic Investigation of Cardiovascular Diseases|The Genebank at Scripps Clinic Registry||Scripps Translational Science Institute|No|Active, not recruiting|June 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|15000|Samples With DNA|Cardiac Catheterization Patients      Blood will be collected from the patients that will undergo heart catheterization for      establishing a gene bank registry. Informed consent will take place prior to cardiac      catheterization. 38 cc of blood collected will be processed to create a repository of DNA,      RNA, and lymphoblastoid cell-line immortalization on selected patient populations, plasma      and serum. The DNA will be amplified in certain patient populations to preserve the      quantity.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from Scripps Health general diagnostic population, cardiology        population, and outside referrals. Upon meeting the inclusion/exclusion criteria, each        eligible patient will be given a consent form and the study will be discussed with them in        a face-to-face discussion with the principal investigator, one of the co-investigators or        one of the research coordinators. The patient (or legal representative) must sign the        informed consent form prior to any study related procedures being performed.|October 2015|October 14, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00722748||152598|
NCT00726531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProAct65+|Promoting Physical Activity in the Over 65s|Multi-centre Cluster Randomised Trial Comparing a Community Group Exercise Programme With Home Based Exercise With Usual Care for Over 65s in Primary Care|ProAct65+|University College, London|Yes|Recruiting|June 2008|May 2013|Anticipated|May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 7, 2010|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726531||152313|
NCT00726544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC1779-006|Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy|A Randomized, Double-blind, Placebo Controlled, Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy||Archemix Corp.|Yes|Terminated|December 2008|March 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|75 Years|No|||November 2009|November 24, 2009|July 30, 2008|No|Yes|Enrollment into study was slower than expected.|No||https://clinicaltrials.gov/show/NCT00726544||152312|
NCT00723307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gla-Met-1 (version 5)|Carotid Atherosclerosis: MEtformin for Insulin ResistAnce Study|A Randomised Placebo-controlled Trial of Metformin on Progression of Carotid Atherosclerosis in Non-diabetic Patients With Cardiovascular Disease Treated With Conventional Risk Reducing Agents|CAMERA|University of Glasgow|No|Completed|February 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|173|||Both|35 Years|75 Years|No|||December 2012|December 7, 2012|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723307||152558|
NCT00723671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00050562|Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus|||University of Michigan||Completed|November 2006|December 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723671||152531|
NCT00723970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00008|Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression|Seroquel XR for the Treatment of Peri and Postmenopausal Women With Major Depressive Disorder: Impact on Mood, Physical Symptoms, Sleep and Quality of Life||McMaster University|No|Completed|June 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|40|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||July 2009|February 7, 2012|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723970||152508|
NCT00723983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-15-NP101-011|Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period|A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period|NP101-011|Teva Pharmaceutical Industries|No|Completed|November 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|23|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00723983||152507|
NCT00724243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04741|Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)|Remicade Treatment Registry in Rheumatoid Arthritis I||Merck Sharp & Dohme Corp.|No|Completed|January 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|N/A|N/A|No|Non-Probability Sample|Subjects for this study will be patients expecting to initiate infliximab, for the first        time, for the diagnoses of rheumatoid arthritis at the National Institute of Rheumatology        Diseases in Piestany, Slovakia.|September 2015|September 3, 2015|July 25, 2008|No|Yes||No|January 28, 2010|https://clinicaltrials.gov/show/NCT00724243||152487|
NCT00724256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI_62-2006|Short-term Antibiotic Therapy for Pyelonephritis in Childhood|Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood.|STUTI|IRCCS Burlo Garofolo|Yes|Terminated|July 2006|July 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|1 Month|5 Years|No|||February 2012|February 15, 2012|July 18, 2008||No|other upcoming studies; patients refusal of invasive follow up (DMSA)|No||https://clinicaltrials.gov/show/NCT00724256||152486|
NCT00724529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100771|Post Marketing Surveillance of Remicade|Post Marketing Surveillance of Remicade in Inflammatory Bowel Disease (IBD)||Janssen Korea, Ltd., Korea||Completed|June 2007|August 2011|Actual|August 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|938|||Both|N/A|N/A|No|Probability Sample|The population of subjects will mainly be taken from the digestive or rheumatoid        departments of internal medicine in university or general hospitals, where patients with        Crohn's Disease and Ankylosing Spondylitis are generally treated. The period of        surveillance is from 23 AUG 2005 to 22 AUG 2011.|January 2013|January 21, 2013|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724529||152465|
NCT00724542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A02-11|Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.|Evaluation of Lifestyle and Therapeutic Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.|EIIGETPCHD|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|July 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1600|||Both|40 Years|75 Years|No|||August 2008|August 22, 2008|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00724542||152464|
NCT00721045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF-AB002|A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure|A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure||Mesoblast, Ltd.|Yes|Completed|August 2008|July 2013|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|60|||Both|20 Years|80 Years|No|||May 2015|May 19, 2015|July 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721045||152726|
NCT00721344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-T-131|A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.|A Phase 1, Randomized, Double-Blind, Cross-Over, Placebo- and Active-Controlled Cardiac Safety Study of Therapeutic and Supratherapeutic Doses of Fumaryl Diketopiperazine Administered as Technosphere® Inhalation Powder in Healthy Subjects||Mannkind Corporation||Completed|April 2008|October 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|July 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721344||152704|
NCT00725751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05255|Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)|Evaluation of Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Patients With/Without Substitution Therapy in Austria||Merck Sharp & Dohme Corp.|No|Completed|September 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|353|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients receiving treatment for hepatitis C with/without substitution therapy at        sites in Austria.|October 2015|October 1, 2015|July 25, 2008|No|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT00725751||152371|
NCT00725764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET111646|Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck|A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck||GlaxoSmithKline|No|Completed|August 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2011|May 31, 2012|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725764||152370|
NCT00726024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-02-23|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2002|||||N/A|N/A|N/A||||||||||||||December 18, 2012|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726024||152350|
NCT00727168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUH81510-9701|Screening for Glaucoma in Namil Area, South Korea|Epidemiologic Study for the Prevalence of Glaucoma in Namil Area, Geumsan City, South Korea||Korean Glaucoma Society|Yes|Completed|November 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1532|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All residents aged over 40 in Namil area in Geumsan city|August 2008|August 1, 2008|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727168||152264|
NCT00727181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS05002TV|An Observational, Prospective Evaluation of the Trifecta™ Valve|An Observational, Prospective Evaluation of the Trifecta™ Valve||St. Jude Medical|Yes|Completed|November 2007|December 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00727181||152263|
NCT00717613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLD2007-01|Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting|Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting||Baylor College of Medicine|No|Completed|July 2007|October 2011|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Male|18 Years|N/A|No|Non-Probability Sample|Convenience sample of men on active surveillance drawn from large academic medical        centers, community hospitals, support groups, and the internet.|November 2011|November 7, 2011|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717613||152984|
NCT00718263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2303E1|Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)|Extension Study to a Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|PHCHBS-WD4070|Novartis||Recruiting|April 2008|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718263||152935|
NCT00718835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA019550|Incentive-based Smoking Cessation for Methadone Patients|Incentive-based Smoking Cessation for Methadone Patients||University of Vermont Medical Center|No|Completed|June 2007|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|65 Years|No|||February 2014|February 20, 2014|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718835||152891|
NCT00719979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078922|Effectiveness of a Technology Assisted Behavioral Intervention in Assisting People With Major Depressive Disorder|Integrated Telemental Health Intervention for Depression in Primary Care||Northwestern University|Yes|Completed|September 2009|July 2012|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|19 Years|N/A|No|||January 2013|March 18, 2014|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00719979||152804|
NCT00719992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4543|Diagnostic Value of HS-CRP in Stable Angina.|Diagnostic Value of HS-CRP in Stable Angina Patients With Positive Exercise Test as Compared With Coronary Angiography.||Shiraz University of Medical Sciences|Yes|Completed|April 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|97|||Both|43 Years|64 Years|No|||July 2008|July 18, 2008|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719992||152803|
NCT00722488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15002|Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma|An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma||Millennium Pharmaceuticals, Inc.||Completed|June 2008|September 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|July 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722488||152618|
NCT00722501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3252K1-1000|Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 24, 2009|July 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00722501||152617|
NCT00723060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11769A|Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder|Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study)||Seoul National University Hospital|Yes|Completed|September 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|65 Years|No|||August 2011|August 5, 2011|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723060||152576|
NCT00722735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINA-003|Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)|A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days|FLUT|MerLion Pharmaceuticals GmbH|Yes|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|55 Years|No|||October 2008|June 10, 2009|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00722735||152599|
NCT00723684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF1|Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy|ADHD and EEG-neurofeedback. A Single-blind Randomized Placebo-controlled Treatment Study.|PANther|Radboud University|Yes|Completed|July 2008|February 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|8 Years|15 Years|No|||March 2013|March 7, 2013|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00723684||152530|
NCT00723996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00048680|Preventive Health Behavior in Women|Preventive Health Behavior in Women||University of Michigan|No|Active, not recruiting|September 2003|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Actual|254|||Female|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who are scheduled for a screening mammogram at a University Medical Center who are        between 50 and 75 years old will recruited.|June 2015|June 1, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723996||152506|
NCT00724009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15809B|Clofarabine Bone Marrow Cytoreduction|Clofarabine Bone Marrow Cytoreduction : Feasibility of Induction as a Bridge to Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Acute Leukemias, Myelodysplastic Syndromes, and Advanced Myeloproliferative Diseases.||University of Chicago|No|Completed|December 2007|September 2012|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|July 25, 2008|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00724009||152505|
NCT00724269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-04 / BP-08-01|Comparison of OPTI-FREE RepleniSH and ReNu Multi-Plus Lens Care Regimens on Corneal Epithelium|||Alcon Research|No|Completed|October 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|20|||Both|18 Years|N/A|No|||November 2011|September 28, 2012|July 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00724269||152485|
NCT00724282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15632|Treatment of Insomnia and Glucose Metabolism|Double-blind Placebo-controlled Study of the Effects of Eszopiclone on Glucose Tolerance, Insulin Secretion, and Insulin Action in Adults With Chronic Insomnia||University of Chicago|No|Completed|April 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|July 25, 2008|Yes|Yes||No|September 10, 2015|https://clinicaltrials.gov/show/NCT00724282||152484|
NCT00724880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plavix studie|Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.|Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery. A Prospective Randomized Controlled Study||Catharina Ziekenhuis Eindhoven||Completed|June 2006|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|135|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724880||152438|
NCT00724555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54NS057405_ASPIRE|Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities|Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities|ASPIRE|Georgetown University|No|Completed|February 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|2005|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult residents of the District of Columbia|January 2014|January 30, 2014|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724555||152463|
NCT00724854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05427|Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)|Evaluation of Rapid Virological Response in HCV Patients Treated With PegIntron and Ribavirin - APEGIN Trial|APEGIN|Merck Sharp & Dohme Corp.|No|Completed|August 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1146|||Both|N/A|N/A|No|Probability Sample|Participants infected with Hepatitis C Virus (HCV) who are undergoing treatment with        PegIntron and Rebetol in accordance with approved labeling at approximately 60 sites in        Brazil. Participants could be treatment-naïve, undergoing re-treatment, or co-infected        with Human Immunodeficiency Virus (HIV).|February 2015|February 6, 2015|July 25, 2008|No|Yes||No|December 23, 2010|https://clinicaltrials.gov/show/NCT00724854||152440|
NCT00720785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080186|Natural Killer Cells and Bortezomib to Treat Cancer|Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib||National Institutes of Health Clinical Center (CC)||Recruiting|July 2008|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|70 Years|No|||February 2016|March 11, 2016|July 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720785||152745|
NCT00720798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA18696|An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies|Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies||Hoffmann-La Roche||Completed|September 2005|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2067|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|July 22, 2008|Yes|Yes||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00720798||152744|
NCT00721058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delineation of tumourbed mamma|Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.|Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.||Maastricht Radiation Oncology|Yes|Completed|August 2008|||October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2010|January 4, 2010|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721058||152725|
NCT00726921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|256-08-FB|Imaging Modalities in Detection of Coronary Artery Disease in End-Stage Renal Disease Patients|Detection of Significant Coronary Artery Disease in Nephropathy Patients Utilizing Coronary CTA and Real Time Perfusion DSE: Comparison With Quantitative Coronary Angiography and Patient Outcome||University of Nebraska|Yes|Not yet recruiting|August 2008|August 2011|Anticipated|August 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|75|||Both|19 Years|65 Years|No|Non-Probability Sample|Adults aged 19-65 with diabetes and end stage renal disease undergoing evaluation for        kidney transplantation.|July 2008|July 31, 2008|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726921||152283|
NCT00717314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21241|A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.|A Randomized, Open Label Study Comparing the Effect of CellCept Combined With 2 Regimens of Reduced Calcineurin Inhibitors on Kidney Function in Liver Transplant Patients||Hoffmann-La Roche||Completed|May 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|July 16, 2008||No||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00717314||153007|
NCT00717327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2008.155|Adolescent Knowledge of Their Medications|Medication Reconciliation List and Adolescent Functional Health Literacy||Brooke Army Medical Center|Yes|Completed|July 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|384|||Both|12 Years|23 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents enrolled in an primary care clinc.|June 2009|June 24, 2009|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717327||153006|
NCT00717899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 4642/ CMC 0064-07|The Effect of Air Pollution on Lung Health Among School Children Living in Haifa Bay Region|The Effect of Air Pollution on Lung Health Among School Children Living in Haifa Bay Region||Carmel Medical Center|No|Completed|December 2008|September 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1200|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00717899||152962|
NCT00718809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00297|Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer|Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)||National Cancer Institute (NCI)||Terminated|June 2008|October 2013|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2014|June 5, 2015|July 18, 2008|Yes|Yes||No|May 15, 2015|https://clinicaltrials.gov/show/NCT00718809||152893|
NCT00718822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3-0327|Outcome of Embryo Culture at Two Oxygen Tensions|Does Reduced Oxygen Tension in Embryo Culture Influence Clinical Outcome of ICSI Cycles? A Prospective Randomized Trial||University Clinical Centre, Maribor|No|Completed|August 2006|September 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|647|||Female|22 Years|44 Years|No|||July 2008|July 18, 2008|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718822||152892|
NCT00719446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|589|Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials|Patient Outcomes 6 and 12 Months After ALTA, OMEGA, EDEN and SAILS ARDS Network Trials|ALTOS|Johns Hopkins University|No|Completed|October 2007|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|922|||Both|18 Years|N/A|No|Non-Probability Sample|Participants who were enrolled in the ALTA, EDEN, OMEGA, or SAILS study.|August 2015|August 31, 2015|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00719446||152845|
NCT00719459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRON-07-04|Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer|A Randomized, Open-Label, Single-Dose, Parallel-Design, Bioequivalence Study of Hospira Iron Sucrose Injection Compared to Venofer® Injection USP in Healthy Subjects.||Hospira, Inc.|No|Completed|June 2008|||July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00719459||152844|
NCT00719134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000220|The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache|The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache||Beth Israel Deaconess Medical Center|No|Completed|September 2008|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|76|||Both|18 Years|80 Years|No|||April 2015|April 8, 2015|July 18, 2008|Yes|Yes||No|February 10, 2015|https://clinicaltrials.gov/show/NCT00719134||152869|Patients were not asked whether or not they thought the pill they took was maxalt or placebo. Thus, it is not possible to determine their actual level of expectation.
NCT00719147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN2|AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone|Avascular Necrosis of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone||St. Jude Children's Research Hospital|No|Completed|July 2001|July 2005|Actual|July 2005|Actual|N/A|Observational|N/A||1|Actual|170|||Both|N/A|N/A|No|Non-Probability Sample|Patients with acute lymphoblastic leukemia enrolled on the SJCRH front-line ALL protocol,        TOTAL XIIIB or the front-line NHL protocol NHL13 from 11/94 to 6/98|September 2011|September 26, 2011|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719147||152868|
NCT00719420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02-24-2|Clarithromycin, Amoxicillin, and Metronidazole Based Regimens to Treat Helicobacter Pylori Infections in Colombia|A Randomized Clinical Trial to Examine the Efficacy of a Clarithromycin-, Amoxicillin-, and Metronidazole-Based Regimen to Eradicate Helicobacter Pylori Infections in Pasto, Colombia||University of North Texas Health Science Center|No|Completed|April 2006|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|29 Years|77 Years|No|||July 2008|July 18, 2008|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719420||152847|
NCT00722761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000754|Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne|A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy Of YAZ Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris||Massachusetts General Hospital|No|Completed|April 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|45 Years|No|||January 2013|January 29, 2013|July 24, 2008|Yes|Yes||No|December 17, 2012|https://clinicaltrials.gov/show/NCT00722761||152597|Early termination leading to small number of subjects analyzed
NCT00723697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05186|Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)|Etude Observationnelle Prospective de l'Utilisation en Situation Reelle; Prospective Real Situation Observational Study of Subutex® or Its Buprenorphine High Dose Generic (BHD) in the Replacement Treatment of Major Opiate Dependence: Following Parameters With Respect to Misuse and Pharmacovigilance|OPUS R|Indivior Inc.|No|Completed|May 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1307|||Both|N/A|N/A|No|Non-Probability Sample|Patients addicted to opiates and requiring replacement treatment with Subutex        (Schering-Plough) or BHD generic (Arrow laboratories)|July 2010|April 14, 2011|July 25, 2008|No|Yes||No|April 14, 2011|https://clinicaltrials.gov/show/NCT00723697||152529|
NCT00723047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2003-1|Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial|Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial|Fibrin glue|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|November 2003|August 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||September 2011|September 2, 2011|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723047||152577|
NCT00723320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A02-03|Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis|Effect of Atorvastatin and Lifestyle Intervention on Progression of Carotid Intima-Media Thickness in Chinese People Without Manifest Atherosclerotic Disease|EALIPPCA|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|February 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|1200|||Both|40 Years|70 Years|No|||July 2008|August 22, 2008|July 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00723320||152557|
NCT00724295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04505|Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)|PEG Intron/REBETOL Combination Therapy Special Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C-||Merck Sharp & Dohme Corp.|No|Completed|April 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1077|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic hepatitis C treated with PegIntron and Rebetol combination therapy        in the clinical practice at approximately 100 to 200 institutions in Japan.|February 2015|February 3, 2015|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00724295||152483|
NCT00724568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.098|Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma|A Multi-Institutional Phase I/II Study of Revlimid® (Lenalidomide), Velcade® (Bortezomib), Dexamethasone, and Doxil®, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|RVDD|University of Michigan Cancer Center|Yes|Active, not recruiting|May 2008|January 2017|Anticipated|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|April 11, 2008|Yes|Yes||No|September 3, 2014|https://clinicaltrials.gov/show/NCT00724568||152462|
NCT00724867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112233|A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States|A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States||GlaxoSmithKline|Yes|Completed|August 2008|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|268|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00724867||152439|
NCT00725140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/31416/51|Standardized sTudy With Almotriptan in eaRly Treatment of Migraine|Standardized sTudy With Almotriptan in eaRly Treatment of Migraine, START. An International, Open-label, Single Arm, Effectiveness and Safety Study of Almotriptan in Primary Care Setting|START|Almirall, S.A.|Yes|Completed|June 2008|July 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|501|||Both|18 Years|65 Years|No|Non-Probability Sample|Following SPC conditions and study requirements, male or female of 18 to 65 years old with        a minimum of one year of migraine history (International Headache Society criteria, see        criteria attached in the protocol Annex 1) of moderate or severe intensity and with a        frequency of 2 to 6 attacks per month for the past 3 months.|May 2015|May 29, 2015|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00725140||152418|
NCT00725153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-006|Evaluation of Deposits on Contact Lenses Worn Daily Wear|||Alcon Research|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|55|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|July 28, 2008|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00725153||152417|
NCT00720772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 02-51-31|Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis|The Treatment Effect of Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis||Ramathibodi Hospital|No|Completed|July 2008|November 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2009|December 16, 2009|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720772||152746|
NCT00721032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00011012|Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia|Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia||Johns Hopkins University|No|Not yet recruiting|June 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721032||152727|
NCT00721643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNRCA2580|Absorption Kinetics of Polyphenols in Angel's Plant (Angelica Keiskei)|Absorption Kinetics of Polyphenols in Angel's Plant (Angelica Keiskei)||Tufts University|No|Active, not recruiting|July 2008|December 2010|Anticipated|March 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 24, 2009|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721643||152681|
NCT00721656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLS1201|Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes|A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|N/A|No|||March 2009|March 16, 2009|July 22, 2008||||No||https://clinicaltrials.gov/show/NCT00721656||152680|
NCT00721669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN388|A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors|A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors||ImmunoGen, Inc.||Completed|June 2008|December 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|July 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721669||152679|
NCT00726674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04137|Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics|Lantus for Diabetic Patients Treated in Clalit Outpatient Clinics|Lapas II|Sanofi|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1229|||Both|21 Years|N/A|No|Non-Probability Sample|Type II diabetes.|March 2012|March 7, 2012|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726674||152302|
NCT00717626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012140|Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A|Pilot Study of Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A||The Hospital for Sick Children|Yes|Completed|July 2008|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|12 Years|24 Years|No|||December 2013|December 17, 2013|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717626||152983|
NCT00718562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107D1201|Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib|A Multi-center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib||Novartis|No|Completed|September 2008|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|20 Years|N/A|No|||March 2014|March 27, 2014|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718562||152912|
NCT00718796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP/CUPW4|Naturopathic Treatment for the Prevention of Cardiovascular Disease|Naturopathic Treatment for the Prevention of Cardiovascular Disease: a Pragmatic Randomized Controlled Trial|Cardio pilot|The Canadian College of Naturopathic Medicine|Yes|Completed|April 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|65 Years|No|||May 2010|May 14, 2010|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00718796||152894|
NCT00718588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDT4478g|A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A in Patients With Rheumatoid Arthritis||Genentech, Inc.||Terminated|July 2008|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|80 Years|No|||March 2012|March 6, 2012|July 16, 2008|No|Yes|Study had completed enrollment but drug injection was halted due to an unacceptable incidence    of rash.|No||https://clinicaltrials.gov/show/NCT00718588||152910|
NCT00718601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRN163L CP14A011|Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma|A Phase I Study of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Geron Corporation|No|Completed|July 2008|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00718601||152909|
NCT00719745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-05-02-KOR|A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients|A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Liver Transplant Recipients||Astellas Pharma Inc|No|Completed|February 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||July 2008|July 18, 2008|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719745||152822|
NCT00719758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|533-CL-005|Drug-Drug Interaction Study of TRK-100STP|TRK-100STP Pharmacokinetic Study in Healthy Volunteers - Evaluation of Pharmacokinetic Interaction Between TRK-100STP and Kremezin||Astellas Pharma Inc|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||October 2008|October 9, 2008|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00719758||152821|
NCT00719433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF ARMin III -1|Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy|Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy||University of Zurich|No|Completed|July 2008|September 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719433||152846|
NCT00719706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000772|The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder|The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder: A Randomized, Placebo-Controlled Trial of Acetyl-L-Carnitine and Alpha-Lipoic Acid for the Treatment of Bipolar Depression||Mclean Hospital|No|Completed|August 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||June 2012|June 13, 2012|July 18, 2008|No|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00719706||152825|
NCT00723346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPALL 2005-01|Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia|Administration of Allogenic of Red Blood Cells Loaded L Asparaginase in Acute Lymphoblastic Leukemia Relapse.|GRASPALL|ERYtech Pharma|Yes|Completed|January 2006|March 2009|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|25|||Both|1 Year|55 Years|No|||January 2012|January 10, 2012|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723346||152555|
NCT00723359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|969|Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), and Safety of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma||Biotest Pharmaceuticals Corporation||Completed|August 2008|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|July 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00723359||152554|
NCT00723385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0104|Effects of Vitamin D on Lipids|Effects of Vitamin D on Lipids||University of California, San Francisco|No|Completed|July 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723385||152553|
NCT00723333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29021|Bone Marrow Transplant Chart Review for RIC|Chart Review of Reduced Intensity Conditioning (RIC) Allogeneic Transplants in Elderly Patients With Myelofibrosis.||University of Utah|No|Completed|May 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|30|||Both|60 Years|N/A|No|Non-Probability Sample|Patients > 60 years of age with Primary Myelofibrosis that have undergone an allogeneic        transplant|October 2009|October 8, 2009|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723333||152556|
NCT00724022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT1850071|Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation|Triple Arm, Prospectively Randomized Multi Centre Study Phase IV to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation in Non-risk Patients|Harmony|University Hospital Freiburg|No|Completed|June 2008|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|75 Years|No|||September 2014|September 30, 2014|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724022||152504|
NCT00724035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEST-ORT-02|Ultrasound-Guided Axillary or Infraclavicular Nerve Block for Upper Limb Surgery|Onset Time of Brachial Plexus Anesthesia With the Axillary or Infraclavicular Approach Under Real-Time Ultrasound Guidance: a Randomized Controlled Trial||University of Parma|No|Completed|May 2008|July 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|80 Years|No|||July 2009|July 14, 2009|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724035||152503|
NCT00724048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACR16 C009|A Study of ACR16 for the Treatment of Patients With Huntington's Disease|A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)|HART|Teva Pharmaceutical Industries|Yes|Completed|October 2008|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|227|||Both|30 Years|N/A|No|||March 2013|March 28, 2013|July 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00724048||152502|
NCT00724308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 07-034|Telephone Care Coordination for Smokers in VA Mental Health Clinics|Telephone Care Coordination for Smokers in Mental Health Clinics|TeleQuit MH|VA Office of Research and Development|Yes|Completed|November 2009|September 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1206|||Both|18 Years|N/A|No|||April 2014|April 6, 2015|July 23, 2008||No||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00724308||152482|
NCT00725179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAP & NAC|Treatment of Acetaminophen Toxicity With N-acetylcysteine|Treatment of Acetaminophen Toxicity With Intravenous vs Oral N-acetylcysteine: A Retrospective Review||Akron Children's Hospital|No|Completed|August 2008|October 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|130|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric and adolescent patients with acetaminophen toxicity|September 2011|September 8, 2011|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00725179||152415|
NCT00724581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612-3681|Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer|Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial|PASCART|Aarhus University Hospital|Yes|Not yet recruiting|August 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|275|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724581||152461|
NCT00724893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04423|Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)|Pegetron® Redipen™ Prospective Optimal Weight-based Dosing Response Program||Merck Sharp & Dohme Corp.|No|Completed|August 2005|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2430|||Both|18 Years|N/A|No|Probability Sample|Treatment-naïve patients with chronic hepatitis C undergoing treatment with Pegetron        Redipen at approximately 100 centers in Canada.|July 2015|July 20, 2015|July 25, 2008|No|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00724893||152437|
NCT00725166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708102|Human Muscle Gene Expression Profiles in Young and Old Men|Human Muscle Gene Expression Profiles in Young and Old Men|CERA|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|41|Samples With DNA|Serum, muscle|Male|19 Years|76 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young : students of the Saint-Etienne's university. Old : men who participate in the PROOF        study|June 2009|June 9, 2009|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00725166||152416|
NCT00718367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC01/31/07|Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens|Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens||National University Hospital, Singapore||Completed|March 2008|November 2013|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|21 Years|N/A|No|Non-Probability Sample|Advanced RCC who had a cytoreductive nephrectomy done. Patients did not receive specific        anti-cancer systemic therapy after the nephrectomy, except after clinical disease        progression. Tumor samples available.|January 2014|January 13, 2014|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718367||152927|
NCT00718380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-227|A Phase 1 Study of ABT-869 in Subjects With Solid Tumors|An Open Label, Phase I Study Evaluating Pharmacokinetics, Safety, and Tolerability of ABT-869 in Subjects With Solid Tumors||Abbott||Completed|September 2008|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|20 Years|75 Years|No|||July 2012|July 13, 2012|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718380||152926|
NCT00718393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-16964|Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)|Compassionate Use of Ceftriaxone in Patients With ALS||Drexel University|No|Withdrawn|June 2007|September 2008|Anticipated|April 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|5|||Both|20 Years|85 Years|No|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope.|March 2011|March 24, 2011|July 14, 2008||No|No further patient to be enrolled. This was a 1 patient compassionate use protocol.|No||https://clinicaltrials.gov/show/NCT00718393||152925|
NCT00718003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-15860|Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).|Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).||Drexel University|No|Terminated|May 2005|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|||Both|20 Years|85 Years|No|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope.|March 2013|March 1, 2013|July 14, 2008||No|Terminated due to difficulty enrolling subjects.|No||https://clinicaltrials.gov/show/NCT00718003||152955|
NCT00730782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA-1_1_03|Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers|Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial||European Malaria Vaccine Initiative|No|Completed|November 2005|August 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730782||151988|
NCT00730795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|692342/001|Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults|A Phase I Open Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Recombinant Mycobacterium Tuberculosis Vaccine, Mtb72F With AS02A Adjuvant, When Administered Intramuscularly to Healthy PPD-Negative Adults||GlaxoSmithKline||Completed|January 2004|||December 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730795||151987|
NCT00730808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-POB-04-NL|Effectiveness and Tolerability of an Oral Nutritional Supplement (PreOP Booster) Given Before Surgery|Efficacy and Tolerability of a Preoperative Oral Nutritional Supplement (PreOP Booster) vs. Placebo in Surgical Patients (Pilot Study)||Fresenius Kabi||Completed|December 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|75 Years|No|||May 2010|May 18, 2010|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730808||151986|
NCT00731354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST40.2|VASER-Assisted Lipoplasty Compared With Suction-Assisted Lipoplasty|A Multi-Center, Prospective, Randomized, Single-Blind, Controlled Clinical Trial Comparing VASER-Assisted Lipoplasty and Suction-Assisted Lipoplasty.|Contra-Lateral|Sound Surgical Technologies, LLC.|No|Completed|July 2007|April 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|21|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00731354||151944|
NCT00731640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-012|Contralateral ReSTOR / Monofocal or Phakic Eye|Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye||Alcon Research||Completed|June 2007|||May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||March 2010|March 19, 2010|August 7, 2008||No||No|September 9, 2009|https://clinicaltrials.gov/show/NCT00731640||151923|
NCT00731133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-P50-DA018197-105242|Open-Label Disulfiram for Methamphetamine Dependence|Open-Label Pilot Study of Disulfiram for Methamphetamine Dependence||University of Arkansas|Yes|Completed|August 2008|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||January 2012|January 20, 2012|August 6, 2008|Yes|Yes||No|November 2, 2011|https://clinicaltrials.gov/show/NCT00731133||151961|Large dropout so few participants had data throughout the trial. No control group so cannot determine whether side effects were related to disulfiram or an artifact of participation.
NCT00731146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHSCA02|Effects of Technique on the Local Anesthetic Dose Required for Interscalene Brachial Plexus Block|Effects of Ultrasound Guidance on the Minimum Effective Anesthetic Volume Required for Interscalene Brachial Plexus Block Versus Nerve Stimulator Guidance||Sunnybrook Health Sciences Centre|No|Recruiting|August 2008|July 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||August 2008|August 5, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731146||151960|
NCT00731952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12472|Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer|Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer||University of Virginia|No|Active, not recruiting|June 2006|January 2012|Anticipated|April 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2011|February 2, 2011|August 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00731952||151899|
NCT00731367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0412-05-A080|Comparative Evaluation of Two AQUACEL Ag Protocols of Care for the Management of Donor Sites|A Phase IIIb, Randomized Comparative Evaluation of Two AQUACEL Ag Protocols of Care for the Management of Donor Sites.||ConvaTec Inc.|No|Completed|October 2005|August 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|N/A|N/A|No|||February 2009|February 2, 2009|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00731367||151943|
NCT00731991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0408080128|Art and Surface Electromyography (EMG)|The Effects of Active Release Technique and Proprioceptive Neurological Facilitation on Surface EMGs of Hypertonic Upper Trapezius Musculature||Logan College of Chiropractic|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2008|July 31, 2009|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731991||151896|
NCT00732004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08 002|Time Course Comparison of Contact Lens Maintenance Systems for Hydrogel Lenses|||University of Melbourne||Completed|August 2008|April 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Anticipated|132|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 30, 2009|August 8, 2008||||No||https://clinicaltrials.gov/show/NCT00732004||151895|
NCT00732576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-3-067|Effects of Omega-3 Fatty Acids and Menaquinone-7 on Thrombotic Tendency|Effects of Omega-3 Fatty Acids and Menaquinone-7 on Thrombotic Tendency||Maastricht University Medical Center|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|57|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 9, 2009|October 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00732576||151851|
NCT00732589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chulalongkorn University|SSNB in Hemiplegic Shoulder Pain|Suprascapular Nerve Block in Hemiplegic Shoulder Pain.|SSNB|Chulalongkorn University|No|Completed|August 2008|May 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|0|||Female|N/A|N/A|No|||August 2008|November 17, 2009|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732589||151850|
NCT00702286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75/08|Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy Catheters|Phase II Prospective Comparison Randomized Placebo Controlled Double Blind Study to Evaluate the Efficacy of the UroShieldTM Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy|NV-US-04-001|Assaf-Harofeh Medical Center|No|Not yet recruiting|August 2008|||||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|24|None Retained|urine culture|Both|18 Years|N/A|No|Probability Sample|All Patients requiring percoutaneous nephrostome drainage for period for more then 4 weeks|May 2008|June 19, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00702286||154147|
NCT00720330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-385|Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain|The Effect of Thoracolumbar Paravertebral Block or Intravenous Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain After Inguinal Herniorrhaphy||Outcomes Research Consortium|No|Terminated|July 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|75 Years|No|||March 2010|March 17, 2010|July 21, 2008||No|Enrollment challenges prohibited study progression.|No||https://clinicaltrials.gov/show/NCT00720330||152779|
NCT00720343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC8413|Effect of Oral Choline Supplementation on Postoperative Pain|Effect of Oral Choline Supplementation on Postoperative Pain||Columbia University|Yes|Terminated|February 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Female|18 Years|60 Years|No|||March 2016|March 23, 2016|July 21, 2008|Yes|Yes|PI left the institution.|No|March 23, 2016|https://clinicaltrials.gov/show/NCT00720343||152778|
NCT00716014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24013|Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita|A Single-Center, Placebo-Controlled, Rising Dose to Tolerance and Safety Study of TD101, an siRNA Designed for Treatment of Pachyonychia Congenita||Pachyonychia Congenita Project|Yes|Completed|January 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1|||Both|10 Years|N/A|No|||November 2008|November 18, 2008|July 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716014||153107|
NCT00716521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001390|Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers|Subject- And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 3-Way Crossover Study To Study Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers||Pfizer|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 22, 2009|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00716521||153068|
NCT00716534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-301|Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment||AbbVie||Completed|June 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|145|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716534||153067|
NCT00716547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-III-03|Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)|Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Study of Safety and Efficacy of Two Dosages of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee||IDEA AG|No|Completed|May 2008|May 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1399|||Both|46 Years|N/A|No|||October 2009|October 15, 2009|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716547||153066|
NCT00716859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111137|A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.|A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.||Pfizer|Yes|Completed|July 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|36 Weeks|18 Years|No|||January 2011|January 31, 2011|July 14, 2008|Yes|Yes||No|November 1, 2010|https://clinicaltrials.gov/show/NCT00716859||153042|
NCT00717158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8742|Lifestyle Intervention's Impact on Health Care Costs|Evaluating Healthcare Utilization, Costs and Health-Related Outcomes of a Medical Nutrition Therapy Intervention on Obese Patients With Type 2 Diabetes - A Pilot Study|ICAN|University of Virginia|No|Completed|May 2001|February 2003|Actual|February 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|147|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2007|July 14, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717158||153019|
NCT00717171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S060501-ACL|Efficacy of the SurgiStim3 Electrical Stimulation Device in Persons Undergoing Anterior Cruciate Ligament Repair|Efficacy of the SurgiStim3 Electrical Stimulation Device in Persons Undergoing Anterior Cruciate Ligament Repair||VQ OrthoCare|No|Terminated|July 2006|June 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|64 Years|No|||January 2009|January 8, 2009|July 14, 2008|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT00717171||153018|
NCT00716833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-UM-0002-DI|Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery|Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery|EPPA|Ludwig-Maximilians - University of Munich|Yes|Terminated|February 2006|December 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|July 15, 2008||No|poor recruitment|No||https://clinicaltrials.gov/show/NCT00716833||153044|
NCT00716846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hamamatsu 18-21|Effects of Statins on the Pharmacokinetics for Midazolam in Healthy Volunteers|Effects of Three Statins, Simvastatin, Atorvastatin, and Pitavastatin, on the Pharmacokinetics for Midazolam in Healthy Volunteers|H-17-21|Hamamatsu University|No|Completed|June 2006|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2009|September 5, 2011|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00716846||153043|
NCT00717132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cost-effectiveness|Cost-effectiveness of Family Based Pediatric Obesity Treatment|Cost-effectiveness of Family Based Pediatric Obesity Treatment||State University of New York at Buffalo|No|Completed|October 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00717132||153021|
NCT00717145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008052|Food Effects on the Relative Bioavailability of Different Dosages of Risedronate|Food Effects on the Relative Bioavailability of a Risedronate 20 mg Delayed-release [DR] Tablet and to Compare the 20 mg DR Tablet to 35 mg DR and 35 mg Immediate-release Tablets||Warner Chilcott|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|94|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|July 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00717145||153020|
NCT00718406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S203-02|Pain Relief of Metoprolol Versus Metoprolol Plus Morphine in Acute Chest Pain|||Sahlgrenska University Hospital, Sweden||Completed||||||Phase 4|Interventional|N/A|2||||||Both|N/A|N/A|No|||August 2002|July 16, 2008|July 16, 2008||||No||https://clinicaltrials.gov/show/NCT00718406||152924|
NCT00718419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11481|A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma|An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma||Eli Lilly and Company|No|Completed|July 2008|August 2012|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718419||152923|
NCT00718666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112021|The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers|The Long Term Antibody Persistence Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered as 1 or 2 Doses to Healthy Toddlers at 9-12 Months of Age and as a Booster Dose at 5 Years Post-primary Vaccination||GlaxoSmithKline||Completed|October 2008|March 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|387|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718666||152904|
NCT00718653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03EY015674|Effects of Antioxidants on Human Macular Pigments|Effects of Antioxidants on Human Macular Pigments||National Eye Institute (NEI)|No|Completed|September 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||February 2009|February 27, 2009|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718653||152905|
NCT00730821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1239.1|Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors|A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors||Boehringer Ingelheim||Completed|January 2007|||August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|75 Years|No|||August 2009|August 20, 2009|August 5, 2008||||No||https://clinicaltrials.gov/show/NCT00730821||151985|
NCT00730834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALM Study|Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis|Phase 4 Study of Use of a Customized Acoustic Stimulus to Reduce the Disturbing Symptoms of Tinnitus and Hyperacusis|CALM|Neuromonics, Inc.|No|Active, not recruiting|June 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 24, 2009|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730834||151984|
NCT00730847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108160|Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs & Above|Post-marketing Surveillance Study to Monitor Safety of Vaccination (Accor to Prescribing Information) With GlaxoSmithKline Biologicals' Human Papillomavirus Vaccine (HPV-16/18 L1/AS04) in Healthy Filipino Females (3,000; Aged >/= 10 Yrs)||GlaxoSmithKline||Terminated|September 2008|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|596|||Female|10 Years|N/A|Accepts Healthy Volunteers|||October 2012|November 21, 2012|August 6, 2008|Yes|Yes|GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study|No|November 21, 2012|https://clinicaltrials.gov/show/NCT00730847||151983|
NCT00731159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54/08|Sperm Capacitation Assay as a Tool to Predict Sperm Potential to Fertilize in IVF Treatment|Sperm Capacitation Assay as a Tool to Predict Sperm Potential to Fertilize in IVF Treatment||Assaf-Harofeh Medical Center|No|Recruiting|July 2008|July 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients requiring IVF within the "routine" work of an IVF Unit|July 2008|August 7, 2008|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731159||151959|
NCT00731380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APF-001|A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer|Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)||University Health Network, Toronto|No|Active, not recruiting|July 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00731380||151942|
NCT00731692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2306|FTY720 in Patients With Primary Progressive Multiple Sclerosis|A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis|INFORMS|Novartis||Completed|July 2008|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|969|||Both|25 Years|65 Years|No|||April 2015|April 13, 2015|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00731692||151919|
NCT00731705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612-01/ IUCRO-0180|In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells|In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells||Indiana University|Yes|Withdrawn|January 2007|January 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|peripheral blood, apheresis samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Bone Marrow Transplant service at the Indiana University Melvin and Bren        Simon Cancer Center.|September 2014|September 18, 2014|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731705||151918|
NCT00701740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP|Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial|Phase II Randomized Controlled Trial to Evaluate the Clinical and Histological Effects of Oral Isotretinoin for the Treatment of Photoaging on Face and Forearms||Federal University of São Paulo|Yes|Completed|July 2007|June 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Female|40 Years|55 Years|No|||June 2008|June 18, 2008|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701740||154189|
NCT00701974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLCRI0208|Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers|Study of Non Inferiority of Product Kollagenase ®, Manufactured by Laboratory Cristália When Compared With Iruxol ®, Manufactured by Abbott Laboratory, in the Treatment of Cutaneous Ulcers||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Suspended|February 2008|||February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2008|October 22, 2010|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701974||154171|
NCT00701987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-357-001|Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma|Dose-escalating, Pilot Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ALS-357 Topically Administered to Patients With Cutaneous Metastatic Melanoma||Advanced Life Sciences, Inc.|Yes|Recruiting|June 2008|||June 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|N/A|No|||February 2010|February 2, 2010|June 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701987||154170|
NCT00697918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014287|Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures|An Extension Study to Evaluate the Safety and Effectiveness of RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures||SK Life Science||Completed|March 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|16 Years|N/A|No|||January 2013|January 15, 2013|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697918||154475|
NCT00698230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 13739-202|Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics|Randomized Study to Evaluate the Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetic Subjects||Incyte Corporation|No|Completed|May 2008|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|302|||Both|18 Years|75 Years|No|||March 2012|March 13, 2012|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698230||154452|
NCT00716027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2034-08|Applying Social Comparison Theory to Behavioral Weight Loss: Does Modifying Group Membership Improve Outcome?|Applying Social Comparison Theory to Behavioral Weight Loss: Does Modifying Group Membership Improve Outcome?||The Miriam Hospital|Yes|Completed|July 2008|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|70 Years|No|||July 2008|September 28, 2010|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716027||153106|
NCT00716040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2006-61277-6|Social-Psychological Intervention to Improve Adherence to HAART|Effectiveness of a Social-Psychological Intervention to Improve Adherence to Antiretroviral Drug Regimens for AIDS: a Randomized Controlled Trial|SPIAH-Q|University of Sao Paulo|No|Active, not recruiting|March 2008|November 2008|Anticipated|September 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||July 2008|July 15, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716040||153105|
NCT00716274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12212|Effects of Atomoxetine on Brain Activation During Attention and Reading Tasks in Patients With ADHD & Comorbid Dyslexia|Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment||Eli Lilly and Company|No|Active, not recruiting|September 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|10 Years|16 Years|No|||January 2016|January 18, 2016|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716274||153087|
NCT00716560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05C.202|Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin|Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin||Thomas Jefferson University|No|Terminated|May 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|University practice patients with metastatic melanoma|August 2010|August 18, 2010|July 14, 2008||No|Administratively terminated.|No||https://clinicaltrials.gov/show/NCT00716560||153065|
NCT00716573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.495|Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure|COREV : A Multi-center, Randomized, Open-label Study Evaluating the Efficacy on Renal Function of Everolimus in Heart Transplant Recipients With Established Chronic Renal Failure|COREV|Hospices Civils de Lyon|Yes|Active, not recruiting|July 2008|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|N/A|No|||December 2010|March 8, 2012|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716573||153064|
NCT00717184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP01/02/06|A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma|A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma||National University Hospital, Singapore||Completed|May 2007|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|75 Years|No|||April 2010|April 7, 2010|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717184||153017|
NCT00717457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC21625|A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.|Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus||Hoffmann-La Roche||Completed|July 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1189|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717457||152996|
NCT00717470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1210|A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection|A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study)|OSAKA|Astellas Pharma Inc|Yes|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1252|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717470||152995|
NCT00717730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCN172226|Folic Acid and Vitamin B12 in Young Indian Children|Routine Administration of Folic Acid and Vitamin B12 to Prevent Childhood Infections in Young Indian Children||Centre For International Health|Yes|Completed|January 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1000|||Both|6 Months|30 Months|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717730||152975|
NCT00719290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ1 08/0124|Primary Angle Closure Glaucoma and Aqueous Dynamics|A Randomised Comparative Study of the Effects of Cataract Extraction With Lens Implant Alone Versus Cataract Extraction With Lens Implant and Goniosynechialysis on Outflow Facility in Patients With Primary Angle Closure Glaucoma.||Guy's and St Thomas' NHS Foundation Trust|Yes|Completed|July 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|N/A|No|||August 2015|August 18, 2015|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719290||152857|
NCT00719524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD10620|AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor|An Open-label, Non-randomized, Dose Evaluation, Safety and Pharmacokinetics Phase I Study of AVE8062 in Combination With Platinum Salts (Cisplatin or Carboplatin) and Taxanes (Docetaxel or Paclitaxel), Every 3 Weeks, in Patients With Advanced Solid Tumors.||Sanofi|No|Completed|July 2008|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||March 2013|March 8, 2013|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719524||152839|
NCT00719849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.00|Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease|Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen||Fred Hutchinson Cancer Research Center|No|Terminated|November 2005|December 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|N/A|69 Years|No|||February 2014|February 18, 2014|July 19, 2008|No|Yes|A new protocol was developed to replace this protocol in 2008, with removal of ATG and    extension of MMF duration.|No||https://clinicaltrials.gov/show/NCT00719849||152814|
NCT00718965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6909|Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia|A Double-blind, Randomized, 12-month, Placebo-controlled, Parallel Group, Fixed-dose Study to Evaluate the Efficacy and Safety of AVE5530 25mg/Day and AVE5530 50 mg/Day in Patients With Primary Hypercholesterolemia||Sanofi|No|Terminated|July 2008|June 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|826|||Both|18 Years|N/A|No|||September 2009|September 22, 2009|July 18, 2008|Yes|Yes|AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|No||https://clinicaltrials.gov/show/NCT00718965||152882|
NCT00719264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001L2201|Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer|A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney||Novartis||Completed|November 2008|April 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|365|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 15, 2008|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT00719264||152859|
NCT00731172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-ID-037-CTIL|A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease|A Pilot Single Center,Randomized,Double Blind Placebo Controlled Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Inducing Remission in Patients With Moderately Active Crohn's Disease.|Cop1CD|Tel-Aviv Sourasky Medical Center|No|Recruiting|September 2008|July 2011|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||March 2009|March 1, 2009|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00731172||151958|
NCT00731393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100351|Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04|To Determine the Immunogenicity and Reactogenicity of a Thiomersal Free Trivalent Influenza Split Vaccine 2003/2004 or of GSK Biologicals' Standard Formulation Influsplit SSW®/Fluarix™ 2003/2004 in Children Aged From 6 Months Until 6 Years||GlaxoSmithKline|No|Completed|October 2003|||August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|157|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|August 7, 2008||||No||https://clinicaltrials.gov/show/NCT00731393||151941|
NCT00731718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS/LB-001|Control of Head Lice Infestations in Children and Adults|Control of Head Lice in Children and Adults||Larada Sciences, Inc.|Yes|Completed|June 2007|July 2008|Actual|June 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|543|||Both|6 Years|N/A|No|||August 2008|August 8, 2008|April 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00731718||151917|
NCT00731731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00672|Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|July 2009|||February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||March 2015|April 28, 2015|August 8, 2008|Yes|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT00731731||151916|
NCT00732017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5612|Effects Of High Voltage Pulsed Current On Post-Traumatic Injuries|Effects Of High Voltage Pulsed Current On Ankle Post-Traumatic Injuries||Universidad Industrial de Santander|Yes|Completed|February 2004|December 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|26 Years|No|||August 2008|August 6, 2008|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00732017||151894|
NCT00732030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-005|Low Cylinder Toric|Evaluation of the Acrysof Toric Model SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.03 Diopters (D)||Alcon Research|No|Completed|June 2007|||March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|21 Years|N/A|No|||March 2010|March 25, 2010|August 7, 2008|Yes|Yes||No|April 29, 2009|https://clinicaltrials.gov/show/NCT00732030||151893|
NCT00701753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TheraGenetics-002|A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses|A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses||TheraGenetics Limited|No|Terminated|May 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only||3|Actual|24|Samples With DNA|Whole blood DNA RNA|Both|19 Years|65 Years|No|Non-Probability Sample|Patients of Vancouver Coastal Health|March 2009|March 11, 2009|June 17, 2008||No|Insufficient subject recruitment.|No||https://clinicaltrials.gov/show/NCT00701753||154188|
NCT00702000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0081|Study of Intensive Care Unit (ICU)-Acquired Weakness (Handgrip Strength Study)|Clinical Determinants of Handgrip Strength in Critically Ill Adults: Pilot Study||Ohio State University|Yes|Completed|May 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|||Both|18 Years|N/A|No|Probability Sample|subjects requiring prolonged mechanical ventilation in the ICU|January 2016|January 15, 2016|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00702000||154169|
NCT00698243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-027-101|Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma|A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma||Astellas Pharma Inc|No|Completed|June 2008|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00698243||154451|
NCT00698256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132\\2007|Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins|Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins|maxsta|University of Eastern Finland|No|Completed|February 2008|December 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00698256||154450|
NCT00716053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-C08-001|Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema|Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema||Aeris Therapeutics|Yes|Withdrawn|December 2008|December 2009||December 2009||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|225|||Both|N/A|N/A|No|||January 2010|January 14, 2010|July 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716053||153104|
NCT00716287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC01/03/07|Characterisation of Gene Variants in the Angiogenic Pathway|Characterisation of Gene Variants in the Angiogenic Pathway||National University Hospital, Singapore||Active, not recruiting|March 2007|||December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Anti-angiogenic targeted therapies are used in a wide range of solid tumors including        NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.|January 2014|January 13, 2014|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716287||153086|
NCT00716872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13685|Improving the Sleep of Cancer Patients Using an Internet-Based Program|Evaluating Internet-Based Interventions for Insomnia in Cancer Patients|SHUTi-C|University of Virginia|No|Completed|July 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|22|||Both|21 Years|N/A|No|||February 2010|February 24, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00716872||153041|
NCT00718432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC0970301|An Interventional Study of Geriatric Frailty, Osteoporosis, and Depression|Interventional Study of Geriatric Frailty, Osteoporosis, and Depression in a Community Based Randomized Trial.||National Health Research Institutes, Taiwan|Yes|Completed|April 2008|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|406|||Both|65 Years|79 Years|No|||June 2009|June 24, 2015|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718432||152922|
NCT00717483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23285|BMI and Its Relationship to Hypoglycemic Seizures in Children With Insulin-requiring Diabetes|||Baylor College of Medicine||Completed|July 2008|May 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|108|||Both|2 Years|17 Years|No|Non-Probability Sample|Subjects are patients with type 1 diabetes mellitus|September 2010|September 16, 2010|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717483||152994|
NCT00717496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0893|Telephone Support Intervention to Improve Breastfeeding|Telephone Support Intervention to Improve Breastfeeding Rates in Low-Income Women||University of Colorado, Denver|No|Completed|April 2005|August 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|339|||Female|18 Years|N/A|No|||July 2008|January 4, 2013|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717496||152993|
NCT00717743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC02/31/06|T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)|T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)||National University Hospital, Singapore||Completed|March 2007|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|21 Years|N/A|No|Probability Sample|RCC patients scheduled for nephrectomy|April 2010|April 7, 2010|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717743||152974|
NCT00717756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-HC-212|Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial|Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial||Brown University|Yes|Completed|January 2009|January 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|19 Years|N/A|No|||June 2014|June 26, 2014|July 15, 2008|Yes|Yes||No|February 20, 2014|https://clinicaltrials.gov/show/NCT00717756||152973|
NCT00718042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7B5-02-06P06|Evaluation of Chagas Blood Screening and Confirmatory Assays|Evaluation of ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay||Abbott Diagnostics Division|No|Completed|June 2008|September 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|41862|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|March 2, 2012|July 16, 2008|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00718042||152952|
NCT00728520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK0010|Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy|A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study||Kansas City Veteran Affairs Medical Center|Yes|Recruiting|July 2008|June 2012|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|60 Years|N/A|No|||August 2008|August 5, 2008|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00728520||152160|
NCT00728819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807264|Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters|Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters||University of Pennsylvania|No|Completed|August 2008|August 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|90 Years|No|||June 2012|June 13, 2012|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728819||152137|
NCT00729157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00178|Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy|A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy||National Cancer Institute (NCI)|Yes|Completed|August 2008|November 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||December 2014|June 1, 2015|August 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729157||152113|
NCT00719862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP439|A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-036 in Patients With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|481|||Female|12 Years|N/A|No|||January 2010|January 27, 2010|July 21, 2008|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00719862||152813|
NCT00719875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803003591|HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer|A Dose-Escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer||Yale University|No|Recruiting|December 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Female|18 Years|N/A|No|||June 2009|June 5, 2009|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719875||152812|
NCT00720109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00312|Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)||National Cancer Institute (NCI)||Completed|July 2008|September 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|2 Years|30 Years|No|||November 2015|December 28, 2015|July 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720109||152795|
NCT00700609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18651|Family Based Treatment of Depressed Adolescents|Family-Based Treatment of Depressed Adolescents: An Empirical Study With Norwegian Adolescents in Specialty Mental Health Care|BudFam|Helse Stavanger HF|Yes|Terminated|June 2008|December 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|13 Years|17 Years|No|||July 2015|July 30, 2015|June 13, 2008||No|The PI moved to another city and position|No||https://clinicaltrials.gov/show/NCT00700609||154275|
NCT00700908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701M99406|Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes|The Impact of an Automated Telephone Intervention on HbA1c in Type 2 Diabetes: A Randomized Controlled Trial||University of Minnesota - Clinical and Translational Science Institute|No|Completed|June 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|55 Years|N/A|No|||February 2013|February 20, 2013|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700908||154252|
NCT00701181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0451004|Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema|A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy And Safety Of PF-04523655 Versus Laser Therapy (DEGAS)|DEGAS|Quark Pharmaceuticals|Yes|Terminated|June 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|184|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|June 17, 2008|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00701181||154232|
NCT00701194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH059780|Early Intervention Foster Care: A Prevention Trial|Early Intervention Foster Care: A Prevention Trial|EIFC|Oregon Social Learning Center|No|Active, not recruiting|December 1999|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|177|||Both|3 Years|6 Years|No|||June 2008|June 18, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701194||154231|
NCT00701454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INMU-2006-01|Survey of Thai-Muslim Health Status|Survey of Thai-Muslim Health Status||Mahidol University|No|Completed|September 2005|April 2006|Actual|April 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1488|Samples Without DNA|Blood serum|Both|35 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thai muslim residents in 4 muslim communities in and around Bangkok.|September 2005|June 17, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701454||154211|
NCT00701441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0221|The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea|The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea||Ohio State University|No|Completed|February 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|Samples With DNA|Blood and tissue biopsy|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People screened for sleep apnea with a completed sleep study who do not have hypertension        or coronary artery disease.|October 2013|October 29, 2013|May 15, 2008||No||No|August 12, 2011|https://clinicaltrials.gov/show/NCT00701441||154212|Small Feasibility trial only.
NCT00702026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-1-031|The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients|The Effect of a Multispecies Probiotic on Hypersensitivity in IBS Patients||Maastricht University Medical Center|No|Completed|August 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||January 2013|January 28, 2013|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00702026||154167|
NCT00702299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0638-04|Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer|Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer||University of Arizona|Yes|Completed|September 2007|October 2012|Actual|January 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|June 19, 2008|Yes|Yes||No|October 1, 2012|https://clinicaltrials.gov/show/NCT00702299||154146|A limitation of this study is that max treatment dose was not definitively determined, in that the trial did not proceed at accrue patients at a dose level less than 1,000 mg/m2.
NCT00702312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q0605/13|A Bengali Dietary Salt Study to Control Blood Pressure|A Multi-method Study of a Low-salt Dietary Approach to Control Blood Pressure in the Bangladeshi Chronic Kidney Disease Population.||Barts & The London NHS Trust|No|Completed|June 2008|July 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|75 Years|No|||July 2009|July 28, 2009|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702312||154145|
NCT00698269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3532|An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment|Efficacy and Safety Study in Subjects Using Levemir® (Insulin Detemir), NovoMix®30 (Biphasic Insulin Aspart 30) and/or NovoRapid® (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|5926|||Both|N/A|N/A|No|Probability Sample|A non-randomized sample of Type 1 or Type 2 diabetics|July 2012|July 12, 2012|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00698269||154449|
NCT00698282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9831C00005|Single and Multiple Ascending Doses of AZD1981 in Japan|A Randomised, Placebo-Controlled, Double-Blind, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of AZD1981 in Healthy Male Japanese and Caucasian Subjects|JSAD/JMAD|AstraZeneca|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|47|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00698282||154448|
NCT00716300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-HDL2008|High Density Lipoprotein (HDL) Functionality in Metabolic Syndrome|Functional Studies of High Density Lipoprotein in the Metabolic Syndrome||The University of Western Australia|Yes|Recruiting|July 2008|December 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|Samples With DNA|DNA plasma|Both|20 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|15 men with features of the metabolic syndrome 15 age-matched normolipidaemic men|February 2009|February 17, 2009|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716300||153085|
NCT00716313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VS-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2007|||||N/A|N/A|N/A||||||||||||||July 15, 2008|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716313||153084|
NCT00716586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-2005-0551|Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration|Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration||University of Illinois at Chicago|No|Recruiting|October 2005|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Male|18 Years|N/A|No|||December 2014|December 12, 2014|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716586||153063|
NCT00718068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007185|Safety of Continuous Potassium Chloride Infusion in Critical Care|Assessing the Safety of a Continuous Potassium Chloride Infusion in Critical Care: A Randomised Controlled Trial|ASPIC|The Queen Elizabeth Hospital|No|Completed|October 2008|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||November 2009|July 26, 2010|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718068||152950|
NCT00718081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARX-C-005|A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery|A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery||AcelRx Pharmaceuticals, Inc.||Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|88|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|July 16, 2008|No|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT00718081||152949|
NCT00727415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC0606|Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy|A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients.|LLC0606|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|February 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00727415||152245|
NCT00727428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112219|Immunogenicity and Safety of GSK Biologicals' FluLaval® TF|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral®, Thimerosal-free (FluLaval® TF), in Adults 18 to 60 Years of Age.||GlaxoSmithKline||Completed|August 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|August 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00727428||152244|
NCT00718679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVN-CAT-001B|Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial|Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial|IVN-CAT-001B|University of Zurich|No|Completed|July 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||February 2010|February 10, 2010|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00718679||152903|
NCT00718978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|928/07|Clinical Application of Autologous Three-Cellular Cultured Skin Substitutes (CSS)|Clinical Application of Autologous Three-Cellular Cultured Skin Substitutes (CSS) Based on Esterified Hyaluronic Acid Scaffold: Our Experience||University of Roma La Sapienza|No|Completed|June 2003|July 2007|Actual|July 2004|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|1 Year|70 Years|No|||July 2008|September 5, 2008|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00718978||152881|
NCT00728832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0401-016|A Pharmacokinetic (PK) Study of Extended-Release Epidural Morphine in Upper Abdominal Surgery|A Phase 1 Study to Evaluate the Effects of Lidocaine/Epinephrine Test Dose Administration on the Pharmacokinetic Profile of a Single Dose of Thoracic Extended-Release Epidural Morphine in Patients Undergoing Major Upper Abdominal Surgery||EKR Therapeutics, Inc|Yes|Completed|May 2002|||February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|39|||Both|18 Years|N/A|No|||August 2008|August 12, 2008|August 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00728832||152136|
NCT00729170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1_Tremblay|Milk Supplementation and Energy Balance.|Impact of Milk Supplementation on Body Composition, Bone Density and Satiety in Women Following a Weight Loss Program.||Laval University|Yes|Completed|October 2006|February 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|41|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 29, 2012|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00729170||152112|
NCT00725725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05705|Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705AM3)(TERMINATED)|A Multi-center, Double-blind, Fixed Dose Trial Examining the Efficacy and Safety of Org 25935 Versus Placebo as Augmentation to Cognitive Behavioral Therapy in Subjects With Panic Disorder||Merck Sharp & Dohme Corp.|No|Terminated|July 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|65 Years|No|||October 2014|October 27, 2014|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725725||152373|
NCT00729144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1J06-FI|Adaptive Behaviors Among Women With Bowel Incontinence: The ABBI Trial|Adaptive Behaviors Among Women With Bowel Incontinence: The ABBI Trial|ABBI|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|June 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Female|N/A|N/A|No|Non-Probability Sample|women with a primary complaint of FI (with or without UI or POP) who are seeking treatment|October 2010|January 9, 2011|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00729144||152114|
NCT00700921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMRC HS-2163|Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)|Lovastatin as a Potential Modulator of Apoptosis in COPD||National Jewish Health|Yes|Completed|April 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|45 Years|N/A|No|||November 2012|November 26, 2012|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00700921||154251|
NCT00701207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0006|Study of Nicotine Patches in Patients With Sarcoidosis|Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors||Ohio State University|Yes|Suspended|July 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 2, 2013|June 17, 2008|Yes|Yes|Interim Analysis|No||https://clinicaltrials.gov/show/NCT00701207||154230|
NCT00701467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-4743-07-MG-CTIL|Change in Heart Rate Variability Prior to Tachyarrhythmia in ICD Implanted Patients|HRV Registry to Investigate Changes During the Time Before a Spontaneous Episode of Ventricular Tachyarrhythmia|HRV|Sheba Medical Center|No|Completed|March 2008|March 2013|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|ICD clinic|November 2013|November 17, 2013|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701467||154210|
NCT00701766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1216.20|BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia|An Open, Randomised Clinical Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Efficacy, Safety and Pharmacokinetics of Repeated Three-week Courses of a Single Dose i.v. BI 2536 on Day 1 in Comparison to Single Doses i.v. BI 2536 on Days 1, 2 and 3 in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia||Boehringer Ingelheim||Completed|October 2006|||October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|71|||Both|60 Years|N/A|No|||October 2013|April 30, 2014|June 18, 2008||||No||https://clinicaltrials.gov/show/NCT00701766||154187|
NCT00702013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070102|Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics|Ontogenesis of the P-glycoprotein in Human Lymphocytes: Influence of the Human Immunodeficiency Virus (HIV) and Antiretroviral Therapeutics|Onto-Pgp|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2007|August 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||8|Actual|310|Samples With DNA|blood sample for DNA extraction and genetic polymorphism of Mdr1|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV Patients children and adults and controls|October 2010|November 10, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702013||154168|
NCT00702325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589BL00003|Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans|A 12-wk, Rand., Double-blind, Double Dummy, Multi-ctr., Phase IV Study Comparing Efficacy and Safety of SYMBICORT® pMDI 160/4.5 ug x 2 Actuations Twice Daily Versus Pulmicort® (Budesonide Inhalation Powder DPI) 180 ug x 2 Inhalations Twice Daily, in Adult and Adolescent African American Subjects With Asthma|Titan|AstraZeneca|No|Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|311|||Both|12 Years|N/A|No|||October 2012|October 10, 2012|June 19, 2008|Yes|Yes||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00702325||154144|
NCT00697931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/021|Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders|Study to Compare the Immunogenicity and Reactogenicity of GSK Biologicals; (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine With That of Engerix™-B in an Adult Non-Responder Population||GlaxoSmithKline||Completed|May 1997|June 1998|Actual|June 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697931||154474|
NCT00698204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 03 -157- 2|Cox-2 Inhibition in Radiation-induced Oral Mucositis|Cyclooxygenase-2 Inhibition in Radiation-Induced Oral Mucositis||University of Connecticut Health Center|Yes|Completed|July 2003|December 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|43|||Both|18 Years|75 Years|No|||May 2014|May 7, 2014|June 12, 2008|Yes|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT00698204||154453|
NCT00716599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-036|Training in Fever Case Management With Rapid Diagnostic Tests (RDTs) for Malaria in Uganda|Effectiveness and Safety of Training in Fever Case Management Incorporating Rapid Diagnostic Tests (RDTs) for Malaria at Peripheral Health Centers in Uganda||University of California, San Francisco|No|Completed|January 2008|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|14000|||Both|N/A|N/A|No|||July 2008|July 15, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716599||153062|
NCT00717197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGG-001|Study of Capecitabine to Treat Recurrent High Grade Gliomas|Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria||University of Florida|Yes|Completed|July 2008|May 2013|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|July 15, 2008|Yes|Yes||No|February 18, 2013|https://clinicaltrials.gov/show/NCT00717197||153016|
NCT00717509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|snh003|Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia|Cross-Sectional Study of the Association Between Multiple Genetic Polymorphisms and the Metabolic Side Effects in Patients With Schizophrenia Taking Clozapine More Than 1 Year||Seoul National Hospital|Yes|Recruiting|October 2007|October 2009|Anticipated|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|peripheral blood|Both|18 Years|65 Years|No|Probability Sample|patients with schizophrenia taking clozapine more than 1 year|June 2009|June 9, 2009|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717509||152992|
NCT00717769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBI 404|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis||Daiichi Sankyo Inc.|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717769||152972|
NCT00727064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-4414|Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects|A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|July 29, 2008|No|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00727064||152272|
NCT00728013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A02-12|China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome|China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome|CHILLAS|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|December 2006|December 2010|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Both|18 Years|80 Years|No|||August 2008|August 22, 2008|July 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00728013||152199|
NCT00727714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHF 5690.11, REK S-08083a|Lung Function and Inflammatory Markers in Cement Dust Exposed Workers: A Cross-shifts Study|Circulating Inflammatory Markers, Exhaled NO and Lung Function in Cement Production Workers; a Cross-shifts Study|LIS|Sykehuset Telemark|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|95|Samples With DNA|Whole blood serum|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|All employees of two Norwegian cement production plants are invited to participate.|April 2010|April 9, 2010|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00727714||152222|
NCT00728000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-06-030|Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma|Phase II Study Of Neoadjuvant Chemotherapy With Gemcitabine, Oxaliplatin And Erlotinib (Gemoxt) In Borderline Resectable Pancreatic Adenocarcinoma||University of Cincinnati|No|Withdrawn|August 2008|August 2010|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2009|April 24, 2009|July 31, 2008|No|Yes|study withdrawn due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT00728000||152200|
NCT00728247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bush-headneck|Objective Kinematic Correlates of Palpatory Diagnosis|Objective Kinematic Correlates of Palpatory Diagnosis||Michigan State University|No|Completed|July 2008|June 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 17, 2010|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728247||152181|
NCT00728260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA38|36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds|Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Recipients 2 to 10 Years of Age.||Sanofi|No|Completed|July 2005|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1421|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Past receipt of Menactra vaccine|February 2015|February 10, 2015|May 7, 2008|Yes|Yes||No|January 7, 2015|https://clinicaltrials.gov/show/NCT00728260||152180|
NCT00729482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0801|RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment|A Phase II Study of RAD001 (Everolimus) in Patients With Fluoropyrimidine and Platinum-refractory Advanced Gastric Cancer||Asan Medical Center|No|Completed|July 2008|March 2013|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|75 Years|No|||December 2013|December 31, 2013|August 4, 2008||No||No|December 31, 2013|https://clinicaltrials.gov/show/NCT00729482||152088|
NCT00729729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCA pharmacokinetics 1|Pharmacokinetic Study for PCA Derivate Formulations|Phase 4, Three Way Cross-over, Pharmacokinetic Study for PCA Derivate Formulations in Healthy Subjects|PCA 1|Hadassah Medical Organization|Yes|Completed|July 2008|December 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 27, 2012|August 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00729729||152069|
NCT00725738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-583|Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA STUDY.|Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA Study.|TRACIA|National Heart Institute, Mexico|No|Recruiting|May 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|20 Years|75 Years|No|||July 2008|July 29, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725738||152372|
NCT00729456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02ME06|Evaluation of Education in the Secondary Prevention of Foot Ulceration in Diabetes|Evaluation of Education in the Secondary Prevention of Foot Ulceration in Diabetes|ESP|Nottingham University Hospitals NHS Trust|No|Completed|April 2003|December 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|172|||Both|18 Years|N/A|No|||July 2008|August 4, 2008|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729456||152090|
NCT00700622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-117|Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks|A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period||Mannkind Corporation|No|Terminated|May 2008|March 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|80 Years|No|||October 2014|October 9, 2014|June 16, 2008|Yes|Yes|Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2    inhaler)|No|July 22, 2014|https://clinicaltrials.gov/show/NCT00700622||154274|- Early termination of trial leading to small numbers of subjects analyzed.
NCT00701220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0118|Statin Therapy for Ischemic and Nonischemic Cardiomyopathy|Statin Induced Augmentation of Circulating Endothelial Progenitor Cells and Myocardial Viability in Patients With Ischemic and Nonischemic Cardiomyopathy||Ohio State University|No|Completed|April 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2011|April 12, 2011|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00701220||154229|
NCT00701480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-E-1-002/51|Safety and Efficacy of Skin Cleanser Contained Roselle Extract in Acne|Randomized Double-Blind Case Control Study of Safety and Efficacy of Skin Cleanser Contained Hibiscus Sabdariffa Extract in Acne Treatment.||Thammasat University|Yes|Recruiting|April 2008|September 2008|Anticipated|July 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|12 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 17, 2008|June 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701480||154209|
NCT00701779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siami104907|Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia|Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH||Siami, Paul F., M.D.|Yes|Completed|September 2005|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Male|50 Years|N/A|No|||December 2014|December 18, 2014|June 17, 2008|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00701779||154186|
NCT00702039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 0702002303|Effect of Music Therapy on Patients Undergoing Intravitreal Injections|Effect of Music Therapy on Patients Undergoing Intravitreal Injections||Yale University|Yes|Recruiting|February 2007|February 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving intravitreal injections seen at the Yale Eye Center.|June 2008|June 16, 2008|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00702039||154166|
NCT00702052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001N2201|Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy.|An Open-label, Single-arm Phase II Study of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® (Bortezomib).|PILLAR-1|Novartis|No|Completed|August 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|90 Years|No|||May 2013|May 10, 2013|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00702052||154165|
NCT00702338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05713|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Ovulation Induction in Clinical Trial 107010 for the Development of Org 36286 (Corifollitropin Alfa)|Care|Merck Sharp & Dohme Corp.|No|Completed|May 2008|December 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1|||Female|18 Years|39 Years|No|Non-Probability Sample|Women with an ongoing pregnancy at least 10 weeks after bolus injection of hCG in base        study P05693 (NCT00697255).|March 2015|March 26, 2015|June 18, 2008|No|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT00702338||154143|
NCT00697944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBIDEX|Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients|Ambisome® Preemptive Treatment of Multiple Colonizations by Candida in Intensive Care Patients With a Sepsis|AMBIDEX|Fovea|Yes|Recruiting|March 2008|March 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2009|June 13, 2008|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00697944||154473|
NCT00697957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40093/02|Bone Adaptation to Impact Loading|Bone Adaptation to Impact Loading - Significance of Loading Intensity||University of Oulu|No|Completed|May 2002|June 2003|Actual|June 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Female|35 Years|40 Years|No|||June 2008|June 13, 2008|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697957||154472|
NCT00726258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-00336-20|Association of Intravenous Ketamine With Thoracic Epidural Analgesia: Effects on Pain and Respiratory Function Following Thoracotomy.|Association of Intravenous Ketamine With Thoracic Epidural Analgesia: Effects on Pain and Respiratory Function Following Thoracotomy.||Assistance Publique Hopitaux De Marseille|No|Terminated|March 2008|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|85 Years|No|||August 2014|August 27, 2014|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726258||152333|
NCT00726557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04408|Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)|Quality Assurance of HCV-therapy With PegIntron® Plus Rebetol® in Drug-substituted Patients - SUPPORT Project Post-Marketing Surveillance Study|SUPPORT|Merck Sharp & Dohme Corp.|No|Completed|October 2005|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|246|||Both|18 Years|N/A|No|Non-Probability Sample|Previous intravenous drug abusers with chronic hepatitis C receiving substitution therapy        (buprenorphine, methadone or other) at approximately 100 sites in Germany.|October 2015|October 8, 2015|July 30, 2008|No|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00726557||152311|
NCT00726570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICU-ICU-01|Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs|Effects of Sequential Compression Devices on Coagulation Parameters Assessed by TEG® in Patients Undergoing Major Abdominal Surgery|TEGLeg|University of Parma|No|Terminated|August 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|July 29, 2008||No|Failed to reach the expected enrollment rates by the end of 2010|No||https://clinicaltrials.gov/show/NCT00726570||152310|
NCT00727077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04397|Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)|Treatment of Chronic Hepatitis C in Children With Intron Vial or Pen and Rebetol According to German Law (§ 67 Abs 6 AMG)||Merck Sharp & Dohme Corp.|No|Terminated|June 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|3 Years|17 Years|No|Non-Probability Sample|Children age 3 to 17 years, with chronic hepatitis C, treated in clinical practice at 10        German sites|April 2015|April 7, 2015|July 30, 2008|No|Yes|Study halted due to low recruitment. The 3 participants at time of termination transferred    into study P04538 (NCT00727077). See NCT00727077 for details/results.|No||https://clinicaltrials.gov/show/NCT00727077||152271|
NCT00726856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05171|Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)|A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice||Merck Sharp & Dohme Corp.|No|Completed|May 2007|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1200|||Both|20 Years|75 Years|No|Non-Probability Sample|Patients diagnosed with dyslipidemia who did not respond adequately based on NCEP ATP III        target to previous lipid lowering treatment, and have received dual inhibition therapy,        such as ezetimibe plus statins, ezetimibe plus fenofibrate or ezetimibe alone, for at        least 3 months|April 2015|April 15, 2015|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726856||152288|
NCT00727727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIR-002/K|SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)|Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.||Desitin Arzneimittel GmbH|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Morbus Parkinson who require therapy with dopamine agonists|February 2009|February 24, 2009|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727727||152221|
NCT00728559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lapmar1.CTIL|Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy|Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy||The Baruch Padeh Medical Center, Poriya|Yes|Not yet recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|February 2, 2011|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728559||152157|
NCT00728572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0331080126|Logan Basic Technique Measured by Surface Electromyography (EMG)|The Effect of Logan Basic Technique Apex Contact Adjustment on the Motor Recruitment Pattern in the Erector Spinae.||Logan College of Chiropractic|No|Recruiting|July 2008|November 2008|Anticipated|November 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2008|August 22, 2008|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728572||152156|
NCT00728273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neys-code VT 188|Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming in Vietnamese School Children|Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming on Reducing Anemia Prevalence, and Improving Micronutrient Status, Cognitive Function, and Growth in Vietnamese School Children||Neys-van Hoogstraten Foundation, The Netherlands|No|Completed|January 2007|June 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|510|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||November 2008|December 3, 2008|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00728273||152179|
NCT00728533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS26|Open-Label, Randomised Parallel-Group Study|The Rationale of the Study is to Demonstrate That Degarelix Given at Three-month Dosing Intervals Will Produce and Maintain Androgen Deprivation in Prostate Cancer Patients Through Immediate and Prolonged Testosterone Suppression, and to Provide Confirmatory Evidence of the Safety of Degarelix.||Ferring Pharmaceuticals|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||March 2011|March 17, 2011|January 18, 2008|Yes|Yes|Terminated due to awaiting data from Phase II study.|No||https://clinicaltrials.gov/show/NCT00728533||152159|
NCT00728546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080515M|NAT2 in Re-challenge of INH in Patients With Hepatitis|The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis||National Taiwan University Hospital|Yes|Recruiting|June 2008|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2012|December 26, 2012|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728546||152158|
NCT00726362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CTW-CRE-2007/1|To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia|To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia||AstraZeneca|No|Completed|December 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3270|||Both|20 Years|N/A|No|Probability Sample|based on regular practice and judged by physicians, patients with hyperlipidemia who need        to start prescribed with a statin; or to switch from current therapy to a statin, or        require dosage adjustment for statin|December 2010|December 2, 2010|July 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00726362||152325|
NCT00700635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA61|Dose Comparison Study of Menactra® in US Children|Exploratory Evaluation of a Two-dose Schedule Versus a One-dose Schedule of Menactra® (Meningococcal [Groups A, C, Y and W 135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) in Children in the US||Sanofi|No|Completed|June 2008|October 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|333|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|May 7, 2008|Yes|Yes||No|December 11, 2010|https://clinicaltrials.gov/show/NCT00700635||154273|
NCT00700648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-3531|An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects|A Multicenter, Open Label, Nonrandomized, Non Interventional, Observational, Safety and Efficacy Study in Hospitalized Subjects Using Intravenous NovoRapid® (Insulin Aspart)||Novo Nordisk A/S|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3024|||Both|N/A|N/A|No|Non-Probability Sample|Hospitalized subjects requiring intravenous insulin therapy|August 2014|August 8, 2014|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700648||154272|
NCT00700947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0120|Using Beta Blockers to Treat Mitral Regurgitation|Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation|REGURG|Ohio State University|No|Active, not recruiting|October 2007|July 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 15, 2009|December 26, 2007||No||No||https://clinicaltrials.gov/show/NCT00700947||154249|
NCT00700973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-264|Treating Violence-Prone Substance Use Disorder Patients|Treating Violence-Prone Substance Use Disorder Patients||VA Office of Research and Development|No|Completed|February 2009|November 2013|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|141|||Both|18 Years|N/A|No|||February 2014|April 6, 2015|June 17, 2008||No||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00700973||154247|A limitation of the trial (not a result or conclusion) is that high proportions of patients reported abstinence at baseline.
NCT00701233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708M13705|Botulinum Toxin for Carpal Tunnel Syndrome|Evaluation of Intercarpal Botox Versus Steroid Injections for Carpal Tunnel Syndrome||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|June 2012|June 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00701233||154228|
NCT00701493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002239|A Phase 1 Bioavailability Study of Topiramate Oral Liquid Formulation Compared to the Marketed Sprinkle Capsule Formulation in Healthy Adults|An Open-Label, Randomized, 2-Way Crossover Study of the Bioavailability of an Oral Liquid Formulation Relative to the Marketed Sprinkle Capsule Formulation of Topiramate RWJ-17021-000 in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2004|December 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|June 17, 2008||||||https://clinicaltrials.gov/show/NCT00701493||154208|
NCT00701506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSMED-OA-02|Patterned Electrical Neuromuscular Stimulation and Therapeutic Exercise for Osteoarthritis of the Knee: Pilot Study|Patterned Electrical Neuromuscular Stimulation and Therapeutic Exercise for Osteoarthritis of the Knee: Pilot Study||RS Medical|No|Completed|May 2008|November 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701506||154207|
NCT00701519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0055|The Prevalence of Sleep Disordered Breathing in Hospitalized Patients With Acutely Decompensated Heart Failure Syndrome|The Prevalence of Sleep Disordered Breathing in Hospitalized Patients With Acutely Decompensated Heart Failure Syndrome||Ohio State University|No|Completed|June 2007|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1600|||Both|18 Years|N/A|No|Non-Probability Sample|Every patient with heart failure at the OSU is offered the opportunity to receive free        screening for sleep apnea.|May 2014|May 21, 2014|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701519||154206|
NCT00701792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N/1993/04|Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis|Randomized Trial Comparing Liver Transplantation to Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis|TRANSCIAL|Centre Hospitalier Universitaire de Besancon|No|Completed|March 1994|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||June 2008|June 18, 2008|June 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00701792||154185|
NCT00702065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27904|A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment|A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment|MusiQoL|EMD Serono||Completed|November 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|599|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|June 2014|June 16, 2014|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702065||154164|
NCT00702351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05788|A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)|A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 μg or 150 μg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI Using a Long Protocol of GnRH Agonist (Study 38833)|Realize|Merck Sharp & Dohme Corp.|No|Completed|December 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|39 Years|No|||May 2014|May 21, 2014|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702351||154142|
NCT00698932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00005|Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control|A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise.||AstraZeneca|Yes|Completed|June 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|568|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|June 16, 2008|Yes|Yes||No|September 20, 2010|https://clinicaltrials.gov/show/NCT00698932||154400|
NCT00697970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/006|Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine|Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine in Healthy Adult Volunteers||GlaxoSmithKline||Completed|November 1993|April 1995|Actual|April 1995|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|6||Actual|321|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 13, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00697970||154471|
NCT00697983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-029|Cohort Study on Associations Between Purinergic Receptor SNPs and Osteoporosis Risk|Purinergic Signalling in Human Osteoporosis: Evaluation of Variability in Purinergic Receptor Genes and Receptor Function|ATPBone|Maastricht University Medical Center|No|Completed|August 2008|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|Whole blood, serum, plasma|Both|50 Years|N/A|No|Non-Probability Sample|Fracture patients of 50 years and older attending an osteoporosis outpatient clinic at the        Maastricht University Medical Center|April 2011|April 19, 2011|June 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00697983||154470|
NCT00726583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-866-001|Phase I Trial of Oral PX-866|A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients With Advanced Solid Tumors||Oncothyreon Inc.|No|Completed|June 2008|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||October 2011|October 27, 2011|July 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00726583||152309|
NCT00726596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080803|Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer|NJ 1808: Autophagic Cell Death With Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy For Prostate Cancer.||Rutgers, The State University of New Jersey|No|Active, not recruiting|August 2008|October 2016|Anticipated|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Male|18 Years|N/A|No|||December 2015|December 16, 2015|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726596||152308|
NCT00726869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuLuc63-1702|A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.|A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.||Abbott|Yes|Terminated|May 2008|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||June 2012|August 22, 2012|July 29, 2008|Yes|Yes|Enrollment has been halted|No||https://clinicaltrials.gov/show/NCT00726869||152287|
NCT00727090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507-10|Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients|Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients||Northwestern University|No|Terminated|August 2008|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|85 Years|No|||April 2013|April 30, 2013|July 30, 2008||No|Enrollment below goal.|No|July 21, 2010|https://clinicaltrials.gov/show/NCT00727090||152270|
NCT00727441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0810, CDR0000600355|Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery|A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|July 2008|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|87|||Both|18 Years|120 Years|No|||March 2016|March 8, 2016|August 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00727441||152243|
NCT00727454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3163/08/79|Effects of Continuous Positive Airway Pressure (CPAP) in Heart Remodeling by Magnetic Resonance Imaging (MRI)|Effects of Continuous Positive Airway Pressure on Heart Remodeling in Patients With Obstructive Sleep Apnea: A Randomized Study With Cardiovascular Magnetic Resonance Imaging|OSA-MRI|University of Sao Paulo|No|Terminated|July 2007|December 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|July 28, 2008||No|Difficulty of recruiting patients and cost limitations.|No||https://clinicaltrials.gov/show/NCT00727454||152242|
NCT00728286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3639b|Assessment of Thrombogenicity in Acute Coronary Syndrome|Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|October 2008|May 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with non-ST elevation myocardial infarction - Acute Coronary syndrome (ACS) and        on existing medication will undergo chamber study|October 2015|October 7, 2015|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728286||152178|
NCT00729196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 DK70777 (completed)|A Trial of Two Diets for Weight and Diabetes Management|A Trial of Two Diets for Weight and Diabetes Management|Two-for-2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|July 2005|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||January 2011|January 31, 2011|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00729196||152110|
NCT00729209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-103|A Study of ARRY-371797 in Patients With Rheumatoid Arthritis|||Array BioPharma|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|28|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|August 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729209||152109|
NCT00728845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600241|Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer|(NJ 1508) Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study||Rutgers, The State University of New Jersey|No|Terminated|June 2008|December 2016|Anticipated|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|August 5, 2008|Yes|Yes|Slow accrual|No|September 18, 2013|https://clinicaltrials.gov/show/NCT00728845||152135|
NCT00729183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-031|BMD Efficacy and Safety of Odanacatib in Postmenopausal Women (0822-031)|A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK0822) on Bone Micro-architecture in Postmenopausal Women Treated With Vitamin D||Merck Sharp & Dohme Corp.|No|Completed|October 2008|March 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|214|||Female|45 Years|85 Years|No|||December 2015|December 11, 2015|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729183||152111|
NCT00729469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-50821|Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity|Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Dose With Placebo in Postmenopausal Women||Shionogi Inc.||Completed|July 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|919|||Female|40 Years|80 Years|No|||March 2013|May 21, 2013|August 4, 2008|Yes|Yes|||March 19, 2013|https://clinicaltrials.gov/show/NCT00729469||152089|
NCT00725400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-CRO0000192008|Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma|Phase II Open Label Comparative Study of Cetuximab and Radiation Therapy Vs Surgery Before or After Radiation Therapy in Patients With Stage II to IV Colorectal Carcinoma||American Scitech International|No|Withdrawn|February 2010|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|40 Years|N/A|No|||July 2011|July 19, 2011|July 28, 2008|No|Yes|Study is withdrawn due to unavailability of eligible subject population. We will request the    sponsors to extend the time for enrollment.|No||https://clinicaltrials.gov/show/NCT00725400||152398|
NCT00725413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06473|A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)|A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)||Merck Sharp & Dohme Corp.|No|Completed|November 2001|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 6, 2015|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725413||152397|
NCT00700713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA62|Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26|Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Three Years Earlier in Study MTA26||Sanofi|No|Completed|June 2008|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|181|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||January 2016|January 16, 2016|May 7, 2008|Yes|Yes||No|January 16, 2016|https://clinicaltrials.gov/show/NCT00700713||154267|
NCT00700960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1859|Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control|Observational Study on Efficacy on Glycaemic Control of Slow-acting Insulin Analogue in Type 2 Diabetes|LIGHT|Novo Nordisk A/S|No|Completed|June 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2745|||Both|45 Years|N/A|No|Non-Probability Sample|Patients with type 2 diabetes|March 2016|March 2, 2016|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700960||154248|
NCT00701246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FANUT 302004|Treatment and Prevention of Anemia With Ferrous Sulfate Plus Folic Acid in Children in Goiania - Goias, Brazil|Nutritional Anemia: Prevention and Treatment in Early Childhood||Universidade Federal de Goias|No|Completed|April 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|4||Actual|196|||Both|6 Months|24 Months|No|||March 2014|March 12, 2014|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701246||154227|
NCT00701532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070150|Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction|Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study|CAIMAN|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2009|January 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Male|18 Years|65 Years|No|||April 2013|April 10, 2013|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701532||154205|
NCT00701545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLBC-HP-PM-001|A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)|A Canadian, Multi-center, Prospective, Open-label, Observational, Pharmacovigilance Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) in Patients Transitioning From Treatment With Currently Available Humate-P®||CSL Behring|No|Completed|February 2008|April 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|N/A|N/A|No|Non-Probability Sample|Patients with von Willebrand disease treated with Humate P® ivr in Canada|February 2011|February 10, 2011|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701545||154204|
NCT00701805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-312|Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)|Phase II Study of Paricalcitol Injection Extension Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism||Abbott|No|Completed|July 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|107|||Both|20 Years|N/A|No|||March 2011|March 18, 2011|June 17, 2008||No||No|December 28, 2010|https://clinicaltrials.gov/show/NCT00701805||154184|The dose titration scheme was revised because of the incidence of hypercalcemia in the early weeks of the study.
NCT00701818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20070097|Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke|Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke Prevalence and Characteristics as Measured by CT Angiography, Echocardiography and Biomarkers|CORAIS|Vejle Hospital|No|Completed|May 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|The study is a prospective, consecutive study of patients primarily admitted to the        Department of Neurology, Vejle Hospital with symptoms suggestive of an acute ischemic        stroke according to the World Health Organization criteria|June 2015|June 2, 2015|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701818||154183|
NCT00702078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17417|Home-based Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD)|Randomised Clinical Study on the Effect of Home-based Treatment of Patients With COPD. Improved Cooperation Between Hospital and Primary Healthcare System.|COPD-HOME|St. Olavs Hospital|Yes|Active, not recruiting|April 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|95 Years|No|||May 2015|May 12, 2015|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702078||154163|
NCT00702091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMI-C10-PVFS-1|Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions||Roxane Laboratories|No|Completed|January 2005|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 19, 2008|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702091||154162|
NCT00698945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5358|Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)|Randomized, Investigator Masked Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)||Bp Consulting, Inc||Completed|June 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 2, 2008|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698945||154399|
NCT00699218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715749-1|A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression|A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment of Bipolar Depression|TMS-BD|University of California, Davis|No|Completed|May 2008|April 2010|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||October 2012|October 10, 2012|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699218||154381|
NCT00699231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/002|Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients|Study to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine Versus Engerix™-B, in Haemodialysis Patients||GlaxoSmithKline||Completed|February 1992|December 1992|Actual|December 1992|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|30|||Both|18 Years|N/A|No|||June 2008|June 16, 2008|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699231||154380|
NCT00727467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-6-08|A Randomised Controlled Trial (RCT) to Evaluate Use of an Individual Auditory Cueing Device's (IACD's) on Freezing and Gait in People With Parkinson's Disease (PD)|A Randomised Controlled Trial Evaluating the Effect of an Individual Auditory Cueing Device on Freezing and Gait Speed in People With Parkinson's Disease||University of Dublin, Trinity College|Yes|Not yet recruiting|September 2008|March 2009|Anticipated|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Both|18 Years|90 Years|No|||August 2008|December 30, 2008|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727467||152241|
NCT00727480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0535|Finger Imaging to Detect Blood Flow in the Fingertips|Finger Imaging and Biometric System||University of Michigan|No|Terminated|September 2002|December 2011|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 1, 2015|July 30, 2008||No|No longer acruing data for this study.|No||https://clinicaltrials.gov/show/NCT00727480||152240|
NCT00727740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502027420|A Double-Blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis|A Prospective, Multicenter, Randomized, Double-Blind Controlled Study to Determine Whether a Single Dose of Intraduodenal Indomethacin Can Decrease the Incidence and Severity of Post-ERCP Pancreatitis||Yale University|No|Recruiting|August 2005|August 2012|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|624|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|July 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00727740||152220|
NCT00727753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-770|VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)|Effects of Vascular Endothelial Growth Factor Antagonism With Ranibizumab or Bevacizumab in Patients With Neovascular Macular Degeneration||University of Zurich|No|Completed|July 2008|October 2013|Actual|December 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|54|||Both|18 Years|80 Years|No|Probability Sample|See eleigibility criteria|May 2015|May 27, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00727753||152219|
NCT00728026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/112|Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea|Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome, Irritable Bowel Syndrome, Postural Orthostatic Tachycardia Syndrome, Functional Abdominal Pain or Chronic Nausea||Medical College of Wisconsin|No|Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||5|Anticipated|50|||Both|5 Years|18 Years|No|Non-Probability Sample|Diagnosis of either: Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),        Chronic nausea, Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal        Pain (FAP)|September 2015|September 3, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728026||152198|
NCT00728039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/82|Quality of Life (QOL), Coping and Psychological Symptoms in Children and Adolescents With Cyclic Vomiting Syndrome|Quality of Life, Coping and Psychological Symptoms in Children and Adolescents With Cyclic Vomiting Syndrome||Medical College of Wisconsin|No|Active, not recruiting|April 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|9 Years|18 Years|No|Probability Sample|Children aged 9-10 will complete 5 questionnaires Adolescents aged 11-18 will complete 6        questionnaires Youth aged 11-18 will fill out an additional questionnaire that asks how        they cope with stress related to CVS symptoms Parents will complete 4 questionnaires|September 2015|September 3, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728039||152197|
NCT00728858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941227|The Efficacy, Safety and Genetic Polymorphism of Hypoca and Adalat OROS in Hypertensive Patients|An Open-Label, Randomized Clinical Study to Evaluate the Efficacy, Safety and Genetic Polymorphism of Hypoca(Barnidipine)and Adalat OROS(Nifedipine) in Mild to Moderate Hypertensive Patients||National Taiwan University Hospital|Yes|Completed|April 2006|February 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|43|Samples With DNA|Extract DNA from buffy coat. Test drug concentration in plasma.|Both|22 Years|87 Years|No|Probability Sample|Hypertension patients living in Taiwan|April 2008|August 1, 2008|May 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00728858||152134|
NCT00728871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700838|The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis|The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and CIN Patients and Their Prognosis||National Taiwan University Hospital||Recruiting|December 2005|December 2011|Anticipated|January 2006|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|600|||Female|18 Years|80 Years|No|||August 2008|August 5, 2008|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728871||152133|
NCT00729521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00007160|Dissemination of Injury Interventions|Facilitating Dissemination of Injury Interventions: A Randomized Controlled Trial||Medical College of Wisconsin|No|Completed|July 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|35037|||Both|65 Years|N/A|No|||February 2015|February 3, 2015|July 31, 2008||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT00729521||152085|E coding of injuries can be incomplete, but 99.7% of records with a diagnostic code in the range 800-995.89 had an E code. We may have included more than one admission for the same fall, but we excluded admissions from an acute care facility.
NCT00729755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIC-08DE00101B|Creatine Augmentation Treatment in Major Depressive Disorder Subjects|Efficacy and Safety of Augmentation of Creatine for the Patients With Major Depressive Disorder||Seoul National University Hospital|Yes|Completed|August 2008|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|19 Years|65 Years|No|||June 2012|June 27, 2012|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729755||152067|
NCT00729495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00007|Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib|Phase I, Randomized, Open-Label, 2-Way Crossover Study to Evaluate Relative Bioavailability of Single Oral Dose of Celecoxib Administered as Marketed Product, or Overencapsulated Capsule in Healthy Volunteers||POZEN|No|Completed|July 2008|October 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 12, 2009|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729495||152087|
NCT00725426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1106|Effect of Rifampin on Bosutinib When Both Are Given to Healthy People|A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Bosutinib When Administered Concomitantly to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 24, 2009|July 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00725426||152396|
NCT00725439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT0700BEL001|An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne|An Open Label Pilot Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment of Moderate to Severe Facial Acne||GlaxoSmithKline|No|Completed|September 2004|December 2007|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|16 Years|50 Years|No|||September 2011|September 23, 2011|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00725439||152395|
NCT00729742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-008|Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)|A Phase 1b, Multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK0646 in Advanced Non-Small-Cell Lung Cancer||Merck Sharp & Dohme Corp.||Completed|February 2009|May 2011|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|August 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729742||152068|
NCT00726037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200732|A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer|A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer||Loyola University|Yes|Terminated|October 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|July 29, 2008|No|Yes|Manufacturer of Ontak withdrew support for the study due to drug supply interruption.|No||https://clinicaltrials.gov/show/NCT00726037||152349|
NCT00726050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080189|Brain Activity in Time Discrimination and Sensory Input|The Relationship Between Temporal Discrimination and Cortical Excitability in Humans||National Institutes of Health Clinical Center (CC)||Completed|July 2008|April 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|September 26, 2015|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00726050||152348|
NCT00726063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2613|A Prospective Study Evaluating the Performance of Nanotite Osseotite Implants When Placed by Graduate Student Programs|A Prospective Randomized-controlled Evaluation of Nanotite and Osseotite Surfaced Implant Performance in Graduate Student Programs|CollegeBowl|Biomet, Inc.|Yes|Completed|April 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 29, 2008|Yes|Yes||No|November 19, 2013|https://clinicaltrials.gov/show/NCT00726063||152347|
NCT00726661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4349n|An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)|An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer|VIRGO|Genentech, Inc.||Completed|June 2008|March 2013|Actual|March 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1287|Samples With DNA|Whole blood and tissue|Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic|January 2014|January 31, 2014|July 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00726661||152303|
NCT00700986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1520C00020|Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056|A Randomised, Double-Blind, Placebo-Controlled, 2-Period Cross-Over Study in Healthy Male Volunteers, to Investigate Retinal Function Following a Single 800mg Oral Dose of AZD9056||AstraZeneca|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700986||154246|
NCT00700999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-002-08S|Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)|Neurofunctional Markers of SSRI Treatment Response in PTSD||VA Office of Research and Development|Yes|Completed|October 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|65|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|June 17, 2008|No|Yes||No|September 9, 2013|https://clinicaltrials.gov/show/NCT00700999||154245|
NCT00702364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A07022R01|Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)|Strattera(Atomoxetine) for the Treatment of Attention Disorders in Individuals With Traumatic Brain Injury||Craig Hospital|Yes|Completed|January 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||August 2014|August 28, 2014|June 18, 2008||No||No|September 3, 2013|https://clinicaltrials.gov/show/NCT00702364||154141|
NCT00702377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-33|Evaluation of SYSTANE Ultra Lubricant Eye Drops|||Alcon Research|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|June 19, 2008||No||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00702377||154140|
NCT00697996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06102008-1196|Rituximab for Pediatric Renal Transplant Rejection|A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation||Stanford University||Completed|June 2005|August 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||20|||Both|5 Years|21 Years|No|||December 2008|December 19, 2008|June 11, 2008||||||https://clinicaltrials.gov/show/NCT00697996||154469|
NCT00698009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0752|Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma|Study to Infuse Haploidentical Natural Killer Cells in Patients With Relapsed or Refractory Neuroblastoma||M.D. Anderson Cancer Center|No|Terminated|June 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|N/A|No|||October 2012|October 23, 2012|June 12, 2008|Yes|Yes|Slow accrual.|No|October 23, 2012|https://clinicaltrials.gov/show/NCT00698009||154468|
NCT00698321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH082666|A School-Based HIV/STD Prevention Program to Reduce Risky Sexual Behaviors Among Adolescents in Liberia|Liberia School-Based HIV/STD Prevention Program||Pacific Institute for Research and Evaluation|No|Completed|November 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|866|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698321||154446|
NCT00698334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/NACO/2006|Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis|Efficacy of Thrice Weekly Intermittent Short Course Antituberculosis Chemotherapy in Tuberculosis Patients With and Without HIV Infection||All India Institute of Medical Sciences, New Delhi|No|Completed|April 2006|April 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|No|||November 2011|November 5, 2011|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00698334||154445|
NCT00698633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12380-5|A Clinical Investigation of the M2a- Taper™ Hip System|M2a- Taper™ Hip System Prospective Data Collection||Biomet, Inc.||Terminated|December 2001|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have already made the decision to undergo total hip replacement and will        receive the M2a- Taper™ Hip System.|October 2012|October 31, 2012|June 13, 2008|No|Yes|due to low follow up|No||https://clinicaltrials.gov/show/NCT00698633||154423|
NCT00698646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAH631BUS08|Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.|A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very Elderly Patients With Essential Hypertension||Novartis|No|Completed|April 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|384|||Both|70 Years|N/A|No|||April 2011|April 15, 2011|June 13, 2008|Yes|Yes||No|November 16, 2010|https://clinicaltrials.gov/show/NCT00698646||154422|
NCT00698919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB : 2008-A00361-54|Bacterial Infection Diagnosis Using Blood DNA|Bacterial DNA Detection as a Diagnostic Tool of Infection in Critical Ill Patients With SIRS||Delafontaine Hospital|No|Not yet recruiting|September 2008|November 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|Sample with bacterial DNA (and no human DNA will be studied)      We will have also some blood and plasma for cytokines,peptidoglycan and endotoxin      measurement.|Both|18 Years|N/A|No|Non-Probability Sample|All ICU patients older than 18 years old, with a SIRS, severe sepsis or septic shock will        be included in this cohort study.        SIRS, Severe sepsis and shock septic will be defined according to the definition used by a        panel of experts from the American College of Chest Physicians/Society of Critical Care        Medicine|June 2008|June 16, 2008|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698919||154401|
NCT00698958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUMO/2002/01|Ambulatory Adaptation to Non-Invasive Mechanical Ventilation|A Randomized Trial to Compare the Effectiveness of Hospital or Ambulatory Approach for Adaptation to Non-Invasive Mechanical Ventilation in Patients With Chronic Respiratory Failure Secondary to Neuromuscular Diseases or Thoracic Cage Alterations||Hospital Clinic of Barcelona|No|Completed|June 2003|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|75 Years|No|||June 2008|June 16, 2008|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698958||154398|
NCT00699244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61267|Comparison of Central Versus Peripheral Placement of Local Anesthetic|Selective Local Anesthetic Placement Using Ultrasound-guidance and Neurostimulation for the Infraclavicularbrachial Plexus Block||Vanderbilt University|Yes|Completed|December 2006|March 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|N/A|No|||September 2012|February 4, 2013|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00699244||154379|
NCT00699504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC CAN 08 01|Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers|A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers||The Medicines Company|No|Completed|June 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|5||Actual|67|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 13, 2012|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699504||154359|
NCT00728052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN111282|A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers.|A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses (75mg and Above) of GSK598809 in Otherwise Healthy Volunteers.||GlaxoSmithKline|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00728052||152196|
NCT00728299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiant Development #202528|The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness|The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness||Radiant Research|No|Completed|September 2003|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|384|||Both|45 Years|74 Years|Accepts Healthy Volunteers|||August 2008|August 4, 2008|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00728299||152177|
NCT00728312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-017-08S|Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial|Double-blind Placebo Controlled Trial of Aripiprazole for Amphetamine||VA Office of Research and Development|No|Withdrawn|August 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|65 Years|No|||June 2015|June 25, 2015|July 31, 2008|No|Yes|PI left the VA.|No||https://clinicaltrials.gov/show/NCT00728312||152176|
NCT00728585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL0521|Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant|A Group-Wide Double-Blind Randomized Placebo-Controlled Trial of Palifermin to Prevent Chemotherapy and/or Radiotherapy Induced Oral Mucositis in Children Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation||Children's Oncology Group|No|Withdrawn|January 2009|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|1 Year|16 Years|No|||May 2013|May 30, 2013|August 5, 2008|Yes|Yes|Withdrawn due to lack of drug supply|No||https://clinicaltrials.gov/show/NCT00728585||152155|
NCT00729222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7418-503|Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Hemodynamic Effects of Rolofylline Injectable Emulsion in the Treatment of Patients With Heart Failure||Merck Sharp & Dohme Corp.||Completed|November 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729222||152108|
NCT00729508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP002|Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects|A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Efficacy of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber.||Circassia Limited|No|Completed|August 2008|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|120|||Both|18 Years|65 Years|No|||July 2009|July 7, 2009|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729508||152086|
NCT00725465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0411007608|Prospective Evaluation of Combined Laparoscopy With CO2 Intraoperative Colonoscopy Treatment for Colorectal Lesions|Prospective Evaluation of Combined Laparoscopy With CO2 Intraoperative Colonoscopy Treatment for Colorectal Lesions||Weill Medical College of Cornell University|No|Recruiting|January 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|30 surgical patients, male and female undergoing laparoscopic surgical treatment for        colorectal conditions managed with intra-operative colonoscopy for standard care of their        medical condition|March 2012|March 7, 2012|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00725465||152393|
NCT00725452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04900|Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)|Real Life Treatment Regimen of Remicade (Infliximab) in Austria, Monitored Over 5 Years in Plaque Psoriasis Therapy||Merck Sharp & Dohme Corp.|No|Completed|October 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with moderate-to-severe plaque psoriasis will receive Infliximab induction        therapy in specialized centers.|July 2015|July 15, 2015|July 25, 2008|No|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00725452||152394|
NCT00725777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC-08-01|Treatment of Non-falciparum Malaria|Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon||Albert Schweitzer Hospital|No|Completed|July 2008|February 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|6 Months|60 Years|No|||February 2012|February 16, 2012|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00725777||152369|
NCT00716716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN-FIXFc-07-001|Phase I/IIa Study of FIXFc in Hemophilia B Patients|A Phase I/IIa Safety and Pharmacokinetic Study of Intravenous FIXFc in Previously Treated Hemophilia B Patients||Biogen|Yes|Completed|April 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||March 2015|March 19, 2015|July 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00716716||153053|
NCT00716729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2007-0129|Development of Outcome-measures for Physically Active Patients With Hip and Groin Pain|Development of Outcome-measures for Physically Active Patients With Hip and Groin Pain||Amager Hospital|No|Completed|July 2009|October 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with hip and/groin pain for more than 8 weeks|July 2008|October 18, 2010|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716729||153052|
NCT00726375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.139|The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease|The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease||University of Michigan Cancer Center|Yes|Completed|May 2008|September 2014|Actual|July 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|N/A|N/A|No|||December 2015|December 4, 2015|July 28, 2008|Yes|Yes||No|July 8, 2014|https://clinicaltrials.gov/show/NCT00726375||152324|Due to difficulties obtaining approval for insurance coverage of the study drug, only 34 of 50 patients were enrolled. The study was terminated prematurely and findings were reported for 34 patients.
NCT00701844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO #06-0391 (2)|Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors|Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors||University of North Carolina, Chapel Hill|No|Completed|July 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|315|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|June 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00701844||154181|
NCT00702104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000596996|Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area|PSA Screening of African-American Men in The San Francisco Area||University of California, San Francisco|No|Completed|January 2003|||January 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|||||Male|35 Years|N/A|No|Non-Probability Sample|community sample|May 2013|May 13, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702104||154161|
NCT00702416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEST-ORT-01|Ultrasound Guidance for Interscalene Brachial Plexus Block|Ultrasound Guidance or Electrical Nerve Stimulation for Interscalene Brachial Plexus Block: a Randomized, Controlled Trial||University of Parma|No|Completed|May 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||November 2009|November 13, 2009|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702416||154138|
NCT00698022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-205|A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers|A 4-week, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers||Corcept Therapeutics|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|76|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 1, 2012|June 12, 2008|Yes|Yes||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00698022||154467|
NCT00698035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-067519|Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients|A Phase II Study of Vaginal Testosterone Cream vs. the ESTRING for Vaginal Dryness or Decreased Libido in Early Breast Cancer Patients Treated With Aromatase Inhibitors|E-String|University of California, San Francisco|No|Completed|March 2007|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|76|||Female|18 Years|80 Years|No|||May 2014|May 27, 2014|June 11, 2008|No|Yes||No|April 29, 2014|https://clinicaltrials.gov/show/NCT00698035||154466|
NCT00698347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomet 12380-82|A Clinical Investigation of the M2a-Magnum™ Hip System|A Prospective, Non-controlled, Clinical Investigation of the M2a-Magnum™ Hip System||Biomet, Inc.|No|Terminated|November 2004|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|249|||Both|N/A|N/A|No|Non-Probability Sample|Patients that have already made the decision to undergo Total Hip Replacement and will        receive the M2a-Magnum™ Hip System|April 2015|April 15, 2015|June 13, 2008|No|Yes|Centers would not continue follow-up; two centers transitioned patients to a new study.|No||https://clinicaltrials.gov/show/NCT00698347||154444|
NCT00698659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC2/15/07|Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies|A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth||National University Hospital, Singapore|No|Terminated|August 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|||||Both|21 Years|N/A|No|Non-Probability Sample|Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab,        sunitinib, and sorafenib) as part of routine clinical management|April 2012|December 10, 2013|June 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00698659||154421|
NCT00698672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10642(NSD)|RSA-Study of Cemented Hip Prostheses With Five Different Articulations|A Prospective Randomized RSA-Study of Cemented Hip Prostheses With Five Different Articulations||Haukeland University Hospital|No|Active, not recruiting|November 2004|June 2017|Anticipated|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|150|||Both|59 Years|80 Years|No|||July 2015|July 29, 2015|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00698672||154420|
NCT00699257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomet 12380-63|A Clinical Investigation of the Oxford® Partial Knee System|A Prospective, Non-controlled, Clinical Investigation of the Oxford® Partial Knee System||Biomet, Inc.|No|Terminated|July 2004|December 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|85|||Both|N/A|N/A|No|Non-Probability Sample|Patients that have already made the decision to undergo knee surgery and will receive the        Oxford® Partial Knee System.|June 2012|June 27, 2012|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699257||154378|
NCT00731302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL65082|Aspirin Resistance in Systemic Lupus Erythematosus (SLE)|Vascular Damage in Systemic Lupus Erythematosus (SLE)||Vanderbilt University|No|Active, not recruiting|April 2005|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00731302||151948|
NCT00728325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074312|Impact of Supported Employment Versus Standard Vocational Rehabilitation in Veterans With Post-traumatic Stress Disorder|The Impact of Supported Employment Versus Standard Vocational Rehabilitation in Veterans With PTSD||Tuscaloosa Research & Education Advancement Corporation|No|Active, not recruiting|May 2008|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|19 Years|60 Years|No|||December 2013|December 4, 2013|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00728325||152175|
NCT00728598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561702008|Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis|Vitreous Levels of Patients With Proliferative Diabetic Retinopathy.||National Taiwan University Hospital||Completed|January 1998|December 1998|Actual|December 1998|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|Vitreous sample and blood sample|Both|N/A|N/A|No|Non-Probability Sample|Patients with proliferative diabetic retinopathy, who will receive vitrectomy.|August 2008|August 5, 2008|August 1, 2008||||No||https://clinicaltrials.gov/show/NCT00728598||152154|
NCT00728884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2406|Study of Certain Prevail Implants Used to Treat All Types of Edentulism in the Maxilla and Mandible|Observational Study of Certain Prevail Implant System in Maxillary and Mandibular Regions|PrevailMulti|Biomet, Inc.|Yes|Completed|October 2005|December 2011|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|||Both|18 Years|N/A|No|Non-Probability Sample|These will be patients who are otherwise seeking dental implant therapy and belong to the        study centers' standard patient population.|May 2015|May 14, 2015|August 1, 2008||No||No|July 7, 2009|https://clinicaltrials.gov/show/NCT00728884||152132|
NCT00729768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD4230g|A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation|A Phase II/III, Randomized, Open-Label, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab Compared With Cyclosporine, Both in Combination With Mycophenolate Mofetil and Corticosteroids, As an Immunosuppressant Regimen in De Novo Renal Transplantation||Genentech, Inc.||Withdrawn||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2009|March 12, 2009|August 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729768||152066|
NCT00719953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-NV-305-CTIL|Study to Assess the Efficacy of Cognitex|A Single-Center, Open-label Study to Assess the Efficacy of Cognitex in Elderly Subjects With Memory Impairment|Cognitex001|Tel-Aviv Sourasky Medical Center|No|Completed|August 2008|August 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||July 2008|April 18, 2010|July 21, 2008||No||No|January 10, 2010|https://clinicaltrials.gov/show/NCT00719953||152806|
NCT00720551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-374|Calibration and Validation of the STISIM Driving Simulator|Calibration and Validation of the STISIM Driving Simulator: Simulated Driving Performance Under the Influence of Alcohol (0.05%, 0.08% AND 0.11%), and Placebo||Utrecht Institute for Pharmaceutical Sciences|No|Completed|June 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|1||Actual|27|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720551||152762|
NCT00725790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-01|A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury|Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury|SCI|China Rehabilitation Research Center||Not yet recruiting|August 2008|September 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Male|18 Years|65 Years|No|||July 2008|July 28, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725790||152368|
NCT00716443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10098|Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections|Open-Label, Randomized, Split-Face Study to Evaluate the Efficacy, Safety and Subject Satisfaction of Pain Management During and After Restylane® Dermal Filler Injections for the Correction of Nasolabial Folds||Galderma Laboratories, L.P.|No|Terminated|July 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|30 Years|65 Years|No|||September 2012|September 21, 2012|July 14, 2008||No|Sponsor decision|No|September 25, 2009|https://clinicaltrials.gov/show/NCT00716443||153074|
NCT00716755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156/2007|Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.|The Minimal Effective Dose of Antipsychotic Medication in Older Patients With Schizophrenia: a PET Study.||Centre for Addiction and Mental Health|Yes|Completed|October 2009|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|50 Years|N/A|No|||February 2016|February 25, 2016|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716755||153050|
NCT00717015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR02/06/06|Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer|Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer||National University Hospital, Singapore||Completed|November 2005|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|||||Female|18 Years|N/A|No|Probability Sample|We aim to enroll 200 patients onto our study over a period of 2 years. Patients will be        recruited from the oncology outpatient clinic in National University Hospital.        Participation in the study will be strictly voluntary and written informed consent will be        obtained from all subjects according to institutional and governmental guidelines. Consent        will be obtained by attending doctors or co-investigators of the study prior to blood        sampling.|April 2012|April 2, 2012|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717015||153030|
NCT00717002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS02/21/05|Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study|Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study||National University Hospital, Singapore|No|Completed|February 2008|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|||||Both|18 Years|N/A|No|Probability Sample|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical        management to drain off excess pleural fluid. Even though taking a sample of the tumour        tissue present on the pleural/ lining of the lung may not routinely form part of a routine        thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.        Patients from Group 2 should have tumour samples obtained previously for diagnosis, and        these will be obtained from the Department of Pathology. If they are undergoing        thoracoscopy as part of their routine clinical management, a sample of the tumour tissue        present on the pleural/ lining of the lung will also be obtained during the procedure and        sent to the laboratory for testing.|December 2013|December 10, 2013|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717002||153031|
NCT00702117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJUAR|Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias|Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias|AJUAR|Hospital Clinic of Barcelona|No|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|123|||Both|10 Years|80 Years|No|||January 2010|December 14, 2010|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702117||154160|
NCT00702403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2223.00|Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia|A Multicenter Phase I/II Study of the Prophylactic Inhibition of BCR-ABL Tyrosine Kinase by Tasigna ® (Nilotinib) After Hematopoietic Cell Transplantation for Philadelphia Chromosome-Positive Leukemias.||Fred Hutchinson Cancer Research Center|Yes|Completed|April 2008|||December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||December 2014|December 9, 2014|June 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00702403||154139|
NCT00698048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIG07nov002|Serial Vasopressin and Copeptin Levels in Children With Sepsis and Septic Shock|Serial Vasopressin and Copeptin Levels in Children With Sepsis and Septic Shock|VaCoSS|KK Women's and Children's Hospital|No|Completed|August 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|136|Samples With DNA|Blood samples|Both|N/A|16 Years|No|Non-Probability Sample|Children between one day of age and sixteen years old.|September 2015|September 7, 2015|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00698048||154465|
NCT00698360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREAM 1|Circadian Rhythm of Erythropoietin And Melatonin in Renal Disease|Circadian Rhythm of Erythropoietin and Melatonin in Patients With Various Degrees of Renal Insufficiency|CREAM 1|Meander Medical Center|No|Completed|July 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|34|Samples Without DNA|serum|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with various degrees of renal insufficiency, admitted to Meander Medical Center          -  A: Patients with renal insufficiency (clearance 10-30 ml/min)          -  B: Patients with renal insufficiency (clearance 30-60 ml/min)          -  C: Patients with renal insufficiency (clearance 60-80 ml/min)          -  D: Patients with normal renal function (clearance > 80 ml/min)|June 2008|June 16, 2008|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698360||154443|
NCT00698685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0624-04|Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation|Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)||University of Arizona|Yes|Terminated|November 2005|November 2010|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|June 14, 2008|Yes|Yes|Pentostatin/alemtuzumab regimen had greater risk of graft failure.|No|December 28, 2010|https://clinicaltrials.gov/show/NCT00698685||154419|We did not meet criteria to stop the study because of nonrelapse mortality (safety endpoint). However, we stopped accrual to the study because of failure to meet minimal criteria for engraftment (efficacy endpoint).
NCT00698984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN/BLEND-06.06|Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health|Pilot Study To Investigate The Effect Of Bonistein(R) Bone Blend Containing Genistein, Polyunsaturated Fatty Acids (N-3 PUFAS) And Vitamins K1 And D3 On Bone Mineral Density (BMD), Bone Mineral Content (BMC) And Biomarkers Of Bone Health In Early Postmenopausal Women||DSM Nutritional Products, Inc.|Yes|Completed|January 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||January 2009|January 15, 2009|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698984||154397|
NCT00731549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-08-248|Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia|ASPIRE|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|December 2008|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1081|||Both|18 Years|65 Years|No|||November 2014|November 14, 2014|August 5, 2008|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00731549||151930|
NCT00731562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051088|An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation|Phase 1, Open-Label, Randomized, Single-Dose, Two-Way Crossover Study To Evaluate The Effect Of Food On The Oral Bioavailability Of A Varenicline Controlled Release Formulation In Healthy Adult Smokers||Pfizer|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 7, 2010|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00731562||151929|
NCT00731874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608008711|Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status|Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status by Biopsy and mRNA Profiles (TIMELY Study)|TIMELY|Weill Medical College of Cornell University|No|Terminated|August 2008|July 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|August 7, 2008|Yes|Yes|A higher rate of late rejection was seen in the low tacrolimus arm.|No|December 21, 2015|https://clinicaltrials.gov/show/NCT00731874||151905|The population reported is small because the study was stopped early due to the increase in late antibody mediated rejection (occurring after month 15) that was seen in Arm 2 (target tacrolimus trough 3 to 5 ng/mL).
NCT00728897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN111283|A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.|An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of a 100mg Capsule Compared to Four 25mg GSK598809 Capsules and the Effect of Food on the Pharmacokinetics of the 100mg Capsule in Healthy Male and Female Volunteers.||GlaxoSmithKline||Completed|July 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|August 4, 2008||||No||https://clinicaltrials.gov/show/NCT00728897||152131|
NCT00729235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BITAC - ITAC04|Biventricular Tachycardias Outcome Trial|Biventricular Tachycardias Outcome Trial|BITAC|LivaNova|Yes|Completed|May 2006|November 2011|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|481|||Both|18 Years|N/A|No|||June 2010|December 21, 2011|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729235||152107|
NCT00729534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080193|Research Participants Perceptions of Their Experience in Clinical Studies|Research Participant Perception of Care Project: Part 1: Focus Groups of Research Participants and Research Professionals to Identify Key Dimensions of the Research Participant Experience||National Institutes of Health Clinical Center (CC)||Completed|August 2008|May 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|14|||Both|18 Years|N/A|No|||May 2013|February 19, 2014|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00729534||152084|
NCT00720200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33584-C|ICU Family Communication Study|A Randomized Trial of an Interdisciplinary Communication Intervention to Improve Patient and Family Outcomes in the Intensive Care Unit||University of Washington|Yes|Completed|June 2008|May 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|593|||Both|18 Years|N/A|No|||September 2014|September 13, 2014|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720200||152789|
NCT00720213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0731-ASV3-MS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2008|||||N/A|N/A|N/A||||||||||||||November 9, 2009|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720213||152788|
NCT00720226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P50HL084945|Efficacy of Losartan in Preventing Progression of COPD|Efficacy of Losartan in Preventing Progression of COPD||Johns Hopkins University|Yes|Active, not recruiting|July 2008|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|N/A|No|||April 2013|April 1, 2013|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720226||152787|
NCT00720564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600335|Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma|A Phase I Study of the Combination of Radiation Therapy (RT), Arsenic Trioxide (ATO) and Temozolomide (TMZ) in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM)||City of Hope Medical Center|Yes|Completed|April 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||August 2010|August 9, 2010|July 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720564||152761|
NCT00716183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Promast08|Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis|Phase 2/3 Evaluation of Three Lactobacilli Strains Isolated From Human Milk for the Treatment of Infectious Mastitis During the Lactation Period||Universidad Complutense de Madrid|Yes|Completed|July 2008|May 2009|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|300|||Female|19 Years|38 Years|No|||May 2009|May 22, 2009|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716183||153094|
NCT00716456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-055|Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib|A Phase I/II Trial of Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib||Memorial Sloan Kettering Cancer Center||Completed|July 2008|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 15, 2008|Yes|Yes||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00716456||153073|
NCT00716742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro2|Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)|||Allergan||Completed|September 2004|September 2009|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1099|||Both|18 Years|N/A|No|Non-Probability Sample|Patients can be either: (a) newly diagnosed and require, in the judgment of the treating        physician, one of study agents as first-line treatment, (b) have an insufficiently        controlled IOP on their current medication (any but not more than two in combination), and        a treatment switch to one of study agents is an acceptable option.|November 2011|November 30, 2011|July 14, 2008||No||No|November 30, 2011|https://clinicaltrials.gov/show/NCT00716742||153051|Data for 2-year and 3-year follow-up not interpretable due to extremely high drop out rates.
NCT00717028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198/2005|Functional Endoscopic Evaluation of Swallowing|Achados da avaliação videoendoscópica da deglutição em crianças Com Paralisia Cerebral.||Fortaleza University|No|Completed|September 2005|November 2005|Actual|November 2005|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|9|||Both|1 Year|10 Years|No|Non-Probability Sample|Children with cerebral palsy|September 2005|July 14, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717028||153029|
NCT00717639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasovist MA-01|Vasovist Magnetic Resonance Angiography (MRA) in Peripheral Arterial Occlusive Disease|Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients With Peripheral Artery Disease||Heidelberg University|No|Terminated|May 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||July 2010|August 5, 2011|June 30, 2008||No|Required contrast media (Vasovist) withdrawn from market|No||https://clinicaltrials.gov/show/NCT00717639||152982|
NCT00702442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|597/4-6-2008|Role of Droperidol in Postoperative Vomiting|Role of Droperidol in Postoperative Vomiting: Phase IV Study||Aristotle University Of Thessaloniki|Yes|Completed|June 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||September 2009|July 25, 2011|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702442||154136|
NCT00730106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMCP-97-017|Endoscopic Findings in Patients With Typical Gastroesophageal Reflux Disease (GERD) Symptoms|Endoscopic Findings in Taiwan Patients Presenting With Characteristic Symptoms of Gastroesophageal Reflux Disease||Lotung Poh-Ai Hospital|Yes|Completed|May 2008|December 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1000|||Both|18 Years|90 Years|No|Probability Sample|Adult outpatients with characteristic GERD symptoms, in a district general hospital|October 2010|October 18, 2010|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00730106||152040|
NCT00730392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020197|Etanercept in New Onset Type 1 Diabetes|"ENBREL® (Etanercept) Administration to Patients Newly Diagnosed With Type 1 Diabetes Mellitus: Feasibility-Safety Study" ("Study")||University at Buffalo|Yes|Completed|October 2002|January 2008|Actual|October 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|3 Years|18 Years|No|||August 2008|August 5, 2008|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730392||152018|
NCT00730405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114554|Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis||GlaxoSmithKline|No|Completed|July 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|584|||Both|18 Years|75 Years|No|||August 2012|August 9, 2012|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00730405||152017|
NCT00731055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5649/NIDA-17572-4|Effects of Varenicline on Cigarette Self Administration|Effects of Varenicline on Cigarette Self Administration||New York State Psychiatric Institute|Yes|Completed|February 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|21|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||December 2009|April 15, 2015|August 6, 2008|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT00731055||151967|
NCT00731068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000|Platelet Rich Plasma (PRP) as a Treatment for ACHILLES Tendon Tears|PRP as a Treatment for ACHILLES Tendon Tears - Randomized-Double-Blind-Placebo Control Trail||Meir Medical Center|Yes|Completed|February 2007|March 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||October 2013|October 23, 2013|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731068||151966|
NCT00731315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12132-32499-02|Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers|Computer-Assisted Treatment in the Management of Adult Female Patients With Symptoms of Urinary Tract Infection in Emergency Departments and Community Health Centers: A Randomized Trial|UTI-Kiosk|University of California, San Francisco|Yes|Terminated|August 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|200|||Female|18 Years|64 Years|No|||March 2015|March 5, 2015|August 5, 2008||No|Funding Period ended, did not reach full sample size due to limited numbers of eligible    patients|No||https://clinicaltrials.gov/show/NCT00731315||151947|
NCT00732199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-019-07F|Determinants of Age Related Breathing Instability During Non-Rapid-Eye-Movement (NREM) Sleep|Determinants of Age-specific Breathing Instability During Sleep||VA Office of Research and Development|Yes|Completed|October 2008|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|92|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732199||151880|
NCT00732498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0303-04|Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma|PHASE II TRIAL OF YTTRIUM-90-IBRITUMOMAB TIUXETAN (ZEVALIN) RADIOIMMUNOTHERAPY AFTER CYTOREDUCTION WITH ESHAP CHEMOTHERAPY IN PATIENTS WITH RELAPSED FOLLICULAR NON-HODGKIN'S LYMPHOMA||University of Arizona|Yes|Recruiting|May 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|August 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732498||151857|
NCT00719095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA019989|Effective Treatment for Prescription Opioid Abuse|Effective Treatment for Prescription Opioid Abuse||University of Vermont Medical Center|No|Completed|April 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|65 Years|No|||July 2008|April 12, 2013|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719095||152872|
NCT00719381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-07-00308|Effect of Pioglitazone on Inflammation in Cystic Fibrosis|Effect of Pioglitazone on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Cystic Fibrosis||University of Southern California|Yes|Completed|January 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719381||152850|
NCT00719615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136-08-EP|Assess Vitamin D Levels in Those With & Without Thyroid Cancer|The Relationship Between Vitamin D and Thyroid Cancer||University of Nebraska|No|Completed|March 2008|June 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|111|Samples With DNA|Whole blood.|Both|19 Years|N/A|No|Non-Probability Sample|The Thyroid Tumor and Cancer Collaborative Registry (TCCR) is a thyroid cancer and thyroid        nodule database at the University of Nebraska Medical Center. The database serves as a        registry and biospecimen bank for those who wish to participate in multidisciplinary        research. The database will be accessed to query for individuals with a diagnosis of        thyroid cancer, both active disease and in remission, as well as a diagnosis of thyroid        nodules. Those meeting eligibility requirements will then have their registry information        and stored biospecimens accessed for testing and review.|March 2010|June 2, 2015|July 17, 2008||No||No|January 27, 2010|https://clinicaltrials.gov/show/NCT00719615||152832|The trial limitations include that it was mostly done on Caucasian subjects; the controls were those with thyroid nodules not subjects without any thyroid disease; the sample size was small; & a small number of Vit D assays used different methods.
NCT00719628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAS-001|Depth of Anaesthesia and Cognitive Dysfunction|Depth of Anaesthesia and Presence of Postoperative Cognitive Dysfunction||Rigshospitalet, Denmark|Yes|Completed|September 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|60 Years|N/A|No|Non-Probability Sample|Patients above 60 years eligible for surgery|April 2009|April 6, 2009|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00719628||152831|
NCT00720239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86606|Taliderm Dressing for Venous Ulcers|Safety and Wound Healing Efficacy of the TalidermR Wound Dressing a Poly-N-acetyl Glucosamine-derived Membrane Material in Humans With Venous Stasis Ulcers: a Pilot Study.||Medical University of South Carolina|Yes|Completed|February 2008|August 2010|Actual|September 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|50|||Both|45 Years|N/A|No|||February 2013|February 20, 2013|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00720239||152786|
NCT00720252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0029-08-EMC|Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?|Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?||HaEmek Medical Center, Israel||Terminated|July 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Female|18 Years|48 Years|No|||March 2015|March 20, 2015|July 19, 2008||No|TECHNICAL ISSUES|No||https://clinicaltrials.gov/show/NCT00720252||152785|
NCT00716781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBS FVG 2004-2006|Management of Infants Born to Group B Streptococcus Positive Mothers.|Management of Infants Born to Group B Streptococcus Positive Mothers: Laboratory Tests vs Physical Examination||IRCCS Burlo Garofolo|No|Completed|July 2004|December 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|16394|||Both|N/A|N/A|No|Non-Probability Sample|All newborns born in Friuli Venezia Giulia Region (Italy) during the study period|July 2008|July 14, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716781||153048|
NCT00716196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502-23|A Prospective Study of Thin Prep Versus Papanicolau in Suspected Malignant Lesions During Endoscopic Ultrasound (EUS)|A Prospective Study of Thin Prep Versus Papanicolau in Suspected Malignant Lesions During EUS||Indiana University|No|Completed|March 2005|July 2008|Actual|April 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Convenience sample from patients presenting at the GI endoscopy unit for an EUS.|September 2012|September 11, 2012|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716196||153093|
NCT00716794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE3235-0201|A Phase I/II Study of HE3235 in Patients With Prostate Cancer|A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer||Harbor Therapeutics|No|Completed|July 2008|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Male|18 Years|N/A|No|||March 2011|March 8, 2011|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716794||153047|
NCT00717353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS05/25/04|Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype|Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype||National University Hospital, Singapore||Active, not recruiting|October 2005|||December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Our laboratory has conducted a pilot study to look at UGT1A expression in both normal and        cancer tissue using RT PCR. We have found that in UGT1A6 is the predominant UGT1A enzymes        expressed in normal lung and the expression of UGT1A6 enzymes is down regulated in lung        cancer (unpublished data). The distribution of UGT1A enzymes in the lung suggests that        UGT1A6 may be important in the glucuronidation of inhaled UGT substrates including        chemicals from tobacco smoking.|January 2014|January 13, 2014|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717353||153004|
NCT00717366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH19707|A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis|An Open Label Multi-center, Multiple Dose Study to Determine the Optimum Starting Dose of Intravenous MIRCERA for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis||Hoffmann-La Roche||Active, not recruiting|July 2008|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|5 Years|17 Years|No|||March 2016|March 1, 2016|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717366||153003|
NCT00717652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATTGLE0508|Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma|Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).|melasma|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Suspended|July 2008|||July 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||July 2008|October 22, 2010|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717652||152981|
NCT00717379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-EC-2R01|Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation|Open-Label, Randomized, Multicenter, Parallel-Group Efficacy and Safety Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation||Astellas Pharma Inc|No|Completed|May 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||April 2009|April 13, 2009|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717379||153002|
NCT00734643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 06/117|Family Adaptation Study Following the Diagnosis of Hypoplastic Left Heart Syndrome in a Newborn|Family Stress, Coping and Outcomes Following the Diagnosis of Hypoplastic Left Heart Syndrome in a Newborn||Medical College of Wisconsin|No|Active, not recruiting|June 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|130|||Both|N/A|3 Years|No|Non-Probability Sample|Parents of all patients diagnosed with complex congenital heart disease requiring        hospitalization or intervention during the neonatal period will be eligible to        participate. Parents unable to speak or read English will be excluded. An attempt will be        made to obtain consent for participation from both the mother and father of the affected        infant. If no father is involved in the care of the infant, measures will be obtained from        mothers alone. The model will be tested using mothers' reports of family variables. Single        parents will be able to participate but will not be included in comparisons between        mothers and fathers. Nurse coordinators at participating centers will conduct subject        screening and consenting.|February 2016|February 1, 2016|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734643||151693|
NCT00731081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU04107|Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®|Observational Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme||Sanofi|No|Completed|March 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples Without DNA|urine and plasma oligosaccharides|Both|18 Years|N/A|No|Non-Probability Sample|Patients with severe late onset of Pompe disease with respiratory deficiency and treated        by Myozyme|February 2014|February 4, 2014|August 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00731081||151965|
NCT00731575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VINKU2|Viral Inception of Asthma: Prospective Study From Infancy to School-age|Viral Inception of Asthma: Prospective Study From Infancy to School-age.|VINKU2|University of Turku|Yes|Active, not recruiting|June 2007|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|200|||Both|3 Months|24 Months|Accepts Healthy Volunteers|||August 2011|August 11, 2011|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00731575||151928|
NCT00731588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710747|Red Blood Cell (RBC) Survival Following Transfusion in Infants|Red Blood Cell Survival Following Transfusion in Infants||University of Iowa|Yes|Completed|June 2008|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|140|||Both|N/A|6 Months|No|||December 2014|December 23, 2014|August 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00731588||151927|
NCT00731887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-157B|Large Burn Outcome Study|Assessment of the Treatment of the Severely Burned With Anabolic Agents on Improved Wound Healing, Recovery and Rehabilitation: Large Burn Outcome Study|LBO|The University of Texas Medical Branch, Galveston|No|Withdrawn|June 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|Samples Without DNA|Blood and urine collected for this study will be retained for possible re-analysis if needed      for the duration of the study.|Both|16 Years|N/A|No|Non-Probability Sample|Those that have received a burn injury at least 3 years ago and that recieved acute burn        treatment at Shriners Hospital for Children - Galveston between 1986-2005.|December 2013|January 7, 2014|July 30, 2008||No|Personnel involved in this protocol are no longer associated with this study|No||https://clinicaltrials.gov/show/NCT00731887||151904|
NCT00731900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561707009|Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction|||National Taiwan University Hospital||Recruiting|April 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|17 Years|70 Years|No|Probability Sample|patients with epilepsy or patients with migraine treated by topiramate|August 2008|August 8, 2008|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731900||151903|
NCT00731614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F6441-R|Cognitive Behavior Therapy (CBT) and Mirror Training for Phantom Limb Pain|Psychosocial and Visual Feedback Intervention for Phantom Limb Pain||VA Office of Research and Development|No|Completed|November 2008|December 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|21 Years|N/A|No|||June 2015|June 1, 2015|August 5, 2008||No||No|March 3, 2015|https://clinicaltrials.gov/show/NCT00731614||151925|
NCT00731913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8229|A Comparison of Monosyn and Monocryl Sutures in Surgical Wounds|A Randomized, Prospective Trial Evaluating Surgeon-Preference in Selection of Absorbable Suture Material||Tufts Medical Center|Yes|Completed|July 2007|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with skin lesions requiring surgical removal were eligible for our study.|March 2015|March 17, 2015|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731913||151902|
NCT00732212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-013-07F|Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage|Doppler Ultrasound Probe for Blood Flow Detection in Severe UGI Bleed||VA Office of Research and Development|Yes|Completed|February 2009|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00732212||151879|
NCT00732225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-015|DisCoVisc Comparative Evaluation|A Prospective, Non-randomized Comparison of DisCoVisc to Dispersive and Cohesive Ophthalmic Viscosurgical Devices (OVDs) in Non-eventful Cataract Surgery||Alcon Research|No|Completed|May 2007|||February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|173|||Both|49 Years|N/A|No|||June 2010|June 30, 2010|August 7, 2008|No|Yes||No|March 31, 2010|https://clinicaltrials.gov/show/NCT00732225||151878|At the time of surgery, patients were assigned to a study group based on the availability of study Ophthalmic Viscosurgical Devices (OVDs).
NCT00732251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13414|Allopurinol Maintenance Study for Bipolar Disorder|An Open Label, Naturalistic Study With Allopurinol Augmentation for Prevention of Mania in Bipolar Disorder||Cedars-Sinai Medical Center|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|70 Years|No|||March 2012|March 26, 2012|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732251||151876|
NCT00732264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS/LB-003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2008|||||N/A|N/A|N/A||||||||||||||October 17, 2008|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732264||151875|
NCT00732277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM CHI 434|Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study|Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis (Steroids in Paediatric Sepsis, StePS) - a Randomised Pilot Study|StePS|University Hospital Southampton NHS Foundation Trust.|Yes|Recruiting|April 2008|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|3 Months|14 Years|No|||August 2010|August 20, 2010|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732277||151874|
NCT00719394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3225A1-1001|Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males|Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Male|20 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 8, 2009|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719394||152849|
NCT00719641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080173|Experimental Device to Improve Colonoscopy|A Trial of Segmental Stiffening Wires to Improve the Efficiency and Patient Tolerability of Colonoscopy||National Institutes of Health Clinical Center (CC)||Recruiting|July 2008|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|103|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|July 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719641||152830|
NCT00719966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0834|Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer|Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function||Mayo Clinic|Yes|Active, not recruiting|June 2008|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Female|40 Years|80 Years|No|Non-Probability Sample|Patients with recently diagnosed breast cancer|March 2015|March 31, 2015|July 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00719966||152805|
NCT00716469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-5008|Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas|Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using Intratumoral Delivery of Non-coherent Light for Photoactivation of LS11 in Children With Plexiform Neurofibromas|PDT|Children's Hospital of Philadelphia|Yes|Terminated|July 2008|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|3 Years|21 Years|No|||April 2015|April 14, 2015|July 14, 2008|No|Yes|The study is terminated due to expiration of study materials.|No||https://clinicaltrials.gov/show/NCT00716469||153072|
NCT00716768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010962|Trial of Laparoscopic Compared to Open Inguinal Hernia Repair in Children Younger Than 3 Years|Randomized Controlled Trial of Laparoscopic Compared to Open Inguinal Hernia Repair in Children Younger Than 3 Years of Age||Johns Hopkins University|No|Recruiting|October 2007|June 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|152|||Both|N/A|3 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716768||153049|
NCT00716222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B40320084032|Hormonal and Metabolic Consequences of Sleep Disorders in Young Obese Patients|Hormonal and Metabolic Consequences of Sleep Disorders in Young Obese Patients|SOM|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|May 2008|May 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|70|||Both|13 Years|25 Years|No|Non-Probability Sample|Patients of the output clinics in the endocrinology and pediatric endocrinology        departments at the university hospital.|January 2009|January 20, 2009|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716222||153091|
NCT00717041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 24085|Epidemiology of Depression, Anxiety, and Cognitive Impairment|Epidemiology of Depression, Anxiety, and Cognitive Impairment Among Emergency Department Patients||University of Rochester|No|Completed|May 2008|February 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1206|||Both|60 Years|N/A|No|Non-Probability Sample|All older adults arriving at participating hospital emergency departments to obtain        emergency care.|June 2015|June 12, 2015|July 14, 2008||No||No|May 22, 2015|https://clinicaltrials.gov/show/NCT00717041||153028|Single center, limited generalizabilityLarge proportion of individuals lost to follow upED visit may have heightened symptomsValidity of instruments in the ED setting is unknown
NCT00717080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PR1210826|The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction|Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients|ACO|Aurolab|Yes|Completed|July 2008|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|65 Years|No|||October 2009|January 24, 2012|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717080||153025|
NCT00717405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21531|A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.|An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy||Hoffmann-La Roche||Completed|October 2008|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|July 16, 2008||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT00717405||153000|
NCT00717054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00659737|Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting|A Randomized, Double-blind Comparison of Oral Aprepitant Alone vs Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting||Drexel University|Yes|Completed|February 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|May 1, 2014|July 15, 2008|Yes|Yes||No|March 5, 2014|https://clinicaltrials.gov/show/NCT00717054||153027|
NCT00717067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001075|Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function|An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function||ViiV Healthcare|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2010|November 10, 2010|July 15, 2008|No|Yes||No|November 16, 2009|https://clinicaltrials.gov/show/NCT00717067||153026|
NCT00717392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5327-LG-CTIL|Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders|Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders||Sheba Medical Center|No|Completed|September 2008|July 2012|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|40|||Both|5 Years|17 Years|No|Non-Probability Sample|Hippotherapy subjects will be taken from horseback riding farms. Control subjects will be        taken from a tertiary care clinic.|February 2013|February 28, 2013|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717392||153001|
NCT00730717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 04-37|Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum|Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum||Wright State University|Yes|Withdrawn|May 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|August 4, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00730717||151993|
NCT00730730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP084|The Complete® Self-Expanding Stent and Stent Delivery System Registry|The Medtronic Complete® Self-Expanding Stent and Stent Delivery System Registry: a Non-randomized Prospective, Multicenter, Consecutive Registry||Medtronic Endovascular|Yes|Completed|November 2007|August 2012|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 5, 2008|No|Yes||No|November 11, 2010|https://clinicaltrials.gov/show/NCT00730730||151992|
NCT00730704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD1877|Acceptance of Human Papillomavirus Vaccination in Postpartum Women|Acceptance of Human Papillomavirus Vaccination in Postpartum Women|HPV Acceptance|Columbia University|No|Completed|May 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Female|18 Years|26 Years|No|Non-Probability Sample|Women, aged 18-26, hospitalized during the postpartum period after a normal spontaneous        vaginal delivery, assisted vaginal delivery or Cesarean section.|November 2012|November 2, 2012|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00730704||151994|
NCT00731120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_309|Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder||Takeda|No|Completed|June 2008|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|457|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|August 6, 2008|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00731120||151962|
NCT00731653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBM-IT-01-EXT|Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)|An Open-Label Extension Study to Assess the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder||Massachusetts General Hospital|No|Completed|July 2008|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|65 Years|No|||October 2013|October 24, 2013|August 7, 2008||No||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00731653||151922|This was an open-label study. Conclusions regarding the efficacy of the combination study drug were not made.
NCT00731627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-000277-30|Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial|Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial|STASH|Cambridge University Hospitals NHS Foundation Trust|Yes|Completed|January 2007|February 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|803|||Both|18 Years|65 Years|No|||June 2014|June 24, 2014|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00731627||151924|
NCT00731926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0707-028-212|Effect of Antioxidant on Endurance Performance in Healthy Men|Effect of Antioxidant on Endurance Performance in Healthy Men -Double Blind Randomized Placebo and Active Controlled Trial-||Seoul National University Hospital|No|Completed|September 2007|February 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|69|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||August 2008|August 10, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00731926||151901|
NCT00732238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4747-P|Multifaceted Treatment of Catheter-related Urinary Tract Infection|Multifaceted Treatment of Catheter-related Urinary Tract Infection||VA Office of Research and Development|No|Completed|July 2007|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|August 6, 2008||No||No|October 28, 2014|https://clinicaltrials.gov/show/NCT00732238||151877|
NCT00732875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05645|A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)|A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)||Merck Sharp & Dohme Corp.|No|Completed|August 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|75 Years|No|||April 2015|April 10, 2015|August 8, 2008|No|Yes||No|June 2, 2009|https://clinicaltrials.gov/show/NCT00732875||151829|
NCT00732888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-077|Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers|Effect of Calcium Supplements on Nilotinib Hydrochloride Pharmacokinetics in Healthy Volunteers (CAMN107DUS10T) (UPCI 08-077)||University of Pittsburgh|Yes|Completed|November 2008|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 17, 2013|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732888||151828|
NCT00720265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-05-01-KOR|A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients|A PHASE III, Randomized, Open-Label, Comparative, Multi - Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Kidney Transplant Recipients||Astellas Pharma Inc|No|Completed|February 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|19 Years|65 Years|No|||July 2008|July 18, 2008|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720265||152784|
NCT00720278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP438|A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 Compared to Placebo in Patients With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|August 2007|November 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|526|||Both|12 Years|N/A|No|||February 2010|February 19, 2010|July 21, 2008|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00720278||152783|
NCT00715962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6326-W|Efficacy and Safety of a Hospital Walking Program for Older Adults|Efficacy and Safety of a Hospital Walking Program for Older Adults||VA Office of Research and Development|Yes|Completed|January 2010|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|65 Years|N/A|No|||February 2016|February 23, 2016|July 11, 2008||No||No|January 22, 2016|https://clinicaltrials.gov/show/NCT00715962||153111|Study may not be generalizable as subjects mostly male and not demented or delirious. Study sample is small and needs to be replicated in a larger cohort.
NCT00716209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSIRB 04-116|Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers|Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers||National University Hospital, Singapore||Active, not recruiting|September 2012|||December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|To examine associations between candidate markers and patient response, toxicity and other        clinicopathological characteristics, standard descriptive statistics will be used,        according to the variable type (e.g. continuous, discrete, parametric, non-parametric).        Associations with patient outcome will be assessed by Kaplan Meier analysis and        independence examined in multivariate models by Cox proportional hazard analysis. To        discriminate prognostic and predictive significance, outcome associations of candidate        markers will be examined with respect to the treatment status of cohorts as outlined in        the "Introduction" and as performed previously.|March 2014|March 3, 2014|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716209||153092|
NCT00715975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALGLE0508|Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis|Clinical Trial of Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis Plate, and as Comparator the Product Psorex (Clobetasol Propionate).|halobetasol|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|July 2008|August 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||August 2010|August 31, 2010|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715975||153110|
NCT00716495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGI - 101H/01-2007|Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma|A Phase I/IIa, Open-Label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 Month Extended Dosing With AGI - 101H Vaccine in the Treatment of Patients With Advanced Melanoma||AGIRx Ltd.|Yes|Recruiting|June 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|75 Years|No|||July 2008|July 15, 2008|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716495||153070|
NCT00716482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00152-53|Ultrasound Elastography of Breast Lesions|Assessment of the Clinical Value of SuperSonic Shear Wave Elastography in the Ultrasonic Evaluation of Breast Lesions|BE1|SuperSonic Imagine|No|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1681|||Female|21 Years|N/A|No|Non-Probability Sample|Population will consist of women who have been referred to a public or private hospital or        clinic for a breast ultrasound evaluation. The sites are located various cities throughout        the United States and Europe.|September 2013|September 2, 2013|July 14, 2008||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00716482||153071|follow up on BI-RADS 2 lesions was not performedoperators knew the BI-RADS score of the lesion before performing SWEmore BI-RADS 3 and 4 lesions were recruited because of the study design
NCT00717704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCI-2007-528|Solid Tumors Using Ixabepilone and Dasatinib|A Phase I Study of Ixabepilone Combined With Dasatinib in Patients With Solid Tumors||Washington Hospital Center|Yes|Completed|July 2008|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2012|May 29, 2012|July 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00717704||152977|
NCT00717418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.E.S.T.O.R.E.|Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease|||Allergan||Completed|September 2004|August 2008|Actual|August 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|781|||Both|N/A|N/A|No|Non-Probability Sample|Patients can either:          1. be newly diagnosed or changing therapies and require, in the judgment of the treating             physician, a prescription treatment          2. have insufficiently controlled dry eye symptoms necessitating use of over-the-counter             treatments|December 2011|December 5, 2011|July 14, 2008||No||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00717418||152999|Due to actual dry eye treatment used, data were not interpretable by separate treatment arms. Hence, Outcomes are only reported as a single group.
NCT00717691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.003|Hallux Limitus Treated With Dynamic Splinting: A Randomized, Controlled Trial|Hallux Limitus Treated With Dynamic Splinting: A Randomized, Controlled Trial||Dynasplint Systems, Inc.|Yes|Completed|July 2008|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||April 2012|April 27, 2012|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717691||152978|
NCT00717977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-2403|Continuous Glucose Sensor Profiles in Non-Diabetic Subjects|A Study to Assess Continuous Glucose Sensor Profiles in Healthy Non-Diabetic Subjects||JDRF Artificial Pancreas Project|Yes|Completed|July 2008|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|74|||Both|8 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 30, 2010|July 16, 2008||No||No|August 2, 2010|https://clinicaltrials.gov/show/NCT00717977||152957|
NCT00730457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX125-01|Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine|A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study||VaxInnate Corporation|Yes|Completed|July 2008|June 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|56|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|August 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730457||152013|
NCT00731094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-154|The VA-STRIDE Study|Expert System-Based Feedback in Sedentary Overweight Veterans||VA Office of Research and Development|Yes|Completed|June 2010|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|April 6, 2015|August 5, 2008||No||No|September 18, 2014|https://clinicaltrials.gov/show/NCT00731094||151964|
NCT00731107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRM-001|XCEL Bladeless Trocar Versus Veress Needle: A Randomised Controlled Trial Comparing These Two Entry Techniques in Gynaecological Laparoscopic Surgery.|XCEL Bladeless Trocar Versus Veress Needle: A Randomised Controlled Trial Comparing These Two Entry Techniques in Gynaecological Laparoscopic Surgery.||Southern Health|Yes|Not yet recruiting|September 2008|December 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731107||151963|
NCT00731939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK057CC|Titan® One Touch Release Inflatable Penile Prosthesis|Titan® One Touch Release Inflatable Penile Prosthesis||Coloplast A/S|No|Completed|November 2007|April 2010|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Male|18 Years|N/A|No|||March 2014|March 7, 2014|August 7, 2008|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00731939||151900|
NCT00731328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600351|Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome|HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY||Asan Medical Center|No|Completed|April 2008|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|75 Years|No|||December 2015|December 29, 2015|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00731328||151946|
NCT00731601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LotungPAH|Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding|Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial|PPI|Lotung Poh-Ai Hospital|Yes|Completed|May 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|80 Years|No|||April 2009|April 6, 2009|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731601||151926|
NCT00732290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801068|Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine|Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine|PLATINE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2013|March 22, 2013|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732290||151873|
NCT00732537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F990225003|Inhaled Nitric Oxide by Oxygen Hood in Neonates|Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation||University of Alabama at Birmingham|No|Completed|March 1999|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|N/A|1 Week|No|||August 2008|August 8, 2008|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732537||151854|
NCT00732303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN08-129|Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer|A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129||Hoosier Cancer Research Network|Yes|Terminated|August 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 7, 2008|No|Yes|Study terminated due to slow accrual|No||https://clinicaltrials.gov/show/NCT00732303||151872|
NCT00732550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Single trocar HMO-CTIL|Comparison of Single Trocar Cholecystectomy to Standard Laparoscopic Cholecystectomy|Comparison of Single Trocar Cholecystectomy to Standard Laparoscopic Cholecystectomy||Hadassah Medical Organization|No|Active, not recruiting|July 2008|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||July 2015|July 12, 2015|August 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00732550||151853|
NCT00719667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|op 001|German Off Pump Coronary Artery Bypass in Elderly Study|German Off Pump Coronary Artery Bypass in Elderly Study|GOPCABE|German Off Pump Coronary Artery Bypass in Elderly Study Group|Yes|Completed|July 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|July 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00719667||152828|
NCT00719680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgPro20_3001|Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)|A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID)||CSL Behring||Completed|June 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|2 Years|75 Years|No|||December 2012|March 5, 2014|July 21, 2008|Yes|Yes||No|November 27, 2012|https://clinicaltrials.gov/show/NCT00719680||152827|
NCT00719693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-442|Assessment of the Effect of Food on ABT-143 Bioavailability|||AstraZeneca|No|Completed|July 2008|||September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|115|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|July 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00719693||152826|
NCT00720018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-15-NP101-006|Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers|A Phase I, Single Center, Open Label, Single-Dose, Five-Period Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) in Healthy Volunteers|NP101-006|Teva Pharmaceutical Industries|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|4|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|July 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720018||152801|
NCT00720005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-07-002|Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction|Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction||Medical University of South Carolina|No|Completed|September 2007|December 2008|Actual|December 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|20|||Both|40 Years|90 Years|No|Probability Sample|Subjects 18 years or older who had cataract surgery.|October 2010|October 1, 2010|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720005||152802|
NCT00720291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 17069|Inflammation and Treatment of Bacterial Vaginosis Near Term|Inflammation and Treatment of Bacterial Vaginosis Near Term||Medical University of South Carolina|No|Recruiting|February 2006|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|520|||Female|18 Years|45 Years|No|||January 2010|January 21, 2010|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00720291||152782|
NCT00716001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTSB|Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure|||Osaka General Medical Center|No|Not yet recruiting|July 2008|||June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|20 Years|N/A|No|||July 2008|July 11, 2008|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00716001||153108|
NCT00716248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-94|Bucillamine Study of Holding Remission After Infliximab Dose-off|The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate||Saitama Medical University||Active, not recruiting|January 2007|||December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|20 Years|N/A|No|||September 2009|January 4, 2011|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00716248||153089|
NCT00717093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051104|Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use|A Randomized, Multicenter, Double Blind, Placebo Controlled Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use||Pfizer|No|Completed|August 2008|July 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|432|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|July 15, 2008|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00717093||153024|
NCT00717106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-007|Observational Study of the Sleuth Implantable ECG Monitoring System|Observational Study of the Sleuth Implantable ECG Monitoring System|OBSERV-ECG|Transoma Medical|No|Enrolling by invitation|July 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|cardiology or primary care clinics|May 2009|May 4, 2009|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717106||153023|
NCT00717119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GES-DUM-2008/3|Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.|Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.||AstraZeneca|No|Completed|April 2008|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|6356|||Both|N/A|N/A|No|Non-Probability Sample|Data base of patients with work leave due to a sprain of ankle|July 2008|September 12, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00717119||153022|
NCT00716807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NIDCR R01 DE018526-1|Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain|Modeling Kappa Opioid Analgesic Mechanisms in Chronic Orofacial Pain Disorders||University of California, San Francisco|Yes|Terminated|January 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|46|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|July 14, 2008|Yes|Yes|Unable to recruit a sufficient number of subjects.|No|August 13, 2013|https://clinicaltrials.gov/show/NCT00716807||153046|Dr. Robert Gear led this study and maintained data on his computer. Co-investigators have spent many hours trying to locate data on the deceased investigators' computer, but could find nothing other than the minimal results data entered here.
NCT00716820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181175|Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).|Special Investigation For Gist Of Sutent (Regulatory Post Marketing Commitment Plan).||Pfizer|No|Completed|May 2008|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|480|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6181175 prescribes the SUNITINIB        MALATE(Sutent).|October 2015|October 6, 2015|July 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00716820||153045|
NCT00717444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-251-2|Healthy Activities for Prize Incentives|Healthy Activities for Prize Incentives|HAPI|University of Connecticut Health Center|No|Completed|September 2008|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|65 Years|No|||July 2013|July 23, 2013|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717444||152997|
NCT00718016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-903|Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient|Assessment of the Cyberlink Control System for Use by the ALS Patient||Drexel University|No|Terminated|December 2004|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1|||Both|18 Years|75 Years|No|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope.|March 2013|March 1, 2013|July 14, 2008||No|New protocol was developed based on preliminary results from this study.|No||https://clinicaltrials.gov/show/NCT00718016||152954|
NCT00717990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/05.35|Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment|A Phase II Study of Irinotecan, Capecitabine and Avastin in Patients With Metastatic Colorectal Cancer, Who Have Progressed After 1ST Line Therapy With Folfox/Avastin.||University Hospital of Crete|No|Terminated|April 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|72 Years|No|||October 2015|October 6, 2015|July 16, 2008||No|Poor Accrual|No||https://clinicaltrials.gov/show/NCT00717990||152956|
NCT00718328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR025005|Simvastatin For Intracerebral Hemorrhage Study|Simvastatin For Intracerebral Hemorrhage Study||Johns Hopkins University|Yes|Terminated|October 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|85 Years|No|||December 2011|December 14, 2011|July 15, 2008||No|Poor recruitment, trial terminated|No||https://clinicaltrials.gov/show/NCT00718328||152930|
NCT00730769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALGAN-03|Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients|Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients.||Hospital Universitari de Bellvitge|Yes|Completed|March 2004|July 2008|Actual|July 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730769||151989|
NCT00730743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT08017|Study on Clinical Outcome of Vascular Inflow Occlusion in Open Liver Resection|Open Liver Resection With or Without Vascular Inflow Occlusion: a Randomized Control Trial||Chinese University of Hong Kong|No|Completed|May 2008|August 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730743||151991|
NCT00730756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR111158|A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis|A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents With Irritant (Non-Allergic) Rhinitis||GlaxoSmithKline||Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|12 Years|N/A|No|||June 2014|June 12, 2014|February 27, 2008|Yes|Yes||No|October 13, 2009|https://clinicaltrials.gov/show/NCT00730756||151990|
NCT00731341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFHYS_WH_ 121207 VER 0.1|Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata|Feasibility Study of Hysteroscopic Cryoablation Treatment of Symptomatic Uterine Fibroids in Women Who do Not Desire Further Pregnancies||Galil Medical|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|30 Years|50 Years|No|||October 2011|October 25, 2011|August 7, 2008||No||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00731341||151945|Due to the nature of this feasibility study, a very small number of participants was evaluated.
NCT00731666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US001SU|Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)|Prospective, Non-randomized, Multi-center Clinical Trial to Assess the Effectiveness of the Coloplast Titan® IPP at Maintaining or Increasing Penile Length After Implantation||Coloplast A/S|No|Completed|December 2007|May 2011|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|25 Years|75 Years|No|||September 2013|September 27, 2013|August 7, 2008|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00731666||151921|
NCT00731679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFIB3007|Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)|A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome|TARGET 1|Valeant Pharmaceuticals International, Inc.|No|Completed|July 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|623|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|July 16, 2008|Yes|Yes||No|June 30, 2014|https://clinicaltrials.gov/show/NCT00731679||151920|
NCT00731965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAART|Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis|Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine|VAART|UMC Utrecht|Yes|Completed|May 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|140|||Both|4 Years|9 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00731965||151898|
NCT00731978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0045|NIRF Trial: Near-Infrared Spectroscopy for Intraoperative Restriction of Fluids Trial|Near-Infrared Spectroscopy for Intraoperative Restriction of Fluids Trial A Prospective Randomized Study of Near-infrared Spectroscopy Directed Fluid Therapy vs Standard Fluid Therapy in Patients Undergoing Open Elective Colorectal Surgery|NIRF|Hutchinson Technology Inc|Yes|Completed|September 2008|October 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|27|||Both|18 Years|N/A|No|||October 2009|October 28, 2009|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731978||151897|
NCT00732914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09072008-13772|Sequential Study to Treat Renal Cell Carcinoma|A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma||Sponsor GmbH|No|Completed|January 2009|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|272|||Both|18 Years|85 Years|No|||April 2014|April 22, 2014|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00732914||151826|
NCT00702273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05716|Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)|Follow-up Protocol to Collect the Outcome of Frozen-thawed Embryo Transfer Cycles After Cryopreservation of Embryos in Clinical Trial 38819||Merck Sharp & Dohme Corp.|No|Completed|September 2006|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|344|||Female|18 Years|36 Years|No|Probability Sample|Women from whom embryos have been cryopreserved in Base Trial P05787 (NCT00696800).|November 2014|November 18, 2014|June 18, 2008|No|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00702273||154148|
NCT00720304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5307|Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck|A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck||Case Comprehensive Cancer Center|Yes|Completed|November 2007|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|July 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720304||152781|
NCT00720317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI-08-001|Diabetic Retinopathy and Sickle Trait|Diabetic Retinopathy and Sickle Cell Trait||Medical University of South Carolina|No|Completed|May 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|||Both|N/A|N/A|No|Probability Sample|African-Americans with type II diabetes mellitus experience increased systemic vascular        morbidity and mortality, even after adjustment for socioeconomic factors.|September 2010|September 15, 2010|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720317||152780|
NCT00715988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24569|Methadone Pharmacokinetics and Cardiac Effects in Newborns|Safety and Single Dose Population Pharmacokinetics and Bioavailability of Methadone and Its Enantiomers in Newborns and Young Infants At 29-48 Weeks Post Menstrual Age||University of Utah|Yes|Active, not recruiting|October 2007|July 2014|Anticipated|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|4|||Both|29 Weeks|48 Weeks|No|||January 2014|January 11, 2014|July 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715988||153109|
NCT00716235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5185-LG-CTIL|Characterization of Executive Functions and Patterns of Eye Movements in Children With Developmental Disabilities|Characterization of Executive Functions and Patterns of Eye Movements in Children With Developmental Disabilities||Sheba Medical Center|No|Recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|160|||Both|4 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|January 2009|January 15, 2009|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716235||153090|
NCT00716261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204-08-TLV|Bio-Feedback to Improving Stability in Elderly Population|Using Bio-Feedback for Improving Stability in Walking and Everyday Activity||Tel-Aviv Sourasky Medical Center|Yes|Active, not recruiting|January 2008|November 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||||||Both|50 Years|90 Years|No|||July 2008|July 15, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716261||153088|
NCT00716508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010200|Surgical Treatment for Acute Patella Tendon Rupture|Surgical Treatment for Acute Patella Tendon Rupture: a Prospective, Randomized Study Comparing Transpatellar Suture Tunnels Method vs. Suture Anchors.||Emory University|No|Terminated|September 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|July 15, 2008||No|Our PI left our institutions as we could not longer continue.|No||https://clinicaltrials.gov/show/NCT00716508||153069|
NCT00717431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20492|A Multicenter Study of Hippocampal Electrical Stimulation (HS, in Mesial Temporal Lobe Epilepsy|Medical vs Electrical Therapy for Temporal Lobe Epilepsy|METTLE|University of Calgary|Yes|Terminated|January 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|July 15, 2008||No|insufficient enrolment|No||https://clinicaltrials.gov/show/NCT00717431||152998|
NCT00718029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK: 33132|Cerebrospinal Fluid (CSF) Raltegravir Substudy|MK: Raltegravir Concentrations in Cerebrospinal Fluid||University of California, San Diego||Enrolling by invitation|July 2008|||July 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|CSF, PBMC, plasma|Both|N/A|N/A|No|Non-Probability Sample|Participants will be selected from participants already enrolled in Merck-sponsored        Raltegravir Clinical Trials.|July 2008|July 23, 2008|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718029||152953|
NCT00718055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060096|Magnetic Resonance Imaging (MRI) Using Liverspecific Oral Contrast Agent in Metastatic Colorectal Cancer Patients|MR Skanning Med Leverspecifikt Oralt Kontraststof Sammenlignet Med CT Skanning Hos Colorectalcancer Patienter Med Levermetastaser||Copenhagen University Hospital at Herlev||Withdrawn|November 2006|||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|consekutive group of liver metastatic patients|February 2009|February 9, 2009|October 4, 2006||No||No||https://clinicaltrials.gov/show/NCT00718055||152951|
NCT00717717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACT|A Clinical Controlled Trial on the Effect of Physical Activity After Cancer Treatment (PACT)|Physical Activity After Cancer Treatment (PACT)- A Clinical Controlled Trial on the Effect of a One-year Physical Activity Program for Cancer Patients Following Cytostatic Treatment|PACT|Rigshospitalet, Denmark|No|Completed|November 2006|February 2012|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|214|||Both|18 Years|75 Years|No|||October 2015|October 26, 2015|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717717||152976|
NCT00682916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715061-2|Compare Effects of a Soluble Fiber on Weight and Blood Cholesterol|CCRC: FBCx® And Body Weight Regulation in Overweight Humans||University of California, Davis|Yes|Completed|April 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2008|October 25, 2012|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682916||155617|
NCT00715689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8630-1823|Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083|Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC126-0083 in Growth Hormone Deficient Adults (GHDA)||Novo Nordisk A/S|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|33|||Both|20 Years|65 Years|No|||March 2012|July 5, 2012|July 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715689||153132|
NCT00715702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00020|Safety Study of AZD5672 in Renally Impaired Subjects|An Open-Label, Single-Centre, Parallel Group, Phase I Study To Compare the Pharmacokinetics of AZD5672 Single Dose in Patients With Renal Impairment and Healthy Volunteers||AstraZeneca|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 28, 2009|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715702||153131|
NCT00715117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU-IRB-27793|The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease|The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease|LDN-Ped|Penn State University|Yes|Completed|July 2008|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|6 Years|17 Years|No|||May 2013|May 29, 2013|July 14, 2008|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00715117||153176|This was a pseudo-crossover trial where 6 subjects received placebo for 8 wks then were crossed over to active drug for 8 wks to increase the N treated with active drug. A smaller cohort of subjects on placebo were for safety & toxicity comparison.
NCT00715130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC-6334|Move and Moderate in Balance|Move and Moderate in Balance (MOVE'M): A TREC Worksite Health Study|MOVE'M|Fred Hutchinson Cancer Research Center|Yes|Completed|September 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 6, 2011|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715130||153175|
NCT00724685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD07/3-Y|Interest of Continuous Ropivacaine Administration Through an Elastomeric Pump (Pain Buster) for the Surgery of Latissimus Dorsi and Serratus Micro Anastomotic Flaps|Interest of Continuous Ropivacaine Administration Through an Elastomeric Pump (Pain Buster ) for the Surgery of Latissimus Dorsi and Serratus Micro Anastomotic Flaps||Nantes University Hospital||Terminated|January 2008|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|No|||February 2013|February 7, 2013|July 25, 2008||||No||https://clinicaltrials.gov/show/NCT00724685||152453|
NCT00724698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04706|Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria|Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients|Aerius|Merck Sharp & Dohme Corp.|No|Completed|October 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3011|||Both|12 Years|N/A|No|Probability Sample|Filipino patients diagnosed to have Allergic Rhinitis or Chronic Idiopathic Urticaria|January 2016|January 22, 2016|July 25, 2008||No||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00724698||152452|
NCT00724984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0403|Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma|Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma|PCYC-0403|Pharmacyclics|No|Completed|July 2008|||November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|July 28, 2008|No|Yes||No|February 27, 2014|https://clinicaltrials.gov/show/NCT00724984||152430|
NCT00724997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHB-CS01|Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers|Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers|GHBCS-01|AVIR Green Hills Biotechnology AG|Yes|Completed|March 2007|August 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2009|December 7, 2009|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724997||152429|
NCT00720577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHT-P-05-005|Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.|Two-Part,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Study to Evaluate the Effect of Simvastatin,Losartan,and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised From Patients w/PAD|LEAP|ev3|No|Completed|December 2005|August 2007|Actual|July 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|164|||Both|18 Years|90 Years|No|||July 2008|July 22, 2008|July 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720577||152760|
NCT00720889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16079A-S2|Glucose Metabolism and Sleep in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk.||University of Chicago|No|Completed|July 2008|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|21 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy non-obese community-living men and women with a parent, sibling or grandparent who        has type 2 diabetes|September 2013|September 4, 2013|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720889||152738|
NCT00721136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00011273|Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation|Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation||Johns Hopkins University|No|Completed|September 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|104|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721136||152719|
NCT00721162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13923|Study of Ramucirumab in Ovarian Cancer|A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Eli Lilly and Company|Yes|Completed|August 2008|August 2015|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|July 21, 2008|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00721162||152717|
NCT00721786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWHRC-RFM-SMK-PhVI|Internet Stop Smoking Study - Phase VI|Internet Health Research Center: Smoking, Latinos, and the Web|TC4|University of California, San Francisco|No|Completed|September 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18154|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721786||152670|
NCT00679575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-CRE-2007/1|Statins and Risk of Myocardial Infarction in Real Life in France|Statins and Risk of Myocardial Infarction in Real Life in France||AstraZeneca|Yes|Completed|March 2007|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|13171|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cases : Patients recruited by a cardiologist in hospital / Referents : Patients recruited        by a GP, community sample|December 2010|December 6, 2010|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679575||155870|
NCT00679887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-05-102-07.05|Chronic Shoulder Pain Treated by Pressures With the Thumbs on the Trigger Points|Chronic Shoulder Pain of Myofascial Origin,a Randomised Clinical Trial Using Ischemic Compression Therapy.||Guy Hains Chiropractor|Yes|Completed|September 2003|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|59|||Both|30 Years|60 Years|No|||May 2008|May 16, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679887||155846|
NCT00680719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA17023|Preventing HIV/Aids in Drug Abusing Youth|Preventing HIV/Aids in Tx-Resistant Drug-Abusing Youth||Oregon Research Institute|No|Completed|June 2004|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|15 Years|20 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680719||155782|
NCT00680979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080139|Preventing Excessive Weight Gain in Adolescent Girls at High-Risk for Adult Obesity|Preventing Excessive Weight Gain in Adolescent Girls at High-Risk for Adult Obesity||National Institutes of Health Clinical Center (CC)||Completed|May 2008|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|166|||Female|12 Years|17 Years|No|||August 2015|August 21, 2015|May 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00680979||155763|
NCT00680992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062004|Study of Denosumab in Subjects With Giant Cell Tumor of Bone|An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone||Amgen||Recruiting|June 2008|December 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|530|||Both|12 Years|N/A|No|||January 2016|January 18, 2016|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680992||155762|
NCT00681317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0850C00002|AZD6280 Multiple Ascending Dose Study|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6280 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-child Bearing Potential|MAD|AstraZeneca|No|Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681317||155737|
NCT00681603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200708015M|Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization|The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization||National Taiwan University Hospital|Yes|Completed|August 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|10 Years|70 Years|No|||August 2007|May 20, 2008|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681603||155715|
NCT00681954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7507-24725-04|Mild Pulmonary Function Changes With Transfusion|Mild Pulmonary Function Changes With Transfusion||University of California, San Francisco|No|Completed|October 2005|January 2014|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|Samples Without DNA|Biospecimens are retained for cytokine and inflammatory marker analyses.|Both|16 Years|75 Years|No|Non-Probability Sample|The study population is all adult spine surgery patients aged 16 to 75 who are scheduled        for orthopedic spine surgery at UCSF who are expected to lose at least 1000 cc of blood        during their surgery and who will receive both stored blood and cell-salvaged blood during        their surgery.|January 2015|January 14, 2015|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681954||155688|
NCT00682669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002938|Asthma and Mindfulness-Based Stress Reduction (MBSR)|Asthma and Mindfulness-Based Stress Reduction (MBSR)||University of Massachusetts, Worcester|Yes|Completed|September 2006|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|83|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 18, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682669||155635|
NCT00714389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22847|Uroflow Measurements in Healthy Volunteers|Uroflow Measurements in Healthy Volunteers||University of Rochester|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Urogynecology clinic|January 2013|January 31, 2013|July 8, 2008||No||No|January 5, 2010|https://clinicaltrials.gov/show/NCT00714389||153232|Limited number of participants
NCT00714649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIRON 2008-01|Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery|Neoadjuvant Cetuximab Monotherapy Followed by Surgery in Squamous Cell Carcinoma of Head and Neck: Phase I/II Study|CHIRON|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|July 2008|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714649||153212|
NCT00714883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-07|Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution in Native Coronary Artery Lesions|A Prospective, Multi-Center Study of the Conor Cobalt Chromium Reservoir Based Stent (NevoTM) With Sirolimus Elution in Native Coronary Artery Lesions (NEVO RES-II)|NEVO RES-II|Cordis Corporation|Yes|Terminated|June 2008|October 2012|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|July 10, 2008||No|The NEVO™ stent will not be commercialized. Cordis decided to close the study after 3 years.    This decision took the absence of safety signals into account.|No||https://clinicaltrials.gov/show/NCT00714883||153194|
NCT00715676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deltanoid 2MD-3H-2B|Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density|A Phase 2, Double-blind, Randomized, Placebo-Controlled, Daily-dose, Proof-of-concept Study of a Vitamin D Compound in Postmenopausal Women With Osteopenia|2MD-3H-2B|Deltanoid Pharmaceuticals|Yes|Completed|March 2007|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|157|||Female|55 Years|80 Years|No|||December 2009|December 7, 2009|July 14, 2008|Yes|Yes||No|September 16, 2009|https://clinicaltrials.gov/show/NCT00715676||153133|
NCT00724711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-164-0216|Safety and Efficacy Study of Switching From Epzicom to Truvada|A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen|SWIFT|Gilead Sciences|No|Completed|July 2008|April 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|July 25, 2008|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00724711||152451|
NCT00725010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04816|Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)|Temodal (TMZ) in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program||Merck Sharp & Dohme Corp.|No|Completed|April 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64|||Both|N/A|N/A|No|Probability Sample|Subjects with newly diagnosed Glioblastoma multiforme|September 2015|September 8, 2015|July 25, 2008|No|Yes||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00725010||152428|
NCT00725023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM01|Use of TPD Heat Lamp for Tennis Elbow Pain - a Randomized-controlled Trial|A Randomized Double-blind Study to Assess the Use of TDP© Heat-lamp as an Effective Therapy for Tennis Elbow Pain (Lateral Epicondylitis Pain)||Queen's University|No|Terminated|August 2008|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|65 Years|No|||September 2011|September 13, 2011|July 28, 2008||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00725023||152427|
NCT00720590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|573|Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors|Effect of HIV-1 Protease Inhibitors on Endothelial Function and Glucose Metabolism in Normal, HIV-Uninfected Subjects: Atazanavir or Lopinavir/Ritonavir or Placebo||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|November 2003|October 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|30|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2008|August 29, 2008|July 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720590||152759|
NCT00720902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB9681 (Serono-001)|Adult Growth Hormone Deficiency and Cardiovascular Risk|Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas||Columbia University|No|Terminated|February 2007|May 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|8|||Both|19 Years|65 Years|No|||May 2013|May 14, 2013|June 16, 2008|No|Yes|poor enrollment|No||https://clinicaltrials.gov/show/NCT00720902||152737|
NCT00721149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWI03130TXA|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study|AFTX|Biosense Webster, Inc.|No|Terminated|September 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|July 21, 2008|Yes|Yes|Enrollment stopped after CDRH Advisory Panel (Nov 20, 2008) recommended NAVISTAR® THERMOCOOL®    catheter approval.|No|February 8, 2013|https://clinicaltrials.gov/show/NCT00721149||152718|Because of early study termination, the study did not reach its targeted enrollment and study data analysis was not fully conducted, thus study results may not be interpretable.
NCT00721799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801758|F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients|F-18 Fluorothymidine (FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)||University of Iowa|Yes|Active, not recruiting|February 2008|June 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00721799||152669|
NCT00722085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1096165|Amniotic Fluid Sludge in Cerclage Patients as an Indicator for Increased Risk of Preterm Delivery and Neonatal Outcome.|Amniotic Fluid Sludge in Cerclage Patients as an Indicator for Increased Risk of Preterm Delivery and Neonatal Outcome.||Center For Maternal Fetal Medicine|Yes|Completed|January 2008|May 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|177|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Patients at CMFM|July 2008|July 23, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722085||152648|
NCT00679900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10480|Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties|Comparison of the Safety and Efficacy of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week, Randomized, Double-blind,Comparative, Parallel-group Study|DREAMS|Sanofi|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679900||155845|
NCT00681005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950204|A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes|A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes||National Taiwan University Hospital|No|Completed|April 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|178|||Both|N/A|N/A|No|||December 2013|December 9, 2013|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00681005||155761|
NCT00681018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3379-1|Feeding Study in Premature Infants|Feeding Study in Premature Infants||Mead Johnson Nutrition|No|Completed|September 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|143|||Both|N/A|40 Days|Accepts Healthy Volunteers|||August 2010|August 30, 2010|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00681018||155760|
NCT00681031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTV02C|Zostavax® at Minimum Release Specification Approaching Expiry|||Sanofi Pasteur MSD|No|Completed|May 2008|October 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|98|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 3, 2009|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00681031||155759|
NCT00681330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-OKA2402|Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Esophageal Cancer||Tokyo University|Yes|Completed|May 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||November 2009|November 18, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681330||155736|
NCT00681616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-4073|Study of New Catheter & Pressure Monitor System to Help Prevent Compartment Syndrome From Developing in the Injured Leg|Randomized Clinical Trial of Tissue Ultrafiltration and Pressure Monitoring for the Diagnosis and Prevention of Compartment Syndrome|TS2|Twin Star Medical, Inc.|Yes|Recruiting|January 2009|December 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|March 3, 2009|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681616||155714|
NCT00681967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0525|Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer|Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial|IRESSA&H&N|AstraZeneca|No|Completed|February 2004|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00681967||155687|
NCT00681980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278|Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)|Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil||University of Sao Paulo|No|Completed|February 2008|December 2015|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681980||155686|
NCT00682318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807069|Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers|Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers: a Randomized Double-blinded Trial on the Modulation of the Eicosanoid and Isoprostane Pathways in Healthy Subjects by Omega-3 Polyunsaturated Fatty Acids and Red Wine.||University of Pennsylvania|No|Active, not recruiting|May 2008|||November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|May 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00682318||155660|
NCT00714402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pct.ctil|Procalcitonin Level and Kinetics in Children With Bacterial Infections|Procalcitonin Level as a Prognostic Marker and Its' Kinetics in Children With Bacterial Infections||Shaare Zedek Medical Center||Completed|August 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|None Retained|whole blood|Both|N/A|16 Years|No|Non-Probability Sample|hospitalized patients at date of admission|January 2009|May 17, 2011|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714402||153231|
NCT00714415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A1-4406|Registry For Patients Treated With BeneFix In Usual Care Setting In Germany|Benefix Pharmacovigilance Evaluation||Pfizer|No|Recruiting|January 2008|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with hemophilia B|March 2016|March 16, 2016|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00714415||153230|
NCT00714896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA009253-14-DevStudy2|Interventions for Smoking Among Persons in Recovery|A Stepped-Care Intervention for Current and Former Smokers in Outpatient Chemical Dependency Treatment|INSPIRE|University of California, San Francisco|Yes|Completed|April 2007|August 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 25, 2013|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714896||153193|
NCT00715429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0255|Vitamin D for Painful Nocturnal Leg Cramps|Nocturnal Leg Cramps in the Elderly: Randomized Controlled Trial of Ergocalciferol (Vitamin D2) for a Painful and Distressing Problem||University of Wisconsin, Madison|Yes|Terminated|August 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 14, 2013|July 10, 2008||No|We exhausted potential candidates before reaching goal of 70; recruited 29, 29 completed the    study|No||https://clinicaltrials.gov/show/NCT00715429||153152|
NCT00715442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0511|Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)|Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2008|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||September 2015|September 17, 2015|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715442||153151|
NCT00715728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRWS|Efficacy of Warming Device During Surgery|Efficacy of a New Intraoperative Resistive Warming Device||Outcomes Research Consortium|No|Recruiting|June 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing major plastic surgery lasting approximately 5 hours.|June 2009|June 18, 2009|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715728||153129|
NCT00711685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95033|Topical Vancomycin in Prevention of Methicillin-Resistant Staphylococcal Related Mediastinitis in Patients Receiving Coronary Artery Bypass Graft|Topical Vancomycin in Prevention of Methicillin-Resistant Staphylococcal Related Mediastinitis in Patients Receiving Coronary Artery Bypass Graft||Far Eastern Memorial Hospital|Yes|Completed|January 2007|||December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|50|||Both|20 Years|N/A|No|||July 2008|July 8, 2008|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00711685||153439|
NCT00720603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ00607|This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.|Expanded Acess Study of Plerixafor and G-CSF for the Mobilization and Collection of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease or Multiple Myeloma|EAP|Sanofi||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2015|March 19, 2015|July 21, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00720603||152758|
NCT00720616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4481|Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.|Effects of a Fixed Low Dose Growth Hormone Therapy on Insulin Sensitivity, Metabolic Profile, Adipocyte IGF-I and Insulin Signalling, Intramyocellular and Intrahepatic Lipids, and Cortisol Metabolism in Subjects With Metabolic Syndrome.||Oregon Health and Science University|No|Withdrawn|October 2010|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|65 Years|No|||February 2013|February 18, 2013|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720616||152757|
NCT00720915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMG-2007-DODS|D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months|A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing|DODS|McMaster University|Yes|Active, not recruiting|September 2008|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|75 Years|No|||February 2016|February 25, 2016|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720915||152736|
NCT00721175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE500636|Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma|Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial||Khon Kaen University|No|Completed|November 2007|September 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|July 21, 2008||No||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00721175||152716|
NCT00725075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05695|Adjuvant Treatment With a Glycine Uptake Inhibitor in Subjects With Chronic Schizophrenia (Study 172003)(COMPLETED)(P05695)|A Multi-center, Double-blind, Flexible-dose Efficacy Trial With Org 25935 Versus Placebo as add-on Therapy in Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia Treated With a Stable Dose of a Second Generation Antipsychotic|GIANT|Merck Sharp & Dohme Corp.|No|Completed|April 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|246|||Both|18 Years|55 Years|No|||November 2014|November 3, 2014|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00725075||152423|
NCT00721487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCA-8F16|Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections|A Case Series of Investigator-Identified Fluconazole Failures: Outcome Characterization of Patients Who Fail to Respond to Fluconazole Treatment of Severe Infections Caused by Candida Albicans||CPL Associates|No|Completed|July 2008|December 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|28|||Both|4 Years|85 Years|No|Non-Probability Sample|This is a multi-center study of adult and pediatric patients hospitalized with severe        infection caused by C. albicans. An announcement of this case series collection study will        be sent to our ongoing list of primary care practitioners, hospitalists, specialists in        infectious diseases, pulmonologists, clinical pharmacists, and other investigators        throughout the USA.|July 2014|July 21, 2014|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721487||152693|
NCT00721500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0812|A Comparison of Two Daily Disposable Contact Lenses.|An Evaluation of the Lens Fit of Narafilcon A Soft Contact Lenses||Johnson & Johnson Vision Care, Inc.||Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|60 Years|No|||May 2015|May 5, 2015|July 22, 2008|Yes|Yes||No|May 7, 2010|https://clinicaltrials.gov/show/NCT00721500||152692|
NCT00722683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-0184|Evaluate Breast Masses Using a New Method of Ultrasound Contrast to Detect Abnormal Blood Flow in Breasts|Characterization of Breast Masses Using a New Method of Ultrasound Contrast Agent Imaging in 3D Mapping of Vascular Anomalies||University of Michigan|Yes|Completed|April 2001|||August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||September 2011|October 17, 2011|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722683||152603|
NCT00722696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01-2008-1|Metabolic Effects of Eccentric Endurance Training|Metabolic Effects of Eccentric Endurance Training||Vorarlberg Institute for Vascular Investigation and Treatment|No|Not yet recruiting|July 2008|November 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2008|July 24, 2008|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00722696||152602|
NCT00712972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#200808|Evaluation of the Medial Parapatellar Knee Injection Technique|Evaluation of the Effectiveness of the Medial Parapatellar Knee Injection Technique||Oklahoma State University Center for Health Sciences|Yes|Completed|July 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|5 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients enrolled in this study are those whom present to our institution for elective        knee arthroscopy. All patients scheduled to receive a knee arthroscopy scheduled through        the office of Dr. Harold Battenfield will be asked to participate in the study on the day        of their procedure as long as they do not fall into one of the exclusion criteria        categories.        The patient population often encountered in our practice includes a variety of patient        demographics. We enjoy patient referrals from numerous primary care physicians in the        community as well as through Oklahoma State University Medical Center's emergency        department. Additionally we work closely with one of the regions primary workers        compensation agencies. Because of our numerous referral resources, our patient population        is considerably varied and provides an ample mixture of patient demographics to allow us        to reasonably extrapolate and compare our study results to the general population|July 2009|July 16, 2009|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00712972||153340|
NCT00713206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2604|Prospective Study of NanoTite Implants Placed Into Fresh Sinus-Lift Augmentation Sites (VSSL)|A Prospective, Randomized-Controlled, Multicenter Study of NanoTite Implants Placed Into Fresh Sinus Lift Augmentation Sites||Biomet, Inc.|Yes|Completed|September 2006|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 9, 2008|Yes|Yes||No|August 6, 2013|https://clinicaltrials.gov/show/NCT00713206||153322|
NCT00713544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00009|A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis|A Randomised, Double Blind, Placebo Controlled, Phase IIb Dose Ranging Study (With Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate.|ESCAPE|AstraZeneca|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|373|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|July 9, 2008|Yes|Yes||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00713544||153297|Hybrid ACR, ACRn, individual ACR components, Erythrocyte sedimentation rate (ESR), Short-form-36 (SF-36), Rheumatoid Arthritis Quality of Life (RAQoL) and Patient Insight Questionnaire (PIQ) did not provide extra information so are not presented
NCT00713804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02427|Impact of Genetic Counseling for Individuals With Mental Illness|Genetic Counseling for Individuals With Mental Illness: Impact on Knowledge, Risk Perception, Perceived Control and Internalized Stigma.||University of British Columbia|No|Completed|July 2008|November 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|3||Actual|120|||Both|19 Years|N/A|No|||July 2012|July 11, 2012|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713804||153277|
NCT00714077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMS_rectal cancer_01|Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer|Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|April 2008|June 2018|Anticipated|January 2018|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|570|||Both|18 Years|75 Years|No|Probability Sample|Multicenter patients enrollment|February 2016|February 15, 2016|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714077||153256|
NCT00714662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803055R|High Flux Hemodialysis Thrice Versus Once|Effects of Different Frequencies of High-Flux Membranes on Blood Pressure, Fluid Balance, and Indices of Nutrition, Inflammation, and Dialysis Adequacy in Chronic Hemodialysis Patients - Comparisons Between Thrice vs Once Weekly||National Taiwan University Hospital|Yes|Recruiting|June 2008|March 2009|Anticipated|February 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|80 Years|No|||July 2008|July 11, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714662||153211|
NCT00715156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peach allergy|Role of Recombinants in Peach Allergy|Classification of Different Forms of Peach Allergy and the Role of Recombinant Allergens in the Diagnosis||Niguarda Hospital|No|Completed|July 2008|November 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|148|Samples With DNA|Blood sample|Both|18 Years|80 Years|No|Non-Probability Sample|Peach allergic subjects at major risk of anaphylaxis|February 2012|February 20, 2012|July 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715156||153173|
NCT00711711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNS-DORE 13DPD3-120298|Manual Lymphatic Drainage Following Total Knee Arthroplasty Surgery|Outcome of Manual Lymphatic Drainage Following Total Knee Arthroplasty Surgery||Haute Ecole Cantonale Vaudoise de Santé|No|Completed|June 2008|March 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|N/A|No|||April 2011|April 13, 2011|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00711711||153437|
NCT00715715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01-IVA6|Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients|A Pilot Study of Adefovir Dipivoxil Alone and After Prednisone Priming for the Treatment of Asian Patients With HBeAg-positive Chronic Hepatitis B||Maimonides Medical Center|No|Withdrawn|April 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|N/A|No|||April 2012|April 18, 2012|July 11, 2008||No|Withdrawn studies.|No||https://clinicaltrials.gov/show/NCT00715715||153130|
NCT00725049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2611|An Evaluation of Integration Success and Maintenance of Short Implants in Maxillas Needing Sinus Augmentation|A Prospective, Multicenter, Randomized Multicenter Study of Short Implants Used to Obviate the Need for Sinus Augmentation: an Assessment of Clinical Outcomes and Resource Allocation.|Romeo|Biomet, Inc.|Yes|Completed|February 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 28, 2008|Yes|Yes||No|August 6, 2013|https://clinicaltrials.gov/show/NCT00725049||152425|
NCT00722722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-000556|The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates|The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates||Mayo Clinic|No|Active, not recruiting|June 2008|July 2015|Anticipated|April 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722722||152600|
NCT00723619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007067|Investigation of Lungfunction Normal Values in Children and Adolescent in Germany (Spirometry, Ultrasonic Pneumography and Exhaled NO)|Investigation of Lungfunction Normal Values in Children and Adolescent in Germany|LUNOKID-Studie|Marien Hospital Wesel|No|Completed|June 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2007|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|children and adolescents from classes and kindergarten in the regions Wesel,Düsseldorf and        Hannover|July 2008|February 16, 2010|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00723619||152535|
NCT00723944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2302|A Study of the Performance of Certain Prevail Implants Used in Short Fixed Cases|A Prospective, Randomized-controlled Multicenter Study of the Osseotite Certain Lateralized Implanting Short-span Fixed Bridge Cases for Preservation of Crestal Bone|RadioCity|Biomet, Inc.|Yes|Completed|February 2005|May 2011|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 25, 2008|Yes|Yes||No|June 26, 2009|https://clinicaltrials.gov/show/NCT00723944||152510|
NCT00720681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0014|Plating of Humeral Shaft Fractures in Multiple Trauma Patients.|Plating of Acute Humeral Diaphyseal Fractures Via an Anterior Lateral Approach in Multiple Trauma Patients.|HUMERUS|Grant Medical Center|No|Enrolling by invitation|August 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated by our practice for diaphyseal fracture of the humerus after multiple        trauma.|July 2008|July 21, 2008|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720681||152752|
NCT00720694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS2005|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2006|||||N/A|N/A|N/A||||||||||||||July 22, 2008|July 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720694||152751|
NCT00720980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB5074|Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy|Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy||Henry Ford Health System|No|Completed|May 2008|July 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|6|||Both|N/A|N/A|No|Probability Sample|The investigators reported 6 cases of resistant GA that resolved after a 3-month treatment        course of monthly rifampin, ofloxacin, and minocycline (ROM) therapy. ROM therapy has been        successfully used to treat patients with paucibacillary leprosy, which has morphologic and        histologic similarities to GA.|May 2008|July 21, 2008|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00720980||152731|
NCT00723242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unknown|The Role of Dendritic Cells in Hepatitis C Infection|||University College, London||Completed|April 2002|December 2004|Actual|December 2004|Actual|N/A|Interventional|Primary Purpose: Basic Science|||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2008|July 24, 2008|July 24, 2008||||No||https://clinicaltrials.gov/show/NCT00723242||152563|
NCT00680459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB08-064|Ethanol Locks for the Treatment of Central Venous Line Infections|Ethanol Locks for the Treatment of Central Venous Line Infections||Baystate Medical Center|No|Terminated|May 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|13|||Both|6 Months|23 Years|No|||January 2014|January 29, 2014|May 16, 2008||No|inability to enroll adequate number of patients|No|September 3, 2013|https://clinicaltrials.gov/show/NCT00680459||155802|
NCT00680472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKT-500-US08|HKT-500 in Adult Patients With Shoulder Pain|Protocol HKT-500-US08: A Randomized, Multicenter, Double-blind, Placebo-controlled, Two-week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Acute Shoulder Pain|Pain|Hisamitsu Pharmaceutical Co., Inc.|Yes|Completed|April 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|368|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680472||155801|
NCT00712985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H US113|Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)|Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)|CTIBL|Milton S. Hershey Medical Center|No|Completed|September 2005|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 24, 2014|July 9, 2008|Yes|Yes||No|June 11, 2013|https://clinicaltrials.gov/show/NCT00712985||153339|18 patients were able to be enrolled in this trial & only 13 were able to be analyzed. This was an insufficient number to analyze/interpret data.
NCT00713219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-050|Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer|Phase II Study of Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity -Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer||Memorial Sloan Kettering Cancer Center||Completed|July 2008|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|July 9, 2008|Yes|Yes||No|April 7, 2015|https://clinicaltrials.gov/show/NCT00713219||153321|
NCT00713557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH|Shanghai Registry of Acute Coronary Events|Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|March 2005|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|20000|||Both|18 Years|N/A|No|Non-Probability Sample|patients admitted to the hospital with acute coronary syndrome|July 2015|July 13, 2015|July 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00713557||153296|
NCT00713570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612069R|Explore the Nature Factors Relevant to Learning-Pioneering Natural Factors That Influences Science Learning II|the Cognitive Ability Dose Associate With COMT, 5HT6, BDNF and Biological Systemic Pathway Candidate Genes in General Population||National Taiwan University Hospital|Yes|Recruiting|August 2006|||July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2800|||Both|16 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Taiwan genernal population|December 2010|December 10, 2010|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713570||153295|
NCT00713817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCL0404 Part B|A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain|A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex® in the Treatment of Subjects With Neuropathic Pain. This Will be Followed by a Randomised-withdrawal Phase (Part B) for a Subset of Patients||GW Pharmaceuticals Ltd.|No|Completed|March 2007|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|19|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|July 10, 2008||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00713817||153276|
NCT00714090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAD-001|Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression|Repetitive Transcranial Magnetic Stimulation Efficacy for Major Resistant Depression Compared or Associated With Venlafaxine : a Multicentric Study.||Club rTMS et Psychiatrie|Yes|Completed|May 2008|July 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|170|||Both|18 Years|N/A|No|||July 2013|July 18, 2013|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714090||153255|
NCT00714103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0144|8-Chloro-Adenosine in Chronic Lymphocytic Leukemia|A Phase I Study of 8-Chloro-Adenosine in Previously Treated Patients With Chronic Lymphocytic Leukemia.||M.D. Anderson Cancer Center|Yes|Active, not recruiting|June 2008|||August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|July 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00714103||153254|
NCT00714428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6237-R|Development of Quality of Life Tool for TBI|Development of a Quality of Life Tool for Deployment Related TBI|TBIQOL|VA Office of Research and Development|No|Completed|April 2009|September 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|485|None Retained|None retained|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with deployment related traumatic brain injury and clinicians who treat those        veterans.|September 2015|September 3, 2015|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714428||153229|
NCT00714909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K070104|Determination of Predictive Value of Echography Doppler Abnormalities|CAVECCAS Value of Risk Factors for Symptomatic Catheter Related Thrombosis in Patients With Breast Cancer Treated With Adjuvant Chemotherapy|CAVECCAS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2008|May 2012|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|18 Years|80 Years|No|Non-Probability Sample|All consecutive patients treated receiving adjuvant chemotherapy for localized breast        cancer in the participating centers|February 2011|February 22, 2011|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00714909||153192|
NCT00715455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG1-CLIN210|Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI|Phase 2a, Multi-Center, Open Label, Randomized, Feasibility/Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Subjects Undergoing Elective PCI After Pretreatment With Clopidogrel and Aspirin|REVERSAL-PCI|Regado Biosciences, Inc.|Yes|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|80 Years|No|||May 2013|May 29, 2013|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715455||153150|
NCT00680836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWRA-014-05F|Gulf War Digestive Health Study|Diarrhea-Predominant Irritable Bowel Syndrome in Persian Gulf Veterans||VA Office of Research and Development|No|Completed|October 2007|December 2013|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|35 Years|72 Years|No|||August 2014|August 19, 2014|May 16, 2008||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00680836||155774|
NCT00681148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009836|Botulinum Toxin Injection With Prostate Brachytherapy|Botulinum Toxin Injection With Prostate Brachytherapy: A Randomized, Placebo-controlled Study Monitoring Urinary Symptoms and PSA||Emory University|No|Withdrawn||July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||November 2013|November 19, 2013|May 19, 2008|Yes|Yes|No funding|No||https://clinicaltrials.gov/show/NCT00681148||155750|
NCT00711724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000911|Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD|Comparison of Self and Clinician Administered Rating Scales in Patients With Attention Deficit Hyperactivity Disorder (ADHD)||Massachusetts General Hospital|No|Completed|July 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|13 Years|18 Years|No|Non-Probability Sample|Adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who are        enrolled in the study Protocol 2003-P-001313: "Prevention of Cigarette Smoking in ADHD        Youth with CONCERTA."|June 2010|June 21, 2010|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00711724||153436|
NCT00711997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-07-05|Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer|Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 in Patients With Unresectable Pancreatic Cancer||BioCancell Ltd.|No|Completed|August 2009|December 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|79 Years|No|||September 2013|September 29, 2013|July 8, 2008|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00711997||153415|
NCT00723632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04588|Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)|Cost of Treatment of Chronic Hepatitis C Using Combination of Peginterferon α-2b Plus Ribavirin||Merck Sharp & Dohme Corp.|No|Completed|September 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|901|||Both|18 Years|N/A|No|Probability Sample|Participants with chronic hepatitis C treated with peginterferon alfa-2b and ribavirin at        approximately 81 sites in the Czech Republic.|October 2015|October 1, 2015|July 25, 2008|No|Yes||No|November 11, 2011|https://clinicaltrials.gov/show/NCT00723632||152534|
NCT00721227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-07-0005|Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates|Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates||Ethicon Endo-Surgery|No|Completed|April 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|21 Years|60 Years|No|||September 2010|September 1, 2010|July 9, 2008||No||No|July 21, 2010|https://clinicaltrials.gov/show/NCT00721227||152712|
NCT00721240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trial No. 25.08.2005|Investigation to Identify Predictors of Response to a Treatment With Montelukast|Investigation to Identify Predictors of Response to a Treatment With Montelukast||Marien Hospital Wesel|No|Completed|February 2006|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Years|14 Years|No|||July 2008|February 16, 2010|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721240||152711|
NCT00721253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-002|Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA|Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis Multifocal Intraocular Lens (IOL) or Acri.LISA IOL||Alcon Research|No|Completed|July 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 4, 2010|July 21, 2008|Yes|Yes||No|September 18, 2009|https://clinicaltrials.gov/show/NCT00721253||152710|
NCT00720941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108844|Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma|Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma|COMPARZ|GlaxoSmithKline|Yes|Active, not recruiting|August 2008|November 2016|Anticipated|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|927|||Both|18 Years|N/A|No|||November 2015|December 24, 2015|July 22, 2008|Yes|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00720941||152734|
NCT00721188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN05033|Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients|Single-Dose Pharmacokinetics of Venofer (Iron Sucrose Injection) in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients Receiving or Not Receiving Erythropoiesis Stimulating Agents (ESA's)||Luitpold Pharmaceuticals||Completed|January 2006|January 2010|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|12 Years|16 Years|No|||April 2015|April 28, 2015|July 21, 2008|No|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00721188||152715|
NCT00721513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 60108|Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer|Phase II Study to Evaluate the Efficacy and Toxicity of Multimodality Treatment With Induction Taxotere/Cisplatin?5-FU (TPF) Chemotherapy Followed by Concomitant Cetuximab and Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|September 2008|||September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|120 Years|No|||October 2015|October 22, 2015|July 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721513||152691|
NCT00721526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-BOG_AA016555|Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder|Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder||University of New Mexico|Yes|Completed|August 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|July 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00721526||152690|
NCT00712452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070707|Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve|Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve.|IROCHIM|Assistance Publique - Hôpitaux de Paris|No|Terminated|June 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|19|||Female|18 Years|35 Years|No|||May 2013|May 13, 2013|July 2, 2008||No|problems of insuffisant recruitment|No||https://clinicaltrials.gov/show/NCT00712452||153380|
NCT00712465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00010|An Interaction Study With Digoxin and AZD1305|A Phase I, Randomised, Open, Single-centre, Three-period Crossover Study to Evaluate the Effect of AZD1305 on the Pharmacokinetics of Digoxin After Repeated Oral Administration of AZD1305 and Digoxin to Young Healthy Male Volunteers||AstraZeneca|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00712465||153379|
NCT00680732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUGR Malaria|Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component|Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso: the Malaria Component||Institute of Tropical Medicine, Belgium|No|Completed|June 2003|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1370|||Female|15 Years|44 Years|No|||September 2010|September 12, 2010|April 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00680732||155781|
NCT00713232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705052R|The Construction of a Chinese Picture Naming Test and Its Preliminary Normative Data|The Construction of a Chinese Picture Naming Test and Its Preliminary Normative Data||National Taiwan University Hospital|No|Completed|May 2007|September 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|522|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. university student          2. normal subjects|May 2007|July 9, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713232||153320|
NCT00713245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804012R|A Long Term Follow up Study in Late-onset Pompe Disease|A Long Term Follow up Study in Late-onset Pompe Disease||National Taiwan University Hospital|No|Recruiting|May 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|individuals with acid alpha glucosidase deficiency but without obvious symptoms|December 2013|December 3, 2013|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713245||153319|
NCT00713583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA023608-01|Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence|Contingency Management Plus Levodopa/Carbidopa for Treatment of Cocaine Dependence||The University of Texas Health Science Center, Houston|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|60 Years|No|||March 2012|March 1, 2012|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713583||153294|
NCT00713830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6015|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea|GETGOAL-S|Sanofi|Yes|Completed|July 2008|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|859|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|July 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713830||153275|
NCT00714116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3227K2-1002|Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus|An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Subjects With Systemic Lupus Erythematosus||Pfizer|No|Completed|February 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||December 2012|December 20, 2012|July 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00714116||153253|
NCT00714441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DK061937-05A1|Reducing Distress and Improving Self-Care in Diabetes|Reducing Distress and Improving Self-Care in Diabetes|REDEEM|University of California, San Francisco|Yes|Completed|July 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|392|||Both|21 Years|75 Years|No|||April 2012|April 17, 2012|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714441||153228|
NCT00714454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97269358-APS|5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris|5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris: A Double-Blind, Placebo Controlled Trial||University of Miami|No|Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|39 Years|Accepts Healthy Volunteers|||July 2008|July 11, 2008|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00714454||153227|
NCT00714675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070127|Citrulline and Protein Metabolism in the Malnourished Elderly People|Citrulline Supplementation in Elderly Malnourished and Hospitalised Subjects: Effects on Protein Metabolism|CIPROAGE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|70 Years|N/A|No|||December 2013|December 29, 2013|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00714675||153210|
NCT00715182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2107|A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer|A Phase I/II Multi-center, Open Label Study of TKI258 Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC)||Novartis||Completed|July 2008|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715182||153171|
NCT00715195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051029|Improving Quality of Life of Fibromyalgia Patients|Evaluation of Improving Quality of Life of Fibromyalgia Patients Treated With a Plurifocal Program : a Controlled Study With 12 Months Monitoring.|Aquavip|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2007|April 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|115|||Both|18 Years|65 Years|No|||November 2013|December 18, 2013|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715195||153170|
NCT00680589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-052|Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response|Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response||Memorial Sloan Kettering Cancer Center||Completed|July 2006|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|7 Years|N/A|No|||March 2011|March 25, 2011|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680589||155792|
NCT00680602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/50829-8|Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial|Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient.|GCBTVF|University of Sao Paulo|No|Completed|January 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|158|||Both|18 Years|65 Years|No|||February 2009|February 13, 2009|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680602||155791|
NCT00681161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23NS056009|Autonomic Function in Obstructive Sleep Apnea|Autonomic Function in Obstructive Sleep Apnea (OSA)||Vanderbilt University|No|Active, not recruiting|March 2006|December 2012|Anticipated|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|21 Years|80 Years|No|||July 2012|July 31, 2012|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681161||155749|
NCT00722436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07120134|Tranexamic Acid for Craniofacial Surgery|Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery||University of Pittsburgh|No|Terminated|July 2008|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|6 Months|18 Years|No|||June 2013|June 25, 2013|July 23, 2008||No|Study dose changed based on recent publications|No||https://clinicaltrials.gov/show/NCT00722436||152621|
NCT00722462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OttawaFC|The Effect of Acupuncture on Pregnancy Rates in Women Undergoing Embryo Transfer|The Effect of Acupuncture on Pregnancy Rates in Women Undergoing Embryo Transfer After in Vitro Fertilization: A Prospective Randomized Sham-controlled Trial|AcuIVF|Ottawa Fertility Centre|No|Terminated|August 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 7, 2015|July 23, 2008||No|Recent abstract publication questioning the need for our study|No||https://clinicaltrials.gov/show/NCT00722462||152620|
NCT00724789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05966|Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)|An Open-label, Observational Trial to Monitor the Incidence of Congenital Malformations in Infants of Women With an Ongoing Pregnancy After Controlled Ovarian Hyperstimulation Using Puregon® (recFSH)/Orgalutran® (Ganirelix) Followed by IVF/ICSI, or a Long Protocol With a GnRH Agonist as Historical Controls.||Merck Sharp & Dohme Corp.|No|Completed|November 2000|November 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2066|||Female|18 Years|39 Years|No|Non-Probability Sample|Single site study; A total of approximately 2000 infants born after IVF or ICSI: app. 1000        infants born after ongoing pregnancies resulting from COH including Puregon/Orgalutran        treatment followed by IVF or ICSI and app. 1000 infants born after treatment with a long        agonist protocol followed by IVF or ICSI as controls.|July 2015|July 13, 2015|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724789||152445|
NCT00724802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|canavangta|Oral Glyceryl Triacetate (GTA) in Newborns With Canavan|Oral Glyceryl Triacetate (GTA) in Newborns With Canavan||Shaare Zedek Medical Center||Recruiting|March 2008|||August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|N/A|18 Months|No|||June 2011|June 20, 2011|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00724802||152444|
NCT00722098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #006-123|Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients|Melanoma Peptide-Loaded Dendritic Cell Vaccine in HLA-A*0201 Patients With Stage IV Melanoma: A Phase II Randomized Trial to Compare Vaccination With and Without Cyclophosphamide Treatment.||Baylor Research Institute|Yes|Terminated|June 2008|July 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|75 Years|No|||July 2013|July 5, 2013|July 23, 2008|Yes|Yes|Early termination due to lesser accrual, and data analysis not done.|No||https://clinicaltrials.gov/show/NCT00722098||152647|
NCT00722410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRKP-HMO-CTIL|Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia|Safety and Efficacy Study of Eradication of Carbapenem Resistant Klebsiella Pneumonia From the Gastrointestinal Tract by Probiotics.||Hadassah Medical Organization|No|Not yet recruiting|September 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||July 2008|July 24, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00722410||152623|
NCT00712998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803085R|X-Ray Computed Tomography and Blood Reactive Oxygen Species Level|Effect of X-Ray Computed Tomography Examination on the Blood Reactive Oxygen Species Level in Apparently Healthy Adults||National Taiwan University Hospital|No|Terminated|May 2008|July 2008|Anticipated|July 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|None Retained|only peripheral blood will be collected for measurement of reactive oxygen species.|Both|50 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|participants of health check program at our hospital|March 2008|May 17, 2009|July 9, 2008||No|Beacuse of unexpected administrative barriers, only 5 cases were enrolled in a year.|No||https://clinicaltrials.gov/show/NCT00712998||153338|
NCT00713843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL21128.091|Effectiveness of Manual Therapy in Patients With Neck Pain.|Effectiveness of Manual Therapy and Physical Therapy in Patients With Subacute and Chronic Non-specific Neck Pain. A Randomized Controlled Trial.|NECKproject|Radboud University|Yes|Completed|September 2008|February 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|70 Years|No|||March 2015|March 16, 2015|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00713843||153274|
NCT00714129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK078133-01|De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease|De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease|LINC|University of California, San Francisco|No|Active, not recruiting|September 2007|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714129||153252|
NCT00714467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TURSG-03-102-01 PBP|Expert System and Family Assisted Interventions for Chinese Smokers|Expert System and Family Assisted Interventions for Chinese Smokers||University of California, San Francisco|Yes|Completed|August 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1280|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 26, 2013|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714467||153226|
NCT00714142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW HS IRB 2008-0097|Renal Blood Flow Measurement With Positron Emission Tomography (PET)|Renal Blood Flow Measurement With PET||Proportional Technologies, Inc.|Yes|Recruiting|August 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 2, 2008|July 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00714142||153251|
NCT00714688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014566|A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder|A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder||Janssen-Cilag International NV|No|Completed|February 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|279|||Both|18 Years|65 Years|No|||April 2014|April 24, 2014|July 10, 2008|Yes|Yes||No|April 2, 2010|https://clinicaltrials.gov/show/NCT00714688||153209|Study was not designed to statistically compare the 54 mg with the 72 mg dose. Study medication was not titrated to the assigned dose as in clinical practice. This could have differentially affected treatment emergence of AEs and patient retention.
NCT00714922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25516|Comparison of Photorefractive Keratectomy (PRK) and Sub-Bowman's Keratomileusis (SBK)|Comparison of Photorefractive Keratectomy (PRK) and Sub-Bowman's Keratomileusis (SBK): Assessment of Visual Function and Patient Satisfaction||University of Utah|No|Completed|October 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|21 Years|80 Years|No|||September 2010|September 14, 2010|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714922||153191|
NCT00714935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-07207a|Shared Decision-making: Effects on Cardiac Risk Factor Modification Behavior|Effects of a Decision Aid for Patients With Coronary Artery Disease on Cardiac Risk Factor Modification Behavior and Health Outcomes||Oslo University Hospital|No|Completed|April 2008|March 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|363|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00714935||153190|
NCT00715169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN1202|Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease|Phase 2 A, Double-Blind, Randomized, Placebo-Controlled Trial Measuring the Effects of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease||Millennium Pharmaceuticals, Inc.|Yes|Completed|August 2005|||April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|35 Years|N/A|No|||July 2008|July 14, 2008|July 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00715169||153172|
NCT00715208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05012|Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma|A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.||Millennium Pharmaceuticals, Inc.||Completed|September 2008|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||April 2013|April 26, 2013|July 11, 2008|Yes|Yes||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00715208||153169|
NCT00680368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-164|Resident Supervision Index: Assessing Feasibility and Validity|Resident Supervision Index: Assessing Feasibility and Validity||VA Office of Research and Development|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|97|None Retained|The study did not involve a biospecimen. None was collected. None was retained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents|August 2014|April 6, 2015|May 16, 2008||No||No|August 29, 2014|https://clinicaltrials.gov/show/NCT00680368||155809|Single site study limiting generalizability of findings
NCT00680875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA98555|Intranet-based Tobacco Prevention Program for Children||Intranet|Oregon Research Institute|No|Completed|March 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3225|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||October 2011|October 13, 2011|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680875||155771|
NCT00680849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL077120|Enhancing Support for Women With Type 2 Diabetes: Follow-Up|Enhancing Support for Women With Type 2 Diabetes: Follow-Up||Oregon Research Institute|Yes|Completed|December 2003|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|227|||Female|40 Years|75 Years|No|Probability Sample|Participants in prior study: Enhancing Support for Women With Type 2 Diabetes, "The        Mediterranean Lifestyle Program."|October 2011|October 11, 2011|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680849||155773|
NCT00680862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-158|Qualitative Assessment of Implementing Routine Rapid HIV Testing|Qualitative Assessment of Implementing Routine Rapid HIV Testing||VA Office of Research and Development|Yes|Completed|June 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|key informant VA employees|September 2014|September 26, 2014|May 15, 2008||No||No|August 27, 2014|https://clinicaltrials.gov/show/NCT00680862||155772|
NCT00723281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H627-29905|Comparison of CT Angiography With Conventional Angiography and Intravascular Ultrasound in Heart Transplant Patients|Comparison of CT Angiography With Conventional Angiography and Intravascular Ultrasound in Heart Transplant Patients||University of California, San Francisco|Yes|Completed|January 2007|April 2013|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|N/A|No|Non-Probability Sample|All heart transplant patients at UCSF with known transplant coronary artery disease will        be candidates for the study|August 2014|August 15, 2014|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00723281||152560|
NCT00724490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ocdbs-Psy-120304|Unilateral Deep Brain Stimulation (DBS) of the Nucleus (Nucl.) Accumbens (Acc.) in Patients With Treatment Resistant Obsessive Compulsive Disorder (OCD)|Unilateral Deep Brain Stimulation of the Nucleus Accumbens in Patients With Treatment Resistant Obsessive Compulsive Disorder||University of Cologne|No|Completed|February 2004|February 2008|Actual|September 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|21 Years|65 Years|No|||July 2008|July 28, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724490||152468|
NCT00724503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STX0206|FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer|Randomised Comparative Study Of Folfox6m Plus Sir-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma|SIRFLOX|Sirtex Medical|Yes|Active, not recruiting|August 2006|April 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|518|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|July 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00724503||152467|
NCT00720629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15033|Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation|A Phase II Study of Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|December 2007|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|60 Years|No|||April 2014|July 10, 2014|July 21, 2008|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT00720629||152756|Study closed early during the first stage, did not proceed to the second stage comparison as planned. Investigators exercised right to close the study prematurely for lack of efficacy, although no protocol-defined end points had been met.
NCT00720928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTS-2008-1|Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease|A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease||Asan Medical Center|Yes|Recruiting|July 2008|May 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2008|July 28, 2008|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720928||152735|
NCT00731419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/2007|Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice|Distal Malignant Biliary Obstruction: A Prospective Randomised Trial Comparing Metal and Plastic Stents in Palliation of Symptomatic Jaundice||University of Cape Town|No|Recruiting|June 2007|August 2009|Anticipated|May 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2007|August 5, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00731419||151940|
NCT00731744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706003R|Generation of Dendritic Cell Precursors From Cord Blood Stem Cells|Generation of Dendritic Cell Precursors From Cord Blood Stem Cells||National Taiwan University Hospital|No|Recruiting|January 2007|December 2010|Anticipated|February 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 8, 2008|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731744||151915|
NCT00731757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 04-36|Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis|A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis||Wright State University|Yes|Withdrawn|May 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|August 6, 2008||Yes||||https://clinicaltrials.gov/show/NCT00731757||151914|
NCT00712712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589594|Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer|Evaluation of the Effectiveness of the Radiofrequency Ablation for Reducing Refractory Pain From Bone Metastases||National Cancer Institute (NCI)||Recruiting|October 2007|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Supportive Care|1||Anticipated|63|||Both|18 Years|75 Years|No|||July 2009|December 13, 2009|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00712712||153360|
NCT00713011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12716|Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients|Randomized Open-label 2-arm Parallel Design Comparator Study of the Effect of Adalat® XL® Compared to Diltiazem on Proteinuria and Blood Pressure in Patients With Diabetes and Mild to Moderate Hypertension When Used as an Add on to Avalide®|CARDINAL|Bayer|No|Withdrawn|November 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||November 2012|November 14, 2012|July 9, 2008||No|Study was stopped by sponsor prior to first patient assignment to groups due to operational    reasons.|No||https://clinicaltrials.gov/show/NCT00713011||153337|
NCT00713622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-406|Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate|A Multicentre, Randomised, Active Comparator, Parallel Group Study To Compare The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate||Eisai Inc.||Completed|June 2008|April 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00713622||153291|
NCT00713856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25339|Comparison of Conventional and Custom Photorefractive Keratectomy (PRK)|Comparison of Conventional and Custom With Iris Registration PRK Ablations: Assessment of Visual Function and Patient Satisfaction||University of Utah|No|Completed|November 2007|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|80 Years|No|||October 2010|October 15, 2010|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00713856||153273|
NCT00713869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20052092|Oocyte Cryopreservation: Evaluation of an Oocyte Freezing and Thawing Technique|Evaluation of the Affects of an Oocyte Freezing and Thawing Technique in Patients Undergoing In-vitro Fertilization (IVF)|Slow-freeze|West Coast Fertility Centers|Yes|Active, not recruiting|April 2006|April 2011|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Female|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infertility patient|January 2011|January 5, 2011|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713869||153272|
NCT00714155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15184|Outcomes and Patient Satisfaction After Colpocleisis for Pelvic Organ Prolapse|Outcomes and Patient Satisfaction After Colpocleisis for Pelvic Organ Prolapse||University of Rochester|No|Completed|July 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|48|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Urogynecology clinic|November 2011|June 13, 2012|July 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00714155||153250|
NCT00714701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0139 00-04-14-10|Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)|Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)|CAPS4|Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|June 2008|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|900|Samples With DNA|blood, pancreatic juices|Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|asymptomatic high risk patients|February 2016|February 26, 2016|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00714701||153208|
NCT00714948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-168|Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Phase II Study of Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma||Memorial Sloan Kettering Cancer Center||Terminated|July 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|July 10, 2008|Yes|Yes|Lack of accrual|No|April 14, 2015|https://clinicaltrials.gov/show/NCT00714948||153189|Early termination leading to no subjects analyzed. Only two participants were enrolled and treated on this study. Neither completed the study as they both came off due to adverse events.
NCT00714961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5133|Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction|A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy|CLARITY-TIMI28|Sanofi|Yes|Completed|February 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3491|||Both|18 Years|75 Years|No|||March 2009|March 24, 2009|July 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00714961||153188|
NCT00680355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59-1956-6-656|Bioavailability of Golden Rice Carotenoids in Humans|Bioavailability of Golden Rice Carotenoids in Humans||Tufts University|No|Completed|August 2004|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|14|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2013|June 28, 2013|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680355||155810|
NCT00680615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA118575|An Internet-Based Smokeless Tobacco Cessation Program for Teens|QuitSpit: An Internet-Based Smokeless Tobacco Cessation Program for Teens||Oregon Research Institute|No|Completed|May 2008|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1716|||Both|14 Years|25 Years|Accepts Healthy Volunteers|||September 2012|September 3, 2012|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680615||155790|
NCT00680628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-08-01A|Clot Dissolving Treatment for Blood Clots in the Lungs|Randomized Trial of Tenecteplase to Treat Severe Submassive Pulmonary Embolism||Carolinas Healthcare System|Yes|Terminated|May 2008|October 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|May 16, 2008|Yes|Yes|PI changed institution and impossible to solve problem with contract's sites|No|October 29, 2013|https://clinicaltrials.gov/show/NCT00680628||155789|
NCT00680901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF110656|LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib|A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib||GlaxoSmithKline|No|Active, not recruiting|June 2008|February 2017|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|545|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|May 15, 2008|Yes|Yes||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00680901||155769|
NCT00681512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.0040|The Effect of Berries on Lung Cancer Tumors|Berry Interventional Trial (BIT) in Resected Non-Small Cell Lung Cancer||James Graham Brown Cancer Center|Yes|Terminated|April 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|May 19, 2008||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00681512||155722|
NCT00730587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105169|Study of Body Composition Methodology in Young Children (InfantPod)|Development of a Body Composition Method for Infants and Children||Arkansas Children's Hospital Research Institute|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|Samples Without DNA|Urine will be collected from all study participants.|Both|5 Months|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children in the greater Little Rock area.|January 2016|January 6, 2016|August 6, 2008||No|This study will not be conducted. A new study is replacing this one.|No||https://clinicaltrials.gov/show/NCT00730587||152003|
NCT00730600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 02-50-30|Effect of THAI Traditional Massage on Bone Markers|Acute Changes in Biochemical Markers of Bone Resorption and Formation After THAI Traditional Massage||Mahidol University|No|Completed|June 2007|July 2008|Actual|September 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Female|20 Years|40 Years|No|||July 2008|August 6, 2008|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730600||152002|
NCT00730613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01020|Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma|Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones||City of Hope Medical Center|Yes|Completed|February 2002|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||August 2011|August 11, 2011|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730613||152001|
NCT00724204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Safety Salivarius|Safety Assessment of Lactobacillus Salivarius CECT5713 in 6 Months Old Children|Functional Evaluation of a Follow on Formula Supplemented With Lactobacillus Salivarius CECT5713|P010|Puleva Biotech|Yes|Completed|April 2006|December 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|80|||Both|6 Months|6 Months|Accepts Healthy Volunteers|||July 2008|July 28, 2008|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724204||152490|
NCT00724217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0530080135|Standard Process 21 Day Purification Program Project|The Effects of the Standard Process 21 Day Purification Program, on Serum Lipids, C-Reactive Protein, Homocystine, Blood Pressure, and Heart Rate Variability in Normal Weight and Overweight Participants Who Have Total Cholesterol Levels Over 180.|SPPP|Logan College of Chiropractic|No|Recruiting|July 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||July 2008|July 28, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724217||152489|
NCT00730886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF023|ExAblate Treatment of Uterine Fibroids for Fertility Enhancement|A Randomized Study to Evaluate the Effectiveness and Safety of ExAblate Surgery Compared With Myomectomy for the Enhancement of Fertility Following Treatment of Uterine Fibroids in Women Seeking Pregnancy||InSightec|No|Terminated|July 2008|||July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Female|21 Years|40 Years|No|||September 2012|September 13, 2012|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730886||151980|
NCT00730899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOT-001|Association Study of Gene Polymorphisms With Cardiac Performance|Observational Association Study of G Protein Polymorphisms With Cardiac Performance in Coronary Artery Disease Patients Undergoing Coronary Artery Bypass Grafting||University Hospital, Essen|No|Recruiting|May 2008|June 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|whole blood|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with coronary artery disease scheduled for coronary artery bypass grafting in the        university hospital|August 2008|August 4, 2008|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00730899||151979|
NCT00731185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03218|Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)|A Multi-center, Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety of Mometasone Furoate Nasal Spray (MFNS) in the Post Surgical Treatment of Nasal Polyposis||Merck Sharp & Dohme Corp.|No|Completed|September 2003|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|August 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00731185||151957|
NCT00731770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 29024|Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep|TITLE: Double-Blinded, Double-Dummy, Study Comparing Fluticasone-Salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence.||Penn State University|No|Not yet recruiting|September 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|45 Years|75 Years|No|||August 2008|August 8, 2008|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731770||151913|
NCT00732342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-053-2|Contingency Management Treatment Duration|Contingency Management Treatment Duration|Duration|University of Connecticut Health Center|No|Completed|February 2008|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|310|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732342||151869|
NCT00732654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00014511|The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy|The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy||Johns Hopkins University|Yes|Active, not recruiting|August 2008|June 2015|Anticipated|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|6 Years|21 Years|No|||March 2012|March 29, 2012|August 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732654||151845|
NCT00713258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-005-IM|The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)|A 24-week, International, Multi Centre, Randomised, Double-blind, Double-dummy, Parallel Group, Phase IV Clinical Trial Investigating Changes in Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) Treated With Either 100 µg PTH(1-84) Daily or 70 mg Alendronate Weekly||Nycomed|No|Terminated|April 2008|September 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Female|50 Years|N/A|No|||May 2012|May 4, 2012|July 2, 2008|No|Yes|Slow enrolment|No|July 28, 2011|https://clinicaltrials.gov/show/NCT00713258||153318|Early termination leading to small number of subjects analyzed.
NCT00713271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0570C00002|Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD3199 (a B2-agonist) Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men|AZD3199MAD|AstraZeneca|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713271||153317|
NCT00713284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTXP_US28_MYFIIRP07|Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic|A Pilot Study to Evaluate the Safety and Efficacy of Mycophenolate Sodium (Myfortic®) in Combination With Sirolimus (Rapamune®) in Stable Renal Allograft Recipients|MYFIIRP|California Pacific Medical Center Research Institute|No|Completed|May 2007|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713284||153316|
NCT00713596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009614|Study Evaluating Benefit of Using Fibrin Glue in Septorhinoplasty|The Use of Fibrin Sealant During Septorhinoplasty: Short and Long Term Benefits||Mayo Clinic|Yes|Terminated|July 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|70 Years|No|||July 2012|July 23, 2012|July 9, 2008|Yes|Yes|Lead investigator moved to a new medical center; study was stopped when he left.|No|April 19, 2012|https://clinicaltrials.gov/show/NCT00713596||153293|Study was terminated due to principal investigator leaving the institution.
NCT00713609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114570|Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne|A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl Peroxide/Clindamycin Gel and Tazarotene Cream When Used in Combination in the Treatment of Acne Vulgaris||GlaxoSmithKline|No|Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|591|||Both|12 Years|45 Years|No|||February 2012|February 23, 2012|July 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713609||153292|
NCT00683579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 071|Neurocognitive Assessment in Youth Initiating HAART|Neurocognitive Assessment in Youth Initiating HAART||Westat|Yes|Completed|December 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|220|||Both|18 Years|24 Years|No|Non-Probability Sample|English or Spanish speaking youth, 18 years 0 days to 24 years 364 days, with HIV-1        infection acquired after age 9 via behavioral means, in the following immunological and        treatment categories:          1. Early initiation of HAART and enrolled in 061 Arm A; CD4+ T cells above 350 cells/mm3             and HIV RNA >1,000 copies/ml;          2. Initiation of HAART per DHHS guidelines (standard of care) but not yet meeting             criteria. There will be 25 participants from ATN 061 preferentially enrolled into             this protocol; an additional 25 participants will be enrolled with similar biomedical             characteristics.          3. Initiation of HAART per DHHS guidelines (not part of ATN 061).          4. Meeting DHHS guidelines for initiating HAART, but not initiating due to unwillingness             or providers' expectation of poor adherence.|February 2016|February 29, 2016|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683579||155567|
NCT00683592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDA-07-DP-02|Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)|A Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD)||Forest Laboratories|No|Completed|March 2008|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|481|||Both|18 Years|70 Years|No|||October 2010|October 5, 2010|May 21, 2008|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00683592||155566|
NCT00679107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S99-01US|A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions|A Prospective, Randomized, Controlled, Multicenter, Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions||Olympus Biotech Corporation|No|Completed|June 1999|July 2005|Actual|December 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|81 Years|No|||June 2011|June 9, 2011|May 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679107||155906|
NCT00679120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070258|Oxford Partial Knee Replacement. A Randomized Clinical Trial of Three Implant Types|Oxford Partial Knee Replacement: A Randomized Clinical Trial of Three Implant Types.||University of Aarhus|Yes|Active, not recruiting|May 2009|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679120||155905|
NCT00679432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-01-02/01|(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis|Efficacy and Safety of New Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablet Formulations in Patients With Mild or Moderate, Active Ulcerative Colitis. A Multicenter, Randomized, Double-blind, Double Dummy Comparative Study Versus Placebo, With an Additional Reference Arm Evaluating Asacol® 2400 mg.||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2008|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|510|||Both|18 Years|75 Years|No|||July 2014|July 3, 2014|May 14, 2008|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00679432||155881|
NCT00679146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETOP_R_02693|Efficacy Safety of a Combination Thiocolchicoside+Ketoprofen Compared to Thiocolchicoside Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain|Efficacy and Safety of a Fixed Combination (Thiocolchicoside 8 mg + Ketoprofen 100 mg ) Compared to Thiocolchicoside 8 mg Administered Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain|TIOKET|Sanofi||Completed|April 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|334|||Both|20 Years|55 Years|No|||June 2010|June 10, 2010|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00679146||155903|
NCT00679770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-200A|Study of Different Doses of a Novel Treatment for Onychomycosis|A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 2.5%, 5.0%, and 7.5% Solutions vs. Vehicle for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail||Anacor Pharmaceuticals, Inc.|No|Completed|June 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|65 Years|No|||July 2012|July 26, 2012|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679770||155855|
NCT00680043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-15|Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA|AFX01-15: A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Undergoing Hemodialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment||Affymax|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|May 15, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00680043||155834|
NCT00680056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIOFOR|Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients|Randomised Cross-over Study to Compare the Effect of Formoterol Plus Tiotropium Versus Formoterol Monotherapy on Breathlessness, Dynamic Hyperinflation and Exercise Tolerance in Moderate-to-severe Stable COPD Patients||Federal University of São Paulo|No|Completed|November 2007|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|40 Years|N/A|No|||October 2009|January 12, 2010|May 15, 2008||No||No|January 26, 2009|https://clinicaltrials.gov/show/NCT00680056||155833|
NCT00681200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602|Evaluating Mechanisms of Blood Pressure Reduction Using Meditation in Hypertensive African Americans|Mechanisms of Meditation in Hypertension in Blacks|HMEC|Maharishi University of Management|Yes|Completed|April 2008|May 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|152|||Both|40 Years|N/A|No|||March 2013|March 11, 2013|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681200||155746|
NCT00681850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00071|OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.|OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.|Optimise|AstraZeneca|No|Completed|March 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4027|||Both|18 Years|N/A|No|Probability Sample|General Practioners|June 2010|June 1, 2010|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681850||155696|
NCT00682201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|storkhemo-08-GG|Hemodynamic Changes During Normal Pregnancy|Hemodynamic Changes During Normal Pregnancy: A Prospective Cohort Study of 100 Healthy Pregnant Women||Oslo University Hospital|Yes|Completed|August 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healty pregnant women scheduled for delivery at the Birth Clinic, Rikshospitalet        University Hospital.|June 2009|July 3, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682201||155669|
NCT00682565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 1221|Pharmacokinetics (PK) and Tolerability of Intravenous (IV) and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina|Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina||Cytokinetics||Completed|April 2008|March 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||February 2010|February 3, 2010|May 20, 2008|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00682565||155643|
NCT00731445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07010101|Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)|Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral Z-208 in Patients With Advanced Hepatocellular Carcinoma||Zeria Pharmaceutical|Yes|Completed|July 2008|June 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|43|||Both|20 Years|79 Years|No|||June 2012|June 29, 2012|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00731445||151938|
NCT00730561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo01|Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy|Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy in Patients With Diabetes Mellitus Type 2:A Randomized Controlled Trial.||Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|March 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|74 Years|No|||July 2008|August 7, 2008|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00730561||152005|
NCT00730574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-07-0070-CTIL|Examining B12 Deficiency Associated With C677T Mutation on MTHFR Gene in Terms of Commonness and Endothelial Function|Examining the Commonness of the C677T Mutation in the MTHFR Gene in Subjects With B12 Deficiency and the Influence of the B12 Deficiency Combined With the C677T Mutation on the MTHFR Gene on Endothelial Function.||Carmel Medical Center|No|Terminated|July 2008|January 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|100|||Both|20 Years|60 Years|No|||September 2014|September 8, 2014|August 7, 2008||No|completed patient rectuitment|No||https://clinicaltrials.gov/show/NCT00730574||152004|
NCT00731198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Changhai-080615|Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)|Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial||Changhai Hospital|Yes|Completed|August 2008|July 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|650|||Both|18 Years|90 Years|No|||November 2009|August 31, 2010|August 6, 2008||No||No|September 14, 2009|https://clinicaltrials.gov/show/NCT00731198||151956|
NCT00731432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-3|Herbal Periodontal Patch (THPP) for Gingival Inflammation in Diabetics|The Effect Of A Transmucosal Herbal Periodontal Patch (THPP) on Gingival Inflammation in Diabetic Patients||Izun Pharma Ltd|No|Suspended|August 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||August 2008|July 19, 2011|August 7, 2008||No|Failure to recruit|No||https://clinicaltrials.gov/show/NCT00731432||151939|
NCT00732355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SY-101|Syph-Check Syphilis Antibody Point of Care (POC) Test|One-Step Syphilis Point of Care Test for Rapid Immunoassay Screening of Antibodies to Treponema Pallidum|SyphPoc|Healthcare Providers Direct, Inc.|No|Terminated|March 2009|September 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Point of Care clinics and doctor's office that test routine patients (both male and        female), i.e. STD clinics, planned parenthood, pre-marital, blood donors, pre-employment,        and general populations from different geographic locations having varying prevalence        populations.|February 2016|February 29, 2016|August 8, 2008||No|insufficient patient populations|No||https://clinicaltrials.gov/show/NCT00732355||151868|
NCT00732368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04459|A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)|A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|May 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|16 Years|N/A|No|||May 2015|May 4, 2015|August 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732368||151867|
NCT00732966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ronit3|Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?|Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?||Assaf-Harofeh Medical Center|No|Not yet recruiting|September 2008|||September 2009|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2008|August 11, 2008|August 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00732966||151822|
NCT00713037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-162|Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas|Hypoxia-PET and IMPT Dose Painting in Patients With Chordomas: A Pilot Study||Massachusetts General Hospital|Yes|Active, not recruiting|June 2008|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00713037||153335|
NCT00713297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803060R|Implementation of a Novel Computerized Physician Order Entry System|Implementation of a Novel Computerized Physician Order Entry System to Reduce Medication Errors||National Taiwan University Hospital|No|Recruiting|September 2007|December 2009|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|80|||Both|24 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|NTUH pharmacists|June 2008|July 9, 2008|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00713297||153315|
NCT00683306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791AC00008|Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment|Multicentre, Open Label, Extension Study of Treatment With Gefitinib(IRESSA™) for Patients Completing Other Gefitinib Clinical Studies Who May Benefit From Gefitinib Treatment||AstraZeneca||Active, not recruiting|January 2005|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|533|||Both|18 Years|130 Years|No|||February 2016|February 1, 2016|May 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683306||155588|
NCT00683319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000590666|Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy|CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday||National Cancer Institute (NCI)||Active, not recruiting|April 2008|||March 2034|Anticipated|Phase 3|Observational|N/A|||Anticipated|50|||Both|N/A|2 Years|No|||June 2009|September 19, 2013|May 21, 2008||||No||https://clinicaltrials.gov/show/NCT00683319||155587|
NCT00683332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-102235|Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)|A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release)||Pfizer|No|Completed|April 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|621|||Both|N/A|N/A|No|Non-Probability Sample|All patients who receive one dose of tigecycline|June 2011|June 9, 2011|May 21, 2008|No|Yes||No|May 2, 2011|https://clinicaltrials.gov/show/NCT00683332||155586|
NCT00683618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D356FC00007|Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia|A Randomised, Double-blind Trial to Compare the Efficacy of Rosuvastatin 5 and 10 mg to Atorvastatin 10 mg in the Treatment of High Risk Patients With Hypercholesterolemia Followed by an Open Label Treatment Period With Rosuvastatin Up-titrated to the Maximum Dose of 20 mg for Those Patients Who do Not Achieve Goal||AstraZeneca|No|Completed|May 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|934|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|May 21, 2008|Yes|Yes||No|July 9, 2010|https://clinicaltrials.gov/show/NCT00683618||155565|
NCT00679133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-102|Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies|Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies||Mirati Therapeutics Inc.|No|Completed|April 2008|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|May 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679133||155904|
NCT00679172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS01.13|Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults|A Randomised, Double-Blind, Placebo-Controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC‾ssaV‾) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA.||Emergent BioSolutions|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|187|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|January 30, 2009|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679172||155901|
NCT00679159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB014|A Study of MVA85A in Healthy Children and Infants|A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth||University of Oxford|Yes|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|168|||Both|6 Months|11 Years|Accepts Healthy Volunteers|||February 2010|February 8, 2010|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00679159||155902|
NCT00679458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-06-005|Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine|A Randomized, Double-blind, Cross-over Trial Comparing the Analgesic Potency and Side Effects of Buprenorphine and Ultra-low-dose Naloxone to Buprenorphine Alone||University of California, Los Angeles|No|Completed|September 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||November 2009|January 6, 2010|May 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679458||155879|
NCT00679445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVI-006|A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy|A Feasibility Study to Evaluate the Safety And Tolerability of the EPI-RAD90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization (CNV) in Patients With Age-Related Macular Degeneration (AMD) That Have Failed Primary Anti-VEGF Therapy|ROSE|NeoVista|No|Completed|December 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|N/A|No|||July 2011|July 26, 2011|May 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679445||155880|
NCT00679783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00020|Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer|Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response||AstraZeneca|No|Active, not recruiting|July 2008|December 2016|Anticipated|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|130 Years|No|||January 2016|January 8, 2016|May 15, 2008|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00679783||155854|
NCT00680069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0022|H5N1 (Clade 2) Vaccination of Adults and Elderly|A Randomized, Double-Blinded, Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of an Inactivated Influenza Vaccine Derived From A/H5N1/Indonesia/05/05 (Clade 2) in Healthy Adults and Elderly Who Participated in a Previous A/H5N1/Vietnam/1203/2004 (Clade 1) Vaccine Study||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2008|November 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|517|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2009|October 30, 2014|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680069||155832|
NCT00680381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA15762|Transitional Treatment of Adolescents in Family Therapy|Transitional Treatment of Adolescents in Family Therapy|Transitions|Oregon Research Institute|No|Completed|January 2004|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680381||155808|
NCT00681863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.642|Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome|Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome||Boehringer Ingelheim||Terminated|May 2008|||October 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|45|||Both|6 Years|17 Years|No|||May 2014|May 7, 2014|May 19, 2008|Yes|Yes|Terminated for slow enrollment.|No|October 13, 2010|https://clinicaltrials.gov/show/NCT00681863||155695|The sponsor cancelled this trial prematurely. Thus, enrollment for 248.642 (NCT00681863) was significantly less than what was planned (120 planned vs. 45 entered). Therefore, the objectives of this study could not be fully assessed.
NCT00681551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91103|Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis|Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor||Bayer|No|Completed|February 2003|March 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|20 Years|N/A|No|||December 2014|December 11, 2014|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00681551||155719|
NCT00681876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/05.32|Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer|Phase II Study of Avastin Plus Erbitux Plus Irinotecan as 2nd Line Treatment of Locally Advanced or Metastatic Colorectal Cancer in Patients Achieving Disease Progression as Best Response After 1st Line Treatment With FOLFIRI+Avastin or XELIRI+Avastin||Hellenic Oncology Research Group|No|Terminated|April 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|72 Years|No|||February 2013|February 12, 2013|May 19, 2008||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00681876||155694|
NCT00681889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11-069|Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)|Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)||Massachusetts Eye and Ear Infirmary|No|Completed|April 2008|September 2010|Actual|September 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|May 19, 2008|Yes|Yes||No|October 10, 2012|https://clinicaltrials.gov/show/NCT00681889||155693|Further and larger studies are needed to better establish the efficacy profile of this drug and optimize its dosing and formulation.
NCT00731796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSRPFOM01|Testing of a Functional Outcome Measure for Those With Visual Field Defects|Testing of a Functional Outcome Measure for Those With Visual Field Defects|FOM|NovaVision, Inc.|No|Suspended|September 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|190|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal participants who have not suffered a stroke and do not have a visual field deficit.        Individuals who have suffered a stroke and do not have a visual field deficit. Individuals        who have suffered a stroke and do have a visual field deficit.|March 2011|March 5, 2011|August 7, 2008|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00731796||151911|
NCT00730912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05539|Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)|Protocol for Post-approval Commitment Study of Loratadine for PPK Analysis in Japanese Pediatric and Adults Patients||Merck Sharp & Dohme Corp.|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|261|||Both|3 Years|64 Years|No|||September 2015|September 1, 2015|August 6, 2008|No|Yes||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00730912||151978|
NCT00730925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.41|Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients|A Phase II Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC||Boehringer Ingelheim||Completed|June 2008|||January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|June 30, 2008||||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00730925||151977|
NCT00730938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kikuyu01|The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery|The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery||Presbyterian Church East Africa Kikuyu Hospital|No|Completed|February 2008|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|6 Months|15 Years|No|||August 2008|August 7, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730938||151976|
NCT00732394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCT06-002|A Comparative Study: Non-Surgical Spinal Decompression and Spinal Manipulative Therapy- Utilizing a Quantifiable Musculoskeletal Functional Assessment Risk Analysis Tool (MSDR®) in Patients With Chronic Low Back Pain|This is a Study is for the Purpose of Quantifying Function of the Back and Lower Extremities, and to Assess the Inter-Regional Biomechanical Relationships of the Neck, Upper Extremities, Back, and Lower Extremities in Patients Suffering From Chronic Low Back Pain.||MedAppraise, Inc.|Yes|Recruiting|August 2008|January 2010|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 8, 2008|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732394||151865|
NCT00732407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ronit2|Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)|Effect of Aliskiren on Arterial Stiffness and Platelet Function in Patients With Type 2 Diabetes Mellitus, a Comparison With Losartan||Assaf-Harofeh Medical Center|No|Not yet recruiting|September 2008|||September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2008|August 11, 2008|August 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00732407||151864|
NCT00732979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-01|Infrahepatic Inferior Vena Cava Clamping During Hepatectomy|IVC CLAMP: Infrahepatic Inferior Vena Cava Clamping During Hepatectomy - A Randomized Controlled Trial|IVC CLAMP|Heidelberg University|Yes|Completed|March 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732979||151821|
NCT00733239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA010017-02|Drug Discrimination in Methadone-Maintained Humans Study 2|Drug Discrimination in Methadone-Maintained Humans Study 2|OMDD2|University of Arkansas|Yes|Completed|August 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|65 Years|No|||April 2012|April 16, 2012|August 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733239||151801|
NCT00683007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232664|Esophageal Echo Assessment of LV Function During Acute Normovolemic Hemodilution Using Crystalloid or Hypertonic Saline|Use of Transesophageal Echocardiography to Assess Left Ventricular Performance During Acute Normovolemic Hemodilution and Randomized Replacement With Intravenous Crystalloid or Hypertonic Saline||University of California, Davis|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|17 Years|70 Years|No|||August 2012|August 1, 2012|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00683007||155610|
NCT00683033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-081-2|Contingency Management for Smoking in Substance Abusers|Contingency Management for Smoking in Substance Abusers|R21|University of Connecticut Health Center|No|Completed|May 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00683033||155608|
NCT00683631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TheraSphere - 421.03|TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)|TheraSphere HUD For Treatment of Unresectable HCC|TheraSphere|University of Louisville|Yes|Completed|January 2004|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00683631||155564|
NCT00679185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000587736|Expressive Writing in Improving Quality of Life in Patients With Breast Cancer and Lymphedema|Effects of Expressive Writing in Breast Cancer Survivors With Lymphedema||Vanderbilt University|Yes|Completed|January 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|107|||Female|21 Years|80 Years|No|||June 2012|June 20, 2012|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679185||155900|
NCT00679497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RisVac02|A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection|A Phase I Study of MVA-B in Healthy Volunteers at Low Risk of HIV Infection|RisVac02|Hospital Clinic of Barcelona|Yes|Completed|June 2008|December 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679497||155876|
NCT00679471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC27122|Brain Structure and Development in Pre-Term and Full-Term Infants|The Relationship Between Early Brain Structure and Development in Full-Term and Pre-Term Infants||Christiana Care Health Services|No|Completed|November 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|47|||Both|N/A|30 Months|Accepts Healthy Volunteers|Non-Probability Sample|Pre-term or full-term infants who are admitted to the Neonatal Intensive Care Unit (NICU)        at Christiana Hospital.|June 2013|June 3, 2013|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679471||155878|
NCT00679484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSE-866-45|Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24|A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)|OLMEBNP|Daiichi Sankyo Inc.|No|Terminated|June 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|85 Years|No|||August 2010|August 6, 2010|May 14, 2008|Yes|Yes|Lack of subject recruitment|No||https://clinicaltrials.gov/show/NCT00679484||155877|
NCT00679796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109737|The Effectiveness of Varicella Vaccination in Children in Germany|The Effectiveness of Varicella Vaccination in Children in Germany||GlaxoSmithKline|No|Completed|February 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1012|Samples With DNA|samples from skin lesions|Both|1 Year|N/A|Accepts Healthy Volunteers|Probability Sample|All children 12 months of age or older and born on or after 1 July 2003 whose parents        contact the pediatrician at the selected sites for suspected varicella after study start.        Pediatric practices in Munich and the Munich area will be initially selected.|October 2012|October 25, 2012|May 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00679796||155853|
NCT00680082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-CRE-2007/2|Observational Usage Study of Statins in Primary Care in France|Observational Usage Study of Statins in Primary Care in France||AstraZeneca|Yes|Completed|February 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2100|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients recruited by a GP, community sample|December 2010|December 1, 2010|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680082||155831|
NCT00680394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 1.2.1|Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone|Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone||Gynuity Health Projects|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|440|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|March 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00680394||155807|
NCT00680641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007RESP06|Simvastatin in Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease||University of East Anglia|No|Active, not recruiting|April 2008|February 2012|Anticipated|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|45 Years|85 Years|No|||August 2011|August 4, 2011|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680641||155788|
NCT00680888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-SER-2006/1|Adherence in Adolescents and Children Treated on Quetiapine|Adherence in Adolescents and Children Treated on Quetiapine||AstraZeneca|No|Completed|August 2005|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|7 Years|17 Years|No|Non-Probability Sample|Children and adolescents with psychosis in outpatients setting on treatment with        quetiapine started from january 2003 to june 2006|December 2010|December 7, 2010|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680888||155770|
NCT00681902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-705|Jet Lidocaine for Pain Relief During Needle Insertion in a Pediatric Emergency Department|Jet Lidocaine for Pain Relief During Needle Insertion in a Pediatric Emergency Department.||New York University School of Medicine|Yes|Completed|March 2007|July 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|5 Years|19 Years|Accepts Healthy Volunteers|||February 2009|February 4, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681902||155692|
NCT00681915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00002|AZD7325 Multiple Ascending Dose Study|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7325 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-child Bearing Potential|MAD|AstraZeneca|No|Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681915||155691|
NCT00682227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMU-01|Peptide Vaccination in Treating Patients With Esophageal Cancer|Phase I Study of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma||University of Yamanashi|Yes|Recruiting|August 2006|December 2009|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|80 Years|No|||May 2008|May 23, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682227||155667|
NCT00731809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004945|Evaluation of PET CT in the Management of Patients With Crohn's Disease.|Evaluation of PET CT in the Management of Patients With Crohn's Disease.||Rabin Medical Center|Yes|Recruiting|April 2008|October 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2008|December 22, 2008|August 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00731809||151910|
NCT00731822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZC111348|A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)|Study HZC111348, a Repeat-dose Study of GW685698/GW642444 Inhalation Powder Versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|40 Years|80 Years|No|||April 2014|April 17, 2014|August 8, 2008||Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00731822||151909|
NCT00731783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3177 38145|Staphylococcus Aureus Decolonization Study|Household vs. Individual Approach to Decolonization of Community-acquired Methicillin-resistant Staphylococcus Aureus.|SuDS|Washington University School of Medicine|Yes|Completed|July 2008|December 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Both|6 Months|21 Years|No|||April 2012|April 23, 2012|August 7, 2008||No||No|March 2, 2011|https://clinicaltrials.gov/show/NCT00731783||151912|
NCT00732095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA017136|Promoting Self-Change From Alcohol Problems: Mechanisms of Change in a Community-Based Intervention|Promoting Self-Change From Alcohol Problems: Mechanisms of Change in a Community-Based Intervention|PSC3|Nova Southeastern University|No|Completed|March 2008|August 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|283|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 13, 2010|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732095||151888|
NCT00732420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYT109091|Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors|A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in Combination With Pazopanib in Subjects With Advanced Solid Tumors||GlaxoSmithKline|No|Completed|September 2008|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|50|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732420||151863|
NCT00732433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-0227|Digital Mammography: Computer-Aided Breast Cancer Diagnosis|Digital Mammography: Computer-Aided Breast Cancer Diagnosis||University of Michigan|Yes|Active, not recruiting|June 2000|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Female|18 Years|80 Years|No|||December 2015|December 8, 2015|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732433||151862|
NCT00732069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrinolysis in Dialysis|Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis|Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 2||Vanderbilt University|Yes|Completed|August 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|19|||Both|18 Years|N/A|No|||June 2013|June 22, 2013|August 6, 2008|Yes|Yes||No|July 18, 2012|https://clinicaltrials.gov/show/NCT00732069||151890|
NCT00732082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0265|Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer|Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer||Washington University School of Medicine|No|Terminated|February 2009|September 2012|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|18|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|August 6, 2008|No|Yes|Company manufacturing study drug was unable to continue production.|No||https://clinicaltrials.gov/show/NCT00732082||151889|
NCT00732680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005015|Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome|Prospective Case Series Evaluating Short and Long Term Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome||Mayo Clinic|No|Terminated|December 2008|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||December 2013|December 30, 2013|August 8, 2008|Yes|Yes|Lead investigator moved to a new medical center; study was stopped when he left.|No|November 13, 2013|https://clinicaltrials.gov/show/NCT00732680||151844|No study data was collected in the study. The Lead investigator moved to a new medical center; the study was stopped when he left.
NCT00732693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIC/Sargent-178000-R35464|Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure|Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters||University of Edinburgh|No|Completed|February 2002|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|N/A|N/A|No|||August 2008|August 11, 2008|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00732693||151843|
NCT00732992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181165|A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies|Phase 1 Study Of Sunitinib (SU011248) In Combination With Pemetrexed In Patients With Advanced Solid Malignancies In Japan||Pfizer|No|Completed|August 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|N/A|No|||March 2011|March 15, 2011|August 8, 2008||No||No|October 27, 2010|https://clinicaltrials.gov/show/NCT00732992||151820|
NCT00733265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00015|Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers|Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers||AstraZeneca|No|Completed|February 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 2, 2010|August 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733265||151799|
NCT00733278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12670-01|Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section|Acceptability and Technical Feasibility of Insertion of a Copper IUD at Time of Elective C-section: A Pilot Study||Los Angeles Biomedical Research Institute|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|50 Years|No|||July 2014|July 16, 2014|August 11, 2008||No||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00733278||151798|Pilot study involving only seven subjects, which limits generalizability of findings.
NCT00683345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P REK NORD 60/2007|Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome|Fatigue and IL-1 Blockade in Primary Sjøgrens Syndrome||Helse Stavanger HF|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||August 2015|August 18, 2015|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00683345||155585|
NCT00683644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI Grant RT 06 10|Zinc to Treat Tinnitus|Zinc to Treat Tinnitus in the Elderly||University of Iowa||Recruiting|January 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|60 Years|N/A|No|||February 2009|February 13, 2009|May 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00683644||155563|
NCT00679198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X071029007|Improving Osteoporosis Care in High-Risk Home Health Patients|Improving Osteoporosis Care in High-Risk Home Health Patients Through a High-Intensity Intervention||University of Alabama at Birmingham|No|Completed|March 2009|August 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|667|||Both|N/A|95 Years|No|||January 2013|January 14, 2013|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679198||155899|
NCT00679211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM4374g|A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer|A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer||Genentech, Inc.||Completed|August 2008|April 2011|Actual|September 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||May 2013|May 23, 2013|May 14, 2008|Yes|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00679211||155898|
NCT00679510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21726/0204/001-0001|Rosuvastatin in Rheumatoid Arthritis (RORA)|Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis|RORA|University of Dundee|Yes|Completed|February 2004|January 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|N/A|No|||January 2016|January 7, 2016|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679510||155875|
NCT00679809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011945|Safety, Fatigue, and Continuity in the Intensive Care Unit (ICU)|Safety, Fatigue, and Continuity in the ICU: a Pragmatic Mixed-methods Study||The Hospital for Sick Children|Yes|Completed|October 2008|December 2013|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|N/A|N/A|No|Probability Sample|Residents will be on their 2-month ICU rotations at one of two university affiliated        hospitals in Toronto medical-surgical ICU. Residents in these ICU rotations are from        internal medicine, surgery, emergency medicine and anesthesia training programs, and are        supported by 2-3 critical care fellows, and 1 staff physician|May 2015|May 28, 2015|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679809||155852|
NCT00680095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-101|Cumulative Irritation Test|21-Day Cumulative Irritation Test||Anacor Pharmaceuticals, Inc.|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|May 15, 2008|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680095||155830|
NCT00680108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-102|A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution|A Double-Masked, Randomized, Placebo-Controlled, Rising-Dose Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution in Patients With Mild to Moderate Dry Eye Disease.||Merck Sharp & Dohme Corp.||Completed|September 1999|May 2000|Actual|May 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|62|||Both|N/A|N/A||||August 2015|August 26, 2015|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680108||155829|
NCT00681213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#19990664|Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation|Tacrolimus and Mycophenolate Versus Tacrolimus and Sirolimus vs. Neoral and Sirolimus Used in Combination in Cadaver and Non-HLA Identical Living Related Kidney Transplants||University of Miami|Yes|Completed|May 2000|December 2002|Actual|December 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|16 Years|N/A|No|||May 2008|May 23, 2008|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681213||155745|
NCT00681525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-367|A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe|||Abbott||Completed|April 2008|||June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 18, 2010|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00681525||155721|
NCT00681538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWSP0604|A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)|A Two-phase, Phase 3 Study of the Safety and Efficacy of Sativex, in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis: Phase A - Single-blind Response Assessment; Phase B - Double-blind, Randomised, Placebo Controlled, Parallel Group Study.||GW Pharmaceuticals Ltd.|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|572|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|May 19, 2008||No||No|March 23, 2011|https://clinicaltrials.gov/show/NCT00681538||155720|
NCT00681837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GFR-DUM-2008/1|Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France|Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France||AstraZeneca|No|Completed|May 2008|September 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2500|||Both|N/A|17 Years|Accepts Healthy Volunteers|Probability Sample|children recruited by both GPs and paediatricians|November 2008|November 17, 2008|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681837||155697|
NCT00682617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #290|Hip Osteoarthritis: Effects of Exercise Programs on Pain and Disability|Hip Osteoarthritis: Effects of Structured Exercise Programs on Pain and Long-term Disability||Oregon Health and Science University|No|Recruiting|August 2006|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 6, 2013|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682617||155639|
NCT00682877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102204a|A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old|A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time - In Subjects Over 65 Years of Age|GETOver65|The SmartPill Corporation|No|Completed|July 2007|November 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|23|||Both|65 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with gastroparesis referred to a tertiary motility center - 65 years of age and        older.|May 2008|May 22, 2008|May 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00682877||155620|
NCT00731497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AI50087_Register|Solar Water Disinfection Intervention Trial in Bolivia|Solar Water Disinfections: Randomized Intervention Trial|SODIS_Bolivia|University of California, Berkeley|No|Completed|September 2004|June 2006|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1163|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731497||151934|
NCT00731510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/WNo01/16|MEDEX Hidden Valley 2008|MEDEX Hidden Valley 2008||Medical Expeditions Ltd|No|Active, not recruiting|June 2008|December 2008|Anticipated|October 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|May 6, 2009|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731510||151933|
NCT00732381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05529|Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)||Merck Sharp & Dohme Corp.|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|351|||Both|12 Years|N/A|No|||May 2015|May 27, 2015|August 8, 2008|Yes|Yes||No|October 7, 2009|https://clinicaltrials.gov/show/NCT00732381||151866|
NCT00732446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRA-07-02|Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis|An Evaluation of the Safety and Efficacy of the Administration of a Fixed Combination of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops Compared With the Individual Administration of Moxifloxacin 0.5% and Dexamethasone 0.1% in the Treatment of Bacterial Ocular Inflammation and Infection (Blepharitis and/or Keratitis and/or Conjunctivitis)|BRA-07-02|Federal University of São Paulo|Yes|Completed|August 2008|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||August 2008|June 21, 2011|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00732446||151861|
NCT00732706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHSCHOACFNB|Femoral Nerve Block: Anatomical Insertion Point - A Prospective Randomised Double-Blind Controlled Trial|Femoral Nerve Block: Anatomical Insertion Point - A Prospective Randomised Double-Blind Controlled Trial|FNB|Sunnybrook Health Sciences Centre|No|Not yet recruiting|August 2008|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2008|August 11, 2008|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732706||151842|
NCT00733005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05528|Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)||Merck Sharp & Dohme Corp.|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|324|||Both|12 Years|N/A|No|||November 2014|November 7, 2014|August 8, 2008|Yes|Yes||No|October 13, 2009|https://clinicaltrials.gov/show/NCT00733005||151819|
NCT00733291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-008|Evaluation of Daily Disposable Lenses With Multi-Purpose Solution (MPS)|||Alcon Research|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|64|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|August 11, 2008|Yes|Yes||No|April 10, 2009|https://clinicaltrials.gov/show/NCT00733291||151797|
NCT00733304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD7111396|An Extension to Study MD7108240|An Extension Study to Protocol MD7108240: Pazopanib Eye Drops in Subjects With Neovascular Age-related Macular Degeneration||GlaxoSmithKline||Completed|June 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|99|||Both|50 Years|N/A|No|||April 2015|April 14, 2015|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733304||151796|
NCT00733655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS5|Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia|||Imperial College London||Active, not recruiting|September 2008|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Histological samples|Both|N/A|N/A|No|Non-Probability Sample|Patients with hereditary hemorrhagic telangiectasia (HHT)|August 2008|May 28, 2015|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733655||151769|
NCT00682760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meditoxin_Botox|Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm|Double-Blind, Randomized, Phase 3, Comparative Study of a New Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm||Pacific Pharmaceuticals|Yes|Completed|October 2005|August 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||May 2008|May 21, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682760||155628|
NCT00682773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12214|Enhancing the Safety of Warfarin in Nursing Homes|Enhancing the Safety of Warfarin in Nursing Homes||University of Massachusetts, Worcester|No|Completed|September 2006|September 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|26|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2011|August 2, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682773||155627|
NCT00683020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS017261|Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan|Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan|SMARTSteps|University of California, San Francisco|Yes|Completed|April 2009|April 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|362|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|May 21, 2008||No||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00683020||155609|
NCT00683657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-066|Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone|A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial To Evaluate The Efficacy And Safety Of Saxagliptin In Comparison To Placebo As Add On Treatment To Metformin XR In Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet And Exercise And A Stable Dose Of Metformin ≥1500 mg/Day||AstraZeneca|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|77 Years|No|||May 2015|May 8, 2015|May 21, 2008|Yes|Yes||No|February 19, 2010|https://clinicaltrials.gov/show/NCT00683657||155562|
NCT00679536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT 0208|Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors|Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Using Fludarabine, Busulfan, 400 cGy Total Body Irradiation, and Thymoglobulin||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Recruiting|May 2008|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|21 Years|No|||January 2014|January 22, 2014|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679536||155873|
NCT00679822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0043|The Prevalence and Risk Factors of Sleep Disordered Breathing in a Heart Failure Program|The Prevalence and Risk Factors of Sleep Disordered Breathing in a Heart Failure Program||Ohio State University|No|Completed|June 2007|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|195|||Both|18 Years|N/A|No|Non-Probability Sample|Out-patients at OSU's Heart Failure clinics|February 2014|February 12, 2014|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679822||155851|
NCT00679835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-PEDS-07-02|PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections|An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Two to Six Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection||Cubist Pharmaceuticals LLC|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|2 Years|6 Years|No|||July 2015|July 27, 2015|May 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00679835||155850|
NCT00680121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11236|High Dose Vitamin B1 to Reduce Abusive Alcohol Use|The Effectiveness of Benfotiamine in Reducing Abusive Drinking Among Family History Positive and Negative Alcoholics|B1AS|University of Kansas Medical Center|No|Completed|July 2008|April 2013|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|60 Years|No|||September 2014|September 23, 2014|May 15, 2008|Yes|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT00680121||155828|
NCT00680134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-203|Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis|An Open Label, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 1% and 5% Solutions for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail||Anacor Pharmaceuticals, Inc.|No|Completed|June 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||May 2008|May 15, 2008|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680134||155827|
NCT00680407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT003566-02|Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis|A Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Orally Administered Silymarin Preparation (Legalon®) for the Treatment of Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis|SyNCH|Madaus Inc|Yes|Completed|April 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|May 15, 2008|No|Yes||No|December 23, 2015|https://clinicaltrials.gov/show/NCT00680407||155806|
NCT00680654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11917|Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID|Interaction Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics of Single Doses of 0.5 and 1 mg of BAY 63-2521 in Patients With PAH and Stable Treatment of Sildenafil 20 mg TID in a Non-randomized, Non-blinded Design||Bayer|No|Completed|October 2008|November 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680654||155787|
NCT00680914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110808|Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A or Prevenar™ Co-administered With Hiberix™||GlaxoSmithKline||Completed|June 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|503|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||March 2011|January 12, 2012|May 16, 2008|Yes|Yes||No|May 13, 2010|https://clinicaltrials.gov/show/NCT00680914||155768|
NCT00680927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 446|Reveal® XT Performance Trial (XPECT)|Reveal® XT Performance Trial||Medtronic BRC|No|Completed|September 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|247|||Both|18 Years|N/A|No|||January 2009|June 2, 2015|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680927||155767|
NCT00681226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273/06|Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease|ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease||Bayside Health|No|Completed|January 2008|January 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|200|||Both|40 Years|85 Years|No|||April 2012|April 4, 2012|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00681226||155744|
NCT00681239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00017953|Atkins Plus KetoCal for Childhood Epilepsy|An Open-label Evaluation of KetoCal in Initial Combination With the Modified Atkins Diet for the Treatment of Intractable Childhood Epilepsy||Johns Hopkins University|No|Completed|May 2008|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|3 Years|17 Years|No|||December 2009|December 30, 2009|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681239||155743|
NCT00682890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD047298|Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)|Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)||Virginia Commonwealth University|Yes|Terminated|November 2005|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 1, 2014|May 21, 2008|Yes|Yes|Lack of recruitment|No|January 21, 2014|https://clinicaltrials.gov/show/NCT00682890||155619|study duration was relatively brief,earlier serum markers of the inflammatory process,e.g.,IL-6, were not evaluated,sample size planned was not achieved despite intensive recruitment efforts.
NCT00683176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S348.2.001|Effect of Choline Fenofibrate (SLV348) on Macular Edema|Effect of Choline Fenofibrate (SLV348) on Macular Edema Measured by Optical Coherence Tomography in Subjects With Diabetic Macular Edema - a One-year, Placebo-Controlled, Randomized Study||Abbott|No|Completed|September 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|30 Years|N/A|No|||August 2011|August 24, 2011|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00683176||155597|
NCT00683488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 069|Integrated Treatment of Marijuana Abuse for HIV+ Youth|Integrated Treatment of Alcohol and/or Marijuana Abuse for HIV-Infected Youth - Phase I||Westat|Yes|Completed|April 2008|April 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|16 Years|24 Years|No|||February 2016|February 29, 2016|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683488||155574|
NCT00732108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H48626-32352-01|Is Topiramate Effective in Treating Dizziness in Patient's With Migraine-Associated Dizziness|Efficacy of Topiramate in Patients Wih Migraine-Associated Dizziness||University of California, San Francisco|Yes|Withdrawn|November 2008|||August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||March 2015|March 4, 2015|August 7, 2008|Yes|Yes|No subjects enrolled|No||https://clinicaltrials.gov/show/NCT00732108||151887|
NCT00732459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-20080808|Clinical Trial of Electro-Acupuncture Preconditioning in Patients Underwent Heart Valve Replacement Surgery|Clinical Trial of The Myocardial Protective Effects of Repeated Electroacupuncture Preconditioning in Heart Valve Replacement Surgery||Xijing Hospital|Yes|Enrolling by invitation|January 2007|December 2008|Anticipated|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|40 Years|65 Years|No|Non-Probability Sample|This study enrolls a group of 40-65years patients who have heart valve disease who need        valve replacement.|August 2008|August 15, 2008|August 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00732459||151860|
NCT00724659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0761|Pre and Post Arthrogram Ultrasound Images of Joints|An Evaluation of Pre and Post Arthrogram Ultrasound Images of Joints: Does Arthrography Have a Role in Ultrasonography?||University of Michigan|No|Completed|September 2004|November 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|9|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00724659||152455|
NCT00732719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0500-04-U332|Compression Device Safety Study on Edema|A Phase II Non-Comparative Study Evaluating the Effects of the Compression Test Device on Oedema||ConvaTec Inc.|No|Completed|October 2004|December 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Actual|12|||Both|18 Years|80 Years|No|||August 2008|October 29, 2008|July 23, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00732719||151841|
NCT00732732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAC 08-01-165|A Controlled Trial of Plantain Powder in Infantile Diarrhea|A Controlled Trail of Plantain Powder (Green Banana) in Infantile Diarrhea.||Georgia Regents University|No|Terminated|September 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|5 Months|24 Months|No|||August 2011|August 5, 2011|August 8, 2008||No|Closed by US IRB due to lack of an adequate system for continuing review by the Indian IRB. No    subjects enrolled in US.|No||https://clinicaltrials.gov/show/NCT00732732||151840|
NCT00733018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 4.2007.515|Nutrigenomics Diet Intervention Study Comparing Effects of Western and Balanced Diet in Healthy Subjects|Health Risk Assessment of Dietary Carbohydrates in Chronic Disease Development|Foodgene|Norwegian University of Science and Technology|Yes|Completed|December 2007|July 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733018||151818|
NCT00733668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449C00009|Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder|An Open-Label, Non-Comparative, Multi-Centre, Phase II Prospective Trial to Assess the Efficacy of Quetiapine Fumarate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) in SSRI-Resistant Major Depressive Disorder.|UNIQUE|AstraZeneca|No|Completed|March 2006|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733668||151768|
NCT00721422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361023|A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.|A Phase 1, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD 0332334 In Subjects With Various Degrees Of Renal Function||Pfizer|No|Terminated|August 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 16, 2010|July 22, 2008|No|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00721422||152698|
NCT00721708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC/TUHS IRB 7737|Pharmacokinetics of Carnosine|Pharmacokinetics of Carnosine||Tufts University|No|Completed|April 2007|July 2008|Actual|October 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|4|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||December 2009|December 14, 2009|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721708||152676|
NCT00683046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11300A|T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies|T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies||University of Chicago|Yes|Completed|November 2001|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|204|||Both|N/A|100 Years|No|||October 2015|October 5, 2015|May 21, 2008||No||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00683046||155607|
NCT00683059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX207-GU07CA|Single Agent Abraxane as Second Line Therapy in Bladder Cancer|A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium||Sunnybrook Health Sciences Centre|No|Recruiting|March 2008|September 2011|Anticipated|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683059||155606|
NCT00679549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0011|The Role of Sleep Apnea in the Acute Exacerbation of Heart Failure|The Role of Sleep Apnea in the Acute Exacerbation of Heart Failure||Ohio State University|Yes|Active, not recruiting|March 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679549||155872|
NCT00679848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-EC-003|Transoral Gastric Volume Reduction as an Intervention for Weight Management|Transoral Gastric Volume Reduction as an Intervention for Weight Management (TRIM): A Non-Randomized Multicenter Feasibility Study of Subjects With Class II or Low Grade Class III Obesity|TRIM|C. R. Bard|No|Completed|May 2008|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|60 Years|No|||August 2011|August 3, 2011|May 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679848||155849|
NCT00679861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2_P4, 01EB0420|Smoking Interventions in General Medical Practices|Different Types of Proactive Smoking Interventions for General Medical Practices: An Implementation Study|PRO GP|University Medicine Greifswald|Yes|Active, not recruiting|October 2004|June 2009|Anticipated|August 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|3215|||Both|18 Years|N/A|No|||May 2008|May 16, 2008|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00679861||155848|
NCT00680147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP ID# 33546|Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers|HPV Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers||Syracuse University|No|Completed|July 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|614|||Both|11 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680147||155826|
NCT00680160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-202|Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)|An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis||Anacor Pharmaceuticals, Inc.|No|Completed|April 2006|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||May 2008|May 15, 2008|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680160||155825|
NCT00680420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4191|DNA Microarray Study of Pancreas Cancer|DNA Microarray Analysis of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsies to Discriminate Benign From Malignant Pancreatic Lesions||Oregon Health and Science University|Yes|Completed|June 2008|June 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|patients with suspected pancreas mass|March 2013|March 6, 2013|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680420||155805|
NCT00680667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS019|Clinical Trial of Trametes Versicolor in Women With Breast Cancer|Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer||Masonic Cancer Center, University of Minnesota|Yes|Completed|April 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|21 Years|75 Years|No|||November 2012|November 6, 2012|May 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00680667||155786|
NCT00681252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-MKA0201|Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Gastric Cancer||Tokyo University|Yes|Completed|May 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||November 2009|November 18, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681252||155742|
NCT00681564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLCIENCIAS 110634319239|Periodontal Infection and Endothelial Dysfunction|Impact of Periodontal Therapy on Endothelial Function||Universidad del Valle, Colombia|Yes|Completed|May 2008|January 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|102|||Both|25 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 31, 2014|May 19, 2008||No||No|November 26, 2013|https://clinicaltrials.gov/show/NCT00681564||155718|1. Patient recruitment take more time that previously expected, 2. Longer time than expected for the standardization for laboratory techniques, 3. Changes of the study personnel during patient recruitment and laboratory analysis of biological samples
NCT00682903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/24|Use of a Bearable Continuous Interstitial Glucose Monitoring Device (GuardianR) During Teaching Sessions to Functional Insulin Therapy Concept in Patients Suffering From Type 1 Diabetes: Evaluation at 6 and 12 Months|Use of a Bearable Continuous Interstitial Glucose Monitoring Device (GuardianR) During Teaching Sessions to Functional Insulin Therapy Concept in Patients Suffering From Type 1 Diabetes: Evaluation at 6 and 12 Months||Assistance Publique Hopitaux De Marseille|No|Completed|January 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|64|||Both|18 Years|70 Years|No|||August 2014|August 27, 2014|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00682903||155618|
NCT00683189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#07/063|Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy|Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy||The Cooper Health System|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|10 Years|No|||March 2011|March 18, 2011|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683189||155596|
NCT00731835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #2, Version 1|Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone|Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone? A Randomized Controlled Trial||University of Pittsburgh|Yes|Terminated|July 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|110 Years|No|||March 2016|March 10, 2016|August 6, 2008||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT00731835||151908|
NCT00731848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUP-0205-1X|Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer|An Open-label Extension Study of the Effects of Pomegranate Extract on Rising Prostate-specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer.||Roll International Corporation|Yes|Active, not recruiting|February 2008|January 2015|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||March 2012|March 15, 2012|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731848||151907|
NCT00732121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-33283|Bone Turnover in Type 2 Diabetes Patients|Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes||University of Vermont|No|Active, not recruiting|August 2008|August 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|80 Years|No|||February 2009|June 25, 2010|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732121||151886|
NCT00732134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS/LB-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||August 8, 2008|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732134||151885|
NCT00725231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL 2006-1B / ACT-2|Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP|Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly|A-CHOP-14|University of Göttingen|Yes|Recruiting|February 2008|March 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|274|||Both|61 Years|80 Years|No|||May 2012|May 4, 2012|July 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725231||152411|
NCT00732745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6507|Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction|Phase I/II Study of the Combination of Oxaliplatin / Docetaxel and ZACTIMA for the Treatment of Advanced Cancers of the Esophagus and Gastroesophageal Junction||Case Comprehensive Cancer Center|Yes|Terminated|October 2008|||June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||August 2011|August 19, 2011|August 9, 2008|Yes|Yes|Lost funding for Phase II portion of study|No||https://clinicaltrials.gov/show/NCT00732745||151839|
NCT00733031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2785C00002|Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients With Refractory Solid Malignancies||AstraZeneca|No|Terminated|August 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|August 8, 2008|No|Yes|PK results demonstrate low and variable plasma concentrations so that achieving therapeutic    concentrations is unlikely.|No||https://clinicaltrials.gov/show/NCT00733031||151817|
NCT00733317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.0.İEG.0.11.00.01- 1864|Budesonide for Emergency Treatment of Acute Wheezing in Children|Phase 4 Study of Budesonide for Emergency Treatment of Acute Wheezing in Children||Kecioren Education and Training Hospital|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|6 Months|6 Years|No|||December 2011|December 17, 2011|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733317||151795|
NCT00721721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1412|Analyzing Genetic Factors Involved in Blood Pressure Changes Due to Salt and Potassium Intake (The GenSalt Study)|Genetic Epidemiology Network of Salt Sensitivity|GenSalt|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|October 2003|||July 2005|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1906|||Both|18 Years|60 Years|No|||August 2008|August 29, 2008|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721721||152675|
NCT00721110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-454|Lidocaine and Ketamine in Abdominal Surgery|Effects of Perioperative Lidocaine and Ketamine Infusions on Acute Functional Recovery After Abdominal Hysterectomy||Outcomes Research Consortium|No|Terminated|July 2008|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|64|||Female|18 Years|75 Years|No|||August 2011|August 18, 2011|July 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00721110||152721|
NCT00683358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMSUT-PPKVEGFR12402|Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer|Phase Ⅰ/Ⅱ Trial of Human Leukocyte Antigen (HLA)-A*2402-Restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination Combined With Gemcitabine for Advanced Pancreatic Cancer||Tokyo University|Yes|Active, not recruiting|May 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||January 2009|May 6, 2009|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00683358||155584|
NCT00679224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110094|An Observational Study For Ambrisentan|A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)|VOLT|GlaxoSmithKline|No|Completed|June 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|800|||Both|N/A|N/A|No|Probability Sample|subjects who have been prescribed ambrisentan for a medically appropriate use. (See        approved product label e.g. Summary of Product Characteristics. )|November 2013|November 7, 2013|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679224||155897|
NCT00679874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiotox_001|Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)|Characterization of the Cardiotoxic Effects of Chemotherapies With Anthracyclines and Trastuzumab for Breast Cancer by Contrast-enhanced Cardiovascular Magnetic Resonance Imaging (CMR).|Cardiotox|University of Calgary|Yes|Terminated|May 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|66|||Female|N/A|N/A|No|Probability Sample|Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom        Baker Cancer Centre (TBCC) and included into the study, if they are going to receive        chemotherapy with anthracyclines and / or Trastuzumab and do not have contra-indications        for the CMR study.|October 2011|October 2, 2011|May 15, 2008||No|No subjects indentifiable|No||https://clinicaltrials.gov/show/NCT00679874||155847|
NCT00680173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB- 950419|Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients|Analysis of Gene Expression of PBMC in the Hepatitis C Virus Genotype 1b-infected Patients During Peg-interferon-α Plus Ribavirin Combination Therapy|PBMC|Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|August 2006|March 2016|Actual|March 2016|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|80 Years|No|||March 2016|March 11, 2016|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680173||155824|
NCT00680433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 07281|Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)|A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)||Northside Clinic, Australia|No|Completed|April 2008|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680433||155804|
NCT00680680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUR|Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker|Phase 4 Study of Dual Five Alpha Reductase Inhibition Combined With Alpha Blockade in Men With Refractory Urinary Retention Secondary to BPH|AUR|Franklin D. Gaylis, MD Inc.|No|Completed|May 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Male|50 Years|90 Years|No|||May 2008|May 19, 2008|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680680||155785|
NCT00681265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-001|Tear Film Break-up Time After Instillation of Artificial Tears|A Randomized, Masked Exploratory Trial Comparing the Effect of Two Different Over-the-Counter Artificial Tear Preparations on Tear Film Break-up Time||Eyeon Therapeutics, Inc.|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 24, 2012|May 19, 2008||No||No|September 16, 2012|https://clinicaltrials.gov/show/NCT00681265||155741|
NCT00680940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-60/7260|A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer|Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel and Cisplatin in Advanced Non Small Cell Lung Cancer.|NSCLC|Cadila Pharnmaceuticals|Yes|Completed|June 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|N/A|No|||August 2012|August 4, 2012|May 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00680940||155766|
NCT00681928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07006|Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy|The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer||City of Hope Medical Center|Yes|Completed|October 2007|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|72|||Female|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer patients and healthy control subjects|November 2011|November 30, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00681928||155690|
NCT00682240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pascal Study|Morphological and Functional Retinal Changes Following Retinal Photocoagulation|Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion|pascal|Medical University of Vienna||Completed|October 2007|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|64|||Both|18 Years|90 Years|No|||February 2015|February 13, 2015|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682240||155666|
NCT00682253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKF-0805|Use of Bone Scintigraphy, CT and MRI in Breast Cancer|Use og Bone Scintigraphy, CT and MRI for Detection of Metastases in Patients With Breast Cancer||University of Aarhus||Recruiting|May 2008|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Female|18 Years|80 Years|No|Probability Sample|women aged 18-80 years with suspicision of disseminated breast cancer seen at Dept. of        Oncology, Aarhus University Hospital|September 2009|September 8, 2009|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682253||155665|
NCT00683202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56/2001|Low-Dose Aspirin in in Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Treatments|The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study||University of Oulu|Yes|Completed|March 2001|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|374|||Female|18 Years|39 Years|No|||March 2001|May 22, 2008|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683202||155595|
NCT00683228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5538|Effect of Using a Structured Tobacco Cessation Education Program|Effect of Using a Structured Tobacco Cessation Education Program in Resident Training on Reducing Secondhand Smoke Exposure in Children||State University of New York - Upstate Medical University|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|N/A|15 Days|Accepts Healthy Volunteers|||November 2014|November 26, 2014|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00683228||155594|
NCT00683514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM 0259 CA 304 J1|Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer|Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study||Pierre Fabre Medicament|No|Recruiting|April 2005|||December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|75 Years|No|||May 2008|May 22, 2008|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00683514||155572|
NCT00724087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16079A-S4|Sleep Loss and Energy Metabolism in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk.||University of Chicago|No|Completed|July 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724087||152499|
NCT00732147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pramlintide-080157|Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM|Effects of Pramlintide on Endogenous Production of VLDL-Triglyceride and Glucose in the Post Prandial State in Type 2 Diabetes Mellitus||University of Maryland|No|Withdrawn|April 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 2, 2012|August 6, 2008||No|Sponsor could not fund.|No||https://clinicaltrials.gov/show/NCT00732147||151884|
NCT00720850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-LENAMA-022|Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)|Lenalidomide Maintenance Therapy in Patients With MDS or AML With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|LENAMAINT|Technische Universität Dresden|No|Terminated|April 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|July 17, 2008||No|Low recruitment, scientific rationale not applicable anymore to all patients and possible    induction of GvHD by the study drug|No||https://clinicaltrials.gov/show/NCT00720850||152740|
NCT00721097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 07/6-X|Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics|Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics|EXPRESA|Nantes University Hospital|Yes|Terminated|June 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with severe asthma|September 2013|September 27, 2013|July 7, 2008||No|Number of included patients is sufficient.|No||https://clinicaltrials.gov/show/NCT00721097||152722|
NCT00721409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481003|Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer|Phase 1/2, Open-label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Letrozole Plus Pd 0332991 (Oral Cdk 4/6 Inhibitor) And Letrozole Single Agent For The First-line Treatment Of Er Positive, Her2 Negative Advanced Breast Cancer In Postmenopausal Women||Pfizer|No|Active, not recruiting|September 2008|July 2018|Anticipated|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|177|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|July 22, 2008|Yes|Yes||No|March 4, 2015|https://clinicaltrials.gov/show/NCT00721409||152699|
NCT00721461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V930-001|A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)|Probe Study of the Tolerability of an Investigational Electroporation Device, MedPulser (Trademark) DNA Delivery System (DDS) in Healthy Adults 18 to 35 Years of Age||Merck Sharp & Dohme Corp.||Completed|July 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00721461||152695|
NCT00721474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1110|Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects|An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 5, 2009|July 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00721474||152694|
NCT00679237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-07041a (REK)|Risk Reduction in Coronary Heart Disease|Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study|SPREK!|Sorlandet Hospital HF|No|Recruiting|September 2007|December 2019|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|18 Years|79 Years|No|||April 2014|April 11, 2014|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT00679237||155896|
NCT00679523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-201 Cohort 1 & 2|Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail|An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail||Anacor Pharmaceuticals, Inc.|No|Completed|November 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||May 2008|May 16, 2008|May 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00679523||155874|
NCT00680186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.46|Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)|A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication|RE-COVER II|Boehringer Ingelheim||Completed|April 2008|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|2589|||Both|18 Years|N/A|No|||December 2013|May 8, 2014|May 16, 2008||||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00680186||155823|
NCT00680446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-SCIG-07-42|Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency|An Open-Label Study of Ig NextGen 16% Administered by Subcutaneous Infusion in Patients With Primary Immunodeficiency (PID).||CSL Limited|No|Completed|April 2008|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|3 Years|N/A|No|||June 2013|June 18, 2013|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680446||155803|
NCT00680693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003619-02|Mindfulness vs. Support Groups for Irritable Bowel Syndrome|Mindfulness for Irritable Bowel Syndrome|M-IBS|University of North Carolina, Chapel Hill|Yes|Completed|October 2006|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|N/A|No|||February 2010|November 17, 2011|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680693||155784|
NCT00680953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG162-A-J301|Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis|A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)|DIRECT|Daiichi Sankyo Inc.|Yes|Completed|May 2008|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1262|||Both|50 Years|N/A|No|||February 2015|February 19, 2015|May 16, 2008|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00680953||155765|
NCT00681278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2008/2|Retrospective Survey for Patients With Hypertension and Diabetes Mellitus|A Retrospective, Multi Centre, Non-interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Type II Diabetes Mellitus Patients With Hypertension.|CRYSTAL|AstraZeneca||Completed|April 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with type II Diabetes mellitus, receiving hypertension medication during at least        1 year.|December 2010|December 1, 2010|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681278||155740|
NCT00681291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC2007.04.01|Strattice in Repair of Inguinal Hernias|Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias|RING|LifeCell|No|Completed|April 2008|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|May 15, 2008|No|Yes||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00681291||155739|
NCT00681577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-MKA2402|Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Gastric Cancer||Tokyo University|Yes|Completed|May 2008|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|85 Years|No|||November 2009|November 18, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681577||155717|
NCT00682266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251076|High-intensity Exercise Training or Multidisciplinary Treatment in Extremely Obese Adolescents|Reducing Cardiovascular Risk Factors In Overweight Adolescents: Multidisciplinary Treatment and Intensity Controlled Interval Training||Norwegian University of Science and Technology|No|Completed|February 2004|March 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|13 Years|17 Years|No|||January 2012|January 5, 2012|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682266||155664|
NCT00682279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPT109098|A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors|A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Oral Topotecan in Combination With Lapatinib in Subjects With Advanced Solid Tumors||GlaxoSmithKline||Withdrawn|September 2008|March 2011|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|May 20, 2008|||Cancelled before enrollment|No||https://clinicaltrials.gov/show/NCT00682279||155663|
NCT00682630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-009-07|Bioequivalence of Pyronaridine Artesunate to-be-Marketed Tablet to the Clinical Trial Reference Tablet|Bioequivalence Trial of Pyronaridine:Artesunate to-be-Marketed Tablet to the Clinical Trial Reference Tablet|SP-C-009-07|Medicines for Malaria Venture|Yes|Completed|September 2007|September 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 21, 2009|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00682630||155638|
NCT00682643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFR110537|A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhinitis||GlaxoSmithKline|No|Completed|June 2008|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|550|||Both|12 Years|N/A|No|||August 2014|August 18, 2014|May 20, 2008|Yes|Yes||No|December 8, 2011|https://clinicaltrials.gov/show/NCT00682643||155637|
NCT00715143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR05-005|Post Approval Study: NOVATION Ceramic Articulation Hip System|Post Approval Study: NOVATION Ceramic Articulation Hip System A Multi-Center, Open-Label Study to Evaluate the Mid and Long-Term Safety and Effectiveness of the Exactech NOVATION Ceramic Articulation Hip System||Exactech|No|Recruiting|June 2008|December 2023|Anticipated|December 2023|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|21 Years|N/A|No|||February 2015|February 9, 2015|July 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00715143||153174|
NCT00715416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1/2006|PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents|Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial||Vienna General Hospital|No|Completed|June 2004|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|N/A|N/A|No|||January 2006|July 11, 2008|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00715416||153153|
NCT00724672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05521|A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)|Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.||Merck Sharp & Dohme Corp.|No|Withdrawn|September 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Actual|0|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from a single center at the National Institute of Rheumatology        and Physiotherapy, Budapest, the largest center for biological therapy in Hungary.        Subjects will be patients who are scheduled and permitted to receive anti-TNF-alpha        treatment due to their rheumatoid arthritis.|May 2015|May 29, 2015|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00724672||152454|
NCT00724360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD04/2-T|Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)|A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-acute Lymphoblastic Leukemia Patients.||Nantes University Hospital||Terminated|November 2006|November 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||October 2013|October 4, 2013|July 25, 2008||No|Difficulties of recruitment|No||https://clinicaltrials.gov/show/NCT00724360||152478|
NCT00724646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|End-of-Life Care|Perspectives on End-of-Life Care for Medically-Fragile Children and Young Adults|Direct Care Staff and Parents'/Legal Guardians' Perspectives on End-of-Life Care in a Long-Term Care Facility for Medically Fragile and Intellectually Disabled Pediatric and Young Adult Residents||Akron Children's Hospital|No|Completed|February 2009|June 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|125|||Both|N/A|N/A|No|Non-Probability Sample|Parents/ legal guardians and habilitation assistants|September 2009|September 14, 2009|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00724646||152456|
NCT00724932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05699|Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)|A Multi-center, Randomized, Parallel-group, Comparative, Active-controlled, Safety-assessor Blinded Trial in Adult Subjects Comparing the Efficacy and Safety of Sugammadex (SCH 900616, ORG 25969) Administered at 1-2 PTC With Neostigmine Administered at Reappearance of T2 in Subjects Undergoing Laparoscopic Cholecystectomy or Appendectomy Under Propofol Anesthesia||Merck Sharp & Dohme Corp.|Yes|Completed|July 2008|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|July 28, 2008||No||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00724932||152434|
NCT00724945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1485CK|Comparison of Two Soft Bifocal Contact Lenses|||Johnson & Johnson Vision Care, Inc.||Completed|July 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|113|||Both|35 Years|70 Years|No|||May 2015|May 5, 2015|July 25, 2008|Yes|Yes||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00724945||152433|
NCT00724958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04052|Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)|Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension||Merck Sharp & Dohme Corp.|No|Completed|December 2004|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|348|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with active luminal and/or fistulizing CD who are treated with Remicade in the        hospital and non-hospital setting.|October 2015|October 1, 2015|July 25, 2008|No|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00724958||152432|
NCT00724971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K3-1104|Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab|A Phase 1 Study Of Inotuzumab Ozogamicin (CMC-544) Administered In Combination With Rituximab In Subjects With B-Cell Non-Hodgkin's Lymphoma||Pfizer|Yes|Completed|July 2008|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|74 Years|No|||February 2013|February 14, 2013|July 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00724971||152431|
NCT00725244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|556/05|Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias|A Randomized Prospective Study of Endoscopy Bipolar Eletrocoagulation and Argon Plasma Coagulation of Chronic Rectal Bleeding From Radiation Telangiectasias||Federal University of São Paulo|Yes|Completed|May 2005|July 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|88 Years|No|||July 2008|October 16, 2008|July 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00725244||152410|
NCT00720876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07195|Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma|A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma||City of Hope Medical Center|Yes|Active, not recruiting|July 2008|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|July 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720876||152739|
NCT00721123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA18695|A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis|Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822||Hoffmann-La Roche||Completed|August 2005|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|538|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|July 22, 2008|Yes|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00721123||152720|
NCT00721773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDRRF|Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients|Effects of Benazepril,Valsartan or Combination of Both on Residual Renal Function in Peritoneal Dialysis Patients||Sun Yat-sen University|Yes|Completed|September 2008|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Both|20 Years|75 Years|No|||May 2015|May 18, 2015|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00721773||152671|
NCT00679250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAY09|To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis|A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis||University of Dundee|No|Completed|November 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|16 Years|75 Years|No|||May 2008|May 15, 2008|May 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00679250||155895|
NCT00680199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB # 20615|Information Processing at Sleep Onset and During Sleep in Patients With Insomnia|Information Processing at Sleep Onset and During Sleep in Patients With Insomnia|COTE|University of Rochester|No|Completed|June 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|25 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Community Sample|October 2010|October 26, 2015|May 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00680199||155822|
NCT00680706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-059|Thiamine and Acute Decompensated Heart Failure: Pilot Study|Targeting Myocardial Energy Metabolism for the Treatment of Acute Heart Failure: The Effect of Thiamine on Biochemical, Electrocardiographic and Respiratory Parameters in Hospitalized Patients.||Baystate Medical Center|No|Completed|January 2008|June 2012|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|May 16, 2008||No||No|July 27, 2012|https://clinicaltrials.gov/show/NCT00680706||155783|
NCT00680966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA021357|Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD|Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD|Sequencing|Oregon Research Institute|No|Completed|January 2008|June 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|13 Years|17 Years|No|||March 2014|March 10, 2014|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00680966||155764|
NCT00681304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-0728|Ultrasound Based Localization of Lumpectomy Bed in Anatomical Coordinate System|"Ultrasound Based Localization of Lumpectomy Bed in Anatomical Coordinate System" (J-0728)||Sidney Kimmel Comprehensive Cancer Center|No|Completed|August 2007|July 2012|Actual|June 2012|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Non-Probability Sample|Women with breast cancer, who are status post lumpectomy and are scheduled to have        radiation therapy, will be eligible.|November 2012|November 15, 2012|May 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00681304||155738|
NCT00681590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070018|Safety of Vitamin D Supplementation in Older Persons|Safety of Vitamin D Supplementation in the Elderly||University of Miami|Yes|Completed|April 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|105|||Both|65 Years|95 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|May 15, 2008||No||No|February 5, 2016|https://clinicaltrials.gov/show/NCT00681590||155716|
NCT00681941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCARB00105|An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis|An Open Label, Dose Titration of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis||Sanofi||Completed|January 2006|March 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|May 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00681941||155689|
NCT00682292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHLillle|Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk|Multicenter Randomized Study to Compare Induction Therapy With Polyclonal Antithymocytes Globulins (ATG) Versus Monoclonal Anti-IL2R Antibody (Daclizumab) in a Triple Drug Regimen in Renal Transplant Recipients With High Immunological Risk.|TAXI|University Hospital, Lille|Yes|Completed|May 2001|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|65 Years|No|||February 2004|May 21, 2008|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00682292||155662|
NCT00682305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TreoALL|Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)|Allogeneic Stem Cell Transplantation With Treosulfan, VP-16 and Cyclophosphamide for Patients With Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-containing Conditioning Regimen: A Phase II-study||Universitätsklinikum Hamburg-Eppendorf|No|Completed|March 2007|August 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||May 2015|May 12, 2015|May 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00682305||155661|
NCT00682656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPSH/CPqRR 21/2006|Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis|Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis|PCL01|Oswaldo Cruz Foundation|No|Terminated|June 2008|September 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|14 Years|65 Years|No|||July 2011|October 16, 2014|May 20, 2008||No|Efficacy issues on test arm|No||https://clinicaltrials.gov/show/NCT00682656||155636|
NCT00740532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-01/2007|Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients|Observational Study Assessing Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients||Istituto Clinico Humanitas|No|Completed|October 2007|August 2010|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|11|Samples With DNA|Paraffine embedded tumor sections|Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients treated with Herceptin-based therapy|September 2010|September 1, 2010|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740532||151248|
NCT00741728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-39|Heart Rate, Baroreflex Sensitivity and Cardiovascular Morbidity and Mortality in the Population|Heart Rate, Baroreflex Sensitivity and Cardiovascular Morbidity and Mortality in the Population. The Paris Prospective Study III|PPSIII|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|June 2008|December 2019|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Blood samples and DNA taken from fresh blood|Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult men and women affiliated to the public French Health Insurance System who benefited        from a free general health check up paid by the French Health Insurance System|December 2011|December 8, 2011|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741728||151156|
NCT00740363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JANUVIA-08|Sitagliptin in Renal Transplant Recipients|The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08||University of Oslo School of Pharmacy|No|Completed|September 2008|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740363||151261|
NCT00743678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-04-018|Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis|A Phase II Study of Neoadjuvant FOLFOX6 Plus Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis||Samsung Medical Center|No|Completed|June 2008|June 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743678||151007|
NCT00743691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNL 50124|Impact Study of Community Based Treatment of Neonatal Infection by Health Extension Workers on Neonatal Mortality|Impact of Strengthened Health Extension Program and Community Based Treatment of Neonatal Infections on Neonatal Mortality in Oromia and South Nation and Nationalities & People Region(SNNPR), Ethiopia||Save the Children|Yes|Not yet recruiting|April 2009|October 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|660000|||Both|N/A|4 Weeks|No|||February 2009|February 5, 2009|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743691||151006|
NCT00740922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004156|Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers|A Multicenter Clinical Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 1999|April 2001|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|563|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic full thickness diabetic ulcers who were treated with becaplermin or        placebo gel in two previous studies|April 2010|June 6, 2011|August 21, 2008||||||https://clinicaltrials.gov/show/NCT00740922||151218|
NCT00740038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13782|Support for People Undergoing Chemotherapy|Study of Stress Management and Exercise Intervention During Cancer Chemotherapy||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|August 2006|August 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|471|||Both|18 Years|N/A|No|||August 2011|September 11, 2012|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740038||151286|
NCT00741481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|earlyPETmCRC|PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.|Evaluation of Prognostic and Predictive Value of PETSCAn in ColoRectal Cancer (CRC)|earlyPETmCRC|Jules Bordet Institute|No|Completed|June 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients >18 yrs old advanced evaluable colorectal cancer beginning a new line of        chemotherapy|February 2011|February 23, 2011|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741481||151175|
NCT00741494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008PICSI03|Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI)|Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI) for Patients Having a Low Versus High Proportion of Hyaluronan Binding Sperm (HBA)||Biocoat|No|Completed|August 2008|||December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Actual|801|||Both|18 Years|40 Years|No|||December 2010|December 26, 2010|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741494||151174|
NCT00740558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051934|Heart Rate Variability Modulation Following a Manipulation in Pain Free Patients Versus Patients in Pain|Heart Rate Variability Modulation Following a Manipulation in Pain Free Patients Versus Patients in Pain||Universite du Quebec a Montreal|Yes|Completed|July 2004|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|53|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 26, 2008|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740558||151246|
NCT00740571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82310-98-8612|Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer|A Randomised Controlled Trial in the Palliative Setting Regarding Off-Label Medication: Investigating the Efficiency of Amitriptyline Versus Pregabalin From a Societal Perspective|Off-label|Radboud University|Yes|Recruiting|September 2008|December 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2009|February 4, 2009|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740571||151245|
NCT00742339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1264P|Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome|Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome (HRS): An Open Multicentric Randomized Study||University of Padova|No|Terminated|May 2005|October 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|75 Years|No|||October 2014|October 11, 2014|August 26, 2008||No|Decision of independent monitoring committee: Risk of non-response to treatment significantly    higher in midodrine group than in terlipressin group.|No||https://clinicaltrials.gov/show/NCT00742339||151109|
NCT00751712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511086|Cerebral Oximetric Monitoring of the Posterior Circulation|Cerebral Oximetric Monitoring of the Posterior Circulation in Neonates and Infants During Complex Aortic Arch Reconstruction.|CerebralOx|Children's Hospitals and Clinics of Minnesota|No|Completed|May 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|14|||Both|N/A|12 Months|No|||June 2012|June 8, 2012|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751712||150396|
NCT00748358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070404|An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer|An Open Label Phase II Study of Oral Treatment With Sunitinib (SUTENT) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen|PROSUT|Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2008|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|18 Years|N/A|No|||September 2008|September 17, 2013|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748358||150651|
NCT00752297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-03a|Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Dose Pivotal Trial to Demonstrate the Safety and Efficacy of PurTox® for the Treatment of Glabellar Rhytides ("Frown Lines")|PT-03a|Mentor Worldwide, LLC|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752297||150352|
NCT00752583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/232|Peritoneal Dialysis Versus Haemodialysis|Clinical Study in Order to Quantify Solute Removal in Peritoneal Dialysis Versus Haemodialysis||University Hospital, Ghent|No|Recruiting|September 2008|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752583||150330|
NCT00748943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2_Shinada|Clinical and Microbiological Effects of a Mouthwash Containing Chlorine Dioxide|The Clinical Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor and Salivary Periodontal and Malodorous Bacteria Using for 7days||Tokyo Medical and Dental University|No|Completed|March 2007|June 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|15|||Male|19 Years|38 Years|Accepts Healthy Volunteers|||September 2008|September 11, 2008|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00748943||150606|
NCT00740623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015463|A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.||SK Life Science||Completed|January 2009|April 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|547|||Both|16 Years|N/A|No|||January 2013|January 15, 2013|August 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00740623||151241|
NCT00748605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702A2824 revised|Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet|A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0 or 1600 mg/Day of S-2367 Administered Orally Once Daily With an Initial 6-Week Low Calorie Diet in Obese Males and Females||Shionogi Inc.|No|Completed|June 2007|January 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|842|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|September 13, 2011|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00748605||150632|
NCT00743665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/130|Quality of Life And Psychological Symptoms In Children With Cyclic Vomiting Syndrome (CVS)|Quality of Life And Psychological Symptoms In Children With Cyclic Vomiting Syndrome||Medical College of Wisconsin|No|Active, not recruiting|June 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|2 Years|12 Years|No|Probability Sample|Youth who meet consensus criteria for CVS as determined by Dr. B. Li and their parents        will be recruited from those being seen in the weekly outpatient CVS clinic at Children's        Hospital of Wisconsin|September 2015|September 3, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00743665||151008|
NCT00739336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#5657|Diabetes Prevention and Control in the Workplace: A Pilot Study|Diabetes Prevention and Control in the Workplace: A Pilot Study||State University of New York - Upstate Medical University|No|Active, not recruiting|July 2008|||February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 29, 2009|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00739336||151337|
NCT00741741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015295|TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.|Phase I, Double Blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Multiple (Monthly) Intramuscular and Subcutaneous Doses of TMC278LA.||Tibotec Pharmaceuticals, Ireland|No|Terminated|July 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|August 22, 2008|||Strategic decision|No||https://clinicaltrials.gov/show/NCT00741741||151155|
NCT00749424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRDIT 00-01/03|The Study of the Crushing Technique Application Using SES in Coronary Bifurcations.|CORONARY BIFURCATIONS: APPLICATION OF THE CRUSHING TECHNIQUE USING SIROLIMUS-ELUTING STENTS - The "CACTUS" Trial|CACTUS|Cordis Corporation|Yes|Completed|January 2004|April 2009|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|N/A|No|||February 2010|February 3, 2010|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749424||150569|
NCT00744042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-002-08|Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)|A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of Asfotase Alfa in up to 10 Severely Affected Patients With for the Treatment of Severely Affected Patients With Infantile Hypophosphatasia (HPP)||Alexion Pharma GmbH|Yes|Completed|September 2008|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|36 Months|No|||January 2016|January 25, 2016|August 27, 2008|Yes|Yes||No|May 15, 2011|https://clinicaltrials.gov/show/NCT00744042||150979|
NCT00739414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589A1101|Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors|A Phase IA, Dose-escalating Study of LBH589 Administered Intravenously in Adult Patients With Advanced Solid Tumors||Novartis||Completed|July 2008|||November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|N/A|No|||March 2010|April 16, 2014|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00739414||151331|
NCT00739752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0205-04|Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics|Interventions to Increase HBV Vaccinations in STD Clinics||Indiana University|Yes|Completed|June 2003|October 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|1749|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 21, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739752||151307|
NCT00740337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|582|Factors That Affect the Development of COPD Symptoms|Specialized Center of Clinically Oriented Research: Alveolar and Airway Mechanisms of COPD. Airway Determinants: Innate Immune Signaling (Project 4)||Washington University School of Medicine|Yes|Enrolling by invitation|October 2007|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|82|Samples With DNA|Plasma, serum, isolated RNA and DNA, lung tissue|Both|18 Years|N/A|No|Non-Probability Sample|People in this study will be invited to participate if they plan to undergo lung resection        surgery at BJH.|September 2012|September 14, 2012|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00740337||151263|
NCT00740350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0627080139|Logan Basic During Pregnancy on Labor and Childbirth|Does the Logan Basic Protocol for Chiropractic Care During Pregnancy Reduce Labor Time and Increase the Ease of Labor and Childbirth?||Logan College of Chiropractic|No|Recruiting|March 2007|February 2009|Anticipated|February 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Female|18 Years|50 Years|No|||August 2008|August 22, 2008|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740350||151262|
NCT00740935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 06.117|Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.|Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.|IVANHOE|University Hospital, Brest|Yes|Completed|May 2007|June 2011|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7204|||Both|6 Weeks|12 Weeks|No|||June 2012|October 18, 2013|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740935||151217|
NCT00741208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2804|Modification of Asthma With Soy Isoflavone|Modification of Asthma With Soy Isoflavone||Northwestern University|No|Completed|August 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|20|||Both|18 Years|N/A|No|||June 2011|June 3, 2011|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00741208||151196|
NCT00741182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAO_06_011|Effect of PTH(1-34) Treatment on Fracture Healing in Vivo|Effect of PTH(1-34) Treatment on Fracture Healing in Vivo||Glostrup University Hospital, Copenhagen|Yes|Withdrawn|October 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Female|50 Years|85 Years|No|||August 2009|March 17, 2015|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741182||151198|
NCT00741195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.09|Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer|Docetaxel Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC||Hellenic Oncology Research Group|No|Recruiting|April 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741195||151197|
NCT00741793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100762|Biologic Treatment Registry Across Canada|BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)|BioTRAC|Janssen Inc.|No|Recruiting|October 2010|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with RA, AS, or PsA will be selected primarily from community centers and        some academic centers.|March 2016|March 23, 2016|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741793||151151|
NCT00741780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD31003102LTF|Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).|Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240µg/kg) Plus G-CSF (10µg/kg) Versus G-CSF (10µg/kg) Plus Placebo to Mobilize and Collect ≥ 6X 10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation||Sanofi|No|Completed|June 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|164|||Both|N/A|N/A|No|Non-Probability Sample|Patients from the AMD3100-3102 study (NCT00103662) who received a at least one dose of        study treatment (plerixafor or placebo).|March 2015|March 19, 2015|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741780||151152|
NCT00742066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-2-115|Role of AT1-receptor Blockers in Insulin-induced Vasodilation.|Insulin-induced Microvascular Activity in Patients With Essential Hypertension: a Possible Role for Angiotensin II AT1-receptor Blockers.||Maastricht University Medical Center|No|Active, not recruiting|March 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2011|March 16, 2011|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00742066||151130|
NCT00745940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-MIND2-476|Mindfulness-Based Cognitive Therapy Intervention to Treat Depression in Individuals With a Traumatic Brain Injury|A Multi-site, Randomized, Controlled Trial of a Mindfulness-based Cognitive Therapy Intervention for Treating Depression in a Traumatic Brain Injury Population.||Lakehead University|No|Completed|November 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|September 2, 2008||No||No|June 28, 2013|https://clinicaltrials.gov/show/NCT00745940||150836|It is not possible to generalize our findings to the general population of people with a traumatic brain injury. Participants self-selected. Some did not complete the intervention. The control group was a “wait-list” control group.
NCT00752882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0025|Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration|Comparison of Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration||University Hospital, Clermont-Ferrand||Not yet recruiting||June 2009|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|September 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00752882||150307|
NCT00752895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU98308|American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL|A Phase III Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX®) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients With Chronic Lymphocytic Leukemia||Wake Forest NCORP Research Base|Yes|Completed|September 2008|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|293|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 13, 2008||No||No|September 28, 2015|https://clinicaltrials.gov/show/NCT00752895||150306|
NCT00752908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070678|Tissue Penetration of Antibiotics in Obesity|Tissue Penetration of Antibiotics in Obesity||Washington University School of Medicine|No|Completed|February 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|Samples Without DNA|plasma, interstitial fluid|Both|18 Years|N/A|No|Probability Sample|Surgical Patients at BJH|April 2012|April 10, 2012|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752908||150305|
NCT00748644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 070703|Efficacy Study of Two Treatments in the Remission of Vasculitis|MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis|MAINRITSAN|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2008|June 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|75 Years|No|||January 2012|August 2, 2013|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748644||150629|
NCT00740636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-065|Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer|Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer||Memorial Sloan Kettering Cancer Center||Completed|August 2008|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|August 22, 2008|Yes|Yes||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00740636||151240|
NCT00740649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3248A1-1001|Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016|Single Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of HSD-016 Administered Orally To Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 30, 2009|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740649||151239|
NCT00748332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API 2007|Protein-energy Oral Supplementation Enriched With Omega-3 Fatty Acids in Cardiac Cachexia|Effects of a Protein-energy Oral Supplement Enriched With Omega-3 Fatty Acids Compared to a Standard Protein-energy Supplement in Cardiac Cachexia||Centre Hospitalier Universitaire de Nice|No|Terminated|March 2008|August 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|85 Years|No|||June 2009|August 21, 2012|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00748332||150653|
NCT00748618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382-08-FB|Vitamin D Replacement After Kidney Transplant|Vitamin D Replacement After Kidney Transplant||University of Nebraska|Yes|Not yet recruiting|October 2008|March 2010|Anticipated|October 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|144|||Both|19 Years|N/A|No|||September 2008|September 5, 2008|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00748618||150631|
NCT00739687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0527a|Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure|A Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure|BENEFICIAL|Synvista Therapeutics, Inc|No|Terminated|August 2008|October 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|August 21, 2008|Yes|Yes|Study has been termination early due to financial constraints.|No||https://clinicaltrials.gov/show/NCT00739687||151311|
NCT00740298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15480A|Thermal Analgesia in Newborns|Thermal Analgesia in Newborns||University of Chicago|No|Active, not recruiting|July 2008|July 2014|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|N/A|2 Days|Accepts Healthy Volunteers|||October 2013|October 8, 2013|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00740298||151266|
NCT00749437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040801|Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer|Feasibility of 3-D Conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage, Node Negative Breast Cancer Patients Using Acculoc Fiducial Markers: A Phase I Trial||Rutgers, The State University of New Jersey|No|Completed|October 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|45 Years|N/A|No|||June 2012|June 13, 2012|September 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749437||150568|
NCT00744926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20750|A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise||Hoffmann-La Roche||Completed|August 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|373|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744926||150913|
NCT00744302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGHD-001|Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.|Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.||Sun Yat-sen University|Yes|Completed|April 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|14 Years|65 Years|No|||May 2015|May 20, 2015|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744302||150959|
NCT00745160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-104|Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes|Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes||Memorial Sloan Kettering Cancer Center||Completed|August 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|Samples With DNA|blood sample for DNA analysis|Both|18 Years|N/A|No|Non-Probability Sample|Never-smokers with lung cancer        Internet recruitment The study will be advertised through a specifically designed website        linked to the MSKCC Lung Cancer webpage. The website will be designed after approval of        the study. The website will be accordingly reviewed by the IRB. We plan to advertise this        study by word-of mouth at scientific meetings and on patient associations' websites and/or        bulletins, with permission. The website will post a description of the study and an        invitation to participate.        Interested patients will be given an email or mail address and/or phone number        866-854-4652 to contact MSKCC investigators about the study.|March 2011|March 29, 2011|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745160||150896|
NCT00741507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2008-329|Unhealthy Alcohol Drinking and Anesthetic Requirement in Women|Unhealthy Alcohol Drinking and Anesthetic Requirement in General Anesthesia in Women|UNADAREW|Nanjing Medical University|Yes|Completed|September 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|5||Actual|200|||Female|19 Years|45 Years|No|||July 2009|July 14, 2009|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00741507||151173|
NCT00741520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2431/04/051|Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients|Cardiovascular Impact of Obstructive Sleep Apnea in Normotensive Patients and the Effects of Continuous Positive Airway Pressure|OSA-NORMO|University of Sao Paulo|No|Completed|August 2008|July 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|36|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||August 2008|October 27, 2010|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741520||151172|
NCT00745394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072007-057|Validation of Near Infrared Spectroscopy (NIRS) During Heart-Lung Bypass in Children|Validation of Somatic and Cerebral Near Infrared Spectroscopy (NIRS) During Cardiopulmonary Bypass In Pediatric Patients: A Prospective Clinical Study|NIRS|University of Texas Southwestern Medical Center|No|Recruiting|April 2008|December 2008|Anticipated|August 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|18 Years|No|Non-Probability Sample|Children who undergo surgical correction of their congenital heart disease that require        cardiopulmonary bypass.|September 2008|September 2, 2008|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00745394||150878|
NCT00745654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-058|Chronic Pain After Lung Transplantation, an Incidence Study|Chronic Pain After Lung Transplantation, an Incidence Study||Rigshospitalet, Denmark|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|111|||Both|18 Years|N/A|No|Non-Probability Sample|Post lung transplantation patients in Denmark|September 2008|November 3, 2008|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00745654||150858|
NCT00745667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMA1|The LAMA Trial: Laparoscopic Correction of Perforated Peptic Ulcer Versus Open Correction|The LAMA Trial: Laparoscopic Correction of Perforated Peptic Ulcer Versus Open Correction by Upper Laparotomy|LAMA|Erasme University Hospital|No|Completed|July 1999|January 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||September 2008|September 2, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745667||150857|
NCT00746226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danisco - TBPA06|Probiotics for Birch Pollen Allergy|Probiotic Intervention for Children With Birch Pollen Allergy||Danisco|No|Completed|March 2006|February 2007|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|2 Years|10 Years|No|||September 2008|September 2, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746226||150815|
NCT00746239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-013R|Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety|Ramelteon for Sleep Initiation Insomnia in Panic Disorder Who Are Also on Escitalopram for Anxiety: A Double Blind, Randomized Clinical Trial||Penn State University||Terminated|August 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|50 Years|No|||September 2015|September 14, 2015|September 2, 2008|Yes|Yes|Funding for continuation was not received.|No|June 18, 2015|https://clinicaltrials.gov/show/NCT00746239||150814|
NCT00752622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05587|Treatment With Infliximab in a Medical Setting (Study P05587)|Optimization of Treatment With Infliximab in a Medical Setting|OPTIMIST|Merck Sharp & Dohme Corp.|No|Terminated|November 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|September 12, 2008||No|Factors that led to termination: recruitment challenges and a lower incidence of flares than    estimated, causing a high risk of the study being underpowered.|No|June 23, 2011|https://clinicaltrials.gov/show/NCT00752622||150327|Due to early study termination, no statistical analysis was performed for the interventional part of this study, therefore, endpoints dedicated to this phase of the study have not been analyzed.
NCT00752635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR007129|Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris|Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris||Johnson & Johnson Taiwan Ltd||Completed|September 2004|September 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|48|||Female|15 Years|49 Years|No|||April 2010|May 18, 2011|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00752635||150326|
NCT00748371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM15431-JAO1|Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration|Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration||Vanderbilt University|No|Terminated|June 2004|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|150|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|September 5, 2008|Yes|Yes|Funding issue|No||https://clinicaltrials.gov/show/NCT00748371||150650|
NCT00741559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011429|Combined Role of Position Emission Tomography (PET) and Magnetoencephalography (MEG) in Nonlesional Epilepsy|Combined Role of PET and MEG in Nonlesional Epilepsy in Pediatric Population||The Hospital for Sick Children|No|Completed|March 2008|June 2011|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|59|||Both|N/A|18 Years|No|||May 2014|May 12, 2014|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741559||151169|
NCT00741572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08.3.048|Individual Sensitivity for Interstitial Lung Diseases|Individual Sensitivity for Interstitial Lung Diseases||Maastricht University Medical Center|No|Completed|August 2008|September 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|The patients will be asked to donate 5L exhaled air and 20 ml blood.|Both|18 Years|N/A|No|Non-Probability Sample|Participants in this study include both men and women, who are 18 years of age or older        and diagnosed with ILD using lung biopsy, X ray or BALF (broncho-alveolar lavage fluid)        analysis and are either treated for this with anti-inflammatory agents or not. There's no        maximum age set for this study since ILD can occur at all ages. Additional criteria are        non smoking, no pregnancy or lactation and no use of vitamins or nutritional supplements.        The inclusion of both treated and untreated patients enables us to study the effectiveness        of anti-inflammatory agents on a larger scale.|September 2009|September 23, 2009|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741572||151168|
NCT00752869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK 111504|Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement|Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: "Implications for Prostate Safety"|DUT/T|The Miriam Hospital|Yes|Completed|September 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|40 Years|85 Years|No|||February 2013|February 25, 2013|September 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752869||150308|
NCT00749190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.10|BI 10773 add-on to Metformin in Patients With Type 2 Diabetes|A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy||Boehringer Ingelheim||Completed|August 2008|||October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|495|||Both|18 Years|79 Years|No|||May 2014|May 16, 2014|September 8, 2008||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00749190||150587|
NCT00748345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070601|Pharmacokinetics of Caspofungin in Burn Patients|Pharmacokinetics of Caspofungin in Burn Patients|Caspo-brûlés|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2009|December 2010|Actual|February 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|60 Years|No|||July 2011|December 15, 2011|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00748345||150652|
NCT00748878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28645|Platelet Function During ECMO (Extra Corporeal Membrane Oxygenation)|Platelet Function During ECMO||University of Utah|No|Completed|June 2008|June 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|N/A|N/A|No|Non-Probability Sample|Any patient on ECMO will be eligible for study.|October 2013|October 11, 2013|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00748878||150611|
NCT00749177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHA-MHA-B2W|Blending Two Worlds: Traditional Aboriginal Healing Strategies for Depression and Anxiety|Blending Two Worlds: Traditional Aboriginal Healing Strategies for Depression and Anxiety. Possible Options for Children, Youth and Families|B2W|Fraser Health|No|Terminated|November 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|4|||Both|N/A|18 Years|No|||March 2015|March 4, 2015|September 5, 2008||No|Primary investigator left program: unable to recruit a replacement|No||https://clinicaltrials.gov/show/NCT00749177||150588|
NCT00746005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/112|Efficacy of Fish Oil Supplementation on Cognition in MCI Patients and the Influence of the APOE4 Allele|Challenge Study: The Efficacy of Fish Oil Supplementation on Cognitive Performance in MCI Patients and the Influence of the APOE-epsilon4 Allele||Wageningen University|No|Completed|October 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|N/A|No|||January 2011|January 11, 2011|August 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00746005||150832|
NCT00745186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLC061|Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers|A Randomized, Open Label, Four Way Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety After Intramuscular (IM) Administration of Mayne Glucagon for Injection With Glucagen® (Novo Nordisk) in Healthy Volunteers.||Hospira, Inc.|No|Completed|August 2007|March 2008|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745186||150894|
NCT00740597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07216|Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma|Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas||City of Hope Medical Center|Yes|Terminated|July 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|August 22, 2008|Yes|Yes|No patients were enrolled on the study|No|June 12, 2014|https://clinicaltrials.gov/show/NCT00740597||151243|Study closed 05/12/2010 (opened 7/25/2008): No patients were accrued and treated per protocol in nearly two years (2 patients were screened). The study was terminated by the IRB when the PI decided not to continue. Protocol objectives were not met.
NCT00740610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-228-0101|Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)|A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)||Gilead Sciences|Yes|Completed|August 2008|September 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|124|||Both|18 Years|75 Years|No|||January 2014|January 3, 2014|August 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00740610||151242|
NCT00745173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1135|Study Evaluating Premarin and Bazedoxifene Potential Interaction|An Open-Label, Single/Multiple Dose Non-Randomized, 3-Period, Crossover Study To Determine The Potential Drug Interaction Of Conjugated Estrogens (CE) On Bazedoxifene In Healthy Postmenopausal Women.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||February 2009|February 11, 2009|September 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00745173||150895|
NCT00745446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLVO 3ARM|The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation|The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation||University of Edinburgh|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2008|September 4, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745446||150874|
NCT00745407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC 200511|Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients|||Gachon University Gil Medical Center|Yes|Completed|January 2005|August 2008|Actual|||Phase 4|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment|1||||||Both|25 Years|80 Years|No|||September 2008|September 2, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745407||150877|
NCT00745420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0601|Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)|Unrelated Donor Reduced Intensity Bone Marrow Transplant for Children With Severe Sickle Cell Disease (BMT CTN #0601)|SCURT|Medical College of Wisconsin|Yes|Active, not recruiting|August 2008|December 2017|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|3 Years|19 Years|No|||November 2015|November 17, 2015|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745420||150876|
NCT00745433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3558|Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide|REPAMET 2: Observational Study of the Switch From Metformin Monotherapy to Bitherapy With Metformin and Repaglinide|REPAMET 2|Novo Nordisk A/S|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|906|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject with type 2 diabetes treated with metformin|March 2016|March 2, 2016|September 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00745433||150875|
NCT00745953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIRP Study US 73|Regression of Fatty Heart by Valsartan Therapy|Regression of Fatty Heart by Valsartan Therapy||University of Texas Southwestern Medical Center|Yes|Recruiting|August 2007|August 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|50 Years|No|||August 2009|August 17, 2009|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745953||150835|
NCT00747071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0180-08-HMO - CTIL|Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies|Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies||Hadassah Medical Organization|Yes|Withdrawn|September 2011|November 2013|Anticipated|November 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||June 2011|August 27, 2012|September 3, 2008||No|Sponsors decision|No||https://clinicaltrials.gov/show/NCT00747071||150750|
NCT00740688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0225080130|Basic and Balance: Logan Basic Technique on Bilateral Weight Balance|The Effects of Logan Basic Technique on Bilateral Weight Balance||Logan College of Chiropractic|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 21, 2008|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740688||151236|
NCT00740701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G000078|Effects of Transcranial Magnetic Stimulation to the Cerebellum on Cognition|fMRI and TMS Analysis of Cerebellar Cognitive Function||Johns Hopkins University|No|Enrolling by invitation|April 2000|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|188|||Both|19 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|August 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00740701||151235|
NCT00740948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEARS|Tolerance and Efficacy of Rituximab in Sjogren's Disease|Tolerance and Efficacy of Rituximab in Sjogren's Disease|TEARS|University Hospital, Brest|Yes|Completed|March 2008|January 2013|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|80 Years|No|||March 2015|March 4, 2015|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740948||151216|
NCT00741247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-08-332|Mediastinal Staging of Lung Cancer With EBUS-TBNA and EUS-B-FNA|Minimally Invasive Mediastinal Staging of Potentially Operable Lung Cancer With Endobronchial Ultrasound Guided Transbronchial Needle Aspiration(EBUS-TBNA) and Transesophageal Aspiration Using Ultrasonic Bronchoscope (EUS-B-FNA)||National Cancer Center, Korea|Yes|Completed|August 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|N/A|N/A|No|||June 2009|June 23, 2009|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741247||151193|
NCT00741260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-2206|Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer|A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer||Puma Biotechnology, Inc.|No|Active, not recruiting|December 2008|December 2017|Anticipated|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|August 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741260||151192|
NCT00749203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-1199|Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)|Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder|KetPTSD|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2009|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|55 Years|No|||December 2012|December 10, 2012|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749203||150586|
NCT00749216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12025|Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease|Multiple-Dose Safety in Japanese Subjects With Mild-to-Moderate Alzheimer's Disease||Eli Lilly and Company|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|50 Years|N/A|No|||May 2010|May 27, 2010|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749216||150585|
NCT00741221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.10|Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer|Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)||Hellenic Oncology Research Group|No|Recruiting|June 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741221||151195|
NCT00749489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-0721|Improving Pain and Function in Hip Fracture|Improving Pain and Function in Hip Fracture||Icahn School of Medicine at Mount Sinai|Yes|Completed|November 2008|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|60 Years|N/A|No|||June 2014|June 24, 2014|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749489||150564|
NCT00748891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1330C00003|DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)|Exploratory Open-Label, Non-randomised, Single Centre Methodology Study Comparing DCE-CT and DCE-MRI as Markers of Changes in Vascular Activity Mediated by a Positive Control Agent [Cediranib (Recentin™; AZD2171), a Potent Inhibitor of VEGF-driven Angiogenesis] in Patients With Advanced Solid Tumour||AstraZeneca|No|Completed|August 2008|November 2010|Actual|February 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00748891||150610|
NCT00748904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801009635|Rifaximin Versus Lactulose in Renal Failure|A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure||Weill Medical College of Cornell University|Yes|Recruiting|June 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||January 2011|January 3, 2011|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00748904||150609|
NCT00748917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||May 31, 2013|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748917||150608|
NCT00742079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH060450|Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia|Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia||Massachusetts General Hospital|No|Completed|September 2006|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||September 2014|September 3, 2014|August 25, 2008|Yes|Yes||No|August 11, 2014|https://clinicaltrials.gov/show/NCT00742079||151129|The cross-over design of this study produced results that are difficult to interpret due to a significant order effect. Larger and longer trials are needed to assess whether this treatment may benefit patients with medication resistant delusions.
NCT00742092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-056A202|Miglustat in Cystic Fibrosis|Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation||Actelion|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|12 Years|N/A|No|||March 2014|March 5, 2014|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742092||151128|
NCT00746278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH-CL-080512|A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian Reserve|A Random Clinical Trial of the Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst||Shandong Provincial Hospital|Yes|Completed|September 2008|February 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Female|18 Years|40 Years|No|||May 2008|February 25, 2010|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00746278||150811|
NCT00744913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010740|Study of Nicotine Replacement Therapy in Pregnancy|Randomized, Controlled Open-Label Study of Nicotine Replacement Therapy in Pregnancy||The Hospital for Sick Children|Yes|Withdrawn|August 2008|March 2010|Anticipated|February 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|40 Years|No|||August 2013|August 14, 2013|August 29, 2008||No|Discontinued due to difficulty in recruitment|No||https://clinicaltrials.gov/show/NCT00744913||150914|
NCT00745693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Res08/A116|The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin|The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin||University of Edinburgh|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2008|September 4, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745693||150855|
NCT00745966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NKR-SER-2008/1|Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder|A 8-Week, Multicenter, Open-Label, Observational Study of Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder|POLE|AstraZeneca|No|Completed|July 2008|||September 2008|Actual|N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|65 Years|No|||September 2008|October 3, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745966||150834|
NCT00745992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801019R|Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients|Voriconazole Therapeutic Drug Monitoring and CYP2C19 Genetic Polymorphisms in Taiwanese Patients||National Taiwan University Hospital|No|Not yet recruiting|October 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|plasma|Both|N/A|N/A|No|Probability Sample|Hospitalization patient or ambulatory patients, Patients with invasive fungal infections,        Patients who take PO/IV voricoanzole more than 3 days|September 2008|September 2, 2008|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00745992||150833|
NCT00746252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043695|Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder|Investigating Metabolic Side Effects of Antipsychotic Medications in Children|PAMS|University of Maryland|Yes|Completed|June 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|7 Years|12 Years|No|||June 2012|June 19, 2012|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746252||150813|
NCT00745680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701057R|Speckle Tracking Imaging and Realtime 3 Dimensional Echocardiograhy to Study LV Function and Remodeling After Acute Myocardial Infarction (AMI)|Morphodynamic Study of Left Ventricular Remodeling With Possible Mechanisms for Pharmacologic Therapy: Assessment by Real-time 3-dimensional Echocardiography and 2-dimensional Speck Tracking Imaging.||National Taiwan University Hospital|No|Recruiting|October 2007|October 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|90 Years|No|Non-Probability Sample|Patients after AMI|January 2011|January 20, 2011|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00745680||150856|
NCT00746811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-08007|Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia|A Double-blind, Randomized, Placebo-controlled, Two-period Crossover Trial to Assess the Effects of 4 g/d P-OM3 on LDL-C and Other Aspects of the Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia||Provident Clinical Research|No|Recruiting|January 2010|October 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|79 Years|No|||January 2010|January 26, 2010|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746811||150770|
NCT00740376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uniglide MBK|Uniglide™ Mobile Bearing Unicondylar Knee System vs the Uniglide™ Fixed Bearing Unicondylar Knee System|A Prospective, Comparative, Randomized, Double Blind, Multi-center Study of the Uniglide™ Mobile Bearing Unicondylar Knee System vs. Uniglide™ Fixed Bearing Unicondylar Knee System|MBK|Corin|Yes|Terminated|August 2008|January 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|40 Years|80 Years|No|||June 2013|June 10, 2013|August 21, 2008|Yes|Yes|enrollment closed|No||https://clinicaltrials.gov/show/NCT00740376||151260|
NCT00740389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014992|TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.|A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.||Tibotec Pharmaceuticals, Ireland||Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|55 Years|No|||April 2010|June 8, 2011|August 21, 2008||||No||https://clinicaltrials.gov/show/NCT00740389||151259|
NCT00740714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS050324|Effects of Coenzyme Q10 (CoQ) in Parkinson Disease|Effects of Coenzyme Q10 in Parkinson Disease - Phase III|QE3|Weill Medical College of Cornell University|Yes|Terminated|December 2008|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|600|||Both|30 Years|N/A|No|||December 2012|December 24, 2012|August 22, 2008|Yes|Yes|The investigational drug is unlikely to demonstrate efficacy over placebo for this indication.    However, no safety issues were discovered.|No|July 24, 2012|https://clinicaltrials.gov/show/NCT00740714||151234|The planned interim analysis for futility based on the first 300 subjects has reached the pre-specified termination criterion.
NCT00740662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK248_07|Intraoperative Measuring of Small Bowel Length Compared to Measuring by Magnetic Resonance Imaging (MRI) in Morbid Obese Patients|Prospective Study for the Quantification of a Compensatory Increase in Small Bowel Length After Roux-en-Y Gastric Bypass in Morbid Obese Patients by Pre- and Postoperative Length-Measuring With MRI Compared to Intraoperative Length-Measuring||University Hospital Inselspital, Berne|No|Terminated|January 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Morbid obese patients scheduled for distal gastric bypass|December 2012|December 19, 2012|August 22, 2008||No|Recruiting problems|No||https://clinicaltrials.gov/show/NCT00740662||151238|
NCT00740961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8Y07|Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer|The Vulnerable Elders Survey Study of Older Cancer Patients||Case Comprehensive Cancer Center|Yes|Terminated|March 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|63|Samples Without DNA|Approximately 13mls of blood will be drawn at each of the three time-points for testing for      biologic correlates of frailty (pre study, mid-study and post-study).|Both|65 Years|N/A|No|Probability Sample|Primary Care clinic|October 2015|October 1, 2015|August 22, 2008||No|low accrual|No||https://clinicaltrials.gov/show/NCT00740961||151215|
NCT00741845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Embil-2008Peru|Prevention of Persistence of Bacterial Vaginosis|Prevention of Persistence of Bacterial Vaginosis: The Effects of High Dose Intravaginal Metronidazole||Embil Pharmaceutical Co. Ltd||Terminated|June 2008|||June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|117|||Female|18 Years|40 Years|No|||March 2012|March 5, 2012|August 25, 2008|Yes|Yes|Terminated for site documentation and monitoring issues - not safety, study drug, or adverse    event issues.|No||https://clinicaltrials.gov/show/NCT00741845||151147|
NCT00741858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC 2002-0232|Duragen Versus Duraguard in Chiari Surgery|Prospective Randomized Study of Duragen vs. Duraguard in Chiari Surgery||University of Illinois at Chicago|No|Completed|April 2003|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|No|||July 2015|July 8, 2015|August 25, 2008||No||No|June 15, 2015|https://clinicaltrials.gov/show/NCT00741858||151146|
NCT00741234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB939-2006-001|A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine|A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies||S*BIO|No|Completed|April 2007|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741234||151194|
NCT00741533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS-01|Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital|Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital||Chulalongkorn University|No|Completed|February 2008|July 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|172|||Female|15 Years|85 Years|No|Non-Probability Sample|Cervical intraepithelial neoplasia (CIN) or cervical cancer patients|November 2010|November 17, 2010|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741533||151171|
NCT00741546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D in cardiac surgery|Association of Low Vitamin D Levels With Mortality in Patients With Reduced Left Ventricular Function Referred to Cardiac Surgery|Association of Low Vitamin D Levels With Mortality in Patients With Reduced Left Ventricular Function Referred to Cardiac Surgery||Johann Wolfgang Goethe University Hospitals|Yes|Enrolling by invitation|March 2007|||September 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|80 Years|No|Probability Sample|Patients admitted for cardiac surgery intervention|August 2008|August 25, 2008|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741546||151170|
NCT00748631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050323|Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.|Assessment of Percutaneous Balloon Kyphoplasty in the Treatment of Malignant Vertebral Fractures (Multiple Myeloma and Osteolytic Metastases) : "Observational Study"|KYPHOK|Assistance Publique - Hôpitaux de Paris|No|Terminated|October 2007|November 2010|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2014|March 23, 2015|September 5, 2008||No|the data collected are enough to obtain a qualitative analysis.|No||https://clinicaltrials.gov/show/NCT00748631||150630|
NCT00748930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04868|The Canadian Follow-up Program for the ATTRACT Study (P04868)(TERMINATED)|The Canadian ATTRACT Follow-up Program||Merck Sharp & Dohme Corp.|No|Terminated|September 2006|October 2007|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13|||Both|N/A|N/A|No|Non-Probability Sample|Subjects previously enrolled in the ATTRACT trial from three Canadian sites.|February 2015|February 12, 2015|September 5, 2008||No|Challenging data collection|No||https://clinicaltrials.gov/show/NCT00748930||150607|
NCT00742677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612328|Feeding Schedules After Surgery in Patients With Gynecologic Cancer|Early Oral Feeding After a Gynaecologic Oncologic Laparotomy: A Randomized Controlled Trial||National Cancer Institute (NCI)||Active, not recruiting|January 2007|||March 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|2||Anticipated|180|||Female|N/A|75 Years|No|||July 2009|September 19, 2013|August 27, 2008||||No||https://clinicaltrials.gov/show/NCT00742677||151084|
NCT00745706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI-01|Discerning Symptomatic and Asymptomatic Episodes Pre and Post Radiofrequency Ablation of Atrial Fibrillation|Discerning Symptomatic and Asymptomatic Episodes Pre and Post Radiofrequency Ablation of Atrial Fibrillation|DISCERN-AF|Ottawa Heart Institute Research Corporation|No|Completed|September 2008|December 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745706||150854|
NCT00745719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A111-102|Parathyroidectomy in Endstage Renal Disease|A Pilot Study to Evaluate the Efficacy of Total Parathyroidectomy in Retarding Cardiovascular Calcification in End-stage Renal Disease Patients||The University of Hong Kong|Yes|Completed|March 2007|January 2012|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|80 Years|No|||June 2013|June 19, 2013|September 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745719||150853|
NCT00746018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-092|Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy|Evaluation of Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2008|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|21 Years|N/A|No|||August 2015|August 26, 2015|September 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00746018||150831|
NCT00745459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPO-11-01/S-01|Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy|Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Open-label Study)||Nihon Pharmaceutical Co., Ltd|Yes|Completed|September 2008|August 2009|Actual|April 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||November 2010|November 8, 2010|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00745459||150873|
NCT00746824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2022|A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.|TM30339: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Repeated Subcutaneous Dose-range Study Designed to Determine the Weight Loss in Obese Subjects.||7TM Pharma A/S|No|Terminated|August 2008|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|192|||Both|18 Years|60 Years|No|||August 2012|August 31, 2012|August 27, 2008|No|Yes|The IND was withdrawn.|No||https://clinicaltrials.gov/show/NCT00746824||150769|
NCT00747084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLVA0055|Can Simple and Inexpensive Techniques Enhance Patient Comfort|Can Simple and Inexpensive Techniques Enhance Patient Comfort in Sedation Risk-free Screening and Surveillance Colonoscopy?||VA Office of Research and Development|No|Terminated|December 2007|December 2015|Anticipated|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|82|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|September 3, 2008||No|Instruments necessary to continue project have been removed via medical center staff.    Therefore, the project cannot continue until they have been replaced.|No||https://clinicaltrials.gov/show/NCT00747084||150749|
NCT00746265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK080430|Behavioral Treatment for Weight Loss|Acceptance-based Behavior Treatment: An Innovative Weight Control|MYH|Drexel University|Yes|Completed|September 2008|June 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 5, 2013|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746265||150812|
NCT00746538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE500636(subproject)|Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent|Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial||Khon Kaen University|No|Recruiting|January 2008|July 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2008|September 3, 2008|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746538||150791|
NCT00747916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-00027|Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space("ICE PLS")|A Pilot Study of the Safety, Efficacy, and Side Effects of Interventional Cryotherapy for the Eradication of Disease in the Pleural Space ("ICE PLS")||CSA Medical, Inc.|No|Terminated|August 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|September 4, 2008||No|Business Reasons|No|July 2, 2014|https://clinicaltrials.gov/show/NCT00747916||150685|
NCT00740402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPalma|Motor Learning of a Planning Task in Stroke Patients: the Maze Paradigm Measured Through Time and Error as Variables|Motor Learning of a Planning Task in Stroke Patients||Faculdades Metropolitanas Unidas|Yes|Completed|January 2008|January 2009|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|20|None Retained|no biospecimens are to be retained|Both|45 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|patients after stroke|August 2008|April 15, 2010|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740402||151258|
NCT00741650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801622-611704|Ibedrift- A Trial Comparing a New Approach to Musculoskeletal Pain Consisting of Education and Peer Involvement to Treatment as Usual|Ibedrift- Health Related Coping. A Randomized Controlled Trial Comparing a Worksite Educational Intervention With or Without Referral to Treatment as Usual.|Ibedrift|Uni Research|No|Completed|September 2008|December 2012|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2097|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741650||151162|
NCT00741897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M016455C_4001|Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis|A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis.||Sanofi||Completed|March 2002|||December 2003|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|264|||Both|6 Years|11 Years|No|||September 2009|September 14, 2009|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00741897||151143|
NCT00740675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U18 HS016790-01|Ambulatory Medication Reconciliation Following Hospital Discharge|Ambulatory Medication Reconciliation Following Hospital Discharge: Project 4 From "Center for Education and Research on Therapeutics (CERT) on Health Information Technology"||Brigham and Women's Hospital|No|Active, not recruiting|April 2008|February 2011|Anticipated|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|912|||Both|55 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 5, 2011|December 28, 2007||No||No||https://clinicaltrials.gov/show/NCT00740675||151237|
NCT00741273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-005|Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults|An Open-label, Two-stage, Dose-escalation, Parallel Group Study to Evaluate the Safety and Pharmacokinetics Profile of Proellex® (CDB-4124) in Female Patients With Impaired Hepatic Function and Healthy Adult Volunteers||Repros Therapeutics Inc.|No|Completed|October 2008|June 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Female|18 Years|62 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|August 25, 2008|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT00741273||151191|
NCT00741611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEP-4408-2007|Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation|A Randomized Controlled Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard High Density Mesh Ablation System (MAGELLAN)|MAGELLAN|C. R. Bard|Yes|Terminated|July 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|21 Years|75 Years|No|||September 2012|September 26, 2012|August 25, 2008|No|Yes|Business reasons|No|August 27, 2012|https://clinicaltrials.gov/show/NCT00741611||151165|Due to the study’s early termination and enrollment of only 7 randomized patients, predefined study endpoints were not evaluable. Treated patients were followed through 12 months postprocedure and data were summarized where possible.
NCT00741871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB1518-2007-002|A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies|A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies||S*BIO|No|Completed|July 2008|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741871||151145|
NCT00741884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051090|A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation|A Phase 2, Seven Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group Study To Evaluate The Safety And Efficacy Of Three Doses Of A Controlled Release Formulation Of Varenicline For Smoking Cessation||Pfizer|Yes|Withdrawn|August 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|August 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741884||151144|
NCT00741819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIN-PH-401|Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects|An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension.||United Therapeutics|No|Completed|September 2008|December 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|75 Years|No|||January 2013|January 16, 2013|August 23, 2008|No|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00741819||151149|Small, open-label study without comparison arm.
NCT00742105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGT226A1101|Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan|A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan||Novartis||Completed|November 2008|||March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|20 Years|N/A|No|||October 2011|October 16, 2011|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742105||151127|
NCT00742118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-API-08|Effects of the Soluble Mediators of Mastocytes on the Intestinal Epithelial Barrier and of the Enteric Nervous System During the Syndrome of the Irritable Bowel|Effects of the Soluble Mediators of Mastocytes on the Intestinal Epithelial Barrier and of the entérique Nervous System During the Syndrome of the Irritable Bowel||Centre Hospitalier Universitaire de Nice|No|Recruiting|February 2008|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|200|||Both|18 Years|70 Years|No|||September 2015|September 29, 2015|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742118||151126|
NCT00750113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12313|Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.|A Multicenter Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control and Beyond: Comparison of Two Treatment Strategies.||Bayer|No|Completed|October 2007|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|405|||Both|18 Years|75 Years|No|||December 2014|December 4, 2014|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750113||150516|
NCT00742404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612434|Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM)||National Cancer Institute (NCI)||Active, not recruiting|July 2008|||July 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2010|December 17, 2013|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00742404||151104|
NCT00745732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0787|Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)|A Phase I Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Terminated|October 2008|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|September 2, 2008|Yes|Yes|Sponsor withdrew support.|No||https://clinicaltrials.gov/show/NCT00745732||150852|
NCT00745745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T83|Septal Positioning of Ventricular Implanted Cardioverter Defibrillator (ICD) Leads|Septal Positioning of Ventricular ICD Leads|SPICE|St. Jude Medical|No|Completed|August 2008|January 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745745||150851|
NCT00746031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC number 08/MRE00/30|Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids|Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids.||University of Edinburgh|No|Completed|December 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|30|||Female|18 Years|N/A|No|||October 2010|October 22, 2010|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00746031||150830|
NCT00746317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-001US|A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)|A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 Administered Weekly in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)||Chugai Pharmaceutical|No|Completed|September 2008|October 2012|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||October 2012|October 15, 2012|September 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00746317||150808|
NCT00746551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|296/2551(EC3)|Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment|Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial|EIVF|Mahidol University|Yes|Completed|September 2008|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|September 2, 2008||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT00746551||150790|
NCT00746564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60020941D|Study of New Implantable Loop Recorder|Confirm Implantable Cardiac Monitor Study||St. Jude Medical|No|Completed|September 2008|June 2014|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|No|||November 2015|November 1, 2015|September 2, 2008|Yes|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00746564||150789|
NCT00746837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00018|AZD5672 Absolute Bioavailability Study|A Phase I Study to Assess Absolute Bioavailability of AZD5672 at Steady-state in Healthy Volunteers||AstraZeneca|No|Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746837||150768|
NCT00747097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62202-788|Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study|Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study|ECHO|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|September 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||February 2011|February 9, 2011|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747097||150748|
NCT00747110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-57/UCA|Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)|Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With 9 mg Budesonide or 3 g Mesalazine in Patients With Active Ulcerative Colitis||Dr. Falk Pharma GmbH|Yes|Completed|October 2007|August 2010|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|343|||Both|18 Years|75 Years|No|||June 2012|June 25, 2012|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747110||150747|
NCT00747396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00011741|The Bucharest Early Intervention Project|The Bucharest Early Intervention Project: Effects of Early Psychosocial Deprivation on Mental Health in Adolescence|BEIP|Children's Hospital Boston|Yes|Active, not recruiting|September 2000|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|136|||Both|12 Years|13 Years|No|||July 2015|July 27, 2015|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747396||150725|
NCT00747682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18833|Cerebral Perfusion, Oxygenation, Electrical Activity|Alterations in Cerebral Perfusion, Oxygenation, Electrical Activity, and Markers of Cerebral Damage Associated With Cerebro-spinal Fluid Reservior Aspiration in Neonates With Post Hemorrhagic Hydrocephalus||University of Utah|No|Completed|July 2006|August 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Infants enrolled in this study will be identified at the time of neurosurgical evaluation        for placement of a shunt or an Omaya reservoir for post-hemorrhagic hydrocephalus. Infants        who have received vasoactive drugs (e.g. non-steroidal anti-inflammatory, dopamine,        dobutamine, epinephrine, etc), will not be excluded from the study but the measurements        will be postponed until 72 hrs after discontinuation of the medications.|June 2010|June 22, 2010|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747682||150703|
NCT00740415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589544|Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma|First-line Treatment of Mantle Cell Lymphoma of Old Patients . Evaluate the Efficacy, Toxicity, and Molecular Prognostic Factors of Velcade®) in Association With Chemotherapy and Immunotherapy With Rituximab|ManteauRiBVD|French Innovative Leukemia Organisation|Yes|Completed|June 2007|August 2015|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|65 Years|80 Years|No|||March 2016|March 15, 2016|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740415||151257|
NCT00741663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318P|Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)|Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis|SVSSF|University of Padova|No|Completed|April 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||September 2008|September 24, 2008|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00741663||151161|
NCT00740974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8580|Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula|||Mead Johnson Nutrition||Completed||||||N/A|Observational|N/A|||||||Both|N/A|12 Months|Accepts Healthy Volunteers||children previously randomized in a clinical study consuming LCP-supplemented infant        formula|August 2008|August 22, 2008|August 22, 2008||||No||https://clinicaltrials.gov/show/NCT00740974||151214|
NCT00740987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIREA2|Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)|Evaluation of Intermittent Pneumatic Compression Associated With Elastic Stockings and Anticoagulant Prophylaxis Versus Anticoagulant Prophylaxis Alone on Venous Thromboembolism Incidence in ICU Patients Without High Risk of Bleeding|CIREA2|University Hospital, Brest||Completed|October 2007|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|621|||Both|18 Years|N/A|No|||December 2014|February 10, 2015|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740987||151213|
NCT00741624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0165|Pain Reduce Following Refractive Surgery|Mitigating Pain Following Refractive Surgery||FORSIGHT Vision3|Yes|Completed|September 2008|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|60 Years|No|||June 2009|June 2, 2009|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00741624||151164|
NCT00741637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-PR-02|Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults|A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Single Dose Regimen of Live Attenuated Oral Cholera Vaccine (Choleragarde®) in HIV-Seropositive Adults in Thailand||International Vaccine Institute|Yes|Completed|July 2010|June 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|45 Years|No|||March 2012|March 29, 2012|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741637||151163|
NCT00742443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0091|Juvista in Scar Revision Surgery of Disfiguring Scars|A Double Blind, Within Patient, Placebo Controlled Trial to Assess the Efficacy of Juvista (Avotermin) in Conjunction With Scar Revision Surgery for the Improvement of Disfiguring Scars.|Revise|Renovo|No|Completed|December 2008|February 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|350|||Both|18 Years|85 Years|No|||March 2011|March 2, 2011|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742443||151101|
NCT00741585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYGIA|Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment|Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment|HYGIA|University of Vigo|Yes|Recruiting|January 2008|December 2020|Anticipated|June 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741585||151167|
NCT00741598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1060|Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder|The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder||Icahn School of Medicine at Mount Sinai|Yes|Completed|September 2008|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||August 2015|August 4, 2015|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741598||151166|
NCT00741832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU-4950900021|The Effects of a Positive Expiratory Pressure (PEP) on Dyspnea and Dynamic Hyperinflation During Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effects of a Positive Expiratory Pressure (PEP) on Dyspnea and Dynamic Hyperinflation During Exercise in COPD Patients||Khon Kaen University|Yes|Recruiting|March 2008|February 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|11|||Both|N/A|70 Years|No|||November 2008|November 13, 2008|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00741832||151148|
NCT00741806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHB-CS03|Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults|Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults|GHB-CS03|AVIR Green Hills Biotechnology AG|Yes|Completed|August 2008|March 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741806||151150|
NCT00743002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIN-201|A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione|A Multi-center, Double-blind, Randomized, Placebo-controlled Study of TT223 in Patients With Type 2 Diabetes Treated With Metformin and/or TZD||Transition Therapeutics|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|75 Years|No|||June 2013|June 13, 2013|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743002||151059|
NCT00743015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.21|Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks|Relative Bioavailability Following Single Oral Administration of 200 mg of BI 44370 During and Between Migraine Attacks in Male and Female Migraine Patients. An Open-label, Fixed-sequence, Two-period Study With Intraindividual Comparison||Boehringer Ingelheim||Completed|September 2008|||March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||Actual|19|||Both|18 Years|65 Years|No|||October 2013|October 31, 2013|August 27, 2008||||No||https://clinicaltrials.gov/show/NCT00743015||151058|
NCT00746330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMFF258C2204|Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Multi-centre, 4-way Cross-over Study to Compare the Single Dose Bronchodilatory Effect of Formoterol Fumarate in Combination With Mometasone Furoate Delivered Via Pressurized Metered Dose Inhaler (pMDI) to Placebo Delivered Via pMDI in Children Aged 5-11 Years Old With Persistent Asthma||Novartis||Completed|August 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|5 Years|11 Years|No|||June 2011|June 3, 2011|September 3, 2008|No|Yes||No|November 21, 2010|https://clinicaltrials.gov/show/NCT00746330||150807|
NCT00746590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR003-CLN-pro001|Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma|A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC)||BTG International Inc.|No|Withdrawn|September 2008|August 2009|Actual|June 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|September 3, 2008||No|Strategic reasons: Sponsor seeks oncology partner to explore Prolarix potential|No||https://clinicaltrials.gov/show/NCT00746590||150787|
NCT00746291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alyn3CTIL|Heart Rate Variability (HRV) Among Children With Brain Damage|Assessment of Autonomic Nervous System With Analysis of Heart Rate Variability in Children With Brain Damage.||Alyn Pediatric & Adolecent Rehabilitation Center|No|Terminated|June 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|80|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00746291||150810|
NCT00746304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709002R|Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin|Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin||National Taiwan University Hospital|Yes|Completed|September 2007|December 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|164|||Both|N/A|5 Years|No|Non-Probability Sample|A total of 373 patients with strabismus were treated with botulinum toxin injection by a        single surgeon (AH Wang) at the Department of Ophthalmology, National Taiwan University        Hospital, Taipei, Taiwan from 1992 to 2005.|September 2007|August 31, 2008|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00746304||150809|
NCT00746850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAC Trial|Harmonic in Laparoscopic Cholecystectomy for Acute Cholecystitis|Randomized, Double-blind, Controlled Trial of Harmonic(H) Versus Monopolar Diathermy (M) for Laparoscopic Cholecystectomy (LC) for Acute Cholecystitis (AC) in Adults.|HAC|University of Bologna|No|Completed|September 2008|December 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||September 2008|October 12, 2011|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746850||150767|
NCT00747123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A011-04|A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma|A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma||Celgene|Yes|Completed|September 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|September 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00747123||150746|
NCT00747136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010020-P-001|WavSTAT® Optical Biopsy System to Target Esophageal Biopsies|A Prospective Evaluation of the WavSTAT® Optical Biopsy System to Target Esophageal Biopsies: An Adjunctive Tool to Assist the Endoscopist to Identify Dysplasia or Cancer||SpectraScience|Yes|Suspended|August 2008|March 2013|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|esophageal biopsies will be collected.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Barrett's esophagus|April 2011|April 11, 2011|September 2, 2008|Yes|Yes|Study has been suspended while company continues to develop the technology|No||https://clinicaltrials.gov/show/NCT00747136||150745|
NCT00747409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnaHum|Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes|Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes.||Munich Municipal Hospital|Yes|Active, not recruiting|July 2004|June 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|80 Years|No|||September 2008|September 4, 2008|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747409||150724|
NCT00747968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brainandheart|The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET|The Effect of the GLP-1 Analogue Exenatide on Glucose Metabolism in the CNS and Heart During Hyperglycemia in Type-2 Diabetic Patients Assessed by PET||University of Aarhus|No|Completed|February 2010|March 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|8|||Male|50 Years|70 Years|No|||June 2011|June 29, 2011|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00747968||150681|
NCT00740428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-10|Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction|The Effectiveness of Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction.||UPECLIN HC FM Botucatu Unesp|No|Completed|March 2008|July 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|48|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740428||151256|
NCT00741325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD31003101LTF|Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).|Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240µg/kg) Plus G-CSF (10µg/kg) Versus G-CSF (10µg/kg) Plus Placebo to Mobilize and Collect ≥ 5X 10^6 CD34+ Cells/kg in Non-Hodgkin's Lymphoma Patients for Autologous Transplantation||Sanofi|No|Completed|June 2006|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|178|||Both|N/A|N/A|No|Non-Probability Sample|Patients from the AMD3100-3101 study (NCT00103610) who received at least one dose of study        treatment (plerixafor or placebo)|February 2014|February 10, 2014|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741325||151187|
NCT00741338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID02307|Immune Tolerance Study With Aldurazyme® (Laronidase)|A Trial of Antigen-specific Immune Tolerance Induction in Mucopolysaccharidosis I (MPS I) Patients Initiating Enzyme Replacement Therapy With Aldurazyme® (Laronidase)||Sanofi|Yes|Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|N/A|5 Years|No|||June 2014|June 2, 2014|August 13, 2008|Yes|Yes||No|June 2, 2014|https://clinicaltrials.gov/show/NCT00741338||151186|Study was discontinued on September 10,2013 due to changing standards of care for this population, practical infeasibility of routinely monitoring plasma CsA in clinical setting, inconclusive results of interim analysis and not due to safety concern.
NCT00741000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0331080127|Cervical Stairstep and Effects on Range of Motion (ROM)|The Effects of Cervical Stairstep on Cervical Range of Motion|CSEROM|Logan College of Chiropractic|No|Recruiting|July 2008|October 2008|Anticipated|October 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|50 Years|No|||August 2008|August 22, 2008|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00741000||151212|
NCT00741013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1137|Quantifying Airway Inflammation With Radiologic Tests|Imaging Biomarkers of Pulmonary Inflammation||Washington University School of Medicine|Yes|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|19 Years|44 Years|Accepts Healthy Volunteers|||April 2014|April 22, 2014|August 21, 2008|Yes|Yes||No|August 4, 2009|https://clinicaltrials.gov/show/NCT00741013||151211|
NCT00742183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA 415|Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®|An Open, Parallel, Randomized, Comparative, Multi-centre Investigation in US Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene® in the Treatment of Partial Thickness Burns.||Molnlycke Health Care AB|No|Completed|August 2008|November 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|5 Years|N/A|No|||October 2010|October 11, 2010|August 19, 2008||No||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00742183||151121|
NCT00742456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2-031 MEC|Microvascular Dilatation After Endogenous Induced Hyperinsulinemia|Insulin-induced Microvascular Dilatation During a Physiological Stimulus - Studies in Hypertension and Obesity.||Maastricht University Medical Center|No|Completed|January 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 22, 2011|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742456||151100|
NCT00742144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMB111148|Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia|An Open-label Phase I Study of Ofatumumab (GSK1841157) in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia||GlaxoSmithKline||Completed|September 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|79 Years|No|||February 2011|May 31, 2012|August 26, 2008||||No||https://clinicaltrials.gov/show/NCT00742144||151124|
NCT00742157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061-03|Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)|An Open-label Evaluation of the Long-term Efficacy and Safety of a Standardized Regimen of Growth Hormone, Glutamine and a Modified Diet in the Treatment of Patients With Short Bowel Syndrome||University of Nebraska|No|Terminated|March 2003|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|78 Years|No|||August 2011|August 15, 2011|August 26, 2008|Yes|Yes|Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT00742157||151123|
NCT00742417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG0602|Efficacy and Safety of Plasma Exchange With 5% Albutein in Beta-Amyloid Peptide Clearance in Cerebrospinal Fluid|A Phase II Study to Evaluate the Efficacy and Safety of Plasma Exchange With 5% Albutein in Beta-Amyloid Peptide Clearance in Cerebrospinal Fluid, and Its Effects in Patients With Mild-Moderate Alzheimer's Disease||Grifols Biologicals Inc.|No|Completed|April 2009|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|42|||Both|55 Years|85 Years|No|||March 2012|March 8, 2012|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00742417||151103|
NCT00742378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2008-0076-Reproducibility|Discriminating Ability of the Cirrus High Definition (HD) Optical Coherence Tomography (OCT) for Glaucoma|Discriminating Ability of the Cirrus HD OCT for Glaucoma||Yonsei University|Yes|Recruiting|September 2008|December 2008|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Glaucoma patients and normal controls|September 2008|September 22, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742378||151106|
NCT00742391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-014|A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05% In Patients With Actinic Keratoses ON Non-head Locations (REGION-I)||Peplin|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|N/A|No|||March 2012|February 18, 2015|August 25, 2008|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00742391||151105|
NCT00743548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01078|Comparing the Inter-dental Brush to Dental Floss|Comparison of Inter-dental Brush to Dental Floss for Reduction of Plaque and Bleeding in Areas With Intact Papilla: A Clinical Trial||University of British Columbia|No|Completed|August 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 12, 2010|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743548||151017|
NCT00746876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMI-UNI-BIPOL|Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures.|Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures. A Randomized Trial of RSA Measurements of Acetabular Wear.|HEMIUNIBIPOL|Sykehuset Asker og Baerum|No|Active, not recruiting|September 2009|December 2015|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|70 Years|N/A|No|||November 2014|November 17, 2014|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746876||150765|
NCT00746889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 051420|Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis|Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis: A Randomized Placebo-Controlled Clinical Trial||University of California, San Diego|No|Completed|March 2004|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||September 2008|July 29, 2010|September 3, 2008|Yes|Yes||No|April 5, 2010|https://clinicaltrials.gov/show/NCT00746889||150764|
NCT00747162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009004|Muscle Oxygenation and Skin Pigmentation|Correlation Between Muscle Oxygenation and Skin Pigmentation||Emory University|No|Withdrawn|August 2008|February 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 26, 2013|August 27, 2008||No|incorporated into other study|No||https://clinicaltrials.gov/show/NCT00747162||150743|
NCT00746577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA022081|Organizational Factors Influencing Practice Improvement in Community Based Care|Organizational Factors Influencing Practice Improvement in Community Based||Virginia Commonwealth University|No|Completed|August 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|910|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|February 21, 2012|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746577||150788|
NCT00746863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1890|Randomized Control Trial to Assess Postoperative Pain After Sling Placement|Injection of 0.125% Marcaine During Mid-Urethral Sling Placement for Pain Relief: A Randomized Control Trial||University of North Carolina, Chapel Hill|No|Completed|January 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|No|||June 2010|June 15, 2010|September 3, 2008||No||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00746863||150766|Our exclusion criteria were strict, and as such, results presented here may have limited generalizability. Other limitations include that we can only address operations performed under general anesthesia.
NCT00747448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-00030|CryoSpray Ablation (TM) GI Patient Registry|CryoSpray Ablation (TM) GI Patient Registry||CSA Medical, Inc.|No|Completed|May 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|199|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of patients who are being treated, or were treated, with the        CryoSpray Ablation™ System for malignant or pre-malignant conditions of the esophagus,        including:          1. Barrett's esophagus with or without dysplasia          2. Squamous dysplasia of the esophagus          3. Esophageal cancer, any stage, as evidenced by histology.|February 2016|February 1, 2016|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747448||150721|
NCT00747981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K 070601|Thoracic Computed Tomography Scan for Diagnosis of Aspirated Foreign Bodies.|Management and Assessment of Thoracic CT Scan for Diagnosis of Aspirated Foreign Bodies in Children|SICE|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2008|October 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|311|||Both|6 Months|16 Years|No|||August 2011|December 14, 2011|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00747981||150680|
NCT00747422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-102|Evaluation of the Effectiveness and Safety of the Ulthera™ System for the Treatment of Wrinkles Around the Eyes|Evaluation of the Effectiveness and Safety of the Ulthera™ System for the Treatment of Periorbital Wrinkles||Ulthera, Inc|No|Completed|July 2008|May 2009|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|September 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00747422||150723|
NCT00747435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G040002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2007|||||N/A|N/A|N/A||||||||||||||March 4, 2016|September 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00747435||150722|
NCT00744159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2005-08-041|Prospective Comparison of Immunological Benefit of Laparoscopic Colectomy|Prospective Comparative Study of Immunological Benefit Between Laparoscopic Colectomy and Open Colectomy||Samsung Medical Center|No|Completed|January 2006|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|84|||Both|20 Years|80 Years|No|Non-Probability Sample|hospital based cohort|August 2008|August 28, 2008|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00744159||150970|
NCT00744172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Finhyst 2006|Finhyst 2006: Study on Morbidity of Hysterectomies in Finland|Finhyst 2006: Incidence, Methods, Complications and Effect on Quality of Life of Hysterectomies in Finland in 2006|Finhyst 2006|Society for Gynecological Surgery in Finland|Yes|Completed|January 2006|December 2010|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5279|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744172||150969|
NCT00742508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRV110734|A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure|A Study to Evaluate the Safety and Tolerability of SK&F-105517-D in Patients With Chronic Heart Failure- An Open-label Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SK&F-105517-D in Patients With Chronic Heart Failure (Phase I/II Study)||GlaxoSmithKline|No|Completed|August 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|80 Years|No|||May 2012|July 19, 2012|August 26, 2008||No||No|May 17, 2010|https://clinicaltrials.gov/show/NCT00742508||151096|
NCT00742521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#010733|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Question 3||Vanderbilt University|No|Completed|March 2001|June 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|22|||Both|18 Years|50 Years|No|||June 2015|June 9, 2015|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742521||151095|
NCT00741910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNI-1493-CD06|Extension Study of Semapimod 60 mg IV x 3 Days|Extension Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease|CD06|Ferring Pharmaceuticals|No|Completed|July 2003|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|August 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741910||151142|
NCT00742196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2008-0076-2|Retinal Nerve Fiber Layer Thickness Measurement on Parapapillary Atrophy With the Cirrus High-Definition (HD) Optical Coherence Tomography (OCT)|Retinal Nerve Fiber Layer Thickness Measurement on Parapapillary Atrophy With||Yonsei University|Yes|Not yet recruiting|September 2008|March 2009|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with or without parapapillary atrophy|August 2008|August 26, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742196||151120|
NCT00742209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111381|Prevention Study in Adult Patients Suffering From Migraine Headaches|Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache||XenoPort, Inc.|No|Completed|August 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|526|||Both|18 Years|N/A|No|||October 2011|July 15, 2013|August 26, 2008|Yes|Yes||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00742209||151119|
NCT00742235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-0003000/1|hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects|hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects||Massachusetts General Hospital|No|Completed|July 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|August 25, 2008||No||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00742235||151117|
NCT00742469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFID3003|Rifaximin for Prevention of Travellers' Diarrhea|A Randomized,Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travellers' Diarrhea||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2005|April 2007|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 21, 2009|August 24, 2008||||No||https://clinicaltrials.gov/show/NCT00742469||151099|
NCT00742482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 0101 INT|Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy|A Phase III Study With Freeze Dried HL10, Three Dosages of 200 mg/kg Ideal Body Weight Versus Standard Therapy in ALI/ARDS Patients||LEO Pharma|Yes|Terminated|January 2003|June 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|418|||Both|18 Years|N/A|No|||February 2009|February 16, 2009|August 26, 2008||No|A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher    mortality in the treatment group.|No||https://clinicaltrials.gov/show/NCT00742482||151098|
NCT00742170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P000711|Transdermal Electroacupuncture for Opioid Detoxification|Transdermal Electroacupuncture for Opioid Detoxification||Mclean Hospital|No|Completed|August 2007|January 2010|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|59 Years|No|||October 2014|October 15, 2014|August 25, 2008||No||No|October 15, 2014|https://clinicaltrials.gov/show/NCT00742170||151122|
NCT00742430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108-1081875-1993|Resistance on Antithrombotic Drugs in Ischemic Heart Disease|Assessment of Aspirin and Clopidogrel Resistance in Ischemic Heart Disease Using Multiplate Function Analyser and it's Correlation With Major Adverse Cardiac Events||University of Zagreb|No|Completed|February 2009|August 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|141|||Both|N/A|N/A|No|Non-Probability Sample|patients with coronary artery disease|February 2012|February 11, 2012|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742430||151102|
NCT00742729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGT-04-210-01-CPPB|Increasing Colorectal Cancer Screening Among Filipino Americans|Increasing Colorectal Cancer Screening Among Filipino Americans||University of California, Los Angeles|No|Completed|September 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Actual|906|||Both|50 Years|70 Years|No|||November 2010|May 9, 2011|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742729||151080|
NCT00743028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-454|Assess the Oral Bioavailability of New ABT-263 Formulations|A Single Dose Study Evaluating the Oral Bioavailability and Pharmacokinetics of the Capsule Formulation of ABT-263 in Subjects With Cancer||Abbott||Completed|August 2008|||August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|N/A|No|||September 2010|October 6, 2010|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743028||151057|
NCT00742131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET111647|A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors||GlaxoSmithKline||Completed|March 2005|August 2011|Actual|May 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||August 2013|September 5, 2013|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00742131||151125|
NCT00742716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA018-CL-2002|Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease|An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis||OPKO Health, Inc.|No|Completed|October 2008|June 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|80 Years|No|||June 2011|October 30, 2014|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00742716||151081|
NCT00743561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX - 2007/04|Assessment of Ambulatory Polygraphy in the Detection of Sleep Apnea in Multiple System Atrophy (SAMSA)|Study of the Performance of Ambulatory Nocturnal Polygraphy in the Diagnosis of Sleep Apnea in Multiple System Atrophy||University Hospital, Bordeaux|No|Completed|June 2008|January 2011|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|30|||Both|30 Years|80 Years|No|||April 2012|April 27, 2012|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743561||151016|
NCT00739570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071970|The Effect of Manipulations of the Lumbar Spine on Six Different Outcome Measures|The Effect of Manipulations of the Lumbar Spine on Six Different Outcome Measures.||Universite du Quebec a Montreal|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|81 Years|Accepts Healthy Volunteers|||August 2008|August 22, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739570||151320|
NCT00747175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00002|A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes|A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in T2DM Subjects|MAD|AstraZeneca||Completed|August 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|52|||Both|30 Years|75 Years|No|||December 2010|December 2, 2010|September 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00747175||150742|
NCT00747188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAEED1|The Impact of Problem-Based Learning (PBL) and Lecturing|The Impact of Problem-Based Learning (PBL) and Lecturing on the Behavior and Attitudes of Iranian Nursing Students: a Randomised Controlled Trial (RCT)|PBL|University of Tasmania|Yes|Completed|February 2006|January 2008|Actual|July 2007|Actual|N/A|Interventional|Primary Purpose: Health Services Research|2||||||Both|19 Years|23 Years|Accepts Healthy Volunteers|||September 2008|September 3, 2008|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747188||150741|
NCT00747474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC388-101|Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors|A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) When Administered to Patients With Advanced Solid Tumors||Taiwan Liposome Company|Yes|Completed|September 2008|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|September 3, 2008|No|Yes||No|January 5, 2012|https://clinicaltrials.gov/show/NCT00747474||150719|
NCT00747487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-II-003|Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy|A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy|RHODOS|Santhera Pharmaceuticals|Yes|Completed|November 2007|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|14 Years|65 Years|No|||May 2013|May 24, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747487||150718|
NCT00747461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-00026|Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")|Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD")|ICEtheBAD|CSA Medical, Inc.|No|Terminated|October 2008|March 2011|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|September 4, 2008||No|Business Reasons|No|June 4, 2015|https://clinicaltrials.gov/show/NCT00747461||150720|
NCT00747149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00072|A Diabetes Study to Treat A Population Previously Not at Target|12-week, Open-label, Multi-center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL (Low Density Lipoprotein)-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients|ADAPT|AstraZeneca|Yes|Completed|May 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|598|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|September 2, 2008|Yes|Yes||No|August 6, 2010|https://clinicaltrials.gov/show/NCT00747149||150744|
NCT00747994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070203|Genetic Study of Families Affected by Paget's Disease of Bone|Genetic Study of Families Affected by Paget's Disease of Bone|PAGET|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Actual|83|Samples With DNA|collection of extracted DNA, RNA and serum samples and urinary samples|Both|18 Years|N/A|No|Probability Sample|15 patients affected by Paget's disease of bone and their relatives at the first or second        degree of relativeness total of about 100 individuals|July 2010|July 12, 2010|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00747994||150679|
NCT00743873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4000|Platelet-rich Plasma (PRP) Treatment for Medial Retinaculum Tear Post Medial Patellar Dislocation|PRP Treatment for Medial Retinaculum Tear - Randomized-Double-Blind-Placebo Control Trail||Meir Medical Center|Yes|Completed|January 2008|March 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||July 2011|July 10, 2011|August 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743873||150992|
NCT00747695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013945|A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive|A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With GERD 1 to 11 Years Old, Inclusive||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2008|September 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|1 Year|11 Years|No|||January 2011|January 7, 2011|September 4, 2008||||||https://clinicaltrials.gov/show/NCT00747695||150702|
NCT00744419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL Panto 01|Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants|A Multicenter, Open-label, Single and Multiple Dose Pharmacokinetic Study of IV Pantoprazole in Preterm Infants and Infants 0-11 Months With a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the Need for Acid Suppression||University of Louisville|Yes|Completed|May 2009|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|28 Weeks|11 Months|No|||December 2015|December 1, 2015|August 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00744419||150950|
NCT00744445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022-1994|Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity|Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity||Sunnybrook Health Sciences Centre|No|Completed|October 1993|August 1998|Actual|August 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||August 2008|August 29, 2008|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744445||150949|
NCT00741286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECLIPse|Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler|Study for the Multi-Center Placebo-Controlled Double-Blind Clinical Trial for the Evaluation of the Effect of Cilostazol on Pulsatility Index of Transcranial Doppler in the Acute Lacunar Infarction Patients|ECLIPse|Inje University|No|Completed|November 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|203|||Both|45 Years|N/A|No|||August 2010|August 4, 2011|August 25, 2008||No||No|August 3, 2010|https://clinicaltrials.gov/show/NCT00741286||151190|
NCT00741299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GKN2007|A Study of the Association Between Tobacco Smoking and Bipolar Affective Disorder|Association Between Tobacco Smoking and Bipolar Affective Disorder.Clinico-epidemiological, Cross-sectional, Retrospective Study.||Tirat Carmel Mental Health Center|No|Completed|August 2007|September 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|65 Years|No|Probability Sample|The sample will consist of all patients ascertained in database of Tirat Carmel Mental        Health Center and Psychiatric Outpatients Clinic, Rambam Medical Center|July 2012|July 25, 2012|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741299||151189|
NCT00739323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK76937|Impaired Wound Healing in Diabetic Foot Ulceration|Impaired Wound Healing in Diabetic Foot Ulceration|EPC|Beth Israel Deaconess Medical Center|Yes|Completed|December 2006|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|137|||Male|21 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects may be selected from the Beth Israel Deaconess Foot Clinic or from the Boston        area and surrounding locations.|July 2014|July 16, 2014|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00739323||151338|
NCT00739999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581172|8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia|A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia||Pfizer|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|39|||Both|6 Years|17 Years|No|||June 2009|August 19, 2010|August 21, 2008|No|Yes||No|March 15, 2010|https://clinicaltrials.gov/show/NCT00739999||151289|
NCT00741923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMAF-HEINZbeans|Effect of Consuming Beans for One Month on Blood Lipids, Satiety, Intake Regulation and Body Weight|Beans and Potatoes in the Regulation of Food Intake and Risk Factors for Chronic Diseases. Effect of Consuming Beans for One Month on Blood Lipids, Satiety, Intake Regulation and Body Weight||University of Toronto|No|Completed|November 2007|December 2009|Actual|September 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|35 Years|55 Years|No|||June 2012|June 14, 2012|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741923||151141|
NCT00741936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PID-002|An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation|Chinese Herbal Medicine for Functional Constipation: A Randomized, Double-blind, Placebo Controlled Trial||Hong Kong Baptist University|Yes|Completed|July 2008|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||March 2015|March 18, 2015|August 25, 2008||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00741936||151140|
NCT00742222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR-0186|Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer|Electronic Xoft Intersociety Brachytherapy Trial|EXIBT|Xoft, Inc.|Yes|Completed|May 2008|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Female|50 Years|N/A|No|||July 2015|July 17, 2015|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00742222||151118|
NCT00742742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWC-2008|Walnut Intervention on Metabolic Syndrome (WIMS)|The Effects of Walnut Supplement on Cardio-Metabolic Risk Factors in Patients With Metabolic Syndrome|WIMS|Chinese Academy of Sciences|No|Completed|March 2009|December 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|35 Years|60 Years|No|||February 2015|February 4, 2015|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742742||151079|
NCT00743041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-PTSD-82508|The Effect of EFT on Psychological States in a Veterans Population|The Effect of EFT (Emotional Freedom Techniques) on Psychological States in a Veterans Population: A Randomized Controlled Trial||Soul Medicine Institute|No|Completed|December 2008|May 2010|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2010|May 28, 2010|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743041||151056|
NCT00743249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-23|Punctal Plug Study to Determine the Safety and Retention Times of Various Lengths of Canalicular Stents in Volunteers|A Three-Month Safety Study to Determine the Retention Times of Side-Arm Canalicular Stents||Alcon Research|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|60|||Both|45 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 3, 2013|August 26, 2008|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00743249||151040|
NCT00743262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD778|Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis|Second Amendment on Phase I Trial NO7VEG 'Assessment of a Next Generation Indwelling Provox Voice Rehabilitation System (Vega)': Vega Siri Addendum.||Atos Medical AB|No|Completed|April 2008|April 2009|Actual|August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||October 2010|October 13, 2010|August 15, 2008|Yes|Yes||No|August 2, 2010|https://clinicaltrials.gov/show/NCT00743262||151039|Provox ActiValve users have short device life with normal indwelling prostheses (and hence use the Provox ActiValve). Therefore, the device life measured in this patient group is very short and not representative of the normal Provox Vega user.
NCT00743574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YaleU-0807003992|Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)|Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)||Yale University|Yes|Completed|August 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|40 Years|No|||June 2013|June 20, 2013|August 28, 2008||No||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00743574||151015|No limitations
NCT00747201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079994|Adapting the Bipolar Care Model for Chronic Care Management in Community-based Health Care Sites|Implementing Chronic Care Management for Bipolar Disorder||University of Michigan|No|Completed|September 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|384|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747201||150740|
NCT00747214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-102-002|A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA|A Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to That of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects With RA||Zalicus|No|Completed|November 2004|November 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|September 3, 2008||No||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00747214||150739|
NCT00747734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANP4509g|A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Completed|September 2008|||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|September 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00747734||150699|
NCT00747708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/Q0603/13|Bone Marrow Derived Adult Stem Cells for Chronic Heart Failure|Randomised Control Trial to Compare the Effects of G-CSF and Autologous Bone Marrow Progenitor Cells Infusion on the Quality of Life and Left Ventricular Function in Patients With Heart Failure Secondary to Ischaemic Heart Disease|REGEN-IHD|Barts & The London NHS Trust|Yes|Completed|August 2005|May 2013|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747708||150701|
NCT00747721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005016|Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU|Pharmacokinetics of Intravenous Dexmedetomidine for Prolonged Infusion in Critically Ill, Ventilated Patients in Intensive Care Unit; an Open, Non-Randomised, Single Centre Study|DEX PK|Orion Corporation, Orion Pharma|No|Completed|September 2008|February 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||April 2009|April 20, 2009|September 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00747721||150700|
NCT00743886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5000|Influence of Plasma Rich in Growth Factors (PRGF) on Healing of Medial Collateral Ligament (MCL) Tear|Influence of PRGF on Healing of MCL Tear - Randomized-Double-Blind-Placebo Control Trail||Meir Medical Center|Yes|Withdrawn|January 2008|March 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||July 2011|July 10, 2011|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743886||150991|
NCT00748020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVB-MKL|Narrow-Band UVB-Therapy in Psoriasis|Narrow-Band UVB-Therapy in Psoriasis: Randomised Double-Blind Comparison of Erythematogenic and Suberythematogenic Irradiation Regimens||Radboud University|No|Completed|January 2003|January 2007|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 5, 2008|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748020||150677|
NCT00748033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-CLO-0005|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2008|||||N/A|N/A|N/A||||||||||||||September 27, 2012|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748033||150676|
NCT00743847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051100|A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia|A Phase 2 6-Week, Double-Blind, Placebo-Controlled, Multicenter Trial Of Varenicline Tartrate (CP-526,555) For Cognitive Impairment In Subjects With Schizophrenia||Pfizer|Yes|Withdrawn|March 2009|November 2009|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||February 2009|February 20, 2009|August 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743847||150994|
NCT00743860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPL112498|A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848|A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and Its Metabolites in Healthy Volunteers.||GlaxoSmithKline|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|August 28, 2008||||No||https://clinicaltrials.gov/show/NCT00743860||150993|
NCT00744198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2008|Autologous Versus Synthetic Versus Biological Sling for Trans-obturator Correction of Urinary Stress Incontinence|A Comparison in Terms of Efficacy and Safety Among Three Different Materials for Trans-obturator Correction of Urinary Stress Incontinence: Autologous, Synthetic and Biological Sling||University Magna Graecia||Recruiting|August 2012|||August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|8|||Female|18 Years|80 Years|No|||April 2013|April 5, 2013|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00744198||150967|
NCT00741312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182-07|Influence of Physical Exercise on Endothelial Function in Pregnant Women|Influence of Physical Exercise on Endothelial Function in Pregnant Women: Randomized Clinical Trial||Universidad del Valle, Colombia|No|Completed|October 2008|January 2011|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|64|||Female|16 Years|30 Years|Accepts Healthy Volunteers|||January 2011|January 20, 2011|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00741312||151188|
NCT00740272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-FR01|Af Ablation In Brady-Tachy Syndrome|Af Ablation In Brady-Tachy Syndrome|Alternative|St. Jude Medical|No|Terminated|March 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|80 Years|No|||October 2011|October 17, 2011|August 20, 2008||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00740272||151268|
NCT00741676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHGS01|Comparison of the Laparoscopy-Assisted Distal Gastrectomy and Open Distal Gastrectomy for Advanced Gastric Cancer|Comparison of the Laparoscopy-Assisted Distal Gastrectomy(LADG) and Open Distal Gastrectomy (ODG) for Advanced Gastric Cancer (Stage Ib and II).||The Catholic University of Korea|Yes|Recruiting|August 2008|July 2013|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|124|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2008|December 30, 2008|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741676||151160|
NCT00741104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05417|A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)|A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients|REQUEST|Merck Sharp & Dohme Corp.|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|363|||Both|N/A|N/A|No|Non-Probability Sample|Subjects are Swedish patients on maintenance therapy for RA with infliximab for >= the        past 12 months.|August 2015|August 24, 2015|July 30, 2008|No|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00741104||151204|
NCT00741117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008493|Conjugated Hyperbilirubinemia and Pulse Oximetry|The Influence of Conjugated Hyperbilirubinemia on Pulse Oximetric Accuracy in Liver Disease||Emory University|No|Terminated|October 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|4|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|August 25, 2008||No|Study stopped due to insufficient personnel required to conduct trial.|No||https://clinicaltrials.gov/show/NCT00741117||151203|
NCT00743080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-07-015|Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators|GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study||University Magna Graecia||Completed|January 2008|January 2010||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||||||Female|18 Years|80 Years|No|||August 2008|November 2, 2010|August 26, 2008||||No||https://clinicaltrials.gov/show/NCT00743080||151053|
NCT00742755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-03-1-067|Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women|Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women||University of California, Los Angeles|No|Completed|September 2003|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|160|||Female|40 Years|N/A|No|||November 2010|November 22, 2010|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742755||151078|
NCT00743054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-MiRNARCC|microRNA Expression in Renal Cell Carcinoma|microRNA Expression in Renal Cell Carcinoma||Sun Yat-sen University|Yes|Completed|July 2008|August 2011|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|50|Samples With DNA|The tumor tissues and tumor adjacent tissues will be collected when patients receive renal      cell carcinoma resection.      The blood and urine will be collected before patients receive operation. And the blood and      urine of some healthy volunteers will be collected as the control group.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Inpatients in the department of Urology of 1st Affiliated Hospital, Sun Yat-Sen University|May 2015|May 19, 2015|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743054||151055|
NCT00743067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET111648|A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors||GlaxoSmithKline||Completed|August 2006|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743067||151054|
NCT00743275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC41|A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination|Immunogenicity and Safety Among Adults of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)||Sanofi|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 17, 2014|August 27, 2008|Yes|Yes||No|February 1, 2010|https://clinicaltrials.gov/show/NCT00743275||151038|
NCT00743288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612441|Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma|A Phase I/II Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM)||Oncotherapeutics|No|Completed|July 2008|December 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|August 27, 2008|No|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT00743288||151037|
NCT00743587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001383|A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb|A Randomized, Double-Blind, Placebo And Active Controlled Methodology Study Investigating The Effects Of Tramadol And Naproxen On The Pain Thresholds Of Patients With Severe Pain Due To Osteoarthritis Of The Thumb||Pfizer|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|36|||Both|18 Years|N/A|No|||March 2010|March 10, 2010|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743587||151014|
NCT00743600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM1500|Ultrasound Evaluation of the Rotator Cable and Associated Structures.|||University of Michigan|No|Completed|September 2005|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|123|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743600||151013|
NCT00739297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-388|The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)|A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK0476 in Patients With Chronic Asthma||Merck Sharp & Dohme Corp.||Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|68|||Both|15 Years|65 Years|No|||May 2015|May 28, 2015|August 19, 2008|No|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00739297||151340|
NCT00746902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803|Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome|Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome|RHOOSAS|University Hospital, Grenoble|No|Completed|June 2008|September 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|70 Years|No|||November 2014|November 6, 2014|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746902||150763|
NCT00746915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG-CA001-IS|Phase I Study Evaluating The Safety And Efficacy of a Device for Collection of Electrical Bioimpedance Data|A Prospective, Single-Center, Phase I Study Evaluating the Safety and Initial Efficacy of the Epidetect Device for Collection of Bioimpedance Data of Human Tissues in Patients Undergoing Elective Pain Relief Treatment of Lumbar Epidural Steroid Injection Under Fluoroscopy||ImpediGuide Ltd|Yes|Recruiting|March 2009|July 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||June 2009|June 3, 2009|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746915||150762|
NCT00747513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA- 08-5401-LL-CTIL|A Multi-component Program to Reduce Obesity in Children|A Multi-component Program to Improve Lifestyle Habits and Reduce Obesity in Children||Sheba Medical Center|No|Completed|September 2009|March 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3600|||Both|5 Years|13 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747513||150716|
NCT00747500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-97-52030-213|Non Interventional Post Marketing Programme in Acromegaly|An Observational, Multicentre, Open Label, Non Interventional Programme to Assess the Long-term Safety and Efficacy of Somatuline® Autogel® in the Treatment of Acromegaly When Administered by Patients or Their Partners ("Home Injection Group") or Administered by Healthcare Professionals.||Ipsen|No|Completed|July 2008|March 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Acromegaly seen in routine clinic|April 2013|April 22, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747500||150717|
NCT00748007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709028M|Efficacy of Rivastigmine in Patients With Down Syndrome|Efficacy of Rivastigmine in Patients With Down Syndrome||National Taiwan University Hospital|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|14|||Both|8 Years|N/A|No|||November 2012|November 27, 2012|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748007||150678|
NCT00748046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15303|Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton|Phase 1, Open-label, Single Ascending-dose Study to Assess Safety, Pharmacokinetics, Biodistribution and Radiation Dosimetry of Intravenous Doses of Alpharadin™ Injection (Radium-223 Chloride) in Patients With HRPC and Skeletal Metastases||Bayer|No|Completed|August 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|N/A|No|||June 2014|June 24, 2014|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00748046||150675|
NCT00743912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFDI1008|Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers|A Phase 1, Single Arm, Open-Label Study to Evaluate the Effect of Rifaximin 550 MG Tablets TID on the Pharmacokinetics of Orally Administered Midazolam in Healthy Male and Female Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|September 2008|November 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 21, 2009|August 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743912||150989|
NCT00744185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/27|Propranolol in Capillary Hemangiomas|Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas|HEMANGIOMA|University Hospital, Bordeaux|Yes|Terminated|October 2008|April 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|N/A|4 Months|No|||July 2012|July 18, 2012|August 28, 2008||No|Study halted prematurely due to some difficulties in recruitment of patients|No||https://clinicaltrials.gov/show/NCT00744185||150968|
NCT00744471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091014|Tanezumab in Osteoarthritis Of The Hip|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Hip||Pfizer|Yes|Completed|November 2008|June 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|627|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744471||150947|
NCT00744484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2007.679 (REK)|A 12 Week Physical Training Programme for Patients With Chronic Obstructive Pulmonary Disease|A 12 Week Physical Training Programme for Patients With Chronic Obstructive Pulmonary Disease (COPD)-a Comparison of Water Based and Land Based Group Training||Norwegian University of Science and Technology|Yes|Completed|February 2008|September 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|22|||Both|50 Years|75 Years|No|||January 2012|January 5, 2012|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744484||150946|
NCT00741052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-022|Ciprofloxacin Multiple Dose for Adult Cholera|Randomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy of Multiple-dose Ciprofloxacin With Single Dose Azithromycin Therapy for Adults With Cholera Due to Multiply Resistant Strains of V. Cholerae O1 or O139||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|July 2007|June 2010|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|218|||Male|18 Years|60 Years|No|||August 2008|July 11, 2011|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00741052||151208|
NCT00740519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3573|Observational Study on Safety of Self-titration of Once Daily Levemir®|Evaluation on Safety of Self-titration in Insulin naïve People With Type 2 Diabetes Treated With Levemir® (Insulin Detemir) and Oral Antidiabetic Agents|SOLVE™|Novo Nordisk A/S|No|Completed|September 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|882|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from a primary care setting who have been deemed appropriate to receive Levemir®        as new treatment and as part of routine out-patient care by the prescribing health care        professional.|June 2012|June 22, 2012|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00740519||151249|
NCT00742781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSA-PPA-1|Vitamin D Supplementation in Crohn's Patients|Vitamin D and Crohn's Disease" From the Bench to the Clinic|CTSA|Penn State University|No|Completed|May 2009|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|21|||Both|18 Years|70 Years|No|||July 2013|July 8, 2013|August 26, 2008||No||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00742781||151076|The main limitation of the study was the lack of placebo control and the small size of the study.
NCT00741715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6911|Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia|A Multicenter, Randomized, Placebo-controlled, "Factorial" Design, 12-month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day Co-administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia||Sanofi|No|Terminated|August 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|15||Actual|1736|||Both|18 Years|N/A|No|||November 2009|November 10, 2009|August 25, 2008|No|Yes|AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|No||https://clinicaltrials.gov/show/NCT00741715||151157|
NCT00742495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-108|Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.|A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma.|BCX1777-108|Mundipharma Research Limited|Yes|Terminated|March 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|2 Years|18 Years|No|||February 2012|October 23, 2012|August 26, 2008||No|Slow Recruitment|No||https://clinicaltrials.gov/show/NCT00742495||151097|
NCT00742768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-012|Comparison of Absorption of Vitamin K2|Comparison of Absorption of Vitamin K2 Human Study Gelpell||Maastricht University Medical Center|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||March 2009|March 9, 2009|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742768||151077|
NCT00743301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB2008-056|The Effect of Palm Olein, Olive Oil and Lard and on Risk Markers of Cardiovascular Disease|Effects of Palm Olein Versus Olive Oil on Blood Lipids, Lipoproteins and Novel Risk Markers of Cardiovascular Disease|A305|University of Copenhagen|No|Recruiting|August 2008|December 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|45|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 27, 2008|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743301||151036|
NCT00739986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNI-1493-CD04|Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo|A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. Placebo|CD04|Ferring Pharmaceuticals|No|Completed|October 2002|August 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|August 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739986||151290|
NCT00740246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT05006|Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia|A Multi-Center, Randomized, Blinded, Placebo Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia||Luitpold Pharmaceuticals|No|Completed|June 2005|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A||||August 2008|August 21, 2008|August 21, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00740246||151270|
NCT00747227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBLK-102-PRSM|Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)|Clinical Evaluation of a Modified Light Transmission IOL||Abbott Medical Optics|No|Completed|December 2006|June 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 6, 2011|September 3, 2008|No|Yes||No|March 4, 2011|https://clinicaltrials.gov/show/NCT00747227||150738|
NCT00747526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013948|A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive|A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects With GERD 1 to 11 Months Old, Inclusive||Janssen Research & Development, LLC|Yes|Completed|December 2007|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|1 Month|11 Months|No|||July 2013|July 5, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747526||150715|
NCT00747760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920050194|TSH Receptor Mutations Among a Consanguineous Community|The Prevalence of TSH Receptor Mutation Among the Arab Population of Israel|TSHR|HaEmek Medical Center, Israel|No|Completed|December 2005|December 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|209|Samples With DNA|Blood samples were taken with EDTA and Genomic DNA was extracted from peripheral mononuclear      cells using the Blood Amp Kit (QIAGEN Inc., Valencia, CA)|Both|N/A|N/A|No|Non-Probability Sample|Subjects belonging to extended family of the index case|September 2008|September 10, 2008|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747760||150697|
NCT00747747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-01-2007|Sinuclean's Treatment Of Sinusitis' Symptoms|Safety and Efficacy (for Symptoms Remission) of the Treatment of the Acute Episode of Sinusitis With Ecballium Elaterium (SINUclean DM® Nasal Spray) as Co-adjuvant of the Antibiotic Therapy: Comparative, Prospective, Randomized, Open Study.|SToSS|Galsor S.r.l.|No|Completed|November 2007|February 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|N/A|No|||March 2012|March 12, 2012|September 4, 2008||No||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00747747||150698|Clinical diagnosis could not be confirmed before treatment start due to logistics problems to make cranial MRI in due time.
NCT00743925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-CVD2224|FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes|FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes|FRANCIS-ACS|Anthera Pharmaceuticals|No|Completed|July 2008|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|625|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|August 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743925||150988|
NCT00743899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-06-027|Conservative Versus Aggressive Revascularization in Patients With Intermediate Lesions Undergoing Percutaneous Coronary Intervention With Angiography Guidance Alone|Conservative Versus Aggressive Revascularization in Patients With Intermediate Lesions Undergoing Percutaneous Coronary Intervention With Angiography Guidance Alone (SMART-CASE)|SMART-CASE|Samsung Medical Center|Yes|Active, not recruiting|January 2009|June 2016|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|899|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743899||150990|
NCT00744211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURG-001-07F|Proteolytic Enzyme Induction Within the Human Myocardial Interstitium|Proteolytic Enzyme Induction Within the Human Myocardial Interstitium||VA Office of Research and Development|Yes|Completed|July 2008|April 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Myocardial interstitial fluid|Both|18 Years|80 Years|No|Probability Sample|Women and Men|November 2014|November 5, 2014|August 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00744211||150966|
NCT00744510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dmw2|Reflexology's Effect on Polycystic Ovary Syndrome (PCOS)|Reflexology's Effect on Polycystic Ovary Syndrome (REPOS): A Pilot Study|REPOS|University of Nottingham|No|Not yet recruiting|December 2012|December 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|20 Years|38 Years|No|||December 2012|December 3, 2012|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744510||150944|
NCT00744523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2850|Proximal Protection With The Mo.Ma Device During Carotid Stenting|ARMOUR: Proximal Protection With The Mo.Ma Device During Carotid Stenting|ARMOUR|Medtronic Endovascular|Yes|Completed|September 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|262|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 29, 2008|Yes|Yes||No|March 10, 2010|https://clinicaltrials.gov/show/NCT00744523||150943|
NCT00742248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM PR 3301 002 03|Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)|Double Blind, Double Dummy, Multicentre, Randomised, Placebo- Controlled, Crossover Design Clinical Trial of 12 μg (Single Dose and Repeated Doses) Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant or DPI (Aerolizertm Inhaler) in Patients With Partially Reversible COPD||Chiesi Farmaceutici S.p.A.|No|Completed|September 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|40 Years|N/A|No|||August 2008|August 26, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742248||151116|
NCT00740285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390/00|Effectiveness and Safety of Lidocaine for Scleroderma|Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial||Federal University of São Paulo|Yes|Completed|April 2004|April 2007|Actual|April 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|60 Years|No|||August 2008|August 21, 2008|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00740285||151267|
NCT00741364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2140|Vitamin D Effects on Prostate Pathology|Randomized Trial of the Effects of Vitamin D on Prostate Cancer-associated Lesions and on Vitamin D Metabolites in Prostate|DProstate|University of Toronto|No|Active, not recruiting|September 2008|July 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Male|30 Years|85 Years|No|||September 2011|September 29, 2011|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741364||151184|
NCT00741377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBHQ880A2102|A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients|A Phase Ib/II Multicenter Dose-determination Study, With an Adaptive, Randomized, Placebo-controlled, Double-blind Phase II, Using Various Repeated IV Doses of BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients With Prior Skeletal-related Event||Novartis||Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|78 Years|No|||February 2013|February 15, 2013|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741377||151183|
NCT00741390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDDC-08-001|Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose|Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose When Using Different Currently Marketed Lancing Devices and Lancets||Becton, Dickinson and Company|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|250|||Both|18 Years|70 Years|No|||March 2010|March 5, 2010|August 22, 2008|Yes|Yes||No|September 2, 2009|https://clinicaltrials.gov/show/NCT00741390||151182|
NCT00742274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAG 05-04|A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection|A Randomized European Study Comparing Endoluminal Stent Grafting and Best Medical Therapy (BMT) to BMT Alone in the Treatment of Acute Uncomplicated Type B Aortic Dissection|ADSORB|W.L.Gore & Associates|Yes|Completed|August 2008|October 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|80 Years|No|||November 2013|November 8, 2013|August 25, 2008|No|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00742274||151114|
NCT00743613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREPARED 001|Predicting Peripheral Arterial Disease in Men With Erectile Dysfunction|Predicting Peripheral Arterial Disease in Men With Erectile Dysfunction|PREPARED|Bruton Avenue Family Practice|No|Completed|February 2005|May 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|175|||Male|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men 50 years old or older with either diabetes, hypertension, hyperlipidemia and/or a        history of tobacco use.|September 2008|September 2, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743613||151012|
NCT00739310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0088|Study Assessing High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations|A Pilot Study to Assess the Efficacy and Effectiveness of High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations in Children With Muscle Weakness and Restrictive Lung Disease CR-0088||Hill-Rom|No|Completed|August 2008|July 2011|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Both|18 Months|18 Years|No|||August 2015|August 24, 2015|August 20, 2008||No||No|April 20, 2015|https://clinicaltrials.gov/show/NCT00739310||151339|Study design was sub-optimal due to lack of control group and lack of randomization
NCT00743314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000611987|Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer|Integration of SPECT/CT Lymphoscintigraphy Into Breast Cancer Radiation for LymphaticSparing||Mayo Clinic|Yes|Active, not recruiting|September 2008|||September 2015|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|August 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743314||151035|
NCT00740870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G050186|Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Original IDE Cohort|Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients With Dysfunctional RVOT Conduits: A Feasibility Study|Melody IDE|Medtronic Cardiovascular|Yes|Active, not recruiting|January 2007|January 2020|Anticipated|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|5 Years|80 Years|No|||October 2015|October 20, 2015|August 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00740870||151222|
NCT00747240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00008854|Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression|Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression And The Incidence Of Chronic Lung Disease (Cld) In Very Low Birth Weight Infants||University of Utah|No|Completed|February 2002|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|139|||Both|N/A|5 Days|No|Non-Probability Sample|Eligible Patients        Patients hospitalized in the NICU who:          1. weigh ≤ 1500 grams at birth,          2. are enrolled at age ≤ 5 days,          3. require mechanical ventilation or continuous positive airway pressure (CPAP),          4. have parents or guardians that have signed the informed consent document. Excluded             Patients Infants with major congenital anomalies will be excluded.|July 2014|May 11, 2015|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747240||150737|
NCT00747253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AutoLITT™ FIM|Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors|AutoLITT™ FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors||Monteris Medical|Yes|Completed|August 2008|April 2010|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|September 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00747253||150736|
NCT00747266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFLX-102-6820|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2007|||||N/A|N/A|N/A||||||||||||||September 4, 2008|September 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00747266||150735|
NCT00747786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-97-52030-215|Non Interventional Post Marketing Programme in Neuroendocrine Tumours|An Observational, Multicentre, Open Label, Non Interventional Programme to Assess the Long-Term Safety and Efficacy of Somatuline Autogel in the Treatment of Neuroendocrine Tumours When Administered by Patients or Their Partners ("Home Injection Group") or Administered by Healthcare Professionals||Ipsen|No|Completed|December 2008|August 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with neuroendocrine tumours seen in routine clinic|October 2013|October 7, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747786||150695|
NCT00747799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAY43-9006-2008003|Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)|Phase II Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Are Failure of Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)||Sun Yat-sen University||Completed|January 2009|November 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||November 2011|December 8, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747799||150694|
NCT00747773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-00008-00|Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung|A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung|CSAir 1|CSA Medical, Inc.|Yes|Completed|November 2007|August 2008|Actual|June 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747773||150696|
NCT00748059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030752|The Pathophysiology of Orthostatic Hypotension|The Pathophysiology of Orthostatic Hypotension||Vanderbilt University|No|Active, not recruiting|December 1996|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|1||Anticipated|25|||Both|12 Years|70 Years|No|||December 2014|June 15, 2015|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00748059||150674|
NCT00748072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDAVP 01|1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy|1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial||University of Bari|No|Completed|August 2008|December 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|162|||Both|16 Years|80 Years|No|||December 2014|December 30, 2014|September 5, 2008|Yes|Yes||No|December 30, 2014|https://clinicaltrials.gov/show/NCT00748072||150673|A possible limitation of the study is the single-center design of the study, which could reduce the generalizability of our results and their external validity.
NCT00743938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-017|A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC|A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients||Bristol-Myers Squibb|No|Completed|March 2009|June 2012|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|August 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743938||150987|
NCT00744224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2008pred003|PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide|Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers|PREDEX|VU University Medical Center|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744224||150965|
NCT00741143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJRI-BT-PR-8947|Effect of Iron Fortified Wheat Flour on Cognition and Iron Status in Indian School Children|Effect of Iron Fortified Wheat Flour on Cognition and Iron Status in Indian School Children||St. John's Research Institute|No|Completed|August 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|194|||Both|7 Years|15 Years|Accepts Healthy Volunteers|||August 2008|August 25, 2008|August 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00741143||151201|
NCT00741156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012255|The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution|The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection||The Hospital for Sick Children|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|2 Months|5 Years|No|||November 2015|November 16, 2015|August 25, 2008||No||No|July 26, 2013|https://clinicaltrials.gov/show/NCT00741156||151200|
NCT00743626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pap Smear Study|Pap Smear Research Study|Evaluation of the Role of Human Papillomavirus Testing and p16 Expression in the Management of Patients Undergoing Cervical Cancer Screening||University Health Network, Toronto|No|Recruiting|December 2006|January 2011|Anticipated|December 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1712|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 28, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743626||151011|
NCT00743639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP3758|Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy|Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy: Randomized Clinical Trial|SDILCM|Instituto de Cardiologia do Rio Grande do Sul|Yes|Completed|July 2005|June 2008|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||June 2008|August 28, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743639||151010|
NCT00751920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010635|Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules|Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules||The Hospital for Sick Children|No|Terminated|August 2008|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|2 Years|18 Years|No|||January 2016|January 4, 2016|September 10, 2008||No|The sponsor-investigator relocated to a different institution and was not able to continue the    study.|No||https://clinicaltrials.gov/show/NCT00751920||150381|
NCT00751933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16816 NSD|Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis|A Controlled Study of Salmonella Ty21a and Cholera/ ETEC-vaccine and the Role of Oats in Daily Diet as a New Treatment in Patients With Mild or Moderate Ulcerative Colitis.||Haukeland University Hospital|No|Terminated|October 2008|June 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|3|||Both|18 Years|80 Years|No|||April 2015|April 10, 2015|September 11, 2008||No|Lack of patients compatible with the protocol´s criteria|No|April 10, 2015|https://clinicaltrials.gov/show/NCT00751933||150380|
NCT00740844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIREA 1|Efficacy of Intermittent Pneumatic Compression (IPC) on Venous Thromboembolism Incidence in Intensive Care Unit (ICU) Patients With High Bleeding Risk|Evaluation of Intermittent Pneumatic Compression (IPC) of the Lower Limbs Associated With Elastic Stockings (ES) Compared to ES Alone on Venous Thromboembolism Incidence in Patients With High Bleeding Risk Hospitalized in Intensive Medical Care Units|CIREA1|University Hospital, Brest||Completed|November 2007|December 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|408|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740844||151224|
NCT00740857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-08-24|Study Comparing the Efficacy of Two Ibuprofen Formulations|A Study Comparing the Efficacy of Two Ibuprofen Formulations||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|211|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|August 22, 2008|Yes|Yes||No|October 30, 2009|https://clinicaltrials.gov/show/NCT00740857||151223|
NCT00741975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078750|Affect Management Intervention for Early Adolescents Wtih Mental Health Problems|Affect Management Intervention for Early Adolescents With Mental Health Problems|Project TRAC|Rhode Island Hospital|No|Completed|April 2007|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|138|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||February 2012|April 12, 2012|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741975||151137|
NCT00741988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 179|Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer|Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|September 2008|September 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|August 25, 2008||No||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00741988||151136|
NCT00742833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUC1203|A Phase II Study of KUC-7483 in Patients With Overactive Bladder|A Randomized, Double Blind, Placebo Controlled, Phase II Study of KUC-7483 in Patients With Overactive Bladder||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|N/A|No|||September 2009|September 2, 2009|August 5, 2008||||No||https://clinicaltrials.gov/show/NCT00742833||151072|
NCT00752843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-16|A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers|A Phase I, Open-Label, Fixed-Sequence Study to Determine the Effect of Single and Multiple Oral Doses of CORLUX (TM) (Mifepristone) on the Pharmacokinetics of a Single Oral Dose of Fluvastatin (a CYP2C9 Probe) in Healthy Volunteers||Corcept Therapeutics|Yes|Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|September 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00752843||150310|
NCT00742547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-r86/zoo8|Type 2 Diabetes Mellitus: New Approaches to Optimize Medical Care in General Practice|DIANA - Diabetes Mellitus: Neue Wege Der Optimierung Der allgemeinärztlichen Betreuung|DIANA|German Cancer Research Center|No|Completed|October 2008|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|204|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742547||151093|
NCT00742560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuLuc63-1703|A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma|A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma||AbbVie|Yes|Active, not recruiting|August 2008|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|102|||Both|18 Years|99 Years|No|||March 2016|March 4, 2016|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00742560||151092|
NCT00739635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/3001|Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus|A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus|EASE|Merz Pharmaceuticals GmbH|No|Completed|September 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|411|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00739635||151315|
NCT00739973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A2305|Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension|An 8-week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension||Novartis|No|Completed|September 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Actual|2694|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|August 20, 2008|No|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00739973||151291|
NCT00743704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/04 Ozelot|Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model|Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|August 2008|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 18, 2009|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743704||151005|
NCT00747539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH083553|Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy|Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy||University of California, Los Angeles|Yes|Active, not recruiting|September 2008|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|330|Samples Without DNA|Urine samples will be collected.|Both|18 Years|N/A|No|Non-Probability Sample|The study population will include 165 HCV-monoinfected and 165 HIV/HCV-coinfected        participants who are receiving HIV and/or HCV treatment through the VA Greater Los Angeles        Health Care System, the AIDS Healthcare Foundation, or the Kaiser-Permanente Infectious        Disease Program.|December 2013|December 10, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747539||150714|
NCT00747552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13833|Intra-Abdominal Hypertension in Neonatal Intensive Care Patients|Intra-Abdominal Hypertension in Neonatal Intensive Care Patients||University of Utah|No|Completed|January 2006|May 2009|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|N/A|2 Months|No|Non-Probability Sample|This is a prospective observational study. A convenience sample of 50 NICU patients will        be planned to be enrolled at Primary Children's Medical Center and/or the University of        Utah Hospital.|January 2010|January 22, 2010|September 3, 2008||No||No|July 21, 2009|https://clinicaltrials.gov/show/NCT00747552||150713|
NCT00739401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP04-002|Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm|Endologix Powerlink® Suprarenal Proximal Cuff||Endologix|Yes|Active, not recruiting|May 2006|July 2013|Anticipated|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739401||151332|
NCT00739713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESB|Effects of Sea Buckthorn Oil on Dry Eye|Effects of Sea Buckthorn Oil on Dry Eye|DESB|University of Turku|No|Active, not recruiting|September 2008|March 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||February 2009|June 24, 2010|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00739713||151309|
NCT00748098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXP110908|Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance|Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance||XenoPort, Inc.|No|Completed|October 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|N/A|No|||January 2013|July 15, 2013|September 5, 2008|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00748098||150671|
NCT00748085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0106|CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)|A Multi-Center Study of CryoSpray Ablation(tm)in Malignant Airway Disease to Determine, Safety, and Tissue Effect in the Lung (ICE the MAD)|ICEtheMAD|CSA Medical, Inc.|Yes|Terminated|October 2008|August 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|September 4, 2008||No|Business Reasons|No|June 16, 2014|https://clinicaltrials.gov/show/NCT00748085||150672|
NCT00740545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB06.050|Prevention of Unexplained Recurrent Abortion by Enoxaparine|Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées|PREFIX|University Hospital, Brest|Yes|Terminated|April 2007|September 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|258|||Female|18 Years|45 Years|No|||March 2015|March 4, 2015|August 22, 2008||No|Stopped for futility|No||https://clinicaltrials.gov/show/NCT00740545||151247|
NCT00744237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-19|Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients|Glycemic Effects of Nebivolol Compared With Metoprolol Extended Release and Compared With Hydrochlorothiazide In Hypertensive Patients With Type 2 Diabetes Mellitus: A Pilot Study||Forest Laboratories|No|Completed|August 2008|||July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|231|||Both|18 Years|85 Years|No|||June 2011|June 30, 2011|August 27, 2008|No|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00744237||150964|
NCT00744497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-227|Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer|A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer|READY|Bristol-Myers Squibb|Yes|Completed|October 2008|July 2015|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1930|||Male|18 Years|N/A|No|||August 2015|August 13, 2015|August 29, 2008|Yes|Yes||No|November 15, 2013|https://clinicaltrials.gov/show/NCT00744497||150945|
NCT00740909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000565|Cognitive Behavioral Therapy for Trichotillomania|Cognitive Behavioral Therapy for Trichotillomania|CBT for TTM|Massachusetts General Hospital||Completed|November 2008|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740909||151219|
NCT00739648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpex-302|A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients||Forest Laboratories|Yes|Completed|October 2008|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|322|||Both|40 Years|N/A|No|||December 2011|January 31, 2012|August 20, 2008|No|Yes||No|September 4, 2011|https://clinicaltrials.gov/show/NCT00739648||151314|
NCT00752557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100N0-2213|Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD|A Phase 2, Multicenter, Randomized, Active-controlled, Parallel-group, Dose-finding And Safety Study Of Recombinant Human Bone Morphogenetic Protein-2 (Rhbmp-2)/Calcium Phosphate Matrix (Cpm) In Subjects With Decreased Bone Mineral Density||Pfizer|Yes|Completed|December 2008|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|50|||Female|65 Years|85 Years|No|||June 2015|June 15, 2015|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752557||150332|
NCT00752570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070307|A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma|A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma||Amgen||Completed|November 2008|June 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752570||150331|
NCT00752258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-03c|A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows|A Phase III, Multi-Center, Long-Term, Repeat-Treatment, Open-Label, Single-Arm Trial to Demonstrate the Safety of Repeat Treatment With PurTox® for the Treatment of Glabellar Rhytides ("Frown Lines")|PT-03c|Mentor Worldwide, LLC|No|Completed|February 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|576|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752258||150355|
NCT00752271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0105|AMS Study: Inflammatory and Biomechanical Contributors to Arthritis Development Following Arthroscopic Meniscectomy|Inflammatory and Biomechanical Contributors to Arthritis Development Following Arthroscopic Meniscectomy||National Institute on Aging (NIA)|No|Terminated|May 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|32|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Orthopedic and arthritis clinics in the Baltimore/Washington DC area|December 2009|December 17, 2009|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752271||150354|
NCT00752544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015418|TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers|Phase I, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Ascending Oral Doses of TMC435350 After Single and Repeated Dosing in Healthy Japanese Male Subjects||Tibotec Pharmaceuticals, Ireland||Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|30|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|September 11, 2008||||||https://clinicaltrials.gov/show/NCT00752544||150333|
NCT00752830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0190C00009|To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328|A Phase I, Open, Randomized, Single-Dose, Two-Treatment (Fed Versus Fasting), Two-Period Cross-Over Single-Centre Study to Evaluate the Effect of Food on the Pharmacokinetics of AZD0328 Following Oral Administration (Capsule) in Healthy Male Subjects||AstraZeneca|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752830||150311|
NCT00748592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4251026|A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia|PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover, Multicenter Polysomnography Trial Of PD 0200390 In Elderly Subjects With Primary Insomnia||Pfizer|No|Withdrawn|January 2009|June 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|65 Years|N/A|No|||February 2009|February 11, 2009|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748592||150633|
NCT00743353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5-100|Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5|An Exploratory, Multi-Center, Open Label, Non-Randomized Study of F-18 RGD-K5|K5|Siemens Molecular Imaging|No|Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2009|January 29, 2009|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743353||151032|
NCT00743652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3010|Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.|A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.||Pfizer|Yes|Completed|January 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|373|||Both|42 Days|5 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|August 27, 2008|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT00743652||151009|
NCT00743093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB #06-1265|Aminotransferase Trends During Prolonged Acetaminophen Dosing|Aminotransferase Trends During Prolonged Therapeutic Acetaminophen Dosing||Denver Health and Hospital Authority|Yes|Completed|August 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|398|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 6, 2013|August 26, 2008|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00743093||151052|This study was limited to healthy volunteers. The ingestion of each dose of study drug and use of other medications was self-reported.
NCT00743106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5508|The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery|The Effect of Fenoldopam on Renal Function in Solitary Partial Nephrectomy Surgery||Outcomes Research Consortium|No|Terminated|September 2002|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|80 Years|No|||March 2010|March 23, 2010|August 26, 2008||No|Executive committee determined to close study after interim analysis.|No||https://clinicaltrials.gov/show/NCT00743106||151051|
NCT00739349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVG08B112|NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye|A Phase II, Multi-Center, Double-Masked, Randomized Study of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions Compared to Vehicle for the Treatment of the Signs and Symptoms of Dry Eye||Novagali Pharma|Yes|Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|132|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|August 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739349||151336|
NCT00739362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908191|Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment|The Effects of Transcranial Direct Current Stimulation (TDCS) on Food Intake and Weight Loss||National Institutes of Health Clinical Center (CC)||Recruiting|August 2008|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 20, 2016|August 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739362||151335|
NCT00739661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4489g|A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission||Genentech, Inc.||Completed|December 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|N/A|No|||April 2012|April 2, 2012|August 21, 2008|Yes|Yes||No|February 10, 2012|https://clinicaltrials.gov/show/NCT00739661||151313|
NCT00739674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-335|SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)|Randomized Open-label Trial to Evaluate the Effectiveness of Diet Management With a Losartan Titration Regimen Versus Losartan Titration Regimen Alone on Blood Pressure Reduction in Hypertensives.||Merck Sharp & Dohme Corp.||Completed|February 2008|January 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|992|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|August 20, 2008|No|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00739674||151312|
NCT00740064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL111429|Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects|A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects|SHIELD|Denver Infectious Disease Consultants, PLLC|Yes|Active, not recruiting|May 2008|November 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|August 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00740064||151284|
NCT00739765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5660, R01 MH079078|Effectiveness of Three Different Psychotherapies for Chronic Post-Traumatic Stress Disorder|Psychotherapies for Chronic Post-Traumatic Stress Disorder||New York State Psychiatric Institute|Yes|Completed|April 2008|March 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|65 Years|No|||April 2014|January 25, 2016|August 20, 2008||No||No|September 8, 2015|https://clinicaltrials.gov/show/NCT00739765||151306|Limited generalizability of unmedicated sample; incomplete therapist fidelity rating; limited sample size.
NCT00740051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.50|A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate|A Randomised, db, Placebo-controlled, Parallel Group Efficacy and Safety Study of BI 1356 (5mg), Administered Orally Once Daily for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients With Insufficient Glycaemic Control for Whom Metformin Therapy is Inappropriate (Intolerability or Contraindication)||Boehringer Ingelheim||Completed|August 2008|||August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|227|||Both|18 Years|80 Years|No|||December 2013|June 17, 2014|August 21, 2008||||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00740051||151285|Primary analysis (at interim) was rerun using final study database
NCT00739739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4291043|An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis|A Phase 2, 12 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof Of Concept Study Evaluating The Efficacy And Safety Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis/Painful Bladder Syndrome.||Pfizer|No|Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|161|||Both|18 Years|N/A|No|||March 2011|March 16, 2011|August 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739739||151308|
NCT00740584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-003|Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.|Assessment of Local Retention and Duration of Activity of SPL7013 Following Vaginal Application of 3% SPL7013 Gel (VivaGel) in Healthy Volunteers||Starpharma Pty Ltd|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|August 21, 2008|No|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT00740584||151244|
NCT00743951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2006724-01H|Feasibility Study: Effect of Patient Decision Aids for Total Joint Replacement on Surgical Referrals|Feasibility Study: Does Screening Plus Patient Decision Aids Reduce Unnecessary Surgical Referrals for Total Joint Arthroplasty in Practices With Long Waiting Lists for Surgical Consults?||Ottawa Hospital Research Institute|No|Completed|January 2007|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|142|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 8, 2015|July 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00743951||150986|
NCT00740324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPO-11-01/SE-02|Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men|Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men During Endoscopy||Nihon Pharmaceutical Co., Ltd|Yes|Completed|August 2008|July 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 8, 2010|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740324||151264|
NCT00740883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB06.076|Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.|Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Pulmonary Embolism: a Multicentre Double-blind Randomized Controlled Trial. "PADIS-PE" Study.|PADIS EP|University Hospital, Brest|Yes|Completed|July 2007|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|374|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740883||151221|
NCT00740896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-2222|Acute Effects of Smoking on Airway Dendritic Cells|Acute Effects of Smoking on Airway Dendritic Cells||University of Rostock|No|Completed|June 2008|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 7, 2009|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740896||151220|
NCT00742053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bard 3001|Electrocardiogram (ECG) Guided Peripherally Inserted Central Catheter (PICC) Placement|A Study of Electrocardiogram (ECG) Guidance for Placement of Peripherally Inserted Central Catheters (PICC)||C. R. Bard|No|Terminated|June 2008|March 2009|Actual|December 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Both|18 Years|80 Years|No|||July 2012|July 27, 2012|August 25, 2008||No|Enrollment rate was too slow.|No|April 25, 2012|https://clinicaltrials.gov/show/NCT00742053||151131|The study was terminated early due to poor enrollment.
NCT00752284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 06-218 T/1243|Safety of Coronectomy vs Excision of Wisdom Teeth|Randomized Controlled Trial of Safety of Coronectomy Versus Excision of Wisdom Teeth|coronrct|The University of Hong Kong|No|Completed|June 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|349|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2008|December 5, 2008|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00752284||150353|
NCT00751959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-439|Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks|Surfactant Application During Spontaneous Breathing With CPAP or During Mechanical Ventilation in the Therapy of IRDS in Premature Infants < 27 Weeks|NINSAPP|University of Cologne|Yes|Completed|April 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|213|||Both|23 Weeks|26 Weeks|No|||July 2012|July 18, 2012|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751959||150378|
NCT00752856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 589|Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients|Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients||California Collaborative Treatment Group|Yes|Completed|September 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|September 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00752856||150309|
NCT00752596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005076|Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient|Compassionate Use Study to Assess the Long Term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in One Patient Following Termination of the SHIELD Open-label Study 2001060||Warner Chilcott|No|Completed|September 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|N/A|N/A|No|||March 2010|March 22, 2010|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752596||150329|
NCT00744640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-Nr. 92/05|Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma|Gemcitabine, Oxaliplatin and Capecitabine (GEMOXEL) for Patients With Advanced Pancreatic Adenocarcinoma (APC): A Phase I/II Study|GEMOXEL|University Hospital, Basel, Switzerland|No|Completed|October 2005|December 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744640||150934|
NCT00734682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08103|A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas|A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas||University of California, San Francisco|Yes|Completed|August 2008|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2014|January 5, 2015|August 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734682||151690|
NCT00735007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28733|12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.|International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS)||EMD Serono|No|Completed|July 2008|||January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|65 Years|No|||October 2013|October 21, 2013|August 12, 2008|Yes|Yes||No|July 14, 2010|https://clinicaltrials.gov/show/NCT00735007||151665|
NCT00735241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STX0207|FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma|Pilot Study of FOLFOX6 Plus Sir-Spheres® Microspheres (Chemo-radiotherapy) in Combination With Bevacizumab (Avastin) as a First Line Treatment in Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma|FAST|Sirtex Medical|Yes|Withdrawn|July 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|August 13, 2008|Yes|Yes|Withdrawn by the study sponsor.|No||https://clinicaltrials.gov/show/NCT00735241||151648|
NCT00735514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5808|Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer|Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers||Case Comprehensive Cancer Center|Yes|Completed|July 2008|May 2010|Actual|April 2010|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|83|||Female|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|October 2015|October 1, 2015|August 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00735514||151627|
NCT00735553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-303|Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids|A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids||Repros Therapeutics Inc.|Yes|Terminated|August 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|77|||Female|18 Years|48 Years|No|||August 2014|August 5, 2014|August 13, 2008|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00735553||151624|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00735852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH 14404|Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women|A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|December 2008|August 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|45 Years|No|||July 2011|July 19, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735852||151601|
NCT00735865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-049|Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion|Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion||Lahey Clinic|No|Completed|July 2003|May 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|N/A|No|||May 2009|May 22, 2009|August 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00735865||151600|
NCT00735878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0412|Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer|A Phase I/II Pharmacokinetic and Pharmacodynamic Study of ABT-751 in Combination With Carboplatin in Patients With Advanced Lung Cancer||Dartmouth-Hitchcock Medical Center|Yes|Terminated|September 2004|January 2009|Actual|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||April 2009|April 29, 2009|August 13, 2008|Yes|Yes|It was decided to close the study to further enrollment based on data from a similar study    using ABT-751 and Pemetrexed that did not show efficacy.|No||https://clinicaltrials.gov/show/NCT00735878||151599|
NCT00736775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABE4427g|A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease|A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Mild to Moderate Alzheimer's Disease||Genentech, Inc.||Completed|August 2008|||May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|56|||Both|50 Years|86 Years|No|||October 2010|October 26, 2010|August 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00736775||151532|
NCT00737035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0130-00|Effectiveness of a Web-based Intervention for Guardians of Children Whose One Parent Has Murdered the Other|Testing an IHCA for Guardians of Survivors of Intraparental Homicide||University of Virginia|Yes|Withdrawn|July 2008|June 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|August 14, 2008||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00737035||151512|
NCT00737269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015043|A Complicated Skin and Soft-tissue Infection Patient Registry|A Prospective, Multi-center, Observational Registry Involving Patients Hospitalized With Complicated Skin and Soft Tissue Infections (cSSTI) for IV Antibiotic Therapy||Ortho-McNeil Janssen Scientific Affairs, LLC||Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|1081|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with complicated skin and soft tissue infections (specifically, diabetic foot        infections, surgical site infections, deep soft tissue abscess, cellulitis)|March 2013|March 1, 2013|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00737269||151494|
NCT00742326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080201|Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections|Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection||National Institutes of Health Clinical Center (CC)|Yes|Terminated|August 2008|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|August 26, 2008|Yes|Yes|Enrollment stopped prior to complete enrollment due to slow accrual|No|April 10, 2014|https://clinicaltrials.gov/show/NCT00742326||151110|The study failed to enroll to the originally established sample size due to slow enrollment.
NCT00742352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-EES-253-CTIL|PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy|||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|September 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|65 Years|N/A|No|Non-Probability Sample|Breast cancer patients at the Tel-Aviv Sourasky Medical Center Lung cancer patients at the        Tel-Aviv Sourasky Medical Center|August 2008|September 8, 2008|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742352||151108|
NCT00742937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIPVITA-001|Impact of Maternal Supplementation With Dual Megadose of Vitamin A|Impact of Supplementation With Dual Megadose of Vitamin A in the Post-partum About Vitamin A Levels in Breast Milk, Serum Levels of Vitamin A and Iron in the Binomial Mother-son and Growth and Morbidity of Children Under 6 Months||Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|July 2007|December 2008|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|239|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2009|July 28, 2009|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742937||151064|
NCT00742950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINPHACO|Refractive Change Induced by 2.8-mm Corneal Incision|Study of Refractive Change Induced by 2.8-mm Corneal Incisions for Cataract Surgery|CINPHA|Hospital Universitario Ramon y Cajal|Yes|Completed|August 2008|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|108|||Both|50 Years|80 Years|No|||May 2010|June 24, 2011|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742950||151063|
NCT00743184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-153-08-1|Trial of the Safety and Efficacy of Ozarelix in Patients With Benign Prostatic Hyperplasia (BPH)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)||Spectrum Pharmaceuticals, Inc|No|Terminated|September 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|860|||Male|50 Years|N/A|No|||August 2013|December 2, 2013|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743184||151045|
NCT00743431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04085|Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)|Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE).||Merck Sharp & Dohme Corp.|No|Completed|February 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|224|||Female|N/A|N/A|No|Non-Probability Sample|Women with advanced ovarian cancer with:        previous platin/taxane therapy and        documented measurable and/or evaluable advanced or metastatic cancer by radiological        imaging or increase of serum cancer antigen 125 (CA 125) according to Rustin et al.|March 2015|March 26, 2015|August 26, 2008|No|Yes||No|May 21, 2010|https://clinicaltrials.gov/show/NCT00743431||151026|
NCT00743444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00020|TLESR-impedance Study in Patients|A Double-blind, Placebo Controlled, Randomized, Two Centre Phase IIA Pharmacodynamic Cross-over Study to Assess the Effect of AZD3355, 65 mg Bid, on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in GERD Patients With an Incomplete Response to PPI Treatment||AstraZeneca|No|Completed|February 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|70 Years|No|||July 2013|July 17, 2013|August 26, 2008|Yes|Yes||No|March 16, 2011|https://clinicaltrials.gov/show/NCT00743444||151025|
NCT00743730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 05/02, HRRC 008-05|Parent Nurse Controlled Analgesic in Pediatric Patients With Developmental Delay|Outcomes And Parent Satisfaction Associated With Parent/Nurse Controlled Analgesia In Pediatric Patients With Developmental Delay|PNCA|Medical College of Wisconsin|No|Active, not recruiting|June 2005|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|300|||Both|4 Years|18 Years|No|||January 2013|January 2, 2013|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00743730||151003|
NCT00747617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060679|Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)|Theca Cell Function in Women With Polycystic Ovary Syndrome||University of California, San Diego|Yes|Completed|September 2007|September 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|25|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|September 4, 2008|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00747617||150708|
NCT00744939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13256|Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist|Prospective Non-randomized Observational (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Magnevist® Injection in Patients With Moderate Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information.||Bayer|No|Completed|November 2008|November 2013|Actual|July 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|168|Samples Without DNA|Serum creatinine must be obtained within 6 weeks of the administration of Magnevist, or as      currently recommended by the American College of Radiology. At the Baseline within 48 hrs.      pre-injection a chemistry panel will be obtained in all patients after intravenous access      has been obtained.|Both|2 Years|N/A|No|Probability Sample|All patients who are scheduled to undergo CE-MRI with Magnevist and for which the        inclusion and exclusion criteria are fulfilled are eligible for enrolment into the study.|September 2014|September 17, 2014|August 20, 2008|No|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT00744939||150912|Bayer HealthCare was informed about the release from the postmarketing surveillance (PMS) for Magnevist with a letter dated 02 JUN 2011. As a consequence Bayer HealthCare stopped enrollment for this study on 01 AUG 2011.
NCT00744653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-074|Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.|Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.||Copenhagen University Hospital at Herlev|Yes|Terminated|October 2008|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|August 29, 2008||No|Primary endpoint measure not suitable for evaluation|No|March 22, 2011|https://clinicaltrials.gov/show/NCT00744653||150933|Early termination due to too few objective respondes using the primary endpoint.
NCT00738907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK77493 (completed)|Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes.|Assessment of Beta Cell Mass by PET Scans With [11C] DTBZ in Longstanding Type 1 Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|November 2006|May 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 diabetes|February 2011|September 23, 2014|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738907||151370|
NCT00734695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitcbrn.CTIL|Comparing the Use of Vitamin c (Ascorbic Acid) in Eye Burn in Subconjunctival Injection to Topical or Oral Treatment.|The Effect of Subconjunctival Vitamin c on Recovery Rate and End Result From Eye Burn.||The Baruch Padeh Medical Center, Poriya|No|Withdrawn|July 2009|February 2010|Anticipated|November 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|N/A|90 Years|No|||February 2010|February 28, 2010|August 13, 2008||No|couldn't recruit patients|No||https://clinicaltrials.gov/show/NCT00734695||151689|
NCT00734994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003239|Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer|Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy||Duke University|No|Completed|April 2008|March 2011|Actual|February 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||June 2015|June 1, 2015|May 4, 2008|Yes|Yes||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00734994||151666|
NCT00735254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-352|Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars|Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars||The Cleveland Clinic|Yes|Completed|July 2008|January 2010|Actual|July 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|20|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||January 2010|January 18, 2010|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735254||151647|
NCT00735280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01408|Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI|Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions|ISAR-REACT-3A|Deutsches Herzzentrum Muenchen|No|Completed|August 2008|March 2011|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2505|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735280||151645|
NCT00735293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASER AxHH|VASER Treatment of Axillary Hyperhidrosis/Bromidrosis|The Use of the VASER System in the Treatment of Axillary Hyperhidrosis and/or Axillary Bromidrosis|VASER AxHH|Commons Aesthetic Plastic Surgery|No|Completed|April 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 17, 2008|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00735293||151644|
NCT00735566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS 04-105|Antiangiogenic Factors in Gastric Cancer|The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression||National Cancer Center, Korea|No|Completed|April 2006|January 2012|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|Samples Without DNA|Serum for protein assay using ELISA|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Eligible patients will undergo subtotal or total gastrectomy with D2 lymph node dissection|October 2012|October 16, 2012|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735566||151623|
NCT00735579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-BR-21/08-1|Wound Healing Abnormalities in Major Abdominal Surgery|Incidence of Wound-healing-abnormalities in Major Abdominal Surgery - Association With Factors of Coagulation|INWOUND|Klinikum St. Georg gGmbH|No|Recruiting|July 2008|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|260|Samples Without DNA|1) serum samples for measurement of coagulation factors|Both|18 Years|85 Years|No|Non-Probability Sample|patients undergoing major abdominal surgery|December 2015|December 27, 2015|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735579||151622|
NCT00736541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-acetylcysteine in OLT|N-Acetylcysteine in Liver Transplantation|Investigation of the Efficacy of N-Acetylcysteine (NAC) to Protect Against Hepato-Renal Ischemia-Reperfusion Injury in Patients Undergoing Orthotopic Liver Transplantation|NAC|University of Pittsburgh|Yes|Completed|July 2004|January 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|N/A|No|||August 2008|August 15, 2008|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736541||151550|
NCT00737048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015109|A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain|A Double-Blind Comparative Study of JNS013 in Patients With Post-Tooth-Extraction Pain||Janssen Pharmaceutical K.K.|No|Completed|March 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|328|||Both|20 Years|74 Years|No|||April 2015|April 13, 2015|August 14, 2008|Yes|Yes||No|March 25, 2013|https://clinicaltrials.gov/show/NCT00737048||151511|
NCT00737282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-305|Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids|A Phase III, Open-Label, Parallel, Randomized, Multicenter Study Evaluating the Safety of 25 And 50 mg Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids||Repros Therapeutics Inc.|Yes|Terminated|October 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Female|18 Years|48 Years|No|||August 2014|August 5, 2014|August 14, 2008|Yes|Yes|Repros stopped study for safety and FDA put study on hold.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00737282||151493|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00742638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00057|To Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.|An Open Label, Randomised, Valproate-Controlled Study to Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|March 2008|August 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||August 2008|August 26, 2008|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742638||151086|
NCT00746499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #08-0984|Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.|A Phase 1, Open-Label Study, Investigating First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Uninfected Women||University of North Carolina, Chapel Hill|No|Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|September 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00746499||150794|
NCT00746772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 023|Efficacy of Purslane in Treatment of Oral Lichen Planus|Treatment of Oral Lichen Planus Lesions||Qazvin University Of Medical Sciences|No|Completed|April 2006|August 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|25 Years|70 Years|No|||September 2010|September 7, 2010|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746772||150773|
NCT00747019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0106|Prosocial Behavior and Exercise Among Older Adults|Prosocial Behavior and Exercise Among Older Adults||National Institute on Aging (NIA)|Yes|Recruiting|December 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||June 2009|June 30, 2009|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747019||150754|
NCT00747032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYC 0462-01-01|To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis|Multi-Center, Double-Blind, Randomized, Vehicle-controlled, Parallel-Group Study Comparing NYC-0462 Ointment To a Vehicle Control||Nycomed|No|Withdrawn|September 2010|April 2011|Anticipated|February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|September 1, 2008|Yes|Yes|Study withdrawn due to business decisions. No subjects were treated.|No||https://clinicaltrials.gov/show/NCT00747032||150753|
NCT00747344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015313|A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis||Centocor, Inc.|Yes|Completed|December 2008|March 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|121|||Both|20 Years|N/A|No|||March 2013|March 22, 2013|September 4, 2008|Yes|Yes||No|September 5, 2012|https://clinicaltrials.gov/show/NCT00747344||150729|
NCT00744315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP3549|Induced Angiogenesis by Genic Therapy in Advanced Ischemic Cardiomyopathy|Induced Angiogenesis by Genic Therapy With VEGF165 in Advanced Ischemic Cardiomyopathy - Historical Controlled Trial|THEANGIOGEN|Instituto de Cardiologia do Rio Grande do Sul|Yes|Recruiting|November 2007|May 2009|Anticipated|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|75 Years|No|||July 2008|October 14, 2008|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00744315||150958|
NCT00744666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07142008|IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids|IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids|IVTA:PRE-TREAT|Hotel Dieu Hospital|No|Recruiting|September 2008|July 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|70|||Both|18 Years|N/A|No|||August 2009|August 4, 2009|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744666||150932|
NCT00745485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HAU27|Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid|A Phase IV Study of the Safety and Feasibility of Rooms-based Infusion of Zoledronic Acid for Women With Post-menopausal Osteoporosis|LISA|Novartis||Completed|August 2008|||July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|186|||Female|70 Years|N/A|No|||February 2012|February 1, 2012|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00745485||150871|
NCT00745199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4146|Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus|Phase II Study of the Effect of Oral Cromolyn Sodium on Uremic Pruritus and Serum Tryptase Levels of Hemodialysed Patients||Shiraz University of Medical Sciences|Yes|Completed|May 2008|June 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|75 Years|No|||August 2009|August 17, 2009|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745199||150893|
NCT00745472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30071993|Auditory Evoked Potentials and Experimental Pain|The Amplitude of Auditory Evoked Potentials and the Intensity of Experimental Pain Stimulation in Healthy Volunteers||Odense University Hospital|No|Completed|October 2007|July 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|September 2008|September 2, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745472||150872|
NCT00734734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P7S|Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009, When Administered to Elderly Subjects||Novartis||Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|64|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|August 13, 2008||No||No|December 21, 2015|https://clinicaltrials.gov/show/NCT00734734||151686|
NCT00735020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V104P1|Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines|A Phase I, Observer-Blind, Randomized, Single-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines in Healthy Adults Aged 18 to 39 Years.||Novartis||Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|72|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735020||151664|
NCT00735267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361022|A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)|A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder||Pfizer|No|Terminated|October 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|468|||Both|18 Years|65 Years|No|||November 2012|November 9, 2012|August 12, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00735267||151646|
NCT00735033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|coetica-130/2004|The Effects of the Swiss Ball on Cerebral Vascular Accident|The Effects of the Swiss Ball on Patients With Hemiplegia Due to Cerebral Vascular Accident||Fortaleza University|Yes|Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|19 Years|65 Years|Accepts Healthy Volunteers|||May 2008|August 18, 2008|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735033||151663|
NCT00735891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-009|A Trial for Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer|Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second Line Treatment of Stage IIIB or IV NSCLC||Milton S. Hershey Medical Center|Yes|Active, not recruiting|December 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|August 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00735891||151598|
NCT00736242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04584|Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)|Treatment of Chronic Hepatitis C in HIV-infected Patients With PegIntron Pen and Rebetol According to German Law (§ 67 Abs 6 AMG)||Merck Sharp & Dohme Corp.|No|Completed|December 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|232|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects coinfected with HIV and HCV seen in common medical practice by general        practitioners and clinical doctors at 30 sites all over Germany.|February 2015|February 2, 2015|July 30, 2008|No|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT00736242||151572|
NCT00736229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-206|Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients|Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit||Saint Luke's Health System|Yes|Completed|August 2008|August 2012|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|August 14, 2008|Yes|Yes||No|June 4, 2013|https://clinicaltrials.gov/show/NCT00736229||151573|Modest number of patients enrolled, not powered to examine the effects of exenatide on hard clinical outcomes, no randomization, differences in baseline glucose levels and duration of therapy.
NCT00736788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0980C00005|Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers|A Phase 1, Single-Centre, Randomised, Double-Blind (Within Panels), Placebo-Controlled Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1704 After Administration of Oral Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers||AstraZeneca|Yes|Terminated|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|August 14, 2008||No|AZD1704 has essentially similar PK profile in Japanese subjects as in Caucasians. One of the    main purposes of the study has thereby been achieved.|No||https://clinicaltrials.gov/show/NCT00736788||151531|
NCT00737074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806056R|Macular Hole in Diabetic Retinopathy|Macular Hole in Proliferative Diabetic Retinopathy With Fibrovascular Proliferation||National Taiwan University Hospital|Yes|Completed|January 2002|December 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|23|||Both|20 Years|80 Years|No|Non-Probability Sample|Paitient with proliferative diabetic retinopathy|August 2008|August 15, 2008|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00737074||151509|
NCT00737295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT Biliary Dyskinesia|Ultrasound for Diagnosis of Biliary Dyskinesia|Study to Investigate the Role of Ultrasound for Diagnosis of Biliary Dyskinesia||Texas Tech University Health Sciences Center|No|Terminated|May 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|89 Years|No|||November 2010|November 15, 2010|August 14, 2008||No|PI left institution, study interest wained-so stopped.|No||https://clinicaltrials.gov/show/NCT00737295||151492|
NCT00737607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97034|Clinical Outcome Study of Minimally Invasive Decompression for Lumbar Spinal Stenosis|Clinical Study of Microendoscopic Decompressive Laminotomy for Treatment of Lumbar Spinal Stenosis|MEDLLSS|Far Eastern Memorial Hospital|Yes|Recruiting|January 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|40 Years|N/A|No|Probability Sample|The patients with degenerative lumbar spinal stenosis who failed conservative treatment.|August 2008|August 18, 2008|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737607||151468|
NCT00737620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11111|Evaluation of Heparin Bonded Vascular Graft Versus Standard Graft in Prosthetic Arteriovenous Access for Hemodialysis|Evaluation of Heparin Bonded Vascular Graft Versus Standard Graft in Prosthetic Arteriovenous Access for Hemodialysis||Shaare Zedek Medical Center|No|Completed|March 2008|||November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||December 2011|October 29, 2012|August 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00737620||151467|
NCT00746200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801047R|Acupuncture for Chronic Constipation|Randomised Controlled Trial of Acupuncture for Patients With Chronic Constipation||National Taiwan University Hospital|Yes|Completed|October 2008|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 10, 2010|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00746200||150817|
NCT00746213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-059|Chronic Pain After Thoracotomy, an Incidence Study|Chronic Pain After Thoracotomy, an Incidence Study||Rigshospitalet, Denmark|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1340|||Both|18 Years|N/A|No|Non-Probability Sample|Post thoracotomy patients after lung cancer in Denmark|June 2009|June 3, 2009|July 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00746213||150816|
NCT00746798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-244-004|Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults|Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults.|WinVax004|Sanofi|Yes|Completed|October 2008|December 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|479|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 17, 2015|September 2, 2008|Yes|Yes||No|September 27, 2011|https://clinicaltrials.gov/show/NCT00746798||150771|
NCT00747045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080721|Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients|A Prospective Single Blind Controlled Study to Assess the Efficacy of a Lung Protective Ventilation Strategy in the Prevention of Reperfusion Lung Injury Following PTE||University of California, San Diego|Yes|Completed|August 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|128|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747045||150752|
NCT00747058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0361006|A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects||Pfizer|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 7, 2010|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00747058||150751|
NCT00747357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBM-VS-57INDICOR/CRI/07-02/n-c|INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent|The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent to Treat Coronary Artery Disease in a Real World Scenario|INDICOR|Heart Centre Rotenburg|Yes|Completed|September 2008|January 2016|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747357||150728|
NCT00747630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS Study|Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome (FAS)|Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome||Texas Tech University Health Sciences Center|No|Terminated|May 2006|January 2010|Actual|January 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|99|||Female|12 Years|16 Years|No|||December 2012|December 14, 2012|September 4, 2008|No|Yes|This project was not a clinical trial requiring registration|No||https://clinicaltrials.gov/show/NCT00747630||150707|
NCT00747877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC-HM05/7287|High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy|Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue.||National Cancer Institute (NCI)||Recruiting|April 2008|||April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||June 2009|August 9, 2013|September 4, 2008||||No||https://clinicaltrials.gov/show/NCT00747877||150688|
NCT00747890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5551817|Surgical Treatment of Mild Obstructive Sleep Apnea|The Effects of Surgical Treatment on Mild Obstructive Sleep Apnea and Its Co-morbidities||Kuopio University Hospital|No|Recruiting|September 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|65 Years|No|||October 2011|October 31, 2011|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747890||150687|
NCT00744055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00032|Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).|The Use of Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).||Yale University|Yes|Completed|January 2009|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|21 Years|65 Years|No|||December 2015|December 11, 2015|August 28, 2008||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT00744055||150978|
NCT00744679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS406|A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State|An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions||Biogen|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|55 Years|No|||February 2015|February 6, 2015|August 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00744679||150931|
NCT00744692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008753|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders|A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation||Duke University|No|Completed|October 2008|April 2014|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|21 Years|No|||July 2014|July 23, 2014|August 28, 2008|Yes|Yes||No|July 23, 2014|https://clinicaltrials.gov/show/NCT00744692||150930|
NCT00745225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A111-101|Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients|Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?|PPAR|The University of Hong Kong|Yes|Completed|February 2006|December 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|20 Years|75 Years|No|||October 2015|October 14, 2015|September 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745225||150891|
NCT00745498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0801-053-004|Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy|Efficacy Study of Pre- and Intra-operative Intravitreal Bevacizumab Injection on Postoperative Vitreous Hemorrhage After Diabetic Vitrectomy|IBDV|Seoul National University Bundang Hospital|Yes|Completed|June 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|126|||Both|20 Years|N/A|No|||November 2015|November 17, 2015|September 2, 2008||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00745498||150870|
NCT00735319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7034|Transcutaneous Bilirubinometers in the Community|Transcutaneous Bilirubinometers in the Community and the Reduction of Morbidity Associated to Jaundice: A Clustered Randomized Controlled Trial.|TcB RCT|University of Alberta|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|10000|||Both|N/A|2 Weeks|No|||January 2010|January 11, 2010|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735319||151642|
NCT00734708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCB-1D-03|Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)|||Kaken Pharmaceutical|No|Completed|August 2008|||March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|328|||Both|20 Years|N/A|No|||June 2012|June 14, 2012|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734708||151688|
NCT00735046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR-683-KUR-0000-I|Cognitive Behavioural Therapy of Early Dementia|Cognitive Behavioural Resource-based Therapy of Early Dementia in the Everyday Setting|KORDIAL|Technische Universität München|Yes|Completed|April 2008|April 2010|Actual|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|None Retained|not required|Both|18 Years|95 Years|No|Non-Probability Sample|Patients referred to memory clinics and specialist (psychiatrist, neurologist) offices|July 2008|January 13, 2011|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735046||151662|
NCT00735592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012-08-EMC|Value of Radiological Follow up in Children Hospitalized With Lobar Pneumonia|The Study Intend to Evaluate the Usefulness of Performing a Follow up X Rays in Children Admitted With Lobar Pneumonia.||HaEmek Medical Center, Israel|No|Completed|March 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|3 Months|18 Years|No|Probability Sample|All pediatric patients admitted during the years 2006 and 2007 with the diagnosis of lobar        pneumonia.|August 2011|August 25, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735592||151621|
NCT00735605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anismus surgical and non|Comparative Study Between Surgical and Non Surgical Treatment of Anismus in Patients|Comparative Study Between Surgical and Non Surgical Treatment of Anismus in Patients With Symptoms of Obstructed Defecation||Mansoura University|Yes|Completed|September 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|20 Years|69 Years|No|||January 2010|January 12, 2010|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735605||151620|
NCT00736255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001248|Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study|Lis-dexamphetamine (LDX/SPD489)as a Treatment for Smoking Cessation in Nicotine Dependent Individuals With ADHD||Duke University|No|Completed|December 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|May 21, 2013|August 13, 2008|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00736255||151571|Limitations of the study: 1. Our sample size was quite small and this can realistically only be considered a pilot trial. 2.We did not collect systematic follow-up data on our sample after the end of treatment.3.the duration of our trial was short.
NCT00736554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-173|What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?|Prevalence of MRSA in Skin and Soft Tissue Infections in Two Ontario Emergency Departments.|CA-MRSA|Lawson Health Research Institute|No|Completed|July 2008|November 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|||Both|18 Years|N/A|No|Non-Probability Sample|Selection of Participants: The objective of this prospective study is to determine the        prevalence of MRSA and community acquired MRSA (CA-MRSA) in adult patients (>17 yrs old)        presenting with skin or soft tissue infections to the emergency departments (EDs) of an        academic health care setting in London, Ontario.|January 2011|January 4, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736554||151549|
NCT00736801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-1111|Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma|Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma||University of Rostock|No|Completed|September 2005|April 2007|Actual|January 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736801||151530|
NCT00737061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0071|Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)|A Multi-Center, Prospective Evaluation of the Adiana System for Transcervical Sterilization Using Electrothermal Energy in Women Aged 18-45 - The EASE Trial|EASE|Hologic, Inc.|Yes|Terminated|November 2002|December 2015|Anticipated|December 2005|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|770|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|February 7, 2013|August 14, 2008|Yes|Yes|Product Pre-Market Approval withdrawn|No|August 26, 2009|https://clinicaltrials.gov/show/NCT00737061||151510|At the time of analysis, 481 completed 3 years. Due to the cumulative nature of the analysis, subjects may be lost to follow-up at one time and return to follow-up at a subsequent point. All subjects who have not withdrawn consent will be followed.
NCT00737633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-231|Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults|An Open-Label, Non-Randomized Multicenter Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults||VIVUS, Inc.|No|Terminated|August 2008|June 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|19 Years|70 Years|No|||September 2012|September 5, 2012|August 17, 2008|Yes|Yes|Limited regulatory value to uncontrolled trials. No safety/efficacy concerns.|No|July 31, 2012|https://clinicaltrials.gov/show/NCT00737633||151466|
NCT00737646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-4555|Evaluation of an Intervention to Increase Colorectal Cancer Screening in Primary Care Clinics|Evaluation of an Intervention to Increase Colorectal Cancer Screening in Primary Care Clinics||Centers for Disease Control and Prevention|No|Completed|July 2009|December 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|5066|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737646||151465|
NCT00746512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-088|A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)|A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Access the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler Ultrasound Signal of Synovium in Patients With Rheumatoid Arthritis||Merck Sharp & Dohme Corp.||Completed|September 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|September 3, 2008|No|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00746512||150793|
NCT00746525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS063275|Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke|Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke||Louis Stokes VA Medical Center|No|Recruiting|September 2008|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|1||Anticipated|66|||Both|22 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 23, 2014|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746525||150792|
NCT00746785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1AA014886|A New Pharmacotherapy for Alcohol Dependence: Olanzapine|A New Pharmacotherapy for Alcohol Dependence: Olanzapine||The Mind Research Network|No|Completed|September 2002|September 2011|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|304|||Both|21 Years|55 Years|No|||January 2014|January 30, 2014|September 2, 2008|Yes|Yes||No|November 15, 2013|https://clinicaltrials.gov/show/NCT00746785||150772|
NCT00747643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15444|Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement|Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|163|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|November 21, 2013|September 4, 2008||No||No|July 27, 2011|https://clinicaltrials.gov/show/NCT00747643||150706|
NCT00747903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613601|Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer|Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma||National Cancer Institute (NCI)||Recruiting|February 2008|||December 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|N/A|No|||July 2009|January 9, 2014|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00747903||150686|
NCT00743769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-MI-101|A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 1 Study of the Safety and Tolerability of the Intravenous Administration of Thymosin Beta 4 and Its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers||RegeneRx Biopharmaceuticals, Inc.|No|Completed|April 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|August 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743769||151000|
NCT00744068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018208-01A1|Four Models of Telephone Support for Stimulant Recovery|Four Models of Telephone Support for Stimulant Recovery||University of California, Los Angeles|Yes|Completed|April 2006|September 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|302|||Both|18 Years|65 Years|No|||May 2013|May 3, 2013|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744068||150977|
NCT00744081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG-R1|Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)|Open-Label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)||Johann Wolfgang Goethe University Hospitals||Recruiting|July 2004|||December 2007|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|130|||Both|18 Years|N/A|No|||August 2008|August 28, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744081||150976|
NCT00745212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508080|Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women|Prospective Multicentric Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women With a Risk of Thromboembolism and/or a Risk of Placental Vascular Complication, Strategy Determined With a Risk Score.|STRATHEGE|Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|June 2008|June 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2280|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|November 2013|November 6, 2013|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00745212||150892|
NCT00745758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803080R|The Factors Cause Vasospasm After Aneurysmal Subarachnoid Hemorrhage|The Factors Cause Vasospasm After Aneurysmal Subarachnoid Hemorrhage||National Taiwan University Hospital|Yes|Recruiting|May 2008|September 2008|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|CSF|Both|18 Years|80 Years|No|Non-Probability Sample|patient of spontaneous SAH|September 2008|September 2, 2008|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00745758||150850|
NCT00745771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-II-02|Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness|Multiple Dose, Double-Blind, Double-Dummy, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness From Exercise||IDEA AG|No|Completed|October 2007|November 2008|Actual|February 2008|Actual|Phase 2|Interventional|Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 19, 2009|September 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00745771||150849|
NCT00746044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO07-CLG/COVOL|Measurement of MRP2 Function Using Urinary Coproporphyrins|Evaluation of the Ratio of Urinary Coproporphyrins I and III as a Potential Biomarker of MRP2 Function in Man|COVOL|University Hospital, Tours|No|Completed|February 2008|April 2009|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples With DNA|24h urine DNA|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|40 healthy subjects > 18 y 20 male, 20 female|May 2009|May 14, 2009|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00746044||150829|
NCT00735332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLN-232-202|Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma|A Phase IIa Study of TLN-232 as Second-line Therapy for Patients With Metastatic Melanoma||Thallion Pharmaceuticals|No|Terminated|August 2008|October 2010|Anticipated|December 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||August 2010|August 4, 2010|August 13, 2008|Yes|Yes|License termination.|No||https://clinicaltrials.gov/show/NCT00735332||151641|
NCT00735306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001597|Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma|A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma|TART|Duke University|No|Completed|July 2008|October 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2015|May 22, 2015|August 13, 2008|Yes|Yes||No|October 14, 2011|https://clinicaltrials.gov/show/NCT00735306||151643|
NCT00735904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061038|Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer|Phase 2 Trial Of AG-013736 As First-Line Treatment For Patients With Squamous Non-Small Cell Lung Cancer Receiving Treatment With Cisplatin And Gemcitabine||Pfizer|No|Completed|December 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|August 13, 2008|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00735904||151597|
NCT00736814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000609880|First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Genotype-driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy||National Cancer Institute (NCI)||Recruiting|June 2008|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|117|||Both|18 Years|N/A|No|||August 2009|February 23, 2011|August 15, 2008||||No||https://clinicaltrials.gov/show/NCT00736814||151529|
NCT00736567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0008|Evaluation of a Diagnostic Enteric Card for Management of Diarrhea|Evaluation of a Diagnostic Enteric Card for Management of Diarrhea in a Clinical Site in Fortaleza, Brazil||PATH|No|Completed|May 2008|May 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|436|Samples Without DNA|Stool samples are retained for future research.|Both|N/A|N/A|No|Non-Probability Sample|Patients presenting with diahrreal symptom to out-patient care facilities in Fortaleza,        Brazil.|September 2009|October 27, 2014|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736567||151548|
NCT00736580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20783|Glove Perforation When Using Blunt Verses Sharp Needles in Cesarean Delivery|Glove Perforation When Using Blunt vs. Sharp Needles in Cesarean Delivery||West Virginia University|No|Completed|June 2008|September 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|240|||Female|18 Years|N/A|No|||December 2012|December 18, 2012|August 14, 2008||No||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00736580||151547|
NCT00737308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRG5180145|Properties and Clinical Performance of Zirconia-based Dental Ceramics|Properties and Clinical Performance of Zirconia-based Dental Ceramics||Mahidol University|No|Completed|June 2008|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|August 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00737308||151491|
NCT00737321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0051|Mechanisms Regulating Wound Vascularization|Mechanisms Regulating Wound Vascularization||Ohio State University|No|Active, not recruiting|August 2008|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|All participnts with wounds will have 3 mm punch biopsy performed twice or three times in      the whole study period.Obtained tissue sample will be processed immidiately and frozen in      liquid nitrogen.The tissue sample will transport to research lab for genomic analysis.|Both|18 Years|69 Years|No|Non-Probability Sample|Patients (n=80)including controlled group will be recruited from the OSU outpatient wound        care center located at Morehouse plaza and OSU East, OSU plastic surgery, OSU diabetic        clinics.|September 2015|September 28, 2015|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737321||151490|
NCT00743782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080203|Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism|Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism||National Institutes of Health Clinical Center (CC)||Completed|August 2008|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|7 Years|70 Years|No|||April 2014|October 9, 2014|August 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743782||150999|
NCT00747370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5302421|Dynamic MRI of the Behaviour of Female Pelvic Floor|The Suitability of Dynamic MRI for Pelvic Floor, Bladder Neck and Midurethra||Kuopio University Hospital|No|Completed|January 2002|June 2008|Actual|December 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|74|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2008|September 4, 2008|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747370||150727|
NCT00747383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0201/57|How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.|Influence of Improving Glycaemic Control on Glucagon-Like-Peptide-1 Response to an Oral Glucose Load. Comparison of Sulphonylurea With DPP-4 Inhibition.|MSD-GLP1|The Royal Bournemouth Hospital|Yes|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|80 Years|No|||September 2008|December 4, 2012|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747383||150726|
NCT00743808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03527-06-C|Hypertension and Diabetes Initiative - Improving Hypertension Control in Individuals With Diabetes|Improving Hypertension Control in Individuals With Diabetes||HealthPartners Institute|No|Completed|December 2006|September 2010|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11510|||Both|18 Years|75 Years|No|Probability Sample|Primary care clinic|August 2013|November 30, 2015|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00743808||150997|
NCT00744705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2008-0076-3|Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians|Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians||Yonsei University|Yes|Not yet recruiting|September 2008|December 2008|Anticipated|November 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal subjects who recieved a regular medical check-up in a comprehensive medical testing        center of our institute|August 2008|August 29, 2008|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744705||150929|
NCT00744718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000878-20|Bevacizumab and Carboplatin for Patients With Ovarian Cancer|Bevacizumab and Carboplatin for Patients With Platin Resistant Epithelial Ovarian Cancer. A Phase II Study.||Vejle Hospital|Yes|Active, not recruiting|August 2008|August 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744718||150928|
NCT00744952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5515|Use of MRI and PET for Assessing Disease Activity in Takayasu's Arteritis|VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-vessel Vasculitis (Takayasu's Arteritis):Development as Clinical Trial Outcome Measures||University of Pennsylvania|Yes|Recruiting|August 2008|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Participants in this study will have been diagnosed with Takayasu's arteritis and will be        currently enrolled in the Vasculitis Clinical Research Consortium (VCRC) Longitudinal        Study #5503.|September 2015|September 4, 2015|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744952||150911|
NCT00744965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032011-086|Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo|A Randomized Controlled Clinical Trial of Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo||University of Texas Southwestern Medical Center|No|Active, not recruiting|August 2008|January 2016|Anticipated|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|395|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744965||150910|
NCT00746057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2-E|Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft (Protocol DPRC Array)|Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft.||Nantes University Hospital|No|Terminated|May 2006|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|134|||Both|18 Years|65 Years|No|||September 2013|September 27, 2013|September 2, 2008||No|The number of included patients is sufficient.|No||https://clinicaltrials.gov/show/NCT00746057||150828|
NCT00746603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB4447|Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors|A Feasibility Study to Evaluate the Safety of Simvastatin in Young Adults Treated for Hodgkin's Disease||Columbia University|Yes|Terminated|January 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|35 Years|No|||July 2013|July 17, 2013|September 2, 2008||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00746603||150786|
NCT00735943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751031|Macugen Observational Study|Macugen Observational Study||Pfizer|No|Terminated|November 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|90 Years|No|Non-Probability Sample|To be eligible for enrollment in this study, patients must receive the first injection of        Macugen intravitreal in at least one eye for treatment of wet age-related macular        degeneration (AMD).|August 2011|August 26, 2011|August 14, 2008||No|See termination reason in detailed description.|No|July 21, 2011|https://clinicaltrials.gov/show/NCT00735943||151594|Outcome measures were not designated as primary or secondary measures as this study was an observational non-interventional study.
NCT00735618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0028|Relaxation and Heart Rate Variability|Pilot Study on the Effects of a Brief Relaxation Program on Heart Rate Variability in Cancer Patients||M.D. Anderson Cancer Center|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||November 2011|November 15, 2011|August 12, 2008||No||No|March 3, 2009|https://clinicaltrials.gov/show/NCT00735618||151619|
NCT00735917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00194|Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer|A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer||National Cancer Institute (NCI)||Completed|October 2008|October 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2013|April 25, 2014|August 14, 2008|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT00735917||151596|
NCT00735930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00269|Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase 1 Trial of Flavopiridol in Combination With Lenalidomide in Patients With Relapsed or Refractory B-Cell CLL/SLL||National Cancer Institute (NCI)||Completed|August 2008|November 2014|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2015|April 1, 2015|August 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00735930||151595|
NCT00736619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-084|Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2008|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|100 Years|No|||September 2015|September 25, 2015|August 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00736619||151544|
NCT00736632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103002|Vitamin D, Insulin Resistance, and Cardiovascular Disease|Vitamin D, Insulin Resistance, and Cardiovascular Disease||Washington University School of Medicine|Yes|Recruiting|May 2006|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|25 Years|80 Years|No|||June 2015|June 1, 2015|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736632||151543|
NCT00737087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT0515|Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder|A Multi-centred, Non-comparative, Non-randomised, Open, Post Marketing Investigation to Look at the Long-term Clinical Efficacy of the Delta Xtend Reverse Total Shoulder Used in the Treatment of Shoulders With Rotator Cuff Deficiencies.||DePuy International|No|Terminated|October 2007|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|18 Years|85 Years|No|||August 2014|August 4, 2014|August 15, 2008||No|Study was stopped due to low follow-up compliance at study sites.|No||https://clinicaltrials.gov/show/NCT00737087||151508|
NCT00737100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.339|Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis|A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 mcg and 5 mcg) Administered Once Daily Via the Respimat Device for 12 Weeks in Patients With Cystic Fibrosis.||Boehringer Ingelheim||Completed|September 2008|||April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|510|||Both|N/A|N/A|No|||January 2014|May 7, 2014|August 15, 2008||||Yes|March 21, 2011|https://clinicaltrials.gov/show/NCT00737100||151507|
NCT00737113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001910|Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant|Recombinant Human Growth Hormone(RH-GH) For Accelerating Immune Reconstitution In Pediatric and Adult Patients Undergoing Allogeneic Stem Cell Transplantation||Duke University|No|Terminated|September 2008|December 2013|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|12 Years|N/A|No|||March 2014|March 18, 2014|August 15, 2008|No|Yes|Study was terminated early due to low accrual.|No||https://clinicaltrials.gov/show/NCT00737113||151506|
NCT00737659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21706|CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients|Phase IV, Open-Label, Multicenter, Randomized Study Comparing Mycophenolate Mofetil (MMF) Dose Adjustment Based on Blood MPA Concentration to Standard Care Treatment With MMF in Renal Transplant Recipients Receiving Tacrolimus|MMF|Rabin Medical Center|No|Recruiting|August 2008|August 2013|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|70 Years|No|||December 2008|March 25, 2010|August 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00737659||151464|
NCT00747656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA006-0708-01|Prehospital Evaluation and Economic Analysis of Different Coronary Syndrome Treatment Strategies - PREDICT|The Impact of Prehospital 12 Lead ECG With Advanced Emergency Department Notification on Time to In-hospital Reperfusion Strategy in Patients With Acute ST Segment Elevation Myocardial Infarction - A Prospective Study|PREDICT|St. Joseph's Healthcare Hamilton|No|Active, not recruiting|February 2009|May 2013|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted across Ontario. Selected regions representing approximately        17% of the population of Ontario and 6.4% of the popluation of Canada. Covering an area of        181426 per square kilometers with variable population densities from 2.5 to 234 person per        square kilometers and representing rural, suburban, urban, and metropolis areas will be        the catchment area for the study. A variety of EMS operators under the control of EMS Base        Hospital programs will be involved in the data collection for this study. Patients        presenting with suspected ischemic chest pain will be tracked as a part of the trial.|May 2013|May 7, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747656||150705|
NCT00744094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-3-062B|Resistance Training in Elderly|The Influence of Resistance Training on Body Composition and Muscle Characteristics in Healthy Elderly||Maastricht University Medical Center|No|Completed|January 2007|July 2008|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||August 2008|September 22, 2015|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744094||150975|
NCT00744107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59-2004|Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease|The Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease||Medlogics Device Corporation|Yes|Active, not recruiting|August 2008|September 2010|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|258|||Both|18 Years|N/A|No|||April 2009|August 4, 2009|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00744107||150974|
NCT00744367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20963|A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone||Hoffmann-La Roche||Completed|October 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|326|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744367||150954|
NCT00744380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0570|Dexmedetomidine Versus Midazolam for Facilitating Extubation|Dexmedetomidine vs. Midazolam for Facilitating Extubation in Medical and Surgical ICU Patients: A Randomized, Double-Blind Study||University of Colorado, Denver|No|Completed|August 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|August 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744380||150953|
NCT00744328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH057102|Postpartum Depression: Transdermal Estradiol Versus Sertraline|Postpartum Depression: Transdermal Estradiol Versus Sertraline|E2SERT|Northwestern University|Yes|Terminated|August 2008|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Female|18 Years|45 Years|No|||October 2014|October 20, 2014|August 28, 2008||No|Recruitment Issues|No|October 13, 2014|https://clinicaltrials.gov/show/NCT00744328||150957|
NCT00744341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S320.2.011|Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure|A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subjects Hospitalized With Acute Decompensated Heart Failure and Renal Dysfunction (Reno-Defend 1)||Solvay Pharmaceuticals|Yes|Terminated|February 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|46|||Both|18 Years|N/A|No|||September 2010|September 16, 2010|August 28, 2008|Yes|Yes|This study was stopped 29OCT2009 due to strategic drug development considerations|No||https://clinicaltrials.gov/show/NCT00744341||150956|
NCT00744354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0715|Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|October 2008|April 2015|Actual|December 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|August 29, 2008|No|Yes|Drugs unavailable|No||https://clinicaltrials.gov/show/NCT00744354||150955|
NCT00744731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333369EPY3014|An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures|The Open Label Extension Portion of the Study Entitled A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.||SK Life Science||Completed|January 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|403|||Both|16 Years|N/A|No|||June 2013|June 10, 2013|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744731||150927|
NCT00745511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-DAMD-01|Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)|A Randomized, Multi-Center, Double Blind, 3 Arm, Phase I/II Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)||Ora Bio Ltd.|Yes|Recruiting|March 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|96|||Both|50 Years|N/A|No|||June 2009|June 7, 2009|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745511||150869|
NCT00746616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-100|Durom(R) Hip Resurfacing System Multicenter Trial|Durom(R) Hip Resurfacing System Multicenter Trial||Zimmer, Inc.|No|Completed|June 2007|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||April 2013|April 2, 2013|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746616||150785|
NCT00746629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD54871 (completed)|Familial Overweight: Comparing Use of Strategies|Behavioral Skill Adherence in Pediatric Obesity Treatment|FOCUS|Seattle Children's Hospital|No|Completed|May 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746629||150784|
NCT00735670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDNO60032SS|Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury|Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury||University of Michigan|Yes|Recruiting|June 2008|August 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||January 2011|March 2, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735670||151615|
NCT00735631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/489|Evaluation of the Accuracy, Safety and Robustness of a Single-input-single-output (SISO) Model-based Predictive Closed-loop System to Guide Patient-individualized ICU Sedation|Evaluation of the Accuracy, Safety and Robustness of a Single-input-single-output (SISO) Model-based Predictive Closed-loop System to Guide Patient-individualized ICU Sedation.||University Hospital, Ghent|No|Completed|June 2008|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|75 Years|No|||December 2011|December 6, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735631||151618|
NCT00735644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC02|Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines|Lot-to-lot Consistency, Bridging, and Safety Trial of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines||Sanofi|Yes|Completed|August 2008|August 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|1200|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||April 2015|April 1, 2015|August 14, 2008||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00735644||151617|
NCT00736593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEX-SKI-001|A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.|A Phase 1 Randomized, Prospective, Within-Subject, Double-Blind, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Full-Thickness Punch Wounds||CoDa Therapeutics Inc.|Yes|Completed|September 2008|April 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2009|April 23, 2009|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736593||151546|
NCT00736606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1520C00008|A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy Volunteers|A Phase I, Single Centre, Open-Label Study to Assess the Pharmacokinetics of Both AZD9056 (Steady State) and Simvastatin (Single Dose) When Co-Administered in Healthy Volunteers||AstraZeneca|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736606||151545|
NCT00736840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIS-EX-408|BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis|Pivotal Study to Evaluate the Efficacy and Safety of the BreathID® System for Detection of Cirrhosis Using the ¹³C-methacetin Breath Test(MBT)|MBT|Exalenz Bioscience LTD.|Yes|Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|414|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|August 14, 2008|Yes|Yes||No|June 16, 2011|https://clinicaltrials.gov/show/NCT00736840||151527|Technical problems caused the termination of 2 subjects who did not complete breath test. Liver biopsy, 1 patient refused and others had signs of HCC thus disqualified.
NCT00736827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anae_ICU_Ulm_BKV|BK Virus and Renal Dysfunction in Postoperative/Posttraumatic Critically Ill Patients|BK Virus and Renal Dysfunction in Postoperative/Posttraumatic Critically Ill Patients|BICUK|University of Ulm|No|Completed|August 2008|December 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|51|Samples With DNA|Whole blood, serum, white blood cells; urine|Both|18 Years|N/A|No|Probability Sample|Postoperative/posttraumatic critically ill patients admitted to the intensive care unit|December 2015|December 2, 2015|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736827||151528|
NCT00737334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:095|EEG, Cerebral Oximetry, and Arterial to Jugular Venous Lactate to Assess Cerebral Ischemia During Carotid Endarterectomy|A Comparison of the EEGo Monitor, BIS Monitor, and FORE-SIGHT Cerebral Oximeter With Arterial to Jugular Venous Lactate Difference to Assess Cerebral Ischemia During Carotid Endarterectomy||University of Manitoba|No|Completed|September 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|85 Years|No|||November 2009|November 9, 2009|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737334||151489|
NCT00737347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309-015|Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone|Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone||Northwestern University|No|Completed|September 2003|April 2008|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|39|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2008|August 18, 2008|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737347||151488|
NCT00738478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMC-RCTGastric01|Quality of Life After Routine Nasogastric Decompression After Distal Gastrectomy for Gastric Cancer Patients|Phase III Study for the Significance of Nasogastric Decompression Tube After Curative Distal Gastrectomy for Gastric Cancer Patients||Wakayama Medical University|Yes|Completed|February 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|20 Years|80 Years|No|||February 2009|February 17, 2009|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738478||151403|
NCT00744848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPLE Hemorrhoidectomy 312|Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy|Phase 3, Multicenter, Randomized, Double-Blind, Parallel-group, Active-control Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy||Pacira Pharmaceuticals, Inc|No|Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|204|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|August 28, 2008|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00744848||150919|
NCT00747669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3274-401|Pharmacokinetic Study of Synera™ in Neonates and Infants|A Pharmacokinetic Study of Synera™ (Lidocaine 70 mg and Tetracaine 70 mg Topical Patch) to Evaluate the Systemic Exposure to Lidocaine and Tetracaine in Neonates and Infants||ZARS Pharma Inc.|No|Suspended|September 2008|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|11|||Both|N/A|4 Months|No|||March 2012|March 22, 2012|September 3, 2008|No|Yes|Difficulty with enrollment|No||https://clinicaltrials.gov/show/NCT00747669||150704|
NCT00747929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701A2823|Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet|A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800, or 1600 mg/Day of S-2367 Administered Orally Once Daily With a Reduced Calorie Diet in Obese Males and Females||Shionogi Inc.|No|Completed|June 2007|January 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|724|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|September 13, 2011|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00747929||150684|
NCT00747942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-1165|Support for Increased Physical Activity (Stöd Till Aktivare Motion)|Intervention Program for Physically Inactive and Overweight Immigrant Women From the Middle East and Latin America Living in Sweden|STAM|Karolinska Institutet|No|Active, not recruiting|October 2006|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|234|||Female|25 Years|64 Years|No|||September 2008|September 5, 2008|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747942||150683|
NCT00743795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-196-0103|Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS 9190, in Combination With Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection (GS-US-196-0103)||Gilead Sciences|Yes|Completed|October 2008|September 2013|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|252|||Both|18 Years|70 Years|No|||October 2013|October 11, 2013|August 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743795||150998|
NCT00744393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEMC-8479|The Effect of Sodium Oxybate on Sleep Architecture|The Effect of Sodium Oxybate on Sleep Architecture in Critically Ill Patients: A Double-Blind, Crossover Pilot Study||Tufts Medical Center|No|Withdrawn|October 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 29, 2008|Yes|Yes|Sponsor pulled funding secondary to economy issues|No||https://clinicaltrials.gov/show/NCT00744393||150952|
NCT00744120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0108|Lymphoma Follow-up|Lymphoma Follow-up Protocol||National Institutes of Health Clinical Center (CC)|No|Completed|October 2003|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|51|Samples Without DNA|Blood serum|Both|21 Years|N/A|No|Non-Probability Sample|Patients, previously entered on NIH study who may be eligible if they have rare, unusual,        interesting or unknown conditions that require diagnosis|December 2013|December 19, 2013|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744120||150973|
NCT00744978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051101|Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease|A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Crossover Trial of Varenicline Tartrate (CP-526,555) in Patients With Mild to Moderate Alzheimer's Disease||Pfizer|Yes|Completed|July 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|55 Years|85 Years|No|||October 2011|October 12, 2011|August 29, 2008|Yes|Yes||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00744978||150909|
NCT00745238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801|Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy|Four Weeks Withdrawal of Non-invasive Ventilation (NIV) in Patients With Myotonic Dystrophy: Cardiovascular, Metabolic and Daytime Vigilance Induced Changes||University Hospital, Grenoble|No|Recruiting|June 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Both|18 Years|N/A|No|||September 2008|August 10, 2012|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00745238||150890|
NCT00745784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-100|Prolonged Grief in Young Bereaved Spouses and Partners|Lost to Cancer: Prolonged Grief in Young Bereaved Spouses and Partners||Memorial Sloan Kettering Cancer Center||Completed|January 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|20 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Only spouses/partners of deceased Calvary and Memorial Sloan Kettering patients will be        assessed in this study.|August 2011|August 17, 2011|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745784||150848|
NCT00746343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08020071|Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study|Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study|MedRisk|University of Pittsburgh|No|Completed|September 2008|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|55 Years|No|||December 2013|December 11, 2013|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746343||150806|
NCT00746356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40005027|Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds|A Clinical Evaluation of the Current™ Radio Frequency (RF) Implantable Cardioverter Defibrillator (ICD) Models 2215/1215 and Promote™ RF Cardiac Resynchronization Therapy Defibrillator (CRT-D) Model 3215 Pulse Generators||St. Jude Medical|No|Completed|August 2008|January 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|September 2, 2008|Yes|Yes||No|July 24, 2011|https://clinicaltrials.gov/show/NCT00746356||150805|
NCT00746928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-CHUG-23|Cardiovascular Consequences of Intermittent Hypoxia in Healthy Subjects|Cardiovascular Consequences of Intermittent Hypoxia in Healthy Subjects||University Hospital, Grenoble|No|Active, not recruiting|September 2005|October 2008|Anticipated|July 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 3, 2008|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00746928||150761|
NCT00746941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111JC101|Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)|A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)||Biogen|No|Terminated|January 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|75 Years|No|||July 2014|July 2, 2014|September 3, 2008|Yes|Yes|Primary endpoint not achieved|No|January 3, 2013|https://clinicaltrials.gov/show/NCT00746941||150760|From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early.
NCT00735995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186036/V50|Effectiveness of Cognitive Behavioral Therapy (CBT) for Child Anxiety Disorders in Community Clinics in Norway|Effectiveness of Group and Individual Treatment of Childhood Anxiety Disorders in Community Clinics. A Randomized Controlled Trial.||Regionsenter for barn og unges psykiske helse|No|Completed|August 2008|December 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|165|||Both|7 Years|12 Years|No|||April 2014|April 11, 2014|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735995||151591|
NCT00736008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-08-EMC|Thrombophilic Risk Factors in Pediatric Patients Diagnosed at the Ha'Emek Medical Center|The Study Will Summarize the Clinical and Laboratory Data of All the Pediatric Patients Diagnosed With Thrombotic Events at the Pediatric Hematology Unit||HaEmek Medical Center, Israel|No|Completed|May 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|20 Years|No|Non-Probability Sample|The population cohort will include about 100 patients diagnosed with thrombotic events at        the Pediatric Hematology Unit|August 2011|August 25, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736008||151590|
NCT00736268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003707|Coping Skills for Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Caregivers|Telephone-based Intervention for Patients With COPD and Their Caregivers||Duke University|Yes|Completed|August 2008|||May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|746|||Both|21 Years|N/A|No|||August 2014|August 6, 2014|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00736268||151570|
NCT00736281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-ENT-1118937|Sublingual Immunotherapy for Food Allergy|Sublingual Immunotherapy for Food Allergy||University of Missouri-Columbia|Yes|Active, not recruiting|October 2008|October 2019|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|4 Years|N/A|No|||October 2015|October 28, 2015|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736281||151569|
NCT00737672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR 06-01|GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis|GORE VIABAHN® Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients|REVISE|W.L.Gore & Associates|Yes|Completed|September 2008|June 2013|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|293|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|August 15, 2008|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT00737672||151463|
NCT00737126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo02|The Effect of Folic Acid Administration in the Progression of Microalbuminuria|Folic Acid Administration Reduces the Progression of Microalbuminuria||Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|January 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2008|August 18, 2008|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737126||151505|
NCT00738166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2007-0078|Content, Bioavailability and Health Effects of Trace Elements and Bioactive Components in Organic Agricultural Systems||OrgTrace|University of Copenhagen||Recruiting|October 2007|December 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|August 20, 2008|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738166||151425|
NCT00744536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MDS-PI-128|Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat Higher Risk Myelodysplastic Syndromes|Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: a Phase 2 Study"|REMMYDYS|Sunnybrook Health Sciences Centre|Yes|Completed|January 2008|December 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744536||150942|
NCT00744861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-SPINE0907|Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar Surgery|EXO-SPINE: A Prospective, Multi-center, Double-blind, Randomized, Placebo Controlled Pivotal Study of Ultrasound as Adjunctive Therapy for Increasing Posterolateral Fusion Success Following Single Level Posterior Instrumented Lumbar Surgery|EXO-SPINE|Bioventus LLC|No|Terminated|September 2008|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|81 Years|No|||July 2013|July 23, 2013|August 29, 2008|Yes|Yes|Terminated following interim analysis|No||https://clinicaltrials.gov/show/NCT00744861||150918|
NCT00747955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080205|Evaluation of Assessments of Motor Performance, Physical Impairments and Functional Abilities|Evaluation of Assessments of Motor Performance, Physical Impairments and Functional Abilities||National Institutes of Health Clinical Center (CC)||Recruiting|August 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|May 20, 2015|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00747955||150682|
NCT00743821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075553|Eye-Tracking Rapid Attention Computation|Eye-Tracking Rapid Attention Computation|Eye-TRAC|Brain Trauma Foundation|No|Completed|October 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|426|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|TBI patients will be recruited from an outpatient TBI clinic Normals will be        friends/family of TBI patients who have not suffered a TBI, as well as individuals        recruited from the community|May 2014|May 5, 2014|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743821||150996|
NCT00744133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0053|Malaria Challenge With NF54 Strain|An Interventional Plasmodium Falciparum Malaria Challenge Model Utilizing the NF54 Strain of Parasite Transmitted by Aseptic A. Stephensi Mosquitoes to Healthy Malaria-Naïve Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2009|November 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|August 7, 2014|August 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744133||150972|
NCT00745004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08027|Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D)|Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D): Identifying the "Responder"||University of Nottingham|No|Completed|January 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||January 2012|January 23, 2012|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00745004||150907|
NCT00744744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600461|Health-Related Quality of Life in Patients With Bladder Cancer|A CROSS-SECTIONAL STUDY OF PATIENT-REPORTED OUTCOMES FOR BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE||Baylor College of Medicine|No|Completed|May 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|138|||Both|18 Years|N/A|No|Non-Probability Sample|Persons diagnosed with bladder cancer within 4 years of study entry|February 2012|February 1, 2012|August 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00744744||150926|
NCT00744991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11496|A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma|A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma||Eli Lilly and Company|No|Completed|September 2008|February 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744991||150908|
NCT00745251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-204|A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults||VIVUS, Inc.|No|Completed|August 2008|December 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|30 Years|65 Years|No|||September 2012|September 5, 2012|August 31, 2008|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00745251||150889|
NCT00745264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-033-I-04|Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise|Multi-Centre, Open-Label, Two Segment, Parallel Group Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise||IDEA AG||Completed|October 2007|May 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 19, 2009|September 2, 2008||||No||https://clinicaltrials.gov/show/NCT00745264||150888|
NCT00745277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB#4133|High and Low Dose Treatment of Carbidopa in Parkinson's Disease|A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.||Oregon Health and Science University|Yes|Completed|August 2008|May 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|35 Years|85 Years|No|||November 2012|November 28, 2012|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745277||150887|
NCT00745524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801026R|Screening for Attention-deficit/Hyperactivity Disorder (ADHD) in Adolescent and Adult High Risk Populations|Screening for Attention-deficit/Hyperactivity Disorder (ADHD) in Adolescent and Adult High Risk Populations||National Taiwan University Hospital|Yes|Completed|February 2008|December 2009|Actual|||N/A|Observational|Observational Model: Case Control||1|Actual|1910|||Both|13 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Imprisoned adults; adolescents with problems in school and followed by three private        charitable organizations; community sample|April 2012|May 16, 2012|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00745524||150868|
NCT00746070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200611031R|Postoperative Cardiovascular Index Change of Primary Aldosteronism|Postoperative Cardiovascular Index Change of Primary Aldosteronism|TAIPAI|National Taiwan University Hospital|No|Enrolling by invitation|January 2007|January 2013|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|aldosteronism Patients enrolled from initial screening test and recorded in the Taiwan        Primary Aldosteornism Investigation (TAIPAI) database. The database was constructed for        quality assurance since 2003 in one medical center (National Taiwan University Hospital,        Taipei, Taiwan) and its three branch hospitals in different cities (National Taiwan        University Hospital Yun-Lin branch, Yun-Lin, southern Taiwan; Far-Eastern Memorial        Hospital, Taipei; Tao-Yuan General Hospital, Tao-Yuan, middle Taiwan). All patients with        intention to confirm and requiring suppression test or adrenal venous sampling were        recruited and data were prospectively collected.|April 2010|May 3, 2010|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00746070||150827|
NCT00746642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-EV -1.0|Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study|Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study||Mellitor|No|Not yet recruiting|October 2009|October 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2009|June 2, 2009|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746642||150783|
NCT00746954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP-006-07F|Buspirone as a Potential Treatment for Recurrent Central Apnea|Buspirone as a Potential Treatment for Recurrent Central Apneas|CSA treatment|VA Office of Research and Development|Yes|Terminated|September 2008|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|8|||Both|40 Years|75 Years|No|||February 2016|February 16, 2016|September 2, 2008||No|Patient recruitment and Funding inadequate to finish trial|No|November 5, 2013|https://clinicaltrials.gov/show/NCT00746954||150759|VA population turned out to have a high number of heart failure patients who had psychiatric co-morbidity or were empirically treated with antidepressants, precluding participation.There were not enrolled enough participants.
NCT00736658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00012|AZD1386 Japanese Multiple Ascending Dosing Study|A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Japanese Young and Elderly Subjects After Oral Multiple Doses.|JMAD|AstraZeneca|No|Completed|June 2008|September 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 29, 2009|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736658||151541|
NCT00735956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006998|PARTNER Recruitment and Brief Intervention Pilot Study|PARTNER: The Underage Drinking: Building Health Care System Research|PARTNER|Duke University|No|Completed|September 2008|August 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||August 2010|August 19, 2010|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735956||151593|
NCT00735969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080149|High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1|High Dose Ribavirin in Combination With Peginterferon for Patients With Chronic Hepatitis C Genotype 1 Infection Who Have Failed to Respond or Relapsed After Standard Therapy||National Institutes of Health Clinical Center (CC)|No|Completed|August 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|65 Years|No|||October 2014|October 10, 2014|August 14, 2008|Yes|Yes||No|June 16, 2014|https://clinicaltrials.gov/show/NCT00735969||151592|
NCT00736645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000611962|Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer|A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy||Roswell Park Cancer Institute|Yes|Active, not recruiting|August 2008|||December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|55|||Male|18 Years|120 Years|No|||October 2015|October 12, 2015|August 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00736645||151542|
NCT00737919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215953|The Influence of Dietary Plant Sterols and Plant Stanols on Cholesterol and Plant Sterol Levels in Atheromatous Plaques|The Influence of Dietary Plant Sterols and Plant Stanols on Cholesterol and Plant Sterol Levels in Atheromatous Plaques||Helsinki University|No|Completed|May 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|80 Years|No|||August 2008|February 9, 2011|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00737919||151444|
NCT00737932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-LAQ-201|Laquinimod Phase IIa Study in Active Crohn's Disease|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn's Disease.||Teva Pharmaceutical Industries||Completed|May 2010|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|75 Years|No|||March 2015|March 19, 2015|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737932||151443|
NCT00737906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-505DHH|Surgical Reduction of the Inferior Turbinates for Nasal Obstruction|Surgical Reduction of the Inferior Turbinate Using a Coblation® Device for Treatment of Nasal Obstruction: A Prospective, Multi-center Clinical Study||ArthroCare Corporation|No|Terminated|October 2007|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|6 Years|17 Years|No|||August 2015|August 25, 2015|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737906||151445|
NCT00744549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0580-B|Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance|The Impact of Antioxidants on MRI Markers of Cell Proliferation and Hypoxia Among Men on Active Surveillance With Early Stage Prostate Cancer||University Health Network, Toronto|No|Suspended|May 2008|||December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|N/A|No|||July 2015|July 14, 2015|August 29, 2008||No|Study is currently on hold and recruitment may resume in the future|No||https://clinicaltrials.gov/show/NCT00744549||150941|
NCT00744562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M18-001|A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors||OncoMed Pharmaceuticals, Inc.|No|Completed|August 2008|January 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||October 2012|October 10, 2012|August 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00744562||150940|
NCT00743834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIIT-07-LCR001a|Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)|Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD||Rogers Center for Research & Training, Inc.|No|Not yet recruiting|September 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 3, 2008|August 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743834||150995|
NCT00744146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOPK 4439|First Time in Human Study of Protexia|Phase I, Randomized, Controlled, Third-party Double-blind, Dose Escalating Study of Protexia Administered Intramuscularly at One or Two Time Points in Healthy Human Volunteers||PharmAthene, Inc.|Yes|Completed|September 2008|November 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 16, 2010|August 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00744146||150971|
NCT00745303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH91-365-1|Effect of Tai Chi Chuan on Autonomic Nervous Modulation in Aged Subjects|Effect of Tai Chi Chuan on Autonomic Nervous Modulation, Blood Lipid and Cytokines Production in Aged Subjects||Taipei Veterans General Hospital, Taiwan|No|Completed|May 2002|March 2004|Actual|May 2003|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples Without DNA|Blood sample obtained from each subject was withdrawn for the quantitative measurements of      total cholesterol (TC), high-density lipoprotein--cholesterol (HDL-C), high-density      lipoprotein--cholesterol (LDL-C), triglyceride (TG), fasting blood sugar (FBS), and uric      acid (UA). The immunoenzymometric assays for the quantitative measurement of tumor necrosis      factor-α (TNF-α) and interferon-γ (IFN-γ) in the serum were also performed on the blood      sample from each subject.|Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy aged subjects|September 2008|September 1, 2008|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00745303||150885|
NCT00744757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014785|An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)|A Phase II Multi-center Study of 5-AZA-2'-Deoxycytidine (Decitabine) Single Agent in Taiwanese Patients With Myelodysplastic Syndrome (MDS)||Johnson & Johnson Taiwan Ltd|No|Completed|August 2008|August 2012|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||August 2013|August 26, 2013|August 29, 2008|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00744757||150925|
NCT00745290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPLE TKA 311|A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Active Control Study to Evaluate the Safety and Efficacy of a Single Intraoperative Administration of SKY0402 For Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty|TKA|Pacira Pharmaceuticals, Inc|No|Completed|August 2008|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|245|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|August 29, 2008|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00745290||150886|
NCT00745537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7473|T- BOOM Teens--Building Options and Opportunities for Moms|Teens--Building Options and Opportunities for Moms|T-BOOM|University of Pittsburgh|No|Completed|April 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|23|||Female|10 Years|17 Years|No|||May 2015|May 27, 2015|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745537||150867|
NCT00745797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLC0801|Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy|Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy：A Multi-center Randomized Phase ⅢTrial|PCI|Chinese Society of Lung Cancer|Yes|Terminated|April 2008|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|75 Years|No|||January 2014|January 27, 2014|September 2, 2008|Yes|Yes|this trial enroll extremely slow and No funding support|No||https://clinicaltrials.gov/show/NCT00745797||150847|
NCT00745810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705022R|Anesthetic Management and Remote Reperfusion Injuries|The Effects of Anesthetic Management on Oxidative Injuries After Cardiopulmonary Bypass||National Taiwan University Hospital|No|Completed|August 2008|December 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|None Retained|whole blood and plasma|Both|20 Years|75 Years|No|Non-Probability Sample|patients who receive an open heart surgery under cardiopulmonary bypass|June 2011|October 13, 2011|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00745810||150846|
NCT00746369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005355|IMARA, Adapting SiHLE for Detained African American Adolescent Females|IMARA, Adapting SiHLE for Detained African American Adolescent Females|IMARA|Emory University|No|Completed|October 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|188|||Female|13 Years|17 Years|Accepts Healthy Volunteers|||May 2013|November 18, 2013|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746369||150804|
NCT00746382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2351-001-EM|A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)|A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis||Nycomed|No|Withdrawn|November 2008|September 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||May 2012|May 4, 2012|September 3, 2008|Yes|Yes|Study withdrawn due to business decisions. No subjects were treated.|No||https://clinicaltrials.gov/show/NCT00746382||150803|
NCT00746655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-042|SBRT + TACE for Primary Hepatocellular Carcinoma|A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)||University of Pittsburgh|Yes|Withdrawn|July 2009|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|September 2, 2008|Yes|Yes|Unable to recruit|No||https://clinicaltrials.gov/show/NCT00746655||150782|
NCT00746668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6246-R|A Multi-Center Study of Reading Rehabilitation in Macular Disease|A Multi-Center Study of Reading Rehabilitation in Macular Disease||VA Office of Research and Development|No|Completed|August 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|7||Actual|36|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|September 3, 2008||No||No|December 22, 2014|https://clinicaltrials.gov/show/NCT00746668||150781|
NCT00746967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481133|An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder|An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder||Pfizer||Completed|January 2003|February 2004|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|267|||Female|18 Years|N/A|No|||September 2008|September 3, 2008|March 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746967||150758|
NCT00747279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSD001|Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke|Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke||Hospital Sao Domingos|No|Recruiting|June 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||September 2008|September 8, 2008|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747279||150734|
NCT00736294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608066|Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter|Prevention of Atrial Fibrillation by the Prescription of Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter|PREFACE|Centre Hospitalier Universitaire de Saint Etienne|Yes|Terminated|July 2008|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 14, 2008||No|Difficulty to include patients|No||https://clinicaltrials.gov/show/NCT00736294||151568|
NCT00737360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS106-9905|Phase II Study of TAS-106 to Treat Head and Neck Cancer|Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy||Taiho Pharmaceutical Co., Ltd.|Yes|Terminated|August 2008|February 2012|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|August 18, 2008|Yes|Yes||No|April 20, 2012|https://clinicaltrials.gov/show/NCT00737360||151487|
NCT00737373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLOT65+|Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer|A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile||Krankenhaus Nordwest|No|Completed|August 2007|March 2011|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|65 Years|N/A|No|||August 2012|September 18, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737373||151486|
NCT00744575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200/08|Assessment of a Specific Neurophysiological Brain Pattern in Patients Suffering From Chronic Back Pain|Assessment of a Specific Neurophysiological Brain Pattern in Patients Suffering From Chronic Back Pain||University Hospital Freiburg|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|72|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|chronic back pain|January 2009|October 8, 2010|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744575||150939|
NCT00744588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA016668|Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism|Stress, HPA Dysfunction, and Relapse in Alcoholism||University of Texas Southwestern Medical Center|No|Completed|August 2007|March 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|75|Samples With DNA|serum plasma whole blood urine|Male|18 Years|60 Years|No|Non-Probability Sample|Inpatient treatment facility for substance use disorders.|January 2013|January 2, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00744588||150938|
NCT00744250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC-2712|Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control|Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency||Digestive Care, Inc.|No|Terminated|August 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|3|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|August 28, 2008|No|Yes|No longer required study by FDA for NDA approval.|No||https://clinicaltrials.gov/show/NCT00744250||150963|
NCT00746187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-MIC-0003|Study to Compare Marginal Bone Loss Around Implants From Two Dental Implant Systems.|An Open, Randomized Study to Compare Two Dental Implant Systems With Regard to Changes in Marginal Bone Level.||Dentsply Implants|No|Completed|December 2002|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||March 2014|March 12, 2014|September 2, 2008|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT00746187||150818|
NCT00736112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-ENT- 1120277|Food Allergy - Tubes - Adenoids (FATA) Trial|A New Approach to Otitis Media With Effusion (OME)|FATA|University of Missouri-Columbia|Yes|Withdrawn|October 2008|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|N/A|4 Years|No|||May 2015|May 27, 2015|August 14, 2008||No|The investigator left the institution|No||https://clinicaltrials.gov/show/NCT00736112||151582|
NCT00745069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004183|Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis|4-Week Randomized Multicenter DB, Placebo- and Active-controlled, Parallel-group, Forced-titration Phase 2B Study of Efficacy and Safety With CG5503 Prolonged Release (PR) to 233 mg BID and Oxycodone PR to 20 mg BID vs Placebo in Subjects With Moderate to Severe Chronic Pain of Knee Osteoarthritis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2004|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|670|||Both|40 Years|N/A|No|||April 2010|May 17, 2011|August 29, 2008||||||https://clinicaltrials.gov/show/NCT00745069||150902|
NCT00745095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6428-R|Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage|Efficacy and Safety of Bowel Preparations for Colonoscopy in SCI||VA Office of Research and Development|No|Completed|March 2009|May 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|6||Actual|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|July 2, 2014|September 2, 2008|No|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT00745095||150901|
NCT00744406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160/2001|Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression|Patient Dimensions as Predictors of Response, Relapse and Recurrence Following Cognitive-Behavioral Therapy, Interpersonal Psychotherapy and Pharmacotherapy Treatment of Patients With Major Depression.||Centre for Addiction and Mental Health|No|Completed|July 2003|||September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|60 Years|No|||August 2008|August 29, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744406||150951|
NCT00744770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002524|TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.|A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial in Subjects on Stable Methadone Maintenance Therapy, to Investigate the Potential Interaction Between TMC278 25 mg q.d. and Methadone, at Steady-state.||Tibotec Pharmaceuticals, Ireland||Completed|October 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|August 29, 2008||||No||https://clinicaltrials.gov/show/NCT00744770||150924|
NCT00745316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161HF201|Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency|POSEIDON|Biogen|Yes|Terminated|February 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|34|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 2, 2008|Yes|Yes|Company Decision|No||https://clinicaltrials.gov/show/NCT00745316||150884|
NCT00745550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB1518-2008-003|A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis|A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis||S*BIO|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|September 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00745550||150866|
NCT00745823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-071|A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)|A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients||Merck Sharp & Dohme Corp.|Yes|Terminated|September 2008|May 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|775|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|September 2, 2008|Yes|Yes|Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg    once daily versus raltegravir 400 mg twice daily|No|March 6, 2012|https://clinicaltrials.gov/show/NCT00745823||150845|The study was terminated before the 96-week efficacy analysis. Adverse event data were collected for the entire treatment period up to a maximum of Week 108, which defines the Overall Study period.
NCT00745836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-200508|Effects of Atorvastatin on Adiponectin Levels and Insulin Sensitivity In Hypercholesterolemic Patients|||Gachon University Gil Medical Center|Yes|Completed|January 2005|August 2008|Actual|||Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|1||||||Both|25 Years|80 Years|No|||September 2008|September 2, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745836||150844|
NCT00746083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21033|Challenge!, a Health Promotion/ Obesity Prevention Program for Teens|Randomized Controlled Trial for Health Promotion/ Obesity Prevention Targeting Low-Income, Urban, African-American Adolescents||University of Maryland|Yes|Completed|April 2001|January 2007|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|235|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||September 2008|September 2, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746083||150826|
NCT00746096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKH-01-6|Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea|Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Primary Dysmenorrhea.||Nobelpharma|Yes|Completed|September 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|115|||Female|16 Years|N/A|No|||June 2014|June 12, 2014|August 29, 2008||No||No|April 8, 2014|https://clinicaltrials.gov/show/NCT00746096||150825|
NCT00746395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-096|Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy|Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy||University of South Alabama|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|46|||Both|19 Years|90 Years|Accepts Healthy Volunteers|||June 2013|June 26, 2013|September 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746395||150802|
NCT00746681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8881001|Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder|A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder||Pfizer|No|Completed|December 2005|November 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|188|||Female|18 Years|N/A|No|||December 2009|December 18, 2009|April 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746681||150780|
NCT00746694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05020|A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)|Epidemiological Study to Assess the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Pegylated Liposomal Doxorubicin||Merck Sharp & Dohme Corp.|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|154|||Female|18 Years|N/A|No|Non-Probability Sample|Participants with metastatic ovarian or breast cancer, to be recruited from the Oncology        Departments of 16 centers for a period of 12 months.|August 2015|August 26, 2015|September 3, 2008|No|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT00746694||150779|
NCT00743392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34339-A|HPV Infections in Older Women|HPV Infections in Older Women||University of Washington|No|Completed|July 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|503|Samples With DNA|Vaginal swab samples for HPV DNA testing|Female|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|25 to 65 year old women who date online|November 2013|November 15, 2013|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00743392||151029|
NCT00743405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110623|Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects|Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects||GlaxoSmithKline||Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 29, 2009|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743405||151028|
NCT00737139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDV-08012802|Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine|A Prospective, Randomized, Double-Blind Controlled Clinical Trial to Evaluate the Post-Operative Blood Loss and Transfusion Rate Following Total Joint Arthroplasty With Intra-articular Injection of Bupivacaine and Epinephrine||Rush University Medical Center|No|Terminated|September 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|August 15, 2008||No|Prohibitively expensive and efficacy of tranexamic acid rendered topic clinically less    relevant.|No||https://clinicaltrials.gov/show/NCT00737139||151504|
NCT00737386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|leishpeduel-HMO-CTIL|Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank|||Hadassah Medical Organization|No|Enrolling by invitation|September 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|600|None Retained|Blood samples|Both|3 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|People living on regullar basis in Peduel (the site of current leishmania tropica        epidemic)with and without cutaneous signs of leishmania infection|August 2011|August 15, 2011|August 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00737386||151485|
NCT00748111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080201|Thrombus and Inflammation Study in Sudden Cardiac DEath|Thrombus and Inflammation in Sudden Cardiac DEath|TIDE|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2008|December 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|380|||Both|18 Years|80 Years|No|||December 2015|December 15, 2015|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00748111||150670|
NCT00736853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015112|An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain|A Phase 3 Study of JNS013 in Patients With Chronic Pain||Janssen Pharmaceutical K.K.|No|Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|321|||Both|20 Years|N/A|No|||July 2013|July 22, 2013|August 14, 2008|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00736853||151526|
NCT00737685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPHO-SCT0401|Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)|Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Bone Marrow (or Mobilized Peripheral Blood) Transplantation in Severe Aplastic Anemia||The Korean Society of Pediatric Hematology Oncology|No|Active, not recruiting|January 2006|December 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|25 Years|No|||March 2012|March 23, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737685||151462|
NCT00745641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807056R|Abdominal Computed Tomography and the Blood Reactive Oxygen Species Level|Effect of Abdominal X-ray Computed Tomography Examination on the Blood Reactive Oxygen Species Level||National Taiwan University Hospital|No|Withdrawn|September 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|None Retained|only peripheral blood will be collected for measurement of reactive oxygen species.|Both|20 Years|80 Years|No|Non-Probability Sample|patients with abdominal illness that needs a computed tomography examination|March 2009|August 5, 2009|September 1, 2008||No|because of the presence of unexpected administrative barrier to interfere the collection of    case|No||https://clinicaltrials.gov/show/NCT00745641||150859|
NCT00744874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFI-40|Ablation of the Pulmonary Veins for Paroxysmal Afib|Multi-Array Ablation of the Pulmonary Veins for Paroxysmal Atrial Fibrillation|MAP-PAF|Medtronic Atrial Fibrillation Solutions|No|Completed|October 2007|July 2011|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|70 Years|No|||December 2012|December 11, 2012|August 28, 2008||No||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00744874||150917|
NCT00736710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121/2007|rTMS Effects on Smoking Cessation and Cognition in Schizophrenia|Effects of rTMS on Smoking Cessation and Cognitive Outcomes in Outpatients With Schizophrenia Treated With Transdermal Nicotine Patch||Centre for Addiction and Mental Health|No|Completed|December 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|60 Years|No|||December 2012|December 4, 2012|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736710||151537|
NCT00736424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1616|Brain Stimulation for Epilepsy Long Term Follow-up|Brain Stimulation for Epilepsy Long Term Follow-up|SUDEP|MedtronicNeuro|Yes|Completed|June 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|9|||Both|N/A|N/A|No|Non-Probability Sample|The study will initially include five sites that conducted physician-sponsored studies in        the US and Canada. Centers may be added as additional patients are identified.|January 2014|January 10, 2014|June 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00736424||151559|
NCT00744796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102006-017|Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty|Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) in Patients With Corneal Endothelial Cell Dysfunction: Clinical Outcomes and Diagnostic Imaging Analysis|DSAEK|University of Texas Southwestern Medical Center|No|Recruiting|December 2006|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 29, 2008|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744796||150923|
NCT00745017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091/2003|Stress Generation and Recurrent Depression: The Role of Differential Treatment Response|Stress Generation and Recurrent Depression: The Role of Differential Treatment Response||Centre for Addiction and Mental Health|No|Completed|July 2001|||July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|60 Years|No|||August 2008|August 29, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00745017||150906|
NCT00745563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIDGE1 20/7/2008|Effects of Intra-uterine Slow-Release Insemination on Pregnancy Rate in Women Designated for Artificial Insemination|Testing the Effect of Intra-uterine Slow-Release Insemination (SRI) on the Pregnancy Rate in Women Designated for Artificial Insemination||Fertiligent|Yes|Completed|October 2008|December 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|20 Years|40 Years|No|||December 2008|June 8, 2011|August 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745563||150865|
NCT00745576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-1112|Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered|An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Verapamil Immediate Release (IR) and a Single Dose of SAM-531 When Co-administered Orally to Healthy Young Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 5, 2010|September 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00745576||150864|
NCT00745849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Efficacy Esomeprazole NAR|Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial|Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial||University of Texas Southwestern Medical Center|No|Completed|June 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||August 2008|August 29, 2008|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745849||150843|
NCT00745862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-096|Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma|Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma||Memorial Sloan Kettering Cancer Center||Completed|August 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|118|||Female|18 Years|N/A|No|Non-Probability Sample|Female melanoma patients during their regularly scheduled surgical clinic appointment at        MSKCC.|July 2013|July 23, 2013|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00745862||150842|
NCT00746109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-143|Study of Wound Packing After Superficial Skin Abscess Drainage|Randomized Clinical Trial of Wound Packing Following Incision and Drainage of Superficial Skin Abscesses in the Pediatric Emergency Department||New York University School of Medicine|Yes|Completed|September 2008|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|24 Years|No|||January 2011|January 3, 2011|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746109||150824|
NCT00746408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW Diss 3000490|Tailored Internet Information Supply for Patients|Study of the Quality of Self-Diagnosis by Headache Patients Getting Tailored Internet Information||Health & Life Sciences University, Tryol|Yes|Recruiting|January 2009|September 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|500|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|All German speaking adults in the German-speaking part of Europe who suffer at least        occasionally from headaches and have not been examined (concerning these headaches) by a        physician yet.          -  The population of the main study is narrowed down to a heterogeneous group of             insurants of a health insurance company.          -  The population of the online study is self-selecting.|June 2009|June 15, 2009|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746408||150801|
NCT00746421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009874|Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder|Phase IV Study of Quetiapine XR Aimed at Disability and Cognitive Impairments.||Emory University|Yes|Terminated|January 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||March 2014|March 31, 2014|September 3, 2008|Yes|Yes|Sponsor withdrew funding|No|September 13, 2013|https://clinicaltrials.gov/show/NCT00746421||150800|We were unable to perform the pre-planned primary and secondary statistical analyses between group comparisons as the groups sizes were too small to compare meaningfully.
NCT00746707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|feigenberg HMO-CTIL|Biologic Glue for First Degree Perineal Tears|Randomized Control Trial for the Comparison of Biologic Glue Versus Suturing for First Degree Perineal Tears||Hadassah Medical Organization|No|Completed|September 2008|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 17, 2011|September 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746707||150778|
NCT00746720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02B2005|Modulation of the Surgical Inflammatory Response by Etoricoxib|Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral Versus Central||University of Erlangen-Nürnberg Medical School|Yes|Terminated|May 2006|December 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|23|||Both|55 Years|80 Years|No|||May 2012|May 2, 2012|September 3, 2008||No|Patient recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00746720||150777|
NCT00748163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS098|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|August 2008|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|September 5, 2008|Yes|Yes|Study has been abandoned for lack of available funding.|||https://clinicaltrials.gov/show/NCT00748163||150666|
NCT00744003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006685|An Observational Study of Early Coagulopathy, or Clotting Disorder, in Injured Patients|Early Trauma Induced Coagulopathy (ETIC): A Pilot Study to Determine Its Definition and Risk Factors||Emory University|No|Withdrawn|July 2008|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Trauma patients arriving at a Level I trauma center who activated the Trauma Team criteria        for a "stat pack" trauma admission|November 2013|November 15, 2013|August 27, 2008||No|PI no longer at Emory; no participants enrolled, study not conducted|No||https://clinicaltrials.gov/show/NCT00744003||150982|
NCT00748124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN-06-001|PleuraSeal Pivotal Study (US)|A Prospective Multicenter Randomized Clinical Study to Evaluate the PleuraSeal Sealant System as an Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy||Integra LifeSciences Corporation|No|Terminated|August 2008|April 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|September 4, 2008|Yes|Yes|Interim analysis results were not supportive of primary endpoint|No||https://clinicaltrials.gov/show/NCT00748124||150669|
NCT00748137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/04/26/5.01|Bolus Insulin Card Calculator Randomised Controlled Study|Bolus Insulin Card Calculator Randomised Controlled Study||John Hunter Children's Hospital|No|Recruiting|March 2008|January 2011|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|11 Years|18 Years|No|||August 2009|February 5, 2010|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748137||150668|
NCT00737399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-CHOL-82008|Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)|Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)||Soul Medicine Institute|No|Recruiting|September 2008|December 2018|Anticipated|April 2018|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|14|||Both|18 Years|89 Years|No|||January 2016|January 14, 2016|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737399||151484|
NCT00743964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2008-04-027|Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)|A Randomized Phase II Study of Combination Chemotherapy With Epirubicin , Cisplatin and Capecitabine (ECX) or Cisplatin and Capecitabine (CX) in Advanced Gastric Cancer||Samsung Medical Center|No|Completed|April 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|N/A|75 Years|No|||January 2010|January 13, 2010|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743964||150985|
NCT00744263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3006|Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults|A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease|CAPITA|Pfizer|Yes|Completed|September 2008|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|84496|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 1, 2014|August 27, 2008|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00744263||150962|
NCT00744276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP1198-001|A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease|FP1198-001|FemmePharma Global Healthcare, Inc.|No|Completed|January 2007|June 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Female|18 Years|N/A|No|||May 2010|May 25, 2010|August 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744276||150961|
NCT00745927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802031R|Application of CO2 Insufflations in Colonoscopy Randomized Trial|Application of CO2 Insufflations in Colonoscopy Examination-A Single-blinded Randomized Trial||National Taiwan University Hospital|Yes|Recruiting|June 2008|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2012|August 13, 2012|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00745927||150837|
NCT00736463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004506|Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)|Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein||Oregon Health and Science University|No|Recruiting|January 2005|||January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2008|July 20, 2011|August 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00736463||151556|
NCT00736944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0911 / 201105504|Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer|Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy||Washington University School of Medicine|No|Active, not recruiting|October 2008|August 2020|Anticipated|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|August 13, 2008|Yes|Yes||No|November 18, 2013|https://clinicaltrials.gov/show/NCT00736944||151519|
NCT00744458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAHADIRA|Treat Arterial Hypertension and Diabetes in Rural Africa|A Prospective Randomised Trial Comparing Three Interventions to Improve Treatment Adherence Among Patients With Arterial Hypertension or Diabetes in Rural Cameroon (TAHADIRA-trial 1)|TAHADIRA|Cooperation Afrique|Yes|Completed|August 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|223|||Both|18 Years|N/A|No|||August 2009|May 26, 2010|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744458||150948|
NCT00744809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015088|TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.|A Phase I, Double-blind, Double-dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-state and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-state on the QT/QTc Interval, in 2 Randomized Panels of Healthy Volunteers||Tibotec Pharmaceuticals, Ireland||Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|||Actual|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|June 8, 2011|August 29, 2008||||||https://clinicaltrials.gov/show/NCT00744809||150922|
NCT00745030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-028R|Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism|Efficacy and Tolerability of Ramelteon in Patients With REM Behavior Disorder and Parkinsonism: A Placebo Controlled, Double Blind, Randomized, Prospective Pilot Study||Northwestern University|Yes|Terminated|June 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|N/A|N/A|No|||April 2011|April 18, 2011|August 28, 2008|Yes|Yes|Low subject recruitment and enrollment.|No|October 12, 2010|https://clinicaltrials.gov/show/NCT00745030||150905|
NCT00745043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTX/05/04/035|Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study|Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD?|BOLD|Waikato Hospital|No|Completed|May 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|11|||Both|40 Years|N/A|No|||August 2008|August 29, 2008|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00745043||150904|
NCT00745329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-SF-182-CTIL|The Effect of Infliximab on Sperm Quality|The Effect of Infliximab,Adalimumab, Azathioprines and 5-Aminosalicylate on Semen Quality in Men With Inflammatory Bowel Disease||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with inflammatory bowel disease (IBD) and healthy volunteers|September 2008|September 2, 2008|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00745329||150883|
NCT00745342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92-23|Optimizing Adherence and Glycemia in Youth With New Insulin-dependent Diabetes Mellitus (IDDM)|Optimizing Adherence and Glycemia in Youth With New IDDM||Joslin Diabetes Center|Yes|Completed|March 1999|October 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|8 Years|17 Years|No|||August 2015|August 6, 2015|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00745342||150882|
NCT00745589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A111-104|Sevelamer Hydrochloride in Peritoneal Dialysis Patients|Use of Sevelamer Hydrochloride to Control Hyperphosphatemia and Reduce Calcification Burden in the Poor Peritoneal Dialysis Patients||The University of Hong Kong|Yes|Completed|July 2008|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|80 Years|No|||September 2015|September 6, 2015|September 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745589||150863|
NCT00745875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00035|ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study|A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen||AstraZeneca|Yes|Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|September 2, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00745875||150841|
NCT00745888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709132|Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit|Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit||National Taiwan University Hospital|No|Recruiting|May 2007|||||Phase 3|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood sample|Both|18 Years|N/A|No|Probability Sample|Patients admitted to surgical ICU|August 2009|September 4, 2009|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745888||150840|
NCT00746135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H37|TRI-V Heart Failure (HF) Implanted Cardioverter Defibrillator (ICD) Study|TRI-V Resynchronization in Paced Heart Failure Patients With ICD Indication.|TRI-V|St. Jude Medical|No|Completed|November 2007|December 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00746135||150822|
NCT00746434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2351-002-EM|A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis|A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis||Nycomed|Yes|Withdrawn|November 2008|September 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||May 2012|May 4, 2012|September 3, 2008|No|Yes|Study withdrawn due to business decisions. No subjects were treated.|No||https://clinicaltrials.gov/show/NCT00746434||150799|
NCT00743132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 11-2008|Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection|Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection|StV 11-2008|University of Zurich|No|Completed|April 2008|December 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|569|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with benign and malign liver diseases of the Swiss HPB (Hepato-Pancreato-Biliary)        Center undergoing liver resection from 2002 - 2007|January 2010|January 22, 2010|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743132||151049|
NCT00743379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-402|Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors|A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors||Threshold Pharmaceuticals|No|Completed|August 2008|March 2014|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743379||151030|
NCT00734942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GT0619|Development and Implementation of Evidence-Based Family-Oriented Support for Young Carers and Their Families in Germany|Improved Health-Related Quality of Life for Young Carers and Their Families in Germany on the Basis of Evidence-Based Family-Oriented Support||University of Witten/Herdecke|No|Not yet recruiting|January 2009|March 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|8 Years|18 Years|No|||August 2008|December 22, 2008|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734942||151670|
NCT00734955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007857|An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients|An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients||Duke University|Yes|Recruiting|May 2006|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|530|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 10, 2015|August 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734955||151669|
NCT00744016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPUC3003|Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2004|October 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|305|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|August 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00744016||150981|
NCT00743977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URG/STEROP/001|Bioequivalence of Phenazopyridine HCl in Healthy Volunteers|2 Treatment, 2 Period, Randomized, Single Blinded, Crossover Bioequivalence of Phenazopyridine HCl in 24 Healthy Volunteers||Universal Enterprises|Yes|Active, not recruiting|August 2008|||November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2008|August 28, 2008|August 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743977||150984|
NCT00743990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29273|Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough|Effect of a Medicated Topical Therapy, Petrolatum, and No Treatment on Nocturnal Cough and Congestion for Children With Upper Respiratory Infections||Penn State University|Yes|Completed|October 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|143|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||August 2009|May 7, 2010|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743990||150983|
NCT00745108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06470|Tibolone Endometrium Study (Study 32972)(P06470)|A Multinational, Multicenter, Randomized, Double-blind, Parallel Group, Active Controlled, Comparative Trial, to Assess the Endometrial Histological Profile Following Treatment With Tibolone (Org OD14) Versus Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA) in Postmenopausal Women|THEBES|Merck Sharp & Dohme Corp.|Yes|Completed|October 2001|July 2005|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|32|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745108||150900|
NCT00745121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OSS-0007|Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis|An Open, Prospective, Non-randomized, Controlled, Multicenter Study to Evaluate Clinical Outcome of the ASTRA TECH Implant System, OsseoSpeed™ Implant in Women Over 60 Years of Age With Osteoporosis/Osteopenia||Dentsply Implants|No|Active, not recruiting|August 2008|||December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|60 Years|N/A|No|||March 2016|March 23, 2016|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745121||150899|
NCT00745134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0644|Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer|A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2008|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745134||150898|
NCT00744887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015421|TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.|Phase I, Open-label, Randomized, 3-way Crossover Trial to Assess the Pharmacokinetics of Darunavir (DRV) Given Once-daily With Different Doses of Ritonavir in Healthy Subjects.||Tibotec Pharmaceuticals, Ireland||Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|June 8, 2011|August 29, 2008||||||https://clinicaltrials.gov/show/NCT00744887||150916|
NCT00744900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFPC 07-01|Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)|A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL).|GFPC 07-01|University Hospital, Brest|Yes|Completed|September 2008|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||July 2009|July 24, 2009|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00744900||150915|
NCT00745147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803029M|Comparison of TCM and Laxatives for Adults With Chronic Constipation|Comparison of Chinese Herbal Formula and Lactulose for Adults With Chronic Constipation-a Randomized ,Double-Blind, Controlled Trial||National Taiwan University Hospital|Yes|Completed|July 2008|April 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|93|||Both|20 Years|N/A|No|||April 2010|May 3, 2010|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00745147||150897|
NCT00736723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anae_ICU_Ulm_NT-proBNP|NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock|NT-proBNP in Postoperative/Posttraumatic Critically Ill Patients With Severe SIRS/Sepsis and Shock|NICUPS|University of Ulm|No|Completed|August 2008|December 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|Samples With DNA|Whole blood, serum, white blood cells|Both|18 Years|N/A|No|Probability Sample|Postoperative/posttraumatic critically ill patients admitted to the intensive care unit|February 2013|February 5, 2013|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736723||151536|
NCT00737204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4839/5892R|Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS|Armodafinil Treatment for Fatigue in HIV+ Patients||New York State Psychiatric Institute|Yes|Completed|June 2008|September 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||March 2013|June 11, 2014|August 14, 2008|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00737204||151499|
NCT00744822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4066|Vibration Response Imaging (VRI) in Lung Transplant Recipients|Vibration Response Imaging (VRI) in Lung Transplant Recipients||Hannover Medical School|Yes|Completed|March 2006|March 2007|Actual|March 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|55|||Both|18 Years|65 Years|No|Non-Probability Sample|50 lung transplant recipients will be enrolled in the study. Subjects will be selected        from lung transplant recipients, who have undergone single or double lung transplantation        during the last six months|December 2005|August 28, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744822||150921|
NCT00745056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1436|Examining the Relationship Between Hormone Therapy and Cognitive Function (The WHIMS-ECHO Study)|Women's Health Initiative Memory Study--Epidemiology of Cognitive Health Outcomes|WHIMS-ECHO|Wake Forest Baptist Health|Yes|Active, not recruiting|August 2008|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2922|||Female|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants will include women who participated in the WHIMS study.|June 2015|June 1, 2015|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00745056||150903|
NCT00745355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-076|Quality of Life in Patients With Bladder Cancer|A Prospective Study of Quality of Life in Patients With Bladder Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2008|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|18 Years|99 Years|No|Non-Probability Sample|All eligible MSKCC patients.|September 2015|September 25, 2015|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00745355||150881|
NCT00745602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW IRB 092007-020|The Effect of Atrial Fibrillation Hemodynamics on Regulation of Cerebral Blood Flow|The Effect of Atrial Fibrillation Hemodynamics on Regulation of Cerebral Blood Flow||University of Texas Southwestern Medical Center|No|Recruiting|October 2007|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2008|February 17, 2010|August 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00745602||150862|
NCT00746122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA07/37/64|Immediate Management of the Patient With Aneurysm Rupture : Open Versus Endovascular Repair|Can Emergency Endovascular Aneurysm Repair (eEVAR) Improve the Survival From Ruptured Abdominal Aortic Aneurism?|IMPROVE|Imperial College London|Yes|Active, not recruiting|September 2009|July 2016|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|613|||Both|50 Years|N/A|No|||February 2014|April 16, 2015|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00746122||150823|
NCT00742859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-015|Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin|A PHASE 2, RANDOMIZED, PARALLEL GROUP, DOSE FINDING, MULTICENTER, MULTINATIONAL STUDY OF THE SAFETY, TOLERABILITY AND PILOT EFFICACY OF THREE BLINDED DOSES OF THE ORAL FACTOR Xa INHIBITOR BETRIXABAN COMPARED WITH OPEN LABEL DOSE-ADJUSTED WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (EXPLORE Xa)|EXPLORE-Xa|Portola Pharmaceuticals|Yes|Completed|October 2008|November 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|508|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00742859||151070|
NCT00742872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUB-IM.AS1.21|Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome|A Prospective Double-Blind Placebo-Controlled Trial of Mosapride in Patients With Constipation-Predominant Irritable Bowel Syndrome||American University of Beirut Medical Center|No|Terminated|September 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|75 Years|No|||February 2013|February 27, 2013|August 27, 2008||No|Poor recruitment, high drop out rate|No|February 27, 2013|https://clinicaltrials.gov/show/NCT00742872||151069|High placebo response rate, high dropout rate.
NCT00742885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111756|Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine|Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1557484A.||GlaxoSmithKline||Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|August 27, 2008|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00742885||151068|
NCT00743145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5693|Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana|Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana||New York State Psychiatric Institute||Completed|May 2008|September 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|48|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00743145||151048|
NCT00743158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X08-01-0060|Transfer Impedance in Cystic Fibrosis|Transfer Impedance in Cystic Fibrosis (Ztr)|Ztr|Children's Hospital Boston||Recruiting|August 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|2 Years|25 Years|No|Probability Sample|Cystic Fibrosis Patients|August 2009|August 19, 2009|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743158||151047|
NCT00734968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108717|Does Post-Operative Prophylaxis With Macrobid Reduce the Incidence of Post-Operative Urinary Tract Infection in Patients Undergoing Placement of a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence|Does Post-Operative Prophylaxis With Macrobid Reduce the Incidence of Post-Operative Urinary Tract Infection in Patients Undergoing Placement of a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: A Randomized, Double Blinded Placebo Controlled Clinical Trial||University of Missouri-Columbia|Yes|Completed|May 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|July 21, 2011|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734968||151668|
NCT00734981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBI-02-V2|Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System|Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System||Lotus Bio Inc.|Yes|Not yet recruiting|January 2012|December 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|60|None Retained|Semen|Male|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male volunteers|June 2011|June 22, 2011|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734981||151667|
NCT00744601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA023203|Impulsivity, Neural Deficits and Cocaine Addiction|Impulsivity, Neural Deficits, and Relapse in Cocaine Addiction||University of Texas Southwestern Medical Center|No|Completed|April 2007|September 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|90|Samples With DNA|urine, blood, plasma, and erythrocytes|Both|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from residential treatment programs at the VA North Texas        Health Care System, Nexus Recovery Inc., and Homeward Bound Inc. Healthy controls will be        recruited from the Greater Dallas community.|December 2012|December 31, 2012|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00744601||150937|
NCT00735800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR010559|Telephone Support for Dementia Caregivers|Psychosocial Telephone Intervention for Dementia Caregivers||Rhode Island Hospital|Yes|Completed|February 2008|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|250|||Both|50 Years|90 Years|No|||May 2015|May 4, 2015|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735800||151605|
NCT00736125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01226|A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events|A Comparison of Intraoperative Embolic Events During Total Knee Arthroplasty Performed With CarboJet Assisted Versus Standard Orthopedic Techniques: A Pilot Study||Kinamed Incorporated|No|Completed|December 2007|March 2011|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20|||Both|50 Years|N/A|No|||April 2013|April 17, 2013|August 14, 2008|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00736125||151581|
NCT00736138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-02-001-OSi|Hyperpronation and Foot Pain|Effect of Training and Pellots in Treatment of Foot Pain Caused by Hyperpronation||Northern Orthopaedic Division, Denmark||Completed|June 2007|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|110 Years|No|||December 2015|December 10, 2015|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736138||151580|
NCT00736437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-609-013|Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis|Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis||Medivir|No|Completed|August 1999|August 2000|Actual|August 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|417|||Both|18 Years|65 Years|No|||August 2008|August 14, 2008|August 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00736437||151558|
NCT00736450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|462-07|Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R||University of Nebraska|Yes|Terminated|July 2008|October 2022|Anticipated|October 2022|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|19 Years|N/A|No|||October 2012|October 11, 2012|August 14, 2008|Yes|Yes|Manufacturer is no longer making the drug.|No||https://clinicaltrials.gov/show/NCT00736450||151557|
NCT00736476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V99P2|Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults|Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity, and Efficacy of an Novartis' Investigational H. Pylori Vaccine in H. Pylori-Negative Adults||Novartis||Completed|October 2008|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|63|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00736476||151555|
NCT00736489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0570C00007|Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199|A Phase II, Double-blind, Placebo-controlled, Randomised, 6-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a β2-agonist) Compared to Formoterol in Asthmatic Patients||AstraZeneca|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|37|||Both|18 Years|N/A|No|||April 2014|May 8, 2014|August 15, 2008||No||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00736489||151554|
NCT00736502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1527|PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.|Longterm Efficacy and Safety of NVP-based HAART in HIV-1 Positive Patients in the Daily Clinical Practice.||Boehringer Ingelheim||Completed|September 2008|||July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|280|||Both|18 Years|N/A|No|Non-Probability Sample|patients|February 2014|February 3, 2014|July 7, 2008||||No|July 30, 2012|https://clinicaltrials.gov/show/NCT00736502||151553|
NCT00736736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801069R|Effects of Hip Abductor and External Rotator Strength Training in Patients With Patellofemoral Pain Syndrome|||National Taiwan University Hospital||Completed|March 2008|||July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Both|19 Years|50 Years|No|||June 2008|August 14, 2008|August 14, 2008||||No||https://clinicaltrials.gov/show/NCT00736736||151535|
NCT00744835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFI-20|Atrial Fibrillation Ablation Pilot Study|Atrial Fibrillation Ablation Pilot Study- Study Number AFI-20||Medtronic Atrial Fibrillation Solutions|Yes|Completed|August 2006|July 2008|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|70 Years|No|||June 2012|June 4, 2012|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744835||150920|
NCT00741754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/FOA-Unesp-01|Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use HcT20|Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use of Lauryl-Diethylene-Glycol-Ether Sodium Sulfate Associated With Calcium Hydroxide (hCt20).|EUWSFDAR|UPECLIN HC FM Botucatu Unesp|Yes|Completed|June 2005|July 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|40 Years|82 Years|No|||August 2008|March 30, 2009|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741754||151154|
NCT00742014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012265|The Assessment of Right Ventricular Contractility in Response to Sildenafil|The Assessment of Right Ventricular Contractility in Response to Sildenafil in Pediatric Patients With Pulmonary Arterial Hypertension||The Hospital for Sick Children|No|Suspended|August 2008|||June 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|18 Years|No|||December 2013|December 13, 2013|August 25, 2008||No|absorption of oral sildenafil not consistent|No||https://clinicaltrials.gov/show/NCT00742014||151134|
NCT00742300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-0198|Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases|Phase I/II Open-Label Monocentric Clinical Trial for Induction of Tolerance With CD34-Enriched Autologous Hematopoietic Stem Cell Transplantation After High-Dose Chemotherapy With Cyclophosphamide and Rabbit-Antithymocyte Globulin for Refractory Autoimmune Diseases|ASTRAD|Charite University, Berlin, Germany|No|Active, not recruiting|January 1998|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|60 Years|No|||November 2008|November 21, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742300||151112|
NCT00742586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080373|Autonomic Failure Patients for RNA Blood Sampling|Identification of Autonomic Failure Patients, Controls and Blood Sampling for Pilot Study||Vanderbilt University|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|N/A||1|Anticipated|30|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|15 patients with diagnosis of autonomic disorder characterized by orthostatic hypotension,        Pure Autonomic Failure, Multiple System Atrophy or Parkinson's Plus.        15 controls without a neurological disorder|January 2010|January 4, 2010|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742586||151090|
NCT00742599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPO-11-01/C-01|Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy|Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Randomized, Double-blind, Parallel-assignment , Placebo-controlled Study)||Nihon Pharmaceutical Co., Ltd|Yes|Completed|September 2008|July 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|N/A|No|||November 2010|November 8, 2010|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742599||151089|
NCT00742612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC1779-008|Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy|A Study of the Effect of ARC1779 Injection on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy||Archemix Corp.|Yes|Terminated|February 2009|April 2010|Anticipated|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||July 2009|February 9, 2010|August 25, 2008|Yes|Yes|Enrollment slower than expected|No||https://clinicaltrials.gov/show/NCT00742612||151088|
NCT00739440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Birmex-01-2008|Randomized Controlled Trial to Compare Two Anti-scorpion Serums|Randomized Controlled Trial to Evaluate Efficiency and Safety of the Polyvalent Antiscorpion Serum of Birmex Versus Other Commercial Serum||Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.|No|Completed|August 2008|November 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|15 Years|60 Years|No|||August 2013|August 6, 2013|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00739440||151330|
NCT00739453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-103|A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)|A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors||Astellas Pharma Inc|No|Completed|October 2008|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00739453||151329|
NCT00739778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFIS-08-001|Effect of a Novel Sweetener on the pH of Dental Plaque.|Effect of a Novel Sweetener on the pH of Dental Plaque.||Cargill|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2008|December 16, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739778||151305|
NCT00739791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612335|Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer|Pilot Trial of Gene Expression Modulation by Intervention With Nutrition and Lifestyle||University of California, San Francisco||Completed|September 2003|June 2005|Actual|June 2005|Actual|N/A|Interventional|Primary Purpose: Treatment|1||Anticipated|34|||Male|N/A|N/A|No|||September 2012|September 12, 2012|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00739791||151304|
NCT00744289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X08-0161|Hepatitis B Acceptability and Vaccination Incentive Trial|A Randomised Controlled Trial to Evaluate the Effectiveness of a Small Financial Incentive After the Second and Third Dose of a Hepatitis B Vaccine, on Vaccine Completion in People Who Inject Drugs|HAVIT|Kirby Institute|No|Completed|September 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|204|||Both|16 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 14, 2011|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00744289||150960|
NCT00744614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-115|Use Of Capnography As Surrogate Measure Of PC02 In Medical Intensive Care Unit (ICU) Patients|Use Of Capnography As Surrogate Measure Of PC02 In Medical ICU Patients||Lahey Clinic|No|Terminated|November 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|MICU patients who are at risk of intubation and who have a history of asthma, COPD, ILD or        coronary disease.|October 2010|October 19, 2010|August 29, 2008||No|Principal Investigator (central contact) has left the organization and requests the study be    terminated|No||https://clinicaltrials.gov/show/NCT00744614||150936|
NCT00744627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_311|Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder||Takeda|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|August 29, 2008||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00744627||150935|
NCT00735488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0011-08-EMC|Sickle Cell Anemia Screening and Prevention in Northern Israel|Summary of the Data From the Prevention Programme for Hemoglobinopathies in Northern Israel||HaEmek Medical Center, Israel|Yes|Completed|May 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|69|||Both|18 Years|N/A|No|Probability Sample|The program for prevention of hemoglobinopathies in Northern Israel, instituted since        1987, covered the northern part of Israel, including the Jezreel valley, the Nazareth        area, the upper Galilee, the Hula valley and the northern part of the seashore region7.        The overall population in this region is about a million inhabitants with about 50 % of        Arab population, and a significant percentage of them from Bedouin origin, a population        that at least partially is of African origin.|August 2015|August 30, 2015|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735488||151629|
NCT00735813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17344|Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia|A Randomised Study of Taurolock for the Locking of Tunneled Central Venous Catheters in Children With Malignant Diseases.||Aarhus University Hospital|No|Completed|April 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|129|||Both|N/A|17 Years|No|||September 2012|September 4, 2012|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735813||151604|
NCT00736151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-1029/001/II/2003|Phase II Dose Titration Study in Patients With Neuropathic Pain|A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain||Newron||Completed|May 2004|||April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Actual|272|||Both|18 Years|85 Years|No|||August 2009|August 6, 2009|August 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00736151||151579|
NCT00736164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000611981|Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer|A Randomized, Double Blind, Placebo Controlled Clinical Trial of Supplementation of L-Selenomethionine in Patients With Prostate Cancer Prior to Prostatectomy or Brachytherapy (Se Pre-Prostatectomy/Pre-Brachytherapy Trial)||Roswell Park Cancer Institute||Withdrawn|August 2008|||June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||February 2012|February 3, 2012|August 14, 2008|Yes|Yes|No accrual|No||https://clinicaltrials.gov/show/NCT00736164||151578|
NCT00736177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB-08-0012|Comparison of Transfers of Fresh and Thawed Embryos in Patients With Prior Failed Embryo Transfer Cycles|Comparison of Transfers of Fresh and Thawed Embryos in Patients With Prior Failed Embryo Transfer Cycles||Fertility Center of Las Vegas|No|Withdrawn|August 2008|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2009|April 8, 2014|August 13, 2008||No|No recruitment|No||https://clinicaltrials.gov/show/NCT00736177||151577|
NCT00736190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0123|A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection|A Phase IV Study to Evaluate the Efficacy, Safety and Tolerability of Tenofovir DF in Asian-American Adults With Chronic Hepatitis B Infection||Gilead Sciences|No|Completed|August 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|75 Years|No|||November 2011|November 30, 2011|August 13, 2008|No|Yes||No|July 7, 2011|https://clinicaltrials.gov/show/NCT00736190||151576|
NCT00736515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC4-5702-205-CHN|Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes|Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus|CODMS|Servier (Tianjin) Pharmaceutical Co. LTD.|Yes|Recruiting|October 2008|January 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|35 Years|65 Years|No|||August 2010|August 19, 2010|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736515||151552|
NCT00736749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE05N1|Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies|Umbrella Long-Term Follow-Up Protocol||Children's Oncology Group|No|Recruiting|May 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|7500|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Hodgkin lymphoma enrolled on CCG-5942, POG-9425, POG-9426, COG-AHOD0031;        patients with brain tumors enrolled on CCG-A9961; patients with acute lymphoblastic        leukemia enrolled on COG-A3973; patients with rhabdomyosarcoma|September 2015|September 21, 2015|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736749||151534|
NCT00741429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-126|A 2-Month Safety Follow-Up Trial|A 2-Month Safety Follow-up Trial of Subjects From MannKind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030||Mannkind Corporation||Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|649|||Both|18 Years|70 Years|No|Non-Probability Sample|The study population consists of eligible type 1 and type 2 diabetic subjects who have        completed any of the 4 MKC parent trials (MKC-TI-103, MKC-TI-009, MKC-TI-102, MKC-TI-030).|December 2014|December 1, 2014|August 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741429||151179|
NCT00741442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA806-501|A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout|Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout||Ardea Biosciences, Inc.|No|Completed|July 2008|September 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|3|||Both|18 Years|75 Years|No|||January 2014|January 7, 2014|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741442||151178|
NCT00741455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0345|Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies|Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|June 2004|December 2017|Anticipated|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|75 Years|No|||September 2015|September 16, 2015|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741455||151177|
NCT00741468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-007|Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects|An Open-Label, Multiple-Dose, Non-Randomized Study to Assess the Drug-Drug Interactions of Proellex® (CDB-4124) With Cytochrome P450 Isoenzymes CYP1A2, 2C9, 2C19, 2D6, and 3A4 in Healthy Female Subjects||Repros Therapeutics Inc.|No|Completed|July 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 25, 2008|Yes|Yes||No|July 3, 2014|https://clinicaltrials.gov/show/NCT00741468||151176|
NCT00741767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3582|The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD|The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (Advair and Quality of Sleep in COPD)|AQuOS-COPD|Northwestern University|No|Withdrawn|August 2008|February 2012|Actual|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|40 Years|N/A|No|||October 2015|October 5, 2015|August 22, 2008||No|Study subject enrollment difficulties|No||https://clinicaltrials.gov/show/NCT00741767||151153|
NCT00742027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589E2214|Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma|A Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma After High-dose Chemotherapy With Autologous Stem Cell.||Novartis||Completed|September 2008|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|August 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00742027||151133|
NCT00742040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012229|Rapid Versus Prolonged Inpatient Up-Titration of Captopril|Rapid Versus Prolonged Inpatient Up-Titration of Captopril: A Randomized Clinical Trial||The Hospital for Sick Children|Yes|Recruiting|August 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|18 Years|No|||August 2008|August 26, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742040||151132|
NCT00742313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009897|Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)|Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)||Duke University|No|Terminated|June 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2013|February 17, 2014|August 25, 2008|Yes|Yes|No statistical differences on study endpoints between groups.|No|November 8, 2013|https://clinicaltrials.gov/show/NCT00742313||151111|This study was terminated early
NCT00743717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010204|Evaluation of the Safety and Effectiveness of the Kinamed Gem Ceramic Femoral Component for Total Knee Replacement|Clinical Trial on the Zirconia Femoral Component for the Gem Total Knee System||Kinamed Incorporated|No|Completed|February 2004|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|4|||Both|N/A|N/A|No|||May 2013|May 21, 2013|August 27, 2008|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00743717||151004|
NCT00739817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-6-199-R|Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide|Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide||Ziv Hospital||Not yet recruiting|July 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community|August 2009|August 15, 2009|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00739817||151303|
NCT00739830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-007|Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)|A Randomized Phase II Trial of Ridaforolimus (AP23573; MK-8669) Compared to Progestin or Chemotherapy in Female Adult Patients With Advanced Endometrial Carcinoma||Merck Sharp & Dohme Corp.|No|Completed|August 2008|July 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Female|18 Years|N/A|No|||June 2015|June 30, 2015|August 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739830||151302|
NCT00740077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV4266|Bioavailability of Flavonoids and Phenolic Acids From Cranberry Juice Cocktail in Healthy Older Adults|Bioavailability of Flavonoids and Phenolic Acids From Cranberry Juice Cocktail in Healthy Older Adults||Tufts University|Yes|Completed|August 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||January 2009|February 6, 2009|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00740077||151283|
NCT00734656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-218S-2|Pharmacogenetics of Alcohol: Treatment Implications|Subjective and Physiological Effects of Alcohol: Role of Genetic Variation and Adrenal Hormones||University of Connecticut Health Center|No|Completed|March 2007|July 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|94|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|July 31, 2008|No|Yes||No|October 27, 2011|https://clinicaltrials.gov/show/NCT00734656||151692|
NCT00734669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 84/08|Risk of Hypoglycemia in Type 2 Diabetes|Risk of Hypoglycemia in Type 2 Diabetes - Effects of Glibenclamide and Exercise on Cardiovascular, Hormonal, and Metabolic Parameters||University of Giessen|No|Active, not recruiting|July 2008|December 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Type 2 diabetes|July 2008|August 13, 2008|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734669||151691|
NCT00735228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCAP0802|Tight Glycemic Control by Artificial Pancreas|Benefit of Tight Glycemic Control in Surgical Patients: Prospective Randomized Clinical Trial|KMS|Kochi University|Yes|Recruiting|August 2008|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2008|August 15, 2008|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735228||151649|
NCT00735501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1938|Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes|Safety of Levemir® (Insulin Detemir) Treatment in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|314|||Both|18 Years|N/A|No|Probability Sample|Patients aged 18 or above, with type 2 diabetes, who together with their physician, have        decided to switch to Levemir® from human basal insulin treatment|October 2014|October 28, 2014|August 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00735501||151628|
NCT00735527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INLOR|Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children|Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial|INLOR|All India Institute of Medical Sciences, New Delhi|Yes|Completed|May 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|6 Years|14 Years|No|||May 2009|May 4, 2009|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735527||151626|
NCT00735540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0022-08-EMC|Clinical Diagnosis of Teenagers Admitted to Pediatric Departments|The Purpose of This Study is to Analyze the Clinical Characteristics of Teenagers Admitted to Pediatric Departments||HaEmek Medical Center, Israel|Yes|Completed|May 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|1389|||Both|14 Years|20 Years|No|Non-Probability Sample|About 800 teenagers are admitted each year to the pediatric departments at the Ha'Emek        Medical Center. Three principal conditions are the causes of admission: chronic diseases,        acute "organic" diseases, and psychiatric diseases including suicide attempts, anorexia,        and others.|August 2015|August 30, 2015|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735540||151625|
NCT00735826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0828|A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer|A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|March 2009|||December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735826||151603|
NCT00735839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V710-006|V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck S. Aureus Vaccine (V710) in Healthy Male Japanese Subjects||Merck Sharp & Dohme Corp.||Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Male|20 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|August 13, 2008|No|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00735839||151602|
NCT00736203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008250|Memory and Picture Viewing Study|Memory and Picture Viewing Study|MPVS|Duke University|No|Completed|July 2008|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|Samples With DNA|saliva, blood|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|generally healthy, right-handed non-smokers, between the ages of 18-55, having smoked less        than 50 cigarettes in their lifetime|January 2013|February 6, 2013|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00736203||151575|
NCT00736216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11806|Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults|Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults||Case Comprehensive Cancer Center|Yes|Withdrawn|July 2008|||July 2009|Actual|Phase 1|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|24 Years|No|Non-Probability Sample|Community based outreach in an urban Mid-west area|March 2015|March 17, 2015|August 14, 2008||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT00736216||151574|
NCT00736528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401002|A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers|An Investigator And Subject-Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 In Healthy Elderly Subjects||Pfizer|No|Terminated|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|10|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||February 2009|February 23, 2009|August 15, 2008|No|Yes|See Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00736528||151551|
NCT00736762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136/07|Effects of Global Postural re-Education Program|Effects of Global Postural re-Education Program on the Biomechanical Characteristics of the Elderly Balance.||University of the State of Santa Catarina|No|Completed|February 2008|August 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 15, 2008|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736762||151533|
NCT00741169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015412|TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.|Phase I, Open-label, 3-way Crossover Trial in Healthy Volunteers to Determine the Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.||Tibotec Pharmaceuticals, Ireland|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741169||151199|
NCT00742625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00443|Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years||National Cancer Institute (NCI)||Completed|September 2008|December 2012|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|60 Years|75 Years|No|||June 2014|September 4, 2014|August 27, 2008|Yes|Yes||No|January 2, 2013|https://clinicaltrials.gov/show/NCT00742625||151087|
NCT00742898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0820|Evaluation of Opt-Out Rapid HIV Testing in the Emergency Department|Non-targeted Opt-out Rapid HIV Screening in the Emergency Department: a Controlled Clinical Trial||Denver Health and Hospital Authority|No|Completed|April 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120000|||Both|16 Years|N/A|No|||September 2009|September 14, 2009|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00742898||151067|
NCT00742911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI26679|Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver|Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver||University of Utah|Yes|Completed|July 2008|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00742911||151066|
NCT00742924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST06P1|Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma|Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma||Children's Oncology Group|Yes|Completed|August 2008|||April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|N/A|40 Years|No|||June 2014|June 4, 2014|August 27, 2008|No|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00742924||151065|
NCT00743171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH 2008-3|Long-Term Study On Home Spirometry After Lung Transplantation|Long-Term Study On Home Spirometry After Lung Transplantation||Hannover Medical School|No|Completed|January 2000|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|152|||Both|18 Years|70 Years|No|Probability Sample|lung transplant recipients surviving to outpatient follow-up >6 months in Hannover Medical        School|August 2008|August 27, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00743171||151046|
NCT00743418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIP-K.3.1.|Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease|The Use of Advanced Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease and Related Cognitive Disorders|SenTra|Tel-Aviv Sourasky Medical Center||Recruiting|June 2007|||December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|300|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 27, 2008|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743418||151027|
NCT00739466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-II-01|Biorest Liposomal Alendronate With Stenting sTudy (BLAST)|Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation|BLAST|BIOrest Ltd.|No|Completed|September 2008|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|226|||Both|18 Years|80 Years|No|||January 2016|January 17, 2016|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739466||151328|
NCT00747864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14083|Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life|Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life||University of Utah|No|Completed|April 2006|January 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|106|||Both|N/A|48 Hours|Accepts Healthy Volunteers|Probability Sample|Infants born at >28 weeks gestation will be eligible for enrollment in this study. Infants        with fetal malformations, chromosomal anomalies, clinically significant sepsis        (retractable hypotension, neutropenia, and thrombocytopenia), or no urine output for the        first 48 hours will be excluded. Infants that meet criteria will be enrolled in this study        if the parent(s) sign the consent form. There are no patient safety or adverse event        issues as this study is non-invasive and observational only.|July 2010|July 21, 2010|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747864||150689|
NCT00748189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMB110911|Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia|A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia|COMPLEMENT 1|GlaxoSmithKline|No|Active, not recruiting|December 2008|June 2022|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||February 2015|March 12, 2015|September 5, 2008|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00748189||150664|
NCT00735072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA9001DE|Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure|Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure||University of California, San Francisco|Yes|Completed|September 2008|July 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|August 12, 2008|Yes|Yes||No|June 5, 2011|https://clinicaltrials.gov/show/NCT00735072||151660|
NCT00749307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFAHRV01|Effects of Docosahexaenoic Acid (DHA) on Heart Rate Variability in Elderly Patients|Effects of Supplementation With Algal Triacylglycerols Versus Placebo on Heart Rate Variability in Elderly Patients||Campus Bio-Medico University|No|Completed|June 2008|November 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|65 Years|N/A|No|||November 2009|November 24, 2009|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749307||150578|
NCT00749632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP1097-002|A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence|An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence|FP1097-002|FemmePharma Global Healthcare, Inc.|No|Completed|July 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|75 Years|No|||October 2009|October 13, 2009|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749632||150553|
NCT00749606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK078553|Study to Promote Weight Loss in Primary Care Practices|Weight Loss in Primary Care: a Translation of the Diabetes Prevention Program||State University of New York - Upstate Medical University|Yes|Completed|September 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|257|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|December 15, 2014|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749606||150555|
NCT00749619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAURO 070908|Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?|||Western Galilee Hospital-Nahariya|No|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Primary Purpose: Prevention|3||||||Both|N/A|N/A|No|||September 2008|September 8, 2008|September 7, 2008||||No||https://clinicaltrials.gov/show/NCT00749619||150554|
NCT00749892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0704|Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma|A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2008|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749892||150533|
NCT00749905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5217-SBH-CTIL|Low Fiber Diet for Bowel Preparation for Colon Capsule Examination|A Prospective Randomized Controlled Investigator-blinded Study of Low Fiber Diet for Bowel Preparation for Colon Capsule Examination||Sheba Medical Center|No|Terminated|January 2009|||July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|75|||Both|50 Years|70 Years|No|||July 2010|July 21, 2010|September 8, 2008||No|was not able to recruit enough patients|No||https://clinicaltrials.gov/show/NCT00749905||150532|
NCT00750984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU9|A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing|A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing||Biomet, Inc.|No|Active, not recruiting|September 2008|February 2017|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|29 Years|61 Years|No|||April 2014|June 23, 2015|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750984||150452|
NCT00750711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocole 08-006|Typical Flutter Ablation:A Comparison of 4 mm Versus 2 mm Irrigated cathéters|Typical Flutter Ablation:A Comparison of 4 mm Versus 2 mm Irrigated cathéters||University Hospital, Geneva|No|Recruiting|March 2008|||January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2008|September 15, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750711||150473|
NCT00751322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-008069|Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients|Project 2 (Mayo): Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients|TRALI2|Mayo Clinic|No|Completed|August 2008|December 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|N/A|No|||January 2012|January 27, 2012|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00751322||150426|
NCT00751634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1507-009|Temperature Control in Central Fever in the Neuro-ICU|Temperature Control in Central Fever in the Neuro-ICU||Northwestern University|No|Completed|January 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|85 Years|No|||April 2013|April 30, 2013|September 10, 2008||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00751634||150402|
NCT00751335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPHC SLA 2008|ThermoSmart® Versus Conventional Humidification in Continuous Positive Airway Pressure (CPAP)|Prospective, Randomized, Double-Blind Cross-Over Study Comparing ThermoSmart® to Conventional Heated Humidity in Patients Suing Continuous Positive Airway Pressure||Fisher and Paykel Healthcare|No|Completed|August 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||June 2009|June 22, 2009|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751335||150425|
NCT00751348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110876|Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136|Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136||GlaxoSmithKline||Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|475|||Both|11 Months|24 Months|Accepts Healthy Volunteers|||August 2011|January 12, 2012|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751348||150424|
NCT00751647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807-068|Cystic Fibrosis Core Strengthening and Respiratory Exercise Program|Cystic Fibrosis Core Strengthening and Respiratory Exercise Program (CSREP)|CSREP|Children's Hospitals and Clinics of Minnesota|No|Completed|December 2008|December 2013|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|6|||Both|10 Years|21 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751647||150401|
NCT00737841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probio-Bifid-IBS|Effect of Bifidobacterium on Irritable Bowel Syndrome|Effect of Bifidobacterium on Irritable Bowel Syndrome|PBIBS|Tohoku University|No|Recruiting|January 2006|September 2008|Anticipated|August 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2008|August 19, 2008|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737841||151450|
NCT00738400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13171|Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome|Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC)||Bayer|No|Completed|November 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Male|18 Years|64 Years|No|||November 2015|November 12, 2015|August 19, 2008||No||No|November 26, 2010|https://clinicaltrials.gov/show/NCT00738400||151408|
NCT00738088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007DM02|Variation in Sulphonylurea Response in Type 2 Diabetes|The Use of Glycaemic Response to Sulphonylureas as a Tool to Investigate Type 2 Diabetes Pathophysiology||NHS Tayside|No|Enrolling by invitation|June 2007|January 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|35 Years|70 Years|No|||August 2008|August 18, 2008|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738088||151431|
NCT00738361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08076|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery|A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|August 2008|April 2013|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|August 19, 2008|Yes|Yes||No|October 28, 2015|https://clinicaltrials.gov/show/NCT00738361||151411|
NCT00738374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21445|A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.|A Study of Chlorambucil Plus MabThera as Induction Therapy Followed in Responders by Maintenance Therapy Versus Observation on Response Rate in Patients >=60 Years With Previously Untreated Chronic Lymphocytic Leukemia||Hoffmann-La Roche||Completed|November 2008|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|60 Years|N/A|No|||February 2015|February 12, 2015|August 18, 2008||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00738374||151410|
NCT00738660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|START1DM|Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy|Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy|START1DM|Postgraduate Institute of Medical Education and Research|No|Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|14 Years|N/A|No|||August 2008|August 19, 2008|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738660||151389|
NCT00738946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPTCVP17|A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children|A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children|IPTc/ITNs|London School of Hygiene and Tropical Medicine|Yes|Completed|August 2008|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|6000|||Both|3 Months|59 Months|No|||June 2010|June 3, 2010|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00738946||151367|
NCT00734747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCLP09002|Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)|Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)||MediGus Ltd|No|Completed|May 2008|July 2015|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|August 13, 2008|Yes|Yes||No|May 15, 2015|https://clinicaltrials.gov/show/NCT00734747||151685|
NCT00735657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rp0822|Anesthesia for Pars Plana Vitrectomy (PPV) With Insulin Needle|Anesthesia for PPV Using Insulin Needle||King Khaled Eye Specialist Hospital|Yes|Recruiting|August 2008|December 2010|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|N/A|No|||February 2010|February 24, 2010|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00735657||151616|
NCT00749047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6E-AY-O017|How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?|A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes.||Christchurch Hospital|No|Active, not recruiting|September 2008|March 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|70 Years|No|||September 2009|September 15, 2009|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749047||150598|
NCT00749060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060107|Comparison of Balloon Kyphoplasty, Vertebroplasty and Conservative Management in Acute Osteoporotic Vertebral Fractures|Prospective Randomized Comparative Study of Balloon Kyphoplasty,Vertebroplasty and Conservative Management in Acute Osteoporotic Vertebral Fractures of Less Than 6 Weeks|OSTEO-6|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|50 Years|N/A|No|||December 2014|December 13, 2014|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749060||150597|
NCT00749684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04083|Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)|Efficacy and Safety of High-dose Treatment With the Immunomodulator Interferon-α-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma.||Merck Sharp & Dohme Corp.|No|Completed|December 1996|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|138|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult participants in Austria with malignant melanoma at high risk of relapse|October 2015|October 16, 2015|September 8, 2008|No|Yes||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00749684||150549|
NCT00749645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT06-AG-02|Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients|Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients|FANG30-RA|Universidad Austral de Chile|Yes|Completed|October 2006|February 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||October 2014|January 22, 2016|September 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00749645||150552|
NCT00749658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 10047|Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence|Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence|ChanBan|National Institute on Drug Abuse (NIDA)|Yes|Completed|November 2008|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|July 9, 2012|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749658||150551|
NCT00749918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609M92006|Effect of Vitamin D Deficiency and Vitamin D Supplementation on Glucose Metabolism|Improved Insulin Sensitivity With Therapeutic Vitamin D Replacement in Pre-Diabetic Vitamin D Deficient Individuals||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749918||150531|
NCT00716638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-KP-343|Trauma-focused CBT Versus EMDR in the Treatment of Posttraumatic Stress Disorder|Trauma-focused CBT vs. EMDR in the Treatment of Posttraumatic Stress Disorder||VU University of Amsterdam|No|Recruiting|July 2008|July 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||October 2013|October 31, 2013|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716638||153059|
NCT00750997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01GM076101-02|Hypertonic Modulation of Inflammation Following Injury|Hypertonic Modulation of Inflammation Following Injury||National Institute of General Medical Sciences (NIGMS)|Yes|Terminated|November 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|119|Samples Without DNA|plasma|Both|15 Years|N/A|No|Non-Probability Sample|Patients enrolled in clinical trial of Hypertonic Resuscitation based on prehospital        evidence of hypovolemic shock or severe brain injury|August 2010|August 4, 2010|September 10, 2008|Yes|Yes|Enrollment in the clinical trial was stopped for futility|No||https://clinicaltrials.gov/show/NCT00750997||150451|
NCT00717210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOA-04|Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide|NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide|NOA-04|Neuro-Oncology Working Group of the German Cancer Society|Yes|Completed|June 1999|March 2008|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|318|||Both|18 Years|N/A|No|||July 2008|July 16, 2008|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717210||153015|
NCT00751660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598586|Screening Methods in Finding Lung Cancer Early in Current or Former Smokers|Early Detection of Lung Cancer - A Pan Canadian Study|Pan Can|British Columbia Cancer Agency|No|Active, not recruiting|September 2008|||March 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|2504|||Both|50 Years|75 Years|No|||March 2012|March 7, 2012|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751660||150400|
NCT00737854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG022|Free Soft Tissue Graft in Treatment of Oral Lichen Planus|Free Soft Tissue Graft in Treatment of Oral Lichen Planus|TOLP|Qazvin University Of Medical Sciences|Yes|Recruiting|May 2008|December 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|70 Years|No|||August 2008|December 9, 2008|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737854||151449|
NCT00737867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11066741577|Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer|Vinorelbine Plus Gemcitabine (VG) Versus Vinorelbine Plus Carboplatin (VC) in Advanced Non-small Cell Lung Cancer. An Open Randomized Multicenter Phase III Trial From Norwegian Lung Cancer Study Group (NLCG)||The Norwegian Lung Cancer Study Group|No|Completed|September 2007|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|444|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00737867||151448|
NCT00738673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS27|Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer|An Open-Label, Multi-Centre, Uncontrolled, Exploratory Trial Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment After PSA-Failure in GnRH Agonist Treated Patients With Prostate Cancer||Ferring Pharmaceuticals|No|Completed|July 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Male|18 Years|N/A|No|||December 2012|December 12, 2012|August 18, 2008|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00738673||151388|
NCT00738127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHQ-0808-A|Safety Study of Surgical Technique to Treat Acute Dorsal Trans-Scaphoid Perilunate Dislocations|Surgical Techniques for Acute Dorsal Trans-Scaphoid Perilunate Dislocations|ADTPD|The Second Hospital of Qinhuangdao|Yes|Completed|October 1992|October 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|801|||Both|18 Years|60 Years|No|||August 2008|August 19, 2008|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00738127||151428|
NCT00738101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23365|Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants|Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants||Baylor College of Medicine|Yes|Recruiting|September 2008|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|5 Years|No|||January 2016|January 12, 2016|August 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00738101||151430|
NCT00738985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_019|Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors|Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Patients With Mixed Hyperlipidemia and Two or More Risk Factors to Cardiovascular Disease.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Withdrawn|November 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||March 2015|March 23, 2015|August 19, 2008|Yes|Yes|The study was cancelled due to budget limitations|No||https://clinicaltrials.gov/show/NCT00738985||151364|
NCT00738998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1038|Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer|Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2008|||June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|102|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00738998||151363|
NCT00734773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 05H7|Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL|A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-dose Methotrexate (MTX)-Based Chemo-immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma||Northwestern University|Yes|Withdrawn|November 2008|||||Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|August 13, 2008|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00734773||151683|
NCT00738959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0190C00008|Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0328 in Healthy Young Japanese and Caucasian Male Volunteers After Oral Single and Multiple Ascending Doses||AstraZeneca|No|Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|64|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00738959||151366|
NCT00738972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0653A-168|Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)|Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.||Fundación Lindavista del Corazón AC||Terminated|January 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||August 2013|August 17, 2013|August 19, 2008|Yes|Yes|Study terminated early due to sample size, not possible to perform further statistical    analysis.|No|July 20, 2013|https://clinicaltrials.gov/show/NCT00738972||151365|This study was terminated early and due to sample size it was not possible to perform further statistical analyses.
NCT00734760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO! NR05323|An Intervention to Reduce Prehospital Delay to Treatment in Acute Coronary Syndrome|Reducing Prehospital Delay in Acute Myocardial Infarction|PROMOTION|University of California, San Francisco|Yes|Completed|February 2001|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3522|||Both|30 Years|90 Years|No|||August 2008|August 12, 2008|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734760||151684|
NCT00735358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95DHA0100359|Comparison of Endoscopic Injection of Conventional and Double Doses Cyanoacrylate for Gastric Variceal Hemorrhage|||Taipei Veterans General Hospital, Taiwan|No|Completed|September 2005|October 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|80 Years|No|||August 2008|October 4, 2010|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735358||151639|
NCT00749320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-078|Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749320||150577|
NCT00749671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-186|Bispectral Index Monitoring During Testing in the Electrophysiology Lab|To Assess the Utility of BIS Monitoring in the Administration of Moderate Sedation in Patients Undergoing Implantable Cardioverter -Defibrillator (ICD) Implantation With Defibrillatory Threshold (DFT) Testing||Baystate Medical Center|No|Terminated|October 2007|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|21 Years|65 Years|No|||August 2013|January 26, 2015|November 13, 2007||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00749671||150550|
NCT00749931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-03-001|MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery|MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery|Pivotal|Dune Medical Devices|No|Completed|October 2008|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|664|||Female|18 Years|90 Years|No|||May 2014|May 26, 2014|September 7, 2008|Yes|Yes||No|May 26, 2014|https://clinicaltrials.gov/show/NCT00749931||150530|
NCT00749944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051115|Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo|An Experimental Medicine, Randomized, Double-Blind Study Assessing Neuropsychiatric Symptoms In Quitting Smokers Treated With Varenicline Tartrate Or Placebo||Pfizer|No|Completed|September 2008|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|No|||August 2010|August 24, 2010|September 9, 2008|Yes|Yes||No|July 7, 2010|https://clinicaltrials.gov/show/NCT00749944||150529|
NCT00750269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0813|Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer|Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients||Radiation Therapy Oncology Group|Yes|Active, not recruiting|February 2009|||September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|110|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750269||150504|
NCT00749970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2008/1|Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia|Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia|SWN-K|AstraZeneca|No|Completed|July 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patient aged 18-year old or older with a diagnosis of schizophrenia, schizoaffective        disorder, or shizophreniform disorder|December 2010|December 8, 2010|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00749970||150527|
NCT00716950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPV004DIM2008|Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients|Evaluation of Antihypertensive Activity of Valsartan and Amlodipine Compared to Losartan and Amlodipine Through Ambulatory Blood Pressure Monitoring in Moderate Hypertensive Patients in a Randomized, Controlled, Double-Blind Study||University of Pavia|Yes|Recruiting|July 2008|February 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|187|||Both|35 Years|75 Years|No|||July 2008|July 16, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716950||153035|
NCT00717275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METS-001|Study of Temozolomide to Treat Newly Diagnosed Brain Metastases|A Phase II Study of Temozolomide (TMZ) Following Stereotactic Radiosurgery (SRS) for Patients With Newly Diagnosed Brain Metastases||University of Florida|Yes|Terminated|September 2008|June 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2012|September 14, 2012|July 15, 2008|Yes|Yes|Slow accrual.|No|July 10, 2012|https://clinicaltrials.gov/show/NCT00717275||153010|This single center study was terminated early due to slow accrual; therefore, statistical analysis of the 3 participants was not done.
NCT00716885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1781|The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing|The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing|OXIS-PACING|VU University Medical Center|Yes|Not yet recruiting|September 2008|September 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Bloodsamples|Both|N/A|N/A|No|Probability Sample|Patients admitted to the OLVG hospital for worsening congestive heart failure selected for        biventricular pacemaker implantation|May 2008|July 14, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716885||153040|
NCT00717223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21263|A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes|A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes||Baylor College of Medicine|No|Recruiting|June 2007|July 2010|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|1 Year|N/A|No|Non-Probability Sample|Children with diabetes attending clinic followup at Texas Children's Hospital|August 2010|August 23, 2010|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717223||153014|
NCT00717522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-STSAR-001|Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma|A Phase 2, Multicenter, Open-label, Single Arm, Two-stage Study to Evaluate the Efficacy and Safety of CC-4047 (Pomalidomide) in Patients With Advanced Soft Tissue Sarcomas Who Have Relapsed or Are Refractory to Systemic Anticancer Therapy||Celgene|Yes|Terminated|August 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|July 16, 2008|Yes|Yes|Study enrollment was terminated due to a corporate strategic decision unrelated to patient    safety.|No|March 6, 2013|https://clinicaltrials.gov/show/NCT00717522||152991|
NCT00737880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-KSM-III/6/00|Histidine-Tryptophane-Ketoglutarate (HTK) vs University of Wisconsin (UW) Perfusion in Clinical Pancreas Transplantation|A Prospective Randomized Multicenter Trial Comparing Histidine-Tryptophane-Ketoglutarate (HTK) Versus University of Wisconsin (UW) Perfusion Solution in Clinical Pancreas Transplantation||Medical University Innsbruck|No|Completed|July 2001|December 2005|Actual|January 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|60 Years|No|||August 2008|August 19, 2008|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00737880||151447|
NCT00738140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-081|Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors|Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors||Massachusetts General Hospital|Yes|Completed|September 2007|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Male|18 Years|N/A|No|||July 2013|July 9, 2013|June 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00738140||151427|
NCT00738686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTAX|Austrian Multivessel Taxus-Stent Registry|Austrian Multivessel Taxus-Stent Registry|AUTAX|Medical University of Vienna|Yes|Completed|June 2004|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|441|||Both|18 Years|80 Years|No|||August 2008|August 20, 2008|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738686||151387|
NCT00738699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb003-003PR|An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer|A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety oF MORAb-003(Farletuzumab) in Combination With Paclitaxel Therapy in Subjects With Platinum-Resistant or Refractory Relapsed Ovarian Cancer|FAR-122|Morphotek|Yes|Terminated|September 2008|October 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|412|||Female|18 Years|N/A|No|||April 2015|April 24, 2015|August 18, 2008|Yes|Yes|study did not meet pre-specified criteria for continuation following interim futility analysis|No||https://clinicaltrials.gov/show/NCT00738699||151386|
NCT00739011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPHC240/250Val|Validation of HC250 and HC240 Series.|Validation of Customer Requirements for the HC244/HC254||Fisher and Paykel Healthcare|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2008|December 7, 2008|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00739011||151362|
NCT00735085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S334.2.002|A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.|A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics After Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients With Moderate and Severe Traumatic Brain Injury||Abbott|Yes|Terminated|April 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|16 Years|65 Years|No|||September 2011|September 9, 2011|November 30, 2007|Yes|Yes|This study was stopped 20 May 2010 due to strategic considerations|No||https://clinicaltrials.gov/show/NCT00735085||151659|
NCT00735345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_ECa|Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma|Chemotherapy Induction and Chemoradiotherapy Combined With Cetuximab Respectively in Patients With Non-Metastatic Esophageal Carcinoma: A Multicentric Phase II Study||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Terminated|August 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|August 13, 2008||No|because of safety concerns the study was terminated prematurely|No||https://clinicaltrials.gov/show/NCT00735345||151640|
NCT00735683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A01-03|A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety|Double-Blind, Randomized, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of ATHX-105 Phosphate for the Treatment of Obesity||Athersys, Inc|No|Withdrawn|September 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|65 Years|No|||May 2015|May 29, 2015|August 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00735683||151614|
NCT00735696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13914|A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer|A Phase 2, Open-label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-line Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer||Eli Lilly and Company|Yes|Completed|January 2009|January 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|August 13, 2008|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT00735696||151613|
NCT00749710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-ES-143-CTIL|Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel|Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||September 2008|September 8, 2008|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749710||150547|
NCT00749983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0849/07|Effects of Creatine Supplementation in Women With Knee Osteoarthritis and Fibromyalgia|||University of Sao Paulo||Completed|June 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|25 Years|80 Years|No|||October 2012|October 1, 2012|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00749983||150526|
NCT00749073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05NOV2007|The Vertos MILD™ Preliminary Patient Evaluation Study|A Single-center, Prospective, Clinical Study to Assess the Clinical Application and Outcomes of Minimally Invasive Lumbar Decompression With the MILD™ Devices in Patients With Symptomatic Central Foraminal Lumbar Spinal Stenosis.||Vertos Medical, Inc.|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|September 8, 2008|No|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00749073||150596|Small pilot series with short follow-up. Procedure experience of investigator limited. Minimal information available regarding appropriate patient selection, thus patient pool confined to complex cases wait-listed for more aggressive laminectomy.
NCT00749086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060108|Comparison of Balloon Kyphoplasty and Vertebroplasty in Subacute Osteoporotic Vertebral Fractures|Prospective Randomized Study of Balloon Kyphoplasty and Vertebroplasty in Subacute (Older Than 6 Weeks) Osteoporotic Vertebral Fractures (STIC2)|OSTEO+6|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|50 Years|N/A|No|||December 2014|December 13, 2014|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749086||150595|
NCT00749333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1320C00001|Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.|A Phase I, Randomised, Double Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Oral Doses of AZD8566 in Healthy Volunteers||AstraZeneca|No|Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|108|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 29, 2009|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749333||150576|
NCT00749697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3047|Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases|Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine||Royal Marsden NHS Foundation Trust|No|Recruiting|May 2008|July 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|10|||Both|18 Years|N/A|No|||September 2008|September 8, 2008|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749697||150548|
NCT00749957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGTC-RPE65-002|Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis|A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2||Applied Genetic Technologies Corp|Yes|Active, not recruiting|December 2008|December 2027|Anticipated|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|6 Years|N/A|No|||June 2015|June 25, 2015|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749957||150528|
NCT00750282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311741|Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers|An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection/Exclusion of Cerebral Amyloid Beta in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers||Piramal Imaging SA|No|Completed|August 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|422|||Both|55 Years|N/A|No|||July 2014|July 15, 2014|September 9, 2008|Yes|Yes||No|June 16, 2014|https://clinicaltrials.gov/show/NCT00750282||150503|
NCT00717574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13800|Addition of Nitrous Oxide and Its Effects on Depth of Anesthesia|Addition of Nitrous Oxide to a Sevoflurane or Propofol Based Anesthetic and Its Effects on Depth of Anesthesia Indices (N20)|N20|University of Oklahoma|Yes|Completed|March 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|42|||Both|18 Years|55 Years|No|||June 2012|June 13, 2012|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00717574||152987|
NCT00716898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasser-2008-1CTIL|Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients|Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase||Shaare Zedek Medical Center|Yes|Recruiting|February 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|patients treated at SZMC|February 2009|May 29, 2011|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00716898||153039|
NCT00716911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99061|Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant|CMV Specific Cellular Immunity in Recipients of Allogeneic Bone Marrow Transplantation: Association of CMV-Specific HLA-Peptide Tetramer Binding With Cytotoxic T-Cell Function, CMV Infection and Other Clinical Events||City of Hope Medical Center|Yes|Completed|January 2000|July 2007|Actual|July 2007|Actual|N/A|Interventional|Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716911||153038|
NCT00717561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12669|A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia|A National, Prospective, Randomized, Open Label Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin vs IV Ceftriaxone + IV Azithromycin Followed by PO Amoxicilline/Clavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia||Bayer|No|Completed|February 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2014|November 2, 2014|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717561||152988|
NCT00717834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880701|Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine|A Blinded Phase 1/2 Dose Escalation Study to Assess Safety and Immunogenicity and Investigate the Optimal Dose Level of a Formalin-Treated, UV-Inactivated, Vero Cell-Derived Ross River Virus (RRV) Vaccine in Healthy Volunteers Aged 18 to 40 Years||Nanotherapeutics, Inc.|Yes|Completed|June 2008|October 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Anticipated|400|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2015|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00717834||152967|
NCT00717535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598111|Studying Umbilical Cord Blood From African-American Donors|Investigation of the Total Nucleated Cell Yield of Cord Blood Units Collected From African-American Donors in Correlation With Gestational and Other Health Variables||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|August 2005|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|None Retained|Cord blood unit (CBU)will be collected in utero and transported to the Stem Cell Processing      Laboratory. The volume of the CBU will be measured and cell count will be obtained.|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|African American cord blood donors|April 2013|April 25, 2013|July 16, 2008||No|Funding unavailable|No||https://clinicaltrials.gov/show/NCT00717535||152990|
NCT00717548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH05.06.2008|Efficacy of Narrative Exposure Therapy (NET) in Treating Women After Human Trafficking or Forced Prostitution|The Effectiveness of Narrative Exposure Therapy in Treating Women After Trafficking and Forced Prostitution||University of Konstanz|No|Completed|June 2008|July 2011|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|70 Years|No|||November 2012|November 2, 2012|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717548||152989|
NCT00738153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3536|An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes|Efficacy and Safety Study of Levemir® (Insulin Detemir) to Treat Type 1 and 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|June 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|798|||Both|7 Years|N/A|No|Non-Probability Sample|Any subject with type 1 or type 2 diabetes is eligible for the study, including        newly-diagnosed subjects who have never received insulin or an insulin analogue before|August 2014|August 13, 2014|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00738153||151426|
NCT00738452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07152|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy|A Phase I Trial of Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66) After Completion of Radiation Therapy Alone, or Radiation Therapy Plus Systemic Therapy in Unresectable or Medically Inoperable, Non-metastatic CEA-Producing Stage I-IIIB Non-Small Cell Lung Cancer||City of Hope Medical Center|Yes|Active, not recruiting|August 2008|||July 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00738452||151404|
NCT00738413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804009771|Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both|An Iron Balance Study Comparing Deferasirox, Deferoxamine and the Combination of Both Drugs||Weill Medical College of Cornell University|Yes|Recruiting|August 2008|December 2009|Anticipated|September 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|6|||Both|18 Years|50 Years|No|||November 2010|November 4, 2010|August 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738413||151407|
NCT00738712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00041815|Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies for Vascular, Abdominal, and Pelvic Exams|Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies for Vascular, Abdominal, and Pelvic Exams||University of Michigan|Yes|Active, not recruiting|May 2011|November 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738712||151385|
NCT00739024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 0690|A Study of a Melatonin Receptor Agonist to Prevent Migraine|A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine||Swedish Medical Center|No|Terminated|April 2008|September 2010|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|65 Years|No|||August 2012|August 22, 2012|August 19, 2008|No|Yes|Recruitment slow and administrative reasons|No|July 22, 2011|https://clinicaltrials.gov/show/NCT00739024||151361|Early termination leading to small numbers of subjects analyzed
NCT00739037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3186A1-1103|Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease|A Randomized, Single Dose, Placebo-Controlled, 2 Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAZ 417 in Cerebrospinal Fluid, When Administered Orally to Subjects With Alzheimer's Disease||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|August 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|10|||Both|55 Years|N/A|No|||August 2009|August 3, 2009|August 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00739037||151360|
NCT00734799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMR01252|Treating Co-Morbid Sleep Difficulties in Veterans With Posttraumatic Stress Disorder (PTSD): A Pilot Study|Treating Co-Morbid Sleep Difficulties in Veterans With PTSD: A Pilot Study||Durham VA Medical Center|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|N/A|N/A|No|||August 2015|August 11, 2015|August 12, 2008||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00734799||151681|
NCT00734786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN 08-003|Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles|Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles. Study # CLN 08-003.||Phytotox SA|No|Withdrawn|August 2008|September 2008|Anticipated|September 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|15|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||August 2008|August 22, 2008|August 7, 2008||No|Study cancelled.|No||https://clinicaltrials.gov/show/NCT00734786||151682|
NCT00735098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KneeOAExercise-2|The Effects of Home-Based Rehabilitation Treatments Among Persons With Symptomatic Knee Osteoarthritis|The Effects of Home-Based Rehabilitation Treatments Among Persons With Symptomatic Knee Osteoarthritis.||University of Zululand||Completed|January 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|44|||Both|50 Years|N/A|No|||February 2013|February 4, 2013|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735098||151658|
NCT00736307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROYAN-EYE-001|Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients|Transplantation of Ex-Vivo Expanded Human Limbal Epithelial Stem Cells (LSC) on Amniotic Membrane (AM) for Limbal Stem Cell Deficiency (LSCD)||Royan Institute|Yes|Completed|October 2007|October 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||April 2010|July 14, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736307||151567|
NCT00736320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD16|HD16 for Early Stage Hodgkin Lymphoma|HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET|HD16|University of Cologne|Yes|Active, not recruiting|November 2009|||May 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1150|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00736320||151566|
NCT00749372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803009687|MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions|T2* Cardiac MRI Screening of Highly Transfused Patients With Myelodysplastic Syndrome|T2*MRI|Weill Medical College of Cornell University||Recruiting|September 2008|June 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2010|November 4, 2010|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749372||150573|
NCT00749385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-114|A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels|A Randomized, Open-Label, 4-Way Crossover Study to Evaluate Naproxen and Esomeprazole Plasma Levels in Healthy Subjects Following Oral Administration of PN 400, Enteric-Coated Naproxen 500mg Plus Enteric-Coated Esomeprazole 20mg, Enteric-Coated Naproxen 500mg Alone, and Enteric-Coated Esomeprazole 20mg Alone.||POZEN|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2008|December 19, 2008|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749385||150572|
NCT00749996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAM™ Study|Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease|Herniectomy vs. Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease||Medtronic Spinal and Biologics|No|Completed|November 2006|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|20 Years|60 Years|No|||January 2016|January 26, 2016|September 9, 2008||No||No|April 24, 2014|https://clinicaltrials.gov/show/NCT00749996||150525|The current study was limited by not reaching the target enrollment. Because of the low patient recruitment rate, despite major efforts by the investigators and sponsor, enrollment was stopped prematurely.
NCT00750295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBR759A2101|A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis|An Open Label, Multiple Dose, Time-lagged, Switch Study to Evaluate the Safety, Tolerability and Activity of Escalating SBR759 Doses in Patients With Chronic Kidney Disease on Hemodialysis||Novartis|No|Completed|February 2007|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|60|||Both|18 Years|85 Years|No|||August 2011|October 16, 2013|September 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00750295||150502|
NCT00750308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060198|Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i|Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi||Vanderbilt University|No|Completed|December 2006|May 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|12||Actual|27|||Both|18 Years|70 Years|No|||December 2014|December 8, 2014|September 5, 2008|Yes|Yes||No|January 6, 2010|https://clinicaltrials.gov/show/NCT00750308||150501|
NCT00750321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R03NR10405-Placebo|Placebo Transcutaneous Electrical Nerve Stimulation (TENS)|||University of Iowa||Completed||||||N/A|Interventional|N/A|3||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 9, 2008|September 9, 2008||||No||https://clinicaltrials.gov/show/NCT00750321||150500|
NCT00750009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE18Z09|Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial|Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT)||Case Comprehensive Cancer Center|Yes|Completed|April 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|583|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750009||150524|
NCT00750672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHRI 2008-361|Follow-up Care After Treatment for Endometrial Cancer|Follow-up After Primary Therapy for Endometrial Cancer; Implementation of a Cancer Care Ontario Guideline: A Pilot Evaluation Study.||Ottawa Hospital Research Institute|No|Completed|August 2008|February 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|The study will employ a convenience sample of women with endometrial cancer treated at the        Ottawa Hospital Cancer Centre who have been discharged from follow-up after September        2005. Women will be identified from the Cancer Centre health records. The primary care        providers will also be identified by health records as provided by the endometrial cancer        patient when they registered with the TOHCC.|July 2012|July 11, 2012|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750672||150476|
NCT00718211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA01/12/06|A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore|A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore.||National University Hospital, Singapore||Recruiting|May 2006|||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|Probability Sample|To review medical records of all patients diagnosed with the disease at the two specified        centres.        The medical records will be obtained through both paper and electronic medical systems.        All data will be contained in a password secured database and will be securely located        behind institutional firewalls.|July 2008|July 18, 2008|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00718211||152939|
NCT00716924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9317|CASTLE (Clopidogrel And Serum Troponin Level Elevation)|Clopidogrel 600 mg and 300 mg as a Loading Dose Prior to Percutaneous Coronary Intervention And Serum Troponin Level Elevation: A Pilot Study|CASTLE|Sanofi|No|Completed|May 2004|||February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716924||153037|
NCT00716937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6148|Karydakis Procedure Versus Excision With Healing by Secondary Intention (EHSI) in Sacrococcygeal Pilonidal Sinus|Recurrence, Complications, Work-off Date, Healing Time and Patients Willingness in Karydakis Technique for Treatment of Sacrococcygeal Pilonidal Sinus Versus Excision With Healing by Secondary Intention (EHSI)Technique||Tehran University of Medical Sciences|Yes|Completed|September 2007|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|321|||Both|10 Years|90 Years|No|||December 2014|December 15, 2014|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716937||153036|
NCT00717847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS01/19/05|A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib|A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib||National University Hospital, Singapore||Completed|February 2006|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|||||Both|18 Years|N/A|No|Probability Sample|Any patient with NSCLC receiving erlotinib or gefitinib. Patients with unexpected and/or        severe treatment related toxicity whilst receiving EGFR TKI.|December 2013|December 10, 2013|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00717847||152966|
NCT00737893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010941|Erythropoietin to Enhance Erection Recovery in Men Following Radical Prostatectomy|Erythropoietin to Enhance Erection Recovery in Men Following Radical Prostatectomy|EPO|Johns Hopkins University|No|Recruiting|June 2008|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|40 Years|65 Years|No|||September 2013|September 20, 2013|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00737893||151446|
NCT00739076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30359-G|Pain Control After Trauma|Pain Control After Trauma|VRHTrauma|University of Washington|No|Completed|August 2007|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|184|||Both|12 Years|N/A|No|||April 2015|April 1, 2015|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739076||151357|
NCT00734851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010747|Multimodality Phase II Study in Prostate Cancer|Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study||Duke University|Yes|Terminated|December 2008|November 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|N/A|No|||September 2015|November 18, 2015|August 13, 2008|Yes|Yes|Dose Limiting Toxicities|No|September 21, 2015|https://clinicaltrials.gov/show/NCT00734851||151677|
NCT00734864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007909|Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma|Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma||Duke University|No|Withdrawn|June 2009|June 2012|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|May 4, 2008|No|Yes|Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB.|No||https://clinicaltrials.gov/show/NCT00734864||151676|
NCT00735150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-137|Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk|Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk||Memorial Sloan Kettering Cancer Center||Completed|March 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|39 Years|No|Non-Probability Sample|Prospective participants will be recruited through the MSKCC clinics that serve high-risk        patients (e.g. Clinical Genetics Service, Special Surveillance Breast Program, etc.)|October 2010|October 8, 2010|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735150||151654|
NCT00738426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCL-001|Study of Low Level Laser Therapy for Body Contouring|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Body Contouring of the Waist, Hips and Thighs Clinical Study Protocol||Erchonia Corporation|No|Completed|October 2007|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|August 18, 2008|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT00738426||151406|
NCT00738439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-08-1850|Multi-Center Prospective Evaluation of Operative Versus Nonoperative Treatment for Adult Spinal Deformity|Multi-Center Prospective Evaluation of Operative Versus Nonoperative Treatment for Adult Spinal Deformity: Differentiating Clinical and Radiographic Features and Evaluation of Treatment Outcomes|PON|International Spine Study Group Foundation|No|Enrolling by invitation|October 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|936|||Both|18 Years|N/A|No|Non-Probability Sample|Patients greater than 18 years of age who meet inclusion criteria.|March 2015|March 23, 2015|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738439||151405|
NCT00739050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0733-271|Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)|Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus||Merck Sharp & Dohme Corp.||Terminated|September 2007|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||September 2015|September 3, 2015|August 19, 2008|Yes|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00739050||151359|The Investigator was not able to recruit the required patients and was not able to get the necessary equipment. The protocol was terminated for Administrative Reasons.
NCT00739063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0613|Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer|Study of Erlotinib, Small Molecule Targeting Epidermal Growth Factor Receptor (EGFR) in Treatment of Patients w/EGFR-overexpressing 'Triple Receptor-negative' Metastatic Carcinoma of Breast That Progressed on Anthracyclines and Taxanes||M.D. Anderson Cancer Center|No|Terminated|July 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|N/A|N/A|No|||February 2012|February 10, 2012|August 19, 2008||No|Poor Accrual|No|December 21, 2011|https://clinicaltrials.gov/show/NCT00739063||151358|
NCT00734825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607012|Emergency Department CT Scanning for Appendicitis|Emergency Department CT Scanning for Appendicitis: IV Contrast vs. IV and Oral Contrast||WellSpan Health|No|Completed|November 2006|September 2010|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734825||151679|
NCT00734838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008003|Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy|Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy||Duke University|Yes|Completed|January 2006|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 8, 2015|August 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00734838||151678|
NCT00736034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SharpPS™-Gold 001|The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment|A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment||Enzymotec||Completed|September 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||April 2009|March 26, 2010|August 14, 2008||No||No|March 4, 2010|https://clinicaltrials.gov/show/NCT00736034||151588|
NCT00734812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002591/1|Laparoscopic Supracervical Hysterectomy Versus Total Laparoscopic Hysterectomy|LSH vs. TLH, A Randomized Single Blind Trial||Brigham and Women's Hospital|No|Withdrawn|May 2008|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|August 12, 2008||No|Study was withdrawn prior to any enrollment.|No||https://clinicaltrials.gov/show/NCT00734812||151680|
NCT00735111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOL-001|Do Self-Rated Performance Status Scores Correlate With Health-Care-Provider-Scores?|Do Self-Rated Karnofsky Performance Status (KPS) Scores Correlate With Health-Care-Provider-Rated Scores?||University of Florida|No|Completed|February 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|200|||Both|18 Years|90 Years|No|||January 2013|January 15, 2013|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735111||151657|
NCT00735124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14002|Post-Operative Pain Scores and Analgesic Requirements After Elective Inguinal Herniorrhaphy|An Investigation of Post-Operative Pain Scores and Analgesic Requirements After Ambulatory Inguinal Herniorrhaphy With Pre-Operative Gabapentin Therapy||University of Oklahoma|Yes|Suspended|November 2008|December 2012|Anticipated|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||June 2012|June 13, 2012|August 13, 2008|Yes|Yes|Need amendments in application process and require IBD number from FDA|No||https://clinicaltrials.gov/show/NCT00735124||151656|
NCT00735371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-305|Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire|No|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|314|||Both|13 Years|17 Years|No|||June 2011|June 21, 2011|August 12, 2008|Yes|Yes||No|February 1, 2010|https://clinicaltrials.gov/show/NCT00735371||151638|
NCT00747812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRISM-UK-05|Study of Occipital Nerve Stimulation for Drug Refractory Migraine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Occipital Nerve Stimulation for Drug Refractory Migraine|PRISM UK|Boston Scientific Corporation|No|Terminated|May 2006|May 2012|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|September 4, 2008||No|Sponsor closed enrollment early based on interim data from the PRISM US Pivotal Study.|No|June 28, 2012|https://clinicaltrials.gov/show/NCT00747812||150693|Insufficient data collected from limited number of implanted subjects.
NCT00747825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ-M101|Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma|A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, and Determination of Radiation Dosimetry for 131-I-MIP-1145||Molecular Insight Pharmaceuticals, Inc.|No|Terminated|December 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|September 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00747825||150692|
NCT00749736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707-04|The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.|The Role of Vitamin D in Immune Function in Patients With CKD Stages 3 and 4.||Indiana University|Yes|Completed|July 2008|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|100|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749736||150545|
NCT00749723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2005-002618-40|Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children|Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents|HIT-REZ-2005|University Hospital, Bonn|Yes|Active, not recruiting|February 2006|January 2016|Anticipated|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|3 Months|30 Years|No|||July 2015|July 7, 2015|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749723||150546|
NCT00750022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCPC-0101|Feasibility of Integrating Indirect Calorimetry (IC) Technology in Primary Care|Feasibility Study of Integrating IC Technology With the WatchWT Comprehensive Weight Reduction Program.||Colorado Center for Chronic Care Innovations, Inc.|No|Completed|January 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|September 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00750022||150523|
NCT00750334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOMDS01206|A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)|A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)||Sanofi|No|Terminated|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|September 9, 2008|No|Yes|Terminated to focus on comparable trial, CLOMDS02507|No||https://clinicaltrials.gov/show/NCT00750334||150499|
NCT00750347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0037|Antagonistic Interaction CB1-paracetamol|Evaluation of the Interaction of Rimonabant (Antagonist of CB1 Receptor) on the Analgesic Effect of Paracetamol in Intravenous Administration||University Hospital, Clermont-Ferrand||Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2011|January 18, 2011|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750347||150498|
NCT00750685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-101-0501-8|Study of the Mentor Becker Expander/Breast Implant in Subjects Who Are Undergoing Primary Breast Reconstruction|Study of the Safety and Effectiveness of the Mentor Becker Expander/Breast Implant in Subjects Who Are Undergoing Primary Breast Reconstruction||Mentor Worldwide, LLC|No|Terminated|March 2007|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|315|||Female|18 Years|N/A|No|||December 2014|December 17, 2014|September 9, 2008|Yes|Yes|Sponsor Terminated|Yes||https://clinicaltrials.gov/show/NCT00750685||150475|
NCT00750698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0403|A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib|A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib||Syndax Pharmaceuticals|No|Completed|August 2008|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2010|March 17, 2011|September 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00750698||150474|
NCT00717236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87094|Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis|A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.|REALISTIC|UCB Pharma|No|Completed|July 2008|March 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1648|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|July 15, 2008|Yes|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00717236||153013|
NCT00717249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1513|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2007|||||N/A|N/A|N/A||||||||||||||September 13, 2013|July 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717249||153012|
NCT00717262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQP 2008-002|Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects|A Phase 1, Double-Blind, Placebo Controlled, Repeat-Dose Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Volunteers||HemaQuest Pharmaceuticals Inc.|No|Completed|May 2008|September 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|41|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 15, 2009|July 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00717262||153011|
NCT00718757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIDML|Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies|A Phase I Trial Using Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies||St. Jude Children's Research Hospital|Yes|Completed|January 2005|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|21 Years|No|||August 2013|August 26, 2013|July 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00718757||152897|
NCT00738738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361036|6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)|A Phase 3, 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder||Pfizer|No|Withdrawn|January 2009|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||November 2012|November 30, 2012|August 12, 2008|Yes|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00738738||151383|
NCT00738751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15461|Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers|Phase I Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|November 2008|February 2015|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|August 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00738751||151382|
NCT00745615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAQ/5063OL|An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients|[An Active Extension of LAQ/5062 Study. A Multinational, Multi-center, Randomized, Double-blind, Parallel-group Study, to Evaluate the Safety, Tolerability and Efficacy of Two Doses (0.3mg and 0.6mg) of Laquinimod,] Orally Administered in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects Followed by an Open Label Phase of Laquinimod 0.6 mg Daily.||Teva Pharmaceutical Industries|Yes|Active, not recruiting|December 2006|October 2023|Anticipated|October 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|211|||Both|18 Years|50 Years|No|||March 2016|March 1, 2016|September 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745615||150861|
NCT00745901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015055|Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females|An Open Label Study to Evaluate Cycle Control With Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) and Yaz (Drospirenone/Ethinyl Estradiol) in Healthy Sexually Active Females||Ortho-McNeil Janssen Scientific Affairs, LLC||Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|355|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|June 8, 2011|September 2, 2008||||No|April 22, 2010|https://clinicaltrials.gov/show/NCT00745901||150839|
NCT00746148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dmw1|Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study|Reflexology's Effect on Polycystic Ovary Syndrome (REPOS): A Pilot Study|REPOS|University of Nottingham|No|Not yet recruiting|December 2012|December 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|20 Years|38 Years|No|||December 2012|December 3, 2012|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746148||150821|
NCT00738725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRP-001|BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population|A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population Combining Targeted and Unsupervised Biological Measurements With Non-Invasive Imaging Modalities to Identify Biomarkers That Predict Near Term (1-3-years) Outcomes||BG Medicine, Inc|No|Completed|January 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|7687|Samples With DNA|Serum, plasma, RNA and DNA|Both|55 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Recruitment will be limited to the Humana membership base using health insurance claims        information to identify potential study candidates. Candidate selection algorithms have        been developed to identify members who have no prior history of cardiovascular disease,        but most likely would be at intermediate to high risk for atherosclerotic cardiovascular        events. The target is to recruit a population that has similar demographics to the US        population in terms of race and ethnicity.        The participant selection criteria for the Humana database extraction to represent a        medium to high risk population*: current Humana member with at least 3 months continuous        enrollment; resides in one of the three study markets; pharmacy or medical claim for        diabetes, hypertension, obesity or abnormal lipid.        *Note: A separate selection will be for patients without any pharmacy claims to represent        20% of the study population.|October 2013|January 26, 2015|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738725||151384|
NCT00736047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIC002A2201|Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.|A Double Blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.||Novartis|No|Completed|August 2008|||October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||October 2009|October 29, 2009|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736047||151587|
NCT00736060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0027-08-EMC|Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever|Study the Clinical and Laboratory Characteristics and the Outcome of Sickle Cell Anemia Patients Admitted to the Pediatric Ward Because of Fever as the Presenting Symptom||HaEmek Medical Center, Israel|No|Completed|May 2008|November 2008|Actual|||N/A|Observational|Time Perspective: Retrospective||2|Anticipated|60|||Both|N/A|N/A|No|Probability Sample|60 patients treated at the Pediatric Hematology Unit in the Ha'Emek Medical Center        suffering from sickle cell anemia or sickle cell thalassemia admitted with fever as the        presenting symptom.|August 2011|August 25, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736060||151586|
NCT00735137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/HW/10|Randomized Study of Pessary Versus Standard Management in Women With Increased Chance of Premature Birth|Randomized Study of Pessary vs Standard Management in Women With Increased Chance of Premature Birth||King's College Hospital NHS Trust|Yes|Recruiting|August 2008|February 2012|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|2780|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 2, 2009|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735137||151655|
NCT00735709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_305|Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder||Takeda|No|Completed|August 2008|August 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|560|||Both|18 Years|75 Years|No|||October 2013|October 25, 2013|August 14, 2008||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00735709||151612|
NCT00736021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO_SHALEV_02|Treatment of Post-traumatic Stress Disorder With High Doses of Escitalopram|Post-marketing, Twelve Weeks, Open Label Study of up to 40 mg. Escitalopram in Chronic PTSD||Hadassah Medical Organization|No|Completed|September 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|21 Years|65 Years|No|||September 2008|March 21, 2010|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736021||151589|
NCT00747838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR Outcomes|A Multicenter Data Registry for Outcomes From Surgical Treatment of Atrial Arrhythmias|Surgical Treatment for Atrial Arrhythmia Registry (STAR Outcomes)|STAR|Virginia Commonwealth University|No|Terminated|September 2008|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with paroxysmal (intermittent) or persistent atrial fibrillation undergoing        surgical correction.|May 2013|May 24, 2013|September 4, 2008||No|Low enrollment.|No||https://clinicaltrials.gov/show/NCT00747838||150691|
NCT00748150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V78P6S|Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects|A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects||Novartis|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|143|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 4, 2012|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748150||150667|
NCT00720122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MassGH|Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa|Effects of Recombinant Human Insulin Like Growth Factor-1 (rhIGF-1) on Bone Metabolism in Adolescent Girls With Anorexia Nervosa|814|Massachusetts General Hospital|Yes|Completed|July 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|12 Years|26 Years|No|||February 2012|February 28, 2012|July 18, 2008|Yes|Yes||No|January 27, 2012|https://clinicaltrials.gov/show/NCT00720122||152794|
NCT00750035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95.59.14|Total Versus Subtotal Hysterectomy:a Randomised, Prospective Multicentre Study of the Effect on Urinary, Sexual and Bowel Function|||St George's Healthcare NHS Trust|Yes|Completed|January 1996|April 2000|Actual|April 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|279|||Female|18 Years|60 Years|No|||September 2008|October 23, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750035||150522|
NCT00750048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0036|Impact of Naloxone on the Analgesic Effect of Paracetamol in Healthy Volunteers|Impact of Naloxone on the Analgesic Effect of Paracetamol in Healthy Volunteers||University Hospital, Clermont-Ferrand||Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750048||150521|
NCT00750360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218352/054|Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.|Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Influenza Split Vaccine FLUARIX™ Administered According to the Prescribing Information in Korean Subjects Aged > 6 Months of Age at the Time of Vaccination.||GlaxoSmithKline||Completed|October 2003|||December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|883|||Both|6 Months|N/A|Accepts Healthy Volunteers|||April 2009|April 8, 2009|September 9, 2008|Yes|Yes||No|December 23, 2008|https://clinicaltrials.gov/show/NCT00750360||150497|
NCT00750724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faculty of Medicine, Khon Kaen|Efficacy Study of "Go On" in Magnetic Resonance Imaging (MRI) Improvement in Osteoarthritis (OA) Knee|Phase 3 Study GoON and MRI Improvement in OA Knee|GoOn MRI|Khon Kaen University|Yes|Completed|July 2008|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|80 Years|No|||July 2009|May 25, 2010|September 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00750724||150472|
NCT00749801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Geneferm-N01|Efficacy and Safety of Geneferm Nattokinase|A Randomized, Double-Blind, Placebo-Controlled, Parallel Comparison Study to Evaluate the Efficacy and Safety of Oral Administration of Nattokinase (From GeneFerm Biotechnology Co., Ltd.) Taken by Dyslipidemia Patients||Chi Mei Medical Hospital|No|Completed|May 2007|April 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|47|||Both|40 Years|N/A|No|||September 2008|September 8, 2008|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749801||150540|
NCT00749814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-YS-371-CTIL|Sleep Disturbances in Hospitalized Children|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|October 2008|||December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||August 2008|September 8, 2008|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749814||150539|
NCT00717587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600332|Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer|A Histopathologic and Imaging Study of Renal Cell Carcinoma Vasculature in the Setting of Sunitinib Therapy Prior to Cytoreductive Nephrectomy||National Cancer Institute (NCI)||Recruiting|June 2008|||July 2010|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2009|January 9, 2014|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00717587||152986|
NCT00718510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAT7176|L-arginine in Treatment as Usual in Schizophrenia|A Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia||University of Alberta|Yes|Completed|September 2009|October 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||December 2013|December 9, 2013|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718510||152916|
NCT00750438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0707/99|Effect of Fibre Products on Appetite and Weight|Increased Short Chain Fatty Acids in the Colon Are Associated With Improved Energy Homeostasis and Insulin Sensitivity.||Imperial College London|Yes|Active, not recruiting|September 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|97|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750438||150491|
NCT00745368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33113|Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women|Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women||University of Rochester|No|Completed|September 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|September 1, 2008|No|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00745368||150880|Due to limited sample size and large intersubject variability, more study comparing male and female GT concentrations is needed.
NCT00745628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A02-08|Chinese Cohort Study of Coronary Heart Disease|Cross-Sectional Investigation of Secondary Prevention on Coronary Heart Disease and Generalization of Standardized Secondary Prevention in Chinese Coronary Heart Disease Patients|CCS-CHD|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|May 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Diagnosed coronary heart disease|May 2008|September 2, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745628||150860|
NCT00745914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A111-103|Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients|A Randomized Placebo-Controlled Study to Evaluate the Efficacy of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Inducing Carotid Atherosclerotic Plaque Regression in Diabetic End-Stage Renal Disease Patients||The University of Hong Kong|Yes|Completed|September 2008|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|75 Years|No|||September 2015|September 5, 2015|September 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00745914||150838|
NCT00746161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMU-GC02|Evaluation of Double Tract Reconstruction After Total Gastrectomy in Patients With Gastric Cancer|A Prospective Randomized Controlled Trial Comparing Double Tract Method With Roux-en-Y Method After Total Gastrectomy in Patients With Gastric Cancer||Wakayama Medical University|Yes|Completed|April 2002|April 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|N/A|80 Years|No|||September 2008|September 3, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746161||150820|
NCT00746447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-27/UCR|Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)|Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Maintenance of Remission in Patients With Ulcerative Colitis||Dr. Falk Pharma GmbH|No|Completed|May 2005|March 2008|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|648|||Both|18 Years|75 Years|No|||June 2012|June 25, 2012|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746447||150798|
NCT00735384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/02|Muscle Force Assessment in the Intensive Care Unit and in Primary Myopathies|Application of Methodology of Non-invasive Stimulated Muscle Force Assessment to ICU Patients and Patients With Primary Myopathies to Characterize Their Muscle Weakness - Extension of the Study Protocol: 2008 to 2016||University Hospital, Basel, Switzerland|No|Recruiting|September 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|November 2015|November 23, 2015|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735384||151637|
NCT00735397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-307|Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures||Eisai Inc.|Yes|Completed|October 2008|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1218|||Both|12 Years|N/A|No|||February 2016|February 11, 2016|August 13, 2008|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT00735397||151636|
NCT00735410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V44P12S|Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2008/2009 When Administered to Adult and Elderly Subjects||Novartis||Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|134|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 4, 2011|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735410||151635|
NCT00746980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070823|Efalizumab in the Treatment of Alopecia, Phase II|Efalizumab in the Treatment of Alopecia Totalis/Universalis in Young Adults, Phase II||Northwestern University|Yes|Withdrawn|August 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|40 Years|No|||March 2011|March 31, 2011|September 2, 2008|Yes|Yes|Newly identified safety concerns have changed the risk and benefit considerations|No||https://clinicaltrials.gov/show/NCT00746980||150757|
NCT00736333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04878|A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)|Observational Program of Caelyx in MBC - Prevention and Treatment of PPE and Infusion Reactions||Merck Sharp & Dohme Corp.|No|Completed|November 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|167|||Both|N/A|N/A|No|Non-Probability Sample|Patients with metastatic breast cancer|October 2014|October 31, 2014|July 25, 2008|No|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00736333||151565|
NCT00736346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 81128 (CIHR)|Treatment of Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain|Efficacy of Three Treatment Modalities for Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain|MADONA|Universite du Quebec a Montreal|No|Recruiting|October 2005|June 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|204|||Both|18 Years|N/A|No|||August 2008|August 14, 2008|August 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00736346||151564|
NCT00736866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEP- HCor 001/08|The Acetylcysteine for Contrast-Induced Nephropathy Trial|A Pragmatic Randomized Clinical Trial Evaluating the Effect of Acetylcysteine for Contrast-induced Nephropathy|ACT|Hospital do Coracao|No|Completed|August 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2300|||Both|18 Years|N/A|No|||August 2008|July 8, 2010|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736866||151525|
NCT00736879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-032|Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise||AstraZeneca|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|497|||Both|18 Years|77 Years|No|||September 2015|September 23, 2015|August 15, 2008|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00736879||151524|
NCT00720135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03131|Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma|A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma||City of Hope Medical Center|Yes|Completed|January 2008|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||June 2015|June 3, 2015|July 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720135||152793|
NCT00720473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002493|Lamotrigine Therapy in Geriatric Bipolar Depression|Lamotrigine Therapy in the Treatment of Geriatric Bipolar Depression: An Evaluation of Markers of Cerebral Energy Metabolism||Mclean Hospital|Yes|Completed|April 2006|December 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 4, 2012|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720473||152768|
NCT00720460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080185|Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging in Normal Volunteers|Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|July 2008|||||Phase 0|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00720460||152769|
NCT00716118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-02|Oocyte Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.|Oocytes Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.|WCFC|West Coast Fertility Centers|Yes|Completed|July 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|21 Years|37 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women of reproductive age who undergo controlled ovarian hyperstimulation (COH) for IVF        are recruited for this study.|January 2011|January 5, 2011|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00716118||153099|
NCT00716352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC/03/10/48|Prospective Registry of Outcomes and Management of Acute Ischaemic Syndromes|Prospective Registry of Outcomes and Management of Acute Ischaemic Syndromes||Royal Brompton & Harefield NHS Foundation Trust||Completed|March 2004|November 2005|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|2||Actual|1340|||Both|N/A|N/A|No|||July 2008|July 15, 2008|July 15, 2008||||No||https://clinicaltrials.gov/show/NCT00716352||153081|
NCT00750464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pr-118-8061 ver. 001|Collection of Raw Data of Thermal Imaging for the Purpose of Developing a Device for Early Detection of Breast Cancer|Collection of Raw Data of Thermal Imaging for the Purpose of Developing a Device for Early Detection of Breast Cancer||Real Imaging Ltd.|No|Completed|November 2008|August 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|575|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects with a breast abnormality (identified by mammography, ultrasound, MRI and/or a        clinical examination) requiring a biopsy|October 2009|October 12, 2009|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750464||150489|
NCT00718523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO 014|Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer|A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer||Translational Research in Oncology|Yes|Terminated|January 2009|November 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|July 17, 2008|Yes|Yes|The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial.|No|October 22, 2015|https://clinicaltrials.gov/show/NCT00718523||152915|
NCT00751140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15441|Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection|Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|N/A|N/A|No|||December 2012|December 4, 2012|September 10, 2008||No||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00751140||150440|The sample size was small because it was a single institution study. It was thus underpowered to achieve a cancer-specific endpoint pertaining to the oncological merit of performing a modified RPLND in the context of UUT-UC.
NCT00745381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-105|A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors|Gastroenteropancreatic and Unknown Primary Neuroendocrine Registry A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2008|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|All participants will be invited to provide a DNA (blood sample) and tissue sample for the      purposes of developing a tissue repository. Blood samples will be collected. Expected      accrual is 150 patients per year. Patients who donate blood and/or tissue samples are      considered evaluable for protocol; however, it is preferred that both are obtained.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with GEPNET or NET of unknown primary|August 2015|August 14, 2015|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00745381||150879|
NCT00746759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADx-0001: IDE G090194|Airway Epithelium Gene Expression: AEGIS IDE|Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS IDE|AEGIS IDE|Allegro Diagnostics, Corp.|No|Completed|February 2010|February 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1331|Samples With DNA|Cells, Blood|Both|21 Years|N/A|No|Non-Probability Sample|Patients of enrolled medical centers who are undergoing clinically indicated bronchoscopy        for suspect lung cancer and who are current or former cigarette smokers.|June 2015|June 2, 2015|September 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746759||150774|
NCT00747006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-119|Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake|A Phase 2, Single-Center, Open-Label, Pharmacodynamic Clinical Trial to Evaluate the Effect of Technosphere® Insulin Inhalation Powder Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Postprandial Glucose Levels in Subjects With Type 1 and Type 2 Diabetes Mellitus Ingesting Meals With Varied Carbohydrate Content||Mannkind Corporation||Terminated|September 2008|May 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|70 Years|No|||October 2014|October 21, 2014|September 3, 2008|Yes|Yes|Business reasons|No|July 22, 2014|https://clinicaltrials.gov/show/NCT00747006||150755|- Early termination of trial leading to small numbers of subjects analyzed.
NCT00746174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK CRT49653/250|Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone|Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone||University of Texas Southwestern Medical Center|Yes|Completed|February 2004|February 2008|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|65 Years|No|||September 2008|September 2, 2008|August 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746174||150819|
NCT00746460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-08001|The Healthy Options Feasibility Study|The Effectiveness of CVD Risk Profiles When Used by Allied Health Care Providers (HCP) Within a "Groupe de Médecine de Famille": The Healthy Options Feasibility Study.||McGill University|No|Completed|June 2008|October 2009|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|30 Years|79 Years|No|||January 2014|January 10, 2014|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746460||150797|
NCT00746733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-113|Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC|A Phase I, Open-Label, Randomized, Four Period Crossover Drug Interaction Study to Evaluate the Pharmacokinetic Profiles of VYVANSE™ and ADDERALL XR When Each is Administered Alone and in Combination With the Proton Pump Inhibitor Prilosec OTC™ in Healthy Adult Volunteers||Shire||Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|September 2, 2008|No|Yes||No|October 14, 2009|https://clinicaltrials.gov/show/NCT00746733||150776|
NCT00746993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD5101|Randomized Controlled Trial of Structured Contraceptive Counseling in Adult Women|Structured Contraceptive Counseling--A Randomized Controlled Trial||Columbia University|No|Completed|October 2008|February 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|250|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 11, 2012|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746993||150756|
NCT00747292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H1111/70|Peri-Operative Management of Patients Undergoing Laparoscopic Colorectal Surgery|Randomised Controlled Trial Comparing the Effects of Epidural, Spinal and PCA in Patients Undergoing Laparoscopic Colectomy.||Minimal Access Therapy Training Unit|No|Recruiting|December 2007|October 2009|Anticipated|October 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|N/A|No|||September 2008|September 4, 2008|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747292||150733|
NCT00747565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIOL-104-TCNS & DIOL-101-TCNS|Safety and Effectiveness of a Multifocal Intraocular Lens (IOL)|Clinical Evaluation of the Tecnis Multifocal Intraocular Lens (IOL), Model ZM900, Original Study (DIOL-101-TCNS); Clinical Evaluation of the Tecnis Multifocal Intraocular Lens, Model ZM900, Expansion Study (DIOL-104-TCNS)||Abbott Medical Optics|No|Completed|November 2004|November 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|470|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 27, 2013|September 3, 2008|No|Yes||No|August 14, 2009|https://clinicaltrials.gov/show/NCT00747565||150712|Results from the original study (DIOL-101-TCNS) and the expansion study (DIOL-104-TCNS) were analyzed together. The original study enrolled both multifocal and monofocal control subjects; the expansion study enrolled additional multifocal subjects.
NCT00720486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH070400|Effectiveness of Anger Management Treatment in Reducing Anger-Related Behaviors in Female Juvenile Offenders|Anger Management Treatment for Female Juvenile Offenders||Drexel University|Yes|Completed|June 2008|February 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Female|12 Years|19 Years|No|||March 2014|March 26, 2014|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720486||152767|
NCT00720499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.9|Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Randomised, Double-blind, Cross-over Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 2 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination (FDC) With 5 Microgram Tiotropium Bromide (Delivered by the Respimat® Inhaler) in Patients With COPD||Boehringer Ingelheim||Completed|July 2008|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|141|||Both|40 Years|N/A|No|||July 2015|July 20, 2015|July 21, 2008||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT00720499||152766|
NCT00716144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT0720-201-INT|Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis|A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Study of the Safety and Efficacy of Oral R115866 and R115866 Placebo in the Treatment of Plaque Psoriasis||GlaxoSmithKline|No|Completed|June 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|176|||Both|18 Years|N/A|No|||September 2011|September 23, 2011|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716144||153097|
NCT00716131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-16827|Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program|ALS Tissue Donation Program||Drexel University|No|Recruiting|April 2007|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|300|Samples With DNA|Blood (Serum and DNA) Urine (Serum and DNA) CSF Blood specimens and tissue specimens (from      brain, spinal cord, gastrointestinal tract, skeletal muscle and peripheral nerve)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope, along with families and caregivers. Also        those with ALS who have donated their bodies to research.|May 2014|September 18, 2015|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716131||153098|
NCT00716378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908183|Teenage Passenger Influences on Driving Performance of Teenage Drivers|Teenage Passenger Influences on the Simulated Driving Performance of Teenage Drivers||National Institutes of Health Clinical Center (CC)||Completed|July 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|1||Anticipated|36|||Male|16 Years|18 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716378||153079|
NCT00716365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0152-07MMC|USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous Procedures|USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous|USF-Hemostasis|Meir Medical Center||Completed|January 2008|August 2011|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|278|||Both|18 Years|80 Years|No|||August 2011|August 15, 2011|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00716365||153080|
NCT00716651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBB1|Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome|A Phase II, Single Center Open Label, Prospective Trial to Evaluate the Efficacy and Safety of Mepolizumab for Patients With Refractory or Relapsing Churg Strauss Syndrome|MEPOCHUSS|University of Schleswig-Holstein|Yes|Completed|July 2008|||July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||June 2012|June 14, 2012|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716651||153058|
NCT00750477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN # C0504|Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis|A Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of Natural Eggshell Membrane (NEM) in the Treatment of Pain & Stiffness Associated With Moderate Osteoarthritis of the Knee|OPTION|ESM Technologies, LLC|No|Completed|December 2004|May 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|67|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00750477||150488|
NCT00750126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0039|Allogeneic Hematopoietic Stem Cell Transplantation|Feasibility Study on Allogeneic Hematopoietic Stem Cell Transplantation Following Fludarabine-Busulfan-ALS-based Reduced-intensity Conditioning in Children With Hematological Malignancy or Solid Tumor Not Responding to Standard Therapy or for Which the Indication for Allograft is Maintained But Cannot be Carried Out Due to the Toxicity Involved in Myeloablative Conditioning.|RICE|University Hospital, Clermont-Ferrand||Recruiting|April 2007|April 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|20 Years|No|||January 2011|January 18, 2011|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750126||150515|
NCT00751478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-01-07-205|Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)|A Randomized, Double-Blind, Triple-Dummy, Single-Dose, Four-Way Crossover Study to Determine the Relative Bioavailability, Pharmacodynamic Effects, and Safety of Equivalent Doses of Whole and Crushed ALO-01 Versus Morphine IR in Opioid Experienced, Non-Dependent Subjects||Pfizer|No|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 13, 2013|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751478||150414|
NCT00746473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-12|Assessment of Cytokine Values in Serum and by RT-PCR in HIV-1 Individuals With and Without HAART|Assessment of Cytokine Values in Serum and by Specific cDNA Amplification and Detection Using RT-PCR in HIV-1 Infected Individuals With and Without Highly Active Anti-Retroviral Therapy (HAART)||UPECLIN HC FM Botucatu Unesp|Yes|Completed|August 2004|October 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|73|||Both|22 Years|66 Years|Accepts Healthy Volunteers|Non-Probability Sample|All 73 HIV-1 infected individuals were submitted to full clinical observation including        associated opportunistic diseases at time of blood collection for cytokine detection.|September 2008|September 3, 2008|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00746473||150796|
NCT00736931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01297|Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam|Randomized, Comparative, Double-blind, Placebo-controlled, Triple-dummy, Four-way Cross-over Study to Investigate Neurocognitive Effects of Brivaracetam in Healthy Subjects||UCB Pharma|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2008|May 25, 2012|August 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00736931||151520|
NCT00737477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21421|MISTRAL Study: A Study of Monthly Subcutaneous Mircera for Maintenance Treatment of Patients With Chronic Kidney Disease on Peritoneal Dialysis.|A Single Arm, Open-label, Multi-center Study to Assess the Maintenance of Haemoglobin Levels With Once Monthly Subcutaneous Mircera in Patients With Chronic Kidney Disease on Peritoneal Dialysis||Hoffmann-La Roche||Completed|September 2008|December 2011|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737477||151478|
NCT00737737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080190|Hormone Function in Men Treated for Pain With Opioids or Placebo|Effects of Chronic Musculoskeletal Pain and Opioidergic Versus Placebo Interventions on Neuroendocrine Function in Men||National Institutes of Health Clinical Center (CC)|No|Completed|August 2008|April 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Male|30 Years|65 Years|No|||April 2015|April 9, 2015|August 16, 2008|Yes|Yes||No|April 9, 2015|https://clinicaltrials.gov/show/NCT00737737||151458|
NCT00747331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FenoldopamCPB|Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass|Fenoldopam Prophylaxis of Splanchnic Organs Underperfusion During Cardiopulmonary Bypass: a Randomized, Controlled Trial.||IRCCS Policlinico S. Donato|No|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2009|April 10, 2009|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747331||150730|
NCT00746746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USA-MCI-01|A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma|A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b (PEG-Intron)and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma||Ochsner Health System|Yes|Active, not recruiting|June 2008|June 2011|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|N/A|No|||September 2008|January 12, 2011|September 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00746746||150775|
NCT00747851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00011919|Necrotizing Enterocolitis (NEC) & Platelet-Activating Factor (PAF)-Stimulated Protein Translation in Premature Infants|Necrotizing Enterocolitis (NEC) & Platelet-Activating Factor (PAF)-Stimulated Protein Translation in Premature Infants||University of Utah|No|Recruiting|October 2003|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|388|||Both|N/A|1 Hour|Accepts Healthy Volunteers|Non-Probability Sample|Patients hospitalized in the NICU who were less than or equal to 1500 grams or less than        30 weeks gestational age at birth|December 2015|December 2, 2015|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747851||150690|
NCT00747305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612590|Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery|Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma||Medical University of South Carolina|Yes|Terminated|October 2008|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|120 Years|No|||April 2015|October 21, 2015|September 4, 2008|Yes|Yes|Study terminated early due to low accrual.|No||https://clinicaltrials.gov/show/NCT00747305||150732|
NCT00747318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-3-006|A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005|A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005, Incorporating Amendment 1 and 2||SkyePharma AG|No|Completed|September 2008|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|280|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|September 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00747318||150731|
NCT00747578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08129|Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan|Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan||Taichung Veterans General Hospital||Recruiting|September 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|65 Years|No|Non-Probability Sample|We will invite at least 100 patients with AS who fit the modified New York criteria (1984)        [19] , at least 100 patients with RA who fit the American College of Rheumatology (ACR)        criteria (1987) [20] and at least 100 patients with SLE who fit the ACR revised criteria        for the classification of SLE (1997) [21] in the outpatient clinics of the Division of        Rheumatology at Taichung Veterans General Hospital to participate in the study.|September 2008|September 5, 2008|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00747578||150711|
NCT00747591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10870|Urine Concentration of S100B in Extremely Premature Infants|Correlation of Urine Concentration of S100B in Extremely Premature Infants With Gestational Age and Severity of Intraventricular Hemorrhage||University of Utah|No|Completed|November 2002|April 2005|Actual|February 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|68|||Both|N/A|7 Days|No|Probability Sample|Preterm infants born at <28 weeks gestation will be eligible for enrollment in this study.|July 2010|July 21, 2010|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00747591||150710|
NCT00716690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-04-HMO-CTIL|Multi Donor Mismatched Stem Cell Transplantation (MDT)|Enhancement of Hematopoietic Stem Cell Engraftment by Multi Donor Stem Cell Transplantation (MDT) From 2 Mismatched Donors, a Phase I-II Open Study||Hadassah Medical Organization|No|Recruiting|July 2008|June 2020|Anticipated|January 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|70 Years|No|||February 2016|February 18, 2016|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716690||153055|
NCT00716976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL0431|Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy|A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children||Children's Oncology Group|Yes|Active, not recruiting|June 2008|||September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|131|||Both|1 Year|18 Years|No|||January 2016|January 4, 2016|July 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00716976||153033|
NCT00716391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTCC-2007-01|TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.|Open Label Randomized, Multi-centre Phase III Trial of TPF Plus Conc. Treatment With Cisplatin and Radiotherapy Versus Conc. Cetuximab and Radiotherapy in Locally Advanced, Unresectable Head and Neck Cancer.||Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|No|Recruiting|July 2008|December 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|458|||Both|18 Years|70 Years|No|||February 2011|February 12, 2011|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716391||153078|
NCT00716664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0404/81|Do Musculoskeletal Techniques Improve Forced Expiratory Volume in One Second in Adults With Cystic Fibrosis?|Pilot Study: Do Physiotherapy Musculoskeletal Techniques Improve Forced Expiratory Volume in One Second in Adults With Cystic Fibrosis?||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|March 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|N/A|No|||July 2008|March 10, 2009|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00716664||153057|
NCT00716677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0708/35|Dysfunctional Breathing in Difficult Asthma.|Ambulatory Respiratory Inductance Plethysmography (RIP). Can it be Used to Help Identify Dysfunctional Breathing in Difficult Asthma?||Royal Brompton & Harefield NHS Foundation Trust|No|Withdrawn|October 2009|December 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with physician diagnosis of difficult asthma|December 2012|December 31, 2012|July 15, 2008||No|Life shirt technology no longer available|No||https://clinicaltrials.gov/show/NCT00716677||153056|
NCT00716963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ2008lr|Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?|Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction?||McMaster University|No|Completed|July 2008|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|7|||Both|18 Years|60 Years|No|||April 2015|April 30, 2015|July 14, 2008|Yes|Yes||No|April 14, 2015|https://clinicaltrials.gov/show/NCT00716963||153034|
NCT00717873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0080|Evaluation of High-Frequency Chest Wall Oscillation|Evaluation of High-Frequency Chest Wall Oscillation Using the Vest Airway Clearance System Compared to Conventional Chest Physical Therapy at Barnes-Jewish Hospital||Hill-Rom|No|Completed|June 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|July 1, 2008|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT00717873||152964|
NCT00750516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5625|Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet|Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet||State University of New York - Upstate Medical University|No|Suspended|September 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Hypotensive, non pregnant by history, Emergency Medicine patients|June 2009|June 24, 2009|September 9, 2008||No|Insufficient patient enrolled|No||https://clinicaltrials.gov/show/NCT00750516||150486|
NCT00750828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hacettepe # FON 03/6-14|Gingival Wetness and Gingival Crevicular Fluid Volume in Patients With Dry Mouth|Gingival Wetness and Gingival Crevicular Fluid Volume in Patients With Dry Mouth||Hacettepe University|Yes|Completed|January 2004|March 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|28|||Female|46 Years|56 Years|No|Probability Sample|The data for this study were taken from 28 subjects at the Department of Periodontology,        Hacettepe University from 2004 to 2007. The study group consisted of 14 patients with dry        mouth complaints. All of them had the diagnosis of Sjögren's syndrome and ten of them were        on therapy for sicca symptoms.        Fourteen randomly selected age-matched systemically healthy females were also included as        a control group|September 2008|September 10, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750828||150464|
NCT00750841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00029|Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours|A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours||AstraZeneca|No|Active, not recruiting|September 2008|January 2017|Anticipated|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|130 Years|No|||December 2015|December 16, 2015|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750841||150463|
NCT00746486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-56/PBC|Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)|Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study Comparing the Combination of Ursodeoxycholic Acid Capsules Plus Budesonide Capsules to Ursodeoxycholic Acid Capsules Plus Placebo in the Treatment of Primary Biliary Cirrhosis||Dr. Falk Pharma GmbH|No|Active, not recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|183|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|September 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00746486||150795|
NCT00736697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3110A1-1005|Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin|An Open-Label, Randomized, Single-Dose, Parallel-Group Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Moxidectin Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 14, 2011|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736697||151538|
NCT00737490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007865|Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)|Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)|Devise-CRT|Duke University|No|Completed|June 2005|July 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||April 2013|July 31, 2014|May 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00737490||151477|
NCT00737984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-08-004|Improving the Pregnancy Rate With Endometrial Sampling Before Intrauterine Insemination|Improving the Pregnancy Rate With Endometrial Sampling Before Intrauterine Insemination||McGill University Health Center|No|Terminated|August 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Female|N/A|N/A|No|||October 2009|April 19, 2012|August 18, 2008||No|Because very low number of patients were enrolled|No||https://clinicaltrials.gov/show/NCT00737984||151439|
NCT00747604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W-TG-52800-010 (MS305)|IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex|Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex||Ipsen|Yes|Terminated|June 2006|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|1378|||Both|N/A|N/A|No|Non-Probability Sample|Eligible patients will be patients beginning therapy with Increlex® or those previously        treated with Increlex.|April 2015|April 2, 2015|September 3, 2008|No|Yes|Shortage of Increlex supply|No||https://clinicaltrials.gov/show/NCT00747604||150709|
NCT00738530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17705|A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy|A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma||Hoffmann-La Roche||Completed|June 2004|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|649|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738530||151399|
NCT00738543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMUGAmuch|Povidone-iodine Against Sodium Hypochlorite as Skin Antiseptics|Comparative Study of 10% Povidone-iodine Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers.||Universidad de Guanajuato|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|June 18, 2013|August 18, 2008||No||No|July 17, 2009|https://clinicaltrials.gov/show/NCT00738543||151398|
NCT00748176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200805027R|The Relationship of Abdominal Circumference and Trunk Length With the Level of Spinal Anesthesia in Obstetric Patients|The Relationship of Abdominal Circumference and Trunk Length With the Level of Spinal Anesthesia in Obstetric Patients||National Taiwan University Hospital|Yes|Completed|July 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|45 Years|No|Non-Probability Sample|Obstetric patients for C/S|December 2009|December 14, 2009|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00748176||150665|
NCT00744029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project Z1b|Reduction of Prehospital Delays in Stroke and Transient Ischaemic Attack (TIA)|Population-Based Intervention to Reduce Prehospital Delays in Patients With Stroke and Transient Ischaemic Attack|BASS|Charite University, Berlin, Germany|No|Completed|February 2004|June 2007|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1388|||Both|50 Years|N/A|No|||August 2008|August 29, 2008|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00744029||150980|
NCT00716703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB9986|CT Scan Using IV Contrast Alone for Pediatric Appendicitis|CT Scan Using IV Contrast Alone for Pediatric Appendicitis||University of Rochester|No|Completed|November 2003|October 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|250|||Both|3 Years|18 Years|No|||July 2008|July 15, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716703||153054|
NCT00716989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.457|Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections|LBP003: Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections|LBP003|Hospices Civils de Lyon|Yes|Terminated|November 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2010|December 22, 2010|July 15, 2008||No|Third group realisation has not been necessary regarding the results of the first two groups    (no sufficient modifications in the immune response)|No||https://clinicaltrials.gov/show/NCT00716989||153032|
NCT00717288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0210|Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir|Transitioning Post-cardiothoracic Surgery Patients From Intravenous Insulin to the Subcutaneous Route With Insulin Detemir.||Ohio State University|Yes|Completed|July 2008|June 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|75 Years|No|||August 2011|August 30, 2011|July 15, 2008|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00717288||153009|
NCT00717600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21679|Bacteriuria Eradication Through Probiotics|Bacteriuria Eradication Through Probiotics|BERP|Baylor College of Medicine|Yes|Enrolling by invitation|January 2008|September 2008|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|N/A|18 Years|No|||July 2008|July 16, 2008|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717600||152985|
NCT00717860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-062|A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)|A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections||Merck Sharp & Dohme Corp.||Completed|August 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|20 Years|N/A|No|||February 2016|February 21, 2016|July 16, 2008|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00717860||152965|
NCT00750152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90200/FI/3001|Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris|A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris||Merz Pharmaceuticals, LLC|No|Completed|September 2008|February 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|334|||Both|12 Years|N/A|Accepts Healthy Volunteers|||October 2012|April 15, 2013|September 9, 2008|Yes|Yes||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00750152||150513|
NCT00750451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-05/11|Low Molecular Weight Heparin in Recurrent Implantation Failure|Empirical Low Molecular Weight Heparin Administration in the Luteal Phase in Patients With Recurrent Implantation Failures: a Randomized Open Labeled Trial||V.K.V. American Hospital, Istanbul||Completed|January 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||||||Female|18 Years|38 Years|No|||March 2009|March 19, 2009|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750451||150490|
NCT00750204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00017371|Airway Pressure Release Ventilation in Acute Lung Injury|Airway Pressure Release Ventilation in Acute Lung Injury||Johns Hopkins University|No|Recruiting|July 2008|July 2010|Anticipated|July 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2008|September 9, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750204||150509|
NCT00750217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-54/2007|Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches|Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone.||Psychiatric University Hospital, Zurich|Yes|Recruiting|August 2008|May 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||August 2008|September 9, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750217||150508|
NCT00751153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP #33040|Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment|Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen.||Peter J. Ruane, M.D., Inc.|No|Recruiting|March 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2008|October 8, 2008|September 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751153||150439|
NCT00751166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03736|A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)|A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)||Merck Sharp & Dohme Corp.|No|Terminated|March 2004|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|149|||Both|12 Years|70 Years|No|||May 2015|May 4, 2015|September 10, 2008|Yes|Yes|Study could not be re-supplied with study medication in a timely manner.|No||https://clinicaltrials.gov/show/NCT00751166||150438|
NCT00751179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05700|Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)|A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety Assessor Blinded Trial in Adult Subjects Comparing Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Subjects Undergoing Short Surgical Procedures in Out-patient Surgicenters||Merck Sharp & Dohme Corp.|No|Completed|November 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|September 10, 2008|Yes|Yes||No|February 23, 2012|https://clinicaltrials.gov/show/NCT00751179||150437|The potassium change from baseline interval included most/all of the intubation/surgical period for the sug but not the suc or roc analysis. AE reporting interval included the entire intubation/surgery period for the suc but not the roc-sug group.
NCT00750854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN# C0104|Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders|A Double Arm Study to Evaluate the Effectiveness of NEM Compositions for the Treatment of Joint and Connective Tissue Pain||ESM Technologies, LLC|No|Completed|November 2003|April 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750854||150462|
NCT00750867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-12784|Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins|Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins||University of Massachusetts, Worcester|No|Completed|June 2008|December 2012|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 9, 2008|Yes|Yes||No|December 26, 2013|https://clinicaltrials.gov/show/NCT00750867||150461|The main study limitation is its small size and open label character.
NCT00736918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-MISP-01|RCT of Post-Suicide Attempt Case Management (ACTION-J)|A Randomized Controlled Multicenter Trial of Post-Suicide Attempt Case Management for the Prevention of Further Attempts in Japan (ACTION-J)|ACTION-J|Japan Foundation for Neuroscience and Mental Health|Yes|Completed|June 2006|October 2013|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|914|||Both|20 Years|N/A|No|||January 2014|January 14, 2014|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736918||151521|
NCT00737503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-024|Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab|Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|September 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4550|||Both|6 Weeks|20 Weeks|Accepts Healthy Volunteers|||August 2008|June 25, 2011|August 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00737503||151476|
NCT00737178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD0438|Immediate Versus Delayed Insertion of the Copper Intrauterine Device (IUD) After Medication Abortion|A Randomized Trial of Immediate Versus Delayed Insertion of the Copper T380A Following Medication Abortion||Columbia University|No|Completed|July 2008|August 2011|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Female|18 Years|N/A|No|||September 2014|September 18, 2014|August 14, 2008||No||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00737178||151501|
NCT00737191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588630|Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain|Analgesic Effect of Olanzapine in Cancer Pain: A Double-Blind Randomized Placebo-Controlled Parallel Group Pilot Study||Mayo Clinic|Yes|Withdrawn|August 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|3||Actual|0|||Both|18 Years|70 Years|No|||March 2012|March 7, 2012|August 15, 2008|No|Yes|No accrual; No patients enrolled|No||https://clinicaltrials.gov/show/NCT00737191||151500|
NCT00737997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009741|Effect of Early Morphine Administration on the Development of Acute Opioid Tolerance During Pediatric Scoliosis Surgery|Effect of Early Administration of Morphine on the Development of Acute Opioid Tolerance During Infusion of Remifentanil for Pediatric Scoliosis Surgery||The Hospital for Sick Children|No|Completed|December 2006|February 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|11 Years|18 Years|No|||November 2014|November 18, 2014|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737997||151438|
NCT00738218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHUCORE64|Diagnostic Accuracy of Multi-Detector Spiral Computed Tomography Angiography Using 64 Detectors|Coronary Evaluation Using Multi-Detector Spiral Computed Tomography Angiography Using 64 Detectors: "CORE-64" Study|CORE-64|Johns Hopkins University|Yes|Completed|October 2005|||February 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|405|||Both|40 Years|N/A|No|||August 2008|August 19, 2008|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00738218||151421|
NCT00738556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.15.8.08|Spot Drug-Eluting Stenting for Long Coronary Stenoses|Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study||Cardiovascular Research Society, Greece|Yes|Completed|January 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|85 Years|No|||January 2009|January 28, 2009|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738556||151397|
NCT00738816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klinfarm|Effect of Systematic Medication Review in Elderly Patients Admitted to an Orthopedic Department|The Effect of Systematic Medication Review in Elderly Patients Admitted to an Orthopedic Department.||University of Aarhus|No|Completed|April 2009|April 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|108|||Both|65 Years|N/A|No|||December 2010|December 13, 2010|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00738816||151377|
NCT00739154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005062|Protective Effect of Phenytoin on Glaucoma|Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma||Rabin Medical Center|No|Not yet recruiting|November 2008|December 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|patients of a tertiary hospital's specialized epilepsy clinic|August 2008|August 20, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739154||151351|
NCT00748956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO-05-0986|Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers|Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers|NPY|Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2010|January 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|10|||Male|25 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748956||150605|
NCT00749229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060109|Feasibility Study of Balloon Kyphoplasty in Traumatic Vertebral Fractures Needing Surgical Fixation|Prospective Cohort Study on the Feasibility and Reliability of 'Open' Balloon Kyphoplasty in Types A3.2, A3.3, B1 and C1 MAGERL Classification Vertebral Fractures(STIC 4)|TRAUMAA3B1C1|Assistance Publique - Hôpitaux de Paris|No|Terminated|December 2007|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Both|18 Years|N/A|No|||December 2014|December 13, 2014|September 8, 2008||No|the number of patients recruited at present is sufficient for analysis.|No||https://clinicaltrials.gov/show/NCT00749229||150584|
NCT00717301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C806001|S-100B as Pre-Head CT Scan Screening Test After Mild Traumatic Brain Injury|Accuracy of S-100B as Pre-Head CT Scan Screening Test After Mild Traumatic Brain Injury||University of Rochester|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1252|Samples Without DNA|Serum|Both|N/A|N/A|No|Non-Probability Sample|Patients presenting to Emergency Departments that are a part of the AHCC (Academic Health        Center Consortium) and/or ERNES (Emergency Research Network of the Empire State) networks.|June 2015|June 10, 2015|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00717301||153008|
NCT00749502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-4827-001|A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)|A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies||Tesaro, Inc.|No|Completed|September 2008|June 2013|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|113|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749502||150563|
NCT00749515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07090349|Pilot Study for Patients With Poor Response to Deferasirox|Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)||Children's Hospital Boston|No|Completed|March 2008|November 2008|Actual|October 2008|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||December 2010|December 1, 2010|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749515||150562|
NCT00750165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA CPAP; 254 Validation, NYU|Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Auto CPAP Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome.||Fisher and Paykel Healthcare|Yes|Completed|May 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2008|September 10, 2008|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00750165||150512|
NCT00750191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 07-594|Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty|A Randomized, Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty for Treatment of Discogenic Lower Back Pain||Baylis Medical Company|Yes|Completed|September 2007|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|September 9, 2008||No||No|September 13, 2013|https://clinicaltrials.gov/show/NCT00750191||150510|
NCT00750893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111700|Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants|Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ or Rotarix™ Liquid Formulation (Oral Suspension or Prefilled Syringe) When Administered According to the Prescribing Information in Korea||GlaxoSmithKline||Completed|September 2008|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3111|||Both|6 Weeks|24 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Infants aged at least 6 weeks will be administered two doses of Rotarix™ or Rotarix™        liquid formulation (oral suspension or prefilled syringe) orally as per the prescribing        information in Korea.|October 2014|October 23, 2014|September 10, 2008|No|Yes||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00750893||150459|
NCT00750529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0038|Alzheimer and Sleep|Effects of Galantamine and Donépézil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease.||University Hospital, Clermont-Ferrand||Completed|November 2008|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|65 Years|N/A|No|||July 2014|July 4, 2014|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750529||150485|
NCT00750555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0153|Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer|Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer||Geisinger Clinic|No|Terminated|September 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|September 9, 2008|Yes|Yes|Dr. Amy Law left Geisinger Health System. 4 patients enrolled|No||https://clinicaltrials.gov/show/NCT00750555||150484|
NCT00750880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA21573|An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.|International Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy.||Hoffmann-La Roche||Completed|September 2008|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1681|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|September 10, 2008||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00750880||150460|
NCT00751205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91695|Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)|(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.||Bayer|No|Completed|August 2008|August 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|70 Years|No|||October 2014|October 27, 2014|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751205||150435|
NCT00737009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OVN-ARI-2008/1|An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment|An Observational Study of Adherence to Adjuvant Anastrozole Therapy in Postmenopausal Patients With Early Breast Cancer Over One Year Follow-up.||AstraZeneca|No|Completed|August 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|259|||Female|N/A|N/A|No|Probability Sample|The target study population comprised of postmenopausal women with early breast cancer who        were treated with anastrozole for at least one month and are willing to give written        informed consent to participate.|June 2011|June 21, 2011|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737009||151514|
NCT00737750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR 04 2001A|Effectiveness of Kneehab in Strengthening the Quadriceps of Patients Post Anterior Cruciate Ligament (ACL) Reconstruction|Phase III Study in Patients Undergoing Rehabilitation Post-Surgical Reconstruction of the Anterior Cruciate Ligament (ACL)|NMES|Bio-Medical Research, Ltd.|No|Completed|April 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|131|||Both|18 Years|N/A|No|||August 2008|August 27, 2008|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00737750||151457|
NCT00738010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR 04 2001|Effectiveness of Kneehab in Strengthening Quadriceps in Rehabilitation Post Anterior Cruciate Ligament (ACL) Reconstruction|The Effectiveness of Kneehab in Strengthening the Quadriceps of Patients in Rehabilitation After Anterior Cruciate Ligament Reconstruction|NMES|Bio-Medical Research, Ltd.|No|Completed|April 2005|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|131|||Both|18 Years|N/A|No|||September 2008|September 16, 2008|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738010||151437|
NCT00738231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/37|Training Methods for a Doctrine Of Life With Healthy Heart|Two Distinct Training Methods for Healthy Heart in Low Social and Economical Society||Eskisehir Osmangazi University|No|Enrolling by invitation|September 2007|December 2009|Anticipated|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|498|||Both|40 Years|N/A|No|||August 2008|June 18, 2009|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738231||151420|
NCT00738569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck HIV|Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen|A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen||National Jewish Health|No|Completed|July 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738569||151396|
NCT00738582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-009-003 Amatuximab|An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma|An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma|Amatuximab|Morphotek|Yes|Completed|December 2008|January 2014|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738582||151395|
NCT00738829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL-5|Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL|Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Completed|October 2008|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00738829||151376|
NCT00739167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07Q1|Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer|A Quality of Life Study for Patients With Primary or Metastatic Liver Cancer Who Are Treated With Radioembolization (Y90 Microspheres) or Transcatheter Arterial Embolization (TACE)||Northwestern University|Yes|Completed|April 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|74|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of hepatocellular carcinoma being treated with either TACE, RFA,        or Y90.|October 2015|October 14, 2015|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739167||151350|
NCT00739180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-08-JF-27|Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes|Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes||University of Pittsburgh|Yes|Completed|November 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Male|12 Years|18 Years|Accepts Healthy Volunteers|||October 2012|November 2, 2012|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739180||151349|
NCT00748670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-MMF-0003|Treatment With Fixture Microthread™ in Patients With Poor Bone Quality and no Teeth in the Upper Jaw, When Using Two-Stage Surgery|An Open, Prospective, Multicenter Study to Evaluate Treatment of Edentulous Upper Jaws With an Implant-Supported Prosthesis Retained by Astra Tech Dental Implants, Fixture Micro-Macro in Patients With Poor Bone Quality||Dentsply Implants|No|Terminated|September 1999|||October 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|No|||September 2008|September 5, 2008|September 5, 2008|Yes|Yes|Decision to modify the product under study as a result of feedback regarding subjective    feeling during installation procedure. For more info, see brief summary.|No||https://clinicaltrials.gov/show/NCT00748670||150627|
NCT00748683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080816R|Development of an Integrated Health Care Environment for Elderly With RFID Technology|Development of an Integrated Health Care Environment for Elderly With RFID Technology||National Taiwan University Hospital|No|Completed|September 2008|August 2009|Actual|February 2009|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|15|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2008|December 14, 2009|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00748683||150626|
NCT00748969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808M43681|Clinical Trial of Growth Hormone in MPS I, II, and VI|Phase II/III, Randomized, Clinical Trial of the Effects of Nutropin AQ® on Growth and Bone Metabolism in Children With MPS I, II, and VI and Short Stature||Los Angeles Biomedical Research Institute|No|Terminated|November 2008|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|5 Years|17 Years|No|||November 2014|November 19, 2014|September 8, 2008|Yes|Yes|Insufficient recruitment.|No|October 30, 2014|https://clinicaltrials.gov/show/NCT00748969||150604|
NCT00748982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00013|Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction|A Single-centre, Single-blind, Randomised, Placebo-controlled Phase IIa Study to Investigate the Effect of AZD1305 Given as an Intravenous (iv) Infusion on Left Ventricular Performance in Patients With Left Ventricular Dysfunction||AstraZeneca|No|Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|80 Years|No|||June 2011|June 22, 2011|September 5, 2008|Yes|Yes||No|January 25, 2011|https://clinicaltrials.gov/show/NCT00748982||150603|
NCT00749528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-11|Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing|Sectional Prospective Randomised Study of Evaluation Toxic Metals, Trace Elements Status and Total Antioxidant Activity in Children With Recurrent Wheezing.||Kecioren Education and Training Hospital|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|95|Samples Without DNA|Group 1: Children with recurrent wheezing. Plasma and Hair specimen are retined Group 2:      Healthy children. Plasma and Hair specimen are retined|Both|6 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|Group 1: Children with recurrent wheezing Group 2: Age and sex matched healthy children|August 2008|March 14, 2012|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749528||150561|
NCT00749827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-US-0048|Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy (CIN)|Exploring the Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy|CIN|Memorial University of Newfoundland|No|Not yet recruiting|September 2008|September 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|N/A|No|||September 2008|September 18, 2008|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749827||150538|
NCT00750139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 90200-0736/1|Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis|A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis||Merz Pharmaceuticals, LLC|No|Completed|August 2008|December 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|707|||Both|12 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 19, 2013|September 8, 2008|Yes|Yes||No|February 13, 2012|https://clinicaltrials.gov/show/NCT00750139||150514|
NCT00750503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|458|Workplace Tobacco Cessation And Oral Cancer Screening Study|Workplace Tobacco Cessation And Oral Cancer Screening Study||Tata Memorial Hospital|Yes|Completed|June 2007|August 2008|Actual|June 2008|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|104|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2008|September 9, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750503||150487|
NCT00749866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZB/4/451|Long Term Nebulised Gentamicin in Patients With Bronchiectasis|Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis||University of Edinburgh|No|Completed|May 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||August 2010|August 9, 2010|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749866||150535|
NCT00751231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-116|A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI|A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI|INNOVATE-PCI|Portola Pharmaceuticals|Yes|Completed|December 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|652|||Both|18 Years|75 Years|No|||June 2012|June 26, 2012|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751231||150433|
NCT00751244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-051H-1|Mothers Overcoming and Managing Stress|Breaking the Cycle for Women With Behavioral Problems and Crime|MOMS|University of Connecticut Health Center|No|Completed|January 2005|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|147|||Female|18 Years|50 Years|No|||September 2010|September 24, 2010|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751244||150432|
NCT00751530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11|BRAVO: Background Regimen of Raltegravir on Virologic Outcome|Outcomes of Early Raltegravir Experience: Comparison of Virologic Response in Regimens Not Containing a Protease Inhibitor in the Antiretroviral Background Regimen Versus a Protease Inhibitor in the Background Regimen|BRAVO|Community Research Initiative of New England|No|Completed|March 2008|June 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|442|||Both|16 Years|N/A|No|Non-Probability Sample|The study population consists of individuals who were previously enrolled in raltegravir        expanded access program(EAP) and completed at least 8 weeks of treatment with raltegravir,        whose chart from EAP program is available for review, and whose resistance testing prior        to initiation of raltegravir is available.|July 2012|July 31, 2012|September 11, 2008||No||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00751530||150410|
NCT00737022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200805056R|Macular Appearance After Diabetic Vitrectomy|Macular Appearance After Diabetic Vitrectomy for Fibrovascular Proliferation -An Optical Coherence Tomography Study||National Taiwan University Hospital|Yes|Completed|May 2005|December 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|108|||Both|20 Years|85 Years|No|Non-Probability Sample|Proliferative diabetic retinopathy|July 2006|August 14, 2008|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00737022||151513|
NCT00736957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015115|A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain|A Study of a Long-term Administration of JNS013 in Patients With Chronic Pain||Janssen Pharmaceutical K.K.|No|Completed|May 2008|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|219|||Both|20 Years|N/A|No|||June 2014|June 23, 2014|August 14, 2008|Yes|Yes||No|March 25, 2013|https://clinicaltrials.gov/show/NCT00736957||151518|
NCT00736970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-009|Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)|A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer||Merck Sharp & Dohme Corp.|No|Completed|July 2008|May 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|18 Years|N/A|No|||August 2015|August 26, 2015|August 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00736970||151517|
NCT00736983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD 08-01|Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's|Adalimumab for the Treatment of Perianal Fistulas in Crohn's Disease More Effective Alone or Combined to Ciprofloxacin|Adafi|Foundation for Liver Research|No|Completed|September 2008|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|70 Years|No|||April 2012|April 16, 2012|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736983||151516|
NCT00736996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1215|Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)|Pioglitazone and Exercise Effects on Older Adults With MCI and Metabolic Syndrome|POEM|University of Colorado, Denver|No|Completed|November 2008|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|78|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 14, 2008|Yes|Yes||No|November 6, 2015|https://clinicaltrials.gov/show/NCT00736996||151515|
NCT00737763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0007365|Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab|Beta Cell Rescue in New Onset Type 1 Diabetes Mellitus With the LFA-1 Antibody Efalizumab|BRiTE|Emory University|Yes|Withdrawn|October 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|35 Years|No|||May 2014|May 9, 2014|August 19, 2008|No|Yes|drug withdrawn from market|No||https://clinicaltrials.gov/show/NCT00737763||151456|
NCT00737516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T00004|Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation|A Centralized Cord Blood Registry to Facilitate Allogeneic, Unrelated Donor Umbilical Cord Blood Transplantation||National Marrow Donor Program|Yes|Completed|January 2000|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3621|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 12, 2013|August 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00737516||151475|
NCT00738244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44DC007246-02A2|Effectiveness of Hearing-aid Based Wind-noise Algorithm|Methods of Wind Noise Suppression in Hearing Aids||University of Iowa|No|Completed|November 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups (30 each) of subjects will be recruited to participate: Normal hearing adults        and adults with mild to moderately severe hearing loss, ages 18-65. Pure tone audiometrics        (re ANSI, 1996) will be done to ascertain the hearing sensitivity through 6ooo Hz. Normal        hearing will be defined as thresholds at or better than 20 dB HL (re ANSI, 1996). The only        exclusion criterion for the group exhibiting hearing loss is that no thresholds up to and        including 3000 Hz will exceed 75 dB, so as to minimize the inclusion of subjects with        "dead regions" in the cochlea.|September 2011|September 23, 2011|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738244||151419|
NCT00738283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23224|Zinc and Copper Absorption in Neonates With Bilious Losses|Zinc and Copper Absorption in Neonates With Bilious Losses||Baylor College of Medicine|No|Completed|September 2008|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|Samples Without DNA|Blood, stool, gastric residuals, and urine|Both|N/A|N/A|No|Non-Probability Sample|Subjects will be selected from the patient population at the Neonatal Intensive Care Units        of Texas Children's Hospital and Ben Taub General Hospital.|July 2015|July 23, 2015|August 18, 2008||No||No|September 24, 2012|https://clinicaltrials.gov/show/NCT00738283||151417|Only 10 infants achieved a majority of enteral feeds with the ostomy in place, of which only 7 were fully enterally fed at the time of the study. This is a mixed group, but nonetheless representative of infants with small intestinal ostomies.
NCT00738842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00050|Uric Acid Study in Healthy Male Volunteers|A Randomised, Double-Blind, Two-Period Crossover Study to Assess the Effect of AZD6140 on Uric Acid Levels in Healthy Male Volunteers||AstraZeneca|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|August 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00738842||151375|
NCT00738855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oral gastrografin|Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO)|Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO).||Mansoura University|Yes|Completed|February 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||August 2008|November 25, 2008|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738855||151374|
NCT00738868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589673|Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery|Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Completed|October 2007|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||July 2009|May 12, 2011|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00738868||151373|
NCT00748995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|566|Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study|CSP #566 - Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study||VA Office of Research and Development|Yes|Active, not recruiting|August 2010|September 2016|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|817|None Retained|No Biospecimens were collected|Both|18 Years|N/A|No|Non-Probability Sample|Surviving members of the NDHS cohort of 1595 participants|March 2016|March 23, 2016|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748995||150602|
NCT00749008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP#07-130-1-HPH1|Study of Generalized Movements for Early Prediction of Cerebral Palsy|Early Prediction of Cerebral Palsy in Preterm Infants and Term Infants Using Detection of Generalized Movements||Hawaii Pacific Health|Yes|Completed|September 2008|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|63|||Both|N/A|2 Months|Accepts Healthy Volunteers|Non-Probability Sample|Preterm and term infants in the state of Hawaii, with and without lung disease, who are at        risk for development of cerebral palsy.|February 2014|February 24, 2014|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749008||150601|
NCT00749021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4332s|Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments|A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.||Southern California Desert Retina Consultants, MC|No|Completed|September 2008|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|50 Years|N/A|No|||October 2012|October 3, 2012|September 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749021||150600|
NCT00749268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS08011|AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair|Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair: A Prospective, Randomized Comparison to Evaluate the Incidence of Post-operative Pain Associated With Absorbable Fixation (AbsorbaTack) vs Conventional Fixation (ProTack) Following Laparoscopic Hernia Repair||Medtronic - MITG|No|Completed|October 2008|November 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|September 8, 2008||No||No|October 14, 2013|https://clinicaltrials.gov/show/NCT00749268||150581|
NCT00749242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060110|Comparative Study of Balloon Kyphoplasty and Conservative Treatment|Prospective Randomized Study Comparing Balloon Kyphoplasty and Conservative Treatment in Acute Traumatic Vertebral Fractures, Types A1, A2, AND A3.1 According to the Magerl Classification (STIC 3)|TRAUMAA1-2-3|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||November 2012|December 13, 2014|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749242||150583|
NCT00749255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708052|Collect Breast Cancer Patients' Digital Mammography Images With Corresponding Reports for the Development of Software|R2 Case Collection||WellSpan Health|No|Terminated|May 2008|January 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Known breast cancer patients|January 2011|January 17, 2011|September 5, 2008||No|not enough personnel to conduct study at site|No||https://clinicaltrials.gov/show/NCT00749255||150582|
NCT00749541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitamin d|Vitamin d Levels and Coronary Catheterization|25 Hydroxy Vitamin d Levels in Patients Undergoing an Elective Coronary Catheterization||Assaf-Harofeh Medical Center|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|blood samples|Both|18 Years|N/A|No|Probability Sample|patients undergoing an elective coronary catheterization over the age of 18.|September 2008|December 15, 2010|September 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00749541||150560|
NCT00749840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0011|Attitudes and Beliefs and the Steps of HIV Care|Attitudes and Beliefs and the Steps of HIV Care||M.D. Anderson Cancer Center|No|Completed|April 2008|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a new diagnosis of HIV infection.|February 2013|February 12, 2013|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749840||150537|
NCT00749879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-008|Crossover Study of the Safety and PK Properties of Proellex®|A Phase I, Open-Label, Randomized, Single-Center, Unblinded, Single-Dose, Five-Way Crossover Study of the Safety and PK Properties of Proellex®||Repros Therapeutics Inc.|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|17|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||February 2010|February 10, 2010|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749879||150534|
NCT00750568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10904|Intravenous Terbutaline in Severe Status Asthmaticus|Pharmacokinetics and Pharmacodynamics of Terbutaline Given as a Continuous Intravenous Infusion in Severe Status Asthmaticus||Wayne State University|No|Enrolling by invitation|October 2007|August 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|36|Samples Without DNA|Plasma|Both|2 Years|18 Years|No|Non-Probability Sample|Inpatients in Pediatric ICU with a diagnosis of status asthmaticus|August 2008|September 9, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750568||150483|
NCT00750230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN# A0803|Pilot Study of the Efficacy & Safety of Natural Eggshell Membrane (NEM) for Joint & Connective Tissue Disorders|A Single Arm Pilot Study to Evaluate the Effectiveness of Eggshell Membrane Compositions for the Treatment of Pain Associated With Connective Tissue and Joints||ESM Technologies, LLC|No|Completed|October 2003|January 2004|Actual|December 2003|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00750230||150507|
NCT00750243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-NS001-002|Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation|A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation||Logical Therapeutics|No|Completed|September 2008|April 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|120|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||October 2010|October 4, 2010|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00750243||150506|
NCT00750256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX111427|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects|A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects||GlaxoSmithKline|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 15, 2012|September 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00750256||150505|
NCT00750581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT734510|An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants|An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants- A Randomized Pilot Study||University of Calgary|Yes|Recruiting|August 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||January 2010|January 11, 2010|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00750581||150482|
NCT00750906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H898-32701|ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes|The Muscle Biochemical, Serum Potassium and Cardiovascular Changes After Succinylcholine in Patients Undergoing Electroconvulsive Therapy.||University of California, San Francisco|No|Suspended|October 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing electroconvulsive therapy.|March 2013|March 6, 2013|September 9, 2008||No|Study on hold since 2009. Awaiting FDA approval of Sugammdex to complete second arm of study.|No||https://clinicaltrials.gov/show/NCT00750906||150458|
NCT00750919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05721|Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)|A Twenty-six Weeks, Open-label Extension Trial to Evaluate Safety and Efficacy of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 21106||Merck Sharp & Dohme Corp.|No|Terminated|October 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|184|||Both|18 Years|65 Years|No|||July 2015|July 2, 2015|September 10, 2008|No|Yes|This trial was stopped prematurely due to the Sponsor's decision not to continue the    development of esmertazapine for this indication.|No|May 22, 2014|https://clinicaltrials.gov/show/NCT00750919||150457|This study was terminated due to the Sponsor's decision not to continue development of esmertazapine for this indication.
NCT00737568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0121|Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine|A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects With Chronic Hepatitis B Who Are Resistant to Lamivudine||Gilead Sciences|Yes|Completed|September 2008|February 2015|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|August 15, 2008|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00737568||151471|There were no limitations affecting the analysis or results.
NCT00737581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1648|Spinal Cord Stimulation Research Study|Posture Responsive Spinal Cord Stimulation Research Study||MedtronicNeuro|No|Completed|August 2008|April 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with a spinal cord stimulator.|April 2009|April 27, 2009|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737581||151470|
NCT00737230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000601214|Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis|Effective Management of Radiation-induced Bowel Injury: A Randomized Controlled Trial||National Cancer Institute (NCI)||Completed|April 2007|July 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Health Services Research|1||Anticipated|250|||Both|N/A|N/A|No|||June 2009|August 23, 2013|August 15, 2008||||No||https://clinicaltrials.gov/show/NCT00737230||151497|
NCT00737243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI UNKPRI 20|Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site|A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site||SCRI Development Innovations, LLC|No|Active, not recruiting|August 2008|September 2015|Anticipated|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|August 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00737243||151496|
NCT00737217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0464|Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease|Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease||University of Michigan|No|Completed|March 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|74|||Both|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Parkinson's disease, either with or without memory or concentration        difficulties, and normal control persons between the ages of 50-85 years are eligible to        participate in this study. Participants should be willing and able to comply with study        requirements. Normal control persons should not have a history of brain or mental        disorders. Both males and females are eligible.|June 2013|June 24, 2013|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737217||151498|
NCT00737789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pentasa FE999907 CS06|Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.|Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.||Ferring Pharmaceuticals|No|Completed|November 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00737789||151454|
NCT00737776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3547|Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes|NovoMix® 30 UPGRADE (NovoMix® 30 Use for Progressed Glycemic Control in Realistic Administration to DiabEtes Mellitus): A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Efficacy and Safety Study in Patients Using Biphasic Insulin Aspart 30 (NovoMix® 30) for the Treatment of Diabetes Mellitus|UPGRADE|Novo Nordisk A/S|No|Completed|May 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1068|||Both|N/A|N/A|No|Non-Probability Sample|Any patient with type 1 and type 2 diabetes who are prescribed with NovoMix® 30|August 2014|August 11, 2014|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00737776||151455|
NCT00738257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-GB-50|A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.|A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen.|SMART|Novartis||Completed|June 2000|||December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|75 Years|No|||May 2010|May 14, 2010|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738257||151418|
NCT00738595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVT 302/3009|Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.|Phase II Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation, Effect on it Own and in Combination With Open Label Nicotine Replacement Therapy.||Evotec Neurosciences GmbH|No|Completed|August 2008|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|70 Years|No|||May 2009|May 28, 2009|August 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738595||151394|
NCT00738621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scott and White|Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients|A Comparison of Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients||Scott and White Hospital & Clinic|Yes|Completed|July 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||August 2008|December 18, 2013|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738621||151392|
NCT00738881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00663|Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer|MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib|MARVEL|National Cancer Institute (NCI)||Terminated|October 2008|December 2014|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||December 2014|October 6, 2015|August 20, 2008|Yes|Yes|Slow accrual|No|November 27, 2013|https://clinicaltrials.gov/show/NCT00738881||151372|
NCT00738894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLX 06-03|GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study|GORE® HELEX® Septal Occluder / GORE® Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients With Patent Foramen Ovale (PFO)|HLX 06-03|W.L.Gore & Associates|Yes|Active, not recruiting|August 2008|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|664|||Both|18 Years|60 Years|No|||February 2015|February 6, 2015|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738894||151371|
NCT00748722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-YB-0181-CTIL|Pre-Operative Imaging of Abdominal Wall Perforators Using CT Angiography|Pre-Operative Imaging of Abdominal Wall Perforators Using CT Angiography for DIEP Breast Reconstruction|DIEP|Tel-Aviv Sourasky Medical Center|Yes|Active, not recruiting|September 2008|August 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|60 Years|No|Non-Probability Sample|Female patients, age 18-60 years eligible for lower abdominal breast reconstruction|September 2008|September 7, 2008|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00748722||150623|
NCT00749034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPM1002-GE-1.01TB|Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers|Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination||Vakzine Projekt Management GmbH|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|May 19, 2010|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749034||150599|
NCT00749554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-RCT-Burnham|Trial of Disc Biacuplasty to Treat Chronic Discogenic Low Back Pain|Blinded Randomised Placebo-Controlled Trial of TransDiscal Biacuplasty for Patients With Mechanical Low Back Pain of Disc Origin|TD-RCT-002|Baylis Medical Company|No|Terminated|April 2008|||August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2010|June 4, 2010|September 8, 2008|Yes|Yes|Primary Investigator Retired.|No||https://clinicaltrials.gov/show/NCT00749554||150559|
NCT00749853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ufktem1|Efficacy of Ovarian Stimulation Based on FSHR Genotype Status|Prospective, Randomized Open Trial to Evaluate the Efficacy of an Ovarian Stimulation Protocol Based on FSH Receptor Genotype||Medical University of Vienna|No|Suspended|May 2015|June 2015|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Female|18 Years|40 Years|No|||May 2015|May 3, 2015|September 8, 2008||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT00749853||150536|
NCT00750178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-008|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)|A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.||Completed|November 2004|November 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|September 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00750178||150511|
NCT00750594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00026512|Patent Foramen Ovale in Children With Migraine Headaches|Patent Foramen Ovale in Children With Migraine Headaches||University of Utah|No|Completed|April 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|109|||Both|6 Years|17 Years|No|Non-Probability Sample|pediatric neurology clinic|June 2012|June 4, 2012|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750594||150481|
NCT00750620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-038|A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment|A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Effect of Mild, Moderate and Severe Renal Impairment on the Pharmacokinetics of YM178||Astellas Pharma Inc|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|33|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00750620||150480|
NCT00750932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOHP07-PD Pro-Muco|Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis|Study of the Biodistribution of PMN Serine Proteases in Sputum of Patients Affected by Cystic Fibrosis: Towards New Anti-Inflammatory Therapies|Pro-Muco|University Hospital, Tours|Yes|Recruiting|January 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|Whole blood Sputum|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults and children with cystic fibrosis|November 2008|November 13, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750932||150456|
NCT00750945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COA No. 623/2008|Treadmill and Music Cueing for Gait Training in Mild to Moderate Parkinson's Disease|Treadmill and Music Cueing for Gait Training in Mild to Moderate Parkinson's Disease: a Preliminary Study||Chulalongkorn University|Yes|Completed|September 2008|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Male|60 Years|80 Years|No|||July 2009|September 25, 2009|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750945||150455|
NCT00751283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR0052|Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities|Minnow Medical GRST Peripheral Catheter System First-in-Man Study Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities||Vessix Vascular, Inc|Yes|Withdrawn|August 2007|May 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|September 9, 2008||No|Data was inconclusive|No||https://clinicaltrials.gov/show/NCT00751283||150429|
NCT00751296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rev-06-0099|Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)|A Phase 2 Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)|Rev-CLL|University Health Network, Toronto|Yes|Terminated|August 2006|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 10, 2008|Yes|Yes|The study had completed seven years of follow-up and final analysis was done in December 2012.    Active patients have been moved to the Rev Aid program.|No||https://clinicaltrials.gov/show/NCT00751296||150428|
NCT00751582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-018|Effective Means to Address Moderately Malnourished Children|Effective Means to Address Moderately Malnourished Children Within BINP Communities||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|July 1998|November 1998|Actual|November 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|300|||Both|6 Months|2 Years|No|||September 2008|March 20, 2016|May 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00751582||150406|
NCT00751595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS T-002|Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine|A Phase II Randomized, Open Label, Immunogenicity and Safety Trial of the Vaccine Based on the Recombinant Biologically Active HIV-1 Tat Protein in Anti-Tat Negative HIV-1 Infected HAART-treated Adult Subjects.|ISS T-002|Istituto Superiore di Sanità|Yes|Completed|September 2008|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|55 Years|No|||March 2016|March 3, 2016|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751595||150405|
NCT00737594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH0721|Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension|A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension||Sucampo Pharma Americas, LLC|Yes|Terminated|July 2008|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|August 15, 2008|Yes|Yes|Failure to enroll a suitable number of qualified subjects.|No|February 16, 2016|https://clinicaltrials.gov/show/NCT00737594||151469|
NCT00737256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0124|A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence|A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence||Denver Research Institute|Yes|Recruiting|August 2008|May 2014|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|65 Years|No|||September 2012|September 6, 2012|August 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00737256||151495|
NCT00737542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor470408CTIL|Local Lidocaine Infiltration for Pain Management Post Cesarean Delivery.|A Prospective Randomized Double-blind, Placebo-controlled Study of the Effect of Preoperative Analgesia With Local Lidocaine Infiltration for Pain Management Post Cesarean Delivery.||Soroka University Medical Center||Not yet recruiting||||||N/A|Interventional|N/A|2||||||Female|18 Years|45 Years|No|||August 2008|November 25, 2009|August 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00737542||151473|
NCT00737529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MCL-001|A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial|A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantel Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Refractory To Bortezomib|EMERGE|Celgene|Yes|Active, not recruiting|December 2008|April 2017|Anticipated|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|August 15, 2008|Yes|Yes||No|June 28, 2013|https://clinicaltrials.gov/show/NCT00737529||151474|
NCT00737802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK059500|In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter|In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter||Feinstein Institute for Medical Research|No|Recruiting|February 2005|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal control subjects without GERD and patients with GERD|June 2015|June 23, 2015|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737802||151453|
NCT00738049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0380|Darusentan Effect on PET Uptake Heterogeneity|A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan|Darusentan|The University of Texas Health Science Center, Houston|No|Completed|June 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|August 19, 2008|Yes|Yes||No|January 25, 2013|https://clinicaltrials.gov/show/NCT00738049||151434|The trial was stopped after 20 enrollments as the manufacturer of darusentan halted further development of the drug after a negative phase 3 trial in resistant hypertension.
NCT00738062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa NOH303|Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)|An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension|NOH303|Chelsea Therapeutics|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|August 19, 2008|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT00738062||151433|
NCT00738075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-NG-0283-CTIL|Automatic Recognition of Freezing of Gait Episodes|Online Automatic Recognition of Freezing of Gait Episodes||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2008|October 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|30|||Both|40 Years|80 Years|No|Probability Sample|Patients with Parkinson's disease prone to freezing of gait|August 2008|August 19, 2008|August 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00738075||151432|
NCT00738023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|967-2003|Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes|Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes||Emory University|Yes|Completed|March 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 18, 2014|August 19, 2008||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00738023||151436|
NCT00738036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 001 07|Acute Pain Episodes in Patients Under Opioid Maintenance Therapy : Clinical Management and Long Term Effects|Acute Pain Episodes in Patients Under Opioid Maintenance Therapy : Clinical Management and Long Term Effects||University Hospital, Toulouse|No|Completed|April 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|151|||Both|18 Years|N/A|No|Non-Probability Sample|Patients under opioid maintenance therapy|September 2015|September 29, 2015|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738036||151435|
NCT00738296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_018|Vytorin on Carotid Intima-media Thickness and Overall Rigidity|Vytorin on Carotid Intima-media Thickness and Overall Rigidity|VYCTOR|Hospital Regional 1o de Octubre||Completed|April 2005|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|90|||Both|30 Years|75 Years|No|||August 2008|June 23, 2015|August 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738296||151416|
NCT00738608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-000451-17|Etoricoxib as a Pre-emptive Analgesic in Therapeutic Arthroscopy|Etoricoxib as a Pre-emptive Analgesic in Therapeutic Arthroscopy||Marienkrankenhaus Soest|No|Completed|June 2006|September 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|66|||Both|19 Years|70 Years|No|Probability Sample|66 pat. with knee arthrosocpy|September 2009|September 17, 2009|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738608||151393|
NCT00738920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK77738|Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome|Self Administered CBT for IBS: A Multisite Trial||State University of New York at Buffalo|Yes|Recruiting|August 2010|August 2017|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|480|||Both|18 Years|70 Years|No|||May 2015|May 20, 2015|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738920||151369|
NCT00738933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231857|Dietary Phytosterols and Human Aortic Valve|Effects of Dietary Plant Sterols and Stanols on Sterol Composition and Structure of the Human Aortic Valve||Helsinki University|No|Recruiting|April 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|40 Years|80 Years|No|||February 2011|February 11, 2011|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00738933||151368|
NCT00734721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEH-2007FIV|Assessment of Psychological Strain and Perioperative Fear in Intravitreal Injections|Fear of Intravitreal Injection - Assessment of Psychological Strain and Potential Contributing Factors|FIVA|University Hospital Tuebingen|No|Recruiting|December 2007|||December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|N/A|No|||August 2008|August 13, 2008|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734721||151687|
NCT00748735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-2008-CRT|Left Ventricular Lead Position in Cardiac Resynchronization Therapy|Optimal Definition of Left Ventricular Lead Position in Cardiac Resynchronization Therapy by Myocardial Deformation Imaging||RWTH Aachen University|No|Completed||||||N/A|Observational|Time Perspective: Retrospective||1|Actual|55|||Both|18 Years|80 Years|No|Probability Sample|Consecutive patients with end-stage heart failure and sinus rhythm, scheduled for new        implantation of a biventricular pacemaker were included in the study. Criteria for CRT        implantation were New York Heart Association (NYHA) functional class III (N=35) or IV        (N=21) despite optimal pharmacologic therapy and evidence of LV systolic dysfunction with        ejection fraction <35% and a QRS >120ms.|January 2008|September 8, 2008|September 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00748735||150622|
NCT00749294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THALS1570|Anogenital Wart Burden and Cost of Illnesses|Measurement of Anogenital Wart Burden, and Cost of Illnesses in Bangkok||Mahidol University|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting with anogenital warts, conducted at Rajavithi General Hospital and        Bangrak Hospital|August 2010|August 6, 2010|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749294||150579|
NCT00749281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.8.9.2008|Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease|Neutrophil Gelatinase-associated Disease: a Potential Biomarker of the Severity of Coronary Artery Disease||Cardiovascular Research Society, Greece|Yes|Completed|September 2008|September 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|73|Samples Without DNA|Serum|Both|18 Years|85 Years|No|Non-Probability Sample|Patients admitted for coronary angiography.|August 2009|July 7, 2010|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749281||150580|
NCT00749567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.15|Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer|Combination of Erlotinib (Tarceva®) and Bevacizumab (Avastin®) as Second-line Treatment in Locally Advanced / Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC) Patients: A Phase II Study||Hellenic Oncology Research Group|No|Terminated|July 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 8, 2008||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00749567||150558|
NCT00749580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-MK0518|A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen|A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir Versus NRTIs as a Backbone in HIV-Infected Patients Switched From a Stable Boosted PI Regimen||University of South Florida|No|Completed|November 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|80 Years|No|||June 2014|December 2, 2014|September 5, 2008|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00749580||150557|This is a pilot study and has a small sample size.
NCT00749593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaHASE STH13503|Study of UK Adults With Congenital Adrenal Hyperplasia.|Cross-Sectional Multi-Centre Study of UK Adults With Congenital Adrenal Hyperplasia.|CaHASE|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|August 2004|December 2011|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|65 Years|No|Non-Probability Sample|UK Adults with Congenital Adrenal Hyperplasia|June 2012|June 8, 2012|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749593||150556|
NCT00750633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-13|A Phase III Study of an Otic Formulation in Acute Otitis Externa|||Alcon Research|Yes|Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|990|||Both|6 Months|N/A|No|||November 2012|November 29, 2012|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00750633||150479|
NCT00750646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-08-54|Observational Study of How Patients Take Eye Drops|The Relationship Between Glaucoma Medication Self-Efficacy, Outcome Expectations, Eye Drop Tech., Adherence and IOP.||Robin, Alan L., M.D.|Yes|Recruiting|September 2008|August 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be enrolled for a single site, private practice.|September 2008|September 9, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750646||150478|
NCT00750659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5288-AN-CTIL|Nilotinib Pre and Post Allogeneic Stem Cell Transplantation|Open-label Trial of Nilotinib in Patients With Advanced (>CP1) Chronic Myeloid Leukemia or Ph+ Acute Lymphatic Leukemia Pre- and Post- Allogeneic Stem Cell Transplantation.||Sheba Medical Center|No|Active, not recruiting|July 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750659||150477|
NCT00750958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807119|PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard|PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard|PREVENT|Datascope Patient Monitoring|Yes|Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|287|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 10, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750958||150454|
NCT00750971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-1306|Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)|An Open-Label, Phase II Multicenter Cohort Study of Immunoablation With Cyclophosphamide and Antithymocyte-Globulin and Transplantation of Autologous Cd34-Enriched Hemapoietic Stem Cells Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Refractory Systemic Lupus Erythematosus|ASSIST|Charite University, Berlin, Germany|Yes|Recruiting|August 2008|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||August 2009|July 20, 2011|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750971||150453|
NCT00751309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LARGO|Lung Allograft Rejection Gene Expression Observational (LARGO) Study|Lung Allograft Rejection Gene Expression Observational (LARGO) Study|LARGO|XDx|No|Terminated|April 2004|January 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2044|Samples Without DNA|venous blood plasma|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Lung and heart-lung transplant recipients who will undergo transbronchial biopsy.|December 2008|December 17, 2008|September 10, 2008||No|Restructuring and refocus of company.|No||https://clinicaltrials.gov/show/NCT00751309||150427|
NCT00751608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPL180A2207|Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients|A Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Effect of APL180 on Endothelial Function in Patients With Familial Hypercholesterolemia||Novartis|No|Withdrawn|September 2006|||February 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|50 Years|No|||November 2008|November 4, 2008|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751608||150404|
NCT00751621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB07_002CR|Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)|A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)||CSL Behring|No|Completed|August 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|2 Years|65 Years|No|||December 2012|March 5, 2014|September 11, 2008|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00751621||150403|
NCT00738114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011938|Diabetes in the Perioperative Period|Type 2 Diabetes in the Perioperative Period: Prevalence and Clinical Outcome||Emory University|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|3184|||Both|18 Years|N/A|No|Probability Sample|all patients admitted for non-cardiac surgery during the period of 01/01/07 and 06/30/2007|November 2013|November 20, 2013|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738114||151429|
NCT00738387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2302|A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer|A Phase III, Randomized, Double-blind, Placebo-controlled Multi-center Study of ASA404 in Combination With Docetaxel in Second-line Treatment of Patients With Locally Advanced or Metastatic (Stage IIIb/IV) Non-small Cell Lung Cancer (NSCLC)|ATTRACT-2|Novartis||Terminated|December 2008|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|900|||Both|18 Years|N/A|No|||May 2012|December 29, 2015|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738387||151409|
NCT00737815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-LIU|Randomized Crossover Study of Magnesium Supplementation|Magnesium Supplements, Plasma Inflammatory Markers, and Gene Expression in Overweight Individuals With Metabolic Syndrome: a Randomized , Controlled Crossover Trial||University of California, Los Angeles|No|Completed|June 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|14|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737815||151452|
NCT00737828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/0114|Cardiopulmonary Exercise Testing and Preoperative Risk Stratification|A Randomised Controlled Trial of the Utility of Cardiopulmonary Exercise (CPX) Testing for Preoperative Risk Stratification to Guide Perioperative Care and Thereby Reduce Postoperative Morbidity||University College London Hospitals|No|Completed|August 2008|May 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|228|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737828||151451|
NCT00737555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-2797-003|A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours|A Phase 1b Dose-escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours||Chroma Therapeutics|Yes|Completed|August 2006|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737555||151472|
NCT00738335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612064|Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases|A Phase I Open-Label, Dose-Finding Study to Evaluate the Safety and Efficacy of Concurrent Radiosurgery and Erlotinib Administration in Non-Small Cell Lung Cancer Patients With Brain Metastases||University of California, San Francisco|Yes|Withdrawn|January 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00738335||151413|
NCT00738348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESAR|Effect of Perioperative Sivelstat Administration for Liver Resection|Effect of Perioperative Sivelstat Administration for Liver Resection|KMS|Kochi University|Yes|Completed|April 2007|July 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2012|June 6, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738348||151412|
NCT00738647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Filtek|Assessment of a New Resin-based Composite Filling Material|Assessment of a New Resin-based Composite Restorative Material||University of Aarhus|No|Active, not recruiting|May 2007|August 2019|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2011|November 4, 2011|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738647||151390|
NCT00738309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006HSGDEF13|Prospective Study of Scheuermann's Kyphosis|Prospective Study of Scheuermann's Kyphosis|PSK|Setting Scoliosis Straight Foundation|No|Enrolling by invitation|May 2006|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|146|||Both|N/A|21 Years|No|Non-Probability Sample|Patients who present to the investigator's clinic, who meet the inclusion criteria will be        offered enrollment in the study.|December 2013|December 20, 2013|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738309||151415|
NCT00738322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3191C00001|To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects|A Single-Centre, Single-Blind, Randomised, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD1305 in Healthy Male Japanese Subjects||AstraZeneca|No|Completed|July 2008|October 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00738322||151414|
NCT00738634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/008 HREC|IN2SHAPE: A Study of Physical Activity and Depressive Symptoms in Adolescence|IN2SHAPE Intervention to Stay Healthy and Physical Everyday: A Randomised Controlled Trial for the Feasibility and Effectiveness of a Self-motivated Physical Activity Intervention on the Mental Health of Adolescents.|IN2SHAPE|Australian National University||Completed|July 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|26|||Both|11 Years|17 Years|No|||July 2012|July 18, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738634||151391|
NCT00735059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSEL0702|Test of the Nipro ELISIO H Dialyzer in Different Dialysis Treatment Procedures|Test of the Nipro ELISIO H Dialyzer in Different Dialysis Treatment Procedures||EXcorLab GmbH|No|Completed|August 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735059||151661|
NCT00700050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011620|Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways|Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways - A Pilot Study||The Hospital for Sick Children|No|Recruiting|April 2008|April 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|N/A|22 Years|Accepts Healthy Volunteers|||June 2008|June 17, 2008|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00700050||154318|
NCT00700336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBP08-01|Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)|Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma||CanBas Co. Ltd.|No|Completed|May 2008|November 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||October 2011|December 19, 2012|June 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00700336||154296|
NCT00742846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #26378|Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis|Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis||Milton S. Hershey Medical Center|No|Withdrawn|August 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|75 Years|No|||February 2015|February 25, 2015|August 26, 2008|Yes|Yes|No enrollment|No||https://clinicaltrials.gov/show/NCT00742846||151071|
NCT00750061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN102A|Efficacy and Safety of Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries|Efficacy and Safety pf Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries: a Double-Blind, Randomized, Placebo-Controlled Clinical Trial||China Spinal Cord Injury Network|Yes|Completed|August 2008|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||April 2015|April 28, 2015|August 30, 2008||No||No|January 6, 2015|https://clinicaltrials.gov/show/NCT00750061||150520|
NCT00739388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 30/07|Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy|5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial.||Swiss Group for Clinical Cancer Research|No|Completed|July 2008|November 2012|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739388||151333|
NCT00751010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-139|Relationship: Interstitial Cystitis & Vulvodynia-Part 2|Relationship: Interstitial Cystitis & Vulvodynia-Part 2||William Beaumont Hospitals|No|Completed|September 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|127|||Female|18 Years|N/A|No|Non-Probability Sample|Patients who received a mailed survey (Part 1 of this study), with a documented diagnosis        of IC who agreed to be contacted for an in-office examination.|October 2008|October 10, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751010||150450|
NCT00742534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPD2008|Phase 1 Intravenous Citrulline for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants|Phase 1 Intravenous Citrulline for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants||Vanderbilt University|Yes|Withdrawn|August 2008|August 2009|Anticipated|August 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|14 Days|No|||December 2011|December 27, 2011|August 25, 2008|Yes|Yes|Study never began|No||https://clinicaltrials.gov/show/NCT00742534||151094|
NCT00751400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13129|Naproxen Sodium Extended-Release Actual Use Study|An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting||Bayer|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|497|||Both|12 Years|N/A|No|||August 2015|August 12, 2015|September 11, 2008|Yes|Yes||No|January 3, 2011|https://clinicaltrials.gov/show/NCT00751400||150420|No control group, detailed data collected for up to 10 days during 1 month followup, data recall by subjects may vary
NCT00698191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC30772014|Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)|Phase I/IIa: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus||Nanjing Medical University|Yes|Recruiting|March 2007|December 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|70 Years|No|||June 2008|June 16, 2008|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698191||154454|
NCT00698178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMCP-97-009|Waist Circumference Versus Body Mass Index to Predict Severity of Gastroesophageal Reflux Disease|Waist Circumference Versus Body Mass Index to Predict Severity of Gastroesophageal Reflux Disease||Lotung Poh-Ai Hospital|Yes|Completed|June 2008|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|500|||Both|20 Years|70 Years|No|Probability Sample|Outpatients at a general hospital with 1000 beds in north-eastern Taiwan|October 2010|October 18, 2010|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698178||154455|
NCT00698867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.EX001|A Clinical Investigation of the Discovery™ Elbow System|A Prospective, Non-controlled, Clinical Investigation of the Discovery™ Elbow System||Biomet, Inc.|No|Active, not recruiting|June 2002|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in need of relief from painful or disabling Joint Disease in need of total elbow        replacment.|July 2015|July 14, 2015|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00698867||154405|
NCT00699439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070206|A Reminder System for Paper-Based Asthma Guidelines in the Pediatric Emergency Department|A Reminder System for Paper-Based Asthma Guidelines in the Pediatric Emergency Department||Vanderbilt University|No|Enrolling by invitation|July 2009|January 2011|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||August 2009|August 19, 2009|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00699439||154364|
NCT00699725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GES-DUM-2008/2|Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients|Compliance of Gastroprotection Treatment in the Prevention of Gastrointestinal Risk in Non-Steroidal Anti-inflammatory Drug (NSAID) Using Patients|GADES|AstraZeneca|No|Completed|May 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients attending secondary care clinics who are prescribed NSAID and gastroprotection        for at least 15 days following standard clinical practice.|December 2010|December 6, 2010|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00699725||154343|
NCT00699738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/297|Influence of Pregnancy and Post-partum Feeding Method (Breastfeeding Versus Bottlefeeding) on Maternal Hemodynamics (Central and Peripheral) and Vascular Function|Influence of Pregnancy and Post-partum Feeding Method (Breastfeeding Versus Bottlefeeding) on Maternal Hemodynamics (Central and Peripheral) and Vascular Function||University Hospital, Ghent|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|150|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699738||154342|
NCT00700063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-015|A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)|A Multicenter, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)||Peplin|No|Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|265|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|June 15, 2008|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00700063||154317|
NCT00699426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2007-00405237|The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes|The Effect of Nexium and Cardi-04 Yoghurt on Insulin Secretion and Effect and Cardi Vascular Risk Factors Associated With the Insulin Syndrome in Patients With Type 2 Diabetes - a Randomized Double-blind, Prospective, Placebo Controlled 2 x 2 Factorial Design 3 Month's Study.|Nexium|Steno Diabetes Center|Yes|Completed|June 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|41|||Both|40 Years|70 Years|No|||August 2012|August 31, 2012|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00699426||154365|
NCT00700076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701002174|Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects|Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects||Yale University|Yes|Active, not recruiting|December 2006|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700076||154316|
NCT00699712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIL-CDNP-CT003|Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)|Multi-Center, Open Label, Dose Escalating, Sequential Group Study to Assess the Hemodynamic Effects, Safety and Tolerability of CD-NP in Patients With Stabilized Acute Heart Failure (AHF)|PreCONDITION|Nile Therapeutics|Yes|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||March 2009|March 23, 2009|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00699712||154344|
NCT00700674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 0729|Effect of Usage of Electroencephalogram (EEG) Entropy on the Incidence of Postoperative Cognitive Dysfunction in Geriatric Patients|Is the Ese of EEG Entropy as Intra-operative Monitor Improves Postoperative Cognitive Dysfunction||King Khaled Eye Specialist Hospital|Yes|Recruiting|January 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|60 Years|75 Years|No|Probability Sample|60 Elderly patient, ASA 1-2|February 2010|February 24, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00700674||154270|
NCT00700687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA32540-109|Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib|Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib|PA32540-109|POZEN|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|90|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 9, 2009|June 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700687||154269|
NCT00700934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema|Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema. A National Registry.||Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2005|February 2012|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Emphysema associated alpha-1 antitrypsin deficiency|June 2008|December 6, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00700934||154250|
NCT00749749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-005|Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy|A Phase II, Randomized, Single-dose, Unblinded Study to Compare the Efficacy and Safety of the CollaRx Bupivacaine Implant With the ON-Q PainBuster Post-op Pain Relief System in Women Following Abdominal Hysterectomy||Innocoll|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|75 Years|No|||April 2013|April 29, 2013|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749749||150544|
NCT00749762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10831|Pulmonary Function During Prone and Supine Positioning in NICU Infants Requiring Assisted Ventilation|Pulmonary Function During Prone and Supine Positioning in Neonatal Intensive Care Unit (NICU) Infants Requiring Assisted Ventilation||University of Utah|No|Withdrawn|October 2002|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|6 Months|No|Non-Probability Sample|For stable NICU infants who require assisted mechanical ventilation beginning after the        1st 24 hours of life and repeating every 2 to 7 days|May 2010|May 1, 2015|September 8, 2008||No|Computers/hardware for data collection/storage are outdated and unserviceable.|No||https://clinicaltrials.gov/show/NCT00749762||150543|
NCT00749775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141113|Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness|ESSENCE|Pfizer|No|Completed|June 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3338|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6141113 prescribes the Selara tablet.|November 2013|November 20, 2013|September 5, 2008|No|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT00749775||150542|
NCT00740506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908199|Behavioral and Environmetal Factors and Time to Delivery|Behavioral and Environmental Factors and Time to Delivery||National Institutes of Health Clinical Center (CC)||Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1|||510|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2009|September 26, 2015|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740506||151250|
NCT00741351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2007-005279-32|Anesthesiological Strategies in Elective Craniotomy|Anesthesiological Strategies in Elective Craniotomy: Randomized, Equivalence, Open Trial|Neuromorfeo|Azienda Ospedaliera San Gerardo di Monza|Yes|Completed|December 2007|December 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|411|||Both|18 Years|75 Years|No|||September 2011|September 7, 2011|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00741351||151185|
NCT00741702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231-2001|Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples|Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples|DREAM3|Sunnybrook Health Sciences Centre|No|Completed|September 2001|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741702||151158|
NCT00751374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/FR/08-007|Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis|Prospective, Randomized, Open-Label Study of Topical Antibiotic Prophylaxis at the Catheter Exit Site: Continuous Daily Gentamicin Cream Versus Cyclical Gentamicin Cream and Mupirocin 2% Cream Alternating at Monthly Basis.||Kwong Wah Hospital|Yes|Not yet recruiting|September 2008|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||September 2008|September 10, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751374||150422|
NCT00751361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-2000|Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial|Prospective, Randomized, Controlled Clinical Study Evaluating the Efficacy of Rheopheresis for Dry Age-Related Macular Degeneration Dry AMD Treatment With Rheopheresis Trial - ART|ART|Apheresis Research Institute|Yes|Completed|November 1998|January 2003|Actual|January 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|50 Years|85 Years|No|||September 2008|September 10, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751361||150423|
NCT00751673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU74|TESS Shoulder Arthroplasty Data Collection|A Prospective, Multicentre Study Evaluating the Clinical Performance of the T.E.S.S Anatomic and Reverse Shoulder Prostheses||Biomet, Inc.|No|Active, not recruiting|January 2006|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive series of patients received TESS prostheses|May 2015|June 22, 2015|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751673||150399|
NCT00752609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01_202|Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.|A Phase 2 Study of the Safety and Efficacy of Hematide Injection for the Maintenance Treatment of Anemia in Subjects With Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa||Takeda|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|90 Years|No|||June 2012|June 26, 2012|September 11, 2008|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00752609||150328|
NCT00698555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/025|Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y|Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 18-40 Years||GlaxoSmithKline||Completed|March 1997|||May 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|163|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 16, 2008|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698555||154428|
NCT00698568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208141/016|Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects|Study to Evaluate the Safety of GSK Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease||GlaxoSmithKline||Completed|October 1996|April 1999|Actual|April 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|7460|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 16, 2008|June 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698568||154427|
NCT00698542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80093|Evaluation of the Patient Safety Screening Tool (PSST) for Sepsis|A Validation of a Patient Safety Screening Tool for Sepsis||Vanderbilt University|Yes|Enrolling by invitation|May 2008|July 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be located in the 22 bed Vanderbilt University Medical Center Neuro Care        Unit (NCU). Every patient will be screened for sepsis according to the following workflow        upon admission to the NCU. The patient population of the NCU is generally bimodal; the        first group consists of post-operative patients with an average length of stay of three to        five days. The second group consists of subarachnoid hemorrhage patients with an average        length of stay of 45 days.|December 2008|December 12, 2008|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00698542||154429|
NCT00699153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526|Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery|Safety and Efficacy of Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|June 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|June 13, 2008|Yes|Yes||No|July 9, 2010|https://clinicaltrials.gov/show/NCT00699153||154385|
NCT00699166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDNK333B2201|Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter 2-Week Pilot Study to Evaluate the Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) Given Orally in Female Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|CDNK333B2201|Novartis||Completed|April 2004|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|135|||Female|18 Years|N/A|No|||June 2008|June 12, 2008|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699166||154384|
NCT00699452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCK-AS|The Potential of Candesartan to Retard the Progression of Aortic Stenosis|The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves|ROCK-AS|Helsinki University|Yes|Recruiting|May 2009|December 2014|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2009|May 18, 2009|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00699452||154363|
NCT00700349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA-2004-SA|Evaluation of Impacts of Access to Credit and Loan Size for Microcredit Clients in South Africa|Evaluation of Impacts of Access to Credit and Loan Size for Microcredit Clients in South Africa||Innovations for Poverty Action||Completed|September 2004|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|3000|||Both|18 Years|N/A|No|||June 2008|June 17, 2008|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00700349||154295|
NCT00700362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIIFU_00|Insulin Infusion and Infectious Diabetic Foot Ulcers (IIIFU)|The Effect of Insulin-Glucose Infusion on Metabolic Control (Primary) and Inflammation (Secondary) in Diabetic Patients Treated for Acute Foot Ulcer Infection or Surgical Wound Infection||Karolinska Institutet|Yes|Withdrawn|December 2011|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||December 2011|April 8, 2015|June 16, 2008||No|This study is a part of the IINDU study|No||https://clinicaltrials.gov/show/NCT00700362||154294|
NCT00700661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-907|A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Study to Determine the Efficacy of Montelukast in the Treatment of Exacerbations in Asthmatic Patients Aged 2-to-5 Years||Merck Sharp & Dohme Corp.||Completed|January 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|2 Years|5 Years|No|||June 2015|June 22, 2015|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00700661||154271|
NCT00700375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBECP|Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection|Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection in Patients Undergoing an Emergent Coronary Procedure||Osaka General Medical Center|Yes|Completed|July 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|59|||Both|20 Years|N/A|No|||March 2010|July 12, 2010|June 16, 2008|Yes|Yes||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00700375||154293|Single center trial
NCT00700700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1082-07|Cardiac Resynchronization Therapy, Dyspnea and Exercise Tolerance in Patients With Congestive Heart Failure (CHF)|Effects of Cardiac Resynchronization Therapy on Dyspnea and Exercise Tolerance in Patients With Congestive Heart Failure||Queen's University|No|Terminated|October 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|90 Years|No|||July 2011|July 4, 2011|May 16, 2008||No|Stopped due to an inability to recruit eligible subjects.|No||https://clinicaltrials.gov/show/NCT00700700||154268|
NCT00749151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIUSOM-08-004|Effectiveness of the American Lung Association Reactive Anti-Smoking Telephone Help Line in Illinois|A Randomized Controlled Trial on the Effectiveness of the American Lung Association Reactive Anti-Smoking Telephone Help Line in Illinois|QUITLINE|Southern Illinois University|Yes|Completed|December 2002|March 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|990|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 17, 2010|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00749151||150590|
NCT00749164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBR-0137-08-HMO-CTIL|Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment|Allogeneic Mesenchymal Stem Cell Infusion for Treatment Of Steroid Resistant GVHD|MSCGVHD|Hadassah Medical Organization|Yes|Not yet recruiting|September 2009|August 2012|Anticipated|February 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||August 2009|August 10, 2009|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00749164||150589|
NCT00749450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613042|Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer|Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer||Cancer Research UK, Glasgow|Yes|Recruiting|March 2008|||March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|9500|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|September 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00749450||150567|
NCT00749463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP4009|Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment|Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|September 8, 2008|Yes|Yes||No|April 23, 2010|https://clinicaltrials.gov/show/NCT00749463||150566|
NCT00750087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NRO-SER-2008/1|Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR|Non-interventional Study to Observe Treatment Efficacy in Maintaining Symptoms Control in Patients With Schizophrenia, Treated With Seroquel XR||AstraZeneca|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|578|||Both|N/A|N/A|No|Probability Sample|The programme will include schizophrenia patients stabilized on Seroquel XR from community        sample|February 2010|February 4, 2010|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750087||150518|
NCT00750100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC REF 2006-157|Low Dose hCG in the Late Follicular Phase|Among ICSI Patients Undergoing Antagonist Protocols With Recombinant FSH, Does Replacement of Recombinant FSH by 200 IU of hCG in the Late Follicular Phase Compared With Continuing Recombinant FSH, Result in a Similar Number of Oocytes?||Universitair Ziekenhuis Brussel|No|Completed|September 2007|November 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|36 Years|No|||September 2008|October 8, 2010|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750100||150517|
NCT00750373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0257|Early Surgery Versus Conventional Treatment in Infective Endocarditis|A Randomized Comparison of Early Surgery Versus Conventional Treatment Strategy in Patients With High Embolic Risk of Infective Endocarditis|EASE|Asan Medical Center|No|Completed|September 2006|September 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|15 Years|80 Years|No|||April 2015|April 6, 2015|September 8, 2008||No||No|June 29, 2012|https://clinicaltrials.gov/show/NCT00750373||150496|The EASE trial was a limited study in scope, in that it included patients with severe valvular disease and large vegetations, and excluded those with major stroke, prosthetic valve endocarditis or aortic abscess.
NCT00750737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0020|Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)|Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant||M.D. Anderson Cancer Center|Yes|Completed|June 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|September 10, 2008||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT00750737||150471|
NCT00751023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#18440|Effects of Modafinil in Methamphetamine Dependence|Effects of Modafinil in Methamphetamine Dependence||Medical University of South Carolina|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2009|August 4, 2011|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751023||150449|
NCT00751036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107DBR01|Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg|Randomized Phase III Trial Comparing Nilotinib 800mg to Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumors Refractory to Imatinib 400 mg|MACS0375|Novartis|No|Terminated|June 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|September 9, 2008||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00751036||150448|Patients were limited (planned 300, Actual 94). Early termination of study; not sufficient power to test the original primary hypothesis with respect to PFS. Only descriptive analyses were carried out for this study.
NCT00750750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02683|Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)|Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis||Merck Sharp & Dohme Corp.|No|Completed|January 2003|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|981|||Both|12 Years|N/A|No|||April 2015|April 20, 2015|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00750750||150470|
NCT00751049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200PG005|A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom|A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in the United Kingdom||Pfizer|No|Completed|December 1992|December 1993|Actual|December 1993|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|294|||Both|40 Years|N/A|No|||September 2008|September 10, 2008|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751049||150447|
NCT00751699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007011|Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers|A Randomized, Open-label, Multiple Dose, Parallel Group Study to Evaluate 5 ASA and N Ac 5 ASA Pharmacokinetics Following Administration of Oral Doses of Asacol 2.4 g/Day and Lialda 2.4 g/Day for 7 Days in Healthy Volunteers||Warner Chilcott|No|Completed|March 2007|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|37|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751699||150397|
NCT00698581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01276|A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures|An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization||UCB Pharma|No|Terminated|August 2008|February 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|16 Years|75 Years|No|||April 2015|April 29, 2015|June 12, 2008|Yes|Yes|An interim analysis revealed the study was unlikely to attain a positive outcome for the    efficacy analysis. No safety concerns were detected.|No||https://clinicaltrials.gov/show/NCT00698581||154426|
NCT00698880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preop_PVE_HVE|Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization|Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy||Asan Medical Center|Yes|Completed|March 2007|April 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|20 Years|75 Years|No|||June 2008|June 16, 2008|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00698880||154404|
NCT00699179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3557|Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes|EFFicacious glycaEmia Control, Treatment Goal achIevement Very simplE With NovoMix 30: A Single-country, Multicentre, Prospective, Open Label, Non-controlled, Observational, 26-week Study in Serbian Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Diabetes Mellitus in Everyday Clinical Practice|EFFECTIVE|Novo Nordisk A/S|No|Completed|June 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2308|||Both|18 Years|N/A|No|Non-Probability Sample|Type 1 and 2 diabetes|August 2014|August 12, 2014|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699179||154383|
NCT00699192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2318|Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension|A Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients With Essential Hypertension Not Adequately Controlled After Four Weeks on Amlodipine 5 mg Once Daily||Novartis|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|965|||Both|65 Years|N/A|No|||May 2011|May 4, 2011|June 9, 2008||No||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00699192||154382|
NCT00699114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARIBU-020|Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain|Analgesic Effect of Ibuprofen 400, 600 and 800 mg, Paracetamol 500 and 1000 mg, and Paracetamol 1000 mg Plus 60 mg Codeine: Single-dose, Randomized, Placebo-controlled and Double-blind Study on Acute Pain After Third Molar Surgery||Oslo University Hospital|No|Completed|June 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|350|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2009|July 3, 2011|June 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699114||154388|
NCT00699127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY-19-2008-CTIL|Organizing the Information Given to Parents of NICU Infants in Order to Reduce Their Anxiety|Dose Organizing the Information Given to Parents of NICU Infants Reduce Their Anxiety?||Hillel Yaffe Medical Center|No|Withdrawn|July 2008|July 2008|Anticipated|July 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|N/A|4 Months|Accepts Healthy Volunteers|||July 2008|July 3, 2008|June 14, 2008||No|After a discussion, we decided to withdraw the study.|No||https://clinicaltrials.gov/show/NCT00699127||154387|
NCT00699140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG202|Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura|Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura|ITP|Grifols Biologicals Inc.|No|Completed|February 2008|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|82 Years|No|||January 2016|January 9, 2016|June 16, 2008|Yes|Yes||No|June 16, 2015|https://clinicaltrials.gov/show/NCT00699140||154386|The patient number was based on European Medicines Agency guidance to evaluate IVIG products in ITP patients (EMEA/CPMP/BPWG/388/95 rev.1, June 2000, in force when the study was designed): at least 15 subjects were sufficient for the analysis.
NCT00699764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208141/017|Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease|Safety of GSK Biologicals' (Previously Smith Kline Beecham Biologicals') Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Subjects With Genital Herpes Disease||GlaxoSmithKline||Completed|March 1996|October 1999|Actual|October 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2491|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 18, 2008|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699764||154340|
NCT00699777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007141|Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects|A Randomized, Open-label, 2-period, Crossover Study to Assess the Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets Administered as a Single Oral Dose in Healthy Male and Female Subjects||Warner Chilcott|No|Completed|January 2008|April 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|June 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699777||154339|
NCT00699751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15245|A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases|A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases|ALSYMPCA|Bayer|Yes|Completed|June 2008|February 2014|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|921|||Male|18 Years|N/A|No|||October 2015|October 26, 2015|June 17, 2008|Yes|Yes||No|June 29, 2013|https://clinicaltrials.gov/show/NCT00699751||154341|
NCT00700089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AID-trial Copenhagen|AID-trial Assertive Intervention After Deliberate Self-harm|AID-trial:A Randomized Clinical Trial Comparing the Effect on Repeated Self-harm of Assertive Intervention and Standard Treatment After Deliberate Self-harm|AID|University of Copenhagen|Yes|Completed|November 2007|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|243|||Both|12 Years|N/A|No|||March 2012|March 20, 2012|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00700089||154315|
NCT00700726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0102|Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma|Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma||Ohio State University|Yes|Completed|June 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|blood, nasal lavage (optional)|Both|18 Years|50 Years|No|Non-Probability Sample|primary care clinic|February 2014|February 11, 2014|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700726||154266|
NCT00749476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090X1-4405|Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX|Reformulated BeneFIX Efficacy and Safety After Conversion From a pdFIX||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Male|12 Years|N/A|No|||June 2011|June 6, 2011|September 8, 2008||No||No|January 29, 2010|https://clinicaltrials.gov/show/NCT00749476||150565|
NCT00749788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT302-U-06-003|Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-302 Administered Daily for Four Weeks in Subjects With Low HDL-C Levels||Akros Pharma Inc.|No|Completed|December 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|65 Years|No|||January 2013|January 31, 2013|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749788||150541|
NCT00750776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NDK-DUM-2002/1|KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment|KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment|KvaliMed|Psychiatric Centre Rigshospitalet|No|Terminated|August 2003|August 2012|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|212|||Both|N/A|N/A|No|Non-Probability Sample|Patients that are treatet with antipsycotic medicine - by a specialist in psychiatry - the        patients can stay at the hospital or receive outpatient treatment|April 2013|April 14, 2013|September 10, 2008||No|Due to lack of financial support|No||https://clinicaltrials.gov/show/NCT00750776||150468|
NCT00751088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2008|A Randomized Controlled Study Comparing Three Single-incision Devices for Female Urinary Stress Incontinence|A Comparison Among Three Single-incision Devices for the Treatment of Female Urinary Genuine Stress Incontinence: a Randomized Controlled Study.||University Magna Graecia||Completed|September 2008|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||||||Female|18 Years|80 Years|No|||July 2009|February 26, 2013|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751088||150444|
NCT00750074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200608720|Slope of the Pressure-Time Waveform Predicts Resistance and Compliance in Mechanically Ventilated Subjects|Slope of the Pressure-Time Waveform Predicts Respiratory System Resistance and Elastance in Mechanically Ventilated Subjects||University of Iowa|No|Recruiting|November 2007|||September 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Probability Sample|Inclusion Criteria        Subjects may be included in the study if they meet the following inclusion criterion and        no exclusion criteria:        [1] Adult medical or surgical ICU patients who are mechanically ventilated. Using a random        number generator each subject will be assigned to pressure control or volume control for        initial set of measurements.|September 2008|September 9, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750074||150519|
NCT00750386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/07.07|Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas|Dose Dense Administration of Paclitaxel and Carboplatin Combination as 1st Line Treatment in Patients With Ovarian Carcinoma||Hellenic Oncology Research Group||Completed|January 2008|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|75 Years|No|||May 2011|May 20, 2011|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750386||150495|
NCT00751413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0633-023|Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)|A Multicenter, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 6 to Less Than 12 Years||Merck Sharp & Dohme Corp.||Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|6 Years|11 Years|No|||May 2015|May 29, 2015|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751413||150419|
NCT00751738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001060|Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)|A Multi-center, Open-label, Follow-up Study to Assess the Long-term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in Patients With an Implantable Cardioverter Defibrillator||Warner Chilcott|No|Completed|October 2002|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|330|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751738||150395|
NCT00751062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200PG006|A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia|A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in Scandinavia||Pfizer|No|Completed|November 1992|December 1993|Actual|December 1993|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|267|||Both|40 Years|N/A|No|||September 2008|September 10, 2008|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751062||150446|
NCT00751387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4519|Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia|Australian Descriptive Epidemiology Study of Severity of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Exposure to Biological Disease Modifying Anti-rheumatic Drugs (bDMARDs)||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|559|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care|November 2010|November 27, 2010|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751387||150421|
NCT00752310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012565|TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet|A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects Receiving DRV Combined With RTV Low Dose to Compare the Oral Bioavailability of DRV Suspension to That of DRV 300 mg Tablet Under Fasted and Fed Conditions, and to Assess Multiple Dose Pharmacokinetics of the DRV Suspension||Tibotec Pharmaceuticals, Ireland||Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|June 8, 2011|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00752310||150351|
NCT00752323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1305|Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma|Fluorescence-Guided Detection of Malignant Gliomas: A Dose Ranging Study Using 5-Aminolevulinic Acid (ALA) Induced Protoporphyrin (PpIX) in a Multicenter Phase II Clinical Trial||Case Comprehensive Cancer Center|Yes|Recruiting|August 2008|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752323||150350|
NCT00698594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/98/08/KE|Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis|Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis Allergic to Grass Pollen||Medical Universtity of Lodz|Yes|Completed|September 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|6 Years|18 Years|No|||August 2011|August 19, 2011|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698594||154425|
NCT00698607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCELLENT|Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing|Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions|EXCELLENT|Seoul National University Hospital|Yes|Active, not recruiting|June 2008|April 2014|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1466|||Both|18 Years|N/A|No|||June 2010|June 28, 2010|June 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00698607||154424|
NCT00698893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208141/001|Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-Positive Adults|An Open Study in Healthy Herpes Simplex Virus (HSV)-Positive Adults to Evaluate the Safety of GSK Biologicals' Candidate gD Vaccine, With or Without MPL||GlaxoSmithKline||Completed|May 1992|July 1992|Actual|July 1992|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 16, 2008|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698893||154403|
NCT00699465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2007-006206-24|Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage|A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH)||University of Oulu|Yes|Recruiting|August 2008|December 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00699465||154362|
NCT00699803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PKT-0312081-P|Study of T-PRED(TM) Compared to Pred Forte(R)|||Bausch & Lomb Incorporated|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|56|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|June 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699803||154337|
NCT00699816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIC-I01|Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients|Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'Green Cross CELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection(PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea||Green Cross Cell Corporation|No|Completed|July 2008|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|20 Years|80 Years|No|||August 2015|August 23, 2015|June 17, 2008||No||No|June 18, 2015|https://clinicaltrials.gov/show/NCT00699816||154336|
NCT00700401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21543|POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).|An Open Label Study to Investigate the Effect of PEGASYS Plus Copegus on Sustained Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Who Have a Virological Response at Week 4||Hoffmann-La Roche||Completed|November 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|266|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700401||154291|
NCT00700102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18147|A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.|A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination||Hoffmann-La Roche||Completed|February 2006|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|820|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|June 17, 2008|No|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT00700102||154314|Patients in the study who were randomized to receive bevacizumab could continue to receive bevacizumab following discontinuation of chemotherapy, thereby minimizing any potential bias introduced by differential follow-up time in the treatment arms.
NCT00700388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69/08|Efficacy of Temporary Positive Expiratory Pressure (TPEP) in Chronic Hypersecretion|Multicenter Controlled Trial on Efficacy of TPEP Device in Adult Patients With Chronic Hypersecretion|UNIKO|Villa Pineta Hospital|Yes|Completed|July 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|25 Years|85 Years|No|||January 2010|August 2, 2011|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700388||154292|
NCT00701571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26745|Video/Audio Distraction Analgesia for Simulated Oncology Procedure Pain|Video/Audio Distraction Analgesia for Simulated Oncology Procedure Pain||University of Washington|No|Completed|September 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 12, 2011|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701571||154202|
NCT00701831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_03502|Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control|Assessment of Forced Titration to Reach the Effective Dose for Good Glycemic Control in Lantus Treated Type 2 Patients|LANTIT|Sanofi||Completed|May 2008|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|18 Years|N/A|No|||November 2010|November 3, 2010|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701831||154182|
NCT00750789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0061-08-EMC|The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults|||HaEmek Medical Center, Israel|No|Not yet recruiting|September 2008|||November 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 10, 2008|August 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00750789||150467|
NCT00742963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-403|Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma|A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma||Threshold Pharmaceuticals|No|Completed|August 2008|October 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00742963||151062|
NCT00743457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004484|Study of Ultrasound of the Eye for Children With Suspected Shunt Failure|Pediatric Ocular Ultrasound for VPS Failure||Oregon Health and Science University|No|Completed|August 2008|March 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|6 Months|18 Years|No|Non-Probability Sample|Patients 6 months to 18 years of age with VPS and symptoms of potential shunt failure        presenting the the emergency department|October 2012|October 12, 2012|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743457||151024|
NCT00750763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHHS|Tolerability, Efficacy and Mucosal Inflammation Associated With Orally Administered Colon Cleansing for Colonoscopy|A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy||Fremantle Hospital and Health Service|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|676|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00750763||150469|
NCT00751075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02692|Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)|Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis||Merck Sharp & Dohme Corp.|No|Completed|December 2003|June 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|981|||Both|12 Years|N/A|No|||June 2015|June 29, 2015|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751075||150445|
NCT00751985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPH - 1948b|Web-based Ultra-brief Intervention for Heavy Drinkers Trial|Web-based Ultra-brief Intervention for Heavy Drinkers - a Randomized Controlled Trial Comparing Personalized Normative Feedback With Self-help Material||University of Southern Denmark|Yes|Completed|September 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1380|||Both|18 Years|N/A|No|||May 2009|April 13, 2011|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751985||150376|
NCT00751751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-866/36|Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly|Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension.||Daiichi Sankyo Inc.|No|Completed|June 2003|June 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|441|||Both|65 Years|N/A|No|||September 2008|September 11, 2008|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751751||150394|
NCT00751972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW003|Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure|Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure|ADVANCE|HeartWare, Inc.|Yes|Completed|August 2008|August 2013|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|140|||Both|18 Years|N/A|No|||March 2014|April 2, 2014|September 10, 2008|Yes|Yes||No|March 15, 2013|https://clinicaltrials.gov/show/NCT00751972||150377|
NCT00698295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2003-009-0|Linear and Non-linear Analysis of EEG Changes in Schizophrenia After Atypical Antipsychotics Medication|Study of the Relationship Between EEG and Clinical Changes in Drug-Naive or Drug-Free Patients With Schizophrenia After Atypical Antipsychotic Treatment Based on Linear and Non-Linear EEG Analysis||Seoul National University Hospital|Yes|Active, not recruiting|September 2004|September 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|routine lab for changes in medical condition|Both|15 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with schizophrenia receiving antipsychotic treatment|September 2009|September 15, 2009|June 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00698295||154447|
NCT00699829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070158|Mohs Versus Traditional Surgery - Basal-Cell Carcinomas (BCC)|Comparative Medico-Economic Evaluation of Micrographic Mohs Surgery (MMS) and Traditional Surgical Excision With Immediate or Differed Reconstruction to Treat High Recurrence Risk Basal-Cell Carcinomas (BCC)|BACHIMO|Hospital Ambroise Paré Paris|Yes|Recruiting|June 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|||Both|18 Years|N/A|No|Probability Sample|Patients de services de dermatologie et/ou chir plastique|February 2009|February 12, 2009|May 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00699829||154335|
NCT00698906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208129/026|Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y|Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 19-40 Years||GlaxoSmithKline||Completed|June 1997|||February 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|160|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||June 2008|June 16, 2008|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698906||154402|
NCT00700115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006876|Kaletra-isentress Treatment Evaluation|A Pilot Study to Assess the Safety, Efficacy, and PK Profile of a Switch in Antiretroviral Therapy to a RTI Sparing Combination of LPV/r and RAL in Virologically Suppressed HIV-infected Patients|KITE|Emory University|No|Completed|June 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|June 16, 2008||No||No|June 7, 2012|https://clinicaltrials.gov/show/NCT00700115||154313|The findings of the KITE study should be interpreted in the context of a pilot study with a small sample size. Furthermore, adverse effects were self-reported, and the lack of blinding may have introduced biases in the collection of the data.
NCT00699478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0460|Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy|Effect of Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy||Yonsei University|No|Completed|April 2008|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||July 2012|July 18, 2012|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00699478||154361|
NCT00699790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB114-005|Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance|A 12-Week Randomized, Double-Blinded Study to Evaluate the Effects of Daily Oral Doses of BMS-741672 in Drug-Naive Type 2 Diabetic Patients||Bristol-Myers Squibb|No|Completed|February 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699790||154338|
NCT00700752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0728|A Comparison of Two Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|June 17, 2008|Yes|Yes||No|August 25, 2010|https://clinicaltrials.gov/show/NCT00700752||154264|
NCT00700765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3528|Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes|Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1531|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject with type 1 or type 2 diabetes who is prescribed insulin detemir at the        physician's discretion|July 2012|July 24, 2012|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700765||154263|
NCT00700739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 05/25|Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease|A Multi-Centre, Prospective, Randomized, Post Marketing Surveillance Study Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Cervical Degenerative Disc Disease||DePuy International|Yes|Terminated|May 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||September 2015|September 2, 2015|June 18, 2008||No|study progress and recruitment rate too low|No|July 13, 2015|https://clinicaltrials.gov/show/NCT00700739||154265|Study was terminated early therefore the latest clinical data available is at the 12 month post-operative timepoint and the latest radiographic data available is at the 6 month post-operative timepoint.
NCT00701012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMU512|Comparison of Low and High Ligation in the Rectal Cancer|Comparison of Functional Results of High Ligation and Low Ligation After Anterior Resection for Rectal Cancer - Randomized Controlled Trial-||Wakayama Medical University|Yes|Completed|January 2008|December 2011|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||December 2013|December 17, 2013|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701012||154244|
NCT00701259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRSW-GN-305|Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn|A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn||Novartis|No|Completed|January 2007|August 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|852|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|June 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00701259||154226|
NCT00701558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20951|A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer.|An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Disease Progression in Patients With Unresectable Advanced and/or Metastatic Non-small Cell Lung Cancer||Hoffmann-La Roche||Completed|August 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701558||154203|
NCT00701857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0612-04|Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Stage III or Stage IV Esophageal Cancer or Gastroesophageal Junction Cancer|PHASE I STUDY OF CONCOMITANT PEMETREXED AND CDDP PLUS RADIATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL OR GASTROESOPHAGEAL (GEJ) CARCINOMAS||University of Arizona|Yes|Recruiting|February 2008|||December 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|June 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00701857||154180|
NCT00750399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4519s|Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma|An Open Label Study to Evaluate the Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma||The New York Eye Cancer Center|No|Completed|October 2008|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|N/A|No|||April 2012|April 25, 2012|September 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00750399||150494|
NCT00750412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC 2008-0987|An Assessment of Voluntary Adolescent Mental Health Screening and Referral in a Children's Hospital Emergency Department|An Assessment of Voluntary Adolescent Mental Health Screening and Referral in a Children's Hospital Emergency Department||Children's Hospital Medical Center, Cincinnati|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|112|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00750412||150493|
NCT00742664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPWR-CBT-001|Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project|Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project||University of South Florida|No|Completed|September 2008|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|6 Years|17 Years|No|||July 2011|August 4, 2011|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742664||151085|
NCT00751426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Psy 225/98|Treatment of Hepatitis C in Psychiatric Patients|Treatment of Chronic Hepatitis c With Interferon-Alpha 2a and Ribavirin: a Comparison of Patients With Psychiatric Disorders and Controls||Charite University, Berlin, Germany|Yes|Completed|August 1999|May 2002|Actual|February 2002|Actual|Phase 4|Observational|N/A|||Actual|81|||Both|18 Years|70 Years|No||HCV-infected Controls, Psychiatric patients, Patients with former drug addiction and        patients with methadone substitution|August 2008|September 11, 2008|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00751426||150418|
NCT00751764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3110A1-1002|Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women|An Open-Label, Single-Dose Study to Evaluate the Excretion of Moxidectin Into the Breast Milk of Lactating, Non-breastfeeding Women.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 15, 2010|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751764||150393|
NCT00751777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELT207|Traveler's Diarrhea (TD) Automated Process|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults||Intercell USA, Inc.|No|Completed|September 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|September 11, 2008|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00751777||150392|
NCT00739843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15813B|Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients|Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients||University of Chicago|Yes|Recruiting|November 2007|November 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|60 Years|N/A|No|Non-Probability Sample|All prevalent and incident hemodialysis patients over the age of 60, receiving        hemodialysis treatments at the University of Chicago outpatient dialysis program at the        time of the study will be invited to participate.|August 2008|August 21, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739843||151301|
NCT00739856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMCPTSD_ECT2005|Use of Electroconvulsive Therapy (ECT) in Chronic, Severe, Treatment Resistant Posttraumatic Stress Disorder|Efficacy of ECT in Chronic, Severe, Antidepressant- And CBT-Refractory Posttraumatic Stress Disorder: An Open, Prospective Study||Government Medical College Srinagar|No|Completed|January 2005|||December 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||August 2008|August 21, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739856||151300|
NCT00740090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908194|Malaria Vaccine for Children in Mali|Phase 1, Randomized, Double-Blind, Dose-Escalating Study of the Safety, Reactogenicity, and Immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Children in Mali||National Institutes of Health Clinical Center (CC)||Completed|August 2008|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1|||200|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||June 2009|September 4, 2009|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740090||151282|
NCT00699491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00284|Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|Phase I/II Trial of IMC-A12 in Combination With Temsirolimus in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2008|January 2016|Anticipated|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2015|May 5, 2015|June 17, 2008|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT00699491||154360|
NCT00699842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07C.446|A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients|A Phase I/II Optimal Dose Study of Lenalidomide in the Non-5q- LOW and INT-1 Risk MDS Patients||Thomas Jefferson University|Yes|Terminated|July 2008|May 2012|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|June 13, 2008|Yes|Yes|Administratively terminated per FDA recommendation|No|February 27, 2014|https://clinicaltrials.gov/show/NCT00699842||154334|Study was terminated as the objectives of this study have already been addressed in a larger study, and therefore the study is unlikely to yield any new information. The study closed before any data for the outcome measures was able to be collected.
NCT00700427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9655|A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study||Eli Lilly and Company|No|Completed|June 2008|October 2013|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2017|||Both|18 Years|50 Years|No|||June 2014|June 12, 2014|June 16, 2008|Yes|Yes||No|August 23, 2012|https://clinicaltrials.gov/show/NCT00700427||154289|
NCT00700440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62202-770|Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy|Phase II Study of Cetuximab Combined With Intensity Modulated Radiotherapy (IMRT) and Concurrent Chemotherapy of Cisplatin in Nasopharyngeal Carcinoma|ENCORE|Sun Yat-sen University|Yes|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|69 Years|No|||February 2009|March 9, 2010|June 17, 2008||No||No|January 11, 2010|https://clinicaltrials.gov/show/NCT00700440||154288|
NCT00700778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06827|Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations|Genomic Markers of Breast Cancer Prevention Induced by HCG in Women at High Risk||Fox Chase Cancer Center|No|Active, not recruiting|July 2008|||March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2|||Female|20 Years|40 Years|No|||March 2016|March 1, 2016|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00700778||154262|
NCT00700414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPACTR|International Pediatric Adrenocortical Tumor Registry|International Pediatric Adrenocortical Tumor Registry||St. Jude Children's Research Hospital|No|Recruiting|May 2001|December 2040|Anticipated|December 2040|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|9999|Samples With DNA|Peripheral blood sample with DNA and RNA; Tumor Tissue (of any histology); Adrenocortical      tumors;|Both|N/A|21 Years|No|Non-Probability Sample|Age ≤ 21 years old at diagnosis of adrenocortical tumor.        Relatives of the ACT patients of any age with a diagnosis of malignant tumor.|October 2015|October 16, 2015|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700414||154290|
NCT00701272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0385-T|FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation|FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of HCV Recurrence and Progression Post Liver Transplantation||University Health Network, Toronto|No|Enrolling by invitation|June 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|Samples With DNA|Blood samples; liver biopsy tissue|Both|18 Years|70 Years|No|Non-Probability Sample|Individuals undergoing liver transplantation due to end-stage liver disease caused by        Hepatitis C Virus or alcoholic cirrhosis|July 2013|July 24, 2013|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701272||154225|
NCT00701584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1456|The Role of Diet and Lifestyle in Breast Cancer Survival|The Role of Diet, Complementary Treatment and Lifestyle in Breast Cancer Progression and Survival|DietCompLyf|University College London Hospitals|Yes|Active, not recruiting|January 2005|December 2014|Anticipated|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3390|Samples With DNA|Serum, plasma, buffy coat, urine|Female|18 Years|75 Years|No|Probability Sample|Breast cancer clinics in UK|May 2014|May 19, 2014|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00701584||154201|
NCT00702130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|310UT|Pravastatin and Ventilatory Associated Pneumonia|The Effect of Pravastatin on the Incidence and in the Natural Course of Ventilatory Associated Pneumonia in the Intensive Care Unit Patients|EPRAVAP|University of Thessaly|Yes|Completed|June 2008|April 2010|Actual|April 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|152|||Both|14 Years|N/A|No|||November 2011|November 29, 2011|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00702130||154159|
NCT00702429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00632-51|Immunoregulation of Periodontal Disease|Immunoregulation of Periodontal Disease||Assistance Publique Hopitaux De Marseille|No|Completed|August 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00702429||154137|
NCT00750425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00020|Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours|A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours||AstraZeneca|No|Completed|August 2008|January 2011|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00750425||150492|
NCT00742989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCUMB-2005-01|Effect of Osteopathic Lymphatic Treatment on Plasma Volume, Protein Concentration and Albumin Concentration.|The Short-Term Effect of Osteopathic Lymphatic Treatment on Blood Cell Count, Plasma Protein, and Blood Pressure: A Pilot Study in a Cross-Over Design||Kansas City University of Medicine and Biosciences|No|Completed|May 2005|July 2006|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2008|August 27, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742989||151060|
NCT00743197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-08-002|Women With Chest Pain and Normal Coronary Arteries Study|Women With Chest Pain and Normal Coronary Arteries Study: A Randomized Study of Medical Treatment and Therapeutic Lifestyle Changes||Northwestern University|No|Terminated|May 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3|||Female|30 Years|90 Years|No|||November 2011|November 30, 2011|August 26, 2008|Yes|Yes|Terminated due to departure of PI from institution.|No|September 13, 2011|https://clinicaltrials.gov/show/NCT00743197||151044|Study terminated due to departure of PI; all work including analyses ceased upon departure.In addition,study end points were based on changes b/w groups treatment vs. usual care) at 12 mo follow up- none of the subjects completed the Mo 12 visit.
NCT00743210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P01HD030367-ARG|Oral L-Citrulline and ADMA in Pregnancy|Phase 1 Study of Oral L-citrulline on ADMA/L-arginine and Endothelial-dependent Vascular Function in Pregnancy.||University of Pittsburgh|Yes|Completed|January 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|41|||Female|14 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00743210||151043|
NCT00743483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVT.BSSL-002|Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency|An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency||Swedish Orphan Biovitrum|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|August 26, 2008||No||No|November 5, 2014|https://clinicaltrials.gov/show/NCT00743483||151022|
NCT00743470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-457|A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects|A Comparison of the Bioavailability of Rifabutin With and Without Lopinavir/Ritonavir in Healthy Adult Subjects||Abbott||Terminated|August 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 29, 2010|August 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743470||151023|
NCT00743743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resveratrol2008|Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease|Randomized, Placebo-controlled Clinical Trial of Resveratrol Supplement Effects on Cognition, Function and Behavior in Patients With Mild-to-moderate Alzheimer's Disease||Medical College of Wisconsin|Yes|Withdrawn|September 2008|December 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|90 Years|No|||August 2015|August 21, 2015|August 27, 2008||No|PI has left institution|No||https://clinicaltrials.gov/show/NCT00743743||151002|
NCT00739479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816190-1|CCRC: Effects of Partially Hydrolyzed Whey Peptides (PHWP) On Weight Loss In Individuals With The Metabolic Syndrome (METS)|CCRC: Effects of Partially Hydrolyzed Whey Peptides (PHWP) On Weight Loss In Individuals With The Metabolic Syndrome (METS)||University of California, Davis|Yes|Completed|August 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||August 2008|October 25, 2012|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00739479||151327|
NCT00740103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNI-1493-CD05|Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease|Long-term Study of Semapimod (CNI-1493) for Treatment of Moderate to Severe Crohn's Disease With Reference to Study CNI-1493-CD-04, 1 or 3 Days' Treatment vs. Placebo|CD05|Ferring Pharmaceuticals|No|Completed|December 2002|September 2004|Actual|July 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|August 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00740103||151281|
NCT00739505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-001-08|Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)|A Multicenter, Open-Label, Dose Escalating Study of the Safety, Tolerability and Pharmacology of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)||Alexion Pharma GmbH|Yes|Completed|August 2008|February 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|80 Years|No|||May 2014|May 27, 2014|August 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00739505||151325|
NCT00740116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr 2006-006714-14|Tranexamic Acid in Surgery of Advanced Ovarian Cancer|Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study||University Hospital, Linkoeping|No|Completed|March 2008|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||June 2012|June 26, 2012|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740116||151280|
NCT00699517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10145|A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies|A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.||Sanofi|Yes|Completed|June 2008|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|May 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00699517||154358|
NCT00732173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8808|Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer|Survivors of Uterine Cancer Empowered By Exercise and Healthy Diet (SUCCEED)||Case Comprehensive Cancer Center|Yes|Completed|July 2008|March 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|74|||Female|18 Years|N/A|No|||February 2013|February 7, 2013|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732173||151882|
NCT00732771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699A2206|Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism|A Pilot, Single-blind, Forced-titration Study to Assess the Hemodynamic and Hormonal Effects, Safety and Tolerability of the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism||Novartis||Completed|June 2008|||May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||August 2009|August 25, 2009|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00732771||151837|
NCT00732472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105211|A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days|A Randomised, Double-blind, Placebo-controlled, Dose Ascending, 2-cohort, Parallel Group Study to Examine the Safety, Tolerability and Pharmacokinetics of Once-daily Inhaled Doses of GSK573719 Formulated With the Excipient Magnesium Stearatein COPD Subjects for 7 Days||GlaxoSmithKline|No|Completed|October 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|37|||Both|40 Years|75 Years|No|||March 2014|March 27, 2014|August 11, 2008||No||No|January 2, 2014|https://clinicaltrials.gov/show/NCT00732472||151859|Subject 303 and Subject 317 correspond to the same participant who was randomized and dosed on two separate occasions. This participant has been counted as two separate participants on all the outputs.
NCT00732758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HD052550-01A2|Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3|Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3|Vitamin D RCT|University of Pittsburgh|No|Completed|October 2008|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|157|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|August 7, 2008||No||No|September 22, 2015|https://clinicaltrials.gov/show/NCT00732758||151838|No limitations.
NCT00733044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0012|Cost-effectiveness of Multidisciplinary Management of Tinnitus|Cost-effectiveness of Multidisciplinary Management of Tinnitus at a Specialised Tinnitus Centre||Maastricht University Medical Center|No|Completed|September 2007|July 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|492|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00733044||151816|
NCT00701025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0189|Mechanisms of Exercise-induced Bronchospasm|Mechanisms of Exercise-induced Bronchospasm||Ohio State University|Yes|Completed|April 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|Samples Without DNA|blood, sputum, urine for pregnancy testing|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|EIB is one of the most common triggers of bronchospasm in asthmatics. It is identified as        a trigger in 80-90% of asthmatics. It also occurs frequently (10-15%) in healthy        volunteers without asthma. Inclusion of a heterogenous population of asthmatics and        non-asthmatics will help provide much needed information to help compare/contrast EIB that        occurs in these two groups.|February 2011|February 8, 2011|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701025||154243|
NCT00701285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-PTV-703|South Korean Pitavastatin Heart Failure Study|A Prospective, Randomized, Two Group Comparison Study to Evaluate the Effect of Statin on Heart Function in Patients With Chronic Ischemic Heart Failure.|SAPHIRE|JW Pharmaceutical||Completed|July 2008|May 2014|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|N/A|No|||May 2014|May 12, 2014|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00701285||154224|
NCT00701597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-020606|Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma|Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma.||Medical University of Vienna|Yes|Completed|April 2007|October 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 18, 2008|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701597||154200|
NCT00701610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-4132-TS-CTIL|Levels of Von Willebrand Factor Multimers and VWF-Cleaving Protease (ADAMTS-13) in Preterm and Neonate|Levels of Von Willebrand Factor Multimers and VWF-Cleaving Protease (ADAMTS-13) in Preterm and Neonate||Sheba Medical Center|No|Recruiting|August 2007|August 2009|Anticipated|August 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|blood will be taken from cord blood at birth from fullterm and preterm infantsinfants|Both|24 Weeks|42 Weeks|No|Non-Probability Sample|All infants born n our hospital between August 2007 and August 2009 will enter|July 2007|June 18, 2008|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00701610||154199|
NCT00701870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.2102|Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non‑Small Cell Lung Cancer|Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Chemotherapy Induced Neutropenia in Patients With Locally Advanced or Metastatic Non‑Small Cell Lung Cancer Receiving First-Line Chemotherapy||Telik|No|Terminated|October 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|June 18, 2008|No|Yes|Study TLK199.2102 was terminated for lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00701870||154179|
NCT00734279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-3125|Follicle-Stimulating Hormone (FSH) and the Onset of Puberty|Follicle-Stimulating Hormone (FSH) and the Onset of Puberty||University of Utah|No|Completed|March 2006|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|11|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||August 2008|November 30, 2015|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00734279||151721|
NCT00742365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH073797|Predicting Effectiveness of Light Treatment for Winter Seasonal Affective Disorder|Predicting Light Treatment's Effectiveness on Reducing Depression and Cardiovascular Risk in Seasonal Affective Disorder||University of Maryland|Yes|Active, not recruiting|November 2007|September 2015|Anticipated|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|64 Years|No|Non-Probability Sample|Patients with history of recurrent winter depression|January 2011|April 9, 2015|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742365||151107|
NCT00743535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/2008|Anterior Defect Correction With Mesh Plus Treatment of Stress Incontinence With Transobturator or Transvaginal Approach|A Comparison in Terms of Efficacy and Safety Between Transobturator and Transvaginal Tape Performed at the Same Time of Anterior Defect Correction With Mesh||University Magna Graecia||Terminated|February 2008|||February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|80 Years|No|||April 2013|April 5, 2013|August 28, 2008||No|Low recruitment rate.|No||https://clinicaltrials.gov/show/NCT00743535||151018|
NCT00743223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-UNIFESP1175/06|The Frequency Forward Head Posture in Subjects With Temporomandibular Disorder|The Frequency Forward Head Posture in Subjects With Temporomandibular Disorder||Federal University of Mato Grosso do Sul|No|Completed|October 2006|December 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The study was randomized with one hundred subjects that were divided fifty for study group        and fifty of the control group with age between 18 and 65 years old, of both sexes. The        volunteers were selected among the individuals who went to the clinic of orofacial pain        and TMD of São Paulo Hospital and the dental offices of the researchers|August 2008|August 27, 2008|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00743223||151042|
NCT00743496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJGD2|A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma|A Phase I Trial Of The Humanized Anti-GD2 Antibody (HU14.18K322A) In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma||St. Jude Children's Research Hospital|No|Recruiting|August 2008|June 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|N/A|21 Years|No|||February 2016|February 3, 2016|August 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743496||151021|
NCT00743756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1404-2005|Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)|Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With T2Dm||Emory University|No|Terminated|April 2006|December 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|38|||Both|65 Years|85 Years|No|||June 2014|June 7, 2014|August 27, 2008||No|slow patient enrollment|No||https://clinicaltrials.gov/show/NCT00743756||151001|
NCT00739492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01074|Testing Strategies for Weight Loss, II|||University of Pennsylvania|No|Completed|June 2008|January 2010|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||January 2009|July 21, 2011|May 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739492||151326|
NCT00739518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00041731|Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies for Neurological Exams|||University of Michigan|No|Recruiting|October 2004|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739518||151324|
NCT00740129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446K2418|Re-treatment of Patients With Paget's Disease Using Zoledronic Acid|An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies||Novartis|No|Completed|October 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||April 2013|April 30, 2013|August 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00740129||151279|
NCT00731536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015394|Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands|A Retrospective Review of Reports of Hepatosplenic T-cell Lymphoma in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief [PALGA]), a Database of Pathology Results for The Netherlands||Centocor Ortho Biotech Services, L.L.C.|No|Completed|October 2008|April 2010|Actual|April 2010|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|15|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Hepatosplenic T-cell Lymphoma (HSTCL).|October 2013|October 14, 2013|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00731536||151931|
NCT00731861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0412-21/ IUCRO-0101|Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors|Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors||Indiana University|Yes|Completed|May 2005|August 2010|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00731861||151906|
NCT00732160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080248|Aldosterone and Glucose Homeostasis|Aldosterone and Glucose Homeostasis||Vanderbilt University|Yes|Completed|September 2008|December 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|68|||Both|18 Years|70 Years|No|||July 2014|July 8, 2014|August 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732160||151883|
NCT00732784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-072|Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers|Effect of Calcium Supplements on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS 280) (UPCI 08-072)||University of Pittsburgh|Yes|Completed|November 2008|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 17, 2013|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732784||151836|
NCT00733057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI-GRANT-02T-244|Minocycline for the Treatment of Early-Phase Schizophrenia|A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia||Shalvata Mental Health Center|No|Completed|August 2003|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|35 Years|No|||August 2008|August 11, 2008|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733057||151815|
NCT00733356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBHR|The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading|The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading|VBHR|University of California, Irvine|Yes|Completed|July 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|42|||Both|6 Years|12 Years|No|||April 2011|April 6, 2011|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733356||151792|
NCT00733369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 06/03|A Study to Compare the Press Fit Condylar (P.F.C.) Sigma Rotating-platform High-flexion (RP-F) Versus The Press Fit Condylar (P.F.C.) Sigma Rotating-platform (RP) Knee Implants|A Prospective, Single Blinded, Multi-centre Randomised Controlled Trial Comparing the Post Operative Range of Motion of the P.F.C. Sigma RP-F Knee With the P.F.C. Sigma RP Knee in Primary Total Knee Arthroplasty.||DePuy International|No|Terminated|November 2007|April 2012|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|45 Years|75 Years|No|||August 2014|August 25, 2014|August 12, 2008|Yes|Yes|This study was closed for the reason of slow recruitment with only 16% of the target subjects    recruited over a 29 month period.|No|March 22, 2014|https://clinicaltrials.gov/show/NCT00733369||151791|
NCT00733707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant-806|Improving Adherence With Oral Contraceptives Using Daily Text Messaging Reminders|Improving Adherence With Oral Contraceptives Using Daily Text Messaging Reminders||Planned Parenthood League of Massachusetts|No|Completed|August 2008|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|82|||Female|14 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733707||151765|
NCT00733330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 03/10|Minimally Invasive Total Knee Replacement - Navigated Versus Non-navigated Study|Computer Assisted Navigation in Minimally Invasive Total Knee Arthroplasty: Comparing the Alignment Achieved Using the DePuy Ci Minimally Invasive (Mi) Versus the DePuy Non Navigated Conventional Total Knee Arthroplasty.||DePuy International|No|Terminated|January 2005|December 2010|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|80 Years|No|||July 2014|July 29, 2014|August 11, 2008|Yes|Yes|A sample size recalculation indicated an increase from 154 to 1500 subjects was required so    the study stopped as new target was considered unfeasible.|No|March 24, 2014|https://clinicaltrials.gov/show/NCT00733330||151794|
NCT00733343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure|Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients With Heart Failure|Serve-HF|ResMed|Yes|Active, not recruiting|February 2008|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1313|||Both|22 Years|N/A|No|||May 2013|September 18, 2014|February 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733343||151793|
NCT00733681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 02/14|The Press Fit Condylar (P.F.C.) Sigma Rotating Platform (RP) TC3 Revision Knee in Revision Knee Arthroplasty|A Prospective, Non-comparative Study to Evaluate the Performance of the DePuy P.F.C. Sigma Rotating Platform TC3 Knee Prosthesis in Revision Knee Arthroplasty.|TC3|DePuy International|No|Terminated|March 2004|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|181|||Both|21 Years|N/A|No|||January 2015|January 21, 2015|August 11, 2008|No|Yes|Subjects were no longer able to remain compliant with follow-up intervals|No||https://clinicaltrials.gov/show/NCT00733681||151767|
NCT00733694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 99/33|Outcome Study of Total Knee Arthroplasty in Asian Patients|Clinical Evaluation of the Low Contact Stress (LCS) Classic and Universal Mobile-bearing Total Knee System. The Asian LCS User Group - 'The Dragon Knee Study'|DRAGON|DePuy International|No|Completed|April 2000|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|607|||Both|N/A|75 Years|No|||December 2015|December 17, 2015|August 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733694||151766|
NCT00734305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-01-100|Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment|A Phase I and Pharmocologic Study of MM-121 in Patients With Refractory Advanced Solid Tumors||Merrimack Pharmaceuticals|Yes|Completed|July 2008|September 2013|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|August 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00734305||151719|
NCT00733954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10012|Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis|A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate Ointment With Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Plaque Psoriasis||Galderma Laboratories, L.P.|No|Completed|August 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|August 11, 2008||No||No|April 30, 2009|https://clinicaltrials.gov/show/NCT00733954||151746|
NCT00733967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22707|Varenicline-Methamphetamine Interaction Study (2008)|A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline In Methamphetamine-Dependent Volunteers Receiving Methamphetamine||Baylor College of Medicine|Yes|Withdrawn|January 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|18 Years|55 Years|No|||July 2012|July 25, 2012|August 11, 2008|Yes|Yes|No longer active|No||https://clinicaltrials.gov/show/NCT00733967||151745|
NCT00730418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-08-118|Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia|A Prospective Study for the Effects of Chronic Use of Doxazosin on Alpha 1-adrenergic Receptors in Men With Benign Prostatic Hyperplasia||Samsung Medical Center|Yes|Completed|January 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|25|||Male|50 Years|N/A|No|||August 2010|August 25, 2010|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00730418||152016|
NCT00730431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355-002|Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)|A Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IDX184 After Oral Administration in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Anticipated|48|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730431||152015|
NCT00742976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-001602-16|Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients|Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention and Weight in Type 2 Diabetic Patients|Le-Na|Rigshospitalet, Denmark|Yes|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|80 Years|No|||June 2008|January 19, 2010|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742976||151061|
NCT00739544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH2101project.1.2008|Chronic Pain After Operation for Breast Cancer|Examination of Healthy Female Subjects in the Project: Disposing Factors for Chronic Pain After Operation for Breast Cancer||Rigshospitalet, Denmark|No|Enrolling by invitation|August 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|20|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||August 2008|August 20, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739544||151322|
NCT00739557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0257|A Pilot Study to Evaluate the Systemic Inflammatory Response of Thoracoabdominal Aortic Aneurysm Repair.|A Pilot Study to Evaluate the Systemic Inflammatory Response of Thoracoabdominal Aortic Aneurysm Repair.||The University of Texas Health Science Center, Houston|No|Withdrawn|August 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Blood and saliva samples will be obtained for the purposes of this study and will be      maintained until complete analysis of the samples for all patients is complete.|Both|18 Years|N/A|No|Non-Probability Sample|patients entering the hospital for elective TAAA repair|December 2015|December 3, 2015|August 19, 2008||No|Investigator left the institution, another PI has not been named.|No||https://clinicaltrials.gov/show/NCT00739557||151321|
NCT00739219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP00006|Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)|Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO) Using the Apieron NO Analyzer|Outcomes|Apieron|No|Terminated|December 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|12 Years|N/A|No|||October 2008|January 19, 2009|August 19, 2008|Yes|Yes|Study terminated due to lack of care guidelines in the protocol.|No||https://clinicaltrials.gov/show/NCT00739219||151346|
NCT00739232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3248A1-1000|Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016|Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 31, 2009|August 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00739232||151345|
NCT00739245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Model 311|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld||||||N/A|N/A|N/A||||||||||||||August 20, 2008|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739245||151344|
NCT00743509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.049|A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma|A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma|OCR|University of Michigan Cancer Center||Completed|August 2008|September 2012|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|16 Years|N/A|No|||August 2015|August 31, 2015|August 27, 2008|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00743509||151020|
NCT00743522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|448|Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication|Programming Implantable Cardioverter Defibrillators (ICDs) in Patients With Primary Prevention Indication to Prolong Time to First Shock|PROVIDE|St. Jude Medical|Yes|Completed|September 2008|December 2011|Actual|September 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1670|||Both|18 Years|N/A|No|Probability Sample|Patients with approved ICD/CRT-D indications|June 2015|June 4, 2015|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00743522||151019|
NCT00739193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105|A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure|A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure||Prism Pharmaceuticals|No|Withdrawn|August 2008|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||October 2008|October 23, 2008|August 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00739193||151348|
NCT00739206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT10004|Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.|A Multicenter, Open Label, Efficacy and Safety Study of Parenteral SAR97276A in the Treatment of Symptomatic Uncomplicated and Severe Malaria in Adults and Children||Sanofi|Yes|Terminated|August 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|113|||Both|6 Months|65 Years|No|||June 2010|June 15, 2010|August 20, 2008|Yes|Yes|In accordance with protocol's predefined criteria and Data Monitoring Committee recommendation    due to insufficient level of efficacy|No||https://clinicaltrials.gov/show/NCT00739206||151347|
NCT00740142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 341/2008|Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy|Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy||Mahidol University|Yes|Recruiting|September 2008|August 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|80 Years|No|||December 2008|June 25, 2009|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740142||151278|
NCT00740155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD11|Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults|Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years||Sanofi|Yes|Completed|August 2008|January 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|154|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00740155||151277|
NCT00732186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-033|Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia|Phase Ib Study Evaluating the Safety and Exploring the Molecular and Cytogenetic Response of Combination Therapy With Dasatinib and Ipilimumab in Patients With Chronic or Accelerated Phase Chronic Myeloid Leukemia||Bristol-Myers Squibb|No|Withdrawn|August 2009|February 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2009|February 16, 2016|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00732186||151881|
NCT00732485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-389|Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate|The Role of Mitochondrial Oxidation on Insulin Resistance in Burn Patients Treated With Fenofibrate||The University of Texas Medical Branch, Galveston|Yes|Withdrawn|August 2008|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|7 Years|20 Years|No|||December 2012|December 10, 2012|August 8, 2008||No|Principal Investigator Changed|No||https://clinicaltrials.gov/show/NCT00732485||151858|
NCT00733070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVC-003-00|Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries|A Multicenter Multinational Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries||Ovalum|No|Terminated|August 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|80 Years|No|||July 2013|July 6, 2013|August 10, 2008||No|no interest to develop the product|No||https://clinicaltrials.gov/show/NCT00733070||151814|
NCT00732836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0857|Hepatic Arterial Infusion (HAI) of Abraxane|Phase I Trial of Hepatic Arterial Infusion of Abraxane With a Pharmacokinetic Study in Advanced Solid Cancer Patients With Predominant Hepatic Metastases||M.D. Anderson Cancer Center|No|Completed|June 2008|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|August 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732836||151832|
NCT00733382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212110|Effect of Dexamethasone on Migraine Headache|The Effect of Dexamethasone in the Attack of Migraine Headache and to Prevent of Its Relapse After Discharge From Emergency Department: a Randomized, Double-Blind, Controlled Trial.||Shiraz University of Medical Sciences|No|Active, not recruiting|February 2008|August 2009|Anticipated|December 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|15 Years|40 Years|No|||August 2008|August 11, 2008|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733382||151790|
NCT00733720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01DA-6-8867|Buprenorphine Naltrexone-P1 A-Cocaine|Attenuation of Opioid Effects of Three Different Doses of Sublingual Buprenorphine / Naloxone by Oral Naltrexone in Healthy Volunteers||National Institute on Drug Abuse (NIDA)||Completed|August 2008|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 8, 2009|August 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733720||151764|
NCT00733993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA09262|Caffeine and Cocaine|Experiment 1: Adenosine Receptor A2A Antagonists and Cocaine Dependence||Virginia Commonwealth University|Yes|Completed|April 2008|October 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|67|||Both|18 Years|55 Years|No|||January 2016|January 5, 2016|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733993||151743|
NCT00733980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106139|A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder|A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder||GlaxoSmithKline|No|Completed|October 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|64 Years|No|||August 2012|August 30, 2012|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733980||151744|
NCT00734292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-2-002|Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma|A Randomized, Placebo-controlled, Double-blind, Crossover, Single-dose Exposure Study to Evaluate the Early Bronchodilating Effect of FlutiForm 100/10 µg HFA pMDI and FlutiForm 250/10 µg HFA pMDI, Compared to Placebo in Adult Subjects With Mild to Moderate Asthma||SkyePharma AG|No|Completed|September 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|39|||Both|18 Years|N/A|No|||August 2010|August 24, 2010|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734292||151720|
NCT00730119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 327|Evaluation Of The GE Monitor Product Line|Evaluation Of The GE Monitor Product Line||GE Healthcare|No|Completed|October 2001|May 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|1500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All populations (neonatal, pediatrics, and adults).|April 2012|April 2, 2012|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730119||152039|
NCT00729833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021024|Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors|Phase 1, Open Label, Sequential Cohort, Dose Escalation Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors||Pfizer|No|Terminated|September 2008|April 2013|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|July 30, 2008|No|Yes|See termination reason in detailed description.|No|April 11, 2014|https://clinicaltrials.gov/show/NCT00729833||152061|This study was terminated prematurely. Subsequently, ADA samples were not assayed and the pharmacokinetics of sunitinib plus its metabolite were not analyzed.
NCT00730132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05464|Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)|Observational Study of Approaches to Lipid-lowering Therapy in Russian Patients With Coronary Heart Disease (<<Treat to Goal>>)||Merck Sharp & Dohme Corp.|Yes|Completed|January 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|712|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with established diagnosis of coronary heart disease (CHD) and        hypercholesterolemia who did not achieve the target values for total cholesterol (TC) and        low density lipoprotein-C (LDL-C) with existing statin therapy|June 2015|June 23, 2015|July 25, 2008|No|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00730132||152038|
NCT00730444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE 122-008|Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma|Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma||GE Healthcare||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||November 2009|November 5, 2009|August 5, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00730444||152014|
NCT00742690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1442P|Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome|Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study.||University of Padova|No|Recruiting|May 2005|March 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||October 2014|October 11, 2014|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742690||151083|
NCT00742703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9808|Study of the Effects of a Mineralized Water Ingestion Upon Lipidic Absorption Mechanisms|Study of the Effects of a Mineralized Water Ingestion Upon Lipidic Absorption Mechanisms||Multimed|No|Completed|August 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|12|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 6, 2009|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742703||151082|
NCT00740168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-ANF1|Bevacizumab Treatment and Retinal Vessel Monitoring|Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy|BevaRet|Technische Universität Dresden|No|Completed|May 2007|April 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Cancer patients with first bevacizumab treatment|January 2016|January 20, 2016|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00740168||151276|
NCT00740181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-AML-217|Decitabine, Cytarabine, GCSF for Refractory AML/MDS|A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-morbidities.||Brown University|Yes|Terminated|August 2008|April 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|19 Years|N/A|No|||July 2014|July 27, 2014|August 21, 2008||No|Lack of efficacy|No|May 14, 2013|https://clinicaltrials.gov/show/NCT00740181||151275|
NCT00739531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP00014|Measuring Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System|Measuring the Fractional Concentration of Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System||Apieron|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|5 Years|N/A|No|Non-Probability Sample|Up to 150 asthma patients recruited from the site center's population of patients.|August 2008|August 20, 2008|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739531||151323|
NCT00740441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1411-C-202|A Phase II Study of AS1411 in Renal Cell Carcinoma|A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma||Antisoma Research|No|Active, not recruiting|August 2008|March 2010|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 24, 2009|August 22, 2008||Yes||||https://clinicaltrials.gov/show/NCT00740441||151255|
NCT00740727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASI Access II|EASI Access II --- Follow-up Study to the EASI Access Trial|Enzymatically Augmented Subcutaneous Infusion (EASI) Access II Trial||Massachusetts General Hospital|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 10, 2009|August 21, 2008|Yes|Yes||No|March 3, 2009|https://clinicaltrials.gov/show/NCT00740727||151233|
NCT00740740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wallstrength_01|Biomarkers of Aneurysm Wall Strength|Biological and Biochemical Markers of Aneurysm Wall Degradation; Towards Non-Invasive Wall Strength Analysis.||Radboud University|No|Recruiting|June 2007|January 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|50|Samples With DNA|whole blood, serum, white cells, urine, tissue|Both|18 Years|N/A|No|Probability Sample|Tertiary care clinic. Patients scheduled for transbadominal aortic surgery|August 2008|August 22, 2008|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740740||151232|
NCT00739869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|571|Evaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study)|Effects of Hormone Therapy on Subclinical Neurological Pathology-The WHIMS-MRI Collaborative Study|WHIMS-MRI|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|May 2004|March 2007|Actual|April 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1426|||Female|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who participated in the WHIMS study and receive medical care at clinics        participating in this study.|October 2015|October 16, 2015|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739869||151299|
NCT00739882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27808|TRUST Study: Raptiva ® in Hand & Foot Psoriasis|A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva ® in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Involving Hands and/or Feet, With or Without Pustules.|TRUST|Merck KGaA||Terminated|April 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||January 2014|January 26, 2014|August 20, 2008||No|The study was terminated after the European Medicines Agency recommended to suspend the    marketing authorisation of Raptiva in the European Union|No|June 28, 2010|https://clinicaltrials.gov/show/NCT00739882||151298|Following the recommendation of the European Medicines Agency (EMEA) to suspend the marketing authorization of Raptiva® and the subsequent premature termination of this trial analysis of efficacy-related endpoints was not performed
NCT00741039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005|Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older|Phase II Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older||Memorial Sloan Kettering Cancer Center||Completed|August 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|126|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|August 22, 2008|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00741039||151209|
NCT00732797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0107-12069|A Trial of Booklet Based Self Management of Dizziness|Evaluation of the Cost-effectiveness of Booklet-based Self-management of Dizziness in Primary Care, With and Without Expert Telephone Support||University of Southampton|No|Completed|October 2008|June 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|337|||Both|18 Years|N/A|No|||January 2010|August 11, 2011|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00732797||151835|
NCT00732810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04716|SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)|A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers||Merck Sharp & Dohme Corp.|No|Completed|July 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|97|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732810||151834|
NCT00732823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0500-05-U337|Compression Device Safety Study|A Phase II Randomized Study to Evaluate the Safety of the Compression Test Device Using Intermittent Pneumatic Compression Mode in Subjects With Venous Insufficiency and Oedema||ConvaTec Inc.|No|Completed|July 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|N/A|No|||August 2008|October 29, 2008|July 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00732823||151833|
NCT00732849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|surg nutr|The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery|The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.||Jagiellonian University|No|Completed|June 2002|November 2007|Actual|September 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2008|August 8, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00732849||151831|
NCT00733083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOM|A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients|A Comparative Study With Pre-Emptive Parenteral Oxycodone, Morphine and Dexamethasone in the Treatment of Postoperative Pain in Paediatric Patients 4 to 12 Years of Age|DOM|University of Turku|No|Not yet recruiting|September 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|4 Years|12 Years|No|||August 2008|August 8, 2008|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00733083||151813|
NCT00733395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e4652|Hood to Coast Injury Study|Comparison of Two Juice Drinks in Preventing the Symptoms of Muscle Pain Among Runners||Oregon Health and Science University|No|Not yet recruiting|August 2008|||August 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|50 Years|No|||August 2008|August 11, 2008|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733395||151789|
NCT00733733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Euro-NHB|Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor|A Prospective, Randomized, Open, Multicenter Study to Evaluate the Efficacy and Tolerability of Induction Therapy With a Single High-Dose Anti-T-Lymphocyte Globulin (ATG) in Renal Transplant Patients With a Kidney From a Non-Heart-Beating Donor and Tacrolimus, Mycophenolate Mofetil, and Steroids as Basic Immunosuppression.|ATG|Radboud University|No|Recruiting|January 2008|June 2010|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2008|August 12, 2008|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733733||151763|
NCT00734318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3503|Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma|A Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm® pMDI 250/10µg (2 Puffs Bid) vs Fluticasone pMDI 250µg (2 Puffs Bid) Plus Formoterol pMDI 12µg (2 Puffs Bid) Administered Concurrently in Adult Subjects With Severe Persistent, Reversible Asthma.||Mundipharma Research Limited|No|Completed|September 2008|October 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1667|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734318||151718|
NCT00734331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-NM-300-CTIL|Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2008|September 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|serum, colonic tissue, whole blood|Both|18 Years|75 Years|No|Non-Probability Sample|Patients- inflammatory bowel disease patients under going colonoscopy controls- average        risk patients without inflammation under going colonoscopy|August 2008|August 13, 2008|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734331||151717|
NCT00729846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPDT2006|Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)|Combination Bevacizumab and Verteporfin (Standard and Reduced Fluence)in the Treatment of Neovascular Age-Related Macular Degeneration||California Retina Consultants|No|Completed|May 2006|July 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|50 Years|N/A|No|||December 2013|December 10, 2013|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00729846||152060|
NCT00734344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080416007|Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection|Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis||University of Alabama at Birmingham|No|Completed|September 2008|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|N/A|No|||June 2015|July 11, 2015|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734344||151716|
NCT00730145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361032|A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis|A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis||Pfizer|No|Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|65 Years|No|||February 2010|February 16, 2010|August 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730145||152037|
NCT00730158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005|A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer|A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer||University of Pittsburgh|Yes|Recruiting|December 2008|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00730158||152036|
NCT00730171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-305|An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation|An Open-label, Long-term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation||Ironwood Pharmaceuticals, Inc.||Completed|September 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1743|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|August 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00730171||152035|
NCT00743236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-89108|Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer|A Phase III Multi-Institutional Randomized Clinical Trial: Effect of Type of Ischemia - Warm vs Cold During Partial Nephrectomy - on Renal Function||Comprehensive Cancer Center of Wake Forest University||Completed|August 2008|||June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00743236||151041|
NCT00739271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RK2|Early Enteral Feeding After Intestinal Anastomosis|Early Enteral Feeding After Intestinal Anastomosis||Christian Medical College and Hospital, Ludhiana, India|No|Completed|October 2005|December 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|12 Years|N/A|No|||August 2008|August 21, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739271||151342|
NCT00739284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJVsPCN08|A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney||JJVsPCN08|Rabin Medical Center|Yes|Recruiting|August 2008|||August 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2008|August 20, 2008|August 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739284||151341|
NCT00740454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDVIGE|Single Complete Compression Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy and Postpartum|Diagnostic Exclusion Value of a Negative Single Distal and Proximal Lower Limb Veins Compression Ultrasonography in Pregnant and Post-partum Women With a Clinically Suspected Deep Vein Thrombosis|EDVIGE|University Hospital, Brest|No|Completed|January 2006|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant or post-partum women referred to primary care vascular medicine physicians or        diagnostic imaging units of referral hospitals in Brittany (France) and Geneva        (Switzerland)|December 2010|December 27, 2010|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740454||151254|
NCT00740467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592923|Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders|Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation||National Cancer Institute (NCI)||Recruiting|January 2008|||January 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|60 Years|No|||July 2009|January 27, 2010|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740467||151253|
NCT00741026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28230|A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers|A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers||Milton S. Hershey Medical Center|Yes|Completed|August 2008|May 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|August 22, 2008|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00741026||151210|One episode of orthostatic hypotension requiring unblinding. One individual with emesis after glucose challenge and that individual's glucose tolerance data were unavailable analysis.
NCT00740779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI08001|Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.|A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome||Watson Pharmaceuticals|No|Completed|September 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|153|||Male|18 Years|N/A|No|||January 2012|January 23, 2012|August 21, 2008|Yes|Yes||No|January 23, 2012|https://clinicaltrials.gov/show/NCT00740779||151229|
NCT00740792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP4004|A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.||Meda Pharmaceuticals|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|776|||Both|12 Years|N/A|No|||August 2012|August 7, 2012|August 22, 2008|Yes|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT00740792||151228|
NCT00732511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glaxo Smith Kline 111105|Coreg CR, Blood Vessel Stiffness and Blood Vessel Function|Effect of Coreg CR on BP, Endothelial Function, Exhaled Nitric Oxide, and Nitric Oxide Production and Oxidation||State University of New York - Downstate Medical Center|No|Recruiting|April 2008|April 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|80 Years|No|||February 2011|February 9, 2011|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732511||151856|
NCT00732862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#8842-NIDDM|Metabolic Adaptation to Diabetes|Metabolic Adaptation to Diabetes||Vanderbilt University|No|Completed|February 1998|December 2008|Actual|March 2000|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|August 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00732862||151830|
NCT00733408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6628|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer|Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib||University of Washington|No|Active, not recruiting|April 2008|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Female|N/A|N/A|No|||January 2016|January 5, 2016|August 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733408||151788|
NCT00733746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z5041|Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|April 2009|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733746||151762|
NCT00733759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC/CLS10|Contrast Echocardiography in Patients With Pulmonary Arteriovenous Malformations (PAVMs)|The Evaluation of Intra-Cardiac Shunts in Patients With Pulmonary Arteriovenous Malformations||Imperial College London||Active, not recruiting||||||N/A|Observational|Time Perspective: Prospective|||Anticipated|45|||Both|N/A|N/A|No|||August 2008|August 12, 2008|August 12, 2008||||No||https://clinicaltrials.gov/show/NCT00733759||151761|
NCT00734032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPL110118|A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients|A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients - A Multicenter, Randomized, Double-blind, Placebo-controlled Study of SB-480848 to Evaluate the Efficacy and Safety -||GlaxoSmithKline||Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|107|||Both|20 Years|80 Years|No|||May 2012|June 21, 2012|August 12, 2008||||No||https://clinicaltrials.gov/show/NCT00734032||151740|
NCT00734045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB-13|Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples|Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples|WB-13|Nanogen, Inc.|No|Completed|February 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|450|||Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients to be recruited for the study should either:          -  have clinically confirmed heart failure (NYHA class I-IV) or have presented to an             emergency room or clinic with signs, symptoms and/or risk factors suggestive of heart             failure, OR          -  be non-CHF controls greater than 45 years of age with no history of heart failure or             cardiovascular disease.|December 2008|December 8, 2008|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00734045||151739|
NCT00734006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0018|Cortico-cortical Connectivity During Midazolam Sedation in Humans; a TMS/EEG Study|Cortico-cortical Connectivity During Midazolam Sedation in Humans; a TMS/EEG Study||University of Wisconsin, Madison|Yes|Completed|July 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy right-handed men aged 18-35 who do not smoke or have any metallic implants may be        eligible for this study.|May 2015|May 6, 2015|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00734006||151742|
NCT00734019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 04/16|Survivorship of the Press Fit Condylar (P.F.C.) Sigma Fixed Bearing Knee With a Cobalt Chrome Tibial Tray|A Prospective, Non-comparative, Multicentre, Multinational Study to Determine the Survivorship of the P.F.C. Fixed Bearing Knee System Using a Moderately Cross-linked Polyethylene Insert and a Cobalt Chrome Tibial Tray.||DePuy International|No|Active, not recruiting|October 2005|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|650|||Both|N/A|80 Years|No|||February 2016|February 8, 2016|August 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00734019||151741|
NCT00734357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00019769|Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients|Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients||University of Michigan||Completed|October 2009|October 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|413|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734357||151715|
NCT00729859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33853-A|CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men|Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men|CEP-1|University of Washington|No|Completed|December 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|31|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 12, 2012|August 5, 2008|Yes|Yes||No|June 2, 2011|https://clinicaltrials.gov/show/NCT00729859||152059|
NCT00729872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG011-MDUC-201|A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis|A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis||ActoGeniX N.V.|Yes|Completed|July 2008|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|60|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00729872||152058|
NCT00730470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3P1287/01|Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-Finding Study to Assess the Safety and Tolerability of U3-1287 (AMG 888), a Human Monoclonal Antibody Targeting HER3 in Patients With Advanced Solid Tumors.||U3 Pharma GmbH|No|Completed|August 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2010|July 28, 2010|August 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00730470||152012|
NCT00739258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-970077|Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison|Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison and Set up the Notional Halfway Home in Union Area of Medical Facility||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|April 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort||3|Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The samples are obtained from Kaohsiung prison, Kaohsiung women's prison, Pingtung prison        and the Kaohsiung Medical University Chung-Ho Memorial Hospital in Kaohsiung, Taiwan.|December 2011|January 20, 2012|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00739258||151343|
NCT00739583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00011971|Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions|Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions|site marking|Johns Hopkins University|No|Completed|August 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|21 Years|N/A|No|||June 2013|June 5, 2013|August 20, 2008|Yes|Yes||No|March 9, 2010|https://clinicaltrials.gov/show/NCT00739583||151319|Non-standardization of the amount of ink used to mark each site.The use of only one type of marking pen.No measurement of the amount of pressure use to apply the skin cleaning solutions.Potential subjectivity of surgeons viewing initials
NCT00739960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 15630B|Safety Study of Abatacept to Treat Refractory Sarcoidosis|Sarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive Sarcoidosis|STAR|University of Chicago|Yes|Terminated|August 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|August 20, 2008|No|Yes|Funding has been pulled|No||https://clinicaltrials.gov/show/NCT00739960||151292|
NCT00739895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Athletes_001|Assessment of Cardiac Involvement of Common Cold in High Performing Athletes by Cardiac Magnetic Resonance Imaging (MRI)|Left Ventricular Dilatation in Athletes With Common Colds; a Cardio-vascular MRI Study||University of Calgary|Yes|Terminated|June 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|high performance athletes, during acute viremia and at variable training intensities.        Healthy individuals from the general public will serve as a reference group.|October 2011|October 2, 2011|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739895||151297|
NCT00739908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX157-200|A Study of CX157 (TriRima) for the Treatment of Depression|A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder|CX157-200|CeNeRx BioPharma Inc.|Yes|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|285|||Both|18 Years|60 Years|No|||June 2012|June 26, 2012|August 20, 2008|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00739908||151296|Subjects were asked to take 6 capsules 3 times a day for 6 weeks. Non-adherence with the study medication was high based on the population PK data. This likely contributed to the results in CX157 treatment group.
NCT00739921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9272-26987-05|The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA|PCR Analysis of Nasal Polyps for Fungal DNA||University of California, San Francisco|No|Recruiting|June 2006|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 30, 2014|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00739921||151295|
NCT00740194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/279|Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men|Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men.||University Hospital, Ghent|No|Completed|August 2008|August 2010|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2011|August 29, 2011|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740194||151274|
NCT00740207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP-113|Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA|A Phase IV Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)||Bracco Diagnostics, Inc|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|33|||Both|18 Years|N/A|No|||May 2011|May 5, 2011|August 20, 2008|Yes|Yes||No|September 13, 2010|https://clinicaltrials.gov/show/NCT00740207||151273|
NCT00740220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG02-489|Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation|Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation|6MWT|Wake Forest School of Medicine|No|Completed|September 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be carried out in a population of subjects who are taking part in        Pulmonary Rehabilitation.|April 2009|January 13, 2010|August 20, 2008||No||No|February 13, 2009|https://clinicaltrials.gov/show/NCT00740220||151272|Study was conducted in a Pulmonary Rehabilitation Population and may not be generalizable.
NCT00740753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDE 2377|Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option|A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma|Y-90HDE|Oregon Health and Science University|No|Enrolling by invitation|August 2004|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|August 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00740753||151231|
NCT00740766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#02-017|Perinatal Outcomes in Nutritionally Monitored Obese Pregnant Women|Perinatal Outcomes in Nutritionally Monitored Obese Pregnant Women||Jamaica Hospital Medical Center|No|Completed|June 1998|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|257|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|August 22, 2008||||No||https://clinicaltrials.gov/show/NCT00740766||151230|
NCT00741689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00003|A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Oral Doses of AZD1656 in Japanese Healthy Male Volunteers||AstraZeneca||Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|36|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|August 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00741689||151159|
NCT00742261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET111516|A Study to Investigate the Bioavailability of Two Forms of GSK1363089 in Subjects With Solid Tumors|An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of Two Forms ofGSK1363089 in Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2011|May 31, 2012|August 26, 2008||||No||https://clinicaltrials.gov/show/NCT00742261||151115|
NCT00732524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #04-128|Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA|Combination of Sulfonylureas and Insulin Glargine as Safety Net Outpatient Therapy for Unstable Diabetes and Impending Diabetic Ketoacidosis (DKA)||John H. Stroger Hospital|Yes|Completed|September 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||August 2008|August 11, 2008|August 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732524||151855|
NCT00733421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008HV001|The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery|The Effect of Anti-inflammatory Analgesics on Bone Repair, Pain and Gastro-intestinal Side Effects After Hallux Valgus Surgery; a Prospective Randomised Double-blind Placebo Controlled Study.||Karolinska Institutet|No|Completed|October 2008|August 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|65 Years|No|||August 2009|January 15, 2010|August 12, 2008||No||No|December 7, 2009|https://clinicaltrials.gov/show/NCT00733421||151787|
NCT00733434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707036R|The Use of Prostaglandin E1 in Head and Neck Microsurgery|Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery|PGE1HNM|National Taiwan University Hospital|Yes|Recruiting|July 2008|July 2010|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|242|||Both|20 Years|80 Years|No|||October 2009|October 26, 2009|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733434||151786|
NCT00733772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSCX1-YW-02|Flaxseed Intervention on Metabolic Syndrome|The Effects of Flaxseed Supplement on Cardio-metabolic Risk Factors in Patients With Metabolic Syndrome|FIMS|Chinese Academy of Sciences|No|Completed|March 2009|December 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|35 Years|60 Years|No|||February 2015|February 4, 2015|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733772||151760|
NCT00734058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-AF-080808|SOLAR & ATRILAZE Atrial Fibrillation Trial|Atrial Fibrillation Treatment Using Laser Ablation of Cardiac Tissue During Concomitant Cardiac Surgery|SAAF-T|EndoPhotonix, Inc.|No|Not yet recruiting|December 2008|June 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||August 2008|August 12, 2008|August 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734058||151738|
NCT00734396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08.119|Mesenchymal Stem Cells and Subclinical Rejection|Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Allograft Rejection After Renal Transplantation|Measure|Leiden University Medical Center|No|Completed|February 2009|December 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||January 2013|January 4, 2013|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734396||151712|
NCT00734370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-2008-518|Virtual Reality Exposure Therapy in Agoraphobic Participants|Virtual Reality Exposure Therapy in Agoraphobic Participants||VU University of Amsterdam|No|Completed|October 2008|January 2012|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|65 Years|No|||March 2013|March 20, 2013|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00734370||151714|
NCT00734383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-70456|Propofol Cardioprotection for Type II Diabetics|PRO-TECT II: Propofol Cardioprotection for Type II Diabetics||University of British Columbia|Yes|Completed|April 2005|June 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|137|||Both|19 Years|29 Years|No|||July 2012|July 11, 2012|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734383||151713|
NCT00729885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V200601|Visual Feedback Goggle for Positional Vertigo Treatment|Visual Feedback Goggle For The Treatment Of Benign Paroxysmal Positional Vertigo in a Randomized Single-Blind Study||Vertigone Inc.|No|Active, not recruiting|November 2006|||August 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|80 Years|No|||August 2008|August 7, 2008|August 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00729885||152057|
NCT00730184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2510|Does Potassium Bicarbonate Improve the Effect of Dietary Protein on Bone and Muscle?|Does Potassium Bicarbonate Improve the Effect of Dietary Protein on Bone and Muscle?||Tufts University|No|Completed|February 2007|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|23|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00730184||152034|
NCT00730197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISO-0701|Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg|Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets(40 mg; Mylan) and Sular® Extended Release Tablets (40 mg; First Horizon) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|February 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2008|August 7, 2008|August 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00730197||152033|
NCT00730483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0739 CDR0000601054|Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors|Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|February 2009|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|August 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00730483||152011|
NCT00730496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803889|Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates|Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates of Day 3 Embryo Transfer: a Randomized Clinical Trial in Patients Who Underwent in Vitro Fertilization- Embryo Transfer.||Shen-Zhen City Maternity and Child Healthcare Hospital|Yes|Completed|January 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Female|23 Years|39 Years|Accepts Healthy Volunteers|||August 2008|November 4, 2010|July 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00730496||152010|
NCT00739622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010762|TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.|A Phase I, Open-label Drug-drug Interaction Trial to Investigate the Effect of TMC278 25 mg q.d. on the Steady State Pharmacokinetics of Ethinylestradiol and Norethindrone, in Healthy Women||Tibotec Pharmaceuticals, Ireland||Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|August 20, 2008||||No||https://clinicaltrials.gov/show/NCT00739622||151316|
NCT00741416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-08-US-0001|Biorepository: Indiana Health Study|Collection and Storage of Human Biological Materials (Blood Sample) and Linked Phenotypic Information (Health History) for Research Purposes|IHS|Fairbanks Institute|Yes|Recruiting|June 2008|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1400|Samples With DNA|70ml of whole blood: 3-10 ml EDTA tubes for collection of whole blood 3-10 ml SST tubes (red      tops) for collection of serum 2-3ml PAXgene tubes for collection of RNA A minimum of 1 EDTA      and 1 SST tube is required for enrollment into the study.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This initial study will include 750 individuals with CAD (the CAD Group) and 750        individuals who are age, gender, and ethnicity matched to the CAD Group, but without        presentation of clinical evidence of CAD (the Control Group). To reflect the growing        representation of Hispanics in Central Indiana, Hispanics will be overly recruited in both        groups so that the study population accurately reflects the general population of Central        Indiana.|June 2011|June 30, 2011|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741416||151180|
NCT00739596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AUS03|Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans|An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension|ATLAAST|Novartis|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|August 21, 2008|No|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00739596||151318|
NCT00739609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG2100|IDO Inhibitor Study for Relapsed or Refractory Solid Tumors|A Phase I Study of Indoximod [1-methyl-D-tryptophan (D-1MT)] in Patients With Relapsed or Refractory Solid Tumors|D-1MT|NewLink Genetics Corporation|Yes|Terminated|August 2008|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|August 20, 2008|Yes|Yes|Lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00739609||151317|
NCT00739934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501088|Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection|An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To <12 Years Who Are At High Risk For Systemic Fungal Infection||Pfizer|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|2 Years|11 Years|No|||January 2011|January 26, 2011|August 20, 2008|Yes|Yes||No|September 17, 2010|https://clinicaltrials.gov/show/NCT00739934||151294|
NCT00739947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3202V1-1000|Arthroscopic Surgical Outcome Study In Subjects With Rotator Cuff Tears|A Prospective Study To Evaluate Surgical Outcomes In Subjects With Full-Thickness Rotator Cuff Tears Treated By Means Of A Double-Row Arthroscopic Repair||Pfizer|No|Completed|October 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|||Both|21 Years|75 Years|No|Non-Probability Sample|Community Sample|July 2014|July 25, 2014|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00739947||151293|
NCT00740805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00262|Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma|A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2008|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|December 14, 2015|August 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00740805||151227|
NCT00740818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR1120070131|Logan Basic and Dysmenorrhea|A Pilot Study: Logan Basic Technique and Auxiliary Abdominal Contacts for Reducing Symptomatology of Primary Dysmenorrhea||Logan College of Chiropractic|No|Recruiting|July 2008|November 2008|Anticipated|November 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|30|||Female|18 Years|N/A|No|||August 2008|August 22, 2008|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740818||151226|
NCT00740480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA 2008-01|Study of the ENTact Septal Staple System for Tissue Approximation During Septoplasty|A Prospective, Non-Randomized, Limited-Use Evaluation of the ENTact Septal Staple System for Tissue Approximation During Septoplasties||ENTrigue Surgical, Inc.|No|Completed|April 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients (ages 18-65) with clinically significant nasal septum deviation.|August 2009|August 20, 2009|August 21, 2008|No|Yes||No|July 15, 2009|https://clinicaltrials.gov/show/NCT00740480||151252|
NCT00742794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-HVA-001|Frequency of Hymenoptera-stings in Patients Under Allergen-Specific Immunotherapy (SIT)|Frequency of Hymenoptera-stings in Patients Under and After Allergen-specific Immunotherapy: a Retrospective Data-analysis Considering Socio-economic Aspects|ZU-HVA-001|University of Zurich|Yes|Completed|August 2008|August 2010|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|5 Years|90 Years|No|Probability Sample|Hymenoptera sting allergic patients under allergen specific immunotherapy|September 2008|August 18, 2010|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742794||151075|
NCT00742807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/291|Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols|Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols||University Hospital, Ghent|No|Recruiting|August 2008|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|43 Years|No|||December 2014|December 4, 2014|August 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00742807||151074|
NCT00742820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-RTG-01-01|Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers|Randomized, Controlled, 3-Arm, Open Label, Cross-Over Bioequivalence Study Comparing Liquid PhosLo vs. PhosLo Gelcaps Using Calcium Citrate as a Positive Control in Healthy Volunteers||Fresenius Medical Care North America|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2009|February 6, 2009|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00742820||151073|
NCT00732563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000601525|Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery|Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer||Roswell Park Cancer Institute|Yes|Active, not recruiting|January 2004|March 2016|Anticipated|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|120 Years|No|||January 2016|January 14, 2016|August 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00732563||151852|
NCT00733096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-6891|A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy|||Johns Hopkins University|No|Completed|August 2008|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|70 Years|No|||September 2010|October 5, 2012|August 11, 2008||No||No|August 24, 2012|https://clinicaltrials.gov/show/NCT00733096||151812|Subjects who failed to obtain benefit were unblinded after 1-month, which limits conclusions regarding long-term efficacy.
NCT00733109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN 2|Management of Cervical Intraepithelial Neoplasia Grade 2|Management of Cervical Intraepithelial Neoplasia Grade 2|CIN2|Universidade Cidade de Sao Paulo|Yes|Completed|March 2003|July 2007|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|61 Years|No|||August 2008|January 8, 2010|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00733109||151811|
NCT00733122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_016|Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)|Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.||Merck Sharp & Dohme Corp.||Suspended|October 2009|October 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|600|||Female|16 Years|26 Years|Accepts Healthy Volunteers|||January 2011|January 13, 2011|August 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00733122||151810|
NCT00733135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHT-P-07-003|Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)|Determination of Safety and Effectiveness of the SilverHawk™ Peripheral Plaque Excision System for Calcium (SilverHawk LS-C) and the SpiderFX™ Embolic Protection Device for the Treatment of Calcified Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries (DEFINITIVE Ca++)||Medtronic Endovascular|No|Completed|October 2008|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|133|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|August 8, 2008|Yes|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00733135||151809|
NCT00733447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-142|SynCardia Freedom Driver System Study|SynCardia Freedom Driver System Study||SynCardia Systems. Inc.|Yes|Approved for marketing|March 2010|May 2014|Anticipated|August 2013|Actual|N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||July 2015|July 28, 2015|August 11, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00733447||151785|
NCT00733460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFPET P-01|A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET|A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of BFPET as a Potential Myocardial Perfusion Imaging (MPI) Agent for PET||Fluoropharma, Inc.|No|Completed|March 2008|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|August 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733460||151784|
NCT00733785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVA109939|PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers|A Two Cohort Study in Healthy Volunteers to Characterise the Pharmacokinetic Properties of the Rosiglitazone XR Formulation Manufactured at the GlaxoSmithKline Crawley Facility.|Rosi XR|GlaxoSmithKline|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|May 31, 2012|August 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00733785||151759|
NCT00733798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM601-011|A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma|A Phase 1/2, Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Melanoma||TransMolecular|No|Terminated||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||May 2009|May 8, 2009|August 11, 2008|No|Yes|For Strategic Reasons|No||https://clinicaltrials.gov/show/NCT00733798||151758|
NCT00734071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_310|An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder||Takeda|No|Completed|June 2008|March 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|August 11, 2008|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00734071||151737|
NCT00734084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 01/34|A Study to Evaluate the DePuy Minimally Invasive Unicompartmental Knee|A Prospective, Non-Comparative Multi-centre Study to Evaluate the Safety and Performance of the DePuy Minimally Invasive (Preservation) Unicompartmental Knee and Instrumentation.||DePuy International|No|Terminated|June 2001|April 2008|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|247|||Both|40 Years|75 Years|No|||June 2015|June 5, 2015|August 11, 2008|No|Yes|After a review of status, request of investigators & since similar data was available from    other sources|No||https://clinicaltrials.gov/show/NCT00734084||151736|
NCT00734409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00002117|Combining Objective and Subjective Sedation Assessment Tools|Combining Objective and Subjective Sedation Assessment Tools - Second Study|COST_2|Duke University|No|Completed|May 2008|July 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||August 2012|March 21, 2013|June 3, 2008|Yes|Yes||No|August 10, 2012|https://clinicaltrials.gov/show/NCT00734409||151711|
NCT00729898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3512|Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes|Safety of NovoMix® 30 (Biphasic Insulin Aspart) Treatment in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|243|||Both|N/A|N/A|No|Non-Probability Sample|Study population type 2 diabetes strated on NovoMix® 30|August 2014|August 11, 2014|August 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729898||152056|
NCT00729911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AATAC-AF|Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD|Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD||Texas Cardiac Arrhythmia Research Foundation|No|Active, not recruiting|October 2008|December 2015|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|August 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729911||152055|
NCT00729924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080536|Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid|Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid||Vanderbilt University|No|Completed|August 2008|August 2011|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 2, 2015|August 4, 2008|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00729924||152054|There were no limitations to this trial.
NCT00730210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT #008-000606-36)|Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life|Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life|HypoPTH|University of Aarhus|Yes|Completed|June 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|25 Years|80 Years|No|||October 2012|October 23, 2012|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00730210||152032|
NCT00730223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040062|Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors|Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors||Vanderbilt University|Yes|Completed|March 2004|August 2009|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|August 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00730223||152031|
NCT00730509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIVR_REUM_01|Effects of 5-Methyltetrahydrofolate and Vitamin B12 Supplemetation on Red Cell Membrane in Children With Cystic Fibrosis|Preliminary Evidences of Active Form of Folic Acid and Vitamin B12 Supplementation to Ameliorate Cell Membrane in Children With Cystic Fibrosis||Universita di Verona|No|Completed|April 2004|March 2006|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||May 2008|August 4, 2008|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00730509||152009|
NCT00730522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-02001|Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence|Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study||Catalyst Pharmaceuticals, Inc.|No|Terminated|July 2008|November 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|August 5, 2008|No|Yes|To conserve remaining capital, Sponsor decided to terminate the study early.|No||https://clinicaltrials.gov/show/NCT00730522||152008|
NCT00740259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flunarizine for schizophrenia|Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol|Is Flunarizine a Cheap, Well-Tolerated and Long-Acting Atypical Antipsychotic? A Randomized Double-Blind Flexible-Dose Clinical Trial Versus Haloperidol for the Treatment of Schizophrenia||Ambulatório de Bipolaridade|No|Completed|September 2004|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|70|||Both|18 Years|60 Years|No|||August 2008|August 20, 2008|August 20, 2008||||No||https://clinicaltrials.gov/show/NCT00740259||151269|
NCT00742287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 083056|Cardiovascular Effects of Oligomeric Procyanidins (OPCs) in Smokers|The Effects of Oligomeric Procyanidins (OPCs) on Vascular Function, Biomarkers of Oxidative Stress and Inflammation in Smokers: a Pilot Study|INC001|Maastricht University Medical Center|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|28|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 28, 2011|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00742287||151113|
NCT00740233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCAIM2008|Web-Based Survey of Pain, Stress and Complementary and Alternative Medicine||PROCAIM|University of California, Los Angeles|No|Completed|June 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|In general, participants will be: at least 18 years of age; ambulatory (i.e., not        depending upon a wheelchair for mobility); and meet general criteria for psychosomatic or        functional disorders including irritable bowel syndrome, other functional disorders,        fibromyalgia, chronic pain, or related mood and anxiety disorders.|February 2009|March 26, 2014|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00740233||151271|
NCT00740493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB06.019 PADIS TVP|Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)|Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Proximal Deep Vein Thrombosis: a Multicentre Double-Blind Randomized Controlled Trial. "PADIS-TVP" Study.|PADIS TVP|University Hospital, Brest|Yes|Active, not recruiting|July 2007|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|374|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|August 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00740493||151251|
NCT00741065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESWT,Version:02; May 21,2008|DESWT-Pilot Study on the Safety of Myocardial Regeneration by Direct Epicardial Shock Wave Therapy in Combination With Coronary Artery Bypass Grafting|DESWT-Pilot Study on the Safety of Myocardial Regeneration by Direct Epicardial Shock Wave Therapy in Combination With Coronary Artery Bypass Grafting|DESWT|Cardiac Regeneration Technologies, LLC|No|Active, not recruiting|September 2008|February 2010|Anticipated|June 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2010|February 10, 2010|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741065||151207|
NCT00741078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-200504|Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension|Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension||Gachon University Gil Medical Center|Yes|Completed|December 2004|August 2008|Actual|||Phase 4|Interventional|Intervention Model: Crossover Assignment, Primary Purpose: Treatment|1||||||Both|25 Years|75 Years|No|||August 2008|August 28, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00741078||151206|
NCT00733148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM1|Correlation Between the Interstitial and Arterial Glucose in Post Surgery Patients|Randomised Trial to Investigate the Correlation Between the Interstitial and Arterial Blood Concentrations of Glucose During Subcutaneous Microdialysis Glucose Monitoring in Post Surgery Patients at the Intensive Care Unit.||Medical University of Graz|Yes|Completed|July 2004|April 2005|Actual|January 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|40|||Both|18 Years|90 Years|No|Probability Sample|Patients with a blood glucose level of more than 120 mg/dl (6.7mM) at admission to the ICU        after surgery|August 2008|August 7, 2008|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00733148||151808|
NCT00732901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA 024157|Clinical Neurobiology of Serotonin and Addiction|Project 1: Clinical Neurobiology of Serotonin and Addiction||Virginia Commonwealth University|Yes|Completed|June 2008|February 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|160|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|August 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00732901||151827|
NCT00733811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOVCervello|Efficacy Study of the Use of Sequential DFP-DFO Versus DFP|Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients|SEQDFPDFO|Azienda Ospedaliera V. Cervello|Yes|Completed|September 2000|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|213|||Both|13 Years|60 Years|No|||July 2008|August 12, 2008|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00733811||151757|
NCT00734097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00116|A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)|An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)|NEON|AstraZeneca|No|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|314|||Both|18 Years|N/A|No|||August 2012|September 10, 2012|August 11, 2008||No||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00734097||151735|
NCT00734110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 99/24|Long-term Study of The Press Fit Condylar (P.F.C.) Sigma Total Knee Replacement System|Multi-Centre Clinical Study of the P.F.C.® Sigma Total Knee System||DePuy International|No|Terminated|July 2000|June 2010|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|723|||Both|N/A|N/A|No|||June 2015|June 5, 2015|August 11, 2008|No|Yes|The study achieved the stated objective to record pre & post operative outcomes at a minimum 5    years.|No||https://clinicaltrials.gov/show/NCT00734110||151734|
NCT00734448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myo-1954|Myo-inositol Administration in Gestational Diabetes|Effect of Myo-inositol Administration on Insulin Sensitivity in Gestational Diabetes Patients by Continuous Glucose Monitoring System (CGMS)||University of Messina|No|Recruiting|November 2013|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|April 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00734448||151708|
NCT00734461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-801-XM|Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse|A Single-Center, Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse||Pain Therapeutics|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||July 2011|April 27, 2015|August 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00734461||151707|
NCT00734422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-2007-226|Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants|Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants||VU University of Amsterdam|No|Completed|July 2008|July 2010|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|65 Years|No|||May 2011|August 3, 2011|August 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00734422||151710|
NCT00734435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZ-101|Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects|A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis||Orexigen Therapeutics, Inc|No|Terminated|September 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|No|||November 2012|November 27, 2012|August 12, 2008|Yes|Yes|Sponsor Decision- Financial Considerations|No||https://clinicaltrials.gov/show/NCT00734435||151709|
NCT00729937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0040|Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"|Strategies Using Off-Patent Antibiotics for Methicillin-Resistant Staphylococcus Aureus ("STOP MRSA") - A Phase IIB, Multi-Center, Randomized, Double-Blind Clinical Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2009|June 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2265|||Both|13 Years|N/A|No|||September 2013|January 29, 2015|August 7, 2008|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT00729937||152053|
NCT00730236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|733-005 / UP1002|A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)|A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy||Aegerion Pharmaceuticals, Inc.|Yes|Completed|December 2007|October 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2013|January 15, 2014|August 6, 2008|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00730236||152030|
NCT00730249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6520-0650-13|Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA|Quality Assurance of Administering Methylphenidate in Adults With ADHD|QUMEA|Medice Arzneimittel Pütter GmbH & Co KG|No|Completed|September 2008|||January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730249||152029|
NCT00730860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHB002|Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE|Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation Associated With Postoperative Transhepatic Arterial Chemoembolization——a Prospective Randomized Clinical Trial||Southwest Hospital, China|Yes|Recruiting|December 2008|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||November 2012|November 23, 2012|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00730860||151982|
NCT00730873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135/07|Fatty Liver and Obstructive Sleep Apnea|Fatty Liver and Obstructive Sleep Apnea||Assaf-Harofeh Medical Center||Completed||||||N/A|Interventional|Primary Purpose: Treatment|1||||||Both|30 Years|60 Years|No|||August 2008|August 7, 2008|August 6, 2008||||No||https://clinicaltrials.gov/show/NCT00730873||151981|
NCT00741130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2008-0076|Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT|Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT||Yonsei University|Yes|Recruiting|July 2008|January 2009|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers of our opthalmologic clinic|August 2008|August 25, 2008|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741130||151202|
NCT00741403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-CPI-613-002|A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies|An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients||Cornerstone Pharmaceuticals, Inc.|No|Active, not recruiting|August 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00741403||151181|
NCT00743119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5603|Characterization of the Analgesic Effects of Oral THC and Smoked Marijuana in Non-treatment Seeking Marijuana Smokers|Characterization of the Analgesic Effects of Oral THC and Smoked Marijuana in Non-treatment Seeking Marijuana Smokers||New York State Psychiatric Institute|No|Completed|June 2008|December 2012|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|26|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743119||151050|
NCT00742573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5692|Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics|Improving the Effectiveness of Treatment for Depression in Hispanics||New York State Psychiatric Institute|Yes|Active, not recruiting|August 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|79 Years|No|||December 2014|December 8, 2014|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00742573||151091|
NCT00739700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001777|Non-invasive Blood Pressure (BP) Monitoring Compared to A-Line BP Monitoring|Accuracy and Precision of Oscillometric Blood Pressure Monitoring in the Calf and Thighs of Medical ICU Patients When Compared to Invasive Arterial Blood Pressure Monitoring|NIBP vs IABP|Wake Forest School of Medicine|No|Active, not recruiting|June 2007|December 2016|Anticipated|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Medical Intensive Care Unit patients with intra-arterial blood pressure catheters will be        enrolled. Blood pressure cuff measurements will be made in both arms and both legs.|December 2014|December 12, 2014|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739700||151310|
NCT00740012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucoday BL|Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)|Blutzucker-Nachtprofile Mit Wecker Und Selbstmessungen gegenüber Fremdmessungen Durch Spezialisiertes Pflegepersonal: Eine Analyse Mittels Kontinuierlichem Glukose-Monitoring (Glucoday®)||Diabeteszentrum Bad Lauterberg im Harz|No|Completed|March 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|32|||Both|18 Years|75 Years|No|||September 2008|September 25, 2008|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00740012||151288|
NCT00740025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Sharara|Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART)|A Prospective Randomized Study of QD vs BID Dosing in ART|QD vs BID|Virginia Center for Reproductive Medicine|No|Completed|January 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Female|21 Years|39 Years|No|Non-Probability Sample|Women between 21-40 yo|October 2010|October 12, 2010|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00740025||151287|
NCT00743327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0107|Androgen Deprivation Therapy Study|Metabolic and Cardiovascular Complications in Men With Prostate Cancer Undergoing Long-term Androgen Deprivation Therapy|ADT|National Institutes of Health Clinical Center (CC)|No|Terminated|October 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1|Samples Without DNA|Serum, Muscle biopsy specimens|Male|18 Years|N/A|No|Probability Sample|Community sample of men ages 18 and older with prostate cancer|August 2012|August 3, 2012|August 26, 2008||No|No Participants completed study|No||https://clinicaltrials.gov/show/NCT00743327||151034|
NCT00743340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-162-0112|Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine|A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa With Continued Access to Emtricitabine||Gilead Sciences|No|Active, not recruiting|November 2005|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|1 Month|17 Years|No|||January 2016|January 25, 2016|August 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00743340||151033|
NCT00697892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6930-27654|Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations|Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combinations, Artesunate/Amodiaquine and Artemether/Lumefantrine.||University of California, San Francisco||Completed|July 2005|December 2010|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||May 2013|June 4, 2013|June 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00697892||154477|
NCT00733473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.0.İEG.0.11.00.01-3246|Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing|Phase 4 Study of Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing||Kecioren Education and Training Hospital|No|Completed|September 2007|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|6 Months|6 Years|No|||December 2011|December 17, 2011|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00733473||151783|
NCT00698490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208141/015|Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines|Study to Compare, in Healthy HSV Seronegative and HSV Seropositive Subjects, the Humoral and Cellular Immune Response of Herpes Simplex Candidate Vaccines Containing gD From Two Different Cell Lines and Using gD-Alum as Control||GlaxoSmithKline||Completed|August 1995|January 1997|Actual|January 1997|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|130|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2008|June 16, 2008|June 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698490||154433|
NCT00698503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12380-6|A Clinical Investigation of the M2a- 38™ Hip System|M2a- 38™ Hip System Prospective Data Collection||Biomet, Inc.||Terminated|January 2002|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|190|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have already made the decision to undergo Total Hip Replacement and will        receive the M2a- 38™ Hip System|October 2012|March 19, 2014|June 13, 2008|No|Yes|due to low follow up|No||https://clinicaltrials.gov/show/NCT00698503||154432|
NCT00698828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBI 307|SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease||Daiichi Sankyo Inc.|No|Completed|March 2008|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|225|||Both|50 Years|N/A|No|||October 2015|October 19, 2015|May 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00698828||154408|
NCT00698841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-315|Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors|A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors||Eli Lilly and Company|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 16, 2008|Yes|Yes||No|April 14, 2011|https://clinicaltrials.gov/show/NCT00698841||154407|
NCT00699088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomet 13594-117|A Clinical Investigation of the Balance® Microplasty™ Hip System|A Prospective, Non-controlled, Clinical Investigation of the Balance® Microplasty™ Hip System||Biomet, Inc.|No|Completed|January 2005|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients requiring relief from painful or disabling joint disease|March 2013|March 19, 2013|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00699088||154390|
NCT00729950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX010-15|Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma|An Open-Label Pharmacokinetic and Safety Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma||Bristol-Myers Squibb|No|Completed|July 2003|June 2007|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||April 2010|April 23, 2010|August 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00729950||152052|
NCT00730262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLN-4601-201|Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme|A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme||Thallion Pharmaceuticals|No|Terminated|August 2008|June 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2009|December 29, 2009|August 6, 2008|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00730262||152028|
NCT00699699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.426|Observational Non-Interventional Study With Spiriva Respimat in COPD Patients|Assessment of Physical Activity (PF10 Sub Domain of SF-36 Activity Score) and Tolerability in COPD Patients During Treatment With Spiriva® Respimat®||Boehringer Ingelheim||Completed|June 2008|||January 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1280|||Both|18 Years|N/A|No|Non-Probability Sample|Patients|March 2014|March 12, 2014|June 17, 2008||||No|January 13, 2010|https://clinicaltrials.gov/show/NCT00699699||154345|
NCT00730535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-08-069|Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients|Exploring Predictors of Symptoms Relapse After Discontinuation of Successful Treatment With a Tolterodine Prolonged Release Capsules (4 mg, Once Daily) in Overactive Bladder Patients: A Prospective Randomized Multicenter Trial||Samsung Medical Center|Yes|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|173|||Female|18 Years|80 Years|No|||April 2011|April 21, 2011|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00730535||152007|
NCT00730548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_7|Compare Remote Patient Management and Standard Care in CRT-D and ICD-patients to Assess the Effect on Heart Failure|Clinical Evaluation to Assess the Effect of the Combination of a Pre-Defined Management Pathway to Reduce Fluid Overload in Cardiac Decompensation With Carelink Remote Management, Connexus Remote Telemetry and the OptiVol Early Warning System on Health Care Utilization|ConnectOptiVol|Medtronic Bakken Research Center|No|Completed|November 2007|August 2013|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00730548||152006|
NCT00700310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-306|Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures||Eisai Inc.||Completed|August 2008|January 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|712|||Both|12 Years|120 Years|No|||November 2015|December 17, 2015|June 17, 2008|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT00700310||154298|
NCT00700596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707002884|Effects of Salvinorin A in Healthy Controls|Psychotomimetic Effects of Kappa Opioid Receptor Agonist Salvinorin A in Healthy Controls||Yale University||Active, not recruiting|January 2009|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|41|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00700596||154276|
NCT00700323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-NV-263|PS-Omega3 Supplementation to Attention Deficit Hyperactivity Disorder (ADHD) Children|Phase 2b Study of PS-Omega3 Conjugate Supplementation to ADHD Diagnosed Children|ADHD-3|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|8 Years|13 Years|No|||June 2008|June 17, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700323||154297|
NCT00742001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-0040|Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival|IMPROVE: Inactivation of Whole Blood With Mirasol (R): Performance in Red Blood Cells, Platelets and Plasma Investigation|IMPROVE|Terumo BCTbio|No|Terminated|September 2008|September 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 15, 2010|August 25, 2008|No|Yes|An endpoint difference between 3 energies was not observed. Correlations between recovery and    ATP were established, and will be used for a Whole Blood system.|No||https://clinicaltrials.gov/show/NCT00742001||151135|
NCT00743366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5685|Effect of Quetiapine on Marijuana Withdrawal and Relapse|Effect of Quetiapine on Marijuana Withdrawal and Relapse||New York State Psychiatric Institute|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|20|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|August 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00743366||151031|
NCT00740311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD06/9-O|Filling of Tooth Sockets With MBCP Gel TM Versus Technical Without Filling|Comparative Clinical Study of the Prevention of the Reduction of Alveolar Crest by Alveoli Filling With an Injectable Calcium Phosphate After Extraction of Mandibular Molar or Pre Molar||Nantes University Hospital||Recruiting|November 2007|May 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|75 Years|No|||June 2010|June 1, 2010|August 21, 2008||||No||https://clinicaltrials.gov/show/NCT00740311||151265|
NCT00739375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112|The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.|The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.||Shaare Zedek Medical Center|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|August 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00739375||151334|
NCT00740831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL07-022|PGL4001 Versus GnRH-agonist in Uterine Myomas|A Phase III, Randomised, Parallel Group, Double-blind, Double-dummy, Active Comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of PGL4001 vs GnRH-agonist for Pre-operative Ttt of Symptomatic Uterine Myomas|PEARLII|PregLem SA|Yes|Completed|August 2008|June 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|301|||Female|18 Years|50 Years|No|||December 2012|December 13, 2012|August 22, 2008||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT00740831||151225|
NCT00741091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2029|A Carotid Stenting Boston Scientific Surveillance Program|A Carotid Stenting Boston Scientific Surveillance Program Carotid WALLSTENT Monorail Endoprosthesis FilterWire EZ™ Embolic Protection System|CABANA|Boston Scientific Corporation|No|Completed|December 2008|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1097|||Both|18 Years|N/A|No|||August 2011|August 22, 2011|August 25, 2008|No|Yes||No|June 2, 2011|https://clinicaltrials.gov/show/NCT00741091||151205|
NCT00741949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/29|Broncho-alveolar Lavage Under Noninvasive Ventilation With Propofol TCI in Patient With AHRF|Fiberoptic Bronchoscopy With Broncho-alveolar Lavage Under Noninvasive Ventilation With Propofol Target Controled Infusion in Patient With Acute Hypoxemic Respiratory Failure. A Randomized Controlled Study : SEDA-FIBRO.|SEDA-FIBRO|University Hospital, Bordeaux|No|Completed|September 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|90 Years|No|||August 2011|August 25, 2011|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741949||151139|
NCT00741962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adaptogen Study 001|A Study on the Effects of VR-3 Herbal Blend Intake on Acute and Chronic Stress in Healthy Adults|A Pilot Double-Blind Crossover Study on the Effects of VR-3 Herbal Blend Intake on Acute and Chronic Stress and Their Biomarkers in Healthy Adults||NEMA Research, Inc.||Completed|August 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Both|35 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 11, 2009|August 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00741962||151138|
NCT00751686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109355|Estimation of the Burden of Rotavirus Gastroenteritis (RV GE) in Children Less Than 5 Years in Greece|To Estimate the Burden of Rotavirus Gastroenteritis (RV GE) in Children < 5 Years of Age in Greece||GlaxoSmithKline||Completed|July 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|128|Samples Without DNA|Stool sample|Both|N/A|5 Years|No|Non-Probability Sample|Children < 5 years of age seen at the selected hospital sites for acute GE (e.g. subjects        treated at the hospital or visiting the emergency room for an acute GE episode or        developed acute GE at least 48 hours after hospitalisation) with a rapid screen positive        test result to RV.|February 2013|February 14, 2013|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751686||150398|
NCT00751946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-035H-2|Girls In Recovery From Life Stress (GIRLS) Study|Girls In Recovery From Life Stress (GIRLS) Study|GIRLS|University of Connecticut Health Center|Yes|Completed|March 2006|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|13 Years|17 Years|No|||September 2010|September 24, 2010|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751946||150379|
NCT00697905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 06-01|Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma|An Open Labeled, Multicentre, Randomized Phase II Trial of Combination Gemcitabine and Carboplatin Chemotherapy in Patients With Metastatic or Recurrent Nasopharyngeal Carcinoma||Ministry of Health, Malaysia|No|Completed|January 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||April 2010|November 20, 2014|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00697905||154476|
NCT00698165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHE 1100|Observational Study on Costs and Caregiver Burden in Alzheimer's Disease|Observational Study on Costs and Caregiver Burden in Alzheimer's Disease||AstraZeneca|No|Completed|June 2007|January 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|2400|||Both|N/A|N/A|No|Non-Probability Sample|Adults with Alzheimer's Disease and their informal caregivers are recruited from both        outpatient settings and long-term residential care settings|February 2009|February 19, 2009|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00698165||154456|
NCT00698516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104864/111127|Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer|An Open-label, Multicenter, Non-comparative, Phase II Study of Oral Topotecan in Combination With Bevacizumab for Second-line Treatment in Subjects With Relapsed Small-cell Lung Cancer (SCLC)||GlaxoSmithKline|No|Completed|July 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2011|March 22, 2012|June 16, 2008||Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00698516||154431|
NCT00698529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079730|Effectiveness of Communication Technology in Disseminating HIV Prevention Training to Non-governmental Organizations|Communication Technology to Disseminate Evidence-Based HIV Interventions to NGOs||Medical College of Wisconsin|No|Active, not recruiting|November 2008|June 2016|Anticipated|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|99|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 16, 2015|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00698529||154430|
NCT00698854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.K005|A Clinical Investigation of the Vanguard™ Complete Knee System|A Prospective, Non-controlled, Clinical Investigation of the Vanguard™ Complete Knee System||Biomet, Inc.|No|Enrolling by invitation|March 2004|January 2026|Anticipated|January 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in need of relief from painful or disabling joint disease|April 2015|June 22, 2015|June 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00698854||154406|
NCT00699101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENORX-S07-002|Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy|A Multi-site Prospective, Non Randomized Study Utilizing the Conture® Multi-Lumen Balloon (MLB) Breast Brachytherapy Applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use||SenoRx, Inc.|Yes|Terminated|June 2008|June 2013|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|342|||Both|50 Years|N/A|No|||June 2013|June 14, 2013|June 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00699101||154389|
NCT00699413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCORE1|Supplements for Controlling Resistance to Insulin|Supplements for Controlling Resistance to Insulin|SCORE|University of Southern California|No|Terminated|February 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||June 2008|March 24, 2009|June 16, 2008|Yes|Yes|Sponsor decided to withdraw from study.|No||https://clinicaltrials.gov/show/NCT00699413||154366|
NCT00700024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030|Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men|The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men||Odense University Hospital|Yes|Active, not recruiting|April 2008|February 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Male|65 Years|78 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00700024||154320|
NCT00700037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wakayamamu08-001|Change in Plaque Characteristics With Atorvastatin|Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography|EASY-FIT|Wakayama Medical University|No|Completed|August 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|75 Years|No|||October 2014|October 28, 2014|June 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00700037||154319|
NCT00700297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rrc-23|Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease|A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet`s Disease||Tehran University of Medical Sciences|Yes|Completed|August 2002|May 2006|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|169|||Both|14 Years|60 Years|No|||May 2008|June 17, 2008|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00700297||154299|
NCT00765661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP - Tacro 2017|Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients|A Phase 2, Open-Label, Multi-Center, Randomized Trial To Demonstrate The Pharmacokinetics Of LCP-Tacro™ Tablets Once Daily and Prograf® Capsules Twice Daily In Adult De Novo Kidney Transplant Patients||Veloxis Pharmaceuticals|No|Completed|September 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|October 2, 2008|Yes|Yes||No|July 9, 2014|https://clinicaltrials.gov/show/NCT00765661||149335|
NCT00766532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0144|Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?|Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?||University of Wisconsin, Madison|Yes|Completed|January 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Female|N/A|N/A|No|||September 2012|September 13, 2012|October 2, 2008||No||No|July 6, 2012|https://clinicaltrials.gov/show/NCT00766532||149269|
NCT00762476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM&R-0062-08-TXC|Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses|A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II EFFICACY TRIAL OF AV LOTION (FORMULA NO. 3804-250A) FOR THE PREVENTION OF COLD ILLNESS IN HUMAN SUBJECTS||The Dial Corporation|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|411|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|September 26, 2008|Yes|Yes||No|February 8, 2012|https://clinicaltrials.gov/show/NCT00762476||149578|
NCT00762463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191348|Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis|A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy||Pfizer|No|Completed|July 2009|August 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|65 Years|No|||July 2011|July 26, 2011|September 29, 2008|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00762463||149579|The protocol does not specify time points for secondary endpoints; these are described in the statistical analysis plan.
NCT00762762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004000685|Investigate Plaque and Gingival Index|Investigate Plaque and Gingival Index||Colgate Palmolive|Yes|Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|September 26, 2008|Yes|Yes||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00762762||149556|
NCT00763035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hundley-2|Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)|Comparison of Dobutamine and Regadenoson Stress CMR||Wake Forest Baptist Health|No|Terminated|January 2009|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|40 Years|85 Years|No|||April 2010|July 28, 2011|September 26, 2008|Yes|Yes|Potential participants with COPD/asthma unwilling to participate.|No||https://clinicaltrials.gov/show/NCT00763035||149535|
NCT00763373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antibiotic Switch|Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch|Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch||Sorlandet Hospital HF|No|Completed|November 2006|March 2007|Actual|January 2007|Actual|Phase 3|Observational|N/A||2|Actual|187|||Both|15 Years|N/A|No|||September 2008|September 29, 2008|August 16, 2007||No||No||https://clinicaltrials.gov/show/NCT00763373||149510|
NCT00763685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35195|Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery|Double-Blind, Randomized, Placebo -Controlled Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery||East Tallinn Central Hospital|No|Terminated|June 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|40|||Female|18 Years|50 Years|No|||January 2012|January 29, 2012|September 30, 2008||No|The gynecological laparoscopic surgery transition to day surgery made following the study    protocol not possible.|No||https://clinicaltrials.gov/show/NCT00763685||149486|
NCT00763672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051060|MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study|Impact of a Single Second-trimester Plasma sFlt-1 and/or Urinary PlGF Assay on Maternofetal Morbidity/Mortality|MOMA|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2008|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1040|||Female|18 Years|50 Years|No|||March 2013|March 26, 2013|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763672||149487|
NCT00763958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA019838|Relapse Prevention to Reduce HIV Among Women Prisoners|Relapse Prevention to Reduce HIV Among Women Prisoners||University of Alabama at Birmingham|Yes|Completed|May 2008|September 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Female|19 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 1, 2012|September 29, 2008|No|Yes||No|February 4, 2011|https://clinicaltrials.gov/show/NCT00763958||149466|Slow recruitment with poor retention. Transient population that was difficult to effectively track.
NCT00763971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-325|Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17|A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire||Completed|October 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|336|||Both|6 Years|17 Years|No|||August 2013|June 6, 2014|September 30, 2008|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00763971||149465|
NCT00761189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015079|PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia|An Open Label, Prospective, Non-comparative Study to Evaluate Flexible Dose of Paliperidone Extended-Release and Clinical Response in the Treatment of Subjects With Schizophrenia|PANDORA|Janssen Korea, Ltd., Korea|No|Completed|February 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|491|||Both|18 Years|65 Years|No|||January 2014|January 22, 2014|September 25, 2008|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT00761189||149675|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.
NCT00761501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00001|Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E|Phase I, Open-label, Randomized, 3-way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E in Healthy Volunteers||AstraZeneca|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761501||149652|
NCT00761514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W06-407|Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira|Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR)|VIVIR|Abbott|No|Terminated|November 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||October 2009|October 23, 2009|September 25, 2008||No|The study was terminated due to low enrollment.|No|August 26, 2009|https://clinicaltrials.gov/show/NCT00761514||149651|This study was terminated early due to lack of enrollment. Only 7 subjects completed 24 weeks of treatment. That number is too small to provide reliable data on the effectiveness of the treatment.
NCT00761813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR055267|Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)|Fixation Using Alternative Implants for the Treatment of Hip Fractures: A Multi-Centre Randomized Trial Comparing Sliding Hip Screws and Cancellous Screws on Revision Surgery Rates and Quality of Life in the Treatment of Femoral Neck Fractures||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1500|||Both|50 Years|N/A|No|||June 2015|June 17, 2015|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761813||149628|
NCT00762138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM 306|The AutoloGel™ Post-Market Surveillance (TAPS) Program|The AutoloGel™ Post-Market Surveillance (TAPS) Program|TAPS|Cytomedix|Yes|Terminated|September 2008|June 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|131|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||February 2014|February 25, 2014|September 24, 2008||No|Discontinued due to favorable results|No||https://clinicaltrials.gov/show/NCT00762138||149603|
NCT00757484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25003|Evaluation of Postoperative Blood Pressure Changes After Benign Gynecologic Surgery|Evaluation of Postoperative Blood Pressure Changes After Benign Gynecologic Surgery||University of Rochester|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|528|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Gynecologic patients|May 2015|December 15, 2015|September 19, 2008||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00757484||149959|
NCT00757497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080211|Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia|Safety of Transcranial Direct Current Brain Stimulation (TDCS) for Improvement of Psychotic Symptoms and Cognitive Functioning in Childhood Onset Schizophrenia (COS)||National Institutes of Health Clinical Center (CC)||Terminated|September 2008|August 2015|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|20|||Both|10 Years|N/A|No|||August 2015|August 19, 2015|September 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00757497||149958|
NCT00757406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQLDEX02|Assessment of Unilateral Lymphoedema of the Leg|Assessment of Unilateral Lymphoedema of the Leg||ImpediMed Limited|Yes|Completed|August 2008|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1 - Test group - will be recruited through advertisements placed at Qld Lymphoedema        and Breast Oncology Physiotherapy, Lymphoedema Association of QLD, Gynecological Cancer        Support Group and notification to other private therapists to inform them of the study.        Group 2 - Control group - will be through advertisements placed at Qld Lymphoedema and        Breast Oncology Physiotherapy.|April 2009|April 14, 2009|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00757406||149965|
NCT00757419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00030|AZD3355 Dose-escalation Study in Healthy Males|A Phase 1 Single Centre Single-blind Randomised Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD3355 After Administration of Single Ascending Doses and Multiple Repeated Doses in Healthy Male Volunteers||AstraZeneca|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757419||149964|
NCT00757432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25638|Recovery After Robotic Urogynecological Surgery: The Patient's Perspective|Recovery After Robotic Urogynecological Surgery: The Patient's Perspective||University of Rochester|No|Completed|September 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|22|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who underwent DaVinci-assisted laparoscopic surgery|April 2011|April 8, 2011|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757432||149963|
NCT00757783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015439|Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment|A Multicenter, Open-label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-daily Darunavir Versus Atazanavir in HIV-infected Treatment-naive Adult Patients||Tibotec, Inc||Completed|October 2008|July 2012|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|99 Years|No|||November 2015|November 30, 2015|September 19, 2008|Yes|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00757783||149936|65 subjects were enrolled/treated in the main study. 3 subjects were enrolled, randomized, not treated and excluded from analyses (n=68). An additional 18 subjects were enrolled in a substudy extension and excluded from the main analyses.
NCT00765934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RapydanClinicalChemistry|Influence of Rapydan on Clinical Chemistry and Hematology Measurements|Does Rapydan Influence Routine Clinical Chemistry and Hematology Measurements?||LabNoord|Yes|Completed|November 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 17, 2010|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765934||149314|
NCT00766207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS017093-01|Electronic Notification of Teratogenic Risks|Preconception Risk Evaluation Via Electronic Medical Record Notification of Teratogenic Risks|PREVENT|University of Pittsburgh|Yes|Completed|October 2008|May 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|2593|||Female|18 Years|45 Years|No|||May 2011|May 11, 2011|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00766207||149293|
NCT00766545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-91-001|Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.|Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.|CSPS|Otsuka Pharmaceutical Co., Ltd.|Yes|Completed|April 1992|March 1997|Actual|March 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1095|||Both|20 Years|80 Years|No|||January 2009|January 8, 2009|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766545||149268|
NCT00766558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28860|The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population|Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology||Penn State University|Yes|Not yet recruiting|November 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|50|||Both|14 Years|50 Years|No|Non-Probability Sample|Patients in the Penn State Hershey Adolescentand Adult Eating Disorders Partial        Hospitalization Program|September 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766558||149267|
NCT00766506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015211|An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery|Comparison of Ionsys and Routine Care With Morphine IV (Intravenous) PCA in the Management of Early Post-operative Mobilisation, Ability to Mobilise and in Time to Fitness For Discharge||Janssen-Cilag Ltd.|No|Terminated|May 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|October 3, 2008|Yes|Yes|Product class one recall|No|January 21, 2013|https://clinicaltrials.gov/show/NCT00766506||149271|Study was temporarily stopped due to an issue with a batch of drug outside the study and later permanently stopped.
NCT00766519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01436-47|Effect of Intraoperative Volume Optimization on Outcome After Intrabdominal Surgery|Effect of Intraoperative Volume Optimization on Outcome After Intrabdominal Surgery: a Multicenter, Randomized, Double-blind, Comparative Study|EVOLUTION|University Hospital, Lille|No|Completed|February 2009|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766519||149270|
NCT00762489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28148|Comparison of Three Methods of Taking Temperatures in the Well Baby Nursery|Comparison of Temporal Artery, Axillary, and Rectal Temperatures in Newborn Patients in the Well Baby Nursery.||Christiana Care Health Services|No|Completed|October 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment|2||Actual|104|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||April 2011|April 28, 2011|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762489||149577|
NCT00762788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-4472|Clinical Trial of Several Contact Lenses in Extended Wear|||Johnson & Johnson Vision Care, Inc.||Completed|February 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|6||Actual|350|||Both|18 Years|39 Years|No|||June 2015|June 1, 2015|September 26, 2008|Yes|Yes||No|September 11, 2014|https://clinicaltrials.gov/show/NCT00762788||149554|Cautions for results: low completed enrollment numbers and number of non-neophytes lower than required per protocol. Arms not gender matched; Proportion of neophytes/non-neophytes not balanced; High rate of drop-out among subjects enrolled.
NCT00762775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33497|The Interaction Between Calcium and Vitamin D Intake|The Interaction Between Calcium and Vitamin D Intake|PTH Modified|Winthrop University Hospital|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|78|||Female|45 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762775||149555|
NCT00763386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-500|A Study to Compare the NexGen LPS and LPS-Flex Knee Implants|Prospective Randomized Multicenter Study of NexGen LPS-Flex Knee||Zimmer, Inc.|No|Completed|June 2001|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|331|||Both|21 Years|80 Years|No|||May 2012|May 25, 2012|September 26, 2008||No||No|December 13, 2011|https://clinicaltrials.gov/show/NCT00763386||149509|
NCT00763698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 435|Safety and Efficacy Study of the QuickFlex Micro Model 1258T Left Heart Pacing Lead|QuickFlex Micro Model 1258T Left Heart Pacing Lead||St. Jude Medical|No|Completed|October 2008|May 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|September 29, 2008|Yes|Yes||No|July 26, 2011|https://clinicaltrials.gov/show/NCT00763698||149485|
NCT00763711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1006|Injectable Bulking Agent Needle Guide|Injectable Bulking Agent Needle Guide|NG|Carbon Medical Technologies|No|Terminated|June 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|N/A|N/A|No|||January 2012|January 9, 2012|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763711||149484|
NCT00763997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA3480005|Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages|Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation||Ruhr University of Bochum|No|Completed|February 2004|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|80|||Both|18 Years|80 Years|No|||September 2008|September 29, 2008|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763997||149463|
NCT00764257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111990-0104-3|PREVELLE Shape (CX002) Dermal Filler Protocol|A Multicenter, Evaluator-Masked Study to Assess the Efficacy and Safety of Mentor's CX002 Dermal Filler Medical Device, When Applied as an Intradermal Implant for the Correction of Facial Wrinkles and Lip Augmentation (CX002 Dermal Filler Protocol)||Mentor Worldwide, LLC|Yes|Completed|October 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|N/A|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 19, 2011|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764257||149443|
NCT00763984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01NR007618-06A1|Self-Care to Prevent Birth-Related Urinary Incontinence in Diverse Women|PERL 4: Promoting Effective Recovery From Labor||University of Michigan|Yes|Completed|October 2007|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|432|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763984||149464|
NCT00761527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05634|Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)|Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients||Merck Sharp & Dohme Corp.|No|Completed|March 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|2980|||Both|6 Months|11 Years|No|Non-Probability Sample|A total of 3000 prospective outpatient pediatric participants with either allergic        rhinitis or chronic idiopathic urticaria will be enrolled in the study coming from about        300 sites in the Phillipines|July 2015|July 15, 2015|September 25, 2008|No|Yes||No|November 4, 2011|https://clinicaltrials.gov/show/NCT00761527||149650|
NCT00762164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA---19-07-01|Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol|Comparative Efficacy of a Vytorin 10/80 Tablet Split Into 4 (Estimated Dose Ezetimibe 2.5 + Simvastatin 20) Versus Simvastatin 20 Milligrams on LDL Cholesterol||Bronx VA Medical Center|No|Completed|March 2007|May 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 19, 2013|September 29, 2008||No||No|April 16, 2013|https://clinicaltrials.gov/show/NCT00762164||149601|
NCT00762177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0108-BACT-PS-NJ|Investigate Oral Bacteria in Adult Population|Investigate Oral Bacteria in Adult Population||Colgate Palmolive|No|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2011|February 22, 2011|September 26, 2008|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00762177||149600|
NCT00761826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL 80-2006-2|Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism|A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D||Carl Zeiss Meditec, Inc.|Yes|Completed|January 2007|December 2009|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 22, 2013|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761826||149627|
NCT00761839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XVA 41-027|Does Use of a Wound After-care Summary Improve Patient Satisfaction and Time to Wound Healing?|Does Use of a Wound After-care Summary Improve Patient Satisfaction and Time to Wound Healing?||VA Office of Research and Development|No|Withdrawn|July 2008|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|September 29, 2008||No|Study was withdrawn because of a problem with the software used for generating the aftercare    summary.|No||https://clinicaltrials.gov/show/NCT00761839||149626|
NCT00762151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN0128 Periodontal Plaque|A Study to Investigate the Anti-Plaque Effect of AN0128 Toothpaste|Clinical Research Study to Investigate the Anti-Plaque Effect of a Prototype Toothpaste Containing an Anacor Material Via the MGMPI Method||Anacor Pharmaceuticals, Inc.|No|Completed|November 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|June 22, 2015|September 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762151||149602|
NCT00757510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006304|Congenital Heart Disease Research Registry|Congenital Heart Disease Research Registry|CHDRR|Emory University|No|Terminated|January 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|861|Samples With DNA|Blood and serum collected from Registry subjects will be cryopreserved for potential future      genetic and/or protein-based studies.|Both|N/A|N/A|No|Non-Probability Sample|All patients with suspected or diagnosed with congenital heart disease receiving care at        Children's Healthcare of Atlanta or Emory University Adult Congenital Heart Clinic|December 2014|December 8, 2014|September 22, 2008||No|Insufficient funding|No||https://clinicaltrials.gov/show/NCT00757510||149957|
NCT00757523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S194 -401|Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris|A Multi-center, Randomized, Evaluator-blind, Parallel-group Evaluation of the Efficacy, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Topical Treatment of Facial Acne Vulgaris||GlaxoSmithKline|No|Completed|September 2008|June 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|12 Years|45 Years|No|||July 2011|July 11, 2011|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00757523||149956|
NCT00757458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDTA-652|Evaluation of Bacterial and Fungal Contamination During Propofol Continuous Infusion|Evaluation of Bacterial and Fungal Contamination During Propofol Continuous Infusion in Patients Undergoing General Anesthesia||University of Sao Paulo|Yes|Not yet recruiting|December 2008|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|652|||Both|18 Years|N/A|No|||September 2008|September 22, 2008|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757458||149961|
NCT00757471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-5-CI-2008|Brillant Blue Versus Indocyanine Green for Macular Hole Surgery|Membranepeeling With Brillant Blue Versus Membranepeeling With Indocyanine Green for Patients With Idiopathic Macular Holes.||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|August 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00757471||149960|
NCT00757796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143/06|Obstructive Sleep Apnea Syndrome and Attention Executive Function Disturbances|Obstructive Sleep Apnea Syndrome and Attention Executive Function Disturbances||Assaf-Harofeh Medical Center||Not yet recruiting|October 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|20 Years|70 Years|No|Probability Sample|Patients aged 20 - 70 years with obstructive sleep apnea.|September 2008|September 21, 2008|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00757796||149935|
NCT00757809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1116|Study Evaluating The Tolerability Of Multiple Doses Of HKI-272|A Blinded, Randomized, Multiple-Dose, Parallel Group Study to Characterize the Occurrence of Mild to Moderate Diarrhea After Administration of Neratinib Either 240-mg Once Daily or 120-mg Twice Daily for 14 Days to Healthy Subjects||Puma Biotechnology, Inc.|No|Completed|October 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|September 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00757809||149934|
NCT00757822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-008-08S|Prevention of Postoperative Nausea and Vomiting in Surgical Patients|Prevention of Postoperative Nausea and Vomiting in Surgical Patients|PONV|VA Office of Research and Development|Yes|Active, not recruiting|December 2009|March 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757822||149933|
NCT00766246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-009|Phase II Avastin Trial for Stage IIIB/IV NSCLC|A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer||Pharmatech|Yes|Active, not recruiting|October 2008|August 2013|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00766246||149290|
NCT00766259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eng-MRSA|Relationship of Staphylococcal Colonization to Infection|Relationship of Staphylococcal Colonization to Infection||Veterans BioMedical Research Institute|No|Not yet recruiting|July 2009|June 2012|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|4400|None Retained|only bacterial strains collected|Both|N/A|N/A|No|Non-Probability Sample|all patients admited|October 2008|October 2, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766259||149289|
NCT00762502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-4498|Comparison of Senofilcon A Toric Lenses to Balafilcon A Toric Lenses Over Extended Wear Period|Comparison of Senofilcon A Toric Lenses to Balafilcon A Toric Lenses Over Extended Wear Period||Johnson & Johnson Vision Care, Inc.|No|Completed|June 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|112|||Both|18 Years|45 Years|No|||May 2015|May 6, 2015|September 26, 2008|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00762502||149576|
NCT00762515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2007-GIN-03-RR|Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes|Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes||Colgate Palmolive|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 14, 2010|September 26, 2008|Yes|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00762515||149575|
NCT00762528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-1107-INF-ECU-FP|Compare Anti-inflammatory Dentifrices|Compare Anti-inflammatory Dentifrices||Colgate Palmolive|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|September 26, 2008|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT00762528||149574|
NCT00766818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #06-0653|The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet|The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet: A Longitudinal Investigation in the Second and Third Trimesters Including Empiric Dosage Adjustment||University of North Carolina, Chapel Hill|No|Completed|January 2007|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||May 2011|May 11, 2011|October 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00766818||149248|
NCT00763061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-06-02|Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension|A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|May 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|September 26, 2008||No||No|April 28, 2009|https://clinicaltrials.gov/show/NCT00763061||149533|
NCT00763074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obesity_2006_1|Exercise and Diet in Type 2 Diabetic Women|Clinical Trial of Exercise and Diet in Type 2 Diabetic Women||Eulji University Hospital|Yes|Completed|April 2006|March 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|70|||Female|N/A|N/A|No|||September 2008|December 11, 2008|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763074||149532|
NCT00762801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-32|Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects|Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects|RLIP76 Healthy|University of North Texas Health Science Center|Yes|Recruiting|September 2008|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|100 healthy volunteers|September 2008|April 16, 2010|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762801||149553|
NCT00763048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2007-GIN-05-GB|Collection of Gingival Crevicular Fluid From Periodontitis Patients|Collection of Gingival Crevicular Fluid From Periodontitis Patients||Colgate Palmolive|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|26 Years|68 Years|Accepts Healthy Volunteers|||June 2011|June 10, 2011|September 26, 2008|Yes|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00763048||149534|
NCT00763724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12016|Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults|A Propensity-Matched Retrospective Cohort Study of Antidepressant Drug Exposure and Risk of Suicide Attempt in Adults From a Large U.S. Managed Care Population||Eli Lilly and Company|No|Completed|June 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||7|Actual|254432|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be based on data from the PharMetrics Patient-Centric Database, a        commercially available claims database provided by PharMetrics, Inc., a Unit of IMS.|March 2010|March 9, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763724||149483|
NCT00763737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220084540|Randomized Control Trial of Fetoscopic Endoluminal Tracheal Occlusion With a Balloon Versus Expectant Management During Pregnancy in Fetuses With Left Sided Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia.|Randomized Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) Versus Expectant Management During Pregnancy in Fetuses With Left Sided and Isolated Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia.|TOTAL|University Hospital, Gasthuisberg|Yes|Recruiting|September 2008|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Female|18 Years|N/A|No|||September 2008|January 11, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763737||149482|
NCT00763750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-Brain-223|BrUOG-Brain-223:A Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103)|BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.||Brown University|Yes|Completed|October 2008|July 2012|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|September 30, 2008|Yes|Yes||No|May 9, 2013|https://clinicaltrials.gov/show/NCT00763750||149481|
NCT00764010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175|Diet and Omega-3 Intervention Trial on Atherosclerosis|Diet and Omega-3 Intervention Trial on Atherosclerosis|DOIT|Oslo University Hospital|Yes|Completed|May 1997|December 2001|Actual|December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|563|||Male|64 Years|76 Years|No|||September 2008|June 30, 2011|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00764010||149462|
NCT00764283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/278|The Prevention of Postoperative Epidural Catheter Migration: a Comparison of Three Types of Dressing|The Prevention of Postoperative Epidural Catheter Migration: a Comparison of Three Types of Dressing||University Ghent|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|200|||Both|18 Years|N/A|No|||April 2009|April 14, 2009|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764283||149441|
NCT00764595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615628|Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor|Phase II Multicenter Clinical Trial on Imatinib Treatment for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)||National Cancer Institute (NCI)||Active, not recruiting|October 2008|||September 2014|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|20 Years|N/A|No|||July 2009|September 19, 2013|October 1, 2008||||No||https://clinicaltrials.gov/show/NCT00764595||149417|
NCT00764270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT002034-2|The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease|The Role of R-alpha Lipoic Acid in Treatment of Atherosclerotic Vascular Disease||Oregon State University|Yes|Active, not recruiting|August 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|50 Years|70 Years|No|||June 2015|June 4, 2015|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764270||149442|
NCT00764569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-DOD-LAMMP- 2008-6355|The Investigation of a Fluorescence/Elastic Scattering Spectroscopy (F-ESS) Device for Oral Tissue Characterization|a Non-invasive Device for the Detection, Diagnosis and Screening of Oral Pathology||University of California, Irvine|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|N/A||1|Actual|77|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|August 2015|August 5, 2015|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764569||149419|
NCT00762190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-559-016|Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus||Takeda|No|Terminated|November 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|348|||Both|25 Years|65 Years|No|||November 2012|November 8, 2012|September 26, 2008|Yes|Yes|Hepatic safety signal identified.|No||https://clinicaltrials.gov/show/NCT00762190||149599|
NCT00762216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-08-001|Rotational Stability of the AcrySof® Toric|Rotational Stability of the AcrySof® Toric||Alcon Research|No|Completed|May 2008|||June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|40 Years|80 Years|No|||May 2010|October 26, 2012|September 26, 2008|Yes|Yes||No|April 14, 2010|https://clinicaltrials.gov/show/NCT00762216||149598|
NCT00757536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-3-CI-2008|Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment|Primary Vitrectomy Combined With 360° Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment (V.E.E. Study)||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|May 2006|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00757536||149955|
NCT00757887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHMI-8B|Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites|Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites||Radboud University|Yes|Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2009|November 8, 2010|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757887||149929|
NCT00757900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRU02 (Ethics ref no 080212)|Efficacy of Influenza Vaccine in HIV Infected Adults|Efficacy of Influenza Vaccine in HIV Infected Adults||University of Witwatersrand, South Africa|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|507|||Both|18 Years|55 Years|No|||September 2008|October 8, 2008|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757900||149928|
NCT00758173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000589199|Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Prostate Cancer in East Anglia, Trent and West Midlands||National Cancer Institute (NCI)||Recruiting|February 2008|||||N/A|Observational|N/A|||Anticipated|2000|||Male|18 Years|74 Years|No|||September 2008|August 23, 2013|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00758173||149907|
NCT00757835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6219|24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG|24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma||Aristotle University Of Thessaloniki|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|85 Years|No|||May 2014|May 9, 2014|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757835||149932|
NCT00757848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00009|A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis|A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Cystic Fibrosis|INCA|AstraZeneca|No|Completed|October 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|56|||Both|16 Years|N/A|No|||August 2012|August 14, 2012|September 22, 2008|Yes|Yes||No|January 24, 2012|https://clinicaltrials.gov/show/NCT00757848||149931|
NCT00758134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2007-001|Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients|Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509)||Istituto Clinico Humanitas|No|Terminated|July 2008|December 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2013|May 27, 2013|September 22, 2008||No|Insufficient accrual|No||https://clinicaltrials.gov/show/NCT00758134||149910|
NCT00758147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGC085012CTIL|Force Feedback Joystick in Upper Limb Rehabilitation Following Stroke|Assessment of Force Feedback Joystick in Upper Limb Rehabilitation Following Stroke||Rabin Medical Center|Yes|Not yet recruiting|November 2008|June 2010|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|65 Years|86 Years|No|||September 2008|September 22, 2008|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00758147||149909|
NCT00766272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-0003|Lokomat Training Effects on MS Gait Abnormalities|Gait Rehabilitation for Multiple Sclerosis Using Robot-assisted Body-weight-supported Treadmill Training (Lokomat)||VA Office of Research and Development|No|Terminated|June 2008|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||September 2013|September 19, 2013|October 2, 2008||No|Study re-designed|No||https://clinicaltrials.gov/show/NCT00766272||149288|
NCT00766285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0069|High Dose Influenza in Immunosuppressed Subjects|Safety and Immunogenicity of High Dose Baculovirus-Expressed Recombinant Trivalent HA Influenza Vaccine in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: Phase II Double-Blind Trial||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||December 2009|July 30, 2015|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766285||149287|
NCT00766298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406003|Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss|Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss|SHELL|University of Pittsburgh|Yes|Active, not recruiting|June 2004|December 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|102|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||March 2009|March 25, 2009|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766298||149286|
NCT00762554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|goodman-1|Depodur vs Fentanyl Infusion for Post-C/S Analgesia|A Comparison of Single Dose Depodur With Fentanyl Infusion for Post-Cesarean Section Analgesia||Goodman, Evan, M.D.|Yes|Not yet recruiting|October 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2008|September 29, 2008|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762554||149572|
NCT00762827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001875|The Impact of Reducing Inflammation on Vascular Function in the Metabolic Syndrome|The Impact of Reducing Inflammation on Vascular Function in the Metabolic Syndrome||Brigham and Women's Hospital|No|Completed|November 2005|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2011|June 24, 2011|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762827||149551|
NCT00766831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014806|An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain|Hydromorphone OROS in Korean Cancer Patients: Evaluation of Its Clinical Usefulness in Improvement of Sleep Disturbance||Janssen Korea, Ltd., Korea|Yes|Completed|October 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|20 Years|N/A|No|||September 2013|September 13, 2013|October 3, 2008|Yes|Yes||No|June 19, 2013|https://clinicaltrials.gov/show/NCT00766831||149247|
NCT00763763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030425|Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive|Study to Evaluate Efficacy and Safety of Glivec® in Combination With Vincristine and Dexamethasone in Patients With Lymphoid Blast Crisis CML or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Relapse or Refractory|AFR07|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2004|January 2010|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||October 2011|October 4, 2011|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00763763||149480|
NCT00763399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-0549B|Effect of Probiotics on Intestinal Bacterial Population and Immune Modulation|Phase 4 Study of Probiotics on Intestinal Bacterial Population and Immune Modulation||Chang Gung Memorial Hospital|Yes|Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|300|||Both|3 Months|10 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00763399||149508|
NCT00764296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-003|Collection of Samples for the Evaluation of Wound Biofilm in Acute and Chronic Wounds|Collection of Samples for the Evaluation of Wound Biofilm in Acute and Chronic Wounds||Southwest Regional Wound Care Center|Yes|Completed|December 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|Samples With DNA|The debridement sample will be processed to extract DNA for 16s rDNA evaluation in order to      determine the microbial population of the sample using a more sensitive means than standard      culture.|Both|18 Years|N/A|No|Non-Probability Sample|The Specific Aim of examining wounds microscopically is to attempt to demonstrate the        presence of biofilm in chronic wounds and to understand these populations on a cellular        level.|September 2011|September 6, 2011|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764296||149440|
NCT00764309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-267|Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis|An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis||Bristol-Myers Squibb|No|Completed|January 2009|April 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|October 1, 2008|Yes|Yes||No|January 30, 2012|https://clinicaltrials.gov/show/NCT00764309||149439|
NCT00764608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-012|Study of the Human Skin Microbiome|Study of the Human Skin Microbiome||Southwest Regional Wound Care Center|Yes|Withdrawn|June 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|Samples With DNA|The subjects' samples will be analyzed using DNA methods in order to identify the types of      microbes present on the swabs. Other substances such as proteins, RNA, and other metabolites      may also be analyzed. DNA or other molecular components of the sample will be extracted.      Alternately, microbes in the sample can be cultured directly. The samples will be explored      using molecular analyses. The backbone of the analyses will be shotgun metagenomic      sequencing and 16S rDNA amplicon sequencing. The results of these analyses will be used to      identify and describe the microbiome of the skin.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|It is the goal of the study to survey multiple skin locations of humans at multiple time        points|November 2015|November 24, 2015|September 30, 2008||No|No Participants enrolled, per PI discretion|No||https://clinicaltrials.gov/show/NCT00764608||149416|
NCT00764933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PfVMS-T4|Structured Information During the Intensive Care Unit Stay|A Randomized Controlled Multi Center Study to Evaluate the Efficacy of a Structured Information Program During ICU Stay||Martin-Luther-Universität Halle-Wittenberg|No|Completed|January 2008|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|211|||Both|18 Years|N/A|No|||January 2010|June 1, 2010|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764933||149391|
NCT00764946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-055|A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)|A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients||Merck Sharp & Dohme Corp.||Completed|October 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|209|||Both|16 Years|N/A|No|||July 2015|July 6, 2015|October 1, 2008|Yes|Yes||No|February 13, 2012|https://clinicaltrials.gov/show/NCT00764946||149390|
NCT00764907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613220|Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia|A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Recruiting|November 2002|||October 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|4000|||Both|N/A|18 Years|No|||July 2009|July 7, 2009|October 1, 2008||||No||https://clinicaltrials.gov/show/NCT00764907||149393|
NCT00764920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2008-6307|Skin Imaging With Technologies in Development|Non-invasive Imaging Modalities for Assessment of Normal and Lesional Skin||University of California, Irvine|No|Recruiting|October 2008|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|N/A||1|Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from University of California Irvine Medical Clinic|February 2016|February 5, 2016|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764920||149392|
NCT00761852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-003331Ruboxistaurin|Signaling Mechanisms and Vascular Function in Diabetes Mellitus|Signaling Mechanisms and Vascular Function in Diabetes Mellitus||Brigham and Women's Hospital|Yes|Completed|May 1999|October 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2008|September 29, 2008|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761852||149625|
NCT00761865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23552|Lateral Ankle Sprain Study|Lateral Ankle Sprain Study||University of Rochester|No|Terminated|October 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|September 29, 2008||No|low enrollment|No|December 3, 2013|https://clinicaltrials.gov/show/NCT00761865||149624|
NCT00761878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI-2007-07|Evaluation of the PlasmaJet Neutral Argon Plasma System to Treat Skin Ageing|Evaluation of the PlasmaJet Neutral Argon Plasma System for Skin Regeneration and Comparison With the Rhytec Portrait PSR Plasma System||Plasma Surgical Inc|No|Completed|December 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2009|July 3, 2009|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761878||149623|
NCT00761891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061190|Validation of an Assay to Measure Cyclooxygenase-1 Activity|Validation of an Ex Vivo Cyclooxygenase-1 Catalytic Assay in Humans||Vanderbilt University|No|Completed|May 2007|January 2010|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761891||149622|
NCT00757549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC057M|3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx|Comparison of FLT and FDG PET in the Evaluation of Response to Cetuximab, Cisplatin and Radiation Therapy in Advanced Head and Neck Malignancies or Response to Standard Chemo-radiotherapy in Esophageal Malignancies||Mayo Clinic|Yes|Active, not recruiting|September 2008|||August 2011|Actual|Phase 0|Interventional|Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00757549||149954|
NCT00757913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 92/08|n-3 Enriched Nutrition Therapy and Postoperative Cognitive Dysfunction After Cardiac Surgery|The Effect of n-3 Enriched Nutrition Therapy on Postoperative Cognitive Dysfunction and Delirium After Elective Cardiac Surgery||University Hospital, Basel, Switzerland||Terminated|September 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|65 Years|N/A|No|||February 2010|February 23, 2010|September 22, 2008||No|Insufficient recruitment rate|No||https://clinicaltrials.gov/show/NCT00757913||149927|
NCT00758186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colonic-Stenting-001|Randomized Trial of Colonic Stents as a Bridge to Surgery|Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-Sided Malignant Colonic Obstruction: A Prospective Randomized Trial.||Singapore General Hospital|No|Completed|October 2004|June 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2008|September 23, 2008|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758186||149906|
NCT00758199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0036|Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery|Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery||Bp Consulting, Inc|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|80 Years|No|||March 2012|March 14, 2012|September 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00758199||149905|
NCT00757874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StJustineH|Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus|A Double Blind Phase II Study Comparing Safety and Efficacy of Tacrolimus Versus Topical Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus.||St. Justine's Hospital|No|Completed|April 2006|January 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Female|2 Years|N/A|No|||September 2015|September 5, 2015|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757874||149930|
NCT00758160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015331|The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD||Johnson & Johnson Taiwan Ltd|No|Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|296|||Both|6 Years|18 Years|No|||March 2014|March 10, 2014|September 19, 2008|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00758160||149908|
NCT00766844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC 2007-0899|Cervical Spinal Cord Stimulation for the Prevention of Cerebral Vasospasm|Cervical Spinal Cord Stimulation for the Prevention of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Using MTS Trial System 3510||University of Illinois at Chicago|Yes|Completed|April 2008|November 2009|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|65 Years|No|||January 2013|January 21, 2013|October 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00766844||149246|
NCT00762814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0890|The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease|The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease||Washington University School of Medicine|Yes|Terminated|May 2008|June 2009|Anticipated|March 2009|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|50 Years|80 Years|No|||June 2009|June 24, 2009|September 23, 2008||No|There was no funding for the device to be used in the study.|No||https://clinicaltrials.gov/show/NCT00762814||149552|
NCT00764049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050902|Single Pass Albumin Dialysis in Patients With Cirrhosis|Prospective Pilot Study Assessing Safety and Efficacy of Single Pass Albumin Dialysis in Patients With Acute on Chronic Liver Failure|DACAR|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2009|July 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764049||149459|
NCT00764322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0801|Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen|Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|June 2008|August 2015|Anticipated|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|501|||Female|21 Years|N/A|No|||November 2013|November 1, 2013|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764322||149438|
NCT00764023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-010|A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host-Microbe Scientific Study|A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune,or Host-Microbe Scientific Study||Southwest Regional Wound Care Center|Yes|Completed|March 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|97|Samples With DNA|The intent of this protocol is to salvage human-related material that is normally destined      for destruction, so it can be used in infection-related scientific studies|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The samples can include material such as wound debridement, removed orthopedic implants,        removed catheters or shunts, excised tonsils, amputated tissue, sputum, stool, or other        excretions.|November 2015|November 24, 2015|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764023||149461|
NCT00764036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M33/2|Study of Artesunate in Metastatic Breast Cancer|Prospective Open Uncontrolled Phase I Study of Compatibility, Safety&Pharmacokinetics of Artesunate, a Semisynthetic Derivative of Artemisinin From the Chinese Herb Artemisia Annua in Patients With Metastatic/Locally Advanced Breast Cancer|ARTIC-M33/2|Heidelberg University|Yes|Active, not recruiting|October 2008|September 2011|Anticipated|August 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||February 2009|July 14, 2011|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764036||149460|
NCT00764621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91789|Health Economic Evaluation of Primovist-enhanced Liver MRI|Multi-center, Randomized Comparison Study to eVALUatE Outcomes and Resource Needs of Imaging and Treatment Following Primovist-enhanced MRI of the Liver in Comparison to Extracellular Contrast Media (ECCM)-Enhanced MRI and Contrast-enhanced Computed Tomography (CT) in Patients With a History of Colorectal Cancer and Known or Suspected Metachronous Liver Metastases.||Bayer|No|Completed|October 2008|November 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|360|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764621||149415|
NCT00764959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 800|Retrospective Study of the Linear™ Hip|Post-Market Study of the Linear™ Hip System||Encore Medical, L.P.|No|Terminated|October 2007|February 2011|Actual|February 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who meet the indications for use of the Linear Hip device AND who meet the        inclusion/exclusion criteria|February 2011|February 8, 2011|September 30, 2008|Yes|Yes|Enrollment and data collection insufficient to continue study.|No||https://clinicaltrials.gov/show/NCT00764959||149389|
NCT00764972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McG 0713|Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer|A Phase IB/II Trial of Combination of Vinorelbine With Sorafenib (BAY 43-9006) as First-Line Treatment in Patients With Metastatic Breast Cancer||McGill University|Yes|Recruiting|October 2007|December 2011|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|19 Years|65 Years|No|||October 2008|October 17, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764972||149388|
NCT00765258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00008209|Utility of CT Fluoroscopy Guidance During Percutaneous Sacroplasty With Quality of Life Assessment|Utility of CT Fluoroscopy Guidance During Percutaneous Sacroplasty With Quality of Life Assessment||Medical College of Wisconsin|No|Completed|January 2008|February 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Patient's with pain and decreased mobility as a result of sacro-iliac insufficiency        fracture(s).|August 2013|August 19, 2013|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765258||149366|
NCT00765271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT026|Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects|A Study Investigating Plasma Abacavir and Its Intracellular Anabolite Carbovir-triphosphate Pharmacokinetics in the Absence and in the Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects.||St Stephens Aids Trust|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||November 2009|November 17, 2009|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765271||149365|
NCT00758550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-06-17|Visual Function After Bilateral Implantation of AcrySof® Toric|Visual Function After Bilateral Implantation of AcrySof® Toric||Alcon Research|No|Completed|April 2007|||June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|80 Years|No|||March 2010|March 4, 2010|September 23, 2008||No||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00758550||149878|
NCT00758888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0801080145|Effect of Orthopedic Blocking on Cervical Spine Flexion and Extension Strength|Effect of Orthopedic Blocking on Cervical Spine Flexion and Extension Strength||Logan College of Chiropractic|No|Recruiting|September 2008|October 2008|Anticipated|October 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2008|July 23, 2009|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758888||149852|
NCT00761566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012617|The Effect of Remote Preconditioning on the Exercise Performance of the Elite Swimmers|Double Blind Randomized Controlled Trial of the Effect of Remote Preconditioning on the Exercise Performance of the Elite Swimmers||The Hospital for Sick Children|No|Completed|October 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|24|||Both|13 Years|22 Years|Accepts Healthy Volunteers|||August 2013|August 14, 2013|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761566||149647|
NCT00761579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015250|Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission|An Open-Label Prospective, Non-Comparative Study To Explore The Tolerability, Safety and Effectiveness Upon Transition to Paliperidone Slow-Release Tablet in Schizophrenic Patients|PERFECT|Janssen Korea, Ltd., Korea|No|Completed|April 2008|December 2010|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|18 Years|65 Years|No|||May 2014|May 1, 2014|September 25, 2008|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00761579||149646|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.
NCT00762255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15629|A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma|A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2008|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|September 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762255||149595|
NCT00757588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-057|Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin|A Multicenter, Randomized, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin||AstraZeneca|Yes|Completed|November 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|455|||Both|18 Years|78 Years|No|||May 2015|May 8, 2015|September 22, 2008|Yes|Yes||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00757588||149951|
NCT00762229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA---19-07-051|Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)|Prospective Evaluation of LDL Levels in Patients Converted From Zetia (Ezetimibe)10 mg to 5 mg||Bronx VA Medical Center|Yes|Completed|July 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|39|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|September 29, 2008||No||No|April 17, 2013|https://clinicaltrials.gov/show/NCT00762229||149597|
NCT00762242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000669|Metabolomic Profiling of Novel Mediators of Vascular Function|Metabolomic Profiling of Novel Mediators of Vascular Function||Brigham and Women's Hospital|Yes|Terminated|May 2007|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|48|Samples Without DNA|plasma samples for assays of novel biomarkers|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|August 2013|August 15, 2013|September 26, 2008||No|Study enrollment was no adequate.|No||https://clinicaltrials.gov/show/NCT00762242||149596|
NCT00757562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02994|Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)|Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages >=2 to <12 Years, Who Are Poor Metabolizers of Desloratadine||Merck Sharp & Dohme Corp.|No|Completed|November 2002|October 2003|Actual|October 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|2 Years|12 Years|No|||April 2015|April 27, 2015|September 22, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00757562||149953|
NCT00757575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4424|Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan|Epidemiological Surveillance Network Study To Assess the Disease of Pneumonia in Infants and Children in Japan||Pfizer|Yes|Completed|February 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28511|||Both|N/A|60 Months|No|Non-Probability Sample|Infants and children less than 5 years of age living in Okinawa and Eastern Hokkaido.|March 2012|March 26, 2012|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757575||149952|
NCT00757926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL/BRV-TV/PhI/2008/0100|Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants|Phase I/II, Randomized, Double-blind, Placebo-controlled, Staged Dosage Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Infants Concurrently With Other Standard EPI Vaccines||Shantha Biotechnics Limited|Yes|Withdrawn|September 2009|September 2010|Anticipated|August 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|240|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||February 2010|February 2, 2010|September 22, 2008||No|Replaced with an alternate study|No||https://clinicaltrials.gov/show/NCT00757926||149926|
NCT00758212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|azw6gmHHMO-CTIL|Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem|Influenza Vaccination at a Reduced Dose of 1:10 Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem||Hadassah Medical Organization|No|Enrolling by invitation|November 2008|April 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||September 2008|October 8, 2008|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758212||149904|
NCT00758446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX914-001|Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis|A Double-blind, Randomized, Placebo-controlled, Cross-over, Allergen Challenge Study to Evaluate the Efficacy, Safety and Tolerability of BLX-028914 in Subjects With Allergic Rhinitis||Dart NeuroScience, LLC|No|Completed|September 2008|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|50 Years|No|||March 2013|March 12, 2013|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00758446||149886|
NCT00758784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-S&E-0417082-P|Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease|||Bausch & Lomb Incorporated|No|Completed|August 2008|||June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|September 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758784||149860|
NCT00758797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU1213|A Novel Treatment for Metastatic Melanoma|In Situ Photoimmunotherapy: A Tumor Directed Treatment for Advanced Melanoma With Cutaneous Metastases||Northwestern University|Yes|Terminated|April 2008|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|June 23, 2008|Yes|Yes|Study was not renewed during annual Northwestern Cancer Center review.|No||https://clinicaltrials.gov/show/NCT00758797||149859|
NCT00766857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2008exe001|Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure|The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial||VU University Medical Center|No|Completed|May 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766857||149245|
NCT00762541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL 80-2006-1|Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia|A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D||Carl Zeiss Meditec, Inc.|Yes|Completed|October 2006|July 2009|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 22, 2013|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762541||149573|
NCT00763412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1109|Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis|Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis||Arbelaez, Ana Maria|Yes|Completed|November 2006|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|12 Years|24 Years|No|||January 2013|January 28, 2013|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763412||149507|
NCT00763425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200888|Prospective Randomized Comparison of Cold Snare Polypectomy and Conventional Polypectomy||COLD|Showa Inan General Hospital|No|Completed|September 2008|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|20 Years|N/A|No|||November 2015|November 17, 2015|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763425||149506|
NCT00763438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12009A|Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia|A Prospective, Open-label, Single-arm, Multinational, Multi-centre, Flexible-dose, Extension Study of the SCoP 99824 With Sertindole for Patients Suffering From Schizophrenia||H. Lundbeck A/S|No|Completed|November 2007|October 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763438||149505|
NCT00762840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apexum Trial|Safety and Efficacy of the Apexum Ablator|Clinical Study to Evaluate the Safety and Efficacy of the Apexum Ablator in Subjects With Periapical Lesions Associated With Root Canal Infection||Apexum Ltd.|No|Recruiting|October 2006|||April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2009|June 4, 2009|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762840||149550|
NCT00763087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0953|Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet|Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet||Washington University School of Medicine|Yes|Completed|September 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|43|||Both|40 Years|90 Years|No|||March 2011|March 10, 2011|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00763087||149531|
NCT00764647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02-1779|Education Program for Family Caregivers|Evaluation of Education Program for Family Caregivers of Frail Elders||CAMC Health System|No|Active, not recruiting|March 2006|February 2017|Anticipated|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764647||149413|
NCT00764985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTOP-08-024|Evaluation of Syncope,Its Diagnosis, Treatment, Outcome and Prognosis|E-STOP Registry: A Registry for the Evaluation of Syncope,Its Diagnosis, Treatment, Outcome and Prognosis Using Our SELF-Pathway|E-STOP|St. Luke's-Roosevelt Hospital Center|No|Completed|June 2008|July 2010|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|540|||Both|18 Years|N/A|No|Non-Probability Sample|All patietns admitted to the adult medicine service at St. Luke's-Roosevelt Hospital with        diagnossi of syncope or near syncope|July 2010|July 1, 2010|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764985||149387|
NCT00764335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2005.1527b|Treatment and Rehabilitation of Patients With Hip Arthroplasty to Regain Walk and Work Efficiency and Quality of Life|Treatment and Rehabilitation of Patients With Hip Arthroplasty to Regain Walk and Work Efficiency and Quality of Life||Norwegian University of Science and Technology|No|Completed||July 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4||40|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Subjects selected from orthopaedic out-patient department|June 2010|June 22, 2010|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764335||149437|
NCT00761332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11837|Back Pain in Patients With Severe Osteoporosis|An Observational Study to Assess Back Pain in Patients With Severe Osteoporosis Treated With Teriparatide Versus Antiresorptives||Eli Lilly and Company|No|Completed|February 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|650|||Both|40 Years|N/A|No|Non-Probability Sample|Routine clinical practice|June 2011|June 20, 2011|September 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761332||149665|
NCT00761683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORO-ZOL-2007/1|Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS|Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS|ESIS|AstraZeneca|No|Terminated|October 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Female|18 Years|N/A|No|Probability Sample|The programme will include the patients diagnosed with endometriosis that the doctors have        already decided to treat with Zoladex within the last month, before inclusion in this        program.|September 2009|September 8, 2009|September 26, 2008||No|Anticipated number of patients not achieved. All Patients recruited in the study completed all    study visits.|No||https://clinicaltrials.gov/show/NCT00761683||149638|
NCT00761696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-926-01|A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies|A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies||Infinity Pharmaceuticals, Inc.|No|Completed|September 2008|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|September 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761696||149637|
NCT00761709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-28|Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761709||149636|
NCT00761982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVISEV-01|Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.|Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment||Hospital Universitario Central de Asturias|No|Completed|September 2008|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||November 2011|November 27, 2011|September 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00761982||149615|
NCT00759564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8811009|A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function|An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function||Pfizer|No|Completed|November 2008|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|29|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|September 23, 2008|No|Yes||No|December 11, 2015|https://clinicaltrials.gov/show/NCT00759564||149800|
NCT00761904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001010|The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians|A Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples|SAMPLES|Brigham and Women's Hospital|No|Not yet recruiting|December 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|660|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2010|May 3, 2010|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761904||149621|
NCT00760734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU IRB #7051|Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)|HBOT in Chronic Traumatic Brain Injury/Post Concussion Syndrome and TBI/PTSD Pilot Trial||Louisiana State University Health Sciences Center in New Orleans|Yes|Completed|September 2008|June 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||January 2015|January 1, 2015|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760734||149710|
NCT00757601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-002|A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)|A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK1006.||Merck Sharp & Dohme Corp.|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|25|||Both|18 Years|55 Years|No|||February 2016|February 4, 2016|September 22, 2008|No|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00757601||149950|
NCT00757939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-068|A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)|A Two-Part Cross-Sectional and Longitudinal Study to Assess Regional Cerebral Blood Flow by Dynamic Arterial Spin Labeling as an Alzheimer's Disease Biomarker as Compared to FDG-PET in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects||Merck Sharp & Dohme Corp.|No|Completed|September 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|55 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757939||149925|
NCT00758225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN T-II-001-E|Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)|A Phase II Open-label Extension Study to Obtain Long-term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001||Santhera Pharmaceuticals|Yes|Completed|September 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Male|N/A|N/A|No|||May 2011|May 30, 2011|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758225||149903|
NCT00758238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-42213|Development and Pilot-Testing of a Patient Self Management Approach for Hypertension Using Personal Electronic Health Records|Evidence-Based Development and Initial Evaluation of a Facilitated Patient Self Management e Health Strategy Intervention for Hypertension|myBP|McMaster University|No|Not yet recruiting|September 2008|September 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|40 Years|N/A|No|||September 2008|September 23, 2008|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758238||149902|
NCT00758459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4260C00003|Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236as an Oral Tablet in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|CERA|AstraZeneca|No|Completed|September 2008|March 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|40 Years|N/A|No|||July 2011|July 25, 2011|September 23, 2008||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00758459||149885|
NCT00758472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET UK 08|ReCap Total Hip Resurfacing Prospective Data Collection|ReCap Total Hip Resurfacing Prospective Data Collection||Biomet, Inc.|No|Terminated|March 2005|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suitable for Total Hip Resurfacing|May 2012|May 4, 2012|September 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00758472||149884|
NCT00758810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608999|Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors|Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors, Daily Physical Activity, Dietary Habits and Blood Glucose and Fatty Acids in Coronary Syndromes Patients|OLIMPIC|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|354|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with acute coronary syndrome or myocardial infarctus|June 2009|June 16, 2009|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00758810||149858|
NCT00763464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD female 2006-MB|Coronary Artery Disease (CAD) in Postmenopausal Women|Coronary Artery Disease in Postmenopausal Women. Comparison of Myocardial Szintigraphy With Sress-Echocardiography and Stress-MRI.|FEMCAD|RWTH Aachen University|No|Completed|October 2006|June 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|40 Years|N/A|No|||July 2011|July 6, 2011|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763464||149503|
NCT00763789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-031|Local Anaesthesia and Remifentanil Sedation Versus Total Intravenous Anaesthesia for Hysteroscopic Surgery in an Ambulatory Surgery Department.|Local Anaesthesia and Remifentanil Sedation Versus Total Intravenous Anaesthesia for Hysteroscopic Surgery in an Ambulatory Surgery Department. A Randomized Clinical Trial.||Copenhagen University Hospital at Herlev||Recruiting|August 2008|September 2010|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|96|||Female|18 Years|N/A|No|||January 2010|January 5, 2010|September 30, 2008||||No||https://clinicaltrials.gov/show/NCT00763789||149478|
NCT00764062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040408|Amoxicillin Susceptibility of Oral Streptococci After a 3-Day or a 7-Day Amoxicillin Therapy|Randomized Controlled Trial Short Antibiotic Therapy (3-Day) Versus Long Antibiotic Therapy (7-Day) in Odontology-Stomatology: Impact on the Resistance of Oral Streptococci|ODAMOX|Assistance Publique - Hôpitaux de Paris|No|Terminated|September 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|60 Years|No|||September 2008|September 30, 2008|September 30, 2008||No|The trial was stopped earlier than planned because of the slow accrual rate.|No||https://clinicaltrials.gov/show/NCT00764062||149458|
NCT00763776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K070105|Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector|Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector : Randomized Comparative Study.|SECCI|Assistance Publique - Hôpitaux de Paris|No|Terminated|July 2008|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||January 2011|February 26, 2014|September 30, 2008||No|difficulty for the patient recruiting|No||https://clinicaltrials.gov/show/NCT00763776||149479|
NCT00761059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-905|Analgesic Efficacy of Oral Glucose in Preterm Neonates During Suctioning|Prospective, Placebo-Controlled Blinded Clinical Trial to Study the Efficacy of Orally Administered Glucose 20% for Relieving Pain During Nasopharyngeal Suctioning in Preterm Infants > 1500g Under CPAP-Therapy|Glucose FG|University of Cologne|No|Recruiting|October 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|N/A|N/A|No|||February 2009|February 24, 2009|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00761059||149685|
NCT00765804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-002|Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye|Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for Treatment of Dry Eye in the Controlled Adverse Environment Model||Eyegate Pharmaceuticals, Inc.|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|89|||Both|12 Years|N/A|No|||August 2010|August 27, 2010|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765804||149324|
NCT00761033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-010908|Music to Reduce Pain and Anxiety in the Pediatric Emergency Department|Music to Reduce Pain and Anxiety in the Pediatric Emergency Department: a Randomized Controlled Trial of Children 3-6 Years Undergoing Intravenous Placement||University of Alberta|No|Completed|October 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|3 Years|6 Years|No|||April 2010|April 16, 2010|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761033||149687|
NCT00761046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET DE 02|Retrospective Study on Cenos Stem With BoneMaster HA|Retrospective Study on Cenos Stem With BoneMaster HA||Biomet, Inc.|No|Withdrawn|October 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients Who Received CENOS prosthesis for Intended Uses|December 2011|December 2, 2011|September 25, 2008||No|No data have been obtained at all in this time.|No||https://clinicaltrials.gov/show/NCT00761046||149686|
NCT00761722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA PH US 2008 CL008|Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma|A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma|RACE|Celgene|No|Active, not recruiting|August 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761722||149635|
NCT00761995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-CT-08-003|Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension|||Alcon Research|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||January 2012|July 17, 2012|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761995||149614|
NCT00762008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-151-2|Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure|Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure||University of Connecticut Health Center|No|Recruiting|December 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|serum|Both|18 Years|N/A|No|Probability Sample|Recruitment will take place in the University of Connecticut Health Center, both hospital        inpatients and Cardiopulmonary clinic out-patients.          1. The target population will be heart failure patients of any etiology. We anticipate             that 20% of all recruited subjects will be African American and 5% to be Hispanic.             This represents the distribution of populations recruited in the past for heart             failure studies.          2. Healthy individuals with no prior history of heart attack or heart failure will be             recruited to use as controls.|January 2014|April 24, 2014|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762008||149613|
NCT00762320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-017|Comparison of Liquid Kaletra and Low Dose Kaletra Tablets|Comparison of Liquid Kaletra and Low Dose Kaletra Tablets in HIV-Positive Children||Phoenix Children's Hospital|No|Completed|October 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|3 Years|18 Years|No|||February 2014|February 5, 2014|September 29, 2008|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00762320||149590|Early termination leading to small number of subjects analyzed.
NCT00760136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461712133|The Role of Quadriceps Contraction in Patellar Repositioning - a Computed Tomography Study|The Role of Quadriceps Contraction in Patellar Repositioning-a Computed Tomography Study||National Taiwan University Hospital|No|Recruiting|August 2006|July 2009|Anticipated|||Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Both|20 Years|50 Years|No|Probability Sample|Patients with patellofemoral pain.|September 2008|October 23, 2008|April 10, 2007||No||No||https://clinicaltrials.gov/show/NCT00760136||149756|
NCT00759850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM_DES01|Drug Eluting Stent (DES) in Primary Angioplasty|PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial|PASEO|San Giuseppe Moscati Hospital|No|Completed|October 2003|December 2007|Actual|October 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|85 Years|No|||September 2008|September 24, 2008|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759850||149778|
NCT00761280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP 12009-G005|Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma|Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.|SAPPHIRE|Isarna Therapeutics GmbH|Yes|Terminated|December 2008|June 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|70 Years|No|||November 2014|November 4, 2014|September 26, 2008|Yes|Yes|Unable to recruit the projected patient number. All analyses are descriptive, only.|No|August 7, 2014|https://clinicaltrials.gov/show/NCT00761280||149668|Early termination of the study leading to recruitment of 27 of 180 planned subjects and incomplete collection of data. Survival results are based on post-study collection of additional survival data under a protocol amendment.
NCT00761631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3011|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years|A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States||Pfizer|No|Completed|December 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1200|||Both|15 Months|17 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|September 25, 2008|Yes|Yes||No|July 15, 2011|https://clinicaltrials.gov/show/NCT00761631||149642|
NCT00761644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0384|Doxil, Bevacizumab and Temsirolimus Trial|A Phase I Trial of Doxil, Bevacizumab and Temsirolimus||M.D. Anderson Cancer Center|No|Recruiting|August 2008|||August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|206|||Both|12 Years|N/A|No|||December 2015|December 3, 2015|September 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761644||149641|
NCT00761657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-SM4592-017|Phase 2 Study of FG-4592 in Subjects With Anemia and Chronic Kidney Disease Not Requiring Dialysis|A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects With Chronic Kidney Disease Not Requiring Dialysis||FibroGen|Yes|Completed|November 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|117|||Both|18 Years|75 Years|No|||January 2013|January 28, 2013|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761657||149640|
NCT00757627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-113|Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)|Patient-reported Outcomes With Etoricoxib in Real Life||Merck Sharp & Dohme Corp.||Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|20 Years|N/A|No|||August 2015|August 13, 2015|September 22, 2008|No|Yes||No|January 4, 2010|https://clinicaltrials.gov/show/NCT00757627||149948|Open-labeled, non-controlled
NCT00758563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0907-PLA-18-RR|Train New Examiners Via Modified Gingival Margin Plaque|Train New Examiners Via Modified Gingival Margin Plaque||Colgate Palmolive|Yes|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|November 20, 2008|September 23, 2008|Yes|Yes||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00758563||149877|
NCT00758576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-44|ReSTOR Natural +3.0D Study In Japan|ReSTOR Natural +3.0D (Diopter) Study In Japan||Alcon Research|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|20 Years|N/A|No|||December 2010|December 6, 2010|September 23, 2008|Yes|Yes||No|October 8, 2010|https://clinicaltrials.gov/show/NCT00758576||149876|
NCT00758485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05767|Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)|A Randomized, Safety-assessor Blinded Trial Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in Adult Subjects Scheduled for Surgery Requiring Profound Neuromuscular Blockade||Merck Sharp & Dohme Corp.|No|Completed|October 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|September 23, 2008|No|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT00758485||149883|
NCT00758498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3065/ES/MN|Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder|A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder||Teva Pharmaceutical Industries|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|427|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|September 23, 2008|Yes|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00758498||149882|
NCT00758823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMEGA-IZ2008-V6|Randomized Controlled Trial Comparing Efficacy and Tolerance of Four Pediculicides|Randomized Controlled Trial Comparing Efficacy and Tolerance of Four Pediculicides Acting Mechanically With Reference Product Acting Chemically (Prioderm)||Omega Pharma|Yes|Completed|August 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|750|||Both|3 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 23, 2009|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00758823||149857|
NCT00758836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-046|A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)|A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK0974 Co-administered With Ibuprofen or Acetaminophen in Patients With Migraine With or Without Aura||Merck Sharp & Dohme Corp.|No|Completed|December 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|683|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|September 23, 2008|Yes|Yes||No|July 18, 2014|https://clinicaltrials.gov/show/NCT00758836||149856|
NCT00760500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIVFRC|Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China|Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China||St. Jude Children's Research Hospital|No|Completed|January 2004|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|13201|Samples Without DNA|Nasopharyngeal specimen taken by swab|Both|N/A|18 Years|No|Non-Probability Sample|Children between the ages of 0 months and 18 years (inclusive) who have been seen at the        pediatric clinic of the First Affiliated Hospital within 7 days of the onset of signs and        symptoms of febrile respiratory illness suspected to be of viral origin (temperature >        37.7ºC or reliable history of fever before being examined, and respiratory symptoms and        signs such as cough, sore throat, and coryza).|February 2015|February 16, 2015|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760500||149728|
NCT00764348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-002|Evaluation of Wound Biofilm in Acute and Chronic Wounds|Evaluation of Wound Biofilm in Acute and Chronic Wounds||Southwest Regional Wound Care Center|No|Withdrawn||||||N/A|Observational|Time Perspective: Prospective||1|Actual|0|Samples With DNA|traumatic, diabetic foot ulcer, decubitus ulcer, venous leg ulcer|Both|18 Years|N/A|No|Non-Probability Sample|Acute and Chronic Wounds|September 2011|September 6, 2011|September 30, 2008||No|withdrawn as MSU approval obained|No||https://clinicaltrials.gov/show/NCT00764348||149436|
NCT00764634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rBV A/B-02|Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B|A Phase 2, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Dosing Schedule and Antibody Kinetics of Recombinant Botulinum Vaccine A/B, rBV A/B-40, in Healthy Adults||DynPort Vaccine Company LLC, A CSC Company|Yes|Completed|September 2008|December 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|440|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764634||149414|
NCT00765817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H80-US-GWCO|Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus|A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications||AstraZeneca|No|Completed|October 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|October 1, 2008|Yes|Yes||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00765817||149323|
NCT00765830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23137E1|Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)|A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency||Novartis|Yes|Completed|September 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|349|||Both|18 Years|85 Years|No|||January 2013|January 2, 2013|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765830||149322|
NCT00761345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-GI-021|Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer|Phase I Study of Low-Dose Fractionated Radiotherapy as a Chemosensitizer for Gemcitabine and Erlotinib in Patients With Locally Advanced or Limited Metastatic Pancreatic Cancer||Fox Chase Cancer Center|Yes|Active, not recruiting|September 2008|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761345||149664|
NCT00766090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112202|Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma|A Multi-Centre, Randomized, Double Blind Cross-over Study to Assess the Non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma||GlaxoSmithKline|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|190|||Both|12 Years|N/A|No|||August 2014|August 4, 2014|October 2, 2008|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00766090||149302|
NCT00766389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2008-0113|Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus Optical Coherence Tomography (OCT)|Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus OCT||Yonsei University|No|Recruiting|October 2008|February 2009|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Defined glaucoma patients and glaucoma suspects|October 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766389||149279|
NCT00766662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-55|Intermittent Preventive Treatment in Infant in Mali|||University of Bamako|No|Completed|October 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||||||Both|N/A|23 Months|Accepts Healthy Volunteers|||September 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766662||149260|
NCT00762632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ADE01|Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia|An Open-label Phase I/II (Proof of Concept) Trial of an Combination of Nilotinib (AMN 107) and RAD001 in Patients With Acute Myeloid Leukemia||Technische Universität München|Yes|Completed|December 2007|||June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762632||149566|
NCT00762645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-06-04|Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)|A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma||Alcon Research|No|Completed|February 2007|||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2010|March 12, 2010|September 24, 2008||No||No|January 7, 2010|https://clinicaltrials.gov/show/NCT00762645||149565|
NCT00770380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16RT-0074|Hypnosis for Smoking Relapse Prevention|Hypnosis for Smoking Relapse Prevention|HypnoRelapse|University of California, San Francisco|No|Completed|June 2007|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2011|September 15, 2011|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770380||148982|
NCT00760409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00050584|Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI|Prospective Study Differentiating Recurrent Brain Tumor Versus Radiation Injury Using Magnetic Resonance (MR) Spectroscopy, Diffusion Tensor Imaging and Diffusion Weighted Imaging on 3T(Tesla) MR Scanner||University of Michigan|Yes|Active, not recruiting|September 2008|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have had a previous brain tumor and their physician has ordered a follow up        MRI because your tumor may have returned.|December 2015|December 10, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00760409||149735|
NCT00761956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-300|A Study to Compare the NexGen CR and CR-Flex Knee Implants|Prospective Randomized Multicenter Study of NexGen CR-Flex Knee||Zimmer, Inc.|No|Completed|September 2004|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|189|||Both|21 Years|80 Years|No|||June 2012|June 12, 2012|September 26, 2008||No||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00761956||149617|
NCT00762281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL 80-2004-2|Safety and Effectiveness Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Hyperopia|A Prospective, Randomized, Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of ≤ +6.0 D Of Hyperopia With Or Without Astigmatism Of +0.50 D To +3.50 D And MRSE ≤ +6.50 D||Carl Zeiss Meditec, Inc.|Yes|Completed|July 2004|October 2008|Actual|October 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 9, 2012|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762281||149593|
NCT00758277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kep-F10.2.01|Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients|Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients|Keppra-2|Charite University, Berlin, Germany|Yes|Completed|May 2007|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|201|||Both|18 Years|70 Years|No|||August 2009|June 22, 2011|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758277||149899|
NCT00759278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBPHS 5215|Comparison Fetal Hemodynamic Measurements Antihypertensive Versus Control|A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-Hypertensive Medication and Controls||State University of New York - Upstate Medical University|No|Not yet recruiting|August 2008|August 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with established singleton pregnancy at least 18 years of age, with diagnosis of        chronic hypertension or with no diagnosis of hypertension|September 2008|September 24, 2008|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759278||149822|
NCT00758511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B1_122676|Pain Reactivity to Non-Pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit|Pain Reactivity to Non-pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit|PAMINA|University of Basel|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|71|||Both|N/A|15 Days|No|||February 2010|November 13, 2013|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758511||149881|
NCT00758524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699A2201|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension||Novartis|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|526|||Both|18 Years|75 Years|No|||May 2012|May 31, 2012|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758524||149880|
NCT00758849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-II-005|Fipamezole in Neurogenic Orthostatic Hypotension|A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease|Foehn|Juvantia Pharma Ltd|No|Not yet recruiting|September 2008|May 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|80 Years|No|||September 2008|September 30, 2008|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758849||149855|
NCT00758862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD1414-C22|The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo|The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo||LEO Pharma|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||August 2009|December 19, 2013|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758862||149854|
NCT00758875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET DE 01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2006|||||N/A|N/A|N/A||||||||||||||February 11, 2012|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758875||149853|
NCT00760162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIB001|Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure|Pilot-Scale Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Chronic Kidney Failure|Probiotics|Kibow Biotech Inc.|Yes|Completed|August 2007|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|180|||Both|18 Years|75 Years|No|Probability Sample|Out patient Hospital setting|August 2011|August 2, 2011|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760162||149754|
NCT00760175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7407|Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients|A Randomized, Controlled Trial Comparing Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients||University of Alberta|Yes|Completed|October 2008|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760175||149753|
NCT00765310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT002034-1|Lipoic Acid and Prevention of Heart Disease|The Role of R-alpha Lipoic Acid in Prevention of Atherosclerotic Vascular Disease||Oregon State University|Yes|Active, not recruiting|April 2009|July 2015|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765310||149362|
NCT00760773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012686|Impact of Emergency Department Probiotic Treatment of Diarrheal Illness on Daycare Attendance|Impact of Emergency Department Probiotic Treatment of Diarrheal Illness on Daycare Attendance: Randomized Controlled Trial and Economic Analysis||The Hospital for Sick Children|Yes|Terminated|April 2009|March 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|132|||Both|4 Months|48 Months|No|||December 2014|December 8, 2014|September 25, 2008||No|Funding ended and fewer than required number of patients enrolled.|No||https://clinicaltrials.gov/show/NCT00760773||149707|
NCT00766675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015319|An Efficacy Study of Combination of Tramadol and Acetaminophen Tablets in the Treatment of Participants With Fibromyalgia Pain|Ultracet (Tramadol HCL [37.5 mg]/Acetaminophen [325 mg]) Combination Tablets in the Treatment of the Pain of Fibromyalgia||Johnson & Johnson Taiwan Ltd|No|Completed|October 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|20 Years|75 Years|No|||May 2013|May 29, 2013|October 3, 2008|Yes|Yes||No|February 18, 2013|https://clinicaltrials.gov/show/NCT00766675||149259|
NCT00766103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06213|The Effects of PaCO2 Levels on Cerebral Metabolism and Perfusion During Induced Hypothermia.|The Effects of PaCO2 Levels on Cerebral Metabolism and Perfusion During Induced Hypothermia.||Tampere University Hospital||Recruiting||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A|No|||November 2013|November 25, 2013|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766103||149301|
NCT00762658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-PSR-102|A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test|A Phase I, Randomized, Observer-Blind, Single-Center, Vehicle- and Comparator-Controlled, Initial Dose-Ranging Study to Assess the Antipsoriatic Efficacy of Different Concentrations of AN2728 Ointment in a Psoriasis Plaque Test||Anacor Pharmaceuticals, Inc.|No|Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|12|||Male|18 Years|N/A|No|||October 2008|October 22, 2008|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762658||149564|
NCT00762905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDL-0601|Clinical Trial of MedLogic LiquiBand Laparoscopic Versus Dermabond in the Closure of Surgical Incisions|A Prospective, Randomised, Controlled, Double-masked, Multi-center Clinical Trial of MedLogic LiquiBand Laparoscopic Versus Dermabond in the Closure of Surgical Incisions||MedLogic Global Limited|No|Completed|April 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762905||149545|
NCT00763178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0612002110|Effects of Duloxetine on Fear Conditioning in Posttraumatic Stress Disorder (PTSD)|Effects of Duloxetine on Fear Conditioning in PTSD||Yale University|No|Completed|February 2007|December 2009|Actual|April 2009|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Male|18 Years|65 Years|No|||April 2015|April 21, 2015|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT00763178||149524|
NCT00763191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/10-Z|Analysis of Oculo-motor Deficiencies Associated With FMR1 Gene Expression (Genetic Abnormality Predisposing to a Neurodegenerative Disease)|Analysis of Oculo-motor Deficiencies Associated With FMR1 Gene Expression (Genetic Abnormality Predisposing to a Neurodegenerative Disease)||Nantes University Hospital|No|Terminated|June 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|27|||Male|18 Years|50 Years|No|||December 2012|December 7, 2012|September 29, 2008||No|departure of the principal investigator and nobody else was able to continue this study.|No||https://clinicaltrials.gov/show/NCT00763191||149523|
NCT00761007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAK 03|Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)|Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Effect of a 4-week Treatment With Oral Doses of Ibodutant (Code: MEN15596) in Irritable Bowel Syndrome (IBS).|IRIS|Menarini Group|No|Completed|July 2008|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|554|||Both|18 Years|70 Years|No|||March 2012|March 20, 2012|September 25, 2008||No||No|September 8, 2010|https://clinicaltrials.gov/show/NCT00761007||149689|
NCT00771043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US 010-07-NAT|A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a|Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a|PRTOECT|Biogen|No|Withdrawn|November 2008|June 2010|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|No|||July 2009|July 29, 2009|October 7, 2008||No|Sponsor decision to withdraw study at this time.|No||https://clinicaltrials.gov/show/NCT00771043||148932|
NCT00757965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598882|Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Colorectal Cancer in East Anglia||National Cancer Institute (NCI)||Recruiting|February 2008|||||N/A|Observational|N/A|||Anticipated|2000|||Both|18 Years|69 Years|No|||September 2008|August 23, 2013|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00757965||149923|
NCT00758914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG013975|Vitamin E and Infection in the Elderly|Vitamin E and Infection in the Elderly||Tufts University|Yes|Completed|May 1997|||August 2001|Actual|N/A|Interventional|N/A|||||||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 23, 2008|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00758914||149850|
NCT00759863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pz-A102b|LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia|LifeZig System for Individuals With Alzheimer's Disease|Lifezig|Photozig, Inc.||Completed|August 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|242|||Both|21 Years|N/A|No|||February 2010|February 22, 2010|September 23, 2008||No||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00759863||149777|
NCT00760149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRIORI 4.1|Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis|Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.|High RIF|Radboud University|Yes|Completed|July 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|65 Years|No|||September 2013|September 6, 2013|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760149||149755|
NCT00759577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VESI-8E01|Feasibility of "At-home" Titration of Solifenacin|Feasibility of "At-home" Titration of Solifenacin 5 and 10mg and Effect on Symptoms and Quality of Life in a Typical OAB Population||New York University School of Medicine|Yes|Terminated|September 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 24, 2008|No|Yes|difficulty with enrollment|No|November 18, 2011|https://clinicaltrials.gov/show/NCT00759577||149799|Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.
NCT00759590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|584|Comparison of Two Methods to Estimate the Lung Recruitment|Comparisons of Two Methods to Estimate the Lung Recruitment||Policlinico Hospital|No|Recruiting|September 2008|||March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Non-Probability Sample|ALI/ARDS patients|October 2015|October 19, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759590||149798|
NCT00759603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0208|Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia|Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292||M.D. Anderson Cancer Center|Yes|Completed|September 2008|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|September 24, 2008|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT00759603||149797|
NCT00760747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12305|Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)|A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning Compared With Fast Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD)|ADHD SWITCH|Eli Lilly and Company|No|Completed|September 2008|September 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|6 Years|16 Years|No|||August 2011|August 2, 2011|September 25, 2008|Yes|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00760747||149709|
NCT00764998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN237|Influenza Vaccine in HIV|A Controlled Trial to Assess the Immunogenicity and Efficacy of Three Vaccine Dosing Strategies in HIV Infected Adults||Ottawa Hospital Research Institute||Completed|October 2008|August 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|285|||Both|18 Years|60 Years|No|||August 2010|August 19, 2010|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764998||149386|
NCT00765011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTCC-2007-02|TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer|A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF||Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|No|Recruiting|October 2008|May 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|92|||Both|18 Years|70 Years|No|||February 2011|February 12, 2011|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765011||149385|
NCT00765843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORT 067|A Trial of Custom Foot Orthoses for the Treatment of Plantar Heel Pain|A Randomized Controlled Trial of Custom Foot Orthoses for the Treatment of Plantar Heel Pain||Rosalind Franklin University of Medicine and Science|No|Completed|October 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|75 Years|No|||June 2014|June 19, 2014|October 2, 2008||No||No|April 28, 2014|https://clinicaltrials.gov/show/NCT00765843||149321|
NCT00765570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRID|Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy|Treatment of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy A Phase II Randomized Trial||Summa Health System|No|Terminated|February 2003|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|80 Years|No|||April 2015|April 29, 2015|October 2, 2008||No|Accrual too slow - would not enroll enough subjects to determine outcome|No|February 16, 2015|https://clinicaltrials.gov/show/NCT00765570||149342|
NCT00766688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10841|Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia|A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AVE5530 When Added to Ongoing Stable Statin Therapy at High Doses in Patients With Severe Primary Hypercholesterolemia||Sanofi|No|Terminated|October 2008|June 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|643|||Both|18 Years|N/A|No|||November 2009|November 10, 2009|October 3, 2008|Yes|Yes|AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|No||https://clinicaltrials.gov/show/NCT00766688||149258|
NCT00766935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQSFB7+-01|The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device|The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device||ImpediMed Limited|No|Completed|November 2007|April 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|||Female|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1 - Primary care clinic Group 2 - Community sample|October 2008|October 2, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766935||149240|
NCT00766948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 08-5022|The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry|The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry||Scripps Translational Science Institute|No|Active, not recruiting|August 2008|August 2030|Anticipated|August 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood or Saliva|Both|30 Years|N/A|No|Non-Probability Sample|Patients 30 years of age or older with the diagnosis idiopathic Parkinson's disease|October 2015|October 14, 2015|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766948||149239|
NCT00762918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-12-5688|Vitamin D3 for the Treatment of Low Vitamin D in Cystic Fibrosis|Vitamin D and Its Non-Classic Roles in Cystic Fibrosis||Children's Hospital of Philadelphia|Yes|Withdrawn|March 2008|September 2008|Anticipated|September 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|10 Years|25 Years|No|||February 2010|February 19, 2010|September 26, 2008||No|Recruitment|No||https://clinicaltrials.gov/show/NCT00762918||149544|
NCT00763204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-PSR-103|A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test|A Phase I, Randomized, Observer-Blind, Single-Center, Vehicle- and Comparator-Controlled, Initial Dose-Ranging Study to Assess the Antipsoriatic Efficacy of Different Concentrations of AN2728 Cream in a Psoriasis Plaque Test||Anacor Pharmaceuticals, Inc.|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|12|||Male|18 Years|N/A|No|||October 2008|October 22, 2008|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00763204||149522|
NCT00763217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 05/15|Clinical Biological and Pharmacological Factors Influencing Stroke Outcome|Characterization of Clinical, Biological and Pharmacological Markers of Stroke Outcome|biostroke|University Hospital, Lille|No|Completed|June 2005|June 2012|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|550|Samples Without DNA|whole blood and serum|Both|40 Years|N/A|No|Probability Sample|Cohort of stroke patient|May 2015|May 12, 2015|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00763217||149521|
NCT00769548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9413|Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer|A PHASE III TRIAL COMPARING WHOLE PELVIC IRRADIATION FOLLOWED BY A CONEDOWN BOOST TO BOOST IRRADIATION ONLY AND COMPARING NEOADJUVANT TO ADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS)||Radiation Therapy Oncology Group|Yes|Active, not recruiting|April 1995|||April 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1322|||Male|N/A|120 Years|No|||November 2015|November 14, 2015|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769548||149043|
NCT00769561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMD_Jue2008|Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders|Comparison of a Biofeedback-Based Cognitive Behavioral Treatment and Occlusal Splint Therapy for Temporomandibular Disorders. A Randomized Clinical Trial.||Philipps University Marburg Medical Center|Yes|Completed|August 2008|April 2011|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|70 Years|No|||December 2013|December 4, 2013|October 8, 2008||No||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00769561||149042|
NCT00770744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12396A|Efficacy of Lu 31-130 in Patients With Schizophrenia|A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Exploring the Efficacy and Safety of 12 Weeks Treatment With Lu 31-130 in Patients With Schizophrenia||H. Lundbeck A/S|Yes|Completed|September 2008|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|65 Years|No|||July 2010|July 1, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770744||148955|
NCT00771316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-054|Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)|A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated Urinary Tract Infection||Merck Sharp & Dohme Corp.||Terminated|December 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|October 9, 2008|Yes|Yes|feasibility and low enrollment|No|April 22, 2010|https://clinicaltrials.gov/show/NCT00771316||148911|The reason for early termination: Study was terminated early due to feasibility issues including slow enrollment.
NCT00771628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-111|Comparison of Flex-It Stylet to Malleable Stylet for GlideScope Intubation: A Randomized Controlled Trial|Comparison of Flex-It Stylet to Malleable Stylet for GlideScope Intubation: A Randomized Controlled Trial||Lawson Health Research Institute|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||July 2009|July 10, 2009|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771628||148888|
NCT00767195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB97-01-02A|Power Spectral Analysis of Breath Sound in Pulmonary Edema|Power Spectral Analysis of Lung Sounds Detected at Bilateral Lung Bases in Patients With Cardiogenic and Non-cardiogenic Pulmonary Edema||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|July 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|20 Years|95 Years|No|Non-Probability Sample|Patients without pulmonary edema (control group), with cardiogrnic edema (study group 1)        and non-cardiogrnic edema (study group 2)|June 2010|June 6, 2010|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00767195||149222|
NCT00760422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-115-25|Clinical Evaluation of NIR (Non-Invasive Infrared) Thermometer Performance||NIR|Medisim Ltd|Yes|Completed|December 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|500 patients from both genders, 0-18 years old|August 2008|April 19, 2012|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760422||149734|
NCT00760435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01FD003514-01|Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease|Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease||University of California, San Diego|Yes|Completed|March 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|N/A|17 Years|No|||November 2014|November 12, 2014|September 25, 2008|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00760435||149733|The major limitation of our study was the low rate of treatment-resistance in the placebo arm (11%, compared to historical IVIG resistance rates of 20%), which decreased our power to detect a difference in the primary outcome measure.
NCT00760448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1449|Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia|Trial Investigating the Hypoglycaemic Response to Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|April 2004|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|25|||Both|18 Years|N/A|No|||November 2012|August 12, 2014|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760448||149732|
NCT00764673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 703|The 3DKnee™ System: A Post-Market Study|The 3DKnee™ System: A Post-Market Study||Encore Medical, L.P.|No|Completed|October 2006|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||February 2011|February 8, 2011|September 30, 2008|Yes|Yes||No|November 19, 2010|https://clinicaltrials.gov/show/NCT00764673||149411|
NCT00765583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-04-003|A Study to Determine How Long Restylane® Will Last After Initial Treatment With 2 Different Re-treatment Schedules.|A Randomized, Evaluator-Blind, Multi-Center, Comparison of the Efficacy and Persistence of Correction of Nasolabial Folds With Restylane® Using Two Different Re-Treatment Schedules||Medicis Aesthetics, Inc.|No|Completed|November 2005|February 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 20, 2011|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765583||149341|
NCT00766129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N403 2786 33|Comparison of Safety and Efficacy of Two Different Drug Eluting Stents Implanted Into Saphenous Vein Grafts|Comparison of Safety and Efficacy of Drug Eluting Stents : TAXUS (Boston Scientific) vs. LUC-Chopin (Balton, Poland) Implanted Into Saphenous Vein Grafts. Study With Serial Intravascular Ultrasounds.||Institute of Cardiology, Warsaw, Poland|No|Active, not recruiting|February 2008|December 2011|Anticipated|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||July 2011|July 4, 2011|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766129||149299|
NCT00766116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090516|Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)|A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML||University of California, San Diego|Yes|Completed|July 2005|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|90 Years|No|||September 2015|September 11, 2015|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766116||149300|
NCT00766402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015322|An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)|A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet®) vs. Diclofenac (Voltaren®) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)||Johnson & Johnson Taiwan Ltd|No|Terminated|October 2008|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|No|||October 2014|October 14, 2014|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766402||149278|
NCT00766415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9831C00002|14729-D9831C00002- 1 Month Biopsy Study|A Double-blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Biopsy|AstraZeneca|Yes|Completed|November 2008|June 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|40 Years|N/A|No|||January 2014|January 27, 2014|October 3, 2008||No||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00766415||149277|
NCT00762372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLM-240-003|Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)|Phase 2/3 Clinical Study With BLM-240 in Adult Surgery Patients That Need General Anesthesia||Baxter Healthcare Corporation|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|216|||Both|20 Years|69 Years|No|||August 2011|August 16, 2011|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762372||149586|
NCT00762385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0713|Clinical Comparison of Two Silicone-Hydrogel Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|August 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|September 29, 2008|Yes|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00762385||149585|
NCT00766740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC-001|Long Term Clinical Efficacy of Thrombectomy Devices in Acute ST Elevation Myocardial Infarction|Individual-Patient-Data Pooled-Analysis Comparing Long Term Clinical Outcome in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention With or Without Prior Thrombectomy|ATTEMPT|Catholic University of the Sacred Heart|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2686|||Both|18 Years|N/A|No|||October 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766740||149254|
NCT00762359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-1749-CCT-351|A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers|A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.||Takeda|Yes|Terminated|May 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|461|||Both|20 Years|N/A|No|||February 2012|February 1, 2012|September 26, 2008||No|AG-1749 superior to Gefarnate in ulcer prevention|No|February 3, 2011|https://clinicaltrials.gov/show/NCT00762359||149587|On September 2008, the Efficacy and Safety Evaluation Committee recommended that this study be discontinued based on the interim analysis.
NCT00762931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-01|Neurostimulation for the Relief of Acute Bronchoconstriction|Neurostimulation for the Relief of Acute Bronchoconstriction||ElectroCore LLC|No|Completed|September 2008|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|No|||March 2015|March 12, 2015|September 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762931||149543|
NCT00760513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-12-59. (R&D: RHM MED 0836)|Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids|The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease||University Hospital Southampton NHS Foundation Trust.|No|Active, not recruiting|November 2009|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760513||149727|
NCT00760786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2007-09-006|Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque|Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque: Serial Virtual Histology Intravascular Ultrasound Analysis||Samsung Medical Center|Yes|Recruiting|July 2008|||February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|80 Years|No|||September 2008|September 25, 2008|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760786||149706|
NCT00769821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616135|The Impact of Lymphedema on Breast Cancer Survivors|The Impact of Lymphedema on Local and Overall Functioning||University of California, San Francisco|No|Completed|February 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|||Female|21 Years|N/A|No|Non-Probability Sample|Breast cancer survivors|December 2012|December 11, 2012|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769821||149024|
NCT00769834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0019|Disc Edema in Patients With Chronic Kidney Disease|Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease||University of Mississippi Medical Center|No|Withdrawn|January 2010|April 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|323|||Both|18 Years|80 Years|No|Non-Probability Sample|The study sample will be drawn from the population of patients with chronic kidney        diseases attending the kidney disease clinics and the hemodialysis units at the University        of Mississippi Medical Center and the Jackson Medical Mall|April 2009|April 28, 2009|October 8, 2008||No|Study withdrawn due to logistic reasons and will be re-organized at a later date|No||https://clinicaltrials.gov/show/NCT00769834||149023|
NCT00770107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thiamine in Heart Failure|Thiamine Supplementation to Improve Cardiac Function in Patients With Congestive Heart Failure|Thiamine Supplementation to Improve Cardiac Function in Patients With Congestive Heart Failure on Long-term Treatment With Diuretic Drugs||Luzerner Kantonsspital||Completed|June 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00770107||149003|
NCT00770393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201089|Laryngeal Preservation in Pyriform Sinus Carcinoma|Randomized Phase III Trial Comparing Induction Chemotherapy Followed by Radiotherapy to Concomitant Chemoradiotherapy for Laryngeal Preservation in T3MO Pyriform Sinus Carcinoma||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2002|June 2007|Actual|June 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|70 Years|No|||October 2008|October 9, 2008|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770393||148981|
NCT00770406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTXA2008|Intravesical Instillation of Botulinum Toxin Type A to Patients With Urge Urinary Incontinence|Intravesikal Instillation af Botulinum Toxin Type A Til Patienter Med Urge Urininkontinens||Glostrup University Hospital, Copenhagen|No|Recruiting|January 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||August 2009|August 3, 2009|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770406||148980|
NCT00770757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1093 / 201106102|CC-4047 (Pomalidomide) for Graft vs. Host Disease|A Phase 2, Open-Label, Single-Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients With Advanced Chronic Graft-Versus-Host Disease Developing After Allogeneic Hematological Stem Cell Transplantation||Washington University School of Medicine|No|Completed|February 2009|October 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|October 7, 2008|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00770757||148954|
NCT00770770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-08-006|Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina|A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien™ (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Edema Secondary to Retinal Vein Occlusion|FAVOR|Alimera Sciences|No|Terminated|May 2009|||October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|October 9, 2008|Yes|Yes||No|April 17, 2015|https://clinicaltrials.gov/show/NCT00770770||148953|
NCT00761670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMISU_L_01008|Efficacy Study on Cognitive Functions in Schizophrenic Patients|Comparative Efficacy of Amisulpride vs Risperidone on Cognitive Functions in Patients With Chronic Schizophrenia|AMIMIND|Sanofi|No|Completed|September 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|No|||December 2010|December 8, 2010|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761670||149639|
NCT00767507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CAN-08-02|Maintenance of Platelet Inhibition With Cangrelor|BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry|Bridge|The Medicines Company|Yes|Completed|October 2008|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|90 Years|No|||February 2014|February 21, 2014|October 6, 2008|Yes|Yes||No|April 23, 2013|https://clinicaltrials.gov/show/NCT00767507||149198|
NCT00765323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP107-001|Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly|Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly||Endo Pharmaceuticals|No|Terminated|September 2008|June 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|80 Years|No|||September 2013|September 20, 2013|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765323||149361|
NCT00765856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202 036|Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects|An Open-Label Safety and Tolerability Study of Immediate-Release and Extended-Release Oxymorphone in Opioid-Tolerant Pediatric Subjects With Chronic Pain.||Endo Pharmaceuticals|No|Terminated|October 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|6 Years|17 Years|No|||June 2015|June 10, 2015|October 2, 2008|No|Yes|Terminated new protocol developed which incorporated Pharmacokinetics|No||https://clinicaltrials.gov/show/NCT00765856||149320|
NCT00766142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599511|Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer|Clinical Phase II Study Evaluating Systemic Chemotherapy in Combination With Cetuximab as Adjuvant Treatment in Patients With Completely Surgically Resected Peritoneal Carcinomatosis of Colorectal Origin||National Cancer Institute (NCI)||Recruiting|May 2007|||December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|October 2, 2008||||No||https://clinicaltrials.gov/show/NCT00766142||149298|
NCT00766454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573065|Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer|Metabolic Genotypes and Oncogenic Damage in Breast Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|November 1998|||January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1104|||Female|N/A|120 Years|No|Non-Probability Sample|Those with newly diagnosed breast cancer who are planning to undergo a diagnostic biopsy        or surgery.|October 2015|October 22, 2015|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766454||149275|
NCT00766441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H1005/46|Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan|Sitagliptin Versus Sulphonylurea Based Treatments in Muslim Patients With Type 2 Diabetes During Ramadan||University of Manchester|Yes|Terminated|August 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|78 Years|No|||October 2008|January 11, 2010|October 3, 2008|No|Yes|inadequate recruitment|No||https://clinicaltrials.gov/show/NCT00766441||149276|
NCT00762983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05834|Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)|Claritin® Tablet 10 mg, Claritin® RediTabs® 10 mg, Claritin® Dry Syrup 1% Drug Use Investigation (Pediatrics)||Merck Sharp & Dohme Corp.|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1003|||Both|3 Years|15 Years|No|Non-Probability Sample|Pediatric patients who are treated with Claritin at a department of pediatrics, department        of otorhinology, department of dermatology, etc. at approximately 120 institutions|February 2015|February 12, 2015|September 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762983||149539|
NCT00763269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0208-TOT-SEN-PR|The Efficacy of a Toothpaste to Reduce Sensitivity|The Efficacy of a Toothpaste to Reduce Sensitivity||Colgate Palmolive|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|626|||Both|12 Years|80 Years|Accepts Healthy Volunteers|||June 2011|March 5, 2012|September 26, 2008|Yes|Yes||No|August 24, 2010|https://clinicaltrials.gov/show/NCT00763269||149517|
NCT00762398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6221|Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients|Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients||University of California, Irvine|No|Enrolling by invitation|September 2008|July 2009|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood sample for the measurement of Hct, and ABG|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients in UCI Medical Center undergoing surgery|September 2008|September 29, 2008|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762398||149584|
NCT00762671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-003331Ebselen|Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus|Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus||Brigham and Women's Hospital|Yes|Completed|May 1999|October 2007|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2008|September 29, 2008|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762671||149563|
NCT00762684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-559-028|Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus||Takeda|No|Terminated|November 2004|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|25 Years|75 Years|No|||November 2012|November 8, 2012|September 26, 2008|Yes|Yes|Hepatic safety signal identified.|No||https://clinicaltrials.gov/show/NCT00762684||149562|
NCT00762944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET WL 01|Total Temporomandibular Joint Replacement System Post Approval Study|Total Temporomandibular Joint Replacement System Post Approval Study||Biomet, Inc.|No|Completed|September 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|N/A|N/A|No|Non-Probability Sample|Patients who received TMJ systems from the IDE study|October 2011|October 17, 2011|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762944||149542|
NCT00762957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-559-029|Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of a Combination of TAK-559 and Metformin Compared to Placebo and Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus||Takeda|No|Terminated|November 2004|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Both|25 Years|75 Years|No|||February 2012|February 24, 2012|September 26, 2008|Yes|Yes|Hepatic Safety Signal Identified.|No||https://clinicaltrials.gov/show/NCT00762957||149541|
NCT00760526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 011|Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM|A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children (4 to <10 Year Olds)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|September 2010|January 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|146|||Both|4 Years|9 Years|No|||January 2014|January 10, 2014|September 25, 2008||No||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00760526||149726|
NCT00760539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-08|Safety and Efficacy of Travoprost/Timolol BAC-free|A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|20 Years|N/A|No|||July 2014|July 14, 2014|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760539||149725|
NCT00760799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06101_B|Randomized Study of Anular Repair With the Xclose Tissue Repair System|Randomized Study of Anular Repair With the Xclose Tissue Repair System||Anulex Technologies, Inc.|No|Completed|March 2007|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|750|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760799||149705|
NCT00761072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-05-6048|Remifentanil Propofol Infusion in Pediatric Spinal Surgery|An Evaluation of RemifentanilPropofol Infusion in Pediatric Spinal Surgery||Children's Hospital of Philadelphia|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|12|||Both|N/A|18 Years|No|Probability Sample|Pediatric patients having spinal surgery procedures completed at CHOP from April 2007        through March 2008|March 2013|March 5, 2013|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761072||149684|
NCT00761358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99010301|To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia|To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms||Zeria Pharmaceutical|No|Completed|September 2008|August 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|820|||Both|20 Years|64 Years|No|||November 2010|November 21, 2010|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761358||149663|
NCT00761371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1456-IMIQ|Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients|Exploratory Evaluation of Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Treated With HAART (CD4+ ≥ 200 Cells mm3): An Open Labeled, Non-comparative Study||MEDA Pharma GmbH & Co. KG||Completed|August 2002|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|69 Years|No|||April 2015|April 9, 2015|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761371||149662|
NCT00761735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02538: Part 2|5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)|Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C||Merck Sharp & Dohme Corp.|Yes|Completed|July 2007|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|3 Years|17 Years|No|||September 2015|September 11, 2015|September 5, 2008|No|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00761735||149634|
NCT00762021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-06-26|Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens|||Alcon Research|No|Completed|December 2006|||August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|50 Years|N/A|No|||November 2010|November 24, 2010|September 26, 2008|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00762021||149612|
NCT00762034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9707|A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer|Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer||Eli Lilly and Company|Yes|Completed|December 2008|December 2014|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|939|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 26, 2008|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00762034||149611|
NCT00762047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1004|A Prospective, Multi-center, Randomized, Blinded Study to Evaluate Durasphere FI for the Treatment of Fecal Incontinence|Phase 2 IDE Study of Durasphere FI in the Treatment of Fecal Incontinence||Carbon Medical Technologies|No|Terminated|June 2004|June 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|July 29, 2013|September 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762047||149610|
NCT00767520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-261|Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer|A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (AromasinÂ®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)||Bristol-Myers Squibb|Yes|Completed|February 2009|December 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||July 2012|February 22, 2013|October 6, 2008|Yes|Yes||No|May 8, 2012|https://clinicaltrials.gov/show/NCT00767520||149197|
NCT00771056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-088|Hydroxychloroquine in Untreated B-CLL Patients|Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.||Northwell Health|No|Suspended|July 2008|January 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||May 2011|May 26, 2011|October 8, 2008|Yes|Yes|study suspended while data is reviewed for safety and efficacy.|No||https://clinicaltrials.gov/show/NCT00771056||148931|
NCT00765596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#041129|Ghrelin Changes After Roux-en-Y Gastric Bypass|Ghrelin Changes After Roux-en-Y Gastric Bypass: Does Gastric Pouch vs. Gastric Remnant Feeding Affect Secretion?||Vanderbilt University|No|Completed|January 2005|||December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|14|Samples With DNA|plasma, tissues|Both|18 Years|60 Years|No|Non-Probability Sample|Subjects were morbidly obese, scheduled for RYGB with gastric tube placement. Controls        were matched to subjects by BMI, age, gender.|November 2011|November 15, 2011|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765596||149340|
NCT00765869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC10403|Randomised Controlled Trial of a Literacy Sensitive Decision Aid for Bowel Cancer Screening|A Randomised Controlled Trial of a Bowel Cancer Screening Decision Aid for Adults With Low Education and Literacy||University of Sydney|No|Recruiting|July 2008|February 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|555|||Both|55 Years|64 Years|Accepts Healthy Volunteers|||October 2008|October 2, 2008|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765869||149319|
NCT00765882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-01|Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks in Patients With Chronic Constipation||Forest Laboratories||Completed|September 2008|August 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|633|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|October 1, 2008|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00765882||149318|
NCT00765895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND - DK-GpCRC-2NORIG|Nortriptyline for Idiopathic Gastroparesis|Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)|NORIG|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|January 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|21 Years|65 Years|No|||April 2015|April 15, 2015|October 2, 2008|Yes|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00765895||149317|
NCT00766155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40054-22062|Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer|Preoperative Chemoradiotherapy and Postoperative Chemotherapy With Capecitabine and Oxaplatin vs.Capecitabine Alone in Locally Advanced Rectal Cancer (PETACC-6)|PETACC-6|European Organisation for Research and Treatment of Cancer - EORTC||Completed|August 2008|||September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1094|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|October 2, 2008||||No||https://clinicaltrials.gov/show/NCT00766155||149297|
NCT00766168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDSHI154|High Refractive Index Material 510(k)|Prospective Study of Substantial Equivalence of Rigid Gas Permeable HDS HI 1.54™ Daily Wear Lenses for Correction of Naturally Occurring Myopia and Hyperopia From +20 to - 20 D Sphere (Spectacle Plane) With and Without Astigmatism.|PVS-07-07|Paragon Vision Sciences|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|76|||Both|12 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 12, 2012|October 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00766168||149296|
NCT00766701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT1|Spectroscopic Evaluation of Cervical Neoplasia|Pivotal Study for Assessment of Cervical Neoplasia Using Fluorescence and Reflectance Spectroscopy||Guided Therapeutics|Yes|Completed|January 2003|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1599|Samples With DNA|histology slides|Female|16 Years|N/A|No|Probability Sample|Double-blind, Prospective, Safety-efficacy study|October 2008|October 3, 2008|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766701||149257|
NCT00762424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607030|Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis|Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis|Flowmax|WellSpan Health|No|Completed|June 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|September 26, 2008|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00762424||149582|
NCT00763282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-203|Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)|Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury||VA Office of Research and Development|Yes|Completed|November 2008|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|144|||Both|18 Years|N/A|No|||October 2014|April 6, 2015|September 26, 2008||No||No|November 24, 2014|https://clinicaltrials.gov/show/NCT00763282||149516|The study was underpowered because of difficulties encountered with recruitment and retention. Delivering an adequate “dose” of the treatments and site coordinator fidelity to the MI intervention were also limitations.
NCT00762697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-006|Obtaining and Storing Blood Samples and Debridement Samples for Wound Related Research|Obtaining and Storing Blood Samples and Debridement Samples for Wound Related Research||Southwest Regional Wound Care Center|Yes|Completed|June 2007|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Analytical methods used to examine the blood or debridement can investigate morphological,      molecular, immunological, cellular, viral, biochemical, chemical, genetic, and/or      transcriptional components of the samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with venous insufficiency, diabetic foot ulcers, decubitus ulcers.|November 2015|November 24, 2015|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762697||149561|
NCT00760565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP21617|A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).|A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease||Hoffmann-La Roche||Completed|September 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|72|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760565||149723|
NCT00760825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-WC-02|A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children|An Open Label Post Licensure Trial to Evaluate the Safety and Immunogenicity of Indigenously Manufactured Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine(Shanchol™)||International Vaccine Institute|Yes|Completed|March 2012|August 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|1 Year|40 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760825||149703|
NCT00761436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91677|Pilot Study of Safety and Efficacy of Spheramine|Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.||Bayer|No|Terminated|February 2000|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|40 Years|70 Years|No|||November 2014|November 27, 2014|September 26, 2008|No|Yes|Study was completed, only life long extended follow-up phase was discontinued after 12 years|No||https://clinicaltrials.gov/show/NCT00761436||149657|
NCT00760812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077730|Comparing Parent-Implemented Interventions for Toddlers With Autism Spectrum Disorders|Effects of Parent-Implemented Intervention for Toddlers With Autism Spectrum (The ESI Study)||Florida State University|Yes|Completed|April 2007|January 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|16 Months|20 Months|No|||February 2014|February 19, 2014|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760812||149704|
NCT00761085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0938|Methadone in Pediatric and Adult Sickle Cell Patients|Methadone in Pediatric and Adult Sickle Cell Patients|MSCD|Washington University School of Medicine|No|Recruiting|January 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|7 Years|40 Years|No|||August 2015|August 13, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00761085||149683|
NCT00761098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0410007526/1104-564|Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)|A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis||Weill Medical College of Cornell University|No|Recruiting|May 2005|August 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||January 2011|January 3, 2011|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761098||149682|
NCT00761384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6th radioimmunotherapy prot.|High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma|A Prospective Study With Individually Adjusted High Dose 90Y-Ibritumomab Tiuxetan Treatment With Peripheral Blood Stem Cells Support to Improve Outcome for Patients With Refractory/Recurrent B-cell Lymphoma, Stage II-IV|HITT|Lund University Hospital|No|Completed|April 2008|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2015|February 18, 2016|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761384||149661|
NCT00761397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0360|Adherence to Swallowing Exercises in Oropharyngeal Cancer|Adherence to Swallowing Exercises in Oropharyngeal Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|September 2008|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|350|||Both|18 Years|N/A|No|Probability Sample|Patients with head and neck cancer who previously had radiation treatment|February 2016|February 8, 2016|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761397||149660|
NCT00761748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK189OS|Comparison of Two Urostomy Bags (2-piece).|A Comparative, Randomised, Crossover Study With SenSura Uro 2-piece Versus ConvaTec 2-piece Among 30 Urostomy-operated Persons in Germany||Coloplast A/S|No|Completed|September 2008|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|September 26, 2008||No||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00761748||149633|
NCT00762086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-AHR-01|Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II|A Prospective, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of a New Intermittent Pneumatic Compression Device on Initial Claudication Distance in Patients With Peripheral Arterial Disease Stage II.||Mego Afek Ltd.|No|Completed|March 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|90 Years|No|||August 2012|August 27, 2012|September 28, 2008||No||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00762086||149607|
NCT00771069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2008/3|Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension|A Retrospective, Multi Centre, Non-interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Type II Diabetes Mellitus Patients With DM Related Complication and Hypertension.|CRYSTAL-CO|AstraZeneca|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Type II Diabetes Mellitus patients with Complication and Hypertension|December 2010|December 2, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00771069||148930|
NCT00762333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-252-2|Circulating Markers for Ischemic Heart Disease|Circulating Markers for Ischemic Heart Disease||University of Connecticut Health Center|No|Recruiting|June 2007|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|There are two arms to this study:        The investigators hope to enroll 350 healthy individuals, as defined by having no prior        diagnosis of heart disease to determine baseline levels and diurnal variations of the        markers.        Participants being evaluated for an acute Myocardial Infarction as determined by positive        CK MB/troponin levels, will be asked to enroll.|January 2013|January 16, 2013|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762333||149589|
NCT00765609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0904/93|To Evaluate the Paediatric Analgesia Slide|To Evaluate the Paediatric Analgesia Slide, a New Device Developed to Assist Parents in Administering Paracetamol to Children at Home||County Durham and Darlington NHS Foundation Trust|No|Not yet recruiting|December 2008|March 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|140|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|parents administering analgesic medication to their children|September 2008|October 2, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765609||149339|
NCT00765635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO2008/4503|Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal|Randomized, Placebo-Controlled Evaluation of Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal||Hospital Clinic of Barcelona|Yes|Completed|September 2008|||October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||October 2008|October 2, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765635||149337|
NCT00766753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-115|Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas|A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas||University of Pittsburgh|Yes|Active, not recruiting|December 2006|December 2014|Anticipated|February 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|June 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766753||149253|
NCT00762411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11271|Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo|Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo|IDENTITY-2|Eli Lilly and Company|Yes|Completed|September 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1111|||Both|55 Years|N/A|No|||January 2015|January 28, 2015|September 26, 2008|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT00762411||149583|All dosing for 4-week post-study drug cessation timeframe outcome measures stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants. No assessments made during 32-week follow up.
NCT00766493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEF-06-08|GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN)|GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (GORE EMBOLDEN)|EMBOLDEN|W.L.Gore & Associates|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|October 3, 2008|Yes|Yes||No|June 28, 2012|https://clinicaltrials.gov/show/NCT00766493||149272|
NCT00766467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-341|A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas|A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment||Dana-Farber Cancer Institute|Yes|Completed|September 2008|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|81|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766467||149274|
NCT00766714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZGhent 002|Efficacy Study of the Embryo Transfer Catheter|The Efficacy of the Embryo Transfer Catheter in IVF and ICSI is Operator-Dependent: a Randomized Clinical Trial||University Hospital, Ghent|No|Completed|January 2000|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1446|||Female|18 Years|N/A|No|||October 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766714||149256|
NCT00766727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||July 1, 2011|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766727||149255|
NCT00762996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0707|The Clinical Evaluation of Two Daily Disposable Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|August 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|65|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|September 26, 2008|Yes|Yes||No|October 24, 2008|https://clinicaltrials.gov/show/NCT00762996||149538|
NCT00763295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-015|Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?|Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?||Northwell Health|No|Completed|May 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients with HIV confirmed by standard methods|October 2012|October 25, 2012|September 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00763295||149515|
NCT00763308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|535|A Web-Based Cardiovascular Intervention for the Workplace|Fast Track Program to Create a Web-Based Cardiovascular Intervention for the Workplace||National Heart, Lung, and Blood Institute (NHLBI)|No|Not yet recruiting|April 2009|February 2010|Anticipated|February 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2008|September 26, 2008|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00763308||149514|
NCT00763581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078967-01|Personal Adherence Evaluation of Medication Use for Adult Bipolar Disorder Patients|Personal Adherence Evaluation of Individuals Receiving Treatment for Bipolar Disorder (PAE in BD)||Case Western Reserve University|Yes|Completed|April 2008|January 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Twenty adults (10 men and 10 women) receiving standard outpatient mental health treatment        at Connections, a community mental health clinic (CMHC).|June 2013|June 27, 2013|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00763581||149494|
NCT00763594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M59-08|Linköping University Relational and Interpersonal Psychotherapy Project|Randomized Controlled Trial of Interpersonal and Brief Relational Psychotherapy for Major Depressive Disorder.|LURIPP|Linkoeping University|No|Recruiting|September 2008|December 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|17 Years|65 Years|No|||August 2015|August 31, 2015|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763594||149493|
NCT00763607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-02/2007|Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)|Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer||Istituto Clinico Humanitas|No|Completed|November 2007|December 2009|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|454|Samples With DNA|Paraffine embedded tumor sections|Both|18 Years|N/A|No|Non-Probability Sample|Radically resected non small cell lung cancer patients|September 2010|September 1, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763607||149492|
NCT00761124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA102486|Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men|Informed Decision-Making Regarding PSA Screening|PSA|University of California, Los Angeles|No|Active, not recruiting|April 2003|December 2008|Anticipated|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1006|||Male|50 Years|70 Years|No|||September 2008|September 26, 2008|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761124||149680|
NCT00761449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMDSG07A|Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5|A Multicentre Phase II Study of the Efficacy and Safety of Lenalidomide in High-risk Myeloid Disease (High-risk MDS and AML) With a Karyotype Including Del(5q) or Monosomy 5||Nordic MDS Group|Yes|Completed|October 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2010|April 26, 2012|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761449||149656|
NCT00761774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01315|An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam|An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.||UCB Pharma|No|Active, not recruiting|November 2008|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|16 Years|N/A|No|||March 2016|March 4, 2016|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761774||149631|
NCT00761111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU63-0023|Could a Simple Information Booklet Modify Low Back Pain Patients Beliefs After Lumbar Discectomy?|Could a Simple Information Booklet Modify Low Back Pain Patients Beliefs After Lumbar Discectomy?||University Hospital, Clermont-Ferrand||Active, not recruiting|June 2007|||May 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|140|||Both|18 Years|80 Years|No|||October 2008|October 7, 2008|August 22, 2007||No||No||https://clinicaltrials.gov/show/NCT00761111||149681|
NCT00761410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT0153|A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee System|A Prospective, Non-Comparative Multi Centre Study to Evaluate the Clinical Performance of the DePuy Press Fit Condylar (P.F.C.) Sigma Rotating Platform High Flexion Knee.||DePuy International|No|Active, not recruiting|October 2004|January 2029|Anticipated|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|45 Years|75 Years|No|||September 2012|September 11, 2012|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761410||149659|
NCT00761423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET NL 02|The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial|The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial|PRICT|Biomet, Inc.|No|Completed|August 2008|August 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|70 Years|No|||December 2011|December 5, 2011|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761423||149658|
NCT00761761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chengappa Sensoril|Sensoril(Ashwaganhda)for Bipolar Disorder|Sensoril® (Ashwagandha) - A Standardized Extract From a Medicinal Plant - (Withania Somnifera) for Cognitive Enhancement in Persons With Bipolar Disorder: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study||University of Pittsburgh|Yes|Completed|October 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2013|January 11, 2013|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761761||149632|
NCT00757757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCS110A2101|A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases|A Phase I/II Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases||Novartis|No|Terminated|September 2008|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|18 Years|N/A|No|||February 2013|February 9, 2013|September 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00757757||149938|
NCT00757770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444563/033|Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine|Study to Assess the Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine in Terms of Immunogenicity and Safety When Given to Healthy Infants at 2 and 4 Months of Age||GlaxoSmithKline|No|Completed|August 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|854|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||August 2013|August 8, 2013|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00757770||149937|
NCT00762060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISScolorectal|Multicenter Infection Surveillance Study Following Colorectal Procedures|Phase IV Multicenter Infection Surveillance Study Following Colorectal Procedures|MISS|Halyard Health|No|Completed|November 2006|September 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|289|||Both|18 Years|N/A|No|Probability Sample|Surgical patients Colorectal procedures|December 2014|March 17, 2015|September 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762060||149609|
NCT00762073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPI-101-01|Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis|Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents||Shire|No|Completed|November 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|82|||Both|2 Years|18 Years|No|||March 2014|September 2, 2015|September 29, 2008|Yes|Yes||No|August 3, 2015|https://clinicaltrials.gov/show/NCT00762073||149608|
NCT00765375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX-D-001|Safety and Efficacy of the Use of Botox on Acne|Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A Injections for Subjects With Mild to Moderate Acne Vulgaris||DeNova Research|Yes|Terminated|September 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|50 Years|No|||April 2015|April 28, 2015|September 30, 2008||No|Investigator decision|No|August 29, 2012|https://clinicaltrials.gov/show/NCT00765375||149357|Study terminated after 5 subjects
NCT00765622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ucb123cestari|Assessment of Pelvic Floor Function in Elderly|Assessment of Pelvic Floor Function in Women With Urinary Incontinence||Catholic University of Brasília|Yes|Completed|April 2007|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|153|Samples Without DNA|Women|Female|58 Years|87 Years|Accepts Healthy Volunteers|Probability Sample|elderly women|August 2008|October 2, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765622||149338|
NCT00766480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615602|Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus|An Investigational Study of Chemoradiosensitivity Prediction With Genetic Profiling of Esophageal Biopsy for Squamous Cell Carcinoma of the Esophagus||National Cancer Institute (NCI)||Recruiting|January 2007|||March 2010|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|74 Years|No|||July 2009|August 23, 2013|October 3, 2008||||No||https://clinicaltrials.gov/show/NCT00766480||149273|
NCT00766194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22939/36001|Nasopharyngeal Pressure Measurement During Neonatal Nasal Respiratory Support|Nasopharyngeal Pressure Measurement During Neonatal Nasal Respiratory Support||University of Utah|No|Terminated|May 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|72 Hours|No|Non-Probability Sample|Any infant admitted to neonatal intensive care who is treated with a modality of        non-invasive respiratory support, such as low or high flow nasal cannula; nasal prong,        catheter or mask continuous distending pressure; or nasal ventilation either intermittent        mandatory, synchronized or high frequency will be eligible for study.|September 2013|September 10, 2013|September 3, 2008||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT00766194||149294|
NCT00762437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA07005|Non-Invasive Cooling of Fat Cells|||Zeltiq Aesthetics|No|Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|June 16, 2011|September 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762437||149581|
NCT00762450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2008-PLA-01-AM|Effect on Bacterial Glycolytic Acid Formation on Plaque|Effect on Bacterial Glycolytic Acid Formation on Plaque||Colgate Palmolive|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|6|||Both|72 Years|79 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|September 26, 2008|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00762450||149580|
NCT00762710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA017184-01|Study of the Medication Prazosin for Alcohol Dependence|Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence||Seattle Institute for Biomedical and Clinical Research|Yes|Recruiting|January 2009|November 2013|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762710||149560|
NCT00762970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1561AB|Controlling Myopia Progression With Soft Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|April 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|8 Years|12 Years|No|||July 2015|July 1, 2015|September 26, 2008|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT00762970||149540|
NCT00762723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-016|Clinical Outcomes of the Trinica(R) Anterior Lumbar Plate: Fixed Screws vs. Variable Screws|A Comparison of Clinical Outcomes Comparing Fixed-angle, Variable-angle, and Hybrid Screw Configuration for the Trinica(R) Anterior Lumbar Plate System||Zimmer, Inc.|No|Terminated|February 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|N/A|N/A|No|||March 2014|March 26, 2014|September 26, 2008||No|Study was stopped due to slow enrollment|No|February 10, 2014|https://clinicaltrials.gov/show/NCT00762723||149559|
NCT00762736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-OPI-525|Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS™) in Combination With TAK-536 in Subjects With Type II Diabetes||Takeda|No|Completed|July 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|704|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00762736||149558|
NCT00762749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPHNCO1003|Study to Evaluate Diphenhydramine in Children and Adolescents|An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Diphenhydramine in Children and Adolescents||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|2 Years|17 Years|No|||October 2011|October 4, 2011|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762749||149557|
NCT00763009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-202-1|Persantine: Variation in Response Trial|Persantine: Variation in Response Trial||University of Connecticut Health Center|Yes|Terminated|September 2002|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|21 Years|N/A|No|||November 2012|November 8, 2012|September 24, 2008||No|Limited numbers of patients qualified for trial|No||https://clinicaltrials.gov/show/NCT00763009||149537|
NCT00763321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-277|Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)|A Phase 3, Open-Label Period Followed by a Randomized, Double-blind Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain||AbbVie|No|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|287|||Both|21 Years|75 Years|No|||January 2014|January 8, 2014|September 26, 2008|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00763321||149513|
NCT00763633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B601|B6 Treatment for Nausea and Vomiting in Pregnancy|Vitamin B6 Concentration and Treatment in Nausea and Vomiting of Pregnancy||Showa University|Yes|Recruiting|January 2008|October 2008|Anticipated|October 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|150|||Female|15 Years|40 Years|Accepts Healthy Volunteers|||September 2008|December 30, 2008|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763633||149490|
NCT00763620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080502|Assessment of the Diagnostic Capacity of the Mini-broncho Alveolar Lavage Performed Through a Suction Catheter|Assessment of the Diagnostic Capacity of a New Sampling Technique for Lower Respiratory Tract Culture for Patients With Acute Infectious Pneumonia Admitted in Intensive Care Unit and Non Intubated.|Mini-LBA|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|36|||Both|18 Years|N/A|No|||June 2011|September 22, 2011|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763620||149491|
NCT00760851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01852|Yogurt Study in Children 2-4 Years Old Attending Daycare|Study to Investigate the Potential of Probiotics II|SIPPY II|Georgetown University|Yes|Completed|September 2008|July 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|190|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||February 2011|March 17, 2011|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00760851||149701|
NCT00761137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH004-2|Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients|A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients|NH004-2|NeuroHealing Pharmaceuticals Inc.|Yes|Completed|March 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|19|||Both|50 Years|80 Years|No|||April 2013|September 22, 2015|September 25, 2008||No||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00761137||149679|
NCT00761150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-385|Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)|A Phase 3, Open-Label Period Followed by a Randomized, Double-blind, Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain||AbbVie|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|308|||Both|21 Years|75 Years|No|||January 2014|January 9, 2014|September 25, 2008|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00761150||149678|
NCT00761787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARGO II|Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY|Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY|CARGOII|XDx|No|Completed|May 2005|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples Without DNA|venous blood whole blood white blood cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New and existing cardiac allograft recipients.|March 2009|March 5, 2009|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761787||149630|
NCT00762099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-PFE-01|Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery|The Short and Long Term Effects of Perioperative Pregabalin Use on Functional Rehabilitation, Pain Outcomes and Anxiety Following Total Hip Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.|RCT|Sunnybrook Health Sciences Centre|No|Recruiting|May 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|75 Years|No|||April 2011|April 7, 2011|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762099||149606|
NCT00762112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-559-017|Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Long-Term, Open-Label, Phase 3a Safety Study of Oral TAK-559 (32 mg QD) in the Treatment of Patients With Type 2 Diabetes Mellitus||Takeda|No|Terminated|November 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|316|||Both|25 Years|80 Years|No|||November 2012|November 8, 2012|September 26, 2008|Yes|Yes|Hepatic safety signal identified.|No||https://clinicaltrials.gov/show/NCT00762112||149605|
NCT00762125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR044724-07|Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment|Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment||University of Washington||Completed|December 2005|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|266|||Female|18 Years|65 Years|No|||December 2014|December 1, 2014|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762125||149604|
NCT00757445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sorlandet Hospital HF|Treatment Results on Patients With Debridement and Prosthesis Retention in the Hip|Treatment Results on Patients With Debridement and Prosthesis Retention in the Hip 1997-2007||Sorlandet Hospital HF|No|Completed|January 1997|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|105|||Both|15 Years|N/A|No|Probability Sample|Patients with prosthesis infection in hip|September 2008|September 22, 2008|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757445||149962|
NCT00758082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00389-46|Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients|Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study|TELFIT|University Hospital, Grenoble|No|Completed|July 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||March 2010|March 10, 2010|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00758082||149914|
NCT00758095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR05-006|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2006|||||N/A|N/A|N/A||||||||||||||November 20, 2013|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758095||149913|
NCT00766181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113-03P|Satisfaction With Pediatric Intravenous Catheter Placement in the Emergency Department|An Evaluation of Parent and Nurse Satisfaction Associated With Pediatric Peripheral Intravenous Catheter Placement Using Standard of Care vs. ZingoTM in the Emergency Department||Anesiva, Inc.|No|Terminated|October 2008|April 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|55 Years|No|Non-Probability Sample|Pediatric patients in Emergency Department requiring peripheral IV catheter placement.|November 2008|May 24, 2010|October 1, 2008||No|Product withdrawn from distribution|No||https://clinicaltrials.gov/show/NCT00766181||149295|
NCT00765921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-06-040|Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma|A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma||Massachusetts Eye and Ear Infirmary|No|Active, not recruiting|June 2008|December 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|October 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00765921||149315|
NCT00766220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0779|Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver|Phase II Randomized Study of SIR-Spheres, Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Metastases to the Liver||M.D. Anderson Cancer Center|Yes|Withdrawn|October 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 28, 2012|October 1, 2008|Yes|Yes|Slow Accrual and withdrawn/exclusion of 2 participants.|No||https://clinicaltrials.gov/show/NCT00766220||149292|
NCT00766779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003514-34|HCT Versus CT in Elderly AML|Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission||European Group for Blood and Marrow Transplantation|Yes|Recruiting|January 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|231|||Both|60 Years|75 Years|No|||April 2015|April 2, 2015|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766779||149251|
NCT00766792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/288|Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis|Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis||University Hospital, Ghent|No|Completed|December 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||October 2008|October 30, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766792||149250|
NCT00766805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-PHT-01|Endoscopic Variceal Ligation (EVL)+ Drugs Versus Endoscopic Variceal Ligation (EVL) Alone For Secondary Prophylaxis|Endoscopic Variceal Ligation Plus Propranolol And Isosorbide Mononitrate Versus Endoscopic Variceal Ligation Alone For Secondary Prophylaxis Of Variceal Bleeding: A Randomized Controlled Trial|Secondary|Govind Ballabh Pant Hospital|No|Completed|October 2002|June 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|177|||Both|8 Years|75 Years|No|||October 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766805||149249|
NCT00766766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMOKN5|Reduction of Environmental Tobacco Smoke (ETS) Exposure In Pediatric Cancer Patients|Reduction of Environmental Tobacco Smoke (ETS) Exposure In Pediatric Cancer Patients||St. Jude Children's Research Hospital|No|Completed|September 2002|June 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|166|||Both|N/A|17 Years|No|||September 2013|September 5, 2013|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766766||149252|
NCT00763022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-559-014|Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus||Takeda|No|Completed|November 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|302|||Both|25 Years|75 Years|No|||November 2012|November 8, 2012|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763022||149536|
NCT00763347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-SYR-619-003|Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate Treatment With SYR-619 in Subjects With Type 2 Diabetes||Takeda|No|Terminated|November 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|82|||Both|18 Years|80 Years|No|||May 2012|May 18, 2012|September 26, 2008|Yes|Yes|Voluntarily terminated based on preliminary non-clinical findings.|No||https://clinicaltrials.gov/show/NCT00763347||149512|
NCT00763360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-S-07-01|To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.|To Compare the Ability of DiscoVisc® Ophthalmic Viscosurgical Device (OVD) to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.||Alcon Research|No|Completed|May 2008|||September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|184|||Both|49 Years|N/A|No|||December 2011|December 20, 2011|September 26, 2008|Yes|Yes||No|December 20, 2011|https://clinicaltrials.gov/show/NCT00763360||149511|
NCT00763659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2032-06/07|Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)|Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)|LUTEGA|University of Jena|No|Completed|May 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|172|||Both|50 Years|95 Years|No|||July 2012|July 19, 2012|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763659||149488|
NCT00763646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McG 0620|Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma|Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma||McGill University|Yes|Recruiting|April 2007|||December 2010|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|80 Years|No|||September 2008|October 20, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763646||149489|
NCT00763932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02003|Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies|A Multicenter, Open-Label Extension Study of the Long-Term Safety and Efficacy of Recombinant Human Acid α-Glucosidase (rhGAA) in Patients With Pompe Disease (Glycogen Storage Disease Type II) Who Were Previously Enrolled in Genzyme-Sponsored Enzyme Replacement Therapy Studies||Sanofi|Yes|Completed|April 2003|July 2006|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763932||149468|
NCT00760877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2405|Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Pts With Evidence of Persistent Leukemia by RQ-PCR (ENESTcmr).|An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.||Novartis|No|Completed|June 2009|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760877||149699|
NCT00761163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701004892|The Body's Response to Aerobic Versus Resistance Exercise|||Purdue University||Completed|February 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761163||149677|
NCT00761176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGI-08-08-1|A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers|A Controlled Study Comparing Basic Wound Care to the Provant® Therapy System as an Adjunct to Basic Wound Care for Wound Surface Area Reduction in Diabetic Plantar Foot Wounds||Regenesis Biomedical, Inc.|No|Terminated|July 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|September 25, 2008|No|Yes|Protocol Violations noted for 6 of 8 patients|No|October 26, 2015|https://clinicaltrials.gov/show/NCT00761176||149676|
NCT00761475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIMA TRIAL|Primary Mesh Closure of Abdominal Midline Wounds|Primary Mesh Closure of Abdominal Midline Wounds; a Prospective Randomized Multicenter Trial|PRIMA|Erasmus Medical Center|Yes|Recruiting|February 2009|December 2014|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|460|||Both|18 Years|N/A|No|||November 2012|November 11, 2012|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761475||149654|
NCT00761488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK-Toric-YIU-01|Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric|||Alcon Research||Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|40 Years|80 Years|No|||January 2010|May 8, 2015|September 25, 2008|No|Yes|Primary Investigator resigned from hospital|No||https://clinicaltrials.gov/show/NCT00761488||149653|
NCT00761462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100201|BAY 0 9867 Cipro Pediatric Use Study (QUIP)|A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses||Bayer|Yes|Completed|October 1999|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1029|||Both|2 Months|16 Years|No|||July 2015|July 13, 2015|September 26, 2008|Yes|Yes||No|December 19, 2008|https://clinicaltrials.gov/show/NCT00761462||149655|The study was not randomized or blinded; the demographic and baseline infection characteristics were not comparable for the treatment groups; the long term followup times were different for the two groups (5 year versus 2 years).
NCT00761800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04087|Dermacyd Teen Care Tangerina Mix - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermal Irritability, Dermal Sensitivity) of Dermacyd Teen Care Tangerina Mix .||Sanofi|No|Completed|May 2008|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|51|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2009|May 28, 2009|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00761800||149629|
NCT00753428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X080331005|Community-based Evaluation of a Pilot PMTCT Project in Kafue District|CIDRZ 1236 - Community-based Evaluation of a Pilot PMTCT Project in Kafue District: Impact of HAART to Prevent Pediatric AIDS in Rural Zambia.||University of North Carolina, Chapel Hill|No|Completed|November 2008|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|4129|Samples With DNA|Finger/Heel pricks will be performed for Dried Blood Spot Cards.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Households will be eligible for the full survey if they report that a child was born to a        household member within the past two years. If the answer to this question is "yes," an        attempt will be made to speak with the mother of the child. If the mother of the child is        not available, then the primary care-taker of the child will be interviewed at that time.|September 2014|September 16, 2014|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753428||150266|
NCT00753441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-02|Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic Head|Endoscopic Biliary Stenting on Demand Versus Surgical Biliary Bypass for Palliation of Patients With Advanced Cancer of the Pancreatic Head: STENTBY - A Randomized Controlled Trial|STENTBY|Heidelberg University|Yes|Recruiting|September 2008|January 2016|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753441||150265|
NCT00754351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.01|Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer|Docetaxel, Gemcitabine and Bevacizumab as Salvage Therapy for Metastatic Breast Cancer||University Hospital of Crete|No|Completed|September 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||June 2012|June 26, 2012|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754351||150197|
NCT00754572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21530|A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis||Hoffmann-La Roche||Completed|February 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|418|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|September 17, 2008||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT00754572||150180|
NCT00756574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6273-15-2008|Randomized Control Trial to Study the Efficacy of the Surgical Mask Versus the N95 Respirator to Prevent Influenza|A Randomized Control Trial of Surgical Masks vs N95 Respirators to Prevent Influenza in Health Care Workers||McMaster University|Yes|Completed|October 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|447|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2009|July 15, 2009|September 19, 2008||No||No|July 15, 2009|https://clinicaltrials.gov/show/NCT00756574||150029|
NCT00756587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004|Cup Versus Bottle Feeding for Late Preterm Infants|Cup Versus Bottle Feeding for Hospitalized Late Preterm Infants in Egypt||Cairo University|No|Completed|December 2003|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|34 Weeks|37 Weeks|No|||September 2008|October 30, 2008|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756587||150028|
NCT00755326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040954|Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee|Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee|TCM-OAK|University of Maryland|Yes|Completed|April 2007|July 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|N/A|No|||February 2013|February 19, 2013|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755326||150122|
NCT00755339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080215|Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome|Understanding the Anatomy and Physiology of the Sensory Experience and Its Role in Generating Tics in Tourette Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|September 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 19, 2015|September 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00755339||150121|
NCT00755924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03635-07-C|Prospective Randomized Clinical Trial Evaluating the Impact of Vinegar on High Density Lipoprotein|||HealthPartners Institute|No|Completed|June 2008|July 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|November 25, 2015|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755924||150078|
NCT00766064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804003717|Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)|Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)||Yale University|No|Completed|September 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|No|||April 2015|April 28, 2015|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00766064||149304|
NCT00757068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVINER01|Strategies to Avoid Returning to Smoking|Addressing Postpartum Mood and Weight Concerns to Sustain Smoking Cessation|STARTS|University of Pittsburgh|Yes|Completed|September 2007|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Female|14 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757068||149991|
NCT00757081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD-001|Study to Evaluate the Effect of Injection Lypolysis (Lipodissolve) Treatments to Reduce Body Fat|Metabolic And Structural Effects Of Phosphatidylcholine And Deoxycholate Injections On Subcutaneous Fat||BodyAesthetic Research Center|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2009|February 6, 2013|September 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00757081||149990|
NCT00757094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFMC IRB-08-040|Safety and Feasibility of Fasting While Receiving Chemotherapy|Safety and Feasibility of Fasting While Receiving Chemotherapy||King Fahad Medical City|No|Completed|September 2008|March 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Fasting patients who are schedulled to receive chemotherapy during the month of Ramadan|February 2010|February 24, 2010|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757094||149989|
NCT00764218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS2001/0398|Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome|Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome : Role of Hypertension|SAS-HTA|University Hospital, Grenoble|Yes|Recruiting|March 2001|December 2008|Anticipated|December 2003|Anticipated|Phase 0|Interventional|Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2001|September 30, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764218||149446|
NCT00764881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91548|Effects of SH T00658ID on Libido|Multi-center, Double-blind, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive Containing Estradiol Valerate and Dienogest (SH T00658ID) Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon) Over 6 Treatment Cycles on Alleviating Complaints of Reduced Libido in Women With Acquired Female Sexual Dysfunction (FSD) Associated With Oral Contraceptive Use||Bayer|No|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Female|18 Years|50 Years|No|||December 2014|December 8, 2014|October 1, 2008||No||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00764881||149395|
NCT00764894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 701|Foundation Knee Study - Retrospective|Post-Market Study of the Foundation Knee System||Encore Medical, L.P.|No|Terminated|October 2007|February 2011|Actual|February 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who meet the indications for use of the Foundation Knee device AND who meet        the inclusion/exclusion criteria|February 2011|February 8, 2011|September 30, 2008|Yes|Yes|Enrollment and data collection insufficient to continue study.|No||https://clinicaltrials.gov/show/NCT00764894||149394|
NCT00764842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 802|Efficacy of the CLP® Hip - Retrospective|Post-Market Study: The Efficacy of the CLP® Hip||Encore Medical, L.P.|No|Terminated|January 2008|February 2011|Actual|February 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|61|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who meet the indications for use of the CLP Hip Stem AND who meet the        inclusion/exclusion criteria|February 2011|February 8, 2011|September 30, 2008|Yes|Yes|Enrollment and data collection insufficient to continue study.|No||https://clinicaltrials.gov/show/NCT00764842||149398|
NCT00765193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-175 ex 07/08|The Impact of Total Body Skin Examination on Skin Cancer Detection|The Impact of Total Body Skin Examination on Skin Cancer Detection|TBSE|Medical University of Graz|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14381|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||April 2010|April 14, 2010|August 14, 2008||No||No|June 27, 2009|https://clinicaltrials.gov/show/NCT00765193||149371|
NCT00765739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMES1|The Effect of Neuromuscular Electrical Stimulation (NMES)|The Effect of Neuromuscular Electrical Stimulation (NMES) in Inducing Muscle Hypertrophy and Improvement in Muscle Torque Output Within the Quadriceps Muscle of Elderly People|NMES|University of Pittsburgh|No|Completed|October 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765739||149329|
NCT00765986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-24319|Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy|A Study to See if a New Type of Imaging Can Help Our Understanding of the Course of Non-small Cell Lung Cancer in Patients Undergoing Treatment With Radiotherapy or Chemoradiotherapy||AHS Cancer Control Alberta|No|Recruiting|October 2008|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with inoperable NSCLC undergoing radiotherapy or chemoradiotherapy|October 2014|October 2, 2014|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765986||149310|
NCT00765999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-02|An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation|An Open-Label, Long-Term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation||Forest Laboratories|No|Completed|October 2008|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1557|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|October 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00765999||149309|
NCT00753168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-730-C01|Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma|A Randomized, Parallel-Group, Multi-Center, Investigator-Masked, Active-and Placebo-Controlled, Phase 1-2 Evaluation of the Safety and Efficacy of OT-730 Ophthalmic Solution in Reducing the Intraocular Pressure in Subjects With Ocular Hypertension or Open-Angle Glaucoma||Othera Pharmaceuticals|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|80 Years|No|||January 2009|January 6, 2009|September 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00753168||150285|
NCT00755365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28576EM|Intraoperative Angioembolization in the Management of Pelvic Fracture-Related Hemodynamic Instability|Intraoperative Angioembolization in the Management of Pelvic Fracture-Related Hemodynamic Instability||Penn State University|No|Active, not recruiting|January 2003|September 2008|Anticipated|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|15|||Both|18 Years|90 Years|No|Non-Probability Sample|The subjects in this study are trauma patients over 18 years of age who suffered pelvic        fractures and developed associated hemodynamic instability between January 1, 2003 and        December 31, 2007. All patients were treated at Hershey Medical Center and received        intraoperative angioembolization as a part of their medical management.|September 2008|September 17, 2008|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00755365||150119|
NCT00755378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1960C00001|AZD8529 Single Ascending Dose Study|Phase I, Single-Center, Randomized, Double-Blind, Placebo Controlled Single-Ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and PK of AZD8529 in Healthy Subjects Part B: A Randomized, Open Label Study to Assess the Effect of Food on AZD 8529|SAD|AstraZeneca|No|Completed|September 2008|March 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|58|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 25, 2009|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00755378||150118|
NCT00787475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD1689|Northern Manhattan Diabetes Community Outreach Project|Northern Manhattan Diabetes Community Outreach Project|NOCHOP|Columbia University|No|Completed|September 2008|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|360|||Both|35 Years|70 Years|No|||February 2015|February 2, 2015|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787475||147685|
NCT00787748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI061228|COPD and Cardiovascular Risk in the Population|COPD and Cardiovascular Risk in the Population|CORSAIB|Cimera|Yes|Completed|October 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|623|Samples Without DNA|Samples of serum were frozen at -80 ºC|Both|40 Years|81 Years|Accepts Healthy Volunteers|Probability Sample|Random population sample, and a sample of hospital cardiovascular patients|June 2012|June 14, 2012|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787748||147664|
NCT00755937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02793|Remicade® Crohn's Disease Registry Across Canada (Study P02793)|Remicade® Treatment Registry Across Canada in Crohn's Disease|RemiTRAC®|Merck Sharp & Dohme Corp.|No|Terminated|February 2002|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|556|||Both|N/A|N/A|No|Non-Probability Sample|Primarily from community centers and some academic centers.|May 2015|May 26, 2015|August 26, 2008|No|Yes|Satisfied a post-marketing commitment to Canadian Health Authorities.|No|September 29, 2008|https://clinicaltrials.gov/show/NCT00755937||150077|This was an observational study. There were no imposed interventions from the Sponsor including imposing specific duration of treatment or data collection beyond the standard of care.
NCT00755950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042363|Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis|A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period||University of Maryland|Yes|Terminated|October 2008|December 2015|Anticipated|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|70|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|September 17, 2008||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT00755950||150076|
NCT00765284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-12|Effect of Niaspan on Cholesterol in Men|Effect of Niaspan on Parameters of Reverse Cholesterol Transport and HDL-C Subclasses in Male Subjects With Low HDL-C Levels||KineMed|No|Completed|December 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|15|Samples With DNA|Stool, urine, and blood samples will be taken and analyzed as part of the study.|Male|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Study will include a total of 15 subjects, non-diabetic men with low HDL-C, defined as <40        mg/dL. Subjects will be aged 18 to 70 years and have a BMI between 18.5-40 kg/m2.|June 2011|June 29, 2011|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765284||149364|
NCT00765297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-3-045|Identify Subjects at Risk for Falling Using Acceleration Based Gait Analysis System|Identify Subjects at Risk for Falling Using Acceleration Based Gait Analysis System|stumble|Maastricht University Medical Center|Yes|Recruiting|September 2007|October 2010|Anticipated|October 2010|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||July 2010|July 26, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765297||149363|
NCT00765557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122004-038|Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome|Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome||University of Texas Southwestern Medical Center||Available||||||N/A|Expanded Access|N/A|||||||Both|4 Years|21 Years||||October 2008|October 2, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765557||149343|
NCT00755391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4819|Cognitive Behavioral Therapy for Adolescents With Bulimia|Cognitive Behavioral Therapy for Adolescents With Bulimia||New York State Psychiatric Institute|No|Completed|February 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|12 Years|18 Years|No|||October 2012|October 25, 2012|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755391||150117|
NCT00756821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BforSMA|A Pilot Study of Biomarkers for Spinal Muscular Atrophy|A Pilot Study of Biomarkers for Spinal Muscular Atrophy|BforSMA|New England Research Institutes|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|130|Samples With DNA|Whole blood, plasma, PBMCs, and urine|Both|2 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children's Hospitals Unviersity Hospitals|October 2012|October 23, 2012|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756821||150010|
NCT00756834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS-SP04-04|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2006|||||N/A|N/A|N/A||||||||||||||September 19, 2008|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756834||150009|
NCT00766077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29496|Bone Geometry, Strength, and Biomechanical Changes in Runners With a History of Stress Fractures|Bone Geometry, Strength, and Biomechanical Changes in Runners With a History of Stress Fractures||University of Utah|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Participants must be competitive female distance runners between the ages of 18-35.        Athletes must currently be healthy, have been training for a minimum of 5 years and        running 25 or more miles per week during their competitive season.|April 2010|April 12, 2010|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766077||149303|
NCT00766376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERf-02|Safety and Efficacy Evaluation of Erbium Treatment|Safety and Efficacy Evaluation of Fractional Erbium Treatment||Palomar Medical Technologies, Inc.|No|Active, not recruiting|July 2007|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|September 30, 2008|Yes|Yes||No|January 6, 2010|https://clinicaltrials.gov/show/NCT00766376||149280|
NCT00764231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML001|A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML)|A Pilot Study of a Home-based Exercise Intervention for Patients With AML||Toronto Rehabilitation Institute|No|Completed|October 2008|April 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|79 Years|No|||February 2012|February 7, 2012|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764231||149445|
NCT00764244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030426|Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema|VITRILASE Study: Prospective Randomized Trial Comparing the Effect of Laser, Vitrectomy and Intravitreal Triamcinolone Injection for Diabetic Macular Edema|VITRILASE|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2005|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||November 2014|March 23, 2015|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764244||149444|
NCT00765518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-55-0712-1|Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)|Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy||Vericel Corporation|Yes|Completed|September 2008|February 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|86 Years|No|||October 2012|October 1, 2012|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765518||149346|
NCT00764855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/250|Validation of the Effect of Propofol and Opiates Closed-loop Administration Device During Anesthesia and Sedation|Validation of the Effect of Propofol and Opiates Closed-loop Administration Device During Anesthesia and Sedation||University Hospital, Ghent|No|Completed|October 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients undergoing a surgery with general anesthesia|May 2012|May 4, 2012|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764855||149397|
NCT00764868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-306|Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study|A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire|No|Completed|October 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|269|||Both|13 Years|17 Years|No|||January 2014|January 10, 2014|September 29, 2008|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00764868||149396|
NCT00765505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405764|Muscle Lipid and Insulin Resistance in the Elderly|Muscle Lipid and Insulin Resistance in the Elderly|MIRA|University of Pittsburgh|Yes|Recruiting|July 2004|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||March 2009|March 25, 2009|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765505||149347|
NCT00766324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AURA-6202-007|PHA-739358 for Treatment of Hormone Refractory Prostate Cancer|A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer||Nerviano Medical Sciences|No|Completed|September 2007|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Male|18 Years|N/A|No|||May 2014|May 13, 2014|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766324||149284|
NCT00766337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-003|Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration|A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|EMERALD|Santen Inc.|No|Terminated|December 2008|March 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|62|||Both|50 Years|N/A|No|||July 2010|January 8, 2013|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766337||149283|
NCT00762853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2008-PLA-16-RR|Development of Clinical Method to Triclosan Retention in Plaque Following Brushing|Development of Clinical Method to Triclosan Retention in Plaque Following Brushing||Colgate Palmolive|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|February 16, 2012|September 26, 2008|Yes|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00762853||149549|
NCT00766571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080224|Clinical and Genetic Studies of VACTERL Association|Clinical and Genetic Studies of VACTERL Association||National Institutes of Health Clinical Center (CC)||Completed|September 2008|||||N/A|Observational|N/A|||Actual|304|||Both|N/A|100 Years|No|||February 2016|February 18, 2016|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766571||149266|
NCT00755079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162-C|Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury|A Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Determine the Effect of an Oral Beta-2 Agonist on Respiratory Muscle Strength in Spinal Cord Injury||VA Office of Research and Development|No|Completed|April 2007|December 2014|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||February 2015|February 24, 2015|September 15, 2008||No||No|June 16, 2014|https://clinicaltrials.gov/show/NCT00755079||150141|
NCT00754624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-010|An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial|A Four-year, Safety and Tolerability, Open-Label, "Follow on" Trial Evaluating Technosphere® Insulin in Subjects With Type 2 Diabetes Mellitus.||Mannkind Corporation||Completed|May 2004|October 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|229|||Both|18 Years|80 Years|No|||October 2014|October 9, 2014|September 16, 2008|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00754624||150176|
NCT00787761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000618483|Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer|Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors||Northside Hospital, Inc.|No|Completed|April 2007|May 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|75 Years|No|||August 2012|August 29, 2012|November 7, 2008|Yes|Yes||No|July 9, 2012|https://clinicaltrials.gov/show/NCT00787761||147663|
NCT00755092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2008-416|Effect of Doula in Nulliparas and Multiparas|Analgesic Efficacy of Doula in Nulliparous and Multiparous Women|DINAM|Nanjing Medical University|Yes|Completed|September 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|150|||Female|19 Years|45 Years|No|||February 2009|February 10, 2009|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755092||150140|
NCT00755105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC049|Measurements of Body Iron Excretion of Healthy Adults|Body Iron Excretion of Healthy Adults as Measured by Isotope Dilution||USDA Grand Forks Human Nutrition Research Center|No|Completed|September 1998|December 2005|Actual|December 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|77|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult men and women who previously participated in iron absorption studies using        iron-55 isotope.|August 2011|August 4, 2011|September 16, 2008||No||No|December 30, 2008|https://clinicaltrials.gov/show/NCT00755105||150139|
NCT00755118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.28|Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc|Phase II Study Of Weekly Administration Oxaliplatin Plus 5-Fu/Lv (Aio Regimen) Plus Bevacizumab, Alternative With Irinotecan Plus 5-Fu/Lv(Aio Regimen) Plus Cetuximab, As Salvage Treatment In Pretreated Patients With Mcrc||University Hospital of Crete|No|Terminated|October 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|72 Years|No|||October 2015|October 6, 2015|September 17, 2008||No|Due to poor Accrual|No||https://clinicaltrials.gov/show/NCT00755118||150138|
NCT00755404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-003-05|Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)|Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-Carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis||Iperboreal Pharma Srl|No|Recruiting|June 2007|December 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755404||150116|
NCT00765791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7527|Shoulder Function After Level IIB Neck Dissection: A Randomized Controlled Study|Shoulder Function After Level IIB Neck Dissection: A Randomized Controlled|2B/Not 2B|University of Alberta|Yes|Enrolling by invitation|December 2008|February 2014|Anticipated|February 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765791||149325|
NCT00755963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-20070724|Effects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women|The Influence of Hormone Replacement Therapy on the Cerebral Serotonin-1A Receptor Distribution and Mood in Postmenopausal Women||Medical University of Vienna|Yes|Completed|May 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 20, 2011|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755963||150075|
NCT00756873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etoric-TE-1|Etoricoxib in Ear Nose Throat Surgery|Analgesic Efficacy and Safety of Etoricoxib in Ear Nose Throat Surgery||University of Regensburg|No|Not yet recruiting|October 2008|December 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||September 2008|September 19, 2008|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756873||150006|
NCT00764582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPH0109|Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery|A Randomized, Observer-masked, Parallel-group, Multicenter Trial Evaluating the Ocular Penetration of 1.5% Levofloxacin Ophthalmic Solution and 0.5% Moxifloxacin Ophthalmic Solution in Subjects Undergoing Corneal Transplant Surgery||Santen Inc.|No|Terminated|September 2008|||March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2009|August 24, 2009|September 26, 2008||No|Study terminated due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00764582||149418|
NCT00765219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H23798|Cognitive Behavior Treatment of Older Adults With Generalized Anxiety Disorder in Primary Care|Treating Late-life GAD in Primary Care: Enhancing Outcomes and Translational Value||Baylor College of Medicine|No|Completed|May 2008|April 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|222|||Both|60 Years|N/A|No|||July 2015|July 21, 2015|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765219||149369|
NCT00765765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615000|Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer|Phase I/II Study of Ixabepilone in Combination With the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients With Metastatic Breast Cancer||Rutgers, The State University of New Jersey|No|Terminated|February 2009|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|October 2, 2008|Yes|Yes|Slow accrual|No|November 6, 2013|https://clinicaltrials.gov/show/NCT00765765||149327|
NCT00765206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18134|A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)|Randomized, Crossover Pharmacodynamic Study Comparing the Effects of Zegerid® (20 mg Omeprazole/Sodium Bicarbonate) and Prilosec OTC® Tablets (20 Mg-equivalent Omeprazole)||Bayer|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|September 30, 2008|Yes|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00765206||149370|
NCT00766012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00004|Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects|A Phase I, Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Oral Doses of AZD2066 in Japanese Healthy Male Subjects||AstraZeneca|No|Completed|September 2008|July 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|132|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766012||149308|
NCT00766870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12279A|Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder|A Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active-referenced Study Evaluating the Efficacy and Safety of Three Fixed Dose Regimens of Lu AA34893 in the Treatment of Major Depressive Disorder||H. Lundbeck A/S|No|Terminated|September 2008|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|35|||Both|18 Years|75 Years|No|||September 2010|September 28, 2010|October 3, 2008||No|Study was previously paused and is now terminated|No||https://clinicaltrials.gov/show/NCT00766870||149244|
NCT00762567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHEALY1006|Phenylephrine Pediatric Pharmacokinetic Study|An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Phenylephrine in Children and Adolescents||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|2 Years|17 Years|No|||October 2011|October 4, 2011|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762567||149571|
NCT00762866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080606|Psychiatric Genotype/Phenotype Project Repository|Psychiatric Genotype/Phenotype Project|PGPP|Vanderbilt University|No|Enrolling by invitation|September 2008|December 2022|Anticipated|December 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|300|Samples With DNA|Blood, urine, saliva|Both|16 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient Mental Health Clinic, Inpatient Psychiatric Hospital, Research Volunteers|June 2015|June 8, 2015|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762866|2 Weeks|149548|
NCT00763113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET CA 01|A Prospective Randomized Study on Vanguard Cruciate Retaining Versus Vanguard High Flex Posterior Stabilized Total Knee System in the Early Range of Motion|A Prospective Randomized Study on Vanguard Cruciate Retaining Versus Vanguard High Flex Posterior Stabilized Total Knee System in the Early Range of Motion||Biomet, Inc.|No|Completed|June 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|N/A|N/A|No|||July 2012|July 12, 2012|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00763113||149529|
NCT00763100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708023|Efficacy of Tomosynthesis in the BIRADS 3 Population|The Efficacy of Tomosynthesis in the BIRADS 3 Population Including Surveillance of Patients in the Treatment or Post-Treatment for Breast Cancer|BIRADS|WellSpan Health|Yes|Completed|May 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|690|||Female|26 Years|N/A|No|Non-Probability Sample|Three groups of patients will be enrolled:        Group 1 will enroll patients that have been categorized as a BIRADS 3 on the basis of        screening and diagnostic conventional imaging work-up.        Group II will enroll patients that have been categorized as a BIRADS 3 for surveillance        imaging because they have undergone breast conservation therapy for breast cancer.        Group III will enroll patients that have been categorized as a BIRADS 3 for surveillance        imaging because they are currently undergoing primary systemic therapy.|January 2011|January 5, 2011|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00763100||149530|
NCT00787176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-034|The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes|The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes||Northwestern University|No|Terminated|September 2007|July 2012|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|252|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|November 6, 2008||No|Study concluded prematurely prior to meeting intended goal recruitment.|No||https://clinicaltrials.gov/show/NCT00787176||147706|
NCT00755430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807036R|Structural and Functional Connectivity in Autism Spectrum Disorders|Structural and Functional Connectivity in Autism Spectrum Disorders by Using Diffusion Spectrum Imaging and Functional Magnetic Resonance Imaging Studies||National Taiwan University Hospital|Yes|Not yet recruiting|January 2009|December 2012|Anticipated|||N/A|Observational|Observational Model: Cohort||1|Anticipated|150|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|3 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|The sample will consist of 50 children with DSM-IV ASD (autistic disorder and Asperger's        disorder) aged 3-15, their siblings, and 50 age-, sex-, and handedness-matached healthy        controls.|September 2008|September 18, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755430||150114|
NCT00754585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082007|The Effectiveness of the Logic Back™Support.|The Effectiveness of the Logic Back™Support in Promoting a Comfortable Neutral Low Back Position, Reduced Muscular Effort, Improved Performance, and Decreased Postural Shifts in Seating.||Canadian Memorial Chiropractic College|No|Completed|August 2008|October 2009|Actual|October 2009|Actual|Phase 0|Observational|N/A||1|Anticipated|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males only, ages between 20-55 years of age|November 2010|November 16, 2010|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00754585||150179|
NCT00754598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2006|||||N/A|N/A|N/A||||||||||||||September 17, 2008|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754598||150178|
NCT00754611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN4162008|The Evolution and Management of Migraine Recurrence Beyond 24 Hours|The Evolution and Management of Migraine Recurrence Beyond 24 Hours: A Prospective Study of Tertiary Care Center Patients||Rutgers, The State University of New Jersey|No|Active, not recruiting|December 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients at the University Headache Center, aged 18 or older, with a diagnosis of migraine        with and/or without aura as defined by ICHD-II criteria|February 2010|February 3, 2010|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00754611||150177|
NCT00754858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000614308|Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer|Phase II Study of Camtobell Inj.(Belotecan) in Combination With Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer||Yonsei University|No|Completed|October 2008|June 2012|Actual|May 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|75 Years|No|||November 2014|November 26, 2014|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754858||150158|
NCT00755417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREEZE 1|Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women||Depomed|No|Completed|September 2008|October 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|541|||Female|18 Years|70 Years|No|||February 2012|February 3, 2012|September 17, 2008|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00755417||150115|
NCT00755729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCZH-0809-110|The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway|The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway||Shanghai Changzheng Hospital|Yes|Completed|November 2006|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|25 Years|75 Years|No|||September 2008|September 18, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755729||150093|
NCT00755976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-03 ICORG|Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma|Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma||ICORG- All Ireland Cooperative Oncology Research Group||Completed|August 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||October 2012|December 30, 2014|September 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00755976||150074|
NCT00755703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0701-2|Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.|A Phase I, Dose-Ranging Safety and Immunogenicity Study of an Adenovirus-vectored Intranasal, Pandemic (Hemagglutinin H5) Influenza Vaccine, ADhVN1203/04.H5, in Healthy Adults||Altimmune, Inc.|Yes|Completed|October 2008|December 2011|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|48|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||September 2012|December 31, 2015|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755703||150095|
NCT00755716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-114-1|Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study|Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study||University of Connecticut Health Center|No|Completed|April 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755716||150094|
NCT00756613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|465FS|The VA Diabetes Trial Follow-up Study (VADT-FS)|CSP #465FS - VA Diabetes Trial Long Term Follow-up Study|VADT-F|VA Office of Research and Development|Yes|Active, not recruiting|February 2008|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1350|||Both|40 Years|N/A|No|Non-Probability Sample|To be eligible for the VADT, subjects had to be over 40 years old, have type 2 diabetes        and be non-responsive (A1c > 7.5%) to a maximum daily dose of one or more oral agents or        on insulin. And to participate in the VADT-FS the participant had to be active in the VADT        study.|January 2016|January 21, 2016|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756613||150026|
NCT00756860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070885|A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)|A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®) on Phosphate Binding in Healthy Volunteers||Amgen||Completed|May 2008|September 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00756860||150007|
NCT00765232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-000747 LDN|Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy|The Efficacy of Continuous Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy: a Double Blinded Randomized Placebo Controlled Trial.||Mayo Clinic|No|Completed|October 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|65 Years|No|||December 2011|December 21, 2011|September 30, 2008|Yes|Yes||No|November 18, 2011|https://clinicaltrials.gov/show/NCT00765232||149368|
NCT00766038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTTBIMS-GH RCT|Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.|A Phase II, Randomized Controlled Trial of Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.|Growth-TBI|University of Texas Southwestern Medical Center|Yes|Completed|September 2008|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|50 Years|No|||December 2015|December 31, 2015|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766038||149306|
NCT00766051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23739|A Study of Neurophysiologically Based Occupational Therapy Intervention (NBOTI) for Feeding in the NCCU.|The Efficacy of Neurophysiologically Based Occupational Therapy Intervention in the Neonatal Intensive Care Unit: An Exploratory Study|NBOTI|University of Utah|No|Completed|November 2007|March 2010|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|29 Weeks|44 Weeks|No|||September 2012|September 9, 2012|September 3, 2008||No||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00766051||149305|The limitation of this study is that the effectiveness of the neurophysiologically based occupational therapy intervention applies to the diagnostic groups of the infants that participated in this study.
NCT00765752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707002830|Cortical GABA Concentrations in Insomnia|The Association of Cortical GABA Concentrations in Subjects With Primary Insomnia and Depression in Partial Remission With Residual Insomnia||Yale University|No|Completed|November 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|23|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|January 2013|January 18, 2013|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765752||149328|
NCT00766584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201085|Autonomic Nervous System Activity, Aging and Sleep Apnea/Hypopnea|Autonomic Nervous System Activity, Aging and Sleep Apnea/Hypopnea in a Prospective Cohort of Subjects Aged 67 Years|SYNAPSE|Centre Hospitalier Universitaire de Saint Etienne|No|Active, not recruiting|January 2003|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|852|Samples Without DNA|Serum|Both|67 Years|68 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and        were eligible if aged 65 at the inclusion date in the PROOF study|February 2016|February 19, 2016|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766584||149265|
NCT00766597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1071|Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents|Phase I/II Open-Label Study to Evaluate the PK, Safety, Tolerability and Antiviral Activity of Vicriviroc, a Novel CCR5 Antagonist in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|August 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|2 Years|18 Years|No|||December 2015|December 28, 2015|October 3, 2008|No|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT00766597||149264|Study was terminated early with Merck's announcement on July 15, 2010 on the discontinuation of the development of Vicriviroc, with 4 participants given study drug and only 1 participant reached Week 24.
NCT00766883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080220|Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant|A Phase II Clinical Trial to Determine the Effectiveness of Problem Solving Education in Caregivers and Patients During Allogeneic HSCT||National Institutes of Health Clinical Center (CC)||Completed|September 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|195|||Both|18 Years|N/A|No|||May 2015|May 30, 2015|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766883||149243|
NCT00759889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-005|Obtaining and Storing Standard of Care Wound Biopsies for Immediate or Future Wound-Related Scientific Study|Obtaining and Storing Standard of Care Wound Biopsies for Immediate or Future Wound Related Scientific Study||Southwest Regional Wound Care Center|Yes|Recruiting|March 2007|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5|Samples With DNA|Wound edge biopsies that are obtained through standard of care protocols will be subjected      to additional microscopic and molecular analyses following the completion of standard      medical assessment.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Wound edge biopsies that are obtained through standard of care protocols will be subjected        to additional microscopic and molecular analyses following the completion of standard        medical assessment.|December 2015|December 10, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759889||149775|
NCT00763126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5053|Does Having a Spouse Present During Epidural Analgesia Affect Stress Levels in the Parturient and Her Spouse?|The Effect of the Presence of a Spouse on the Parturient's and Her Spouse's Stress Level During Epidural Analgesia During Labor as Measured by Salivary Amylase||Rabin Medical Center||Not yet recruiting|October 2008|||October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|60 Years|No|||September 2008|September 29, 2008|September 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00763126||149528|
NCT00763451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10743|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin|GETGOAL-F1|Sanofi|Yes|Completed|September 2008|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|484|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763451||149504|
NCT00763802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/SAU-OSM/72635/2006|Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2|Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2|CPM|Association for Innovation and Biomedical Research on Light and Image||Completed|September 2007|May 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|35 Years|75 Years|No|Non-Probability Sample|Type 2 diabetic patients with Mild non-prolipherative retinopathy fulfilling the inclusion        criterion.|April 2014|April 4, 2014|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763802||149477|
NCT00754390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC042|Effects of Calcium and Phytate on Zinc Absorption|Effects of Calcium and Phytate on Zinc Absorption||USDA Grand Forks Human Nutrition Research Center|No|Completed|November 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|September 16, 2008|No|Yes||No|December 17, 2008|https://clinicaltrials.gov/show/NCT00754390||150194|
NCT00755170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.18|Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer|A Phase II Study of the Combination of Metronomic Vinorelbine and Bevacizumab as 2nd Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)||Hellenic Oncology Research Group|No|Recruiting|November 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755170||150134|
NCT00755768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0504/46|More Time Better Outcome - a Randomised Trial to Investigate the Effect of More Dietetic Time in Dialysis Patients|More Time Better Outcome - a Randomised Trial to Investigate the Effect of More Dietetic Time on Phosphate Levels in End Stage Renal Failure Patients||Royal Free Hampstead NHS Trust|No|Completed|January 2006|September 2006|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research||||75|||Both|18 Years|80 Years|No|||September 2008|September 18, 2008|September 17, 2008||||No||https://clinicaltrials.gov/show/NCT00755768||150090|
NCT00754871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13180|Pharmacodynamic Characterization of Dienogest|A Double-blind, Randomized, Dose-controlled Study to Evaluate Pharmacodynamic Properties of Four Oral Doses of Dienogest (DNG) in 100 Healthy Young Female Volunteers Over a Period of Two Cycles up to a Maximum of 72 Days||Bayer|No|Completed|September 2008|September 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|102|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754871||150157|
NCT00755131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNINA-15775|Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction|Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction||Federico II University|No|Completed|September 2008|October 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|75|||Both|35 Years|75 Years|No|||December 2009|January 25, 2010|September 17, 2008||No||No|November 5, 2009|https://clinicaltrials.gov/show/NCT00755131||150137|
NCT00756275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1DA02465201|Varenicline and Motivational Advice for Smokers With Substance Use Disorders|Varenicline and Motivational Advice for Smokers With SUD|VARSUD|Brown University|Yes|Recruiting|January 2009|March 2013|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|274|||Both|18 Years|75 Years|No|||February 2009|June 24, 2011|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756275||150052|
NCT00756626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-11-295E|Feeding Young Children Study: Bottle Weaning Intervention|Feeding Young Children Study (FYCS)- a Randomized Control Trial of a Bottle Weaning Intervention Aimed at Reducing the Risk of Overweight in Low Income Multi-ethnic Toddlers.|FYCS|Montefiore Medical Center|No|Active, not recruiting|October 2008|June 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|464|||Both|12 Months|13 Months|No|||October 2010|October 1, 2010|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756626||150025|
NCT00756249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11767A|Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke|Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke||H. Lundbeck A/S|Yes|Completed|October 2007|December 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|16|||Both|50 Years|90 Years|No|||September 2010|September 24, 2010|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756249||150054|
NCT00756899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-12795|Vitamin D Deficiency and Low Bone Mineral Content in Children|The Relationship Between Vitamin D Deficiency and Low Bone Mineral Content in Children|VDS|University of Massachusetts, Worcester|No|Completed|July 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|45|||Both|3 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prepubertal children|October 2012|October 25, 2012|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756899||150004|
NCT00765245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HEM 0835|Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma|A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma||Vanderbilt-Ingram Cancer Center|Yes|Active, not recruiting|October 2008|July 2015|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|October 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00765245||149367|
NCT00765531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101-577|Hypercalciuria and Calcium Stone Disease in Caucasian Patients|Hypercalciuria and Calcium Stone Disease in Caucasian Patients||University of Texas Southwestern Medical Center||Available||||||N/A|Expanded Access|N/A|||||||Both|4 Years|20 Years||||October 2008|October 30, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765531||149345|
NCT00758017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aku-08|Efficacy of Different Acupuncture Methods for Chronic Low Back Pain|Efficacy of Different Acupuncture Methods for Chronic Low Back Pain||Charite University, Berlin, Germany|No|Completed|January 2009|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00758017||149919|
NCT00758303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cortria-001|A Study to Evaluate the Lipid Regulating Effects of TRIA-662|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of TRIA-662||Cortria Corporation|Yes|Completed|September 2007|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|211|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758303||149897|
NCT00766025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560C00059|Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin|A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium||AstraZeneca|No|Completed|September 2008|February 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 27, 2009|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766025||149307|
NCT00766350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00024|Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia|A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia||Universidad de Granada|No|Completed|November 2008|October 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|70 Years|No|||December 2014|December 1, 2014|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00766350||149282|
NCT00766623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL23651.081.08|Elucidation and Monitoring Postprandial Endothelial Function|Elucidation and Monitoring Postprandial Endothelial Function|EMPEF|Wageningen University|No|Completed|October 2008|March 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Anticipated|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||September 2009|September 28, 2009|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766623||149263|
NCT00759304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9808112|Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events|Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events on a Prospective Cohort of Subjects Aged 65 Years|PROOF|Centre Hospitalier Universitaire de Saint Etienne|No|Active, not recruiting|January 2001|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1011|Samples With DNA|Serum, DNA|Both|65 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and        were eligible if aged 65 at the inclusion date.|March 2016|March 9, 2016|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759304||149820|
NCT00764075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT-Study|Guided Placement of CRT-Leads|CT and 3D-Echocardiography Placement of CRT-Leads|EK138/08|RWTH Aachen University|No|Completed|October 2008|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|132|||Both|18 Years|N/A|No|||July 2011|July 6, 2011|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00764075||149457|
NCT00765024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM001-2008|Ivermectin Versus Albendazole for Chronic Strongyloidiasis|Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis||Mahidol University|No|Enrolling by invitation|July 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|90 Years|No|||September 2008|June 18, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765024||149384|
NCT00764361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-DOX-NT/003|Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers|A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of NanoDOX™ Hydrogel(1.0% Doxycycline Monohydrate)in Diabetic Adult Subjects With Lower Extremity Ulcers Compared to Placebo Hydrogel.||Nanotherapeutics, Inc.|Yes|Completed|January 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|October 1, 2008|Yes|Yes||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00764361||149435|enrollment stopped before reaching the initial 40 subjects anticipated due to slow enrollment of subjects
NCT00764660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05718|Trial Investigating the Efficacy and Safety of Org 25935 in Relapse Prevention in Subjects With Alcohol Dependence (Study 172009)(P05718AM3)|A Prospective, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 25935 in Relapse Prevention in Subjects With Alcohol Dependence|OD-H|Merck Sharp & Dohme Corp.|No|Terminated|February 2009|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|September 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00764660||149412|
NCT00754403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-OPIXT-010|Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects on Glycemic Control With Concomitantly Administered Pioglitazone HCl and Metformin HCl Extended Release (Fortamet®) in Subjects With Type 2 Diabetes||Takeda|No|Completed|July 2005|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||July 2010|July 1, 2010|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754403||150193|
NCT00756327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-08-001|AquaLase Capsule Wash for Pediatric Eyes|AquaLase Capsule Wash for Pediatric Eyes||Medical University of South Carolina|No|Completed|August 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|20|||Both|6 Years|15 Years|No|Probability Sample|Children with bilateral cataract undergoing surgery for cataract aspiration and IOL        implantation. Bilateral cataract in a child aged 6-15 years old.|August 2009|August 14, 2009|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756327||150048|
NCT00756678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-OPT-08-001|Efficacy and Acceptability of Two Lubricant Eye Drops|||Allergan|No|Completed|September 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 22, 2011|September 18, 2008|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00756678||150021|
NCT00755742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0545-AE|Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C|Evaluation of the Impact of a Combined Program of Diet, Exercise and Behavior Modification on the Insulin Resistance and Adipokine Profile in Obese Patients With Current and Cured Chronic Hepatitis C.||University Health Network, Toronto|Yes|Completed|November 2008|August 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|No|||September 2011|September 21, 2011|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755742||150092|
NCT00755989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|morphine gel|Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds|A Phase 3, Single-Centered, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Trial of Morphine Sulfate Gel 0.1% in Patients With Stage 2-3 Wounds||Banner Health|Yes|Not yet recruiting|December 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||September 2008|September 18, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755989||150073|
NCT00756002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-375-081|Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia|A Randomized, Double-Blind, Placebo-Controlled, Polysomnography Plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults With Chronic Insomnia||Takeda|No|Completed|August 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|259|||Both|18 Years|64 Years|No|||May 2010|May 31, 2010|September 17, 2008||No||No|April 3, 2009|https://clinicaltrials.gov/show/NCT00756002||150072|
NCT00756262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6283|Probiotic Lactobacillus GG to Eliminate VRE Colonization|Probiotic Lactobacillus GG to Eliminate VRE Colonization|VRE|Tufts Medical Center|Yes|Terminated|March 2003|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 19, 2008|Yes|Yes|Insufficient recruitment, no additional funding available|No||https://clinicaltrials.gov/show/NCT00756262||150053|
NCT00756015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO 07-0915|Post-op Rehabilitation's Influence on Tendon Healing & Clinical Outcomes Following Arthroscopic Rotator Cuff Repair|Healing After Arthroscopic Rotator Cuff Repair: A Prospective, Randomized Trial of Early Range of Motion Versus Immobilization||Washington University School of Medicine|No|Completed|November 2007|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|40 Years|65 Years|No|||October 2013|October 11, 2013|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756015||150071|
NCT00756288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU2574|Photo-therapy With a Topical Retinoid Versus Photo-therapy Alone for Actinic Keratoses|A Randomized Controlled Paired Comparison of Photo-therapy With a Topical Retinoid Cream Pretreatment Versus PDT Alone for Actinic Keratoses||Northwestern University|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||February 2016|February 24, 2016|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756288||150051|
NCT00756639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0933|Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium|Prophylactic Cranial Irradiation (PCI) for Patients With Small Cell Carcinoma of the Urothelium||M.D. Anderson Cancer Center|No|Recruiting|June 2008|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756639||150024|
NCT00756886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080722005|Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study|Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study||University of Alabama at Birmingham|No|Completed|September 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|73|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2012|February 26, 2013|September 18, 2008||No||No|May 31, 2012|https://clinicaltrials.gov/show/NCT00756886||150005|
NCT00752999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-015|Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus Patients With Active Disease|SOLEIL|Rigel Pharmaceuticals|Yes|Withdrawn|November 2008|March 2010|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|September 15, 2008|Yes|Yes|Study was withdrawn for business reasons before study start.|No||https://clinicaltrials.gov/show/NCT00752999||150298|
NCT00753012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000121|Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults|An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Massachusetts General Hospital|No|Completed|April 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|60 Years|No|||August 2012|August 22, 2012|September 12, 2008|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT00753012||150297|
NCT00765544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-0002|Targeted Lower Extremity Joint Training|Robot-assisted Ankle Rehabilitation for Multiple Sclerosis (Anklebot)||VA Office of Research and Development|Yes|Terminated|September 2008|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|75 Years|No|||September 2013|September 19, 2013|October 2, 2008||No|Study re-design|No||https://clinicaltrials.gov/show/NCT00765544||149344|
NCT00765778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-YC-249-CTIL|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community:the Role of Family Members and Caregivers in Dissemination of MDR in Rehabilitation Centers||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2008|January 2014|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Family members or caregivers of patient hospitalized in rehabilitation centers and who is        known carrier of the target resistant population.|October 2008|October 15, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765778||149326|
NCT00758316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149/2008|A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions|A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions||Singapore General Hospital|No|Completed|September 2008|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758316||149896|
NCT00766363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-007|Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease||FORUM Pharmaceuticals Inc|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|49|||Both|50 Years|90 Years|No|||April 2012|April 18, 2012|October 1, 2008|Yes|Yes||No|June 16, 2011|https://clinicaltrials.gov/show/NCT00766363||149281|
NCT00758940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK-Restor-YIU-01|Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL|A Six-months, Open-labelled Clinical Assessment of Visual Function After Bilateral Implantation of Arcysof ReSTOR Multifocal Intra-ocular Lens||Alcon Research|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|N/A|No|||January 2010|May 8, 2015|September 23, 2008|No|Yes|Primary Investigator resigned from Hospital|No||https://clinicaltrials.gov/show/NCT00758940||149848|
NCT00758953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZ2-201-601-725036|Pain Associated With Endometriosis|||Lumara Health, Inc.|No|Completed|February 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|66|||Female|18 Years|50 Years|No|||March 2012|March 2, 2012|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758953||149847|
NCT00763815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6017|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone|GETGOAL-P|Sanofi|Yes|Completed|September 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|484|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763815||149476|
NCT00765037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 902|Retrospective Encore Reverse Shoulder Prosthesis Study|Post Market Study on the Efficacy of the Encore Reverse Shoulder Prosthesis in a Small Group of Subjects||Encore Medical, L.P.|No|Completed|August 2008|May 2009|Actual|May 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who meet the indications for use of the RSP device AND who meet the        inclusion/exclusion criteria|August 2010|August 3, 2010|September 30, 2008|Yes|Yes||No|June 8, 2009|https://clinicaltrials.gov/show/NCT00765037||149383|
NCT00754117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801009588|Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)|Early Response Assessment in Patients With Diffuse Large B-cell Lymphoma Using 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)||Weill Medical College of Cornell University|No|Recruiting|May 2008|||December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed diffuse large b cell lymphoma patients planning to receive 6-8 cycles of        R/CHOP chemotherapy.|October 2010|October 27, 2010|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00754117||150215|
NCT00754130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-011|MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).|A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 in Japanese Patients With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|16|||Both|20 Years|65 Years|No|||February 2015|February 23, 2015|September 16, 2008|No|Yes||No|August 31, 2012|https://clinicaltrials.gov/show/NCT00754130||150214|
NCT00755157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.06|Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer|A Phase II Study of the Combination of Metronomic Docetaxel and Bevacizumab as 2nd Line Treatment in Patients With Small Cell Lung Cancer (SCLC)||University Hospital of Crete|No|Withdrawn|April 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755157||150135|
NCT00756938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-337|Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)|A Phase III, Randomized, Open-Label, Parallel-Group, Dose-Ranging Clinical Trial to Study the Safety and Efficacy of MK954/Losartan Potassium in Pediatric Patients With Hypertension||Merck Sharp & Dohme Corp.|Yes|Completed|March 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|6 Months|6 Years|No|||January 2015|January 14, 2015|September 18, 2008|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00756938||150001|
NCT00755443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIABETES I TRIAL|Sirolimus-Eluting Stent Versus Standard Stent in Diabetic|A Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients|DIABETES|Hospital San Carlos, Madrid|Yes|Completed|February 2003|December 2005|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|N/A|N/A|No|||September 2008|September 18, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755443||150113|
NCT00755456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-002-05|Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)|Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis||Iperboreal Pharma Srl|No|Recruiting|January 2008|December 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755456||150112|
NCT00755755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL07-021|PGL4001 Versus Placebo in Uterine Myomas|A Phase III, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of PGL4001 (Ulipristal) Versus Placebo for Pre-Operative Treatment of Symptomatic Uterine Myomas|PEARLI|PregLem SA|Yes|Completed|October 2008|August 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|241|||Female|18 Years|50 Years|No|||December 2012|December 11, 2012|September 18, 2008||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT00755755||150091|
NCT00756665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33567-K|Prostate Active Surveillance Study|Canary Prostate Active Surveillance Study|PASS|University of Washington|Yes|Recruiting|July 2008|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|serum, plasma, white cells, DNA, urine, prostate tissue|Male|21 Years|N/A|No|Non-Probability Sample|Urology Clinic|December 2014|December 2, 2014|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756665||150022|
NCT00756912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5564-A001-102|A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors|A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors||Eisai Inc.|No|Terminated|September 2008|||November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|55 Years|No|||July 2014|July 10, 2014|September 18, 2008|No|Yes|This study was terminated in November 2008 due to "a business decision (resources)".|No||https://clinicaltrials.gov/show/NCT00756912||150003|
NCT00753285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-040|Renal Denervation in Patients With Refractory Hypertension|Renal Denervation in Patients With Refractory Hypertension||Medtronic Vascular|No|Completed|September 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753285||150276|
NCT00756652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030053|Mentor MemoryGel Post-Approval Study|MemoryGel Silicone Gel-Filled Breast Implant Post-Approval Study|MGPAS|Mentor Worldwide, LLC|No|Active, not recruiting|November 2006|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|43046|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MemoryGel™ PAS uses a current cohort design of 41,900 gel participants and 1,000 saline        participants.|October 2015|October 21, 2015|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756652||150023|
NCT00753909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.17|Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer|Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer||Hellenic Oncology Research Group|No|Recruiting|November 2008|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00753909||150231|
NCT00754221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061053|Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia|A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia||Pfizer|Yes|Terminated|May 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|390|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|September 16, 2008|Yes|Yes|This study has been terminated early as the esreboxetine development program is being    discontinued. There are no safety or efficacy concerns.|No||https://clinicaltrials.gov/show/NCT00754221||150207|
NCT00762307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JM07001|Non-invasive Cooling of Subcutaneous Fat|||Zeltiq Aesthetics|No|Completed|January 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 4, 2012|September 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00762307||149591|
NCT00757692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-011|Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.|A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.||British Columbia Cancer Agency|No|Completed|January 2009|November 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Male|18 Years|N/A|No|||February 2013|February 19, 2013|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757692||149943|
NCT00758004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581175|Bioequivalence Study Of Pediatric Appropriate Formulation|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 80 Mg (2x40 mg) Pediatric Appropriate Formulation To A 80 Mg Commercial Atorvastatin Calcium Tablet Formulation In Healthy Subjects||Pfizer|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|November 16, 2009|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758004||149920|
NCT00763503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18118|Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis|Pharmacokinetic and Pharmacodynamic Study of CD 2027 3µg/g Oily Spray Applied Twice Daily for 3 Weeks Under Conditions of Maximized Use in Adults With Plaque-type Psoriasis||Galderma||Completed|September 2008|February 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||January 2012|January 6, 2012|September 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763503||149500|
NCT00763516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0704-PC02|Proton Radiation for Resectable Carcinoma of the Pancreas|A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas|PC02|University of Florida|Yes|Recruiting|February 2009|September 2040|Anticipated|September 2039|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763516||149499|
NCT00758615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21CA133418-01|Pilot Evaluation of a Walking School Bus Program|Pilot and Feasibility Evaluation of a Walking School Bus Program Intervention for Elementary School Students||Seattle Children's Hospital|No|Completed|September 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|149|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00758615||149873|
NCT00758966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF-101|Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder|A Proof-of-Concept, Multicenter, Randomized, Double-Blind, Parallel Study of Naltrexone Sustained-Release (SR) and/or Fluoxetine Therapy in the Treatment of Subjects With Obsessive-Compulsive Disorder (OCD)||Orexigen Therapeutics, Inc|No|Terminated|September 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|60 Years|No|||November 2012|November 27, 2012|September 22, 2008|Yes|Yes|Sponsor Decision- Financial Considerations|No||https://clinicaltrials.gov/show/NCT00758966||149846|
NCT00758979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET UK 01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2002|||||N/A|N/A|N/A||||||||||||||March 5, 2014|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758979||149845|
NCT00764686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS/2008/83|A Study Investigating an Exercise and Education Programme for Individuals With Ankylosing Spondylitis|A Study Investigating an Exercise and Education Programme for Individuals With Ankylosing Spondylitis.||University College Dublin|Yes|Completed|June 2008|January 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|65 Years|No|||September 2009|September 28, 2009|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764686||149410|
NCT00765336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-0104-18|A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Minocycline Extended-Release Tablets on Spermatogenesis in Human Males||Medicis Pharmaceutical Corporation|Yes|Completed|November 2006|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|180|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 2, 2011|September 30, 2008|Yes|Yes||No|September 28, 2011|https://clinicaltrials.gov/show/NCT00765336||149360|
NCT00754884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIECD-010|Calcitonin in the Treatment of Fibromyalgia|Phase IV Study of Nasal Salmon Calcitonin in the Treatment of Symptoms and Signs of Fibromyalgia|CALFI|Unidad de Investigacion en Enfermedades Cronico-Degenerativas|No|Withdrawn|October 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|50 Years|No|||December 2015|December 3, 2015|September 16, 2008||No|Study drug was not longer available in our country.|No||https://clinicaltrials.gov/show/NCT00754884||150156|
NCT00755144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET UK 05|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2007|||||N/A|N/A|N/A||||||||||||||February 11, 2012|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755144||150136|
NCT00754897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-06-7001|Feasibility Study for PANDAS|Feasibility Study for Pediatric NeuroDevelopmental Assessment Study (PANDAS)||Children's Hospital of Philadelphia|No|Completed|November 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|72|||Both|N/A|3 Years|No|Non-Probability Sample|Children less than 1 year of age that have undergone inguinal hernia surgery during the        years of 1999-2007, and children who have had inguinal hernia surgery between the ages of        1 and 3 years during the years 1999-2007.        We will then do a telephone interview of the parents of these children to determine if        there are siblings that are within three years of age and have not had any exposure to        anesthetics agents or sedatives before their 3rd birthday.|September 2009|September 14, 2009|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754897||150155|
NCT00756951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-SCV-MUC-P2-001|Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Safety and Efficacy of SC-07 for the Delay to Onset of Severe Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck.|SCV-07 OM|SciClone Pharmaceuticals|Yes|Completed|September 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3|||59|||Both|18 Years|N/A|No|||December 2008|November 20, 2009|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756951||150000|
NCT00756028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KvL|Short Versus Long Protocol for IVF and IVF+ICSI|Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study|KvL|Hvidovre University Hospital|No|Completed|January 2009|December 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1099|||Female|18 Years|39 Years|No|||January 2016|January 12, 2016|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756028||150070|
NCT00756301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00002610|Cutaneous Administration of Local Anesthetic for Spine Injection Procedures|Cutaneous Administration of Local Anesthetic for Spine Injection Procedures: A Prospective Randomized Controlled Trial of Patient Preferred Method||Stanford University||Completed|June 2009|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|55|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756301||150050|
NCT00753025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCT001|Autologous Bone Marrow For Lower Extremity Ischemia Treating|Randomized Double Blind Placebo-Controlled Research Of Treatment Efficiency For Patients With Lower Extremity Arteriosclerosis Obliterans By Autologous Transplantation Of Bone Marrow Progenitor Cells||Clinical Center of Cellular Technologies, Russia|Yes|Completed|October 2006|February 2008|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Male|39 Years|70 Years|No|||September 2008|September 15, 2008|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00753025||150296|
NCT00753298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-CLO-0002|A Randomized, Fully-blinded Parallel Groups Study of Catheter Materials Used for Clean Intermittent Catheterisation|A Multi-centre, Double-blind, Randomized, Parallel Groups Study Comparing PVC and Polyolefin-based Elastomer (POBE) as Catheter Materials, Outcomes Will be Measured by Subject Perception.||Wellspect HealthCare|No|Completed|January 2007|||March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|September 15, 2008|Yes|Yes||No|April 6, 2009|https://clinicaltrials.gov/show/NCT00753298||150275|
NCT00753610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-354|Endothelial Progenitor Cells in Cervical Cancer Patients Receiving Chemoradiation|Effect of Concurrent Chemoradiation on Circulating Endothelial Progenitor Cells in Cervical Cancer|EPC|Mackay Memorial Hospital|Yes|Recruiting|January 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Female|20 Years|80 Years|No|Non-Probability Sample|Cervical cancer stage Ib - IVA|September 2008|September 15, 2008|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753610||150253|
NCT00757146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17091|Neonatal Intensive Care (NICU) Course and Hospital Outcome of Infants With BPD Treated Using Inhaled Nitric Oxide|NICU Course and Hospital Outcome of Infants With Bronchopulmonary Dysplasia Treated Using Inhaled Nitric Oxide||University of Utah|No|Completed|March 2006|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|18|||Both|N/A|28 Days|No|Non-Probability Sample|Any patient who at 28 days of life was requiring oxygen therapy in the Neonatal Intensive        Care Unit and who was then treated with iNO would be eligible for chart review. Since iNO        therapy has only been available for a few years, this study will attempt to capture all        patients who qualify. Any patient who received iNO treatment under an IRB study protocol        after 28d of life would not be eligible for chart review.|June 2010|June 22, 2010|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757146||149985|
NCT00754247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060131|A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars|A Prospective, Randomized, Investigator-blinded, Placebo-controlled, Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars||University of Miami|No|Completed|March 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|October 18, 2010|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00754247||150205|
NCT00757705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014308|An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia|An Open-label Prospective Trial to Evaluate the Tolerability, Safety and Maintained Efficacy of a Transition to Paliperidone ER in Subjects With Schizophrenia Previously Unsuccessfully Treated With Other Oral Antipsychotics||Johnson & Johnson Taiwan Ltd|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|299|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|September 19, 2008|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT00757705||149942|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.
NCT00758030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004933|Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Evaluate and Compare the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Subjects.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|July 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|60|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|September 19, 2008||||No||https://clinicaltrials.gov/show/NCT00758030||149918|
NCT00758628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.|Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.||Bp Consulting, Inc|No|Completed|August 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||September 2009|September 3, 2009|September 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00758628||149872|
NCT00764088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-008|A Retrospective Analysis of Patients With Full Thickness Wounds on a Case by Case Basis|A Retrospective Analysis of Patients With Full Thickness Wounds on a Case by Case Basis||Southwest Regional Wound Care Center|Yes|Completed|August 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic- Southwest Regional Wound Care Center|November 2015|November 24, 2015|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00764088||149456|
NCT00764374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443-CL-501|A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia|A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia||Astellas Pharma Inc|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|412|||Both|20 Years|79 Years|No|||October 2014|October 28, 2014|September 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00764374||149434|
NCT00764387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91780|Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.|Contrast-enhanced MRI Examination of Cerebral Neoplastic Enhancing Lesions: Comparison of Diagnostic Efficacy of Gd-DOTA 0.5M and Gadobutrol 1.0 M at 0.1 mmol/kg Body Weight: Intraindividual Comparison Clinical Study.||Bayer|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|166|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00764387||149433|
NCT00765050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000693-20|A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF|A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF||PETHEMA Foundation|Yes|Terminated|January 2009|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|75 Years|No|||April 2014|April 4, 2014|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765050||149382|
NCT00765349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0902/11|Clinical Observational Study Investigating the Role of Diastolic Dysfunction in Determining Abnormal Cardiorespiratory Exercise Testing Parameters in Patients Undergoing Major Surgery|||Newcastle-upon-Tyne Hospitals NHS Trust|No|Recruiting|May 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|65 Years|N/A|No|Probability Sample|Patients undergoing major elective surgery|October 2015|October 7, 2015|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765349||149359|
NCT00765362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 200|Mobile - Bearing Knee Study|Encore Mobile - Bearing Knee Study #200||Encore Medical, L.P.|No|Completed|January 2000|August 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|419|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|September 30, 2008|Yes|Yes||No|June 16, 2010|https://clinicaltrials.gov/show/NCT00765362||149358|
NCT00754650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21206|A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia|ML21206 - Bevacizumab in Chronic Lymphocytic Leukemia: A Proof of Concept Study||Hoffmann-La Roche||Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|September 17, 2008||No||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00754650||150174|
NCT00755469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|opt002|Post-conditioning to Reduce Infarct Size|Modification of Reperfusion by "Post-Conditioning" Reduces Infarct Size in Acute Myocardial Infarction||Minneapolis Heart Institute Foundation|No|Completed|September 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|80 Years|No|||December 2013|December 3, 2013|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755469||150111|
NCT00755482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARC005-080|Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee|Randomised, Placebo Controlled Trial to Examine the Effect of Aquamin F on NSAID Dose Reduction in Subjects With Osteoarthritis of the Knee.||Marigot Ltd.|No|Completed|January 2006|September 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|29|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 18, 2008||||No||https://clinicaltrials.gov/show/NCT00755482||150110|
NCT00755495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-375-067|Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Proof-of-Concept Study to Evaluate the Safety and Efficacy of Ramelteon Taken in Combination With Doxepin for the Treatment of Subjects With Chronic Insomnia||Takeda|No|Completed|July 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|472|||Both|18 Years|80 Years|No|||February 2012|February 27, 2012|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755495||150109|
NCT00756964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20081132|Lowering Serum Uric Acid to Prevent Acute Kidney Injury|Effect of Rasburicase on Acute Kidney Injury, Kidney Function, the Incidence of Renal Replacement Therapy and All-cause Mortality Following Cardiac Surgery.|RasbAKI|University of Florida|Yes|Completed|October 2008|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|September 19, 2008|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00756964||149999|The limitation of the pilot study is that it was not powered to provide definite answers, an inherent limitation attributed to the absence of similar studies.
NCT00756925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR18441|Gender and Neural Substrates of Stress and Craving|Exploring Gender Differences in the Neural Substrates of Stress Induced Drug Craving||Medical University of South Carolina|Yes|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|A total of 20 cocaine dependent subjects (10 cocaine dependent females and 10 cocaine        dependent males) will be enrolled in the study. Inclusion/exclusion criteria are listed in        Section E, Human Subjects. Cocaine subjects will be matched for age and nicotine        dependence. Women taking birth control pills, or Depo Provera (medroxyprogesterone        acetate) will be excluded from study participation.        Subjects will be recruited through the use of flyers, advertisements on the MUSC website,        MUSC broadcast messages, advertisement in local newspapers and weeklies, and similar        ongoing studies within the Clinical Neuroscience Division.|July 2011|August 4, 2011|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756925||150002|
NCT00757159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZER-PA_01-2008|Study on Regenerative Treatment of Intra-bony Defects|Randomised, Clinical Controlled Study on Treatment of Intra-bony Defects With Enamel Matrix Protein (Emdogain®) vs. Nanocrystalline Hydroxyapatite (Ostim®)||Technische Universität Dresden|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||January 2012|January 16, 2012|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757159||149984|
NCT00753038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 015|Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma|Phase 2 Study of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.||Oncolytics Biotech|No|Completed|August 2008|May 2013|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753038||150295|
NCT00753311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/07ssr-msd01-3407|Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.|A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms.||IRCCS San Raffaele|No|Completed|July 2009|October 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||October 2011|October 7, 2011|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753311||150274|
NCT00753324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDRZ 1222/F070821006|Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia|Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia).||University of North Carolina, Chapel Hill|No|Completed|May 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|284|||Female|N/A|N/A|No|||September 2014|September 16, 2014|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753324||150273|
NCT00753623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-000988|Clinical Management of Neuropathic Pain With Ramelteon|Clinical Management of Neuropathic Pain With Ramelteon||Massachusetts General Hospital|No|Terminated|September 2008|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||June 2014|June 19, 2014|September 15, 2008|Yes|Yes|Recruitment did not accrue as expected.|No|November 1, 2013|https://clinicaltrials.gov/show/NCT00753623||150252|Problems with recruitment and termination of the study consequently resulted in uninterpretable data.
NCT00753597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTH/2006/4071|Rescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS)|Immunotherapeutic Rescue of Steroidogenic Function in Autoimmune Adrenocortical Failure: Pilot Study|RADS|Newcastle University|Yes|Completed|September 2008|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|16 Years|65 Years|No|||February 2013|February 5, 2013|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00753597||150254|
NCT00753896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWDC|Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin|Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin||AstraZeneca|No|Completed|October 2008|November 2009|Actual|July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|18 Years|N/A|No|||March 2015|April 20, 2015|September 15, 2008|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00753896||150232|
NCT00754260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-277|Caffeine Reduction and Overactive Bladder Symptoms|Caffeine Reduction Education And Overactive Bladder Symptoms||University of New Mexico|Yes|Active, not recruiting|March 2008|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00754260||150204|
NCT00762892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|raltegravir atazanavir naive|Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients|A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients|RAN|The University of Texas Health Science Center, Houston|No|Completed|January 2009|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|September 26, 2008|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00762892||149546|Limitations are the relatively small sample size and loss to follow-up. Medical records of patients that were lost to follow up was reviewed to ensure that no SAE occurred. We also attempted multiple times to contact patients.
NCT00763152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMT-07-08|CMT-07-08: The PROstate Bed Evaluation Study|The Probe Study - The PROstate Bed Evaluation - A Study to Record the Implant Experience, Transponder Stability and Tracking Data of the Calypso 4D Localization Study in the Prostate Bed||Varian Medical|No|Completed|September 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with cancer of the peri-prostatic tissue or prostate bed|October 2015|October 13, 2015|September 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00763152||149526|
NCT00763165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/06/Dent/99|Periodontal Disease and Cardiovascular Disease|Periodontal Disease and Cardiovascular Disease||Colgate Palmolive|Yes|Active, not recruiting|November 2000|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|438|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2008|September 30, 2008|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763165||149525|
NCT00763828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRS-01-07-01|Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack?|Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack?|CHIPAHA|Life Recovery Systems|Yes|Not yet recruiting|February 2016|February 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763828||149475|
NCT00763841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07019|Transcranial Magnetic Stimulation (TMS) for Treatment of Auditory Hallucinations|A Pilot Study Using Transcranial Magnetic Stimulation (TMS) to Investigate the Role of the Temporal Cortex in Schizophrenic Patients With Auditory Hallucinations||The University of New South Wales|No|Completed|September 1999|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||November 2009|January 19, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763841||149474|
NCT00764114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050607-AOM05031|Comparison of Two Antimicrobial Therapy Duration for Spondylodiscitis|Comparison of Two Antimicrobial Therapy Duration (6 Weeks Versus 12 Weeks)for Spondylodiscitis|DTS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2006|April 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|N/A|No|||February 2011|May 3, 2013|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764114||149454|
NCT00764101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60-60105-98-128|Attentional Bias Modification in Patients With Posttraumatic Stress Disorder|Effects of Attentional Bias Modification on Attentional Bias and Symptoms of Posttraumatic Stress Disorder||PsyQ|No|Completed|September 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2011|July 7, 2011|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00764101||149455|
NCT00764400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15DC009690|Treatment for Word Retrieval Impairments in Aphasia|Communication Outcomes for Naming Treatments in Aphasia||Old Dominion University|No|Recruiting|August 2008|July 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Both|21 Years|90 Years|No|||May 2012|May 18, 2012|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764400||149432|
NCT00764699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB08-00213|Effect of Increlex® on Children With Crohn Disease|Effect of Increlex® on Children With Crohn Disease||Nationwide Children's Hospital|No|Terminated|October 2008|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|5 Years|15 Years|No|||June 2010|May 14, 2015|October 1, 2008|Yes|Yes|PI left institution|No||https://clinicaltrials.gov/show/NCT00764699||149409|
NCT00764712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POINT-protocols|Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients|Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients||Charles University, Czech Republic|No|Completed|February 2008|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|90 Years|No|||March 2012|March 9, 2012|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764712||149408|
NCT00765063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301086|The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)|A 6 Month, Prospective, Open-Label Multiple Center Extension Trial To Evaluate The Long Term Safety And Sustained Efficacy Of Fragmin In The Treatment Of Chronic Foot Ulcers In Diabetic Patients With Peripheral Arterial Occlusive Disease||Pfizer|No|Completed|October 2008|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|September 30, 2008||No||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00765063||149381|Study enrollment was terminated before planned number of participants was obtained. Although randomized participants were allowed to complete entire course of therapy according to protocol and study status was therefore designated as completed.
NCT00765076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112147|Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older|Observer-blind Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects||GlaxoSmithKline||Completed|October 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|192|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|June 14, 2012|October 1, 2008|Yes|Yes||No|March 8, 2012|https://clinicaltrials.gov/show/NCT00765076||149380|
NCT00765089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508144|Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation|Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation||University of Pittsburgh|Yes|Completed|December 2005|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|90 Years|No|||February 2016|February 11, 2016|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765089||149379|
NCT00765102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPI-08-0006|Trial of Romidepsin and Bortezomib for Multiple Myeloma|A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease||Celgene|No|Terminated|September 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||September 2012|November 21, 2012|September 30, 2008|Yes|Yes|There was a change in the Sponsor's research strategy; safety concerns were not a factor.|No|September 26, 2012|https://clinicaltrials.gov/show/NCT00765102||149378|
NCT00755183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004-16|Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction|A Single-Center, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Testosterone 0.03% Ophthalmic Solution Compared to Vehicle for the Treatment of Meibomian Gland Dysfunction||ORA, Inc.|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|N/A|No|||March 2012|March 15, 2012|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755183||150133|
NCT00756067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111652|Evaluation of Pneumococcal Vaccine Formulations in Elderly|A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189241A) in Elderly Subjects.||GlaxoSmithKline||Completed|September 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|168|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756067||150068|
NCT00756314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APA-1|Contraceptive Counseling Following an Abortion|Effectiveness of Contraceptive Counseling of Women Following an Abortion in Recife, Brasil: a Randomized Controlled Intervention Study.|APA|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|July 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|246|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||March 2010|October 6, 2010|September 19, 2008||No||No|September 9, 2010|https://clinicaltrials.gov/show/NCT00756314||150049|The time of the follow up of six months after the abortion, not having the possibility to evaluate the effectiveness of the measurement in longer term.However, this decision may have contributed to overestimate the intervention effect.
NCT00753103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK2031|Anti-Cytokine Therapy for Vasculitis|Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis|ACTIVE|University Hospital Birmingham NHS Foundation Trust|No|Completed|January 2003|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||September 2008|September 15, 2008|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753103||150290|
NCT00753116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-041|Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension|Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension||Medtronic Vascular|Yes|Completed|September 2008|December 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|September 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00753116||150289|
NCT00757172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z4051|Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction|A Phase II Study of Neoadjuvant Therapy With Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of the Distal Esophagus||Alliance for Clinical Trials in Oncology|Yes|Completed|January 2009|December 2014|Actual|November 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 22, 2008|Yes|Yes||No|July 25, 2014|https://clinicaltrials.gov/show/NCT00757172||149983|
NCT00753051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE501122|Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)|Treatment of Clozapine-resistant Schizophrenia : Comparison Between Augmentation With Haloperidol and Electroconvulsive Therapy|TCRS|Khon Kaen University|No|Completed|June 2008|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|September 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753051||150294|
NCT00753064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AScVS vs Prazosin|AScVS and/ or Prazosin for Scorpion Envenomation|Comparative Study of Efficacy of Antiscorpion Venom Serum(AScVS)vs Prazosin in the Management of Severe Scorpion(Mesobuthus Tamulus Concanesis Pocock)Envenomation and Evaluation of Effects of the Combination of AScVS + Prazosin Therapy.||Haffkine Bio-Pharmaceutical Corporation Ltd.|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|81|||Both|12 Years|65 Years|No|||September 2008|September 15, 2008|September 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00753064||150293|
NCT00753337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP085|The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study|The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study Using the Medtronic Assurant Cobalt Iliac Balloon-Expandable Stent System|ACTIVE|Medtronic Endovascular|Yes|Completed|October 2008|September 2013|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|September 15, 2008|No|Yes||No|February 10, 2012|https://clinicaltrials.gov/show/NCT00753337||150272|
NCT00753649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103506|Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants||GlaxoSmithKline||Completed|September 2008|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|224|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2013|February 20, 2014|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753649||150250|
NCT00753636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Isradipine II|Parkinson's Disease Isradipine Safety Study|Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II||Northwestern University|Yes|Completed|April 2008|February 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|30 Years|75 Years|No|||April 2013|April 29, 2013|September 13, 2008||No||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00753636||150251|
NCT00753922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-009-0799-01|Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses|Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision||Mentor Worldwide, LLC|No|Completed|September 2000|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1008|||Female|18 Years|N/A|No|||March 2014|March 21, 2014|September 15, 2008|Yes|Yes||Yes|June 12, 2013|https://clinicaltrials.gov/show/NCT00753922||150230|Adverse events were not coded according to the MedDRA dictionary, rather they were collected as Complications in alignment with the 2006 FDA Guidance for Industry and FDA Staff – Saline, Silicone Gel, and Alternative Breast Implants.
NCT00754520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU11|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2009|||||N/A|N/A|N/A||||||||||||||June 25, 2015|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754520||150184|
NCT00754754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 050960|Brain Retraction Monitoring Sensor Study|Brain Retraction Monitoring Sensor||Vanderbilt University|No|Completed|September 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2011|July 26, 2011|September 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00754754||150166|
NCT00763529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03197|Elocon vs Fluticasone in Localized Psoriasis (P03197)(COMPLETED)|Elocon vs Fluticasone in Localized Psoriasis||Schering-Plough|No|Completed|January 2003|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||October 2008|October 14, 2008|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763529||149498|
NCT00763867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018007|Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)|Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)|RELAX|Duke University|Yes|Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||July 2013|July 14, 2014|September 30, 2008|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00763867||149473|
NCT00764127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5217 DK074503-01|The Development of an Eating Laboratory for Overweight Adolescents|The Development of an Eating Laboratory for Overweight Adolescents||New York State Psychiatric Institute|Yes|Completed|February 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|36|Samples Without DNA|10 cc (2 teaspoons) of blood will be drawn during the screening assessment to screen for      medical illness.      60 cc (12 teaspoons) of blood will be drawn from an indwelling IV catheter during the      single-item meal to assay for meal-related hormones (ghrelin, leptin,cholecystokinin,      insulin, peptideY). Bariatric surgery participants may have an additional 20 cc of blood      taken to measure glucose responses to the meal.|Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|January 2013|January 30, 2013|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764127||149453|
NCT00764413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15002|Chronotherapy in Acute Multiple Sclerosis (MS) Attack|Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment?||Sykehuset Innlandet HF|No|Terminated|April 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||February 2014|November 21, 2014|October 1, 2008||No|Low inclusion frequency and not enough human resources for completing study|No||https://clinicaltrials.gov/show/NCT00764413||149431|
NCT00764725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0 3013 Swefot|Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)|A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX|SWEFOT|Karolinska Institutet|No|Completed|December 2002|December 2008|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|487|||Both|18 Years|N/A|No|||December 2008|December 22, 2008|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764725||149407|
NCT00764738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4495s|Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration|Study Investigating High Resolution OCT, Multifocal ERG and Microperimetry Outcomes of Monthly vs As Needed Ranibizumab in Neovascular Age-Related Macular Degeneration||Retina Macula Institute|Yes|Completed|October 2008|November 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|50 Years|N/A|No|||March 2013|March 18, 2013|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764738||149406|
NCT00764751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 19123-C24|Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris|LEO 19123 Cream in the Treatment of Psoriasis Vulgaris||LEO Pharma|No|Completed|September 2008|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|N/A|No|||April 2009|October 18, 2013|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764751||149405|
NCT00765908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN 2008-1|Ischaemic Pre-Conditioning in Elective Percutaneous Coronary Intervention (PCI) Patients|Ischaemic Pre-Conditioning in Elective PCI Patients - Attenuation of Subsequent Ischaemia in a Validated Animal Model||University Health Network, Toronto|No|Not yet recruiting|October 2008|October 2009|Anticipated|October 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|80 Years|No|||August 2008|October 2, 2008|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765908||149316|
NCT00755781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIS001|Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation|A Multi-Center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation|CIS001|APT Pharmaceuticals, Inc.|Yes|Completed|September 2008|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|284|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755781||150089|
NCT00756041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-128-006|Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy|An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy||Takeda|No|Terminated|September 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|221|||Both|18 Years|70 Years|No|||February 2012|February 27, 2012|September 17, 2008|Yes|Yes|Lack of Efficacy.|No||https://clinicaltrials.gov/show/NCT00756041||150069|
NCT00756691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-24367|A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA|A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA||AHS Cancer Control Alberta|No|Recruiting|October 2008|November 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known primary or suspected metastatic carcinoma of the following: squamous        cell carcinoma (SCC) of the head and neck, small (SCLC) and non-small cell lung        cancer(NSCLC), Glioblastoma multiforme (GBM), lymphoma, or neuroendocrine tumours (NET).|June 2014|June 4, 2014|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756691||150020|
NCT00754000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMT-03-08|The AIM Study: Assessing the Impact of Margin Reduction|The AIM Study: Assessing the Impact of Margin Reduction|AIM|Varian Medical|No|Completed|July 2008|September 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Male|18 Years|N/A|No|Non-Probability Sample|Males diagnosed with prostate cancer|April 2012|April 27, 2012|September 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00754000||150224|
NCT00757185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801003437|Compromised Microcirculation in Women With Polycystic Ovary Syndrome|Compromised Microcirculation in Women With Polycystic Ovary Syndrome||Yale University||Completed|February 2008|December 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757185||149982|
NCT00757198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070206|Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.|Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.|REMISYD|Kuopio University Hospital|No|Completed|September 2008|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|80 Years|No|||September 2013|September 11, 2013|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757198||149981|
NCT00753077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804052R|Three Dimensional Morphology of Upper Respiratory Tract and Mandibular Position on Obstructive Sleep Apnea|||National Taiwan University Hospital|Yes|Completed|August 2008|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Male|20 Years|65 Years|No|Probability Sample|patients referred from sleep center|September 2011|September 2, 2011|September 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00753077||150292|
NCT00753662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-AA-0397-CTIL|Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease|Phase 2 (Feasibility) Study of Transcranial Magnetic Stimulation as Additional Therapy to Drug Treatment in Patients With Alzheimer's Disease|TMS in AD|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|November 2008|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|50 Years|80 Years|No|||September 2011|September 12, 2011|September 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00753662||150249|
NCT00753948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4335-V|Exhaled Levels of Nitric Oxide|The Effect of Nitric Oxide on Pulmonary Resistances and Blood Pressure in Persons With Tetraplegia||VA Office of Research and Development|No|Completed|December 2006|August 2010|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|July 2, 2014|September 15, 2008|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00753948||150228|
NCT00753961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU289|Effect Of The Consumption Of Fermented Dairy Drink On Common Infections In Shift-Workers|EFFECT OF THE CONSUMPTION OF FERMENTED DAIRY DRINK ON COMMON INFECTIONS IN SHIFT-WORKERS||Danone Research|Yes|Completed|September 2008|September 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1340|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|June 16, 2010|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00753961||150227|
NCT00753935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040065|Aspirin Resistance in Coronary Artery Disease|Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease||Vanderbilt University|No|Active, not recruiting|June 2006|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|160|||Both|40 Years|N/A|No|||October 2010|October 12, 2010|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753935||150229|
NCT00754273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0775-P6H|An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS|Prospective Evaluation Of Protected Alveolar Lavage (PAL) Staphylococcus Aurues Resistance Patterns|MRSA|University of Kentucky|No|Completed|September 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1250|||Both|N/A|N/A|No|Probability Sample|One hundred consecutive isolates of MRSA will be analyzed.|March 2011|March 22, 2011|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754273||150203|
NCT00755001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET EP 01|Clinical Study on BiHapro Total Hip System With Different Surface Coatings|Clinical Study on BiHapro Total Hip System With Different Surface Coatings||Biomet, Inc.|No|Terminated|May 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|N/A|80 Years|No|Non-Probability Sample|Total Hip Arthroplasty|February 2012|February 29, 2012|September 16, 2008||No|The site decided to stop the study|No||https://clinicaltrials.gov/show/NCT00755001||150147|
NCT00763542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-KP-342|Combined Treatment for Patients With Comorbid Substance Use Disorders and Post-traumatic Stress Disorder (PTSD): an Integration of Cognitive-behavioral Treatment (CBT) and Trauma-focused Structured Writing Therapy|A Randomized Controlled Trial Comparing (1) a Combined Treatment of CBT for Substance Use Disorders (SUD) and Trauma-focused Structured Writing Therapy With (2) CBT for SUD Alone in Patients With Comorbid SUD and PTSD||VU University of Amsterdam|No|Completed|July 2008|May 2013|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|80 Years|No|||November 2013|November 3, 2013|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763542||149497|
NCT00763555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18119|Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis|A Multicenter, Randomized, Vehicle-controlled, Efficacy and Safety Study of CD2027 3µg/g Oily Spray Applied Twice Daily for 8 Weeks in Subjects With Plaque-type Psoriasis||Galderma||Completed|September 2008|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||January 2012|January 6, 2012|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763555||149496|
NCT00763568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-3037|4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C|Study of a 4-Week Lead-In With Nitazoxanide Followed By 36 Weeks of Nitazoxanide Plus Peginterferon Alfa-2a in the Treatment of Chronic Hepatitis C||Romark Laboratories L.C.|No|Completed|August 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2008|September 26, 2008|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00763568||149495|
NCT00763880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMTT # 4040-05|Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction|Hematoma Blocks in Forearm Fractures: An Effective Adjunct to Procedural Sedation?||Rhode Island Hospital|Yes|Terminated|November 2005|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|September 26, 2008||No|Recruitment was taking longer than originally anticipated.|No||https://clinicaltrials.gov/show/NCT00763880||149472|
NCT00764140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960010|Tumor Growth Factors in Hepatocellular Carcinoma|Insulin-like Growth Factors (IGF) Axis (IGFs, Its Binding Proteins,Receptors), Transforming Growth Factor Alpha and Beta 1 and Epidermal Growth Factor in the Urine and Serum of Patients With Hepatocellular Carcinoma.||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|January 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|400|Samples Without DNA|Blood and/or urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with aspiration cytology or biopsy proved HCC and sex- and age-matched healthy        controls.|April 2013|April 17, 2013|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00764140||149452|
NCT00764153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2005-OS-2|Hemiarthroplasty or Internal Fixation for Displaced Femoral Neck Fractures - 5 Years Follow up|Hemiarthroplasty or Internal Fixation for Displaced Femoral Neck Fractures - 5 Years Follow up||Oslo University Hospital|No|Completed|October 2002|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|222|||Both|60 Years|N/A|No|||October 2014|October 22, 2014|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00764153||149451|
NCT00764777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-006|Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions|Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions|BRAVISSIMO|Flanders Medical Research Program|No|Completed|December 2008|December 2012|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|325|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764777||149403|
NCT00764426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA 03 06|Alcohol, Inflammation and Atherosclerosis|Clinical Study of the Effect of Different Alcoholic and Non-Alcoholic Beverages on Markers of Inflammation||European Research Advisory Board|No|Completed|June 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 1, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764426||149430|
NCT00765648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001|Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department|A Phase IV, Randomized Trial to Determine the Efficacy and Safety of Cardene Intravenous (I.V.) Versus Labetalol for Management of Hypertensive Emergencies in the Emergency Department Setting|CLUE|The Cleveland Clinic|Yes|Completed|October 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||July 2011|December 11, 2014|October 1, 2008||No||No|July 18, 2011|https://clinicaltrials.gov/show/NCT00765648||149336|
NCT00765401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29239|An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients|An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients||Penn State University|No|Not yet recruiting|November 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|42|||Both|5 Years|18 Years|No|Non-Probability Sample|Patients will be enrolled from CF population seen at the Milton S. Hershey Medical Center        CF center if they meet the inclusion and exclusion criteria at their scheduled out patient        visit to CF clinic.|September 2008|September 30, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765401||149355|
NCT00756340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADBEV|A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors|A Phase I Trial of RAD001 (Everolimus) and Avastin(R) (Bevacizumab) in Children With Recurrent Solid Tumors||St. Jude Children's Research Hospital|No|Completed|July 2008|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|21 Years|No|||October 2015|October 13, 2015|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00756340||150047|
NCT00756353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04933|Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)|Out of Care Patient Survey||Indivior Inc.|No|Completed|June 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|600|||Both|N/A|N/A|No|Non-Probability Sample|The population in this survey includes drug users who are in the "out of care" population,        found in various places (streets, railway stations) and via the "snow ball" technique.|September 2008|April 14, 2011|September 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00756353||150046|
NCT00756704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA021607|The Effectiveness of Smoking Cessation Guidelines in the Emergency Department|The Effectiveness of Smoking Cessation Guidelines in the Emergency Department||University of Iowa|Yes|Completed|September 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|789|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 2, 2011|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756704||150019|
NCT00756717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200431|Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer|A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery|MK-0752|Loyola University|Yes|Active, not recruiting|May 2008|May 2018|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Female|18 Years|N/A|No|||April 2015|April 1, 2015|September 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756717||150018|
NCT00753402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220003283|The Effects of Epinephrine in Endotoxemia in Normal Volunteers|The Effects of Epinephrine in Endotoxemia in Normal Volunteers|Epi|Rutgers, The State University of New Jersey|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|37|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00753402||150268|
NCT00757211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598878|Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Breast Cancer in East Anglia||National Cancer Institute (NCI)||Recruiting|February 2008|||||N/A|Observational|N/A|||Anticipated|6000|||Both|18 Years|70 Years|No|||September 2008|August 23, 2013|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00757211||149980|
NCT00757224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147/08|Parental Education on Passive Smoke Exposure and Respiratory Diseases in Infants|||Assaf-Harofeh Medical Center||Not yet recruiting|October 2008|October 2009|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|N/A|3 Days|Accepts Healthy Volunteers|||September 2008|September 22, 2008|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00757224||149979|
NCT00753090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU13A|Vanguard™ Deep Dish Rotating Platform Knee Clinical Evaluation|Vanguard™ Deep Dish Rotating Platform Knee Clinical Evaluation||Biomet, Inc.|No|Active, not recruiting|June 2009|August 2021|Anticipated|August 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|329|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753090||150291|
NCT00753350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-101-MZ|METHOD (Minimally Invasive, Endoscopically-delivered, Tolerable by Human Individuals, Non-morbid Obesity Device) Study|An Open-label, Single-center, Feasibility Study Designed to Evaluate the Safety and Tolerability of Sensate™ Anchored Gastric Device in Subjects With Non-morbid Obesity|SENSATE|Sensate LLC|No|Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|25 Years|55 Years|No|||March 2013|March 1, 2013|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753350||150271|
NCT00753974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0338|Studying Cardiac Tissue in Patients With Heart Failure|Biologic Commonalities Associated With Degeneration in Function of Cardiac, Skeletal and Respiratory Muscles in Patients With Heart Failure.||University of Kentucky|No|Enrolling by invitation|June 2008|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00753974||150226|
NCT00753987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008380|Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis|Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis||The Hospital for Sick Children|No|Completed|March 2006|January 2007|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|2 Months|2 Years|No|||August 2013|August 30, 2013|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753987||150225|
NCT00754299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28862|Smoking Cessation in Nonunion, Malunion, Osseous Infection|Outcome of a Prospective Protocol for Smoking Cessation in Nonunion, Malunion, Osseous Infection, and Infected Nonunion Patients|nicotine|Penn State University|No|Withdrawn|October 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Our study will include 60 tobacco-using patients of all ages above 18 with osseous        nonunion, malunion, established bone infection, or combined diagnoses.|September 2008|August 5, 2011|September 15, 2008||No|Study could not get funding; research never initiated.|No||https://clinicaltrials.gov/show/NCT00754299||150201|
NCT00754286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01-017|A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer|A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer||Montefiore Medical Center|Yes|Recruiting|July 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|132|||Both|7 Years|21 Years|No|||March 2010|March 4, 2010|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00754286||150202|
NCT00754507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-406|A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.|Efficacy of WelChol as an Add-on to Atorvastatin Therapy||Daiichi Sankyo Inc.|No|Completed|November 2002|April 2005|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754507||150185|
NCT00755287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC20965|A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.|A Multicenter, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naïve Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy||Hoffmann-La Roche||Completed|November 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1072|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755287||150125|
NCT00763230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07305|A Study of Transcranial Direct Current Stimulation (tDCS) to Treat Depression|A Sham-controlled Study of Transcranial Direct Current Stimulation (tDCS) as a Treatment for Depression||The University of New South Wales|No|Completed|April 2008|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|75 Years|No|||March 2011|April 29, 2011|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00763230||149520|
NCT00763893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060210|Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome|Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome|MARFANSARTAN|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|September 2008|December 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|303|||Both|10 Years|N/A|No|||October 2015|November 3, 2015|September 30, 2008||No|A similar publication has been released, suggesting a beneficial effect of sartans, and only    15 patients remained to be seen for their visit at 36 months.|No||https://clinicaltrials.gov/show/NCT00763893||149471|
NCT00764439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP2010|Pilot Study of a New Nicotine Replacement Therapy|Pilot Study on Usage Patterns of a Novel Nicotine Replacement Therapy - A Multi-Center, Open, 3-Week Randomized Low Intervention Study of Two Different Directions for Use in Smokers Motivated to Quit||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764439||149429|
NCT00764452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1800-30|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2006|||||N/A|N/A|N/A||||||||||||||May 3, 2012|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764452||149428|
NCT00764764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01-2014|Study of the Effect of Neck Treatment on Shoulder Impingement|Shoulder Impingement: A By-Product of Cervical Spine Dysfunction?||CAMC Health System|Yes|Terminated|May 2008|||December 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|70 Years|No|||July 2009|July 15, 2009|October 1, 2008||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00764764||149404|
NCT00765115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9384|A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.|Assessment of LY450139-Mediated Inhibition of Amyloid Beta Formation Determined by 13C6-Leucine In Healthy Subjects||Eli Lilly and Company|No|Completed|July 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|27|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 30, 2008|September 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00765115||149377|
NCT00765388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK188OS|A Randomised Cross-over Study With Two 1-piece Urostomy Bags.|A Comparative, Randomised, Crossover Study With 2 Urostomy Bags Among 30 Urostomy-operated Persons in UK|DK188OS|Coloplast A/S|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|27|||Both|18 Years|N/A|No|||August 2012|January 27, 2014|October 1, 2008||No||No|September 19, 2011|https://clinicaltrials.gov/show/NCT00765388||149356|
NCT00765141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-011|A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study|A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study||Southwest Regional Wound Care Center|Yes|Withdrawn|June 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|The samples can include material such as wound debridement, removed orthopedic implants,      removed catheters or shunts, excised tonsils, amputated tissue, sputum, stool, or other      excretions.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The samples can include material such as wound debridement, removed orthopedic implants,        removed catheters or shunts, excised tonsils, amputated tissue, sputum, stool, or other        excretions.|November 2015|November 24, 2015|September 30, 2008||No|No participants enrolled per PI discretion|No||https://clinicaltrials.gov/show/NCT00765141||149375|
NCT00765414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU02103|Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.|An Open-Label Extension Study of the Long-Term Safety and Efficacy of Recombinant Human Acid α-Glucosidase (rhGAA) Given as Enyzme Replacement Therapy to a Single Patient With Pompe Disease (Glycogen Storage Disease Type II) Who Were Previously Enrolled in Genzyme-Sponsored Enzyme Replacement Therapy Studies||Sanofi|Yes|Completed|April 2003|August 2006|Actual|April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|16 Years|N/A|No|||February 2014|February 4, 2014|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765414||149354|
NCT00765674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAH100A2302|Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension|An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension||Novartis|No|Completed|September 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1191|||Both|18 Years|N/A|No|||April 2011|April 15, 2011|October 2, 2008|Yes|Yes||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00765674||149334|
NCT00756366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005982-01H|CPAP Therapy in Patients With Heart Failure and Obstructive Sleep Apnea.|Effects of Continuous Positive Airway Pressure Therapy on Myocardial Energetics and Sympathetic Nerve Function in Patients With Heart Failure and Obstructive Sleep Apnea.|PET-OSA|Ottawa Heart Institute Research Corporation|No|Completed|July 2005|December 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756366||150045|
NCT00756730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-09|Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r|Randomized, Open-label Study of Switch From Lopinavir/Ritonavir (LPV/r) or Fosamprenavir/Ritonavir (FPV/r) to Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r) (Plus Background Nucleoside Reverse Transcriptase Inhibitors) in Patients Experiencing Triglyceride Elevations While Receiving LPV/r or FPV/r.|LARD|Community Research Initiative of New England||Completed|September 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|September 18, 2008|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00756730||150017|
NCT00756743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0911002|Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers|A Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04802540 After Multiple Oral Dose Administration To Healthy Adult Volunteers||Taisho Pharmaceutical Co., Ltd.|No|Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|40|||Both|21 Years|54 Years|Accepts Healthy Volunteers|||January 2009|March 17, 2010|September 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00756743||150016|
NCT00753363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCG-003-05F|Exercise and Inflammation in the Elderly|Exercise, Inflammation and Pro-thrombotic Modulators in the Elderly|IRIS|VA Office of Research and Development|Yes|Active, not recruiting|April 2007|November 2016|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|119|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|September 12, 2008||No||No|October 15, 2014|https://clinicaltrials.gov/show/NCT00753363||150270|
NCT00753675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200L00007|Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer|A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)|VANGOGH|AstraZeneca|No|Completed|October 2008|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|174|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|September 15, 2008|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00753675||150248|
NCT00753688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEG110727|Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy|A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy|PALETTE|GlaxoSmithKline|Yes|Completed|October 2008|December 2012|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|369|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|September 12, 2008|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT00753688||150247|
NCT00754780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1835-99|Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1|Phase II Clinical Trial of Pirfenidone for the Treatment of Patients With Neurofibromatosis Type I||Mayo Clinic|No|Completed|September 2000|||August 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||March 2012|March 15, 2012|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754780||150164|
NCT00754767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000614311|L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer|Pilot Study of L-Carnitine Supplementation in the Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Metastatic Breast Cancer||HealthPartners Institute|No|Completed|June 2006|October 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|2|||Female|18 Years|120 Years|No|||October 2015|December 15, 2015|September 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00754767||150165|
NCT00755300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614481|Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques|Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques||University of California, Davis|No|Completed|June 2006|June 2009|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients scheduled for elective total knee replacement|August 2011|August 11, 2011|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755300||150124|
NCT00763243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808-01B|Pilot Study of the Feasibility and Efficacy of Working Memory Training in Children With Cochlear Implants|Pilot Study of the Feasibility and Efficacy of Working Memory Training in Children With Cochlear Implants||Indiana University|Yes|Active, not recruiting|August 2008|August 2012|Anticipated|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|7 Years|16 Years|No|||April 2012|May 2, 2012|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00763243||149519|
NCT00763256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004000841/2004/201|The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics|The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics||Colgate Palmolive|Yes|Completed|May 2006|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|September 26, 2008|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT00763256||149518|
NCT00764192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK DD 2022 CM|Influence of Hemodialysis on Endothel-Depending Dilatation of Peripheral Arteries|Angiologic Study of the Influence of Hemodialysis on Endothelial Function||RWTH Aachen University|No|Completed|October 2006|October 2007|Actual|February 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|21 Years|N/A|No|||January 2009|January 12, 2009|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00764192||149448|
NCT00764465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL112237|An Interaction Study to Assess Drug Levels in Healthy Adult Subjects|Steady State Pharmacokinetics (PK) of Fosamprenavir (FPV) Alone or in Combination With Low Dose Ritonavir (/r) (1400mg BID, 1400mg/100mg QD or 700/100mg BID) and the Chemokine Receptor 5 (CCR5) Entry Inhibitor Maraviroc (MVC) 300mg BID in Healthy Volunteers||Garden State Infectious Disease Associates, PA|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label|6||Actual|45|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|October 1, 2008|No|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00764465||149427|Data for primary outcomes are not available per intervention . Values reported as means are uncertain measure type (data no longer available).
NCT00764790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111751|Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children|Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children||GlaxoSmithKline||Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3317|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||October 2012|October 11, 2012|October 1, 2008|Yes|Yes||No|February 25, 2010|https://clinicaltrials.gov/show/NCT00764790||149402|
NCT00765128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-000747 PNL|Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy|The Efficacy of Continuous Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy: a Double Blinded Randomized Placebo Controlled Trial||Mayo Clinic|No|Completed|October 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||December 2011|December 21, 2011|September 30, 2008|Yes|Yes||No|November 18, 2011|https://clinicaltrials.gov/show/NCT00765128||149376|
NCT00765427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET HV 01|Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers|A Phase 1a, Repeat-Dose Escalation Study to Investigate the Safety and Tolerability of a 7-Day Repeated Dose of Retinoid QLT091001 in Healthy Volunteers||QLT Inc.|Yes|Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 27, 2009|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00765427||149353|
NCT00765687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446ECN07|Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates|A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates|BLEST|Sun Yat-sen University|Yes|Completed|August 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|432|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 8, 2013|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00765687||149333|
NCT00765947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2360|Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension|A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension.||Novartis|No|Completed|September 2008|August 2009||August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|256|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|October 2, 2008|Yes|Yes||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00765947||149313|
NCT00766233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA HT-PR 01|Optimal Application Dose of Superficial Hyperthermia|Phase III Study for Analysis of the Optimal Application Dose of Superficial Hyperthermia||Universitätsmedizin Mannheim|No|Active, not recruiting|January 2008|February 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766233||149291|
NCT00756379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0312|Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease|Randomized Trial of Comprehensive Lifestyle Modifications, Optimal Pharmacological Treatment and PET Imaging for Detection and Management of Stable Coronary Artery Disease|Century|The University of Texas Health Science Center, Houston|No|Recruiting|March 2009|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1300|||Both|40 Years|N/A|No|||October 2015|October 20, 2015|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00756379||150044|
NCT00756392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-24315|Magnetic Resonance (MR) Spectroscopy in Localized Prostate Cancer|MR Spectroscopy in Localized Prostate Cancer||AHS Cancer Control Alberta|Yes|Completed|October 2008|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756392||150043|
NCT00757237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-205-0110|Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa|An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam for Inhalation Solution (AZLI) Versus Tobramycin Inhalation Solution (TIS) in an Intermittent Aerosolized Antibiotic Regimen in Subjects With Cystic Fibrosis Followed by an Open-Label, Single Arm Extension (European Union [EU] Only)||Gilead Sciences|Yes|Completed|August 2008|November 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|274|||Both|6 Years|N/A|No|||June 2011|June 7, 2011|September 22, 2008|Yes|Yes||No|April 8, 2011|https://clinicaltrials.gov/show/NCT00757237||149978|
NCT00753727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSG01|Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma|A Phase IB/II Study of Sunitinib in Combination With Neoadjuvant Radiation in Patients With Resectable Soft-tissue Sarcoma|SUNXRT|Australasian Sarcoma Study Group|Yes|Recruiting|September 2008|March 2016|Anticipated|March 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|16 Years|N/A|No|||December 2010|June 21, 2011|September 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00753727||150245|
NCT00753740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVAR0801|Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.|A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression.||Cerulean Pharma Inc.|Yes|Terminated|September 2008|May 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Female|18 Years|78 Years|No|||March 2012|July 9, 2014|September 12, 2008|Yes|Yes|Poor trial recruitment|No||https://clinicaltrials.gov/show/NCT00753740||150244|
NCT00754312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0302|A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer|A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer||Syndax Pharmaceuticals|No|Withdrawn|June 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|30|||Female|18 Years|N/A|No|||February 2010|February 2, 2010|September 15, 2008|Yes|Yes|This study has been transfered from a sponsored trial to an investigator initiated trial.|No||https://clinicaltrials.gov/show/NCT00754312||150200|
NCT00754325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-158|Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor|Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor||Bristol-Myers Squibb|Yes|Completed|September 2008|January 2014|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|August 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00754325||150199|
NCT00754533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08005|Continuous Versus Interval Training in Patients With Coronary Artery Disease: FRAXIO Study|Influence of Different Exercise Training Programs in Patients With Coronary Artery Disease on Cardiac and Respiratory Parameters|FRAXIO|University Hospital, Limoges|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|64|||Both|18 Years|80 Years|No|||October 2008|September 7, 2011|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754533||150183|
NCT00754793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33501-B|Sinusitis and Facial Pain Disorders Anti-Depression Trial|Sinusitis and Facial Pain Disorders Anti-Depression Trial|SFPAT|University of Washington|No|Terminated|January 2009|December 2012|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|September 16, 2008|Yes|Yes|poor recruitment|No|June 13, 2012|https://clinicaltrials.gov/show/NCT00754793||150163|
NCT00755014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB No: 96-01-11A|Study Effect of Red Wine Consumption on Endothelial Progenitor Cells and Endothelial Function|Taipei Veterans General Hospital||Taipei Veterans General Hospital, Taiwan|No|Completed|September 2007|July 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||September 2008|September 17, 2008|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00755014||150146|
NCT00755313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613050|Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer|Effects of Chemotherapy on Brain Structure and Function||University of California, San Francisco|Yes|Active, not recruiting|May 2007|December 2016|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|81|||Female|35 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|women with newly diagnosed, early stage breast cancer|December 2014|December 12, 2014|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755313||150123|
NCT00756223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1257.1|Phase I Study of BI 831266 in Patients With Advanced Solid Tumours|An Open-label Phase I Single Dose Escalation Trial of Two Dosing Schedules of BI 831266 Administered Intravenously Over 24 h Continuously in Patients With Advanced Solid Tumours||Boehringer Ingelheim||Completed|November 2008|||October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|September 19, 2008||||No||https://clinicaltrials.gov/show/NCT00756223||150056|
NCT00763906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH/JF-11-2002|Norepinephrine Weaning in Septic Patients|Continuous Administration of Norepinephrine Assisted by Fuzzy Logic Assisted Control in Septic Shock Patients|CATECHOFLOU|Association pour le Développement de la Recherche et de l'Enseignement en Médecine d'Urgence|Yes|Completed|November 2004|January 2007|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2008|September 30, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763906||149470|
NCT00764504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 300|Reverse Shoulder Prosthesis Study|Encore Reverse Shoulder Prosthesis|RSP|Encore Medical, L.P.|No|Completed|October 2002|August 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|516|||Both|18 Years|N/A|No|||March 2011|March 21, 2011|September 30, 2008|Yes|Yes||No|November 19, 2010|https://clinicaltrials.gov/show/NCT00764504||149424|
NCT00764166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 03108|A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel|Non-Metastatic High-Risk Prostate Cancer Patients With Biochemical Relapse Only After Local Treatment. A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel|RisingPSA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2003|November 2010|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Male|18 Years|N/A|No|||September 2008|September 30, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764166||149450|
NCT00764179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/12-P|Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat")|Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat")|Proneonat|Nantes University Hospital|No|Recruiting|March 2008|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|126|||Both|34 Weeks|39 Weeks|No|||February 2013|February 4, 2013|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764179||149449|
NCT00764803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 702|3DKnee™ System vs. the MJS Knee System|Post-Market Study: The Efficacy of the 3DKnee™ System vs. the MJS Knee System||Encore Medical, L.P.|No|Terminated|January 2008|December 2009|Actual|November 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who meet either the indications for use of the 3DKnee or the MJS knee system.        Subjects must also meet the inclusion/exclusion criteria.|March 2010|March 9, 2010|September 30, 2008|Yes|Yes|Corporate decision to discontinue distribution of MJS Knee.|No||https://clinicaltrials.gov/show/NCT00764803||149401|
NCT00765154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 028|NNRTI/PI Toxicity Switch to Darunavir Study|Phase IV, Two-arm, Open-label, Single-centre Randomised Pilot Study to Assess the Feasibility of Immediate or Deferred Switching of HIV-infected Individuals Intolerant of Efavirenz, Ritonavir-boosted Lopinavir or Ritonavir-boosted Darunavir||St Stephens Aids Trust|No|Terminated|October 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||October 2010|October 29, 2010|October 1, 2008||No|Difficulties in recruitment due to a change in the nature of practice.|No||https://clinicaltrials.gov/show/NCT00765154||149374|
NCT00765700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLP-110-101|Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel™ (Ketoprofen Topical Cream 10%) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury.||Imprimis Pharmaceuticals, Inc.|No|Completed|September 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|70 Years|No|||September 2013|September 20, 2013|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765700||149332|
NCT00765960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC 08-002|Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure|Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure|iLASIK|Medical University of South Carolina|No|Terminated|September 2008|October 2009|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Approximately 20 patients (40 eyes) of both sexes and any race undergoing bilateral        wavefront-guided LASIK will be included.|October 2010|August 11, 2011|October 1, 2008|No|Yes|Prinicipal Investigator separating employment from University.|No||https://clinicaltrials.gov/show/NCT00765960||149312|
NCT00756990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708310|Depot Naltrexone Treatment of Opioid Dependent Parolees|Depot Naltrexone Treatment of Opioid Dependent Parolees||University of Pennsylvania|Yes|Completed|November 2005|August 2011|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756990||149997|
NCT00753714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200L00012|Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine|Phase II, Randomised, Double-blind, Two-arm, Parallel Study of Vandetanib (ZACTIMA™ , ZD6474) Plus Gemcitabine (Gemzar® ) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.|ZELIG|AstraZeneca|No|Completed|October 2008|December 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|70 Years|N/A|No|||January 2013|January 30, 2013|September 15, 2008|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT00753714||150246|
NCT00753753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERIfynow FRENCH registrY|VerifyNow French Registry|Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)|VERIFRENCHY|Association Pour le Développement des Soins Cardiologiques de la ville de Chartres|Yes|Completed|February 2008|November 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1001|||Both|18 Years|N/A|No|Probability Sample|real world patient referred for coronary angioplasty with stent|June 2015|June 24, 2015|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753753||150243|
NCT00754065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13108|To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Ortho Tri-Cyclen Lo on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment.||Bayer|No|Completed|September 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|409|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|September 16, 2008|Yes|Yes||No|May 10, 2012|https://clinicaltrials.gov/show/NCT00754065||150219|
NCT00754013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-336|Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10|A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10||Eisai Inc.|Yes|Terminated|September 2008|December 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|6 Years|10 Years|No|||January 2013|January 11, 2013|September 15, 2008|Yes|Yes|Sufficient evidence of efficacy not met.|No|July 21, 2011|https://clinicaltrials.gov/show/NCT00754013||150223|Due to the study terminating early,only 9 subjects were enrolled and these subjects receive only limited exposure to study medications with no subject reaching his/her maximum targeted dose. Therefore,the planned efficacy criteria were not analyzed.
NCT00754026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.072|Insertion Distance of Interscalene Perineural Catheters in the Context of Shoulder Surgery.|Influence of the Insertion Distance on Loss of Sensation Produced by Interscalene Perineural Catheters in the Context of Shoulder Surgery.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00754026||150222|
NCT00754338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/279/07/L|Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens|Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens||University of Waterloo|No|Completed|January 2008|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|76|||Both|17 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 28, 2010|September 17, 2008|No|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT00754338||150198|
NCT00754546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21261|Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD|Effects of Arformoterol on Exercise Endurance Time and Breathlessness in COPD: Cycle Ergometer vs. Treadmill|ARFEET|Dartmouth-Hitchcock Medical Center|Yes|Completed|August 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|N/A|No|||May 2013|May 28, 2013|September 16, 2008|Yes|Yes||No|August 3, 2009|https://clinicaltrials.gov/show/NCT00754546||150182|Study completed with no reported adverse effects. One limitation of the study is frequent exercise tests involving 7 visits for each participant
NCT00754806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1687-2007|Prospective Randomized Comparison of Clinical Results of Hand Assisted Laparoscopic Splenectomies and Open Splenectomies|Prospective Randomized Study Between Open and Hand Assisted Splenectomies||Istanbul University|Yes|Completed|February 2007|January 2008|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|27|||Both|N/A|N/A|No|Probability Sample|Patients with splenomegaly who will have splenectomy procedures either open or HALS|September 2008|September 17, 2008|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754806||150162|
NCT00754819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL0001|Targeting Inflammation in Acute Coronary Syndrome Using Colchicine|Colchicine Compared With Placebo to Reduce Hs-CRP in Patients With Acute Coronary Syndromes- Targeting Inflammation in Atherosclerosis Trial|COOL|McMaster University|Yes|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|85 Years|No|||October 2009|October 7, 2009|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754819||150161|
NCT00755027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRHSCSP/07/14|Rasagiline and Apathy in Parkinson's Disease|A Randomised Placebo-controlled Trial of Rasagiline in Parkinson Disease Patients With Symptoms of Apathy||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|September 2008|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755027||150145|
NCT00756561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34593-B|HOP-2A - Intratesticular Hormone Levels|Intratesticular Hormone Levels in Healthy Young Men|HOP-2A|University of Washington|No|Completed|September 2008|December 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|10|Samples Without DNA|serum blood, testicular tissue|Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy males|May 2013|May 1, 2013|September 18, 2008||No||No|November 8, 2010|https://clinicaltrials.gov/show/NCT00756561||150030|Early termination of study leading to data analysis of the first ten of eleven men receiving aspirations.
NCT00763919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078967-02|Customized Medication Adherence Enhancement for Treating Adults With Bipolar Disorder|Customized Adherence Enhancement in Bipolar Disorder (CAE in BD)||Case Western Reserve University|Yes|Completed|July 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|September 29, 2008||No||No|October 24, 2011|https://clinicaltrials.gov/show/NCT00763919||149469|
NCT00764517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004180|Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma|Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma||OHSU Knight Cancer Institute|Yes|Active, not recruiting|August 2008|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764517||149423|
NCT00764530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 100|Cementless Alumina-Alumina Total Hip and Hybrid|Keramos Ceramic/Ceramic Total Hip System||Encore Medical, L.P.|No|Completed|November 2003|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|342|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764530||149422|
NCT00764478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05691|Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)|A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects With Bipolar 1 Disorder Experiencing an Acute Manic or Mixed Episode (Protocol P05691 [Formerly 041044])||Merck Sharp & Dohme Corp.|No|Completed|April 2012|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|367|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|September 30, 2008|Yes|Yes||No|March 26, 2015|https://clinicaltrials.gov/show/NCT00764478||149426|
NCT00764491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G030106|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2003|||||N/A|N/A|N/A||||||||||||||September 19, 2013|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00764491||149425|
NCT00765167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-2007-PLA-01-RR|Training and Calibration of Dental Examiners|Training and Calibration of Dental Examiners||Colgate Palmolive|No|Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 2, 2008|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765167||149373|
NCT00765440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599477|Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract|Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract||Centre Antoine Lacassagne|No|Completed|July 2007|April 2011|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|311|||Both|18 Years|75 Years|No|||February 2015|February 8, 2015|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765440||149352|
NCT00765713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP PI-719|Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias|Sleep Apnea-hypopnea Syndrome and Ventricular Arrhythmias in Patients With Systolic Ventricular Dysfunction and Implantable Cardioverter-defibrillator. Incidence and Effect of CPAP Treatment|SAHS-ICD|Hospital Universitario La Paz|No|Completed|October 2008|January 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2008|April 1, 2013|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765713||149331|
NCT00765973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS601|Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors|A Phase 1 Study of Topotecan Liposomes Injection (TLI) in Subjects With Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors||Spectrum Pharmaceuticals, Inc|No|Active, not recruiting|September 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|October 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765973||149311|
NCT00753129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 685/2007|Head Elevation in Prone Position|Influence of Head Elevation in Prone Position on Gas Exchange and Lung Mechanics in Patients With ALI/ARDS||Medical University of Vienna|No|Completed|October 2008|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|89 Years|No|||May 2010|May 3, 2010|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753129||150288|
NCT00753389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PORC_main|Muscle Relaxants and Post-Anesthesia Complications|Epidemiologic Study on Short and Long-Term Effects of Anesthesia With Muscle Relaxants (Epidemiologische Untersuchung Kurz- Und längerfristiger Auswirkungen Der Anästhesie Mit Muskelrelaxanzien)|PORC|Technische Universität München||Recruiting|September 2008|March 2009|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|All patients receiving anesthesia|September 2008|September 15, 2008|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753389||150269|
NCT00753142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|898-2003|Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises|Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises||Emory University|Yes|Completed|March 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|September 12, 2008||No||No|July 7, 2014|https://clinicaltrials.gov/show/NCT00753142||150287|
NCT00755690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01018|Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease|Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease||University of British Columbia|No|Completed|September 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|19 Years|N/A|No|||February 2014|February 17, 2014|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755690||150096|
NCT00754039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-403|Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol|The Effects of the Combination of Welchol and Tricor Compared to TriCor Alone in Patients With Mixed Hyperlipidemia||Daiichi Sankyo Inc.|No|Completed|February 2003|March 2004|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|30 Years|70 Years|No|||April 2015|April 2, 2015|September 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754039||150221|
NCT00754052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-335|Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17|A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17||Eisai Inc.||Terminated|September 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|192|||Both|11 Years|17 Years|No|||December 2008|December 10, 2008|September 15, 2008|Yes|Yes|Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.|No||https://clinicaltrials.gov/show/NCT00754052||150220|
NCT00754832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1357|American Ginseng Treatment for Multiple Sclerosis Related Fatigue|A Double-blinded, Placebo-controlled Crossover Pilot Study of American Ginseng Treatment for Multiple Sclerosis Related Fatigue||Oregon Health and Science University|No|Completed|September 2005|March 2011|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||January 2012|January 20, 2012|September 16, 2008||No||No|September 9, 2011|https://clinicaltrials.gov/show/NCT00754832||150160|
NCT00755053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13071|Comparative Efficacy of Ovule vs Tablet|An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis||Bayer|No|Completed|September 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|466|||Female|14 Years|50 Years|No|||July 2015|August 4, 2015|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755053||150143|
NCT00754559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21469|A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.|"Effectiveness After Four and Twentyfour Weeks and Safety of Tocilizumab in Patients With Active RA"||Hoffmann-La Roche||Completed|August 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|286|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 17, 2008||No||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00754559||150181|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT00755066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2505|Effect of Intranasal Corticosteroids on Systemic Allergen Specific IgE|The Effect of Intranasal Corticosteroid on the Immune Response Following Nasal Allergen Challenge in Patients Suffering From Seasonal Allergic Rhinitis||Medical University of Vienna||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|50 Years|No|||September 2008|September 25, 2008|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755066||150142|
NCT00755352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-407|A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.|Efficacy of WelChol as an Add-on to Pravastatin Therapy||Daiichi Sankyo Inc.|No|Completed|November 2002|April 2005|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755352||150120|
NCT00755677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pulse Study|Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease|Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease||St. Boniface General Hospital Research Centre|No|Completed|March 2007|July 2008|Actual|January 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Both|40 Years|82 Years|No|||March 2012|March 20, 2012|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00755677||150097|
NCT00755040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 0766|Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder|Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation||Vanderbilt-Ingram Cancer Center|Yes|Active, not recruiting|October 2008|October 2015|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|165|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755040||150144|
NCT00763945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADMIRE|Infarction Register|Aachen Digital Myocardial Infarction Register|ADMIRE|RWTH Aachen University|No|Completed|March 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who present to the hospital with acute coronary syndrome|September 2009|September 17, 2009|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00763945||149467|
NCT00764205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070224|Randomized Trial of Prehospital Tropin Levels in Acute Coronary Syndrome (ACS)|Randomized Trial of Prehospital Troponin Assessment Using the i-STAT Blood Analyzer||Redmond Fire Department Medic One|No|Active, not recruiting|November 2006|November 2010|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seen and treated by Redmond Fire Department Medic One.|September 2008|September 30, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764205||149447|
NCT00764543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052005-008|Ambulatory Blood Pressure Measurement in Children With Congenital Urine Flow Obstruction|Ambulatory Blood Pressure Measurement in Children With Congenital Urine Flow Obstruction||University of Texas Southwestern Medical Center||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|24 Months||||October 2008|October 1, 2008|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764543||149421|
NCT00764556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGH-ClinPharm-1|Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards|Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards|IPS2008|St George's, University of London|Yes|Completed|May 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|N/A|No|||October 2009|October 13, 2009|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764556||149420|
NCT00764816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807-03|Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4|Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4||Indiana University|No|Completed|October 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00764816||149400|
NCT00764829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC - 1980.00|Blood Samples to Evaluate Biomarkers of Donor Chimerism|Blood Samples to Evaluate Biomarkers of Donor Chimerism||Fred Hutchinson Cancer Research Center|No|Completed|September 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|plasma,DNA|Both|18 Years|N/A|No|Non-Probability Sample|Hematopoietic stem cell transplant patients receiving fludarabine and mycophenolate        mofetil.|February 2012|February 13, 2012|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00764829||149399|
NCT00765180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRE2|Comparison of Transparent Retractable Extension Device and Narrow Band Imaging on Colorectal Adenoma Detection|||Showa Inan General Hospital|No|Completed|January 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|200|||Both|20 Years|100 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00765180||149372|
NCT00765453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q0603/76|Bone Marrow Derived Adult Stem Cells for Acute Anterior Myocardial Infarction|Randomised Controlled Clinical Trial of the Use of Autologous Bone Marrow Derived Progenitor Cells to Salvage Myocardium in Patients With Acute Anterior Myocardial Infarction|REGEN-AMI|Barts & The London NHS Trust|Yes|Active, not recruiting|March 2008|March 2018|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||August 2015|August 6, 2015|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765453||149351|
NCT00765466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McG 0710|A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies|A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies||McGill University|Yes|Recruiting|October 2007|December 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|70 Years|No|||September 2008|October 21, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00765466||149350|
NCT00765479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615902|Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer|Randomized Placebo-Controlled Adjuvant Study of Prevention of Prostate Cancer Recurrence After Radical Prostatectomy by Soy Protein Isolate||National Cancer Institute (NCI)||Completed|December 2006|July 2013|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|284|||Male|40 Years|75 Years|No|||August 2009|September 19, 2013|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00765479||149349|
NCT00765492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1960C00002|AZD8529 Multiple Ascending Dose Study in Healthy Subjects|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8529 When Given as Single and Multiple Ascending Oral Doses in Healthy Subjects||AstraZeneca|No|Completed|October 2008|March 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|47|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 25, 2009|October 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00765492||149348|
NCT00765726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-4418|Study Evaluating The Safety Of Xyntha In Usual Care Settings|A Postauthorization Safety Surveillance Study Of Xyntha In Usual Care Settings||Pfizer|No|Terminated|February 2009|August 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|12 Years|N/A|No|||December 2011|December 16, 2011|October 2, 2008|Yes|Yes|See termination reason in detailed description.|No|December 16, 2011|https://clinicaltrials.gov/show/NCT00765726||149330|The study was discontinued because the sponsor had ongoing studies collecting similar safety data.
NCT00766311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRCISL|Aerobic and Strengthening Exercise for Acute Leukemia|Aerobic and Strengthening Exercise for Acute Leukemia|XRCISL|St. Jude Children's Research Hospital|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|5 Years|10 Years|No|||January 2012|January 5, 2012|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00766311||149285|
NCT00757263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598881|Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Ovarian Cancer in East Anglia, Oxford, Trent and West Midlands||National Cancer Institute (NCI)||Recruiting|February 2008|||||N/A|Observational|N/A|||Anticipated|2000|||Both|18 Years|74 Years|No|||September 2008|August 23, 2013|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00757263||149976|
NCT00757276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 68/08|Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study|Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study||University Hospital, Basel, Switzerland||Completed|June 2008|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|bood sampling|Both|18 Years|N/A|No|Probability Sample|All patients >18 years who are tested for the diagnosis of DI because of a history of        polyuria (>40ml/kg per 24 hours) in the presence of polydipsia Patients with known DI will        be contacted whether they agree to participate in the study and to undergo again a water        deprivation test to measure copeptin to confirm the diagnosis.|December 2014|December 12, 2014|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757276||149975|
NCT00737165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-MISP-02|A Community Intervention Trial of Multimodal Suicide Prevention Program in Japan (NOCOMIT-J)|A Community Intervention Trial of Multimodal Suicide Prevention Program in Japan (NOCOMIT-J)|NOCOMIT-J|Japan Foundation for Neuroscience and Mental Health|Yes|Completed|July 2006|March 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1951060|||Both|N/A|N/A|No|||October 2013|October 30, 2013|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737165||151502|
NCT00769574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00192-53|Assessment of New Biomarkers in the Management and Triage of Patients With Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome.|Assessment of New Biomarkers in the Management and Triage of Patients With Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome.||Assistance Publique Hopitaux De Marseille|No|Completed|June 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|143|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769574||149041|
NCT00767273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0004|Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx|Pilot Study to Investigate the Role of Metabolic Imaging in Predicting Tumor Response and Outcome After Therapy for Pancreatic Cancer||Stanford University||Completed|October 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767273||149216|
NCT00771407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC2008.01.01|Parastomal Reinforcement With Strattice|A Prospective, Multicenter, Randomized, Controlled, Third-party Blinded Study of Strattice Fascial Inlay for Parastomal Reinforcement in Patients Undergoing Surgery for Permanent Abdominal Wall Ostomies|PriSm|LifeCell|No|Completed|December 2008|July 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|120|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|October 10, 2008|Yes|Yes||No|August 20, 2013|https://clinicaltrials.gov/show/NCT00771407||148904|
NCT00771108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0039|Exercise Dose and Nonalcoholic Fatty Liver Disease|Exercise Dose and Nonalcoholic Fatty Liver Disease|ED|Washington University School of Medicine|No|Completed|May 2006|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 2, 2011|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00771108||148927|
NCT00771121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO2008-CT-01|Effect of Moisturizing Creams on Skin Barrier Function|||ACO Hud Nordic AB|No|Recruiting||||||Phase 4|Interventional|N/A|2||||||Both|18 Years|65 Years|No|||October 2008|October 10, 2008|October 10, 2008||||No||https://clinicaltrials.gov/show/NCT00771121||148926|
NCT00767312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080221|Analysis of HIV-1 Replication During Antiretroviral Therapy|Analysis of HIV-1 Replication During Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|September 2008|||||N/A|Observational|Time Perspective: Prospective|||Actual|43|||Both|18 Years|100 Years|No|||January 2016|February 3, 2016|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767312||149213|
NCT00768118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597010|A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants|A Pilot Study of Biomarker Alterations By Nutritional Agents||Barbara Ann Karmanos Cancer Institute|Yes|Completed|April 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 10, 2014|October 4, 2008|Yes|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT00768118||149152|The study has small numbers, it was a proof-of-concept study only to demonstrate that agents taken orally can alter biomarkers, similar to the results obtained from in vitro studies, it was to open doors for future studies.
NCT00768469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A2-1115|Study Evaluating Safety And Tolerability, Solid Tumor|A Phase 1 Study Of Neratinib (HKI-272) In Combination With Paclitaxel In Subjects With Solid Tumors||Puma Biotechnology, Inc.|Yes|Completed|October 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||May 2012|May 10, 2012|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768469||149125|
NCT00768482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-810|A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence|A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence|PRO-810|Titan Pharmaceuticals|Yes|Terminated|September 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||October 2012|January 25, 2013|October 7, 2008|Yes|Yes|This study was terminated for reasons not related to efficacy or safety|No||https://clinicaltrials.gov/show/NCT00768482||149124|
NCT00769145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071015|Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery|Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery||Bascom Palmer Eye Institute|No|Completed|October 2008|March 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769145||149073|
NCT00769405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595024|Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer|Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer||National Cancer Institute (NCI)||Recruiting|February 2008|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|70 Years|No|||September 2009|April 19, 2011|October 8, 2008||||No||https://clinicaltrials.gov/show/NCT00769405||149053|
NCT00757341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1112-US|Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606|An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled Bosutinib in Healthy Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 24, 2009|September 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00757341||149970|
NCT00757354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU46|A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty|A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty||Biomet, Inc.|Yes|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|70 Years|No|||June 2015|June 22, 2015|September 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00757354||149969|
NCT00753207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-30 ICORG|Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30|An Open-Label Phase I Study of Fixed Dose Lapatinib in Combination With an Escalating Dose of Epirubicin in Metastatic Breast Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Completed|October 2007|March 2012|Actual|November 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|120 Years|No|||January 2014|February 12, 2016|September 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00753207||150282|
NCT00756847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11435|Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors||Sanofi||Completed|September 2008|October 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00756847||150008|
NCT00762580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060109|Features to Predict Success With Nonoperative Treatment of Patients With Rotator Cuff Tears|Features to Predict Success With Nonoperative Treatment of Patients With Rotator Cuff Tears|MOON|Vanderbilt University|Yes|Active, not recruiting|January 2006|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults between the ages of 18-100 with full thickness rotator cuff tears.|July 2015|July 20, 2015|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762580||149570|
NCT00762593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEAT F1|Trial Evaluating Transvaginal Electrical Stimulation With a Home Use Programmable Device for Urinary Stress Incontinence|A Multicenter Double Blind Randomized Placebo Controlled Trial Evaluating Transvaginal Electrical Stimulation With a Home Use Programmable Device for Urinary Stress Incontinence|KEAT F1|Akontis|Yes|Active, not recruiting|January 2006|October 2008|Anticipated|October 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|N/A|No|||October 2008|October 16, 2008|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762593||149569|
NCT00762606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-08-002|Phaco Versus Small Incision Cataract Surgery (SICS) Health Economic Study|A Twelve-Months, Single-Masked, Parallel Group, Health Economic Study of Phacoemulsification Versus Small Incision Cataract Surgery (SICS) in Chinese Patients With Senile Cataract.||Alcon Research|No|Completed|September 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|106|||Both|50 Years|70 Years|No|||August 2011|October 26, 2012|September 26, 2008||No||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00762606||149568|
NCT00762619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2007-IMPLANT-PS|Clinical Study to Examine Brushing on Dental Implants|Clinical Study to Examine Brushing on Dental Implants||Colgate Palmolive|No|Completed|April 2007|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|76 Years|Accepts Healthy Volunteers|||January 2011|January 4, 2011|September 26, 2008|Yes|Yes||No|August 24, 2010|https://clinicaltrials.gov/show/NCT00762619||149567|
NCT00754663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Exercise Training in Patients With Cardioverter-Defibrillators|BETA: Beneficial Effects of Exercise Training in Patients With Implantable Cardioverter-Defibrillators|BETA|University Hospital Tuebingen|No|Recruiting|May 2008|November 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2008|September 17, 2008|August 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00754663||150173|
NCT00754429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_025|The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)|The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients||Taipei Veterans General Hospital, Taiwan||Completed|June 2004|July 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|No|||October 2013|October 22, 2013|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754429||150191|
NCT00768976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinical trial experience|Study of Patient Satisfaction With the Cancer Clinical Trial Experience|Study of Patient Satisfaction With the Cancer Clinical Trial Experience||Summa Health System|No|Completed|October 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Participant must have participated in a clinical trial conducted by the Summa Health        System Hospitals Cancer Research Program.|May 2012|May 22, 2012|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768976||149086|
NCT00769275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD|Detection of Ischemia in Asymptomatic Diabetics|Detection of Ischemia in Asymptomatic Diabetics|DIAD|Yale University|Yes|Completed|August 2000|January 2008|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1123|Samples Without DNA|blood|Both|50 Years|75 Years|No|Non-Probability Sample|Asymptomatic patients with type 2 diabetes mellitus|October 2008|October 8, 2008|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769275||149063|
NCT00769847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22034|Endoscopic Treatment for Isolated, Single Suture Craniosynostosis|Endoscopic Treatment for Isolated, Single Suture Craniosynostosis||University of Utah|No|Withdrawn|September 2008|September 2013|Anticipated|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|1 Month|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|Male and female infants, from 1 to 6 months of age with isolated, single-suture sagittal        craniosynostosis.|May 2015|May 29, 2015|October 7, 2008||No|Study was withdrawn due to lack of resources.|No||https://clinicaltrials.gov/show/NCT00769847||149022|
NCT00770146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301012-CS12|Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients||Sanofi|Yes|Completed|November 2008|October 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|October 8, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00770146||149000|
NCT00771420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-3001-0702|A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis|A Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 in Patients With Rheumatoid Arthritis.||MedImmune LLC|Yes|Completed|October 2008|February 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|38|||Both|18 Years|70 Years|No|||July 2012|July 19, 2012|October 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771420||148903|
NCT00771147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13102|A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®|Prospective Open-label Non-interventional, Non-controlled Multi Observational and Pharmaco-economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar® Treatment Under Daily-life Treatment Conditions|PONDIAC|Bayer|No|Completed|June 2008|November 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of advanced Renal Cell Carcimona|June 2012|June 14, 2012|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00771147||148924|
NCT00771160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-397|MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)|MK0476 Phase III Long-term Study -Perennial Allergic Rhinitis-||Merck Sharp & Dohme Corp.||Completed|September 2004|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|15 Years|N/A|No|||April 2015|April 21, 2015|October 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00771160||148923|
NCT00767000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-007|Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin||Merck Sharp & Dohme Corp.||Terminated|October 2008|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|813|||Both|21 Years|70 Years|No|||February 2015|February 2, 2015|October 3, 2008|Yes|Yes||No|June 19, 2012|https://clinicaltrials.gov/show/NCT00767000||149235|
NCT00767013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiac imaging DSCT|Preoperative Assessment of Aortic Valve Stenosis and Coronary Artery Disease|Preoperative Assessment of Aortic Valve Stenosis and Coronary Artery Disease: Dual-source Computed Tomography Compared With Invasive Coronary Angiography and Transthoracic Echocardiography||Luzerner Kantonsspital|Yes|Recruiting|May 2007|||December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|65|||Both|40 Years|N/A|No|||April 2013|April 16, 2013|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767013||149234|
NCT00767026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F31NR010645-01|COPE Intervention for Parents of Children With Epilepsy|COPE Intervention for Parents of Children With Epilepsy||Children's Hospital Boston|Yes|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|88|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767026||149233|
NCT00766974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSNCL-0003|Compression Aided Management of Edema in Patients With C3 Venous Disease|Compression Versus Anti-Embolism Stockings in Patients With Leg Edema: Objective Investigation of Interface Compression and Edema Measurements, Clinical Outcomes, and Quality of Life.||BSN Medical Inc|No|Recruiting|October 2008|December 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||October 2008|October 3, 2008|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00766974||149237|
NCT00766987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007437-01H|Cardiac FDG PET Viability Registry|Ontario Provincial Registry Project for Cardiac Viability Assessment Using FDG PET|CADRE|Ottawa Heart Institute Research Corporation|No|Recruiting|April 2007|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Patients referred for cardiac FDG PET viability imaging|January 2016|January 4, 2016|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766987||149236|
NCT00767572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7151-32792-01|Statins and Endothelial Function in Patients With Coarctation of the Aorta|Effects of Statins on Endothelial Function in Patients With Coarctation of the Aorta||University of California, San Francisco|Yes|Terminated|August 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|September 24, 2008|Yes|Yes|low enrollment|No|November 9, 2012|https://clinicaltrials.gov/show/NCT00767572||149193|All patients were enrolled and completed the study interventions and assessments. Technical problems with measurements may have led to some unreliable data.
NCT00767585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OSI-DUM-2008/1|An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice|An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice||AstraZeneca|No|Completed|August 2008|June 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||8|Anticipated|560|||Female|55 Years|65 Years|No|Probability Sample|Institute of Oncology|July 2009|July 2, 2009|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00767585||149192|
NCT00768521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-107|A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)|A Randomized, Placebo Controlled, Crossover Study to Evaluate the Effects of Tolterodine Tartrate on Urodynamic Parameters in Patients With Overactive Bladder||Merck Sharp & Dohme Corp.||Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|20|||Female|40 Years|75 Years|No|||July 2015|July 22, 2015|October 7, 2008|No|Yes||No|August 1, 2014|https://clinicaltrials.gov/show/NCT00768521||149121|The analysis presented includes all patients. An analysis excluding patients who were misdosed yielded different results with a similar conclusion and are not presented.
NCT00769418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-002|Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)|A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Multiple Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0822 in Healthy Male and Postmenopausal Female Subjects||Merck Sharp & Dohme Corp.||Completed|September 2004|September 2006|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769418||149052|
NCT00769691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL 00012384|Monitoring of Cerebral Blood Flow Autoregulation Using Near Infrared Spectroscopy|Cerebral Autoregulation Monitoring in Adults Undergoing Cardiac Surgery: Comparison of Near Infrared Spectroscopy With Transcranial Doppler||Johns Hopkins University|No|Completed|April 2008|July 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|225|||Both|60 Years|N/A|No|Probability Sample|Adult patients undergoing cardiac surgery|October 2008|March 7, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769691||149033|
NCT00766636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0459|Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy|A Randomized Phase II Study of Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy for Patients With Resectable Adenocarcinoma of the Pancreas||M.D. Anderson Cancer Center|Yes|Terminated|September 2008|||November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|October 3, 2008||No|Slow Accrual|No|August 19, 2015|https://clinicaltrials.gov/show/NCT00766636||149262|
NCT00766649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090008|Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD|Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration|SIRGA|National Institutes of Health Clinical Center (CC)|Yes|Completed|October 2008|July 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|55 Years|N/A|No|||April 2014|April 7, 2014|October 3, 2008|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT00766649||149261|
NCT00766896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0292/07|Platelet Hyperreactivity to Aspirin and Stroke|Platelet Hyperreactivity to Aspirin and Stroke: A Prospective Study With Clinical Outcomes|PLARAS|University of Sao Paulo|Yes|Completed|July 2009|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|203|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00766896||149242|
NCT00766909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080060|Diabetogenicity of Cyclosporine and Tacrolimus|Diabetogenicity of Cyclosporine and Tacrolimus|CSATAC|University of Aarhus|Yes|Completed|March 2008|November 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766909||149241|
NCT00753493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804M29861|Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients|Phase I Pharmacokinetic and Safety Study of Intravenous Topiramate in Adult Patients||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|August 2008|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753493||150261|
NCT00753506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI/SPHS: 2007-02|Artemisinin to Reduce The Symptoms of Schizophrenia|Double-Blind Trial of Artemisinin to Reduce The Symptoms of Schizophrenia||Sheppard Pratt Health System|Yes|Completed|August 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||February 2012|February 27, 2012|September 15, 2008||No||No|August 22, 2011|https://clinicaltrials.gov/show/NCT00753506||150260|
NCT00757107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBMET.CR.ROWEU1|Taperloc Versus Taplerloc Microplasty|Clinical Evaluation of Taperloc Total Hip System With Two Different Stem Lengths||University Hospital, Linkoeping|Yes|Completed|October 2011|June 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|70 Years|No|||March 2016|March 11, 2016|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757107||149988|
NCT00757367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-122|A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)|A Phase 1, Open-Label, Controlled Clinical Trial to Determine the Pulmonary Residence Time of Insulin and Fumaryl Diketopiperazine, Utilizing Bronchoalveolar Lavage, After Administration of Technosphere® Insulin Inhalation Powder in Healthy Subjects||Mannkind Corporation||Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|September 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00757367||149968|
NCT00754923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08017|Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Single Agent Sorafenib in Non-small Cell Lung Cancer Patients Who Never Smoked or Were Former Light Smokers.||Ohio State University Comprehensive Cancer Center|Yes|Terminated|October 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|September 17, 2008|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT00754923||150153|The study was discontinued, after withdrawal from the sponsor due to slow accrual. The discovery of EGFR mutations changed the scope of the trial.
NCT00755196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-PSR-202|Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis|A Double-Blind, Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis||Anacor Pharmaceuticals, Inc.|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2011|February 9, 2011|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755196||150132|
NCT00754910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000614438|Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease|Immunobiology of Photodynamic Therapy in Lung Cancer Patients||National Cancer Institute (NCI)||Recruiting|December 2008|||October 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||June 2009|February 2, 2010|September 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00754910||150154|
NCT00769860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10656|Arimoclomol in Sporadic Inclusion Body Myositis|Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis||University of Kansas Medical Center|Yes|Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|50 Years|N/A|No|||March 2013|March 5, 2013|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769860||149021|
NCT00770159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-005|A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)|A Double-Blind, Placebo-Controlled, Once-Weekly, Multiple-Dose Study to Investigate the Safety, Tolerability, Plasma Concentration Profile and Effects on Biochemical Markers of Bone Resorption of MK0822 in Healthy Postmenopausal Female Subjects||Merck Sharp & Dohme Corp.|No|Completed|November 2004|November 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|February 4, 2016|October 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00770159||148999|
NCT00766961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAE|TAE and Surgery in Patients With Peptic Ulcer Bleeding Uncontrolled by Endoscopic Therapy|Randomized Comparison of Trans-catheter Arterial Embolization (TAE) and Surgery in Patients With Major Peptic Ulcer Bleeding Uncontrolled by Endoscopic Therapy||Chinese University of Hong Kong|No|Recruiting|April 2007|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00766961||149238|
NCT00771433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599535|G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer|Evaluation of the Efficacy of Adding Daily G-CSF (Granulocyte Colony Stimulating Factor) for Prevention of Hematologic Toxicity Due to Neoadjuvant or Adjvuant Chemotherapy in Breast Cancer||National Cancer Institute (NCI)||Completed|October 2007|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Supportive Care|2||Anticipated|120|||Female|18 Years|N/A|No|||December 2008|May 12, 2011|October 10, 2008||||No||https://clinicaltrials.gov/show/NCT00771433||148902|
NCT00768196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GKR-DUM-2008/1|Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients|Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients|Preedom|AstraZeneca|No|Completed|September 2008|February 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|80 Years|No|Probability Sample|general hospital sample|December 2010|December 6, 2010|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00768196||149146|
NCT00768209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-105|A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment|A Phase I, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment and In Healthy Control Subjects||VIVUS, Inc.|No|Completed|October 2008|July 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768209||149145|
NCT00767325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-179|A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography|Multi-Center, Open Label Study to Assess Early Response to Abatacept With Background Methotrexate Using Power Doppler Ultrasonography in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate||Bristol-Myers Squibb|No|Completed|December 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|104|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|October 6, 2008|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00767325||149212|Power Doppler ultrasonography values from 1 site (8 participants were excluded due to technical and quality issues with PDUS scoring and compliance issues.)
NCT00767598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-109|The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects|The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors(PDE5I) in Male Subjects|CYP3APDE5I|Inje University|Yes|Completed|December 2007|July 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|21|||Male|20 Years|N/A|Accepts Healthy Volunteers|||July 2008|October 6, 2008|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767598||149191|
NCT00768170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0633-028|MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)|A Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK0633 in Japanese Asthmatic Children Aged 12 to Less Than 16 Years||Merck Sharp & Dohme Corp.|No|Completed|September 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|12 Years|15 Years|No|||July 2015|July 2, 2015|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768170||149148|
NCT00768781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT003678|Mindfulness-Based Approaches to Insomnia|Augmenting Behavior Therapy for Insomnia With Mindfulness Meditation||Rush University Medical Center|No|Completed|November 2008|April 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Both|21 Years|N/A|No|||May 2013|May 28, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768781||149101|
NCT00768846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S03008|Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World|Randomized Comparison of Zotarolimus- and Everolimus-Eluting Stents for Coronary Treatment|ZEPPELIN|Deutsches Herzzentrum Muenchen|Yes|Recruiting|September 2008|June 2011|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2600|||Both|18 Years|N/A|No|||October 2008|October 11, 2008|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00768846||149096|
NCT00768859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M08TRA|Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study|Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study|TRAIN|The Netherlands Cancer Institute|Yes|Completed|September 2008|May 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768859||149095|
NCT00769158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13521|Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study|Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study||University of Virginia|Yes|Completed|October 2008|December 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|21 Years|45 Years|No|||February 2012|February 3, 2012|October 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769158||149072|
NCT00769171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11647|Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)|A Prospective, Randomized, Double-blinded, Multi-center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidazole 500mg Every 12h for the Treatment of Patients With Complicated Intra-abdominal Infections|DRAGON|Bayer|No|Completed|October 2005|January 2007|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769171||149071|
NCT00756600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-07-0320|A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants|A Multi-site Randomised Controlled Trial Comparing Regional and General Anaesthesia for Effects on Neurodevelopmental Outcome and Apnoea in Infants|GAS|Children's Hospital Boston|Yes|Active, not recruiting|October 2006|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|720|||Both|N/A|60 Weeks|No|||December 2013|December 5, 2013|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00756600||150027|
NCT00753519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080212|Transcranial Magnetic Stimulation to Treat Parkinson's Disease|Intermittent Theta-Burst Transcranial Magnetic Stimulation (TBS) for the Treatment of Parkinson Disease||National Institutes of Health Clinical Center (CC)|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|80 Years|No|||October 2012|October 14, 2012|September 13, 2008||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT00753519||150259|
NCT00753532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPOB-USM-Version 1.4|Neuroprotective and Cardioprotective Effects Of Palm Vitamin E Tocotrienols|A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E)||University of Science Malaysia|Yes|Completed|November 2007|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|241|||Both|35 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 5, 2014|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753532||150258|
NCT00753818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3370-2(-4)|Developmental Effects of Infant Formula Supplemented With LCPUFA|||Mead Johnson Nutrition||Completed||||||N/A|Interventional|N/A|4||||||Both|N/A|5 Days|Accepts Healthy Volunteers|||September 2008|September 16, 2008|September 16, 2008||||No||https://clinicaltrials.gov/show/NCT00753818||150238|
NCT00753831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PR1220827|Efficacy of Aurosling in Frontalis Sling Suspension Surgery|Randomized, Double Blind, Active Controlled Study of the Efficacy, Surgical Outcome and Complications of Silicone Rod Sling in Frontalis Sling Suspension Surgery||Aurolab|Yes|Completed|January 2009|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||July 2012|July 11, 2012|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00753831||150237|
NCT00755794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-384|The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)(COMPLETED)|An 8 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Adding Montelukast Sodium 10 mg Per Day to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma|SAS|Merck Sharp & Dohme Corp.||Completed|June 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|800|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755794||150088|
NCT00755508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-375-055|Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study to Evaluate the Safety and Efficacy of ROZEREM™ Taken in Combination With Gabapentin for the Treatment of Subjects With Chronic Insomnia||Takeda|No|Completed|November 2005|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|378|||Both|18 Years|80 Years|No|||February 2012|February 27, 2012|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755508||150108|
NCT00755521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0134-08-MMC|Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia|Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures||Meir Medical Center|Yes|Recruiting|September 2008|December 2012|Anticipated|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|75 Years|No|||August 2012|August 9, 2012|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00755521||150107|
NCT00771381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-24334/KT-FAZ-004|A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer|A Phase II Pre-Treatment Hypoxia PET Imaging Study Using 18F-FAZA in Patients With Invasive Duct Carcinoma of the Breast||AHS Cancer Control Alberta|No|Recruiting|November 2008|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2012|October 1, 2014|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00771381||148906|
NCT00770848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070611|AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer|A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer||Amgen||Completed|November 2008|April 2012|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|162|||Male|18 Years|N/A|No|||February 2014|February 6, 2014|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770848||148947|
NCT00770861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-16|A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients|A Multicenter, Prospective, Randomized, Double-blind, Placebo-Controlled, Dose-Titration Study of Nebivolol Monotherapy in Hispanic Patients With Stage 1 or Stage 2 Hypertension||Forest Laboratories|No|Completed|September 2008|||November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|277|||Both|18 Years|80 Years|No|||December 2010|December 21, 2010|October 9, 2008|Yes|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00770861||148946|
NCT00767039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23371|Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants|Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome.|CAST|Boston Medical Center|No|Terminated|January 2005|January 2009|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|N/A|8 Hours|No|||October 2008|September 28, 2011|December 17, 2007||No|Slow recruitment,changes in protocols, larger than anticipated differences|No|April 27, 2011|https://clinicaltrials.gov/show/NCT00767039||149232|The primary limitations are the small number of patients, the high rate of chronic lung disease in the beractant group and the open-label design of the study.
NCT00767052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4260C00006|Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236|A Randomised Single Centre Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral Multiple Ascending Daily Doses of AZD1236 Tablet by a Single-Blind, Placebo-Controlled, and Single Dose Relative Bioavailability of the Oral Suspension and Oral Tablet Formulations by an Open Cross-Over in Healthy Japanese Men||AstraZeneca|No|Completed|September 2008|December 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767052||149231|
NCT00767065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRT/SP2008/1|Early Cardiac Computed Tomography (CT) In Patients Admitted With Acute Chest Pain|The Role of Early X-Ray Cardiac Computed Tomography in Patients Admitted With Acute Chest Pain|EXACCT|Chelsea and Westminster NHS Foundation Trust|No|Not yet recruiting|January 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|40 Years|N/A|No|||September 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767065||149230|
NCT00768495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-023|Hyperspectral Imaging Pre and Post Endovascular Intervention|Evaluation of the Success of Endovascular Peripheral Revascularization for the Treatment of Chronic Limb Ischemia by Measuring OxyHb and DeoxyHb Using a New Hyperspectral Imaging Device (OxyVu).|CLI-Pre/Post|HyperMed|No|Recruiting|October 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|50 Years|85 Years|No|Non-Probability Sample|Patients who have chronic limb ischemia and present with the symptoms of claudication,        rest pain or having minor non-healing ulcers or gangrene (Rutherford category 1 to 6) who        also require percutaneous endovascular revascularization.|June 2009|June 2, 2009|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00768495||149123|
NCT00768508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12790|Combined Pharmacotherapies for Alcoholism|Combined Pharmacotherapies for Alcoholism||University of Virginia|Yes|Completed|September 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|300|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|October 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00768508||149122|
NCT00767871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMCIRB2007-01-024|Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder|Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder||Samsung Medical Center|Yes|Completed|March 2007|December 2008|Actual|August 2007|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|46|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767871||149170|
NCT00768222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-08-002|Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery|Pilot Evaluation of Cosmetic Outcome and Surgical Site Infection Rates of Coated VICRYL* Plus Antibacterial (Polyglactin 910) Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery||Ethicon, Inc.|No|Completed|October 2008|May 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|October 7, 2008||No||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00768222||149144|
NCT00768235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCByoga123|Yoga Program in Respiratory Function|Influence of Yoga Program in Respiratory Function of Older Women||Catholic University of Brasília|Yes|Completed|March 2007|June 2007|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|51 Years|76 Years|Accepts Healthy Volunteers|||October 2008|October 7, 2008|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768235||149143|
NCT00768872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1644|Spinal Cord Stimulation Research Study|Neuro Ambulatory Data Recorder (ADR) Spinal Cord Stimulation (SCS) Study|ADR-SCS|MedtronicNeuro|No|Completed|October 2008|||April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|N/A|No|Non-Probability Sample|Candidates for Spinal Cord Stimulation|March 2013|March 12, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768872||149094|
NCT00768885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDPTLD0809|Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs.|Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs||Bausch & Lomb Incorporated|No|Completed|September 2008|January 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 15, 2013|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768885||149093|
NCT00756236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1638|A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement|A Comparison of the Effect of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement||University of Oklahoma|Yes|Active, not recruiting|October 2008|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|60|||Both|18 Years|75 Years|No|||December 2014|December 2, 2014|September 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756236||150055|
NCT00757393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012269|Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis|Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis||The Hospital for Sick Children|No|Recruiting|September 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|28|||Both|5 Years|16 Years|No|||September 2013|September 5, 2013|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757393||149966|
NCT00753233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080210|Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy|Long Term Follow Up of Children and Adolescents Diagnosed With Hypertrophic Cardiomyopathy: Identification of Risk Factors That Predict Arrhythmia Events||National Institutes of Health Clinical Center (CC)||Completed|September 2008|January 2012||||N/A|Observational|Time Perspective: Retrospective|||Actual|145|||Both|N/A|21 Years|No|||January 2012|September 26, 2015|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00753233||150280|
NCT00753857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS-15879-2|The Drug Facts Box: Helping Consumers Understand Drugs for Risk Reduction|The Drug Facts Box: Helping Consumers Understand Drugs for Risk Reduction||White River Junction VAMC|No|Completed|October 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||September 2008|September 16, 2008|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00753857||150235|
NCT00754195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.071|Insertion Distance of Thoracic Epidural Catheters in the Context of Thoracotomy Procedures.|Influence of Catheter Insertion Distance on the Quality of Thoracic Epidural Analgesia in the Context of Thoracotomy Procedures.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00754195||150209|
NCT00753844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-29|Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer|Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10||Kinki University||Completed|November 2006|July 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|20 Years|80 Years|No|||April 2012|April 4, 2012|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00753844||150236|
NCT00756080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 07/12-D|"Effects of Oral Citrulline on Protein Metabolism in Healthy Humans: a Prospective, Randomized, Double-blind , Cross-over Study" (Citrugrêle)|"Effects of Oral Citrulline on Protein Metabolism in Healthy Humans: a Prospective, Randomized, Double-blind , Cross-over Study"||Nantes University Hospital|No|Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|March 8, 2010|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756080||150067|
NCT00756093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-08-10|Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops|||Alcon Research|No|Completed|September 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|September 17, 2008||No||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00756093||150066|
NCT00770484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080722|Effect of Exercise in OI|Effects of Exercise in Orthostatic Intolerance||Vanderbilt University|No|Completed|November 2008|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||June 2015|June 16, 2015|October 9, 2008|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00770484||148974|
NCT00771134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12601A|Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression|Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder||H. Lundbeck A/S|No|Terminated|December 2008|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|65 Years|No|||May 2014|May 14, 2014|October 10, 2008|Yes|Yes|Study was previously suspended and is now terminated|No||https://clinicaltrials.gov/show/NCT00771134||148925|
NCT00767091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002578-36|Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentric Trial|CHoPA-I|University Hospital, Lille|No|Completed|March 2009|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|80 Years|No|||March 2009|April 23, 2012|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00767091||149229|
NCT00767858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908225|Cultural Congruence in International Genetics Research|Cultural Congruence in International Genetics Research: Perceptions of Opportunities and Challenges Among Researchers||National Institutes of Health Clinical Center (CC)||Terminated|September 2008|February 2016||||N/A|Observational|Time Perspective: Prospective|||Anticipated|45|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767858||149171|
NCT00768183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA33687|Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water|A Phase 1, Single-Center, Open-Label, Drug Interaction Study to Evaluate the Effect of Alcohol Ingestion on the Pharmacokinetics of Alpharma Branded Products Division Inc. (KADIAN) Morphine Sulfate Extended-Release Capsules in Healthy Adult Volunteers Under Fasting and Fed Conditions and Relative Bioavailability Assessment of an Immediate Release Morphine Solution||Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.||Completed|May 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||October 2008|October 3, 2008|October 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768183||149147|
NCT00767338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMN-VIA|Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis|A Prospective, Randomized, Study of Microsurgical Varicocelectomy Versus Observation in the Treatment of Male Partners With a Palpable Varicocele and an Abnormal Semen Analysis|VIA|Yale University|Yes|Terminated|May 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3|||Male|18 Years|50 Years|No|||June 2013|June 24, 2013|October 3, 2008||No|The DSMB recommended stopping the study because of concerns about the dismal recruitment, the    drain on network resources, and the need for a study redesign.|No|December 12, 2012|https://clinicaltrials.gov/show/NCT00767338||149211|
NCT00767624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08132008-1277|TRIAD - Treatment of Insomnia and Depression|Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants||Stanford University||Active, not recruiting|December 2008|||April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|75 Years|No|||November 2013|November 27, 2013|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767624||149189|
NCT00767637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11810|Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone|Open Label, Non-controlled Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone in Patients With Hyperphosphatemia Receiving Dialysis||Bayer|No|Completed|June 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|N/A|No|||June 2014|June 19, 2014|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767637||149188|
NCT00768248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD Phantom Pilot|Naval Medical Center San Diego (NMCSD) - Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain|Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain||University of California, San Diego|No|Terminated|October 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|October 7, 2008|Yes|Yes|No longer enrolling patients, not enough enrollment|No||https://clinicaltrials.gov/show/NCT00768248||149142|
NCT00768534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4454|Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media|Microbiological Analysis Of Spontaneous Draining Acute Otitis Media Including Serotype Distribution Of Pneumococcal Isolates||Pfizer|No|Recruiting|October 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|Samples Without DNA|Middle ear fluid and anasopharyngeal swab|Both|2 Months|5 Years|No|Non-Probability Sample|community sample|October 2015|October 1, 2015|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768534||149120|
NCT00768547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|risk stratification|Risk Stratification in Acutely Admitted Medical Patients|Risk Stratification in Acutely Admitted Medical Patients||Ribe County Hospital|No|Completed|August 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5900|||Both|15 Years|N/A|No|Non-Probability Sample|Any patient acutely admitted to the medical department of Ribe County Hospital|August 2008|July 21, 2011|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768547||149119|
NCT00757120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|577|Biomarkers and Genetic Factors Related to Emphysema|SCCOR: Alveolar and Airway Mechanisms for COPD Project 3: Membrane-Type 1 Matrix Metalloproteinase and Extracellular Matrix Metalloproteinase Inducer in Cigarette Smoke-Induced Lung Inflammation and Emphysema Pathogenesis||Washington University School of Medicine|Yes|Active, not recruiting|October 2007|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|145|Samples With DNA|Blood cells, serum, extracted RNA and DNA, lung fluid|Both|45 Years|N/A|No|Non-Probability Sample|Participants in this study will include current and former smokers who previously        participated in the National Lung Screening Trial. Patients will also be recruited from        the pulmonary clinic at Washington University School of Medicine Jacqueline Maritz Lung        Center, the Barnes Jewish Hospital Pulmonary Rehabilitation Program, the Smoking Cessation        Clinic of the Siteman Cancer Center, and the Pulmonary Clinic at St. Louis ConnectCare.|September 2012|September 14, 2012|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757120||149987|
NCT00752960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44MH073291|DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics|DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics|DIMS|Genomas, Inc|No|Recruiting|January 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Anticipated|1000|Samples With DNA|DNA extracted from whole blood|Both|18 Years|59 Years|No|Non-Probability Sample|Patients treated for psychoses|September 2008|September 12, 2008|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752960||150301|
NCT00753246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAG101-BSA05|Nimotuzumab in Adults With Glioblastoma Multiforma|Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV||Oncoscience AG|Yes|Completed|August 2007|January 2012|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||November 2012|November 30, 2012|November 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00753246||150279|
NCT00754208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|380-08|Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children|Long Acting Stimulant Treatment of ADHD in Young Children||University of Nebraska|No|Recruiting|October 2008|August 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|4 Years|5 Years|No|||May 2009|May 28, 2009|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00754208||150208|
NCT00754442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28679|Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism|Clinical and Molecular Characterization of Suspected Partial 25-hydroxyvitamin D-1-alpha-hydroxylase Deficiency|1hydroxylase|University of Maryland|Yes|Completed|February 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Female|40 Years|59 Years|Accepts Healthy Volunteers|||February 2014|May 13, 2014|September 17, 2008|Yes|Yes||No|January 17, 2013|https://clinicaltrials.gov/show/NCT00754442||150190|
NCT00755534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/05.31|Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC|A Parallel Phase II Study With Irinotecan/Cetuximab (Until PD) Followed by XELOX/Cetuximab (Until PD) vs the Reverse Sequence in Metastatic CRC With Previous Benefit on Irinotecan/Bevacizumab Based Therapy||Hellenic Oncology Research Group|No|Terminated|November 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|72 Years|No|||February 2013|February 12, 2013|September 18, 2008||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00755534||150106|
NCT00755807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11666|Duloxetine for Multiple Sclerosis Pain|Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.||Eli Lilly and Company|No|Completed|October 2008|November 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|September 17, 2008|Yes|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00755807||150087|
NCT00756106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600751|MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma|Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques||Massachusetts General Hospital|Yes|Terminated|July 2008|||September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed GBM|February 2014|February 6, 2014|September 18, 2008|Yes|Yes|Funding ended|No||https://clinicaltrials.gov/show/NCT00756106||150065|
NCT00756119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-R-COstatus-1A-H|Measurement of Cardiac Output and Blood Volumes Using Transonic Ultrasound Dilution Technology|Measurement of Cardiac Output and Blood Volumes Using Transonic Ultrasound Dilution Technology - Clinical Evaluation and Validation||Transonic Systems Inc.|No|Completed|December 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|||Both|21 Years|N/A|No|Non-Probability Sample|Post cardiac surgery adult patients|May 2012|May 30, 2012|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00756119||150064|
NCT00770510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-126|A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)|A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia||Eisai Inc.|No|Completed|September 2008|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|192|||Both|21 Years|64 Years|No|||December 2012|December 28, 2012|October 9, 2008||No||No|December 28, 2012|https://clinicaltrials.gov/show/NCT00770510||148972|
NCT00770874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10020380|Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer|Phase III Study of S-1 + Cisplatin Compared With Single-agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix||Taiho Pharmaceutical Co., Ltd.|No|Active, not recruiting|September 2008|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Female|20 Years|N/A|No|||February 2016|February 23, 2016|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770874||148945|
NCT00770887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2404|Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate|Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate: A Pilot Observational Study of Feasibility and Acceptability|SAD|University of North Carolina, Chapel Hill|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will enroll 50 English-speaking/literate women at least 18 years of age of any        race who have sought contraception with DMPA at the Planned Parenthood of Southwest and        Central Florida in Tampa and Fort Myers. Patients who choose to begin DMPA or who have        already been using DMPA will be approached regarding voluntary participation in the study.        Because DMPA is contraindicated in pregnancy, women with a positive urine pregnancy will        not be eligible. Should a woman become pregnant during the study, she will receive no        further DMPA injections|August 2011|August 9, 2011|October 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00770887||148944|
NCT00771524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014227|Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone|Open-Label, Pharmacokinetic Study of the Penetration of Ceftobiprole Into Bone||Basilea Pharmaceutica|No|Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|22|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|October 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771524||148895|
NCT00771537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601-09|HIV Testing & Womens Attitudes on HIV Vaccine Trials|HIV Testing & Womens Attitudes on HIV Vaccine Trials||Indiana University|Yes|Completed|November 2006|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|16||Actual|2031|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 28, 2013|October 10, 2008||No||No|April 7, 2013|https://clinicaltrials.gov/show/NCT00771537||148894|
NCT00767351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Variation in Serum Levels of Metformin in Patients With Reduced Renal Function|Intraindividual Variation of Serum Metformin in a Cohort of Patients With Type 2 DM and Moderately Reduced Renal Function||Skane University Hospital|No|Completed|October 2008|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients with type 2 DM followed at the out-patient department at the hospital will be        asked to join the study|September 2009|July 22, 2010|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767351||149210|
NCT00767364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP #35817|Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome|Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome: A Pilot Study||Children's Hospital of Michigan|Yes|Completed|July 2009|November 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|6 Weeks|18 Months|Accepts Healthy Volunteers|||June 2014|June 11, 2014|October 6, 2008|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT00767364||149209|The small sample size makes generalization of the study data difficult.
NCT00767650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080222|Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia|Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Completed|September 2008|June 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|7|||Both|15 Years|N/A|No|||June 2011|September 26, 2015|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767650||149187|
NCT00767884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|413-08-EP|Effect of Panretinal Photocoagulation on Optic Nerve Head Topography|Effect of Panretinal Photocoagulation on Optic Nerve Head Topography and Nerve Fiber Layer Parameters|PRP|University of Nebraska|No|Terminated|October 2008|September 2013|Actual|September 2013|Actual|N/A|Observational|N/A||1|Actual|9|||Both|19 Years|N/A|No|Non-Probability Sample|Ophthalmology Clinic at UNMC|February 2014|February 18, 2014|October 3, 2008||No|Low subject recruitment|No||https://clinicaltrials.gov/show/NCT00767884||149169|
NCT00768261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH060883-06|Corticolimbic Degeneration and Treatment of Dementia|Corticolimbic Degeneration and Treatment of Dementia||Washington University School of Medicine|No|Completed|November 2004|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|39|||Both|50 Years|95 Years|No|||July 2012|July 19, 2012|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768261||149141|
NCT00768560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13012|Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study|Evaluation of the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of BAY A1040 CR Tablet on High Dose Administration in Patients With Essential Hypertension.||Bayer|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|20 Years|75 Years|No|||May 2015|May 13, 2015|October 7, 2008||No||No|September 28, 2009|https://clinicaltrials.gov/show/NCT00768560||149118|
NCT00768573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481257|Taste Test of a New Formulation of Sildenafil (Revatio)|A Single-Blind Study In Healthy Adult Volunteers To Investigate The Palatability Of Different Oral Suspension Formulations Of Revatio®||Pfizer|No|Completed|January 2008|January 2008|Actual|January 2008|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Actual|4|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|April 2015|April 27, 2015|September 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768573||149117|
NCT00769769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH078999|Comparing Delivery Methods of Cognitive Behavioral Therapy for Depressed African-American Dementia Caregivers|Telephone CBT for Depressed African-American Dementia Caregivers||Florida State University|Yes|Completed|October 2008|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769769||149028|
NCT00769782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615624|Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor|Phase II Multicenter Clinical Trial on Surgery for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)||National Cancer Institute (NCI)||Active, not recruiting|October 2008|||September 2014|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|20 Years|N/A|No|||July 2009|September 19, 2013|October 8, 2008||||No||https://clinicaltrials.gov/show/NCT00769782||149027|
NCT00757133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/379|Prevention of Incisional Hernia by Mesh Augmentation After Midline Laparotomy for Aortic Aneurysm Treatment|Prevention of Incisional Hernia by Mesh Augmentation After Midline Laparotomy for Aortic Aneurysm Treatment.|PRIMAAT|University Hospital, Ghent|No|Completed|November 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00757133||149986|
NCT00752973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALG-0813|Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice|Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis||Taro Pharmaceuticals USA|No|Completed|September 2008|January 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|6 Months|24 Months|No|||July 2014|July 14, 2014|September 15, 2008|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT00752973||150300|
NCT00752986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200L00009|ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial|A Randomized,Double-blind,Parallel-group,Multicentre,Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo)With Fulvestrant (Loading Dose)in Postmenopausal Advanced BC Patients|ZACFAST|AstraZeneca|No|Terminated|December 2008|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|41|||Female|45 Years|N/A|No|||October 2014|October 6, 2014|September 15, 2008|Yes|Yes||No|September 15, 2014|https://clinicaltrials.gov/show/NCT00752986||150299|
NCT00753259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-4-043|Atrial Fibrillation (AF) Clinic to Improve the Treatment of Patients With Atrial Fibrillation.|The Effect of a Nurse-driven ICT-supported Disease Management Program to Improve the Treatment of Patients With Atrial Fibrillation.|AFClinic|Maastricht University Medical Center|No|Completed|June 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|712|||Both|18 Years|N/A|No|||April 2010|April 19, 2010|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753259||150278|
NCT00753545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00019|Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer|Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens||AstraZeneca|No|Completed|August 2008|November 2012|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|265|||Female|18 Years|N/A|No|||February 2013|February 6, 2013|September 12, 2008|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00753545||150257|For OM DoR: The subset of patients evaluable for response who responded to study treatment.Values in results table may be under-estimates as some patients had not progressed at final analysis,so true duration is likely to be greater than in database.
NCT00753558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor475808CTIL|Selective Digestive Decontamination in Carriers of Carbapenem-resistant Klebsiella Pneumoniae|A Randomized,Double-Blind,Placebo-Controled Trial of Selective Digestive Decontamination Using Oral Gentamicin and Oral Polymyxin E for Eradication of Carbapenem-Resistant Klebsiella Pneumoniae Carriage||Soroka University Medical Center|Yes|Completed|November 2008|July 2010|Actual|June 2010|Actual|N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||September 2010|September 19, 2010|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00753558||150256|
NCT00754936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079414-01A1|Treatment Response of Geriatric Depression|ERPs, Cognitive Dysfunction and Treatment Response of Geriatric Depression|ERP|Weill Medical College of Cornell University|Yes|Recruiting|May 2007|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||February 2011|February 18, 2011|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754936||150152|
NCT00755222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-801|The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease|A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Two Times a Week for Up to Three Treatment Cycles (2 x 3) in Subjects With Peyronie's Disease||Endo Pharmaceuticals|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Male|18 Years|N/A|No|||June 2015|June 12, 2015|September 16, 2008|Yes|Yes||No|January 18, 2011|https://clinicaltrials.gov/show/NCT00755222||150130|
NCT00754455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX 755.201|Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults|A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults||Novavax|Yes|Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|317|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754455||150189|
NCT00754676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040924005|Endoscopic Stenting for Chronic Abdominal Pain|Randomized Single Blind Trial of Endoscopic Stenting for Chronic Pancreatitis-Associated Abdominal Pain||University of Alabama at Birmingham|No|Completed|October 2004|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women diagnosed with chronic pancreatitis.|December 2011|December 5, 2011|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754676||150172|
NCT00756132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BernLCyto-Cog|Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca|Role of Inflammatory Markers in Predicting Disease Recurrency and Cognitive Performance in Women With High Risk and Locally Advanced Breast Cancer|Cyto-Cog|University Health Network, Toronto|No|Active, not recruiting|August 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|120|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Women ages 18-65 with a newly diagnosed locally advanced breast cancer and healthy women        ages 18-65.|March 2016|March 4, 2016|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00756132||150063|
NCT00770523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-004|Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells|Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies||Cooperative Study Group A for Hematology|No|Completed|December 2003|December 2008|Actual|March 2008|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|15 Years|55 Years|No|Probability Sample|acute leukemia chronic myelogenous leukemia myelodysplastic syndrome|June 2011|June 8, 2011|October 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00770523||148971|
NCT00770536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070182|AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR|A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer||Amgen|No|Completed|January 2009|June 2015|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|N/A|No|||September 2015|September 25, 2015|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770536||148970|
NCT00767611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909001|Molecular Markers of Human Sperm Function|Molecular Markers of Human Sperm Function||National Institutes of Health Clinical Center (CC)||Withdrawn|October 2008|July 2009|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|19 Years|N/A|No|||May 2012|May 9, 2012|October 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00767611||149190|
NCT00767390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rep2952|CARTO 3 Human Patch Study|CARTO 3 ACL Patches Effectiveness Over Prolonged Clinical Case|Human Patch|Biosense Webster, Inc.|No|Withdrawn|October 2008|||||Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|October 2015|October 12, 2015|October 3, 2008||No|The required results were obtained through alternate methodology|No||https://clinicaltrials.gov/show/NCT00767390||149207|
NCT00767403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13846|Internet Intervention for Childhood Encopresis|An Internet Intervention for Childhood Constipation and Encopresis||University of Virginia||Completed|January 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|290|||Both|5 Years|12 Years|No|||April 2012|April 2, 2012|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767403||149206|
NCT00767104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006471|A Study to Evaluate the Efficacy of Silk - Like Bedding Fabric, as Used in a Standard Pillow Case, in the Treatment of Acne Vulgaris|A Study to Evaluate the Efficacy of Silk - Like Bedding Fabric, as Used in a Standard Pillow Case, in the Treatment of Acne Vulgaris||Wake Forest School of Medicine|No|Recruiting|October 2008|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|N/A|No|||October 2008|October 14, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767104||149228|
NCT00767117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015526|TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.|A Phase I, Open-label, Randomized Cross-over, 2-period, 2-way Interaction Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Subjects.||Tibotec Pharmaceuticals, Ireland||Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|June 8, 2011|October 3, 2008||||No||https://clinicaltrials.gov/show/NCT00767117||149227|
NCT00767377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOF-MGC|Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC|Phase II Trial of Epirubicin, Oxaliplatin and 5-day 5-fluorouracil in Patients With Advanced and Metastatic Gastric Cancer||Fudan University|No|Completed|May 2007|March 2013|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|18 Years|75 Years|No|||October 2013|October 12, 2013|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767377||149208|
NCT00767897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807-02|The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients|The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients||Indiana University|Yes|Recruiting|November 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|120|||Female|9 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Girls age 9-18 who are healthy, have chronic kidney disease stage 3 or 4, are on dialysis,        or have had a functioning kidney transplant for longer than 6 months and are on the same        immunosuppression regimen.|April 2015|April 14, 2015|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00767897||149168|
NCT00767910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-03-07 Rev E, HP-03-07 Rev E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2007|||||N/A|N/A|N/A||||||||||||||January 4, 2016|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00767910||149167|
NCT00767923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-011|Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities|Clinical Validation of HyperMed OxyVu Tissue Oximeter for Assessing Level of Amputation With Comparison to Other Modalities|LOA|HyperMed|No|Active, not recruiting|July 2008|February 2010|Anticipated|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|18 to 85 years of age, males and females, varying skin tones, varying racial origins, and        with and without diabetes.|June 2009|June 2, 2009|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767923||149166|
NCT00768274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX222-CS-003|Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol|A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)||Resverlogix Corp||Completed|September 2008|||August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|October 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00768274||149140|
NCT00768586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUVienna|Analysis of the Early Development of the Visual Function in Extreme Premature Infants Under 28th Weeks of Gestation|Analysis of the Early Development of the Visual Function in Extreme Premature Infants Under 28th Weeks of Gestation. - A Prospective Study to Identify Normal Values of Flash Visual Evoked Potentials in This Population|fVEP|Medical University of Vienna|No|Recruiting|February 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|23 Weeks|29 Weeks|No|Non-Probability Sample|Premature infants between the 23-29th week of gestation are included.|September 2008|October 14, 2008|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768586||149116|
NCT00768599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D79-2902-07|A Study of Econazole Foam 1% in Athlete's Foot|A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis||AmDerma|No|Completed|March 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|October 7, 2008|Yes|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00768599||149115|
NCT00769535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-930047|Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma|Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma|HSP70|Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|January 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 26, 2013|February 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00769535||149044|
NCT00769795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6857|Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer|Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy||University of Washington|Yes|Completed|October 2008|November 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|18 Years|N/A|No|||October 2015|October 6, 2015|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769795||149026|
NCT00753272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106372|Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older|Observer-blind Superior Efficacy Trial With GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects||GlaxoSmithKline||Completed|September 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|43695|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2014|May 14, 2015|September 12, 2008|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00753272||150277|
NCT00753571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUTH-1|Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response|Cistanche Total Glycosides Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response||Peking University|No|Recruiting|January 2008|October 2010|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||September 2008|December 29, 2009|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753571||150255|
NCT00753870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2060 (GCRC 2670)|Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers|Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers||University of North Carolina, Chapel Hill|No|Terminated|August 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|September 15, 2008|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00753870||150234|
NCT00753883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_024|Ezetrol Post-Marketing Study|A Randomized, Open-Labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety of Ezetimibe Alone Versus Statin in the Treatment of Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|July 2006|||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|80 Years|No|||September 2008|September 16, 2008|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753883||150233|
NCT00755235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH082924|Feasibility of Depression Care Management by E-mail|Pilot Trial of Depression Care Management by Electronic Secure Messaging||Group Health Cooperative|No|Completed|April 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|208|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|September 17, 2008||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00755235||150129|Findings apply only to patients who choose to communicate by online messaging.
NCT00755209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 510606|Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Traumatic Brain Injury|Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Adults With Traumatic Brain Injury; a Randomised, Double-blinded, Placebo-controlled Trial||Khon Kaen University|No|Completed|October 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|238|||Both|16 Years|N/A|No|||November 2013|November 20, 2013|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00755209||150131|
NCT00755547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-5-08-2489-JM|A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth|Physical Activity for Overweight Youth at Risk for Type 2 Diabetes Mellitus (POWER) Trial|POWER|University of Manitoba||Completed|April 2008|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|120|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755547||150105|
NCT00755560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOXOCARA-ALBENDAZOLE|Treatment of Asymptomatic Toxocariasis With Albendazole in Children|Treatment of Asymptomatic Toxocariasis With Albendazole in Children. A Prospective, Randomized, Placebo-controlled Clinical Trial||Hospital de Niños R. Gutierrez de Buenos Aires|Yes|Active, not recruiting|September 2008|July 2017|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|15 Years|No|||February 2016|February 18, 2016|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755560||150104|
NCT00756756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-3454|The Effect of Granulocyte Colony Stimulating Factor (G-CSF) on Myocardial Function After Acute Anterior Myocardial Infarction, a Prospective Double Blind Randomized Placebo Controlled Study|The Effect of Granulocyte Colony Stimulating Factor (G-CSF) on Myocardial Function After Acute Anterior Myocardial Infarction, a Prospective Double Blind Randomized Placebo Controlled Study||Shiraz University of Medical Sciences|Yes|Completed|June 2007|February 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|80 Years|No|||September 2008|September 19, 2008|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756756||150015|
NCT00756977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI850-301|BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy||Braintree Laboratories|No|Completed|August 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|394|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|September 18, 2008|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00756977||149998|
NCT00771446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-201|Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency|Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) in Patients With Acute on Chronic Hepatitis (AOCH)|ELAD|Vital Therapies, Inc.|Yes|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|19 Years|69 Years|No|||April 2013|April 5, 2013|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00771446||148901|
NCT00771459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0111|Local Infiltration Analgesia in Major Spine Surgery With Ropivacaine Versus Placebo|Lokal Infiltrations Analgesi Med Ropivakain 0,5 % Versus Placebo Ved Rygkirurgi for Spinalstenose: et Prospektivt Randomiseret, Dobbeltblindet, Placebo-kontrolleret Studie||Hvidovre University Hospital||Completed|October 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|80 Years|No|||October 2008|June 22, 2011|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771459||148900|
NCT00771485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL08.01|Study of Efficacy of Bowel Preparation Before Colonoscopy|Study of Efficacy of Bowel Preparation Before Colonoscopy||C.B. Fleet Company, Inc.|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|148|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|October 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771485||148898|
NCT00771498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A06-295|An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin|An Evaluation of the Pharmacological Interaction of Lopinavir 800mg - Ritonavir 200mg Combination and Rifampin in Subjects Presenting Tuberculosis, With Contraindication for Antiretroviral Regimens Including Efavirenz|A06-295|Oswaldo Cruz Foundation|No|Completed|November 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771498||148897|
NCT00771511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD5899|Cervical Capsaicin for Labor Induction and Pain Relief|Cervical Capsaicin for Labor Induction and Pain Relief||Columbia University|Yes|Withdrawn|October 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|50 Years|No|||February 2013|February 6, 2013|October 10, 2008|Yes|Yes|PI left the institution.|No||https://clinicaltrials.gov/show/NCT00771511||148896|
NCT00767962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00342-51|A Prospective Randomised Study of Efficacy, Safety and Costs of Talc Pleurodesis Under Medical Thoracoscopy and Pleurodesis Under Video-assisted Thoracoscopy Surgery for Recurrent Primary Spontaneous Pneumothorax|A Prospective Randomised Study of Efficacy, Safety and Costs of Talc Pleurodesis Under Medical Thoracoscopy and Pleurodesis Under Video-assisted Thoracoscopy Surgery for Recurrent Primary Spontaneous Pneumothorax||Assistance Publique Hopitaux De Marseille|No|Completed|February 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|15 Years|55 Years|No|||August 2015|August 21, 2015|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767962||149163|
NCT00767975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707047M|Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison|Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison|LTBI_prison|National Taiwan University Hospital|Yes|Completed|January 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2384|||Male|N/A|N/A|No|||November 2010|November 25, 2010|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00767975||149162|
NCT00768287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB1001-01|Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B|Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B||Cangene Corporation|Yes|Active, not recruiting|January 2009|November 2014|Anticipated|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|77|||Male|5 Years|N/A|No|||June 2013|January 29, 2014|October 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00768287||149139|
NCT00768300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-231-0101|(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF|ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)|ARTEMIS-IPF|Gilead Sciences|Yes|Terminated|December 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|494|||Both|40 Years|80 Years|No|||February 2014|February 27, 2014|October 7, 2008|Yes|Yes|Lack of efficacy|No|July 15, 2013|https://clinicaltrials.gov/show/NCT00768300||149138|
NCT00767936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0013|Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocelluar Carcinoma|Viral and Host Factors Associated With Development of Hepatitis B Virus-related Hepatocellular Carcinoma||Stanford University||Terminated|March 2008|September 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|Samples Without DNA|blood|Male|18 Years|N/A|No|Non-Probability Sample|liver cancer and non-cancer liver conditions|October 2013|October 9, 2013|October 3, 2008||No|lack of progress|No||https://clinicaltrials.gov/show/NCT00767936||149165|
NCT00767949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1009-Oph-001|Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration|A Phase 1, Dose-Escalating, Multi-Center, Study of iSONEP (Sonepcizumab [LT1009]) Administered as an Intravitreal Injection to Subjects With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration||Lpath, Inc.|No|Active, not recruiting|October 2008|August 2012|Anticipated|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|50 Years|N/A|No|||April 2012|April 13, 2012|October 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00767949||149164|
NCT00769522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616169|FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia|Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia|CLL10|German CLL Study Group|Yes|Active, not recruiting|September 2008|January 2018|Anticipated|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|564|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769522||149045|
NCT00768937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORATACE1|Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma|Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response||Medical University of Vienna|No|Completed|September 2008|November 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||November 2010|November 8, 2010|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00768937||149089|
NCT00769236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00080-55|Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease|Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease||Assistance Publique Hopitaux De Marseille|No|Completed|June 2008|August 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|160|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769236||149066|
NCT00734877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103668|UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma|UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma: A Randomized Trial Comparing Standard Total Therapy 3 (S-TT3) With TT3-LITE (L-TT3)|TT4|University of Arkansas|Yes|Recruiting|July 2008|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|75 Years|No|||September 2015|September 29, 2015|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734877||151675|
NCT00754234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC003|Iron Bioavailability From MyPyramid Menus|Iron Bioavailability From MyPyramid Menus||USDA Grand Forks Human Nutrition Research Center|No|Completed|September 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|September 16, 2008|No|Yes||No|December 30, 2008|https://clinicaltrials.gov/show/NCT00754234||150206|
NCT00754468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16-00017|Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.|A STUDY OF CRYOSPRAY ABLATIONTM USING SURGICAL RESECTION SPECIMENS TO DETERMINE TREATMENT EFFECT, DEPTH OF INJURY, AND SIDE EFFECTS IN THE ESOPHAGUS (CSA Depth 3)|ESODOI|CSA Medical, Inc.|Yes|Completed|February 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|September 16, 2008||No||No|June 9, 2014|https://clinicaltrials.gov/show/NCT00754468||150188|single center, small number of subjects
NCT00754689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10231|Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes|A Multicenter, Double Blind, Placebo Controlled Randomized Study of the Efficacy and Safety of Two Rimonabant/Metformin Combinations for Reducing A1C in the Treatment of Patients With Type 2 Diabetes Mellitus Who Are Not on Current Drug Therapy.||Sanofi|No|Terminated|September 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|750|||Both|18 Years|N/A|No|||November 2008|November 7, 2008|September 17, 2008|Yes|Yes|Company decision taken in light of demands by certain national health authorities|No||https://clinicaltrials.gov/show/NCT00754689||150171|
NCT00755248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAPPY|Coronary Artery Bypass Grafting: Factors Related to Late Events and Saphenous Graft Patency|Coronary Artery Bypass Grafting: Factors Related to Late Events and Saphenous Graft Patency||Centro Cardiologico Monzino|No|Recruiting|January 2007|January 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Plasma,serum, whole blood|Both|18 Years|89 Years|No|||September 2008|September 16, 2008|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00755248||150128|
NCT00756145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/421|The Use of Low Molecular Weight Heparin in Hemodiafiltration|The Use of Low Molecular Weight Heparin in Hemodiafiltration||University Hospital, Ghent|No|Completed|September 2008|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756145||150062|
NCT00756418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-396|Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)|A Randomized Open-Label Comparative Study of Montelukast Versus Theophylline Added to Inhaled Corticosteroid in Pediatric Patients With Bronchial Asthma||Merck Sharp & Dohme Corp.||Completed|June 2003|August 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|6 Years|14 Years|No|||April 2015|April 24, 2015|September 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756418||150041|
NCT00756405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08202008-1284|Effects of Dietary Antioxidants on Cardiovascular Risk Factors|Potential Health Benefits of Dietary Antioxidants From Supplements v. Foods||Stanford University||Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 29, 2010|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756405||150042|
NCT00757250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2008-001|Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy|A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART||US Biotest, Inc.|Yes|Terminated|September 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|13|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|September 21, 2008|No|Yes|Difficulty recruiting subjects to dosing cohort 5.|No||https://clinicaltrials.gov/show/NCT00757250||149977|
NCT00771199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014602|An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain|An Open-label, Multicenter Study to Evaluate the Safety/Tolerability and Clinical Utility of Low-dose TTS-Fentanyl D-TRANS in Taiwan Patients With Cancer Pain||Janssen-Cilag Ltd.|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|October 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771199||148920|
NCT00771212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014656|Observational Study on the Patients With Pain Medications|Observational Study on the Patients With Pain Medications||Johnson & Johnson Taiwan Ltd||Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2636|||Both|18 Years|N/A|No|Probability Sample|Outpatients; Patients must have pain, previously treated with and without medication and        have a VAS (Visual analogue scale) score recorded at the enrolment time; Patient must have        a VAS score >4|May 2014|May 22, 2014|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771212||148919|
NCT00771225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-07-002|National,Multicentric Randomised Study of the Correction of Genital Prolapse With Fascial Repair or Mesh-Prolift|A National Multicentric Randomised Study of the Correction of Genital Prolapse With Fascial Repair or Mesh (Prolift)||University of Sao Paulo|Yes|Active, not recruiting|November 2008|November 2013|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|180|||Female|50 Years|80 Years|No|||October 2008|February 2, 2010|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771225||148918|
NCT00767715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7313|A Study in the Treatment of Acute Mania|A Randomized Open Label Study on the Efficacy, Tolerability, and Total Costs of Olanzapine Versus Conventional Antipsychotics in the Treatment of Acute Mania in Sweden||Eli Lilly and Company|No|Terminated|October 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|60 Years|No|||October 2008|October 3, 2008|October 3, 2008|No|Yes|Trial discontinued due to low enrollment|No||https://clinicaltrials.gov/show/NCT00767715||149182|
NCT00767988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23245|Probiotics in Girls With Spina Bifida|Probiotics Improvement of Gastrointestinal and Genitourinary Health in Girls With Spina Bifida (H-23245)||Baylor College of Medicine|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|3 Months|17 Years|No|||September 2015|September 11, 2015|October 6, 2008|||Withdrawn by PI|No||https://clinicaltrials.gov/show/NCT00767988||149161|
NCT00767663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3|Persantin Preceding Elective PCI|Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI|P3|Radboud University|No|Completed|October 2008|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767663||149186|
NCT00767676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|828-101-09-011|Contact Sensitization Potential of 828 Ointment|Evaluation of the Contact Sensitization Potential of 828 Ointment in Normal Healthy Adults||Healthpoint|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|259|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|October 4, 2008|Yes|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00767676||149185|
NCT00767689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-069|A Randomized Trial to Determine if Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Treated With Capecitabine Chemotherapy|||John H. Stroger Hospital|No|Recruiting|May 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|96|||Both|N/A|N/A|No|||August 2009|August 3, 2009|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767689||149184|
NCT00768911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-322.003|CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme|Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme||Adnexus, A Bristol-Myers Squibb R&D Company|No|Active, not recruiting|October 2008|June 2011|Anticipated|October 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2010|October 26, 2010|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768911||149091|
NCT00769223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597000|Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer|Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer||University of California, San Francisco|No|Recruiting|February 1993|June 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|3500|||Male|18 Years|N/A|No|Probability Sample|Prostate Cancer patients|October 2014|October 13, 2014|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769223||149067|
NCT00768924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-012|CopiOs(TM) Bone Void Filler in the Post-Harvest Iliac Crest|CopiOs(TM) Bone Void Filler in the Post-Harvest Iliac Crest||Zimmer, Inc.||Completed|March 2007|December 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|CopiOs will be used to fill the bony deficit as a result of iliac crest autograft harvest        during spinal fusion surgery.|February 2009|September 28, 2011|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00768924||149090|
NCT00739089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004073|Presep and Vascath Interaction Study|A Pilot Study to Compare the Interaction Between Central Venous Mixed Venous Oxygen Saturation Catheters and Central Venous Hemodialysis Catheters||Wake Forest School of Medicine|No|Terminated|August 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|medical intensive care unit (MICU) patients in an academic tertiary care referral medical        center.|February 2009|January 13, 2010|August 20, 2008||No|Study stopped due to a lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00739089||151356|
NCT00739102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05-6201|S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease|S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease (STROLL)|STROLL|Cordis Corporation|Yes|Completed|August 2008|April 2013|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|30 Years|N/A|No|||March 2014|March 28, 2014|August 20, 2008|Yes|Yes||No|July 8, 2013|https://clinicaltrials.gov/show/NCT00739102||151355|
NCT00739115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-026-1-HPH1|The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study|The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study||Hawaii Pacific Health|Yes|Completed|September 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|13|||Both|N/A|12 Hours|No|||August 2015|August 25, 2015|August 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00739115||151354|
NCT00739128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15363.ct.il|Response to Hepatitis B Vaccine in Celiac Disease Patients|Intradermal Immunization Against Hepatitis B Virus in Celiac Disease- a Randomized Controlled Trial||Shaare Zedek Medical Center|No|Terminated|February 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|1 Year|N/A|No|||April 2011|April 14, 2011|August 20, 2008|Yes|Yes|Believed that a better study was to compare the response to engerix B vs Sci-B-Vac vaccine in    this patient group.|No||https://clinicaltrials.gov/show/NCT00739128||151353|
NCT00754481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000004888|Hypothermia for Cardiac Arrest in Paediatrics|Hypothermia for Cardiac Arrest in Paediatrics (HypCAP) - Pilot Study||The Hospital for Sick Children|Yes|Completed|January 2005|September 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|N/A|17 Years|No|||July 2015|July 29, 2015|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754481||150187|
NCT00754702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.27|Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer|Vinorelbine Metronomic Plus Lapatinib as Salvage Therapy for Patients With Overexpressing HER-2 Metastatic Breast Cancer. A Multicenter Phase II Study||University Hospital of Crete|No|Terminated|October 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|75 Years|No|||September 2015|September 25, 2015|September 17, 2008||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00754702||150170|
NCT00754715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2080C00001|Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers|A Phase I, Single-Centre, Randomised, Double-Blind, Placebo-Controlled Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 in Young and Elderly Healthy Volunteers After Oral Single Ascending Doses||AstraZeneca|No|Completed|September 2008|December 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|72|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2008|December 12, 2008|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754715||150169|
NCT00754949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-502-003|Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis|A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical and Anti-Microbial Efficacy and Safety of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone in the Treatment of Subjects With Blepharoconjunctivitis||InSite Vision|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|12 Years|N/A|No|||March 2014|March 3, 2014|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754949||150151|
NCT00754962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-T10-PVFS-1|Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Way Crossover Bioequivalency Study of Protriptyline Tablets 10 mg Under Fasted Conditions||Roxane Laboratories|No|Completed|December 2006|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2008|September 17, 2008|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754962||150150|
NCT00756431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET UK 06|Clinical Evaluation on HA Coated Dynamic Hip Screws for Trochanteric Femoral Fractures|Prospective Randomized Double Blinded Clinical Evaluation on HA Coated Dynamic Hip Screws for Trochanteric Femoral Fractures||Biomet, Inc.|No|Withdrawn|January 2004|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||November 2011|December 5, 2011|September 19, 2008||No|No data so far|No||https://clinicaltrials.gov/show/NCT00756431||150040|
NCT00756782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC101-204|A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma|Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma||Taiho Oncology, Inc.|No|Withdrawn|October 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|September 19, 2008|Yes|Yes|Terminated due to safety concerns.|No||https://clinicaltrials.gov/show/NCT00756782||150013|
NCT00756769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSC HR10852|Systemic Lupus Erythematosus in Gullah Health|Systemic Lupus Erythematosus in Gullah Health|SLEIGH|Medical University of South Carolina|No|Recruiting|April 2003|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|750|||Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sea Island Community|August 2011|August 11, 2011|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756769||150014|
NCT00757029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETADHD|Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)|Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate|NETADHD|Hallym University Medical Center|No|Completed|October 2005|August 2010|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|6 Years|18 Years|No|||December 2010|October 4, 2011|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757029||149994|
NCT00770965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2204|Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis|Phase II Single Dose, Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Study to Assess the Efficacy of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis||Novartis|No|Completed|September 2008|||September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|October 9, 2008|Yes|Yes||No|February 2, 2015|https://clinicaltrials.gov/show/NCT00770965||148938|
NCT00767130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R44 HL091697-01|DNA Diagnostic System for Statin Safety and Efficacy|DNA Diagnostic System for Statin Safety and Efficacy|SIM|Genomas, Inc|No|Recruiting|January 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|750|Samples With DNA|DNA extracted from blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated for hypercholesterolemia at Hartford Hospital, University of        California-San Francisco, or the Rogosin Clinic at New York Presbyterian Hospital|October 2008|October 3, 2008|October 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00767130||149226|
NCT00767728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPUC3004|Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2004|October 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|256|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00767728||149181|
NCT00737412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1285-TD-M02|Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults|A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults.||Bio-K Plus International Inc.|Yes|Completed|April 2008|January 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|277|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 19, 2010|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00737412||151483|
NCT00768001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0012|Genetic Analysis of Liver Cancer|Genetic Analysis of Liver Cancer||Stanford University||Terminated|June 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|Samples With DNA|tumor sample|Male|18 Years|N/A|No|Non-Probability Sample|liver cancer patients|January 2012|January 30, 2012|October 3, 2008||No|low accrual|No||https://clinicaltrials.gov/show/NCT00768001||149160|
NCT00768612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153B1-2208|Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia|A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Withdrawn|November 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|0|||Both|20 Years|65 Years|No|||January 2013|January 28, 2013|October 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00768612||149114|
NCT00768625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA|Cardiovascular Risk Stratification in Patients With Obstructive Sleep Apnea|Cardiovascular Risk Stratification in Patients With Obstructive Sleep Apnea|ERA|Associacao Fundo de Incentivo a Psicofarmcologia|No|Recruiting|April 2005|December 2012|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|1000 OSA patients and 1000 controls enrolled from Instituto do Sono database 500 subjects        with body mass index less than 25|October 2008|October 7, 2008|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768625||149113|
NCT00768898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-08-01|Defining the Conjunctival Staining Method: Instillation Volume and Time Course to Assess Staining With Lissamine Green|||Alcon Research|No|Completed|August 2008|||September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|March 2012|March 19, 2012|October 6, 2008||No||No|September 21, 2009|https://clinicaltrials.gov/show/NCT00768898||149092|
NCT00768638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA2580119|Study of Atorvastatin Dose Dependent Reduction of Proteinuria|The Renal Protective Effects of Low-dose and High-dose Atorvastatin in Patients With Glomerular Disease and Proteinuria: a Randomized Controlled Double Blinded Study|SARP|Laval University|No|Completed|October 2008|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|80 Years|No|||April 2015|April 28, 2015|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768638||149112|
NCT00768651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7331|Incretin Effect and Use After Clinical Islet Transplantation|Pilot Study of Safety and Efficacy of Combined Use of Dipeptidyl-peptidase Inhibitor (Sitagliptin) and Proton Pump Inhibitor (Pantoprazole) to Prevent Beta-cell Apoptosis and Promote Islet Regeneration in Islet Transplant Recipients With Early Graft Dysfunction||University of Alberta|No|Completed|October 2008|December 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||May 2015|May 29, 2015|October 7, 2008||No||No|May 10, 2015|https://clinicaltrials.gov/show/NCT00768651||149111|The major weaknesses of the study are the small sample size and the lack of a control group.
NCT00738777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N08AFT|Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer|A Randomized, Prospective Trial of 2-6 Weeks Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-study).||The Netherlands Cancer Institute|No|Recruiting|July 2008|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|250|||Both|N/A|N/A|No|||July 2015|September 28, 2015|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738777||151380|
NCT00738790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGBRJG0108|Preoperative Radiotherapy and Local Excision in Rectal Cancer|The Randomised Study of Preoperative Radiotherapy and Local Excision for Radiosensitive Rectal Cancer||Polish Colorectal Cancer Study Group|Yes|Recruiting|November 2003|November 2013|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||April 2010|April 14, 2010|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738790||151379|
NCT00734916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW/MV/20307|Immune Modulation by Parenteral Lipids|Immune Modulation by Omega-3 Versus Omega-6 Based Parenteral Lipids in Healthy Volunteers||Radboud University|No|Completed|August 2008|February 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|8|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2010|February 3, 2010|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00734916||151672|
NCT00734929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001404|Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy|A Comparison of the Combination of Aprepitant and Dexamethasone Versus the Combination of Ondansetron and Dexamethasone for the Prevention of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Craniotomy||Duke University|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|115|||Both|18 Years|75 Years|No|||January 2016|February 12, 2016|August 13, 2008|Yes|Yes||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00734929||151671|
NCT00754494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02984|Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma|A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon||National Cancer Institute (NCI)||Completed|July 2008|September 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|45|||Both|18 Years|N/A|No|||March 2014|December 22, 2014|September 17, 2008|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT00754494||150186|
NCT00754728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBCT-H01-07|"JACTAX" Trial Drug Eluting Stent Trial|"JACTAX" Trial Drug Eluting Stent Trial||Boston Scientific Corporation|Yes|Completed|July 2007|January 2010|Actual|November 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754728||150168|
NCT00754741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK64695|Multi-arm Intervention Diabetes Adherence Study|Phase III Clinical Trial of the Effectiveness of Adherence Data and Motivational Interviewing to Improve Medication Adherence and Both Glycated Hemoglobin and Cholesterol Control|MIDAS|Henry Ford Health System|Yes|Completed|July 2008|December 2012|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1692|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 16, 2008||No||No|March 23, 2015|https://clinicaltrials.gov/show/NCT00754741||150167|
NCT00754975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBCT-H02-07|JACTAX LD Drug Eluting Stent Trial|A Clinical Trial Comparing the Performance of the JACTAX LD DES With the TAXUS™ Libertè™ DES||Boston Scientific Corporation|Yes|Completed|January 2008|July 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754975||150149|
NCT00755820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5457|Food Exposure Therapy in Anorexia Nervosa|Food Exposure Therapy in Anorexia Nervosa||New York State Psychiatric Institute|No|Completed|January 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Inpatients receiving treatment for anorexia nervosa|October 2012|October 25, 2012|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755820||150086|
NCT00755833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3674|Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months|A Prospective, Multicentre, Open Label, Un-controlled , Observational, 12-month Study in Subjects Using: NovoMix® 50 (Biphasic Insulin Aspart 50) for Treatment of Type 2 Diabetes Mellitus in Slovenia||Novo Nordisk A/S|No|Completed|September 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|||Both|18 Years|N/A|No|Non-Probability Sample|Type 2 diabetes patients from both general and speciality practice settings who have been        deemed appropriate to receive NovoMix® 50 as new treatment and as part of routine        out-patient care by the prescribing physician.|August 2014|August 12, 2014|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00755833||150085|
NCT00756795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053-08|Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study)|Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study)|I-PAP|University of Nebraska|No|Terminated|February 2009|August 2010|Actual|August 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|0|||Both|19 Years|N/A|No|||August 2010|August 31, 2010|September 18, 2008||No|PI chose not to continue with this unfunded study|No||https://clinicaltrials.gov/show/NCT00756795||150012|
NCT00757042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070620|Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis||Amgen||Completed|October 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 19, 2011|September 18, 2008||||No||https://clinicaltrials.gov/show/NCT00757042||149993|
NCT00757289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET NL 03|Platelet-rich-plasma Treating Tennis Elbow|Use of Platelet-rich-plasma to Treat Tennis Elbow, A Blinded and Randomized Single Center Study||Biomet, Inc.|No|Completed|August 2007|January 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||September 2011|September 27, 2011|September 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00757289||149974|
NCT00757003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09112008-1299|To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease|A Clinical Study of the TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Diseases for Non-Surgical Candidates Under the Physician Sponsored IDE.||Stanford University||Completed|October 2001|May 2014|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00757003||149996|
NCT00757016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SundsvallH|Injection Treatment of Corticosteroid to Pelvic Ligament Insertions on Women With Longlasting Backpain After Pregnancy|Injection Treatment of Slow-Release Corticosteroid to the Sacrospinous Ligament Insertions on Women With Long-Lasting Low Back Pain Starting in Pregnancy.||Sundsvall Hospital|Yes|Completed|October 2004|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Female|N/A|N/A|No|||September 2008|September 19, 2008|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00757016||149995|
NCT00771563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOGA 0601|Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)|Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cisplatin Based First Line Chemotherapy: the SYRINGES Trial|SYRINGES|University Hospital, Antwerp|No|Completed|June 2008|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771563||148893|
NCT00767702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908217|Use of Population Descriptors in Human Genetic Research|Exploring the Use of Population Descriptors in Human Genetic Research||National Institutes of Health Clinical Center (CC)||Completed|September 2008|August 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|18|||Both|21 Years|N/A|No|||August 2012|October 23, 2014|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767702||149183|
NCT00767442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806021D|Least Invasive Nonlinear Light Microscopy|Least Invasive Nonlinear Light Microscopy||National Taiwan University Hospital|No|Recruiting|December 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Clinics|December 2009|December 14, 2009|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767442||149203|
NCT00737425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-PS-02-001|Safety and Efficacy Study of Pain Shield Device to Treat Subjects Following Laparoscopic-Assisted Abdominal Surgery|Evaluation of Safety and Efficacy of the PainShield Device for the Treatment of Subjects Who Underwent Laparoscopic-Assisted Abdominal Surgery||Shaare Zedek Medical Center||Recruiting|September 2008|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2008|October 27, 2008|August 17, 2008||||No||https://clinicaltrials.gov/show/NCT00737425||151482|
NCT00737438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-081|Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma|A Phase II Study of Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Completed|August 2008|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 15, 2008|Yes|Yes||No|January 4, 2016|https://clinicaltrials.gov/show/NCT00737438||151481|
NCT00737698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rMS v exercise in COPD|Comparison of Repetitive Magnetic Stimulation (rMS) and Exercise Versus no Active Treatment on Quadriceps Function in Chronic Obstructive Pulmonary Disease (COPD)|Is the Anaerobic Quadriceps Muscle Phenotype in Chronic Obstructive Pulmonary Disease Mediated by Reduced Muscle Concentrations of Peroxisome Proliferator-Activated Receptors Alpha and Delta?||Imperial College London|No|Completed|January 2007|October 2010|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|71|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2008|February 17, 2016|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737698||151461|
NCT00768313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB-012008|Phase IV Comparing Rods of Yield Strengths to Correct Adolescent Idiopathic Scoliosis.|A Multi-Centre Randomized Phase IV Clinical Trial Comparing Rods of Varying Yield Strengths and Their Ability to Hold Correction of Adolescent Idiopathic Scoliosis.||Queen's University|No|Terminated|September 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|10 Years|20 Years|No|||May 2010|May 14, 2010|October 7, 2008||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00768313||149137|
NCT00738491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/S1101/6|Effects of Ambient Air Pollution Exposure in Patients With Stable Angina Pectoris During Normal Daily Activities|Effects of Ambient Air Pollution Exposure in Patients With Stable Angina Pectoris During Normal Daily Activities||University of Edinburgh|No|Terminated|August 2008|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|1|Samples Without DNA|Plasma samples Serum samples|Both|N/A|N/A|No|Non-Probability Sample|Patients with stable angina pectoris and documented coronary artery disease|December 2014|December 1, 2014|August 19, 2008||No|Study performed in alternative location (Beijing China)|No||https://clinicaltrials.gov/show/NCT00738491||151402|
NCT00738764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDL192-1801|A Trial of PDL192 in Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors||Abbott|No|Completed|July 2008|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Both|18 Years|N/A|No|||December 2011|January 5, 2012|August 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738764||151381|
NCT00738504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSaoDomingos N 051/2008|Intensive Insulin Therapy and Acute Kidney Injury. Analysis Using RIFLE Criteria.|INTENSIVE INSULIN THERAPY REALLY REDUCES THE INCIDENCE OF ACUTE KIDNEY INJURY IN CRITICALLY ILL PATIENTS? An Analysis Using the RIFLE Criteria for Definition of Acute Kidney Injury.||Hospital Sao Domingos|Yes|Completed|June 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4||337|||Both|18 Years|N/A|No|Probability Sample|We are going to evaluate retrospectively the occurrence of acute kidney injury defined by        the RIFLE criteria in a population of patients submitted to two different strategies for        glycemic control: a carbohydrate restrictive strategy or intensive insulin therapy. The        protocol of the original trial that we are going to summarize below, was approved by the        Research Ethical Committee of the Federal University of Maranhão. We included 337 adult        patients, non pregnant, admitted from July 1, 2004 to December 31, 2006, to a 20-bed        multidisciplinary ICU of a general hospital and to an 11-bed trauma center ICU that had at        least two blood glucose levels above 150 mg/dl from three measurements obtained in the        first 12 hours after admission.|August 2008|August 19, 2008|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738504||151401|
NCT00738803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2615|Restoration of Leg Length, Offset, and Center of Rotation in Total Hip Replacement|Restoration of Leg Length, Offset, and Center of Rotation in Total Hip Replacement||Tennessee Orthopedic Alliance|No|Recruiting|June 2007|April 2010|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 5, 2009|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738803||151378|
NCT00739141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-087|Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.|A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.||Memorial Sloan Kettering Cancer Center||Recruiting|August 2008|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|70 Years|No|||February 2016|February 26, 2016|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00739141||151352|
NCT00767533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0033|Immunobiology of Cancer|Immunobiology of Cancer||Stanford University|Yes|Terminated|October 2008|October 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|Samples With DNA|peripheral blood mononuclear cells|Both|18 Years|N/A|No|Non-Probability Sample|Participants who have cancer or participants who do not have cancer and/or an autoimmune        disorder and are age 18 or over.|October 2011|October 31, 2011|October 3, 2008||No|PI left|No||https://clinicaltrials.gov/show/NCT00767533||149196|
NCT00754988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC21713|A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.|A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.||Hoffmann-La Roche||Completed|October 2008|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|666|||Both|18 Years|75 Years|No|||October 2011|October 17, 2011|September 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754988||150148|
NCT00755261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J07133|Phase II Study of Doxorubicin and Avastin® in Sarcoma.|Phase II Study of Doxorubicin and Avastin® for Patients With Advanced Soft-tissue Sarcomas.||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|September 2008|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|September 17, 2008|Yes|Yes|The study has been terminated due to low accrual.|No|April 15, 2015|https://clinicaltrials.gov/show/NCT00755261||150127|
NCT00755573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081172/8967|Pain and Chronic Pancreatitis - Clinical End Experimental Studies|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical and Experimental Pilot Study of Pregabalin in Patients With Chronic Pancreatitis|CPP|Aalborg Universitetshospital|Yes|Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|No|||July 2009|August 19, 2010|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755573||150103|
NCT00755846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-003|Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison Study to Determine the Efficacy and Safety of SYR110322 in Patients With Type 2 Diabetes, Who Are Either Receiving No Current Treatment or Currently Treated With Diet and Exercise, Sulfonylurea, Metformin or a Combination of Sulfonylurea and Metformin||Takeda|No|Completed|March 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|265|||Both|18 Years|75 Years|No|||February 2012|February 1, 2012|September 17, 2008|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00755846||150084|
NCT00756158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712085R|Molecular Studies on the Candidate Genes of Dopaminergic and Noradrenergic Systems in ADHD|Molecular Studies on the Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention-deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|August 2008|July 2011|Anticipated|||N/A|Observational|Observational Model: Family-Based||1|Anticipated|100|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments|Both|7 Years|18 Years|No|Non-Probability Sample|The sample will consist of 100 probands with ADHD, aged 7-18. Their biological parents (n        = 200) and siblings (estimated number = 75) born to the same biological parents will be        recruited as the parent controls and sibling controls, respectively, for the family-based        case control study.|July 2010|July 14, 2010|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756158||150061|
NCT00756808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-050|Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?|Is Tuberculin Skin Testing Effective in Screening for Latent TB in Elderly Residents of Nursing Homes? Comparison With a New IFN-y Based Assay||Northwell Health|No|Completed|October 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|135|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|65 and older|February 2014|February 6, 2014|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756808||150011|
NCT00757055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2008/Iva/DD|If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure|If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure||St Vincent's University Hospital, Ireland|No|Withdrawn|December 2012|January 2014|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||November 2014|November 24, 2014|September 19, 2008||No|Difficulty recruit pts with PSHF HR > 70 & high BNP.|No||https://clinicaltrials.gov/show/NCT00757055||149992|
NCT00753155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTx-2778|Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Lung Transplantation (Ergo-LTx)|Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Lnug Transplantation|Ergo-LTx|Hannover Medical School|Yes|Active, not recruiting|January 2002|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|89|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||September 2008|September 15, 2008|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00753155||150286|
NCT00753415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V934-002|A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)|A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|August 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|37|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|September 15, 2008|No|Yes||No|March 19, 2014|https://clinicaltrials.gov/show/NCT00753415||150267|
NCT00767416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP147|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children|A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-559, a Live Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus in Healthy 1 to <24 Month-Old Children|MEDI-559|MedImmune LLC|Yes|Completed|October 2008|August 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|1 Month|23 Months|Accepts Healthy Volunteers|||August 2012|August 8, 2012|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00767416||149205|
NCT00767455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|828-101-09-010|Cumulative Irritation Potential of 828 Ointment|Evaluation of the Cumulative Irritation Potential of 828 Ointment in a Population of Normal Healthy Subjects||Healthpoint|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|October 4, 2008|Yes|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00767455||149202|
NCT00767481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-16|1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT|||Alcon Research|No|Terminated|October 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||November 2011|July 18, 2012|October 3, 2008||No|Project Cancelled|No||https://clinicaltrials.gov/show/NCT00767481||149200|
NCT00767494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-63|Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT|||Alcon Research|No|Terminated|October 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|17|||Both|18 Years|N/A|No|||July 2009|September 18, 2012|October 3, 2008|No|Yes|Project Cancelled|No||https://clinicaltrials.gov/show/NCT00767494||149199|
NCT00737711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21822|A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Two Weekly Administration of Intravenous MIRCERA for the Treatment of Chronic Renal Anaemia in Dialysis Patients Not Currently Treated With ESA.||Hoffmann-La Roche||Completed|July 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737711||151460|
NCT00737724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C43-06|Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment|Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial.||Instituto Nacional de Enfermedades Respiratorias|Yes|Terminated|March 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|60 Years|No|||March 2015|March 24, 2015|August 19, 2008||No|Other published trials showed definitive expected superiority of Group 1|No||https://clinicaltrials.gov/show/NCT00737724||151459|
NCT00737958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHF FS/07/048|The Effects of Diesel Exhaust Inhalation On Exercise Capacity In Patients With Stable Angina Pectoris|The Effects of Diesel Exhaust Inhalation On Exercise Capacity In Patients With Stable Angina Pectoris||University of Edinburgh|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|19|Samples Without DNA|Plasma samples Serum samples|Both|N/A|N/A|No|Non-Probability Sample|Patients will be recruited from the cardiology outpatient clinics|July 2008|March 30, 2010|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00737958||151441|
NCT00737971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108/08|Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema|A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema|ATEMD|Federal University of São Paulo|No|Recruiting|August 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||August 2008|June 21, 2011|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00737971||151440|
NCT00738179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVE001|Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease|Sleep Apnea cardioVascular Endpoints Study - Investigating the Effectiveness of Treatment With CPAP vs Standard Care in Reducing CV Morbidity and Mortality in Patients With Co-existing CV Disease and Moderate-severe Obstructive Sleep Apnea.|SAVE|Adelaide Institute for Sleep Health|Yes|Active, not recruiting|September 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2500|||Both|45 Years|75 Years|No|||February 2015|February 4, 2015|August 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00738179||151424|
NCT00738192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2008-311|Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia|Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia in Gynecological Laparoscopic Surgeries|CARAN|Nanjing Medical University|Yes|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Female|19 Years|45 Years|No|||March 2009|March 10, 2009|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738192||151423|
NCT00771667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015238|A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy|A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy||Centocor, Inc.|Yes|Completed|December 2008|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|526|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|October 10, 2008|Yes|Yes||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00771667||148885|
NCT00771680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3655|Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes|Evaluation of Effectiveness and Safety of Levemir® (Insulin Detemir), NovoMix® (Biphasic Insulin Aspart) and/or NovoRapid® (Insulin Aspart) in Insulin naïve Subjects With Type 2 Diabetes.||Novo Nordisk A/S|No|Completed|October 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10408|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of both genders who, in practice settings, have been deemed appropriate to        receive Levemir®, NovoMix® 30 or and/or NovoRapid® as new treatment and as part of routine        out-patient care by the prescribing physician.|July 2012|July 12, 2012|October 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771680||148884|
NCT00767234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI0003|Permission to Collect Blood Over Time for Research|Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers||Stanford University|Yes|Recruiting|August 2008|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|345|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Active cancers of the GI tract|May 2014|May 20, 2014|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767234||149219|
NCT00767247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-ATA-2008/1|Analysis of Antihypertensive Treatment Efficacy|Analysis of Antihypertensive Treatment Efficacy|ATACA|AstraZeneca|No|Terminated|May 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|outpatient clinics|December 2010|December 2, 2010|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767247||149218|
NCT00767780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141/08|The Effect of a New Biomechanical Device|||Assaf-Harofeh Medical Center|No|Completed|October 2006|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Anticipated|200|||Both|30 Years|90 Years|No|Non-Probability Sample|Patients suffering from one of the following conditions: knee\hip OA, knee\hip joint        replacement, ankle fractures\instability, NSLBP|October 2008|October 5, 2008|October 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00767780||149177|
NCT00767793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08650|A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Ascending Dose Study of INS117548 Ophthalmic Solution in Subjects With Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma||Merck Sharp & Dohme Corp.||Completed|September 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|80 Years|No|||October 2015|October 1, 2015|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00767793||149176|
NCT00755274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC40|Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2008-2009 Formulation)||Sanofi|No|Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|September 16, 2008|Yes|Yes||No|February 1, 2010|https://clinicaltrials.gov/show/NCT00755274||150126|
NCT00755586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40-41200-98-040|Stem Cell Therapy to Improve the Muscle Function of Patients With Partly Denervated Muscles of the Arm|Autologous Bone Marrow Transplantation for Muscle Improvement in Traumatic Brachial Plexus Injuries||Leiden University Medical Center|No|Recruiting|January 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||August 2009|August 17, 2009|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755586||150102|
NCT00756171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPE_08|Colesevelam Versus Placebo in Cholestatic Pruritus|Colesevelam Versus Placebo in Cholestatic Pruritus. A Double-blind, Placebo-controlled Study|COPE|Foundation for Liver Research|Yes|Completed|September 2008|December 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756171||150060|
NCT00756444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080008|A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck|A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (Amended Version 20-March-2009)||Amgen|Yes|Completed|October 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|September 18, 2008|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00756444||150039|
NCT00756457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R15AR054507|Bracing and Strengthening for Posterior Tibial Tendon Dysfunction|The Effect of Bracing and Strengthening Exercises on Posterior Tibial Tendon Dysfunction||Ithaca College|No|Completed|July 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|40 Years|80 Years|No|||June 2014|June 30, 2014|September 19, 2008|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT00756457||150038|
NCT00756509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107DDE06|Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib|An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment||Novartis||Active, not recruiting|August 2008|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756509||150034|
NCT00754078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-24329|A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy|A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy||AHS Cancer Control Alberta|Yes|Recruiting|September 2008|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00754078||150218|
NCT00754091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008046|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2008|||||N/A|N/A|N/A||||||||||||||April 14, 2015|July 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00754091||150217|
NCT00754364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2007-003|Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients|A Randomized Phase II Study of Progression Free Survival Comparing Gemcitabine (1000 mg/m2 Infusion) Versus Carboplatin (AUC5 Infusion) Plus Alimta (500 mg/m2 Infusion) as First-line Chemotherapy in Elderly Patients With Locally Advanced (Stage IIIb) or Metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)||Istituto Clinico Humanitas|No|Terminated|October 2008|December 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|70 Years|N/A|No|||January 2014|January 28, 2014|September 17, 2008||No|low enrollment rate|No||https://clinicaltrials.gov/show/NCT00754364||150196|
NCT00757302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4126|Intraoperative Gamma Camera for Breast Cancer Surgery|Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer||University Hospital, Strasbourg, France|No|Completed|September 2008|September 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|N/A|No|||September 2015|September 29, 2015|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757302||149973|
NCT00737152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-DMII 0808|Evaluate the Side Effects and Benefits of RAS 130 With or Without Diet and Exercise in Type II Diabetes Mellitus|Phase II, Open-Label Study to Assess the Cardiovascular Side Effects and Efficacy for Reducing Blood Glucose Level in Type II Diabetes Mellitus Patients Being Treated With RAS 130 With or Without Diet and Exercise|ASI-DMII|American Scitech International|No|Not yet recruiting|July 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|460|||Both|30 Years|60 Years|No|||July 2011|July 19, 2011|August 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00737152||151503|
NCT00770419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130601|Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers|Perception of Caregiver Burden||Rutgers, The State University of New Jersey|Yes|Withdrawn|May 2008|February 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Caregivers and patients with late-stage oncological disease.|May 2015|May 27, 2015|October 9, 2008||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00770419||148979|
NCT00770783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSG-05-001|Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression|Efficacy of Magnetic Seizure Therapy (MST) in Refractory Major Depression||University Hospital, Bonn|No|Active, not recruiting|February 2005|May 2014|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||October 2013|October 28, 2013|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770783||148952|
NCT00737945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804|Prognostic Value of Endothelial Dysfunction and Coronary Complexity|Incremental Significance of Endothelial Function Assessed by Reactive Hyperemia Peripheral Arterial Tonometry to Improve Risk Stratification in High Risk Patients for Cardiovascular Events||Kumamoto University|No|Active, not recruiting|August 2006|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|30 Years|90 Years|No|Probability Sample|Kumamoto University Hospital and Yokohama City University Medical Center|June 2012|June 21, 2012|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737945||151442|
NCT00738517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPG 01/08|Immunoadsorption and Immunoglobulin Substitution for Heart Failure After Myocardial Infarction|Immunoadsorption With Subsequent Immunoglobulin Substitution for Patients With Heart Failure After Myocardial Infarction||University Medicine Greifswald|No|Recruiting|September 2008|December 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00738517||151400|
NCT00767260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sc-dm-2008|Bone Marrow Mononuclear Cell and Hyperbaric Oxygen Therapy in Diabetes Mellitus|Autologous Bone Marrow Mononuclear Cell Infusion With Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus||Fuzhou General Hospital|Yes|Active, not recruiting|March 2008|March 2015|Anticipated|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Both|40 Years|65 Years|No|||September 2014|September 6, 2014|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767260||149217|
NCT00767546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004988|Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients|Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients||Rabin Medical Center|No|Not yet recruiting|May 2009|August 2010|Anticipated|August 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|October 6, 2008|October 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00767546||149195|
NCT00755599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDEAMC 07-15|Eisenhower's Alternative Speculum Examination|The EASE Trial: Eisenhower's Alternative Speculum Examination|EASE|Eisenhower Army Medical Center|No|Active, not recruiting|September 2008|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|1200|||Female|18 Years|N/A|No|||September 2008|September 18, 2008|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00755599||150101|
NCT00755638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A031-01|A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ACE-031 (ActRIIB-IgG1) in Healthy, Postmenopausal Volunteers||Acceleron Pharma, Inc.|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|48|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|September 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00755638||150100|
NCT00755859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgANSTAZA|"Steroids and Azathioprine Versus Steroids Alone in IgAN"|Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial.||A. Manzoni Hospital|Yes|Completed|May 1998|September 2007|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|16 Years|70 Years|No|||August 2008|September 18, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755859||150083|
NCT00756470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0818|Phase II Neoadjuvant in Inflammatory Breast Cancer|A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (Her2/Neu)||M.D. Anderson Cancer Center|No|Terminated|October 2008|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||November 2014|November 4, 2014|September 19, 2008||No|Slow accrual.|No|October 30, 2014|https://clinicaltrials.gov/show/NCT00756470||150037|
NCT00756483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107957-UMC|Stability Plus - Outcomes From Extended Continuum of Care|Study the Effects of Pre- and Post-Operative Resistive Exercise in Total Arthroplasty Patients Using the Stability Plus Exercise System||Stability Plus, LLC|Yes|Not yet recruiting|October 2008|October 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients that have undergone total joint replacement - hip or knee|September 2008|September 19, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00756483||150036|
NCT00756496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS-SP04-06|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2006|||||N/A|N/A|N/A||||||||||||||June 29, 2009|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00756496||150035|
NCT00756522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|575|Analyzing Lung Tissue in People With and Without Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation|Specialized Center of Clinically Oriented Research: Alveolar and Airway Mechanisms for COPD. Detection: Lung Imaging and Profiling (Project 1)||Washington University School of Medicine|Yes|Enrolling by invitation|October 2007|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|63|Samples With DNA|Plasma, serum, isolated RNA and DNA, and lung tissue|Both|18 Years|N/A|No|Non-Probability Sample|Participants in this study will be adults with a clinically established need for lung        transplantation and who are listed at Barnes-Jewish Hospital for lung transplantation        because of COPD.|September 2012|September 14, 2012|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756522||150033|
NCT00756535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JOE2008|Exercise Training in a Geriatric Hospital Ward|||Health Center of the City of Joensuu|No|Not yet recruiting|October 2008|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|160|||Both|75 Years|N/A|No|||September 2008|September 19, 2008|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756535||150032|
NCT00756548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI850-302|BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy||Braintree Laboratories|No|Completed|August 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|386|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|September 18, 2008|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00756548||150031|
NCT00754104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-371|Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors|A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-hematologic Malignancy||Abbott||Withdrawn|September 2008|||December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2009|January 17, 2011|September 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00754104||150216|
NCT00762879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-10-5528|Spine Quantitative Computed Tomography (QCT)|Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children|Spine QCT|Children's Hospital of Philadelphia|No|Active, not recruiting|April 2008|June 2016|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|127|Samples Without DNA|urine|Both|5 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|200 control patients and 30 study patients|February 2016|February 29, 2016|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762879||149547|
NCT00754377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP 08-194|Developing a Practice-Based Learning and Improvement Quality Improvement (QI) Systems Impact Assessment Questionnaire|Developing a PBLI QI Systems Impact Assessment Questionnaire||VA Office of Research and Development|No|Completed|January 2008|December 2011|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|92|||Both|25 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Internal Medicine residents|April 2015|April 27, 2015|September 16, 2008||No||No|August 29, 2014|https://clinicaltrials.gov/show/NCT00754377||150195|While necessary limitations for initial assessment tool development, concerns will be addressed in the multi-site trial of the curriculum, including assessment of the training manual and codebooks that were developed during this project.
NCT00754845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA17R|Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy|A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)||Canadian Cancer Trials Group|Yes|Active, not recruiting|October 2004|November 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1918|||Female|N/A|120 Years|No|||March 2016|March 22, 2016|September 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00754845||150159|
NCT00786916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080209|Efficacy of IV Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Sedation|Efficacy of Intravenous Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Procedural Sedation||Akron Children's Hospital|No|Completed|February 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|109|||Both|2 Years|7 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|November 5, 2008|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00786916||147724|No complications or adverse reactions were associated with either study drug dose.
NCT00767156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E11UE15UE25US14C|Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging|Subjective and Instrumental Evaluation of the Effects of Treatments With Two Sea Buckthorn Oil Products on Cutaneous Aging|SBanti-aging|Institute of Skin and Product Evaluation, Italy|No|Not yet recruiting|October 2008|December 2008|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Anticipated|60|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 3, 2008|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767156||149225|
NCT00767169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tandskruv1|Bisphosphonate-coated Dental Implants|||University Hospital, Linkoeping|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||December 2013|December 9, 2013|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767169||149224|
NCT00767429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-042|Development of an Acceleration Based Fall Risk Detector|Development of an Acceleration Based Fall Risk Detector|field|Maastricht University Medical Center|Yes|Recruiting|August 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||July 2010|July 26, 2010|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00767429||149204|
NCT00737451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96051|Association of Thyroid Autoimmunity and Chronic Urticaria|Association of Thyroid Autoimmunity and Chronic Urticaria in Taiwan||Far Eastern Memorial Hospital|Yes|Completed|March 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|155|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients aged 18 and above with complaint of skin itching|September 2009|March 26, 2012|June 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00737451||151480|
NCT00737464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21810|A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous or Subcutaneous MIRCERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|August 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00737464||151479|
NCT00770796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prato0702|Statins for Prevention of Contrast Induced Nephropathy|Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease||Ospedale Misericordia e Dolce|Yes|Completed|April 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|304|||Both|N/A|N/A|No|||October 2015|October 15, 2015|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770796||148951|
NCT00770809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01073|Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery|Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2008|||January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|305|||Both|18 Years|N/A|No|||March 2015|May 7, 2015|October 9, 2008|Yes|Yes||No|May 7, 2015|https://clinicaltrials.gov/show/NCT00770809||148950|
NCT00771095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0430-03|Pounds Off Digitally Study: A Podcasting Weight Loss Intervention|Pounds Off Digitally Study: A Podcasting Weight Loss Intervention|POD|University of North Carolina, Chapel Hill|No|Completed|January 2008|June 2008|Actual|May 2008|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 9, 2008|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00771095||148928|
NCT00738205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Easypod|Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector|Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector When Administering Saizen® Growth Hormone to Children With Growth Disorders||Merck KGaA||Completed|June 2007|June 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|834|||Both|2 Years|17 Years|No|Non-Probability Sample|Overall, 834 children using the electronic auto-injector were recruited. Of these, 824        children were included in the evaluable population. Of the 824 evaluable children, 601        were treatment-naïve and 223 were treatment-experienced.|March 2014|March 10, 2014|August 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00738205||151422|
NCT00771355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001137/1|In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy|In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy||Massachusetts General Hospital|No|Terminated|August 2008|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|40|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects 20-70 years of age with the clinical diagnosis of vitiligo, melasma,        post-inflammatory hypo or depigmentation or post-inflammatory hyperpigmentation will be        recruited from Dermatology practice at the Massachusetts General Hospital.|March 2011|March 28, 2011|October 9, 2008||No|Lack of study staff.|No||https://clinicaltrials.gov/show/NCT00771355||148908|
NCT00768131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-322|A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel|A Randomized Phase II Trial to Assess the Predictive Value of Increased EGFR Copy Number by FISH in Patients With Advanced / Metastatic NSCLC Treated With Cetuximab and Carboplatin / Paclitaxel||Eli Lilly and Company|No|Withdrawn|October 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|October 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00768131||149151|
NCT00768144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-056|Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma|A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma||Dana-Farber Cancer Institute|Yes|Completed|September 2008|February 2013|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|September 29, 2008|Yes|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00768144||149150|
NCT00768729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-01|Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation|Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|1 Year|20 Years|No|||February 2013|February 14, 2013|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00768729||149105|
NCT00768742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL00635|Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study|Clinical Study to Assess the Safety and Effectiveness of VizAblate(tm) Intrauterine Ultrasound-guided RF Ablation (IUUSgRFA) of Submucosal and Intramural Uterine Fibroids on the Reduction of Pictorial Blood Loss Assessment Scores|FAST|Gynesonics|No|Withdrawn|September 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|25 Years|N/A|No|||November 2013|November 22, 2013|October 6, 2008|No|Yes|study revised and reinitiated under another protocol|No||https://clinicaltrials.gov/show/NCT00768742||149104|
NCT00755651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 6056|Studies on the H Pipelle, a New Device for Endometrial Sampling at Hysteroscopy|Studies on the H Pipelle, a New Device for Endometrial Sampling at Hysteroscopy||Royal Free Hampstead NHS Trust|No|Completed|January 2003|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|180|||Female|20 Years|80 Years|No|||September 2008|September 18, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755651||150099|
NCT00755872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007120|Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate|Influence of a High-fat Meal on the Bioavailability of a Two Different Formulations of Risedronate||Warner Chilcott|Yes|Completed|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|76|||Female|40 Years|70 Years|No|||October 2011|October 7, 2011|September 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00755872||150082|
NCT00755885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000614059|Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer|A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients With Oestrogen (ER) or Androgen Receptor (AR) Positive Advanced or Metastatic Breast Carcinoma||Cancer Research UK||Active, not recruiting|October 2008|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755885||150081|
NCT00756184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5133|Value of an Intervention to Enhance Adherence in Glaucoma Patients|1-year Randomized Control Trial Investigating the Value of an Intervention to Enhance Adherence in Glaucoma Patients Receiving Prostaglandin Monotherapy and in Patients Who Are Candidates for Adjunctive Therapy||Aristotle University Of Thessaloniki|No|Completed|September 2007|September 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|107|||Both|21 Years|80 Years|No|||September 2011|September 27, 2011|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00756184||150059|
NCT00756197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-00016-00|CryoSpray Ablation(TM)to Determine Safety and Feasibility in Radiation Induced Proctitis|A Single Center Pilot Study of CryoSpray Ablation(TM) to Determine Safety and Feasibility in Radiation Induced Proctitis (CSA LGI-2)|CSALGI2|CSA Medical, Inc.|No|Withdrawn|October 2008|September 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|September 18, 2008||No|Considering more robust design.|No||https://clinicaltrials.gov/show/NCT00756197||150058|
NCT00756210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DepG0002|Lifestyle and Obesity|||University College of Antwerp||Completed||||||N/A|Interventional|N/A|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 18, 2008||||No||https://clinicaltrials.gov/show/NCT00756210||150057|
NCT00753766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-004-04F|Multifactorial Pre-operative Intervention in Diabetes Mellitus|Multifactorial Pre-Operative Intervention in Diabetes Mellitus||VA Office of Research and Development|Yes|Completed|October 2005|September 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|N/A|N/A|No|||October 2014|October 20, 2014|September 12, 2008||No||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00753766||150242|
NCT00753779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-405|A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.|Efficacy of WelChol® as an Add-on to Simvastatin Therapy||Daiichi Sankyo Inc.|No|Completed|November 2002|April 2005|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|September 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753779||150241|
NCT00757380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-4-CI-2008|Trypan Blue Versus Brillant Blue for Epiretinal Membranes|Membranepeeling With Trypan Blue Versus Membranpeeling With Brillant Blue for Patients With Idiopathic Epiretinal Membranes||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|July 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|September 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00757380||149967|
NCT00753220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRITICAL001|Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer|A Phase I/IIa Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy With Autologous Immature Dendritic Cells (VDC2008) in Chemo-naïve Men With Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone|CRITICAL|Bostwick Laboratories|No|Terminated|August 2009|December 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|18 Years|N/A|No|||November 2014|November 3, 2014|September 12, 2008|Yes|Yes|Withdrew the IND with the FDA.|No|July 25, 2013|https://clinicaltrials.gov/show/NCT00753220||150281|
NCT00763139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AR056116|Inflammation and Insulin Resistance in Rheumatoid Arthritis|Inflammation and Insulin Resistance in Rheumatoid Arthritis||Vanderbilt University|Yes|Completed|April 2009|December 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|September 26, 2008|No|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT00763139||149527|Study relatively small, but efficiently designed. Crossover design has the advantage of comparing changes in the same patient and the disadvantage that subtle, undetected carryover effects may occur. 8 week drug exposure shorter than most trials.
NCT00786929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB-68/02|Acute Pancreatitis and Acute Fluid Collections|Randomized Controlled Trial on Sterile Fluid Collections Management in Acute Pancreatitis||University Medical Center, Tuzla|No|Completed|March 2003|December 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|N/A|N/A|No|||November 2008|February 3, 2009|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786929||147723|
NCT00763477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01276|Ghrelin in Cystic Fibrosis|The Effect of Ghrelin on Appetite and Immune Function in Patients With Cystic Fibrosis|ghrelin|Papworth Hospital|Yes|Recruiting|April 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|80 Years|No|||July 2010|July 26, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00763477||149502|
NCT00763490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|umcc 2007.137|Trial Of Double Umbilical Cord Blood Transplantation|Trial Of Double Umbilical Cord Blood Transplantation||University of Michigan Cancer Center|Yes|Active, not recruiting|December 2008|December 2015|Anticipated|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|65 Years|No|||January 2015|January 5, 2015|September 30, 2008|Yes|Yes||No|January 5, 2015|https://clinicaltrials.gov/show/NCT00763490||149501|
NCT00767182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808025|Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers|Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers - Monocentric Prospective Cohort|VOLUPLA|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|August 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|plasma and serum samples|Female|18 Years|50 Years|No|Non-Probability Sample|community sample|March 2016|March 22, 2016|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767182||149223|
NCT00767468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0717|Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis|A Phase IB Study of Sorafenib for Patient With Locally Advanced or Metastatic Hepatocellular Carcinoma and Child's B Cirrhosis||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|October 2008|November 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|October 4, 2008|No|Yes|Funding unavailable|No||https://clinicaltrials.gov/show/NCT00767468||149201|
NCT00770120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616162|S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery|Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)||Southwest Oncology Group|Yes|Active, not recruiting|December 2008|June 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770120||149002|
NCT00770133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|572|Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.|A Multi-center, Double-masked, Randomized, Placebo-controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis.||Bausch & Lomb Incorporated|No|Completed|February 2010|June 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|133|||Both|6 Years|N/A|No|||November 2013|November 22, 2013|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770133||149001|
NCT00767559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEBH 2008-016|Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery|Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities|DVT|The New England Baptist Hospital|Yes|Active, not recruiting|November 2008|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 23, 2011|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00767559||149194|
NCT00767806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12360|A Study for Patient With Chronic Low Back Pain|Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain||Eli Lilly and Company|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||September 2010|September 30, 2010|October 3, 2008|Yes|Yes||No|June 24, 2010|https://clinicaltrials.gov/show/NCT00767806||149175|
NCT00767819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C24114|Treatment of Patients With RAD001 Who Have Progressive Sarcoma|Multicenter, Triple-arm, Single-stage, Phase II Trial to Determine the Preliminary Efficacy and Safety of RAD001 in Patients With Histological Evidence of Progressive or Metastatic Bone or Soft Tissue Sarcomas||Novartis||Active, not recruiting|March 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|N/A|No|||March 2016|March 20, 2016|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767819||149174|
NCT00771082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0109|Osteoarthritis and Body Composition: Evaluation of Systematic Mediators|Osteoarthritis and Body Composition: Evaluation of Systematic Mediators||National Institute on Aging (NIA)|No|Terminated|January 2003|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1033|Samples Without DNA|Banked serum and urine samples|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Baltimore Longitudinal Study on Aging|June 2012|June 5, 2012|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00771082||148929|
NCT00771693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2006-007031-27|Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)|Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With NIDDM: a Placebo-controlled Dose-response Study With Insulin Aspart (Novorapid®)||Karolinska Institutet|No|Completed|May 2007|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|18|||Both|N/A|70 Years|No|||November 2010|November 4, 2010|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771693||148883|
NCT00768404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-106|A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment|A Phase I, Open-Label, Parallel-Group, Single Dose, Non-Randomized Study To Compare The Pharmacokinetics Of Each Individual Component (Topiramate And Phentermine) Of The Combination Product VI-0521 In Subjects With Mild, Moderate And Severe Renal Impairment To Subjects With Normal Renal Function||VIVUS, Inc.|No|Completed|October 2008|July 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768404||149130|
NCT00767832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08252008-1287|Thromboelastography to Assess Hemostatic Changes in Patients Undergoing Elective Cesarean Delivery.|Thromboelastography to Assess Hemostatic Changes in Patients Undergoing Elective Cesarean Delivery.||Stanford University||Completed|August 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|None Retained|Venous blood|Female|N/A|N/A|No|Non-Probability Sample|healthy pregnant patients undergoing elective cesarean delivery with spinal anesthesia.|November 2009|November 6, 2009|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767832||149173|
NCT00768157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-HCC004|Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma|Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Recruiting|April 2007|August 2010|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||February 2009|February 6, 2009|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00768157||149149|
NCT00768417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511003189|Availability of Lipids in Almonds in Healthy Individuals|Mastication of Almonds: Effects of Lipid Bioaccessibility, Appetite, and Hormone Response||Purdue University|Yes|Completed|April 2006|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|20|Samples With DNA|Plasma, feces|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|University and community sample|November 2013|November 15, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768417||149129|
NCT00755664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30572071|Effects of Low-dose Complex B-vitamins on Homocysteine and Framingham Risk Score Among Chinese Elderly|Effects of Low-dose B-vitamins Supplementation on Plasma Homocysteine and Framingham Risk Score: Double Blind Randomized Controlled Trial in Healthy Chinese Elderly||Peking University|Yes|Completed|July 2007|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|390|||Both|60 Years|74 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|September 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00755664||150098|
NCT00755898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2003:089|Urinary Excretion of Acetylamantadine by Cancer Patients|Urinary Excretion of Acetylamantadine by Cancer Patients||University of Manitoba|No|Completed|December 2003|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|September 18, 2008|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00755898||150080|
NCT00755911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-02|Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy|Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy||University of Michigan|Yes|Completed|June 2008|May 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|70 Years|No|||May 2015|May 28, 2015|September 17, 2008|Yes|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT00755911||150079|
NCT00753454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87084|Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)|A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.|Dose Flex II|UCB Pharma|No|Completed|September 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|18 Years|N/A|No|||July 2012|August 26, 2014|June 5, 2008|Yes|Yes||No|May 10, 2012|https://clinicaltrials.gov/show/NCT00753454||150264|
NCT00753792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORTEM|Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse|Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse||Germans Trias i Pujol Hospital|No|Completed|November 2008|January 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|59 Years|No|||June 2011|June 1, 2011|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00753792||150240|
NCT00754143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-3019-029|Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy|A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study of Safety, Pharmacokinetics and Pharmacodynamics of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy on Background ACEi and/or ARB Therapy||FibroGen|Yes|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|80 Years|No|||January 2011|January 10, 2011|September 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00754143||150213|
NCT00754156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0694-F2L|ABRA Abdominal Closure System in Open Abdomen Management|A Prospective, Controlled Evaluation of ABRA Abdominal Wall Closure System in Combination With V.A.C. Therapy Compared to V.A.C. Alone in the Management of Open Abdomen|ABRA|University of Kentucky|No|Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|70 Years|No|||February 2014|February 15, 2014|September 16, 2008|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT00754156||150212|Limited by small sample size, and lack of closely matched patient groups.Limited by product change from the original VAC to the ABThera system mid study.Limited by a significant learning curve in application and use of the ABRA device.
NCT00754416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET FR 02|S.E.S Shoulder Arthroplasty Data Collection|A Prospective, Multicentre Study Evaluating the Clinical Performance of the S.E.S Shoulder Prosthesis||Biomet, Inc.|No|Terminated|March 2003|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive series of patients received S.E.S prostheses|May 2015|June 4, 2015|September 16, 2008||No|Product no more sold|No||https://clinicaltrials.gov/show/NCT00754416||150192|
NCT00753480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMU4506g|A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of D4064A Administered Intravenously to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer After a Platinum-Containing Regimen||Genentech, Inc.||Suspended|September 2008|||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|56|||Both|18 Years|N/A|No|||November 2008|November 6, 2008|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753480||150262|
NCT00753805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H15-04|Dietetic Effects of Mare's Milk in Patients With Atopic Dermatitis|Dietetic Effects of Oral Intervention With Mare's Milk on the SCORAD, Faecal Microbiota and Immunological Parameters in Patients With Atopic Dermatitis||University of Jena|Yes|Completed|August 2004|July 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|54 Years|No|||June 2008|September 15, 2008|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753805||150239|
NCT00770432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18130|Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)|A Randomized, Placebo-Controlled, Double-Blind, Trial of Polyethylene Glycol 3350 Laxative for the Treatment of Occasional Constipation.||Bayer|No|Completed|November 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|203|||Both|17 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|October 9, 2008|Yes|Yes||No|June 24, 2009|https://clinicaltrials.gov/show/NCT00770432||148978|
NCT00770445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS K028|Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.|Impact of Pioglitazone, Metformin and the Combination of Both on Cardiovascular Risk in Insulin-treated Patients With Type 2 Diabetes - The PIOcomb Study|PIOcomb|Takeda|No|Completed|May 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|121|||Both|30 Years|75 Years|No|||August 2010|August 17, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770445||148977|
NCT00771394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-JC-001|Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride||Astellas Pharma Inc|No|Completed|October 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|638|||Male|50 Years|N/A|No|||February 2013|February 13, 2013|October 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771394||148905|
NCT00767299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12185|A Study of Arzoxifene to Treat Korean Women With Osteoporosis|Effects of Arzoxifene on Bone Mineral Density in Korean Postmenopausal Women With Osteoporosis||Eli Lilly and Company|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Female|60 Years|85 Years|No|||April 2015|April 8, 2015|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00767299||149214|
NCT00771368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP 7|Reduction of Bacteria in MRSA Positive Ulcers|A Clinical Trial on the Reduction of Bacteria (Including MRSA) in MRSA Positive Ulcers and Lesions||Nitric BioTherapeutics, Inc|No|Terminated|January 2009|June 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||January 2012|January 18, 2012|October 10, 2008||No|limited recruitment|No||https://clinicaltrials.gov/show/NCT00771368||148907|
NCT00767286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000077690|Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer|A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE||National Cancer Institute (NCI)||Completed||November 2003|Actual|||Phase 3|Interventional|Primary Purpose: Treatment|||||||Male|50 Years|N/A|No|||July 2011|January 27, 2014|October 4, 2008||||No||https://clinicaltrials.gov/show/NCT00767286||149215|
NCT00767845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600455|Symptom Management in African-American Men With Localized Prostate Cancer|PROSTATE CANCER SYMPTOM MANAGEMENT FOR LOW LITERACY MEN||National Cancer Institute (NCI)||Recruiting|May 2008|||December 2009|Anticipated|N/A|Interventional|Primary Purpose: Health Services Research|1||Anticipated|30|||Male|18 Years|N/A|No|||July 2009|July 14, 2009|October 4, 2008||||No||https://clinicaltrials.gov/show/NCT00767845||149172|
NCT00768456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-030|Local Infiltration Analgesia With Ropivacaine Versus Placebo in Vaginal Hysterectomy: a Randomized, Double-Blind Study|Lokal Infiltrations Analgesi Med Ropivakain 0,5 % Versus Placebo VED Vaginal Hysterektomi: ET Prospektivt Randomiseret, Dobbeltblind ET, Placebo-kontrolleret Studie||Hvidovre University Hospital|No|Completed|October 2008|December 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|48|||Female|18 Years|N/A|No|||July 2008|June 22, 2011|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768456||149126|
NCT00769106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-senU 5010|Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer|A Randomized Controlled Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients With Hepatocellular Carcinoma Who Underwent Radical Resection.|HCC-CIK|Sun Yat-sen University|Yes|Completed|June 2008|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769106||149076|
NCT00769119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00010|A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis|A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Bronchiectasis|NEPAL|AstraZeneca|No|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|80 Years|No|||August 2012|August 14, 2012|October 6, 2008|Yes|Yes||No|January 24, 2012|https://clinicaltrials.gov/show/NCT00769119||149075|
NCT00769132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-075|A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia||Merck Sharp & Dohme Corp.||Completed|August 2007|November 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|October 7, 2008|No|Yes||No|October 30, 2008|https://clinicaltrials.gov/show/NCT00769132||149074|
NCT00768430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0114|Optimization of IV Ketamine for Treatment Resistant Depression|Optimization of Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Placebo-Controlled, Triple-masked, Clinical Trial||Baylor College of Medicine|Yes|Completed|November 2008|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|21 Years|80 Years|No|||December 2013|December 27, 2013|October 7, 2008|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00768430||149128|Limitations of our trial include stringent enrollment criteria due to concerns about ketamine’s psychoactive effects and abuse liability. A proportion of screened patients (17.2%) refused or were unable to tolerate psychotropic washout.
NCT00768443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GHR-NEX-2008/1|Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)|Epidemiological Study to Assess the Symptom Patterns and Management Strategies in Patients Consulting With Persistent GERD Symptoms in Primary Care|PHENIX|AstraZeneca|No|Completed|September 2008|February 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|2674|||Both|18 Years|N/A|No|Non-Probability Sample|PPI-treated patients consulting with persistent GERD symptoms in Primary Care. The        patients must have a diagnosis of GERD with predominant typical GERD symptoms and fail to        obtain satisfactory symptomatic response after the first full course of standard dose PPI.        The patients must have been on continuous PPI treatment with unchanged doses according to        local labelling during the last 4-8 weeks prior to the enrolment visit.|December 2010|December 6, 2010|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768443||149127|
NCT00757315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5244|NdYag Laser for Acne Keloidalis Nuchae|Prospective, Controlled Study of the Efficacy of NdYag for Acne Keloidalis Nuchae||Henry Ford Health System|No|Active, not recruiting|September 2008|December 2013|Anticipated|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00757315||149972|
NCT00757328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2008/3|Treatment Clinical Practice in Bipolar Depression in Spain|EPIDEP. Epidemiologic Study in Bipolar Depression: Evaluation of the Usual Clinical Practice of Psychiatrists in Spain|EPIDEP|AstraZeneca|No|Completed|July 2008|December 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|378|||Both|18 Years|N/A|No|Non-Probability Sample|Adult bipolar I or II patients with no more than 10 years of evolution of the bipolar        disorder, with continued assistance in ambulatory settings and whose psychiatrist has        recorded the treatment strategy used for of at least 2 depressive episodes within the        patients' bipolar condition in the clinical history|February 2009|February 16, 2009|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757328||149971|
NCT00753181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK21|Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes|Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes||Abbott Nutrition|No|Completed|August 2008|March 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|75 Years|No|||April 2009|April 24, 2009|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00753181||150284|
NCT00753194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2612|False Positive Results in Newborn Hearing Screening|False-Positive Results in Newborn Hearing Screening: Possible Causes|NHS|Federal University of São Paulo|No|Completed|March 2005|January 2007|Actual|March 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1110|||Both|N/A|48 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Newborns|September 2008|September 15, 2008|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00753194||150283|
NCT00753467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TONG-HBV-0801|A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B|Protocol Title: A Phase II Open-labeled Study to Determine the Safety and Preliminary Efficacy of Interferon-gamma 1b (IFN-γ 1b) in Patients With Chronic Hepatitis B Who Are HBV DNA Positive||Huntington Medical Research Institutes|Yes|Not yet recruiting|September 2008|August 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|75 Years|No|||September 2008|October 20, 2010|September 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00753467||150263|
NCT00754169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080198|Warfighter Head Injury Study|Warfighter Head Injury Study a Comprehensive, Multidisciplinary Research Evaluation||National Institutes of Health Clinical Center (CC)||Terminated|September 2008|January 2013||||N/A|Observational|N/A|||Actual|314|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2013|February 19, 2014|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754169||150211|
NCT00754182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2454/C.E.|Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision|Comparison of Esthetic Results Between Subcuticular Suture and Synthetic Glue in Thyroidectomy Incision: a RCT|SCSvsSG|Azienda Ospedaliera - Universitaria di Modena|No|Completed|September 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|100|||Both|N/A|N/A|No|||March 2009|May 3, 2010|September 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00754182||150210|
NCT00754637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|335|Microplasty Tibial Tray Data Collection|Microplasty Tibial Tray Multi-Center Data Collection|MTT|Biomet, Inc.|No|Withdrawn|December 2009|June 2023|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in need of relief frm painful or disabling Joint Disease, and meeting the 510(k)        inclusion criteria on the cleared device.|January 2012|January 25, 2012|September 17, 2008|No|Yes|The study was withdrawn because it no longer fit the business need.|No||https://clinicaltrials.gov/show/NCT00754637||150175|
NCT00736905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR007465|TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.|Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function||Tibotec Pharmaceuticals, Ireland||Completed|June 2008|November 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|August 14, 2008||||No||https://clinicaltrials.gov/show/NCT00736905||151522|
NCT00736671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00003450|Striatal and Extra-striatal Mechanisms of Falling in Parkinson's Disease|Striatal and Extra-striatal Mechanisms of Falling in Parkinson's Disease||University of Michigan|No|Completed|July 2006|August 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|88|||Both|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Parkinson's disease and normal control persons between the ages of 50-85        years are eligible to participate in this study. Participants should be willing and able        to comply with study requirements. Normal control persons should not have a history of        brain or mental disorders. Both males and females are eligible.|March 2016|March 2, 2016|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736671||151540|
NCT00736892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0915-EPI|Incidence of Acute Lung Injury: The Alien Study|Acute Lung Injury: Epidemiology and Natural History. The ALIEN Study|ALIEN|Villar, Jesus, M.D.|No|Completed|September 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|282|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted into intensive care units of participating hospitals across Spain        meeting the American-European Consensus Conference definition of acute lung injury.|September 2012|September 13, 2012|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736892||151523|
NCT00758381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001781-32|Metastatic Advanced Pancreas Sorafenib|A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial|MAPS|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|No|Recruiting|August 2007|August 2009|Anticipated|August 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|75 Years|No|||October 2008|October 9, 2008|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00758381||149891|
NCT00758680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-004|A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1006.||Merck Sharp & Dohme Corp.|No|Terminated|August 2008|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|112|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|September 23, 2008|No|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT00758680||149868|
NCT00758706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4260C00007|A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Double-blind, Randomised, Placebo-controlled, Parallel Group Multi-centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Bood and Uine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Period.|BICO|AstraZeneca|No|Completed|September 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|40 Years|N/A|No|||April 2015|April 14, 2015|September 23, 2008||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00758706||149866|
NCT00759057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G020291|A Clinical Study of the Dynesys(R) Spinal System|A Clinical Study of the Dynesys(R) Spinal System As a Non-fusion Device for Spinal Stabilization||Zimmer, Inc.|No|Terminated|March 2003|December 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|399|||Both|20 Years|80 Years|No|||June 2012|June 26, 2012|September 23, 2008|Yes|Yes|PMA not approved. FDA granted permission to close the study.|No||https://clinicaltrials.gov/show/NCT00759057||149839|
NCT00759070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPOTAR-07|Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism|Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects|LIPOTAR-07|Hospital Clinic of Barcelona|No|Active, not recruiting|September 2008|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00759070||149838|
NCT00759382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01071|Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.|Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.||European Lung Cancer Working Party|Yes|Recruiting|July 2008|January 2020|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|340|||Both|18 Years|N/A|No|Non-Probability Sample|All patients presenting with non metastatic non small cell lung carcinoma, treated in the        participating centres with curative intent|January 2016|January 26, 2016|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759382||149814|
NCT00759083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-07-02|Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients|Bivalirudin PCI Registry in HIT/HITTS Patients||The Medicines Company|No|Completed|September 2008|||September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Both|18 Years|N/A|No|||November 2011|November 8, 2011|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759083||149837|
NCT00759421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11286B|Exploratory Cognition Study of Sertindole in Patients With Schizophrenia|An Exploratory Cognition Study Conducted as an add-on to Clinical Trial 11286, to Evaluate the Neurocognitive Effects of 12 Weeks Treatment With Sertindole and Olanzapine in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|October 2006|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|65 Years|No|||September 2013|September 13, 2013|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759421||149811|
NCT00760045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-54|Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time|||Alcon Research|No|Completed|August 2008|||October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||January 2010|January 5, 2010|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00760045||149763|
NCT00760058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-06-02|Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL|Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL||Alcon Research|No|Withdrawn|June 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|50 Years|N/A|No|||March 2010|May 8, 2015|September 24, 2008|Yes|Yes|Enrollment not initiated for study.|No||https://clinicaltrials.gov/show/NCT00760058||149762|
NCT00760006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07090352|Preoperative Antibiotics Study|Efficacy of Preoperative Prophylactic Antibiotics in Preventing Complications in the Primary Repair of Cleft Palates||Children's Hospital of Pittsburgh|Yes|Completed|May 2008|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|3 Months|18 Years|No|||August 2015|August 6, 2015|September 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00760006||149766|
NCT00760266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2411|Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population|An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension|ACTION|Novartis|No|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|451|||Both|55 Years|N/A|No|||March 2011|March 31, 2011|September 25, 2008|Yes|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00760266||149746|
NCT00760890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD040315|Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation|Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation|BFe01B1|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|June 2001|October 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|171|||Both|1 Month|24 Months|Accepts Healthy Volunteers|||September 2008|September 25, 2008|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760890||149698|
NCT00761202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGN/OPH/DE/002|Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms|||Allergan|No|Completed|August 2007|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|September 25, 2008||No||No|January 12, 2010|https://clinicaltrials.gov/show/NCT00761202||149674|
NCT00751907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0138|Cerebral and Peripheral Perfusion Pilot Study|Impact of Atorvastatin on Cerebral Perfusion and Endothelial Function|CAPP|University of Wisconsin, Madison|Yes|Completed|June 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 27, 2010|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751907||150382|
NCT00752180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WosulinR/PK-PD/type1/EMEA/2008|Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics|A Single Dose,Single Centre,Double Blind,Crossover Study Comparing the Pharmacokinetic Profiles of Wockhardt's Insulin Human Injection, Soluble (Recombinant DNA Origin) for Injection and Actrapid in Type 1 Diabetics||Wockhardt|No|Completed|August 2008|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|28|||Both|18 Years|45 Years|No|||December 2012|December 26, 2012|September 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00752180||150361|
NCT00752193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/438|Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System.|Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System||University Ghent|No|Recruiting|October 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|206|||Female|18 Years|50 Years|No|||June 2015|June 3, 2015|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752193||150360|
NCT00752206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC012|A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung|A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung||Sarcoma Alliance for Research through Collaboration|Yes|Active, not recruiting|March 2009|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|15 Years|74 Years|No|||July 2014|July 16, 2014|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752206||150359|
NCT00718445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-17445|Pennsylvania Consortium: Clinical Database|Pennsylvania Consortium: Clinical Database||Drexel University|No|Terminated|March 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|25|||Both|18 Years|89 Years|No|Non-Probability Sample|Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine        Patients seen in the Department of Neurology at Drexel University College of Medicine|March 2013|May 1, 2014|July 16, 2008||No|Terminated due to lack of funding and support staff|No||https://clinicaltrials.gov/show/NCT00718445||152921|
NCT00718692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sym001-03|Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)|A Multi-centre, Single Intravenous Dose, Exploratory Dose-finding, Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) in RhD Positive, Non-splenectomized Adult Subjects.||Symphogen A/S|Yes|Completed|July 2008|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718692||152902|
NCT00718991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-005|EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study|A Physician Initiated Prospective Multicenter Study on Excimer Laser Recanalisation in the Treatment of Long Infrapopliteal Lesions in Patients With Critical Limb Ischemia|EXCELLENT-BTK|Flanders Medical Research Program|No|Terminated|July 2008|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|July 18, 2008||No|too slow enrollment|No||https://clinicaltrials.gov/show/NCT00718991||152880|
NCT00719576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACI00206|A Comparison Between the Performance of Chondrocytes Versus Microfracture Technique on Knee Symptoms|A Prospective Randomized Open-label Parallel-group Multi-center Study to Demonstrate the Superiority of Matrix-induced Autologous Chondrocyte Implantation (MACI®) Versus Arthroscopic Microfracture for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea.|SUMMIT|Vericel Corporation|Yes|Completed|July 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|55 Years|No|||August 2015|August 17, 2015|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719576||152835|
NCT00720512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598567|Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab|AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB.|BEBYP|Gruppo Oncologico del Nord-Ovest||Terminated|June 2008|March 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|July 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00720512||152765|
NCT00720525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 248|Pulsatile and Steady State Hemodynamics in Diastolic Heart Failure|Diagnostic Value of Measures of Pulsatile Versus Steady State Hemodynamics in Diastolic Heart Failure||Klinikum Wels-Grieskirchen|No|Completed|April 2008|July 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|362|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing invasive assessment for exertional dyspnea|July 2011|July 15, 2011|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720525||152764|
NCT00716404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0015|Post-Market Observational Study of Intra-Renal Drug Delivery|Post-Market Observational Study of Intra-Renal Drug Delivery|PROVIDE|FlowMedica, Inc.|No|Withdrawn|April 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients in whom one or more components of the Benephit Infusion System are        planned to be used.|February 2010|February 3, 2010|July 15, 2008|No|Yes|FlowMedica was purchased by AngioDynamics. Study will be re-started by AngioDynamics.|No||https://clinicaltrials.gov/show/NCT00716404||153077|
NCT00716417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.37|Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours|A Phase Ib Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Continuous Dosing With BIBW 2992 Combined With Two Different Regimens of Backbone Chemotherapy: Cisplatin Combined With 5 Fluorouracil and Cisplatin Combined With Paclitaxel in Patients With Advanced Solid Tumors.||Boehringer Ingelheim||Completed|July 2008|||July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||August 2013|June 3, 2014|July 15, 2008||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00716417||153076|
NCT00758108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080213|Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions|WAGR Syndrome and Other 11p Contiguous Gene Deletions: Clinical Characterization and Correlation With Genotype||National Institutes of Health Clinical Center (CC)||Completed|September 2008|April 2015||||N/A|Observational|N/A|||Actual|197|||Both|2 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 30, 2015|September 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00758108||149912|
NCT00758394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0907-PLA-14-RR|Clinical Study to Compare Dental Plaque Control|Clinical Study to Compare Dental Plaque Control||Colgate Palmolive|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|53 Years|Accepts Healthy Volunteers|||August 2013|August 8, 2013|September 23, 2008|Yes|Yes||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00758394||149890|
NCT00758719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-045|Evaluate Effectiveness of the Biomet Lumbar Spinal Fusion System|A Prospective Multicenter Lumbar Spine Fusion Study to Evaluate the Effectiveness of the Biomet Lumbar Spinal Fusion System||Biomet, Inc.|No|Completed|September 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|53|||Both|18 Years|75 Years|No|Non-Probability Sample|This study is open to all patients with one or two level Degenerative Disease who are        between the ages of 18 and 75.|September 2012|February 26, 2016|September 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00758719||149865|
NCT00759096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-06-03|Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL|Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL||Alcon Research|No|Completed|May 2007|||July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|N/A|No|||January 2010|January 25, 2010|September 23, 2008|No|Yes||No|September 11, 2009|https://clinicaltrials.gov/show/NCT00759096||149836|
NCT00759109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02733|Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)|Long-term Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation: a Multicenter Study of Hepatocellular Carcinoma Prevention in Patients Non-responders to Combined Therapy With Alpha Interferon + Ribavirin or Peginterferon Alpha + Ribavirin or to Interferon Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|March 2002|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|70 Years|No|||June 2015|June 8, 2015|August 26, 2008|No|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00759109||149835|
NCT00759746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1014|Childhood Obesity Treatment: A Maintenance Approach|Childhood Obesity Treatment: A Maintenance Approach|COMPASS|Washington University School of Medicine|Yes|Completed|October 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|482|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00759746||149786|
NCT00759759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-699-1N|Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study Comparing the Bioavailability of a Morphine Sulfate Sustained Release Capsule 1 x 200mg to KADIAN 2 x 100mg Capsules Under Fasting Conditions||Actavis Inc.||Completed|September 2004|October 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|September 24, 2008|No|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00759759||149785|
NCT00760305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|158707/V10|Pro-self Pain Management in Norway|Pro-self - a Nursing Intervention to Support and Educate Cancer Patients and Their Caregivers so That the Patient Can Stay Home|Pro-self|Oslo University Hospital|No|Completed|October 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|167|||Both|18 Years|N/A|No|||September 2008|May 23, 2011|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760305||149743|
NCT00760032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-149-07-09-1|Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients|Association of Serum Levels of Lipopolysaccharide Binding Protein (LBP) With the Evolution of Pro- and Anti-inflammatory Cytokines, and the Development of Severe Infectious Events in Cirrhotic Patients||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|September 24, 2008||No|was not possible to measure LBP levels because we cannot found the kit|No||https://clinicaltrials.gov/show/NCT00760032||149764|
NCT00760279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRU10820|An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates|An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates Pediatric Pharmacology Research Unit, Children's Hospital of Michigan||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|September 2005|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|16|||Both|N/A|30 Days|No|||September 2008|September 25, 2008|September 25, 2008||||No||https://clinicaltrials.gov/show/NCT00760279||149745|
NCT00761215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-104|Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections|A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections||Trius Therapeutics LLC|No|Completed|September 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|18 Years|75 Years|No|||August 2014|August 8, 2014|September 25, 2008|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00761215||149673|
NCT00752219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXL104/2002|Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections|A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults||Novexel Inc|No|Completed|March 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||December 2009|December 1, 2009|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752219||150358|
NCT00752232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134K1-2202|Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease|A Phaseiia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.||Pfizer|Yes|Completed|December 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|September 11, 2008||No||No|May 9, 2014|https://clinicaltrials.gov/show/NCT00752232||150357|
NCT00752245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/373|Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis|Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Sepsis/Multi-organ Failure||University Hospital, Ghent|No|Recruiting|September 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752245||150356|
NCT00752531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|596|Effectiveness of Home Automated Telemanagement in Chronic Obstructive Pulmonary Disorder|Evaluation of Home Automated Telemanagement in COPD||Johns Hopkins University|No|Completed|December 2003|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|280|||Both|21 Years|N/A|No|||March 2013|March 21, 2013|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752531||150334|
NCT00718458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-17016|EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)|EEG-Based Brain-Computer Interface Project for Individuals With ALS|BCI|Drexel University|No|Recruiting|August 2007|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope.|October 2015|October 28, 2015|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00718458||152920|
NCT00719030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUP-0515-02|A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy|A Randomized, Placebo-controlled, Pre-surgical Study of the Effects of Pomegranate Pills in Men With Prostate Cancer Prior to Radical Prostatectomy||University of California, Los Angeles|No|Completed|February 2009|May 2012|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Male|18 Years|N/A|No|||June 2014|June 10, 2014|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00719030||152877|
NCT00718705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060216|Reduction of Spontaneous Prematurity by Antibiotic Treatment (Josamycin)|Reduction of Spontaneous Prematurity: Impact of Antibiotic Treatment (Josamycin) in Case of Positive PCR for Ureaplasma Spp and/or Mycoplasma Hominis in Amniotic Fluid|PREMYC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2008|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3200|||Female|18 Years|N/A|No|||May 2011|December 27, 2011|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718705||152901|
NCT00719589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-152|Outcomes of Pudendal InterStim|Outcomes of Pudendal InterStim||William Beaumont Hospitals|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at William Beaumont Hospital-Royal Oak who have had implantation of an Interstim        with a pudendal lead.|March 2010|March 23, 2010|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719589||152834|
NCT00720161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3830|Metformin in Children With Motor Deficit|Metformin in Children With Motor Deficit||Universitaire Ziekenhuizen Leuven|Yes|Completed|November 2006|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|8 Years|35 Years|No|||September 2011|September 28, 2011|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720161||152791|
NCT00716170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1301831410|GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia|The Role of GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia||Herlev Hospital|Yes|Completed|July 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|Samples With DNA|Blood plasma and leucocytes|Both|35 Years|N/A|No|Non-Probability Sample|The patients will be recruted from the outpatient clinic of Department of Endocrinology,        Herlev Hospital.|April 2009|November 27, 2013|July 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00716170||153095|
NCT00716430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQUIP-ACS 1|European Quality Improvement Programme for Acute Coronary Syndromes|Improving the Management of Non-ST Elevation Acute Coronary Syndrome: Systematic Evaluation of a Quality Improvement Programme|EQUIP-ACS|Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|August 2007|February 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3500|||Both|N/A|80 Years|No|||July 2008|July 15, 2008|July 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00716430||153075|
NCT00748657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00611|Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary|A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC 704865, IND 7921) for Recurrent Sex Cord-Stromal Tumors of the Ovary||National Cancer Institute (NCI)||Active, not recruiting|September 2008|||January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|N/A|No|||May 2014|May 27, 2015|September 5, 2008|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00748657||150628|
NCT00758121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-091008-H|Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients|CORRELATE-HF: Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients|CORRELATE-HF|Boston Scientific Corporation|No|Terminated|November 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients with an implanted CRT-D.|November 2009|November 4, 2009|September 19, 2008||No|Inappropriate therapy associated with certain right ventricular (RV) lead complications may    occur more frequently if the Respiratory Sensor is programmed On|No||https://clinicaltrials.gov/show/NCT00758121||149911|
NCT00758407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6520-9959-02|Methylphenidate Treatment of Cancer-Related Fatigue|Placebo Controlled Double Blind Study With Methylphenidate in Treatment of Adults With Cancer-Related Fatigue|EMF|Medice Arzneimittel Pütter GmbH & Co KG|No|Completed|August 2006|||January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|60 Years|No|||January 2010|January 12, 2010|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00758407||149889|
NCT00758745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-06-03|Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).|||Alcon Research|No|Completed|January 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|50 Years|N/A|No|||August 2011|August 15, 2014|September 23, 2008|Yes|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00758745||149863|
NCT00758732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/05.09|Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma|A Multicenter Randomized Phase II Study of Docetaxel/Carboplatin Versus Docetaxel/Pegylated Liposomal Doxorubicin as Second Line Treatment in Patients With Platinum Sensitive Disease||Hellenic Oncology Research Group||Terminated|October 2005|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|N/A|No|||September 2015|September 25, 2015|September 24, 2008||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00758732||149864|
NCT00759122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarkers in MDD|Electroencephalography (EEG) Biomarkers of Response in Depression|EEG Biomarkers of Response in Depression||University of California, Los Angeles|No|Completed|November 2002|December 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||September 2008|September 23, 2008|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759122||149834|
NCT00760071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|387/2005|Magnetic Resonance Imaging (MRI) for Early Diagnosis of Cystic Fibrosis (CF)|Evaluation of Morphological and Functional Magnetic Resonance Imaging (MRI) for Early Diagnosis of Lung Changes in Children (0-6 Years) With Cystic Fibrosis (CF)||German Cancer Research Center|Yes|Completed|July 2006|September 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|30|||Both|N/A|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Diagnosed CF-patients (male/female), age 0-6 years|April 2010|April 14, 2010|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00760071||149761|
NCT00760916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-303|FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)|FREEDOM DR: An International, Multi-Center, 12-Week, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study Followed by a 12-Week Open-Label Extension Study to Assess the Efficacy, Safety, and Dose Response of UT-15C SR in Subjects With Pulmonary Hypertension||United Therapeutics|No|Withdrawn|December 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|70 Years|No|||January 2013|January 29, 2013|September 25, 2008|Yes|Yes|Study stopped prior to subject enrollment.|No||https://clinicaltrials.gov/show/NCT00760916||149696|
NCT00760292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034|Genetic Variants and Phenotypic Characteristics of Patients With T2DM|Genetic Variants and Phenotypic Characteristics of Patients With T2DM|GenVarT2DM|Odense University Hospital|No|Active, not recruiting|May 2008|April 2011|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|2000|Samples With DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Diabetic Patients from Dept. of Endocrinology, Odense University Hospital          2. Non-diabetic volunteers found from advertising at Odense University Hospital|June 2008|September 25, 2008|September 25, 2008||||No||https://clinicaltrials.gov/show/NCT00760292||149744|
NCT00760656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJLIFE|Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer|Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer|SJLIFE|St. Jude Children's Research Hospital|No|Recruiting|April 2007|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|8000|Samples With DNA|Control Participants - Storage of Biological Specimens      Blood, serum and urine:      A peripheral blood order will be placed in MILLI by a member of the clinical staff and the      control participant will have 23cc of peripheral blood (6cc each in 3 NaHeparin tube, 5cc in      red top) collected for the study. The collected peripheral blood sample will be stored in      the institutional tissue bank. The sample will be tagged accordingly and will be only      released to fulfill future objectives of the SJLIFE protocol.|Both|5 Years|N/A|No|Non-Probability Sample|Childhood cancer survivors treated at SJCRH recruited from selected diagnostic groups of        almost 4000 adults surviving 10 or more years from their diagnosis of childhood cancer.        Adults who are non-first degree relatives or friends of St. Jude patients or former St.        Jude patients will be invited to participate as a control in this study during the time of        the child's St. Jude clinic visit. Controls will be recruited by, and should discuss their        desire to participate with, a member of the St. Jude Life clinical and/or research staff.        The individual will then be registered as a "Research Participant" by a member of the        study team and informed consent will be obtained using the SJLIFE Banking Control consent        document.|October 2015|October 6, 2015|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760656||149716|
NCT00761241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07124|Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT|A Phase II Protocol in Borderline Resectable Pancreatic Cancer Using Gemcitabine/Docetaxel Chemotherapy and An Oxaliplatin-Based Chemoradiation.||Benaroya Research Institute|No|Completed|September 2008|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761241||149671|
NCT00717782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPA001|Pain Relief for Thrombosed External Haemorrhoids|Randomized Clinical Trial of Botulinum Toxin Injection for Pain Relief in Patients With Thrombosed External Haemorrhoids||University of Palermo|No|Completed|January 2003|January 2006|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||July 2008|July 17, 2008|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717782||152971|
NCT00717795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-067|Physical Activity Intervention for Lung Cancer Survivors|Physical Activity Intervention for Lung Cancer Survivors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|52|||Both|21 Years|N/A|No|Probability Sample|In total, we will recruit and enroll a random sample of 70 lung cancer survivors who are        at least one year post thoracic surgical resection and have no evidence of NSCLC or any        other cancer at the time of study enrollment and not receiving any adjuvant treatment.|July 2015|July 21, 2015|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717795||152970|
NCT00718094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390.05|Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis|A Phase IIa Pilot Study to Determine the Safety of an Oral Dose of Green Tea Extract (Polyphenon E®) and Provide Preliminary Evidence to Support Its Efficacy in Ulcerative Colitis||University of Louisville|Yes|Completed|March 2008|April 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|85 Years|No|||June 2012|June 29, 2012|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718094||152948|
NCT00718107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-15894|Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology|Satisfaction Survey for ALS Patients Comparing Rooms With and Without Assistive Technology||Drexel University|No|Terminated|June 2005|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|5|||Both|18 Years|90 Years|No|Non-Probability Sample|In-patients from the neurology floor of Hahnemann Hospital|March 2013|March 1, 2013|July 14, 2008||No|The study was discontinued due to low enrollment. A survey has been implemented in place of a    formal study.|No||https://clinicaltrials.gov/show/NCT00718107||152947|
NCT00718120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110584|Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years|Immunogenicity and Safety Study of a Single Injection of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2008 - 2009 Season) in Adults Aged 18 to 60 Years and Over 60 Years.||GlaxoSmithKline||Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 8, 2009|July 17, 2008|Yes|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00718120||152946|
NCT00719043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110624|Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years|A Trial to Evaluate the Safety & Immunogenicity of Monovalent H5N1 Vaccine in Adults >=18 Yrs of Age||GlaxoSmithKline||Completed|July 2008|February 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|841|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 22, 2014|July 18, 2008|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00719043||152876|
NCT00719056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEICO01|Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty|Efficacy of Teicoplanin for the Prevention of Surgical Site Infections After Total Hip or Knee Arthroplasty: A Prospective, Open-Label Randomized Study||University of Athens|No|Completed|August 2004|December 2007|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|616|||Both|18 Years|N/A|No|||July 2008|July 18, 2008|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00719056||152875|
NCT00719342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-030606|Effect of Breathing a Mixture of 92% Oxygen (O2) + 8% Carbon Dioxide (CO2) on Flicker Induced Blood Flow Changes in Ocular Perfusion|Effect of Breathing a Mixture of 92% O2 + 8% CO2 on Flicker Induced Blood Flow Changes in Ocular Perfusion||Medical University of Vienna||Completed|July 2008|December 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00719342||152853|
NCT00720538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAL−005414−20|Thalidomide in Pediatric Inflammatory Bowel Diseases.|Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.|TALIBDP|IRCCS Burlo Garofolo|Yes|Completed|August 2008|June 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|2 Years|18 Years|No|||October 2012|October 25, 2012|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00720538||152763|
NCT00748384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP-UU2|Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients|Usability of the Foresee Home in Intermediate Age Related Macular Degeneration Patients|UU2|Notal Vision Ltd|No|Completed|February 2009|May 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|50 Years|N/A|No|Non-Probability Sample|Subjects diagnosed as Intermediate AMD|May 2013|May 14, 2013|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00748384||150649|
NCT00748397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-MMF-0002|Evaluation of Treatment With Fixture Microthread™ in Patients Missing All Teeth in the Upper Jaw, When Using One-Stage Surgery|An Open, Prospective, Multicenter Study to Evaluate Treatment of Edentulous Upper Jaws With Fixed Detachable Bridges Retained by Astra Tech Dental Implants, Fixture Micro-Macro||Dentsply Implants|No|Terminated|January 1999|||December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|75 Years|No|||September 2008|September 5, 2008|September 5, 2008|Yes|Yes|Decision to modify the product under study as a result of feedback regarding subjective    feeling during installation procedure. For more info, see brief summary.|No||https://clinicaltrials.gov/show/NCT00748397||150648|
NCT00748410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUC111342|Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis|An Open Label, 7-day Repeat Dose Study to Evaluate the Pharmacodynamics of SB-656933-AAA in Patients With Ulcerative Colitis.||GlaxoSmithKline|No|Terminated|January 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||February 2012|March 15, 2012|September 5, 2008||No|SB-656933 is no longer being developed for ulcerative colitis.|No||https://clinicaltrials.gov/show/NCT00748410||150647|
NCT00758420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV013|Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence|A Randomized, Single Blind, Placebo Controlled, Multicenter Study to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence.|Pilot|BTG International Inc.|No|Completed|October 2008|August 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|65 Years|No|||February 2015|February 19, 2015|September 22, 2008|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00758420||149888|
NCT00758758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 003-99|Performance of the Hedrocel(R) Cervical Fusion Device|Performance of the Hedrocel(R) Cervical Fusion Device||Zimmer, Inc.|No|Completed|December 2001|June 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Actual|231|||Both|18 Years|70 Years|No|||August 2013|August 9, 2013|September 23, 2008|No|Yes||No|May 9, 2013|https://clinicaltrials.gov/show/NCT00758758||149862|
NCT00759135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX02-0016|Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)|Phase 2 Multicenter Randomized Two Dose Level and Non-Inferiority Clinical Evaluation of Transrectal Administration of NX-1207 for the Treatment of BPH||Nymox Corporation|No|Completed|May 2007|May 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|85|||Male|45 Years|75 Years|No|||June 2012|June 12, 2012|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759135||149833|
NCT00759148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-40|Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis|||Alcon Research|No|Completed|October 2008|||March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1179|||Both|1 Month|N/A|No|||February 2011|February 23, 2011|September 23, 2008|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00759148||149832|
NCT00759161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-PSR-201|Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis|A Double-Blind, Randomized Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis||Anacor Pharmaceuticals, Inc.|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||February 2011|February 9, 2011|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759161||149831|
NCT00759434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELP1|A New Method of Surgically Treating Varicose Veins and Venous Ulcers - a Study to Assess Clinical and Economic Value|A Dual Centre, Randomised Controlled Trial of the Clinical and Cost Effectiveness of Endovenous Laser Therapy (EVLT) in the Treatment of Varicose Veins and Venous Ulcers||University of Hull|No|Active, not recruiting|March 2004|||August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00759434||149810|
NCT00759447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2007|||||N/A|N/A|N/A||||||||||||||September 24, 2008|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759447||149809|
NCT00760682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 21|Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study|Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study||Rigshospitalet, Denmark|Yes|Recruiting|June 2008|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760682||149714|
NCT00760357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-007|A Retrospective Analysis of Patients With Full Thickness Wounds in Limbs With Critical Ischemia|A Retrospective Analysis of Patients With Full Thickness Wounds in Limbs With Critical Ischemia||Southwest Regional Wound Care Center|Yes|Completed|April 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|190|Samples With DNA|Once the patients are identified that have a full thickness wound on a limb clearly      identified as having critical limb ischemia, these patients will be evaluated. The data that      will be extracted from each chart will include patient's age, patient's gender, number of      office visits, presence of diabetes, presence of osteomyelitis, type and amount of      antibiotic administered, number of hyperbaric oxygen treatments, and if the wound healed.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Once the patients are identified that have a full thickness wound on a limb clearly        identified as having critical limb ischemia, these patients will be evaluated. The data        that will be extracted from each chart will include patient's age, patient's gender,        number of office visits, presence of diabetes, presence of osteomyelitis, type and amount        of antibiotic administered, number of hyperbaric oxygen treatments, and if the wound        healed.|November 2015|November 24, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00760357||149739|
NCT00760669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100768|An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants|Post Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Patients||Janssen Korea, Ltd., Korea|No|Completed|May 2007|April 2011|Actual|April 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1061|||Both|N/A|N/A|No|Non-Probability Sample|Participant with ankylosing spondylitis, rheumatoid arthritis, psoriasis and psoriatic        arthritis will be observed at rheumatology departments in university or general hospitals        where they are commonly treated.|September 2013|September 25, 2013|September 24, 2008|No|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00760669||149715|
NCT00760903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0053|Magnetic Resonance (MR) Spectroscopy and Diffusion Tensor Imaging in Determining Brain Injury and Subsequent Clinical Outcome in Patients of Moderate Brain Trauma|||University of Michigan|No|Completed|June 2003|September 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control||5|Actual|90|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Have had a clinically ordered CT exam performed within 24 hours of admission to the        hospital. We will be enrolling 5 different groups of subjects into this study. These        groups include patients18 years of age or older with moderate to severe head trauma.        Children under 18 years of age with moderate to severe head trauma. A group of patients of        any age who have already undergone conventional MRI of the brain and a group of volunteers        who are part of another research study.|February 2014|February 11, 2014|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760903||149697|
NCT00761592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLBL001|Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm|||Allergan|No|Completed|July 2006|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|September 25, 2008||No||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00761592||149645|This was a pilot study.
NCT00761605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015253|Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants|An Open-label Prospective, Non-comparative Study to Evaluate the Subjective Experiences Upon Transition to Paliperidone Extended Release(ER) in Subjects With Schizophrenia|PASS|Janssen Korea, Ltd., Korea|No|Completed|April 2008|October 2010|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|387|||Both|18 Years|65 Years|No|||September 2014|September 3, 2014|September 25, 2008|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT00761605||149644|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.
NCT00717808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112007|Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)|A Phase 1, Blinded, Randomised, Crossover Pilot Study to Investigate the Safety, Tolerability and Pharmacokinetics of Tranilast in Patients With Rheumatoid Arthritis on Methotrexate||Imperial College London|No|Withdrawn|September 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||September 2011|May 27, 2015|July 14, 2008||No|Due to unforeseen circumstances this study will not now start.|No||https://clinicaltrials.gov/show/NCT00717808||152969|
NCT00717821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21145|A Study of Once Monthly Intravenous or Subcutaneous Mircera in Patients With Chronic Kidney Disease on Hemodialysis.|A Randomized, Controlled, Open Label, French Multicenter Parallel Group Study to Compare the Hemoglobin Maintenance With Once Monthly Administration of Mircera Versus Epoetin Beta or Darbepoetin Alfa in Patients With Chronic Kidney Disease on Hemodialysis||Hoffmann-La Roche||Completed|October 2008|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00717821||152968|
NCT00718133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 4643/ CMC 0066-07|The Effect of Air Pollution on Lung Health Among Children Living in Haifa Bay Region, Israel|The Effect of Air Pollution on Lung Health Among Children Living in Haifa Bay Region, Israel.||Carmel Medical Center|No|Completed|December 2008|September 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718133||152945|
NCT00719069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3165A1-1108|Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke|A Double-Blind, Placebo-Controlled, Randomized, Single-Dose, 2-Period Crossover Study of the Pharmacodynamics of Orally Administered PSI-697 in Healthy Subjects Who Smoke||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2008|July 21, 2008|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00719069||152874|
NCT00719355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0477|Polestriding Versus Walking for Subjects With Poor Leg Circulation|Polestriding Versus Walking for PAD Rehabilitation||University of Illinois at Chicago|No|Completed|June 2005|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|21 Years|N/A|No|||February 2013|February 7, 2013|July 17, 2008||No||No|May 15, 2012|https://clinicaltrials.gov/show/NCT00719355||152852|Due to the small number of women in the trial, results cannot be generalized to women.
NCT00752648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015415|TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule|A Phase I, Open-label, 3-way Crossover Trial in Healthy Subjects to Compare the Bioavailability of a Single Oral Dose of TMC435350 Formulated as 2 Different Solid Formulations to That of a Single Oral Dose of TMC435350 Formulated as a Powder Blend Capsule.||Tibotec Pharmaceuticals, Ireland||Completed|July 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00752648||150325|
NCT00748696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-API-04|Combined Effects of Resistance Training and Nutritional Supplements in the Treatment of Sarcopenia|Combined Effects of Resistance Training and Nutritional Supplements in the Treatment of Sarcopenia||Centre Hospitalier Universitaire de Nice|No|Terminated|December 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|70 Years|80 Years|Accepts Healthy Volunteers|||June 2009|February 20, 2012|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00748696||150625|
NCT00758433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-04-01|Civamide Patch Safety, Tolerability and PK Study|Randomized, Double-Blind, Placebo-Controlled Evaluation of the Tolerability of Two Civamide (Zucapsaicin) Patch Strengths Compared to Placebo Patch in Healthy Volunteers||Winston Laboratories|No|Completed|September 2008|April 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|39|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|September 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00758433||149887|
NCT00758771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02116|Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents|Using State-of-the-art Rheological Methods to Characterize CF Sputum and the Effects of Mucoactive Agents: A Pilot Study|GIST|University of California, San Francisco|No|Completed|October 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|38|Samples Without DNA|Sputum|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|People who have cystic fibrosis and those who do not have any lung disease|January 2014|January 22, 2014|September 22, 2008||No||No|January 22, 2014|https://clinicaltrials.gov/show/NCT00758771||149861|
NCT00759174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481259|A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION|Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION||Pfizer|No|Completed|November 2008|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|673|||Male|45 Years|N/A|No|Non-Probability Sample|Potential cases of acute NAION will be prospectively identified by approximately 125        ophthalmology centers in the US and Europe. Patients must have presented to an        ophthalmologist within 3 weeks of symptom onset.|August 2013|August 8, 2013|September 22, 2008|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00759174||149830|Potential for bias from inaccuracies in recall of exposure and exposure-based enrollment were evaluated. Although these sources of bias cannot be excluded, they were unlikely to have substantially affected the primary results.
NCT00759460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11286C|Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia|An Exploratory Study Conducted as an add-on to Clinical Trial 11286, to Evaluate the Metabolic Effect of up to 12 Weeks Treatment With Sertindole and Olanzapine in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|March 2007|April 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|65 Years|No|||September 2013|September 19, 2013|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759460||149808|
NCT00759772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|829|The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa|The Role of PTH in Low Bone Mass in Anorexia Nervosa||Massachusetts General Hospital|No|Active, not recruiting|September 2008|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Female|30 Years|70 Years|No|||February 2016|February 27, 2016|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759772||149784|
NCT00760708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-115-1|Circulating Adenosine Levels Before and After Intravenous (IV) Persantine|Circulating Adenosine Levels Before and After Intravenous (IV) Persantine||University of Connecticut Health Center|No|Terminated|September 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|221|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|Subjects undergoing a Persantine nuclear stress test for medically-indicated reasons.        There are no control subjects.|January 2013|January 16, 2013|September 24, 2008||No|Persantine is no longer being used at UCHC for pharmacological stress testing|No||https://clinicaltrials.gov/show/NCT00760708||149712|
NCT00761228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3337|Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury|A Double-blind, Placebo-controlled, Randomized Study of the Safety and Efficacy of NH001 in Improving the Functional Outcome of Patients in a Vegetative State or Minimally Conscious State Following a Severe Traumatic Brain Injury|NH001-2|NeuroHealing Pharmaceuticals Inc.|Yes|Suspended|July 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|50 Years|No|||April 2013|August 6, 2015|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761228||149672|
NCT00761540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3533|To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo|A Dose Escalation Study to Investigate the Pharmacokinetics, Tolerability and Safety of Liraglutide After Multiple s.c. Doses in Healthy Chinese Male Subjects||Novo Nordisk A/S|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|37|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|September 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00761540||149649|
NCT00761553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509003026|Dietary Supplements and Exercise in Aging Adults|||Purdue University||Completed|October 2005|June 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|49|||Both|55 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761553||149648|
NCT00718146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT83|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)||Sanofi|No|Completed|June 2008|September 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 16, 2014|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00718146||152944|
NCT00718159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12266|Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia|Phase 1 Study of LY573636-sodium in Patients With Essential Thrombocythemia and Acute Myeloid Leukemia||Eli Lilly and Company|No|Completed|August 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|July 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00718159||152943|
NCT00718172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080182|Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C|Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C||National Institutes of Health Clinical Center (CC)||Completed|July 2008|August 2014|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|July 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00718172||152942|
NCT00718471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071101|STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)|Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events|ATOLL|Assistance Publique - Hôpitaux de Paris|Yes|Completed|August 2008|August 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|910|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718471||152919|
NCT00718484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM2002|A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma|A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma|PICASSO|Ziopharm|No|Active, not recruiting|August 2008|April 2014|Anticipated|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|July 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718484||152918|
NCT00718718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015214|A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Centocor, Inc.|Yes|Completed|August 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|187|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00718718||152900|
NCT00718731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3225A1-1000|Study GSI-136 in Healthy Young and Healthy Elderly Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI 136 Administered Orally to Healthy Young and Healthy Elderly Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 1, 2010|July 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00718731||152899|
NCT00720174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00285|Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma|A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma||National Cancer Institute (NCI)||Active, not recruiting|June 2008|||January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|16 Years|N/A|No|||March 2016|March 10, 2016|July 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00720174||152790|
NCT00752921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54661.ctil|Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache|Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache||Shaare Zedek Medical Center|No|Not yet recruiting|September 2008|October 2008|Anticipated|October 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2008|September 15, 2008|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00752921||150304|
NCT00752934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59/08|Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?|||Shaare Zedek Medical Center||Recruiting|October 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|1 Year|18 Years|No|||September 2008|April 17, 2011|September 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00752934||150303|
NCT00752947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHBJH-STY-1|Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors|Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors||Beijing Hospital|Yes|Recruiting|September 2008|May 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|September 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752947||150302|
NCT00748436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BET207|Efficacy Study of Betahistine on Body Weight in Obese Female Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects||OBEcure Ltd.|Yes|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|187|||Female|18 Years|50 Years|No|||May 2009|May 6, 2009|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748436||150645|
NCT00748709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.26|Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.|An Open Label Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.||Boehringer Ingelheim||Terminated|October 2008|||November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|September 8, 2008||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00748709||150624|Due to early study termination, only data on the primary efficacy endpoint were summarized, no CIs were produced and efficacy and safety results were presented for the overall population rather than by tumor category.
NCT00759187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0607-PLA-11-RR|Evaluate Clinical Research From Commerical Oral Care Products|Evaluate Clinical Research From Commerical Oral Care Products||Colgate Palmolive|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|February 24, 2010|September 23, 2008|Yes|Yes||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00759187||149829|
NCT00759200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABF656B2202|Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients|An Open-label, Randomized, Multicenter, Active-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of Albinterferon Alfa 2b Administered Every 4 Weeks Plus Ribavirin in Interferon Alfa-naïve Patients With Genotype 2/3 Chronic Hepatitis C||Novartis||Completed|October 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|525|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00759200||149828|
NCT00759473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRs#17972, 19784|D-Cycloserine Facilitation of Cocaine - Cue Extinction|D-Cycloserine Facilitation of Cocaine - Cue Extinction||Medical University of South Carolina|Yes|Completed|September 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|79|||Both|18 Years|65 Years|No|||July 2013|July 10, 2013|September 24, 2008|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00759473||149807|
NCT00759785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-013|A Study of Dalotuzumab (MK0646) in Breast Cancer Patients (0646-013)|A Study to Establish Proof-of-Biology for MK0646 in Breast Cancer||Merck Sharp & Dohme Corp.|No|Completed|October 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|N/A|No|||April 2015|April 24, 2015|September 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00759785||149783|
NCT00760318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB Pharma- Keppra|Keppra for Cervical Dystonia|Prospective Double Blind Evaluation of Levetiracetam (Keppra) for the Treatment of Cervical Dystonia|Keppra|University of South Florida|No|Suspended|November 2005|December 2008|Anticipated|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|September 24, 2008|No|Yes|Sponsor decided to stop enrollment to review data.|No||https://clinicaltrials.gov/show/NCT00760318||149742|
NCT00760331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I06026|Long Term Follow up of a Cohort of Children With TCF2 Mutation:Evolution of Endocrine and Renal Function|A Long Term Follow up of a Cohort of Children With TCF2 Mutation:Evolution of Endocrine and Renal Function|TCF2|University Hospital, Limoges|No|Recruiting|June 2008|July 2028|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|pediatric patients presenting an abnormality of kidney developmentdue to TCF2 mutation or        deletion.|September 2008|September 25, 2008|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760331||149741|
NCT00760344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-SYR-472-006|Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Treatment With SYR-472 in Subjects With Type 2 Diabetes||Takeda|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|386|||Both|18 Years|80 Years|No|||May 2012|May 18, 2012|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760344||149740|
NCT00760110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|A Cohort Study of Morning Home Blood Pressure Measurement in Type 2 Diabetic Patients|Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients: Long-Term Results of a Prospective Longitudinal Study||Nagaoka Red Cross Hospital|No|Completed|November 1997|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|23 Years|87 Years|No|Non-Probability Sample|Subjects comprised 400 Japanese patients with type 2 diabetes enrolled between 1999 and        2005.|September 2008|September 30, 2008|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760110||149758|
NCT00760084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACO-021|Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|An Expanded Access Protocol to Administer Decitabine to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome||Eisai Inc.||Completed|July 2005|February 2008|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|September 24, 2008|No|Yes||No|August 5, 2009|https://clinicaltrials.gov/show/NCT00760084||149760|
NCT00760097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aTDCS in MDD|Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression|Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression|aTDCS|University of California, Los Angeles|Yes|Completed|September 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|75 Years|No|||February 2013|February 4, 2013|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760097||149759|
NCT00760383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01HD057332|Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation|Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation||University of Oregon|Yes|Completed|June 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 25, 2008||No||No|April 17, 2014|https://clinicaltrials.gov/show/NCT00760383||149737|
NCT00760396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT002|Multiple-Dose Study of VGX-1027 in Healthy Subjects|A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety and Pharmacokinetics of VGX-1027 in Healthy Subjects||VGX Pharmaceuticals, LLC|No|Completed|September 2008|April 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 6, 2009|September 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00760396||149736|
NCT00760695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033|Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa|Cannabinoid CB1 Receptor Agonist Treatment in Severe Chronic Anorexia Nervosa||Odense University Hospital|Yes|Completed|October 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760695||149713|
NCT00760929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21160|A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).|A Randomized, Placebo Controlled Study to Determine the Effect of Two Dose Schedules of R1507 or Placebo, Both in Combination With Erlotinib (Tarceva®), on Progression-free Survival in Patients With Advanced Non-small Cell Lung Cancer With Disease Progression After First or Second Line Chemotherapy||Hoffmann-La Roche||Completed|November 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|167|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760929||149695|
NCT00760942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14132|Liquid Preterm Formula Versus Powdered Human Milk Fortifier in VLBW Infants|Randomized Study of a Liquid High-Calorie Preterm Formula Versus Powdered Human Milk Fortifier in Very-Low Birthweight Infants||University of Oklahoma|Yes|Completed|October 2008|September 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|84|||Both|N/A|10 Weeks|No|||December 2013|December 9, 2013|September 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00760942||149694|
NCT00718185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-11-5636|Pharmacokinetics and Pharmacdynamics of Sildenafil|The Pharmacokinetics and Pharmacodynamics of Sildenafil in Pediatric and Adult Patients||Children's Hospital of Philadelphia|No|Terminated|May 2008|February 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|Blood specimens|Both|N/A|N/A|No|Non-Probability Sample|Infants, Children, and Adults receiving sildenafil as standard of care for the treatment        of pulmonary hypertension.|February 2010|March 11, 2015|July 16, 2008||No|Similar study completed.|No||https://clinicaltrials.gov/show/NCT00718185||152941|
NCT00718198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHSEndo01|Effects of a Computerized Physician Order Entry (CPOE)-Based Inpatient Insulin Protocol on Glycemic Outcomes|Effects of a Computerized Physician Order Entry (CPOE)-Based Inpatient Insulin Protocol on Glycemic Outcomes||John H. Stroger Hospital|No|Completed|March 2006|June 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|413|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetic patients admitted to Medicine Services|February 2009|February 10, 2009|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00718198||152940|
NCT00718497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internal-17018|Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population|Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population||Drexel University|No|Completed|August 2007|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|89 Years|No|Non-Probability Sample|ALS clinic patients at MDA/ALS Center of Hope.|March 2013|March 1, 2013|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00718497||152917|
NCT00718744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-001194-96|Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units|Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units||Laboratorios Leti, S.L.|No|Completed|June 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|50 Years|No|||August 2010|August 4, 2010|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00718744||152898|
NCT00719927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2040-08|Comadres Weight Loss Pilot Program|Comadres Weight Loss Pilot Program||The Miriam Hospital||Active, not recruiting|June 2008|March 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||June 2008|February 5, 2009|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00719927||152808|
NCT00719940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCP00/04|Tinnitus Treatment by Structured Cognitive Behavioral Therapy|Randomized Controlled Clinical Trial of Efficacy and Safety of Individual Cognitive Behavioral Therapy (CBT) Within the Setting of the Structured Therapy Program sTCP (Structured Tinnitus Care Program) in Patients With Tinnitus Aurium|TCP|University Hospital Tuebingen|No|Completed|October 2000|November 2006|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Both|14 Years|90 Years|No|||June 2008|July 18, 2008|June 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00719940||152807|
NCT00752336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTx-2777|Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation|Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation|Ergo-HTx|Hannover Medical School|Yes|Active, not recruiting|January 2002|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|87|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||September 2008|September 12, 2008|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752336||150349|
NCT00752349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200702029R|To Evaluate Oral Phase Swallowing Function Using Submental Ultrasound|To Evaluate Oral Phase Swallowing Function Using Submental Ultrasound||National Taiwan University Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|20 Years|N/A||||September 2008|September 12, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00752349||150348|
NCT00752362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The PAINT Trial|Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT)|PercutAneous INTervention With Biodegradable- Polymer Based Paclitaxel-eluting, Sirolimus-eluting, or Bare Stents for the Treatment of de Novo Coronary Lesions.||Sahajanand Medical Technologies Pvt. Ltd.|Yes|Completed|March 2006|||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|280|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752362||150347|
NCT00748202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1145_1001|Berinert P Study of Subcutaneous Versus Intravenous Administration|Pharmacokinetics Berinert P Study of Subcutaneous Versus Intravenous Administration in Subjects With Moderate Hereditary Angioedema - The Passion Study|PASSION|Johann Wolfgang Goethe University Hospitals|No|Completed|September 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00748202||150663|
NCT00752687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-573|A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults|||Abbott||Completed|September 2008|||May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|October 19, 2010|September 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00752687||150322|
NCT00748423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060701|Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)|Bicentric Study of the Effect of Inhaled Nitric Oxide Compared to Placebo in Acute Chest Syndrome of Adult Sickle Cell Patients|INOSTA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2008|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||July 2013|August 1, 2013|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748423||150646|
NCT00748449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051074|Colonography Versus Colonoscopy in High Risk Patient|Acceptability and Effectiveness of Colonography Compared to Colonoscopy for the Detection of Advanced Adenomas in Patients at High Risk for Colorectal Cancer|COLO-TDM|Assistance Publique - Hôpitaux de Paris|No|Terminated|June 2008|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|39|||Both|18 Years|80 Years|No|||August 2011|September 9, 2011|July 31, 2008||No|No more inclusions|No||https://clinicaltrials.gov/show/NCT00748449||150644|
NCT00759213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27215|Discharge Planning Assessment of Family Needs|Discharge Planning Assessment of Family Needs and Concerns at the Time of Infant's Discharge in the NICU||Christiana Care Health Services|No|Completed|December 2007|September 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|N/A|12 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants in the NICU|February 2012|February 16, 2012|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759213||149827|
NCT00759486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509046|Pediatric Facial Fracture Study|Pediatric Facial Fracture Growth and Development Study||Children's Hospital of Pittsburgh|Yes|Recruiting|October 2005|||October 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|18 Years|No|Non-Probability Sample|All races ages ranging from birth to 18 years who have sustained a craniofacial fracture.|July 2015|July 28, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759486||149806|
NCT00759798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0431|Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)|Prospective Identification of Significant Prognostic Factors in Patients Treated With Fludarabine, Cyclophosphamide, and Rituximab (FCR) as Initial Therapy for Chronic Lymphocytic Leukemia.||M.D. Anderson Cancer Center|No|Recruiting|August 2008|||August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|16 Years|N/A|No|||February 2016|February 22, 2016|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759798||149782|
NCT00759291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-001861|The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome|The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome||Brigham and Women's Hospital|Yes|Active, not recruiting|April 2006|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 15, 2013|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759291||149821|
NCT00759616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET CA 03|Outcome Analysis of the Oxford Partial Knee Arthroplasty|Outcome Analysis of the Oxford Partial Knee Arthroplasty||Biomet, Inc.|No|Completed|April 2003|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|N/A|N/A|No|||February 2012|February 11, 2012|September 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00759616||149796|
NCT00760370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003777-13|Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer|Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone||Vejle Hospital|Yes|Completed|December 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|N/A|N/A|No|||December 2011|December 6, 2011|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760370||149738|
NCT00761267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851008|Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis|A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia||Pfizer|Yes|Recruiting|February 2009|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|1 Month|17 Years|No|||March 2016|March 10, 2016|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761267||149669|
NCT00760955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-583-006|Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy||Takeda|Yes|Completed|September 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|338|||Both|18 Years|75 Years|No|||May 2012|May 18, 2012|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760955||149693|
NCT00760968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-783-EC201|Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms in Subjects With Rheumatoid Arthritis||Takeda|No|Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00760968||149692|
NCT00760981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07112008-1254|A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease|A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease||Stanford University||Active, not recruiting|September 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2010|February 17, 2010|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760981||149691|
NCT00761254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-153|Domperidone for Relief of Gastrointestinal Disorders|Oral Domperidone for Relief of Gastrointestinal Disorders in Patients Who Failed Standard Therapy||Carle Physician Group|No|Terminated|August 2008|September 2012|Actual|September 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|September 25, 2008|Yes|Yes|PI withdrew due to increased responsibilities in clinical department.|No||https://clinicaltrials.gov/show/NCT00761254||149670|
NCT00719082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-IRB-01-7-7-08|Fall Prevention:Dynamic Posturographic Measurements in the Geriatric Population|Fall Prevention:Dynamic Posturographic Measurements in the Geriatric Population||Carrick Institute for Graduate Studies|Yes|Withdrawn|July 2008|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|0|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteer subjects will be accepted from participants who are over the age of 50 years at        the September, 2008 AARP convention in Washington, DC. All subjects must be able to stand        with their eyes closed for 30 seconds without falling to be considered eligible for the        research study.|January 2016|January 26, 2016|July 17, 2008||No|Lack of Funding|No||https://clinicaltrials.gov/show/NCT00719082||152873|
NCT00719368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01267755|Neurophysiological Characterization of Postherniotomy Pain|Quantitative Sensory Testing in Persistent Postherniotomy Pain Patients||Rigshospitalet, Denmark|No|Completed|January 2006|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|persistent posthenriotomy patients|October 2012|April 4, 2014|July 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00719368||152851|
NCT00719602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1068s|Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART|P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Completed|April 2009|August 2013|Actual|August 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|105|||Both|6 Months|35 Months|No|||July 2015|July 13, 2015|July 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00719602||152833|
NCT00751439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0802-024|Verification of Pulse Oximetry in Neonatal Population|Verification of Pulse Oximetry in Neonatal Population||Children's Hospitals and Clinics of Minnesota|No|Completed|June 2008|September 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|30 Days|No|Non-Probability Sample|Neonates 25 weeks gestation to full term|June 2010|June 10, 2010|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751439||150417|
NCT00751452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0040|Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children|Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children||University Hospital, Clermont-Ferrand||Recruiting|April 2008|September 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|30|||Both|N/A|18 Years|No|Probability Sample|screening|January 2011|January 18, 2011|September 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00751452||150416|
NCT00751790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEB-TRI6M-301|Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer|A Multicenter, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics and Safety of Two Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer.||Debiopharm International SA|No|Completed|July 2006|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Male|N/A|N/A|No|||August 2012|July 17, 2014|September 11, 2008|No|Yes||No|December 21, 2009|https://clinicaltrials.gov/show/NCT00751790||150391|
NCT00751998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7012|Spy II Clinical Registry|A Clinical Registry to Assess Performance and Clinical Utility of the SpyGlass Direct Visualization System||Boston Scientific Corporation||Completed|November 2006|October 2009|Actual|April 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|297|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|September 11, 2008|No|Yes||No|March 16, 2011|https://clinicaltrials.gov/show/NCT00751998||150375|
NCT00752011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0623|Phase I Study of TAS-106 in Combo With Carboplatin|Phase I Dose Escalating Study Of Tas-106 In Combination With Carboplatin In Patients With Solid Tumors||M.D. Anderson Cancer Center|No|Completed|June 2008|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|September 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00752011||150374|
NCT00752661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013900|An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain|An Exploratory Study of an Active Ingredient of JNS013-tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain||Janssen Pharmaceutical K.K.||Completed|June 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|119|||Both|20 Years|74 Years|No|||August 2010|May 16, 2011|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00752661||150324|
NCT00752700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/384|Resistance Exercise Training For Radically Treated Respiratory Cancer|Resistance Training in Radically Treated Respiratory Cancer Patients: a Prospective Randomized Multicenter Study|REINFORCE|University Hospital, Ghent|No|Completed|January 2009|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|113|||Both|18 Years|80 Years|No|||December 2014|December 4, 2014|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752700||150321|
NCT00748215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA-2008-0005|Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan|Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients With Metastatic Colorectal Cancer||M.D. Anderson Cancer Center|Yes|Completed|February 2009|||August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748215||150662|
NCT00748488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-50310-98-034|Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease|The ParkFit Study; Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease|ParkFit|Radboud University|Yes|Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|700|||Both|40 Years|75 Years|No|||January 2012|January 27, 2012|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748488||150641|
NCT00759226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONKO-101|Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer|An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer|CONKO-101|CONKO-Studiengruppe|Yes|Completed|July 2002|August 2007|Actual|July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||September 2008|September 25, 2008|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759226||149826|
NCT00759239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD-06-02|Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension|||Alcon Research|No|Completed|September 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||January 2012|July 17, 2012|September 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00759239||149825|
NCT00759499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-004|Obtaining and Storing Wound Debridment Samples For Immediate or Future Wound-Related Scientific Study|Obtaining and Storing Wound Debridment Samples for Immediate or Future Wound-Related Scientific Study||Southwest Regional Wound Care Center|Yes|Enrolling by invitation|January 2007|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|829|Samples With DNA|The intent of this protocol is to salvage wound material that is normally destined for      destruction, so it can be used in wound-related scientific studies|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects will be identified because their wound(s) possesses something of special        interest. A special interest wound can include, but will not be limited to wounds that are        rapidly deteriorating, wounds diagnosed as pyoderma gangrenosum, wounds showing unusually        rapid wound healing, wounds with abnormal microorganisms, non-healing wounds, young        wounds, and others.|May 2015|May 27, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759499||149805|
NCT00759512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSC - 09|Effects of Therapeutic Touch on Osteoarthritis of the Knee|||University of Toledo Health Science Campus|No|Completed|August 2003|||August 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|60|||Both|50 Years|N/A|No|||February 2009|February 2, 2009|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759512||149804|
NCT00759811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP4062|METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial)|METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure: Randomized Double-blind, Placebo-controlled Trial (METIS Trial)|METIS|Instituto de Cardiologia do Rio Grande do Sul|Yes|Completed|December 2007|November 2008|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||March 2013|March 29, 2013|September 24, 2008||No||No|September 4, 2009|https://clinicaltrials.gov/show/NCT00759811||149781|
NCT00759876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-004e-DMD|Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)|A Phase 2a Extension Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy||PTC Therapeutics|No|Terminated|July 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|N/A|N/A|No|||August 2013|August 13, 2013|September 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00759876||149776|
NCT00760461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809004202|Domperidone in Refractory Gastroparesis|Domperidone in Refractory Gastroparesis||Yale University|No|Suspended|October 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|September 24, 2008|Yes|Yes|Subjects currently unable to receive drug from dispensing pharmacy.|No||https://clinicaltrials.gov/show/NCT00760461||149731|
NCT00760474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081211|An fMRI Study Of Brain Response In Patients With Fibromyalgia|A Double-Blind, Placebo-Controlled Cross-Over Study In Fibromyalgia Subjects To Examine Effects Of Pregabalin On Brain Response To Mechanical Pain As Assessed By Functional Magnetic Resonance Imaging, Proton Magnetic Resonance Spectroscopy And Subjective Ratings||Pfizer|No|Completed|January 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|27|||Female|18 Years|70 Years|No|||June 2012|June 22, 2012|September 25, 2008|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00760474||149730|
NCT00760487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCONsurtor001.06|Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens|||Alcon Research|No|Completed|October 2006|||June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|21 Years|N/A|No|||January 2012|January 12, 2012|September 25, 2008|Yes|Yes||No|September 22, 2009|https://clinicaltrials.gov/show/NCT00760487||149729|
NCT00761917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS010|Diagnostic Evaluation of the Tear Film|Analysis of the Tear Film Lipid Layer||TearScience, Inc.|No|Completed|June 2008|November 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|229|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects undergoing routine eye examination in ophthalmic practices|March 2015|March 30, 2015|September 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00761917||149620|
NCT00761930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2007-GIN-04-RR|Compare the Clinical Efficacy of Prototype Toothpastes.|Compare the Clinical Efficacy of Prototype Toothpastes.||Colgate Palmolive|No|Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 8, 2013|September 26, 2008|Yes|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00761930||149619|
NCT00761943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061180|Correlating Clinical Disease State With Color Doppler Ultrasound|"Adhesive Capsulitis-Correlating Clinical Disease State With Color Doppler Ultrasound"||Vanderbilt University|Yes|Completed|December 2006|December 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients between the ages of 18 and 80 with Adhesive Capsulitis of the shoulder without        previous shoulder surgery. Not including patients with secondary adhesive capsulitis        related to trauma, surgery or other known cause.|July 2015|July 21, 2015|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00761943||149618|
NCT00761618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0808|Intrapleural Catheter Daily Versus Three Times a Week Drainage|Effectiveness of Daily Versus Three Times a Week Drainage After Placement of Intrapleural Catheters for the Palliative Management of Pleural Effusions Associated With Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2009|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761618||149643|
NCT00757614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598879|Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands||National Cancer Institute (NCI)||Recruiting|February 2008|||||N/A|Observational|N/A|||Anticipated|14000|||Both|18 Years|69 Years|No|||April 2010|August 23, 2013|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00757614||149949|
NCT00750802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0850C00014|A Sedation/Cognition/EEG Study Using AZD6280 and Comparator|A Phase 1, Single Centre, Single Dose, Double-Blind, Double-Dummy, Four-Way Crossover, Placebo-Controlled, Randomized Study to Investigate the Effects of AZD6280 on Sedation, Cognition and EEG in Comparison With Lorazepam in Healthy Male Volunteers||AstraZeneca|No|Completed|September 2008|December 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|17|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 25, 2009|September 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00750802||150466|
NCT00750815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15399|Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)|An Open Label Phase I/II Study of the Safety and Efficacy of Cyclophosphamide, Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL), and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2008|May 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||September 2013|December 3, 2013|September 10, 2008|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT00750815||150465|Trial closed early after 58 patients were enrolled due to slow accrual and shortage of pegylated liposomal doxorubicin. Only 54 participants had cytogenetics and fluorescence in situ hybridisation (FISH) results available for risk stratification.
NCT00751101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613046|Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer|Pilot Study of Nicotine Patches to Reduce Hand-Foot Syndrome Associated With Capecitabine Chemotherapy in Patients With Metastatic Breast Cancer||University of California, San Francisco|Yes|Active, not recruiting|August 2007|December 2015|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|24|||Both|18 Years|75 Years|No|||January 2015|January 15, 2015|September 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751101||150443|
NCT00751114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_C_02761|Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients|Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled|EASIE|Sanofi||Completed|November 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|515|||Both|35 Years|70 Years|No|||September 2012|September 3, 2012|September 10, 2008|Yes|Yes||No|July 6, 2012|https://clinicaltrials.gov/show/NCT00751114||150442|
NCT00751127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9200PG004|A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension|A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United States.||Pfizer|No|Completed|January 1993|February 1994|Actual|February 1994|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|268|||Both|40 Years|N/A|No|||September 2008|March 24, 2011|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751127||150441|
NCT00752024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006AA301B50-1|Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study|Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study（SATIH）|SATIH|Huazhong University of Science and Technology|Yes|Not yet recruiting|September 2008|December 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2008|September 12, 2008|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00752024||150373|
NCT00752037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV 08/08|Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients|Safety and Efficacy of Lopinavir/Ritonavir in Combination With Raltegravir in HIV-infected Patients||Saint Michael's Medical Center|No|Completed|September 2008|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2008|July 19, 2011|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752037||150372|
NCT00752375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6545|Antibiotic Prophylaxis in Children With Pyelonephritis|A Randomized Controlled Trial of Antibiotic Prophylaxis in Children With Pyelonephritis in the Abscence of Vesicoureteral Reflux||University of Alberta|No|Withdrawn|February 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|12 Years|No|||January 2015|January 14, 2015|September 11, 2008||No|No participants|No||https://clinicaltrials.gov/show/NCT00752375||150346|
NCT00752401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitaD-1|Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients|VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome|VITA-D|Medical University of Vienna|No|Active, not recruiting|May 2009|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||January 2014|January 20, 2014|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752401||150344|
NCT00748462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SiEC 145/2551 (EC4)|Fractional CO2 Treatment of Acne Scars in Asians|Clinical Quality Assurance Study: Fractional CO2 Treatment of Acne Scars in Asians|CO2|Mahidol University|Yes|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 24, 2014|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00748462||150643|
NCT00748475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TE0602-1|Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus|Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus||University of Konstanz|No|Completed|September 2008|||May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||February 2013|February 19, 2013|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748475||150642|
NCT00748228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040769|Dopamine in Orthostatic Tolerance|Dopamine in Orthostatic Tolerance||Vanderbilt University|No|Terminated|November 2004|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|September 5, 2008||No|This study is being replaced by another protocol.|No||https://clinicaltrials.gov/show/NCT00748228||150661|
NCT00759252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0141|Perceptions Regarding Investigational Screening for Memory Problems in Primary Care|Perceptions Regarding Investigational Screening for Memory Problems in Primary Care: The PRISM-PC Study|PRISM-PC|Indiana University|No|Completed|February 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|954|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary Care Clinic|August 2015|August 27, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759252||149824|
NCT00761319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-047|Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health|An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution||Alcon Research|No|Completed|October 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|705|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|September 25, 2008|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00761319||149666|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)
NCT00757640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Firenze 1|Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery|The CHOLEGAS Study: Multicentric Randomized, Double-Blinded, Controlled Trial of Gastrectomy Plus Prophylactic Cholecystectomy Versus Gastrectomy Only, in Adults Submitted to Gastric Cancer Surgery With Curative Intent.|CHOLEGAS|Italian Research Group for Gastric Cancer|No|Recruiting|September 2008|September 2015|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||September 2008|September 20, 2008|September 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00757640||149947|
NCT00757653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET UK 04|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2003|||||N/A|N/A|N/A||||||||||||||March 5, 2014|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00757653||149946|
NCT00757666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CA-082808-B|APPROPRIATE - Rate Adaptive Pacing Sensor|Assessment of Proper Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation or Accelerometer|APPROPRIATE|Boston Scientific Corporation|No|Terminated|October 2008|August 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|September 19, 2008||No|Difficulty in enrollment; higher than planned patient attrition and data attrition|No||https://clinicaltrials.gov/show/NCT00757666||149945|
NCT00757679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F02207 GE 205|Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran|Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran. An Exploratory Placebo-controlled Clinical Trial in Fibromyalgia Out-patients||Pierre Fabre Medicament||Completed|September 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|153|||Female|18 Years|70 Years|No|||July 2013|July 10, 2013|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757679||149944|
NCT00759824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01081|A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide|A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide||European Lung Cancer Working Party|Yes|Completed|September 2008|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759824||149780|
NCT00759837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1111|Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects|An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Bosutinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 15, 2009|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00759837||149779|
NCT00760123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID1124|Lymphedema Prevention in Breast Cancer|Lymphedema Prevention in Breast Cancer: a Simple Blind, Randomized, Prospective Clinical Trial of the Efficacy of Physical Therapy||University of Alcala|Yes|Completed|May 2005|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|70 Years|No|||August 2014|August 22, 2014|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760123||149757|
NCT00768664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471027|Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer|Clinical Phase 2 Multicenter Trial Of PF-00299804 In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck||Pfizer|No|Completed|November 2008|April 2012|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|October 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00768664||149110|
NCT00768677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-04-063|Topiramate for Binge Eating Disorder Among Adolescents|Open-Label Study of Topiramate for Binge Eating Disorder and Bulimia Nervosa Among Adolescents||The Zucker Hillside Hospital|No|Completed|July 2003|||||N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||||||Both|12 Years|23 Years|No|||September 2008|October 7, 2008|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768677||149109|
NCT00762268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000276|A Trial of SAMe for Treatment-Resistant Bipolar Depression|Intermittent-Dose Oral SAMe (S-adenosyl-L-methionine) in Persistent and Treatment-Refractory Bipolar Depression: A Double-Blind Pilot Trial With an Optional Open-label Follow-up||Mclean Hospital|No|Completed|September 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||August 2014|August 25, 2014|September 26, 2008|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT00762268||149594|
NCT00758251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NLV-SER-2008/1|Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment|Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment||AstraZeneca|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinics|December 2010|December 8, 2010|September 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00758251||149901|
NCT00758264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111393|Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration|Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-administered With GSK Biologicals' Pneumococcal Vaccine GSK1024850A in Healthy 12-23-month-old Children Previously Primed With GSK1024850A||GlaxoSmithKline||Completed|October 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|363|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||June 2010|June 29, 2010|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00758264||149900|
NCT00758537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRY1STU|Tryptophan Metabolism in Kidney Disease|||Charite University, Berlin, Germany||Completed|January 2007|October 2008||||N/A|Observational|Time Perspective: Prospective||4|Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|tertiary care academic center, university hospital|July 2009|July 13, 2009|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758537||149879|
NCT00751465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK198082007|Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability|Clinical Specificity of Dysfunctional Habitual Attention Processes in Fear of Blushing and Their Changeability||Technische Universität Dresden|Yes|Completed|November 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751465||150415|
NCT00751803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1246.4|BI 44370 TA in Acute Migraine Attack|A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity||Boehringer Ingelheim||Completed|August 2008|||May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|5||Actual|416|||Both|18 Years|65 Years|No|||November 2014|November 12, 2014|August 25, 2008||||No||https://clinicaltrials.gov/show/NCT00751803||150390|
NCT00752388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.658|Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease|Application of the WHO-5 Well-being Index (WHO-5) as a Screening Instrument for Depression in Parkinson's Disease||Boehringer Ingelheim||Completed|November 2008|||November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1588|||Both|30 Years|N/A|No|Non-Probability Sample|resident physician|November 2013|November 18, 2013|September 12, 2008||||No||https://clinicaltrials.gov/show/NCT00752388||150345|
NCT00751829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-866/37|Isolated Systolic Hypertension in the Elderly and Very Elderly|Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension||Daiichi Sankyo Inc.|No|Completed|July 2003|February 2005|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|417|||Both|65 Years|N/A|No|||September 2008|September 11, 2008|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751829||150388|
NCT00752674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-2006|Neuromuscular Balance in Low Back Pain|The Effectiveness of Neuromuscular Balance in Low Back Pain||Fortaleza University|Yes|Completed|August 2006|November 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|55 Years|No|||September 2008|September 11, 2008|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752674||150323|
NCT00752414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpex-301|A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients|Phase 1b, Randomized, Single-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Administered for 5 Days to Chronic Bronchitis Patients||Forest Laboratories|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|20|||Both|40 Years|N/A|No|||December 2008|December 22, 2008|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00752414||150343|
NCT00752739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-0395-01|Selenium in Treating Patients With Prostate Cancer|Phase II Chemoprevention Trial of Selenium and Prostate Cancer (Watchful Waiting With Selenium Trial)||University of Arizona||Completed|August 2002|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|220|||Male|N/A|85 Years|No|||August 2012|August 13, 2012|September 12, 2008||||No||https://clinicaltrials.gov/show/NCT00752739||150318|
NCT00748748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERA 437|Effect of Lactobacillus Probiotic on Healthy Adults|Effect of Lactobacillus Probiotic on Healthy Adults||Fargo VA Medical Center|No|Completed|February 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|64 Years|No|||July 2012|July 3, 2012|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748748||150621|
NCT00748761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH081864|Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|Cognitive-Behavioral Therapy & Glutamatergic Neurometabolites in Pediatric OCD||University of California, Los Angeles|No|Active, not recruiting|June 2008|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00748761||150620|
NCT00748774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0117|Brain Tumor Patient-Caregiver Congruence, MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)|Primary Brain Tumor Patient and Caregiver Congruence in Symptom Report Using the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)||M.D. Anderson Cancer Center|No|Completed|May 2008|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with a brain tumor who are going to have neurocognitive testing as part of        routine care and their caregivers.|January 2016|January 5, 2016|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748774||150619|
NCT00748787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAN-EC-PEDIA-01|Trial to Evaluate the Effect of Plantago Ovata Husk in the Remission of Metabolic Syndrome in Children and Adolescents|Multicenter, Double Blind, Randomized, Controlled With Placebo, to Evaluate the Effect of the Treatment With Plantago Ovata Husk in the Incidence of the Remission of Metabolic Syndrome in Children and Adolescents Between 10 to 16 Years Old.||Rottapharm Spain|No|Terminated|October 2008|June 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|10 Years|16 Years|No|||June 2011|June 7, 2011|September 8, 2008||No|It was very difficult to fulfill the inclusion criteria, therefore the expected time of    inclusion was delayed so much time.|No||https://clinicaltrials.gov/show/NCT00748787||150618|
NCT00761020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1490|Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection|Analysis of Anti-Plasmodium Falciparum Merozoite Surface Protein 1 Antigen Specific Antibodies in a Human Malaria Challenge Using Mefloquine Prophylaxis to Confirm Assay Sensitivity and Establish Key Antibody Kinetic Parameters||Walter Reed Army Institute of Research (WRAIR)|Yes|Completed|September 2008|December 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 2, 2010|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00761020||149688|
NCT00761306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11492C|Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults|A Long-term, Open-label Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|June 2007|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|65 Years|No|||December 2013|December 23, 2013|September 26, 2008||No||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00761306||149667|
NCT00762294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-043-2|Anastrozole and Letrozole|Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer: A Pilot Study||University of Connecticut Health Center|No|Completed|May 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Female|40 Years|N/A|No|Non-Probability Sample|Women receiving treatment for breast cancer, who will be starting Arimidex or Femara|December 2011|December 14, 2011|September 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00762294||149592|
NCT00760760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUFA-ATI1|n-3 Polyunsaturated Fatty Acids in Obesity|Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients|PUFA-ATI|Medical University of Vienna|No|Completed|September 2008|March 2016|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|55|||Both|20 Years|65 Years|No|||March 2016|March 14, 2016|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760760||149708|
NCT00760721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01CA109091-01A1|Increasing Hepatitis B Screening Among Korean Church Attendees|Increasing Hepatitis B Screening Among Korean Church Attendees (Component Project) Program Project Title: Liver Cancer Control Interventions for Asian Americans||University of California, Los Angeles|No|Completed|September 2006|August 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|1123|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760721||149711|
NCT00760994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA017130-01|Reducing Alcohol Use & Post-traumatic Stress Disorder (PTSD) With Cognitive Restructuring & Experiential Acceptance|Reducing Alcohol Use & PTSD w/ Cognitive Restructuring & Experiential Acceptance|COPE|Seattle Institute for Biomedical and Clinical Research|Yes|Completed|January 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|133|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760994||149690|
NCT00768950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMFCD-Idei-320/2007|The Characterization of Small Bowel and Colonic Involvement in Patients With Seronegative Spondyloarthritides|The Characterization of Small Bowel and Colonic Involvement in Patients With Seronegative Spondyloarthritides|SPONDILENDO|Carol Davila University of Medicine and Pharmacy|Yes|Completed|January 2008|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Probability Sample|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic        arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset        spondyloarthritis, and undifferentiated spondyloarthritis) reffered to a Universitary        Clinic of Internal Medicine and Rheumatology|August 2013|August 13, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768950||149088|
NCT00757952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000614811|Exhaled Breath Biomarkers in Finding Ovarian Epithelial Cancer in Patients With Newly Diagnosed Ovarian Epithelial Cancer, Polycystic Ovarian Syndrome, or Endometriosis and in Healthy Participants|Early Detection of Epithelial Ovarian Cancer Using Exhaled Breath Markers: GC/FT-ICR Mass Spectrometry and Canine Olfaction.||National Cancer Institute (NCI)||Recruiting|November 2007|||December 2009|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|1||Anticipated|120|||Female|21 Years|N/A|Accepts Healthy Volunteers|||June 2009|July 1, 2009|September 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00757952||149924|
NCT00758901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET FR 03|ROCC Knee Data Collection|A Prospective, Multicentre Study Evaluating the Clinical Performance of the ROCC Knee Prosthesis||Biomet, Inc.|No|Terminated|November 2003|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive series of patients received ROCC Knee prostheses for osteoarthritis,        rheumatoid arthritis and bone necrosis affecting two knee compartments, correction of genu        varus, genu valgus or post-traumatic deformities, sequelae of prior procedures|December 2011|December 2, 2011|September 23, 2008|No|Yes|Site Decision|No||https://clinicaltrials.gov/show/NCT00758901||149851|
NCT00759265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-3-031|Improving Mobility in Diabetic Patients Through Resistance Training|Improving Mobility in Diabetic Patients Through Resistance Training||Maastricht University Medical Center|No|Completed|May 2006|January 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||July 2010|October 6, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759265||149823|
NCT00751816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613863|Head & Neck Cancer Survivorship: Physical and Functional Status|Head & Neck Cancer Survivorship: Physical and Functional Status||Vanderbilt University|No|Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|21 Years|N/A|No|Non-Probability Sample|Head and Neck Cancer Patients|December 2015|December 8, 2015|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751816||150389|
NCT00752050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-03b|Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows|A Phase 3, Multi-Center Trial to Demonstrate the Safety and Efficacy of Repeat Treatment With PurTox® for the Treatment of Glabellar Rhytides ("Frown Lines")|PT-03b|Mentor Worldwide, LLC|No|Completed|November 2007|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|699|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752050||150371|
NCT00751842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/P3/07/5|A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT|A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (USA)||Diamyd Therapeutics AB|Yes|Terminated|September 2008|July 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|331|||Both|10 Years|20 Years|No|||October 2012|October 9, 2012|September 11, 2008|Yes|Yes|Based on other clinical trial results it was unlikely the study would meet the efficacy    endpoints|No||https://clinicaltrials.gov/show/NCT00751842||150387|
NCT00752076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804019R|Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment|Detection of Epithelial Growth Factor Receptor (EGFR) Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment|EGFR|National Taiwan University Hospital|No|Recruiting|April 2008|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2009|November 25, 2009|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00752076||150369|
NCT00752063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-SRG-P001|Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma|A Phase IIa Trial of Sorafenib With Capecitabine and Oxaliplatin in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma|SECOX|The University of Hong Kong|Yes|Recruiting|September 2007|December 2008|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|80 Years|No|||September 2008|September 12, 2008|September 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00752063||150370|
NCT00748241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-MIC-0002|Study to Evaluate Implant Survival Rate of Astra Tech Fixture ST in the Posterior Maxilla With One-stage Surgery and Early Loading|An Open Prospective Study to Evaluate the Survival Rate and Marginal Bone Response of Astra Tech Dental Implants, Fixture ST, in Patients With Tooth Loss in the Posterior Maxilla.||Dentsply Implants|No|Completed|September 2000|||August 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||January 2012|January 12, 2012|September 5, 2008|Yes|Yes||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00748241||150660|
NCT00752440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3865/06|Inspiratory Muscle Training in Patients With Autonomic Neuropathic|Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial||Instituto de Cardiologia do Rio Grande do Sul|Yes|Recruiting|August 2006|July 2009|Anticipated|November 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|24|||Both|35 Years|75 Years|No|||September 2008|September 15, 2008|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752440||150341|
NCT00748501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-509-0801|Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Phase 2 Repeat-Dosing Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis|ALS|Sangamo Biosciences|No|Completed|September 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|85 Years|No|||October 2012|October 30, 2012|September 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748501||150640|
NCT00748254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00003693|Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis|Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis||University of Michigan|No|Recruiting|February 2008|October 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00748254||150659|
NCT00749346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-15|NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer|An Open Label Pilot Study of NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer||NovoCure Ltd.|No|Completed|May 2008|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749346||150575|
NCT00749359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR111656|PAXIL CR Bioequivalence Study|An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga||GlaxoSmithKline|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|166|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749359||150574|
NCT00761969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PID-PAB|Prevention of Ischemic Events in Patients With Peripheral Arterial Disease|Prevention of Ischemic Events in Patients With Peripheral Arterial Disease by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice|PID-PAB|KRKA|Yes|Completed|December 2004|December 2014|Actual|December 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1455|Samples With DNA|blood (16 ml) for analysis of inflammatory markers (from serum) and genotyping, to be      correlated with clinical outcomes.      Anonymity of patients is proveded by coding the samples and the patients clinical records.|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with stable, objectively confirmed PAD, recruited from primary care settings in        Slovenia, Europe.        Control subjects of comparable age- and sex-distribution, without PAD, recruited from        primary care settings in Slovenia, Europe.|November 2015|November 12, 2015|September 28, 2008||No||No|September 29, 2015|https://clinicaltrials.gov/show/NCT00761969||149616|
NCT00757978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-406|Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms|Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study||Hospital de Clinicas de Porto Alegre|No|Completed|January 2006|March 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|60 Years|No|||September 2008|December 17, 2008|September 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00757978||149922|
NCT00758290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2008-PLA-13-RR|Clinical Study to Evaluate Dental Plaque|Clinical Study to Evaluate Dental Plaque||Colgate Palmolive|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|51 Years|Accepts Healthy Volunteers|||November 2008|November 20, 2008|September 23, 2008|Yes|Yes||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00758290||149898|
NCT00758589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00004|One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids|A Double-blind, Randomised, Parallel Group, Multicentre Phase IIb, Placebo-Controlled, 1 Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids|OLIVE|AstraZeneca|No|Completed|September 2008|July 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|368|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|September 23, 2008||No||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00758589||149875|
NCT00758927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-OM-9408|The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients|The Effects of OMACOR on the LDL Sub-fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia||Inje University|Yes|Recruiting|July 2009|July 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|40 Years|70 Years|No|||August 2009|August 3, 2009|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758927||149849|
NCT00768690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-687|A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333|||Abbott||Completed|October 2008|||February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|5||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 11, 2010|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768690||149108|
NCT00768326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11613A|Efficacy of Lu 31-130 in Patients With Schizophrenia|A Double-blind, Randomised, Parallel-group, Placebo-controlled Study of the Safety, Tolerability and Efficacy Following Sequential Dose Regimens of Lu 31-130 to Patients With Schizophrenia||H. Lundbeck A/S|Yes|Completed|March 2007|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|280|||Both|18 Years|65 Years|No|||September 2013|September 19, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768326||149136|
NCT00768963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080012|Ranibizumab for the Inhibition of Neovascularization in Pterygia|Ranibizumab for the Inhibition of Neovascularization in Pterygia||Bascom Palmer Eye Institute|No|Completed|October 2008|January 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768963||149087|
NCT00769249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8Z07|Positive Changes in Quality of Life of Older Cancer Patients and Their Caregivers|Correlates of Post-Traumatic Growth in Cancer Patients and Their Partners||Case Comprehensive Cancer Center|Yes|Withdrawn|February 2008|||December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|March 2015|March 17, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769249||149065|
NCT00770081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23138E1|Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)|A 28-week Extension to a 24-week Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Sitagliptin (25 mg qd) in Patients With Type 2 Diabetes and Severe Renal Insufficiency||Novartis|Yes|Completed|September 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|85 Years|No|||May 2012|January 2, 2013|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770081||149005|
NCT00770094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBLWL-001|Multi Laser Platform Comparison Study for LASIK|A Prospective, Randomized, Multi Center Clinical Comparison Of Fellow Eyes Undergoing Lasik Using The Amo/Visx Customvue™ , The Bausch And Lomb Zyoptix And Planoscan And The Wavelight Allegretto Wave™ Wavefront Guided And Wavefront Optimized Excimer Laser Systems|VBLWL-001|Durrie Vision|No|Active, not recruiting|October 2008|February 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 4, 2009|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770094||149004|
NCT00751192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-6194-J|Effect of an Online Video-Based Intervention to Increase HIV Testing in Men Who Have Sex With Men in Peru|||NGO Via Libre|No|Completed|October 2007|May 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Screening|2||||||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2008|October 8, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751192||150436|
NCT00751218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03735|A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)|A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)||Merck Sharp & Dohme Corp.|No|Completed|May 2004|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|174|||Both|12 Years|70 Years|No|||May 2015|May 4, 2015|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751218||150434|
NCT00751491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARD55|Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)|Randomized Comparison of Adenosin Intracoronary Infusion and Clopidogrel Pretreatment on Myonecrosis Occurence in Elective PCI|RACE|University of Roma La Sapienza|No|Recruiting|September 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||May 2009|May 5, 2009|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751491||150413|
NCT00752427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004423|24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia|R076477-SCH-702: a 24 Week Open-Label Extension to R076477-SCH-302||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2004|November 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|86|||Both|65 Years|N/A|No|||April 2010|June 6, 2011|September 11, 2008||||||https://clinicaltrials.gov/show/NCT00752427||150342|
NCT00752089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z3120510|Experimental Dentifrice Remineralization/ Fluoride Uptake in an In Situ Model|Exploratory Evaluation of an Experimental Fluoride Dentifrice Formulation Using an In Situ Remineralization/Fluoride Uptake Model||GlaxoSmithKline||Completed|September 2007|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment||||25|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||September 2008|September 12, 2008|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00752089||150368|
NCT00752713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENC in AMI|Strain-Encoded Magnetic Resonance Imaging in Acute Myocardial Infarction|Strain-Encoded Magnetic Resonance Imaging for Evaluation of Left Ventricular Function and Acute Myocardial Infarction|137-2005|RWTH Aachen University|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Consecutive Patients with AMI 3+/-1 days after successful reperfusion          -  Ten healthy volunteers serving as control group|September 2008|September 15, 2008|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752713||150320|
NCT00752453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/375|Uremic Toxins in the Intensive Care Units (ICU): Patients With Lactate Acidosis|Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Lactate Acidosis||University Hospital, Ghent|No|Recruiting|September 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752453||150340|
NCT00752466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003283|A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately|A Drug Interaction Study of the Pharmacokinetics of Flunarizine and Topiramate (RWJ-17021-000) During Mono- and Concomitant Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2003|March 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|75|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|May 17, 2011|September 11, 2008||||||https://clinicaltrials.gov/show/NCT00752466||150339|
NCT00748267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08029|Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer|Use of Pre-Operative Hypnosis to Reduce Post-Operative Pain and Anesthesia Related Side-Effects||City of Hope Medical Center|Yes|Completed|August 2008|December 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Female|18 Years|N/A|No|||March 2011|March 3, 2011|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748267||150658|
NCT00748800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA019245|An Affect Management Intervention for Juvenile Offenders|An Affect Management Intervention for Juvenile Offenders||Rhode Island Hospital|No|Completed|September 2004|October 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|95|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||February 2009|February 5, 2009|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748800||150617|
NCT00748813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71P7S|Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Sub||Novartis||Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|133|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00748813||150616|
NCT00748826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03236|Remicade Safety Line (Study P03236)(COMPLETED)|Remicade Safety Line||Merck Sharp & Dohme Corp.|No|Completed|August 2002|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|576|||Both|N/A|N/A|No|Non-Probability Sample|The goal is to document all patients in the clinic that meet the inclusion criteria within        the scope of the project.|September 2015|September 2, 2015|September 5, 2008|No|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00748826||150615|
NCT00749099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI092206|Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)|092206: Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum) From PANCRECARB® (Pancrelipase), Delayed Release Capsules, Buffered and Enteric-Coated Microspheres||Digestive Care, Inc.|Yes|Terminated|April 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|11|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|September 7, 2008|No|Yes|No longer required study by FDA for NDA approval.|No||https://clinicaltrials.gov/show/NCT00749099||150594|
NCT00749112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE08-004|Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias|Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias||Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|August 2008|August 2010|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|16 Years|N/A|No|||August 2010|August 27, 2010|September 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00749112||150593|
NCT00749411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB1111581|Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD||GlaxoSmithKline|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|40 Years|80 Years|No|||October 2012|October 17, 2012|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749411||150570|
NCT00757991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598880|Blood Samples From Healthy Volunteers for Genetic Studies in the East Anglia Region of the United Kingdom|A Population Based Control Collection for Genetic Studies in East Anglia||National Cancer Institute (NCI)||Recruiting|February 2008|||||N/A|Observational|N/A|||Anticipated|4000|||Both|35 Years|69 Years|Accepts Healthy Volunteers|||September 2008|August 23, 2013|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00757991||149921|
NCT00758602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21740|A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.|A Randomized, Open Label Study Comparing the Effect of CellCept Combined With Low Dose Versus Standard Dose Tacrolimus, and Corticosteroids, on Kidney Function in Renal Transplantation Patients||Hoffmann-La Roche||Completed|September 2008|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Both|N/A|75 Years|No|||July 2014|July 8, 2014|September 24, 2008||No||No|July 8, 2014|https://clinicaltrials.gov/show/NCT00758602||149874|
NCT00768014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1707B|fMRI Measurements on Pain Relief Methods in First Stage Labor Pain|fMRI Measurements on the Effect of Transcutaneous Electrical Nerve Stimulation (TENS) on Acupuncture Points Verses Spontaneous Normal Vaginal Delivery to Relief of Labor Pain|TENS|Chang Gung Memorial Hospital|Yes|Recruiting|March 2008|December 2010|Anticipated|July 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|October 2008|October 6, 2008|October 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00768014||149159|
NCT00759525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-001404|The Role of Mineralocorticoid Receptors in Vascular Function|The Role of Mineralocorticoid Receptors in Vascular Function||Brigham and Women's Hospital|No|Completed|February 2002|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 24, 2008|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00759525||149803|
NCT00759538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-2008-4|Effect of Early Pulmonary Rehabilitation After Lung Transplantation|Effect of Early Pulmonary Rehabilitation After Lung Transplantation in Patients With a Prolonged Length of Stay on the Waiting List and Hospitalization After Transplantation||Hannover Medical School|No|Completed|July 2007|December 2008|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|17 Years|67 Years|No|Probability Sample|lung transplant patients performing a three week lasting rehabilitation program|July 2012|July 30, 2012|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759538||149802|
NCT00759551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-536-002|Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients With Mild to Moderate Uncomplicated Essential Hypertension||Takeda|No|Completed|August 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|555|||Both|18 Years|N/A|No|||June 2010|June 17, 2010|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759551||149801|
NCT00759317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ven Nls I|Physiologic Monitoring of Antidepressant Treatment Response|Physiologic Monitoring of Antidepressant Medication Effects in Normal Controls Subjects I|Ven Nls I|University of California, Los Angeles|No|Completed|June 2001|September 2002|Actual|August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 1, 2014|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759317||149819|
NCT00759330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU FT-US06-01|Flurbiprofen Tape for Treatment of Chronic Low Back Pain|A Multi Center Randomized, Double-Blind, Placebo-Controlled Trial of Flurbiprofen Tape for Treatment of Chronic Low Back Pain (LBP)|LBP|Teikoku Pharma USA|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|127|||Both|18 Years|80 Years|No|||June 2012|June 14, 2012|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759330||149818|
NCT00759343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-00151|Stone Centre Urine and Serum Bank|Stone Centre Urine and Serum Bank||University of British Columbia|No|Active, not recruiting|June 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|500|Samples With DNA|Urine and serum of stone-forming individuals and non-stone forming controls will be banked      for analysis of protein biomarkers and predisposing factors. Ureteral stents removed from      patients that would otherwise be discarded will be processed and stored to assess for      bacterial and biofilm adherence.      Serum and Urine specimens will be collected, de-identified, and banked/retained.|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Accepts patients with stone disease and healthy volunteers as controls|March 2016|March 14, 2016|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00759343||149817|
NCT00759356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-700-1N|Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study Comparing the Bioavailability of a Morphine Sulfate Sustained Release Capsule 1 x 200mg to KADIAN 2 x 100mg Capsules Under Fed Conditions||Actavis Inc.||Completed|August 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|September 24, 2008|No|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00759356||149816|
NCT00769262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105137|Weaning Thermoregulatory Support in Preterm Neonates|Effect of Conservative Weaning of Thermoregulatory Support on Weight Gain and Length of Stay in Preterm Neonates||University of Missouri-Columbia|No|Withdrawn|January 2009|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||January 2013|January 24, 2013|October 8, 2008||No|insufficient funds|No||https://clinicaltrials.gov/show/NCT00769262||149064|
NCT00759915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-072-SA|Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions|A Randomized Two-way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Formulation of KADIAN (2 x 10mg) Capsules Compared to a KADIAN 20 mg Capsule in Healthy Adult Subjects Under Fed Conditions||Actavis Inc.||Completed|August 2006|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|September 24, 2008|No|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00759915||149773|
NCT00760201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9360|Qualitative Analysis of Hospital Executives, Physician Administrators, and Hospital Legal Counsels' Perceptions of End-of-Life Care|Analysis of Hospital Executives, Physician Administrators, and Hospital Legal Counsels� Perceptions of End-of-Life Care|HospExe|VA Office of Research and Development|No|Completed|August 2008|December 2010|Actual|August 2010|Actual|N/A|Observational|N/A||1|Anticipated|14||Qualitative Analysis|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|hospital executive, physician administrator or hospital legal counsel in a hospital        setting (academic, governmental, private or community hospital)|April 2011|April 18, 2011|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760201||149751|
NCT00760227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOBIT3|Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation|Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation||St. Jude Children's Research Hospital|No|Completed|January 2003|||December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|189|||Both|6 Years|18 Years|No|||September 2011|September 27, 2011|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760227||149749|
NCT00751504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00040|Quetiapine in the Treatment of Psychotic Depression - a Pilot Study|Quetiapine in the Treatment of Psychotic Depression - a Pilot Study||Ruhr University of Bochum|Yes|Completed|September 2008|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||January 2013|January 23, 2013|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751504||150412|
NCT00751517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCM 01|Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides|Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.||University of Parma|No|Active, not recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|80 Years|No|||September 2008|September 11, 2008|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751517||150411|
NCT00751868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM9-NEO-ADIXERN|FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC|NEO-ADIXERN (NEO-ADjuvant IXabepilone in Breast Cancer). A Feasibility Study of Dose-dense FEC With G-CSF Support Followed by Dose-dense Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in Breast Cancer|GIM9|Consorzio Oncotech|Yes|Completed|September 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|70 Years|No|||December 2014|December 16, 2014|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751868||150385|
NCT00752479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC TX|Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance|Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance||Mario Negri Institute for Pharmacological Research|No|Terminated|May 2008|December 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|4|||Both|18 Years|80 Years|No|||April 2015|April 8, 2015|July 23, 2008||No|Necessity of major revision of the protocol|No||https://clinicaltrials.gov/show/NCT00752479||150338|
NCT00752726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W3600586|Effect of Orlistat in Body Composition|The Effects of Weight Reduction With Orlistat vs. Placebo on Changes in Body Composition||GlaxoSmithKline|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|September 11, 2008|Yes|Yes||No|July 21, 2010|https://clinicaltrials.gov/show/NCT00752726||150319|
NCT00752115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hamamatsu 18-66|Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer|Randomized Phase II Study of Combination Chemotherapy With Sildenafil Plus Carboplatin and Weekly Paclitaxel in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer||Hamamatsu University|Yes|Completed|February 2007|December 2010|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|75 Years|No|||April 2009|September 5, 2011|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752115||150366|
NCT00748514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2008-08-012|A Capsular Incision and Biochemical Recurrence After Radical Perineal Prostatectomy|Impact of a Capsular Incision on Biochemical Recurrence After Radical Perineal Prostatectomy||Samsung Medical Center|Yes|Completed|June 1995|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|266|Samples Without DNA|prostate gland|Male|43 Years|78 Years|No|Non-Probability Sample|the prostate cancer patients treated with radical perineal prostatectomy at single        tertiary institution|October 2008|October 6, 2008|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748514||150639|
NCT00748527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-PH2/051|Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Cancer Research UK Randomised, Multicentre, Phase II Trial of the DNAhypomethylating Agent, 5-Aza-2'-Deoxycytidine (Decitabine) Given Intravenously in Combination With Carboplatin, Versus Carboplatin Alone Given 4 Weekly in Patients With Progressive, Advanced Ovarian Cancer||National Cancer Institute (NCI)||Terminated|July 2007|November 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||September 2008|July 9, 2013|September 5, 2008|||The study was "withdrawn" due to certain adverse events [hypersensitivity].|No||https://clinicaltrials.gov/show/NCT00748527||150638|
NCT00748540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060227|Safety and Efficacy of the Vibrant Soundbridge (VSB) for Mixed and Conductive Hearing Losses|Clinical Trial of the Vibrant Soundbridge as a Treatment for Conductive and Mixed Hearing Losses, Using Direct Round Window Cochlear Stimulation.|VSBRW|Med-El Corporation|No|Completed|December 2007|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748540||150637|
NCT00748553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI53993|A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer|A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer|VA|University of Utah|No|Active, not recruiting|September 2008|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|September 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00748553||150636|
NCT00748865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-08-09|Acute Comfort and Blur of Systane Ultra and Systane|||Alcon Research|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|September 5, 2008||No||No|September 25, 2009|https://clinicaltrials.gov/show/NCT00748865||150612|
NCT00748839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801016|Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical|Heparin-Induced Thrombocytopenia : Development and Validation of a Predictive Clinical Score: a Prospective Multicenter Study Under the Auspices of the French Haemostasis and Thrombosis Study Group (GEHT)in Cooperation With the French Association of Regional PharmacoVigilance Center (AFCRPV)|Score-TIH|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2700|Samples Without DNA|blood sample|Both|18 Years|N/A|No|Probability Sample|community sample|November 2012|November 22, 2012|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748839||150614|
NCT00748852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT302-U-06-004|Safety Study of JTT-302 in Subjects With Low HDL-C Levels|An Eight Week, Open-label Extension Study Evaluating the Safety of JTT-302 Administered Once Daily in Subjects With Low HDL-C Levels Who Have Completed the Treatment Phase of Study AT302-U-06-003||Akros Pharma Inc.|No|Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|65 Years|No|||January 2013|January 31, 2013|September 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00748852||150613|
NCT00719888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.00|Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease|Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen||Fred Hutchinson Cancer Research Center|No|Recruiting|November 2005|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|6 Months|45 Years|No|||October 2015|October 1, 2015|July 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00719888||152811|
NCT00767741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-0417-08-HMO|Evaluation of the Effects of Heating or Massaging or Vibrating at the Vicinity of the Insulin Delivery Site|Evaluation of the Effects of Heating or Massaging or Vibrating at the Vicinity of the Insulin Delivery Site||Insuline Medical Ltd.|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|65 Years|No|||June 2011|April 3, 2013|October 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00767741||149180|
NCT00767754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2006-07-091|Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder|Phase 4 Study of Panic Disorder That Expresses to Change of Cerebral Glucose Metabolism After 12 Week of Paroxetine Treatment||Samsung Medical Center|Yes|Completed|January 2007|December 2008|Actual|June 2007|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767754||149179|
NCT00768027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-012|Outcome Assessment in Patients Treated With Hyperbaric Oxygen Using OxyVu Tissue Oxygenation Monitoring System|Outcome Assessment in Patients Treated With Hyperbaric Oxygen Using OxyVu Tissue Oxygenation Monitoring System|HBOT|HyperMed|No|Suspended|August 2008|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|18 to 85 years of age, males and females, and with and without diabetes and untreatable        peripheral vascular disease.|June 2009|June 2, 2009|October 6, 2008||No|Seeking additional funds|No||https://clinicaltrials.gov/show/NCT00768027||149158|
NCT00767208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRNHRA-06-002|Diabetes and Metabolic Postprandial Responses|Comparison of Postprandial Metabolic Responses Between Type 2 Diabetic and Healthy Overweight Subjects||Centre de Recherche en Nutrition Humaine Rhone-Alpe|No|Completed|January 2005|May 2008|Actual|May 2006|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2|||24|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 19, 2009|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00767208||149221|
NCT00768339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-204|A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas|AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas||Aegera Therapeutics|No|Terminated|September 2008|September 2011|Anticipated|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|October 6, 2008|No|Yes|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00768339||149135|
NCT00768352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2008.017e|Educational Intervention for Optimizing Adolescent Mental Health Screening and Treatment in Pediatric Residency|An Educational Intervention for Optimizing Adolescent Mental Health Screening Skills and Treatment in Pediatric Residency||Brooke Army Medical Center||Recruiting|February 2008|June 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|October 7, 2008|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768352||149134|
NCT00759018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|275|Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD|Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD||Mesoblast, Ltd.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|2 Months|17 Years||||October 2015|October 20, 2015|September 23, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00759018||149842|
NCT00759369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11451|Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Water as Therapy in Autosomal Dominant Polycystic Kidney Disease||University of Kansas Medical Center|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|50 Years|No|||February 2012|February 24, 2012|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759369||149815|
NCT00759629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. I00800|Beyond 12 Hours Reperfusion AlternatiVe Evaluation Trial|An International, Multicenter, Randomized Trial Assessing the Value of Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting > 12 Hours From Onset of Symptoms|Brave-2|Deutsches Herzzentrum Muenchen|Yes|Completed|May 2001|August 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|365|||Both|18 Years|80 Years|No|||September 2008|September 24, 2008|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759629||149795|
NCT00759642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11495|Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy|Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (ER and/or PR +) HER-2 Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy||University of Kansas Medical Center|Yes|Active, not recruiting|March 2009|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||December 2013|February 23, 2015|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759642||149794|
NCT00759902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-073-SA|Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions|A Randomized Two-way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Formulation of KADIAN (2 x 10mg) Capsules Compared to a KADIAN 20 mg Capsule in Healthy Adult Subjects Under Fasted Conditions||Actavis Inc.||Completed|August 2006|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|September 24, 2008|No|Yes||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00759902||149774|
NCT00760188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET AU 01|Prospective Data Collection on Cementless Oxford Partial Knee|Prospective Clinical Evaluation of the Cementless Oxford Partial Knee||Biomet, Inc.|No|Withdrawn|July 2004|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients Who Received Cementless Oxford Partial Knee for Its Indications for Use/Intended        Uses - primary diagnoses in the medial compartment of the knee:          -  Osteoarthritis,          -  Avascular necrosis|November 2011|December 13, 2011|September 25, 2008|No|Yes|No patients recruited into study.|No||https://clinicaltrials.gov/show/NCT00760188||149752|
NCT00760240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-08-64|Ability of Patients With Low Vision to Properly Instill Eye Drops|Objective Evaluation of the Ability of Patients With Decreased Vision or Restricted Visual Fields to Properly Instill Eye Drops||Mid-Atlantic Glaucoma Experts|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients reporting for appointments at outpatients referral practices shared by 2 glaucoma        and 3 retina specialists|April 2010|April 23, 2010|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760240||149748|
NCT00760552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-145|Trial of Low and High Intensity Strategies to Maintain BP Control|Trial of Low And High Intensity Strategies to Maintain Blood Pressure Control||VA Office of Research and Development|Yes|Completed|November 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|249|||Both|18 Years|N/A|No|||November 2014|April 6, 2015|September 24, 2008|No|Yes||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00760552||149724|
NCT00751855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YEH-08-044|Cortisol Augmentation of Prolonged Exposure Therapy|Cortisol Augmentation of Prolonged Exposure Therapy||Bronx VA Medical Center|No|Completed|July 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||October 2010|July 26, 2012|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751855||150386|
NCT00752102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abbott #20128|Vitamin D and Coronary Calcification Study|A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4|VCOR|University of Pennsylvania|No|Recruiting|September 2008|January 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|25 Years|N/A|No|||November 2011|November 14, 2011|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752102||150367|
NCT00752492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNREB08-0019B|Acceleration of Recovery From General Anesthesia - Efficacy of Isocapnic Hyperpnoea in Obese Patients Undergoing Isoflurane Anesthesia|Acceleration of Recovery From General Anesthesia - Efficacy of Isocapnic Hyperpnoea in Obese Patients Undergoing Isoflurane Anesthesia||University Health Network, Toronto|No|Completed|September 2008|April 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|80 Years|No|||April 2011|April 19, 2011|July 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00752492||150337|
NCT00752752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC2008-083|The Acute Cardiovascular Effects of Marathon Running Using Magnetic Resonance Imaging|The Acute Cardiovascular Effects of Marathon Running Using Magnetic Resonance Imaging|MARATHON-MRI|William Beaumont Hospitals|No|Completed|September 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|Serum|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Twenty-five (25) participants with plans of completing the Detroit Free Press Marathon in        Detroit, Michigan on October 19, 2008.|April 2012|April 2, 2012|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752752||150317|
NCT00748293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802030R|Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet|Achievement of Better Examinee Compliance on Colon Cleansing Before Colonoscopy Without Sacrificing Cleansing Effect - A Multi-Center Endoscopist-Blinded Randomized Trial Using Commercialized Low-Residue Diet||National Taiwan University Hospital|Yes|Recruiting|September 2008|January 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|224|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2008|September 5, 2008|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748293||150656|
NCT00748306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111834|Study in Mild Asthmatic Patients|A Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With GSK2190915 on the Allergen-induced Asthmatic Response in Subjects With Mild Asthma||GlaxoSmithKline|No|Completed|December 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|55 Years|No|||March 2012|March 22, 2012|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748306||150655|
NCT00749125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH064821-04|fMRI Studies of Emotional Brain Circuitry in People With Major Depression|fMRI Studies of Emotional Circuitry in Major Depression||National Institute of Mental Health (NIMH)|No|Completed|July 2001|June 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|September 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00749125||150592|
NCT00749138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102453081873|Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy|Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy||Bader, Ted, M.D.|No|Completed|November 2008|October 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||March 2010|March 7, 2010|September 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00749138||150591|
NCT00749398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05047|Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047)|Atlas of the Evolution of Psoriasis Lesions Under Remicade® : A Dynamic Standardized Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab|PHODYPSO|Merck Sharp & Dohme Corp.|No|Completed|September 2007|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|18 Years|N/A|No|Non-Probability Sample|Participation to the observational study will be proposed to Dermatology departments by        the medical department of the sponsor. Subjects with moderate-to-severe psoriasis        initiating infliximab in accordance with the terms of the European label will be asked to        participate.|July 2015|July 15, 2015|September 5, 2008|No|Yes||No|August 31, 2011|https://clinicaltrials.gov/show/NCT00749398||150571|
NCT00719901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00255|Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma||National Cancer Institute (NCI)||Terminated|July 2008|June 2012|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||October 2013|January 9, 2015|July 19, 2008|Yes|Yes|This trial was terminated due to slow accrual and the drug supply of Obatoclax during the    phase I; therefore, the phase II portion will never open.|No|August 8, 2013|https://clinicaltrials.gov/show/NCT00719901||152810|This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open. No results from the phase II portion are available.
NCT00771641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9003|Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck|Phase III Randomized Comparison of Radiotherapy Fractionation in Advanced Squamous Cell Carcinoma of the Head and Neck: Twice-Daily Hyperfractionation vs Split-Course Accelerated Hyperfractionation vs Accelerated Fractionation With Concomitant Boost vs Standard Fractionation||Radiation Therapy Oncology Group|Yes|Completed||November 2013|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1113|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771641||148887|
NCT00771654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08-01A|Phentermine/Gastric Band Weight Loss Study|Does the Addition of Phentermine Increase Weight Loss in the Obese After Gastric Band Operation?||Carolinas Healthcare System|Yes|Withdrawn|February 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|October 10, 2008||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT00771654||148886|
NCT00767221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-03-003|Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study|Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study||Pharmalink AB|No|Completed|October 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2009|April 20, 2009|October 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00767221||149220|
NCT00758329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET UK 09|Retrospective Data Review of ReCap Total Hip Resurfacing|Retrospective Data Review of ReCap Total Hip Resurfacing||Biomet, Inc.|No|Withdrawn|April 2004|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who received ReCap Total Hip Resurfacing|November 2011|December 5, 2011|September 23, 2008|No|Yes|No further contact with the site|No||https://clinicaltrials.gov/show/NCT00758329||149895|
NCT00758342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-06-01|Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)|A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma||Alcon Research|No|Terminated|May 2006|||March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|September 23, 2008|No|Yes|difficulty of enrolling patients|No|September 10, 2009|https://clinicaltrials.gov/show/NCT00758342||149894|
NCT00758992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBSCRV|Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages|Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages||St. Jude Children's Research Hospital|No|Completed|October 2006|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|Samples With DNA|Blood|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Adult Research Participants|March 2016|March 11, 2016|September 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00758992||149844|
NCT00759031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2007-PLA-23-RR|Investigation of Dental Plaque and Gingival Index|Investigation of Dental Plaque and Gingival Index||Colgate Palmolive|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2012|September 23, 2008|Yes|Yes||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00759031||149841|
NCT00759044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTM023A|Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function|Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function||Association for Innovation and Biomedical Research on Light and Image||Completed|March 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with AMD or DME followed regularly by their ophthalmologist at the AIBILI        Clinical Trial Center will be asked to perform additional optical examinations as a        continuation of the routine fluorescein angiographies (FA).|October 2015|October 13, 2015|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759044||149840|
NCT00759967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006 77401H|Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control|Randomized Cross-over Study of Short Daily Hemodialysis Compared to Conventional Hemodialysis to Determine the Mechanisms of Hypertension Control||Ottawa Hospital Research Institute|Yes|Completed|September 2007|June 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759967||149769|
NCT00759980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28156|Transfusing Neonates Based on Platelet Mass|Transfusing Neonates Based on Platelet Mass in the Neonatal Intensive Care Unit: A Randomized Pilot Study||Christiana Care Health Services|No|Completed|October 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|12 Months|No|Non-Probability Sample|Infants who are thrombocytopenic and hospitalized in the NICU|March 2011|March 22, 2011|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759980||149768|
NCT00759655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-3315|Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age|An Open-Label Study To Evaluate The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age In Usual Care Settings||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|June 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|N/A|5 Years|No|||February 2011|February 3, 2011|September 23, 2008|Yes|Yes|See termination reason in detailed description.|No|December 14, 2010|https://clinicaltrials.gov/show/NCT00759655||149793|
NCT00759928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 175|PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors|Pharmacokinetic Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors||SCRI Development Innovations, LLC|No|Completed|October 2008|June 2014|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|September 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00759928||149772|
NCT00760214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-491-020|Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension|A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension||Takeda|No|Completed|January 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|885|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|September 24, 2008||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00760214||149750|
NCT00760838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/445|AZISAST Study: AZIthromycin in Severe ASThma Study|The AZIthromycin in Severe ASThma (AZISAST) Study: a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy, Safety and Cost-effectiveness of Azithromycin as add-on Therapy in Adult Subjects With Severe Persistent Asthma, Who Remain Inadequately Controlled Despite GINA (2006) Step 4 or 5 Therapy|AZISAST|University Hospital, Ghent|No|Completed|March 2009|September 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|75 Years|No|||June 2014|June 25, 2014|September 25, 2008||No||No|October 22, 2013|https://clinicaltrials.gov/show/NCT00760838||149702|
NCT00751257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA015369|N-Acetylcysteine and Smoking Reduction|A Randomized Controlled Trial of Oral N-acetylcysteine for Smoking Reduction: a Pilot Study||Medical University of South Carolina|No|Completed|December 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||September 2008|September 11, 2012|September 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00751257||150431|
NCT00751270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrTK01|Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas|A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas|BrTK01|Advantagene, Inc.|Yes|Completed|November 2005|January 2011|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751270||150430|
NCT00751543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705059R|The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy|The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy||National Taiwan University Hospital|Yes|Recruiting|January 2008|||December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2010|June 28, 2010|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751543||150409|
NCT00751556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13106|Single/Multiple Dose Bioavailability Trial|An Open Label, Randomized, Two-Way Crossover Trial to Determine the Pharmacokinetic Profile of an Extended Release Naproxen Sodium Tablet Relative to Aleve Tablets Following Single and Multiple Dose Administration in Healthy Adult Subjects||Bayer|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00751556||150408|
NCT00751569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808006R|microRNA Profile in Umbilical Cord Blood NK Cells|microRNA Profile in Umbilical Cord Blood NK Cells||National Taiwan University Hospital|No|Recruiting|September 2008|September 2009|Anticipated|||N/A|Observational|N/A||1|Anticipated|5|Samples With DNA|Umbilical cord blood|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|normal pregnant women|September 2008|September 11, 2008|September 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00751569||150407|
NCT00752765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28727|The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee|The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee||Penn State University|Yes|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will be looking at obese patients with co-morbidity of knee osteoarthritis.|May 2012|June 2, 2015|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752765||150316|
NCT00752778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4118|Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri|MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri||University Hospital, Strasbourg, France|No|Terminated|December 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||November 2012|November 9, 2012|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752778||150315|
NCT00748280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/B/4/8253|Vital Pulp Therapy to Treat Irreversible Pulpitis|Pulpotomy Versus Root Canal Therapy to Treat Irreversible Pulpitis in Human Permanent Molars: A Multicenter Randomized Non-inferiority Trial.|VPT|hahid Beheshti University of Medical Sciences|Yes|Active, not recruiting|April 2008|September 2013|Anticipated|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|615|||Both|9 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|September 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00748280||150657|
NCT00748566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281173|One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome|A One-Year, Phase IV, Open-Label, Non-Comparative Trial Of The Effect Of Ziprasidone HCL On Metabolic Syndrome Risk Factors In Patients With Psychotic Disorders||Pfizer|No|Terminated|December 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|65 Years|No|||April 2013|April 29, 2013|September 5, 2008|No|Yes|See Detailed Description|No|April 29, 2013|https://clinicaltrials.gov/show/NCT00748566||150635|The study was prematurely terminated by sponsor due to changes in organizational strategy and resources, not due to safety concerns.
NCT00748579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 1124|Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency|A Phase II Open-Label Study to Investigate the Effects of CK-1827452 Injection on Ventricular Performance, Myocardial Oxygen Consumption, and Myocardial Efficiency in Patients With Heart Failure and Left Ventricular Systolic Dysfunction||Cytokinetics|Yes|Terminated|September 2008|July 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|April 21, 2008|Yes|Yes|Decision to discontinue due to challenges of trial design and constraints on enrolling    eligible and consenting patients.|No|July 30, 2010|https://clinicaltrials.gov/show/NCT00748579||150634|Inadequate enrollment led to early termination of study and insufficient number of patients for analysis.
NCT00719316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL19926.041.07|Aliskiren and Muscle Sympathetic Nerve Activity|Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease|MSNA|UMC Utrecht|Yes|Recruiting|July 2008|January 2010|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|95 Years|No|||July 2008|January 13, 2010|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719316||152855|
NCT00719537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-054|Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia|Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia in Patients With a Prior History of Preeclampsia: A Prospective, Randomized Clinical Trial||William Beaumont Hospitals|Yes|Terminated|July 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3|||Female|18 Years|50 Years|No|||January 2013|January 16, 2013|July 17, 2008|Yes|Yes|inability to find qualifying participants|No||https://clinicaltrials.gov/show/NCT00719537||152838|
NCT00771329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211RA101|BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.||Biogen|Yes|Completed|October 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||May 2011|September 12, 2013|October 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771329||148910|
NCT00771342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP 6|Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)|A Blinded Placebo Controlled Single Cross-over Clinical Trial to Evaluate Fungicidal Activity With Topical Application of 1% Gaseous Nitric Oxide in Subjects With Moderate to Severe Tinea Pedis (Athlete's Foot)||Nitric BioTherapeutics, Inc|No|Completed|December 2008|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|19 Years|N/A|No|||February 2010|February 2, 2010|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771342||148909|
NCT00758043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-950-111|A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response|A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®)||Vertex Pharmaceuticals Incorporated|Yes|Completed|October 2008|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|540|||Both|18 Years|70 Years|No|||June 2011|September 30, 2013|September 19, 2008|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00758043||149917|
NCT00758056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598877|Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Endometrial Cancer in East Anglia, Oxford Trent and West Midlands||National Cancer Institute (NCI)||Recruiting|February 2008|||||N/A|Observational|N/A|||Anticipated|2000|||Female|18 Years|74 Years|No|||September 2008|August 23, 2013|September 22, 2008||||No||https://clinicaltrials.gov/show/NCT00758056||149916|
NCT00758355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.FR04|Data Collection on ReCap/Magnum in Total Hip Replacement and Resurfacing|A Prospective, Multicentre Study Evaluating the Clinical Performance of the ReCap/Magnum in Total Hip Replacement and Resurfacing||Biomet, Inc.|No|Active, not recruiting|March 2008|February 2018|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive series of patients received Total Hip Replacement or Resurfacing with        ReCap/Magnum for Their Respective Indications for Use/Intended Uses|February 2015|June 24, 2015|September 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00758355||149893|
NCT00758641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiometNL_16400076|Platelet Rich Plasma to Treat Plantar Fasciitis|Use of PRP to Treat Plantar Fasciitis, Blinded and Randomized as a Multi Center Study||Biomet, Inc.|No|Active, not recruiting|September 2009|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00758641||149871|
NCT00759005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDD|Effect of Stress on Heroin-Related Memory Retrieval|||National Institute on Drug Dependence, China||Completed|March 2007|September 2008|Actual|June 2008|Actual|N/A|Interventional|N/A|1||||||Male|20 Years|40 Years|No|||September 2008|September 23, 2008|September 23, 2008||||No||https://clinicaltrials.gov/show/NCT00759005||149843|
NCT00759681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-004|ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial|A Prospective, Multi-center, Randomized Study to Evaluate the Safety and Efficacy of ArterX Vascular Sealant.|StEPS|Tenaxis Medical, Inc.|Yes|Completed|September 2008|March 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|September 23, 2008|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT00759681||149791|There were no significant trial limitations.
NCT00759694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC002-99|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 1999|||||N/A|N/A|N/A||||||||||||||October 16, 2014|September 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759694||149790|
NCT00759707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P-000424|Endothelial Function in Lower Extremity Bypass Grafts|Endothelial Function in Lower Extremity Bypass Grafts||Brigham and Women's Hospital|Yes|Completed|April 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|19|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759707||149789|
NCT00759720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-02-TL-559-013|Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of a Combination of TAK-559 and Glyburide Compared to Placebo and Glyburide in the Treatment of Patients With Type 2 Diabetes Mellitus|ORIGAMI|Takeda|No|Terminated|November 2003|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|447|||Both|25 Years|75 Years|No|||February 2012|February 1, 2012|September 24, 2008|Yes|Yes|Potential hepatic safety signal|No||https://clinicaltrials.gov/show/NCT00759720||149788|
NCT00759993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|crmpicc01|Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.|A 6 Week, Blinded, Randomized, Controlled Pilot Study to Evaluate the Safety and Efficacy of Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.||State University of New York - Upstate Medical University|No|Terminated|September 2008|March 2013|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2012|September 6, 2012|September 24, 2008|Yes|Yes|inability to recruit and retain|No||https://clinicaltrials.gov/show/NCT00759993||149767|
NCT00759668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT 06 01|Visual Function and Patient Satisfaction After Bilateral Implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT)|||Alcon Research|No|Completed|May 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|50 Years|75 Years|No|||January 2011|January 5, 2011|September 24, 2008|Yes|Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00759668||149792|Visual acuity data were collected in different units (i.e. c, twentieth, decimal, Jaeger) and were converted to LogMAR after inclusion in the database. This led to inevitable approximations of the data.
NCT00759941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-07-08|A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin|A Comparison of Brinzolamide Ophthalmic Suspension, 1% (Azopt) TID vs. Placebo TID Added to Latanoprost Ophthalmic Solution, 0.005% (Xalatan) in Patients With Elevated IOP on a Prostaglandin||Alcon Research|No|Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|35 Years|N/A|No|||July 2012|December 11, 2013|September 24, 2008|Yes|Yes||No|July 12, 2012|https://clinicaltrials.gov/show/NCT00759941||149771|
NCT00759954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-701-1N|Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study Comparing the Bioavailability of a Morphine Sulfate Sustained Release Capsule 1 x 200mg to KADIAN 2 x 100mg Capsules Administered Orally as a Sprinkle on Applesauce||Actavis Inc.|No|Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|September 24, 2008|No|Yes||No|December 1, 2008|https://clinicaltrials.gov/show/NCT00759954||149770|
NCT00760604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806009855|A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer|A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Patients With Locally Advanced Esophageal Cancer||Weill Medical College of Cornell University|No|Terminated|September 2008|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|85 Years|No|||August 2012|August 10, 2012|September 25, 2008||No|Closed due to slow patient accrual.|No||https://clinicaltrials.gov/show/NCT00760604||149720|
NCT00751881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10531|An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis|A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis|TOWER|Sanofi|Yes|Completed|August 2008|August 2015|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1169|||Both|18 Years|55 Years|No|||August 2015|August 26, 2015|May 7, 2008|Yes|Yes||No|April 16, 2013|https://clinicaltrials.gov/show/NCT00751881||150384|
NCT00752128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP091|RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population|RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population|R-Int|Medtronic Vascular|Yes|Completed|August 2008|December 2012|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2349|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients eligible for drug-eluting stent implantation with the elective        use of the Endeavor Resolute stent in one or more target lesions are candidates to be        enrolled|April 2013|April 18, 2013|September 12, 2008||No||No|October 31, 2011|https://clinicaltrials.gov/show/NCT00752128||150365|The data collection in this registry was limited to the collection of MACE (death, myocardial infarction (Q- and non-Q-wave), emergent cardiac bypass surgery and TLR) and stent thrombosis events.
NCT00752141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTG0801|Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers|Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers||Watson Pharmaceuticals||Completed|September 2008|||October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|153|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||September 2011|September 22, 2011|September 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00752141||150364|
NCT00752518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR009058|A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients|A Phase I/II Study of JNJ-26866138 (Bortezomib) in Japanese Patients With Relapsed or Refractory Multiple Myeloma||Janssen Pharmaceutical K.K.||Completed|May 2004|January 2006|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|20 Years|75 Years|No|||April 2010|May 16, 2011|September 11, 2008||||No||https://clinicaltrials.gov/show/NCT00752518||150335|
NCT00752791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01_201|Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.|A Phase 2 Study of the Safety and Efficacy of Hematide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin||Takeda|No|Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|90 Years|No|||August 2012|August 13, 2012|September 11, 2008|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00752791||150314|
NCT00752804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/374|Uremic Toxins in the ICU: Patients After Cardiac Surgery|Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients After Cardiac Surgery||University Hospital, Ghent|No|Recruiting|September 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00752804||150313|
NCT00719004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00007286|Sonographic Features of Normal Soft Tissues of the Feet|Sonographic Features of Normal Soft Tissues of the Feet||University of Michigan|No|Completed|February 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 8, 2014|July 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00719004||152879|
NCT00719303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0225|Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?||Gynecologic Oncology Group|No|Recruiting|June 2012|December 2020|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1070|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719303||152856|
NCT00719329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THRASHER-02827-0|Impact of Chlorhexidine Cleansing on Bacteria Colonizing the Umbilical Cord of Infants in Bangladesh|Bacterial Colonization of the Neonatal Umbilical Cord and Impact of 4.0% Chlorhexidine Cleansing on the Bacteriological Profile of the Umbilical Cord of Newborns in Sylhet District, Bangladesh||Johns Hopkins Bloomberg School of Public Health|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1931|||Both|N/A|7 Days|Accepts Healthy Volunteers|||March 2012|March 28, 2012|July 17, 2008||No||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00719329||152854|Not all possible swab data were available for each baby due to staff leave/holiday, unplanned work stoppage, child/mother absent/moved/died, swab collected but not processed - these reasons did not differ between the groups
NCT00719550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060317|AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer|A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102||Amgen||Completed|February 2009|June 2013|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|130|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|July 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00719550||152837|
NCT00719563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N07C2|American Ginseng in Treating Patients With Fatigue Caused by Cancer|The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study||Alliance for Clinical Trials in Oncology|Yes|Completed|October 2008|August 2013|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|364|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|July 18, 2008|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT00719563||152836|
NCT00757718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio: 08-21|Sleep Disordered Breathing and Gestational Hypertension|Sleep Disordered Breathing and Gestational Hypertension||University of Saskatchewan|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Female|18 Years|45 Years|No|||September 2009|September 4, 2009|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757718||149941|
NCT00757744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014718-05A1S1|Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China|Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China||Yale University|No|Completed|September 2007|September 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|N/A|No|||May 2011|May 16, 2011|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757744||149939|
NCT00758069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-045|Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)|Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects||Merck Sharp & Dohme Corp.|No|Completed|July 2005|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|20 Years|69 Years|No|||August 2015|August 3, 2015|September 22, 2008|Yes|Yes||No|August 17, 2009|https://clinicaltrials.gov/show/NCT00758069||149915|Reported overdoses, regardless of association with reported adverse events, were considered as serious adverse events in this study. The patients for whom the event of overdose was reported had no concomitant AEs with the overdose.
NCT00758693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-LEUK-07-MCC/CI|Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)|Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia: A Phase II Study||University of Kentucky|No|Withdrawn|October 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||September 2011|January 10, 2012|September 19, 2008|Yes|Yes|Funding was withdrawn due to insufficient accrual|No||https://clinicaltrials.gov/show/NCT00758693||149867|
NCT00758368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS021062-21|Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease|Comparison of Continuous and Pulsatile Apomorphine Administration in Parkinson's Disease Complicated by Levodopa-induced Dyskinesia||Oregon Health and Science University|No|Withdrawn|March 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|N/A|No|||July 2011|July 21, 2011|September 23, 2008|Yes|Yes|Inadequate support to conduct the study|No||https://clinicaltrials.gov/show/NCT00758368||149892|
NCT00758654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI-021|Strain-Encoded Cardiac Magnetic Resonance Imaging for Dobutamine Stress Testing|Strain-Encoded Cardiac Magnetic Resonance Imaging as an Adjunct for Dobutamine Stress Testing.||Heidelberg University|No|Completed|January 2007|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|320|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive patients with suspected or known coronary artery disease and healthy        volunteers serving as a contol group.|March 2012|March 28, 2012|September 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00758654||149870|
NCT00758667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010518|Chemically Assisted Capsulectomy-A New Clinical Approach|Chemically Assisted Capsulectomy-A New Clinical Approach||Vanderbilt University|No|Terminated|January 2005|December 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|65 Years|No|||December 2014|December 8, 2014|September 23, 2008||No|preliminary analysis showed no difference|No|December 23, 2013|https://clinicaltrials.gov/show/NCT00758667||149869|
NCT00759395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0880C00021|Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)|An Investigation of the Antidepressant Efficacy of a Selective, High, Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder||AstraZeneca|Yes|Completed|January 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||October 2012|October 10, 2012|September 24, 2008|Yes|Yes||No|October 10, 2012|https://clinicaltrials.gov/show/NCT00759395||149813|
NCT00759408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-003126|The Role of Endothelin in Pulmonary Hypertension|The Role of Endothelin in Pulmonary Hypertension||Brigham and Women's Hospital|Yes|Active, not recruiting|February 1999|June 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2010|May 3, 2010|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00759408||149812|
NCT00759733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBPHS 5123|Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease|Prospective Cohort Evaluation of Cardiac Function With Echocardiography and Serum B-type Natriuretic Peptide (BNP) in Obstetrical Patients With and Without a History of Cardiac Disease||State University of New York - Upstate Medical University|No|Not yet recruiting|July 2008|December 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women at least 18 years of age with a history of cardiac disease for the study        group and a second group of pregnant women at least 18 years of age with no history of        heart disease as controls|August 2010|August 4, 2010|September 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00759733||149787|
NCT00760019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-001406|Inflammation and Vascular Function in Atherosclerosis|Inflammation and Vascular Function in Atherosclerosis||Brigham and Women's Hospital|Yes|Completed|August 2005|February 2011|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 14, 2013|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760019||149765|
NCT00760253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807070R|Compare the Side Effects and Difference Awake Level of Three TCI Propofol Formula in TVOR Patients|Compare the Side Effects and Differences Awake Level of Propofol by Using Three TCI Formula of Anesthesia in TVOR Patients||National Taiwan University Hospital|No|Completed|September 2008|December 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|118|||Female|25 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|ASA physical status I or II women age between 25 and 45 y/o participating to receive TVOR        procedure.|December 2008|December 14, 2009|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760253||149747|
NCT00760578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSDC-C003|A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator|A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazone™ in Type 2 Diabetic Patients||Metabolic Solutions Development Company|No|Completed|September 2008|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|70 Years|No|||March 2013|March 19, 2013|September 25, 2008|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00760578||149722|
NCT00760591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-41|Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)|Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)||Soon Chun Hyang University|No|Recruiting|September 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|None Retained|Serum, Urine|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|18-65 year old volunteers who want to get colonoscopy|September 2008|September 25, 2008|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00760591||149721|
NCT00760617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111737|Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older|Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects.||GlaxoSmithKline||Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|526|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|October 4, 2012|September 25, 2008|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT00760617||149719|
NCT00760630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIRB08031108|Measurements to Assess Severity of Epicardial Stenoses|Simultaneous Measurements Of Pressure Gradient, Blood Flow and Percentage Area Stenosis Of Coronary Epicardial Lesions To Assess Severity Of Epicardial Stenosis And Myocardial Infarction|MASES|University of Cincinnati|No|Suspended|December 2009|April 2012|Anticipated|October 2011|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|76|||Both|18 Years|75 Years|No|||September 2010|September 3, 2010|September 24, 2008||No|IRB Approval on study expired May 28, 2009|No||https://clinicaltrials.gov/show/NCT00760630||149718|
NCT00760643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET EP 02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2011|||||N/A|N/A|N/A||||||||||||||May 1, 2012|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760643||149717|
NCT00760864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-715-005|Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis||Takeda|No|Completed|August 2004|September 2005|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|432|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|September 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00760864||149700|
NCT00751894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0041|Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)|Haematopoietic Progenitor Cell Mobilization in Children With Malignancies: Evaluation of Pegfilgrastim at 200µg/kg After Chemotherapy|MEG-5|University Hospital, Clermont-Ferrand||Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|30|||Both|N/A|18 Years|No|||January 2011|January 18, 2011|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00751894||150383|
NCT00752154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-12-051|Curcumin in Rheumatoid Arthritis|Curcumin in Rheumatoid Arthritis - ACross-Over Pilot Study||University of California, Los Angeles|No|Recruiting|January 2010|January 2011|Anticipated|December 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2008|July 1, 2010|September 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752154||150363|
NCT00752167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK 110189|Diagnosis of Exercise-Induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes|Diagnosis of EIB and Asthma in NCAA Division I Athletes||University of Arizona|No|Recruiting|February 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|NCAA Varsity Division I athletes attending the University of Arizona|September 2008|September 12, 2008|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752167||150362|
NCT00752505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061061|A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.|A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients.||Pfizer|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|September 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00752505||150336|
NCT00752817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSI 3|Creating a Proficiency-Based Virtual Reality Simulation Training Programme for Laparoscopic Assisted Colectomy|Creating and Implementing a Proficiency-Based Progression Virtual Reality Training Programme for Higher Surgical Trainees for Laparoscopic Assisted Sigmoid Colectomy.|LAC|Royal College of Surgeons, Ireland|Yes|Recruiting|September 2008|September 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 6, 2008|September 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00752817||150312|
NCT00748319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070153|Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma|Analysis of Killer Immunoglobulin-like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T-cell Lymphomas (Mycosis Fungoid and Sézary Syndrome) in Patients With Erythroderma or Erythematous Patches/Plaques.|KIR|Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2009|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|495|||Both|18 Years|95 Years|No|||August 2012|August 21, 2012|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00748319||150654|
NCT00719017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/2007|Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery|Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery: a Randomized Controlled Study.||University Magna Graecia|Yes|Recruiting|September 2007|June 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Female|18 Years|80 Years|No|||April 2013|April 5, 2013|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00719017||152878|
NCT00719914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T101|A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks|IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial|IC TITAN|Brigham and Women's Hospital|Yes|Terminated|November 2007|January 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|January 7, 2008|Yes|Yes|Poor enrollment|No|July 24, 2012|https://clinicaltrials.gov/show/NCT00719914||152809|Early termination due to poor enrollment.
NCT00720148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003549|A Phase I Trial of Bortezomib and Sunitinib|Phase IB Dose Escalation Study of Bortezomib (VELCADE) Administered Weekly for 4 Weeks and Sunitinib (SU-011248) Administered Daily for 4 Weeks Followed by a 14 Day Rest in Patients With Refractory Solid Tumors||Emory University|No|Completed|February 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|July 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00720148||152792|
NCT00716157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04C.466|Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation|A Prospective Study to Evaluate the Incidence and Patterns of Nausea and Vomiting in Patients Receiving Combined Chemotherapy and Radiation||Thomas Jefferson University|No|Completed|October 2004|September 2011|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|University practice patients with aerodigestive malignancy|December 2014|December 3, 2014|July 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00716157||153096|
NCT00762346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446ECN06T|Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis|Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis||Sun Yat-sen University|Yes|Completed|September 2008|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|18 Years|N/A|No|||December 2011|December 8, 2013|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00762346||149588|
NCT00757731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F02207 GE 304|FMS European Long-Term Study|A European Phase III, Multicentre, Double-blind, Randomised, Monotherapy, 12-month Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome||Pierre Fabre Medicament||Completed|September 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|490|||Both|18 Years|71 Years|No|||July 2013|July 10, 2013|September 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00757731||149940|
NCT00785473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSvitD1|Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis|Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study||University Hospital of North Norway|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|50 Years|No|||September 2011|September 2, 2011|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785473||147835|
NCT00785122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Nr. 2007-005666-12|IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)|An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-treatment With Low-dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy.|IMA910-101|immatics Biotechnologies GmbH|Yes|Completed|June 2008|May 2013|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785122||147862|
NCT00785135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSofB 20081276|Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria|Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study||Vision Specialists of Birmingham|No|Completed|November 2008|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|13|||Both|14 Years|N/A|No|||December 2015|December 8, 2015|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00785135||147861|
NCT00785148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04298|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety|Safety Dermatological Evaluation: Genital Mucous Irritation - Product Tested: Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid).||Sanofi||Completed|August 2008|||September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Female|10 Years|20 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785148||147860|
NCT00785161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 1953.A|Penumbra Imaging Collaborative Study (PICS)|Penumbra Imaging Collaborative Study (PICS): A Multicenter Trial to Assess Outcome of Patients Revascularized by the Penumbra™ System|PICS|Penumbra Inc.|No|Completed|August 2009|July 2014|Actual|June 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|289|||Both|N/A|N/A|No|Non-Probability Sample|A stroke cohort who were revacularized by the Penumbra System|April 2015|April 30, 2015|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00785161||147859|
NCT00785434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPS/04/2008|Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD|Phase IV Pilot Study to Examine the Efficacy and Safety of Escitalopram in Doses up to 50 mg for the Treatment of Patients With Major Depressive Disorder (MDD).||Community Pharmacology Services Ltd|No|Completed|October 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||January 2010|January 12, 2010|November 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785434||147838|
NCT00781079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-227|Do Consumer Providers Enhance Recovery?|Promoting Recovery Using Mental Health Consumer Providers|PEER|VA Office of Research and Development|Yes|Completed|April 2008|January 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|285|||Both|N/A|N/A|No|||September 2014|April 6, 2015|October 27, 2008||No||No|September 18, 2014|https://clinicaltrials.gov/show/NCT00781079||148169|1. cluster randomized trial - teams may have exerted influence on the findings. 2. analyses were intent-to-treat, but about half the veterans in the PS group did not receive any PS services. 3. the study involved a small number of peers (n=6)
NCT00782197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTI-01-EC/07/ART|Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA|Efficacy and Safety of the Infiltration of Autologous Plasma Rich in Growth Factors (PRGF) in the Symptomatic Treatment of Knee Osteoarthritis||Biotechnology Institute IMASD|No|Completed|January 2008|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|72 Years|No|||October 2010|October 1, 2010|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782197||148084|
NCT00782171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 06/03|Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface|Immediate and Delayed Loading of 4.1 mm and 4.8 mm Implants in the Posterior Mandible & Maxilla: A Controlled Randomized Study of Single or 2-4 Unit Restorations Loaded Immediately After Surgery or Four Weeks After Surgery||Institut Straumann AG|No|Completed|July 2004|February 2010|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00782171||148086|
NCT00782184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-134|Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)|A Randomized, Double-Blind, Active-Controlled Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk and Not Adequately Controlled With Atorvastatin: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin Versus Doubling the Baseline Dose of Atorvastatin||Merck Sharp & Dohme Corp.|No|Completed|November 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|79 Years|No|||October 2015|October 12, 2015|October 29, 2008|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00782184||148085|
NCT00782535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0810-PR-0001|Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)|EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH SINGLE DOSES OF CHF 4226 pMDI IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE A Multicenter, Randomized, Double-Blind,Placebo-Controlled, 5-Way Crossover Study||Chiesi Pharmaceuticals Inc.|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|20|||Both|40 Years|75 Years|No|||November 2011|November 17, 2011|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782535||148058|
NCT00782860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-08-2008|Early Pregnancy Failure: Factors Affecting Successful Medical Termination Treatment|||Western Galilee Hospital-Nahariya||Completed||||||N/A|Observational|Time Perspective: Prospective||2|||||Female|18 Years|45 Years|No|Non-Probability Sample|Women with missed abortion or anembryonic pregnancy, with existing intrauterine pregnancy        sac|March 2009|March 30, 2009|October 28, 2008||||No||https://clinicaltrials.gov/show/NCT00782860||148034|
NCT00783107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611109|Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)|Clinical Investigation of Aerosol Immunotherapy in COPD: A Phase I Placebo-Controlled Dose Escalation/Deescalation Trial of Aerosol Cyclosporine (CyIS) in Patients With Gold Stage III Chronic Obstructive Pulmonary Disease||University of Pittsburgh|Yes|Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|45 Years|70 Years|No|||December 2012|December 10, 2012|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783107||148015|
NCT00783471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 2D/07|Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)|Docetaxel Combined With Pulsatile Erlotinib (Tarceva®) In Patients With Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)|DOPERLO|Hellenic Cooperative Oncology Group|No|Terminated|November 2008|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|75 Years|No|||June 2010|June 15, 2010|October 30, 2008||No|The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both    treatment arms.|No||https://clinicaltrials.gov/show/NCT00783471||147987|
NCT00780117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070305|Characterization of At-risk Population for Pre-sacral Tumor in CURRARINO Syndrome|Characterization of At-risk Population and Prognosis Factors for SACRO-coccygeal Teratoma in CURRARINO Syndrome. A Clinical, Molecular and Pathological Study.|Currarino|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2008|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|Samples With DNA|Pathological tumoral tissue analysis after surgical removal · Annual serum alpha-foeto      protein level monitoring|Both|N/A|N/A|No|Non-Probability Sample|specialized consultations in the currarino syndrom network|July 2012|July 25, 2012|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780117||148240|
NCT00780351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705036M|Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)|Pharmacokinetics and Dosing of Vancomycin in Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)||National Taiwan University Hospital|No|Completed|October 2008|August 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients in intensive care unit.|October 2009|October 21, 2009|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00780351||148222|
NCT00776243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCMC08MI168|Short-term Effect of Intensive Insulin Therapy on Incretin Secretion|Short-term Effect of Intensive Insulin Therapy on Incretin Secretion||The Catholic University of Korea|No|Completed|October 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|plasma serum|Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Subjects with normal glucose tolerance          2. Early diabetic patients with disease duration of less than 5years          3. Uncontrolled diabetic patients|October 2009|May 10, 2010|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776243||148536|
NCT00776555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-112|Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution|A Single-Blind, Randomized Study of the Comparative Drug Likeability and Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as a Solution||Shire|No|Terminated|November 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|3|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||June 2010|March 3, 2015|October 20, 2008|No|Yes|The study was stopped by the sponsor based on a non-safety related business priority decision.|No|May 5, 2010|https://clinicaltrials.gov/show/NCT00776555||148512|Shire decided to cancel this study on march 31, 2009 due to changes in business priorities. The study termination was not related to any data or safety concerns.
NCT00776256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07002V|Effects of Oligofructose and Barley on Satiety and Energy Intake|The Effect of Meal Replacement Bars Containing Different Types of Fibres (Oligofructose and/or Barley) on Satiety and Energy Intake||Unilever R&D|No|Completed|February 2007|April 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00776256||148535|
NCT00776269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8724|Comparison of Argon Laser and Radiofrequency in Trichiasis Treatment|Comparison the Result of Argon Laser and Radiofrequency in Trichiasis Treatment of Patients Referred to Labbafinejad Oculoplastic Clinic||hahid Beheshti University of Medical Sciences|No|Recruiting|October 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||September 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776269||148534|
NCT00776789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dranuthukral|Effect of Early Skin to Skin Contact on Breast Feeding Behaviour in Term Newborns: A Randomized Controlled Trial|Effect of Early Skin to Skin Contact on Breast Feeding Behaviour in Term Newborns: A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|41|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|October 20, 2008||No||No|June 1, 2010|https://clinicaltrials.gov/show/NCT00776789||148494|This study evaluated breast feeding behaviour of term neonates with only one video, which may not have been an accurate marker of feeding behavior.There could a possibility of inadvertent bias at the time of intervention.
NCT00776802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-CS010|GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Phase 1/2 Study of GCS-100 in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B Cell Lymphoma|GCS-100LE|La Jolla Pharmaceutical Company|No|Withdrawn|July 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|October 19, 2008|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00776802||148493|
NCT00776815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-009|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||October 20, 2008|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776815||148492|
NCT00784875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12063|An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia|A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study of the Safety and Efficacy of LY2624803 in Outpatients With Insomnia|SLUMBER|Eli Lilly and Company|Yes|Completed|October 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|643|||Both|18 Years|85 Years|No|||January 2012|January 30, 2012|October 31, 2008|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT00784875||147881|
NCT00785226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15507|RDEA119 and Sorafenib Combination Dose Escalation Study|A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer||Bayer|No|Completed|November 2008|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|November 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785226||147854|
NCT00784823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.05.109B|Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma|A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction With High Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma|Mel-Vel|Hackensack University Medical Center|Yes|Completed|January 2007|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|76 Years|No|||February 2014|February 1, 2014|October 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784823||147885|
NCT00784836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108MS303|Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients|A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis||Biogen|No|Terminated|October 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|60 Years|No|||April 2014|April 7, 2014|October 29, 2008|Yes|Yes|Terminated early by Sponsor for business reasons unrelated to safety.|No|February 17, 2010|https://clinicaltrials.gov/show/NCT00784836||147884|Early termination with partial data from 3 subjects, therefore, no statistical analysis performed.
NCT00785200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14633A (R01 CI000373-03)|MRSA Colonization and Control in the Dallas County Jail|MRSA Colonization and Control in the Dallas County Jail||University of Chicago|No|Completed|January 2009|February 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|4194|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|June 11, 2013|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00785200||147856|
NCT00781144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPD-OST06030201X|Determination of Forces Used in Palpatory Diagnosis|The Effect of Experience and Gender on the Palpatory Forces Exerted by Novice and Experienced Osteopaths in Australia||Nova Southeastern University|No|Completed|August 2007|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|82|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|first year osteopathic students, fourth and fifth year osteopathic students and        experienced osteopathic clinicians|October 2008|October 27, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781144||148164|
NCT00781157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-4061-2007|Phenylephrine for Spinal Induced Hypotension|Up-down Determination of the ED90 of Phenylephrine for Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery||IWK Health Centre|Yes|Completed|January 2008|October 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|66|||Female|18 Years|N/A|No|||May 2013|May 22, 2013|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781157||148163|
NCT00784797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PitocinPGMyf-HMO-CTIL|Misopristol Versus Pitocin for Second Trimester Abortion|Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion||Hadassah Medical Organization||Completed|January 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Female|18 Years|50 Years|No|||November 2013|November 20, 2013|November 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00784797||147887|
NCT00784810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN4502 (2008-002426-10)|A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis|A Double-blind, Double-dummy, Parallel Group, Randomised Study to Compare the Efficacy & Tolerability of Oxycodone/Naloxone Prolonged Release (OXN PR) & Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis||Napp Pharmaceuticals Limited|No|Completed|February 2009|June 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|November 3, 2008||No||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00784810||147886|
NCT00781092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUSE-01|A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes|A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes||Durrie Vision|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 19, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781092||148168|
NCT00781105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600ACN03|Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B|An Open-label, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B|Chinese PAC|Novartis||Completed|August 2008|||September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2200|||Both|16 Years|65 Years|No|||May 2012|May 3, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781105||148167|
NCT00781118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALERTS Study|AngelMed for Early Recognition and Treatment of STEMI|AngelMed for Early Recognition and Treatment of STEMI|ALERTS|Angel Medical Systems|Yes|Active, not recruiting|December 2008|June 2015|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1020|||Both|21 Years|N/A|No|||July 2013|March 18, 2015|October 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781118||148166|
NCT00781391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-C-U301|Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation|A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)|EngageAFTIMI48|Daiichi Sankyo Inc.|Yes|Completed|November 2008|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|21105|||Both|21 Years|N/A|No|||March 2015|March 12, 2015|October 28, 2008|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00781391||148146|
NCT00781638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ada-UC-08-101|ADAPT Adacolumn Pediatric Trial in Ulcerative Colitis|Open Uncontrolled Investigation to Assess the Efficacy and Safety of Adacolumn® Granulocytes, Monocytes / Macrophage Apheresis Device in Children and Adolescents With Active Ulcerative Colitis||Otsuka Frankfurt Research Institute GmbH|No|Completed|October 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|18 Years|No|||April 2012|April 2, 2012|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781638||148127|
NCT00781651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2007|||||N/A|N/A|N/A||||||||||||||October 28, 2008|October 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781651||148126|
NCT00781924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-2007-0066|Interventional Sonography Guided by Image Fusion|Interventional Sonography Guided by Image Fusion||Rigshospitalet, Denmark|No|Completed|January 2008|September 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|patients with focal liver lesions where biopsy is needed or the lesion has to be verified        by sonography|August 2009|August 4, 2011|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781924||148105|
NCT00782574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00021|Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients|A Phase I Open Label, Multi Centre Study of AZD2281 Administered Orally in Combination With Cisplatin, to Assess the Safety and Tolerability in Patients With Advanced Solid Tumours||AstraZeneca|Yes|Active, not recruiting|November 2008|December 2016|Anticipated|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|99 Years|No|||March 2016|March 2, 2016|October 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782574||148055|
NCT00782548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA20003|Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults|A Phase IV, Comparative, Randomized, Double Blind, Single-Dose, 2-Way Crossover Study to Evaluate the Pharmacokinetics and Safety of Alpharma Branded Products Division (KADIAN)and Ligand Pharmaceuticals Inc. (Avinza) 30 mg Morphine Sulfate Sustained-Release Capsules in Healthy Adult Volunteers Under Fed Conditions||Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.||Completed|May 2004|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||October 2008|October 29, 2008|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782548||148057|
NCT00782561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-MC3019-026|Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental Glomerulosclerosis||FibroGen|No|Terminated|April 2008|March 2011|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|12 Years|64 Years|No|||July 2009|July 14, 2009|October 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782561||148056|
NCT00783120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESIS|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia - a Multicenter Study|RESIS|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|Yes|Completed|January 2008|December 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|60 Years|No|||November 2013|November 1, 2013|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783120||148014|
NCT00783133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03177|Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)|Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|November 2002|June 2003|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|131|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783133||148013|
NCT00783783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0659|CYP2D6 Pharmacogenetics in Risperidone-Treated Children|CYP2D6 PHARMACOGENETICS IN RISPERIDONE-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHIATRIC OR NEURODEVELOPMENTAL DISORDERS||Children's Hospital Medical Center, Cincinnati|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|47|Samples With DNA|DNA from blood, buccal swab, or saliva|Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will include up to 41 risperidone-treated children and adolescents with        psychiatric or neurodevelopmental (ND) disorders who participated in one of two previous        risperidone pharmacokinetics investigations.        To have a larger sample of poor metabolizer subjects, we plan to enroll at least 8        additional subjects who are on stable treatment with risperidone, and perform risperidone        pharmacokinetics analyses. Prospectively enrolled subjects (n = 8) will be CYP2D6 poor        metabolizers and will include White / Caucasian subjects, of any socioeconomic status, and        will be recruited from inpatients or outpatients at Cincinnati Children's Hospital|December 2012|December 10, 2012|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783783||147963|
NCT00779558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11132007-879|Heparin and the Reduction of Thrombosis (HART) Trial|Heparin and Catheter-related Thrombosis in Neonates and Infants Following Cardiac Surgery||Stanford University|No|Completed|November 2005|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|N/A|1 Year|No|||June 2015|June 10, 2015|October 22, 2008||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00779558||148283|
NCT00780416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A6|Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naïve Subjects With Genotype 1 Hepatitis C||Mitsubishi Tanabe Pharma Corporation|No|Completed|November 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|189|||Both|20 Years|65 Years|No|||April 2014|April 16, 2014|October 24, 2008||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00780416||148217|
NCT00780728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNOHI|Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension|Addition of Sildenafil to Bosentan Monotherapy in Patients With Pulmonary Arterial Hypertension (PAH)||University Health Network, Toronto|No|Withdrawn||||||Phase 3|Interventional|N/A|1||||||Both|18 Years|N/A||||November 2009|November 12, 2009|October 27, 2008||||No||https://clinicaltrials.gov/show/NCT00780728||148194|
NCT00780741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-142|Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old|A Randomized Trial Comparing Immediate Probing in an Office Setting With Deferred Probing in a Facility Setting for Treatment of Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old|NLD3|Jaeb Center for Health Research|Yes|Completed|October 2008|January 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|6 Months|10 Months|No|||October 2012|October 11, 2012|October 27, 2008||No||No|August 23, 2012|https://clinicaltrials.gov/show/NCT00780741||148193|Conclusions not definitive--would need larger sample size.Participants with bilateral NLDO excluded, so results not generalizable to bilateral cases.Actual costs may vary by region and payer.Did not include costs of follow up visits.
NCT00780754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-27|Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia|Effect of 5α Reductase Inhibitor Dutasteride on the Prevention of the Prostate Cancer in Men With High Grade Intraepithelial Neoplasia of the Prostate||Kaunas University of Medicine|No|Recruiting|April 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Male|40 Years|80 Years|No|||October 2008|October 27, 2008|October 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00780754||148192|
NCT00780767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Angiojet in MPE|Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism|Angiojet Rheolytic Thrombectomy In Case of Massive Pulmonary Embolism A Prospective Single Center Feasibility and Safety Pilot Trial|ART-MPE|University Hospital, Geneva|No|Completed|September 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2008|August 15, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780767||148191|
NCT00776568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URG/UQ/002/01|Treatment of Refractory Angina Pectoris by Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Refractory Angina Pectoris||Universal Research Group|Yes|Active, not recruiting|February 2008|||August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776568||148511|
NCT00785265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000223|A Randomized Trial to Reduce the Disparity in Live Donor Kidney Transplantation|A Randomized Trial to Reduce the Disparity in Live Donor Kidney Transplantation||Beth Israel Deaconess Medical Center|No|Active, not recruiting|August 2007|July 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Anticipated|180|||Both|21 Years|80 Years|No|||January 2016|January 11, 2016|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00785265||147851|
NCT00785213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-001-08-1028|Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone|An Open-Label Drug-Drug Interaction Study to Investigate the Effects of Steady State Quinine on the Single-Dose Pharmacokinetics of Rosiglitazone Maleate in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|October 24, 2008|No|Yes||No|October 20, 2009|https://clinicaltrials.gov/show/NCT00785213||147855|
NCT00785447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001680|Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing|Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing in Non-paralyzed Adult Patients Under General Anesthesia||Massachusetts General Hospital|No|Completed|March 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|59 Years|No|||April 2012|April 24, 2012|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00785447||147837|
NCT00785460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benfo Smoker|Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers|Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers||Ruhr University of Bochum|No|Completed|January 2008|||May 2008||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|20|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2008|November 4, 2008|November 4, 2008||||No||https://clinicaltrials.gov/show/NCT00785460||147836|
NCT00781404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUValldHebronRI|Myocardial Protection With Adenosine During Primary Percutaneous Coronary Intervention in Pts With STEMI|Myocardial Protection During reperfusión in Patients With Acute Coronary Syndrome With ST Segment Elevation Submitted to Primary Angioplasty: Effect of Intracoronary Adenosine on Infarct Size and Ventricular Remodeling.|PROMISE|Hospital Universitari Vall d'Hebron Research Institute|No|Completed|October 2008|July 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|201|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781404||148145|
NCT00781664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2718-TP-101|Cumulative Irritation Test|21-Day Cumulative Irritation Test||Anacor Pharmaceuticals, Inc.|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|9||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 19, 2008|October 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00781664||148125|
NCT00781911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13929|A Study of IMC-A12 in Islet Cell Cancer|A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma||Eli Lilly and Company|Yes|Active, not recruiting|February 2009|February 2016|Anticipated|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781911||148106|
NCT00782210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.11|12 / 48 Week Pivotal PFT vs PBO in COPD I|Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|November 2008|||September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|625|||Both|40 Years|N/A|No|||March 2014|June 3, 2014|October 29, 2008||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00782210||148083|
NCT00782223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0135-08-TLV|Assessment of Digital Radiograph Measurements of Hip,Spine and Lower Limbs|Assessment of Hip, Spine and Lower Limbs Digital Radiograph Measurements in Pediatric Population: Using PACS Integrated Computer Software (TraumaCad From OrthoCrat)||Tel-Aviv Sourasky Medical Center|No|Active, not recruiting|July 2008|||December 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|50|||Both|2 Months|30 Years|No|Non-Probability Sample|Digital X-rays from PACS system|October 2008|October 29, 2008|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782223||148082|
NCT00782587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-08-01|Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer|Phase I Safety and Tolerability Study of Immediate Post-Operative Intravesical Instillation of Chemophase® (Recombinant Human Hyaluronidase in Combination With Mitomycin) in Patients With Non-Muscle-Invasive Bladder Cancer|IPOP|Halozyme Therapeutics|No|Completed|October 2008|August 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2010|February 5, 2010|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782587||148054|
NCT00782886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-LC-2007-01|Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer|Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer||Pathfinder Therapeutics|Yes|Completed|April 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|Participants receiving surgery for Liver disease.|January 2011|January 25, 2011|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00782886||148032|
NCT00782873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|424-02-08|Balanced Propofol Sedation During Upper Endoscopy in Morbidly Obese Patients|Balanced Propofol Sedation During Upper Endoscopy in Morbidly Obese Patients: Assessment of Cardiopulmonary Parameters||Research Associates of New York, LLP|No|Completed|March 2008|September 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|The research subjects will be selected from a private practice.|October 2008|October 29, 2008|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782873||148033|
NCT00783146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04054|Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)|A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)||Merck Sharp & Dohme Corp.|No|Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|728|||Both|12 Years|N/A|No|||April 2015|April 6, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783146||148012|
NCT00783484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0831001|A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects|A Double-Blind (3rd Party Open), Placebo-Controlled, Crossover, Dose Escalating Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539, To Assess The Potential Of PF-03716539 To Inhibit CYP3A4 (In Vivo) And To Evaluate The Drug Interaction Potential Between PF-03716539 And Darunavir Or Maraviroc In Healthy Adult Subjects||Pfizer|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|37|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 28, 2009|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783484||147986|
NCT00783497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599|Evaluating the Relationship Between Stress, Ethnicity, and Blood Pressure|Stress, Blood Pressure, & Ethnicity||University of California, San Diego|Yes|Completed|October 2005|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|203|Samples With DNA|Serum, urine|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample in the San Diego, California metropolitan area|December 2015|December 16, 2015|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783497||147985|
NCT00784329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-031|Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease|Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease||Lahey Clinic|No|Active, not recruiting|March 2008|March 2016|Anticipated|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|October 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00784329||147922|
NCT00780715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008DM05|Response To Oral Agents in Diabetes (ROAD)- Pilot Study|Response To Oral Agents in Diabetes (ROAD)- Pilot Study|ROAD|University of Dundee|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|36 Years|79 Years|No|||January 2016|January 7, 2016|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780715||148195|
NCT00780442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#16454|D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals|D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals||Medical University of South Carolina|Yes|Completed|September 2006|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|28|||Both|18 Years|65 Years|No|||October 2008|October 24, 2008|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780442||148215|
NCT00776295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC 14955|Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer|Phase II Trial of Autologous Peripheral Blood Hematopoietic Cell Transplantation (PBHCT) Followed by Dendritic Cell p53 Vaccination and Adoptive T Cell Transfer in Patients With Limited Stage Small Cell Lung Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|May 2007|August 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|October 20, 2008|Yes|Yes|Low accrual|No|October 4, 2011|https://clinicaltrials.gov/show/NCT00776295||148532|Early termination of trial due to small number of subjects thus leading to unreliabe data
NCT00776282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118_LORAT_06|Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study on Loratadine Formulations Comparing Loratadine 10 mg Orally Disintegrating Tablets of Ohm Laboratories, Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With Claritin® Reditabs® 10 mg Tablet (Containing Loratadine 10 mg) of Schering- Plough Healthcare Product Inc, in Healthy, Adult, Male, Human Subjects Under Fed Condition||Ranbaxy Inc.|Yes|Completed|July 2006|September 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776282||148533|
NCT00781196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIGO|Folic Acid Supplementation in Phenytoin Induced Gingival Overgrowth|Effect of Low Dose Oral Folic Acid Supplementation on Phenytoin Induced Gingival Overgrowth: A Randomized Double Blind Controlled Trial.|PIGO|All India Institute of Medical Sciences, New Delhi|Yes|Completed|May 2008|July 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|6 Years|15 Years|No|||August 2009|August 3, 2009|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781196||148160|
NCT00781456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-105-201|A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches|A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo For the Management of Menstrually-Related Migraine Headaches.||Teva Pharmaceutical Industries|No|Completed|January 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|109|||Female|18 Years|34 Years|No|||August 2014|August 19, 2014|October 28, 2008|Yes|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT00781456||148141|
NCT00785239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-00031|CryoSpray Ablation(tm)Thoracic Patient Registry|CryoSpray Ablation(tm)Thoracic Patient Registry||CSA Medical, Inc.|No|Withdrawn|April 2009|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of subjects treated with the CryoSpray Ablation™ System in        the airway or for thoracic diseases.|June 2015|June 23, 2015|November 4, 2008||No|Business Reasons|No||https://clinicaltrials.gov/show/NCT00785239||147853|
NCT00785252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100731 (completed)|EZIO Compared to Central Venous Lines for Emergency Vascular Access|Randomized Study of the EZIO Compared to Central Venous Lines Used for Emergency Vascular Access||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Recruiting|September 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2011|February 4, 2011|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785252||147852|
NCT00785486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-001-07-1001|Drug-Drug Interaction Study of Qualaquin and Midazolam|A Pharmacokinetic Interaction Study Evaluating the Effect of Qualaquin (Quinine Sulfate) Capsules on Midazolam||Mutual Pharmaceutical Company, Inc.|No|Completed|March 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|November 4, 2008|No|Yes||No|March 11, 2009|https://clinicaltrials.gov/show/NCT00785486||147834|
NCT00781131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-4101-2007|Trial of Pregabalin for Post-operative Pain in Women Undergoing Abdominal Hysterectomy|A Randomized, Placebo Controlled Trial of Pregabalin for Post-operative Pain in Women Undergoing Abdominal Hysterectomy||IWK Health Centre|Yes|Completed|May 2008|January 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|101|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 22, 2013|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781131||148165|
NCT00781417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atlanta VAMC|Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease|Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease|POSH-D|Atlanta VA Medical Center|No|Completed|October 2008|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|85 Years|No|||February 2012|February 4, 2012|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781417||148144|
NCT00781677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anx_Dep|Using Neuroimaging to Investigate Major Depressive Disorder|Using Neuroimaging to Investigate Neurobiological Correlates of Treatment Resistance Associated With Co-morbid Anxiety in Major Depressive Disorder||University of Texas Southwestern Medical Center|No|Recruiting|May 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|50 Years|No|Non-Probability Sample|community sample|January 2010|January 11, 2010|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781677||148124|
NCT00781937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-1923|Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance|Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period||Novo Nordisk A/S|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|422|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|October 28, 2008|Yes|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00781937||148104|
NCT00782236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 02/06|Comparison of Straumann BoneCeramic vs. Allograft Bone in Extraction Sockets|Comparison of an Alloplast (Straumann Bone Ceramic) to an Allograft of Freeze Dried Bone (FDBA) for Preservation of the Alveolar Ridge Following Tooth Extraction: a Prospective, Randomized, Controlled Clinical Study||Institut Straumann AG|No|Terminated|June 2006|October 2009|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|October 28, 2008||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00782236||148081|
NCT00782249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/238|Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy|Prospective Randomized Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy||University Hospital, Ghent|No|Recruiting|October 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|16 Years|N/A|No|||December 2014|December 4, 2014|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782249||148080|
NCT00783172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU-20978 and 35686EP|Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer|OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study||Penn State University|Yes|Terminated|January 2009|October 2011|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|October 30, 2008|Yes|Yes|Problems with IRB|No||https://clinicaltrials.gov/show/NCT00783172||148010|
NCT00783159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32.5.8051.0113.0|Fit in the Aged by Professional Training|The Effect of Different Training Modalities and Vitamin D Supplementation on Functionality in Prefrail Elderly Persons|FiAT|University of Erlangen-Nürnberg Medical School|No|Completed|June 2008|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|69|||Both|65 Years|N/A|No|||January 2011|January 11, 2011|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783159||148011|
NCT00784069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04367|Dermacyd Breeze (Lactic Acid) Pocket BR - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Breeze Pocket BR.||Sanofi||Completed|October 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|27|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784069||147942|
NCT00784316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5204005|Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery|Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery||Kuopio University Hospital|No|Completed|August 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|316|||Both|N/A|N/A|No|||November 2011|November 23, 2011|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784316||147923|
NCT00784342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-02|Validation of PROMIS Banks With COPD Exacerbations|Validation of PROMIS Banks With COPD Exacerbations||University of North Carolina, Chapel Hill|No|Completed|July 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|188|||Both|40 Years|N/A|No|Non-Probability Sample|People presenting to primary care or specialty clinics with COPD either with exacerbation        or without exacerbation. People admitted to the hospital with a COPD exacerbation.|December 2012|December 12, 2012|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784342||147921|
NCT00779922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVIR|Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function|||Poitiers University Hospital|No|Recruiting|November 2008|||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study|1|||46|||Both|18 Years|N/A|No|||January 2010|January 29, 2010|October 23, 2008||||No||https://clinicaltrials.gov/show/NCT00779922||148255|
NCT00779935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04041|Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)|Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study||Merck Sharp & Dohme Corp.|No|Completed|October 2004|February 2007|Actual|October 2005|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|70 Years|No|||April 2015|April 15, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779935||148254|
NCT00780403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04573|Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)|A Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications||Merck Sharp & Dohme Corp.|No|Completed|August 2005|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|220|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|October 23, 2008|Yes|Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00780403||148218|
NCT00780156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-004131-38|The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel|The ITALIC Study Is There A LIfe for DES After Discontinuation of Clopidogrel : The ITALIC Study|ITALIC|French Cardiology Society|Yes|Terminated|November 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1235|||Both|18 Years|N/A|No|Probability Sample|Patients after drug eluting stent implantation|September 2013|September 27, 2013|October 24, 2008||No|No more information will be given. No consequences on security and treatment of patients:    standard therapy is already performed for all patients.|No||https://clinicaltrials.gov/show/NCT00780156||148237|
NCT00780429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2006/REVO|Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients|Evaluation of Pharmacokinetic and Pharmacodynamic Parameters in Renal Transplant Patients Receiving Mycophenolic Acid and Stable for at Least 3 Months||IRCCS Policlinico S. Matteo|No|Active, not recruiting|June 2006|||||N/A|Observational|N/A||3|Actual|54|||Both|18 Years|70 Years|No|Non-Probability Sample|Male and female renal transplant patients|October 2008|October 24, 2008|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780429||148216|
NCT00780780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0754/07|Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema|A Randomized Parallel, Masked to Evaluate the Efficacy of Triamcinolone Associated With Nepafenac (Nevanac) Compared With Intravitreal Injection of Triamcinolone for Treatment of Clinically Significant Diabetic Macular Edema|NEVANAC|Federal University of São Paulo|No|Active, not recruiting|July 2007|October 2008|Anticipated|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2008|October 27, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780780||148190|
NCT00776880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2008-MZ08|Does American Society of Anesthesiologists (ASA) Physical Status Scale Enough in Patients Assessment|Reevaluating the American Society of Anesthesiologists (ASA) Physical Status System in Patients Assessment and Compared With a New Scale of Physical-psycho-social Gauge Raised by Our Institution|ASAINPA|Nanjing Medical University|Yes|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1500|||Both|18 Years|65 Years|No|Non-Probability Sample|All patients undergoing surgical operations|November 2009|December 22, 2009|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776880||148487|
NCT00776893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||October 20, 2008|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776893||148486|
NCT00776906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008|Advance® 18PTX® Balloon Catheter Study|Advance® 18PTX® Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery With a Paclitaxel-coated Balloon||Cook||Completed|October 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2014|January 19, 2015|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776906||148485|
NCT00776594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-190|Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy|Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2008|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||June 2015|June 2, 2015|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776594||148509|
NCT00781209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC - 08 - BC - 270 - CTIL|The Role of Posterior Fossa Irradiation (PFI) Plus Stereotactic Radiosurgery (SRS) for Cerebellar Metastases|A Phase II Trial Evaluating the Role of Posterior Fossa Irradiation (PFI) Plus Stereotactic Radiosurgery (SRS) for Cerebellar Metastases||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2008|December 2010|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2008|October 27, 2008|October 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781209||148159|
NCT00781469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112009|A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood|A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood||Imperial College London|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|29|Samples With DNA|Blood and synovium|Both|18 Years|75 Years|No|Non-Probability Sample|Adult men and non-pregnant, non-lactating women between 18 and 75 years of age with a        clinical history of rheumatoid arthritis.|September 2011|May 27, 2015|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781469||148140|
NCT00785499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoMS D204|Milk Components and Metabolic Syndrome|The Effect of Milk, Whey and Casein on Weight Loss and Risk Markers of Metabolic Syndrome in Overweight Children|MoMS|University of Copenhagen|No|Completed|November 2008|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|193|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||March 2012|March 19, 2012|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785499||147833|
NCT00781430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1111|Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease|An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Neratinib In Subjects With Chronic Hepatic Impairment And In Matched Healthy Adults||Puma Biotechnology, Inc.|No|Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781430||148143|
NCT00781443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILR4544g|A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma||Genentech, Inc.||Completed|December 2008|||November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|55 Years|No|||May 2010|May 4, 2010|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781443||148142|
NCT00781950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10941-011|Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease|A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease|FLAXPAD|St. Boniface General Hospital Research Centre|Yes|Active, not recruiting|October 2008|December 2017|Anticipated|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|110|||Both|40 Years|100 Years|No|||November 2015|November 23, 2015|October 28, 2008||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00781950||148103|
NCT00782899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2008/2|Four Dimensions in Schizophrenia|Prospective Observational Study About Progress of Subjective Well-being Sensation in Schizophrenic Patients|4D|AstraZeneca|No|Completed|October 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|||Both|18 Years|65 Years|No|Non-Probability Sample|Schizophrenic patients with a acute episode or worsening of clinical status treated in        outpatients clinics. Defined acute episode or worsening as clinical status that need a        significant change in the therapeutic plan.|December 2009|December 8, 2010|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782899||148031|
NCT00783523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H42145-30334-02|Influence of MMP on Brain AVM Hemorrhage|Influence of Matrix Metalloproteinase on Brain Arteriovenous Malformation Hemorrhage||University of California, San Francisco|No|Completed|March 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|33|||Both|13 Years|N/A|No|||August 2013|August 6, 2013|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783523||147983|
NCT00783510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-262|Juvenile Idiopathic Arthritis (JIA) Registry|A Long-term, Multi-center, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE|STRIVE|AbbVie|No|Active, not recruiting|July 2008|January 2024|Anticipated|January 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|||Both|2 Years|17 Years|No|Non-Probability Sample|Patients who are diagnosed at any time with moderately to severely active polyarticular or        polyarticular-course JIA, (defined as arthritis affecting greater than 5 joints at the        time of diagnosis of polyarticular or polyarticular-course JIA), prescribed and treated in        a routine clinical setting either with Humira® (adalimumab), or MTX. Approximately 800        patients will be enrolled in the United States, EU countries, and Australia. Approximately        40 to 45 physicians will be included based on participation in prior AbbVie Humira        sponsored clinical JIA studies.|January 2016|January 27, 2016|October 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783510||147984|
NCT00783796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-383|SPIRIT Small Vessel Registry|Spirit Small Vessel Registry (SPIRIT SV)|SPIRIT SV|Abbott Vascular|Yes|Completed|October 2008|December 2013|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|October 30, 2008|Yes|Yes||No|November 29, 2011|https://clinicaltrials.gov/show/NCT00783796||147962|
NCT00784082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080102|Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease|Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease||Assistance Publique - Hôpitaux de Paris|No|Completed|May 2009|November 2012|Actual|October 2012|Actual|N/A|Observational|N/A||2|Actual|62|Samples With DNA|Sample with DNA|Both|3 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Homozygous SS sickle cell children, aged > 3 years, of sub-Saharian Africa heterozygous AS        parents or siblings of the patients, and AA siblings or healthy African unrelated        subjects, aged > 3 years|January 2013|January 30, 2013|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00784082||147941|
NCT00779948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-0806|Dynamic Internal Fixation of Femoral Neck Fractures|Dynamic Internal Fixation of Femoral Neck Fractures|DIFINE|Aesculap AG|No|Completed|December 2008|February 2013|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|171|||Both|55 Years|N/A|No|Non-Probability Sample|Primary Care Patients|August 2013|August 5, 2013|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00779948||148253|
NCT00780169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTT 06-08|Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer|A Phase I Study of Sorafenib (Nexavar®) in Combination With FOLFIRI as First Line Therapy for Metastatic Colorectal Cancer||Ottawa Hospital Research Institute|Yes|Completed|October 2008|December 2012|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00780169||148236|
NCT00780455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13089|Rehabilitation Study in MS Patients|Multicenter, Open Label, Randomized and Parallel Group Phase IV Pilot Study Evaluating the Effectiveness of Functional Rehabilitation Protocol in RRMS Patients Treated With Betaferon®||Bayer|No|Terminated|October 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|May 28, 2008|Yes|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00780455||148214|Due to the very low number of patients enrolled in the study, no statistical report was done. Study was early terminated.
NCT00780468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#18523|A Pilot Study to Evaluate a Revised Method of Assessing Food in a Commercial Weight Management Program Format|A Pilot Study to Evaluate a Revised Method of Assessing Food in a Commercial Weight Management Program Format||Medical University of South Carolina|No|Completed|October 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00780468||148213|
NCT00776607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004662-14|Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)|Randomized, Controlled, Parallel-Group Prospective Study to Investigate the Clinical Effectiveness of Early Insulin Treatment in Patients With Latent Autoimmune Diabetes in Adults|LIT|Abertawe Bro Morgannwg University NHS Trust|Yes|Recruiting|April 2007|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||September 2008|October 20, 2008|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776607||148508|
NCT00776620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10381502|Bioequivalence Study of Glimepiride 1mg Tablets Under Fed Conditions|A Relative Bioavailability Study of Glimepiride 1 MG Tablets Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|July 2003|September 2003|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776620||148507|
NCT00776321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No: 2006-003191-35|Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia|A Placebo Controlled, Double Blind, Randomised, 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia||Karo Bio AB|Yes|Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||Actual|142|||Both|18 Years|65 Years|No|||October 2008|October 20, 2008|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776321||148530|
NCT00776334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B025507|Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Fosinopril Sodium 40 mg Tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) With That of Monopril® (Bristol-Myers Squibb, Lot No. 1D47960), in Healthy Adult Subjects Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|October 2002|December 2002|Actual|November 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776334||148529|
NCT00777218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-185|Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine|Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine||University of South Alabama|No|Recruiting|August 2007|July 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|90|||Both|8 Years|17 Years|No|||June 2010|June 23, 2010|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777218||148461|
NCT00777231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-7621-042298|Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies|1)Mixed Chimerism to Treat Sickle Cell Disease: Extended Protocol 2)Mixed Chimerism to Treat Non-Malignant Disorders of the Hematopoietic Stem Cell 3)Transplantation of Allogeneic Bone Marrow Enriched for Graft Facilitating Cells in the Treatment of Aplastic Anemia||University of Louisville|Yes|Completed|January 2005|August 2013|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|N/A|N/A|No|||October 2015|October 29, 2015|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777231||148460|
NCT00781482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-104-SEPR|Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem|Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem||Kettering Health Network|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|0|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|October 27, 2008|Yes|Yes|Sponsor elected not to conduct study at this time.|No||https://clinicaltrials.gov/show/NCT00781482||148139|
NCT00781742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6702C00009|AZD6765 Severe Major Depressive Disorder (MDD) IV|A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants||AstraZeneca||Completed|October 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|65 Years|No|||July 2012|July 16, 2012|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781742||148119|
NCT00781989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1089|Ultrasonography as a Biomarker in Early Rheumatoid Arthritis|Qualification of Ultrasonography as a Biomarker of Prognosis and Response to Treatment in Early Rheumatoid Arthritis||Imperial College London|No|Completed|September 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|Samples With DNA|whole blood / serum|Both|18 Years|N/A|No|Non-Probability Sample|hospital Rheumatology outpatient departments|September 2011|September 29, 2011|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781989||148100|
NCT00781170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Auto/Allo Plasmozytom|Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma|Dose-Reduced Allogeneic Stem Cell Transplantation as Induction of a Graft-Versus-Myeloma-Effect After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma Stage II/III||Universitätsklinikum Hamburg-Eppendorf|No|Completed|May 2000|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|66 Years|No|||May 2009|May 27, 2009|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00781170||148162|
NCT00782262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050226|Weight Loss Effects on Heart and Blood Vessel Function in Obesity|Effects of Obesity and Diet Induced Weight Loss on Cardiovascular Risk Factors, Vascular and Ventricular Structure and Function in Obese Men||University of Adelaide|Yes|Recruiting|April 2005|||January 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 29, 2008|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00782262||148079|
NCT00782600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6341011|Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers|A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers||Pfizer|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 5, 2009|October 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782600||148053|
NCT00783185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRET|Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment|Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis||University of Konstanz|No|Completed|January 2006|January 2010|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||October 2008|January 11, 2010|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783185||148009|
NCT00783198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05233|Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma||Merck Sharp & Dohme Corp.|Yes|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|565|||Both|18 Years|50 Years|No|||December 2015|December 16, 2015|October 30, 2008|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00783198||148008|
NCT00784095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAD 07-162|Outlook Quality of Life Intervention|Outlook: An Intervention to Improve Quality of Life in Serious Illness||VA Office of Research and Development|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|36|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 30, 2008||No||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00784095||147940|Therefore, due to the small sample size, finding are met with caution. Subjects were not randomized by any condition. As a result, those in the Control arm were more functionally able than the other two arms at baseline.
NCT00783809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI-34-2008|Measurement of Optic Nerve Sheath in Traumatic Raised Intracranial Pressure|Measurement of Optic Nerve Sheath in Traumatic Raised Intracranial Pressure|MOONSTRIP|McMaster University|No|Active, not recruiting|October 2008|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|560|||Both|16 Years|N/A|No|Non-Probability Sample|Patients who present to the emergency department with suspected closed head injury as a        result of blunt trauma and require CT head|April 2012|April 26, 2012|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783809||147961|
NCT00784680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033IE/0029|ATAC - Quality of Life Sub-Protocol|A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women||AstraZeneca|Yes|Completed|April 1998|April 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|308|||Female|45 Years|N/A|No|||April 2009|April 30, 2009|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784680||147896|
NCT00784966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB 4196|Islet After Kidney Transplant for Type 1 Diabetes|Pancreatic Islet Transplantation in Patients With Type 1 Diabetes Mellitus||Virginia Commonwealth University|Yes|Withdrawn|August 2011|September 2017|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||September 2014|September 12, 2014|November 4, 2008|Yes|Yes|University decision.|No||https://clinicaltrials.gov/show/NCT00784966||147874|
NCT00779961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010915|An Investigation for the Optimal Timing of a Cleft Palate Repair|An Investigation for the Optimal Timing of a Cleft Palate Repair||The Hospital for Sick Children|No|Recruiting|April 2008|April 2013|Anticipated|April 2011|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|N/A|5 Months|No|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779961||148252|
NCT00780793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 07127|Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study|Effect of TNF-blocker Injections Spacing on Rheumatoid Arthritis Inflammatory Activity in Patients in Clinical Remission or Low Disease Activity|STRASS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2008|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||October 2008|February 1, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780793||148189|
NCT00780806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-1003|Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults|An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780806||148188|
NCT00776308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004241|Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery|Molecular Breast Imaging in the Preoperative Evaluation of Women With Biopsy Proven Breast Cancer|MBI|Mayo Clinic|No|Completed|October 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|98|||Female|25 Years|N/A|No|Non-Probability Sample|Recruitment will be from the pool of patients undergoing surgical evaluation for breast        cancer at Mayo Clinic Rochester.|January 2012|January 23, 2012|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776308||148531|
NCT00780819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-2-039|Borderzone Sampling|Does Borderzone Contrast Enhancement on Intraoperative MRI During High Grade Glioma Resection Correlate With Residual Tumor?|BZS|Maastricht University Medical Center|Yes|Completed|October 2008|December 2012|Actual|July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780819||148187|
NCT00776646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107_HYDRO¬_06|Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two- Sequence, Single-Dose, Crossover Bioavailability Study Comparing Hydrochlorothiazide 50 mg Tablet of Ohm Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals USA) With Hydrochlorothiazide 50 mg Tablet of IVAX Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fasting Condition||Ranbaxy Inc.|Yes|Completed|May 2006|August 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776646||148505|
NCT00776633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01508|Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation|Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting|ISAR-TRIPLE|Deutsches Herzzentrum Muenchen|Yes|Active, not recruiting|September 2008|September 2014|Anticipated|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|614|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776633||148506|
NCT00782665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012008Faro|Myometrial Biopsy for the Detection of Infection|Myometrial Biopsy for the Detection of Infection||The Woman's Hospital of Texas|No|Recruiting|July 2008|July 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||October 2008|October 28, 2008|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00782665||148048|
NCT00782691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/060|Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.|Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.||Radboud University||Recruiting|July 2008|||December 2009|Anticipated|N/A|Observational|N/A||1|Anticipated|15|Samples With DNA|Head-and-neck cancer patients will undergo a therapeutic lymph node dissection of the      cervical nodes. This treatment is given whether the patient is enrolled in the study or not.      Histological specimens of cancer patients are always stored for possible future refference      in the routine clinical practice.|Both|18 Years|N/A|No|Non-Probability Sample|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical        nodes.|October 2008|October 29, 2008|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782691||148047|
NCT00782938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S235-2008|The Role of Serum Anticholinergic Activity in ACVB Patients|Serum Anticholinergic Activity (SAA) and BIS-EEG as Potential Markers for Cognitive Ability and/or the Anticholinergic Medication in ACVB Patients||Heidelberg University|No|Completed|May 2008|January 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|55 Years|90 Years|No|Probability Sample|ACVB patients:        Ages Eligible for Study: 55 years to 90 years Genders Eligible for Study: Both Accepts        Healthy Volunteers: No|October 2008|January 13, 2010|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782938||148028|
NCT00782951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05800|A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800)|A Randomized, Double-blind, Active and Placebo Controlled Trial to Compare the Relative Analgesic Efficacy and Safety of a Single Intravenous Dose of ORG 28611 3 mcg/kg, Morphine Sulfate 0.12 mg/kg, and Placebo in Patients Experiencing Moderate to Severe Pain After Dental Impaction Surgery.||Merck Sharp & Dohme Corp.|No|Terminated|July 2007|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|11|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782951||148027|
NCT00781690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1456|Reduction of Heparin Dose in Dialysis With Evodial System|Pilot, Prospective, Multicenter, Open and Non-randomised Study: Definition of an Index of Anti Xa Value at the End of Hemodialysis Treatment.|RHODES|Gambro Lundia AB|No|Completed|September 2008|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2010|February 15, 2010|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781690||148123|
NCT00781703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR-06-039|Evaluation of a Natural Experiment to Improve Statewide Depression Care in Minnesota (MN)|DIAMOND Study: Evaluation of a Natural Experiment to Improve Statewide Depression Care in MN|DIAMOND|HealthPartners Institute|No|Completed|February 2008|February 2014|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|2631|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781703||148122|
NCT00781963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 08-295|Implementing Sleep Interventions for Older Veterans|Implementing Sleep Interventions for Older Veterans||VA Office of Research and Development|No|Completed|May 2010|December 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|519|||Both|60 Years|N/A|No|||June 2014|April 6, 2015|October 28, 2008||No||No|September 17, 2014|https://clinicaltrials.gov/show/NCT00781963||148102|The study sample was predominantly older male veterans, so results may not be generalizable to older women.
NCT00782613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-2074-205|Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis|Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Wafety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic||Synvista Therapeutics, Inc|No|Terminated|November 2008|March 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||January 2009|January 29, 2009|October 29, 2008||No|Study has been termination early due to financial contraints.|No||https://clinicaltrials.gov/show/NCT00782613||148052|
NCT00782626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001|Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas|A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas||Dana-Farber Cancer Institute|Yes|Completed|June 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|3 Years|21 Years|No|||December 2015|December 30, 2015|October 29, 2008|Yes|Yes||No|December 30, 2015|https://clinicaltrials.gov/show/NCT00782626||148051|
NCT00782912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 08-155|Postpartum Anemia and Postpartum Depression|Is Postpartum Anemia an Independent Risk Factor for Development of Postpartum Depression?|PPADS|St. Michael's Hospital, Toronto|No|Completed|November 2008|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|103|Samples With DNA|Blood samples|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women after term elective cesarean section|April 2015|April 20, 2015|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782912||148030|
NCT00783211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04053|Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)|A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)||Merck Sharp & Dohme Corp.|No|Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|722|||Both|12 Years|N/A|No|||April 2015|April 27, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783211||148007|
NCT00783822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL24252.031.08|Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients|Behavioral and Psychosocial Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients: a Multicenter Study|TIME|The Netherlands Cancer Institute|No|Completed|November 2008|March 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|265|||Female|18 Years|N/A|No|||November 2012|November 8, 2012|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783822||147960|
NCT00784979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS_100109|Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation|Reduction of PRA (Panel Reactive Antibody) in Sensitized Patients Awaiting Live-Donor Renal Transplantation||Tampa General Hospital|No|Completed|January 2002|April 2012|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 4, 2008|Yes|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT00784979||147873|
NCT00784992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02025|A Comparison of Endonasal Dacryocystorhinostomy With and Without Silicone Tubes|A Randomised Controlled Trial to Compare Success and Complication Rates in Endonasal Dacryocystorhinostomy Surgery With and Without Silicone Tubes||University of British Columbia|No|Recruiting|November 2008|January 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 1, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00784992||147872|
NCT00784355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5200616|Laparoscopic Cholecystectomy in Idiopathic Pancreatitis|Does Laparoscopic Cholecystectomy Prevent Recurrence in Idiopathic Pancreatitis? A Prospective Multicentre Randomized Study||Kuopio University Hospital|No|Recruiting|January 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784355||147920|
NCT00784641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|496|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||February 13, 2013|October 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784641||147899|
NCT00784654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-326|Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17|A Phase III, Double-blind, Placebo-controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention- Deficit/Hyperactivity Disorder (ADHD)||Shire||Completed|January 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|276|||Both|6 Years|17 Years|No|||August 2012|May 12, 2015|November 3, 2008|Yes|Yes||No|July 16, 2012|https://clinicaltrials.gov/show/NCT00784654||147898|
NCT00784667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2008/03282|Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib|Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab (Erbitux) and Erlotinib (Tarceva) in Patients With Chemotherapy-refractory Colorectal Cancer|Dux|Austin Health|Yes|Active, not recruiting|October 2008|February 2011|Anticipated|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2008|November 29, 2010|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784667||147897|
NCT00785590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04300|Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower.||Sanofi||Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785590||147826|
NCT00775918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-312|Bioequivaelnce Study of Doxycycline Monohydrate 100mg Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Doxycycline Monohydrate 100 mg Tablets in Healthy Volunteers||Ranbaxy Inc.|Yes|Completed|June 2005|August 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775918||148560|
NCT00780481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061160|Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation|Characterization of Brachial Arterial t-PA Release, Vasodilator Function, and Vascular Compliance and Correlation With Fibrinolytic Balance, Oxidative Stress, and Inflammation Measures (SCCOR Project 1 Aim 3B)|P1A3B|Vanderbilt University|Yes|Recruiting|January 2007|May 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 11, 2009|October 24, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00780481||148212|
NCT00780494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI0002|Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma|A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma||Stanford University|Yes|Recruiting|February 2009|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||September 2012|September 3, 2012|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780494||148211|
NCT00780208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#16784|Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD|The Evaluation of the Safety and Efficacy of the Methylphenidate Patch in Former Stimulant Users With ADHD||Medical University of South Carolina|No|Completed|April 2007|February 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780208||148233|
NCT00780507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007096|Fecal Biomarker Study for Patients With Ulcerative Colitis|Fecal Biomarker Study for Patients From a Once Daily Study for Efficacy in a Ulcerative Colitis Maintenance Study||Warner Chilcott|No|Completed|August 2007|July 2009|Actual|July 2009|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|89|None Retained|Human feces protein biomarkers Enrollment is number of specimens rather than number of      subjects|Both|18 Years|N/A|No|Probability Sample|The population of ulcerative colitis patients willcome from clients within the United        States and are participants in the QDIEM Asacol study (2007021/NCT00505778)|May 2013|May 29, 2013|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780507||148210|
NCT00780832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB #4121|Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder|Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder||IWK Health Centre|No|Terminated|May 2008|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Female|N/A|N/A|No|||May 2013|February 23, 2016|October 27, 2008||No|Insufficient elligible patients available in a reasonable time frame.|No||https://clinicaltrials.gov/show/NCT00780832||148186|
NCT00776347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSK-08096|Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)|Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)||Osaka University|No|Completed|October 2008|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|24|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776347||148528|
NCT00776360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29/2008|The Effect of Oxytocin on the Gastric Emptying|The Effect of Oxytocin on Gastric Emptying in Patients With Gastro Paresis||Skane University Hospital|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776360||148527|
NCT00776659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991088|An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin|An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin||Pfizer|No|Terminated|December 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|||Female|18 Years|75 Years|No|Non-Probability Sample|Patients with early breast cancer receiving adjuvant therapy with Aromasin® will be        eligible.|September 2013|September 12, 2013|October 20, 2008||No|See termination reason in detailed description.|No|September 12, 2013|https://clinicaltrials.gov/show/NCT00776659||148504|Study was terminated due to slow enrollment and observational nature of the study. Low number of participants enrolled was not sufficient to conduct the planned analysis. Study was not terminated due to safety concerns.
NCT00776672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B025508|Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Fosinopril Sodium 40 mg Tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) With That of Monopril® in Healthy Adult Subjects Under Non-Fasting Conditions||Ranbaxy Inc.|Yes|Completed|October 2002|December 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776672||148503|
NCT00776945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0635|Feasibility and Functionality of fPAM Imaging in Melanoma|Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Characterization and Early Diagnosis of Melanoma|fPAM|Washington University School of Medicine|No|Terminated|January 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|Samples Without DNA|Tissue biopsies may be performed if locoregional recurrence validated by clinical      examination.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Stage I - III melanoma.|November 2013|June 5, 2015|October 20, 2008||No|no funding|No||https://clinicaltrials.gov/show/NCT00776945||148482|
NCT00777257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA21|Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine|Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine)||Sanofi|Yes|Completed|April 2005|September 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1345|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|October 21, 2008|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00777257||148458|
NCT00773318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-433|SPECT-CT Guided Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) in Prostate Cancer|SPECT-CT Guided Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) in Prostate Cancer||Lawson Health Research Institute|No|Terminated|April 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Male|18 Years|N/A|No|||March 2012|March 2, 2012|July 25, 2008||No|1 patient has been enrolled. No complications reported. The research team decided to terminate    the clinical trial due to insufficient patients' accrual.|No||https://clinicaltrials.gov/show/NCT00773318||148758|
NCT00773578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070201|Exhaled Nitric Oxide and Nasal Lavage Fluid|Impact of Environmental Tobacco Smoke on Exhaled Nitric Oxide and on Biomarkers of Nasal Inflammation in Atopic Asthmatic Children|NOLN|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2007|February 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|49|Samples Without DNA|Whole blood|Both|5 Years|16 Years|No|Non-Probability Sample|Atopic asthmatic children followed in the Asthma Center, Trousseau Hospital, Paris|February 2009|February 12, 2009|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773578||148738|
NCT00781716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0-Sep 10, 2008|Safety and Efficacy Study of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction (STEMI) and Analysis of Current Status of Emergency PCI Green Channel for STEMI Patients in China|Comparison of Safety and Efficacy of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction and Analysis of Current Status of Emergency PCI Green Channel for Patients With ST Elevation Myocardial Infarction in China|CREST-MI|Beijing Chao Yang Hospital|No|Not yet recruiting|October 2008|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1020|||Both|18 Years|75 Years|No|||October 2008|October 28, 2008|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781716||148121|
NCT00781729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG030448-01A1|Yoga for Kyphosis Trial|Phase 2 Study of Yoga for Excess Thoracic Curvature.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|September 2004|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|118|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2008|October 28, 2008|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781729||148120|
NCT00781976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV689-102|Antiviral Activity of AZD7295 in HCV Carriers|A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease||Arrow Therapeutics|Yes|Completed|November 2008|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||March 2010|March 30, 2010|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781976||148101|
NCT00782275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-184|Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma|A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 2009|January 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782275||148078|
NCT00782288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-003456-01|Phase II Study of Digitoxin to Treat Cystic Fibrosis|Phase II Study of Digitoxin to Treat Cystic Fibrosis||Johns Hopkins University|Yes|Active, not recruiting|August 2010|February 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|45 Years|No|||January 2016|January 21, 2016|October 29, 2008|No|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT00782288||148077|Steady states of digitoxin were not achieved in subjects until relatively late the in 28 day treatment period. This would suggest that it may require a much longer treatment course to meaningfully effect inflammation in the airways.
NCT00782925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.511|An Educational and Exercise Program as Secondary Prevention of Recurrent Lower Back Pain in Healthcare Workers|An Educational and Exercise Program as Secondary Prevention of Recurrent Lower Back Pain in Healthcare Workers: A Randomized, Controlled, 2-year Follow-up Study.|PRESLO|Hospices Civils de Lyon|Yes|Completed|October 2008|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|351|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782925||148029|
NCT00783224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04512|A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)|Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|September 2005|December 2005|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|351|||Both|16 Years|N/A|No|||May 2015|May 4, 2015|October 30, 2008|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00783224||148006|
NCT00783536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-102380|A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis|An Randomized, Open Label, Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate With DMARD Therapy in Subjects With Active Early Rheumatoid Arthritis|DOTAR|Wyeth is now a wholly owned subsidiary of Pfizer|No|Withdrawn|November 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|402|||Both|18 Years|80 Years|No|||June 2009|June 1, 2009|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00783536||147982|
NCT00783549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111596|A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.|A Study in Healthy Volunteers of Single Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin||GlaxoSmithKline|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 19, 2011|October 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783549||147981|
NCT00784693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091023|A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis|A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Pain Associated With Endometriosis||Pfizer|No|Terminated|December 2008|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|49 Years|No|||April 2011|April 22, 2011|November 3, 2008|Yes|Yes|Further recruitment into the study was ceased on 10th December 2009, not attributed to safety.    All patients recruited in the study completed all study visits.|No||https://clinicaltrials.gov/show/NCT00784693||147895|
NCT00774969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET/PK/01|Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease|Phase 1 Study to Evaluate the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri-Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease||S.L.A. Pharma AG|Yes|Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Basic Science|1||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 16, 2008||||No||https://clinicaltrials.gov/show/NCT00774969||148633|
NCT00775294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 08-0418|Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue|A Phase IV, Open Label Study in Healthy Male Subjects to Investigate the Extent of Maraviroc Exposure in Blood, Saliva, Seminal Fluid, and Rectal Mucosal Tissue Following Single and Multiple Dosing of Maraviroc||University of North Carolina, Chapel Hill|No|Completed|May 2008|March 2010|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||May 2011|May 11, 2011|October 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00775294||148608|
NCT00775307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0703|Adjuvant Pazopanib in Stage I NSCLC|A Randomized, Double-blind, Placebo-controlled Phase II-III Multi-centre Study to Evaluate the Effect of Adjuvant Pazopanib (GW786034) Versus Placebo on Post-surgical Disease-free Survival in Patients With Stage I Non Small Cell Lung Cancer and Tumor Size Equal or Inferior to 5 cm.||Intergroupe Francophone de Cancerologie Thoracique|Yes|Active, not recruiting|November 2008|December 2016|Anticipated|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775307||148607|
NCT00785343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-618-08|Study of Robot-assisted Arm Therapy for Acute Stroke Patients|Effectiveness of Adding Robotic Therapy to Conventional Therapy for Acute Stroke Patients With Upper Extremity Paresis||Kessler Foundation|Yes|Recruiting|September 2008|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|65 Years|84 Years|No|||December 2009|December 23, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785343||147845|
NCT00775931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2008-20|Allogeneic Transplantation For Severe Osteopetrosis|Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|August 2008|October 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|23|||Both|N/A|45 Years|No|||April 2015|April 22, 2015|October 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775931||148559|
NCT00779974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#27370|Electromyography Evaluation of Subscapularis Function After Total Shoulder Arthroplasty|Electromyography Evaluation of Subscapularis Function After Total Shoulder||Milton S. Hershey Medical Center|No|Completed|August 2008|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|45 Years|N/A|No|Non-Probability Sample|The subject population for this study consists of adult patients with a primary diagnosis        of osteoarthritis who have had a total shoulder arthroplasty preformed by the PI between        September 2003 through December 2007.|February 2015|February 25, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779974||148251|
NCT00780520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF-01-144/98|The Effect of Glutamine on Systemic Inflammation During Human Experimental Endotoxemia|The Effect of Glutamine Infusion on the Inflammatory Response and HSP-70 in BMNCs During Human Experimental||Rigshospitalet, Denmark|Yes|Completed|June 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2008|October 24, 2008|October 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780520||148209|
NCT00780845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-3438.0.000.140-08|AKIN Criteria: Acute Kidney Injury After On-Pump Coronary Artery Bypass Graft (CABG)|AKIN (Acute Kidney Injury Network): Acute Kidney Injury After On-Pump Coronary Artery Bypass Graft Surgery||Hospital de Base|No|Completed|January 2003|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|817|||Both|18 Years|N/A|No|Probability Sample|Groups AKI (-) and AKI (+) selected consecutively after admission in cardiac surgery        postoperative care unit|October 2008|November 3, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780845||148185|
NCT00780858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIMAD-JMS-09-2008-02|Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI|GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI|LP|IVI Madrid|No|Completed|October 2008|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|662|||Female|18 Years|40 Years|No|Non-Probability Sample|Healthy women with patent tubes who were undergoing IUI due to infertily of unknown        origin.|May 2015|May 5, 2015|October 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00780858||148184|
NCT00776373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 25406|Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies|A Phase I/II, Open-label Single Institution Study Evaluating Rapamycin in Combination With High-dose Etoposide and Cytarabine in Relapsed or Refractory Aggressive Lymphoid Malignancies|UPCC 25406|University of Pennsylvania|Yes|Terminated|January 2007|June 2010|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|65 Years|No|||September 2010|September 29, 2010|October 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776373||148526|
NCT00776971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070134A|Effect of Carbonated Soft Drinks on Appetite-Regulation|Carbonated Soft Drinks May Alter Appetite Sensation and Appetite-Regulating Hormone Level and Lead to Increased Energy Intake.||Aarhus University Hospital|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||August 2008|October 21, 2008|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00776971||148480|
NCT00776984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.417|Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma||Boehringer Ingelheim||Completed|October 2008|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|453|||Both|18 Years|75 Years|No|||September 2014|September 9, 2014|October 13, 2008||||No|July 20, 2012|https://clinicaltrials.gov/show/NCT00776984||148479|
NCT00776958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0067|Lynne Cohen Consortium Project: Multi-Center Database/Registry|Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project||M.D. Anderson Cancer Center|No|Completed|July 2008|||July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|176|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women seen at a member clinic of the Lynne Cohen Consortium having, or at high risk of        either ovarian or breast cancer.|July 2014|July 30, 2014|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776958||148481|
NCT00777283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008Khome_CP_001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2008|||||N/A|N/A|N/A||||||||||||||March 6, 2015|October 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777283||148456|
NCT00777296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-105|Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)|Phase 1b/2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.||Insmed Incorporated|Yes|Completed|February 2007|February 2010|Actual|February 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|6 Years|N/A|No|||May 2012|May 3, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00777296||148455|
NCT00773331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21904|A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.|An Open Label Randomized Controlled Study to Compare the Efficacy and Safety of Once Every 4 Weeks Administration of Mircera Versus Short-acting Epoetin for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia.||Hoffmann-La Roche||Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|281|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773331||148757|
NCT00773344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA200-001|Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin|Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin||Bristol-Myers Squibb|No|Completed|December 2005|August 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773344||148756|
NCT00773591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201 SB_2001|Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders|Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders (Snoring Study)|Snoring|Merz Pharmaceuticals GmbH|No|Withdrawn|March 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|October 15, 2008||No|The BfArM (CA)approved the trial in Nov 2008. However, the responsible EC refused approval in    March 2009.|No||https://clinicaltrials.gov/show/NCT00773591||148737|
NCT00773604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Private donor|Deep Brain Stimulation in Patients With Dystonia|Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) in Patients With Dystonia|STN DBS|University of California, San Francisco|No|Completed|June 2008|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|7 Years|80 Years|No|||August 2015|August 5, 2015|October 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773604||148736|
NCT00782301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001080|Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients|A Multicenter, Randomized, Open, Comparative Trial Of Maraviroc Versus Etravirine Each In Combination With Darunavir/Ritonavir And Raltegravir For The Treatment Of Antiretroviral-Experienced HIV-1 Subjects Co-Infected With Hepatitis C And/Or Hepatitis B||ViiV Healthcare|No|Withdrawn|March 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|N/A|No|||January 2012|January 18, 2012|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782301||148076|
NCT00782314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RSI-SYM-2008/1|Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice|Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice||AstraZeneca|No|Completed|April 2008|April 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|patients visiting pulmologist's office|July 2009|July 23, 2009|October 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782314||148075|
NCT00782639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP114|Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients|RECARE (REnal Safety Following the Intra-Arterial Administration of Iopamidol vs. Iodixanol During Coronary AngiogRaphy in DiabEtic Patients)|RECARE|Bracco Diagnostics, Inc|No|Terminated|March 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|23|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|October 28, 2008|No|Yes|This study was terminated early due to slow enrollment.|No|June 29, 2011|https://clinicaltrials.gov/show/NCT00782639||148050|This study was terminated early due to low enrollment. Only 1 patient in the Iopamiro-370 group had CIN (per all 3 definitions [first 3 secondary outcome measures] of CIN); therefore, no formal analyses were performed.
NCT00782652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOT43|The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients|The Effects of Nitric Oxide for Inhalation on Survival or the Need for Dialysis or a Right Ventricular Assistance Device (RVAD) in Right Ventricular Infarction Patients||INO Therapeutics|Yes|Terminated|March 2006|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||November 2008|November 4, 2008|October 29, 2008|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00782652||148049|
NCT00783835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013999|Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Multicenter Open Trial to Evaluate the Effectiveness and Quality of Life in Adults With Attention Deficit /Hyperactivity Disorder (ADHD) Treated With Long Acting Methylphenidate (CONCERTA)||Janssen-Cilag Farmaceutica Ltda.|No|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||July 2013|July 19, 2013|October 31, 2008|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00783835||147959|
NCT00784108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2008-6439|Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.|Non-contact Imaging Device (Camera) Can Help Improve Treatment for Patients With Basal Cell Carcinoma.||University of California, Irvine|Yes|Completed|October 2008|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784108||147939|
NCT00775281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_146_05|Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.|Mediators of Neurogenic Inflammation in the Urinary Tract as Key Factors in the Painful Bladder Syndrome / Interstitial Cystitis and Bladder Dysfunction||University Hospital Inselspital, Berne|No|Completed|October 2006|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|Samples With DNA|cold cut bladder biopsies|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|university hospital clinic|April 2010|April 25, 2010|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775281||148609|
NCT00775320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT- Brain Study|Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-flourothymidine PET|Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-fluorothymidine Positron Emission Tomography||University of Oklahoma|Yes|Terminated|October 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|35|Samples Without DNA|Tissue from brain tumor|Both|18 Years|N/A|No|Probability Sample|Subjects diagnosed with a brain tumor and to undergo surgery|September 2010|September 27, 2010|October 17, 2008|Yes|Yes|Study closed by institutional review board|No||https://clinicaltrials.gov/show/NCT00775320||148606|
NCT00785044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBG313|Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event|An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup||GE Healthcare|No|Completed|June 2008|February 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|471|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Failure Subjects who participated in MBG 311/312/312C.|April 2010|April 28, 2010|November 4, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00785044||147868|
NCT00775593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML1107|Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|AML1107|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|December 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|60 Years|N/A|No|||March 2015|March 15, 2015|October 17, 2008||No||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00775593||148585|
NCT00781313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23261|Disaster Preparedness Among Families Caring for Children With Diabetes|Pre-hurricane Disaster Preparedness: A Survey in Pediatric Type 1 Diabetes||Baylor College of Medicine|No|Completed|June 2008|October 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|115|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The target populations for our study are the families attending the Diabetes/ Endocrine        Clinic at Texas Children Hospital.|December 2010|December 7, 2010|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781313||148152|
NCT00779987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP261|Autologous Serum Efficacy Study in Patients With Severe Dry Eye|Autologous Serum Efficacy Study in Patients With Severe Dry Eye||University of Chile|Yes|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||October 2008|December 2, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779987||148250|
NCT00780221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSJQ-30725036|C-Reactive Protein (CRP) Gene Variants and Coronary Artery Disease in a Chinese Han Population|CRP Gene Variants and Coronary Artery Disease in a Chinese Han Population|CRP-Han|Fudan University|Yes|Recruiting|October 2008|December 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Blood sample will be examined and DNA variants be analyzed.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|in-hospital patients and community healthy individual|October 2008|October 24, 2008|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780221||148232|
NCT00780533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712088R|Changes in and Determinants of Movement Performance, Functional Status, and Health-Related Quality of Life After Stroke Rehabilitation|Changes in and Determinants of Movement Performance, Functional Status, and Health-Related Quality of Life After Stroke Rehabilitation||National Taiwan University Hospital||Active, not recruiting|August 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|50 Years|71 Years|No|Non-Probability Sample|a group of stroke patients|October 2008|October 24, 2008|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780533||148208|
NCT00776386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200805052R|Determinants and Practical Significance of Change in Motor Ability, Functional Performance, and HRQOL After Stroke|Determinants and Practical Significance of Change in Motor Ability, Functional Performance, and HRQOL After Distributed Constraint-Induced Therapy in Stroke||National Taiwan University Hospital||Active, not recruiting|July 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|a group of stroke patients|July 2008|October 20, 2008|October 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00776386||148525|
NCT00776685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adventure|Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse|Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals|Adventure|King's College London|Yes|Completed|May 2007|May 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|3190|||Both|13 Years|16 Years|Accepts Healthy Volunteers|||December 2010|June 24, 2011|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776685||148502|
NCT00776997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1802|LINX Reflux Management System Clinical Study Protocol|LINX Reflux Management System Clinical Study Protocol||Torax Medical Incorporated|No|Completed|November 2008|September 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|75 Years|No|||November 2013|November 22, 2013|October 20, 2008|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00776997||148478|
NCT00777335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO 016|Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer|A Randomized Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer||Translational Research in Oncology|No|Terminated|February 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||October 2015|October 27, 2015|October 21, 2008|Yes|Yes|Very low recruitement rate.|No|January 6, 2012|https://clinicaltrials.gov/show/NCT00777335||148452|The recruitment rate has shown to be very low worldwide. In total, 4 patients only were recruited, instead of the 132 initially targeted. Due to the very small number of subjects randomized in this study, only descriptive analyses have been made.
NCT00777322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC Ref: 07/H0721/94|T-Cat Laser & Cross-linking for Keratoconus|Pilot Study of Excimer Laser Topography-Computer Assisted Treatment (T-Cat) Combined With Corneal Collagen Cross-linking With Riboflavin and UV Light|T-Cat|Moorfields Eye Hospital NHS Foundation Trust|Yes|Completed|October 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|50 Years|No|||April 2009|July 20, 2011|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777322||148453|
NCT00773617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077571|Testing an Alternative Therapy for Bulimia Nervosa|Integrative Cognitive Affective Therapy for Bulimia Nervosa (ICAT)||Neuropsychiatric Research Institute, Fargo, North Dakota|Yes|Completed|March 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||April 2013|April 22, 2013|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773617||148735|
NCT00773864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-YC-254-CTIL|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community-Healthcare Workers|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community- the Role of Healthcare Workers|MOSAR|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2008|January 2014|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Healthcare employees) including: doctors, nurses, nurse aids, physical therapists,        dietitians, Janitors and other medical staff) who work in the rehabilitation center|October 2008|October 15, 2008|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00773864||148716|
NCT00773877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0342|Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients|Comparison of RNFL Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients||Yonsei University|Yes|Recruiting|October 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|||Both|10 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary open angle glaucoma|October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773877||148715|
NCT00774215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R07-09-016|Evaluation of the Avaulta Procedure for the Correction of Pelvic Organ Prolapse - Results at 1 Year|Retrospective Cohort of the Avaulta Vaginal Mesh Procedure as a Treatment of Pelvic Organ Prolapse||Atlantic Health System|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|103|||Female|18 Years|N/A|No|Non-Probability Sample|All patients who underwent surgery with the Avaulta synthetic mesh kit from 1/06 - 4/08.|October 2008|January 25, 2010|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774215||148689|
NCT00783237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03431|Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)|Onset of Action of Mometasone Furoate Nasal Spray vs. Placebo in Induced Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|December 2003|February 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|340|||Both|12 Years|N/A|No|||April 2015|April 15, 2015|October 30, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00783237||148005|
NCT00783562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP001032008|Preventive Intervention in Nursery School Teachers|Effectiveness of an Extension-Oriented Exercise Program in Preventing Neck and Low Back Complaints in Nursery School Teachers||University of Bologna|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|71|||Female|18 Years|70 Years|No|||October 2008|October 30, 2008|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783562||147980|
NCT00774423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040904|Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)|Multicentric, Randomized, Double-blind Study Versus Placebo, With Two Parallel Groups Treated to Evaluate the Efficacy and the Tolerance of Riluzole in Children and Young Adults (6 to 20 Years of Age) With SMA. (Type II and Type III)|ASIRI|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2006|December 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|6 Years|20 Years|No|||September 2011|February 13, 2013|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774423||148674|
NCT00774696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B025512|Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Under Non-Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|December 2002|February 2003|Actual|December 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2|||24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774696||148654|
NCT00774956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/432|Shoulder Training: Muscle Recruitment Patterns and the Effect of an Exercise Program|Shoulder Training: Muscle Recruitment Patterns and the Effect of an Exercise Program||University Ghent|No|Completed|September 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 19, 2012|September 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00774956||148634|
NCT00774982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1/13/6MP-02|Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients|Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease||Teva GTC|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|12|||Both|18 Years|50 Years|No|||July 2009|July 16, 2009|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774982||148632|
NCT00774995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110073|Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.|Study to Evaluate the Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With GSK Biologicals' Engerix™-B Vaccine, Approximately 20 Years Ago.||GlaxoSmithKline||Completed|November 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|49|||Both|19 Years|22 Years|Accepts Healthy Volunteers|||July 2011|October 2, 2014|October 16, 2008|Yes|Yes||No|May 26, 2011|https://clinicaltrials.gov/show/NCT00774995||148631|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).The table shows updated results following complete retesting and reanalysis
NCT00785616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-03086E|A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence|A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence||Montefiore Medical Center|No|Completed|September 2008|October 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|19 Years|N/A|No|||July 2010|July 22, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785616||147824|
NCT00775606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE-001|Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease|A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease||Rush University Medical Center|No|Terminated|October 2008|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|60 Years|No|||May 2014|May 30, 2014|October 17, 2008|Yes|Yes|Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.|No|June 28, 2013|https://clinicaltrials.gov/show/NCT00775606||148584|Study was terminated due to the slow recruitment and the small number of subjects.
NCT00775619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023/CARVE-12.5/03|Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|September 2003|December 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775619||148583|
NCT00781560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CCN-CRE-2008/1|Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal|A Cross-sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks|CRE NIS|AstraZeneca|No|Completed|October 2008|July 2009|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|2575|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who has been diagnosed as hypercholesterolemia and decided by physician to use        Crestor® 5mg or 10mg or other regimens (TLC or other lipid-lowering agents)|August 2009|August 6, 2009|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781560||148133|
NCT00780234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-005-08S|Pioglitazone for Lung Cancer Chemoprevention|Pioglitazone for Lung Cancer Chemoprevention||VA Office of Research and Development|Yes|Completed|August 2009|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|391|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780234||148231|
NCT00780884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015-08|Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients|Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients||HaEmek Medical Center, Israel|Yes|Completed|April 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|65 Years|No|||June 2015|June 21, 2015|October 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00780884||148183|
NCT00776399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-993 Mie-U-IRB|Radiofrequency Ablation in Resectable Colorectal Lung Metastasis|Radiofrequency Ablation in Resectable Colorectal Lung Metastasis: A Phase-II Clinical Trial||Mie University|Yes|Active, not recruiting|October 2008|August 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|20 Years|N/A|No|||July 2015|July 28, 2015|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776399||148524|
NCT00776698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21563|A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.|An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-squamous Non-small Cell Lung Cancer.||Hoffmann-La Roche||Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776698||148501|
NCT00776711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090012|Vaccine for Prevention of Bird Flu|An Open-Label, Randomized Phase I Study in Healthy Adults of 4 Prime-Boost Schedules With Monovalent Influenza Subunit Virion (H5N1) Vaccine (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine (VRC, NIAID)||National Institutes of Health Clinical Center (CC)||Completed|October 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|18 Years|60 Years|No|||January 2011|January 15, 2011|October 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00776711||148500|
NCT00778505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/21|Use of Closed-loop Anesthesia in Pediatric Patients|Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison in Pediatric Patients Between Manual Perfusion and Automated Perfusion|LoopPed|Hopital Foch|No|Terminated|October 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Both|6 Years|16 Years|No|||September 2013|September 10, 2013|October 22, 2008||No|difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT00778505||148363|
NCT00778518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-ARX201-701|Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).|Phase IIb Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).||Ambrx, Inc.|No|Completed|July 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|36|||Male|18 Years|30 Years|No|||October 2009|October 9, 2009|October 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00778518||148362|
NCT00777348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-00982-3256|To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol|Clinical Trial to Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol in Comparison to the Single Components and Placebo in Adults With Exercise Induced Asthma Randomised, Placebo-Controlled, Double-Blind, Crossover, Multicentre Study|AERIA|MEDA Pharma GmbH & Co. KG|Yes|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|65 Years|No|||April 2009|April 7, 2009|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777348||148451|
NCT00783315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|450|Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)|Practice-Based Opportunities for Weight Reduction Trial at Johns Hopkins|POWER|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|January 2008|||February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|390|||Both|21 Years|N/A|No|||April 2009|May 11, 2009|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783315||147999|
NCT00783614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC-002|Aspirin and Antiretroviral Therapy in HIV Infected Patients|The Effect of Aspirin and Antiretroviral Therapy on Cardiovascular Risk in HIV Infected Patients: A Pilot Study||Minneapolis Medical Research Foundation|No|Terminated|October 2008|June 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|22|||Both|18 Years|60 Years|No|||October 2012|October 3, 2012|October 31, 2008|Yes|Yes|Lack of funding|No|January 16, 2012|https://clinicaltrials.gov/show/NCT00783614||147976|
NCT00783900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5204006|Intravenous Administration of Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery|Intravenous Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery||Kuopio University Hospital|No|Completed|January 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|316|||Both|N/A|N/A|No|||November 2011|November 23, 2011|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783900||147955|
NCT00783913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090021|Using Transcranial Direct Current Stimulation (tDCS) to Enhance the Benefit of Movement Training in Stoke Patients|Enhancing the Beneficial Effects of Upper Extremity Visuomotor Training With tDCS||National Institutes of Health Clinical Center (CC)||Completed|October 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|85 Years|No|||October 2011|October 25, 2011|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783913||147954|
NCT00773838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-095|Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ)|An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma||Merck Sharp & Dohme Corp.|Yes|Completed|December 2008|April 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|143|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|October 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773838||148718|
NCT00774176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA DOH RFA-02-07-20|Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations|Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)|PA-SCOPE|Temple University|Yes|Completed|June 2004|May 2008|Actual|May 2008|Actual|N/A|Observational|N/A||3|Anticipated|1000|Samples With DNA|Ancillary studies collect blood specimens for gene expression and genetic factors.|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Phase 1: inpatients hospitalized for COPD exacerbations Phase 2: Moderate to severe COPD|October 2008|August 3, 2011|January 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00774176||148692|
NCT00774449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5108|Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation|Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation||Hannover Medical School|Yes|Recruiting|July 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|261|Samples Without DNA|bronchoalveolar lavage, transbronchial biopsies, blood samples|Both|18 Years|68 Years|No|Non-Probability Sample|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at        Hannover Medical School 6 months prior to inclusion|July 2009|July 19, 2011|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774449||148672|
NCT00774709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCP 08 / 20- 679|Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction|Ancillary Study of the Registry Karolinska-Rennes (KaRen) : Prospective Study of Dyssynchrony in Heart Failure With Preserved Ejection Fraction|KaRen|French Cardiology Society|Yes|Completed|October 2008|November 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Probability Sample|Patients presenting acutely of congestive heart failure and diagnosed according to current        ESC guidelines to have an heart failure with preserved ejection fraction (LV EF > or =        45%)|September 2013|September 27, 2013|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774709||148653|
NCT00784732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAV680A2202|A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber|A Randomized, Partially-blinded, Placebo-controlled, Two-way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model||Novartis|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|65 Years|No|||September 2010|September 1, 2010|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784732||147892|
NCT00785031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-00702-98-084 ZonMw|Internet Based Vascular Risk Factor Intervention and Self Management Study|Internet-based Vascular Risk Factor Management for Patients With Clinical Manifest Vascular Disease; a Randomized Controlled Trial|IRIS|UMC Utrecht|No|Completed|October 2008|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|80 Years|No|||June 2012|June 13, 2012|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785031||147869|
NCT00785629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNT001|A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD|A Double Blind Randomized Placebo Controlled Trial of Maintenance of Normal Serum Phosphorus in Chronic Kidney Disease (CKD)||Denver Nephrologists, P.C.|Yes|Completed|February 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|148|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|November 4, 2008|Yes|Yes||No|August 27, 2012|https://clinicaltrials.gov/show/NCT00785629||147823|Single center study; Modest size of study; pilot study not powered to detect differences among subgroups of actively treated patients
NCT00781573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dallas VA IRB #08-048|Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)|Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)|SCORE|North Texas Veterans Healthcare System|Yes|Active, not recruiting|September 2008|March 2014|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|21 Years|N/A|No|||November 2013|November 1, 2013|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781573||148132|
NCT00780546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808047R|Spatial Epidemiology of Tuberculosis (TB) Infection|Spatial Epidemiology of Tuberculosis Infection||National Taiwan University Hospital|Yes|Not yet recruiting|October 2008|July 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|NTUH patients|October 2008|October 24, 2008|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780546||148207|
NCT00780559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6017-R|Improving Neuropathy and Mobility in People With Early Diabetes|Improving Neuropathy and Mobility in Subjects With Early Diabetes|INMED|VA Office of Research and Development|No|Recruiting|November 2009|February 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|142|||Both|30 Years|80 Years|No|||February 2016|February 10, 2016|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780559||148206|
NCT00780897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040801|Premature Ovarian Failure (Genetic and Physiopathologic Analysis)|Premature Ovarian Failure : Genetic and Physiopathologic Analysis|GéNIOP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2005|March 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|87|Samples With DNA|One ovarian biopsy during the protocol to evaluate ovocytes number and transcriptome      analysis.|Female|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|POF patients & controls|October 2008|October 27, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780897||148182|
NCT00777673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE 01-08|Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.|Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer||University of Tennessee Cancer Institute|Yes|Active, not recruiting|October 2008|October 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2013|January 3, 2013|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777673||148427|
NCT00777985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0722|Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea|Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan|BOSAS|University Hospital, Grenoble|Yes|Completed|December 2007|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|80 Years|No|||May 2014|May 20, 2014|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00777985||148403|
NCT00778219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808060R|Comparison of Heart Rate Variability Among Tracheal Intubation Methods|Comparison of Autonomic Stimulation Among Different Tracheal Intubation Methods -- Using Non-invasive Heart Rate Variability Spectral Power as an Indicator||National Taiwan University Hospital|Yes|Completed|October 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|65 Years|No|Probability Sample|60 ASA class I-II patients , age 18-65, scheduled for surgery and need general anesthesia        with tracheal intubation|December 2009|December 14, 2009|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778219||148385|
NCT00778232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-826|Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Non-Fasting Conditions||Ranbaxy Inc.|Yes|Completed|October 2002|November 2002|Actual|November 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778232||148384|
NCT00782964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2007/4|Antidepressant Incomplete Response Depression|Assessment of Therapeutic Strategies in Unipolar Depression With Incomplete Response to a Antidepressant Treatment in Regular Clinical Practicing.|DRIA|AstraZeneca|No|Completed|October 2008|November 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|364|||Both|18 Years|65 Years|No|Non-Probability Sample|Outpatient with major depressive disorder, who has a change in pharmacological therapeutic        plan after an incomplete response or intolerance to a treatment with an adecuate dosage of        an antidepresant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent)        for at least 6 weeks.|December 2009|December 23, 2009|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782964||148026|
NCT00783328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471005|A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors|A Clinical Phase 1 Safety And Pharmacokinetic/Pharmacodynamic Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors||Pfizer|Yes|Completed|November 2008|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|75 Years|No|||June 2011|June 22, 2011|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00783328||147998|
NCT00783653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 10/07|Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years|Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age||Universitätsklinikum Hamburg-Eppendorf|No|Completed|August 2008|||July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|60 Years|N/A|No|||September 2013|September 20, 2013|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783653||147973|
NCT00783627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 050310|Sickle Cell Disease and Endothelial Progenitor Cells (EPCs)|Evaluation of Angiogenic Potential in Sickle Cell Disease. CARACTERIZATION of Endothelial Progenitor Cells|DREPANOPEC|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2006|November 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|66|Samples With DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sickle cell patient : followed by the participating center. Healthy volunteers : matched        on sex, age and BMI with the patients.|February 2011|February 22, 2011|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00783627||147975|
NCT00783640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04371|Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Femina Pocket BR.||Sanofi||Completed|October 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|27|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783640||147974|
NCT00783926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810801|Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)|Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years||Nanotherapeutics, Inc.|Yes|Completed|July 2008|July 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|422|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|October 7, 2015|October 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783926||147953|
NCT00783939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04307|Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.|Safety Dermatological Evaluation: Vaginal Mucous Irritation - Product Tested: Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid).||Sanofi||Completed|September 2008|||September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Female|10 Years|20 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783939||147952|
NCT00773851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_11/05|Transfacial Sutures Versus Stapler for Mesh Fixation in Laparoscopic Ventral Hernia Repair|Mesh Shrinkage Following Transfacial Suturing Versus Stapler for Mesh Fixation in Laparoscopic Ventral Hernia Repair: a Prospective, Randomised Blinded Study||University Hospital Inselspital, Berne|No|Completed|April 2005|October 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773851||148717|
NCT00774189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020/CLARI-250/03|Bioequivalence Study of Clarithromycin 250mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Clarithromycin Formulations, Comparing Clarithromycin 250 mg Tablets of Ranbaxy Laboratories With Biaxin 250 mg Tablets of Abbott Laboratories in Healthy, Adult, Human Subjects Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|July 2003|November 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774189||148691|
NCT00774202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0301005964|Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP|A Randomized Trial Comparing Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment||Weill Medical College of Cornell University|Yes|Completed|November 2003|February 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|N/A|2||||||Both|12 Years|N/A|No|||December 2011|December 22, 2011|October 15, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00774202||148690|
NCT00774436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-118|Study of Focal Cryoablation in Low-Risk Prostate Cancer|A Phase II Study of Focal Cryoablation in Low-Risk Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|21 Years|N/A|No|||November 2015|November 2, 2015|October 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00774436||148673|
NCT00774735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111405|GSK1349572 Drug Interaction Study With Protease Inhibitors|A Phase I, Open Label, Randomized, Two Period, One-way Two Sequence Crossover Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING111405).||GlaxoSmithKline|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 9, 2010|October 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00774735||148651|
NCT00784134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVH06|Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III|Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III|CLEAR III|Johns Hopkins University|Yes|Completed|July 2009|January 2016|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|80 Years|No|||January 2016|January 21, 2016|October 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784134||147937|
NCT00784407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18858|Thyroid Surgery With the New Harmonic Scalpel: a Prospective Randomized Study|Thyroid Surgery With the New Harmonic Scalpel: a Prospective Randomized Study||Hippocration General Hospital|Yes|Completed|February 2008|October 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|N/A|N/A|No|||October 2008|November 3, 2008|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784407||147916|
NCT00784420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271019|Drug Interaction Study Between Raltegravir And UK-453,061|Open-Label, Randomized, 3-Way Crossover Study To Estimate The Interaction Between Multiple Dose Raltegravir And UK-453,061 In Healthy Subjects||Pfizer|No|Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2008|November 17, 2008|September 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00784420||147915|
NCT00785395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-4329-2008|Up-Down Oxytocin Infusion|Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery||IWK Health Centre|Yes|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Actual|40|||Female|18 Years|N/A|No|||November 2008|November 1, 2011|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00785395||147841|
NCT00785369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LI058054|In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis|In Vivo Reflectance Confocal Microscopy for Pigmented Lesion Diagnosis: A Multi-center Study||Lucid, Inc.|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|441|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785369||147843|
NCT00785382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-4298-2008|Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery|A Randomized, Placebo Controlled Trial of Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery||IWK Health Centre|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|N/A|65 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785382||147842|
NCT00781001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-SD-118|Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy|Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy||Center for Medicinal Cannabis Research|Yes|Completed|July 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|17|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|October 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00781001||148174|
NCT00781326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH067710-01|Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression|Treatment of Depression Occurring in the Setting of Cerebrovascular Risk -- A Pilot Study||University of Pittsburgh|No|Terminated|August 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|50 Years|N/A|No|||January 2016|January 8, 2016|October 27, 2008||No|Final cost of study medication was significantly greater than initial estimate,|No||https://clinicaltrials.gov/show/NCT00781326||148151|
NCT00782093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M200|A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration|||Ophthotech Corporation|No|Completed|October 2008|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|50 Years|N/A|No|||June 2012|October 11, 2012|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782093||148092|
NCT00782106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160602|Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously|Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)||Baxter Healthcare Corporation|No|Completed|December 2006|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|16 Years|N/A|No|||October 2010|October 28, 2010|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782106||148091|
NCT00780572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAB 05-224|Implementation of Real-time ADE Surveillance and Decision Support|Implementation of Real-Time ADE Surveillance and Decision Support|VA ADE|VA Office of Research and Development|No|Completed|December 2008|March 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|595|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|October 24, 2008||No||No|October 15, 2015|https://clinicaltrials.gov/show/NCT00780572||148205|
NCT00776724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803006M|Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm|A Randomized Phase III Study of Docetaxel/ Epirubicin Versus Tailored Regimens as Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm|TaiNAC|National Taiwan University Hospital|Yes|Recruiting|November 2008|May 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|272|||Female|20 Years|N/A|No|||November 2012|November 15, 2012|October 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00776724||148499|
NCT00777361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3690C00017|Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers|An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers With Different CYP2D6 Genotype|MB|AstraZeneca|No|Terminated|October 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|9|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777361||148450|
NCT00777647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070134B|Effect of Carbonated Soft Drinks on the Body Weight|Effect of Carbonated Soft Drinks on Body Weight, Fat Distribution and Metabolic Risk Factors||Aarhus University Hospital|No|Completed|May 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|47|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777647||148428|
NCT00777699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11442|Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of XL765 in Combination With Erlotinib in Subjects With Solid Tumors||Sanofi||Completed|August 2008|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|October 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00777699||148425|
NCT00783575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 02/142|Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease|Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease||Medical College of Wisconsin|Yes|Withdrawn|October 2002|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|0|Samples With DNA|DNA extraction, serology|Both|N/A|18 Years|No|Non-Probability Sample|Children from Southeast Wisconsin diagnosed with Inflammatory Bowel Disease at Children's        Hospital of Wisconsin and their biological parents.|August 2015|August 21, 2015|October 29, 2008||No|PI has left institution|No||https://clinicaltrials.gov/show/NCT00783575||147979|
NCT00784121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04366|Dermacyd Breeze (Lactic Acid) Pocket BR - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Breeze Pocket BR.||Sanofi||Completed|October 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|54|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784121||147938|
NCT00783666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04309|Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINBACK Tangerine Mix||Sanofi||Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783666||147972|
NCT00783952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000420|Validation of Mixed Venous Blood Oxygen Saturation Obtained With a Novel Mathematical Equation|Validation of Mixed Venous Blood Oxygen Saturation Obtained With a Novel Mathematical Equation Using Arterial Oxygen Saturation and Various Local Tissue Oxygen Saturations.||Massachusetts General Hospital|No|Terminated|November 2008|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 30, 2008||No|Inability to recruit subjects|No||https://clinicaltrials.gov/show/NCT00783952||147951|
NCT00784186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.3.1|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial||Gynuity Health Projects|No|Completed|August 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784186||147933|
NCT00784459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0405|The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics|Costimulation Inhibition in Asthma|CIA|Washington University School of Medicine|No|Completed|October 2008|February 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|50 Years|No|||December 2013|December 16, 2013|November 3, 2008|Yes|Yes||No|June 11, 2013|https://clinicaltrials.gov/show/NCT00784459||147912|
NCT00784472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN 1|Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL|Visceral Pain Originating From the Upper Urinary Tract - a Randomized Controlled Trial on the Effect of Morphine and Oxycodone in Patients Undergoing Percutaneous Nephrolithotomy (PCNL)||Fredericia Hosptial|Yes|Completed|December 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00784472||147911|
NCT00774462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051204|Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis|FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis|FORCE|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||December 2007|December 10, 2012|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774462||148671|
NCT00774722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET/02|A Randomised Controlled Trial of the Use of Topical Metronidazole (10%) to Reduce Pain After Haemorrhoidectomy|Phase 2 Study Evaluation of Topical 10% Metronidazole Ointment for the Reduction of Pain After Haemorrhoidectomy||S.L.A. Pharma AG|No|Completed|September 2006|March 2008|Actual|March 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774722||148652|
NCT00775008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0430-02|Media Effects Study on Health-Related Content|||University of North Carolina, Chapel Hill|No|Completed|October 2008|November 2008|Actual|October 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 2, 2009|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00775008||148630|
NCT00784433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR478108CTIL|The CArdiovasCulAr Diabetes & Ethanol (CASCADE) Trial|Cardiovascular and Metabolic Effects of Moderate Alcohol Consumption in Type 2 Diabetes|CASCADE|Ben-Gurion University of the Negev|Yes|Active, not recruiting|May 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|200|||Both|40 Years|75 Years|No|||August 2009|February 8, 2012|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784433||147914|
NCT00784745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-087|Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect|Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect||University Hospital, Gentofte, Copenhagen|No|Completed|November 2008|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784745||147891|
NCT00785057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2008/4|Retrospective Treatment Pattern Survey for the Patient With and Without History of Stroke|A Retrospective, Multi Centre, Non-interventional, Observational Study to Compare Treatment Pattern and Factors That Affect BP Control in Patients With and Without Stroke|SAPIENCE|AstraZeneca|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Hypertension outpatients coming to the Neurology Department|December 2010|December 2, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785057||147867|
NCT00785070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSPECT|Pre and Post Orthopedic Surgery Sleep and Cardiac Testing (PROSPECT)|Pre and Post Orthopedic Surgery Sleep and Cardiac Testing (PROSPECT)|PROSPECT|Memorial Health System|No|Completed|April 2008|February 2009|Actual|January 2009|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Orthopedic Total Hip or Knee Joint Replacement|February 2009|February 5, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785070||147866|
NCT00781352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|efno1008|Nitrous Oxide and Risk of Cancer Recurrence After Colorectal Surgery: A Randomized, Blinded Study|Nitrous Oxide Does Not Increase the Risk of Cancer Recurrence After Colorectal Surgery: A Randomized, Blinded Study||Outcomes Research Consortium|No|Completed|November 1998|March 2007|Actual|November 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|408|||Both|18 Years|80 Years|No|||October 2008|October 28, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781352||148149|
NCT00781027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-081|Fuchs' Torsional Phaco Study|Fuchs' Endothelial Dystrophy and Cataract Surgery: Can Torsional Phacoemulsification Decrease the Risk for Corneal Decompensation||Maastricht University Medical Center|No|Completed|December 2008|||May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|95 Years|No|||May 2010|May 19, 2010|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781027||148173|
NCT00781339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0803|Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients|A Phase IIa Open Label Study to Evaluate the Safety and Antimicrobial Effects of NVC-422 on Bacteriuria in Chronically Catheterized Subjects||NovaBay Pharmaceuticals, Inc.|No|Completed|October 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|October 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781339||148150|
NCT00782496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2008-09|Glucose Meter Study|A New Contour Blood Glucose Monitoring System With High Frequency Testing Patients||Ascensia Diabetes Care|No|Completed|November 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Both|21 Years|N/A|No|||January 2016|January 29, 2016|October 28, 2008|Yes|Yes||No|September 27, 2010|https://clinicaltrials.gov/show/NCT00782496||148061|
NCT00777010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-09-17-01|Energy Metabolism and Cognitive Aging|Energy Metabolism and Cognitive Aging||University of Cincinnati|No|Recruiting|September 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|N/A|No|||November 2015|November 30, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777010||148477|
NCT00777023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREEZE 2|Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women||Depomed|No|Completed|October 2008|October 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|565|||Female|18 Years|70 Years|No|||February 2012|February 21, 2012|October 21, 2008|Yes|Yes||No|January 16, 2012|https://clinicaltrials.gov/show/NCT00777023||148476|
NCT00780949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071206|Immunological Consequences of CARD15/NOD2 Mutations in Crohn's Disease|Immunological Consequences of CARD15/NOD2 Mutations in Crohn's Disease|PLAC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|110|||Both|5 Years|65 Years|No|||July 2012|August 2, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780949||148178|
NCT00776737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090002|Studies of Measures of Attention|Studies of Measures of Attention||National Institutes of Health Clinical Center (CC)||Completed|October 2008|January 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|36|||Both|6 Years|60 Years|No|||January 2011|January 15, 2011|October 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00776737||148498|
NCT00776750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2394|Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients|Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients||Universitaire Ziekenhuizen Leuven|No|Completed|September 2003|May 2004||May 2004||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|407|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776750||148497|
NCT00777387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oocyte cryopreservation|Randomized Controlled Trial Comparing Slow-freezing to Vitrification of Oocytes|Cryopreservation of Oocytes: A Randomized Controlled Trial Comparing Slow-freezing to Vitrification||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Terminated|August 2008|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|October 20, 2008||No|Studies emerged that demonstrated the superiority of vitrification|No||https://clinicaltrials.gov/show/NCT00777387||148448|
NCT00782704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 30-2008|Development and Validation of a Morbidity Index for Complications in Minor and Major Abdominal Surgery|Development and Validation of a Morbidity Index for Complications in Minor and Major Abdominal Surgery||University of Zurich|Yes|Completed|October 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|219|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients: all patients of the Department of Visceral and Transplantation Surgery of the        University Hospital of Zurich Nurses: Staff nurses of the University Hospital of Zurich        Physicians: from different units of the University Hospital of Zurich (Visceral-,        Thoracic, Cardiovascular Surgery, Anesthesiology, Intensiv Care Unit, Urology)|February 2015|February 9, 2015|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782704||148046|
NCT00782717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-43|A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients|A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients||Alcon Research|No|Completed|November 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|263|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|October 29, 2008|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00782717||148045|
NCT00785005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0849|What Makes Exercise Feel More Difficult to Women With and Without Type 2 Diabetes|Exercise-related Perceived Rate of Exertion at Steady-State Workloads (ExPRESS) in Type 2 Diabetes Mellitus|ExPRESS|University of Colorado, Denver|Yes|Completed|May 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|99|Samples Without DNA|During the first visit, blood will be drawn for measurements of overall health (complete      blood count and comprehensive metabolic panel), glucose and insulin levels, lipid levels,      plasma FSH concentration, and HbA1C.      On two separate visits, blood samples will be drawn from a warmed IV site to measure muscle      metabolites which change with exercise (e.g., glucose, calcium, lactate, H+, K+, and HCO3-)      and may be associated with muscle pain or fatigue.|Female|50 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Twenty-five sedentary post-menopausal women with uncomplicated T2DM (of duration ≤ 10        years) between the ages of 50-70 and twenty-five sedentary non-diabetic post-menopausal        women between the ages of 50-70 will be recruited.|April 2012|April 17, 2012|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00785005||147871|
NCT00785018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VECTOR study 2008/197|In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia|In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia|VECTOR|Radboud University|No|Completed|November 2008|August 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2009|April 21, 2011|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785018||147870|
NCT00780663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3-07-003|Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma|A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma||Cylene Pharmaceuticals|No|Completed|October 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780663||148198|
NCT00783965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000618240|Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back|A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome||Children's Hospital & Research Center Oakland|Yes|Completed|July 2004|January 2014|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|October 31, 2008|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT00783965||147950|Non-compliance and large drop-out rates leading to small numbers of data analyzed.
NCT00784485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xolair CT|Non-invasive Measures of Effects of Xolair in Asthma|Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Treatment With Omalizumab||University of California, Los Angeles|No|Terminated|February 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Female|18 Years|65 Years|No|||March 2011|March 8, 2011|November 3, 2008|Yes|Yes|Terminated due to poor enrollment.|No||https://clinicaltrials.gov/show/NCT00784485||147910|
NCT00784498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-PH-0272-CTIL|Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department|Procedural Sedation for Painful Orthopedic Manipulations With Propofol vs. Midazolam/Ketamine in the Adult Emergency Department||Tel-Aviv Sourasky Medical Center|Yes|Completed|November 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2008|July 31, 2010|November 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00784498||147909|
NCT00784784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0189-A|Zanamivir Versus Trivalent Split Virus Influenza Vaccine|A Pilot Study for a Randomized Controlled Trial to Compare Trivalent Split Virus Influenza Vaccine to Seasonal Antiviral Prophylaxis in Healthcare and Other Healthy Adults: Assessment of Zanamivir Versus Vaccine (Stop-Flu-2)|Stop-Flu-2|Mount Sinai Hospital, Canada|No|Completed|November 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|November 3, 2008||No||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00784784||147888|Pilot study: Limited number of participants
NCT00784147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMB-202 Amendment 2|Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1|A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1(Amended to 24-Weeks)|TMB-202|TaiMed Biologics Inc.|Yes|Completed|August 2008|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|70 Years|No|||April 2014|April 17, 2014|October 30, 2008|Yes|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT00784147||147936|ACTG Adherence Questionnaire data were incomplete due to insufficient data collection methods. No clinically meaningful information was gained upon review of these results.
NCT00784446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO KRK 0205|First-line Therapy of Stage IV Colorectal Cancer|A Phase I/II Study of Capecitabine/Oxaliplatin (XELOX) in Combination With Bevacizumab and Imatinib as First-line Treatment of Patients With Stage IV Colorectal Cancer||University of Cologne|Yes|Completed|April 2008|December 2012|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784446||147913|
NCT00784758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fenzian|Fenzian Asthma Multicenter Outcomes Study|Effect of Fenzian™ Treatment on Symptoms, Pulmonary Function and Albuterol/Salbutamol Use in Patients With Mild to Moderate Persistent Asthma: A Multicenter, Sham-Controlled Clinical Trial|FAMOUS|University of California, Los Angeles|No|Active, not recruiting|February 2009|July 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|12 Years|80 Years|No|||March 2011|March 8, 2011|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784758||147890|
NCT00785083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2102|A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma|A Double-Blind, Randomized, Placebo-Controlled, Parallel, Time-Lagged, Ascending, Multi-Centre, Multiple-Dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma||Novartis|No|Completed|September 2008|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||May 2009|May 8, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785083||147865|
NCT00785096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30-2008|How do Patients, Nurses and Physicians Perceive Negative Postoperative Events?|Perception of Surgical Complications - Agreements Among Patients, Nurses and Physicians||University of Zurich|Yes|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|615|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who will admit for a minor or major surgical procedure Nurses from the University        Hospital of Zurich Different physicians of the University Hospital of Zurich (surgeons,        anesthesia, urologist ans ICU-care specialists)and other institutions.|February 2015|February 9, 2015|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785096||147864|
NCT00781599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11500|Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers|Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers||University of Kansas Medical Center|No|Completed|October 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||June 2012|June 27, 2012|October 27, 2008|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00781599||148130|
NCT00781612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM4529g|An Extension Study of Trastuzuma Emtansine in Patients Previously Treated With Trastuzuma Emtansine|An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 (T-DM1) Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Treated With the Equivalent T-DM1 Regimen in a Genentech and/or F. Hoffmann-La Roche Ltd.-Sponsored T-DM1 Study||Genentech, Inc.||Enrolling by invitation|October 2008|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781612||148129|
NCT00781586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12956|Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.|A Randomized, Single Center, Double-blind, Three-way Crossover Trial to Evaluate the Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.||Bayer|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|22|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 20, 2013|October 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00781586||148131|
NCT00781833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMF CP-005|Use of Implanted Microstimulators for Decreasing Spasticity and Improving Motion Following Spinal Cord Injury|Case Study Testing the Use of Implanted Microstimulators for Decreasing Spasticity and Improving Motion Following Spinal Cord Injury||The Alfred E. Mann Foundation for Scientific Research|No|Terminated|October 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|55 Years|55 Years|No|||January 2012|January 19, 2012|October 27, 2008|No|Yes|Participation of single subject enrolled was terminated.|No||https://clinicaltrials.gov/show/NCT00781833||148112|
NCT00782145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613668|A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families|HSCT-CHESS to Enhance Hematopoietic Transplant Recovery||Tufts Medical Center|Yes|Completed|June 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Actual|198|||Both|2 Months|18 Years|No|||July 2011|July 11, 2011|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782145||148088|
NCT00782158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909016|Hepatitis B and HIV Co-Infection in Patients in Uganda|Hepatitis B and HIV Co-Infection in Uganda||National Institutes of Health Clinical Center (CC)||Completed|October 2008|||||N/A|Observational|N/A|||Anticipated|11000|||Both|18 Years|99 Years|No|||January 2016|February 12, 2016|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782158||148087|
NCT00780091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2005/04|Optimisation of Monitoring for Clinical Research Studies|Evaluation of Efficacy and Cost of Two Monitoring Strategies for Public Clinical Research - OPTIMON: Optimisation of Monitoring for Clinical Research Studies|OPTIMON|University Hospital, Bordeaux|Yes|Completed|May 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1800|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All type of patients enrolled in the eligible studies|August 2010|August 11, 2010|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00780091||148242|
NCT00777075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B VP2.A-7140-00-37/4020796|L-Arginine and Erectile Dysfunction|Oral Administration of L-Arginine in Patients With Erectile Dysfunction||Hannover Medical School|No|Completed|July 2003|November 2005||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||57|||Male|20 Years|65 Years|No|||October 2008|October 21, 2008|October 21, 2008||||No||https://clinicaltrials.gov/show/NCT00777075||148472|
NCT00777088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVPUFS0398|Pipeline for Uncoilable or Failed Aneurysms|Pipeline for Uncoilable or Failed Aneurysms|PUFS|ev3|No|Active, not recruiting|October 2008|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|21 Years|75 Years|No|||June 2015|June 15, 2015|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777088||148471|
NCT00782379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617648|Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer|A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies||Northside Hospital, Inc.|No|Completed|October 2008|April 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|No|||March 2013|October 28, 2013|October 29, 2008|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00782379||148070|
NCT00783250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|350|Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effect of Bronchodilators on Respiratory Mechanics in COPD Patients With Poor Reversibility||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Terminated|September 2008|July 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|85 Years|No|||July 2012|July 16, 2012|October 30, 2008||No|Problems with data collection|No||https://clinicaltrials.gov/show/NCT00783250||148004|
NCT00780676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0574|Personalized Treatment Selection for Metastatic Breast Cancer|Personalized Treatment Selection for Metastatic Breast Cancer||M.D. Anderson Cancer Center|No|Terminated|June 2009|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|97|||Female|18 Years|N/A|No|||July 2015|July 16, 2015|October 24, 2008|Yes|Yes|Closed early for futility.|No|June 10, 2015|https://clinicaltrials.gov/show/NCT00780676||148197|Study terminated according to early stopping rules.
NCT00780702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908426|Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients|Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients||National Institutes of Health Clinical Center (CC)||Completed|May 2008|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2014|October 30, 2015|October 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780702||148196|
NCT00784537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL-HD0801|High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients|Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients|HD0801|Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|September 2008|January 2016|Anticipated|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|520|||Both|18 Years|70 Years|No|||January 2016|January 25, 2016|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784537||147906|
NCT00784199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-04a|Validating PROMIS Instruments in Depression|Validating PROMIS Instruments in Depression||University of Pittsburgh|No|Completed|June 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|No|Non-Probability Sample|Adults who have started treatment for an episode of major depressive disorder in the last        4 months at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA. WPIC houses        the Department of Psychiatry at the University of Pittsburgh Medical Center (UPMC) and        serves as the flagship for the UPMC Behavioral Health Network, the psychiatric specialty        division of the UPMC Health System. Each year, WPIC provides more than 350,000 patient        contacts in its ambulatory care sites.|May 2013|May 13, 2013|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784199||147932|
NCT00784511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8095|Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans|Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans||Tufts University|No|Completed|July 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|40 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 13, 2014|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784511||147908|
NCT00784524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007LS094|Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca|A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer||Masonic Cancer Center, University of Minnesota|Yes|Terminated|September 2008|December 2015|Anticipated|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|N/A|No|||April 2015|April 10, 2015|November 1, 2008|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00784524||147907|
NCT00784160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04308|Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid)- Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINBACK Tangerine Mix.||Sanofi||Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|53|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784160||147935|
NCT00784173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unique protocol|Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome|Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome||Pontificia Universidade Catolica de Sao Paulo|No|Completed|January 2007|June 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Male|N/A|N/A|No|Non-Probability Sample|Children with velocardiofacial syndrome|October 2008|October 31, 2008|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784173||147934|
NCT00785109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin K Study|Vitamin K Supplement for Inhibition of the Progress in Aortic Valve Calcification|Vitamin K Containing Nutritional Supplement for Activation of Matrix-GIa-proteins (MGP) and Inhibition of Aortic Valve Calcification Process|08-002|RWTH Aachen University|No|Completed|January 2010|August 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|50 Years|N/A|No|||September 2015|September 22, 2015|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785109||147863|
NCT00785408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFA104|Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects||AstraZeneca|No|Completed|December 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|273|||Both|18 Years|65 Years|No|||December 2014|January 16, 2015|November 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785408||147840|
NCT00781040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5101409|Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients|Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients||Kuopio University Hospital|No|Recruiting|December 2006|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|137|||Both|18 Years|70 Years|No|Probability Sample|Neutropenic patients in haematology ward having neutropenic fever with or without severe        sepsis|March 2015|March 10, 2015|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781040||148172|
NCT00781053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD003-P144-08|Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study|Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study With P144 Topical Adminsitration for Skin Fibrosis in Patients With Systemic Sclerosis||ISDIN|No|Completed|July 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|65 Years|No|||February 2013|February 8, 2013|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00781053||148171|
NCT00781378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001BA703B13|Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China|Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China||Beijing Chao Yang Hospital|Yes|Completed|June 2002|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|75 Years|No|||October 2008|October 28, 2008|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781378||148147|
NCT00781846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-010|Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)|A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers||Merck Sharp & Dohme Corp.|No|Completed|October 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|October 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00781846||148111|
NCT00781859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-006|Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.|A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion||ThromboGenics|Yes|Completed|December 2008|April 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|326|||Both|18 Years|N/A|No|||April 2014|December 2, 2014|October 28, 2008|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00781859||148110|
NCT00782119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0230|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2008|||||N/A|N/A|N/A||||||||||||||October 29, 2008|October 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782119||148090|
NCT00782132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 06-248|Access to Infertility Services: Clinic Perspective|Access to Infertility Services in Ontario for Couples in Which One or Both Partners is HIV-Positive||St. Michael's Hospital, Toronto|No|Completed|November 2006|August 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|23|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ontario clinics offering advanced reproductive/infertility services|October 2008|November 3, 2008|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782132||148089|
NCT00781872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS22MSC-HMO-CTIL|Mesenchymal Stem Cells for the Treatment of MS|Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS)||Hadassah Medical Organization|No|Active, not recruiting|October 2006|||December 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|35 Years|65 Years|No|||October 2008|October 28, 2008|October 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781872||148109|
NCT00782847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiaNe-Studie|Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy|A Prospective Controlled Randomized Multicenter Trial to Evaluate the Effect of a Structurized Multifactorial Behavior Modifying Consultation and Support Programme DiaNe for People With Diabetic Nephropathy|DiaNe|DiaNe HCM GmbH|No|Completed|July 2004|January 2007|Actual|January 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|125|||Both|18 Years|80 Years|No|||October 2008|October 30, 2008|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782847||148035|
NCT00780624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCR2008053|Nasal Intermittent Positive Pressure Ventilation In Newborn Infants With Respiratory Distress Syndrome|Nasal Intermittent Positive Pressure Ventilation In Newborn Infants With Respiratory Distress Syndrome||Third Military Medical University|Yes|Recruiting|January 2008|December 2012|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|28 Days|No|||December 2012|December 17, 2012|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780624||148201|
NCT00780650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044873|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine||University of Maryland|Yes|Recruiting|May 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780650||148199|
NCT00780975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-B-011-02|A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer|A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..||PharmaMar|No|Terminated|February 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2010|October 27, 2014|October 27, 2008|Yes|Yes|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00780975||148176|
NCT00780988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09112008-1298|Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer|A Pilot Study to Assess the Safety and Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination Prior to Autologous Hematopoietic and Immune Cell Rescue in Metastatic Colorectal Cancer||Stanford University||Withdrawn||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 21, 2012|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780988||148175|
NCT00776529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA06-01|Combination of Strength and Sensorimotor Training|Randomized Controlled Trial of Two Combinations of Strength and Sensorimotor Training: Effects on Strength, Power and Balance||University of Applied Sciences of Western Switzerland|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 28, 2009|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776529||148514|
NCT00784849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU #6169|Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)|Pilot Trial to Determine the Feasibility of a One Step Sentinel Lymph Node Biopsy Procedure Using Radiolabeled Methylene Blue (IND 70,627)||Louisiana State University Health Sciences Center in New Orleans|Yes|Completed|November 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|62|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 17, 2012|November 3, 2008|Yes|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT00784849||147883|
NCT00784862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033IA/0029|ATAC - Pharmacokinetics (PK) Sub-Protocol|A Randomised, Double Blind Trial to Assess the Pharmacokinetics of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women||AstraZeneca|Yes|Completed|June 1998|March 1999|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|9358|||Female|45 Years|N/A|No|||May 2009|May 14, 2009|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784862||147882|
NCT00784212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2203|Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy|A Multicenter, Single-blind, Within-subject, Placebo-controlled Proof of Concept Study to Assess the Effect of Single Oral Doses of BGG492 on the Photoparoxysmal EEG Response in Patients With Photosensitive Epilepsy||Novartis||Completed|October 2008|||September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|65 Years|No|||February 2013|February 11, 2013|October 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784212||147931|
NCT00784225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617778|S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000|S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE)|SEE|Southwest Oncology Group|Yes|Active, not recruiting|July 2004|October 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|2970|||Male|50 Years|120 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|October 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784225||147930|
NCT00785174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV-CPAP-CPE|Non-Invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema: a Multicentre Study|||University of Monastir|No|Completed|January 2005|July 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||November 2008|November 4, 2008|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785174||147858|
NCT00785187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|goldenhersh1|Affect of Dose Rate on UVR Induced Skin Erythema|Randomized Open Crossover Study Researching Affect of Dose Rate on UVR Induced Skin Erythema||Goldenhersh, Michael, M.D.|No|Not yet recruiting|December 2008|||February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2008|November 4, 2008|November 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00785187||147857|
NCT00784771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lichtenberg4 CTIL|Hypnotherapeutic Olfactory Conditioning for Posttraumatic Stress Disorder (PTSD)|Hypnotherapeutic Olfactory Conditioning for Chronic Combat-Related Posttraumatic Stress Disorder||Herzog Hospital|No|Completed|January 2005|February 2007|Actual|February 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|18 Years|N/A|No|||November 2008|November 19, 2015|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784771||147889|
NCT00785421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONKO 004|Chemotherapy With or Without Enoxaparin in Pancreatic Cancer|A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT)|PROSPECT|CONKO-Studiengruppe|Yes|Completed|April 2004|June 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785421||147839|
NCT00781066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT 06-00051|Controlled Cord Traction During Third Stage of Labor|Controlled Cord Traction During Third Stage of Labor: Pilot Trial|CCT|Universidad de la Republica|Yes|Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 27, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781066||148170|
NCT00781365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07116|Home Blood Pressure Telemonitoring and Case Management to Control Hypertension|Home Blood Pressure Telemonitoring and Case Management to Control Hypertension|Hyperlink|HealthPartners Institute|Yes|Completed|March 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|450|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 12, 2014|October 28, 2008||No||No|February 27, 2014|https://clinicaltrials.gov/show/NCT00781365||148148|
NCT00781898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808422|Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site|Prevention of Relapse to Opioid Addiction Using Depot Naltrexone||University of Pennsylvania|Yes|Active, not recruiting|June 2008|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|October 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781898||148107|
NCT00781625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08458d (REK)|Probiotics as a Prophylactic Aid in Women With Recurrent Urinary Tract Infections (UTI's)|Probiotics/Lactobacillus as a Prophylactic Aid in Recurrent Bacterial Cystitis in Women. A Randomized, Prospective, Double-Blinded, Placebo Controlled, Multi-Center Study.||University Hospital, Akershus|Yes|Recruiting|October 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|120|||Female|18 Years|70 Years|No|||October 2008|October 29, 2008|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781625||148128|
NCT00781885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS-MR-PAH-201|A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients|A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients||Lung Biotechnology PBC|No|Completed|January 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||April 2012|April 13, 2012|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781885||148108|
NCT00782522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/380|Effect Study of an Eccentric Training Program and Stretching for Patients With Chronical Rotator Cuff Tendinopathy|Effect Study of an Eccentric Training Program and Stretching for Patients With Chronical Rotator Cuff Tendinopathy||University Ghent|No|Completed|April 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782522||148059|
NCT00783458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04208|Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)|A Preference Evaluation of Nasonex® Nasal Spray (Unscented) vs. Flonase® Nasal Spray (Scented) in Subjects With Symptomatic Allergic Rhinitis (AR) - Single-Dose Cross-over||Merck Sharp & Dohme Corp.|No|Completed|December 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||June 2015|June 29, 2015|October 30, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00783458||147988|
NCT00776477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCD20080101|The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease|||China National Center for Cardiovascular Diseases||Recruiting|December 2007|||December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||October 2008|October 20, 2008|October 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00776477||148518|
NCT00776490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10381501|Bioequivalence Study of Glimepiride 1mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Glimepiride 1 MG Tablets Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|July 2003|September 2003|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776490||148517|
NCT00779896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McG 0722|Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study|Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study||McGill University|No|Recruiting|October 2008|December 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779896||148257|
NCT00780130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1028080161|SPARQ and Core Proprioception|The Relationship of Core Stability to Core Proprioception||Logan College of Chiropractic|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|20|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|asymptomatic normals|October 2008|October 27, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00780130||148239|
NCT00780364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-18|Sour Taste and Cold Temperature in Dysphagia|Sour Taste and Cold Temperature Effects on Pharyngeal Transit Time After Ischemic Stroke:Anatomic and Functional Bases.||UPECLIN HC FM Botucatu Unesp|No|Terminated|March 2008|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|50 Years|80 Years|No|Probability Sample|patients in hospital|June 2012|May 29, 2015|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780364||148221|
NCT00780377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080823|Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients|The Effects of Cardiac Innervation on Intra-Coronary t-PA Release|P1A4D|Vanderbilt University|Yes|Recruiting|October 2008|May 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2009|June 24, 2009|October 24, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00780377||148220|
NCT00773305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostate Seed Implantation|Efficacy of Prostate Seed Implantation for Local Control of Early Stage Prostate Cancer|Chart Review of the Efficacy of Prostate Seed Implantation for Local Control of Early Stage Prostate Cancer||Summa Health System|No|Completed|October 2008|October 2012|Actual|November 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|200|||Male|18 Years|80 Years|No|Probability Sample|Prostate seed implantation for the treatment of early stage prostate cancer|December 2012|December 26, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773305||148759|
NCT00773565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFSD-CRP-2008|Identification of Novel Targets for Regulation of Adipose Tissue Mass|Identification of Novel Targets for Regulation of Adipose Tissue Mass||Heidelberg University|No|Completed|October 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|62|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773565||148739|
NCT00773825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040440|Genomic Imprinting and Assisted Reproductive Technologies|Assessment of the Risk of Imprinting Defects in Children Born Following Assisted Reproductive Technologies (ART)|EPIGEN|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2007|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|542|Samples With DNA|whole blood (serum, ADN) and placenta samples|Female|26 Years|40 Years|No|Non-Probability Sample|Women followed in a participating ART departments|June 2015|June 17, 2015|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773825||148719|
NCT00774163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDA IND# 13710|Safety of Lactobacillus Reuteri in Healthy Volunteers|Phase 1: Safety of Lactobacillus Reuteri in Healthy Volunteers||Tulane University School of Medicine|No|Completed|February 2010|October 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|October 15, 2008|No|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00774163||148693|
NCT00806767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626779|Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer|Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies||National Cancer Institute (NCI)||Completed|March 2007|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|56 Years|74 Years|No|||July 2009|May 14, 2011|December 10, 2008||||No||https://clinicaltrials.gov/show/NCT00806767||146229|
NCT00806780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1209/02/E|Role of Routine on-Table Cholangiography in Laparoscopic Cholecystectomy|Is There a Role for Routine Intraoperative Cholangiography During Laparoscopic Cholecystectomy||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|June 2003|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|80 Years|No|||December 2008|December 10, 2008|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806780||146228|
NCT00806806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C109|Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers|A Phase 1 Randomized, Single-blind, Sequential Cohort, Crossover Study to Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers|TTO|Pacira Pharmaceuticals, Inc|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|128|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 31, 2010|December 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806806||146227|
NCT00807742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA023995-01|Contingency Management for Smoking in Substance Abusers|Contingent Vouchers for Smoking in Substance Abusers as Adjunct to Nicotine Patch|SCMSUD|Brown University|No|Recruiting|October 2008|March 2013|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|274|||Both|18 Years|N/A|No|||February 2009|June 23, 2011|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807742||146158|
NCT00775944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08118|Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS/Stop Together Trial)|Trial Comparing Different Methods of Support With Stopping Smoking Offered Through The National Health Service (NHS) Smoking Helpline|PORTSSS|University of Nottingham|No|Completed|February 2009|September 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|2591|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 26, 2012|October 17, 2008||No||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00775944||148558|
NCT00771706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-076|Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux|Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux||Massachusetts Eye and Ear Infirmary|No|Withdrawn|January 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|October 10, 2008||No|This study was not activated, no data was collected.|No||https://clinicaltrials.gov/show/NCT00771706||148882|
NCT00808522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD-10-08|Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women|Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women.||New York Downtown Hospital|No|Recruiting|December 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|84|||Female|30 Years|75 Years|No|||December 2008|December 15, 2008|December 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00808522||146098|
NCT00804271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90001/AD/3001|Memantine and Validation of a New Alzheimer's Disease Scale|Open Label, Single-Arm, Multi-Centre, Study to Validate a New Alzheimer's Disease Scale in Patients With DAT, Treated With Memantine||Merz Pharmaceuticals GmbH|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|487|||Both|50 Years|N/A|No|||February 2013|February 21, 2013|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804271||146416|
NCT00804284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5A11|Database Surveillance Safety Study of PENTACEL® Vaccine|Post-Licensure Safety Surveillance Study of Routine Use of PENTACEL® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine||Sanofi|No|Completed|September 2008|January 2015|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|62538|||Male|6 Weeks|24 Months|Accepts Healthy Volunteers|Non-Probability Sample|Receipt of DTaP vaccine during the study period by a previously unvaccinated subjects|August 2015|August 17, 2015|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804284||146415|
NCT00783770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31247|Maternal and Infant Cord Blood Monosaccharide Content|Comparison of Monosaccharide Content of Maternal and Umbilical Venous Cord Blood in Term and Preterm Pregnancies||Arkansas Children's Hospital Research Institute|No|Completed|July 2005|||March 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|48|Samples Without DNA|plasma will be stored|Female|18 Years|35 Years|No|Non-Probability Sample|Twenty-four generally healthy mother-infant pairs.|May 2011|May 16, 2011|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783770||147964|
NCT00784056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04306|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)||Sanofi||Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784056||147943|
NCT00784927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0882|Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma|A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy||Mayo Clinic|Yes|Completed|November 2008|August 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|120 Years|No|||April 2015|January 7, 2016|November 1, 2008|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT00784927||147877|
NCT00781755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1988|Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal|Phase 4 Study of Treating Schizophrenic Smokers Using Varenicline and Behavioral Intervention: Effects on Craving, Cues and Withdrawal||VA Boston Healthcare System|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||December 2008|June 3, 2015|October 28, 2008|Yes|Yes|Study design was altered such that a treatment component was removed through the VA IRB. We    did not and will not begin this clinical trial.|No||https://clinicaltrials.gov/show/NCT00781755||148118|
NCT00782002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13941|Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy|Phase 1 Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) Monoclonal Antibody IMC-18F1 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy is Available||ImClone LLC|Yes|Completed|July 2006|November 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|October 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782002||148099|
NCT00785291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00476|Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer|A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|October 2008|||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|799|||Both|18 Years|N/A|No|||March 2015|June 5, 2015|November 4, 2008|Yes|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT00785291||147849|
NCT00785304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075299|Advanced MRI in Blast-related TBI|ADVANCED MRI IN BLAST-RELATED TBI||Washington University School of Medicine|Yes|Enrolling by invitation|November 2008|July 2016|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Active duty military personnel serving in Iraq, Afghanistan, and other areas presenting to        Landstuhl Regional Medical Center for care.|December 2014|December 8, 2014|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785304||147848|
NCT00785525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBSC|Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors|Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors||Center for International Blood and Marrow Transplant Research|Yes|Recruiting|February 1997|January 2022|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35000|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785525||147831|
NCT00785538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13932|A Study of IMC-A12 in Patients With Tumors Who No Longer Respond to Treatment or Who No Treatment if Available|Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available||ImClone LLC|No|Completed|October 2005|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||June 2011|June 14, 2011|November 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00785538||147830|
NCT00773019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1607|SynchroMed II Post-Approval Study|SynchroMed II Programmable Drug Infusion System Post-Approval Study||MedtronicNeuro|No|Completed|November 2004|November 2008|Actual|June 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects planning to receive a new or replacement drug pump.|June 2009|June 9, 2009|August 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00773019||148781|
NCT00772720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALMET-VOLHCB|Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers|Study on the Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers|RALMET-VOLHCB|Hospital Clinic of Barcelona|No|Recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 30, 2010|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772720||148804|
NCT00773539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYO-BAD-KROZ|A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy|Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy|CRYO-RF|Herz-Zentrums Bad Krozingen|Yes|Recruiting|July 2008|August 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|78|||Both|18 Years|75 Years|No|||October 2008|October 14, 2008|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00773539||148741|
NCT00806247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004189|A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of Tapentadol IR for Postoperative Pain Following Bunionectomy Surgery|A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of CG5503 (Tapentadol) IR for Postoperative Pain Following Bunionectomy Surgery||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2005|August 2005|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|480|||Both|18 Years|75 Years|No|||April 2010|May 17, 2011|December 8, 2008||||||https://clinicaltrials.gov/show/NCT00806247||146268|
NCT00806468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPOPA-2008|Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease|A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease|DEPOPA|Johannes Gutenberg University Mainz|No|Terminated|February 2009|February 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|85 Years|No|||June 2010|December 17, 2010|December 9, 2008||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT00806468||146251|
NCT00806819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.14|Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC|Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy||Boehringer Ingelheim||Completed|December 2008|December 2015|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|718|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 10, 2008||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00806819||146226|The Data Monitoring Committee recommended termination of recruitment due to low likelihood of the study meeting its primary objectives.
NCT00807170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00085|Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases|A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-small Cell Lung Cancer (NSCLC)||AstraZeneca|Yes|Terminated|May 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2011|January 11, 2011|December 9, 2008||No|Very slow recruitment|No||https://clinicaltrials.gov/show/NCT00807170||146200|
NCT00807183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16336-CP-001|Indoor Woodsmoke PM and Asthma|Indoor Woodsmoke PM and Asthma: a Randomized Trial|ARTIS|National Institute of Environmental Health Sciences (NIEHS)|No|Completed|December 2008|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|122|||Both|10 Years|17 Years|No|||April 2015|April 14, 2015|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807183||146199|
NCT00775632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 07-0436C|Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants|A Phase II Randomized Study Comparing Low Dose Alemtuzumab and Cyclosporine With Standard of Care for the Prevention of Chronic Extensive GVHD for Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Hematological Malignancies||University Health Network, Toronto|Yes|Recruiting|October 2008|September 2012|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|16 Years|70 Years|No|||October 2008|October 17, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775632||148582|
NCT00775645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617081|S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy|S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III||Southwest Oncology Group|Yes|Completed|September 2009|June 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|437|||Female|18 Years|N/A|No|||January 2014|January 13, 2014|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775645||148581|
NCT00775957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT-NHL|Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma|Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgknin's Lymphoma||University of Oklahoma|Yes|Terminated|October 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|35|||Both|18 Years|N/A|No|Probability Sample|Subjects diagnosed with lymphoma and are about to start treatment with chemotherapy|September 2010|September 27, 2010|October 17, 2008|Yes|Yes|Terminated by institutional review board|No||https://clinicaltrials.gov/show/NCT00775957||148557|
NCT00775970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI07-DJ APS|Walking, Spontaneous Physical Activity and Lipid Oxidation After Dietary Treatment of Obesity|Influence of Walking on Spontaneous Physical Activity and on Lipid Oxidation Following Dietary Treatment of Obesity||University Hospital, Tours|No|Recruiting|May 2008|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Female|18 Years|50 Years|No|||October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775970||148556|
NCT00771719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015304|Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia|Open-Label Exploratory, Multiple-Dose Study of Ceftobiprole to Evaluate the Pharmacokinetics and Broncho-Alveolar Penetration in Adults With Ventilator-Associated Pneumonia||Basilea Pharmaceutica|No|Terminated|October 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|October 9, 2008|No|Yes|Study closed due to lack of enrollment; challenging patient population.|No||https://clinicaltrials.gov/show/NCT00771719||148881|
NCT00771732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.002|Using Light Therapy to Treat Toe Nail Fungus|Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study||Nomir Medical Technologies|Yes|Recruiting|May 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2008|October 10, 2008|July 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771732||148880|
NCT00771966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT_PROST_ORTO|Radical Prostatectomy and Perioperative Fluid Therapy|Radical Prostatectomy and Perioperative Fluid Therapy||Rigshospitalet, Denmark||Completed|October 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Male|18 Years|80 Years|No|||October 2012|October 19, 2012|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00771966||148862|
NCT00771979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8180C00033|Relative Bioavailability of Phase II and Phase III Formulations of AZD0530|A Phase I, Randomised, Open-Label, Cross-Over, Single Centre Study in Healthy Volunteers to Determine the Relative Bioavailability of the Phase III Tablet Formulation to the Phase II Tablet Formulation of AZD0530||AstraZeneca|No|Completed|November 2008|March 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 17, 2009|October 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00771979||148861|
NCT00772278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-07-0094-CTIL|Comparing Carotid Stenting With Endarterectomy in Severe Asymptomatic Carotid Stenosis|A Randomized Evaluation of Short Term and Long Term Outcome After Endovascular Repair by Stenting of Carotid Artery Stenosis in Patients With Severe (70% and Higher) Asymptomatic Carotid Stenosis||Carmel Medical Center|Yes|Recruiting|January 2009|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||October 2014|October 25, 2014|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00772278||148838|
NCT00784602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-242|Observing Pelvic Organ Prolapse Symptoms And Treatment Outcomes|Observing Pelvic Organ Prolapse Symptoms And Treatment Outcomes||William Beaumont Hospitals|No|Active, not recruiting|October 2008|December 2028|Anticipated|October 2028|Anticipated|N/A|Observational|N/A||1|Anticipated|5000|||Female|21 Years|N/A|No|Non-Probability Sample|Patients with genital prolapse.|December 2015|December 8, 2015|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784602||147901|
NCT00784940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033ID/0029|ATAC - Bone Density Sub-Protocol|A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women||AstraZeneca|Yes|Completed|June 1998|April 2007|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|308|||Female|45 Years|N/A|No|||April 2009|April 24, 2009|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784940||147876|
NCT00784953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RTW-SYM-2008/1|Real Life Effectiveness in Patients With Not Optimally Controlled Asthma|Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA||AstraZeneca|No|Completed|October 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|842|||Both|N/A|N/A|No|Probability Sample|Medical center|November 2015|November 9, 2015|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784953||147875|
NCT00782028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 HDJ2810-01A1|Integrating Well-Woman and Well-Baby Care to Improve Parenting and Family Wellness|Integrating Well-Woman and Well-Baby Care to Improve Parenting and Family Wellness||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Not yet recruiting|October 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|170|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|October 28, 2008|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00782028||148097|
NCT00785551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-001-07-1008|Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment|A Single-Dose, Open-Label Comparative Study of the Pharmacokinetics, Safety,and Tolerability of Oral Quinine Sulfate in Healthy Volunteers and Adults With Mild and Moderate Renal Impairment||Mutual Pharmaceutical Company, Inc.|No|Terminated|November 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|5|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|November 3, 2008|No|Yes|poor enrollment|No||https://clinicaltrials.gov/show/NCT00785551||147829|
NCT00781222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM181-4288|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||October 27, 2008|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781222||148158|
NCT00781248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-NGS-06-001|Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage|Evaluation of Safety and Efficacy of the NasoGastric Shield (NG Shield) in Healthy Subjects With Indwelling Nasogastric Tube||Nanovibronix|Yes|Completed|September 2008|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 24, 2009|October 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00781248||148157|
NCT00781261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|570989|Osteonecrosis of the Hip and Bisphosphonate Treatment|A Randomised Controlled Trial of Bisphosphonate Therapy in Osteonecrosis of the Hip|BONES|University of Sydney|No|Recruiting|August 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|90 Years|No|||January 2013|January 11, 2013|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781261||148156|
NCT00772733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RDK-DUM-2007/1|A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment|A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment|KOSMOS|AstraZeneca|No|Completed|October 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|936|||Both|35 Years|N/A|No|Non-Probability Sample|Diagnosed patients with COPD, verified by spirometry in general practise and/or        municipalities.|February 2011|February 21, 2011|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772733||148803|
NCT00773032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071529_OA|Age-Dependent Memory Benefits From Pharmacologically Enhanced Naps?|||University of California, San Diego||Recruiting|October 2008|||June 2009|Anticipated|N/A|Interventional|N/A|3||||||Both|60 Years|75 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|October 15, 2008||||No||https://clinicaltrials.gov/show/NCT00773032||148780|
NCT00806481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3563|Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease|Does Phosphate Binding With Sevelamer Carbonate Improve Cardiovascular Structure and Function in Patients With Early Chronic Kidney Disease?||University Hospital Birmingham NHS Foundation Trust|No|Completed|February 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|80 Years|No|||November 2011|November 22, 2011|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00806481||146250|
NCT00806494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221058|UK Study Assessing Flexible Dose Fesoterodine in Adults|A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.|SAFINA|Pfizer|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|331|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|December 9, 2008|Yes|Yes||No|January 4, 2011|https://clinicaltrials.gov/show/NCT00806494||146249|This was a single arm, non-comparative study. Hence no formal hypothesis testing was performed, and assessment of efficacy was based on changes from baseline in efficacy endpoints.
NCT00806832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0087-08-EMC|The Effects of Medical Clowning on Blood Pressure and Pulse Rate of Patients Undergoing Cataract Surgery Under Local Anesthesia|The Effects of Medical Clowning on Blood Pressure and Pulse Rate of Patients Undergoing Cataract Surgery Under Local Anesthesia||HaEmek Medical Center, Israel|No|Completed|December 2008|March 2010|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|40 Years|N/A|No|Probability Sample|The study population will include patients from the town of Afula and its surrounding        region who are scheduled for cataract surgery in Ha'Emek Medical Center.|July 2015|July 6, 2015|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806832||146225|
NCT00775021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0814|A Clinical Comparison of Two Daily Disposable Contact Lenses.|||Johnson & Johnson Vision Care, Inc.|No|Completed|August 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|45 Years|No|||May 2015|May 5, 2015|October 15, 2008|Yes|Yes||No|February 7, 2011|https://clinicaltrials.gov/show/NCT00775021||148629|
NCT00775333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU 508-03|Nerve Entrapment in Diabetic Patients|Clinical Outcomes of Surgical Release Among Diabetic Patients With Carpal Tunnel Syndrome. A Prospective Study With Matched Controls||Skane University Hospital|No|Completed|December 2003|April 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|67|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients referred to a specialized hand clinic|October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775333||148605|
NCT00807144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICKTI08TX02|Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation|A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation|TAESR|Hammersmith Hospitals NHS Trust|Yes|Recruiting|December 2008|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|75 Years|No|||June 2011|June 27, 2011|December 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807144||146202|
NCT00807157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOSTRESS 11008|Evaluation of a Probiotic On Anxiety and Stress in Healthy Adults Sensible to Daily Stress|Evaluation Des Effets Anti-Stress D'un Probiotique Nomme PROBIOSTICK® Sur Des Sujets Humains Volontaires Sains Sensibles Au Stress De La Vie Quotidienne|BIOSTRESS|Institut Rosell Lallemand|Yes|Completed|December 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|66|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 23, 2009|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00807157||146201|
NCT00807456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-PRO-0001|Study to Evaluate an Implant With a Sloped Top in Patients With a Sloped Jaw Bone|A Prospective, Open, Single Arm, Multi-center Study to Evaluate Maintenance of Lingual Bone in Healed Ridges With the ASTRA TECH Implant System, OsseoSpeed™ Profile Implant. A 3-year Follow-up Study||Dentsply Implants|No|Completed|November 2008|||June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|70 Years|No|||January 2016|January 12, 2016|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807456||146179|
NCT00775658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071260|Olopatadine Eye Drops and Allergy Skin Testing|Effect of Olopatadine Hydrochloride 0.2% Ophthalmic Solution on Epicutaneous Skin Prick Testing With Histamine and Saline||Vanderbilt University|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|24|||Both|18 Years|75 Years|No|||October 2008|October 17, 2008|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775658||148580|
NCT00775671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080496|Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome|Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome||Vanderbilt University|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|46|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 23, 2012|October 17, 2008|Yes|Yes||No|September 23, 2012|https://clinicaltrials.gov/show/NCT00775671||148579|
NCT00772317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSI-003|A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)|A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)|STAR|SonaCare Medical|Yes|Active, not recruiting|July 2008|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Male|40 Years|85 Years|No|||January 2016|January 11, 2016|October 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00772317||148835|
NCT00772330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2007|||||N/A|N/A|N/A||||||||||||||May 4, 2015|October 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00772330||148834|
NCT00772590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-CORAL 1|Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response|Randomised Double-blind Placebo Controlled Study to Measure the Effect of Antiretroviral Therapy (ART) Intensification With Raltegravir and/or Hyper-immune Bovine Colostrum on CD4+ T Cell Count in ART Treated, HIV-1 Infected Individuals With Suboptimal CD4+ T Cell Responses|CORAL|Kirby Institute|No|Completed|March 2009|June 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|October 14, 2008||No||No|May 6, 2012|https://clinicaltrials.gov/show/NCT00772590||148814|Effect of interventions only measured in peripheral blood
NCT00772837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602-Med/ERC-06|Effect of Eradication of Helicobacter Pylori on the Dyspeptic Symptoms|Effect of Eradication of Helicobacter Pylori on the Dyspeptic Symptoms.|EEHPDS|Aga Khan University|No|Completed|August 2006|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|370|||Both|18 Years|65 Years|No|||November 2009|November 9, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772837||148795|
NCT00771992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/09 ZAP-SFB|Ex Vivo Effect of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma|Ex Vivo Effect of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|October 2008|June 2010|Actual|October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|55 Years|No|||August 2010|August 3, 2010|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00771992||148860|
NCT00772005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/2034/SZ/MN|Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia|A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia||Teva Pharmaceutical Industries|Yes|Completed|September 2008|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|287|||Both|18 Years|65 Years|No|||June 2012|June 21, 2012|October 10, 2008|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00772005||148859|
NCT00772291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pregabalin RCT|Chronic Pain Management After Herniorraphy|Chronic Pain Management After Herniorraphy:Pregabalin vs Placebo. A Double-blinded Randomised Controlled Clinical Trial.|pregabalin|Erasmus Medical Center|Yes|Completed|May 2007|October 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772291||148837|
NCT00772304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-21|Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis|||Alcon Research|No|Completed|October 2008|||November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 23, 2010|October 13, 2008|Yes|Yes||No|December 3, 2009|https://clinicaltrials.gov/show/NCT00772304||148836|Small sample size. The severity of symptoms experienced by patients may have masked their ability to detect taste and smell.
NCT00784615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fux-2|Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome|Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome||Universidad Nacional de Córdoba|No|Recruiting|December 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|80|Samples Without DNA|Blood samples|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women in reproductive age with diagnosis of polycystic ovary syndrome according to        Rotterdam criteria|October 2008|November 18, 2008|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784615||147900|
NCT00781495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2DM_insulin_weight gain|Determinants of Insulin-induced Weight Gain in Type 2 Diabetes Mellitus|Determinants of Insulin-induced Weight Gain in Type 2 Diabetes Mellitus||Radboud University|No|Recruiting|December 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|85 Years|No|Probability Sample|Patients with type 2 diabetes mellitus, selected from the out-patient clinic of the        Radboud University Nijmegen Medical Centre and four other non-academic hospitals.|September 2009|July 11, 2011|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781495||148138|
NCT00772525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT10573|Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis|A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis||Sanofi|Yes|Completed|September 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|October 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00772525||148819|
NCT00782015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TuftsIRB8723|Effects of Almonds on Vascular Reactivity in Patients With Coronary Artery Disease|Effects of Almonds on Vascular Reactivity and Biomarkers of Inflammation, Oxidative Stress and Endothelial Function in Patients With Coronary Artery Disease||Tufts University|No|Active, not recruiting|October 2008|November 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|80 Years|No|||December 2009|December 7, 2009|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00782015||148098|
NCT00782327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/503|Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers|Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers||University Hospital, Ghent|Yes|Recruiting|June 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|174|||Both|10 Years|N/A|No|||June 2015|June 2, 2015|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782327||148074|
NCT00782340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa NOH301|A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa|Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH|NOH301|Chelsea Therapeutics|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|October 29, 2008|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT00782340||148073|
NCT00772746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSK 021|Cognitive Behavioral Therapy in Panic Disorder|Effectiveness of Specific Model of Cognitive-Behavioral Therapy in Panic Disorder Patients With Agoraphobia|CBT|Universidade Federal do Rio de Janeiro|Yes|Completed|March 2006|March 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|None Retained|None retained|Both|18 Years|70 Years|No|Non-Probability Sample|panic disoder patients over 18 years old|October 2008|October 14, 2008|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772746||148802|
NCT00773045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIJNICU2/Z06.11|Pain Measurement and Pain Management in the Intensive Care Unit(ICU)|Pain Measurement and Pain Management in the ICU|PIJNICU2|St. Antonius Hospital|No|Completed|April 2006|October 2007|Actual|August 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|190|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients, 18 years and older|October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773045||148779|
NCT00773058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QHB-YY 2008|Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS)|Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency||Southeast University, China|No|Active, not recruiting|December 2008|||April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|85 Years|No|||January 2009|February 17, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00773058||148778|
NCT00806507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0339|Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients|Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients||M.D. Anderson Cancer Center|No|Completed|November 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients treated with chemotherapy and Herceptin (trastuzumab)|July 2012|July 19, 2012|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00806507||146248|
NCT00806520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03671-08-C|Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control|Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)||HealthPartners Institute|No|Completed|April 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Participants in the Amylin BCB106 Protocol Main Study|August 2011|November 30, 2015|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00806520||146247|
NCT00806845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RegMedNet-001|Examination of B Cell Responses in Human Blood|Gewinnung Humaner antikörperproduzierender Zellen Aus Dem Blut||Regenerative Medicine Network|Yes|Completed|July 2008|February 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Actual|50|Samples Without DNA|peripheral blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV patients and controls attending specialised clinics, Germany|May 2015|May 12, 2015|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806845||146224|
NCT00806858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS236-3663|Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus|NovoPen®4 Clinical Experience Programme: A Multicentre, Observational Study of NovoPen®4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus||Novo Nordisk A/S|No|Completed|November 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|526|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject with Type 1 or Type 2 diabetes|July 2012|July 17, 2012|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806858||146223|
NCT00775034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/433|Drainage Versus Sealant in Double Blinded Monocentric Open Incisional Hernia Repair|Drainage Versus Sealant in Double Blinded Monocentric Open Incisional Hernia Repair|DREAM|University Hospital, Ghent|No|Recruiting|November 2008|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775034||148628|
NCT00775047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-EPID-52|Pharmacist-Administered Injections for Contraception|Pharmacist-Administered Injections of Depo-Medroxyprogesterone Acetate for Contraception: A Pilot Randomized Controlled Trial|PAD|University of North Carolina, Chapel Hill|No|Completed|August 2006|July 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00775047||148627|
NCT00775346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04212008|A Multi-Center Study to Assess the Performance of Saturation Patterns.|A Multi-Center Study to Assess the Performance of the Saturation Pattern Detection (SPD) Software Algorithm.||Medtronic - MITG|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are undergoing a standard sleep lab study/evaluation will have their data        analyzed for this clinical trial.|August 2014|August 5, 2014|October 16, 2008||No||No|March 15, 2010|https://clinicaltrials.gov/show/NCT00775346||148604|
NCT00775359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA01824|Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Abbott (TriCor®) 160 mg Fenofibrate Tablets in Healthy Adult Volunteers Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|August 2002|October 2002|Actual|September 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775359||148603|
NCT00772018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600591|Quality of Life and Symptom Management in Patients With Bladder Cancer|A Qualitative Study of Patients With Non-Invasive Bladder Cancer||Baylor College of Medicine|No|Completed|May 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Urology specialty clinic|February 2012|February 1, 2012|October 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00772018||148858|
NCT00773175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-08-03|Subcutaneous Rehydration Compared to Intravenous Rehydration|Subcutaneous Rehydration With Hylenex Compared to Intravenous Rehydration in Infants and Young Children With Mild to Moderate Dehydration|PEDs-II|Halozyme Therapeutics|No|Completed|October 2008|December 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|N/A|3 Years|No|||December 2011|December 2, 2011|October 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773175||148769|
NCT00773422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0710003188|The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse|The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse||Yale University|Yes|Active, not recruiting|January 2008|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|55 Years|No|||October 2015|October 8, 2015|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00773422||148750|
NCT00773669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Male Breast Cancer|Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007|Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007||Summa Health System|No|Completed|October 2008|December 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|24|||Male|18 Years|80 Years|No|Probability Sample|Males with breast cancer.|May 2013|May 30, 2013|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773669||148731|
NCT00773162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AzSeroSP|Flushing in Social Anxiety Disorder on Seroquel|A Single-center, Randomized, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Extended Release Tablets) to Placebo in Social Phobia Patients and Changes in Their Vasodilatory Response to Methyl-Nicotinate||START Clinic for Mood and Anxiety Disorders|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773162||148770|
NCT00773409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSF-101|Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)|A Prospective Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 4 to 5 Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents Within the Past 10 Years||Bracco Diagnostics, Inc|No|Completed|October 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|405|Samples Without DNA|fixed tissue samples and tissue sample for testing of GBCA.|Both|N/A|N/A|No|Non-Probability Sample|A total of 400 patients will be enrolled into this study based on their renal function        (eGFR) and the fact that they have been GBCA free for the past 10 years.|September 2012|September 14, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773409||148751|
NCT00785577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11977|A Study for Treatment of Pain in Patients With Diabetic Neuropathy.|A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Painful Diabetic Neuropathy.||Eli Lilly and Company|No|Completed|November 2008|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|273|||Both|18 Years|70 Years|No|||April 2012|April 30, 2012|November 3, 2008|Yes|Yes||No|August 25, 2011|https://clinicaltrials.gov/show/NCT00785577||147827|
NCT00781274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A9|Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|20 Years|65 Years|No|||April 2014|April 16, 2014|October 24, 2008||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00781274||148155|
NCT00781768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106578|Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea|A Prospective, Randomized Phase III Trial of Oral Ondansetron and Dexamethasone Versus Oral Ondansetron, Dexamethasone and Apreptant (MK-869)for the Prevention of N/V Associated With Highly Emetogenic Preparative Regimens Prior to Stem Cell Transplantation.||Loyola University|No|Completed|August 2003|July 2010|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781768||148117|
NCT00772785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-809|Study of Probuphine in Patients With Opioid Dependence|An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence|PRO-809|Titan Pharmaceuticals|Yes|Terminated|September 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||October 2012|January 25, 2013|October 9, 2008|Yes|Yes|This study was terminated for reasons not related to efficacy or safety|No||https://clinicaltrials.gov/show/NCT00772785||148799|
NCT00772798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9X|A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer|A Phase I/II Non-Comparative Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat in Patient With Advanced, Recurrent, Epithelial Ovarian Cancer||Herlev Hospital|Yes|Recruiting|June 2007|June 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|18 Years|N/A|No|||October 2008|October 14, 2008|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772798||148798|
NCT00782353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA598-502|Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection|A Phase 1, Randomized, Double-Blind, Ascending Multiple-Dose Study of the Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Chronic Hepatitis C Infection||Hoffmann-La Roche|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|65 Years|No|||November 2012|November 12, 2012|October 28, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782353||148072|
NCT00782366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007414|Predictive Genetic Risk Assessment Trial|Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment|PGT|Mayo Clinic|No|Completed|March 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients and physicians from the Mayo Clinic Rochester Executive Health (EH) program will        be recruited to participate in this study|April 2011|April 25, 2011|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782366||148071|
NCT00773084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARID-HF|Aliskiren and Renin Inhibition in Diastolic Heart Failure|Aliskiren and Renin Inhibition in Diastolic Heart Failure in Mexican Americans|ARID-HF|Texas Tech University Health Sciences Center|No|Withdrawn|September 2008|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|70 Years|No|||March 2011|May 11, 2015|October 15, 2008|Yes|Yes|Difficulty in recruiting patients and then the PI left the institution|No||https://clinicaltrials.gov/show/NCT00773084||148776|
NCT00805623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004994|Sucking and Sucrose as Pain Relief for Infants|Partial Blinded Controlled Study to Compare SucroseVs Water, With and Without Pacifier as Pain Reliever During Venous Puncture in Infants 3-12 Months Old||Rabin Medical Center|No|Not yet recruiting|March 2009|October 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|3 Months|12 Months|No|||December 2008|December 8, 2008|December 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00805623||146314|
NCT00805636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST-CA004CTIL|Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.|Evaluation of Efficacy and Safety of 18FML10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Non-Hematological Solid Tumors to Radiation Therapy||Aposense Ltd.||Recruiting|November 2008|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2010|May 11, 2010|December 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805636||146313|
NCT00805922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3707|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand|DiabCare Asia 2008. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia|DiabCare Asia|Novo Nordisk A/S|No|Completed|December 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2342|Samples With DNA|Capillary or venous blood will be drawn for analysing HbA1c.|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus being treated at general hospitals, diabetes clinics and        referral clinics will be selected according to the inclusion and exclusion criteria.|August 2014|August 12, 2014|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805922||146292|
NCT00805935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-05|Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)|A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR® Versus FOLLISTIM® in Polycystic Ovarian Syndrome (PCOS) Patients||Ferring Pharmaceuticals|No|Completed|January 2009|September 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|110|||Female|18 Years|42 Years|No|||January 2012|January 26, 2012|December 9, 2008|Yes|Yes||No|November 28, 2011|https://clinicaltrials.gov/show/NCT00805935||146291|
NCT00806546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-15-NP101-009|An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months|An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months|NP101-009|Teva Pharmaceutical Industries|No|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|514|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|December 10, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00806546||146245|
NCT00806559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-000135|Space and Interaction Trial: Room Design and Patient-physician Interaction|SIT Trial: The Effect of Clinical Room Design on the Quality of the Clinical Encounter|SIT|Mayo Clinic|Yes|Completed|July 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2011|December 13, 2011|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806559||146244|
NCT00806871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prövningsprotokoll 080723|Steroid Injection Treatment of Carpal Tunnel Syndrome|Local Steroid Injection in the Treatment of Idiopathic Carpal Tunnel Syndrome: A Randomized Double-blind Placebo-controlled Trial Among Patients Planned for Surgical Treatment||Region Skane|Yes|Completed|November 2008|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|112|||Both|18 Years|70 Years|No|||March 2011|April 3, 2012|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806871||146222|
NCT00775983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1176030877|Dilapan Versus Laminaria|Same-day Dilapan Versus Overnight Laminaria for Cervical Preparation for Early Second-trimester Surgical Abortion|DvL|University of California, San Francisco|Yes|Completed|October 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 18, 2013|October 16, 2008|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00775983||148555|-inadequate power to compare complications directly between study groups. Procedure time was chosen as a proxy for procedural difficulty and thus potential complications
NCT00775996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA06461|Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions|The Objective of This Study Was to Compare the Single-Dose Relative Bioavailability of Ranbaxy and Abbott (Tranxene® T-Tab®) 15 mg Clorazepate Dipotassium Tablets Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|August 2003|November 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775996||148554|
NCT00775372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPU-N-015/CLARI-250/05|Bioequivaelnce Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Four-Period, Two- Sequence, Single-Dose, Crossover Fully Replicated, Bioavailability Study on Clarithromycin Formulations Comparing Clarithromycin 250 mg/5 mL Powder for Oral Suspension of Ranbaxy Laboratories With Biaxin® Granules 250 mg/5 mL Oral Suspension in Healthy, Adult,Human, Male Subjects Under Fed Conditions.||Ranbaxy Inc.|Yes|Completed|September 2005|December 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2|||40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775372||148602|
NCT00771745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pre-Tx Thymo|Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients|Prospective, Single Center, Pilot Study of Pretransplant Thymoglobulin Administration and Early Corticosteroid Withdrawal in Living Donor Renal Transplant Recipients Under Mycophenolate Mofetil (MMF) and Tacrolimus Immunosuppression||University of Cincinnati|No|Completed|September 2008|July 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|11|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 10, 2008|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT00771745||148879|
NCT00772850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804007R|Rotator Cuff Injury in Antegrade Locked Nailing for Humeral Fractures|Sonographic Evaluation of Rotator Cuff Injury in Antegrade Locked Nailing for Humeral Fractures|SRC|National Taiwan University Hospital|Yes|Completed|October 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|15 Years|N/A|No|Probability Sample|Patients operated in National Taiwan University hospital|July 2010|July 14, 2010|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772850||148794|
NCT00772863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976I_6012|Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer|The Evaluation of Efficacy and Safety of Subsequent Cisplatin and Docetaxel Regimen In The First Line Treatment of Advanced Epithelial Ovarian Cancer|Tax-Over|Sanofi|No|Completed|September 2003|||June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Female|18 Years|70 Years|No|||October 2009|October 28, 2009|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772863||148793|
NCT00772876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1446A-05/20/08|A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies|An Open Label, Multicenter Phase I Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies||Piramal Enterprises Limited|No|Completed|December 2008|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772876||148792|
NCT00773435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A41256|Effects of Echinacea in Children|Assessing the in Vivo Effect of Echinacea Purpurea on Markers of Immune Activities in Children||University of Washington|Yes|Withdrawn|November 2008|August 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||December 2008|November 30, 2015|October 14, 2008|Yes|Yes|Decided to conduct study in adults first|No||https://clinicaltrials.gov/show/NCT00773435||148749|
NCT00773448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004723-01H|Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism|Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism: an Open Randomized Controlled Trial Using a Comprehensive Abdomen/Pelvis Computed Tomography|SOME|Ottawa Hospital Research Institute|Yes|Completed|September 2008|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|862|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00773448||148748|
NCT00773695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21744|A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer|A Multicenter, Randomized, ph II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadj Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Ref to the Obtained Responses in Patients With Large Primary HER2 Neg Breast Cancers||Hoffmann-La Roche||Active, not recruiting|November 2008|January 2023|Anticipated|January 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773695||148729|
NCT00773682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|339/07|Efficacy and Tolerability of Mud Packs Therapy in Osteoarthritis of the Hand|Efficacy and Tolerability of Mud Packs Therapy in Osteoarthritis of the Hands: a One Year Follow-up|mdph|University of Siena|No|Completed|June 2008|January 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|50 Years|75 Years|No|||September 2008|November 16, 2011|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773682||148730|
NCT00785330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL 2004-R3|Allo-hNHL (FluBuCy)|Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|Yes|Active, not recruiting|April 2004|April 2014|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||November 2008|April 16, 2009|September 13, 2005||No||No||https://clinicaltrials.gov/show/NCT00785330||147846|
NCT00785564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0995|Imaging Cardiac Electrical Remodeling With Electrocardiogram Imaging (ECGI)|Imaging Cardiac Electrical Remodeling With ECGI||Washington University School of Medicine|No|Recruiting|November 2007|November 2009|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of a pacemaker clinic|November 2008|November 4, 2008|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00785564||147828|
NCT00781508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO1RR000080|Effects of Viagra on Heart Function in Patients With Heart Failure|Single Dose Sildenafil in Heart Failure Patients Improves 6-minute Walk Test by a Reduction in Left Ventricular Filling Pressure||MetroHealth Medical Center|No|Completed|December 2006|November 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|25 Years|75 Years|No|||June 2014|June 23, 2014|October 28, 2008||No||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00781508||148137|The study was limited by the small number of participants. Additionally, the inclusion criterion of a systolic pulmonary artery pressure of > 40 mmHg was no longer present in the majority of patients at the time they presented for study.
NCT00772252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806004R|Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment|Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment||National Taiwan University Hospital|No|Recruiting|August 2008|December 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients require liver support treatment|June 2010|June 28, 2010|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772252||148840|
NCT00782743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marcumar-ASS-Study|Comparison of Phenprocoumon and Acetylsalicylic Acid (ASA)|Prospective Comparison of Phenprocoumon (Marcumar) and Acetylsalicylic Acid (ASA)With Regard to the Progress of Valvular and Coronary Calcification||RWTH Aachen University|No|Completed|February 2008|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|157|Samples Without DNA|Biomarkers for inflammation, measuring of inhibitors of calcification|Both|50 Years|90 Years|No|Non-Probability Sample|Patients with required therapy with either ASS or phenprocoumon|September 2015|September 22, 2015|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782743||148043|
NCT00772772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP-0626|Vitamin D Repletion in Chronic Kidney Disease|The Effect of Vitamin D3 Repletion in Chronic Kidney Disease Stage 3||Rockefeller University|No|Completed|March 2008|October 2009|Actual|June 2009|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|October 13, 2008|Yes|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00772772||148800|
NCT00773097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030214|Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma|Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma||University of Pittsburgh|Yes|Completed|October 2008|October 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|46|||Both|40 Years|70 Years|No|||February 2014|February 12, 2014|October 15, 2008|Yes|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00773097||148775|
NCT00805948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigational Plan #109|Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)|Descending Thoracic Aortic Aneurysm Endovascular Repair Post-approval Study (THRIVE)|THRIVE|Medtronic Endovascular|No|Active, not recruiting|January 2009|July 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|256|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805948||146290|
NCT00806260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-205|A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.|A Phase 2, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Psychomotor Effect of VI-0521 in Healthy Overweight and Obese Subjects.||VIVUS, Inc.|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|December 9, 2008|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00806260||146267|Due to technical issues, an additional cohort of subjects were added to Period 1 only, which produced two additional treatment arms, alcohol only and alcohol placebo only. No change was made in the data analysis.
NCT00806273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004769|An in Vivo Comparison of the Debridement Efficiency of Needle Irrigation Versus Ultrasonic Irrigation|An in Vivo Comparison of the Debridement Efficacy of Needle Irrigation and Ultrasonic Root Canal Irrigation Techniques||Oregon Health and Science University|No|Withdrawn|January 2009|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|December 8, 2008||No|Manufacturer changed device so no study will be done; ie it was never started|No||https://clinicaltrials.gov/show/NCT00806273||146266|
NCT00774475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000|Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition|Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation|DANTE|University of Florence|No|Not yet recruiting|November 2008|January 2011|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|442|||Both|20 Years|90 Years|No|||October 2008|October 23, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774475||148670|
NCT00774748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Insuflon07-1631|Once Weekly Subcutaneous Ports for the Administration of Anticoagulants|Once Weekly Subcutaneous Ports for the Administration of Anticoagulants - A Prospective Pharmacokinetic and Clinical Utilization Study||University of North Carolina, Chapel Hill|No|Completed|August 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|21|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|October 15, 2008|No|Yes||No|April 8, 2011|https://clinicaltrials.gov/show/NCT00774748||148650|
NCT00772343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-030-011|Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection|A Phase II Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of A Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection (CDI)||Sanofi|Yes|Completed|February 2009|June 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|116|||Both|18 Years|85 Years|No|||September 2013|September 6, 2013|October 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00772343||148833|
NCT00771758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015064|Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis|A Randomized, Double-Blind, Placebo- and Oxycodone Immediate Release (IR)-Controlled Study of Tapentadol IR for the Treatment of Acute Pain Caused by Vertebral Compression Fractures Associated With Osteoporosis||Ortho-McNeil Janssen Scientific Affairs, LLC|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|108|||Both|50 Years|85 Years|No|||April 2014|April 24, 2014|October 10, 2008|Yes|Yes||No|December 8, 2010|https://clinicaltrials.gov/show/NCT00771758||148878|Insufficient number of participants enrolled to meet proposed sample size, so that statistical inferences could not be made.
NCT00772603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804P301|Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures|Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures|PROSPER1|Supernus Pharmaceuticals, Inc.|No|Completed|November 2008|November 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|366|||Both|18 Years|65 Years|No|||December 2013|December 23, 2013|October 10, 2008|Yes|Yes||No|April 9, 2013|https://clinicaltrials.gov/show/NCT00772603||148813|
NCT00773188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21247|A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.|A Single-arm, Open-label, Multicenter Feasibility Trial of Bevacizumab Given in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Locally Advanced Unresectable Non-squamous, Non-small Cell Lung Cancer||Hoffmann-La Roche||Completed|December 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773188||148768|
NCT00773461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21753|A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.|A Randomized, Double Blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With DMARD Therapy, in Patients With Active Rheumatoid Arthritis and Inadequate Response to Current DMARD Therapy||Hoffmann-La Roche||Completed|October 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|209|||Both|18 Years|70 Years|No|||October 2013|October 7, 2013|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773461||148747|
NCT00773734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-005|Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)|A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)||Celgene|Yes|Completed|September 2008|May 2015|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|352|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|October 14, 2008|Yes|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT00773734||148726|
NCT00773708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISCOR-RAL|Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product|Pilot Study to Assess the Role of Immune Activation and Apoptosis as a Marker for Treatment Intensification With Raltegravir in Hiv-infected Patients on Antiretroviral Therapy With Long-term Viral Suppression and Unfavourable Immunologic Response (Discordant Patients: v+i-)||Germans Trias i Pujol Hospital|No|Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|60 Years|No|||September 2011|March 10, 2015|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00773708||148728|
NCT00773721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA131008|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||September 26, 2014|October 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773721||148727|
NCT00773981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2007-061|Transrectal Vacuum Assisted Drainage: A New Method of Treating Anastomotic Leakage After Rectal Resection|Transrectal Vacuum Assisted Drainage: A NEW METHOD OF TREATING ANASTOMOTIC LEAKAGE AFTER RECTAL RESECTION. A Prospective Randomized Multicenter Study in Cooperation With "The Danish Colorectal Cancer Group"||Hvidovre University Hospital|No|Recruiting|October 2008|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2008|November 3, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773981||148707|
NCT00781287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34908-D|Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1|Impact of Raltegravir (Isentress/MK-0518) - Containing Regimens on HIV-1 Infected CD4+ T-Cells During Acute and Early HIV-1 Infection: A Randomized, Controlled Study Comparing Standard Antiretroviral Therapy to Standard Therapy Plus Raltegravir|UW PIC 330|University of Washington|No|Terminated|February 2009|October 2013|Anticipated|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|October 24, 2008|Yes|Yes|Enrollment too slow.|No||https://clinicaltrials.gov/show/NCT00781287||148154|
NCT00771927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0942|Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures|Post-Authorization Safety Study to Evaluate the Long-Term Safety and Tolerability of Vimpat® (Lacosamide) as Add-On Therapy in Epilepsy Patients With Partial-Onset Seizures Who Are Uncontrolled on Current Therapy|PASS|UCB Pharma|No|Completed|October 2008|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1005|||Both|16 Years|N/A|No|Non-Probability Sample|Institutions, hospitals, primary care clinics and community based|May 2013|October 17, 2014|October 13, 2008||No||No|March 8, 2013|https://clinicaltrials.gov/show/NCT00771927||148865|
NCT00771940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2007008|Peripheral Metabolic Effects of Ghrelin|Peripheral Metabolic Effects of Intra Arterial Ghrelin Infusion in Healthy Controls||University of Aarhus|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 2, 2009|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00771940||148864|
NCT00772265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WosulinN/PK-PD/HV/FDA/10/v3|Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects|A Randomized Single Center Double Blind 2 Period Crossover Glucose Clamp Study to Test for Bioequivalence Between 2 Recombinant Human Isophane Insulins Wockhardt's Human Isophane Insulin Injection100IU/ml With Novolin N in Healthy Subjects||Wockhardt|No|Completed|September 2010|April 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 26, 2012|October 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00772265||148839|
NCT00772538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.416|Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma||Boehringer Ingelheim||Completed|October 2008|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|459|||Both|18 Years|75 Years|No|||July 2014|July 30, 2014|October 13, 2008||||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00772538||148818|
NCT00772551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT027|Raltegravir and Ezetimibe PK Study|Evaluation of the Pharmacokinetics and Safety of Raltegravir and Ezetimibe When Co-administered to Male and Female Healthy Volunteers||St Stephens Aids Trust|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00772551||148817|
NCT00782444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/12587|Computer Navigation vs Conventional Technique in Knee Arthroplasty|Computer Navigation vs Conventional Technique in Knee Arthroplasty. A Prospective, Randomised, Clinical and Radiostereometric Trial|CAOS|Haukeland University Hospital|Yes|Active, not recruiting|January 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|50 Years|85 Years|No|||July 2015|July 13, 2015|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00782444||148065|
NCT00782457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-08-00770|Prospective Randomised Study Comparing Laparoscopic Versus Open Surgery in Patients With Rectal Cancer|||Hospital Universitario Virgen de la Arrixaca||Completed|January 2002|December 2010||February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||October 2008|March 17, 2015|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782457||148064|
NCT00773110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO888|Study of Albumin to Reduce Inflammation Following Surgery|Scavenging Free Haemoglobin Attenuates the Systemic Inflammatory Response Following Surgery||Imperial College London|Yes|Terminated|December 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|16 Years|N/A|No|||May 2010|May 27, 2014|October 15, 2008|Yes|Yes|Recruitment under target, Finding|No||https://clinicaltrials.gov/show/NCT00773110||148774|
NCT00773123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0342|Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.|||Yonsei University|Yes|Recruiting|October 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|300|||Both|10 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|primary open angle glaucoma|October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773123||148773|
NCT00773357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0808004163|Modeling Stress-precipitated Smoking Behavior for Medication Development|Modeling Stress-precipitated Smoking Behavior for Medication Development||Yale University|Yes|Recruiting|October 2008|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|60 Years|No|||October 2015|October 8, 2015|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00773357||148755|
NCT00805675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AHK01|Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB|A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB||Novartis||Completed|November 2008|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|83|||Both|18 Years|40 Years|No|||January 2012|January 26, 2012|December 9, 2008|Yes|Yes||No|December 12, 2011|https://clinicaltrials.gov/show/NCT00805675||146310|
NCT00805961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CNS 10|RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM|A Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in the First-line of Treatment of Patients With Glioblastoma Multiforme||SCRI Development Innovations, LLC|No|Completed|January 2009|May 2013|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||August 2012|July 1, 2013|December 9, 2008|No|Yes||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00805961||146289|
NCT00806286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-U202|Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer|Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Naïve Subjects With Metastatic Non-Small Cell Lung Cancer||Daiichi Sankyo Inc.|No|Completed|December 2008|August 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|December 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806286||146265|
NCT00775385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0801|TAilored Post-Surgical Therapy in Early Stage NSCLC|Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-squamous Non Small Cell Lung Cancer (NSCLC).|TASTE|Intergroupe Francophone de Cancerologie Thoracique|Yes|Active, not recruiting|April 2009|June 2016|Anticipated|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775385||148601|
NCT00775684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808425|Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass|A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes||University of Pennsylvania|No|Completed|October 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|70 Years|No|||January 2013|January 31, 2013|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775684||148578|
NCT00775697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AABB1948|Montelukast in Children With Wheezing|Montelukast Effects on Pulmonary Function in Children With Wheezing Aged Less Than 2 Years||Universita di Verona|Yes|Enrolling by invitation|September 2009|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|6 Months|24 Months|No|||June 2013|June 18, 2013|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775697||148577|
NCT00772616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/13|Influence of Intraoperative Analgesia on the Postoperative Morphine Consumption|Influence of Intraoperative Analgesia (Sufentanil Administered According to the Usual Criteria or Remifentanil Administered by a Closed-loop System Using Bispectral Index as the Controller) on the Postoperative Morphine Consumption||Hopital Foch|No|Completed|September 2008|January 2011|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2011|January 22, 2011|October 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00772616||148812|
NCT00772889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111738|Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly|Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly||GlaxoSmithKline||Completed|October 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|971|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2012|October 25, 2012|October 10, 2008|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT00772889||148791|
NCT00772902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-EU-164-0206|ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial|A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol|ROCKET II|Gilead Sciences|No|Completed|October 2008|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||November 2011|November 18, 2011|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772902||148790|
NCT00773201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071001|Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation|Identification of the Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation at a Pharmacological and Physiological Stimulus in an Apparently Normal Population|Generepol|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2008|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|997|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|July 25, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773201||148767|
NCT00773747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-088|Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)|An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma||Merck Sharp & Dohme Corp.|Yes|Completed|December 2008|June 2015|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|637|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|October 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773747||148725|
NCT00774020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446K2419|Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)|A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China||Novartis||Completed|October 2008|||January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|30 Years|N/A|No|||April 2012|April 23, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774020||148704|
NCT00774033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070307|Epidermal Cells Delivery and Acute Burns|A Randomized Trial Comparing Recell® Autologous Epidermal Cells Harvesting Kits Versus Classic Skin Grafts for the Treatment of Acute Burn in Adults and Children|ENSEM|Assistance Publique - Hôpitaux de Paris|No|Terminated|December 2008|May 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|N/A|N/A|No|||March 2012|July 25, 2012|October 15, 2008||No|Not enough patients included|No||https://clinicaltrials.gov/show/NCT00774033||148703|
NCT00773994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07100381|Pilot Study Evaluating Characteristic Closure Patterns of the Normal Velopharyngeal Portal|Pilot Study Evaluating Characteristic Closure Patterns of the Normal Velopharyngeal Portal||Children's Hospital of Pittsburgh|No|Completed|May 2008|||July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 28, 2015|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773994||148706|
NCT00774007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-01/03|A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome|Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study.||SOFAR S.p.A.|Yes|Completed|September 2004|November 2005|Actual|November 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774007||148705|
NCT00776204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBCT-H03-07|The Optical Coherence Tomography Drug Eluting Stent Investigation|The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)|OCTDESI|Boston Scientific Corporation|Yes|Completed|May 2008|February 2011|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776204||148539|
NCT00771953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822GCC HP-00043076|0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer|0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients||University of Maryland|Yes|Completed|November 2008|December 2014|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||June 2015|June 13, 2015|October 10, 2008|No|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT00771953||148863|This study is limited by the relatively low numbers and the hetereogeneity between concurrent treatments (docetaxel vs. pemetrexed). However, in analyses stratified by docetaxel and pemetrexed, results for an affect of apricoxib were still null.
NCT00782418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-104|A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)|A Randomized Clinical Trial to Study Glucose Dependent Insulin Secretion Methodologies in Healthy Lean Male Subjects||Merck Sharp & Dohme Corp.||Completed|September 2008|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|October 29, 2008|No|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00782418||148067|
NCT00782431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|720801|Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older|Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older||Nanotherapeutics, Inc.|Yes|Completed|November 2008|July 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|3195|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 7, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782431||148066|
NCT00783029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC29113|Measurement of the Eye's Blood Vessels Using the Dynamic Vessel Analyzer (DVA)|Reproducibility of Dynamic Vessel Analyzer Measurements and Establishment of Standards||Penn State University|No|Completed|October 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|87|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Subjects|February 2012|February 6, 2012|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783029||148021|
NCT00782990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVTvsBURCH_2001_HSVO|A 3 Year Follow-up Prospective Open Randomized Trial of TVT Versus Colposuspension for Primary Stress Incontinence|A Three Year Follow-up Prospective Open Randomized Trial of Tension-Free Vaginal Tape and Colposuspension for Primary Urodynamic Stress Incontinence||Hospital Severo Ochoa||Completed|January 2001|June 2007|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|35 Years|70 Years|No|||November 2008|November 4, 2008|October 30, 2008||||No||https://clinicaltrials.gov/show/NCT00782990||148024|
NCT00783276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA009262-14|An fMRI Study of SYN115 in Cocaine Dependent Subjects|An fMRI Study of SYN115 in Cocaine Dependent Subjects||Virginia Commonwealth University|Yes|Completed|October 2008|January 2013|Actual|January 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|50 Years|No|||January 2016|January 5, 2016|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783276||148002|
NCT00783289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP197|A Phase 2a Study to Evaluate the Safety and Tolerability of MEDI-563 in Adults With Asthma|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple-dose Subcutaneous Administration of MEDI-563, a Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma|MEDI-563|MedImmune LLC|No|Completed|November 2008|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||August 2012|August 20, 2012|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783289||148001|
NCT00805974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0513|Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I|Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I|DIAPASOM|University Hospital, Grenoble|No|Terminated|October 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|||Actual|23|||Both|18 Years|60 Years|No|||January 2009|January 13, 2009|December 9, 2008||No|difficulties for including diabetic patients|No||https://clinicaltrials.gov/show/NCT00805974||146288|
NCT00806299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOPDIR1007|Loperamide Grapefruit Juice Interaction PK Trial|An Open Label, Randomized, Single-dose, Fixed-Sequence Crossover Drug Interaction Study of Loperamide HCL With Grapefruit Juice||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|November 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|33|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806299||146264|
NCT00806533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-O-H-0509|Non-Interventional (Observational) Post-Authorization Safety Study of HES 130/0.42 in Paediatric Patients|Infusion of Venofundin 6% or Tetraspan 6% in Paediatric Patients Aged up to 12 Years||B. Braun Melsungen AG|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1130|||Both|N/A|12 Years|No|Probability Sample|paediatric patients aged up to 12 years|May 2009|May 15, 2009|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806533||146246|
NCT00771771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18993|Early Supported Discharge After Stroke in Bergen|Early Supported Discharge After Stroke in Bergen. An RCT Looking at the Collaboration Between Hospital Service and Primary Health Care.||Haukeland University Hospital|No|Completed|December 2008|December 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|306|||Both|N/A|N/A|No|||February 2014|February 24, 2014|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771771||148877|
NCT00771784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68144|Effects of Tracheal Intubation on Ventilation With a Laryngeal Mask During Percutaneous Dilatation Tracheostomy|Effects of Short- and of Long-term Tracheal Intubation on Ventilation With a Laryngeal Mask During Percutaneous Dilatation Tracheostomy.||University of Padova|Yes|Completed|July 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|80 Years|No|Probability Sample|ICU patients.|August 2012|August 21, 2012|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771784||148876|
NCT00772031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CRC-01|NINDS CRC Chronic Migraine Treatment Trial|NINDS Clinical Research Collaboration Chronic Migraine Treatment Trial|CMTT|The EMMES Corporation|Yes|Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|191|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 20, 2012|October 14, 2008|Yes|Yes||No|October 18, 2011|https://clinicaltrials.gov/show/NCT00772031||148857|
NCT00772629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA16|Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults|Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults Who Were Either Previously Vaccinated With Unconjugated Meningococcal Polysaccharide (Serogroups A, C or Serogroups A, C, Y, and W-135) Vaccine or Not Vaccinated With Meningococcal Vaccine||Sanofi|No|Terminated|January 2004|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|October 13, 2008|No|Yes|See detailed description for termination reason|No|March 16, 2009|https://clinicaltrials.gov/show/NCT00772629||148811|Enrollment was terminated before the planned sample size was achieved because the principal investigator and the Sponsor decided that sufficient sera had been obtained to meet the secondary objective of the study.
NCT00772941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051109|Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Champix (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|February 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3939|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A3051109 prescribes the Varenicline(Champix).|January 2014|January 28, 2014|October 13, 2008|No|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00772941||148787|
NCT00772915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616057|Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Trial of Revlimid® and "On Demand" Dexamethasone Dosing in Patients With Newly Diagnosed Symptomatic Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|December 2008|May 2016|Anticipated|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|120 Years|No|||March 2015|February 5, 2016|October 12, 2008|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00772915||148789|
NCT00773474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG BRE07-126|Lonafarnib in Metastatic Breast Cancer|A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer||Hoosier Cancer Research Network|Yes|Terminated|October 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 14, 2008|No|Yes|funding terminated|No|December 15, 2015|https://clinicaltrials.gov/show/NCT00773474||148746|
NCT00773487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/06 DEP-SFB|Influence of Diesel Exhaust Particles (DEP) With and Without Organic Compounds on the Allergic Inflammation in Asthmatic Subjects|Influence of Diesel Exhaust Particles (DEP) With and Without Organic Compounds on the Allergic Inflammation in Asthmatic Subjects||Fraunhofer-Institute of Toxicology and Experimental Medicine||Completed|October 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|55 Years|No|||July 2009|July 24, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00773487||148745|
NCT00773760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITK-1|MOR and COMT SNP Polymorphism and Pain|Does mu Opioid Receptor (MOR) and Catechol-O-methyltransferase (COMT) Genes Polymorphism Correlate of Clinical Postoperative Pain and Response to Analgesics||East Tallinn Central Hospital|Yes|Recruiting|October 2008|December 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood|Both|18 Years|75 Years|No|Probability Sample|patients with prostate cancer|August 2009|August 4, 2009|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773760||148724|
NCT00774046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11884A|High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML|High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia||University of Chicago|Yes|Completed|December 2002|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|10 Years|N/A|No|||January 2014|January 16, 2014|October 15, 2008|Yes|Yes||No|December 17, 2012|https://clinicaltrials.gov/show/NCT00774046||148702|
NCT00774059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-1-024|Evaluation of Safety and Performance of the Orbix Breast Lift System|Phase 1 Study to Evaluate the Safety and Performance of the Orbix Breast Lift System||Maastricht University Medical Center|Yes|Not yet recruiting|January 2009|January 2011|Anticipated|January 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774059||148701|
NCT00774306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23NS058669|Antiepileptic Drugs and Vascular Risk Markers|The Effects of Antiepileptic Drugs on Serum Lipids and Inflammation in Patients With Subarachnoid Hemorrhage||Thomas Jefferson University|No|Terminated|April 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Both|N/A|N/A|No|||November 2014|November 19, 2014|October 16, 2008||No|study no longer consistent with current clinical practice|No|November 19, 2014|https://clinicaltrials.gov/show/NCT00774306||148682|Study terminated due to 1) change in clinical practice; 2) inadequate recruitment and follow-up.Number of pts providing full data was <15% of goal. Because of this, any analysis of data was considered futile, and no analyses were performed.
NCT00776217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213_LORAT_06|Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study on Loratadine Formulations Comparing Loratadine 10 mg Orally Disintegrating Tablets of Ohm Laboratories, Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With Claritin® Reditabs 10 mg Tablet (Containing Loratadine 10 mg) of Schering- Plough Healthcare Product Inc, in Healthy, Adult, Male, Human Subjects Under Fasting Condition||Ranbaxy Inc.|Yes|Completed|June 2006|September 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776217||148538|
NCT00781794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3230A1-1005|Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|January 2009|August 2009|Anticipated|August 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|30|||Both|18 Years|55 Years|No|||July 2009|July 21, 2009|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781794||148115|
NCT00783380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK No 805 (EK 151/03)|Influenza Vaccination in Immunocompromized Patients|Double Blind Randomized Comparison of a Subunit- and a Virosomal Influenza Vaccine in Immunocom-Promized Patients||University Hospital Inselspital, Berne|No|Completed|October 2005|March 2008|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|304|||Both|18 Years|N/A|No|||October 2008|October 31, 2008|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783380||147994|
NCT00783419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 07-042|Rate of Pelvic Inflammatory Disease at St. Michael's Hospital|Rate of Pelvic Inflammatory Disease and Tubo-ovarian Abscess at SMH||St. Michael's Hospital, Toronto|No|Completed|March 2007|January 2011|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|55|||Female|N/A|N/A|No|Non-Probability Sample|Women with pelvic-inflammatory disease or tubo-ovarian abscess|October 2008|September 2, 2011|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783419||147991|
NCT00782756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-126|Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma|A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|October 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782756||148042|
NCT00782769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-OXY-302|A Safety Extension Study of DR-OXY-301|A Multicenter, Parallel-Group Extension Study to Evaluate the Safety of Two Doses of DR-3001 in Women With Overactive Bladder||Teva Pharmaceutical Industries|No|Completed|September 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Female|18 Years|N/A|No|||August 2013|August 30, 2013|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782769||148041|
NCT00783003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112146|A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects|A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705 and GW642444 as Monotherapies and in Combination in Healthy Japanese Subjects||GlaxoSmithKline|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783003||148023|
NCT00783016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSKim|Effect of Pain Control on the Diagnosis of Acute Appendicitis on the Diagnostic Accuracy of General Surgeon|||Seoul National University Hospital||Completed|October 2008|May 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|234|||Both|16 Years|90 Years|No|||July 2011|July 25, 2011|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783016||148022|
NCT00783302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-012-096|Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care|A Prospective, Multi-Center Registry Study for Clinical Outcome in Subjects Undergoing Coronary Computed Tomography Angiography (CCTA) Examination (VISIPAQUE Registry Study)||GE Healthcare|No|Completed|September 2008|April 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|885|||Both|18 Years|N/A|No|Non-Probability Sample|Patient suspected of having coronary artery disease or CAD.|December 2014|December 9, 2014|October 30, 2008|No|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00783302||148000|
NCT00773890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101-201|TRF-1101 Assessment in Sickle Cell Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Activity of TRF-1101 on Microvascular Blood Flow, Vascular Endothelial Injury, and Vasoocclusive Pain in Patients With Sickle Cell Disease||TRF Pharma, Inc|Yes|Terminated|July 2008|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2009|May 7, 2009|October 14, 2008|Yes|Yes|Study was stopped due to perceived futility because the baseline pain score in first 40    patients was too low to be able demonstrate an improvement|No||https://clinicaltrials.gov/show/NCT00773890||148714|
NCT00773903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-200V|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2008|||||N/A|N/A|N/A||||||||||||||November 24, 2008|October 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773903||148713|
NCT00773916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-208|The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder|||Federal University of Rio Grande do Sul|Yes|Completed|March 2006|July 2009|Actual|July 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|130|||Both|5 Years|18 Years|No|||August 2009|August 14, 2009|October 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773916||148712|
NCT00774228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITX-08-002|I-ZIP Ocular Bandage Pivotal Study|Clinical Evaluation of the I-ZIP® Ocular Bandage as a Protective Ocular Bandage in Subjects Undergoing Clear Corneal Cataract Surgery With IOL Implantation: A Pivotal Study||Ocular Therapeutix, Inc.||Completed|November 2008|||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||August 2009|August 7, 2009|October 16, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00774228||148688|
NCT00772044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C009|Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea|Randomized, Double-blind Study to Compare Safety and Effectiveness of the ProventTM Professional Sleep Apnea Therapy Device to Sham for the Non-invasive Treatment of OSAH|AERO|Ventus Medical, Inc.|No|Completed|November 2008|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2010|March 31, 2010|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772044||148856|
NCT00772356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000559|A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes|A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes||Hoffmann-La Roche||Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|14|||Male|18 Years|65 Years||||June 2010|March 1, 2016|October 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00772356||148832|
NCT00772369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5A08|Retrospective Survey of Safety of Fourth Dose Pentacel® in Children|Retrospective Safety Survey of Selected Events in the 6 Months Following the 4th Dose of the Pentacel® Vaccination Series in Children||Sanofi|No|Completed|September 2003|April 2005|Actual|April 2004|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3214|||Both|12 Months|24 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children residing in the Canadian Province of British Columbia who have received the 4th        dose of the Pentacel® series before their 2nd birthday|January 2014|January 20, 2014|October 13, 2008|Yes|Yes||No|March 15, 2010|https://clinicaltrials.gov/show/NCT00772369||148831|
NCT00772954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-030-010|Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity|A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of Two Doses of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18 - 55 Years)||Sanofi|No|Terminated|March 2006|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|October 10, 2008|Yes|Yes|Issues with CTM stability.|No|March 13, 2012|https://clinicaltrials.gov/show/NCT00772954||148786|This study was terminated early in light of issues with CTM stability. All other study procedures and visits were performed per protocol.
NCT00773214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18926|Inter Individual Variation in Weight Loss Response to Exercise|Identification and Characterization of Individual Variability in Exercise-induced Weight Loss: Biological and Behavioral Markers of Success.||Norwegian University of Science and Technology|Yes|Completed|April 2008|December 2009|Actual|February 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773214||148766|
NCT00773500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U18HS0169705E|Impact of Vendor Systems on Ambulatory Medication Safety|Impact of Vendor Systems on Ambulatory Medication Safety|BWHCERT5E|Weill Medical College of Cornell University|No|Completed|September 2008|October 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Our study will take place in 2 NYS communities. We will select 2 communities in order to        assemble a study population with the following characteristics: use of at least 2        different vendor-based systems, different implementation times (with some communities        being early adopters and others experienced users), and inclusion of urban underserved and        federally defined rural areas.        We will select the following 2 communities/organizations: the community health centers        implementing electronic prescribing with the New York City Department of Health (NYC DOH)        and the Taconic Health Information Network and Community (THINC) in the Hudson Valley of        New York. Both communities have expressed their interest in participating in this study.|February 2012|February 27, 2012|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00773500||148744|
NCT00773773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-114|Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer|A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2008|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Male|18 Years|N/A|No|||January 2016|January 27, 2016|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773773||148723|
NCT00774085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003886|An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone|Electronic Schizophrenia Treatment Adherence Registry|e-STAR|Janssen Cilag N.V./S.A.|No|Completed|November 2004|December 2007|Actual|December 2007|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|408|||Both|N/A|N/A|No|Non-Probability Sample|Patients with schizophrenia|April 2012|April 26, 2012|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774085||148699|
NCT00774098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-06-012|Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections|Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections||McGill University Health Center|No|Completed|January 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2010|March 31, 2010|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774098||148698|
NCT00774345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CLL-002|A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)||Celgene|Yes|Active, not recruiting|January 2009|October 2020|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00774345||148679|
NCT00774319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWHHT08-01|TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer|A Randomised Study of TPF as Neoadjuvant Chemotherapy Followed by Concomitant Chemoradiotherapy (CRT) With Conventional Radiotherapy (RT) Versus Concomitant CRT With Accelerated RT in Patients With Locally Advanced Head and Neck Squamous Cell Cancer (HNSCC) in Good Condition. The Condor Study. A Study of the Dutch Head and Neck Cancer Group (DHNCG).|Condor|Radboud University|Yes|Recruiting|December 2008|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||April 2012|April 10, 2012|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774319||148681|
NCT00774332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-011|A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL|A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL||Cooperative Study Group A for Hematology|No|Recruiting|June 2006|December 2009|Anticipated|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|15 Years|65 Years|No|||October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774332||148680|
NCT00781547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHNIDDM|Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus||GHDM|Göteborg University|No|Completed|January 1999|May 2005|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|40 Years|65 Years|No|||October 2008|October 28, 2008|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781547||148134|
NCT00782080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stei-Sed-0106|Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD|Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) Versus Placebo in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)||Johannes Gutenberg University Mainz|Yes|Completed|July 2008|June 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|155|||Both|6 Years|17 Years|No|||March 2014|March 12, 2014|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782080||148093|
NCT00782054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-05-08573|Evaluation of Post Burn Rehabilitation Population for Itch Control|Evaluation of Provase in the Post Burn Rehabilitation Population for Itch Control and Moisturization Properties||Swiss-American Products, Inc|Yes|Completed|September 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||October 2008|October 27, 2008|October 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782054||148095|
NCT00782067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPKC412D2201|Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia|A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease||Novartis|No|Active, not recruiting|October 2008|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782067||148094|
NCT00783692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13007|Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease|A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease|GEMINI II|Millennium Pharmaceuticals, Inc.|Yes|Completed|December 2008|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1116|||Both|18 Years|80 Years|No|||June 2014|June 19, 2014|October 31, 2008|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00783692||147970|
NCT00783341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3205K2-1001|Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously|An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 16, 2009|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783341||147997|
NCT00783354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03147|A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)|A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® "Continuous Treatment" Versus Aerius® "PRN Regimen" on Chronic Idiopathic Urticaria Patient Quality of Life|ATTITUD|Merck Sharp & Dohme Corp.|No|Completed|April 2003|April 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783354||147996|
NCT00774241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21343|PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer|An Open Label Study of the Effect of First Line Combination Treatment With Avastin and Docetaxel on Disease Response in Patients With Metastatic Breast Cancer||Hoffmann-La Roche||Withdrawn|January 2010|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 16, 2008||No|Study was put on hold then out of Medical Plan therefore cancelled|No||https://clinicaltrials.gov/show/NCT00774241||148687|
NCT00774488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIP-Genexpression Study|Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue|||German Institute of Human Nutrition|Yes|Completed|January 2006|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|17|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774488||148669|
NCT00774501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-117|The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy|A Pilot Study to Assess the Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy||Memorial Sloan Kettering Cancer Center||Completed|October 2008|February 2016|Actual|February 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|80 Years|No|||February 2016|February 17, 2016|October 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00774501||148668|
NCT00774761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-087|A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Multiple-Dose,Double-Blind,Crossover Trial to Assess the Systemic Exposure of Fluticasone Propionate (FP)/Formoterol Fumarate (FF) Fixed-Dose Combination in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Dey|No|Completed|November 2008|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|97|||Both|40 Years|N/A|No|||May 2013|May 10, 2013|October 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00774761||148649|
NCT00775398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K847-08-4003|Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters.|A Phase 4, Multicenter, Open-Label, Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® (Thrombin, Topical U.S.P [Bovine Origin]) on Coagulation Parameters|MOSAIC|Pfizer|No|Completed|November 2008|November 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|553|None Retained|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Adult men and women who are scheduled to undergo qualified surgeries that are likely to        require the use of an active topical hemostatic agent.|June 2012|June 6, 2012|October 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00775398||148600|
NCT00775060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-066|Maastricht IBS Cohort|Maastricht IBS Cohort: Phenotypical and Genotypical Characterization of Patients With Irritable Bowel Syndrome.||Maastricht University Medical Center|No|Recruiting|September 2009|September 2024|Anticipated|September 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|At least 400 patients with (suspected) IBS referred to the GI-outpatient clinic of the        University Hospital Maastricht will be asked to participate in the study.|April 2011|April 19, 2011|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775060||148626|
NCT00775073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C24100|Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001|Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001||Treiber, Gerhard|Yes|Completed|October 2008|April 2012|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775073||148625|
NCT00772057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-PHT-02|Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)|Early Primary Prophylaxis With Beta-Blockers In Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: A Randomized Controlled Trial||Govind Ballabh Pant Hospital|No|Completed|October 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|164|||Both|12 Years|80 Years|No|||October 2008|December 18, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772057||148855|
NCT00772382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-A06|Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia|A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|October 10, 2008|Yes|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT00772382||148830|
NCT00773253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allergan cervical dystonia|Botox for Cervical Dystonia Following EMG Mapping|Pre-injection, Multi-channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia.||University of California, San Francisco|No|Completed|April 2008|January 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||September 2011|September 9, 2011|October 14, 2008||No||No|February 15, 2011|https://clinicaltrials.gov/show/NCT00773253||148763|One patient received single channel injection, but did not get multi-channel injection because the frontalis test showed immunity to botulinum toxin indicating no possibility of clinical benefit. This is an exclusion criterion.
NCT00773227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020908|Treatment of Dysphagia in Oculopharyngeal Muscular Dystrophy by Autologous Transplantation of Myoblasts|Treatment of Dysphagia in Oculopharyngeal Muscular Dystrophy by Autologous Transplantation of Myoblasts|OPMD|Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2004|October 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773227||148765|
NCT00773240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-18|A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment|A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis||ALK-Abelló A/S|No|Completed|April 2008|February 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|65 Years|No|||August 2011|August 27, 2011|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773240||148764|
NCT00774072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tobra nasal CF pilot|Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization|Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways||University of Jena|Yes|Completed|October 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|8 Years|N/A|No|||December 2014|December 3, 2014|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774072||148700|
NCT00774124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071694|Improving Outcomes in Underserved Women With GDM|Improving Outcomes in Underserved Women With GDM||Temple University|No|Completed|August 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|57|||Female|18 Years|45 Years|No|||November 2015|November 2, 2015|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774124||148696|
NCT00774878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD10631|Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer|Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer||Sanofi|No|Terminated|October 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Female|18 Years|N/A|No|||March 2011|March 2, 2011|October 16, 2008|Yes|Yes|Company decision to discontinue the AVE1642 development program, not due to any safety or    efficacy concerns|No||https://clinicaltrials.gov/show/NCT00774878||148640|
NCT00775216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080811|Project Diabetes: Prescription for Healthy Living|Project Diabetes: Prescription for Healthy Living||Vanderbilt University|No|Terminated|October 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|13|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|October 7, 2008||No|grant funding ended and lack of sufficient participants to complete trial|No||https://clinicaltrials.gov/show/NCT00775216||148614|
NCT00774618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB e4073|Evaluation of Surgical Treatment on Pain and Disability for Chronic, Non-healing Rib Fracture|Prospective Trial of Operative Management of Rib Fracture Non-Union||Oregon Health and Science University|Yes|Completed|October 2008|December 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|34|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|October 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00774618||148659|
NCT00781807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSfH-Project-No. F/05/08|Rehabilitation and Outcome for Patients on LVAD Support|Multi-module Rehabilitation for Patients on LVAD Support - Impact on Long-term Outcomes||Hannover Medical School|Yes|Recruiting|November 2008|April 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Both|18 Years|N/A|No|||August 2009|August 24, 2009|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781807||148114|
NCT00782795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-PENQEX-1R21AA017271|Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality|Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality||University of Michigan|Yes|Completed|November 2008|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00782795||148039|
NCT00782470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12749|Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A|A Prospective, Non-interventional, Multi-center, Open-label Study to Evaluate the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Subjects With Severe Hemophilia A Receiving Prophylaxis and On-demand Treatment Regimen||Bayer|No|Completed|December 2007|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|38|||Male|14 Years|29 Years|No|Non-Probability Sample|Cohort 1 - Prospective Prophylaxis Group Cohort 2 - Prospective On-demand Group Cohort 3 -        Retrospective On-demand Group|October 2014|October 31, 2014|October 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00782470||148063|
NCT00782782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|366-28.12.07|Vascular Sensitivity to Adrenergic Agonists in Patients With CHF and in Healthy Subjects|Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects||Hadassah Medical Organization|No|Active, not recruiting|August 2008|December 2011|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|samples for norepinephrine and PRA will be retained|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with congestive heart failure NYHA I-II and healthy subjects|October 2008|October 28, 2008|October 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00782782||148040|
NCT00783991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-05|Investigating the Impact of Mode of Administration on Item Response|Investigating the Impact of Mode of Administration on Item Response||Stony Brook University|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|Community samples with at least one of these conditions: chronic obstructive pulmonary        disease (COPD), depression (DEP), or rheumatoid arthritis (RA).|June 2013|June 5, 2013|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783991||147948|
NCT00783679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000222|The Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation|Determining the Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation||Massachusetts General Hospital|No|Withdrawn|November 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|October 30, 2008||No|Understaffing and inadequate funding|No||https://clinicaltrials.gov/show/NCT00783679||147971|
NCT00775086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002209|Bioequivalence Study of Patches With Different Equilibration Profiles|A Definitive Bioequivalence Study of ORTHO EVRA Exhibiting Faster Equilibration Profile and Currently Marketed ORTHO EVRA in Healthy Female Volunteers||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|August 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Health Services Research|||Actual|42|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|June 6, 2011|June 19, 2008||||||https://clinicaltrials.gov/show/NCT00775086||148624|
NCT00775099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/S1103/46|Combustion Derived Air Pollution and Vascular Function|The Effects of Combustion-Derived Air Pollution on Vascular Vasomotor and Fibrinolytic Function in Healthy Volunteers (Diesel Exposure)||University of Edinburgh|No|Completed|September 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|16|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775099||148623|
NCT00775411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-019|Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)|||Allergan|No|Completed|November 2008|April 2010|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|50 Years|N/A|No|||August 2012|August 1, 2012|October 16, 2008|Yes|Yes||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00775411||148599|
NCT00775710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV-JS1|Clinical Trial Assessing Two Protocols to Withdraw Non-invasive Ventilation in Hypercapnic Respiratory Failure|A Randomized Controlled Trial Comparing Two Protocols to Withdraw Non-invasive Ventilation (NIV) After an Episode of Hypercapnic Respiratory Failure||Hospital Clinic of Barcelona|No|Completed|March 2006|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|128|||Both|N/A|N/A|No|||October 2008|June 21, 2011|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775710||148576|
NCT00776009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124EUS21|Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.|A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.||Novartis||Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|165|||Both|6 Years|12 Years|No|||June 2011|June 6, 2011|October 16, 2008|Yes|Yes||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00776009||148553|
NCT00776022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11849|Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions|An Open Label, Randomized, Single-center, Single-dose, Two-treatment, Two-period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec® Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fed Condition||Ranbaxy Inc.|Yes|Completed|April 2005|June 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776022||148552|
NCT00772083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00008944|Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors|Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors||Medical College of Wisconsin|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|N/A|No|||August 2010|August 10, 2010|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772083||148853|
NCT00772395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-745/4|Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty|Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study|PREVENT|Danderyd Hospital|No|Completed|April 2006|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|40 Years|70 Years|No|||September 2014|September 18, 2014|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772395||148829|
NCT00772408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 95-2314-B-182A-030|Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis|Relationship Between TLR2 Polymorphism and Pulmonary Tuberculosis||Chang Gung Memorial Hospital|Yes|Completed|August 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|Samples With DNA|peripheral blood leukocyte DNA and plasma|Both|20 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Case: patients visiting the Pulmonary department of Chang Gung Memorial Hospital,        Kaohsiung, Taiwan Control:healthy subjects visiting the Center of health examination at        Chang Gung Memorial Hospital, Kaohsiung, Taiwan|October 2008|February 27, 2013|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772408||148828|
NCT00772928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5A07|Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™|Immunogenicity Assessment of Pentacel™ (Hybrid CP20/20/5/3DT-mIPV//PRP-T) When Given at Different Times From or Concurrently With a Pneumococcal Conjugate Vaccine||Sanofi|Yes|Completed|October 2003|November 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1167|||Both|42 Days|89 Days|Accepts Healthy Volunteers|||January 2012|January 30, 2012|October 13, 2008|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00772928||148788|
NCT00773526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21895|A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.|An Open Label Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO5126766, a Dual Raf and MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors||Hoffmann-La Roche||Completed|November 2008|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773526||148742|
NCT00773513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH21260|A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.|A Randomized, Open Label Study to Assess All-cause Mortality and Cardiovascular Morbidity in Patients With Chronic Kidney Disease on Dialysis and Those Not on Renal Replacement Therapy Under Treatment With Mircera or Reference ESAs.||Hoffmann-La Roche||Recruiting|December 2008|November 2019|Anticipated|November 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2800|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773513||148743|
NCT00774891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-091|Comparison Of Left Ventricular Volume And Wall Stress With Dobutamine And Exercise Echocardiography|Comparison Of Left Ventricular Volume And Wall Stress With Dobutamine And Exercise Echocardiography||Lahey Clinic|No|Withdrawn|October 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|30 Years|80 Years|No|Non-Probability Sample|Lahey Clinic patients referred by their physician for stress echocardiograms for clinical        indications. Approximately 30 patients referred for an exercise stress echocardiography        and approximately 30 patients referred for a dobutamine stress echocardiography.|February 2012|February 16, 2012|October 16, 2008||No|difficulty enrolling patients into this study|No||https://clinicaltrials.gov/show/NCT00774891||148639|
NCT00774904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPN|Adiponectin and Insulin Resistance in Diabetic Nephropathy|Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan||Xi’an Jiaotong University College of Medicine||Completed|April 2007|November 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Both|18 Years|N/A|No|||October 2008|October 17, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774904||148638|
NCT00775229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806M36061|Naltrexone in the Treatment of Trichotillomania|A Double-blind, Placebo-controlled Study of Naltrexone in Trichotillomania||University of Chicago|Yes|Completed|August 2008|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|75 Years|No|||January 2014|January 31, 2014|October 16, 2008|Yes|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00775229||148613|
NCT00775528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S245.3.128|Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis||Solvay Pharmaceuticals|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|1 Month|6 Years|No|||October 2010|October 25, 2010|October 17, 2008|Yes|Yes||No|September 9, 2010|https://clinicaltrials.gov/show/NCT00775528||148590|
NCT00781820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12999|Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste|A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste||Bayer|No|Completed|October 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|693|||Both|18 Years|N/A|No|||June 2013|June 9, 2013|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00781820||148113|
NCT00783055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-1-52G|Autonomy Among Physically Frail Older People in Nursing Homes|Autonomy Among Physically Frail Older People in Nursing Homes: a Study Protocol for an Intervention Study||University of Southern Denmark|No|Completed|March 2005|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|66|||Both|65 Years|N/A|No|||August 2008|October 30, 2008|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783055||148019|
NCT00783068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 20388.091.07|Anti-inflammatory Effects of GTS-21 After LPS|The Effect of the Alpha-7 Nicotinic AChR Agonist GTS-21 on Inflammation and End-organ Dysfunction During Human Endotoxemia||Radboud University|Yes|Completed|August 2008|August 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2008|November 4, 2010|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783068||148018|
NCT00783042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1840M00006|Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements|A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Transthoracic Doppler Echocardiography Method as a Non-Invasive Method for Coronary Function Measurements; Ability to Detect Short-Term Statin Effects in Patients With Increased Cardiovascular Risk||AstraZeneca|No|Completed|October 2008|May 2009|Actual|||Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|45 Years|75 Years|No|||June 2009|June 29, 2009|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783042||148020|
NCT00783367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02408|Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas|Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|July 2008|||December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|December 14, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783367||147995|
NCT00784004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001371|Investigation of Efficiency of Breathing With Different Breathing Patterns|Investigation of Efficiency of Breathing With Different Breathing Patterns in Healthy Volunteers and Patients With Respiratory Failure||Massachusetts General Hospital|No|Completed|November 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784004||147947|
NCT00783705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00839|Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia|Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol Versus Placebo in Smokers With Bronchial Dysplasia||National Cancer Institute (NCI)||Completed|November 2008|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|85|||Both|45 Years|79 Years|No|||June 2014|July 28, 2015|October 31, 2008|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT00783705||147969|
NCT00783978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 07019|Surfactant Disorders and Chronic Lung Disease|Surfactant Disorders Associated With Chronic Lung Disease in Children.|APSE|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|58|Samples With DNA|Whole blood, plasma, DNA|Both|1 Month|17 Years|No|Non-Probability Sample|French pulmonary units participating to the study|November 2012|November 16, 2012|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783978||147949|
NCT00775424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807682|PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection|A PHASE Ib PARTIALLY RANDOMIZED PILOT STUDY INTENDED TO EVALUATE THE SAFETY AND IMMUNOLOGICAL EFFECTS OF HIV-1 DNA IMMUNIZATION (PENNVAX-B) WITH OR WITHOUT CO-ADMINISTRATION OF CONSTRUCTS CONTAINING DNA ENCODING FOR THE EXPRESSION OF EITHER IL-12 OR IL-15 IN HIV INFECTED INDIVIDUALS||University of Pennsylvania|Yes|Completed|September 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|38|||Both|18 Years|50 Years|No|||June 2010|June 18, 2010|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775424||148598|
NCT00775437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-444|Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use|Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA)||AbbVie|No|Completed|March 2009|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|2 Years|4 Years|No|||December 2015|December 17, 2015|October 17, 2008|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00775437||148597|
NCT00775450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID21|Influenza Vaccine Revaccination in Ambulatory Elderly Subjects|Safety and Immunogenicity of Revaccination With Influenza Vaccine in Ambulatory Elderly Subjects Previously Vaccinated With Fluzone ID, Fluzone HD, and Fluzone® IM||Sanofi|No|Completed|October 2008|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|807|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 5, 2013|October 16, 2008|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00775450||148596|
NCT00775723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1673|Melatonin Production Delay in Preterm Infants|Term-Born Infants at 9 and 12 Months of Age: A Randomized Controlled Trial||Tel Aviv University|No|Completed|January 2008|May 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|9 Months|12 Months|No|Probability Sample|Design: Forty-six infants (23 full term and 23 preterm babies) infants and their mothers        were randomly recruited from a successive list of preterm and term labors at a large urban        medical center in Northern Israel and were assigned to the study. We calculated that a        sample size of 30 mother-infant dyads is sufficient to show a significant effect of the        intervention with a power of 90% and 5% risk of type alpha error (Cohen , chen, West &        Aiken, 2003). This calculation was based on the effect size found in full-term infants        melatonin secetion (1).|October 2008|October 30, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775723||148575|
NCT00776035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1128|Sex and Obesity: Effects on Heart Failure Study|Sex and Obesity Effects on Myocardial Blood Flow and Metabolism||Washington University School of Medicine|No|Active, not recruiting|January 2008|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Non diagnostic genetic samples|Both|20 Years|65 Years|No|Non-Probability Sample|obesity related heart failure patients|June 2015|June 4, 2015|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776035||148551|
NCT00772668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20070963|Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma|Pilot Study of RCVELP as First Line Therapy for Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)||University of Miami Sylvester Comprehensive Cancer Center|Yes|Terminated|September 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|17 Years|N/A|No|||August 2013|July 25, 2014|October 12, 2008|No|Yes|Funding|No|January 18, 2013|https://clinicaltrials.gov/show/NCT00772668||148808|This study was terminated early due to lack of funding. All patients were removed from the study. No results were analyzed.
NCT00773786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASRC956|Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)|A Double-Blind, Crossover Study to Assess the Effects of Nebulized Brovana Added to Tiotropium on FEV1, Hyperinflation, and Exercise Endurance Capacity in COPD||Saint Francis Care|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|90 Years|No|||December 2013|May 19, 2015|October 14, 2008|Yes|Yes||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00773786||148722|
NCT00774111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111603|GSK1349572 Drug Interaction Study With Etravirine|A Phase I, Open Label, Two Period, Single Fixed-Sequence Crossover Study to Evaluate the Effect of Etravirine on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING111603)||GlaxoSmithKline||Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|June 4, 2009|October 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00774111||148697|
NCT00774631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 060217|IHPOTOTAM : Induced HyPOthermia TO Treat Adult Meningitis|Mild Induced Hypothermia to Treat Severe Community Acquired Meningitis in Adults Admitted to Intensive Care Unit|IHPOTOTAM|Assistance Publique - Hôpitaux de Paris|No|Terminated|March 2009|July 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||July 2012|September 14, 2012|October 16, 2008||No|The sponsor stoppes the study for the security problem.|No||https://clinicaltrials.gov/show/NCT00774631||148658|
NCT00774644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B025511|Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.|The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|December 2002|February 2003|Actual|January 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|November 17, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774644||148657|
NCT00774657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-090|Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography|Patterns Of Left Ventricular Remodeling In Patients With Aortic Stenosis Assessed By Two-Dimensional And Three-Dimensional Echocardiography||Lahey Clinic|No|Withdrawn|September 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|90 Years|No|Non-Probability Sample|Lahey Clinic patients who have been referred to the echocardiography lab for clinical        indications, found to have a aortic stenosis|February 2012|February 16, 2012|October 16, 2008||No|Unable to identify and recruit suitable study subjects|No||https://clinicaltrials.gov/show/NCT00774657||148656|
NCT00774917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSC-IBS/05-2007|Numen Stent Assessment Using OCT Technique in a Single Center Study|Numen Stent Assessment Using OCT Technique in a Single Center Study|NAUTIC|International Biomedical Systems S.p.A.|No|Recruiting|October 2008|March 2010|Anticipated|September 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2009|June 22, 2009|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774917||148637|
NCT00775541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11066|Hyperglycemia and Oxidative Stress in the Human Brain With Diabetes|Hyperglycemia and Oxidative Stress in the Human Brain With Diabetes||University of Kansas Medical Center|Yes|Terminated|October 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|30 Years|55 Years|No|||June 2012|June 15, 2012|October 17, 2008||No|Insufficient dose for MRI scanning|No||https://clinicaltrials.gov/show/NCT00775541||148589|
NCT00775554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-118|Comparison Study of Using Ultrasound Guidance for Hematoma Blocks vs. Traditional Approach|"Are Ultrasound-guided Hematoma Blocks for Distal Forearm Fractures Superior to the Landmark-guided Method for Hematoma Blocks?"||St. Luke's-Roosevelt Hospital Center|Yes|Withdrawn|September 2008|||August 2009|Anticipated|N/A|Interventional|N/A|2||Actual|0|||Both|18 Years|N/A|No|||October 2008|October 13, 2015|October 17, 2008||No|no participants enrolled|No||https://clinicaltrials.gov/show/NCT00775554||148588|
NCT00782483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104344|Personalized Interactive Laser Therapy of Port Wine Stain|Personalized Interactive Laser Therapy of Port Wine Stain - Study 2||University of Arkansas|Yes|Terminated|October 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|3 Months|17 Years|No|||June 2014|June 19, 2014|October 29, 2008||No|PI moved out of state.|No|January 6, 2014|https://clinicaltrials.gov/show/NCT00782483||148062|PI relocated and protocol was terminated, and no subject returned for treatment under protocol.
NCT00782808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 011|Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV|||South East Asia Research Collaboration with Hawaii|No|Completed|March 2009|April 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected individuals meeting MOPH criteria to initiate HAART and planning to initiate        HAART within a month of screening. Consequently, all participants will have plasma CD4        counts at less than 250 cells.|September 2014|September 25, 2014|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782808||148038|
NCT00783081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-134-2.01US|Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication|||Kowa Research Institute, Inc.|Yes|Completed|November 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|387|||Both|40 Years|N/A|No|||March 2012|March 21, 2012|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783081||148017|
NCT00783432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP432|Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis|Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis||Meda Pharmaceuticals|No|Completed|July 2006|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|862|||Both|12 Years|N/A|No|||October 2009|October 1, 2009|October 30, 2008|No|Yes||No|December 29, 2008|https://clinicaltrials.gov/show/NCT00783432||147990|
NCT00783718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13006|Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis|A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis|GEMINI I|Millennium Pharmaceuticals, Inc.|Yes|Completed|January 2009|March 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|895|||Both|18 Years|80 Years|No|||June 2014|June 19, 2014|October 31, 2008|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00783718||147968|
NCT00783393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03745|SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)|SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma||Merck Sharp & Dohme Corp.|Yes|Completed|May 2003|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783393||147993|
NCT00783406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7881010|Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.|A Phase 2A, Double Blind (3rd Party Open), 4 Way Cross-Over, Placebo Controlled Study To Investigate The Pharmacokinetics, Safety, Toleration And Efficacy Of Single Inhaled Doses Of PF-00610355 In Moderate COPD Patients.|A7881010|Pfizer|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|20|||Both|40 Years|80 Years|No|||October 2010|October 27, 2010|October 30, 2008||||No||https://clinicaltrials.gov/show/NCT00783406||147992|
NCT00784238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015391|Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants|An Open-label, Prospective, Non-Comparative Study to Evaluate Subjective Well-Being and Responses in Patients With Schizophrenia Who Had Switched to Paliperidone Extended-Release Tablets|Power|Janssen Korea, Ltd., Korea|No|Completed|April 2008|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|289|||Both|18 Years|65 Years|No|||February 2014|February 7, 2014|October 31, 2008|Yes|Yes||No|February 7, 2014|https://clinicaltrials.gov/show/NCT00784238||147929|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.
NCT00775463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-DU-201|Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine|DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study|DISTOL-1|United Therapeutics|No|Completed|May 2009|July 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|October 17, 2008|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00775463||148595|
NCT00775736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3665|Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin|Observational Study Evaluating Safety in Patients With Type 2 Diabetes Treated With NovoMix® 30 or NovoMix® 50 or NovoMix®70 (Biphasic Insulin Aspart)|Mix2Mix|Novo Nordisk A/S|No|Completed|October 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|611|||Both|N/A|N/A|No|Non-Probability Sample|After the participating physicians' decision has been made to initiate NovoMix® therapy,        any patient with type 2 diabetes who is currently treated with a human premix insulin        therapy.|June 2012|June 15, 2012|October 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00775736||148574|
NCT00776048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E56806|Validation of an Obstacle Course Used in Patients With Muscle Tightness|The Validation of a New Method to Evaluate the Effects of Chemoneurolytic Intervention on Balance and Community Ambulation in Spastic Hemiplegic Patients||Kessler Foundation|No|Enrolling by invitation|January 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects ages > 18 years of age for this study. A total of up to 10 age matched controls        and 30 clinical patients with lower extremity spasticity will be enrolled. Of the 30        clinical patients, 20 clinical patients will have received BOTOX ® injections from their        clinical physician after their first visit.|October 2008|June 23, 2010|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00776048||148550|
NCT00771797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAOD Study|Peripheral Artery Occlusive Diseases (PAOD) Study - Clinical Assessment|Clinical Study to Assess the Clinical Efficacy of Flavanol-rich Cocoa on Vascular Function in Diabetic Patients With PAOD||RWTH Aachen University|No|Withdrawn|October 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 10, 2008||No|investigator took study to university hospital duesseldorf|No||https://clinicaltrials.gov/show/NCT00771797||148875|
NCT00772993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0340|Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma|Efficacy of RNFL / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma||Yonsei University|Yes|Recruiting|October 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|400|||Both|10 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|prospective consecutive recruitment from a tertialry glaucoma subspecialty practise|October 2008|October 15, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00772993||148783|
NCT00773006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPCIR02474|Canadian Anticoagulant Percutaneous Coronary Intervention Registry|Canadian Prospective, Observational Study on the Use of LMWH in the Setting of Percutaneous Coronary Intervention|CAPCIR|University of Alberta|No|Completed|February 2008|September 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|747|||Both|18 Years|N/A|No|Non-Probability Sample|UA, STEMI and NSTEMI ACS patients treated prior to PCI with LMWH and/or patients treated        with LMWH during PCI i.e. in catheterization laboratory.|October 2011|October 3, 2011|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00773006||148782|
NCT00772642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909004|Immune Parameters in the Cord Blood of Newborns Exposed to Malaria in the Womb|Profiling Immunological Parameters in the Cord Blood of Neonates Exposed to Plasmodium Falciparum in Utero||National Institutes of Health Clinical Center (CC)||Completed|October 2008|September 2010||||N/A|Observational|N/A|||Anticipated|120|||Female|18 Years|N/A|No|||September 2010|September 11, 2010|October 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00772642||148810|
NCT00772655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-No.:2006-005778-34|Zevalin® First Line in Follicular Lymphoma|Multicenter European Pilot Study of 90Yttrium-Ibritumomab Tiuxetan as First Line Therapy for Stage III - IV Follicular Lymphoma (and Selected Patients With Extended Stage II) Followed by Consolidation Rituximab for Patients in Complete Remission But With Persistent Molecular Disease||Charite University, Berlin, Germany|Yes|Active, not recruiting|October 2007|June 2015|Anticipated|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|50 Years|N/A|No|||July 2012|July 31, 2012|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772655||148809|
NCT00774358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-6-5354|Interleukin-2 Treatment for Wiskott-Aldrich Syndrome|Reinstituting Natural Killer Cell Cytotoxicity and Cytoskeletal Dynamics in Wiskott-Aldrich Syndrome With IL-2 Therapy|WAS|Children's Hospital of Philadelphia|Yes|Recruiting|October 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|24 Months|N/A|No|||December 2015|December 30, 2015|October 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00774358||148678|
NCT00774371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGPB-04-258-01-CPPB|Weight Reduction Intervention for Breast Cancer Survivors|The Survivors' Health And Physical Exercise Study|SHAPE|University of California, San Diego|No|Completed|January 2005|December 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|253|||Female|18 Years|N/A|No|||September 2011|September 16, 2011|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774371||148677|
NCT00774150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07110273|Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study|Transdisciplinary Studies of CBT for Anxiety in Youth|CATS|University of Pittsburgh|Yes|Completed|October 2008|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774150||148694|
NCT00774384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SysVac01 - C60P2|Regulation of Mucosal Immune Response to Systemic MenB Vaccine|A Phase II, Open Label, Randomised, Single Centre Study To Evaluate The Importance Of Naturally Induced Immune Regulation On The Mucosal Immune Response To Meningococcal Serogroup B Outer Membrane Vesicle (Omv) Vaccine When Administered Intramuscularly To Adults & Adolescents||University Hospitals Bristol NHS Foundation Trust|No|Recruiting|September 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|35|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||January 2010|February 3, 2012|October 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00774384||148676|
NCT00808496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901|The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis|A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis|MRx|McMaster University|Yes|Active, not recruiting|June 2009|April 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|186|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808496||146100|
NCT00775567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07111|Effect of Fructose on Colonic Microflora|Colonic Microbial and Clinical Adaptation to Large Doses of Fructose|MEF|Sir Mortimer B. Davis - Jewish General Hospital|Yes|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|45|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2009|August 9, 2011|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775567||148587|
NCT00782821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05274|Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients|Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B-Cell Depleting Therapy in Combination With Anti-Thymocyte Globulin [Rabbit] (Thymoglobulin®, Genzyme), Tacrolimus (Prograf®, Astellas), Mycophenolate Mofetil (CellCept®, Roche) and Corticosteroid Minimization||University of Cincinnati|No|Completed|September 2008|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|40|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|October 29, 2008|Yes|Yes||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00782821||148037|
NCT00782509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.12|12 / 48 wk Pivotal PFT vs PBO in COPD II|Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD||Boehringer Ingelheim||Completed|February 2009|||September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|644|||Both|40 Years|N/A|No|||June 2014|June 17, 2014|October 29, 2008||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00782509||148060|
NCT00783445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|610|Evaluating the Effectiveness of a Community Exercise Program to Reduce the Risk of Metabolic Syndrome Among Black Americans|Community Exercise and Metabolic Syndrome in Black Families||Johns Hopkins University|Yes|Completed|December 2008|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|21 Years|65 Years|No|||March 2014|March 10, 2014|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783445||147989|
NCT00783731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSI study|Low Dose of Midazolam is Superior to Conventional Dose for Rapid Sequence Intubation in Emergency Department (ED)|||Seoul National University Hospital||Completed|October 2008|January 2011|Actual|October 2010|Actual|N/A|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|90 Years|No|||July 2011|July 25, 2011|October 30, 2008||||No||https://clinicaltrials.gov/show/NCT00783731||147967|
NCT00783744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4027|Insulin Glargine Combination Therapies in Type II Diabetics|28-week, Open, Randomized, Multinational, Multicenter Clinical Trial to Compare Efficacy and Safety of Combination Therapy of Glimepiride Plus Metformin Plus HOE901 Insulin Analogue Versus a Two-injection Conventional Therapy With Premixed Insulin NPH 30/70 Bid in Type 2 Diabetes Mellitus Patients Poorly Controlled With Oral Antidiabetic Drug Treatment.|LAPTOP|Sanofi||Completed|December 2001|||August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|375|||Both|35 Years|75 Years|No|||September 2009|September 25, 2009|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783744||147966|
NCT00784251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33606-J|Validating PROMIS Instruments in Back and Leg Pain|Validating PROMIS Instruments in Back and Leg Pain||University of Washington|No|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|226|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with back and leg pain who are scheduled for epidural steroid injections and who        have had pain for at least 6 weeks.|December 2013|December 10, 2013|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784251||147928|
NCT00784264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CHK-DUM-2008/1|A Study on Intima Media Thickness (IMT) in Middle-aged Subjects|A Study on Intima Media Thickness (IMT) in Middle-aged Subjects|IMT|AstraZeneca|No|Completed|October 2008|June 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|45 Years|N/A|No|Non-Probability Sample|aged 55 or above with central obesity, male more than 90 cm; female more than 80 cm|January 2010|January 11, 2010|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00784264||147927|
NCT00784550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111114|A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS 250/50mcg Plus SPIRIVA HANDIHALER Versus SPIRIVA HANDIHALER Plus Placebo DISKUS in Subjects With Chronic Obstructive Pulmonary Disease (COPD). SPIRIVA and HANDIHALER Are Trade Marks of Boehringer Ingelheim|A 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID|ADC111114|GlaxoSmithKline|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|342|||Both|40 Years|N/A|No|||September 2012|September 13, 2012|October 31, 2008|Yes|Yes||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00784550||147905|
NCT00775749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PONV|Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)|Transdermal Nicotine in Female Patients at High Risk for PONV||Ochsner Health System|Yes|Withdrawn|April 2009|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|560|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|October 17, 2008||No|The study is not feasible with the number of subjects needed to complete it.|No||https://clinicaltrials.gov/show/NCT00775749||148573|
NCT00776074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENG K001 GF|A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.|3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients With Uterine Fibroids||Takeda|No|Completed|June 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|N/A|No|||June 2010|June 17, 2010|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00776074||148549|
NCT00771810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2007-002|Safety/Efficacy Study of a Drug to Reduce Thrombocytopenia in Patients Receiving Chemotherapy for Ovarian, Fallopian Tube or Peritoneal Cancer|Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma||US Biotest, Inc.|No|Terminated|October 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|34|||Female|18 Years|N/A|No|||April 2013|April 30, 2013|October 9, 2008|Yes|Yes|Insufficient incidence of thrombocytopenia in control population|No|February 25, 2013|https://clinicaltrials.gov/show/NCT00771810||148874|Feasibility considerations (e.g., slow patient enrollment and lower incidence of Grade 3-4 thrombocytopenia than planned) necessitated early termination of the study after 34 patients had been enrolled.
NCT00772070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA17|Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine|Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD||Sanofi|Yes|Completed|March 2003|May 2004|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|173|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|October 13, 2008|No|Yes||No|March 26, 2009|https://clinicaltrials.gov/show/NCT00772070||148854|
NCT00774137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|588|Examining New Diagnostic Tests for Acute Kidney Injury After Heart Surgery|Phase IV Multi Center Validation Study of Novel Biomarkers of Acute Kidney Injury After Cardiac Surgery||Yale University|No|Completed|April 2007|February 2014|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1550|Samples With DNA|Urine, plasma, buffy coat (optional)|Both|N/A|N/A|No|Non-Probability Sample|1. Adults undergoing CABG surgery or heart valve surgery.          2. Children undergoing cardic surgery (requiring CABG) to correct congenital heart             defects.|February 2015|February 2, 2015|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774137||148695|
NCT00772967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-105|A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)|A Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Analgesic Effects of Naproxen and Ultracet in a Walking Model of Osteoarthritis Knee Pain||Merck Sharp & Dohme Corp.|No|Completed|June 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|6||Actual|22|||Both|45 Years|N/A|No|||October 2015|October 16, 2015|October 13, 2008|No|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00772967||148785|
NCT00772980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/3002|Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus|A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus||Merz Pharmaceuticals GmbH|No|Completed|November 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||June 2010|June 30, 2010|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772980||148784|
NCT00773812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0096|Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders|Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine||Ohio State University|No|Completed|July 2007|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|4 Years|12 Years|No|||April 2014|April 7, 2014|October 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00773812||148720|
NCT00774683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 0706 Sub-study A|A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women|A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women||University of North Carolina, Chapel Hill|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|Samples With DNA|blood specimens and cervicovaginal fluids|Female|18 Years|49 Years|No|Non-Probability Sample|UNC ID Clinic, Durham County Health Department, Wake County Health Department|October 2011|October 21, 2011|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774683||148655|
NCT00807430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMD-00|Treatment Period and Long-term Effect of Functional Electric Stimulation (FES) for Bruxism|A Single Centre, Randomised, Clinical Placebo Controlled Study of the Optimal Treatment and Long-term Effect of FES on Bruxism||Medotech A/S|No|Terminated|February 2009|October 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||October 2009|October 20, 2009|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00807430||146181|
NCT00774930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-55-52030-730|An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome|A Double-blind, Randomized Placebo-controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome|ELECT|Ipsen|Yes|Completed|May 2009|December 2015|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||December 2015|January 7, 2016|October 15, 2008|No|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT00774930||148636|
NCT00774943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060169|A Study of AMG 557 in Adults With Systemic Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus||Amgen||Completed|December 2008|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|70 Years|No|||April 2013|April 5, 2013|October 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00774943||148635|
NCT00775242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/PAF/06|Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.|Comparative Efficacy and Safety Study of Three Different Doses of a Formulation Composed of Crystalline Estradiol and Progesterone Microspheres, Indicated for Monthly IM Injection for the Treatment ot Climacteric Symptoms.||Centro A.F. de Estudios Tecnologicos, S.A.|No|Completed|April 2007|November 2008|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|103|||Female|40 Years|65 Years|No|||August 2009|August 21, 2009|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775242||148612|
NCT00775255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPU-M-025/CLARI-250/05|Bioequivalence Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioavailability Study on Clarithromycin Formulations Comparing Clarithromycin 250 mg/5 mL Powder for Oral Suspension of Ranbaxy Laboratories With Biaxin® Granules 250 mg/5 mL Oral Suspension in Healthy, Adult, Human, Male Subjects Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|September 2005|December 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775255||148611|
NCT00775268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080200|18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma|A Pilot Study of 18F Fluorothymidine (FLT) PET/CT in Lymphoma||National Institutes of Health Clinical Center (CC)||Terminated|September 2008|October 2014|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|31|||Both|18 Years|100 Years|No|||October 2014|November 18, 2015|October 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00775268||148610|
NCT00775580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-310|Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Atenolol 100 mg Capsules in Healthy Volunteers||Ranbaxy Inc.|Yes|Completed|May 2005|July 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775580||148586|
NCT00775879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2004/01|Interest of the Induction With Target-controlled Inhalation of Sevoflurane on Spikes Wave Occurrence|Interest of the Induction With Target-controlled Inhalation of Sevoflurane on Spikes Wave Occurrence|SIZE|University Hospital, Bordeaux|No|Completed|March 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|34|||Female|18 Years|60 Years|No|||May 2013|May 17, 2013|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775879||148563|
NCT00775892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-ACL1B|SeriACL™ Device (Gen IB) Trial for Anterior Cruciate Ligament (ACL) Repair|A Multi-Center Open Label Study to Evaluate the SeriACL™ Device (Gen IB) for Primary Anterior Cruciate Ligament Repair||Serica Technologies, Inc.|Yes|Completed|September 2008|||May 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|No|||August 2011|August 7, 2011|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775892||148562|
NCT00782834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107DUS05T|Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)|Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib|07060|Fox Chase Cancer Center|No|Terminated|July 2008|October 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|October 29, 2008|Yes|Yes|Stopped early for futility, unable to meet accrual goals|No|December 17, 2010|https://clinicaltrials.gov/show/NCT00782834||148036|The study failed to meet its accrual goals. Study terminated prior to accruing 17 subjects due to futility of meeting endpoint.
NCT00784017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-ASP.5/ALL|Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia|Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia||medac GmbH|Yes|Completed|October 2008|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|199|||Both|1 Year|18 Years|No|||February 2013|February 26, 2013|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784017||147946|
NCT00784277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014326|A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Arm, Multicenter Study in Subjects With End-Stage Joint Disease to Compare the Frequency of Constipation Symptoms in SubjectsTreated With Tapentadol IR and Oxycodone IR Using a Bowel Function Patient Diary||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|597|||Both|18 Years|80 Years|No|||January 2012|January 9, 2012|October 31, 2008|Yes|Yes||No|July 22, 2010|https://clinicaltrials.gov/show/NCT00784277||147926|
NCT00784576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502-11-429|Incidence and Predictors of Delirium After Cardiac Surgery|Incidence and Predictors of Delirium After Cardiac Surgery: A Prospective Observational Cohort Study|IPDACS|Medical Universtity of Lodz|No|Completed|November 2004|October 2008|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|563|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the Department of Cardiac Surgery in Lodz, Poland|November 2008|December 2, 2008|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784576||147903|
NCT00784563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6261-R|Effects of Aerobic Exercise in Parkinson's Disease|Effects of Aerobic Exercise in Parkinson's Disease||VA Office of Research and Development|Yes|Completed|February 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|50 Years|80 Years|No|||August 2015|August 25, 2015|October 30, 2008||No||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00784563||147904|We adapted our design in response to recruitment challenges and preliminary results over the course of the study. This uncontrolled study cannot prove efficacy, but provides guidance for a future Phase III study on aerobic exercise in PD.
NCT00771823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT025|Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers|A Placebo Controlled Study of the Impact on Insulin Sensitivity and Lipid Profile of Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers||St Stephens Aids Trust|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|July 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00771823||148873|
NCT00772096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 151/08|Septic Encephalopathy and Late Cognitive Dysfunction|Septic Encephalopathy and Late Cognitive Dysfunction in Patients With Sepsis - the Role of Inflammation||University Hospital, Basel, Switzerland||Completed|October 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772096||148852|
NCT00772109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID31|Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults|Lot Consistency, Immunogenicity, and Safety Study of Three Lots of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years||Sanofi|No|Completed|October 2008|July 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|4292|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|October 13, 2008|Yes|Yes||No|July 16, 2011|https://clinicaltrials.gov/show/NCT00772109||148851|
NCT00772421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1636|Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Rhythm|Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Rhythm (SANTE RR)|SANTE RR|MedtronicNeuro|Yes|Completed|January 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|29|||Both|N/A|N/A|No|Non-Probability Sample|The study will enroll the number of patients necessary to achieve the required sample size        of 18 responders and 18 non-responders at a minimum of six (6) centers participating in        the U.S. SANTE study.|January 2012|January 27, 2012|October 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00772421||148827|
NCT00773266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-APHAKIA-08|Intraocular Position of Secondary Iris-Fixated IOLs in Aphakic Eyes|Intraocular Architecture of Secondary Implanted Anterior Chamber Iris-Fixated Lenses in Aphakic Eyes Evaluated With Anterior Segment Optical Coherence Tomography||Johann Wolfgang Goethe University Hospitals|No|Completed|September 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|16|||Both|16 Years|84 Years|No|Probability Sample|Patients with long standing Aphakia and eligibility for secondary IOL implantantion were        retrospectively examined|September 2012|September 26, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773266||148762|
NCT00773279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS290-1971|Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics|A Multi-centre, Randomised, Open-label, Cross-over Study to Explore Effectiveness, Safety, and Preference of a New Disposable Pen PDS290 Versus FlexPen® in Subjects With Type 1 or Type 2 Diabetes||Novo Nordisk A/S|No|Completed|September 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|October 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773279||148761|
NCT00774397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.5|Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)|Antiviral Effect, Safety and Pharmacokinetics of BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naïve and Treatment-experienced Patients for 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Double-blinded, Randomised, Placebo-controlled, Phase II)||Boehringer Ingelheim||Completed|October 2008|||November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|719|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|October 16, 2008||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT00774397||148675|
NCT00807976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODET1|Orthostatic Hypotension and Diabetes Mellitus|The Orthostatic Hypotension in the Diabetic Elderly Patients Trial (ODET)|ODET|Medical Research Foundation, The Netherlands|No|Completed|January 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|500|||Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Type 2 diabetic patients aged 70 years and older|October 2010|October 7, 2010|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807976||146140|
NCT00808210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT4562g|A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab|A PHASE II RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE, COMPARED TO INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB||Genentech, Inc.||Terminated|March 2009|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 11, 2008|Yes|Yes|Based on analysis of results and consideration of available treatments, the overall benefit to    risk profile of ocrelizumab was not favorable in RA.|No||https://clinicaltrials.gov/show/NCT00808210||146122|
NCT00808223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0485-CL-0004|Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis|A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]||Astellas Pharma Inc|Yes|Completed|April 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|12 Years|17 Years|No|||December 2013|December 10, 2013|December 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00808223||146121|
NCT00807729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9437-10261-12|Randomized Trial of ERCP Then Laparoscopic Cholecystectomy vs. Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration in Patients With Likely Choledocholithiasis|Prospective Randomized Trial of Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration (LC + LCBDE) Versus Endoscopic Retrograde Cholangiopancreatography Sphincterotomy Plus Laparoscopic Cholecystectomy (ERCP/S + LC) for Common Bile Duct Stone Disease|ERCP/CBDE|University of California, San Francisco|No|Completed|January 1997|November 2007|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|65 Years|No|||September 2009|September 2, 2009|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807729||146159|
NCT00808249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00006|AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)|A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD)||AstraZeneca||Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|725|||Both|18 Years|65 Years|No|||April 2011|June 15, 2011|December 12, 2008|Yes|Yes||No|January 28, 2011|https://clinicaltrials.gov/show/NCT00808249||146119|
NCT00808782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|277/07|The Use of rTMS to Improve Theory of Mind Among Adults With Autism and Asperger's Disorder|The Use of rTMS to Improve Theory of Mind Among Adults With Autism and Asperger's Disorder||Bayside Health|No|Completed|December 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||February 2013|February 6, 2013|December 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00808782||146078|
NCT00808795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487|Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease|Efficacy of N-Acetylcysteine in Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization in Patients With Diabetes Mellitus and Chronic Kidney Disease: A Randomized Clinical Trial||Tehran University of Medical Sciences|Yes|Completed|April 2006|October 2006|Actual|October 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|N/A|No|||December 2008|December 15, 2008|December 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00808795||146077|
NCT00804557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-065|Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization|Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization||Lahey Clinic|No|Terminated|October 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|25|||Male|18 Years|N/A|No|Probability Sample|Outpatients from Lahey Clinic Urology Service and colleague referrals|May 2011|May 5, 2011|December 5, 2008|No|Yes|pending design changes to the device|No||https://clinicaltrials.gov/show/NCT00804557||146394|
NCT00804570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11359|A Study for the Treatment of Alcohol Dependence.|A Phase 2 Study of LY2196044 Compared With Placebo in the Treatment of Alcohol Dependence.||Eli Lilly and Company|No|Completed|November 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|371|||Both|21 Years|65 Years|No|||December 2010|December 9, 2010|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804570||146393|
NCT00783094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12757|Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks Followed by an Open-Label Extension to Evaluate the Long-Term Safety and Efficacy of Tadalafil in Japanese Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|November 2008|April 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|422|||Male|45 Years|N/A|No|||March 2011|March 18, 2011|October 30, 2008|Yes|Yes||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00783094||148016|
NCT00784030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-774|High Water Intake to Slow Progression of Polycystic Kidney Disease|The Effect of Water Loading on Urinary Biomarkers||New York University School of Medicine|No|Active, not recruiting|November 2008|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00784030||147945|
NCT00784043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-EL NA 013|Bilateral Cochlear Implantation in Children With the MED-EL Cochlear Implant|Longitudinal Efficacy in Young Children Implanted Bilaterally With MED-EL COMBI 40+ / PULSARCI100/SONATATI100 Cochlear Implant Systems.||Med-El Corporation|No|Suspended|March 2004|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Months|36 Months|No|||January 2015|January 28, 2015|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784043||147944|
NCT00784589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/068/HP|Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus|Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthéra))and General Corticotherapy Treatment in Patients With Pemphigus|Rituximab 3|University Hospital, Rouen|Yes|Active, not recruiting|July 2009|December 2016|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||October 2015|October 22, 2015|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00784589||147902|
NCT00784901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807069R|Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmemtosa|Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmemtosa||National Taiwan University Hospital|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Medical recordings of the RP patients who visited the Out-Patient Department of        Ophthalmology in NTUH during June, 2003 to June, 2008|November 2008|November 10, 2008|November 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00784901||147879|
NCT00784914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07064|A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors|A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors||City of Hope Medical Center|Yes|Completed|June 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|November 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00784914||147878|
NCT00784888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991087|Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy|A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients|TAMARA|Pfizer|No|Completed|June 2008|December 2011|Actual|December 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|344|||Female|40 Years|N/A|No|Non-Probability Sample|Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who        received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved        to switch to aromatase inhibitor treatment during the patient recruitment period.        Patients who were informed about the study and accepted to participate.|March 2012|March 14, 2012|October 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00784888||147880|
NCT00785512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-17|A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy|A Prospective, Randomized, Double-Blind, Placebo Controlled Study of the Long-Term Efficacy of Nebivolol in Hypertensive Patients After Withdrawal of Therapy||Forest Laboratories|No|Completed|November 2008|||August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|79 Years|No|||August 2010|August 19, 2010|November 3, 2008|Yes|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00785512||147832|
NCT00771836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RambamMC1866CTIL|Airway Reactivity in Children Before and After BMT Bone Marrow Transplantation|Airway Reactivity in Children Before and After Bone Marrow Transplantation|AHR|Rambam Health Care Campus|No|Completed|July 2004|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|None Retained|Not retained|Both|4 Years|20 Years|No|Probability Sample|Children who underwent SCT in the Department of Pediatric Hemato-Oncology at Meyer        Children's Hospital and were referred to the Pediatric Pulmonary Unit.|October 2008|October 14, 2008|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00771836||148872|
NCT00772122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERM0103|Use of G-CSF for the Treatment of Unexplained Recurrent Miscarriage|Controlled Trial in Women With Recurrent Miscarriage of G-CSF Versus Placebo||University of Florence|Yes|Completed|January 2000|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|68|||Female|25 Years|39 Years|No|||October 2008|October 14, 2008|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00772122||148850|
NCT00772135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH 2008 HR 2006 / 2 / 0012 TM|Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients|Pulmonary Hypertension in Adolescents and Adults With Congenital Heart Disease||Oslo University Hospital|No|Recruiting|September 2008|April 2009|Anticipated|February 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|1||Anticipated|15|||Both|16 Years|25 Years|No|||October 2008|October 14, 2008|October 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00772135||148849|
NCT00772434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA-0637|Assessment of Bleeding Symptoms in Normal Individuals Using a Comprehensive History Phenotyping Instrument|Assessment of Bleeding Symptoms in Normal Individuals Using a Comprehensive History Phenotyping Instrument||Rockefeller University|No|Completed|September 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|412|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from a variety of community venues including the existing        Rockefeller healthy volunteer database, the Tri-Institutional campus, area universities        and medical centers, local colleges, and local business bulletin boards.|November 2011|November 17, 2011|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772434||148826|
NCT00772681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976F_6007|Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma|Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx|Tax-Nazo|Sanofi|No|Completed|October 2004|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|19 Years|N/A|No|||December 2009|December 4, 2009|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772681||148807|
NCT00773292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cro423|Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)|The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP|HAM05|Imperial College London|Yes|Completed|August 2006|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|16 Years|75 Years|No|||April 2013|April 12, 2013|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773292||148760|
NCT00773552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0917.01|Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder|Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder||Stamford Hospital|No|Withdrawn|November 2008|November 2009|Anticipated|April 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|October 15, 2008||No|Investigator Left Institution|No||https://clinicaltrials.gov/show/NCT00773552||148740|
NCT00807443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERRADVIH-02|Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1|Pilot Study Of The Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 In Patients Taking Highly Active Antiretroviral Therapy||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807443||146180|
NCT00808002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARAVIBOOST|Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine|Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine.||Germans Trias i Pujol Hospital|No|Completed|February 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808002||146138|
NCT00808262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNF-K-001|Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease|A Phase I/II, Open-label, Escalating Dose, "Optimal Two-stage", Study of TNFα-Kinoid (TNF- K) Immunization in Crohn's Disease Patients||Neovacs|Yes|Completed|October 2008|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|65 Years|No|||June 2011|June 7, 2011|December 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00808262||146118|
NCT00808275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010590|Caloric Restriction and Body Weight in Adults|Effect of Dietary Calcium on Body Weight Regulation in Adults||Vanderbilt University|Yes|Completed|September 2004|October 2007|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 2, 2011|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808275||146117|
NCT00807989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109887|The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy|An Open Label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies (Phase Ⅳ)||Yonsei University|No|Completed|March 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|16 Years|N/A|No|||June 2015|June 29, 2015|November 28, 2008||No||No|January 20, 2014|https://clinicaltrials.gov/show/NCT00807989||146139|
NCT00808236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-CP1012|Pre-ROSC Intra-Nasal Cooling Effectiveness|Trans-Nasal Cooling With the RhinoChill Device Following Cardiac Arrest: A Pilot Study|PRINCE|BeneChill, Inc|No|Completed|November 2008|September 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|December 11, 2008||No||No|May 21, 2010|https://clinicaltrials.gov/show/NCT00808236||146120|
NCT00783757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-305|TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer|Functional Metabolic Near-infrared Tomographic Optical Breast Imaging (TOBI) to Monitor Response to Neoadjuvant Therapy in Breast Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|August 2008|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Female|18 Years|N/A|No|||November 2014|November 10, 2014|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783757||147965|
NCT00784290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taiho132070|Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma|Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma||Taiho Pharmaceutical Co., Ltd.|No|Completed|September 2003|March 2012|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|20 Years|74 Years|No|||March 2012|March 22, 2012|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784290||147925|
NCT00784303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-201|Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology|Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology||Eisai Inc.|No|Completed|August 2009|September 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00784303||147924|
NCT00785317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080818|Effects of Estradiol on Menopausal Breast|Effects of Oral 1 mg Oestradiol (E2)/ 2 mg of Drospirenone (DRSP) Compared to Oral 1 mg of Oestradiol (E2)/ 0.5 mg Noresthisterone Acetate (NETA)on the Postmenopausal Breast; a Double Blind Randomized Prospective Study|BrAVA|Karolinska Institutet|No|Recruiting|November 2008|April 2010|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|50 Years|60 Years|Accepts Healthy Volunteers|||November 2008|November 4, 2008|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785317||147847|
NCT00785278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-619-08|Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During Propulsion|Computationally Quantifying Wheelchair Set-Up to Minimize Peak Shoulder Joint Forces Throughout Manual Wheelchair Propulsion: A Pilot Study||Kessler Foundation|No|Recruiting|July 2008|July 2010|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The racial, gender and ethnic characteristics of the proposed subject population reflects        the demographics of Northern New Jersey and the surrounding area and/or the patient        population of the Kessler Medical Rehabilitation Research and Education Center (KMRREC).        Subjects will be recruited from database search and word of mouth.|November 2008|November 4, 2008|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785278||147850|
NCT00781183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6255L00002|Does Pulmonary Rehabilitation Change Self-Selected And Maximum Sustainable Walking Speed In Patients With Lung Disease?|Does Pulmonary Rehabilitation Change The Self-Selected And Maximum Sustainable Walking Speed In Patients With Symptomatic Lung Disease?||West Park Healthcare Centre|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|64|||Both|N/A|N/A|No|||December 2012|December 20, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781183||148161|
NCT00771849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA15|Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children|Antibody Responses for Serogroup C After One Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine Versus a Non-meningococcal Control Vaccine in Children Who Have Previously Received a Monovalent Meningococcal C Conjugate Vaccine||Sanofi|No|Completed|August 2003|May 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|103|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|October 13, 2008|No|Yes||No|March 16, 2009|https://clinicaltrials.gov/show/NCT00771849||148871|
NCT00772148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro 2018|Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients|A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-Tacro™ Tablets Once Daily and Prograf® Capsules Twice Daily in Adult De Novo Liver Transplant Patients||Veloxis Pharmaceuticals|No|Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|October 14, 2008|Yes|Yes||No|May 12, 2015|https://clinicaltrials.gov/show/NCT00772148||148848|
NCT00772161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124DDE03|Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Single-Center, Single-Blind, Randomized, Oral Dose Cross-Over Study in Prepuberal Boys With ADHD to Investigate Efficacy and Bioequivalence of 20 mg Ritalin LA Compared to 20 mg Medikinet Retard After Treatment With o.d. Doses Over 7 Days Each.|MPH-Kinetics|University Hospital Freiburg|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|8 Years|14 Years|No|||January 2009|January 20, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772161||148847|
NCT00772447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1790C00003|China Registration Study in Patients With Skin Infections|A Phase 3, Multicentre, Randomised, Investigator-blinded, Parallel-groupStudy of the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects With cSSSI||AstraZeneca|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|75 Years|No|||February 2015|February 23, 2015|October 9, 2008|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT00772447||148825|
NCT00772694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12602|Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy|Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy|GCT|Fondation Wygrajmy Zdrowie|Yes|Recruiting|September 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|75 Years|No|||October 2008|October 23, 2008|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772694||148806|
NCT00773799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-YC-239-CTIL|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community|MOSAR|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2008|January 2014|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|A rehabilitation center's department in which the hospitalized patients are older then 18        years old.|October 2008|October 15, 2008|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00773799||148721|
NCT00788125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07053|Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors|Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial||City of Hope Medical Center|Yes|Active, not recruiting|September 2008|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|143|||Both|1 Year|25 Years|No|||February 2016|February 10, 2016|November 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788125||147636|
NCT00788463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-542|A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps|A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps||Lawson Health Research Institute|No|Recruiting|March 2008|December 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2008|November 7, 2008|November 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788463||147612|
NCT00788736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2008270-01H|Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism|Development and Validation of Clinical Prediction Rules for Bleeding for Patients on Anticoagulant Therapy for Venous Thromboembolism||Ottawa Hospital Research Institute|No|Active, not recruiting|September 2008|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2450|Samples With DNA|Subjects may consent to optional DNA and plasma banking|Both|18 Years|N/A|No|Non-Probability Sample|Outpatients being treated for venous thromboembolism|July 2014|July 29, 2014|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788736||147591|
NCT00789009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090030|Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection|Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection||National Institutes of Health Clinical Center (CC)||Recruiting|November 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|100 Years|No|||January 2016|February 10, 2016|November 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00789009||147570|
NCT00789620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_155_08|Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery|Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery: A Prospective, Randomised, Placebo Controlled, Double-blind, Phase III Study||University Hospital Inselspital, Berne|No|Completed|November 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|76|||Both|N/A|N/A|No|||March 2011|March 23, 2011|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789620||147523|
NCT00789880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN CATH 03|Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3|Analysis of the Response of Subjects With Atopic Dermatitis to Oral Vitamin D3 by Measurement of Antimicrobial Peptide Expression in Skin and Saliva||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|November 11, 2008|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00789880||147503|
NCT00785668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QGUY/2007/AER 001/-04|A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects|A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects||Aerovance, Inc.|No|Completed|November 2007|February 2008|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2008|November 4, 2008|November 3, 2008||||No||https://clinicaltrials.gov/show/NCT00785668||147820|
NCT00785681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04302|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower||Sanofi||Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|53|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785681||147819|
NCT00785967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK0518-048-00, Version 2.2|Immune Responses in Patients Treated With Raltegravir|Immune Responses to Neo-Antigens in Patients Treated With Raltegravir: Insights on V(D)J Recombination and RAG-1/2 Recombinase Function|RAG-1/2|McGill University Health Center|No|Withdrawn|January 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Male|18 Years|N/A|No|||April 2015|April 13, 2015|November 4, 2008||No|Unexpected and severe difficulties in recruitment.|No||https://clinicaltrials.gov/show/NCT00785967||147797|
NCT00786201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015235|A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis||Centocor, Inc.|Yes|Completed|December 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|126|||Both|40 Years|80 Years|No|||November 2015|November 24, 2015|November 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00786201||147779|
NCT00786500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes II|Anti-diabetic Effect of Gynostemma Pentaphyllum Tea in Type 2 Diabetic Patients|Anti-diabetic Effect of Gynostemma Pentaphyllum Tea in Type 2 Diabetic Patients||Hanoi Medical University|No|Completed|February 2007|December 2007|Actual|September 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|70 Years|No|||November 2008|December 3, 2010|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786500||147756|
NCT00772564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ator2685Hdm2[2]|The Use of Statins for Myocardial Death Prevention|The Use of Statins for Myocardial Death Prevention: From Cell to Bedside||Rambam Health Care Campus|No|Completed|August 2008|August 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Both|30 Years|90 Years|No|||May 2012|May 25, 2012|October 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00772564||148816|
NCT00773955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01058|R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer|A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|November 2008|August 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2011|April 23, 2014|October 15, 2008|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00773955||148709|
NCT00774514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 08-113M|The Cardiovascular Effects of Nitrogen Dioxide Exposure|The Cardiovascular Effects of Nitrogen Dioxide Exposure||University of Edinburgh|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Male|N/A|N/A|Accepts Healthy Volunteers|||April 2009|April 8, 2009|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774514||148667|
NCT00773370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6329-R|Adaptive Physical Activity for Chronic Stroke|Adaptive Physical Activity for Chronic Stroke|APA-Stroke|VA Office of Research and Development|No|Completed|January 2009|April 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|75|||Both|40 Years|N/A|No|||May 2014|May 5, 2014|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773370||148754|
NCT00773630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-08-101|A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions|||Otsuka Frankfurt Research Institute GmbH|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|September 8, 2011|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773630||148734|
NCT00773929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-593_101|Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer|A Multicenter Phase I Clinical and Pharmacokinetic Study of Oral TAK-593 in Subjects With Nonhematologic Advanced Cancer||Millennium Pharmaceuticals, Inc.|No|Completed|January 2009|April 2010|Actual|January 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2010|April 23, 2010|October 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00773929||148711|
NCT00776503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM VOR 2007-01|Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia|A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes|GFMVOR2007|Groupe Francophone des Myelodysplasies|Yes|Completed|May 2008|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||November 2011|March 19, 2014|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776503||148516|
NCT00776516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-070|Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers|A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178)||Astellas Pharma Inc|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|October 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00776516||148515|
NCT00786942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Puddu|Bone Graft Necessity in Opening-Wedge High Tibial Osteotomy|Bone Graft Necessity in Opening-Wedge High Tibial Osteotomy. A Randomized Clinical Trial||University of Campinas, Brazil|No|Completed|April 2006|April 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|20 Years|60 Years|No|||May 2010|May 21, 2010|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786942||147722|
NCT00787800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003618|The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock|Reduction And Prevention of Tachyarrhythmias and Shocks Using Reduced Ventricular Pacing With Atrial Algorithms (The RAPTURE Study)|RAPTURE|Mayo Clinic|No|Completed|November 2008|December 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|90 Years|No|||July 2014|July 2, 2014|November 6, 2008|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT00787800||147660|
NCT00788476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0490|Childhood Cancer Survivor Survey|Needs Assessment Survey in Childhood Cancer Survivors and Their Parents||M.D. Anderson Cancer Center|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|167|||Both|8 Years|34 Years|Accepts Healthy Volunteers|Non-Probability Sample|Childhood cancer survivors between ages of 8 and 28 years of age and their primary        caregivers.|October 2013|January 7, 2015|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788476||147611|
NCT00788749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAY07|Medical Polypectomy and Predictors of Response|A Proof Of Concept Study to Investigate the Clinical, Histological And Molecular Predictors of Response to Oral and Intranasal Corticosteroid in Nasal Polyposis||University of Dundee|No|Completed|May 2004|November 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||November 2008|November 10, 2008|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788749||147590|
NCT00788762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6798|Myocilin Variations and Familial Glaucoma in Taxiarchis|Myocilin Variations and Familial Glaucoma in Taxiarchis, A Small Greek Village.|Taxiarchis|Aristotle University Of Thessaloniki|No|Recruiting|August 2007|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Myocilin screening was performed from blood or saliva specimens taken from the village. The      promoter region and exons 1-3 of myocilin were sequenced at the Portland Veterans      Administration Medical center. Microsatellite marker analysis in the GLC1A region, including      D1S452, D1S1619, D1S2790 and D1S242 was performed at deCODE (Reykjavik, Iceland).|Both|1 Year|90 Years|No|Non-Probability Sample|Villagers from Taxiarchis|May 2014|May 9, 2014|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788762||147589|
NCT00789022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uriel111|Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment|||Shalvata Mental Health Center|No|Not yet recruiting|January 2009|||July 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hospitalized patients First degree ralatives Healthy subjects from the community|November 2008|November 10, 2008|November 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00789022||147569|
NCT00789360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-104|Staccato Loxapine Pulmonary Safety in Healthy Volunteers|Pulmonary Safety of Repeat Doses of Staccato® Loxapine for Inhalation in Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|November 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 4, 2009|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00789360||147543|
NCT00789893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-127|Study of Vaginal Dilator Use After Pelvic Radiotherapy|A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy||Memorial Sloan Kettering Cancer Center||Completed|November 2008|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Female|21 Years|85 Years|No|Non-Probability Sample|All women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal        cancer who will receive external beam pelvic radiation or brachytherapy.|June 2015|June 10, 2015|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789893||147502|
NCT00785694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-196-001|Recurrence of Bladder Cancer After Transurethral Resection With Hexvix|Recurrence of Bladder Cancer After Transurethral Resection With Hexvix||GE Healthcare|No|Withdrawn|December 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|November 4, 2008|No|Yes|Rejected ethics approval in UK and Holland|No||https://clinicaltrials.gov/show/NCT00785694||147818|
NCT00785980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-001-08-1027|Drug - Drug Interaction Study of Quinine Sulfate and Ciprofloxacin|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Ciprofloxacin HCl on the Single-Dose Pharmacokinetics of Quinine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|November 3, 2008|No|Yes||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00785980||147796|
NCT00786214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/06/479|Treatment of Functional Dyspepsia With Acupuncture|Treatment of Functional Dyspepsia With Acupuncture: A Randomized, Blinded, Sham Acupuncture Controlled Study||National University Hospital, Singapore|No|Completed|February 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||June 2013|June 20, 2013|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786214||147778|
NCT00786487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804M29862|Training Effects on Skeletal Muscle Fatty Acid Metabolism|Training Effects on Skeletal Muscle Fatty Acid Metabolism||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|November 5, 2008|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00786487||147757|
NCT00786773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GVN-DUM-2008/1|Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.|Epidemiological Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment||AstraZeneca|No|Completed|October 2008|June 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|2091|||Both|18 Years|N/A|No|Probability Sample|The target survey population is existing GERD patients or newly diagnosed GERD patients,        who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy ...        at Visit 1 and will come back after 4 weeks for clinical re-assessment (Visit 2)|December 2010|December 6, 2010|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786773||147735|
NCT00772577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AUS07|Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension|An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension|ATTAIN|Novartis|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|386|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|October 10, 2008|No|Yes||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00772577||148815|
NCT00774787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08US02IMIQ-Rigel|Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses|A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses||Rigel Dermatology|No|Completed|October 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||November 2010|November 1, 2010|October 16, 2008|Yes|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00774787||148647|Open label; small patient number; planned secondary endpoint of change in only lesions treated with cryotherapy (baseline) not determinable as only all lesions (baseline + new) consistently captured.
NCT00773383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21746|A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.|An Open-label Study to Determine the Effect of R1507 Plus Tarceva (Erlotinib) on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) With Progressive Disease After Clinical Benefit to Second or Third Line Tarceva Monotherapy.||Hoffmann-La Roche||Terminated|November 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|October 15, 2008|Yes|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00773383||148753|
NCT00773396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA140508|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||October 15, 2008|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00773396||148752|
NCT00773643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07110284|Osteogenic Profiling of Tissue From Children With Craniosynostosis|Osteogenic Profiling of Tissue From Children With Craniosynostosis||Children's Hospital of Pittsburgh|No|Recruiting|April 2008|||April 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|2 Months|18 Years|No|||July 2015|July 28, 2015|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773643||148733|
NCT00773942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSA290200500381 T02|Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries|Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries||University of Illinois at Chicago|No|Completed|November 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|637|||Both|65 Years|N/A|No|||October 2009|October 30, 2009|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773942||148710|
NCT00787501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07100326|Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression|Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression|ssrifMRI|University of Pittsburgh|Yes|Completed|June 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|55 Years|No|||February 2016|February 2, 2016|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787501||147683|
NCT00788138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inpatient Vitamin D in CF|Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis|||Atlanta VA Medical Center|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||October 2010|October 8, 2010|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788138||147635|
NCT00789035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.9|12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients|A Phase IIb, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (5 mg, 10 mg and 25 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo, as Monotherapy, With an Additional Open-label Metformin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control||Boehringer Ingelheim||Completed|October 2008|||October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|408|||Both|18 Years|80 Years|No|||May 2014|May 16, 2014|October 13, 2008||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00789035||147568|
NCT00789386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHPRG-RemiCaps2|The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers|The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers|RemiCaps2|Medical University of Vienna|No|Recruiting|November 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||May 2009|May 20, 2009|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789386||147541|
NCT00789633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB07012|A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer|A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer||AB Science|Yes|Active, not recruiting|November 2008|December 2013|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00789633||147522|
NCT00789646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI 271/2008|Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients|Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients.||Mahidol University|No|Enrolling by invitation|June 2008|June 2009|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||June 2008|November 11, 2008|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789646||147521|
NCT00789906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223CTIL|Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia|Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia||BeerYaakov Mental Health Center||Recruiting|July 2008|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|700|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|700 healthy adults (350 women and 350 men, aged from 18 to 89)|November 2008|November 12, 2008|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789906||147501|
NCT00789919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-1114|Mild Preeclampsia Near Term: Deliver or Deliberate?|Mild Preeclampsia Near Term: Deliver or Deliberate?||University of Mississippi Medical Center|No|Completed|March 2002|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|185|||Female|18 Years|50 Years|No|||November 2008|November 12, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789919||147500|
NCT00785707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-EL NA 020|Littlears Auditory Questionnaire: Validation Study in CI Children|Littlears Auditory Questionnaire Validation Study in CI Children With LittlEARS My Diary: Language: North American English|LittlEars|Med-El Corporation|No|Completed|May 2008|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Both|N/A|24 Months|No|Non-Probability Sample|Children under the age of 24 months at time of cochlear implantation recommended by the        cochlear implant clinic.|March 2016|March 4, 2016|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785707||147817|
NCT00785993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703-C-017-AC|Egg-Banking and Ovo-donation|Impact of Egg-Banking in an Ovum-donation Program||Instituto Valenciano de Infertilidad, IVI VALENCIA||Completed|November 2008|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|320|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785993||147795|
NCT00786227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01|Initial Validation of PROMIS Physical Function/Disability Scales in Rheumatoid Arthritis (RA)|Initial Validation of PROMIS Physical Function/Disability Scales in Rheumatoid Arthritis (RA)||Stanford University|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|761|||Both|18 Years|N/A|No|Probability Sample|Patients from three sources will be included in the study: ARAMIS RA cohort, Stanford RA        registry, and Stanford RA clinical trials patients.|May 2013|May 1, 2013|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786227||147777|
NCT00773656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 08234|Patients Overexposed for a Prostate Adenocarcinoma|Surveillance of the Cohort of Patients Overexposed in a Course of Conformational Radiotherapy for a Prostate Adenocarcinoma in Jean MONNET Hospital, Epinal, France. Epinal: Patients Overexposed for a Prostate Adenocarcinoma|EPOPA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2008|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|249|Samples With DNA|White cells, serum and DNA|Male|18 Years|N/A|No|Non-Probability Sample|Consecutive patients treated for a prostate adenocarcinoma in the radiation department of        the Jean MONNET Hospital between 2000 and 2006.|February 2014|February 26, 2014|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773656||148732|
NCT00774254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090009|Reactions to Disease Risk Information|Participant Reactions to Disease Risk Information||National Institutes of Health Clinical Center (CC)||Completed|October 2008|||||N/A|Observational|Time Perspective: Prospective|||Actual|132|||Both|25 Years|40 Years|No|||May 2015|May 29, 2015|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774254||148686|
NCT00774267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-4000|Study Evaluating Changes In Mammographic Breast Density|Evaluation Of Changes In Mammographic Breast Density Associated With Bazedoxifene Acetate/Conjugated Estrogens, Raloxifene And Placebo In Postmenopausal Women: An Ancillary Study Of Protocol 3115A1-303-WW||Pfizer|No|Completed|January 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|507|||Female|40 Years|75 Years|No|Non-Probability Sample|Women with osteoporosis risk factors who were participants in a phase 3 trial for        osteoporosis prevention (study 3115A1-303-WW)|March 2014|March 10, 2014|October 16, 2008|No|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00774267||148685|
NCT00774800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-08-05|Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus|Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humulin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients||Halozyme Therapeutics|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|65 Years|No|||August 2014|August 25, 2014|October 15, 2008|Yes|Yes||No|April 27, 2010|https://clinicaltrials.gov/show/NCT00774800||148646|
NCT00775151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50366|Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions|The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fed State Subjects.||Ranbaxy Inc.|Yes|Completed|July 2005|November 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775151||148619|
NCT00774774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070160|Face Masks for Preventing Influenza Transmission|a Randomized Controlled Trial Evaluating the Effectiveness and the Safety of Surgical Masks Wared by the Index Patient for Preventing Secondary Transmission of Influenza A in Households|GRIPMASK|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|372|||Both|5 Years|N/A|No|||September 2008|April 22, 2011|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774774||148648|
NCT00787202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921063|A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.|A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study In Order To Investigate Safety And Efficacy Of CP- 690 550 In Subjects With Moderate To Severe Ulcerative Colitis.||Pfizer|No|Completed|December 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|195|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|November 6, 2008||No||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00787202||147704|Pharmacokinetic (PK) parameters and their correlation with clinical response and inflammatory biomarkers were not reported as data from future studies were to be pooled for analysis.
NCT00787215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF-2008-3|A Survey on the Rate of Glucose Intolerance in Hong Kong Chinese|A Survey on the Rate of Glucose Intolerance in Hong Kong Chinese: Validation of the Chinese University Diabetes Screening Score||Chinese University of Hong Kong||Active, not recruiting|November 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hong Kong Chinese without history of diabetes|August 2015|August 21, 2015|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787215||147703|
NCT00787813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC after cerclage|N-Acetyl Cysteine After Cervical Cerclage|Effect of Oral N-Acetyl Cysteine on Pregnancy Outcome After Cervical Cerclage: a Randomized Controlled Trial|NAC-CC|Assiut University|No|Completed|June 2008|November 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||November 2008|November 19, 2008|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00787813||147659|
NCT00787826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15207.a|Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine|A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4 in Healthy Adults At-Risk for Exposure to Francisella Tularensis||U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|January 2009|April 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787826||147658|
NCT00788775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-244|Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma|A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 2009|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788775||147588|
NCT00788788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heliox-PoC|Heliox in Experimental Upper Airway Obstruction|PoC Study of Heliox With Helium-Fractions Between 25 and 75% in Experimental Upper Airway Obstruction||University of Witten/Herdecke|Yes|Completed|November 2007|||December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2008|November 20, 2008|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788788||147587|
NCT00789048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cupangle-HMO-CTIL|The Influence of "Operating Table Position Simulating Radiographs" on Acetabular Cup Angle During Primary Total Hip Replacement|The Influence of "Operating Table Position Simulating Radiographs" on Acetabular Cup Angle During Primary Total Hip Replacement||Hadassah Medical Organization|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2008|April 27, 2011|November 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00789048||147567|
NCT00789061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950805|Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation|Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation||National Taiwan University Hospital|Yes|Recruiting|August 2006|July 2009|Anticipated|March 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|120|||Both|N/A|N/A|No|||November 2008|November 10, 2008|July 8, 2007||No||No||https://clinicaltrials.gov/show/NCT00789061||147566|
NCT00789399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00508826|A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis|A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis||Prairie Education and Research Cooperative|Yes|Active, not recruiting|October 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|630|||Both|18 Years|90 Years|No|||October 2014|October 27, 2014|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00789399||147540|
NCT00789659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0142|Incisional Wound Vac in Obese Patients|Incisional Wound Vac in Obese Patients||University of Mississippi Medical Center|No|Active, not recruiting|December 2010|November 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|64 Years|No|||April 2012|April 5, 2012|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789659||147520|
NCT00789932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAR-UCLA-2009|Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial|Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial|BIACA-2|University of California, Los Angeles||Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|7 Years|11 Years|No|||February 2013|February 1, 2013|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789932||147499|
NCT00789945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-147|Timing of Insulin Before Meals Everyday|The Importance of Insulin Timing in Type 1 Diabetes|TIME|University of New Mexico|Yes|Completed|December 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789945||147498|
NCT00785720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04303|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Photo Avaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower||Sanofi||Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785720||147816|
NCT00786006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_P_01|Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer|Randomized Phase II Trial of FOLFIRI3 vs. FOLFOX in Gemcitabine-refractory Advanced Pancreatic Cancer||Asan Medical Center|No|Completed|March 2007|September 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786006||147794|
NCT00786240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221063|Phase1, Single Dose, Crossover Study to Determine Bioequivalence|A Phase 1, Open-Label, Randomized, Single-Dose, 2-Way Crossover Study To Determine Bioequivalence Of 4 Mg Fesoterodine SR Tablet Between Formulation D And Formulation E(1) In Healthy Subjects.||Pfizer|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 8, 2010|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786240||147776|
NCT00786253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11875|Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction|A Randomized, Explorative, Double-blind, Double-dummy, Multi-center, Parallel Group Study to Assess Sustainable Efficacy of Once Daily Vardenafil (10 mg) for 12 and 24 Weeks Versus Vardenafil PRN in Men With Mild or Mild to Moderate ED||Bayer|No|Completed|October 2005|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|236|||Male|18 Years|64 Years|No|||October 2014|October 27, 2014|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00786253||147775|
NCT00786266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SETS-novice|Sleep Enhancement Training Study for Novice Shiftworkers|Sleep Enhancement Training Study for Novice Shiftworkers|SETS-novice|University of California, San Francisco|No|Completed|November 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786266||147774|
NCT00786552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panthera|Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer|Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer|Panthera|University of Schleswig-Holstein||Recruiting|November 2008|November 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||January 2011|January 19, 2011|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786552||147752|
NCT00786513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011132|Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy|Randomized Double Blind Controlled Trial of the Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy in Chronic Pseudomonas Aeruginosa Infected Cystic Fibrosis Patients||The Hospital for Sick Children|No|Completed|November 2008|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|N/A|N/A|No|||April 2014|April 2, 2014|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786513||147755|
NCT00786526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF7854|Diaphragmatic Function in Ventilated Patients|Ventilator-Induced Diaphragmatic Dysfunction (VIDD) in Critically Ill Patients||University Hospital, Montpellier|No|Completed|March 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|85 Years|No|Non-Probability Sample|Intubated patients in intensive care unit|October 2013|October 29, 2013|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786526||147754|
NCT00787085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10024-05|The Significance of Funguria in Hospitalized Patients|The Significance of Funguria in Hospitalized Patients (FACES)|FACES|Los Angeles Biomedical Research Institute|Yes|Completed|September 2001|February 2006|Actual|February 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|919|Samples Without DNA|Urine and blood cultures|Both|N/A|N/A|No|Non-Probability Sample|Patients hospitalized at the Harbor-UCLA Medical Center and Cedars-Sinai Medical Center|November 2008|November 6, 2008|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787085||147713|
NCT00774566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKK-001|PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF)|A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial|FreezeAF|Staedtisches Klinikum Karlsruhe|No|Completed|October 2008|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|322|||Both|18 Years|75 Years|No|||December 2014|December 7, 2014|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774566||148663|
NCT00775164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811M53986|Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study|Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study||University of Minnesota - Clinical and Translational Science Institute|Yes|Withdrawn|January 2009|February 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|10 Years|17 Years|No|||August 2012|August 30, 2012|October 16, 2008|Yes|Yes|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT00775164||148618|
NCT00775112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lumbar puncture pillow|Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology|Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology||Centre Leon Berard|No|Completed|July 2004|||September 2006||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|124|||Both|2 Years|18 Years|No|||October 2008|October 16, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775112||148622|
NCT00775125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015208|VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.|A Phase I, Open-label, Randomized, 2-way Crossover Trial in 40 Healthy Subjects to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.||Tibotec BVBA||Completed|June 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|55 Years|No|||December 2010|December 16, 2010|October 16, 2008||||No||https://clinicaltrials.gov/show/NCT00775125||148621|
NCT00787514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3029|FR in Stored Plasma|Measurement of the Folate Receptor in Stored Plasma From Patients With Ovarian Cancer||Royal Marsden NHS Foundation Trust|No|Recruiting|July 2008|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|N/A||1|Anticipated|27|||Female|N/A|N/A|No|Probability Sample|In the first stage of the study 13 samples will be analysed. If thee is one or more        positive results the study will progress to the 2nd state to include 14 more samples.|November 2008|November 6, 2008|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787514||147682|
NCT00787527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0484|SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma|A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Completed|November 2008|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|November 6, 2008||No||No|September 2, 2014|https://clinicaltrials.gov/show/NCT00787527||147681|
NCT00788151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD24|Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years|Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru||Sanofi|No|Completed|October 2008|December 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788151||147634|
NCT00788164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0656 CDR0000617261|Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia|A Phase I Efficacy and Safety Study of HPV16-specific Therapeutic DNA-vaccinia Vaccination in Combination With Topical Imiquimod, in Patients With HPV16+ High Grade Cervical Dysplasia (CIN3)||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2008|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788164||147633|
NCT00788177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-06102G|Subretinal Macugen® for Neovascular Age-Related Macular Degeneration|Subretinal Macugen® for Neovascular Age-Related Macular Degeneration (SUMANA)||Klinikum Ludwigshafen|No|Recruiting|November 2008|December 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|N/A|No|||July 2009|September 26, 2011|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788177||147632|
NCT00788801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-423|Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain|||Abbott||Completed|December 2008|||March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|11|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2010|November 1, 2010|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788801||147586|
NCT00788814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH079818-01A1|Study of Pathways Curriculum for Use With WPD|Women Physical Disability and Depression: Communities Responding Now!||Oregon Health and Science University|Yes|Completed|June 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Female|18 Years|N/A|No|||October 2012|October 15, 2012|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788814||147585|
NCT00789074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qmul120508|Use of Varenicline for 4-weeks Prior to Quitting|Effects of an Extended Period of Varenicline Use Prior to Quitting Smoking on Post-quitting Urges to Smoke||Queen Mary University of London|No|Completed|July 2009|March 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 18, 2013|November 7, 2008||No||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00789074||147565|
NCT00789412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI-154-01|Surgical Stress Index as a Tool for Monitoring Analgesia and/or Sedation in Critically Ill Patients|SSI for Monitoring of Analgesia and Sedation in Critically Ill Patients||University of Schleswig-Holstein|No|Completed|August 2008|October 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|postoperative patients with admission to the intensive care unit who are intubated and        mechanically ventilated|October 2009|October 27, 2009|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789412||147539|
NCT00789958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0809|S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct|A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)||Southwest Oncology Group|Yes|Active, not recruiting|December 2008|December 2017|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00789958||147497|
NCT00785733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RRO-SYM-2008/1|NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART|SMART Way of Treating Asthma. Non-interventional Study to Evaluate Clinical Efficacy of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Patients With Moderate and Severe Asthma||AstraZeneca|No|Completed|November 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1182|||Both|18 Years|N/A|No|Probability Sample|The programme will include patients with moderate and severe asthma stabilized on        Symbicort SMART from community sample|November 2010|November 30, 2010|November 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00785733||147815|
NCT00785746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-06--010|Improving Balance in Frail Elderly|Improving Balance in Frail Elderly: A Randomized Clinical Trial of Two Methods to Enhance Strength (Stretch and Strength Versus Core Strength)||McGill University|No|Completed|August 2006|December 2009|Actual|December 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|N/A|N/A|No|||March 2010|February 1, 2013|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785746||147814|
NCT00786019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1152|Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes|Influence Of Endothelial Function On Central and Peripheral Causes Of Exercise Impairment In Type 2 Diabetes|InsITE|University of Colorado, Denver|Yes|Completed|May 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|98|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786019||147793|
NCT00786279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-000164 AAAPILOT|Alcohol and Atherosclerosis Pilot Study|Alcohol and Atherosclerosis Pilot Study|AAAPILOT|Beth Israel Deaconess Medical Center|Yes|Completed|November 2008|April 2015|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|39|||Both|55 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786279||147773|
NCT00786799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816175-1|Omega-3 Fatty Acids for Autism Treatment|A Randomized, Double-Blind, Placebo-Controlled 12-week Study to Investigate the Effect of Omega-3 Fatty Acids on Hyperactivity in Childhood Autism||University of California, San Francisco|Yes|Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|3 Years|8 Years|No|||July 2012|July 31, 2012|November 5, 2008|Yes|Yes||No|September 14, 2011|https://clinicaltrials.gov/show/NCT00786799||147733|Small sample size which results in a limited power to detect small to moderate treatment effects.Relatively mild level of hyperactivity in both groups.
NCT00773968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21439|ORION Study: A Study of Monthly Subcutaneous Mircera in Predialysis Patients With Chronic Renal Anemia|"A Single Arm, Open Label Study Evaluating Once-monthly Subcutaneous Mircera for the Maintenance of Hemoglobin Levels in Pre-dialysis Patients With Chronic Renal Anemia"||Hoffmann-La Roche||Completed|October 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773968||148708|
NCT00774826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL−FOLL05|Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma|Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma||Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|December 2005|March 2014|Anticipated|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|534|||Both|18 Years|75 Years|No|||February 2011|February 14, 2011|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00774826||148644|
NCT00774839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-124|Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients|A Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2008|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|65 Years|N/A|No|Non-Probability Sample|We will be recruiting from eight sites of care that serve different populations, which        will allow us to sample Medicare-eligible individuals with a range of income, insurance        coverage and socio-demographic characteristics. These sites are: Memorial Sloan-Kettering        Cancer Center (MSKCC); four MSKCC Network locations (Commack, Phelps,Mercy, and Basking        Ridge); SUNY Downstate Medical Center;Ralph Lauren Cancer Center and Albert Einstein        College of Medicine/Montefiore Medical Center|January 2016|January 5, 2016|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774839||148643|
NCT00774527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-002|Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT|Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome|CyFluCyATG|Cooperative Study Group A for Hematology|No|Completed|March 2003|January 2011|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|15 Years|60 Years|No|||February 2011|February 16, 2011|October 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00774527||148666|
NCT00774540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Knemikro01|Acute Pain and Inflammation After Surgery|Acute Pain and Role of Ketolorac in Inflammatory Mediators After Knee Arthroscopy Evaluated by Microdialysis|Knemikro01|Oslo University Hospital|Yes|Completed|August 2008|December 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||April 2015|April 22, 2015|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774540||148665|
NCT00774553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00015|To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin|A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Subjects With T2DM Treated With Metformin||AstraZeneca||Completed|October 2008|January 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|30 Years|75 Years|No|||January 2010|January 14, 2010|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774553||148664|
NCT00775762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-004626-17|Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events|||Catholic University of the Sacred Heart|Yes|Not yet recruiting|November 2008|December 2010|Anticipated|January 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|213|||Both|40 Years|75 Years|No|||October 2008|October 17, 2008|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775762||148572|
NCT00775775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R45303|Fatigue, Sleep Disorders and Endocrine Abnormalities in TBI Patients|The Relationship Between Fatigue, Sleep Disorders and Endocrine Abnormalities Following Traumatic Brain Injury||Kessler Foundation|No|Recruiting|May 2003|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|70 Years|No|Non-Probability Sample|The study will consist of 50 participants taken from the outpatient brain injury program        at Kessler.|October 2009|October 2, 2009|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775775||148571|
NCT00775138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-107|A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis.|A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace™) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa||Insmed Incorporated|Yes|Completed|June 2008|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||May 2012|February 12, 2015|October 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775138||148620|
NCT00787839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-138|Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care|Screening for Prediabetes and Early Diabetes in Primary Care||VA Office of Research and Development|No|Completed|June 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1939|None Retained|blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|initial primary study population will be drawn primarily from veterans receiving primary        care at the Decatur Clinic CBOC in metropolitan Atlanta, GA|October 2014|April 6, 2015|November 6, 2008||No||No|December 5, 2014|https://clinicaltrials.gov/show/NCT00787839||147657|Study in a single healthcare system, in a convenience sample of patients receiving care in a VA primary care clinic, in a population that was largely older, heavier, and predominantly male, and a single OGTT was used as the “gold standard”.
NCT00788203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11052008-1335|Prevention of Childhood Obesity|The Development of an Early Intervention for the Prevention of Childhood Obesity||Stanford University||Completed|August 2008|May 2011|Actual|May 2011|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|130|||Both|2 Years|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 2-4 years at risk for overweight with at least one overweight/obese parent|July 2011|July 21, 2011|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00788203||147630|
NCT00788489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETLAB-06Jan2006|A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy|A Prospective Study to Evaluate the Role of 2-[18F]Fluoro-2-deoxy-D-glucose (FDG)-Positron Emission Tomography (PET), Breast Magnetic Resonance Imaging (MRI), and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|PETLAB|Ontario Clinical Oncology Group (OCOG)|No|Completed|January 2006|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Female|18 Years|N/A|No|Non-Probability Sample|Approximately 100 patients will be accrued over a 5-year period.|October 2011|October 3, 2011|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788489||147610|
NCT00789087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105/04|Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion|Analysis of Clinical and Radiological Results of Two Methods of Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion||University of Sao Paulo|Yes|Completed|January 2005|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|90 Years|No|||November 2008|November 10, 2008|November 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00789087||147564|
NCT00789425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-IMW-POLYPHENOL-001|Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women|A Randomised, Double Blind, Parallel Group, 12-month Comparison of a Standardized Olive Extract With Placebo in Postmenopausal Women With Decreased Bone Mineral Density||BioActor|No|Active, not recruiting|September 2008|August 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||February 2010|February 16, 2010|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00789425||147538|
NCT00789672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-141|Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia|A Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia in 8 to 17 Year Olds|ATS14|Jaeb Center for Health Research|Yes|Completed|January 2009|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|8 Years|17 Years|No|||May 2012|May 16, 2012|October 27, 2008|Yes|Yes||No|September 14, 2010|https://clinicaltrials.gov/show/NCT00789672||147519|Without a patching-only control group, no conclusions can be made regarding efficacy, safety, or side effects with this treatment. Placebo controlled trial is needed to see if levodopa can augment occlusion therapy in the treatment of amblyopia.
NCT00789685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPCLI001|Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II|A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.||Faron Pharmaceuticals Ltd|Yes|Completed|February 2009|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|November 11, 2008||No||No|May 11, 2015|https://clinicaltrials.gov/show/NCT00789685||147518|
NCT00789971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sligogh|Triamcinolone Versus Topical Treatment in Post Operative Phacoemulsification|A Comparison of a Single Orbital Floor Injection of Triamcinolone Versus Conventional Steroid and Antibiotic Drops Used Post Operatively in Uneventful Phacoemulsification Surgery||Sligo General Hospital|Yes|Completed|March 2007|April 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|150|||Both|40 Years|N/A|No|||November 2008|November 12, 2008|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789971||147496|
NCT00785759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALZ201|Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers|An Open-label Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers|ALZ201|GE Healthcare|Yes|Completed|September 2008|December 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|78|||Both|25 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 4, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785759||147813|
NCT00786318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010411|Ziprasidone vs Standard Therapy for Agitated Patients in the ED|Prospective Double Blind Randomized Trial of Intramuscular Ziprasidone Compared With Standard Antipsychotic Therapy For The Treatment Of The Acutely Agitated Patient In The Emergency Department||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Active, not recruiting|September 2008|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2010|June 18, 2010|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00786318||147770|
NCT00786032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|567|A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients|Cooperative Studies Program (CSP) #567 - A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients|ALS|VA Office of Research and Development|Yes|Completed|September 2011|August 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|79 Years|No|Non-Probability Sample|The subjects were patients at five VA medical centers who were severely disabled by        amyotrophic lateral sclerosis (ALS).|January 2015|January 6, 2015|November 4, 2008||No||No|March 26, 2014|https://clinicaltrials.gov/show/NCT00786032||147792|Some limitations would be the Caregivers willingness and ability to support BCI user. In addition, the caregivers limited availability and the time commitment of the usage of the BCI system.
NCT00786292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK276112007|Evaluation of Variable Pressure Support Ventilation in the Therapy of Acute Lung Injury|Evaluation of Variable Pressure Support Ventilation in the Therapy of Acute Lung Injury (EVA-Trial)|EVA|Technische Universität Dresden|No|Completed|July 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|75 Years|No|||July 2009|September 3, 2012|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786292||147772|
NCT00786305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATB-2004|Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia|Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa||Groupe Hospitalier Pitie-Salpetriere|No|Completed|October 2004|November 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2008|November 5, 2008|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786305||147771|
NCT00786539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-20022608|Mitochondria Inborn Errors of Metabolism and ANT Defects in Mitochondria Diseases|Investigation of the Nature and Prevalence of Mitochondria Disease||University of California, Irvine|No|Completed|October 2006|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|18|||Both|N/A|N/A|No|Non-Probability Sample|Study population with mitochondrial disorder and/or their relatives will be referred to        MITOMED by Primary Care Physicians or by Clinical Specialists.|August 2015|August 5, 2015|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786539||147753|
NCT00787384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILG-HES1-03|Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes|Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes|NILG-HES1-03|Northern Italy Leukemia Group|No|Completed|October 2004|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|15 Years|N/A|No|||December 2010|December 28, 2010|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787384||147691|
NCT00774280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-005|Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen|Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome|BuCyvsBUFlu|Cooperative Study Group A for Hematology|Yes|Completed|May 2002|December 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|15 Years|70 Years|No|||February 2011|February 10, 2011|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774280||148684|
NCT00774852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN034AI|Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis|A Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis|ACCESS|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|November 2008|June 2014|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|137|||Both|16 Years|N/A|No|||January 2016|January 15, 2016|October 16, 2008|Yes|Yes||No|August 18, 2014|https://clinicaltrials.gov/show/NCT00774852||148642|
NCT00774813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPMS-7003|Nexalin Therapy for the Treatment of Depressive Symptoms|Phase II Study Using Nexalin Therapy for the Treatment of Depressive Symptoms Associated With Mild to Moderate Depression Episodes||Kalaco Scientific, Inc.|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|65 Years|No|||October 2008|October 16, 2008|July 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00774813||148645|
NCT00775502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIW-8962-001|Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma|Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma||Kyowa Hakko Kirin Pharma, Inc.|No|Terminated|October 2008|October 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|75 Years|No|||October 2012|October 10, 2012|October 17, 2008|Yes|Yes|lack of efficacy in Multiple myeloma|No||https://clinicaltrials.gov/show/NCT00775502||148592|
NCT00775476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBnet # 247162|Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine|Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine|NAC|State University of New York - Upstate Medical University|Yes|Suspended|March 2009|June 2019|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|478|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 12, 2013|October 17, 2008|Yes|Yes|Funds from original NIH grant, AT4332, have been exhausted. While new funding is thought with    revised study design, no new patients will be recruited.|No||https://clinicaltrials.gov/show/NCT00775476||148594|
NCT00788190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHRI 001|Treatment of Distal Radius Fractures in Elderly Patients|Treatment of Distal Radius Fractures in Elderly Patients, a Randomized Controlled Trial||Hand and Upper Limb Clinic, Canada|No|Withdrawn|November 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|65|||Both|65 Years|N/A|No|||November 2008|April 7, 2011|November 7, 2008||No|The inclusion/Exclusion criteria was too strict which restricted recruitment|No||https://clinicaltrials.gov/show/NCT00788190||147631|
NCT00787878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1975|Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects|Comparison of Safety in Small for Gestational Age (SGA) Subjects Treated With Norditropin® (Somatropin) 5 Years Ago With Untreated SGA Subjects and With Normal Average for Gestational Age (AGA) Subjects||Novo Nordisk A/S|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|153|Samples With DNA|Blood samples|Both|18 Years|24 Years|No|Non-Probability Sample|GH treated SGA and controls of non-treated SGA and AGA|April 2014|April 29, 2014|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00787878||147654|
NCT00788515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10550|Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties|Comparison of the Safety and Efficacy of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week,Randomized, Double-blind, Comparative, Parallel-group Study.|REST|Sanofi|Yes|Terminated|November 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||August 2009|August 27, 2009|November 10, 2008|Yes|Yes|Sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary    insomnia with predominant sleep maintenance problems|No||https://clinicaltrials.gov/show/NCT00788515||147608|
NCT00788528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0813A2825|Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects|Open-Label Extension (OLE) Safety and Efficacy Study of Velneperit (S-2367) Following the Year-Long Controlled Clinical Trials of S-2367 in Obese Males and Females|OLE|Shionogi Inc.|No|Completed|August 2008|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|766|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|September 13, 2011|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788528||147607|
NCT00788502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11052008-1334|Stress Reduction During In Vitro Fertilization|Stress Reduction During In Vitro Fertilization||Stanford University||Recruiting|October 2008|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|18 Years|42 Years|No|||May 2010|May 21, 2010|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00788502||147609|
NCT00789100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nottingham-001|Evaluation of Remote Patient Monitoring.|Evaluation of a Home-based Telemonitor Service||Brunel University|Yes|Withdrawn|February 2009|February 2011|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD)        and co-morbidities referred to the community specialist nurse or care matron|July 2014|July 15, 2014|November 10, 2008||No|Nottingham PCT withdrew for financial reasons|No||https://clinicaltrials.gov/show/NCT00789100||147563|
NCT00789438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI-154-02|Evaluation of the Surgical Pleth Index During Spinal and General Anesthesia|The Effects of Sedation and Analgesia on the Surgical Pleth Index (SPI)||University of Schleswig-Holstein|No|Completed|October 2008|May 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|69|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for short-term (30-90 min) surgery.|October 2009|July 6, 2010|November 10, 2008||No||No|October 27, 2009|https://clinicaltrials.gov/show/NCT00789438||147537|
NCT00789451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP 1|The Effect of Ischaemic-reperfusion on the Endogenous Fibrinolysis in Man|The Effect of Ischaemic-reperfusion on the Endogenous Fibrinolysis in Man||University of Edinburgh|No|Completed|August 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789451||147536|
NCT00789698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050234|Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia|A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)|PEARL 3 Ext|Sunovion|Yes|Completed|December 2008|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|75 Years|No|||May 2015|May 19, 2015|November 10, 2008|Yes|Yes||No|March 27, 2012|https://clinicaltrials.gov/show/NCT00789698||147517|
NCT00789711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3682|An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes|A Multicentre, Open-label, Nonrandomised, Non-interventional, Observational Study to Compare Safety and Effectiveness of Biphasic Insulin Aspart 30 (NovoMix 30) and Insulin Detemir (Levemir) for the Treatment of Diabetes Mellitus|SAFE|Novo Nordisk A/S|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3131|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject with diabetes mellitus who needs insulin treatment at the time of inclusion is        eligible for the study, including newly diagnosed subjects who have never received insulin        or an insulin analogue before|August 2014|August 12, 2014|November 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00789711||147516|
NCT00786045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A11-M107-02A|Fitness Intervention Trial for Stroke|Fitness Intervention Tiral for Stroke: Enhancing Walking Endurance Using Home Rehabilitation Programs|FITS|McGill University|No|Completed|November 2002|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|N/A|N/A|No|||April 2013|April 26, 2013|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786045||147791|
NCT00786565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/04|Clinical Evaluation of a New Aspheric Intraocular Lens.|Clinical Evaluation of a New Aspheric Intraocular Lens. A Prospective, Multi-Center, Comparative Study.||Bausch & Lomb Incorporated|No|Completed|January 2004|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|75|||Both|50 Years|85 Years|No|||December 2011|December 7, 2011|November 3, 2008||No||No|February 20, 2009|https://clinicaltrials.gov/show/NCT00786565||147751|
NCT00786812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ABR03|Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|MACS0439|Novartis||Completed|August 2008|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786812||147732|
NCT00787098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0076|Investigating Modes of Progressive Mobility|Investigating Modes of Progressive Mobility||Hill-Rom|No|Completed|November 2007|July 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||July 2009|July 2, 2009|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787098||147712|
NCT00787397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08010426|Sleep, Mood, and Behavior Study|Sleep, Mood, and Behavior Study:Transdisciplinary Studies of CBT for Anxiety in Youth||University of Pittsburgh|Yes|Completed|February 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|9 Years|14 Years|No|||January 2016|January 6, 2016|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00787397||147690|
NCT00774293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boiron 041052|Homoeopathic Association in Aortic Valve Surgery|Preliminary Study of a Homoeopathic Association in Patients Undergoing Aortic Valve Surgery.|OMEO|BOIRON|No|Completed|September 2004|August 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||October 2008|October 16, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774293||148683|
NCT00775515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081635|Laparoscopic Prostatectomy for Chronic Prostatitis|Laparoscopic Prostatectomy for Chronic Prostatitis||The Krongrad Institute|No|Recruiting|October 2008|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|30 Years|N/A|No|||April 2011|April 29, 2011|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775515||148591|
NCT00775177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-313|Bioequivalence Study of Doxycycline Monohydrate 100mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Doxycycline Monohydrate 100 mg Tablets in Healthy Volunteers||Ranbaxy Inc.|Yes|Completed|June 2005|August 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775177||148617|
NCT00775489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNToronto001|Nasal Steroids in Controlled Glaucoma|The Effect of Beclomethasone Nasal Spray on Intraocular Pressure in Ocular Hypertension or Controlled Glaucoma||University Health Network, Toronto|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|85 Years|No|||October 2008|January 4, 2011|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775489||148593|
NCT00776087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS043|European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)|European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)|EuroEco|Biotronik SE & Co. KG|No|Recruiting|July 2008|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|416|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776087||148548|
NCT00787891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014833|A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients|A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endoscopically Proven GERD||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|January 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|1 Year|11 Years|No|||January 2013|January 22, 2013|November 6, 2008|Yes|Yes||No|July 27, 2012|https://clinicaltrials.gov/show/NCT00787891||147653|
NCT00788554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVEL|LEVEL Trial: Correction of Inguinal Hernia, Endoscopic Versus Lichtenstein|LEVEL Trial: Correction of Inguinal Hernia, Endoscopic Versus Lichtenstein. A Randomised Controlled Clinical Trial.|LEVEL|Erasmus Medical Center|Yes|Completed|August 2000|March 2011|Actual|March 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|660|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|November 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00788554||147605|
NCT00788840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2008/14/FHMS|Detemir Energy Expenditure Study|A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes|DEES|University of Surrey|Yes|Recruiting|January 2008|||August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2008|November 10, 2008|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788840||147583|
NCT00788827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSC 005|Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant|A Phase I Safety and Tolerability Study Following the Infusion of Autologous Expanded Progeny of an Adult CD34+ Stem Cell Subset (InsulinCytes) to Patients With Type I Diabetes Mellitus and a Successful Renal Transplant||Imperial College London|Yes|Completed|November 2008|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|16 Years|65 Years|No|||July 2011|January 21, 2015|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788827||147584|
NCT00789724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU-ART|Anakinra to Prevent Post-infarction Remodeling|Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART)|VCU-ART|Virginia Commonwealth University|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||September 2010|February 21, 2012|November 11, 2008|No|Yes||No|July 30, 2010|https://clinicaltrials.gov/show/NCT00789724||147515|
NCT00789984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1022/07|Corneal Specular Microscopy in Infectious and Noninfectious Uveitis|||Federal University of São Paulo|Yes|Completed||||||Phase 4|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients with infectious and noninfectious uveitis who were attended at local        ophthalmology center.|November 2008|November 12, 2008|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789984||147495|
NCT00789997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007791-01H|TNF-alpha Antagonists for Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|TNF-alpha Antagonists for Acute Exacerbations of COPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial||Ottawa Hospital Research Institute|Yes|Completed|November 2008|October 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|35 Years|N/A|No|||October 2011|October 20, 2011|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789997||147494|
NCT00785772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451169|A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment|A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment||Pfizer|No|Terminated|March 2010|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1|||Both|20 Years|64 Years|No|||October 2011|October 31, 2011|November 3, 2008|Yes|Yes|See termination reason in detailed description.|No|March 29, 2011|https://clinicaltrials.gov/show/NCT00785772||147812|The study was completed with an enrollment of 1 subject because prolongation of the study period or a change in the inclusion criteria (the upper limit of age was deleted) did not lead to further enrollment of subjects.
NCT00786331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOIRC 02/2006|Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC|Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-small-cell Lung Cancer (NSCLC).||Gruppo Oncologico Italiano di Ricerca Clinica|Yes|Recruiting|July 2007|December 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||July 2009|July 31, 2009|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00786331||147769|
NCT00786578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708M13941|Evaluation of Skeletal Muscle Lipid Content by Magnetic Resonance Spectroscopy|Evaluation of Intramyocellular Lipid Content (IMCL) in Skeletal Muscle by Magnetic Resonance Spectroscopy||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn|January 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|blood will be sampled and retained for future metabolic testing as needed|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects on regular running program.|October 2014|October 23, 2014|November 5, 2008||No|not funded|No||https://clinicaltrials.gov/show/NCT00786578||147750|
NCT00786825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9412M09040|Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla|Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla|Glycogen|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2004|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00786825||147731|
NCT00787111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPL-2008-4-AUTUS-005|Extended Management and Measurement of Autism|Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic Disorder|EMMA|Neuropharm|No|Terminated|November 2008|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|5 Years|18 Years|No|||February 2010|February 22, 2010|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787111||147711|
NCT00787410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0094|An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma|An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma||AstraZeneca|No|Completed|September 2003|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|November 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787410||147689|
NCT00787423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909020|Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment Population|Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment Population||National Institutes of Health Clinical Center (CC)||Recruiting|October 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787423||147688|
NCT00774579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHD1|The Effect of Growth Hormone Replacement on Liver Fat|Growth Hormone Replacement in Adults With Growth Hormone Deficiency (GHD) - The Effect on Liver Fat.||Imperial College London|No|Completed|March 2008|October 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples Without DNA|plasma, serum, leucocytes, 24-hour urine|Both|20 Years|70 Years|No|Non-Probability Sample|Patients will be recruited from the endocrine clinics of Imperial College Healthcare NHS        Trust.|December 2009|June 3, 2015|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774579||148662|
NCT00776139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11821|Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions|An Open Label, Randomized, Single-Center, Single-Dose, Two-Treatment, Two-Period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec® Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fasting Condition||Ranbaxy Inc.|Yes|Completed|October 2004|December 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776139||148544|
NCT00776152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||October 20, 2008|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776152||148543|
NCT00775190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-184|Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives|Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives||William Beaumont Hospitals|No|Terminated|October 2008|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|9|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|October 17, 2008||No|unale to recruit , progress report not filed by PI|No||https://clinicaltrials.gov/show/NCT00775190||148616|
NCT00775788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7006|Autologous Fat Grafting to the Breast|Autologous Fat Grafting to the Breast||Louisiana State University Health Sciences Center in New Orleans|No|Recruiting|June 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|50|||Female|17 Years|70 Years|Accepts Healthy Volunteers|||October 2008|November 17, 2008|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00775788||148570|
NCT00775801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-125|Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease|An IDE Study of the Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease|FLD|AxioMed Spine Corporation|Yes|Active, not recruiting|September 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|65 Years|No|||May 2014|May 27, 2014|October 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00775801||148569|
NCT00776100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0724|Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated With Systemic Therapy Plus Either Radiotherapy to All Sites of Gross Residual Disease or No Radiotherapy||Alliance for Clinical Trials in Oncology|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776100||148547|
NCT00788216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008129|Development & Validation of Utilities for Health States Relevant to Cervical Cancer Patients|Development and Validation of A Comprehensive Instrument to Determine Utilities for Health States Relevant to Cervical Gynecologic Cancer Patients||Duke University|No|Completed|September 2008|June 2013|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Members of the Public- Members of the public are considered the standard group to assign        utilities for health-economic purposes. Forty-five members of the public, without a        diagnosis of cervical cancer, will be recruited.        Cervical Cancer Patients- Fifteen patients, with a diagnosis of cervical cancer (either        currently being treated or previously treated).|July 2013|July 11, 2013|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00788216||147629|
NCT00789126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-509-002|Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Single-Dose Escalation Study and Multiple-Dose Escalation Study of VX-509 in Healthy Subjects||Vertex Pharmaceuticals Incorporated||Completed|October 2008|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double-Blind|||Anticipated|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|November 7, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00789126||147561|
NCT00788853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3677|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia|DiabCare Asia 2008. A Cross-sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and to Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia. DiabCare Asia 2008 - Indonesia|DiabCare Asia|Novo Nordisk A/S|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1832|Samples With DNA|Blood sample|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to inclusion        and exclusion criteria. Patients will be selected randomly from clinic record/list to        avoid any bias.|June 2014|June 23, 2014|November 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788853||147582|
NCT00790010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-142|Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma|A Phase I Trial of Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2009|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|46|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790010||147493|
NCT00785785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107G2301|A Study of Nilotinib Versus Imatinib in GIST Patients|A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)|ENESTg1|Novartis||Completed|March 2009|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|644|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|November 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785785||147811|
NCT00785798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0711003269|Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas|A Phase I/II Trial of Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas||Yale University|No|Recruiting|January 2009|November 2010|Anticipated|November 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||June 2009|June 5, 2009|November 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785798||147810|
NCT00786058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONKO 003|A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003|A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)||CONKO-Studiengruppe||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||June 2009|June 12, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786058||147790|
NCT00786357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SETS-exp|Sleep Enhancement Training Study for Experienced Shiftworkers|Sleep Enhancement Training Study for Experienced Shiftworkers|SETS-exp|University of California, San Francisco|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|40 Years|N/A|No|||June 2010|June 22, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786357||147767|
NCT00786591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/05/194|Study of New Biological Markers for Prediction of Severe Acute Pancreatitis|Clinical Evaluation of Novel Biological Markers for the Prediction of Severe Acute Pancreatitis||National University Hospital, Singapore|No|Completed|June 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|75|Samples With DNA|Whole blood; Serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients with clinical presentation suggestive of acute pancreatitis|December 2012|December 27, 2012|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786591||147749|
NCT00786604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5484|Glucose Study, Spinal Cord Injury|Continuous Glucose Monitoring in Individuals With Spinal Cord Injury||University of California, Irvine|No|Completed|June 2007|September 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|18-65 years old, male or female, have a neurologic deficit as a result of spinal damage,        pass a medical examination by the study physician, and must speak English. The        characteristics of the control group are that subjects must be 18-65 years old, male or        female, healthy without any physical ailments, pass a medical examination by the        physician, and must speak English.|November 2010|November 2, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786604||147748|
NCT00786838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014917|A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram|A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|65 Years|No|||March 2014|March 13, 2014|November 4, 2008|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00786838||147730|
NCT00786851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL LEN-DEX MCL 07|Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)|Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)||Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|July 2008|July 2011|Anticipated|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||November 2007|June 22, 2011|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786851||147729|
NCT00787124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007939|Transfusions and Nitric Oxide Level in Preterm Infants|Transfusions and Nitric Oxide Level in Preterm Infants||Duke University|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|Samples Without DNA|blood specimens for measurement of SNO-Hb. Samples will be discarded after measurement.|Both|N/A|365 Days|No|Non-Probability Sample|Infants < 28 weeks gestation at birth undergoing a packed red blood cell transfusion|December 2013|December 13, 2013|November 6, 2008||No||No|July 24, 2013|https://clinicaltrials.gov/show/NCT00787124||147710|no AE observed
NCT00787436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEL-20237|Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE|Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using Thalidomide||The Cleveland Clinic|Yes|Withdrawn|May 2006|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|November 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00787436||147687|
NCT00774592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069229|HIV Risk Reduction in Youth in the Bahamas|Adolescent Risk Reduction in the Bahamas-Peers and Parents||Wayne State University|No|Active, not recruiting|September 2004|December 2018|Anticipated|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|7||Actual|1360|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00774592||148661|
NCT00774605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051118|A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin|A Phase 1, Open-Label, Nonrandomized, Single Dose Study To Characterize The Pharmacokinetics Of A Varenicline (CP-526,555) Transdermal Solution And A Varenicline Transdermal Delivery System Applied To The Skin Of Adult Smokers||Pfizer|No|Completed|December 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|January 22, 2009|October 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00774605||148660|
NCT00776165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL/GCSF/N/2007/0100|Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)|A Phase 3 Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on Myelosuppressive Therapy for Non Myeloid Malignancies.||Shantha Biotechnics Limited|No|Completed|October 2007|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|126|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776165||148542|
NCT00771862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phantom limb pain PREVENTION|Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks|Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks||University of California, San Diego|No|Active, not recruiting|October 2008|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|18|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00771862||148870|
NCT00771875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05273|Randomized Trial for Mixed Acute Rejection|B-Cell Targeted Therapy for Acute Renal Allograft Rejection With an Antibody Mediated Component: A Prospective, Randomized, Open-Label Study||University of Cincinnati|Yes|Completed|September 2008|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|October 14, 2008|Yes|Yes||No|October 27, 2015|https://clinicaltrials.gov/show/NCT00771875||148869|
NCT00772174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-PIO-108|Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes|Double-blind, Randomized, Multicenter, Parallel-Group Study to Evaluate the Effects of Pioglitazone on Metabolic Syndrome in Patients With Type 2 Diabetes Treated With Metformin|PRISMA|Takeda|No|Completed|January 2007|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|418|||Both|35 Years|75 Years|No|||July 2010|July 1, 2010|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00772174||148846|
NCT00772187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rambam2690CTIL|Intraoperative and Postoperative Analgesia for Laparoscopic Surgery.|Intraoperative and Postoperative Analgesia for Laparoscopic Surgery.||Rambam Health Care Campus||Completed|October 2007|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||July 2010|September 21, 2010|May 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00772187||148845|
NCT00772460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HotDogVienna|Comparison of a New Patient Warming System Using Polymer Conductive Warming With Forced Air Warming During Surgery|Comparison of a New Patient Warming System Using Polymer Conductive Warming With Forced Air Warming During Surgery|HDV|Medical University of Vienna|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|90 Years|No|||September 2009|September 18, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772460||148824|
NCT00776113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021/CARVE-12.5/03|Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|August 2003|December 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00776113||148546|
NCT00776126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0803|Digital Breast Tomosynthesis Preference Study|Radiologists' Preference Study - Digital Breast Tomosynthesis|NRR|UNC Lineberger Comprehensive Cancer Center|No|Completed|October 2008|June 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776126||148545|
NCT00788229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dhpat02|Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome|A Phase II, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Safety of DHP-101, DHP-300, DHP-500 in Patients With Dry Eye Syndrome||Dhp Korea Co., Ltd.|Yes|Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788229||147628|
NCT00788541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-049|A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension|A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|Yes|Terminated|December 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|197|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|November 7, 2008|Yes|Yes|Project cancellation|No||https://clinicaltrials.gov/show/NCT00788541||147606|
NCT00789477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0706|DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact|A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (DME)|DA VINCI|Regeneron Pharmaceuticals|No|Completed|December 2008|September 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|221|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|November 7, 2008|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00789477||147534|
NCT00789464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23187|Probiotics for Girls With Recurring Urinary Tract Infections|H-23187: Probiotic Prophylaxis Against Recurrent Pediatric Urinary Tract Infection||Baylor College of Medicine|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|3 Months|17 Years|No|||September 2015|September 11, 2015|November 10, 2008|No|Yes|Withdrawn by PI|No||https://clinicaltrials.gov/show/NCT00789464||147535|
NCT00790023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-622|Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis|A Randomized, Multicenter, Double Blind, Placebo Controlled, Parallel Group, Phase III Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older.||Sunovion|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|707|||Both|12 Years|N/A|No|||November 2013|November 26, 2013|November 11, 2008|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT00790023||147492|This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg
NCT00790036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001N2301|Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy|A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy|PILLAR2|Novartis||Active, not recruiting|July 2009|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|741|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|November 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790036||147491|
NCT00790049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-107|A Safety Study of ARRY-371797 in Healthy Subjects|||Array BioPharma|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790049||147490|
NCT00785811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LARAS_L_02921|Effect of Chronic Supplementation of L-arginine in the Muscular Performance|Randomized, Double Blind, Placebo Controlled Study of Parallel Groups to Evaluate the Effect of Chronic Supplementation of L-arginine in the Muscular Performance.||Sanofi||Terminated|October 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|36|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|November 4, 2008||No|Required by the investigator. The site could not recruit patients anymore.|No||https://clinicaltrials.gov/show/NCT00785811||147809|
NCT00785824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08080129|African-American Bone Metabolism and Lactation Study|A Prospective Cohort Pilot Study of Bone Metabolism in Lactating and Non-lactating Postpartum African-American Women and Healthy Non-pregnant African-American Women||University of Pittsburgh|Yes|Completed|January 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|58|Samples Without DNA|archival blood serum and plasma|Female|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|New African-American mothers who are either almost exclusively breast-feeding or        bottle-feeding; normal controls to match the lactating mothers|October 2013|October 30, 2013|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785824||147808|
NCT00786071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-119|Metabolic Evaluation of Nutrition in Rett Syndrome|A Systematic Metabolic Approach to the Evaluation of Nutrition in Rett Syndrome According to the Cardiorespiratory Phenotype in Dutch Rett Girls||Maastricht University Medical Center|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|13|Samples Without DNA|Whole blood, serum, dried blood spot, leukocytes, erythrocytes, urine.|Female|2 Years|20 Years|No|Non-Probability Sample|The study population consists of a well-defined group of thirteen Dutch RTT girls with        complete clinical, molecular and neurophysiological work-up.|March 2010|March 3, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786071||147789|
NCT00786344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AG021108-04|USC Well Elderly Study 2|Health Mediating Effects of the Well Elderly Program||University of Southern California|Yes|Completed|November 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|460|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2008|November 4, 2008|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786344||147768|
NCT00786370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 08-045|Dexmedetomidine vs. Propofol for Cataract Surgery|Dexmedetomidine vs. Propofol for Monitored Anesthesia Care During Cataract||The Cooper Health System|No|Completed|April 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||November 2008|February 9, 2012|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786370||147766|
NCT00786630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1131|Intervention to Reduce Injection Drug Use|Intervention to Reduce Injection Drug Use||University of Colorado, Denver|No|Completed|November 2007|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|726|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786630||147746|
NCT00786617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-122|The Efficacy of Nurse-driven, Protocol Guided Ventilator Weaning in a Medical-Surgical Intensive Care Unit (ICU)|The Efficacy of Nurse-driven, Protocol Guided Ventilator Weaning in a Medical-Surgical ICU||St. Luke's-Roosevelt Hospital Center|Yes|Completed|December 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|202|||Both|18 Years|N/A|No|Probability Sample|Mechanically Ventilated Patients in Medical-Surgical ICU|March 2015|March 18, 2015|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00786617||147747|
NCT00786864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fanucchi et al|Exercise for Low Back Pain in Children|School-Based Specific Exercise Programme Reduces the Prevalence and Intensity of Low Back Pain in 12-13 Year Old Children: a Randomized Controlled Trial|LBP|University of Witwatersrand, South Africa|No|Completed|January 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|72|||Both|12 Years|13 Years|No|||November 2008|November 5, 2008|October 14, 2008||No||No|October 14, 2008|https://clinicaltrials.gov/show/NCT00786864||147728|Only 2 schools, in a similar geographic and socioeconomic area were included, and therefore the results may not necessarily be generalized to a larger population
NCT00786877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000332|Cookstove Replacement for Prevention of ALRI and Low Birthweight in Nepal|Cookstove Replacement for Prevention of ALRI and Low Birthweight in Nepal||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|August 2009|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|4678|||Both|N/A|36 Months|Accepts Healthy Volunteers|||January 2015|January 15, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786877||147727|
NCT00787137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG102-01|Single Dose PG102 in Patients With Active Psoriatic Arthritis|A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis||PanGenetics UK Limited|Yes|Terminated|December 2008|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|60 Years|No|||October 2010|October 15, 2010|November 6, 2008||No|poor recruitment|No|August 12, 2010|https://clinicaltrials.gov/show/NCT00787137||147709|Termination prior to accrual of planned numbers of participants
NCT00787735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA016375|Improving Delivery of Mental Health Services for Patients With Drug Use and Other Behavioral and Emotional Problems|Services Research: Psychiatric Comorbidity in Drug Abuse||Johns Hopkins University|No|Completed|January 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|80 Years|No|||March 2013|March 8, 2013|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787735||147665|
NCT00774865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-190|Long Term Follow-up of Robotic Assisted Surgical Revascularization|Long Term Follow-up of Robotic Assisted Surgical Revascularization With CT Angiography|ZEUSFUPCTA|Lawson Health Research Institute|No|Enrolling by invitation|June 2008|December 2014|Anticipated|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|30 Years|N/A|No|Non-Probability Sample|All 150 living robotically-assisted CABG surgery patients will be contacted and their        participation in the study requested. Patients will receive an initial request by mail,        with an informative letter signed by the principal investigator outlining the purpose of        the study, what participation in the study involves, and the specific aims of the cardiac        team at the conclusion of the study. A follow-up phone call will be done within 3-weeks of        mailing the letter to go over the content and answer any questions that patients may have.|October 2013|October 7, 2013|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00774865||148641|
NCT00775203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04ACL3-001|A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.|A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.||Labopharm Inc.||Completed|June 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|412|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|October 17, 2008|Yes|Yes||No|February 25, 2010|https://clinicaltrials.gov/show/NCT00775203||148615|
NCT00776178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909007|Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health|Feasibility Study: Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health||National Institutes of Health Clinical Center (CC)||Completed|October 2008|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|68|||Both|30 Years|79 Years|No|||March 2016|March 19, 2016|October 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00776178||148541|
NCT00771888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL16194.091.07|Open-Label Extension of LOCKCYST Trial|Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers|LOCKCYST-ext|Radboud University|No|Active, not recruiting|April 2008|August 2009|Anticipated|October 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|88 Years|No|||November 2008|November 12, 2008|October 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00771888||148868|
NCT00772200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTE07C1|Neuropsychological and Behavioral Testing in Younger Patients With Cancer|Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer||Children's Oncology Group|No|Recruiting|September 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|755|||Both|1 Month|21 Years|No|Non-Probability Sample|Patients on COG Phase III clinical trials.|September 2015|September 21, 2015|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772200||148844|
NCT00772707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-14|A Multi‐Center Investigation of Patient Acceptability of OPTI‐FREE RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)|A 30 Day, Multi‐Centered, Open Label Study To Determine Comfort and Overall Contact Lens Wearing Experience Using OPTI‐FREE RepleniSH® MPDS as Compared to COMPLETE®MPS Easy Rub™ or ReNu MultiPlus® in Daily Wear Soft Contact Lens Patients||Alcon Research|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|65 Years|No|||August 2012|August 31, 2012|October 7, 2008|Yes|Yes||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00772707||148805|
NCT00788866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pomegranate-1|Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)|Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)|POM-1|Washington University School of Medicine|No|Completed|December 2008|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|80|||Female|N/A|N/A|No|||October 2014|October 16, 2014|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788866||147581|
NCT00789113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308M51662|Determination of Absorption and Elimination of Lamotrigine-XR|Determination of Bioavailability and Clearance of Lamotrigine-XR by a Stable Isotope Technique||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2008|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|65 Years|N/A|No|||December 2015|December 14, 2015|November 7, 2008|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT00789113||147562|
NCT00789490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sickkids REB 1000007811|Relative Bioavailability of Iron and Folic Acid in New Test Supplement|Relative Bioavailability of Iron and Folic Acid From a New Powdered Supplement Compared to a Traditional Tablet in Pregnant Women||University of Toronto|Yes|Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|18|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 12, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789490||147533|
NCT00789737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-305|Welchol as Monotherapy for Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus||Daiichi Sankyo Inc.|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|November 10, 2008|Yes|Yes||No|December 4, 2013|https://clinicaltrials.gov/show/NCT00789737||147514|
NCT00790062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070910007|Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT|Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery||University of Alabama at Birmingham|Yes|Completed|November 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1798|||Female|N/A|N/A|No|||December 2013|December 10, 2013|November 12, 2008||No||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00790062||147489|
NCT00790075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20034920|Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children|Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children||Stony Brook University|No|Completed|January 2003|December 2004|Actual|June 2004|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|4 Years|12 Years|No|||November 2008|November 12, 2008|November 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00790075||147488|
NCT00785837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hydrotherapy|Effects of Hydrotherapy in Pain and Quality of Sleep's Cycles in Preterm Newborn on Neonatal Intensive Care Units|Effects of Hydrotherapy in Pain and Quality of Sleep's Cycles in Preterm Newborn on Neonatal Intensive Care Units|hydrotherapy|Universidade Luterana do Brasil|Yes|Recruiting|July 2005|January 2009|Anticipated|September 2008|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|8|||Both|N/A|36 Weeks|No|||September 2008|November 4, 2008|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785837||147807|
NCT00786084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21065-A|Study of Paraesophageal Hernia Repair With Small Intestine Submucosa|Randomized Prospective Controlled Trial of Paraesophageal Hernia Repair With Small Intestine Submucosa (SIS)|PEH|University of Washington|Yes|Active, not recruiting|September 2008|December 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|108|None Retained|None retained.|Both|18 Years|N/A|No|Non-Probability Sample|Prior enrollment in the Phase I study.|September 2009|September 30, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786084||147788|
NCT00786097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04305|Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix||Sanofi||Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|53|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786097||147787|
NCT00786643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WITMMCC0301|Study of Gamma Interfereon in Metastatic Colorectal Carcinoma|Phase II Study of Gamma Interferon (IFN-γ) Added to Bolus + Infusional 5-Fluorouracil (5-FU) and Leucovorin (LV) +/- Bevacizumab (BV) in Metastatic Colorectal Carcinoma|GFL|Accelerated Community Oncology Research Network|Yes|Completed|February 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||February 2012|February 28, 2012|November 3, 2008|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT00786643||147745|Enrollment to stratum 1 was closed early due to difficulty accruing the required number of patients in this stratum.
NCT00786890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF-2008-2|A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong|A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong: The Joint Asia Diabetes Evaluation (JADE) Program Sub-study 2 (JADE-HK2)|JADE-HK2|Chinese University of Hong Kong||Active, not recruiting|November 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Hong Kong Chinese with pre-diabetes|August 2015|August 21, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786890||147726|
NCT00787150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0661003|A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation|A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF||Pfizer|Yes|Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|222|||Both|20 Years|N/A|No|||April 2013|April 23, 2013|November 5, 2008||No||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00787150||147708|
NCT00787462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAS-2007-HC-01|Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy|Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy||University of Alberta|No|Suspended|October 2008|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 9, 2010|November 6, 2008||No|As a result of restrictive inclusion criteria and a limited pool of suitable subjects with    SFN, this study has been suspended pending review.|No||https://clinicaltrials.gov/show/NCT00787462||147686|
NCT00787722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAD Devic's Disease Auto 2008|Hematopoietic Stem Cell Transplant in Devic's Disease|Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease||Northwestern University|No|Recruiting|October 2008|October 2018|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|65 Years|No|||March 2016|March 21, 2016|October 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787722||147666|
NCT00779519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP435-201|Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss|A Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study to Assess Safety and Tolerability of TTP435 in Obese (Class 1-2) Subjects Over 8 Weeks of Treatment||vTv Therapeutics|No|Completed|February 2009|||December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779519||148286|
NCT00775814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLO K025|Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.|Double-blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous ß-blocker or Calcium Channel Blocker||Takeda|No|Completed|October 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Both|35 Years|70 Years|No|||August 2012|August 6, 2012|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775814||148568|
NCT00775827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|028/FENOF-160/02|Bioequivalency Study of Fenofibrate 160mg Tablets Under Fasting Conditions|A Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Fenofibrate Formulations Comparing Fenofibrate 160 mg Tablets of Ranbaxy Laboratories With Tricor 160 mg Tablets of in Healthy, Adult, Human Subjects Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|November 2002|December 2002|Actual|December 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 17, 2008|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00775827||148567|
NCT00771914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study Protocol 112421|The Effects of Omega-3 Fatty Acids on Aspirin Resistance|The Effects of Omega-3 Fatty Acids on Aspirin Resistance||University of Rochester|Yes|Completed|November 2008|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 31, 2012|October 14, 2008|No|Yes||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00771914||148866|
NCT00771901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1114|Effect of Endoplasmic Reticulum Stress on Metabolic Function|Effect of Endoplasmic Reticulum Stress on Metabolic Function|TUDCA/PBA|Washington University School of Medicine|No|Completed|February 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|101|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771901||148867|
NCT00772213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 159/02|The Multifunctional Image Guided Therapy Suite (MIGTS) in Emergency Multiple Trauma Care|The Impact of a Multifunctional Image Guided Therapy Suite (MIGTS) on Emergency Multiple Trauma Care - a Controlled Clinical Pilot Study|MIGTS|University Hospital, Basel, Switzerland|No|Completed|February 2003|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|N/A|N/A|No|||October 2013|October 29, 2013|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772213||148843|
NCT00772226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080031|The Use of Music as Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy in a Day Care Unit|The Use of Music as Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy in a Day Care Unit||Randers Regional Hospital|No|Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||September 2012|September 9, 2012|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772226||148842|
NCT00772473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine IISP 33467|Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine|Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine||Clinvest|No|Completed|February 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|34|None Retained|saliva|Both|18 Years|65 Years|No|Non-Probability Sample|Patients at a mid west headache specialty clinic|May 2009|May 22, 2009|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772473||148823|
NCT00789139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPIDXT|Recurrence of Arrhythmias After Pulmonary Veins Isolation Detected by ICM|Recurrence of Arrhythmias After Pulmonary Veins Isolation Detected by ICM|RAPID XT|Hospital St. Joseph, Marseille, France|Yes|Completed|October 2008|July 2013|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|47|||Both|18 Years|75 Years|No|||June 2015|June 18, 2015|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789139||147560|
NCT00789152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03609|The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)|The Effects of Desloratadine and Levocetirizine on Nasal Obstruction in Subjects With Induced Allergic Rhinitis in the VCC Assessed Clinically and With Nasal Rhinomanometry and Nasal Flowmetry||Merck Sharp & Dohme Corp.|No|Completed|December 2003|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|45 Years|No|||May 2015|May 4, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00789152||147559|
NCT00789165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297368|Empiric Quinidine for Asymptomatic Brugada Syndrome|A Prospective Trial Of Empiric Quinidine Therapy For Asymptomatic Brugada Syndrome.||International Registry of Asymptomatic Brugada Syndrome|No|Recruiting|December 2009|||December 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|November 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00789165||147558|
NCT00789503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bread Vitamin D|Nursing-Home Residents Given Bread Fortified With Vitamin D3|Long-Term Effects of Giving Nursing-Home Residents Bread Fortified With 125 Micrograms (5000 IU) Vitamin D3 Per Daily Serving||University of Toronto|No|Completed|November 2004|December 2005|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|58 Years|89 Years|Accepts Healthy Volunteers|||November 2008|November 12, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789503||147532|
NCT00789789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-002219-14|Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials|Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|December 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|488|Samples With DNA|Blood specimen collection (serum, plasma and whole blood)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers.|January 2016|January 14, 2016|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789789||147510|
NCT00789750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-306|Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)||Daiichi Sankyo Inc.|No|Completed|April 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|562|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00789750||147513|
NCT00789763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD 0701|Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma|Open-label, Multicentric Phase I-II Trial to Evaluate the Efficacy and Safety of the Combination of Sorafenib (BAY 43-9006), Gemcitabine and Concurrent Radiotherapy, in Locally Advanced Pancreatic Carcinoma||Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Completed|December 2007|January 2012|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789763||147512|
NCT00785850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04301|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety.|Safety Dermatological Evaluation: Genital Mucous Irritation - Product Tested: Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower.||Sanofi||Completed|August 2008|||September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Female|10 Years|20 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785850||147806|
NCT00786110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-000759-91|Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients|Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy|PAXO|University of Turin, Italy|Yes|Recruiting|April 2008|October 2010|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2009|February 23, 2009|November 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00786110||147786|
NCT00786123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/06/136|Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome|Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome: a Randomized Double Blind Placebo Controlled Study||National University Hospital, Singapore|No|Completed|May 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|68 Years|No|||March 2011|March 2, 2011|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786123||147785|
NCT00786383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13919|Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy|Phase 1 Study of Every Other Week Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded To Standard Therapy||Eli Lilly and Company|No|Completed|February 2006|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|November 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00786383||147765|
NCT00786149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708M14444|Improving Varenicline Adherence and Outcomes in Homeless Smokers|Improving Varenicline Adherence and Outcomes in Homeless Smokers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2007|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|428|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 2, 2014|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00786149||147783|
NCT00786396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DA 0179059|Directly Observed Therapy for Community-Released HIV+ Prisoners|Directly Observed Therapy for Community-Released HIV+ Prisoners|Connect|Yale University|No|Completed|July 2004|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786396||147764|
NCT00786656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909026|Community Cancer Centers Pilot Patient Survey|NCI Community Cancer Center Pilot Program Patient Survey||National Institutes of Health Clinical Center (CC)||Completed|November 2008|May 2015||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|6000|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 12, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786656||147744|
NCT00786669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITAC|A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors|A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Relapsed/Refractory Pediatric Solid Tumors|VITAC|Children's Hospital Medical Center, Cincinnati|Yes|Completed|October 2008|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|1 Year|30 Years|No|||February 2015|February 24, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786669||147743|
NCT00786903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-322 ex 07/08|Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?|Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?||Medical University of Graz|Yes|Completed|November 2008|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|202|Samples With DNA|Respiratory secretions, blood, lung tissue|Both|18 Years|N/A|No|Probability Sample|adult patients with and without infiltration of the lungs and with and without intubation        and mechanically ventilation|April 2015|April 2, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786903||147725|
NCT00787163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amnioinfusion-001|Amnioinfusion Initiative|Open Randomized Trial Comparing Perinatal Outcome Following Expectant Management Versus Amnioinfusion in PPROM <25 Wks With Persistent Oligohydramnios||Università degli Studi di Brescia|Yes|Recruiting|September 2008|December 2013|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Female|18 Years|45 Years|No|||November 2008|January 21, 2009|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787163||147707|
NCT00789841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080121|Gastrointestinal Motility in Patients With Neuroendocrine Tumors|Gastrointestinal Motility in Patients With Neuroendocrine Tumors-Effects of Sandostatin LAR||University of Aarhus|No|Completed|September 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|N/A||1|Actual|13|Samples With DNA|Blood samples wich are destroyed after analysis|Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are scheduling 12 subjects (30-80 years of age) with NET and carcinoid syndrome with        diarrhea. Patients are recruited through the Department of Medicine V, Aarhus University        Hospital.|October 2010|October 25, 2010|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789841||147506|
NCT00790179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1989md|Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty|Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty||Northwell Health|Yes|Completed|January 2003|March 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2008|November 12, 2008|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790179||147480|
NCT00775840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLO K026|Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.|Candesartan "Added" Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months||Takeda|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|45 Years|N/A|No|||June 2010|June 17, 2010|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775840||148566|
NCT00775853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090010|Biomarkers of Risk of Parkinson Disease|Biomarkers of Risk of Parkinson Disease||National Institutes of Health Clinical Center (CC)||Recruiting|October 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|220|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|October 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00775853||148565|
NCT00772239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07018/ROTEM CTV|Perioperative Coagulation Management in Cardiac Surgery.|Perioperative Coagulation Management in Cardiac Surgery. Rotem Versus Standard Pratctice. A Randomized Trial.|ROTEM|University Hospital, Limoges|No|Terminated|October 2008|||August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2011|April 23, 2011|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00772239||148841|
NCT00772512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0911003|A Study Of The Effect Of PF-04802540 On Sleep Measures|Subject- And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 3-Way Crossover Study To Study Effects Of PF-04802540 On Polysomnography Endpoints In Healthy Volunteers||Taisho Pharmaceutical Co., Ltd.|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|March 17, 2010|October 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00772512||148820|
NCT00772759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0570C00005|Assess Safety, Tolerability and PK of AZD3199 in Japanese|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Japanese Healthy Men||AstraZeneca|Yes|Completed|October 2008|February 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 4, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772759||148801|
NCT00772486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL-35-104|A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL|A Phase 1b Study of Repeated Doses of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Combination With Fludarabine, Cyclophosphamide and Rituximab (FCR) in Subjects With Chronic Lymphocytic Leukemia (CLL)||Memgen, LLC|Yes|Active, not recruiting|September 2008|||April 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|October 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00772486||148822|
NCT00772499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|866-432|Vascular Improvement With Olmesartan Medoxomil Study|Vascular Improvement With Olmesartan Medoxomil Study|VIOS|Daiichi Sankyo Inc.|No|Completed|November 2002|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||October 2008|October 14, 2008|October 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00772499||148821|
NCT00789178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154/08|Cognitive and Memory Function in Patients With Fibromyalgia|Cognitive and Memory Function in Patients With Fibromyalgia and Their Influence on Disability||Assaf-Harofeh Medical Center|No|Not yet recruiting|December 2008|April 2010|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|50 patients with fibromyalgia 30 patients with RA 20 healthy controls|November 2008|November 10, 2008|November 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00789178||147557|
NCT00789191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3511|Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes|Effect of Detemir and Sitagliptin on Blood Glucose Control in Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|November 10, 2008|Yes|Yes||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00789191||147556|
NCT00789802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1026|A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC|A Randomized, Controlled Trial of Oral Naproxen and Transdermal Estradiol for Prevention of Unscheduled Bleeding in New Users of Levonorgestrel Intrauterine Contraception||Washington University School of Medicine|Yes|Completed|November 2008|January 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|129|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|November 11, 2008||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00789802||147509|
NCT00789776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2230.00|Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer|A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial||Fred Hutchinson Cancer Research Center|Yes|Recruiting|October 2008|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||November 2015|November 16, 2015|November 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00789776||147511|
NCT00785863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000904-10|Modulation of Remifentanil-induced Postinfusion Hyperalgesia|Modulation of Remifentanil-induced Analgesia and Postinfusion Hyperalgesia by Parecoxib or Ketorolac in Humans||Oslo University Hospital|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|16|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||November 2008|June 30, 2011|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785863||147805|
NCT00786136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNH-20081028|Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes|Multicenter Randomized Controlled Study of Rosuvastatin for Prevention of Contrast Induced Acute Kidney Injury in Patients With Diabetes and Slight to Moderate Renal Insufficient|TRACK-D|Shenyang Northern Hospital|Yes|Completed|December 2008|November 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2998|||Both|18 Years|75 Years|No|||April 2013|April 9, 2013|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786136||147784|
NCT00778011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0506018|Uncomplicated Nausea and Vomiting in the Emergency Department|Ondansetron 4 mg vs. 2 mg vs. Metoclopramide 10 mg for Nausea and Vomiting in the Emergency Department: A Randomized, Double-Blind Clinical Trial||WellSpan Health|No|Completed|November 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|137|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|October 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00778011||148401|
NCT00778258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AADCRC-MSSM-02|An Interventional Study of Milk Allergy and Tolerance in Children|Dietary Intervention in Milk Allergy and Tolerance Development||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2008|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|170|||Both|4 Years|10 Years|No|||January 2015|January 16, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00778258||148382|
NCT00778557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098|Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions|A Three-Way Crossover, Blinded, Single-Dose, Fasting, Bioequivalence Study of One Test Formulation of Cefprozil 250 mg/5 mL Oral Suspension Versus Two Reference Formulation of Cefzil TM Powder for Oral Suspension (250 mg/5 mL) in Normal Healthy Non-Smoking Male and Female Subjects||Ranbaxy Inc.|Yes|Completed|June 2005|July 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|3||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778557||148359|
NCT00778908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUIKEGONG-0816004-40|Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma|Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial||Guangxi Medical University|Yes|Completed|January 2008|December 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||August 2012|August 17, 2012|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778908||148333|
NCT00779207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 37948A|Effect of Weight Loss and Exercise on Liver and Muscle Fat in Obese Elderly|Effect of Weight Loss and Exercise on Intrahepatic and Intramyocellular Fat in Obese Older Adults||Washington University School of Medicine|Yes|Completed|November 2006|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779207||148310|
NCT00790192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050233|Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.|A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)|PEARL 3|Sunovion|Yes|Completed|October 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|488|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|November 10, 2008|Yes|Yes||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00790192||147479|
NCT00775866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0641-C|MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy|MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy||University Health Network, Toronto|Yes|Active, not recruiting|October 2006|October 2016|Anticipated|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|90|||Male|18 Years|N/A|No|||June 2015|June 12, 2015|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775866||148564|
NCT00804804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/17|Aging, Sleep, Cognitive Process|Aging,Sleep and Cognitive Process|SOMVIE|University Hospital, Bordeaux|No|Completed|December 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|28|||Male|20 Years|75 Years|Accepts Healthy Volunteers|||March 2011|March 4, 2011|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804804||146376|
NCT00808808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA-181|Assessing Choice in the Employer Setting (ACES) Study|Assessing Choice in the Employer Setting (ACES Study): An Observational Study to Assess the Impact of Offering Intranasal Vaccine on Influenza Vaccination Rates in the Employer Setting|MA181|MedImmune LLC|No|Completed|September 2008|December 2008|Actual|November 2008|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|4411|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults at least 18 years of age who are current employees attending the influenza clinic        sponsored by their employer|October 2013|October 28, 2013|December 12, 2008||No||No|July 30, 2012|https://clinicaltrials.gov/show/NCT00808808||146076|The study was conducted during a single season, data to evaluate effects of the intervention by race were unavailable, baseline vaccination data were available at the company level only, and vaccines received outside the workplace were not assessed.
NCT00808821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|544-2006-IDF-CTIL|Pharyngeal Carriage Rates and Genetic Typing of Group A Streptococcus and Streptococcus Pneumonia Among Israeli Military Basic Trainees|Pharyngeal Carriage Rates and Genetic Typing of Group A Streptococcus and Streptococcus Pneumonia Among Israeli Military Basic Trainees||Medical Corps, Israel Defense Force||Completed||||||N/A|Observational|N/A|||||||Both|N/A|N/A||||October 2008|December 15, 2008|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808821||146075|
NCT00805077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070119|Pulmonary Surgery and Protective Mechanical Ventilation|Pulmonary Surgery and Protective Mechanical Ventilation|VPP|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2008|July 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|347|||Both|18 Years|90 Years|No|||July 2013|July 26, 2013|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805077||146355|
NCT00805311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00805311|Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis|Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis|AMTEC|Russian Cardiology Research and Production Center|Yes|Terminated|April 2009|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|40 Years|80 Years|No|||October 2015|October 7, 2015|December 8, 2008||No|Due to the clear advantage of carotid endarterectomy|No||https://clinicaltrials.gov/show/NCT00805311||146337|
NCT00773071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-377|Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers|Added-value of SPECT/CT in Patients Undergoing Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) for Gynecological Cancers||Lawson Health Research Institute|Yes|Completed|April 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Female|18 Years|N/A|No|||June 2012|June 7, 2012|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00773071||148777|
NCT00789204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FB001022008|Postural Re-education in Low Back Pain|Effectiveness of a "Global Posture Reeducation" Program for Patients With Low Back Pain||University of Bologna|No|Completed|May 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||September 2009|September 21, 2009|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789204||147555|
NCT00789217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 001/08|Penicillin Skin Testing in Patients With History of Allergic Reactions to Betalactams|The Comparative Results of Penicillin Testing in Patients With History of Allergic Reactions to Betalactams Between Using In-house Penicillin Test Preparation and Commercial Available Penicillin Testing Kit||Chulalongkorn University|No|Completed|December 2008|August 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|63|||Both|15 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 26, 2010|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00789217||147554|
NCT00789815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-0257B|Bispectral Index-guided Sedation for Flexible Bronchoscopy|Sedation for Flexible Bronchoscopy and Real Time Endobronchial Ultrasound -A Comparison Between Bispectral Index-guided Sedation and Conventional Sedation||Chang Gung Memorial Hospital|No|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|500|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|November 10, 2008||No||No|February 3, 2010|https://clinicaltrials.gov/show/NCT00789815||147508|The bronchoscopists were not blinded to sedative procedures. It was difficult to accomplish totally blind conditions. The bronchoscopist would realize which protocol it was when only observing responses of the investigator.
NCT00790114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00005|Determine the Effect of Multiple Doses of AZD7325, CYP Study|A Phase I Open-Labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD7325 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)|CYP|AstraZeneca|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 12, 2008|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790114||147485|
NCT00790088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUR04|INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy|International Report on Routine Practice of Sensor-enabled Pump Therapy||Medtronic|No|Active, not recruiting|February 2009|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|capillary blood samples for HbA1c analysis|Both|N/A|N/A|No|Non-Probability Sample|Patients with type 1 diabetes on insulin infusion pump therapy|February 2012|February 3, 2012|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790088||147487|
NCT00790101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR4003B_4033|Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation|An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis||Sanofi||Terminated|June 2004|October 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|6|||Female|N/A|65 Years|No|||January 2011|January 10, 2011|November 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00790101||147486|
NCT00790127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQP-2008-003b|Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia|A Multi-National, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HQK-1001 in Subjects With Beta Thalassemia Intermedia, Including Hemoglobin E Beta Thalassemia||HemaQuest Pharmaceuticals Inc.|Yes|Completed|March 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|12 Years|60 Years|No|||May 2011|May 18, 2011|November 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790127||147484|
NCT00785876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012792|Implementation of the Low Risk Ankle Rule|Controlled Radiography for Ankle Injury Cases in Kids in the Emergency Department: Implementation of the Low Risk Ankle Rule||The Hospital for Sick Children|No|Completed|November 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|3000|||Both|3 Years|16 Years|No|||May 2014|May 12, 2014|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785876||147804|
NCT00778024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03197|Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions|The Objective of This Randomized, Single-dose, Two-way Evaluation is to Compare the Bioequivalence of a Test Fluoxetine HCL Formulation (Ranbaxy Laboratories Limited, Lot No. 6320101) to an Equivalent Oral Dose of the Commercially Available Fluoxetine HCL (Prozac®, Dista Products Company, Lot No 6RK57M) in a Test Population of 36 Adult Subjects Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|August 2003|December 2003|Actual|October 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 11, 2009|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778024||148400|
NCT00777712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0270|Mechanisms Underlying Impaired Diabetic Wound Healing|Mechanisms Underlying Impaired Diabetic Wound Healing|WoundVac|Ohio State University|No|Recruiting|September 2008|September 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|150|Samples With DNA|Blood, Wound Vac Sponge.|Both|21 Years|80 Years|No|Non-Probability Sample|Patients will be recruited at the Comprehensive Wound Care Centers: Martha Morehouse        Medical Plaza, OSU East, and University Hospitals|September 2015|September 8, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777712||148424|
NCT00788398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHS-03-08-06|Fluid Lavage of Open Wounds|Fluid Lavage of Open Wounds (FLOW): A Multi-center, Blinded, Factorial Trial Comparing Alternative Irrigating Solutions and Pressures in Patients With Open Fractures|FLOW|Greenville Health System|Yes|Completed|June 2009|April 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|2540|||Both|14 Years|85 Years|No|||February 2016|February 10, 2016|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788398||147616|
NCT00788697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR1-128|SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization|Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard||Bracco Diagnostics, Inc|No|Completed|September 2009|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|349|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|November 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788697||147594|
NCT00788710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-097|A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Tolerability of MK0663/Etoricoxib in the Treatment of Pain After Abdominal Hysterectomy||Merck Sharp & Dohme Corp.|No|Completed|October 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|430|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|November 5, 2008|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00788710||147593|11 participants were screened & 10 participants were randomized at site 0028. An audit showed study medication dispensing logs were not kept. These 10 participants were invalidated and excluded from both efficacy & safety analyses.
NCT00788983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112008|Induced Hypoxia Study for Validation of SpO2 Accuracy|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia||Nonin Medical, Inc|No|Completed|November 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, consenting, non-smoking subjects, 18 years or greater, both genders and a range        of skin tones|December 2008|September 19, 2013|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788983||147572|
NCT00789295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29102008|Mediterranean Diet and Postprandial Lipemia|Mediterranean vs. Low-Carbohydrate Diet : Which is the Best Dietary Approach for Treating Postprandial Lipid Abnormalities and Improving Glucose Control in Type 2 Diabetic Patients?||Federico II University|No|Completed|March 2004|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|40 Years|65 Years|No|||October 2008|November 10, 2008|November 10, 2008||||No||https://clinicaltrials.gov/show/NCT00789295||147548|
NCT00789308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-01A|Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation|Open Randomized Mult-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation (CIT-01A)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2008|August 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||August 2015|August 12, 2015|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789308||147547|
NCT00789334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLL-07-07|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||August 21, 2009|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00789334||147545|
NCT00789555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-32|Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis|Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis||Alcon Research|No|Completed|November 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1260|||Both|12 Years|N/A|No|||August 2012|August 8, 2012|November 11, 2008|Yes|Yes||No|August 8, 2012|https://clinicaltrials.gov/show/NCT00789555||147528|
NCT00789568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTC-001|A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects|A Phase 1, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Effects of Sapropterin Dihydrochloride Oral Administration on QTc Intervals in Healthy Adult Subjects||BioMarin Pharmaceutical|No|Completed|October 2008|October 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|November 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00789568||147527|
NCT00786188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N30-002|Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause|A Phase 2, Exploratory, Eight-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause||Noven Therapeutics|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|102|||Female|41 Years|N/A|No|||October 2015|October 14, 2015|November 4, 2008|Yes|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT00786188||147780|
NCT00775905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50365|Bioequivalence Study of Amlodipine Tablets Under Fasting Conditions|The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fasted Subjects.||Ranbaxy Inc.|Yes|Completed|July 2005|October 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2008|October 16, 2008|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00775905||148561|
NCT00776191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-005434-12|Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism|Randomized, Multicenter Cross-over Study in Investigating the Effect of Bicarbonate-based Solutions (Physioneal 35 vs. 40) on Protein Metabolism in Children and Adolescents on Chronic Peritoneal Dialysis|NephropaedPD01|University of Erlangen-Nürnberg Medical School|No|Terminated|September 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|3 Months|18 Years|No|||June 2015|June 3, 2015|October 20, 2008||No|al study sites stoped on 15/05/2012 because of insufficient recrutement.|No||https://clinicaltrials.gov/show/NCT00776191||148540|
NCT00804830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001783-75|Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer|Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer||Region Skane|Yes|Active, not recruiting|April 2008|December 2014|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||August 2012|August 20, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804830||146374|
NCT00804583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK066368|Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease|Genetic Modifiers of CF Liver Disease||University of North Carolina, Chapel Hill|No|Recruiting|March 2004|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|A one time blood draw of 35 mls|Both|2 Years|N/A|No|Non-Probability Sample|CF and liver disease|March 2016|March 7, 2016|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804583||146392|
NCT00804817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKH-Project|Somatic-psychosocial Care Concept for Oncologic Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|Somatic-psychosocial Multidisciplinary Care Concept for Oncologic Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): a Prospective Non-randomized Clinical Trial||Martin-Luther-Universität Halle-Wittenberg|No|Completed|December 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|84|||Both|14 Years|N/A|No|||December 2008|August 26, 2010|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804817||146375|
NCT00805649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-KTAMD-2008|Combined Therapy in Age-Related Macular Degeneration (ARMD)|Combined Therapy in ARMD - Retrospective Case Series||Johann Wolfgang Goethe University Hospitals|No|Completed|January 2006|July 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|N/A|N/A|No|||September 2012|September 26, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805649||146312|
NCT00805324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03472|Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)|Evaluation of the Efficacy and Safety of Desloratadine Syrup in Children Suffering From Seasonal Allergic Rhinitis With or Without Intermittent Asthma||Merck Sharp & Dohme Corp.|No|Completed|May 2003|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|6 Years|12 Years|No|||April 2015|April 20, 2015|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805324||146336|
NCT00789516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID11-48-16|The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation|The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation||Mahidol University|No|Completed|June 2006|December 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|60|Samples Without DNA|Blood|Both|1 Year|18 Years|Accepts Healthy Volunteers|Probability Sample|The subjects were classified into 3 groups; β-thalassemia post SCT (Thal-SCT),        β-thalassemia treated with regular transfusion (Thal-RT) and NC.|March 2013|March 6, 2013|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789516||147531|
NCT00789828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001M2301|Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)|A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)|EXIST-1|Novartis||Completed|August 2009|October 2014|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|N/A|N/A|No|||January 2016|January 4, 2016|November 12, 2008|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00789828||147507|
NCT00790140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900/429/1|Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery|Randomized Double Blinded Trial to Investigate Effects of an Enteral Nutritional Supplement Enriched With Eicosapentaenoic Acid on Body Composition,Complications,Stress Response,Immune Function & Quality of Life in After Esophagectomy||University of Dublin, Trinity College|Yes|Recruiting|July 2005|July 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||November 2008|November 12, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790140||147483|
NCT00778271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA01819|Bioequivalence Study of Gabapentin 400 mg Capsules Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Park:-Davis (Neurontin®) 400 mg Gabapentin Capsules in Healthy Adult Volunteers Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|September 2002|December 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778271||148381|
NCT00787774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAL-dyn|Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression|Integrase Resistance Analysis in Treated Experienced HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression|RAL-dyn|Hospital Clinic of Barcelona|No|Recruiting|November 2008|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|20|||Both|N/A|N/A|No|||March 2010|March 30, 2010|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00787774||147662|
NCT00788073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22001|Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome|A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome||Seaside Therapeutics, Inc.|Yes|Completed|November 2008|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|6 Years|40 Years|No|||March 2013|March 22, 2013|November 7, 2008|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT00788073||147639|
NCT00788424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#72REV00|Topical Application of AS101 for the Treatment of Psoriasis|Study of Topical Application of AS101 for the Treatment of Psoriasis||BioMAS Ltd|No|Withdrawn|November 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||June 2008|July 22, 2015|November 10, 2008||No|Sponsor's considerations|No||https://clinicaltrials.gov/show/NCT00788424||147615|
NCT00788437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOI-12|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||December 15, 2009|November 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788437||147614|
NCT00788450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU12|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2014|||||N/A|N/A|N/A||||||||||||||January 14, 2014|November 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788450||147613|
NCT00788723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNRC-AAU-08-1|Cortical Excitability in Patients With Severe Brain Injury|Cortical Excitability in Patients With Severe Brain Injury||University of Aarhus|No|Recruiting|July 2008|May 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 10, 2008|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788723||147592|
NCT00788996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPT0701|Reduction of Environmental Tobacco Smoke (ETS) Exposure at Home: the BIBE Study|Effectiveness of a Brief Intervention Opportunistic Targeting Parents Who Smoke to Reduce Exposure to Secondhand Smoke in Babies: STUDY BIBE|BIBE|Jordi Gol i Gurina Foundation|Yes|Not yet recruiting|January 2009|January 2011|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|552|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 12, 2008|November 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00788996||147571|
NCT00789321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-106|A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)|A Randomized Clinical Trial to Evaluate the Effects of Multiple Doses of Amlodipine 10 mg on Pedal Edema Measurements in Middle-Aged and Elderly Healthy Subjects and Patient With Hypertension||Merck Sharp & Dohme Corp.||Completed|July 2008|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|47|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|November 10, 2008|No|Yes||No|April 30, 2010|https://clinicaltrials.gov/show/NCT00789321||147546|
NCT00789581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 145|A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer|Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer|TITAN|SCRI Development Innovations, LLC|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|614|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|November 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00789581||147526|
NCT00789594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS017201-01|Improving Laboratory Monitoring in Community Practices: A Randomized Trial|Improving Laboratory Monitoring in Community Practices: A Randomized Trial|LabMon|VA Boston Healthcare System|No|Active, not recruiting|April 2009|March 2013|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 19, 2012|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789594||147525|
NCT00785642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04304|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.|Safety Dermatological Evaluation: Genital Mucous Irritation - Product Tested: Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid).||Sanofi||Completed|August 2008|||September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Female|10 Years|20 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785642||147822|
NCT00789854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00044|Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients|A Randomised, 6-week, Multicentre, Open-label, Rater-blinded Parallel Group Study Comparing Quetiapine Extended Release Monotherapy and Augmentation With Lithium Augmentation in Patients With Treatment Resistant Depression|RUBY|AstraZeneca|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|688|||Both|18 Years|65 Years|No|||April 2012|April 23, 2012|November 11, 2008|Yes|Yes||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00789854||147505|
NCT00786461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000494-22|The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate|The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate||University of Aarhus|Yes|Recruiting|March 2007|December 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||November 2008|November 5, 2008|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786461||147759|
NCT00786474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017344|Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)|Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery||Duke University|Yes|Completed|July 2009|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1884|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 8, 2016|November 5, 2008|Yes|Yes||No|January 6, 2016|https://clinicaltrials.gov/show/NCT00786474||147758|
NCT00808509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W10-046|A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission|A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)|ADMIRE|AbbVie|No|Completed|January 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|33|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|December 12, 2008|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT00808509||146099|
NCT00772811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-001|Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma|Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma|Flu-Mel|Cooperative Study Group A for Hematology|Yes|Completed|July 2001|December 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|15 Years|65 Years|No|||February 2011|February 16, 2011|October 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00772811||148797|
NCT00773136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070706|Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes|Effect of Bimatoprost (Lumigan) in Gel Suspension Applied to the Eyelashes on Eyelash Growth||University of Miami|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|October 15, 2008||No||No|June 22, 2013|https://clinicaltrials.gov/show/NCT00773136||148772|A larger and longer term study would help assess the incidence of ocular side effects related to the Bimatoprost. This randomized controlled study evaluated patients after only 6 weeks of application of the drug.
NCT00805337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADLG3|Low Levels of Electromagnetic Fields to Treat Advanced Cancer|Compassionate Treatment of Advanced Cancer With Amplitude-Modulated Electromagnetic Fields|ADLG3|Pasche, Boris, M.D.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|90 Years||||December 2008|December 6, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805337||146335|
NCT00805662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|355/02|Nasal Oxcytocin During IUI|Nasal Oxcytocin Fails to Increase Pregnancy Rate of IUI|Oxy|Ludwig-Maximilians - University of Munich|Yes|Completed|May 2003|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|43 Years|No|||December 2008|December 8, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805662||146311|
NCT00789529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-101|Objective Testing of Tear Film Stability|Objective Testing of Tear Film Stability||Manhattan Vision Associates|No|Completed|September 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2013|April 22, 2013|November 11, 2008|Yes|Yes||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00789529||147530|
NCT00777101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A2-3003|Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer|A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer||Puma Biotechnology, Inc.|Yes|Active, not recruiting|February 2009|December 2017|Anticipated|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|233|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777101||148470|
NCT00777725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-04/08|Non-invasive Assessment of Liver Stiffness/Fibrosis by Transient Elastography (Fibroscan) in Patients With Left and/or Right Sided Heart Failure|Non-invasive Assessment of Liver Stiffness/Fibrosis by Transient Elastography (Fibroscan) in Patients With Left and/or Right Sided Heart Failure||Monash University|No|Completed|January 2009|March 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|125|Samples Without DNA|Blood samples for fibrotic biomarkers.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Acute and chronic heart failure patients|July 2011|July 20, 2011|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777725||148423|
NCT00777738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060207|Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia|A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia|WM2|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||October 2008|January 17, 2013|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00777738||148422|
NCT00787787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6553|Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer|The CapSul Trial: A Phase II Study of Sunitinib and Capecitabine for the Treatment of Unresectable or Metastatic Hepatocellular Carcinoma (HCC)||University of Washington|No|Terminated|September 2008|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|19 Years|N/A|No|||May 2013|May 7, 2013|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00787787||147661|
NCT00788099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-A-010-08|Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas||PharmaMar|No|Completed|December 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|November 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788099||147638|
NCT00788112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617655|Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast|A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast||University of California, San Francisco|Yes|Active, not recruiting|July 2009|December 2013|Anticipated|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Female|18 Years|N/A|No|||August 2013|August 6, 2013|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788112||147637|
NCT00789347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806061R|Analysis of Cortical Excitability in Neuropathic Pain|Analysis of Cortical Excitability in Neuropathic Pain: an Electrophysiology Study.||National Taiwan University Hospital|No|Recruiting|October 2008|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|80|Samples With DNA|Genomic polymorphism of neurotrophic factors.|Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic healthy volunteer|March 2010|April 1, 2010|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789347||147544|
NCT00789373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12560|A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer|A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung Cancer.||Eli Lilly and Company|No|Active, not recruiting|November 2008|January 2016|Anticipated|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|939|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|November 10, 2008|Yes|Yes||No|June 20, 2011|https://clinicaltrials.gov/show/NCT00789373||147542|
NCT00789607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0271-C|Fiducial Localization and Individualized Radiotherapy -Prostate Cancer|Fiducial Localization and Individualized Radiotherapy in Prostate Cancer (FLIP)|FLIP|University Health Network, Toronto|Yes|Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||June 2015|June 12, 2015|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789607||147524|
NCT00789867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro851|Single Dose of pGM169/GL67A in CF Patients|Evaluation of Safety and Gene Expression With a Single Dose of pGM169/GL67A Administered to the Nose and Lung of Individuals With Cystic Fibrosis||Imperial College London|Yes|Completed|November 2008|December 2010|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|16 Years|70 Years|No|||August 2009|June 2, 2015|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789867||147504|
NCT00785655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04299|Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower||Sanofi||Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|1||Actual|53|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 21, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785655||147821|
NCT00785941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13933|A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available|Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 Administered Every Other Week in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available||ImClone LLC|No|Completed|April 2006|November 2007|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|N/A|No|||October 2011|October 12, 2011|November 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00785941||147799|
NCT00785954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-9803-004|Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]|Inhibition of Delta-protein Kinase C for the Reduction of Infarct Size in Acute Myocardial Infarction|PROTECTION AMI|KAI Pharmaceuticals|Yes|Completed|November 2008|May 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1180|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785954||147798|
NCT00786747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI -1R01CA131386-01A1|Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities|Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities||University of California, Davis|No|Completed|February 2010|November 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|1164|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786747||147737|
NCT00804596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2008-18|Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System|Labeling Comprehension and Performance Evaluation of the Apollo Blood Glucose Monitoring System With Capillary Blood [Commercial Name is CONTOUR® USB]||Ascensia Diabetes Care|No|Completed|December 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|74|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|December 5, 2008|Yes|Yes||No|December 16, 2009|https://clinicaltrials.gov/show/NCT00804596||146391|
NCT00772824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLU_07|Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients|Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial||Banaras Hindu University|No|Recruiting|December 2007|December 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|30|||Female|18 Years|85 Years|No|||August 2009|August 10, 2009|October 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00772824||148796|
NCT00773149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051003|Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia|Phase I/II Study of Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia (ALL) or ALL in Relapse.|Campath|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2006|July 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|15 Years|N/A|No|||February 2011|July 25, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00773149||148771|
NCT00805090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFC-PK-009|Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects|An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of DIC075V in Subjects With Mild or Moderate Chronic Renal Insufficiency and in Subjects With Mild Chronic Hepatic Impairment Compared to Healthy Adult Volunteers and a Randomized, Open-Label, Single-Dose, Two-Way, Crossover Study to Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Adult Volunteers.||Javelin Pharmaceuticals|No|Completed|December 2008|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2009|April 29, 2009|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805090||146354|
NCT00805350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10844|Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties|Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties: a 6-week, Randomized, Double-blind, Placebo-controlled, Polysomnography Study.|ECLIPSE|Sanofi|Yes|Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|637|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805350||146334|
NCT00805688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0582|Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer|A Feasibility Study for Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2008|||November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood drawn (around 3½ tablespoons) before treatment starts to measure cytokines      (biomarkers) and DNA.|Both|18 Years|N/A|No|Probability Sample|The study participants will comprise 100 consecutive outpatients with metastatic disease        being treated at the GI Medical Oncology clinic at M. D. Anderson.|February 2016|February 1, 2016|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805688||146309|
NCT00789542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/W/NEU/12|A RCT to Establish the Effectiveness of Intermittent Pneumatic Compression to Prevent Post Stroke DVT|A Randomised Trial to Establish the Effectiveness of Intermittent Pneumatic Compression to Prevent Post Stroke Deep Vein Thrombosis (DVT).|CLOTS-3|University of Edinburgh|Yes|Completed|December 2008|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2876|||Both|16 Years|N/A|No|||December 2014|December 3, 2014|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00789542||147529|
NCT00787189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHL-001|Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals|The Effects of the Erchonia Hearing Laser on Word Recognition in Hearing Impaired Individuals Clinical Study Protocol||Erchonia Corporation|Yes|Completed|August 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 7, 2014|November 6, 2008|Yes|Yes||No|June 23, 2009|https://clinicaltrials.gov/show/NCT00787189||147705|
NCT00787488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008510|Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca|A Pilot Study of Intravenous and Intraperitoneal Chemotherapy Plus Abdominal Hyperthermia to Treat Optimally Debulked and Recurrent Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers||Duke University|No|Withdrawn|April 2009|April 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|72 Years|No|||November 2014|November 10, 2014|November 6, 2008|Yes|Yes|Study not funded|No||https://clinicaltrials.gov/show/NCT00787488||147684|
NCT00777244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-007262-38|Efficacy of Adjuvant Mitotane Treatment (ADIUVO)|Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence|ADIUVO|University of Turin, Italy|Yes|Recruiting|April 2008|December 2015|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777244||148459|
NCT00777920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-300-0124|Study of Ambrisentan in Subjects With Pulmonary Hypertension|ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension|ABS-LT|Gilead Sciences|Yes|Active, not recruiting|November 2008|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777920||148408|
NCT00778453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC97-2314-B-182-004-MY3|Relative Effects and Predictive Models of Contemporary Upper Limb Training Programs in Stroke Patients|Relative Effects and Predictive Models of Contemporary Upper Limb Training Programs in Stroke Patients Delivered in Hospital-based and Home-based Settings||Chang Gung Memorial Hospital|No|Completed|August 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|150|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|October 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00778453||148367|
NCT00778843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIU-CHC-08|Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C|Efficacy and Safety of Viusid as Antioxidant and Immunomodulator Nutritional Supplement in Patients With Chronic Hepatitis C and Non-responders to Standard Antiviral Therapy. A Randomized and Double Blind Controlled Trial||Catalysis SL|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||May 2012|May 2, 2012|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00778843||148338|
NCT00779480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2449-US-002|Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)|Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia||Kyowa Hakko Kirin Pharma, Inc.|Yes|Terminated|January 2009|December 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|October 22, 2008|Yes|Yes|Failure to demonstrate a tolerable dose that had potential for efficacy.|No||https://clinicaltrials.gov/show/NCT00779480||148289|
NCT00779779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111664|Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants|Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.||GlaxoSmithKline||Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|522|||Both|6 Weeks|19 Weeks|Accepts Healthy Volunteers|||November 2010|November 24, 2010|October 23, 2008|Yes|Yes||No|June 29, 2010|https://clinicaltrials.gov/show/NCT00779779||148266|
NCT00779441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-275|Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions|An Open Label, Relative Bioavailability Study of 10 mg Zolpidem Tablet Under Non-Fasting Conditions||Ranbaxy Inc.|Yes|Completed|August 2005|November 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779441||148292|
NCT00779454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOX-P|Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma|Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma||Vejle Hospital|Yes|Active, not recruiting|September 2008|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||March 2015|March 24, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779454||148291|
NCT00780598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-2797-038|Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML|The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia|OPAL|Chroma Therapeutics|Yes|Completed|October 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|60 Years|N/A|No|||March 2012|June 27, 2012|October 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780598||148203|
NCT00777062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808641|VIVITROL as a Treatment for Cocaine and Alcohol Dependence|A Phase II, Randomized, Double-Blind Pilot Trial of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) for the Treatment of Cocaine and Alcohol Dependence||University of Pennsylvania|Yes|Completed|July 2009|September 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||June 2014|June 30, 2014|October 21, 2008|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00777062||148473|
NCT00780923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-558|Effect of Continuous Positive Airway Pressure Treatment on Inflammation in Patients With Obstructive Sleep Apnea|A Longitudinal Study of Short-Term Effects of CPAP Treatment on Airway and Systemic Inflammation in Patients With Obstructive Sleep Apnea||Kyoto University, Graduate School of Medicine|Yes|Completed|January 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780923||148180|
NCT00780312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF-2006-6097|Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer|Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment|HOHF|Rigshospitalet, Denmark|Yes|Completed|December 2008|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|97|||Both|18 Years|N/A|No|||July 2012|July 1, 2013|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780312||148225|
NCT00779870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0708/2|Airway Smooth Muscle and Asthma Severity|Evaluating the Role of Oxidant/Anti-oxidant Balance and the Relationship of Asthma Severity on Airway Smooth Muscle Proliferation, Migration and Cytokine Release.||Imperial College London|No|Completed|October 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|52|Samples With DNA|endobronchial biopsies and cultured airway smooth muscle cells|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mild, moderate and severe asthmatics, with a control group of healthy non-smoking        volunteers|June 2011|March 25, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779870||148259|
NCT00769665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-15|A 2-week Clinical Comparison of SYSTANE® Ultra to Sensitive Eyes Rewetting Drops in Contact Lens Wearing Patients.|||Alcon Research|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|January 2012|January 31, 2012|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769665||149035|
NCT00769678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epiphrenic II Pilot Trial|Stimulation of the Diaphragm in Patients With Severe Heart Failure Following Heart Surgery|Biventricular Pacing and Stimulation of the Diaphragm in Patients With Severe Heart Failure Following Heart Surgery (Epiphrenic II Pilot Trial)||Luzerner Kantonsspital||Completed|October 2008|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00769678||149034|
NCT00769093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-3678|Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy|Pilot Study to Compare Dynamic MR Imaging Changes in Patients With Recurrent High Grade Glioma, Receiving an Antiangiogenic Drug, Bevacizumab, Versus Dexamethasone. Dual Agent MR Imaging Study, Using Gadolinium and Ferumoxytol (Code 7228)||OHSU Knight Cancer Institute|Yes|Terminated|October 2008|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|6|||Both|18 Years|75 Years|No|||November 2014|November 17, 2014|October 7, 2008|Yes|Yes|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT00769093||149077|
NCT00770237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042356|Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia|Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia||University of Maryland|No|Completed|October 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|44|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00770237||148993|
NCT00770562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18542|A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic Purpura||Hoffmann-La Roche||Completed|July 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|October 9, 2008||No||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00770562||148969|
NCT00770900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_563|Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)|Prospective, Randomized, Double-blind, Study to Evaluate the Eosinophils Activation Parameters and Phagocyte Function in Patients With Persistent Asthma Treated With Montelukast||University of Brasilia||Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|2 Years|18 Years|No|||January 2010|December 17, 2010|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770900||148943|
NCT00770913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-304|Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis|Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis||Eisai Inc.||Completed|October 2008|March 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|337|||Both|20 Years|N/A|No|||June 2010|April 16, 2012|October 9, 2008||No||No|September 13, 2011|https://clinicaltrials.gov/show/NCT00770913||148942|In the Participant flow section, there is only one "Reason for Not Completed" per participant reported, even if there were multiple reasons.
NCT00771173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201073|CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial|THE CAT(H) STUDY CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial A CREST 2010 Project|CATH|Loyola University|No|Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|258|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|October 9, 2008||No||No|April 20, 2015|https://clinicaltrials.gov/show/NCT00771173||148922|One limitation of our study was inconsistent collection of our primary outcome data. Nursing staff and house staff failed to collect VAS scores consistently.
NCT00777608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-086|A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, With Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the CogState Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients||Merck Sharp & Dohme Corp.||Completed|December 2008|April 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|55 Years|N/A|No|||August 2015|August 11, 2015|October 21, 2008|No|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00777608||148431|
NCT00777621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01DK080886|Caloric Restriction, Exercise, and Glucoregulation in Humans|Caloric Restriction, Exercise, and Glucoregulation in Humans|CREG|St. Louis University|No|Completed|April 2008|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|69|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777621||148430|
NCT00777556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-LEV-302|Emergency Contraception Actual Use Study|Plan B® 1.5 Emergency Contraception Actual Use Study in Adolescents||Teva Pharmaceutical Industries|No|Completed|October 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|343|||Female|11 Years|16 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|October 21, 2008|Yes|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT00777556||148435|
NCT00777569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA 013333|Comparisons of Nicotine-Free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine|Study 2: Comparisons of Nicotine-Free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine||National Institute on Drug Abuse (NIDA)|Yes|Completed|March 2005|November 2006|Actual|September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2008|December 12, 2008|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777569||148434|
NCT00778180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10540344|Bioequivalence Study of Furosemide 80mg Tablets Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Aventis Formulations of Furosemide 80 mg Tablets in Healthy Adult Volunteers Under Fasted Condition.||Ranbaxy Inc.|Yes|Completed|October 2005|November 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778180||148388|
NCT00778466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10640303|Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Bristol Myers Squibb Formulations of Metformin 1000 mg Tablets in Healthy Adult Volunteers Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|February 2006|April 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778466||148366|
NCT00779155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD pilot 2|Study of Magnetic Fields for Treatment of Parkinson's Disease|A Double-blind, Sham-stimulation Controlled Study of the Application of Magnetic Fields Using the Jacobson Resonator for the Treatment of Parkinson's Disease.||pico-tesla Magnetic Therapies, LLC|Yes|Completed|August 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|30 Years|80 Years|No|||July 2011|July 7, 2011|October 22, 2008|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00779155||148314|
NCT00779467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB5917|Epidural Neostigmine for Labor Pain|Epidural Neostigmine Dose Response for the Treatment of Labor Pain||Wake Forest School of Medicine|Yes|Completed|October 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|157|||Female|18 Years|50 Years|No|||June 2014|June 4, 2014|October 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779467||148290|
NCT00779805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|016/ PSEUD-120/ 04|Bioequivalence Study of Pseudoephedrine HCl 120 mg ER Tablets Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Pseudoephedrine Hydrochloride Formulations Comparing Pseudoephedrine Hydrochloride 120 mg ER Tablets of Ranbaxy Laboratories With Sudafed 120 mg ER Tablets of Pfizer Consumer Health Care in Healthy, Adult, Human Subjects Under Fed Conditions.||Ranbaxy Inc.|Yes|Completed|June 2004|October 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779805||148264|
NCT00780273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF 245|Success Rate of Immediately Loaded Implants With Platform Switched Design Placed in Anterior Part of Mandible and Restored With Fixed Prostheses|Success Rate of Immediately Loaded Implants With Platform Switched Design Placed in the Anterior Part of the Mandible and Restored With Fixed Prostheses: a Randomized, Split-mouth, Masked, Prospective, Open, Comparison, Monocenter Trial||Dentsply International|No|Completed|September 2008|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|19|||Both|18 Years|80 Years|No|||August 2014|August 18, 2014|October 24, 2008||No||No|March 17, 2014|https://clinicaltrials.gov/show/NCT00780273||148228|
NCT00780286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008068|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||April 14, 2015|October 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780286||148227|
NCT00777686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0492|Measuring Non-Enhancing Glioblastoma Progression|Quantifying Progression of Non-Enhancing Tumor in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Agents||M.D. Anderson Cancer Center|No|Completed|August 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, 18 years or older, with "recurrent" intracranial glioblastoma or gliosarcoma        being treated with chemotherapy or will be treated.|March 2012|March 29, 2012|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00777686||148426|
NCT00777998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Auto-Allo TSCT in MM|Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma|Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy With Thalidomide/ DLI for Patients With Multiple Myeloma (MM) and Age < _60 Years: A Phase II-study||Universitätsklinikum Hamburg-Eppendorf|No|Active, not recruiting|August 2008|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|60 Years|No|||May 2015|May 12, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00777998||148402|
NCT00778245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA27169|Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions|An Open - Label, Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg Cefprozil Tablets in Healthy Adult Volunteers Under Fed Conditions.||Ranbaxy Inc.|Yes|Completed|May 2005|October 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778245||148383|
NCT00779883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL-35-101|A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)|A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)||Memgen, LLC|Yes|Completed|June 2006|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2008|October 23, 2008|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00779883||148258|
NCT00779246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28116|Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections|Cost-Effectiveness of Chlorhexidine Bathing vs. Active Surveillance Cultures to Prevent Acquisition of Methicillin-resistant Staphylococcus Aureus and Other Hospital-Acquired Infections: A Pilot Study||Christiana Care Health Services|No|Completed|June 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1518|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|October 22, 2008||No||No|August 1, 2011|https://clinicaltrials.gov/show/NCT00779246||148307|Single-center, single-unit study limits generalizabilityMRSA acquisition rates lower during both intervention groups than expected, resulting in under-powering of studyBaseline rate of acquisition of colonization unknown
NCT00769704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/05|Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma|A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease||BioVex Limited|Yes|Completed|April 2009|September 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|October 7, 2008|Yes|Yes||No|September 22, 2015|https://clinicaltrials.gov/show/NCT00769704||149032|
NCT00769938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2008-03|WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)|What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing|WOEST|R&D Cardiologie|Yes|Completed|December 2008|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|573|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 12, 2013|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769938||149015|
NCT00769964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|913-001|VA111913 TS: First in Human Study|A First in Human Study Consisting of a Two-Part, Double-Blind, Placebo-Controlled, Escalating Single and Multiple Dose Study of VA111913 TS in Adult Non-Pregnant Women Volunteers With a Single Dose, Open, Fed vs. Fasting Crossover Phase||Vantia Ltd||Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|98|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 24, 2009|October 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769964||149013|
NCT00770575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS K015|Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease|Double Blinded Study of the Effects of Pioglitazone in Combination With Atorvastatin in Comparison to Atorvastatin Treatment Alone on Intima-Media Thickness in Patients at Risk for Vascular Complications||Takeda|No|Completed|June 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|30 Years|70 Years|No|||July 2010|July 1, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770575||148968|
NCT00770926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK067896-01A2|Reducing Disparities in Diabetes Risk Through Lifestyle Changes in Community Settings|Physical Activity and Diet to to Reduce Disparities in Diabetes Risk|LWBW|University of California, San Francisco|No|Completed|September 2006|May 2013|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|230|||Both|25 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 19, 2013|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770926||148941|
NCT00771186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-12-078x|Intraoperative Laryngeal Electromyography (LEMG) in Children With Vocal Fold Immobility: a Longitudinal Study|Intraoperative Laryngeal Electromyography (LEMG) in Children With Vocal Fold Immobility: a Longitudinal Study||Massachusetts Eye and Ear Infirmary|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with vocal fold immobility|June 2010|June 16, 2010|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771186||148921|
NCT00771472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-089|Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)|Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)||Merck Sharp & Dohme Corp.|No|Completed|August 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||April 2015|April 2, 2015|October 9, 2008|No|Yes||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00771472||148899|
NCT00777634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000779|Follow-Up Extension to the Family Study of Binge Eating Disorder|Follow-Up Extension to the Family Study of Binge Eating Disorder||Mclean Hospital|No|Completed|June 2005|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|268|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study includes individuals with binge eating disorder, individuals without binge        eating disorder, and their relatives.|April 2012|April 23, 2012|October 20, 2008||No||No|March 9, 2012|https://clinicaltrials.gov/show/NCT00777634||148429|
NCT00777595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0808-PR-0036|Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers|A Randomized, Double Blind, Single Dose, Positive and Placebo Controlled, Crossover Study of the Effects of Inhaled Carmoterol, at the Proposed Therapeutic and Supratherapeutic Doses, on the QTc Intervals in Healthy Subjects|CT14|Chiesi Farmaceutici S.p.A.|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 26, 2009|October 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00777595||148432|
NCT00777933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-07-02|Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation|Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation||Samsung Medical Center|No|Completed|July 2000|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|15 Years|N/A|No|||April 2011|April 21, 2011|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777933||148407|
NCT00778193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Healing Study|Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers|A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing|Lesions2|Research Associates of New York, LLP|No|Completed|October 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|N/A|5||Actual|125|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|July 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00778193||148387|
NCT00778479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSPRAY00508|Evaluation of the Safety of Sepraspray in Open Abdominal Surgery|Evaluation of the Safety of Sepraspray in Open Abdominal Surgery||Sanofi|Yes|Terminated|October 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|October 22, 2008|No|Yes|Terminated by Sponsor: see details below|No||https://clinicaltrials.gov/show/NCT00778479||148365|
NCT00778492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5119-SP-CTIL|Thrombelastogram in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery|Thrombelastogram and Predicting Microvascular Bleeding in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery||Sheba Medical Center|No|Recruiting|May 2008|December 2008|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with the history of ingestion of aspirin and/or ADP receptor antagonist        (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients        undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent        basis.|October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778492||148364|
NCT00779792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001678-34|Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation|Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation|WA+TR_1|Odense University Hospital|Yes|Active, not recruiting|September 2008|November 2008|Anticipated|November 2008|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779792||148265|
NCT00780299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071005|Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability in Post-resuscitation Shock|Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability (HDHP) During the Early Period of Post-resuscitation Shock|Hyperdia|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2008|November 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|43|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780299||148226|
NCT00780611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043968|Investigating the Improvement in 4D CT Images Using AV Biofeedback|Investigating the Improvement in 4D CT Images Using Audiovisual Biofeedback: An Intra-fraction and an Inter-fraction Evaluation.|GCC0832|University of Maryland|Yes|Completed|November 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|86 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Abdominal & Thoracic malignancies who consent to recieving Radiation        treatment at the University of Maryland, Baltimore, will be offered this protocol design.|March 2015|March 16, 2015|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780611||148202|
NCT00776464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#10-001|Treating Onychomychosis|||Nomir Medical Technologies||Not yet recruiting|November 2008|January 2010|Anticipated|November 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|64 Years|No|||October 2008|October 20, 2008|October 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776464||148519|
NCT00778531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 521-01|Protocol for the Post-approval Study of ArteFill® for Correction of Nasolabial Folds|Protocol for the Post-approval Study of ArteFill® for Correction of Nasolabial Folds||Suneva Medical, Inc.|No|Completed|September 2007|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1008|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 18, 2014|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00778531||148361|
NCT00778544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60250|Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg-42.9 mg/ 5 mL Oral Suspension Under Fed Conditions|Randomized, Open-Label, 2 - Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg- 42.9 mg/ 5 mL Oral Suspension and Augmentin ES-600 (Reference) Following a 600 mg- 42.9 mg Dose in Healthy Subjects Under Fed Conditions.||Ranbaxy Inc.|Yes|Completed|June 2006|September 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778544||148360|
NCT00778895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111635|Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control|Clinical Study in Children, 6 Months to 3 Years of Age, to Assess the Immunogenicity and Safety of Two Dose Levels of Thimerosal-free Fluviral® Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control||GlaxoSmithKline||Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|390|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||May 2013|July 3, 2013|October 23, 2008|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00778895||148334|
NCT00780390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071060|Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome|Autonomic Dysfunction and Spinal Cord Stimulator in Complex Regional Pain Syndrome|CRPS|Vanderbilt University|No|Terminated|January 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|10|||Both|18 Years|65 Years|No|||December 2014|December 19, 2014|May 8, 2008||No|Lack of enrollment and discontinued funding|No||https://clinicaltrials.gov/show/NCT00780390||148219|
NCT00769431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600594|Evaluating Symptom Management Educational Materials for Patients With Prostate Cancer|FOCUS GROUP EVALUATION OF PROSTATE CANCER SYMPTOM MANAGEMENT EDUCATION MATERIALS||Baylor College of Medicine|No|Completed|May 2008|July 2009|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|7|||Male|18 Years|N/A|No|||July 2013|July 24, 2013|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769431||149051|
NCT00769951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9Y07|Study of Physical and Mental Health of Older Patients With Newly Diagnosed Cancer|The Geriatric-Oncology Database: A Resource for Advancing Research in Older Cancer Patients||Case Comprehensive Cancer Center|Yes|Completed|February 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|65 Years|N/A|No|Probability Sample|Primary care clinics|October 2015|October 1, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769951||149014|
NCT00769730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960331|Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication|Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|January 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|25|Samples With DNA|serum|Both|N/A|N/A|No|Non-Probability Sample|patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by        transcatheter arterial chemoembolization|July 2009|August 2, 2009|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00769730||149030|
NCT00770250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RFR-DUM-2008/1|National Survey on Asthma|A Mirror Assessment of the Words Used By Patients and Physicians to Express Asthma Symptoms, According To the Patient's Level of Asthma Control In General Medicine|SYMPTOMES|AstraZeneca|No|Completed|September 2008|March 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1704|||Both|18 Years|N/A|No|Probability Sample|The first 2 consecutive patients seen during the GP's visit with a diagnosis of persistent        asthma|November 2010|November 30, 2010|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00770250||148992|
NCT00770263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1092 / 201108327|Erlotinib and Temsirolimus for Solid Tumors|Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies||Washington University School of Medicine|No|Completed|May 2009|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|46|||Both|18 Years|N/A|No|||December 2014|June 2, 2015|October 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00770263||148991|
NCT00770588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00071|Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)|A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy|INFORM|AstraZeneca|No|Completed|September 2008|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|296|||Both|18 Years|N/A|No|||August 2012|January 15, 2016|October 9, 2008|Yes|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT00770588||148967|
NCT00770601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2201|Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease|A Multi-Center, Open Label, 24-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics of Canakinumab (Anti-IL-1 Beta Antibody) in Patients With NOMID / CINCA Syndrome||Novartis||Terminated|January 2009|||February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|25 Years|No|||May 2012|May 3, 2012|October 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00770601||148966|
NCT00770939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001|Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers|A Cohort Study to Evaluate the Effect of Vivostat Platelet Rich Fibrin on Diabetic Foot Ulcers.||Vivostat|No|Completed|July 2008|August 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770939||148940|
NCT00770952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS K020|Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.|Effects of Pioglitazone in Combination With Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients With Type 2 Diabetes Mellitus||Takeda|No|Completed|December 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|30 Years|75 Years|No|||July 2010|July 1, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770952||148939|
NCT00770614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prato0703|Hydration and Contrast-Induced Nephropathy in Primary Angioplasty|Hydration and Contrast-Induced Nephropathy in Primary Angioplasty. A Randomized, Placebo Controlled, Trial.||Ospedale Misericordia e Dolce|Yes|Completed|March 2004|December 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|450|||Both|N/A|N/A|No|||May 2012|May 6, 2012|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770614||148965|
NCT00777946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A2303|Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone|A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy||Novartis|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|818|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|October 20, 2008||No||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00777946||148406|
NCT00778206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUDOS-01|PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry|PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry|PKUDOS|BioMarin Pharmaceutical|No|Recruiting|September 2008|September 2023|Anticipated|September 2023|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|3500|||Both|N/A|N/A|No|Non-Probability Sample|Diagnosis of Phenylketonuria with hyperphenylalaninemia|December 2015|December 7, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00778206||148386|
NCT00783263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-139|A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)|A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease||Merck Sharp & Dohme Corp.|No|Completed|November 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|440|||Both|18 Years|79 Years|No|||January 2015|January 19, 2015|October 30, 2008|Yes|Yes||No|August 10, 2011|https://clinicaltrials.gov/show/NCT00783263||148003|
NCT00780936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01222008-984|Effects of a Peripheral Nerve Block on Biomarkers of Pain and Inflammation|Effect of Peripheral Nerve Block on Inflammatory and Nociceptive Biomarkers in a UV-B Burn Model in Humans||Stanford University||Completed|October 2007|July 2008||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Prevention||||15|||Both|18 Years|50 Years|No|||November 2008|November 21, 2008|October 24, 2008||||No||https://clinicaltrials.gov/show/NCT00780936||148179|
NCT00776451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP-US-01|Usability of the PreView PHP for Home Use in Intermediate AMD Patients|Usability of the PreView PHP for Home Use in Intermediate Age Related Macular Degeneration Patients||Notal Vision Ltd|Yes|Completed|November 2008|March 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|66|||Both|65 Years|N/A|No|Non-Probability Sample|Dry AMD subjects|June 2009|June 2, 2009|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776451||148520|
NCT00777036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-226|A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib|A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib||Bristol-Myers Squibb|Yes|Active, not recruiting|February 2009|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|139|||Both|N/A|18 Years|No|||October 2015|March 11, 2016|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777036||148475|
NCT00777049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO 017|Study of Panobinostat Monotherapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer|A Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer||Translational Research in Oncology|No|Completed|February 2009|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Female|18 Years|N/A|No|||October 2015|October 27, 2015|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777049||148474|
NCT00779220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JA21963|A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy||Chugai Pharmaceutical|No|Terminated|October 2008|March 2015|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|152|||Both|20 Years|N/A|No|||March 2015|March 24, 2015|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779220||148309|
NCT00779506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00062|Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)|A 8-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) With Daily Dose 400mg-800mg in the Treatment of Acute Schizophrenic Patients|QUENCH|AstraZeneca|No|Completed|November 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|65 Years|No|||May 2010|October 19, 2011|October 22, 2008||No||No|May 20, 2010|https://clinicaltrials.gov/show/NCT00779506||148287|
NCT00779818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1117060051|Electrical Acupuncture and Laser Therapy for Low Back Pain|Electrical Acupuncture and Laser Therapy for Low Back Pain||Logan College of Chiropractic|No|Recruiting|October 2008|January 2009|Anticipated|January 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|60 Years|No|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779818||148263|
NCT00779597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF-T3|Improvement of Self Management for Oncologic Patients With Pain|Improvement of Self Management Skills for Oncologic Patients With Pain Through a Trans Institutional Nursing Intervention: a Cluster Randomized Multi Center Study||Martin-Luther-Universität Halle-Wittenberg|No|Completed|October 2008|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|208|||Both|18 Years|80 Years|No|||October 2008|August 26, 2010|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779597||148280|
NCT00769184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-LCDSTRD|Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis|A Steroid-Sparing Effect of Supplemental LCD Treatment in Patients With Moderate-to-Severe Localized Psoriasis Lesions: a Pilot Study.||NeoStrata Company, Inc.|Yes|Completed|October 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|October 7, 2008||No||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00769184||149070|This was a bilateral study in which 15 subjects total were recruited and randomized to receive both interventions simultaneously by dividing treatment arms to each side of the body.
NCT00769470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616008|Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery|A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment With Single-Agent Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) With Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients With HER2/Neu-Amplified Operable Breast Cancer||Translational Oncology Research International|Yes|Completed|April 2009|||November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Female|18 Years|70 Years|No|||January 2016|January 20, 2016|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769470||149049|
NCT00769717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRHMC 02708|Evaluation of a Health at Every Size vs a Behavioral Weight Loss Approach for Obese Women|Comparative Health Improvements and Rate of Relapse in Weight-Centered vs. Wellness-Centered Interventions for Obese Women||The Reading Hospital and Medical Center|No|Active, not recruiting|October 2008|May 2011|Anticipated|May 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 26, 2009|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769717||149031|
NCT00770016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM_HYPO_2008|Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism|Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism||University of Aarhus|Yes|Terminated|January 2010|January 2011|Anticipated|January 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|October 8, 2008||No|no longer interested in doing the study|No||https://clinicaltrials.gov/show/NCT00770016||149010|
NCT00770302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00004|Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin|An Open Label, Pharmacokinetic Study of Single and Multiple Doses of 5 mg Saxagliptin in Healthy Chinese Subjects Living in China||AstraZeneca|No|Completed|October 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|October 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00770302||148988|
NCT00769990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS035|Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases|Phase I-II Trial of Genistein in Subjects Receiving Palliative External Beam Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|September 2008|April 2010|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2011|July 1, 2011|October 8, 2008|Yes|Yes|No patient accrual.|No||https://clinicaltrials.gov/show/NCT00769990||149012|
NCT00770003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0540C00003|Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848|A Double-blind, Placebo Controlled, Randomized, Parallel Group Study to Investigate the Tolerability, Safety, Pharmacodynamics and Pharmacokinetics of Repeated Weekly Doses of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients||AstraZeneca|No|Completed|September 2008|February 2010|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Male|18 Years|45 Years|No|||August 2015|August 13, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770003||149011|
NCT00770276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOS|Mannheim Obesity Study|Mannheim Obesity Pilot Study: Evaluation of Metabolic Und Cardiovascular Risk in Obesity|MOS|Universitätsmedizin Mannheim|No|Recruiting|January 2005|January 2017|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|88 Years|No|Non-Probability Sample|outpatient department of an university hospital|March 2013|March 9, 2013|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770276||148990|
NCT00770289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B-102374|Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)|Open Label, Observational, Non-interventional Study for the Evaluation of Remission Rates in Patients With MDD Under Treatment With Various Anti-depressives|B2411003|Pfizer|No|Completed|May 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|851|||Both|18 Years|75 Years|No|Probability Sample|Patients diagnosed with MDD who are either changing treatment or have never received        treatment.|August 2012|August 1, 2012|October 8, 2008||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00770289||148989|Protocol did not indicate primary or secondary endpoints and designation of endpoints as primary or secondary endpoints was arbitrary.
NCT00770627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-08-08-3103039|Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children|A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children||Laboratoires URGO|No|Enrolling by invitation|October 2008|December 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||April 2010|April 12, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770627||148964|
NCT00771238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0095|Pilot Study of Incidence and Change in Existing Pressure Ulcers: TC500 Bed Compared With Standard Beds|A Pilot Study of Pressure Ulcer Incidence and Change in Existing Pressure Ulcers Comparing Subjects Placed on the TC500 Bed With Standard Beds in the 850-SICU Unit||Hill-Rom|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Both|19 Years|N/A|No|||August 2015|August 25, 2015|October 10, 2008||No||No|March 23, 2015|https://clinicaltrials.gov/show/NCT00771238||148917|
NCT00778856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007760|Hand Transplantation for the Reconstruction of Below the Elbow Amputations|Hand Transplantation for the Reconstruction of Below the Elbow Amputations|VCA-01|Emory University|Yes|Terminated|September 2008|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|55 Years|No|||March 2015|March 26, 2015|October 7, 2008||No|Principal Investigator relocated to another institution|No||https://clinicaltrials.gov/show/NCT00778856||148337|
NCT00778869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04465|Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)|Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls||Merck Sharp & Dohme Corp.|No|Completed|August 2005|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|October 23, 2008|Yes|Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00778869||148336|
NCT00778882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM106-KR-01|Gene Therapy for Chronic Granulomatous Disease in Korea|An Open-label, Uncontrolled, Single Center, Phase I/II Trial to Assess the Safety and Efficacy of Autologous Hematopoietic Stem Cells Transduced With MT-gp91 Retroviral Vector in gp91 Defective Chronic Granulomatous Disease Patients||ViroMed Co., Ltd. dba VM BioPharma|No|Active, not recruiting|January 2007|October 2022|Anticipated|October 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|N/A|N/A|No|||February 2016|February 10, 2016|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00778882||148335|
NCT00777959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-002|Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)|A Phase II Randomized, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus (Ridaforolimus) in Men With Asymptomatic, Metastatic Castrate-resistant Prostate Cancer||Merck Sharp & Dohme Corp.|Yes|Completed|October 2008|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|22|||Male|18 Years|N/A|No|||August 2015|August 18, 2015|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777959||148405|
NCT00777972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B035501|Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions|A Bioequivalence Study of Test and Reference Fosinopril Sodium/ Hydrochlorothiazide 20/12.5 mg Tablets Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|March 2003|April 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00777972||148404|
NCT00781300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1104/03|Intraocular Pressure With Loteprednol and Dexamethasone|A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery||Federal University of São Paulo|No|Completed|March 2006|February 2007|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 27, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00781300||148153|
NCT00781521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8280A-PRT021|Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children|A Pilot, Multicenter, Open Label, Non Comparative Study of the Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children With Tympanostomy Tubes||Daiichi Sankyo Inc.|No|Completed|November 2002|April 2003|Actual|April 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|6 Months|12 Years|No|||October 2008|October 28, 2008|October 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00781521||148136|
NCT00783588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL-35-102|A Phase I Extension Trial of Repeated Infusions of ISF35|A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914||Memgen, LLC|Yes|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Both|18 Years|N/A|No|||October 2008|October 30, 2008|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00783588||147978|
NCT00783601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-008|MK0524 Asthma POC Study (0524-008)(COMPLETED)|A Multicenter, Randomized, Double Blind, Crossover Study Comparing the Effect of MK0524 With Placebo and Concomitant Administration of MK0524 Plus Montelukast in Adult Patients With Chronic Asthma||Merck Sharp & Dohme Corp.||Completed|October 2004|May 2005|Actual|May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|October 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00783601||147977|
NCT00780078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCR060013|Clinical Evaluation of Swallowing Disorders as a Predictor of Extubation Failure|Clinical Evaluation by Physical Therapist of Swallowing Disorders as a Predictor of Extubation Failure in Patients Intubated Orotracheally for Over 6 Days|EVAKIN|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|the objective of this study is to validate a scale previously devised and used for        physiotherapist bedside evaluation of the swallowing function and oropharyngal motricity,        among patients intubated for over 6 days, to determine whether this scale is a good        predictor of airway secretion-related extubation failure|September 2008|December 1, 2008|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780078||148243|
NCT00778284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA02873|Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg Amoxicillin (as the Trihydrate)/57 mg Clavulanic Acid (as the Potassium Salt) Chewable Tablets in Healthy Adult Volunteers Following Administration of a Two Tablet Dose Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|October 2002|December 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778284||148380|
NCT00778583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|024/NITRO-100/03|Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions|An Open Label, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Nitrofurantoin Formulations Comparing Nitrofurantoin 100 mg Capsules of Ranbaxy Laboratories With Macrobid 100 mg Capsules in Healthy, Adult, Human Subjects Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|September 2003|December 2003|Actual|October 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778583||148357|
NCT00778921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A2304|Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone|A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy||Novartis|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|847|||Both|18 Years|N/A|No|||February 2011|February 25, 2011|October 23, 2008||No||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00778921||148332|
NCT00777374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-SkinSIT-003|Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration|Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind Preseasonal Study to Assess Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration|ZU-SkinSIT-003|University of Zurich|Yes|Completed|October 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|65 Years|No|||January 2011|January 31, 2011|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777374||148449|
NCT00778596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST-L-1|Prednisolone Priming Study in Patients With Chronic Hepatitis B|A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B||Chang Gung Memorial Hospital|No|Recruiting|February 2009|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||May 2012|May 24, 2012|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00778596||148356|
NCT00778609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91550|Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Microgynon on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment||Bayer|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|449|||Female|18 Years|50 Years|No|||January 2016|January 13, 2016|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778609||148355|
NCT00779532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05802|Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)|A Randomized, Double-blind, Placebo and Positive Controlled, Parallel Group Trial to Investigate the Effect of Multiple Doses of NOMAC-E2 on QT/QTc Interval in Healthy Women||Merck Sharp & Dohme Corp.|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|189|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00779532||148285|
NCT00779545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03748|A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)|Dose Finding and Dose Regimen Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|April 2004|August 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|455|||Both|16 Years|N/A|No|||April 2015|April 8, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779545||148284|
NCT00768794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acidophilus|Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy|A Trial Using Acidophilus for the Treatment and Prevention of Oral Candidiasis in Head and Neck Cancer Patients Undergoing Radiation Therapy||Summa Health System|No|Completed|July 2006|September 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||May 2013|May 30, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768794||149100|
NCT00768807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOera-03|Structural and Functional Left Ventricular Remodelling in Patients With Obstructive Sleep Apnea|Structural and Functional Left Ventricular Remodelling in Patients With Obstructive Sleep Apnea||Associação Fundo de Incentivo à Pesquisa|No|Completed|October 2009|September 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|450|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00768807||149099|
NCT00768820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMCI082455CTIL|The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome|The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors|VCFS|The Chaim Sheba Medical Center|Yes|Recruiting|May 2001|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|N/A|N/A|No|||January 2016|January 28, 2016|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768820||149098|
NCT00768833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4453|Study Evaluating the Nasopharyngeal Carriage in Healthy Children|Nasopharyngeal Carriage in Children After Introduction of General Pneumococcal Immunization in Germany|Carriage|Pfizer|No|Completed|October 2008|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|242|||Both|3 Months|4 Months|Accepts Healthy Volunteers|Non-Probability Sample|community sample|August 2014|August 20, 2014|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768833||149097|
NCT00769483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0910|MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer|A Phase I/ Randomized Phase II Study of Gemcitabine Plus Erlotinib Plus MK-0646; Gemcitabine Plus MK-0646 and Gemcitabine Plus Erlotinib for Patients With Advanced Pancreatic Cancer (IISP#33337)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2008|||November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769483||149048|
NCT00769496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11551|BAY 77-1931 Long-term Extension From Phase II Study|A Long-term, Open Label Extension, Non-controlled Study to Assess the Efficacy and Safety of BAY 77-1931 (Lanthanum Carbonate) for Hyperphosphatemia in Patients Undergoing Hemodialysis||Bayer|No|Completed|January 2005|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|20 Years|75 Years|No|||January 2013|January 21, 2013|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769496||149047|
NCT00769457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_8|OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network|OptiLink HF Study (Optimization of Heart Failure Management Using Medtronic OptiVol® Fluid Status Monitoring and Medtronic CareLink® Network)|OptiLink-HF|Medtronic Bakken Research Center|Yes|Completed|September 2008|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1002|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769457||149050|
NCT00770328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030497|The Effects of Pentoxifylline on PAI-1 in an Obese Population|The Effects of Pentoxifylline on PAI-1 in an Obese Population||Vanderbilt University|No|Active, not recruiting|May 2003|June 2009|Anticipated|May 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 27, 2009|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770328||148986|
NCT00770341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-002|A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)|A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA||Merck Sharp & Dohme Corp.||Completed|September 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|122|||Both|20 Years|N/A|No|||August 2015|August 6, 2015|October 9, 2008|Yes|Yes||No|May 17, 2011|https://clinicaltrials.gov/show/NCT00770341||148985|
NCT00770315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05234|Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma||Merck Sharp & Dohme Corp.|Yes|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|784|||Both|18 Years|50 Years|No|||October 2015|October 12, 2015|October 9, 2008|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00770315||148987|
NCT00770640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS K029|Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.|Comparison of the Effects of Pioglitazone vs. Placebo When Given in Addition to Standard Insulin Treatment in Patients With Type 2 Diabetes Mellitus and Renal Failure|PIOren|Takeda|No|Completed|August 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|80 Years|No|||August 2010|August 31, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770640||148963|
NCT00770978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014911|Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU|Open-Label, Parallel Group, Multiple-dose Study of Ceftobiprole to Evaluate the Plasma Pharmacokinetics in Adults in Intensive Care Units||Basilea Pharmaceutica|No|Completed|November 2008|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|October 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00770978||148937|
NCT00771251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015343|A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)|A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis||Janssen Pharmaceutical K.K.|No|Completed|May 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|311|||Both|20 Years|74 Years|No|||November 2015|November 2, 2015|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771251||148916|
NCT00784706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1391B|Effect of Combined Therapy on Neglect Syndrome in Stroke Patients|Effect of Combined Therapy on Neglect Syndrome in Stroke Patients||Chang Gung Memorial Hospital|No|Completed|October 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 26, 2012|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00784706||147894|
NCT00784719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921034|A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.|A Phase I/II Prospective, Randomized, Double Masked, Vehicle And Comparator Controlled, Dose Ranging Study Of CP-690,550 In Subjects With Dry Eye Disease.||Pfizer|No|Completed|November 2008|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|327|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|November 3, 2008|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00784719||147893|In this study, a variance was made in the planned analysis. At the time of data analysis, results from Stage 1 and 2 were combined for efficacy and safety analyses. Hence, results are presented together for both stages.
NCT00779493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4893|Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial|Study Title: Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial|CuTIBS|Kaiser Permanente|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779493||148288|
NCT00778570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006800-01H|Advanced Surface Ablation (ASA) vs Laser-Assisted In Situ Keratomileusis (LASIK)|A Combined Retrospective and Prospective Chart Review Analysis of Visual Outcomes Following Excimer Laser Vision Correction||Ottawa Hospital Research Institute|No|Recruiting|February 2007|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|N/A||2|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|Male and female participants from the Ottawa/Gatineau region requesting laser vision        correction to correct nearsightedness, farsightedness, and/or astigmatism.|November 2014|November 28, 2014|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00778570||148358|
NCT00778037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125_CYCLO_06|Bioequivalence Study of Cyclobenzaprine Hydrochloride 10 mg Tablets, USP Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study Comparing Cyclobenzaprine Hydrochloride 10 mg Tablet of Ohm Labs Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc USA.) With Flexeril® 10 mg Tablet (Containing Cyclobenzaprine Hydrochloride 10 mg) Manufactured by Merck & Co Inc., USA and Distributed by McNeil Consumer & Speciality Pharmaceuticals, in Healthy, Adult, Male, Human Subjects Under Fasting Condition.||Ranbaxy Inc.|Yes|Completed|September 2006|November 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778037||148399|
NCT00778934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-5739-1|In-Home Use Study to Evaluate Use of an Intimate Health Product in Females|A Single-blind, Multi-center, In-home Use Study to Evaluate Sexual Enhancement Effects of Product PD-F-5394 in Females||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|December 2007|April 2008|Actual|February 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|79|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00778934||148331|
NCT00779909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-AT003714|Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model|Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model||Boston University|No|Completed|December 2008|September 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|35|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2012|August 2, 2012|October 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00779909||148256|
NCT00778947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Harmonic Scalpel HARMONIC 001|Single Centre Study to Compare Harmonic Scalpel to Conventional Diathermy in Free Tissue Transfer Breast Reconstruction|Comparison of Harmonic Scalpel to Conventional Diathermy in Free Tissue Transfer for Breast Reconstruction|HARMONIC001|St Andrew's Centre for Plastic Surgery||Not yet recruiting|November 2008|||September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|30|||Female|18 Years|80 Years|No|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778947||148330|
NCT00779233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10440303|Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and GlaxoSmithKline Formulation of Zidovudine Tablets 300 mg in Healthy Adult Volunteers Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|September 2004|October 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779233||148308|
NCT00769197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0082|Optic Discs in Children With Cerebral Palsy|Optic Nerve Head Morphology in Children With Perinatal Onset Static Encephalopathy||University of Mississippi Medical Center|No|Completed|June 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|61|||Both|N/A|17 Years|No|Non-Probability Sample|Study population will include all children attending the pediatric neurology clinic and        carry a diagnosis of static encephalopathy or equivalent terms- CNS malformation syndrome        or cerebral palsy.|April 2009|April 28, 2009|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769197||149069|
NCT00769509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE - 0057.0.008.000-06|Energy Expenditure Assessment of Premature Infants|Energy Expenditure Assessment of Preterm Infant With Very Low Birth Weight Fed With Human Milk or Preterm Formula||Oswaldo Cruz Foundation|Yes|Completed|March 2009|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|2||Actual|25|||Both|N/A|5 Weeks|No|||July 2015|July 20, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769509||149046|
NCT00770354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1402-C-201|Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer|A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer||Antisoma Research|Yes|Terminated|September 2008|August 2011|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||August 2009|August 7, 2009|October 9, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00770354||148984|
NCT00769756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD 22/06|Evaluation of Three New Strategies to Fight Obesity in Families|Evaluation of Three New Strategies to Fight Obesity in Families||University of Magdeburg|No|Completed|April 2006|December 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Actual|261|Samples Without DNA|blood samples|Both|6 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|The participating families were recruited by means of newspaper advertisements in the area        around the German city of Magdeburg. The children had to be older than 7 years to ensure        that they were able to read, and younger than 13 to minimize interferences due to puberty.        177 families responded by telephone and received a letter de-scribing the aim and        character of the study. 110 families then decided to participate and were invited to the        first of four meetings with intervals of one week between successive meetings.|October 2008|October 8, 2008|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769756||149029|
NCT00771277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 08-383|Team Based Initiative Support|Team Based Initiative Support||VA Office of Research and Development|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|6|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|October 8, 2008||No||No|September 5, 2014|https://clinicaltrials.gov/show/NCT00771277||148914|
NCT00770705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#071183|Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery|Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery||Vanderbilt University|Yes|Not yet recruiting|October 2008|||January 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|N/A|6 Months|No|||October 2008|October 9, 2008|October 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00770705||148958|
NCT00770653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS K024|Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.|Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia||Takeda|No|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|75 Years|No|||September 2010|September 13, 2010|October 9, 2008||No||No|September 13, 2010|https://clinicaltrials.gov/show/NCT00770653||148962|
NCT00770666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220055373|Combination Medications vs. Patch Alone for Medically-Ill Smokers|Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness||Rutgers, The State University of New Jersey|No|Completed|September 2005|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|No|||October 2008|October 9, 2008|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770666||148961|
NCT00770991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-34501-13965|Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)|A Pilot Study To Investigate the Biological Modulation of Familial Adenomatous Polyposis (FAP) by Lyophilized Black Raspberries||The Cleveland Clinic|No|Completed|December 2005|December 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|October 9, 2008|No|Yes||No|February 11, 2016|https://clinicaltrials.gov/show/NCT00770991||148936|
NCT00771004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS K021|Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.|Pilot Trial Studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients With Type II Diabetes and Insulin Resistance Undergoing Elective PTCA. A Randomized Double-blinded Phase II Study.||Takeda|No|Completed|August 2006|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||July 2010|July 1, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00771004||148935|
NCT00771602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0767|Alemtuzumab + Rituximab Consolidation in CLL|A Randomized Trial of Rituximab vs Alemtuzumab vs Alemtuzumab + Rituximab as Consolidation Therapy for Patients With Chronic Lymphocytic Leukemia (CLL) With Evidence of Residual Disease Following Prior Chemo(Immuno)Therapy||M.D. Anderson Cancer Center|No|Terminated|August 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|October 10, 2008||No|Lack of accrual.|No|April 4, 2011|https://clinicaltrials.gov/show/NCT00771602||148890|
NCT00771615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111729|Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years|A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age||GlaxoSmithKline||Completed|October 2008|December 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|9||Actual|469|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2014|September 4, 2014|October 10, 2008|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00771615||148889|
NCT00784368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014299|A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection|A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection.||Janssen Pharmaceutical K.K.|Yes|Completed|January 2008|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|79 Years|No|||June 2013|June 19, 2013|October 23, 2008|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00784368||147919|
NCT00784381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 05118|Computer Prescribing System and Impaired Renal Function|Impact of a Counselling System Coupled With a Computer Prescribing System to Optimize the Use of the Drugs for Old Subjects Having Renal Function Impairment|Ordoclic-IR|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 3|Observational|Time Perspective: Prospective||2|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|Patients hospitalized in geriatric units|October 2008|November 16, 2012|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00784381||147918|
NCT00784394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00523|Diindolylmethane in Preventing Cancer in Healthy Volunteers|Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-indolylmethane (DIM)||National Cancer Institute (NCI)|No|Completed|April 2004|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|October 7, 2014|November 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00784394||147917|
NCT00785603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-374|Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study|Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study||University of Southern Denmark|Yes|Active, not recruiting|August 2008|February 2009|Anticipated|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 12, 2009|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00785603||147825|
NCT00783848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009919|Validating PROMIS Instruments in Congestive Heart Failure Patients Receiving a Heart Transplant|Validating PROMIS Instruments in Congestive Heart Failure Patients Receiving a Heart Transplant||Duke University|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be recruited through heart transplant program registries and in        consultation with practicing cardiologists at Duke University, Stanford University, and        the University of Pittsburgh.|April 2013|April 26, 2013|October 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00783848||147958|
NCT00783861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04370|Dermacyd Femina (Lactic Acid) Pocket BR - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Femina Pocket BR.||Sanofi||Completed|October 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|54|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783861||147957|
NCT00783887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 06053|Diagnosis of Primary Ciliary Dyskinesia|Molecular Diagnosis of Primary Ciliary Dyskinesia|DCP|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|125|Samples With DNA|DNA, Serum, White blood cells|Both|1 Month|N/A|No|Non-Probability Sample|Patients with suspected or confirmed primary ciliary dyskinesia (followed by the        participating centers)|August 2013|August 6, 2013|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00783887||147956|
NCT00777751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0489|Radiation Therapy and Cardiac Enzymes|Radiation Therapy and Cardiac Biomarkers||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2008|||October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with tumors in the chest in close proximity to the heart, including        histologically proven primary lung cancer, esophageal cancer, or thymoma, to be treated        with single modality RT.|December 2015|December 7, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777751||148421|
NCT00779259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-001-07-1002|Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline|A Pharmacokinetic Drug-Drug Interaction Study to Evaluate the Effect of Steady-State Quinine Sulfate on the Pharmacokinetics of Single-Dose Theophylline in Healthy Adult Males||Mutual Pharmaceutical Company, Inc.|No|Completed|August 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 20, 2009|October 22, 2008|No|Yes||No|May 27, 2009|https://clinicaltrials.gov/show/NCT00779259||148306|
NCT00778297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FluvalAB-H-05|Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine|Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine With 6 Mcg HA/Strain/Dos Antigen Content||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|Yes|Completed|November 2007|May 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|234|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 18, 2012|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778297||148379|
NCT00780143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-A-007-06|Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia|Phase I/II Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia||PharmaMar|No|Terminated|November 2007|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||November 2013|October 27, 2014|October 24, 2008|Yes|Yes|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00780143||148238|
NCT00779272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 29-2008|Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases|Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases||University of Zurich|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|184|||Both|N/A|N/A|No|Probability Sample|Records from 184 consecutive patients undergoing liver resection due to colorectal        metastases between 2003 and July 2008 were reviewed from a prospective database|October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779272||148305|
NCT00769210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012064|The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure|The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure||University of Utah|No|Completed|May 2005|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|85 Years|No|||November 2011|November 15, 2011|December 22, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769210||149068|
NCT00770679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00002253|Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging|Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging||Johns Hopkins University|No|Recruiting|July 2007|June 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|40 Years|90 Years|No|||August 2009|August 3, 2009|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770679||148960|
NCT00770068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH075891|Examining the Link Between Depression and Seasonal Allergies|Seasonality of Depression and Airborne Allergens||University of Maryland|Yes|Active, not recruiting|July 2006|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|Samples Without DNA|Serum|Both|18 Years|64 Years|No|Non-Probability Sample|A community sample will be recruited via local press and radio advertising. Referrals from        mental health providers will be used to supplement this population.|October 2008|April 9, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770068||149006|
NCT00770029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201 - 0724 / 1|IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines. No. 2||Merz Pharmaceuticals GmbH|No|Completed|October 2008|June 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|October 8, 2008|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00770029||149009|
NCT00770718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21152|Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage|A Comparison of Recombinant Activated Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma for Anticoagulation Reversal in Warfarin-Associated Acute Intracranial Hemorrhage: A Dose Ranging Pilot Study||University of Utah|Yes|Terminated|April 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 22, 2011|October 9, 2008|Yes|Yes|poor enrollment|No||https://clinicaltrials.gov/show/NCT00770718||148957|
NCT00770731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0425|Study of Temsirolimus, Topotecan, and Bortezomib|A Phase I Study of Temsirolimus, Topotecan, and Bortezomib in Patients With Advanced Malignancy||M.D. Anderson Cancer Center|No|Completed|September 2008|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|No|||February 2013|February 12, 2013|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770731||148956|
NCT00771030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070264|Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis||Amgen||Completed|November 2008|July 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||April 2015|May 13, 2015|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00771030||148933|
NCT00736684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGAINT-ES-08|Proximal Femoral Nail Antirotation™ (PFNA) Versus Gamma Nail 3™ (Gamma3) for Intramedullary Nailing of Unstable Trochanteric Fractures|Proximal Femoral Nail Antirotation™ (PFNA) Versus Gamma Nail 3™ (Gamma3) for Intramedullary Nailing of Unstable Trochanteric Fractures - a Multicenter Randomized Controlled Trial|PROGAINT-ES|AO Clinical Investigation and Documentation|Yes|Completed|November 2007|September 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|55 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 10, 2011|August 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00736684||151539|
NCT00785356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-302|Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids|A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy||Repros Therapeutics Inc.|Yes|Terminated|October 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|8|||Female|18 Years|48 Years|No|||August 2014|August 5, 2014|November 3, 2008|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00785356||147844|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00781534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0824|A Clinical Trial of Ginseng in Diabetes|A Clinical Trial of Ginseng for Glucose Intolerance||Washington University School of Medicine|No|Completed|September 2003|September 2008|Actual|December 2004|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 18, 2010|October 27, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00781534||148135|
NCT00782041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_8311|Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer|Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or Metastatic Cervical Cancer.||Sanofi|No|Terminated|January 2003|||August 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||September 2009|September 14, 2009|October 28, 2008||No|protocol violation|No||https://clinicaltrials.gov/show/NCT00782041||148096|
NCT00782730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20862|Assessment of Third Trimester Post-void Residual and Validation of Bladder Scanner in Pregnancy and Post-partum|Assessment of Third Trimester Post-void Residual Along With Determining Validity of the Bladder Scanner in the Third Trimester of Pregnancy and Postpartum||West Virginia University|No|Completed|October 2008|||December 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|35|||Female|18 Years|N/A|No|Non-Probability Sample|All adult patients undergoing elective or non-emergent Cesarean delivery will be asked to        enroll. Also adult patients having a labor epidural placed during labor will be asked to        participate.|June 2013|June 11, 2013|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782730||148044|
NCT00782977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:129|Apneic Oxygenation Via Nasal Cannulae Prevents Arterial Hypoxemia|Oxygenation Via Nasal Cannulae Prevents Arterial Hypoxemia During the Apneic Period in Paralyzed Patients||University of Manitoba|No|Completed|November 2008|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|65 Years|No|||May 2011|December 19, 2012|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782977||148025|
NCT00777400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACD4520 Efalizumab|Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells|A Pilot Trial to Assess the Effect of CNI Conversion to Efalizumab in T Regulatory Cells in Renal Transplantation||University of California, San Francisco|Yes|Withdrawn|December 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|70 Years|No|||May 2013|May 13, 2013|October 20, 2008|Yes|Yes|New safety information reported in the post-marketing setting with efalizumab for treatment of    chronic plaque psoriasis and trial conduct feasibility issues.|No||https://clinicaltrials.gov/show/NCT00777400||148447|
NCT00777413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-135|Bioequivalecne Study of Minocycline 100mg Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Minocycline 100 mg Capsules in Healthy Volunteers||Ranbaxy Inc.|Yes|Completed|November 2002|January 2003|Actual|November 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00777413||148446|
NCT00778050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02 - 914|Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 600 mg Amoxicillin Dispersible Tablets vs 400 mg/ 5 mL Amoxil ® for Oral Suspension Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|October 2002|December 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778050||148398|
NCT00778648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPCC|Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms|Effectiveness of an Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms||Charite University, Berlin, Germany|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|543|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 9, 2010|October 21, 2008||No||No|September 9, 2010|https://clinicaltrials.gov/show/NCT00778648||148353|
NCT00778674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-260|Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets in Healthy Volunteers||Ranbaxy Inc.|Yes|Completed|October 2004|December 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778674||148351|
NCT00778687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200809046R|Heart Rate Variability Change After Liver Transplantation|Effects of Liver Transplantation on the Heart Rate Variability in Patients With End-Stage Liver Disease||National Taiwan University Hospital|No|Completed|October 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with end stage liver disease undergoing liver transplantation|December 2013|December 22, 2013|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778687||148350|
NCT00779571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-814d 6.2008.453|The Female Health Dietary Intervention Study|Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study|FEMIN|The Hospital of Vestfold|No|Completed|October 2008|February 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|19 Years|38 Years|No|||October 2014|October 9, 2014|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779571||148282|
NCT00779584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05248|A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Gemcitabine in Patients With Solid Tumors or Lymphoma (Study P05248)|A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma||Merck Sharp & Dohme Corp.|No|Completed|October 2008|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|October 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00779584||148281|
NCT00778960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT004951-01|Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.|Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.||Oregon Health and Science University|No|Completed|January 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|102|||Both|25 Years|65 Years|No|||July 2015|July 9, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778960||148329|
NCT00778973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10540324|Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Pfizer Formulation of Sertraline 100 mg Tablets in Healthy Adult Volunteers Under Fed Conditions.||Ranbaxy Inc.|Yes|Completed|August 2005|October 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00778973||148328|
NCT00779285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04057|Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)|Cardiac Safety Profile of Caelyx Therapy in Anthracyclin Pretreated Metastatic Breast Cancer Patients.||Merck Sharp & Dohme Corp.|No|Terminated|February 2006|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|N/A|No|||June 2015|June 18, 2015|October 23, 2008|Yes|Yes||No|February 11, 2010|https://clinicaltrials.gov/show/NCT00779285||148304|
NCT00779610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0810080147|The Effects of Passive and Active Vibration Therapy on Grip Strength and Myoelectric Activity|The Effects of Passive and Active Vibration Therapy on Grip Strength and Myoelectric Activity||Logan College of Chiropractic|No|Recruiting|October 2008|November 2008|Anticipated|November 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779610||148279|
NCT00779623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-00756|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||October 23, 2008|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779623||148278|
NCT00770042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-011|To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil|A Phase I, Single-Centre, Open-Label, Randomized, One-sequence Crossover, Three-Group Study to Evaluate the Effect of Ketoconazole, Ritonavir and Erythromicin on the Safety and Pharmacokinetics of Avanafil (TA-1790) in Healthy Male Subjects||VIVUS, Inc.|No|Completed|October 2008|December 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|October 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770042||149008|
NCT00769808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|564|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2008|||||N/A|N/A|N/A||||||||||||||May 30, 2013|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769808||149025|
NCT00735423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77556|Infant Diet Effects on Brain Function and Language Processing (fMRI)|Effects of Neonatal Diet on Language, Neurocognitive Functions at Eight Years Old: fMRI, ERP and Standardized Behavioral Measures||Arkansas Children's Hospital Research Institute|No|Recruiting|August 2008|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|90 Months|101 Months|Accepts Healthy Volunteers|Non-Probability Sample|healthy 8-year-old children|November 2015|November 11, 2015|August 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00735423||151634|
NCT00735436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006308|A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)|Phase II Trial for Patients With Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Avastin Plus Irinotecan||Duke University|No|Terminated|December 2008|October 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2012|February 4, 2013|August 13, 2008|Yes|Yes|Study enrollment was halted due to slow accrual.|No|December 31, 2012|https://clinicaltrials.gov/show/NCT00735436||151633|
NCT00770692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-150|A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)|A Phase III Study of SEP-190 (Eszopiclone) in Patients With Insomnia||Eisai Inc.||Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|369|||Both|20 Years|84 Years|No|||October 2012|October 24, 2012|October 9, 2008||No||No|October 24, 2012|https://clinicaltrials.gov/show/NCT00770692||148959|
NCT00771017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616570|Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer|A Randomized, Phase II Trial of Brief Androgen-Ablation Combined With Cell-based CG1940/CG8711 Immunotherapy For Prostate Cancer in Patients With Non-Metastatic, Biochemically Relapsed Prostate Cancer||Eastern Cooperative Oncology Group||Withdrawn|July 2008|||April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||August 2013|August 16, 2013|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00771017||148934|
NCT00771264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPC082008|Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms||SUmiT|Uroplasty, Inc||Completed|September 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 13, 2012|October 9, 2008|No|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00771264||148915|
NCT00736073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005149|A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|A Randomized, Double-Blind, Prospective Trial of Oral Administration of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis||Duke University|No|Completed|August 2007|November 2012|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|60 Years|No|||April 2015|June 18, 2015|August 13, 2008|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00736073||151585|Unable to control for pre-procedure dosing
NCT00736372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-12-004|A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer|A Phase Ib Trial of PX-12 Administered as a 72-Hour Infusion Every 21 Days in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer That is Refractory to Standard Treatment||Oncothyreon Inc.|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|August 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00736372||151563|
NCT00771576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB0002|PET Scan Imaging of Beta Cell Mass|PET Scan Imaging of Pancreatic Beta Cell Mass With DTBZ||Columbia University|Yes|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|30|None Retained|Blood|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potential subjects with diabetes will be recruited from among the patients cared for at        the Naomi Berrie Diabetes Center. Nondiabetic subjects will either be referred by their        physicians or by word of mouth. Primary care physicians will be made aware of the study by        fliers.|July 2013|July 29, 2013|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771576||148892|
NCT00771589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804002682|Active Knee Prosthesis Study for Improvement of Locomotion for Above Knee Amputees|The Active Knee Prosthesis Will be Tested to Evaluate How Well it Improves the Gait Symmetry and Reduces the Metabolic Cost of an Amputee During Walking. The Prosthesis Will be Attached to the Socket of the Amputee.||Providence VA Medical Center|Yes|Recruiting|May 2008|April 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 10, 2008|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00771589||148891|
NCT00776230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-314|Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling|Immunogenicity of a Commercial Batch of the Japanese Encephalitis Vaccine IC51 up to Twenty-four Months Post Filling. An Open-label, Multicenter, Phase 3 Study||Valneva Austria GmbH|No|Completed|September 2008|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|304|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|October 20, 2008||No||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00776230||148537|
NCT00776542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-134|Bioequivalence Study of Minocycline 100mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Minocycline 100 mg Capsules in Healthy Volunteers||Ranbaxy Inc.|Yes|Completed|October 2002|January 2003|Actual|November 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 20, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776542||148513|
NCT00781781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALOTIRNE-EC06007|Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning|Multicenter, Openlabel, Phase II Intergroups (GELTAMO/GETH) Trial, on the Use of Alemtuzumab for Unrelated Donor Reduced Intensity Conditioning Allogenic Transplant in Hematological Malignancies Patients||CABYC|No|Terminated|July 2008|December 2011|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|40 Years|65 Years|No|||October 2008|February 3, 2015|October 28, 2008||No|Inability to recruit the number of patients established in the study protocol (34 of 40)|No||https://clinicaltrials.gov/show/NCT00781781||148116|
NCT00782392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45092|Bioavailability and Dosing of a Monosaccharide Supplement in Adults|Bioavailability and Dosing of an Oral Monosaccharide Supplement in Adults and Effects on Resting Brain Activity||Arkansas Children's Hospital Research Institute|No|Completed|January 2007|||June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|15|Samples Without DNA|Plasma|Male|18 Years|28 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Caucasian Males|May 2011|May 16, 2011|October 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00782392||148069|
NCT00782405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D114432C00027|Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine|Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine||Technische Universität München|No|Completed|October 2008|||April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||April 2011|April 18, 2011|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00782405||148068|
NCT00779168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08012|White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy|A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer||City of Hope Medical Center|Yes|Active, not recruiting|September 2008|||February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Male|N/A|N/A|No|||September 2015|September 24, 2015|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00779168||148313|
NCT00778622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV138-097|Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients|The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes||Bristol-Myers Squibb|No|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|371|||Both|17 Years|79 Years|No|||August 2013|August 19, 2013|October 22, 2008|Yes|Yes||No|June 14, 2013|https://clinicaltrials.gov/show/NCT00778622||148354|
NCT00778700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-203|A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis|A Double-Blind, Randomized, Vehicle-Controlled Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis||Incyte Corporation|No|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|199|||Both|18 Years|75 Years|No|||March 2012|March 13, 2012|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00778700||148349|
NCT00778713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B035502|Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions|A Bioequivalence Study of Test and Reference Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Non-Fasting Conditions||Ranbaxy Inc.|Yes|Completed|March 2003|April 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778713||148348|
NCT00778986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF-RPM-UHN|Effects of Remote Patient Monitoring on Heart Failure Management|Effects of Remote Patient Monitoring on Heart Failure Management: A Randomized Controlled Trial||University Health Network, Toronto|No|Completed|March 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00778986||148327|
NCT00779298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 709/2004|Effect of Commercial Rye Whole-Meal Bread on Postprandial Blood Glucose and Gastric Emptying in Healthy Subjects|Effect of Commercial Rye Whole-Meal Bread on Postprandial Blood Glucose and Gastric Emptying in Healthy Subjects||Lund University Hospital|Yes|Completed||||||N/A|Observational|N/A||1|||||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects were recruited from the population in a southern county of Sweden.|October 2008|October 23, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779298||148303|
NCT00779311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFMSMCRC0706|A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer|A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer||Accelerated Community Oncology Research Network|No|Terminated|October 2008|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2011|October 31, 2011|October 23, 2008|Yes|Yes|Dose limiting toxicity at the lowest planned dose level.|No|September 9, 2011|https://clinicaltrials.gov/show/NCT00779311||148302|Early termination due to the MTD determined to be Dose Level 1, leading to a small number of subjects analyzed.
NCT00779636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03284|Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)|Efficacy and Safety of Desloratadine 10 mg Daily vs. Placebo in Subjects With Allergic Airway Disease During the Pollen Season||Merck Sharp & Dohme Corp.|No|Completed|July 2003|November 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|506|||Both|18 Years|65 Years|No|||April 2015|April 27, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779636||148277|
NCT00779649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUSTER|MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial|MoviPrep® Versus HalfLytely® for Colon Cleansing: An Investigator-blinded, Randomized Trial.|LUSTER|Research Associates of New York, LLP|No|Completed|September 2008|October 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|220|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2009|October 29, 2009|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779649||148276|
NCT00770055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592835|Internet Use Among Women With Recurrent Metastatic Breast Cancer|Internet Use Among Women With Recurrent Breast Cancer||Rutgers, The State University of New Jersey|No|Completed|November 2001|January 2011|Actual|February 2010|Actual|N/A|Interventional|Primary Purpose: Health Services Research|||Actual|70|||Female|18 Years|75 Years|No|||January 2011|January 27, 2011|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770055||149007|
NCT00735176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.211 (REK)|The Norwegian Cervical Arthroplasty Trial|Treatment of Cervical Radiculopathy With Arthroplasty Compared With Discectomy With Fusion and Cage (ACDF. Clinical, Radiological and Biomechanical Aspects. A Randomized Multicenter Study.|NORCAT|Norwegian University of Science and Technology|Yes|Active, not recruiting|September 2008|September 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|146|||Both|25 Years|60 Years|No|||August 2015|August 27, 2015|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735176||151652|
NCT00770367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Takeda 07-060|Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes|Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes||Medical University of South Carolina|No|Completed|October 2008|June 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|40 Years|75 Years|No|||December 2011|December 2, 2011|October 9, 2008|Yes|Yes||No|July 8, 2010|https://clinicaltrials.gov/show/NCT00770367||148983|
NCT00735722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF07004AF|A(f)MAZE-CABG Study|A Prospective Randomized Trial Comparing Freedom From Atrial Fibrillation at One Year Post CABG in Patients Undergoing Concomitant Left Atrial Ablation Using HIFU Versus CABG in Patients With Persistent or Long Standing Persistent AF|AFMAZE-CABG|St. Jude Medical|Yes|Terminated|July 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|August 14, 2008||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00735722||151611|
NCT00735735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK 26|Measurement of Substance P in Saliva of Low Back Pain Patients|Study of the Measurement of Substance P in the Saliva of Patients With Low Back Pain||Kovacs Foundation|Yes|Suspended|February 2009|||January 2012|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 11, 2014|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735735||151610|
NCT00736086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD-640-0057|RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System|A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization||Abbott Vascular|Yes|Completed|March 2006|December 2006|Actual|November 2006|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|165|||Both|18 Years|85 Years|No|Non-Probability Sample|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular,        diagnostic catheterization procedure|August 2008|August 14, 2008|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00736086||151584|
NCT00736398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01000-T02|Fusion Assessment Clinical Trial|Fusion Assessment Clinical Trial (FACT)|FACT|Flexuspine, Inc.|No|Completed|August 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|30 Years|N/A|No|Non-Probability Sample|Patients requiring spinal fusion|April 2013|April 1, 2013|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00736398||151561|
NCT00771290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB6097|Comparision of Air Versus CO2 for Distention During Sigmoidoscopy|Prospective,Randomized Trial Comparing Colonic Distension After Intra-operative Sigmoidoscopy Using Ambient Air or Carbon Dioxide||Columbia University|No|Terminated|March 2008|March 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 13, 2012|October 10, 2008||No|Unknown|No||https://clinicaltrials.gov/show/NCT00771290||148913|
NCT00771303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B0-120760|Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study|Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study||University Hospital, Geneva|Yes|Recruiting|September 2008|April 2016|Anticipated|January 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Nt-pro BNP measurement|Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant women with suspected PE.|May 2015|May 27, 2015|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00771303||148912|
NCT00777153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00055|Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma|A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone|REGAL|AstraZeneca|Yes|Active, not recruiting|October 2008|January 2017|Anticipated|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|423|||Both|18 Years|100 Years|No|||December 2015|January 11, 2016|October 20, 2008|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT00777153||148466|
NCT00777166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004929-99|Cardiac Effects of Oxytocin Administrated During Cesarean Section, Signs of Myocardial Ischemia|Phase 4 Study of Oxytocin Used During Cesarean Section||Uppsala University|No|Completed|December 2005|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777166||148465|
NCT00777127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-03016-3271|Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses|Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)|LEIDA|MEDA Pharma GmbH & Co. KG|No|Completed|December 2008|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777127||148468|
NCT00777426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 007|HIV-1 Specific Immune Responses in Thai Individuals With HIV Dementia|||South East Asia Research Collaboration with Hawaii|Yes|Completed|September 2008|October 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|Samples Without DNA|PBMC, Plasma, Urine|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 60 participants will be enrolled. They will be in 3 groups          1. ARV-naïve, HIV-positive ≥ 20 year of age with HAD (n=25) who intend to start ARV          2. ARV-naïve, HIV-positive ≥ 20 year of age without HAD (n=25), who intend to start ARV          3. HIV-negative ≥ 20 year of age (n=10). The protocol team will work with the primary             care physician to ensure that the subjects receive standard HIV and ARV care;             however, initiation of ARV is not a requirement of the study and ARV will not be             provided by the study.|September 2014|September 25, 2014|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777426||148445|
NCT00777764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4465g|The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)|The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)||Genentech, Inc.||Completed|August 2008|||March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||April 2011|April 13, 2011|October 21, 2008|Yes|Yes||No|August 19, 2010|https://clinicaltrials.gov/show/NCT00777764||148420|
NCT00778076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#: 14017|The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics|The Biomechanical Impact of Intra-Articular Hyaluronic Acid in Knee Osteoarthritis Patients: A Randomized, Double Blind, Placebo Controlled Study||University of Western Ontario, Canada|No|Active, not recruiting|July 2008|May 2009|Anticipated|May 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|60 Years|80 Years|No|||March 2009|March 31, 2009|October 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00778076||148396|
NCT00778310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONCERTAATT4087|Neuroimaging of the Effects of Concerta in the Treatment of ADHD|Functional Neuroimaging of Acute Concerta Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Differences Across Development||The University of Texas Health Science Center at San Antonio|No|Completed|November 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|76|||Both|9 Years|25 Years|No|||April 2012|June 8, 2012|October 22, 2008|No|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00778310||148378|No typically developing control group compared to either the adult or child group.
NCT00778323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ20070901|Clinical Trial of Remote Preconditioning in Patients Undergoing Cervical Decompression Surgery|Effects of Remote Ischemic Preconditioning on Biochemical Markers and Neurological Outcomes in Patients Undergoing Elective Cervical Decompression Surgery||Xijing Hospital|Yes|Completed|September 2007|April 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|51|||Both|30 Years|75 Years|No|||November 2008|February 24, 2011|August 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00778323||148377|
NCT00778661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA02872|Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg Amoxicillin (as the Trihydrate)/57 mg Clavulanic Acid (as the Potassium Salt) Chewable Tablets in Healthy Adult Volunteers Following Administration of a Two Tablet Dose Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|October 2002|December 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778661||148352|
NCT00778726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-256|Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets in Healthy Volunteers||Ranbaxy Inc.|Yes|Completed|September 2004|December 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778726||148347|
NCT00778739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3079|Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fed Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefprozil 250 mg/5 mL Oral Suspension Versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) in Normal Healthy Non-Smoking Male and Female Subjects||Ranbaxy Inc.|Yes|Completed|June 2005|July 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778739||148346|
NCT00778999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05696|Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)|A Randomized, Open-Label Clinical Trial to Identify Predictive Factors for Controlled Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH in GnRH Antagonist Regimen With or Without Oral Contraceptive Scheduling|Xpect|Merck Sharp & Dohme Corp.|No|Completed|October 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|442|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|October 23, 2008|Yes|Yes||No|June 23, 2009|https://clinicaltrials.gov/show/NCT00778999||148326|
NCT00779012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04042|A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)|Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis||Merck Sharp & Dohme Corp.|No|Completed|October 2004|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|70 Years|No|||April 2015|April 28, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779012||148325|
NCT00779025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-6020-1|A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use Conditions|A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use Conditions||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|82|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|October 23, 2008|Yes|Yes||No|March 30, 2011|https://clinicaltrials.gov/show/NCT00779025||148324|
NCT00779324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-08-11B|Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study|A Multi-Center, Parallel-Group, Randomized, Double-Blind, Placebo-Controlled Trial of Amantadine Hydrochloride in the Treatment of Chronic Traumatic Brain Injury Irritability and Aggression: A Replication Study||Carolinas Healthcare System|Yes|Completed|August 2009|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|16 Years|75 Years|No|||August 2014|August 11, 2014|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779324||148301|
NCT00779337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QIMR P1167|Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas|Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas|EPL|Queensland Institute of Medical Research|No|Completed|October 2008|May 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779337||148300|
NCT00780195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 8177|Metabolic Adaptations to Diabetes in African Americans|Metabolic Adaptations to Diabetes||Vanderbilt University|No|Completed|July 1998|December 2010|Actual|November 2000|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|4||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780195||148234|
NCT00780000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA201-002|Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer|Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer||Bristol-Myers Squibb|No|Terminated|April 2008|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||October 2015|October 12, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780000||148249|
NCT00735163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0806|Blood Glucose Control With A Software-Algorithm In Intensive Care Unit (ICU) Patients|Mono-Centric, Open, Non-Controlled Study To Investigate The Feasibility Of Blood Glucose Control With The Software-Algorithm eMPC (Enhanced Model Predictive Control) In ICU Patients|Aldea _01|B. Braun Melsungen AG|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2009|April 15, 2009|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735163||151653|
NCT00735462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW01-0805|Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts|A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts||Graceway Pharmaceuticals, LLC|No|Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|511|||Both|12 Years|N/A|No|||June 2011|June 21, 2011|August 14, 2008|Yes|Yes||No|April 24, 2011|https://clinicaltrials.gov/show/NCT00735462||151631|There was a high percentage of lost to follow up in this study. Since the disease studied in this study can be wait and watch, typically a high lost to follow up rate were seen in these kind of trials.
NCT00735475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-USF-07-41|A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine|A Phase IV, Randomized, Observer-Blind, Multi-Center, Non Inferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Inactivated Split-Virion Influenza Vaccine in Adults Aged Greater Than or Equal to 65 Years||CSL Limited||Completed|October 2008|June 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|1268|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 6, 2011|August 13, 2008|Yes|Yes||No|July 3, 2011|https://clinicaltrials.gov/show/NCT00735475||151630|
NCT00735449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-COM-07-XTC|Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects|Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects||Allergan||Completed|July 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|August 13, 2008|Yes|Yes||No|October 17, 2011|https://clinicaltrials.gov/show/NCT00735449||151632|
NCT00735748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/526|Comparison of Tramadol Orally Versus an Optimized Dose of Intravenous Tramadol for Postoperative Pain Relief in Ambulatory Surgery|Comparison of the Therapeutic Efficacy and Side Effects of Tramadol Per os (Tradonal Odis® Orodispersible Tablets) Versus an Optimised Dosis of Intravenous Tramadol for Postoperative Pain Relief in Ambulatory Surgery.||University Hospital, Ghent|No|Recruiting|March 2008|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||December 2014|December 4, 2014|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735748||151609|
NCT00768365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/675|Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma|Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma: Myth or Reality?|adrenal|Istanbul University|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|105|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study parameters at the patients with AI (group 1) were compared with and control        subjects.        Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group        (group 2). The other control group (group 3) of 35 healthy individuals matched for sex,        age, BMI, metabolic syndrome criteria.|September 2008|October 7, 2008|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00768365||149133|
NCT00768378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCB1-005|Safety and Efficacy Study of BrainPort® Balance Device in Peripheral Vestibular Dysfunction.|A Controlled Clinical Study to Evaluate the Safety and Efficacy of the BrainPort® Balance Device When Used to Improve Balance in Subjects With Peripheral Vestibular Dysfunction||Wicab|No|Completed|July 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|79 Years|No|||June 2012|June 27, 2012|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00768378||149132|
NCT00736385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006196|Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)|Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial|NAFLD|Duke University|No|Terminated|April 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|70 Years|No|||March 2015|March 27, 2015|August 13, 2008|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT00736385||151562|Study was terminated early due to difficulties with enrollment.
NCT00736411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28.005-2|In Vitro Fertilization (IVF) and Acupuncture for Infertility|IVF and Acupuncture for Infertility: A Randomized Controlled Trail||Pacific Fertility Center|Yes|Terminated|August 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|320|||Female|21 Years|42 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|August 13, 2008||No|Adjustments to ensure clear outcomes and scientific merit integrated. Study closed at 14    subjects. New protocol submitted to IRB.|No||https://clinicaltrials.gov/show/NCT00736411||151560|
NCT00776828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILON-T|The Efficacy of CILostazol ON Ischemic Complications After DES Implantation|Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation|CILON-T|Seoul National University Hospital|Yes|Completed|November 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|960|||Both|18 Years|80 Years|No|||December 2013|December 15, 2013|October 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00776828||148491|
NCT00776763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIA-ProRet|Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab|The Profile of the Growth Factors and Other Mediators of Angiogenesis in the Ocular Fluids in Proliferative Retinopathies (AMD and PDR) Before and After the Intravitreal Administration of Bevacizumab (Avastin) as an Anti-VEGF Blocker|KIA-ProRet|Ophthalmological Association Edelweiss||Completed|October 2008|December 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|150|||Both|20 Years|N/A|No|||October 2008|July 20, 2011|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776763||148496|
NCT00776776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0954|Follow-up of Adolescent Bariatric Surgery|Follow-up of Adolescent Bariatric Surgery|FABS|Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|April 2005|April 2010|Anticipated|April 2007|Actual|N/A|Observational|Observational Model: Cohort||2|Anticipated|180|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients Seeking Treatment for Obesity at Cincinnati Children's Hosptial Medical Center in        Cincinnati, OH.|August 2008|October 21, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776776||148495|
NCT00777114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806009862|Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy|Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy||Weill Medical College of Cornell University|Yes|Recruiting|October 2008|||November 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777114||148469|
NCT00777777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-C/08/149|The eSVS (TM) Mesh External Saphenous Vein Support Trial|The eSVS(TM)Mesh External Saphenous Vein Support Trial|eSVS|National University Hospital, Singapore|No|Recruiting|August 2008|September 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|21 Years|80 Years|No|||October 2008|October 21, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00777777||148419|
NCT00778063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.135.C|Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients|Intranasal Dexmedetomidine Decreases Emergence Delirium in Pediatric Patients After Sevoflurane Based General Anesthesia|PED-DEX|Ochsner Health System|Yes|Recruiting|March 2009|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00778063||148397|
NCT00777829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH080992-01|Memory Consolidation in Pharmacologically Enhanced Naps|Understanding Memory Consolidation by Studying Pharmacologically Enhanced Naps.||University of California, San Diego|Yes|Completed|September 2008|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|5||Actual|30|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|October 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00777829||148415|
NCT00778089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D82-3001-07|Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing|Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing||Suneva Medical, Inc.|No|Terminated|July 2008|December 2010|Anticipated|September 2008|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|498|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 19, 2010|October 21, 2008|Yes|Yes|Closed incomplete due to Artes Medical Closing|No||https://clinicaltrials.gov/show/NCT00778089||148395|
NCT00778336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEARL|A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters|Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters||Boston Scientific Corporation|No|Completed|January 2007|April 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|452|||Both|N/A|N/A|No|Non-Probability Sample|Patient with peripheral thrombosis treated with a AngioJet mid-length catheter that is        indicated for thrombosis removal.|October 2014|October 8, 2014|October 22, 2008||No||No|February 22, 2011|https://clinicaltrials.gov/show/NCT00778336||148376|Non randomized observational registry
NCT00778349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/METFO-500/02|A Comparitive Bioavailability Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fasting Conditions and After Low and High Fat Meal|A Randomized, Three-Treatment, Three-Period, Six-Sequence, Single-Dose, Crossover Pharmacokinetic Study on Metformin Hydrochloride Solution 100 mg/mL of Ranbaxy Laboratories Comparing the Pharmacokinetic Profile of Metformin Under Fasting Condition, After a Low Fat Meal and After a High Fat Meal in Healthy, Adult, Human Male Subjects.||Ranbaxy Inc.|Yes|Completed|April 2002|July 2002|Actual|May 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778349||148375|
NCT00778752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Revlimid as maintenance in MM|Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma|Dose-finding Study of Lenalidomide as Maintenance Therapy in Multiple Myeloma After Allogeneic Stem Cell Transplantation||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2009|December 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778752||148345|
NCT00779350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10540323|Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Pfizer Formulations of Sertraline 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|August 2005|October 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779350||148299|
NCT00779662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07- 0070|The Prevalence of Rheumatic Heart Disease in School Children in Fiji|The Prevalence of Rheumatic Heart Disease in School Children in Fiji||Queensland Institute of Medical Research||Active, not recruiting|February 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|5 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted in the Central Division of Fiji within a selection of up to16        primary schools located in the Korovou/Tailevu and Rewa/Nausori sub-divisions.|October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779662||148275|
NCT00780182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-103|Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers|An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability||Chimerix|Yes|Completed|October 2008|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 1, 2010|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780182||148235|
NCT00780013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/METFO-500/01|Bioequivalence Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fed Conditions|Crossover Bioavailability Study on Metformin Formulations Comparing Metformin Hydrochloride Liquid 500 mg/5mL of Ranbaxy Laboratories With GlucophageA® 1000 mg Tablets of Bristol-Myers Squibb in Healthy, Adult, Male and Female Volunteers Under Fed Conditions, Following a 1000 mg Dose||Ranbaxy Inc.|Yes|Completed|May 2002|June 2002|Actual|May 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00780013||148248|
NCT00734890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080087|Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma|Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|March 2008|February 2011|Actual|June 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|August 13, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00734890||151674|
NCT00734903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-001-08S|A Randomized Controlled Trial on Women's Substance Abuse Treatment|A Randomized Controlled Trial on Women's Substance Abuse Treatment|WPR|VA Office of Research and Development|Yes|Active, not recruiting|October 2010|January 2017|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|65 Years|No|||January 2016|January 19, 2016|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00734903||151673|
NCT00768040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2244|Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema|A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema||Novartis|No|Terminated|September 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|85 Years|No|||February 2012|February 2, 2012|October 6, 2008|Yes|Yes|Inadequate enrollment|No|February 2, 2012|https://clinicaltrials.gov/show/NCT00768040||149157|This study was terminated early due to low recruitment of patients. The study lacked power against the original objective of statistically significance for changes in central retinal thickness due to the much reduced sample size.
NCT00768053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4508|Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients|Open-Label Study To Evaluate The EULAR-RAID Score, Rheumatoid Arthritis Impact Of Disease Score, In Rheumatoid Arthritis Patients Eligible To Etanercept And Who Will Receive Etanercept|Rainbow|Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2008|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|October 3, 2008||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00768053||149156|
NCT00768066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070443|The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)|A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.|TAC-HFT|University of Miami|Yes|Completed|August 2008|September 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|65|||Both|21 Years|90 Years|No|||November 2015|November 9, 2015|October 3, 2008|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT00768066||149155|
NCT00735761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-06|Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients|A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients||Medivir|No|Completed|December 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||August 2008|August 14, 2008|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00735761||151608|
NCT00735774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3099001|Suitability of 11C-ORM-13070 as a PET Tracer|Suitability of 11C-ORM-13070 as a Positron Emission Tomography Tracer; an Open Study in Healthy Males||Orion Corporation, Orion Pharma|No|Completed|August 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|August 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00735774||151607|
NCT00735787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-405|Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet|Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet||Abbott|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||October 2010|October 11, 2010|August 13, 2008|Yes|Yes||No|September 1, 2010|https://clinicaltrials.gov/show/NCT00735787||151606|Based on one investigator's non-compliance with the protocol at one site, ITT analyses were conducted in a smaller number of subjects that excluded all 9 subjects from this one site.
NCT00736099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.40|Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM|A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 1356 (5 mg) as Monotherapy or in Combination With Other Antidiabetic Medications in Type 2 Diabetic Patients.||Boehringer Ingelheim||Completed|August 2008|||December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2122|||Both|18 Years|82 Years|No|||December 2013|June 18, 2014|August 14, 2008||||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00736099||151583|
NCT00769288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00248|FAU in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-B-D-arabinofuranosyl) Uracil, NSC#678515) in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|July 2009|||December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|October 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769288||149062|
NCT00770458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-Trisomy21-0100|Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker||Sequenom, Inc.|No|Completed|June 2008|December 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples Without DNA|Plasma|Female|18 Years|N/A|No|Probability Sample|Fetal care and genetic counseling patients.|January 2010|January 4, 2010|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770458||148976|
NCT00768703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01765|Percutaneous Endoscopic Tracheal Plug/Unplug for CDH|Percutaneous Endoscopic Tracheal Plug/Unplug for Congenital Diaphragmatic Hernia||University of California, San Francisco|Yes|Active, not recruiting|October 2008|December 2017|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 10, 2015|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768703||149107|
NCT00776581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2008-MZ013|Ten-year Practice of Labor Pain Control in China|A Ten-year Practice of Labor Pain Control in China|POPIC|Nanjing Medical University|Yes|Completed|January 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Retrospective||4|Actual|40000|||Female|18 Years|45 Years|No|Non-Probability Sample|All parturients delivered in the investigator's institution since from January 1999 to        December 2008|September 2009|September 17, 2009|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776581||148510|
NCT00776854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.001a|Bioburden Reduction of Diabetic Foot Ulcer|Noveon Laser Treatment to Effect Bioburden Reduction or Elimination in Diabetic Foot Ulcer: A Davice Performance Clinical Study||Nomir Medical Technologies||Not yet recruiting|November 2008|November 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||October 2008|October 20, 2008|October 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00776854||148489|
NCT00777140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TANDEM-1|Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion|Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator|TANDEM-1|Germans Trias i Pujol Hospital|Yes|Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|80 Years|No|||July 2012|July 4, 2012|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777140||148467|
NCT00777465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-3436.0.000.140-08|Acute Kidney Injury After Cardiac Surgery Based on KDIGO Criteria|Prognostic Value of Acute Kidney Injury After Cardiac Surgery According to Kidney Disease: Improving Global Outcomes Definition and Staging (KDIGO) Criteria||Hospital de Base|No|Completed|January 2003|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|2804|||Both|18 Years|N/A|No|Probability Sample|Patients selected consecutively after cardiac surgery (CABG or CVS) in a setting of        postoperative intensive care unit.|May 2014|May 19, 2014|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777465||148442|
NCT00777478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO20083|Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer|A Phase I Dose Escalation Study With Sunitinib (SutentR) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer|sutent-capiri|Radboud University|Yes|Recruiting|December 2008|December 2012|Anticipated|May 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||January 2012|February 2, 2012|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777478||148441|
NCT00777790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA19|Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents|Antibody Responses to a Booster Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, Menactra® in Adolescents Who Previously Received Menomune® or Menactra®||Sanofi|Yes|Completed|February 2004|April 2005|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|241|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|October 21, 2008|Yes|Yes||No|December 2, 2008|https://clinicaltrials.gov/show/NCT00777790||148418|
NCT00777803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201 GL_3002|NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines|A Prospective, Multicenter, Randomized, Rater- and Subject-Blind, Parallel Group Trial to Investigate the Non-Inferiority of NT 201, Free of Complexing Proteins, in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines|Head2Head|Merz Pharmaceuticals GmbH|No|Completed|November 2008|May 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|381|||Female|18 Years|50 Years|No|||March 2012|March 7, 2012|October 21, 2008||No||No|January 23, 2012|https://clinicaltrials.gov/show/NCT00777803||148417|
NCT00778102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO18725|A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.|A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus Bevacizumab (OLIVIA)||Hoffmann-La Roche||Completed|October 2008|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 22, 2008||No||No|July 10, 2015|https://clinicaltrials.gov/show/NCT00778102||148394|
NCT00778765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA01820|Bioequivalence Study of Gabapentin 400 mg Capsules Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Parke-Davis (Neurontin®) 400 mg Gabapentin Capsules in Healthy Adult Volunteers Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|September 2002|December 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778765||148344|
NCT00778362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200805057R|Splenic Function After Spleen-Preserving Distal Pancreatectomy With Excision of Splenic Artery and Vein|Splenic Function After Spleen-Preserving Distal Pancreatectomy With Excision of Splenic Artery and Vein||National Taiwan University Hospital|No|Active, not recruiting|January 2006|December 2012|Anticipated|October 2008|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients received splenectomy (patient list will be applied from Dept. of Pathology)        at National Taiwan University Hospital in the last 20 years.|October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778362||148374|
NCT00778375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0039|Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Completed|October 2008|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|60 Years|N/A|No|||January 2016|January 28, 2016|October 21, 2008|Yes|Yes||No|January 28, 2016|https://clinicaltrials.gov/show/NCT00778375||148373|
NCT00779363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC CR TAN2007-012|A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients|A Prospective Clinical Trial of the TANTALUS System In Treatment of Obese to Morbidly Obese Patients||MetaCure (USA), Inc.|Yes|Completed|June 2004|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|70 Years|No|||April 2013|April 30, 2013|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779363||148298|
NCT00779376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA26101|Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and GlaxoSmithKline (Retrovir ® ) 300 mg Zidovudine Tablets in Healthy Adult Volunteers Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|February 2005|April 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779376||148297|
NCT00779389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-124|Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family|Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers||University of Pittsburgh|No|Completed|January 2009|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|58|||Both|18 Years|N/A|No|||February 2015|January 12, 2016|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779389||148296|
NCT00779675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05319|Assessment of Long-Term Infliximab for Psoriasis (P05319)|Real-World Assessment of Long-Term Infliximab Therapy for Psoriasis|REALITY|Merck Sharp & Dohme Corp.|No|Completed|October 2008|August 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|660|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with plaque-type psoriasis in which the treating physician has selected for        treatment with infliximab, in accordance with local clinical practices, will be advised        about this trial. It is highly recommended that 30% of the participants enrolled be naïve        to previous biologic therapy. For example, if a site recruits 10 participants, 3 out of        these 10 participants should be naïve to previous biologic therapy.|October 2015|October 30, 2015|October 23, 2008|No|Yes||No|September 27, 2012|https://clinicaltrials.gov/show/NCT00779675||148274|
NCT00780247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton6|Environmental Influences on Vitamin D Status|Environmental Influences on Vitamin D Status|Alaska/Hawaii|Creighton University|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Age of Subjects: The subjects will be between ages 18-60. The upper age is limited to age        60 as aging skin is less able to make vitamin D, therefore a separate study of elderly        people would be more appropriate.        Racial and Ethnic Origin: Both sites have a diverse ethnic and racial population and the        subjects will be as representative of the population as possible.|October 2008|October 24, 2008|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780247||148230|
NCT00735189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|epicore ams1|Does Anticoagulant Control Change Following Referral Back to the Primary Care Physician?|Does Anticoagulant Control Change Following Referral Back to the Primary Care Physician? A Prospective Randomized Trial||University of Alberta|No|Completed|November 2007|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|96|||Both|18 Years|N/A|No|||June 2010|June 23, 2010|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735189||151651|
NCT00735215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OBE-FAS-2008/1|Faslodex Registry: Fulvestrant in Current Clinical Practice|Faslodex Registry: a Belgian Observational Study to Evaluate the Use of Fulvestrant in Current Clinical Practice||AstraZeneca|No|Completed|October 2008|December 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|N/A|N/A|No|Probability Sample|Woman with post-menopausal breast cancer.|December 2009|December 21, 2009|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00735215||151650|
NCT00769600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0881|A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer|A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer|Itraconazole|Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|October 2008|October 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|October 8, 2008|Yes|Yes|Low accrual.|No||https://clinicaltrials.gov/show/NCT00769600||149039|
NCT00768391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13937|Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available|Phase I Study of Anti-Platelet Derived Growth Factor Receptor Alpha (PDGFRa) Monoclonal Antibody IMC-3G3 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom no Standard Therapy is Available||ImClone LLC|No|Completed|December 2006|January 2010|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768391||149131|
NCT00768716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8600|Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics|Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics||Tufts University|No|Recruiting|September 2008|April 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2008|October 7, 2008|October 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768716||149106|
NCT00768989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-376|Phase IIB Pilot of Atazanavir + Raltegravir|A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Combination With Tenofovir/Emtricitabine QD in Treatment Naive HIV-Infected Subjects|SPARTAN|Bristol-Myers Squibb|No|Terminated|November 2008|May 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|October 6, 2008|Yes|Yes|Efficacy endpoint met, but overall experimental dosing regimen not considered optimal to    support further clinical development in this population.|No|October 19, 2011|https://clinicaltrials.gov/show/NCT00768989||149085|
NCT00769002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AI077102|PET-CT Scans in Healthy Volunteers After Flu Vaccination|Impact of Bilateral Priming on Response to Unilateral Flu Vaccination|Pro00000226|Hackensack University Medical Center|Yes|Completed|September 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769002||149084|
NCT00770471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0801 CDR0000616542|ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Temozolomide and ABT-888 in Subjects With Newly Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center||Completed|June 2009|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770471||148975|
NCT00770822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSI-002|Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer|A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU|SetPace|SonaCare Medical|Yes|Active, not recruiting|April 2007|December 2017|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|466|||Male|40 Years|75 Years|No|||December 2013|January 11, 2016|October 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770822||148949|
NCT00769587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599564|Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis|Phase II Study of Thalidomide in Mastocytosis||Centre Hospitalier Universitaire, Amiens|Yes|Completed|June 2007|October 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769587||149040|
NCT00776867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-091|Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors|Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|21 Years|No|||September 2015|September 16, 2015|October 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00776867||148488|
NCT00777439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLA102024|Domperidone for Refractory Gastrointestinal Disorders|An Investigational New Drug Program for the Use of Domperidone in the Treatment of Refractory Gastroesophageal Reflux Disease and Other Gastrointestinal Motility Disorders||Arnold, George, M.D.|Yes|Recruiting|October 2008|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777439||148444|
NCT00777452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2004-05-21|A Prospective Longitudinal Study of Health-Related Quality of Life in Men With Clinically Localized Prostate Cancer|A Prospective Quality of Life Study in Men With Clinically Localized Prostate Carcinoma Treated With Different Treatment Modalities||Samsung Medical Center|Yes|Completed|March 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|93|||Male|43 Years|82 Years|No|Non-Probability Sample|patients with clinically localized prostate cancer at single tertiary institution|October 2008|October 21, 2008|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777452||148443|
NCT00777192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0637|Longitudinal Study of Symptoms in Colorectal Cancer|Prospective Study of Symptoms Related to Oxaliplatin-based Regimens in the Treatment of Colorectal Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2008|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Serum and cell samples will also be collected during chemotherapy for analysis of cytokines      and their relationship to symptom production.|Both|18 Years|N/A|No|Probability Sample|Patients having oxaliplatin chemotherapy as a treatment for colorectal cancer.|February 2016|February 18, 2016|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00777192||148463|
NCT00777491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0712|Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery|A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant Chemotherapy||Radiation Therapy Oncology Group|Yes|Active, not recruiting|December 2008|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777491||148440|
NCT00777816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052070|Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis|A Blinded, Placebo-controlled, Study of the Safety and Pharmacokinetics of XOMA 052 Administered to Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis||XOMA (US) LLC|No|Suspended|February 2009|||October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777816||148416|
NCT00778778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA27168|Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions|Blinded, Comparative, Randomized, Single-Dose, Three Way Crossover Bioavailability Study of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg Cefprozil Tablets in Healthy Adult Volunteers Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|May 2005|August 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|3||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778778||148343|
NCT00778388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC43-101|Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers|Against Pseudomonas Aeruginosa in Healthy Volunteers||Valneva Austria GmbH|Yes|Completed|September 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|157|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778388||148372|
NCT00779038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015121|Safety and Efficacy Study of Fentanyl Iontophoretic Transdermal System (ITS) for Management of Moderate to Severe Acute Pain in Participants Who Have Undergone Elective Spine or Orthopedic Surgery|Clinical Outcome Study in Postoperative Pain Management to Demonstrate the Efficacy and Safety of IONSYS (Fentanyl ITS Iontophoretic Transdermal System) in Daily Clinical Practice and to Assess Its Convenience (IPAC)||Janssen Cilag N.V./S.A.|No|Terminated|August 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|October 23, 2008||No|Stopped prematurely in 2008 due to IONSYS withdrawal off the market globally|No|January 10, 2013|https://clinicaltrials.gov/show/NCT00779038||148323|No efficacy results were reported because the study was prematurely terminated, following the worldwide voluntary withdrawal of Fentanyl Iontophoretic Transdermal System (IONSYS) by Janssen-Cilag.
NCT00779051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-274|Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions|An Open Label, Relative Bioavailability Study of 10 mg Zolpidem Tablet Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|August 2005|October 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779051||148322|
NCT00779064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11390|BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status|BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status||Bayer|No|Completed|July 2004|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|20 Years|N/A|No|||December 2014|December 23, 2014|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00779064||148321|
NCT00779090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRCGARS-1|Functional Residual Capacity (FRC) Guided Alveolar Recruitment Strategy|The Influence of a Functional Residual Capacity Guided Alveolar Recruitment Strategy After Open Endotracheal Suctioning on Oxygenation and Regional Ventilation||University of Luebeck|No|Completed|October 2007|October 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Actual|59|||Both|18 Years|N/A|No|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779090||148319|
NCT00779402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-11|Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer|Autologous PAP-loaded Dendritic Cell Vaccine (APC8015, Provenge [TM]) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial|PROTECT|Dendreon||Completed|September 2001|April 2015|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|176|||Male|19 Years|79 Years|No|||February 2016|February 29, 2016|October 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779402||148295|
NCT00779688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-2008-ERCP-01|A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers|Endoscopic Retrograde CholangioPancreatography Endomicroscopy Registry Outcomes Database||Mauna Kea Technologies|No|Completed|November 2008|October 2010|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Non-Probability Sample|Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde        Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct        Cancers|February 2011|February 9, 2011|October 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779688||148273|
NCT00780260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DA013131-06A2|Case Management Alternatives for African American Women at High Risk for HIV|Case Management Alternatives for African American Women at High Risk for HIV||Nova Southeastern University|No|Completed|May 2007|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|562|||Female|18 Years|50 Years|No|||December 2013|December 10, 2013|October 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00780260||148229|
NCT00776412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090013|Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults|Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults||National Institutes of Health Clinical Center (CC)||Recruiting|October 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|375|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|February 5, 2016|October 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00776412||148523|
NCT00767767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710009434|The Effect of Intravenous Anesthetics on Fear Learning and Memory|The Effect of Intravenous Anesthetics on Fear Learning and Memory||Weill Medical College of Cornell University|No|Active, not recruiting|October 2008|June 2013|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|October 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00767767||149178|
NCT00769873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5698|Anticoagulation Post Laparoscopic Splenectomy|Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698||University of Alberta|No|Terminated|October 2006|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|N/A|No|||June 2009|June 23, 2009|October 8, 2008||No|Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered    trial.|No||https://clinicaltrials.gov/show/NCT00769873||149020|
NCT00770172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599523|G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy|Moderate Persistent Neutropenia: Comparison of Administration of G-CSF (Granulocyte Colony Stimulating Factor) 1 Day Out of 2 Versus Traditional Schedules to Maintain Dose Intensity. Phase III Multicenter Study in Patients With Solid Tumors Receiving Chemotherapy||National Cancer Institute (NCI)||Completed|October 2007|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||December 2008|May 12, 2011|October 8, 2008||||No||https://clinicaltrials.gov/show/NCT00770172||148998|
NCT00769886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|571|Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.|A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis||Bausch & Lomb Incorporated|No|Completed|October 2008|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|144|||Both|6 Years|N/A|No|||November 2013|November 22, 2013|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769886||149019|
NCT00769899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00010|AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects|A Phase I,Single-Center,Randomised,Double-Blind,Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7325 in Healthy Male Japanese Subjects|JSAD|AstraZeneca|Yes|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 17, 2009|October 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769899||149018|
NCT00770835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-PIO-109|Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.|Effects of Pioglitazone on Endothelial Progenitor Cells in Type 2 Diabetic Patients With Vascular Complications - The SPLENDOR Study.|SPLENDOR|Takeda|No|Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|40 Years|70 Years|No|||July 2011|July 11, 2011|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770835||148948|
NCT00777517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581174|Bioequivalence Study On Pediatric Appropriate Formulation|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A Pediatric Appropriate Formulation To A 10 Mg Commercial Atorvastatin Calcium Tablet Formulation In Healthy Subjects||Pfizer|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|August 26, 2009|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777517||148438|
NCT00777530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1114|Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects|Ascending Single-Dose Of The Safety, Tolerability, And Pharmacokinetics Of Bosutinib Administered Orally With Multiple Doses Of Ketoconazole To Healthy Adult Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00777530||148437|
NCT00777179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00077|Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy|Randomized, Double-blinded, Placebo-controlled Phase II Study of Vandetanib (ZactimaTM) Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy||AstraZeneca|No|Completed|October 2008|December 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|October 21, 2008||No||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00777179||148464|
NCT00777504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO200801|Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors|Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors||Radboud University|Yes|Recruiting|October 2008|April 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2011|September 15, 2011|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777504||148439|
NCT00777842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-010|Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery|Silencing the c-Myc Gene Using Third Generation Antisense Restenosis Therapy||Cook||Terminated|November 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||March 2015|December 29, 2015|October 20, 2008||No|In this feasibility study device did not perform as well as expected.|No||https://clinicaltrials.gov/show/NCT00777842||148414|
NCT00777855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|warfarin-6006|Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.|The Effects of Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers.||University of California, San Francisco|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 8, 2013|October 20, 2008|No|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00777855||148413|
NCT00778154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003096|Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate|A Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Long-Term Alendronate or Risedronate||Warner Chilcott|No|Completed|January 2004|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|105|Samples Without DNA|bone biopsies|Female|N/A|N/A|No|Probability Sample|Outpatients from bone research centers who have taken alendronate or risedronate for 3 to        5 or more years|June 2013|June 3, 2013|October 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00778154||148390|
NCT00778427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10640302|Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Bristol Myers Squibb Formulations of Metformin 1000 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|February 2006|April 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778427||148369|
NCT00778791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B045502|Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Metformin HC1 750 mg Extended-Release Tablets (Ranbaxy) With That of Glucophage® XR 750 mg Tablets (Bristol Myers Squibb) in Healthy, Adult, Subjects Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|April 2004|July 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778791||148342|
NCT00779077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-OSM-403|Cystic Fibrosis (CF) Flow Rates Study|An Open, Observational, Non-Interventional Study of Inspiratory Flow Rates and Volumes in Subjects With Cystic Fibrosis Inhaling Via a Spirometer With the High Resistance RS01 Dry Powder Inhaler Device in Series||Pharmaxis|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|25|||Both|6 Years|50 Years|No|Non-Probability Sample|CF 6yrs and above|April 2009|April 22, 2009|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779077||148320|
NCT00779415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB26682EP|Long Term Prognosis of MRI Diagnosed Partial Thickness Tears of the Rotator Cuff|Long Term Prognosis of MRI Diagnosed Partial Thickness Tears of the Rotator Cuff||Milton S. Hershey Medical Center|No|Completed|July 2008|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|10|||Both|18 Years|N/A|No|Probability Sample|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of        shoulder pain and were treated by the Orthopaedic Department.|February 2015|February 26, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779415||148294|
NCT00779727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/99|Post-Cesarean Wound Drainage is Not Necessary in Women at Increased Risk of Hemorrhage|||University of Zurich||Terminated|October 1999|June 2004||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||September 2008|October 23, 2008|September 4, 2008||||No||https://clinicaltrials.gov/show/NCT00779727||148270|
NCT00779701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU10526|Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation|Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation||Temple University|No|Completed|March 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|October 22, 2008|Yes|Yes||No|May 22, 2015|https://clinicaltrials.gov/show/NCT00779701||148272|
NCT00779714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101.321-13/07|Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC|Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma|ChemoSensMM|University of Wuerzburg|Yes|Recruiting|October 2008|April 2013|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00779714||148271|
NCT00776425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20197|A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies.|QUALITY OF LIFE BENEFIT IN ANEMIC CANCER PATIENTS TREATED WITH NEORECORMON (EPOETIN BETA): QUALITY OF LIFE TREATMENT RESPONSE AND CLINICAL EVALUATION OF ONCE-WEEKLY DOSING||Hoffmann-La Roche||Completed|March 2007|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00776425||148522|
NCT00776438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID25|Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines|Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route||Sanofi|No|Completed|September 2007|April 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|160|||Both|18 Years|85 Years|No|||June 2015|June 16, 2015|October 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00776438||148521|
NCT00768079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP186|A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563|A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults|MEDI-563|MedImmune LLC|No|Completed|February 2009|May 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|60 Years|No|||May 2012|May 3, 2012|October 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00768079||149154|
NCT00768105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00014|To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin|A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Subjects With T2DM Treated With Insulin||AstraZeneca||Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|75 Years|No|||December 2010|December 2, 2010|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768105||149153|
NCT00769015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01EY018819|Low Vision Depression Prevention Trial for Age Related Macular Degeneration|Low Vision Depression Prevention Trial for Age Related Macular Degeneration|VITAL|Thomas Jefferson University|Yes|Completed|June 2009|June 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|188|||Both|65 Years|N/A|No|||November 2014|November 13, 2014|October 7, 2008||No||No|October 9, 2014|https://clinicaltrials.gov/show/NCT00769015||149083|
NCT00769028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISS01|AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis|A Double-Blind Placebo-Controlled Pilot Study of Safety and Tolerability of AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis||Daval International Limited|Yes|Active, not recruiting|December 2008|September 2011|Anticipated|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|August 16, 2011|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769028||149082|
NCT00769041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-140|A Thorough EKG Safety Study of TA-1790 (Avanafil)|A Blinded, Randomized Crossover Trial to Define the ECG Effects of TA-1790 (Avanafil) Using a Single Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin in Healthy Men: A Thorough ECG Trial||VIVUS, Inc.|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|57|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 5, 2011|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00769041||149081|
NCT00769366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008|Randomized, Controlled Study on Short-Term Psychotherapy After Acute Myocardial Infarction|Randomized, Controlled Study on Short-Term Psychotherapy After Acute Myocardial Infarction: The Step-in-AMI Trial (Short TErm Psychotherapy IN Acute Myocardial Infarction)|STEP-IN-AMI|San Filippo Neri General Hospital|No|Recruiting|May 2005|||December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|70 Years|No|||September 2008|October 7, 2008|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769366||149056|
NCT00769379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00702|Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy|A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2008|||March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Female|18 Years|N/A|No|||December 2015|March 24, 2016|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769379||149055|
NCT00770185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I192|Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer|A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer||Canadian Cancer Trials Group|No|Completed|August 2008|February 2015|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|No|||February 2015|February 13, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770185||148997|
NCT00776919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114677|Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne|A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris||GlaxoSmithKline|No|Completed|October 2008|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1315|||Both|12 Years|45 Years|No|||February 2012|February 9, 2012|October 21, 2008|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00776919||148484|
NCT00776932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07040263|Chronic Knee Pain Study|Disparity in Joint Replacement: Pathway to Intervention|JRPIT|University of Pittsburgh|No|Completed|June 2007|June 2013|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|852|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|African Americans and Whites over the age of 50 with chronic knee pain.|May 2015|May 26, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00776932||148483|
NCT00776841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL No: TRC 037/10072|A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers||Galmed Medical Reserch|Yes|Completed|September 2008|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|41|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 2, 2010|October 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00776841||148490|
NCT00778115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B045521|Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions|A Relative Bioavailability Study of Loperamide HCl 2 mg and Simethicone 125 mg Tablets to Imodium® Advanced Caplets Under Fasting Condition||Ranbaxy Inc.|Yes|Completed|November 2004|December 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778115||148393|
NCT00778128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4126-111|A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour|A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour||Clavis Pharma|No|Completed|October 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||September 2010|September 3, 2010|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778128||148392|
NCT00778401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-825|Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Fasting Condition||Ranbaxy Inc.|Yes|Completed|October 2002|December 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778401||148371|
NCT00778414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60249|Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions|Randomized, Open - Label, 2 - Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 600mg - 42.9 mg/ 5 mL Oral Suspension and Augmentin ES - 600 (Reference) Following a 600 mg - 42.9 mg Dose in Healthy Subjects Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|June 2006|September 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778414||148370|
NCT00778440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08/90242|Risk Level of Suffering From Traffic Injury in Primary Health Care: LESIONAT Project|Risk Level of Suffering From Traffic Injury in Primary Health Care: LESIONAT Project|LESIONAT|Jordi Gol i Gurina Foundation|Yes|Enrolling by invitation|January 2009|September 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1540|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|drivers with active medical records of 16 years old or more|August 2009|August 6, 2009|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778440||148368|
NCT00778804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4159|Preventing Heart Disease in Underserved Patients|Preventing Heart Disease in Underserved Patients||Temple University|Yes|Completed|July 2004|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|465|||Both|22 Years|85 Years|No|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778804||148341|
NCT00779116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04574|Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)|A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications||Merck Sharp & Dohme Corp.|No|Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|217|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|October 23, 2008|Yes|Yes||No|February 17, 2010|https://clinicaltrials.gov/show/NCT00779116||148317|
NCT00779103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3326-300Former03-CPP-HIS-300|Histrelin Subcutaneous Implant in Children With Central Precocious Puberty|Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty||Endo Pharmaceuticals|No|Completed|September 2004|April 2012|Actual|August 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|2 Years|10 Years|No|||June 2015|June 8, 2015|October 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00779103||148318|
NCT00779740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04419|Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)|Clinical Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray||Merck Sharp & Dohme Corp.|No|Completed|February 2005|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|16 Years|N/A|No|||May 2015|May 4, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779740||148269|
NCT00779753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019880597|Determination of Lysine Requirement in the Parenterally Fed Neonate|Determination of Lysine Requirement in the Parenterally Fed Neonate||The Hospital for Sick Children|Yes|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|6|||Both|N/A|N/A|No|||August 2013|August 1, 2013|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779753||148268|
NCT00780026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00016106|Intraoperative Glucose Control in Liver Transplant|Effect Of Intraoperative Strict Glycemic Control During Liver Transplantation On Postoperative Morbidity And Mortality||University of Michigan|No|Recruiting|July 2008|July 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|90 Years|No|||October 2011|October 18, 2011|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00780026||148247|
NCT00779181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX415-301|A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension|A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension||Addrenex Pharmaceuticals, Inc.|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|75 Years|No|||December 2008|December 16, 2008|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779181||148312|
NCT00779194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#5658|Prospective Study of Rapamycin for the Treatment of SLE|Prospective Study of Rapamycin for the Treatment of SLE|Rapamune|State University of New York - Upstate Medical University|Yes|Active, not recruiting|October 2008|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 5, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779194||148311|
NCT00768755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061039|Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer|Randomized Phase 2 Study Of Cisplatin/Pemetrexed With Or Without Axitinib (AG-013736) As First-Line Treatment For Patients With Non-Squamous Non-Small Cell Lung Cancer||Pfizer|No|Completed|January 2009|March 2012|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|180|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 7, 2008|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00768755||149103|
NCT00769054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-035|Local Infiltration Analgesia With Ropivacaine in Posterior Vaginal Wall Prolapse:a Randomized, Double-Blind Study|Lokal Infiltrations Analgesi Med Ropivakain 1 % Versus Placebo VED Vaginale Descensusoperationer: ET Prospektivt Randomiseret, Dobbeltblindet, Placebo- Kontrolleret Studie||Hvidovre University Hospital||Completed|October 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|48|||Female|18 Years|N/A|No|||October 2008|July 8, 2010|October 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00769054||149080|
NCT00769067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471028|A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen|A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen||Pfizer||Completed|November 2008|August 2014|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|99 Years|No|||September 2015|September 22, 2015|October 7, 2008|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT00769067||149079|
NCT00769392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-076|Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection|Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection||Lahey Clinic|No|Active, not recruiting|September 2008|October 2012|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|40 Years|N/A|No|||May 2012|May 9, 2012|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769392||149054|
NCT00769301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154-08158d|Symptom Clusters in Cancer Patients and Their Caregivers- a Longitudinal Study|Advancing the Science of Symptom Management and Support for Cancer Patients and Their Caregivers||Oslo University Hospital|Yes|Active, not recruiting|November 2008|December 2014|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|DNA analyses for genotyping subgroups of patients based on their experience with pain,      fatigue, sleep disturbance and depression will test the hypothesis that gene polymorphisms      within the selected candidate genes will exhibit significant differences in frequency      distribution among the different patient subgroups that are identified through cluster      analysis.|Both|18 Years|N/A|No|Non-Probability Sample|500 cancer outpatients (125 with breast cancer and 125 with head and neck cancer receiving        radiation therapy and 125 ovarian cancer patients and 125 colon cancer patients receiving        chemotherapy)        and their caregivers|June 2011|June 29, 2011|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769301||149061|
NCT00769314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA2005/21/02|Phase 3 Clinical Study for the Treatment of Cold Sore|A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad® 50 mg Muco-adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients.|LIP|Onxeo|No|Completed|May 2007|August 2009|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1727|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|October 8, 2008|Yes|Yes||No|October 26, 2011|https://clinicaltrials.gov/show/NCT00769314||149060|
NCT00769327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML0408|Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia|Front-line Treatment of Philadelphia Positive (Ph Pos), BCRABL Positive, Chronic Myeloid Leukemia (CML) With Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imotinib) A Phase II Exploratory Multicentric Centre.|CML0408|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|February 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769327||149059|
NCT00769340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-0508-B|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2008|||||N/A|N/A|N/A||||||||||||||October 8, 2008|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00769340||149058|
NCT00769353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP2OD001210-01|Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness|Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness||University of Pittsburgh|Yes|Completed|January 2008|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|90|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00769353||149057|
NCT00769613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615167|Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections|Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections||National Cancer Institute (NCI)||Active, not recruiting|August 2008|||August 2014|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|2 Years|N/A|No|||August 2010|December 17, 2013|October 8, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00769613||149038|
NCT00769626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DES-529-2008|Standardizing Management of Patients With Low Back Pain in Primary Care and Physical Therapy|Standardizing Management of Patients With Low Back Pain in Primary Care and Physical Therapy: A Randomized Clinical Trial||Intermountain Health Care, Inc.|No|Terminated|September 2008|May 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|60 Years|No|||October 2008|July 15, 2011|October 8, 2008||No|Unable to recruit patients|No||https://clinicaltrials.gov/show/NCT00769626||149037|
NCT00769912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000799-25|Evaluation of of a Prefixed 50% N2O- 50%O2 Mixture in Legal Abortion Under Local Analgesia|Evaluation of of a Prefixed 50% N2O- 50%O2 Mixture in Legal Abortion Under Local Analgesia||Assistance Publique Hopitaux De Marseille|No|Completed|October 2008|June 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Female|18 Years|65 Years|No|||January 2011|August 28, 2014|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769912||149017|
NCT00770198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-gp130|sgp130 in Chronic Human Liver Disease|Study of IL-6 Transsignaling in Chronic Human Liver Disease||Erasme University Hospital|No|Completed|January 2005|October 2008|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|129|Samples Without DNA|plasma, liver biopsies, and peripheral blood mononuclear cell culture medium.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients of Erasme University Hospital|October 2008|October 8, 2008|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00770198||148996|
NCT00770497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS K023|Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.|Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-blinded Phase II Study.||Takeda|No|Completed|March 2007|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|172|||Both|30 Years|75 Years|No|||July 2010|July 1, 2010|October 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00770497||148973|
NCT00777270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS-PI051023|Continuous Versus Interrupted Sutures for Repair of Episiotomy or Second Degree Tears: a Randomised Controlled Trial|Continuous Versus Interrupted Sutures for Repair of Episiotomy or Second Degree Tears: a Randomised Controlled Trial||Hospital Universitario Principe de Asturias|Yes|Completed|September 2005|October 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|445|||Female|N/A|N/A|No|||October 2008|October 21, 2008|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777270||148457|
NCT00777309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-209|A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase 2 Study of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)||ArQule|No|Completed|September 2008|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|October 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777309||148454|
NCT00777205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 08-325|Improving Depression Management Through Peer Support|Improving Depression Management Through Peer Support|DIAL-UP|VA Office of Research and Development|Yes|Completed|February 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|443|||Both|18 Years|N/A|No|||November 2014|April 6, 2015|October 21, 2008||No||No|December 30, 2014|https://clinicaltrials.gov/show/NCT00777205||148462|56 of the patients randomized to the telephone-based peer support intervention were excluded from main study analyses because of an unforeseen disruption in their 6-month intervention that was unrelated to patient characteristics.
NCT00777543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-079|Increasing Ferulic Acid Bioavailability in Bran|The Effect of Pre-treatment of Bran on the Bioavailability of Ferulic Acid and Other Bioactive Compounds From Wholegrain Breads Enriched in Bran||Maastricht University Medical Center|No|Active, not recruiting|November 2008|December 2009|Anticipated|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|8|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 12, 2009|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00777543||148436|
NCT00777894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 77/07|Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|External Beam Radiotherapy for Unresectable Hepatocellular Carcinoma. A Multicenter Phase I/II Trial.||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|November 2008|December 2016|Anticipated|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|18 Years|N/A|No|||January 2015|January 18, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777894||148410|
NCT00777907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-0004|Complete Occlusion of Coilable Aneurysms|Complete Occlusion of Coilable Aneurysms|COCOA|Chestnut Medical Technologies|No|Completed|October 2008|April 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|21 Years|75 Years|No|||August 2015|August 5, 2015|October 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00777907||148409|
NCT00778141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B045503|Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions|A Relative Bioavailability Study of Metformin HCl 750 mg XR Tablets Under Non-Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|April 2004|June 2004|Actual|April 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|October 22, 2008|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00778141||148391|
NCT00778167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00286|Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase I/Randomized Phase II Study of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Completed|October 2008|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||March 2013|May 6, 2014|October 22, 2008|Yes|Yes||No|January 15, 2013|https://clinicaltrials.gov/show/NCT00778167||148389|Phase I of the study was completed but because of concerns about the achievable dose intensity at the maximum tolerated dose (MTD), the expansion into a randomized phase II study comparing full-dose erlotinib with the combination was cancelled.
NCT00778817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00291|IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery|Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone||National Cancer Institute (NCI)|Yes|Terminated|December 2008|March 2014|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2013|March 28, 2014|October 22, 2008|Yes|Yes|The trial was permanently halted due to futility concerns.|No|August 30, 2013|https://clinicaltrials.gov/show/NCT00778817||148340|After the treatment of 20 subjects, a protocol defined interim analysis was completed for safety and futility. The trial was permanently halted based on futility concerns.
NCT00778830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-505|Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)|An Asia Pacific Non-randomized, Open-label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)|APEC|Merck KGaA|No|Completed|February 2009|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|289|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|October 22, 2008||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT00778830||148339|
NCT00779129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02948|A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)|Phase II Trial of Caelyx and Cyclophosphamide in Metastatic Breast Cancer||Merck Sharp & Dohme Corp.|No|Completed|March 2003|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|75 Years|No|||September 2015|September 29, 2015|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00779129||148316|
NCT00779142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5865 Methotrexate|Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies|Evaluation of the Utility of Intravitreal Methotrexate in Patients With Recalcitrant Diabetic Macular Edema in an Open Label, Nonrandomized, Uncontrolled, Interventional Pilot Trial||Wake Forest School of Medicine|No|Terminated|September 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|85 Years|No|||June 2014|June 27, 2014|October 22, 2008|Yes|Yes|recent research indicates Lucentis to be an effictive treatment|No|May 27, 2014|https://clinicaltrials.gov/show/NCT00779142||148315|
NCT00779428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA200-002|Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin|Phase 2 Clinical Trial of Tanespimycin in Patients With Advanced Malignancies After Failure of Previous Anti-cancer Therapy Regimens Who Have Participated on a Prior Protocol Investigating Tanespimycin||Bristol-Myers Squibb|No|Completed|July 2006|July 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00779428||148293|
NCT00779766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107638|Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects|Efficacy, Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects||GlaxoSmithKline||Active, not recruiting|October 2008|January 2016|Anticipated|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6051|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|October 23, 2008|Yes|Yes||No|April 12, 2012|https://clinicaltrials.gov/show/NCT00779766||148267|At the time of the event-triggered analysis at Month 24, some safety results remain blinded and are not presented here since the study is still ongoing. These results will be updated once they become available.
NCT00780585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05719|A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)|A Multi-center Cardiac Safety Study of Subjects Who Participated in Organon Sponsored Phase 1 and Phase 2 Completed and Discontinued Trials With Org 24448||Merck Sharp & Dohme Corp.|No|Completed|April 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|95|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be selected from subjects who participated in previous Org 24448 trials|December 2014|December 18, 2014|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780585||148204|
NCT00780039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03625|A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)|Phase II, Open-Label, Study of CAELYX and Carboplatin Intermediate Platinum-Sensitive (6-12 Months Treatment-free Interval) Relapsed Epithelial Ovarian Cancer.||Merck Sharp & Dohme Corp.|No|Completed|October 2003|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Female|18 Years|N/A|No|||May 2015|May 19, 2015|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780039||148246|
NCT00780052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04701|Infusional C-myb ASODN in Advanced Hematologic Malignancies|Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies|UPCC 04701|University of Pennsylvania|Yes|Completed|September 2002|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||December 2011|December 19, 2011|October 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00780052||148245|
NCT00780065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V12-03|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2008|||||N/A|N/A|N/A||||||||||||||October 24, 2008|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780065||148244|
NCT00780910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A8|Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment||Mitsubishi Tanabe Pharma Corporation|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|20 Years|65 Years|No|||April 2014|April 16, 2014|October 24, 2008||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00780910||148181|
NCT00779831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA16795|Bioequivalence Study on Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions|Comparative, Randomized, Single Dose, 2 Way Crossover Bioavailability Study of Ranbaxy and Warner - Lambert (Sudafed ® 12 Hour) 120 mg Pseudoephedrine Hydrochloride Extended - Release Tablets in Healthy Adult Volunteers Under Fasting Conditions.||Ranbaxy Inc.|Yes|Completed|June 2004|December 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2008|October 23, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00779831||148262|
NCT00768768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-N-111|Iontophoretic Application of Terbinafine Gel to the Large Toe Nail|A Study of Skin/Nail Sensation and the Pharmacokinetics of the Uptake of Terbinafine in the Great Toe Nail and Systemically Following Treatment With the Electrokinetic Transungual System (ETS)-Terbinafine Gel in Healthy Normal Voluneteers||Transport Pharmaceuticals|No|Completed|October 2008|March 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2009|March 10, 2009|October 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00768768||149102|
NCT00769080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OCN-ARI-2008/1|The Performance of Patient Support Program in Early Stage Breast Cancer|A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence With Adjuvant Aromatase Inhibitors (AI) Medication for Postmenopausal, Early Stage Breast Cancer|ARI NIS|AstraZeneca|No|Completed|September 2008|October 2010|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|524|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women with hormone sensitive early breast cancers to whom have been        prescribed upfront adjuvant AI medication (aromatase inhibitors; anastrozole or letrozole)        according to the current product SmPC. The upfront AI medication must not have exceeded        eight weeks.|November 2011|November 28, 2011|October 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00769080||149078|
NCT00770224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615104|S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma|A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma||Southwest Oncology Group|No|Active, not recruiting|April 2009|December 2017|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|October 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00770224||148994|
NCT00769652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592862|Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer|The Influence of Changes in Body Composition on Quality of Life in Cancer Patients and The Impact of Medical Nutrition Therapy by a Registered Dietitian on Outcome||Rutgers, The State University of New Jersey|No|Terminated|October 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|8|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|October 8, 2008||No|slow accrual|No|November 15, 2013|https://clinicaltrials.gov/show/NCT00769652||149036|
NCT00769925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH072952|Assessing Different Methods of Anxiety Care in Pediatric Settings|Improving Care for Anxiety in Pediatric Settings||University of California, San Diego|Yes|Active, not recruiting|November 2008|February 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|8 Years|13 Years|No|||January 2012|January 6, 2012|October 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00769925||149016|
NCT00770211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201 - 0741 / 1|IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines.||Merz Pharmaceuticals GmbH|No|Completed|October 2008|June 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|N/A|No|||October 2011|October 5, 2011|October 8, 2008|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00770211||148995|
NCT00777582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00024|Phase I Comparative Bioavailability Study|A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours||AstraZeneca|No|Active, not recruiting|October 2008|March 2016|Anticipated|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|228|||Both|18 Years|130 Years|No|||March 2016|March 2, 2016|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777582||148433|
NCT00777868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-IDP-108-P2-01|A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis|||Dow Pharmaceutical Sciences||Completed|October 2007|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|135|||Both|18 Years|65 Years|No|||June 2012|June 20, 2012|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00777868||148412|
NCT00777881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 07-134|Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma|A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma||University of Pittsburgh|Yes|Active, not recruiting|January 2008|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00777881||148411|
NCT00791687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08/0027|Prenatal Corticosteroids and Antioxidants in Preterm Infants|Prenatal Corticosteroids Enhance the Antioxidant Defense System in Extremely Low Gestational Age Neonates|RESOX|Fundacion Para La Investigacion Hospital La Fe|No|Completed|January 2003|January 2005|Actual|January 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|57|||Both|N/A|N/A|No|Non-Probability Sample|Extremely low gestational age neonates < 28 weeks gestation whose mothers received or not        antenatal glucocorticosteroids.|November 2008|November 13, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791687||147365|
NCT00792220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSU|"Mobile Stroke-Unit" for Reduction of the Response Time in Ischemic Stroke|"Mobile Stroke-Unit" for Reduction of the Response Time in Ischemic Stroke|MSU|University Hospital, Saarland|Yes|Completed|November 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|80 Years|No|||May 2015|May 31, 2015|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00792220||147324|
NCT00791986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU-475090015-0|Loaded Breathing Training in Essential Hypertension|Effects of Loaded Breathing Training on Blood Pressure in Essential Hypertensive Patients||Khon Kaen University|Yes|Terminated|May 2006|December 2008|Anticipated|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|30|||Both|35 Years|65 Years|No|||November 2008|November 14, 2008|November 14, 2008||No|End of study time and budget permission|No||https://clinicaltrials.gov/show/NCT00791986||147342|
NCT00792467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/07/2357/31|Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients|Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients||Italfarmaco|Yes|Completed|February 2008|September 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792467||147305|
NCT00792480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIP 06-05-04A|Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial|Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial|WIP|Carolinas Medical Center|Yes|Terminated|October 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||November 2008|November 17, 2008|November 14, 2008||No|Resident research project limited by restrictions of residency program.|No||https://clinicaltrials.gov/show/NCT00792480||147304|
NCT00792805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2333|Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, 26-week Multicenter Randomized Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|November 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|563|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|November 17, 2008||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00792805||147280|
NCT00792792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2007-5891|Monitoring of Tissue Transfer Flaps by Modulated Imaging|Non-contact, Intra-operative & Post-operative Device, Evaluation of Tissue Transfer Flaps After Reconstructive Surgery.||University of California, Irvine|No|Recruiting|January 2007|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Study population will be selected from Surgical Department as outpatients and in-patient        bases that require reconstructive surgery using a pedicle or free tissue transfer flap.|February 2016|February 5, 2016|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792792||147281|
NCT00793052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-BS-062-CTIL|Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery|Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery: A Prospective, Double-Blind Study||Tel-Aviv Sourasky Medical Center|No|Active, not recruiting|November 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 16, 2008|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793052||147263|
NCT00793338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 05-369|Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure|Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure||University of New Mexico|Yes|Not yet recruiting|November 2008|February 2011|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2008|November 18, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793338||147241|
NCT00793585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGIgAN-002|A Controlled Study of Uric Acid on the Progression of IgA Nephropathy|A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy||Sun Yat-sen University|Yes|Completed|July 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|November 17, 2008||No||No|October 28, 2009|https://clinicaltrials.gov/show/NCT00793585||147223|
NCT00793598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-104|CMX001 in Post-transplant Patients With BK Virus Viruria|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria||Chimerix|Yes|Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2011|March 15, 2011|November 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793598||147222|
NCT00794495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03181|Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)|Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|December 2002|July 2003|Actual|July 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|122|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794495||147154|
NCT00795899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TECHNO|Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)|Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer||German Breast Group|Yes|Completed|January 2002|September 2008|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|230|||Female|18 Years|65 Years|No|||August 2011|August 15, 2011|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795899||147050|
NCT00795912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVUH -HFU-015|A Study Of The Usage Of Statins In A Community Heart Failure Population|A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis||St Vincent's University Hospital, Ireland|Yes|Completed|May 2003|January 2008|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 20, 2008|November 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00795912||147049|
NCT00796159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0021004|Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide|A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension||Pfizer|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1723|||Both|18 Years|65 Years|No|Non-Probability Sample|Filipino patients with Uncontrolled Mild to Moderate Essential Hypertension|December 2009|December 21, 2009|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00796159||147031|
NCT00796172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601|Evaluating the Effectiveness of a Computerized Medication Adherence System at Reducing Cardiovascular Disease Risk Factors|Clinic-based Intervention to Improve Medication Adherence to Reduce Cardiovascular Disease Risks||PHCC LP||Completed|December 2008|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|308|||Both|19 Years|80 Years|No|||April 2015|April 27, 2015|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796172||147030|
NCT00796627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00018037|HIF-1 Regulated Endothelial Progenitor Cell (EPC) Recruitment in Burn Wound Healing|HIF-1 Regulated Endothelial Progenitor Cell Recruitment in Burn Wound Healing||Johns Hopkins University|No|Recruiting|December 2006|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|14 Years|75 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796627||146996|
NCT00796640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004279|A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations|A Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics Under Fasting and Fed Conditions of 2 Paliperidone Extended-release Pellet Formulations With Paliperidone Oral Solution in Healthy Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2003|November 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796640||146995|
NCT00796653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.14|Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|January 2009|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|937|||Both|40 Years|N/A|No|||June 2014|June 17, 2014|November 21, 2008||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00796653||146994|
NCT00800878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03TW007588|Chronic Kidney Disease in Pakistani Population|Chronic Kidney Disease in the Pakistani Population|CKD|Aga Khan University||Recruiting|February 2008|April 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|650|||Both|40 Years|N/A|No|Probability Sample|All individuals aged aged 40 years and above in a representative sample of Karachi        Demographic Survey constituted the sampling frame. Individuals were screened for        hypertension and diabetes and the final sample of about 650 subjects will be randomly        selected|November 2008|December 8, 2008|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800878||146676|
NCT00800891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODF0801CTIL|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||April 1, 2009|November 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800891||146675|
NCT00791427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4154s|ERG/EOG Study in AMD Patients Treated With Ranibizumab|ERG/EOG Study in AMD Patients Treated With Ranibizumab|FVF4154s|Retina Center, Minnesota||Completed|November 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|55 Years|N/A|No|Non-Probability Sample|Patients will have AMD with choroidal neovascularization and above age 55 years.|May 2015|May 7, 2015|November 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791427||147385|
NCT00790478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8173|Melatonin & Ulcerative Colitis|Melatonin and Ulcerative Colitis: A Pilot Clinical Trial|Melatonin & UC|Emory University|Yes|Recruiting|January 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||February 2009|December 22, 2009|November 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00790478||147457|
NCT00790491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-11|Automated Guidance Tool for Medical Encounters Addressing Therapeutic Lifestyle Changes (AuGMEnT).|Automated Guidance Tool for Medical Encounters Addressing Therapeutic Lifestyle Changes (AuGMEnT)||Griffin Hospital|No|Completed|October 2007|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|240|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790491||147456|
NCT00790751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-301|Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in Subjects With Generalized Erectile Dysfunction|REVIVE|VIVUS, Inc.|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|646|||Male|18 Years|N/A|No|||June 2012|June 27, 2012|November 10, 2008|Yes|Yes||No|May 25, 2012|https://clinicaltrials.gov/show/NCT00790751||147437|
NCT00791076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010957|The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients|The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 (Auto-immune) and Post-pancreatectomy Diabetic Patients||Johns Hopkins University|No|Active, not recruiting|October 2007|June 2011|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||March 2010|March 25, 2010|November 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791076||147412|
NCT00792259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Topcon 01|Topcon 3D OCT-1000 Optical Coherence Tomography System|Topcon 3D OCT-1000 Optical Coherence Tomography System for Measurements of Retinal and RNFL Thicknesses: Precision and Agreement Study||Topcon Medical Systems, Inc.|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|ophthalmology practice|June 2015|June 15, 2015|November 14, 2008|No|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00792259||147321|
NCT00792272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-013|Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients|Prevalence of Aspirin Resistance in Hemodialysis Patients||Northwell Health|Yes|Completed|June 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|all hemodialysis patients on aspirin|July 2013|July 19, 2013|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792272||147320|
NCT00791674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50/07|Opiate Sleep Disordered Breathing Study|Sleep Disordered Breathing in Patients With Chronic Pain and Long Term Opiate Therapy||Adelaide Institute for Sleep Health|No|Recruiting|December 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Pain clinic outpatients were contacted if they were on the specified doses (|November 2008|November 13, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791674||147366|
NCT00792246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004318|Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease|Define the Pharmacokinetics of Oral Voriconazole in Children With Extensive Gastrointestinal Graft Versus Host Disease||Duke University|No|Completed|December 2008|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|N/A|18 Years|No|||November 2012|November 9, 2012|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00792246||147322|
NCT00792233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60 AR047784-Project 2|Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA|Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA||Children's Hospital Medical Center, Cincinnati|Yes|Completed|June 2009|October 2015|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|4 Years|20 Years|No|||January 2016|January 5, 2016|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792233||147323|
NCT00793351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-073|Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation With Reduced-intensity Conditioning in Children With Neuroblastoma Who Have Failed a Prior Autologous Transplantation||Samsung Medical Center|Yes|Active, not recruiting|September 2008|March 2016|Anticipated|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|20 Years|No|||November 2015|November 23, 2015|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793351||147240|
NCT00793650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080-2005|Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study|Combination High Dose Melphalan and Autologous PBSC Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study||Emory University|Yes|Terminated|May 2005|September 2011|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||August 2012|August 17, 2012|November 17, 2008|No|Yes||No|March 14, 2012|https://clinicaltrials.gov/show/NCT00793650||147218|
NCT00793065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508190240|Evaluating the Effects of EHRs, P4P and Medical Home Redesign in the Hudson Valley|Evaluating the Effects of EHRs, P4P and Medical Home Redesign in the Hudson Valley||Weill Medical College of Cornell University|No|Active, not recruiting|October 2008|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All primary care physicians (i.e. general internists, pediatricians and family practice        physicians) in the Hudson Valley who are members of the Taconic Independent Practice        Association (IPA).|June 2013|June 17, 2013|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00793065||147262|
NCT00793910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAMC WU# 08-6960|Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy|Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial||Walter Reed Army Medical Center||Completed|July 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 10, 2014|November 18, 2008||No||No|November 21, 2011|https://clinicaltrials.gov/show/NCT00793910||147198|
NCT00793611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-102|Hypnotherapy for Treatment of Overactive Bladder|Hypnotherapy for Treatment of Overactive Bladder: A Feasibility Study||University of New Mexico|Yes|Completed|November 2008|March 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 20, 2011|October 6, 2008||No||No|August 16, 2011|https://clinicaltrials.gov/show/NCT00793611||147221|
NCT00793624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.13|Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|February 2009|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|906|||Both|40 Years|N/A|No|||June 2014|June 17, 2014|November 18, 2008||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00793624||147220|
NCT00796185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004270|As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations|Comparison of Steady-state Pharmacokinetics of Paliperidone After Extended-release OROS� Paliperidone 15 mg and Immediate-release Oral Risperidone 8 mg b.i.d. in Subjects With Schizophrenia or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2003|January 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|62|||Both|18 Years|50 Years|No|||March 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796185||147029|
NCT00796198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COS16102007|Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure|A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy||University of Turin, Italy|No|Not yet recruiting|December 2008|July 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|65 Years|No|||November 2008|November 24, 2008|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796198||147028|
NCT00796211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRx-197-002|A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis|A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis|197-002|Zalicus|No|Completed|November 2008|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|20|||Both|18 Years|70 Years|No|||January 2009|January 14, 2009|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796211||147027|
NCT00796224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661190|Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media|A Open Label, Randomized, Single Dose, Parallel Arm Study To Determine Pharmacokinetics Of Azithromycin Following Oral Administration Of Immediate-Release Or Extended-Release Formulation In Pediatric Subjects With Acute Otitis Media||Pfizer|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|6 Months|11 Years|No|||February 2010|February 1, 2010|November 18, 2008|Yes|Yes||No|December 15, 2009|https://clinicaltrials.gov/show/NCT00796224||147026|
NCT00801229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000971|Effect of Vyvanse on Driving in Young Adults With ADHD|The Effects of Vyvanse on the Driving Performance of Young Adults With ADHD: A Randomized, Double-Blind, Placebo-Controlled Study||Massachusetts General Hospital|No|Completed|December 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|24 Years|No|||February 2014|February 5, 2014|December 2, 2008|Yes|Yes||No|June 20, 2011|https://clinicaltrials.gov/show/NCT00801229||146649|
NCT00801242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS29|Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer|An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy||Ferring Pharmaceuticals|No|Completed|December 2008|July 2013|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|220|||Male|18 Years|N/A|No|||September 2014|September 2, 2014|December 2, 2008|Yes|Yes||No|August 8, 2014|https://clinicaltrials.gov/show/NCT00801242||146648|
NCT00791713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR007561|A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER|A Randomized, Open-label, Single-center, Crossover Study of the Potential Effects of Paroxetine on the Pharmacokinetics of a Single Dose of Paliperidone Extended-release in Healthy Men||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2006|July 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|May 18, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791713||147363|
NCT00791726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-448-f-S|Microperimetry in Macular Edema|Place of Fundus-related Microperimetry in Uveitic Macular Edema||St. Franziskus Hospital|No|Completed|November 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with noninfectious uveitis, macular edema|March 2011|July 19, 2011|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791726||147362|
NCT00791089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVZ111900|Effects of Fish Oil on Post Ablation Arrhythmias|Effect of Omega-3 Fatty Acids on Short and Long-Term Maintenance of Sinus Rhythm After Radiofrequency Catheter Ablation for Atrial Fibrillation||University of Michigan|Yes|Recruiting|November 2008|October 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||November 2008|November 13, 2008|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00791089||147411|
NCT00791102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16504B (ASP2002-AR-01)|Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC)||University of Chicago|No|Completed|January 2010|December 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|55 Years|Accepts Healthy Volunteers|||July 2013|July 8, 2013|November 13, 2008|Yes|Yes||No|March 6, 2013|https://clinicaltrials.gov/show/NCT00791102||147410|
NCT00791401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004207|A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function|The Pharmacokinetics of ER OROS Paliperidone in Subjects With Varying Degrees of Impaired Renal Function (Mild, Moderate, and Severe) as Compared to Subjects With Normal Renal Function||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|April 2004|February 2005|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2010|June 9, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791401||147387|
NCT00791414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB # 20071829|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2007|||||N/A|N/A|N/A||||||||||||||March 2, 2009|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791414||147386|
NCT00792558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA195-001|Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers|A Phase I Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb||Withdrawn|January 2009|November 2010|Anticipated|November 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2009|August 31, 2015|November 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00792558||147299|
NCT00791999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDP870-275-08-001|Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX.||Otsuka Pharmaceutical Co., Ltd.|No|Completed|November 2008|January 2011|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|316|||Both|20 Years|74 Years|No|||August 2012|August 9, 2012|November 14, 2008||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00791999||147341|
NCT00792818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si134/2008|The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen in Knee Osteoarthritis|The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen for Therapy of Patients With Knee Osteoarthritis, the Randomized Double-blinded Controlled Trial, Multicenter Study||Mahidol University|Yes|Completed|December 2008|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|367|||Both|50 Years|75 Years|No|||October 2012|October 27, 2012|November 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00792818||147279|
NCT00792506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/07/2357/29|Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma|Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma||Italfarmaco||Terminated|October 2008|July 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2012|May 23, 2013|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792506||147302|
NCT00792519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703002442|Cognitive Behavioral Treatment to Reduce Alcohol Use Among HIV-Infected Kenyans|Alcohol & HIV in Kenya: Stage 1 Trial of a Peer-Led Alcohol Behavior Intervention|KHBS|Brown University|Yes|Completed|February 2009|December 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||January 2011|June 20, 2011|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792519||147301|
NCT00793923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lucedex|A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD|A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet Age-related Macular Degeneration|Lucedex|Bay Area Retina Associates|No|Completed|January 2008|December 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|40|||Both|50 Years|N/A|No|||December 2012|December 18, 2012|November 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793923||147197|
NCT00799539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015310|A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients|An International Single-Arm Study to Provide Further Safety and Efficacy Data on the Bortezomib(Velcade)/Melphalan/Prednisone Regimen in Previously Untreated Transplant Ineligible Multiple Myeloma Patients||Janssen-Ortho Inc., Canada|No|No longer available||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|99 Years|No|||November 2015|November 30, 2015|November 26, 2008||No|Company decision to cancel due to public funding|No||https://clinicaltrials.gov/show/NCT00799539||146778|
NCT00793637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLS-Pre-08|Evaluation of Handling and Possible Complications Related to the Newly Developed Angular Stable Locking System (ASLS)|Prospective Multicenter Case Series to Evaluate Handling and Possible Complications Related to the Angular Stable Locking System in Patients With Proximal and Distal Tibial, Femoral and Humeral Fractures Treated With Intramedullary Nails|ASLS-Pre|AO Clinical Investigation and Documentation|No|Completed|August 2008|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|orthopedic clinics|August 2009|August 5, 2009|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793637||147219|
NCT00794508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA Gene Therapy|MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID|MND-ADA Transduction Of CD34+ Cells From The Umbilical Cord Blood Of Infants Or The Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)||University of California, Los Angeles|Yes|Active, not recruiting|November 2008|December 2029|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Month|18 Years|No|||March 2015|March 31, 2015|November 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00794508||147153|
NCT00794534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBC-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||November 19, 2008|November 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794534||147152|
NCT00794547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.042|Phase I/II Calcitriol in Lung Cancer|A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer||University of Michigan Cancer Center|Yes|Terminated|December 2008|August 2013|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|November 19, 2008|Yes|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT00794547||147151|
NCT00794196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS PI070546|Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care|Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing|PRODEFAR|Fundació Sant Joan de Déu|No|Active, not recruiting|October 2008|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|75 Years|No|||July 2011|July 22, 2011|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00794196||147177|
NCT00794482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-03/2006 (CIR)|Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.|A Multi-centre, Multi-national Open Study in Patients With Hepatic Cirrhosis to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.||Norgine|Yes|Completed|March 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1200|||Both|18 Years|80 Years|No|||October 2009|October 7, 2009|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794482||147155|
NCT00790244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2007-001152-39|A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall|A Scandinavian Sarcoma Group Treatment Protocol for Adult Patients With Non-metastatic High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall|SSGXX|Oslo University Hospital|Yes|Recruiting|October 2007|October 2022|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|188|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2008|July 3, 2011|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790244||147475|
NCT00790257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-HIA-002|Safety and Efficacy Study of Encapsulated Human Islets Allotransplantation to Treat Type 1 Diabetes|A Monocentre Phase 1 Trial to Assess a Monolayer Cellular Device in the Treatment of Type 1 Diabetes||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|November 2008|April 2019|Anticipated|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|30 Years|80 Years|No|||May 2015|May 19, 2015|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790257||147474|
NCT00795652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3556|Mom: Managing Our Mood, Part of The Family Help Program|Evidence-based, Distance Treatment for Postpartum Depression, Mom: Managing Our Mood, Part of The Family Help Program|MOM|IWK Health Centre|No|Completed|May 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|19 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795652||147069|
NCT00795665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626157|Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma|Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas|UCDCC#208|University of California, Davis|Yes|Completed|June 2008|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00795665||147068|
NCT00795925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOGEPHA-8403030|Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder|Dose-Escalating Study of Propiverine Hydrochloride (Mictonetten®) in Children Suffering From Frequency-Urgency-Syndrome and Urinary Incontinence Indicative of Detrusor Overactivity (Overactive Bladder)||APOGEPHA Arzneimittel GmbH||Completed|October 2004|December 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|30|||Both|5 Years|10 Years|No|||November 2008|November 20, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00795925||147048|
NCT00795938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481266|Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.|An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of An Experimental Tablet Of Sildenafil With Or Without Water Relative To Viagra® Conventional Oral Tablet With Water.||Pfizer|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795938||147047|
NCT00800904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RTH-DUM-2008/1|Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand|Asthma Control Among Patients Who Were Receiving Inhaled Corticosteroids in General Practice in Thailand||AstraZeneca|No|Completed|May 2009|November 2009|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1210|||Both|12 Years|N/A|No|Non-Probability Sample|Patient aged 12 years and older who established persistent asthma and currently treated        with any inhaled corticosteroid for 3 months or longer.|December 2010|December 2, 2010|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800904||146674|
NCT00800917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEV-CCI-779-GBM-02|A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme|A Phase II Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme||Rigshospitalet, Denmark|No|Completed|November 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2010|June 1, 2010|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800917||146673|
NCT00800930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-031|Therapeutic Induction of Endogenous Antibiotics|Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|January 2005|January 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|55 Years|No|||December 2008|December 6, 2011|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00800930||146672|
NCT00801255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP22205|A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients|A Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability and Antiviral Activity of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591) in Genotype 1 Chronic Hepatitis C Patients. INFORM 1||Hoffmann-La Roche||Completed|November 2008|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|88|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801255||146647|
NCT00791752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2060C00001|Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017|A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase 1Study in Healthy Volunteers to Assess the Safety, Tolerability andPharmacokinetics of AZD4017 After Single Ascending Oral Doses||AstraZeneca||Completed|November 2008|March 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 15, 2009|November 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00791752||147360|
NCT00802841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2404|Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib|A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib|LASOR|Novartis|Yes|Completed|May 2009|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|191|||Both|16 Years|N/A|No|||October 2015|October 15, 2015|December 3, 2008|Yes|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT00802841||146526|
NCT00791700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001031|An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children|An Open-label, Multicenter, Multiple-dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-experienced Ccr5-tropic Hiv-1 Infected Children 2 - <18 Years Of Age||ViiV Healthcare|Yes|Active, not recruiting|April 2009|July 2019|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|2 Years|18 Years|No|||January 2016|January 28, 2016|November 12, 2008|Yes|Yes||No|October 6, 2015|https://clinicaltrials.gov/show/NCT00791700||147364|Although the Participant Flow Table title indicates "Overall Study", the data presented in that table is Subject Discontinuations Through Week 48. The study is ongoing.
NCT00792012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0562.cc|A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma|A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)||University of Colorado, Denver|Yes|Active, not recruiting|November 2005|November 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00792012||147340|
NCT00792571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS-MR-PAH-202|An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients|An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients.||Lung Biotechnology PBC|No|Completed|February 2009|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|75 Years|No|||May 2014|May 19, 2014|November 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792571||147298|
NCT00792532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iMRI|Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes|Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes|iMRI|University of California, San Francisco|No|Recruiting|July 2003|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|N/A|No|||May 2015|May 20, 2015|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792532||147300|
NCT00793104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP2008|Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.|Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Focal Cartilage Lesions in the Femoral Condyle||RTI Surgical|No|Terminated|November 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|November 17, 2008||No|Slow enrolment & potential regulatory changes for allograft in cartilage repair|No|July 12, 2013|https://clinicaltrials.gov/show/NCT00793104||147259|Enrollment was closed early due for 2 factors:1) Slow enrollment and 2) A potential change in the regulatory pathway for allografts used in cartilage repair1 patient was lost to follow up, with no data collected at the 24-month visit.
NCT00793078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCS2009|Arterial Blood Pressure-complexity in Septic Patients|Investigation of Arterial Blood Pressure-complexity and Its Relation to Outcome in Comparison Between Cardiac Surgery Versus Non-cardiac Surgery Septic Patients||University Hospital, Bonn|No|Suspended|January 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|72|||Both|18 Years|N/A|No|Probability Sample|patients treated at the Intensive Care Unit of a University Hospital|January 2011|February 28, 2011|November 17, 2008||No|Awaiting decision on financial support by Deutsche Forschungsgemeinschaft (DFG)|No||https://clinicaltrials.gov/show/NCT00793078||147261|
NCT00793091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-0109|Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract|A Phase 2, Randomized, Placebo-Controlled, Double-Masked, Multicenter Safety and Efficacy Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Acuity Due to Age-Related Cataract||Chakshu Research, Inc.|No|Recruiting|November 2008|September 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|85 Years|No|||November 2008|November 26, 2008|November 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793091||147260|
NCT00799552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004-03|Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye|A Phase II, Multi-Center, Double-Masked, Randomized, Placebo Controlled, Study on the Safety and Efficacy of RX-10045 on the Signs and Symptoms of Dry Eye in Every Day Environmental Conditions and During Provocation Using the Controlled Adverse Environment (CAE) Model||Resolvyx Pharmaceuticals, Inc|Yes|Completed|November 2008|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|No|||September 2010|September 20, 2010|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799552||146777|
NCT00799812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT 371-121|Test for Preoperative Skin Preparations|ChloraPrep Triple Swabsticks, Hibiclens and Sterile Triple Swabsticks (Using Sterile Deionized Water)||CareFusion|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|5||Actual|111|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799812||146757|
NCT00793936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160.08|Criteria for Choice of Right Double Lumen Tube (DLT)|Criteria for Choice of Right Double Lumen Tube for Lung Surgery||Assaf-Harofeh Medical Center|Yes|Not yet recruiting|November 2008|December 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|After obtaining informed consent, male and female patients over 18 years of age,        candidates for elective thoracic surgery obliging DLT intubation, will be enrolled in the        study. Children, pregnant and mentally incompetent patients will not be included.|November 2008|November 18, 2008|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793936||147196|
NCT00794209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEF-07|Study Evaluating Inhaled AeroLEF Delivered in 4 Aerosol Delivery Devices in Healthy Volunteers|Phase lb, Five Period Crossover, Open-Label Study Evaluating a Single Dose Administration of 3mL or 5mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 Mcg/mL), Delivered by up to Four Aerosol Delivery Devices in Healthy Subjects|LEF-07|YM BioSciences|No|Completed|March 2003|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|November 17, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00794209||147176|
NCT00800111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFA2008-01|Study of Endothelial Keratoplasty Outcomes|Open-enrollment, Prospective Study of Endothelial Keratoplasty Outcomes||Cornea Research Foundation of America|Yes|Recruiting|February 2008|||February 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4000|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00800111||146735|
NCT00800124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNC2008|Study on Cemented Versus Non-cemented Hemiarthroplasty in Elderly With Hip Fractures|A Prospective Randomized Multicenter Study on Cemented and Non-cemented Hemiprosthesis in Older Patients With Dislocated Hip Fracture.|CNC|Sykehuset Innlandet HF|No|Completed|June 2005|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|334|||Both|75 Years|N/A|No|||November 2008|November 21, 2014|November 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00800124||146734|
NCT00800384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2007|Shockless Implant Evaluation|Shockless Implant Evaluation|SIMPLE|Boston Scientific Corporation|Yes|Completed|January 2009|May 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|2500|||Both|18 Years|N/A|No|||March 2014|January 5, 2016|November 27, 2008|Yes|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT00800384||146714|
NCT00800397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MorpheusHx002|Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients|Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients||WideMed LTD.|Yes|Completed|December 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|cardiac and suspected sleep disordered breathing patients|August 2009|August 11, 2009|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800397||146713|
NCT00800683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.43|Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive|Safety in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 vs. Placebo, DB, Parallel Group, Randomized, Insulin Background Inclusive||Boehringer Ingelheim||Completed|December 2008|||January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|80 Years|No|||May 2014|May 15, 2014|December 1, 2008||||No|December 30, 2011|https://clinicaltrials.gov/show/NCT00800683||146691|
NCT00800696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/08|Preventive Oral Care|||Shaare Zedek Medical Center||Active, not recruiting|September 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|66|||Both|3 Months|40 Years|No|||April 2011|April 20, 2011|November 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00800696||146690|
NCT00801008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-091-01-CPPB|Exercise and Relaxation Intervention for Young Adult Cancer Survivors|||The Miriam Hospital|No|Recruiting|July 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|39 Years|No|||April 2012|April 19, 2012|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801008||146666|
NCT00800280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361030|Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body|A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of Steady-State Cimetidine On The Pharmacokinetics Of A Single Dose Of PD 0332334 In Healthy Subjects||Pfizer|No|Terminated|January 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 16, 2010|December 1, 2008|No|Yes|Please see Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00800280||146722|
NCT00800293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10216925|Randomized Study to Compare the Bioavailability of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams|Bioequivalence of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams||Perrigo Company|No|Completed|December 2002|January 2003|Actual|January 2003|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|116|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|March 2012|March 15, 2012|November 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00800293||146721|
NCT00800592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481262|Sildenafil IV Bolus Study|An Open Single Dose Study To Assess The Safety, Tolerability And Pharmacokinetics Of An Intravenous Bolus Dose (10 Mg) Of Sildenafil In Patients With Pulmonary Arterial Hypertension (PAH).||Pfizer|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||May 2011|May 30, 2011|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00800592||146698|
NCT00800605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|720802|Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection|Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection||Nanotherapeutics, Inc.|Yes|Completed|December 2008|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|7252|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2015|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800605||146697|
NCT00800618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0461002|A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women|A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration, Pharmacology And Pharmacokinetics, Of Multiple Doses Of PF-02413873 In Healthy Female Subjects.||Pfizer|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|42|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2010|February 9, 2010|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800618||146696|
NCT00800631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200708002R|The Biomarker and Cardiac Function in Sepsis|The Biomarker and Associated Cardiac Function in the Patients With Sepsis||National Taiwan University Hospital|Yes|Recruiting|January 2008|December 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|sepsis|December 2008|December 1, 2008|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800631||146695|
NCT00803361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11517|Duloxetine for the Treatment of Generalized Anxiety Disorder|Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China||Eli Lilly and Company|No|Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|N/A|No|||November 2010|November 19, 2010|December 3, 2008|Yes|Yes||No|November 19, 2010|https://clinicaltrials.gov/show/NCT00803361||146486|
NCT00803374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-007|Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma|A Phase I, Multiple Ascending Dose Study of BMS-663513 (Anti CD137) in Combination With Ipilimumab (BMS-734016/Anti-CTLA-4) in Subjects With Unresectable Stage III or Stage IV Melanoma||Bristol-Myers Squibb|No|Withdrawn|November 2010|January 2013|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||November 2011|November 18, 2011|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803374||146485|
NCT00803140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81818CSSvC|Cutaneous Scarring of Scalpel Versus Cautery|A Pilot Study Comparing Cutaneous Scarring When Scalpel Versus Cautery is Used to Make Skin Incisions||Scott and White Hospital & Clinic|No|Terminated|November 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|December 3, 2008||No|Slow accrual of subject enrollment.|No||https://clinicaltrials.gov/show/NCT00803140||146503|
NCT00792025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000618219|Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer|A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent®) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease||National Cancer Institute (NCI)||Completed|December 2008|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2009|May 14, 2011|November 14, 2008||||No||https://clinicaltrials.gov/show/NCT00792025||147339|
NCT00792038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080161|Effect of Cognitive Behavioral Therapy in OCD Highlighted by Neuropsychological Tests and MRI: Pathophysiology and Treatment Outcome Predictors|Effect of Cognitive Behavioral Therapy in OCD Highlighted by Neuropsychological Tests and MRI: Pathophysiology and Treatment Outcome Predictors||University of Aarhus|Yes|Completed|January 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|88|Samples With DNA|Full blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|OCD patients from the primary care clinics in middle Jutland, Denmark|August 2012|August 1, 2012|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792038||147338|
NCT00792285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-SR CRC|RCT of Automated Telephone Outreach to Improve Colorectal Cancer Screening|Automated Telephone Outreach With Speech Recognition to Improve Colorectal Cancer Screening: A Randomized Controlled Trial||Harvard Pilgrim Health Care|No|Completed|March 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80000|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||November 2008|November 13, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00792285||147319|
NCT00792298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-006|Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)|A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK-4305 in Patients With Primary Insomnia||Merck Sharp & Dohme Corp.||Completed|November 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|254|||Both|18 Years|64 Years|No|||February 2015|February 23, 2015|November 10, 2008|Yes|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT00792298||147318|
NCT00792831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/06/2357/21|Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia|Open Label, Uncontrolled, Pilot, Phase II Study of Histone-deacetylase Inhibitor ITF2357 Administered Orally to Subjects With Chronic Lymphocytic Leukemia (CLL) Refractory/Relapsed After Conventional Chemotherapy or Relapsed After Autologous Bone Marrow Transplantation||Italfarmaco|Yes|Terminated|February 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||February 2012|May 23, 2013|November 14, 2008||No|protocol needs complete restructuring in order to make it feasible and to complete the    enrollment of 23 patients|No||https://clinicaltrials.gov/show/NCT00792831||147278|
NCT00803127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-7-25.2-1|VS-Sense Result Reading Clarity|VS-Sense Result Reading Clarity||Carmel Medical Center||Completed|January 2009|May 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|VAGINAL DISCHARGE|Female|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Symptomatic and asymptomatic women, ages 18 and above.|August 2009|August 10, 2009|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803127||146504|
NCT00793364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINERVA 01|Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet|Effect of Plant Stanol Ester-Containing Spread Based on Extra Virgin Olive Oil on Estimated Cardiovascular Risk, and Lipid-Inflammatory-Haemostatic Factors in Comparison to Mediterranean Diet: A Randomized, Placebo-Controlled Trial.||Hellenic Atherosclerosis Society|Yes|Completed|November 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|150|||Both|45 Years|80 Years|No|||May 2009|May 27, 2009|November 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793364||147239|
NCT00793377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gepar-Duo|Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer|A Randomized, Multicenter, Open Phase III Study Comparing a Dose-Intensified 8 Week Schedule of Adriamycin and Docetaxel (ADOC) With a Sequential 24 Week Schedule of Adriamycin/Cyclophosphamide Followed by Docetaxel (AC-DOC) Regimen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast (T2-3 N0-2 M0)||German Breast Group||Completed||September 2001|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|913|||Female|18 Years|N/A|No|||November 2008|November 18, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793377||147238|
NCT00799825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111955|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008||GlaxoSmithKline||Completed|January 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|346|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 18, 2013|November 26, 2008|Yes|Yes||No|July 18, 2013|https://clinicaltrials.gov/show/NCT00799825||146756|
NCT00799799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK TRIAL|Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells|Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells||University of Bologna|Yes|Recruiting|October 2005|December 2009|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2009|September 23, 2009|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00799799||146758|
NCT00800709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT_12484A|Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease|Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study||Shanghai Mental Health Center|Yes|Completed|July 2008|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|26|||Both|50 Years|90 Years|No|||December 2010|December 2, 2010|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00800709||146689|
NCT00801034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2008.01.SKM|The Effects of Potassium on Physiological and Cardiovascular Variables in Healthy Persons|The Effects of Potassium on Physiological Variables in the Kidney and Cardiovascular Variables in Healthy Persons in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study||Regional Hospital Holstebro|Yes|Completed|November 2008|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|August 19, 2015|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801034||146664|
NCT00801047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rem-epi-nov-2008- HMO-CTIL|Intravenous Remifentanil Patient-controlled Analgesia (PCA) and Epidural Patient Controlled Epidural Analgesia (PCEA) for Labor Analgesia|Comparison of the Efficacy Intravenous Remifentanil PCA and Epidural PCEA for Labor Analgesia||Hadassah Medical Organization|No|Completed|February 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|40 Years|No|||February 2010|April 19, 2015|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801047||146663|
NCT00799760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060209|Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir|Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomises Double Blind Controlled Trial Study|BIVIR|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|December 2008|November 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|541|||Both|18 Years|N/A|No|||November 2008|March 16, 2012|November 28, 2008||No|Just Terminated for the end of the pandemia|No||https://clinicaltrials.gov/show/NCT00799760||146761|
NCT00800046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. 1436|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||December 1, 2015|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800046||146740|
NCT00800059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008519-01H|Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma|A Dose Escalation Study of Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM)|TMI-ASCT|Ottawa Hospital Research Institute|Yes|Recruiting|November 2008|November 2025|Anticipated|November 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|60 Years|No|||July 2015|July 23, 2015|November 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00800059||146739|
NCT00800306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102|Effects of Levosimendan on Microcirculation in Septic Shock|Levosimendan and Inhaled Nitric Oxide for Resuscitating the Microcirculation in Septic Shock. A Randomized Controlled Trial||University of Roma La Sapienza|No|Completed|November 2007|April 2009|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2009|October 14, 2009|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800306||146720|
NCT00802451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10216928|Bioavailability Study of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations|A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations||Perrigo Company|No|Completed|February 2003|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802451||146556|
NCT00802464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112077|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years|Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older||GlaxoSmithKline||Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|410|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 21, 2010|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802464||146555|
NCT00803101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE1116_3003|An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure|An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure|BE1116_3003|CSL Behring||Completed|February 2009|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|N/A|No|||March 2014|March 18, 2015|December 4, 2008|Yes|Yes||No|January 12, 2014|https://clinicaltrials.gov/show/NCT00803101||146506|
NCT00802854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851025|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (Registered) Iv||Pfizer|No|Recruiting|March 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|200 subjects will be studied according to the review result by the MFDS for the request        for the adjustment of number of subjects.        To achieve the target sample size, the study is being conducted in prospective study        design and retrospective study design.          1. Prospective Study -Subjects will be enrolled by continuous registration method.          2. Retrospective Study -Physician should enroll patients consecutively who had received             at least one dose of Eraxis IV after Eraxis IV approval date (30 May 2008).|October 2015|October 27, 2015|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802854||146525|
NCT00802542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CLV-ATA-2008/1|In-practice Evaluation of Atacand 16mg Antihypertensive Effect|In-practice Evaluation of Atacand 16mg Antihypertensive Effect||AstraZeneca|No|Completed|November 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|out-patient departments|December 2010|December 2, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802542||146549|
NCT00803166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10316926|Randomized Study to Compare the Bioavailability of Three Halobetasol Propionate 0.05% Topical Creams|Bioequivalence of Three Halobetasol Propionate 0.05% Topical Creams||Perrigo Company|No|Completed|January 2004|January 2004|Actual|January 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|March 2012|March 15, 2012|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803166||146501|
NCT00803413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSSW2002|Effect of Back School and Supervised Walking in Sedentary Women With Chronic Low Back Pain|Effect of Back School and Supervised Walking in Sedentary Women With Chronic Low Back Pain: a Randomized Controlled Trial.||University of Sao Paulo|No|Completed|August 2002|March 2004|Actual|June 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|119|||Female|30 Years|60 Years|No|||December 2008|December 4, 2008|November 7, 2008||No||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00803413||146482|
NCT00792051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GML003.4|Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children|A Randomised Controlled Trial of the Effectiveness of Vaccinating Children to Reduce Household Transmission of Influenza||The University of Hong Kong|Yes|Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2800|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 29, 2014|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00792051||147337|
NCT00792311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-02|Tsui Test as a Predictor of Bupivacaine Consumption in Labour Epidurals|Tsui Test as a Predictor of Bupivacaine Consumption in Labour Epidurals||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00792311||147317|
NCT00803387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20080020H|Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative|Dry Eye and Irritation Comparison of Latanoprost 0.005% With the Preservative Benzalkonium Chloride (BAC) Vs Travoprost 0.004% Without BAC||United States Air Force||Completed|April 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Must be eligible for care at WHMC ie active duty, military retirees and their dependents          -  patient must already be using xalatan for at least 1 month prior to study enrollment             in both eyes and have complaints of dry eye and/or irritation.          -  any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without             pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)          -  tear break up times (TBUT) < 6 seconds on xalatan monotherapy.|December 2008|December 4, 2008|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803387||146484|
NCT00804037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORLHCFMUSP 1|Injection Snoreplasty: Comparison Between Ethanol and Ethanolamine Oleate|Injection Snoreplasty: Comparison Between Ethanol and Ethanolamine Oleate. A Randomized, Placebo-Controlled Study in Human Patients||University of Sao Paulo||Active, not recruiting|January 2007|||December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2008|December 5, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804037||146434|
NCT00804050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO2006-AISSM04|Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts|Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts||Fondazione Italiana Sindromi Mielodisplastiche Onlus|Yes|Terminated|March 2007|March 2010|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|December 5, 2008||No|Difficulties of enrollment|No||https://clinicaltrials.gov/show/NCT00804050||146433|
NCT00802815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20031148|Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis|Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis||Washington University School of Medicine|No|Completed|April 2005|May 2014|Actual|May 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||May 2014|May 28, 2014|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802815||146528|
NCT00802828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40103|Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions||Perrigo Company||Completed|June 2004|||June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802828||146527|
NCT00804011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS/486/Res/507|Automatic Tube Compensation (ATC) for Weaning Patients With Severe Neurotoxic Snake Envenoming|Automatic Tube Compensation Versus Pressure Support in Weaning Patients With Severe Neurotoxic Snake Envenoming|ATC|Postgraduate Institute of Medical Education and Research|No|Completed|July 2004|April 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|41|||Both|N/A|N/A|No|||December 2008|December 5, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804011||146436|
NCT00804024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080711|ClearWay™ RX Registry Trial|Multi-center, Registry Trial of ClearWay™ RX Local Therapeutic Infusion Catheter for All Indications||Atrium Medical Corporation||Completed|August 2008|October 2010|Actual|October 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|N/A|N/A|No|Non-Probability Sample|The ClearWay Rx Registry enrolled subjects who required the use of the ClearWay Rx Local        Therapeutic Infusion Catheter.|April 2013|April 18, 2013|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804024|1 Day|146435|
NCT00803647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FC-6|A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver|A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver||NSABP Foundation Inc|No|Completed|January 2010|November 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803647||146464|
NCT00803998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93.01|Ocular Hypertension Treatment Study (OHTS)|Ocular Hypertension Treatment Study||The New York Eye & Ear Infirmary||Completed|February 1994|December 2006||||N/A|Observational|N/A|||||||Both|40 Years|80 Years|Accepts Healthy Volunteers|||December 2008|October 31, 2013|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803998||146437|
NCT00800137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI-02|Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial|Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL)|BRUISECONTROL|Ottawa Heart Institute Research Corporation|Yes|Terminated|December 2008|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|984|||Both|N/A|N/A|No|||April 2013|April 8, 2013|November 26, 2008||No|At time of pre-specified 2nd interim analysis|No||https://clinicaltrials.gov/show/NCT00800137||146733|
NCT00800410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F012089-049555|REACH Detroit Partnership Family Intervention|A Pilot Randomized Diabetes Intervention Among Inner-City African American and Latino Adults||University of Michigan|No|Completed|September 2004|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|183|||Both|18 Years|N/A|No|||October 2008|December 1, 2008|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00800410||146712|
NCT00800722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP6383|A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.|Phase I Combined Use of Pulsed Dye Laser and Rapamycin||University of California, Irvine|Yes|Completed|November 2008|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800722||146688|
NCT00801060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152CL202|Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination With Lumiliximab Versus FCR Alone in Subjects With Previously Untreated Chronic Lymphocytic Leukemia||Biogen|No|Terminated|February 2008|September 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2011|September 17, 2015|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801060||146662|
NCT00801073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0060 / 04|Comparison Amongst Scleral, Corneal and Amniotic Membrane Grafts to Restore Scleral Thinning|||Federal University of São Paulo|No|Enrolling by invitation|February 2005|||February 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|49|||Both|40 Years|80 Years|No|||December 2008|December 2, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801073||146661|
NCT00801359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8657/2007|BSSPlus Versus Lactated Ringer's for Phacoemulsification|Comparison of Corneal Changes After Phacoemulsification Using BSSPlus Versus Lactated Ringer's Irrigating Solution||University of Sao Paulo|Yes|Completed|January 2008|October 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|50 Years|N/A|No|||December 2008|December 15, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801359||146639|
NCT00800332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT003-QbG10 09|Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy|Double-blind, Placebo-controlled Dose-finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy||Cytos Biotechnology AG|No|Completed|November 2008|November 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||November 2010|November 11, 2010|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800332||146718|
NCT00800345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATDTRPST0802|Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors|A Phase I Trial of Oral Metronomic Topotecan in Combination With Oral Pazopanib Utilizing a Daily Dosing Schedule to Treat Recurrent or Persistent Gynecologic Tumors||Vector Oncology|No|Active, not recruiting|April 2009|April 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800345||146717|
NCT00800657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFRCTC1|Stem Cells and Resynchronization Cardiac|Stem-Cells and Heart Failure in Several Ethiologies. Alternative Indication With Cardiac Resynchronization|RCT and SCT|Instituto de Molestias Cardiovasculares|Yes|Recruiting|November 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00800657||146693|
NCT00801307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-07-C2-012|Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease|A Single Site,Exploratory,Phase I/II,Randomised Trial Comparing the Effect of He/O2 Mixtures(He/O2 78:22 and He/O2 65:35) to Medical Air on Pulmonary Function in Moderate/Severe Asthma and COPD Patients and Healthy Volunteers||Air Liquide SA|Yes|Completed|June 2008|March 2010|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801307||146643|
NCT00803114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSHREB 01-0227-A|Epidural Morphine Following Vaginal Delivery|Epidural Morphine Following Vaginal Delivery: A Randomised, Double-Blind, Placebo-Controlled Trial||Mount Sinai Hospital, Canada|No|Completed|March 2002|February 2005|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|228|||Female|16 Years|50 Years|No|||December 2008|January 13, 2009|November 7, 2008||No||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00803114||146505|
NCT00802555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-114|Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)|A Phase 1b Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)||ArQule|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802555||146548|
NCT00802867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3T10|Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™|Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T)||Sanofi|Yes|Completed|February 2004|September 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|989|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|December 4, 2008|Yes|Yes||No|September 24, 2009|https://clinicaltrials.gov/show/NCT00802867||146524|
NCT00803426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0495-B|Ultrasound Guided Popliteal Fossa Block. Does Blockade Distal to Sciatic Nerve Bifurcation Speed Onset Time? A Prospective, Randomized Trial|Ultrasound Guided Popliteal Fossa Block. Does Blockade Distal to Sciatic Nerve Bifurcation Speed Onset Time? A Prospective, Randomized Trial||University Health Network, Toronto|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|85 Years|No|||July 2009|August 7, 2009|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803426||146481|
NCT00803153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-038|PASCAL: Safety and Complications, Experience After 1301 Consecutive Cases|Pattern Scan Laser Photocoagulation: Safety and Complications, Experience After 1301 Consecutive Cases.||Asociación para Evitar la Ceguera en México|Yes|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|10 Years|90 Years|No|Non-Probability Sample|All patients which has been treated with the pattern scan laser system between november        2007 to july 2008.|December 2008|December 4, 2008|December 3, 2008||||No||https://clinicaltrials.gov/show/NCT00803153||146502|
NCT00803686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGL-OR0803|A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women|A Randomized, Open-Label, Placebo-Controlled, Two-Period Crossover Study of the Effect on CTx-1 Concentrations of a Single 200 μg Recombinant Salmon Calcitonin (rsCT) Dose Given at Night to Normal, Healthy, Postmenopausal Women||Tarsa Therapeutics, Inc.|No|Completed|December 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|12|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|December 4, 2008|Yes|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00803686||146461|
NCT00803699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC009|Predicting Dietary Selenium Needs to Achieve Target Blood Selenium Levels|Predicting Dietary Selenium Needs to Achieve Target Blood Selenium Levels|LoDoSe|USDA Grand Forks Human Nutrition Research Center|No|Completed|November 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 4, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00803699||146460|
NCT00803712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070360|20070360 Incident Dialysis|Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis||Amgen|No|Completed|February 2009|September 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|313|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|November 26, 2008||No||No|December 3, 2013|https://clinicaltrials.gov/show/NCT00803712||146459|This was an open-label study and neither investigators nor subjects were blinded to treatment modality. Cinacalcet was dosed by forced titration. Active vitamin D administration was at the discretion of the investigator in each treatment arm.
NCT00804063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 325/08|Serum Citrate in Diagnosis and Follow-up for Glaucoma|Serum Citrate in Diagnosis and Follow-up for Glaucoma||University Hospital, Basel, Switzerland|No|Completed|December 2008|July 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples With DNA|blood, urine, serum, aqueous|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|tertiary university center|January 2015|January 7, 2015|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804063||146432|
NCT00803660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CVN-DUM-2008/1|Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes|In Practice Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes.||AstraZeneca|No|Completed|November 2008|May 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1060|||Both|18 Years|N/A|No|Probability Sample|type 2 diabetic patients who are currently using antihypertensive treatment for at least 3        months, with same regimen for a minimum of 4 weeks prior to the survey|July 2009|July 8, 2009|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00803660||146463|
NCT00803673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110106|A Healthy Volunteer Study With Inhaled GSK573719 and Placebo|A Single Centre, Randomized ,Double-Blind, Dose Ascending, Placebo-Controlled Study, in Two Parts, to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Inhaled Doses of GSK573719 and Placebo Formulated With the Excipient Magnesium Stearate, in Healthy Subjects an||GlaxoSmithKline||Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 29, 2009|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803673||146462|
NCT00799838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETOP_L_03102|Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients|Local, Phase IV, Multicenter, Double-blind, Randomized, Parallel, With Two Treatment Arms, Placebo-controlled Study to Evaluate the Reduction of Inflammatory Symptoms in the Treatment of Bacterial Pharyngitis With Ketoprofen and Amoxicillin in Pediatric Patients.|DROPS|Sanofi|No|Terminated|November 2008|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|4 Years|11 Years|No|||March 2014|October 23, 2014|November 28, 2008||No|Recruitment challenges despite several attenpts to increase enrollment|No||https://clinicaltrials.gov/show/NCT00799838||146755|
NCT00799851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1244/04|A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices|Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection||Federal University of São Paulo|Yes|Completed|November 2004|August 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|80 Years|No|||November 2008|November 28, 2008|November 28, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00799851||146754|
NCT00799565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01|Mitral Valve Prolapse (MVP) - France Study|Genetic Polymorphisms in Idiopathic Mitral Valve Prolapse :A French Prospective Study Using a Genome Wide Analysis|MVP-France|French Cardiology Society|Yes|Completed|December 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1179|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 13, 2011|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00799565||146776|
NCT00800436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22023|A Dose Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and HER2 Positive Female Patients|An Open-label, Two-part, Multi-center Dose-finding Study in Healthy Male Volunteers and Women Who Have Previously Received Herceptin to Compare Exposure of Single Dose Trastuzumab After Intravenous (IV) and Subcutaneous (SC) Administration.||Hoffmann-La Roche||Completed|December 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|70|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800436||146710|
NCT00800423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5189|Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema|Phase 3 Study of Brimonidine Tartrate Drops Efficacy in Reducing Post Operative Corneal Edema After Cataract Surgery||Rabin Medical Center|No|Not yet recruiting|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||November 2008|December 1, 2008|November 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00800423||146711|
NCT00801086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO 02-03|Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain|Phase II Double-Blind, Placebo-Controlled Study of the Safety and Preliminary Effectiveness of MTS-01 for the Prevention of Alopecia Induced by Whole Brain Radiotherapy||Mitos Pharmaceuticals|No|Recruiting|November 2008|June 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|N/A|No|||December 2008|December 2, 2008|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801086||146660|
NCT00801385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000618003|Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy|A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens||National Cancer Institute (NCI)||Recruiting|September 2008|||June 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||August 2009|August 21, 2009|December 2, 2008||||No||https://clinicaltrials.gov/show/NCT00801385||146637|
NCT00797628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X071211009|Web-delivered Provider Intervention for Tobacco Control|QUIT-PRIMO: Web-Delivered Clinical Microsystem Intervention for Tobacco Control|QUIT-PRIMO|University of Massachusetts, Worcester|Yes|Completed|March 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|174|||Both|19 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 27, 2013|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797628||146922|
NCT00797641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GEU-DUM-2008/2|European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)|European Survey of Non-Variceal Upper Gastro Intestinal Bleeding|ENERGIB|AstraZeneca|No|Completed|January 2009|March 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the hospital, or inpatients admitted for another reason, presenting        with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting,        melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss        from the upper gastrointestinal tract|December 2009|December 3, 2009|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797641||146921|
NCT00802165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0806080149|Effect of Electroacupuncture on Pain Threshold|Effect of Electroacupuncture on Pain Threshold||Logan College of Chiropractic|No|Recruiting|December 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|70 Years|Accepts Healthy Volunteers|||December 2008|December 3, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802165||146578|
NCT00802178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.613|First Presentation of Parkinson Disease Patients to Neurologist|CEE PMSS (Central Eastern European Post-Marketing Surveillance Study) First Presentation of Mirapexin in Parkinson Patients||Boehringer Ingelheim||Completed|February 2006|||September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2448|||Both|18 Years|N/A|No|Non-Probability Sample|neurogologists|March 2014|March 14, 2014|December 3, 2008||||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00802178||146577|
NCT00802438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0311|Eosinophilic Airway Inflammation and Mepolizumab|Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab||University of Wisconsin, Madison|Yes|Active, not recruiting|June 2008|March 2018|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|50 Years|No|||December 2014|December 1, 2014|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802438||146557|
NCT00798421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL10421|Study to Evaluate Nosocomial Transmission of Influenza|Pilot Study to Develop a Model to Evaluate Nosocomial Transmission of Influenza||University Hospitals, Leicester|No|Not yet recruiting|December 2008|May 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Throat and nose swabs|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Healthy subject volunteers > 18 years of age          2. Children with confirmed influenza presenting to the Children's Hospital, Leicester             Royal Infirmary|November 2008|November 25, 2008|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798421||146861|
NCT00802893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISH-001|Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel Study of Oral 6R-BH4 in Subjects Wity Isolated Systolic Hypertension and Endothelial Dysfunction||Johns Hopkins University|Yes|Recruiting|December 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|100|||Both|40 Years|N/A|No|||December 2008|December 4, 2008|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802893||146522|
NCT00803400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDHFMEDUBA0709|Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment|Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial|AEIPDT|University of Buenos Aires|No|Completed|July 2005|October 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|60 Years|No|||April 2009|April 21, 2009|November 7, 2008||No||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00803400||146483|Panic patients may sometimes be reluctant to use medication. This could lead to early drop outs.Possible difficulties in following the exercise protocol.
NCT00803738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPL-202|Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis|A Multi-center, Randomized, Investigator-blinded, Parallel-group Study, Designed to Evaluate the Safety and Clinical Equivalence of Terconazole Vaginal Suppositories, 80 mg (Test Product) and Terconazole Vaginal Suppositories, 80 mg (Reference Product) in the Treatment of Vulvovaginal Candidiasis Caused by Candida Species||Perrigo Company|No|Completed|December 2002|December 2003|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|572|||Female|18 Years|N/A|No|||January 2013|January 17, 2013|December 5, 2008|Yes|Yes||No|May 11, 2012|https://clinicaltrials.gov/show/NCT00803738||146457|
NCT00804076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP2/P1/07/1|Gene Transfer for Cancer Pain|Gene Transfer for Intractable Pain: A Phase I Clinical Trial to Determine the Maximum Tolerable Dose of a Replication-Defective Herpes Simplex Virus Type I (HSV-1) Vector Expressing Human Preproenkephalin (NP2) in Patients With Malignancies||Diamyd Inc|Yes|Completed|February 2008|July 2013|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|December 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00804076||146431|
NCT00799578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1699|A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)|||University of California, San Diego|No|Completed|October 2008|January 2010|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|10 Years|N/A|No|||December 2013|December 13, 2013|November 28, 2008|Yes|Yes||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00799578||146775|
NCT00799864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002677|A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years|A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged > = 6 to <18 Years||Janssen Sciences Ireland UC|Yes|Recruiting|January 2011|October 2023|Anticipated|October 2023|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|6 Years|17 Years|No|||March 2016|March 11, 2016|November 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00799864||146753|
NCT00800150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08076|Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment|Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With Advanced and Hematological Malignancies Who Are Not Eligible for Fully Myeloablative Regimen||City of Hope Medical Center|Yes|Terminated|November 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|6|||Both|16 Years|N/A|No|||June 2015|June 3, 2015|November 27, 2008|No|Yes|Protocol objective could not be met. A new study with amended eligibility criteria will be    developed.|No||https://clinicaltrials.gov/show/NCT00800150||146732|
NCT00800449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSH001|Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)|Prospective Assessment of the Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)||Carmel Medical Center|Yes|Completed|August 2007|September 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|Samples Without DNA|Hp phenotype in blood test.|Both|24 Weeks|35 Weeks|No|Non-Probability Sample|All preterm neonates ( a total of 150 preterm babies, 35 weeks or younger) admitted to the        NICU in Carmel hospital.|February 2012|February 13, 2012|November 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00800449||146709|
NCT00800462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-SCI-M3-488|Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity|Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity||Toronto Rehabilitation Institute|No|Completed|March 2008|December 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|75 Years|No|||April 2013|April 4, 2013|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800462||146708|
NCT00800735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV21928|A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols|An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS®) as Monotherapy or in Combination With Ribavirin (COPEGUS®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols||Hoffmann-La Roche||Completed|April 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|October 23, 2008|No|Yes||No|July 5, 2013|https://clinicaltrials.gov/show/NCT00800735||146687|
NCT00800748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19387|A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C|An Open, Phase IV, Multicentric Study, Evaluating Safety and Efficacy of Ribavirin (Copegus®) and Peginterferon Alfa-2a (Pegasys®) Combination in Specific Groups||Hoffmann-La Roche||Completed|January 2006|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|373|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00800748||146686|
NCT00801099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSII|Benefit of a Single Preoperative Dose of Antibiotics for the Prevention of Surgical Site Infections|Benefit of a Single Preoperative Dose of Antibiotics in a Sub-Saharan District Hospital: Minimal Input, Massive Impact|SSI2|Swiss Tropical & Public Health Institute|No|Completed|December 2004|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|276|||Both|15 Years|N/A|No|||July 2015|July 16, 2015|November 6, 2008||No||No|November 6, 2008|https://clinicaltrials.gov/show/NCT00801099||146659|
NCT00801398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3203-010|Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.|An Open-Label, Ascending, Two-Part, Single- and Multiple-Dose Evaluation of the Safety, Pharmacokinetics, and Effectiveness of Oxymorphone for Acute Postoperatiave Pain in Pediatric Subjects||Endo Pharmaceuticals|Yes|Completed|December 2008|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00801398||146636|
NCT00801658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FunkSLT|Efficacy of SLT in Patients With Insufficient IOP Control Under Maximum Tolerated Drug Therapy (Eye Drops)|||University of Zurich|No|Completed|January 2008|July 2009||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2008|December 3, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801658||146616|
NCT00796744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC127-2008-01|Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers|Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Evaluate the Safety and Effectiveness of DSC127 in Treating Subjects With Diabetic Ulcers||US Biotest, Inc.|No|Completed|October 2008|May 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|November 20, 2008|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00796744||146987|
NCT00800943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC005|Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy|A Clinical Research Consortium (CRC) Phase II Study of Subcutaneous Campath-1H in Patients With B-Cell Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy|CRC005|Chronic Lymphocytic Leukemia Research Consortium|Yes|Active, not recruiting|December 2003|August 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2008|December 2, 2008|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800943||146671|
NCT00800956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061018|Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine|An Open Label, Single Oral Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Esreboxetine.|ADME|Pfizer|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|4|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800956||146670|
NCT00800969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIS-UGI-1|Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach|||University of Zurich||Recruiting|October 2008|||January 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00800969||146669|
NCT00802776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 15615-FLAK|Femtosecond Laser Assisted Keratoplasty||FLAK|University of Michigan||Active, not recruiting|October 2007|December 2016|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|No|||June 2015|June 4, 2015|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802776||146531|
NCT00802789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-421|Montelukast in Chronic Asthma|Montelukast in Chronic Asthma: Non-interventional Study With Montelukast 10 mg||Merck Sharp & Dohme Corp.||Completed|April 2007|October 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Mild to moderate adult asthmatics (≥18 years of age) insufficiently treated with ICS or        ICS + LABA|November 2013|November 15, 2013|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802789||146530|
NCT00802802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1070|Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children|Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-infected and HIV/TB Co-infected Infants and Children 3 Months to Less Than 36 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|October 2009|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|155|||Both|3 Months|35 Months|No|||January 2016|January 7, 2016|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802802||146529|
NCT00797654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH081760-02|HIV Prevention and Trauma Treatment in Men Who Have Sex With Men and Who Have a History of Sexual Abuse|Integrated HIV Prevention and Trauma Treatment in MSM With Sexual Abuse History (Project THRIVE)||Fenway Community Health|No|Active, not recruiting|August 2008|August 2011|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Male|18 Years|N/A|No|||March 2010|February 2, 2011|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797654||146920|
NCT00797667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-049|MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)|A Phase IIa, Multicenter, Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine||Merck Sharp & Dohme Corp.|Yes|Terminated|November 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|660|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 24, 2008|Yes|Yes|The study was terminated based on a recommendation of the DSMB following the identification of    two patients with significant elevations in serum transaminases|No|August 13, 2014|https://clinicaltrials.gov/show/NCT00797667||146919|Based on a recommendation from the external Data Safety Monitoring Board (DSMB), a decision to terminate the trial was made on 26-Mar-2009.
NCT00803465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10316906|Randomized Study to Compare the Bioequivalence of Two Fluticasone Propionate 0.05% Topical Creams|Bioequivalence of Two Fluticasone Propionate 0.05% Topical Creams||Perrigo Company|No|Completed|April 2003|June 2003|Actual|June 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|115|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|March 2012|March 15, 2012|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803465||146478|
NCT00803478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 18730-IDES|The Effect of Hinge Position and Hinge Width on Corneal Sensation and Dry Eye After IntraLase LASIK Procedure|The Effect of Hinge Position and Hinge Width on Corneal Sensation and Dry Eye After IntraLase LASIK Procedure|IDES|University of Michigan|No|Withdrawn|June 2004|December 2015|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|70 Years|No|||February 2016|February 1, 2016|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803478||146477|
NCT00803179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900005|Growth Hormone Therapy for Wasting in Cystic Fibrosis|Growth Hormone Therapy for Wasting in Cystic Fibrosis||University of Massachusetts, Worcester|No|Terminated|November 2008|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|December 4, 2008|Yes|Yes|Poor enrollment, patients were lost to follow up|No|November 13, 2012|https://clinicaltrials.gov/show/NCT00803179||146500|
NCT00803192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40104|Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions||Perrigo Company||Completed|June 2004|||June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803192||146499|
NCT00803725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0683-A|Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy|Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy Surgery||University Health Network, Toronto|No|Completed|August 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|80 Years|No|||January 2010|January 22, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803725||146458|
NCT00803439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10416918|Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams|Bioequivalence of Two Clobetasol Propionate 0.05% Topical Foams||Perrigo Company|No|Completed|April 2005|April 2005|Actual|April 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|March 2012|March 15, 2012|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803439||146480|
NCT00803764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40062|Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Two Oral Formulations of Naproxen 500 mg Tablets Administered as 1 x 500 mg Tablet in Healthy Subjects Under Fed Conditions||Perrigo Company||Completed|June 2004|||July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803764||146455|
NCT00804089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR1-001-2008|Traditional Acupuncture and Myofascial Trigger Point Dry Needling and Acupressure for Chronic Low Back Pain|Randomised Comparative Pragmatic Clinical Trial of Traditional Acupuncture and Superficial Dry Needling and Acupressure of Myofascial Trigger Points for the Treatment of Patients With Chronic Mechanical Low Back Pain||Hermano Miguel Foundation|Yes|Recruiting|December 2008|||March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||December 2008|December 5, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804089||146430|
NCT00804102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EST-2008|Transcorneal Electrical Stimulation Therapy for Retinal Disease|Transcorneal Electrical Stimulation Therapy for Retinal Disease - A Randomized, Single-blind Pilot Study||Okuvision GmbH|Yes|Completed|January 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|12||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 3, 2012|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804102||146429|
NCT00799591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-4448|French Study In ICU Patients Treated With Tigecycline|French Prospective Observational Study In Intensive Care Unit (ICU) Patients Treated With Tigecycline||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|156|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive Care Unit|September 2011|November 15, 2011|November 26, 2008|No|Yes||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00799591||146774|
NCT00799877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-023|Chronic Plaque Psoriasis (Ps) Registry|A 10-Year, Post-marketing, Observational, Registry to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)||AbbVie|No|Active, not recruiting|September 2008|September 2022|Anticipated|September 2022|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|99 Years|No|Non-Probability Sample|primary care clinic, departments of dermatology|January 2016|January 25, 2016|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799877||146752|
NCT00800163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|St. Francis Heart Center-EHART|Improving Door-to-Balloon Time in STEMI|Emergency Department Physician Activation of the Catheterization Laboratory and Immediate Transfer to an Immediately Available Catheterization Lab Reduce Door-to-Balloon Time in ST-Elevation Myocardial Infarction|EHART|St. Francis Hospitals & Health Centers|No|Recruiting|September 2005|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1000|||Both|18 Years|N/A|No|||November 2008|July 22, 2010|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00800163||146731|
NCT00800176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC21587|A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus|A Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled 12-week Study to Investigate Glycemic Parameters of Efficacy, Safety/ Tolerability and Pharmacokinetics of Five Dose Levels of RO4998452 in Patients With Type 2 Diabetes Mellitus||Hoffmann-La Roche||Completed|January 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|405|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800176||146730|
NCT00800475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0116|Bioequivalence Study Between Two Oral Formulations of Gemfibrozil Tablets|A Relative Bioequivalence Study of 600 mg Gemfibrozil Tablets Under Fasting Conditions||Blu Caribe|No|Completed|July 2005|September 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 9, 2013|November 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00800475||146707|
NCT00800488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 06 047|Procalcitonin for Predicting Serious Bacterial Infection in Infants Less Than 3 Months|Usefulness of Serum Procalcitonin for Predicting Serious Bacterial Infection in Febrile Infants Less Than 3 Months|PRONOUR|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2008|April 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2209|||Both|N/A|3 Months|No|Non-Probability Sample|children 7 days older to 3 month older with fever|April 2011|July 25, 2014|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00800488||146706|
NCT00800761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFO-DFP in TM|Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major|Increased Survival and Reversion of Iron-Induced Cardiac Disease in Patients With Thalassemia Major Receiving Intensive Combined Chelation Therapy|DFODFPTM|Ospedale Microcitemico|No|Completed|December 2001|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||December 2001|December 1, 2008|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800761||146685|
NCT00800774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARVO - BN - 2009|Ten-year Follow-up of Laser in Situ Keratomileusis in Patients 8 to 15 Years Old|Ten-year Follow-up of Laser in Situ Keratomileusis in Patients 8 to 15 Years Old||Instituto de Olhos de Goiania|Yes|Completed|January 1998|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||September 2008|November 21, 2009|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800774||146684|
NCT00801411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000624374|Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery|A Randomised Phase 2 Study of Neoadjuvant Docetaxel and Cyclophosphamide Compared to Doxorubicin and Cyclophosphamide in Operable Node Negative Breast Cancer With Normal Topoisomerase IIα Expression||National Cancer Institute (NCI)||Recruiting|October 2008|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|318|||Female|21 Years|N/A|No|||June 2009|June 16, 2009|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801411||146635|
NCT00801671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111|Russian Study of the Effect of Continuous Positive Airway Pressure (CPAP) in Hypertension|Study of Independent Role of Continuous Positive Airway Pressure Therapy on Systemic Arterial Pressure in Patients With Sleep Apnea Syndrome and Arterial Hypertension||Russian Cardiology Research and Production Center|No|Completed|September 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||June 2011|June 15, 2011|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00801671||146615|
NCT00797056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0043 / 201106083|Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease|Pilot Study of Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease (STEMPAD Trial)|STEMPAD|Washington University School of Medicine|Yes|Completed|April 2008|April 2012|Actual|April 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00797056||146963|
NCT00801554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001951|Autism Spectrum Disorders (ASD) Characterization Study|A Characterization Study of Individuals With Autism Spectrum Disorders||Massachusetts General Hospital|No|Completed|October 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|26|||Both|6 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and adults with ASDs.        Controls: healthy volunteers who have never been diagnosed with an Autism Spectrum        Disorder.|October 2013|October 21, 2013|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801554||146624|
NCT00801866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-035|Avastin for Post-Photocoagulation Macular Edema|Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab.||Asociación para Evitar la Ceguera en México|Yes|Completed||||||Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|15 Years|80 Years|No|||December 2008|December 3, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00801866||146601|
NCT00798122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD CSDA 2006066|Study of Women With Acute Coronary Syndromes and Nonobstructive Coronary Artery Disease|Study of Women With Acute Coronary Syndromes and Nonobstructive Coronary Artery Disease|SWAN|New York University School of Medicine|Yes|Active, not recruiting|March 2006|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||December 2015|December 31, 2015|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00798122||146884|
NCT00798161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.46|Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design|A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Free Combination of BI 1356 2.5 mg + Metformin 500 mg, or of BI 1356 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg Twice Daily), and BI 1356 (5.0 mg Once Daily) Over 24 Weeks in Drug Naive or Previously Treated (4 Weeks Wash-out and 2 Weeks Placebo run-in) Type 2 Diabetic Patients With Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|December 2008|||May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|857|||Both|18 Years|80 Years|No|||December 2013|December 11, 2013|November 24, 2008||||No|May 20, 2011|https://clinicaltrials.gov/show/NCT00798161||146881|
NCT00803491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUS08001|Health Related Quality of Life After a Self-promoting Learning Program for People With Rheumatic Diseases|Health Related Quality of Life After a Self-promoting Problem-based Learning Program for People With Rheumatic Diseases: a Randomized Controlled Trial||Spenshult Hospital|No|Active, not recruiting|December 2008|February 2013|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|N/A|No|||August 2010|August 17, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803491||146476|
NCT00803205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-009-CF|Study of Ataluren (PTC124™) in Cystic Fibrosis|A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis||PTC Therapeutics|Yes|Completed|July 2009|October 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|238|||Both|6 Years|N/A|No|||August 2013|August 14, 2013|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803205||146498|
NCT00803751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infant Truview|A Comparison of the Infant Truview EVO2 Video Laryngoscope and the Macintosh Laryngoscope in Pediatric Patients|A Comparison of the Infant Truview EVO2 Video Laryngoscope and the Macintosh Laryngoscope in Pediatric Patients|Truview|The University of Texas Health Science Center, Houston|No|Completed|May 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|50|||Both|N/A|12 Months|No|||February 2010|February 1, 2010|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803751||146456|
NCT00803452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lipidtearfilm|Lipids of the Human Tear Film and Their Effect on Tear Stability|Lipids of the Human Tear Film and Their Effect on Tear Stability||University of Louisville|No|Recruiting|July 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2010|November 23, 2010|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00803452||146479|
NCT00803777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2008-23|In-Clinic and Home-Use Study of a New Blood Glucose Monitoring System|In-Clinic and Home-Use Study of the AVATAR Blood Glucose Monitoring System in Children and Young Adults||Ascensia Diabetes Care|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|147|||Both|4 Years|24 Years|No|||January 2016|January 29, 2016|December 5, 2008|Yes|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00803777||146454|
NCT00804115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00.24|The International Collaborative Exfoliation Syndrome Treatment Study|The International Collaborative Exfoliation Syndrome Treatment Study||The New York Eye & Ear Infirmary|Yes|Active, not recruiting|August 2000|December 2008|Anticipated|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|277|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||December 2008|December 5, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804115||146428|
NCT00799604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-08-02|Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)|An Open-label Study in Patients Undergoing Cardiac Surgery to Evaluate the Effect of Bolus Clevidipine Administration (SPRINT)|SPRINT|The Medicines Company|No|Completed|November 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|November 26, 2008|Yes|Yes||No|July 30, 2012|https://clinicaltrials.gov/show/NCT00799604||146773|
NCT00799890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPREMES-01|Sunphenon in Progressive Forms of Multiple Sclerosis|Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis|SUPREMES|Charite University, Berlin, Germany|No|Completed|May 2009|March 2016|Actual|March 2016|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2016|March 21, 2016|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00799890||146751|
NCT00799903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100601|The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial|LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)|STABILITY|GlaxoSmithKline|Yes|Completed|December 2008|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15828|||Both|18 Years|N/A|No|||May 2014|July 9, 2015|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799903||146750|
NCT00800189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA002|Evaluation of the Informational Content of Setup Verification Images for Patients Receiving Breast Radiation Therapy (Anterior EPI)|A Prospective Evaluation of the Informational Content of Setup Verification Images for Patients Receiving Breast Radiation Therapy Tangentially With or Without Supraclavicular Treatment|Anterior EPI|British Columbia Cancer Agency|Yes|Completed|August 2008|August 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|N/A|No|||March 2012|March 7, 2012|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00800189||146729|
NCT00801138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-647|The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine|The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine||Outcomes Research Consortium|No|Terminated|November 2008|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|218|||Both|18 Years|75 Years|No|||February 2011|February 17, 2011|December 2, 2008||No|Based on a strong primary outcome (prolonged analgesia with dexamethasone) and futility for    type of local anesthetic, study was terminated.|No||https://clinicaltrials.gov/show/NCT00801138||146656|
NCT00800787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4210|Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation|A Phase 3, Multicenter, Open Label Study to Assess the Safety and Efficacy of Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Associated Liver Disease Who Underwent Liver Transplantation|Nabi-HB-SC|Biotest Pharmaceuticals Corporation|Yes|Withdrawn|April 2010|September 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||June 2010|January 15, 2016|November 26, 2008|Yes|Yes|New sponsor's existing product under evaluation for this indication|No||https://clinicaltrials.gov/show/NCT00800787||146683|
NCT00801112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-001MC|Bioimpedance as a Tool for Fluid Management in Peritoneal Dialysis (PD) Patients|Developing Bioimpedance (BIA) as a Tool for Fluid Management in Peritoneal Dialysis Patients: A Validation Study||University Hospital of North Staffordshire|No|Not yet recruiting|January 2009|January 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|Samples Without DNA|Whole blood, urine and peritoneal fluid.|Both|16 Years|N/A|No|Non-Probability Sample|Incident and prevalent PD patients.|December 2008|December 2, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801112||146658|
NCT00801125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN51-309-503|Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy|A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy||Elan Pharmaceuticals||Withdrawn|December 2008|||May 2010|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2009|January 23, 2009|December 1, 2008||Yes|Study sponsor decided to withdraw the current study prior to enrollment of first participant.|No||https://clinicaltrials.gov/show/NCT00801125||146657|
NCT00801684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK27-001|ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD|Efficacy, Safety, Tolerability, and Pharmacokinetics of Trospium Inhalation Powder (TrIP) Administered to Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Alkermes, Inc.|No|Completed|February 2009|July 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|24|||Both|40 Years|80 Years|No|||May 2011|August 17, 2011|December 2, 2008|Yes|Yes||No|March 18, 2011|https://clinicaltrials.gov/show/NCT00801684||146614|
NCT00802646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.|The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers|Randomized, Double-Blind, Placebo-Controlled Study of Effects of Combined Spinal Epidural Analgesia on Intrapartum Fever.|CSE|Ochsner Health System|Yes|Withdrawn|June 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|168|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||July 2009|July 2, 2009|December 4, 2008||No|study moved to alternate site|No||https://clinicaltrials.gov/show/NCT00802646||146541|
NCT00797693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|324/2|Misoprostol in Termination of First Trimester Missed Abortion|Oral Versus Vaginal Misoprostol as Cervical Ripening Agent Prior to Surgical Termination of First Trimester Missed Abortions in Hawler Maternity Teaching Hospital in Erbil/Iraq||Hawler Medical University|Yes|Completed|January 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|20 Years|35 Years|No|||November 2008|November 24, 2008|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797693||146917|
NCT00797875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803064R|PNF Stretching for TKA on ROM|The Effects of PNF Stretching on Knee Motion Following TKA||National Taiwan University Hospital|No|Not yet recruiting|December 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||November 2008|November 24, 2008|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797875||146903|
NCT00797030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dry eye|Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus|Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus||Universidade Federal do Rio de Janeiro|Yes|Active, not recruiting|October 2006|November 2008|Anticipated|July 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|No|||November 2008|November 21, 2008|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797030||146965|
NCT00797368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0828|Manual Therapy and Exercise Versus Home Exercises in the Management of Patients Status Post Ankle Sprain|Manual Therapy and Exercise Versus Home Exercises in the Management of Patients Status Post Ankle Sprain: A Multi-Center Randomized Clinical Trial||Franklin Pierce University|No|Completed|November 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|74|||Both|16 Years|60 Years|No|||July 2013|July 8, 2013|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797368||146942|
NCT00798460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-0809-055|Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients|A Multicenter, Randomized, Controlled Tial of Combination Therapy for Lamivudine-resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir||Inje University|Yes|Terminated|December 2008|November 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|November 25, 2008||No|could not enroll patients|No||https://clinicaltrials.gov/show/NCT00798460||146858|
NCT00804180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/137, GC 742|Group Therapy Intervention for Children and Adolescents With Injection-Related Anxiety and Their Caregivers|Evaluation of a Group Therapy Intervention for Children and Adolescents With Injection-Related Anxiety and Their Caregivers||Medical College of Wisconsin|No|Withdrawn|October 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|8 Years|17 Years|No|||June 2015|June 19, 2015|December 5, 2008||No|Lack of recruitment/participants|No||https://clinicaltrials.gov/show/NCT00804180||146423|
NCT00803842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL-120407|Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash|Evaluation of Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash||Northwestern University|Yes|Withdrawn|October 2008|||December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|December 5, 2008|Yes|Yes|Investigator left the institution and decided not to continue with the study.|No||https://clinicaltrials.gov/show/NCT00803842||146449|
NCT00803790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0217A-253|A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)(COMPLETED)|A 2-Part, Open-Label, Randomized, Crossover Study to Evaluate the Bioequivalence of the 70-mg Alendronate/5600 IU Vitamin D3 Final Market Combination Tablet to a 70-mg Alendronate Marketed Tablet, and the Relative Bioavailability of Vitamin D3||Merck Sharp & Dohme Corp.||Completed|May 2006|September 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|318|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|December 4, 2008|No|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00803790||146453|
NCT00803803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-914E|Dose, Effects and Characteristics of Pilocarpine|Dose, Effects and Characteristics of Pilocarpine||Wills Eye|No|Completed|August 1978|December 1979|Actual|August 1979|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|90 Years|No|||December 2008|December 8, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803803||146452|
NCT00804128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616972|Contrast-Enhanced MRI in Women With Ductal Breast Carcinoma in Situ and in Healthy Volunteers|Contrast-enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)||University of California, San Francisco|No|Recruiting|October 2008|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|healthy volunteers Women with DCIS|December 2014|December 15, 2014|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00804128||146427|
NCT00799630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00982-53|Effects of Nutraperf Consumption in Runners|Identification of the Effects of NUTRAPERF Consumption on Performance in Endurance-Type Exercise.||Lescuyer Laboratory|No|Completed|November 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 28, 2008|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00799630||146771|
NCT00799916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM 001|Saline Solution Versus Voluven®: A Controlled Study of Fluid Resuscitation in Severe Sepsis|Saline Solution Versus Voluven®: A Controlled Study of Fluid Resuscitation in Severe Sepsis||Universidad Nacional de La Plata|No|Completed|January 2006|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 14, 2009|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00799916||146749|
NCT00799617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AG030644|The Testosterone Trial in Older Men|Randomized, Placebo-controlled, Double-blind Study of Five Coordinated Testosterone Treatment Trials in Older Men||University of Pennsylvania|Yes|Active, not recruiting|November 2009|June 2016|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Male|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 3, 2015|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799617||146772|
NCT00800501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0029-001|A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis|A Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump||Newron Sweden AB|Yes|Completed|December 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|75 Years|No|||December 2011|December 5, 2011|November 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00800501||146705|
NCT00800800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-452-0003|Effects of Rosuvastatin on Aortic Stenosis Progression|Effect of Cholesterol Lowering on the Progression of Aortic Stenosis in Patients With Mild to Moderate Aortic Stenosis (ASTRONOMER)Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin and The Sub-Study Protocol.|ASTRONOMER|AstraZeneca|No|Completed|November 2002|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|378|||Both|18 Years|82 Years|No|||December 2010|December 2, 2010|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00800800||146682|
NCT00801450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2995/2007|Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery|||University of Sao Paulo|Yes|Active, not recruiting|September 2007|February 2009|Anticipated|December 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||October 2009|October 8, 2009|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801450||146632|
NCT00801424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/1258-31-4|Warmed Humidified Carbon Dioxide (CO2) for Open Surgery|Randomized Clinical Study for Core and Topical Warming of the Open Wound Cavity With Warmed Humidified CO2 Versus Control in Colon Surgery|S2|Karolinska University Hospital|No|Completed|November 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00801424||146634|
NCT00802035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK29-002|ALK29-002: A Study of Baclofen Formulations in Healthy Adults|A Phase 1, Single-Center, Open-Label Study of the Pharmacokinetics of Baclofen Formulations Administered to Healthy Adults||Alkermes, Inc.|No|Completed|November 2008|February 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802035||146588|
NCT00802308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-EG-010|Effects of a Single Dose of Egalet® Morphine Combined With a Single Dose of Alcohol in Healthy Moderate Drinkers|A Randomized, Partially Blind, Four-way Crossover Study to Determine the Effects of a Single Dose of Egalet® Morphine Combined With a Single Dose of Alcohol in Healthy Male and Female Moderate Drinkers||Egalet Ltd|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|24|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00802308||146567|
NCT00802321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-217S-2|Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects|Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects||University of Connecticut Health Center|No|Completed|April 2006|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver)|1||Actual|40|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 22, 2010|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802321||146566|
NCT00798473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCH002-56|Zoledronate for Osteopenia in Pediatric Crohn's|A Randomized Controlled Trial of Zoledronate in the Treatment of Osteopenia in Children and Adolescents With Crohn's Disease||McGill University Health Center|Yes|Completed|September 2004|November 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|6 Years|18 Years|No|||November 2008|November 25, 2008|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798473||146857|
NCT00797043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0606-SK01|Photon/Proton Radiation Therapy for Carcinoma of the Skin of the Head and Neck|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Skin of the Head and Neck With Perineural Invasion|SK01|University of Florida|No|Terminated|September 2008|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated at radiation oncology clinic|March 2016|March 3, 2016|November 24, 2008||No|Slow enrollment, feasibility issues|No||https://clinicaltrials.gov/show/NCT00797043||146964|
NCT00797381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN2009|Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety, Tolerability of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia||Shanghai Public Health Clinical Center|No|Not yet recruiting|May 2009|May 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|3 ml plasm of each subject on week 4,8,12 and 24|Both|18 Years|65 Years|No|Non-Probability Sample|treatment-experienced HIV-1 infected adult patients with hemophilia|November 2008|November 24, 2008|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797381||146941|
NCT00797680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ef1|Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest|Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest||University of Pittsburgh|Yes|Completed|October 2008|April 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|N/A|17 Years|No|||January 2016|January 15, 2016|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797680||146918|
NCT00797901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S06GM008224|Depression Treatment in General Medical Settings|Depression Treatment in General Medical Settings||University of Puerto Rico|Yes|Completed|August 2004|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|179|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797901||146901|
NCT00803855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00001|Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 Including an Open Food Effect Panel in Healthy Male and Non-Fertile Female Volunteers|SAD|AstraZeneca|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|110|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2009|May 14, 2009|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803855||146448|
NCT00803868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6|Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia|Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia||University of South Florida|Yes|Terminated|May 2009|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||July 2012|July 23, 2012|December 4, 2008|No|Yes|The DSMB recommended that the study be stopped as a result of concerns regarding safety and    intolerability and insufficient evidence of efficacy.|No||https://clinicaltrials.gov/show/NCT00803868||146447|
NCT00803816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004876-10|Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A|Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A||St. Franziskus Hospital|Yes|Completed|November 2007|December 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803816||146451|
NCT00804141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200K1-3358|Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation|An Open-Label Study To Evaluate The Long-Term Safety Of Subcutaneous MOA-728 For Treatment Of Opioid-Induced Constipation In Subjects With Nonmalignant Pain||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1040|||Both|18 Years|N/A|No|||June 2011|August 29, 2014|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804141||146426|
NCT00804154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090039|Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer|A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer||National Institutes of Health Clinical Center (CC)||Suspended|December 2008|December 2020|Anticipated|June 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2015|June 23, 2015|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00804154||146425|
NCT00804167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2008/1|National Survey on Hypertension|Profile of Hypertensive Patients Aged of 75 Years and Older Seen in General Practitioner According to Their Renal Damage.|SERENITE|AstraZeneca|No|Completed|December 2008|July 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|4500|||Both|75 Years|N/A|No|Probability Sample|The first 3 consecutive patients seen during the GP's visit with a diagnosis of        Hypertension and with renal damage|July 2009|July 19, 2009|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804167||146424|
NCT00799643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 06-20-2|Targeting Inflammation Using Salsalate for Type 2 Diabetes-stage II|Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate|TINSAL-T2D-II|Joslin Diabetes Center|Yes|Completed|November 2008|||September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|638|||Both|18 Years|75 Years|No|||March 2014|March 25, 2014|November 26, 2008|Yes|Yes||No|September 13, 2013|https://clinicaltrials.gov/show/NCT00799643||146770|
NCT00799656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI10569|Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain|Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-blind, Placebo-controlled, Cross-over Study|SERENEATI|Sanofi|No|Completed|November 2008|September 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|75 Years|No|||March 2011|March 31, 2011|November 27, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799656||146769|
NCT00799929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JZ-09-08|IVF Clinical Trial of Two Different Treatment Protocols.|Efficiency and Patient Satisfaction of Two Different IVF Protocols.||New Hope Fertility Center|Yes|Completed|December 2008|October 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|564|||Female|18 Years|38 Years|No|||December 2015|December 22, 2015|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799929||146748|
NCT00799942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579-0738/1|Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus|Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus||Merz Pharmaceuticals GmbH|No|Terminated|May 2009|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|81 Years|No|||June 2010|June 30, 2010|November 27, 2008||||No||https://clinicaltrials.gov/show/NCT00799942||146747|
NCT00800202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21823|A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis|An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis||Hoffmann-La Roche||Completed|April 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|December 1, 2008||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT00800202||146728|
NCT00800215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP616|A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927|A Multicenter, Double-blind, Double-dummy, Randomized Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization||UCB Pharma|Yes|Completed|March 2004|November 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|N/A|N/A|No|||May 2015|May 26, 2015|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800215||146727|
NCT00800813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-135|Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy|Assessing the Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy||Memorial Sloan Kettering Cancer Center||Completed|November 2008|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|121|||Male|21 Years|N/A|No|Non-Probability Sample|Patients undergoing open, laparoscopic, or robotic-assisted laparoscopic radical        prostatectomy at MSKCC.|July 2014|July 10, 2014|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800813||146681|
NCT00801151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 GENE 05|Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer|A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer.||Institut Claudius Regaud|No|Terminated|January 2009|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2010|May 19, 2010|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801151||146655|
NCT00801164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20080508H|Exploratory Study of Iocide Oral Rinse in a Diabetic Population|Exploratory Study of Iocide Oral Rinse in a Diabetic Population|Diabetes|Biomedical Development Corporation|No|Completed|December 2008|June 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|35 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 1, 2012|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801164||146654|
NCT00801437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641053|Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.|Non Interventional Study in Slovak Patients With Primary Open Angle Glaucoma and/or Ocular Hypertension Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy Due to Ineffectivity or Intolerance.||Pfizer|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|457|||Both|18 Years|N/A|No|Non-Probability Sample|Patients >18 years with primary open angle glaucoma or ocular hypertension|June 2011|June 28, 2011|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00801437||146633|
NCT00801463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0801|Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis|Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis||Nanjing University School of Medicine|Yes|Completed|January 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|60 Years|No|||April 2009|May 17, 2011|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801463||146631|
NCT00801697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 077|Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector|A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Subtype 35 (rAd35) and Subtype 5 (rAd5) HIV-1 Vaccines When Given as a Heterologous Prime-boost Regimen or as Boosts to a Recombinant DNA Vaccine in Healthy, Ad5-Naïve and Ad5-Exposed, Low Risk, HIV-1 Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2009|April 2015|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|8||Actual|192|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00801697||146613|
NCT00802048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2007/26|Local Anesthetic Infusion and Sternotomy|Study of Effectiveness of a Ropivacaïne Continuous Sternal Infusion to Reduce Postoperative Hyperalgesia Induced by Sternotomy After Cardiac Surgery|CARDIODOLAL|University Hospital, Bordeaux|No|Terminated|February 2009|August 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|50 Years|75 Years|No|||December 2011|December 12, 2011|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802048||146587|
NCT00802672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPL-302|Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis|A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis||Perrigo Company|No|Completed|December 2003|May 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|561|||Both|10 Years|N/A|No|||January 2013|January 17, 2013|December 4, 2008|Yes|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00802672||146539|
NCT00798772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 238|Micronutrients and Antioxidants in HIV Infection|A Randomized Control Clinical Trial Of Micronutrient & Antioxidant Supplementation in Persons With Untreated HIV Infection|MAINTAIN|Ottawa Hospital Research Institute|Yes|Active, not recruiting|January 2009|November 2015|Anticipated|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798772||146834|
NCT00797394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-RD-01-CLN|Efficacy of Natural Extract 2007RD01 Combined With Saw Palmetto in Benign Prostatic Hyperplasia Patients Compared to Saw Palmetto|||innoVactiv Inc.||Completed|November 2008|||July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Male|50 Years|75 Years|No|||April 2011|April 11, 2011|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797394||146940|
NCT00798174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0045|The Effect of an Azygos Vein Coil on Defibrillation Threshold|The Effect of an Azygos Vein Coil on Defibrillation Threshold||Washington University School of Medicine|No|Suspended|November 2008|||January 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|November 24, 2008|Yes|Yes|Failure of an inroducer sheath used in the technique specified by the study. posing a risk. No    adverse outcome has occurred in a study patient.|No||https://clinicaltrials.gov/show/NCT00798174||146880|
NCT00799279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15053|Integrating Smoking Cessation Into Routine Primary Care Practice|Comparative Evaluation of the Efficacy and Cost-effectiveness of Two Interventions for Integrating Smoking Cessation Into Routine Primary Care Practice: A Cluster-randomized Trial||University of Waterloo|No|Completed|January 2009|September 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|835|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 5, 2010|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00799279||146797|
NCT00799292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASW 123|Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial|Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy||Ascher-Walsh, Charles, M.D.|No|Completed|January 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 26, 2008|October 21, 2008||No||No|October 21, 2008|https://clinicaltrials.gov/show/NCT00799292||146796|
NCT00799305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0046-08-HYMC|Correlation of Airflow Limitation and Other Respiratory Characteristics With Radiologic Changes of Lung Structure|||Hillel Yaffe Medical Center||Not yet recruiting|January 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients with COPD attending pulmonary clinic in the internal disease department at the        Hillel Yaffe Medical Center|November 2008|November 26, 2008|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799305||146795|
NCT00804219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSME low-responder 1.1|Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination|Characterization of Humoral and Cellular Immunity of Low and High-responders After TBE Vaccination||Medical University of Vienna||Completed|December 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|July 20, 2011|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804219||146420|
NCT00799669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626365|Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use|Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2009|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|370|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Smokers Residing in Puerto Rico|February 2016|February 23, 2016|November 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00799669||146768|
NCT00799682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA6111ZH|Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®|An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z®||Ophthalmic Consultants of Long Island||Completed|October 2008|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 20, 2011|November 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00799682||146767|
NCT00799955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01726|Comparing 2 Types of Pain Relief After Cesarean Delivery: Spinal Morphine and TAP Block|Comparison of Efficacy and Side Effects of Intrathecal Morphine and TAP Block for Post-cesarean Analgesia||University of British Columbia|Yes|Completed|October 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Female|19 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799955||146746|
NCT00799968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA703B07-UK|12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China|Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China|UKPTEC|Beijing Chao Yang Hospital|Yes|Completed|June 2002|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|75 Years|No|||November 2008|November 28, 2008|November 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799968||146745|
NCT00799981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-LOF-00015|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||September 27, 2012|November 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799981||146744|
NCT00800514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01|Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)|Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury||Carolinas Healthcare System|Yes|Terminated|January 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|16|||Both|18 Years|55 Years|No|||July 2011|July 18, 2011|December 1, 2008||No|Principal investigator took a position at another institution. No subjects enrolled.|No||https://clinicaltrials.gov/show/NCT00800514||146704|
NCT00800826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950910|The Combination Effect of Dexmedetomidine and Morphine in Postoperative Patient-Controlled Analgesia|||National Taiwan University Hospital||Completed|November 2006|April 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|||Actual|150|||Both|18 Years|65 Years|No|||December 2008|December 1, 2008|December 1, 2008||||No||https://clinicaltrials.gov/show/NCT00800826||146680|
NCT00801177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14088|Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy|Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy||ImClone LLC|No|Completed|November 2004|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|No|||October 2010|October 11, 2010|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00801177||146653|
NCT00801476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI REB 07-458|Pre-operative Magnetic Resonance Imaging (MRI) in Young Breast Cancer Patients|A Prospective Cohort Study to Evaluate the Impact of Preoperative Breast Magnetic Resonance Imaging (MRI) on Surgical Decision-Making in Young Patients With Breast Cancer||McMaster University|No|Recruiting|April 2008|May 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|44|||Female|N/A|50 Years|No|||November 2009|November 17, 2009|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801476||146630|
NCT00801710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-0001|CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study|CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study||BridgePoint Medical|No|Completed|September 2008|September 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|19 Years|N/A|No|||December 2009|December 2, 2009|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801710||146612|
NCT00802061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trope 003|Sleep at 30 Degrees in Glaucoma|||University Health Network, Toronto|Yes|Completed||||||N/A|Interventional|N/A|||||||Both|40 Years|80 Years|No|||December 2008|December 3, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00802061||146586|
NCT00802334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 095|TDM of Generic Lopinavir/Ritonavir 200/50 mg|Therapeutic Drug Monitoring of the Generic Lopinavir/Ritonavir Tablets 200/50 mg in the Thai HIV-infected Patient||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|May 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00802334||146565|
NCT00793845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-002|Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma|Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma||Samsung Medical Center|Yes|Active, not recruiting|August 2008|January 2018|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||November 2015|November 19, 2015|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793845||147203|
NCT00793858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16651A (SEP 1)|A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray|A Pilot Investigation of the Nasal Mucosal Absorption, Retention, and Metabolism of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray When Each Formulation Is Administered to Currently Symptomatic Patients (18 Years or Older) With Documented Perennial Allergic Rhinitis (PAR).||University of Chicago|No|Withdrawn|February 2009|||September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|0|||Both|18 Years|65 Years|No|||June 2013|June 6, 2013|November 14, 2008|No|Yes|Cost prohibitive and company withdrew support.|No||https://clinicaltrials.gov/show/NCT00793858||147202|
NCT00795041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS1|Temporally Splitting Ovarian Stimulation and Embryo Transfer|Temporally Splitting Ovarian Stimulation and Embryo Transfer||University of Luebeck|No|Completed|November 2008|September 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Female|18 Years|36 Years|No|Non-Probability Sample|women with indication for ART with ICSI or IVF|November 2008|October 15, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795041||147115|
NCT00795288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3857 - 54118B|Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)|Effect of Statins on Cerebral Blood Flow After Subarachnoid Hemorrhage||Washington University School of Medicine|No|Completed|August 2008|December 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 20, 2008|Yes|Yes||No|December 8, 2014|https://clinicaltrials.gov/show/NCT00795288||147096|
NCT00797914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFM-01|Evaluation of Handheld Colonoscopy Force Monitor by Expert Endoscopists in the Performance of Colonoscopy|Phase I Study for Evaluation of Handheld Colonoscopy Force Monitor by Expert Endoscopists in the Performance of Colonoscopy||Artann Laboratories|No|Enrolling by invitation|July 2008|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|30 Years|75 Years|No|Non-Probability Sample|All adult male and female patients between the ages of 30 and 75 presenting to the Chevy        Chase Endoscopy Center for screening or diagnostic colonoscopy to be performed by any of        the investigators will be considered for inclusion.|January 2016|January 20, 2016|November 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00797914||146900|
NCT00799331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2300C00001|Exploratory Study to Assess the Pharmacokinetics of AZD5985|An Exploratory Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Pharmacokinetics of Increasing Oral Doses of AZD5985 in Healthy Male Volunteers||AstraZeneca|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 8, 2009|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00799331||146794|
NCT00799344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9 of Nov 24 2008|REVEAL Study: Vessel Healing After Angioplasty|Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) Trial: Rationale, Objectives and Design|REVEAL|CeloNova BioSciences, Inc.|No|Completed|June 2008|December 2009|Actual|October 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|21 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients that have two significant short lesions|January 2014|January 15, 2014|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00799344||146793|
NCT00795015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06010501|Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With IV Insulin|Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With an Intravenous Insulin Infusion||Rush University Medical Center|No|Completed|April 2006|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|80 Years|No|||March 2011|March 15, 2011|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795015||147117|
NCT00795028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01685|Preventing Falls and Disability in Older Adults After Hip Fracture|Preventing Falls and Disability in Older Adults After Hip Fracture||University of British Columbia|No|Withdrawn||||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment|2||Actual|0|||Female|65 Years|N/A|No|||March 2013|March 26, 2013|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795028||147116|
NCT00790738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001|Liothyronine (T3) for Bipolar Depression|Randomized Double-Blind Trial of Liothyronine (T3) Augmentation to Treatment as Usual vs Placebo For The Treatment of Bipolar Depression|T3|Northwell Health|Yes|Completed|July 2008|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||June 2015|June 5, 2015|November 10, 2008|Yes|Yes||No|May 21, 2015|https://clinicaltrials.gov/show/NCT00790738||147438|Despite several changes made in order to enhance recruitment during the study period, the study was markedly underpowered. Therefore, no definitive conclusions could be drawn from the data.
NCT00804193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPL-402|Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis|A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Topical Suspension to Reference Ciclopirox Topical Suspension 0.77% in the Treatment of Tinea Pedis||Perrigo Company|No|Completed|June 2004|April 2005|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|553|||Both|10 Years|N/A|No|||January 2014|January 9, 2014|December 5, 2008|Yes|Yes||No|September 10, 2012|https://clinicaltrials.gov/show/NCT00804193||146422|
NCT00804206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-040|Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation|Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation||Asociación para Evitar la Ceguera en México||Recruiting|July 2008|||July 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|40 Years|70 Years|No|||December 2008|December 5, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00804206||146421|
NCT00799695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F10030|Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population|Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population||Henry Ford Health System|No|Completed|January 2008|November 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|561|||Both|18 Years|N/A|No|||November 2008|November 28, 2008|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799695||146766|
NCT00800267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96TIPG005|A Study of Glaucoma or Ocular Hypertension in Patients Within the United States|A 6-Month, Randomized, Double-Masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-Month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Multicenter Study in the United States||Pfizer|No|Completed|July 1997|June 1999|Actual|June 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|418|||Both|18 Years|N/A|No|||March 2009|March 5, 2009|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800267||146723|
NCT00800566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0905|Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)|Phase I Study of Oral Clofarabine for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|Yes|Withdrawn|November 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|December 1, 2008|No|Yes|Sponsor terminated.|No||https://clinicaltrials.gov/show/NCT00800566||146700|
NCT00800228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0110|Salt Study: Inhibited Breathing Pattern and Sodium Inhibitors in Sodium Sensitivity of Blood Pressure|Inhibited Breathing Pattern and Sodium Inhibitors in Sodium Sensitivity of Blood Pressure||National Institute on Aging (NIA)|No|Completed|March 2003|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|96|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community|November 2008|November 30, 2008|November 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00800228||146726|
NCT00800241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RTH-SYM-2008/1|Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand|Budesonide/Formoterol for Maintenance and Reliever Therapy: A Medication Use Evaluation Among Persistent Asthma Patients in General Practice in Thailand||AstraZeneca|No|Completed|May 2009|November 2009|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1020|||Both|12 Years|N/A|No|Non-Probability Sample|Patient aged 12 years or older who established persistent asthma and currently treated        with Symbicort SMART for 3 months or longer.|December 2010|December 2, 2010|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800241||146725|
NCT00800527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4ISM4350015-009/295|Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy|Phase 4 Study of Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy||Usak State Hospital|No|Completed|November 2007|October 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|15 Years|85 Years|No|||November 2008|December 1, 2008|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00800527||146703|
NCT00800839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0261|Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide|Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.||M.D. Anderson Cancer Center|No|Completed|September 2008|||July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|6 Months|75 Years|No|||July 2015|July 2, 2015|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800839||146679|
NCT00801190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HES|This Study Will Compare the Effect of Starch Containing to Non-Starch Containing Intravenous Fluid on Blood Loss During Coronary Artery Bypass Graft Surgery|A Prospective Randomized Double-Blind Placebo-Controlled Trial of the Effects of Colloid (HES 130/0.4) Versus Crystalloid (Ringer's Lactate) on Bleeding in Patients Undergoing Cardiopulmonary Bypass for Primary CABG, Single Valve Repair/Replacement, or Combined Single Valve/CABG Surgery"||St. Boniface General Hospital Research Centre|Yes|Not yet recruiting|December 2008|April 2011|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|500|||Both|18 Years|85 Years|No|||December 2008|December 2, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801190||146652|
NCT00792207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001317/2;MGH|The Role of a Virtual Coach in Improving Adherence to an Activity Program for Overweight Adults|The Role of a Virtual Coach in Improving Adherence to an Activity Program for Overweight Adults|StepUp|Massachusetts General Hospital|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 2, 2009|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00792207||147325|
NCT00801723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-01-02/04|(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.|Randomised, Double-Blind, Multi-Centre, 12 Month Extension Study to Evaluate the Safety And Efficacy of Daily Budesonide MMX 6 mg Versus Placebo in the Maintenance of Remission in Subjects With Ulcerative Colitis.||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2008|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|75 Years|No|||April 2014|April 8, 2014|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801723||146611|
NCT00793546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A6-2206|Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer|A Phase 2, Randomized, Open-Label Study Of Bosutinib Administered In Combination With Exemestane Versus Exemestane Alone As Second Line Therapy In Postmenopausal Women With Locally Advanced Or Metastatic ER+/PgR+/ErbB2- Breast Cancer||Pfizer|No|Terminated|February 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|No|||October 2012|October 4, 2012|October 29, 2008|Yes|Yes|See termination reason in detailed description.|No|October 4, 2012|https://clinicaltrials.gov/show/NCT00793546||147226|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.
NCT00793299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00025699|Burden of Cancer in Children: A Pilot Study to Investigate the Impact and Content of Video Illness Narratives|Burden of Cancer in Children: A Pilot Study to Investigate the Impact and Content of Video Illness Narratives||University of Rochester|No|Completed|November 2008|September 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|10 Years|18 Years|No|||April 2015|April 24, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793299||147244|
NCT00793559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161/08|Terlipressin Administration in Septic Shock Refractory to Catecholamines|Terlipressin Administration in Septic Shock Refractory to Catecholamines Bolus vs. Continuous Drip-Phase II||Assaf-Harofeh Medical Center|No|Not yet recruiting|November 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|90 Years|No|||November 2008|November 18, 2008|November 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793559||147225|
NCT00795314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-2008-FY10MZ31|Propofol-butorphanol Anesthesia During Uterine Curettage|Propofol-butorphanol Combined Anesthesia During Uterine Curettage on Abortion|PABADUC|Nanjing Medical University|Yes|Completed|November 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Female|19 Years|45 Years|No|||July 2009|July 14, 2009|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795314||147094|
NCT00795327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLYL_L_02508|Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring|The Canadian Study of the Use of Injectable Poly-L-Lactic Acid Dermal Implant for the Treatment of Hill and Valley Acne Scarring||Sanofi|No|Completed|October 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795327||147093|
NCT00798759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-050|Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN|Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN®||Alcon Research|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||May 2012|May 25, 2012|November 24, 2008|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00798759||146835|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)
NCT00799032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PC-002|The ATLANTA First in Man Study of the Catania Stent|Assessment of The Latest Non-Thrombogenic Angioplasty Stent (ATLANTA): Prospective, First in Man, Non-Randomized, Single Center for Patients With Documented Myocardial Ischemia Undergoing PCI|ATLANTA|CeloNova BioSciences, Inc.|Yes|Completed|May 2007|August 2008|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||November 2008|November 27, 2008|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00799032||146815|
NCT00795600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3614|Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment|A Multi-centre, Open-labelled, Randomised, Two-group Parallel Trial Comparing the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After 26 Weeks of Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily, Both With Insulin Aspart at Mealtimes||Novo Nordisk A/S|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|November 20, 2008|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00795600||147073|
NCT00795847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KurumeU-08058|Morning Hypertension and Preminent Therapy Study|The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension||Kurume University|Yes|Completed|November 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|20 Years|N/A|No|||November 2010|June 22, 2011|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795847||147054|
NCT00796562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0820|Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy|A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched Bone Marrow for Patients With Hematologic Malignancies|mylehaplo|Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|November 2008|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|96|||Both|6 Months|65 Years|No|||October 2015|October 30, 2015|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00796562||147001|
NCT00796575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8080-A-U102|Effects of Multiple Doses of CS-8080 in Healthy Volunteers|A Randomized, Placebo-Controlled, Multiple Ascending Dose Study To Assess The Safety, Pharmacokinetics and Pharmacodynamics Of CS-8080 In Healthy Volunteers||Daiichi Sankyo Inc.|No|Terminated|November 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|November 21, 2008|No|Yes|Safety concerns|No||https://clinicaltrials.gov/show/NCT00796575||147000|
NCT00794781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6201-A001-102|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors||Eisai Inc.||Active, not recruiting|June 2008|February 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794781||147133|
NCT00794794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03826|Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)|A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications||Merck Sharp & Dohme Corp.|No|Completed|November 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|204|||Both|6 Years|11 Years|No|||September 2015|September 21, 2015|November 19, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00794794||147132|
NCT00799708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-094|A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Effects of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women||Merck Sharp & Dohme Corp.||Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|27|||Female|40 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 18, 2016|November 26, 2008|No|Yes||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00799708||146765|
NCT00799994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-653|Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?|Effect of Acutely Lowering Intraocular Pressure on Multifocal Visual Evoked Potential Testing||Wills Eye|No|Completed|October 2004|January 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|23|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|glaucoma service|November 2008|December 2, 2008|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00799994||146743|
NCT00791960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01|Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting|Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting: A Randomized, Double Blind, Placebo-Controlled Trial||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|149|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791960||147344|
NCT00800254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0074|Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement|Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement||University of Colorado, Denver|No|Completed|October 2008|November 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|50 Years|85 Years|No|||July 2015|July 14, 2015|November 30, 2008||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00800254||146724|
NCT00800540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-16|Circadian Ocular Perfusion Pressure and Ocular Blood Flow|Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma||Alcon Research|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|December 1, 2008|No|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00800540||146702|
NCT00800553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT108999|fMRI-behavioral Study of Cholinergic Augmentation With Donepezil in Healthy Sleep Deprived Adults|The Neural and Behavioral Correlates of How Donepezil Modulates Memory and Inhibitory Efficiency in the Context of 24 Hours of Sleep Deprivation||Duke-NUS Graduate Medical School|Yes|Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|43|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800553||146701|
NCT00791648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081238|Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery|Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery||Vanderbilt University|Yes|Active, not recruiting|July 2009|December 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|653|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00791648||147368|
NCT00791934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005003|Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide|Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide (Kenalog-40)|DELIVER|Acclarent|No|Completed|August 2008|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|17 Years|N/A|No|||July 2014|July 18, 2014|November 13, 2008|Yes|Yes||No|May 6, 2014|https://clinicaltrials.gov/show/NCT00791934||147346|
NCT00791947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG-T-01|A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT|A Nordic Phase II Study of Peripheral T-cell Lymphomas Based on Dose-intensive Induction and High-dose Consolidation With Autologous Stem Cell Rescue||University of Aarhus|No|Completed|October 2001|August 2010|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|18 Years|67 Years|No|||September 2011|September 7, 2011|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00791947||147345|
NCT00793286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_89_04|Stapler Versus Glue for Laparoscopic Groin Hernia Repair|Stapler Versus Glue for Laparoscopic Groin Hernia Repair||University Hospital Inselspital, Berne|No|Completed|August 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||November 2008|November 21, 2008|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793286||147245|
NCT00793884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00013340|Emory Latino Diabetes Education Program|Emory Latino Diabetes Education Program|ELDEP|Emory University|No|Recruiting|October 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Spanish speaking patients with Diabetes|September 2015|September 29, 2015|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793884||147200|
NCT00799045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOPI_L_03563|Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects|Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study)|CANOA|Laval University|No|Active, not recruiting|October 2008|April 2016|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799045||146814|
NCT00796146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH010/ RV 254|Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population|||South East Asia Research Collaboration with Hawaii|No|Recruiting|April 2009|July 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|271|Samples With DNA|serum, PBMC|Both|18 Years|N/A|No|Non-Probability Sample|The population seeking VCT at the TRCAC will be screened. They are comprised of both men        and women of different ages, economic stratus and education level: a large portion of whom        are at high risk for HIV infection through commercial sex work and MSM.|May 2015|May 27, 2015|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796146||147032|
NCT00796588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFH:6100|The Effect of Remote Ischemic Preconditioning in Patients Undergoing Major Liver Surgery|The Effect of Remote Ischemic Preconditioning in Patients Undergoing Major Liver Surgery||Royal Free Hampstead NHS Trust|No|Enrolling by invitation|April 2005|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|48|||Both|18 Years|90 Years|No|||November 2008|November 21, 2008|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796588||146999|
NCT00796900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 197/2004|Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)|Dantrolene as a Treatment for Hyperthermia in Patients After Subarachnoidal Hemorrhage|DTH1|Medical University of Vienna|No|Terminated|May 2008|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|80 Years|No|||September 2009|May 11, 2011|November 20, 2008||No|organizationally not possible|No||https://clinicaltrials.gov/show/NCT00796900||146975|
NCT00790764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008--03-II|Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)|Phase II Study for the Transfer of Bone Marrow-Derived Mononuclear and Mesenchymal StemCells Into the Myocardium for the Treatment of Severe Coronary Ischemia||TCA Cellular Therapy|Yes|Suspended|November 2008|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||April 2011|May 7, 2014|November 12, 2008|Yes|Yes|Suspended due to lack of funding.|No||https://clinicaltrials.gov/show/NCT00790764||147436|
NCT00791063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST-CA001CTIL|18F ML-10 for Early Detection of Response of Brain Metastases to WBRT|An Open-Label Study to Evaluate 18F ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Whole Brain Radiation Therapy (WBRT)||Aposense Ltd.|Yes|Completed|March 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|July 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00791063||147413|
NCT00791375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA134197|Web-based Physical Activity Intervention for Young Adult Cancer Survivors|Web-based Physical Activity Intervention for Young Adult Cancer Survivors||The Miriam Hospital|No|Completed|May 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|39 Years|No|||April 2012|April 19, 2012|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00791375||147389|
NCT00791661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-005|MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)|A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-1006 in Japanese Subject With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|64 Years|No|||January 2016|January 6, 2016|November 10, 2008|No|Yes||No|September 7, 2012|https://clinicaltrials.gov/show/NCT00791661||147367|
NCT00791388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005046|Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 Days|Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of PG 760564 Administered Twice Daily to Healthy Male and Female Volunteers for 14 Days (27 Doses).||Procter and Gamble|No|Completed|August 2005|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 27, 2011|November 13, 2008|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00791388||147388|
NCT00800579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-221-0101|Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers||Gilead Sciences|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 20, 2009|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00800579||146699|
NCT00800852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-10-040|Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome|Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome||Samsung Medical Center|Yes|Completed||||||N/A|Observational|N/A|||||||Both|N/A|18 Years|Accepts Healthy Volunteers|Probability Sample|Fourteen children with PWS and control subjects|November 2008|December 1, 2008|November 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00800852||146678|
NCT00800865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-097|A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)|A 2-Stage, Open Label, Phase Ib Clinical Trial to Evaluate Biomarkers in Patients With Solid Tumor and Receiving a Single Dose of Cytotoxics||Merck Sharp & Dohme Corp.|No|Completed|January 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|36|||Both|18 Years|70 Years|No|||October 2015|October 9, 2015|December 1, 2008|No|Yes||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00800865||146677|
NCT00791973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16367B (OC 3)|Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen|Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen||University of Chicago|No|Completed|November 2008|May 2010|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 6, 2014|November 13, 2008|Yes|Yes||No|June 6, 2014|https://clinicaltrials.gov/show/NCT00791973||147343|
NCT00792493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098002|Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741|Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Multiple Ascending Doses of ORM-12741||Orion Corporation, Orion Pharma|Yes|Completed|December 2008|September 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 23, 2009|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792493||147303|
NCT00792779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE - 0023.0.263.000-08|Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty|Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty||Centro Medico Campinas|No|Active, not recruiting|November 2008|June 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||November 2009|November 4, 2009|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792779||147282|
NCT00792740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/06/2357/23|Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease|Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease|Chron Disease|Italfarmaco|Yes|Terminated|October 2007|February 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|88 Years|No|||February 2012|February 1, 2012|November 14, 2008||No|As no safety warnings were detected,Interim analysis from the first 40 patients reccomends to    stop the trial for futility|No||https://clinicaltrials.gov/show/NCT00792740||147285|
NCT00792753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELX-CL-0801|Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"|A Randomized, Single Blind, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Durable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions And A Randomized, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions||Elixir Medical Corporation|Yes|Active, not recruiting|October 2008|December 2016|Anticipated|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|360|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792753||147284|
NCT00792766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB# 2008-0333|Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)|Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis||Children's Hospital Medical Center, Cincinnati|Yes|Completed|December 2008|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||September 2013|September 17, 2013|November 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00792766||147283|
NCT00793312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 3.0 - 12 Nov 2008|China Endeavor Registry: A Registry With The Endeavor Zotarolimus Eluting Coronary Stent in China|To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor™ Zotarolimus Eluting Coronary Stent System in Chinese Patients, A Prospective, Multicenter Registry||Medtronic Vascular|No|Completed|November 2007|September 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2210|||Both|18 Years|N/A|No|Probability Sample|Patients with an indication for coronary stent implantation according to the 'Instructions        for Use' of the Endeavor™ Zotarolimus Eluting Coronary Stent System, or at investigators'        discretion. All consecutive patients who receive one or more Endeavor™ stents in one or        more target lesions should be included.|October 2012|October 16, 2012|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793312||147243|
NCT00793325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281292|Long Term Use of Somatropin in Patients Small for Gestational Age|Special Investigation Of Long Term Use Of Genotropin For SGA (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|February 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|920|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6281292 prescribes the Somatropin        (Genotropin® ).|December 2013|December 17, 2013|November 17, 2008|No|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00793325||147242|
NCT00793013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456789|Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation|Primary Resuscitation Using Airway Pressure Release Ventilation Improves Recovery From Acute Lung Injury or Adult Respiratory Distress Syndrome and Reduces All Cause Mortality Compared to ARDS Net Low Tidal Volume-Cycled Ventilation.|PRESSURE|University of Tennessee, Chattanooga|No|Recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|368|||Both|18 Years|85 Years|No|||August 2015|August 10, 2015|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793013||147265|
NCT00793026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04365|Dermacyd Breeze Pocket BR (Lactic Acid) - Acceptability|Safety Dermatological Evaluation: Genital Mucous Irritation - Test in Use - Dermacyd Breeze Pocket BR (Lactic Acid).||Sanofi||Completed|November 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793026||147264|
NCT00793897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA191-005|Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors|A Phase I Multiple Ascending Dose Study of BMS-754807 in Combination With Paclitaxel and Carboplatin in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|April 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|November 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793897||147199|
NCT00794183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0303M44604|A Pilot Study Comparing the Programmed Delay Between the Atrial and Ventricle Interval|A Pilot Study of theRelationship Between Atrio-Ventricular Delay and Changes in Biochemical Markers of Chronic Heart Failure During Cardiac Resynchronization Therapy (BRAVO-CRT)|BRAVO-CRT|University of Minnesota - Clinical and Translational Science Institute|No|Terminated|June 2004|November 2010|Actual|May 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|November 18, 2008||No|funding difficulty|No||https://clinicaltrials.gov/show/NCT00794183||147178|
NCT00795860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA - 1-03-JF-10 (completed)|Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise|Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|June 2003|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795860||147053|
NCT00795873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITAC07|OVATIO CRT and SITUS OTW LV Lead Post Approval Study|OVATIO CRT and SITUS OTW LV Lead Post Approval Study||ELA Medical, Inc.|No|Completed|December 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2260|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients needing CRT therapy|March 2012|September 16, 2013|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795873||147052|
NCT00795886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI14044|Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)|CHP-753, Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)||University of Utah|Yes|Completed|August 2005|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|N/A|21 Years|No|||July 2013|July 23, 2013|November 19, 2008||No||No|March 1, 2011|https://clinicaltrials.gov/show/NCT00795886||147051|
NCT00795301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR02/06/07|A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab|A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status.||National University Hospital, Singapore||Active, not recruiting|July 2008|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||74|||Both|21 Years|N/A|No|||January 2014|January 13, 2014|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795301||147095|
NCT00795613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GITIL - HD0607|Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)|Multicenter Clinical Study With Early Treatment Intensification In Patients With High- Risk Hodgkin Lymphoma, Identified As FDG-PET Scan Positive After 2 Conventional ABVD Courses|HD0607|Ospedale Santa Croce-Carle Cuneo|Yes|Active, not recruiting|June 2008|October 2015|Anticipated|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|60 Years|No|||October 2015|October 16, 2015|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795613||147072|
NCT00796601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061054|Maintenance of Efficacy.|A 6-Month, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Maintenance Of Effect Study Of Esreboxetine (PNU-165442g) Administered Once Daily (QD) In Patients With Fibromyalgia.||Pfizer|Yes|Withdrawn|May 2009|November 2010|Anticipated|May 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||March 2009|March 17, 2009|November 20, 2008|Yes|Yes|This study has been cancelled as the esreboxetine development program is being discontinued.    Safety and efficacy were not factors.|No||https://clinicaltrials.gov/show/NCT00796601||146998|
NCT00796614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.51|Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder|A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months||Boehringer Ingelheim|No|Completed|January 2008|February 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|231|||Both|2 Years|16 Years|No|||September 2015|September 29, 2015|November 20, 2008|Yes|Yes||No|August 6, 2012|https://clinicaltrials.gov/show/NCT00796614||146997|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00796913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISG2|Remission Induction and Sustenance in Graves' Disease 2|Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy||Aalborg Universitetshospital|No|Active, not recruiting|January 2008|January 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|250|||Both|18 Years|N/A|No|||January 2015|December 30, 2015|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796913||146974|
NCT00796926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R632/53/2008|Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes|Randomised Controlled Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes||Singapore National Eye Centre|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|65 Years|No|||October 2011|October 4, 2011|November 21, 2008||No||No|June 20, 2011|https://clinicaltrials.gov/show/NCT00796926||146973|
NCT00823888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEBH 2008-012|Mechanics of Knee Bracing|Mechanics of Knee Bracing||The New England Baptist Hospital|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00823888||144929|
NCT00823901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001828|Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea|A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks||Massachusetts General Hospital|Yes|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|January 14, 2009|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT00823901||144928|This study is limited by relatively small number of subjects. In addition, overall assessment of acne rosacea severity as determined by subjects’ self-assessment was not performed.
NCT00824174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0080|Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer|Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer||M.D. Anderson Cancer Center|No|Completed|December 2008|||September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|289|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, 18 years or older, with oral cavity or cutaneous cancer receiving surgical        treatment.|October 2012|October 1, 2012|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824174||144907|
NCT00824460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-CL-03A|Study of Phosphate Levels in Patients With Chronic Kidney Disease|An Open-label, Randomised, Active Controlled Multi-center Phase II Dose Finding Study to Evaluate the Ability of PA21 to Lower Serum Phosphate Levels and the Tolerability in Patients With Chronic Kidney Disease on Maintenance Hemodialysis|PA21|Vifor Inc.|No|Completed|December 2008|March 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|154|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|January 9, 2009|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00824460||144885|
NCT00824473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP443|A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Subjects With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|506|||Both|12 Years|N/A|No|||February 2010|February 19, 2010|January 14, 2009|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00824473||144884|
NCT00793988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02244|Vibration-Assisted Anaesthesia|Vibration-Assisted Anaesthesia: A Randomised Controlled Trial to Investigate Whether Vibration Reduces the Pain of Anaesthetic Injection in Eyelid Surgery||University of British Columbia|No|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 2, 2009|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793988||147193|
NCT00790894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 11A08|Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)|Phase II Randomized Trial of Ixabepilone Administered Weekly or Every Three Weeks in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Chemotherapy in the Neo-adjuvant or Adjuvant Setting|HIT|Hellenic Cooperative Oncology Group|No|Terminated|November 2008|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Female|18 Years|75 Years|No|||May 2011|May 17, 2011|November 13, 2008||No|The low accrual rate of the study (25% of the expected accrual rate)|No||https://clinicaltrials.gov/show/NCT00790894||147426|
NCT00791206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012859|Trial of the Effects of Remote Preconditioning on the Tissue Metabolism During Exercise and Ischemia|Single Blind Randomized Controlled Crossover Trial of the Effects of Remote Preconditioning on the Tissue Metabolism During Exercise and Ischemia||The Hospital for Sick Children|No|Active, not recruiting|November 2008|June 2014|Anticipated|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|20|||Both|16 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791206||147402|
NCT00794573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVITA|Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial|Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial|EVITA|McGill University|Yes|Completed|September 2009|December 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|302|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794573||147149|
NCT00790283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS/04-2007|Assessment of the Numen Stent With Evaluation in a Randomized Study|Assessment of the Numen Stent With Evaluation in a Randomized Study|ANSWERS|International Biomedical Systems S.p.A.|No|Recruiting|September 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2009|February 16, 2009|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790283||147472|
NCT00790582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28.013|A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Lithium|Forbes Norris MDA/ALS Research Center|Yes|Active, not recruiting|May 2008|July 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|80 Years|No|||March 2009|March 11, 2009|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790582||147449|
NCT00794170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001335|Interactive Study to Increase Glaucoma Adherence to Treatment|I-SIGHT: Interactive Study to Increase Glaucoma adHerence to Treatment Phase 2: Participant Recruitment & Intervention Delivery and Evaluation|I-SIGHT|Emory University|No|Completed|August 2008|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|312|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|November 17, 2008||No||No|August 15, 2012|https://clinicaltrials.gov/show/NCT00794170||147179|There may have been a selection bias that contributed to a placebo effect in the control group. The “control” patients may have already been motivated to seek knowledge or involvement in management of glaucoma.
NCT00790205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-082|Sitagliptin Cardiovascular Outcome Study (MK-0431-082)|TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control|TECOS|Merck Sharp & Dohme Corp.|Yes|Completed|December 2008|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14724|||Both|50 Years|N/A|No|||June 2015|June 30, 2015|November 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790205||147478|
NCT00790231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_105_08|Effects of Thoracic Epidural Anesthesia on Lower Urinary Tract Function|Effects of Thoracic Epidural Anesthesia on Lower Urinary Tract Function||University Hospital Inselspital, Berne|No|Completed|October 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|32|||Both|N/A|N/A|No|Non-Probability Sample|open kidney surgery with lumbotomy, thoracic epidural analgesia|November 2009|November 19, 2009|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790231||147476|
NCT00790777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012085|A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville|A Single-dose, Open-label, Randomized, 2-way Crossover Pivotal Bioequivalence Study of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville Under Fasted Condition in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|72|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|May 17, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00790777||147435|
NCT00790790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11978|A Study in the Treatment of Osteoarthritis Knee Pain|A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain||Eli Lilly and Company|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|147|||Both|40 Years|70 Years|No|||April 2012|April 11, 2012|November 12, 2008|Yes|Yes||No|August 25, 2011|https://clinicaltrials.gov/show/NCT00790790||147434|
NCT00791115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0350-CE|Salvage Prostatectomy After Radiotherapy|Salvage Prostatectomy After Radiotherapy: Whole-Mount Histopathological Validation for Tumor-Targeted Salvage HDR Brachytherapy||University Health Network, Toronto|Yes|Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Male|18 Years|N/A|No|||June 2015|June 12, 2015|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791115||147409|
NCT00823108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08-23B|Rapid Administration of Insulin in Sepsis|Rapid Administration of Insulin in Sepsis: A Pilot Study||Carolinas Healthcare System|Yes|Completed|March 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|January 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823108||144989|
NCT00823563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01092009-1542|Sex Differences in Coronary Pathophysiology|Sex Differences in Symptomatic Non-Obstructive Coronary Disease: Do Women Have a Unique Coronary Pathophysiology?||Stanford University|Yes|Recruiting|June 2007|||June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|126|||Both|18 Years|N/A|No|Non-Probability Sample|Adult women and men with angina who have been referred for an elective coronary angiogram        because of a reasonable clinical suspicion of coronary ischemia.|July 2014|July 7, 2014|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823563||144954|
NCT00823576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CIR-03|Efficacy of Ropivacaine Continuous Wound Instillation Versus Single Shot After Spine Fusion Surgery|Efficacy of Ropivacaine Continuous Wound Instillation Versus Single Shot After Spine Fusion Surgery||Centre Hospitalier Universitaire de Nice|No|Terminated|December 2008|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2009|May 31, 2011|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823576||144953|
NCT00823589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008 -21|Immune Status of Elderly Population Admitted in an Acute Geriatric Unit|Immune Status of Elderly Population Admitted in an Acute Geriatric Unit||Assistance Publique Hopitaux De Marseille|No|Completed|January 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|78|||Both|75 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 24, 2014|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823589||144952|
NCT00792857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP201-CL-1007|Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)|Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis||OPKO Health, Inc.|No|Completed|November 2008|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|80 Years|No|||November 2009|September 26, 2014|November 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00792857||147276|
NCT00792844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Seto|Comparison of Two Formulations of Bio-K|Comparison of Two Formulations of Lactobacillus Acidophilus and Lactobacillus Casei in the Prevention of Antibiotic-Associated Diarrhea: a Pilot Study||McMaster University||Not yet recruiting|February 2009|May 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|65 Years|N/A|No|||November 2008|November 17, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792844||147277|
NCT00793117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-87-01-48-6841|The Effect of Packing in Post Operative Management of FESS|The Evaluation of Effect of Pva Sponge in Prevention of Complications in Fess||Tehran University of Medical Sciences|Yes|Completed|November 2008|December 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|66|||Both|N/A|N/A|No|||June 2012|June 2, 2012|November 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793117||147258|
NCT00790296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-269-2|Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue|A Pilot, Randomized Double-Blind Placebo-Controlled Crossover Study of Synthetic Thyrotropin Releasing Hormone (TRH) Administration for the Treatment of Fatigue in Patients With Cancer||University of Connecticut Health Center|Yes|Terminated|December 2006|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|No|||April 2011|April 5, 2011|November 10, 2008|Yes|Yes|Interim analyses showed statistically and clinically significant results.|No|January 31, 2011|https://clinicaltrials.gov/show/NCT00790296||147471|Limitation: small sample size
NCT00793390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909033|Case-Control Study of Inflammatory Breast Cancer in North Africa|||National Institutes of Health Clinical Center (CC)||Recruiting|November 2008|||||N/A|Observational|N/A|||Anticipated|1200|||Female|18 Years|N/A|No|||November 2015|December 2, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793390||147237|
NCT00793676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4171|Asthma, Inflammation and G Protein-coupled Receptors (GPCR)|G Protein Coupled Receptor (GPCR)Signature as Biomarker of Chronic Pulmonary Inflammatory Diseases and of Therapeutic Follow-up||University Hospital, Strasbourg, France|No|Recruiting|September 2008|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|310|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793676||147216|
NCT00793975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13918|Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy|Phase I Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded to Standard Therapy||Eli Lilly and Company|No|Completed|January 2005|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|37|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|November 14, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793975||147194|
NCT00790907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108888|Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)|FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)|FUTURA/OASIS 8|GlaxoSmithKline|Yes|Completed|February 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3235|||Both|21 Years|N/A|No|||June 2012|July 9, 2015|November 13, 2008|Yes|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00790907||147425|
NCT00791219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70850702|Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis|A Randomized, Double Blind, Multiple-site, Placebo-Controlled Study, Comparing the Efficacy and Safety of SUBA™-Itraconazole Capsules Compared to SPORANOX® (Itraconazole) Capsules in the Treatment of Onychomycosis of the Toenail||Halcygen Pharmaceuticals Limited|No|Completed|November 2008|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791219||147401|
NCT00791505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/UR/08-20|Trimethoprim-Sulfamethoxazole Versus Ciprofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation|Antibiotic Comparison Exacerbation COPD||University of Monastir|No|Completed|July 2002|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||November 2008|November 13, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00791505||147379|
NCT00791830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT no: 2008-001267-11|Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan|Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study|SAFIR|University of Aarhus|Yes|Completed|April 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|82|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|November 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791830||147354|
NCT00792103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-15-NP101-008|An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months|An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months|NP101-008|Teva Pharmaceutical Industries|No|Completed|January 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|198|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|November 14, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00792103||147333|
NCT00794456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJ 3002-08|Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety|Double Blind, Randomized Study, Controlled by Valeriana Officinalis, of Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Patients With Mild and Moderate Anxiety||Marjan Industria e Comercio ltda|Yes|Completed|September 2009|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794456||147157|
NCT00794469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDR-HMO-CTIL|Water Induced Thermogenesis in Obese Children|Water Induced Thermogenesis in Obese Children||Hadassah Medical Organization|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|6 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|obese children participating in a lifestyle education and weight management program.|November 2008|August 1, 2013|November 19, 2008||No||No|June 21, 2009|https://clinicaltrials.gov/show/NCT00794469||147156|
NCT00790530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-05-JF-40|Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study|Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study|ATO-SR-DM|Harvard Pilgrim Health Care|No|Completed|June 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 11, 2008|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790530||147453|
NCT00790803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4499 Pegaptanib in uveitis|Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema|Vascular Endothelial Growth Factor (VEGF)Blockade With Intravitreal Pegaptnib in Non-Infectious Uveitic Cystoid Macular Edema (CME)||Wake Forest School of Medicine|No|Completed|March 2009|March 2012|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|November 12, 2008|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00790803||147433|Implementing screening protocols to catch less progressed CME cases could improve outcomes.
NCT00791141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCRA-HN|Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer|Multicenter, Open-label Phase II Trial on Post-surgery Chemoradiation in Combination With Cetuximab in Squamous Cell Carcinoma of the Head and Neck With High Risk of Locoregional Recurrence.|ACCRA-HN|Heinrich-Heine University, Duesseldorf|Yes|Completed|August 2008|September 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|70 Years|No|||January 2014|January 22, 2014|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00791141||147407|
NCT00791440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5808|Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy|Psychosis in Schizophrenia: Mechanisms of Recovery||New York State Psychiatric Institute|No|Completed|November 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|50 Years|No|||December 2012|December 12, 2012|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791440||147384|
NCT00823134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2231-109|Evaluation of ApneaLink Plus Scoring Capabilities|Evaluation of ApneaLink Plus Scoring Capabilities||ResMed|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the sleep lab Wangen, Allgäu, Germany.|January 2009|October 31, 2011|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00823134||144987|
NCT00792064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB No_378|Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation|Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation- a Prospective Cohort Study||Hannover Medical School|Yes|Recruiting|February 2009|July 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|700|||Both|18 Years|70 Years|No|Probability Sample|patients immediately after solid organ transplantation|August 2009|August 24, 2009|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792064||147336|
NCT00823342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000733-21|ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy|ANRS HB 05 : A Randomized, Double Blind, Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Terminated|December 2008|September 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||May 2009|May 7, 2009|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823342||144971|
NCT00823355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1777-J01|Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies|A Phase I, Open Label, Dose Ascending Study of BCX1777 (Oral) in Patients With Recurrent or Refractory T/NK-cell Malignancies||Mundipharma K.K.|No|Completed|January 2009|||August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|N/A|No|||September 2013|September 20, 2013|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00823355||144970|
NCT00823615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-319-C-005 sub 7|Comparison of Two New Silicone Hydrogel Multifocal Products|Comparison of Two New Silicone Hydrogel Multifocal Products||Alcon Research||Completed|December 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|N/A|No|||January 2012|June 26, 2012|January 13, 2009|Yes|Yes||No|September 7, 2010|https://clinicaltrials.gov/show/NCT00823615||144950|
NCT00794001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOE-01-10-07|Feedback Intervention and Treatment Times in ST- Elevation Myocardial Infarction|Feedback Intervention and Treatment Times in ST- Elevation Myocardial Infarction (FITT-STEMI): A Multicenter Trial Analyzing the Effects of Systematic Data Feedback on Treatment Quality and Survival Rates.|FITT-STEMI|St.Bernward Hospital|No|Recruiting|October 2007|December 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50000|||Both|N/A|N/A|No|||November 2015|November 10, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794001||147192|
NCT00794248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03179|Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)|Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|November 2002|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|122|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794248||147173|
NCT00793130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-ID-348-CTIL|The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label|The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|November 2008|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2008|November 18, 2008|November 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793130||147257|
NCT00790309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNA-Early DM Resolution|Early Diabetes Resolution After Weight Loss Surgery|Hormonal and Inflammatory Parameters Affecting Early Diabetes Resolution Following Weight Loss Surgery||Vanderbilt University|No|Enrolling by invitation|December 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|plasma and serum|Both|18 Years|65 Years|No|Non-Probability Sample|Subjects scheduled for weight loss surgery or other abdominal surgeries will be considered        for the study.|January 2016|January 19, 2016|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790309||147470|
NCT00790322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBG-2-03|Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Assess the Efficacy and Safety of SBG on Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Chemotherapy||Biotec Pharmacon ASA|No|Completed|October 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||February 2010|February 18, 2010|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790322||147469|
NCT00790595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-03-129|Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy|Phase I, Open Label, Single Center, Multiple Dose, Dose Escalation Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy||Jonsson Comprehensive Cancer Center|Yes|Completed|June 2006|||July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|6|||Male|18 Years|75 Years|No|||July 2012|July 27, 2012|November 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00790595||147448|
NCT00790920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12402A|Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke|A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke|DIAS-3|H. Lundbeck A/S|Yes|Completed|December 2008|||July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|492|||Both|18 Years|85 Years|No|||September 2015|September 17, 2015|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00790920||147424|
NCT00791232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004273|A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Phase 1 Study to Compare the Tolerability of OROS Paliperidone (Extended Release) With Immediate-release (IR) Risperidone in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2003|June 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|113|||Both|18 Years|65 Years|No|||March 2010|June 6, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791232||147400|
NCT00791245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTO - DeNovo NT 03-07-02|Post Market Study of DeNovo NT, Natural Tissue Graft|A Post Market Study of Articular Cartilage Defects of the Knee Treated Wtih DeNovo NT, Natural Tissue Graft||Zimmer Orthobiologics, Inc.||Completed|January 2006|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|55 Years|No|Non-Probability Sample|Clinical population|August 2014|August 7, 2014|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791245||147399|
NCT00791518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111891|Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy|An Evaluation of Lung Function and Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy|LABD|GlaxoSmithKline|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1084|||Both|40 Years|N/A|No|Probability Sample|Patients with diagnosed COPD who are on only one long acting bronchodilator medication to        control their COPD symptoms.|October 2012|July 24, 2014|November 13, 2008||No||No|March 25, 2010|https://clinicaltrials.gov/show/NCT00791518||147378|
NCT00791843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant AG00599|The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure|The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure|GHRH|University of Pennsylvania|Yes|Completed|March 2004|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|3|||Both|50 Years|N/A|No|||December 2013|December 9, 2013|November 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791843||147353|
NCT00792116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gum and math scores|The Effects of Gum Chewing on Math Scores in Adolescents|The Effects of Gum Chewing on Standardized Math Scores in Adolescents||Baylor College of Medicine||Completed|February 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|13 Years|16 Years|Accepts Healthy Volunteers|||November 2008|November 18, 2008|October 24, 2008||||No|October 24, 2008|https://clinicaltrials.gov/show/NCT00792116||147332|
NCT00792376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00045-2008|"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"|"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"||Argentine Tennis Association|No|Completed|August 2009|February 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|50 Years|No|||August 2013|August 2, 2013|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792376||147312|
NCT00790543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012206|Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease|Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease|RS|Emory University|No|Active, not recruiting|November 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|At time of enrollment, whole blood for DNA and serum will be collected in all patients.      Fresh fecal samples will also be requested. For gene expression analysis, biopsy specimens      will be collected during regularly scheduled endoscopies.|Both|N/A|16 Years|No|Probability Sample|Study population will consist of children newly diagnosed with Crohn's disease at primary        care clinics.|March 2015|March 3, 2015|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790543||147452|
NCT00790816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111767|Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents|An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors||Novartis|No|Active, not recruiting|October 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|297|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00790816||147432|
NCT00791128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-6|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||March 4, 2016|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791128||147408|
NCT00791154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060534|A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer|Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer||Amgen||Completed|December 2008|February 2013|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|204|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|October 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791154||147406|
NCT00791453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0001|Clarksdale Diabetes and Metabolism Clinic CHEC Study|Clarksdale Diabetes and Metabolism Clinic Consumer Health Education Center Study|CHEC|University of Mississippi Medical Center|Yes|Completed|April 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|No biospecimens are retained|Both|18 Years|64 Years|No|Non-Probability Sample|Established patients at a diabetes clinic.|May 2009|May 11, 2009|January 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00791453||147383|
NCT00791739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZD-PGB-2008|Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia|Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)||Universidad de Granada|No|Completed|April 2008|October 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00791739||147361|
NCT00792077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0945|A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue|A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2008|||November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00792077||147335|
NCT00792883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP: 7378|Clinical Protocol Validation to Identify Prognostic Markers for Critical Care Pediatric Patients|Clinical Protocol Validation to Identify Prognostic Markers for Critical Care Pediatric Patients|PCL07|Oswaldo Cruz Foundation|Yes|Completed|October 2007|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1000|Samples With DNA|DNA extracts from blood or oral swab|Both|1 Month|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|children in intensive care unit|October 2015|October 26, 2015|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792883||147274|
NCT00823368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22001A|Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001|Biomarker Testing and DNA Collection in Subjects Participating in a Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome||Seaside Therapeutics, Inc.|Yes|Completed|January 2009|||March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||Samples With DNA|DNA from blood,plasma|Both|6 Years|40 Years|No|Non-Probability Sample|Fragile x syndrome subjects that meet the inclusion and exclusion criteria and consent to        participate in protocol 22001|July 2013|July 30, 2013|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823368||144969|
NCT00823602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1387YAZDRCCI|Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH|Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART||Yazd Research & Clinical Center for Infertility||Recruiting|March 2008|January 2009|Anticipated|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Female|N/A|35 Years|Accepts Healthy Volunteers|||January 2009|January 14, 2009|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823602||144951|
NCT00792584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-136|Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz|Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz|SWITCH-EE|University Hospital, Geneva|Yes|Completed|November 2008|June 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2011|September 9, 2011|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792584||147297|
NCT00794261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALM|Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma|Assessment of the Efficacy and Tolerance, and Health Economic Study of a Single Administration of Pegfilgrastim in Lymphoma or Myeloma Patients Treated With Intensive Chemotherapy and Autologous Peripheral Stem Cell Transplantation|PALM|Centre Leon Berard|No|Completed|September 2008|June 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2010|July 7, 2010|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794261||147172|
NCT00794586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-207-0103|Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection|A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa||Gilead Sciences|Yes|Completed|November 2008|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|November 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794586||147148|
NCT00794599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03182|Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)|Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|December 2002|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|118|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794599||147147|
NCT00790348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709005250|Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes|Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes||Wayne State University|No|Recruiting|July 2008|||July 2009|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|45|Samples Without DNA|Serum of patients will be kept for future studies|Both|18 Years|80 Years|No|Probability Sample|Patients with type 2 diabetes on oral agent that require Metformin or Januvia only|October 2008|November 12, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790348||147467|
NCT00790634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5473-SH-CTIL|Mechanisms of Fronto-Subcortical Dysfunction: Comparing PD and OCD|Characterizing Mechanisms of Fronto-Subcortical Dysfunction: A Comparison Between Parkinson's Disease and Obsessive-Compulsive Disorder||Sheba Medical Center|No|Not yet recruiting|December 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|||Both|16 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|private and hospital-based clinics, healthy volunteers|November 2008|November 12, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790634||147445|
NCT00790608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP 5|Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)|A Phase II Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus in MRSA Positive Ulcers||Nitric BioTherapeutics, Inc|No|Terminated|January 2009|August 2011|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||November 2011|November 28, 2011|November 12, 2008||No|Limited recruitment|No||https://clinicaltrials.gov/show/NCT00790608||147447|
NCT00790621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2007|||||N/A|N/A|N/A||||||||||||||November 12, 2008|November 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790621||147446|
NCT00790946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-RCT-2006-06|Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)|Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension|KACT|Kagoshima University|Yes|Recruiting|June 2006|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|N/A|N/A|No|||December 2008|June 2, 2010|October 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00790946||147422|
NCT00791258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8663-404|A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure|A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy|BP CRUSH|Daiichi Sankyo Inc.|No|Completed|November 2008|September 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|999|||Both|18 Years|N/A|No|||September 2010|September 30, 2010|November 13, 2008|Yes|Yes||No|September 2, 2010|https://clinicaltrials.gov/show/NCT00791258||147398|
NCT00791271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0450|Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion|A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma||M.D. Anderson Cancer Center|Yes|Completed|September 2008|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00791271||147397|
NCT00791531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC1464|Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers|Phase 1 Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers||KEMRI-Wellcome Trust Collaborative Research Program|No|Completed|March 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791531||147377|
NCT00791856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007016|Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch|An Open-label, Multiple-dose, Randomized, Two-period Crossover Study to Assess Bioequivalence of the 300 Mcg/Day Testosterone Reduced-size Patch (14 cm2) Relative to the 300 Mcg/Day Testosterone Reference Patch (28 cm2)||Warner Chilcott|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|110|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|November 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791856||147352|
NCT00791869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133-31868|Pharmacogenetics of Bupropion Metabolism|Pharmacogenetics of Bupropion Metabolism||University of California, San Francisco|No|Completed|June 2008|November 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects with selected CYP2B6 genotypes.|May 2013|May 20, 2013|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00791869||147351|
NCT00792129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATV-03-002|MIS MiLIF Versus Open|A Multi-Center Study to Evaluate MiLIF(R) Versus Open Posterior Unilateral Lumbar Interbody Fusion (TLIF)||Zimmer, Inc.|No|Completed|April 2004|June 2009|Actual|March 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|113|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with chronic low back and/or leg pain who are candiates for elective lumbar        interbody fusion through a postierior unilateral approach, that present to either group of        surgeons, will be screened for inclusion in the study. If the patient meets all of the        eligibility criteria, they wil be enrolled into the study and have either the MiLIF or        open procedure depending on the surgoen they present to (i.e., what group their surgeon        agreed to participate in).|February 2012|February 14, 2012|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00792129||147331|
NCT00792142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06143|Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma|A Phase II Study of Maintenance Treatment With Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Multiple Myeloma||City of Hope Medical Center|Yes|Active, not recruiting|January 2008|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|70 Years|No|||February 2016|February 10, 2016|November 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792142||147330|
NCT00790556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8245-004|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245.||Merck Sharp & Dohme Corp.||Completed|October 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|November 7, 2008|No|Yes||No|September 10, 2010|https://clinicaltrials.gov/show/NCT00790556||147451|Stat. analysis of HGP was not performed as insulin suppression lead to a near complete suppression of HGP in both placebo and MK-8245 treated subjects, making it impossible to determine if MK-8245 could lead to a greater insulin effect than placebo
NCT00790829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20075594|Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery|Preemptive Use of Nicotine Patch for Postoperative Pain Relief in Open Abdominal Surgery||Stony Brook University|Yes|Recruiting|August 2007|September 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 11, 2011|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00790829||147431|
NCT00802204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#080861 and 061246|Dopamine and Insulin Resistance|Dopamine and Insulin Resistance||Vanderbilt University|No|Completed|December 2008|December 2012|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|December 12, 2015|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802204||146575|
NCT00802503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocole 07-098|Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients|Impact of Supplemental Parenteral Nutrition (SPN) on Infection Rate, Duration of Mechanical Ventilation and Rehabilitation in Intensive Care Unit Patients: A Quality Control Program for the Implementing of New Nutrition Guidelines||University Hospital, Geneva|No|Completed|May 2008|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|305|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|December 3, 2008||No||No|January 7, 2013|https://clinicaltrials.gov/show/NCT00802503||146552|The trial was limited by the fact that it was not double blinded by design. However, the risk of bias was reduced because the investigators worked independently from the physicians in charge of the patients.
NCT00802516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC03-046.3|Long Term Effects of Plant Sterol and Stanol Esters|Effects of Long-Term Daily Consumption of Plant Sterol or Stanol Esters in Statin-Treated Patients|LTS|Maastricht University Medical Center|No|Completed|June 2003|June 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2008|December 4, 2008|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802516||146551|
NCT00793143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLEEVEPASS|Laparoscopic Gastric Bypass Versus Sleeve Gastrectomy to Treat Morbid Obesity|A Randomized Prospective Three-center Study: Laparoscopic Gastric Bypass vs. Laparoscopic Sleeve Gastrectomy in the Treatment of Morbid Obesity|SLEEVEPASS|Turku University Hospital|No|Completed|April 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|240|Samples With DNA|Tissue samples|Both|18 Years|60 Years|No|Probability Sample|Patients rederred to three tertiary referral hospitals (Turku University Central Hospital,        Vaasa Central Hospital and Peijas Hospital)for treatment of morbid obesity|May 2010|May 24, 2010|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793143||147256|
NCT00792324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 029|Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125|A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125.||St Stephens Aids Trust|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||November 2009|November 17, 2009|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792324||147316|
NCT00792337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004(II)/51|The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma|The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma||Mahidol University|No|Completed|December 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|70 Years|No|||September 2009|September 10, 2013|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792337||147315|
NCT00793689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC00994614|Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy|Comparison of the Prognostic Value of Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test in the Evaluation of Parathyroid Function After Total Thyroidectomy||Aristotle University Of Thessaloniki||Completed|March 2008|October 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|127|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing total thyroidectomy|October 2009|October 15, 2009|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793689||147215|
NCT00794274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP0005|The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis|The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis||University of Cincinnati|Yes|Completed|November 2008|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||April 2013|April 10, 2013|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794274||147171|
NCT00794287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-AgNT-004|Performance of CAST (Cellular Antigen Stimulation Test) in Patients With Wasp Venom Allergy: Evaluation of Neutralizing IgG Subclasses|Performance of CAST (Cellular Antigen Stiumulation Test)in Patients With Wasp Venom Allergy. Evaluation of Neutralizing IgG Subclasses||University of Zurich|Yes|Withdrawn|January 2009|||December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|0|Samples Without DNA|Blood samples|Both|18 Years|75 Years|No|Probability Sample|Wasp venom allergic patients grade III and IV according to H.L. Müller in the age group of        18-75 years|June 2015|June 3, 2015|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794287||147170|
NCT00794300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Repro100|Reproducibility of Magnetic Resonance Myocardial Salvage Index|Reproducibility of Myocardial Salvage Index in Acute Myocardial Infarction by Cardiac Magnetic Resonance Imaging||University of Leipzig|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|ST-elevation myocardial infarction|November 2008|November 19, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794300||147169|
NCT00794612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04369|Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.|Safety Dermatological Evaluation: Genital Mucous Irritation - Test in Use - Dermacyd Femina Pocket BR (Lactic Acid).||Sanofi||Completed|November 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2008|December 18, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00794612||147146|
NCT00794625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH080050|Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)|Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD||National Institute of Mental Health (NIMH)|Yes|Recruiting|November 2008|April 2013|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|270|||Both|6 Years|12 Years|No|||July 2012|July 13, 2012|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794625||147145|
NCT00794638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008002|A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma|A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma||SymBio Pharmaceuticals|Yes|Completed|November 2008|May 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|75 Years|No|||May 2010|May 27, 2010|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794638||147144|
NCT00790361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13652|The Natural History of Traumatic Spinal Cord Injury Using fMRI, MRS and DTI|Mapping the Natural History of Traumatic Spinal Cord Injury in the Sensorimotor Cortex Using Functional Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging||Lawson Health Research Institute|No|Not yet recruiting|January 2012|January 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|30 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Ten patients and ten controls will be recruited from the Clinical Neurological Sciences        outpatient clinic at the London Health Sciences Centre, University Campus|June 2010|June 2, 2010|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790361||147466|
NCT00790647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000618857|Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis|Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis||Boston Medical Center|Yes|Completed|June 2008|November 2014|Actual|December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||March 2015|January 14, 2016|November 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790647||147444|
NCT00790660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0016|A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.|A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Assess the Safety and Tolerability of ASP1941 in Adult Subjects With Type 2 Diabetes Mellitus||Astellas Pharma Inc|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|61|||Both|18 Years|75 Years|No|||June 2015|June 5, 2015|November 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790660||147443|
NCT00792168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-06-291|Physiologic Monitoring of Antidepressant Treatment Response|Physiologic Monitoring of Antidepressant Treatment Response||University of California, Los Angeles|No|Completed|November 1996|December 1998|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|N/A|N/A|No|||November 2008|November 14, 2008|November 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792168||147328|
NCT00791882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST|Social Skills Training in Refractory Schizophrenia|Evaluation of Social Skills Training in Reducing Negative Symptoms in Patients With Refractory Schizophrenia|SST|University of Sao Paulo|Yes|Recruiting|August 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|55 Years|No|||November 2009|November 27, 2009|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00791882||147350|
NCT00792155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0304006105|Polycystic Kidney Disease Data Repository|Autosomal Dominant Polycystic Kidney Disease Data Repository||The Rogosin Institute|No|Recruiting|November 2002|December 2026|Anticipated|December 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|All patients enrolled in this study will have the diagnosis of autosomal dominant kidney        disease. The diagnostic criteria for at-risk individuals (i.e., with a first degree family        member with ADPKD) includes the presence of at least two(unilateral or bilateral) renal        cysts, and two cysts in each kidney are considered sufficient for diagnosis in aged 15 to        29 years and in 30 to 59 years, respectively. In families of unknown genotype, the        presence of three or more (unilateral or bilateral) renal cysts is sufficient for        establishing the diagnosis in individuals aged 15 to 39 years, two or more cysts in each        kidney is sufficient for individuals aged 40-59 years and four or more cysts in each        kidney is required in individuals ≥60 years of age.|February 2016|February 8, 2016|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792155||147329|
NCT00801346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000624471|Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission|The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).||National Cancer Institute (NCI)||Recruiting|November 2008|||January 2015|Anticipated|Phase 1|Observational|N/A|||Anticipated|45|||Both|1 Year|20 Years|No|||November 2008|August 11, 2009|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00801346||146640|
NCT00801021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23281|Treatment and/or Prevention of Urinary Tract Infections|Treatment and/or Prevention of Urinary Tract Infections|UTI|Biomedical Development Corporation|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3|||Female|18 Years|N/A|No|||November 2009|March 4, 2010|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801021||146665|
NCT00801333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0511-08-HMO|Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells|Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells||Hadassah Medical Organization||Active, not recruiting|November 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will use human somatic cells from existing collections.|February 2016|February 28, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801333||146641|
NCT00801593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMJ PROSPECT2008|Magnetic Resonance Imaging Follow-up on Temporomandibular Arthritis in Children With Juvenile Idiopathic Arthritis|Arthritis of the Temporomandibular Joints in Children With Juvenile Idiopathic Arthritis- Pilot Study on Diagnostic Value of Ultrasonography and Magnetic Resonance Imaging and Influence of Drug Treatment||University Hospital Tuebingen|No|Recruiting|May 2008|June 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|7 Years|17 Years|No|Probability Sample|Children with JIA.|December 2008|December 2, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801593||146621|
NCT00801892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HL089522-01A2|Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management|OSA, Sleepiness, and Activity in Diabetes Management|OSA_DM|University of Pittsburgh|Yes|Completed|April 2009|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|23|||Both|40 Years|65 Years|No|||February 2014|February 11, 2014|December 3, 2008||No||No|February 11, 2014|https://clinicaltrials.gov/show/NCT00801892||146599|
NCT00802217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-03-01|Oral Civamide Safety, Tolerability First in Human Study|A Phase 1 Open-Label, Single-Dose, Dose Escalation Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of Orally Administered Civamide (Zucapsaicin)||Winston Laboratories|Yes|Terminated|November 2008|July 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|November 26, 2008|No|Yes|PK results demonstrated no systemic absorption|No||https://clinicaltrials.gov/show/NCT00802217||146574|
NCT00802529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1135|Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease|Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial||Imperial College London|No|Completed|April 2009|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||February 2016|February 29, 2016|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802529||146550|
NCT00793416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDX01-22-2003|ShuntCheck Accuracy in Detecting Shunt Obstruction Normal Pressure Hydrocephalus (NPH) Patients|Accuracy of ShuntCheck and MRI in Detection of Shunt Obstruction in Patients Receiving Shunt Patency Test||NeuroDx Development|No|Withdrawn|November 2008|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|35 Years|90 Years|No|||October 2013|October 28, 2013|November 17, 2008||No|Loss of study staffing|No||https://clinicaltrials.gov/show/NCT00793416||147235|
NCT00793156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC120-8231|A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)|A Randomized-Withdrawal Phase 3 Study Evaluation the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)|AC120-8231|Acologix, Inc.|No|Not yet recruiting|December 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|80 Years|No|||February 2010|February 3, 2010|November 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793156||147255|
NCT00793403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-102317|Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study|Current Adoption Of Composite Indices In Evaluating Rheumatoid Arthritis Patients: An Observational Study ("NEW INDICES Study")|New Indices|Pfizer|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|293|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|December 2012|December 31, 2012|November 17, 2008||No||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00793403||147236|
NCT00794014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-08-073|Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion|Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion||Samsung Medical Center||Completed|November 2007|February 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00794014||147191|
NCT00794313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e4717|Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease|Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease||Oregon Health and Science University|No|Terminated|September 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|4|||Both|21 Years|N/A|No|||September 2012|September 11, 2012|November 19, 2008|Yes|Yes|Funding Ended|No||https://clinicaltrials.gov/show/NCT00794313||147168|
NCT00794651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR_08_MK_01|Osteoarthritis Bedside Testing Kit|Development of a Bedside Pain Assessment Kit for Evaluating Effectiveness of Drugs for Osteoarthritis||Analgesic Solutions|No|Not yet recruiting|January 2009|June 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|50 Years|85 Years|No|Non-Probability Sample|moderate to severe osteoarthritis of the knee .|November 2008|November 19, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794651||147143|
NCT00790335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22326953211|Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis|Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial|ATTRACT|Washington University School of Medicine|Yes|Active, not recruiting|November 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|692|||Both|16 Years|75 Years|No|||January 2016|January 7, 2016|October 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790335||147468|
NCT00791297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #422|Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914|A Phase 2, Randomized Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914 on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women||Population Council|No|Completed|October 2008|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|November 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00791297||147395|
NCT00791570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08062|Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy|Histocompatibility Leukocyte Antigen (HLA)-A*2402 and A*0201 Restricted Peptide Vaccine Therapy in Patients With Neovascular Maculopathy||Osaka University|Yes|Completed|October 2008|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|40 Years|85 Years|No|||October 2012|October 14, 2012|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00791570||147374|
NCT00790933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13008|An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease|A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease|GEMINI LTS|Millennium Pharmaceuticals, Inc.|Yes|Active, not recruiting|May 2009|August 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|2200|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790933||147423|
NCT00791544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10630|Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma|Dose-finding, Safety, Pharmacokinetic and Pharmacodynamic Study of AVE1642, an Anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination With Other Anti Cancer Therapies (Sorafenib or Erlotinib) in Patients With Advanced Liver Carcinoma||Sanofi|Yes|Terminated|November 2008|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|13|||Both|18 Years|N/A|No|||August 2010|August 3, 2010|November 13, 2008|Yes|Yes|Company decision to discontinue the AVE1642 development program, not due to any safety or    efficacy concerns|No||https://clinicaltrials.gov/show/NCT00791544||147376|
NCT00791557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-07-14|Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease|An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum||University Hospital Case Medical Center|No|Completed|October 2008|February 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||May 2014|May 20, 2014|November 13, 2008||No||No|September 3, 2013|https://clinicaltrials.gov/show/NCT00791557||147375|Due to timing of the study, only 2 subjects were enrolled.
NCT00791895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-2174|Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs|NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy|1-2-3|Novo Nordisk A/S|No|Completed|June 2003|November 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|November 13, 2008||||No||https://clinicaltrials.gov/show/NCT00791895||147349|
NCT00792441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU4950900071|Specific Inspiratory Muscle Training (SIMT)in the Patients With Ventilatory Dependence|Effect of Specific Inspiratory Inspiratory Training(SIMT)in the Patients With Ventilatory Dependence on Lung Function and Weaning Outcomes|SIMT|Khon Kaen University|Yes|Active, not recruiting|January 2007|December 2015|Anticipated|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|N/A|No|||April 2015|April 1, 2015|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792441||147307|
NCT00792428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-000346|Non-invasive Brain Stimulation and Occupational Therapy To Enhance Stroke Recovery|Facilitating Motor Recovery After Stroke Using tDCS|TDCS+OT|Beth Israel Deaconess Medical Center|No|Active, not recruiting|June 2006|December 2016|Anticipated|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 24, 2016|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792428||147308|
NCT00792688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLYC-101-1b|Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation|Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.||Glycotex, Inc.||Completed|October 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|November 14, 2008|Yes|Yes||No|June 23, 2011|https://clinicaltrials.gov/show/NCT00792688||147289|
NCT00801372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0522-08- HMO-CTIL|Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells|Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells||Hadassah Medical Organization|No|Active, not recruiting|November 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pregnant, healthy females older than 18 who signed an informed consent for the termination        of the pregnancy.        pregnant healthy couples older than 18 who signed an informed consent for a c-section.        healthy male newborns, undergoing surgical circumcision who's parents older than 18 signed        an informed consent.|February 2016|February 28, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801372||146638|
NCT00801619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P001624|Bilicurves: Using Information Technology to Improve the Management of Neonatal Hyperbilirubinemia|Bilicurves: Using Information Technology to Integrate Clinical Practice Guidelines Into the Management of Neonatal Hyperbilirubinemia||Massachusetts General Hospital|Yes|Completed|November 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|273|||Both|N/A|1 Month|Accepts Healthy Volunteers|Non-Probability Sample|Providers who care for infants in the newborn nursery at MGH will be study eligible. All        newborns 35 weeks or more weeks of gestation will be study eligible.|March 2016|March 14, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801619||146619|
NCT00801606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICTBSG|Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis|Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients|ICTBSG|All India Institute of Medical Sciences, New Delhi|Yes|Completed|December 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|403|||Both|6 Months|15 Years|No|||February 2016|February 8, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801606||146620|
NCT00801905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPAFENAC IN PRFC|Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation|Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation|NEPAF|Asociación para Evitar la Ceguera en México|No|Recruiting|August 2008|March 2009|Anticipated|December 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2008|December 3, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00801905||146598|
NCT00802230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Select-B1B2|Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure|Beta-Receptor SELECTivity of Carvedilol and Metoprolol Succinnate in Patients With Heart Failure: A Randomized Dose Ranging Trial (SELECT Trial)|SELECT|University of Utah|No|Completed|September 2002|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|N/A|N/A|No|||December 2008|December 3, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00802230||146573|
NCT00792597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00524|Comparison of Three Methods of Hemoglobin Monitoring|Comparison of Three Methods of Hemoglobin Monitoring in Patients Undergoing Spine Revision or Hip Revision Surgery.||University of California, San Francisco|No|Completed|April 2009|December 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|See inclusion/exclusion criteria|March 2013|March 6, 2013|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792597||147296|
NCT00792870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209707|Evaluation of the Shape Up Rhode Island Campaign|Evaluation of the Shape Up Rhode Island Campaign: Study 4 Does Adding Behavioral Weight Control Information to Shape-Up Rhode Island Improve Outcomes?||The Miriam Hospital|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792870||147275|
NCT00793429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBR-9|Safety Study of Prucalopride in Healthy Volunteers|A Double-Blind, Placebo-Controlled, Two-Way Cross-Over in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Prucalopride at Steady-State||Movetis|No|Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2008|November 20, 2008|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793429||147234|
NCT00793702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESEC-01|Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration|An Open Phase I Clinical Trial on the Safety and Risk of Sensitisation by Escalating Doses and Repeated Injections of the rdESAT-6 + rCFP-10 Skin Test Reagent Following Intradermal Administration to Healthy Adults||Statens Serum Institut|Yes|Completed|November 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793702||147214|
NCT00793715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H231|Laparotomy Versus Percutaneous Puncture in Patients With Abdominal Compartment Syndrome During Acute Pancreatitis|Decompressive Laparotomy With Temporary Abdominal Closure Versus Percutaneous Puncture With Placement of Abdominal Catheter in Patients With Abdominal Compartment Syndrome During Acute Pancreatitis:Multicenter, Randomised, Controlled Study|DECOMPRESS|University of Belgrade|No|Recruiting|July 2010|June 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||June 2010|July 22, 2010|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793715||147213|
NCT00794027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H40997-33062-01|The Effects of a Yoga Program in Heart Failure Patients|The Clinical Outcomes Associated With a Modified Yoga Program in Heart Failure|YOGA|University of California, San Francisco|No|Completed|November 2008|December 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|30 Years|75 Years|No|||July 2013|July 31, 2013|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00794027||147190|
NCT00790673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF102-103HCV|A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1|A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Safety, Tolerability, Biological Activity, and Pharmacokinetics of Orally Administered CF102 in Subjects With Chronic Hepatitis C Genotype 1||Can-Fite BioPharma|Yes|Completed|July 2009|July 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|60 Years|No|||March 2012|March 31, 2015|September 17, 2008||No||No|March 5, 2015|https://clinicaltrials.gov/show/NCT00790673||147442|
NCT00790959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHHPSASA1|The SASA! Study: An Evaluation of a Community Intervention to Address Gender-based Violence and Reduce HIV/AIDS Risk in Uganda|The SASA! Study: a Cluster Randomised Controlled Trial of a Community Mobilisation Intervention to Prevention Violence Against Women and Reduce HIV/AIDS Risk in Kampala, Uganda|SASA!|London School of Hygiene and Tropical Medicine|No|Recruiting|October 2007|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00790959||147421|
NCT00794664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPO3500108|Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis|A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis||Sanofi|Yes|Completed|January 2009|October 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|November 19, 2008|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT00794664||147142|
NCT00791583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007|ED Residents MBP During CVC Placement: Sim Lab Based Training|Emergency Medicine Residents Performance in Maximum Barrier Precautions During Central Venous Catheter Placement: Effect of Stimulation-based Training|EM CVC MBP|St. Luke's-Roosevelt Hospital Center|No|Completed|May 2008|August 2012|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Emergency Medicine Residents|August 2012|August 22, 2012|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00791583||147373|
NCT00791596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP001012008|Effectiveness of Ergonomic Intervention|Effectiveness of an Ergonomic Intervention on Work-Related Posture and Low Back Pain in Video Display Terminal Operators: a 3 Year Cross-Over Trial||University of Bologna|No|Completed|January 2005|December 2007|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|70 Years|No|||October 2008|November 13, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791596||147372|
NCT00791908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-STU81|Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata|Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata||Northwestern University|No|Completed|September 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|95 Years|No|||February 2015|February 18, 2015|November 14, 2008|No|Yes||No|August 30, 2010|https://clinicaltrials.gov/show/NCT00791908||147348|Absence of a cost analysis; all the participants were white; only one set of parameters (ie, for lasers, pulse duration and fluence; and for electrodesiccation, energy level) was used for treatment with each modality.
NCT00792181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPA Dnr 151:2008/4564|To Relieve Pain and Anxiety - an Intervention Study in Ambulance Services|Intervention Study to Relieve Pain and Anxiety in Acute Myocardial Disease Focusing on Treatment With Benzodiazepines(Midazolam)and the Importance of a Caring Relation.||Sahlgrenska University Hospital, Sweden|Yes|Completed|June 2008|||November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2800|||Both|N/A|N/A||||November 2008|November 14, 2008|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792181||147327|
NCT00792454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3399|Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program|||Maine Medical Center|No|Recruiting|October 2008|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792454||147306|
NCT00792701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000625070|S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer|Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)||Southwest Oncology Group|No|Active, not recruiting|November 2008|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|November 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792701||147288|
NCT00792714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-PK-102|Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients|Determination of the Pharmacokinetics of Inhaled Mannitol After Single and Multiple Dosing in Cystic Fibrosis Patients|DPM-PK-102|Pharmaxis|No|Completed|December 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|6 Years|N/A|No|||January 2010|January 31, 2010|November 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00792714||147287|
NCT00792974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EoL|End-of-Life Fear in Patients With End-Stage Lung Disease (COPD)|End-of-Life Fear in Patients With End-Stage Lung Disease: Fears of Death and Dying, Wishes and Needs of Patients With Severe COPD||Philipps University Marburg Medical Center|Yes|Recruiting|October 2008|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|199|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from the Pulmonary Rehabilitation Units of the Berchtesgadener        Klinikum Schönau, Germany, through direct recruitment and use auf administrative        databases. All patients who are alert and can provide consent are invited to participate,        if they have a chronic obstructive pulmonary disease with stage II, III or IV by        GOLD-criteria. An open three group comparison is made of one-hundred patients with severe        COPD (stage III and IV), thirty-three patients with moderate COPD (stage II), thirty-three        patients with hip prosthesis and thirty-three mental healthy persons in match-able age.|February 2009|February 4, 2009|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792974||147267|
NCT00793000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0581001|Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults|A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After First Time Administration Of Ascending Single Oral Doses To Healthy Adult Subjects||Pfizer|No|Completed|November 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|10||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 3, 2011|November 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793000||147266|
NCT00801645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 3200B0-103853|Effects of Exercise on Arterial Function and Insulin Resistance Syndrome in Pre-pubertal Obese Children|Effects of Aerobic Exercise Training on Arterial Function and Insulin Resistance Syndrome in Obese Children: A Randomized Controlled Trial||University Hospital, Geneva|No|Completed|August 2004|June 2010|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|67|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801645||146617|
NCT00801944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-002|Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms|Solifenacin in the Treatment of Urgency Symptoms of Overactive Bladder in a Rising Dose, Randomized, Placebo-controlled, Double-blind Trial|SUNRISE|Astellas Pharma Inc|No|Completed|April 2004|October 2005|Actual|October 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|973|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00801944||146595|
NCT00801632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN036ST|Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection|Renal Allograft Tolerance Through Mixed Chimerism||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2008|November 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|60 Years|No|||November 2015|November 6, 2015|December 2, 2008|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT00801632||146618|
NCT00801918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC8963|Denileukine Diftitox for Relapsed ALCL|A Phase II Pilot Multicenter Study of Denileukin Diftitox Alone and in Combination With ICE (ICED) Chemotherapy in Children, Adolescents and Young Adults (CAYA) With Relapsed or Refractory Anaplastic Large Cell Lymphoma||Columbia University|Yes|Withdrawn|December 2008|June 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|24 Years|No|||October 2009|May 14, 2013|December 3, 2008||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00801918||146597|
NCT00801931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC3457|Double Cord Blood Transplantation|Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders||Columbia University|Yes|Terminated|September 2007|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|1|||Both|N/A|30 Years|No|||July 2013|July 17, 2013|May 5, 2008||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00801931||146596|
NCT00802880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1299 / 201109179|Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma|Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma||Washington University School of Medicine|No|Completed|March 2009|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802880||146523|
NCT00793182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1323-07-872|Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography|A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Optiray 320 mgI/mL and Visipaque 320 mgI/mL on Renal Function in Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography|CINOPSIS CT|Mallinckrodt|No|Terminated|January 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|10|||Both|18 Years|N/A|No|||June 2009|June 16, 2009|November 17, 2008|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00793182||147253|
NCT00793195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012566|Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?|Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? A Pilot Double Blind Randomized Controlled Trial||The Hospital for Sick Children|Yes|Active, not recruiting|January 2009|January 2012|Anticipated|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|N/A|24 Months|No|||November 2011|November 2, 2011|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793195||147252|
NCT00793442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000089 1R01HL091757-01A1|Endothelium in Severe Sepsis|Endothelial Cell Signaling and Microcirculatory Flow in Severe Sepsis||Beth Israel Deaconess Medical Center|Yes|Recruiting|June 2008|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency department patients with severe sepsis|November 2015|November 13, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793442||147233|
NCT00793728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR131/08|Prospective Randomized Trial Comparing Two Techniques of Sleeve Gastrectomy|Prospective Randomized Trial Comparing Two Techniques of Sleeve Gastrectomy||Hospital Universitari de Bellvitge|No|Completed|October 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|60 Years|No|||August 2015|August 19, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793728||147212|
NCT00793741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9711M00055|Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness|Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Endocrinology clinic, community|January 2016|January 12, 2016|November 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793741||147211|
NCT00794040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090034|A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation|A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation||National Institutes of Health Clinical Center (CC)||Recruiting|November 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|160|||Both|7 Years|17 Years|No|||January 2016|February 6, 2016|November 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794040||147189|
NCT00794677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM6997|Effects of Ezetimibe on the Absorption of Oxidized Cholesterol|A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Plasma Appearance of 7-Ketocholesterol After an Oral Bolus in Patients With Primary Hypercholesterolemia||Children's Hospital & Research Center Oakland|No|Completed|June 2006|September 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2009|July 31, 2009|November 19, 2008|Yes|Yes||No|January 30, 2009|https://clinicaltrials.gov/show/NCT00794677||147141|
NCT00790998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3110A1-3000|Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection|A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus||World Health Organization|Yes|Completed|April 2009|May 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1497|||Both|12 Years|N/A|No|||November 2013|November 26, 2013|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00790998||147418|
NCT00791011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060340|Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat|A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma||Amgen||Completed|February 2008|August 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|33|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00791011||147417|
NCT00790972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15419A|The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity|The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity||University of Chicago|No|Completed|June 2007|June 2013|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00790972||147420|
NCT00790985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOA-04P|Efficacy of Flavocoxid Compared With Naproxen in Subjects With Moderate-severe Osteoarthritis of the Knee|Phase 3. Efficacy of Flavocoxid Compared With Naproxen in Subjects With Moderate-severe Osteoarthritis of the Knee||Primus Pharmaceuticals|Yes|Completed|January 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00790985||147419|
NCT00791284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004204|A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function|Pharmacokinetics of Paliperidone in Subjects With Moderate Hepatic Impairment as Compared to Subjects With Normal Hepatic Function.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2004|December 2004|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791284||147396|
NCT00791609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OpVe-HI-08-001|Evaluation the Feasibility of the FOSTI Device|Evaluation the Feasibility of the FOSTI Device Accurately and in a Real Time Way to Differentiate Malignant From Benign Tissue (Performed ex Vivo) in Cancer Surgery||Optivasive Ltd.|No|Active, not recruiting|March 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of subjects who undergo cancer surgery|November 2008|November 13, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791609||147371|
NCT00791921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDP870-275-08-003|Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated.||Otsuka Pharmaceutical Co., Ltd.|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|20 Years|74 Years|No|||August 2012|August 5, 2012|November 14, 2008||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00791921||147347|
NCT00792194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01452-51|Improvement of Aerobic Capacity in Cystic Fibrosis Patients With a One-year Home Training Period|Improvement of Aerobic Capacity in Cystic Fibrosis Patients With a One-year Home Training Period||University Hospital, Strasbourg, France|No|Completed|December 2008|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|15 Years|65 Years|No|||September 2015|September 29, 2015|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792194||147326|
NCT00792727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKT-500-US07|HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee||Hisamitsu Pharmaceutical Co., Inc.|No|Completed|September 2007|May 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|380|||Both|45 Years|N/A|No|||May 2015|May 12, 2015|November 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792727||147286|
NCT00793260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeepDive|Deep Dive Randomized Control Trial|Deep Dive Randomized Control Trial||Health Dialog|No|Completed|July 2006|May 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|174120|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2008|November 18, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793260||147247|
NCT00801970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-MB-0064-CTIL|Fear of Childbirth (Tokophobia) - Etiology, Essence and Clinical Implications|Fear of Childbirth (Tokophobia) - Etiology, Essence and Clinical Implications||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|January 2008|January 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|150|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2008|December 3, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00801970||146593|
NCT00801983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08030467|The Effect of Alternative Keyboards on Discomfort and Typing Kinematics|The Effect of Alternative Keyboards on Discomfort and Typing Kinematics||University of Pittsburgh|Yes|Completed|January 2009|August 2013|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|December 3, 2008||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00801983||146592|
NCT00801957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506-06-27|Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis|A Double Blind, Multicentre, Randomised, Parallel Group Study to Demonstrate the Equivalence of the Response to Vaccination of a Tacrolimus Ointment Regimen to a Steroid Ointment Regimen in Children With Moderate to Severe Atopic Dermatitis||Astellas Pharma Inc|No|Completed|March 2003|November 2004|Actual|November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|260|||Both|2 Years|11 Years|No|||September 2014|September 17, 2014|December 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00801957||146594|
NCT00802243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003545-32|Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid|Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study|ARABUL|University Hospital, Limoges|Yes|Recruiting|September 2007|||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|65 Years|N/A|No|||December 2008|December 3, 2008|December 3, 2008||||No||https://clinicaltrials.gov/show/NCT00802243||146572|
NCT00793208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004|Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)|Active Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) Using Fibroblasts Transfected With DNA From Autologous Tumor (Phase IB Study)||University of Pittsburgh|Yes|Recruiting|June 2012|January 2025|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793208||147251|
NCT00794053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAlexandria|The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer|The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer||Faculty of Medicine, University of Alexandria|Yes|Completed|December 2002|April 2009|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|N/A|N/A|No|||July 2009|July 14, 2009|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794053||147188|
NCT00793754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People|Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People|RATIONAL|Fundacion GESICA|Yes|Completed|March 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|30|||Both|50 Years|N/A|No|||October 2011|October 25, 2011|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793754||147210|
NCT00790374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-52-58064-003|BN83495 in Prostate Cancer|A Phase I Dose Escalating Study Evaluating the Pharmacodynamic Profile and Safety of BN83495 in Patients With Prostate Cancer With Evidence of Disease Progression While on Androgen Ablative Therapy|STX64PC|Ipsen|Yes|Completed|January 2009|February 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Male|18 Years|N/A|No|||February 2011|February 28, 2011|November 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790374||147465|
NCT00791310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1 01/03/2008|Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology|Phase 3b,Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology||Central Hospital, Nancy, France|No|Recruiting|November 2008|October 2010|Anticipated|October 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||December 2010|December 30, 2010|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791310||147394|
NCT00823784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siccr trial THD/stapler|Prospective Randomized Trial Comparing THD Versus Stapler Operation for 3rd Degree Hemorrhoids|Prospective Randomized Trial Comparing Transanal Doppler de-Arterialization (THD) Versus Stapler Operation for 3rd Degree Hemorrhoids|THD/stapler|Societa Italiana di Chirurgia ColoRettale|No|Recruiting|January 2008|July 2009|Anticipated|January 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|70 Years|No|||January 2009|January 15, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00823784||144937|
NCT00824083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01ER0807|Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment|Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment||University Hospital Muenster|No|Recruiting|July 2009|July 2014|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2200|||Both|6 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ewing sarcoma survivors and 1:1 matched control group of healthy subjects|July 2009|September 25, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824083||144914|
NCT00824096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-IRB09512014|Use Bronchoscopy to Predict Post-Extubation Stridor in Critical Ill Patients|||Chimei Medical Center|No|Recruiting|December 2006|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2009|January 15, 2009|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00824096||144913|
NCT00824356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110159|Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo|A Randomised, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Assess the Efficacy and Safety of Single Dose Intranasal GSK1004723 Compared With Placebo in an Allergen Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis||GlaxoSmithKline||Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|54|||Male|18 Years|65 Years|No|||June 2009|June 18, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00824356||144893|
NCT00824330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02237|Home-Based Walking Study in Older Adults With Type 2 Diabetes|The Use of a Home-based Walking Program to Treat Orthostatic Hypotension in Older Adults With Type 2 Diabetes||University of British Columbia|No|Recruiting|January 2009|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|65 Years|N/A|No|||August 2015|August 14, 2015|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00824330||144895|
NCT00824343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/21/08|A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer|An Open Label, Multicenter Phase II Study to Evaluate Efficacy and Safety of P276-00 in Indian Subjects With Recurrent, Metastatic or Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck|MONARCH|Piramal Enterprises Limited|No|Completed|September 2008|June 2013|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824343||144894|
NCT00824655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3012|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children|A Phase 3, Open-Label Trial, Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Previously Partially Immunized With Prevenar||Pfizer|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|234|||Both|140 Days|392 Days|Accepts Healthy Volunteers|||August 2011|August 4, 2011|January 16, 2009|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00824655||144871|
NCT00824928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1040|Salvage Cryotherapy in Recurrent Prostate Cancer|A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study|SCORE|University of Colorado, Denver|No|Terminated|January 2007|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Male|30 Years|80 Years|No|Non-Probability Sample|Academic Institutions and Community Urologic Oncology Clinics in the United States of        America and the United Kingdom|June 2010|May 26, 2015|January 15, 2009||No|Study was ended due to low enrollment|No||https://clinicaltrials.gov/show/NCT00824928||144850|
NCT00824902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0949|Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy|A Pilot Trial Evaluation of Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer in Patients Undergoing Radical Prostatectomy||M.D. Anderson Cancer Center|No|Terminated|December 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|N/A|N/A|No|||December 2013|January 7, 2015|January 15, 2009||No|Technical Issues|No||https://clinicaltrials.gov/show/NCT00824902||144852|
NCT00824915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT1623319|Enhanced Surveillance of RV Lead Integrity Alert (RVLIA)|Enhanced Surveillance of RV Lead Integrity Alert (RVLIA)|RVLIA|Medtronic Cardiac Rhythm Disease Management|No|Completed|August 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1779|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a confirmed Lead Integrity Algorithm download with a device download within        the open and closed date of data collection|June 2013|June 24, 2013|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824915||144851|
NCT00802282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00020767|Psilocybin and Spiritual Practice|Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior||Johns Hopkins University|Yes|Completed|August 2009|May 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|75|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|December 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802282||146569|
NCT00802256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63sh138|Comparative Evaluation of Pulpotomized Primary Molars With Mineral Trioxide Aggregate and New Endodonthic Cement|Comparative Evaluation of Pulpotomized Primary Molars With Mineralized Trioxide Aggregate & New Endodonthic Cement||hahid Beheshti University of Medical Sciences|Yes|Recruiting|October 2008|December 2009|Anticipated|December 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||April 2009|April 9, 2009|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802256||146571|
NCT00802269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-032|Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.|Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.||Asociación para Evitar la Ceguera en México|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||December 2008|December 3, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802269||146570|
NCT00802906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-RCS-2008|Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)|Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy||Johann Wolfgang Goethe University Hospitals|No|Completed|May 2007|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|21 Years|N/A|No|||September 2012|September 26, 2012|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802906||146521|
NCT00802919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081/C02|Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors|Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study||Nathan Kline Institute for Psychiatric Research|No|Recruiting|September 2008|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2012|May 16, 2012|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802919||146520|
NCT00802568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626720|Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment|Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning in Treating Patients With Multiple Myeloma||National Cancer Institute (NCI)||Completed|April 2007|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|65 Years|No|||December 2008|May 13, 2011|December 4, 2008||||No||https://clinicaltrials.gov/show/NCT00802568||146547|
NCT00802581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0728-B|Circumferential Spread of Anesthetic and Success in Sciatic Nerve Blockade|Does Ensuring Circumferential Local Anesthetic Spread Improve the Success of Ultrasound Guided Sciatic Nerve Block at the Popliteal Fossa?||University Health Network, Toronto|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|85 Years|No|||May 2010|December 8, 2011|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802581||146546|
NCT00793767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080016|Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration|Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men||Aarhus University Hospital|No|Completed|January 2009|||April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|10|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2009|May 28, 2009|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793767||147209|
NCT00794339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000624407|Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines|Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer|ACRIN 6682|American College of Radiology Imaging Network|Yes|Active, not recruiting|July 2009|March 2015|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|73|||Female|18 Years|N/A|No|||October 2014|October 27, 2014|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794339||147166|
NCT00794352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090032|Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System|Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the CNS||National Institutes of Health Clinical Center (CC)||Recruiting|November 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1200|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||January 2016|February 13, 2016|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794352||147165|
NCT00794326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1449|Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD|Multicentric, Parallel, Controlled, Randomized, Single-blind Clinical Evaluation of New Low Sodium Peritoneal Dialysis Solution on Patients With Hypertension Treated With Continuous Ambulatory or Automated Peritoneal Dialysis|PDOne|Fresenius Medical Care Deutschland GmbH|Yes|Completed|October 2008|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||September 2014|February 26, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794326||147167|
NCT00790387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC2006|Tirofiban and Enoxaparin in High Risk Coronary Intervention|High Bolus Dose Tirofiban and Enoxaparin Provides Reduced Thrombin Generation and Inflammatory Markers in Patients With High Risk Undergoing Percutaneous Intervention||The Prince Charles Hospital|No|Completed|June 2004|December 2006|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2008|March 23, 2010|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790387||147464|
NCT00790400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001M2302|Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)|A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)|EXIST-2|Novartis|Yes|Completed|April 2009|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 10, 2008|Yes|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00790400||147463|
NCT00790686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2008/24|Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter|Study of Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in the Treatment of Chronic Strictures of the Ureter|TOTEME|University Hospital, Bordeaux|Yes|Completed|November 2008|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790686||147441|
NCT00790699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE 001|Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port|A Randomized, Parallel, Single Center, Comparison, Pilot Study Evaluating the Safety and Efficacy of Using Symlin Alongside Insulin in a Multiple Injection Port (I-PORT)||Texas Diabetes & Endocrinology, P.A.|Yes|Terminated|August 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||December 2009|November 16, 2011|November 10, 2008|Yes|Yes|Lack of patient population|No||https://clinicaltrials.gov/show/NCT00790699||147440|
NCT00791024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC06|Development of a New Method for Analgesia|Phase One Study and Two of a New Method for Local Analgesia||Hvidovre University Hospital|Yes|Completed|November 2008|January 2010|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|126|||Both|18 Years|70 Years|No|||August 2015|August 25, 2015|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00791024||147416|
NCT00791037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6658|Vaccine Therapy in Treating Patients With Stage IV Breast Cancer|Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer||University of Washington|No|Active, not recruiting|October 2008|||July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|November 13, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00791037||147415|
NCT00791323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-ACU-08-001|Efficacy of Ketorolac 0.4% in Prostaglandin Suppression|||Allergan|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|N/A|No|||September 2011|September 21, 2011|November 12, 2008|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00791323||147393|
NCT00791336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802788|Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer|A Phase II Trial of the HIV Protease Inhibitor Nelfinavir and Concurrent Radiation and Chemotherapy in Patients With Stage III Non Small Cell Lung Cancer||University of Iowa|Yes|Terminated|August 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|November 13, 2008|Yes|Yes|Poor enrollment.|No||https://clinicaltrials.gov/show/NCT00791336||147392|
NCT00823797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6803|Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma|A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)||University of Washington|Yes|Active, not recruiting|October 2008|||December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823797||144936|
NCT00824109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR07-001|Prospective, Multicenter Study of the Second Generation Antimicrobial Graft in the Abdominal Position|Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in the Abdominal Position||Datascope Corp.|No|Recruiting|July 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||December 2010|December 2, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00824109||144912|
NCT00824369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271038|A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1|A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1 Infected Subjects||Pfizer|No|Terminated|July 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|January 15, 2009|Yes|Yes|See termination reason in detailed description.|No|January 16, 2014|https://clinicaltrials.gov/show/NCT00824369||144892|
NCT00824382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.22|Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD|Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL Delivered by the Respimat Inhaler in Japanese Patients With COPD||Boehringer Ingelheim||Completed|January 2009|||March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|328|||Both|40 Years|N/A|No|||May 2014|June 17, 2014|January 15, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00824382||144891|
NCT00824668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1832|Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes|A Randomised, Open-labelled, 2-period Crossover Trial Investigating Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 Thrice Daily and Basal-bolus Therapy With Insulin Glargine & Insulin Glulisine in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|August 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|65 Years|No|||June 2015|June 23, 2015|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00824668||144870|
NCT00824941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090064|Brain-Gut Interactions in Overweight and Normal Weight Patients With Chronic Abdominal Pain|Brain-Gut Interactions in Overweight and Normal Weight Patients With Chronic Abdominal Pain||National Institutes of Health Clinical Center (CC)||Recruiting|January 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|13 Years|45 Years|Accepts Healthy Volunteers|||July 2015|August 6, 2015|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824941||144849|
NCT00824954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0043|Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease|Evaluation of Extracorporeal Photochemotherapy in Children and Young Adults With Refractory Acute Graft Versus Host Disease After Allogeneic Stem Cell Transplantation||University Hospital, Clermont-Ferrand||Recruiting|June 2009|December 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|30 Years|No|||January 2011|January 18, 2011|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00824954||144848|
NCT00825214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHTM/HILL/08/01|Evaluation of Zapperclick Device for Relief From Mosquito Bites|Evaluation of a Piezoelectric Device (Zapperclick) for Relief From Mosquito Bites||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|March 2008|February 2009|Anticipated|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 16, 2009|January 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00825214||144828|
NCT00825227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/2036/ON/US|Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Armodafinil Treatment (150 mg/Day) for Patients With Fatigue Associated With Taxane Chemotherapy Alone or in Combination With Other Agents||Teva Pharmaceutical Industries|No|Terminated|December 2008|February 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|January 15, 2009|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00825227||144827|This trial was discontinued early after only 10 of 160 planned subjects had been recruited. No efficacy data was analyzed.
NCT00802594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|289-C-003|A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis|Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis||Immtech Pharmaceuticals, Inc|No|Completed|August 2001|November 2004|Actual|August 2002|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|16 Years|N/A|No|||December 2008|December 4, 2008|December 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802594||146545|
NCT00802607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909046|Collection of Tissue Specimens for Analysis and Establishment of Cell Cultures|Procurement of Normal and Abnormal Bone, Dermis and Adipose Tissue for Establishment of Cell Cultures and Tissue Analysis||National Institutes of Health Clinical Center (CC)||Completed|December 2008|October 2010||||N/A|Observational|N/A|||Anticipated|50|||Both|N/A|N/A|No|||October 2010|September 26, 2015|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802607||146544|
NCT00802633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081018|Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?|Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?||Vanderbilt University|No|Terminated|November 2008|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|19 Years|85 Years|No|||December 2013|December 21, 2013|December 3, 2008||No|Enrollment was stopped after eighty patients were enrolled.|No|December 21, 2013|https://clinicaltrials.gov/show/NCT00802633||146542|Study terminated after 80 subjects
NCT00802932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15303|Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Tx|Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Treatment||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|March 2008|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|61|||Female|18 Years|N/A|No|Probability Sample|Research subjects will be recruited from the clinical practice of the Breast Program        referred for radiation therapy at Moffitt Cancer Center who meets the eligibility        criteria. This provides a potential pool of about 450 patients over a 12 month period.|January 2013|January 29, 2013|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802932||146519|
NCT00803218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10216916|Randomized Study to Compare the Bioavailability of Two Fluticasone Propionate 0.005% Topical Ointments|Bioequivalence of Two Fluticasone Propionate 0.005% Topical Ointments||Perrigo Company|No|Completed|November 2002|November 2002|Actual|November 2002|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|56|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|March 2012|March 15, 2012|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803218||146497|
NCT00794079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1147|Omega-3 Fatty Acids and Muscle Protein Synthesis|Omega-3 Fatty Acids and Muscle Protein Synthesis||Washington University School of Medicine|Yes|Completed|June 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|43|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794079||147186|
NCT00794703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCFGCN02-0|A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections|A Multi-center, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of Mycamine® vs Itraconazole Oral Solution for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant||Astellas Pharma Inc|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|288|||Both|18 Years|70 Years|No|||February 2010|February 8, 2010|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794703||147139|
NCT00794716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-01/2007 (FLD)|Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)|Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients With Clinical Evidence for Non-alcoholic Fatty Liver Disease (NAFLD): Supporting the Disease Staging Into Fatty Liver Disease Versus Non-alcoholic Steatohepatitis (NASH)||Norgine|No|Completed|June 2008|November 2011|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|125|||Both|18 Years|80 Years|No|||August 2010|June 9, 2015|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794716||147138|
NCT00794690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR and the liver|Safety Study of Black Cohosh Use by Postmenopausal Women on the Liver|Influence of Black Cohosh (Cimicifuga Racemosa) Use by Postmenopausal Women on Total Hepatic Perfusion and Liver Functions|CR-LIVER|Assiut University|No|Completed|January 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 31, 2009|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794690||147140|
NCT00791050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMAneste002|Examine the Effects of Maintaining Body Core Temperature During CABGs|To Examine the Effects on Patients Outcomes of Maintaining Body Core Temperature During CABGs With Thermowrap||Centro Cardiologico Monzino|No|Not yet recruiting|January 2009|March 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|85 Years|No|||October 2008|November 13, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791050||147414|
NCT00791349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004201|A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone|A Placebo- and Positive-controlled, Randomized Study Evaluating QT and QTc Intervals Following Administration of Immediate-release Paliperidone in Subjects With Schizophrenia or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2005|May 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|141|||Both|18 Years|50 Years|No|||March 2010|June 6, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791349||147391|
NCT00791362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAHVZ|Evaluation Research of a National Accreditation and Improvement Programme for General Practice|Effects and Costs of a National Continuous Improvement Programme on Cardiovascular Diseases in Primary Care||Radboud University|No|Completed|December 2008|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1685|||Both|N/A|N/A|No|||May 2012|July 8, 2013|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791362||147390|
NCT00791622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011056|A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating QT/QTc Intervals Following Administration of Extended-release Paliperidone and Quetiapine in Subjects With Schizophrenia or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2006|June 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|110|||Both|18 Years|50 Years|No|||April 2010|May 17, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791622||147370|
NCT00791635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0095|Pelvic Exenteration for Gynecologic Malignancy|Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy||M.D. Anderson Cancer Center|No|Recruiting|September 2008|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Women having gynecological cancer that was either treated with or will be treated with        pelvic exenteration surgery.|November 2015|November 17, 2015|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791635||147369|
NCT00823810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCORE|Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT|Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT|RESCORE|Turku University Hospital|No|Terminated|December 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|40 Years|80 Years|No|||October 2014|October 8, 2014|January 15, 2009||No|Recruitment promlems|No||https://clinicaltrials.gov/show/NCT00823810||144935|
NCT00824122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10914|Vancomycin Associated Red Man Syndrome (RMS)|Genetic Polymorphisms Associated With Histamine Disposition in Children With Vancomycin Associated Red Man Syndrome (RMS)||Children's Mercy Hospital Kansas City|No|Completed|January 2008|October 2011|Actual|December 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|544|Samples With DNA|Frozen blood has been maintained for future genetic studies|Both|6 Months|21 Years|No|Non-Probability Sample|Eligible patients will be identified by a search of patients who are receiving vancomycin        therapy throughout the study period. Chart review/patient interview will then be performed        to identify patients who developed symptomatology consistent with RMS while receiving        vancomycin infusion. For the purposes of this study, red man syndrome (RMS) will be        defined as: erythematous rash, flushing of the face, neck, or torso, itching, or a        lowering of systolic or diastolic blood pressure by >10mm/hg. A subset of patients who        remained asymptomatic throughout their vancomycin therapy will also be evaluated as a        control group.|October 2011|October 11, 2011|January 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00824122||144911|
NCT00824694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigator Initiated|Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes|Impact of Accu-Chek 360 View on Practice Patterns and HBA1C in Veterans With Type 2 Diabetes.||Biomedical Research Institute of New Mexico|Yes|Completed|March 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|348|||Both|18 Years|85 Years|No|||June 2011|June 21, 2011|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824694||144868|
NCT00824681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-00891|Effect of Music Therapy on Families of Burn Patients|Sound Of Family Together (S.O.F.T.) Music Program: A Randomized-Controlled Study to Investigate the Effect of Music Therapy on the Coping and Adjustment of Children of Adults With Major Burns|MTS3|MetroHealth Medical Center|No|Terminated|September 2007|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|6 Years|14 Years|No|||July 2010|July 22, 2010|January 15, 2009||No|Music therapist left position.|No||https://clinicaltrials.gov/show/NCT00824681||144869|
NCT00824967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-PP-03|Non Pharmacological Management of Behavioural Symptoms in Nursing Home|Not Pharmacologic Treatment Has Illness of Alzheimer and Pathologies Related. Application in Disturbances of Behaviour in EHPAD||Centre Hospitalier Universitaire de Nice|No|Terminated|October 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|306|||Both|60 Years|90 Years|No|||January 2009|March 23, 2012|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824967||144847|
NCT00825253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1831|Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes|A Randomised, Open-labelled, 4-period Crossover Trial Characterising Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 Administered Once, Twice or Thrice Daily and Biphasic Human Insulin 30 Administered Once Daily in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00825253||144825|
NCT00825240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0296|Formative Study of Tailored Survivor Health Promotion|Formative Study of Tailored Survivor Health Promotion||M.D. Anderson Cancer Center|No|Completed|December 2008|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Probability Sample|Stage IIB or III Colorectal cancer patients over 18 years of age ending cancer treatment        or have completed cancer treatment.|March 2015|March 6, 2015|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00825240||144826|
NCT00801996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806009874|Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab Countries|Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab Countries|ProstateCA|Weill Medical College of Cornell University|No|Recruiting|November 2008|November 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|700|Samples With DNA|Blood and tissue will be collected from individuals with prostate cancer. Only blood will be      collected from normal controls.|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Individuals of Arab descent from Qatari peninsula          -  Individuals from the Qatari Peninsula whose ancestors up to three generations back             were natives of Qatar|December 2015|December 18, 2015|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00801996||146591|
NCT00802009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0896-B|Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade|Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade||University Health Network, Toronto|No|Completed|May 2009|November 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|60 Years|No|||January 2010|January 22, 2010|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00802009||146590|
NCT00802022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-118|Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy|Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy (PDP Study) A Pilot Study|SCS|Maastricht University Medical Center|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||July 2010|July 7, 2010|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802022||146589|
NCT00802295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-JR-0204-307-11|Aneuploidies and Different Stimulation Protocols|Influence of Ovarian Stimulation and Embryo Aneuploidy||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802295||146568|
NCT00802620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0616/04|Amniotic Membrane Associated With Conjunctival Autograft Versus Conjunctival Autograft for Recurrent Pterygia|||Federal University of São Paulo|Yes|Enrolling by invitation|June 2005|||June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|15 Years|80 Years|Accepts Healthy Volunteers|||December 2008|December 4, 2008|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802620||146543|
NCT00803504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-120905|Correlation of Optic Disk Morphology and Ocular Perfusion Parameters in Patients With Primary Open Angle Glaucoma|Correlation of Optic Disk Morphology and Ocular Perfusion Parameters in Patients With Primary Open Angle Glaucoma||Medical University of Vienna|Yes|Completed|November 2006|August 2007|Actual|||N/A|Observational|N/A|||Actual|103|||Both|18 Years|N/A|No|||December 2008|December 4, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00803504||146475|
NCT00803231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12401|Follow-up Data of Patients Treated With XIGRIS® in France|Follow-up Data of Patients Treated With XIGRIS® DROTRECOGIN ALFA (ACTIVATED) in France||Eli Lilly and Company|No|Completed|November 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|1004|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients treated with Xigris® between January 1st, 2006 and August 31st 2008 in        intensive care units in France will be enrolled retrospectively, whereas all adult        patients treated with Xigris® between September 1st, 2008 and September 1st, 2009 will be        enrolled prospectively.|February 2010|February 1, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803231||146496|
NCT00794365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051079|Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients|Post-Marketing Surveillance Study To Observe The Safety And Effectiveness Of Varenicline (Champix) Tablets In Smoking Cessation Among Filipino Subjects||Pfizer|No|Completed|July 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|330|||Both|18 Years|N/A|No|Non-Probability Sample|This post-marketing surveillance study will be conducted nationwide and will enroll        approximately 3,000 study patients. Subject enrollment of less than 3,000 will be        acceptable in case of less than expected use of Varenicline (Champix™) by physicians.|November 2010|November 19, 2010|November 19, 2008|No|Yes||No|November 19, 2010|https://clinicaltrials.gov/show/NCT00794365||147164|
NCT00794378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03829|Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)|A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications||Merck Sharp & Dohme Corp.|No|Completed|November 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|202|||Both|6 Years|11 Years|No|||July 2015|July 3, 2015|November 19, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00794378||147163|
NCT00790426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2201|Phase II Study of TKI258 in Advanced Urothelial Carcinoma|A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma||Novartis||Completed|March 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|November 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00790426||147461|
NCT00790439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-01B|Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant|Open Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran (LMW-SD) in Islet Transplantation After Kidney Transplantation (CIT-01B)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn|July 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||June 2014|June 10, 2014|November 10, 2008||No|Due to funding limitations|No||https://clinicaltrials.gov/show/NCT00790439||147460|
NCT00790413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|385/2005|Haploidentical Stem Cell Transplantation in Neuroblastoma|High-dose MIBG With Subsequent Transplantation of Haploidentical Stem Cells in Children With Therapy Resistant Neuroblastoma||Lund University Hospital||Active, not recruiting|August 2005|||December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|6 Months|21 Years|No|||March 2016|March 3, 2016|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790413||147462|
NCT00823030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-221|Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis|Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis||Northwell Health|No|Withdrawn|January 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|80 Years|No|||October 2015|October 12, 2015|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823030||144995|
NCT00823277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130109|Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight|Indicators for the Metabolic Syndrome as Well as the Influence of Different Gen-polymorphs on Weightloss and the Maintenance of Lower Weight Among Children in Treatment for Overweight||Roskilde County Hospital|No|Completed|January 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|517|Samples With DNA|Blood samples of Whoole Blood.|Both|5 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Overweight and obese Children. 5-20 Years old. Paediatric Department, University Hospital        Holbaek,Region Zealand, University of Copenhagen, Denmark|April 2014|April 30, 2014|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823277||144976|
NCT00823524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632275|Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer|Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study||Asan Medical Center|No|Completed|January 2009|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|15 Years|75 Years|No|||February 2013|February 18, 2013|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823524||144957|
NCT00824135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REFLEX|Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies|Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies||St. Jude Children's Research Hospital|Yes|Active, not recruiting|January 2009|November 2016|Anticipated|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|N/A|21 Years|No|||December 2015|December 3, 2015|January 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00824135||144910|
NCT00824395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-4675|The Genetics of Diabetes in Southern California Chinese Americans|Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort||University of California, Irvine|No|Recruiting|January 2006|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|500|Samples With DNA|whole blood and serum|Both|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are currently recruiting Chinese Americans living in Southern California, espcially in        Orange and Los Angeles Counties. We are particularly in need of Chinese American men and        women with diabetes as well as healthy male controls. We can arrange for offsite weekend        trips to cities within LA or Orange Counties for eligible groups of 10 or more people.|February 2011|February 2, 2011|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824395||144890|
NCT00825279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-CECI|A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent|Comparison Among a Paclitaxel Eluting Stent With Biodegradable Polymer Versus an Uncoated Bare Metal Stent. A Prospective, Multicentric and Randomized Study.(EUCATAX Trial)|EUCATAX|Centro de estudios en Cardiologia Intervencionista|Yes|Completed|August 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|85 Years|No|||May 2010|May 27, 2010|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00825279||144823|
NCT00824980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMTM_IP10.C8_II/1|Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis|Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis - Phase II Single Center Study||Immune Technologies & Medicine GmbH|No|Recruiting|January 2009|September 2009|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|N/A|No|||January 2009|January 16, 2009|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824980||144846|
NCT00825266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09052008-1295|Insulin Resistance in Pulmonary Arterial Hypertension|The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension||Stanford University||Terminated|September 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||July 2011|July 22, 2011|January 16, 2009|Yes|Yes|difficulty in finding eligible subjects|No||https://clinicaltrials.gov/show/NCT00825266||144824|
NCT00825565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alwextin 3.0%-04|Study of Alwextin® Cream in Treating Epidermolysis Bullosa|Open-label, Pilot Study to Investigate the Safety and Tolerability of Alwextin 3.0% Cream in the Treatment of Epidermolysis Bullosa||Northwestern University|Yes|Completed|February 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|6 Months|N/A|No|||May 2015|May 15, 2015|January 19, 2009|Yes|Yes||No|February 22, 2012|https://clinicaltrials.gov/show/NCT00825565||144802|
NCT00825578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0708/84|Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema|Comparative Study of Bronchoscopic Lung Volume Reduction to Evaluate Relative Efficacy in Patients With Non-Upper Lobe Emphysema||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|No|||February 2012|February 3, 2012|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825578||144801|
NCT00825838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH19-001|Effect of Chili Pepper Extract on Weight and Fat Loss and Metabolism Increase|A Randomized Double-Blind Placebo-Controlled Clinical Trial of a Purified Chili Pepper Extract (CH-19 Sweet Extract) to Evaluate Its Safety and Efficacy for Weight and Fat Loss and Metabolism Change in Overweight or Obese Healthy Male and Female Adults||Ajinomoto USA, INC.||Completed|April 2006|March 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 20, 2009|January 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00825838||144781|
NCT00825851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smokaw_3|Effect of Smoking, Abstention and Nicotine Replacement Therapy on Wound Healing|Effect of Smoking, Abstention and Nicotine Replacement Therapy on Wound Healing||Bispebjerg Hospital|No|Completed|August 2000|January 2001|Actual|December 2000|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|78|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2009|January 20, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00825851||144780|
NCT00802945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PIR-05|Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer|A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Breast Cancer Whose Disease Has Failed Prior Taxane-Based Treatment||Nektar Therapeutics|No|Completed|October 2008|January 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802945||146518|
NCT00803244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO60.08|Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis (With or Without Asthma)|A Randomised, Double-blind, Placebo-controlled, Multi National, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT), Starting 2 Months Before the Grass Pollen Season, Administered as Allergen Based Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis (With or Without Asthma)||Stallergenes|No|Completed|January 2009|January 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Both|12 Years|65 Years|No|||September 2011|September 23, 2011|November 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00803244||146495|
NCT00803257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07030166|Effect of Lumbrical Stretching on Carpal Tunnel Syndrome|Effect of Lumbrical Stretching on Carpal Tunnel Syndrome||University of Pittsburgh|Yes|Completed|March 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|124|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803257||146494|
NCT00803829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20509|Synbiotic Treatment of Ulcerative Colitis Patients|Synbiotic Treatment of Ulcerative Colitis Patients||University of Dundee|No|Completed|January 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||July 2011|July 5, 2011|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803829||146450|
NCT00794729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909011|Evaluating the Quality of Different Methods of Obtaining Informed Consent|Sub-Study Evaluating the Quality of Different Methods of Obtaining Informed Consent"||National Institutes of Health Clinical Center (CC)||Completed|October 2008|September 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 26, 2015|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794729||147137|
NCT00794742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTUHSC-L09-014|Antimicrobial Resistance of Bacteria in Burn Patients|Analyzing the Antimicrobial Resistance Profile of Bacterial Isolates Obtained From Severely Burned Patients||Texas Tech University Health Sciences Center|No|Completed|November 2008|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|32|Samples Without DNA|Bacterial isolates of infected burn wounds|Both|N/A|N/A|No|Probability Sample|Patients with open,unhealed,burn wounds|April 2015|April 9, 2015|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794742||147136|
NCT00826956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30672026|The Change of Pulmonary Blood Flow During One Lung Ventilation|The Changes of Pulmonary Blood Flow in Nondependent Lung During One Lung Ventilation||Sichuan University||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|65 Years||||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826956||144695|
NCT00826969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/CH-101|Ciclesonide for the Treatment of Airway Hyperresponsiveness|Ciclesonide for the Treatment of Airway Hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A Double-blind, Randomized, Parallel Group Study.||Takeda|No|Completed|September 2008|October 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|70 Years|No|||February 2013|February 4, 2013|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826969||144694|
NCT00822783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2412|Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients|An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis.||Medical University of Vienna|No|Completed|October 2001|April 2003||||Phase 4|Interventional|N/A|2||||||Both|12 Years|60 Years|No|||January 2009|January 13, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822783||145013|
NCT00790725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001377|Proportional Assist Ventilation vs Pressure Support Ventilation|Proportional Assist Ventilation vs. Pressure Support Ventilation in the Management of Patients Referred to a Respiratory Acute Care Unit||Massachusetts General Hospital|No|Terminated|November 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|November 11, 2008||No|The patient population in RACU has changed significantly, we can not find potential subjects    to recruit. The enrollment rate has reached zero.|No||https://clinicaltrials.gov/show/NCT00790725||147439|
NCT00822809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-CAT-AC-03|CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers|Two-arm, Randomized, Open-label, Phase IIIb Study Investigating the Safety of a 3 Hour i.p. Infusion of Catumaxomab With and Without Prednisolone Premedication in Patients With Malignant Ascites Due to Epithelial Cancer|CASIMAS|Neovii Biotech|Yes|Completed|December 2008|April 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||August 2012|October 2, 2012|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00822809||145011|
NCT00823043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPH0110|A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs|A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With Timolol Hemihydrate 0.5% Solution Once or Twice Daily Versus Timolol Maleate in Sorbate||Vistakon Pharmaceuticals|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|103|||Both|21 Years|N/A|No|Non-Probability Sample|The study will be performed in centers in the United States with substantial populations        of patients prescribed timolol hemihydrate and timilol maleate in sorbate.|February 2015|February 18, 2015|January 14, 2009|Yes|Yes||No|August 2, 2010|https://clinicaltrials.gov/show/NCT00823043||144994|
NCT00823290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BDE02|Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)|A Phase I Trial of Sorafenib and LBH589 in the Treatment of Advanced HCC||University of Erlangen-Nürnberg Medical School|No|Recruiting|January 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2009|January 11, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823290||144975|
NCT00823537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TES-RCT|Power-Assisted Therapeutic Electrical Stimulation to Upper Extremities|Power-Assisted Therapeutic Electrical Stimulation to Upper Extremities in Acute Stroke Patients. A Randomized Controlled Trial.|TES|Fujita Health University|No|Not yet recruiting|January 2009|February 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||||||Both|10 Years|90 Years|No|||January 2009|January 14, 2009|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823537||144956|
NCT00824707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-005|Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-Related Primary Liver Cancer|A Randomized, Controlled Study to Evaluate the Efficacy and Significant of the Anti-Virus Therapy for the Unresectable Hepatitis B Virus-Related Primary Liver Cancer||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|December 2008|December 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2009|January 16, 2009|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824707||144867|
NCT00824993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0960|Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients|A Randomized, Controlled Study of Ibandronate for the Prevention of Bone Loss in Patients Who Have Received Allogeneic Bone Marrow Transplantation for Hematological Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2008|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824993||144845|
NCT00825604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr: 056-08|Quality of Life and Target Achievement After Treatment of Patients With Stable Angina Pectoris|Quality of Life and Achievement of Target of Treatment After Optimized Medical Treatment, Physical Training and Smoking Cessation With or Without Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris.|LOBSTR|Göteborg University|No|Withdrawn|January 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|January 20, 2009|No|Yes|Because of poor inclusion difficulties to find patient|No||https://clinicaltrials.gov/show/NCT00825604||144799|
NCT00825591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804003699|Biological Clock Dysfunction in Optic Nerve Hypoplasia|Identification and Treatment of Biological Clock Dysfunction in Optic Nerve Hypoplasia||Yale University|No|Recruiting|October 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|2 Years|10 Years|No|||February 2011|February 7, 2011|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00825591||144800|
NCT00825864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-03-3123-HLV-CTIL|Diclofenac vs Dexamethasone in Combined Surgery|Evaluation the Effect of Diclofenac Drops vs Dexamethasone Drops in Trabeculectomy and Cataract Surgery||Sheba Medical Center|No|Completed|January 2004|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|N/A|No|||January 2009|January 18, 2009|January 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00825864||144779|
NCT00826189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNU01 (Phase III)|Influence of Probiotics on Atopy With Focus on Respiratory Allergic Diseases- Follow-up to 7 Years|A Follow-up Study to 7 Years of a Randomized, Double-blinded, Placebo-controlled Study on the Influence of Probiotics on Atopy With Focus on Respiratory Allergic Diseases||National University Hospital, Singapore|Yes|Completed|May 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|253|||Both|5 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects who have completed NCT00318695 and NCT00365469 studies will be invited to        participate in this study.|January 2014|January 8, 2014|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826189||144754|
NCT00826202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08I/C33|D-serine for the Schizophrenia Prodrome|D-Serine vs Placebo for the Schizophrenia Prodrome||Nathan Kline Institute for Psychiatric Research|Yes|Active, not recruiting|March 2009|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|13 Years|35 Years|No|||June 2011|October 24, 2012|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826202||144753|
NCT00826501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080108003|Randomized Trial Comparing Endoscopy and Surgery for Pancreatic Cyst-gastrostomy|Randomized Trial Comparing Endoscopy and Surgery for Pancreatic Cyst-gastrostomy||University of Alabama at Birmingham|No|Completed|January 2009|January 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|85 Years|No|||March 2013|March 15, 2013|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826501||144730|
NCT00826514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091019|An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis|A Phase 2, 16 Week, Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel Group Proof-Of-Concept Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis||Pfizer|No|Completed|March 2009|March 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Male|18 Years|N/A|No|||March 2011|March 14, 2011|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826514||144729|
NCT00802659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1149|A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain|A Phase I/II Dose Escalation Study to Evaluate Pain Response Using Extracranial Stereotactic Radiosurgery to Treat Paraspinal Metastasis in Patients Who Have Received Prior Spinal Irradiation||Washington University School of Medicine|Yes|Terminated|March 2008|December 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|December 4, 2008|Yes|Yes|Terminated due to low accrual|No|November 10, 2014|https://clinicaltrials.gov/show/NCT00802659||146540|The study was closed early due to slow accrual.
NCT00802958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10216913|Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments|Bioequivalence of Two Halobetasol Propionate 0.05% Topical Ointments||Perrigo Company|No|Completed|July 2003|August 2003|Actual|August 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|76|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|March 2012|March 15, 2012|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802958||146517|
NCT00802971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRH - FOS|Idiopathic Reactive Hypoglycaemia and Treatment With Fructo-Oligosaccharide|Prevalence of Idiopathic Reactive Hypoglycaemia and Impact of Fructo-Oligosaccharide Supplementation on Blood Glucose Variability||Asker & Baerum Hospital|No|Completed|December 2008|June 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2009|November 16, 2009|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802971||146516|
NCT00802984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11092007-868|Endovascular Repair of Descending Thoracic Aortic Aneurysms|Endovascular Treatment of Thoracic Aortic Aneurysms Using the TALENT Stent Graft System||Stanford University||Completed|January 2002|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||100|||Both|18 Years|N/A|No|||December 2008|December 12, 2008|December 4, 2007||||||https://clinicaltrials.gov/show/NCT00802984||146515|
NCT00803543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080718009|Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrence and Viral Shedding|Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daiy Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding||University of Alabama at Birmingham||Completed|January 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|103|||Both|19 Years|N/A|Accepts Healthy Volunteers|||November 2013|December 2, 2014|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00803543||146472|
NCT00803517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-05-030|Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy|Comparison of Multifocal Electroretinogram Assessment Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy||Samsung Medical Center|Yes|Completed|March 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|20 Years|80 Years|No|Non-Probability Sample|1. Laser Group: extrafoveal focal leakage on FAG          2. photodynamic therapy Group: no definite focal leak on FAG subfoveal or juxtafoveal             focal leakage on FAG, or s-RPED involving foveal center|February 2009|March 11, 2009|November 12, 2008||No||No|November 12, 2008|https://clinicaltrials.gov/show/NCT00803517||146474|
NCT00826683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08002|Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)|Detection of Circulating Endothelial Progenitor Cells (EPCs) in Peripheral Blood From Non-small Cell Lung Cancer Patients|CBNPC:PCE|University Hospital, Limoges|No|Recruiting|March 2009|January 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 2, 2009|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00826683||144716|
NCT00826696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008021|A Retrospective Review of the Seasonality of Pre-Eclampsia|A Retrospective Review of the Seasonality of Pre-Eclampsia||Oklahoma State University Center for Health Sciences|Yes|Completed|January 2009|July 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Women of all races who were admitted to OSUMC for delivery of a baby (both cesarean and        vaginal deliveries) between 1/1/05 and 12/31/07, with or without a diagnosis of        pre-eclampsia.|January 2010|January 26, 2010|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826696||144715|
NCT00822796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I.2008.030|Thermogard™ Efficacy Trial|Thermogard™ Efficacy Trial||Brooke Army Medical Center|Yes|Terminated|September 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|70 Years|No|||July 2013|July 22, 2013|January 13, 2009||No|Difficulty in obtaining surrogate consent on critically ill subjects.|No||https://clinicaltrials.gov/show/NCT00822796||145012|
NCT00823056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2|The Effect of Probiotics on Infections in Toddlers|The Effect of Probiotics on Infections in Toddlers||Roskilde County Hospital|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|454|||Both|6 Months|7 Months|Accepts Healthy Volunteers|||April 2012|April 22, 2012|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823056||144993|
NCT00823069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1400-03|Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose|A Randomized, Double-Blind Study Comparing Safety and Tolerability of Perlane® With and Without Addition of 0.3% Lidocaine HCL During Correction of Nasolabial Folds||Medicis Global Service Corporation|No|Completed|January 2009|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||November 2010|November 1, 2010|January 14, 2009|Yes|Yes||No|August 25, 2010|https://clinicaltrials.gov/show/NCT00823069||144992|
NCT00823303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22095|Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)|A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism|PACE|Washington University School of Medicine|Yes|Completed|February 2009|September 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|December 12, 2008||No||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00823303||144974|
NCT00823823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-09-0430|Randomized Trial of Casting Techniques for Displaced Forearm Fractures|Randomized Trial of Bivalved and Circumferential Casting for Displaced Forearm Fractures in Children||Children's Hospital Boston|Yes|Completed|January 2009|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Both|4 Years|16 Years|No|||September 2014|September 2, 2014|January 15, 2009||No||No|September 2, 2014|https://clinicaltrials.gov/show/NCT00823823||144934|
NCT00823836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106066|Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease|Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease||GlaxoSmithKline|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|302|||Both|20 Years|N/A|No|||October 2011|October 13, 2011|January 15, 2009||No||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00823836||144933|
NCT00825019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5379|Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine|A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode.||Sanofi||Completed|September 2003|December 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|306|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|January 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00825019||144843|
NCT00825292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002653 00|Detection and Classification of Colon Polyps|Detection and Classification of Colon Polyps: A Comparison of High Definition White Light and Narrow Band Imaging (Endoscopic Trimodal Imaging; ETMI)||Mayo Clinic|Yes|Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 20, 2009|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00825292||144822|
NCT00825305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M49P8|Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)|A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China||Novartis||Completed|November 2008|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|825|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|January 19, 2009||No||No|January 25, 2010|https://clinicaltrials.gov/show/NCT00825305||144821|
NCT00825318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-09|Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis|Pilot Trial To Study Blood Pressure, Weight and Hydration State in Patients Undergoing A Treatment Regimen of Daily Ultrafiltration and Twice-weekly Hemodialysis As Compared to Conventional Three Times Per Week Hemodialysis||Renal Research Institute|No|Completed|July 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|January 16, 2009||No||No|February 18, 2014|https://clinicaltrials.gov/show/NCT00825318||144820|
NCT00825877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090067|Long-term Follow-up of HALT-C Sustained Virological Responders|Long-Term Follow-Up of HALT-C Sustained Virologic Responders||National Institutes of Health Clinical Center (CC)||Completed|January 2009|June 2012||||N/A|Observational|N/A|||Actual|4|||Both|18 Years|N/A|No|||June 2012|October 9, 2014|January 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00825877||144778|
NCT00826215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04060191|Electroacupuncture for Chronic Neck Pain|A Randomized Controlled Trial of the Long-Term Efficacy of Electroacupuncture for Chronic Neck Pain||Hong Kong Baptist University|No|Active, not recruiting|March 2007|February 2009|Anticipated|February 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826215||144752|
NCT00826527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURC-01-2006|Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)|Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH)||Seattle Urology Research Center|Yes|Recruiting|January 2007|||December 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Male|18 Years|N/A|No|||January 2009|January 21, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826527||144728|
NCT00826761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B257|ProSat - Effect of Probiotics on Satiety|Probiotics and Satiety - Acute Effects and Persistence of Acute Effects|ProSat|University of Copenhagen||Completed|January 2009|||June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|22|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826761||144710|
NCT00802997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SInergy|Trial Assessing Cooled Radiofrequency Denervation as a Treatment for Sacroiliac Joint Pain Using the Sinergy System|A Double Blind, Randomized, Controlled Trial Assessing Cooled Radiofrequency Denervation as a Treatment fr Sacroiliac Joint Pain Using the Sinergy System||Baylis Medical Company|No|Completed|June 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 8, 2013|December 4, 2008|No|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00802997||146514|
NCT00803270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIMOSA (terminated)|Mixed Incontinence: Medical Or Surgical Approach?|Mixed Incontinence: Medical Or Surgical Approach?|MIMOSA|New England Research Institutes|Yes|Terminated|October 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|21 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 8, 2013|December 4, 2008||No|Feasibility Period ended.|No|March 26, 2012|https://clinicaltrials.gov/show/NCT00803270||146493|Early termination leading to small numbers of participants for data analysis.
NCT00803530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AISSM02A|Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes|Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes||Fondazione Italiana Sindromi Mielodisplastiche Onlus|No|Terminated|September 2005|August 2010|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|80 Years|No|||June 2011|June 27, 2011|December 4, 2008||No|difficulties of enrollement|No||https://clinicaltrials.gov/show/NCT00803530||146473|
NCT00794755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB #2008555-01H|Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy|A Phase III Pilot RCT (Randomized, Controlled Trial) to Assess the Effectiveness of Low Dose Vitamin K1 (200 Micrograms Per Day) on Improving Anticoagulation Control in Unstable Patients on Warfarin|LOCK|Ottawa Hospital Research Institute|Yes|Completed|November 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|July 26, 2011|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794755||147135|
NCT00803881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF_Sinusitis_LS|Longitudinal Pathogen-colonization in Cystic Fibrosis Airways and Ability to Smell|Prevalence of Chronic Rhinosinusitis, Pathogen-colonization in the Upper and Lower Airways and Ability to Smell in Cystic Fibrosis||University of Jena|No|Recruiting|December 2008|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|N/A|N/A|No|Non-Probability Sample|patients of the CF outpatients clinic and hospitalized CF patients|January 2016|January 19, 2016|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803881||146446|
NCT00803894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0752-022|A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor|A Randomized Clinical Trial to Study the Effects of MK0752 Versus Placebo on Biomarkers in Healthy Young Adult Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|December 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803894||146445|
NCT00790452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0266|Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma|A Randomized Phase II Trial of Aspirin for Primary Prophylaxis of Venous Thromboembolism in Glioblastoma||M.D. Anderson Cancer Center|Yes|Terminated|November 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|November 7, 2008||No|Low accrual.|No|November 4, 2011|https://clinicaltrials.gov/show/NCT00790452||147459|Study terminated early due due to a drug supply issue.
NCT00826462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002283-26|Treatment Study of Steroid Injection and Physical Therapy for Acute Lateral Epicondylitis|Physiotherapy Alone, in Combination With Corticosteroid Injection or Wait-and-see for Acute Lateral Epicondylitis in General Practice: a Randomised, Placebo-controlled Study With 12 Months Follow-up||University of Oslo|No|Completed|March 2009|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|177|||Both|18 Years|70 Years|No|||May 2015|May 28, 2015|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826462||144733|
NCT00822575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZC-001|Study of a Device to Relieve Mosquito Bite Itching.|Relief From Itching of Mosquito Bites Clinical Study Protocol.||Ecobrands, Ltd.|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 13, 2009|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822575||145029|
NCT00826982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006640|Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer|Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer|Sonoma|Mayo Clinic|No|Completed|January 2008|||August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care|May 2012|May 15, 2012|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826982||144693|
NCT00824148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.1607|Use of Real-time Continuous Glucose Monitoring System in Patients With Type 1 Diabetes Mellitus|Use of Real-time Continuous Glucose Monitoring System to Control Blood Glucose in Patients With Type 1 Diabetes Mellitus||Norwegian University of Science and Technology|Yes|Completed|January 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|50 Years|No|||July 2012|July 25, 2012|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824148||144909|
NCT00824408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.5|Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC|A Randomised Open-label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-small Cell Lung Cancer||Boehringer Ingelheim||Active, not recruiting|March 2009|January 2015|Anticipated|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|143|||Both|18 Years|N/A|No|||October 2014|October 7, 2014|January 15, 2009||||No||https://clinicaltrials.gov/show/NCT00824408||144889|
NCT00824421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271015|A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1|A Phase 2B Multicenter, Randomized, Double-Blind, Comparative Trial Of UK-453,061, In Combination With Tenofovir Df And Emtricitabine Versus Efavirenz In Combination With Tenofovir DF And Emtricitabine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects||Pfizer|Yes|Completed|February 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|195|||Both|18 Years|N/A|No|||November 2011|December 9, 2013|January 15, 2009|Yes|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00824421||144888|
NCT00824434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2051|A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)|A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)|PLATINUM QCA|Boston Scientific Corporation|Yes|Completed|March 2009|August 2010|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||August 2012|August 17, 2012|January 15, 2009|No|Yes||No|December 20, 2011|https://clinicaltrials.gov/show/NCT00824434||144887|
NCT00824720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1630|Safety and Efficacy of a Glaucoma Drug Delivery System|||Vistakon Pharmaceuticals||Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|55|||Both|21 Years|N/A|No|||February 2015|February 18, 2015|January 9, 2009|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00824720||144866|
NCT00824733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08153|Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase II Open-label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Terminated|February 2009|April 2014|Actual|February 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|January 16, 2009|Yes|Yes|Inaccurate patient accrual for trial|No|August 19, 2015|https://clinicaltrials.gov/show/NCT00824733||144865|
NCT00824746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791JL00001|Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)|Retreatment of Gefitinib in the Patients With Non-small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study|ReGaiN|Chonnam National University Hospital|No|Completed|January 2009|December 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|January 16, 2009||No||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00824746||144864|Our study has several limitations such as lack of generalizability outside a clinically and molecularly enriched population and the small number of repeat biopsies.
NCT00825032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEET0307|Efficacy of Arm Training in COPD Patients|Effects of Unsupported Upper Extremity Exercise Training in Patients With Chronic Obstructive Pulmonary Disease: a Randomized Clinical Trial|UEET-COPD|Villa Pineta Hospital|No|Completed|March 2007|April 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||May 2009|August 2, 2011|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00825032||144842|
NCT00794222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCH28113|A Mobile Phone Self-Monitoring Tool to Increase Emotional Self-Awareness and Reduce Depression in Young People|A Randomised Controlled Trial Investigating a Mobile Phone Self-Monitoring Tool (Mobiletype) to Increase Emotional Self-Awareness and Reduce Depressive Symptoms in Young People.|mobiletype|Murdoch Childrens Research Institute|Yes|Not yet recruiting|February 2009|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|14 Years|24 Years|No|||November 2008|November 19, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794222||147175|
NCT00825617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19963561|Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy|Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy||University of Aarhus|Yes|Completed|October 1996|June 2000|Actual|October 1999|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2009|January 20, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00825617||144798|
NCT00825630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-BID 608|13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)|The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates||Exalenz Bioscience LTD.|Yes|Completed|November 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|123|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|January 19, 2009||No||No|June 19, 2011|https://clinicaltrials.gov/show/NCT00825630||144797|It was hard to get people to agree to return for multiple tests within a few days, so the enrollment was difficult
NCT00825890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USK-1|The High Cup/Disc Ratio in Children|||Kim's Eye Hospital||Completed|January 2009|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|high cup disc ratio in children|September 2015|September 2, 2015|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825890||144777|
NCT00825903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10460|The Effects of Exercise on Physiological and Psychological Parameters in an Asthmatic Population|The Effects of Exercise on Physiological and Psychological Parameters in an Asthmatic Population||Washington State University|Yes|Completed|September 2008|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|16|||Both|18 Years|40 Years|No|||December 2011|December 31, 2011|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00825903||144776|
NCT00825916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OL-ASCAR-04|A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars|A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product Following Excision of Keloids||Capstone Therapeutics|No|Completed|March 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|59|||Both|18 Years|65 Years|No|||September 2012|September 10, 2012|January 20, 2009|Yes|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00825916||144775|
NCT00826228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00003009|Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)|Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury||Northwestern University|No|Completed|June 2009|December 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||June 2013|June 3, 2013|January 20, 2009|Yes|Yes||No|April 17, 2013|https://clinicaltrials.gov/show/NCT00826228||144751|Small numbers of subjects analyzed with considerable between-subject variability.
NCT00794131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genelux - P01|Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors|Phase I Study of the Safety, Tolerability,and Tumor-Specific Replication of the Intravenous Administration of Green Fluorescent Protein Encoded Genetically Engineered Attenuated Vaccinia Virus, GL-ONC1, in Patients With Advanced Solid Organ Cancers.||Genelux Corporation|Yes|Completed|November 2008|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2015|December 11, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794131||147182|
NCT00794144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-02|Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age|||Alcon Research|No|Completed|October 2008|||December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|132|||Both|2 Years|5 Years|No|||February 2010|February 23, 2010|November 17, 2008|Yes|Yes||No|January 12, 2010|https://clinicaltrials.gov/show/NCT00794144||147181|
NCT00794404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESPA|Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy|Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy in Patients With Uncertain Diagnosis Consulting for Clinical Symptoms Suggestive of Spondylarthropathy|EchoSpA|Groupe Français d'Etude Génétique des Spondylarthropathies|No|Active, not recruiting|January 2005|September 2009|Anticipated|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|489|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a symptomatology which can lead to a SPA diagnosis but with no confirmed        diagnosis yet for any rheumatic didease.|November 2008|November 19, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794404||147161|
NCT00794157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B1302|Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|November 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|347|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|November 17, 2008||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00794157||147180|
NCT00790465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-GR-370-CTIL|Efficacy of Dark Chocolate in Achalasia Patients|Efficacy of Dark Chocolate in Achalasia Patients: Placebo-Controlled Study||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2008|November 2010|Anticipated|November 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2008|November 12, 2008|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790465||147458|
NCT00794417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-ST-0708|A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma|A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma||Regeneron Pharmaceuticals|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794417||147160|
NCT00794430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V3381-2DPNP-02|Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain|A Randomised, Double-blind, Placebo-controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for up to 13 Weeks in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)||Vernalis (R&D) Ltd|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|75 Years|No|||January 2015|January 9, 2015|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794430||147159|
NCT00826709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-05|Prospective Evaluation of the Fluid Rapid Influenza Test|CLINICAL STUDY PROTOCOL for the Prospective Evaluation of the fluID Rapid Influenza Test||Nanogen, Inc.|No|Suspended|February 2009|||October 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|1300|||Both|N/A|N/A|No|||April 2009|April 14, 2009|January 20, 2009|No|Yes|The 2008-09 North American peak influenza season ended prior to study completion.|No||https://clinicaltrials.gov/show/NCT00826709||144714|
NCT00826722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVE-T1000-PVFS-1|Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 1g Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|June 2007|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 21, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00826722||144713|
NCT00823316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-MSC003|Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation|Phase 1/2 Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells Infusion for Promotion of Engraftment and Prevention of an Graft Rejection and Graft-versus-Host Disease After Unrelated Hematopoietic Stem Cell Transplantation.||Medipost Co Ltd.|Yes|Completed|August 2008|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|2 Years|19 Years|No|||April 2012|April 20, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00823316||144973|
NCT00822822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14731|Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assess|Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assessment||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|March 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|17|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People receiving services at Moffitt Cancer Center or Lifetime Cancer Screening Center|October 2010|November 21, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822822||145010|
NCT00823550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0296|Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients|A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase||Yonsei University|Yes|Active, not recruiting|January 2009|July 2015|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|462|||Both|18 Years|N/A|No|||January 2009|December 15, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823550||144955|
NCT00823849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246-08-802-01|Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker|A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker||Otsuka Beijing Research Institute|No|Completed|October 2008|March 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Both|40 Years|75 Years|No|||April 2010|April 21, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823849||144932|
NCT00824161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS109-0403|Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer|A Phase II Study of TAS-109 Given by Continuous Intravenous 14-day Infusion in Patients With Chemotherapy-refractory Advanced Colorectal Cancer||Taiho Pharmaceutical Co., Ltd.|Yes|Terminated|January 2009|December 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|January 14, 2009|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00824161||144908|
NCT00824447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0602/1|Long-term Efficacy and Safety Study With Oralgen Grass Pollen|A Randomised, DB, Plcb Controlled, Multicentre, Multinat. Phase II/III FU Study to Assess Longterm Efficacy and Safety of 3 Different Dose Regimens of Oralgen® GrassPollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis||Artu Biologicals|No|Completed|August 2007|January 2009|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|356|||Both|18 Years|51 Years|No|||May 2010|May 4, 2010|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824447||144886|
NCT00825006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5076-MG-CTIL|The Effects of Anodal Stimulation on Echocardiographic Outcome in Patients With Cardiac Resynchronization Therapy|The Effects of Anodal Stimulation on Left Ventricular Desynchrony and Hemodynamics in Patients With a Biventricular Pacemaker||Sheba Medical Center|No|Recruiting|January 2009|December 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2009|January 16, 2009|March 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00825006||144844|
NCT00793663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-8-08-A-401|Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia|1) The Effect of Xenon and Sevoflurane on Hypnosis Monitors. 2) Prevention of Postoperative Nausea and Vomiting. 3) Rescue Treatment of Established Postoperative Nausea and Vomiting. Sevoflurane.|XABP|RWTH Aachen University|No|Completed|November 2008|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|220|||Both|18 Years|75 Years|No|||May 2011|May 16, 2011|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793663||147217|
NCT00793962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC2008A06|A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer|A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|June 2008|May 2021|Anticipated|May 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|810|||Female|18 Years|75 Years|No|||January 2016|January 29, 2016|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793962||147195|
NCT00794235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sorafenib and Dacarbazine|Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine|Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine||University of Zurich|No|Completed|December 2008|January 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2010|January 7, 2010|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794235||147174|
NCT00794560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA 630 00 23|Self-management of Low Molecular Weight Heparin Therapy|Self-management of Heparin Therapy - Drug Use Problems and Compliance With Self-injected Low Molecular Weight Heparin in Ambulatory Care||University Hospital, Basel, Switzerland|No|Completed|June 2007|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|154|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|November 18, 2008|Yes|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00794560||147150|
NCT00790270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB2003-1234|Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial|Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial||Stony Brook University|No|Completed|January 2003|January 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|November 12, 2008||No||No|October 19, 2009|https://clinicaltrials.gov/show/NCT00790270||147473|
NCT00790569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000616663|Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking|Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers||Butler Hospital|Yes|Completed|September 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|315|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|November 11, 2008|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00790569||147450|
NCT00793572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2070.00|Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma|Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|October 2008|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793572||147224|
NCT00793871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181177|Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor|A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate|GIST|Pfizer|No|Completed|November 2008|October 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|November 17, 2008|Yes|Yes||No|April 14, 2015|https://clinicaltrials.gov/show/NCT00793871||147201|
NCT00794443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|529-CL-028|ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients|A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.||Astellas Pharma Inc||Completed|November 2008|April 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|692|||Both|45 Years|N/A|No|||April 2015|April 30, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794443||147158|
NCT00790218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF102-102HCC|A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma|A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma||Can-Fite BioPharma|Yes|Completed|February 2009|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|80 Years|No|||August 2014|February 26, 2015|November 11, 2008|Yes|Yes||No|August 12, 2014|https://clinicaltrials.gov/show/NCT00790218||147477|
NCT00790504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5470-VE-CTIL|Transperineal Ultrasound for the Female Pelvic Floor in Women With Multiple Gestation|Prospective Follow up of the Female Pelvic Floor in Multiple Gestation Using Transperineal Ultrasound||Sheba Medical Center|No|Not yet recruiting|November 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Female|17 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with multiple gestations recruited from the prenatal care or high risk pregnancy        units|November 2008|November 12, 2008|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790504||147455|
NCT00794768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03178|Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)|Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|November 2002|July 2003|Actual|July 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|118|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794768||147134|
NCT00790517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK076775|Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)|Reducing Weight and Diabetes Risk in an Underserved Population|STRIDE|Kaiser Permanente|Yes|Completed|June 2009|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00790517||147454|
NCT00823082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG0801|Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass|A Prospective Randomized Pilot Study to Evaluate the Effect of Preoperative Antithrombin Supplementation on Postoperative Levels of Antithrombin in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass||Grifols Biologicals Inc.|No|Completed|May 2009|September 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|January 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823082||144991|
NCT00823862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV3-HCV-01|Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection|A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study of SD-101 to Assess the Safety, Pharmacodynamics, and Preliminary Evidence of Anti-Viral Effect in Subjects Diagnosed With Chronic Hepatitis C, Genotype 1||Dynavax Technologies Corporation|No|Completed|October 2008|February 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|55 Years|No|||August 2015|February 26, 2016|January 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823862||144931|
NCT00823875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260-08-803-01|Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject|A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject||Otsuka Beijing Research Institute|No|Completed|March 2009|July 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|40 Years|80 Years|No|||January 2010|November 30, 2010|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00823875||144930|
NCT00807794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP027|A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection|Phase I Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection||MedImmune LLC||Completed|February 1997|January 1998|Actual|November 1997|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|13|||Both|18 Years|N/A|No|||December 2008|December 10, 2008|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00807794||146154|
NCT00808067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.71|RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial|RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes||Boehringer Ingelheim||Completed|November 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|5897|||Both|18 Years|N/A|No|||March 2014|June 3, 2014|December 12, 2008||Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00808067||146133|Non-serious adverse events were not collected on subjects in this study.
NCT00808340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1485FA|Comparison of Three Soft Bifocal Contact Lenses|||Johnson & Johnson Vision Care, Inc.||Completed|November 2008|||December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|37|||Both|35 Years|70 Years|No|||May 2015|May 5, 2015|December 12, 2008|Yes|Yes||No|July 30, 2010|https://clinicaltrials.gov/show/NCT00808340||146112|
NCT00808600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFB-application 32|Empowerment of Lung and Heart-lung Transplant Patients|Empowerment of Lung and Heart-lung Transplant Patients by a Multimodal Resource-activating Behavioural Training Programme and Cardiopulmonary Exercise - a Randomised Controlled Study||Hannover Medical School|No|Not yet recruiting|October 2009|January 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|68 Years|No|||August 2009|August 18, 2009|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808600||146092|
NCT00808314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-271|Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress|Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole||Cardiovascular Imaging Technologies|No|Active, not recruiting|December 2008|September 2012|Anticipated|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|32|||Both|35 Years|90 Years|No|||August 2012|August 1, 2012|December 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00808314||146114|
NCT00808327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-03|Spinal Anesthesia for Cesarean Delivery: Bupivacaine With or Without Fentanyl|Spinal Anesthesia for Cesarean Delivery: Bupivacaine With or Without Fentanyl||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||November 2009|November 19, 2009|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00808327||146113|
NCT00804388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08366a|Wear Measurements of E-Poly in an Uncemented THA With Either 32 or 36 mm Caput of Ceramics.|Comparing Polyethylene Wear Using 3. Generation Highly Crosslinked Polyethylene in an Uncemented Total Hip Prostheses With Either 32 mm or 36 mm Caput of Ceramics||Lovisenberg Diakonale Hospital|No|Active, not recruiting|December 2008|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|65 Years|No|||January 2011|January 6, 2011|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804388||146407|
NCT00808626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11556|Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis|Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis||Temple University||Withdrawn|December 2008|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|75 Years|No|||May 2015|May 1, 2015|December 12, 2008|Yes|Yes|Lack of funding to complete trial. A lead member of research team retired.|No||https://clinicaltrials.gov/show/NCT00808626||146090|
NCT00804401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40061|Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Two Oral Formulations of Naproxen 500 mg Tablets Administered as 1 x 500 mg Tablet in Healthy Subjects Under Fasting Conditions||Perrigo Company||Completed|June 2004|||July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00804401||146406|
NCT00804414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBG-1-13|Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers|A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Soluble Beta-1,3/1,6-glucan (SBG) in Chronic Foot Ulcers in Patients With Diabetes||Biotec Pharmacon ASA|No|Completed|October 2008|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||January 2010|January 25, 2010|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804414||146405|
NCT00804687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015709|An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis|A Randomized, Single-Dose, Single-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-Over Study to Compare the Relative Efficacy of JNJ-39220675, Pseudoephedrine and Placebo for the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|53|||Both|18 Years|65 Years|No|||September 2013|September 27, 2013|December 8, 2008|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT00804687||146385|
NCT00804908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-440|A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma||AbbVie|Yes|Completed|February 2009|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|346|||Both|18 Years|99 Years|No|||February 2016|February 7, 2016|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804908||146368|
NCT00807664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR008WS|Biatain Ag vs Biatain in the Treament of Leg Ulcers|Clinical Assessment of Biatain Ag Dressings Compared to Biatain Dressings in the Treatment of Leg Ulcers||Coloplast A/S|No|Completed|December 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||June 2010|June 2, 2010|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807664||146164|
NCT00807677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-901_101|A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies|A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Completed|March 2009|March 2013|Actual|September 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00807677||146163|
NCT00807040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-00002|Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation|Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic Ischemic Mitral Regurgitation||Icahn School of Medicine at Mount Sinai|Yes|Completed|December 2008|March 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807040||146210|
NCT00807053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-602|Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)|A Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR)||Takeda|No|Completed|April 2007|July 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|480|||Both|12 Years|N/A|No|||December 2008|May 4, 2012|December 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807053||146209|
NCT00807014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114567|Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne|Single-blind, Multicenter, Parallel, Comparative, Randomized, Phase 4 Clinical Trial for the Evaluation of the Quality of Life, Efficacy and Tolerance of Duac® Gel Against Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris.||GlaxoSmithKline|No|Completed|November 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|12 Years|39 Years|No|||February 2012|March 15, 2012|December 10, 2008||No||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00807014||146212|
NCT00792363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-004923-48|Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations|A Phase II Study of Irinotecan and Panitumumab as 3rd Line Treatment of Patients With Metastatic Colorectal Cancer Without KRAS Mutations||Vejle Hospital|Yes|Completed|November 2008|August 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792363||147313|
NCT00792649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.386.07|Comparison Between HD+ Endoscopy and Standard Videoendoscopy in Screening Colonoscopy|||Johannes Gutenberg University Mainz|No|Enrolling by invitation|February 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients scheduled for screening colonoscopy were examined using HD+        colonosccopes and standardendoscopes.|February 2008|November 17, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792649||147292|
NCT00792662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|470-08-FB|Improving Function, Quality of Life, Glycemia in Diabetics With Dementia|Improving Function, Quality of Life, Glycemia in Diabetics With Dementia||University of Nebraska|Yes|Recruiting|January 2009|January 2011|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|N/A|No|||January 2010|January 12, 2010|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792662||147291|
NCT00792922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00018439|Partnership for Rapid Elimination of Trachoma|Research to Programs for Trachoma Elimination: Antibiotic Trial|PRET|Johns Hopkins University|Yes|Completed|May 2008|June 2014|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|20586|||Both|N/A|12 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|November 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792922||147271|
NCT00806572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN007AI|Treatment With hOKT3gamma1(Ala-Ala) in T1DM|Phase II Multiple Dose Treatment of Type 1 Diabetes Mellitus With hOKT3gamma1(Ala-Ala)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|May 2002|August 2007|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|7 Years|30 Years|No|||July 2014|July 28, 2014|December 9, 2008|Yes|Yes|adverse events related to drug lot|No||https://clinicaltrials.gov/show/NCT00806572||146243|
NCT00806585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0736-007|Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)|A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy & Tolerability of MK0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) in Patients With T2DM and Hypertension||Merck Sharp & Dohme Corp.|No|Terminated|December 2008|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|620|||Both|18 Years|75 Years|No|||September 2015|September 18, 2015|December 10, 2008|Yes|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT00806585||146242|
NCT00806598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0115|Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome|Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Completed|May 2005|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|15 Years|N/A|No|||March 2013|March 8, 2013|December 9, 2008||No||No|January 30, 2013|https://clinicaltrials.gov/show/NCT00806598||146241|
NCT00806923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17704|A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC||Hoffmann-La Roche||Completed|February 2005|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1044|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806923||146218|
NCT00807235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL4-CPAP-01|Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants|An Open Label, Multicenter, Phase 2, Pilot Evaluation of SURFAXIN®(Lucinactant) Delivered as an Aerosol Via Nasal Continuous Positive Airway Pressure (nCPAP) in the Prevention of Respiratory Distress Syndrome in Premature Infants||Discovery Laboratories, Inc.|No|Terminated|January 2005|September 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|N/A|30 Minutes|No|||May 2012|May 11, 2012|December 10, 2008|No|Yes|Slow enrollment|No|April 2, 2012|https://clinicaltrials.gov/show/NCT00807235||146195|
NCT00807469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23440|Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD|Acute and Chronic Inflammatory Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD: From Specific Disease Phenotyping Towards Novel Made Therapy (Study 1)||Top Institute Pharma|Yes|Not yet recruiting|January 2009|January 2015|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|120|Samples With DNA|Blood will be retained to investigate diffences in candidate genes (SNPs) for COPD between      the 5 different groups.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy individuals and COPD patients with GOLD stage II. For detailed describtion see        studie cohorts.|December 2008|December 11, 2008|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807469||146178|
NCT00807482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-1015|Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease|Diagnostic and Clinical Characterization of Patients With Unusual Genetic Disorders of the Airways||University of North Carolina, Chapel Hill|No|Recruiting|January 2004|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|Samples With DNA|Blood samples, buckle scrape, semen, and scrape biopsy of nasal cells|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who have a high suspicion for the diagnosis of PCD, based on clinical features.|February 2016|February 11, 2016|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807482||146177|
NCT00807495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14004|Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma|A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma||Millennium Pharmaceuticals, Inc.|No|Completed|February 2009|April 2011|Actual|January 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807495||146176|
NCT00807508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-3-062A|Leucine Supplementation in Elderly Men|The Influence of Leucine Supplementation on Body Composition and Muscle Characteristics in Healthy Elderly||Maastricht University Medical Center|No|Completed|January 2007|December 2008|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|29|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||December 2008|December 11, 2008|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807508||146175|
NCT00807807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|617|Evaluating the Effects of Folic Acid Supplementation in Older Adults: The Folic Acid Supplementation Trial (The FAST Study)|Phase III Study of the Effects of Folic Acid Supplementation on Serum Folate and Plasma Homocysteine in Older Adults: A Dose-Response Trial|FAST|National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|June 1996|September 1996|Actual|September 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|133|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 12, 2008|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807807||146153|
NCT00808080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070768|A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)|A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia|AMLCTL|University of California, San Diego|Yes|Terminated|January 2010|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|No|||January 2016|January 25, 2016|December 12, 2008|Yes|Yes|lack of accrual|No|November 30, 2015|https://clinicaltrials.gov/show/NCT00808080||146132|Accrual trial was insufficient. No patient became eligible for CTL infusion. Cell culture information gleaned from a comparison of different culture methods will greatly facilitate future studies of autologous CTL-directed immunotherapy for AML.
NCT00808613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR07-001|Optetrak Posterior Stabilized Versus Optetrak Hi-Flex|A Prospective, Single-center, Non-randomized, Consecutive Series Clinical Study Comparing the Functional Differences Between a Standard Posterior Stabilized Total Knee Replacement and a High-flexion Posterior Stabilized Total Knee Replacement||Exactech|No|Withdrawn|December 2008|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|80 Years|No|||February 2013|February 25, 2013|December 15, 2008||No|Study withdrawn prior to initiation|No||https://clinicaltrials.gov/show/NCT00808613||146091|
NCT00804375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PX-SP-02|Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain|Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain.||Smerud Medical Research International AS|No|Recruiting|December 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804375||146408|
NCT00808639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-208|Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma|A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|December 2008|December 2015|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|December 15, 2008|Yes|Yes||No|January 14, 2014|https://clinicaltrials.gov/show/NCT00808639||146089|
NCT00805792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005098|Mayo Acute Stroke Trial for Enhancing Recovery|Mayo Acute Stroke Trial for Enhancing Recovery|MASTER|Mayo Clinic|No|Completed|November 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|December 9, 2008|Yes|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT00805792||146302|
NCT00806117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU50102008049|Comparison of Post-surgery Adjuvant Therapy for Cervical Carcinoma|Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma||Sun Yat-sen University|Yes|Recruiting|February 2008|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|990|||Female|18 Years|65 Years|No|||March 2016|March 13, 2016|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00806117||146278|
NCT00807079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626790|Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer|Phase I/II Study of Carboplatin in Association With Weekly Oral Topotecan in Patients With Metastatic or Recurrent Cervical Cancer||ARCAGY/ GINECO GROUP|Yes|Completed|September 2008|||May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||October 2014|October 28, 2014|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807079||146207|
NCT00807898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OICB080587|Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making|Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making||University of Louisville||Completed|January 2009|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Female|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mother and daughter pairs (n =75) will be recruited.|January 2011|January 28, 2011|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807898||146146|
NCT00807339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-00384|CyberKnife for Unresectable Renal Tumors|CyberKnife Stereotactic Radiation for Unresectable Renal Tumors/PhaseI Study||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|March 2006|||October 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|95 Years|No|||April 2011|April 7, 2011|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807339||146187|
NCT00792389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAT-HWA-001|Study of the Use of Humidified Warmed Gas and the Effect on Post-Operative Pain in Laparoscopic Cholecystectomies|Randomised Controlled Trail of Warmed Humidified Insufflation Versus Cold Non-Humidified Insufflation in Elective Laparoscopic Cholecystectomies: Does This Reduce Post-Operative Pain?||Pennine Acute Hospitals NHS Trust|No|Not yet recruiting|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2008|November 14, 2008|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792389||147311|
NCT00792636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110948|A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period|Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults||GlaxoSmithKline|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|407|||Both|18 Years|65 Years|No|||March 2011|July 26, 2012|November 17, 2008|Yes|Yes||No|October 7, 2010|https://clinicaltrials.gov/show/NCT00792636||147293|
NCT00793221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIBELES|Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent|Randomized Comparison Between Sirolimus-eluting and Everolimus-eluting Coronary Stents in Chronic Coronary Occlusions|CIBELES|Spanish Society of Cardiology|Yes|Completed|November 2008|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793221||147250|
NCT00793455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS017163-01|Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders|Using Precision Performance Measurement To Conduct Focused Quality Improvement. Sub-Study 1.|UPQUAL|Northwestern University|No|Completed|October 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|628|||Both|N/A|N/A|No|||October 2011|October 24, 2011|November 17, 2008||No||No|September 1, 2011|https://clinicaltrials.gov/show/NCT00793455||147232|This study does not identify the timing of the intervention that would have the most impact. Mailings occurred 3 months or more after the order was placed, contacting patients sooner may have been more effective.
NCT00793468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108428|Relapse Prevention Study in Newly Abstinent Smokers|A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.||GlaxoSmithKline|No|Withdrawn|December 2008|December 2008|Anticipated|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||February 2016|February 11, 2016|November 18, 2008|Yes|Yes|Study halted prior to enrollment of patients|No||https://clinicaltrials.gov/show/NCT00793468||147231|
NCT00806611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08D.380|Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer|A Randomized, Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients With Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer||Thomas Jefferson University|Yes|Completed|September 2008|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|438|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806611||146240|
NCT00806936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3675|Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects|A 16-week Multicentre, Open Label, Non-interventional, Observational Study to Investigate the Status of Human Insulin or Insulin Analogue Treatments With Focusing on Efficacy and Safety in Type 2 Diabetes Subjects Inadequately Controlled With Two or More Oral Antidiabetic Drugs in China||Novo Nordisk A/S|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|4847|||Both|18 Years|N/A|No|Non-Probability Sample|Type 2 diabetic subjects inadequately controlled with two or more oral antidiabetic drugs        (OAD) and currently treated with either human insulin or insulin analogues at the        discretion of physicians|August 2014|August 12, 2014|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806936||146217|
NCT00806962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV01-102|Phase 1 Norwalk Vaccine Study|Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-like Particle Vaccine ( Norwalk VLP Antigen, MPL®, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL®, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device||Takeda|Yes|Completed|November 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|61|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806962||146216|
NCT00807248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12213A|Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder|Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of Escitalopram in Combination With Two Fixed Doses of Gaboxadol Compared to Escitalopram in Major Depressive Disorder||H. Lundbeck A/S|No|Completed|November 2008|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|490|||Both|18 Years|65 Years|No|||December 2012|December 13, 2012|December 10, 2008||No||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00807248||146194|
NCT00807261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_03981|Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy|PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional||Asan Medical Center|Yes|Enrolling by invitation|September 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|16 Years|N/A|No|||December 2008|December 11, 2008|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807261||146193|
NCT00807521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/214|Steroid-induced Reduction of Surgical Stress Study|Reduction of the Cardiac Proapoptotic Stress Response by Dexamethasone in Patients Undergoing Coronary Artery Bypass Grafting Surgery|STRESS|VU University Medical Center|No|Withdrawn|December 2008|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|75 Years|No|||December 2014|December 16, 2014|December 11, 2008||No|Research question was integrated in other study protocol|No||https://clinicaltrials.gov/show/NCT00807521||146174|
NCT00807820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11386-24294|Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy|Phase I Study of Targeting Dominant Intraprostatic Lesion Using Functional MR Spectroscopy and High Dose Rate Brachytherapy||University of California, San Francisco|No|Completed|March 2008|January 2012|Actual|June 2011|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Male|N/A|N/A|No|Probability Sample|All patient who are candidate for prostate HDR brachytherapy will be offered this protocol|January 2014|January 23, 2014|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807820||146152|
NCT00804700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-316|Impact of Two Methods of Listening to Music During Exercise on Perceived Exertion and Overall Physical Activity|Impact of Two Methods of Listening to Music During Exercise on Perceived Exertion and Overall Physical Activity||Georgetown University|Yes|Completed|December 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|46|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2008|April 21, 2010|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804700||146384|
NCT00804934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4421S|Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis|Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months||Retina Institute of Hawaii|Yes|Completed|February 2008|January 2009|Actual|February 2008|Actual|Phase 2|Observational|N/A||1|Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2012|May 24, 2012|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804934||146366|
NCT00808353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFDA No: 93.859|Genomic Approaches to Common Chronic Disease - Ancillary to ARIC|Genomic Approaches to Common Chronic Disease||University of Michigan|Yes|Completed|July 1985|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15792|Samples With DNA|Blood and urine|Both|45 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|The ARIC study is a prospective epidemiologic study conducted in four U.S. communities The        ARIC study began in 1987, with each field center randomly selecting and recruiting a        cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in        their community. These participants were reexamined every three years with the first        screen (baseline) occurring in 1987-89, the second in 1990-92, the third in 1993-95, and        the fourth and last exam was in 1996-98. Follow-up occurs yearly by telephone to maintain        contact with participants and to assess health status of the cohort.|December 2008|December 12, 2008|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808353||146111|
NCT00805519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870919|Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee|Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee Treated With Fixed Dose Combination of Glucosamine and Chondroitin Sulfate.||Ardabil University of Medical Sciences|Yes|Completed|February 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|230|||Both|40 Years|85 Years|No|||April 2010|April 29, 2010|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805519||146322|
NCT00805805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBC|Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis|Phase III Trial of Tetrathiomolybdate (TM) in Primary Biliary Cirrhosis||University of Michigan|Yes|Completed|April 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||December 2008|January 25, 2013|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805805||146301|
NCT00805818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-TBI-001|Study of NNZ-2566 in Patients With Traumatic Brain Injury|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury|INTREPID2566|Neuren Pharmaceuticals Limited|Yes|Completed|April 2010|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|261|||Male|18 Years|70 Years|No|||March 2016|March 21, 2016|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805818||146300|
NCT00806130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dialysesortrondelag|Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients|Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients, a Cross-Sectional Study||Norwegian University of Science and Technology|No|Completed|September 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|40|||Both|18 Years|N/A|No||Patients with end-stage renal disease and in active dialysis treatment in the Norwegian        county of Sør-Trøndelag.|December 2008|December 9, 2008|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806130||146277|
NCT00806143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMSDEP|Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression|Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression||Institute of Neuroscience, Florence, Italy|Yes|Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||February 2011|February 23, 2011|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806143||146276|
NCT00807378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-CMR-004|Rijavithi Viral and Mycobacterium PCR Arrays in CNS Infection Study|Cerebrospinal Fluid Polymerase Chain Reaction Arrays for Central Nervous System Neurotropic Viral Infection and Mycobacterium Infection Study|VIMPAC|Rajavithi Hospital|Yes|Completed|July 2008|March 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|CSF DNA/RNA virus|Both|15 Years|N/A|No|Non-Probability Sample|CNS VIRAL INFECTION AIDS/NON-AIDS|May 2010|May 19, 2010|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00807378||146184|
NCT00807391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELIOS 2090|Transbronchial Catheter Aspiration and Transbronchial Needle Aspiration in the Diagnosis of Lung Cancer|Transbronchial Catheter Aspiration Compared to Transbronchial Needle Aspiration in the Diagnosis of Peripheral Nodules and Masses of the Lung||Helios Klinik Ambrock|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|18 Years|N/A|No|||August 2009|June 22, 2011|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00807391||146183|
NCT00807365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00005793|Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly|Six Month Treatment of GHRH in the Elderly|PP2|Johns Hopkins University|Yes|Active, not recruiting|December 2007|August 2011|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|65 Years|85 Years|No|||March 2010|March 25, 2010|December 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807365||146185|
NCT00808158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|612|Examining the Relationship Between Tobacco Exposure, Abdominal Obesity, and Metabolic Syndrome in Adolescents (The STRONG Kids Study)|Metabolic Syndrome in Adolescents: Contribution of Tobacco and Central Fat|STRONG Kids|University of Rochester|Yes|Completed|October 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|117|Samples With DNA|Serum, whole blood, white blood cells, saliva, urine|Both|9 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|A community sample of 240 9- to 10-year olds with varying abdominal obesity levels (all        having a waist circumference equal to or above the 50th percentile for age and gender) and        varying tobacco smoke exposure levels (from none to high levels)|November 2012|November 29, 2012|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808158||146126|
NCT00807690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182-04066|Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo|Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study||Oslo University Hospital||Completed|November 2005|January 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||December 2008|December 11, 2008|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807690||146162|
NCT00792402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI07/91020|Computerized Guideline in Heart Failure: Implementation Process and Impact Evaluation|Implementation Process and Impact of the Heart Failure Electronic Clinical Guideline in the Catalan Health Institute Primary Care Health Board||Jordi Gol i Gurina Foundation|Yes|Completed|November 2007|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|13008|||Both|30 Years|N/A|No|Non-Probability Sample|Setting: 20 general practices in Barcelona (intervention group),with an assigned        population of 558515 inhabitants and Girona (control Group) with 23 general practices, and        an assigned population of 480827.In 2007, the intervention region had a rate of 1499        patients per GP and from 16 to 52 thousand listed patients per practice with and average        of attending rate of 68%, and the control region had a rate of 1558 patients per GP and        from 4 to 47 thousand listed patients per practice with and average of attending rate of        76%.        Subjects: Managers and general and nurse practitioners from Barcelona and Girona primary        care practices included in the study. Patients with diagnoses related to Heart Failure.|November 2011|November 22, 2011|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792402||147310|
NCT00792935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-017|A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)|A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy||Merck Sharp & Dohme Corp.||Completed|January 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|November 14, 2008|Yes|Yes||No|June 28, 2012|https://clinicaltrials.gov/show/NCT00792935||147270|
NCT00793481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2008-6415|Vascular Reactivity in Metabolic Syndrome and Diabetic Patients Using Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Measure Microvascular Changes in Metabolic Syndrome and Diabetes Mellitus in Order to Assess Cardiovascular Disease Risk.||University of California, Irvine|No|Completed|November 2008|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|45 Years|75 Years|No|Non-Probability Sample|primary care clinic, community sample|August 2015|August 5, 2015|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00793481||147230|
NCT00793780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808004106|Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia|Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia||Yale University|No|Completed|December 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|70 Years|No|||August 2015|August 10, 2015|November 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00793780||147208|
NCT00794066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARIS-Study2009|Peripheral Arteriopathy Rate In Stroke|Prevalence of Peripheral Arterial Disease in Acute Ischemic and Hemorrhagic Stroke Patients|PARIS|University of Erlangen-Nürnberg Medical School|No|Recruiting|August 2008|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|consecutive patients with acute ischemic or hemorhagic stroke.|December 2015|December 1, 2015|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794066||147187|
NCT00806624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-C-J226|DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation|A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects With Non-Valvular Atrial Fibrillation||Daiichi Sankyo Inc.|Yes|Completed|October 2007|November 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|234|||Both|18 Years|80 Years|No|||January 2015|January 15, 2015|December 10, 2008||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT00806624||146239|
NCT00807833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007|Cerebral Blood Flow (CBF) Disturbances Following Traumatic Brain Injury (TBI) and Subarachnoid Hemorrhage (SAH)|Cerebral Blood Flow (CBF) Disturbances Following Traumatic Brain Injury (TBI) and Subarachnoid Hemorrhage (SAH)||Azienda Ospedaliera San Gerardo di Monza|No|Completed|February 2009|December 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|16 Years|N/A|No|Non-Probability Sample|Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be        monitored on clinical ground will be also monitored with a TD probe and routinely tested        for cerebral autoregulation, thus obtaining the CBF corresponding at a given the "best        CPP" and autoregulation status. Continuous CBF measures and PRx monitoring may allow more        accurate identification and early detection of adverse cerebral conditions. This approach        may bring us a step closer to the goal of outcome improvements in patients suffering from        intracranial insult.|August 2015|August 17, 2015|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807833||146151|
NCT00807274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0404/75|Renal Function in Adults With Congenital Heart Disease.|Prospective Evaluation of Renal Function in Adults With Congenital Heart Disease.||Royal Brompton & Harefield NHS Foundation Trust|No|Withdrawn|September 2008|December 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples Without DNA|Plasma, serum and urine samples|Both|18 Years|N/A|No|Non-Probability Sample|Stable adult patients with congenital heart disease|September 2009|September 24, 2009|December 10, 2008||No|Alternative trial planned|No||https://clinicaltrials.gov/show/NCT00807274||146192|
NCT00808093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106777|Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects|Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects||GlaxoSmithKline||Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00808093||146131|
NCT00807534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI 244.2513|Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)|Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase 2: Sensitivity of the Step Test and Shuttle Walk to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD||Laval University|No|Completed|October 2008|June 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|44|||Both|50 Years|N/A|No|||May 2010|February 7, 2011|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807534||146173|
NCT00807547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHX0562|Intraseasonal Short-time Up-dosing With Alutard SQ Grasses|A Randomised, Parallel-group, Double-blind, Placebo-controlled, Multicentre Phase III Trial Assessing the Pharmacodynamic Efficacy and Safety of an Intra-seasonal Short-time Updosing Schedule for Alutard SQ||ALK-Abelló A/S|No|Completed|April 2008|January 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00807547||146172|
NCT00804427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12042008-1358|Effect of Fish Oil on Plasma Triglycerides in Adults|Effect of Fish Oil as an Ethyl Ester or Triglyceride Preparation on Plasma Triglycerides in Hypertriglyceridemic Adults||Stanford University||Completed|December 2008|April 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 21, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00804427||146404|
NCT00804947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BuMel-MM|Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen|Ensayo Fase II de Trasplante autólogo de Sangre periférica en Pacientes Con Mieloma múltiple Tras Acondicionamiento Con Busulfan Intravenoso y Melfalan||Fundacion Para La Investigacion Hospital La Fe|No|Recruiting|September 2005|March 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||December 2008|December 8, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804947||146365|
NCT00805207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0692|Sex Steroids, Sleep, and Metabolic Dysfunction in Women|Sex Steroids, Sleep, and Metabolic Dysfunction in Women|SCOR|Washington University School of Medicine|No|Completed|September 2007|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|61|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 11, 2013|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805207||146345|
NCT00805532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-019-06F|Behavioral Activation for Posttraumatic Stress Disorder (PTSD)/ Depression Treatment in Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans|Behavioral Activation for PTSD, Depression Treatment in OIF/OEF Veterans||VA Office of Research and Development|Yes|Completed|May 2009|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805532||146321|
NCT00806156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PIR-04|Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer|A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer||Nektar Therapeutics|No|Completed|October 2008|January 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Female|18 Years|N/A|No|||August 2014|August 12, 2014|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806156||146275|
NCT00806390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040965|Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol|GCC0766: Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol||University of Maryland|Yes|Terminated|July 2008|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|December 8, 2008||No|Poor enrollment|No|May 19, 2014|https://clinicaltrials.gov/show/NCT00806390||146257|
NCT00807963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-08-02|Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone|Phase I, Open-Label, Pharmacokinetic, Safety and Tolerability Study of Subcutaneously Administered Bisphosphonate With Recombinant Human Hyaluronidase (rHuPH20) vs Bisphosphonate||Halozyme Therapeutics|No|Active, not recruiting|December 2008|September 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|72|||Both|18 Years|60 Years|No|||June 2009|June 3, 2009|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807963||146141|
NCT00807703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-010|Select Stim: Selective Stimulation of the Subthalamic Nucleus in Parkinson's Disease. "A Feasibility Study"|Select Stim: Selective Stimulation of the Subthalamic Nucleus in Parkinson's Disease. "A Feasibility Study"|Select Stim|Maastricht University Medical Center|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|40 Years|75 Years|No|||December 2009|December 16, 2009|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807703||146161|
NCT00807924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR001|American Breast Laser Ablation Therapy Evaluation|American Breast Laser Ablation Therapy Evaluation (ABLATE): Monitoring the Long Term Safety and Efficacy of Novilase™ Breast Interstitial Laser Therapy in Real World Application|ABLATE|Novian Health Inc.|No|Recruiting|December 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Patients undergoing Novilase for the treatment of benign breast conditions at Novian        Health affiliated breast centers.|March 2016|March 21, 2016|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807924||146144|
NCT00807937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00014|Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325|A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, With a Lorazepam Arm, in Subjects With Generalized Anxiety Disorder (GAD)||AstraZeneca||Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|369|||Both|18 Years|65 Years|No|||September 2010|September 16, 2010|December 12, 2008|Yes|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT00807937||146143|
NCT00792948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00800|Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia|Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)||National Cancer Institute (NCI)|No|Active, not recruiting|September 2009|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|60 Years|No|||November 2015|March 22, 2016|November 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792948||147269|
NCT00793793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.2|Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced|Safety, Antiviral Activity, and Pharmacokinetics of Multiple Rising Oral Doses of BI 201335 NA in Treatment-naïve Patients With Chronic Hepatitis C Infection for 14 Days Monotherapy Followed by Combination With Pegylated Interferon and Ribavirin for an Additional 14 Days (Double-blind, Placebo Controlled), and in Treatment-experienced Patients With Chronic Hepatitis C Infection for 28 Days as Combination Therapy With Pegylated Interferon and Ribavirin (Open-label)||Boehringer Ingelheim||Completed|September 2007|||January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|96|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|September 23, 2008||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT00793793||147207|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information".
NCT00793806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2007-5572|Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease|Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease||University of California, Irvine|No|Completed|August 2008|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|August 2015|August 5, 2015|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00793806||147206|
NCT00794092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/R/CAR/15|Magnetic Resonance Imaging of Aortic Aneurysm Instability|Magnetic Resonance Imaging of Aortic Aneurysm Instability||University of Edinburgh|No|Recruiting|November 2008|August 2010|Anticipated|August 2010|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|40 Years|N/A|No|||April 2010|April 7, 2010|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00794092||147185|
NCT00807287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|517/2004|Evaluation of Two Methods of Jejunal Placement of Enteral Feeding Tubes in Critically Ill Patients|Evaluation of Two Methods of Jejunal Placement of Enteral Feeding Tubes in Critically Ill Patients: Endoscopic Versus Unguided, Frictional Method||Medical University of Vienna|No|Completed|February 2005|April 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|N/A|No|||December 2008|December 10, 2008|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807287||146191|
NCT00807573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-109|Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment|A Phase II Trial of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment||Memorial Sloan Kettering Cancer Center|Yes|Completed|December 2008|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|December 11, 2008|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00807573||146170|
NCT00808119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTI-336-001|Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects|A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects||RTI International|Yes|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 17, 2009|December 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00808119||146129|
NCT00808106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090035|Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism|Clinical, Cellular, and Molecular Investigations Into Oculocutaneous Albinism||National Institutes of Health Clinical Center (CC)||Recruiting|December 2008|||||N/A|Observational|N/A|||Anticipated|300|||Both|1 Year|80 Years|No|||January 2016|February 6, 2016|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808106||146130|
NCT00808366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV4104A2007593|Efficacy and Safety of RV4104A Ointment in Onychomycosis|A Randomized, Parallel-Group, Multicentre, Open-Labelled, Active-Controlled Study to Assess the Efficacy, Safety and Tolerability of RV4104A Ointment Versus Bifonazole-Urea Ointment for the Complete Removal of the Clinically Infected Nail Plate Area in Patients With Toenail Onychomycosis||Pierre Fabre Dermo Cosmetique|No|Recruiting|October 2008|October 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|N/A|No|||December 2008|December 12, 2008|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808366||146110|
NCT00807560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0216|Parent-Based Treatment for Pediatric Overweight|Parent-Based Treatment for Pediatric Overweight|PO|Icahn School of Medicine at Mount Sinai|No|Completed|September 2008|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|13 Years|17 Years|No|||December 2015|December 2, 2015|December 11, 2008||No||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00807560||146171|
NCT00804440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30470|Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Ibuprofen Tablet Formulations in Fasted Normal, Healthy Subjects||Perrigo Company||Completed|January 2004|||January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00804440||146403|
NCT00804713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-021|Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits|Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits|LTBI|Uniformed Services University of the Health Sciences|No|Active, not recruiting|March 2009|July 2015|Anticipated|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|1||Actual|2017|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 14, 2014|December 8, 2008|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00804713||146383|A limitation of this study is the lack of a gold standard for determining the presence of M. tuberculosis infection, making it difficult to assess the true significance of discordance between TST and the interferon-gamma release assays (IGRAs).
NCT00805233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4442|Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration|Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration||Oregon Health and Science University|No|Completed|December 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||October 2009|July 20, 2011|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805233||146343|
NCT00805220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWS-001|Nordic Walking as Gait Training for Frail Elderly|Nordic Walking for Frail Elderly: a Randomized Pilot Trial||McGill University|Yes|Completed|December 2008|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|65 Years|N/A|No|||September 2009|September 1, 2009|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805220||146344|
NCT00805831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDH -AAA-P-01|Safety and Efficacy of Using HDH Device and Method - a Novel Sutureless Vascular Anastomosis|Safety and Efficacy of Using HDH Device and Method - a Novel Sutureless Vascular Anastomosis||HDH Medical Ltd|No|Completed|October 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2010|July 4, 2010|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00805831||146299|
NCT00807066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2008-001|Randomized Gefitinib Trial|Multicentric Randomized Phase III Study Comparing Gefitinib Versus Platinum-Based Chemotherapy In EGFR Fish Positive NSCLC Patients (Range)|RANGE|Fondazione Humanitas per la Ricerca|No|Completed|November 2008|October 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||October 2010|April 20, 2012|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807066||146208|
NCT00806416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-226|A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D|A 2-Part, Open-Label, Randomized, Crossover Study to Evaluate the Bioequivalence of the 70 mg Alendronate/2800 IU Vitamin D3 Final Market Combination Tablet to a 70 mg Alendronate Marketed Tablet, and the Relative Bioavailability of Vitamin D3||Merck Sharp & Dohme Corp.|No|Completed|May 2003|January 2004|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|244|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|December 9, 2008|No|Yes||No|January 8, 2010|https://clinicaltrials.gov/show/NCT00806416||146255|
NCT00807352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERC CTAS|The Canadian Triage and Acuity Scale for Children; A Prospective Multi-Center Evaluation.|The Canadian Triage and Acuity Scale for Children; A Prospective Multi-Center Evaluation.|PERC CTAS|St. Justine's Hospital|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1464|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|All children presenting to a pediatric emergency department|July 2011|August 4, 2011|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807352||146186|
NCT00807651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD006|Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes|Safety and Efficacy Study of Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes-a Phase II Study||Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|February 2008|February 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|14 Years|35 Years|No|||February 2014|February 15, 2014|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807651||146165|
NCT00795106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1014.01|Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain|Double-blinded, Cross-over Randomized Controlled Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain||Stamford Hospital|Yes|Withdrawn|November 2009|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2009|December 13, 2012|November 20, 2008|Yes|Yes|Difficulty finding a monitor|No||https://clinicaltrials.gov/show/NCT00795106||147110|
NCT00808197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-140501|Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation|Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation||Medical University of Vienna||Completed||||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|41|||Both|N/A|N/A|No|||December 2008|December 12, 2008|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808197||146123|
NCT00792415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHRI#05-08-0074|Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool|Validation of a Pediatric Abstinence Syndrome Scoring Tool Utilizing a Standardized Hospital-Based Guideline for Iatrogenic Opioid Dependence||Banner Health|No|Recruiting|November 2009|December 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric Intensive Care Unit patients|December 2009|April 23, 2010|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792415||147309|
NCT00792675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|267-02-FB|Effect of Exercise on the Disease Activity of Rheumatoid Arthritis||RA&Ex|University of Nebraska|No|Completed|January 2003|November 2007|Actual|April 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||November 2008|November 17, 2008|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00792675||147290|
NCT00793234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-402-004|Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery|Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery: A Dose-Escalating, Multicenter, Randomised, Active- Controlled Open Label Study||ThromboGenics|Yes|Completed|December 2008|March 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|316|||Both|18 Years|80 Years|No|||April 2014|April 4, 2014|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793234||147249|
NCT00793832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 837|The Effect of Supervised Exercise on Physical Fitness and Energy Expenditure in Post Bariatric Surgery Patients|The Effect of Supervised Cardiorespiratory Endurance Exercise Training on Physical Fitness and Energy Expenditure in Roun-en-Y Gastric Bypass and Gastric Banding Surgery Patients.||University of Texas Southwestern Medical Center|No|Completed|July 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|No|||January 2010|June 27, 2013|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793832||147204|
NCT00794105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cohenmed.CTIL|Observation of Gas Exchange in the Middle Ear|||Shaare Zedek Medical Center|No|Not yet recruiting|November 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|8 Years|80 Years|No|Non-Probability Sample|Patients treated as a routine treatment in the outpatient or patients admitted for        treatment of sudden hearing loss.|November 2008|November 18, 2008|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794105||147184|
NCT00794118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-102321|Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)|Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study|DOSE|Pfizer|Yes|Completed|June 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|299|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|April 2012|April 12, 2012|November 17, 2008||No||No|April 12, 2012|https://clinicaltrials.gov/show/NCT00794118||147183|Protocol did not indicate primary or secondary endpoints and all determination of primary or secondary endpoints were arbitrary.
NCT00794391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13940 (FRSQ ID)|Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)|Effects of a Brief Motivational Intervention on Risky Injection Practices Among Injecting Drug Users||Université de Sherbrooke|No|Completed|November 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|219|||Both|16 Years|N/A|No|||April 2014|April 2, 2014|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794391||147162|
NCT00807846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191342|A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects|A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.||Pfizer|Yes|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|2 Years|17 Years|No|||October 2015|October 7, 2015|December 10, 2008|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT00807846||146150|
NCT00807859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062042|Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer|An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer||Amgen||Completed|March 2009|October 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|65|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807859||146149|
NCT00808691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707012|Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit|Microcirculation and Oxidative Stress in Critically Ill Patients in Surgical Intensive Care Unit||National Taiwan University Hospital|No|Completed|September 2007|July 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|124|||Both|18 Years|N/A|No|Non-Probability Sample|Paitents admitted to intensive care unit with the following conditions Sepsis        Postoperative care ARDS Renal Failure Liver failure Brain death|January 2015|January 5, 2015|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808691||146085|
NCT00808379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260|Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers|Concurrent Chemo-Radiotherapy vs Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers. A Randomized Phase II Study||Tata Memorial Hospital|Yes|Active, not recruiting|May 2006|July 2009|Anticipated|February 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||December 2008|December 12, 2008|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808379||146109|
NCT00808392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M37P2|Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b|A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Investigate Immunogenicity and Safety of Haemophilus Influenzae Type b Vaccine in 2 - 4 Months Old Healthy Infants in China, According to the Recommended Regimen of 3 Intramuscular Doses Given One Month Apart||Novartis||Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|916|||Both|2 Months|4 Months|Accepts Healthy Volunteers|||December 2011|December 26, 2011|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808392||146108|
NCT00808652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-5431-08-DG-CTIL|Prevalence and Outcome of Brachial Artery Endothelial Function in Morbidly Obese Patients Undergoing Bariatric Surgery|Prevalence and Outcome of Brachial Artery Endothelial Function in Morbidly Obese Patients Undergoing Bariatric Surgery||Sheba Medical Center|No|Recruiting|March 2009|||June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Morbisly obese patients scheduled to undergo bariatric surgery|June 2011|June 20, 2011|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808652||146088|
NCT00804960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR #5/17/08-2|Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?|Controlled Ovarian Stimulation With Letrozole Supplementation|Cost-Less|Center for Human Reproduction|No|Withdrawn|September 2008|April 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|21 Years|38 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|December 5, 2008||No|lack of recruitment at this site|No||https://clinicaltrials.gov/show/NCT00804960||146364|
NCT00804973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12258|Study in Subjects With Acute Migraines Headaches.|A Safety, Tolerability, and Efficacy Study of LY2590443 in the Treatment of Acute Migraine Headache||Eli Lilly and Company|No|Terminated|November 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2010|April 16, 2010|December 5, 2008|Yes|Yes|Due to efficacy results of interim analysis|No||https://clinicaltrials.gov/show/NCT00804973||146363|
NCT00805844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H50805-31889|Motor Evoked Potentials and SedLine|Monitoring Depth of Anesthesia With the SedLine Facilitates Motor Evoked Potential (MEP) Monitoring During Corrective Spinal Surgery||University of California, San Francisco|No|Terminated|September 2008|September 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing corrective spinal procedures, for whom MEP monitoring has been        requested by the surgeon.|July 2011|July 13, 2011|December 9, 2008||No|Sponsor terminated the study|No||https://clinicaltrials.gov/show/NCT00805844||146298|
NCT00805857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.144|Surveillance Cohort Long-Term Toxicity Antiretrovirals in HIV-Infected Patients Enrolled in TPV Cohort|SCOLTA: SURVEILLANCE COHORT LONG-TERM TOXICITY ANTIRETROVIRALS||Boehringer Ingelheim||Withdrawn|June 2008|||December 2009|Anticipated|N/A|Observational|N/A|||Anticipated|150|||Both|18 Years|N/A|No|||December 2008|December 9, 2008|June 10, 2008||||No||https://clinicaltrials.gov/show/NCT00805857||146297|
NCT00805545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/S- Antibiotics|Timing of Antibiotic Prophylaxis for Cesarean Deliveries|The Timing of Antibiotic Prophylaxis for Cesarean Delivery||University of Florida|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 19, 2012|December 5, 2008||No||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00805545||146320|There were no limitations to the study. No technical problems occurred during the study.
NCT00806403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWEDES 23/09/01|Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction|Very Early Initiation of Treatment With Thrombolysis and Low Molecular Weight Heparin, Versus Abciximab and Low Molecular Weight Heparin Followed by Percutaneous Coronary Intervention, for Acute ST-Elevation Myocardial Infarction|SWEDES|Sahlgrenska University Hospital, Sweden|Yes|Completed|November 2001|June 2004|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|75 Years|No|||November 2008|December 2, 2008|November 7, 2008||No||No|November 7, 2008|https://clinicaltrials.gov/show/NCT00806403||146256|
NCT00806728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP042|Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease|Phase I Study of MEDI-507 in the Treatment of Adult Patients With at Least Grade II Steroid-Resistant Acute Graft-Versus-Host Disease||MedImmune LLC||Completed|May 1998|December 1998|Actual|November 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||December 2008|December 10, 2008|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806728||146232|
NCT00806429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712003306|Transvaginal Appendectomy|Transvaginal Appendectomy||Yale University|No|Recruiting|August 2008|||December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|65 Years|No|||December 2008|December 8, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00806429||146254|
NCT00806754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY9010/M1-490|Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)|Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy||Takeda|No|Completed|November 2006|August 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|N/A|No|||December 2008|May 4, 2012|December 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806754||146230|
NCT00806741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-300708|Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans|Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans||Medical University of Vienna|Yes|Completed|September 2009|September 2012|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806741||146231|
NCT00795691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-180|Diabetes Dietary Study- Low Carbohydrate and Low-Fat Diets in Type 2 Diabetes|High and Low Carbohydrate Weight Loss Approaches to Type 2 Diabetes Mellitus AKA The Diabetes Dietary Study (DDS)||Albert Einstein College of Medicine of Yeshiva University|Yes|Active, not recruiting|May 2004|December 2008|Anticipated|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|65 Years|No|||November 2008|November 20, 2008|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795691||147066|
NCT00795405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sporting events|Cardiovascular Effects of Sporting Events|Cardiovascular Effects of Major Sporting Events in Subjects With Coronary Heart Disease||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38|||Male|18 Years|70 Years|No|||August 2009|August 4, 2009|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795405||147087|
NCT00792961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13082008|Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery|In Vivo Confocal Endomicroscopy During da Vinci Robot Assisted Prostatectomy: Feasibility Study||Optiscan Pty Ltd|No|Completed|November 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Male|18 Years|N/A|No|||April 2014|April 7, 2014|November 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00792961||147268|
NCT00793494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probaclac-HSJ|Efficacy of Probaclac in Irritable Bowel Syndrome in Children Aged 8 to 18 Years|Randomized Controlled Trial of Probaclac Versus Placebo in Children Aged 8 to 18 Years With Irritable Bowel Syndrome|POPSII|St. Justine's Hospital|Yes|Terminated|January 2009|May 2015|Actual|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|8 Years|18 Years|No|||May 2015|May 19, 2015|November 17, 2008||No|Recruitment impossible|No||https://clinicaltrials.gov/show/NCT00793494||147229|
NCT00825799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00435|Serum Markers as a Bioassay for Unipolar Depression|Validation of Serum Markers as a Bioassay for Unipolar Depression||Steward St. Elizabeth's Medical Center of Boston, Inc.|No|Completed|November 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|160|Samples Without DNA|serum, plasma|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from the community by advertisement.|June 2013|January 2, 2014|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825799||144784|
NCT00826436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3208A1-1008|Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 in Japanese Postmenopausal Women|A Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of PRA-027 Administered Orally to Japanese Postmenopausal Women||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|16|Samples With DNA|whole blood|Female|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|March 2009|March 5, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826436||144735|
NCT00826449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0353|Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)|Phase I-II Study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Terminated|February 2009|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|16 Years|N/A|No|||September 2015|September 18, 2015|January 20, 2009|No|Yes|Closed early due to determination of futility/efficacy.|No|September 18, 2015|https://clinicaltrials.gov/show/NCT00826449||144734|
NCT00808405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34708-A|GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women|Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women|PK/GUD|University of Washington|No|Completed|January 2009|July 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|88|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 15, 2013|November 25, 2008|Yes|Yes||No|April 20, 2012|https://clinicaltrials.gov/show/NCT00808405||146107|
NCT00808704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-200312|Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy|Effect of Erythropoietin on Neonatal Hypoxic Ischemic Encephalopathy||Zhengzhou University|Yes|Completed|August 2003|July 2008|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|167|||Both|N/A|48 Hours|No|||December 2008|December 15, 2008|December 15, 2008||||No||https://clinicaltrials.gov/show/NCT00808704||146084|
NCT00804453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1455|Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line|Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line: A Pilot Monocentric Open Randomized and Cross-over Study.||Gambro Lundia AB|No|Completed|November 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||March 2011|March 7, 2011|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804453||146402|
NCT00808665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-081331|Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion|Does Continuous Perioperative Dexmedetomidine Infusion Reduce Time to Discharge in Patients Undergoing Major Lumbar Fusion? A Double-Blind, Placebo-Controlled Study|DEXREDLOS|Vanderbilt University|Yes|Completed|June 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|85 Years|No|||January 2014|January 29, 2014|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808665||146087|
NCT00808678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-662|Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium|||AstraZeneca|No|Completed|December 2008|||January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00808678||146086|
NCT00805246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL095115|Assessing the Prognosis of Pulmonary Embolism Using Clinical and Imaging Biomarkers (Retrospective & Prospective )|Identifying CT Imaging Biomarkers Associated With Prognosis of Pulmonary Embolism||University of Pittsburgh|Yes|Active, not recruiting|December 2008|July 2016|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|910|||Both|18 Years|N/A|No|Non-Probability Sample|Adults > 18 years of age who either present to University of Pittsburgh Medical Center        (UPMC) or Washington University in St. Louis hospitals with acute PE or develop acute PE        while admitted to the hospital diagnosed by CT.|January 2016|January 26, 2016|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805246||146342|
NCT00805259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU HS08-605|Promoting Mental Acuity in Elderly Populations Through Incentive for Technology Use|Promoting Mental Acuity in Elderly Populations Through Incentive for Technology Use||Carnegie Mellon University|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|312|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805259||146341|
NCT00806169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-KTDRP-2008|Combined Triple Therapy in Diabetic Retinopathy (DRP)|Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Diabetic Retinopathy||Johann Wolfgang Goethe University Hospitals|No|Completed|April 2006|November 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|21 Years|N/A|No|||September 2012|September 26, 2012|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00806169||146274|
NCT00806182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrasher Award 02826-2|Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome|Cytokines as Biomarkers and Therapeutic Targets in Paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS)|OMS|National Pediatric Myoclonus Center|No|Recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|400|Samples Without DNA|serum, plasma, cerebrospinal fluid|Both|1 Year|18 Years|Accepts Healthy Volunteers|Probability Sample|Referrals to National Pediatric Myoclonus Center Website, www.omsusa.org|January 2014|January 24, 2014|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00806182||146273|
NCT00807404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000628769|Optical Coherence Tomography in Tissue Samples From Women Undergoing Mastectomy for the Treatment or Prevention of Breast Ductal Intraepithelial Neoplasia|Forward Image Guided Ductoscopy for Early Cancer Screening||City of Hope Medical Center||Completed|November 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||May 2010|May 26, 2010|December 10, 2008||||No||https://clinicaltrials.gov/show/NCT00807404||146182|
NCT00807092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3681|Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes|Comparison of the Efficacy on Glycaemic Control and Safety Profile of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 Both in Combination With Metformin in Insulin-naïve Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Therapy||Novo Nordisk A/S|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|80 Years|No|||February 2015|February 13, 2015|December 10, 2008|Yes|Yes||No|November 12, 2010|https://clinicaltrials.gov/show/NCT00807092||146206|
NCT00807105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013-07 SHA|Evaluation of the H-coil Transcranial Magnetic Stimulation TMS Device - Safety and Feasibility Study for Acute and Maintenance Treatment in Major Depressive Episode|||Shalvata Mental Health Center|Yes|Completed|June 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|65 Years|No|||January 2012|January 4, 2012|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00807105||146205|
NCT00796328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-4462-2008|Up-Down Determination of the ED90 of Phenylephrine for Hypotension Prophylaxis in Cesarean Delivery|Up-down Determination of the ED90 of the Initial Rate of Infusion of Phenylephrine for the Prophylaxis of Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery||IWK Health Centre|Yes|Terminated|November 2008|July 2009|Actual|February 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|45|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 3, 2014|November 19, 2008||No|Results Invalid, study closed, analysis cannot proceed.|No|March 14, 2014|https://clinicaltrials.gov/show/NCT00796328||147018|
NCT00795964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intraoperative tidalvolume-25|Influence of Tidal Volume on Postoperative Pulmonary Function|Influence of Tidal Volume on Postoperative Pulmonary Function|tidalvolume|Heinrich-Heine University, Duesseldorf|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|101|||Both|50 Years|N/A|No|||September 2010|September 23, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795964||147045|
NCT00793247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBR-7|Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)|A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP).||Movetis||Completed||||||Phase 2|Interventional|N/A|||||||Both|18 Years|N/A|No|||November 2008|November 18, 2008|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00793247||147248|
NCT00793520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-16|Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia|||Forest Laboratories|No|Terminated|November 2008|||April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|70 Years|No|||June 2010|June 1, 2010|November 17, 2008|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00793520||147227|Early termination leading to small numbers of subjects enrolled. Technical problems with MRI equipment resulted in early study termination. No analysis was performed.
NCT00793819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI08005|A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia|A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia||Watson Pharmaceuticals|No|Completed|January 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|215|||Male|50 Years|N/A|No|||February 2012|February 7, 2012|November 17, 2008|Yes|Yes||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00793819||147205|
NCT00826150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-08-01|Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer|Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer||BioCancell Ltd.|Yes|Completed|June 2009|October 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|N/A|No|||November 2012|November 12, 2012|January 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826150||144757|
NCT00826163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-B-01-MG-14-5114|Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients|Innate Immune Responses in Chronic Obstructive Pulmonary Disease Patients||Mahidol University|No|Completed|January 2009|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||September 2013|September 10, 2013|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00826163||144756|
NCT00808418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4783-12|A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer|A Phase 1 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC)||Synta Pharmaceuticals Corp.|No|Completed|November 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Male|18 Years|N/A|No|||January 2014|January 31, 2014|December 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00808418||146106|
NCT00804466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909045|Human Papillomavirus Epidemiology in Nigeria|Epidemiologic and Molecular Features of Cervical Cancer in Nigeria - Project Itoju (Care)||National Institutes of Health Clinical Center (CC)||Completed|December 2008|November 2012|Actual|November 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1500|||Female|15 Years|100 Years|No|||October 2015|October 20, 2015|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804466||146401|
NCT00804479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPXAPD-0072-138|The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)|Unblinded, Multicenter, Prospective Follow-up of Long-term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.|CALM-PD Cohort|University of Rochester|No|Terminated|January 2002|March 2004|Actual|March 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|222|||Both|N/A|N/A|No|Non-Probability Sample|Available 301 subjects enrolled in CALM-PD|January 2016|January 20, 2016|December 4, 2008||No|Funding for the CALM-PD Cohort Study was terminated by sponsor.|No||https://clinicaltrials.gov/show/NCT00804479||146400|
NCT00804492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710010R|Establishment of an Integrated Model for Prevention of Elderly Falls|Bureau of Health Promotion,Department of Health, R.O.C. (Taiwan)||National Taiwan University Hospital|No|Completed|June 2008|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|900|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 28, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00804492||146399|
NCT00804726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580|Evaluation of the Safety and Effectiveness of the Akreos MI Five-0 Intraocular Lens.|A Prospective, Open-label, Monocular Feasibility Clinical Evaluation of the Bausch & Lomb Akreos MI Five-O Accommodating Intraocular Lens.||Bausch & Lomb Incorporated|No|Terminated|November 2008|July 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|50 Years|N/A|No|||January 2014|January 15, 2014|December 8, 2008|No|Yes|Test lens did not meet near visual efficacy endpoints|No||https://clinicaltrials.gov/show/NCT00804726||146382|
NCT00805584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03442|Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)|A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius.||Merck Sharp & Dohme Corp.|No|Completed|May 2003|June 2003|Actual|June 2003|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|311|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805584||146317|
NCT00805597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC2008B06|Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes|A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes||Chinese Academy of Medical Sciences|Yes|Suspended|June 2008|||June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|75 Years|No|||February 2012|February 13, 2012|December 8, 2008||No|The recuiting was to slow to complete the study|No||https://clinicaltrials.gov/show/NCT00805597||146316|
NCT00805558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-0001-CM|Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis|Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole as Adjunctive Therapy to Mechanical Treatment of Patients With Chronic Periodontitis||Facultad Nacional de Salud Publica|Yes|Completed|February 2009|April 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||October 2009|May 10, 2010|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805558||146319|
NCT00805571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-196|Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients|Urinary Kidney Injury Molecule-1 As Diagnostic Biomarker of Proximal Tubular Injury in Adult and Pediatric Transplant Recipients||Northwell Health|Yes|Completed|October 2008|||February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Urine|Both|3 Years|18 Years|No|Non-Probability Sample|Adult and pediatric patients with chronic renal failure who are listed at Mount Sinai        Hospital for a deceased donor kidney transplant and/or who are in the process of having a        living donor evaluation are eligible to participate. One urine sample will be sent for        KIM-1 measurement before transplantation, once the patient or the caregiver of the patient        consents to participation in the study. The next specimen of urine will only be collected        status post kidney transplant in the immediate post-operative phase and on routine visits        thereafter. The study does not require obtaining any extra blood or urine specimens, but        uses urine that would otherwise be discarded.|March 2010|March 11, 2010|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805571||146318|
NCT00805870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-02-31|The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers|The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers||Western Michigan University|No|Completed|March 2009|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|December 9, 2008|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00805870||146296|
NCT00806442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008p001696|Treatment of Bronchial Asthma With Borage and Echium Seed Oils|Treatment of Bronchial Asthma With Borage and Echium Seed Oils||Brigham and Women's Hospital|No|Recruiting|December 2008|March 2011|Anticipated|March 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|65 Years|No|||May 2010|May 3, 2010|December 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806442||146253|
NCT00799136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2007-CATCH|A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL|Feasibility Study of CO-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma|CATCH|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|February 2008|September 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799136||146807|
NCT00799461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2258.00|Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications|INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation||Fred Hutchinson Cancer Research Center|No|Completed|August 2008|||November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|3||Actual|1337|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799461||146784|
NCT00807716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/2436|Effect of Physiotherapy After Total Knee Replacement|The Immediate and Long Term Effects of a Walking-skill Program Compared to Usual Physiotherapy Care in Patients Who Have Undergone Total Knee Arthroplasty (TKA): A Randomized Controlled Trial||University of Oslo|Yes|Completed|October 2008|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|55 Years|N/A|No|||December 2014|December 4, 2014|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807716||146160|
NCT00807950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR04/18/08|Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer|Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer||National University Hospital, Singapore|No|Active, not recruiting|March 2008|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment||||100|||Female|18 Years|N/A|No|||January 2014|January 21, 2014|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807950||146142|
NCT00804609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07022008-1228|Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery|A Study to Evaluate the Effects of Epidural Lidocaine Administration on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® (Morphine Sulfate Extended-release Injection) in Patients Undergoing Cesarean Delivery||Stanford University|No|Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|40 Years|No|||February 2016|February 7, 2016|October 23, 2008||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT00804609||146390|
NCT00804622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AHK01|Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)|A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB||The University of Hong Kong|No|Completed|December 2008|March 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|December 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00804622||146389|
NCT00793273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3694|Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.|Evaluation of Glycaemic Control After Initiation of Levemir® in Patients With Type 2 Diabetes Mellitus and Time Period Between Diagnosis of Type 2 Diabetes Mellitus and Insulin Initiation.||Novo Nordisk A/S|No|Completed|November 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1074|||Both|18 Years|N/A|No|Probability Sample|Patients from general practice setting who have been deemed appropriate to receive        Levemir® as part of routine out-patient care by the prescribing physician.|May 2014|August 13, 2014|November 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00793273||147246|
NCT00793507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0198|Oral Health Care Early Intervention Project|Oral Health Care Early Intervention Project||University of Colorado, Denver|No|Completed|November 2008|April 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1178|||Both|N/A|36 Months|No|||January 2009|February 4, 2013|November 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00793507||147228|
NCT00825487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 621-101|Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies|A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies||ArQule|No|Completed|August 2009|September 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00825487||144808|
NCT00825500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-104-202|Staccato Loxapine in Migraine (Out Patient)|A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Outpatients With Migraine Headache||Alexza Pharmaceuticals, Inc.|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|366|||Both|18 Years|65 Years|No|||August 2009|August 28, 2009|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825500||144807|
NCT00822588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-DRA-0001|Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not|A Prospective, Randomized, Controlled Trial of Retransfusion of Intra-operatively Collected Filtered Whole Blood in Total Hip Surgery||Wellspect HealthCare|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|January 13, 2009||No||No|February 18, 2011|https://clinicaltrials.gov/show/NCT00822588||145028|
NCT00826124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00022479|Does Magnetic Resonance Imaging (MRI) Improve Interventional Outcomes for Lumbosacral Radiculopathy?|Does MRI Improve Interventional Outcomes for Lumbosacral Radiculopathy? A Randomized Study Comparing Epidural Steroid Injections Based on Clinical Findings Alone, or Clinical Findings and MRI||Johns Hopkins University|Yes|Completed|January 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|131|||Both|18 Years|N/A|No|||January 2009|June 22, 2011|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826124||144759|
NCT00826137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor472908ctil|Preventing Childhood Antibiotic-associated Diarrhea by Prebiotics|Prebiotics in the Prevention of Antibiotic-associated Diarrhea in Children|WGAAD|Soroka University Medical Center|No|Completed|December 2008|July 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|6 Months|14 Years|No|||June 2012|June 13, 2012|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00826137||144758|
NCT00804518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.2177|Effect of Exercise on Heart Function in Healthy Elderly People|Aerobic Interval Training Reduces and Compensates Age Related Decline in Cardiac Function||Norwegian University of Science and Technology|Yes|Completed|November 2008|August 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|45|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 7, 2010|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804518||146397|
NCT00804739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH082141-01|Perinatal Depression Treatment in a Pediatric Setting- Pilot Phase|Adapting Collaborative Care Perinatal Depression Treatment to a Pediatric Setting - Pilot Phase|MITT|University of Rochester|Yes|Completed|January 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Female|18 Years|N/A|No|||February 2012|February 23, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804739||146381|
NCT00804752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0040-08-HYMC|Vitamin D Treatment in Patients With Chronic Hepatitis C|||Hillel Yaffe Medical Center||Recruiting||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A|No|||December 2008|December 8, 2008|December 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00804752||146380|
NCT00804999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-08-15|Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure|Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure||University of Iowa|No|Recruiting|November 2008|||March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 8, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804999||146361|
NCT00805012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCST-L-0004|Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)|A Randomized, Multicenter, Phase II Study of Docetaxel and TS-1 Combination as a First-line Treatment in Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)||Seoul National University Hospital|No|Terminated|December 2008|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||July 2011|July 23, 2011|December 6, 2008||No|slow accrual rate|No||https://clinicaltrials.gov/show/NCT00805012||146360|
NCT00804986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12134|A Study for Patients With Type 2 Diabetes Mellitus|A 12-Week,Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company||Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|247|||Both|18 Years|70 Years|No|||July 2011|July 12, 2011|December 8, 2008|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00804986||146362|
NCT00805610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB 124|Hepatocyte Transplantation in Liver Failure|The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure.||Virginia Commonwealth University|Yes|Withdrawn|June 2014|June 2018|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|70 Years|No|||August 2014|August 1, 2014|December 5, 2008|Yes|Yes|Investigator taking position at another university-0 enrolled under this protocol.|No||https://clinicaltrials.gov/show/NCT00805610||146315|
NCT00805883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLTT 001|MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer Followed by Radical Prostatectomy|MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer Followed by Radical Prostatectomy||University Health Network, Toronto|No|Completed|February 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|40 Years|80 Years|No|||December 2008|May 26, 2011|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805883||146295|
NCT00806195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P23|Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants|A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants||Novartis||Completed|December 2008|November 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|7744|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||May 2013|May 13, 2013|December 9, 2008|Yes|Yes||No|May 13, 2013|https://clinicaltrials.gov/show/NCT00806195||146272|
NCT00806208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP046|Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)|Phase I Evaluation of Safety, Pharmacokinetics and Activity of Escalating Dose Levels of MEDI 507 in Patients Receiving Methylprednisolone for Initial Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)||MedImmune LLC||Completed|January 1999|March 2000|Actual|January 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|34|||Both|18 Years|N/A||||December 2008|December 10, 2008|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806208||146271|
NCT00806221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002726|Eczema Prevention Study|An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis||Oregon Health and Science University|No|Recruiting|November 2006|November 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|N/A|1 Month|No|||December 2008|December 9, 2008|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00806221||146270|
NCT00807118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221052|Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect|A Phase 1, Open-Label, Randomized, Single-Dose, 2-Cohort, 3-Way Crossover Study To Determine Bioequivalence Of 4 Mg And 8 Mg Fesoterodine SR Tablet Of Commercial Formulation And 8 Mg Fesoterodine SR Tablet Between Formulation E(1) And Formulation F And Investigate Food Effect On Commercial Formulation In Healthy Subjects.||Pfizer|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|108|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 23, 2010|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807118||146204|
NCT00807131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402736/2005-2|Effectiveness of Pharmaceutical Care on Primary Care Patients With Uncontrolled Hypertension|Effectiveness of a Pharmaceutical Care Program on Primary Care Patients With Uncontrolled Hypertension- A Brazilian Multicenter RCT|EPHACA|Hospital de Clinicas de Porto Alegre|No|Completed|September 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|301|||Both|18 Years|N/A|No|||December 2008|December 10, 2008|October 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00807131||146203|
NCT00795119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK3748|A Trial to Determine the Efficacy of Near Infrared Spectroscopy to Detect Intracranial Hemorrhage in Children|A Clinical Assessment of the Reliability of Near Infrared Spectroscopy for the Detection of Intracranial Hemorrhage in Young Children|NIRS|IWK Health Centre|No|Completed|September 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|73|||Both|N/A|36 Months|Accepts Healthy Volunteers|||November 2008|April 2, 2009|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795119||147109|
NCT00795132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI12073|Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies|Reduced Intensity Conditioning Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation||University of Utah|Yes|Completed|April 2004|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|N/A|21 Years|No|||July 2013|July 23, 2013|November 19, 2008||No||No|January 30, 2012|https://clinicaltrials.gov/show/NCT00795132||147108|Participants who experienced early relapse or death before engraftment were excluded from analysis.
NCT00799474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-558377|Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination|Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination||University of North Carolina, Chapel Hill|No|Completed|December 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|609|||Male|18 Years|59 Years|Accepts Healthy Volunteers|Probability Sample|Approximately 600 men (ages 18-59) who have agreed to participate in a periodic panel        through the private survey company, Knowledge Networks.|January 2010|February 25, 2016|November 26, 2008||No||No|December 7, 2009|https://clinicaltrials.gov/show/NCT00799474||146783|
NCT00795418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAD106A2202|Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients|A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106||Novartis||Completed|October 2008|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|40 Years|85 Years|No|||May 2012|May 2, 2012|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00795418||147086|
NCT00796692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA703B07|Nadroparin for the Initial Treatment of Pulmonary Thromboembolism|Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism：a Multi-Centre, Randomised Controlled Trial in China|NATSPUTE|Beijing Chao Yang Hospital|Yes|Completed|June 2002|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|75 Years|No|||November 2008|November 21, 2008|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796692||146991|
NCT00796705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ARA05|Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)|Switching Anti-TNF-alpha Agents in Patients With RA With An Inadequate Response to TNF-alpha Inhibition||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|November 2008|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||August 2012|September 28, 2012|November 20, 2008|Yes|Yes|Lack of Enrollment|No|July 5, 2012|https://clinicaltrials.gov/show/NCT00796705||146990|The study terminated early due to recruitment feasibility issues. Thirteen subjects were enrolled and received treatment. No mechanistic analyses were performed.
NCT00825201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08059|Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity|Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity||City of Hope Medical Center|Yes|Active, not recruiting|January 2009|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|19 Years|N/A|No|||December 2015|December 16, 2015|January 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00825201||144829|
NCT00825513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|566|Safety and Effectiveness of the Akreos Toric Intraocular Lens.|Monocular Study to Evaluate the Safety and Effectiveness of the Akreos™ Toric IOL When Used to Correct Primary Aphakia With the Reduction of Astigmatism||Bausch & Lomb Incorporated|No|Completed|February 2009|September 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|January 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825513||144806|
NCT00825812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05768|Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)|A Multi-center, Randomized, Parallel-group, Active-controlled, Safety-assessor Blinded Trial, Comparing the Efficacy and Safety of 2.0 mg.Kg-1 Sugammadex With 50 μg.Kg-1 Neostigmine Administered at Reappearance of T2 After Rocuronium in Chinese and European ASA I-III Subjects Undergoing Elective Surgery Under Propofol Anesthesia||Merck Sharp & Dohme Corp.|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|308|||Both|18 Years|64 Years|No|||October 2015|October 30, 2015|January 15, 2009|No|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00825812||144783|
NCT00823095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNO-1B|Topical Nitric Oxide Trial in Chronic Non-Healing Wounds|The Observational Effects of the Topical Application of ViaNOx-H (Gaseous Nitric Oxide) on the Bio-Burden in Chronic Non-Healing Colonized Ulcers of the Lower Extremities||Loma Linda University|Yes|Terminated|December 2005|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2014|January 28, 2016|January 13, 2009|Yes|Yes|Subject recuitment halted and won't resume; subjects are no longer being treated.|No|August 2, 2013|https://clinicaltrials.gov/show/NCT00823095||144990|No data available for this study due to dissolution of company contracted to perform study analysis.
NCT00826475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|423/08|Randomized Trial to Evaluate the Effectiveness of a Mindfulness Based Intervention (MBSR) for Patients Suffering From Migraine|Randomized Trial to Evaluate the Effectiveness of a Mindfulness Based Intervention (MBSR) for Patients Suffering From Migraine||University Hospital Freiburg|No|Completed|January 2009|July 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|No|||January 2009|August 12, 2011|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826475||144732|
NCT00808730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/29|Role of Mitochondria in Non Severe Asthma|Role of Mitochondria in Human Bronchial Smooth Muscle Remodeling in Non Severe Asthma|MITASTHME|University Hospital, Bordeaux|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|32|||Both|18 Years|N/A|No|||February 2010|February 15, 2010|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808730||146082|
NCT00804765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM07093|Impact of Education During Pregnancy in Overweight Pregnant Women|Impact of Pregnant Women Education in Case of Overweight or Obesity on Risk of Child Overweight and Pregnancy Outcome|ETOIG|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2008|November 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|275|||Female|18 Years|N/A|No|||August 2014|August 25, 2014|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804765||146379|
NCT00804778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chumingyidoc@sohu.com|Comparison of USCOM Cardiac Output and Continuous Thermodilution Cardiac Output|Comparison of USCOM Cardiac Output and Continuous Thermodilution Cardiac Output in Patients With Coronary Artery Bypass Grafting||Beijing Chao Yang Hospital|No|Completed|March 2006|July 2006|Actual|July 2006|Actual|N/A|Observational|N/A||2|Actual|18|||Both|42 Years|78 Years|No|Probability Sample|18 post-CABG coronary artery disease patients receiving treatment in the SCCU of Beijing        Chaoyang Hospital from March to July 2006, male (10) and female (8), with average age of        61.71士10.07 years.For all the patients after operation, pericardial cavity or left thorax        close drainage, small tidal volume (6-8ml/kg) capacity controlled ventilation of breathing        machine, appropriate pressure support (10-15cmH2O) and appropriate positive end-expiratory        pressure were applied. Institutional ethics approval was obtained for the conduct of the        trial.|December 2008|December 8, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804778||146378|
NCT00805025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-219-0102|Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis|An Open-Label, Multicenter Trial to Validate the Quality of Life Questionnaire-Bronchiectasis and to Evaluate Perception of Symptom Improvement Following One Course of Aztreonam for Inhalation Solution (AZLI) in Subjects With Bronchiectasis and Gram-negative Bacteria in the Airways||Gilead Sciences|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|December 5, 2008|Yes|Yes||No|September 9, 2013|https://clinicaltrials.gov/show/NCT00805025||146359|
NCT00805038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-00301|Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation|Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation||Case Western Reserve University|Yes|Completed|January 2009|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|167|||Both|18 Years|70 Years|No|||December 2008|June 20, 2011|December 8, 2008||No||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00805038||146358|
NCT00805272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070311|Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients|Medical and Economical Evaluation of New Diagnosis Tests of Mycobacterium Tuberculosis, Specific Immune Responses in HIV-infected Adults|IGRAVIH|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2009|February 2012|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|536|||Both|18 Years|N/A|No|||November 2008|March 16, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805272||146340|
NCT00798031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS replication of YA-OSS-0001|Case Series Evaluation of a Short Dental Implant|Case Series Evaluation of a Short Dental Implant Placed in the Posterior Maxilla in an Early Loading Protocol|Short implant|University of Iowa|Yes|Suspended|October 2008|August 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 24, 2010|November 24, 2008||No|Recruitement currently suspended to allow project personnel to focus on other research.    Recruitment should open in 2010.|No||https://clinicaltrials.gov/show/NCT00798031||146891|
NCT00798044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020799|Patient Feedback Effectiveness Study|Patient Feedback Effectiveness Study||University of Pennsylvania|No|Completed|November 2006|April 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|118|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00798044||146890|
NCT00805896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-1001|Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma|Effectiveness and Safety Study of TACE Plus Oral Songyou Granule for Unresectable HCC||Fudan University|Yes|Active, not recruiting|December 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|75 Years|No|||December 2008|December 30, 2008|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00805896||146294|
NCT00805909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0401-02|NI-0401 in Patients With Acute Renal Allograft Rejection|A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection||NovImmune SA|Yes|Completed|August 2007|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||June 2009|June 8, 2009|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805909||146293|
NCT00806234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH080270|Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics|Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)|IMPACT|Johns Hopkins University|Yes|Completed|January 2009|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|127|||Both|8 Years|19 Years|No|||May 2014|May 15, 2014|December 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806234||146269|
NCT00806455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0319|Exercise-Induced Bronchospasm in Cystic Fibrosis|Exercise-Induced Bronchospasm in Cystic Fibrosis||Ohio State University|No|Completed|July 2008|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|Samples Without DNA|blood, sputum|Both|12 Years|N/A|No|Non-Probability Sample|Forty patients with cystic fibrosis and mild lung disease (defined by FEV1≥ 70%        predicted), age 12 years and older, are our target enrollments.|November 2013|November 18, 2013|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806455||146252|
NCT00798876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-07-026|Low-Fat Fish Oil Diet for Prostate Cancer Prevention|Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|December 2001|||September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|70|||Male|40 Years|75 Years|No|||September 2015|September 9, 2015|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798876||146826|
NCT00795977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198|Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer|Phase I/II Study on Intratumor Dendritic Cell Injection Immunotherapy Using Immature Dendritic Cells With S Pyogenes Preparation (OK-432) for Patients With Resectable Pancreatic Cancer||Fukushima Medical University|No|Active, not recruiting|November 2003|November 2012|Anticipated|November 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|No|||September 2011|September 7, 2011|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795977||147044|
NCT00796302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077907|Treatment of Severe Childhood Aggression (The TOSCA Study)|Stimulant and Risperidone in Children With Severe Physical Aggression||Ohio State University|Yes|Active, not recruiting|August 2008|July 2013|Anticipated|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|6 Years|12 Years|No|||May 2013|May 16, 2013|November 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796302||147020|
NCT00796315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008014|Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children|A Single-dose, Open-label, Multi-center Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Ages 2 to < 18 Years||Procter and Gamble|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|41|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|November 18, 2008|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00796315||147019|Incidences of mild sedation are consistent with doxylamine's indication as an OTC sleep aid. Conclusive evaluation of sedation couldn't be undertaken in the absence of a control group. Also, children may nap in daytime confounding sedation assessment
NCT00795990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31769|Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants|Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants||University of Utah|No|Completed|November 2008|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|350|||Both|N/A|3 Months|No|Non-Probability Sample|Premature infants born weighing less than 1200 gms with echo confirmed PDA|December 2014|December 4, 2014|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795990||147043|
NCT00804297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(H)N-2877|Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia|Comparison of Octreotide and Standard Therapy vs. Standard Therapy Alone for the Treatment of Hypoglycemia in Patients Taking Sulfonylureas or a Combination of Insulin and Sulfonylureas Presenting to the Emergency Department||Albert Einstein Healthcare Network||Completed|June 2005|January 2007||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||40|||Both|18 Years|N/A|No|||December 2008|December 5, 2008|December 5, 2008||||No||https://clinicaltrials.gov/show/NCT00804297||146414|
NCT00805103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0602-C|Perfexion Brain Metastasis|Hypofractionated Stereotactic Radiotherapy (HF-SRT) for Large-Volume Brain Metastases|HF-SRT|University Health Network, Toronto|Yes|Active, not recruiting|December 2008|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805103||146353|
NCT00805116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1523 Hvalolje (NIFES)|Marine Oils and Arthritis|Whale Oil Versus Cod Liver Oil in Rheumatoid Arthritis||National Institute of Nutrition and Seafood Research, Norway|No|Terminated|December 2008|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2010|January 7, 2010|December 8, 2008||No|Recruitment to slow, most patients to well for treatment|No||https://clinicaltrials.gov/show/NCT00805116||146352|
NCT00805129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-123|Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium|Phase II Study of Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|December 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805129||146351|
NCT00796718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21800|A Study of Xeloda (Capecitabine) Plus Radiotherapy in Patients With Locally Advanced Rectal Cancer|An Open Label Study of the Effect of Xeloda and Radiotherapy on Pathological Response Rate in Patients With Locally Advanced Rectal Cancer.||Hoffmann-La Roche||Completed|October 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796718||146989|
NCT00804843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-111|Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)|A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA)|MCAT|Merck Sharp & Dohme Corp.|No|Completed|April 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|90 Years|No|||September 2015|September 28, 2015|December 8, 2008|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00804843||146373|
NCT00825526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 6349|HARMONY Study (Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga)|HARMONY Study (Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga)|HARMONY|Sunnybrook Health Sciences Centre|No|Completed|July 2008|||March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825526||144805|
NCT00825539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAQW051A2202|Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia|A Single-dose, Placebo-controlled, Stratified, Randomized, Double-blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-week Multiple-dose Safety and Tolerability in People With Chronic Stable Schizophrenia.||Novartis||Completed|January 2009|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|60 Years|No|||February 2013|February 21, 2013|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825539||144804|
NCT00825825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00397|Brain Effects of Escitalopram and Citalopram Using fMRI|A Comparison of the CNS Effects of Equivalent Doses of Escitalopram and Racemic Citalopram Using BOLD fMRI||Steward St. Elizabeth's Medical Center of Boston, Inc.|No|Completed|May 2007|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|January 19, 2009|Yes|Yes||No|June 11, 2012|https://clinicaltrials.gov/show/NCT00825825||144782|Data from several subjects had to be excluded due to one or more fMRI scans with poor data quality (usually high motion) or scheduling problems that prevented a scan from occuring during the specified time window.
NCT00822835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3226K1-1000|Study Evaluating Single Doses of ILV-095 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-095 Administered Subcutaneously to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00822835||145009|
NCT00822848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000631580|Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma|Antiangiogenic Potentiation of Preoperative Chemoradiotherapy for High Risk Extremity Soft Tissue Sarcomas: A Phase I Study of Sorafenib With Epirubicin, Ifosfamide, Hypofractionated Radiation, and Surgery||OHSU Knight Cancer Institute||Active, not recruiting|February 2009|||September 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|15 Years|120 Years|No|||February 2016|February 11, 2016|January 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00822848||145008|
NCT00808743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUN 2008-4198|Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis|Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP)|PreDuoFAP|Radboud University|No|Completed|May 2009|January 2013|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|70 Years|No|||August 2010|May 15, 2013|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808743||146081|
NCT00804791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-08-11|Residence Time Evaluation of Marketed OTC Ophthalmic Products|||Alcon Research|No|Completed|November 2008|||February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804791||146377|
NCT00805051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/08|Acquired Von Willebrand Syndrome in Severe Aortic Stenosis|Does an Acquired Von Willebrand Syndrome Influence Perioperative Blood Loss in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement?||University Hospital, Basel, Switzerland|No|Completed|October 2008|August 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for aortic valve replacement for severe aortic stenosis|September 2011|September 29, 2011|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805051||146357|
NCT00805064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-KTRVO-2008|Combined Triple Procedure in Retinal Vein Occlusion (RVO)|Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Retinal Vein Occlusion||Johann Wolfgang Goethe University Hospitals|No|Completed|January 2006|November 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|21 Years|N/A|No|||September 2012|September 26, 2012|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00805064||146356|
NCT00805285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30365|The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis|Oral Budesonide and Rectal Hydrocortisone for the Treatment of Extensive Ulcerative Colitis: A Pilot Study||University of Maryland|Yes|Terminated|October 2008|March 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2013|March 30, 2013|December 8, 2008||No|Study terminated due to insufficient enrollment|No|January 24, 2013|https://clinicaltrials.gov/show/NCT00805285||146339|The study was terminated early by the University of Maryland HRPO secondary to limited recruitment of participants. This resulted in an inability to analyze the results.
NCT00798356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11067|Yoga on Arrhythmia Burden and Quality of Life in Paroxysmal Atrial Fibrillation|The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Paroxysmal Atrial Fibrillation||University of Kansas Medical Center|No|Completed|November 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|84|||Both|25 Years|80 Years|No|||June 2012|June 13, 2012|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798356||146866|
NCT00798343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL10548|Heterosubtypic Immune Responses to Influenza in Older People|Evaluation of Heterosubtypic Immune Responses in Older People Before and After Seasonal and Pandemic Influenza Vaccination||University Hospitals, Leicester|Yes|Completed|January 2009|September 2013|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|292|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 2, 2014|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798343||146867|
NCT00798616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHC 07-08-36|Steroids Helping Albuterol Responders Exclusively|Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol ("Albuterol Responders")?|SHARE|University Hospital Case Medical Center|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|N/A|24 Months|No|||October 2010|December 5, 2014|November 25, 2008||No|We were unable to enroll a sufficient number of patients due to manpower.|No||https://clinicaltrials.gov/show/NCT00798616||146846|
NCT00798629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15280|Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured|A Dose Ranging Trial of Adenovirus CCL-21 Transduced MART-1/gp100 Peptide-Pulsed Dendritic Cells Matured Using Cytokines for Patients With Chemotherapy-Resistant Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|November 2008|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|November 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00798629||146845|
NCT00799487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015118|CONCERTA Lab School Study|Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children With ADHD (The ABC Study)||Ortho-McNeil Janssen Scientific Affairs, LLC||Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|9 Years|12 Years|No|||March 2011|May 18, 2011|November 26, 2008|Yes|Yes||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00799487||146782|
NCT00795717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVZ111888|Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial|Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial|HALO|Tufts University|Yes|Completed|July 2008|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|November 19, 2008|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00795717||147064|We had low numbers that may not represent the overall population. There was not an HIV negative control arm. The 4 week wash out was too short and therefore difficult to compare the post-treatment vs true post placebo effects.
NCT00804310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626165|Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors|Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors|UCDCC#207|University of California, Davis|Yes|Terminated|August 2009|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2012|March 27, 2012|December 5, 2008|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00804310||146413|
NCT00805454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-07-202|Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712|A Phase I, Open-Label,Positron Emission Tomography (PET) Study Healthy Subjects Following a Single Oral Dose of OPC-34712||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Basic Science|||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805454||146327|
NCT00805467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-935788-012|Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies|An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study||AstraZeneca|Yes|Terminated|August 2008|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|624|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|December 5, 2008|Yes|Yes|AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to    Rigel Pharmaceuticals.|No|January 22, 2014|https://clinicaltrials.gov/show/NCT00805467||146326|
NCT00804856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.4|Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia|An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia||Boehringer Ingelheim||Active, not recruiting|November 2008|July 2016|Anticipated|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 18, 2008||||No||https://clinicaltrials.gov/show/NCT00804856||146372|
NCT00805415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91271|Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens|Multicenter, Open-label, Randomized, Comparative Study to Evaluate Ovulation Inhibition With Two 4-phasic Oral Contraceptive Regimens Containing Estradiol Valerate and Dienogest Applied Daily for Three Cycles to 200 Healthy Female Volunteer||Bayer|No|Completed|March 2003|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|209|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2011|July 14, 2011|December 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805415||146330|
NCT00805428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC|Importance of CD4+CD25+ly in UC1. Investigation of Difference Between Blood Concentration IL 17, IL 33, Regulatory T ly in Patients With UC and Control Group|||Clinical Hospital Center, Split|No|Recruiting|September 2008|||||N/A|Observational|Observational Model: Case Control||2|Anticipated|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with UC and control group|December 2008|December 8, 2008|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805428||146329|
NCT00825552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19091979|Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation|Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation. An Open Trial With Risperidone.||Federal University of Rio Grande do Sul|Yes|Enrolling by invitation|January 2009|November 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|20|||Both|7 Years|17 Years|No|||January 2009|January 20, 2009|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00825552||144803|
NCT00826176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05775|Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)|A Multi-center, Open Label Trial, to Show Efficacy and Safety of 4.0 mg.Kg-1 Sugammadex Administered at a Depth of Neuromuscular Blockade of 1-2 PTC Induced by Rocuronium in Chinese and European ASA I-III Subjects Undergoing Elective Surgery Under Propofol Anesthesia||Merck Sharp & Dohme Corp.|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|64 Years|No|||October 2015|October 6, 2015|January 15, 2009|No|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00826176||144755|
NCT00826488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBT11212008|A Comparison of Breast Tomosynthesis Mammography and Conventional Breast Imaging in the Characterization of Breast Masses|A Comparison of Breast Tomosynthesis Mammography and Conventional Breast Imaging in the Characterization of Breast Masses: A Pilot Study||Washington University School of Medicine|Yes|Completed|March 2009|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|136|||Female|35 Years|80 Years|No|||June 2015|June 1, 2015|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826488||144731|
NCT00826735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070035|The Effect of Guided Imagery on the Third Stage of Labor|The Effect of Guided Imagery on the Third Stage of Labor||Vanderbilt University|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Primary Purpose: Prevention|1||||||Female|18 Years|34 Years|Accepts Healthy Volunteers|||January 2009|January 21, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826735||144712|
NCT00822601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR07067|Study of Repetitive Transcranial Magnetic Stimulation Efficacy on Obsessive Compulsive Disorder (OCD)|A Controlled Study of rTMS Over Supplementary Motor Area (SMA) in Obsessive Compulsive Disorder|TMS-TOC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||January 2009|July 30, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822601||145027|
NCT00822614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL_700_014|Safety of Fentanyl TAIFUN Treatment|The Safety of Fentanyl TAIFUN Treatment After Titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients|FINDS|Akela Pharma, Inc.|No|Recruiting|December 2008|January 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822614||145026|
NCT00823329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORI-DGI-001|Calorie Balance Monitoring and Analysis of Body Composition and Hydration Status|Calorie Balance Monitoring and Analysis of Body Composition and Hydration|PCMMS|Ori Diagnostic Instruments LLC|No|Suspended|October 2012|October 2012||October 2012||Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|January 13, 2009||No|lack of funding|No||https://clinicaltrials.gov/show/NCT00823329||144972|
NCT00796952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM009|Muscle Composition and Function for Swallowing in Head/Neck Cancer Patients|Muscle Composition and Function for Swallowing in Head/Neck Cancer Patients Undergoing Radiotherapy: a Randomized Controlled Trial of Swallowing Therapy"|Pharyngocise|University of Florida|No|Completed|November 2001|April 2005|Actual|July 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|58|||Both|21 Years|90 Years|No|||September 2011|September 16, 2011|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796952||146971|
NCT00804531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070157|Intra-discal Steroid Injection for MODIC I Discopathy|Intra-discal Steroid Injection for MODIC I Discopathy: A Randomized Control Trial|PREDID|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2008|November 2015|Anticipated|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804531||146396|
NCT00797537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07027/chondrocalcinose|Ultrasound and X-ray in Detecting Articular Cartilage Calcification|Concordance Entre l'échographie du Genou et la Radiographie Standard Dans la détection Des Calcifications Dans le Cadre de la Chondrocalcinose Articulaire|chondro|University Hospital, Limoges|No|Completed|May 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|166|||Both|70 Years|N/A|No|||September 2010|September 3, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00797537||146929|
NCT00797550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-55-0509-1|Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion|Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion||Vericel Corporation|No|Completed|April 2006|October 2008|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||November 2008|November 24, 2008|November 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00797550||146928|
NCT00805298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000866-22|Assessment of the Operative Course in Connection With Removal of Lower Third Molars|Assessment of the Operative Course in Connection With Removal of Lower Third Molars With Particular Consideration to the Occurence of Pain and Swelling||University of Aarhus|Yes|Completed|August 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|154|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 23, 2012|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805298||146338|
NCT00797797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-15|Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia|A Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran When Added to Pregabalin in the Treatment of Fibromyalgia||Forest Laboratories|No|Completed|November 2008|January 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|70 Years|No|||January 2011|January 20, 2011|November 24, 2008|Yes|Yes||No|November 18, 2010|https://clinicaltrials.gov/show/NCT00797797||146909|
NCT00798915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0861A|Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus|Restoration of the GIP-mediated Incretin Effect in Persons With Type 2 Diabetes Mellitus||Washington University School of Medicine|Yes|Completed|December 2008|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|November 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00798915||146823|
NCT00799162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35115-A|Prediction of Post-Cesarean Section Pain|Prediction of Post-Cesarean Section Pain|PPCSP|University of Washington|Yes|Recruiting|November 2008|November 2013|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|whole blood|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with a scheduled elective cesarean section|September 2011|September 23, 2011|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00799162||146805|
NCT00798642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003204|Ulcerative Colitis Relapse Prevention Trial, Hypnosis|National Center for Complementary & Alternative Medicine, The Role of Gut-Directed Hypnotherapy in Relapse Prevention for Ulcerative Colitis|UCRPT|Northwestern University|Yes|Completed|July 2007|June 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|55|||Both|18 Years|70 Years|No|||April 2014|April 1, 2014|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798642||146844|
NCT00798889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181030|Rollover Protocol for Prior SU011248 Protocols|A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol||Pfizer|No|Completed|March 2004|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|314|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|November 25, 2008|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00798889||146825|
NCT00798902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFX-100|Pilot Study to Assess Safety/Preliminary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery|A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion||BioSurface Engineering Technologies, Inc|Yes|Active, not recruiting|November 2008|October 2012|Anticipated|July 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|70 Years|No|||March 2012|March 7, 2012|November 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00798902||146824|
NCT00799149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-045-06|Etoricoxib Versus Gabapentin for Knee Arthroscopy|Phase 4 Study Comparing the Efficacy of Etoricoxib Versus Gabapentin as Part of a Multimodal Analgesic Regimen for Ambulatory Knee Arthroscopy||Meir Medical Center|No|Completed|June 2006|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||November 2008|November 26, 2008|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799149||146806|
NCT00795704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0053|Impact of Mulberry Leaf on Type 2 Diabetes|Effect of Mulberry Leaf Extract on Glycemic Durability in Non-insulin Dependent Diabetes Mellitus: a Double-blind, Randomized, Placebo-controlled Pilot Study (Mul-DM)|Mul-DM|University of Mississippi Medical Center|No|Completed|April 2008|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|November 19, 2008||No||No|April 16, 2012|https://clinicaltrials.gov/show/NCT00795704||147065|
NCT00808535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRI_Perfusion Study|Cardiac Magnetic Resonance Imaging for Detecting Endothelial Dysfunction|A Pilot Study of Cardiac Magnetic Resonance Imaging For Detection of Myocardial Perfusion Abnormalities in Endothelial Dysfunction||University of California, Los Angeles|No|Not yet recruiting|February 2009|March 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Diagnosed diabetics (less than 5 years) without documented coronary artery disease        recruited from UCLA Ambulatory clinics.        Healthy controls from general population.|February 2009|February 6, 2009|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808535||146097|
NCT00805142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015532|Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants|Phase II Study of JNS024PR in Cancer Pain Patients||Janssen Pharmaceutical K.K.|No|Completed|November 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|20 Years|N/A|No|||June 2013|June 20, 2013|December 8, 2008|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00805142||146350|
NCT00805155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10316908|Randomized Study to Compare the Bioavailability of Three Mometasone Furoate 0.1% Topical Lotions|Bioequivalence of Three Mometasone Furoate 0.1% Topical Lotions||Perrigo Company|No|Completed|February 2004|March 2004|Actual|March 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|March 2012|March 15, 2012|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805155||146349|
NCT00805168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13085|Inhaled Amikacin Solution (BAY 41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia|INHALE 2|Bayer|Yes|Recruiting|May 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805168||146348|
NCT00805441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12422|A Study in the Treatment of Alcohol Dependence.|A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence||Eli Lilly and Company|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Both|21 Years|65 Years|No|||May 2010|May 27, 2010|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00805441||146328|
NCT00826748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809009975|Effect of Inhaled Steroids on Gene Expression in the Lungs - 2|Effect of Inhaled Steroids on Gene Expression in the Lungs of Healthy Smokers||Weill Medical College of Cornell University|Yes|Active, not recruiting|November 2010|October 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|October 15, 2014|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826748||144711|
NCT00822861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI ASM8-206|Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma|A Single Center, Open Label, Stepwise, Dose Profiling Study to Evaluate the Efficacy and Safety of Four Dose Regimens of Inhaled TPI ASM8 in Patients With Allergic Asthma||Pharmaxis|Yes|Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822861||145007|
NCT00822874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT-JSMDV2008pilot|Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential|Influence of a Prematuration Culture With a PDE3-I on Embryonic Aneuploidy Rate and Developmental Potential - a Pilot Study||Universitair Ziekenhuis Brussel|Yes|Terminated|January 2009|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|115|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|January 13, 2009||No|Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) has been replaced by other    system|No||https://clinicaltrials.gov/show/NCT00822874||145006|
NCT00822627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Influenza Vaccination in the Emergency Department|Influenza Vaccination in the Emergency Department||University of Arizona|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|140|||Both|6 Months|N/A|Accepts Healthy Volunteers|||January 2009|January 13, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00822627||145025|
NCT00822887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0870.cc|Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas|A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas|IRUSZACT0073|University of Colorado, Denver|Yes|Completed|March 2007|January 2011|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00822887||145005|
NCT00797238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709017R|DNA Repair Genes and Outcomes in Patients With Stage III NSCLC|||National Taiwan University Hospital|Yes|Recruiting|September 2007|August 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|lung cancer tissue before and after treatment|Both|18 Years|90 Years|No|Non-Probability Sample|Taiwanese NSCLC patients with stage III|July 2010|July 14, 2010|July 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00797238||146951|
NCT00797225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-56418-0703|Efficacy and Safety Study in Endometriosis With NBI-56418; Placebo and Active Controlled|A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis||AbbVie|No|Completed|November 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|174|||Female|18 Years|45 Years|No|||January 2013|January 2, 2013|November 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00797225||146952|
NCT00797823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4311|Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone|A Comparison of Two Sensor-Augmented Glycemic Control Systems in Persons With Type 1 Diabetes Mellitus: Subcutaneous (SC) Insulin and Glucagon Delivery vs. SC Insulin Only||Legacy Health System|No|Completed|November 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|14|||Both|21 Years|65 Years|No|||August 2009|October 4, 2011|November 24, 2008|Yes|Yes||No|June 24, 2011|https://clinicaltrials.gov/show/NCT00797823||146907|
NCT00797810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMOS ALL1105|Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults|Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults||University of Bologna|Yes|Recruiting|December 2006|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2009|September 14, 2009|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797810||146908|
NCT00798057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0701-PI01|Proton Radiation Therapy for Pituitary Adenoma|Clinical Outcomes Study of Proton Radiation Therapy for Pituitary Adenoma|PI01|University of Florida|No|Terminated|October 2007|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|100 Years|No|Non-Probability Sample|Patients treated at a radiation oncology clinic|October 2015|October 2, 2015|November 24, 2008||No|Due to slow enrollment and feasibility issues.|No||https://clinicaltrials.gov/show/NCT00798057||146889|
NCT00794820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0591|Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline|Fludarabine, Cyclophosphamide, and Multiple Dose Rituximab as Frontline Therapy in Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Completed|December 2003|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|16 Years|N/A|No|||December 2014|December 19, 2014|November 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00794820||147130|
NCT00794846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03180|Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)|Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|December 2002|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|124|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794846||147129|
NCT00794859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005091-13|Sorafenib in Previously Treated Malignant Mesothelioma|Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy|SMS|King's College London|No|Active, not recruiting|October 2008|||December 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||August 2009|August 3, 2009|November 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00794859||147128|
NCT00794807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A Study of an Extended Regimen|Safety and Tolerability of Repeat Courses of IM Alefacept|A 12-Week Open-Label Followed by 4-Week Double-Blind Study to Determine the Safety and Efficacy of an Extended Course of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis||Charite University, Berlin, Germany|No|Completed|February 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2008|November 19, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794807||147131|
NCT00795145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951151|A Study To Assess The Effect Of Linezolid On QTc Interval|Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects||Pfizer|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Actual|49|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 17, 2010|November 20, 2008|No|Yes||No|March 2, 2010|https://clinicaltrials.gov/show/NCT00795145||147107|
NCT00795158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02988|How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)|An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria||Merck Sharp & Dohme Corp.|No|Completed|November 2002|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|282|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00795158||147106|
NCT00804648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPH0111|Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Vistakon Pharmaceuticals|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|30|||Both|21 Years|N/A|No|||February 2015|February 18, 2015|December 5, 2008|Yes|Yes||No|September 1, 2010|https://clinicaltrials.gov/show/NCT00804648||146388|
NCT00804869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-037|A-Mode vs PalmScan Ultrasonography: Biometric Measurements.|Standard A-Mode Ultrasonography vs PalmScan Ultrasonography: Biometric Measurements.||Asociación para Evitar la Ceguera en México|Yes|Completed|October 2008|||December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|50 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|All patients who need axial length calculation.|December 2008|December 6, 2008|December 3, 2008||||No||https://clinicaltrials.gov/show/NCT00804869||146371|
NCT00804895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080602|Cluster Headache Cortivazol Injection (CHCI)|A Double Blind Randomized Controlled Trial of Greater Occipital Nerve Infiltration in Cluster Headache|CHCI|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|No|||November 2012|November 23, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804895||146369|
NCT00805194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.13|LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer|Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy||Boehringer Ingelheim||Active, not recruiting|December 2008|June 2016|Anticipated|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1314|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 8, 2008||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00805194||146346|
NCT00805506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03349-05-A|Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes|Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes||HealthPartners Institute|No|Completed|February 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|adults with diabetes who are treated with insulin|December 2008|November 25, 2015|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00805506||146323|
NCT00805753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006328|Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy|A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN)|MN|Mayo Clinic|Yes|Completed|January 2009|September 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805753||146305|
NCT00826774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805684|Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial)|Practice-based Opportunities for Weight Reduction Trial at University of Pennsylvania|Power-UP|University of Pennsylvania|Yes|Completed|January 2008|June 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|390|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 14, 2012|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826774||144709|
NCT00826787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVE-T750-PVFD-1|Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|August 2005|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 21, 2009|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00826787||144708|
NCT00826800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-162|Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer|A Pilot Study of Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer||Memorial Sloan Kettering Cancer Center||Terminated|February 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|90 Years|No|||April 2015|April 3, 2015|January 20, 2009|No|Yes|Lack of accrual|No|April 3, 2015|https://clinicaltrials.gov/show/NCT00826800||144707|Early termination lead to small numbers of subjects analyzed.
NCT00791466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITCH-01|Maternal Iodine Supplementation and Effects on Thyroid Function and Child Development|Iodine Supplementation in Pregnant Women Living in Mild-to-moderately Iodine Deficient Areas in India and Thailand: Effects on Pregnancy Outcome and Infant Development|MITCH|Wageningen University|Yes|Active, not recruiting|September 2008|December 2015|Anticipated|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791466||147382|
NCT00791479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12565|Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes|Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions||Eli Lilly and Company|No|Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|167|||Both|18 Years|75 Years|No|||December 2014|December 8, 2014|November 12, 2008|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00791479||147381|
NCT00822900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014409|Progesterone for the Treatment of Traumatic Brain Injury III|Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.|ProTECT|Emory University|Yes|Terminated|March 2010|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|882|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 14, 2009|Yes|Yes|futility: low conditional power to demonstrate benefit of progesterone|No|April 1, 2015|https://clinicaltrials.gov/show/NCT00822900||145004|The trial was stopped early for futility with respect to the primary outcome.
NCT00823121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654YazdRCCI|Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification|Can Fresh Embryo Transfers be Replaced by Cryopreserved-thawed Embryo Transfers in Assisted Reproductive Cycles?||Yazd Research & Clinical Center for Infertility|Yes|Recruiting|August 2008|December 2009|Anticipated|February 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||April 2009|January 19, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823121||144988|
NCT00797836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070312|Quantiferon for Detection of Latent Tuberculosis in Healthcare Workers|Cost-effectiveness of Quantiferon Gold in VITRO Test of T-lymphocytic Response for Detection of Latent Tuberculosis in At-risk Healthcare Workers|QUANTIPS|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2008|November 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1024|||Both|18 Years|N/A|No|||November 2008|January 9, 2012|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797836||146906|
NCT00797563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2008-17|Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood|Clinical Evaluation of the Apollo Blood Glucose Monitoring System With Capillary and Venous Blood [Commercial Name is CONTOUR® USB]||Ascensia Diabetes Care|No|Completed|November 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|November 24, 2008|Yes|Yes||No|November 17, 2009|https://clinicaltrials.gov/show/NCT00797563||146927|
NCT00798369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2255|Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients|An Adaptive Dose-ranging, Multi-center, Single-blind, Double-dummy, Active-controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine||Novartis||Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|200|||Both|18 Years|80 Years|No|||April 2012|April 9, 2012|November 25, 2008|Yes|Yes||No|January 20, 2011|https://clinicaltrials.gov/show/NCT00798369||146865|
NCT00798070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANTHER SBG2004-1|Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients|PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients|PANTHER|Karolinska University Hospital|Yes|Active, not recruiting|February 2007|January 2022|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2017|||Female|18 Years|65 Years|No|||June 2015|June 8, 2015|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00798070||146888|
NCT00798655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-120|Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer|A Phase II Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer||University of Pittsburgh|Yes|Active, not recruiting|November 2007|June 2020|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00798655||146843|
NCT00798668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607004184|The Body's Response to Food Intake in Trained, Older Adults|||Purdue University||Completed|September 2006|May 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2010|September 23, 2013|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798668||146842|
NCT00807196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEV0701|Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma|Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma||Maisonneuve-Rosemont Hospital|Yes|Recruiting|September 2008|December 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2008|December 10, 2008|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807196||146198|
NCT00807209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C211|Dose Finding Posterolateral Thoracotomy Study|A Phase 2 Open-Label, Parallel Group, Randomized, Dose-Finding Study to Assess the Efficacy and Safety of Intercostal SKY0402 in Subjects Undergoing Posterolateral Thoracotomy||Pacira Pharmaceuticals, Inc|No|Terminated|December 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|N/A|No|||November 2011|April 15, 2012|December 9, 2008|Yes|Yes|Sponsor decision unrelated to safety|No|November 29, 2011|https://clinicaltrials.gov/show/NCT00807209||146197|The study was terminated early due to Sponsor's decision, unrelated to safety. As there was only one patient in each group, no efficacy analyses were performed.
NCT00795171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK URO 4|Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer|Randomized, Controlled Biomarker Study Evaluating the Anti-angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel||Medical University of Vienna|No|Recruiting|November 2008|July 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Male|18 Years|N/A|No|||August 2010|August 17, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795171||147105|
NCT00808015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051112|ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking|ASIA CHOICES CHampix Observational Investigation in the CEssation of Smoking|ASIA CHOICES|Pfizer|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1373|||Both|18 Years|N/A|No|Non-Probability Sample|This study is in Asian patients. The patients enrolled should be of legal adult age who        regularly smoke and whose main tobacco product is cigarettes. The patients must be willing        to make an attempt to stop smoking.|April 2015|April 21, 2015|December 12, 2008|No|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00808015||146137|Outcome measures were not designated as primary or secondary measures as this study was a post-marketing, prospective, non-comparative and non-interventional study.
NCT00808028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-2001|A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents|A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years||Pfizer|No|Completed|February 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|4||Actual|538|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||March 2015|March 27, 2015|December 12, 2008||No||No|March 27, 2015|https://clinicaltrials.gov/show/NCT00808028||146136|
NCT00795444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERRADVIH-01|Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1|Pilot Study Of The Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 In Patients Taking Highly Active Antiretroviral Therapy||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Completed|March 2008|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00795444||147085|
NCT00795457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-057|Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas|A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas||University of Pittsburgh|Yes|Completed|January 2009|July 2015|Actual|February 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||December 2015|December 13, 2015|November 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00795457||147084|
NCT00808288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7881013|A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.|A7881013|Pfizer|Yes|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|405|||Both|40 Years|80 Years|No|||October 2011|October 6, 2011|December 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00808288||146116|
NCT00804882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L08-174|Hispanics With Metabolic Syndrome and Non-ischemic Heart Failure|Correlation in Hispanics of Accelerated Metabolic Risk Profile and Non-ischemic Heart Failure (CHAMP-HF)|CHAMP-HF|Texas Tech University Health Sciences Center|No|Withdrawn|October 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Actual|0|Samples Without DNA|Blood will be collected|Both|18 Years|59 Years|No|Non-Probability Sample|Mexican Americans and Non-Hispanic White Americans with heart failure|April 2015|April 9, 2015|December 8, 2008||No|Principal investigator is leaving the institution to obtain further training.|No||https://clinicaltrials.gov/show/NCT00804882||146370|
NCT00804921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP After Bevacizumab|Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab|Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results||University of Sao Paulo|Yes|Completed||||||Phase 2|Interventional|N/A|||||||Both|50 Years|N/A|No|||December 2008|December 8, 2008|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804921||146367|
NCT00805181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER08-170|Kinetics of Biomarkers in Acute Pyelonephritis|Kinetics of Procalcitonin, C-reactive Protein and Pyuria in Uncomplicated Pyelonephritis in Women: A Pilot Study||University Hospital, Geneva|No|Completed|December 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|N/A|No|Non-Probability Sample|30 adult females with acute uncomplicated pyelonephritis|June 2010|October 6, 2010|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00805181||146347|
NCT00805480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2212|Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis|Phase II Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Multiple-loading Dose Regimen Study to Assess the Safety, Efficacy and Duration of Response of AIN457 in Patients With Chronic Plaque-type Psoriasis.||Novartis|No|Completed|December 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|130|||Both|18 Years|65 Years|No|||January 2015|January 28, 2015|December 5, 2008|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00805480||146325|
NCT00805493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090042|Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder|Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder||National Institutes of Health Clinical Center (CC)|No|Terminated|November 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Both|9 Years|17 Years|No|||June 2013|October 6, 2015|December 6, 2008|No|Yes|Insufficient recruitment of participants|No|June 17, 2013|https://clinicaltrials.gov/show/NCT00805493||146324|Limitations in enrollment led to early termination of the study.
NCT00826540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N054C|Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|September 2009|||January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|January 21, 2009|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00826540||144727|
NCT00791167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011437|A Study of the Dose Proportionality of Extended Release Paliperidone|Evaluation of the Dose Proportionality of Two Dose Strengths (1.5 and 3 mg) of Extended-release Paliperidone After a Single Administration to Healthy Men||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2006|August 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|58|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2009|May 17, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791167||147405|
NCT00791180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002|Posterior Lateral Fusion (PLF) With Dynesys|Clinical Outcomes Following Posterior Lateral Fusion With the Dynesys(R) Spinal System||Zimmer, Inc.|No|Completed|March 2006|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|20 Years|80 Years|No|Non-Probability Sample|Clinical outcomes following postierior lateral fusion with the Dynesys(R) Spinal System|September 2011|September 28, 2011|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791180||147404|
NCT00791791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI-134-1|Evaluation of Surgical Stress Index (SSI) During Sevoflurane/Remifentanil Anesthesia|||University of Schleswig-Holstein|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|2||Actual|24|||Female|18 Years|65 Years|No|||June 2012|June 14, 2012|November 14, 2008||||No||https://clinicaltrials.gov/show/NCT00791791||147357|
NCT00791804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLXLEF0|Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery|A Phase II Study Evaluating Inhaled AeroLEF(Liposome-Encapsulated Fentanyl 500mcg/mL)for Post-Operative Pain in Adults After ACL Knee Surgery.|Pain|YM BioSciences|No|Completed|February 2004|December 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|60 Years|No|||November 2008|November 14, 2008|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00791804||147356|
NCT00791817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005046B|Study to Evaluate Potential Food Effects|An Open-label, Single Dose, Randomized, Crossover Study to Evaluate Potential Food Effects||Procter and Gamble|No|Completed|August 2005|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|November 13, 2008|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00791817||147355|
NCT00791765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080014|Moderate to Severe Plaque Psoriasis With Scalp Involvement|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis||Amgen||Completed|October 2008|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|November 14, 2008||||No|September 3, 2010|https://clinicaltrials.gov/show/NCT00791765||147359|
NCT00791778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12007|Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer|A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy||Bayer|No|Completed|November 2008|December 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|246|||Both|18 Years|N/A|No|||June 2015|August 26, 2015|November 14, 2008|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT00791778||147358|
NCT00798382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK54|Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants|Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants||Abbott Nutrition|Yes|Completed|December 2008|September 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|154|||Both|N/A|8 Days|Accepts Healthy Volunteers|||June 2012|June 12, 2012|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798382||146864|
NCT00798395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05794|A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)|A Randomized Double-blind, Placebo-controlled, 4-period Cross-over Study to Assess the Effect of Single and Multiple Doses of 1.5 mg and 4.5 mg Org 50081 and a Single Dose of 7.5 mg Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers.||Merck Sharp & Dohme Corp.|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|November 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00798395||146863|
NCT00798083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA001|Neuropathic Pain Caused by Radiation Therapy|Topical Amitriptyline, Ketamine and Lidocaine in Neuropathic Pain Caused by Radiation Skin Reaction: a Pilot Study|NP|British Columbia Cancer Agency|Yes|Completed|April 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00798083||146887|
NCT00798941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08033609|ICU Patient and Family Comfort Study|||University of California, San Francisco|Yes|Completed|February 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|July 6, 2010|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798941||146822|
NCT00799175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAK-total|Local Infiltration Analgesia Following Total Knee Arthroplasty|Local Infiltration Analgesia With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Total Knee Arthroplasty|RAK-total|University Hospital Orebro|Yes|Completed|April 2007|September 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Female|20 Years|85 Years|No|||November 2008|November 26, 2008|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799175||146804|
NCT00808041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012068|Chemotherapy Monitoring With Breast Computed Tomography (CT)|Breast Cancer Chemotherapy Monitoring With Dedicated Breast Computed Tomography||Emory University|No|Completed|July 2009|July 2015|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Female|18 Years|N/A|No|Non-Probability Sample|The target population for this study is women who will undergo pre-operative hormonal        therapy for breast cancer before lumpectomy or mastectomy.|July 2015|July 21, 2015|December 12, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00808041||146135|
NCT00807755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000628772|Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors|Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC)||University of California, Davis|Yes|Terminated|January 2009|||August 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 11, 2008|No|Yes|The study was closed because of the number of known toxicities observed despite a    treatment-naïve population.|No||https://clinicaltrials.gov/show/NCT00807755||146157|
NCT00808548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08169|Exploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi Syndrome|||Taichung Veterans General Hospital|Yes|Not yet recruiting|December 2008|December 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|8|||Both|6 Years|12 Years|No|Non-Probability Sample|a person who care and live with childre with Prader-Willi syndrome|December 2008|December 15, 2008|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808548||146096|
NCT00808561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #3, V1, Fistula|Randomized Fistula Study|Prospective Randomized Trial of Fistula vs. Forearm AV Graft in Patients With Poor Venous Access; Protocol #3, Version 1||University of Pittsburgh|Yes|Terminated|December 2008|January 2013|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 12, 2008||No|Slow enrollment due to multiple screen failures|No||https://clinicaltrials.gov/show/NCT00808561||146095|
NCT00808574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0346|Screening for Obstructive Sleep Apnea Among Members of an Internet Weight Loss Community|Effect of a Web-Based Presentation on Communication With Healthcare Providers||The University of Texas Health Science Center, Houston|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|168|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 12, 2008|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808574||146094|
NCT00804323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-041|PASCAL Trabeculoplasty|Semi-Automated Patterned Laser Trabeculoplasty||Asociación para Evitar la Ceguera en México|Yes|Recruiting|December 2007|December 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|90 Years|No|||December 2008|December 6, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804323||146412|
NCT00804336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-087|Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors|Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2008|October 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||April 2014|April 27, 2014|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804336||146411|
NCT00806377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP001|Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures|Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures|Dinosur|Minneapolis Heart Institute Foundation|No|Completed|December 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective, non-thoracic surgical procedures will be enrolled.|May 2013|May 9, 2013|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806377||146258|
NCT00806663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-II-005 /2008-001515-37|FOLFIRI and Sunitinib in Metastatic Colorectal Cancer|A Prospective Angiogenic Imaging Study With DCE-MRI and DCE-USI in Patients With Colorectal Cancer and Liver Metastases Receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy||Central European Society for Anticancer Drug Research|No|Completed|August 2008|September 2011|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|80 Years|No|||September 2012|September 7, 2012|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806663||146236|
NCT00806364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090049|Normal Blood, Bone Marrow and Buccal Mucosa Protocol|Normal Blood, Bone Marrow and Buccal Mucosa Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|December 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806364||146259|
NCT00805779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMK1208|Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder|Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder||EMKinetics, Inc|No|Terminated|December 2008|April 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|December 8, 2008|Yes|Yes|Major protocol changes needeed|No||https://clinicaltrials.gov/show/NCT00805779||146303|
NCT00790842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE1003|Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction|A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function|PrE1003|PrECOG, LLC.|Yes|Active, not recruiting|December 2008|March 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00790842||147430|
NCT00790855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0634|Bendamustine in Acute Leukemia and MDS|Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Terminated|November 2008|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|16 Years|N/A|No|||December 2012|December 3, 2012|November 13, 2008|Yes|Yes|Lack of Response|No|June 22, 2012|https://clinicaltrials.gov/show/NCT00790855||147429|
NCT00791492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX-006|An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy|An Open-Label Extension Of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy||Pfizer|No|Completed|July 2008|October 2010|Actual|August 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|75 Years|No|||November 2012|November 16, 2012|November 13, 2008|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00791492||147380|Instead of intended endpoint 'heat pain and cooling threshold', results of 'summated 3 score for small nerve fiber function' were reported. Designation of outcomes as primary and secondary was based on study team input as study did not specify this.
NCT00792896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803051R|Intervention Toward Truth-Telling and Advanced Directives in the Patient With Advanced or Metastatic Disease|A Longitudinal Study That Assessed the Effectiveness of Intervention Toward||National Taiwan University Hospital|Yes|Recruiting|May 2008|||December 2010|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|20 Years|N/A|No|||May 2008|November 17, 2008|November 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00792896||147273|
NCT00793169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-stu1404|Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery|Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery||Northwestern University|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|75 Years|No|Non-Probability Sample|This study is a cross-sectional study of 20 subjects with basal cell carcinoma or squamous        cell carcinoma of the face or neck requiring Mohs micrographic surgery.|February 2015|February 19, 2015|November 17, 2008||No||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00793169||147254|Serum rather than plasma lidocaine levels were measured. For lidocaine levels, plasma and serum levels are similar, and serum levels are more routinely reported by reference laboratories. Hence our selection of serum levels for this study.
NCT00792090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL006|Prevention of Cow's Milk Allergy in Children|Use of Fermented Milk in Prevention of Cow's Milk Allergy in New Born and Infant||Bledina|Yes|Completed|November 2003|July 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|142|||Both|N/A|N/A|No|||November 2008|November 14, 2008|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792090||147334|
NCT00792350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14690|INSIGHT - Post Marketing Surveillance|International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)|INSIGHT|Bayer|No|Completed|April 2008|April 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|791|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|In and outpatients with diagnosis of hepatocellular carcinoma (HCC) and decision taken by        the investigator to prescribe Nexavar.|May 2014|May 13, 2014|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00792350||147314|
NCT00798109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 070156|Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse|An Open Multicentric Randomized Clinical Trial Assessing the Impact of Motivational Interviewing on Cannabis Consumption in Patients With Psychiatric Disease|SCHIZOCAN|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2008|April 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|September 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00798109||146885|
NCT00798681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFT-001/2008-BR|Evaluating the Influence of Ready-to-use (RTU) Parenteral Nutrition in the Clinical Outcome of Patients Study|EPICOS- Evaluating the Influence of RTU Parenteral Nutrition in the Clinical Outcome Patients Study|EPICOS|Fernandes Tavora Hospital|Yes|Completed|July 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|406|||Both|18 Years|N/A|No|||July 2010|August 9, 2010|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798681||146841|
NCT00798408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0-0509003024|The Body's Response to Food Intake in Older Adults|||Purdue University||Completed|February 2006|January 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2009|September 23, 2013|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798408||146862|
NCT00794872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chemoreflex-Sensitivity-Study|Chemoreflex Sensitivity in Chronic Kidney Disease|Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease||RWTH Aachen University|Yes|Completed|January 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|65|Samples Without DNA|Measurement of the venous partial pressure of oxygen in blood samples|Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2008|November 19, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794872||147127|
NCT00795184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-2008-BE-01|Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy|Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy|DONT BIOPCE|Mauna Kea Technologies|No|Completed|November 2008|February 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|110|||Both|18 Years|N/A|No|||March 2010|March 11, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795184||147104|
NCT00808054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE0049028720308|Evaluation of Analgesia With EMLA and Glucose Oral Solution|Evaluation of Analgesia With the Use of Eutectic Mixture of Local Anesthetics (Lidocaine and Prilocaine) and Oral Solution of Glucose to 25% in Preterm Neonates During Arterial Puncture and / or the Installation of Percutaneous Catheter||Federal University of Minas Gerais|Yes|Completed|November 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|60|||Both|N/A|7 Days|Accepts Healthy Volunteers|||July 2014|July 24, 2014|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808054||146134|
NCT00808301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA-07-01|Oat Products in the Treatment of Coeliac Disease in Children|Multicentre Clinical Trial on Oat Products in the Treatment of Coeliac Disease in Children||Heinz Italia SpA|No|Active, not recruiting|January 2009|October 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|300|||Both|4 Years|14 Years|No|||March 2015|March 17, 2015|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808301||146115|
NCT00808587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 08-5069|Scripps Genomics Health Initiative|Scripps Genomics Health Initiative||Scripps Translational Science Institute|No|Active, not recruiting|October 2008|March 2029|Anticipated|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Scripps Health employees, friends, family, and the general population|February 2015|February 9, 2015|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00808587||146093|
NCT00804349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-3025|Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients|Apnea Rampant In Acute Decompensated Heart Failure II|ARIA-II|Albert Einstein Healthcare Network|No|Completed|October 2008|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804349||146410|
NCT00804362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-093|Validation of the Sickle Cell Disease Pain Burden Interview|||Connecticut Children's Medical Center||Completed|December 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|7 Years|21 Years|No|Non-Probability Sample|Children and adolescents diagnosed with sickle cell disease.|July 2013|July 29, 2013|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804362||146409|
NCT00804661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070202|Sleep in Patients With Cystic Fibrosis|Predictors of Nocturnal Hypoventilation in Patients With Cystic Fibrosis|Sommeil|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|76|||Both|8 Years|N/A|No|Non-Probability Sample|Patients from the pneumology centers participating to the study|May 2010|June 2, 2010|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00804661||146387|
NCT00804674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Pain Study Using Intermittent Bupivacain Injections After Breast Reconstruction With DIEP Flap|Improved Pain Relief Using Intermittent Bupivacain Injections at the Donor Site After Breast Reconstruction With Deep Inferior Epigastric Artery Perforator (DIEP) Flap||Oslo University Hospital|No|Completed|August 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|47|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2011|June 30, 2011|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00804674||146386|
NCT00806689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-046|Full Disclosure Observational Cardiac Rhythm Documentation Follow-up After Surgical Atrial Fibrillation Therapy|||University of Luebeck|No|Recruiting|July 2007|July 2011|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients who are scheduled for cardiac surgery and who also present with any kind of        atrial fibrillation.|December 2008|July 1, 2010|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806689||146234|
NCT00806715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI 07-004|Iron Overload in Stem Cell Transplant Recipients|Impact of Iron Overload in Pediatric Patients Undergoing Stem Cell Transplantation||Children's Hospital Boston|No|Completed|February 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|Samples With DNA|Peripheral blood specimens.|Both|5 Years|N/A|No|Non-Probability Sample|Children undergoing allogeneic stem cell transplantation.|June 2011|June 22, 2011|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806715||146233|
NCT00806676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERCK_33610|Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease|Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease||Johns Hopkins University|No|Completed|December 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|67|||Female|9 Years|21 Years|No|||August 2015|August 31, 2015|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806676||146235|
NCT00807027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IcmLCBT_301|Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea|Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea||Green Cross Cell Corporation|No|Completed|December 2008|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|70 Years|No|||October 2012|October 24, 2012|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807027||146211|
NCT00806650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07241|Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer|Development of a Blood Test of Anti-IMP3 Autoantibody and Serum MicroRNA Signature for the Detection of Renal Cell Carcinoma With Metastasis and Metastatic Potential||City of Hope Medical Center|Yes|Recruiting|June 2008|||November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|230|||Both|N/A|N/A|No|||October 2015|October 1, 2015|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806650||146237|
NCT00790868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH081116|Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder|Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder|DCSPanic|Boston University|Yes|Active, not recruiting|April 2008|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|80 Years|No|||April 2013|May 23, 2013|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00790868||147428|
NCT00790881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEACAT 2.4.1|Artemether/Lumefantrine and Nevirapine Interaction Study in HIV-infected Adults|Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults||University of Cape Town|Yes|Completed|October 2008|December 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||June 2010|June 25, 2010|November 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00790881||147427|
NCT00791193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013474|A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR|Pharmacokinetic Evaluation of the Relative Bioavailability of Three Paliperidone Extended Release (ER) Formulations With Different in Vitro Release Profiles, and Comparison to Paliperidone Immediate Release (IR), in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2007|May 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|May 17, 2011|November 13, 2008||||||https://clinicaltrials.gov/show/NCT00791193||147403|
NCT00792610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701049M|The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines|The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines||National Taiwan University Hospital|Yes|Completed|August 2007|February 2009|Actual|January 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|127|||Both|18 Years|23 Years|Accepts Healthy Volunteers|||August 2009|October 5, 2009|November 16, 2008|Yes|Yes||No|August 16, 2009|https://clinicaltrials.gov/show/NCT00792610||147295|The possible presence of T cell memory among the seronegative patients for HBsAg(+), anti-HBc(+), and anti-HBs(+) could be a concern.
NCT00792623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208133/178|Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).|The Immunogenicity and Safety of GSK Biologicals' Varicella Vaccine (VARILRIXTM), Given as a Primary Vaccination at 4.5 M and 6.5 M Post-transplantation, in Autologous Stem Cell/Bone Marrow Transplantation Recipients Aged 18 Years and Older.||GlaxoSmithKline||Completed|September 2003|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|45|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|November 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792623||147294|
NCT00792909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111736|Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A|Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children||GlaxoSmithKline||Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|172|||Both|36 Months|46 Months|Accepts Healthy Volunteers|||November 2012|November 15, 2012|November 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00792909||147272|
NCT00807222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-NRP104|Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)|Study of the Effect of Vyvanse (Lisdexamfetamine Dimesylate) on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)||Clinical Study Centers, LLC|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|6 Years|12 Years|No|||December 2008|December 10, 2008|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00807222||146196|
NCT00806910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-4040|Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion|Evaluation of the Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion||Albert Einstein Healthcare Network|No|Withdrawn|October 2008|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|December 10, 2008|No|Yes|Sponsor support withdrawn|No||https://clinicaltrials.gov/show/NCT00806910||146219|
NCT00798694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-875|How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?|Ocular Surface Changes With Topical Prostaglandin Analog Therapy||Wills Eye|No|Completed|November 2008|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|21 Years|N/A|No|||December 2012|December 20, 2012|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798694||146840|
NCT00807768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0249|Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer|A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma||Gynecologic Oncology Group|No|Active, not recruiting|March 2009|||December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|555|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807768||146156|
NCT00807781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0298 / 201110267|Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Mammaglobin-A DNA Vaccine in Breast Cancer Patients With Metastatic Disease||Washington University School of Medicine|No|Completed|October 2009|December 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||January 2015|January 2, 2015|December 11, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00807781||146155|
NCT00795808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAuckland|PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene|Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome|PCOSMIC|University of Auckland, New Zealand|Yes|Completed|August 2003|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||November 2008|November 20, 2008|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795808||147057|
NCT00795821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11313|A Study in Adult Patients With Major Depressive Disorder|A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder||Eli Lilly and Company|Yes|Completed|December 2008|March 2011|Actual|February 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|495|||Both|18 Years|65 Years|No|||April 2011|April 7, 2011|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00795821||147056|
NCT00796094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 20943|Imaging of Soft Tissues|Elasticity Imaging of Soft Tissues||University of Michigan|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Males and non pregnant females with soft tissue abnormalities.|November 2009|July 9, 2015|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796094||147036|
NCT00796107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21161|A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer|An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.||Hoffmann-La Roche||Completed|January 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|November 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796107||147035|
NCT00796497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONDAN-1|Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)|Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study||Institute of Neuroscience, Florence, Italy|Yes|Completed|March 2008|December 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|55 Years|No|||February 2011|February 23, 2011|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796497||147006|
NCT00797719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0106-C|Short Neoadjuvant Hemithoracic IMRT for MPM|A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma||University Health Network, Toronto|Yes|Recruiting|October 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797719||146915|
NCT00797966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-08-211|Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|May 2009|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|850|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|November 24, 2008|Yes|Yes||No|August 7, 2015|https://clinicaltrials.gov/show/NCT00797966||146896|
NCT00797433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-931|Outcomes of Mechanically Ventilated Patients With Low Serum Testosterone|Outcomes of Mechanically Ventilated Patients With Low Serum Testosterone||The University of Texas Health Science Center, Houston|No|Completed|December 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|28|||Male|18 Years|N/A|No|Non-Probability Sample|All adult male patients with acute respiratory failure on mechanical ventilation|September 2010|September 20, 2010|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797433||146937|
NCT00797940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX321-1-05|Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)|Phase II, Multi-center, Open-Label, Single-Arm Study of Intratumoral Infusion of PRX321 in Subjects With Glioblastoma Multiforme at First Recurrence or Progression|CLARITY-1|Sophiris Bio Corp|No|Withdrawn|January 2009|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 30, 2012|November 24, 2008|No|Yes|No funding for study|No||https://clinicaltrials.gov/show/NCT00797940||146898|
NCT00797953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T89-005-0003-US|Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina|A Phase II, Double Blind, Placebo-controlled, Randominzed, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of T89 in Patient With Chronic Stable Angina Pectoris|T89 phase 2|Tasly Pharmaceuticals, Inc.|Yes|Completed|February 2007|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|80 Years|No|||December 2012|December 10, 2012|November 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00797953||146897|
NCT00798213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04717|SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)|A Phase 2 Study of SCH 727965 in Subjects With Relapsed and Refractory Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia||Merck Sharp & Dohme Corp.|No|Terminated|January 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|November 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00798213||146877|
NCT00795054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIBMTR HS 07-02|The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family|The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family: A Pilot Study||Center for International Blood and Marrow Transplant Research|No|Completed|March 2009|August 2015|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric and adult allogeneic stem cell transplant recipients and their care givers from        three U.S. transplant medical centers.|October 2015|October 5, 2015|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795054||147114|
NCT00787020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005900|Ventriculostomies in SAH: ICP Open or Not?|Ventriculostomies in SAH: ICP Open or Not?|VISION|Duke University|No|Completed|November 2008|February 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|37|||Both|18 Years|N/A|No|Non-Probability Sample|Subarachnoid hemorrhage|March 2011|October 11, 2015|November 6, 2008||No||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00787020||147717|
NCT00787319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751032|Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice|Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice||Pfizer|No|Completed|January 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|108|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients|October 2013|October 8, 2013|November 6, 2008||No||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00787319||147696|
NCT00787332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DES-08-01|A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome|A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)|HIT|Canyon Pharmaceuticals, Inc.|No|Terminated|September 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|N/A|No|||January 2013|January 6, 2013|November 6, 2008|Yes|Yes|Low enrollment|No|November 29, 2012|https://clinicaltrials.gov/show/NCT00787332||147695|Study stopped early due to poor enrollment.
NCT00787631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK01/2008|Analysis of Immunological Reactions to Foods in Birch Pollen-Allergic Patients|Analysis of Immunological Reactions to Pollen-Related Foods in Birch Pollen-Allergic Patients||Medical University of Vienna|No|Not yet recruiting|December 2008|December 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|50 Years|No|Non-Probability Sample|otherwise healthy birch pollen allergic (rhinoconjunctivitis)persons suffering also from        oral allergy syndrome to apple.|October 2008|November 6, 2008|October 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00787631||147673|
NCT00787904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-cells in osteoporosis|Role of T-cells in Post-Menopausal Osteoporosis|The Role of T-cells in Women Undergoing Surgical Menopause||Atlanta VA Medical Center|No|Completed|December 2006|December 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|19|Samples Without DNA|Serum|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pre-menopausal Women|January 2014|January 7, 2014|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00787904||147652|
NCT00787917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2437|An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)|An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA)||Novartis||Terminated|November 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|12 Years|N/A|No|||September 2011|September 22, 2011|November 7, 2008||No||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00787917||147651|
NCT00797186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13761|Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus|Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus Using Regadenoson Stress Cardiac Magnetic Resonance Imaging||University of Virginia|Yes|Recruiting|November 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|21 Years|85 Years|No|||May 2011|May 26, 2011|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797186||146955|
NCT00795834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/S0704/110|Effects of a Beverage Rich in Fruit Extracts on Risk Factors Associated With Cardiovascular Disease|Pilot Study to Assess Effects of Novel Beverages on Established and Novel Risk Markers for Vascular Disease||University of Glasgow|No|Recruiting|June 2008|March 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|55 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 19, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795834||147055|
NCT00796510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321002|Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety|A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension||Pfizer|No|Terminated|July 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|16 Years|80 Years|No|||April 2011|January 20, 2012|November 20, 2008|Yes|Yes|Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,    specifically new emerging evidence of hepatic injury|No|December 9, 2011|https://clinicaltrials.gov/show/NCT00796510||147005|Due to the premature termination only 3 participants were recruited into this study. No summarization or analysis was done.
NCT00795561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN05023126|Management of Nausea and Vomiting of Pregnancy|Randomized Controlled Trial of Day Care Versus Inpatient Management of Nausea and Vomiting of Pregnancy|DIM|University College Cork|Yes|Completed|April 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Female|N/A|N/A|No|||January 2014|January 13, 2014|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795561||147076|
NCT00795574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS2006|Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa|Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa|HS2006|Florida Academic Dermatology Centers|Yes|Completed|June 2005|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|16 Years|N/A|Accepts Healthy Volunteers|||November 2008|November 21, 2008|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00795574||147075|
NCT00796848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10172008-1323|Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring|Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring||Stanford University||Withdrawn|March 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|7 Years|20 Years|No|||March 2015|March 5, 2015|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796848||146979|
NCT00797134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTM025AOCT|Retinal Thickness Analysis Using Optical Coherence Tomography|Retinal Thickness Analysis Using Optical Coherence Tomography||Association for Innovation and Biomedical Research on Light and Image|No|Completed|November 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects followed regularly by their ophthalmologist performing, as part of their        follow-up, optical coherence tomography with OCT, and fulfilling the inclusion/exclusion        criteria will be included.|February 2015|February 2, 2015|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797134||146957|
NCT00797446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0601-OP01|Photon/Proton Radiation Therapy for Oropharyngeal Cancers|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Oropharyngeal Cancers|OP01|University of Florida|No|Terminated|September 2007|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the Radiation Oncology Clinic|March 2016|March 3, 2016|November 24, 2008||No|Slow enrollment, feasibility issues|No||https://clinicaltrials.gov/show/NCT00797446||146936|
NCT00797732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT004415-01|A Pilot Study of Acupuncture Treatment for Dysphagia|Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer Patients: A Pilot Randomized Control Trial||Dana-Farber Cancer Institute|Yes|Completed|December 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797732||146914|
NCT00797979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080501|Implant System for Fixation of Cranial Bone Flaps After Craniotomy for Brain Surgery|Implant System for Fixation of Cranial Bone Flaps After Craniotomy for Brain Surgery|CRANIOSG|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2012|November 23, 2012|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797979||146895|
NCT00798252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-030|Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers|A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors||Bristol-Myers Squibb|No|Completed|March 2009|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|111|||Both|18 Years|75 Years|No|||July 2015|July 3, 2015|November 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00798252||146874|
NCT00798265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090024|A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults|A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults||National Institutes of Health Clinical Center (CC)||Completed|October 2008|February 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|26|||Both|12 Years|26 Years|No|||November 2015|December 2, 2015|November 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00798265||146873|
NCT00798278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKVATS2007|Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood|Exploratory Multicentre Clinical Trial to Compare the Efficacy of Urokinase Versus Video-assisted Thoracoscopic for Treatment of Complicated Parapneumonic Empyema in Childhood||Spanish Society of Pediatric Surgery|No|Completed|July 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|1 Year|15 Years|No|||November 2008|October 27, 2010|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798278||146872|
NCT00798226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-093|Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood|Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood: Interventional Trial in the COPSAC2010 (Copenhagen Studies on Asthma in Childhood) Birth Cohort||Copenhagen Studies on Asthma in Childhood|No|Active, not recruiting|November 2008|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798226||146876|
NCT00798239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFX-101|Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery|A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion||BioSurface Engineering Technologies, Inc|Yes|Active, not recruiting|November 2008|July 2012|Anticipated|May 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|70 Years|No|||March 2012|March 7, 2012|November 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00798239||146875|
NCT00798525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003122-28|Argatroban Versus Lepirudin in Critically Ill Patients|Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial|ALiCia|Heinrich-Heine University, Duesseldorf|Yes|Terminated|January 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|November 25, 2008|Yes|Yes|Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012|No||https://clinicaltrials.gov/show/NCT00798525||146853|
NCT00798785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK_TX_06|Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients|Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients||AZ-VUB|No|Recruiting|October 2006|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|65 Years|No|||December 2013|December 27, 2013|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798785||146833|
NCT00798798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-STU2545|Effect of Externally Implantable Tissue Expansion Device on Scar Length|Effect of Externally Implantable Tissue Expansion Device on Scar Length||Northwestern University|No|Withdrawn|April 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||May 2014|May 22, 2014|November 24, 2008|Yes|Yes|Inability to recruit eligible subjects|No||https://clinicaltrials.gov/show/NCT00798798||146832|
NCT00799058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 020|A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States|A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.||International Partnership for Microbicides, Inc.|Yes|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|180|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 24, 2011|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799058||146813|
NCT00799383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH085005|Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia|Counteracting Risperidone-Induced Hyperprolactinemia in Youths||University of Iowa|No|Completed|November 2008|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|51|||Male|5 Years|17 Years|No|||April 2014|April 2, 2014|November 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799383||146790|
NCT00795366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060949|Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients|Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients|AVP|University of Miami|No|Completed|September 2008|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|November 20, 2008||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT00795366||147090|
NCT00786760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13930|Natural History of HPV Infection in Men: The HIM Study|Natural History of HPV Infection in Men: The HIM Study||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|June 2005|||December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|1431|Samples With DNA|This study will create a specimen repository with which to test future novel hypotheses      related to HPV infection among men. To assess other genetic, infectious, or environmental      factors that may influence acquisition and persistence of HPV infections in men, whole      blood, serum, exfoliated penile cell samples, and oral cells will be stored in aliquots for      future analyses as funding becomes available. Using banked specimens preserved for DNA, RNA,      and protein analyses, we will be able to assess novel biomarkers such as methylation status      of oncogenic HPV, polymorphisms in genes involved in innate immunity (e.g., TLR genes), and      mRNA of the E6 and E7 HPV oncoproteins in the future.|Male|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|1. Men ages 18-44; a pilot study group, ages 45-70;          2. residents of 3 sites - southern Florida, US, Sao Paulo, Brazil, or state of Morelos,             Mexico          3. report no prior diagnosis of penile or anal cancers          4. have never been diagnosed with genital and anal warts          5. have not participated in a HPV vaccine study          6. report no prior diagnosis with acquired immune deficiency syndrome (AIDS) or human             immunodeficiency virus (HIV)          7. report no current penile discharge or burning during urination          8. are not currently being treated for a sexually transmitted disease          9. have not been imprisoned or homeless during the last 6 months         10. have not been in drug treatment during the last 6 months         11. no plan to relocate in the next 4 years         12. willing to comply with 10 scheduled visits every 6 months for 4 years|December 2015|December 3, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786760||147736|
NCT00787072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3801C00001|AZD8075 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD8075 in Healthy Male Volunteers||AstraZeneca|No|Terminated|October 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|72|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|November 6, 2008|No|Yes|After reports of turbidity in urine in 4 of 8 volunteers in the 4th cohort, the study was    halted temporarily.|No||https://clinicaltrials.gov/show/NCT00787072||147714|
NCT00787345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-094|Simulation-based Training for Surgery Residents in Aseptic Techniques|General Surgery Residents Education in Maximum Barrier Precautions During Central Venous Catheter Placement: Effect of Simulation-Based Training|CVC|St. Luke's-Roosevelt Hospital Center|No|Completed|May 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2008|September 20, 2010|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787345||147694|
NCT00787358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC-018|A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women|A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women With Intertrochanteric Fracture of the Hip|SHIFT|Zelos Therapeutics|No|Withdrawn|December 2008|July 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|N/A|No|||June 2009|June 3, 2009|November 6, 2008|No|Yes|Change in company direction|No||https://clinicaltrials.gov/show/NCT00787358||147693|
NCT00787644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLITZ Asthma|Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)|A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics. (The GLITZ Asthma Study)|GLITZ|University of Vermont|Yes|Terminated|January 2009|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|60 Years|No|||February 2015|February 25, 2015|November 5, 2008|Yes|Yes|new safety concerns which emerged about pioglitazone during the trial|No|January 8, 2015|https://clinicaltrials.gov/show/NCT00787644||147672|Early termination leading to small numbers of subjects analyzed
NCT00787930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007867|Bipolar Disorder in Late Life|Bipolar Disorder in Late Life (Evaluation of MRI Hyperintensities and DTI in Bipolar Disorder)|BPD|Duke University|No|Completed|October 2005|December 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|19|Samples With DNA|DNA collected for genetic databank.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects recruited from the adult inpatient and outpatient psychiatric clinics at Duke        University Medical Center and John Umstead Hospital (Butner, NC).|July 2014|July 3, 2014|November 6, 2008|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00787930||147650|Acute MRI hypothesis unable to be tested due to high subject response. Five subject scans could not be evaluated by DTI computer program.
NCT00796523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|941|An Intervention to Decrease Infant Crying|A Randomized, Controlled Trial to Decrease Infant Crying||Riverside Methodist Hospital|Yes|Completed|August 2005|May 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|N/A|5 Days|Accepts Healthy Volunteers|||November 2008|November 21, 2008|October 16, 2008||No||No|October 16, 2008|https://clinicaltrials.gov/show/NCT00796523||147004|
NCT00796549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.40|BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients|A Phase II Single-arm Trial of BIBW 2992 in EGFR FISH Positive Non-small Cell Lung Cancer Patients||Boehringer Ingelheim||Completed|December 2008|||May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|November 21, 2008||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00796549||147002|
NCT00797160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0011.0.287.000-08|Propofol Versus Midazolam as Premedication for Preterm Neonates With Respiratory Distress Syndrome (RDS)|Propofol and Remifentanil Versus Midazolam and Remifentanil as Premedication Allowing Very Early Extubation After Surfactant Treatment in Preterm Neonates With Respiratory Distress Syndrome||Federal University of Minas Gerais|Yes|Recruiting|August 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|||Anticipated|20|||Both|N/A|2 Days|No|||August 2008|November 24, 2008|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00797160||146956|
NCT00798304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108K2-2000|Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants|An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants||Pfizer|Yes|Terminated|January 2009|September 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|46|||Both|42 Days|98 Days|No|||November 2014|November 21, 2014|November 25, 2008||No|Following program review within Pfizer, decision was made not to go ahead with this study.    This study is cancelled|No|November 21, 2014|https://clinicaltrials.gov/show/NCT00798304||146870|Immunogenicity results were not reported because the study was terminated due to the reactogenicity profile of the vaccine in infants prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.
NCT00797459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1100-001|Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds|A Randomized, Double-Blind Study Comparing Safety and Tolerability of Restylane® With and Without Addition of 0.3% Lidocaine HCL During Correction of Nasolabial Folds||Medicis Global Service Corporation|No|Completed|November 2008|March 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|November 24, 2008|Yes|Yes||No|August 11, 2010|https://clinicaltrials.gov/show/NCT00797459||146935|
NCT00798317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-007|Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.|A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.||ThromboGenics|Yes|Completed|December 2008|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|326|||Both|18 Years|N/A|No|||April 2014|December 2, 2014|November 25, 2008|Yes|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00798317||146869|
NCT00799409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015046|Lab School Day Study for CONCERTA of Older Children With ADHD|The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD||Ortho-McNeil Janssen Scientific Affairs, LLC|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|9 Years|12 Years|No|||April 2014|April 24, 2014|November 26, 2008|Yes|Yes||No|June 14, 2010|https://clinicaltrials.gov/show/NCT00799409||146788|
NCT00798538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H97HA03800-03|Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)|Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)|BELIEVE|Yale University|No|Completed|August 2005|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798538||146852|
NCT00798811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-12-009|High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors|Multicenter Clinical Trial to Evaluate Efficacy of High-dose Chemotherapy With Autologous Stem Cell Rescue for Children With High-risk Brain Tumors||Samsung Medical Center|Yes|Active, not recruiting|September 2008|August 2016|Anticipated|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|N/A|N/A|No|||October 2009|November 23, 2015|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798811||146831|
NCT00799396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043419|Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)|Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)||University of Maryland|Yes|Recruiting|August 2006|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|700|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 28, 2012|November 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00799396||146789|
NCT00800007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZ-521-101|Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus|A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Intravenous Doses of ANZ-521 in Hepatitis C Patients||Anza Therapeutics, Inc.|Yes|Terminated|November 2008|February 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||February 2009|February 19, 2009|November 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00800007||146742|
NCT00800033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO0822|Effectiveness of Pulse-Based Foods Combined With Exercise for Improving Components of the Metabolic Syndrome|Effectiveness of Pulse-Based Foods Combined With Exercise for Improving Components of the Metabolic Syndrome||University of Saskatchewan|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|87|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00800033||146741|
NCT00787059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|365|AC6 Gene Transfer for CHF|Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure||Hammond, H. Kirk, M.D.|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|November 6, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787059||147715|
NCT00787657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13852|Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment|Betaferon Prospective Study on Adherence, Coping and Nursing Support|BEACON|Bayer|No|Completed|June 2008|October 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1723|||Both|12 Years|N/A|No|Probability Sample|Patients after clinical events suggestive of MS according to SMPC) and patients with        elapsing / Remitting Multiple Sclerosis (RRMS) within the first two years of diagnosis|October 2015|October 15, 2015|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787657||147671|
NCT00787943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-032408|Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris|A Split-face, Paired-comparison, Pilot Study to Evaluate Safety and Efficacy of Two Topical Benzoyl Peroxide 10.0% Creams for Mild to Moderate Acne Vulgaris||Northwestern University|Yes|Completed|May 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|13 Years|35 Years|Accepts Healthy Volunteers|||March 2015|April 10, 2015|November 6, 2008||No||No|September 24, 2010|https://clinicaltrials.gov/show/NCT00787943||147649|
NCT00788242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 08-032|The Effect of Glucose-Insulin-Potassium Infusion in Patients Undergoing Cardiac Surgery|The Effect of Glucose-Insulin-Potassium Infusion on Myocardial Injuries and Cardiac Function in Patients Undergoing Cardiac Surgery||University Hospital, Geneva|No|Completed|January 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|85 Years|No|||December 2014|December 2, 2014|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788242||147627|
NCT00788567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18496|CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants|A Randomized, Open-label Study of the Achievement of a Mycophenolic Acid Therapeutic Window During Treatment With 2 Dosing Regimens of Oral CellCept Administered as a Component of Standard Immunosuppressive Therapy in Patients With Kidney Transplants||Hoffmann-La Roche||Completed|June 2005|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788567||147604|
NCT00796874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000618738|Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance|MR Imaging to Stratify Prostate Cancer Progression Risk in Patients on Active Surveillance||Roswell Park Cancer Institute|Yes|Withdrawn|October 2008|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Male|18 Years|N/A|No|||July 2013|July 24, 2013|November 21, 2008|No|Yes|PI decided to terminate study.|No||https://clinicaltrials.gov/show/NCT00796874||146977|
NCT00796887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS-5284|Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery|Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery||Henry Ford Health System|Yes|Completed|April 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|85 Years|No|||September 2012|September 12, 2012|November 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796887||146976|
NCT00796120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015769|An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)|A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|November 2008|August 2014|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 20, 2008|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT00796120||147034|
NCT00796133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #427|A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women|A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women||Population Council|No|Completed|November 2008|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|18|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|November 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796133||147033|
NCT00796861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI25224|Trial of Sunitinib for Refractory Malignant Ascites|Phase II Pilot Efficacy Trial of Sunitinib for Refractory Malignant Ascites||Milton S. Hershey Medical Center|Yes|Terminated|May 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|November 21, 2008|Yes|Yes|Phycisican decided to terminate study due to slow patient accrual.|No||https://clinicaltrials.gov/show/NCT00796861||146978|
NCT00798551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|519-07-EP|Emergency Department Interventions to Improve Blood Pressure Follow-up|Emergency Department Interventions to Improve Blood Pressure Follow-up||University of Nebraska|No|Active, not recruiting|November 2008|June 2010|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|19 Years|N/A|No|||January 2010|January 11, 2010|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798551||146851|
NCT00798824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:072|The Impact of Nasogastric Indwelling Versus Oral Intermittent Tube Feeding Methods on Premature Infants|The Impact of Nasogastric Indwelling Versus Oral Intermittent Tube Feeding Methods on Premature Infants||University of Manitoba|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|30 Weeks|33 Weeks|Accepts Healthy Volunteers|||October 2010|October 12, 2010|September 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00798824||146830|
NCT00798590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00022551|The Efficacy of GLP - 1(7-36) Amide for Glycemic Control in Critically Ill Patients|The Efficacy of GLP - 1 (7-36) Amide for Glycemic Control in Critically Ill Surgical Patients||Johns Hopkins University|Yes|Enrolling by invitation|December 2008|June 2011|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|21 Years|75 Years|No|||March 2010|March 25, 2010|November 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00798590||146848|
NCT00798603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0821|Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2)||Alliance for Clinical Trials in Oncology|No|Completed|December 2008|May 2013|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|70 Years|N/A|No|||July 2015|July 3, 2015|November 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00798603||146847|
NCT00799071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 08.01|Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)|Investigation of POsaconazole Prophylaxis in Children With Chronic Granulomatous Disease (CGD): Pharmacokinetics and Tolerability (iPOD)|iPOD|Radboud University|No|Completed|February 2009|August 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|2 Years|16 Years|No|||May 2012|May 30, 2012|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799071||146812|
NCT00799084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA030724|Automated Telephone Monitoring for Symptom Management|Automated Telephone Monitoring for Symptom Management|ATSM|Michigan State University|No|Completed|April 2003|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|526|||Both|21 Years|N/A|No|||December 2011|December 6, 2011|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00799084||146811|
NCT00798837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAX|Intraprostatic MAXimal Simultaneous Boost|A Dose-escalation Study Using a Maximal Simultaneous Intraprostatic Boost With RapidArc Intensity Modulated Radiotherapy in Intermediate Risk Prostate Cancer||British Columbia Cancer Agency|Yes|Terminated|December 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|N/A|N/A|No|||September 2015|September 28, 2015|November 24, 2008||No|Excess risk in rectal bleeding of first 10 patients|No||https://clinicaltrials.gov/show/NCT00798837||146829|
NCT00798850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEY- REF-2424|Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease|Randomised Controlled Trial of Percutaneous Transluminal Angioplasty (PTA) Versus a Supervised Exercise Programme (SEP) in the Management of Intermittent Claudication (IC) Due to Femoro-popliteal Disease||University of Hull|No|Completed|August 2002|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|178|||Both|N/A|N/A|No|||April 2015|April 7, 2015|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798850||146828|
NCT00795067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KurumeU-08060|Relation of Circulating Endothelium-derived Microparticle to Carotid Atherosclerosis|Relation of Circulating Endothelium-derived Microparticle to Carotid Atherosclerosis||Kurume University|Yes|Completed|November 2008|November 2013|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|154|Samples Without DNA|platelet-poor plasma whole blood urine|Both|20 Years|N/A|No|Non-Probability Sample|Patients who undergo carotid ultrasound examination for screening of atheroscrelosis|March 2015|March 30, 2015|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795067||147113|
NCT00795340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR29|Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer||Canadian Cancer Trials Group|Yes|Completed|November 2008|January 2014|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|N/A|No|||June 2015|November 18, 2015|November 20, 2008||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT00795340||147092|Early termination at phase II part of the trial, leading to small numbers of subjects analyzed, and limited follow up time.
NCT00795353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A.W.A.R.E.-2|Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Amevive Wisdom Acquired Through Real-world Evidence - 2 (A.W.A.R.E.-2) Program: Long-Term Study|AWARE-2|Astellas Pharma Inc|No|Terminated|July 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|64|Samples With DNA|10mL blood sample - Biomarker Substudy only|Both|18 Years|N/A|No|Non-Probability Sample|Canadian subjects with moderate to severe chronic plaque psoriasis for which Amevive is        clinically indicated|March 2011|February 27, 2013|November 11, 2008|No|Yes|The study was terminated early due to insufficient subject enrolment in order to meet the    primary and secondary endpoints|No||https://clinicaltrials.gov/show/NCT00795353||147091|
NCT00795626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS and HCPA 06570|Impact of Systematic Nursing Orientations in the Reduction of Predicted Cardiovascular Risk in Patients With Coronary Artery Disease.|Impact of Systematic Nursing Orientations in the Reduction of Predicted Cardiovascular Risk in Patients With Coronary Artery Disease.|NERE-CR|Hospital de Clinicas de Porto Alegre|Yes|Completed|January 2007|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795626||147071|
NCT00795639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321001|Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension||Pfizer|Yes|Terminated|December 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|183|||Both|16 Years|80 Years|No|||March 2015|March 4, 2015|November 20, 2008|Yes|Yes|Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,    specifically new emerging evidence of hepatic injury.|No|January 30, 2012|https://clinicaltrials.gov/show/NCT00795639||147070|Study terminated early.
NCT00799734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-740|Chinese Medicine Therapy on Menopausal Symptoms|A Double-blind Randomized Placebo-controlled Clinical Trial on the Effects of Chinese Medicine Formula (Erxian Decoction) on Menopausal Symptoms||The University of Hong Kong|Yes|Completed|April 2009|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|November 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799734||146763|
NCT00786786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6465|Perceived Barriers to Exercise in Individuals Living With Spinal Cord Injury|Perceived Barriers to Exercise in Individuals Living With Spinal Cord Injury.||University of California, Irvine|No|Completed|August 2008|September 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Any person with a spinal cord injury who is at least 18 years of age, lives in the United        States of America, and can read English.|November 2010|November 2, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786786||147734|
NCT00788255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10242008-1327|In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.|In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.||Stanford University||Completed|October 2008|||June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|25|None Retained|Venous blood|Female|N/A|N/A|No|Non-Probability Sample|healthy pregnant patients awaiting elective induction of labor or cesarean delivery.|November 2009|November 5, 2009|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00788255||147626|
NCT00788580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0718|S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors|S0718: Phase I Study Evaluating The Combination of GW786034 (Pazopanib; NSC-737754; IND-XXXX) and CCI-779 (Temsirolimus; NSC-683864; IND-XXXX) in Patients With Advanced Solid Tumors||Southwest Oncology Group||Withdrawn||||||Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|November 8, 2008|No|Yes|Study was discontinued.|No||https://clinicaltrials.gov/show/NCT00788580||147603|
NCT00788879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-05-0488|Tu Salud Si Cuenta Media Campaign|Evaluation of a Media Campaign: Tu Salud Si Cuenta|TSSC|The University of Texas Health Science Center, Houston|No|Completed|February 2003|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788879||147580|
NCT00788892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTR0308-204|Trial of CPX-351 in Newly Diagnosed Elderly AML Patients|PHASE IIB, MULTICENTER, RANDOMIZED, OPEN LABEL TRIAL OF CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME INJECTION VERSUS CYTARABINE AND DAUNORUBICIN IN PATIENTS WITH UNTREATED AML 60-75 YEARS OF AGE.||Celator Pharmaceuticals|Yes|Completed|October 2008|December 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|60 Years|75 Years|No|||May 2012|May 16, 2012|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788892||147579|
NCT00797212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2008-19|A New Glucose Meter With Alternative Site Testing|Clinical Evaluation of the Apollo Blood Glucose Monitoring System With Alternative Site Testing [Commercial Name is CONTOUR® USB]||Ascensia Diabetes Care|No|Completed|November 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|November 24, 2008|Yes|Yes||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00797212||146953|
NCT00797511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD525|Immunogenicity and Safety of Adacel Polio Vaccine|Immunogenicity and Safety of ADACEL POLIO (TdcP-IPV Vaccine) Administered at 6 to 8 Years of Age as a Fifth Dose in Healthy Children in Taiwan||Sanofi|No|Completed|November 2008|July 2009|Actual|April 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|132|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|November 24, 2008||No||No|October 24, 2012|https://clinicaltrials.gov/show/NCT00797511||146931|
NCT00796536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AR055716|Using Functional MRI to Evaluate Cognitive Behavioral Therapy Treatment Response in Adults With Chronic Pain|Using fMRI to Evaluate CBT Treatment Response for Patients With Chronic Pain||University of Vermont|No|Completed|June 2009|July 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796536||147003|
NCT00797992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-05-2008-AR|Bevacizumab Intravitreal for Myopic Choroidal Neovascularization|Bevacizumab Intravitreal for Myopic Choroidal Neovascularization||Instituto de Olhos de Goiania|Yes|Completed|January 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2008|November 24, 2008|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797992||146894|
NCT00798291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK32|Evaluation of AN777 in Elderly Subjects|Evaluation of AN777 in Elderly Subjects||Abbott Nutrition|Yes|Completed|October 2008|January 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|108|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 19, 2010|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798291||146871|
NCT00797758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 060206|Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia|Assessment of Reduction of Cord Blood Transplantation Toxicity by Using Reduced Intensity Conditioning in Patients With Acute Myeloid Leukemia.|MINICORD|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2007|December 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|4 Years|65 Years|No|||March 2013|March 7, 2013|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797758||146912|
NCT00798005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI6144|Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Different Doses and Schedules of Administration of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.|TALISMAN202|Sanofi||Completed|June 2002|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|71|||Both|45 Years|N/A|No|||September 2010|September 2, 2010|November 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00798005||146893|
NCT00802685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070871|Timing of PDA Closure and Respiratory Outcome in Premature Infants|Timing of PDA Closure and Respiratory Outcome in Premature Infants||University of Miami|Yes|Terminated|November 2007|February 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|N/A|14 Days|No|||December 2013|January 3, 2014|December 4, 2008||No|Lack of availability of IV ibuprofen as of 8/10 due to a manufacturer's recall|No|June 17, 2013|https://clinicaltrials.gov/show/NCT00802685||146538|
NCT00802698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-039|The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform|||Asociación para Evitar la Ceguera en México||Recruiting|April 2008|||April 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|50 Years|N/A|No|||December 2008|December 4, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802698||146537|
NCT00798564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34797|Exercise Induced Asthma and Airway Reactivity in Athletes|Explorative Study "Exercise Induced Asthma and Airway Reactivity in Athletes"||Skåne University Hospital|No|Completed|March 2008|December 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|300|||Both|16 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|100 elite swimmers 100 elite tennis players 100 aged matched non-atletic subjects, 30        aged-matcked healthy non-atopic controls|September 2008|August 2, 2011|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798564||146850|
NCT00798577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-03|Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment|||Alcon Research|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|1 Year|N/A|No|||March 2010|March 30, 2010|November 25, 2008|No|Yes||No|March 2, 2010|https://clinicaltrials.gov/show/NCT00798577||146849|
NCT00799110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-380|Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod|Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With GM-CSF and Imiquimod||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2008|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|23|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|November 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799110||146809|
NCT00799123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/072/08/2|Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants|||Charite University, Berlin, Germany|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100||urine|Both|N/A|48 Hours|No|Probability Sample|VLBW infants|April 2010|April 9, 2010|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799123||146808|
NCT00799097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DC0005805|Determinants of Surgical Outcomes in Chronic Sinusitis|Determinants of Surgical Outcomes in Chronic Sinusitis||Oregon Health and Science University|No|Completed|July 2004|December 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|516|||Both|18 Years|N/A|No|Non-Probability Sample|The multi-institutional study population consists of adult (>17 years) patients who have        had a diagnosis of chronic rhinosinusitis, have failed maximum medical management,and have        elected for endoscopic sinus surgery as their next treatment option.|November 2008|May 19, 2010|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799097||146810|
NCT00799422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-08-02|Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients|Evaluation of Lens Fit, Lens Parameters, and Circumlimbal Conjunctival Staining (CSS) in Normal Patients||Alcon Research|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|26|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|November 25, 2008|Yes|Yes||No|October 16, 2012|https://clinicaltrials.gov/show/NCT00799422||146787|
NCT00795093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120N00005|Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US|Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient|REMAIN|AstraZeneca|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|552|||Both|18 Years|N/A|No|Probability Sample|Patients with Gastroesophageal Reflux Disease (GERD) classified as partial responders to        proton pump inhibitors (PPIs).|May 2010|May 10, 2010|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795093||147111|
NCT00795080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 18481|Dynamic MRI and Quantitative MR CSF Flow Studies in Craniovertebral Junction Anomalies|Dynamic Magnetic Resonance Imaging (MRI) and Quantitative MR Cerebral Spinal Fluid (CSF) Flow Studies in Craniovertebral Junction Anomalies||University of Michigan|No|Active, not recruiting|July 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|40|||Both|12 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pilot group consisting of 10 healthy volunteers. Patients recruited w/incidental findings        of Chiari 1 malformations and Patients recruited with known Chiari and other CVJ        malformations (prior to surgery)|June 2015|June 16, 2015|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795080||147112|
NCT00787670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006703|Impact of GBS on CVD in Type 2 Diabetes Mellitus|Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus||Duke University|No|Completed|November 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|84|||Both|18 Years|60 Years|No|||February 2013|February 4, 2013|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787670||147670|
NCT00787371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04508|Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)|Study to Confirm Dose Response With PegIntron (SCH 54031) Monotherapy in Patients With Chronic Hepatitis C||Merck Sharp & Dohme Corp.|No|Completed|June 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|69|||Both|20 Years|N/A|No|||April 2015|April 9, 2015|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787371||147692|
NCT00788281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJLS01|A Multi-Center Randomised Controlled Study to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer|||Beijing Friendship Hospital||Recruiting|April 2008|April 2016|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||November 2008|November 12, 2008|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788281||147625|
NCT00788294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091013|Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously|Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study||Pfizer|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 14, 2009|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788294||147624|
NCT00788593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-002|A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)|A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI)||Forest Laboratories|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|November 10, 2008|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT00788593||147602|
NCT00788606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 2719|R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma|Feasibility Study of R-CHOP Plus Bevacizumab in Patients With Diffuse Large B Cell Lymphoma (DLBCL)||Royal Marsden NHS Foundation Trust|Yes|Terminated|May 2008|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788606||147601|
NCT00788905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065-08|Comparison of Conventional Dialysis and the Allient System|Uremic Toxin Removal, Blood Cell Kinetics, and Inflammatory Response in Patients Treated With the Allient System||Renal Research Institute|No|Active, not recruiting|November 2008|January 2014|Anticipated|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||March 2013|March 27, 2013|September 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788905||147578|
NCT00788918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS-0078-HCVCNS|Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)|Study of Cerebral Function in Patients With Chronic Hepatitis C Infection Before and After Pegylated Interferon Alfa-2a and Ribavirin Therapy||University of Aarhus|Yes|Completed|November 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788918||147577|
NCT00801203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNEU-01-004|A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence|A Phase II/III Controlled Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence||Pneumoflex Systems, LLC|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|180|||Female|25 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 8, 2012|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801203||146651|
NCT00801216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCNSL1|High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement|High-Dose Sequential Chemotherapy and Rituximab (R-HDS) in Patients With Systemic B-Cell Lymphoma With Central Nervous System Involvement at Diagnosis or Relapse|SCNSL1|IRCCS San Raffaele|Yes|Recruiting|January 2007|January 2012|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|19 Years|65 Years|No|||October 2008|December 2, 2008|November 28, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00801216||146650|
NCT00797745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05104|A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)|A Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104)|NEXT-1|Merck Sharp & Dohme Corp.|Yes|Completed|November 2008|September 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|111|||Both|18 Years|55 Years|No|||January 2015|January 21, 2015|November 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00797745||146913|
NCT00797771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-HU-01|User Satisfaction Using the ADI Insulin Pump|Evaluation of User Satisfaction Using the ADI Insulin Pump||NiliMedix|No|Completed|December 2008|January 2010|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2009|June 8, 2011|November 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00797771||146911|
NCT00797784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FADC|The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus|A Phase 2 Open Label Study to Assess the Efficacy and Safety of Etanercept (Enbrel®)for the Treatment of Discoid Lupus Erythematosus|DISCLUP2008|Florida Academic Dermatology Centers|Yes|Recruiting|October 2008|April 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|May 25, 2010|November 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00797784||146910|
NCT00797472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-HDII 1108|Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease|A Phase II Open Label, Multicenter, Randomized, Parallel Study Comparing the Efficacy of R-mabHD Alone and a Combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD)in Treating Patients With Hodgkin's Disease.||American Scitech International|No|Not yet recruiting|July 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||July 2011|July 19, 2011|November 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00797472||146934|
NCT00797485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617983|Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Maintenance and Reinduction Chemotherapy With Avastin in Metastatic Colon Cancer: The MARTHA (SICOG 0803) Trial||National Cancer Institute (NCI)||Recruiting|July 2008|||July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|672|||Both|18 Years|75 Years|No|||June 2009|August 23, 2013|November 22, 2008||||No||https://clinicaltrials.gov/show/NCT00797485||146933|
NCT00797498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0604-SI01|Photon/Proton Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses|SI01|University of Florida|No|Completed|August 2006|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|174|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the Radiation Oncology Clinic|March 2016|March 3, 2016|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797498||146932|
NCT00798330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-059-2|Dental Study in Cancer Patients With Central Venous Catheters|Pilot Study on Transient Bacteremia and Blood Stream Infections After Invasive Dental Procedures in Cancer Patients With Central Venous Catheters||University of Connecticut Health Center|Yes|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer outpatients with central venous catheters (Medport or PICC lines)|November 2013|November 19, 2013|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798330||146868|
NCT00803036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-96-12-01|Observational Study of Cortical Spreading Depression in Human Brain Trauma|Spreading Depressions as Secondary Insults After Traumatic Injury to the Human Brain|COSBID-TBI|University of Cincinnati|Yes|Recruiting|January 2009|September 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients admitted to study hospitals who require neurosurgery for acute traumatic brain        injury.|November 2010|November 8, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803036||146511|
NCT00798863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASS|Study Of The Safety And Efficacy Video Assisted Submandibular Gland Resection Using A New Two Step Technique|Video Assisted Submandibular Resection, Two Step Technique|VANSsubmand|Faculty of Medicine, University of Alexandria|Yes|Completed|January 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||July 2009|July 14, 2009|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798863||146827|
NCT00803556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA201-001|Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy|Phase 1 Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel||Bristol-Myers Squibb|No|Completed|January 2006|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||June 2011|June 23, 2011|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803556||146471|
NCT00803569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000628730|Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen||Ludwig Institute for Cancer Research|Yes|Completed|November 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||June 2011|June 21, 2011|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803569||146470|
NCT00799435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|613|Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure|Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction||Baylor College of Medicine||Terminated|July 2009|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|30 Years|N/A|No|||July 2014|July 15, 2014|November 26, 2008|Yes|Yes|Inability to recruit adequate Sample Size who met the entry criteria|No||https://clinicaltrials.gov/show/NCT00799435||146786|
NCT00799448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1524|Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes|Multi-centre, Open, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled With SU +/ Biguanide Therapy, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime Insulin vs. Insulin Alone||Novo Nordisk A/S|No|Terminated|September 2003|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|40 Years|75 Years|No|||March 2013|March 6, 2013|November 26, 2008|||Low recruitment status|No||https://clinicaltrials.gov/show/NCT00799448||146785|
NCT00795379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC 5-1006|Testing the Use of Interoceptive Exposure to Reduce Barriers to Psychotherapy|Testing the Use of Interoceptive Exposure to Reduce Barriers to Psychotherapy||G.V. (Sonny) Montgomery VA Medical Center|No|Recruiting|November 2008|||November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2008|November 20, 2008|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795379||147089|
NCT00795392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMU200811010|Preoperative Psychological Evaluation as Predictor of Outcomes|Preoperative Psychological Evaluation as Predictor of Post-surgical Outcomes|PEPO|Nanjing Medical University|Yes|Completed|November 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|65 Years|No|Non-Probability Sample|All types of patients undergoing surgical operations|September 2009|September 17, 2009|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795392||147088|
NCT00799721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/072/08-1|Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants|||Charite University, Berlin, Germany||Recruiting|August 2008|December 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|Samples Without DNA|Urine samples that are centrifugated to get rid of any cells where stored at -80°C until      ELISA is done.|Both|N/A|32 Weeks|No|Non-Probability Sample|Pretarem infants of less than 32 weeks of gestation or birth weight below 1500g.|August 2008|November 28, 2008|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00799721||146764|
NCT00787683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V7.0|Home-Monitoring in Implantable Cardioverter Defibrillator (ICD) Patients|Home-Monitoring in ICD Patients|Monitor-ICD|Charite University, Berlin, Germany|No|Active, not recruiting|October 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|416|||Both|18 Years|80 Years|No|||June 2012|June 25, 2012|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787683||147669|
NCT00787956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10032008-1315|Internet Chronic Disease Self-Management Program for Australia|Evaluation of an Internet Chronic Disease Self-Management Program for Australia||Stanford University||Completed|October 2008|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787956||147648|
NCT00787969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N078D|Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|April 2009|||April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|November 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787969||147647|
NCT00788307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0252|Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy|Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine||Mayo Clinic|Yes|Recruiting|July 2009|||September 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|120 Years|No|||January 2016|January 7, 2016|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788307||147623|
NCT00788320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D in TB|Vitamin D in Active Tuberculosis (TB) Study|Antimicrobial Peptide LL-37 (Cathelicidin) Production in Active Tuberculosis Disease: Role of Vitamin D Supplementation||Atlanta VA Medical Center|No|Withdrawn|October 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|November 7, 2008||No|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT00788320||147622|
NCT00788619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00013752|Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization (IVF)|Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization||Johns Hopkins University|No|Suspended|January 2009|March 2012|Anticipated|January 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|21 Years|37 Years|Accepts Healthy Volunteers|||November 2011|November 1, 2011|November 10, 2008||No|consent form is being revised|No||https://clinicaltrials.gov/show/NCT00788619||147600|
NCT00788632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X080219004|Improving Care of Osteoporosis: Multi-Modal Intervention to Increase Testing and Treatment (ICOMMIITT)|Improving Care of Osteoporosis: Multi-Modal Intervention to Increase Testing and Treatment (ICOMMIITT)|ICOMMIITT|University of Alabama at Birmingham|No|Completed|May 2010|October 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|12128|||Female|65 Years|N/A|No|||March 2013|March 20, 2013|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788632||147599|
NCT00788931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589C2114|A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer|A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)||Novartis||Completed|December 2008|||August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|N/A|No|||November 2012|November 26, 2012|October 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788931||147576|
NCT00789243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP 2|The Effect of Ischaemic-Reperfusion and Ischaemic Preconditioning on the Endogenous Fibrinolysis in Man|The Effect of Ischaemic-Reperfusion and Ischaemic Preconditioning on the Endogenous Fibrinolysis in Man||University of Edinburgh|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789243||147552|
NCT00801502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMNUT0044|Salmon in Pregnancy Study|The Effects of Oily Fish in Pregnancy on Markers and Manifestations of Allergic Diseases in Infants at Risk of Atopy|SiPS|University Hospital Southampton NHS Foundation Trust.|Yes|Completed|May 2007|March 2012|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|124|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2008|November 27, 2014|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801502||146628|
NCT00801515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001090|A Compassionate Access Protocol For Those Patients Who Have Completed A4001029|A Compassionate Access Protocol For Those Patients Who Have Completed A4001029||ViiV Healthcare|No|No longer available|August 2009|July 2011|Actual|July 2011|Actual|Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||July 2011|July 21, 2011|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00801515||146627|
NCT00797199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TiBS-HRT|Monitoring of Breast Tissue Change Due to Hormone Replacement Therapy in Post-menopausal Women Using OBS|Short-term Evaluations of Breast Tissue Change in Post-menopausal Women Using Optical Breast Spectroscopy (OBS)|TiBS-HRT|University Health Network, Toronto|No|Completed|September 2011|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|14|Samples With DNA|Whole blood|Female|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Post-menopausal women attending the Endocrinology Clinic at St. Michael's Hospital        (Toronto, Ontario, Canada) who have elected to undergo a 1-year HRT regiment but had no        prior HRT treatment. The comparison group (control) will comprise of post-menopausal women        not on HRT and had no prior HRT treatment. Controls will be recruited among women at the        University Health Network or attending the Endocrinology Clinic at St. Michael's Hospital        (Toronto, Ontario, Canada).|March 2016|March 22, 2016|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00797199||146954|
NCT00801736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN02370070|ERCC1 Targeted Trial|A Multicentre, Randomised, Phase III Trial of Platinum-based Chemotherapy Versus Non-platinum Chemotherapy, After ERCC1 Stratification, in Patients With Advanced/Metastatic Non-small Cell Lung Cancer|ET|University College, London|Yes|Terminated|October 2009|||July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|648|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 9, 2013|December 2, 2008||No|The antibody used did not appear prognostic/predictive based on interim results.|No||https://clinicaltrials.gov/show/NCT00801736||146610|
NCT00801749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410|Sleep and Daytime Activity in Healthy Subjects|||Nagoya University||Completed|March 2005|March 2008|Actual|March 2007|Actual|N/A|Interventional|N/A|||||||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2008|December 5, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801749||146609|
NCT00798018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICLT|Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence Phenomena|Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence Phenomena||Sichuan University|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|100|||Female|18 Years|60 Years|No|||November 2009|December 17, 2009|November 24, 2008||No||No|June 1, 2009|https://clinicaltrials.gov/show/NCT00798018||146892|
NCT00802347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK.006|I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation|Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation||Quark Pharmaceuticals|Yes|Completed|December 2008|May 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|374|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802347||146564|
NCT00802724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD047709-04|Classification-Directed Treatment of Low Back Pain|Classification-Directed Treatment of Low Back Pain||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|February 2007|November 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|60 Years|No|||October 2012|October 18, 2012|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802724||146535|
NCT00803010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15372|Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation|Phase II Trial of Tacrolimus and Rapamycin vs. Tacrolimus and Methotrexate as GVHD Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|September 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|74|||Both|16 Years|70 Years|No|||December 2013|July 10, 2015|December 4, 2008|Yes|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT00803010||146513|
NCT00803023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004|Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia|Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia||Jazz Pharmaceuticals|No|Completed|March 2010|||July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|129|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|December 3, 2008|Yes|Yes||No|July 21, 2011|https://clinicaltrials.gov/show/NCT00803023||146512|
NCT00803907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0559/07|Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma|Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma|Imiquimod|University of Sao Paulo|No|Recruiting|December 2008|February 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||June 2012|June 12, 2012|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00803907||146444|
NCT00804232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiabetesVardal|Childhood Diabetes|Childhood Diabetes - Family Based Health Interventions for Child Health||Vardalinstitutet The Swedish Institute for Health Sciences|No|Recruiting|January 2008|December 2015|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|3 Years|15 Years|No|||December 2008|December 5, 2008|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00804232||146419|
NCT00804245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 85207|C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer|A Pilot Study of Use of 11C-Choline PET-CT in the Metastatic Evaluation of Patients With Newly Diagnosed High Risk Adenocarcinoma of the Prostate||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|August 2008|August 2013|Actual|June 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Male|30 Years|120 Years|No|||July 2014|September 29, 2015|December 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804245||146418|
NCT00804258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07007|Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer|Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer||City of Hope Medical Center|Yes|Completed|August 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|||Female|18 Years|N/A|No|Probability Sample|Patients under the care of the Medical Oncology department at the City of Hope|November 2015|November 4, 2015|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00804258||146417|
NCT00787696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA17509-4|Healthy Teen Girls: HIV Risk Reduction|HIV Risk Reduction Among Young Incarcerated Females||Mississippi State University|No|Completed|September 2003|December 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|333|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||October 2011|October 19, 2011|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787696||147668|
NCT00787995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-001|A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)|A Multicenter, Multinational, Longitudinal Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)||BioMarin Pharmaceutical|No|Terminated|October 2008|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|353|||Both|N/A|N/A|No|Non-Probability Sample|Subjects diagnosed with MPS IVA|December 2014|December 5, 2014|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787995||147645|
NCT00787982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIS-BR-08-001|Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors|Pilot Study Evaluating the Feasibility of Real-Time, Magnetic Resonance Thermal Imaging and Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors||Visualase, Inc.|Yes|Recruiting|September 2008|September 2010|Anticipated|September 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||December 2009|December 30, 2009|October 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787982||147646|
NCT00788008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010070|Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly|Does Inhalational Anesthesia Accelerate Postoperative Cognitive Decline?||Duke University|Yes|Completed|November 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|65 Years|N/A|No|||March 2015|March 23, 2015|November 6, 2008|Yes|Yes||No|December 24, 2014|https://clinicaltrials.gov/show/NCT00788008||147644|
NCT00788645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6256M00017|The Use of a Forecasting System for Predicting Exacerbations of COPD|The Use of a Forecasting System for Predicting Exacerbations of COPD: Effect on Symptoms and Hospitalisation and Relevance of Viral Infections||AstraZeneca|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|98|||Both|40 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 30, 2010|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788645||147598|
NCT00788944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B1-4433|Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl|An Open-Label Study To Evaluate The Prevalence Of Phenotypic Poor Metabolizers At CYP2D6 Among Venlafaxine-Treated Outpatients With Depression||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|October 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|971|||Both|18 Years|N/A|No|||January 2011|January 5, 2011|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788944||147575|
NCT00789230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUMP|Mesh Versus Suture Repair for Umbilical Hernias|Mesh Versus Suture Repair for Umbilical Hernias: a Double Blinded, Randomised Controlled Clinical Trial|HUMP|Erasmus Medical Center|Yes|Active, not recruiting|January 2006|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|November 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00789230||147553|
NCT00789256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0337|Low Dose Melphalan and Bortezomib for AML and High-Risk MDS|A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||October 2011|May 29, 2013|October 6, 2008|Yes|Yes||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00789256||147551|
NCT00789269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhubarb ischemia|Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From a Stroke|||Fudan University||Active, not recruiting|January 2009|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2009|May 26, 2010|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00789269||147550|
NCT00801268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0802|Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease|Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)||Nanjing University School of Medicine|Yes|Terminated|November 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|15 Years|70 Years|No|||March 2015|March 27, 2015|November 25, 2008|Yes|Yes|high rate of drop-out|No||https://clinicaltrials.gov/show/NCT00801268||146646|
NCT00801528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-0202-07|Diclofenac vs. Ropivacaine for Cesarean Section|The Analgesic Efficacy of Continuous Wound Instillation With Diclofenac or Ropivacaine Following Cesarean Section: a Randomized, Double-blind, Placebo Controlled Study||Meir Medical Center|Yes|Completed|April 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Female|N/A|N/A|No|||December 2008|May 2, 2010|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801528||146626|
NCT00801801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080703006|Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC|Pilot Phase IIa Study of Metronomic Chemotherapy With Taxotere (Docetaxel) Plus Nexavar (Sorafenib) as First-Line Therapy in Performance Status-2 Patients With Advanced Non-Squamous Cell Non-Small Cell Lung Cancer||University of Alabama at Birmingham|Yes|Terminated|January 2008|March 2011|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|N/A|No|||February 2016|February 1, 2016|December 2, 2008|Yes|Yes|Sponsors withdrew funding; preliminary efficacy data was not encouraging.|No|June 8, 2012|https://clinicaltrials.gov/show/NCT00801801||146605|The study initially sought to accrue a maximum sample size of 43 subjects. However, due to subjects' measured response and levels of clinical benefit in addition to a cut in funding, the study was stopped early and terminated.
NCT00797524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023RLAOCT|Function and Structure Imaging in Different Retinal Diseases: Retinal Leakage Analyzer Versus Optical Coherence Tomography|Function and Structure Imaging in Different Retinal Diseases. Retinal Leakage Analyzer vs. Optical Coherence Tomography.||Association for Innovation and Biomedical Research on Light and Image|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects followed regularly by their ophthalmologist at the AIBILI Clinical Trial Center        (Azinhaga de Santa Comba - Celas, Coimbra, Portugal), performing, as part of their        follow-up, fluorescein angiography with the Heidelberg Retina Angiograph (HRA) and optical        coherence tomography with OCT, and fulfilling the inclusion/exclusion criteria will be        included.|February 2015|February 2, 2015|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797524||146930|
NCT00802100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH090001-02|Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia|Comparison of Optimal Antipsychotic Treatments for Schizophrenia Pilot Study|COATS|National Institute of Mental Health (NIMH)|Yes|Completed|December 2008|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|40 Years|No|||April 2012|January 3, 2013|December 3, 2008|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00802100||146583|It was determined in this pilot study that the existing procedures and eligibility criteria could not be adequately implemented and that a larger-scale study was not feasible.
NCT00802113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5185|Autologous and Allogeneic Transplant for Relapsed Lymphoma|Sequential Myeloablative Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease||Columbia University|Yes|Completed|June 2003|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|N/A|55 Years|No|||April 2015|April 22, 2015|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00802113||146582|
NCT00802074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL112775|An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects|A Randomized, Open-Label, Six-Period, Drug Interaction Study to Assess Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics Following Administration of RTG 400 mg BID for 14 Days Alone and in Combination With 14 Days of Either Fosamprenavir (FPV) 1400 mg BID, FPV 700 mg BID + RTV 100 mg BID or FPV 1400 mg + RTV 100 mg QD in Healthy Adult Subjects When Under Fasting Conditions||Garden State Infectious Disease Associates, PA|No|Completed|December 2008|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label|6||Actual|45|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|December 3, 2008|No|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT00802074||146585|Data for Primary outcome measure assessments are not available per intervention. Values reported as means are of uncertain measure type (data are no longer available).
NCT00802087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-EG-001|Single Dose Pharmacokinetics of Egalet® Hydrocodone|A Single-Centre, Single Dose, Randomized,Open Label, Exploratory, 5-way Crossover Study Evaluating the Pharmakokinetic Profiles of Various Egalet® Hydrocodone Formulations In Healthy Volunteers Under Fasting Conditions.||Egalet Ltd|No|Completed|November 2008|April 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00802087||146584|
NCT00802711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-33 ICORG|3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer|Phase II Randomised Clinical Trial of Accelerated Partial Breast Irradiation (APBI) Comparing 3-Dimensional Conformal Radiation Therapy and Multi-Catheter Interstitial Brachytherapy.||ICORG- All Ireland Cooperative Oncology Research Group||Terminated|September 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Female|50 Years|N/A|No|||October 2012|December 30, 2014|December 4, 2008||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00802711||146536|
NCT00802191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDavis Wii|WiiMote Game Controller as a Device to Study Movement Disorders|WiiMote Game Controller as a Device to Study Movement Disorders||Vanderbilt University|No|Terminated|August 2007|August 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|18 Years and older, females of childbearing potential, healthy volunteers and adults with        movement disorders.|August 2014|August 29, 2014|December 2, 2008||No|Lack of study participants, no data published.|No||https://clinicaltrials.gov/show/NCT00802191||146576|
NCT00803595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8958-A-J301|A Multinational Phase III Study of CS-8958 (MARVEL)|A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection|MARVEL|Daiichi Sankyo Inc.|No|Completed|November 2008|June 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1002|||Both|20 Years|N/A|No|||November 2011|November 29, 2011|December 4, 2008||No||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00803595||146468|
NCT00803608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK05907405A1|The CareFUL Prevention Trial|Prospective, Randomized, Multiple Site Clinical Trial Comparing the Effectiveness of Novel Pressure Based Insoles to Current Care For Ulcer Prevention|CareFULPrevent|DIApedia, LLC|Yes|Completed|February 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|December 4, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803608||146467|
NCT00799500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS06/0559|Bacterial Vaginosis in Pregnancy: Detection by Weekly Vaginal pH Testing|Impact on Prematurity of a First-trimester Screening for Bacterial Vaginosis in Pregnancy Through Weekly Vaginal pH Determination. An Interventional, Community Study.||Hospital Clinic of Barcelona|No|Completed|January 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1049|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 4, 2013|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00799500||146781|
NCT00803933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|289-C-006|Trial of DB289 for the Treatment of Stage I African Trypanosomiasis|Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis||Immtech Pharmaceuticals, Inc|No|Completed|February 2003|June 2005|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|15 Years|50 Years|No|||December 2008|December 5, 2008|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803933||146442|
NCT00803946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30275|Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Ibuprofen Tablet Formulations in Normal, Healthy Men and Women Following Standard Meal||Perrigo Company||Completed|November 2003|||November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00803946||146441|
NCT00803283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015328|A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain|A Randomized, Open-Labeled, Multi-Center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Comparing With Morphine SR in Cancer Pain Patients||Johnson & Johnson Taiwan Ltd||Terminated|November 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|December 4, 2008|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00803283||146492|This study had inadequate number of participants. 'The study was terminated early and the data for efficacy assessments were missing.
NCT00803296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMI-INK|Incretin Effect in Lean and Obese Subjects|The Impact of Obesity and Insulin Resistance on the Incretin Effect in Patients With Type 2 Diabetes and Healthy Subjects|BMI-INK|University Hospital, Gentofte, Copenhagen|No|Completed|January 2006|June 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|32|Samples With DNA|Blood samples|Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Lean and obese patients with type 2 diabetes; and matched healthy control subjects.|December 2008|January 12, 2010|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803296||146491|
NCT00803309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05498|Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients|Optimization of Treatment for Patients With Chronic Hepatitis C Infected With HCV-genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response|OPTEX2/3|HepNet Study House, German Liverfoundation|Yes|Terminated|November 2008|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|December 4, 2008||No|At the end of the planned recruitment period the expected number of subjects could not be    included in the trial.|No||https://clinicaltrials.gov/show/NCT00803309||146490|
NCT00803582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003879|Effectiveness of Acupuncture for Phonotraumatic Injuries|Effectiveness of Acupuncture for Phonotraumatic Injuries||The University of Hong Kong|Yes|Recruiting|February 2007|February 2010|Anticipated|February 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|135|||Both|20 Years|55 Years|No|||January 2010|January 20, 2010|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803582||146469|
NCT00803920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03404-06-C|Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide|CGM Substudy, Addendum 2, of the Following Exenatide LAR Protocol 2993LAR-105: A Randomized, Open-Label, Multicenter, Comparator Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications)||HealthPartners Institute|No|Completed|December 2006|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|||Both|16 Years|N/A|No|Non-Probability Sample|Up to eighteen subjects at the International Diabetes Center study site will be selected        for this substudy in accordance with protocol 2993LAR-105|August 2013|December 2, 2015|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803920||146443|
NCT00803348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0895-B|Continuous Femoral Nerve Blockade and Readiness to Discharge Following Total Knee Arthroplasty|The Secret Recipe for Femoral Nerve Blockade After Total Knee Arthroplasty: A Randomized, Placebo-controlled, Double-blind Trial||University Health Network, Toronto|No|Completed|May 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|85 Years|No|||January 2010|April 25, 2012|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803348||146487|
NCT00803972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ2-08-04|Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20|A Phase I, Randomized, Dose-Ranging, Pharmacokinetic, Glucodynamic, Safety, and Tolerability Study of SC Administered Humulin R and Humalog With or Without Recombinant Human Hyaluronidase (rHuPH20) in Healthy Volunteers||Halozyme Therapeutics|No|Active, not recruiting|November 2008|January 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803972||146439|
NCT00787709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-08-00437|Translational Obesity Research|Translational Research: Applying Drug Prevention to Obesity Prevention|Pathways|University of Southern California|Yes|Recruiting|May 2007|April 2012|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2400|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2008|November 6, 2008|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787709||147667|
NCT00788333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA191-004|Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer|A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin®) in Subjects With Advanced or Metastatic Her-2-positive Breast Cancer||Bristol-Myers Squibb|No|Completed|July 2009|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||July 2012|July 12, 2012|November 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788333||147621|
NCT00788346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5.12.05|Reducing the Unnecessary Use of Heavily Marketed Medications: A Randomized Controlled Trial|Reducing Unnecessary Use of Heavily Marketed Medicines: A Randomized Controlled Trial of Computerized Prescribing Alerts and Clinician Education||VA Boston Healthcare System|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|257|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2008|December 19, 2012|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788346||147620|
NCT00788658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC 5139|Cognitive Behaviour Therapy for Patients With IBS|Cognitive Behavior Therapy (CBT) as Compared With Standard Therapy for Patients With IBS and Other Functional Gastrointestinal Disorders|EFI|Rabin Medical Center|Yes|Not yet recruiting|December 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||November 2008|November 10, 2008|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788658||147597|
NCT00788957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060447|Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)|A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab Versus Panitumumab Alone in Subject With Wild-Type KRAS Metastatic Colorectal Cancer||Amgen||Completed|October 2008|October 2013|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|153|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|October 23, 2008|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT00788957||147574|
NCT00789282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200500865|Improving the Care of Diabetic Patients: A Randomized Trial of a Family Physician Office-Based Chronic Disease Care Model for Patients With Type 2 Diabetes|Single-blinded, Two-arm, Randomized Clinical Trial of Patients With Type 2 Diabetes Mellitus That Will Compare'Usual Care' With an 'Enhanced Care' Model of Chronic Disease Management That is Based in the Practices of Family Physicians Participating in Primary Care Networks (PCN's).||University of Alberta|No|Recruiting|February 2008|December 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|306|||Both|40 Years|75 Years|No|||November 2011|November 23, 2011|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00789282||147549|
NCT00803634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CLV-08-01|Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)|A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)|PRONTO|The Medicines Company|Yes|Completed|December 2008|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|December 3, 2008|Yes|Yes||No|June 3, 2014|https://clinicaltrials.gov/show/NCT00803634||146465|
NCT00801489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0147|Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias|A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Recruiting|April 2007|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801489||146629|
NCT00800098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11252008-1355|Effects of an Herbal Topical Cream on Osteoarthritis Symptoms, Biomarkers, and Disease Progression in the Knee|Effects of an Herbal Topical Cream on Osteoarthritis Symptoms, Biomarkers, and Disease Progression in the Knee||Stanford University||Completed|December 2008|February 2010|Actual|September 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|40 Years|70 Years|No|||June 2013|June 21, 2013|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00800098||146736|
NCT00802360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-04|MENOPUR® Versus FOLLISTIM®|A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR® Versus FOLLISTIM® in GnRH Antagonist Cycles||Ferring Pharmaceuticals|No|Completed|December 2008|January 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|173|||Female|18 Years|42 Years|No|||October 2011|October 31, 2011|December 3, 2008|Yes|Yes||No|May 3, 2011|https://clinicaltrials.gov/show/NCT00802360||146563|This was an exploratory study that could be used as the basis for larger, adequately-powered studies. This limitation is the reason no statistical analyses are offered for study outcomes.
NCT00802373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-001|Solifenacin Succinate Versus Tolterodine 4mg Once Daily|Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial|STAR|Astellas Pharma Inc|No|Completed|July 2003|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1355|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|December 2, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00802373||146562|
NCT00802386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 07-358|Bacterial Vaginosis Screening at IUD Insertion|Screening for Bacterial Vaginosis Screening at IUD Insertion: Is There a Role?||St. Michael's Hospital, Toronto|No|Completed|January 2008|May 2011|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|Samples With DNA|WHOLE BLOOD; VAGINAL SWAB|Female|18 Years|48 Years|Accepts Healthy Volunteers|Probability Sample|Women between the ages of 18 and 48, who request to have an IUD inserted, both for        contraceptive and noncontraceptive indications, will be asked to participate in the study.|July 2015|July 30, 2015|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802386||146561|
NCT00802399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0300/08|Partial Lacrimal Punctual Occlusion|Partial Lacrimal Punctual Occlusion in the Management of Dry Eye|PLPO|University of Sao Paulo General Hospital|Yes|Completed|September 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|40 Years|70 Years|No|||August 2008|January 21, 2009|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802399||146560|
NCT00799747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2060C00007|Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study in Healthy Japanese Male Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD4017 After Single Ascending Oral Doses||AstraZeneca|No|Completed|December 2008|April 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|56|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 30, 2009|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799747||146762|
NCT00795730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3230A1-1002|Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|January 2009|June 2009|Anticipated|June 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 20, 2009|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00795730||147063|
NCT00800072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-07-MD-015|NOWOX Oxygen Therapy Monitoring Device|Evaluation of NOWOX: a Medical Device Developed to Record Duration of Oxygen Use and Respiration Rate in Patients Requiring Oxygen Therapy||Air Liquide SA|No|Completed|November 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|75 Years|No|||February 2014|February 26, 2014|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00800072||146738|
NCT00800319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33-001|ALK33-001: A Study of RDC-0313 Administered to Healthy Adults|ALK33-001: A Phase 1 Study of the Pharmacokinetics of RDC-0313 Administered to Healthy Adults||Alkermes, Inc.|Yes|Completed|December 2008|June 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 19, 2011|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00800319||146719|
NCT00801541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTM326_A9010002|Characterization of Early Markers of Choroidal Neovascularization|Characterization of Early Markers of Choroidal Neovascularization in Fellow Eyes of Patients With AMD and CNV in One Eye. (CNV-Markers)|CNV-Markers|Association for Innovation and Biomedical Research on Light and Image|Yes|Completed|December 2005|June 2014|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|50 Years|N/A|No|Non-Probability Sample|Patients of either sex, any race, aged over 50 years and over, diagnosed with exudative        (wet) AMD in one eye (non-study eye) and non-exudative (dry) AMD (intermediate or        large/confluent drusen, with hyperpigmentation, and no CNV or geographic atrophy) in the        other eye (study eye) that is at risk for progressing to exudative (wet) AMD and meet all        the inclusion and exclusion criteria.|April 2014|March 18, 2015|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801541||146625|
NCT00802412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUA-003-08S|Topiramate to Aid Smoking Cessation in Alcohol Dependent Men|Topiramate to Aid Smoking Cessation in Recovering Alcohol Dependent Men||VA Office of Research and Development|Yes|Active, not recruiting|January 2009|June 2015|Anticipated|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Male|18 Years|70 Years|No|||May 2015|May 13, 2015|December 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802412||146559|
NCT00802425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-111-CL-08-01|Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss|Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study||Auris Medical, Inc.|Yes|Completed|December 2008|October 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|60 Years|No|||June 2014|June 24, 2014|December 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802425||146558|
NCT00800085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD_BF_01|Beta Cell Function in (Pre) Type 1 Diabetes|Beta Cell Function in (Pre) Type 1 Diabetes||AZ-VUB|No|Enrolling by invitation|October 2006|October 2015|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|5 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00800085||146737|
NCT00788359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0366|Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation|Multi-center Trial to Validate Protein Biomarkers of a Pulmonary Exacerbation in Cystic Fibrosis||University of Colorado, Denver|No|Completed|December 2007|July 2014|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|123|Samples Without DNA|Blood (plasma)|Both|10 Years|N/A|No|Non-Probability Sample|Individuals with CF greater than or equal to 10 years of age who are being started on        intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation. Patients        must demonstrate at least 3 of the 11 criteria for pulmonary exacerbation as defined by a        Cystic Fibrosis Foundation (CFF) Consensus Conference. Treatment with a minimum of two IV        antibiotics is required. We expect to enroll an approximately equal number of males and        females. Most CF patients in our clinics are of white, non-Hispanic origin and we        anticipate this ethnic mix to persist in this study. The majority of pediatric CF subjects        will be admitted to the hospital for treatment purposes whereas many adults receive their        IV antibiotics at home.|December 2014|December 1, 2014|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00788359||147619|
NCT00788671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0094|Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC)|A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2008|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||September 2015|September 2, 2015|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788671||147596|
NCT00788684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-166|Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers|A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid Malignancies||AbbVie|No|Active, not recruiting|July 2009|September 2016|Anticipated|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|99 Years|No|||January 2016|January 7, 2016|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00788684||147595|
NCT00788970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lichtenberg3|Shiatsu Adjuvant Therapy And Placebo For Schizophrenia|Shiatsu Adjuvant Therapy And Placebo For Schizophrenia:a Double Blind Study||Herzog Hospital|Yes|Not yet recruiting|January 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||January 2009|January 12, 2009|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00788970||147573|
NCT00780962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000095|N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients|N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients||Beth Israel Deaconess Medical Center|Yes|Recruiting|October 2007|October 2011|Anticipated|October 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|||Anticipated|800|||Both|18 Years|N/A|No|||October 2008|October 27, 2008|October 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00780962||148177|
NCT00801762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10142008-1319|Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology|Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology||Stanford University||Recruiting|September 2008|June 2009||||N/A|Observational|Time Perspective: Prospective||||30|||Both|N/A|N/A|No|||December 2008|December 2, 2008|December 2, 2008||||No||https://clinicaltrials.gov/show/NCT00801762||146608|
NCT00801775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mayr-PD-01|Improved Diagnosis of Peritoneal Dialysis Peritonitis by Calorimetry|Improved Diagnosis of Peritoneal Dialysis Peritonitis by Calorimetry||University Hospital, Basel, Switzerland|No|Terminated|August 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|N/A|N/A|No|Non-Probability Sample|Patients on peritoneal dialysis|June 2011|June 10, 2011|December 3, 2008||No|The study was stopped march 2009 due to recruitment problems.|No||https://clinicaltrials.gov/show/NCT00801775||146607|
NCT00801788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC-EG-001|Single Dose Pharmacokinetics of Egalet® Oxycodone|||Egalet Ltd|No|Completed|September 2008|February 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 30, 2013|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801788||146606|
NCT00802477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU9339|Application Of Autologous Blood Products During Modified Radical Mastectomy|Prospective Randomized Study Comparing Mastectomy Outcomes With Versus Without the Application of Autologous Blood Products to the Surgical Site||Marshall University|Yes|Recruiting|December 2008|March 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|July 29, 2011|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802477||146554|
NCT00802490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-A/07/472|Effectiveness of a Electroencephalogram (EEG) Biofeedback for the Treatment of ADHD|Pilot Trial of a Brain-computer Interface System Based Programme for the Treatment of ADHD|EEG|National Healthcare Group, Singapore|Yes|Completed|May 2008|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|7 Years|12 Years|No|||February 2013|February 20, 2013|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00802490||146553|
NCT00801567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001958|Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation|A Magnetic Resonance Spectroscopy Study of Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation||Mclean Hospital|No|Withdrawn|June 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|December 2, 2008||No|Departure of essential Co-Investigator from McLean Hospital|No||https://clinicaltrials.gov/show/NCT00801567||146623|
NCT00801580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL0206|My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia|Open Label, Non-randomized, Phase II Study on Fractioned Cyclophosphamide, Vincristine, Liposomal Doxorubicin or Doxorubicin, and Dexamethasone (MY HYPER-CVAD) in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia||University of Bologna||Recruiting|March 2008|September 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|N/A|No|||September 2009|September 14, 2009|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801580||146622|
NCT00803322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Improving Community Based Tuberculosis Care in Ethiopia|Community Health Workers Improve Tuberculosis Case Notification and Treatment Success in Southern Ethiopia|community|University of Bergen|No|Completed|September 2006|April 2008|Actual|September 2007|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|318|||Both|N/A|N/A|No|Probability Sample|suspects of pulmonary tuberculosis in the study are. In group two suspects were identified        and treated bo community health workers while in group on used the conventional health        facility based tuberculosis diagnosis and treatment|December 2008|December 4, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00803322||146489|
NCT00803335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08135-08-076|The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse|The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial||TriHealth Inc.|No|Completed|December 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Female|45 Years|N/A|No|||February 2014|May 25, 2015|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00803335||146488|
NCT00795743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070692|Coagulation Changes in Trauma Patients|The Effect of Central Venous Catheters on Systemic Coagulation||University of Miami|No|Completed|February 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|PAtients requiring placement of a central venous catheter.|May 2014|May 5, 2014|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795743||147062|
NCT00794885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ausa-CSPPT|China Stroke Primary Prevention Trial|Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.|CSPPT|Shenzhen Ausa Pharmed Co.,Ltd|Yes|Completed|May 2008|June 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20702|||Both|45 Years|75 Years|No|||August 2014|August 11, 2014|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794885||147126|
NCT00800644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0023|Pelvic Fractures and Radiation Therapy for Cervical Cancer|Evaluation of Bone Density and Pelvic Fractures in Women Undergoing Definitive Pelvic Radiation Therapy for Cervical, Endometrial or Vaginal Cancer||M.D. Anderson Cancer Center|No|Recruiting|November 2008|||November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Female|N/A|N/A|No|Non-Probability Sample|Cervical, endometrial, or vaginal cancer patients who will receive extended field        radiation, brachytherapy, or pelvic radiation therapy.|December 2015|December 18, 2015|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800644||146694|
NCT00801281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-CVP/CHOP|First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.|First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG.|PLRG4|Polish Lymphoma Research Group|Yes|Active, not recruiting|February 2007|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801281||146645|
NCT00801294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1239.2|A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer|A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer||Boehringer Ingelheim||Completed|July 2006|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|46|||Both|19 Years|N/A|No|||October 2013|October 30, 2013|December 2, 2008||||No||https://clinicaltrials.gov/show/NCT00801294||146644|
NCT00802152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095618|Using Health Information Technology (HIT) to Improve Ambulatory Chronic Disease Care: Smart Device Substudy|Using Health Information Technology (HIT) to Improve Ambulatory Chronic Disease Care: Smart Device Substudy||University of Missouri-Columbia|No|Completed|May 2009|June 2011|Actual|December 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||August 2011|August 9, 2011|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00802152||146579|
NCT00802737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111827|Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)|A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406||GlaxoSmithKline|No|Completed|January 2009|May 2013|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|December 4, 2008|Yes|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00802737||146534|
NCT00802750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-LSM-0001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||September 27, 2012|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802750||146533|
NCT00803062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01084|Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer|A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix||National Cancer Institute (NCI)|Yes|Completed|April 2009|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|450|||Female|18 Years|N/A|No|||February 2015|May 22, 2015|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803062||146509|
NCT00803075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11092007-864|Endovascular Repair of Abdominal Aortic Aneurysms|TALENT Endoluminal Stent Graft System for the Treatment of Abdominal Aortic Aneurysms||Stanford University||Completed|February 2002|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||200|||Both|18 Years|N/A|No|||December 2008|December 18, 2008|December 4, 2007||||||https://clinicaltrials.gov/show/NCT00803075||146508|
NCT00803088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01|Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma|A Multicenter Clinical Trial Evaluating the Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma.|3to2|Asthmatx, Inc.|Yes|Withdrawn|July 2010|||December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||June 2015|June 17, 2015|December 4, 2008|No|Yes|Current treatment regimen of 3 procedures considered acceptable.|No||https://clinicaltrials.gov/show/NCT00803088||146507|
NCT00797329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222CTIL|Biological and Cognitive Markers of Violent Behavior in Forensic Patients With Polysubstance Use: Retrospective Evaluation|||BeerYaakov Mental Health Center||Active, not recruiting|July 2008|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Male|19 Years|65 Years|No|Non-Probability Sample|Age between 19-65 years; men with verified diagnoses of alcohol and polydrug use according        to DSM-IV criteria; hospitalized in maximum security department between 2002 - 2008.|November 2008|November 24, 2008|November 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00797329||146944|
NCT00797342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0881001|A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers|A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of PF-04629991 in Healthy Volunteers||Pfizer|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 1, 2009|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00797342||146943|
NCT00788021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000709|Protective Immunity Project 01|Characterization of the Impact of Chronic Immunosuppressive Regimens on Protective Immunity Over Time in Renal Transplant Recipients|PIP-01|Emory University|Yes|Completed|September 2006|October 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|124|Samples Without DNA|Whole blood, serum, PBMCs|Both|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing deceased or living donor renal transplant|November 2013|November 21, 2013|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788021||147643|
NCT00788034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12473A|Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder|A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder||H. Lundbeck A/S|No|Completed|October 2008|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|459|||Both|18 Years|75 Years|No|||December 2012|June 22, 2015|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00788034||147642|
NCT00788372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015583|An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain|A Long-Term Study of JNS020QD in Patients With Chronic Pain||Janssen Pharmaceutical K.K.|No|Completed|November 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|142|||Both|20 Years|N/A|No|||June 2013|June 25, 2013|November 6, 2008|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT00788372||147618|
NCT00788385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDX01-22-2001|Multi-Center Study of ShuntCheck|Multi-Center Study of ShuntCheck||NeuroDx Development|No|Withdrawn|June 2009|December 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|0|||Both|1 Month|19 Years|No|||April 2015|April 13, 2015|November 7, 2008|No|Yes|Insufficient funding|No||https://clinicaltrials.gov/show/NCT00788385||147617|
NCT00780325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807821|Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition|A Single Center, Double-blind, Placebo-controlled Phase I Single-dose Cross-over Study in Healthy Subjects to Investigate the Inhibitory Effect of CG100649, Celecoxib, Naproxen, and Acetazolamide on the Activity of Cyclooxygenases (COX-1, COX-2) and Carbonic Anhydrases (CA-I, CA-II)||University of Pennsylvania|No|Terminated|October 2008|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|October 24, 2008|No|Yes|A total of three parts were planned for this study. The sponsor funded only Part 1, so that    neither Part 2 nor Part 3 of this study has been conducted.|No||https://clinicaltrials.gov/show/NCT00780325||148224|
NCT00780338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-023277|Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes|Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes|AGTO|RAND|No|Completed|June 2008|March 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|376|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|October 24, 2008||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00780338||148223|
NCT00780637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070517|Brachial Artery t-PA Release in Heart Transplant Recipients|Characterization of Brachial Arterial t-PA Release, Vasodilator Function, and Vascular Compliance and Correlation With Fibrinolytic Balance, Oxidative Stress, and Inflammation Measures in Heart Transplant Recipients (SCCOR Project 1, Aim 3C)|P1A3C|Vanderbilt University|Yes|Enrolling by invitation|October 2008|May 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2009|June 24, 2009|October 24, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00780637||148200|
NCT00786682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617998|Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer|A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer||Rutgers, The State University of New Jersey|No|Terminated|December 2008|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|18 Years|N/A|No|||September 2013|September 23, 2013|November 5, 2008|Yes|Yes|Lack of improved efficacy compared to historical controls, competing studies|No|September 23, 2013|https://clinicaltrials.gov/show/NCT00786682||147742|
NCT00786695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/00/764|Study Using Esomeprazole as a Diagnostic Test for GERD in Patients With NCCP|Esomeprazole as a Diagnostic Test for Gastroesophageal Reflux Disease in Patients With Noncardiac Chest Pain|ECP|National University Hospital, Singapore|No|Completed|May 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2011|March 2, 2011|November 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00786695||147741|
NCT00799513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-003729-18|Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma|A Phase II Trial to Evaluate the Safety and Activity of Single-agent Lenalidomide Given as Maintenance Therapy After Response to Second-line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-dose Chemotherapy and ASCT||IRCCS San Raffaele|Yes|Recruiting|October 2009|November 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|65 Years|N/A|No|||March 2012|March 21, 2012|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799513||146780|
NCT00799526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1075/08|Transplant of Epithelium Conjunctival Human Autologous Cultivated ex Vivo in Amniotic Membrane for the Treatment of Symblepharon|||Federal University of São Paulo|Yes|Active, not recruiting|November 2008|November 2010|Anticipated|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|16 Years|90 Years|Accepts Healthy Volunteers|||November 2008|November 28, 2008|November 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00799526||146779|
NCT00803985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|596/2007|Study Comparing Total Extraperitoneal Patch "TEP" Versus Lichtenstein According Chronic Pain|Prospective Randomised Study Comparing TEP vs Lichtenstein in Primary Unilateral Inguinal Hernias According Chronic Pain|TEP-LICH|Skane University Hospital|No|Recruiting|April 2008|December 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|30 Years|75 Years|No|||December 2008|May 4, 2012|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00803985||146438|
NCT00799773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|558|Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)|STAR - Study of TTP and Rituximab, A Randomized Clinical Trial|STAR|New England Research Institutes|Yes|Terminated|April 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|12 Years|N/A|No|||July 2013|July 18, 2013|November 26, 2008|Yes|Yes|Low enrollment rate|No|May 7, 2013|https://clinicaltrials.gov/show/NCT00799773||146760|One treatment arm had only one subject, so to protect patient confidentiality, results are not being entered.
NCT00801320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-319|Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Study of Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer (Ovarian Spore)||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2008|December 2016|Anticipated|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00801320||146642|
NCT00801814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL-5051|Effect of Escalating Doses of a Novel Viscous Polysaccharide on Postprandial Glycemia|Effect of Adding Escalating Doses of a Novel Highly Viscous Polysaccharide to Either a Liquid or a Solid Test Meal on Post Prandial Glycemia in Healthy Subjects: Determination of the Glycemic Reduction Index Potential (GRIP)||Glycemic Index Laboratories, Inc|No|Completed|April 2006|August 2006|Actual|May 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2008|December 3, 2008|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00801814||146604|
NCT00801879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB0129|Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection|Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection||Columbia University|No|Completed|September 2003|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 28, 2014|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00801879||146600|
NCT00795470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 08-287|Factorial Trial of Antimicrobial Therapy and/or Catheter Change for Catheter Urinary Tract Infections.|A Pilot Concealed Randomized Double-blinded Placebo-controlled Factorial Trial of Antimicrobial Therapy and/or Catheter Change for Catheter-associated Urinary Tract Infections in the Critically Ill|CAUTION|St. Michael's Hospital, Toronto|Yes|Withdrawn|January 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|November 20, 2008||No|Not pursuing the study due to funding issues|No||https://clinicaltrials.gov/show/NCT00795470||147083|
NCT00794898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03027|Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)|Onset of Efficacy of Anti-TNF Chimeric Monoclonal Antibody (Remicade) in the Treatment of Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment||Merck Sharp & Dohme Corp.|No|Completed|July 2003|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|November 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00794898||147125|
NCT00794911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000171|Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation|Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation||Beth Israel Deaconess Medical Center|Yes|Completed|September 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|75|||Both|21 Years|70 Years|No|||March 2011|March 9, 2011|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00794911||147124|
NCT00796003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015406|A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome|A Phase I/II Clinical Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome||Janssen Pharmaceutical K.K.|Yes|Completed|July 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|20 Years|N/A|No|||October 2013|October 10, 2013|November 20, 2008||No||No|May 31, 2013|https://clinicaltrials.gov/show/NCT00796003||147042|
NCT00801827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#061246|PET Imaging and Bariatric Surgery|PET Imaging and Bariatric Surgery||Vanderbilt University|No|Completed|January 2007|June 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|plasma and serum|Both|18 Years|60 Years|No|Non-Probability Sample|BMI greater than 35, ages 18-60, pending weight loss surgery|March 2011|December 12, 2015|December 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801827||146603|
NCT00801853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPD/2007/AER 001 DPI/2b|A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL|A Phase IIb Study to Investigate the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients Not Fully Controlled on Current Therapy||Aerovance, Inc.|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|424|||Both|18 Years|N/A|No|||November 2009|January 25, 2011|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00801853||146602|
NCT00802763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-7-28.1-1 VER-2|Performance Proof of the New NORMA-SENSE|Performance Proof of the New NORMA-SENSE Panty Liner - in-Vivo STUD||Carmel Medical Center|Yes|Not yet recruiting|February 2009|August 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|224|None Retained|VAGINAL SECRETIONS|Female|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Women, age greater then 18 without symptoms of vaginal infection.|December 2008|December 4, 2008|December 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00802763||146532|
NCT00803621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07009|Cerebral Toxoplasmosis and AIDS|Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii.|TOXODFA|University Hospital, Limoges|No|Completed|June 2009|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|AIDS patients from the French West Indies and French Guiana having clinical and        radiological suspicion of cerebral toxoplasmosis|December 2013|March 22, 2014|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00803621||146466|
NCT00803959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ValUE (completed)|Value of Urodynamic Evaluation|A Randomized Trial of Urodynamic Testing Before Stress-Incontinence Surgery|ValUE|New England Research Institutes|No|Completed|November 2008|June 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|630|||Female|21 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 3, 2013|December 5, 2008||No||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00803959||146440|
NCT00796367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-305|A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)|A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.||VIVUS, Inc.|Yes|Completed|December 2008|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|676|||Both|18 Years|70 Years|No|||September 2012|September 5, 2012|November 20, 2008|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00796367||147015|
NCT00796380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TNC-00000097|Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases|Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases||Shenzhen Children's Hospital|Yes|Not yet recruiting|December 2008|July 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|1|||Both|1 Month|18 Years|No|||November 2008|November 21, 2008|November 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796380||147014|
NCT00788047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451022|A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan|A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects||Pfizer|No|Completed|November 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|November 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788047||147641|
NCT00788060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000548|A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma|A Single Arm, Phase Ib Study of RAD001 and Sunitinib in Patients With Advanced Renal Cell Carcinoma|Rad/Sutent|Duke University|No|Completed|October 2008|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|November 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00788060||147640|
NCT00780104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02407|Sirolimus in Combination With MEC in High Risk Myeloid Leukemias|A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias|UPCC 02407|University of Pennsylvania|Yes|Completed|July 2007|June 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|October 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00780104||148241|
NCT00786162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-002440|Blood Pressure Self Management for Hypertension & Prehypertension Using an Internet Enabled, Automated Self Management Program|Blood Pressure Self Management for Hypertension & Prehypertension Using an Internet Enabled, Automated Self Management Program||Massachusetts General Hospital|No|Completed|April 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|404|||Both|30 Years|65 Years|No|||March 2012|March 14, 2012|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00786162||147782|
NCT00786409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15960A|Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women|Immunogenicity and Safety of the Quadrivalent HPV Vaccine Gardasil in Female Systemic Lupus Erythematosus Patients Aged 9-26||University of Chicago|No|Completed|November 2008|December 2011|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|27|||Female|9 Years|26 Years|No|||December 2012|September 4, 2013|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786409||147763|
NCT00786968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRC-001-01|Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I|An Extension Study of Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis I||Dickson, Patricia I., M.D.|Yes|Terminated|January 2008|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|8 Years|N/A|No|||February 2013|February 19, 2013|June 17, 2008|No|Yes|Due to slow enrolment.|No||https://clinicaltrials.gov/show/NCT00786968||147721|
NCT00800358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No: CT 08-02|Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism|A Multi Centre, Open Label, Parallel Group, Randomized Controlled Trial to Compare the Safety and Efficacy of Oral Paricalcitol Versus Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Dialysis Patients||Penang Hospital, Malaysia|Yes|Completed|November 2008|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|November 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00800358||146716|
NCT00800371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Silent Arthritis PROSPECT 2008|Magnetic Resonance Imaging (MRI) in Asymptomatic Patients With Juvenile Idiopathic Arthritis (JIA)|Diagnostic Value of MRI and Ultrasound in Patients With JIA||University Hospital Tuebingen|No|Recruiting|May 2008|June 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|7 Years|17 Years|No|Probability Sample|Patients with JIA|November 2008|December 1, 2008|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00800371||146715|
NCT00799786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11212008-1350|Building Better Caregivers Online: An Online Workshop for Caregivers of Those With Traumatic Brain Injury, Post Traumatic Stress Disorder, or Alzheimer's or Other Dementia|Building Better Caregivers Online||Stanford University||Completed|November 2008|December 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 12, 2010|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799786||146759|
NCT00802126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81613|Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy|Efficacy of Combining Intravitreal Bevacizumab With Photodynamic Therapy Using Reduced Light Fluence Rate in Choroidal Neovascularization Secondary to Pathologic Myopia.||Second University of Naples|Yes|Completed|November 2007|May 2009|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|35 Years|60 Years|No|||February 2016|February 5, 2016|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00802126||146581|
NCT00802139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-VNF-402|Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin|A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia||JW Pharmaceutical|Yes|Completed|February 2008|October 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|18 Years|N/A|No|||March 2012|March 28, 2012|December 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00802139||146580|
NCT00794924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotics and elderly|Probiotics and Hospital Outcome in the Elderly|Effects of Commercially Available Probiotics on Hospital Outcome|PROAGE|Kaplan-Harzfeld Medical Center|Yes|Completed|February 2004|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|345|||Both|N/A|N/A|No|||November 2008|November 19, 2008|October 28, 2008|Yes|Yes||No|October 28, 2008|https://clinicaltrials.gov/show/NCT00794924||147123|
NCT00795197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD02808|A Screening Study Evaluating Disease Status of Gaucher Type I Patients|A Screening Protocol to Characterize the Disease Status of Gaucher Type 1 Patients for Potential Inclusion in a Subsequent Phase 3 Clinical Study||Sanofi|No|Withdrawn|December 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|N/A||1|Actual|0|Samples Without DNA|Blood sample/Urine sample|Both|16 Years|65 Years|No|Non-Probability Sample|Gaucher Disease Type 1|May 2015|May 7, 2015|November 19, 2008||No|No recruitment of patients|No||https://clinicaltrials.gov/show/NCT00795197||147103|
NCT00796341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endometrial injury study|Endometrial Injury and IVF-ET Outcome|Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial||Bangalore Assisted Conception Centre|No|Completed|November 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Female|18 Years|37 Years|No|||November 2008|December 1, 2008|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796341||147017|
NCT00796354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL920-01/2008 (IBSc)|Constipation Associated With Irritable Bowel Syndrome (IBS-C)|A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® With Placebo in Patients With Constipation Associated With Irritable Bowel Syndrome (IBS)||Norgine|No|Completed|November 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|80 Years|No|||February 2010|February 15, 2010|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796354||147016|
NCT00796731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED6829|SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma|A Dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Once Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma (NHL)||Sanofi|No|Completed|October 2008|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|November 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796731||146988|
NCT00797017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015409|Study on Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain|Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain: Multicenter, Open Label, Prospective, Observational Study||Janssen Korea, Ltd., Korea|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|1576|||Both|20 Years|N/A|No|Probability Sample|Patients who had unsatisfactory treatment with previous medication (severe pain: NRS = 7)        and no experience with fentanyl matrix will be eligible|April 2014|April 24, 2014|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00797017||146966|
NCT00796757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO21609|A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).|An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.||Hoffmann-La Roche||Completed|December 2008|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|146|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|November 21, 2008||No||No|August 4, 2014|https://clinicaltrials.gov/show/NCT00796757||146986|
NCT00796770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB #008-017|Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)|Vaccination of HIV-1 Infected Patients With Ex-vivo Generated Interferon-α Dendritic Cells Loaded With HIV-1 Lipopeptides and Activated With Lipopolysaccharide in Addition to Antiretroviral Treatment: Exploratory Phase I Study-(DALIA Trial)||Baylor Research Institute|Yes|Completed|November 2008|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2013|May 23, 2013|November 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796770||146985|
NCT00779844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/02|Anesthesic Propofol and Remifentanil Requirements in Obese Patients|Intravenous Anesthesia in Obese Patients: Propofol and Remifentanil Requirements|LoopObese|Hopital Foch|No|Terminated|December 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|October 23, 2008||No|difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT00779844||148261|
NCT00779857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2008-2|AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery|Exclusion of the Left Atrial Appendage With the AtriClip LAA Exclusion Device in Patients Undergoing Concomitant Cardiac Surgery|EXCLUDE|AtriCure, Inc.|Yes|Completed|September 2008|October 2011|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|October 23, 2008|No|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT00779857||148260|
NCT00785889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBIRE-GI-001|RCT of Air Insufflation Versus Water Infusion Colonoscopy|A Randomized Controlled Comparison of Warm Water Infusion in Lieu of Air Insufflation vs. Air Insufflation for Aiding Colonoscopy Insertion in Sedated Patients Undergoing Colorectal Cancer (CRC) Screening and Surveillance.||East Bay Institute for Research and Education|Yes|Completed|March 2008|October 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|1||Actual|56|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||November 2008|November 13, 2008|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00785889||147803|
NCT00785902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2008-1|AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial Fibrillation||A|AtriCure, Inc.|Yes|Withdrawn||||||Phase 3|Interventional|N/A|||||||Both|18 Years|N/A|No|||February 2011|February 18, 2011|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785902||147802|
NCT00786422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13238|Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer|The EINSTEIN CYP Cohort Study Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-vein Thrombosis or Pulmonary Embolism Using a Strong CYP 3A4 Inducer||Bayer|Yes|Completed|May 2009|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 5, 2008|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00786422||147762|
NCT00786708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1584|Sensitivity and Specificity of NGAL in an Emergency Room Population|Sensitivity and Specificity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in an Emergency Room Population||Columbia University|No|Completed|December 2006|July 2013|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2304|Samples Without DNA|Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the hospital through the emergency room who meet the inclusion /        exclusion criteria for this study.|February 2014|February 7, 2014|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786708||147740|
NCT00797888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI 2007-271|Bronx A1c: Bring it Down for Health|Bronx A1c: Bring it Down for Health|Bronx A1c|Albert Einstein College of Medicine of Yeshiva University|No|Completed|September 2008|June 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|941|||Both|18 Years|85 Years|No|||September 2012|September 5, 2012|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797888||146902|
NCT00798707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-3359|Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (25 and 50 mg/Day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder||Pfizer|No|Completed|December 2008|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|709|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|November 25, 2008|Yes|Yes||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00798707||146839|
NCT00798135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809-10; IUCRO-0239|A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer|A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer||Indiana University|Yes|Completed|November 2008|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|November 24, 2008||No||No|August 25, 2014|https://clinicaltrials.gov/show/NCT00798135||146883|
NCT00800670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-001|Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine|Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine||McMaster University|Yes|Terminated|June 2009|July 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|December 1, 2008||No|Study was terminated after the low dose cohort had been enrolled|No||https://clinicaltrials.gov/show/NCT00800670||146692|
NCT00803049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS6050|Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis|Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses||Sanofi|Yes|Completed|October 2006|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|742|||Both|18 Years|55 Years|No|||January 2016|January 26, 2016|December 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00803049||146510|
NCT00799188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.489/32|CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial|CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial|CERTICOEUR|Hospices Civils de Lyon|Yes|Active, not recruiting|October 2008|||September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|65 Years|No|||December 2013|December 11, 2013|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799188||146803|
NCT00799201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01-1897|Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients|A Prospective, Randomized Trial of Enteral Naloxone Versus a Traditional Bowel Regimen in Prevention of Constipation and Decreased Gastric Motility in Critically Ill Trauma Patients||CAMC Health System|Yes|Terminated|August 2007|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3|||Both|18 Years|65 Years|No|||July 2015|July 27, 2015|November 24, 2008||No|Naloxone became unavailable due to manufacturing shortatges requiring the study to be    terminated.|No||https://clinicaltrials.gov/show/NCT00799201||146802|
NCT00795782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-09-048|Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma|Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial||Samsung Medical Center|Yes|Recruiting|January 2009|June 2014|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|258|||Both|18 Years|70 Years|No|||July 2011|July 21, 2011|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795782||147059|
NCT00795210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63639A|Effects of Short-term Growth Hormone in HIV-infected Patients|Effects of Short-term Growth Hormone in HIV-infected Patients||Massachusetts General Hospital|No|Completed|February 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|60 Years|No|||October 2013|December 6, 2013|November 20, 2008|Yes|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00795210||147102|The study was completed early due to the lack of availability of study drug for one of the arms.
NCT00795483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIH-ZOL|Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort|Efficacy and Security of Annual and Biennial Zoledronic Acid for Osteoporosis Treatment in an HIV-infected Patients' Cohort||Germans Trias i Pujol Hospital|No|Completed|November 2009|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795483||147082|
NCT00795756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILG-ALL 10/07|Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia|A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL||Northern Italy Leukemia Group|Yes|Completed|January 2008|October 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|65 Years|No|||October 2014|October 21, 2014|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795756||147061|
NCT00796029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004276|A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose|Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2003|July 2003|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|5|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796029||147041|
NCT00796042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONF-2004-SCI-SC-01|Interdisciplinary Pressure Management & Mobility Program as an Alternative to Usual Care: A Pilot Study|Interdisciplinary Pressure Management & Mobility Program as an Alternative to Bed Rest: A Pilot Study|WOUND|University of Western Ontario, Canada|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|80 Years|No|||June 2012|June 4, 2012|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796042||147040|
NCT00797407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-297|Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs|Creatine Supplementation for the Prevention of Statin Myalgia||The Cleveland Clinic|No|Completed|August 2006|December 2006|Actual|December 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|N/A|No|||November 2008|November 24, 2008|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797407||146939|
NCT00790153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00012|To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension|A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter Regulatory Response During Hypoglycaemia in Healthy Male Volunteers After a Single Oral Dose of AZD1656 Suspension in Comparison With Insulin Infusion||AstraZeneca||Completed|November 2008|February 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2009|April 9, 2009|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790153||147482|
NCT00790166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA CPAP,ThemoSmartMCC, Brasil|Effects of Humidity (During CPAP Treatment) on Mucociliary Clearance in Patients With Obstructive Sleep Apnea|Effects of nCPAP With and Without Humidification on: Inspiratory Temperature, Humidity, Saccharine Transit Time, Nasal Lavage and in Vitro Mucus Properties in Patients With Obstructive Sleep Apnea|CIA-6|Fisher and Paykel Healthcare||Terminated|October 2008|March 2010|Anticipated|October 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|No|||June 2009|June 23, 2009|November 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00790166||147481|
NCT00786175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.336|A Survey to Evaluate the Rate of Abnormal Glucose Tolerance Among Hong Kong Chinese Subjects With Coronary Heart Disease|A Cross-sectional Observational Survey to Evaluate the Rate of Diabetes and Glucose Intolerance (Both Diagnosed and Undiagnosed) Among Hong Kong Chinese Subjects With Coronary Heart Disease||Chinese University of Hong Kong|Yes|Withdrawn|October 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Hong Kong Chinese with history of coronary heart disease being diagnosed in 2008 in HA        hospitals|August 2015|August 21, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786175||147781|
NCT00786981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-36472|Epidural Steroid Injection Versus Epidural Steroid Injection and Manual Physical Therapy and Exercise in the Management of Lumbar Spinal Stenosis|Epidural Steroid Injection Versus Epidural Steroid Injection and Manual Physical Therapy and Exercise in the Management of Lumbar Spinal Stenosis; a Randomized Clinical Trial||Franklin Pierce University|No|Recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|90 Years|No|||August 2015|August 10, 2015|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786981||147720|
NCT00787241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-015|Platelet Count Trends in Pre-eclamptic Parturients|Platelet Count Trends in Pre-eclamptic Parturients: What is the Predictive Value of an Initial Platelet Count During Labor?||Northwestern University|No|Completed|September 2002|May 2003|Actual|May 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|445|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women|March 2014|March 17, 2014|November 6, 2008||No||No|August 16, 2011|https://clinicaltrials.gov/show/NCT00787241||147702|Retrospective trial and obtaining platelet counts was not done per protocol so cannot predict the greatest interval that is acceptable to demonstrate platelet counts greater than 150,000 during labor and delivery.
NCT00798447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0603|Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery|A Prospective, Randomized, Double Blind Study to Compare the Efficacy and Safety of a n-3 Fatty Acid-containing Lipid Emulsion During Parenteral Nutrition in Patients Considered for Major Surgery for Gastric and Colorectal Cancer.||B. Braun Melsungen AG|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||June 2011|June 8, 2011|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798447||146859|
NCT00798148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-01-36-6853|131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma|Evaluation of Benefit and Side Effects of 131I-MIBG in Combination With Myeloablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma||Tehran University of Medical Sciences||Recruiting|September 2008|||July 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|14 Years|No|||May 2012|May 31, 2012|November 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00798148||146882|
NCT00798733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27355|Study of Sacral Fractures Using Patient Based and Objective Outcomes|A Multicenter Prospective Cohort Study of Sacral Fractures Using Patient Based and Objective Outcomes||Boston Medical Center|Yes|Recruiting|October 2008|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients will be recruited through the Emergency Department or Orthopaedic Clinic|November 2015|November 16, 2015|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798733||146837|
NCT00800982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOO - ENBREL-2008|Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis|A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Tolerability of Narrow Band UVB Phototherapy in Enhancing Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque-Type Psoriasis||University of California, San Francisco|Yes|Completed|October 2008|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 26, 2013|May 13, 2008|No|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00800982||146668|Of the 30 subjects enrolled, 3 were lost to follow-up, one moved out of state, and one voluntarily withdrew due to worsening of psoriasis.
NCT00800995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUG-0501|Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)|SOD as Antioxidant Treatment OF ARMD||Centre de Recherche en Nutrition Humaine Rhone-Alpe|No|Completed|September 2005|June 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|46|||Both|N/A|N/A|No|||December 2008|December 2, 2008|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00800995||146667|
NCT00798954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKT|Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial|A Multi-center Trial to Evaluate Paclitaxel- and Sirolimus-eluting Stents in Provisional T-stenting With Kissing Balloon Technique in the Treatment of Bifurcation Lesions|SINGLEKISS|Vulnerable Plaque Society|Yes|Completed|June 2007|March 2010|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|80 Years|No|||June 2010|June 9, 2010|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00798954||146821|
NCT00798967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-020|Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects|A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome|STEPS|Shire|Yes|Completed|November 2008|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||January 2015|November 10, 2015|November 25, 2008|Yes|Yes||No|December 23, 2011|https://clinicaltrials.gov/show/NCT00798967||146820|
NCT00798980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14015|Scandinavian Mirena Insertion Nulliparous Trial.|Scandinavian Mirena Insertion Nulliparous Trial of an Observational Study.||Bayer|No|Completed|February 2007|November 2009|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|224|||Female|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Clinic Patients|April 2015|April 21, 2015|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00798980||146819|
NCT00798993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCGH25OHD2008|Effect of 25-hydroxyvitamin D and a Structured Exercise Program on Dialysis Patients|The Effect of 25-hydroxyvitamin D Supplementation and a Structured Exercise Program on Exercise Capacity and Quality of Life in Dialysis Patients||Sir Charles Gairdner Hospital|No|Completed|January 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00798993||146818|
NCT00799214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02330|BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study|Back to BASICS: Boric Acid, Alternate Solution for Intravaginal Colonization, Comparing Intravaginal Metronidazole to Boric Acid in Women Symptomatic for Bacterial Vaginosis||University of British Columbia|No|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00799214||146801|
NCT00799227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-018|Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema|||Allergan|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|November 26, 2008|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00799227||146800|
NCT00796458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOUP-01/04|Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer|Phase III Study of Chemo-hormonal Therapy Versus Hormonal Therapy Alone in Advanced Hormone-naives Prostate Cancer Patients.||National Cancer Institute (NCI)||Recruiting|April 2005|||October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Male|18 Years|N/A|No|||November 2008|August 9, 2013|November 21, 2008||||No||https://clinicaltrials.gov/show/NCT00796458||147009|
NCT00796471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004282|A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations|A Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics Under Fasting and Fed Conditions of 2 Paliperidone Extended-release Formulations With Paliperidone Oral Solution in Healthy Adults||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2003|August 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796471||147008|
NCT00796484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL888-001|Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors||Exelixis||Terminated|November 2008|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|November 20, 2008|No|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT00796484||147007|
NCT00796068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2275.00|Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant|Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen||Fred Hutchinson Cancer Research Center|No|Recruiting|October 2008|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|65 Years|No|||December 2015|December 16, 2015|November 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796068||147038|
NCT00795496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232685|Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up|Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up||Helsinki University|No|Completed|November 2008|August 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|50|Samples Without DNA|Serum is collected for measurement of IgE|Both|N/A|N/A|No|Probability Sample|The investigators invite all patients who participated in the FG-506-06-21 tacrolimus        ointment study, and who at baseline in that study were tested for bronchial        hyperreactivity.|November 2008|April 19, 2011|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795496||147081|
NCT00795509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121187|Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).|Special Investigation For Long Term Use Of Detrusitol (Regulatory Post Marketing Commitment Plan).||Pfizer|No|Completed|August 2007|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|374|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6121187 prescribes the Tolterodine tartrate        (Detrusitol® Capsule).|June 2012|June 5, 2012|November 19, 2008|No|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00795509||147080|
NCT00795769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2247.00|Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant|Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells||Fred Hutchinson Cancer Research Center|No|Completed|August 2008|||September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|21 Years|N/A|No|||August 2010|August 26, 2010|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00795769||147060|
NCT00796055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP177|Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors|A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression|MEDI-547|MedImmune LLC|No|Terminated|August 2009|June 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|November 20, 2008|No|Yes|MI-CP177 study closed per sponsor decision.|No||https://clinicaltrials.gov/show/NCT00796055||147039|
NCT00796393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10308|Study of the Effects of Probiotics Upon Infectious Episodes in Subject Aged More Than 60, During Winter.|Effects of Daily Consumption of a Probiotic on the Evolution of Infectious Episodes (ENT, Gastro-intestinal and Pulmonary), in Subject Aged 60 Years or Over, During Winter.||Institut Rosell Lallemand|No|Completed|November 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|200|||Both|60 Years|74 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796393||147013|
NCT00796419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002187|Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)|Phase III Study Comparing Albumin and Hetastarch Therapy in Acute Lung Injury|CEASE|Emory University|Yes|Terminated|January 2009|July 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796419||147012|
NCT00797082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070149|Magnetic Resonance Diabetic Cardiac Stress Imaging|Magnetic Resonance Diabetic Cardiac Stress Imaging : MRDIABETICS|MRDiabetics|Assistance Publique - Hôpitaux de Paris|No|Terminated|November 2008|July 2012|Actual|March 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|62|||Both|18 Years|N/A|No|||July 2012|July 29, 2012|October 27, 2008||No|default of inclusion|No||https://clinicaltrials.gov/show/NCT00797082||146961|
NCT00798187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0594|Cancer Support Programs|Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2009|||November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|240|||Both|21 Years|N/A|No|Probability Sample|Participants, 21 years of age or older, diagnosed with Prostate Cancer or Breast Cancer.|February 2016|February 29, 2016|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00798187||146879|
NCT00798200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WorkForceOntario 001|Community Based Exercise Program for Well Cancer Survivors|CanWell: YMCA Based Exercise Program for Well Cancer Survivors|CanWell|McMaster University|No|Completed|March 2009|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|200|||Both|16 Years|N/A|No|||March 2016|March 2, 2016|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798200||146878|
NCT00785915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6702C00013|AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects|A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects|JSAD/JMAD|AstraZeneca|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|November 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00785915||147801|
NCT00785928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12409|A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy|Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy||Eli Lilly and Company|No|Completed|October 2008|December 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|158|||Both|18 Years|75 Years|No|||February 2011|February 11, 2011|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00785928||147800|
NCT00786721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2002-2608|Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort|Diffuse Optical Spectroscopy Measurement Technique is Helping Develop More Effective Diagnostic Tools and Therapeutic Regimes for Diabetes, Metabolic Syndrome and Other Mitochondrial Diseases Some Time in the Future||University of California, Irvine|No|Completed|November 2006|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic, community sample, residents in a Southern California Chinese Cohort|August 2015|August 5, 2015|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786721||147739|
NCT00787007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-CT01|Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers|Randomized, Double-Blind, Single Rising Dose Study of S-equol in Normal Volunteers||Ausio Pharmaceuticals, LLC|Yes|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|November 6, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00787007||147718|
NCT00787254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-1749-CCT-352|Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs|A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug||Takeda|Yes|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|366|||Both|20 Years|N/A|No|||February 2012|February 1, 2012|November 6, 2008||No||No|February 3, 2011|https://clinicaltrials.gov/show/NCT00787254||147701|This study was prematurely discontinued due to results available from a parallel study (AG-1749-CCT-351; NCT00762359) demonstrating a preventive effect on ulcer occurrence which impacted the risk/benefit profile.
NCT00787540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0051-08 HYMC|Chest Pain, Illness Perception Compliance and Psychosocial Outcome After Coronary Arteriography|||Hillel Yaffe Medical Center||Not yet recruiting|January 2009|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Both|18 Years|88 Years|No|Probability Sample|Patients who present to the coronary unit at the Hillel Yaffe Medical Center, Hadera,        Israel|November 2008|November 6, 2008|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787540||147680|
NCT00787553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920/2006|Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy|Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy||University of Campinas, Brazil|Yes|Active, not recruiting|July 2006|December 2008|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|75|||Female|32 Years|72 Years|No|||November 2008|November 6, 2008|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787553||147679|
NCT00798746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0465|Quality of Life After Esophagectomy for Cancer|Role of Pyloric Drainage in Reflux Symptoms After Esophagectomy for Cancer||M.D. Anderson Cancer Center|No|Completed|November 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|88|||Both|18 Years|N/A|No|Non-Probability Sample|Adults who received minimally invasive or transthoracic or transhiatal or three-field        esophagectomy for primary esophageal cancer at MDACC during or after 2004.|July 2012|July 27, 2012|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798746||146836|
NCT00799006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0961001|A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Subjects||Pfizer|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 17, 2009|November 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799006||146817|
NCT00798434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221045|A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.|A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.|SOFIA|Pfizer|No|Completed|June 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|794|||Both|65 Years|N/A|No|||November 2011|November 8, 2011|November 25, 2008||No||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00798434||146860|The descriptive statistics and analyses of outcome measure 12 as defined in the protocol are not presented. Results are presented as defined in the statistical analysis plan.
NCT00798720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0229|Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer|Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer||University of Wisconsin, Madison|No|Active, not recruiting|December 2008|June 2013|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798720||146838|
NCT00795223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461/2551(EC1)|Comparative Pain Control Between 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for FNB After TKA|Comparative Effect of 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for Femoral Nerve Block After Total Knee Replacement||Mahidol University|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|45 Years|75 Years|No|||September 2009|September 28, 2009|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00795223||147101|
NCT00795236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 4664|Melatonin Studies of Totally Blind Children|Melatonin Studies in Young Blind Children and Adolescents||Oregon Health and Science University|No|Recruiting|November 2009|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|5 Years|20 Years|Accepts Healthy Volunteers|||July 2011|July 15, 2011|November 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00795236||147100|
NCT00795522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02540|An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)|An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria||Merck Sharp & Dohme Corp.|No|Completed|July 2003|March 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00795522||147079|
NCT00795535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060938|Heart Rate Variability in Trauma Patients|Heart Rate Variability in Trauma Patients|HRV|University of Miami|No|Completed|May 2007|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|95|||Both|18 Years|N/A|No|Non-Probability Sample|All trauma patients|February 2015|February 4, 2015|November 19, 2008||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00795535||147078|
NCT00796835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004210|A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone|Dose-proportionality Study of the Five ER OROS Paliperidone To-be-marketed Tablet Strengths (3, 6, 9, 12, and 15 mg) in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2004|October 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|50|||Male|18 Years|55 Years|No|||March 2010|May 20, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796835||146980|
NCT00796796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1259 / 201012882|Temsirolimus and Radiation for Non-Small Cell Lung Cancer|A Phase I Study of Temsirolimus and Thoracic Radiation in Non-Small Cell Lung Cancer (NSCLC)||Washington University School of Medicine|No|Completed|March 2009|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|November 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796796||146983|
NCT00796809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0930-04|Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis|Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis||University of Arizona|Yes|Completed|October 2007|October 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|598|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with an inflammatory arthritis receiving care at our Rheumatology ambulatory        clinic at the University of Arizona|December 2015|December 11, 2015|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796809||146982|
NCT00796822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|614|Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications|A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy||Indiana University|Yes|Completed|January 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|November 21, 2008|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00796822||146981|
NCT00796432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004267|A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone|Open-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2003|June 2003|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|4|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2010|June 8, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796432||147011|
NCT00796445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111482|A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor|GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma||GlaxoSmithKline||Terminated|December 2008|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1351|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 21, 2008|Yes|Yes|The study was terminated early following assessment of the two co-primary endpoints showing    the lack of efficacy of the study product.|No||https://clinicaltrials.gov/show/NCT00796445||147010|
NCT00796783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-410|A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia|A Study to Confirm the Presence of Recurrent or Persistent Cushing's Syndrome in Patients With Clinical Signs or Symptoms of Hypercortisolemia Who Have Been Treated for Cushing's Disease||Corcept Therapeutics|No|Terminated|February 2009|||June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with presumed Cushing's disease who have failed pituitary surgery and/or        radiation and require adjuvant medical treatment for recurrent or persistent Cushing's        syndrome.|June 2014|June 19, 2014|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796783||146984|
NCT00797069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK20|Comparison of Nutritional Products for People With Type 2 Diabetes|Comparison of Nutritional Products for People With Type 2 Diabetes||Abbott Nutrition|No|Completed|November 2008|July 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|58|||Both|18 Years|75 Years|No|||March 2010|July 29, 2010|November 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00797069||146962|
NCT00797095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909023|Health Behaviors in School-age Children: 2009-2010|Health Behaviors in School-Age Children: 2009/2010||National Institutes of Health Clinical Center (CC)||Completed|November 2008|October 2014||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|14672|||Both|11 Years|15 Years|No|||October 2014|October 21, 2014|November 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00797095||146960|
NCT00798486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2008-14|Evaluation of the A1CNow+ Test Kit|In-Clinic Evaluation of the Redwood A1c Test Kit With Lay-Users and Professionals||Ascensia Diabetes Care|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|November 24, 2008|Yes|Yes||No|December 3, 2009|https://clinicaltrials.gov/show/NCT00798486||146856|
NCT00798499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0960M00006|A Feasibility Study to Collect Data in Patients With Haemophilia|A Multi Centre Study With no Treatment, Designed to Gain Information About the Haemophilia Patient Population||AstraZeneca||Completed|December 2008|June 2009|Actual|||Phase 0|Observational|Observational Model: Case-Only||1|Anticipated|50|Samples Without DNA|plasma|Male|18 Years|N/A|No|Non-Probability Sample|Patients with haemophilia|July 2009|July 1, 2009|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00798499||146855|
NCT00798512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N999|Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.|DESERVE: Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device. A Prospective, Multicenter Study.|DESERVE|Invatec S.p.A.|Yes|Completed|February 2008|March 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|127|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00798512||146854|
NCT00786435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-5395|Carbohydrate Study, Chronic SCI|Carbohydrate Metabolism Impairments in Chronic Human Spinal Cord Injury||University of California, Irvine|No|Completed|August 2007|September 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The characteristics of the proposed subject population are that all subjects must be 18-65        years old, male or female, pass a medical examination by the study physician, and must        speak English.|November 2010|November 2, 2010|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00786435||147761|
NCT00786448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12245|Post Marketing Surveillance Study on Emselex After Launch in Germany|Post-Marketing Surveillance Study Emselex||Bayer|No|Completed|January 2005|February 2006|Actual|February 2006|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5821|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from routine practice|April 2010|April 29, 2010|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786448||147760|
NCT00787267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008303|Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC|Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|TOP0801|Duke University|Yes|Terminated|September 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|November 6, 2008|Yes|Yes|Poor Accrual|No|December 19, 2014|https://clinicaltrials.gov/show/NCT00787267||147700|
NCT00787566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRG-002|Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting|A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic Chemotherapy||Shin Nippon Biomedical Laboratories, Ltd.||Completed|October 2008|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|68|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|November 5, 2008|Yes|Yes||No|May 24, 2011|https://clinicaltrials.gov/show/NCT00787566||147678|
NCT00787579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Essilor|Assessment of Bifocal and Prismatic Bifocal Spectacles for Myopia Control in Children|Assessment of Bifocal and Prismatic Bifocal Spectacles for Myopia Control in Children||Essilor International|No|Completed|April 2003|||April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|135|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||November 2008|November 6, 2008|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00787579||147677|
NCT00787852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-NSCL-216|A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.||Brown University|No|Terminated|March 2009|December 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|19 Years|N/A|No|||July 2014|July 24, 2014|November 7, 2008|Yes|Yes|for efficacy and safety reasons|No|July 22, 2013|https://clinicaltrials.gov/show/NCT00787852||147656|
NCT00787865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11050010|Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease|Diffusion Tensor Imaging (DTI) as a Tool to Identify Infants With Krabbe Disease in Urgent Need of Treatment||University of Pittsburgh|No|Active, not recruiting|April 2008|April 2025|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|||Both|N/A|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with a low levels of galactocerebrosidase, a family history of Krabbe disease or        has been diagnosed with Krabbe disease, or is a child at risk of developing motor        disability. Newborn screening State of New York and newborns with low enzyme.|February 2016|February 11, 2016|November 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00787865||147655|
NCT00794989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 81906|Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer|A Study Evaluating the Effect of Flaxseed on Biomarkers of Breast Cancer Risk||Roswell Park Cancer Institute|Yes|Completed|April 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Female|21 Years|50 Years|No|||January 2016|January 6, 2016|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00794989||147119|
NCT00795002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00298|Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, Previously Untreated, Poor Risk Acute Myelogenous Leukemias (AML)||National Cancer Institute (NCI)||Completed|November 2008|September 2012|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||December 2012|June 3, 2015|November 20, 2008|Yes|Yes||No|January 8, 2013|https://clinicaltrials.gov/show/NCT00795002||147118|
NCT00799019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCU 1/2008|A Prospective, Immunogenicity Surveillance Registry of Erythropoiesis Stimulating Agent (ESA) With Subcutaneous Exposure in Thailand|A Prospective, Immunogenicity Surveillance Registry of Erythropoiesis Stimulating Agent (ESA) With Subcutaneous Exposure in Thailand||Chulalongkorn University|Yes|Active, not recruiting|July 2008|June 2014|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6500|||Both|18 Years|N/A|No|Non-Probability Sample|Registry subjects will be adult men and women who are receiving or about to receive        (within 1 month) a marketed ESA product by the s.c. route of administration at the time of        enrollment.|January 2014|January 27, 2014|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799019||146816|
NCT00799240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11386|MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer|MK-0646 IMPACT Study: MK-0646, Insulin Growth Factor 1 Receptor Antibody in Stage IIIB or IV Metastatic Non-Squamous Lung Cancer, Combined With Pemetrexed (Alimta) and Cisplatin, a Randomized Phase II Trial.|IMPACT|University of Kansas Medical Center|Yes|Completed|June 2009|July 2014|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||December 2013|November 5, 2014|November 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00799240||146799|
NCT00799266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2337|An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids|A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous (i.v.) Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids||Novartis|Yes|Recruiting|December 2008|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|5 Years|17 Years|No|||September 2015|September 21, 2015|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799266||146798|
NCT00794950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sutent V5 / November 9, 2009|Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma|A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma|Sutent|University of Michigan|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00794950||147122|
NCT00795795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0802-C-046-CR|Preimplantation Genetic Screening in Women of Advanced Maternal Age|Randomized Controlled Trial (RCT) of Preimplantation Genetic Screening (PGS) in Women of Advanced Maternal Age (AMA)||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|December 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|640|||Both|38 Years|44 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795795||147058|
NCT00796081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002371|A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder|Open-label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-dose Extended-release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2006|August 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|10 Years|17 Years|No|||March 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796081||147037|
NCT00797121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS-5010|Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma|Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor)||Sun Yat-sen University|Yes|Recruiting|May 2008|May 2013|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|82|||Both|18 Years|75 Years|No|||November 2008|November 24, 2008|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797121||146958|
NCT00797108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8811020|A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization|A Phase 2 Randomized, Double-blind, Double-dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin/Clavulanate Potassium (Augmentin) In Subjects With Community Acquired Pneumonia (Cap) Requiring Hospitalization||Pfizer|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 24, 2008|Yes|Yes||No|July 8, 2015|https://clinicaltrials.gov/show/NCT00797108||146959|
NCT00797420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011454|Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers|Pharmacokinetics of a Fluconazole Loading Dose in Infants and Toddlers||Duke University|No|Completed|November 2008|September 2011|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|N/A|2 Years|No|||March 2013|March 18, 2013|November 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00797420||146938|
NCT00797706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-201|Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers|A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers||Kringle Pharma Europe AB|No|Active, not recruiting|November 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|40 Years|N/A|No|||February 2010|February 4, 2010|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797706||146916|
NCT00797927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200702010M|Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia|Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Patients With Schizophrenia||National Taiwan University Hospital|No|Completed|January 2007|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|65 Years|No|||April 2009|April 27, 2009|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797927||146899|
NCT00799357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526-08-EP|Utility of Bedside Ultrasound in the Prediction of Difficult Airway|Utility of Bedside Ultrasound in the Prediction of Difficult Airway||University of Nebraska|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|162|||Both|19 Years|N/A|No|Probability Sample|Pre-op patients|January 2010|January 11, 2010|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00799357||146792|
NCT00799370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.477|Randomized Control Trial on Postoperative Weight Bearing After High Tibial Osteotomy (HTO)|Prospective Study on Postoperative Weight Bearing After Opening Wedge High Tibial Osteotomy (HTO): Early Weight Bearing Versus Delayed. Open Labelled Randomized Clinical Study||Hospices Civils de Lyon|No|Completed|November 2008|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|40 Years|65 Years|No|||June 2014|June 25, 2014|November 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00799370||146791|
NCT00786734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-PTV-705|Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)|A Randomized, Open Label, Comparative Study to Evaluate Effect of Pitavastatin for Reduction of Myocardial Damage in Patient Are Scheduled Elective PCI for Stable Angina Pectoris||JW Pharmaceutical|No|Withdrawn|August 2008|July 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|45 Years|75 Years|No|||March 2012|March 28, 2012|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00786734||147738|
NCT00786994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAK-08|The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses|Randomized, Multicenter, Double Blind Study to Compare the Efficacy and Tolerability of Oleogel-S-10 for 3 Month Versus Placebo Only in Patients With Mild to Moderate Actinic Keratoses Located at the Face and Head Oleogel-S-10 in Actinic Keratoses Trial||Birken AG|No|Completed|October 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|165|||Both|18 Years|N/A|No|||August 2015|August 30, 2015|November 5, 2008||No||No|April 2, 2015|https://clinicaltrials.gov/show/NCT00786994||147719|
NCT00787033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0761001|A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies|A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies|B0761001|Verastem, Inc.|No|Completed|December 2008|February 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|November 5, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00787033||147716|
NCT00787306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-1048|Cardiovascular Health And Risk Modification in Family Health Teams|Multidisciplinary Cariovascular Health And Risk Modification in Family Mealth Teams|Multi-CHARM|University of Toronto|No|Recruiting|September 2008|July 2009|Anticipated|May 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|480|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2010|June 30, 2010|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787306||147697|
NCT00787280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002610|Diet, Imaging and Energy Balance Trial (DIET)|Diet, Imaging and Energy Balance Trial|DIET|Duke University|No|Completed|August 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|51|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 18, 2013|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787280||147699|
NCT00787293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-010P|Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients|A Multi-center Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure|PTOLEMY-2|Viacor|Yes|Suspended|October 2008|November 2015|Anticipated|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|No|||February 2011|February 10, 2011|November 5, 2008||No|Company ended operations January 2011|No||https://clinicaltrials.gov/show/NCT00787293||147698|
NCT00787592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11-174|SSD vs Collagenase in Pediatric Burn Patients|A Prospective Comparison of Silver Sulfadiazine Cream and Collagenase Ointment for the Treatment of Burns in Children||Children's Mercy Hospital Kansas City|Yes|Active, not recruiting|January 2008|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|2 Months|18 Years|No|Non-Probability Sample|Children between the ages of 2 months and 18 years of age that have at least second degree        burns that involve less than 25% of their total body surface area.|June 2011|June 27, 2011|November 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00787592||147676|
NCT00787605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2409|Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus|An 8-week Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus|ASTRIDE|Novartis|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|860|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|November 5, 2008|Yes|Yes||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00787605||147675|
NCT00787618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-006|Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females|A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX® (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers||Repros Therapeutics Inc.|No|Terminated|October 2008|July 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|6|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|November 6, 2008|Yes|Yes|Increased LFTs|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00787618||147674|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00795275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0749|Incretin Effect in People With Impaired Fasting Glucose|Exploring the Incretin Effect in People With IFG|1651|University of Colorado, Denver|No|Completed|January 2008|November 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||November 2008|December 27, 2012|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795275||147097|
NCT00795587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0816|Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring|Compared Effects of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension||University Hospital, Grenoble|Yes|Terminated|October 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|80 Years|No|||November 2012|November 7, 2012|November 20, 2008||No|evolution of patient's care allows no more recruitment|No||https://clinicaltrials.gov/show/NCT00795587||147074|
NCT00795262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-064 QUALITY|Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension|A 22-week Randomized, Cross-over Study Comparing the Effects of Quinapril and Quinapril Plus Alpha-lipoic Acid (ALA) on Patients With Diabetes Mellitus and Hypertension|QUALITY|InVasc Therapeutics, Inc.|Yes|Completed|July 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|75 Years|No|||May 2011|May 4, 2011|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795262||147098|
NCT00794963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-177|Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia|Aggressive Treatment of Metabolic Syndrome in Patients Treated With Clozapine for Schizophrenia|ATOMICS|Northwell Health|No|Terminated|November 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|19 Years|79 Years|No|||November 2011|April 14, 2015|November 19, 2008||No|Difficulty recruiting|No|July 19, 2011|https://clinicaltrials.gov/show/NCT00794963||147121|
NCT00794976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1779|Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of a Dexamethasone Iontophoretic Transdermal Patch for the Treatment of Pain Associated With Lateral Epicondylitis||Travanti Pharma Inc.|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|216|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00794976||147120|
NCT00795249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KurumeU-08061|Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle|Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle||Kurume University|Yes|Completed|November 2008|November 2010|Actual|November 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|100|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||May 2010|June 22, 2011|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795249||147099|
NCT00795548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZARELA_HHU_2007|Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation|Phase-II Trial to Assess the Efficacy and Toxicity of 5-Azacitidine in Addition to Standard DLI for the Treatment of Patients With AML or MDS Relapsing After Allogeneic Stem Cell Transplantation||Heinrich-Heine University, Duesseldorf|No|Completed|November 2008|August 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795548||147077|
NCT00821613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pr-118-8061 ver. 004|Data Collection Study of Raw Thermal Images for the Purpose of Developing a Device for Early Detection of Breast Cancer|Collection of Raw Data of Thermal Imaging for the Purpose of Developing a Device for Early Detection of Breast Cancer||Real Imaging Ltd.|No|Completed|September 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|1827|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with a breast abnormality (identified by mammography, ultrasound, MRI and/or a        clinical examination) summoned for breast biopsy or subjects summoned for a routine        screening examination.|February 2012|February 7, 2012|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821613||145102|
NCT00821626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMU-Flu|Rapid Flu Tests in Travelers With Fever|Utility of Rapid Flu Tests in the Medical Management of Returning Travelers With Fever||University of Lausanne Hospitals|No|Completed|January 2009|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821626||145101|
NCT00821639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUMS-6870|Reduction of Secondhand Smoke Exposure in Healthy Infants|Reduction of Secondhand Smoke Exposure in Healthy Infants||Tehran University of Medical Sciences|Yes|Completed|July 2008|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|130|||Both|N/A|12 Months|Accepts Healthy Volunteers|||October 2009|October 4, 2009|January 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00821639||145100|
NCT00821925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-PP-04|Estimation of Osteoporosis' Prevalence in France: Pilot Study in the Department of the Alpes-Maritimes|Estimation of Osteoporosis' Prevalence in France: Pilot Study in the Department of the Alpes-Maritimes||Centre Hospitalier Universitaire de Nice|No|Completed|December 2006|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|800|||Female|50 Years|85 Years|No|||January 2009|December 7, 2011|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821925||145079|
NCT00817999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-15073|The Impact of Grapefruit Juice on the Response to Clopidogrel|The Impact of Grapefruit Juice on the Response to a Loading Dose and Maintenance Dose of Clopidogrel in Healthy Volunteers||Creighton University|Yes|Completed|November 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|32|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|January 6, 2009||No||No|August 8, 2011|https://clinicaltrials.gov/show/NCT00817999||145375|
NCT00822237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V210-057|Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)|Safety, Tolerability, and Immunogenicity of VARIVAX (2007 Commercial VZV Bulk Process) Administered Concomitantly With M-M-R II in Healthy Children 12-to-23 Months of Age||Merck Sharp & Dohme Corp.|No|Completed|January 2009|December 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|598|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||October 2015|October 29, 2015|January 9, 2009|Yes|Yes||No|October 28, 2010|https://clinicaltrials.gov/show/NCT00822237||145055|
NCT00822250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-PP-05|Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis|Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis||Centre Hospitalier Universitaire de Nice|No|Completed|April 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|1 Year|15 Years|No|||October 2010|October 20, 2010|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822250||145054|
NCT00817986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-B-083|A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms||XenoPort, Inc.|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|161|||Both|18 Years|65 Years|No|||September 2010|September 14, 2010|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817986||145376|
NCT00817960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR476508CTIL|Effects of Ritalin on Postural Stability of Old Adults|Effects of Methylphenidate on Postural Stability of Old Adults Under Single and Dual Task Conditions.||Soroka University Medical Center|Yes|Completed|July 2011|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2008|June 19, 2012|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00817960||145378|
NCT00817973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-PPL (5A) LSM|Differential Effects of Protein Quality on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes: Comparison of Whey, Casein, Gluten, and Cod Protein|Differential Effects of Protein Quality on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes: Comparison of Whey, Casein, Gluten, and Cod Protein||Aarhus University Hospital|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|12|||Both|40 Years|75 Years|No|||January 2009|January 8, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00817973||145377|
NCT00818350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGOC O1|Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer|Phase II Study of Sunitinib in Metastatic and Pretreated Urothelial Cancer||Campania Younger Oncologists Association|No|Active, not recruiting|January 2009|January 2011|Anticipated|August 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2009|January 6, 2009|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818350||145348|
NCT00818363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C803-017|A Safety and Effectiveness Study of SABER™-Bupivacaine for Pain Following Shoulder Surgery|A Double-Blind, Multi-Center, Placebo-Controlled Trial of SABER™-Bupivacaine for Post-Operative Pain Control and Opioid Sparing/Opioid-Related Adverse Event Reduction Following Arthroscopic Shoulder Surgery||Durect|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||August 2014|August 20, 2014|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818363||145347|
NCT00819039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-148|A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)|A Multi-center, 2-Part Study to Evaluate the Pharmacokinetics Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery||Merck Sharp & Dohme Corp.|No|Completed|January 2009|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|98|||Both|6 Months|17 Years|No|||June 2015|June 8, 2015|January 7, 2009|No|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT00819039||145296|
NCT00819052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1526|Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients|An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program||Boehringer Ingelheim||Completed|December 2008|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|445|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|January 7, 2009||||No|December 13, 2011|https://clinicaltrials.gov/show/NCT00819052||145295|
NCT00819923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-003|Comparison of Bio-Active-Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome|Comparison of Bio-Active-Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome (A Prospective, Randomized and a Multicenter Clinical Study)|BASE-ACS|The Hospital District of Satakunta|Yes|Active, not recruiting|November 2008|December 2014|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|825|||Both|18 Years|N/A|No|||May 2011|May 4, 2011|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819923||145229|
NCT00820105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX10059-206|ADX10059 Migraine Prevention Study|A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine||Addex Pharma S.A.|No|Terminated|December 2008|||January 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|350|||Both|18 Years|65 Years|No|||December 2009|December 23, 2009|January 8, 2009||No|Incidence of abnormalities of liver function tests is higher than expected in this population.|No||https://clinicaltrials.gov/show/NCT00820105||145216|
NCT00821574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BIT02|Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome|Project to Promote the Evaluation of the Cardiovascular Risk in the Clinical Practice and to Evaluate Its Evolution Following the Implementation of a Preventive Multifactorial Strategy Aimed to Reduce the Total Risk Level (SCORE Algorithm), in Subjects Suffering From Metabolic Syndrome and With a Risk Level ≥5%|LesScore|Novartis||Completed|July 2005|||March 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|144|||Both|40 Years|65 Years||||January 2009|June 15, 2010|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821574||145105|
NCT00820157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-021|Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma|A Prospective Randomized Trial Comparing Cytoreductive Surgery Followed by Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Multinodular Hepatocellular Carcinoma (MNHCC)|TACE|Eastern Hepatobiliary Surgery Hospital|Yes|Completed|November 2008|December 2012|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||August 2013|August 10, 2013|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820157||145212|
NCT00820170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-122|Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194|A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2009|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||February 2016|February 2, 2016|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820170||145211|
NCT00820456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN PA 4002|Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI|Angle Interleaved Projection Reconstruction With K-Space Weighted Image Reconstruction for Dynamic Contrast MRI of Cancer Therapy Response||American College of Radiology Imaging Network|Yes|Active, not recruiting|April 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|At each participating site, at least one oncologist treating patients with adenocarcinoma        of the colon and rectum must agree to serve as a co-investigator on the study. However,        all oncologists directly or indirectly affiliated with the participating institution may        serve as a source of participants for this trial. Patients with adenocarcinoma of the        colon or rectum metastatic to the liver who are present candidates for FOLFOX plus        bevacizumab are eligible to enroll in this imaging trial in Arm A. Patients with any        primary carcinoma with metastatic disease to the liver who are in stable treatment        condition prior to and between scnas are eligible to enroll in this imaging trial in Arm        B.|March 2010|December 20, 2011|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820456||145190|
NCT00820794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361034|A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects|A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects||Pfizer|No|Withdrawn|May 2009|June 2009|Anticipated|June 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00820794||145164|
NCT00820807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFIS-08-003|Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes|Novel Fiber Effects on Glucose Metabolism and Insulin Sensitivity for Individuals at High Risk for Diabetes: a Randomized, Placebo-controlled, Double-blind, Parallel Group Clinical Trial||Cargill|No|Terminated|January 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|60|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|January 8, 2009||No|Stopped due to a non-safety-related issue with the beverage (test vehicle).|No||https://clinicaltrials.gov/show/NCT00820807||145163|
NCT00821028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atrium-001|Local Paclitaxel Delivery for SFA Disease|Treatment of Superficial Femoral Artery Atherosclerotic Disease With Local Delivery of Paclitaxel Using an Irrigating Catheter: a Randomized, Single-center Pilot Study|IRRITAX|University of Oklahoma|Yes|Completed|January 2009|April 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|80 Years|No|||December 2013|December 19, 2013|January 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00821028||145146|
NCT00821327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06040|Gemzar, Cisp, Sunitinib Urothelial Ca|Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients With Advanced/Metastatic Urothelial Carcinoma||US Oncology Research|No|Completed|August 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|January 9, 2009|No|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT00821327||145124|
NCT00821301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-CL2|Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma|Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma||Immune Control|Yes|Recruiting|December 2008|October 2010|Anticipated|August 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2009|January 12, 2009|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00821301||145126|
NCT00821652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1390|Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination|Phase I Randomized, Double-blind, Placebo-controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1||Icahn School of Medicine at Mount Sinai|Yes|Completed|February 2009|December 2014|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||December 2014|January 6, 2015|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821652||145099|
NCT00821665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-3-004|Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose|Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose||Maastricht University Medical Center|No|Completed|March 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|39|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||January 2009|January 12, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821665||145098|
NCT00822510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0376-02|Telephone Counseling: Men With Prostate Cancer & Partners|||University of Arizona|Yes|Recruiting|September 2006|October 2009|Anticipated|September 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|N/A|No|||January 2009|January 13, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00822510||145034|
NCT00822523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58360|Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies|Strain Gauge Feasibility Assessment & Correlation With Compound Muscle Action Potential & Surface Electromyogram Parameters Before & After a Single Intramuscular Injection of Botulinum Toxin Type A Into Extensor Digitorum Brevis Muscle||Loma Linda University|No|Active, not recruiting|January 2009|June 2015|Anticipated|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|15|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822523||145033|
NCT00822484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3226K2-1001|Study Evaluating Single Doses of ILV-095 in Healthy Japanese Male Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-095 Administered Subcutaneously to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822484||145036|
NCT00818389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS049640|Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)||Massachusetts General Hospital|Yes|Terminated|January 2009|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||March 2011|March 18, 2011|January 6, 2009||No|NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of    84 subjects.|No|May 10, 2010|https://clinicaltrials.gov/show/NCT00818389||145345|
NCT00818688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401080|POST (Prospective Observational Superfial Thrombophlebitis)|Superficial Thrombophlebitis and Venous Thromboembolism: A Large Prospective Epidemiological Study|POST|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2005|January 2007|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|844|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic ST of the lower limbs.|January 2009|January 12, 2009|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00818688||145322|
NCT00818376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LutheranUB|Staining and Calculus Formation After 0.12% Chlorhexidine Rinses|Staining And Calculus Formation After 0.12% Chlorhexidine Rinses In Plaque-Free And Plaque-Covered Surfaces. A Randomized Trial.||Lutheran University of Brazil|Yes|Completed|June 2006|December 2008|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2009|January 29, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818376||145346|
NCT00818675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-021|A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)|A Randomized Discontinuation Phase II Trial of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS Mutations||Merck Sharp & Dohme Corp.|No|Terminated|March 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|January 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818675||145323|
NCT00819650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-014-1|A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection|Eastern Hepatobiliary Surgical Hospital||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2009|February 3, 2009|January 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00819650||145249|
NCT00819663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007338|Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography|Intestinal Wall Remodeling After Initiation of Infliximab Therapy in Crohn's Disease Patients Undergoing Serial CT Enterography||Mayo Clinic|Yes|Completed|February 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|67|||Both|18 Years|80 Years|No|Probability Sample|(Retrospectively) Established Crohn's disease patients who underwent CTE imaging before        and after initiating infliximab therapy.|August 2011|August 17, 2011|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819663||145248|
NCT00816257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0101|Lung Transplant Specimen Repository and Data Registry Protocol|Lung Transplant Specimen Repository and Data Registry Protocol||Ohio State University|No|Completed|November 2005|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|64|Samples With DNA|BAL specimen blood lung biopsy specimens|Both|18 Years|N/A|No|Non-Probability Sample|lung transplant recipients|November 2013|November 18, 2013|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816257||145508|
NCT00816504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-124|Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5|Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5||Northwell Health|No|Withdrawn|December 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|60 Years|No|||September 2015|September 3, 2015|December 31, 2008|Yes|Yes|Under additional IRB Review|No||https://clinicaltrials.gov/show/NCT00816504||145489|
NCT00819897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-05|Longitudinal Study in Clinically Isolated Syndrome (CIS) Patients Treated With Interferon Beta|Longitudinal Study in Clinical Isolated Syndrome Patients Treated With Interferon Beta. Correlation With Cognitive Disorders and Quality of Life.|QUALICIS|Centre Hospitalier Universitaire de Nice|No|Terminated|June 2008|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with CIS and temporo spatial dissemination for less than one year without prior        immunomodulatory treatment|December 2011|December 6, 2011|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819897||145231|
NCT00820469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 140 03|Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab|Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders.|PK-rituximab|University Hospital, Toulouse|No|Completed|September 2008|January 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820469||145189|
NCT00820820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-38|IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis|Immunotherapy of Atopic Dermatitis in Adult Patients by Anti-measles Vaccination IDA (Immunothérapie de la Dermatite Atopique)Protocol|IDA-Adult|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|January 2009|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|80 Years|No|||October 2012|October 8, 2012|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820820||145162|
NCT00821041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2004:112|Internet-based Treatment for Chronic Insomnia|Evaluation of an Internet-based Treatment for Chronic Insomnia||University of Manitoba|No|Completed|September 2006|June 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|85 Years|No|||August 2013|August 2, 2013|January 8, 2009||No||No|May 5, 2011|https://clinicaltrials.gov/show/NCT00821041||145145|
NCT00821054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111582|A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients|An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients||GlaxoSmithKline||Completed|March 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|25|||Both|18 Years|65 Years|No|||November 2012|November 8, 2012|December 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00821054||145144|
NCT00821340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPE65-HMO-CTIL|Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations|Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations||Hadassah Medical Organization||Recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|8 Years|N/A|No|||February 2010|March 1, 2010|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821340||145123|
NCT00821314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-128.3|The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome|The Effect of Position (Sit/Stand up vs Supine Position) on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome||Maastricht University Medical Center|Yes|Recruiting|April 2009|||December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of two groups. One group consist of patients with OAB. The        second group consist of volunteers without micturition complaints. (25 male & 25 female)        The second group of patients with OAB. (25 male& 25 female) Both groups will be subjected        to the exact same protocol.|June 2010|June 15, 2010|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821314||145125|
NCT00822497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-00147|Efficacy of Music Therapy Protocols for Burn Debridement|The Efficacy of Music Therapy Protocols for Decreasing Pain, Anxiety, and Muscle Tension Levels During Burn Debridement: A Prospective Randomized Crossover Trial|MTS1|MetroHealth Medical Center|No|Completed|October 2004|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|50|||Both|7 Years|N/A|No|||July 2010|July 22, 2010|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822497||145035|
NCT00822289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5071|The Effect of Radioactive Iodine Administration for Thyroid Diseases on H.Pylori Eradication|Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases||Rabin Medical Center|No|Enrolling by invitation|February 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|85 Years|No|Probability Sample|Consecutive patients with thyroid diseases referred to the Isotopic Institute at the Rabin        Medical Center, Campus Beilinson for either radioactive iodine (131I) thyroid scan or        radioactive iodine (131I)treatment for their disease, will be tested, prior to the        radioactive iodine, for H. pylori infection and CagA protein by serology. Patient with        positive serology for H. pylori will be tested for active gastric infection using the        H.pylori stool antigen test. The study population will include all patients who tested        positive for H.pylori both on serology and stool antigen tests. Six to eight weeks and 6        month after administration of radioactive iodine (131I) , stool antigen or H.pylori will        be tested again to confirm persistence of H.pylori eradication.|January 2009|January 13, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822289||145051|
NCT00818402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILKE-ETMK:47/180/2008|Non-small Cell Lung Cancer and Quality of Life|Treatment of Non-small Cell Lung Cancer -Effects on Quality of Life and Symptom Control|SILKE|University of Turku|No|Completed|August 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|130|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|The patients treated in the clinic of respiratory medicine in Turku, Finland|May 2015|May 28, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818402||145344|
NCT00818415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13965|Naproxen Sodium ER Pharmacokinetic Study|An Open Label, Randomised Two Way Crossover Trial to Determine the Pharmacokinetic Profile of an Extended Release Naproxen Sodium Tablet Relative to Aleve Tablets Following Single and Multiple Dose Administration Under Fed Conditions.||Bayer|No|Completed|November 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|December 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00818415||145343|
NCT00818012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-15050|Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation|Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation In Patients Undergoing Successful Electrical Cardioversion to Sinus Rhythm|APPRAISE|Creighton University|No|Completed|August 2008|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|129|||Both|19 Years|N/A|No|Probability Sample|Patients in Atrial Fibrillation|August 2014|August 11, 2014|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818012||145374|
NCT00818428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410-2008-0503|Randomized Clinical Trial of Phonological Interventions|The Contribution of a Speech Perception Intervention to the Prevention of Phonological Awareness Deficits in Children With Speech Sound Disorders|ECRIP|McGill University|No|Recruiting|November 2008|July 2010|Anticipated|July 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|96|||Both|48 Months|71 Months|No|||September 2009|September 22, 2009|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818428||145342|
NCT00819065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06336|Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity|Randomized Double-blind Clinical Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity||Hospital de Clinicas de Porto Alegre|No|Completed|March 2009|June 2011|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|2 Years|N/A|No|||July 2011|July 6, 2011|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819065||145294|
NCT00819078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GehaMHC|Comparative Study of SR Bupropion for Adolescent Smoking Cessation|Randomized, Double-Blind, Placebo-Controlled Trial of SR Bupropion for Adolescent Smoking Cessation||Geha Mental Health Center|No|Not yet recruiting|January 2009|January 2014|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|13 Years|20 Years|No|||January 2009|January 7, 2009|January 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819078||145293|
NCT00819351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO ALL2008 PEG Asparaginase|ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase|NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion||Rigshospitalet, Denmark|Yes|Recruiting|February 2009|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|1 Year|45 Years|No|||May 2012|May 22, 2012|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819351||145272|
NCT00819364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007024|Early Intervention Program for Children With Autism (BCRI Model)|Early Intervention Program for Children With Autism (BCRI Model)||Sun Yat-sen University|Yes|Enrolling by invitation|August 2009|August 2016|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|30 Months|No|||August 2009|August 10, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819364||145271|
NCT00810212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-SF002|Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion|A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With Mastergraft Granules in Subjects Undergoing Posterolateral Lumbar Fusion With Instrumentation||Mesoblast, Ltd.|Yes|Withdrawn|November 2008|November 2011|Anticipated|November 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|70 Years|No|||October 2008|November 6, 2014|December 17, 2008|Yes|Yes|Sponsor preferred a better study design|No||https://clinicaltrials.gov/show/NCT00810212||145970|
NCT00816816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-0703|Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma|Phase ⅡStudy of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma||Fudan University|Yes|Recruiting|February 2007|June 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|70 Years|No|||January 2009|January 2, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816816||145465|
NCT00817063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117183|Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema|Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy|HANDEL|GlaxoSmithKline|No|Completed|January 2009|August 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|75 Years|No|||March 2013|April 18, 2013|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817063||145446|
NCT00817076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03475|Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)|Evaluation of the Efficacy and Safety of Desloratadine Syrup in Childhood Atopic Dermatitis||Merck Sharp & Dohme Corp.|No|Completed|March 2003|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|6 Years|12 Years|No|||April 2015|April 20, 2015|January 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00817076||145445|
NCT00820183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSB_2006|A Quality Improvement Plan for Hypertension Control|A Quality Improvement Plan for Hypertension Control: the INCOTECA Project|INCOTECA|Jordi Gol i Gurina Foundation|No|Completed|February 2006|April 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|34327|||Both|18 Years|N/A|No|||January 2009|May 6, 2009|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820183||145210|
NCT00821080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-396|Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma|A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma||Massachusetts General Hospital|Yes|Completed|October 2008|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821080||145142|
NCT00821353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N N402 194635|Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy|Sinus Rhythm Maintenance in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation - Randomized Comparison of Antiarrhythmic Therapy vs. Radiofrequency Catheter Ablation (SHAARC)||Institute of Cardiology, Warsaw, Poland|No|Completed|January 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||February 2013|February 4, 2013|January 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00821353||145122|
NCT00821366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEATS|Effective Aids Treatment and Support in the Free State (FEATS)|Effective Aids Treatment and Support in the Free State (FEATS): Adherence and Nutritional Support for Effective and Sustainable Antiretroviral Treatment in Resource Constrained Settings|FEATS|Centre for Health Systems Research & Development, University of the Free State|No|Active, not recruiting|October 2007|June 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|648|||Both|18 Years|N/A|No|||January 2009|February 25, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821366||145121|
NCT00821379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoPPer study - 07/331|CoPPer Study - Complications of Polycystic Ovary Syndrome (PCOS) Pregnancy: Evaluating Risk|Complications of PCOS Pregnancy: Evaluating Risk|CoPPer|UMC Utrecht|No|Completed|April 2008|September 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|Samples With DNA|Whole blood, serum and lithium heparine, urine and placenta tissue|Female|18 Years|40 Years|No|Non-Probability Sample|Women with PCOS and a wish to conceive who attend to the University Hospital in Utrecht.|January 2009|December 19, 2012|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821379||145120|
NCT00822276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADVN MRSA 10|The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)|Pilot Study To Determine The Underlying Mechanisms For Infection And Colonization By Staphylococcus Aureus Of The Skin Of Atopic Dermatitis Subjects With And Without A History Of Eczema Herpeticum (ADVN MRSA 10)|MRSA|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||7|Actual|65|Samples With DNA|Nasal swabs, skin swabs, tape strippings, and blood draws.|Both|1 Year|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|ADEH-, ADEH+ people who may or may not be colonized with MRSA or MSSA, and non-atopic        people not colonized with MRSA or MSSA.|April 2014|April 3, 2014|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00822276||145052|
NCT00822302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract Nos: 2008-000093-21|Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia|Does recHDL Given i.v. Before CEA Prevent Cerebral Ischaemia? - the Reveal Study.|REVEAL|St George's, University of London|Yes|Completed|February 2006|February 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|N/A|N/A|No|||January 2009|June 5, 2015|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822302||145050|
NCT00818025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08070401|Comparing Methods for Tracking Health Information at Home After Lung Transplant|Phase III Trial of Pocket PATH: A Computerized Intervention to Promote Self-Care||University of Pittsburgh|Yes|Completed|January 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|211|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818025||145373|
NCT00822536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071210|Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation|Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation|OPTIDUAL|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2009|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1798|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822536||145032|
NCT00818441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471017|Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung|A Phase 2, Open-Label Trial Of Dacomitinib (PF-00299804) In Selected Patients With Advanced Adenocarcinoma Of The Lung||Pfizer|No|Completed|March 2009|April 2015|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818441||145341|
NCT00818454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.57|4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma|A Multicenter Randomized Study Starting With a 4 Week 2 Way Crossover Double Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4 Week Open Label Combivent Respimat Treatment Phase When All Study Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma (GINA 2007 Treatment Steps 3-5)||Boehringer Ingelheim||Completed|December 2008|||September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||Actual|226|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|January 6, 2009||||No|September 21, 2010|https://clinicaltrials.gov/show/NCT00818454||145340|
NCT00818701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004797|Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction|A Randomized, Double Blinded Placebo Controlled Cross-over Study of Low Dose B-type Natriuretic Peptide (Nesiritide) With or Without Concomitant Phosphodiesterase V (PDE V) Inhibition(Sildenafil) in Congestive Heart Failure Patients With Renal Dysfunction|BNP+PDEVI|Mayo Clinic|Yes|Terminated|February 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|1|||Both|18 Years|90 Years|No|||September 2010|September 23, 2010|January 6, 2009||No|started a NIH study that is competing for same subjects|No||https://clinicaltrials.gov/show/NCT00818701||145321|
NCT00819091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.35|Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug|A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.||Boehringer Ingelheim||Completed|December 2008|||January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|80 Years|No|||December 2013|June 17, 2014|January 7, 2009||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00819091||145292|
NCT00819104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4022L00006|A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components|A Five-arm, Randomised, Open Label, Multi-centre, Prospective Study to Compare the Efficacy, Safety and Tolerability of Metoprolol XL Plus Amlodipine Combination (Selomax TM) With Metoprolol XL and Amlodipine as Individual Components in Management of Hypertension in Indian Patients.|MARS|AstraZeneca|No|Completed|November 2008|August 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|402|||Both|18 Years|80 Years|No|||September 2009|September 7, 2009|January 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819104||145291|
NCT00819377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1004|Milrinone Inhaled in Cardiac Surgery|2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB||Montreal Heart Institute|No|Completed|February 2009|December 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|90 Years|No|||October 2013|October 23, 2013|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819377||145270|
NCT00819390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5258|Chloroquine for Reducing Immune Activation in HIV- Infected Individuals|A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation||AIDS Clinical Trials Group|Yes|Completed|March 2009|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|70|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|January 8, 2009|Yes|Yes||No|August 26, 2014|https://clinicaltrials.gov/show/NCT00819390||145269|
NCT00810225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-012|Study of Gulf War Illness (GWI) by Comparing GWI and Healthy Veterans|CNDP1 Polymorphisms in Gulf War Illness (GWI)||Georgetown University|No|Completed|August 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|516|Samples With DNA|Plasma, serum, urine, and buccal swab samples retained for testing as described in protocol.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All veterans who served in the Armed Forces between August 1990 and July 1991|February 2014|February 24, 2014|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810225||145969|
NCT00810238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3BS-C-07-01|C-Cure Clinical Trial|C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy||Celyad (formerly named Cardio3 BioSciences)|Yes|Completed|December 2008|January 2012|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||September 2012|September 3, 2012|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810238||145968|
NCT00817089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806019|Understanding Treatment Response With Naltrexone Among White Alcoholics|Defining an Endopheneotype for Alcohol Treatment With Naltrexone|DEFINE II|University of Pennsylvania|Yes|Completed|December 2007|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|40|||Male|21 Years|64 Years|No|||August 2011|August 3, 2011|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817089||145444|
NCT00817375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-01-12|Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients|Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients||Samsung Medical Center|Yes|Recruiting|February 2003|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|19 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817375||145422|
NCT00820833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.29.INF|Effect of Formula on Growth of Infants From Overweight or Obese Mothers|Effect of Protein Levels and Caloric Density on the Growth of Formula Fed Infants From Overweight or Obese Mothers||Nestlé|No|Completed|October 2007|December 2014|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|230|||Both|3 Months|12 Months|Accepts Healthy Volunteers|||December 2014|March 25, 2015|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820833||145161|
NCT00820846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 205|Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults|A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2009|September 2014|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|5||Actual|299|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820846||145160|
NCT00821067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS20081121|The Effect of Oral D-Ribose in "Baby Boomers" With Fatigue. A Randomized, Double-Blind Study|The Effect of Oral D-Ribose in "Baby Boomers" With Fatigue. A Randomized, Double-Blind Study||Bioenergy Life Science, Inc.|No|Completed|January 2009|May 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00821067||145143|
NCT00820859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0144|Treatment Routes for Exploring Agitation|Treatment of Agitation in the Nursing Home|TREA|National Institute on Aging (NIA)|No|Recruiting|June 2006|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|60 Years|N/A|No|||July 2009|July 1, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820859||145159|
NCT00821093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2349|Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)|A 12 Week Treatment, Multi-center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 µg o.d.) Via a SDDPI in Patients With Moderate to Severe COPD, Using Salmeterol (50 µg b.i.d.) as an Active Comparator Delivered Via a DISKUS Inhaler|INSIST|Novartis||Completed|January 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1123|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|January 9, 2009|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00821093||145141|
NCT00811811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-516-BE|Behavioral Neurocardiac Training and Hypertension|Behavioral Neurocardiac Training With Biofeedback Augments Vagal-Heart Rate Modulation and Baroreflex Sensitivity Among Patients With Hypertension||University Health Network, Toronto|No|Completed|May 2005|December 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|65|||Both|35 Years|64 Years|No|||December 2008|December 18, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811811||145848|
NCT00821678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHI 08-098|Telemedicine Outreach for Post Traumatic Stress in CBOCs|Telemedicine Outreach for Post Traumatic Stress in CBOCs|TOP|VA Office of Research and Development|Yes|Completed|November 2009|September 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|January 9, 2009||No||No|February 19, 2015|https://clinicaltrials.gov/show/NCT00821678||145097|High enrollment refusal rates may limit external validity.
NCT00821990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-055|Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer|A Patient Preference Randomized Phase III Clinical Trial of Second-line Chemotherapy (SLC) in Advanced Gastric Cancer (AGC) Patients Pretreated With Both Fluoropyrimidines and Platinum||Samsung Medical Center|No|Completed|September 2008|June 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|75 Years|No|||January 2012|January 18, 2012|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00821990||145074|
NCT00812344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1250C00029|Effect of Ketoconazole on Biliary Excretion of AZD0837|An Open, Randomised, Cross-over, Single Centre Pharmacokinetic (Phase I) Study of the Biliary Excretion Following Single Doses of AZD0837, Given in the Duodenum Via a Loc-I-Gut Catheter, Alone or in Combination With Ketoconazole (Once Daily for 4 Days), to Young Healthy Male Subjects||AstraZeneca|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812344||145807|
NCT00821964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6578|Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer|Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases||University of Washington|No|Active, not recruiting|December 2008|||January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00821964||145076|
NCT00821977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237B2201|Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes|||Novartis||Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|338|||Both|18 Years|N/A|No|||May 2012|January 2, 2013|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821977||145075|
NCT00812890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11042008-1333|Exploring Semi-Quantitative Pregnancy Tests and Their Impact on Reproductive Health Service Provision|Exploring Semi-Quantitative Pregnancy Tests and Their Impact on Reproductive Health Service Provision||Stanford University||Completed|November 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 20, 2011|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812890||145765|
NCT00812903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20090005|Neck Pain in Danish Military Pilots and Flight Crew|Neck Pain in Danish Military Pilots and Flight Crew - Environmental Factors With Influence on Performance (PH.D.-Project)||University of Southern Denmark|Yes|Completed|March 2009|August 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812903||145764|
NCT00818038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US 006-08-NAT|A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function|Phase IV, Proof of Concept Study to Evaluate Tysabri Effectiveness in RRMS Patient Bladder Function|TRUST|Biogen|No|Completed|March 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|85 Years|No|Non-Probability Sample|Men and women 18 years or older with relapsing remitting multiple sclerosis who have never        received an infusion of TYSABRI.|June 2014|June 25, 2014|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818038||145372|
NCT00809042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHaghpanah|Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia|The Effect of Combination Therapy of Hydroxyurea With L- Carnitine and Magnesium Chloride on he-Matologic Parameters and Cardiac Function of β-Thalassemia Intermedia Patients.||Shiraz University of Medical Sciences|Yes|Completed|June 2007|December 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|120|||Both|4 Years|35 Years|No|||December 2008|December 15, 2008|December 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809042||146059|
NCT00809926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPV100AUS01|8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension|An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension|VANTAGE|Novartis|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|451|||Both|18 Years|N/A|No|||March 2011|March 31, 2011|December 16, 2008|Yes|Yes||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00809926||145991|
NCT00818714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040255|Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516|0516 GCC: Stereotactic Body Radiation Therapy As A Boost After Definitive Treatment With Concurrent Chemoradiation In Patients With Non-Small Cell Lung Cancer||University of Maryland|Yes|Withdrawn|January 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|January 7, 2009||No|There was no patient accrual nor study activity due to inability to fund PFTs.|No||https://clinicaltrials.gov/show/NCT00818714||145320|
NCT00818727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-5435-AM-CTIL|Bone Density of Newborn Infants to Mothers Treated With Selective Serotonin Reuptake Inhibitor (SSRI)|||Sheba Medical Center|No|Not yet recruiting|February 2009|||January 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|7 Days|No|Probability Sample|Healthy term newborn infants to mothers treated with SSRI and healthy controls. bone        density mesurment will be applied on the 1-7 days of life.|January 2009|January 7, 2009|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00818727||145319|
NCT00818740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098003|Pharmacokinetic Study of ORM-12741 in Healthy Volunteers|Pharmacokinetics of ORM-12741 After Intravenous and Oral Administration and Effects of Food on ORM-12741 Pharmacokinetics; An Open, Randomised, Single Dose, Single Centre, Crossover Study in Healthy Male Subjects||Orion Corporation, Orion Pharma|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|December 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00818740||145318|
NCT00819117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR05033IT|Investigation of Transvenous Versus Epicardial Left Ventricular Stimulation Technique|INvestigation of TRansvenous Versus EPIcarDial Left Ventricular Stimulation Technique|INTREPID|St. Jude Medical|No|Completed|November 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||January 2010|January 6, 2010|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819117||145290|
NCT00819130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|duratech-3607|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2008|||||N/A|N/A|N/A||||||||||||||June 15, 2009|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819130||145289|
NCT00809913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL22172.058.08|Febrile Urinary Tract Infection Randomized Short Treatment Trial|Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days)|FUTIRST|Leiden University Medical Center|Yes|Recruiting|December 2008|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809913||145992|
NCT00816842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC3184|Plasma Citrulline Concentration in Tropical Enteropathy|Plasma Citrulline as Quantitative Biomarker of HIV Associate Villous Atrophy in a Tropical Enteropathy Population||Azienda Ospedaliero-Universitaria di Parma||Completed|October 1998|September 2008|Actual|May 2008|Actual|N/A|Observational|N/A|||||||Both|18 Years|80 Years|No|Non-Probability Sample|Tropical enteropathy with mixed HIV status|January 2009|January 2, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816842||145463|
NCT00817102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLANTA II|Validation of Stenosis Assessment by Coronary Artery Computed Tomography Against Invasive Measurements of Fractional Flow Reserve in Patients With Significant Coronary Artery Stenoses|||Piedmont Healthcare|No|Completed|November 2008|April 2013|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|21 Years|85 Years|No|||April 2014|April 14, 2014|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00817102||145443|
NCT00817388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-294|Correlating Ic/Pbs Symptoms With Urine Biomarkers|Correlating Ic/Pbs Symptoms With Urine Biomarkers||William Beaumont Hospitals|No|Completed|January 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|N/A||1|Actual|26|Samples Without DNA|Urine specimen.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with and without intersitial cystitis/painful pelvic pain will be asked to        provide an urine specimen and complete a brief questionnaire.|June 2010|June 4, 2010|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817388||145421|
NCT00820508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-2845-001|Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies|A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies|CHR-2845-001|Chroma Therapeutics|No|Completed|December 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2011|November 25, 2011|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820508||145186|
NCT00820521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3205A2-1003|Study Evaluating Single Doses of GAP-134|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Withdrawn|February 2009|April 2009|Anticipated|April 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|January 30, 2009|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00820521||145185|
NCT00811343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070310|Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy|Impact of New Immunological Diagnosis Tests of Latent Tuberculosis in Adults Patients Who Need Anti TNF Therapy.|ETAT|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2008|June 2012|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|430|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811343||145884|
NCT00811577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OL-ASCAR-03|A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients|A Phase 2a Double Blind, Placebo Within-Patient Controlled, Multi-Center Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product in Trocar Sites of Arthroscopic Shoulder Surgery Patients||Capstone Therapeutics|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|75 Years|No|||September 2012|September 10, 2012|December 18, 2008|Yes|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT00811577||145866|
NCT00811590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI26943|Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome|Pilot Study of mTOR Inhibitor Therapy for Treatment of Intestinal Polyps in Peutz-Jeghers Syndrome||University of Utah|Yes|Terminated|November 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|November 17, 2008|Yes|Yes|The study was ended early due to low enrollment.|No|March 6, 2012|https://clinicaltrials.gov/show/NCT00811590||145865|Early termination leading to small numbers of subjects analyzed
NCT00812123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calfree|Calcineurin Free Immunosuppression in Renal Transplant Recipients|Open, Single Center, Randomised, Parallel Group Pilot Study to Investigate a Calcineurin Free Immunosuppressive Treatment for de Novo Renal Transplant Recipients: A Comparison of a Rapamycin/MMF/Steroids Regime to a Cyclosporine A Neoral/MMF/Steroids Regimen in the Prevention of Acute Rejection Following Renal Transplantation||University Hospital, Basel, Switzerland|No|Completed|January 2001|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|15 Years|75 Years|No|||December 2008|December 18, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812123||145824|
NCT00812136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMA-102008-001|Parent Mentor Asthma Study|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|PMA|University of Texas Southwestern Medical Center|Yes|Completed||||||N/A|Interventional|Primary Purpose: Prevention|||||||Both|N/A|N/A||||October 2008|December 19, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812136||145823|
NCT00821691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-APN-08|Action of Amantadine on Post-Stroke Aphasic Patients|Action of the Amantadine on Post Stroke Aphasic Patients' Language and Communication|CELIC-1|Centre Hospitalier Universitaire de Nice|No|Completed|March 2009|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||June 2013|April 18, 2014|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00821691||145096|
NCT00812357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RFR-SYM-2008/1|Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France|Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma|SYMBIOSE|AstraZeneca|No|Completed|April 2009|August 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|579|||Both|N/A|N/A|No|Probability Sample|Community sample|December 2011|December 27, 2011|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812357||145806|
NCT00812617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-77|Effects of Mineral Water Consumption on Serum Lipid Parameters|Effects of Mineral Water Consumption on Serum Lipid Parameters: a Double-Blind, Randomized Controlled Trial||Hiroshima University||Completed|December 2008|September 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|90|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2009|October 5, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812617||145786|
NCT00812604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-466|Analgesic Ointment on Temporomandibular Joint and Masticatory Muscle Pain|Effect of an Analgesic Ointment on the Relief of Temporomandibular Joint and Masticatory Muscle Pain: a Randomized, Double Blinded, Placebo-controlled Study.||The University of Hong Kong|No|Completed|April 2007|September 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||May 2014|May 21, 2014|December 19, 2008||No||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00812604||145787|In this study, the subjects were screened by clinical examinations and self-reported questionnaires. Ideally, the diagnosis should be made with a combination of radiographs, Magnetic Resonance Imaging or Computer Tomography.
NCT00809055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0849|MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine|Magnetic Resonance Imaging and Neurodevelopmental Outcomes in Preterm Infants Following Administration of High-Dose Caffeine - A Pilot Study||Washington University School of Medicine|Yes|Completed|November 2008|December 2015|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|24 Weeks|30 Weeks|No|||January 2016|January 26, 2016|December 15, 2008||No||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00809055||146058|
NCT00813189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/64|Efficacy Study of Recombinant Growth Hormone on Muscle Function in Children Long-term Treated With Glucocorticoid|Effects of Growth Hormone on Corticoid Myopathy in Children With Chronic Disease: Effects on Muscle Mass and Strength||Association REMEDE|No|Completed|April 2005|May 2012|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|6 Years|N/A|No|||May 2015|May 4, 2015|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813189||145742|
NCT00809939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0129-08-MMC Ver:1|17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor|||Meir Medical Center|No|Active, not recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|800|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 27, 2011|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809939||145990|
NCT00809952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUMREP-08-0656|Ultrasound Guided Artificial Insemination||UGAI|Hospital de Cruces||Completed||||||Phase 4|Observational|N/A||1|||||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2008|December 15, 2008|December 15, 2008||||No||https://clinicaltrials.gov/show/NCT00809952||145989|
NCT00809341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0802|R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Treatment Intensification With R-ICE and High-Dose Cyclophosphamide for Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|January 2009|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 16, 2008|Yes|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00809341||146036|
NCT00809627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 2006 0051|Caffeine Versus Placebo for Spinal Headaches|A Prospective Trial of IV Caffeine vs Placebo for Post-Dural-Puncture Headache in the Emergency Department||United States Naval Medical Center, Portsmouth|Yes|Completed|January 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|50 Years|No|||October 2013|October 28, 2013|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809627||146014|
NCT00809640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK 27|Active Management for Low Back Pain for 6 to 8 Year Old Schoolchildren|Active Management for Low Back Pain Taught to 6 to 8 Year Old Schoolchildren||Kovacs Foundation|Yes|Completed|February 2009|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|700|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809640||146013|
NCT00810849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPI-TRIAL1|A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis|A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis|IMPI|University of Cape Town|Yes|Completed|December 2008|August 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1400|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810849||145922|
NCT00816530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008002|A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.|A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.|somo•InSIGHT|U-Systems, Inc.|No|Completed|March 2009|December 2012|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15679|||Female|25 Years|N/A|No|Non-Probability Sample|Screening to determine eligibility for enrollment will be open to women of all races and        ethnicities who are asymptomatic for breast cancer and scheduled for routine screening        mammography at the study site. Women younger than 25 years of age will not be eligible to        participate. Potential participants must not be breastfeeding or pregnant at the time of        screening and must not plan on becoming pregnant during the 12 month interval following        anticipated enrollment. Patients who have had breast surgeries or interventional breast        procedures in the past 12 months will also not be eligible to enter screening. Eligible        women who have breast implants will be allowed to participate.|December 2014|December 1, 2014|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816530||145487|
NCT00816543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_R_03761|Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma|A Single Arm Phase II Feasibility Study of Neoadjuvant Docetaxel, Oxaliplatin and S-1 Chemotherapy in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma.||Sanofi||Completed|December 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|75 Years|No|||December 2012|December 17, 2012|December 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00816543||145486|
NCT00817401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-200084001|Systemic Hypothermia Improves Outcome of Hypoxic-Ischemic Encephalopathy|Effect of Systemic Hypothermia on Neonatal Hypoxic-Ischemic Encephalopathy||Zhengzhou University|Yes|Completed|July 2002|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|100|||Both|N/A|10 Hours|No|||January 2009|January 5, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00817401||145420|
NCT00817661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-069|Vitamin A and Maternal-infant Flu Vaccine Response|Effect of Maternal Vitamin A Supplementation on Maternal Immune Response to Inactivated Influenza Vaccination, and on Passive Protection of Infants||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|February 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Female|22 Years|35 Years|Accepts Healthy Volunteers|||January 2009|January 1, 2013|January 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00817661||145400|
NCT00811109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A08-D12-VOL.6|HEMOTOL: Efficacy and Safety of Hemodialysis On-line Monitoring Devices on Hemodynamic Stability in Intensive Care Unit|HEMOTOL: Effects of New Dialysis On-line Monitoring Devices on Hemodynamic Stability During Intermittent Hemodialysis in Critically Ill Patients With Acute Kidney Injury : a Prospective Randomized Study.|HEMOTOL|University Hospital, Caen|Yes|Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00811109||145902|
NCT00811603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|474-07|Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery|Optimal Timing for Antibiotic Prophylaxis for Elective Cesarean Delivery in Term Gestations: A Randomized, Controlled Trial Comparing Cefazolin Administration Prior to Skin Incision Versus Following Cord Clamping||MemorialCare|Yes|Completed|August 2008|September 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811603||145864|
NCT00812396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-082|Biomarkers of Muscle Anabolism (MK-0000-082)|A Randomized, Single-Blind, Placebo-Controlled, Fixed-Sequence, Single-Dose, Parallel Design Study to Utilize Comparative Proteomics to Identify Early Biomarkers of Muscle Anabolism||Merck Sharp & Dohme Corp.|No|Completed|November 2007|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812396||145803|
NCT00811824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8839|Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors|Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors||Columbia University|No|Completed|July 2007|November 2012|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Female|21 Years|70 Years|No|||February 2013|February 21, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811824||145847|
NCT00812929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112025|A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise|A Multi-centre, Randomized, Double-blind, Five-way Crossover Study Evaluating the Dose Response and Duration of Action of GSK2190915 Compared to Placebo in Subjects With Mild Asthma Who Experience Exercise Induced Bronchoconstriction.||GlaxoSmithKline||Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|47|||Both|18 Years|55 Years|No|||February 2010|February 5, 2010|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812929||145762|
NCT00812942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Participation to Colorectal Cancer Screening With Fecal Occult Blood Test and Colonoscopy|Participation to Colorectal Cancer Screening With Faecal Occult Blood Test and Colonoscopy: an Italian, Multicenter, Randomized Population Study||Istituto Superiore di Sanità|No|Completed|November 2003|November 2008|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9889|||Both|55 Years|64 Years|No|||December 2008|December 19, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812942||145761|
NCT00812097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A105-0601-4|Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial|Study of the Safety and Effectiveness of Mentor Siltex® Contour Profile Gel Mammary Prostheses in Patients Who Are Undergoing Primary Breast Augmentation,Primary Breast Reconstruction or Revision|CPG|Mentor Worldwide, LLC|No|Completed|February 2002|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|955|||Female|18 Years|N/A|No|||January 2015|January 22, 2015|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812097||145826|
NCT00812110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081105|Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home|Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home||Akron Children's Hospital|No|Completed|December 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|336|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 13, 2012|December 18, 2008|Yes|Yes||No|October 31, 2011|https://clinicaltrials.gov/show/NCT00812110||145825|Exclusively urban,lower socioeconomic status population limits external generalizability. Study was uncontrolled; historical controls were referenced instead. Baseline vaccination rates were self-reported. Possible bias in at-risk determination.
NCT00812916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPRESSO|European Carto® XP REgistry for Validating Specialized CFAE SOftware|EXPRESSO - European Carto® XP REgistry for Validating Specialized CFAE SOftware|EXPRESSO|Biosense Webster, Inc.|No|Completed|September 2008|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|206|||Both|N/A|N/A|No|Probability Sample|Patients with persistent or longstanding persistent atrial fibrillation (AF), needing        radiofrequency (RF) ablation|January 2016|January 13, 2016|December 19, 2008||No||No|November 12, 2015|https://clinicaltrials.gov/show/NCT00812916||145763|
NCT00813202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR007573|An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure|An Open-label, Single Arm, Multi-centered Clinical Trial on the Hemodynamics and Safety of Nesiritide in the Treatment of Patients With Acute Decompensate Heart Failure||Xian-Janssen Pharmaceutical Ltd.|No|Completed|October 2006|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00813202||145741|
NCT00813215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-PPDysMet-AP|Postprandial Dysmetabolism|Postprandial Dysmetabolism - The Effects of Monounsaturated vs. Saturated Lipids on Lipid and Carbohydrate Metabolism and Inflammation in Healthy 1st Degree Relatives of Patients With Type 2 Diabetes.|PPDysMet|Aarhus University Hospital|Yes|Active, not recruiting|January 2009|August 2011|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2008|March 7, 2011|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813215||145740|
NCT00809354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091025|Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip|A Phase 3, Multi-Center, Randomized, Double-Blind, Controlled Study Of The Long-Term Analgesic Efficacy And Safety of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip||Pfizer|Yes|Terminated|February 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|2720|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|December 16, 2008|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00809354||146035|
NCT00809367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-159|Collection and Banking of Leukemia Cells MDS/AML|Collection and Banking of Leukemia Cells for Vaccine Generation and Research in Patients With Advanced MDS or AML||Dana-Farber Cancer Institute|Yes|Completed|October 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|90|||Both|18 Years|N/A|No|||January 2013|February 6, 2013|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809367||146034|
NCT00810264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELESTIAL|Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar|CELESTIAL Post Approval Registry: Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry|CELESTIAL|Biotronik, Inc.|No|Active, not recruiting|December 2008|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be obtained from the investigators' general patient population according to        the inclusion and exclusion criteria described below.|February 2016|February 24, 2016|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810264||145966|
NCT00810251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S08-001|MatrixRIB Implants for Surgical Stabilization of Flail Chest Injuries: A Registry|A Multi-Site Prospective, Non-Randomized Observational Study Utilizing MatrixRIB Implants for Surgical Stabilization of Flail Chest Injuries|MatrixRIB|Legacy Biomechanics Laboratory|No|Completed|December 2008|May 2011|Actual|April 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|21 Years|80 Years|No|Non-Probability Sample|Flail chest patients admitted to Level I and Level II trauma centers.|July 2011|July 5, 2011|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810251||145967|
NCT00810602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.095|Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant|Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant||University of Michigan Cancer Center|Yes|Completed|January 2009|July 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|December 17, 2008|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00810602||145941|
NCT00810628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSUIRB4613|Cognitive Behavioral Therapy for Depression in Parkinson's Disease|Depression in Parkinson's Disease: A Pilot Project Using Cognitive Behavioral Therapy (CBT) to Improve Depression and Coping||Oregon Health and Science University|No|Terminated|January 2009|December 2009|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|35 Years|85 Years|No|||December 2008|October 23, 2014|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810628||145939|
NCT00810615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20080137H|Treatment of Traumatic Brain Injury With Hyperbaric Oxygen Therapy|Treatment of Moderate to Mild Cognitive Dysfunction Caused by Traumatic Brain Injury (TBI) With Hyperbaric Oxygen Therapy (HBOT)||San Antonio Military Medical Center|Yes|Completed|February 2009|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|60 Years|No|||February 2013|February 28, 2013|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810615||145940|
NCT00810862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pimecrolimus1|Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children|A 3-Week, Single-Blind, Placebo-Controlled, Within-Patient, Randomized Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children||Children's Hospital of Michigan|No|Terminated|November 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|2 Years|17 Years|No|||December 2008|December 17, 2008|December 17, 2008|Yes|Yes|Lack of subject enrollment over the past two years.|No||https://clinicaltrials.gov/show/NCT00810862||145921|
NCT00811148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCBTR|Florida Center for Brain Tumor Research|Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research|FCBTR|University of Florida|No|Recruiting|March 2006|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Tissue, medical information, cerebrospinal fluid, blood and answers to Quality of Life      questionnaires will be stored and made available to researchers.|Both|N/A|N/A|No|Probability Sample|Children and adults scheduled to undergo brain surgery to remove tumor tissue.|January 2016|January 12, 2016|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811148||145899|
NCT00817115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-2008|Evaluation of Exposure Reduction Using Region-of-Interest Fluoroscopy (X-ray Fovea Imaging) in Cardiac Interventions|Trial to Determine Non-inferiority of Exposure Dose Reduction and Diagnostic Performance of Region-of-Interest Fluoroscopy (X-ray Fovea Imaging) Compared to Standard Fluoroscopy in Patients Undergoing Cardiac Interventional Procedures||Sunnybrook Health Sciences Centre||Active, not recruiting|February 2009|||December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|75|||Both|18 Years|N/A|No|||January 2009|August 6, 2009|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00817115||145442|
NCT00817674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#14081A|Sleep Disturbances as a Non-traditional Risk Factor in CKD-Actigraphy|Sleep Disturbances as a Non-traditional Risk Factor in CKD-Wrist Actigraphy|CRIC|University of Chicago|No|Completed|November 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|353|||Both|21 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|CKD subjects; healthy volunteers|September 2013|September 4, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817674||145399|
NCT00813449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|simcere001|Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma|Multicenter, Double-blinding, Randomized Controlled, Phase II Clinical Trial on Combined Chemotherapy of Endostar (Recombinant Human Endostatin) for Untreated Patients With Advanced Melanoma|melanoma|Simcere Pharmaceutical Co., Ltd|Yes|Recruiting|August 2008|August 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||November 2009|December 6, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813449||145722|
NCT00813475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184-08|Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study|Clinical Outcome of Tight Glucose Control of Diabetic Patients Hospitalized In General Internal Medicine Wards A National Israeli Study||Assaf-Harofeh Medical Center|No|Not yet recruiting|January 2009|July 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2008|December 22, 2008|December 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00813475||145721|
NCT00813800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003471|Varenicline in Bipolar Depressed Patients|Varenicline for Smoking Cessation in Bipolar Depressed Patients: An Open-Label 12-week Feasibility Trial|Varenicline|Mayo Clinic|No|Completed|January 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||December 2011|December 23, 2011|December 22, 2008|Yes|Yes||No|November 11, 2011|https://clinicaltrials.gov/show/NCT00813800||145696|Small sample size; limitations finding participants with stable state within their bipolar disorder.
NCT00813488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/3056/BP/US|Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain|A Double Blind, Active Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain||Teva Pharmaceutical Industries||Completed|December 2008|January 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|80 Years|No|||May 2012|May 22, 2012|December 19, 2008|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT00813488||145720|
NCT00811356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111319|A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria|A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects||GlaxoSmithKline|No|Terminated|December 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|December 18, 2008||No|safety issues (toxicity)|No||https://clinicaltrials.gov/show/NCT00811356||145883|
NCT00812630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #412|A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study|A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study||Population Council|No|Completed|December 2008|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|68|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812630||145785|
NCT00812643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1250C00032|Excretion of Radiolabelled AZD0837|An Open, Single Centre Pharmacokinetic (Phase 1) Study of the Biliary Excretion of AZD0837 and Metabolites Following a Single Dose of [3H] AZD0837 Given in the Duodenum Via a Loc-I-Gut Catheter to Young Healthy Male Subjects||AstraZeneca|No|Completed|January 2009|February 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 10, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812643||145784|
NCT00812656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StrokePanel08|Serial Measurement of a Plasma Stroke Biomarker Panel in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Serial Measurement of a Plasma Stroke Biomarker Panel in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Stroke08|Klinikum Ludwigshafen|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Adult patients undergoing cardiac surgery with the use of cardiopulmonary bypass|December 2009|December 2, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812656||145783|
NCT00809133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.12|Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours|A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours||Boehringer Ingelheim||Completed|May 2007|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|4||Actual|83|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|December 16, 2008||||No|February 16, 2016|https://clinicaltrials.gov/show/NCT00809133||146052|
NCT00812370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3070850|The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids|An Open-label, Dose-finding, Pharmacokinetic, Safety and Efficacy Study of Bivalirudin in Children Between 6 Months and 18 Years of Age|UNBLOCK|Children's Hospital Los Angeles|Yes|Completed|September 2008|July 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|6 Months|18 Years|No|||July 2014|July 9, 2014|December 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812370||145805|
NCT00809380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP|Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial|Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial|PP|St. Justine's Hospital|No|Terminated|June 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|12|||Both|8 Years|18 Years|No|||March 2013|March 18, 2013|December 15, 2008||No|Study ws terminated because of a too low recruitment rate.|No||https://clinicaltrials.gov/show/NCT00809380||146033|
NCT00809081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN Vs PN|Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy|A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy||Yonsei University|Yes|Recruiting|July 2007|January 2010|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|85 Years|No|||December 2008|December 15, 2008|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809081||146056|
NCT00809094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12112008-1378|NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients|A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients||Stanford University||Completed|November 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|7 Years|N/A|No|||April 2013|April 15, 2013|December 15, 2008|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT00809094||146055|
NCT00809653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/2008/Patient|Reducing the Pro-ischaemic Effects of Air Pollution Exposure Using a Simple Face Mask|Reducing the Pro-ischaemic Effects of Ambient Particulate Air Pollution in Patients With Coronary Heart Disease Using a Simple Face Mask Intervention||University of Edinburgh|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|N/A|N/A|No|||May 2009|March 30, 2010|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809653||146012|
NCT00809666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00/41 Brown|Measuring Blood Pressure in Pregnancy Using Mercury and Automated Device|A Prospective Randomised Study of Automated Versus Mercury Blood Pressure Recordings in Pregnancy|PRAM|St George Hospital, Australia|No|Completed|May 2000|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|220|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||December 2008|December 15, 2008|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809666||146011|
NCT00809965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014710|An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|November 2008|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15526|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|December 16, 2008|Yes|Yes||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00809965||145988|
NCT00810277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22012|A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs|An Open Label Study to Evaluate the Safety and Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARDs.||Hoffmann-La Roche||Completed|November 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810277||145965|
NCT00810641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KONOS|Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo|Randomized Multicenter Study of Treatment of Horizontal Canal Benign Paroxysmal Positional Vertigo|BPPV-HC|Chonbuk National University|Yes|Completed|January 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|157|||Both|18 Years|80 Years|No|||May 2011|May 31, 2011|December 17, 2008||No||No|May 25, 2011|https://clinicaltrials.gov/show/NCT00810641||145938|In this study, resolution of BPPV was determined using a telephone interview during the follow-ups after one week.
NCT00811161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR12345|An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin|An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin||PerfAction Ltd.|No|Recruiting|May 2009|April 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00811161||145898|
NCT00811395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS6047|Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis|Long-term Extension of the Multinational, Double-blind, Placebo Controlled Studies PDY6045 and PDY6046 to Document the Safety of Teriflunomide When Added to Treatment With Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis With Relapses||Sanofi|Yes|Completed|October 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|182|||Both|18 Years|55 Years|No|||December 2012|December 18, 2012|December 18, 2008|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00811395||145880|
NCT00811642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05551|Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)|A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection||Merck Sharp & Dohme Corp.|No|Completed|November 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|December 18, 2008|No|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00811642||145861|
NCT00817687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21655|A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation|A Randomised, Multicenter, Open-label Study Evaluating the Impact on the Fibrosis at Week 52 of an Early Biopsy at (D10) Versus Standard Management in Patients Who Have Undergone de Novo Renal Transplantation and Received a Marginal Organ Transplant||Hoffmann-La Roche||Completed|January 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00817687||145398|
NCT00817154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH080021|Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI)|Individually Based Psychosocial Rehabilitation for Older People With SMI||Dartmouth-Hitchcock Medical Center|Yes|Completed|November 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|38|||Both|50 Years|N/A|No|||May 2014|May 5, 2014|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817154||145439|
NCT00817440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16.12.2008|Effects of Fasting and Exercise on Insulin and GH Signaltransduction in Muscle and Fat|Effects of Fasting and Exercise on Insulin and GH Signaltransduction in Muscle and Fat|FEIGH|University of Aarhus||Completed|December 2008|||May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2011|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817440||145417|
NCT00817700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#13159A|Impact of a Sleep Debt in Middle-Aged and Older Adults|Alteration of Sleep and Circadian Timing in Aging- Impact of a Sleep Debt in Middle-Aged and Older Adults|PPG|University of Chicago|No|Completed|April 2005|May 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817700||145397|
NCT00813813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-Intradiscal rhGDF-5-01|Intradiscal rhGDF-5 Phase I/II Clinical Trial|Phase I/II, Multicenter, Open-label, Single Administration, Dose Finding, Clinical Trial to Evaluate the Safety and Tolerability of Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration||DePuy Spine|Yes|Completed|June 2008|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 22, 2008|No|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT00813813||145695|
NCT00813826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLC022/201|Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia||Solace Pharmaceuticals|No|Active, not recruiting|January 2009|November 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||July 2009|July 29, 2009|December 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813826||145694|
NCT00811837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RemiSun 1|The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers|The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers|RemiSun 1|Medical University of Vienna|No|Recruiting|January 2009|September 2009|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811837||145846|
NCT00812383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBRA|Carotid With Bivalirudin Angioplasty|Carotid With Bivalirudin Angioplasty|COBRA|Medstar Research Institute||Completed|August 2003|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812383||145804|
NCT00812149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090058|Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3|Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers:The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3||National Institutes of Health Clinical Center (CC)||Completed|December 2008|May 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|86|||Both|18 Years|65 Years|No|||May 2014|December 11, 2015|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812149||145822|
NCT00812968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-007|Study of Lenalidomide to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndromes (MDS) With a Del(5)(q31-33) Abnormality.|A Multicenter, Single-arm Study to Assess the Safety, Pharmacokinetics and Efficacy of Lenalidomide in Japanese Patients With Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5(q31-33) Abnormality and Symptomatic Anemia||Celgene|Yes|Completed|August 2007|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|20 Years|N/A|No|||September 2013|September 30, 2013|December 17, 2008|Yes|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT00812968||145759|
NCT00812409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611004694|Resistance and Aerobic Exercise With Nutritional Supplementation in Men and Women|Resistance and Aerobic Exercise With Nutritional Supplementation in Men and Women|S-017|Purdue University||Completed|April 2007|September 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|580|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812409||145802|
NCT00812422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG_DIBU_2007|The Efficacy and Safety of Dexibuprofen Syrup|Multi-center, Randomized, Double Blinded (Double-dummy), Active-Controlled Parallel-group Comparative, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Dexibuprofen Syrup Compared to Ibuprofen Syrup in Patients With Fever of Common Cold (Acute Upper Respiratory Infection)||Inje University|Yes|Completed|February 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|260|||Both|6 Months|14 Years|No|||January 2010|January 15, 2010|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812422||145801|
NCT00809146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS053031|Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications|A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics|RAMPART|University of Michigan|Yes|Completed|June 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1023|||Both|N/A|N/A|No|||April 2012|April 13, 2012|December 15, 2008|Yes|Yes||No|March 18, 2012|https://clinicaltrials.gov/show/NCT00809146||146051|
NCT00809159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2209|Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis|Randomized, Placebo Controlled Double Blind, Multi-center Phase II Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Moderate to Severe Ankylosing Spondylitis||Novartis||Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|60|||Both|18 Years|65 Years|No|||August 2015|December 7, 2015|December 16, 2008|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT00809159||146050|
NCT00808834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-335-C-008|Non-dispense Comfort Comparison of Two Silicone Hydrogel Lenses|Non-dispense Comfort Comparison of Two Silicone Hydrogel Lenses||Alcon Research|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|N/A|N/A|No|||January 2012|June 26, 2012|December 11, 2008|Yes|Yes||No|June 18, 2010|https://clinicaltrials.gov/show/NCT00808834||146074|
NCT00809068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID: 2005-001|High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone|Effects of Tibolone and PPARα-agonist on HDL Metabolism in Postmenopausal Women|TibFen|Keogh Institute for Medical Research|Yes|Completed|August 2005|October 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 31, 2010|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00809068||146057|
NCT00808860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes II-Study 2|Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients|Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients||Hanoi Medical University|Yes|Completed|February 2008|December 2008|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|70 Years|No|||December 2008|December 3, 2010|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808860||146073|
NCT00810017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT_H446Us|Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer|Phase II Clinical Study Combining Trastuzumab With Etoposide in Treatment of HER2-Positive Metastatic Breast Cancer.||Washington Hospital Center|Yes|Terminated|February 2009|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|December 16, 2008|Yes|Yes|Terminated due to difficulty in accruing patients|No||https://clinicaltrials.gov/show/NCT00810017||145985|
NCT00810030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-IBD-07-COR|FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR|Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease|FER-IBD-COR|Vifor Inc.|No|Completed|October 2008|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|484|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810030||145984|
NCT00810043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0801 - SCORE|Medtronic SCORE Study - Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty|Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty|MDTSCORE|Medtronic Spine LLC|No|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|50 Years|N/A|No|||April 2014|April 3, 2014|December 12, 2008||No||No|October 26, 2011|https://clinicaltrials.gov/show/NCT00810043||145983|
NCT00809393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/27|Dose-ranging Study of Two Doses of Tranexamic Acid During Cardiac Surgery|Comparison of Two Tranexamic Acid Dose Regimens on Transfusion Needs During Cardiac Surgery With Cardiopulmonary Bypass|Exacylcardio|Hopital Foch|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809393||146032|
NCT00809406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0196-07-A717|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2007|||||N/A|N/A|N/A||||||||||||||December 15, 2008|December 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809406||146031|
NCT00809679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K862-08-2002|Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia|A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia||Pfizer|Yes|Terminated|December 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|December 15, 2008|Yes|Yes|Some patients experienced asymptomatic, transient elevations in liver transaminases|No||https://clinicaltrials.gov/show/NCT00809679||146010|
NCT00809991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-0859|Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate|Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|November 2008|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|188|||Male|18 Years|100 Years|No|||October 2015|October 6, 2015|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809991||145987|
NCT00810004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FERGI-MAIN|Maintenance Treatment of Iron Deficiency in IBD Patients|A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT®) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease|FER-IBD-MAIN|Vifor Inc.|No|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810004||145986|
NCT00810875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCVP-1|Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy|Analysis of the Maternal-fetal Interface During Maternal Hepatitis C Virus Infection and Influenza Virus Vaccination||University of California, San Francisco|No|Terminated|April 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|6|Samples With DNA|Plasma, peripheral and cord blood mononuclear cells, placental tissue|Both|N/A|N/A|No|Non-Probability Sample|Both groups will be selected from an outpatient obstetrics clinic.|August 2014|August 21, 2014|December 16, 2008||No|Terminated due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT00810875||145920|
NCT00811408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626799|Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy|Modulating the Expression of Oncoproteins of Papillomavirus (HPV) to Increase Radiosensitivity: a Phase I Study of Antiviral Agent Cidofovir and Chemoradiotherapy Therapy in Cervical Cancers||National Cancer Institute (NCI)||Recruiting|April 2008|||October 2009|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|70 Years|No|||July 2009|January 27, 2010|December 18, 2008||||No||https://clinicaltrials.gov/show/NCT00811408||145879|
NCT00811668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_VentCR_13/2008|Comparison of CPAP With SOMNOventCR in Patients With Underlying Heart Disease, Combined OSA and CSR|Crossover Comparison of Treatment With Continuous Positive Airway Pressure and Treatment With Adaptive Servo Ventilation (SOMNOventCR) in Patients With Underlying Heart Disease, Combined Obstructive Sleep Apnea and Cheyne-Stokes Respiration.|VCR|Wissenschaftliches Institut Bethanien e.V|No|Completed|May 2008|October 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811668||145859|
NCT00811876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-08-EGD-02|Retrospective, Non-interventional Study of Depo-Eligard®.|Monitoring Tolerance, Safety and Acceptance of Depo-Eligard® in an Open Label, Retrospective, Non-interventional Clinical Trial|OCT|Astellas Pharma Inc|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|140|||Male|18 Years|N/A|No|Non-Probability Sample|Patients from Belgian participating investigator sites having been prescribed        Depo-Eligard® in accordance with the terms of the marketing authorization, on treatment        with Depo-Eligard® for at least six months.|January 2010|January 21, 2010|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811876||145843|
NCT00817167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPR0006|Added Value of inReach Software on Performance Characteristics of Standard Bronchoscopy|Open Label, Randomized, Comparative, Single Center, Pilot Study to Assess the Added Value of inReach Technology Software on Performance Characteristics of Standard Bronchoscopy.||superDimension Ltd.|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|January 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00817167||145438|
NCT00817713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257/08|Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?|Can Anthelminthic Treatment Delay the Progression of HIV? Randomised Open-label Trial Testing Presumptive Anthelminthic Treatment on Progression of HIV in ART-naïve HIV-positive Patients in a Rural African Setting With Presumed High Prevalence of Helminth Infections.||Swiss Tropical & Public Health Institute|No|Terminated|January 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|295|||Both|18 Years|N/A|No|||April 2009|February 15, 2011|January 5, 2009||No|Terminated prematurely due to recruitment difficulties. Expansion to more study sites not    planned.|No||https://clinicaltrials.gov/show/NCT00817713||145396|
NCT00813501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07200|Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases|Evaluation of Clinical Utility of the Cylex ImmunKnow Assay in Hematopoietic Cell Transplantation||City of Hope Medical Center|Yes|Terminated|June 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|65 Years|No|Probability Sample|Patients undergoing allogeneic hematopoietic stem cell transplantation at the City of Hope        Medical Center|March 2011|March 3, 2011|December 20, 2008||No|Terminated at the request of the study sponsor|No||https://clinicaltrials.gov/show/NCT00813501||145719|
NCT00813839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H60971-32402-02|Automated Ventilator Controlled Weaning vs Daily Spontaneous Breathing Trial in Difficult to Wean ICU Patients|Comparison of Automated Ventilator Controlled Weaning to Daily Spontaneous Breathing Trial Weaning Protocol in ICU Patients Following Prolonged Mechanical Ventilation.||University of California, San Francisco|No|Withdrawn|November 2008|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|December 19, 2008||No|for inability to enroll subjects.|No||https://clinicaltrials.gov/show/NCT00813839||145693|
NCT00812435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTEEM|Eptifibatide and ST Segment Resolution Following Primary PCI|Eptifibatide and ST Segment Resolution Following Primary PCI|ESTEEM|Medstar Research Institute|Yes|Terminated|August 2007|March 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|February 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812435||145800|
NCT00812981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111954|A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.|Non-inferiority Study of GSK Biologicals' Pandemic Influenza Vaccine 1562902A.||GlaxoSmithKline||Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|320|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||September 2009|September 9, 2009|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812981||145758|
NCT00808873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-7|Socio-Educational Intervention for Rural Suicide Attempters|A Randomized Control Trial of a Socio-Educational Intervention for Rural Suicide Attempters in Tianjin Municipality and Shandong Province of China||Beijing HuiLongGuan Hospital|No|Recruiting|November 2008|March 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|450|||Both|18 Years|N/A|No|||November 2008|December 15, 2008|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808873||146072|
NCT00808886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor478308ctil|Study of Comparison Between Pentacam and locs3|Comparison Between Pentacam Scheimpflug System and locs3 in Grading of Cataract||Soroka University Medical Center|No|Not yet recruiting|December 2008|May 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Probability Sample|catract patients who are coming for pre- surgical evaluation.|November 2008|December 15, 2008|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808886||146071|
NCT00809107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC3471|Frozen Embryo Transfer (FET) in Natural Cycles or in Natural Cycles Controlled by Human Chorionic Gonadotropin (hCG) Administration|Cryopreserved-Thawed Embryo Transfer in Natural Cycle or in Natural Cycles Controlled by External Administration of hCG: a Prospective Randomized Study|FRET|Universitair Ziekenhuis Brussel|No|Completed|October 2006|January 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|17 Years|40 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809107||146054|
NCT00809120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER20357|Tolerance to Electrostimulation in COPD Patients|Investigation of Clinical Tolerance, Cardio-respiratory Response and Muscle Fatigue During Electrostimulation|TOES|Laval University|No|Completed|December 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|40 Years|N/A|No|||September 2008|June 9, 2010|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809120||146053|
NCT00809445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080379|Rapid HIV Testing and Counseling in Drug Abuse Treatment|HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S.||University of Miami|Yes|Completed|January 2009|February 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1281|||Both|18 Years|N/A|No|||September 2014|October 13, 2015|December 16, 2008||No||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00809445||146028|
NCT00812955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-667|Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides|An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects With Hypercholesterolemia||AstraZeneca|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|474|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|December 18, 2008|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00812955||145760|
NCT00809692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10898|In Vivo Assessment of Histamine Pharmacodynamics|In Vivo Functional Assessment of Histamine Pharmacodynamics in Children||Children's Mercy Hospital Kansas City|No|Active, not recruiting|September 2007|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|7 Years|18 Years|No|||April 2013|April 30, 2013|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809692||146009|
NCT00810056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0516b|Fostering Healthy Futures Efficacy Trial for Preadolescent Youth in Foster Care|Fostering Healthy Futures Efficacy Trial for Preadolescent Youth in Foster Care||University of Colorado, Denver|No|Active, not recruiting|June 2007|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|256|||Both|9 Years|11 Years|No|||November 2015|November 10, 2015|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810056||145982|
NCT00810069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12329|Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder|Comparison of Two Different Treatment Strategies in Patients With Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy||Eli Lilly and Company|No|Completed|November 2008|March 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|840|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|December 16, 2008||No||No|February 4, 2011|https://clinicaltrials.gov/show/NCT00810069||145981|
NCT00810290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11214|Lawrence Latino Diabetes Prevention Project|Lawrence Latino Diabetes Prevention Project|LLDPP|University of Massachusetts, Worcester|No|Completed|July 2004|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|312|||Both|25 Years|N/A|No|||February 2010|February 4, 2010|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810290||145964|
NCT00810667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12450A|Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia|A Randomised, Double-blind, Parallel-Group, Fixed Dose Study Exploring the Efficacy and Safety of Lu AE58054 as Augmentation Therapy to Risperidone in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|November 2008|February 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|65 Years|No|||August 2012|August 13, 2012|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810667||145936|
NCT00810654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.0601.54|Effect of Aspergillus Niger Prolyl Endoprotease (AN-PEP) Enzyme on the Effects of Gluten Ingestion in Patients With Coeliac Disease|Study on The Effectiveness of Oral Administration of Prolyl Endoprotease for Gluten Detoxification as a Means to Treat Coeliac Disease||VU University Medical Center|No|Completed|May 2008|December 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|70 Years|No|||May 2009|January 18, 2011|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810654||145937|
NCT00810888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS044283_STOP_IT|The Spot Sign for Predicting and Treating ICH Growth Study|The Spot Sign for Predicting and Treating Intracerebral Hemorrhage Growth Study|STOP-IT|University of Cincinnati|Yes|Active, not recruiting|November 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|184|||Both|18 Years|80 Years|No|||May 2015|May 28, 2015|December 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810888||145919|
NCT00810901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK079684|Intervention to Motivate Teens to be a Designated Organ Donor on Driver's License|Multimedia Intervention to Motivate Ethnic Teens to be Designated Donors|Idecide|University of Hawaii|Yes|Completed|April 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|429|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||January 2015|June 23, 2015|December 17, 2008||No||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00810901||145918|
NCT00811174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAM10-03|Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases|Clinical Study to Evaluate the Efficacy, Safety and Kinetics of Octagam 10% for Replacement Therapy in Primary Immunodeficiency Diseases||Octapharma|No|Terminated|January 2009|||September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|2 Years|75 Years|No|||May 2013|May 6, 2013|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811174||145897|
NCT00811681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070123|Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept|Effect of Pioglitazone Administered to Patients With Friedreich's ATAXIA:Proof of Concept|ACTFRIE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2008|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|7 Years|24 Years|No|||August 2013|September 2, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811681||145858|
NCT00811889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-C-0804|Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease|A 52-Week, Multi-center, Double-blind, Randomized, Placebo-controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2||Reata Pharmaceuticals, Inc.|Yes|Completed|April 2009|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|227|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811889||145842|
NCT00822315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12180 REFLATE TB|Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis|Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|July 2009|May 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822315||145049|
NCT00822549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 05038|Pharmacokinetic, Pharmacodynamic and Pharmacogenetic of Morphine After Surgery|Assessment of the Pharmacokinetic, Pharmacodynamic, Pharmacogenetic Relationships of Morphine and Metabolites After Severe Postoperative Pain in Adults||Assistance Publique - Hôpitaux de Paris|No|Completed|September 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|438|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing major orthopaedic surgery with severe postoperative pain. All the        patients included in the study received intravenous morphine|January 2009|December 10, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822549||145031|
NCT00818051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000629770|Radiation Therapy in Treating Women Who Have Undergone Breast Conservation Surgery and Systemic Therapy for Early Breast Cancer|Randomized Trial Testing Dose Escalated Intensity Modulated Radiotherapy for Women Treated by Breast Conservation Surgery and Appropriate Systemic Therapy for Early Breast Cancer||National Cancer Institute (NCI)||Recruiting|August 2008|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|840|||Female|18 Years|N/A|No|||January 2009|January 6, 2011|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818051||145371|
NCT00812994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3097-19671-08|Neurotrophic Factors and Depression|Blood Levels of Neurosteroids and Neurotrophic Factors in Normal Controls and in Patients With Major Depression|Lex/BDNF|University of California, San Francisco|No|Completed|January 2003|November 2008|Actual|December 2006|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Male|22 Years|55 Years|Accepts Healthy Volunteers|||December 2008|December 19, 2008|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812994||145757|
NCT00808899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB2008|Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma|Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma||St. Jude Children's Research Hospital|No|Terminated|December 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|18 Years|No|||May 2010|May 25, 2010|December 11, 2008|Yes|Yes|Voluntarily closed and terminated by the PI due to lack of feasibility|No|April 19, 2010|https://clinicaltrials.gov/show/NCT00808899||146070|NB2008 was closed because of the publication of a new standard of care for treating high-risk neuroblastoma.At the time of closure, NB2008 had enrolled only 4 patients, which was an insufficient number of patients to answer the primary objective.
NCT00809458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0808|Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer|A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy||New Mexico Cancer Care Alliance|Yes|Terminated|September 2008|February 2013|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|N/A|No|||June 2015|June 22, 2015|December 15, 2008|Yes|Yes|Low rate of accrual.|No|June 6, 2015|https://clinicaltrials.gov/show/NCT00809458||146027|
NCT00809471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-302|Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in the Treatment of Erectile Dysfunction in Diabetic Men|REVIVE-D|VIVUS, Inc.|No|Completed|December 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|390|||Male|18 Years|N/A|No|||August 2012|August 10, 2012|December 15, 2008|Yes|Yes||No|May 25, 2012|https://clinicaltrials.gov/show/NCT00809471||146026|
NCT00809419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVI-008|A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy|A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration in Patients That Require Persistent Anti-VEGF Therapy|MERITAGE|NeoVista|No|Active, not recruiting|November 2008|November 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|50 Years|N/A|No|||July 2011|July 26, 2011|December 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809419||146030|
NCT00809718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBTC 29RR|The Effect of Rifapentine on Raltegravir|The Effect of Rifapentine on Plasma Concentrations of Raltegravir||The University of Texas Health Science Center at San Antonio|Yes|Completed|February 2009|August 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 21, 2015|December 15, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00809718||146007|
NCT00810082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDI001|Randomized ActiveStep Clinical Evaluation|Randomized ActiveStep Clinical Evaluation|RACE|Dartmouth-Hitchcock Medical Center|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Both|65 Years|N/A|No|||February 2012|February 21, 2012|December 16, 2008||No||No|October 24, 2011|https://clinicaltrials.gov/show/NCT00810082||145980|
NCT00810342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA115614|Physical Activity in Women With Infants|Physical Activity in Women With Infants|"NaMikimiki"|University of Hawaii|Yes|Completed|April 2008|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|311|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|June 1, 2015|December 17, 2008||No||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00810342||145960|
NCT00810355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6629-R|Cognitive Behavior Therapy and Work Outcome|Effects of CBT and Cognitive Remediation on Work in Schizophrenia||VA Office of Research and Development|No|Active, not recruiting|October 2009|December 2017|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810355||145959|
NCT00810303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Efavirenz - 2008|Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2|||University Medicine Greifswald|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|December 17, 2008||No||No|June 21, 2010|https://clinicaltrials.gov/show/NCT00810303||145963|
NCT00810316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131015|Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population|Evaluate The Pharmacokinetics Of Two Alprazolam Formulations (Immediate Release And Extended Release Tablets) And A Clonazepam Tablet In A Healthy Mexican Population||Pfizer|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2009|September 30, 2009|December 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00810316||145962|
NCT00810927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-270602|Role of Nitrogen Oxide (NO) in the Control of Choroidal Blood Flow During a Decrease in Ocular Perfusion Pressure|Role of NO in the Control of Choroidal Blood Flow During a Decrease in Ocular Perfusion Pressure||Medical University of Vienna|Yes|Completed|September 2003|August 2005|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||December 2008|December 17, 2008|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810927||145916|
NCT00810914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333-06|Patient Controlled Epidural Analgesia Versus Continuous Epidural Infusion: Obstetrical and Neonatal Outcomes|Patient Controlled Epidural Infusion Vs. Continuous Epidural Infusion: Obstetrical and Neonatal Outcomes|Epidural|MemorialCare|No|Recruiting|March 2006|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|3||Anticipated|270|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00810914||145917|
NCT00811187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-09-395|Paracervical Block During Office Hysteroscopy|Paracervical Block During Office Hysteroscopy: A Randomized Double Blind Placebo-Controlled Trial||Montefiore Medical Center|No|Completed|March 2007|September 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|21 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 17, 2008|December 16, 2008||Yes||No||https://clinicaltrials.gov/show/NCT00811187||145896|
NCT00811421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP.07.31080.002|Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy|Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy|MiPPAD|Hospital Clinic of Barcelona|Yes|Completed|September 2009|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|5820|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 19, 2014|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811421||145878|
NCT00811694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-200104|Neurovascular Coupling in Patients With Open Angle Glaucoma|Neurovascular Coupling in Patients With Open Angle Glaucoma||Medical University of Vienna|Yes|Terminated|October 2006|May 2012|Actual|April 2007|Actual|N/A|Observational|N/A||2|Anticipated|15|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|July 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00811694||145857|
NCT00811902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI10566|Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis|A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.||Sanofi|Yes|Completed|December 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|405|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811902||145841|
NCT00818077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03654-07-A|Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food|Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food||HealthPartners Institute|No|Completed|January 2008|September 2010|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|type 2 diabetes, 18 years of age of older, currently taking metformin|August 2013|November 30, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818077||145369|
NCT00818480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-101|An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155|Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155||Astellas Pharma Inc|No|Completed|February 2006|August 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818480||145338|
NCT00818493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q8003-020|Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty|An Open-Label Pilot Study of the Analgesic Efficacy and Safety Of Q8003 and of the Conversion From IV Morphine PCA Analgesia to Q8003 or to Percocet® in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty or Total Hip Arthroplasty||QRxPharma Inc.|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818493||145337|
NCT00818766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p002164|Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy.|Extended Antibiotic Prophylaxis for the Prevention of Infectious Complications Associated With Tube Thoracostomy in Patients Undergoing Elective Thoracic Surgery: A Prospective, Randomized, Placebo-Controlled Trial||Brigham and Women's Hospital|No|Completed|March 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00818766||145316|
NCT00812669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01 ICORG|CLL-Irl Study. ICORG 07-01, V7|An Open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide and Rituximab in Patients With Chronic Lymphocytic Leukaemia Who Are Newly Diagnosed, Have Relapsed or Are Resistant to First-Line Treatment||ICORG- All Ireland Cooperative Oncology Research Group||Active, not recruiting|August 2008|||June 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|145|||Both|N/A|64 Years|No|||February 2016|February 12, 2016|December 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812669||145782|
NCT00812682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00021|Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler|Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler|REALITY|AstraZeneca|No|Completed|September 2006|August 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|217|||Both|12 Years|N/A|No|Non-Probability Sample|Primary Care|January 2011|January 21, 2011|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812682||145781|
NCT00808912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU2007-028|Does Sildenafil Increase Exercise Performance in Air Pollution?|Decreased Pulmonary Artery Pressure by Oral Sildenafil Injection During Exercise in Air Pollution Increases Exercise Performance.||Marywood University|No|Completed|December 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|24|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2010|June 22, 2010|December 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00808912||146069|
NCT00808925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5524-YE-CTIL|The Impact of Heat Acclimation on Pro- and Anti- Inflammatory Cytokine Response|The Impact of Heat Acclimation on Pro- and Anti- Inflammatory Cytokine Response||Sheba Medical Center|No|Terminated|January 2009|July 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808925||146068|
NCT00809172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.476|Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients|Multicenter Randomised Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients|METHODA|Hospices Civils de Lyon|No|Completed|December 2008|April 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2009|May 13, 2013|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809172||146049|
NCT00810381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-211097|Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects|Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects||Medical University of Vienna|Yes|Completed|January 1999|June 1999|Actual|June 1999|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|14|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||December 2008|December 17, 2008|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810381||145957|
NCT00809432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/2008/Pilot|The Cardiovascular Benefits of Reducing Personal Exposure to Air Pollution|Beneficial Cardiovascular Effects of Reducing Exposure to Particulate Air Pollution With a Simple Facemask||University of Edinburgh|No|Completed|August 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2008|December 15, 2008|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809432||146029|
NCT00809705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP21572|A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of Taspoglutide on Gastric Emptying Measured by a Paracetamol Test After Single Dose and After Multiple Doses in Patients With Type 2 Diabetes||Hoffmann-La Roche||Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809705||146008|
NCT00810329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-481|Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome|Identify Unique Set of Proteins in Cerebrospinal Fluid, Which Are Believed to be Found in Chronic Fatigue Syndrome Participants, But Not in Healthy Controls.||Georgetown University|Yes|Completed|July 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|160|Samples With DNA|Cheek swabs, on the right and left inner cheek. Others:Cerebrospinal fluid samples,Blood      samples Urine samples.|Both|21 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|1. Georgetown University Division of Rheumatology, Immunology and Allergy and other             Divisions          2. IRB-approved websites and support groups.          3. IRB- approved advertisments          4. Self-referral.|February 2014|February 24, 2014|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810329||145961|
NCT00810368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-068|Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)|Carnosine in Gulf War Illness (GWI)||Georgetown University|No|Completed|August 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|34 Years|82 Years|No|||February 2014|February 24, 2014|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810368||145958|
NCT00810680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCH-VAL-01|Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)|Use of Valproic Acid in Relapsed or Refractory Chronic Lymphocytic Leukemia||All India Institute of Medical Sciences, New Delhi|No|Recruiting|September 2008|March 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2008|December 17, 2008|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00810680||145935|
NCT00811213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-08E-108|SensAwake™ Sleep Quality Trial|SASQT: SensAwake™ Sleep Quality Trial A Study to Test the Efficacy of the SensAwake™ Modification to Automatically Titrating Continuous Positive Airway Pressure to Reduce Wake After Sleep Onset in Patients With Moderate to Severe Obstructive Sleep Apnea.|SASQT|Fisher and Paykel Healthcare|No|Completed|October 2008|August 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|65 Years|No|||July 2011|July 10, 2011|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811213||145894|
NCT00811200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09.|Treatment Of Radiation Retinopathy Trial|Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma.|TORR|Leiden University Medical Center|Yes|Not yet recruiting|September 2009|||January 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|220|||Both|18 Years|N/A|No|||June 2009|June 30, 2009|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811200||145895|
NCT00811434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808-19|Study of Lactulose in Children With Chronic Liver Disease|Improvement of Cognitive Function and Healthcare -Related Quality of Life After Lactulose Treatment in Children With Chronic Liver Disease|MHE|Indiana University|Yes|Terminated|January 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|5 Years|18 Years|No|||February 2014|February 7, 2014|December 18, 2008||No|funding period ended|No|October 9, 2012|https://clinicaltrials.gov/show/NCT00811434||145877|
NCT00811447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_02195|Taxotere New Indication - Gastric Cancer Treatment Registration Trial|Open Label, Randomized Multicenter Study Docetaxel + 5-fluorouracil + Cisplatin Compared to Cisplatin + 5-fluorouracil in Patients With Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease||Sanofi|No|Completed|November 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|70 Years|No|||August 2012|August 30, 2012|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811447||145876|
NCT00811915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/125/HP|Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation|A Prospective, Comparative, Multicenter, Randomized Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation|EPARGNE|University Hospital, Rouen|No|Completed|January 2009|June 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|76 Years|No|||June 2014|June 18, 2014|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811915||145840|
NCT00812227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001181|Neural Correlates of Psychodynamic Psychotherapy for Depression|Neural Correlates of Psychodynamic Psychotherapy for Depression||Massachusetts General Hospital|No|Completed|August 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|60 Years|No|||May 2013|May 9, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812227||145816|
NCT00817765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 08.03|Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir|Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir|EPOS|Radboud University|No|Completed|January 2009|October 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 27, 2009|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00817765||145392|
NCT00817778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00019|Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin|A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin||AstraZeneca|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|30 Years|75 Years|No|||October 2012|October 16, 2012|January 5, 2009|Yes|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT00817778||145391|The primary objective of the study was to assess safety and tolerability and hence the study was not sized based on statistical considerations. The most import outcome, "no safety or tolerability concerns were identified", is not a numerical variable
NCT00818090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-LU08-03; CRCST-L-0003|Paclitaxel and Cisplatin for Thymic Neoplasm|A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma||Korean Cancer Study Group|No|Terminated|September 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||September 2012|April 11, 2013|January 5, 2009||No|marginal statistical significance|No||https://clinicaltrials.gov/show/NCT00818090||145368|
NCT00818103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007027|Characteristic Study on Chinese Patients With Multiple Sclerosis|Characteristic Study on Chinese Patients With Multiple Sclerosis||Sun Yat-sen University||Recruiting|January 2006|January 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|600|||Both|N/A|65 Years|No|||September 2009|September 27, 2009|December 31, 2008|No|Yes||Yes||https://clinicaltrials.gov/show/NCT00818103||145367|
NCT00818116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-08-001|Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL|Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation||Alcon Research|No|Completed|December 2008|||July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|50 Years|75 Years|No|||June 2010|June 30, 2010|January 6, 2009|Yes|Yes||No|June 30, 2010|https://clinicaltrials.gov/show/NCT00818116||145366|
NCT00818506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPF-TAD-1|Associations Between Depression and Cardiovascular Disease - a Study of Patients With Late Onset Depression|Associations Between Depression and Cardiovascular Disease in Patients With Late Onset, Single Episode Major Depressive Disorder||University of Aarhus|No|Completed|March 2009|June 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|55|Samples With DNA|Whole Blood|Both|50 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Psychiatric treatment facilities (e.g. psychiatric hospital, private psychiatrist).|November 2012|November 20, 2012|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818506||145336|
NCT00813007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0723|Radical Trachelectomy for Cervical Cancer|Radical Trachelectomy Outcomes in the Treatment of Early Stage Cervical Cancer||M.D. Anderson Cancer Center|No|Recruiting|December 2008|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|40 Years|No|Non-Probability Sample|Women with histologically confirmed, primary adenocarcinoma, squamous cell carcinoma or        adenosquamous carcinoma of the uterine cervix.|September 2015|September 25, 2015|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00813007||145756|
NCT00808938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28508|A Pilot Study of the Use of Magnetic Seizure Therapy for Depression|A Pilot Study of the Use of Magnetic Seizure Therapy for Treatment Resistant Depression|MST|Bayside Health|No|Completed|January 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||December 2008|February 11, 2013|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808938||146067|
NCT00809484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5392L0027|Arimidex Bone Mass Index and Oral Bisphosphonates|A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.|ARBI|Hellenic Breast Surgeons Society|No|Completed|May 2004|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|220|||Female|18 Years|80 Years|No|Non-Probability Sample|Posmenopusal women with endocrine responsive breast cancer who are treated with the        aromatase inhibitor anastrozole|December 2008|January 3, 2009|December 16, 2008||||No||https://clinicaltrials.gov/show/NCT00809484||146025|
NCT00809185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1905|RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes|A Phase 2 Trial of RAD001(Everolimus) in Low and Intermediate-1 Risk Myelodysplastic Syndrome||Case Comprehensive Cancer Center|Yes|Terminated|November 2005|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|December 16, 2008|Yes|Yes|slow accrual|No|January 20, 2012|https://clinicaltrials.gov/show/NCT00809185||146048|The trial was stopped early due to slow accrual. 18-33 patients were needed to address objectives, however only 7 patients were enrolled. Insufficient patients responded to the treatment to allow laboratory correlates with response to be analyzed.
NCT00809198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-08-06|Kynex Versus Refresh Plus Study in Subject With Dry Eye|The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study||Alcon Research|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|20 Years|N/A|No|||February 2012|February 1, 2012|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809198||146047|
NCT00820131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK MUW 613/2007|Chronic Pain After Inguinal Hernia Repair|A Multicenter Prospective Randomized Trial on Chronic Pain After Inguinal Hernia Repair Using a Selfgrip-mesh|GRIP-ME|Medical University of Vienna||Completed|January 2008|December 2014|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|85 Years|No|||January 2009|December 8, 2014|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820131||145214|
NCT00820417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-225/ZD1839|Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib|Phase 1 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of the Combination of Cetuximab (C-225), a Chimeric Monoclonal Antibody Against the Epidermal Growth Factor Receptor (EGFR), and Gefitinib (ZD1839), a Selective EGFR Tyrosine Kinase Inhibitor, in Patients With Advanced Cancer||Harrison Clinical Research|No|Completed|June 2004|May 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label|2||Actual|63|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820417||145193|
NCT00809731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NTW-SER-2008/1|Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment|A Naturalistic Observational Study to Evaluate Efficacy of 2nd-generation Antipsychotics and Remission Status for Patients With Schizophrenia / Schizoaffective Disorder|QTP NIS|AstraZeneca|No|Completed|December 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|490|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with acute episode (first or relapse), or upon revisit and identified not        achieving remission of schizophrenia or schizoaffective disorder (according to remission        criteria of schizophrenia)|December 2010|December 8, 2010|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809731||146006|
NCT00810095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-PRIISM-01|Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study|A Feasibility Trial to Evaluate the MindFrame System in the Recanalization of Occluded Vessels in Patients Experiencing an Ischemic Stroke|PRIISM|MindFrame, Inc.|Yes|Completed|March 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|December 15, 2008||No||No|March 21, 2012|https://clinicaltrials.gov/show/NCT00810095||145979|
NCT00820989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220013432|Inflammation and the Host Response to Injury (In Healthy Volunteers)|Inflammation and the Host Response to Injury (In Healthy Volunteers)|Mono|Rutgers, The State University of New Jersey|No|Completed|February 2000|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|116|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00820989||145149|
NCT00810693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12934|A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)|Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)|PATENT-1|Bayer|Yes|Completed|December 2008|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|445|||Both|18 Years|80 Years|No|||October 2014|October 27, 2014|December 17, 2008|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT00810693||145934|
NCT00810940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbelaTBI2|Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury|Phase 1/2 Multicenter, Randomized, Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury|ABELADRUG200|Abela Pharmaceuticals, Inc.|Yes|Recruiting|October 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|16 Years|70 Years|No|||December 2010|December 6, 2010|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810940||145915|
NCT00810953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-103-P|A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy|A Phase I/II Clinical Study Using Pentamidine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Undergoing Standard Therapy||Oncozyme Pharma Inc.|Yes|Completed|January 2009|June 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810953||145914|
NCT00821587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040658|Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation|Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation||University of Florida|No|Completed|June 2004|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|January 9, 2009|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00821587||145104|
NCT00811460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP21844|A Study of Taspoglutide in Type 2 Diabetic Patients|A Double-blind, Crossover, Randomized, Placebo-controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-phase Insulin Secretion in Type 2 Diabetic Patients||Hoffmann-La Roche||Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811460||145875|
NCT00811707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-970112|Epidural Sonoanatomy Between Parturient and Non-Pregnant|To Compare Epidural Sonoanatomy Between Parturient and Non-Pregnant Young Female in Chinese Population||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|June 2008|August 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Female|25 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|from Kaohsiung Medical University Hospiral ward parturients|August 2008|December 18, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811707||145856|
NCT00822432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061005|Coproporphyrine Isomers and Methotrexate Elimination|Urinary Ratio of the Coproporphyrins Isomers I and III and Its Relationships With Methotrexate Elimination in Patients With a Lymphoid Malignancy|COMETH|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|85|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|-  Patients aged more than 18 y, hospitalized in the neurology or in the haematology             department at PSP hospital of Paris or in the haematology department at CHU of Tours          -  Who should receive high-dose methotrexate (> 1 g/m2) for one of the following             conditions : Central Nervous System Neoplasms; Lymphoma, Large B-Cell, Diffuse;             Precursor B-Cell Lymphoblastic Leukemia-Lymphoma or Burkitt lymphoma|January 2009|July 30, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822432||145040|
NCT00817895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-010|Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence|Clinical Randomized Control Trial of Intraoperative Implanting Chemotherapeutic Drugs Sustained Release Following Resection of Hepatocellular Carcinoma Against Postoperative Short-Term Recurrence||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|75 Years|No|||January 2009|January 6, 2009|January 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00817895||145383|
NCT00817791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liyang2007|Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery|Phase 1 Study of Protective Effect of Hyperbaric Oxygen Preconditioning on Brain and Myocardium Injury During CABG Surgery||Xijing Hospital|Yes|Completed|November 2007|March 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|1||Actual|49|||Male|N/A|80 Years|No|||March 2009|June 12, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00817791||145390|
NCT00818155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-197|Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Desvenlafaxine Succinate Sustained Release Administered Orally to Healthy Chinese Subjects.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00818155||145363|
NCT00818129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1820C00001|Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese|A Phase I, Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7295 Following Single and Multiple Ascending Oral Dose Administration in Healthy Male Japanese Subjects||AstraZeneca|No|Completed|December 2008|May 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 22, 2009|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00818129||145365|
NCT00818142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03653-07-A|Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder|Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder||HealthPartners Institute|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals diagnosed with type 1 diabetes and an eating disorder who manipulate their        insulin will be considered to join the ED/DM Recovery Group.|August 2013|November 30, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818142||145364|
NCT00818519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91772|GA YAZ ACNE in China Phase III|A Multicenter, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of an Oral Contraceptive Preparation YAZ (Drospirenone 3 mg / Ethinylestradiol 20 µg) for 6 Treatment Cycles in Women With Moderate Acne||Bayer|No|Completed|December 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|179|||Female|14 Years|45 Years|No|||August 2015|August 12, 2015|January 6, 2009||No||No|April 6, 2011|https://clinicaltrials.gov/show/NCT00818519||145335|
NCT00818532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-08-04|Corneal Astigmatism Measurement Study|||Alcon Research|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|July 2009|April 6, 2012|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818532||145334|
NCT00813020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3679|A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects|A Randomised, Single Centre, Double-blind, Incomplete Block Trial to Test for Equivalence Between Subcutaneous Injections of the GLP-1 Analogue NN9535 in 1 mg/ml, 3 mg/ml and 10 mg/ml Concentrations in Healthy Male Subject||Novo Nordisk A/S|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|44|||Male|18 Years|55 Years|No|||February 2015|February 20, 2015|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813020||145755|
NCT00819572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLX105CRD02|Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee|A Double-blind, Randomised, Placebo-controlled Phase I/IIa Study to Investigate the Safety, Tolerability and Efficacy on Pain of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee||ESBATech AG|Yes|Completed|December 2008|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|40 Years|N/A|No|||September 2010|September 23, 2010|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819572||145255|
NCT00809770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA022476A|Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill|Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill||University of Washington|No|Active, not recruiting|April 2008|August 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||March 2012|March 28, 2012|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809770||146003|
NCT00820768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA501|A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies|A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies||Celgene Corporation|No|Withdrawn|April 2012|April 2014|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820768||145166|
NCT00821288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC5741|Post-treatment Care of Breast Cancer Survivors|Post-treatment Care of Breast Cancer Survivors||Columbia University|Yes|Completed|July 2007|May 2013|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|140|||Female|18 Years|N/A|No|||July 2015|July 14, 2015|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821288||145127|
NCT00809744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2008-GURI-2|Vitamin D AND Glucose Handling Evaluated by Glucose Clamp|Vitamin D AND Cardiovascular Disease|D-clamp|University Hospital of North Norway|No|Completed|November 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|160|||Both|30 Years|75 Years|No|||November 2011|November 2, 2011|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809744||146005|
NCT00809757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-359|A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma|A Safety, Efficacy, and Tolerability Study of Daily Dosing With Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months With Asthma||Sunovion|No|Completed|December 2008|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|197|||Both|N/A|48 Months|No|||July 2014|July 1, 2014|December 15, 2008|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00809757||146004|
NCT00820716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3825|Exercise Training in Asthma|Comparison of Two Types of Exercise Training for Asthmatic Subjects : Interests and Limits||University Hospital, Strasbourg, France|No|Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|45|||Both|18 Years|45 Years|No|||August 2011|August 29, 2011|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820716||145170|
NCT00821002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 05|A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)|An Open-Label, Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|January 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821002||145148|
NCT00821275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007026|Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma|Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma||Sun Yat-sen University|Yes|Enrolling by invitation|January 2008|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Female|20 Years|50 Years|No|||January 2009|January 9, 2009|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00821275||145128|
NCT00822211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23140|Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy||Novartis||Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|404|||Both|18 Years|78 Years|No|||May 2012|May 4, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822211||145057|
NCT00821236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WLCVLV-001|Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK|A Prospective, Multi Center Clinical Comparison of Fellow Eyes Undergoing Lasik Using the Wavelight Allegretto Wave™ Excimer Laser in One Eye and the Amo/Visx Customvue™ or the Ladarvision 4000 Excimer Laser System in the Contralateral Eye|WLCVLV-001|Durrie Vision|No|Completed|January 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 25, 2013|January 9, 2009||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00821236||145131|
NCT00821249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-520-212|A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma|||Array BioPharma|No|Active, not recruiting|January 2009|||March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821249||145130|
NCT00821873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRB2008|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.|Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR Plug) for Repair of Defects Created at the Harvest Site During the Osteochondral Autograft Transfer System(OATS)Procedure|CRB|RTI Surgical|No|Completed|December 2008|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|55 Years|No|||November 2013|November 6, 2013|January 12, 2009||No||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00821873||145083|Enrollment was closed early due for 2 factors:1) Slow enrollment and 2) A potential change in the regulatory pathway for allografts used in cartilage repair.Of the 9 patients enrolled, 4 were lost to follow-up.
NCT00821886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 139|Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer|Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer||SCRI Development Innovations, LLC|No|Completed|February 2009|October 2014|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|January 12, 2009|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00821886||145082|
NCT00821860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00804|Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma|Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma|MesoVATS|Papworth Hospital NHS Foundation Trust|Yes|Completed|September 2003|May 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00821860||145084|
NCT00822172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPC-08-01|Evaluation of Cilostazol in Combination With L-Carnitine|Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication|ECLECTIC|Colorado Prevention Center|No|Completed|September 2008|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|164|||Both|40 Years|N/A|No|||April 2013|April 11, 2013|January 13, 2009|Yes|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00822172||145060|
NCT00817908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7267|Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients|Quantiferon - CMV and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients||University of Alberta|No|Completed|May 2008|April 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|18 Years|N/A|No|Probability Sample|The study will aim to enrol 120 D+/R- transplant patients.|April 2012|April 20, 2012|October 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00817908||145382|
NCT00817921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRU-07-11|Effect of Prematurity on Renal Function in 5 Years Old Children|Effect of Prematurity on Renal Function in 5 Years Old Children Comparison of Former Premature Children Treated by Ibuprofen in the Neonatal Period to Controls|SUIVIREIN|Maternite Regionale Universitaire|No|Completed|November 2008|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|168|Samples Without DNA|Blood and urine samples|Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|children from a previous trial followed at 3, 4 and 5 years of age|February 2014|February 4, 2014|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00817921||145381|
NCT00818298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|245/2008|24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study|24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study||Centre for Addiction and Mental Health|No|Completed|January 2009|June 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|No|||July 2012|July 6, 2012|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818298||145352|
NCT00818311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-D-121|Skin Safety Profile of Different Exposure to the Light Emitting Diode (LED) in Healthy Subjects|Evaluation of the Effect of Photomodulation on Skin Safety Profile Following Different Schedules of Exposure to the Light Emitting Diode LED (Gentlewaves®) in Randomized Healthy Subjects||L'Oreal|Yes|Completed|June 2008|December 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 6, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818311||145351|
NCT00819286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07071|Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain|A Prospective, Randomized-Controlled, Multicenter Study Evaluating Primary Plating in High-Risk Median Sternotomy Patients for Osteosynthesis and Pain|RESTORE|Biomet, Inc.|No|Completed|November 2008|December 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|January 6, 2009|Yes|Yes||No|December 27, 2011|https://clinicaltrials.gov/show/NCT00819286||145277|
NCT00818168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03275|Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)|Remicade Safety Line (Ankylosing Spondylitis)||Merck Sharp & Dohme Corp.|No|Completed|July 2003|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|320|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with ankylosing spondylitis.|September 2015|September 2, 2015|January 6, 2009|No|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00818168||145362|
NCT00818181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0206st|Open Label Safety Study of a Birch Pollen Allergen Extract|A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy||Allergopharma GmbH & Co. KG||Completed|June 2008|August 2010|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|60 Years|No|||March 2013|March 8, 2013|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818181||145361|
NCT00818584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-CL-2104|An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates|A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates||Astellas Pharma Inc|No|Completed|August 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|13|||Both|N/A|120 Days|No|||March 2013|March 4, 2013|January 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00818584||145330|
NCT00818545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRB-ER4017-07-01|Transcriptomic Study of ER 4017 Topical Application in Elderly Subject|Transcriptomic Study of ER 4017 Topical Application in Elderly Subject||L'Oreal|Yes|Completed|November 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Male|60 Years|75 Years|Accepts Healthy Volunteers|||January 2009|January 6, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818545||145333|
NCT00818805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-292ET|Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)|||Alcon Research|No|Completed|July 2008|||July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2010|May 29, 2012|January 7, 2009||No||No|December 3, 2009|https://clinicaltrials.gov/show/NCT00818805||145313|Technical problems with measurement leading to unreliable or uninterpretable data.
NCT00820677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00024779|Newborn Health Information Study|Innovative Delivery of Newborn Anticipatory Guidance: The Incorporation of Media-Based Learning Into the Primary Care Office.||University of Rochester|No|Completed|November 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|137|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|December 11, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820677||145173|
NCT00809211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-02 ICORG|Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|A Phase II Multi-center, Open-label, Study of Nilotinib at a Dose of 300mg Twice Daily in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||ICORG- All Ireland Cooperative Oncology Research Group||Active, not recruiting|October 2008|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|120 Years|No|||February 2016|February 12, 2016|December 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00809211||146046|
NCT00820144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2003 CTB|Cholera Toxin B Subunit (CTB) Administered by Mucosal Way in Healthy Adult Volunteer|Functional Exploration of the Immune Response Using the B-Subunit of Cholera Toxin Administered by Mucosal Way in Healthy Adult Volunteer: Potential Role in Development of Vaccine Processes||Centre Hospitalier Universitaire de Nice|No|Completed|April 2006|February 2007|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|January 9, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00820144||145213|
NCT00819845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uildm Rome|Ramipril Versus Carvedilol in Duchenne and Becker Patients|Effects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study.||Catholic University, Italy|No|Recruiting|December 2008|December 2016|Anticipated|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|194|||Male|2 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2016|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819845||145235|
NCT00820404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3219K1-1000|Study Evaluating Single Doses of BLI-489 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|54|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 16, 2009|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00820404||145194|
NCT00820703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEX-ULC-003|The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers|A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-escalation, Single-center Study of the Safety and Clinical Effect of Nexagon® in the Treatment of Participants With Diabetic Foot Ulcers||CoDa Therapeutics Inc.|No|Terminated|April 2009|December 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||August 2010|August 29, 2010|January 8, 2009||No|For business reasons|No||https://clinicaltrials.gov/show/NCT00820703||145171|
NCT00821262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO/URC/ER/mm 412/DG|Sevoflurane in Cardiac Surgery|Sevoflurane and Cardiac Protection in High Risk Patients Undergoing Cardiac Surgery. A Randomized Controlled Study.|SEVO AIFA|Università Vita-Salute San Raffaele||Completed|September 2008|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|99 Years|No|||October 2015|October 13, 2015|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821262||145129|
NCT00821899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMATxDM1|Bone Marrow Autotransplantation in Type 1 Diabetes|Regeneration of Insulin Production in Patients With Type 1 Diabetes by Autologous Bone Marrow Blood Infusion||Hospital Clinic of Barcelona|No|Completed|January 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|50 Years|No|||March 2012|March 19, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00821899||145081|
NCT00822224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-03|Use of MEOPA (Equimolar Mixture of Nitrogen Protoxide and Oxygen) for Elderly With Dementia|Use of MEOPA for Elderly With Dementia.||Centre Hospitalier Universitaire de Nice|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|75 Years|N/A|No|||December 2011|December 8, 2011|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822224||145056|
NCT00821938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_10|Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study|CRT in Patients With Narrow QRS, Echodesynchronisation and LV dp/Dt-Response With Pressure Wire|CRT-Narrow|Medtronic Bakken Research Center|No|Active, not recruiting|November 2008|October 2013|Anticipated|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00821938||145078|
NCT00821600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015742|Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia|Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|No|||May 2014|May 20, 2014|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00821600||145103|
NCT00817947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0404/54|Airway Clearance Using High Frequency Chest Wall Oscillation|An Assessment of the Short-Term Effects of the Airway Clearance Technique of High Frequency Chest Wall Oscillation in People With Cystic Fibrosis||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|16 Years|N/A|No|||January 2009|January 6, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00817947||145379|
NCT00822185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1731-3604|Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers|A Single-centre, Randomised, Placebo-controlled, Double-blind, Single-dose, Dose-escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Doses of an Activated Recombinant FVII Analogue (NN1731) in Healthy Japanese Male Subjects||Novo Nordisk A/S|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|20 Years|45 Years|No|||December 2014|December 12, 2014|January 13, 2009|No|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00822185||145059|
NCT00822198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240-05|The Effect of Plantar Vibration on the Progression of Peripheral Neuropathy|The Effect of Plantar Vibration on the Progression of Peripheral Neuropathy||Binghamton University|No|Completed|March 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|30 Years|70 Years|No|||January 2009|January 13, 2009|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822198||145058|
NCT00822445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC0601|S100 Protein in Minor/Mild Traumatic Brain Injury|Diagnostic Value and Prognostic Value of the Blood Level Determination of S100 Protein in Minor or Mild Traumatic Brain Injury (GCS Glasgow Score 9 to 15).|S100|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|500|||Both|18 Years|80 Years|No|Non-Probability Sample|Minor/mild traumatic brain injury|February 2008|October 30, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822445||145039|
NCT00818987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02149|Operative Versus Non Operative Treatment of Proximal Humerus (Shoulder Joint) Fractures|A Multicentre Prospective Randomized Control Trial on the Treatment of Three and Four Part Proximal Humerus Fractures in Patients 70 Years and Older: Comparing Open Reduction and Internal Fixation With Non Operative Treatment||University of British Columbia|No|Recruiting|November 2010|October 2011|Anticipated|May 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|70 Years|N/A|No|||February 2011|February 17, 2011|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818987||145300|
NCT00819000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM032|Therapy Optimization in Multiple Sclerosis (MS)|TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies|TOP MS|Teva Pharmaceutical Industries|No|Completed|December 2008|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2878|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their        therapy from one of the participating Specialty Pharmacies|January 2013|January 28, 2013|January 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819000||145299|
NCT00819299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-P08-020|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2008|||||N/A|N/A|N/A||||||||||||||February 7, 2011|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819299||145276|
NCT00819312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91619|YAZ, Oral Contraceptive Registration in China|A Multicenter, Open-label, Single-arm Study to Investigate the Efficacy and Safety of the Oral Contraceptive YAZ (20 μg Ethinylestradiol, 3 mg Drospirenone) for 13 Cycles in 670 Healthy Chinese Female Volunteers.||Bayer|No|Completed|December 2008|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|675|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 27, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00819312||145275|
NCT00819026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWisHCV-1|Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors|||University of Wisconsin, Madison|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|15|Samples Without DNA|viral RNA|Both|18 Years|70 Years|No|Non-Probability Sample|solid organ transplant patients|December 2014|December 9, 2014|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00819026||145297|
NCT00818597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EISS-1|Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients|PhaseI/II Study of the Safety and Efficacy of the Use of Granulocyte-Concentrates Applied in Extracorporeal Circulation Devices-the EISS-1 Study|EISS-1|University of Rostock|No|Completed|December 2003|June 2008|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2009|January 6, 2009|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818597||145329|
NCT00818844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-10|Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery|||Alcon Research|No|Completed|January 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||February 2012|July 27, 2015|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818844||145310|
NCT00819533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASNG-LFNA-101-CAN|Safety & Accuracy Study of the ActiSight Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Preliminary Safety and Accuracy of the ActiSight Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy||ActiViews Ltd.|No|Completed|January 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||December 2009|December 27, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819533||145258|
NCT00819806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-140|CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors|Phase I Study of Vaccination With CpG 7909 and Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein in Patients With NY-ESO-1-expressing Tumors||University of Pittsburgh|Yes|Completed|January 2009|January 2015|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|21|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00819806||145238|
NCT00820690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135/2008|Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer|Gene Expression Signature and Immunohistochemical Markers Associated With Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer|LABC|Barretos Cancer Hospital|No|Active, not recruiting|July 2008|September 2017|Anticipated|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|Samples With DNA|frozen tissue; parafin tissue|Female|18 Years|70 Years|No|Non-Probability Sample|women breast cancer, clinical stage III; condition to chemotherapy with        doxorubicin/cyclophosphamide and paclitaxel|August 2015|August 3, 2015|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820690||145172|
NCT00819247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS02|The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer|A Six Month, Multi-centre, Open-labelled, 1:1:1 Randomised, Parallel Group Study Investigating the Efficacy and Safety of Three Dose Regimens of FE 200486 in Prostate Cancer Patients||Ferring Pharmaceuticals|No|Completed|March 2001|August 2002|Actual|May 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|129|||Male|18 Years|N/A|No|||May 2011|May 18, 2011|January 7, 2009|Yes|Yes||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00819247||145280|
NCT00820781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTVPCSBGV|Endoscopic Sclerotherapy and/or Ligation Versus Portacaval Shunt for Bleeding Gastric Varices|Endoscopic Sclerotherapy and/or Ligation Versus Portacaval Shunt for Bleeding||University of California, San Diego|Yes|Completed|August 1977|April 2003|Actual|December 1977|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|518|||Both|N/A|N/A|No|||December 2008|January 9, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820781||145165|
NCT00820430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN PA 4001|MRI Markers of Cartilage Damage in Knee With Osteoarthritis|A Multi-Center Trial on MR Image Markers of Knee Articular Cartilage Damage in Osteoarthritis||American College of Radiology Imaging Network|Yes|Completed|November 2006|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This multi-center trial comprises only facilities within Pennsylvania. Study participants        for the normal cohorts will be recruited through print flyers. It is anticipated that the        study participants with mild to moderate OA will be identified by the radiologists        interpreting the knee x-rays.|January 2009|January 9, 2009|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820430||145192|
NCT00821015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0628|Effect of Balloon Cryoablation on Left Atrial Function|Effect of Balloon Cryoablation on Left Atrial Function (CRYO-LA)|CRYO-LA|Icahn School of Medicine at Mount Sinai|Yes|Completed|June 2010|June 2012|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|85 Years|No|||December 2014|December 1, 2014|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821015||145147|
NCT00820729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrosis-ECHO 2009|Biomarkers in Pulmonary Hypertension Associated to Interstitial Lung Disease|The Prevalence of Pulmonary Hypertension and the Significance of Different Biomarkers in Chronic Interstitial Lung Disease||University of Aarhus|No|Completed|March 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|212|Samples With DNA|blood samples|Both|18 Years|N/A|No|Probability Sample|Out-patients with interstitial pulmonary disease.|September 2012|September 17, 2012|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820729||145169|
NCT00820742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751025|Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.|The Efficacy, Safety, and Tolerability of Pegaptanib Sodium in Filipino Patients With Neovascular Age-related Macular Degeneration: A Post Marketing Surveillance Study.||Pfizer|No|Withdrawn|February 2008|May 2009|Anticipated|May 2009|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Actual|0|||Both|50 Years|N/A|No||Male of female 50 years and older, diagnosed with age-related macular degeneration|March 2015|March 4, 2015|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820742||145168|
NCT00820755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62240-506|Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)|Open, Randomized, Multinational Phase IIIb Trial Evaluating the Activity and Safety of Cetuximab as 250 mg/m^2 Weekly and 500 mg/m^2 Every Two Weeks Maintenance Therapy After Platinum-based Chemotherapy in Combination With Cetuximab as First-line Treatment for Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)|NEXT|Merck KGaA||Completed|January 2009|June 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|583|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|January 9, 2009|No|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00820755||145167|Enrollment was stopped prematurely when cetuximab did not gain regulatory approval in this indication.
NCT00821912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaxXel|TaxXel: Taxotere and Xeloda in Esophageal Cancer|A Phase I/II Study on the Treatment With Taxotere in Combination With Xeloda in Patients With Metastatic Oesophageal Cancer or Cancer in the Cardia Region|TaxXel|Karolinska University Hospital|No|Active, not recruiting|March 2006|September 2013|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00821912||145080|
NCT00821951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811004507|Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer|A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer||Yale University|No|Completed|May 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|January 8, 2009|No|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00821951||145077|
NCT00822263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNC-IRAQ-08-040|The Use of Anti-oxidants to Reduce Sequela of Mild Traumatic Brain Injury (mTBI) After Blast Exposure|The Use of Anti-oxidants to Reduce Sequela of Mild TBI (mTBI) After Blast Exposure||Brooke Army Medical Center|Yes|Completed|November 2008|August 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|August 9, 2010|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822263||145053|
NCT00822458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01180|GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment|A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449||National Cancer Institute (NCI)||Completed|January 2009|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|3 Years|21 Years|No|||June 2013|April 1, 2014|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00822458||145038|
NCT00817934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABBPREP1|Safe, Effective, and More Tolerable 16 Tablets Colon Prep|Phase III of the AB Prep Safety and Efficacy in Colon Cleansing|ABP|Long Neck Medical Enterprises|Yes|Active, not recruiting|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|12 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Any patient between the age of 12 and 75, who is eligible for colonoscopy.|January 2009|January 6, 2009|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817934||145380|
NCT00822471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-288|Feasibility and Impact of "ABCs of Diabetes" Self-Management Education Program at an Urban Public Library|Feasibility and Impact of of "ABC's of Diabetes" Self Management Education (DSME) Program for African Americans at an Urban Public Library on A1C, Lipid Lowering Agent Prescriptions and Emergency Department Visits||Medstar Research Institute|No|Completed|January 2003|July 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|360|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00822471||145037|
NCT00818324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037E-08-002|Long Term Administration Study of OPC-12759 Ophthalmic Suspension|Long Term Administration Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2009|January 2011|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|20 Years|N/A|No|||January 2014|January 7, 2014|January 4, 2009||No||No|January 7, 2014|https://clinicaltrials.gov/show/NCT00818324||145350|
NCT00818337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-14888|Aspirin Responsiveness in Women at Risk for Cardiac Events|Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study.||Creighton University|Yes|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Female|19 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 6, 2012|January 6, 2009||No||No|August 8, 2011|https://clinicaltrials.gov/show/NCT00818337||145349|
NCT00818649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS044|Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia|Phase II Trial of Velcade Plus Vorinostat in the Treatment of High Risk MDS and Relapsed/Refractory AML||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|January 7, 2009|Yes|Yes|Met protocol stop rule [i.e., extreme toxicity]|No|January 17, 2013|https://clinicaltrials.gov/show/NCT00818649||145325|Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful. So, secondary outcome measures were not completed.
NCT00818662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160701|A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease|A Randomized, Double-Blind, Placebo-Controlled, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease||Baxalta US Inc.|Yes|Completed|December 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|390|||Both|50 Years|89 Years|No|||October 2014|June 26, 2015|January 7, 2009|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT00818662||145324|
NCT00819013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-261-001|Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults|FLU-A|Sanofi|No|Completed|July 2007|February 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|87|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 16, 2012|October 10, 2008|Yes|Yes||No|November 1, 2011|https://clinicaltrials.gov/show/NCT00819013||145298|
NCT00819338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NottinghamNHST1|The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease|The Effect of n-3 Polyunsaturated Fatty Acid Supplementation in Patients With Non-alcoholic Fatty Liver Disease||University of Nottingham|No|Completed|January 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819338||145273|
NCT00819221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810L00001|AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours|A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx®) in Patients With Advanced Solid Tumors||AstraZeneca|No|Active, not recruiting|January 2009|September 2016|Anticipated|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|150 Years|No|||February 2016|February 16, 2016|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819221||145282|
NCT00819819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P000287|Infant Nutrition and Risk of Celiac Disease|Infant Nutrition and Risk of Celiac Disease: Proposal for an Intervention, Prospective Multicenter Study||Massachusetts General Hospital|Yes|Active, not recruiting|April 2008|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1042|||Both|N/A|6 Months|No|||September 2015|September 23, 2015|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819819||145237|
NCT00820378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAD|The Epidemiology of Aortic Diameter in China|Epidemiology of Aortic Dimensions in Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors||Zhejiang University|Yes|Recruiting|January 2009|December 2015|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|40 Years|N/A|No|Non-Probability Sample|Chinese population with clinically evident arterial disease or cardiovascular risk factors|January 2009|January 12, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820378||145196|
NCT00819585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2251|Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy|A 24-week, Dose-ranging, Multi-center, Double-blind, Double-dummy, Active-controlled Study to Evaluate Canakinumab (ACZ885) for Prophylaxis of Signs and Symptoms of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy||Novartis||Completed|December 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|432|||Both|18 Years|80 Years|No|||April 2011|April 12, 2011|January 8, 2009|Yes|Yes||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00819585||145254|
NCT00819858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSF-nutcon01|Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight|The Effectiveness of Ready to Use Therapeutic Food (RUTF) in Catch up Growth in Children After an Episode of P. Falciparum Malaria||Medecins Sans Frontieres|Yes|Completed|January 2009|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|180|||Both|6 Months|59 Months|No|||October 2013|October 15, 2013|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819858||145234|
NCT00820443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06LJH002|Ceramic on Metal Total Hip Replacement System Multi-Center,Investigational Device Exemption Clinical Trial|Ceramic on Metal Total Hip Replacement System IDE: A Non-Randomized, Multi-center, Historically Controlled Safety and Efficacy Study (Protocol Number:06-LJH-002)|COM|MicroPort Orthopedics Inc.|No|Terminated|June 2007|October 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|253|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|January 8, 2009|Yes|Yes|not move forward with the commercialization of this product based on marketing needs and there    is not a known safety issue or concern|No|May 7, 2015|https://clinicaltrials.gov/show/NCT00820443||145191|
NCT00841555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08119|Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma|A Phase I Trial of Hypofraction Radiotherapy + Temozolomide in the Treatment of Patients With Glioblastoma Multiforme and Anaplastic Astrocytoma of the Brain||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|February 2009|||June 2012|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|February 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00841555||143585|
NCT00842140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP15811/2005|Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women|Metabolic Effects of Multiple Therapies in Polycystic Ovary Syndrome (PCOS) Women||University of Sao Paulo|No|Completed|February 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Female|18 Years|35 Years|No|||February 2009|July 21, 2010|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00842140||143541|
NCT00842959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acri.Tec-RES-DE-273|Check of Optical Features and Accuracy of the Zeiss ZO Lens After Selection and Calculation With OKULIX|Check of Optical Features and Accuracy of the Zeiss ZO Lens of the Company Carl Zeiss Meditec After Selection and Calculation With OKULIX|ZO Okulix|Carl Zeiss Meditec AG|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|N/A|No|||June 2011|June 15, 2011|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842959||143479|
NCT00843232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0007|Characterization of the Incretinpathy in Type 2 Diabetes Initiated After Sixty Years Old|Physiopathology of Type 2 Diabetes Initiated After Sixty Years Old: Characterization of a Diabetic-related Incretinpathy in Aging Subjects.||University of Campinas, Brazil|No|Completed|July 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|24|Samples Without DNA|Sera and plasma|Both|35 Years|80 Years|No|Non-Probability Sample|Adult Type 2 Diabetes subjects|February 2011|February 3, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843232||143459|
NCT00843492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109350|A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery|A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux Versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-surgical Below-Knee Injury|FONDACAST|GlaxoSmithKline|No|Completed|December 2008|June 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1351|||Both|18 Years|N/A|No|||February 2014|February 18, 2016|December 11, 2008||No||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00843492||143439|
NCT00843739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD046903-01A112|Expiratory Muscle Training in Patients With Parkinson's Disease|Expiratory Muscle Training in Patients With Parkinson's Disease|EMST|University of Florida|Yes|Completed|January 2004|December 2008|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|35 Years|85 Years|No|||February 2009|September 16, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843739||143420|
NCT00843752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0011|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||February 12, 2009|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843752||143419|
NCT00844064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP 12009-P001|Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2|An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-β2.||Isarna Therapeutics GmbH|Yes|Completed|January 2005|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|75 Years|No|||November 2011|November 18, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844064||143396|
NCT00844077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLNE 008|Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus|Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus Progression to Dysplasia and Adenocarcinoma||University of Michigan|Yes|Completed|October 2007|||April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|255|Samples With DNA|Plasma,serum, DNA, urine, Barrett's tissue (Fixed and Frozen), Normal Esophagus tissue      (Fixed and Frozen)|Both|18 Years|80 Years|No|Non-Probability Sample|Subjects undergoing clinically-indicated upper endoscopy for surveillance of their        pathologically-confirmed Barrett's intestinal metaplasia. Recruitment is from the        Endoscopy schedules of the collaborating locations.|December 2011|December 5, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844077||143395|
NCT00844363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLO-0651|Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris|Mechanism of Action of Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris||Rockefeller University|No|Terminated|November 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2011|June 29, 2011|February 12, 2009||No|Unable to isolate sufficient cells from the skin biopsy to perform study related experiments|No||https://clinicaltrials.gov/show/NCT00844363||143373|
NCT00820196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEX-ULC-001|A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)|A Randomized, Double-Blind, Vehicle-controlled, Parallel Group, Dose-Ranging, Multi-center Study of the Efficacy and Safety of Nexagon® in the Treatment of Participants With Venous Leg Ulcers||CoDa Therapeutics Inc.|Yes|Completed|March 2009|May 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|98|||Both|18 Years|N/A|No|||September 2012|September 16, 2012|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820196||145209|
NCT00820222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111438|Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer|A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer||GlaxoSmithKline|No|Active, not recruiting|April 2009|December 2016|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|546|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|January 8, 2009|Yes|Yes||No|January 17, 2013|https://clinicaltrials.gov/show/NCT00820222||145208|
NCT00820235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OSS-0003|Study Comparing Appearance and Function of Three Different Dental Implant Designs When Placed in Front Region of Upper Jaw|Prospective, Comparative Assessment of Single-tooth Replacement in Different Implant-abutment Settings||Dentsply Implants|No|Active, not recruiting|February 2009|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820235||145207|
NCT00820482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC- EL-0106-307-9|Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination.|A Prospective, Randomized, Controlled Trial Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination: Ovarian Response and Clinical Outcomes.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820482||145188|
NCT00820495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA084225|Effectiveness of a Web-Assisted Quitline for Smokeless Tobacco Users|Effectiveness of a Web-Assisted Quitline for Smokeless Tobacco Users||Oregon Research Institute|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1683|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 2, 2013|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820495||145187|
NCT00811083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMSA|Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity|DMSA Treatment of Children With Autism and Heavy Metal Toxicity||Southwest College of Naturopathic Medicine|No|Completed|May 2005|April 2007|Actual|April 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|3 Years|8 Years|No|||December 2008|December 17, 2008|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811083||145904|
NCT00843388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2306|A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria|A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria||Steno Diabetes Center|Yes|Not yet recruiting|March 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843388||143447|
NCT00843687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011023|A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.|Comparative Single-Dose Pharmacokinetics and Safety of Gluteal and Deltoid Intramuscular Injection of Long-Acting Injectable Risperidone in Subjects With Chronic Stable Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2005|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|188|||Both|18 Years|55 Years|No|||June 2011|June 2, 2011|February 12, 2009||||||https://clinicaltrials.gov/show/NCT00843687||143424|
NCT00843986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-301|Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)|A Phase-3b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety and Efficacy of Conivaptan in Symptomatic Acute Decompensated Heart Failure (ADHF) Subjects With Hyponatremia|CONVERT-H|Cumberland Pharmaceuticals|No|Terminated|April 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|February 11, 2009|Yes|Yes|The clinical study has been terminated based on difficulties to enroll eligible subjects per    protocol inclusion and exclusion criteria.|No|September 9, 2010|https://clinicaltrials.gov/show/NCT00843986||143401|The study was terminated because of difficulties in enrolling eligible patients per the protocol inclusion and exclusion criteria.Outcome Measures were not analyzed due to the abbreviated enrollment at early study termination.
NCT00844298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632225|Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia||Asan Medical Center|No|Completed|January 2009|July 2014|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|15 Years|N/A|No|||August 2015|August 7, 2015|February 13, 2009||No||No|August 7, 2015|https://clinicaltrials.gov/show/NCT00844298||143378|The limitation of the current study was that this study was not performed in a randomized comparative way, and the advantages of nilotinib over other TKIs were not definitely demonstrated.
NCT00844311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-257|Supplementation With Human Chorionic Gonadotropin (hCG) During Controlled Ovarian Stimulation With Recombinant Follicle-stimulating Hormone (FSH) for In Vitro Fertilisation|Supplementation With hCG During Controlled Ovarian Stimulation With Recombinant FSH for in Vitro Fertilisation. A Randomized Controlled Clinical Study. Clinical, Embryological, Endocrine and Genetic Aspects.||Rigshospitalet, Denmark|Yes|Completed|February 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Female|25 Years|37 Years|No|||February 2009|August 3, 2010|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844311||143377|
NCT00845520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP 002-00|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2009|||||N/A|N/A|N/A||||||||||||||February 2, 2015|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845520||143285|
NCT00841893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B253-IHE-spice2-NTG|Effects of a Specific Spice on Energy Metabolism|Effects of a Specific Spice on Energy Expenditure, Substrate Oxidation, Appetite and Energy Intake||University of Copenhagen|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841893||143559|
NCT00841906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0818-APDxE-MS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2008|||||N/A|N/A|N/A||||||||||||||February 19, 2009|February 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841906||143558|
NCT00845806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Docket # 13127|Neuronal Processing of Diacritics: An fMRI Study|Neuronal Processing of Diacritics: An fMRI Study||University of Massachusetts, Worcester|No|Completed|February 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All subjects will be male native arabic speakers that can read and write english. All will        be healthy with no history of neurological or psychiatric disorders.|November 2011|November 3, 2011|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845806||143263|
NCT00841542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2683|Amlodipine 10 mg Tablets Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Amlodipine 10 mg Tablets Versus Norvasc® 10 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|April 2003|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|February 9, 2009|No|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00841542||143586|
NCT00842400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-107|A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.|A Phase I, Single-Center, Open-Label, Non-randomized, One-Sequence Crossover, Pharmacokinetic Interaction Study of the Combination Product VI-0521 (Phentermine Plus Topiramate) With Metformin, Sitagliptin or Probenecid in Healthy Subjects||VIVUS, Inc.|No|Completed|February 2009|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|20|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 20, 2010|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842400||143521|
NCT00841880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMFE_L_03420|China Medical University Hospital (CMUH) Triapin Listing|A Prospective, Open Label, Randomized, Comparative Study of Ramipril 5mg Plus Felodipine 5mg Combined Regimen and Ramipril 10mg in Uncontrolled Hypertensive Patients||Sanofi||Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|20 Years|N/A|No|||August 2010|August 26, 2010|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841880||143560|
NCT00842621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELYSIS|Long Term Effects of Erythrocyte Lysis|Long Term Effects of Erythrocyte Lysis||St. Jude Children's Research Hospital|No|Active, not recruiting|March 2009|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|390|Samples With DNA|Blood Serum Plasma Urine|Both|5 Years|N/A|No|Non-Probability Sample|Children aged 5 years of age up to 19th birthday with sickle cell disease or other forms        of hemolytic anemia; Adults over the age of 18 with non-sickling hemolytic anemia.|July 2015|July 20, 2015|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842621||143504|
NCT00842634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806383|Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV|A Phase I Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 in HIV-Infected Patients|Zinc-Finger|University of Pennsylvania|Yes|Completed|January 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||January 2013|February 20, 2014|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842634||143503|
NCT00843245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICREC 001-2009|Study of Electrical Bioimpedance in Heart Failure.|Study of Electrical Bioimpedance in Heart Failure Patients Followed at the Heart Failure Unit of the Santa Creu i Sant Pau Hospital.|BELIC|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Blood serum obtained from routine blood test|Both|18 Years|N/A|No|Probability Sample|Consecutive patients attended at the Heart Failure Unit of the Hospital de la Santa Creu i        Sant Pau|June 2011|June 21, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843245||143458|
NCT00843518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12541|Treatment for Aggression and Agitation in Patients With Alzheimer's Disease|Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease||Eli Lilly and Company|No|Completed|February 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|60 Years|N/A|No|||August 2011|September 20, 2011|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843518||143437|
NCT00843531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084511|RAD001 and Erlotinib in Patients With Neuroendocrine Tumors|A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors||University of California, San Francisco|Yes|Active, not recruiting|June 2009|January 2016|Anticipated|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2015|May 15, 2015|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843531||143436|
NCT00843505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|625|Evaluating a Telemedicine Smoking Cessation Program in Rural Primary Care Practices|Telemedicine for Smoking Cessation in Rural Primary Care||University of Kansas Medical Center|No|Completed|June 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|566|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843505||143438|
NCT00843791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 3941|Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin|Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin||Oregon Health and Science University|Yes|Completed|February 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|6|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 4, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843791||143416|
NCT00843765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007AA02Z4B2|Efficiency Study of Traditional Chinese Medicine (TCM) Versus Western Medicine (WM) on Ischemic Stroke|Program of TCM on Early Rehabilitation and Secondary Prevention of Ischemic Stroke||China Academy of Chinese Medical Sciences|Yes|Completed|December 2007|November 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1151|||Both|35 Years|75 Years|No|||February 2012|February 13, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843765||143418|
NCT00844090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-011-08F|The Role of Apathy in Glycemic Control|The Role of Apathy in Glycemic Control||VA Office of Research and Development|Yes|Completed|July 2009|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|21 Years|75 Years|No|||March 2014|March 18, 2014|February 12, 2009|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00844090||143394|
NCT00844376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581164|Bioavailability Study for New Atorvastatin Formulation|An Open Label, Single Dose, Randomized 2-Way Crossover Study To Estimate The Relative Bioavailability Of Atorvastatin Commercial Tablet, And An Extemporaneous Preparation (EP) Suspension Formulation, In Healthy Subjects||Pfizer|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|October 21, 2009|February 13, 2009|Yes|Yes||No|March 5, 2009|https://clinicaltrials.gov/show/NCT00844376||143372|
NCT00844389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT45-GLAUC|Near to Infrared (NIR) Light Neuroprotection in Glaucomatous Optic Neuropathy|Near to Infrared Light Stimulation Effect on Ganglion Cell Function in Glaucomatous Optic Neuropathy||Universidad de Valparaiso|No|Active, not recruiting|April 2009|March 2010|Anticipated|December 2009|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||September 2009|September 30, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844389||143371|
NCT00819936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.W 2008/A|A Controlled Trial of Effectiveness of a Backward Walking Program in Patients Recovering From Abdominal Aorta Surgery|A Controlled Trial of Effectiveness of a Backward Walking Program in Patients Recovering From an Abdominal Aorta Surgery||Medical University of Silesia|No|Completed|January 2005|December 2006||December 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|47|||Male|65 Years|75 Years|No|||January 2009|January 8, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819936||145228|
NCT00820248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN6|Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer|A Phase III Study of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab in Patients With Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and Neck||Canadian Cancer Trials Group|Yes|Active, not recruiting|December 2008|December 2016|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820248||145206|
NCT00842842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-147|Mesh Fixation With Intraperitoneal Tisseel|A Prospective, Controlled, Randomized, Patient and Evaluator Blinded Study to Evaluate Pain and Recovery in Patients Undergoing Laparoscopic Umbilical Hernia Repair by Fixing the Mesh With Tisseel Versus Tackers|MEFIXIT|Herlev Hospital|No|Completed|August 2009|July 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||August 2015|August 17, 2015|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842842||143488|
NCT00843115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA2500065|Observational Study Of Donepezil In Routine Clinical Practice|Ecological Perspective On The Efficacy And Tolerability Of Donepezil In A Routine Clinical Practice: A Patient Centered Observational Study||Pfizer|No|Terminated|February 2007|April 2008|Actual|April 2008|Actual|Phase 4|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|370|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with Alzheimer's Disease with or without other etiologies of dementia|February 2014|February 11, 2014|February 12, 2009||No|See Detailed Description.|No|April 8, 2009|https://clinicaltrials.gov/show/NCT00843115||143467|
NCT00843700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00020535|Women's Depression Treatment Study|Effectiveness of IPT Adapted for Depressed Women With Trauma Histories in a Community Mental Health Center||University of Rochester|Yes|Completed|September 2007|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Female|18 Years|N/A|No|||January 2014|January 8, 2014|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843700||143423|
NCT00845182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2007243H|Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function|Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients|PIO-EX|The University of Texas Health Science Center at San Antonio|Yes|Completed|June 2007|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 8, 2015|February 17, 2009|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00845182||143311|
NCT00841594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001|MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison|MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects||MediQuest Therapeutics|No|Completed|February 2009|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 13, 2011|February 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00841594||143582|
NCT00845819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-Hema-1001|Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies|Randomized Phase II Study of Recombinant Human Epidermal Growth Factor (rhEGF) on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies|EGFOM|Seoul National University Hospital|No|Completed|February 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|138|||Both|18 Years|80 Years|No|||January 2015|January 20, 2015|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845819||143262|
NCT00842179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-003|Groin Complications Post Percutaneous Coronary Intervention Using Either Manual Compression or PERCLOSE Device|Femoral Access Site Groin Complication Rates After 2517 Groin Punctures Undergoing Vascular Closure by Either Manual Compression or the Perclose Vascular Closure Device||Clinyx, LLC|No|Completed|June 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2517|||Both|18 Years|N/A|No|Probability Sample|Patients who require vascular closure post percutaneous coronary intervention|February 2009|February 11, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00842179||143538|
NCT00842413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060605|Investigating the Role of the Premotor Cortex in Higher Cognitive Functions|What Part Does the Premotor Cortex Play in Subjective Visual Perception and in the Perception of Others' Actions?||Assistance Publique - Hôpitaux de Paris|No|Terminated|May 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The visual pereption of subjects willl be studied, but no attempt will be made at        modifying it, or treating any problem that they might have.|November 2008|February 11, 2009|February 11, 2009||No|not enough enrollment|No||https://clinicaltrials.gov/show/NCT00842413||143520|
NCT00842647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC05|Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma|Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma|HCC|Sun Yat-sen University|Yes|Recruiting|July 2006|August 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|75 Years|No|Non-Probability Sample|Between July 2006 and July 2009          1. All the patients who receive hepatomy in our department          2. Diagnose as HCC          3. Diagnosis of HCC is confirmed by noninvasive criteria for HCC as used by the American             Association for the Study of the Liver guidelines          4. No history of previous treatments          5. No pathological diagnosis before treatment|April 2009|April 7, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842647||143502|
NCT00842946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRX-17819|Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety|Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety||Drexel University|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|February 11, 2009||No||No|May 1, 2014|https://clinicaltrials.gov/show/NCT00842946||143480|
NCT00843258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mild hip dysplasia|Treatment for Mild Hip Dysplasia in Newborns|Immediate Treatment Compared With Active Sonographic Surveillance in the Management of Mild Hip Dysplasia in Newborn Infants: A Randomized, Controlled Trial||University of Bergen|Yes|Completed|February 1998|April 2003|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|N/A|5 Days|No|||February 2009|February 11, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00843258||143457|
NCT00843544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170-05|Integrative Medicine Approach to the Management of Asthma in Adults|Effect of an Integrative Medicine Approach to the Management of Asthma in Adults on Quality of Life and Clinical Outcomes||Beth Israel Medical Center|No|Completed|March 2006|July 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|80 Years|No|||February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843544||143435|
NCT00843557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9481|Impact of Gender on Hospitalized Patients|||University of Virginia|No|Active, not recruiting|September 2001|April 2010|Anticipated|May 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to general surgery and trauma ICU|September 2009|September 3, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843557||143434|
NCT00811928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05387|Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)|A Randomized, Open Label Parallel Controlled, Multicenter Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension Vs. Fluconazole (Capsule) in High-risk Leukopenic Patients for Prevention of Invasive Fungal Infection||Merck Sharp & Dohme Corp.|No|Completed|November 2008|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|252|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|December 18, 2008|Yes|Yes||No|May 26, 2011|https://clinicaltrials.gov/show/NCT00811928||145839|
NCT00843804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/07|Surveillance for Nosocomial Infections in Pediatric Cancer Patients|Prospective Surveillance for Nosocomial Infections and Catheter-related Thrombotic Events in Pediatric Patients|Oncoped2006|University Hospital, Bonn|No|Recruiting|March 2007|June 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood culture isolates|Both|N/A|21 Years|No|Non-Probability Sample|Pediatric patients with cancer during intensive induction / reinduction treatment        (including conventional chemotherapy, radiotherapy and stem cell transplantation).|February 2009|June 25, 2010|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843804||143415|
NCT00843778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87080|Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study|A Phase IIIB, Multi-center, Open Label Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With DMARDs in Patients With Active Rheumatoid Arthritis Who Participated in C87076.|CERTAIN 2|UCB Pharma|No|Completed|January 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|January 5, 2009|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00843778||143417|
NCT00844402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT_PBC-2|Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis|Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis||Medical University of Graz|No|Completed|January 2006|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||February 2009|February 13, 2009|February 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00844402||143370|
NCT00844753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1MH079082-01A2|Atomoxetine, Placebo and Parent Management Training in Autism|Atomoxetine, Placebo and Parent Management Training in Autism|Strattera|University of Rochester|Yes|Completed|October 2008|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|128|||Both|5 Years|14 Years|No|||January 2016|January 5, 2016|June 6, 2008|Yes|Yes||No|November 23, 2015|https://clinicaltrials.gov/show/NCT00844753||143344|
NCT00810563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOPOL 08-294|Does Bupivacaine in Laparoscopic Portals Reduce Post Surgery Pain in Tubal Ligation by Electrocoagulation?|Assessment of Postoperatory Pain After Laparoscopic Tubal Ligation by Electrocoagulation With Bupivacaine or Placebo|DOPOL|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|August 2008|August 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810563||145944|
NCT00810823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-080|The Effect of Gastric Bypass Surgery on the Glucose Metabolism Seen in Patients With Type 2 Diabetes|The Effect of Gastric Bypass Surgery on the Glucose Metabolism Seen in Patients With Type 2 Diabetes||Hvidovre University Hospital|No|Completed|January 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|25|Samples Without DNA|Blood samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patiens undergoing gastric bypass surgery with or without type 2 diabetes and patients        with diabetes undergoing gastric banding|December 2008|July 5, 2011|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810823||145924|
NCT00811096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1477|Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax|Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax||Walter Reed Army Institute of Research (WRAIR)|Yes|Completed|November 2008|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||November 2012|November 30, 2012|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811096||145903|
NCT00843401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110404, Rev. C|Clinical Performance Evaluation of Pediatric and Neonatal Low Saturation Oximetry Sensors|Clinical Performance Evaluation of Pediatric and Neonatal Low Saturation Oximetry Sensors||Children's Research Institute|No|Completed|January 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|21 Years|No|Non-Probability Sample|Pediatric intensive care unit Pediatric Cardiac Intensive Care Unit|February 2011|February 1, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843401||143446|
NCT00843427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS048281|fMRI of Language Recovery Following Stroke in Adults|fMRI of Language Recovery Following Stroke in Adults||University of Alabama at Birmingham|No|Completed|September 2008|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|N/A|No|||October 2015|October 30, 2015|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843427||143444|
NCT00844922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05842|Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)|Double-blind, Placebo-controlled Trial Investigating the Safety of Re-exposure to 900 mg of Org 34517, Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features), Who Participated in Trial 28130||Merck Sharp & Dohme Corp.|Yes|Completed|September 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|75 Years|No|||December 2014|December 30, 2014|February 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00844922||143331|
NCT00844935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6052-33761-01|Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients|The Value of Electrocardiographic Autonomic Nervous System Function Measures for Predicting Cardiopulmonary Recovery of Mechanically Ventilated Patients in Intensive Care||University of California, San Francisco|No|Withdrawn|September 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Mechanically ventilated patients in intensive care|March 2012|March 26, 2012|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844935||143330|
NCT00845195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-23|Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid|||Alcon Research|No|Completed|March 2009|||May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|12 Years|N/A|No|||April 2010|April 22, 2010|February 13, 2009|Yes|Yes||No|March 25, 2010|https://clinicaltrials.gov/show/NCT00845195||143310|
NCT00845208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA12827|Network Support for Treatment of Alcohol Dependence|Network and Contingency Management for Alcohol Treatment||University of Connecticut Health Center|No|Completed|March 2002|February 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 19, 2011|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845208||143309|
NCT00841607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18982|Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy|Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy||Tom Baker Cancer Centre||Recruiting|August 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||February 2009|February 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841607||143581|
NCT00842166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008 19|Surveillance of Summer Febrile Syndromes of Viral Origin in South of France|||Assistance Publique Hopitaux De Marseille|No|Completed|February 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|90|||Both|5 Years|N/A|No|||August 2014|August 28, 2014|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842166||143539|
NCT00842192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3735|An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries|A Prospective, Multicentre, Multinational, Open Label, Non-controlled, Observational, 24-week Study in Patients Using Oral Anti-Diabetic (OAD) Drugs + Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Near East Region Countries|BO2NE|Novo Nordisk A/S|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2155|||Both|N/A|N/A|No|Non-Probability Sample|Any subject with type 2 diabetes who is newly diagnosed or treated with OADs only is        eligible for the study. The selection of the subjects as well as the treatment insulin        will be at the discretion of the individual physician based on clinical judgement.|May 2014|August 14, 2014|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842192||143537|
NCT00842205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGA MZ CR NR9412-3|Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection|Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection||Charles University, Czech Republic|No|Recruiting|January 2007|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|60 Years|No|||February 2009|February 11, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842205||143536|
NCT00842426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DK080878|Evaluation of Lifestyle Interventions to Treat Elevated Cardiometabolic Risk in Primary Care|A Pilot of Customized Continuous Care Management of Obesity in Pre-Diabetics|E-LITE|Palo Alto Medical Foundation|Yes|Completed|June 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Actual|241|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842426||143519|
NCT00842439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808689|Healthy Brains & Behavior: Understanding and Treating Youth Aggression|Biosocial Prediction and Intervention on Childhood Aggression|HBB|University of Pennsylvania|No|Recruiting|February 2009|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|500|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||March 2012|March 16, 2012|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00842439||143518|
NCT00842972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2006-0005|Is Carotid Intima-media Thickness Affected by A1C Variability?|||Yonsei University||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|34 Years|79 Years|No|Probability Sample|typeII, Fluroscopy in carotid once a year during 2 years.|September 2009|September 14, 2009|February 11, 2009||||No||https://clinicaltrials.gov/show/NCT00842972||143478|
NCT00811720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12014A|Efficacy of Nalmefene in Patients With Alcohol Dependence|Nalmefene Efficacy Study I: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, As-needed Use, in Patients With Alcohol Dependence|ESENSE1|H. Lundbeck A/S|No|Completed|December 2008|November 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|598|||Both|18 Years|N/A|No|||July 2013|July 5, 2013|December 18, 2008||No||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00811720||145855|
NCT00811941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12013A|Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence|A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence|SENSE|H. Lundbeck A/S|No|Completed|March 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|665|||Both|18 Years|N/A|No|||July 2013|July 5, 2013|December 18, 2008||No||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00811941||145838|
NCT00843817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHAO08-PD BioDNase|RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum|RhDNase Effect on Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum|BioDNase|University Hospital, Tours|No|Not yet recruiting||||December 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843817||143414|
NCT00844103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1320C00002|Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.|A Phase I, Randomised, Double Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of AZD8566 in Healthy Volunteers||AstraZeneca|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 29, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844103||143393|
NCT00844415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.88|Safety and Tolerability of Dabigatran Etexilate in Adolescents|Open-label Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given for 3 Days at the End of Standard Anticoagulant Therapy in Children Aged 12 Years to Less Than 18 Years||Boehringer Ingelheim||Completed|June 2009|||February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|12 Years|17 Years|No|||December 2013|June 3, 2014|February 13, 2009||||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00844415||143369|
NCT00844428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-003B|Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS|An Open-Label, Multi-Center Controlled Clinical Trial Of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive Atypical Hemolytic Uremic Syndrome (AHUS)|aHUS|Alexion Pharmaceuticals|Yes|Completed|July 2009|December 2013|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|12 Years|17 Years|No|||June 2015|June 30, 2015|February 12, 2009|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT00844428||143368|
NCT00844766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL 10268|Validation of a Home-Screening Test for Lactose Intolerance|A Study to Validate a Home-Screening Test for Lactose Intolerant People||University Hospitals, Leicester||Suspended|December 2006|||||Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|People with lactose intolerance|February 2009|February 13, 2009|February 13, 2009||No|This study was stopped as no patient asked to participate was prepared to do so|No||https://clinicaltrials.gov/show/NCT00844766||143343|
NCT00813072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP0206|Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma|A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma||PharmaEngine|Yes|Completed|November 2007|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00813072||145751|
NCT00810576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0658|Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma|A Phase II Study To Determine The Safety and Efficacy Of The Combination of Vorinostat and Bortezomib In Patients With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Terminated|January 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|December 16, 2008||No|Terminated due to slow accrual.|No|June 11, 2010|https://clinicaltrials.gov/show/NCT00810576||145943|
NCT00810589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENM-HS-001|A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial|A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial to Compare the Pharmacodynamic Effects of Single Doses of Insulin Detemir and Neutral Protamin Lispro (NPL) Insulin in Subjects With Type 1 Diabetes|ENM-HS-001|Medical University of Graz|Yes|Completed|November 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||December 2008|December 17, 2008|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810589||145942|
NCT00810836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109RA201|Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis|A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of BG00012 When Given With Methotrexate to Subjects With Active RA Who Have Had an Inadequate Response to Conventional Disease-Modifying Anti-rheumatic Drug Therapy||Biogen|No|Completed|December 2008|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|153|||Both|18 Years|75 Years|No|||March 2011|September 12, 2013|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810836||145923|
NCT00811122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17991|Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly|Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly|11C-PIB PET|University of Utah|Yes|Active, not recruiting|November 2009|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|30 Years|90 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811122||145901|
NCT00844662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT 402|Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride|An Open, Randomised, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride in Haemodialysis Patients With Hyperphosphataemia||Ineos Healthcare Limited|Yes|Terminated|July 2009|October 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||October 2010|October 18, 2010|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00844662||143351|
NCT00844675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-KOR-9035|Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection|Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study||The Catholic University of Korea|No|Completed|October 2007|March 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|70 Years|No|||October 2012|October 16, 2012|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844675||143350|
NCT00844948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000110|Vocal Acoustic Biomarkers in Depression|Development of a Convenient, Automated, Objective Measure of Depression|Speech2|Center for Psychological Research, Madison, WI|No|Completed|October 2008|April 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|125|||Both|18 Years|80 Years|No|Non-Probability Sample|English speaking: Young Adults, age 18-25; Elderly, age 60-80. Chinese speaking (Mandarin        or Cantonese): age 18-80.|April 2012|May 4, 2012|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844948||143329|
NCT00841568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-05-002|A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]|A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]||Otsuka Pharmaceutical Co., Ltd.|No|Completed|April 2006|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|N/A|No|||April 2011|April 7, 2011|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841568||143584|
NCT00841581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-410|Lucentis to Treat Pigment Epithelial Detachment|Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)||Lawson Health Research Institute|No|Completed|December 2008|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|50 Years|N/A|No|||December 2011|December 7, 2011|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841581||143583|
NCT00841958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCVM-029|Endocardial Stem Cells Approach Efficacy|Efficacy of the Endocardial Stem Cells Implantation in Ischemic Heart Failure Patients|ESCAPE|Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|February 2007|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|250|||Both|21 Years|75 Years|No|||April 2012|April 23, 2012|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841958||143554|
NCT00841919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBJHS200901|Insulin Therapy in the Hospital Comparing Two Protocols|Basal/Bolus Insulin Therapy in the Hospital Ward Comparison of Two Protocols: Feasibility Study||John H. Stroger Hospital|No|Completed|December 2006|June 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2009|September 8, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841919||143557|
NCT00842452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Y08|Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery|A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|February 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||April 2013|April 3, 2013|February 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842452||143517|
NCT00811226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05254|Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)|Prospective, Multicentric, Open Clinic Essay to Evaluate the Use of OLMETEC® (Olmesartan Medoxomile) and OLMETEC PLUS® (Olmesartan Medoxomile Hydrochlorothiazide) in Stade I and II, According to JNC VII||Schering-Plough|No|Completed|April 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in Venezuela with arterial hypertension Stade I or Stade II|December 2008|December 16, 2008|July 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00811226||145893|
NCT00811486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1022|Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure|Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure||University of Colorado, Denver|Yes|Withdrawn|January 2009|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||January 2013|January 25, 2013|December 18, 2008||No|Only 1 patient recruited, and he withdrew|No||https://clinicaltrials.gov/show/NCT00811486||145873|
NCT00811733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110921|A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia|A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia||GlaxoSmithKline|No|Completed|March 2009|August 2014|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2015|March 26, 2015|December 18, 2008|Yes|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00811733||145854|
NCT00811954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5257|Comparative Study of Three NNRTI-Sparing HAART Regimens|The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment||AIDS Clinical Trials Group|Yes|Completed|May 2009|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1814|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|December 18, 2008|Yes|Yes||No|June 23, 2014|https://clinicaltrials.gov/show/NCT00811954||145837|
NCT00812240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04030|A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment|A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumour in First Line Medical Treatment||AB Science|Yes|Recruiting|January 2009|December 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|December 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812240||145815|
NCT00812500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-226|Dietary Protein Requirement of Elderly Men and Women|Dietary Protein Requirement of Elderly Men and Women||Purdue University||Completed|May 2002|January 2006|Actual|May 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2008|September 23, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812500||145795|
NCT00844116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI040727|Efficacy of "On Line" Telematic Spirometry|Efficacy of "On Line" Telematic Spirometry||Sociedad Española de Neumología y Cirugía Torácica|No|Completed|January 2009|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|226|||Both|14 Years|70 Years|No|||May 2012|May 15, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844116||143392|
NCT00813059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|edmargolin|Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy|Intravitreal Bevacizumab for Treatment of the Second Eye With Non-Arteritic Ischemic Optic Neuropathy||Mount Sinai Hospital, Canada|Yes|Recruiting|February 2009|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|N/A|No|||February 2012|February 6, 2012|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813059||145752|
NCT00811135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO21926|A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer|A Single Arm Open-label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-line Treatment of Patients With HER2-positive Locally Recurrent or Metastatic Breast Cancer||Hoffmann-La Roche||Active, not recruiting|December 2008|December 2015|Anticipated|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|December 16, 2008||No||No|November 3, 2015|https://clinicaltrials.gov/show/NCT00811135||145900|
NCT00811369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2008-ZAMBONEY|Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer|A Phase II, Multi-Centre, Randomized, Double-blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer|ZAMBONEY|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|August 2009|August 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Female|N/A|N/A|No|||November 2013|November 15, 2013|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00811369||145882|
NCT00811616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The MAXIMUS study|A Safety and Efficacy of Supralimus™ Core™ Sirolimus Eluting Stent at MAX DDHV Institute|Safety And Efficacy Evaluation of Sirolimus Eluting Supralimus-Core™ Stent at MAX DDHV Institute in the Treatment of de Novo Native Coronary Artery Lesions|Maximus|Sahajanand Medical Technologies Pvt. Ltd.|Yes|Completed|July 2006|March 2008|Actual|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||May 2010|May 10, 2010|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811616||145863|
NCT00844688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC|Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)|A Phase II Feasibility Study of Sorafenib and Gemcitabine Combination Treatment in Patients With Advanced Hepatocellular Carcinoma|HCC|Combined Military Hospital, Pakistan|Yes|Recruiting|September 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||February 2009|February 13, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844688||143349|
NCT00845832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX21956|A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate|A Randomized, Active Controlled, Double-blind, Study to Compare the Safety and Reduction in Disease Activity With the Combination of Rituximab (MabThera®)and Tocilizumab (RoActemra®) Versus Tocilizumab in Patients With Active Rheumatoid Arthritis With an Incomplete Response to Methotrexate||Hoffmann-La Roche||Terminated|March 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||December 2014|December 15, 2014|February 17, 2009||No|The study was terminated early because of a related decision to stop the development of    ocrelizumab in rheumatoid arthritis.|No|June 23, 2014|https://clinicaltrials.gov/show/NCT00845832||143261|
NCT00845871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS32|Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food|A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food||Novartis|No|Completed|March 2009|October 2010|Actual|August 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|2 Years|N/A|No|||May 2014|May 7, 2014|February 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00845871||143258|
NCT00845884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVDCF-2008|Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer|A Phase I/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Patients With Advanced Gastric Cancer||Rabin Medical Center|No|Not yet recruiting|February 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Male|18 Years|N/A|No|||February 2009|February 16, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845884||143257|
NCT00841971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08110001|Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients|Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial||University of Pittsburgh|Yes|Completed|February 2010|May 2014|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|February 11, 2009|Yes|Yes||No|December 8, 2014|https://clinicaltrials.gov/show/NCT00841971||143553|
NCT00841932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-002|Performing Fractional Flow Reserve Without Anticoagulation During Diagnostic Catheterization|Retrospective Assessment of the Safety of Performing Fractional Flow Reserve (FFR) of the Myocardium Without Anticoagulation During Diagnostic Cardiac Catheterization||Clinyx, LLC|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent fractional flow reserve (FFR) by Dr. Jonathan Roberts without        anticoagulation during diagnostic catheterization were included in this registry.|February 2009|February 11, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00841932||143556|
NCT00841945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS 02 03|Treatment of Aggressive Localized Lymphoma|Phase III Study of the Interest of Radiotherapy After 4 or 6 Cycles of CHOP 14 Rituximab Regimen of Chemotherapy , Patients With Agressive Localized Lymphoma||French Innovative Leukemia Organisation|Yes|Terminated|April 2005|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|334|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|February 11, 2009||No|other drugs other studies|No||https://clinicaltrials.gov/show/NCT00841945||143555|
NCT00810966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090048, CDR0000629899|ABT-888 and Cyclophosphamide in Treating Patients With Solid Tumors or Lymphoma That Did Not Respond to Previous Therapy|A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2008|||||Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|December 17, 2008|No|Yes||||https://clinicaltrials.gov/show/NCT00810966||145913|
NCT00810992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|337/2008BO1 UKT|Traditional Tibetan Medicine for Patients With Coronary Artery Disease|Behavioral and Nutritional Therapy in Patients With Coronary Artery Disease According to Traditional Tibetan Medicine Protocol|TTM in CAD|University Hospital Tuebingen||Completed|January 2009|April 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|524|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810992||145911|
NCT00842660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1165A3|Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer|Phase III Trial for Primary Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in PET/CT Defined Poor-Prognostic Cervical Cancer Patients||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|February 2009|January 2013|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|172|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||February 2009|January 3, 2010|February 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00842660||143501|
NCT00842673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST101-A001-201|Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease|A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease||Sonexa Therapeutics, Inc.|No|Completed|February 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|168|||Both|50 Years|N/A|No|||June 2012|June 5, 2012|February 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842673||143500|
NCT00812266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOLG7|Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)|Randomized Phase III Trial of Topotecan and Cisplatin Versus Etoposide and Carboplatin in the Treatment of Patients With Previously Untreated Small Cell Lung Cancer and Extensive Disease||Danish Oncological Lung Cancer Group|No|Terminated|January 2006|January 2015|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|281|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|December 19, 2008||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00812266||145813|
NCT00812006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-085|A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis||Merck Sharp & Dohme Corp.|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|December 17, 2008|Yes|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00812006||145833|
NCT00812019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V89P1|Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)|A Phase I/II, Randomized, Observer-blind, Multicenter, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine in Healthy Subjects 18 - 40 Years of Age.||Novartis|Yes|Completed|November 2008|November 2010|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|12||Actual|753|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|December 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812019||145832|
NCT00811967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03811|Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)|Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis||Merck Sharp & Dohme Corp.|No|Terminated|February 2003|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|70 Years|No|||April 2015|April 9, 2015|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811967||145836|
NCT00811980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00392|The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents|The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents||University of Utah|No|Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|60|Samples Without DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects who consent to donate blood.|November 2011|November 23, 2011|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811980||145835|
NCT00812760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-220501|Effect of Levodopa on Human Multifocal Electroretinogram|Effect of Levodopa on Human Multifocal Electroretinogram||Medical University of Vienna||Completed|October 2001|October 2003|Actual|October 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||December 2008|December 19, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812760||145775|
NCT00812773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112356|Study to Evaluate GSK2190915 in Subjects With Mild Asthma|A Randomised, Double-blind, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of Two Doses of GSK2190915 on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma||GlaxoSmithKline|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|55 Years|No|||March 2012|March 22, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00812773||145774|
NCT00812786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006832-23|Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients|Multicentre, Open Study for the Setting up of Population Pharmacokinetic Models and Bayesian Estimators for Individual Dose Adjustment of Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Everolimus) During the First Year Post-grafting in Adult Heart Transplant Recipients.|PIGREC|University Hospital, Limoges|No|Completed|July 2007|May 2012|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Both|18 Years|80 Years|No|||December 2008|August 23, 2013|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812786||145773|
NCT00811382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS044|Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)|Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)|effecT|Biotronik SE & Co. KG|Yes|Completed|May 2008|September 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811382||145881|
NCT00811629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0042|Influence of Acute Respiratory Distress Syndrome (ARDS) and Severe Sepsis on sRAGE Levels in ICU Patients|Soluble Form of the Receptor for Advanced Glycation End Products (sRAGE) Levels in the Pulmonary Edema Fluid and Plasma From ICU Patients With ALI/ARDS and Severe Sepsis : an Observational Prospective Study.||University Hospital, Clermont-Ferrand||Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|60|||Both|18 Years|95 Years|No|Probability Sample|Definied population|September 2013|September 30, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811629||145862|
NCT00811850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-COM-08-009|Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow|||Allergan|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|30 Years|N/A|No|||July 2012|July 25, 2012|December 17, 2008|Yes|Yes||No|October 24, 2011|https://clinicaltrials.gov/show/NCT00811850||145845|
NCT00845533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H40380-31179-01|Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso|||University of California, San Francisco||Completed|August 2007|January 2009|Actual|December 2007|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|6 Months|10 Years||||January 2014|January 15, 2014|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845533||143284|
NCT00845559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801003390|The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults|The Effects of Exenatide on Post-Prandial Glucose Excursions and Vascular Health in Obese/Pre-Diabetic Young Adults||Yale University|No|Withdrawn|August 2008|||March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|13 Years|25 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|February 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845559||143282|
NCT00845845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0601|Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)|Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)||University of Illinois at Chicago|No|Terminated|March 2006|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|February 17, 2009|Yes|Yes|Terminated due to low enrollment.|No|February 6, 2013|https://clinicaltrials.gov/show/NCT00845845||143260|The study was terminated on October 12, 2010 due to low enrollment. Consequently, no analyses were completed.
NCT00845858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METO-IN-002|Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis||Evoke Pharma|No|Completed|April 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|287|||Both|18 Years|75 Years|No|||November 2013|June 17, 2014|February 17, 2009|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT00845858||143259|
NCT00841620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPP|Symptom Control 1-year After Circular Stapler Anopexy or Diathermy Excision for Prolapsed Haemorhoids|Symptom Control 1-year After Circular Stapler Anopey or Diathermy Excision for Prolapsed Haemorrhoids: an International Randomsed Trial (the STOPP-trial||Odense University Hospital|Yes|Completed|September 1999|April 2007|Actual|January 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841620||143580|
NCT00841633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-137|Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study|Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study||UMC Utrecht|No|Terminated|February 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||October 2011|October 11, 2011|October 10, 2008||No|Our RCT recently started. The RCT is similar to the feasibility trial, so it was terminated to    avoid 2 trials running simultaniously.|No||https://clinicaltrials.gov/show/NCT00841633||143579|
NCT00842218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|READ-Mahaudens-01|The Idiopathic Scoliosis and Its Treatment (Orthopaedic and Surgery): Effect of the Severity, the Orthosis and the Arthrodesis on the Gait|Effect of the Severity and the Treatment (Orthosis Versus Surgery)of the Idiopathic Scoliosis on the Locomotor Mechanism of the Gait.|scoliosis|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|January 2009|September 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects girls were recruited in the town and adolescent idiopathic scoliosis        attended our outpatient clinic|February 2009|February 11, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00842218||143535|
NCT00842231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-08-06|Assessment of Visual Performance in Patients With Low Levels of Astigmatism|||Alcon Research|No|Completed|January 2009|||March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were selected from a single investigator's primary care clinic.|September 2010|September 23, 2010|February 11, 2009||No||No|August 11, 2010|https://clinicaltrials.gov/show/NCT00842231||143534|
NCT00810732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321005|Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects|The Effects Of Sitaxsentan Once Daily Dosing On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Subjects With Chronic Kidney Disease.|FCRD01|Pfizer|No|Completed|May 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|70 Years|No|||August 2012|August 8, 2012|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810732||145931|
NCT00810979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLx-4090-08-06|Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Different Doses of SLx-4090 in Combination With a Statin vs. Statin Mono-therapy in Patients With Hyperlipidemia||Kadmon Corporation, LLC|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|133|||Both|18 Years|65 Years|No|||January 2015|January 16, 2015|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810979||145912|
NCT00811746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#924|Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?|Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?||Southern California Institute for Research and Education|No|Completed|December 2008|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Anticipated|90|||Both|18 Years|65 Years|No|||May 2013|May 28, 2013|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811746||145853|
NCT00811473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D144AC00001|Pediatric Bipolar Depression|An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression||AstraZeneca||Completed|January 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|10 Years|17 Years|No|||July 2014|July 2, 2014|December 18, 2008|Yes|Yes||No|October 27, 2011|https://clinicaltrials.gov/show/NCT00811473||145874|
NCT00811759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626803|Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma|Open-label, Single Center, Uncontrolled Phase I/II Study Evaluating the Safety and Maximum Tolerated Dose of Daily Sorafenib Administered in Combination With Prolonged Temozolomide in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Active, not recruiting|June 2007|||May 2009|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||July 2009|October 6, 2010|December 18, 2008||||No||https://clinicaltrials.gov/show/NCT00811759||145852|
NCT00813137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|simcere0803|FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer|A Multi-center Study of Folfox4 Combined With Recombinant Human Endostatin(Endostar)in Advanced Colorectal Cancer||Simcere Pharmaceutical Co., Ltd|Yes|Recruiting|October 2008|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|No|||December 2009|December 6, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813137||145746|
NCT00812253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0197|Intensive Glycemic Control for Congestive Heart Failure Exacerbation|Intensive Glycemic Control for Congestive Heart Failure Exacerbation||Ohio State University|Yes|Completed|January 2009|May 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|December 19, 2008|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00812253||145814|
NCT00813098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol LX1031.1-201-IBS|Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome||Lexicon Pharmaceuticals|No|Completed|December 2008|August 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|70 Years|No|||November 2010|November 4, 2010|December 19, 2008|Yes|Yes||No|October 5, 2010|https://clinicaltrials.gov/show/NCT00813098||145749|
NCT00813111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPLE Breast Augmentation 315|Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation|A Phase 3, Multicenter, Randomized, Double-blind Parallel-group, Active-control Study to Evaluate the Safety and Efficacy of Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Bilateral, Cosmetic Sub-muscular Breast Augmentation||Pacira Pharmaceuticals, Inc|No|Terminated|November 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|136|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 30, 2013|December 9, 2008|Yes|Yes|Sponsor decision, unrelated to safety|No|November 22, 2011|https://clinicaltrials.gov/show/NCT00813111||145748|
NCT00811655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006870|Stereotactic Radiosurgery in Treating Patients With Brain Metastases|Phase II Single-arm Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases.||Duke University|No|Terminated|October 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|December 18, 2008||No|Slow recruitment|No|August 15, 2013|https://clinicaltrials.gov/show/NCT00811655||145860|Early termination leading to small numbers of subjects analyzed.
NCT00811863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1177-07-868|Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection|A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging|SHERLOC|Mallinckrodt|No|Suspended|February 2009|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Serum; Plasma; Fixed tissue samples|Both|N/A|N/A|No|Non-Probability Sample|Subjects with moderate to severe renal insufficiency that have been identified as        requiring (for any indication) a contrast-enhanced MRI using gadoversetamide.|March 2010|March 15, 2010|December 18, 2008|Yes|Yes|Study drug currently unavailable|No||https://clinicaltrials.gov/show/NCT00811863||145844|
NCT00812162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0610004602|Effects of Dietary Pork and Egg on Appetite, Meal-patterning, and Weight Loss in Men|Effects of Dietary Pork and Egg on Appetite, Meal-patterning, and Weight Loss in Men||Purdue University|Yes|Completed|January 2007|July 2011|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Male|21 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812162||145821|
NCT00845234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00293-2008-0356-1|Establishing a Standard for Peri-operative Implantable Cardioverter Defibrillator (ICD) Patient Education|Establishing a Standard for Peri-operative ICD Patient Education: A Demonstration Project||East Carolina University|Yes|Completed|July 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845234||143307|
NCT00845546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA01112|Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D® 24 Hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in Healthy Adult Volunteers Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|June 2002|November 2002|Actual|August 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 16, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00845546||143283|
NCT00845572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070020H|The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center|The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center||The University of Texas Health Science Center at San Antonio|Yes|Completed|January 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||September 2012|September 17, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845572||143281|
NCT00841659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02183-A|Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Paroxetine Hydrochloride 40 mg Film-Coated Tablets and Paxil® 40 mg Film-Coated Tablets Administered as 1 x 40 mg Film-Coated Tablet in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|August 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|February 9, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00841659||143577|
NCT00810745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|starr|What Benefit With a New Stapler Device in the Surgical Treatment of Obstructed Defecation?|What Benefit With a New Stapler Device in the Surgical Treatment of Obstructed Defecation? Two-Year Outcomes From a Randomized Controlled Trial||University of Milan|No|Completed|January 2006|November 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|80|||Both|35 Years|85 Years|No|||February 2009|February 25, 2009|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810745||145930|
NCT00810108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10894|Lopinavir/Ritonavir (Kaletra) PK in Children|Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|June 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Female|6 Years|17 Years|No|||June 2012|June 2, 2012|December 15, 2008|No|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00810108||145978|The AUC of the crushed tablet administration were measured after a single dose only, rather than at steady-state; variable adherence may have impacted results.
NCT00810121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETOP_L_03948|Study of Non Inferiority Bi-Profenid® 200mg Versus Bi-Profenid® 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)|Non-inferiority Study of Bi-Profenid® 200 mg Versus Bi-Profenid® 300 mg in Patients Presenting With Pain Related to Closed, Benign, Acute Post-traumatic Conditions of the Motor System or Acute, Non-infectious Rheumatologic Conditions||Sanofi||Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|409|||Both|18 Years|65 Years|No|||September 2009|September 24, 2009|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810121||145977|
NCT00810394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000628775|Sorafenib in Treating Patients With Advanced Malignant Solid Tumors|Single Agent Sorafenib in Advanced Solid Tumors: Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375)||University of California, Davis|Yes|Completed|December 2008|March 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810394||145956|
NCT00810706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971-ONC-0028-085|Adjuvant Post-Tamoxifen Exemestane Trial|A Phase III Randomized Parallel-Group Multicenter Trial, Designed to Compare 5 Years of Adjuvant Exemestane Versus 5 Years of Observation in Postmenopausal Women With Operable Breast Cancer Who Have Received 5-7 Years of Adjuvant Tamoxifen.|ATENA|Hellenic Breast Surgeons Society|No|Terminated|April 2001|November 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|448|||Female|18 Years|80 Years|No|||December 2008|December 16, 2008|December 16, 2008|||Publication of MA17 results (similar trial in the extented adjuvant setting with letrozole)|No||https://clinicaltrials.gov/show/NCT00810706||145933|
NCT00810407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0061006|Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients|Special Investigation For Non-hiv Patients Of Mycobutin (Regulatory Post Marketing Commitment Plan).||Pfizer|No|Active, not recruiting|November 2008|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A0061006 prescribes the Mycobutin®).|March 2016|March 2, 2016|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00810407||145955|
NCT00811499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-201|A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis|||Array BioPharma|No|Terminated|December 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811499||145872|
NCT00811265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC001|Safety Evaluation of ExAblate MRgFUS for Prostate Cancer|Safety, Compatibility and Imaging Quality of ExAblate Prostate Applicator for Prostate Cancer||InSightec|No|Completed|January 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|N/A|75 Years|No|||March 2016|March 7, 2016|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811265||145890|
NCT00811239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|antivenom|A Controlled Clinical Trial on The Use of a Specific Antivenom Against Envenoming by Bungarus Multicinctus|A Controlled Clinical Trial on The Use of a Specific Antivenom Against Envenoming by Bungarus Multicinctus||Hanoi Medical University|Yes|Completed|March 2004|December 2006|Actual|December 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|N/A|N/A|No|||December 2008|December 17, 2008|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00811239||145892|
NCT00812552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESERT|Drug Eluting Stent Registry of Thrombosis|Drug Eluting Stent Registry of Thrombosis|DESERT|Medstar Research Institute||Completed|September 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|984|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, male or female, over 18 years of age, who are either known to have experienced        late or very late drug-eluting stent thrombosis (Case), or have undergone drug-eluting        stent implantation at the same facility, in the same time period as a matched Case        Subject, and have not experienced drug-eluting stent thrombosis (Control).|April 2013|April 22, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812552||145791|
NCT00812565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAM10-04|Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease|Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%)||Octapharma|Yes|Completed|February 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|58|||Both|50 Years|85 Years|No|||April 2014|April 2, 2014|November 10, 2008|No|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00812565||145790|Small numbers of patients per treatment group (between 5 and 8) and variable total Aβ levels over time.
NCT00813150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015247|Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma|Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma||Janssen-Cilag G.m.b.H|No|Completed|January 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|December 18, 2008||No||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00813150||145745|
NCT00812513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-TEBII1208|Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns|Phase II Study of Efficacy of Recombinant Human Platelet-derived Growth Factor (R-Pdf/Gbb) in Healing Wounds Caused by Third Degree Thermal and Electrical Burns.||American Scitech International|No|Not yet recruiting|July 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|No|||July 2011|July 19, 2011|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812513||145794|
NCT00812526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-190702|Regulation of Choroidal Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Choroidal Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure||Medical University of Vienna||Completed|September 2002|September 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||December 2008|December 19, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812526||145793|
NCT00812799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0801|A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis|A Randomised Double Blind Placebo-controlled, Long-term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis||Artu Biologicals|No|Active, not recruiting|December 2008|December 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|374|||Both|18 Years|60 Years|No|||April 2010|April 29, 2010|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812799||145772|
NCT00812812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112487|Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)|A Randomised, Double-blind, Placebo Controlled, Parallel Group , Flexible Dose Study to Evaluate the Efficacy and Safety of Paxil® Tablets in Children and Adolescents With Major Depressive Disorder<Post-marketing Clinical Study>||GlaxoSmithKline|No|Terminated|March 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|7 Years|17 Years|No|||August 2013|August 29, 2013|December 18, 2008||No||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00812812||145771|
NCT00812825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9391002|A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers|A Phase 1, Active and Placebo-Controlled, Multiple-Dose Escalation Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04171327 (Part 1), and a Single Dose Pharmacokinetic Assessment of a Tablet Formulation (Part 2) in Healthy Volunteers||Pfizer|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|78|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 11, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812825||145770|
NCT00813124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0087|Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)|Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)||M.D. Anderson Cancer Center|No|Completed|December 2008|||September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||September 2014|September 30, 2014|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00813124||145747|
NCT00812175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13414|Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib|Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib|GIDEON|Bayer|No|Completed|January 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3371|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with unresectable HCC who are candidates for systemic therapy and in whom a        decision to treat with Nexavar has been made under real-life practice conditions and in a        variety of patient subsets.|April 2015|April 17, 2015|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812175||145820|
NCT00812188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112004027|Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.|A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea||University of Texas Southwestern Medical Center|No|Completed|November 2004|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812188||145819|
NCT00812448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2009001|Catechin Containing Mask for the Prevention of Influenza Infection|The Effects of Tea Catechin Extracts Containing Mask on the Prevention of Influenza Infection||University of Shizuoka|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|180|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||November 2009|November 24, 2009|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812448||145799|
NCT00812695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-OSA|Effects of Continuous Positive Airway Pressure (CPAP) in Patients With Resistant Hypertension and Obstructive Sleep Apnea (OSA)|Effects of Continuous Positive Airway Pressure in Patients With Resistant Hypertension and Obstructive Sleep Apnea||University of Sao Paulo|Yes|Completed|October 2008|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|65 Years|No|||November 2011|November 21, 2011|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812695||145780|
NCT00812708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-06-072|Morcher Artificial Iris Devices to Treat Light and Glare Sensitivity in Partial or Complete Aniridia|Compassionate Use Study of Morcher Artificial Iris Devices to Treat Light and Glare Sensitivity in Partial or Complete Aniridia||University of California, Los Angeles|Yes|Active, not recruiting|September 2002|December 2030|Anticipated|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|December 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812708||145779|
NCT00845247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|477 980 567|The Effect of Case Management in Complex Cancer Pathways|The Effect of Case Management in Complex Cancer Pathways||University of Aarhus|No|Completed|March 2009|January 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|280|||Both|N/A|N/A|No|||August 2012|August 30, 2012|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00845247||143306|
NCT00845897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0493|Botulinum Toxin Effects on Plantar Ulcer Recurrence|Botulinum Toxin Effects on Plantar Ulcer Recurrence||Washington University School of Medicine|Yes|Completed|March 2005|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|17|||Both|N/A|N/A|No|||February 2012|February 1, 2012|February 16, 2009||No||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00845897||143256|
NCT00810758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1201002|Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691|A Phase 1, Randomized, Placebo Controlled, Blinded (3rd Party Open), Sequential, Multiple-Dose Escalation Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 In Healthy Volunteers||Pfizer|No|Completed|January 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|December 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00810758||145929|
NCT00811005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004519-23|Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis|Comparison of Fumaric Acid Ester-PUVA (FAE-PUVA) Versus Acitretin-PUVA (Re-PUVA) in Pustular Palmoplantar Psoriasis,a Prospective, Randomized, Controlled, Single-blinded Study|FVSA-PUVA|Medical University of Vienna|No|Active, not recruiting|October 2008|October 2010|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||September 2009|September 17, 2009|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811005||145910|
NCT00811018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321007|A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension|A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension|STRIDE-3|Pfizer|No|Terminated|March 2003|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1192|||Both|12 Years|75 Years|No|||November 2011|March 29, 2012|December 9, 2008|Yes|Yes|This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically    emerging evidence of hepatic injury.|No|March 29, 2012|https://clinicaltrials.gov/show/NCT00811018||145909|Mean and dispersion for clinical abnormalities were intended to be reported but due to early termination of study (09-Dec-2010) only number and percent of participants are available.
NCT00810719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000629891|Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer|Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer (OSI 4132s)|UCDCC#211|University of California, Davis|Yes|Completed|April 2009|December 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810719||145932|
NCT00811031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0045|Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)|A Phase II Study of Pre-operative Docetaxel for Progressive Localized Castration Resistant Prostate Cancer||M.D. Anderson Cancer Center|No|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||July 2012|July 27, 2012|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00811031||145908|
NCT00811772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184916/V50 Res. council Norway|Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis|Comparison of the Long-term Effects on Mortality and Cardiovascular Morbidity of Percutaneous Coronary Intervention With Drug-eluting Stent Versus Bare-metal Stent. Randomized, Five-year Prospective, Multicenter Clinical Trial|NORSTENT|University of Tromso|Yes|Active, not recruiting|September 2008|June 2015|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|9000|||Both|19 Years|N/A|No|||January 2009|June 28, 2013|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811772||145851|
NCT00811993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO22068|A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors|Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies||Hoffmann-La Roche||Terminated|February 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|13||Actual|104|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811993||145834|
NCT00811512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sadalla1|Fundus Changes in the Microphthalmy Eyes|Fundus Changes in the Microphthalmy Eyes||Hospital de Olhos Sadalla Amin Ghanem|Yes|Completed|May 2007|October 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|3|||Both|10 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|the study is the description of three cases of microphthalmy with changes to fund of the        eye, all documented with optical coherence tomography and clinical characteristics.|December 2008|December 18, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811512||145871|
NCT00809029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H1001/20|The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo Study|The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Hormone Sensitive Lipase, Lipoprotein Lipase And Adipokine Expression In Human Subcutaneous Adipose Tissue: An In Vivo Study||Aintree University Hospitals NHS Foundation Trust|No|Recruiting|April 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|12|||Male|18 Years|75 Years|No|||December 2011|December 20, 2011|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809029||146060|
NCT00812279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YVD-CS01-EU|Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article|A Controlled, Randomised, Open-Label, 3-Arm Parallel Single-Centre Confinement Study to Investigate Exposure to Selected Smoke Constituents in Smokers Switching From Conventional Cigarettes to SMAR Cigarettes for 5 Days||Philip Morris Products S.A.|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|112|||Both|23 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812279||145812|
NCT00812539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001898/1; MGH|Diabetes Connect: Patients and Providers Use of a Secure Website for Blood Glucose Monitoring in Type-2 Diabetes|A Randomized Clinical Trial of a Secure Website Shared Between Patients and Providers for Blood Glucose Monitoring in Type-2 Diabetes||Massachusetts General Hospital|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812539||145792|
NCT00809848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210669-003|Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma|||Allergan|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|172|||Both|18 Years|75 Years|No|||August 2013|August 13, 2013|December 16, 2008|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00809848||145997|
NCT00809861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCDRS00407|Volar Locking Plate Versus External Fixator/Cast Fixation for the Treatment of Distal Radius Fractures|Volar Locking Plate Versus External Fixator/Cast Fixation for the Treatment of Distal Radius Fractures. A Randomised Controlled Prospective Study||Mackay Base Hospital|Yes|Completed|August 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809861||145996|
NCT00809874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-PPL-JHJ|Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects|Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects||Aarhus University Hospital|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|11|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2009|November 9, 2009|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809874||145995|
NCT00812201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRRT081908H|Evaluation of Left Ventricular AutoThreshold|Evaluation of Left Ventricular AutoThreshold|ELEVATE|Boston Scientific Corporation|No|Completed|December 2008|October 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|October 2012|October 2, 2012|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812201||145818|
NCT00812461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12023A|Efficacy of Nalmefene in Patients With Alcohol Dependence|Nalmefene Efficacy Study II: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, as Needed Use, in Patients With Alcohol Dependence|ESENSE2|H. Lundbeck A/S|No|Completed|March 2009|April 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|678|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|December 19, 2008||No||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00812461||145798|
NCT00812721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iowa RR 01|Tears Substitutions and Their Effects on Higher Order Aberrometery|Tears Substitutions and Their Effects on Higher Order Aberrometery||University of Iowa|Yes|Not yet recruiting|January 2009|July 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|5||Anticipated|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2008|September 24, 2009|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812721||145778|
NCT00845585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/08|Ovine Graft (Omniflow II) Versus PTFE in Below Knee Arterial Reconstruction|Ovine Graft (Omniflow II) Versus PTFE in Below Knee Arterial Reconstruction: A Prospective Randomized Multi Centre Study||University Hospital Inselspital, Berne|No|Withdrawn|January 2009|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|90 Years|No|||November 2010|July 16, 2015|February 16, 2009||No|found not enough centers for recruitment|No||https://clinicaltrials.gov/show/NCT00845585||143280|
NCT00845598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAI04|Azelastine Fluticasone Combination vs. Fluticasone|A Proof of Concept Study to Evaluate Comparative Efficacy of an Azelastine/Fluticasone Combination Nasal Spray vs. Twice the Dose of Fluticasone in Persistent Allergic Rhinitis||University of Dundee|No|Withdrawn|August 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|February 17, 2009||No|Could not get IMP|No||https://clinicaltrials.gov/show/NCT00845598||143279|
NCT00845910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21870|A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer|A Phase II Trial of Evaluating Circulating Endothelial Cell as A Surrogate Marker for Monitoring Treatment Efficacy of Docetaxel Plus Capecitabine With Bevacizumab as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer||Hoffmann-La Roche||Terminated|May 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|65 Years|No|||March 2016|March 1, 2016|February 17, 2009||No|To be confirmed|No||https://clinicaltrials.gov/show/NCT00845910||143255|
NCT00841646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P11|Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects|A Phase II, Open-label, Multi-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects||Novartis||Completed|December 2008|November 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|343|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841646||143578|
NCT00810446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0061007|Safety And Efficacy Of Rifabutin In HIV Patients|Drug Use Investigation For Hiv Infection Patients Of Mycobutin (Regulatory Post Marketing Commitment Plan).||Pfizer|No|Active, not recruiting|June 2009|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A0061007 prescribes the Mycobutin®.|February 2016|February 29, 2016|December 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00810446||145952|
NCT00810459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0713-PTRI-SS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||June 29, 2010|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810459||145951|
NCT00810472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-2008-FANCY|Functional Antigen Matching in Corneal Transplantation|Clinical Trial to Investigate Superiority of HLA Matching in Comparison to Random Graft Assignment With Respect to the Endpoint 'Time to First Endothelial Graft Rejection' in Penetrating Keratoplasty.|FANCY|University Hospital Freiburg|Yes|Active, not recruiting|September 2009|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|650|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810472||145950|
NCT00811252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12541A|Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients|Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients||H. Lundbeck A/S|No|Completed|January 2009|March 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|453|||Both|65 Years|N/A|No|||December 2013|December 23, 2013|December 17, 2008|Yes|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00811252||145891|
NCT00811538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233/07|Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry|Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry (SWISS)|SWISS|University Hospital Inselspital, Berne|No|Recruiting|December 2007|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1368|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke treated with intravenous or intra-arterial        thrombolysis in a Swiss Stroke Unit.|September 2014|September 25, 2014|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00811538||145869|
NCT00812578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKO-1006-2008|Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes|Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes - a Randomized Controlled Trial|ProjectD|University of Aarhus|Yes|Completed|December 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|80 Years|No|||July 2010|July 9, 2010|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812578||145789|
NCT00811525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110390CA-0912-2|Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast Implant|Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast Implant|CPG-CA|Mentor Worldwide, LLC|No|Approved for marketing|August 2004|||||N/A|Expanded Access|N/A|||||||Female|18 Years|N/A||||November 2014|November 25, 2014|December 17, 2008|Yes|Yes||||https://clinicaltrials.gov/show/NCT00811525||145870|
NCT00812032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No: 2007-003186-40|Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients|Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients|DM-ASA 001|Karolinska Institutet|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|50 Years|75 Years|No|||December 2009|July 30, 2010|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812032||145831|
NCT00812838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07-40-04|H-22411: BOTOX® for Peyronie's Disease|The Efficacy of Botulinum Toxin Type a in Treating Peyronie's Disease||Baylor College of Medicine|No|Recruiting|February 2009|January 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|N/A|No|||September 2015|September 16, 2015|December 18, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812838||145769|
NCT00812851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC SG|Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)|Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)||Cantonal Hospital of St. Gallen|No|Completed|April 2005|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|24|||Both|18 Years|N/A|No|||November 2008|February 17, 2009|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00812851||145768|
NCT00812864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07028|Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)|Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥75 Years)|capagec|University Hospital, Limoges|No|Completed|January 2009|November 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|75 Years|N/A|No|||September 2009|December 4, 2012|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812864||145767|
NCT00841789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA-12652|Etanercept in Kawasaki Disease|A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease||Seattle Children's Hospital|Yes|Recruiting|March 2009|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Both|2 Months|20 Years|No|||December 2015|December 10, 2015|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841789||143567|
NCT00842088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQP 2008-004|Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease|A Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects With Sickle Cell Disease||HemaQuest Pharmaceuticals Inc.|Yes|Completed|March 2009|||July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|12 Years|60 Years|No|||July 2011|July 28, 2011|February 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842088||143545|
NCT00809003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/269/07/L|Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease|Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease|JADE|University of Waterloo|No|Completed|September 2007|December 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|||Both|17 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Primary care|December 2008|December 15, 2008|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00809003||146062|
NCT00809289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6061065|Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers|A Randomized, Multiple Dose, Placebo and Active Controlled 3-way Crossover Study to Investigate the Effects of Esreboxetine on QTc Interval in Healthy Volunteers|TQT|Pfizer|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809289||146040|
NCT00809575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOL-MDS0108|Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes|Prognostic Significance and Longitudinal Assessment of Patient-reported Quality of Life and Symptoms in Myelodysplastic Syndromes. A Large-scale International, Observational Study: PROMYS Study|PROMYS|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|November 2008|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1070|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with myelodysplastic syndromes (MDS).|May 2015|May 18, 2015|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809575||146018|
NCT00809887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10882|Micafungin Lock Therapy|Micafungin Lock Therapy to Clear Fungemia While Attempting to Preserve Central Venous Catheters||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Terminated|June 2006|November 2008|Actual|June 2008|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|6 Months|18 Years|No|||November 2008|December 15, 2008|December 15, 2008||No|Inability to enroll subjects|No||https://clinicaltrials.gov/show/NCT00809887||145994|
NCT00812214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESRC024|Treatment of Insomnia in Migraineurs|Treatment of Insomnia in Migraineurs With Eszopiclone (Lunesta™) and Its Effect on Sleep Time, Headache Frequency, and Daytime Functioning: a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study||MedVadis Research Corporation|No|Completed|April 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|113|||Both|18 Years|65 Years|No|||December 2008|December 19, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812214||145817|
NCT00812474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|373-2007|Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis|Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis||Sunnybrook Health Sciences Centre|No|Completed|December 2008|November 2015|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|16 Years|N/A|No|Probability Sample|Secondary progressive Multiple sclerosis|November 2015|November 16, 2015|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812474||145797|
NCT00813033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH080104.2|Use of a Patient Decision Aid for Gastrologic Endoscopy in a Pediatric Setting|Creation and Pilot Evaluation of a Patient Decision Aid as an Adjunct to the Consenting Process for Gastrointestinal Endoscopy in a Pediatric Setting||Children's Mercy Hospital Kansas City|No|Completed|December 2008|March 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 22, 2011|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813033||145754|
NCT00813046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT-gpASIT002|Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis|Preliminary Assessment of the Short Term Clinical Tolerability and Safety of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis||BioTech Tools S.A.|Yes|Completed|December 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|50 Years|No|||May 2014|May 23, 2014|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813046||145753|
NCT00845611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-27|Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer|Tumor Vaccine Therapy Against Advanced Gastric Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10||Kinki University|Yes|Completed|September 2008|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|80 Years|No|||April 2012|April 4, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845611||143278|
NCT00809783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091016|Extension Study Of Tanezumab In Osteoarthritis|A Phase 3, Multicenter, Randomized, Long Term Study Of The Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip||Pfizer|Yes|Terminated|February 2009|June 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2147|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|December 16, 2008|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00809783||146002|
NCT00809796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-103|A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment|A Phase I/II Clinical Study Using Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Folinic Acid, 5-Fluorouracil, or Capecitabine and Oxaliplatin Chemotherapy as Second-line and/or Third-line Treatment||Oncozyme Pharma Inc.|Yes|Completed|March 2008|June 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809796||146001|
NCT00810134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.7 - Oct 15th 2002|Bypass or Thurpass for Superficial Femoral Artery Occlusion? Scandinavian Thurpass Study|A Randomised Controlled Trial for the Treatment of 5 - 25 cm Superficial Femoral Artery oc-Clusions Comparing Femoropopliteal Bypass With 6 mm PTFE-Prosthesis and 6 - 7 mm Viabahn Endoprosthesis||Helsinki University|No|Terminated|January 2003|April 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||December 2008|December 16, 2008|December 15, 2008||No|Due to the results of interim analysis at the time 44 patients were recruited.|No||https://clinicaltrials.gov/show/NCT00810134||145976|
NCT00810147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-013|A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Mild to Moderate Alzheimer's Disease||Bristol-Myers Squibb|Yes|Completed|February 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|209|||Both|50 Years|90 Years|No|||September 2015|September 23, 2015|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810147||145975|
NCT00811044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0589|Regulation of Hepatic Insulin Extraction|Regulation of Hepatic Insulin Extraction:Alterations of Insulin Secretion in Subjects With Genetic Variants That Determine Risk for Non-Insulin Dependant Diabetes Mellitus|RHIE|Washington University School of Medicine|No|Withdrawn|October 2000|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|1250|Samples With DNA|Samples are collected for Glucose & various human peptide measurements and DNA. As peptide      assay evolves, specimens may be re-tested.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers & otherwise healthy diabetic volunteers (do not require insulin for        glucose control).|October 2010|October 1, 2010|December 17, 2008||No|PI, Dr. K. Polonsky has moved to the University of Chicago.|No||https://clinicaltrials.gov/show/NCT00811044||145907|
NCT00811278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-50|Approach to Predict Steroid Sensitivity in Patients With Asthma|A Non-Invasive Approach to Predict Steroid Sensitivity in Patients With Asthma||Children's Mercy Hospital Kansas City|No|Completed|December 2008|||June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|Samples With DNA|Whole blood, DNA, RNA|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients of the allergy and asthma clinics|October 2011|October 7, 2011|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811278||145889|
NCT00810771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-205|Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening|Evaluating a Preference-based Intervention for Increasing CRC Screening|EPIIC|VA Office of Research and Development|Yes|Completed|February 2009|August 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Health Services Research|3||Actual|466|||Both|50 Years|78 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|December 16, 2008||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT00810771||145928|Usual care arm was not true 3rd arm. We identified pts meeting eligibility criteria & randomized ~ 10th pt to be followed, measuring CRC screening 6 mos later. No intervention or survey. Only 79.6% of those enrolled completed survey.
NCT00812591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIG26|Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue for the Treatment of Type-1 Diabetic Patients|Evaluation of a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue for the Treatment of Type-1 Diabetic Patients||Medical University of Graz|Yes|Completed|May 2006|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 18, 2011|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812591||145788|
NCT00812877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-16752|Pulp Capping With Two Different Agents|Mineral Trioxide Aggregate (MTA) vs. Calcium Hydroxide (CaOH) in Direct Pulp Capping in NW PRECEDENT (Northwest Practice-based REsearch Collaborative in Evidence-based DENTistry Practices.|MTA|Oregon Health and Science University|Yes|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|376|||Both|7 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 3, 2015|December 18, 2008|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00812877||145766|Randomization was by practice therefore, some dentists may have used a material with which they had little familiarity.Lack of on-going monitoring of study procedures may have caused an inordinate number of failures in one practice.
NCT00845767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR 08-185M/1|The Cardiovascular Effects of Air Pollution: the Role of Nitric Oxide|The Cardiovascular Effects of Air Pollution: the Role of Nitric Oxide||University of Edinburgh|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 8, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845767||143266|
NCT00813163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP0208|Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer|A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer||PharmaEngine|No|Completed|January 2009|July 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813163||145744|
NCT00813176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20701755|One-Lung Ventilation in the Morbidly Obese Patient: A Comparison of a Left-Sided Broncho-Cath® Double Lumen Tube With the Arndt® Wire-Guided Blocker|||University of Iowa|Yes|Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2008|December 19, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00813176||145743|
NCT00841802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00010040|Chronic Rhinosinusitis With or Without Nasal Polyps Steroid Study|Glucocorticosteroid Action in Inflammatory Disease||Northwestern University|Yes|Recruiting|July 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841802||143566|
NCT00809016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626776|PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy|Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors||National Cancer Institute (NCI)||Completed|May 2007|||May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2009|May 12, 2011|December 13, 2008||||No||https://clinicaltrials.gov/show/NCT00809016||146061|
NCT00809302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aplindore-211|Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)||Neurogen Corporation|Yes|Terminated|December 2008|October 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|9|||Both|30 Years|N/A|No|||August 2009|August 27, 2009|December 15, 2008|Yes|Yes|Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns    identified.|No||https://clinicaltrials.gov/show/NCT00809302||146039|
NCT00812487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0087|Glycemic Control and Variability for Congestive Heart Failure Exacerbation|Glycemic Control and Variability for Congestive Heart Failure Exacerbation||Ohio State University|Yes|Completed|January 2009|September 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||November 2013|November 9, 2013|December 19, 2008|Yes|Yes||No|September 6, 2013|https://clinicaltrials.gov/show/NCT00812487||145796|The study was limited by study drop-out. Sensor glucose values were reduced due to sensor failures, and cardiac assessments were limited due to a high number of patients with ectopy, arrhythmia or paced rhythms at baseline precluding analysis.
NCT00818272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03288|Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)|Remicade Safety Line (Crohn's Disease)||Merck Sharp & Dohme Corp.|No|Completed|December 2002|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with Crohn's disease.|September 2015|September 2, 2015|January 6, 2009|No|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00818272||145354|
NCT00812734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0044|Epidemiologic Multicentre Study of Neuropathic Post-surgical Pain|Etude épidémiologique Multicentrique Des Douleurs Neuropathiques Post-opératoires|EDONIS|University Hospital, Clermont-Ferrand||Completed|April 2006|September 2011|Actual|March 2010|Actual|N/A|Observational|N/A||1|Actual|3322|||Both|18 Years|N/A|No|Probability Sample|Definied population|April 2013|April 2, 2013|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812734||145777|
NCT00812747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-Surg-002|Surgical Wound Infections After Vascular Surgery: Prospective Multicenter Trial|Surgical Wound Infections After Vascular Surgery: Prospective Multicenter Trial||North Karelia Central Hospital|No|Completed|June 2007|June 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|All patients who underwent non-emergency infrarenal aortic or lower limb arterial surgery        between June 2007 and January 2008 were enrolled to this study.|December 2008|December 19, 2008|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00812747||145776|
NCT00818909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARES-3|Systane Clinical Experience Study|Study to Evaluate the Physical Effect of SYSTANE QID in People That Have Moderate to Severe Dry Feeling Eyes||Alcon Research|No|Completed|January 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|941|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00818909||145305|
NCT00818922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||December 8, 2015|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818922||145304|
NCT00818935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWI-0012|Low-Intermediate-Glycemic Index Caribbean Foods Versus High Glycemic Index Foods in Type 2 Diabetes|Glycemic Indices of Caribbean Foods and Application in Dietary Lifestyle Intervention for Management of Type 2 Diabetes Mellitus||University Hospital of the West Indies|Yes|Completed|June 2004|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 6, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818935||145303|
NCT00809497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLC-LZ00108|A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases|A Randomized, Multi-centre, Double-blind and Placebo Controlled Clinical Study of the Propionyl-L-carnitine Hydrochloride Tablets|PLC|Lee's Pharmaceutical Limited|Yes|Completed|May 2008|January 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|239|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||March 2008|March 28, 2012|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809497||146024|
NCT00810420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyposafe-hypo-01|EEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes|EEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes||Hypo-Safe A/S|No|Completed|February 2007|April 2008|Actual|October 2007|Actual|N/A|Observational|N/A|||||||Both|18 Years|60 Years|No||Twenty adult patients with type 1 diabetes will be participating in the study.|December 2008|December 17, 2008|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810420||145954|
NCT00810433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-102|A Clinical Study of the GO-LIF® Approach for Lumbar Spinal Fixation|A Clinical Safety and Feasibility Study of the GO-LIF® Approach||Mazor Robotics|No|Completed|February 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||February 2014|February 6, 2014|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810433||145953|
NCT00810485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX10059-205|ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)|A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multi-centre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 in Patients With Gastroesophageal Reflux Disease (GERD) Who Are Partial Responders to Proton Pump Inhibitor (PPI) Treatment||Addex Pharma S.A.|No|Completed|December 2008|||December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|298|||Both|18 Years|70 Years|No|||July 2012|July 13, 2012|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810485||145949|
NCT00810498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0609-TRI2-SS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||June 29, 2010|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810498||145948|
NCT00810784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUHSC-IRB-00018164|Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients|Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients||University of Utah|Yes|Completed|March 2005|March 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|121|||Both|18 Years|N/A|No|Non-Probability Sample|Data was collected on consecutive patients ≥18 years with a hospital length of stay of >48        hours admitted to the cardiology, pulmonary, or general medical services. Admission dates        were a sample of two different two-week blocks (January 1-14, 2006 and April 1-14, 2006).        These blocks were chosen to be consistent with dates of analysis in the pre-intervention        cohort. Patients receiving therapeutic anticoagulation were excluded.|December 2008|December 17, 2008|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810784||145927|
NCT00812045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4260C00008|Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis|CYBER|AstraZeneca|No|Withdrawn|December 2009|August 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||May 2009|May 5, 2009|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812045||145830|
NCT00812058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG2417-03|A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression|A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression||Repligen Corporation|Yes|Completed|November 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||January 2011|January 13, 2011|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812058||145829|
NCT00811291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08032V|Influence of Vitamin-B-complex on Cognitive Ability of Kindergarten Kids|SIMBA-Study Investigating Mental Acuity Effects of B-vitamins in Children|SIMBA|Ludwig-Maximilians - University of Munich|Yes|Completed|September 2008|December 2011|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811291||145888|
NCT00812071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3369-01|Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin|Phase 1 Study of the Safety and Immunogenicity of RiVax With Alum in Healthy Adults|FDA-OPD|University of Texas Southwestern Medical Center|Yes|Completed|March 2008|May 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|31 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|December 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812071||145828|
NCT00812292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012586|TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation|A Phase I, Open-label, Randomized, Crossover Trial in Healthy Adults to Compare the Oral Bioavailability of TMC278 From Three Concept Pediatric Formulations (Solution, Suspension, Granules) With That From the Adult Phase III Tablet Formulation.||Tibotec Pharmaceuticals, Ireland||Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|June 8, 2011|December 18, 2008||||No||https://clinicaltrials.gov/show/NCT00812292||145811|
NCT00812305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C110|Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects|A Randomized, Double-Blind, Phase 1 Study to Assess the Pharmacokinetics and Safety of SKY0402 in Subjects With Impaired Hepatic Function||Pacira Pharmaceuticals, Inc|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 3, 2010|December 9, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00812305||145810|
NCT00812318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITZ111682|Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.|A Single Dose, Randomized Study to Assess the Relative Bioavailability of Two Formulations and Food Effect on GSK1265744 in Healthy Male and Female Subjects||ViiV Healthcare|No|Completed|June 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|September 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00812318||145809|
NCT00845416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H55235-32562-01|Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population|Newborn Screening for SCID in a High-Risk Population||University of California, San Francisco|No|Completed|March 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1800|||Both|N/A|30 Days|No|Non-Probability Sample|Navajo Indians|July 2012|July 13, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845416||143293|
NCT00845429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCE03|Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects|Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years||Sanofi|Yes|Completed|October 2007|November 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|729|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|February 13, 2009|Yes|Yes||No|November 17, 2012|https://clinicaltrials.gov/show/NCT00845429||143292|
NCT00845780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T377|Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation|Withdrawal of Amiodarone Treatment Versus Continuation in Successfully Treated Patients With Persistent Atrial Fibrillation. A Randomized Study.|WISDOM|University Medical Center Groningen|No|Completed|August 2000|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||June 2009|June 23, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845780||143265|
NCT00846014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Docket # 12937|Asthma Exacerbation and Helium-3 MRI|Asthma Exacerbation and Helium-3 MRI||University of Massachusetts, Worcester|No|Withdrawn|January 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|February 16, 2009|Yes|Yes|Subjects which fit the strict inclusion criteria were not found.|No||https://clinicaltrials.gov/show/NCT00846014||143247|
NCT00842361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3570|Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus|A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIAC Compared to Mix30 (NovoRapid®30Mix) on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|20 Years|N/A|No|||November 2015|November 20, 2015|February 11, 2009|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00842361||143524|
NCT00809315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0516a|Intervention Development and Pilot for Foster Care Youth|Intervention Development and Pilot for Foster Care Youth||University of Colorado, Denver|No|Active, not recruiting|August 2002|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|152|||Both|9 Years|11 Years|No|||January 2016|January 5, 2016|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809315||146038|
NCT00809328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661191|The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)|A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Community Acquired Pneumonia (CAP) Requiring Initial Intravenous Therapy||Pfizer|No|Completed|February 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|16 Years|80 Years|No|||May 2011|May 16, 2011|December 16, 2008|Yes|Yes||No|March 22, 2011|https://clinicaltrials.gov/show/NCT00809328||146037|
NCT00842335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JI-101-001|A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors|A Multicenter, Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors||Jubilant Innovation Ltd.|No|Completed|February 2009|January 2012|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|February 11, 2009|No|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT00842335||143526|
NCT00809588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-218|Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)|A Phase IB Study of Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2003|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809588||146017|
NCT00809601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/69-31/3|Study of Different Kinds of Ear Tubes|Randomized Controlled Study of Transmyringeal Tubes||Danderyd Hospital|No|Active, not recruiting|May 2008|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|400|||Both|1 Year|10 Years|No|||March 2013|March 21, 2013|May 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00809601||146016|
NCT00809614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2206|Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis|Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis||Novartis|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||October 2015|October 14, 2015|December 16, 2008|Yes|Yes||No|February 1, 2015|https://clinicaltrials.gov/show/NCT00809614||146015|
NCT00818285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA06-1035-QC|Reducing Injuries From Medication-Related Falls Using Computerized Alerts for High Risk Patients|Reducing Injuries From Medication-Related Falls by Generating Targeted Computerized Alerts for High Risk Patients Within an Electronic Prescribing System||McGill University|No|Recruiting|September 2008|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|4800|||Both|65 Years|N/A|No|||April 2013|April 25, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818285||145353|
NCT00818623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS07|Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients|An Open-Label, Multi-Center, Parallel and Sequential, Ascending Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486 in Prostate Cancer Patients||Ferring Pharmaceuticals|No|Completed|November 2002|October 2004|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|172|||Male|18 Years|N/A|No|||May 2011|May 18, 2011|January 7, 2009|Yes|Yes||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00818623||145327|
NCT00819260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182DF9|Harmonic Scalpel Vs. Electrocautery in Breast Reduction Surgery|A Randomized Clinical Trial Comparing the Harmonic Scalpel to Electrocautery in Breast Reduction Surgery||Dartmouth-Hitchcock Medical Center|No|Terminated|March 2009|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|N/A|No|||May 2013|May 17, 2013|January 6, 2009|Yes|Yes|Significant result achieved after enrollment of 31 of planned 50 subjects.|No|November 29, 2011|https://clinicaltrials.gov/show/NCT00819260||145279|We made a first analysis after 26 (intended enrollment 50) patients were enrolled and a result was strongly suggested. While the analysis was refined, 5 more patients enrolled. The study was then stopped after 31 patients enrolled.
NCT00819273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2008/5|Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population|Investigation Into the CorrelAtion of pLasma Hs-CRP Concentrations and cardiovascuLar rISk in Korean populaTiOn|CALLISTO|AstraZeneca|No|Completed|March 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1700|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have records of clinic visit with circulatory and endocrine internal        medicines of nationwide tertiary hospitals within the last one year.|December 2010|December 2, 2010|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819273||145278|
NCT00809809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIZnc2008|Zinc for the Treatment of Herpes Simplex Labialis (HSL)|A Randomized, Double-blind, Placebo-controlled, Multi-Center Trial of Zinc for the Treatment of Herpes Simplex Labialis (HSL)||Integrative Medicine Institute|Yes|Completed|December 2008|December 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|65 Years|No|||November 2013|November 19, 2013|December 15, 2008|Yes|Yes||No|March 21, 2012|https://clinicaltrials.gov/show/NCT00809809||146000|There may have been differences between the populations in the different study sites that influenced the outcome of this clinical trial.
NCT00810160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD059127-01|The Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants|Phase 1A Study of Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants||University of California, Davis|Yes|Recruiting|June 2009|April 2015|Anticipated|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 15, 2014|December 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810160||145974|
NCT00811304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08090016|Real-time Ultrasound Guided Labor Epidural Placement|Real-time Ultrasound Guided Labor Epidural Placement||University of Pittsburgh|Yes|Withdrawn|January 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women in labor.|February 2013|February 1, 2013|December 16, 2008||No|We are unable to find a clip used to stabilize the epidural needle on the ultrasound probe to    allow adequate epidural catheter placement.|No||https://clinicaltrials.gov/show/NCT00811304||145887|
NCT00811551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 440|Data Collection Study of Wedge Pressure Data in Patients With CRT-D Devices|zWedge Clinical Feasibility IDE Study|zWedge|St. Jude Medical|No|Completed|December 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects previously implanted with a St. Jude Medical PROMOTE device (Model 3207 or other        with similar capability) according to ACC/AHA/HRS guidelines.|July 2012|July 23, 2012|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811551||145868|
NCT00812084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3015|Costs, Health Status and Outcomes of CAP (Community-Acquired Pneumonia)|Collecting Health Outcomes and Economic Data on Hospitalized Community-Acquired Pneumonia - a Prospective Cohort Study|CHO-CAP|UMC Utrecht|No|Completed|November 2008|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|48634|||Both|65 Years|N/A|No|Non-Probability Sample|The study population consists of community-dwelling persons 65 years and older and taking        part in the CAPITA trial, in total 85,000 persons|June 2015|June 11, 2015|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00812084||145827|
NCT00812331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012604|A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)|An Open-label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.||Tibotec Pharmaceuticals, Ireland|No|Completed|March 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|37|||Both|18 Years|70 Years|No|||July 2014|July 1, 2014|December 18, 2008|Yes|Yes||No|December 24, 2013|https://clinicaltrials.gov/show/NCT00812331||145808|
NCT00845442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-03-16|Dynamic Laryngeal Opening for Bilateral Vocal Fold Paralysis by an Implanted Stimulator|Dynamic Vocal Fold Abduction for Bilateral Paralysis||University Hospital Case Medical Center|No|Recruiting|January 2006|November 2010|Anticipated|January 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|85 Years|No|||January 2010|January 12, 2010|December 26, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845442||143291|
NCT00845455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPQStroke03CTIL|Personality Type as a Predictor to Develop Depression and Reduction in Quality of Life Among Stroke Survivals.|Personality Type as a Predictor to Develop Depression and Reduction in Quality of Life Among Stroke Survivals.|TPQ BDI SSQOL|Rambam Health Care Campus|No|Completed|November 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|85|||Both|40 Years|90 Years|No|Non-Probability Sample|Stroke ( TIA, CVA, ICH ) patients|October 2011|October 24, 2011|February 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00845455||143290|
NCT00841529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D02940|Evaluation of the Cardioblate Closure Device in Facilitating Occlusion of the Left Atrial Appendage|Evaluation of the Cardioblate Closure Device in Facilitating Occlusion of the Left Atrial Appendage||Medtronic Cardiovascular|Yes|Terminated|March 2009|June 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|No|||October 2012|October 18, 2012|February 10, 2009|Yes|Yes|Medtronic Business Decision|No||https://clinicaltrials.gov/show/NCT00841529||143587|
NCT00841815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2684|Amlodipine 10 mg Tablets Under Fed Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Amlodipine 10 mg Tablets Versus Norvasc® 10 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|April 2003|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|February 9, 2009|No|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00841815||143565|
NCT00841828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2006-14|Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients|A Phase II Randomised, Multicentre Compare Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Trastuzumab Versus Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Lapatinib in Women With Primary Resectable Breast Cancer or Locally Advanced Breast Cancer Positive Her 2.||Spanish Breast Cancer Research Group|No|Active, not recruiting|February 2009|December 2013|Anticipated|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Female|18 Years|N/A|No|||June 2013|June 7, 2013|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841828||143564|
NCT00846027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21999|A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer|An Open Label Study to Assess the Effect of First Line Treatment With Avastin in Combination With Paclitaxel and Gemcitabine in Progression-free Survival in Patients With HER-2 Negative Breast Cancer||Hoffmann-La Roche||Completed|January 2009|January 2013|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Female|18 Years|N/A|No|||July 2014|July 9, 2014|February 17, 2009||No||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00846027||143246|
NCT00846040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090081|Reduced Carbohydrate vs. Fat|Selective Reduction of Dietary Carbohydrate Versus Fat: Effects on Metabolism, Endocrine Physiology, Brain Activity and Reward Circuitry||National Institutes of Health Clinical Center (CC)||Completed|February 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|71|||Both|18 Years|45 Years|No|||February 2016|February 12, 2016|February 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00846040||143245|
NCT00841841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/FOA-Unesp-02|Dipyrone Versus Acetaminophen in the Control of Postoperative Pain|Dipyrone Versus Acetaminophen in the Control of Postoperative Pain||University Center of Araraquara|Yes|Completed|March 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|35 Years|No|||February 2013|February 8, 2013|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841841||143563|
NCT00842101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA002|Compartmental Overpressures Associated to Reamed Intramedullary Nails|Effect of Reamed Intramedullary Nails in Tibial Fractures as a Factor of Rising Intracompartmental Pressures: A Clinical Study||University of Andorra|Yes|Completed|December 2005|September 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|None Retained|Serum|Both|N/A|N/A|No|Non-Probability Sample|Patients with tibial shaft fractures|February 2009|February 11, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00842101||143544|
NCT00842348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-55-52030-729|Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour|Open Label Extension Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour|NET729|Ipsen|No|Completed|September 2008|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|February 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842348||143525|
NCT00842569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRNHRA-09-001|Brain Electrophysiological Patterns in Obesity|ERP Study of Brain Electrophysiological Patterns in Obesity||Centre de Recherche en Nutrition Humaine Rhone-Alpe|No|Completed|January 2008|||December 2008|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|69|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|a healthy but normal-weighted or obese population. Depressive state or eating disorders        were carefully evaluated.|February 2009|February 11, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842569||143508|
NCT00818636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03AA016819-01A1|Expressive Writing for Co-Occurring Depression and Alcohol Misuse|Expressive Writing for Co-Occurring Depression and Alcohol Misuse||Baylor College of Medicine|No|Completed|August 2008|December 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818636||145326|
NCT00818948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070283|Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis||Amgen|No|Completed|March 2009|August 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||August 2014|September 11, 2014|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818948||145302|
NCT00818961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000630617|Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer|Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies||Northside Hospital, Inc.|No|Terminated|May 2005|March 2012|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|40 Years|72 Years|No|||October 2013|October 28, 2013|January 7, 2009|Yes|Yes|terminated early due to meeting end point with fewer patients than anticipated|No|March 22, 2013|https://clinicaltrials.gov/show/NCT00818961||145301|
NCT00809510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-745|A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study|||Abbott||Terminated|January 2009|||June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|55 Years|90 Years|No|||September 2011|September 1, 2011|December 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809510||146023|
NCT00809523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810004322|A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)|A Multicenter, Randomized Controlled Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)||Yale University|No|Completed|December 2008|April 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|65 Years|No|||January 2013|January 29, 2013|December 16, 2008|Yes|Yes||No|September 7, 2012|https://clinicaltrials.gov/show/NCT00809523||146022|
NCT00809822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-01-06/E-01|Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(PhaseⅡ).|NPB-01|Nihon Pharmaceutical Co., Ltd|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|N/A|No|||October 2010|October 21, 2010|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00809822||145999|
NCT00811317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000101|Closed-loop Glucose Control for Automated Management of Type 1 Diabetes|Closed-loop Glucose Control for Automated Management of Type 1 Diabetes||Boston University|Yes|Completed|May 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 15, 2010|May 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811317||145886|
NCT00843960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFB-P46-377|Medication Adherence Enhancement in Heart Transplant Recipients|Medication Adherence Enhancement in Heart Transplant Recipients: a Randomized Clinical Trial||Hannover Medical School|Yes|Recruiting|February 2009|December 2013|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|70 Years|No|||October 2009|October 6, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843960||143403|
NCT00844259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180875|Functional Communicative Profile of Children With Down Syndrome|Functional Communicative Profile of Children With Down Syndrome||University of Sao Paulo|Yes|Completed|July 2006|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|15|||Both|5 Years|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|15 children with Down syndrome aged from 5 to 8 years.|February 2009|February 13, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844259||143381|
NCT00811785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090059|Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency|Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency||National Institutes of Health Clinical Center (CC)||Recruiting|December 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|80 Years|No|||June 2015|January 1, 2016|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00811785||145850|
NCT00811798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111712|Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Subjects.||GlaxoSmithKline||Completed|May 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|92|||Female|25 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 8, 2011|December 18, 2008|Yes|Yes||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00811798||145849|
NCT00844870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-007|Exploring New Approaches in Reaching Behavior Post Stroke|Training With or Without Upper Body Restraint During Reaching in Individuals Post Stroke||University of the Sciences in Philadelphia|No|Completed|April 2007|September 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 13, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844870||143335|
NCT00844883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J08110|Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma|Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|February 2009|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|February 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00844883||143334|
NCT00845143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003 HD|Vibration Response Imaging (VRI) in the Preoperative Management in Patients With Non-Small Cell Lung Cancer|Vibration Response Imaging (VRI) in the Preoperative Management in Patients With Non-Small Cell Lung Cancer||Heidelberg University|No|Active, not recruiting|February 2009|August 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|35 Years|80 Years|No|Non-Probability Sample|Patients with operable non-small cell lung cancer|February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845143||143314|
NCT00845793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO- 0584-08|The Meal Tray as a Tool and Platform to Change Eating Habits Among Hospitalized Diabetic Patients - An Intervention Study|The Meal Tray as a Tool and Platform to Change Eating Habits Among Hospitalized Diabetic Patients - An Intervention Study||Hadassah Medical Organization|No|Not yet recruiting|April 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|500|||Both|20 Years|80 Years|No|||February 2009|February 17, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845793||143264|
NCT00841516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0801rB|Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for the Immunological and Histological Evaluation of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v1-FV||Allergopharma GmbH & Co. KG|No|Completed|December 2007|May 2013|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|60 Years|No|||November 2013|November 7, 2013|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841516||143588|
NCT00842907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICCO|Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage|A Clinical, Laboratorial and Quality of Life Study to Evaluate the Efficacy and Safety of Oral Isotretinoin in the Treatment of Cutaneous Photodamage||Federal University of São Paulo|Yes|Active, not recruiting|May 2009|August 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2009|June 7, 2010|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842907||143483|
NCT00842127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEPOROM|Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)|Genetic Polymorphism of Drug Transporters in OROS-Methylphenidate Treatment in Children and Adolescents With Attention Deficit Hyperactivity Disorder(ADHD)||Bundang CHA Hospital|Yes|Completed|March 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|6 Years|18 Years|No|||February 2009|February 11, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842127||143542|
NCT00843167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634111|Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy|Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS)||OHSU Knight Cancer Institute|Yes|Completed|August 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Female|21 Years|120 Years|No|||October 2015|October 20, 2015|February 12, 2009|Yes|Yes||No|December 30, 2014|https://clinicaltrials.gov/show/NCT00843167||143463|
NCT00842114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH-Pro-05|Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)|Association of Rituximab to Immunochemotherapy With CVP + Interferon in Newly Diagnosed Follicular Lymphoma Patients With Intermediate-high FLIPI Score. Phase II Study.|LNH-Pro-05|Fundación Leucemia y Linfoma, Spain|No|Active, not recruiting|February 2006|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||March 2015|March 30, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00842114||143543|
NCT00842894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3716|Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 26-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Macedonia||Novo Nordisk A/S|No|Completed|May 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3421|||Both|N/A|N/A|No|Non-Probability Sample|Patients from speciality practice settings who have been deemed appropriate to receive        biphasic insulin aspart 30 or insulin detemir as new treatment and as part of routine        out-patient care by the prescribing physician.|November 2012|August 13, 2014|February 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842894||143484|
NCT00843440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.510/11|Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study|Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study.|METAFORE|Hospices Civils de Lyon|Yes|Completed|March 2009|March 2012|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|No|||October 2009|May 29, 2013|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843440||143443|
NCT00842582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200777|Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer|Neoadjuvant Azacitidine With Carboplatin and Paclitaxel for Suboptimal Newly Diagnosed Ovarian Cancer||Loyola University|No|Terminated|February 2009|March 2012|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||March 2011|March 8, 2011|February 11, 2009|Yes|Yes|No enrollment. Unable to recruit due to lack of eligible patients.|No||https://clinicaltrials.gov/show/NCT00842582||143507|
NCT00819598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF IRB 08-823|Pilot Study to Determine the Optimal Technique for Measurement of Ankle Blood Pressures|Pilot Study to Determine the Optimal Oscillometric-Based Technique for Measurement of Ankle Blood Pressures for the Ankle-brachial Index||Summit Doppler Systems, Inc.|No|Completed|January 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to Cleveland Clinic's non-invasive vascular lab|November 2009|November 10, 2009|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819598||145253|
NCT00819871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCSP-NFKB1|Nuclear Factor Kappa-B (NFKB1) Polymorphism and Organ Injury After Cardiac Surgery|Association of NFKB1 -94 Polymorphism With Lung and/or Kidney Injury After Cardiac Surgery With Cardiopulmonary Bypass||Changhai Hospital|Yes|Completed|May 2008|December 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|105|Samples With DNA|3ml blood before surgery, after surgery and 24h after surgery respectively|Both|18 Years|N/A|No|Probability Sample|Chinese Han patients undergoing elective cardiac surgery with CPB|May 2013|May 2, 2013|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819871||145233|
NCT00819884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00017|To Evaluate 24-hr Glucose After OD vs BD AZD1656|A Randomised, Two Way Cross-Over, Single-Blind, Phase I Study to Evaluate 24-hr Glucose Profiles in Patients With T2DM When Dosed OD and BD on Top of Metformin for Four Days With AZD1656||AstraZeneca||Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Both|30 Years|75 Years|No|||May 2009|May 6, 2009|January 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00819884||145232|
NCT00809536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361031|Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time|A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Pharmacokinetics Of PD 0332334 And Metformin When Administered Concurrently In Healthy Subjects||Pfizer|No|Terminated|January 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 16, 2010|December 15, 2008|No|Yes|Please Detailed Description for termination reason.|No||https://clinicaltrials.gov/show/NCT00809536||146021|
NCT00809549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006076-01H|Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery|Granulocyte-Colony Stimulating Factor In Ischemic Stroke (GIST): A Pilot Study|GIST|Ottawa Hospital Research Institute|Yes|Active, not recruiting|July 2006|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|45 Years|85 Years|No|||July 2012|July 11, 2012|October 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809549||146020|
NCT00809835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708002943|Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse|Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals||Yale University|Yes|Completed|December 2007|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|50 Years|No|||April 2015|April 8, 2015|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809835||145998|
NCT00811564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-COM-08-008|An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects|||Allergan||Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|December 17, 2008|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00811564||145867|
NCT00844272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIAR-PERMIT|Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment|Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment|Permit|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|May 2005|November 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|70 Years|No|||May 2015|May 27, 2015|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844272||143380|
NCT00844285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87075|SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry|A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease|SECURE|UCB Pharma|No|Enrolling by invitation|January 2009|January 2026|Anticipated|January 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of selected gastroenterologists and internal medicine physicians from both        community-based and academic practice settings (75% and 25% respectively) Each physician        should be able to recruit a minimum of 5 patients prescribed Cimzia® and/or 5 patients        prescribed other treatments.        Recruitment into both cohorts will be monitored and controlled as needed in order to        ensure balanced enrollment over time. In order to ensure reasonable balance between both        cohorts, retrospective frequency matching will be applied for disease severity        (mild/moderate/severe), age categories and gender.|March 2016|March 18, 2016|February 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00844285||143379|
NCT00844571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170883|Effect E-learning Program About Child Maltreatment|The Effectiveness of an E-learning Program About Child Maltreatment for Nurses on an A&E Department: a Randomised Controlled Trial||UMC Utrecht|No|Enrolling by invitation|August 2008|December 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|38|||Both|N/A|N/A|No|Probability Sample|Nurses working at the A&E department of UMC-Utrecht|November 2009|November 23, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844571||143357|
NCT00844584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xinzangwaike0001|Radiofrequency Ablation of Atrial Fibrillation Under Totally Thoracoscope|Clinical Study of Radiofrequency Ablation of Atrial Fibrillation Under Totally Thoracoscope||Xijing Hospital|Yes|Recruiting|October 2008|June 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||January 2009|February 12, 2009|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00844584||143356|
NCT00844896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC Grant No. 8894|Intervention to Reduce Stress in 0-5 Year Olds With Burns|RCT Intervention to Reduce Stress in 0-5 Year Olds With Burns||Massachusetts General Hospital|No|Completed|May 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|57|||Both|N/A|5 Years|No|||October 2014|October 8, 2014|February 12, 2009||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00844896||143333|
NCT00845156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6820-30422|Alpha Lipoic Acid and Insulin Resistance|Alpha Lipoic Acid and Insulin Resistance||University of California, San Francisco|No|Completed|January 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845156||143313|
NCT00842374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acs001|Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin|Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin||Minneapolis Heart Institute Foundation|No|Completed|December 2008|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Probability Sample|Emergency Department|April 2013|April 24, 2013|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842374||143523|
NCT00842608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0145|Pharmacological Management of Delirium|Pharmacological Management of Delirium|PMD|Indiana University|Yes|Completed|February 2009|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|551|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842608||143505|
NCT00842387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GEU-DUM-2008/1|Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)|Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)||AstraZeneca|No|Completed|January 2009|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2370|||Both|18 Years|N/A|No|Probability Sample|Patients with symptoms suggestive of GERD.|December 2009|December 22, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842387||143522|
NCT00842920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-002226-11|Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients|Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients|SIMaMCI|Charite University, Berlin, Germany|Yes|Recruiting|December 2008|March 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|520|||Both|55 Years|90 Years|No|||September 2015|September 15, 2015|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842920||143482|
NCT00843193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106870|Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma|A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients With Severe Asthma||GlaxoSmithKline|No|Completed|December 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|75 Years|No|||February 2012|September 19, 2013|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843193||143461|
NCT00843180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H41337-33343|Massage for Pediatric Oncology|Massage for Children Undergoing Bone Marrow Transplantation||University of California, San Francisco|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|23|||Both|5 Years|18 Years|No|||May 2012|May 2, 2012|February 12, 2009||No||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00843180||143462|small sample sizelimited number of time points for self-report assessments.the dose of the massage intervention averaged 1.8 massages per week, while the target dose was 3 per week.
NCT00842595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R NIMP|Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas|Phase II Study of Treatment of Relapsed Agressive Lymphomas||French Innovative Leukemia Organisation|Yes|Completed|December 2003|May 2010|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||July 2010|July 23, 2013|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842595||143506|
NCT00843726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 124407|Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients With Node Negative, Peripheral Non-Small Cell Lung Cancer||Roswell Park Cancer Institute|Yes|Active, not recruiting|September 2008|||April 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843726||143421|
NCT00843453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS08-165|Long-term Use of Proton Pump Inhibitors May Cause Vitamin B12 Deficiency in the Institutionalized Elderly|Long-term Use of Proton Pump Inhibitors May Cause Vitamin B12 Deficiency in the Institutionalized Elderly||University of Delaware|Yes|Completed|November 2006|April 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|60 Years|89 Years|Accepts Healthy Volunteers|||July 2009|July 21, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843453||143442|
NCT00844350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8725|The Effect of Oxytocin (OT) and Oxytocin Plus Human Chorionic Gonadotropin (hCG), in Cycles Induced by Letrozole or Clomiphene Citrate|||Tabriz University|No|Completed|October 2006|October 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|177|||Female|17 Years|40 Years|No|||February 2009|February 13, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844350||143374|
NCT00819325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSHRF #404N-01|Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients|Prevention of Neointimal Proliferation With Aggressive Reduction of Glucose Concentrations (Pioglitazone) Study -- PPAR-G -- An IVUS Pilot Feasibility Study in Type 2 Diabetic Patients.|PPAR-G|Queen Elizabeth II Health Sciences Centre|No|Completed|August 2002|March 2007|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|30 Years|80 Years|No|||January 2009|January 6, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00819325||145274|
NCT00819611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WM01022009|Working Memory Training in Young ADHD Children|Working Memory Training: A Randomised Controlled Treatment Study in Young ADHD Children||Radboud University|No|Completed|June 2009|December 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|54 Months|88 Months|No|||January 2014|January 9, 2014|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819611||145252|
NCT00819624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001393|A Study to Compare Two Ways of Completing Pain and Sleep Questions and to Evaluate a New Daily Questionaire for Assessing Fatigue in Fibromyalgia Patients|A Non-Drug Methodology Study To Explore The Psychometric Properties Of A Daily Diary Of Fatigue Symptoms And To Compare Two Modes Of Administration Of Pain And Sleep Interference Questions For Use With Fibromyalgia Patients||Pfizer|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|185|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819624||145251|
NCT00809562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22022|A Study of RO4917523 in Patients With Treatment Resistant Depression|An Exploratory Fixed Dose Randomized Double Blind Parallel-group Placebo-controlled Study of the Safety and of the Therapeutic Effects of Ro 4917523 in Patients With Treatment- Resistant Depression||Hoffmann-La Roche||Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|No|||September 2012|September 18, 2012|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809562||146019|
NCT00811057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0249|Tocolysis for Preterm Labor|Tocolysis for Preterm Labor||University of Mississippi Medical Center|No|Completed|June 2004|June 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|301|||Female|16 Years|45 Years|No|||February 2013|February 25, 2013|December 16, 2008|Yes|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT00811057||145906|
NCT00843661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFP01|Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients|Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study.||Ospedale di Circolo - Fondazione Macchi||Recruiting|March 2009|July 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2011|August 1, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843661||143426|
NCT00843674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00257400|Psychotherapy for Depressed Women With Abuse Histories|Psychotherapy for Depressed Women With Abuse Histories||University of Rochester|No|Completed|September 2002|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Female|18 Years|N/A|No|||February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843674||143425|
NCT00844636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blunt Needles - Cesarean|A Trial of Blunt Needles for the Reduction of Needlestick Injuries During Cesarean Section|A Randomized Trial of Blunt Needles for the Reduction of Needlestick Injuries During Cesarean Section||Medical University of South Carolina|No|Completed|January 2005|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|197|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 13, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844636||143353|
NCT00844649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA046|Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas|A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas||Celgene|Yes|Completed|March 2009|April 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|861|||Both|18 Years|79 Years|No|||October 2015|October 19, 2015|February 13, 2009|Yes|Yes||No|October 21, 2013|https://clinicaltrials.gov/show/NCT00844649||143352|
NCT00845481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLQ-002|A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris|A Plaque Test Comparing 4 Steroids With Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris||LEO Pharma|No|Completed|January 2009|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|24|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 16, 2009||No||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00845481||143288|
NCT00844597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-4658-28|Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients|Clinical Study to Assess the Safety fo AVI-4658 in Subjects With Duchenne Muscular Dystrophy Due to a Frame-shift Mutation Amenable to Correction by Skipping Exon 51.||Sarepta Therapeutics|Yes|Completed|January 2009|December 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|19|||Male|5 Years|15 Years|No|||September 2015|September 3, 2015|December 24, 2008||No||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00844597||143355|Due to the small number of study participants, a single adverse event (AE) in 1 patient exceeds the reporting threshold of 5%. Refer to the "Post-Hoc Outcome Measures" #5 for a summary of frequent and related AEs.
NCT00844623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK99UN-HCC1|TK-based Suicide Gene Therapy for Hepatocellular Carcinoma|Phase I Clinical Trial Of Gene Therapy For Hepatocellular Carcinoma By Intratumoral Injection Of TK99UN (An Adenoviral Vector Containing The Thymidine Kinase Of Herpes Simplex Virus)||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|December 2002|March 2008|Actual|November 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||January 2013|January 15, 2013|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844623||143354|
NCT00845169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR 08-185M/2|The Role of Nitric Oxide Synthase Isoforms in the Cardiovascular Effects of Air Pollution|The Role of Nitric Oxide Synthase Isoforms in the Cardiovascular Effects of Air Pollution||University of Edinburgh|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845169||143312|
NCT00841854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0088|Comparison of 7-Day and 14-Day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication|Comparison of 7-Day and 14-Day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.||Asan Medical Center|No|Recruiting|June 2008|November 2009|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||February 2009|February 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841854||143562|
NCT00845468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-4-B368-A1392-22379|Coronary Flow Reserve and Glucometabolic State|Coronary Flow Velocity Reserve According to Glucometabolic State in Acute Myocardial Infarction; Relation to Ventricular Systolic and Diastolic Function||Medicinsk Forsknings Afdeling|No|Completed|January 2006|||August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|190|||Both|N/A|N/A|No|Probability Sample|Patients suffering from a acute myocardial infarction|February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845468||143289|
NCT00842153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OEF0701|Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam|A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis||GlaxoSmithKline|No|Completed|November 2007|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|12 Years|N/A|No|||September 2011|December 21, 2011|February 11, 2009||No||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00842153||143540|
NCT00842933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0207-0012|Adrenal Insufficiency in Septic Shock|An Open-label, Prospective, Randomized, Controlled Clinical Trial of the Use of Reduced Duration Versus Standard Duration Steroid Replacement Therapy for Acute Adrenal Insufficiency in Patients With Septic Shock||The Methodist Hospital System|Yes|Terminated|May 2007|May 2011|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|February 11, 2009||No|Unable to meet enrollment goal prior to PI transfer|No||https://clinicaltrials.gov/show/NCT00842933||143481|
NCT00843219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0851|Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating|Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating||M.D. Anderson Cancer Center|No|Completed|March 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals over the age of 18 with non-small cell lung cancer (NSCLC) and are scheduled        to have a positron emission tomography/computed tomography (PET/CT) scan.|January 2012|February 15, 2016|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843219||143460|
NCT00843479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0006|The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly|The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly.||University of Campinas, Brazil|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|24|Samples Without DNA|Sera and plasma|Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult normoglycemic subjects|March 2013|March 7, 2013|February 12, 2009||No||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00843479||143440|
NCT00843466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002004|Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis|Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis||Wake Forest School of Medicine|No|Completed|May 2007|November 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||February 2009|February 12, 2009|June 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00843466||143441|
NCT00844051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLA-08-00229|Study to Evaluate Impact of School-based Influenza Vaccination on School Populations|Prospective Study of School-based Influenza Vaccination's Impact on School Populations||Children's Hospital Los Angeles|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4500|||Both|4 Years|18 Years|No|||January 2014|January 27, 2014|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844051||143397|
NCT00844701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOLD fMRI|Cue Induced Imaging in Nicotine Dependent Smokers|Validation of Cue Induced Imaging Paradigm in Nicotine Dependent Smokers||Medical University of South Carolina|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|52|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|adult nicotine dependent smokers|October 2009|October 31, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844701||143348|
NCT00819637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASRC947|A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients|A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Presenting to the Emergency Department and to Evaluate Its Side Effect and Safety Profile When Used in This Clinical Situation.||Henry Ford Health System|No|Terminated|January 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|45 Years|No|||March 2015|March 17, 2015|January 8, 2009||No|Unable to enroll r/t study design & staffing issues. The trial terminated.|No|February 17, 2010|https://clinicaltrials.gov/show/NCT00819637||145250|
NCT00819910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2007.122|Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)|Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)|RAFAEL|Brooke Army Medical Center|Yes|Terminated|September 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 8, 2014|January 8, 2009|Yes|Yes|Slow recruitment and increase in deployment overseas limiting follow up|No|February 6, 2013|https://clinicaltrials.gov/show/NCT00819910||145230|First, the study was terminated early per FDA recommendations restricting rosiglitazone use. Second, recruitment of patients was slow due to deployment restraints.
NCT00810797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08063|Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer|Intermittent Exemestane Therapy for Metastatic Breast Cancer||City of Hope Medical Center|Yes|Active, not recruiting|December 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00810797||145926|
NCT00811070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-2203|Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias|A Phase 1/2 Study Of Ski-606 Administered As A Single Agent In Japanese Subjects With Philadelphia Chromosome Positive Leukemias||Pfizer|Yes|Completed|December 2007|June 2015|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|20 Years|74 Years|No|||August 2015|August 7, 2015|December 17, 2008|No|Yes||No|March 3, 2014|https://clinicaltrials.gov/show/NCT00811070||145905|
NCT00811330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3963|Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis|Interest of Statin in Surgical Aortic Stenosis: From Myocardial Preconditioning to Ventricular Reverse Remodeling.||University Hospital, Strasbourg, France|No|Recruiting|December 2008|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|70 Years|80 Years|No|||June 2015|June 18, 2015|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00811330||145885|
NCT00843375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLNE 007|Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas|Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas||University of Michigan|Yes|Completed|December 2005|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|695|Samples With DNA|Tissue (normal colonic mucosa (fixed and frozen) plus adenoma or cancer), plasma, serum,      FOBT cards, frozen stool samples, DNA and urine.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing clinically-indicated colonoscopy. Recruitment is from the endoscopy        schedules for collaborating locations.|March 2011|March 15, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843375||143448|
NCT00843973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1095798|Osteogenic Cell Viability in Bone Graft Obtained Using the Reamer Irrigator Aspirator (RIA) System Versus Iliac Crest Bone Graft|Osteogenic Cell Viability in Bone Graft Obtained Using the Reamer Irrigator Aspirator (RIA) System Versus Iliac Crest Bone Graft||University of Missouri-Columbia|No|Completed|June 2008|December 2013|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|83|||Both|18 Years|N/A|No|Non-Probability Sample|Project involves comparison of small samples taken from patients undergoing iliac crest or        medullary reaming for comparison and review|December 2013|December 20, 2013|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00843973||143402|
NCT00845494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|554|Efficacy of a Behavioral Based Education Intervention to Decrease Medication History Errors Among Professional Nurses.|Efficacy of a Behavioral Based Education Intervention to Decrease Medication History Errors Among Professional Nurses.||Waukesha Memorial Hospital|Yes|Not yet recruiting|February 2009|October 2010|Anticipated|February 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|140|||Both|20 Years|70 Years|No|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845494||143287|
NCT00845507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exenatide|Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults|A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder||University of Cincinnati|No|Completed|December 2008|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|No|||August 2015|August 3, 2015|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845507||143286|
NCT00844909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015910|A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers|A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of CNTO136 Following a Single Subcutaneous Administration to Healthy Japanese and Caucasian Subjects.||Centocor, Inc.||Completed|January 2009|August 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|62|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|April 26, 2010|February 13, 2009||||||https://clinicaltrials.gov/show/NCT00844909||143332|
NCT00841867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61539|The Role of Pulsatile Insulin Secretion (A Study Investigating the Effects of Partial Pacreatectomy on Glucose Metabolism)|A Pilot Study Investigating the Effects of Partial Pancreatectomy on Glucose Tolerance|Pilot OGTT|University of California, Los Angeles|Yes|Completed|December 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841867||143561|
NCT00814489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112076|Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults|A Study to Evaluate GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Healthy Young Adults||GlaxoSmithKline||Completed|January 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|December 23, 2008|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00814489||145643|
NCT00814177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC060425|Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients|Management of Prothrombin Times Outside the Therapeutic Range in Patients on Warfarin and With Otherwise Stable Levels|FORESPEAK-0|McMaster University|Yes|Completed|July 2006|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|December 23, 2008||No||No|October 7, 2009|https://clinicaltrials.gov/show/NCT00814177||145667|
NCT00814190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Internet Intervention in T2D|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM)|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus||Endocrine Research Society|No|Completed|January 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|50|||Both|25 Years|N/A|No|||August 2009|January 5, 2010|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00814190||145666|
NCT00814515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVG06C103|Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome|A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome||Novagali Pharma|Yes|Completed|September 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|482|||Both|18 Years|N/A|No|||July 2010|July 15, 2010|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00814515||145641|
NCT00814528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15725A|Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses|Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses||University of Chicago|No|Terminated|November 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|95 Years|No|||March 2014|March 24, 2014|December 23, 2008|Yes|Yes|Not enough subjects for study to be completed.|No||https://clinicaltrials.gov/show/NCT00814528||145640|
NCT00814814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-01-05 A and B (correction)|Protein S100 Beta as a Predictor of Resuscitation Outcome|Protein S100 Beta as a Predictor of the Outcome of Cardiopulmonary Resuscitation||Shaare Zedek Medical Center|No|Active, not recruiting|August 2008|September 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|313|Samples With DNA|Blood|Both|18 Years|N/A|No|Probability Sample|All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the        absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem        district.|May 2015|May 30, 2015|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00814814||145619|
NCT00815321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIK#3/2008|Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy|Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Chronic Myeloid Leukemia on Standard Drug Therapy||Singapore General Hospital|Yes|Completed|December 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|12 Years|80 Years|No|||May 2012|May 14, 2012|December 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00815321||145580|
NCT00815594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008TR-LX-001|Bleb Vascularity Change After Subconjunctival Injection Bevacizumab|Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab||Capital Medical University|Yes|Active, not recruiting|December 2008|May 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||December 2008|December 29, 2008|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815594||145559|
NCT00815607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTS-M101B'|Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma|Phase 1b' Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12(INXN-3001) in Response to an Oral Activator Ligand in Patients With Unresectable Stage III C or IV Malignant Melanoma||Ziopharm||Completed|April 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||July 2013|July 17, 2013|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00815607||145558|
NCT00815334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-10-094|Efficacy of Endoscopic Subureteral Injection for Vesicoureteral Reflux in Adults With Decreased Bladder Compliance|Efficacy of Endoscopic Subureteral Injection for Vesicoureteral Reflux in Adults With Decreased Bladder Compliance||Samsung Medical Center|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|80 Years|No|||February 2009|June 16, 2009|December 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00815334||145579|
NCT00826553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081170|How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units|Comparison of Polysomnographic Findings in Mechanically Ventilated Patients Sedated With α2 Agonists Versus GABA Agonists|HYPNOS|Vanderbilt University|No|Active, not recruiting|January 2009|December 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|January 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00826553||144726|
NCT00815984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/135/08/KE|Fractional Exhaled Nitric Oxide (FeNO) Result Prediction Factors in Children With Allergic Diseases|FeNO Result Prediction Factors in Children With Allergic Diseases||Medical Universtity of Lodz|No|Completed|January 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|800|||Both|5 Years|18 Years|No|Probability Sample|Children with asthma (allergic), and/or allergic rhinitis and/or atopic dermatitis|February 2010|February 9, 2010|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00815984||145529|
NCT00815997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-28|Novel Angioplasty Using Coronary Accessor|Novel Angioplasty USIng Coronary Accessor|NAUSICA|NAUSICA Investigators|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|N/A|No|||October 2012|September 2, 2013|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815997||145528|
NCT00816244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAST1|Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer|A Phase II Study of Neo-Adjuvant Statin Therapy in Postmenopausal Primary Breast Cancer: A Window-of-Opportunity Study||Lund University Hospital|No|Completed|January 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||March 2012|April 12, 2012|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816244||145509|
NCT00844740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 09-152|Calcimimetics in Hypophosphatemic Rickets|Effect of Cinacalcet on the Long-Term Treatment of Familial Hypophosphatemic Rickets|CHR|Children's Mercy Hospital Kansas City|Yes|Enrolling by invitation|February 2009|||June 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|21 Years|Accepts Healthy Volunteers|||February 2009|February 13, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844740||143345|
NCT00844987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.32/II/06|Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Hepatocyte Growth Factor (HGF) in Patients With Acute Coronary Syndrome (ACS)|The Importance of Vascular Endothelial Growth Factor (VEGF), Hepatocyte Growth Factor (HGF) and Platelet Derived Growth Factor (PDGF) as a New Indicators of Myocardial Ischemic Injury in Comparison With Commonly Used Biomarkers.||Institute of Cardiology, Warsaw, Poland|No|Completed|January 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|serum and plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted to Institute of Cardiology due to ACS|May 2010|May 26, 2010|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844987||143326|
NCT00845000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05550|Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)|Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients||Merck Sharp & Dohme Corp.|No|Completed|April 2009|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|12|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|February 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00845000||143325|
NCT00817531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 21592|Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients|A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3||Baylor Breast Care Center|Yes|Terminated|December 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|80 Years|No|||August 2012|August 27, 2012|January 5, 2009|No|Yes|terminated due to futility after interim analysis|No|May 7, 2012|https://clinicaltrials.gov/show/NCT00817531||145410|The study was terminated after internal analysis due to treatment futility. It does not meet the required number of responses to continue the study.
NCT00817271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00018|To Evaluate the Response to Glucagon During Hypoglycemia|A Randomised, Open, Two-Way Cross-Over, Phase I Study to Evaluate the Response to Glucagon Versus the Spontaneous Counter-Regulatory Response in T2DM Patients Treated With AZD1656 and Metformin During Hypoglycemia||AstraZeneca|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|75 Years|No|||May 2009|May 6, 2009|January 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00817271||145430|
NCT00813605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060579|Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma|A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma||Amgen|No|Completed|March 2009|June 2012|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|155|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|December 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813605||145711|
NCT00813618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP049|Study of MEDI 507 in the Treatment of Pediatric Patients|Phase I Study of MEDI 507 in the Treatment of Pediatric Patients With at Least Grade II Acute Graft-Versus-Host Disease (GvHD)|Pediatric GvHD|MedImmune LLC|No|Completed|September 1999|August 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|2 Years|17 Years|No|||December 2008|December 19, 2008|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813618||145710|
NCT00813904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499G02|Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis|A Phase 4, Open-Label, Single-Group Immunogenicity and Safety Study of Re-exposure to RECOTHROM� (rThrombin) in Surgical Hemostasis||ZymoGenetics|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||November 2011|November 3, 2011|December 19, 2008|No|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00813904||145688|
NCT00814164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000630678|Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study Evaluating Mechanisms of Resistance Following Treatment With Clofarabine and Daunorubicin in Newly Diagnosed Adult Acute Myeloid Leukemia Patients > or = to 60 Years Old||Roswell Park Cancer Institute|Yes|Terminated|December 2008|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|60 Years|N/A|No|||August 2013|August 13, 2013|December 23, 2008|Yes|Yes|Sponsor withdrew support|No||https://clinicaltrials.gov/show/NCT00814164||145668|
NCT00813917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005359|Varenicline for the Treatment of Smokeless Tobacco|Varenicline for the Treatment of Smokeless Tobacco Use|CHANCHEW|Mayo Clinic|No|Completed|February 2009|January 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 10, 2012|December 22, 2008|Yes|Yes||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00813917||145687|
NCT00814203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0248|A Registry of COPD Patients to be Used for Future Studies|The Ohio State University COPD Registry||Ohio State University|No|Recruiting|December 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|April 2015|April 20, 2015|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814203||145665|
NCT00814216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAV680A2201|Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients|Randomized, Double-blind, Two Way Cross-over, Proof of Concept Study to Compare Efficacy, Safety, Pharmacokinetics & Pharmacodynamics of QAV680 Versus Placebo, With an Extended Open-label Corticosteroid Period, in Steroid-free, Mild to Moderate Persistent Asthma Patients.||Novartis||Completed|December 2008|||October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|65 Years|No|||September 2010|September 22, 2010|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814216||145664|
NCT00825331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guidewire Management for PTCA|Improvement of Periprocedural Guidewire Management for Cardiac Catheterization (PTCA)|Improvement of Periprocedural Guidewire Management for Cardiac Catheterization (PTCA)Using Preprocedural Marking of the Arterial Access Site and a Graduated Scheme for Removal of the Guidewire||RWTH Aachen University|No|Withdrawn|January 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||4|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients needing elective cardiac catheterization or PCI or emergency interventions|September 2015|September 22, 2015|January 19, 2009||No|Change of location for Investigators|No||https://clinicaltrials.gov/show/NCT00825331||144819|
NCT00814827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909060|Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma|Mycobacterial and Opportunistic Infections in HIV-Negative Patients Associated With Autoantibodies to Interferon-gamma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|265|||Both|18 Years|85 Years|No|||June 2015|July 24, 2015|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00814827||145618|
NCT00815113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC080000CTIL|Screening for Gastric Cancer in High-risk Population|Screening for Gastric Cancer in High-risk Population|Stomach|Rabin Medical Center|Yes|Recruiting|October 2009|December 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|Samples With DNA|Gastric biopsies|Both|18 Years|60 Years|No|Probability Sample|First degree relatives of gastric cancer patients|December 2012|December 2, 2012|December 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00815113||145596|
NCT00815087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804032R|Functional Electrical Stimulation in Irradiated Nasopharyngeal Carcinoma (NPC)|Efficacy of Functional Electrical Stimulation in Dysphagia of Nasopharyngeal Cancer Post Radiotherapy||National Taiwan University Hospital|Yes|Completed|July 2008|October 2013|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2014|March 2, 2014|December 25, 2008|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT00815087||145598|Lack of information about muscle fibrosis, no control group. and the results from the small amount of subjects.
NCT00815100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Riviera/09|Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome|Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome||Hospital Universitario de Canarias|Yes|Recruiting|April 2009|April 2012|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1270|||Both|18 Years|80 Years|No|||April 2011|April 5, 2011|December 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00815100||145597|
NCT00815347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-287-1|Bosentan for Poorly Controlled Asthma|The Effect of the ET-1 Receptor Antagonist, Bosentan on Patients With Poorly Controlled Asthma-A 17 Week, Double-blind, Placebo Controlled Crossover Trial||University of Connecticut Health Center|Yes|Terminated|December 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||September 2012|September 28, 2012|December 29, 2008|Yes|Yes|Difficulty in recruitment.|No|June 16, 2012|https://clinicaltrials.gov/show/NCT00815347||145578|Early termination leading to small numbers of subjects analyzed.
NCT00826566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STW6041|Anti-inflammatory Effects of Caffeine in Chronic Obstructive Pulmonary Disease (COPD) Subjects|Pilot Study to Investigate the Anti-inflammatory Effects of Caffeine in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Maastricht University Medical Center|No|Withdrawn|January 2009|September 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Male|40 Years|70 Years|No|||September 2009|September 22, 2015|January 21, 2009||No|Suitable subjects could not be recruited within the estimated time frame.|No||https://clinicaltrials.gov/show/NCT00826566||144725|
NCT00826813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009A123456|Trial Using 125I Embedded Stent in Patients With Advanced Esophageal Cancer|Phase IV Study of Self-Expandable Esophageal Stent Loaded With 125I Seeds: a Randomized Controlled Multiple Center Trial in Patients With Advanced Esophageal Cancer||Southeast University, China|Yes|Active, not recruiting|January 2009|March 2011|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|20 Years|80 Years|No|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826813||144706|
NCT00822640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0301|Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis|Clinical Outcome With Attention to Functional Results One Year After Fixed or Mobile Bearing Total Knee Replacement in a Randomized Controlled Trial||Aesculap AG|No|Completed|March 2004|July 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|90 Years|No|||May 2013|May 13, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822640||145024|
NCT00845013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVPAP|Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension|Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension||University of California, San Francisco|No|Active, not recruiting|November 2007|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|Samples With DNA|serum, plasma, PBMCS, BAL|Both|18 Years|N/A|No|Non-Probability Sample|HIV infected individiuals with the clinical diagnosis of pulmonary hypertension or who        have mildly elevated pulmonary arterial pressures|May 2015|May 29, 2015|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00845013||143324|
NCT00845260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP2|Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder|Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial|IP2|Karolinska Institutet|Yes|Completed|December 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|N/A|No|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845260||143305|
NCT00845273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751033|Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration|Special Investigation For Long-term Use Of Macugen (Regulatory Post Marketing Commitment Plan).||Pfizer|No|Completed|November 2008|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3538|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A5751033 prescribes the Macugen®).|September 2015|September 30, 2015|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00845273||143304|
NCT00817011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-03-012|Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness|Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness|PG|Samsung Medical Center|Yes|Recruiting|April 2006|March 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|25 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817011||145450|
NCT00817284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBT-01|Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)|A Randomized Phase II Trial With Bevacizumab, Irinotecan and Cerebral Radiotherapy Versus Bevacizumab, Temozolomide and Cerebral Radiotherapy as First Line Treatment for Patients With Glioblastoma Multiforme||Rigshospitalet, Denmark|No|Completed|November 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2011|November 29, 2011|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817284||145429|
NCT00817297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V60-1050767VP v 2.4|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2009|||||N/A|N/A|N/A||||||||||||||June 27, 2015|January 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817297||145428|
NCT00817544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098004|Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741|Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741; an Open, Non-Randomised, Single Centre Study in Healthy Male Subjects|ALMAS|Orion Corporation, Orion Pharma|No|Completed|January 2009|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 13, 2009|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00817544||145409|
NCT00813280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03735-08-A|Barriers to the Implementation of Complete Insulin Order Sets|Barriers to the Implementation of Complete Insulin Order Sets in the Management of Individuals With Hyperglycemia or Diabetes at Park Nicollet Methodist Hospital||HealthPartners Institute|No|Completed|June 2008|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|hospitalized patients with blood glucose >300 mg/dL|December 2008|November 25, 2015|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813280||145735|
NCT00813631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804050R|The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound|The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound|MFW|National Taiwan University Hospital|No|Recruiting|January 2009|November 2009|Anticipated|May 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2009|May 17, 2009|December 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00813631||145709|
NCT00813644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5166|A Study of Flexible Ureteroscopy Proficiency After Training on the Uromentor Simulator||UROSIMULATOR08|Rabin Medical Center||Active, not recruiting|December 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|urologists|December 2008|December 22, 2008|December 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00813644||145708|
NCT00813930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH-LKSKI|Lifestyle Intervention For Effective Diabetes Management|Lifestyle Intervention For Effective Diabetes Management (LIFE-DM) Trial|LIFE-DM|St. Michael's Hospital, Toronto|No|Active, not recruiting|November 2008|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813930||145686|
NCT00824759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/24NOV/331|Cardioprotective Effects of Increased Endogenous Erythropoietin After Normobaric Oxygen Breathing|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|January 16, 2009||No|Because it seemed not of interest based on the current literature|No||https://clinicaltrials.gov/show/NCT00824759||144863|
NCT00825643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3714|Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes|A Multicentre, Open Label, Observational 24-week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir® (Insulin Detemir) Once-daily in Oral Antidiabetic Drug-treated Patients With Type 2 Diabetes|SOLVE™|Novo Nordisk A/S|No|Completed|April 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18481|||Both|N/A|N/A|No|Non-Probability Sample|Patients from both general and speciality practice settings who have been deemed        appropriate to receive Levemir® as new treatment and as part of routine out-patient care        by the prescribing physician|August 2014|August 12, 2014|January 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00825643||144796|
NCT00815126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 002/08|Nasal Provocation Test With Lysine-Acetylsalicylate (ASA) in Patients With Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Hypersensitivity|Association Between Nasal Provocation Test With Lysine-Acetylsalicylate(ASA) and Clinical Diagnosis in Patients With Aspirin/Nonsteroidal Anti-Inflammatory Drugs(NSAIDs) and/or Acetaminophen Immediate Sensitivity Reactions||Chulalongkorn University|No|Completed|November 2008|April 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|34|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815126||145595|
NCT00815360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002813|Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion|Ranibizumab (rhuFab V2) and Scatter Laser Photocoagulation in Treatment of Patients With Clinically-significant Diabetic Macular Edema With Peripheral Retinal Nonperfusion (RaScaL)|RaScaL|Retina Associates of Florida, P.A.|No|Completed|February 2008|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||October 2014|February 4, 2015|December 26, 2008|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00815360||145577|small study size
NCT00826241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999916005|Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma|A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|January 2009|||January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|October 21, 2015|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826241||144750|
NCT00822666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070117|Clopidogrel and Response Variability Investigation Study 2|Effect of the Genetic Variant 2C19*2 on Clopidogrel Biological Response in Patients With Premature Coronary Artery Disease|CLOVIS2|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Male|18 Years|75 Years|No|||January 2009|December 10, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822666||145022|
NCT00826826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-085|The Effect of Short Term Amiodarone Treatment After Catheter Ablation for Atrial Fibrillation|The Effect of Short Term Amiodarone Treatment on Success Rate and Quality of Life After Catheter Ablation for Atrial Fibrillation|AMIO-CAT|Rigshospitalet, Denmark|Yes|Completed|January 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826826||144705|
NCT00822653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|521-07|The Effects of Plantar Stimulation on Hypotension, Treatment Efficacy and Quality of Life With Adults on Hemodialysis|the Effects of Plantar Stimulation on Hypotension, Treatment Efficacy and Quality of Life||Binghamton University|No|Completed|June 2008|January 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822653||145023|
NCT00845026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12648|A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients|A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia||Eli Lilly and Company|No|Completed|March 2009|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|261|||Both|18 Years|65 Years|No|||February 2011|February 25, 2011|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845026||143323|
NCT00845286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1807/07-II|Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial|Investigation of Myocardial Function and Vascular Adaptation in Association With Genotype in Marathon Runners|MAGIC|Technische Universität München|Yes|Completed|September 2008|August 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|162|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|September 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00845286||143303|
NCT00817024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNSF90709048|Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)|Clinical Study of Herbal Formula in Post PCI Patients.||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|March 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||January 2009|May 31, 2012|January 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00817024||145449|
NCT00817310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDNE4 ML9999 18185 04550|Neurophysiology and Anatomy of Severe Intraventricular Hemorrhage (IVH)|Influence of Altered Cerebral Spinal Fluid and Arterial Flows on Cerebral Processing Functions in Premature Infants With Severe Intraventricular Hemorrhage||Vanderbilt University|Yes|Completed|January 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|N/A|14 Days|No|Non-Probability Sample|Infants with birthweights below 1500g that are between 1 and 14 days of age|December 2013|December 16, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817310||145427|
NCT00817323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02995|What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression?|What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression? Evidence From Selective Neurotransmitter Depletion Studies||University of British Columbia|No|Withdrawn|January 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|0|||Both|19 Years|65 Years|No|||July 2014|July 4, 2014|January 2, 2009||No|Recruitment did not take place for this research due to several delays and then one of the PIs    moved out of the country and the project was closed|No||https://clinicaltrials.gov/show/NCT00817323||145426|
NCT00817557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05|Use of Loteprednol for Contact Lens Intolerance and Dryness|Use of Loteprednol for Contact Lens Intolerance and Dryness||Hom, Milton M., OD, FAAO|Yes|Enrolling by invitation|January 2009|September 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 5, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00817557||145408|
NCT00817570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-5610-08-IS-CTIL|Evaluation of Balance Reactions of Transfemoral Amputees Using the Virtual Analysis System|Evaluation of Balance Reactions of Transfemoral Amputees Using the Virtual||Sheba Medical Center|No|Suspended|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Male|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Transfemoral Amputees and Able bodied.|October 2009|October 21, 2009|January 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00817570||145407|
NCT00813293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-256|Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer|Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|December 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813293||145734|
NCT00813657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01562|Resistance Exercise Training During Pregnancy: a Randomized Controlled Trial|Effects of Resistance Exercise Training Program Performed During the 2nd and 3rd Trimesters of Pregnancy on Maternal and Newborn Health||Universidad Politecnica de Madrid|Yes|Completed|January 2000|March 2002|Actual|March 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Primary Purpose: Prevention|1||Actual|80|||Female|25 Years|35 Years|Accepts Healthy Volunteers|||December 2008|December 22, 2008|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813657||145707|
NCT00813670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPF-001-101|Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers|Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XPF-001 and to Investigate the Effect of Food on the Pharmacokinetics of a Single Dose of XPF-001 in Healthy Subjects||Xenon Pharmaceuticals Inc.||Completed|November 2008|July 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|64|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2009|September 10, 2009|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813670||145706|
NCT00824486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-12084|Home Safety Intervention Using a Safe Home Model|A Randomized Trial of a Home Safety Intervention Using a Safe Home Model||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|June 2003|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment|2||||||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2009|January 15, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824486||144883|
NCT00824499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0456|Development, Implementation and Evaluation of a Complex Regional Intervention for Type 2 Diabetes: Diabetes Project Aalst|Development, Implementation and Evaluation of a Complex Regional Intervention for Type 2 Diabetes.|DPA|Universiteit Antwerpen|Yes|Active, not recruiting|February 2004|June 2009|Anticipated|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|375|||Both|N/A|N/A|No|||January 2009|January 15, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824499||144882|
NCT00825045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270/2008|Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia|Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia||Centre for Addiction and Mental Health|No|Recruiting|December 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|50 Years|N/A|No|||February 2016|February 25, 2016|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00825045||144841|
NCT00825058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC5374|Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine|A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode.||Sanofi|No|Completed|November 2003|October 2004|Actual|May 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|317|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|January 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00825058||144840|
NCT00825656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMAN-0708|Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis|SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis|SMAN|Strategic Biosciences|No|Active, not recruiting|September 2008|January 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|12 Years|N/A|No|||January 2009|January 21, 2009|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825656||144795|
NCT00825942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCK-0108|An Open-Label Study of the Effect of an Ophthalmic Solution on Asteroid Hyalosis|An Open-Label Study of the Effect of C-KAD Ophthalmic Solution on Asteroid Hyalosis||Chakshu Research, Inc.|No|Active, not recruiting|July 2008|November 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|90 Years|No|||April 2009|April 16, 2009|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825942||144773|
NCT00825929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 08.02|Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.|Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)|PANNA|Radboud University|No|Recruiting|February 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|176|Samples Without DNA|Plasma samples will be collected in Week 33 of the pregnancy and at 4-6 weeks after      delivery. At the following time points samples will be collected: T=0 (prior to dosing), and      T=1, 2, 3, 4, 6, 8, 12 and 24h (24h sample only in case of QD regimen) post-dosing (8 or 9      samples).      In case the infant needs post-exposure prophylaxis with at least one of the agents sparse PK      sampling is optional.|Female|18 Years|N/A|No|Non-Probability Sample|HIV-infected pregnant women using at least one of the following antiretroverial agents:        Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF;        Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir,        Aptivus, TPV; Indinavir, Crixivan; Raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc,        Celsentri; Abacavir; Rilpivirine|August 2015|August 12, 2015|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825929||144774|
NCT00826254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03124 (REK)|Nutritional Problems After Lung and Heart Transplantation|Nutritional Problems After Lung and Heart Transplantation||Oslo University Hospital|No|Active, not recruiting|August 2003|December 2011|Anticipated|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|94|||Both|20 Years|70 Years|No|||January 2009|July 3, 2011|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826254||144749|
NCT00826267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.44|6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab|Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients||Boehringer Ingelheim||Completed|January 2009|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Female|18 Years|N/A|No|||August 2013|December 5, 2013|January 20, 2009||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00826267||144748|Because of slow enrollment and a high screen-failure rate, recruitment became a challenge and the sponsor chose to terminate the trial prior to reaching the target enrollment of 120 pat. Small number of subjects lead to some shortcomings in analyses.
NCT00822679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 07-0797-01|Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome|Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome||University of Arizona|No|Recruiting|October 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822679||145021|
NCT00809237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS 01/03/08|Hydroxychloroquine and Gefitinib to Treat Lung Cancer|A Phase II With a Lead in Phase I Study to Examine the Tolerability, Safety Profile and Efficacy of Hydroxychloroquine and Gefitinib in Advanced Non-Small Cell Lung Cancer||National University Hospital, Singapore|Yes|Recruiting|November 2008|November 2014|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|21 Years|N/A|No|||December 2013|December 8, 2013|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00809237||146044|
NCT00817037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/W/CRC/02|Sitaxsentan in Proteinuric Chronic Kidney Disease|The Effect of Sitaxsentan Once Daily Dosing on Proteinuria, 24-Hour Systemic Blood Pressure, and Arterial Stiffness in Subjects With Chronic Kidney Disease||University of Edinburgh|Yes|Active, not recruiting|May 2007|||March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|70 Years|No|||January 2009|January 5, 2009|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817037||145448|
NCT00823628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0902/069-003|Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide|Comparison of Contrast-medium Induced Nephrotoxicity Between Iodixanol and Iopromide in Patients With Renal Insufficiency Undergoing Coronary Angiography||Seoul National University Bundang Hospital|No|Completed|February 2009|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|420|||Both|N/A|N/A|No|||April 2009|July 6, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823628||144949|
NCT00817583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC20081|Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)|Phse II Study of Induction Chemotherapy With TPF Regimen Followed by Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma|TPF for NPC|Fudan University|Yes|Not yet recruiting|January 2009|July 2011|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||January 2009|January 26, 2009|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817583||145406|
NCT00813306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9126C00001|14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations|A Double-blind, Randomized, Placebo-controlled, Single-centre Phase I Pharmacodynamic Cross-over Study to Assess the Effect of a Single Dose of AZD2066 Oral Solution in Comparison to Placebo on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in Healthy Subjects||AstraZeneca|No|Completed|December 2008|November 2009|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813306||145733|
NCT00813319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015576|Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females|Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents|Girls OnGuard|Emory University|Yes|Completed|October 2009|March 2014|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|216|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|December 22, 2008||No||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00813319||145732|Limited sample size; Brevity of the computer-administered intervention; Substantial variability between and within clinics with respect to patient-provider interactions; Lack of a follow-up assessment.
NCT00824187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91771|YAZ Premenstrual Dysphoric Disorder (PMDD) in China|A Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Monophasic Oral Contraceptive YAZ (20 µg Ethinylestradiol, 3 mg Drospirenone) in the Treatment of Chinese Patients With Premenstrual Dysphoric Disorder (PMDD)||Bayer|No|Completed|January 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|187|||Female|18 Years|45 Years|No|||April 2014|April 1, 2014|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824187||144906|
NCT00824200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA RR&D No. D6110R|Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe)|Behavior and Exercise Versus Drug Treatment in Men With Nocturia|BEDTiMe|Atlanta VA Medical Center|No|Active, not recruiting|July 2008|March 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Male|40 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 6, 2014|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824200||144905|
NCT00824772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00012007317-00|Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control|Evaluation of Pharmacogenetic Factors Contributing to Dose Requirement of Fentanyl for Postoperative Pain Control: Genetic Polymorphisms of OPRM1, ABCB1, CYP3A4 and CYP3A5||Inje University|No|Completed|September 2008|December 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|204|Samples With DNA|whole blood|Female|19 Years|65 Years|No|Non-Probability Sample|Gynecologic patients undergoing total abdominal hysterectomy or laparoscpy assisted        vaginal hysterectomy under general anesthesia|May 2013|May 26, 2013|January 16, 2009||No||No|March 25, 2013|https://clinicaltrials.gov/show/NCT00824772||144862|
NCT00824785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3024|REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer|REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer|REAL3|Royal Marsden NHS Foundation Trust|Yes|Terminated|May 2008|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|574|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|January 16, 2009||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00824785||144861|
NCT00825344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU08-6987|Preoperative Etanercept Before Inguinal Hernia Surgery|A Randomized Controlled Study Evaluating Pre-operative Etanercept on the Severity of Postoperative Pain After Inguinal Hernia Surgery.||Johns Hopkins University|Yes|Completed|January 2009|August 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|77|||Both|18 Years|70 Years|No|||January 2009|October 24, 2013|January 20, 2009||No||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00825344||144818|Only one type of surgery studied; more males than females enrolled (function of military treatment facility and type of population)
NCT00825357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-IRB09509002|Biological Markers to Identify Early Sepsis and Acute Lung Injury|||Chimei Medical Center|No|Completed|September 2006|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients admitted to ICU and age ≧18-year-old.|January 2016|January 26, 2016|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00825357||144817|
NCT00825669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-015|Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection|A Randomized Controlled Trial of Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2009|January 23, 2009|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00825669||144794|
NCT00825968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0013|Data Collection and Analysis of Patients Who Have Had an Electrophysiological Procedure|Data Collection and Analysis of Patients Who Have Had an Electrophysiological Procedure Performed at the Ross Heart Hospital||Ohio State University|No|Terminated|July 2008|July 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Female|18 Years|N/A|No|Non-Probability Sample|Patients having procedures completed at the electrophysiology Laboratories at the Ross        Heart Hospital at The Ohio State University Medical Center.|September 2011|September 16, 2011|January 16, 2009||No|PI stopped study to make a more substantial database.|No||https://clinicaltrials.gov/show/NCT00825968||144771|
NCT00825981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/10DEC/350|Primary and Secondary Hemostasis in Elective Coronary Artery Bypass Graft Surgery||HEMOCOR|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|January 2009|March 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|coronary artery bypass graft|July 2010|July 22, 2010|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00825981||144770|
NCT00825994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001313|Omega-3 for Peri- and Postmenopausal Depression|Omega-3 for Peri- and Postmenopausal Depression|O3Meno|Massachusetts General Hospital|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|40 Years|N/A|No|||August 2014|August 5, 2014|January 16, 2009||No||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00825994||144769|
NCT00825955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-034|Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment|A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)|BRISK PS|Bristol-Myers Squibb|Yes|Active, not recruiting|February 2009|December 2015|Anticipated|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|414|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825955||144772|
NCT00826280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3606-CL-3002|Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)|A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson||Astellas Pharma Inc|No|Completed|March 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|347|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|January 21, 2009|Yes|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00826280||144747|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00826579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rhein4031|Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer|Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer||University Hospital, Basel, Switzerland|No|Completed|May 2000|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|192|||Both|N/A|N/A|No|||March 2015|March 11, 2015|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00826579||144724|
NCT00826839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810010037|Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients|A Randomized Controlled Trial of Treatment Protocols to Optimize Outcomes in Poor Responder In Vitro Fertilization (IVF) Patients: E2 Patch/Antagonist Protocol Versus OCP/Microdose Lupron Protocol|OMLET|Weill Medical College of Cornell University|No|Withdrawn|January 2009|January 2012|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|50 Years|No|||June 2013|June 21, 2013|January 21, 2009||No|poor enrollment|No||https://clinicaltrials.gov/show/NCT00826839||144704|
NCT00826852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976B_6020|Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax|Phase II Trial of Weekly Docetaxel and Four Weekly Carboplatin Combination in the First-line Treatment of Advanced Non-small Cell Lung Cancer||Sanofi|No|Completed|October 2003|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|N/A|75 Years|No|||July 2010|July 26, 2010|October 13, 2008||No||No||https://clinicaltrials.gov/show/NCT00826852||144703|
NCT00822692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20080055H|Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection|Prospective Randomized Double Blind, Placebo-Controlled Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection on 30 Day Recurrence Rates.||Wilford Hall Medical Center|No|Completed|July 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 13, 2009||No||No|July 29, 2009|https://clinicaltrials.gov/show/NCT00822692||145020|
NCT00813085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2068|A Randomized Trial of Electronic Integration of Care for Better Diabetes Outcomes; The COMPETE II Study|A Randomized Trial of Electronic Integration of Care for Better Diabetes Outcomes; The COMPETE II Study|COMPETEII|McMaster University|No|Completed|April 2002|December 2003|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|511|||Both|18 Years|90 Years|No|||December 2008|December 19, 2008|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00813085||145750|
NCT00808977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-IBD-1-08|A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis|A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis||Palau Pharma S.A.|No|Completed|December 2008|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|65 Years|No|||November 2010|November 16, 2010|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808977||146064|
NCT00808951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Malactres-BF|In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso|In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso||Centre Muraz|No|Completed|December 2008|February 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|440|||Both|6 Months|15 Years|No|||July 2015|July 30, 2015|December 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00808951||146066|
NCT00809224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS052514|Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)|Tracking Brain Changes During Real and Imagined Movements in People With ALS (Lou Gehrig's Disease) and Healthy Volunteers.||University of Michigan|No|Recruiting|May 2008|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|All are able to participate.|December 2008|May 26, 2009|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809224||146045|
NCT00809250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-160|Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation|Vaccination With Lethally Irradiated Autologous Myeloblasts With Granulocyte Macrophage-colony Stimulating Factor Secreting K562 Cells (GM-K562) in Patients With Advanced MDS or AML After Allogeneic Hematopoietic Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Terminated|November 2008|December 2026|Anticipated|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|December 15, 2008|Yes|Yes|Permanently closed to accrual per investigator|No||https://clinicaltrials.gov/show/NCT00809250||146043|
NCT00823381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-09-25-RESV|Effect of Resvida, a Comparison With Calorie Restriction Regimen|Effect of Resvida(tm) Dietary Supplementation on Muscle Gene Expression: A Comparison With Calorie Restriction Regimen|Resvida|Washington University School of Medicine|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|58|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00823381||144968|
NCT00823394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0970|African American Church-based Cohort|African American Cancer Prevention Project: Establishing a Cohort to Investigate Health Disparities||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2008|||December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1501|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult attendees of Windsor Village United Methodist Church living in Houston.|September 2015|September 2, 2015|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823394||144967|
NCT00824226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT296|Magnesium Treatment in Hypoparathyroidism|Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients||University of Tartu|No|Completed|January 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824226||144903|
NCT00824239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0284/08|Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients|Randomized Trial Comparing Intermittent Sedation and Daily Interruption of Sedation in Mechanically Ventilated Patients||University of Sao Paulo General Hospital|Yes|Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824239||144902|
NCT00823914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002090|Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life|Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life||Massachusetts General Hospital|Yes|Active, not recruiting|December 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Psoriasis patients aged 18 and older|June 2013|June 25, 2013|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823914||144927|
NCT00824213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01640|Pilot Project: Fast Whole-body Spect Scanning to Improve the Detection of Bone Metastases in Patients With Diagnosed Cancer|Pilot Project: Fast Whole-body Spect Scanning to Improve the Detection of Bone Metastases in Patients With Diagnosed Cancer||University of British Columbia|No|Suspended|January 2009|December 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Over the last 3-4 months, 60 anonymized patient studies were acquired using concurrent        acquisition protocol with 20s, 15s, 10s, and 5s per view and with a total of 64 views (32        views/head). The data from these studies will be used to optimize the reconstruction        process and establish the definitive reconstruction parameters to be used in the current        study.        We plan to accrue a total of 25 subjects with suspected bone metastases who will undergo        planar bone scintigraphy, bone SPECT and a Na18F whole-body bone PET scan.|June 2011|June 2, 2011|January 14, 2009||No|The first phase of this project is finished, now we are waiting until LGH gets the new    SPECT/CT camera for the next stage. This will take at least 6 months.|No||https://clinicaltrials.gov/show/NCT00824213||144904|
NCT00824512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-39-00240-133|Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia|A Phase II, Randomised, Double Blind Study Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia||Ipsen|No|Completed|June 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|22|||Both|12 Years|22 Years|No|||April 2013|April 10, 2013|January 15, 2009||No||No|October 30, 2012|https://clinicaltrials.gov/show/NCT00824512||144881|
NCT00825370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 0808278|Protocolized vs Discretionary Use of Opioids in Acute Pain|Protocolized vs Discretionary Use of Opioids in Acute Pain||Montefiore Medical Center|No|Completed|October 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825370||144816|
NCT00825682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4923-DG-CTIL|The Effect of Reflexology on Radiation-Related Fatigue in Breast Cancer Patients|The Effect of Reflexology on Radiation-Related Fatigue and QOL in Breast Cancer Patients: a Pilot Study.||Sheba Medical Center|No|Completed|May 2008|May 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|21 Years|N/A|No|||July 2009|July 2, 2009|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825682||144793|
NCT00825695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-001936|Flavanol-Rich Cocoa and Cerebral Blood Flow|Flavanol-Rich Cocoa, Vascular Responses and Mechanisms||Brigham and Women's Hospital|No|Completed|January 2009|June 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|65 Years|N/A|No|||April 2014|April 28, 2014|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00825695||144792|
NCT00826007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-281|Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes|Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes||William Beaumont Hospitals|No|Completed|January 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|587|None Retained|non applicable|Both|N/A|N/A|No|Non-Probability Sample|Surgical patients|March 2013|March 26, 2013|January 19, 2009||No||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00826007||144768|Point-of-care blood glucose testing was most often the means of measurement. Frequency of glucose monitoring was not standardized. Retrospective review.
NCT00826306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816689-1|Comparison Of Video-based Versus Written Patient Education on Sunscreen|Comparison of Video-based Versus Written Patient Education on Sunscreen Behavior||University of California, Davis|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|94|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826306||144745|
NCT00826293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224-2008|The Clinical Efficacy of Belting Stabilization for Shoulder Pain|The Clinical Efficacy of Belting Stabilization for Shoulder Pain: A Double Blinded Randomized Clinical Trial||Sunnybrook Health Sciences Centre|No|Completed|January 2009|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||July 2013|July 9, 2013|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826293||144746|
NCT00826605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200802|Urobilinogen, Maternal Weight Loss and Impending Parturition at Term|Retrospective Investigation of Presence of Urobilinogen and Maternal Weight Loss as Indications of Impending Parturition in the Term Gravida||Oklahoma State University Center for Health Sciences|Yes|Completed|January 2009|October 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|200|||Female|18 Years|34 Years|Accepts Healthy Volunteers|Probability Sample|Population is mothers between the ages of 18 and 34 years of age with a single        intrauterine pregnancy between 37 weeks and 41 weeks gestational age. (Both very young        mothers and women 35 and older have increased risk of premature delivery.) The patients        will have an admission diagnosis of either active labor or spontaneous rupture of        membranes. Active labor is defined as uterine contractions resulting in changes either in        the cervical dilatation, the effacement of the cervix and/or descent of the fetal head in        the pelvis.|January 2010|January 26, 2010|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826605||144722|
NCT00826865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVE-T750-PVFS-1|Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|August 2005|August 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|27|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 21, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00826865||144702|
NCT00826878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-08-105|An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase 1b/2a Open-Label Study to Evaluate the Safety and Activity of Once Daily Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer||AVEO Pharmaceuticals, Inc.|No|Completed|January 2009|May 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826878||144701|
NCT00826891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACA-2008-GSK1|Study of Cisplatin in Cervical Cancer Stage IVB|Phase II Study of Cisplatin Combined With Topotecan in Advanced (Stage IVB) Recurrent or Persistent Cervical Cancer||Chinese Anti-Cancer Association|No|Not yet recruiting|February 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00826891||144700|
NCT00822978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-490-001|Phase 1 Study for Safety of ACHN-490|A Double-Blind, Randomized, Placebo-controlled, Parallel-Group, Single and Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-490 Injection Administered Intravenously in Healthy Volunteers||Achaogen, Inc.|No|Completed|January 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 24, 2012|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00822978||144999|
NCT00808990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC085077CTIL|The Effect of Probiotics on Non Alcoholic Fatty Liver Disease|Probiotics and Non Alcoholic Steatohepatitis (NASH)||Rabin Medical Center|No|Not yet recruiting|February 2013|September 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 29, 2012|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808990||146063|
NCT00808964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLINPRO-303|Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery|Phase 2 Study of NU172 Anticoagulation in Patients Undergoing Coronary Artery Bypass Graft Surgery OFF-Pump|SNAP-CABG-OFF|ARCA Biopharma, Inc.|Yes|Not yet recruiting|January 2013|September 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|December 12, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00808964||146065|
NCT00823641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cro948|The HAM Infliximab Study|An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP|HAM06|Imperial College London|Yes|Terminated|October 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|16 Years|N/A|No|||April 2013|April 12, 2013|January 14, 2009||No|Higher toxicity rate than observed in studies in Rheumatoid arthritis|No||https://clinicaltrials.gov/show/NCT00823641||144948|
NCT00823927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0197|Alveolar Macrophage Proteomics in HIV-associated Emphysema|Alveolar Macrophage Proteomics in HIV-associated Emphysema|HIVE|Ohio State University|Yes|Active, not recruiting|March 2006|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|365|Samples With DNA|blood lung fluid (optional)|Both|18 Years|N/A|No|Non-Probability Sample|community sample|April 2015|April 20, 2015|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00823927||144926|
NCT00823940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111497|A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects|A Single-blind, Randomized, Placebo Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Healthy Normal Subjects.||GlaxoSmithKline||Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823940||144925|
NCT00824252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0188|Spousal Support in Head and Neck Cancer|Spousal Support, Emotional Disclosure, and Adjustment to Head and Neck Cancer||M.D. Anderson Cancer Center|No|Recruiting|December 2008|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|452|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Head and neck cancer patients who will be starting radiation therapy and their spouses.|February 2016|February 15, 2016|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824252||144901|
NCT00823966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4351010|Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients|Drug Use Investigation For Rescriptor (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|December 2003|March 2009|Actual|March 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A4351010 prescribes the Delavirdine        Mesilate(Rescriptor).|June 2010|June 2, 2010|January 14, 2009|No|Yes||No|March 4, 2010|https://clinicaltrials.gov/show/NCT00823966||144923|There is not enough data to analyze on the efficacy and safety of delavirdine mesylate in the 3 subjects with HIV infection assessed during this study.
NCT00824538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632345|Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow|Pilot Study to Evaluate the Effect of Sunitinib on Occult Tumor Cells in the Bone Marrow of Patients With High Risk Early Stage Breast Cancer||University of California, San Francisco|Yes|Completed|February 2009|December 2013|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|January 15, 2009|No|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00824538||144880|The study was closed early due to results released from a phase III metastatic breast cancer (MBC) study that demonstrated significant sunitinib toxicity without commensurate clinical benefit, the number of patients in this study was small.
NCT00824798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|READ-LOBET-02|Gait Evaluation in Haemophiliac Patients|Gait Evaluation in Haemophiliac Patients||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|January 2009|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Male|4 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|haemophilia A or B, mild, moderate or severe.|July 2014|July 10, 2014|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824798||144860|
NCT00824811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0757|Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel|A Double-Blind Study Evaluating the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion 0.05% [Restasis] in Subjects With Epiphora Secondary to Docetaxel [Taxotere] Treatment for Various Cancers||M.D. Anderson Cancer Center|Yes|Withdrawn|June 2009|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|January 16, 2009|Yes|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00824811||144859|
NCT00825071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJordan|Dexamethasone for Postoperative Nausea and Vomiting|Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.||University of Jordan|Yes|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|70 Years|No|||January 2009|January 15, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00825071||144839|
NCT00825084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451014|A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects|A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects||Pfizer|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 22, 2011|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825084||144838|
NCT00825110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3085|SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer|SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer||Royal Marsden NHS Foundation Trust|Yes|Recruiting|November 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3750|Samples With DNA|biospecimen includes formalin-fixed, paraffin embedded tissue, fresh frozen tissue and blood      smaples|Both|18 Years|N/A|No|Probability Sample|All patients at the Royal Marsden with a diagnosis of colorectal cancer will be eligible        to enter this study.        Adults who have a terminal illness|January 2009|January 16, 2009|January 16, 2009||||No||https://clinicaltrials.gov/show/NCT00825110||144836|
NCT00825383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF498|Effect of Dietary Fiber on Glucose & Lipids in Non Insulin Dependent Diabetes Mellitus (NIDDM)|Effect of Dietary Fiber on Glucose, Lipid, and Mineral Metabolism in Patients With Non Insulin Dependent Diabetes Mellitus||University of Texas Southwestern Medical Center|No|Completed|January 1993|December 1995|Actual|December 1995|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|35 Years|80 Years|No|||June 2013|June 19, 2013|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825383||144815|
NCT00825396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCK-0106|An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension|A Pilot, Open-Label, Controlled Clinical Trial of C-KAD Ophthalmic Solution in Reducing Intraocular Pressure in Patients With Ocular Hypertension||Chakshu Research, Inc.|No|Completed|April 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|50 Years|90 Years|No|||June 2009|June 9, 2009|January 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825396||144814|
NCT00825708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH20107|Evaluation of the Effect of rTMS on Attention in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder (ADHD)|Evaluation of the Effect of rTMS on Attention in Adults Diagnosed With ADHD||Shalvata Mental Health Center|Yes|Recruiting|March 2007|||March 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|65 Years|No|||January 2009|January 20, 2009|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825708||144791|
NCT00825721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-0105|Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract|A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts||Chakshu Research, Inc.|No|Active, not recruiting|November 2007|September 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|81|||Both|35 Years|90 Years|No|||January 2009|January 20, 2009|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825721||144790|
NCT00826020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084-09-FB|Evaluation of Omegaven™ Parenteral Nutrition in Patients With TPN-Induced Cholestasis|Prospective Evaluation of a Parenteral Omega-3 Fatty Acid Preparation (Omegaven™) in Therapy of Patients With TPN-Induced Cholestasis||University of Nebraska|Yes|Enrolling by invitation|April 2009|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||May 2009|May 4, 2009|January 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826020||144767|
NCT00826033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mol Imaing 1|Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer|Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy||Gunma University|No|Completed||||||N/A|Observational|Time Perspective: Prospective||1|||||Both|20 Years|N/A|No|Non-Probability Sample|This study was conducted at the Gunma University Hospital.|January 2009|January 20, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826033||144766|
NCT00826592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816693-1|Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis|Comparison of Video-based Versus Written Patient Education on Atopic Dermatitis||University of California, Davis|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|80|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826592||144723|
NCT00826904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0535|Regulation Of Maternal Fuel Supply And Neonatal Adiposity|Regulation Of Maternal Fuel Supply And Neonatal Adiposity||University of Colorado, Denver|Yes|Recruiting|October 2007|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Lean (BMI 20-26 kg/m2)and Obese (BMI 30-38 kg/m2) pregnant women (age 18-35 yr) without        chronic medical conditions or obstetric complications will be enrolled at 12-14 weeks        gestation.|December 2015|December 9, 2015|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826904||144699|
NCT00822718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-05-07|Obestatin Change in Distal Gastrectomy|||Samsung Medical Center|Yes|Completed|January 2005|July 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 13, 2009|January 12, 2009||||No||https://clinicaltrials.gov/show/NCT00822718||145018|
NCT00822705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 127/07|Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36|Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36: a Phase 1 Study||University Hospital, Basel, Switzerland|No|Completed|August 2008|January 2009|Actual|November 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 13, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822705||145019|
NCT00823238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC2197|Comparison of Antibiotics for Pseudomonas in Early CF|Comparison of Antibiotics for Pseudomonas in Early CF|CAPEC|University of North Carolina, Chapel Hill|Yes|Completed|July 2004|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|3 Months|16 Years|No|||April 2011|April 15, 2011|December 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00823238||144979|
NCT00823251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILLUM-OUS-2008-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2008|||||N/A|N/A|N/A||||||||||||||January 7, 2015|December 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823251||144978|
NCT00810173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fonseca-Guedes|Phone Call in Type 2 Diabetes Patient|Phone Call as an Intervention for Improving Walking Practice in Type 2 Diabetes: Influence of Personality Profile in This Response||University of Sao Paulo|No|Completed|January 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|48|||Both|40 Years|N/A|No|||December 2008|December 16, 2008|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00810173||145973|
NCT00810511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-335-C-007|Evaluation of Two Silicone Hydrogel Lenses Over a One Month Period|Evaluation of Two Silicone Hydrogel Lenses Over a One Month Period||Alcon Research||Completed|November 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|213|||Both|N/A|N/A|No|||January 2012|June 26, 2012|December 17, 2008|Yes|Yes||No|July 23, 2010|https://clinicaltrials.gov/show/NCT00810511||145947|
NCT00809263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDPSCNM2008|Homeopathic Drug Provings|A Randomized, Double-blind, Placebo-controlled, Homeopathic Drug Proving Using a Crossover Design||Integrative Medicine Institute|Yes|Withdrawn|October 2009|December 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|December 15, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00809263||146042|
NCT00823654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-156|Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations|Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer BRCA Mutations||Memorial Sloan Kettering Cancer Center||Recruiting|January 2009|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|320|Samples Without DNA|blood|Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients of premenopausal women with early-stage breast cancer will be recruited from the        Breast Cancer Service at MSKCC and New York Presbyterian Hospital-Weill Medical College of        Cornell University. In addition, breast cancer patients seeking consultation with a        reproductive endocrinologist to address issues of fertility preservation prior to the        start of therapy will be offered participation (Dr. Oktay at New York Medical College.        Patients of unaffected high risk premenopausal women with BRCA mutations will be recruited        from the Breast Cancer Services especially the high risk surveillance clinics at MSKCC and        New York Presbyterian Hospital-Weill Medical College of Cornell Univeristy.|January 2016|January 4, 2016|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823654||144947|
NCT00823667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08034|Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery|Palliative Care for Quality of Life and Symptom Concerns in Early Stage Lung Cancer||City of Hope Medical Center|No|Completed|September 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|198|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823667||144946|
NCT00823953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMC0107|Glycemic Response to Momordica Charantia in Type 2 Diabetes|The Effect of Momordica Charantia on Glycemic Control and Insulin Resistance in Type 2 Diabetes||Services Hospital, Lahore|Yes|Withdrawn|November 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||June 2012|June 9, 2012|January 15, 2009||No|IP could not be made available in sufficient quantity for the expected enrollment|No||https://clinicaltrials.gov/show/NCT00823953||144924|
NCT00823979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271022|A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1|A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1||Pfizer|Yes|Terminated|March 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|January 15, 2009|Yes|Yes|See termination reason in detailed description.|No|January 28, 2014|https://clinicaltrials.gov/show/NCT00823979||144922|The trial was terminated on 12 April, 2012 due to lack of efficacy at the Week 24 analysis. The decision to terminate the trial was not based on any safety concerns.
NCT00824551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1501|The Effects of Hyperbaric Oxygen Therapy (HBOT) on Acute Thermal Burns|The Effects of Hyperbaric Oxygen Therapy on Acute Thermal Burns||Singapore General Hospital|Yes|Recruiting|January 2009|||December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|60 Years|No|||December 2008|January 15, 2009|January 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00824551||144879|
NCT00824824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-12-057|Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)|||Massachusetts Eye and Ear Infirmary|No|Recruiting|January 2009|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Anticipated|40|||Both|40 Years|80 Years|No|||April 2012|April 19, 2012|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824824||144858|
NCT00825097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|READ-Bollens-01|Efficacy Study of Selective Tibial Neurotomy in the Treatment of the Spastic Equinovarus Foot Among Adult Hemiplegic Patients|Study of the Efficacy of the Selective Neurotomy in the Treatment of the Spastic Equinovarus Foot Among Adult Hemiplegic Patient Following the ICF Model. A Prospective, Randomized, Controlled Single Blind Study|Neurotomy|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|October 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|November 14, 2008||No||No||https://clinicaltrials.gov/show/NCT00825097||144837|
NCT00825123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141/07 bayside health|Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals|The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals||Bayside Health|No|Withdrawn|October 2008|December 2012|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2009|November 7, 2011|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00825123||144835|
NCT00825422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/21|Local Anesthetic Infiltration to Prevent Postoperative Pain After Lumbar Surgery|Assessment of Efficacy and Safety of Continuous Wound Infiltration With Local Anesthesics Through a Parietal Paravertebral Catheter for Postoperative Analgesia After Posterior Lumbar Arthrodesis|ICALP|University Hospital, Bordeaux|No|Completed|January 2009|August 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||June 2012|June 19, 2012|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825422||144813|
NCT00825435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032007-067|Coronary CT Angiography in Acute Chest Pain is a Cost Effective Risk Stratification Strategy|Inclusion of Multi-Detector CT Angiography (MDCT) in Low to Intermediate Risk Chest Pain Patients Presenting to the Emergency Department; a Randomized Cost Analysis||University of Texas Southwestern Medical Center|No|Recruiting|October 2008|||June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|60|||Both|35 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 20, 2009|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825435||144812|
NCT00825734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 138|Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer|Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (MBC)||SCRI Development Innovations, LLC|No|Completed|March 2009|August 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|83|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|January 19, 2009|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00825734||144789|
NCT00826046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|276|Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD|Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD||Mesoblast, Ltd.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|70 Years||||October 2015|October 20, 2015|January 19, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00826046||144765|
NCT00826345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD3398|Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV|Patient-Oriented TCM Intervention for DSP in HIV: A Pilot Study|TCMAcuPilot|New York University School of Medicine|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||June 2012|June 20, 2012|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826345||144742|
NCT00826358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-535|Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg|||AstraZeneca|No|Completed|November 2008|||November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|October 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00826358||144741|
NCT00826319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02457|Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time|CanPREDDICT: Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time|CanPREDDICT|University of British Columbia|No|Active, not recruiting|June 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2602|Samples With DNA|Serum,Plasma,Urine, DNA and RNA|Both|19 Years|N/A|No|Non-Probability Sample|Nephrology Clinics across Canada|November 2013|November 27, 2013|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826319||144744|
NCT00826332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0594-08-HMO-CTIL|Transvaginal vs Transabdominal Ultrasound Guided Embryo Transfer|Transvaginal or Transabdominal Ultrasound Guided Embryo Transfer- Which is Better?|TVUSET|Hadassah Medical Organization|Yes|Recruiting|January 2009|December 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|45 Years|No|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826332||144743|
NCT00822731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-068|Samsung Medical Center-Lymphoma Cohort Study|Development of a Predictive Model for Treatment Outcome and Treatment-related Morbidity in a Prospective Cohort Study of Patients With Lymphoma|SMC-LCS|Samsung Medical Center|Yes|Completed|September 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|953|||Both|15 Years|N/A|No|||May 2012|May 22, 2012|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00822731||145017|
NCT00822991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLOG08001|Sonazoid Enhanced Liver Cancer Trial for Early Detection|Sonazoid Enhanced Liver Cancer Trial for Early Detection||Japan Liver Oncology Group|Yes|Recruiting|January 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|760|||Both|20 Years|N/A|No|||January 2009|December 29, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00822991||144998|
NCT00823004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1969yazdRCCI|Antagonist/Letrozole in Poor Responders|GnRH Antagonist /Letrozole Versus Microdose GnRH Agonist Flare Protocol in Poor Responders Undergoing in Vitro Fertilization||Yazd Research & Clinical Center for Infertility|Yes|Completed|June 2008|October 2009|Actual|February 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 20, 2013|January 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823004||144997|
NCT00823758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0577|Understanding Patient's Knowledge and Use of Acetaminophen|Understanding Patient's Knowledge and Use of Acetaminophen||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2008|||December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|124|||Both|13 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Parents of young children (8 years of age or younger) who administered acetaminophen to        their children, Adults and Adolescents (aged 13-20 years of age) familiar with or used OTC        acetaminophen in the last 2 years, and Primary care physicians and Pharmacists. All        Houston, Texas residents.|January 2016|January 21, 2016|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00823758||144939|
NCT00810186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-01/2008|Continuous Monitoring of Lung Ventilation|Continuous Monitoring of Lungs Ventilation Dynamics by Small Surface Patches That Include Safe Mechanical Sensors. A Multicenter Study.||Pneumedicare Ltd.|Yes|Completed|April 2009|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|77|||Both|N/A|N/A|No|Probability Sample|Infants that require tight monitoring of lung ventilation admited to the Neonatal        Intensive Care Unit.|March 2016|March 21, 2016|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00810186||145972|
NCT00810550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYCC CUE-HF|Carotid Ultrasound in the Evaluation of Heart Failure|Carotid Ultrasound in the Evaluation of Heart Failure|CUE-HF|New York University School of Medicine|No|Completed|October 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Actual|150|||Both|18 Years|N/A|No|||December 2008|December 17, 2008|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810550||145945|
NCT00809276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0844|Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY|Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|May 2009|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|N/A|65 Years|No|||January 2015|January 29, 2015|December 16, 2008||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00809276||146041|
NCT00823446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 03.1.1.HS1|Feasibility Study to Evaluate the Safety of Topically Applied Revera in Subjects With Venous Leg Ulcers|A Feasibility, Double Blind, Randomized, Controlled Clinical Study to Evaluate the Safety of Topically Applied Revera vs. Control in Subjects With Venous Leg Ulcers.||Revalesio Corporation|No|Completed|March 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823446||144963|
NCT00823680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP21850|A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin|Multi-center, Randomized, Double-blind, 5-arm Parallel Group, Placebo Controlled 4 Week Study to Investigate the Safety, Tolerability and Efficacy of Two Doses Each (Near to Maximum Tolerated Dose and Lower Dose) of RO5093151 Administered Twice Daily (BID Regimen) and RO5027838 Administered Once da||Hoffmann-La Roche||Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|110|||Both|35 Years|65 Years|No|||March 2016|March 1, 2016|January 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823680||144945|
NCT00823693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R013|Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis|Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Bimosiamose 5% Cream for the Treatment of Patients With Chronic Plaque Type Psoriasis||Revotar Biopharmaceuticals AG||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|January 14, 2009||||No||https://clinicaltrials.gov/show/NCT00823693||144944|
NCT00823992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC22092|A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy|A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Taspoglutide on Glycemic Control, and Its Safety and Tolerability, in Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy.||Hoffmann-La Roche||Completed|January 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|January 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823992||144921|
NCT00824005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580|Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)|Randomized, Controlled, Phase II, Double-Blind Trial of Intramyocardial Injection of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Patients With Chronic Ischemic Heart Disease and Left Ventricular Dysfunction||The University of Texas Health Science Center, Houston|Yes|Completed|March 2009|May 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|January 15, 2009|Yes|Yes||No|August 30, 2012|https://clinicaltrials.gov/show/NCT00824005||144920|Sample size was small and required large improvements in order to show significant treatment effects. SPECT often underestimates reversibility and viability in those with multivessel disease. Presence of cardiac devices limited MRI evaluation.
NCT00824265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110913|Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia|A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia||GlaxoSmithKline|No|Active, not recruiting|March 2009|October 2017|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|352|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|January 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00824265||144900|
NCT00824564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1461002|Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture|Prospective Randomized Phase IV Open Label Comparative Study Of Tranexamic Acid Plus Standard Of Care Versus Standard Of Care For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture||Pfizer|Yes|Completed|April 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|82|||Both|18 Years|50 Years|No|||June 2011|June 6, 2011|January 14, 2009||No||No|June 6, 2011|https://clinicaltrials.gov/show/NCT00824564||144878|The data for hemoglobin levels was planned but not evaluated on the morning of Day 7 post-surgery.
NCT00824837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02975|Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane|Randomised, Cross Over Pilot Study Comparing Removal of beta2-Microglobulin by Standard Haemodialysis to Haemodialysis With a Novel Dialysis Membrane (P2SH) in Chronic Dialysis Patients|HiCOF|Austin Health|Yes|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|80 Years|No|||January 2009|July 6, 2009|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824837||144857|
NCT00825747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeeLensAF 65|Evaluation of Seelens AF, an Aspheric Intra-Ocular Lens|Clinical Evaluation of the Aspheric SeeLens AF Intra-Ocular Lens.||Hanita Lenses|Yes|Not yet recruiting|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||January 2009|January 20, 2009|January 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00825747||144788|
NCT00826059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP1000500|Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window|A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke|ImpACT-24|BrainsGate|Yes|Recruiting|January 2009|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|40 Years|85 Years|No|||September 2015|September 2, 2015|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826059||144764|
NCT00826371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2203|Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months|EXTEND II|Novartis||Completed|January 2009|||July 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|50 Years|N/A|No|||August 2010|August 26, 2010|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00826371||144740|
NCT00826384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-001|Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion|Phase 1,Single-Blind, Randomized, Controlled Study to Evaluate the Safety and Effectivity of TACE Therapy of HCC(Hepatocellular Carcinoma) With Blocking Tumor Blood Temporarily and Enhancing Perfu||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|October 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|352|||Both|18 Years|70 Years|No|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826384||144739|
NCT00826644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCLC-0810|Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient|A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer|COMBAT|Chonnam National University Hospital|No|Recruiting|January 2009|December 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|80 Years|No|||January 2012|January 9, 2012|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826644||144719|
NCT00826618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4148s|Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema|Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema||University of Miami|Yes|Completed|June 2008|September 2013|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||August 2014|August 24, 2014|January 20, 2009|Yes|Yes||No|August 6, 2014|https://clinicaltrials.gov/show/NCT00826618||144721|The main limitation of this study is the small number of patients.There is no comparative arm to better define the relative efficacy of ranibizumab as compared with intraocular steroids or other treatments.
NCT00826631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M158-05|How Does 4 Weeks of Increased Fast Food Intake Affect Metabolism?|How Does 4 Weeks of Increased Fast Food Intake Affect Metabolism?||University Hospital, Linkoeping|No|Completed|April 2006|January 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826631||144720|
NCT00823511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14881|The Human Papillomavirus (HPV) Transmission Pilot Study|The Human Papillomavirus (HPV) Transmission Pilot Study||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|October 2006|December 2014|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|137|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female partners of HIM Study participants - Companion study to MCC-13930. Residents of        Southern Florida.|January 2015|January 27, 2015|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00823511||144958|
NCT00815243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2007-2011|Telemedicine Consultation in Trauma and Orthopedic|Study of Clinical Workflow Changes, Anatomical and Functional Outcomes Due to Telemedicine Consultations in Trauma and Orthopedic|TeleTO|Donetsk National Medical University|No|Completed|September 2007|September 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Both|N/A|N/A|No|||December 2008|December 26, 2008|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815243||145586|
NCT00823771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCC 07.01|A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment|A Pilot Study in the Transfer of Follow-up Reviews to the General Practitioner for Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment|PROFUGO|Barwon Health|No|Suspended|October 2007|||October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|112|||Male|N/A|N/A|No|Non-Probability Sample|Men approximately six months post-completion of radical radiotherapy treatment for        prostate cancer who have not experienced significant treatment toxicities or disease        progression.|February 2013|February 12, 2014|January 14, 2009||No|Met target accrual, suspended for data review.|No||https://clinicaltrials.gov/show/NCT00823771||144938|
NCT00809900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tufts 7903|Bioavailability and Metabolism of Anthocyanins Following Acute Cranberry Consumption|Bioavailability and Metabolism of Anthocyanins Following Acute Cranberry (Vaccinium Macrocarpon)Consumption||Tufts University|No|Completed|June 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|15|||Both|21 Years|80 Years|No|Probability Sample|Subjects aged 21-80 y and with demonstrated endothelial dysfunction and angiographically        proven coronary artery disease|December 2008|December 1, 2009|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00809900||145993|
NCT00810524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-senU 5010 Hepatitis B|Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection|Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection.||Sun Yat-sen University|Yes|Recruiting|January 2007|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|20 Years|45 Years|No|||October 2008|December 17, 2008|December 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00810524||145946|
NCT00823459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08109|Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma|Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma|RAD001|University of California, San Francisco|Yes|Completed|January 2009|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823459||144962|
NCT00823706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122/08|Prevalence of Angle Closure in Caucasian Hyperopes|Prevalence of Chronic Angle Closure in Caucasian Hyperopic Subjects||Assaf-Harofeh Medical Center|No|Recruiting|January 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|N/A|No|Non-Probability Sample|Caucasian subjects aged 40 years or more with hyperopia|January 2009|April 4, 2011|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00823706||144943|
NCT00823719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110927|Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)|A Single Arm, Safety and Efficacy Study of Ofatumumab in Combination With ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma Prior to Autologous Stem Cell Transplantation||GlaxoSmithKline|No|Completed|May 2009|September 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||February 2013|March 7, 2013|January 8, 2009|Yes|Yes||No|June 21, 2012|https://clinicaltrials.gov/show/NCT00823719||144942|
NCT00824018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABO 2008-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||January 15, 2009|January 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00824018||144919|
NCT00824031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2008/4|Study of Mental Care in Spain|Study of Mental Care in Spain||AstraZeneca|No|Completed|January 2009|July 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|76|||Both|18 Years|N/A|No|Non-Probability Sample|Patient aged 18-year old or older who has been diagnosed as schizophrenia|September 2009|September 10, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824031||144918|
NCT00824590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451019|A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function|A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function||Pfizer|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2009|December 29, 2009|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00824590||144876|
NCT00824278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090022|The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study|The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory, Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|January 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|251|||Both|7 Years|21 Years|No|||July 2015|January 12, 2016|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824278||144899|
NCT00824577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812010R|Heart Rate Variability in Chronic Kidney Disease Patients|Heart Rate Variability in Chronic Kidney Disease Patients||National Taiwan University Hospital|Yes|Active, not recruiting|December 2009|September 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples Without DNA|PD effluent and blood sample|Both|15 Years|90 Years|No|Probability Sample|peritoneal dialysis: peritoneal dialysis patient lasting for more than 3 months|June 2010|June 28, 2010|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824577||144877|
NCT00824850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3016|Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort|Characterization of the Prevnar Infant Long-term Immune Response vs a Prevnar Naive Cohort|PILOT|Pfizer|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|75|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|January 16, 2009|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00824850||144856|
NCT00826072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCSP-inflammation|Inflammatory Genetic Polymorphism and Acute Lung Injury After Cardiac Surgery|Association Study of Inflammatory Genetic Polymorphism and Acute Lung Injury After Cardiac Surgery With Cardiopulmonary Bypass||Changhai Hospital|Yes|Completed|May 2008|January 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|107|Samples With DNA|3ml blood before surgery, after surgery and 24h after surgery respectively|Both|18 Years|N/A|No|Probability Sample|Unrelated Chinese Han patients undergoing elective cardiac surgery with CPB|May 2013|May 2, 2013|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826072||144763|
NCT00826085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-08-201|Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall|A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.|DIGNITY|Celsion|No|Completed|February 2013|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826085||144762|
NCT00826397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2299|Randomized Trial of Acupuncture for Aromatase Inhibitor Induced Joint Pain|Pilot Study on the Effect of Acupuncture on Joint Pain Induced by Aromatase Inhibitors in Breast Cancer Patients||Columbia University|No|Completed|June 2005|September 2009|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Female|45 Years|N/A|No|||February 2013|February 19, 2013|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826397||144738|
NCT00826410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230/02|Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery|Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery||University Hospital Freiburg|No|Completed|May 2003|January 2005|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||January 2009|January 20, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826410||144737|
NCT00826657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412519-3|Vitamin B12 Supplementation Study|Assessment of Functional Vitamin B12 Deficiency in Mexican Women||USDA, Western Human Nutrition Research Center|No|Completed|October 2004|November 2006|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|180|||Female|20 Years|59 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00826657||144718|
NCT00826930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP100-201|Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma|Open-label Study to Determine the Effect of Trans Sodium Crocetinate (TSC) on Intra-tumoral Oxygen Concentration, Tolerability, and Pharmacokinetics of TSC in Post-operative Patients With High Grade Glioma (HGG)||Diffusion Pharmaceuticals LLC|Yes|Terminated|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Actual|1|||Both|18 Years|N/A|No|||August 2010|August 11, 2010|January 21, 2009|Yes|Yes|Sponsor business decision, not based on safety or efficacy data.|No||https://clinicaltrials.gov/show/NCT00826930||144697|
NCT00822744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI10560|An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients|An Eight-week, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Study, With Escitalopram (10 mg Daily) as Active Control, to Evaluate the Efficacy, Safety and Tolerability of Three Fixed Doses of SSR411298 (10, 50, or 200 mg Daily) in Elderly Patients With Major Depressive Disorder|FIDELIO|Sanofi|Yes|Completed|December 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|527|||Both|60 Years|N/A|No|||March 2013|March 14, 2013|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822744||145016|
NCT00823017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-00070|Effect of Music on Patients in Intensive Care Units|The Effect of Patient-Preferred Music, Relaxation Music, and Standard Care Environment on Patients in Intensive Care Units|MTS2|MetroHealth Medical Center|No|Completed|July 2006|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|40|||Both|18 Years|N/A|No|||July 2010|July 22, 2010|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823017||144996|
NCT00826917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW07-293|Use of 3D/4D Ultrasound in the Evaluation of Fetal Anomalies|Use of 3D/4D Ultrasound in the Evaluation of Fetal Anomalies - The Use of Volumetry by Three Dimensional Ultrasound in the First Trimester||The University of Hong Kong|Yes|Completed|March 2008|August 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control||4|Actual|195|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|1. Use of XI VOCALTM in 3D fetal volumetry measurements,comparison with multiplanar and             VOCALTM             -restropective(2005-2007),30 singleton pregnancies,11-14 weeks' gestation, at risk of             homozygous αº-thalassaemia.          2. Use of XI VOCALTM in 3D placental volumetry measurements,comparison with multiplanar             and VOCALTM             -retrospective(2005-2007), 32 singleton pregnancies,11-14 weeks' gestation at risk of             homologous alphaº thalassaemia.          3. Comparison of 3DUS volumetry measurement between two models of ultrasound machine             -prospective(December 2007-June 2008),30 singleton normal pregnancies,11-14 weeks'             gestation.          4. Use of 3DUS in fetal, gestational sac and placenta quotient measurement, fetuses at             risk of homozygous αº-thalassemia(Hb Bart's disease) -retrospective(datasets July             2007-Dec 2008),singleton pregnancies,11-14 weeks' gestation,26 affected cases,34             unaffected cases,43 normal control.|May 2015|May 31, 2015|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00826917||144698|
NCT00814957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110269|An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand.||GlaxoSmithKline||Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 9, 2009|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814957||145608|
NCT00815269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-200812-MZ39|Vasodilation Effect of Inhalational Anesthetics|Vasodilation Effect of Inhalational Anesthetics Including Halothane, Isoflurane, Sevoflurane, Desflurane and Enflurane|VEFIHA|Nanjing Medical University|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|300|||Both|19 Years|45 Years|No|||December 2009|December 22, 2009|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815269||145584|
NCT00815490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002400|Validation of Brain Oxygenation Monitor|Calibration and Validation of the Nonin Non-invasive Cerebral Oxygen Saturation Oximeter and Cerebral Sensor in Human Volunteers||Duke University|No|Completed|June 2008|April 2012|Actual|November 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|December 26, 2008|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00815490||145567|
NCT00815503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S20080152|Postoperative Analgesia With Local Infiltration After Periacetabular Osteotomy|Postoperative Analgesia With Local Infiltration After Periacetabular Osteotomy For The Treatment Of Dysplasia||Odense University Hospital|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||March 2011|March 15, 2011|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815503||145566|
NCT00842855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120N00013|Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France|Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient|REMAIN|AstraZeneca|No|Completed|February 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|275|||Both|18 Years|N/A|No|Probability Sample|Patients with Gastroesophageal Reflux Disease (GERD) classified as partial responders to        proton pump inhibitors (PPIs).|February 2011|February 4, 2011|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842855||143487|
NCT00842868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001076|The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases|The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases. An Observational Biomarker Study|CASABLANCA|Massachusetts General Hospital|No|Active, not recruiting|September 2008|September 2020|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1250|Samples Without DNA|serum and plasma|Both|18 Years|N/A|No|Non-Probability Sample|1250 patients undergoing angiography as clinical standard (diagnostic or therapeutic)        care;|April 2015|April 26, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00842868||143486|
NCT00810810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29792-D|Immunomodulation Following Transfusion|Immunomodulation Following Transfusion||University of Washington|No|Completed|July 2006|August 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|287|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00810810||145925|
NCT00823732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08035|Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Palliative Care for Quality of Life and Symptom Concerns in Late Stage Lung Cancer||City of Hope Medical Center|Yes|Completed|October 2008|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|280|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00823732||144941|
NCT00823745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121013|Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects|A Phase 1 Study To Evaluate The Metabolism And Excretion Of [14C] PF-00868554 In Healthy Adult Male Subjects||Pfizer|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 6, 2009|January 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823745||144940|
NCT00824291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-4415|Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2009|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|437|||Both|19 Years|74 Years|No|||March 2011|March 4, 2011|January 14, 2009|Yes|Yes||No|October 26, 2010|https://clinicaltrials.gov/show/NCT00824291||144898|
NCT00824876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT after mastectomy|Orthostatic Tolerance in Mamma Cancer Patients After Anaesthesia|||Rigshospitalet, Denmark|No|Completed|January 2009|||||N/A|Observational|Time Perspective: Prospective||1|||||Female|18 Months|70 Years|No|Non-Probability Sample|Mammasurgery patients|July 2009|July 7, 2009|January 13, 2009||||No||https://clinicaltrials.gov/show/NCT00824876||144854|
NCT00824863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U0275-502|Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis|An Open-Label, Proof of Concept Study to Determine the Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis||Fujita, Wayne, M.D.|Yes|Completed|December 2008|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824863||144855|
NCT00825136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09707-001|Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring|A Study on Mental Health Care by Using Specific Vital Signs||Chimei Medical Center|Yes|Terminated|July 2008|May 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|60 Years|No|||August 2012|August 19, 2012|January 15, 2009||No|The main limitations were the small sample size and low completion rate.|No||https://clinicaltrials.gov/show/NCT00825136||144834|
NCT00825448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00634-51|Alcohol Addiction and Otorhinolaryngology Cancer|Impact for Care for Patients With Alcohol Addiction and Treated for ORL Cancer||Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2009|January 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|115|||Both|18 Years|80 Years|No|||December 2011|March 23, 2012|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00825448||144811|
NCT00826423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004414|Mycobacterium Avium Intracellulare Complex (MAC) Study|Pilot Study to Assess Safety and Efficacy of Short Course Multiple Drug Therapy for Adult Patients With Mycobacterium Avium Intracellulare Complex (MAC) Infection Associated With Mulit Focal Bronchiectasis and Multiple Small Nodules|MAC|Mayo Clinic|No|Completed|June 2008|September 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|Samples Without DNA|sputum and blood collection for analysis|Both|18 Years|N/A|No|Probability Sample|Fifteen adult patients will be included in this pilot study. This sample size was chosen        not on the basis of formal statistical considerations. However, data from 15 patients will        be sufficient to provide rough preliminary estimates of parameters that may be needed for        developing power statements for a follow-up larger (randomized) trial. If macrolide        resistance occurs in 5% or less of patients in this population, with ≥83% probability only        one or zero of the 15 patients will develop resistance. If two or more of the 15 patients        develop resistance then further investigations of resistance will be warranted before        moving on to randomized trials.|July 2012|July 27, 2012|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826423||144736|
NCT00826670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-161|Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study|||University Hospital, Geneva|No|Completed|June 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826670||144717|
NCT00826943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080829|Is Levocetirizine Less Sedating Than Cetirizine?|Is Levocetirizine Less Sedating Than Cetirizine? A Randomized, Double-blind, Placebo Controlled Trial.||Vanderbilt University|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|77 Years|No|||February 2014|February 19, 2014|January 20, 2009|Yes|Yes||No|June 25, 2009|https://clinicaltrials.gov/show/NCT00826943||144696|
NCT00822757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V710-004|Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Single Dose of the Lyophilized Formulation of Merck Staphylococcus Aureus Vaccine (V710) in Healthy Adults||Merck Sharp & Dohme Corp.|No|Completed|August 2007|December 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|51|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|January 13, 2009|No|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00822757||145015|
NCT00822770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0772|Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin|G-CSF and Plerixafor With Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias||M.D. Anderson Cancer Center|No|Completed|January 2009|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||June 2014|June 13, 2014|January 13, 2009|Yes|Yes||No|June 13, 2014|https://clinicaltrials.gov/show/NCT00822770||145014|
NCT00823264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008017|Phenytoin and Multidose Activated Charcoal|Prospective Randomized Study of Multidose Activated Charcoal in Supratherapeutic Phenytoin Serum Levels||Emory University|No|Completed|August 2008|January 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|January 14, 2009||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00823264||144977|
NCT00814710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111188|Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age|Primary Vaccination Course in Healthy Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Tritanrix™-HepB/Hib at 6, 10 and 14 Weeks of Age||GlaxoSmithKline||Completed|March 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|360|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||June 2012|February 6, 2014|December 23, 2008|Yes|Yes||No|October 21, 2010|https://clinicaltrials.gov/show/NCT00814710||145627|
NCT00814983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000993|Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft|Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft||Duke University|Yes|Terminated|July 2007|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||September 2013|September 25, 2013|December 26, 2008|Yes|Yes|IND approval for naive T-cell depletion not obtained|No|September 25, 2013|https://clinicaltrials.gov/show/NCT00814983||145606|
NCT00815256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1970/07|Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus|The Safety and Effectiveness of Collagen Cross Linking With Riboflavin and Ultraviolet-A Light in Progressive Mild and Moderate Grades of Keratoconus.||Federal University of São Paulo|Yes|Recruiting|August 2008|||August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|15 Years|40 Years|No|||November 2008|December 26, 2008|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815256||145585|
NCT00815529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KyungHU|Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain|Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain||Kyunghee University Medical Center||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|65 Years||||December 2008|December 29, 2008|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815529||145564|
NCT00815516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-CL-2303|Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis|A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis|MAGIC-2|Astellas Pharma Inc|Yes|Terminated|February 2013|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|120 Days|No|||October 2015|October 12, 2015|December 27, 2008|Yes|Yes|It was decided to discontinue the study due to insufficient recruitment.|No|August 14, 2015|https://clinicaltrials.gov/show/NCT00815516||145565|
NCT00842881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-01-001|A Trial for Evaluation of Clinical Efficacy and Safety of Healing Stone Navel Belt in Patients With Primary Dysmenorrhea|Clinical Efficacy and Safety of Healing Stone Navel Belt in Patients With Primary Dysmenorrhea|Healingstone|Healingstone Co., Ltd.|Yes|Enrolling by invitation|August 2008|September 2009|Anticipated|March 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|102|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 23, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842881||143485|
NCT00843141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHDA-HMO-CTIL|The Efficacy of Computerized Cognitive Training in Adults With ADHD: Change in ADHD Symptoms, Executive Functions and Quality of Life Following Three Months of Training.|ADHD Symptoms, Executive Functions and Quality of Life Following Three Months of Training.||Hadassah Medical Organization|No|Completed|May 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2009|August 15, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843141||143465|
NCT00810199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA21488|A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment|Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients...||Hoffmann-La Roche||Completed|March 2009|January 2013|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|556|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|December 16, 2008|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT00810199||145971|
NCT00842829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/4027/BP/EU|Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients|A European Multicenter Open-Label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients||Teva Pharmaceutical Industries|No|Terminated|January 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|330|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|January 29, 2009|No|Yes|Recruitment stopped at the end of the recruitment timeframe|No|August 17, 2012|https://clinicaltrials.gov/show/NCT00842829||143489|
NCT00824304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU 2007-121|Long-term Effects of Iron and Zinc Supplementation During Infancy on Cognitive Performance and Growth|Long-Term Effects of Iron and Zinc Supplementation During Infancy on Cognitive Performance and Growth 8 Years Later: A Follow-Up Study|FeZn_FU|Mahidol University|No|Completed|July 2007|July 2009|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|562|Samples Without DNA|Plasma and urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All available children who received iron and zinc study during infancy|January 2009|February 14, 2013|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00824304||144897|
NCT00824317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0394|Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type|Stimulant Drug Treatment of AD/HD, Inattentive Type||Icahn School of Medicine at Mount Sinai|No|Completed|October 2001|February 2005|Actual|February 2005|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|7 Years|13 Years|No|||January 2009|January 15, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824317||144896|
NCT00824603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03425-06-C|Impact of Continuing Medical Education (CME) Insulin Program|Impact of CME Program on Self-Reported Confidence and Use of Insulin in Persons With Type 2 Diabetes||HealthPartners Institute|No|Completed|June 2006|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|294|||Both|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care providers affiliated with the participating healthcare organizations were        invited to attend.|August 2013|November 30, 2015|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00824603||144875|
NCT00824616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-018|A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin||Merck Sharp & Dohme Corp.||Completed|January 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|21 Years|70 Years|No|||July 2015|July 21, 2015|January 16, 2009|Yes|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT00824616||144874|
NCT00825188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0035|A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives|Investigation of Reduction of Blood Pressure and Metabolic Rate in Obese Hypertensive Patients Using Eplerenone: Implications for Treatment of Hypertension and Heart Failure||University of Mississippi Medical Center|Yes|Completed|January 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|N/A|No|||March 2014|March 10, 2014|January 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825188||144830|
NCT00825149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21000|A Study of RO5072759 in Combination With Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (GAUDI)|An Open-label, Multi-centre, Randomized, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-cell Follicular Non-Hodgkin's Lymphoma||Hoffmann-La Roche||Completed|February 2009|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|137|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00825149||144833|
NCT00825162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-USF-06-29|Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years|A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years||CSL Limited|Yes|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1992|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|January 15, 2009|Yes|Yes||No|July 3, 2011|https://clinicaltrials.gov/show/NCT00825162||144832|
NCT00825461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-089|Ghrelin With Anorexia Nervosa|Level of Ghrelin With Anorexia Nervosa (AN) Patients. Subgroup AN: With and Without Tubefeeding.||Maastricht University Medical Center|Yes|Suspended|March 2009|May 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|20|Samples With DNA|Whole blood|Female|12 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Studypopulation: Patiënts: all female, non -age coupled. Subgroup patients without tube        feeding, with tube feeding and a healthy matched control group.        Control group: healthy volunteers of the University of Maastricht.|September 2009|September 23, 2009|January 20, 2009||No|no METC approval obtained|No||https://clinicaltrials.gov/show/NCT00825461||144810|
NCT00825760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPA/904W/003|Clinical Trial to Investigate Treatment With Photodynamic Therapy to Reduce Levels of Bacteria in Leg Ulcers|Phase II Randomised, Placebo Controlled Trial to Investigate Repeat Dose Antimicrobial Photodynamic Therapy in Patients With Chronic Leg Ulcers.||Photopharmica|Yes|Completed|January 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00825760||144787|
NCT00825773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-09-01-19|A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions|A Randomized Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus SirOlimus ELUting Stent With Non-Biodegradable Polymer in the Treatment of PatIents With de nOvo Coronary Artery LesioNs|EVOLUTION|JW Medical Systems Ltd|Yes|Recruiting|October 2008|April 2014|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1944|||Both|18 Years|N/A|No|||January 2009|January 22, 2009|January 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00825773||144786|
NCT00813514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-270907|Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?|Does VEGF or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With CNV?||Medical University of Vienna||Withdrawn|January 2009|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|50 Years|90 Years|No|||November 2014|November 20, 2014|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813514||145718|
NCT00813527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-05-TL-475-031|Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels|A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia||Takeda|No|Completed|February 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|December 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813527||145717|
NCT00813852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612106R|The Study of Skeletal Muscle Function in Obstructive Sleep Apnea|The Study of Skeletal Muscle Function in Obstructive Sleep Apnea||National Taiwan University Hospital|No|Completed|August 2007|July 2011|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|129|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|December 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00813852||145692|
NCT00814086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9921|Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|February 2009|||July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|N/A|N/A|No|||December 2014|December 29, 2014|December 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00814086||145674|
NCT00814424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0452-08-HMO|Quantitive And Qualitive Assessment Of The Oxygen Delivery And EtCO2 Sampling With The Smart Bite Block Mark III During An Upper Endoscopic Procedure Under Sedation|Quantitive And Qualitive Assessment Of The Oxygen Delivery And EtCO2 Sampling With The Smart Bite Block Mark III During An Upper Endoscopic Procedure Under Sedation||Hadassah Medical Organization|No|Not yet recruiting|January 2009|July 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|N/A|N/A|No|||December 2008|December 23, 2008|December 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814424||145648|
NCT00814437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVISEV-001-KIS|Physiological Role of KiSS-1/GPR54 System in the Human Ovary|Physiological Role of KiSS-1/GPR54 System in the Human Ovary|001-KIS|IVI Sevilla|No|Withdrawn|April 2009|||December 2012|Anticipated|N/A|Observational|N/A||1|Actual|0|Samples With DNA|Human granulosa cells|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy oocyte donors|January 2016|January 15, 2016|December 23, 2008||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00814437||145647|
NCT00814450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASNG-LFNA-101-IL|Safety & Accuracy of the ActiSight Needle Guidance System in Percutaneous Chest Aspiration and Biopsy|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating The Preliminary Safety And Accuracy Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Percutaneous Chest Aspiration And Biopsy|ANGS-PCAB|ActiViews Ltd.|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||December 2009|December 29, 2009|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814450||145646|
NCT00814723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-002535-12|Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk|Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk||Medical University of Graz|Yes|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||December 2008|December 24, 2008|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00814723||145626|
NCT00815282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL26.113.000.08|Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease|Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease|HPV-kind|UMC Utrecht|No|Recruiting|February 2009|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|330|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||July 2014|July 29, 2014|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815282||145583|
NCT00815555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135/08|CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients|CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients||Assaf-Harofeh Medical Center|No|Recruiting|December 2008|||December 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|500|Samples With DNA|Blood samples|Female|18 Years|N/A|No|Probability Sample|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen|December 2008|December 29, 2008|December 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00815555||145562|
NCT00815919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-191|Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease|A Phase II Trial of Bortezomib (Velcade) Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease||Dana-Farber Cancer Institute|Yes|Completed|December 2008|January 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|December 30, 2008|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT00815919||145534|
NCT00815893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUHIRB-96-09-02|The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation|Interventional Study of Dexmedetomidine for Sedating Anticipated Difficult Airway Patients Undergoing Awake Fiberoptic Nasal Intubation||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|August 2008|August 2009|Anticipated|August 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|70 Years|No|||December 2008|July 27, 2009|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00815893||145536|
NCT00815906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3227K1-1001|Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis|An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Japanese Subjects With Rheumatoid Arthritis||Pfizer|No|Completed|December 2008|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|20 Years|70 Years|No|||June 2012|June 15, 2012|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00815906||145535|
NCT00843713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL095130-01|Effect of Raltegravir on Endothelial Function in HIV-Infected Patients|A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection||University of California, San Francisco|Yes|Completed|January 2009|February 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 12, 2009|Yes|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT00843713||143422|
NCT00843128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0558-08-HMO-CTIL|The Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Multiple Sclerosis Patients|Phase II Study of the Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Acute Stroke Patients: A Randomized Controlled Trial.||Hadassah Medical Organization|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||February 2009|April 7, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843128||143466|
NCT00843154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANc-CHF14-TIF|Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure|Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function|CANDHEART|Takeda|No|Terminated|December 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|571|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|February 12, 2009||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00843154||143464|
NCT00824889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00064-51|Exploratory Study of Natural Killer Cells in Human Skin|Exploratory Study of Natural Killer Cells in Human Skin||Assistance Publique Hopitaux De Marseille|No|Completed|February 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|7||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 28, 2014|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00824889||144853|
NCT00825175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00002466|Treadmill Training and Orthotic Use in Infants With Down Syndrome|The Effect of Treadmill Training and Orthotic Use on the Development of Walking and Upright Play in Infants With Down Syndrome||University of Michigan|Yes|Completed|March 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|6 Months|36 Months|No|||January 2014|January 24, 2014|January 15, 2009||No||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00825175||144831|small sample size
NCT00816634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-059|Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma|A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Paclitaxel (XT) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma|XP versus XT|Samsung Medical Center|No|Recruiting|October 2008|December 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816634||145479|
NCT00825474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-003|A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma|A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|August 2008|August 2010|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|70 Years|No|||January 2009|January 23, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00825474||144809|
NCT00825786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-671|Ultrasound Guided Supraclavicular Nerve Block|Ultrasound Guided Supraclavicular Nerve Block: Comparison Between a Mixture of Mepivacaine and Ropivacaine, and Sequential Injection of Mepivacaine Followed by Ropivacaine||Outcomes Research Consortium|No|Completed|September 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||August 2011|September 6, 2011|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00825786||144785|
NCT00826098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR07-004|Platelet Rich Plasma (PRP) in Total Knee Replacement|Platelet Rich Plasma (PRP) in Total Knee Replacement: A Prospective, Randomized, Single-blind, Single-center Clinical Study to Evaluate the Effect of Platelet Rich Plasma (PRP) on Short-term Patient Outcomes Following Total Knee Replacement||Exactech|No|Completed|December 2008|February 2013|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|N/A|N/A|No|||February 2015|February 9, 2015|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00826098||144761|
NCT00826111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00427|The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia|The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Co-morbid Anxiety and Insomnia: A Proton MRS Study||Steward St. Elizabeth's Medical Center of Boston, Inc.|No|Completed|August 2007|July 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Female|18 Years|55 Years|No|||June 2012|June 28, 2012|January 19, 2009|Yes|Yes||No|October 27, 2011|https://clinicaltrials.gov/show/NCT00826111||144760|Withdrawal of support by the funding sponsor due to other priorities resulted in a very small sample size with a small placebo group. Participant withdrawal and unusable data explains discrepancies in subject numbers in some analyses.
NCT00813540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1-23950|The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors|The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors: a Randomized Controlled Trial||AHS Cancer Control Alberta|No|Completed|March 2009|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|N/A|No|||April 2012|March 10, 2016|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813540||145716|
NCT00813553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.13.PER|Effect of β-alanine Supplementation on Muscle Carnosine|Effect of Two 8-week β-alanine Supplementation Protocols on Muscle Carnosine|LitmusMagnet|Nestlé|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813553||145715|
NCT00813865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAU-CL-202X|A Long-Term Extension Study of AT2101 in Type 1 Gaucher Patients|An Open-label, Multicenter, Long-term Extension Study to Assess the Safety, Efficacy, and Pharmacodynamics of AT2101 in Adult Patients With Type 1 Gaucher Disease||Amicus Therapeutics|No|Completed|January 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|December 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813865||145691|
NCT00814099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611|Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)|Sedation Management in Pediatric Patients With Acute Respiratory Failure|RESTORE|University of Pennsylvania|Yes|Completed|January 2009|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2449|||Both|N/A|18 Years|No|||July 2015|July 14, 2015|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00814099||145673|
NCT00814749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/197|Value of Urodynamics Prior to Stress Incontinence Surgery 2|a Multicentered Randomised Controlled Trial to Test the Cost Effectiveness of Urodynamics in Women With Symptoms of Stress Urinary Incontinence in Whom Surgical Treatment is Considered|VUSIS 2|Radboud University|Yes|Recruiting|November 2008|January 2011|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2008|December 24, 2008|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00814749||145624|
NCT00814762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112353|Safety of the HIV Vaccine 732461 in HIV Infected Subjects Aged 18 to 55 Years Old|Study to Evaluate the Safety and Reactogenicity of the HIV Vaccine 732461 in HIV Infected Subjects Aged 18 to 55 Years Old||GlaxoSmithKline||Completed|February 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|41|||Both|18 Years|55 Years|No|||October 2011|October 27, 2011|December 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00814762||145623|
NCT00814736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3711051|A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031|A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate The Safety And Toleration Of Single Dose Sildenafil In Subjects Receiving Chronic UK-369,003.||Pfizer|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|22|||Male|40 Years|55 Years|Accepts Healthy Volunteers|||December 2008|December 22, 2008|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT00814736||145625|
NCT00814970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP105|The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions|The Complete® SE SFA Study: The Medtronic Complete Self-Expanding SFA Stent System for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and/or Proximal Popliteal Arteries||Medtronic Endovascular|Yes|Completed|November 2008|December 2013|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|196|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|December 23, 2008|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00814970||145607|
NCT00815295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001516|Study of Sorafenib/Cetuximab in Head and Neck Cancer|Sorafenib and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN):a Phase I B/II Trial||Duke University|Yes|Completed|January 2008|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|December 26, 2008|Yes|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT00815295||145582|
NCT00815542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-2011-MMC|Induction of Labor in Oligohydramnios|Induction of Labor in Oligohydramnios - A Comparison Between Two Modes of Cervical Ripening for Patients With Oligohydramnios at Term||Meir Medical Center|No|Not yet recruiting|June 2012|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|December 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00815542||145563|
NCT00816413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164-07|Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer|T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation||University of Nebraska|Yes|Withdrawn|September 2008|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|75 Years|No|||June 2013|June 17, 2013|December 31, 2008|No|Yes|Screenings yielded inadequate eligible subjects to enroll.|No||https://clinicaltrials.gov/show/NCT00816413||145496|
NCT00815932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR477808CTIL|The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To CRPS or Diabetic Neuropathy|The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To Complex Regional Pain Syndrome (CRPS) or Diabetic Neuropathy-A PILOT, DOUBLE-BLIND, SHAM-CONTROLLED, CROSS-OVER STUDY||Soroka University Medical Center||Not yet recruiting|September 2015|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00815932||145533|
NCT00816179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007C0086|Diagnostic Endoscopic Exploration for Pancreatic Head Mass|Human Clinical Trial of Diagnostic Transgastric Endoscopic Peritoneoscopy for Staging of Pancreatic Head Mass||Ohio State University|No|Terminated|July 2008|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|80 Years|No|||October 2014|October 30, 2014|December 30, 2008||No|Helical CT scans at our institution preclude the necessity for diagnostic laparoscopy in most    cases at our institution.|No||https://clinicaltrials.gov/show/NCT00816179||145514|
NCT00843414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1978H0059|Immunological Characterization of Bronchoalveolar Cells in Normals|Immunological Characterization of Bronchoalveolar Cells in Normals||Ohio State University|No|Completed|March 1978|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1232|Samples With DNA|blood lung fluid (BAL)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|April 2011|April 25, 2011|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843414||143445|
NCT00844324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2451C00007|Bioequivalence Study in Healthy Subjects|A Single Dose, 2-Period, Cross-over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil||AstraZeneca|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|February 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00844324||143376|
NCT00816361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP184|A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists||MedImmune LLC|No|Completed|March 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|December 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00816361||145500|
NCT00816621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH084135|Effectiveness of a Parent Training Program for Parents of Children Adopted Internationally|Early Intervention for Children Adopted Internationally||University of Delaware|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Both|12 Months|36 Months|Accepts Healthy Volunteers|||January 2015|January 4, 2015|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816621||145480|
NCT00816647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPFL08|A Prospective Randomized Study of Medial Patellofemoral Ligament (MPFL) Reconstruction|A Prospective Randomized Study of Medial Patellofemoral Ligament Reconstruction Compared With Medial Reefing||Finnish Defense Forces|No|Terminated|December 2008|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||July 2009|June 13, 2011|December 31, 2008||No|Stopped for benefit of the MPFL reconstruction arm and due to safety concerns of the medial    reefing arm.|No||https://clinicaltrials.gov/show/NCT00816647||145478|
NCT00816660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070701|Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease|Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex (rVWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability in Type 3 Von Willebrand Disease (VWD)||Baxalta US Inc.|Yes|Completed|December 2008|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|32|||Both|18 Years|60 Years|No|||November 2010|June 26, 2015|January 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00816660||145477|
NCT00816920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24/2001/O EM60/2007/O|Natural History of Isolated Deep Vein Thrombosis of the Calf|Diagnosis and Evolution of Isolated Deep Vein Thrombosis of the Calf in Symptomatic Outpatients. The Blind, Prospective "CALTHRO" Study.|CALTHRO|St. Orsola Hospital|Yes|Completed|September 2005|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients with suspected deep vein thrombosis (DVT) of a leg in whom a proximal DVT is        excluded.        The study is not funded. As a result, it will not be possible to enroll all consecutive        eligible patients; rather patients will be included based on the availability of expert        medical staff in the day of their presentation (in general the first patient of the day).|September 2009|September 17, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816920||145457|
NCT00816933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHAPPE 01|Trial on Postoperative Outcomes According to the Number of Trocar During Laparoscopic Appendectomy|Prospective Randomized Trial on the Assessment of Postoperative Outcomes According to the Number of Trocar During Laparoscopic Appendectomy||The Catholic University of Korea|Yes|Recruiting|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|8 Years|75 Years|No|||January 2009|January 5, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816933||145456|
NCT00817193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSA290200600024|Staying Healthy Through Education and Prevention Study|Early Screening and Exercise for Prevention of Disability in Persons Residing in Continuing Care Retirement Communities|STEP|American Association of Homes and Services for the Aging|No|Active, not recruiting|January 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|320|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 27, 2010|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817193||145436|
NCT00817466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2009-012667-34|Bronchiolitis All-study, SE-Norway|Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis?||Oslo University Hospital|Yes|Active, not recruiting|January 2010|December 2013|Anticipated|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|500|||Both|N/A|11 Months|No|||November 2012|November 1, 2012|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817466||145415|
NCT00817726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SchiessRBD6YR2008|RBD Longitudinal as Prognostic for PD|A Natural History Analysis of Rapid Eye Movement Sleep Behavior Disorder as Prognostic for Parkinson's Disease|RBD6YR|The University of Texas Health Science Center, Houston|No|Recruiting|January 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||4|Anticipated|240|Samples With DNA|CSF, blood (serum)|Both|35 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with polysomnographically-documented RBD, non-neurodegenerative diagnosis Age and        gender matched non-RBD diagnosis, non-neurodegenerative diagnosis idiopathic PD diagnosis        atypical PD diagnosis|December 2015|December 3, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817726||145395|
NCT00813878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00080|Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease|Optical Biosensor for the Early Detection of Breast Cancer||City of Hope Medical Center|Yes|Terminated|July 2001|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|126|||Female|18 Years|120 Years|No|||October 2015|October 1, 2015|December 20, 2008|No|Yes|Closed due to low accrual|No||https://clinicaltrials.gov/show/NCT00813878||145690|
NCT00814112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAGS 293/2008|Glycosaminoglycans During Septic Shock - a Temporal Study|GAGS - Glykosaminoglykaner Vid Sepsis|GAGS|Region Skane|No|Recruiting|November 2008|||November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Plasma and Urine.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Septic Shock|October 2009|October 7, 2009|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00814112||145672|
NCT00814125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033IC/0029|ATAC - Endometrial Sub-Protocol|A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women||AstraZeneca|Yes|Completed|June 1997|December 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|285|||Female|45 Years|N/A|No|||April 2009|April 30, 2009|November 3, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814125||145671|
NCT00814788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000628778|Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer|Phase II Trial of Bicalutamide + RAD001 in Patients With Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy|UCDCC#215|University of California, Davis|Yes|Completed|December 2008|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|18 Years|N/A|No|||January 2016|January 7, 2016|December 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814788||145621|
NCT00814996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96-C-036|Social Functioning in Schizophrenia|||Far Eastern Memorial Hospital||Completed|August 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|45 Years|No|Probability Sample|schizophrenia|December 2008|December 26, 2008|December 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00814996||145605|
NCT00815009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2008.171|Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease|Prospective Histopathologic Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease|NAFLD|San Antonio Military Medical Center|No|Completed|October 2008|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|70 Years|No|||July 2012|July 13, 2012|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815009||145604|
NCT00816192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/27|Comparison of Externally Versus Internally Cooled Tip Catheter Ablation in Paroxysmal Atrial Fibrillation|Comparison of Externally Versus Internally Cooled Tip Catheter in Achieving Long-term Electrical Isolation of Pulmonary Veins in Paroxysmal Atrial Fibrillation|CATAFABL|University Hospital, Bordeaux|No|Terminated|December 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|December 30, 2008||No|The production of the device used in this study has been suspended.|No||https://clinicaltrials.gov/show/NCT00816192||145513|
NCT00816699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si325/2008|Effects of Providing Preprint Preoperative Anesthetic Risk Information|Effects of Providing Preprint Preoperative Anesthetic Risk Information||Mahidol University|No|Completed|December 2008|September 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|16 Years|80 Years|No|||March 2011|March 10, 2011|January 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00816699||145474|
NCT00844012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2009|Continuous Postoperative Use of Low-Dose Combined Oral Contraceptivesfor for Endometriosis-Related Chronic Pelvic Pain|Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial.||University Magna Graecia|No|Not yet recruiting|May 2009|July 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|No|||February 2009|March 10, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844012||143400|
NCT00844025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-98-NDR-05|Pharmaceutical Care and Clinical Outcomes for the Elderly Taking Potentially Inappropriate Medication|Pharmaceutical Care and Clinical Outcomes for the Elderly Taking Potentially Inappropriate Medication: a Randomized-Controlled Trial||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Enrolling by invitation|February 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|65 Years|90 Years|No|||March 2009|March 30, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844025||143399|
NCT00844038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSJ1|Stevens-Johnson Syndrome Antimicrobial|Stevens-Johnson Syndrome Associated With Antimicrobial||University of Pernambuco|Yes|Completed|August 2008|December 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Male|20 Years|60 Years|No|Probability Sample|1|February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844038||143398|
NCT00844337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU IRB 1440|Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh|Safety and Efficacy of Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|March 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2490|||Both|N/A|59 Days|No|||September 2014|September 12, 2014|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844337||143375|
NCT00816374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC- 05-805|Tailored Intervention for Melanoma Patient's Families|Tailored Intervention for Melanoma Patient's Families||Fox Chase Cancer Center|No|Completed|August 2005|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|553|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 15, 2014|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816374||145499|
NCT00816959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-HDIII 0109|Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma|Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma||American Scitech International|No|Not yet recruiting|July 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|16 Years|65 Years|No|||July 2011|July 19, 2011|January 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00816959||145454|
NCT00816946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|753-Ped/ERC-07|District-based Mainstreaming Nutrition Project in Rural Pakistan|Scaling up Evidence-based Nutrition Interventions to Address Maternal and Child Health Outcomes in Pakistan: a District-based Demonstration Project in Rural Sindh|NF Nutrition|Aga Khan University|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2009|August 9, 2011|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816946||145455|
NCT00817206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro 3001|Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily|Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt.||Veloxis Pharmaceuticals|Yes|Completed|December 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|326|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|December 19, 2008|Yes|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT00817206||145435|
NCT00817479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11892A|Tumor Gene Expression in Women With Ovarian Cancer|Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer||University of Chicago|Yes|Completed|January 2003|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Female|18 Years|59 Years|No|||November 2014|November 17, 2014|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817479||145414|
NCT00817739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP IIb/95/022 - EC210|Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c|Intermittent Hormonal Therapy With Leuprorelin (3.75 mg SR) and Flutamide in the Treatment of Stage D2 or Tx Nx M1 ≠ M1a Metastatic Cancer of the Prostate||Takeda|No|Completed|December 1996|December 2008|Actual|September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|341|||Male|18 Years|N/A|No|||July 2015|July 27, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817739||145394|
NCT00817752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02202007A|Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation|Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation||National College of Natural Medicine|Yes|Completed|May 2007|February 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2009|March 17, 2010|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00817752||145393|
NCT00814138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11552|Efficacy of Methotrexate in Myasthenia Gravis|Phase II Trial of Methotrexate in Myasthenia Gravis||University of Kansas Medical Center|Yes|Completed|April 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|December 23, 2008|Yes|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT00814138||145670|
NCT00814151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-2008B|MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial|Primary Investigation Into the Performance of the MicroPhage S. Aureus / MSSA / MRSA Test Direct From Blood Culture.||MicroPhage, Inc.|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|712|Samples Without DNA|Retention of discrepant blood culture specimens only.|Both|18 Years|N/A|No|Non-Probability Sample|Blood culture positive specimens from three academic medical centers.|December 2008|December 23, 2008|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00814151||145669|
NCT00814476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005047ctil|The Effects of Regular Home Use Vs Diabetic Team- Supported Use of the Medtronic CareLink Therapy Management System.|The Efficacy, Short and Long Term Effects of Regular Home Use Vs Diabetic Team - Supported Use of the Medtronic CareLink Therapy Management System in Patients With Diabetes|CareLink|Rabin Medical Center|No|Completed|January 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|70|||Both|N/A|35 Years|No|||July 2013|July 9, 2013|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814476||145644|
NCT00814463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004373|Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases|Phase II Single-arm Study of Post-operative Stereotactic Radiosurgery for Brain Metastases.||Duke University|No|Terminated|August 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2013|August 4, 2014|December 23, 2008|No|Yes|Early analysis indicated SRS not as beneficial post-op as pre-op|No|January 23, 2013|https://clinicaltrials.gov/show/NCT00814463||145645|
NCT00814775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-358|Comparison Between the Fastrach and CTrach Laryngeal Mask Airway|Comparison Between the Fastrach and CTrach Laryngeal Mask Airway for Intubation of Patients With a Mallampati Score 3 or 4||Outcomes Research Consortium|No|Terminated|August 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|43|||Both|18 Years|N/A|No|||September 2010|September 3, 2010|December 23, 2008||No|recruitment challenges, device no longer available|No||https://clinicaltrials.gov/show/NCT00814775||145622|
NCT00815022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-200812-MZ32|Influence of Anesthetic Temperature on Cephalad Sensory Blockade With Spinal Anesthesia|Influence of Anesthetic Temperature on Cephalad Sensory Blockade With Spinal Anesthesia for Cesarean Delivery|ATOCEB|Nanjing Medical University|Yes|Completed|December 2008|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|400|||Female|19 Years|45 Years|No|||January 2014|January 11, 2014|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815022||145603|
NCT00815620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZBB-NET-1|Best Therapy for Patients With Neuroendocrine Tumors|Best Therapy for Patients With Neuroendocrine Tumors|BESTTHERAPYNET|Zentralklinik Bad Berka|No|Recruiting|November 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|5|||Both|18 Years|90 Years|No|Non-Probability Sample|patients with neuroendocrine tumors in a tertiary referal center|January 2016|January 4, 2016|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815620||145557|
NCT00815945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-GYN 7|Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors|Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors||AGO Study Group|No|Completed|June 2008|||November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||March 2014|March 6, 2014|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00815945||145532|
NCT00815958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0111|Embolic Events Detected During Total Knee Arthroplasty With the Use of RIA (Reamer-Irrigator-Aspirator)|Embolic Events Detected During Total Knee Arthroplasty With and Without the Use of RIA (Reamer-Irrigator-Aspirator): A Blinded, Randomized, Controlled Clinical Study||Ohio State University|No|Terminated|December 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||September 2009|September 11, 2009|December 30, 2008||No|administrative reasons|No||https://clinicaltrials.gov/show/NCT00815958||145531|
NCT00816205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD102|An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects|An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects||RDD Pharma Ltd|No|Completed||April 2009|Actual|||Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment|1||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 6, 2009|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816205||145512|
NCT00844961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-K|Effectiveness of Internet Delivered Cognitive Behavior Therapy (CBT) for Irritable Bowel Syndrome (IBS)|Study of the Effectiveness of Internet Delivered Cognitive Behavior Therapy in a Sample of Consecutively Recruited Patients Diagnosed With Irritable Bowel Syndrome||Karolinska Institutet|No|Completed|November 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||February 2009|November 8, 2011|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844961||143328|
NCT00845221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIVEC PHASE IV|Glivec in Pediatric Chronic Myeloid Leukemia (CML)|||Poitiers University Hospital||Active, not recruiting|July 2004|December 2011|Anticipated|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|44|||Both|N/A|18 Years|No|||February 2009|February 17, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845221||143308|
NCT00816673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurim I|Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs|Phase II Study of Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs.|Neu I|Neurim Pharmaceuticals Ltd.||Completed|September 1996|September 1997|Actual|May 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|N/A|No|||January 2009|January 4, 2009|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816673||145476|
NCT00817232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPEC/10/08/05|Effectiveness of Microcurrent for Treatment of Tennis Elbow|Effectiveness of Microcurrent in the Treatment of Chronic Tennis Elbow - a Preliminary Trial||University of Hertfordshire|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||August 2009|June 18, 2010|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817232||145433|
NCT00817219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCB 0501 INT|Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris|Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris||LEO Pharma|No|Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|12 Years|17 Years|No|||March 2015|March 25, 2015|January 5, 2009|No|Yes||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00817219||145434|
NCT00817492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#14747A|Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease- University of Illinois|Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease|CRIC|University of Chicago|No|Completed|July 2006|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|89|||Both|21 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Renal Clinic patients at The University of Illinois at Chicago Hospital|September 2013|September 4, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817492||145413|
NCT00817505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00010|To Evaluate the Bioavailability of a Tablet of AZD1656|A Randomized, Open, Single-Dose, Single-Centre, Cross-over, Phase I Study in Type 1 Diabetes Mellitus Patients to Estimate the Extent and Rate of Absorption of AZD1656 After Administration of a Tablet Formulation in the Fasting State and Just Before Food in Comparison With an Oral Suspension of AZD1||AstraZeneca||Completed|December 2008|September 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|20 Years|65 Years|No|||November 2009|November 2, 2009|December 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00817505||145412|
NCT00813228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090055|Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals|Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals||National Institutes of Health Clinical Center (CC)||Completed|December 2008|June 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813228||145739|
NCT00813241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191354|A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers|A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Formulations Of Celecoxib In Healthy Volunteers||Pfizer|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813241||145738|
NCT00813566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI31335|Multi-Tracer PET Assessment of Primary Brain Tumors|Multi-Tracer PET Assessment of Primary Brain Tumors||University of Utah|Yes|Recruiting|December 2008|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Study patients: Adult patients (n = 20) with (Group 1) compelling MRI evidence of a new        primary brain tumor who have not yet undergone surgery or any tumor-directed therapy, or        (Group 2) newly diagnosed primary malignant brain tumors (WHO Grade II-IV glial-based        tumors)who have not had a complete surgical resection and by contrast MRI have residual        tumor greater than 1.0 cm in diameter and will be receiving radiotherapy and/or        chemotherapy, or (Group 3) patients with recurrent primary barin tumor as determined by        standard clinical criteria and MRI imaging. Four to eight patients per year will be        enrolled during the first 3 years, for a total of 20 patients. Enrollment will be weighted        toward lower-grade tumors during year 1 in order to allow for longer followup times during        the life of the project. Dr. Jensen or Dr. Colman will identify and recruit patients for        participation and obtain informed consent.|December 2015|December 21, 2015|December 16, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813566||145714|
NCT00814801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010297|An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease|Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia||Janssen Pharmaceutical K.K.|No|Completed|February 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|580|||Both|45 Years|N/A|No|||March 2014|March 31, 2014|December 24, 2008||No||No|March 13, 2012|https://clinicaltrials.gov/show/NCT00814801||145620|
NCT00814502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001434/1|Zolpidem CR and Hospitalized Patients With Dementia|Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study||Massachusetts General Hospital|Yes|Completed|December 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|60 Years|N/A|No|||December 2013|December 19, 2013|December 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814502||145642|
NCT00815035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2315|Oral Immunotherapy (OIT) for Peanut Allergy|Oral Immunotherapy for Peanut Allergy- Peanut Oral Immunotherapy (PnOIT3)|PnOIT3|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|April 2009|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|1 Year|6 Years|No|||October 2015|October 6, 2015|December 26, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00815035||145602|
NCT00815048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAIN|Remifentanil and Atropine for Intubation in Neonates|Remifentanil and Atropine for Intubation in Neonates; a Randomized Controlled Trial|RAIN|King Saud University|Yes|Completed|January 2006|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|N/A|N/A|No|||December 2008|December 26, 2008|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815048||145601|
NCT00815061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC085095CTIL|Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population|Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population||Rabin Medical Center|No|Recruiting|July 2008|December 2014|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Crohn's and ulcerative colitis patients|December 2012|December 2, 2012|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815061||145600|
NCT00815074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU0001-08-1-TS11|Military Women's Health and Illness Behaviors in Deployed Settings|||Wilford Hall Medical Center|No|Not yet recruiting||||||N/A|Observational|Time Perspective: Retrospective||1|||||Female|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|A total of 50 military women.|December 2008|December 24, 2008|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815074||145599|
NCT00815308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDRTC-0901|Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma|An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)|EXCEL|Shandong Cancer Hospital and Institute|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|70 Years|No|||July 2009|February 4, 2011|December 29, 2008||No||No|October 15, 2010|https://clinicaltrials.gov/show/NCT00815308||145581|
NCT00815568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-020|Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)|Prospective Phase II Clinical Trial of Myeloablative Conditioning Regimen With Fludarabine and Busulfan Plus 400 cGy Total Body Irradiation for Hematologic Malignancies||Samsung Medical Center|Yes|Recruiting|August 2008|December 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|114|||Both|15 Years|65 Years|No|||December 2008|December 29, 2008|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815568||145561|
NCT00815581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8728|Comparison of Photorefraction With Cycloautorefraction and Cycloretinoscopy at Emam Hosein Medical Centre in 2008-2009|Comparison of Photorefraction With Cycloautorefraction and Cycloretinoscopy at Emam Hosein Medical Centre in 2008-2009||hahid Beheshti University of Medical Sciences|Yes|Completed|May 2008|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|1||||||Both|1 Year|10 Years|No|||December 2008|April 7, 2010|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815581||145560|
NCT00815633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0514|A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris|A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris.||Icahn School of Medicine at Mount Sinai|Yes|Terminated|December 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|N/A|No|||November 2009|November 9, 2009|December 29, 2008|Yes|Yes|Failed to enroll patients|No||https://clinicaltrials.gov/show/NCT00815633||145556|
NCT00815971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080012 (ethics committee)|Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib|Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib||Aarhus University Hospital|Yes|Recruiting|May 2008|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|a fine neddle biopsi taken when the diagnosis non-small cell lung carcinoma was made +      severals blood samples taken before and during treatment with erlotinib.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-small cell lung cancer who will start treatment with erlotinib|December 2008|December 30, 2008|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00815971||145530|
NCT00816218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-5014-401|Molecular Mechanisms of Type 2 Diabetes Mellitus|Molecular Mechanisms of Endothelial Dysfunction in Type 2 Diabetes Mellitus||The University of Texas Health Science Center at San Antonio|No|Completed|March 2003|November 2008|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|39|||Both|18 Years|65 Years|No|||May 2012|May 30, 2012|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00816218||145511|
NCT00816231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14671|Drug /Cue Interactions In Alcohol-Tobacco Comorbidity|Drug /Cue Interactions In Alcohol-Tobacco Comorbidity||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|May 2006|October 2016|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|244|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816231||145510|
NCT00844714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RITUXANFMD|Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy|Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy||University of California, San Francisco|No|Completed|November 2009|December 2014|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|February 12, 2009|No|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00844714||143347|
NCT00844727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01/01|Coxib-inhibition of Duodenal Polyp Growth in FAP|Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis||Oslo University Hospital|No|Terminated|September 2003|April 2004|Actual|April 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|70 Years|No|||February 2009|July 3, 2011|February 13, 2009|||Drug withdrawal|No||https://clinicaltrials.gov/show/NCT00844727||143346|
NCT00844974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-p-001665|Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms|Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder Depressed Type: Prevalence and Symptoms With Treating of Depressive Symptoms||Massachusetts General Hospital|No|Completed|December 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|May 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00844974||143327|
NCT00816972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04258|Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)|Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip||Merck Sharp & Dohme Corp.|No|Completed|April 2005|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|540|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00816972||145453|
NCT00816985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14728|Liposuction for Arm Lymphedema Following Breast Cancer Surgery|Liposuction for Arm Lymphedema Following Breast Cancer Surgery||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|7|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00816985||145452|
NCT00813267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fuzhough1221|Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head|Mesenchymal Stem Cell Transplantation in the Treatment of Osteonecrosis of the Femoral Head||Fuzhou General Hospital|Yes|Active, not recruiting|December 2009|August 2015|Anticipated|August 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|12 Years|60 Years|No|||October 2012|October 6, 2012|December 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00813267||145736|
NCT00817245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-47|Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)|Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR)|ICSCR|Tabriz University|Yes|Completed|March 2008|January 2009|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|28 Years|40 Years|No|||January 2009|January 5, 2009|January 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00817245||145432|
NCT00817518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21189|A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors|An Open-label, Dose-escalation Study With Extension to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO4987655, a MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors||Hoffmann-La Roche||Completed|January 2009|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00817518||145411|
NCT00813254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0611|Cost Utility Analysis in Recurrent Ovarian Cancer|Quality of Life and Cost Utility Analysis in the Treatment of Recurrent, Platinum-Resistant Ovarian Cancer||M.D. Anderson Cancer Center|No|Withdrawn|December 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Female|N/A|N/A|No|Probability Sample|Female study participants that were diagnosed with Ovarian Cancer that are now        "Platinum-Resistant."|April 2012|April 18, 2012|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813254||145737|
NCT00813579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212|Study of Prospective Assessment of Living Kidney Donors: Pre and Post Donation|Study of Prospective Assessment of Living Kidney Donors:Pre and Post Donation||Mansoura University|Yes|Enrolling by invitation|January 2008|January 2011|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|21 Years|65 Years|No|Probability Sample|A prspective one arm study of 80 live kidney donors . Pre and post donation        evaluation(clinical evaluation BLOOD PRESURE BMI, Laboratory evaluaion of renal hepatic        functions ,lipid profil, blood sugar, complet blood count,urinanalysis for protein        creatinine ratio ,psychological assesment and renal ultrasound for kidney size and any        abnormality at 3,6,12,24 months post donation.|December 2008|December 22, 2008|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813579||145713|
NCT00813592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI26519|Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma|A Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Who Have Previously Undergone or Are Not Candidates for Additional Surgery or Radiation||University of Utah|Yes|Terminated|November 2008|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|November 17, 2008|Yes|Yes|Original PI left and company withdrew support.|No|April 2, 2014|https://clinicaltrials.gov/show/NCT00813592||145712|
NCT00813891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHC - 1234 - RVH|Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration|Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration||McGill University Health Center|No|Not yet recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|50 Years|N/A|No|||December 2008|December 22, 2008|December 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813891||145689|
NCT00819832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0593|Anderson Circulating Tumor Cell Burden (CTCB) Study|Assessment of Circulating Tumor Cell Burden After Radiofrequency-Based Plasma Ablation (COBLATION®) in Conjunction With Vertebroplasty or Kyphoplasty for Augmenting Painful Vertebral Compression Fractures Secondary to Malignancy||M.D. Anderson Cancer Center|Yes|Terminated|December 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|3|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|January 7, 2009||No|Terminated by sponsor.|No|August 16, 2010|https://clinicaltrials.gov/show/NCT00819832||145236|
NCT00820313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPMC-26.096SLH|A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers|Coronary Events, Risk Factors, and Quality of Life in Men and Women Enrolled in Intensive Lifestyle Interventions - A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers||Preventive Medicine Research Institute|No|Active, not recruiting|October 2006|May 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|131|||Both|21 Years|N/A|No|||January 2009|January 9, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820313||145201|
NCT00820599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-04|PREVAIL EU: Transfemoral Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)|PREVAIL EU Transfemoral Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (EUROPE)|PREVAIL|Edwards Lifesciences|Yes|Active, not recruiting|December 2008|December 2015|Anticipated|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|213|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820599||145179|
NCT00821158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 25-11-2008|The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study|The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study||Maastricht University Medical Center|Yes|Not yet recruiting|February 2009|||February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|30|||Female|18 Years|N/A|No|||January 2009|January 12, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821158||145136|
NCT00821184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-083|Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder|A Prospective Randomized Trial of Behavioral Modification and Solifenacin (Vesicare)vs Solifenacin (Vesicare) Alone for the Treatment of Urge Incontinence in Patients With an Overactive Bladder||Lahey Clinic|No|Terminated|September 2006|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Female|18 Years|80 Years|No|||July 2010|July 29, 2010|January 9, 2009|No|Yes|Insufficient subject availability/findings for data analysis|No|December 4, 2009|https://clinicaltrials.gov/show/NCT00821184||145135|
NCT00819195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03877|Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis|Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis||University of California, San Francisco|No|Completed|December 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|17|Samples Without DNA|Peripheral blood mononuclear cells (PBMC) Serum RNA|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Relapsing-remitting multiple sclerosis patients at the UCSF Multiple Sclerosis Center.|October 2013|October 4, 2013|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00819195||145284|
NCT00819208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO21|Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer|A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)||Canadian Cancer Trials Group|Yes|Recruiting|December 2008|December 2030|Anticipated|December 2029|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|962|||Both|18 Years|N/A|No|||November 2015|March 22, 2016|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819208||145283|
NCT00820092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xerecept: CPDS 0805|Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers|A Phase 1,Dose Escalation Study to Compare the Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Profiles of the 24-hour Intravenous Administration of Xerecept in Healthy Japanese and Caucasian Adult Volunteers||Celtic Pharma Development Services|Yes|Completed|December 2008|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|38|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|December 14, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820092||145217|
NCT00821548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-CIR-01|Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patients|||Centre Hospitalier Universitaire de Nice|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||January 2009|January 12, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821548||145107|
NCT00822393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-FludT.14/L|Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)|Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens||medac GmbH|Yes|Recruiting|November 2008|March 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|960|||Both|18 Years|70 Years|No|||December 2015|December 18, 2015|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822393||145043|
NCT00818857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 00025557|Primary Care Based Randomized Trial to Reduce Cancer Screening Disparities|Primary Care Based Randomized Trial to Reduce Cancer Screening Disparities|Get Screened|University of Rochester|No|Enrolling by invitation|January 2009|||October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2000|||Both|40 Years|75 Years|No|||June 2013|June 17, 2013|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818857||145309|
NCT00818870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCT006|Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH|A Randomized, Open-Label, Cross-Over, Dose-Ranging Study to Assess the Effect of Vecam 40/300 and Vecam 20/300 Administered at Bedtime Compared to Omeprazole 20 mg Administered Before Breakfast on Gastric pH||Vecta Ltd.|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 26, 2010|January 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00818870||145308|
NCT00807625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F071227004|Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia|Mucosal and Systemic Responses to Contraceptives in HIV-Infected Women in Zambia|MSRC|University of Alabama at Birmingham|No|Completed|November 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|66|||Female|16 Years|N/A|No|||July 2012|July 12, 2012|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807625||146166|
NCT00808171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE0450020300008|Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture|Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture||Federal University of Minas Gerais|Yes|Completed|February 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|52|||Both|4 Years|14 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808171||146125|
NCT00808145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-108|Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)|A Phase II Study of Sorafenib With Gemcitabine/Cisplatin in Advanced Hepatocellular Carcinoma||Lahey Clinic|No|Withdrawn|February 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||October 2014|October 21, 2014|December 11, 2008|Yes|Yes|Lack of enrollment, many screen failures and non eligible study participants|No||https://clinicaltrials.gov/show/NCT00808145||146127|
NCT00818779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tekturna 1|Direct Renin Inhibition Effects on Atherosclerotic Biomarkers|Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Heart Disease and Type 2 Diabetes Mellitus||Texas Tech University Health Sciences Center|Yes|Completed|January 2008|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|85 Years|No|||October 2012|October 18, 2012|January 6, 2009||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00818779||145315|Small sample size led to large standard deviation in biomarkers assessed and limited power to detect a diffference
NCT00819143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090062|Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease|Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease||National Institutes of Health Clinical Center (CC)||Completed|December 2008|July 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|3|||Both|18 Years|N/A|No|||July 2011|September 26, 2015|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819143||145288|
NCT00819429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/1170/2008|Supplements and Social Skills Intervention Study|A Nutritional and Social Skills Intervention on Conduct Disorder and Hyperactivity|SASSI|National Healthcare Group, Singapore|Yes|Completed|September 2009|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|282|||Both|7 Years|16 Years|No|||May 2015|May 13, 2015|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819429||145266|
NCT00819442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N N402196135|Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis|Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis.|DESMIN|Ministry of Scientific Research and Information Technology, Poland|Yes|Not yet recruiting|January 2009|June 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|65 Years|No|||January 2009|January 8, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819442||145265|
NCT00819715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0244-07-MMC|Electrogastrography in Small for Gestational Age Preterm Infants|Electrogastrography in Small for Gestational Age Preterm Infants Compared to Appropriate for Gestational Age Infants||Meir Medical Center|Yes|Completed|June 2008|||January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|N/A|2 Days|No|Probability Sample|Preterm infants >31 weeks, - 37 weeks , healthy, on enteralfeeds|June 2009|October 10, 2010|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819715||145245|
NCT00819728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP56976_US1_203|Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer|Multicenter Phase II Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer||Sanofi||Completed|June 2000|January 2003|Actual|||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2011|January 10, 2011|January 7, 2009||||||https://clinicaltrials.gov/show/NCT00819728||145244|
NCT00820053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-014-2|A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection|Eastern Hepatobilliary Surgical Hospital||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|January 2009|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2009|January 10, 2009|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00820053||145219|
NCT00820612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00022847|Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients|A Prospective, Randomized, Controlled Trial of Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients.||University of Michigan|Yes|Terminated|January 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|602|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|January 9, 2009|No|Yes|Stopped by DSMB for overwhelming benefit of indomethacin (unethical to withhold indomethacin    from patients)|No|January 10, 2013|https://clinicaltrials.gov/show/NCT00820612||145178|
NCT00820937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I04014|Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI)|Interest of the Combination of the DaTSCAN Scintigraphy and MRI Scan in the Differential Diagnosis of Lewy Body Dementia From Alzheimer Disease in Patients With Hallucinations|DatScan|University Hospital, Limoges|No|Completed|March 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Actual|20|||Both|65 Years|90 Years|No|||August 2009|August 26, 2009|December 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00820937||145153|
NCT00818194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-012|Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers|A Comparison of Effects of Short-term Low Dose Exposure of Advagraf® and Neoral® Microemulsion Cyclosporine A on Renal Perfusion and Function in Healthy Volunteers||Astellas Pharma Inc|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|January 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00818194||145360|
NCT00818207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051116|Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit|A Pragmatic, Randomized, Controlled Study Evaluating The Impact Of Access To Smoking Cessation Treatment Reimbursement On The Proportion Of Successful Quitters In A Canadian Population Of Smokers Motivated To Quit|ACCESSATION|Pfizer|No|Completed|March 2009|September 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1380|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|January 6, 2009|No|Yes||No|February 29, 2012|https://clinicaltrials.gov/show/NCT00818207||145359|
NCT00819780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070509|PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors|A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer||Amgen||Active, not recruiting|April 2009|April 2016|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|November 6, 2008|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT00819780||145240|
NCT00819793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-002|CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass|Thoratec CentriMag VAS Failure-to-Wean From Cardiopulmonary Bypass Trial||Thoratec Corporation|Yes|Completed|October 2008|September 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819793||145239|
NCT00820651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAMEL_NASH-09|Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis|Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study||Catalysis SL|Yes|Completed|November 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|70 Years|No|||April 2012|April 25, 2012|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820651||145175|
NCT00820664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-122|A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women|A Randomized Clinical Trial to Evaluate the Effects of Estrogen on Uterine Endometrium in Healthy Postmenopausal Women||Merck Sharp & Dohme Corp.|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|29|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 8, 2009|No|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT00820664||145174|The registered secondary outcome: "Mean gene expression intensity after 4 weeks of either 0.5 or 2 mg Estrace compared to placebo" results are not available because of inadequate quantity and quality of tissue samples that were obtained.
NCT00822107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00004529|A Translational Approach to Gitelman Syndrome|A Translational Approach to Gitelman Syndrome||Oregon Health and Science University|No|Not yet recruiting|January 2009|||January 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|21 Years|60 Years|No|||January 2009|January 13, 2009|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00822107||145065|
NCT00822120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000630501|S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma|A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging||Southwest Oncology Group|No|Active, not recruiting|July 2009|April 2020|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|230|||Both|18 Years|60 Years|No|||May 2015|May 8, 2015|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822120||145064|
NCT00816010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telephone intervention|Telephone Intervention in Patients With Acute Coronary Syndrome (ACS) and Diabetes|A Multicentre, Randomised Study to Examine the Effects of Telephone Intervention in Patients With Coronary Heart Disease and Diabetes||Chinese University of Hong Kong|No|Terminated|July 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|137|||Both|45 Years|N/A|No|||February 2012|February 20, 2012|December 30, 2008||No|Due to lack of manpower at the various study sites|No||https://clinicaltrials.gov/show/NCT00816010||145527|
NCT00808431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080673|ST of TN-Salud Con La Familia: Prevent Onset of Ped Obesity|ST of TN-Salud Con La Familia: Prevent Onset of Ped Obesity||Vanderbilt University|No|Completed|July 2008|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|December 4, 2008||No||No||https://clinicaltrials.gov/show/NCT00808431||146105|
NCT00808444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111654|Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age|Non-inferiority of a Commercial Lot of the Pneumococcal Vaccine GSK1024850A Compared to a Clinical Lot.||GlaxoSmithKline||Completed|January 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|466|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||February 2011|February 6, 2014|December 11, 2008|Yes|Yes||No|October 25, 2010|https://clinicaltrials.gov/show/NCT00808444||146104|
NCT00808470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DC008423|Micronutrients to Prevent Noise-induced Hearing Loss|Micronutrient Intervention to Reduce Noise-Induced Hearing Loss: Prevention of Temporary Threshold Changes Induced by Use of a Digital Music Player||University of Michigan|Yes|Completed|October 2008|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|101|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00808470||146102|
NCT00804505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-0804 V1.0|Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study|A 90 Day Multi-Center, Randomized, Parallel Group Daily Wear Investigation of a New Hybrid Lens SynergEyes SA Manufactured With a Rigid Gas Permeable Center (Petrafocon A) and a Silicone Hydrogel Skirt (Larafilcon A) Compared to SynergEyes A (Paflufocon D Hem-iberfilcon A)||SynergEyes, Inc.|No|Completed|June 2008|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 22, 2009|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00804505||146398|
NCT00818792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENAL-DES|Randomized Comparison of xiEnce and visioN Coronary Stents in the sAme muLtivessel Patient With Chronic kiDnEy diSease|A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease|RENAL-DES|European Hospital|Yes|Completed|January 2009|September 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|85 Years|No|||January 2013|January 14, 2013|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00818792||145314|
NCT00819156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS12|Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer|An Open-label, Randomised, Multi-centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months||Ferring Pharmaceuticals|Yes|Completed|February 2004|September 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|189|||Male|18 Years|N/A|No|||December 2011|December 20, 2011|January 7, 2009|Yes|Yes||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00819156||145287|
NCT00819455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT001IDRF-IC|Use of Information Technology in the Prevention of Diabetes|The Role of Information Technology in the Primary Prevention of Type 2 Diabetes||India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals|Yes|Completed|March 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|537|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819455||145264|
NCT00819468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-017|Pharmacokinetics of 20 mg Teduglutide in Subjects With Moderately Impaired Hepatic Function Compared to Healthy Subjects With Normal Hepatic Function|Pharmacokinetics of 20 mg Teduglutide in Subjects With Moderately Impaired Hepatic Function Compared to Healthy Subjects With Normal Hepatic Function||NPS Pharma|No|Completed|July 2007|December 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2009|January 8, 2009|January 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00819468||145263|
NCT00819741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3705|Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs|A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients||Novo Nordisk A/S|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|433|||Both|18 Years|75 Years|No|||June 2012|June 5, 2012|January 8, 2009|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT00819741||145243|
NCT00820950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-201|A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis|A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis||Incyte Corporation|No|Completed|May 2007|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|29|||Both|18 Years|75 Years|No|||March 2012|March 13, 2012|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820950||145152|
NCT00813683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3993|Cephalic Version by Acupuncture for Breech Presentation|Study of Cephalic Version by Acupuncture for Breech Presentation.||University Hospital, Strasbourg, France|No|Completed|February 2008|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|259|||Female|18 Years|N/A|No|||December 2008|October 19, 2015|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813683||145705|
NCT00820339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-002|Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy|Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy About Recurrence and Survival :A Prospective Randomized Trial|SHVE|Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|January 2009|November 2012|Anticipated|December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|70 Years|No|||January 2009|January 9, 2009|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820339||145199|
NCT00821535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001084|Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers|An Open Label Single Dose Study To Investigate Safety And Pharmacokinetics Of Maraviroc Following A Single Oral Dose Of 300 Mg Maraviroc (Two 150 Mg Maraviroc Commercial Tablets) Under Fasting Conditions In Healthy Male Japanese Volunteers||ViiV Healthcare|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 15, 2010|January 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00821535||145108|
NCT00821808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0500-08-U347|A Pressure Relted Study Comparing a Compression Device and Profore® on Healthy Volunteers|A Phase I, Randomized, Open-label, One-arm, Active Controlled Study to Evaluate the Pressure Interface Between Device and Skin of a Compression Device and Profore® on Healthy Volunteers||ConvaTec Inc.|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 12, 2015|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821808||145088|
NCT00818818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lowdoseaging|Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients|Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial.|Sbold|University of Brasilia|No|Completed|August 2008|April 2010|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|65 Years|N/A|No|||October 2010|October 7, 2010|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818818||145312|
NCT00818831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QBI-139 -101|A Study of QBI-139 in Subjects With Advanced Solid Tumors|Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients With Refractory Malignancies||Quintessence Biosciences, Inc.||Active, not recruiting|January 2009|||October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00818831||145311|
NCT00820352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO-001|Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension|Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension|BADDHY|University Teaching Hospital Hall in Tirol|No|Completed|January 2009|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||June 2014|June 27, 2014|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820352||145198|
NCT00820365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC12267-4-2008|SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease|Exploratory, Open-label Study to Demonstrate Efficacy, Safety and Tolerability of SC12267 (35 mg) in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)|ENTRANCE|4SC AG|Yes|Completed|March 2009|March 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|70 Years|No|||May 2011|May 17, 2011|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820365||145197|
NCT00821210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712052R|Obstructive Sleep Apnea and Acute Myocardial Infarction and the Role of Continuous Positive Airway Pressure (CPAP)Treatment|Obstructive Sleep Apnea and Acute Myocardial Infarction and the Role of CPAP Treatment: a Double -Blind, Randomized Control Trial||National Taiwan University Hospital|Yes|Completed|January 2008|November 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|N/A|No|||November 2010|November 30, 2010|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821210||145133|
NCT00815373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0155-08-MMC|The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)|A Comparative Analysis of the Effects of Cosopt® Versus Xalacom® on Ocular Hemodynamics and Intraocular Pressure in Patients With Primary Open-angle Glaucoma|Xal-Cos|Meir Medical Center|Yes|Withdrawn|December 2008|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|December 9, 2008|Yes|Yes|no participants recruded.|No||https://clinicaltrials.gov/show/NCT00815373||145576|
NCT00817830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIST001|Cardiovascular Safety Study of Lodenafil Carbonate in Patients With Coronaropathy During Physical Effort|Cardiovascular Safety Evaluation in Patients With Coronary Artery Disease During Physical Effort After Use Lodenafil Carbonate||Cristália Produtos Químicos Farmacêuticos Ltda.|Yes|Withdrawn|November 2008|October 2009||May 2009||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|60 Years|No|||June 2011|July 15, 2015|December 5, 2008||No|Difficulty in patient recruitment|No||https://clinicaltrials.gov/show/NCT00817830||145387|
NCT00817843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasc-UMCU-10B|The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study|Multicenter,Double Blind,Randomized, 2-period, Crossover Study to Compare Ezetimibe/Simvastatin (10mg/10 mg) Combination Tablet Versus Simvastatin 80mg Tablet on Postprandial Arterial Endothelial Function in Patients With Metabolic Syndrome|PANACEA|UMC Utrecht|No|Completed|April 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|79 Years|No|||January 2013|January 4, 2013|January 6, 2009||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT00817843||145386|One limitation is that the study was conducted in obese patients with the metabolic syndrome.
NCT00817869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13247|The HIP-HOP Flooring Study: Helping Injury Prevention in Hospitalised Older People|Pilot Cluster Randomised Controlled Trial of Flooring to Reduce Injuries From Falls in Elderly Care Units||University of Portsmouth|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|571|||Both|N/A|N/A|No|||November 2014|November 28, 2014|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00817869||145385|
NCT00816517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808M45282|Use of Botulinum Toxin to Treat Psoriasis|Pilot Study on the Safety and Efficacy of Botulinum Toxin Injections in the Treatment of Psoriasis Vulgaris.||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|January 2009|December 2015|Anticipated|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|December 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00816517||145488|
NCT00807911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-0256|Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer|Randomized Phase II Study of Adjuvant Chemotherapy With 5-FU/Leucovorin vs. Oxaliplatin/5-FU/Leucovorin After Preoperative Chemoradiotherapy With Fluoropyrimidines Followed by Surgery in Patients With Locally Advanced Rectal Cancer||Asan Medical Center|Yes|Active, not recruiting|November 2008|December 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00807911||146145|
NCT00796237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW-08-032|Effects of Whole Body Vibration in Subacute Stroke Patients|Effects of Whole Body Vibration Training on Bone Health, Physical Fitness, and Neuromotor Performance in Individuals With Subacute Stroke: a Randomized Controlled Trial||The Hong Kong Polytechnic University|Yes|Recruiting|May 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796237||147025|
NCT00796250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02732|Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)|Efficacy of Infliximab as "Bridging Therapy" in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine||Merck Sharp & Dohme Corp.|No|Terminated|November 2003|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||April 2015|April 21, 2015|November 21, 2008|No|Yes|Due to poor patient recruitment, a decision was made to terminate this trial.|No||https://clinicaltrials.gov/show/NCT00796250||147024|
NCT00808457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2055-06/07|Role of Chest Ultrasound in Diagnosing and Follow-up of Pneumonia|Role of Chest Ultrasound in Diagnosing and Follow-up of Pneumonia. Prospective Comparison Between X-ray Chest Film in Two Planes and "Low-dose" Spiral Computed Tomography||University of Jena|No|Completed|September 2007|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|397|||Both|18 Years|N/A|No|Probability Sample|Patients with clinically suspected community-acquired pneumonia.|August 2011|August 12, 2011|December 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00808457||146103|
NCT00819182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803-13|Breathe for Hot Flashes Randomized Controlled Trial|Breathe-intervention for Hot Flashes, Associated Outcomes, and Interference||Indiana University|Yes|Completed|April 2008|February 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|218|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|January 7, 2009||No||No|May 1, 2013|https://clinicaltrials.gov/show/NCT00819182||145285|
NCT00819169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070411|AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors|A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors||Amgen||Terminated|January 2009|October 2011|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|89|||Both|16 Years|N/A|No|||September 2015|September 16, 2015|January 6, 2009|Yes|Yes|Sponsor decision - subjects rolled over to protocol 20101116|No||https://clinicaltrials.gov/show/NCT00819169||145286|
NCT00819481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 700|Post-Market Study of the 3DKnee™ System|Post-Market Study of the 3DKnee™ System Protocol No. PS -- 700||Encore Medical, L.P.|No|Active, not recruiting|February 2009|December 2017|Anticipated|January 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are over 18 years of age and are candidates for a primary total knee        replacement.|January 2016|January 19, 2016|January 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00819481||145262|
NCT00819754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0TT 03-03|A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer|A Phase I/II Clinical Trial of Combination of Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen With Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer|IXO+A|Ottawa Hospital Research Institute|Yes|Terminated|November 2003|May 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819754||145242|
NCT00820040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hern06R2|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2009|||||N/A|N/A|N/A||||||||||||||July 15, 2015|January 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820040||145220|
NCT00813696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIP-1|Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer|Gemcitabine vs Gemcitabine + Cisplatin in the Treatment of Advanced Pancreatic Cancer (Stage II III IV)|GIP-1|Istituti Tumori Giovanni Paolo II|No|Active, not recruiting|April 2002|September 2009|Anticipated|March 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|75 Years|No|||December 2008|December 22, 2008|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813696||145704|
NCT00821197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-0910-ST|Long-limb or Distal Gastric Bypass for Superobesity - Randomized Study|Long -Limb Gastric or Distal Gastric Bypass in the Treatment of Super Obese Patients - a Prospective Randomized Study||Oslo University Hospital|No|Active, not recruiting|February 2011|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|20 Years|60 Years|No|||October 2015|October 24, 2015|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821197||145134|
NCT00821522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3401|The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery|The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery||Maine Medical Center Research Institute|No|Enrolling by invitation|November 2008|May 2010|Anticipated|March 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||April 2010|July 21, 2010|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00821522||145109|
NCT00822094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTR0308-205|Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)|Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration||Celator Pharmaceuticals|No|Completed|February 2009|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|65 Years|No|||February 2013|February 20, 2013|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822094||145066|
NCT00822380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNN2002-07|Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children|Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children: A Randomized Clinical Trial||Universidad Autonoma de Queretaro|No|Completed|March 2003|November 2004|Actual|November 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|680|||Both|6 Months|42 Months|Accepts Healthy Volunteers|||January 2009|January 13, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822380||145044|
NCT00819520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-00|Ivermectin in the Treatment of Head Lice|A Randomised, Double-Blind, Multicentre Study to Compare the Efficacy and Tolerability of Oral Ivermectin to Malathion 0.5% Lotion in the Treatment of Head Lice Infestation||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2004|October 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|812|||Both|2 Years|N/A|No|||August 2011|August 19, 2011|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819520||145259|
NCT00814840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SilesianCHD-KNW-6501-3/08|Efficiency Study of Triple-Site Cardiac Resynchronization in Patients With Heart Failure|Triple-Site Versus Standard Cardiac Resynchronization Therapy (TRUST CRT) Randomized Trial|TRUST CRT|Silesian Centre for Heart Diseases|Yes|Active, not recruiting|February 2008|January 2015|Anticipated|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00814840||145617|
NCT00815139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0409|Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography|Evaluation in 3 moNths Duration of nEointimAl coVerAge After zOtaRolimus-Eluting Stent Implantation by Optical Coherence Tomography (ENDEAVOR OCT)|ENDEAVOR OCT|Yonsei University|No|Completed|February 2008|||November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples With DNA|Blood|Both|18 Years|80 Years|No|Non-Probability Sample|Patients who present to the cath lab for non-emergent percutaenous coronary intervention        and stenting are eligible for participation|December 2008|December 26, 2008|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815139||145594|
NCT00815659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00079|Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome|Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT)|EFFORT|AstraZeneca|No|Completed|December 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|69 Years|No|||August 2011|August 29, 2011|December 29, 2008||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00815659||145554|
NCT00815672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1703DOD|Exercise for Prostate Cancer Patients|The Influence of Home-based Aerobic and Resistance Exercise on Cancer-Related Fatigue, Strength, and Muscle Mass in Prostate Patients.|EXCAP|University of Rochester|Yes|Active, not recruiting|December 2007|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|122|||Male|21 Years|N/A|No|||November 2015|November 4, 2015|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815672||145553|
NCT00816023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECAL-PCPB-08-02|A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume|CONSERV-1 (Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) A Phase 2 Randomized Placebo-controlled Dose-ranging Study in Subjects Exposed to Cardio-pulmonary Bypass During Primary Coronary Artery Bypass Graft Surgery|CONSERV-1|Cubist Pharmaceuticals LLC|Yes|Completed|March 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|276|||Both|18 Years|85 Years|No|||July 2015|July 21, 2015|December 29, 2008|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00816023||145526|Secondary efficacy variables were considered exploratory and, based on failure of the primary endpoint to meet statistical significance and early termination of the trial, are not presented.
NCT00815646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003158|Prevention and Treatment of Immersion Pulmonary Edema|Effects of the Dive Reflex on Pulmonary Arterial and Pulmonary Artery Wedge Pressures in Subjects Who Have Experienced Immersion Pulmonary Edema||Duke University|No|Completed|January 2008|December 2015|Actual|December 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|December 26, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00815646||145555|
NCT00816829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C LF178P 05 01|Effect of Fenofibrate on Sleep Apnea Syndrome|A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome||Solvay Pharmaceuticals|No|Terminated|September 2005|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|No|||July 2009|July 17, 2009|January 2, 2009||No|The study was prematurely terminated because of slow recruitment|No|January 8, 2009|https://clinicaltrials.gov/show/NCT00816829||145464|Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and includes events started prior to the 1st administration but which worsened after the 1st intake.
NCT00808184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK01/16/08|Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype|Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype||National University Hospital, Singapore|No|Completed|April 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|21 Years|N/A|No|||April 2010|October 31, 2012|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00808184||146124|
NCT00796263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAART for Acute HIV infection|Antiretroviral Therapy for Acute HIV Infection|Antiretroviral Therapy for Acute HIV Infection|AAHIV|South East Asia Research Collaboration with Hawaii|No|Recruiting|April 2009|July 2021|Anticipated|April 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 6, 2016|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796263||147023|
NCT00796666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321003|Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil|A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (NCT00795639)||Pfizer|Yes|Terminated|May 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|131|||Both|16 Years|80 Years|No|||March 2015|March 4, 2015|November 20, 2008|Yes|Yes|Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,    specifically new emerging evidence of hepatic injury.|No|January 26, 2012|https://clinicaltrials.gov/show/NCT00796666||146993|Study terminated early by sponsor, no Week 48 information collected.
NCT00796939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068545|Effects of Light Treatment During Sleep on Young Men|Randomized, Placebo-Controlled Trial of Short Wavelength Light Administered Just Prior to Waking in Young Men||University of California, San Diego|No|Completed|March 2006|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Male|25 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00796939||146972|
NCT00820976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLG-AML-95-002|Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML|A Phase III, Randomized Multicenter Study of Induction With or Without Granulocyte Colony-Stimulating Factor in AML|TLG-AML-95-002|Turkish Leukemia Study Group|Yes|Completed|March 1996|January 2009|Actual|March 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|16 Years|N/A|No|||January 2009|January 9, 2009|January 9, 2009||||No||https://clinicaltrials.gov/show/NCT00820976||145150|
NCT00821223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009|Outcome Following Phacoemulsification Versus Small Incision Cataract Surgery (SICS)|Comparison of Phacoemulsification Versus Manual Small Incision Cataract Surgery (SICS) : A Randomized Control Trial||Iladevi Cataract and IOL Research Center|Yes|Completed|February 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|420|||Both|50 Years|65 Years|No|||May 2010|May 18, 2010|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00821223||145132|
NCT00821561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEX-PED-001|A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects|A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon® in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.||CoDa Therapeutics Inc.|No|Withdrawn|March 2009|March 2010|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|90|||Both|18 Years|N/A|No|||February 2010|February 24, 2010|January 10, 2009|No|Yes|Withdrawn prior to recruitment for business reasons.|No||https://clinicaltrials.gov/show/NCT00821561||145106|
NCT00822406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|marcus@homeozulian.med.br|Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis|Quantitative-Qualitative Clinical Trial to Evaluate the Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis||University of Sao Paulo|Yes|Completed|July 2002|December 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|80 Years|No|||January 2009|January 26, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822406||145042|
NCT00822419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0251-08-TLV|Percutaneous Ketamine Versus Lidocaine for Mid-Sternotomy|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2009|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|No|||January 2009|January 13, 2009|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822419||145041|
NCT00819234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA102E|Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin|Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin in Obese and Overweight Subjects||AstraZeneca|No|Completed|November 2008|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|274|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|December 24, 2008|Yes|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT00819234||145281|
NCT00813709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28981|Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)|Double-blind Extension of the Study 27025 (REFLEX) to Obtain Long-term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New Formulation (REFLEXION)|REFLEXION|Merck KGaA||Completed|December 2008|September 2013|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|402|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|December 22, 2008||No||No|November 27, 2012|https://clinicaltrials.gov/show/NCT00813709||145703|
NCT00813722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMEPA|Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment|Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial||University of Sao Paulo|No|Active, not recruiting|March 1999|June 2009|Anticipated|January 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|400|||Both|18 Years|N/A|No|||December 2008|December 19, 2008|December 17, 2008||No||No||https://clinicaltrials.gov/show/NCT00813722||145702|
NCT00821821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-186-E04|Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke|A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|February 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|40 Years|80 Years|No|||April 2014|April 7, 2014|January 13, 2009||No||No|January 5, 2014|https://clinicaltrials.gov/show/NCT00821821||145087|
NCT00822081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM0501|Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension|||Bp Consulting, Inc|No|Completed|January 2005|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|140|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|January 12, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00822081||145067|
NCT00818558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-APN-08|The Method ISET (Insulation by Size of Epithelial Tumor Cells)|Evaluation of the Value Forecasts of the Identification of the Circulating Tumoral Cells (CTC) in the Broncho-lung Carcinomas Not in Small Cells of Stages I and II by the Method ISET (Insulation by Size of Epithelial Tumor Cells)||Centre Hospitalier Universitaire de Nice||Recruiting|October 2008|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|520|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818558||145332|
NCT00818571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237B2202|Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients|An Open-label, Parallel Group Study to Determine the PK of 25 and 50 mg OD Single and Multiple Dose Over 14 Days, of Vildagliptin and Its Metabolites in Renal Impaired Patients Compared to Matching Healthy Volunteers||Novartis||Completed|December 2008|||May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|96|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00818571||145331|
NCT00814541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-01 ICORG|PAD. ICORG 05-01, V11|Phase II Study to Assess the Safety, Efficacy, and Tolerability of Combination Therapy With Velcade (Bortezomib), Doxorubicin, and Dexamethasone (PAD) as Therapy for Patients With Relapsed or Refractory Multiple Myeloma||ICORG- All Ireland Cooperative Oncology Research Group||Completed|December 2005|December 2012|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|N/A|No|||January 2014|December 30, 2014|December 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814541||145639|
NCT00815152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012826|Coping With High Grade Glioma|Coping With High Grade Glioma||Duke University|Yes|Terminated|December 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|14|||Both|18 Years|N/A|No|||October 2010|May 3, 2013|December 26, 2008||No|PI transferred to new institution.|No||https://clinicaltrials.gov/show/NCT00815152||145593|
NCT00815386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-037P|Safety and Efficacy Study of the PTMA Device to Reduce Mitral Valve Regurgitation in Patients With Heart Failure|Safety and Efficacy of Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure|PTOLEMY2Canada|Viacor|Yes|Suspended|February 2009|December 2015|Anticipated|December 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|N/A|No|||February 2011|February 10, 2011|December 26, 2008||No|Company ended operations in January 2011|No||https://clinicaltrials.gov/show/NCT00815386||145575|
NCT00816036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-113|Improving the Delivery of Smoking Cessation Guidelines in Hospitalized Veterans|Improving the Delivery of Smoking Cessation Guidelines in Hospitalized Veterans||VA Office of Research and Development|Yes|Completed|May 2009|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|898|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 6, 2015|December 29, 2008||No||No|July 8, 2014|https://clinicaltrials.gov/show/NCT00816036||145525|
NCT00816270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1716/07|Liquid Bandage (2-Octyl-Cyanoacrylate) in Upper Lid Blepharoplasty|Comparison Between Liquid Bandage(2-Octyl-Cyanoacrylate)and Traditional Suture Closure in Upper Lid Blepharoplasty||Federal University of São Paulo|Yes|Terminated|April 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|11|||Both|25 Years|70 Years|No|||December 2008|December 31, 2008|December 31, 2008||No|Experimental results were unsatisfatory compared with control.|No||https://clinicaltrials.gov/show/NCT00816270||145507|
NCT00808483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/2325|Walking Skill Training Program Effects in Patients With Total Hip Arthroplasty|Effect of a Walking Skill Training Program in Patients Who Have Undergone Total Hip Arthroplasty: Followup One Year After Surgery||University of Oslo|Yes|Completed|October 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|45 Years|N/A|No|||January 2015|January 8, 2015|December 12, 2008||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT00808483||146101|
NCT00808756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAMBINOL|Study on Fermentable Carbohydrates in Healthy Infants|Study on Fermentable Carbohydrates in Healthy Infants|BAMBINOL|University Rovira i Virgili|Yes|Completed|September 2008|March 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|3||Actual|388|||Both|N/A|1 Month|Accepts Healthy Volunteers|||August 2012|August 7, 2012|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808756||146080|
NCT00808769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008122|Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression|Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression||Procter and Gamble|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|December 15, 2008|Yes|Yes||No|May 19, 2010|https://clinicaltrials.gov/show/NCT00808769||146079|Results of this study were uninterpretable as noted in the Analysis Population Description.
NCT00804544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-383|99mTc-MIBI SPECT/CT in Breast Malignancy|Tc-99m Sestamibi SPECT/CT for Prediction of the Response of Locally Advanced Breast Malignancy to Neoadjuvant Chemotherapy||Lawson Health Research Institute|No|Terminated|September 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|25 Years|90 Years|No|||March 2012|March 2, 2012|December 4, 2008||No|4 patients have been enrolled into the pilot study. No complications reported. Another    clinical trial has been designed.|No||https://clinicaltrials.gov/show/NCT00804544||146395|
NCT00797251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOUS-Compression|Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression|A Novel Simple Technique for Performing Anatomical Right Posterior Sectionectomy of the Liver: the Ultrasound-Guided Finger Compression||University of Milan|Yes|Active, not recruiting|September 2007|January 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|85 Years|No|Non-Probability Sample|The study population include patients with primary or secondary liver tumors in the right        posterior section of the liver eligible to a right posterior sectionectomy as a primary        surgical procedure.|November 2008|November 24, 2008|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797251||146950|
NCT00796679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-003|Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease|A Prospective, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Oral Paricalcitol in Retarding Cardiac Hypertrophy, Reducing Inflammation and Atherosclerosis in Stage 3 - 5 Chronic Kidney Disease||The University of Hong Kong|Yes|Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||May 2012|May 7, 2012|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796679||146992|
NCT00796965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1151C00001|Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects||AstraZeneca|No|Completed|December 2008|March 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 18, 2009|November 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00796965||146970|
NCT00821847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080202|Renal Function Assessment in HIV Patient|Markers of Glomerular Filtration Rate in the HIV Infected Patient - Role of Body Composition|HIVERS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|45|||Male|18 Years|N/A|No|Non-Probability Sample|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30        ml/min (estimated with cockcroft and Gault formulae)|June 2008|July 30, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00821847||145085|
NCT00822133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0250-08-TLV|Percutaneous Ketamine Versus Lidocaine or Placebo, for Post-Surgery Analgesia, in Patients Undergoing Laparoscopic Partial Lung Resection|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2009|December 2009|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|No|||January 2009|January 13, 2009|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822133||145063|
NCT00822146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_11|Cardiac Resynchronization Therapy (CRT) Efficacy Study|||Medtronic Bakken Research Center|No|Completed|December 2008|March 2013|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822146||145062|
NCT00822159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Densiprobe-08|Influence of Bone Strength Measured by DensiProbe on Bone Related Fixation Failure|Prospective Multicenter Cohort Study to Evaluate the Influence of Bone Strength Measured by DensiProbe Hip on Bone Related Fixation Failure in Patients With Hip Fractures Undergoing DHS Surgical Treatment.|Densiprobe|AO Clinical Investigation and Documentation|No|Terminated|November 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|198|||Both|50 Years|N/A|No|||October 2011|October 7, 2011|January 13, 2009||No|Interim analysis showed statistically significant results|No||https://clinicaltrials.gov/show/NCT00822159||145061|
NCT00820118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 141 TIPI|Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults|ARNS 141 TIPI : A Pilot Trial to Assess the Ability of an Intermittent Antiretroviral Therapy in Maintaining an Immunological Stability in Antiretroviral naïve HIV Infected Adults, With CD4 Count Above 500/mm3|TIPI|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|May 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820118||145215|
NCT00820391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIDNET2005|KIDNET Versus Meditation/Relaxation - a Dissemination RCTT for Children in Sri Lanka Traumatized by the War and the Tsunami|KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Treatment Trial for Children in Sri Lanka Traumatized by the War and the Tsunami||University of Konstanz|No|Completed|January 2005|October 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|8 Years|14 Years|No|||January 2009|January 9, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820391||145195|
NCT00819546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-269|RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS|A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819546||145257|
NCT00819559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRCSG1|Preoperative Chemoradiotheray for Rectal Cancer|Role of Preoperative Chemoradiotherapy in Clinically T3No Mid and Low Rectal Cancer : Multi-Institute Clinical Study||Korean Rectal Cancer Study Group|Yes|Not yet recruiting|March 2009|December 2016|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1160|||Both|18 Years|70 Years|No|||January 2009|January 8, 2009|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819559||145256|
NCT00813982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-335-C-009|Daily Wear Comparison of Enhanced and Non-Enhanced Silicone Hydrogel Lenses|Daily Wear Comparison of Enhanced and Non-Enhanced Silicone Hydrogel Lenses||Alcon Research||Completed|November 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||January 2011|June 26, 2012|December 22, 2008|Yes|Yes||No|September 3, 2010|https://clinicaltrials.gov/show/NCT00813982||145682|
NCT00813943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 121974-012|Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status|Cilengitide in Subjects With Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). [The CORE Study]|CORE|EMD Serono||Completed|March 2009|August 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|265|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|December 22, 2008|Yes|Yes||No|August 29, 2014|https://clinicaltrials.gov/show/NCT00813943||145685|
NCT00814229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL 08162|Safety and Immunogenicity of Influenza H9 Vaccine in Humans|Randomised Dose Ranging Observer Blind Single Centre Study to Evaluate Safety and Immunogenicity of Adjuvanted and Non-adjuvanted Influenza H9 Influenza Vaccine in Humans||University Hospitals, Leicester|Yes|Completed|August 2007|September 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|14||Actual|353|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 20, 2009|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814229||145663|
NCT00814242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-009|Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels|A Randomized Control Trial of Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|December 2008|November 2011|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||October 2008|March 24, 2009|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814242||145662|
NCT00814853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-07-0338|Electrical Activity of the Diaphragm During Extubation Readiness Testing|Electrical Activity of the Diaphragm During Extubation Readiness Testing|NAVA|Children's Hospital Boston|Yes|Recruiting|October 2008|March 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|18 Years|No|Non-Probability Sample|Anyone eligible for and extubation readiness test.|August 2009|August 3, 2009|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00814853||145616|
NCT00815399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMD/2007/10|Pioglitazone Versus Metformin in Type 2 Diabetes|Effect of Pioglitazone Compared With Metformin on Endothelial Microparticles in Type 2 Diabetes. A Randomized Trial||Second University of Naples|No|Completed|October 2007|April 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|30 Years|75 Years|No|||November 2015|November 17, 2015|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815399||145574|
NCT00815685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15190|A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia|A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 2007|August 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|25 Years|80 Years|No|||December 2013|December 13, 2013|December 29, 2008|Yes|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT00815685||145552|This was a Pilot Supportive Care Intervention.
NCT00816309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH003|Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?|Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?||NHS Lothian|No|Completed|October 2007|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|60 Years|85 Years|No|||July 2010|March 31, 2011|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816309||145504|
NCT00816283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08047|Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia|BMS CA180157: A Phase I Combination Study of Dasatinib Plus Vorinostat in Accelerated Phase, Chronic Phase Refractory to Second Line Therapy or Blast Crisis Chronic Myelogenous Leukemia (CML), and in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)||City of Hope Medical Center|Yes|Completed|September 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|December 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00816283||145506|
NCT00816296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/159|Evaluation of Intestinal Microbiome in Obese Kids|Evaluation of the Intestinal Microbiome in Obese Children With and Without Non-Alcoholic Fatty Liver Disease||Medical College of Wisconsin|No|Withdrawn|October 2008|October 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Participants will need to give a blood and stool samples on 3 separate occasions.|Both|5 Years|18 Years|No|Non-Probability Sample|Gastroenterology Clinic at Children's Hospital of Wisconsin|August 2015|August 21, 2015|December 30, 2008|No|Yes|PI has left institution|No||https://clinicaltrials.gov/show/NCT00816296||145505|
NCT00795678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4107|Chemotherapeutic Agents in Brain/Breast|Clinical Study to Assess Entry of Chemotherapeutic Agents Into Brain Metastases in Women With Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|September 2008|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Collection of blood before and after chemotherapy is administered and before and after      resection of tumor in the operating room. Analysis of small portions of the brain tumor      obtained at the time of craniotomy for drug collection.|Female|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from a population of breast cancer patients who are to undergo        clinically indicated surgical resection of one of more symptomatic brain metastasis(es)        treated at the investigational centers.|July 2013|July 31, 2013|November 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00795678||147067|
NCT00795951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEKOS 07 29P1/2/3/401|Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents|Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents||Allerderm|No|Completed|November 2008|November 2009|Actual|October 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Both|6 Years|18 Years|No|||December 2013|December 19, 2013|November 20, 2008|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00795951||147046|
NCT00797602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0607-CH01|Proton Therapy for Chordomas and/or Chondrosarcomas|A Clinical Outcomes Protocol of Proton Beam Radiation Therapy for Chordomas and/or Chondrosarcomas of the Base of Skull and/or Spine|CH01|University of Florida|No|Completed|January 2007|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|189|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated at a radiation oncology clinic|March 2016|March 3, 2016|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797602||146924|
NCT00797849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#871|Controlled Study of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees|A Randomized, Controlled Study to Evaluate the Effectiveness of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees||Southern California Institute for Research and Education|No|Completed|November 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|57|||Both|18 Years|N/A|No|||March 2012|March 12, 2012|November 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00797849||146905|
NCT00797576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-07-05-001|Detection of Left Atrial Appendage (LAA) Thrombus: Comparison of Cardiac Magnetic Resonance Imaging and Transesophageal Echocardiogram|Detection of Left Atrial Appendage Thrombus in Patients Referred For Cardioversion: Comparative Analysis of Cardiac Magnetic Resonance Imaging and Transesophageal Echocardiogram||Gundersen Lutheran Medical Foundation|No|Recruiting|June 2008|July 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study cases will consist of subjects referred for TEE prior to cardioversion who are        found to have LAA thrombus present. Control subjects will be patients referred for TEE        with chronic atrial fibrillation that will not be undergoing cardioversion. All subjects        will be patients from our facility, Gundersen Lutheran Health System, La Crosse, WI.|August 2009|June 21, 2010|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797576||146926|
NCT00817882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17891|Working Well With Back Pain (Feasibility RCT of Vocational Rehabilitation)|Changing Perceptions of Work Ability in People With Low Back Pain: Feasibility Randomised Controlled Trial and Economic Evaluation.||University of Nottingham|No|Completed|May 2009|August 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|52|||Both|16 Years|N/A|No|||November 2010|November 22, 2010|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00817882||145384|
NCT00818246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEDP-1|Light Emitting Diode (LED) for the Treatment of Wrinkles|Non-ablative Light Source for the Treatment of Rhytides (Wrinkles)||RoseLab Skin Optics Laboratory|No|Completed||||||Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2009|October 7, 2009|December 3, 2008||No||No|January 7, 2009|https://clinicaltrials.gov/show/NCT00818246||145356|
NCT00818259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-134|A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)|A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy||Merck Sharp & Dohme Corp.|No|Terminated|February 2009|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|92|||Both|N/A|17 Years|No|||April 2015|April 17, 2015|January 6, 2009|No|Yes|Study terminated early prior to completing targeted enrollment of participants <6 months of    age due to recruitment challenges.|No|October 2, 2014|https://clinicaltrials.gov/show/NCT00818259||145355|
NCT00818896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #08-0005|Maternal Hypothyroidism in Pregnancy|A Model Statewide Trial to Detect and Treat Maternal Hypothyroidism in Pregnancy||Women and Infants Hospital of Rhode Island|Yes|Completed|April 2008|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|72|Samples Without DNA|Serum and urine samples from women who consent are to be stored in the freezer. Iodine      measurements will be performed in urine samples and, possibly, serum samples. Consent is      also asked for use of stored samples for other research purposes in the future.|Female|17 Years|44 Years|No|Non-Probability Sample|The subjects will be 176 pregnant women and adolescents discovered to have varying degrees        of hypothyroidism during the first and early second trimesters. This disorder will be        identified by a blood test offered as part of routine prenatal care in a CDC-sponsored        community-based program at prenatal practices in Providence, Rhode Island. These 176 women        all will receive appropriate treatment for their hypothyroidism, and permission will be        sought to record information about the natural history of their condition during the first        postpartum year, as a way to inform future practice. The women will range in age from        about 17 to 44 years. Their racial/ethnic composition will reflect that of the general        population of Rhode Island.|September 2012|September 18, 2012|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818896||145306|
NCT00819494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 003/08|Role of Skin Tests for the Diagnosis of Immediate Hypersensitivity Reactions Due to Iodinated Contrast Media|Role of Skin Tests for the Diagnosis of Immediate Hypersensitivity Reactions Due to Iodinated Contrast Media||Chulalongkorn University|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|63|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819494||145261|
NCT00819767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2406|Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise|An Eight-week, Randomized, Double-blind, Parallel-group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose||Novartis|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|50 Years|N/A|No|||June 2011|June 2, 2011|January 7, 2009||No||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00819767||145241|
NCT00820625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1787|Alster-Lost-AF-Study|Ablation at St. Georg Hospital for Long-Standing Persistent Atrial Fibrillation - Pulmonary Vein Isolation With or Without Ablation of Complex Fragmented Atrial Potentials||Asklepios proresearch|No|Recruiting|May 2008|August 2012|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|75 Years|No|||June 2011|June 21, 2011|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820625||145177|
NCT00820638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05|Myomo e100 NeuroRobotic System Home Safety Study|Myomo NeuroRobotic System Home Safety Study For Use by Stroke Survivors for Upper Extremity Rehabilitation in Their Homes||Myomo|No|Recruiting|November 2008|June 2009|Anticipated|June 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2009|January 9, 2009|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820638||145176|
NCT00813956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11487|A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer|||Sanofi|No|Completed|December 2008|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|December 19, 2008|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00813956||145684|
NCT00814255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK70341FII|Novel Therapies for Resistant FSGS (FONT II): Phase II Clinical Trial|Novel Therapies for Resistant FSGS|FONT II|New York University School of Medicine|Yes|Completed|December 2008|February 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|1 Year|65 Years|No|||April 2014|April 10, 2014|December 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00814255||145661|
NCT00814554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pralimap-0610|Effectiveness Evaluation of Three Strategies of Promotion of Healthy Dietary and Physical Activity Behaviours to Prevent Weight Excess Among Teenagers|PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial|PRALIMAP|University of Nancy|Yes|Completed|September 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|5458|||Both|N/A|N/A|No|||March 2010|June 29, 2010|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814554||145638|
NCT00814866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|crcel08045|Bone Resorption, Osteoclastogenesis and Adalimumab|Bone Resorption, Osteoclastogenesis and Adalimumab|BROCA|Université de Sherbrooke|Yes|Completed|September 2008|March 2011|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814866||145615|
NCT00815165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0043|Cytomegalovirus Cell-Mediated Immunity|Cell-Mediated Immune Responses to Cytomegalovirus gB/MF59 Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2006|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|165|Samples With DNA|Blood.|Female|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of up to 100 healthy participants, ages 12-17 years, who were        vaccinated in 04-039. Additionally, 100 screened subjects enrolled to serve as        positive/negative controls.|September 2013|September 5, 2013|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815165||145592|
NCT00815711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0002|Idiopathic Pulmonary Fibrosis Registry for Future Studies|Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis||Ohio State University|No|Recruiting|December 2008|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|84|Samples With DNA|blood serum BAL fluid lung biopsy|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|August 2014|August 21, 2014|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815711||145550|
NCT00816049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO ALL2008 consolidation|ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy|Nordic Society of Paediatric Haematology and Oncology Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults (18-45 Years of Age) With ALL. Efficacy of Individualised 6MP Dosing During Consolidation Therapy|ALL2008con|Rigshospitalet, Denmark|Yes|Recruiting|June 2009|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|1 Year|45 Years|No|||May 2012|May 22, 2012|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00816049||145524|
NCT00816062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070027/S002|Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms|Endovascular Repair Using the Talent™ Abdominal Stent Graft System in Abdominal Aortic Aneurysms (VITALITY)|VITALITY|Medtronic Endovascular|No|Completed|December 2008|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00816062||145523|
NCT00816322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR93-IRB-87|The Effect of Fish Oil in Major Depressive Disorder|The Effect of Fish Oil in Major Depressive Disorder: a Double-blind Placebo-controlled Monotherapy Trail and a RCT for Recurrence Prevention||National Science Council, Taiwan|Yes|Completed|January 2005|December 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816322||145503|
NCT00816855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-0702|Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma|Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma||Fudan University|Yes|Recruiting|February 2007|June 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|70 Years|No|||January 2009|January 2, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816855||145462|
NCT00816868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG 0807|A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung|A Phase II Study of Erlotinib in Combination With Capecitabine as First-line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)||Sun Yat-sen University|Yes|Completed|January 2009|March 2011|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|65 Years|N/A|No|||February 2012|February 28, 2012|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816868||145461|
NCT00796276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004216|A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone|Disposition of Paliperidone Enantiomers After Treatment With Different Formulations of the Racemate and the Separate Enantiomers and the Determination of the Absolute Bioavailability of IR and ER OROS Paliperidone||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2004|August 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00796276||147022|
NCT00796289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-03|Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females|A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment With Clomiphene Citrate or Placebo in Anovulatory or Oligoovulatory Infertile Females||Ferring Pharmaceuticals|No|Completed|February 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|350|||Female|18 Years|38 Years|No|||August 2015|August 26, 2015|November 20, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796289||147021|
NCT00796978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE10107|Trastuzumab in Treating Older Women With Early-Stage Breast Cancer|Safety and Efficacy of Single Agent Adjuvant Trastuzumab in Older Women With Early Stage Breast Cancer: A Phase II Trial||Case Comprehensive Cancer Center|Yes|Active, not recruiting|November 2008|||November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|65 Years|N/A|No|||July 2015|July 15, 2015|November 21, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00796978||146969|
NCT00797615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081057|Project Diabetes: Weight Gain Prevention in Hispanic Girls (GEMAS Study)|Project Diabetes: Weight Gain Prevention in Hispanic Girls (GEMAS Study)|GEMAS|Vanderbilt University|No|Completed|November 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|132|||Female|8 Years|10 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797615||146923|
NCT00798096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00024|Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma|Phase II, Multicenter, Simon Two-Stage Study of Fostamatinib Disodium in Patients With Relapsed or Refractory T-Cell Lymphoma||AstraZeneca|Yes|Completed|March 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|November 21, 2008|Yes|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00798096||146886|This is a small, non-randomized study.
NCT00816790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB 2008-085|Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock|A Comparison of Standard Vs Renal Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock||Fraser Health|No|Terminated|January 2009|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|19 Years|N/A|No|||September 2015|September 10, 2015|December 31, 2008||No|Study stopped because of study personel movement to another institution.|No||https://clinicaltrials.gov/show/NCT00816790||145467|
NCT00816803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGY-SCI-1|Cell Transplant in Spinal Cord Injury Patients|Autologous Bone Marrow Derived Cell Transplant in Spinal Cord Injury Patients||Cairo University|Yes|Completed|May 2005|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|10 Years|36 Years|No|||January 2009|January 2, 2009|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816803||145466|
NCT00818610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B0-120074/1|Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia|Beta-lactam Monotherapy Versus Beta-lactam - Macrolide Association as Empiric Antibiotherapy Strategies in Non-severe Hospitalized Community-acquired Pneumonia: a Randomized, Non-inferiority, Open Trial.|BICAP|Swiss National Fund for Scientific Research|Yes|Completed|January 2009|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|601|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818610||145328|
NCT00818883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491CLD_306|Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension|A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension||Takeda|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|609|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|January 7, 2009|Yes|Yes||No|January 4, 2012|https://clinicaltrials.gov/show/NCT00818883||145307|
NCT00819507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4590|VANOS Cream and Skin Barrier Function|Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis||Oregon Health and Science University|No|Recruiting|January 2009|||January 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|12 Years|N/A|No|||August 2009|August 11, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819507||145260|
NCT00813332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|simcere002|Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)|A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar（rh Recombined Endostatin）With Single Docetaxel In NSCLC Patients||Simcere Pharmaceutical Co., Ltd|No|Recruiting|October 2008|October 2010|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||December 2009|January 22, 2010|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813332||145731|
NCT00813345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4057|Ambulatory Anesthesia and Light Therapy|A Role for Light Therapy at Immediate Recovery From Short Duration Ambulatory Anesthesia to Prevent Dysregulation of Circadian Rest-Activity Rhythm in Patients Submitted to Colonoscopy.|LI-AMB|University Hospital, Strasbourg, France|No|Recruiting|January 2009|June 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|360|||Both|30 Years|70 Years|No|||April 2009|April 24, 2009|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813345||145730|
NCT00814567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000629768|Radiation Therapy in Treating Women With Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery|Randomised Trial Testing Intensity Modulated and Partial Organ Radiotherapy After Breast Conservation Surgery for Early Breast Cancer||National Cancer Institute (NCI)||Recruiting|October 2006|||June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|1935|||Female|50 Years|N/A|No|||December 2008|January 6, 2011|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00814567||145637|
NCT00814580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015040|Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery|A Randomized, Double-Blind, Multi-Center, Parallel-Group Study of Tapentadol Immediate Release (IR) Versus Oxycodone IR for the Treatment of Subjects With Acute Post-Operative Pain Following Elective Arthroscopic Shoulder Surgery||Ortho-McNeil Janssen Scientific Affairs, LLC|No|Completed|December 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|382|||Both|18 Years|80 Years|No|||November 2012|November 13, 2012|December 23, 2008|Yes|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00814580||145636|No notable study limitations were identified by the Sponsor
NCT00814268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOPI_L_02452|COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke|COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial|COMPRESS|Sanofi|No|Completed|December 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|358|||Both|30 Years|N/A|No|||February 2014|February 27, 2014|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814268||145660|
NCT00815178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inspiratory training diabetes|Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness|Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness: A Randomized, Controlled Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|75 Years|No|||December 2008|December 26, 2008|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815178||145591|
NCT00815412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DP000104-03|ACTIVATE: Standard Worksite Health Program vs. Activated Consumer|ACTIVATE: Standard Worksite Health Program vs. Activated Consumer|ACTIVATE|HealthPartners Institute|Yes|Completed|September 2004|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|631|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2008|November 25, 2015|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815412||145573|
NCT00815425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 AR002278|Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (The CLEAR Registry)|Consortium for the Longitudinal Evaluation of African-Americans With Early Rheumatoid Arthritis (CLEAR) Registry|CLEAR|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Yes|Completed|September 2000|March 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1613|Samples With DNA|Blood, including DNA and serum, and urine|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|African Americans with and without RA|December 2014|December 1, 2014|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815425||145572|
NCT00815698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPODenmark001|Effect of Suture for Mesh Fixation in Lichtenstein Hernia Repair|Effect of Suture for Mesh Fixation in Lichtenstein Hernia Repair, a Prospective Controlled Randomized Trial|Dangrip|Herlev Hospital|No|Completed|December 2008|September 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|334|||Male|18 Years|80 Years|No|||February 2016|February 22, 2016|December 29, 2008||No||No|March 18, 2015|https://clinicaltrials.gov/show/NCT00815698||145551|
NCT00815724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|621|Evaluating a Distance Learning Asthma Education Program for Pediatricians (The DALI Study)|Distributed Asthma Learning Initiative|DALI|University of California, San Francisco|Yes|Completed|February 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 7, 2013|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815724||145549|
NCT00815737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhubarb cerebral hemorrhage|Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage|||Fudan University||Active, not recruiting|January 2009|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2009|May 26, 2010|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815737||145548|
NCT00816075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-DW-1971|Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection|The Efficacy of Distilled Water vs Mitomycin C as a Single Dose Immediate Instillation After Transurethral Resection of Intermediate Risk, Recurrent Superficial Bladder Cancer||Bozyaka Training and Research Hospital|No|Active, not recruiting|February 2009|April 2011|Anticipated|January 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|1||Anticipated|40|||Both|N/A|N/A|No|||February 2009|February 16, 2009|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816075||145522|
NCT00817128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170991004|Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1)|Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I|PEPTOC|Radboud University|No|Completed|January 2009|July 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|80 Years|No|||July 2013|July 23, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817128||145441|
NCT00817141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/12MARS/82|Urinary Catheter and Fast-track Surgery|Is Urinary Catheter Necessary After Fast-Track Colonic Surgery?||Université Catholique de Louvain|No|Completed|March 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for Fast Track colonic surgery|March 2008|January 12, 2010|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817141||145440|
NCT00817414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699A2215|An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension|A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension||Novartis|No|Completed|December 2008|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|63|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817414||145419|
NCT00817427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#14075A|Sleep Disturbances as a Risk Factor in Chronic Kidney Disease|Sleep Disturbance as a Non-Traditional Risk Factor in CKD|CRIC|University of Chicago|No|Completed|October 2008|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|40|||Both|21 Years|74 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817427||145418|
NCT00796991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-078|Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine|A Randomized, Parallel, 3-arm Study to Characterize the Effect of Ipilimumab + Chemotherapy in Patients With Untreated Advanced Melanoma||Bristol-Myers Squibb|No|Completed|February 2009|October 2012|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|November 20, 2008|No|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT00796991||146968|
NCT00797264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060402|Ketamine Associated With Morphine PCA After Total Hip Arthroplasty|Impact of the Route of Administration of Ketamine Associated With Morphine PCA on Analgesia After Total Hip Arthroplasty|KETAMINE|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797264||146949|
NCT00797277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950107|Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia|An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia||National Taiwan University Hospital|No|Completed|July 2006|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|65 Years|No|||September 2014|September 11, 2014|November 24, 2008||No||No|August 12, 2013|https://clinicaltrials.gov/show/NCT00797277||146948|
NCT00797589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001225-34|Effect of Prime Solution on Fluid Balance After Open Heart Surgery|Effect of Prime Solution on Fluid Balance After Open Heart Surgery||Helsinki University|No|Completed|January 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|November 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00797589||146925|
NCT00806312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0070|The Expression and Significance of MiRNA|The Expression and Significance of miRNA Profile and Markers of Inflammation in Patients With Pulmonary Arterial Hypertension||Ohio State University|No|Recruiting|July 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|We expect to enroll 200 patients, who have been referred to the Pulmonary Hypertension        Clinic at the Ohio State University Medical Center, in this study. Patients who are ≥ 18        years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis        as part of their clinical care will be approached for consent and participation in this        study.|February 2014|March 27, 2014|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806312||146263|
NCT00797862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A2307|Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension|A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With Essential Hypertension|ACCELERATE|Novartis|No|Completed|November 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|1254|||Both|18 Years|N/A|No|||June 2011|October 7, 2011|November 24, 2008||No||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00797862||146904|
NCT00817050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04207|Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)|A Preference Evaluation of Nasonex® Nasal Spray (Unscented) vs. Flonase® Nasal Spray (Scented) in Subjects With Symptomatic Allergic Rhinitis (AR) - Single-Dose Cross-over||Merck Sharp & Dohme Corp.|No|Completed|December 2004|January 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||June 2015|June 29, 2015|January 5, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00817050||145447|
NCT00817596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060192|Prometra's Utilization in Mitigating Pain (PUMP)|Prometra's Utilization in Mitigating Pain (PUMP)|PUMP|Flowonix Medical|No|Completed|January 2007|March 2011|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||August 2012|August 13, 2012|January 5, 2009|Yes|Yes||No|March 2, 2012|https://clinicaltrials.gov/show/NCT00817596||145405|
NCT00813735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESRCO66|Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder|Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder||Lehigh Center for Clinical Research|Yes|Completed|September 2006|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|December 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813735||145701|
NCT00813969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-MSC-001|Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS|A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis||The Cleveland Clinic|Yes|Completed|March 2011|May 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|No|||June 2014|June 23, 2014|December 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813969||145683|
NCT00814593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000630437|Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery|Randomized Phase II Trial of Intralesional Lymphokine Activated Killer Cells or Polifeprosan 20 With Carmustine Implant (Gliadel® Wafer) as Consolidation Therapy After Primary Treatment of Newly Diagnosed Resectable Glioblastoma||Caladrius Biosciences, Inc.|No|Terminated|November 2008|September 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|December 24, 2008|Yes|Yes|Hoag Hospital ceased support.|No||https://clinicaltrials.gov/show/NCT00814593||145635|
NCT00814606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16336A|A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C|A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C||University of Chicago|No|Withdrawn|February 2010|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||June 2013|June 28, 2013|December 23, 2008|Yes|Yes|no one ever enrolled|No||https://clinicaltrials.gov/show/NCT00814606||145634|
NCT00814879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811004448|Pilot Study of a Raltegravir Based NRTI Sparing Regimen|A Pilot Randomized, Open-Label Study Comparing the Safety and Efficacy of a Raltegravir Based NRTI Sparing Regimen||Yale University|No|Completed|May 2009|November 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 18, 2008|No|Yes||No|November 23, 2015|https://clinicaltrials.gov/show/NCT00814879||145614|
NCT00815191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1042|Comparison of Vital HEAT (vH2) Temperature Management System to Upper-body Forced-air Warming|A Comparison Study of the Vital HEAT (vH2) Temperature Management System to Upper-body Forced-air Warming in Patients Undergoing Open Abdominal Surgery Under General Anesthesia||Outcomes Research Consortium|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|66|||Both|18 Years|75 Years|No|||February 2011|February 16, 2011|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815191||145590|
NCT00815438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1125518|Transvaginal Cholecystectomy Using Endoscopic Assistance|Laparoscopic Cholecystectomy Using Transvaginal Endoscopic Assistance||University of Missouri-Columbia|No|Withdrawn|January 2009|December 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|80 Years|No|||May 2015|May 27, 2015|December 29, 2008||No|unable to obtain funding|No||https://clinicaltrials.gov/show/NCT00815438||145571|
NCT00816881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDC12007211|Application and Generalization of Flutter Mucus Clearance Device|Application and Generalization of Flutter Mucus Clearance Device||Tongji University|Yes|Completed|January 2009|March 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|356|||Both|40 Years|85 Years|No|||June 2012|June 21, 2012|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816881||145460|
NCT00816582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET/CT Breast|PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer|A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer||British Columbia Cancer Agency|Yes|Recruiting|November 2010|December 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Female|45 Years|N/A|No|||March 2016|March 4, 2016|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816582||145483|
NCT00816894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heresco CTIL147-08|D-serine Monotherapy for Schizophrenia|D-serine Antipsychotic Monotherapy for Treatment Refractory Schizophrenia||Herzog Hospital|Yes|Completed|January 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|70 Years|No|||December 2013|December 9, 2013|January 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00816894||145459|
NCT00797004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35031-B|Olfactory Dysfunction of Rhinosinusitis|Olfactory Dysfunction of Rhinosinusitis|ODOR|University of Washington|No|Completed|November 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Non-Probability Sample|surgical patients from the UW Otolaryngology - Head and Neck surgery clinic|June 2012|June 27, 2012|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00797004||146967|
NCT00797290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0605-NP01|Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx|NP01|University of Florida|No|Terminated|June 2008|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated at radiaton oncology clinic|March 2016|March 3, 2016|November 24, 2008||No|Slow enrollment, Feasibility issues|No||https://clinicaltrials.gov/show/NCT00797290||146947|
NCT00797303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BQ-1-08-ARVO|The Effect of Bevacizumab on Corneal Neovascularization|The Effect of Bevacizumab on Corneal Neovascularization|BQ-1-08-ARVO|Instituto de Olhos de Goiania|Yes|Completed|January 2006|November 2008|Actual|July 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|December 1, 2011|November 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00797303||146946|
NCT00797316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2410|Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension|An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension|AIMS|Novartis|No|Completed|November 2008|December 2009||December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|532|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|November 24, 2008|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00797316||146945|
NCT00806884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0708/25|Do Physiotherapy Techniques Improve Posture During Admission for a Chest Infection in Adults With Cystic Fibrosis?|Do Physiotherapy Joint and Muscle Movement (Musculoskeletal) Techniques Improve Posture, Pain, Sputum Clearance, Lung Function or Quality of Life During Admission for a Respiratory Exacerbation in Adults With Cystic Fibrosis?||Royal Brompton & Harefield NHS Foundation Trust|Yes|Completed|June 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|50|||Both|16 Years|N/A|No|||December 2008|June 4, 2015|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806884||146221|
NCT00806897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3701|Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®|Prospective, Multicentre, Open Label, Non-controlled, 24-week Observation in Type 2 Diabetics Using Once Daily Levemir® (Insulin Detemir) as Part of Their ITT Regimen|LITHULEV1|Novo Nordisk A/S|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetic subjects from specialists' (diabetologists, internists) care who are treated with        intensive insulin treatment by prescription in line with governing prescribing rules. At        baseline subjects are treated with IIT containing NPH as basal insulin.|November 2011|June 28, 2012|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806897||146220|
NCT00817336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08I/C19-0|Biomarkers in Schizophrenia|Effect of an NMDA-based Intervention on Biomarker Measures of Cognitive Dysfunction in Schizophrenia||Nathan Kline Institute for Psychiatric Research|Yes|Completed|June 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|64 Years|No|||June 2011|April 15, 2015|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817336||145425|
NCT00817349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801|Angio-Seal Evolution Device Registry|Clinical Registry of the St. Jude Medical Angio-Seal(TM) Evolution(TM) Vascular Closure Device Following Diagnostic and/or Interventional Endovascular Procedures||St. Jude Medical|No|Completed|July 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1004|||Both|18 Years|N/A|No|Probability Sample|Those needing a diagnostic and/or interventional catheterization procedure.|April 2010|April 23, 2010|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817349||145424|
NCT00817362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-07|Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer|A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of IPI-504 in Combination With Trastuzumab in Patients With Pretreated, Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer||Infinity Pharmaceuticals, Inc.|No|Terminated|March 2009|May 2011|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|January 5, 2009|Yes|Yes|Limited efficacy response observed during interim analysis.|No||https://clinicaltrials.gov/show/NCT00817362||145423|
NCT00817609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008L060A|Effectiveness and Safety of Angongniuhuang Pill on Restoring Consciousness for Patients Who Have Suffered From a Stroke|||Fudan University||Not yet recruiting||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||September 2009|May 26, 2010|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817609||145404|
NCT00813748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4458g|Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing|Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing|X-PAND|Genentech, Inc.||Completed|March 2009|January 2014|Actual|January 2014|Actual|Phase 4|Observational|N/A||1|Actual|118|Samples With DNA|Whole blood|Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|August 2015|August 14, 2015|December 22, 2008|No|Yes||No|August 14, 2015|https://clinicaltrials.gov/show/NCT00813748||145700|Endpoint prioritization was not specified in study protocol; hence, all endpoints are reported as primary.
NCT00813358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005|Zenith TX2® Post-market Approval Study|Zenith TX2® TAA Endovascular Graft Post-approval Study|TX2 2PAS|Cook||Active, not recruiting|July 2009|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|18 Years|N/A|No|||March 2015|December 30, 2015|December 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813358||145729|
NCT00814281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU2007-005|Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?|Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?||Marywood University|No|Completed|May 2007|May 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|24|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2009|May 20, 2009|December 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814281||145659|
NCT00814307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921045|A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis|Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis||Pfizer|Yes|Completed|February 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|611|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|December 22, 2008|Yes|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00814307||145657|
NCT00814320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160603|Gammagard Liquid and rHuPH20 in PID|Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases||Baxalta US Inc.|No|Completed|December 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|2 Years|N/A|No|||October 2015|October 30, 2015|December 23, 2008|Yes|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT00814320||145656|
NCT00814905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO8-098|Treatment of Chorioamnionitis After Delivery|Treatment of Chorioamnionitis After Delivery||United States Naval Medical Center, Portsmouth|No|Recruiting|June 2009|April 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814905||145612|
NCT00814892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0554|Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer|A Phase II Trial to Determine the Safety, Tolerability and Efficacy of an Allogeneic Whole Cell Vaccine Administered With Autologous Myeloid Dendritic Cells to Patients With Non-Metastatic Androgen Independent Prostate Carcinoma||Mayo Clinic|Yes|Terminated|January 2009|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|18 Years|N/A|No|||October 2013|October 8, 2013|December 24, 2008|Yes|Yes|Study was terminated due to funding issues.|No|May 16, 2013|https://clinicaltrials.gov/show/NCT00814892||145613|
NCT00815763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing-002|Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke|Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Multicenter Trial||Xijing Hospital|Yes|Completed|September 2006|September 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|390|||Both|18 Years|75 Years|No|||December 2008|December 29, 2008|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815763||145546|
NCT00816088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0808/154|Diagnostic and Management Strategies for Invasive Aspergillosis|Diagnostic and Management Strategies for Invasive Aspergillosis in Neutropenic Adult Haemato-Oncology Patients With a Proposal for Investigation of a Novel Potential Marker for Early Diagnosis: a Prospective Cohort Study||King's College Hospital NHS Trust|No|Completed|December 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|203|Samples With DNA|Seum, Whole blood, urine, broncho-alveolar lavage, tissue|Both|18 Years|N/A|No|Non-Probability Sample|Haemato-oncology patients undergoing high dose chemotherapy or stem cell transplantation        likely to render them neutropenic.|December 2014|December 22, 2014|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816088||145521|
NCT00816101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSMP-002|Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation|Efficacy of the PROCELLERA™ Wound Dressing in the Healing of Wounds After a Curettage and Electrodesiccation of Skin Lesions||Vomaris Innovations|No|Completed|March 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|80 Years|No|||March 2011|March 4, 2011|October 21, 2008|Yes|Yes||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00816101||145520|
NCT00816114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCR05-0444|Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial|Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial||M.D. Anderson Cancer Center|No|Recruiting|June 2005|||June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|850|||Both|N/A|N/A|No|Non-Probability Sample|MDACC CML patients (from July 1, 1998 to October 31, 2008) in any disease phase (chronic,        accelerated or blast phase) that received imatinib treatment outside an MDACC clinical        trial prior to a MCACC clinic visit.|October 2015|October 1, 2015|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816114||145519|
NCT00816556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-008730|A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis|A Randomized Controlled Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis||Mayo Clinic|No|Terminated|October 2008|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Female|40 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|December 30, 2008|Yes|Yes|Funding|No|February 12, 2014|https://clinicaltrials.gov/show/NCT00816556||145485|
NCT00816569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dvleyes-HMO-CTIL|Orthokeratology for Keratoconus|Orthokeratology Contact Lenses for Keratoconus||Hadassah Medical Organization|No|Not yet recruiting|February 2009|August 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|45 Years|No|||December 2008|December 31, 2008|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816569||145484|
NCT00817180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-03181|Long-term Study, Comparing Vest Therapy to Positive Expiratory Pressure (PEP) Therapy in the Treatment of Cystic Fibrosis|Multi-centre, Long-term Comparative Trial of High Frequency Chest Wall Oscillation Versus Positive Expiratory Pressure Mask in the Treatment of Cystic Fibrosis||University of British Columbia|Yes|Completed|October 2008|July 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|6 Years|N/A|No|||March 2014|March 14, 2014|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00817180||145437|
NCT00817453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SchiessEPDX2008|Early Parkinson's Disease (PD) Cross-Sectional|Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD|EPDX|The University of Texas Health Science Center, Houston|No|Terminated|January 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|150|Samples With DNA|CSF and serum|Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|clinical diagnosis of early PD and age/gender matched controls|April 2011|April 12, 2011|January 5, 2009||No|All subjects transferred to long term study NCT00817726 RBD Longitudinal|No||https://clinicaltrials.gov/show/NCT00817453||145416|
NCT00805376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-310|DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas|Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas||DNAtrix, Inc.|No|Completed|February 2009|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|December 8, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805376||146333|
NCT00805389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112115|Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine|Comparison of the Immunogenicity and Safety of Various Investigational and Licensed Formulations of Hepatitis B Surface Antigen (HBsAg) Vaccines.||GlaxoSmithKline||Completed|December 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|713|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|February 12, 2015|December 5, 2008|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT00805389||146332|
NCT00805402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07021|Interest of Flow Cytometry for the Diagnosis, the Follow up and Specific Immunotherapy (SIT) Arrest of Hymenoptera Venom Allergy|Interest of Flow Cytometry for the Diagnosis, the Follow up and SIT Arrest of Hymenoptera Venom Allergy|Cytoven|University Hospital, Limoges|No|Completed|July 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|70 Years|No|||September 2010|September 3, 2010|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00805402||146331|
NCT00805701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|047838|Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation|Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy||Bay State Clinical Trials, Inc.|No|Completed|January 2009|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|35 Years|90 Years|No|||May 2014|May 12, 2014|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00805701||146308|
NCT00806000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0094|Prevalence of Exercise-Induced Asthma in Select Cohorts of College Athletes|Prevalence of Exercise-Induced Asthma in Select Cohorts of College Athletes||Ohio State University|Yes|Completed|December 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|select athletic teams including men and women's ice hockey, soccer, and lacross|October 2012|October 9, 2012|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806000||146287|
NCT00806013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMM-080601|Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide|Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject||Chinese Academy of Sciences|No|Completed|August 2008|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|36|Samples With DNA|The whole blood samples of each person are stored at -80℃.|Male|21 Years|27 Years|Accepts Healthy Volunteers|Probability Sample|Male Chinese subjects with different geontype of CYP2C9 and CYP2C19 were enrolled in this        study. They are divided into three groups by different geontype.|December 2008|January 26, 2010|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806013||146286|
NCT00806026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081186|Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients|Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome|RLS|Pfizer|Yes|Completed|December 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|731|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|December 9, 2008|Yes|Yes||No|May 7, 2012|https://clinicaltrials.gov/show/NCT00806026||146285|Names of Daytime Function-Participant Reported Outcome (DF-PRO) and Limb Pain-Numerical Rating Scale (Limb Pain-NRS) were updated to RLS-NDI and Limb Pain-VAS respectively to reflect measurement appropriately.
NCT00817622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-4955|Effects of EPA and Vitamin E on Leptin, Adiponectin and Enzymatic Antioxidants in Type 2 DM|Effects of EPA Alone and Combined With Vitamin E on Blood Leptin, Adiponectin and Enzymatic Antioxidants Levels in Type II Diabetic Patients; A Randomized, Double-Blind, Placebo-Controlled Trial|EPA|Tehran University of Medical Sciences|Yes|Completed|January 2007|September 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|129|||Both|30 Years|55 Years|No|||November 2009|November 17, 2009|January 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817622||145403|
NCT00813371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTUHSC-L08-152|Airway Pressure Release Ventilation as a Preventative Strategy|Airway Pressure Release Ventilation as a Preventative Strategy in Patients at Risk for Acute Respiratory Distress Syndrome||Texas Tech University Health Sciences Center|No|Withdrawn|December 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|16 Years|N/A|No|||August 2009|August 24, 2009|December 22, 2008||No|Principal Investigator left the institution before subjects were enrolled|No||https://clinicaltrials.gov/show/NCT00813371||145728|
NCT00813384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080895|A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors|A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 208 in Adult Subjects With Advanced Solid Tumors||Amgen|No|Completed|December 2008|December 2014|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|December 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00813384||145727|
NCT00813995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-074|A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)|A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|December 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|395|||Both|18 Years|78 Years|No|||July 2015|July 21, 2015|December 19, 2008|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00813995||145681|
NCT00814294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP 01-2007-03|Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus|An 18-Week Randomized, Double-Blind, Multicenter, Comparator Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus||Diasome Pharmaceuticals|No|Active, not recruiting|December 2008|October 2009|Anticipated|September 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|230|||Both|18 Years|70 Years|No|||June 2009|June 29, 2009|December 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814294||145658|
NCT00814619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/07|Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer|Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Completed|November 2008|January 2014|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|December 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814619||145633|
NCT00815204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13353|Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder|Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder||Cedars-Sinai Medical Center|No|Completed|May 2008|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|39|Samples Without DNA|Will be collecting blood to check for hormone levels|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from psychiatric clinics at Cedars-Sinai and at the West Los        Angeles VA Center|February 2015|February 2, 2015|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815204||145589|
NCT00815451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-salmoosawi|Effect of Polyphenol-rich Dark Chocolate on Obesity|Effect of Polyphenols on Glucoregulatory Biomarkers, Blood Pressure and Lipid Profile in Overweight and Obese Subjects||Queen Margaret University|Yes|Active, not recruiting|November 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815451||145570|
NCT00815750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15320|Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients|Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|August 2008|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|147|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815750||145547|
NCT00815789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006548|Cholesterol, Hypertension and Glucose Education Study|Prevention of Cardiovascular Outcomes in African Americans With Diabetes|CHANGE|Duke University|No|Completed|December 2008|December 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|362|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00815789||145544|
NCT00816348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-204|Compassionate Use of Omegaven IV Fat Emulsion|Compassionate Use of Omegaven IV Fat Emulsion||Northwell Health|No|Terminated|December 2008|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|5 Years|No|||January 2016|January 11, 2016|December 31, 2008|Yes|Yes||No|August 7, 2015|https://clinicaltrials.gov/show/NCT00816348||145501|
NCT00816595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000630491|Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)||Mayo Clinic|Yes|Active, not recruiting|February 2009|May 2016|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|120 Years|No|||March 2015|January 11, 2016|December 31, 2008|Yes|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00816595||145482|
NCT00816608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAXWEL 09|The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes|Study of MAXimum Weight in Lifetime on Glucose Homeostasis (MAXWEL)|MAXWEL|Seoul National University Bundang Hospital|Yes|Completed|August 2006|September 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3000|||Both|20 Years|N/A|No|Non-Probability Sample|Korean with type 2 diabetes Korean with confirmed IFG or IGT Korean with NGT|October 2013|October 24, 2013|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816608||145481|
NCT00816335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08031|Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors|Pilot Study Evaluating a Combined and Integrated Technological Approach of F-18-FDG-Directed Perioperative PET/CT Imaging and Intraoperative Handheld Gamma Prove Detection of Known and Occult Disease in Patients Undergoing Surgery for Solid Malignancies||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2008|||January 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|65|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|December 31, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00816335||145502|
NCT00816907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH090001-03|The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)|Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study|METS|National Institute of Mental Health (NIMH)|Yes|Completed|January 2009|March 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|65 Years|No|||November 2010|February 13, 2013|January 2, 2009|Yes|Yes||No|January 3, 2013|https://clinicaltrials.gov/show/NCT00816907||145458|Changes over periods of more than 16 weeks are unknown.
NCT00821717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-CARS-03|EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure|A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency|EFFICACY-HF|Vifor Inc.|Yes|Terminated|December 2008|January 2011|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 7, 2009||No|Positive FAIR-HF study data are available, this study is identical as EFFICACY-HF. Due to low    recruitment in EFFICACY-HF the decision was made to terminate it.|No||https://clinicaltrials.gov/show/NCT00821717||145095|
NCT00822003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 127/07, Amendment 1|Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects|Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile Following an Oral Glucose Tolerance Test in Healthy Male Subjects||University Hospital, Basel, Switzerland|No|Completed|February 2008|September 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2009|January 13, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822003||145073|
NCT00805714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTV-KAMI|Livalo Acute Myocardial Infarction Study|A Prospective Clinical Observation Study to Evaluate the Influence of Long Term Treatment of Pitavastatin on the Therapeutic Prognosis and Safety in Acute Myocardial Infarction|LAMIS|JW Pharmaceutical|No|Completed|April 2007|March 2011|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1128|||Both|N/A|N/A|No|Probability Sample|AMI patients who are in need to be treated by statins|March 2012|March 28, 2012|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00805714||146307|
NCT00805740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851022|An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida|Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection||Pfizer|Yes|Terminated|April 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|16 Years|N/A|No|||May 2013|May 30, 2013|November 26, 2008|Yes|Yes|The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not    terminated due to any safety issues or concerns.|No|May 30, 2013|https://clinicaltrials.gov/show/NCT00805740||146306|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns.
NCT00806078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-001-07-1004|Comparison Bioavailability Study of Quinine Sulfate in Chocolate Pudding|A Comparison of the Bioavailability of Quinine Sulfate Capsules Following a 648 mg Dose When Mixed in Chocolate Pudding Relative to That With Intact Capsules in Healthy Adults Under Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|July 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|December 8, 2008|Yes|Yes||No|December 18, 2008|https://clinicaltrials.gov/show/NCT00806078||146281|
NCT00817635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699A2216|A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic|A Phase II, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Multi-center, Dose Ranging Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Resistant Hypertension||Novartis|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|155|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|January 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00817635||145402|
NCT00817648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00071|A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia|A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia||Shanghai Mental Health Center|No|Completed|December 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||June 2010|June 11, 2010|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00817648||145401|
NCT00813397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSPRAY00608|Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.|Manageability and Safety Assessment of the SepraSpray Anti-adhesion Barrier in Abdominal Coelioscopic Surgery|C-MUST|Sanofi|Yes|Completed|September 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813397||145726|
NCT00813410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIG96|Evaluation of a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Adipose Tissue of Diabetic Patients|A Single Center, Open-Labeled Exploratory Study to Evaluate a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue of Type-1 Diabetic Patients||Medical University of Graz|Yes|Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|65 Years|No|||December 2008|December 20, 2008|December 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00813410||145725|
NCT00813761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-4522|Clinical Evaluation of the Long‑Term Effects of Contact Lens Care Systems|||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2008|||August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|473|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|December 17, 2008|Yes|Yes||No|October 24, 2011|https://clinicaltrials.gov/show/NCT00813761||145699|
NCT00814008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-181298|The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp|The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp||Medical University of Vienna||Completed|March 1999|December 2003|Actual|April 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|64|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 22, 2008|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00814008||145680|
NCT00815230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812057R|Effect of Cardiac Computed Tomography Angiography on the Blood Reactive Oxygen Species Level|Effect of Cardiac Computed Tomography Angiography on the Blood Reactive Oxygen Species Level||National Taiwan University Hospital|No|Withdrawn|January 2009|March 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|None Retained|only peripheral blood will be collected for measurement of reactive oxygen species.|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects will be OPD patients who are arranged for cardiac CTA examination because        of suspect coronary artery disease.|December 2008|May 17, 2009|December 25, 2008||No|because of unexpected administrative barrier, it was very difficult to enroll case.|No||https://clinicaltrials.gov/show/NCT00815230||145587|
NCT00815217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01194|The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers|The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers||Washington D.C. Veterans Affairs Medical Center|No|Not yet recruiting|February 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|20 Years|80 Years|No|||December 2008|December 24, 2008|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00815217||145588|
NCT00815464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMG-PR-001|A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B|Efficacy Study of Liquid Acupuncture(Herb Acupoint Injection) Therapeutics in Chronic Hepatitis B(CHB) Based on Patients' Individual Condition|CHB|Yu Medical Garden|Yes|Not yet recruiting|March 2009|March 2010|Anticipated|September 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|No|||December 2008|December 29, 2008|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815464||145569|
NCT00815776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID2007|Treatment Outcomes for Temporomandibular Disorders (TMD) Via the Clayton Intra-aural Device (CID) Clinical Trial|Treatment Outcome of Temporomandibular Disorders Via the Clayton Intra-aural Device (CID): A Randomized Clinical Trial||Ascentia Health, Inc.|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|152|||Both|N/A|N/A|No|||August 2010|August 16, 2010|December 29, 2008||No||No|March 23, 2010|https://clinicaltrials.gov/show/NCT00815776||145545|
NCT00816127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0727|Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction|Intranasal DDAVP in Preventing Bleeding During Dental Extraction in Cirrhotic Patients||Icahn School of Medicine at Mount Sinai|No|Completed|October 2003|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||December 2008|December 31, 2008|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00816127||145518|
NCT00820872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N083E|Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer|Phase II Safety Study of Docetaxel and Carboplatin in Combination With Trastuzumab and Lapatinib in Early Breast Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|February 2009|||December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820872||145158|
NCT00821106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TALENT|Left Versus Right Transradial Approach for Percutaneous Coronary Procedures|Transradial Approach [LEft vs Right] aNd Procedural Times During Percutaneous Coronary Procedures: TALENT Study|TALENT|Policlinico Casilino ASL RMB|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1540|||Both|18 Years|N/A|No|||January 2010|March 18, 2010|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00821106||145140|
NCT00821392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67|Phase III Trial of Febuxostat in Korea Gout Patients|A Randomized, Multi-Center, Double Blinded, Allopurinol-Controlled, Placebo-Controlled Parallel Group, 5-Arm, Dose-Response,Bridging Study to Assess the Efficacy and Safety of Febuxostat in Subject With Gout||SK Chemicals Co.,Ltd.||Completed|August 2006|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|181|||Both|18 Years|85 Years|No|||October 2007|January 12, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821392||145119|
NCT00821405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808062R|Study of Peritoneal/Bowel Morphology and Splanchnic Hemodynamics by Sonography, Doppler Ultrasound and Computed Tomography in CAPD Patients|||National Taiwan University Hospital|Yes|Not yet recruiting|March 2009|March 2010|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|15 Years|90 Years|No|Probability Sample|Patients received peritoenal dialysis more than 3 months|January 2009|January 12, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821405||145118|
NCT00822016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0701C|Observational Study of Best Supportive Care With or Without Surgery, Chemo or Radiotherapy in Pts With Carcinoma of Lung|INST 0701C: An Observational Outcomes Protocol of Standard Practice of Best Supportive Care With or Without Surgery, Chemotherapy or Radiotherapy in Patients With Carcinoma of the Lung||New Mexico Cancer Care Alliance|Yes|Terminated|July 2007|March 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with lung cancer and treated with best supportive care and standard and        investigational chemotherapy regimens, surgery, and radiation therapy at the UNM CRTC and        other NMCCA sites.|June 2012|June 27, 2012|January 13, 2009||No|PI left institution. Insufficient enrollment for analysis.|No||https://clinicaltrials.gov/show/NCT00822016||145072|
NCT00822328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHGH-IRB(173)97B-13-1|Fermented Milk Drink on Human Intestinal Microflora|Effects of a Fermented Milk Drink Containing Lactobacillus Casei Strain Shirota on the Human Intestinal Microflora||Cheng Hsin Rehabilitation Medical Center|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|January 9, 2009||No||No|March 23, 2009|https://clinicaltrials.gov/show/NCT00822328||145048|
NCT00822562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-016|Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer|Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|January 2009|December 2010|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|60 Years|No|||January 2009|January 15, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00822562||145030|
NCT00818064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8226-3703|Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Single- Dose, Dose-escalation Trial of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|December 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00818064||145370|
NCT00806039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1143004|Impact of Early Renal Involvement on the Development of Severe In-hospital Renal Failure|Impact of EArly Renal Involvement on the Developement of Severe In-hospital Renal Failure|EARLI|Saint Louis VA Medical Center|No|Active, not recruiting|December 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||July 2009|July 14, 2009|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806039||146284|
NCT00806052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-P-003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2006|||||N/A|N/A|N/A||||||||||||||May 11, 2011|December 8, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00806052||146283|
NCT00806065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-CL-002|Study of ENMD-2076 in Patients With Multiple Myeloma|A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma||CASI Pharmaceuticals, Inc.|No|Completed|December 2008|January 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|December 9, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806065||146282|
NCT00806637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTCU_pkk2008_02|Vessel Sealing System Uvulopalatoplasty Versus Uvulopalatal Flap|Vessel Sealing System Uvulopalatoplasty vs Uvulopalatal Flap: a Randomized, Control Study of Efficacy and Adverse Effects||Chulalongkorn University|Yes|Enrolling by invitation|October 2008|September 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||October 2008|December 10, 2008|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806637||146238|
NCT00806325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006C0052|Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia|Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia|AML|Ohio State University|No|Completed|November 2007|May 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|baseline blood sample drawn (2 tablespoons or 30 ml) at the beginning of the study. If      subjects experience a fever another blood sample (10 ml up to 2 times) will be drawn at that      time.|Both|18 Years|N/A|No|Non-Probability Sample|university hospital intensive care unit|May 2010|May 26, 2010|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806325||146262|
NCT00806338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSI-1436C-102|An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers|A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers||Genaera Corporation|No|Completed|November 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|22|||Both|18 Years|65 Years|No|||April 2009|April 14, 2009|January 21, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00806338||146261|
NCT00813423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03112|Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy|Autophagic Modulation With Anti-angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine||National Cancer Institute (NCI)||Active, not recruiting|January 2010|||July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 20, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813423||145724|
NCT00813436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0007-07-SHA|The Effect of Intranasal Administration of Oxytocin on Empathic Abilities.|The Effect of Intranasal Administration of Oxytocin on Empathic Abilities of Healthy People and People Who Suffer From Schizophrenia.|20070766|Shalvata Mental Health Center||Recruiting|May 2008|January 2010|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2008|February 4, 2009|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00813436||145723|
NCT00813774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0003|Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers|Open, Randomized, Parallel Group, Single Dose, Bioavailability Comparison of 3 Certolizumab Pegol Solution Formulations (Lyophilized, Liquid, Pre-filled Syringe Formulation) to Healthy Volunteers||UCB Pharma|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|149|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 6, 2013|December 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00813774||145698|
NCT00813787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-24534|Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components|Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using a Specialized MRI Technique Called Multiexponential T2 Component Analysis||AHS Cancer Control Alberta|Yes|Recruiting|February 2009|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A. Any glioma patient who recieves treatment at our clinic (Cross Cancer Institute) who        agrees to take part in the study.        B. Any normal volunteer who agrees to take part in the study.|October 2014|October 1, 2014|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00813787||145697|
NCT00814021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07URO02|Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain|Phase II Study, Multicenter, Open-label, Evaluating Efficacy of Treatment With Sutent® (Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer||Institut Claudius Regaud||Completed|April 2009|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||August 2012|November 4, 2014|December 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00814021||145679|
NCT00814333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11564|Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis|A Randomized Controlled Trial Comparing Outcomes in Patients Treated With Merocel Packing or Thrombin-JMI for Anterior Epistaxis||University of Kansas Medical Center|No|Terminated|December 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|December 23, 2008|Yes|Yes|Product supplier change - bought out. Unable to enroll patients.|No|December 10, 2015|https://clinicaltrials.gov/show/NCT00814333||145655|
NCT00814346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-39-00240-134|Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With: Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal|Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study||Ipsen|No|Completed|October 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|65 Years|N/A|No|||February 2013|February 26, 2013|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814346||145654|
NCT00819676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/220/2007|Analysis of Exhaled Breath by Biosensors in Adults With Asthma|Analysis of Exhaled Breath by Biosensors in Adults With Asthma: Observational Part of the Study "Effects of add-on Therapy With Oral Montelukast on the Analysis of Exhale Breath by Biosensors in Adults With Asthma||Catholic University of the Sacred Heart|Yes|Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|47|||Both|15 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|asthma clinic, community sample|July 2009|July 31, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819676||145247|
NCT00815477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0422-BE|Internet-Based Strategic Transdisciplinary Approach To Risk Reduction And Treatment|I-START: Internet-based Strategic Transdisciplinay Approach to Risk Reduction And Treatment|I-START|University Health Network, Toronto|No|Completed|September 2007|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|387|||Both|46 Years|74 Years|No|||February 2012|February 17, 2012|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815477||145568|
NCT00815802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07017|Detection of Human Cytomegalovirus in the Saliva|Detection of Human Cytomegalovirus in the Saliva of 3 Month to 6 Year-Old Children in Day Care Centers : a Pilot Study.|FcrèchMV|University Hospital, Limoges|No|Completed|July 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|655|||Both|3 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|child aged from 3 month to 6 years in day care centers or in emergency department.|December 2008|December 29, 2008|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815802||145543|
NCT00815815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4698|Effectiveness of High Intensity Inpatient Versus Stepped Intensity Treatment for Anorexia Nervosa|Anorexia Nervosa: The Importance of Treatment Intensity||New York State Psychiatric Institute|No|Completed|February 2004|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|16 Years|N/A|No|||August 2013|August 8, 2013|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815815||145542|
NCT00820534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPP4-DE-401|A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers|A Randomised, Double-blind, Vehicle Controlled, Single Center, Parallel Group, Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers||Novartis|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|126|||Both|18 Years|75 Years|No|||December 2010|April 18, 2012|January 9, 2009||No||No|November 12, 2010|https://clinicaltrials.gov/show/NCT00820534||145184|
NCT00820547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACS09 UC-0140/0802|Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients|Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer|Beverly1|UNICANCER|Yes|Active, not recruiting|January 2009|September 2017|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||December 2014|December 14, 2014|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820547||145183|
NCT00821418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLS-01|Assessment of Treatment With PulseHaler on Patients With Chronic Obstructive Pulmonary Disease (COPD)|Assessment of the Safety and the Effect on Patients With COPD of Treatment With PulseHaler™ - a Novel Device for Pulsating Positive Expiratory Pressure Ventilation||Respinova LTD||Completed|August 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|N/A|No|||May 2010|May 8, 2010|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821418||145117|
NCT00821431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0500-05-U342|Compression Device Versus 4-layer Compression System|A Phase II Study to Compare the Effect of a Compression Device to That of a 4-layer Compression System on Subjects With Venous Leg Ulcers.||ConvaTec Inc.|No|Completed|May 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|January 9, 2009|Yes|Yes||No|September 3, 2014|https://clinicaltrials.gov/show/NCT00821431||145116|
NCT00821730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCH2 446-2008|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Perspectives of Family Members and Friends|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Perspectives of Family Members and Friends||Sunnybrook Health Sciences Centre|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|N/A||1|Anticipated|15|None Retained|This is a qualitative research study|Both|18 Years|N/A|No|Non-Probability Sample|Family members, caregivers and friends of individuals with inflammatory arthritis|January 2011|January 6, 2011|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821730||145094|
NCT00821743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPN-GAB-PARK study|Pedunculo-Pontin Nucleus (PPN) - Deep Brain Stimulation (DBS) in Gait and Balance Disturbance in Parkinson's Disease (PPN-GAB-PARK Study)|Study of Deep Brain Stimulation of the Pedunculo-pontin Nucleus (PPN) for the Treatment of Gait and Balance Disturbances in Patients With Parkinson's Disease (PPN-GAB-PARK Study)||Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|70 Years|No|||March 2010|April 23, 2013|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821743||145093|
NCT00822029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005678-36|Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy|Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy||Centre Hospitalier Universitaire de Nice|No|Terminated|February 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|10 Years|18 Years|No|||November 2011|March 23, 2012|January 13, 2009||No|only 2 patients inclued and Study Principal Investigator has left the hospital|No||https://clinicaltrials.gov/show/NCT00822029||145071|
NCT00822341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-0054-01|Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Single Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TG-0054 in Healthy Subjects||TaiGen Biotechnology Co., Ltd.||Completed|April 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00822341||145047|
NCT00805766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-650-19|Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)|Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650 in Patients With Crohn's Disease (CD)||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2008|July 2010|Actual|November 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|16 Years|75 Years|No|||December 2012|December 5, 2012|December 9, 2008||No||No|September 2, 2012|https://clinicaltrials.gov/show/NCT00805766||146304|
NCT00807300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-000569-21|Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma|Phase-III-Study to Evaluate the Efficacy of CT-guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma.|CEAL|University of Magdeburg|No|Completed|October 2006|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00807300||146190|
NCT00807599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-121|Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L|A Phase II Clinical Trial for Untreated Patients With Multiple Myeloma Eligible for Stem Cell Transplant: Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|December 2008|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807599||146168|
NCT00806351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851021|An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System|Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection||Pfizer|Yes|Terminated|August 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|16 Years|N/A|No|||November 2012|November 20, 2012|November 26, 2008|Yes|Yes|The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not    terminate due to any safety issues or concerns.|No|November 20, 2012|https://clinicaltrials.gov/show/NCT00806351||146260|Study prematurely terminated due to slow enrollment, not due to safety issues. Meaningful interpretation and comparison of treatment outcomes with caspofungin was difficult due to low number of participants (n=3) with confirmed Candida infection.
NCT00814034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPA-HBSS0801|Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy|An Observational, Prospective Cohort Study, on Blood Coagulation Parameters in Postmenopausal Patients With Operable Breast Cancer Who Are Treated as Per Standard Practice With Adjuvant Hormonal Therapy for a Total of 5 Years|COPA|Hellenic Breast Surgeons Society|Yes|Completed|February 2008|December 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|306|||Female|18 Years|80 Years|No|Non-Probability Sample|Postmenopausal, ER and/or PgR positive breast cancer patients eligible for adjuvant        hormonal treatment (HT), who are admitted for treatment and follow-up at the participating        sites, will be enrolled in the trial. Study subjects will be treated with standard        adjuvant hormonal therapy for a total of 5 years or until disease relapse or until HT is        permanently discontinued for other reasons.        The choice of endocrine treatment strategy (drugs to be used or their sequence, if the        sequential option has been decided) is left at the discretion of the participating site.        Adjuvant HT will commence after the completion of adjuvant chemotherapy and/or        radiotherapy.|September 2015|September 4, 2015|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00814034||145678|
NCT00814359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUCOSA-PROTECT|Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis|A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.||Juravinski Cancer Centre Foundation|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|67|||Both|18 Years|N/A|No|||May 2009|January 19, 2011|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814359||145653|
NCT00814632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-134|CC-10004 For The Treatment Of Vulvodynia|A Clinical Trial Of CC-10004 For The Treatment Of Vulvodynia||William Beaumont Hospitals|Yes|Completed|December 2008|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|69 Years|No|||August 2015|August 11, 2015|December 23, 2008|Yes|Yes||No|December 24, 2013|https://clinicaltrials.gov/show/NCT00814632||145632|Small pilot study without placebo arm. Only 7 subjects completed treatment.
NCT00814645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR001 CS02|Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers|A Placebo-Controlled, Phase 1b, Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution (AIR001 INHALATION SOLUTION) in Normal, Healthy Volunteers|AIR001-CS02|Aires Pharmaceuticals, Inc.|No|Completed|December 2008|June 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|December 22, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00814645||145631|
NCT00814918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15929B|Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris|Topical 5-ALA-PDT With Blu-U Therapy Vs. Topical 5-ALA With Pulse Dye Laser In Treatine Recalcitrant Acne Vulgaris||University of Chicago|No|Withdrawn|February 2009|February 2014|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|79 Years|No|||December 2014|December 2, 2014|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814918||145611|
NCT00814931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0114|Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males|A Phase 1, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Examining the Effects of CXB722 in Mitigating Neuroendocrine Stress Response in Healthy Males|CXB722-100|National Institute on Aging (NIA)|No|Completed|December 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Male|18 Years|34 Years|Accepts Healthy Volunteers|||January 2009|January 9, 2009|December 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00814931||145610|
NCT00820274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07011|Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers|Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers|MAUV|University Hospital, Limoges|Yes|Terminated|January 2009|June 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|August 31, 2015|January 9, 2009||No|clinical trial have encountered difficulties enrolling a sufficient number of patients|No||https://clinicaltrials.gov/show/NCT00820274||145204|
NCT00819949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4125-K|Effect of Robot-assisted Gait Training on Freezing of Gait in Parkinson's Disease|Effect of Robot-assisted Gait Training on Freezing of Gait in Parkinson's Disease||VA Office of Research and Development|Yes|Completed|October 2008|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|85 Years|No|||September 2013|September 18, 2013|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819949||145227|
NCT00819962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-652|Perioperative Analgesia Using Ultrasound (US) Guided Transversus Abdominis Plane (TAP) Block|||King Saud University|Yes|Recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|42|||Both|20 Years|50 Years|No|||November 2014|September 13, 2015|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00819962||145226|
NCT00820261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP35341|Molecular Epidemiology of Rotavirus Diarrhea Among Infants and Young Children Attending Maua Methodist Hospital, Kenya|Molecular Epidemiology of Rotavirus Diarrhea Among Infants and Young Children Attending Maua Methodist Hospital, Kenya|Rotavirus|Institute of Primate Research|Yes|Completed|August 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|630|Samples With DNA|The positive samples will be evaluated by sodium dodecyl polyacrylamide gel electrophoresis      (SDS-PAGE) to determine the electropherotypes and genotyped using reverse transcriptase      polymerase chain reaction (RT-PCR) on VP7 and VP4 gene and sequencing. Also, these positive      samples will be retained for quality assurance and quality control.|Both|1 Month|60 Months|No|Probability Sample|Stool specimens will be collected from infants and young children below 5 years of age        with severe diarrhea hospitalized in two government hospital (Maua Methodist hospital,        during a two (2) year period|September 2012|September 6, 2012|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820261||145205|
NCT00821119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIP123|Trial of Non Invasive Ventilation for Respiratoy Distress Syndrome|A Randomized Controlled Trial of Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Pressure as a Primary Mode for Respiratory Distress Syndrome in Preterm Infants||Instituto Materno Infantil Prof. Fernando Figueira|No|Completed|August 2007|September 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|N/A|1 Day|No|||March 2013|March 3, 2013|January 12, 2009||No||No|September 24, 2012|https://clinicaltrials.gov/show/NCT00821119||145139|
NCT00821132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lab01|Genetics of Familial and Sporadic ALS|Identification of Genes Causing Familial ALS or Increasing Risk for Sporadic ALS and ALS With Frontotemporal Dementia and Understanding Disease Mechanism.|ALS|Northwestern University|Yes|Recruiting|January 1991|December 2022|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|15000|Samples With DNA|Whole blood and/or skin and CSF samples      The investigators also collect brain and spinal cord tissue specimans.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Open to all ALS patients and selected family members|March 2016|March 21, 2016|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00821132||145138|
NCT00821444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281191|Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules|Phase 1 Study Of Ziprasidone Pharmacokinetics Of Reduced Food Effect Formulation B16 Under Fed And Fasting Conditions Compared To Commercial Geodon Capsules Under Fed Conditions In Healthy Subjects||Pfizer|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 11, 2011|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00821444||145115|
NCT00821457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0098|Juvista in the Non-surgical Improvement of Existing Scars|A Within Patient, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy of Juvista in Improving the Appearance of Existing Scars That Are 2-6 Months Old||Renovo|No|Withdrawn|January 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|45 Years|No|||March 2010|March 8, 2010|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821457||145114|
NCT00821756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-2005|The Amager Project: Intervention After Suicide Attempt|The Amager Project. Intervention After Suicide Attempt: A Randomized Study.|Amager|Rigshospitalet, Denmark|Yes|Active, not recruiting|January 2005|August 2010|Anticipated|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|133|||Both|12 Years|N/A|No|||January 2009|January 12, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821756||145092|
NCT00821769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-3845-USC2|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2007|||||N/A|N/A|N/A||||||||||||||July 16, 2010|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821769||145091|
NCT00821782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012235|Evaluation of Bacteria in the Mouth and Throat of Healthy Adults Before and After the Administration of Either Levofloxacin or Azithromycin, Both Antibiotic Medications|A Randomized, Open-Label Study Comparing Levofloxacin Once-Daily 750 mg PO for 5 Days and Azithromycin Once-Daily 500 mg on Day One and Then 250 mg Days 2 Through 5 In a Microbiologic Evaluation for Emergence of Resistance in the Oropharyngeal Flora of Healthy Subjects||Ortho-McNeil Janssen Scientific Affairs, LLC||Completed|June 2006|September 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|143|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|May 18, 2011|January 9, 2009||||No||https://clinicaltrials.gov/show/NCT00821782||145090|
NCT00822042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 051037|Corticosteroid-induced Lipodystrophy and Adipokines|Study of Histological and Adipokines Expression Variations in Lipodystrophic Adipose Tissue During Corticosteroids-induced Lipodystrophy|ADIPOKINES|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2006|November 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples Without DNA|Cytopunction (adipocytes), whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients consulting in participating units|January 2009|February 26, 2014|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822042||145070|
NCT00822354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU1199|Tadalafil for the Treatment of Raynaud's|Tadalafil for the Treatment of Secondary Raynaud's Phenomenon||Northwestern University|No|Completed|September 2008|April 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|May 31, 2008||No||No|September 11, 2014|https://clinicaltrials.gov/show/NCT00822354||145046|
NCT00806091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004H0102|Functional Proteomics of Alveolar Macrophages|Functional Proteomics of Alveolar Macrophages||Ohio State University|No|Completed|July 2004|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|Samples With DNA|blood BAL fluid breathe condensation saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|smokers with and without COPD, general population|December 2008|December 9, 2008|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806091||146280|
NCT00806104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOS_QLV2|Fructo-oligosaccharides and Irritable Bowel Syndrome|Effect of Dietary Supplementation With Fructo-oligosaccharides on Visceral Sensitivity and on Taxonomic and Functional Composition of Intestinal Microbiota of IBS Patients||Beghin-Meiji||Completed|March 2009|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2011|January 14, 2011|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806104||146279|
NCT00807612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080257|Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer|A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer||Amgen||Terminated|January 2009|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|December 11, 2008|Yes|Yes|Study was closed due to administrative decision|No||https://clinicaltrials.gov/show/NCT00807612||146167|
NCT00806975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Type 2 Diabetic Patients|Randomized，Open-Label，2-Period，Crossover Comparison of Randomized，Open-Label，2-Period，Crossover Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Adult Patients With Type 2 Diabetes Mellitus||Nagaoka Red Cross Hospital|No|Not yet recruiting|January 2009|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Both|20 Years|80 Years|No|||December 2008|December 10, 2008|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00806975||146215|
NCT00814047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-280604|The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery|The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery||Medical University of Vienna|Yes|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2008|December 22, 2008|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00814047||145677|
NCT00814060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1117|Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)|A Single Dose Bioavailability Study of 2 New Tablet Formulations of Neratinib Compared With a Reference Capsule in Healthy Adult Subjects||Puma Biotechnology, Inc.|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|December 17, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00814060||145676|
NCT00814372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M102-20814|Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MBX-102/JNJ-39659100 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy||CymaBay Therapeutics, Inc.|No|Terminated|December 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|242|||Both|18 Years|70 Years|No|||March 2015|March 30, 2015|December 22, 2008|Yes|Yes|MBX-102 did not meet the target efficacy profile of HbA1c change.|No||https://clinicaltrials.gov/show/NCT00814372||145652|
NCT00814658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014938|The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life|The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life||Janssen-Cilag Farmaceutica Ltda.||Completed|June 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|65 Years|N/A|No|||August 2013|August 22, 2013|December 24, 2008||No||No|November 27, 2012|https://clinicaltrials.gov/show/NCT00814658||145630|The major limitation of this study was the small sample size. This was probably due to the short enrollment period and to the rigorous inclusion criteria that were adopted.
NCT00814671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3524|Study of Daily Rifapentine for Pulmonary Tuberculosis|A Phase 2 Randomized, Open-label Trial of Daily Rifapentine 450mg or 600mg in Place of Rifampicin 600mg for Intensive Phase Treatment of Smear-positive Pulmonary Tuberculosis||Johns Hopkins University|Yes|Completed|April 2010|September 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|December 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00814671||145629|
NCT00814944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DES-001|A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model|A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model||Santen Inc.|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|143|||Both|18 Years|N/A|No|||July 2010|January 8, 2013|December 23, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814944||145609|
NCT00820001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH057727|Resources to Enhance the Adjustment of Children (REACH)|Enhancing Long-Term Outcome in Child Behavior Disorders|REACH|University of Pittsburgh|No|Completed|December 2003|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|254|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00820001||145223|
NCT00820560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 7839-201|Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients With Solid Tumors||Incyte Corporation|No|Completed|January 2005|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820560||145182|
NCT00820573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35464|Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM|Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With Type 2 Diabetes Mellitus||The University of Texas Health Science Center at San Antonio|No|Completed|October 2009|October 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|January 8, 2009|Yes|Yes||No|November 5, 2012|https://clinicaltrials.gov/show/NCT00820573||145181|
NCT00820885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-022|A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide|A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide||Shire|Yes|Completed|July 2006|May 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|8||Actual|95|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||January 2009|November 11, 2015|January 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00820885||145157|
NCT00820898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0129Q|Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||Gynecologic Oncology Group||Completed|February 2009|||January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820898||145156|
NCT00820911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2206E1|Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients|An Extension to a 12-month, Open-label, Randomised, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients||Novartis||Completed|September 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|175|||Both|18 Years|75 Years|No|||March 2015|March 13, 2015|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820911||145155|
NCT00821145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LapAorta2008|Laparoscopic Versus Open Abdominal Aortic Aneurysm (AAA) Exclusion|Laparoscopic Aortic Resection Versus Open Surgery in Patients With AAA|LapAorta|Augusta Hospital Duesseldorf|No|Withdrawn|January 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|0|||Both|40 Years|80 Years|No|||January 2009|July 11, 2012|January 8, 2009||No|inability to recruit sufficient number of patients|No||https://clinicaltrials.gov/show/NCT00821145||145137|
NCT00821470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ref. 98/20|Treatment of Osteonecrosis of the Femoral Head by Bone Marrow Transplantation|Treatment of Osteonecrosis of the Femoral Head With Implantation of Autologous Bone Marrow Cells, a Pilot Study||Erasme University Hospital|Yes|Completed|January 1999|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||January 2009|January 13, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821470||145113|
NCT00821483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRESH|A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine|Phase 3 Study to Assess the Efficacy and Safety of Frovatriptan||SK Chemicals Co.,Ltd.|Yes|Completed|November 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|65 Years|No|||April 2013|April 16, 2013|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00821483||145112|
NCT00822055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM0501|Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|May 2005|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|140|||Both|18 Years|N/A|No|||January 2009|January 13, 2009|January 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00822055||145069|
NCT00822068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aphasia_tDCS|Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation|Improvement of Aphasia After Stroke by Intensive Training and Transcranial Direct Current Stimulation||University Hospital Muenster|No|Recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|80 Years|No|||January 2009|January 13, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822068||145068|
NCT00822367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-10010|Blood Sugar Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes|Assessment of Glycemic Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes Mellitus||Walter Reed Army Medical Center|No|Completed|May 2006|September 2007|Actual|August 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|19|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2009|January 13, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822367||145045|
NCT00817804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V60-1050766VP v 2.3|Cross-over Comparison of the V60 System to Other Bi-Level Noninvasive Ventilators|Cross-over Comparison of the V60 System to Other Bi-Level Noninvasive Ventilators for Pediatric Patients With Respiratory Failure or Respiratory Insufficiency||Respironics, California, Inc.|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|7 Years|18 Years|No|||August 2009|August 12, 2009|January 3, 2009|Yes|Yes||No|May 5, 2009|https://clinicaltrials.gov/show/NCT00817804||145389|Terminated before 20 patients enrolled
NCT00817817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02524|A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)|An Open-Label, Comparative, Randomized, Parallel, Multicenter Study to Determine the Efficacy and Safety of Two Dry Powder Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma||Merck Sharp & Dohme Corp.|No|Completed|October 2002|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|January 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00817817||145388|
NCT00806988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-00003|Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation|Surgical Interventions for Moderate Ischemic Mitral Regurgitation||Icahn School of Medicine at Mount Sinai|Yes|Completed|December 2008|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00806988||146214|
NCT00807001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355-003|Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects|A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected With Genotype 1 Chronic Hepatitis C||Merck Sharp & Dohme Corp.|No|Completed|December 2008|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|December 10, 2008|Yes|Yes||No|October 8, 2010|https://clinicaltrials.gov/show/NCT00807001||146213|Adverse events summarized the 3 days of IDX184 dosing and 14 days of treatment free follow up.
NCT00807885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1838-007|Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase|INcreased Flow Utilizing Subcutaneously-Enabled Fluids Administration Technique Study (INFUSE-AT): A Randomized, Open-Label, Parallel Group, Phase IV, Study Evaluating the Techniques of Administration of Subcutaneous Fluids Enabled by Human Recombinant Hyaluronidase (Hylenex) in Healthy Adult Volunteers|INFUSE-AT|Baxter Healthcare Corporation|No|Completed|December 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 21, 2011|December 10, 2008|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00807885||146147|
NCT00807586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ep002|Corticosteroid Pulse After Ablation|SAAB: Randomized, Double Blind STudy of Corticosteroid Pulse After Ablation|SAAB|Minneapolis Heart Institute Foundation|No|Active, not recruiting|December 2008|December 2013|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807586||146169|
NCT00814073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB06006|A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap|A 24-week With Possible Extension, Prospective, Multicentre, Randomized, Double Blind, Placebo-controlled, 2-parallel Group With a Randomization 1:1, Phase III Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap||AB Science|Yes|Recruiting|December 2008|June 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|December 22, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00814073||145675|
NCT00814385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL10492|Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04|A Randomized, Partially Observer-blind, Single-centre Study to Evaluate Safety and Immunogenicity of MF59-adjuvanted or Non-adjuvanted H5N1 Influenza Vaccines in Adults Primed With Adjuvanted Influenza A/Vietnam/1194/04 (H5N1) Vaccine||University Hospitals, Leicester|Yes|Completed|November 2008|December 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|9||Actual|606|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 2, 2014|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814385||145651|
NCT00814398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVISEV-002SET|Single Embryo Transfer Versus Double Embryo Transfer|Single Embryo Transfer Versus Double Embryo Transfer in Day 3 or Blastocyst Stage||IVI Sevilla|No|Terminated|December 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|199|||Female|18 Years|37 Years|No|||March 2011|January 15, 2016|December 23, 2008||No|Change in cryopreservation protocol|No||https://clinicaltrials.gov/show/NCT00814398||145650|
NCT00814411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCFP|A Trial of Group Versus Individual Family Planning Counseling in Ghana|A Randomized Trial of Group vs. Individual Family Planning Counseling in Ghana|GCFP|Johns Hopkins Bloomberg School of Public Health|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|648|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|December 23, 2008|December 23, 2008||No||No||https://clinicaltrials.gov/show/NCT00814411||145649|
NCT00819416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008640|Fluid Resuscitation in Early Septic Shock|Five Percent Albumin Versus Normal Saline as Fluid Resuscitation Strategies for the Management of Early Suspected Septic Shock|PRECISE|Ottawa Hospital Research Institute|Yes|Completed|February 2009|February 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819416||145267|
NCT00814697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91913-5|Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease|Open-label, Exploratory Study of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Naming and Verbal Fluency in Patients With Alzheimer's Disease With Functional Imaging Correlates||The New York Memory Services|No|Completed|December 2008|August 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|50 Years|90 Years|No|||January 2014|January 8, 2014|December 24, 2008|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00814697||145628|
NCT00819403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040970|Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment|The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome||University of Maryland|No|Completed|January 2009|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|January 7, 2009|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT00819403||145268|
NCT00820014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESBA105CRD03|Ocular Biodistribution Study for Topically Applied ESBA105|Evaluation of Tolerability, Safety and Ocular Pharmacokinetics of Topically Applied ESBA105 in Patients Undergoing Cataract Surgery or Combined Cataract Surgery and Vitrectomy||ESBATech AG|No|Completed|January 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|79|||Both|18 Years|N/A|No|||January 2009|September 23, 2010|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820014||145222|
NCT00820027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-098|Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)|A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK0663/Etoricoxib and Ibuprofen in the Treatment of Postorthopedic Knee Replacement Surgery Pain||Merck Sharp & Dohme Corp.|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|776|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820027||145221|
NCT00820287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APN 2004|Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk|Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk||Centre Hospitalier Universitaire de Nice|No|Terminated|September 2005|June 2011|Actual|January 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|44|||Male|18 Years|35 Years|No|||January 2009|March 23, 2012|January 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00820287||145203|
NCT00820300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 03|A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma|An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|90 Years|No|||September 2013|September 16, 2013|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820300||145202|
NCT00820586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVICPR-003|Intramyocardial Delivery of Autologous Bone Marrow|Intramyocardial Delivery of Autologous Bone Marrow||IRCCS San Raffaele|No|Suspended|May 2007|December 2018|Anticipated|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|21 Years|N/A|No|||February 2012|February 1, 2012|January 8, 2009||No|No more funding support for additional procedures|No||https://clinicaltrials.gov/show/NCT00820586||145180|
NCT00820924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105594|Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells|A Phase II Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Daily Dose of Lapatinib in Advanced Breast Cancer Patients With HER-2 Non-amplified Primary Tumours and HER-2 Positive Circulating Tumour Cells or EGFR Positive Circulating Tumor Cells||GlaxoSmithKline|No|Terminated|June 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|N/A|No|||March 2012|March 22, 2012|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00820924||145154|
NCT00821496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-108|Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects|A Phase I, Open Label, Fixed Sequence, Single-Center Study to Evaluate the Effect of Multiple Dose Administration of VI-0521 on the Pharmacokinetics of a Single Dose of Oral Contraceptive in Healthy Female Subjects||VIVUS, Inc.|No|Completed|January 2009|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|19 Years|64 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|January 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00821496||145111|
NCT00821509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTL460-8|STOPFLU: Is it Possible to Reduce the Number of Days Off in Office Work by Improved Hand-hygiene?|STOPFLU: Is it Possible to Reduce the Number of Days Off in Office Work by Improved Hand-hygiene?||National Institute for Health and Welfare, Finland|No|Completed|January 2009|December 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|683|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|January 12, 2009||No||No|October 5, 2011|https://clinicaltrials.gov/show/NCT00821509||145110|In a pre-study interview, 90% stated "when I have cold I usually come to work if I only can". Participants in the intervention arms, but not those of the control arm, were advised to stay home when sick: possible contribution to outcome measure 1.
NCT00821795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIISTA-596-1|Veterans Inpatient Insulin Study and Transition to Outpatient Therapy|Veterans Inpatient Insulin Study and Transition Algorithm: Efficacy of Insulin Analogs for Inpatient Glycemic Control and Transition to Outpatient Therapy|VIISTA|Lexington VA Medical Center|No|Completed|February 2009|||June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|N/A|No|||October 2013|October 23, 2013|January 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00821795||145089|
NCT00820079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX10059-204|ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)|A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD)||Addex Pharma S.A.|No|Completed|December 2008|||October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||December 2009|December 23, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00820079||145218|
NCT00820963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626713|Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme|Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma||National Cancer Institute (NCI)||Completed|July 2006|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|3||Anticipated|70|||Both|60 Years|N/A|No|||July 2009|May 11, 2011|January 9, 2009||||No||https://clinicaltrials.gov/show/NCT00820963||145151|
NCT00821834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10675|Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned|A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg Once Daily With a 300 mg Loading Dose Versus Ticlopidine 100 mg Twice Daily in Patients With Stable Angina or Old (Healed) Myocardial Infarction to Which Percutaneous Coronary Intervention is Being Planned - With Extended Treatment of Clopidogrel 75 mg Once Daily for 40 Weeks in a Patients' Subset|CLEAN|Sanofi|Yes|Completed|December 2008|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1003|||Both|20 Years|N/A|No|||July 2011|July 25, 2011|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00821834||145086|
NCT00818220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2980022|Protective Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants|Protective Effects of Delayed Cord Clamping in VLBW Infants||University of Rhode Island|Yes|Completed|February 2008|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|211|||Both|N/A|N/A|No|||May 2015|May 26, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00818220||145358|
NCT00818233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601001047|Intra-observer and Inter-observer Variability With Dynamic Contour Tonometry.|Intra-observer and Inter-observer Variability With Dynamic Contour Tonometry.||Yale University|Yes|Withdrawn|January 2009|January 2011|Anticipated|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, competent adults with normal, healthy eyes.|January 2011|January 13, 2011|November 18, 2008||No|Difficulty recruiting patients. PI left research facility.|No||https://clinicaltrials.gov/show/NCT00818233||145357|
NCT00807313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT501|Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer|Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer|tomoligo|Universitair Ziekenhuis Brussel|No|Completed|December 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|53|||Both|18 Years|N/A|No|Probability Sample|Patients with oligometastatic (5 metastases or less) colorectal cancer|April 2013|April 29, 2013|December 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00807313||146189|
NCT00807326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOPDIR4002|A Comparison of Three Medications to Treat Diarrhea in Adults.|A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|November 2008|November 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|415|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00807326||146188|
NCT00808717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0156|Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI)|Efficacy of High Dose Atorvastatin Loading in ST Elevation Myocardial Infarction|STATIN STEMI|Yonsei University|Yes|Completed|July 2007|||December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|80 Years|No|||July 2009|July 14, 2009|December 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00808717||146083|
NCT00807872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2625|Radioimmunoimaging of AL Amyloidosis|Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4||University of Tennessee|No|Completed|December 2008|July 2013|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|21 Years|90 Years|No|||September 2013|September 17, 2013|December 11, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00807872||146148|
NCT00808132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-3307|Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis|A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women||Pfizer|No|Completed|January 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1886|||Female|40 Years|64 Years|No|||March 2014|March 10, 2014|December 12, 2008|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00808132||146128|
NCT00818467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton 7|UVB Light and Sunscreen|3% Dihydroxyacetone (DHA or Sunless Tanning Agent) Inhibits Vitamin D Production in the Skin in Response to Ultraviolet Light|Sunscreen|Creighton University|No|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||November 2009|November 27, 2009|January 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00818467||145339|
NCT00818753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.73|Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention|The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization||Boehringer Ingelheim||Completed|January 2009|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|85 Years|No|||December 2013|June 3, 2014|January 7, 2009||||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00818753||145317|Although a total of 50 patients are included in the FAS, 4 of these patients did not have data for the primary endpoint and are therefore not included in the odd ratio calculation
NCT00819702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040157 (H-27327)|A Safe Environment for Every Kid (SEEK II)|Preventing Child Maltreatment: A Role for Community Pediatricians|SEEK II|University of Maryland|Yes|Completed|May 2006|May 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|905|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 2, 2010|January 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00819702||145246|
NCT00819975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-PPL (5B) LSM|Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes|Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes||Aarhus University Hospital|No|Completed||May 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|12|||Both|40 Years|75 Years|No|||January 2009|January 8, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00819975||145225|
NCT00819988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI2008525|Pregabalin in the Prevention of Postoperative Delirium and Pain|A Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety and Efficacy of the Perioperative Administration of Pregabalin in Reducing the Incidence of Postoperative Delirium and Improving Acute Postoperative Pain Management||Ottawa Hospital Research Institute|No|Completed|May 2009|October 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Both|60 Years|N/A|No|||January 2012|January 9, 2012|January 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00819988||145224|
NCT00820326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I03002|Efficacy of Dolasetron in Patients With Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled, Study of Efficacy of DOLASETRON in Patients With Fibromyalgia|Dolastron|University Hospital, Limoges|No|Completed|March 2004|June 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||January 2009|January 9, 2009|December 27, 2008||No||No||https://clinicaltrials.gov/show/NCT00820326||145200|
NCT00828815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015775|TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.|A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy.||Tibotec Pharmaceuticals, Ireland||Completed|March 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|22|||Both|18 Years|55 Years|No|||October 2010|June 8, 2011|January 22, 2009||||No||https://clinicaltrials.gov/show/NCT00828815||144552|
NCT00829543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8715|Unguided Sacroiliac Injection: Effect on Refractory Buttock Pain in Patients With Spondyloarthropathies|Guide-Free Sacroiliac Injection in Spondyloarthropathies||Tabriz University|Yes|Enrolling by invitation|September 2004|February 2009|Anticipated|January 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|16 Years|50 Years|No|||February 2009|February 2, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829543||144496|
NCT00829842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP 8904/2005|Oral Hygiene With Chlorhexidine and Incidence of Ventilator-Associated Pneumonia in Children Submitted to Heart Surgery|Evaluation of Oral Hygiene With 0.12% Chlorhexidine Antiseptic Solution on the Incidence of Nosocomial Pneumonia and Ventilator-Associated Pneumonia in Children Submitted to Heart Surgery||University of Sao Paulo|Yes|Completed|February 2006|February 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|N/A|18 Years|No|||January 2009|January 26, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829842||144473|
NCT00830128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081209|A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia|An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For The Treatment Of Fibromyalgia||Pfizer|No|Completed|July 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|January 26, 2009|Yes|Yes||No|January 23, 2012|https://clinicaltrials.gov/show/NCT00830128||144451|
NCT00830141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0040-08-EMC|Study of the Molecular Basis in the Pathophysiology of Food Intake and Growth in Children|Study of the Molecular Basis in the Pathophysiology of Food Intake and Growth in Children|Ghrelin|HaEmek Medical Center, Israel|No|Completed|January 2009|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|259|Samples With DNA|Genomic DNA will be isolated from peripheral blood by standard methods. The corresponding      intron-exon boundaries of ghrelin and GHSR genes will be analyzed by direct sequencing using      the ABI Prism 3100 DNA Analyzer|Both|N/A|18 Years|No|Probability Sample|A total of 250 children followed in the pediatric endocrine department at Ha'Emek Medical        Center will be divided into 5 groups: 50 children with GH deficiency,50 obese children, 50        children with failure to thrive (FTT)and 50 children with idiopathic short stature (ISS).        50 children without growth and weight disorders will be included as a control group.|July 2015|July 2, 2015|January 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00830141||144450|
NCT00830778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51480|Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy|Reduced Postoperative Pancreatic Fistula Rate Following Pancreaticoduodenectomy; Multicentric Randomized Controlled Trial on Pancreaticogastrostomy vs. Pancreaticojejunostomy||University Hospital, Gasthuisberg|Yes|Completed|June 2009|September 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|85 Years|No|||September 2012|September 11, 2012|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830778||144401|
NCT00831051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q8003-021|Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients|A Double-Blind, Randomized, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of the Opioid Combination Q8003 to Each of the Individual Milligram Components (Oxycodone and Morphine) in the Management of Acute Moderate to Severe Pain Following Bunionectomy Surgery||QRxPharma Inc.|No|Completed|December 2008|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|197|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831051||144380|
NCT00831727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23614|The Role of Affect Regulation and Self-presentation in the Expressive Writing Intervention|Examining Potential Moderators and Mediators in the Expressive Writing Intervention: The Role of Affect Regulation and Self-presentation.||University of Toronto|No|Active, not recruiting|February 2009|February 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||April 2010|April 14, 2010|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831727||144330|
NCT00831740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R011023|ACT NoW: Assessing the Effectiveness of Communication Therapy in the North West|ACT NoW: Assessing the Effectiveness of Communication Therapy in the North West: a Pragmatic, Multi-centre Randomised Controlled Trial|ACT NoW|University of Manchester|Yes|Completed|October 2006|October 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||October 2010|November 3, 2010|January 28, 2009||||No||https://clinicaltrials.gov/show/NCT00831740||144329|
NCT00831350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4348s|Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations|Posterior Vitreous Detachment (PVD) Assessment During Dual RVO Lucentis Evaluations (PADDLE Study)|PADDLE|Barnes Retina Institute|No|Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2009|January 27, 2009|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831350||144357|
NCT00827463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08009|Early Detection of Anaemia During the Maternity|The Early Detection of Anaemia During the Maternity Decreases the Anaemia at the End of the Maternity.|anémie|University Hospital, Limoges|Yes|Recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|160|||Female|18 Years|55 Years|No|||September 2009|September 8, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00827463||144656|
NCT00827476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0530-08-HMO- CTIL|Improving Human Ovarian Transplantation|Phase 1 Study to Improve Results of Human Ovarian Transplantation||Hadassah Medical Organization|Yes|Active, not recruiting|January 2009|January 2015|Anticipated|January 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|5 Years|40 Years|No|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827476||144655|
NCT00827099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632453|Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer|Transplantation of Two Partially Matched Umbilical Cord Blood Units Following Reduced Intensity Conditioning to Enhance Engraftment and Limit Transplant-Related Mortality in Adults With Hematologic Malignancies||Northside Hospital, Inc.|No|Terminated|June 2006|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||March 2012|March 19, 2012|January 21, 2009|Yes|Yes|Unacceptable morbidity & mortality|No|July 28, 2011|https://clinicaltrials.gov/show/NCT00827099||144684|This study was terminated early, therefore no additional data measures or outcomes are available.
NCT00837187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDEX|Bioavailability of Dexmedetomidine After Intranasal Administration|Bioavailability of Dexmedetomidine After Intranasal Administration in Healthy Subjects|INDEX|University of Turku|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|7|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 12, 2010|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837187||143915|
NCT00827723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251/08|Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma|Makuuchi Versus Barcelona Clinic of Liver Cancer Criteria in Cirrhotic Patients With Hepatocellular Carcinoma. Does Etiology of Cirrhosis Influence the Relationship Between the Portal Pressure and Quantitative Tests of Liver Function?||University of Lausanne Hospitals|Yes|Recruiting|February 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Community sample|January 2016|January 27, 2016|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827723||144636|
NCT00827736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00.058|Comparison of Treatment Success of Botox Injection in the Internal Sphincter Versus Isosorbidedinitrate Ointment in Patients With an Anal Fissure|Botulin Toxin Versus Isosorbidedinitrate Ointment in Treatment Anal Fissure; A Prospective, Blinded, Randomized Trial||Onze Lieve Vrouwe Gasthuis|No|Completed|June 2002|March 2006|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||January 2009|January 22, 2009|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827736||144635|
NCT00827944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC 0607/1|Parietex Progrip Study|ProGrip Mesh Repair Versus Lichtenstein Mesh Repair: a Comparative Randomized Study in Primary Inguinal Hernia||Sofradim Production|No|Active, not recruiting|October 2008|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Male|31 Years|74 Years|No|||May 2012|May 16, 2012|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827944||144619|
NCT00828204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108MS302|Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects|An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects||Biogen|No|Completed|January 2009|October 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|95|||Both|18 Years|65 Years|No|||May 2014|May 8, 2014|January 20, 2009|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00828204||144599|The Initial Subset is too small a population from which to draw conclusions.
NCT00828217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-2008-HO|Adapted Physical Activity, Health-related Quality of Life and Satisfaction With Care in Hospitalized Children|ACTIVHOP: Adapted Physical Activity, Health-related Quality of Life and Satisfaction With Care in Hospitalized Children; a Randomized Controlled Study|ACTIVHOP|Central Hospital, Nancy, France|No|Recruiting|November 2008|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|312|||Both|5 Years|18 Years|No|||September 2010|September 23, 2010|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828217||144598|
NCT00828555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011038|Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting|Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting||Duke University|No|Completed|November 2008|February 2012|Actual|April 2009|Actual|N/A|Observational|N/A||1|Actual|3988|||Female|12 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population Groups:        Adults        Minors        Patients        Pregnant Women        Fetuses|September 2012|October 15, 2012|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828555||144572|
NCT00828893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 08 01|Navigation Guidance Gestures Carried Out Under CT|Interest of the Use of a Navigation Guidance Gestures Carried Out Under CT|CT-Nav|University Hospital, Grenoble|Yes|Completed|October 2009|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828893||144546|
NCT00829218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4763|Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)|A Clinical Trial Examining the Effects of the Food Additive Glutamate on Irritable Bowel Syndrome and Fibromyalgia||Oregon Health and Science University|Yes|Completed|January 2009|May 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|75 Years|No|||December 2013|December 21, 2013|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829218||144521|
NCT00829231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12349|Hepatic Impairment Study|Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006)||Bayer|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|January 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829231||144520|
NCT00828516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632850|Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema|Using Acupuncture and Moxibustion to Promote Wellbeing and Improve Quality of Life for Patients With Upper Body Lymphoedema Secondary to Cancer Treatment|AMWELL-SL|East and North Hertfordshire NHS Trust|No|Completed|April 2008|December 2009|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|56|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|January 23, 2009||No||No|November 9, 2012|https://clinicaltrials.gov/show/NCT00828516||144575|
NCT00830154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP456-041|A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering|A 3 Arm, Double-blind, Placebo-controlled Parallel Group Study to Assess the Efficacy,Safety and Tolerability of Pagoclone for Adults With Stuttering||Endo Pharmaceuticals|No|Completed|February 2009|January 2011|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|321|||Both|18 Years|80 Years|No|||August 2012|August 20, 2012|January 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830154||144449|
NCT00830167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081208|Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia|Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin（CI-1008）In The Treatment Of Fibromyalgia||Pfizer|Yes|Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|498|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|January 26, 2009|Yes|Yes||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00830167||144448|
NCT00829907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098005|A PET Study With ORM-12741|Effect of ORM-12741 on Receptor Occupancy Studied by Positron Emission Tomography; an Open, Single Dose, Dose Ranging Study in Healthy Males||Orion Corporation, Orion Pharma|Yes|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00829907||144468|
NCT00829855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEI_242_2007|Echocardiographic Evaluation of Hypertensive Acute Pulmonary Edema|Echocardiographic Evaluation of Hypertensive Acute Pulmonary Edema||Carol Davila University of Medicine and Pharmacy|Yes|Completed|May 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|51|||Both|18 Years|N/A|No|Probability Sample|Patients admitted in the Cardiac Care Unit of an University and Emergency Hospital, with a        diagnosis of acute cardiogenic pulmonary edema associated with hypertension (systolic        blood pressure ≥160 mmHg)|March 2013|March 4, 2013|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829855||144472|
NCT00831090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02338|Endothelial Function and Vein Graft Remodeling|Endothelial Function and Vein Graft Remodeling|EFVGR|University of California, San Francisco|No|Recruiting|January 2009|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|A segment of vein that would usually be discarded will be taken to a lab for testing of      endothelial reactivity and quantification of endothelial coverage through CD31 staining.|Both|22 Years|89 Years|No|Non-Probability Sample|Vascular Surgery clinic|July 2015|July 2, 2015|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831090||144377|
NCT00831363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-0001-MP|Minimal Invasive Versus Traditional Transgluteal Approach in Total Hip Arthroplasty: a Comparative Gait Analysis|Minimal Invasive Versus Traditional Transgluteal Approach in Total Hip Arthroplasty: a Comparative Gait Analysis||Orthopedic Hospital Vienna Speising||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|N/A|N/A|No|Probability Sample|primary care clinic|January 2009|January 27, 2009|January 27, 2009||||No||https://clinicaltrials.gov/show/NCT00831363||144356|
NCT00831753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L17|Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants|Immunogenicity Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to Infanrix®Hexa, at 2-4-6 Months of Age in Healthy Peruvian Infants||Sanofi|No|Completed|May 2008|November 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|266|||Both|50 Days|71 Days|Accepts Healthy Volunteers|||February 2014|February 14, 2014|January 27, 2009||No||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00831753||144328|
NCT00827138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 2036-01|Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)|A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Leukemias (Ph+CML With T315I Mutation Only)||Deciphera Pharmaceuticals LLC|No|Completed|March 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|January 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00827138||144681|
NCT00827112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001078|A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients|Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naïve HIV-Infected Patients With R5 HIV-1||ViiV Healthcare|Yes|Completed|March 2009|July 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|16 Years|N/A|No|||June 2012|June 8, 2012|January 21, 2009|Yes|Yes||No|July 11, 2011|https://clinicaltrials.gov/show/NCT00827112||144683|
NCT00827125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 032/2008CTIL|Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based, Multiple Parameters|Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based, Multiple Parameters||Trig Medical Inc|No|Recruiting|March 2009|February 2010|Anticipated|February 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|650|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2009|January 4, 2010|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827125||144682|
NCT00827762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MildPKU/Kuvan/White|Behavioral Effects of Kuvan in Children With Mild Phenylketonuria|Behavioral Effects of Kuvan in Children With Mild Phenylketonuria||Washington University School of Medicine|No|Terminated|January 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Both|6 Years|18 Years|No|Non-Probability Sample|Primary care clinic for phenylketonuria.|December 2013|December 3, 2013|January 21, 2009||No|Too few participants recruited within timeframe|No||https://clinicaltrials.gov/show/NCT00827762||144633|
NCT00827983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07EU/Prg06|Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)|Efficacy and Tolerability of Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)||IBSA Institut Biochimique SA||Completed|January 2009|May 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|683|||Female|18 Years|42 Years|No|||January 2013|January 28, 2013|January 22, 2009||No||No|November 26, 2012|https://clinicaltrials.gov/show/NCT00827983||144616|no special limitations of the trial were detected.
NCT00827996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIDRI2007|To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa|Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa|HIDRI2007|Florida Academic Dermatology Centers|Yes|Completed|February 2007|August 2008||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 22, 2009|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827996||144615|
NCT00827749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 05 22|Swallowing Disorders in Geriatrics Studied With Respiratory Plethysmography by Inductance|Contribution of Respiratory Plethysmography by Inductance and of Informatic Tool for the Study of Swallowing Disorders in Geriatrics (PRIOD)|PRIOD|University Hospital, Grenoble|Yes|Completed|November 2008|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 21, 2010|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827749||144634|
NCT00837707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH-97-03|Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia|Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study||Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan|No|Recruiting|June 2008|February 2010|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||February 2009|February 4, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837707||143875|
NCT00837460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/06NOV/207|Effect of Rehabilitation of Patients With a Central Nervous System Lesion|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|September 2006|October 2009|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|15|||Both|16 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 29, 2010|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837460||143894|
NCT00828230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUF-17/RAP|Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis|Randomised, Double-blind, Placebo-controlled, Multicentre, Comparative Phase II Pilot Study on the Efficacy and Tolerability of an 8-week Rectal Treatment With 2 mg Budesonide or Placebo for the Prevention of Acute Radiation Proctitis||Dr. Falk Pharma GmbH|No|Terminated|September 2008|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|17|||Male|18 Years|N/A|No|||January 2012|January 26, 2012|January 22, 2009||No|Study was prematurely stopped due to slow recruitment after 17 of 32 anticipated patients were    recruited.|No||https://clinicaltrials.gov/show/NCT00828230||144597|
NCT00828568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIQ-0403|Bioequivalence Study of Two Imiquimod Cream 5%|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis||Taro Pharmaceuticals USA|No|Completed|June 2008|May 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|425|||Both|18 Years|N/A|No|||December 2013|December 21, 2013|January 22, 2009|No|Yes||No|September 17, 2009|https://clinicaltrials.gov/show/NCT00828568||144571|
NCT00828581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-018|Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects|An Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects||Arena Pharmaceuticals|No|Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|N/A|No|||January 2009|January 23, 2009|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828581||144570|
NCT00828932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-017|Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment|An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment||Arena Pharmaceuticals|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2009|July 27, 2009|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828932||144543|
NCT00828945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581178|Compliance With Treatment For Patients With Hyperlipidemia|A Non-Randomized, Non-Controlled, Open Study In Order To Document The Compliance With Treatment, According To Clinical Praxis And National Guidelines For Patients With Hyperlipidemia. COLL: Control Of Lipid Lowering|COLL|Pfizer|No|Completed|February 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|259|||Both|18 Years|N/A|No|Probability Sample|Aged 18 years or older and able to understand and sign the informed consent form.        • Patients diagnosed with hyperlipidemia and a very high risk developing cardiovascular        disease prescribed statin treatment according to clinical praxis and the recommendations        set forth in the MPA national guideline for treatment of hyperlipidemia.|February 2012|February 16, 2012|January 23, 2009|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00828945||144542|
NCT00829270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSTIC Mitochips|Economic and Medical Evaluation of the Whole Mitochondrial DNA Screening by Surveyor and Mitochips Techniques|Economic and Medical Evaluation of the Whole Mitochondrial DNA Screening by Surveyor and Mitochips Techniques.||Centre Hospitalier Universitaire de Nice|No|Completed|March 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|550|Samples With DNA|patients presenting clinical features of mitochondrial diseases|Both|N/A|N/A|No|Non-Probability Sample|Patients presenting clinical features of mitchondrial diseases|January 2009|December 17, 2012|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829270||144517|
NCT00829933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-C-J225|Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation|A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation||Daiichi Sankyo Inc.|Yes|Completed|March 2007|September 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|536|||Both|20 Years|N/A|No|||February 2015|February 3, 2015|January 26, 2009||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT00829933||144466|
NCT00828906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DART-2|DuoTrav® Eye Drops As Replacement Therapy Program|||Alcon Research|No|Completed|February 2009|||November 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||July 2012|September 18, 2012|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828906||144545|
NCT00828919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061008|Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials|Continuing Access To The Tyrosine Kinase Inhibitor Of VEGFR 2, AG 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials||Pfizer|No|Recruiting|March 2003|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|99 Years|No|||March 2016|March 2, 2016|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828919||144544|
NCT00829244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28613|CONSORT Randomized Controlled Trial in Assisted Reproductive Technology|A Phase IV Prospective, Multicenter, Randomized, Open-label Trial to Assess the Efficacy and Safety of GONAL f® at a Dose Based on Subject Baseline Characteristics Determined According to the CONSORT Calculator Compared With a Standard Dose of GONAL f® 150 IU Per Day for Ovarian Stimulation in Women Undergoing Assisted Reproductive Technology (ART)||Merck KGaA||Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|34 Years|No|||January 2014|January 20, 2014|January 22, 2009||No||No|June 1, 2012|https://clinicaltrials.gov/show/NCT00829244||144519|
NCT00829556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIFJPAR 08-01|Efficacy of InteguSeal for Surgical Skin Preparation in Patients Undergoing Total Joint Replacement|Single-Center, Randomized Trial to Study the Efficacy of InteguSeal for Surgical Skin Preparation in Patients Undergoing||Rothman Institute Orthopaedics|No|Completed|April 2008|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|80 Years|No|||December 2009|December 18, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829556||144495|
NCT00829868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B046502|Zaleplon 10 mg Capsules Under Non-Fasting Conditions|A Relative Bioavailability Study of Zaleplon 10 mg Capsules Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|January 26, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00829868||144471|
NCT00829205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632722|Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment|A Phase I/II Study of Methylselenocysteine (MSC) in Combination With Immunochemotherapy (R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)||National Cancer Institute (NCI)||Withdrawn|January 2009|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2009|August 23, 2013|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829205||144522|
NCT00829881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43MH082461|Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder|Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder||P2D, Inc.|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|22 Years|55 Years|No|||September 2013|September 25, 2013|January 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829881||144470|
NCT00830180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091029|Open Label Extension In Cancer Patients|Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases||Pfizer|Yes|Completed|October 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830180||144447|
NCT00830492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YazdRCCI1388|Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist|Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome.||Yazd Research & Clinical Center for Infertility|Yes|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2009|January 27, 2009|January 27, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00830492||144423|
NCT00830505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE001|Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma|A Randomized, Double-Blind, Cross-Over Study to Demonstrate Superiority of Fluticasone/Salmeterol Over Double the Dose of Fluticasone on Methacholine Hyper-Reactivity in Patients With Persistent, Mild to Moderate Asthma|CLE001|University of Dundee|No|Not yet recruiting|February 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||January 2009|January 27, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830505||144422|
NCT00830518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14005|A Phase 2 Trial of MLN8237 in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome|A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome||Millennium Pharmaceuticals, Inc.|No|Completed|February 2009|September 2011|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830518||144421|
NCT00830466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2008-6383|A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.|A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.||University of California, Irvine|No|Completed|December 2008|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|13 Years|N/A|No|||January 2016|January 29, 2016|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830466||144425|
NCT00830479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08-0354|Study of Endoscopic Versus Open Surgery for Urinary Reflux|A Randomized Trial of Endoscopic vs. Open Anti-Reflux Surgery For Treatment of Low-Grade Vesicoureteral Reflux: Surgical Treatment of Reflux: Endoscopic vs. Traditional CHoices (STRETCH) Study|STRETCH|Children's Hospital Boston|Yes|Withdrawn|January 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|11 Years|No|||August 2011|August 11, 2011|January 27, 2009||No|unable to enroll patients for randomization|No||https://clinicaltrials.gov/show/NCT00830479||144424|
NCT00831376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAI009|Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol|A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics|NAI009|University of Dundee|No|Completed|January 2009|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831376||144355|
NCT00827775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102008-042|Mechanisms and Treatment of Intradialytic Hypertension|Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients|MATCH|University of Texas Southwestern Medical Center|Yes|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|80 Years|No|||January 2014|January 27, 2014|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827775||144632|
NCT00827151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P00246|Bone Mass Accrual in Adolescent Athletes|"2008P-00346: Bone Mass Accrual in Adolescent Athletes"|838|Massachusetts General Hospital|Yes|Withdrawn|December 2008|January 2015|Anticipated|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|21 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|January 16, 2009|Yes|Yes|The study was not funded|No||https://clinicaltrials.gov/show/NCT00827151||144680|
NCT00827489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3253A1-1000|Study Evaluating HTC-867 in Healthy Young and Elderly Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTC-867 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00827489||144654|
NCT00827502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661198|Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections|Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections||Pfizer|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|421|||Both|N/A|N/A|No|Non-Probability Sample|Only patients with acute URTI, presumed to be of bacterial origin as per the clinical        judgment of the investigator will be enrolled in the study.|April 2011|April 25, 2011|January 21, 2009||No||No|March 30, 2010|https://clinicaltrials.gov/show/NCT00827502||144653|
NCT00828269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-123|Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)|Evaluation of RNA Quality and the Reproducibility of Gene Expression Profiling From Liver Tissue Obtained by Fine Needle Aspiration in Patients With Chronic Hepatitis C.||Merck Sharp & Dohme Corp.||Completed|April 2009|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|65 Years|No|||April 2015|April 21, 2015|January 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828269||144594|
NCT00828282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-LEUK-06-MCC|High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL|High-dose HMG-CoA Inhibitor Simvastatin for Patients With Relapsed CLL: Pilot Trial and Pharmacokinetic-pharmacodynamic Studies||University of Kentucky|Yes|Completed|March 2009|April 2014|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828282||144593|
NCT00828243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0156|Genetic Regulation of Surfactant Deficiency|Genetic Regulation of Surfactant Deficiency in Human Newborn Infants||Washington University School of Medicine|Yes|Completed|November 2007|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|773|Samples With DNA|DNA samples and tracheal aspirate samples will be retained on each study participant.|Both|N/A|1 Year|No|Non-Probability Sample|The study population includes infants with and without neonatal respiratory distress        syndrome (N=480) and infants with varying severity of neonatal respiratory distress        syndrome (N=250).|October 2014|October 19, 2014|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828243||144596|
NCT00828256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor477308ctil|Outcome of Arthroscopic Repair of Chronic Rotator Cuff Tears Between 2005-2008|Outcome Study of Arthroscopic Repair of Chronic Rotator Cuff Tears Between 2005-2008, at the Soroka University Medical Center, Beer Sheva, Israel||Soroka University Medical Center||Enrolling by invitation|February 2009|June 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|80 patients, above 18 years of age, who had had an arthroscopic repair of chronic rotator        cuff tear between the years 2005-2008.|January 2009|January 22, 2009|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828256||144595|
NCT00837720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSI-ATA-2005/1|Evaluation of Atacand® (Candesartan) in Daily Medical Practice|A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension||AstraZeneca|No|Completed|March 2006|June 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|750|||Both|18 Years|N/A|No|Non-Probability Sample|patients (outpatient or hospitalised) in whom Atacand is indicated according to the        current Summary of product characteristics (SPC)|February 2009|February 5, 2009|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837720||143874|
NCT00828958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011533|Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.|Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia.||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2006|September 2006|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|53|||Both|18 Years|55 Years|No|||March 2010|May 17, 2011|January 22, 2009||||||https://clinicaltrials.gov/show/NCT00828958||144541|
NCT00829283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK49587|Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care|Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care||Yale University|No|Completed|November 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|January 26, 2009|Yes|Yes||No|October 27, 2015|https://clinicaltrials.gov/show/NCT00829283||144516|
NCT00829608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1124197|Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis|Investigator Initiated Study of Effects of Progression of Recurrent Respiratory Papillomatosis in Patients After They Are Given Human Papillomavirus Quadrivalent Vaccine||University of Missouri-Columbia|No|Withdrawn|January 2009|June 2010|Anticipated|December 2009|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||January 2013|January 24, 2013|January 5, 2009||No|investigator has left the institution|No||https://clinicaltrials.gov/show/NCT00829608||144491|
NCT00830206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-1430|A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions|A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|January 2006|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 26, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00830206||144445|
NCT00830219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10436009|The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions|The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|November 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 26, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00830219||144444|
NCT00829582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-102|Dose-Escalation Study With ETI-204|Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (AnthimTM) [Elusys Protocol Number AH-102]||Elusys Therapeutics|Yes|Completed|February 2009|September 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 18, 2010|January 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829582||144493|
NCT00829595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6355|Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease|Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease||Cedars-Sinai Medical Center|No|Completed|May 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|69|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 26, 2009|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829595||144492|
NCT00829257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAW01|Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma|A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to Fluticasone/Salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma|PAW01|University of Dundee|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829257||144518|
NCT00829569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2003.169|n-3 Fatty Acid Infusion and Type 2 Diabetes|Effects of Marine n-3 Fatty Acid Infusion on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes||St. Olavs Hospital|No|Completed|January 2004|October 2008|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|11|||Both|30 Years|75 Years|No|||November 2011|November 3, 2011|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829569||144494|
NCT00829894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01173|Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Risperidone 1 mg Tablets and Risperdal® 1 mg Tablets Administered as a 1 x 1 mg Tablets in Subjects Under Fed Conditions||Teva Pharmaceuticals USA||Completed|June 2001|July 2001|Actual|July 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 26, 2009|January 26, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00829894||144469|
NCT00830531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURE 07120492|Pilot Study of Bumetanide for Newborn Seizures|Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures||Soul, Janet , M.D.|Yes|Recruiting|January 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|N/A|N/A|No|||October 2015|October 12, 2015|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830531||144420|
NCT00830544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAM 07-03|Study of Neoadjuvant Chemotherapy of Breast Cancer|Phase II Study of Neoadjuvant Chemotherapy of Breast Cancer|Neoadjuvant|Auxilio Mutuo Cancer Center|No|Active, not recruiting|July 2008|December 2012|Anticipated|December 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Female|19 Years|N/A|No|||July 2012|July 12, 2012|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830544||144419|
NCT00830804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5262|Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults|A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects||AIDS Clinical Trials Group|Yes|Completed|April 2009|September 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 26, 2009|No|Yes||No|September 7, 2011|https://clinicaltrials.gov/show/NCT00830804||144399|This is a single-arm study.
NCT00830791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-015|A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)|A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Subjects With Renal Insufficiency||Merck Sharp & Dohme Corp.|No|Terminated|January 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|January 26, 2009|No|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00830791||144400|
NCT00827515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631025|Relative Bioavailability and Food Effect Study|A Phase 1, Randomized, Open-Label, Single Dose, 4-Way Crossover Study In Healthy Volunteers To Assess The Relative Bioavailability Of The Oral Powder In Capsule (PIC) And An Immediate Release (IR) Film-Coated Tablet Of PH-797804 In The Fed And Fasted State||Pfizer|No|Withdrawn|February 2009|May 2009|Anticipated|April 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|0|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827515||144652|
NCT00838045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|451|Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL Intraocular Lens|A Prospective, Multi-Center Clinical Investigation to Evaluate the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL (Model MI60) Intraocular Lens||Bausch & Lomb Incorporated|No|Completed|September 2006|September 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|50 Years|79 Years|No|||December 2011|December 7, 2011|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838045||143849|
NCT00838058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6341012|A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.|An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Controlled And Immediate Release Formulations In Healthy Volunteers||Pfizer|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|8||Actual|11|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 10, 2009|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838058||143848|
NCT00828009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632611|BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation||Eastern Cooperative Oncology Group||Recruiting|December 2010|||January 2016|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828009||144614|
NCT00838981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705002636|Pharmacotherapy & CM for Opioid and Cocaine Dependence|Pharmacotherapy & CM for Opioid and Cocaine Dependence||Yale University|Yes|Completed|May 2008|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|No|||July 2015|July 7, 2015|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00838981||143779|
NCT00839254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112595|Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A|Impact on Nasopharyngeal Carriage, Acute Otitis Media, Immunogenicity and Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A||GlaxoSmithKline||Completed|February 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|6181|||Both|6 Weeks|18 Months|Accepts Healthy Volunteers|||February 2013|February 14, 2013|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839254||143759|
NCT00828607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(Ethics ID: 21295)|Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses|Characterization of Liver Masses With Contrast Enhanced Ultrasound (CEUS): A Comparison With Standard Institutional Contrast Enhanced CT (CECT) or MR Scan (CEMRI)||Foothills Medical Centre|No|Recruiting|January 2009|August 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|90 Years|No|Probability Sample|Any patient with an unknown liver mass|July 2015|July 27, 2015|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828607||144568|
NCT00838266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/05|Study of Growing Biofilm by an Antiplaque Mouthrinse|A Double Blind Randomized, Placebo-controlled, Cross-over Trial to Evaluate the Efficiency of a Mouthrinse, Containing Red Grape Seed Extract and nicométhanol Fluorhydrate, in the Control of Dental Plaque Deposit in a 4-days Plaque Regrowth Model|Bain de bouche|University Hospital, Bordeaux|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838266||143832|
NCT00829296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16310B (EFFORT trial)|Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries|The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetics|EFFORT|University of Chicago|No|Completed|January 2009|April 2013|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|January 26, 2009|Yes|Yes||No|August 4, 2014|https://clinicaltrials.gov/show/NCT00829296||144515|
NCT00829309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0202|Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions|A Relative Bioavailability Study of 80 mg Pravastatin Sodium Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|March 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|January 26, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00829309||144514|
NCT00829322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Modafinil/lung/09|Modafinil for the Treatment of Fatigue in Lung Cancer V9.0|Modafinil for the Treatment of Fatigue in Lung Cancer: a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial||University of Oxford|Yes|Completed|February 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|January 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829322||144513|
NCT00829621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1097637|Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)|Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)||University of Missouri-Columbia|No|Completed|December 2008|December 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 1, 2014|January 26, 2009||No||No|January 1, 2014|https://clinicaltrials.gov/show/NCT00829621||144490|
NCT00829946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-0034/08|Effects of Resistance Strength Training on Functional Capacity and Well Being of Anorexic Patients|Effects of Resistance Strength Training on Functional Capacity and Well Being of Anorexic Patients; A Randomized Controlled Trial||Universidad Europea de Madrid|Yes|Completed|January 2008|March 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|35|||Female|N/A|16 Years|No|||January 2009|January 26, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829946||144465|
NCT00830232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#08-035|Effects of Carotid Stent Design on Cerebral Embolization|Effects of Carotid Stent Design on Cerebral Embolization||Dallas VA Medical Center|No|Completed|December 2008|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|January 26, 2009||No||No|March 8, 2013|https://clinicaltrials.gov/show/NCT00830232||144443|1. Small sample size 2.randomization did not eliminate all pretreatment differences between groups because of the small sample size.3.All patients underwent Stenting under ﬁlter embolic protection.
NCT00830557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|354-06|Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders|Biospecimen Resource for Pancreas Research, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease||Mayo Clinic|Yes|Recruiting|October 2000|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|7500|Samples With DNA|Two 10mL plasma tubes, two 10mL serum tubes and one 10mL heparin tube collected. DNA      extracted from lymphocytes. Possible saliva collection for DNA extraction. Waste tissue from      prior surgery may be collected. Stool samples may be collected.|Both|18 Years|120 Years|No|Non-Probability Sample|Pancreas disease patients|January 2016|January 5, 2016|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830557||144418|
NCT00829920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0018.cc|The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease|The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease||University of Colorado, Denver|Yes|Completed|November 2008|February 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|Samples With DNA|Serum from patients undergoing treatment for muscle-invasive or metastatic bladder cancer      who are planning for surgical bladder removal or chemotherapy will be acquired.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with muscle-invasive or metastatic bladder cancer with plans for cancer        treatment.|June 2013|June 21, 2013|January 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00829920||144467|
NCT00830193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHRI-000001|N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography|N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography: A Randomized Trial||St. Michael's Hospital, Toronto|No|Completed|August 2002|May 2005|Actual|May 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Both|16 Years|N/A|No|||January 2009|January 26, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00830193||144446|
NCT00831402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-PHRC-03|Thyroid Function Throughout Pregnancy With and Without Iodine Supplementation|Assessment of Thyroid Function Throughout Pregnancy With and Without Iodine Supplementation||Centre Hospitalier Universitaire de Nice|No|Completed|June 2007|August 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|111|||Female|18 Years|N/A|No|||February 2009|March 23, 2012|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831402||144353|
NCT00831766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15625|Phase 1/2 Study of Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)|A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|January 2009|August 2016|Anticipated|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831766||144327|
NCT00831103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPB348-0201|A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster|A Randomized, Double-blind, Active-controlled, Multi-center, Parallel-group Dose-ranging Study Assessing the Safety and Efficacy of EPB-348 Versus Valacyclovir Among Immunocompetent Patients With an Acute Episode of Herpes Zoster||Epiphany Biosciences|No|Completed|November 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|373|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831103||144376|
NCT00827164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROG-SCCI 09-001-1|Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer|Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer||University of Alabama at Birmingham|No|Completed|January 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|29|||Both|19 Years|90 Years|No|||May 2015|May 9, 2015|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827164||144679|
NCT00837811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11768|An Open Label Extension Study in Patients With Rheumatoid Arthritis|An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.||Eli Lilly and Company|No|Completed|February 2009|January 2012|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|183|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837811||143867|
NCT00838682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-KOR-18|Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers|Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers||The Catholic University of Korea|No|Terminated|April 2006|March 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|16 Years|N/A|No|||August 2010|August 31, 2010|February 5, 2009||No|Terminated before the complete enrollment due to slow enrollment|No|August 2, 2010|https://clinicaltrials.gov/show/NCT00838682||143801|This was the two-center study and was stopped before the complete enrollment leading to small numbers of subjects statistically underpowered.
NCT00838994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACUP-002|Acupuncture for Residual Insomnia Associated With Major Depressive Disorder|A Randomized Controlled Trial of Acupuncture for Residual Insomnia Associated With Major Depressive Disorder||The University of Hong Kong|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|65 Years|No|||January 2010|January 12, 2010|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00838994||143778|
NCT00839280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12040|Moisturizing Effect of Two Dexpanthenol Formulations|Evaluation of the Moisturizing Effect of Bepanthen Burn Relief Foam Spray New Formula Versus Bepanthen Burn Relief Foam Spray (Current Formula). Equivalence Trial. Intra-individual Design.||Bayer|No|Completed|August 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839280||143757|
NCT00837213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVF0701|Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne|Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne||GlaxoSmithKline|No|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|16 Years|N/A|No|||July 2011|July 12, 2011|February 4, 2009|Yes|Yes||No|April 7, 2010|https://clinicaltrials.gov/show/NCT00837213||143913|Small sample size did not provide adequate power. Even with the limited sample size, total lesion counts provides a more reliable view of the study data due to the greater number of lesions to work with.
NCT00837447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-7|Range of Motion of Standard and High-Flexion Posterior Cruciate Retaining Total Knee Prostheses|Range of Motion of Standard and High-Flexion Posterior Cruciate Retaining Total Knee Prostheses A Prospective, Randomized Study||Ewha Womans University|No|Completed|October 2004|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|N/A|N/A|No|||March 2013|March 5, 2013|February 4, 2009||No||No|June 23, 2011|https://clinicaltrials.gov/show/NCT00837447||143895|First, the knee scoring system is prone to intraobserver variability. Second, we had no interobserver variability and this could have lead to bias in interpreting radiographic results.
NCT00840489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIBACIR-1|Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis|Phase II Trial of Long-term Monotherapy With Ribavirin Against Colchicine on Progression of Chronic Hepatitis C With Advanced Fibrosis in Patients With Non-response to Standard Antiviral Therapy|RIBACIR|Hospital Universitario Ramon y Cajal|No|Terminated|January 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||January 2013|January 30, 2013|February 9, 2009||No|Preliminary analysis|No||https://clinicaltrials.gov/show/NCT00840489||143667|
NCT00839917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-023|A Study of ProQuad™ in Healthy Children in Korea (V221-023)|A Multicenter, Randomized, Open-Label Study to Compare the Immunogenicity, Safety, and Tolerability of Measles, Mumps, Rubella, and Varicella of Combination Vaccine ProQuad With Concomitant Administration of M-M-R II and VARIVAX in Healthy Korean Children||Merck Sharp & Dohme Corp.|Yes|Terminated|February 2008|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||October 2015|October 1, 2015|February 6, 2009|Yes|Yes|Study terminated early because of insufficient enrollment before expiration date of the    investigational vaccine lot|No|September 7, 2012|https://clinicaltrials.gov/show/NCT00839917||143709|Formal testing of the study hypotheses was not possible because of low enrollment
NCT00839930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-099|Cilostazol 50 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 50 mg Cilostazol Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 6, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00839930||143708|
NCT00840177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0919|S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia|S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)||Southwest Oncology Group|Yes|Recruiting|August 2009|February 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|February 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840177||143690|
NCT00840528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1416|Genetic Susceptibility TO Ozone-induced Airway Inflammation in Humans|Genetic Susceptibility TO Ozone-induced Bronchial Airway Inflammatory Responses In Humans|GARBOZ|University of North Carolina, Chapel Hill|No|Active, not recruiting|February 2002|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|July 16, 2015|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00840528||143664|
NCT00840853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23637-MULTIPRAT|Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT|Phase I Study of the Administration of Multi-Virus-Specific Cytotoxic T Lymphocytes Expressing CD19 Chimeric Receptors for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies Post Hematopoietic Stem Cell Transplantation|MULTIPRAT|Baylor College of Medicine|Yes|Active, not recruiting|April 2009|April 2031|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|68|||Both|N/A|N/A|No|||January 2016|January 12, 2016|February 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00840853||143639|
NCT00840866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036557|Cefprozil 500 mg Tablets Under Fed Conditions|A Relative Bioavailability Study of Cefprozil 500 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|February 6, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00840866||143638|
NCT00840879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2825|Meloxicam 15 mg Tablets Under Non-Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Meloxicam 15 mg Tablets Versus Mobic® 15 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|February 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 6, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00840879||143637|
NCT00840892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTERCOM_CCMO_P00.1631L|(Cost-)Effectiveness Interdisciplinary Community-Based COPD Management Program (INTERCOM)|Randomized Controlled Trial to Establish the (Cost-)Effectiveness of an Interdisciplinary Community-Based COPD Management Program Relative to Usual Care.||Maastricht University Medical Center||Completed|January 2002|March 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|199|||Both|N/A|N/A|No|||February 2009|February 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00840892||143636|
NCT00840502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU0801|Ultrasound Study in Pregnant Women With Malaria|Impact of Malaria Infection in Pregnancy on Fetal and Newborn Growth|UPS|University of Oxford|No|Recruiting|February 2009|September 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregant women who present at the SMRU ante natal clinics. The antenatal clinics (ANC) are        based on the Thai-Burmese border, in a region where Karen people (a minority group in        Burma) are the principal inhabitants.|February 2016|February 12, 2016|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840502||143666|
NCT00840515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-5467|PraevoSkin Emulsion in the Prevention of Radiation Induced Dermatitis|A Phase 2,Double Blind Randomized Study of PraevoSkin,a Melatonin Containing Emulsion, in the Prevention of Radiation Induced Dermatitis.||Pharm Olam Pharmaceuticals Ltd.|No|Active, not recruiting|February 2009|August 2009|Anticipated|June 2009|Anticipated|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1|||Female|18 Years|65 Years|No|Probability Sample|Female patientsplanned to receive whole breast radiation.|May 2009|May 5, 2009|February 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00840515||143665|
NCT00830817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBI-1001-101; control # 114963|Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis|A Randomized, Double-Blind Phase I Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Psoriasis.|WBI-1001-101|Welichem Biotech Inc.|Yes|Completed|July 2007|June 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|36|Samples Without DNA|Blood plasma samples retained following PK analyses.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males and female18-65 yo. inclusive Mild to moderate plaque psoriasis|January 2009|January 27, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830817||144398|
NCT00831116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0111|An Observational Study of Cholesterol in Coronary Arteries|Chemometric Observation of Lipid Core Plaques of Interest in Native Coronary Arteries Registry|COLOR|InfraReDx|Yes|Recruiting|February 2009|||February 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from those presenting or referred to the cardiac        catheterization laboratory for elective cardiac catheterization.|February 2016|February 22, 2016|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831116||144375|
NCT00831389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ePID-03|Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia|Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia|ePID-03|Medtronic Diabetes|No|Completed|January 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|13|||Both|12 Years|30 Years|No|||September 2012|September 10, 2012|January 26, 2009|Yes|Yes||No|June 8, 2012|https://clinicaltrials.gov/show/NCT00831389||144354|
NCT00837044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112488|Treximet in Acute Migraine Headache: Assessing Cognitive Function|An Evaluation of Treximet in the Treatment of Acute Migraine Headache: A Placebo-Controlled, Double-Blind, Crossover Study, Assessing Cognitive Function.||Neurological Research Center|No|Recruiting|February 2009|September 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2009|February 4, 2009|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837044||143926|
NCT00837291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-221OA|A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Daily CF101 Administered Orally for 12 Weeks to Patients With Osteoarthritis of the Knee||Can-Fite BioPharma|Yes|Not yet recruiting|November 2016|January 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|90 Years|No|||December 2015|December 16, 2015|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837291||143907|
NCT00837525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVB|Validity Study of a Nasal Valve Implant|Validity of Biodegradable Injectable Implant for the Treatment of External Nasal Valve Collapse.||Nasoform, LLC|No|Enrolling by invitation|February 2009|June 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 4, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837525||143889|
NCT00827177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-116|Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors||ArQule|No|Completed|September 2009|May 2013|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|January 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00827177||144678|
NCT00827190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3216K1-1000|Study Evaluating Single Ascending Doses Of ILS-920|Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of ILS-920 Administered Intravenously To Healthy Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2010|February 2, 2010|December 10, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00827190||144677|
NCT00837538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSHP 63/2007|Screening of Instability of the Spinal Column With Spinal Mouse® and X-ray|A Comparison of Spinal Mouse® and X-ray Film to Measure a Instability of Lumbar Spine||Jyväskylä Central Hospital|No|Completed|February 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|persons of Central finland Health Care District|March 2011|March 18, 2011|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837538||143888|
NCT00839007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIL-CDNP-CT005|Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure|A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure||Nile Therapeutics|Yes|Completed|June 2009|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|77|||Both|18 Years|85 Years|No|||September 2010|September 15, 2010|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839007||143777|
NCT00838331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015316|Adverse Effects of RBC Transfusions: A Unifying Hypothesis|Adverse Effects of RBC Transfusions: A Unifying Hypothesis|INOBA|Emory University|Yes|Completed|April 2009|October 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|February 5, 2009|Yes|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT00838331||143827|Primary limitation is that we are studying transfusion effects of fresh vs stored RBCs in healthy individuals, and not sick, anemic individuals as are often encountered in the hospital.
NCT00838344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33084-D|The Medication Adherence Program|The Medication Adherence Program:Promoting Diabetes Self-Management Through Community Pharmacies|MAP|University of Washington|No|Active, not recruiting|April 2008|June 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|240|||Both|18 Years|N/A|No|||September 2009|September 28, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838344||143826|
NCT00838357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ00808|A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).|Plerixafor and G−CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non−Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) − Safety Study in a General Autologous Transplant Population|PREDICT|Sanofi|No|Completed|September 2008|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|February 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00838357||143825|
NCT00838695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71148|Variability in Adrenergic Response|Variability in Adrenergic Response||Vanderbilt University|No|Active, not recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|February 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838695||143800|
NCT00839956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2253.00|Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant|Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|February 2009|||August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839956||143706|
NCT00840216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02198|Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Extended Release Tablet Formulation of Clarithromycin (500 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Biaxin® XL Filmtab) in 22 Fed, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|August 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 6, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00840216||143687|
NCT00837980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3123|Functional Imaging in HNC Undergoing Chemoradiation|Investigation of the Role of Functional Imaging in Characterising Radiotherapy Target Volumes and Assessing Disease Response in Patients Undergoing Chemoradiation for Head and Neck Cancer (HNC)||Royal Marsden NHS Foundation Trust|No|Recruiting|February 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients who have a head and neck cancer and are planned to receive chemotherapy and        radiotherapy will be invited to participate in the study. Patients who are not in very        good health, have diabetes or kidney failure will not be considered for the study. Also        patients who can not undergo MRI scan or are allergic to contrast injection given prior to        the scan or have had any other form of cancer (except skin cancer) will also be excluded        from the study.|February 2009|February 5, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00837980||143854|
NCT00839943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-CEMLB-128|Effect Of Obesity On Ozone-Induced Airway Inflammation|Effect Of Obesity On Ozone-Induced Airway Inflammation|OBOZ|University of North Carolina, Chapel Hill|No|Completed|May 2006|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||June 2012|August 24, 2012|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839943||143707|
NCT00840190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1446A-05/19/08|A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies|An Open Label, Multicenter Phase I Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies|Serenity|Piramal Enterprises Limited|No|Completed|December 2008|September 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00840190||143689|
NCT00840203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10336014|Mesalamine 4 gm/60 mL Rectal Enema|A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 mL Rectal Enema Formulations||Teva Pharmaceuticals USA|No|Completed|May 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 6, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00840203||143688|
NCT00840541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNTM018A|Phenotyping Diabetic Retinopathy|Observational Study of Type-2 Diabetic Subjects to Validate Diabetic Retinopathy Phenotypes||Association for Innovation and Biomedical Research on Light and Image|No|Completed|January 2009|January 2012|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|80|||Both|18 Years|N/A|No|Probability Sample|Type-2 diabetic subjects diagnosed with DR, followed regularly by their ophthalmologist at        the AIBILI Clinical Trial Center, with a previous follow-up in which systemic data and        ophthalmological examinations were performed regularly.|April 2014|April 4, 2014|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840541||143663|
NCT00840905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck P0806|A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil|A Pilot Observational Study to Determine the Prevalence of HPV Serology in HIV Seropositive Women From Subsaharan Africa and Brasil||University of Witwatersrand, South Africa|No|Completed|February 2009|December 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|487|None Retained|Blood /plasma specimen 10cc|Female|18 Years|N/A|No|Non-Probability Sample|HIV seropositive women from South Africa, Botswana, and Brasil|November 2012|November 6, 2012|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00840905||143635|
NCT00840918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-861|Intravenous Lidocaine and Postoperative Outcomes After Cardiac Surgery|The Effect of Perioperative Intravenous Lidocaine on Postoperative Outcomes After Cardiac Surgery||Outcomes Research Consortium|Yes|Recruiting|February 2009|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1294|||Both|18 Years|90 Years|No|||January 2013|January 28, 2013|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00840918||143634|
NCT00841191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015580|A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors|A Phase 1/2, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors||Centocor, Inc.|Yes|Completed|March 2009|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|84|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|February 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00841191||143613|
NCT00841178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELP 2|Endovenous Laser Therapy (EVLT) for Sapheno-Popliteal Incompetence and Short Saphenous Vein (SSV) Reflux: A RCT|A Randomised Controlled Trial of the Clinical and Cost Effectiveness of Endovenous Laser Therapy in the Treatment of Varicose Veins Secondary to Isolated Sapheno-Popliteal Incompetence and Short Saphenous Reflux||University of Hull|No|Active, not recruiting|October 2005|||August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841178||143614|
NCT00840827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810010063|Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes|A Single-Arm, Open-Label Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes||Weill Medical College of Cornell University|No|Completed|December 2008|||December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840827||143641|
NCT00840840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-544|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions|An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects, Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|August 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 8, 2009|February 6, 2009|No|Yes||No|May 18, 2009|https://clinicaltrials.gov/show/NCT00840840||143640|
NCT00841165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 09-056|Carbon Monoxide Monitoring and Emergency Treatment|Randomized Trial of Carbon Monoxide Elimination Kinetics With Oxygen Delivered by Continuous Positive Airway Pressure Compared to Face Mask|COMET|University of Vermont|Yes|Recruiting|January 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841165||143615|
NCT00841412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-250|Prevention of Weight Loss in Long Term Care Veterans|Prevention of Weight Loss in Long-Term Care Veterans||VA Office of Research and Development|Yes|Completed|February 2009|September 2013|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|65 Years|N/A|No|||October 2014|April 6, 2015|February 9, 2009||No||No|October 28, 2014|https://clinicaltrials.gov/show/NCT00841412||143596|This study was conducted in only two VA facilities in one geographic region with predominately White, male residents. All study results have been published in a series of papers.
NCT00837564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBASP-1|Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression|Differential Responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP)Versus Escitalopram in Chronic Major Depression With and Without Early Trauma||University Hospital Freiburg|No|Recruiting|February 2009|April 2011|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2010|June 29, 2010|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837564||143886|
NCT00837824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL-022-02|Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme|A Phase 2, Randomized, Open Label, Dose-Ranging, Multiple Dose Study of Fabrazyme® In Patients With Fabry Disease and With Severe Renal Disease||Sanofi|Yes|Terminated|December 2002|August 2003|Actual|August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|N/A|No|||March 2015|March 19, 2015|October 23, 2008|Yes|Yes|The trial was terminated early due to inadequate study design.|No|December 5, 2008|https://clinicaltrials.gov/show/NCT00837824||143866|The trial was terminated early due to inadequate study design, leading to small numbers of subjects analyzed.
NCT00838071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG301|Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation|Evaluation of Anti-Hepatitis B Antibodies Levels in Serum After the Intravenous Administration of Specific Anti-Hepatitis B Immunoglobulin (IGIV-HB Grifols) in Patients Having Previously Undergone Liver Transplantation||Grifols Biologicals Inc.|No|Completed|October 2003|August 2004|Actual|July 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|70 Years|No|||February 2009|February 5, 2009|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838071||143847|
NCT00837551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBI-1001-201: Control # 119727|Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis|A Randomized, Double-Blinded, Vehicle-Controlled Phase IIa Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Atopic Dermatitis.|WBI-1001-201|Welichem Biotech Inc.|Yes|Completed|March 2008|October 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 3, 2009|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837551||143887|
NCT00838084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12852|A Safety Study of LY2811376 Single Doses in Healthy Subjects|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2811376 in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|61|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 14, 2009|January 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00838084||143846|
NCT00839319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27158-D|HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone|Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (Short Title (HOP-3)|HOP-3|University of Washington|No|Completed|March 2009|November 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|59|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|February 6, 2009|Yes|Yes||No|October 15, 2010|https://clinicaltrials.gov/show/NCT00839319||143754|
NCT00839306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-G000-306|Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)||Eisai Inc.||Completed|August 2008|January 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|February 5, 2009|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00839306||143755|
NCT00839644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0609|Airway Secretion Clearance in Cystic Fibrosis|Airway Secretion Clearance in Cystic Fibrosis||University of Colorado, Denver|Yes|Terminated|December 1999|June 2003|Actual|December 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|166|||Both|7 Years|N/A|No|||October 2012|October 1, 2012|February 5, 2009||No|High dropout, problems recruiting, and smaller than expected decline in FEV1.|No||https://clinicaltrials.gov/show/NCT00839644||143730|
NCT00840242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97 NITG 001|Smoking Reduction or Cessation With Nicotine Replacement Therapy|Smoking Reduction or Cessation With Nicotine Replacement Therapy. A Placebo Controlled Double Blind Trial With Nicotine Gum or Inhaler.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 1999|May 2000|Actual|May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|314|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840242||143685|
NCT00840255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08070327|Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 2 (BBTIMVII)|Treatment of Insomnia in Military Veterans:Phase 2|BBTIMVII|University of Pittsburgh|Yes|Completed|April 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840255||143684|
NCT00840268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-34|A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye Patients|||Alcon Research|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|427|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840268||143683|
NCT00839540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-07-004|Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins|Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia||Michigan State University|No|Completed|December 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|February 6, 2009||No||No|January 23, 2012|https://clinicaltrials.gov/show/NCT00839540||143737|
NCT00840554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP-001|The Effects of Adding a Home Exercise Program to a Clinical Physical Therapy Program on Cancer-Related Fatigue|The Effects of Adding a Home Exercise Program (HEP) to a Clinical Physical Therapy Program (CPTP) on the Cancer-Related Fatigue Reported by Patients Undergoing Concurrent Radiation and Chemotherapy for High-Grade Glioma (HGG)||University of Florida|Yes|Completed|February 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00840554||143662|
NCT00840931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14998|Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)|A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus "Bystander" Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|February 2009|May 2016|Anticipated|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00840931||143633|
NCT00841204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01115|Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma|Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma||National Cancer Institute (NCI)||Completed|February 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|May 29, 2014|February 10, 2009|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00841204||143612|
NCT00841451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-123|Pulmonary Vein Isolation Outcomes With Fish Oils|Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)|PUFA|St. Luke's-Roosevelt Hospital Center||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2016|March 22, 2016|February 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00841451||143593|
NCT00837096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC 2006-19|A Study Comparing V.A.C. Negative Pressure Wound Therapy (NPWT) to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Amputation Wounds|A Prospective, Randomized, Multicenter, Parallel Study Comparing V.A.C. Negative Pressure Wound Therapy (NPWT) to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Amputation Wounds|VAC 2006-19|KCI USA, Inc.|Yes|Terminated|June 2007|||April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|February 3, 2009||No|Business objectives changed.|No||https://clinicaltrials.gov/show/NCT00837096||143922|
NCT00837330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3761s|Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy|Treatment of Polypoidal Choroidal Vasculopathy With Ranibizumab(Lucentis): A Phase I/II Safety Study.||Southeast Retina Center, Georgia|No|Completed|May 2006|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|35 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|February 4, 2009|Yes|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00837330||143904|
NCT00841438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISU-CLT-07001|Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction|Efficacy of Clotinab in Acute Myocardial Infarction Trial- ST Elevation Myocardial Infarction|ECLAT-STEMI|Yonsei University|Yes|Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|786|||Both|18 Years|80 Years|No|||February 2009|May 3, 2010|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841438||143594|
NCT00841425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2009-012|Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study|Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study||Bispebjerg Hospital||Recruiting|February 2009|June 2010|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|33|Samples Without DNA|Blood (serum, whole blood) Exhaled breath condensate Induced sputum|Both|15 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants were all elite swimmers and part of the Danish National Swimming        Association's talent program for young swimmers at the baseline study.|February 2009|February 23, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841425||143595|
NCT00837057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a085068|Early Continuous Renal Replacement Therapies (CRRT) in Patients With Severe Sepsis or Septic Shock With Acute Kidney Injury|A Randomized Controlled Multi-Center Trial of the Early Application of CRRT in Patients With Severe Sepsis or Septic Shock||Asan Medical Center|No|Not yet recruiting|February 2009|||January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||January 2009|February 4, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837057||143925|
NCT00837070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|264-07111a 2007.345|Percutaneous Rupture of Zygapophyseal Joint Cysts|Percutaneous Rupture of Zygapophyseal Joint Cysts||Ullevaal University Hospital|Yes|Recruiting|January 2009|January 2012|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|N/A|No|||January 2009|March 2, 2010|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837070||143924|
NCT00837304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Med-B_CCE_vs_SC|Colon Capsule Endoscopy Versus Standard Colonoscopy in Ulcerative Colitis|Colon Capsule Endoscopy Versus Standard Colonoscopy in Assessing Disease Activity in Patients With Ulcerative Colitis - A Prospective Trial||University Hospital Muenster|Yes|Terminated|January 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known ulcerative colitis|February 2009|December 7, 2012|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837304||143906|
NCT00838097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070211|European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa|A Prospective Registry Study Observing the Safety and Patterns of Use of Darbepoetin Alfa in EU Paediatric Chronic Kidney Disease Patients Receiving or Not Receiving Dialysis||Amgen||Completed|February 2008|February 2013|Actual|February 2013|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|321|||Both|N/A|16 Years|No|Non-Probability Sample|Specialist Centres|July 2014|July 29, 2014|February 5, 2009||No||No|March 4, 2014|https://clinicaltrials.gov/show/NCT00838097|2 Years|143845|
NCT00838383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321004|Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery|Selective Endothelin Type A Receptor Inhibition In Cardiac Surgery Subjects With Pre-Existing Cardiovascular Risk Factors: A Dose Confirmation Study|FCAD02|Pfizer|No|Completed|August 2006|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|N/A|N/A|No|||February 2012|February 2, 2012|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838383||143823|
NCT00838370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKI-AVL_M07PFU|Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines|Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines||The Netherlands Cancer Institute|Yes|Completed|May 2007|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838370||143824|
NCT00838708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P174954201CD|Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus|A Phase II, Randomised, Double-blind, Vehicle-controlled, Cross-over Study to Determine the Anti-pruritic Efficacy, Safety and Local Dermal Toleration of SRD174 Cream in Subjects With Atopic Dermatitis.||Serentis Ltd.|No|Completed|January 2009|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||October 2009|October 29, 2009|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838708||143799|
NCT00829686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20080055H-Pilot|Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection|Prospective Randomized Controlled Trial of Antibiotic Treatment for Uncomplicated Skin Abscess in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection||Wilford Hall Medical Center|No|Completed|June 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|July 27, 2009|January 26, 2009||No||No|June 5, 2009|https://clinicaltrials.gov/show/NCT00829686||144485|
NCT00839657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|623|Clarification of Optimal Anticoagulation Through Genetics|A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients|COAG|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2009|November 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1015|||Both|18 Years|N/A|No|||May 2013|May 1, 2015|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839657||143729|
NCT00839969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H1101/97|Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding|A Randomized Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding.||Medway NHS Foundation Trust|No|Recruiting|January 2009|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Female|N/A|N/A|No|||February 2009|February 9, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00839969||143705|
NCT00830024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0167|Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Non-fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 26, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00830024||144459|
NCT00840151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-053-2|A SMART Design for Attendance-based Prize CM|A SMART Design for Attendance-based Prize CM||University of Connecticut Health Center|No|Completed|January 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|360|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|February 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00840151||143692|
NCT00840944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2007-003247-70|A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height|Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height.|ZomaTrip|Belgian Study Group for Pediatric Endocrinology|No|Recruiting|January 2008|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|7 Years|15 Years|No|||August 2014|August 7, 2014|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00840944||143632|
NCT00841217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWA_PHR022009|Regulation of Lipoprotein Transport in Metabolic Syndrome|Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome||The University of Western Australia|No|Completed|April 2003|December 2008|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Male|18 Years|65 Years|No|||February 2009|February 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841217||143611|
NCT00841230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8/46/260|Deanxit and Rivotril in Tinnitus Patients|Additional Value of Deanxit in Tinnitus Patients Treated With Rivotril||University Hospital, Antwerp|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2009|August 10, 2009|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00841230||143610|
NCT00841464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1EA-0000071|Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease|Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease||Parkinson's Disease Research, Education, and Clinical Center, Philadelphia|No|Completed|March 2009|May 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|40 Years|80 Years|No|Non-Probability Sample|Subjects with Parkinson's disease will be recruited ONLY at the Parkinson's Disease        Research, Education, and Clinical Center (PADRECC) of the Philadelphia VA Medical Center.|July 2012|July 9, 2012|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841464||143592|
NCT00837109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24172|Randomized Clinical Trial of Imagery Rescripting Treatment In Veterans With Trauma-Related Nightmares And Posttraumatic Stress Disorder (PTSD)|Randomized Clinical Trial of Imagery Rescripting Treatment In Veterans With Trauma-Related Nightmares And Posttraumatic Stress Disorder (PTSD)||VA Office of Research and Development|No|Terminated|February 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|64 Years|No|||September 2010|September 28, 2010|February 3, 2009||No|Primary investigator is no longer a part of the VA|No||https://clinicaltrials.gov/show/NCT00837109||143921|
NCT00837343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00070|A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder|An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder||Guangzhou Mental Hospital|Yes|Recruiting|December 2008|December 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||February 2009|February 4, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837343||143903|
NCT00837356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3522|Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects|A Multi-centre, Multi-national Open-label Sequential Trial Comparing Pharmacokinetics and Safety of N8 and Advate® in Subjects With Haemophilia A||Novo Nordisk A/S|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|12 Years|55 Years|No|||November 2014|November 18, 2014|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837356||143902|
NCT00837590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU-IRB-0901-03|Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls|Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls||Indiana University|Yes|Completed|March 2009|August 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|May 21, 2012|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837590||143884|
NCT00837083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSI-CRE-2006/1|Evaluation of Crestor® (Rosuvastatin) in Daily Practice|Open-Label Non-Interventional Evaluation of Efficacy of Crestor® (Rosuvastatin) in Reduction of LDL-Cholesterol and Cardiovascular Risk Parameters in Patients With Hypercholesterolaemia||AstraZeneca|No|Completed|January 2007|October 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|602|||Both|18 Years|N/A|No|Non-Probability Sample|patients (outpatient or hospitalised) in whom Crestor is indicated according to the        current Summary of product characteristics (SPC)|February 2009|February 5, 2009|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837083||143923|
NCT00837317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oils&Frying|Different Oils For Frying and Endothelial Function|Comparative Effect Of Different Oils For Frying On The Endothelial Function, The Oxidative Stress And The Postprandial Inflammatory Response||Hospital Universitario Reina Sofia|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|1||Actual|26|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2009|May 12, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837317||143905|
NCT00837577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-104|MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)|A Phase III, Randomized, Placebo-controlled, Double-blind Clinical Trial and Subsequent Open-label, Extension Clinical Trial to Study the Efficacy and Safety of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Voglibose Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|February 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|133|||Both|20 Years|N/A|No|||July 2015|July 16, 2015|February 3, 2009|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT00837577||143885|
NCT00837837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-08-01|Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents|A Single-Dose, Open-Label, Pharmacokinetic Study of Chlorpheniramine Maleate Liquid in Children and Adolescents||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837837||143865|
NCT00838396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-B-049|A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease||Indivior Inc.|No|Completed|October 2005|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838396||143822|
NCT00838721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASCAL-1|Evaluation of Pascal Laser Trabeculoplaty|Prospective Evaluation of the Efficacy of Pascal Trabeculoplasty: A Pilot Study|PLT|Santa Clara Valley Health & Hospital System|No|Recruiting|March 2008|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2009|September 28, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838721||143798|
NCT00839020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIOS-TKR|Minimally Invasive Versus Conventional Approaches in Navigated Total Knee Arthroplasty (TKA)|Comparison of a Minimally Invasive and a Conventional Approach in Computer Assisted Total Knee Arthroplasty.||Aesculap AG|No|Terminated|November 2007|January 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|N/A|N/A|No|||June 2015|June 26, 2015|February 6, 2009||No|Number of patients willing to participate in the study too low|No||https://clinicaltrials.gov/show/NCT00839020||143776|
NCT00829439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-10-0490|Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome|A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome||Children's Hospital Boston|Yes|Completed|January 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|4 Years|12 Years|No|||October 2012|October 10, 2012|January 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829439||144504|
NCT00830011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RK0029|Cognitive Behavioral Therapy for Painful Diabetic Neuropathy|Cognitive Behavioral Therapy for Painful Diabetic Neuropathy||VA Connecticut Healthcare System|No|Completed|September 2004|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2011|July 27, 2011|January 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00830011||144460|
NCT00830037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71633|A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease|Pathobiology of Kidney Disease: Role of Iron||Indiana University|Yes|Active, not recruiting|August 2008|August 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830037||144458|
NCT00830323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-517|Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection|Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection|Combina|Hospices Civils de Lyon|Yes|Terminated|January 2009|August 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||October 2009|September 29, 2010|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830323||144436|
NCT00830336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-1375|A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions|A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 26, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00830336||144435|
NCT00841399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-2005|Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients|Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies||Walter Reed Army Medical Center|No|Completed|July 2001|March 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|February 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00841399||143597|
NCT00830921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q1607/48|Does Transcranial Magnetic Stimulation of the Cingulate Cortex Modulate the Perception of Dyspnoea?|A Randomised Crossover Study to Investigate the Effect of Transcranial Magnetic Stimulation of the Anterior Cingulate Cortex on "Air Hunger"|TMS|University of Oxford|No|Terminated|February 2008|January 2012|Actual|||N/A|Observational|N/A||1|Anticipated|12|||Both|18 Years|N/A|No|Probability Sample|Patients attending out-patient clinic|June 2012|June 15, 2012|January 27, 2009||No|Lack of patients|No||https://clinicaltrials.gov/show/NCT00830921||144390|
NCT00831194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#00001685|Stress, Dietary Lapse and Weight Loss Among Adults With Type 2 Diabetes|Stress, Dietary Lapse and Weight Loss Among Adults With Type 2 Diabetes||Johns Hopkins Bloomberg School of Public Health|No|Completed|March 2009|July 2012|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|70|||Both|21 Years|65 Years|No|||July 2012|July 31, 2012|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831194||144369|
NCT00831506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451021|Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects||Pfizer|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 9, 2009|January 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831506||144345|
NCT00831519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB_6.08_1|The Effect of Diabetes on the Newborn|Biochemical, Hematologic, and Inflammatory Effects of Diabetes on the Newborn||Western Galilee Hospital-Nahariya|No|Recruiting|January 2009|December 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Female|18 Years|40 Years|No|Non-Probability Sample|Pregnant women who plan to deliver at Western Galilee Hospital|June 2014|June 19, 2014|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831519||144344|
NCT00831844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01170|Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors||National Cancer Institute (NCI)|Yes|Completed|January 2009|October 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|116|||Both|7 Months|30 Years|No|||March 2015|March 18, 2015|January 28, 2009|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT00831844||144321|
NCT00827294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4925 Mirror Therapy|Home-based Self-delivered Mirror Therapy for Phantom Limb Pain|A Pilot Study of Self-delivered Home-based Mirror Therapy for Phantom Limb Pain||Oregon Health and Science University|Yes|Recruiting|January 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|75 Years|No|||September 2009|September 11, 2009|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00827294||144669|
NCT00827307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8666L00002|Zoladex Plus Tamoxifen in Breast Cancer|The Effects of Adjuvant Zoladex Plus Tamoxifen on Breast Density in Pre- or Peri-menopausal Women With Early-stage Breast Cancer||Zhejiang Cancer Hospital|No|Completed|June 2008|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|50 Years|No|||August 2011|August 5, 2011|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827307||144668|
NCT00837603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGA2009|Physical Training in Transposition of the Great Arteries|Influence of Physical Training on Cardiopulmonary Exercise Capacity and Right Ventricular Function in Patients With D-TGA and Atrial Switch Operation.|TrainingTGA|Hannover Medical School|Yes|Completed|February 2009|January 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|48|||Both|18 Years|40 Years|No|||July 2011|March 8, 2012|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837603||143883|
NCT00837850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-02|SmartSet HV and Palacos R RSA Bone Cements in Primary Total Hip Arthroplasty|A Randomised Prospective Trial of SmartSet HV and Palacos R Bone Cements in Primary Total Hip Arthroplasty. A Radiostereometric Analysis of the Charnley Femoral Component.||Norwegian University of Science and Technology|No|Completed|October 2002|October 2008|Actual|October 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|78 Years|No|||August 2011|August 25, 2011|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837850||143864|
NCT00837863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001194|Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency|A Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin) in Prepubertal Children With Growth Hormone Deficiency||Altus Pharmaceuticals|No|Recruiting|March 2009|||September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|3 Years|13 Years|No|||May 2009|May 6, 2009|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837863||143863|
NCT00838110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451027|A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease|A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|742|||Both|50 Years|N/A|No|||January 2013|January 7, 2013|February 5, 2009|Yes|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT00838110||143844|This safety study did not specify primary or secondary outcome measures. Relevant summaries of all safety assessments are thus provided. Urine blood abnormalities seen are deemed due to interference with dipstick test by a metabolite of dimebon.
NCT00828386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC-NPC2006|Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers|A Randomized, Multicenter, Phase III Trial Comparing Induction Chemotherapy With Docetaxel, Cisplatin and 5-Fluorouracil (TPF) Followed by Concurrent Chemoradiotherapy to Concurrent Chemoradiotherapy Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)|GORTEC-NPC2006|Groupe Oncologie Radiotherapie Tete et Cou||Terminated|January 2009|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|70 Years|No|||March 2015|March 23, 2015|January 22, 2009||No|Low accrual|No||https://clinicaltrials.gov/show/NCT00828386||144585|
NCT00828399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2008-BecaSacyl|Prevention of Acute Radiation Enteritis With Glutamine|Efficacy of Glutamine in the Prevention of Acute Radiation Enteritis Among Patients Treated With Radiation of Abdomen and Pelvis.||Castilla-León Health Service|No|Completed|January 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|N/A|No|||January 2009|May 24, 2011|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828399||144584|
NCT00828698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Finger-96|FINGER; Finland-Germany Myocardial Infarction Study|Finnish-German Prospective, Observational Follow-up Study on Risk Assessment of Mortality After Myocardial Infarction|FINGER|University of Oulu||Completed|January 1996|||January 2000|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||Samples With DNA|DNA samples from Finnish subjects in the study have been retained.|Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients who have been hospitalized for acute myocardial infarction from        Munich, Germany and Oulu, Finland|January 2009|January 23, 2009|January 23, 2009||||No||https://clinicaltrials.gov/show/NCT00828698||144561|
NCT00828711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso-Obs-204|Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor|A Multicenter, Randomized, Double-Blind, Dose-Ranging, Phase II Study to Assess the Efficacy and Safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert for Women Requiring Cervical Ripening and Induction of Labor||Ferring Pharmaceuticals|Yes|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|374|||Female|18 Years|N/A|No|||March 2014|March 10, 2014|January 22, 2009|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT00828711||144560|
NCT00829062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-11-178E|Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes|Presenting Evidence Based Practice to an Insurance Provider to Expand Coverage of Continuous Subcutaneous Insulin Infusion (CSII) in Pediatric Patients With Diabetes||Children's Mercy Hospital Kansas City|Yes|Withdrawn|January 2009|July 2010|Anticipated|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|12 Months|17 Years|Accepts Healthy Volunteers|||July 2010|July 29, 2010|January 22, 2009|No|Yes|No participants met inclusion criteria.|No||https://clinicaltrials.gov/show/NCT00829062||144533|
NCT00829075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-MM-0501-37|Impact of Three Different Gonadotrophin Regimes on Egg Donation Program|A Prospective, Randomized, Controlled Trial Comparing Three Different Gonadotrophin Regimens in Oocyte Donors: Ovarian Response and IVF Outcome||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|January 2005|December 2006|Actual|||Phase 4|Interventional|N/A|3||||||Female|18 Years|34 Years|Accepts Healthy Volunteers|||January 2009|January 23, 2009|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829075||144532|
NCT00829413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR1-130|SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization|Characterization Of Focal Liver Lesions With Sonovue®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Unenhanced Ultrasound Imaging Using Histology Or Combined Imaging/Clinical Data As Truth Standard||Bracco Diagnostics, Inc|No|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|353|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829413||144506|
NCT00829426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0166|Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 18, 2009|January 26, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00829426||144505|
NCT00830063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091015|Tanezumab In Osteoarthritis Of The Knee (2)|A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee||Pfizer|Yes|Completed|May 2009|July 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|848|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830063||144456|
NCT00829699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044874|Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus|Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus, Question 3||University of Maryland|Yes|Completed|July 2009|April 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|31|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829699||144484|
NCT00829712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04162|Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Dexmethylphenidate Hydrochloride, (10 mg), Compared to and Equivalent Dose of a Commercially Available Reference Drug Product (Focalin®, Novartis Pharmaceuticals Corporation) in 24 Fasted, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|June 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 26, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00829712||144483|
NCT00830674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN23-US-02|A Study of KRN23 in X-linked Hypophosphatemia|A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia||Kyowa Hakko Kirin Pharma, Inc.|Yes|Completed|December 2008|May 2013|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|January 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00830674||144409|
NCT00830687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-5582-NS-CTIL|Intracapsular Femoral Neck Fractures Fixation With a Dynamic Locking Plate and Screw System, Targon FN|Intracapsular Femoral Neck Fractures Fixation With a Dynamic Locking Plate and Screw System, Targon FN. Prospective and Retrospective Cohort Study.||Sheba Medical Center|No|Recruiting|January 2009|January 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2010|September 5, 2010|January 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00830687||144408|
NCT00830349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01172|Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Risperidone 1 mg Tablets and Risperdal 1 mg Tablets Administered as a 1 x 1 mg Tablet in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA||Completed|June 2001|July 2004|Actual|July 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 26, 2009|January 26, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00830349||144434|
NCT00830362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18285|Beta-blockade Effects on Memory for Cocaine Craving|Treatment Implications of Beta-blockade Effects on Memory for Cocaine Craving||Medical University of South Carolina|Yes|Completed|February 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2012|October 31, 2012|January 26, 2009|Yes|Yes||No|August 24, 2012|https://clinicaltrials.gov/show/NCT00830362||144433|Lack of a “no retrieval” control group. Lack of determination of plasma propranolol levels following the medicated retrieval session. The sample size was insufficient to assess the more distal effects at 1-week follow-up.
NCT00835393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036582|Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions|A Relative Bioavailability Replicated Crossover Study of Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|December 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|February 2, 2009|February 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00835393||144051|
NCT00835406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00161|Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.|Randomized, 2-Way Crossover, Bioequivalence Study of Teva Pharmaceuticals USA and Merck Sharp & Dohme (USA) (Fosamax®) Alendronate Sodium Tablets Administered as a 1 x 70 mg in Healthy Adult Males Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2000|July 2000|Actual|July 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|140|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|January 30, 2009|No|Yes||No|April 24, 2009|https://clinicaltrials.gov/show/NCT00835406||144050|
NCT00835419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/27/08|Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression|An Open Label, Multicentre, Two Stage, Phase II Study To Evaluate Efficacy And Safety Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression|ENVER|Piramal Enterprises Limited|No|Completed|May 2009|November 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835419||144049|
NCT00830947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA-02|Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement|The OrthoAccel (OATI) Celerect Device Pivotal Study - Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement||OrthoAccel Technologies Inc.|No|Completed|February 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|12 Years|40 Years|No|||November 2013|November 5, 2013|January 26, 2009|Yes|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT00830947||144388|
NCT00831207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-19|Beta-2 Microglobulin and Serum Cytokines x HAART|Beta-2 Microglobulin and Serum Cytokines as Indicators of Antiretroviral Therapy Failure||UPECLIN HC FM Botucatu Unesp|Yes|Completed|August 2004|December 2008|Actual|November 2005|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|109|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|89 HIV-1-infected individuals assisted by the Tropical Diseases Sector of the Botucatu        School of Medicine - UNESP and 20 normal blood donors at the Botucatu Blood Bank.|January 2009|January 27, 2009|December 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00831207||144368|
NCT00831532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451018|Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function|A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function||Pfizer|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2009|September 14, 2009|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831532||144343|
NCT00831545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02064|Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)|Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.||Merck Sharp & Dohme Corp.|No|Completed|December 2000|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|162|||Both|18 Years|70 Years|No|||May 2015|May 25, 2015|January 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831545||144342|
NCT00831857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renimage Protocol|VEGF Imaging in Renal Cell Carcinoma|89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Sunitinib or Bevacizumab Plus Interferon; a Pilot Study|Renimage|University Medical Center Groningen|No|Completed|January 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|26|||Both|18 Years|N/A|No|Probability Sample|Patients locally advanced irresectable or metastatic renal cell cancer.|October 2015|October 1, 2015|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831857||144320|
NCT00827320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVE-T1000-PVFD-1|Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|June 2007|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 21, 2009|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00827320||144667|
NCT00827333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08036|Palliative Care Teaching Sessions for Family Caregivers of Patients With Non-Small Cell Lung Cancer|Palliative Care for Quality of Life and Symptom Concerns in Family Caregivers of Lung Cancer Patients||City of Hope Medical Center|Yes|Completed|September 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|372|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827333||144666|
NCT00827593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070601|Managing Obesity by Combining Behavioral Weight Loss and Commercial Approaches|Managing Obesity by Combining Behavioral Weight Loss and Commercial Approaches||Baruch College City University of New York|Yes|Completed|November 2008|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|144|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827593||144646|
NCT00827606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581173|Atorvastatin Three Year Pediatric Study|A Three Year, Prospective, Open-label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia||Pfizer|Yes|Completed|March 2009|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|272|||Both|6 Years|15 Years|No|||June 2015|June 1, 2015|January 21, 2009|Yes|Yes||No|September 11, 2014|https://clinicaltrials.gov/show/NCT00827606||144645|
NCT00837876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0815|Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery|A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|October 2008|November 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2013|June 13, 2014|February 5, 2009|Yes|Yes||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00837876||143862|
NCT00838123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96-C-044|Cognitive Functioning Related to Job Tenure Among Patients With Schizophrenia|||Far Eastern Memorial Hospital|Yes|Completed|August 2008|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|45 Years|No|Probability Sample|schizophrenia|February 2009|February 5, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838123||143843|
NCT00838136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01304|Lamotrigine 25 mg Chewable Tablets, Non-Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Dispersible Tablets and Lamictal® 25 mg Chewable Dispersible Tablets in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|February 2002|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 5, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00838136||143842|
NCT00828412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC0801|Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis|A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis||Promius Pharma, LLC|No|Completed|March 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|3 Months|12 Years|No|||October 2013|October 14, 2013|January 21, 2009||No||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00828412||144583|
NCT00828425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CCH-DUM-2008/1|Management of Diabetes Mellitus Patients With Retinopathy|Management of Diabetes Mellitus Patients With Retinopathy||AstraZeneca|No|Completed|December 2008|August 2009|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|2500|||Both|N/A|N/A|No|Non-Probability Sample|Diabetic patients with diabetic retinopathy|August 2010|August 17, 2010|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828425||144582|
NCT00828438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-016|Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment|A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment||Arena Pharmaceuticals|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||July 2009|July 27, 2009|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828438||144581|
NCT00828724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-015|Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State|An Open Label, Single Dose, Cross-Over Study to Assess the Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State||Arena Pharmaceuticals|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|January 23, 2009|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828724||144559|
NCT00829088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00008|Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066|An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects||AstraZeneca|No|Completed|January 2009|February 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|35 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 24, 2009|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829088||144531|
NCT00829101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-nr: 548/2008|Articulation and Phonology in Children With Unilateral Cleft Lip and Palate|Articulatory and Phonological Competence at 3 and 5 Years of Age in Children With Unilateral Cleft Lip and Palate Who Have Undergone Different Methods of Primary Palatal Surgery|APCLP|Region Skane|No|Completed|January 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|3 Years|3 Years|No|Non-Probability Sample|Children from the south or western region of Sweden born with unilateral cleft lip and        palate.|July 2014|July 1, 2014|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829101||144530|
NCT00829114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10079|Interactions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs)|Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills||FHI 360|No|Completed|March 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|370|||Female|18 Years|35 Years|No|||October 2011|October 28, 2011|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00829114||144529|
NCT00830388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080520002|Ketoconazole Foam 2% for the Treatment of Versicolor|Ketoconazole Foam 2% for the Treatment of Versicolor||University of Alabama at Birmingham|No|Completed|November 2008|September 2010|Actual|August 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|19 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 21, 2012|January 23, 2009|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00830388||144431|
NCT00830375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806M37821|Memantine Treatment of Compulsive Buying|Memantine Treatment of Compulsive Buying: An Open-Label Study||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|December 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||April 2012|April 9, 2012|January 23, 2009|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00830375||144432|
NCT00830973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedcoTamoxifen1|The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer|Tamoxifen Pharmacogenomics and the Prevention of Recurrent Breast Cancer|MHSLabCorp1|Medco Health Solutions, Inc.|Yes|Completed|October 2007|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|184|Samples With DNA|Buccal swab|Female|50 Years|N/A|No|Non-Probability Sample|The active study group consists of 50 year or older postmenopausal women taking tamoxifen        for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet        all inclusion criteria, and are enrolled members for Medco clients agreeing to        participate.|October 2009|October 12, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830973||144386|
NCT00830960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11299|A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome|A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention||Eli Lilly and Company|Yes|Completed|February 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|720|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|January 27, 2009|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00830960||144387|
NCT00835432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA/2/054|Morphometric, Clinical and Histological Study on One Stage Bone Augmentation Using BoneCeramic (BCP) and Collagen Membranes|Prospective Clinical, Morphometric and Histological Study on Augmentation Using BoneCeramic as Bone Substitute in Combination With Either Cross-Linked or Non Cross-Linked Collagen Membrane in Dehiscent Type of Defects .|BCP+Collagen|Charite University, Berlin, Germany|No|Completed|October 2005|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Actual|40|||Both|22 Years|N/A|No|||February 2009|February 2, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835432||144048|
NCT00835835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0001|Lokomat Treadmill Training Effects on MS Gait|Lokomat Treadmill Training Effects on MS Gait||Mount Sinai Rehabilitation Hospital|No|Completed|February 2008|June 2013|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|25 Years|60 Years|No|||November 2015|November 9, 2015|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00835835||144017|
NCT00831571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-140|Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin|Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated at Dana-Farber Cancer Institute with the chemotherapy drug oxaliplatin.|April 2014|April 27, 2014|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831571||144341|
NCT00831597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-08904|Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|904|Pharmatech|Yes|Active, not recruiting|November 2008|September 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831597||144340|
NCT00826995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816692-1|Comparison of Video-Based Versus Written Patient Education on Melanoma|Comparison of Video-based Versus Written Patient Education on Melanoma||University of California, Davis|No|Completed|January 2009|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00826995||144692|
NCT00827008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/3004|Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus|An Open-Label, Long-Term Treatment Study to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane With Subjective Tinnitus|OLLTT|Merz Pharmaceuticals GmbH|No|Terminated|January 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|821|||Both|18 Years|75 Years|No|||November 2012|November 27, 2012|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827008||144691|
NCT00827346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRL-A2|Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty|Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty||Ottawa Heart Institute Research Corporation|No|Completed|January 2009|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|100|||Both|N/A|N/A|No|||April 2011|April 28, 2011|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00827346||144665|
NCT00827632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB4823|Obesity, Oral Contraception, and Ovarian Suppression|Oral Contraception and Ovarian Suppression in Women With Different Weights|20/30|Columbia University|No|Completed|July 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|226|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|January 21, 2009||No||No|October 11, 2010|https://clinicaltrials.gov/show/NCT00827632||144643|
NCT00828490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24987|Electronic Pharmacotherapy Risk Management|Developing a Utah Pharmacotherapy Risk Management System With an Electronic Surveillance Tool (Utah ePRM)|ePRM|University of Utah|No|Completed|July 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Retrospective||6|Actual|174000|||Both|N/A|N/A|No|Non-Probability Sample|all medicaid recipients in the salt lake area|March 2010|March 21, 2010|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828490||144577|
NCT00827619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-009|Zilver® Flex™ Vascular Stent Study|Evaluation of the Zilver® Flex™ Vascular Stent in the Above-the-Knee Femoropopliteal Artery||Cook||Completed|February 2009|November 2015|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00827619||144644|
NCT00827840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-KOR-9006|Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia|Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial||Chonnam National University Hospital|Yes|Completed|November 2008|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|59 Years|No|||December 2011|December 22, 2011|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827840||144627|
NCT00828087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXAM-08|A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study|A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction.EXAMINATION Study||Spanish Society of Cardiology|No|Completed|December 2008|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1504|||Both|N/A|N/A|No|||May 2015|May 18, 2015|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828087||144608|
NCT00828737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13273|Safety of Gadovist in Renally Impaired Patients|Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Gadovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information|GRIP|Bayer|No|Completed|December 2008|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|927|||Both|2 Years|N/A|No|||February 2016|February 16, 2016|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00828737||144558|
NCT00828750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111433|Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study>||GlaxoSmithKline||Completed|May 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|20 Years|N/A|No|||October 2011|October 31, 2011|January 22, 2009||No||No|September 15, 2011|https://clinicaltrials.gov/show/NCT00828750||144557|
NCT00828763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111853|GSK1349572 Mass Balance Study|An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853)||GlaxoSmithKline||Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||May 2009|June 4, 2009|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828763||144556|
NCT00829127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3801C00004|AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers||AstraZeneca|No|Withdrawn|January 2009|January 2009|Anticipated|January 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 24, 2011|January 20, 2009||No|Due to termination of study D3801C00001, due to reports of turbid urine.|No||https://clinicaltrials.gov/show/NCT00829127||144528|
NCT00829140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-014|To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake|A 56-Day , Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake in Overweight and Obese Patients (TULIP)|TULIP|Arena Pharmaceuticals|No|Completed|November 2008|February 2010|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|56|||Both|18 Years|65 Years|No|||November 2010|November 1, 2010|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829140||144527|
NCT00829452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40181|Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as the Content of 1 x 10 mg Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.||Teva Pharmaceuticals USA||Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 23, 2009||Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00829452||144503|
NCT00829725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-5569-NS-CTIL|Comparison Study of 3-4-screws-internal Fixation With Multi-screw-system Targon FN for Femoral Neck Fracture|Randomized, Prospective, Multi-center, Comparison Study of 3-4-screws-internal Fixation With Multi-screw-system Targon FN for Femoral Neck Fracture||Sheba Medical Center|No|Recruiting|January 2009|January 2012|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2010|September 5, 2010|January 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00829725||144482|
NCT00829738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2-9999-011-DE|Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease|Pantoprazole 20/40 mg in Reflux-Associated Complaints With Focus on Gastrointestinal Symptoms|PARADE|Nycomed|No|Completed|January 2009|June 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4188|||Both|12 Years|N/A|No|Non-Probability Sample|Outpatients|May 2012|May 4, 2012|January 13, 2009||No||No|September 1, 2010|https://clinicaltrials.gov/show/NCT00829738||144481|
NCT00830050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001399|Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients|A Study To Determine The Ability Of FMRI To Detect And Quantify The Effect Of Naproxen On Osteoarthritis Of The Hand||Pfizer||Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Female|50 Years|80 Years|No|||March 2011|March 10, 2011|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830050||144457|
NCT00830401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAtrial|The Impact of Treating Minor Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy in Unselected In Vitro Fertilization (IVF) Cases|Comparative Controlled Trial of Treatment of Minor Unexpected Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy Screening in Women Indicated for IVF||UMC Utrecht|No|Terminated|June 2007|March 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|700|||Female|N/A|36 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|January 26, 2009||No|Abnormality prevalence revealed to be much lower than expected.|No||https://clinicaltrials.gov/show/NCT00830401||144430|
NCT00830700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12537|Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study|Telemental Health to Improve Mental Health Care and Outcomes for Children in Underserved Areas|CATTS|Seattle Children's Hospital|Yes|Completed|September 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|223|||Both|5 Years|12 Years|No|||February 2014|February 7, 2014|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830700||144407|
NCT00830986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIUWHOZ 09-01|Cognition Following Computer Assisted Total Knee Arthroplasty|Cognition Following Computer Assisted Total Knee Arthroplasty: A Prospective Cohort Study|Minimental|Rothman Institute Orthopaedics|No|Completed|July 2005|March 2006|Actual|March 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|100 Consecutive patients requiring a total knee arthroplasty for degenerative arthritis of        the knee|January 2009|April 14, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830986||144385|
NCT00831246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.03.27.E2|Prevention of Ileus After Gynecologic Surgery Using Chewing Gum|Prevention of Post-Op Ileus After Gynecologic Surgery Using Chewing Gum||Aultman Health Foundation|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|N/A|No|||June 2010|June 7, 2010|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831246||144365|
NCT00831233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS28|Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer|A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer||Ferring Pharmaceuticals|No|Terminated|April 2009|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Male|18 Years|N/A|No|||October 2013|October 18, 2013|January 27, 2009|Yes|Yes|Poor recruitment due to rare targeted population|No|June 14, 2011|https://clinicaltrials.gov/show/NCT00831233||144366|Early termination leading to small numbers of subjects analyzed.
NCT00835445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 20188|Biopsies and Polyps|Nasal Features of Subjects With Nasal Polyposis With or Without Asthma||Laval University|No|Completed|July 2007|September 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|Samples Without DNA|Nasal polyps (Biopsies) Normal nasal mucosa (Biopsies) Sputum|Both|18 Years|65 Years|No|Non-Probability Sample|Recruited from the ENT clinic (Laval Hospital, Quebec City, Canada)|December 2010|January 6, 2011|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00835445||144047|
NCT00835458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS GRANT#25206|Endoscopic Treatment of Intestinal Fistulas and Perforations|Closure of Fistulas and Perforations Endoscopically to Avoid Laparoscopic or Open Surgery||Legacy Health System|No|Enrolling by invitation|February 2009|December 2010|Anticipated|October 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|85 Years|No|||February 2009|February 10, 2009|February 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00835458||144046|
NCT00827021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM6X822T|The Clinical Evaluation of the Dose of Erythropoietins Trial|Effects of the Dose of Erythropoiesis Stimulating Agents on Cardiac-cerebrovascular Outcomes Quality of Life and Costs in Hemodialysis Patients. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) Trial|CEDOSE|Consorzio Mario Negri Sud|Yes|Recruiting|June 2009|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827021||144690|
NCT00827359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-313|Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma|A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|March 2009|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827359||144664|
NCT00827372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811-15 /IUCRO-0248|A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer|A Phase II Study of VEGF Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer||Indiana University|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|January 20, 2009|Yes|Yes||No|September 2, 2014|https://clinicaltrials.gov/show/NCT00827372||144663|This study was to enroll 14-15 patients. Due to toxicity and enough patients met the definition of response, enrollment to this study was halted early, leading to a smaller number of subjects analyzed.
NCT00827645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112008-033|Uterine Artery Embolization and Pelvic Floor Symptoms|Effect of Uterine Artery Embolization on Symptoms of Pelvic Floor Dysfunction||University of Texas Southwestern Medical Center|No|Recruiting|January 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|56|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with symptomatic uterine fibroids who are scheduled for uterine artery embolization|January 2010|February 17, 2010|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827645||144642|
NCT00828126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0478|PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma|PET-CT in the Management of Patients With Stage III Or IV Metastatic Melanoma Considered Candidates for Surgery: Evaluation of Additive Value Following Conventional Imaging||M.D. Anderson Cancer Center|No|Completed|January 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals over 18 years of age with metastatic melanoma (melanoma that has spread to        other parts of the body) and are considered a candidate for surgery based on a        contrast-enhanced computer tomography (CT) scan.|March 2012|March 26, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00828126||144605|
NCT00828100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-13|Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B|Comparison of fluID Rapid Influenza and BinaxNOW® Influenza A & B||Nanogen, Inc.|No|Suspended|February 2009|||May 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|650|||Both|N/A|N/A|No|||March 2009|March 5, 2009|January 20, 2009|No|Yes|Study currently suspended due to a lack of available funding.|No||https://clinicaltrials.gov/show/NCT00828100||144607|
NCT00828451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0105|Collaborative Research Group for Necrotizing Enterocolitis|Collaborative Research Group for Necrotizing Enterocolitis||Washington University School of Medicine|Yes|Active, not recruiting|May 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|48|||Both|N/A|7 Days|No|||December 2009|December 17, 2009|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828451||144580|
NCT00829153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8974|U Clip Study - Study to Compare U Clip Anastomosis With Conventional Continuous Prolene Anastomosis|A Pilot, Randomised, Blinded Study to Compare U Clip Anastomosis With Conventional Continuous Prolene Anastomosis for Creating of Autologous Arteriovenous Fistulae||Royal Hobart Hospital|No|Recruiting|January 2007|||August 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 15, 2010|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00829153||144526|
NCT00829166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21977|An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer|A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab Emtansine vs. Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-based Therapy|EMILIA|Hoffmann-La Roche||Active, not recruiting|February 2009|June 2015|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|991|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|January 22, 2009|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00829166||144525|
NCT00829751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-8|The Physiological Consequence of Silicone-hydrogel Care-solution Bio-incompatibility|The Physiological Consequence of Silicone-hydrogel Care-solution Bio-incompatibility||Southern California College of Optometry|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 31, 2013|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829751||144480|
NCT00829764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-064-SA|Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study of Doxycycline Monohydrate 25 mg as a 5 mL Oral Suspension Under Fasting Conditions||Teva Pharmaceuticals USA||Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 26, 2009||Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00829764||144479|
NCT00830076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-110|A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)|A Study to Assess the Effects of Co-Administration of Sitagliptin and Metformin on Incretin Hormone Concentrations||Merck Sharp & Dohme Corp.|No|Completed|December 2008|May 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|65 Years|No|||August 2015|August 3, 2015|January 26, 2009|No|Yes||No|September 29, 2011|https://clinicaltrials.gov/show/NCT00830076||144455|
NCT00830427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7881006|A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects|A Phase IIb Randomised, Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of PF-00610355 Over 4 Weeks In Moderately Asthmatic Subjects.|A7881006|Pfizer|No|Withdrawn|July 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|65 Years|No|||March 2011|March 11, 2011|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830427||144428|
NCT00830713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5385|Vitiligo Skin Transplantation|Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo|MKTP|Henry Ford Health System|No|Completed|January 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2010|September 4, 2012|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830713||144406|
NCT00830999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0195|Fat Metabolism in Response to Acute Diet- and Exercise-induced Changes in Energy Balance|VLDL-triglyceride Metabolism in Response to Acute Diet- and Exercise-induced Changes in Energy Balance|DEV|Washington University School of Medicine|Yes|Completed|April 2006|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|12|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830999||144384|
NCT00831649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN100226-RA251|A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201|A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201||Elan Pharmaceuticals||Terminated|September 2004|||February 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|75 Years|No|||January 2009|January 27, 2009|January 27, 2009||Yes|The biological effect seen with natalizumab was not sufficient to warrant further development    in RA.|||https://clinicaltrials.gov/show/NCT00831649||144336|
NCT00831259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU de Caen|Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO)|Silent Cerebral Infarcts in Patients With Pulmonary Embolism and a Patent Foramen Ovale: a Prospective Diffusion-weighted Magnetic Resonance Imaging Study.|ICEP|University Hospital, Caen|Yes|Completed|October 2007|May 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|90 Years|No|Probability Sample|Consecutive series of patients with a pulmonary embolism|May 2011|May 19, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831259||144364|
NCT00831272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807991|Pharmacogenetic Response to Naltrexone For Alcohol Dependence|Pharmacogenetic Response to Naltrexone for Alcohol Dependence||University of Pennsylvania|Yes|Completed|January 2009|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831272||144363|
NCT00835874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-06-SD-363-CTIL|Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis|Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis||Tel-Aviv Sourasky Medical Center|No|Terminated|June 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|57|||Both|N/A|N/A|No|||August 2012|August 1, 2012|July 5, 2007||No|Difficulty in recruitment. Mothers of infants preferred to take probiotics bought    over-the-counter over the possibility of being in a placebo group|No||https://clinicaltrials.gov/show/NCT00835874||144014|
NCT00835887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESRD-Study|Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease|Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease, a Phase 2 Study|ESRD|RWTH Aachen University|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|February 3, 2009||No|no patients recruited, responsible physician left clinic|No||https://clinicaltrials.gov/show/NCT00835887||144013|
NCT00827034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451020|A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects|A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects||Pfizer|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 20, 2009|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827034||144689|
NCT00827385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809009986|Intraoperative Blood Pressure and Cognitive Performance|Impact of Intraoperative Blood Pressure on Cognitive Performance in Patients With and Without Hypertension: a Prospective Observational Study||Weill Medical College of Cornell University|No|Completed|January 2009|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|40 Years|N/A|No|Non-Probability Sample|- individuals 40 years of age and older, undergoing laminectomy under general anesthesia.|February 2015|February 2, 2015|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827385||144662|
NCT00827658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McMaster 08-053|Ulnar Nerve Block for Procedural Anesthesia - Wrist Versus Palm|Ulnar Nerve Block for Procedural Anesthesia - Wrist Versus Palm||McMaster University|No|Recruiting|February 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 22, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827658||144641|
NCT00827892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0410|Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage|Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage|SHRINC|The University of Texas Health Science Center, Houston|Yes|Completed|March 2009|November 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|80 Years|No|||October 2015|October 1, 2015|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827892||144623|
NCT00827866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD07-140 Quit-Line|Efficacy of Tobacco Quitline for Cancer Survivors|Efficacy of Tobacco Quitline for Cancer Survivors||St. Jude Children's Research Hospital|No|Completed|October 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|946|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827866||144625|
NCT00827879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U49CE001248|Strength at Home Couples Program (PTSD-Focused Relationship Enhancement Therapy for Returning Veterans)|Strength at Home Couples Program (Formerly: PTSD-Focused Relationship Enhancement Therapy for Returning Veterans and Their Partners)||Boston VA Research Institute, Inc.|Yes|Completed|February 2009|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|156|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827879||144624|
NCT00827853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOSTON SCI R&E 9-21-07#2|Study Comparing Two Methods of Expanding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease|PolarCath® Cryoplasty Versus Conventional Balloon Post-dilation of Nitinol Stents for Peripheral Vascular Interventions (COBRA)|COBRA|North Texas Veterans Healthcare System|Yes|Completed|November 2008|February 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Both|21 Years|N/A|No|||November 2013|November 1, 2013|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827853||144626|
NCT00828113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0149|Long-term Varenicline Treatment for Smoking Cessation|Long-term Varenicline Treatment for Smoking Cessation||University of Wisconsin, Madison|Yes|Completed|January 2009|February 2011|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|January 21, 2009|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00828113||144606|Feasibility study with limited statistical power at baseline compounded by a significant rate of attrition during the study.
NCT00828464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U0280-401|Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis|An Open Label Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for the Condition of Chronic Hand Dermatitis||GlaxoSmithKline|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|January 22, 2009|Yes|Yes||No|April 7, 2010|https://clinicaltrials.gov/show/NCT00828464||144579|Open label study
NCT00828477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0144|Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)|Evaluation of Comfort With the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Xibrom (Bromfenac Ophthalmic Solution) 0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)||Bp Consulting, Inc|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 8, 2009|January 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828477||144578|
NCT00828776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPCRI0907|Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure|Clinical Trial of Pharmacodynamic Effects and Non-Clinical Inferiority of the Drug Heparin Sodium Produced by the Laboratory Cristália When Compared With the Product Liquemine of Roche Laboratory in Patients With Chronic Renal Failure|heparin|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|September 2007|March 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||January 2009|January 23, 2009|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828776||144555|
NCT00829777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28.073-2|Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects|A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects.|AIKO-150|California Pacific Medical Center Research Institute|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|8|||Both|21 Years|45 Years|No|||September 2009|September 14, 2009|January 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829777||144478|
NCT00829790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-065-SA|Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study of Doxycycline Monohydrate 25 mg as a 5mL Oral Suspension Under Fed Conditions||Teva Pharmaceuticals USA||Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 26, 2009||Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00829790||144477|
NCT00829803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIS-SNAP-2008-01US|A Study to Assess Indeics of SNAP vs VISTA on Surgical Patients Undergoing General Anesthesia|A Prospective Randomized Double Blinded Study Assessing Indeics of SNAP vs VISTA on Surgical Patients Undergoing General Anesthesia|Precision GA|Stryker Instruments|No|Recruiting|February 2009|December 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|June 22, 2010|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829803||144476|
NCT00830089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09002|Trial of a Transversus Abdominis Plane (TAP) Block in Laparoscopic Colorectal Surgery|A Prospective Randomised Controlled Trial of the Efficacy of a Transversus Abdominis Plane Block in Laparoscopic Colorectal Surgery.||University of Nottingham|No|Completed|September 2009|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|90 Years|No|||January 2012|January 18, 2012|January 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00830089||144454|
NCT00830115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2-9999-010-DE|Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders|Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders|PANDA|Nycomed|No|Completed|January 2009|June 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1045|||Both|12 Years|N/A|No|Non-Probability Sample|Outpatients|May 2012|May 4, 2012|January 13, 2009||No||No|July 20, 2010|https://clinicaltrials.gov/show/NCT00830115||144452|
NCT00831012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 257|Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults|A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2009|||June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|January 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831012||144383|
NCT00830726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20080141|Water- and Salt-homeostasis in Healthy Humans, and in Patients With Heart- or Lung Disease|Water-and Salt-homeostasis in Healthy Humans, and in Patients With Heart- or Lung Disease, Evaluated by the Excretion of Aquaporin-2 and Epithelial Sodium Channels in the Urine||Kolding Sygehus|No|Recruiting|February 2009|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|150|Samples Without DNA|Plasma and Urine samples|Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and Outpatients and admitted patients in Kolding Hospital and Odense        Universitetshospital|June 2011|June 22, 2011|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830726||144405|
NCT00830739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909044|A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control|A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control||National Institutes of Health Clinical Center (CC)||Completed|November 2008|February 2013||||N/A|Observational|N/A|||Anticipated|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|October 23, 2014|January 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00830739||144404|
NCT00831311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L02|Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants|Phase-II Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants||Sanofi|No|Completed|October 2004|March 2007|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|624|||Both|50 Days|70 Days|Accepts Healthy Volunteers|||November 2013|November 21, 2013|January 27, 2009||No||No|September 19, 2013|https://clinicaltrials.gov/show/NCT00831311||144360|
NCT00831662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08637|The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)|||Merck Sharp & Dohme Corp.||Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|490|||Both|18 Years|N/A|No|||December 2014|December 21, 2014|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831662||144335|
NCT00831675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC21|Study of Safety and Immunogenicity of Fluzone® in Healthy Children|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Influenza Virus Vaccine Fluzone® 2004-2005||Sanofi|No|Completed|September 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||January 2014|January 16, 2014|January 28, 2009|Yes|Yes||No|July 20, 2009|https://clinicaltrials.gov/show/NCT00831675||144334|
NCT00831285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:133|Barley Tortillas Study in Healthy Volunteers|A Double-Blind, Randomized, Controlled Study to Examine the Glycemic Response of Barley Tortillas in Healthy Volunteers||University of Manitoba|No|Completed|December 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|6||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2010|February 18, 2010|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00831285||144362|
NCT00831298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-07|Assessment of Sleep Disturbance in Alzheimer Disease|Assessment of Sleep Disturbance in Alzheimer Disease||Centre Hospitalier Universitaire de Nice|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|70|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 8, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831298||144361|
NCT00841243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-70|Nutritional Support During Antiviral Therapy for Hepatitis C|The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial||UMC Utrecht|Yes|Not yet recruiting|March 2009|August 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2009|February 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841243||143609|
NCT00827047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-012|Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma Treatment|A Prospective Randomized Controlled Trial of Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma Treatment||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|January 2009|December 2012|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827047||144688|
NCT00827398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL13729.000.07|Treatment of Steroid Resistant GVHD by Infusion MSC|Treatment of Steroid Resistant Grade II to IV GVHD by Infusion MSCof Mesenchymal Stem Cells Expanded With Human Plasma and Platelet Lysate a Phase I/II Study|MSCforGVHD|UMC Utrecht|No|Completed|January 2009|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|1 Month|68 Years|No|||November 2014|November 5, 2014|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00827398||144661|
NCT00827671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL23124.041.08|Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma|Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab|TRACC|UMC Utrecht|Yes|Terminated|March 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|January 22, 2009||No|Experimental treatment not feasible due to high rate of drop out|No||https://clinicaltrials.gov/show/NCT00827671||144640|
NCT00828529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002545|TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer|A Phase I, Open-label, Randomized Crossover Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Lopinavir/Ritonavir and Single-dose TMC207 in Healthy Subjects.||Tibotec BVBA|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|January 22, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00828529||144574|
NCT00828854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0303|A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing|A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing||Syndax Pharmaceuticals|Yes|Completed|April 2008|||February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|N/A|N/A|No|||February 2010|February 2, 2010|January 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828854||144549|
NCT00828152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha1b|Internet-delivered Cognitive Behavioral Therapy (CBT) for Health Anxiety|Internet-delivered Cognitive Behavioural Therapy for Health Anxiety - a Randomized Controlled Trial|Ha1b|Karolinska Institutet|No|Completed|January 2009|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2010|May 5, 2015|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828152||144603|
NCT00828789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015790|VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer|A Phase I, Open-label, Randomized, Crossover Trial in 20 Healthy Subjects to Investigate the Pharmacokinetic Interactions Between the Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir.||Tibotec BVBA||Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 16, 2010|January 22, 2009||||No||https://clinicaltrials.gov/show/NCT00828789||144554|
NCT00829179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3403|Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma|Role of RhuMab-E25 in Reducing Exhaled NO in Allergic Asthma||Duke University|No|Completed|October 2002|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 22, 2009|No|Yes||No|February 22, 2009|https://clinicaltrials.gov/show/NCT00829179||144524|Pilot study with small sample size.
NCT00829192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV011|Phase II AK Study in Organ Transplant Patients|A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.||Clinuvel Pharmaceuticals Limited|Yes|Active, not recruiting|November 2007|August 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|75 Years|No|||December 2010|December 3, 2010|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829192||144523|
NCT00829465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-013|Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma|Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|85 Years|No|||January 2009|January 26, 2009|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00829465||144502|
NCT00829478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fried0011|Improving the Quality of Care for Atrial Fibrillation by Promoting Patient-Centered Decision Making|Improving Quality of Care for Atrial Fibrillation by Promoting Patient-Centered Decision Making|AFIB|VA Connecticut Healthcare System|Yes|Completed|October 2008|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|135|||Both|45 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 16, 2012|January 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00829478||144501|
NCT00829829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-GA-0810|PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy|PRE-SURGE1|Regeneron Pharmaceuticals||Completed|February 2009|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|241|||Both|18 Years|80 Years|No|||April 2012|April 26, 2012|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829829||144474|
NCT00830102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY2028-2-001|Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients|A Randomized, Placebo-controlled, Double-blind, Six-way Crossover, Single-dose Exposure Study to Compare the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™100/10μg and 250/10μg) in a Single Inhaler (SkyePharma HFA MDI) With the Administration of Fluticasone (250μg) and Formoterol (12μg) Concurrently or Alone in Patients With Asthma||SkyePharma AG|No|Completed|October 2004|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|64|||Both|18 Years|65 Years|No|||June 2011|June 8, 2011|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830102||144453|
NCT00830414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA486|Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women|A Pivotal Study to Evaluate the Bioequivalence of 150 mg/1 mL Medroxyprogesterone Acetate Injection in Postmenopausal Women||Teva Pharmaceuticals USA|No|Completed|April 2002|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|124|||Female|45 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 26, 2009|January 26, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00830414||144429|
NCT00830752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALEX 2009|Neurobiological, Neuropsychological,Linguistic and Gestural Processes and Phenomena in Individuals With Alexithymia|Understanding Alexithymia|ALEX|Charite University, Berlin, Germany|No|Not yet recruiting|February 2009|December 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|whole blood, serum|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|70 individuals between the ages of 18 and 60 years, both genders, who score high on an        alexithymia questionaire (TAS-20) and who are otherwise emotionally and physically        healthy. Individuals are sampled via newspaper and poster advertisements throughout the        greater metropolitan area of Berlin, Germany|January 2009|January 27, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830752||144403|
NCT00831025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6018-PG-PSC-148|Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen|Multicenter, Randomised, Double-blind Placebo-controlled, Subcutaneous Immunotherapy Clinical Trial With Depigmented and Polymerized Allergen Extract of Olea Europaea Pollen in Patients With Hypersensitivity to Olea Pollen|OLEA|Laboratorios Leti, S.L.|No|Completed|January 2008|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|55 Years|No|||August 2011|November 8, 2013|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831025||144382|
NCT00831038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#8819|A Pilot Study of Pulmonary Function in Dysphagic Infants|A Pilot Study of Pulmonary Function in Dysphagic Infants||University of Tennessee|No|Completed|August 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|1 Month|24 Months|Accepts Healthy Volunteers|||November 2011|November 28, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831038||144381|
NCT00831324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632931|Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma|Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma||University of California, San Francisco|Yes|Recruiting|January 2009|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831324||144359|
NCT00827073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0454|Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery|The Effects on Betadine 5% Penetration When Using Lidocaine 2% Jelly Versus Topical Tetracaine 0.5% for Topical Phacoemulsification Cataract Surgery.||Hermann Eye Center|No|Completed|November 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 11, 2014|January 21, 2009||No||No|March 11, 2014|https://clinicaltrials.gov/show/NCT00827073||144686|
NCT00827086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-089-f-S|Influencing Factors in Uveitis|Evaluation of Influencing Factors in Uveitis||St. Franziskus Hospital|No|Completed|March 2008|July 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Uveitis|July 2010|July 20, 2011|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00827086||144685|
NCT00827060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HannoverPro|Observation of Initial Procalcitonin and the Clinical Course of Patients With Acute Respiratory Tract Infections|Observation of the Initial Procalcitonin Values and the Clinical Course of Patients With Acute Respiratory Tract Infections at General Medical Practices in Greater Hannover||Hannover Medical School|No|Completed|December 2006|September 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|702|||Both|18 Years|N/A|No|Probability Sample|primary care patients in 45 practices in greater Hannover|January 2009|January 27, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827060||144687|
NCT00841256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0506st|Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children|... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo||Allergopharma GmbH & Co. KG|No|Completed|February 2008|August 2015|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|4 Years|11 Years|No|||October 2015|October 15, 2015|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00841256||143608|
NCT00841269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28455|Oral Uridine for Treatment of Bipolar Depression in Adolescents|Oral Administration of Uridine for Treatment of Bipolar Depression in Adolescents: A Magnetic Resonance Spectroscopy Study||University of Utah|Yes|Completed|May 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|February 9, 2009|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT00841269||143607|
NCT00827684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007665-22|Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations|Phase II Study of Temsirolimus and Irinotecan in Chemotherapy Refractory Patients With KRAS Mutated Metastatic Colorectal Cancer|TIRASMUS|Vejle Hospital|Yes|Completed|March 2009|June 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||June 2011|June 7, 2011|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827684||144639|
NCT00827697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08120504|A Validation Study for Detecting Chlamydia and Gonorrhea in Rectal Samples|A Validation Study of the Gen-Probe APTIMA Combo2 (AC2) for Detecting Chlamydia Trachomatis and Neisseria Gonorrhoeae in Rectal Samples.||University of Pittsburgh|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 2, 2010|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827697||144638|
NCT00827905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-00003|Substantial Equivalence Study for Kai Sensors RSpot Non-Contact Respiratory Rate Spot Check|Remote Doppler System to Measure Heart Rate and Breathing Pattern||Kai Medical, Inc.|No|Completed|January 2009|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients Hospitalized at the Queen's Medical Center in Honolulu, HI|August 2010|August 4, 2010|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827905||144622|
NCT00828165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-300-101|A Safety Study of ARRY-300 in Healthy Subjects|||Array BioPharma|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828165||144602|
NCT00828867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111341|Single Dose Escalation First Time in Human PK Study|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects||GlaxoSmithKline|No|Completed|November 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00828867||144548|
NCT00828880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-AXW01|Restoration of Disc Height Reduces Chronic Low Back Pain|Restoration of Disk Height Through Non-Invasive Spinal Decompression is Associated With Decreased Discogenic Low-Back Pain: A Retrospective Cohort Study||NEMA Research, Inc.|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2009|January 23, 2009|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828880||144547|
NCT00828828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMU 87-01-120-6003|Antibody Response to Influenza Vaccine in Patients With Sarcoidosis|Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis|IVS|hahid Beheshti University of Medical Sciences|Yes|Completed|December 2008|May 2009|Actual|February 2009|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|49|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Caes are defined as patients known as sarcoidosis and are under follow up at a tertiary        care hospital clinic. Age and sex matched healthy healthcare workers serve as controls.|May 2009|May 20, 2009|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828828||144551|
NCT00828841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC01L08|Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC|A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)||Accelerated Community Oncology Research Network|Yes|Completed|December 2008|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|601|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|January 23, 2009|Yes|Yes||No|August 7, 2013|https://clinicaltrials.gov/show/NCT00828841||144550|
NCT00828139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01182|Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)||National Cancer Institute (NCI)||Active, not recruiting|May 2009|||June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828139||144604|
NCT00828503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2008-004745-28|Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients|Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients|Certi-CMV|Medical University of Vienna|No|Recruiting|December 2008|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828503||144576|
NCT00828802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010179|Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes|A Phase I Study of Lenalidomide in Combination With Decitabine for Patients With High Grade Myelodysplastic Syndromes||Duke University|No|Completed|March 2009|November 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828802||144553|
NCT00829517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP2-8|Computer-Assisted Provision of Reproductive Health Care|Computer-Assisted Provision of Reproductive Health Care||University of Pittsburgh|Yes|Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|814|||Female|18 Years|45 Years|No|||February 2012|February 15, 2012|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829517||144498|
NCT00829530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40180|Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as 1 x 10 mg Capsule in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA||Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 23, 2009||Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00829530||144497|
NCT00829491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0020|Denver Health Cardiovascular Disease (CVD) Prevention Program|Denver Health Cardiovascular Prevention Program||Denver Health and Hospital Authority|No|Completed|March 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|340|||Both|30 Years|64 Years|No|||July 2012|July 13, 2012|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00829491||144500|
NCT00829504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10436008|Ropinirole 0.25 mg Tablets Under Fasting Conditions|The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|October 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 26, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00829504||144499|
NCT00829816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM17|Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil|A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)||Medivation, Inc.|No|Completed|December 2008|August 2010|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|50 Years|N/A|No|||November 2015|November 6, 2015|January 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829816||144475|
NCT00830440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-4|A Multicenter Study for Pre-Surgical Weight Loss|A Multi-Center, Pilot Efficacy Study of the GI Sleeve™ for Pre-Surgical Weight Loss||GI Dynamics|No|Completed|January 2007|September 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||April 2010|April 19, 2010|January 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830440||144427|
NCT00830453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950-352|Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury|Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury|HYBOBI|Intermountain Health Care, Inc.|No|Completed|November 2003|December 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||September 2011|September 2, 2011|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00830453||144426|
NCT00830765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0239|The Use of Progesterone to Reduce Preterm Birth|The Use of Progesterone to Reduce Preterm Birth||University of Mississippi Medical Center|No|Completed|June 2004|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Female|16 Years|45 Years|No|||January 2013|January 17, 2013|December 16, 2008|Yes|Yes||No|May 22, 2012|https://clinicaltrials.gov/show/NCT00830765||144402|
NCT00831064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Kao|A Trial of Four Different Bowel Cleansing Regimens Prior to Colonoscopy|A Randomized Controlled Trial of Four Different Bowel Cleansing Regimens Prior to Colonoscopy: Efficacy, Patient Tolerability and Safety||University of Alberta|No|Completed|September 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|800|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831064||144379|
NCT00831077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3101001|Early Phase I Microdosing Study of ORM-14540 and ORM-12741|Pharmacokinetic Properties of ORM-14540 and ORM-12741 After Administration of a Microdose of 14C-labelled Drug; An Open, Non-randomised, Single Dose, Single Centre Study in Healthy Male Subjects||Orion Corporation, Orion Pharma|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|January 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831077||144378|
NCT00831337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAM 12/06/PB|Evaluation of Probiotics in the Treatment of Portal Hypertension|The Study of Probiotics in Liver Cirrhosis Patients With Portal Hypertension.||Pomeranian Medical University Szczecin|Yes|Completed|April 2007|February 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Actual|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with confirmed liver cirrhosis|July 2011|July 19, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831337||144358|
NCT00831688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meniere trial 037/05|Efficacy of Local Overpressure Treatment for Meniere's Disease|Phase 3 Study of Efficacy of Local Overpressure Treatment for Meniere's Disease||Klinikum der Universitaet Muenchen, Grosshadern|No|Completed|August 2005|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2009|April 20, 2009|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831688||144333|
NCT00831701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Hermanns|Medical Expulsive Therapy of Single Distal Ureteral Stones|Medical Expulsive Therapy of Single Distal Ureteral Stones. A Randomised, Double-blind and Placebo-controlled Study||University of Zurich|No|Completed|September 2006|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2010|May 19, 2010|November 19, 2008||No||No|January 11, 2010|https://clinicaltrials.gov/show/NCT00831701||144332|Not all patients were able to record the exact time of stone passage. Thus, the secondary end point of time to stone passage is based on Kaplan-Meier estimation.
NCT00831714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13802|Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty|Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee|XAMOS|Bayer|No|Completed|February 2009|April 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|19076|||Both|18 Years|N/A|No|Probability Sample|Female and male patients, who are at least 18 years of age and will undergo elective hip        or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment has        been made|April 2014|April 16, 2014|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831714||144331|
NCT00827424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-07-0054CTIL|The Impact of the PACE Program Implementation on Health Services Utilization by Obese Arab Women|The Impact of the PACE Program Implementation on Health Services Utilization by Obese Arab Women (The AWESOME Study: Arab WomEn Study on Obesity Metabolism and Exercise)|AWESOME|Clalit Health Services|No|Completed|December 2008|July 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|35 Years|64 Years|Accepts Healthy Volunteers|||August 2010|August 23, 2010|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827424||144659|
NCT00827437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECID4|Family-Staff Communication Intervention at the Time of Difficult Treatment Decision Making|Family-Staff Communication Intervention at the Time of Difficult Treatment Decision Making||St. Jude Children's Research Hospital|No|Completed|January 2004|||November 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|401|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2011|April 20, 2012|August 6, 2008||No||No||https://clinicaltrials.gov/show/NCT00827437||144658|
NCT00837161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|994043|Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids||Philips Healthcare|No|Completed|January 2009|December 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|59 Years|No|||November 2012|November 30, 2012|February 4, 2009|No|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00837161||143917|
NCT00827918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8998-004|A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)|A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia||Merck Sharp & Dohme Corp.|Yes|Completed|March 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|216|||Both|18 Years|55 Years|No|||October 2015|October 20, 2015|January 22, 2009|Yes|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00827918||144621|
NCT00827931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1461001|Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery|Prospective Randomized Phase IV Open Label Comparative Study Of Tranexamic Acid Plus Standard Of Care Vs Standard Of Care For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery||Pfizer|Yes|Completed|September 2009|May 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|94|||Both|18 Years|N/A|No|||April 2012|April 2, 2012|January 22, 2009||No||No|April 2, 2012|https://clinicaltrials.gov/show/NCT00827931||144620|The intended FAS population was planned to include participants from 2 sites, however due to non-reliability of data from one of the sites, the actual FAS population included participants from a single site only.
NCT00828178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00023813|Efficacy of Fish Oil in Lupus Patients|A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE.||Johns Hopkins University|Yes|Completed|February 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828178||144601|
NCT00828191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07USA/Prg05|Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)|Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) Versus Vaginal Progesterone for Luteal Phase Support in Patients Undergoing In Vitro Fertilization (IVF)||IBSA Institut Biochimique SA||Completed|December 2008|February 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|800|||Female|18 Years|42 Years|No|||January 2013|January 28, 2013|January 22, 2009|Yes|Yes||No|November 26, 2012|https://clinicaltrials.gov/show/NCT00828191||144600|No limitations of the trial reported.
NCT00828542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP4432/2007|Safety of the Etonogestrel-Releasing Implant During the Puerperium of Healthy Women|Safety of the Etonogestrel-Releasing Implant During the Puerperium of Healthy Women||University of Sao Paulo|No|Completed|July 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2009|January 23, 2009|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828542||144573|
NCT00831142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000154|Characterization of Prostate Cancer With 3T MR|Characterization of Prostate Cancer With 3T MR||Beth Israel Deaconess Medical Center|No|Active, not recruiting|June 2006|June 2016|Anticipated|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|236|||Male|40 Years|N/A|No|Non-Probability Sample|The sample will include 50 male patients per year of all races and ethnic origins over 40        years of age who are likely to undergo radical prostatectomy for prostate carcinoma.        Patients will be imaged using MRI/MRS.|November 2015|November 30, 2015|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831142||144373|
NCT00831155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009639|Extinction Based Treatment for Nicotine Dependence|Brain Substrates of Extinction Based Treatment for Nicotine Dependence|Extinction01|Duke University|No|Completed|January 2009|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|January 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831155||144372|
NCT00862004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20081202|Video-assisted Thoracoscopic Surgery for Stage IIIA Non-Small Cell Lung Cancer|Feasibility of Video-Assisted Thoracoscopic Surgery for Clinical Stage IIIA Non-Small Cell Lung Cancer||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|December 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||March 2009|February 1, 2010|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862004||142037|
NCT00862017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJI-01|Effect of Monosodium Glutamate Supplementation on Gastric Emptying and Postprandial Nitrogen Kinetics|Effect of Monosodium Glutamate on Gastric Emptying and Postprandial Nitrogen in Healthy Volunteers||Institut National de la Recherche Agronomique|Yes|Completed|April 2008|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Basic Science|2||Actual|13|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 13, 2009|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862017||142036|
NCT00862381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0726|Hydrocortisone Use After Etomidate in Intensive Care|Opothérapie Par Hydrocortisone après Injection Unique d'Etomidate Chez le Patient de réanimation||University Hospital, Grenoble|Yes|Completed|October 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|79 Years|No|||July 2010|July 23, 2010|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862381||142010|
NCT00862693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090315|Calcitriol in the Treatment of Immunoglobulin A Nephropathy|||Peking University First Hospital||Recruiting|March 2009|March 2011|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||March 2009|February 16, 2011|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862693||141986|
NCT00863018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUMC-09-04|Corneal Endothelium After Glaucoma Surgery|Change in Corneal Endothelium After Glaucoma Surgery; Trabeculectomy and Glaucoma Implant Surgery||Chungnam National University|Yes|Completed|August 2003|January 2009|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|61|||Both|20 Years|N/A|No|Probability Sample|Patients who underwent glaucoma surgery; trabeculectomy and Ahmed glaucoma valve implant        surgery|July 2015|July 27, 2015|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863018||141962|
NCT00827788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo001|Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)|The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Primary Angioplasty for Acute Myocardial Infarction. The CONTRAST-AMI Study.|CONTRAST-AMI|Ospedale San Donato|No|Completed|December 2008|||April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|432|||Both|18 Years|N/A|No|||September 2009|November 15, 2010|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827788||144631|
NCT00828347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KumaNeph2|Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)|A Study of Maintenance Therapy After Intravenous Maxacalcitol for Secondary Hyperparathyroidism||Kumamoto University|Yes|Completed|January 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 22, 2009||No||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00828347||144588|Sample size was small, so it will be necessary to conduct further studies in a larger number of patients.
NCT00829660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11232|Acarbose Cardiovascular Evaluation Trial|A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance|ACE|University of Oxford|Yes|Active, not recruiting|February 2009|June 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6526|||Both|50 Years|N/A|No|||March 2016|March 7, 2016|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829660||144487|
NCT00828308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-Pros-221|Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer|BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study|BrUOG-Pros-221|Brown University|Yes|Active, not recruiting|February 2009|December 2015|Anticipated|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|N/A|No|||May 2015|May 21, 2015|January 22, 2009|Yes|Yes||No|August 20, 2013|https://clinicaltrials.gov/show/NCT00828308||144591|
NCT00828321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40179|Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions|Randomized , 2- Way Crossover, Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as 1 x 10 mg Capsule in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA||Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 12, 2009||Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00828321||144590|
NCT00828334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010278|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2002|||||N/A|N/A|N/A||||||||||||||January 22, 2009|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828334||144589|
NCT00829010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111634|Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.|Primary and Booster Vaccination Course in Human Immunodeficiency Virus (HIV) Infected Infants, HIV Exposed Uninfected Infants and Unexposed Uninfected Infants Receiving the Pneumococcal Vaccine GSK 1024850A.||GlaxoSmithKline||Completed|February 2009|August 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|489|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||September 2015|October 22, 2015|January 22, 2009|Yes|Yes||No|May 8, 2012|https://clinicaltrials.gov/show/NCT00829010||144537|The study aimed to enrol 100 HIV+/+ subjects but succeeded to enrol 83 mainly due to decrease of vertical HIV transmission in South Africa. Some subjects, HIV+ at screening, tested negative at subsequent HIV testing, were reallocated in HIV+/-Group.
NCT00829023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1232-008|Efficacy of Surgical Preparation Solutions in Shoulder Surgery|Efficacy of Surgical Preparation Solutions in Shoulder Surgery||Northwestern University|No|Completed|June 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|150|||Both|18 Years|N/A|No|||January 2009|January 23, 2009|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829023||144536|
NCT00827450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLIBRI|Effects of Coffee on Hepatic Steatosis Induced by a High Fructose Diet|Effects of Coffees With Various Compositions of Antioxidants on Hepatic Steatosis Induced by a High Fructose, Hypercaloric Diet|COLIBRI|University of Lausanne|Yes|Completed|February 2009|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|13|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00827450||144657|
NCT00864656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phenylephrine test|Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 10% Phenylephrine|Comparative Study of Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 1, 2 or 4 Drops of 10% Phenylephrine||University of Sao Paulo|Yes|Completed|September 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|||Both|N/A|N/A|No|Probability Sample|Involutional blepharoptosis patients|March 2009|March 18, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864656||141837|
NCT00864669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-594|A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 500 mg Metformin Hydrochloride Extended Release Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|March 2002|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864669||141836|
NCT00860093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-5971|Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy|A Multi-Site Placebo-Controlled Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Using MPC-5971 as Adjuvant Therapy in Subjects Undergoing Shock Wave Lithotripsy||Mission Pharmacal|Yes|Terminated|April 2010|December 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|135|||Both|18 Years|70 Years|No|||January 2011|January 25, 2011|March 10, 2009|Yes|Yes|Sponsor Corporate Business Decision|No||https://clinicaltrials.gov/show/NCT00860093||142183|
NCT00860106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 04 22|Echo Doppler (ED )Score and D-dimer (DD) Level in the Evaluation of VTE Recurrence After Anticoagulant Treatment Cessation|Study of Predictive Echo Doppler Score and D-dimer Level in Evaluation of the Thromboembolic Event Recurrence After Anticoagulant Treatment Cessation.|VAPRED|University Hospital, Grenoble|Yes|Completed|March 2005|May 2011|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|222|||Both|18 Years|80 Years|No|||October 2011|October 10, 2011|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860106||142182|
NCT00860925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POISE-2 01 2009|PeriOperative ISchemic Evaluation-2 Pilot|PeriOperative ISchemic Evaluation-2 (POISE-2) Trial: A Pilot|POISE2-pilot|McMaster University|No|Completed|May 2009|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|90|||Both|45 Years|N/A|No|||March 2010|March 8, 2010|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00860925||142119|
NCT00860665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BECOP-3|Case Volume and Adenoma Rate During Screening Colonoscopy|Case Volume and Adenoma Detection Rates During Screening Colonoscopy||Charite University, Berlin, Germany|No|Completed|October 2006|March 2009|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12134|||Both|55 Years|85 Years|No|Non-Probability Sample|In Germany screening colonoscopy is reimbursed over the age of 55 years. All persons        willing to undergo screening colonsocopy without contraindications are asked for consent        to be included|March 2009|March 11, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860665||142139|
NCT00860912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 8585|Veritas Collagen Matrix Cystocele Repair Study - Postmarketing|Veritas Collagen Matrix Cystocele Repair Study - Postmarketing Protocol #CP1004||Cleveland Clinic Florida|No|Completed|December 2001|||May 2007|Actual|Phase 4|Interventional|Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00860912||142120|
NCT00861497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11051|Bifeprunox Extension to Extension Study in Patients With Schizophrenia|An Open-label Safety Study of Bifeprunox Investigating Flexible Doses of 20, 30, or 40mg/Day in Patients With Schizophrenia Who Have Completed Studies 10206 or 10265||H. Lundbeck A/S|No|Terminated|January 2006|July 2009|Actual|January 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|March 12, 2009||No|The study stopped after been paused (the patients were switched in the meantime)|No||https://clinicaltrials.gov/show/NCT00861497||142076|
NCT00861770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC28158|Utilizing Blood Volume Measurements in the Treatment of Heart Failure Patients|Prospective Protocol for Utilizing Blood Volume Measurements in the Treatment of Heart Failure Patients|TEAM UF|Christiana Care Health Services|Yes|Completed|November 2008|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861770||142055|
NCT00830830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9385EXT|TREAD-20 Extension - Treatment of Knee Pain Due to Osteoarthritis|A Double-Blind, Randomized Trial of Intra-Articular Injections of 20mg of Hyalgan for the Treatment of Knee Pain Due to Osteoarthritis (Three Injection Regimen for Efficacy and Duration - 20mg/2ml Dose) - Extension Study||Sanofi||Completed|December 2005|October 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|40|||Both|40 Years|N/A|No|||March 2009|March 18, 2009|January 21, 2009||||No||https://clinicaltrials.gov/show/NCT00830830||144397|
NCT00827554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-011|The Role of Low Molecular Weight Heparins (LMWH) Combined With Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma|A Clinical Randomized Control Trial of Combination TACE With and Without Low-Molecular-Weight Heparin in Hepatocellular Carcinoma||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|December 2008|January 2010|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2009|January 21, 2009|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827554||144649|
NCT00862030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24639|CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer|Comparison of Two-versus Three-Dimensional Treatment Planning for Patients Receiving Chest Radiotherapy for Symptom Control||AHS Cancer Control Alberta|No|Completed|April 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|20|August 2011|August 4, 2011|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862030||142035|
NCT00831779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-045|Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes||AstraZeneca|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|35 Years|70 Years|No|||March 2015|March 20, 2015|January 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831779||144326|
NCT00831792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0510|TKI258 in Castrate Resistant Prostate Cancer|An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma.||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2010|||April 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|N/A|N/A|No|||April 2015|April 6, 2015|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831792||144325|
NCT00827203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4783-11|A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors|A Phase 1 Multi-Dose Dose-Escalation Study of Elesclomol Sodium, Administered Once Weekly to Subjects With Solid Tumors||Synta Pharmaceuticals Corp.|No|Suspended|January 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2009|March 6, 2009|January 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827203||144676|
NCT00827216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 06-225|The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia|The Effect of Intravenous Erythromycin on Gastric Emptying in Patients Undergoing Rapid Sequence Intubation for Full Stomach - A Randomised, Placebo-controlled, Double-blind Study||University Hospital, Geneva|No|Completed|January 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827216||144675|
NCT00827528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISAPI 01|SIS Graft and Traditional Repair in Vaginal Wall Prolapse|Surgical Treatment of Anterior Vaginal Wall Prolapse: Comparison of SIS Graft and Traditional Repair.||Federal University of São Paulo|Yes|Completed|August 2006|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Female|30 Years|85 Years|No|||March 2012|March 22, 2012|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827528||144651|
NCT00828048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007845|International Registry for Intraductal Papillary Mucinous Neoplasma|International Registry for Intraductal Papillary Mucinous Neoplasma||Mayo Clinic|No|Active, not recruiting|March 2008|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|560|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care|January 2016|January 12, 2016|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00828048||144611|
NCT00829673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04163|Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Dexmethylphenidate Hydrochloride, (10 mg), Compared to an Equivalent Dose of a Commercially Available Reference Product (Focalin®, Novartis Pharmaceuticals Corporation) in 24 Fed, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|June 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 26, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00829673||144486|
NCT00828633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600597|Health-Related Quality of Life in Gay Men With Localized Prostate Cancer|Patient-Reported Outcomes For Gay Men With Localized Prostate Cancer||Baylor College of Medicine|No|Completed|August 2008|June 2015|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|92|||Male|18 Years|N/A|No|Non-Probability Sample|Convenience sample contacted via Internet|July 2015|July 21, 2015|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828633||144566|
NCT00828646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-012|Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Japanese Subjects and a Comparison to Healthy Elderly Japanese Subjects|JMAD|Bristol-Myers Squibb|No|Completed|October 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2009|January 6, 2011|January 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828646||144565|
NCT00830310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-IRUSQUET0455|Customized Medication Adherence Enhancement for Adults With Bipolar Disorder|Customized Adherence Enhancement (CAE) Among Individuals With Bipolar Disorder|UH CAE|University Hospital Case Medical Center|Yes|Completed|January 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|January 23, 2009||No||No|October 24, 2011|https://clinicaltrials.gov/show/NCT00830310||144437|
NCT00862121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999907 CS05|A Study With Pentasa in Patients With Active Crohn's Disease|PENTASA in Active Crohn's Disease: A 10-week, Double-blind, Multi-centre Trial Comparing PENTASA Sachet 6 g/Day (Mesalazine, Mesalamine) With Placebo.|PEACE|Ferring Pharmaceuticals|No|Terminated|April 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|March 13, 2009|Yes|Yes|Terminated due to poor recruitment|No|October 3, 2011|https://clinicaltrials.gov/show/NCT00862121||142029|Early termination led to small number of participants (20/510; actual/planned). Only the primary efficacy outcome was subject to formal statistical analysis. No conclusions could be drawn on primary and secondary efficacy analyses.
NCT00827957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRB 2008/080/C|Comparing Therapeutic Hypothermia Using External and Internal Cooling for Post-Cardiac Arrest Patients|A Phased Prospective Clinical Study Comparing Controlled Therapeutic Hypothermia Post Resuscitation After Cardiac Arrest Using External and Internal Cooling to Standard Intensive Care Unit Therapy|Hypothermia|Singapore General Hospital|No|Completed|October 2008|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|80 Years|No|||November 2014|November 19, 2014|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00827957||144618|
NCT00827970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cesoirs01|Randomized Population-Based Study on Chlamydia Trachomatis Screening|Populationbased Screening for Urogenital Chlamydia Trachomatis Infections by Use of Home-Obtained and Mailed Samples: A Randomized Study||University of Aarhus|No|Completed|October 1997|August 2007|Actual|February 1998|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|30000|||Both|21 Years|24 Years|Accepts Healthy Volunteers|||January 2009|January 22, 2009|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827970||144617|
NCT00860431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2008-355-0|Kremezin Study Against Renal Disease Progression in Korea|K-STAR (Kremezin STudy Against Renal Disease Progression in Korea) Randomized, Open-label, Controlled Study|K-STAR|Seoul National University Hospital|Yes|Completed|March 2009|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|578|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00860431||142157|
NCT00860678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2152/08|Physical Activity in Patients After Aortic Valve Replacement (Valve-ex)|Influence of Regular Physical Activity on Exercise Capacity, Cardiac Remodeling and Endothelial Function in Patients After Aortic Valve Replacement||Technische Universität München||Enrolling by invitation||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|65 Years|75 Years|No|||March 2009|March 11, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860678||142138|
NCT00860691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198-0000000-3104|Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer|Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer||University Hospital Dubrava|Yes|Recruiting|January 2008|June 2010|Anticipated|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||March 2010|March 24, 2010|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860691||142137|
NCT00860938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 148/06|Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD|Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD)||University Hospital, Basel, Switzerland|Yes|Recruiting|April 2007|May 2010|Anticipated|June 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|N/A|No|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00860938||142118|
NCT00861185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-17043-18|Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of Four Weeks of Oral Senicapoc Administration on Exercise-Induced Asthma||Icagen|No|Completed|March 2009|September 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|50 Years|No|||July 2011|July 8, 2011|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861185||142099|
NCT00861510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090094|A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies|A Pilot Study of the Safety and Efficacy of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies||National Institutes of Health Clinical Center (CC)||Completed|March 2009|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||September 2014|January 27, 2015|March 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861510||142075|
NCT00830843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-citerio|Inhalatorial Sedation in Patient With Subarachnoid Hemorrhage (SAH) Versus Conventional Intravenous Sedation|Inhalatorial Sedation in Patient With SAH Versus Conventional Intravenous Sedation (GAS-SAH)|GAS-SAH|Azienda Ospedaliera San Gerardo di Monza|No|Completed|January 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||November 2011|November 30, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830843||144396|
NCT00830856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZimCrypto03|Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa|Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis.||University of Zimbabwe|Yes|Active, not recruiting|October 2006|October 2009|Anticipated|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||January 2009|February 25, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830856||144395|
NCT00827567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD001JUS48T|Trial of RAD001 in Triple Negative Metastatic Breast Cancer|A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer||Milton S. Hershey Medical Center|Yes|Terminated|April 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||December 2013|December 11, 2013|January 21, 2009|Yes|Yes|Slow accrual|No|August 16, 2011|https://clinicaltrials.gov/show/NCT00827567||144648|
NCT00827580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS20667|Eniluracil Hand Foot Syndrome|A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)||West Virginia University|Yes|Completed|January 2009|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||August 2009|August 27, 2009|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00827580||144647|
NCT00831415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-3350|Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)|A 10-Month Open-Label Evaluation Of The Long-Term Safety Of Desvenlafaxine Succinate Sustained Release In Japanese Adults With Major Depressive Disorder||Pfizer|No|Completed|March 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|304|||Both|20 Years|N/A|No|||December 2011|December 22, 2011|January 27, 2009|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00831415||144352|
NCT00831428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLE004|Screening Scottish Swimmers for Asthma and Rhinitis|A Pilot Study to Identify the Prevalence of Exercise- Induced Asthma and Rhinitis in Scottish Swimmers, Using Mannitol Challenge as a Screening Tool.|CLE004|University of Dundee|No|Completed|February 2009|June 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|97|||Both|11 Years|23 Years|No|Non-Probability Sample|The Scottish national and district swimming teams|May 2009|August 11, 2011|January 28, 2009||No||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00831428||144351|
NCT00831805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB : 2008-A01107-48|Screening of Psycho-cognitive Troubles in Elderly Patients|Impact of a Geriatric Mobile Unit on the Screening of Psycho-cognitive Troubles in Internal Medicine Departments and Circumstances of Calling in This Unit.|EMG|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2008|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|200|||Both|75 Years|N/A|No|Non-Probability Sample|elderly patients hospitalised in the internal medicine department of a suburban Parisian        hopital|December 2008|January 18, 2012|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00831805||144324|
NCT00827229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 019/2008CTIL|Evaluation of Laborpro - a New Device for the Assessment of Progress of Labor|||Trig Medical Inc|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|110|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 21, 2009|January 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00827229||144674|
NCT00827242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10893|Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|January 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|325|||Male|45 Years|N/A|No|||October 2010|October 19, 2010|January 20, 2009|Yes|Yes||No|October 19, 2010|https://clinicaltrials.gov/show/NCT00827242||144673|
NCT00827541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1811048|Post-Authorization Study Evaluating Safety Of Tigecycline|A Phase IV Pharmacovigilance, Post-Authorization Clinical Trial To Evaluate And Assess The Safety Of Tigecycline In The Approved Indications In The Usual Health Care Setting|HORUS|Pfizer|No|Completed|August 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|No|Probability Sample|Patients hospitalized because of complicated intra-abdominal infections (cIAI) or        complicated skin and soft tissue infections (cSSTI), in the usual health care setting|December 2011|December 23, 2011|January 20, 2009|No|Yes||No|December 23, 2011|https://clinicaltrials.gov/show/NCT00827541||144650|
NCT00827801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0722|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program|MDASI-HF: Bridging the Symptom Management Gap in Patients With Cancer and Concurrent Heart Failure to Improve Outcomes||M.D. Anderson Cancer Center|Yes|Completed|January 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|26|||Both|18 Years|N/A|No|Probability Sample|All cancer patients, 18 years of age or older, with a concurrent diagnosis of heart        failure, newly diagnosed or diagnosed within past 1 year.|July 2012|July 19, 2012|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827801||144630|
NCT00829036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6690-R|Wayfinding Information Access System for People With Vision Loss|Wayfinding Information Access System for People With Vision Loss||VA Office of Research and Development|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|January 22, 2009||No||No|February 18, 2014|https://clinicaltrials.gov/show/NCT00829036||144535|
NCT00829374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM18|Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil|CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil|CONCERT|Medivation, Inc.|Yes|Completed|March 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1003|||Both|50 Years|N/A|No|||August 2012|August 27, 2012|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829374||144509|
NCT00829387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6044R|Cognitive Behavioral Therapy for Diabetic Neuropathic Pain|Cognitive Behavioral Therapy for Diabetic Peripheral Neuropathic Pain||VA Connecticut Healthcare System|No|Completed|March 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 24, 2009||No||No|January 2, 2015|https://clinicaltrials.gov/show/NCT00829387||144508|
NCT00829400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDB0010-01101|Cognitive Training to Enhance VA Work Program Outcomes|Cognitive Training to Enhance VA Work Program Outcomes||VA Connecticut Healthcare System|No|Active, not recruiting|May 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2012|December 22, 2014|January 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00829400||144507|
NCT00861562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04372|Clinical Efficacy and Safety Evaluation of the Drug Imescard Compound Water Smartweed Pills|Clinical Efficacy and Safety Evaluation of the Drug Imescard Compound Water Smartweed Pills||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|April 2008|April 2009|Anticipated|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|50 Years|No|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861562||142071|
NCT00829985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-12|Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)|A Biomarker-based Pilot Study of Cockroach Sublingual Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-12)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|55 Years|No|||June 2015|June 2, 2015|January 26, 2009|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT00829985||144462|
NCT00829998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO46501|Zaleplon 10mg Capsules Under Fasting Conditions|A Relative Bioavailability Study of Zaleplon 10mg Capsules Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|January 26, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00829998||144461|
NCT00862134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-2003|Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II, Multi-Center, Open-Label Trial of PR104 and Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer||Proacta, Incorporated||Terminated|March 2009|May 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|March 12, 2009|Yes|Yes|Interim analysis indicated low probability of clinically significant result|No|May 31, 2011|https://clinicaltrials.gov/show/NCT00862134||142028|
NCT00862147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.2381|Effectiveness Study of the International Child Development Program|The Effect of the International Child Development Program - A Randomised Controlled Trial||Norwegian University of Science and Technology|Yes|Terminated|January 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Both|4 Years|4 Years|No|||May 2012|May 10, 2012|March 13, 2009||No|the study was stopped due to failure to recruit sufficient participants|No||https://clinicaltrials.gov/show/NCT00862147||142027|
NCT00828594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001O2101|Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma|A Phase 1 Open Label/ Phase 2 Randomized, Double-blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar®) in Patients With Advanced Hepatocellular Carcinoma||Novartis||Terminated|December 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|January 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00828594||144569|
NCT00828971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12670|A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs|A Prospective, Randomized, Open Label, Active Comparator, Multicenter, National Trial to Compare the Efficacy and Safety of Sequential IV/PO Moxifloxacin 400 mg Once Daily Versus IV Amoxicillin/Clavulanate 2,0/0,2 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanate 875/125 mg Every 8 Hours in the Treatment of Adult Subjects With Complicated Skin and Skin Structure Infections|MERAK|Bayer|No|Completed|November 2008|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828971||144540|
NCT00860444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|622|Cardiovascular Risk Reduction Program Aimed at African American Women (The HHER Lifestyle Program)|The Heart Healthy and Ethnically Relevant (HHER) Lifestyle Program for Cardiovascular Risk Reduction|HHER|The University of Texas Health Science Center at San Antonio|Yes|Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|266|||Female|35 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 6, 2014|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860444||142156|
NCT00860704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 299/2006|Goal Directed Fluid Therapy|Intraoperative Goal Directed Fluid Therapy in Lean and Obese Patients|FLO1|Medical University of Vienna|No|Completed|November 2007|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|80 Years|No|||April 2015|April 6, 2015|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860704||142136|
NCT00860717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINEP 1460/03|The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients|Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial||Para Federal University|No|Completed|November 2006|April 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|N/A|N/A|No|||March 2009|December 12, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860717||142135|
NCT00829959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0624|Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)|Attitudes About Childbearing And Fertility In Women Seeking Genetic Testing For Inherited Breast And Ovarian Cancer Syndromes (HBOC)||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2009|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing genetic counseling within UT MDACC Clinical Cancer Genetics Program for        hereditary breast and ovarian cancer syndrome (HBOC).|August 2015|August 3, 2015|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829959||144464|
NCT00830245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCST-L-0005|A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer|||Clinical Research Center for Solid Tumor, Korea|No|Terminated|January 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|January 24, 2009||No|low accrual rate|No||https://clinicaltrials.gov/show/NCT00830245||144442|
NCT00861198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreaticobiliary disorders|The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders|The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders||University of Florida|No|Completed|November 2006|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have a medical indication for ERCP with cholangioscopy and/or pancreatoscopy        and are referred for the procedure as part of their standard medical care will be        considered for the study.|June 2015|June 29, 2015|March 12, 2009||No||No|June 29, 2015|https://clinicaltrials.gov/show/NCT00861198||142098|
NCT00830258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-971|Pravastatin Sodium 80 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative, Bioavailability Study of Two Formulations of Pravastatin Sodium 80 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|April 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|January 26, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00830258||144441|
NCT00830570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedcoWarfarin1|The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings|in Typical Community Practice Settings|MHSMayoWarf1|Medco Health Solutions, Inc.|Yes|Completed|July 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1635|Samples With DNA|Blood draw and buccal swab|Both|40 Years|75 Years|No|Non-Probability Sample|The active study population consists of male and female covered lives with Medco for        clients have agreed to enroll their members for ages 40-75 for new warfarin starts who        match the inclusion criteria.|November 2010|November 15, 2010|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830570||144417|
NCT00830869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16001|A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies|An Open-Label, Dose Escalation, Phase 1 Study of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Completed|March 2009|June 2012|Actual|April 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|January 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00830869||144394|
NCT00831818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breastfeeding_01|Effects of Breastfeeding on Maternal Plasma Ghrelin and Peptide Tyrosine Tyrosine (PYY) Levels|Effects of Breastfeeding on Maternal Plasma Ghrelin and PYY Levels||Medical University of Vienna|No|Completed|July 2008|November 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Whole blood|Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mothers of healthy infants (babies aged 3-6 months).|May 2011|May 31, 2011|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831818||144323|
NCT00864786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0431002|Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study|A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration, Pharmacokinetics, And Pharmacodynamics Of Multiple Inhaled Doses Of PF-03635659 In Healthy Male Subjects.||Pfizer|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Anticipated|50|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 20, 2009|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00864786||141827|
NCT00864799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1624/EW|Techniques to Improve Efficacy of Second Trimester Medical Termination|Comparison of 3 Regimens Using Mifepristone and Misoprostol for Second Trimester Pregnancy Interruption.||King Edward Memorial Hospital|No|Completed|April 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|302|||Female|16 Years|50 Years|No|||July 2013|July 23, 2013|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864799||141826|
NCT00831441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-068|Phase III Acute Coronary Syndrome|Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome|APPRAISE-2|Bristol-Myers Squibb|Yes|Terminated|March 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|7484|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|January 28, 2009|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT00831441||144350|
NCT00831454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-02/2008|Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection|Relationship of Polymorphisms and Mutations of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors Responsiveness in Non-small-cell Lung Cancer Patients||Istituto Clinico Humanitas|No|Completed|September 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|51|Samples With DNA|blood samples tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|NON-SMALL-CELL LUNG CANCER patients treated with EGFR-TKIs|November 2014|November 27, 2014|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831454||144349|
NCT00828360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM-001|Dobutamine Stress Echocardiography in Cardiac Resynchronization Therapy (CRT) Patients Selection|Efficacy Of Low-Dose Dobutamine Stress-Echocardiography To Predict Cardiac Resynchronization Therapy Response|LODO-CRT|Ospedale Santa Maria di Loreto Mare|No|Active, not recruiting|July 2006|September 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|270|||Both|18 Years|N/A|No|Probability Sample|Patient indicated to CRT according to current guidelines|January 2009|January 22, 2009|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828360||144587|
NCT00828659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD356-013|Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users|A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users||Arena Pharmaceuticals|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|7||Anticipated|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 27, 2009|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828659||144564|
NCT00828672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s51104 - ML5194|Phase II Study of Neo Adjuvant Treatment With Avastin, Xeloda and/or Eloxatin in Colorectal Cancer|A Randomized Phase II Study of Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin in the Preoperative Treatment of Locally Advanced Rectal Cancer|AXE BEAM|Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|June 2009|July 2016|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828672||144563|
NCT00828685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P000301|Early Functional Outcomes After Closed Reduction With Pinning Versus Open Reduction Internal Fixation of Wrist Fractures|Early Functional Outcomes After Closed Reduction Percutaneous Pinning vs. Open Reduction Internal Fixation of Distal Radius Fractures: A Prospective Randomized Trial||Beth Israel Deaconess Medical Center||Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||January 2009|January 23, 2009|January 13, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00828685||144562|
NCT00829049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-TAZ0702|Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris|||Allergan|No|Terminated|October 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|165|||Both|12 Years|N/A|No|||August 2012|August 20, 2012|January 22, 2009|Yes|Yes|Study enrollment was terminated due to company decision before the target enrollment of 220    patients was reached.|No|September 22, 2011|https://clinicaltrials.gov/show/NCT00829049||144534|Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.
NCT00861263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spirus Overtube|The Clinical Utility of Overtube Use at the Time of Endoscopy|The Clinical Utility of Overtube Use at the Time of Endoscopy|Spirus|University of Florida|No|Completed|June 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|193|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 7, 2014|March 12, 2009||No||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00861263||142093|No limitations were found
NCT00861575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH05005|Cardiogenomics Registry|CAD Genotype and Phenotype Cardiac Catheterization Laboratory Registry|CGR|Piedmont Healthcare|No|Suspended|February 2006|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|20 mL of blood are collected and aliquots of whole blood, plasma, serum and buffy coat are      stored.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing a clinical required cardiovascular procedure|August 2013|September 4, 2013|March 12, 2009||No|Staffing resources currently being restructured|No||https://clinicaltrials.gov/show/NCT00861575||142070|
NCT00861848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599-08FB|Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging|Quantification of Ventricular Mechanics and Myocardial Blood Flow Reserve in Adolescents and Adults Ages 13-40 With Congenital or Acquired Heart Disease Using Supine Bicycle Stress With Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging|ECHOBIKE|University of Nebraska|No|Enrolling by invitation|April 2009|June 2011|Anticipated|June 2010|Anticipated|Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|80|||Both|13 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|adults ages 13-40 with congenital and acquired congenital heart disease.|September 2009|September 17, 2009|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861848||142049|
NCT00862836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00083|Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)|Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study|ZACFAST|AstraZeneca|No|Terminated|April 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||August 2012|September 11, 2012|March 16, 2009|Yes|Yes|Lack of efficacy|No|November 2, 2011|https://clinicaltrials.gov/show/NCT00862836||141976|
NCT00862537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD Ext|Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)|An Open-label Extension Study for Subjects Previously Treated Either in Pilot I or Pilot II Studies of the Application of Magnetic Fields Using the Resonator for the Treatment of Parkinson's Disease.||pico-tesla Magnetic Therapies, LLC|Yes|Completed|April 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|N/A||1|Actual|18|||Both|30 Years|82 Years|No|Non-Probability Sample|Previous participants enrolled in one of two prior pico-tesla Magnetic Therapies Resonator        device studies using magnetic fields for treating Parkinson's Disease (PD) symptoms.|June 2011|June 9, 2011|October 22, 2008|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00862537||141998|
NCT00828984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01113|Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer|Polyethylene Glycol for ACF Reduction and Biomarker Modulation in Individuals With CRC Risk||National Cancer Institute (NCI)|Yes|Completed|October 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|140|||Both|18 Years|N/A|No|||February 2015|March 6, 2015|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828984||144539|
NCT00829335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOUS-COMP GENERAL|Anatomical Resection of the Liver for Hepatocellular Carcinoma: a New Ultrasound Guided Approach|Anatomical Segmental and Subsegmental Resection of the Liver for Hepatocellular Carcinoma: a New Approach by Means of Ultrasound-Guided Vessel Compression||University of Milan|Yes|Completed|January 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|No|Probability Sample|Patients reffered to our outpatient clinic for evaluation as carriers of HCC|January 2009|January 26, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829335||144512|
NCT00829972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16687B|Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls|Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls||University of Chicago|No|Recruiting|January 2009|November 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Blood samples|Both|1 Year|12 Years|No|Non-Probability Sample|Children age 1-12 years undergoing surgery|January 2009|January 26, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829972||144463|
NCT00829634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27.092|Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation|||California Pacific Medical Center Research Institute||Completed|October 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|January 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00829634||144489|
NCT00830882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAI007|Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol|A Proof of Concept Study to Evaluate the Peak Bronchoprotection Conferred by Single and Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics.|NAI007|University of Dundee|No|Withdrawn|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|January 27, 2009||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00830882||144393|
NCT00830895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-RENAL-0901|RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)|A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma||Seoul National University Hospital|No|Completed|January 2009|December 2012|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830895||144392|
NCT00830271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C624/07|Vicryl Plus and Monocryl Plus in Breast Surgery|Pilot Study of Vicryl Plus and Monocryl Plus in Breast Surgery||Cardiff and Vale University Health Board|Yes|Completed|December 2008|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|No|||January 2009|February 2, 2015|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00830271||144440|
NCT00831168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEADI2005|BEADI - The Bliss Cluster Randomised Control Trial on the Effects of Active Dissemination of Information (BEADI)|The Bliss Cluster Randomised Control Trial on the Effects of Active Dissemination of Information on Outcomes of Premature Babies.|BEADI|Confidential Enquiry into Maternal and Child Health|No|Active, not recruiting|October 2005|March 2009|Anticipated|March 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|22 Weeks|27 Weeks|Accepts Healthy Volunteers|||January 2009|January 27, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831168||144371|
NCT00830583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-02|Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis|Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis|POPS|Centre Hospitalier Universitaire de Nice|No|Completed|January 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|8 Years|N/A|No|||January 2009|December 7, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830583||144416|
NCT00830596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2P3|Effect of Spinal Manipulation on Sensorimotor Functions in Back Pain Patients|Effect of Spinal Manipulation on Sensorimotor Functions in Back Pain Patients|D2P3|Palmer College of Chiropractic|Yes|Completed|July 2007|July 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|221|||Both|21 Years|65 Years|No|||September 2015|September 4, 2015|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830596||144415|
NCT00827255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-RES-08-002|Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%|||Allergan|No|Completed|January 2009|October 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|35|||Both|16 Years|N/A|No|Non-Probability Sample|The medical charts of all chronic dry eye patients who discontinued their first trial of        RESTASIS® after less than 12 weeks of treatment and who started a second trial of        RESTASIS® prior to June 1, 2008 will be included in the review.|July 2012|July 16, 2012|January 20, 2009|Yes|Yes||No|October 17, 2011|https://clinicaltrials.gov/show/NCT00827255||144672|
NCT00860483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0201|Correlation of Laparoscopic Experience and Functional Brain Activation: A PET Scan Study|GAC 0201 Correlation of Laparoscopic Experience and Functional Brain Activation: A Pet Scan Study||Northwell Health|No|Completed|February 2008|November 2009|Actual|February 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|10|||Both|25 Years|50 Years|No|||December 2012|December 3, 2012|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860483||142153|
NCT00860496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921020|A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers|A Phase I, Open Label, Fixed-Sequence Study to Estimate the Effect of Tacrolimus and Cyclosporine on the Pharmacokinetics of CP-690,550 in Healthy Volunteers||Pfizer|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 12, 2009|March 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00860496||142152|
NCT00827814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-06-022|Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction|Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction: A 24-Week Open-Label, Single-Arm Pilot Study||Samsung Medical Center|No|Completed|June 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Male|50 Years|79 Years|No|||June 2009|June 8, 2009|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00827814||144629|
NCT00828061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-129|A Study of the Effects of Single Dose Corticosteroids on Response to Allergens|A Randomized Clinical Trial to Study the Effects of Single Dose of Corticosteroid on Response to Nasal Allergen Challenge in Patients||Merck Sharp & Dohme Corp.|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|19|||Both|18 Years|55 Years|No|||August 2015|August 4, 2015|January 21, 2009|No|Yes||No|April 12, 2010|https://clinicaltrials.gov/show/NCT00828061||144610|Poor cell yields from nasal lavage significantly reduced the utility of eosinophil count data.
NCT00828074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08103|Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer|Phase I/II Vinorelbine and Sorafenib as Salvage Therapy in Metastatic Breast Cancer||City of Hope Medical Center|Yes|Completed|November 2008|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00828074||144609|
NCT00828373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 08 - 202|The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium|The Effect of Intravenous Lidocaine on the Time Course of Rocuronium Induced Neuromuscular Block. A Randomised, Placebo-controlled, Electrophysiological Study|LidoRoc|University Hospital, Geneva|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|July 14, 2011|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828373||144586|
NCT00861250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08096M|Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT|Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-dexamethasone (Vel/Dex) Followed by HDT With ASCT||Tampere University Hospital|Yes|Completed|March 2009|July 2015|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|65 Years|No|||December 2014|July 1, 2015|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861250||142094|
NCT00861874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26037|A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia||University of Rochester|Yes|Completed|January 2010|||September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861874||142047|
NCT00861614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-043|Study of Immunotherapy to Treat Advanced Prostate Cancer|A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel||Bristol-Myers Squibb|Yes|Completed|May 2009|August 2015|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|988|||Male|18 Years|N/A|No|||March 2016|March 16, 2016|March 12, 2009|Yes|Yes||No|March 15, 2016|https://clinicaltrials.gov/show/NCT00861614||142067|
NCT00862160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T201E1|Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit|Acute Cerebrovascular Events During Extracorporeal Circulation a Comparison of New Minimized Perfusion Circuit to Standard Cardiopulmonary Bypass|ROCsafeTM|Hannover Medical School|Yes|Recruiting|April 2009|October 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|80 Years|No|||October 2009|October 6, 2009|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862160||142026|
NCT00861861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kumamoto-746|Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)|Comparison of Pitavastatin With Atorvastatin in Increasing HDL-C and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease.|COMPACT-CAD|Kumamoto University|No|Completed|September 2008|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|20 Years|85 Years|No|||October 2013|October 11, 2013|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861861||142048|
NCT00839267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-OSM-02|Clopidogrel Efficacy and Acute Coronary Syndromes|The Comparison of Clopidogrel Efficacy in Patients With Acute Myocardial Infarction and Severe Hemodynamic Instability to Patients With Hemodynamically Uncomplicated Myocardial Infarction||Charles University, Czech Republic|No|Completed|June 2006|December 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|Whole blood|Both|18 Years|90 Years|No|Probability Sample|Population of 40 consecutive patients is planned, all of them with acute myocardial        infarction with ST-segment elevation.|February 2009|February 9, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839267||143758|
NCT00839293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-788|Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules|Comparison of Fenofibric Acid Bioavailability From 45 mg and 135 mg Strength ABT-335 Capsules||Abbott||Completed|February 2009|||March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 14, 2010|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839293||143756|
NCT00839592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACUP-001|Acupuncture for Primary Insomnia|Acupuncture Treatment of Primary Insomnia||The University of Hong Kong|No|Completed|July 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2010|January 12, 2010|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839592||143733|
NCT00830284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-07-0328|Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury|Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury|Recruitment|Children's Hospital Boston|Yes|Completed|November 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|1 Month|18 Years|No|||July 2014|July 2, 2014|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00830284||144439|
NCT00830297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2008-005951-84|Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia|Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia (TIP): Efficacy and Safety of a Novel Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression|TIP|Medical University of Vienna|No|Completed|January 2009|May 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830297||144438|
NCT00831181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633360|Combination Chemotherapy in Treating Patients Undergoing Surgery for Rectal Cancer|A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6||National Cancer Institute (NCI)||Recruiting|January 2009|||January 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||June 2009|June 16, 2009|January 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831181||144370|
NCT00831467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-9103-001|Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease|Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease||CureVac AG|Yes|Completed|January 2009|September 2013|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|18 Years|75 Years|No|||October 2013|October 25, 2013|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831467||144348|
NCT00831480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23409|Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal|Neoadjuvant Everolimus (RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01)||Baylor College of Medicine|Yes|Terminated|April 2011|December 2014|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|N/A|No|||December 2014|February 19, 2016|January 27, 2009|No|Yes|Difficulty in accrual and by the order of the cancer center.|No|November 20, 2014|https://clinicaltrials.gov/show/NCT00831480||144347|
NCT00827268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6699-W|Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes|Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes||VA Office of Research and Development|No|Completed|June 2009|July 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||October 2013|October 15, 2013|January 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00827268||144671|
NCT00827281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1728|D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)|D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation||Boston University|No|Withdrawn|August 2008|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|January 21, 2009||No|Study was not funded and pilot work proved impractical.|No||https://clinicaltrials.gov/show/NCT00827281||144670|
NCT00860236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIFF|Giardia Induced Fatigue and Functional Gastrointestinal Diseases|Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention|GIFF|University of Bergen|No|Enrolling by invitation|March 2009|December 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 22, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860236||142172|
NCT00860249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS17163-02|Outreach for Patients That Are Newly Eligible for Colorectal Cancer Screening|Using Precision Performance Measurement To Conduct Focused Quality Improvement. Sub-study 2|UPQUAL|Northwestern University|No|Terminated|March 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|60|||Both|50 Years|50 Years|No|||November 2011|November 30, 2011|March 11, 2009||No|Lack of sufficient participants meeting the eligibility criteria to complete study in proposed    and acceptable time frame.|No|September 2, 2011|https://clinicaltrials.gov/show/NCT00860249||142171|Early termination prior to collection of primary or secondary outcome measures, hence no analyses of the primary or secondary outcomes were performed.Thus, the only results reported are baseline characteristics of enrolled participants.
NCT00827827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6737-R|Strength Training for Skeletal Muscle Adaptation After Stroke|Strength Training for Skeletal Muscle Adaptation After Stroke||VA Office of Research and Development|Yes|Active, not recruiting|April 2009|September 2016|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|40 Years|85 Years|No|||November 2015|November 18, 2015|January 22, 2009||No||No|December 29, 2014|https://clinicaltrials.gov/show/NCT00827827||144628|Scanning results and muscle biopsy outcomes are still pending and won't be available for some time.Numbers of participants qualifying for and agreeing to metabolic testing will be too low to yield reportable results.
NCT00860470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU_IRB 570|Antenatal Micronutrient Supplementation and Infant Survival|Antenatal Multiple Micronutrient Supplementation to Improve Infant Survival and Health in Bangladesh|JiVitA-3|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|January 2008|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44567|||Female|12 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|March 11, 2009||No||No|May 7, 2015|https://clinicaltrials.gov/show/NCT00860470||142154|The study was run in an area where iron deficiency rates were low.
NCT00860756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I2007.242dt|Sleep Disturbance in Deployed Soldiers|Sleep Disturbance in Deployed Soldiers||Brooke Army Medical Center|No|Recruiting|September 2007|July 2009|Anticipated|July 2009|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 11, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860756||142132|
NCT00860769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G071208102|Asha HIV Health Promotion Intervention in India|ASHA HIV Health Promotion Intervention in India||University of California, Los Angeles|No|Active, not recruiting|September 2008|June 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||April 2009|April 10, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860769||142131|
NCT00860977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN 240|Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?|VALacyclovir In Delaying Antiretroviral Treatment Entry|VALIDATE|University Health Network, Toronto|Yes|Active, not recruiting|March 2010|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860977||142115|
NCT00861627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 016|Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation|Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors||Oncolytics Biotech|No|Completed|March 2009|November 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861627||142066|
NCT00863213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARA-08|Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation|Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation|SARA|Hospital Clinic of Barcelona|Yes|Completed|March 2009|December 2012|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|70 Years|No|||April 2013|April 25, 2013|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863213||141947|
NCT00861887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2008-173|Extended Treatment With Vancomycin for Clostridium Difficile Colitis|Comparative Study of 2 Weeks Versus 4 Weeks Treatment With Vancomycin for Clostridium Difficile Colitis||William Beaumont Hospitals|Yes|Withdrawn|February 2009|January 2010|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2010|January 19, 2010|March 13, 2009||No|Difficult enrollment|No||https://clinicaltrials.gov/show/NCT00861887||142046|
NCT00862524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-543-206|A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer|||Array BioPharma||Completed|March 2009|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00862524||141999|
NCT00839605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1124100 Hospira|Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedures and One-Lung Ventilation|Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedure and One-Lung Ventilation(OLV)|Dex-One-Lung|University of Missouri-Columbia|No|Completed|March 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|25|||Both|19 Years|N/A|No|Probability Sample|Those patients whom will be receiving thoracic surgery|February 2010|February 1, 2010|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839605||143732|
NCT00839631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T08-1|Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors|A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid Tumors||Dendreon|No|Completed|March 2009|April 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839631||143731|
NCT00830609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCHE FARMA S.A.|High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3|Effect of High Dose vs. Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3, High Viral Load Without Rapid Virological Response|DARGEN-3|Hospital Universitario Fundación Alcorcón|Yes|Completed|November 2008|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|18 Years|70 Years|No|||March 2012|March 12, 2012|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830609||144414|
NCT00830622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2007:037|Cell Phone Intervention to Support Antiretroviral Therapy (ART) Adherence in Kenya|A Targeted Cell Phone Intervention to Improve Patient Access to Care and Drug Adherence in Patients Taking Antiretroviral (ARV) Medications in Kenya||University of Manitoba|No|Completed|May 2007|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|536|||Both|18 Years|N/A|No|||January 2009|June 18, 2010|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830622||144413|
NCT00862810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014388|Alternate Dosing Schedules Study for HPV Vaccine|Alternate Dosing Schedules Study for HPV Vaccine|ADS|Duke University|No|Completed|March 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Female|9 Years|18 Years|Accepts Healthy Volunteers|||September 2014|November 19, 2014|March 15, 2009|Yes|Yes||No|September 17, 2014|https://clinicaltrials.gov/show/NCT00862810||141978|
NCT00830908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEX0903|HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis|An Open-Label Study of the HairMax LaserComb(r) in the Treatment of Seborrheic Dermatitis of the Scalp.||Lexington International, LLC|Yes|Completed|January 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|50 Years|No|||June 2012|June 25, 2012|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00830908||144391|
NCT00863421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISIFA 08-058-0508|Sleep Disordered Breathing in Patients With Chronic Heart Failure|Prevalence, Incidence and Clinical Characteristics of Sleep Disordered Breathing in Patients With Stable Chronic Heart Failure|VISIFA|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|Yes|Recruiting|September 2008|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood samples|Both|18 Years|80 Years|No|Probability Sample|Participants will be recruited from 4 independent heart failure outpatient clinics in        Vienna.|June 2011|June 15, 2011|March 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00863421||141931|
NCT00831493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0780|Vorinostat Plus Radiation Therapy in Pancreatic Cancer|Phase I/II Trial of Vorinostat and Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Terminated|May 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|January 27, 2009||No|Slow Accrual.|No|February 13, 2012|https://clinicaltrials.gov/show/NCT00831493||144346|
NCT00831831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02007|Can Safety Planning Improve Perinatal Outcomes Among Pregnant Women Exposed to Intimate Partner Violence?|Can Safety Planning Improve Perinatal Outcomes Among Pregnant Women Exposed to Intimate Partner Violence?||University of British Columbia|No|Withdrawn|April 2008|December 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|0|||Female|18 Years|35 Years|No|||July 2012|July 11, 2012|January 27, 2009||No|The team wasn't able to work effectively with the social worker at the site|No||https://clinicaltrials.gov/show/NCT00831831||144322|
NCT00864461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|249-08|Frequency of Metabolic Syndrome in Down Syndrome Patients|||Universidad de Guanajuato||Not yet recruiting|May 2009|July 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|96|Samples With DNA|Whole blood|Both|7 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|March 2009|March 17, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864461||141852|
NCT00864474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001093|Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation For Hiv Infection Patients Of Maraviroc (Regulatory Post Marketing Commitment Plan).||ViiV Healthcare|No|Active, not recruiting|March 2010|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A4001093 prescribes the Maraviroc Tablets        (CELSENTRI® Tablets).|March 2016|March 22, 2016|March 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00864474||141851|
NCT00864487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1110|Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib|A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Neratinib When Administered Concomitantly to Healthy Subjects||Puma Biotechnology, Inc.|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|March 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00864487||141850|
NCT00860808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-101-CL-08-01|Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus|Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study||Auris Medical, Inc.|Yes|Completed|March 2009|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|248|||Both|18 Years|65 Years|No|||February 2013|February 12, 2013|March 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00860808||142128|
NCT00860821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1511M00004|A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)|A Randomised, Double-blind, Placebo-controlled, Two-way Crossover, Single-centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).||AstraZeneca|No|Completed|March 2009|October 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2009|October 27, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860821||142127|
NCT00860197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|immunecoffee|Immune Benefits of Coffee|Effect of Coffee Consumption on Immune and Inflammatory Status in Elderly||University of Chile|No|Completed|March 2009|February 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|116|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860197||142175|
NCT00860782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|629|Parent Educational Program for Children With Sickle Cell Disease|Parent Intervention to Improve Academic Success in Children With Sickle Cell Disease||University of Miami|Yes|Active, not recruiting|August 2008|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|6 Years|12 Years|No|||October 2015|October 2, 2015|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860782||142130|
NCT00860990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-4|VA Gastrointestinal (GI) Quality of Life Survey|VA GI Quality of Life Survey|VA GI QOL|VA Office of Research and Development|No|Terminated|April 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers will be recruited from the spinal cord injury service/clinic, the primary care        service/clinic, the geriatric service/clinic, the chronic kidney service/clinic, and the        rehabilitation service/clinic at the James J. Peters VA Medical Center.|June 2015|June 25, 2015|March 6, 2009||No|Outcome measures are included in another, similar study.|No||https://clinicaltrials.gov/show/NCT00860990||142114|
NCT00861003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSH001|An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder|An Exploratory Study on Comparison of Electronic Monitoring and Other Measures of Adherence to Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder|MEMS-SPR|Korea University Guro Hospital|No|Not yet recruiting|April 2009|August 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|57|||Both|20 Years|65 Years|No|Probability Sample|Clinician rendered diagnosis of schizophrenia or schizoaffective disorder documented by a        checklist of Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition        (DSM-IV) criteria|March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861003||142113|
NCT00861276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot 29/99|Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit|Use of Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit: a Randomized Controlled Trial|SUNIC|University of Lausanne|No|Completed|June 2000|December 2001|Actual|July 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861276||142092|
NCT00861302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU094808B3E|Evaluating a Chronic Pain Treatment Program|Evaluating Outcomes and Response Profiles of a Psychological Treatment for People With Chronic Pain||Wayne State University|No|Completed|September 2008|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861302||142091|
NCT00861588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK4453/05M|Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia|||Chinese University of Hong Kong|No|Completed|February 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|176|||Male|45 Years|85 Years|No|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861588||142069|
NCT00863226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09026-01|Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease|A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol||pico-tesla Magnetic Therapies, LLC||Active, not recruiting|March 2009|January 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|72|||Both|30 Years|85 Years|No|||December 2011|December 13, 2011|March 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863226||141946|
NCT00863525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-006|A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)|A Double-Blind, Randomized, 2-Period Crossover, Placebo Controlled Study to Asses the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MK0822||Merck Sharp & Dohme Corp.||Completed|November 2004|June 2006|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|March 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863525||141923|
NCT00863538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1201|Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|An Open-label, Phase II Study of KPS-0373 in Patients With SCD||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|N/A|No|||February 2010|February 1, 2010|March 16, 2009||||No||https://clinicaltrials.gov/show/NCT00863538||141922|
NCT00862173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008/025/OMI|Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer|Gene-expression Profile as Predictor of Central Nervous System Metastasis Development in Non-small Cell Lung Cancer: a Prospective Study||National Institute of Cancerología|No|Recruiting|March 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|NSCLC Biopsy.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with confirmed or suggested diagnosis of non-small-cell lung cancer, consulting        at the National Institutes of Cancerology or Respiratory Diseases (INCan, INER; Mexico        City, Mexico)|June 2012|June 11, 2012|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00862173||142025|
NCT00862186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-12551|Self-Management of Cancer-Related Fatigue by Adolescents|Self-Management of Cancer-Related Fatigue by Adolescents: Pilot Study of an Evidence Based Educational Resource||Seattle Children's Hospital|No|Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Both|13 Years|18 Years|No|||January 2013|January 11, 2013|March 12, 2009||No||No|April 11, 2012|https://clinicaltrials.gov/show/NCT00862186||142024|Slow enrollment resulting in low accrual - only 15 participants rather than the 60 planned - therefore unable to complete analysis.
NCT00840229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08546|Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder|Rotator Interval and Intra-articular Corticosteroid Injection for Adhesive Capsulitis (Frozen Shoulder): a Randomised, Double Blind, Placebo Controlled Trial||Oslo University Hospital|No|Completed|February 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|122|||Both|25 Years|70 Years|No|||November 2013|November 24, 2013|February 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00840229||143686|
NCT00829647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCLL084993|A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia|A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia||Scripps Health|No|Recruiting|January 2009|June 2010|Anticipated|January 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2009|October 13, 2009|January 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00829647||144488|
NCT00862472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-006|Safety and Efficacy Study of DuoTrav APS Versus DuoTrav|||Alcon Research|No|Withdrawn|March 2009|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|March 16, 2009|No|Yes|Management decision not to conduct an additional efficacy study.|No||https://clinicaltrials.gov/show/NCT00862472||142003|
NCT00863122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0867|Concentration and Activity of Lapatinib in Vestibular Schwannomas|Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas||Sidney Kimmel Comprehensive Cancer Center||Recruiting|June 2009|||December 2013|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|March 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863122||141954|
NCT00863135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS PI070219|Effect of CPAP on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension|Effect of Continuous Positive Airway Pressure (CPAP) Treatment on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension||Corporacion Parc Tauli|No|Recruiting|December 2008|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863135||141953|
NCT00863109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05278|Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)|Evaluation of the Health-Related Quality of Life During Combined Treatment of Chronic Hepatitis Due to Hepatitis C Virus Under Habitual Clinical Practise Conditions.|VIDA|Merck Sharp & Dohme Corp.|No|Completed|April 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with Chronic Hepatitis C, Genotype 1, no other co-infection and compensated        liver disease who receive PEG and RBV in combination therapy according to standard        clinical practice.|April 2015|April 15, 2015|March 12, 2009|No|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00863109||141955|
NCT00863798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-3362|Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|682|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|March 17, 2009|Yes|Yes||No|March 8, 2011|https://clinicaltrials.gov/show/NCT00863798||141903|
NCT00864149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3166|A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions|A Two-Way Crossover, Open-Label, Single Dose, Fed, Bioequivalence Study of Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets in Normal, Healthy, Non-Smoking Male and Female Subjects||Actavis Inc.|No|Completed|October 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864149||141876|
NCT00863785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC R04 - Dr NGUYEN-KHAC|Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone|Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study.|HAA-NAC|Centre Hospitalier Universitaire, Amiens|Yes|Completed|April 2004|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|174|||Both|18 Years|65 Years|No|||October 2009|October 19, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863785||141904|
NCT00864162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-678-1G|A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Under Fed Conditions||Actavis Inc.|No|Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864162||141875|
NCT00864136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14697|Mirena or Conventional Medical Treatment for Menorrhagia|MiCo - Mirena or Conventional Medical Treatment for Menorrhagia||Bayer|No|Completed|November 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|647|None Retained|n.a|Female|18 Years|45 Years|No|Non-Probability Sample|Women with a diagnosis of idiopathic menorrhagia can be enrolled after decision for        treatment has been made.|June 2015|June 30, 2015|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864136||141877|
NCT00860210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHB-PFS-NSS III|Pilot Study Assessing the Feasibility of Treating Foot Drop With the Neurostep™ System.|Pilot Feasibility Study of the Neurostep™ System in Subjects With Gait Disorder Secondary to CNS Lesion.||Neurostream Technologies G.P.|Yes|Completed|October 2007|March 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|70 Years|No|||April 2010|April 9, 2010|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860210||142174|
NCT00860223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1119|Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin|An Open-Label, Nonrandomized, Crossover Study to Evaluate the Potential Effect of Multiple Doses of Neratinib on the Pharmacokinetics of a Single Dose of Digoxin When Administered Orally to Healthy Adult Subjects||Puma Biotechnology, Inc.|No|Completed|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860223||142173|
NCT00860509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC26030|Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism|Phyteaux-II- Regulation of Cholesterol Absorption: Response of LDL to Low and Naturally High Phytosterol Diets|Phyteaux-II|Washington University School of Medicine|No|Completed|November 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860509||142151|
NCT00860522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-031|JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia|A Phase I Trial of the Immunostimulant JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia||Milton S. Hershey Medical Center|Yes|Active, not recruiting|March 2009|October 2015|Anticipated|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|23|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|March 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00860522||142150|
NCT00860795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09A1236|Immunologic Effects of Echinacea|Study of the Immunologic Effects of Echinacea Purpurea in Adults||University of Washington|Yes|Completed|March 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 20, 2010|March 10, 2009|Yes|Yes||No|September 28, 2010|https://clinicaltrials.gov/show/NCT00860795||142129|
NCT00861016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4025L00006|Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension|An Open-Label, Non-Comparative, Multi-Centre Study to Evaluate the Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet (Betaloc Zok) in Patients With Mild to Moderate Essential Hypertension||AstraZeneca|No|Completed|October 2005|May 2006|Actual|April 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|310|||Both|18 Years|70 Years|No|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861016||142112|
NCT00861029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111485|VEG111485: A QTc Study of Pazopanib|VEG111485: A Phase I, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses ofPazopanib (GW786034) on Cardiac Conduction in Subjects withSolid Tumors||GlaxoSmithKline|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||November 2010|January 22, 2011|March 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861029||142111|
NCT00861315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DARTAGNAN|Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation|Phase II Study of High Dose Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation|DARTAGNAN|Association Pour La Promotion A Tours De La Reanimation Medicale|Yes|Recruiting|January 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2009|March 13, 2009|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861315||142090|
NCT00861601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111913|Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease|TPL111913, a Multi-centre, Open Label, Dose Ranging Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease||GlaxoSmithKline||Completed|January 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|20 Years|N/A|No|||February 2011|April 23, 2015|March 5, 2009||No||No|May 11, 2010|https://clinicaltrials.gov/show/NCT00861601||142068|
NCT00863239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLX883-203|Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV|Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron Plus Ribavirin Given Bi-weekly in Comparison With PEG-Intron Plus Ribavirin Given Weekly|SELECT-2|Biolex Therapeutics, Inc.|Yes|Completed|March 2009|November 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|116|||Both|18 Years|69 Years|No|||February 2012|February 1, 2012|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863239||141945|
NCT00863551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-SXR-09-001|Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial|||Allergan||Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|65 Years|75 Years|No|||January 2016|January 28, 2016|March 16, 2009|Yes|Yes||No|November 16, 2011|https://clinicaltrials.gov/show/NCT00863551||141921|Due to technical problems associated with the administration of the BVMT-R test, the results were invalid, therefore, results for Outcome Measures 4 and 5 are not presented.
NCT00863564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-PPL-JHJ-5a|Acute Effects of Dietary Proteins on Postprandial Lipemia, Incretin Responses and Subclinical Inflammation in Obese Subjects|Acute Effects of Dietary Proteins on Postprandial Lipemia, Incretin Responses and Subclinical Inflammation in Obese Subjects||Aarhus University Hospital|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|12|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2009|November 9, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863564||141920|
NCT00840567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1409|Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases|Acquisition of Skin Biopsies and Blood Samples From Normal Volunteers and Patients With Benign, Inherited Hematologic Diseases for Research Purposes||Washington University School of Medicine|No|Terminated|February 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 9, 2013|February 9, 2009||No|Key samples protocols will be provided by a collaborator and we were not able to produce IPS    lines from human fibroblasts.|No||https://clinicaltrials.gov/show/NCT00840567||143661|
NCT00840580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-22|Effect on Wound Healing of Vigamox Versus Cravit|Prospective, Randomized Study Comparing Effect on Wound Healing of Vigamox (Moxifloxacin 0.5% Ophthalmic Solution) and Cravit (Levofloxacin 0.5% Ophthalmic Solution) Administered Post-Surgically in Patients Undergoing Cataract Extraction||Alcon Research|No|Completed|January 2009|||September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|19 Years|N/A|No|||July 2012|July 19, 2012|February 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00840580||143660|
NCT00862485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1910CTIL|MCA Doppler Studies in Neborns Following Exchange Transfusion|||Rambam Health Care Campus||Recruiting|March 2009|||December 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Anticipated|300|||Both|N/A|30 Days|Accepts Healthy Volunteers|Non-Probability Sample|newborns|May 2015|May 7, 2015|March 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00862485||142002|
NCT00862498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077658|Examining Written Disclosure as a Treatment for Post-Traumatic Stress Disorder|Examining Written Disclosure as an Intervention for Posttraumatic Stress Disorder||Boston University|No|Completed|August 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862498||142001|
NCT00862511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KneeIon|Serum Metal Ion Concentration After Total Knee Arthroplasty (TKA)|A Prospective Randomized Comparison of Serum Metal Ion Levels After Implantation of Coated and Uncoated Knee Prostheses||Technische Universität Dresden|No|Active, not recruiting|March 2009|December 2015|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||August 2012|August 10, 2012|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862511||142000|
NCT00863460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRH 07/422/H|Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients|Prospective , Multicentric, Randomized Phase II Study, Evaluating the Role of Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue After Conventional Chemotherapy for Primary Central Nervous System in Young Patients (< 60 y)|PRECIS|Centre Rene Huguenin|Yes|Active, not recruiting|October 2008|February 2017|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||September 2014|September 5, 2014|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863460||141928|
NCT00863473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AkerU_s422|Comminuted Proximal Humeral Fractures. A Randomised Study of Surgical Versus Conservative Treatment|Health and Cost Consequenses of Surgical Versus Conservative Treatment for a Comminuted Humerus Fracture. Do Interlocking Plate Surgery Benefit Displaced Proximal Humerus Fractures? A Randomized Clinical Trial||Oslo University Hospital||Completed|May 2003|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|60 Years|85 Years|No|||April 2015|April 22, 2015|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863473||141927|
NCT00863434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6858|Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease|A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia||University of Washington|No|Terminated|February 2009|||February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||May 2013|May 7, 2013|March 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863434||141930|
NCT00863447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-SEI-SW3|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2009|||||N/A|N/A|N/A||||||||||||||March 16, 2009|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863447||141929|
NCT00864175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 7839-202|Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer|A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer||Incyte Corporation|No|Terminated|July 2007|October 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|68|||Female|18 Years|N/A|No|||January 2012|January 20, 2012|January 26, 2009|Yes|Yes|Incyte suspended development of the compound.|No||https://clinicaltrials.gov/show/NCT00864175||141874|
NCT00864526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0605001|A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864526||141847|
NCT00864500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10504910|Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects|Bioequivalence of Two Clobetasol Propionate 0.05% Topical Lotions||Actavis Inc.|No|Completed|November 2005|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|224|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864500||141849|
NCT00864812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112942|Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea|A Randomized, Open Label, Multicenter, Phase 4 Study for the Comparison of Efficacy of Tiotropium Plus Salmeterol/ Fluticasone Propionate Compared With Tiotropium Alone in COPD Patients||The Korean Academy of Tuberculosis and Respiratory Diseases|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|509|||Both|40 Years|80 Years|No|||March 2010|March 29, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864812||141825|
NCT00861640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-970338|Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding|The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|March 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||July 2009|July 14, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00861640||142065|
NCT00861042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0665|An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy|An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy||UCB Pharma|No|Completed|April 2002|March 2005|Actual|December 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|N/A|N/A|No|||July 2010|September 19, 2014|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861042||142110|
NCT00861328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-06|Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin|A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors||Onconova Therapeutics, Inc.|No|Completed|February 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||December 2011|December 29, 2011|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861328||142089|
NCT00861900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0977|Immune Mechanisms of Rejection in Human Lung Allografts|Immune Mechanisms of Rejection in Human Lung Allografts||Washington University School of Medicine|No|Enrolling by invitation|January 1998|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|||Both|18 Years|70 Years|No|Non-Probability Sample|Any patient who is a candidate for a lung transplant.|July 2009|July 14, 2009|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00861900||142045|
NCT00862212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA013379-05A1|Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting|Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting||Medical University of South Carolina|Yes|Completed|January 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|65 Years|No|||April 2013|April 22, 2013|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862212||142023|
NCT00862225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETRA_IG-RD-001 (Ze339)|MOA Study of Ze 339 in Seasonal Allergic Rhinitis|Randomized, Double-blind Prospective Clinical Study to Examine the Mechanism of Action of IG-RD-001 (Ze-339) Compared to Desloratadine and Placebo in Patients With Seasonal Allergic Rhinitis Who Are Sensitized to Grasses|PETRA|Max Zeller Soehne AG|No|Completed|January 2008|December 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862225||142022|
NCT00862563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-CIR-AA015923|Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism|A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of; Levetiracetam, Zonisamide, Topiramate, and Placebo Control for the Treatment of Alcohol Dependent Subjects.||Boston Medical Center|Yes|Terminated|May 2009|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|85|||Both|21 Years|65 Years|No|||April 2015|April 6, 2015|March 16, 2009|Yes|Yes|Recruitment goals could not be met before ending of funding for this project.|No|March 6, 2015|https://clinicaltrials.gov/show/NCT00862563||141996|Early termination lead to a small number of subjects in each group being analyzed.
NCT00862862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-09-FB|Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus|Evaluation of Pharmacodynamic Target Attainment With Vancomycin Treatment of Infections Due to Staphylococcus Aureus||University of Nebraska|No|Terminated|April 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|250|||Both|19 Years|N/A|No|Non-Probability Sample|Adult patients with suspected or documentd staphylcoccus aureus infection and prescribed        vancomycin|May 2015|May 27, 2015|March 13, 2009|No|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00862862||141974|
NCT00862875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRL-01-2009|Levemir-Body Composition and Energy Metabolism|Effects of Basal Insulin Analogue Detemir on Body Composition, Epicardial Fat and Energy Metabolism||Institut de Recherches Cliniques de Montreal|No|Completed|March 2009|||April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|No|||May 2014|May 6, 2014|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862875||141973|
NCT00863590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-001|A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Single Oral Rising-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK0822 in Healthy Volunteers||Merck Sharp & Dohme Corp.||Completed|June 2004|August 2008|Actual|February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|March 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863590||141918|
NCT00863603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010M69621|The Effect of Oxygen on Healing an Artery From the "Injury" of Surgery|Artery Wall Hypoxia and Intimal Hyperplasia||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|January 2005|August 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|80 Years|No|||May 2012|May 23, 2012|March 16, 2009|Yes|Yes|Clinical changes: graft to fistula first; enrollment of 46/132 planned. NIH approved animal    model: supplemental oxygen/AV fistula.|No||https://clinicaltrials.gov/show/NCT00863603||141917|
NCT00863902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-431|A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers||Actavis Inc.|No|Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863902||141895|
NCT00863915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-679-1G|A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Administered Orally as a Sprinkle on Applesauce||Actavis Inc.|No|Completed|October 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863915||141894|
NCT00830635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0498|Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer|Cancer Information Service Research Consortium: Years 2006-2011 Program Narrative and Overview||University of Colorado, Denver|No|Completed|September 2008|December 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1800|||Both|N/A|N/A|No|||June 2015|June 12, 2015|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830635||144412|
NCT00830648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBK12|Safety of a Second Dose of Biken's Varicella Vaccine|Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina||Sanofi|No|Completed|January 2009|December 2009|Actual|October 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|122|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830648||144411|
NCT00862823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F081030003|The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers|The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation||University of Alabama at Birmingham||Completed|February 2009|May 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||June 2012|August 16, 2012|March 13, 2009|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00862823||141977|Efavirenz exposure was highly variable and relative bioequivalence for efavirenz may have been more appropriately assessed with a larger sample size.
NCT00863148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/7-J|Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)|A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-risk AML, MDS or ALL.|Cloric|Nantes University Hospital|Yes|Completed|October 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||September 2013|September 19, 2013|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863148||141952|
NCT00863187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3097|Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab|||Rambam Health Care Campus|No|Not yet recruiting|February 2009|||February 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|100|||Both|55 Years|N/A|Accepts Healthy Volunteers|||February 2009|March 16, 2009|February 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00863187||141949|
NCT00863200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0327|Identification and Treatment of Depression|Identification and Treatment of Depression in Underserved African American and Latino Patients With Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2009|||March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|166|||Both|18 Years|N/A|No|Probability Sample|African American or Hispanics over 18 years of age being treated for cancer at LBJ General        Hospital in Houston.|November 2015|November 13, 2015|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863200||141948|
NCT00863486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP07-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2007|||||N/A|N/A|N/A||||||||||||||February 22, 2010|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863486||141926|
NCT00863811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRONEK-PG-BB|Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Treatment With Either Beta-blockers or Prostaglandins Eye Drops|Effects of the Oral Administration of an Association of Forskolin With Rutin and Vitamins B on Intraocular Pressure in Patients Affected by Primary Open Angle Glaucoma and Treated With Either Beta-blockers or Prostaglandin Eye Drops||Sooft Italia|Yes|Withdrawn|April 2009|July 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|0|||Both|30 Years|70 Years|No|Probability Sample|Patients affected by POAG and already under observation in the centers that take part in        this study|June 2012|June 5, 2012|March 17, 2009||No|loss of interest before enrolment started|No||https://clinicaltrials.gov/show/NCT00863811||141902|
NCT00863824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-09-EP|NNAL Clearance in Hair and Urine|Elimination of NNAL and Cotinine From Hair and Urine|NNAL|University of Nebraska|No|Not yet recruiting|July 2009|June 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|19 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Caucasians and African Americans who are ready to quit smoking.|March 2009|March 17, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863824||141901|
NCT00864539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/25/47/2027|Comparison of the Efficacy of Calcium-cholecalciferol Foodstuffs and Calcium-cholecalciferol Supplement|The Prevalence of Vitamin D Insufficiency in Primary School Children and Comparison of the Effect of Calcium-Vitamin D-Fortified Milk, -Orange Juice and Calcium-Vitamin D Supplement||National Nutrition and Food Technology Institute|No|Completed|November 2007|June 2010|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|585|||Both|9 Years|11 Years|Accepts Healthy Volunteers|||November 2011|November 12, 2011|March 17, 2009||No||No|July 27, 2010|https://clinicaltrials.gov/show/NCT00864539||141846|Because of very cold winter, it was not possible to extend the intervention period to 12 weeks or longer. Moreover, it was impossible to fortify the foodstuffs with more than 50% of RDA(recommended daily allowance) because of legal problems.
NCT00860561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997L00018|Faslodex Post Marketing Surveillance|Faslodex Post Marketing Surveillance||AstraZeneca|No|Completed|January 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|42|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2        or more prior hormone therapies, or were intolerant to prior hormone therapy and have no        endocrine therapeutic options.|October 2014|October 9, 2014|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860561||142147|
NCT00864513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT2007022|Study of Pemetrexed for Second-Line Pancreas Cancer|A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine||Georgetown University|Yes|Terminated|October 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|March 17, 2009|Yes|Yes|At interim analysis the study did not meet the response criteria to continue|No|March 24, 2011|https://clinicaltrials.gov/show/NCT00864513||141848|study was closed at interim analysis so only 12 subjects were evaluable for response, 15 subjects received treatment and were evaluable for adverse events
NCT00860262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.20|Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension|An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg & Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).||Boehringer Ingelheim||Completed|March 2009|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|858|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|March 11, 2009||||No|December 10, 2010|https://clinicaltrials.gov/show/NCT00860262||142170|
NCT00860275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-019|Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole|A Study of the Effect of Concomitant Administration of Ketoconazole or Fluconazole on the Pharmacokinetics of BMS-708163 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|January 24, 2011|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860275||142169|
NCT00860535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-098|Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)|A Multicenter Phase Ib Trial to Determine Whether a Gene Expression Signature Changes in Response to Treatment With Bcr-Abl Inhibitors in Patients With Blast Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphocytic Leukemia||Merck Sharp & Dohme Corp.|No|Terminated|June 2009|June 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|March 5, 2009|No|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00860535||142149|Part I aimed to have 10 evaluable patients. Due to slow enrollment, 9 patients who met the inclusion/exclusion criteria were enrolled over a period of 9 months. Part I was terminated early and Part II was cancelled due to slow enrollment.
NCT00859976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU27|Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups|Prospective Randomised Control Trial to Compare the Effect Upon Bone Density and Clinical Outcomes When Using BoneMaster HA Coated Acetabular Cups Compared With Plasma Sprayed HA Coated Cups in Patients With Total Hip Replacements||Biomet, Inc.|No|Active, not recruiting|March 2009|August 2024|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|193|||Both|N/A|N/A|No|||August 2013|June 22, 2015|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00859976||142192|
NCT00859989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635687|A Weight-Loss Program in Helping Obese Black Women Lose Weight|Obesity Reduction Black Intervention Trial (ORBIT)||National Cancer Institute (NCI)||Active, not recruiting|July 2004|||April 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized|||Anticipated|200|||Female|30 Years|50 Years|No|||March 2009|December 17, 2013|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859989||142191|
NCT00861068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0655|A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).|A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).||UCB Pharma|No|Completed|February 2002|January 2003|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2009|October 17, 2014|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861068||142108|
NCT00861354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tripps2|Home Monitoring for Atrial Fibrillation Using a Microlife Blood Pressure Monitor|Home Monitoring for Atrial Fibrillation Using a Microlife Blood Pressure Monitor: Trial of Regular vs Irregualr Pulse for the Prevention of Stroke (TRIPPS 2.0)|TRIPPS|Microlife|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients seen in a general medical practice.|January 2010|January 6, 2010|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00861354||142087|
NCT00861913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01163|Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery|Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients||National Cancer Institute (NCI)||Active, not recruiting|April 2009|||September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|March 13, 2009|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT00861913||142044|
NCT00861926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0804-PR-0034|Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics|48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age||Chiesi Farmaceutici S.p.A.|No|Completed|March 2009|April 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2079|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00861926||142043|
NCT00862238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081101501|An Arts Intervention for Drug-Using Homeless Youth|An Arts Intervention for Drug-Using Homeless Youth||University of California, Los Angeles|Yes|Completed|April 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|156|||Both|15 Years|24 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862238||142021|
NCT00862251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-133|Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)|A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin Dose||Merck Sharp & Dohme Corp.|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|808|||Both|18 Years|79 Years|No|||October 2015|October 12, 2015|March 12, 2009|Yes|Yes||No|February 23, 2012|https://clinicaltrials.gov/show/NCT00862251||142020|
NCT00862576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1113-29221|A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome|A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome||University of California, San Francisco|No|Completed|June 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Seen at the Oral Medicine Clinic at the University of California, San Francisco|March 2009|March 16, 2009|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862576||141995|
NCT00862589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KA-20070023|Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)|GLP-1 Suppression of Alpha Cell Secretion in T2DM||University Hospital, Gentofte, Copenhagen|No|Completed|October 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 17, 2009|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862589||141994|
NCT00862888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8361011|Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction|A 2-Cohort, Multi-Centre, Randomised, Double Blind, Placebo Controlled 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses Of PF-00446687 On Erectile Function In Men Suffering From Erectile Dysfunction, Using 100 Mg Sildenafil As A Positive Control.||Pfizer|No|Completed|July 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Male|18 Years|65 Years|No|||April 2009|April 7, 2009|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862888||141972|
NCT00862901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Komen Award ID# -BCTR0707871|Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma|A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy|CLIPT|Tufts Medical Center|Yes|Completed|January 2009|April 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|N/A|No|||September 2011|September 23, 2011|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00862901||141971|
NCT00863577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-BEM-2008-01|Pharmacokinetic Study of Two Oral Bemiparin Formulations|||Rovi Pharmaceuticals Laboratories|No|Completed|March 2009|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|102|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00863577||141919|
NCT00863616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0303/57|High Frequency Chest Wall Oscillation in Chronic Obstructive Pulmonary Disease (COPD)|Self-Administered High Frequency Chest Wall Oscillation Technique for Mucus Clearance in COPD: An Exploratory Pilot Project Using the SMARTVEST Device||East and North Hertfordshire NHS Trust|Yes|Completed|August 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|40 Years|85 Years|No|||March 2009|March 17, 2009|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863616||141916|
NCT00830661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMG1108|Ligation of Intersphincteric Fistula Tract (LIFT) Procedure Versus Use of an Anal Fistula Plug for Anal Fistula Repair|A Randomized, Prospective, Multi-Centered Study Comparing Clinical Outcomes of the Ligation of Intersphincteric Fistula Tract (LIFT)Procedure Versus Use of Anal Fistula Plug (AFP)in the Surgical Repair of Trans-Sphincteric Anal Fistulae of Cryptoglandular Origin|LIFT vs PLUG|Colon and Rectal Surgery Associates, Ltd.|Yes|Recruiting|March 2009|||March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830661||144410|
NCT00830934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRIP1|Trial for the Treatment of Pelvic and Back Pain in Pregnancy|Randomised Controlled Trial for the Treatment of Pelvic Girdle Pain in Pregnancy|GRIP|University College Cork|Yes|Not yet recruiting|April 2009|September 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Female|16 Years|N/A|No|||January 2009|January 27, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00830934||144389|
NCT00863161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00022|Renal Impairment Study|A Phase I, Open Label, Non-randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 130 mg AZD3355||AstraZeneca|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|23|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2011|January 21, 2011|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863161||141951|
NCT00862849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-117-103|Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone|Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic 6-Way Crossover Study of SC Administered Insulin Lispro With Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Lispro Alone in Healthy Volunteers||Halozyme Therapeutics|No|Completed|March 2009|August 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 11, 2014|March 13, 2009|Yes|Yes||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00862849||141975|
NCT00863499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iSPOT-A|International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder|International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.||BRC Operations Pty. Ltd.|No|Recruiting|October 2009|July 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1344|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863499||141925|
NCT00863512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-30506|Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer|A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data||Alliance for Clinical Trials in Oncology|No|Completed|March 2009|November 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863512||141924|
NCT00860834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|634|Parents, Pediatricians, and Asthma Telephone Coaches Partner to Improve Control of Asthma in Children (The PARTNER Study)|Parents, Pediatricians, and Telephone Coaches Partner to Improve Control of Asthma|PARTNER|Washington University School of Medicine|Yes|Active, not recruiting|August 2008|May 2014|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|3 Years|12 Years|No|||March 2014|March 28, 2014|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860834||142126|
NCT00860002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB-98-01-20A|The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids|The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids||Taipei Veterans General Hospital, Taiwan|No|Recruiting|January 2009|December 2014|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||17|Anticipated|1200|||Female|20 Years|60 Years|No|Non-Probability Sample|Women between 2009 and 2014 booked for treatment who had symptomatic uterine myomas, will        be included in the present study. All the treatments for symptomatic uterine myomas,        including medical treatment with different kinds of medication, and uterine-sparing        surgery including myomectomy, which is performed through traditional exploratory        laparotomy (LT), mini-laparotomy (MLT), ultramini-laparotomy (UMLT), laparoscopy (L), the        vagina (V) or hysteroscopy (H), and LUVO and combination therapy, and the definite        treatment of hysterectomy, through different routes, such as vagina, laparoscopic        assistance, and convention exploratory laparotomy. All patients should have uterine        fibroids with symptoms, comprising either menstrual problems such as menorrhagia and pain,        or compression syndrome, including a bulge-like sensation and frequency. These women will        be informed that they can choose to be treated with any one of the above-mentioned        procedures, based on their willingness and preference.|June 2010|June 6, 2010|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860002||142190|
NCT00861341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24695|Effects of Pioglitazone on Platelet Function|Effects of Pioglitazone on Platelet Function|UHEM08014|University of Rochester|Yes|Completed|December 2008|June 2011|Actual|June 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 23, 2015|March 9, 2009||No||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00861341||142088|
NCT00860548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT SCSSc-02|SCOT Scleroderma Treatment Alternative Registry (STAR Registry)|An Observational, Long-term Follow-up Study of Eligible Individuals Declining To Participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study (SCSSc-02)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|June 2005|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|69 Years|No|Non-Probability Sample|Participants with severe systemic sclerosis who are eligible for the SCOT study, but        either decline to participate or are denied insurance coverage, prior to randomization        will be invited to participate in this registry.|April 2015|April 15, 2015|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860548||142148|
NCT00861679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL-SCT-BFM-0321-08-HMO-CTIL|Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International|Therapy Protocol ALL SCT BFM International-Open, Multicenter, Controlled, Prospective Study for Therapy and Therapy Optimisation in Patients With Acute Lymphoblastic Leukemia (ALL) and an Indication for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|ALL SCT BFM|Hadassah Medical Organization|No|Recruiting|January 2007|September 2014|Anticipated|September 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|552|||Both|N/A|18 Years|No|||March 2009|March 15, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861679||142062|
NCT00861367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/08|Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate|Prospektive Doppel-Blind-randomisierte Studie Zur Verwendung Von Aspirin Bei Transurethralen Operationen||University Hospital, Basel, Switzerland|No|Withdrawn|September 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|March 12, 2009||No|difficult enrollment, focus of study no longer of interest|No||https://clinicaltrials.gov/show/NCT00861367||142086|
NCT00861653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-31|Atherosclerotic Plaque Characterization|Atherosclerotic Plaque Characterization Using Multispectral, Multicontrast High Resolution Cardiovascular Magnetic Resonance Imaging|APC|Piedmont Healthcare|No|Completed|October 2006|July 2013|Actual|August 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Serum and tissue samples are collected for markers of inflammation and gene chip analysis|Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with atherosclerosis|April 2014|April 14, 2014|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00861653||142064|
NCT00861666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23892|Forgiveness-Based Writing to Prevent Post-Traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans|Forgiveness-Based Writing to Prevent Posttraumatic Stress Disorder in OEF/OIF Veterans||South Central VA Mental Illness Research, Education & Clinical Center|No|Recruiting|October 2008|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|64 Years|No|||June 2009|June 1, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861666||142063|
NCT00861939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B032032|To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions||Sandoz||Completed|March 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|58 Years|Accepts Healthy Volunteers|||March 2009|March 13, 2009|March 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861939||142042|
NCT00862264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA/PR/033011/005/04|Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma|A 12-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Mild to Moderate Persistent Asthma||Chiesi Farmaceutici S.p.A.|No|Completed|August 2004|September 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|70 Years|No|||February 2012|February 14, 2012|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00862264||142019|
NCT00862914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006|Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi|||Ruhr University of Bochum|No|Completed|July 2008|March 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples With DNA|Paraffin embedded melanocytic skin lesion|Both|18 Years|N/A|No|Non-Probability Sample|dermatologic primary care clinic|October 2012|October 15, 2012|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862914||141970|
NCT00862927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0544|Cue Reactivity in Virtual Reality: The Role of Context|Cue Reactivity in Virtual Reality: The Role of Context||M.D. Anderson Cancer Center|No|Terminated|March 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Smokers, 18 years of age or older.|June 2012|June 19, 2012|March 16, 2009||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT00862927||141969|
NCT00862940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10112|A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease|A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease||H. Lundbeck A/S|No|Completed|September 2005|April 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|277|||Both|50 Years|N/A|No|||August 2012|August 29, 2012|March 16, 2009||No||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00862940||141968|
NCT00863252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roche-ST-01|Mycophenolate Mofetil for IgA Nephropathy|A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade||The University of Hong Kong|No|Completed|March 2002|March 2009|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||March 2009|March 16, 2009|March 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00863252||141944|
NCT00863265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANUSU-phyto3|Phytosterols, Ezetimibe, and Cholesterol Metabolism|Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)|Phyteaux-III|Washington University School of Medicine|Yes|Completed|June 2009|February 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863265||141943|
NCT00863629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-4546789|Tight Glycemic Control Increases Cardiac Stem Cells During Acute Myocardial Infarction|Tight Glycemic Control Increases Cardiac Stem Cells and Reduces Heart Remodeling During Acute Myocardial Infarction in Hyperglycemic Patients||Second University of Naples|Yes|Completed|January 2001|January 2009|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|65|||Both|40 Years|70 Years|No|||March 2009|March 17, 2009|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863629||141915|
NCT00863642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12935-01|Early Versus Delayed Surgery for Gallstone Pancreatitis|Early Versus Delayed Surgery for Gallstone Pancreatitis: A Prospective Randomized||Los Angeles Biomedical Research Institute|Yes|Completed|November 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2011|September 25, 2011|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863642||141914|
NCT00831220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI04/1946|Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease|Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease||Hospital Universitari Son Dureta|No|Completed|March 2005|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|99|Samples Without DNA|Plasma and serum.|Male|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with an exacerbation of COPD admitted to our hospital, stable COPD recruited in        an ambulatory basis, smokers or former smokers and never smokers recruited in our        laboratory.|January 2009|January 27, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00831220||144367|
NCT00863174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOX_21_1477_09|A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of SPARC_147709- Test and Reference, 2mg/ml (30 mg/m2 Dose) in Patients With Multiple Myeloma||Sun Pharma Advanced Research Company Limited|No|Completed|November 2010|April 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863174||141950|
NCT00864188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.29.NRC|The Influence of Probiotics in a Drinkable Yogurt on Skin Health|Phase 1 The Influence of Probiotics in a Drinkable Yogurt on Skin Health||Nestlé|No|Completed|February 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|207|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||September 2009|May 15, 2013|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00864188||141873|
NCT00864201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAH-CTD-2007|A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease|A Pilot Study to Evaluate the Effect of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease||McMaster University|No|Not yet recruiting|April 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2009|March 17, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864201||141872|
NCT00864552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11145|International PMS Study - KOGENATE Bayer|International PMS Study - KOGENATE Bayer||Bayer|No|Completed|December 2002|December 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Male|N/A|N/A|No|Non-Probability Sample|Patients with severe haemophilia A (<2% FVIII:C baseline level) treated with Kogenate        Bayer as their only source of recombinant FVIII|June 2009|June 29, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864552||141845|
NCT00864565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02348|A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System|Randomized, 2-way Crossover, Bioequivalence Study of Fentanyl 25 μg/h Transdermal System and Duragesic 25 μg/h Transdermal System Administrated as 1 x 25 μg/h Single Application in the Healthy Subjects||Actavis Inc.|No|Completed|June 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864565||141844|
NCT00860288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237B2224|Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes|||Novartis||Completed|February 2009|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1988|||Both|18 Years|78 Years|No|||January 2013|January 3, 2013|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00860288||142168|
NCT00860301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Landgren|Acupuncture in Infantile Colic|Acupuncture in Infantile Colic - a Randomised Controlled Double Blind Clinical Study||Lund University|No|Completed|December 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|90|||Both|N/A|8 Weeks|No|||March 2009|March 11, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860301||142167|
NCT00861055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU0901|Neonatal Sepsis and GBS Carriage Study|A Clinical and Microbiological Study of Early Onset Neonatal Sepsis in Refugee Infants and Group B Streptococcal Carriage in Expectant Refugee Mothers Living on the Thai-Burmese Border|NSS|University of Oxford|No|Recruiting|March 2009|December 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|||Both|N/A|N/A|No|Non-Probability Sample|All expectant mothers who follow ANC care at SMRU Maela Refugee Camp and their infants.|January 2010|January 22, 2010|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861055||142109|
NCT00860574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2272.00|Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia|A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL)||Fred Hutchinson Cancer Research Center|Yes|Completed|February 2009|||February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|N/A|60 Years|No|||October 2013|October 29, 2013|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860574||142146|
NCT00860847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wakunaga of America Co., Ltd.|Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)|Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)||Los Angeles Biomedical Research Institute|Yes|Completed|May 2009|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Male|35 Years|84 Years|No|||February 2015|February 28, 2015|March 11, 2009||No||No|January 27, 2013|https://clinicaltrials.gov/show/NCT00860847||142125|
NCT00861393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-08-06|Cognitive Behavioural Therapy (CBT) For Improving Emotional Well Being in Spinal Cord Injuries (SCI)|The Impact of a Brief Cognitive Behavior Therapy Intervention Aimed at Improving Emotional Well-Being and Quality of Life for Individuals With Spinal Cord Injuries|CBT|Toronto Rehabilitation Institute|No|Active, not recruiting|February 2009|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861393||142084|
NCT00861406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0816|Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine|An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients With Resected, Intermediate-Thickness, Node-Negative Melanoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|March 2009|||March 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 23, 2015|March 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861406||142083|
NCT00861952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCNM-0901|Neuragen for Peripheral Diabetic Neuropathy|The Safety and Efficacy of Neuragen in Diabetic Peripheral Neuropathy: A Double-blind Randomized Placebo Controlled Trial||The Canadian College of Naturopathic Medicine|Yes|Withdrawn|January 2010|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|March 13, 2009|Yes|Yes|Study has received ethics approval, however funding limitations have resulted in suspending    date of commencement.|No||https://clinicaltrials.gov/show/NCT00861952||142041|
NCT00862277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA64|Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine|Evaluation of the Persistence of Bactericidal Antibodies in Adolescents and Adults Who Received a Single Dose of Menactra® Four to Eight Years Earlier||Sanofi|No|Completed|December 2008|December 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|763|||Both|14 Years|27 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects that previously received only one dose of meningococcal vaccine, Menactra® in        Study MTA04, MTA12, MTA19 (NCT00777790), or MTA21 (NCT00777257); or Menomune® in Study        MTA04 and age-matched meningococcal vaccine-naive controls.|January 2014|January 10, 2014|March 13, 2009|Yes|Yes||No|December 11, 2010|https://clinicaltrials.gov/show/NCT00862277||142018|
NCT00862290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|microRNA_sepsis|Circulating microRNAs as Biomarkers of Sepsis|Diagnostic and Predictive Value of Circulating microRNAs During Sepsis||Changhai Hospital|Yes|Completed|August 2008|June 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|100|Samples Without DNA|Blood of septic patients is collected on the second day when they are diagnosed with sepsis      in ICU. Blood of SIRS patients is collected on the second day when they are diagnozed with      SIRS after cardiac surgery with cardiopulmonary bypass.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients who develop sepsis and SIRS|May 2013|May 2, 2013|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862290||142017|
NCT00862602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DK071552|Pedometers for Gestational Diabetes|Type 2 Diabetes Risk in Women With Gestational Diabetes|PEG|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Active, not recruiting|July 2009|April 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2010|September 9, 2010|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862602||141993|
NCT00862615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0048|Relationships Between Quality of Ageing and Age-related Degenerated Disease (Compalimage)|Chronic Micro-inflammation and Bone and Muscular Status in Elderly|Compalimage|University Hospital, Clermont-Ferrand||Recruiting|January 2009|January 2011|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|32|||Male|65 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 28, 2010|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00862615||141992|
NCT00863291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFDR-001-07|A Double-Blind Study of Buprenorphine Treatment of Acute Suicidality|Phase 3 Study of the Effects of Buprenophine as Add-on Treatment to Antidepressants in Treating Acutely Suicidal Depressed Inpatients||Abarbanel Mental Health Center|Yes|Active, not recruiting|November 2007|November 2008|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||March 2009|March 16, 2009|March 15, 2009||||No||https://clinicaltrials.gov/show/NCT00863291||141941|
NCT00863304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091018|Tanezumab in Osteoarthritis of the Hip or Knee (2)|A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study of the Analgesic Efficacy And Study of Tanezumab in Patients With Osteoarthritis Of The Hip or Knee||Pfizer|Yes|Completed|May 2009|June 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|849|||Both|18 Years|N/A|No|||May 2011|May 2, 2011|March 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863304||141940|
NCT00863278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-13|Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser|Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser; a Comparative Prospective Study||Centre Hospitalier Universitaire de Nice|No|Terminated|March 2009|December 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|75 Years|No|||June 2009|March 23, 2012|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863278||141942|
NCT00863993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004359|Energy Expenditure and Gastric Bypass Surgery|Energy Expenditure and Gastric Bypass Surgery||Mayo Clinic|Yes|Withdrawn|October 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|60 Years|No|Non-Probability Sample|40 healthy patients (M=F, aged 18-60 years) undergoing gastric bypass bariatric surgery        will be recruited.|February 2015|February 11, 2015|March 17, 2009||No|no patients enrolled.|No||https://clinicaltrials.gov/show/NCT00863993||141888|
NCT00864006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1294|Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions||Sandoz||Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 17, 2009|March 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00864006||141887|
NCT00831610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP-712/06|Post-bariatric Abdominoplasty: Skin Sensation Evaluation|Post-bariatric Abdominoplasty: Skin Sensation Evaluation.||Federal University of São Paulo|Yes|Completed|August 2006|December 2010|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Female|25 Years|55 Years|No|||May 2012|May 25, 2012|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831610||144339|
NCT00864214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-006363|A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone|A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone|HRT|Mayo Clinic|Yes|Completed|June 2008|April 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00864214||141871|
NCT00864578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRONEK-MTMT|Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy|Effects of the Oral Administration of an Association of Forskolin With Rutin and Vitamins B on Intraocular Pressure (IOP) in Patients Affected by Primary Open Angle Glaucoma (POAG) Under Maximun Tolerated Medical Therapy (MTMT)||Sooft Italia|Yes|Withdrawn|April 2009|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|30 Years|70 Years|No|Probability Sample|Patients affected by POAG and already under observation in the centers that take part in        this study|June 2012|June 5, 2012|March 17, 2009||No|loss of interest before enrolment started|No||https://clinicaltrials.gov/show/NCT00864578||141843|
NCT00860340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xMUO-02|Hemodynamic Effects of Spironolactone in Patients With Heart Failure|Hemodynamic Effects of Spironolactone in Patients With Heart Failure||University of Toledo Health Science Campus|No|Completed|February 2003|October 2006|Actual|October 2006|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|80 Years|No|||December 2014|December 9, 2014|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860340||142164|
NCT00860353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1570C00001|Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551|A Double Blind, Randomised, Placebo-controlled, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single, Ascending, Oral Doses of AZD2551 in Healthy Male Subjects||AstraZeneca|No|Terminated|February 2009|May 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|90|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|March 11, 2009||No|Due to portfolio and logistical issues, this study will not be re-started at the present time.    The study is not being terminated for safety reasons.|No||https://clinicaltrials.gov/show/NCT00860353||142163|
NCT00860015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB4160|Alimta Plus Gemcitabine for Advanced Sarcoma|Alimta Plus Gemcitabine as Chemotherapy for Patients With Advanced Sarcoma: A Phase II Clinical||Columbia University|Yes|Completed|August 2005|April 2012|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|March 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860015||142189|
NCT00860028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-O'Malley-P50AA15632-2009|Varenicline for Smoking Cessation in Heavy Drinking Smokers|Varenicline for Smoking Cessation in Heavy Drinking Smokers||Yale University|Yes|Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||January 2013|January 28, 2013|March 10, 2009|Yes|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT00860028||142188|
NCT00860314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE-2383|Antero-posterior Versus Antero-lateral Electrode Position for Electrical Cardioversion of Typical Atrial Flutter|Prospective, Randomized Single-center Study for Efficacy of Antero-posterior and Antero-lateral Electrode Position for External Electrical Cardioversion of Typical Atrial Flutter|APOVERSAL|Universitätsklinikum Hamburg-Eppendorf|No|Terminated|January 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|November 10, 2008||No|Statistical interim analysis showed valid and significant results|No|November 10, 2008|https://clinicaltrials.gov/show/NCT00860314||142166|
NCT00860327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007244|Examining Developmental Changes in Heart Contractions of Children With Congenital Heart Defects|Excitation-contraction Coupling in Human Ventricle Development||Emory University|No|Recruiting|December 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Ventricular tissue, that would have been discarded, and was removed during surgery as part      of the necessary repair for congenital heart defects|Both|N/A|1 Year|No|Non-Probability Sample|Children undergoing surgery for repair of congenital heart defects.|January 2016|January 8, 2016|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860327||142165|
NCT00861081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-08-07-019-01|Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to "Stay Within the Guidelines"|RCT of an Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to "Stay Within the Guidelines" (SUSTAIN)|SUSTAIN|University of California, Los Angeles|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|410|||Both|40 Years|N/A|No|||January 2014|January 6, 2014|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861081||142107|
NCT00861094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595050|Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer|Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.||UNICANCER|Yes|Completed|March 2008|December 2012|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861094||142106|
NCT00861380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111442|Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease|Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease|FinIP|GlaxoSmithKline||Completed|May 2009|October 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|41188|||Both|6 Weeks|18 Months|Accepts Healthy Volunteers|||November 2013|November 7, 2013|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861380||142085|
NCT00861718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1151C00003|Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7268 When Given in Multiple Ascending Oral Doses in Healthy Subjects||AstraZeneca|No|Completed|April 2009|October 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 9, 2009|March 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861718||142059|
NCT00861731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOUSS-Nefologia-001|Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy|The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy|VICTORY|Azienda Ospedaliero Universitaria di Sassari|Yes|Active, not recruiting|November 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|No|||April 2009|April 27, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861731||142058|
NCT00861692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARG-E07|Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II|An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy||Mitsubishi Tanabe Pharma Corporation|No|Completed|April 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 12, 2009||No||No|November 17, 2015|https://clinicaltrials.gov/show/NCT00861692||142061|
NCT00861705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01172|Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery|Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer||National Cancer Institute (NCI)||Completed|May 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|454|||Both|18 Years|N/A|No|||August 2015|September 28, 2015|March 12, 2009|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00861705||142060|
NCT00861965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-001-HM|Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match Alternative to Allogeneic Transplant for Blood Cancers|A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStimTM) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning||Immunovative Therapies, Ltd.|No|Withdrawn|January 2010|||November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 12, 2009|Yes|Yes|withdrawn due to poor recruitment|No||https://clinicaltrials.gov/show/NCT00861965||142040|
NCT00862303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fuzhough0938|DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma|Study of Autologous Dendritic Cells (DC) Loaded With Autologous Tumor Lysate (DC-Vaccine) in Combination With Cytokine-Induced Killer Cell (CIK) in Patients With Renal Cell Cancer||Fuzhou General Hospital|Yes|Recruiting|March 2009|December 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2009|March 7, 2011|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862303||142016|
NCT00862953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWO08-002|Study to Assess the Effects of High Protein Diet in Obesity, the LOWER Study|The Lifestyle, OverWeight, Energy Restriction Study|LOWER|University Medical Center Groningen|No|Completed|July 2008|October 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|317|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2012|February 19, 2012|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862953||141967|
NCT00862966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMC-02-139|Central Venous Catheter Lock Solution|Randomized Control Trial on Citrate as the Central Venous Catheter Lock Solution|CVCLS|University Medical Center, Tuzla|No|Not yet recruiting|April 2009|||April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|N/A|No|||March 2009|March 13, 2009|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862966||141966|
NCT00863317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDP-01|Trial of Montelukast for Treatment of Acute Bronchiolitis|A Randomized, Double Blind, Placebo Controlled Trial of Daily Montelukast for the Treatment of Viral Bronchiolitis||Medical College of Wisconsin|No|Completed|December 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|3 Months|12 Months|No|||June 2015|June 19, 2015|March 16, 2009|Yes|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT00863317||141939|
NCT00863330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636885|Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma|A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma||Aurora Health Care|Yes|Terminated|February 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|March 17, 2009|Yes|Yes|administrative decision- PI retired and treating physician left the institution|No|December 3, 2014|https://clinicaltrials.gov/show/NCT00863330||141938|Study was ended early, before substantial data could be collected, due to Investigators retiring/leaving the institution.
NCT00863655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001Y2301|Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole|A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole|BOLERO-2|Novartis|Yes|Completed|June 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|724|||Female|18 Years|N/A|No|||November 2015|November 25, 2015|March 16, 2009|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00863655||141913|
NCT00864019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-683-1G|A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fed Conditions||Actavis Inc.|No|Completed|August 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864019||141886|
NCT00864032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STS Sorafenib|Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall|Phase I/II Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall||University of California, Davis|Yes|Completed|March 2009|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|March 17, 2009|Yes|Yes||No|January 15, 2013|https://clinicaltrials.gov/show/NCT00864032||141885|
NCT00831623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58116|Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer|Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-risk Prostate Cancer||Loma Linda University|Yes|Recruiting|March 2009|June 2025|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Male|18 Years|N/A|No|||March 2016|March 14, 2016|January 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831623||144338|
NCT00864591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5654-OG-CTIL|Stress Adenosine Cardiac Magnetic Resonance (MR) Comparison With Single Photon Emission Computed Tomography (SPECT) Imaging|Stress Adenosine Cardiac MR Comparison With SPECT Imaging||Sheba Medical Center|No|Not yet recruiting|April 2009|October 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.        The study group will include patients with either normal undergoing SPECT stress imaging        or with mild to severe ischemia, to include the entire spectrum of coronary artery        disease.        Patients will be pre selected and evaluated by a non-dependent cardiologist in order to        verify that patients in whom the repeat stress might pose a serious risk will be excluded        from the study.|March 2009|March 17, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00864591||141842|
NCT00864604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-492|Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers|Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers||Actavis Inc.|No|Completed|April 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864604||141841|
NCT00860041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N08C1|Acute Pain Caused by Paclitaxel in Patients With Cancer|Paclitaxel-Associated Acute Pain Syndrome Natural History Study||Alliance for Clinical Trials in Oncology|No|Completed|February 2009|May 2013|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|306|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with cancer who are planning to receive paclitaxel IV at least 175        mg/m^2 at 2-4 week intervals (course duration of 2, 3, or 4 weeks, respectively) or 70-90        mg/m^2 weekly (3 out of 4 weeks allowed).|July 2015|July 7, 2015|March 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860041||142187|
NCT00860054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC25025|Addition of Phytosterols to a Low Phytosterol Diet|Regulation of Cholesterol Absorption: Dose Response of LDL to Phytosterols Added to a Phytosterol-Poor Diet|phyteaux-I|Washington University School of Medicine|No|Completed|March 2006|October 2008|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2012|April 17, 2012|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860054||142186|
NCT00860587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bakki|Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections|Risk Factors for Colonization and Infection With Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections (IAI). An Open Observational Study|Bakki|University Hospital, Linkoeping|No|Active, not recruiting|February 2006|October 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with evidence of severe intra-abdominal infections.|March 2009|March 11, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860587||142145|
NCT00860600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP014|Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients|The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)||PhytoHealth Corporation|No|Completed|September 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2012|November 3, 2015|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00860600||142144|
NCT00860860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUNMC-PRIT2008|Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer|Phase I Clinical Study of the Feasibility of Pretargeted Radioimmunotherapy of an Anti-CEA Bispecific Antibody and Lu-177-labeled Peptide in Patients With Advanced Colorectal Cancer|PRIT2008|Radboud University|Yes|Completed|July 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2010|March 16, 2012|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860860||142124|
NCT00860873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGSEMS1108|Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis|Randomized Study of Two Dosage Forms (Oral Powder and Capsule) of "Chondroitin + Glucosamine Sulfate" Produced by the Laboratory EMS When Compared to the Product Condroflex (Oral Powder and Capsules) Produced by Laboratory Zodiac in the Treatment of Osteoarthrosis.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|October 2009|November 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|280|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|November 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00860873||142123|
NCT00861107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-002-CRYO|In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation|Phase I/II Study of a Therapeutic Cancer Vacccine Created In-situ in Patients With Refractory or Metastatic Cancer||Immunovative Therapies, Ltd.|No|Completed|August 2009|May 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|March 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861107||142105|
NCT00861419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050170|To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.|An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors||Amgen||Completed|December 2005|September 2012|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|88|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|March 12, 2009||||No||https://clinicaltrials.gov/show/NCT00861419||142082|
NCT00861744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111870|Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age|Immunogenicity of GlaxoSmithKline Biologicals' MMR Vaccine (209762) vs. M-M-R® II, When Co-administered With Hepatitis A, Varicella and Pneumococcal Conjugate Vaccines to Children 12-15 Months of Age||GlaxoSmithKline||Completed|June 2009|May 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1259|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||September 2013|June 5, 2014|March 12, 2009|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT00861744||142057|
NCT00861978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160DE0838A|St. John's Wort Extract LI 160 for the Treatment of Atypical Depression|||Cassella-med GmbH & Co. KG|Yes|Completed|December 2002|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|70 Years|No|||March 2009|March 13, 2009|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00861978||142039|
NCT00862316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA4|Oxford Unicompartmental Knee Arthroplasty With and Without Navigational Unit|Outcome Analysis of the Oxford Unicompartmental Knee Arthroplasty With and Without the Assistance of a Computer Navigational Unit||Biomet, Inc.||Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|No|||February 2012|February 11, 2012|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00862316||142015|
NCT00862329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURPROL|Influence of Protein Source on Satiety and Metabolism|||Institut National de la Recherche Agronomique|Yes|Completed|March 2008|November 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|120|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 21, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862329||142014|
NCT00862628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO-003|The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries|||Nagoya University||Not yet recruiting|October 2009|October 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|85 Years|No|||September 2009|September 18, 2009|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862628||141991|
NCT00862641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3606-CL-3001|A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease|A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD).||Astellas Pharma Inc|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|1009|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|March 15, 2009|Yes|Yes||No|November 15, 2010|https://clinicaltrials.gov/show/NCT00862641||141990|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00862979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE14|A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients|A 15-month, Multi-center, Randomized, Open-label, Parallel Group Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Regimen (Everolimus and Mycophenolic Acid) Versus a Standard Regimen (Cyclosporine A and Everolimus) in de Novo Heart Transplant Recipients|MANDELA|Novartis|Yes|Recruiting|February 2009|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00862979||141965|
NCT00863707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3606-CL-3010|A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment|A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment||Astellas Pharma Inc|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|511|||Both|18 Years|N/A|No|||May 2012|May 11, 2012|March 16, 2009|Yes|Yes||No|December 28, 2010|https://clinicaltrials.gov/show/NCT00863707||141909|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00863668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901M57887|Raltegravir Activity In Lymphoid Tissues|Decay Kinetics of HIV With the Integrase Inhibitor Raltegravir||University of Minnesota - Clinical and Translational Science Institute|Yes|Withdrawn|March 2009|March 2011|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|March 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863668||141912|
NCT00863681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12935|BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension|Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)|PATENT-2|Bayer|Yes|Active, not recruiting|March 2009|April 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|396|||Both|18 Years|80 Years|No|||January 2016|January 19, 2016|March 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863681||141911|
NCT00864370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046058|Bipolar Disorder (BPD) in Pregnancy: Predictors of Morbidity|Bipolar Disorder in Pregnancy: Predictors of Morbidity||Emory University|Yes|Completed|May 2005|June 2013|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|237|Samples With DNA|Plasma, serum and urine samples are processed and stored at each research visit.|Female|18 Years|45 Years|No|Non-Probability Sample|Women of child bearing potential meeting DSM-IV (Diagnostic and Statistical Manual - IV)        criteria for any subtype of Bipolar Disorder|November 2013|November 12, 2013|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00864370||141859|
NCT00864682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06091|Preventing Propofol-associated Injection Pain|Propofol Mixed With Lidocaine Versus Lidocaine Pretreatment With Tourniquet for Alleviation of Pain Associated With Propofol Injection||Benaroya Research Institute|Yes|Completed|January 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|156|||Both|18 Years|80 Years|No|||February 2012|February 4, 2012|March 16, 2009|Yes|Yes||No|March 24, 2009|https://clinicaltrials.gov/show/NCT00864682||141835|
NCT00831636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-204|A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer|A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer||Clavis Pharma|No|Completed|April 2008|April 2010|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||September 2013|September 12, 2013|January 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831636||144337|
NCT00864266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01082|Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer|Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer : a Prospective Study||European Lung Cancer Working Party|Yes|Recruiting|March 2009|March 2021|Anticipated|March 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00864266||141867|
NCT00864279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-432|A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers||Actavis Inc.|No|Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864279||141866|
NCT00864617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0100|A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|May 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|84|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864617||141840|
NCT00860067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP185|A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age|A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age|MI-CP185|MedImmune LLC|Yes|Completed|March 2009|October 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1800|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|March 9, 2009|Yes|Yes||No|June 10, 2011|https://clinicaltrials.gov/show/NCT00860067||142185|
NCT00860379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-001176|The Effect of Selenium Supplementation Among Pediatric Patients With Burns|The Effect of Selenium Supplementation Among Pediatric Patients With Burns||Shriners Hospitals for Children|Yes|Recruiting|January 2009|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|75|||Both|1 Year|18 Years|No|||October 2015|October 7, 2015|March 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00860379||142161|
NCT00860366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URICOICTUS-1-2007|Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke|Randomized, Double Blind Study Assessing the Clinical Efficacy of Combined Treatment With Uric Acid and rtPA Administered Intravenously in Acute Ischemic Stroke Patients Within the First 4.5 Hours of Symptoms Onset|Urico-Ictus|Fundacion Clinic per a la Recerca Biomédica|Yes|Completed|June 2011|October 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860366||142162|
NCT00860613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212250-02091|Medical Nutrition Therapy Program for Pregnant Women With Diabetes|Medical Nutrition Therapy Program for Pregnant Women With Diabetes: Evaluation of Two Different Dietary Strategies on Metabolic Control, Maternal and Fetal Nutritional Status and Cost Effectiveness.||Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes|No|Completed|February 2004|December 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|162|||Female|18 Years|45 Years|No|||March 2009|March 11, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860613||142143|
NCT00861120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007799-13|Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type|Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-type|PaLiDo|Vejle Hospital|Yes|Completed|April 2009|August 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Female|18 Years|N/A|No|||October 2012|October 25, 2012|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861120||142104|
NCT00861133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-008|Cryptogenic Stroke Study|Long-Term Cardiac Monitoring for Detection of Atrial Fibrillation After Cryptogenic Stroke||Transoma Medical|Yes|Recruiting|March 2009|May 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2009|May 4, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861133||142103|
NCT00861432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2341|Evaluation of Questionnaires of Tumor Patients With and Without Additive Homeopathic Therapy|Evaluation of Quality of Life of Tumor Patients With and Without Additive Homeopathy.||Medical University of Vienna|No|Completed|December 2008|April 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||December 2011|December 28, 2011|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861432||142081|
NCT00861757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10487|Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia|A Phase 3, Randomized, Double Blind, Placebo and Tamsulosin Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil Once a Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|612|||Male|45 Years|N/A|No|||June 2011|June 23, 2011|March 12, 2009|Yes|Yes||No|May 10, 2011|https://clinicaltrials.gov/show/NCT00861757||142056|
NCT00861991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT2009|Enhancing Empathy in Medical Communication Through Perspective-Taking|Enhancing Empathy in Medical Communication Through Perspective-Taking||George Washington University|Yes|Completed|June 2006|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|608|||Both|20 Years|45 Years|No|||March 2009|March 13, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00861991||142038|
NCT00862342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2008-0487|Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)|Efficacy and Safety of Second-line Combination Chemotherapy With Avastin in Patients With Metastatic Colorectal Cancer Who Have Received First-line Chemotherapy Plus Avastin|SAFE|Asan Medical Center|No|Completed|January 2009|June 2012|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862342||142013|
NCT00862355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOX_2I_1476_09|Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer|||Sun Pharma Advanced Research Company Limited|No|Completed|March 2010|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Female|18 Years|N/A|No|||June 2012|March 8, 2016|March 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00862355||142012|
NCT00862654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29079|Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis|Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis|Escape|Galderma|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|326|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|March 15, 2009||No||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00862654||141989|
NCT00862667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0871002|A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers.|B0871002|Pfizer|No|Completed|May 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 23, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00862667||141988|
NCT00863343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-ITPOC-01|Clinical Validation of the Point-of-Care MSD Influenza Test|Clinical Validation of the Point-of-Care MSD Influenza Test||Meso Scale Diagnostics, LLC.|No|Terminated|March 2010|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|391|Samples With DNA|Viral transport media containing nasal swab extract.|Both|N/A|N/A|No|Non-Probability Sample|Individuals visiting a primary care site.|January 2012|January 30, 2012|March 16, 2009|Yes|Yes|Funding of study was exhausted prior to completion of study|No|August 5, 2011|https://clinicaltrials.gov/show/NCT00863343||141937|
NCT00863694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|calpro|Fecal Calprotectin in Cystic Fibrosis|Fecal Calprotectin in Cystic Fibrosis||Medical College of Wisconsin|No|Completed|February 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|Samples Without DNA|stool|Both|1 Month|N/A|No|Non-Probability Sample|Patients attending the cystic fibrosis clinics at the Children's Hospital of Wisconsin and        Froedtert Hospital|December 2013|December 12, 2013|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863694||141910|
NCT00863733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHI/050|Study of DMXAA (Now Known as ASA404) in Solid Tumors|Phase I Trial of 5,6 Dimethylxanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors|DMXAA|Cancer Research UK|No|Completed|May 1996|March 2000|Actual|March 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||March 2009|March 17, 2009|March 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863733||141908|
NCT00864058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-08117|A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions|A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions||Actavis Inc.|No|Completed|January 1998|January 1998|Actual|January 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864058||141883|
NCT00864045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11286|Sertindole in Asian Patients With Schizophrenia|A Randomised, Double-blind, Parallel-group, Flexible-dose Trial Evaluating the Efficacy and Safety of 12 Weeks of Treatment With Sertindole or Olanzapine in Patients With Schizophrenia in Asia||H. Lundbeck A/S|No|Completed|March 2007|May 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|394|||Both|18 Years|65 Years|No|||September 2013|September 19, 2013|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864045||141884|
NCT00864695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-21|Role of Anesthesiologist-Patient Relationship|Role of Anesthesiologist-Patient Relationship in Changing Postoperative Perception of Patients Admitted to a Teaching Hospital||UPECLIN HC FM Botucatu Unesp|Yes|Completed|May 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1137|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This descriptive-analytic study was based on opinions and information provided before and        after anesthesia by individuals who were hospitalized in the Botucatu Medical School        Hospital to undergo surgery under anesthesia. A questionnaire was used to determine        patient characteristics and perception of anesthesia/anesthesiologist, as well as fears        and concerns related to anesthesia.|March 2009|March 18, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864695||141834|
NCT00827411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080403|Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy|Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting|ARCTIC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2009|January 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2500|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00827411||144660|
NCT00864292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 001.1|Predictors of Neuro-cognitive Decline and Survival in HIV-infected Subjects|||South East Asia Research Collaboration with Hawaii|No|Completed|August 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|March 2009|May 2, 2011|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864292||141865|
NCT00864305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-09237|A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions|A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions||Actavis Inc.|No|Completed|December 1997|January 1998|Actual|January 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864305||141864|
NCT00864630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSBRI-NBFP01301|Neuroimaging for Depression|Objective Detection, Evaluation and Countermeasures for In-flight Depression||Massachusetts General Hospital|No|Terminated|September 2010|December 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|68|||Both|30 Years|60 Years|No|||May 2011|May 23, 2011|March 17, 2009||No|The study upon which this project depended for subjects and the intervention was terminated    prematurely due to lack of funds.|No||https://clinicaltrials.gov/show/NCT00864630||141839|
NCT00860405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE06-001-C P4|Voluven® in Paediatric Patients|Efficacy and Safety of 6 % Hydroxyethyl Starch 130/0.4 (Voluven®) vs. 5% HSA in Volume Replacement Therapy During Elective Open-heart Surgery in Paediatric Patients||Fresenius Kabi||Completed|March 2009|December 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|2 Years|12 Years|No|||October 2011|November 1, 2011|February 27, 2009|Yes|Yes||No|August 12, 2011|https://clinicaltrials.gov/show/NCT00860405||142159|
NCT00860392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-110|A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)|A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation||Merck Sharp & Dohme Corp.|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 24, 2015|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860392||142160|
NCT00860626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|interferonshorttermnucleoside|Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B|Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B||Sun Yat-sen University|No|Recruiting|January 2008|February 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|55 Years|No|||March 2009|March 11, 2009|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860626||142142|
NCT00860639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 06/10-I|Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk|Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk|LAM2006IR|Nantes University Hospital|Yes|Active, not recruiting|October 2007|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|327|||Both|18 Years|60 Years|No|||January 2016|January 28, 2016|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860639||142141|
NCT00860886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909078|Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer|Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2009|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|800|||Female|25 Years|44 Years|No|||March 2016|March 19, 2016|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860886||142122|
NCT00861146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Cooney-AA011197|Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk|Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk||Yale University|No|Completed|April 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|March 11, 2009||No||No|January 15, 2014|https://clinicaltrials.gov/show/NCT00861146||142102|
NCT00861159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-31|RLIP76 in Human Serum in Adults With Rheumatologic Diseases|Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.||University of North Texas Health Science Center|Yes|Withdrawn|September 2011|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The experimental populations subject to study will be 100 outpatients in the rheumatology        clinic otherwise undergoing routinely scheduled phlebotomy for standard clinical care        purposes.|January 2011|January 11, 2011|September 29, 2008||No|Study withdrawn due to lack of staffing resources and subject interest|No||https://clinicaltrials.gov/show/NCT00861159||142101|
NCT00861445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0614|A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy|A Randomized, Double-Blind Placebo Controlled Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy||UCB Pharma|Yes|Completed|June 2001|February 2003|Actual|January 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|65 Years|No|||July 2010|October 17, 2014|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861445||142080|
NCT00861458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121010|Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State|A Phase 1, Open-Label, Randomized, 3-Way Crossover Study In Healthy Subjects To Estimate The Pharmacokinetics Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State||Pfizer|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 6, 2009|March 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00861458||142079|
NCT00862368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL062165-09|Sustaining Smoking Cessation in Smokers With Kids With Asthma|Sustaining Cessation in Smokers With Kids With Asthma|PAQS2|The Miriam Hospital|Yes|Completed|October 2005|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|573|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 24, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862368||142011|
NCT00862680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0853|4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis|4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis||M.D. Anderson Cancer Center|No|Recruiting|March 2009|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862680||141987|
NCT00862992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A002-A3|Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia|Phase II Study of MP-214 in Patients With Schizophrenia (Exploratory Study)||Mitsubishi Tanabe Pharma Corporation|No|Completed|April 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|20 Years|65 Years|No|||September 2009|September 8, 2009|March 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00862992||141964|
NCT00863005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K201-I/280301BS|Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study|||Moberg Derma AB|No|Completed||||||Phase 1/Phase 2|Interventional|Intervention Model: Parallel Assignment|2||||||Both|18 Years|N/A|No|||November 2009|November 5, 2009|March 12, 2009||||No||https://clinicaltrials.gov/show/NCT00863005||141963|
NCT00863356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis||HemCon Medical Technologies, Inc|No|Completed|March 2009|June 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|October 29, 2012|March 16, 2009|Yes|Yes||No|October 29, 2012|https://clinicaltrials.gov/show/NCT00863356||141936|
NCT00828022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor469208ctil|Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer|A Single-Institution, Open-Label, Single-Arm phase1/2 Study of Measles Vaccine as Consolidation in Patients With Measles Virus-Positive, Stage 3B/4 Non-Small Cell Lung Cancer|SMC4692|Soroka University Medical Center|Yes|Not yet recruiting|March 2009|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||January 2009|January 22, 2009|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828022||144613|
NCT00828035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 03 39|Light Endoscopic Robot Use in Laparoscopic Surgery|Light Endoscopic Robot Use in Abdominal and Urological Laparoscopic Surgery||University Hospital, Grenoble|Yes|Completed|April 2008|April 2011|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00828035||144612|
NCT00828295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-07-29|Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients|A Multicenter, Double-blind, Randomized, Parallel Group, Stratified Study to Assess the Safety and Efficacy of Single IV Doses of Palonosetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients||Helsinn Healthcare SA|No|Completed|August 2008|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|N/A|16 Years|No|||July 2014|March 17, 2015|January 22, 2009|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT00828295||144592|
NCT00864071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3148|A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Female Subjects||Actavis Inc.|No|Completed|November 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864071||141882|
NCT00864383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMoxTB|Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis|A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis|REMoxTB|Global Alliance for TB Drug Development|Yes|Completed|January 2008|February 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1931|||Both|18 Years|N/A|No|||April 2015|May 7, 2015|March 17, 2009|Yes|Yes||No|March 10, 2015|https://clinicaltrials.gov/show/NCT00864383||141858|
NCT00828620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s51276 - ML5241|Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project|Imaging for Early Response Prediction to EGF-receptor Blocking Monoclonal Antibodies in Combination Therapy for Colorectal Cancer||Universitaire Ziekenhuizen Leuven|Yes|Terminated|January 2009|June 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Probability Sample|unresectable stage IV colorectal cancer pathologically proven measurable disease (RECIST)        K-RAS wild type Eligible for 3rd line Irinotecan + Cetuximab Able for tolerate PET/CT        imaging Serum glucose < 200mg/dl|June 2012|August 9, 2012|January 23, 2009||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00828620||144567|
NCT00827710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ 290-2006-000-20|Automated Diabetes Registry Tools to Enhance Patient Self-Management and Provider Performance Feedback|||Denver Health and Hospital Authority|Yes|Completed|December 2007|May 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|5457|||Both|18 Years|75 Years|No|||April 2012|April 29, 2012|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00827710||144637|
NCT00864643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-475-011|Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 (100 mg) Vs Placebo When Coadministered With Atorvastatin (10 or 20 mg) in Subjects With Primary Hypercholesterolemia||Takeda|No|Completed|September 2004|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|79 Years|No|||May 2012|May 23, 2012|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00864643||141838|
NCT00860080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHSU01|Safety Study Investigating Local Tolerability and Pharmacokinetics of PXL01 in Healthy Volunteers|A First in Man, Phase I, Single-blind, Placebo-controlled Study Investigating the Local Tolerability, Safety and Pharmacokinetics in Three Doses of PXL01 and Placebo in 15 Healthy Volunteers||PharmaSurgics AB|Yes|Completed|March 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2010|April 22, 2010|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860080||142184|
NCT00860418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR010546|Pediatric Asthma Alert Intervention for Minority Children With Asthma|Pediatric Asthma Alert Intervention for Minority Children|PAAL|Johns Hopkins University|Yes|Completed|September 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|350|||Both|3 Years|10 Years|No|||June 2011|August 31, 2015|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860418||142158|
NCT00860652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 08.03|Radiotherapy - Adjuvant Versus Early Salvage|Radiotherapy - Adjuvant Versus Early Salvage. A Phase III Multi-centre Randomised Trial Comparing Adjuvant Radiotherapy (RT) With Early Salvage RT in Patients With Positive Margins or Extraprostatic Disease Following Radical Prostatectomy.|RAVES|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Active, not recruiting|March 2009|December 2026|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|333|||Male|18 Years|N/A|No|||January 2016|January 18, 2016|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860652||142140|
NCT00860899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1860|Postoperative Pain and SIRS After Preoperative Analgesia With Clonidine or Levobupivacaine|Postoperative Pain and Systemic Inflammatory Stress Response (SIRS) After Preoperative Analgesia With Clonidine or Levobupivacaine|PPSAPACL|University Hospital Dubrava|No|Completed|December 2007|May 2009|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|42 Years|77 Years|No|||November 2011|November 16, 2011|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860899||142121|
NCT00861172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.532|Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy|Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy|IRM 3T-SEP|Hospices Civils de Lyon|Yes|Completed|February 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|50 Years|No|||June 2013|June 20, 2013|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861172||142100|
NCT00861471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 04-47 (H12554)|Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer|Phase I/II, Open Label Study of Sequential Taxotere® (Docetaxel) and Gleevec® (Imatinib Mesylate) in Hormone Refractory Prostate Cancer||New York University School of Medicine|Yes|Terminated|May 2005|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|N/A|No|||August 2011|August 17, 2011|March 12, 2009|Yes|Yes|due to slow accrual|No|April 29, 2011|https://clinicaltrials.gov/show/NCT00861471||142078|This study was terminated before it reached the target accrual number due to slow accrual, leading to small number of subjects analyzed (12 out of the target number of 37).
NCT00861484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111155|Proof of Mechanism in ELT|A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation|PoM|GlaxoSmithKline|No|Completed|November 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Male|18 Years|50 Years|No|||June 2015|June 1, 2015|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861484||142077|
NCT00831129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14863B (SIROCO)|A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs|Effects of Simvastatin and Rosiglitazone Combination in Patients With the Metabolic Syndrome.|SIROCO|University of Chicago|No|Completed|September 2006|April 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|53|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|January 26, 2009|Yes|Yes||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00831129||144374|
NCT00844493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR259|Low-dose Challenge Model With Enterotoxigenic E Coli|Validation of Low-dose ETEC Challenge Model in U.S. Adults and Re-challenge of Immune Subjects With a Homologous ETEC Strain (H10407)||Johns Hopkins Bloomberg School of Public Health|No|Completed|February 2009|June 2013|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|September 11, 2014|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00844493||143363|
NCT00844506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISA-P53-CTX|p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer|p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial|ISA-P53-CTX|University Medical Center Groningen|Yes|Completed|October 2008|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Female|18 Years|N/A|No|||February 2011|February 24, 2011|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844506||143362|
NCT00844857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12116|A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression|Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder||Eli Lilly and Company|No|Completed|April 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|291|||Both|10 Years|17 Years|No|||January 2013|January 16, 2013|February 13, 2009|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00844857||143336|
NCT00845130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11119|Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes|Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes||University of Kansas Medical Center|Yes|Active, not recruiting|September 2009|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845130||143315|
NCT00845390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR #08033561|Patient Expectations After Implantable-cardioverter Defibrillator (ICD) Implantation|Patient Expectations After ICD Implantation||University of California, San Francisco|Yes|Completed|December 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|ICD Clinic patients|April 2012|April 26, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845390||143295|
NCT00845403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB D/08/376|Antigen-specific Immune Response to Hepatitis B Virus in Utero|Antigen-specific Immune Response to Hepatitis B Virus and Influenza A (H1N1 Strain) in Utero||National University Hospital, Singapore|Yes|Recruiting|September 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Cord Blood of HBsAg+ mothers will be collected at delivery after seeking informed consent.      Mononuclear cells (T cells and monocytes) will be isolated.Purified populations of T cells      will be stimulated with different mixtures of HBV peptides covering HBV proteins and      experiments of ELISPOT or intracellular cytokine staining will be carried out to detect the      specificty of the responsive T cell population. In addition, T cells willbe stained with      HLA-tetramers specific for different HBV epitopes to directly analyze the frequency and      phenotype of HBV-specific CD8+Tcells present in cord blood.|Female|21 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|HBsAg+ mothers are the source of possible in utero infection.Thus, the cord blood        collected from these mothers after delivery would provide information about the cause of        HBV chronicity in Asian patients and about the management of baby born from HBsAg+        mothers.|January 2014|January 10, 2014|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845403||143294|
NCT00845715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-311-3|Early Range of Motion Following Arthroscopic Rotator Cuff Repair|The Effect of Early Range of Motion on Clinical Outcomes, Patient Satisfaction, and Cuff Integrity Following Arthroscopic Rotator Cuff Repair. A Prospective Randomized Study.||University of Connecticut Health Center|No|Active, not recruiting|July 2008|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||November 2012|November 29, 2012|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00845715||143270|
NCT00845728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2348|Exacerbation Study|A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD|INVIGORATE|Novartis|Yes|Completed|March 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3439|||Both|40 Years|N/A|No|||September 2013|September 16, 2013|February 15, 2009|Yes|Yes||No|July 3, 2013|https://clinicaltrials.gov/show/NCT00845728||143269|
NCT00845988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2008-104|Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders|Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-induced Weight Gain||Seoul National University Hospital|Yes|Completed|December 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|February 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00845988||143249|
NCT00841776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTG0703|Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne|Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris||GlaxoSmithKline|No|Completed|August 2007|January 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|12 Years|N/A|No|||July 2011|July 12, 2011|February 10, 2009|Yes|Yes||No|April 7, 2010|https://clinicaltrials.gov/show/NCT00841776||143568|
NCT00833703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS10916|Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation|Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age|CLARINET LT|Sanofi|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|12 Months|N/A|No|||August 2011|August 18, 2011|January 29, 2009|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00833703||144181|
NCT00834067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036544|Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00834067||144153|
NCT00833430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC006-99|Avascular Necrosis (AVN) Long-Term Follow-up|Hedrocel Avascular Necrosis (AVN) Intervention Implant||Zimmer, Inc.|No|Terminated|June 2006|February 2013|Actual|February 2013|Actual|N/A|Observational|N/A||1|Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients enrolled at investigational sites who had Stage I or Stage II Osteonecrosis of        the femoral head and who would qualify for core decompression based upon physical and        radiographic exam and medical history.|February 2016|February 18, 2016|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00833430||144202|
NCT00833443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH_K23|Study of Medical Treatment for Methamphetamine Addiction|Pharmacogenomics and Medication Development for Methamphetamine Dependence|BUP PGx|University of California, Los Angeles|Yes|Completed|January 2009|July 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|January 30, 2009|Yes|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT00833443||144201|
NCT00841711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0711003262|Transitions: Linkages From Jail To Community|Transitions: Linkages From Jail to Community||Yale University|No|Completed|September 2008|August 2013|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|127|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841711||143573|
NCT00842010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNDJHS200902|Characteristics of Non Diabetic Hyperglycemic Inpatients|Hyperglycemic Non Diabetic (HND) Hospital Patients: Are They Different From Diabetic Hyperglycemic and Non-Hyperglycemic Non-Diabetic(NHND) Patients?||John H. Stroger Hospital|No|Completed|March 2006|December 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|Nested sample obtained from patients admitted to John H. Stroger Jr. Hospital from        March-April 2006 and in October 2007.|February 2009|February 11, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842010||143551|
NCT00842023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCP-26060|Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy|A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin.|ABC-HFT|Western University of Health Sciences|Yes|Completed|July 2006|February 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|February 10, 2009||No||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00842023||143550|
NCT00843063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC 2004-016|Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion|Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study||Ruttonjee Hospital|Yes|Completed|August 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|161|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843063||143471|
NCT00843336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPR200801363|Comparison of Two Internet Supported Natural Family Planning Methods|Randomized Comparison of Two Internet Supported Natural Family Planning Methods||Marquette University|No|Completed|February 2009|December 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|358|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843336||143451|
NCT00843635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070918|Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx|Pilot Study of Phosphodiesterase-5 Inhibitor Tadalafil (Cialis) as an Immunomodulator in Patients With Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.||University of Miami|Yes|Completed|September 2008|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|120 Years|No|||September 2015|September 25, 2015|February 12, 2009|No|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT00843635||143428|Race/Ethnicity baseline characteristics reported for 34 of 35 patients enrolled. Data analyzed for outcome measure for the 31 participants who completed the study.
NCT00843895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kingsadu|Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years|Serotyping of Pneumococci|Pneumococci|King Saud University||Not yet recruiting|March 2009|December 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|1||Anticipated|400|||Both|N/A|5 Years|No|||February 2009|February 11, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00843895||143408|
NCT00844168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6697|Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant|Phase I Adjuvant Trial of Sorafenib in Hepatocellular Carcinoma Patients After Liver Transplantation||University of Washington|Yes|Completed|January 2009|||June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00844168||143388|
NCT00844207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661186|A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine|A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine In Healthy Adult Subjects|AZCQ|Pfizer|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 20, 2009|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00844207||143385|
NCT00844220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/080/08|Coronary Artery Disease Management Using Multislice Computed Tomography and Magnetic Resonance Imaging|Coronary Artery Disease Management Using Multislice Computed Tomography and Magnetic Resonance Imaging|CAD-Man|Charite University, Berlin, Germany|Yes|Active, not recruiting|February 2009|September 2018|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|340|||Both|30 Years|N/A|No|||November 2015|November 10, 2015|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844220||143384|
NCT00844519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVCADRFA|Effect of Maraviroc on Endothelial Function in HIV-Infected Patients|||University of California, San Francisco|Yes|Completed|January 2010|June 2014|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|February 13, 2009|No|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00844519||143361|
NCT00844545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-002A|Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS|An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)|aHUS|Alexion Pharmaceuticals|Yes|Completed|May 2009|July 2013|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|February 13, 2009|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT00844545||143359|
NCT00836875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501080|A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children|A Prospective, Open-Label, Non-Randomized, Multi-Center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients||Pfizer|Yes|Terminated|May 2009|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|2 Years|17 Years|No|||June 2014|June 19, 2014|February 3, 2009|No|Yes|This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of    any safety issues or concerns.|No|May 9, 2014|https://clinicaltrials.gov/show/NCT00836875||143939|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.
NCT00832065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-066|Sexual Dysfunction And Hypotestosteronemia In Patients With Obstructive Sleep Apnea Syndrome|Sexual Dysfunction And Hypotestosteronemia In Patients With Obstructive Sleep Apnea Syndrome And Its Effects With CPAP Therapy||Lahey Clinic|No|Active, not recruiting|January 2009|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Male|18 Years|70 Years|No|Probability Sample|Patients from the departments of Pulmonary and Critical Care and Endocrinology Lahey        Clinic|December 2015|December 15, 2015|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832065||144304|
NCT00832364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114549|Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis|Randomized, Controlled Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis||GlaxoSmithKline|No|Withdrawn|October 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2011|April 20, 2015|January 27, 2009|Yes|Yes|Business decision. No patients were enrolled|No||https://clinicaltrials.gov/show/NCT00832364||144282|
NCT00845741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0408|Neutrophil Gelatinase-associated Lipocalin (NGAL) Evaluation in Emergency Department (ED) All-Comers|NGAL Evaluation in ED All-Comers||Biosite|No|Completed|February 2009|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|700|||Both|18 Years|N/A|No|Non-Probability Sample|Adults presenting to the ED and designated for admission to the hospital will be enrolled.|October 2010|January 20, 2011|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845741||143268|
NCT00845754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASW 124|Post-Operative Treatment With Ketorolac After Abdominal Myomectomy|Effects of Ketorolac on Post-Operative Febrile Morbidity and Pain Management in Abdominal Myomectomy Patients||Ascher-Walsh, Charles, M.D.||Completed|September 1999|August 2001|Actual|August 2001|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|112|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 17, 2009|February 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00845754||143267|
NCT00846001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SACRT 022|Resynchronization Surgery Combined Unified Efficacy|Study of Resynchronization and CABG Unified Efficacy in Ischemic Heart Failure Patients|RESCUE|Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|September 2007|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|80 Years|No|||July 2015|July 14, 2015|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00846001||143248|
NCT00833456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NSI-SER-2008/1|NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia|Non-interventional Clinical Study to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia, Treated With Atypical Antipsychotics||AstraZeneca|No|Completed|February 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|106|||Both|18 Years|80 Years|No|Non-Probability Sample|patients visiting psychiatrist's practice|October 2011|October 13, 2011|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833456||144200|
NCT00834782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6902-IDF-CTIL|Comparison of DCT, ORA and GAT in Eyes After Penetrating Keratoplasty|Comparison of Pascal Dynamic Contour Tonometer, Reichart Ocular Response Analyzer and Goldmann Applanation Tonometer in Eyes After Penetrating Keratoplasty||Sheba Medical Center|No|Recruiting|May 2009|May 2010|Anticipated|December 2009|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|90 Years|No|Probability Sample|Patients post keratoplasty surgery|September 2009|September 13, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834782||144098|
NCT00834080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-021|ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals|Open-Label Study of the Safety and Tolerability of VIVITROL Administered to Health Care Professionals Participating in an Extended Outpatient Treatment Program for Opioid Dependence||Alkermes, Inc.|No|Completed|March 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||May 2013|May 30, 2013|February 2, 2009|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT00834080||144152|After screening 49 subjects, Alkermes made a business decision to stop enrollment, resulting in 38 total subjects enrolled.
NCT00834444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B044502|Famciclovir 500 mg Tablets Under Non-Fasting Conditions|A Single Dose, Comparative Bioavailability Study of Two Formulations of Famciclovir 500 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|August 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00834444||144124|
NCT00834743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2734|Metformin ER 750 mg Tablets, Fasting|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Metformin ER 750 mg Tablets Versus Glucophage® XR 750 mg Tablets in Normal Healthy Non-smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|August 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00834743||144101|
NCT00842517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308|Long Term Maintenance of Drug Abstinence|A Behavioral Model for Maintenance of Drug Abstinence||Treatment Research Institute|Yes|Completed|September 2004|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|October 24, 2007||No||No||https://clinicaltrials.gov/show/NCT00842517||143512|
NCT00842530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD23|Efficacy and Safety of Dengue Vaccine in Healthy Children|Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand||Sanofi|Yes|Completed|February 2009|February 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4002|||Both|4 Years|11 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842530||143511|
NCT00842764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2008-6593|Minimally Invasive Holmium:YAG Laser Blepharoplasty|Minimally Invasive Holmium:YAG Laser Blepharoplasty||University of California, Irvine|No|Completed|January 2009|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|30 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|February 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842764||143494|
NCT00842777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17188|Childhood Obesity: a Study of Group Treatment Targeting Parents Behaviour|Childhood Obesity; a Randomized Controlled Study of Group Treatment Targeting Parents Behaviour||Norwegian University of Science and Technology|No|Completed|October 2004|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|7 Years|12 Years|No|||January 2012|January 5, 2012|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842777||143493|
NCT00843076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORT08-PR/VIRO-Stéatose|Impact of Hepatitis C Virus Variability on Steatosis|Impact of the Hepatitis C Virus Variability on Liver Steatosis|Viro-steatosis|University Hospital, Tours|No|Terminated|January 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|Samples With DNA|Liver biopsy      Blood sample|Both|18 Years|75 Years|No|Non-Probability Sample|Patients with chronic hepatitis C|November 2013|November 8, 2013|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843076||143470|
NCT00843349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080536|Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)|Fibroblast Growth Factor-23 Reduction in Predialysis Chronic Kidney Disease||University of Miami|Yes|Completed|July 2009|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|43|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|February 12, 2009||No||No|February 7, 2013|https://clinicaltrials.gov/show/NCT00843349||143450|
NCT00843648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5441-AM-CTIL|Study of the Development of Human Immune System of Newborns by Antigen Chips|||Sheba Medical Center|No|Not yet recruiting|March 2009|March 2011|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|N/A|7 Weeks|No|Probability Sample|term and preterm newborns and their mothers|February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843648||143427|
NCT00843908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H1101/112|Tension Free Vaginal Tape (TVT) Versus the Miniarc Sling|A Randomized Study of the Treatment of Urodynamic Stress Incontinence: the Tension Free Vaginal Tape (TVT) Versus the Miniarc Sling.||Medway NHS Foundation Trust|No|Completed|February 2008|August 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Female|N/A|N/A|No|||August 2009|August 26, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843908||143407|
NCT00843921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC 3694|N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia|N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia||Children's Research Institute|Yes|Recruiting|August 2008|July 2018|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|70 Years|No|||December 2015|December 11, 2015|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843921||143406|
NCT00844246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-9-6124|Translating Evidence Based Developmental Screening Into Pediatric Primary Care|Translating Evidence Based Developmental Screening Into Pediatric Primary Care ( Aims 2 and 3 )|TEDS|Children's Hospital of Philadelphia|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|2314|||Both|N/A|30 Months|Accepts Healthy Volunteers|||November 2011|November 8, 2011|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844246||143382|
NCT00844532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-107 Absolute Pro Arm (AP)|Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.|A Prospective, Non-randomized, 2 Arm (AP Arm & Omni-Link Elite [OE] Arm-separately Posted as: NCT01396525), Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System and the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery. CAUTION: The Omnilink Elite™ Peripheral Balloon-expandable Stent System is an Investigational Device. Limited by Federal (U.S.) Law to Investigational Use Only.|MOBILITY AP|Abbott Vascular|Yes|Completed|March 2009|June 2014|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|18 Years|89 Years|No|||May 2015|May 14, 2015|February 12, 2009|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT00844532||143360|
NCT00844558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807706|Mobility Optimization Through Velocity Exercise|Optimizing Mobility in Older Adults With Knee Osteoarthritis|MOVE|University of Iowa|No|Active, not recruiting|August 2008|June 2012|Anticipated|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|108|||Both|60 Years|N/A|No|||December 2011|December 1, 2011|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844558||143358|
NCT00832702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 14906|Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction|Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction||Cedars-Sinai Medical Center|No|Active, not recruiting|September 2008|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Observational|Time Perspective: Prospective||1|Anticipated|433|Samples With DNA|Blood sample will be collected for future genetic studies to better understand heart artery      disease by identifing genetic factors that contribute to heart artery disorders, and for      extraction and creation of cell lines.|Female|18 Years|85 Years|No|Non-Probability Sample|Women undergoing clinically-ordered coronary angiography for suspected ischemia will be        recruited. See the inclusion and exclusion criteria for details.|August 2015|August 5, 2015|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832702||144256|
NCT00832923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC #207|Improving Asthma Care Through Parental Empowerment|Improving Asthma Care Through Parental Empowerment: Effect on Healthcare Utilization and Parent Self-Efficacy|PEPAC|Children's Research Institute|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|150|||Both|12 Months|12 Years|No|||September 2014|September 10, 2014|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832923||144240|
NCT00833222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24087|Neuroendocrine Mechanisms of Growth and Body Composition in Preterm and Term Infants|Neuroendocrine Mechanisms of Growth and Body Composition in Preterm and Term Infants|PREMA|University of Utah|No|Completed|January 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|72|Samples With DNA|Saliva; Urine|Both|31 Weeks|42 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Premature and full term infants admitted to the University of Utah Newborn Intensive Care        Unit, Intermediate Nursery or Well Baby Nursery|July 2012|July 2, 2012|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833222||144218|
NCT00832689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0191|Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer|||Yonsei University||Completed|June 2008|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|39|||Both|17 Years|75 Years|No|||March 2011|March 25, 2011|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832689||144257|
NCT00832910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|Assessment of Body Image in Patients With Rheumatoid Arthritis|Body Image in Patients With Rheumatoid Arthritis|BIRA|Federal University of São Paulo|No|Completed|June 2007|December 2008|Actual|||N/A|Observational|Observational Model: Case Control||2|Actual|82|None Retained|None Retained|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Rheumatoid arthritis in study group          -  Community sample in control group|January 2009|January 29, 2009|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832910||144241|
NCT00833209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/28|Orbitofrontal Cortex (OFC) Influence on Addictive Medication Overuse Headache (MOH) Deriving From Migraine|Orbitofrontal Cortex (OFC) Influence on Addictive Behaviour in Medication Overuse Headache (MOH) Deriving From Migraine|MOH-PET|University Hospital, Bordeaux|No|Completed|February 2009|May 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 31, 2012|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833209||144219|
NCT00834457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL30512|A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe|A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe||Parirenyatwa Hospital|Yes|Completed|June 2007|July 2009|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834457||144123|
NCT00835224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6161-W|Safety and Efficacy of L-NAME and Midodrine to Increase MAP|Safety and Efficacy of L-NAME and Midodrine to Increase MAP in Persons With Tetraplegia||VA Office of Research and Development|No|Completed|May 2010|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 21, 2014|January 30, 2009|No|Yes||No|September 12, 2013|https://clinicaltrials.gov/show/NCT00835224||144064|Study population was relatively small and were not blinded to the interventions.
NCT00842543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1607330001|Fruit and Vegetable Juice Concentrate Effects on RBP4 and Antioxidant Capacity in Lean and Overweight 6-10 Year Old Boys|Effects Of A Fruit And Vegetable Juice Concentrate (FVJC) In-Vivo On Retinol Binding Protein 4 And Antioxidant Capacity In Normal And Overweight Boys -A Pilot Randomized Placebo Controlled Study|FVJC|Nemours Children's Clinic|Yes|Completed|July 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|39|||Male|6 Years|10 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|February 11, 2009||No||No|May 18, 2012|https://clinicaltrials.gov/show/NCT00842543||143510|
NCT00842790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060407|Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging|Medical and Economical Impact of Predicting the Response to Anti-angiogenic Treatment in Metastatic Renal Cell Carcinoma Using Functional CT and MRI|REMISCAN|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2008|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Both|18 Years|85 Years|No|Non-Probability Sample|oncologic hospital visit|February 2009|October 5, 2015|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842790||143492|
NCT00842803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-08-030|Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant|Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant Recipients Status 1-2. A Prospective Randomized Controlled Trial.||McGill University Health Center|Yes|Not yet recruiting|January 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842803||143491|
NCT00843089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11562|Secondary Prevention After Coronary Bypass Surgery|Secondary Prevention After Coronary Bypass Surgery: A Pilot Study||University of Kansas Medical Center|No|Completed|January 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|115|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843089||143469|
NCT00843102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|330/PI/2007|Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis|Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis||University of Pecs|No|Completed|December 2007|May 2012|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|120|Samples Without DNA|Serum samples|Both|18 Years|90 Years|No|Probability Sample|Systemic sclerosis|June 2012|June 12, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843102||143468|
NCT00834405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B026504|Leflunomide 20 mg Tablets, Non-Fasting|A Relative Bioavailability, Parallel Study of Leflunomide 20 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|April 2002|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00834405||144127|
NCT00843362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spedali Civili 924|24-Hour Vaginal Dinoprostone Pessary Versus Gel for Labour Induction|A Randomised Controlled Trial of 24-Hours Vaginal Dinoprostone Pessary vs. Gel for Induction of Labour in Term Pregnancies With a Bishop Score ≤4||Università degli Studi di Brescia|No|Completed|December 2006|June 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Female|18 Years|N/A|No|||February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843362||143449|
NCT00834717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1028|Granisetron 1 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Granisetron 1 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00834717||144103|
NCT00835159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H# 08-765|Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial|Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial||New York University School of Medicine|No|Completed|December 2008|October 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 26, 2015|February 2, 2009|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00835159||144069|The study was halted prematurely because of a warning letter issued by the rivastigmine manufacturer indicating the possibility of increased mortality associated with the oral administration of the drug in critically ill patients.
NCT00835172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036502|Glimepiride 4 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|March 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00835172||144068|
NCT00835185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13926|Study of IMC-11F8 in Participants With Colorectal Cancer|Open Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of IMC-11F8 in Combination With 5-FU/FA and Oxaliplatin (mFOLFOX-6) in Patients With Treatment-naïve, Locally-advanced or Metastatic Colorectal Cancer||Eli Lilly and Company|No|Completed|August 2007|October 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|February 2, 2009|Yes|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT00835185||144067|
NCT00843934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE500|Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma|Randomized Controlled Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma|ACE500|Nihon University|Yes|Recruiting|March 2009|February 2015|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|20 Years|79 Years|No|||October 2012|October 17, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843934||143405|
NCT00843947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD196|Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan|Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan||University of California, Davis|Yes|Recruiting|June 2007|June 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2009|February 12, 2009|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843947||143404|
NCT00844233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA1016|Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer|A Single Arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients With Resectable Liver Metastases From Colorectal Cancer|PARAGON-II|Biocompatibles UK Ltd|No|Completed|February 2009|October 2012|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|No|||September 2011|March 28, 2013|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00844233||143383|
NCT00835913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06PHR04|Autonomic Nervous System Alteration Induce by Sepsis: Assessment and Prognosis Impact|Autonomic Nervous System Alteration Induce by Sepsis:Assessment and Prognosis Impact|SNA&Sepsis|University Hospital, Grenoble|Yes|Completed|October 2008|September 2011|Actual|September 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|Samples Without DNA|Peptid and protein sAmple|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patient transfer in intensive care unit with sepsis chock or severe sepsis define as        Bone criteria.|July 2010|January 16, 2015|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00835913||144011|
NCT00835926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC16|A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination|Safety and Immunogenicity of Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® 2003/2004||Sanofi|No|Completed|July 2003|September 2003|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 16, 2014|January 27, 2009|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00835926||144010|
NCT00836589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALAXY|Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)|GALAXY Registry: Long-term Evaluation of the Linox Family ICD Leads Registry|GALAXY|Biotronik, Inc.|No|Active, not recruiting|December 2008|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be obtained from the investigators' general patient population according to        the inclusion and exclusion criteria described below.|February 2016|February 24, 2016|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836589||143960|
NCT00832715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0387|Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)|Diagnostic Utility of Endobronchial Ultrasound Guided Mediastinal Lymph Node Sampling in Clinical Stage I and II Non Small Cell Lung Cancer||M.D. Anderson Cancer Center|No|Recruiting|April 2009|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832715||144255|
NCT00832949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCH2 448-2008|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (One-on-one Interviews)|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (One-on-one Interviews)||Sunnybrook Health Sciences Centre|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|N/A||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with inflammatory arthritis|January 2011|January 6, 2011|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00832949||144239|
NCT00833235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-RES-08-001|A Natural History Study of Patients With Dry Eye|||Allergan|No|Active, not recruiting|February 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|284|Samples With DNA|Tear collection|Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|At least 200 dry eye patients (with at least 40% of patients with elevated biomarkers for        ocular surface inflammation) will be enrolled at approximately 15-20 sites. Approximately        40-50 patients will be enrolled in the control group.|January 2016|January 28, 2016|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833235||144217|
NCT00833469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001509|Escitalopram (Lexapro) for the Treatment of Postpartum Depression|Escitalopram for the Treatment of Postpartum Depression|LexaproPPD|Massachusetts General Hospital|No|Completed|January 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|45 Years|No|||August 2014|August 5, 2014|January 29, 2009||No||No|July 11, 2014|https://clinicaltrials.gov/show/NCT00833469||144199|We recruited only 7 patients out of a projected 20. Patients were not referred because they were breastfeeding or preferred to receive treatment from their primary care doctor. We also suspect that many women with PPD do not seek treatment at all.
NCT00833716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3616|Effect of Renal Impairment on the Pharmacokinetics of NN9535|An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NN9535 in Subjects With Normal Renal Function and Various Degrees of Impaired Renal Function||Novo Nordisk A/S|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|January 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00833716||144180|
NCT00833729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-2008-0008|The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab|An Open Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab||Dermatrials Research||Completed|February 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 25, 2010|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833729||144179|
NCT00834119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03270|Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)|Assessment of the Effectiveness of Regular Use of Intranasal Steroids in Alleviating Nasal Symptoms in Allergic Rhinitis When Used Alone or in Combination With Oral Antihistamine||Merck Sharp & Dohme Corp.|No|Completed|September 2003|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||April 2015|April 27, 2015|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00834119||144149|
NCT00833794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT3-005|A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis|||Labopharm Inc.||Completed|October 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1028|||Both|40 Years|80 Years|No|||April 2012|April 25, 2012|January 29, 2009||Yes||No|April 9, 2009|https://clinicaltrials.gov/show/NCT00833794||144174|
NCT00834093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-292|A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma|A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00834093||144151|
NCT00834106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-041|Prevention of HPV in 20 to 45 Year Old Chinese Women (V501-041)|A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women||Merck Sharp & Dohme Corp.|No|Active, not recruiting|December 2008|February 2016|Anticipated|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3006|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00834106||144150|
NCT00834470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atropine-01|Adjunctive Atropine During Ketamine Sedation|Is Atropine Needed With Ketamine Sedation?||Seoul National University Hospital|No|Completed|August 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|12 Months|10 Years|No|||August 2012|August 3, 2012|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00834470||144122|
NCT00834795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01268|Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects|A Randomized, Two-Way Crossover, Single-Dose, Open Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Carvedilol (25 mg), Compared to an Equivalent Dose of COREG® (SmithKline Beecham Pharmaceuticals) in 36 Fasted, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|December 2001|December 2001|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|May 8, 2009|https://clinicaltrials.gov/show/NCT00834795||144097|
NCT00842556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-037|Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects|Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects||AstraZeneca|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|February 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842556||143509|
NCT00842816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST101-A001-202|Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease|A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®)||Sonexa Therapeutics, Inc.|No|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|210|||Both|50 Years|N/A|No|||June 2012|June 5, 2012|February 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00842816||143490|
NCT00834418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02-561|Leflunomide 20 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 20 mg Leflunomide Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2002|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00834418||144126|
NCT00834431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B044501|Famciclovir 500 mg Tablets Under Fasting Conditions|A Single Dose, Comparative Bioavailability Study of Two Formulations of Famciclovir 500 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|August 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00834431||144125|
NCT00835575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-338|15 mg Mirtazapine Orally Disintegrating Tablets, Fasting|A Relative Bioavailability Study of 15 mg Mirtazapine Orally Disintegrating Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|July 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00835575||144037|
NCT00834730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2O|Comparison of N2O Inhalation and Ketamine in Pediatric PSA|Comparison of N2O Inhalation and Ketamine IV Injection for Sedation in the Treatment of Laceration of Pediatric Patients.|PSA|Seoul National University Hospital|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|36 Months|10 Years|No|||September 2011|September 13, 2011|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00834730||144102|
NCT00835536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036553|Ribavirin 200 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|27|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00835536||144040|
NCT00835549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B056502|Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting|A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|March 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00835549||144039|
NCT00836602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV197-002|Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects|Placebo-Controlled, Ascending, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|February 22, 2011|January 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00836602||143959|
NCT00836901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30074|Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Non-Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets and AUGMENTIN® 400 mg-57 mg Chewable Tablets Administered as 1 x 400 mg-57 mg Chewable Tablet in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|February 2, 2009|No|Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00836901||143937|
NCT00832078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK058CC|Test Catheter Pilot Study in Healthy Volunteers|Test Catheter Pilot Study in Healthy Volunteers|Test catheter|Coloplast A/S|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 2, 2012|January 26, 2009||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00832078||144303|
NCT00832377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507A-161|COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)|Prospective, Open-label, Single-arm Study to Evaluate Efficacy and Safety of Combination Therapy of Timolol and Dorzolamide (COSOPT) as Initial Treatment for Patients With Normal Tension Glaucoma||Merck Sharp & Dohme Corp.|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|January 29, 2009|Yes|Yes||No|February 25, 2011|https://clinicaltrials.gov/show/NCT00832377||144281|
NCT00832390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-158|Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)|Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise||Merck Sharp & Dohme Corp.|No|Completed|February 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|30 Years|78 Years|No|||February 2016|February 3, 2016|January 28, 2009|No|Yes||No|June 11, 2009|https://clinicaltrials.gov/show/NCT00832390||144280|Few participants were recruited into this single-site study as the investigator preferred the use of initial combination therapy.Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.
NCT00832429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0266|Sentinel Lymph Node (SLN) Biopsy for Sebaceous Gland Carcinoma of Eyelid|Sentinel Lymph Node Localization and Biopsy for Sebaceous Gland Carcinoma of the Eyelid||M.D. Anderson Cancer Center|No|Recruiting|February 2009|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832429||144277|
NCT00832728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-202|Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)|Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)|ELAD|Vital Therapies, Inc.|No|Withdrawn|March 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|10 Years|65 Years|No|||July 2012|July 24, 2012|January 29, 2009|No|Yes|To focus on another clinical indication.|No||https://clinicaltrials.gov/show/NCT00832728||144254|
NCT00833248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS30|Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer|A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)||Ferring Pharmaceuticals|No|Completed|April 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|246|||Male|18 Years|N/A|No|||September 2012|September 27, 2012|January 30, 2009|Yes|Yes||No|August 27, 2012|https://clinicaltrials.gov/show/NCT00833248||144216|
NCT00833482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-383|Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants|Study to Assess the Pharmacokinetic Drug - Drug Interactions Between Atazanavir Plus Ritonavir Coadministered With Voriconazole in Healthy Subjects||Bristol-Myers Squibb|No|Completed|September 2009|February 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Actual|185|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|January 30, 2009|No|Yes||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00833482||144198|
NCT00833742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA01|Intensive Short-Term Dynamic Psychotherapy (ISTDP) in the Emergency Department|Emotion-Focused Diagnosis and Treatment of Somatization in the ED|ISTDPED|Nova Scotia Health Authority|No|Completed|January 2002|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||January 2009|January 30, 2009|February 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00833742||144178|
NCT00833755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P 000879|Effect of Ketamine on Opioid-Induced Hyperalgesia|Effect of Ketamine on Opioid-Induced Hyperalgesia||Massachusetts General Hospital|Yes|Active, not recruiting|September 2008|December 2015|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|136|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833755||144177|
NCT00833807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0603|Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver|Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver||M.D. Anderson Cancer Center|No|Completed|February 2009|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833807||144173|
NCT00833820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis|Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis|rTMS-ALS|Catholic University of the Sacred Heart|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||January 2009|January 30, 2009|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833820||144172|
NCT00833833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-002|MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma|A Phase I/II Multicenter, Randomized, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Safety, And Efficacy Of CC-4047 Alone Or In Combination With Low-Dose Dexamethasone In Patients Wth Relapsed And Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide And Bortezomib||Celgene|Yes|Completed|June 2008|September 2015|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|259|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 30, 2009|Yes|Yes||No|March 8, 2013|https://clinicaltrials.gov/show/NCT00833833||144171|
NCT00834483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08091607|Use of Knotless Suture for Closure of Total Hip and Knee Arthroplasties|Use of Knotless Suture for Closure of Total Hip and Knee Arthroplasties: A Prospective-randomized Clinical Trial||Rush University Medical Center|Yes|Completed|February 2009|December 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 9, 2014|February 2, 2009||No||No|February 2, 2013|https://clinicaltrials.gov/show/NCT00834483||144121|Five patients were offered enrollment but refused to participate, however this does not alter our data as sixty others did enroll.
NCT00862550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0801|Xerostomia Pilot Fudan: Acupuncture for Prevention of Radiation-Induced Xerostomia|Randomized Pilot Trial of Acupuncture for Prevention of Radiation-Induced Xerostomia||M.D. Anderson Cancer Center|Yes|Active, not recruiting|March 2009|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|23|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862550||141997|
NCT00833690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO-PD-P2-2008|Safety of Urate Elevation in Parkinson's Disease|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease|SURE-PD|The Parkinson Study Group|Yes|Completed|June 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|30 Years|N/A|No|||May 2014|May 30, 2014|January 27, 2009|Yes|Yes||No|December 26, 2013|https://clinicaltrials.gov/show/NCT00833690||144182|
NCT00834756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02183|Azithromycin 600 Mg Tablets, Fasting|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Azithromycin (600 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Zithromax®, Pfizer, Inc.) in 36 Fasted, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|September 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00834756||144100|
NCT00834041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2256|A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age|An 8-day Open-label, Multiple-dose, Multicenter Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age||Novartis|No|Completed|April 2009|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|6 Years|17 Years|No|||April 2011|April 15, 2011|January 30, 2009|Yes|Yes||No|January 18, 2011|https://clinicaltrials.gov/show/NCT00834041||144155|
NCT00834054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/18|Measurement of Lung Water by Transpulmonary Thermodilution in Lung Transplanted Patients|Interest of Repeated Extravascular Lung Water Measurements With the PICCO Device in Lung Transplanted Patients|PICCO-LungT|Hopital Foch|No|Completed|January 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|65 Years|No|Non-Probability Sample|double-lung transplanted patients|July 2011|July 18, 2011|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834054||144154|
NCT00836329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|615|Improving Neurologic Outcomes in People With Diabetes Who Are Undergoing Heart Surgery|Improving Neurologic Outcomes in Diabetics Undergoing Cardiac Surgery||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|December 2008|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|35 Years|N/A|No|||July 2009|September 30, 2014|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836329||143979|
NCT00835978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061046|Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer|Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma||Pfizer|No|Active, not recruiting|August 2009|February 2016|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|213|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 2, 2009|Yes|Yes||No|October 11, 2013|https://clinicaltrials.gov/show/NCT00835978||144006|
NCT00836290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701002257|Positive Lifestyles Using Safety|Positive Lifestyles Using Safety|Project PLUS|Yale University|No|Completed|January 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836290||143982|
NCT00836303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T01CD000146|Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening|A Randomized Controlled Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening Among Latino Immigrants in a Primary Care Facility||New York University School of Medicine|No|Completed|December 2005|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 2, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836303||143981|
NCT00836316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDC-2008|Levobupivacaine During Cholecystectomy|Effects of Intraperitoneal Levobupivacaine on Pain After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-Blinded Study||Ege University||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2009|February 3, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836316||143980|
NCT00836888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4538-01|ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan|ONO-4538 Phase I Study - A Single Center, Open Label, Dose Escalation Single Dose, Followed by Multiple Dose Study of ONO-4538, a Fully Human mAb to PD-1, in Patients With Advanced Malignant Solid Tumors||Ono Pharmaceutical Co. Ltd||Active, not recruiting|January 2009|||September 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|N/A|No|||April 2015|April 21, 2015|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00836888||143938|
NCT00832091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSVS|Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Venous Stasis Ulcers|SSVS|RegeneRx Biopharmaceuticals, Inc.|No|Completed|July 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|79 Years|No|||March 2010|March 24, 2010|January 28, 2009|Yes|Yes||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00832091||144302|
NCT00832403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rinite Atrófica cep/hfr|Gore Tex Implants in the Treatment of Atrophic Rhinitis|Gore Tex Implants in the Treatment of Atrophic Rhinitis|RA|Hospital Felicio Rocho|No|Suspended|November 2006|||February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|5|||Both|N/A|N/A|No|Non-Probability Sample|Patients that were submit to surgery to treat atrophic rhinitis with implants in the nasal        fossa.|January 2009|January 29, 2009|January 27, 2009||No|lack of new patients|No||https://clinicaltrials.gov/show/NCT00832403||144279|
NCT00832416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT3-002|A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee|||Labopharm Inc.||Completed|January 2003|||August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|565|||Both|40 Years|75 Years|No|||April 2012|April 25, 2012|January 29, 2009|No|Yes||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00832416||144278|
NCT00832117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-177|Phase I Combination Ixabepilone + Cisplatin|Phase 1 Study of Ixabepilone in Combination With Cisplatin in Subjects With Advanced Solid Tumors||R-Pharm|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 28, 2009|No|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00832117||144301|
NCT00832741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2007-0080|Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus|Secretion and Significance of the Incretin Hormones on the Postprandial Glycemic Response in Type-1 Diabetes Mellitus||Hvidovre University Hospital|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|N/A|Observational|N/A||1|Actual|30|Samples With DNA|whole blood, plasma|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic patients and community population(control subjects)|January 2009|January 29, 2009|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832741||144253|
NCT00832754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHRC1|Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial|Effects of Restricting the Use of AS-AQ Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial|RDT-ACT|Kintampo Health Research Centre, Ghana|Yes|Completed|March 2009|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3063|||Both|N/A|48 Months|No|||December 2012|December 20, 2012|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832754||144252|
NCT00833495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003-27|Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation|A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (PredMild®) Compared to Prednisolone Acetate 1% Alone or Vehicle Alone in Patients With Mild Ongoing Ocular Allergic Inflammation||Fovea Pharmaceuticals SA|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|155|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 8, 2012|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833495||144197|
NCT00833768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCARB00606|A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis|A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease (CKD) Patients Not on Dialysis|ASPIRE|Sanofi|No|Terminated|January 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|January 29, 2009|Yes|Yes|After an extensive review,the ASPIRE in CKD study was terminated because it was not possible    to complete the study in an appropriate time frame.|No||https://clinicaltrials.gov/show/NCT00833768||144176|
NCT00833781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008p001577|A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects|A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy|PARC002|Massachusetts General Hospital|Yes|Completed|August 2009|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|January 29, 2009|Yes|Yes||No|October 15, 2015|https://clinicaltrials.gov/show/NCT00833781||144175|The trial size is small, precluding detection of small effect sizes.
NCT00833508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0712/117|Effect of Preoperative Chemoradiotherapy on Exercise Capacity as Measured by Cardiopulmonary Exercise Testing|Effect of Preoperative Chemoradiotherapy on Exercise Capacity as Measured by Cardiopulmonary Exercise Testing||Imperial College London|No|Completed|January 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|65 Years|N/A|No|||February 2016|February 15, 2016|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833508||144196|
NCT00833846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090068|Pilot Study of Mitochondrial Biology in Human Platelets|Pilot Study of Mitochondrial Biology in Human Platelets||National Institutes of Health Clinical Center (CC)||Completed|January 2009|October 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|18|||Both|21 Years|60 Years|No|||October 2011|October 25, 2011|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833846||144170|
NCT00833859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15587|Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery|A Phase 2 Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|March 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|January 30, 2009|Yes|Yes|Abandoned - Lack of funding after only 2 patients enrolled|No|March 30, 2011|https://clinicaltrials.gov/show/NCT00833859||144169|Early termination of study due to termination of funding. The study was closed to accrual on 12/17/09 and final closed on 3/12/10. The sample size goal of 33 evaluable participants could not be met.
NCT00834132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02184|Azithromycin 600 Mg Tablets, Fed|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Azithromycin (600 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Zithromax®, Pfizer, Inc.) in 24 Fed, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|July 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00834132||144148|
NCT00834496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08D.12|Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation|Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation||Thomas Jefferson University|Yes|Recruiting|January 2009|December 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|post liver transplant patients taking calcineurin inhibitors (tacrolimus or cyclosporine)        as anti-reject medication|March 2015|March 17, 2015|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00834496||144120|
NCT00834769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/30|Chronic Pain After Thoracotomy, an Incidence Study in a Single Surgical Center|Chronic Pain After Thoracotomy, an Incidence Study in a Single Surgical Center||Hopital Foch|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|65|||Both|18 Years|N/A|No|Non-Probability Sample|thoracotomized patients|April 2009|April 5, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834769||144099|
NCT00835198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-ACZ0801|Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris|||Allergan||Completed|December 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|12 Years|N/A|No|||September 2011|September 22, 2011|January 30, 2009|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00835198||144066|
NCT00835588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036581|Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions|A Relative Bioavailability Study of Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|February 2, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00835588||144036|
NCT00835211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA04887|Desmopressin Acetate 0.2 mg Tablets, Fasting|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg Desmopressin Acetate Tablets in Healthy Adult Subjects Following a 0.8 mg Dose Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|July 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00835211||144065|
NCT00835562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shoulderfractures.RCT|Effect of Osteosynthesis, Primary Hemi-arthroplasty, and Non-surgical Management for Fractures of the Proximal Humerus|Effect of Osteosynthesis, Primary Hemi-arthroplasty, and Non-surgical Management for Displaced Four-part Fractures of the Proximal Humerus in Elderly: a Multi-centre, Randomised Clinical Trial||Herlev Hospital|No|Recruiting|April 2009|||March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|162|||Both|60 Years|N/A|No|||June 2012|June 6, 2012|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835562||144038|
NCT00835939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-20903-RR|Treatment for Achilles Tendinopathy|Treatment for Achilles Tendinopathy||University of Calgary|Yes|Active, not recruiting|September 2007|||January 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|February 3, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00835939||144009|
NCT00835952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-08-10|ATX-101 Abdominoplasty|Phase 1, Open-label Study of the Safety, Tolerability, and Histological Effect of Single Doses of ATX-101 (Sodium Deoxycholate for Injection) Administered in Abdominal Fat in Subjects Undergoing Abdominoplasty|ATX-101-08-10|Kythera Biopharmaceuticals|No|Completed|November 2008|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|14|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 25, 2010|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00835952||144008|
NCT00835965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-Chamchad-2008|Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries|A Randomized, Double-Blind Comparison of Oral Aprepitant and Lower Dose Dexamethasone vs Aprepitant Alone for Preventing Postoperative Nausea and Vomiting After Elective Laparoscopic Surgeries||Main Line Health|No|Not yet recruiting|February 2009|||December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00835965||144007|
NCT00835991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02350|Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed|Randomized, 2-Way Crossover, Bioequivalence Study of Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets and Glucovance® 5 mg/500 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|February 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 3, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00835991||144005|
NCT00836004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30313|Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Clindamycin 300 mg Capsules and Cleocin Hcl Administered as 1 x 300 mg Capsule in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|November 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 3, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00836004||144004|
NCT00836628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS 1100|Study of Busulfan for Refractory Central Nervous System (CNS) Tumors|A Phase I Study Using Submyeloablative DOsing of Intravenous Busulfan (Busulfex) for Refractory Brain Tumors||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Withdrawn|July 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|3 Years|21 Years|No|||February 2016|February 4, 2016|February 3, 2009|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00836628||143958|
NCT00831870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-06-02b|EndoSure Sensor for Long-term Follow-up After Endovascular AAA Repair|PRessure and Imaging—Using the CardioMEMS EndoSure Sensor for Long-term Follow-up After EVAR With Standard Surveillance (Prospective Registry)|PRICELESS|CardioMEMS|No|Enrolling by invitation|October 2008|October 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female subjects, at least 18 years of age, who are post-EndoSure AAA Pressure        Sensor implantation at time of enrollment.|August 2012|August 29, 2012|January 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00831870||144319|
NCT00831883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0128|Partner-Specific HIV Risk Reduction Intervention for Drug-Using Adolescents|Partner-Specific HIV Risk Reduction Intervention for Drug-Using Incarcerated Adolescents|GET UP|Women and Infants Hospital of Rhode Island|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|59|||Both|15 Years|18 Years|No|||December 2012|December 3, 2012|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831883||144318|
NCT00831896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C17001|Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies|A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Completed|March 2009|May 2011|Actual|November 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|January 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00831896||144317|
NCT00832130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF001|Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye|Randomized Clinical Trial for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye||TearScience, Inc.|No|Completed|February 2009|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|January 27, 2009|Yes|Yes||No|September 19, 2011|https://clinicaltrials.gov/show/NCT00832130||144300|
NCT00832455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-385|Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)|A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma||Merck Sharp & Dohme Corp.||Completed|June 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|445|||Both|2 Years|14 Years|No|||October 2015|October 30, 2015|January 28, 2009|No|Yes||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00832455||144275|
NCT00832767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS08012|SILS™ Port Laparoscopic Cholecystectomy Post Market Study|Prospective Randomized Controlled Trial of Traditional Laparoscopic Cholecystectomy Versus SILS™ Port Laparoscopic Cholecystectomy||Medtronic - MITG|Yes|Active, not recruiting|April 2009|August 2012|Anticipated|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|85 Years|No|||January 2012|July 31, 2012|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832767||144251|
NCT00833001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-07-006|Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse|A Prospective, Multi-center Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse||Ethicon, Inc.|No|Completed|April 2008|December 2011|Actual|November 2009|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|126|||Female|18 Years|N/A|No|Non-Probability Sample|Women over 18 with symptomatic pelvic organ prolapse of ICS POP-Q Stage III or IV,        suitable for surgical repair.|May 2014|May 5, 2014|January 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00833001||144235|
NCT00832962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 060410|Routine Fetal RhD Genotyping for RhD- Pregnant Women|Effectiveness of Routine Fetal RhD Genotyping for RhD- Pregnant Women|GENIFERH|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|2532|Samples With DNA|Whole blood sample (0.5 ml)|Female|18 Years|N/A|No|Non-Probability Sample|Adult Rh negative pregnant women followed in the participating centers|March 2015|March 25, 2015|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00832962||144238|
NCT00832975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR08003ES|AVAI: Atrial Ventricular Arrythmia Incidence|Study of Slow Ventricular Tachycardia and Atrial Fibrillation Incidence Documented by Intracardiac Electrogram in Patients Implanted With an Implantable Cardiac Device (ICD) .|AVAI|St. Jude Medical|No|Completed|December 2008|December 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|157|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with a St. Jude Medical ICD|August 2015|August 6, 2015|January 29, 2009||No||No|February 17, 2015|https://clinicaltrials.gov/show/NCT00832975||144237|
NCT00833261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632295|Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer|A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|December 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||May 2014|March 19, 2015|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833261||144215|
NCT00833521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B016539|Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions|A Relative BioAvailability Study of Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2002|February 2002|Actual|February 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|January 30, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00833521||144195|
NCT00834158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-006|Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC|Efficacy of Sequential Arterial and Portal Vein Embolizations on Increasing the Resectability of Hepatitis B Related Primary Hepatocellular Carcinoma|TACEPVE|Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|January 2009|November 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|65 Years|No|||February 2009|February 22, 2009|January 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00834158||144146|
NCT00834145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32/2008|Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure|Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure: Short- Intermediate- and Long-Term Outcomes||Hillel Yaffe Medical Center||Not yet recruiting|March 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|N/A|No|||February 2009|February 2, 2009|February 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00834145||144147|
NCT00863837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC|Prevention of Esophageal Variceal Rebleeding|||National Science Council, Taiwan|No|Enrolling by invitation|December 2006|December 2009|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2009|March 17, 2009|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863837||141900|
NCT00863850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/1039/PK/NL|Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy|Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride Following Intravenous Infusion of [14C] Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy||Teva Pharmaceutical Industries||Completed|May 2009|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|March 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863850||141899|
NCT00863863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3155|A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Female Subjects||Actavis Inc.|No|Completed|January 2006|January 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863863||141898|
NCT00863876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-388/2008|Comparison of WaveLight Analyzer and Alcon LadarWave|||WaveLight AG|Yes|Completed|March 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||9|Anticipated|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy patients and patients following surgery, patients with keratoconus presenting for        examination at the clinic|June 2010|June 28, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863876||141897|
NCT00835601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD Training Study|Resistive/Cardiovascular Training Study|An Integrated Musculoskeletal Countermeasure Battery for Long-Duration Lunar Missions|CCD|University of California, San Francisco|No|Completed|January 2009|May 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men and women 25-55 years of age who are not exercisers|May 2011|May 13, 2011|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00835601||144035|
NCT00835250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLATZERNOTES-2|Laparoscopic Cholecystectomy vs Hybrid Natural Orifice Translumenal Surgery|Prospective Randomized Clinical Trial Comparing Laparoscopic Cholecystectomy and Hybrid Natural Orifice Translumenal Endoscopic Surgery (NOTES)||Hospital Son Llatzer|No|Completed|February 2009|April 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|65 Years|No|||March 2013|March 11, 2013|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835250||144062|
NCT00835614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036558|Cefprozil for Oral Suspension 250 mg/5 mL, Fasting|A Relative Bioavailability Study of Cefprozil for Oral Suspension 250 mg/5 mL Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|April 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00835614||144034|
NCT00835627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF122982|Treatment Trial for Psychogenic Nonepileptic Seizures|Medication and Psychotherapy Treatment Trial for Psychogenic Nonepileptic Seizures|NEST-T_1|Rhode Island Hospital|Yes|Completed|September 2008|June 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|38|||Both|18 Years|95 Years|No|||November 2014|November 7, 2014|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00835627||144033|
NCT00835640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-862|Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fed Conditions.||Teva Pharmaceuticals USA|No|Completed|January 2002|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00835640||144032|
NCT00836355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-131|Enoxaparin and/or Minocycline in Acute Stroke|Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke||New York University School of Medicine|No|Terminated|April 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|95 Years|No|||July 2015|July 7, 2015|February 3, 2009||No|Too few acute stroke patients available to meet enrollment requirements.|No||https://clinicaltrials.gov/show/NCT00836355||143977|
NCT00836342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002240|Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer|Comparison of Skin Carotenoid Levels Between Subjects With History of Cutaneous Squamous Cell Carcinoma and Subjects With History of Basal Cell Carcinoma Versus a Control Group||Massachusetts General Hospital|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|81|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The research population were recruited from Massachusetts General Hospital dermatology        clinics.|June 2012|June 24, 2012|February 2, 2009||No||No|May 14, 2012|https://clinicaltrials.gov/show/NCT00836342||143978|Limitations include a small sample size
NCT00836641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAPSI.FFM.3217|Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics|Prospective Randomized Controlled Phase 4 Study on the Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics|PAPSI|Johann Wolfgang Goethe University Hospitals|Yes|Completed|October 2006|December 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|2 Years|5 Years|No|||July 2013|July 30, 2013|February 3, 2009||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00836641||143957|
NCT00832143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|819/R.Cell 04|Effect of Referral Card on Neonatal Medical Care Seeking for Institutional Births in Urban Lucknow|Effect of Referral Card on Neonatal Medical Care Seeking for Institutional Births in Urban Lucknow|Referral Card|King George's Medical University|No|Completed|March 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1020|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||January 2009|January 28, 2009|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832143||144299|
NCT00832442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTEU08/d5/BBHF|Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure|Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure|BB-META-HF|Royal Brompton & Harefield NHS Foundation Trust|Yes|Enrolling by invitation|August 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|N/A||2|Anticipated|18240|||Both|N/A|N/A|No|Non-Probability Sample|Meta-Analysis of randomised controlled trials investigating mortality & morbidity of        placebo versus beta-blockers in heart failure|January 2009|May 8, 2012|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832442||144276|
NCT00832468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97032R|The Complementary Effect of Ear Acupressure on Older Patients With Chronic Insomnia|The Complementary Effect of Ear Acupressure on Older Patients With Chronic Insomnia and Anxiety||National Yang Ming University|Yes|Completed|December 2008|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|55 Years|75 Years|No|||December 2009|December 7, 2009|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832468||144274|
NCT00833898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0303|Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)|Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome||University of Colorado, Denver|Yes|Completed|November 2008|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|January 30, 2009|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00833898||144166|
NCT00833911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT3-004|An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee|An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee||Labopharm Inc.|No|Completed|April 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|392|||Both|40 Years|75 Years|No|||April 2012|April 25, 2012|January 29, 2009||No||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00833911||144165|
NCT00832988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM LV001|CONFIRM - Comparison of in Office Interrogation Versus Remote Measurements|Comparison of in Office Interrogation vs. Remote Measurements|CONFIRM|St. Jude Medical|Yes|Completed|October 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|No|Probability Sample|primary device clinic|June 2013|June 7, 2013|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832988||144236|
NCT00833014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP07-006|Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation|Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation|DYANA|MiCardia Corporation|No|Recruiting|December 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00833014||144234|
NCT00833274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-CIR-01|Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases|Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases||Centre Hospitalier Universitaire de Nice|No|Completed|February 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00833274||144214|
NCT00833534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2150.00|Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant|Consolidation Therapy With Lenalidomide (Revlimid®) With or Without Rituximab Followed by Maintenance Therapy With Revlimid® After Autologous/Syngeneic Transplant for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Fred Hutchinson Cancer Research Center||Withdrawn|February 2009|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|January 30, 2009|Yes|Yes|No patient enrolled on study. Did not get patients in timely fashion. All referrals for study    when assessed were not eligible.|No||https://clinicaltrials.gov/show/NCT00833534||144194|
NCT00835328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-10-6256|Effect of Exendin-(9-39) On Glucose Requirements To Maintain Euglycemia|Role of GLP-1 In Congenital Hyperinsulinism: Effect Of Exendin-(9-39)On Glucose Requirements To Maintain Euglycemia||Children's Hospital of Philadelphia|No|Recruiting|February 2009|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|12 Months|No|||March 2016|March 7, 2016|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00835328||144056|
NCT00834548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herlev WB-MRA 5|Whole-Body MRA at 3T - A Comparison Between Two Different Scan Protocols|Whole-Body MRA at 3T - A Comparison Between Two Different Scan Protocols||Copenhagen University Hospital at Herlev|Yes|Completed|June 2008|August 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|26|||Both|18 Years|N/A|No||Patients with peripheral arterial disease|February 2009|February 1, 2009|August 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00834548||144116|
NCT00834561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01305|Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions|Randomized, Two-Way Crossover, Single-Dose, Fasting Bioequivalence Study of Lamotrigine 1 x 200 mg Tablet||Teva Pharmaceuticals USA|No|Completed|January 2002|February 2002|Actual|February 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00834561||144115|
NCT00863889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010776|Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome|Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial||Emory University|No|Withdrawn|March 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|17 Years|N/A|No|||September 2013|September 19, 2013|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863889||141896|
NCT00864227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0604|Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)|A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)||Medical College of Wisconsin|Yes|Completed|December 2008|November 2013|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|1 Year|70 Years|No|||July 2015|July 30, 2015|March 17, 2009|Yes|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT00864227||141870|
NCT00834808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT1-011|A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers|||Labopharm Inc.||Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|January 30, 2009|Yes|Yes||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00834808||144096|
NCT00835237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111413|Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.|Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.||GlaxoSmithKline||Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1332|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2011|January 5, 2012|February 2, 2009|Yes|Yes||No|July 8, 2010|https://clinicaltrials.gov/show/NCT00835237||144063|
NCT00835263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01306|Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions|Randomized, 2-Way, Crossover, Bioequivalence Study of Lamotrigine 200 mg Tablets and Lamictal® 200 mg Tablets Administered as 1 x 200 mg Tablet in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|January 2002|February 2002|Actual|February 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00835263||144061|
NCT00835666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B026535|Finasteride 5 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2002|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 3, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00835666||144030|
NCT00836017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedAff BTX-0718|CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy|||Allergan|No|Completed|January 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1046|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Cervical Dystonia whom are being treated with onabotulinumtoxinA|June 2014|June 19, 2014|February 2, 2009|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00836017||144003|
NCT00836030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3710|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore|DiabCare Asia 2008. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia|DiabCare Asia|Novo Nordisk A/S|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|854|Samples With DNA|Blood sample|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to the        inclusion and exclusion criteria.|July 2012|July 16, 2012|January 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00836030||144002|
NCT00836043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13418|Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia|Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (CLL)||Sanofi|No|Terminated|October 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Patients,who are suffering from chronic lymphocytic leukemia (CLL) and are treated with        alemtuzumab (MabCampath)|December 2013|December 2, 2013|February 2, 2009||No|Study terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00836043||144001|
NCT00836056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30312|Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Clindamycin 300 mg Capsules and Cleocin HCl Administered as 1 x 300 mg Capsule in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|November 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 3, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00836056||144000|
NCT00836069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15002|Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder||Cedars-Sinai Medical Center|No|Terminated|October 2008|April 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|15|||Both|18 Years|65 Years|No|||May 2009|May 29, 2009|February 3, 2009|Yes|Yes|Pfizer has terminated the execution of this protocol|No||https://clinicaltrials.gov/show/NCT00836069||143999|
NCT00836654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60117|Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group|Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group||Neovii Biotech||Completed|September 2004|November 2006|Actual|November 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Both|18 Years|N/A|No|||February 2009|February 4, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836654||143956|
NCT00836667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02071|Sertraline Hydrochloride 100 mg Tablets, Fed|Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fed Conditions.||Teva Pharmaceuticals USA|No|Completed|March 2002|April 2002|Actual|April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 3, 2009|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00836667||143955|
NCT00831909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OEU-DUM-2008/1|Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN|Epidemiological Study to Describe Non-small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Europe. Lung|EPICLIN|AstraZeneca|No|Completed|January 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3513|||Both|18 Years|N/A|No|Probability Sample|All NSCLC patients attending the responsible department of treating this type of patients        (e.g. Oncology Department, Pneumology Department) for the first time (regardless of        whether the patient is diagnosed with locally, advanced or metastatic disease) at the        participating sites from the first of January 2009 to the end of March 2009. Patients        diagnosed, or even treated, in other departments within the same hospital or in another        hospital are susceptible to be included in the study if full access to the patient's        medical record is made available.|August 2010|August 9, 2010|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831909||144316|
NCT00831922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04012|Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis|A Multicenter, Open Label, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis With Inadequate Response to at Least One Disease Modifying Anti Rheumatic Drugs (DMARD)||AB Science|No|Completed|September 2004|||October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||August 2009|August 11, 2009|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831922||144315|
NCT00832156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBS 07.116 KC|Application of Cultured Autologous Keratinocytes for Burn Wound Healing|Application of Cultured Autologous Keratinocytes in Combination With a Meshed Split Skin Autograft for Burn Wound Healing|KC|Association of Dutch Burn Centres|Yes|Completed|June 2008|September 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832156||144298|
NCT00833560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005242|A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy|Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)||Janssen-Cilag G.m.b.H|No|Completed|March 2006|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|401|||Both|18 Years|60 Years|No|||November 2014|November 11, 2014|January 23, 2009||No||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00833560||144192|
NCT00833027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-103|ALPHA Sitagliptin Add on to Metformin (0431-103)|A 24 Week, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Adding Sitagliptin 100 mg Once Daily in Patients With T2DM Who Have Inadequate Glycemic Control on Metformin Therapy||Merck Sharp & Dohme Corp.|No|Completed|March 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|608|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 28, 2009|No|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00833027||144233|
NCT00833287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0126|Immunoregulatory Dysfunction in Trauma Patients: Role of Obesity|Immunoregulatory Dysfunction in Trauma Patients: Role of Obesity|ObesityRole|University of Mississippi Medical Center|No|Terminated|November 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Blood|Both|18 Years|80 Years|No|Non-Probability Sample|Adult patient with significant traumatic injury|April 2012|April 5, 2012|January 30, 2009||No|Enrollment process not efficient|No||https://clinicaltrials.gov/show/NCT00833287||144213|
NCT00834171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-RES-08-003|A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin|||Allergan||Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Data to be collected will include: Patient Demographics (age, gender, race, eye color),        medical and ophthalmic history, active ophthalmic disease, active systemic diseases,        concomitant medications, procedure/condition for which Lotemax®/Zylet® were prescribed,        underlying etiology requiring PK (if applicable), history of prior ocular surgery, prior        history of steroid response, history of glaucoma, start/stop date of steroid treatment,        IOP before and after steroid treatment, treatment-related adverse events, and any other        notes/information that the investigator feels may be important.|August 2011|August 17, 2011|January 30, 2009|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00834171||144145|
NCT00833547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sepracor051|Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia|Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia||Massachusetts General Hospital|No|Completed|September 2006|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|25|||Both|18 Years|45 Years|No|||August 2014|August 26, 2014|January 29, 2009|Yes|Yes||No|July 17, 2014|https://clinicaltrials.gov/show/NCT00833547||144193|
NCT00833872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 22811-S21|LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects|LEO 22811 - A Phase I, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects||LEO Pharma|No|Completed|January 2009|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833872||144168|
NCT00834574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B056501|Cefdinir for Oral Suspension 250 mg/5mL, Fasting|A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00834574||144114|
NCT00833885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RKI-NPI|Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal Influenza|Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal Influenza||Robert Koch Institut|No|Completed|January 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|300|||Both|2 Years|N/A|No|||April 2011|April 21, 2011|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833885||144167|
NCT00834951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTBI-NHL-01|Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma|A Prospective Multicenter Phase II Study of MabThera (Rituximab) Plus 2 Weekly CHOP Followed by Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma||University of Aarhus|No|Completed|January 2003|December 2008|Actual|December 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|60 Years|N/A|No|||February 2009|February 2, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834951||144085|
NCT00834964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02354|Venlafaxine 25 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00834964||144084|
NCT00834977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40012|Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|April 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|January 30, 2009|No|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00834977||144083|
NCT00835757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2008-1025|Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy|Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy"||University of Michigan|No|Completed|September 2008|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Two groups of 25 subjects each will be studied: subjects with confirmed diabetic        peripheral neuropathy (DPN) and age- and sex-matched healthy controls.|December 2013|December 13, 2013|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835757||144023|
NCT00864240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10504909|The Dose-response "Pilot" Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects|Dose Response of Clobex 0.05% Lotion||Actavis Inc.|No|Completed|October 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864240||141869|
NCT00864253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA033|A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma|An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma||Celgene|Yes|Completed|April 2009|February 2014|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|529|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|March 16, 2009|Yes|Yes||No|April 16, 2014|https://clinicaltrials.gov/show/NCT00864253||141868|Participation in the PK sampling for participants randomized to the ABI-007 arm was optional; too few samples were available to support the analysis
NCT00863928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB08100|Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain and Morphine Consumption on Patients After Robotic Assisted Laparoscopic Radical Prostatectomy|Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain and Morphine Consumption on Patients After Robotic Assisted Laparoscopic Radical Prostatectomy||Benaroya Research Institute||Completed||||||N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||||||Male|18 Years|N/A|No|||May 2010|May 25, 2010|March 17, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00863928||141893|
NCT00835276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-861|Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|March 2002|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00835276||144060|
NCT00835653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/42|Efficacy of Median Nerve Block Performed Using Echographic Guidance|Efficacy of Median Nerve Block Performed Using Echographic Guidance||Hopital Foch|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled for hand surgery|May 2009|May 27, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835653||144031|
NCT00835289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC9586|The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial|The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial|COD-Fish|Columbia University|Yes|Completed|March 2009|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00835289||144059|
NCT00835679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00014|Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery|A Preoperative Biological Trial of Cetuximab, Dasatinib or the Combination in Colorectal Cancer Patients With Resectable Liver Metastases||National Cancer Institute (NCI)||Terminated|December 2009|August 2011|Actual|February 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|9|||Both|18 Years|N/A|No|||January 2013|May 7, 2014|February 3, 2009|No|Yes||No|March 12, 2012|https://clinicaltrials.gov/show/NCT00835679||144029|Due to study design and slow accrual, no drug was received, no biomarkers were determined and no data obtained. "0" data is entered in the outcomes measures database as suggested by CT.gov previously. Detailed explanations are given.
NCT00836095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 29920|Comparison of ProSeal Laryngeal Mask Airway to Laryngeal Mask Airway Supreme|A Randomized Controlled Trial Comparing the ProSeal Laryngeal Mask Airway With the Laryngeal Mask Airway Supreme in Mechanically Ventilated Patients||Penn State University|Yes|Completed|January 2009|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|52|||Both|18 Years|75 Years|No|||November 2014|November 14, 2014|February 2, 2009||No||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00836095||143997|
NCT00836368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AT002620|In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics|In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics|Gammaphil|University of North Carolina, Chapel Hill|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|50 Years|No|||November 2011|November 4, 2011|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836368||143976|
NCT00836680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPejcl-230109|Clinical Study for the Evaluation of the Efficiency of a Device for the Diagnosis of an Internal Rectal Prolapse, a Pelvic Floor Ptosis and for the Determination of an Internal Hernia Into the Douglas Pouch|Study for the Evaluation of the Efficiency of a Device for the Diagnosis of an Internal Rectal Prolapse, a Pelvic Floor Ptosis and for the Determination of an Internal Hernia Into the Douglas Pouch||Gerhard Pejcl Medizintechnik GmbH|Yes|Recruiting|January 2009|June 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|N/A|No|||February 2009|February 2, 2009|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00836680||143954|
NCT00836693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12229|Effect of Tadalafil Once a Day in Men With Erectile Dysfunction|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors||Eli Lilly and Company|No|Completed|January 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|217|||Male|18 Years|N/A|No|||December 2010|December 15, 2010|February 2, 2009|Yes|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00836693||143953|
NCT00831935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH080819-01A1|Use of Conversation and Acoustic Signals in Measuring Depression Severity|Use of Conversation and Acoustic Signals in Measuring Depression Severity||Boston Medical Center|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample - residents in Boston, Massachusetts area and those referred from Boston        Medical Center primary care and psychiatry departments.|April 2013|April 5, 2013|May 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00831935||144314|
NCT00832169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00015|Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386|An Open, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD1386 to Healthy Male Volunteers||AstraZeneca|No|Completed|January 2009|February 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Male|35 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 27, 2009|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832169||144297|
NCT00832182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1229|Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes|An Open-labelled, Non-randomized, Multi-centre, Multinational Extension Trial Assessing the Safety of Insulin Aspart in Patients With Type I Diabetes Treated With a Basal-bolus Regimen||Novo Nordisk A/S|No|Completed|December 1999|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|75|||Both|18 Years|70 Years|No|||September 2011|June 8, 2012|January 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00832182||144296|
NCT00833599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-IMM-08-0415|Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders|Phase I/II Combinational Investigational New Drug Application: Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders||The University of Texas Health Science Center, Houston|No|Enrolling by invitation|January 2009|December 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|258|Samples With DNA|DNA from blood or saliva|Both|3 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1) Persons with lymphatic dysfunction (e.g. lymphedema, lipedema, dercums, etc.), 2)        Persons with vascular malformation that suggest a lymphatic component, 3) Family members        of persons, whom participated in this study, with a lymphatic dysfunction or vascular        malformation that suggests a lymphatic component and 3) Healthy, normal individuals as        controls|June 2015|January 14, 2016|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833599||144189|
NCT00833300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2009-001|Haloperidol vs Olanzapine for the Management of ICU Delirium|Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial||Nova Scotia Health Authority||Terminated|June 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833300||144212|
NCT00833313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P000896|Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery|Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery||Brigham and Women's Hospital|No|Recruiting|August 2008|August 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|Samples With DNA|Atrial tissue sample|Both|20 Years|80 Years|No|Non-Probability Sample|Adult patients undergoing cardiac surgery|February 2015|February 2, 2015|January 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00833313||144211|
NCT00834184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFCE-2008-002|Safety and PK of Nikkomycin Z in Healthy Subjects|Phase I, Randomized, Double-blind, Placebo Controlled, Multiple-dose Evaluation of the Safety Tolerance and Pharmacokinetics of Nikkomycin Z in Healthy Subjects||University of Arizona|Yes|Completed|October 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2010|February 12, 2013|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00834184||144144|
NCT00833573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GFR-DUM-2008/2|National Survey on GERD Patients (Adults and Children)|National Survey on GERD Patients (Adults and Children)|RGO à trav|AstraZeneca|No|Completed|January 2009|October 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|4400|||Both|N/A|N/A|No|Probability Sample|For GP : the first 3 consecutive adult patients and the first children seen during the        GP's visit with a diagnosis of GERD.For Paediatrics : the first 2 consecutive children        seen during the Paediatric's visit with a diagnosis of GERD.|November 2009|November 13, 2009|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833573||144191|
NCT00834587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-0477|5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting|A Relative Bioavailability Study of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets Under Non-Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|June 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 9, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00834587||144113|
NCT00833937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B016540|Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|March 2002|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|January 30, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00833937||144163|
NCT00834197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-339|15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting|A Relative Bioavailability Study of 15 mg Mirtazapine Orally Disintegrating Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|July 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00834197||144143|
NCT00834938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0005|Comparison Between Patients With or Without Diabetes Recovery After Bariatric Surgery|Long Term Effects of Bariatric Surgery on Diabetes: Comparison Between Patients With or Without Diabetes Recovery.||University of Campinas, Brazil|No|Completed|July 2007|July 2010|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|24|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with DM2 and obesity undergoing RYGB with remission of DM2 and without remission.|August 2011|August 9, 2011|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834938||144086|
NCT00834990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-593|Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00834990||144082|
NCT00835003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAUH091077|Timing of Planned Caesarean Section and Morbidity of the Newborn|Timing of Elective Caesarean Section and Neonatal Morbidity - a Randomised Multicentre Study||Aarhus University Hospital|Yes|Completed|March 2009|March 2014|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1273|||Female|18 Years|N/A|No|||June 2014|June 3, 2014|February 2, 2009||No||No|June 3, 2014|https://clinicaltrials.gov/show/NCT00835003||144081|
NCT00835354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036559|Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting|A Relative Bioavailability Study of Cefprozil for Oral Suspension 250 mg/5 mL Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|May 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00835354||144054|
NCT00835341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDHS-434|Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia|A Cohort Study on Prediction of Malignant Transformation of Oral Epithelial Dysplasia by p16 Methylation||Peking University|Yes|Completed|March 2005|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|93|Samples With DNA|Tissue specimen are collected from outpatients and inpatients with oral leukoplakia by      biopsy or surgical resection, fixed in neutral buffered formalin, and embedded in paraffin.      Genomic DNA is extracted from tissue sections.|Both|N/A|N/A|No|Probability Sample|101 patients with mild or moderate OED were selected from cases with oral leukoplakia,        lichen planus, or chronic discoid erythematosus at Peking University School of Stomatology        between 1995 and 2005. All of the patients with OED had been diagnosed pathologically by        at least two senior pathologists using the criteria from '2005 WHO Classification System'        (Gale et al, 2005). All cases involved primary lesions without any LASER, radiation        therapy or chemotherapy. p16 methylation status of OED samples was analyzed with        methylation-specific PCR combined with denatured high performance liquid chromatography        (Sun et al, 2004). 93 eligible cases with p16-methylated or p16-unmethylated OED were        enrolled into the cohort study.|May 2015|May 7, 2015|February 2, 2009||No||No|October 21, 2009|https://clinicaltrials.gov/show/NCT00835341||144055|
NCT00863941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0646-003|A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Fasted, Normal, Healthy Subjects.||Actavis Inc.|No|Completed|June 2004|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 19, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863941||141892|
NCT00863954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08165-01|Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes|A Controlled Pilot Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes||pico-tesla Magnetic Therapies, LLC|Yes|Completed|January 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|6||Anticipated|60|||Both|21 Years|80 Years|No|||December 2010|December 14, 2010|March 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00863954||141891|
NCT00834860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-960043|Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma|The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Active, not recruiting|January 2007|February 2010|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||February 2009|February 11, 2010|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00834860||144092|
NCT00834873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01269|Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects|A Randomized, Two-Way Crossover, Single-Dose, Open Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Carvedilol (25 mg), Compared to an Equivalent Dose of COREG® (SmithKline Beecham Pharmaceuticals) in 24 Fed, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|December 2001|December 2001|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|May 8, 2009|https://clinicaltrials.gov/show/NCT00834873||144091|
NCT00835302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0220|Development of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation|Development of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation||University of Colorado, Denver|No|Completed|October 2006|March 2009|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|65 Years|No|||February 2009|January 29, 2013|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835302||144058|
NCT00835692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02-663|Clarithromycin 500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Clarithromycin Tablets Under Fasting COnditions||Teva Pharmaceuticals USA|No|Completed|September 2002|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 2, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00835692||144028|
NCT00835705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30073|Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets and AUGMENTIN® 400 mg-57 mg Chewable Tablets Administered as 1 x 400 mg-57 mg Chewable Tablet in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|February 2, 2009|No|Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00835705||144027|
NCT00835718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_533|A Study of MK0594 in Patients With Alcohol Dependence|A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK0594 in Patients With Alcohol Dependence||Merck Sharp & Dohme Corp.||Terminated|February 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|162|||Both|21 Years|N/A|No|||March 2010|March 26, 2010|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00835718||144026|
NCT00836082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0541002|A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers|A Phase 1, Double-Blind (Sponsor Open), Randomised, Placebo-Controlled, Parallel Group, Oral Multiple-Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04457845 In Healthy Volunteers||Pfizer|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|41|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 5, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00836082||143998|
NCT00836394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBV-JIA|Effect of Whole Body Vibration Therapy in Children With Juvenile Idiopathic Arthritis|The Effect of Whole Body Vibration Therapy on Muscle Function and Joint Loading in Children With Juvenile Idiopathic Arthritis|WBV-JIA|Children's Hospital of Eastern Ontario|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|7 Years|18 Years|No|||May 2009|June 27, 2011|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836394||143974|
NCT00836381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-09-006|Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder|Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (Phase Ⅳ)||Samsung Medical Center|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|80 Years|No|||May 2013|May 29, 2013|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836381||143975|
NCT00836706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02-664|Clarithromycin 500 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 500 mg Clarithromycin Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|July 2002|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 2, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00836706||143952|
NCT00836719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT004433-01|Safety of Polyphenon E in Multiple Sclerosis Pilot Study|Safety and Neuroprotective Effects of Polyphenon E in Multiple Sclerosis||Louisiana State University Health Sciences Center in New Orleans|Yes|Completed|February 2009|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||May 2013|May 21, 2013|February 3, 2009|No|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00836719||143951|The study was a pilot study with a small sample size and no control group. The primary endpoint was futility in change in NAA thus the p-values for the primary endpoint are nominal only.
NCT00836732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/9-S|Mesenchymal Stem Cells: Alterations in Genome|MESenchymal Stem Cells: Alterations in GEnome|MESSAGE|Nantes University Hospital|No|Completed|November 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|75 Years|No|||September 2013|September 27, 2013|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836732||143950|
NCT00832481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NovoNorm 301 Chunlin Li|Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions|Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions in Newly Diagnosed Type 2 Diabetes Patients in China||Chinese PLA General Hospital|No|Recruiting|January 2009|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|20 Years|90 Years|No|||August 2009|August 24, 2009|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832481||144273|
NCT00833040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARX-C-003|A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain|A Multicenter, Randomized, Placebo-Controlled, Crossover Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 Compared to Placebo in the Treatment of Cancer Breakthrough Pain||AcelRx Pharmaceuticals, Inc.|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|January 28, 2009|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00833040||144232|
NCT00833053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05315|Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)|A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis|DOSE|Merck Sharp & Dohme Corp.|No|Terminated|October 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|January 29, 2009|Yes|Yes|In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was    discontinued due to low numbers of participants with suboptimal response.|No|March 15, 2012|https://clinicaltrials.gov/show/NCT00833053||144231|
NCT00833079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACR-0707|Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis||Taro Pharmaceuticals USA|No|Completed|October 2008|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|500|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|January 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00833079||144229|
NCT00833950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8/2/12|Phase Out in Tinnitus Patients|Phase Out Treatment for Tinnitus||University Hospital, Antwerp|No|Completed|March 2008|||March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2008|March 2, 2009|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833950||144162|
NCT00833586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10136024|Terbinafine HCl 250 mg Tablet Under Fasting Conditions|The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|January 2002|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00833586||144190|
NCT00833924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-013|Zenith(R) Low Profile AAA Endovascular Graft Clinical Study|Evaluation of the Safety and Effectiveness of the Zenith(R) Low Profile AAA Endovascular Graft||Cook||Active, not recruiting|May 2008|June 2016|Anticipated|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|January 30, 2009|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT00833924||144164|
NCT00834210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-ACZ0802|Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris|||Allergan||Completed|December 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|171|||Both|12 Years|N/A|No|||September 2011|September 22, 2011|January 30, 2009|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00834210||144142|
NCT00834236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS96-CT2-24|Proteiomic Fingerprints of Gastric Juice|Diagnosis of Gastroduodenal Diseases by Proteiomic Fingerprints of Gastric Juice||Kaohsiung Veterans General Hospital.|Yes|Completed|March 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|76|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|November 3, 2015|February 2, 2009||No||No|September 30, 2015|https://clinicaltrials.gov/show/NCT00834236||144140|The trial was performed in a single country
NCT00834600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-074|Renin Profiling in Selection of Initial Antihypertensive Drug|A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug||The Louis & Rachel Rudin Foundation|Yes|Completed|December 2005|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|185|||Both|40 Years|85 Years|No|||October 2010|April 18, 2012|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00834600||144112|
NCT00834613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2735|Metformin ER 750 mg Tablets, Fed|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Metformin ER 750 mg Tablets Versus Glucophage® XR 750 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|August 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00834613||144111|
NCT00844779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3966|Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients|Evaluation of Non Alcoholic Metabolic Liver Diseases in Patients Harboring Central Adiposity and Insulin Resistance by Biochemical and Functional Genomic Approaches||University Hospital, Strasbourg, France|No|Recruiting|February 2009|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples Without DNA|Serum|Both|18 Years|60 Years|No|Non-Probability Sample|Primary care clinic|April 2009|April 24, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844779||143342|
NCT00845039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13928|A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab|A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy|FC-4|ImClone LLC|No|Completed|May 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||July 2011|February 2, 2012|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845039||143322|
NCT00835367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40013|Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions|Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fed Conditions.||Teva Pharmaceuticals USA|No|Completed|March 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|January 30, 2009|No|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00835367||144053|
NCT00835380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V251-069|A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)|A Phase III Open-Label Study of Immunogenicity, Safety, and Tolerability of 2 Doses of VAQTA™ (Formalin, Inactivated, Alum-Adjuvanted Hepatitis A Vaccine) in Healthy Children 12 to 23 Months of Age||Merck Sharp & Dohme Corp.|No|Completed|March 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|80|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 30, 2009|Yes|Yes||No|October 19, 2009|https://clinicaltrials.gov/show/NCT00835380||144052|
NCT00845052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807009889|Survey of Housestaff Attitudes Toward Patient Care and Safety|Changing Housestaff Culture and Tracking Housestaff Attitudes Regarding Patient Care and Safety||Weill Medical College of Cornell University|No|Completed|July 2008|September 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|674|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Housestaff|March 2012|March 16, 2012|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00845052||143321|
NCT00863967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSBH: 216/03|Early Detection of Arteriosclerosis|Prospective Observational Cohort Study for Early Detection of Arteriosclerosis||Kantonsspital Baselland Bruderholz|No|Active, not recruiting|October 2003|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|269|Samples With DNA|Whole blood / serum / white cells / plasma|Both|18 Years|N/A|No|Probability Sample|teaching hospital primary care clinic|March 2009|March 17, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863967||141890|
NCT00863980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-486|Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients|Effects of Telmisartan Compared With Candesartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients: a Multi-center, Prospective, Randomized, Open-labeled, Blinded Endpoints Trial|KCPS|Kyoto Prefectural University of Medicine|Yes|Terminated|April 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1500|||Both|30 Years|85 Years|No|||September 2015|September 1, 2015|March 17, 2009||No|Principle investigator resigned in 2013|No||https://clinicaltrials.gov/show/NCT00863980||141889|
NCT00834886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00834886|Randomized Controlled Trial on the Treatment Effects of Melatonin and Light Therapy on Delayed Sleep Phase Syndrome|Delayed Sleep Phase Syndrome in Adolescents and Young Adults. Sleep, Personality, Developmental History, Circadian Rhythm, Daytime Functioning and Treatment||University of Bergen|Yes|Completed|October 2008|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|16 Years|25 Years|No|||March 2016|March 9, 2016|January 9, 2009||No||No|August 1, 2014|https://clinicaltrials.gov/show/NCT00834886||144090|
NCT00835731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP2-3|Misoprostol Versus Dilapan-S for Cervical Preparation|Cervical Preparation Before Same-day Second Trimester Abortion With Buccal Misoprostol Versus Dilapan-S: A Randomized Placebo Controlled Trial||Planned Parenthood League of Massachusetts|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|125|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 20, 2013|February 3, 2009||No||No|June 13, 2013|https://clinicaltrials.gov/show/NCT00835731||144025|
NCT00835744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/192|Comparison of Clomiphene Citrate and Gonadotropins in Ovulation Induction Cycles|Among Non-IVF Patients Undergoing Ovulation Induction With Clomiphene Citrate (Clomid® 50 mg), Does Administration of an Increased Dose of Clomiphene Citrate (Clomid® 100 mg) Compared With Gonadotropins, Achieve Similar Rates of Folliculogenesis?|cc versus FSH|Universitair Ziekenhuis Brussel|No|Completed|August 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|38 Years|No|||March 2012|March 27, 2012|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00835744||144024|
NCT00836108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG20080707ArmStrategy|Unsupported Arm Exercise and Breathing Strategy in Patients With Chronic Obstructive Pulmonary Disease|Unsupported Arm Exercise and Breathing Strategy in Patients With Chronic||West Park Healthcare Centre|No|Completed|February 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|N/A|N/A|No|||July 2012|July 10, 2012|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836108||143996|
NCT00836121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMECA2009|Anterior Mediastinum Teratoma: A Case Report|Case Report of a 39 Years Old Man That Has Been Cured by a Total Resection of a Anterior Mediastinum Teratoma.||Faculdade de Medicina de Catanduva|Yes|Completed|September 2008|December 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|1|||Male|39 Years|39 Years|No|Probability Sample|primary care clinic|February 2009|February 3, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836121||143995|
NCT00832208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBI 0106|Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL|Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis||Drugs for Neglected Diseases|Yes|Terminated|April 2009|March 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|4 Years|N/A|No|||January 2016|January 20, 2016|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832208||144294|
NCT00836745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181181|Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent|Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent||Pfizer|No|Completed|March 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|75 Years|No|Non-Probability Sample|All patients with advanced renal cell cancer in the treatment naïve or cytokine refractory        settings prescribed Sutent® will be eligible for the study.|November 2013|November 26, 2013|February 2, 2009|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT00836745||143949|Relatively small sample size might limit any useful interpretation and applicability of data for larger populations.
NCT00832494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1404-201|Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer|An Open Label, Randomized, Phase I/II Study of DMXAA in Combination With Carboplatin and Paclitaxel in Patients With Locally Advanced and Metastatic Non-Small Cell Lung Cancer||Antisoma Research|Yes|Completed|September 2004|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|N/A|N/A|No|||January 2009|January 29, 2009|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00832494||144272|
NCT00831948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CIR-02- Dr ROUZIER|Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.|Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.||Centre Hospitalier Universitaire de Nice|No|Recruiting|December 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet        detected by current diagnostic techniques|January 2009|January 28, 2009|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831948||144313|
NCT00832195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02995|Footwear and Injury Prevention Study|Footwear Prevention Study: Investigating the Effects of Running Shoe Pronation Control on the Risk of Injury||University of British Columbia|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 17, 2014|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832195||144295|
NCT00833326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-543-104|A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer|||Array BioPharma|No|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|January 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00833326||144210|
NCT00842985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702002357|Dronabinol Interactions in Humans|Dronabinol Interactions in Humans||Yale University|Yes|Completed|September 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|55 Years|No|||November 2012|November 15, 2012|February 11, 2009||No||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00842985||143477|One dose of modafinil Brief treatment duration and use of a low dose of THC Cognitive testing assessed only two tasks. Outcome measures were limited by small sample size.Limited generalizability because heavy cannibas users were excluded
NCT00842998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080331 - HERLAP|Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer|A Phase II, Randomized Trial With Single Agent Trastuzumab or Lapatinib in Patients With Metastatic HER2-Overexpressing Breast Cancer|HERLAP|Azienda Ospedaliera Ordine Mauriziano di Torino|No|Recruiting|February 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|75 Years|No|||June 2009|June 25, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842998||143476|
NCT00843011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110355|Food and Relative Bioavailability Study|A Open-Label, Randomized, Single-Dose, 3-Way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 2 Different Formulations of Orvepitant and the Effect of Food in Healthy Volunteers.|Food/rel BA|GlaxoSmithKline||Completed|August 2008|November 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 29, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843011||143475|
NCT00843271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA7791|Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA|Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)|MESA-LUNG|Columbia University|Yes|Active, not recruiting|October 2004|November 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4359|||Both|45 Years|84 Years|No|Non-Probability Sample|MESA cohort|January 2012|January 12, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843271||143456|
NCT00843284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081139|Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA|Assessing the Treatment of Patients With Neuropathic Pain Using LYRICA; A Non Interventional Post-marketing Study (NI-PMS)|NI-PMS|Pfizer|No|Completed|September 2006|March 2008|Actual|March 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|691|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with neuropathic pain|October 2009|October 21, 2009|February 12, 2009||No||No|March 11, 2009|https://clinicaltrials.gov/show/NCT00843284||143455|
NCT00833963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4621g|An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (MotHER)|An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta In Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior To Conception|MotHER|Genentech, Inc.||Recruiting|December 2008|December 2022|Anticipated|December 2022|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|This study is recruiting patients from anywhere within the United States. No office visits        are required to participate in this registry. Information is collected from patients based        on their medical charts.|October 2014|October 21, 2014|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833963|21 Months|144161|
NCT00834223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPK-04-101|A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)|A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)||OPKO Health, Inc.|No|Completed|January 2009|May 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2011|March 31, 2011|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834223||144141|
NCT00834249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02355|Venlafaxine 25 mg Tablets Under Non-Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|December 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00834249||144139|
NCT00843830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2005.135|A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma|||University of Michigan Cancer Center|Yes|Terminated|October 2006|April 2010|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|February 12, 2009|Yes|Yes|Study closed early secondary to inability to obtain grant funding to conduct.|No|October 29, 2014|https://clinicaltrials.gov/show/NCT00843830||143413|The study was closed early secondary to inability to obtain grant funding to conduct.
NCT00834626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH-001|Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes|Interventional Study of Effects of Ileal Interposition With Sleeve Gastrectomy for Control of Type 2 Diabetes|IISG|Kirloskar Hospital|Yes|Completed|January 2008|May 2011|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|25 Years|75 Years|No|||August 2012|August 30, 2012|February 1, 2009||No||No|February 3, 2011|https://clinicaltrials.gov/show/NCT00834626||144110|Non-availability of hormonal tests like Glucagon-Like Peptide-1 estimation pre- & post-operative.
NCT00834639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-592|Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00834639||144109|
NCT00845078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07120002|Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer|Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer||University of Pittsburgh|No|Recruiting|December 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|144|||Female|18 Years|70 Years|No|Non-Probability Sample|Patients undergoing mastectomy and radiation for breast cancer, who desire breast        reconstruction after mastectomy|February 2009|February 13, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00845078||143319|
NCT00845065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05685|Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)|A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin||Merck Sharp & Dohme Corp.|Yes|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|February 13, 2009|Yes|Yes||No|October 10, 2011|https://clinicaltrials.gov/show/NCT00845065||143320|
NCT00845299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 04|Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma|An Open-Label, Randomized, Phase 2 Study of the Effects of Artificial Tears Preserved With Benzalkonium Chloride (AT-BAK) on the Response to the Latanoprost Punctal Plug Delivery System (L PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|February 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845299||143302|
NCT00864318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 GENH 06|Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis|Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.|TICE|Institut Claudius Regaud|Yes|Recruiting|March 2009|September 2029|Anticipated|September 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00864318||141863|
NCT00864331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33029|Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy|Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy||International Atomic Energy Agency|Yes|Completed|February 2008|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|251|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864331||141862|
NCT00835315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPS001-HMO-CTIL|Prevalence of Psoriasis Alba in Psoriatic Patients|||Hadassah Medical Organization|Yes|Enrolling by invitation|January 2008|||||N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients of dermatology depatment and outpatient clinic in the hospital|February 2009|August 11, 2010|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00835315||144057|
NCT00836758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDILP-2008-SST-01|Comparison of Breathing Event Detection by a CPAP Device to Clinical Polysomnography|Validation of Breathing Event Detection of the REMstar Auto With Aflex Compared to Clinical Polysomnography||Philips Respironics|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|21 Years|75 Years|No|||July 2010|July 28, 2010|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836758||143948|
NCT00831961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090020|Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics|Prospective, Randomized, Observational Cohort Study of Antibiotic Resistance After Repeated Application of Topical Antibiotics|ARCaNE|Vanderbilt University|No|Completed|January 2009|||November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients age greater than 18 with choroidal neovascularization with planned treatment with        intravitreal injections.|December 2015|December 7, 2015|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831961||144312|
NCT00831974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04010|Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis|Phase IIa, Open-label, Randomized Study of Oral AB1010 in Patients With Systemic Indolent Mastocytosis With Handicap and Not Bearing Activating Point Mutations in the Phosphotransferase Domain of c-Kit Such as the Main Mutation Asp-816-Val (D816V)||AB Science|No|Completed|October 2004|||February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2009|August 13, 2013|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00831974||144311|
NCT00832221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00038|Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL|An Open Label, 1-sequence Cross-over, Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Receptor Occupancy of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) in Healthy Male Volunteers|PET|AstraZeneca|No|Completed|January 2009|September 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00832221||144293|
NCT00832507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-235-0101|Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension||Gilead Sciences|Yes|Terminated|January 2009|March 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|162|||Both|16 Years|70 Years|No|||January 2014|January 3, 2014|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00832507||144271|
NCT00832234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMN-01 (26866138CAN 2021)|Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia|Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network|BDR-WM|European Myeloma Network|No|Completed|September 2006|June 2013|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00832234||144292|
NCT00832806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07 - 01287|Smoke-Free Living Study|Smoking Cessation With Varenicline (Champix) and Integrated Voice Response Technology (IVR)||University of British Columbia|Yes|Completed|January 2008|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832806||144248|
NCT00832780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0810|Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung|INST 0810: Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung||New Mexico Cancer Care Alliance|Yes|Active, not recruiting|January 2008|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00832780||144250|
NCT00832793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCH2 449-2008|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers Patient Perspectives: Perspectives of Health Care Providers|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers Patient Perspectives: Perspectives of Health Care Providers||Sunnybrook Health Sciences Centre|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|N/A||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Health care providers of patients with inflammatory arthritis|January 2011|January 6, 2011|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00832793||144249|
NCT00833066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT-gpASIT003|Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis|Preliminary Assessment of the Clinical Tolerability, Safety and Immunogenicity of Three Different Doses of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis||BioTech Tools S.A.|Yes|Completed|February 2009|November 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|54|||Both|18 Years|50 Years|No|||November 2011|November 16, 2011|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833066||144230|
NCT00843297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COOL-Trial|COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest|Clinical and Neurological Outcome With Two Different Cooling Methods (Invasive and Non-invasive) After Sudden Cardiac Arrest|COOL|University of Leipzig|No|Completed|April 2008|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|N/A|N/A|No|||January 2010|February 1, 2010|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843297||143454|
NCT00843310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-919|Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma|Phase II Study of Revlimid (Lenalidomide), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation||New York University School of Medicine|Yes|Terminated|November 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|February 12, 2009|Yes|Yes|Due to slow accrual|No|August 13, 2013|https://clinicaltrials.gov/show/NCT00843310||143453|
NCT00843583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00808421|A Cross-sectional Study of the Occurrence and Effect of Obstructive Sleep Apnea in Subjects With Resistant Hypertension|A Cross-sectional Study of the Occurrence and Effect of Obstructive Sleep Apnea in Subjects With Resistant Hypertension||The University of Hong Kong|No|Completed|February 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|96|Samples Without DNA|Blood test for glucose, lipid, vascular and metabolic markers|Both|18 Years|65 Years|No|Non-Probability Sample|Consecutive sampling of subjects who attend Hypertension clinic , Department of Medicine,        Queen Mary Hospital, and who fulfill the inclusion criteria.|December 2014|December 29, 2014|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843583||143432|
NCT00843596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 0809|Surgical Bleeding Control of Extra-corporeal Circulation (ECC) by Vacuum Devices||HEMOCARD|University Hospital, Grenoble|Yes|Completed|October 2009|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843596||143431|
NCT00843856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001009-41|Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG)|Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis|MTAC|Imperial College Healthcare NHS Trust|No|Active, not recruiting|February 2009|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||September 2015|February 23, 2016|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843856||143411|
NCT00843570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER01|Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment|A Randomised Controlled Trial of Natural Versus Hormone Replacement Therapy Cycles in Frozen Embryo Replacement IVF: a Pilot Study||University of Oxford|Yes|Completed|November 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Female|18 Years|40 Years|No|||July 2013|July 24, 2013|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843570||143433|
NCT00843843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL083971|Sleep Length and Circadian Regulation in Humans|Sleep Length and Circadian Regulation in Humans|HAM|Rush University Medical Center|No|Completed|March 2008|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 12, 2009||No||No|November 2, 2015|https://clinicaltrials.gov/show/NCT00843843||143412|
NCT00844129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15464|Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)|Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)|Spine|University of Utah|No|Completed|December 2006|||September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|112|Samples With DNA|Urine|Both|6 Years|9 Years|No|Non-Probability Sample|The cohort will be recruited from a primary care clinic.|January 2014|January 17, 2014|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844129||143391|
NCT00841724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/9-P|Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies|Phase II Study of a Reduced-toxicity " Submyeloablative " Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies|ITT 08-01|Nantes University Hospital|No|Completed|January 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|65 Years|No|||May 2012|May 15, 2012|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841724||143572|
NCT00845312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIL|Prognostic Features for Mortality in Young Adults With Pneumonia|Prognostic Features for Mortality in Adult Pneumonia Patients at the Age of Sixty and Beneath.||Rambam Health Care Campus|No|Completed|March 2009|May 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1200|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients that were admitted with community acquired pneumonia to Rambam Medical Center        between the dates January 1, 2004 until December 31, 2008|February 2009|February 13, 2011|February 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00845312||143301|
NCT00845637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04004|Effect of Eggplant Extract on Lipid Profile During Fasting and Postprandial Period|Effect of the Oral Administration of Eggplant Extract Capsules on Lipid Profile During Fasting and Postprandial Period: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Completed|March 2004|March 2008|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 20, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845637||143276|
NCT00864344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-682-1G|A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|August 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864344||141861|
NCT00864357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0605002|A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864357||141860|
NCT00860119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131017|Bioequivalence of Alprazolam Sublingual vs Oral Tablets|Open-Label, Randomized, Single-Dose, 2-Way Crossover Pivotal Bioequivalence Study Comparing Alprazolam Immediate Release (IR) Tablets (Administered Orally) And Alprazolam Sublingual (SL) Tablets (Administered Sublingually)||Pfizer|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|23|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 11, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860119||142181|
NCT00836407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0834|Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|A Phase Ib Trial Evaluating the Safety and Feasibility of Ipilimumab (BMS-734016) Alone or in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene for the Treatment of Locally Advanced, Unresectable or Metastatic Pancreatic Adenocarcinoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|February 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|February 3, 2009|Yes|Yes||No|October 16, 2013|https://clinicaltrials.gov/show/NCT00836407||143973|
NCT00836420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 00/002|Cerebral Microdialysis in Patients With Fulminant Hepatic Failure|Cerebral Microdialysis in Patients With Fulminant Hepatic Failure||Rigshospitalet, Denmark|No|Completed|January 2000|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|microdialysate from the brain as part of rutine monitoring|Both|18 Years|N/A|No|Non-Probability Sample|consecutive patients with fulminant hepatic failure|October 2015|October 26, 2015|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836420||143972|
NCT00836433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-417|CONNECT for Better Falls Prevention in VA Community Living Centers|CONNECT for Better Falls Prevention in VA Community Living Centers|CONNECT|VA Office of Research and Development|Yes|Completed|February 2010|August 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|689|||Both|N/A|N/A|No|||October 2014|April 6, 2015|February 2, 2009||No||No|October 9, 2014|https://clinicaltrials.gov/show/NCT00836433||143971|
NCT00836771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80801|Infant Formula Supplemented With Probiotic Microorganisms and/or Prebiotic.|Evaluation of the Effect of Milk Based Infant Formula Supplemented Either With Probiotic Microorganisms and/or With Prebiotic on the Intestinal Microflora During the First 4 Months of Life of Healthy, Full Term Infants and it's Long Term Effect on Morbidity up to the Age of 9 Months||Materna Laboratories|Yes|Active, not recruiting|July 2009|December 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|270|||Both|N/A|21 Days|Accepts Healthy Volunteers|||May 2012|July 30, 2013|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836771||143947|
NCT00831987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC20|Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine|Annual Study of Safety and Immunogenicity of Influenza Virus Vaccine Fluzone® 2004-2005||Sanofi|No|Completed|August 2004|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|January 28, 2009|Yes|Yes||No|July 20, 2009|https://clinicaltrials.gov/show/NCT00831987||144310|
NCT00832247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELTHEP-02|Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis|Phase 1 Study of Autologous Bone Marrow Mononuclear Cells Infusion in Peripheral Vein in Liver Cirrhosis Due to Hepatitis C Virus|CELTHEP-02|Universidade Federal do Rio de Janeiro|Yes|Recruiting|January 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||January 2009|January 29, 2009|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832247||144291|
NCT00832520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0816|Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight|INST 0816: Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight||New Mexico Cancer Care Alliance|Yes|Terminated|November 2008|June 2011|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|January 29, 2009|Yes|Yes|Low accrual rate.|No|July 20, 2012|https://clinicaltrials.gov/show/NCT00832520||144270|Early termination leading to no subjects analyzed.There will be no publication, as this study was terminated after the original PI left employment with the institution.
NCT00842244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061055|Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer|A Phase 1 Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer||Pfizer|No|Completed|April 2009|October 2012|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|February 11, 2009|No|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT00842244||143533|AUC (0-24) was evaluated and reported for axitinib instead of AUClast as AUC0-24 was a more appropriate measure of steady-state exposure for this drug.
NCT00842465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070608|Prolactin Receptor and Breast Diseases|Characterization and Implication of Prolactin Receptor Mutants in Human Breast Diseases|Prolacsein|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|735|Samples Without DNA|blood collection breast Biopsy or surgery|Female|10 Years|N/A|No|Non-Probability Sample|Benign breast diseases(60 simple FA, 71 other breast diseases) Brest Cancer : 132 Control        : 525|October 2012|November 21, 2013|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00842465||143516|
NCT00833092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC014|Magnesium Nutrition and Sleep Behavior in Older Adults|Magnesium Nutrition and Sleep Behavior in Older Adults||USDA Grand Forks Human Nutrition Research Center|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|51 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 6, 2015|January 27, 2009||No||No|July 27, 2011|https://clinicaltrials.gov/show/NCT00833092||144228|
NCT00844155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#ML25018|Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit|A Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir (Tamiflu®) in Patients in the Intensive Care Unit||University of Manitoba|No|Withdrawn|March 2009|July 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||February 2010|April 1, 2010|February 13, 2009|Yes|Yes|Study has been withdrawn as the H1N1 epidemic made this study redundant|No||https://clinicaltrials.gov/show/NCT00844155||143389|
NCT00844454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARFArct|Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma|Ethanol Ablation Using a Multi-pronged Needle and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma: a Randomized Clinical Trial|QPEAvsRFA|Sun Yat-sen University|Yes|Recruiting|May 2008|May 2011|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||August 2009|August 10, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844454||143366|
NCT00844467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|king Saud university|A Retrospective Epidemiological Study on Pneumococcal Infection in Children in Ministry of Health Hospital at EHSA Region in the Eastern Province|Serotyping of Pneumococci|IPD in saudi|King Saud University||Active, not recruiting|February 2009|December 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|3 Months|5 Years|No|Non-Probability Sample|children under 5 years with invasive pneumococccal dis.|February 2009|February 13, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00844467||143365|
NCT00844805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05336|Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)|Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial|INFAST|Merck Sharp & Dohme Corp.|No|Completed|September 2009|September 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|158|||Both|18 Years|48 Years|No|||February 2015|February 24, 2015|February 13, 2009|No|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT00844805||143340|
NCT00844142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M01|Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)|Randomized Controlled 12 Months Trial With Etanercept (Enbrel ®) vs. Sulfasalazine in Early Axial Spondyloarthritis With Focus on Improvement of Acute Inflammatory Lesions as Detected by MRI. Amendment 4: 1-Year Extension of Study||Charite University, Berlin, Germany|Yes|Recruiting|November 2005|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||February 2009|February 12, 2009|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00844142||143390|
NCT00845091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL092340|Cardiac Autonomic Regulation Enhancement Through Exercise Trial|Cardiac Autonomic Regulation Enhancement Through Exercise Trial|CARE-E|The Miriam Hospital|Yes|Completed|February 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00845091||143318|
NCT00844441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2300.00|Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|Pilot Study of Feasibility, Safety, and Economics of Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Non-APL Acute Myeloid Leukemia||Fred Hutchinson Cancer Research Center||Completed|December 2008|March 2011|Actual|September 2010|Actual|N/A|Interventional|Primary Purpose: Health Services Research|1||Anticipated|96|||Both|18 Years|60 Years|No|||May 2011|May 17, 2011|February 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00844441||143367|
NCT00844792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0604-CE|Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer|A Randomized, Double-Blind Study of Combination Vitamin E, Selenium and Lycopene vs. Placebo in Men Undergoing Radical Prostatectomy for Prostate Cancer||University Health Network, Toronto|No|Completed|October 2008|||December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|N/A|No|||December 2015|December 21, 2015|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844792||143341|
NCT00845962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD07.007|A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia|Spinal Anesthesia With Bupivacaine or 2-chloroprocaine for Outpatient Elective Surgery: a Prospective, Randomized, Double-blind Comparison.||Université de Montréal|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||July 2009|January 26, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845962||143251|
NCT00842049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q1205/170|Lumbar Drainage in Subarachnoid Haemorrhage|Lumbar Drainage of Cerebrospinal Fluid in Aneurysmal Subarachnoid Haemorrhage: A Prospective Randomised Controlled Trial|LUMAS|The Leeds Teaching Hospitals NHS Trust|Yes|Completed|November 2006|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|N/A|No|||February 2009|February 22, 2011|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842049||143548|
NCT00842062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-3000|Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation|Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation||MyoScience, Inc|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|380|||Female|30 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842062||143547|
NCT00842036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406|CRAFT Behavior Therapy: Treatment Entry Component|CRAFT Behavior Therapy Phase 2 Study: Treatment Entry Component||Treatment Research Institute|Yes|Completed|January 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||June 2010|June 24, 2010|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842036||143549|
NCT00842296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLF-05-03|ClosureFAST - Radiofrequency Great Saphenous Vein Treatment|ClosureFAST - Endovascular Radiofrequency Great Saphenous Vein Treatment Using a Catheter With an Integrated Heating Element||VNUS Medical Technologies, A Covidien Company|No|Active, not recruiting|April 2006|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|396|||Both|18 Years|80 Years|No|||March 2012|March 19, 2012|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842296||143529|
NCT00860132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6962-AA-CTIL|Economic Aspects Associated With the Implementation of an Orthogeriatric Setting in a General Hospital|Economic Aspects Associated With the Implementation of an Orthogeriatric Setting in a General Hospital||Sheba Medical Center|No|Not yet recruiting|May 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|65 Years|N/A|No|Probability Sample|approx 1000 patients admitted with traumatic hip fracture to an orthogeriatric ward,        compared with approximately 1000 admissions to orthopaedic ward|March 2009|March 10, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00860132||142180|
NCT00860145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS058634|Radiosurgery or Open Surgery for Epilepsy Trial|Radiosurgery Versus Lobectomy for Temporal Lobe Epilepsy|ROSE|University of California, San Francisco|Yes|Active, not recruiting|September 2009|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|March 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00860145||142179|
NCT00836160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OTW-DUM-2008/1|Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy|Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy||AstraZeneca|No|Completed|August 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|36|||Both|20 Years|N/A|No|Probability Sample|The EGFR-TKI receiver who are suitable for third-line therapy will be followed up for the        regimen of the third-line anti-microtubule agents or non-anti-microtubule agents|September 2012|September 19, 2012|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836160||143992|
NCT00836446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212250-02211|Effects of Physical Activity on Cardiovascular Risk Markers in School-Aged Mexican Children|Effects of Physical Activity on Cardiovascular Risk Markers in School-Aged Mexican Children||Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes|No|Completed|August 2008|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|214|||Both|8 Years|13 Years|No|||March 2009|March 10, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836446||143970|
NCT00836459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120243|Sheffield Physical Activity Booster Trial|A Randomised Controlled Trial and Cost-effectiveness Evaluation of "Booster" Interventions to Sustain Increases in Physical Activity in Middle-aged Adults in Deprived Urban Neighbourhoods.|Booster|University of Sheffield|No|Completed|November 2009|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|282|||Both|40 Years|64 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836459||143969|
NCT00836784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Comparison of New and 3-Month-Old Toothbrush in the Removal of Plaque in Children|Comparing Efficacy of Old Versus New Toothbrushes in Plaque Removal in the Hands of 7-9 Year Old Children.||Shahid Beheshti University|No|Completed|February 2009|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|93|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||May 2009|May 4, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836784||143946|
NCT00842270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04026|Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma||AB Science|No|Completed|January 2006|||July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842270||143531|
NCT00842257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-287|Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer|A Single Arm Phase II Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer||Massachusetts General Hospital|Yes|Not yet recruiting|September 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||May 2010|May 3, 2010|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842257||143532|
NCT00842478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS 06/0060|Effectiveness of Dental Brushing for Preventing Ventilator-Associated Pneumonia|Effectiveness of Dental Brushing for Preventing Ventilator-Associated Pneumonia|RASPALL|Hospital Universitari Joan XXIII de Tarragona.|Yes|Recruiting|May 2005|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2009|February 11, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842478||143515|
NCT00842738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP05010|Can Alternative Treatment Have an Impact on Cervical Dysplasia?|Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia?||University of Copenhagen|No|Enrolling by invitation|March 2009|December 2011|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Female|23 Years|29 Years|Accepts Healthy Volunteers|||February 2009|January 13, 2010|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00842738||143496|
NCT00843024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107979|Migraine Study in Adolescent Patients|TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents||GlaxoSmithKline|No|Completed|December 2008|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|589|||Both|12 Years|17 Years|No|||November 2012|November 21, 2012|February 12, 2009|Yes|Yes||No|January 22, 2011|https://clinicaltrials.gov/show/NCT00843024||143474|
NCT00842686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21901|Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study|Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study|CRAB|Institute of Oncology Ljubljana|Yes|Active, not recruiting|January 2009|August 2014|Anticipated|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2012|March 23, 2012|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842686||143499|
NCT00842699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008p000774|Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab|Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab||Brigham and Women's Hospital|No|Completed|September 2008|March 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|renal transplant recipients and living donors if available|June 2011|June 27, 2011|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00842699||143498|
NCT00844818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P002104|An Intervention to Address Parental Smoking During the Postpartum Hospitalization.|Using the Postpartum Hospital Stay to Address Mother's and Father's Smoking: the NEWS Study|NEWS|Massachusetts General Hospital|No|Completed|February 2005|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|N/A|N/A|No|||February 2009|February 12, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00844818||143339|
NCT00845104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2278.00|Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment|A Phase II Study of Fludarabine (F), Rituxan (R) and Avastin (A) Followed by RA Maintenance in Patients With Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)||Fred Hutchinson Cancer Research Center|Yes|Withdrawn|January 2009|||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 4, 2015|February 17, 2009|No|Yes|No patients enrolled.|No||https://clinicaltrials.gov/show/NCT00845104||143317|
NCT00845338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12331|Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity|A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity||Bayer|No|Terminated|February 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2014|November 28, 2014|February 16, 2009||No|The enrollment rate at most centers was unlikely to result in the recruitment of the planned    sample size of 40 evaluable subjects.|No||https://clinicaltrials.gov/show/NCT00845338||143299|
NCT00845351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13936|Preoperative Bexarotene Treatment for Cushing's Disease|Preoperative Bexarotene Treatment for Cushing's Disease||University of Virginia|No|Recruiting|November 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Both|18 Years|65 Years|No|||May 2011|May 26, 2011|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845351||143298|
NCT00845325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108957|Early Motion Following Carpal Tunnel Release|Early Motion Following Carpal Tunnel Release, a Randomized Control Trial||University of Missouri-Columbia|No|Recruiting|December 2008|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|N/A|N/A|No|||February 2016|February 25, 2016|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845325||143300|
NCT00845663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87045|Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)|Open Label, Randomized, Parallel Group, Single Dose, 2-way Comparison Bioequivalence Study of Certolizumab Pegol Solution Injected Either by a Pre-filled Syringe (Reference) or by an Auto-injection Device (Test) to Healthy Volunteers.||UCB Pharma|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|August 30, 2011|February 13, 2009|No|Yes||No|August 25, 2009|https://clinicaltrials.gov/show/NCT00845663||143274|
NCT00845676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRP ID06-SF-218|Treatment of Acute Hepatitis C Virus in HIV Co-Infection|Treatment of Acute Hepatitis C Virus in HIV Co-Infection||University of California, San Francisco|Yes|Completed|March 2008|December 2013|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|February 17, 2009|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00845676||143273|
NCT00841737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI07/90712|Evaluation of a Psychoeducation Group Program for Mild/Moderate Depression|Evaluation of the Effectiveness and Efficiency of a Psychoeducational Group Sessions Intervention Program in the Depressive Episode Realized by Primary Health Care Center Nurses in Barcelona City.||Jordi Gol i Gurina Foundation|Yes|Recruiting|January 2008|April 2010|Anticipated|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|20 Years|65 Years|No|||August 2009|August 5, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00841737||143571|
NCT00842075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0724(2)|Pramlintide in Adolescents With Type 1 Diabetes|Effects of Pramlintide in Adolescents With Type 1 Diabetes||University of Colorado, Denver|No|Completed|December 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|10|||Both|13 Years|17 Years|No|||September 2012|May 26, 2015|January 20, 2009||No||No|September 17, 2012|https://clinicaltrials.gov/show/NCT00842075||143546|
NCT00842309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001429|D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder|A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder|BDD/DCS|Massachusetts General Hospital|No|Recruiting|November 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842309||143528|
NCT00828997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-nr 2007-006539-29|Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar®|Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar®|PVA|Region Skane|Yes|Enrolling by invitation|August 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|No|||October 2013|November 6, 2013|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00828997||144538|
NCT00829348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61-2005-CTIL|Short Message Service (SMS) Impact on Patient Compliance Receiving Long Term Lipid Lowering Therapy With Statins|Short Massages Service (SMS) Impact on Patient Compliance Receiving Long Term Lipid Lowering Therapy With Statins.||Hillel Yaffe Medical Center|No|Completed|August 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|120|||Both|18 Years|70 Years|No|||December 2009|December 29, 2009|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829348||144511|
NCT00836173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200119|Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase II Study Evaluating Three Cyslces of Ifosfamide, Carboplatin, Etoposide, and Rituximab (RICE) Followed by Two Cycles of Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma MA||Loyola University|Yes|Withdrawn|July 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 3, 2009|Yes|Yes|Gallium is no longer available for the conduct of this study.|No||https://clinicaltrials.gov/show/NCT00836173||143991|
NCT00836186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J08130|Cytokine Expression During Radiation for Breast Cancer|Cytokine Expression During Radiation for Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|N/A|No|||March 2014|March 28, 2014|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00836186||143990|
NCT00841672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A2306|Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension|An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients||Novartis||Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|485|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|February 10, 2009||No||No|January 5, 2011|https://clinicaltrials.gov/show/NCT00841672||143576|
NCT00841685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/109|The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate|The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate||University Hospital, Ghent|No|Recruiting|December 2008|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|20|||Male|18 Years|N/A|No|||December 2014|December 4, 2014|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841685||143575|
NCT00841984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051057|In Vitro NMR Spectroscopy in Neurological Diseases|Evaluation of in Vitro NMR Spectroscopy to Identify Inborn Errors of Metabolism in Patients With Complex Neurological Diseases|SPECMET|Assistance Publique - Hôpitaux de Paris|No|Terminated|July 2006|January 2009|Actual|July 2008|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|271|Samples Without DNA|urines, cerebrospinal fluid|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with an unexplained complex neurological disease|February 2009|February 11, 2009|February 11, 2009||No|not enough enrollment|No||https://clinicaltrials.gov/show/NCT00841984||143552|
NCT00842751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35724-W|Oral T7 Oral Testosterone in Man|Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride|Oral T7|University of Washington|Yes|Completed|July 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|February 10, 2009|Yes|Yes||No|March 21, 2011|https://clinicaltrials.gov/show/NCT00842751||143495|
NCT00842491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOCX|Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer|A Phase II Study of Endostar (Recombinant Human Endostatin ®) With Cisplatin and Capecitabine (Xeloda) as 1st Line Treatment in the Advanced Gastric Cancer||Peking University|Yes|Completed|November 2008|December 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|No|||May 2015|May 17, 2015|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842491||143514|
NCT00842712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200037-014|Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)|Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Cilengitide Regimens in Combination With Cetuximab and Platinum-based Chemotherapy (Cisplatin/Vinorelbine or Cisplatin/Gemcitabine) Compared to Cetuximab and Platinum-based Chemotherapy Alone as First Line Treatment for Subjects With Advanced NSCLC|CERTO|Merck KGaA||Completed|February 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|232|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|February 10, 2009||No||No|July 31, 2014|https://clinicaltrials.gov/show/NCT00842712||143497|
NCT00843050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/23/08|A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma|Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma||Piramal Enterprises Limited|No|Terminated|November 2009|August 2012|Anticipated|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|February 12, 2009|Yes|Yes|The study was terminated based on interim results and all subjects were off study at that    time. No major safety or tolerability concerns|No|February 29, 2012|https://clinicaltrials.gov/show/NCT00843050||143472|The Sponsor has terminated the study based on interim results. All subjects were off study at the time of termination. There are no major safety or tolerability concerns from this study. The study results published here are preliminary results.
NCT00843609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INHS1|International Navigator Hypoglycaemia Study|International Navigator Hypoglycaemia Study: Evaluation of the Incidence and Duration of Hypoglycaemia Using the Freestyle Navigator® Continuous Glucose Monitoring System||University Medical Centre Ljubljana|Yes|Completed|October 2008|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|10 Years|65 Years|No|||June 2009|February 4, 2010|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843609||143430|
NCT00844181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512000875|Racial Differences in Orthostatic Tolerance|Racial Differences in Orthostatic Tolerance||Yale University|No|Completed|October 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|18|Samples With DNA|whole blood|Female|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample of women of reproductive age|February 2009|February 13, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00844181||143387|
NCT00843037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNIPP|Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma|A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma|SNIPP|University Health Network, Toronto|Yes|Recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843037||143473|
NCT00844831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|285.09|Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit|Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit||University of Louisville|No|Active, not recruiting|May 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||April 2009|June 21, 2010|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00844831||143338|
NCT00844844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-002B|Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS|An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)|aHUS|Alexion Pharmaceuticals|Yes|Completed|May 2009|July 2013|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|12 Years|17 Years|No|||June 2015|June 30, 2015|February 13, 2009|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT00844844||143337|
NCT00845117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 7/28/153|Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency|Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency|LECT|University Hospital, Antwerp||Active, not recruiting|July 2008|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|N/A|No|||June 2013|June 19, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845117||143316|
NCT00845364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3217|Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery|Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery|CASPER|University Hospital Birmingham|Yes|Completed|February 2007|April 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|290|||Both|18 Years|N/A|No|||May 2010|May 19, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845364||143297|
NCT00845377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUWAged 0901|Changing Minds - Supporting Depressed Elderly People With an Individually Tailored Service Model|Changing Minds - Studying the Effects of a Tailored Psychosocial Support Model on Depressive Mood and Quality of Life in Depressive Elderly People||Central Union for the Welfare of the Aged|Yes|Recruiting|April 2008|June 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845377||143296|
NCT00845689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-202-LTR|Prevention of Liver Damage During Liver Surgery|Study on the Potential Role of Intraoperative Hepatoprotection During Liver Resections|LTR|Ludwig-Maximilians - University of Munich|No|Active, not recruiting||||||Phase 1/Phase 2|Interventional|N/A|3||||||Both|N/A|N/A||||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00845689||143272|
NCT00845702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-046|Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)|Evaluation of Dotarem-enhanced Magnetic Resonance Angiography (MRA) Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Renal Arterial Disease||Guerbet|No|Terminated|April 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|33|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|February 16, 2009|Yes|Yes|lack of recruitment.|No|September 22, 2011|https://clinicaltrials.gov/show/NCT00845702||143271|The study was not completed due to poor enrollment. The statistical analysis was not performed.
NCT00845975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-001|Study of Low Level Laser Therapy and Tinnitus Relief|A Double-blind, Placebo-controlled Randomized Evaluation of the Application of Low Level Laser Light Therapy Using the Erchonia Hearing Lasers for the Relief of Tinnitus Clinical Study Protocol.||Erchonia Corporation|Yes|Terminated|August 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 7, 2014|February 16, 2009|Yes|Yes|New information suggested a more effective treatment protocol.|No|April 11, 2013|https://clinicaltrials.gov/show/NCT00845975||143250|
NCT00841750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9009001|Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection|The NoTube Study: Evaluation of the Necessity of a Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection.|NOTUBE|Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle|Yes|Recruiting|July 2008|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|N/A|No|||July 2011|July 19, 2011|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841750||143570|
NCT00841763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P13|Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects|A Phase III, Randomized, Controlled, Observer-blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted With MF59 (Fluad-H5N1) in Adult and Elderly Subjects||Novartis||Completed|October 2008|November 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3647|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 18, 2013|February 10, 2009||No||No|July 4, 2011|https://clinicaltrials.gov/show/NCT00841763||143569|
NCT00833183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-6005|Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial Acne|A Study of Safety and Efficacy of Topical Methylaminolevulinate 80mg/g With and Without Occlusion Followed by Red Light Exposure in Subjects With Facial Acne||Photocure|No|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|N/A|No|||January 2009|January 29, 2009|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833183||144221|
NCT00833196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-79-52120-131|Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia|Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia||Ipsen|No|Completed|February 2009|April 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with idiopathic cervical dystonia|July 2010|July 6, 2010|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833196||144220|
NCT00842322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFS1|Fluid Intake in Kidney Failure|The Effect of Increased Fluid Intake on Chronic Renal Failure||Medical University of Vienna|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|70 Years|No|||February 2009|February 12, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842322||143527|
NCT00829361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005156|Stroke Telemedicine for Arizona Rural Residents Trial|Stroke Telemedicine for Arizona Rural Residents Trial|STARR|Mayo Clinic|Yes|Completed|October 2008|January 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|447|||Both|18 Years|120 Years|No|||November 2015|November 23, 2015|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00829361||144510|
NCT00841698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02182-A|Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Paroxetine Hydrochloride 40 mg Film-Coated Tablets and Paxil® 40 mg Film-Coated Tablets Administered as 1 x 40 mg Film-Coated Tablet in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|February 9, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00841698||143574|
NCT00845923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-04-03|Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia|Phase II Proof of Concept Trial of Civamide Patch in the Treatment of Post-herpetic Neuralgia and Post-incisional Neuralgia||Winston Laboratories|No|Completed|March 2009|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|80 Years|No|||May 2014|May 19, 2014|February 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845923||143254|
NCT00845936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin-38CTIL|Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics|Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study||BeerYaakov Mental Health Center||Not yet recruiting|May 2009|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|20 Years|No|||February 2009|February 18, 2009|February 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00845936||143253|
NCT00842283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2007-6094|Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target|Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target||University of California, Irvine|No|Recruiting|November 2008|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Observational|N/A||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Tissue samples will be collected from Dermatopathology Lab, Pathology lab, discarded        tissue from dermatologic surgery at University of California Irvine. Additional biopsies        may be obtained of known lesions.|February 2016|February 5, 2016|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00842283||143530|
NCT00842504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Micafungin PK|Alternate Day Micafungin: A PK Study in Pediatric Patients|Alternate Day Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients: A Pharmacokinetic Study||Children's Hospital Medical Center, Cincinnati|No|Completed|July 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|N/A|10 Years|No|||February 2012|February 15, 2012|February 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00842504||143513|
NCT00843622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM 08-01|Controlled Study of the Ability of a Smokefree Tobacco Product to Increase the Quit Rate Among Cigarette Smokers|A Controlled Study of the Ability of a Traditional Swedish Smokeless Tobacco Product ("Snus") to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking||Swedish Match AB|No|Completed|February 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|February 12, 2009||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT00843622||143429|
NCT00843323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0614/08|Photodynamic Therapy (PDT) Effect on Large Surface Photodamaged Skin|Histological and Immunohistochemical Study of Photodamaged Skin Submitted to MAL-PDT|PDT|University of Sao Paulo|Yes|Completed|December 2008|June 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||June 2010|June 10, 2010|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843323||143452|
NCT00843882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01173|Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia|Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia||National Cancer Institute (NCI)|Yes|Recruiting|January 2009|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|N/A|No|||October 2015|March 24, 2016|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00843882||143409|
NCT00844194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208.34|Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder|A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD||Boehringer Ingelheim||Completed|February 2009|||June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|108|||Both|18 Years|N/A|No|||December 2013|May 2, 2014|February 13, 2009||||No|June 7, 2011|https://clinicaltrials.gov/show/NCT00844194||143386|
NCT00844480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIC-TJS003|Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss|Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss||Northwestern University|No|Terminated|March 2010|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 13, 2009|Yes|Yes|difficulty in enrollment|No||https://clinicaltrials.gov/show/NCT00844480||143364|
NCT00843869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080623004|Reversal of Tobacco-Related Sinusitis|Reversal of Tobacco-Related Sinusitis (Flight Attendant Medical Research Institute (FAMRI) Young Clinical Scientist Award)||University of Alabama at Birmingham|No|Completed|August 2008|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|282|Samples Without DNA|Zinc levels and hair samples will be collected.|Both|19 Years|N/A|No|Non-Probability Sample|Patients with chronic rhinosinusitis undergoing routine sinus and skull base surgery|March 2015|March 24, 2015|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00843869||143410|
NCT00832611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX IX|Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Study of the Effect of the ROX Percutaneous Arteriovenous Fistula System (ROX AC1) on Exercise Capacity and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)||ROX Medical, Inc.|Yes|Completed|November 2008|November 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832611||144263|
NCT00832624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-118|The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)|Open-label, Non Placebo-Controlled Study To Verify the Effect of Sitagliptin In Adult Patients With Type 2 Diabetes and Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Terminated|November 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|January 28, 2009|No|Yes|Business Reasons|No|July 6, 2010|https://clinicaltrials.gov/show/NCT00832624||144262|The planned 18-week study was terminated early due to reconsideration of the study design. None of the 10 patients progressed beyond the second study visit, no laboratory tests were performed, and adverse experience data were not collected.
NCT00832845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|066/2008|Cognitive Behavioral Social Skills Training for Patients With Late-Life Schizophrenia: a Pilot Study|Cognitive Behavioral Social Skills Training for Patients With Late-Life Schizophrenia: a Pilot Study|CBSST|Centre for Addiction and Mental Health|No|Active, not recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|N/A|No|||July 2015|July 20, 2015|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832845||144245|
NCT00833144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015895|Bedside Ultrasound Identifies Congestive Heart Failure|Emergency Physician-Performed Thoracic Ultrasound Rapidly Identifies Patients With Congestive Heart Failure||Emory University|Yes|Completed|February 2009|February 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|375|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to the Emergency Care Center with the chief complaint of shortness of        breath or dyspnea will be eligible for the study.|December 2013|December 12, 2013|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833144||144224|
NCT00839332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12096|A Study for Patients With Pancreatic Cancer|A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer||Eli Lilly and Company|Yes|Completed|March 2009|December 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|85 Years|No|||April 2014|April 14, 2014|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839332||143753|
NCT00834704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-109-101|Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors|Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors|PEG|Halozyme Therapeutics|No|Completed|February 2009|November 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|No|||September 2012|March 24, 2013|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00834704||144104|
NCT00835133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|355-06|Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma|Biospecimen Resource for Familial Pancreas Research, a Data and Tissue Registry (Also Known as a Bio-repository, Bio-bank, Data and Tissue Database, Data and Tissue Bank, Etc.) to Help Advance Research in Familial Pancreas Disease||Mayo Clinic|Yes|Recruiting|August 2002|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Two 10mL plasma tubes and two 10mL serum tubes collected. DNA extracted from blood      lymphocytes. Possible saliva sample for DNA extraction. Waste tissue from previous surgery      may be requested.|Both|18 Years|120 Years|Accepts Healthy Volunteers|Non-Probability Sample|Familial pancreatic cancer kindred|January 2016|January 5, 2016|January 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00835133||144071|
NCT00835146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036552|Ribavirin 200 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00835146||144070|
NCT00840307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072008-039|Changes in Ectopic Fat Following Surgically Induced Weight Loss|Changes in Ectopic Fat Following Surgically Induced Weight Loss: Does it Explain the Resolution of Diabetes?||University of Texas Southwestern Medical Center|No|Completed|August 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|N/A|No|Non-Probability Sample|Patients already scheduled to undergo gastric banding within 1-2 months.        This study does NOT pay for the bariatric surgery, eligible participants must already be        scheduled to have the surgery performed by their own physician|January 2013|May 26, 2015|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00840307||143680|
NCT00840632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2977|Trandolapril 4 mg Tablet Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Trandolapril 4 mg Tablets Versus Mavik® 4 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|October 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|February 6, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00840632||143656|
NCT00840645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-051|A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients|Long-term Study of YM178: Long Term Study of YM178 in Subjects With Overactive Bladder||Astellas Pharma Inc|No|Completed|December 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|204|||Both|20 Years|N/A|No|||January 2016|January 4, 2016|February 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00840645||143655|
NCT00836927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-038|Extension Trial of Deforolimus in Patients With Advanced Cancer (8669-038)|An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer||Merck Sharp & Dohme Corp.|No|Active, not recruiting|February 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||February 2016|February 3, 2016|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836927||143935|
NCT00816465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HoodiaNAFLD-HMO-CTIL|Safety and Efficacy of Hoodia Gordonii for Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|||Hadassah Medical Organization|Yes|Completed|May 2009|August 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||September 2010|September 16, 2010|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816465||145492|
NCT00816478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPHCURE 1|Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor|Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)||Northwell Health|Yes|Terminated|December 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|2 Years|60 Years|No|||September 2015|September 8, 2015|December 31, 2008|Yes|Yes|Study closed by Institutional Review Board|No||https://clinicaltrials.gov/show/NCT00816478||145491|
NCT00816764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008001|A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer|A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-8M4 Given as Monotherapy in Subjects With Advanced Ovarian Cancer||Astellas Pharma Inc|No|Completed|October 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Female|18 Years|N/A|No|||November 2010|February 26, 2013|January 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00816764||145469|
NCT00816777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA1013|Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer|Feasibility and Prospective Randomized Study of Transarterial Chemoembolization Using Irinotecan Bead in Combination With Second Line Chemotherapy in the Treatment of Patients With Unresectable Metastatic Colorectal Cancer|PARAGON|Generic Devices Consulting, Inc.|No|Terminated|December 2008|March 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|January 2, 2009|Yes|Yes|Lack of enrollment|No|August 12, 2014|https://clinicaltrials.gov/show/NCT00816777||145468|
NCT00840814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612406|Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer|Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients||Vanderbilt University||Completed|May 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|55|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult head and neck cancer survivors and Head and neck cancer experts|February 2012|February 20, 2012|February 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840814||143642|
NCT00838305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28.065-1|Role of Serotonin in Acute and Subacute MDMA Effects|||California Pacific Medical Center Research Institute||Completed|February 2009|August 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|January 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00838305||143829|
NCT00838318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0039|Colon Cancer Screening in First-Degree Relatives of Hispanic Colorectal Cancer (CRC) Patients|Colorectal Cancer (CRC) Screening in First-Degree Relatives (FDRs) of Hispanic CRC Patients||M.D. Anderson Cancer Center|No|Completed|February 2004|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Key Informants from Houston Hispanic Health Coaltion having professional expertise        relevant to this study; MDACC Hispanic/Latino CRC Patients, age 18 - 60 years with first        degree relatives between age 40 - 70; First-degree relatives (siblings and children) of        the MDACC CRC cancer patients recruited to this study, who are aged 40 - 70 years.|July 2012|July 26, 2012|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838318||143828|
NCT00836810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME/2008/3031|Timed Release Tablet Prednisone in Polymyalgia Rheumatica|Circadian Variation in Cytokines and the Effect of Timed Release Tablet Prednisone in Polymyalgia Rheumatica||University Hospitals Bristol NHS Foundation Trust|No|Completed|October 2009|March 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|50 Years|85 Years|No|||September 2015|September 4, 2015|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836810||143944|
NCT00832013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02846|Safe Administration of Propofol for Sedation in Children|Safe Administration of Propofol for Sedation in Children||University of British Columbia||Completed|June 2008|August 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||August 2009|August 17, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00832013||144308|
NCT00840125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-NSCLC-2008|Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment|A Phase II Open-Label Study Designed to Evaluate the Efficacy and Safety, of Erlotinib in Combination With Docetaxel in Selected Non Small Cell Lung Cancer Patients Eligible for First Line Treatment||Meir Medical Center|Yes|Completed|February 2009|August 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840125||143694|
NCT00833157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIM-037|Effect of Glucosamine or Ibuprofen Combined With Physical Training in Patients With Knee-Osteoarthritis|Effect of Glucosamine or Ibuprofen Combined With Physical Training in Patients With Knee-Osteoarthritis||Bispebjerg Hospital|No|Active, not recruiting|February 2005|March 2009|Anticipated|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|36|||Both|50 Years|70 Years|No|||January 2009|January 29, 2009|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833157||144223|
NCT00838149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I458|Effect of Glutamine on Intestinal Permeability in Crohn's Disease|Effect of Glutamine Supplementation on the Structure and Function of the Mucosa of Small Intestine in Crohn's Disease: A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|Yes|Completed|November 2005|November 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|15 Years|60 Years|No|||February 2009|February 5, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838149||143841|
NCT00833404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-06-0020|Smoking Cessation and Sexual Health in Men|Effects of Smoking Cessation on Sexual Health in Men||University of Texas at Austin|No|Completed|December 2008|December 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|23 Years|60 Years|No|||September 2011|September 9, 2011|January 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00833404||144204|
NCT00833417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4476g|A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma|A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma||Genentech, Inc.||Completed|February 2009|April 2014|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|January 30, 2009|Yes|Yes||No|February 23, 2012|https://clinicaltrials.gov/show/NCT00833417||144203|
NCT00832871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0817|Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers|INST 0817: Compassionate Use of Mifepristone||New Mexico Cancer Care Alliance|No|Terminated|November 2008|December 2015|Actual|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 29, 2009|Yes|Yes|Low accrual; 4 patients enrolled between 2008-2015|No||https://clinicaltrials.gov/show/NCT00832871||144244|
NCT00834028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-950168|Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization|Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization : The Roles of VEGF, Cathepsin L, Endostatin, and Angiopoietin-2.||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|February 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|Samples With DNA|serum|Both|N/A|N/A|No|Non-Probability Sample|patients with hepatocellular carcinoma|November 2006|February 1, 2009|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00834028||144156|
NCT00839345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO-OSM-01|Clopidogrel Resistance and the Possibility of Its Affection|Resistance to Antiplatelet Agents, Its Etiology and the Possibility of Its Affection||Charles University, Czech Republic||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|90 Years||||February 2009|February 9, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839345||143752|
NCT00839670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070161|Light Constraint Induced Therapy Experiment|Effects of a Modified Constraint Induced Therapy Intervention in Stroke Patients: A Multicenter, Randomized Controlled Trial.|LICITE|Assistance Publique - Hôpitaux de Paris|No|Terminated|February 2009|June 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||February 2009|January 9, 2012|February 6, 2009||No|departure of the investigator coordinator into other country|No||https://clinicaltrials.gov/show/NCT00839670||143728|
NCT00839683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-036|Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects|Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects||AstraZeneca|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|February 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839683||143727|
NCT00839982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2302.00|Clofarabine and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes That Have Relapsed or Not Responded to Treatment|Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML and High-Risk MDS Patients at Least 60 Years of Age||Fred Hutchinson Cancer Research Center|No|Completed|November 2008|||December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|60 Years|N/A|No|||August 2013|August 6, 2013|February 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839982||143704|
NCT00840281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036556|Cefprozil 500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Cefprozil 500 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|February 6, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00840281||143682|
NCT00840320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112842|Repeat Dose Safety Study for Compound to Treat Anemia|A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeat Oral Doses of 1278863A in Healthy Subjects||GlaxoSmithKline|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840320||143679|
NCT00841295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI06-FL / CARNIPREMA|Effects of Parenteral L-carnitine Supplementation in Premature Neonates|Effects of Parenteral L-carnitine Supplementation in Premature Neonates|CarniPrema|University Hospital, Tours|Yes|Completed|July 2008|July 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|53|||Both|N/A|28 Weeks|No|||January 2016|January 5, 2016|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841295||143605|
NCT00841282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBIRE-GI-002|RCT of Air Insufflation Versus Water Infusion Colonoscopy by Supervised Trainees|Comparison of Study Versus Conventional Method for Performing Colonoscopy by Supervised Trainees for Colorectal Cancer Screening and Surveillance||East Bay Institute for Research and Education|Yes|Completed|October 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|62|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 10, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841282||143606|
NCT00837174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908-0284|Relapsed and/or Refractory Non-Hodgkin Lymphoma Study|Phase II Study of Combination Vorinostat and Bortezomib in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma|COMBOSTAT|The Methodist Hospital System|Yes|Withdrawn|June 2010|||April 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837174||143916|
NCT00816491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-06|Comparison Between Chromoendoscopy and Conventional Colonoscopy to Improve the Detection of Neoplasia in Patients With Ulcerative Colitis (UC)|Comparaison de la Chromo Endoscopie Virtuelle FICE (Fujinon Intelligent Chromoendoscopy) Avec la Coloscopie Conventionnelle Dans la détection de la Dysplasie Chez Patients Porteurs de Recto Colite ulcéro hémorragique (RCH).||Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2009|January 15, 2009|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816491||145490|
NCT00823147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4920|Pain Catastrophizing as a Cause for Systemic Inflammation|Pain Catastrophizing as a Cause for Systemic Inflammation||Oregon Health and Science University|No|Recruiting|January 2009|June 2020|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Whole Blood, saliva|Female|18 Years|45 Years|No|Non-Probability Sample|The study population will be 60 women between the age of 18 and 45 having chronic        musculoskeletal pain|September 2009|September 11, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00823147||144986|
NCT00823420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT-JSMDV2008|Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential|Influence of a Prematuration Culture With a PDE3-I on Embryonic Aneuploidy Rate and Developmental Potential||Universitair Ziekenhuis Brussel|Yes|Terminated|May 2009|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|213|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2009|December 4, 2014|January 13, 2009||No|The Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) has been replaced by a    different formulation|No||https://clinicaltrials.gov/show/NCT00823420||144965|
NCT00837031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 106|Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas|A Phase II Study of Lenalidomide in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas||SCRI Development Innovations, LLC|No|Completed|February 2009|June 2012|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|February 4, 2009|No|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT00837031||143927|
NCT00837278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF cytokines|Maternal Serum Cytokine Levels and Angiogenic Factor Levels in IVF vs Spontaneously Conceived Pregnancies|Maternal Serum Cytokine Levels and Angiogenic Factor Levels in Singleton IVF Pregnancies vs Spontaneously Conceived Pregnancies||MemorialCare|No|Recruiting|June 2008|June 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Maternal blood draws are to be performed at four times. These are 10-15 weeks, 22-28 weeks,      34-40 weeks, and 4-8 weeks postpartum. Additionally, placental biopsies and umbilical cord      blood specimens are to be collected for possible future analysis.|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy patients with singleton pregnancies conceived with ART. Only subjects that are        already pregnant and have confirmed singleton intrauterine pregnancies are eligible.|September 2009|September 17, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837278||143908|
NCT00838669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006223|A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone|Evaluation of the Effect of Food and Posture on the Pharmacokinetics of Paliperidone After a Single Administration of 12 mg ER OROS Paliperidone to Healthy Men||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2005|December 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|74|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|May 17, 2011|February 5, 2009||||||https://clinicaltrials.gov/show/NCT00838669||143802|
NCT00838955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201170|Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma|Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma||Loyola University|Yes|Recruiting|January 2009|January 2017|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838955||143781|
NCT00836823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-10-044|Evaluation of Symptom-specific Goal Achievement|The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility||Samsung Medical Center|Yes|Completed|December 2005|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Male|50 Years|N/A|No|||October 2010|October 18, 2010|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836823||143943|
NCT00836797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSI-001-VF|Radiographic Assessment of Bone Regeneration in Alveolar Sockets With PLGA Scaffold|Phase I Radiographic Assessment of Bone Regeneration in Alveolar Sockets With PLGA Bioscaffold After Teeth Extraction||Bio-Scaffold International Pte Ltd|No|Completed|May 2007|July 2008|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|33|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Dental clinic patients undergoing teeth extraction|February 2009|February 3, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836797||143945|
NCT00838162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015952|A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients|A Phase IIa, Open-label, Randomized Trial in Treatment-naive HIV-1-infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 4 Different Dose Regimens of TMC310911 Coadministered With Ritonavir||Tibotec Pharmaceuticals, Ireland|No|Completed|June 2009|February 2011|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|60 Years|No|||June 2013|June 3, 2013|February 5, 2009|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT00838162||143840|
NCT00838409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC003|USDA Behavior, Motivation & Nutrition Study|Examination of Metabolic Determinants of Behavior and Motivation in Obesity: Implication to the Development of New Strategies for Achieving Body Weight Health||USDA, Western Human Nutrition Research Center|No|Completed|May 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|40|Samples With DNA|Blood and saliva samples will be kept for future research purposes.|Female|42 Years|52 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|September 2011|September 13, 2011|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838409||143821|
NCT00833677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2269-32042-02|Community Based Participatory Research With Immigrant Chinese With Diabetes|Community Based Participatory Research With Immigrant Chinese With Type 2 Diabetes: Adapting and Testing Coping Skills Training.||University of California, San Francisco|Yes|Completed|February 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|148|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 29, 2013|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833677||144183|
NCT00839033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080406|Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders|Evaluation of a Mechanical Insufflation-exsufflation Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders: a Prospective, Randomized, Controlled, Multicenter Study|Nemucough|Assistance Publique - Hôpitaux de Paris|No|Terminated|June 2009|December 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|4 Years|N/A|No|||May 2015|May 27, 2015|February 6, 2009||No|No inclusion|No||https://clinicaltrials.gov/show/NCT00839033||143775|
NCT00839358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACHT|Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation|Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation|MACHT|Hospital Clinic of Barcelona|Yes|Recruiting|August 2008|April 2016|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|194|||Both|18 Years|70 Years|No|||March 2015|March 18, 2015|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839358||143751|
NCT00839371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG-CVP 2007-1|Bronchoscopy and Bispectral Index (BIS) - Guided Sedation|Bronchoscopy Under Titrated Sedation With Propofol or Midazolam: a Randomized Trial.||University Hospital, Geneva|No|Completed|January 2005|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2009|February 6, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839371||143750|
NCT00839696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC07104|Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk|Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk||University of Wisconsin, Madison|No|Completed|July 2008|April 2010|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|Samples Without DNA|Serum Xenoestrogen|Female|55 Years|70 Years|No|Probability Sample|Subjects recruited from screening mammography population|December 2014|December 5, 2014|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00839696||143726|
NCT00839709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34710-B|Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion Versus Non-depletion Protocols|Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion vs. Non-depletion Protocols||University of Washington|No|Completed|March 2009|February 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|blood|Both|18 Years|70 Years|No|Non-Probability Sample|liver transplant recipients|March 2011|March 1, 2011|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00839709||143725|
NCT00839722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071006|Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas|Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas|EFU|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2009|July 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|40 Years|No|||June 2011|October 12, 2012|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839722||143724|
NCT00839995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811010079|Use of ROTEM for Multi-level Spine Surgery|A Prospective Observational Study to Evaluate Perioperative Coagulation Profiles Using Rotational Thromboelastometry (ROTEM®) in Patients Undergoing Multi-level Spine Surgery|ROTEM|Weill Medical College of Cornell University|No|Completed|February 2009|December 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|Samples With DNA|a small sample of blood will be obtained from a pre-existing arterial line.|Both|18 Years|80 Years|No|Non-Probability Sample|Large metropolitan hospital.|February 2012|March 2, 2012|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839995||143703|
NCT00841308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBP10|Home Blood Pressure in Hypertension Management|Antihypertensive Drug Treatment Decisions Based on Home Blood Pressure Monitoring|HBP10|University of Athens|No|Recruiting|February 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|25 Years|80 Years|No|||May 2012|May 24, 2012|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841308||143604|
NCT00836940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 8200-301|A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus|A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of GRC 8200, a New Oral DPP -IV Inhibitor, in Patients With Type 2 Diabetes Mellitus.||Glenmark Pharmaceuticals Europe Ltd. (R&D)|Yes|Active, not recruiting|June 2008|October 2009|Anticipated|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|480|||Both|30 Years|N/A|No|||September 2009|September 23, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836940||143934|
NCT00836953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC17|Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®|A Trial for the Collection of Sera in Healthy Children Receiving Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® 2003/2004||Sanofi|No|Completed|September 2003|July 2004|Actual|January 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|33|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||January 2014|January 16, 2014|February 3, 2009|Yes|Yes||No|July 20, 2009|https://clinicaltrials.gov/show/NCT00836953||143933|
NCT00822913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-B-PD|Botulinum A Toxin in Patients With Parkinson's Disease|The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity.|Botox-PD|University Of Perugia|Yes|Enrolling by invitation|June 2008|December 2009|Anticipated|December 2008|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2009|January 14, 2009|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00822913||145003|
NCT00835848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF 01 326257 b|Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI|Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI|POSTCON II|Rigshospitalet, Denmark||Completed|January 2009|May 2015|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00835848||144016|
NCT00836225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 388626-CS1|Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers|A Phase I , Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 388626 Administered to Healthy Volunteers||Ionis Pharmaceuticals, Inc.|Yes|Completed|January 2009|January 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|103|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836225||143987|
NCT00838032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00061|Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia|||Sichuan University|Yes|Recruiting|August 2008|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||March 2009|March 31, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838032||143850|
NCT00835796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B026536|Finasteride 5 mg Tablets, Non-fasting|A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2002|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 3, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00835796||144020|
NCT00836199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-4514|NicVAX/Placebo as an Aid for Smoking Cessation|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation||Nabi Biopharmaceuticals|Yes|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|65 Years|No|||May 2012|May 8, 2012|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836199||143989|
NCT00836212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCS 571|Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring|Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring|TDM|University Hospital, Geneva||Recruiting|March 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||July 2009|July 21, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836212||143988|
NCT00836472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02349|Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets and Glucovance® 5 mg/500 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|April 2003|April 2003|Actual|April 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 3, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00836472||143968|
NCT00832325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001|Adolescent and Young Adult Cancer Survivors: Identity Development|Adolescent and Young Adult Cancer Survivors: Identity Development||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2009|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|15 Years|25 Years|No|Probability Sample|adolescent survivors from MSKCC|February 2016|February 1, 2016|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832325||144285|
NCT00832637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST OX-05-024|Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers|Gemcitabine and Cisplatin With Erlotinib in Hepatocellular Carcinoma (HCC) and Biliary Tree Cancer (BTC) (Intra- and Extra-hepatic Cholangiocarcinoma, Bile Duct Cancer, Adenocarcinoma of the Ampulla of Vater and Gallbladder Carcinoma)|Gem-ox|New Mexico Cancer Care Alliance|Yes|Terminated|August 2007|December 2015|Anticipated|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|January 13, 2009|Yes|Yes|Low accrual|No|June 15, 2015|https://clinicaltrials.gov/show/NCT00832637||144261|
NCT00832286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0053|Longitudinal Study of the Human Intestinal Microbiome|Longitudinal Study of the Human Intestinal Microbiome Before and After Antibiotic Administration||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2009|January 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|March 3, 2016|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00832286||144288|
NCT00832585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC 07-001|Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis|A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis||Rush University Medical Center|No|Completed|January 2008|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2011|March 4, 2011|January 28, 2009|Yes|Yes||No|July 9, 2010|https://clinicaltrials.gov/show/NCT00832585||144265|
NCT00838175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-001023|Characteristics Predictive of Success and Complications in the Use of Suture-Mediated Closure of Femoral Venous Access|Characteristics Predictive of Success and Complications in the Use of Suture-Mediated Closure of Femoral Venous Access||Brigham and Women's Hospital|No|Active, not recruiting|June 2007|May 2009|Anticipated|February 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Adult over the age of 18, who received a suture mediated closure of the femoral vein        following catheterizaton at the BWH cath lab.|February 2009|February 5, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838175||143839|
NCT00838422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH97010|Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound|Repeatability and Reproducibility of Pachymetric Mapping With Fourier Domain Optical Coherence Tomography, Ocular Response Analyzer, Confoscan 4 and Ultrasound||Far Eastern Memorial Hospital|Yes|Recruiting|June 2008|June 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteer who has no prior ocular disease history and prior intraocular surgical        history|February 2009|February 5, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838422||143820|
NCT00838734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH97011|Compare Anterior Chamber Biometry in Healthy and Post-LASIK Patients|Compare Anterior Chamber Biometry in Healthy and Post-LASIK Pati||Far Eastern Memorial Hospital|Yes|Recruiting|June 2008|June 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteer|February 2009|February 5, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838734||143797|
NCT00839046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01ES014566|A Community-based Participatory Research (CBPR) Intervention for Childhood Asthma Using Air Filters and Air Conditioners|A Community Based Participatory Research Intervention for Childhood Asthma Using Air Filters and Air Conditioners|CAAA|University of Michigan|Yes|Completed|August 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|126|||Both|6 Years|12 Years|No|||August 2011|August 18, 2011|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00839046||143774|
NCT00839059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG08-07|Lenalidomide In Patients With Acute Myeloid Leukemia|Open-Label, Multi-Center Phase I Dose-Escalation Study With Lenalidomide In Patients With Acute Myeloid Leukemia||University of Ulm|Yes|Terminated|January 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|January 20, 2009||No|Results of an interim analysis and a hardly ongoing enrolment in the last 10 months in all six    participating centres|No||https://clinicaltrials.gov/show/NCT00839059||143773|
NCT00839735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-120|Trefoil Peptides in Lung Diseases|Trefoil Peptides in Lung Diseases||Bispebjerg Hospital||Recruiting|February 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects with chronic obstruction pulmonary disease (COPD) Subjects with asthma Healthy        volunteers|February 2009|February 6, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839735||143723|
NCT00839748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003H0221|The Ohio State University Asthma Registry|The Ohio State University Asthma Registry||Ohio State University|No|Recruiting|February 2004|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic, community sample|November 2013|November 18, 2013|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839748||143722|
NCT00839761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|The Use of Ultra Rice Compared to Iron Drops Consumed by Anemic Children|Efficacy of Iron Fortified Ultra Rice Compared to Supplemental Iron Drops in Infants and Young Children||Federal University of Minas Gerais|Yes|Completed|December 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|6 Months|24 Months|No|||February 2009|February 9, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00839761||143721|
NCT00840008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-88113|The Dissemination of Consensus Recommendations on Upper Gastrointestinal Bleeding|The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy|REASON-II|McGill University Health Center|No|Completed|September 2008|December 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3157|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00840008||143702|
NCT00840034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12850|A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder|A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment||Eli Lilly and Company|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|65 Years|No|||October 2010|October 25, 2010|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840034||143701|
NCT00841035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080718006|7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients|University of Alabama at Birmingham(UAB 0808), A Phase II Study of Short-course Preoperative Erlotinib Followed by Post-operative Erlotinib-gemcitabine in Patients With Resectable Pancreatic Adenocarcinoma||University of Alabama at Birmingham|Yes|Terminated|February 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|19 Years|80 Years|No|||September 2014|September 29, 2014|February 9, 2009|Yes|Yes|Sponsor stopped due to slow enrollment|No|July 3, 2013|https://clinicaltrials.gov/show/NCT00841035||143625|Early termination by sponsor and No good clinical data was analyzed to the early termination of the study.
NCT00841321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4368-R|Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis|Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis||VA Office of Research and Development|Yes|Completed|January 2009|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||May 2014|May 23, 2014|February 9, 2009|Yes|Yes||No|October 22, 2013|https://clinicaltrials.gov/show/NCT00841321||143603|Limitations include underrepresentation of minorities. Subjects overall had mild impairment.
NCT00837434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ARA06|Anti-TNF Agents for the Treatment of Rheumatoid Arthritis|A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2009|January 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||April 2015|April 10, 2015|February 3, 2009|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT00837434||143896|
NCT00823160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266/2002|Surgical Management of Blood in the Pericardial Sac After Penetrating Trauma|A Randomized Prospective Study of the Definitive Management of the Stable Haemopericardium Following Penetrating Cardiac Injury Utilising Subxyphoid Window and Drainage.||University of Cape Town|Yes|Completed|October 2001|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||April 2009|February 18, 2011|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823160||144985|
NCT00823407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27.112|Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]|Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]|MDA|California Pacific Medical Center Research Institute|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|January 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00823407||144966|
NCT00835861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC08-0898|Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes|Pilot Study of Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)|MIPOD|University of North Carolina, Chapel Hill|No|Completed|August 2008|April 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|N/A|No|||April 2014|April 24, 2014|February 2, 2009|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00835861||144015|Unable to achieve enrollment goal before funding period expired because recruitment progressed more slowly than anticipated.
NCT00835809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811|Multi Marker Approach Interest in Emergency in Acute Respiratory Insufficiency Diagnostic|Multi Marker Approach Interest in Emergency in Acute Respiratory Insufficiency Diagnostic|BIO-IRA|University Hospital, Grenoble|Yes|Completed|October 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples With DNA|Protein sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Emergency and unit intensive care patient.|September 2010|September 6, 2010|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00835809||144019|
NCT00835822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAZ-03-003|Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency|Multicenter, Prospective, Randomized, Double-Blind Study to Assess the Therapeutic Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency||Abbott|No|Completed|May 2005|||October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|65 Years|No|||February 2009|February 3, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835822||144018|
NCT00836498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-027|A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)|V260-027 Safety and Immunogenicity of RotaTeq™ in Elderly Subjects||Merck Sharp & Dohme Corp.||Terminated|January 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|66|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|February 3, 2009|No|Yes|Strategic business decision not to pursue indication due to lack of demonstrable medical need|No|January 12, 2011|https://clinicaltrials.gov/show/NCT00836498||143966|
NCT00832897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1915/07|Evaluation of Topical Riboflavin Exposed to UVA Radiation and Implantation of Corneal Ring|"Evaluation of Topical Riboflavin Exposed to UVA Radiation and Implantation of Intrastromal Corneal Ring for Treatment of Keratoconus and Others Irregulars Astigmatisms."||Federal University of São Paulo|Yes|Completed|March 2008|October 2010|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|January 6, 2011|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832897||144242|
NCT00837616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|908-M01|Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism|Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism||Nemours Children's Clinic|No|Completed|January 2009|December 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Female|13 Years|20 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|February 3, 2009||No||No|May 28, 2013|https://clinicaltrials.gov/show/NCT00837616||143882|
NCT00832026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00019483|Trans Nasal Insuflation for the Treatment of Snoring|Trans Nasal Insuflation for the Treatment of Snoring and Obstructive Sleep Apnea|TNI|Johns Hopkins University|No|Active, not recruiting|July 2004|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|21 Years|N/A|No|Non-Probability Sample|People with obstructive sleep apnea are eligbile to participate in this study.|January 2009|January 28, 2009|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00832026||144307|
NCT00832299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08|Neo-Adjuvant FOLFOX for Rectal Carcinoma|A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6||Beth Israel Medical Center|No|Terminated|January 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|70 Years|No|||March 2013|March 7, 2013|January 27, 2009|Yes|Yes|terminated for lack of enrollment|No|February 25, 2013|https://clinicaltrials.gov/show/NCT00832299||144287|
NCT00839384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114|AdvisaTM IPG Clinical Evaluation Study|Clinical Study to Evaluate System Safety and Clinical Performance of the AdvisaTM IPG||Medtronic Bakken Research Center|No|Recruiting|February 2009|June 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2009|February 23, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839384||143749|
NCT00839397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29060/799|BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder|BRL29060A in Posttraumatic Stress Disorder||GlaxoSmithKline|No|Completed|May 2002|June 2005|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|65 Years|No|||March 2014|March 6, 2014|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00839397||143748|
NCT00838435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-015|Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU|A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria|PKU-015|BioMarin Pharmaceutical|No|Active, not recruiting|February 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|N/A|6 Years|No|||September 2014|September 4, 2014|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838435||143819|
NCT00838448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081302|Interactions Between Physical Activity and Cannabis Use in Adults|Interactions Between Physical Activity and Cannabis Use in Adults||Vanderbilt University|Yes|Completed|January 2009|June 2013|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|January 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00838448||143818|
NCT00838747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3028|Measurement of the Folate Receptor in Blood|Measurement of the Folate Receptor in Blood||Royal Marsden NHS Foundation Trust|No|Recruiting|September 2008|July 2011|Anticipated|January 2011|Anticipated|N/A|Observational|N/A|||Anticipated|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 5, 2009|September 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00838747||143796|
NCT00839072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04ACL1-011|Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers|Crossover Comparative Bioavailability Study of Trazodone Contramid(r) OAD 300 mg Extended-release Caplets and Desyrel(r) 100 mg Immediate-release Tablets in Healthy Adult Volunteers Under Fasting Conditions||Labopharm Inc.|No|Completed|February 2009|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|February 6, 2009||No||No|June 22, 2010|https://clinicaltrials.gov/show/NCT00839072||143772|
NCT00839085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8710|Comparison of Ascorbic Acid and Grape Seed Extract in Oxidative Stress Induced by on Pump Heart Surgery|Effect of Ascorbic Acid and Grape Seed Extract "Vitis Vinifera L." in Oxidative Stress Induced by on Pump Coronary Artery by Pass Grafting Surgery||Tabriz University|No|Active, not recruiting|November 2008|March 2009|Anticipated|January 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|72|||Both|N/A|N/A|No|||February 2009|February 9, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839085||143771|
NCT00840658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR R01DA023877|Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico|Epidemiologic Study on Changing HIV Risks Among FSW-IDUs on the Mexico-US Border|FSW-IDU|University of California, San Diego|Yes|Completed|October 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|584|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 5, 2014|February 7, 2009||No||No|July 2, 2012|https://clinicaltrials.gov/show/NCT00840658||143654|Observed important site differences at enrollment need to be considered in outcome analysis.
NCT00840671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR040301|Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke|A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke|CERE-LYSE-1|Ever Neuro Pharma GmbH|No|Completed|October 2005|July 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|80 Years|No|||December 2010|December 27, 2010|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840671||143653|
NCT00840359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeishDAPDT-HMO-CTIL|Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis|Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis||Hadassah Medical Organization|No|Enrolling by invitation|September 2009|December 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||August 2011|August 15, 2011|February 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00840359||143676|
NCT00836966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scu.Cyt.001|Sampling Biomarkers in Meniscus Injury to the Knee|Diagnostic Utility of Cytokine Biomarkers in the Evaluation of Acute Knee Pain||Scuderi, Gaetano J., M.D.|No|Completed|June 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|Samples Without DNA|saline lavage from joint space|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|68 patients with knee pain < 6 months with either acute or insidious onset who failed        conservative management and elected arthroscopy. Adult volunteers with no history of knee        pain.|February 2009|February 3, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836966||143932|
NCT00837200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007|Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies|Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies||Milton S. Hershey Medical Center|Yes|Completed|March 2009|October 2013|Actual|January 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|February 4, 2009||No||No|May 2, 2014|https://clinicaltrials.gov/show/NCT00837200||143914|
NCT00822926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01072009-1499|Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial|Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial||Stanford University||Suspended|January 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|January 14, 2009|Yes|Yes|Further enrollment is pending analysis of another trial|No||https://clinicaltrials.gov/show/NCT00822926||145002|
NCT00823173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESBA105CRD04|Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis|An Open Label Exploratory Study to Assess the Safety, Tolerability and Clinical Activity of Topically Applied ESBA105 in Patients With Acute Anterior Uveitis||ESBATech AG|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||September 2010|May 25, 2011|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823173||144984|
NCT00823433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-183|Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood|Does Oral Penicillin Reach and Simulate Intravenous Penicillin Levels in Venous Umbilical Cord Blood of Laboring Pregnant Patients?||William Beaumont Hospitals|Yes|Recruiting|January 2009|December 2013|Anticipated|June 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|January 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00823433||144964|
NCT00836264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-12-7023|Pharmacogenomics Analysis of Morphine Pharmacokinetics in Pediatric Tonsillectomy and Adenoidectomy|Pharmacogenomic Analysis of Morphine Pharmacokinetics and Response Variability Following Pediatric Tonsillectomy and Adenoidectomy: A Genome-Wide Association Approach||Children's Hospital of Philadelphia|No|Suspended|December 2015|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1650|Samples Without DNA|PK plasma samples will be obtained|Both|4 Years|18 Years|No|Non-Probability Sample|Children having Tonsillectomy and Adenoidectomy procedures done at The Children's Hospital        of Philadelphia, at the Main Hospital and also at the satellite surgical centers, who have        also consented to participate in "A Study of the Genetic Causes of Complex Pediatric        Disorders" (GCPD study), as approved by the CHOP IRB, 2006-7-4886.|August 2015|August 3, 2015|February 2, 2009||No|Enrollment is on hold dependent upon funding|No||https://clinicaltrials.gov/show/NCT00836264||143984|
NCT00836238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0779|Questionnaire and Fall Risk Assessment|A Cross-Sectional Study of the Predictability of a Questionnaire About Difficulty in Climbing Up or Down Stairs in Objective Measures of Functional Status in Elderly Patients With Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|February 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Male|65 Years|N/A|No|Non-Probability Sample|Males with prostate cancer, 65 years of age or older, who able to ambulate with or without        an assistive device, without assistance from a person.|July 2012|July 31, 2012|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00836238||143986|
NCT00836537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-050|Benazepril HCl 40 mg Tablets, Fed|A Relative Bioavailability Study of 40 mg Benazepril Hydrochloride Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|March 2001|March 2001|Actual|March 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 3, 2009|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00836537||143964|
NCT00837629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RSI-SYM-2006/1|Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)|An Open-label Non-interventional Evaluation of Efficacy of Symbicort® Forte Turbuhaler 320/9 µg (Budesonide / Formoterol) and Symbicort® Turbuhaler® 160/4,5 µg (Budesonide / Formoterol)in Functional Status Improvement of Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca|No|Completed|February 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|743|||Both|18 Years|N/A|No|Non-Probability Sample|patients (outpatient or hospitalised) in whom Symbicort Turbuhaler is indicated according        to the current Summary of product characteristics (SPC)|January 2011|January 21, 2011|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837629||143881|
NCT00837642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/07|Vascular Dysfunction in Offspring of Assisted Reproduction Technologies|Vascular Dysfunction in Offspring of Assisted Reproduction Technologies||University of Lausanne Hospitals|No|Recruiting|March 2008|December 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|N/A|||||||Both|10 Years|18 Years|Accepts Healthy Volunteers|||January 2009|February 4, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837642||143880|
NCT00832650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221057|Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose Study To Investigate The Effects Of 8 Mg Fesoterodine SR Tablets And 10 Mg Solifenacin Tablet On Gastrointestinal Transit In Healthy Female Subjects.||Pfizer|No|Terminated|April 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|January 28, 2009|No|Yes|Protocol A0221057 was terminated on December 25, 2009 for futility. There were no safety    concerns related to this decision.|No|December 2, 2010|https://clinicaltrials.gov/show/NCT00832650||144260|Study was terminated due to futility based on interim analysis with 60 subjects. Although the results of statistical test for the primary endpoint was interpreted, the other endpoint results were interpreted based on statistical inference.
NCT00832884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00570-FB|The Safety of Intravenous Lacosamide|IV Lacosamide: The Safety of Intravenous Lacosamide||Le Bonheur Children's Hospital|Yes|Completed|March 2010|November 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|40|||Both|4 Years|35 Years|No|||October 2014|October 13, 2014|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00832884||144243|
NCT00839774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2006:129|Effect of Pulse Fractions on Indices on Cardiovascular Disease and Diabetes Risk Factors|Effect of Pulse Fractions on Indices of Lipid, Carbohydrate and Energy Metabolism as Well as Oxidative Status in Overweight, Hyperlipidemic Individuals||University of Manitoba|No|Completed|February 2007|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|23|||Both|18 Years|75 Years|No|||August 2008|June 18, 2010|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839774||143720|
NCT00838760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015955|PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir|Phase I, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Increasing Single Oral Doses of TMC558445 With and Without Food, and Increasing Repeated Oral Doses in Combination With a Single Dose of TMC310911||Tibotec Pharmaceuticals, Ireland||Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|February 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00838760||143795|
NCT00840372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Needles|Semi-blunt Needles: is Outcome Better?||Needles|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic hemodialysis patients dialyzed in Cliniques Universitaires Saint-Luc by a native        arterio-venous fistula|September 2009|September 28, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840372||143675|
NCT00840385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-71-143|Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)|Phase II Study of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed PTCL|FAD|Fudan University|No|Recruiting|November 2007|November 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||September 2010|September 14, 2010|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840385||143674|
NCT00841048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2060C00002|Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses|A Randomised, Single-blind, Placebo-controlled, Single Centre, Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses|MAD|AstraZeneca|No|Completed|February 2009|May 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|107|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 29, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841048||143624|
NCT00841061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B530500|Cereals as a Source of Iron for Breastfed Infants|Breast Feeding and Iron: Comparison of Cereals Fortified With Different Forms of Iron|Bfe03B|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|July 2003|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|111|||Both|N/A|1 Year|Accepts Healthy Volunteers|||January 2009|February 9, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841061||143623|
NCT00840996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-209|Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery|Effect of Perioperative Intravenous Lidocaine Administration or Epidural Anesthesia on Postoperative Outcomes in Complex Spine Surgery||Outcomes Research Consortium|No|Completed|May 2008|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|80 Years|No|||August 2012|August 24, 2012|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00840996||143628|
NCT00841009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0523|Effect of Gastric Bypass-induced Weight Loss on Myocardial Structure, Function and Metabolism|Effect of Gastric Bypass-induced Weight Loss on Myocardial Structure, Function and Metabolism||Washington University School of Medicine|No|Completed|July 2005|June 2014|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|18|Samples With DNA|2 tubes of blood (1 tablespoon total) will be collected (with permission), tested and stored      for a length of time|Both|18 Years|55 Years|No|Non-Probability Sample|Patients who are to undergo gastric bypass surgery|December 2014|December 11, 2014|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841009||143627|
NCT00841022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.518|Information and Anaesthesia in Paediatrics|Effects of Comics on Anaesthesia's Anxiety in Paediatrics: A Randomized Controlled Trial||Hospices Civils de Lyon|No|Completed|February 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|115|||Both|6 Years|16 Years|No|||October 2013|October 22, 2013|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841022||143626|
NCT00841347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.525|Sleep and Obesity in Teenagers|Sleep and Obesity in Teenagers: Impact of Sleep Length and Quality on Obesity and Diabetes Risks in Teenagers.||Hospices Civils de Lyon|No|Completed|February 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|15|||Both|15 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841347||143601|
NCT00836979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-08Svand-01-H|Urinary Incontinence: Reproductive/Hormonal Risk Factors|Urinary Incontinence: Reproductive/Hormonal Risk Factors III|RRISK3|Kaiser Permanente|No|Completed|October 2008|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2161|Samples With DNA|Sera will be banked for this cohort.|Female|40 Years|69 Years|No|Non-Probability Sample|A previously identified cohort of approximately 2000 women who are members of Kaiser        Permanente Northern California (KPNC) health plan, having seen a Provider for        bladder/incontinence related issues and have previously participated in the RRISK and        RRISK2 studies. We will also randomly identify an additional cohort of women who are        current members KPNC which report race/ethnicity as Asian, Hispanic or Black/African        American (to total an additional 450 women across all groups.)|April 2015|April 3, 2015|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836979||143931|
NCT00837746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004140|Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate|Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Risedronate Daily or Weekly||Warner Chilcott|No|Completed|April 2003|October 2006|Actual|October 2006|Actual|Phase 4|Observational|N/A||1|Actual|29|||Female|N/A|N/A|No|||June 2013|June 3, 2013|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837746||143872|
NCT00822952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMI-03|Prostate Mechanical Imager (PMI) Clinical Bridging Study|Prostate Mechanical Imager (PMI) Clinical Bridging Study|PMI|Artann Laboratories|No|Completed|October 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|71|||Male|21 Years|N/A|No|Non-Probability Sample|All adult male patients between over the age of 21 presenting to the participating        clinical sites for urologic examination with the DRE detected prostate abnormality and        scheduled for a TRUS-guided prostate biopsy and/ or radical prostatectomy due to an        abnormal DRE, and/or increased PSA, and/or other clinical indications will be considered        for inclusion. All ethnic and racial groups will be included.|March 2014|March 28, 2014|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00822952||145001|
NCT00823186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-0365A3|Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer|Phase I Dose Escalation Study Of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in FIGO IB2 and Bulky IIA Cervical Cancer|Chemothreapy|Chang Gung Memorial Hospital|Yes|Enrolling by invitation|February 2009|January 2013|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||January 2009|January 3, 2010|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00823186||144983|
NCT00823199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICFV12/02|An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia|An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia||Bronx Psychiatric Center|No|Completed|November 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|January 14, 2009||No||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00823199||144982|
NCT00836251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0246|Effects of Antipsychotic Medications on Energy Intake and Expenditure|Effects of Antipsychotic Medications on Energy Intake and Expenditure|DLW|Washington University School of Medicine|No|Completed|April 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|80 Years|No|Non-Probability Sample|Males and females, ages 18-80, diagnosed with schizophrenia or schizoaffective disorder|March 2014|March 12, 2014|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836251||143985|
NCT00836524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-55|Is Serum YKL-40 Capable of Predicting Intrauterine Growth Restriction (IUGR) and Preeclampsia?|"Kan IUGR og præeclampsi Forudsiges ud Fra YKL-40 målt i Serum?" "Metoder Til at Vurdere om Den Gravide Har Risiko for at Udvikle Svangerskabsforgiftning og/Eller væksthæmning Hos Fosteret".||University Hospital Roskilde|No|Active, not recruiting|January 2009|September 2012|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Bloodsamples will be collected as well as placenta tissue for histology.|Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women attending nuchal transcluency examination at Gynækologisk-Obstetrisk dept.        Roskilde University Hospital|October 2011|October 27, 2011|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836524||143965|
NCT00836836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ModAtkins|Modified Atkins Diet in Childhood Epilepsy|Evaluation Of The Efficacy Of The Modified Atkins Diet In Children With Refractory Epilepsy: A Randomized Controlled Trial.|mAD|All India Institute of Medical Sciences, New Delhi|Yes|Completed|May 2009|March 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|2 Years|14 Years|No|||June 2011|June 20, 2011|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836836||143942|
NCT00838461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3248A1-1002|Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016|Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of HSD-016 Administered Orally to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 31, 2009|February 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00838461||143817|
NCT00838474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-346|The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants|The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants||Tel-Aviv Sourasky Medical Center|No|Completed|October 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|60 Days|Accepts Healthy Volunteers|||February 2009|February 5, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838474||143816|
NCT00833170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIBDCRG1|Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry|Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry||Connecticut Children's Medical Center|No|Active, not recruiting|January 2002|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood|Both|1 Month|16 Years|No|Non-Probability Sample|Children <16 years old with inflammatory bowel disease|February 2015|February 3, 2015|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00833170||144222|
NCT00839098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6591-R|Powered Seating Function Usage Among Veterans - Compliance and Coaching|Powered Seating Function Usage Among Veterans - Compliance and Coaching||VA Office of Research and Development|No|Completed|November 2011|November 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|28|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|February 6, 2009||No||No|March 9, 2015|https://clinicaltrials.gov/show/NCT00839098||143770|It was difficult to recruit power wheelchair users to participate in the study. Participants withdrew from the study because the study wheelchair could not meet their needs, or they could not use the Virtual Seating Coach independently.
NCT00839111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bay43-9006-2008005|Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment|A Phase Ⅱ Open Label, Non Randomized Study, in Which Sorafenib is Used in Combination With Irinotecan, Leucovorin and Fluorouracil in Patients With Advanced Colorectal Cancer After Failure of Oxaliplatin Treatment||Fudan University|No|Recruiting|November 2008|November 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|75 Years|No|||September 2010|September 14, 2010|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839111||143769|
NCT00839410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020927|Multicentric Cohort of Melanoma Patients in Ile de France Area|Multicentric Cohort of Melanoma Patients in Ile de France Area|Melan-Cohort|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|September 2003|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1255|Samples With DNA|DNA,RNA,SERUM,PLASMA,PROTEOMICS|Both|18 Years|N/A|No|Non-Probability Sample|Adults with anatomo-pathologically proved melanoma|February 2016|February 10, 2016|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839410||143747|
NCT00840333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpex-206|"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"|A Phase 1B, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Given Daily for 14 Days to Stable Pediatric Cystic Fibrosis Patients.||Forest Laboratories|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|27|Samples Without DNA|Serum and sputum samples for PK measurements|Both|6 Years|16 Years|No|Probability Sample|Pedeatric CF patients ages 6-16 years of age|March 2010|March 1, 2010|February 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00840333||143678|
NCT00840073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-842|Trandolapril 4 mg Tablet Under Non-Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Trandolapril 4 mg Tablets Under Fed Conditions.||Teva Pharmaceuticals USA|No|Completed|October 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|February 6, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00840073||143698|
NCT00840086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3543|Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects|A Multi-centre, Open-label, Non-controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects With Haemophilia A. Sub-trial: Safety and Efficacy of N8 in Prevention and Treatment of Bleeding During Surgical Procedures in Subjects With Haemophilia A|guardian™1|Novo Nordisk A/S|No|Completed|April 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Male|12 Years|65 Years|No|||January 2015|January 7, 2015|February 6, 2009|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00840086||143697|
NCT00840047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METPET|Methionine PET/CT Studies In Patients With Cancer|Methionine PET/CT Studies In Patients With Cancer||St. Jude Children's Research Hospital|No|Recruiting|May 2009|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|650|||Both|N/A|N/A|No|||December 2015|December 2, 2015|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840047||143700|
NCT00840346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANOBIDARA|Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)|A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)|PANOBIDARA|PETHEMA Foundation|Yes|Active, not recruiting|September 2009|December 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|65 Years|N/A|No|||April 2015|April 8, 2015|February 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840346||143677|
NCT00840723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 2799|Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects|Bronchoscopy-Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects|SCCOR Bronch|University of North Carolina, Chapel Hill|No|Completed|February 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|Samples With DNA|Whole blood, Bronchial Lavage Fluid (BALF), cytology brushings|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Current cigarette smokers who are otherwise healthy (no lung disease or other chronic        illness and healthy controls|September 2013|September 3, 2013|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00840723||143649|
NCT00840736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAGBvsVBG7y|LAGB Versus VBG: 7-Year Results|Laparoscopic Adjustable Gastric Banding Versus Open Vertical Banded Gastroplasty: 7-Year Results of a Prospective Randomized Trial||Maastricht University Medical Center|No|Completed|May 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|59 Years|No|||February 2009|February 9, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840736||143648|
NCT00840684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634230|Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia|A PHASE I-II MULTICENTER STUDY OF THE CLORETAZINE-DAUNORUBICIN-ARACYTINE COMBINATION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH UNFAVORABLE CYTOGENETICS||National Cancer Institute (NCI)||Completed|January 2009|||May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|18 Years|60 Years|No|||July 2009|May 12, 2011|February 7, 2009||||No||https://clinicaltrials.gov/show/NCT00840684||143652|
NCT00837226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0499|Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure (IOP)|The Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure|IOP|The University of Texas Health Science Center, Houston|No|Withdrawn|September 2010|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are included in this study will have been evaluated for bariatric surgery and        will meet the current eligibility requirements for bariatric surgery. These requirements        include that the patient must have failed dietary therapy and have a BMI(body mass index)        greater than 40 kg/m2 without associated comorbidities or have a BMI greater than 35 kg/m2        with associated comorbidities. Eleven subjects who will be evaluated for bariatric surgery        but choose not to undergo the surgery will be recruited to serve as controls and to verify        the changes in intraocular pressure (IOP) are due to the weight loss. It is expected that        the IOP of the control patients will be relatively stable, assuming the patients will not        have any other surgery or intervention which could affect the IOP.|December 2015|December 4, 2015|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837226||143912|
NCT00838630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03261|Cilostazol 100 mg Tablet Formulations Under Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Cilostazol, 100 mg, Compared to an Equivalent Dose of a Commercially Available Reference Drug Product in 36 Fasted, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|November 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 5, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00838630||143805|
NCT00838643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gal-01|Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: an Italian Prospective Multicentre Study||Ospedale Santa Croce-Carle Cuneo|No|Active, not recruiting|May 2002|December 2009|Anticipated|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Both|16 Years|N/A|No|Non-Probability Sample|Adult patients given allogeneic HSCT in tertiary care centers or university hospitals in        Piedmont|February 2009|February 6, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838643||143804|
NCT00838656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632859|Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Randomised Feasibility Study of Extended Chemotherapy With Neoadjuvant Carboplatin, Then Surgery Followed by Adjuvant Paclitaxel and Gemcitabine Verses Neoadjuvant Gemcitabine and Carboplatin, Then Surgery, Followed by Adjuvant Paclitaxel||National Cancer Institute (NCI)||Active, not recruiting|October 2007|||June 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|75 Years|No|||June 2011|September 16, 2013|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838656||143803|
NCT00822965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0163|Enhancing Knowledge Implantable Cardioverter-Defibrillators (ICDs)|Patient Knowledge of Pacemaker/Implantable Cardioverter-Defibrillator-Phase II||M.D. Anderson Cancer Center|No|Completed|January 2009|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|104|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients presented to UTMDACC Preoperative Consultation Clinic from January 1,        2000 to November 15, 2008 with an implanted pulse generator.|January 2016|January 5, 2016|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00822965||145000|
NCT00823212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2046|The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions|PLATINUM|Boston Scientific Corporation|Yes|Active, not recruiting|January 2009|November 2014|Anticipated|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1530|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|January 13, 2009|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00823212||144981|
NCT00832039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-004333-42|Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis|Prospective, Randomized Multicenter Trial of Adjunctive Intravenous Therapy With Sodium-selenite(Selenase®, Double-blinded) and a Procalcitonin Guided Causal Therapy (Open) of Severe Sepsis or Septic Shock.|SISPCT|Kompetenznetz Sepsis|Yes|Completed|November 2009|June 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1180|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|January 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00832039||144306|
NCT00832052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401009|A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.|An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 Up To An Exposure Cap In Healthy Elderly Subjects||Pfizer|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|32|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||June 2009|June 9, 2009|January 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00832052||144305|
NCT00836550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-456-001|Video-based Counseling & Rapid HIV Testing for Teens|An RCT to Evaluate the Effectiveness of an Emergency Department Based Multimedia HIV Testing Model in Adolescents||North Bronx Healthcare Network|Yes|Completed|August 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|200|||Both|15 Years|21 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836550||143963|
NCT00836563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444-08-FB|Vascular Changes Following Forearm Loop Arteriovenous Graft Placement|The Natural History of Upper Arm Vessels Following Forearm Loop Arteriovenous||University of Nebraska|No|Recruiting|January 2009|||December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|19 Years|N/A|No|Non-Probability Sample|Patients undergoing forearm arteriovenous loop graft placement|July 2010|July 15, 2010|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836563||143962|
NCT00832663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM_P64_BBH|Influence of Non-steroidal Anti-inflammatory Drugs (NSAID) on Muscle Regeneration|The Influence of Blocking Inflammatory Activity in Vivo on Skeletal Muscle Regeneration in Humans||Bispebjerg Hospital|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2010|March 15, 2010|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832663||144259|
NCT00832676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCH2 447-2008|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (Focus Groups)|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (Focus Groups)||Sunnybrook Health Sciences Centre|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|N/A||1|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with inflammatory arthritis|January 2011|January 6, 2011|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00832676||144258|
NCT00838799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG8-MD-02|Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain||Forest Laboratories|No|Completed|February 2009|||April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|458|||Both|18 Years|75 Years|No|||July 2011|July 6, 2011|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838799||143793|
NCT00838812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGF 03-42008|Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate|Monocentric Study, Prospective, Open and Non Controlled for to Evaluate the Effectiveness, and Tolerability the Safety of Association of Clindamycin Phosphate 1.2% and Tretinoin 0,025% in the Treatment of Acne Vulgaris Mild to Moderate, When Used Once Daily for 12 Weeks.||Igefarma Laboratorios S.A.|No|Completed|March 2009|April 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|12 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 24, 2010|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838812||143792|
NCT00837889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164/08|Cognitive Impairment in Patients With Heart Failure|Cognitive Impairment and Prognosis in Patients With Decompensated Heart Failure|CogImpairHF|University Hospital, Saarland|No|Active, not recruiting|January 2009|May 2011|Anticipated|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|60|Samples Without DNA|Plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|university hospital, saarland|November 2010|November 4, 2010|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00837889||143861|
NCT00839124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1750 (CTRC # 2776)|A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals|A Study of Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers Compared to Allergic Asthmatic Individuals|Endomac|University of North Carolina, Chapel Hill|Yes|Completed|January 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839124||143768|
NCT00839423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11492A|Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults|Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|August 2006|September 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|426|||Both|18 Years|65 Years|No|||April 2014|April 22, 2014|February 6, 2009||No||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00839423||143746|
NCT00839436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090069|Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)|Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)||National Institutes of Health Clinical Center (CC)|Yes|Terminated|February 2009|September 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|February 6, 2009|Yes|Yes|Bankruptcy of Drug manufacturer: Drug not available|No|October 14, 2015|https://clinicaltrials.gov/show/NCT00839436||143745|
NCT00839800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589LC00001|Study to Investigate the Efficacy of Symbicort® SMART.|A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years|SAKURA|AstraZeneca|No|Completed|February 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2091|||Both|16 Years|N/A|No|||November 2012|November 26, 2012|February 4, 2009|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00839800||143718|
NCT00839813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003905-01A2|Efficacy of Yoga for Treatment-Resistant Posttraumatic Stress Disorder|Efficacy of Yoga for Treatment-Resistant PTSD||Justice Resource Institute|Yes|Recruiting|November 2008|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|58 Years|No|||April 2011|April 4, 2011|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00839813||143717|
NCT00839787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901230503p|The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision|The Effect of Opiate Administration in Children With Acute Abdominal Pain and Peritoneal Signs on the Decision for Surgical Intervention||University of Texas Southwestern Medical Center|No|Active, not recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||February 2009|February 9, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839787||143719|
NCT00840450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-226|Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin|Phase II Study of Paclitaxel With Imatinib Mesylate (Gleevec) in Taxane-pretreated Ovarian and Other Cancers of Mullerian Origin||New York University School of Medicine|Yes|Terminated|April 2007|October 2012|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|N/A|No|||November 2012|November 12, 2012|February 9, 2009|Yes|Yes|Due to slow accrual|No|August 18, 2011|https://clinicaltrials.gov/show/NCT00840450||143670|Premature closure led to small numbers of subjects analyzed (12 out of 50 targeted accrual number).
NCT00840749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARS|Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer|International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer|STARS|Accuray Incorporated|Yes|Terminated|December 2008|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|February 7, 2009||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00840749||143647|
NCT00840697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|return to work and exercise|Effect of Interventions in Return to Work for Patients With Neck and Low Back Pain|Facilitating and Inhibiting Factors and Effect of Interventions in Return to Work for Patients With Neck and Low Back Pain||Oslo University Hospital|Yes|Recruiting|August 2009|August 2013|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|60 Years|No|||May 2011|June 24, 2011|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840697||143651|
NCT00840710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-II-IS-001|Clinical Feasibility of Birth- Track II System|Clinical Feasibility of Birth- Track II System|BT|Barnev Ltd|No|Not yet recruiting|February 2010|August 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|15|||Female|17 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women in active labor|February 2009|December 27, 2009|February 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00840710||143650|
NCT00840398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-655|Buspirone Hydrochloride 30mg Tablets, Non-Fasting|A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2001|December 2001|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 9, 2009|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00840398||143673|
NCT00841113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABACAS1|Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer|Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.||Speciality European Pharma Limited|No|Completed|January 1999|February 2003|Actual|February 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|177|||Male|18 Years|N/A|No|||February 2009|February 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841113||143619|
NCT00841360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 067|ID and Testing Via Friendship Networks|A Pilot Study to Identify Undiagnosed Asymptomatic HIV Infections in Adolescent and Young Adult Women||Westat|Yes|Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|535|||Female|13 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Index recruiters will consist of sexually experienced females between the ages of 13 and        24 years old and of African American race, Hispanic/Latina ethnicity, or        mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina        ethnicity.        Friendship network members will also consist of sexually experienced females, aged 13        years and older. Although most members are expected to be of African American race and/or        Hispanic/Latina ethnicity, all races and ethnicities will be included.|February 2016|February 29, 2016|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841360||143600|
NCT00841334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-013|Adolescents Committed to Nutrition and Physical Activity|Adolescents Committed to Improvement of Nutrition and Physical Activity (ACTION)|ACTION|University of New Mexico|Yes|Completed|May 2008|October 2012|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|145|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841334||143602|
NCT00841074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGMB040944|Chlorhexidine & Pneumonia in Nursing Home Residents|Effect of Topical Oral Chlorhexidine in Reducing Pneumonia in Nursing Home Residents||University of Louisville|Yes|Active, not recruiting|January 2006|December 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|75|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 6, 2009|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841074||143622|
NCT00837772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dossett01|Total Knee Replacement Study Using Standard Cutting Guide vs Otismed MRI Generated Cutting Guide|Total Knee Replacement Using Standard Knee Cutting Guides vs Otismed MRI Generated Cutting Guide||Phoenix VA Health Care System|No|Active, not recruiting|January 2008|August 2015|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00837772||143870|
NCT00839228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK 3147|Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome|Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF)||University of Aberdeen|Yes|Completed|March 2009|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|90 Years|No|||November 2015|November 4, 2015|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839228||143761|
NCT00823225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-UK.3/AVK|Urokinase Therapy in Patients With Diabetic Foot Syndrome|Low Dose Urokinase Therapy in Patients With Diabetic Foot Syndrome and Critical Limb Ischemia Versus Conventional Standard Therapy||medac GmbH|No|Terminated|June 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|January 14, 2009||No|Insufficient recruitment of study patients|No||https://clinicaltrials.gov/show/NCT00823225||144980|
NCT00823485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-CIR-03|Clinical Efficacy of In-situ Thrombolysis in Case of Intraventricular Haemorraghia by Aneurysm Rupture|Clinical Efficacy of In-situ Thrombolysis in Case of Intraventricular Haemorraghia by Aneurysm Rupture||Centre Hospitalier Universitaire de Nice|No|Completed|October 2005|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823485||144960|
NCT00823472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LITE study|Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)|Among IVF Patients Undergoing Fixed Antagonist Protocols With Recombinant FSH, Does Administration of Recombinant FSH From Cycle Day 5 Onwards Compared With Cycle Day 2 Onwards, Yield a Higher Number of Good Quality Embryos?|LITE|UMC Utrecht|Yes|Terminated|January 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||January 2009|November 2, 2010|January 13, 2009||No|Inclusion of the study didn't go as fast as expected. Expect: 234 patients in 1 year in 2    centers. After 1,5 year only 147 patients were recruited.|No|November 2, 2010|https://clinicaltrials.gov/show/NCT00823472||144961|Early termination of the trial lead to small number of subjects to be analyzed. Only half of the expected patients were included.
NCT00841477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA017505|An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users|An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2004|December 2009|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1260|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841477||143591|
NCT00837122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909070|Genetics of Type 2 Diabetes in West Africans|Genetics of Tye 2 Diabetes in Diverse Populations||National Institutes of Health Clinical Center (CC)||Recruiting|January 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|9000|||Both|26 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 2, 2015|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837122||143920|
NCT00832338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012185|Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores|Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25||Emory University|Yes|Terminated|April 2009|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|January 29, 2009|Yes|Yes|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT00832338||144284|
NCT00832351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2006.322 (REK)|Akershus Early Mobilisation in Stroke Study|Effect of Immediate Mobilisation After Stroke on Mortality, Morbidity and Functional Outcome|AKEMIS|University Hospital, Akershus|No|Completed|March 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832351||144283|
NCT00837382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24157|Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD)|Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD)||VA Office of Research and Development|No|Terminated|January 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|7|||Both|18 Years|64 Years|No|||September 2010|September 28, 2010|February 3, 2009||No|Primary investigator is no longer a part of the VA.|No||https://clinicaltrials.gov/show/NCT00837382||143900|
NCT00837902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081267|Genetic Determinants of Response to Beta Blockade|Genetic Determinants of Response to Beta Blockade||Vanderbilt University|No|Active, not recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|February 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837902||143860|
NCT00839137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003H0213|Exercise Therapy for Asthma (ETA Trial)|Exercise Therapy for Asthma (ETA Trial)|ETA|Ohio State University|No|Terminated|December 2003|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|13|Samples With DNA|blood|Both|18 Years|50 Years|No|Non-Probability Sample|primary care clinic, community sample|May 2010|May 26, 2010|February 6, 2009||No|Study proved difficult to recruit|No||https://clinicaltrials.gov/show/NCT00839137||143767|
NCT00839449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-2004|Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study|Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage|EVAS|Yamaguchi University Hospital|Yes|Completed|December 2004|December 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|20 Years|N/A|No|||September 2009|September 1, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00839449||143744|
NCT00840060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC009027A-01A2|Efficacy of AMALS in Treating Language Impairment in Children|AMALS: Addressing Multiple Aspects of Language Simultaneously: A Randomized Clinical Trial|AMALS|Lamar University|Yes|Completed|January 2009|December 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|4 Years|6 Years|No|||May 2012|May 14, 2012|February 9, 2009||No||No|April 13, 2012|https://clinicaltrials.gov/show/NCT00840060||143699|Problems with stratification according to dialect prior to randomization lead to difficulty interpreting results related to dialect
NCT00837993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0509|Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System|An Ancillary Study of Patients With Advanced Stage Serous Carcinoma of the Ovary Treated on GOG Protocol 158: A Survival Analysis Based on Reclassification to a Two-tier Grading System||M.D. Anderson Cancer Center|No|Completed|August 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|241|||Female|N/A|N/A|No|Non-Probability Sample|All patients enrolled on GOG protocol 158 with a diagnosis of serous carcinoma of the        ovary.|December 2012|December 20, 2012|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00837993||143853|
NCT00838279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01303|Lamotrigine 25 mg Chewable Tablets, Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Dispersible Tablets and Lamictal® 25 mg Chewable Dispersible Tablets in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2002|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 5, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00838279||143831|
NCT00840411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02197|Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Extended Release Tablet Formulation of Clarithromycin (500 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Biaxin® XL Filmtab) in 66 Fasted, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|September 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 6, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00840411||143672|
NCT00840437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|opt003|Quality of Life in Patients With Refractory Angina|Health Status of Patients Enrolled in the OPTions In Myocardial Ischemic Syndrome Therapy (OPTIMIST) Program||Minneapolis Heart Institute Foundation|No|Completed|December 2008|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Sequential patients seen in the OPTions In Myocardial Ischemic Syndrome Therapy        (OPTIMIST)clinic with documented refractory angina and who have consented to participate        in the OPTIMIST Long-term Follow-up Database|December 2013|December 3, 2013|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00840437||143671|
NCT00841087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3569|Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes|A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIBA Once Daily + NovoRapid® Compared to Insulin Detemir Once Daily + NovoRapid®, All in a Basal-bolus Regimen in Subjects With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|20 Years|N/A|No|||October 2015|October 16, 2015|February 10, 2009|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT00841087||143621|
NCT00836992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005566|Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer|Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy||Mayo Clinic|Yes|Active, not recruiting|January 2009|||September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|132|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with head and neck tumors, lung tumors, and gastrointestinal tumors receiving        radiation therapy at Mayo Clinic Arizona|March 2015|March 31, 2015|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836992||143930|
NCT00838292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AED 1|Study of Impacts of Food Supplementation on Malnourished HIV-Infected Adults in Kenya|Randomized Controlled Evaluation of the Impact of Food Supplements on Malnourished HIV-Infected Adult ART Clients and Malnourished, HIV-Infected Pre-ART Adults in Kenya||Academy for Educational Development|No|Completed|August 2006|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|1049|||Both|18 Years|N/A|No|||February 2009|March 12, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00838292||143830|
NCT00839891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB-118|A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers|A Phase 1 Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group/Crossover Thorough QT/QTc Study to Evaluate the Effect of a Therapeutic Dose and a Supra-therapeutic Dose of VI-0521 on Cardiac Repolarization in Healthy Male and Female Volunteers|TQT|VIVUS, Inc.|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|112|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 20, 2010|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839891||143711|
NCT00823498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0610|Physical Activity in Public Housing - II|Perceptions of School, Recreation, and Transportation Environments Among African American Families in Public Housing--II||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2009|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|84|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|African American parents and youth residing in selected Houston public housing        developments.|February 2016|February 1, 2016|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00823498||144959|
NCT00824057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0850C00015|Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)|A Phase I Open-labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)|CYP|AstraZeneca|No|Completed|January 2009|March 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 30, 2009|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00824057||144916|
NCT00824044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000838|Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression|QEEG Predictors of Response for Psychotherapy Compared to Pharmacotherapy in Depression||Massachusetts General Hospital|No|Completed|July 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|33|||Both|18 Years|75 Years|No|||December 2012|December 5, 2012|January 14, 2009||No||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00824044||144917|
NCT00824629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX001|Embryo Transfer: Direct Versus Afterloading Trial|Direct Transfer vs Previous Cervical Canalization Transfer ("Afterloading"): Randomized Clinical Trial.||Institut Universitari Dexeus|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|42 Years|No|||August 2009|October 25, 2010|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00824629||144873|
NCT00841490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGMB080062|Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults|Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults||University of Louisville|Yes|Active, not recruiting|September 2008|June 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|Samples With DNA|Samples of dental plaque.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|A study involving 110 intellectually disabled and/or developmentally disabled (ID/DD)        participants aged 18 to 90 years of age at a facility in Kentucky will be conducted. An        age and gender matched control group (n = 110) will also be evaluated for oral H. pylori        prevalence and H. pylori gastric infections. The control group will be recruited and        enrolled from the general dental clinics at the University of Louisville School of        Dentistry.|May 2010|June 1, 2010|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00841490||143590|
NCT00841503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|buckwheat study|Exploring Buckwheat's Glucose Lowering Potential|A Double-Blind, Randomized, Controlled Study to Determine Buckwheat's Glucose Lowering Effects in Healthy Volunteers and Volunteers With Type 2 Diabetes||St. Boniface General Hospital Research Centre|No|Completed|September 2008|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|A total of 24 volunteers were recruited from the community; 12 healthy volunteers and 12        volunteers with Type 2 Diabetes|March 2012|March 20, 2012|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841503||143589|
NCT00837135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806693|GI-4000 With Adoptive Transfer in Pancreatic Cancer|Pilot Study Of Safety And Feasibility Of GI-4000, An Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With Adoptive Transfer And Chemoradiation in Locally Advanced Pancreatic Cancer||University of Pennsylvania|No|Withdrawn|January 2008|October 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|February 4, 2009|No|Yes|Withdrawn due to transfer of Investigator|No||https://clinicaltrials.gov/show/NCT00837135||143919|
NCT00837369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|566-08-FB|Regadenoson R-T Perfusion Imaging Trial|Regadenoson Real Time Perfusion Imaging Trial||University of Nebraska|Yes|Completed|May 2009|December 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|100|||Both|30 Years|N/A|No|||July 2012|July 19, 2012|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837369||143901|
NCT00837395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0292|Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma|Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma||Ohio State University|No|Recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|blood|Female|18 Years|N/A|No|Non-Probability Sample|primary care clinic, community sample|April 2015|April 23, 2015|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837395||143899|
NCT00837928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08142|Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors|Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1- 4 Brain Metastases From Solid Malignancies||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|February 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837928||143858|
NCT00837941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-115|A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)|Qualification of Single Dose Administration of Analgesic Therapy in the Treatment of Chronic Neuropathic Pain in Patients With Painful Diabetic Neuropathy||Merck Sharp & Dohme Corp.|No|Withdrawn|April 2009|September 2009|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|55 Years|No|||July 2015|July 24, 2015|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837941||143857|
NCT00838773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA023854|International Social Network Intervention|HIV Prevention Within High-Risk Social Networks||Medical College of Wisconsin|Yes|Active, not recruiting|May 2007|December 2016|Anticipated|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1640|||Both|14 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 16, 2015|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838773||143794|
NCT00839150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P041009|Retinal Function in Diabetic Patients Without Retinopathy|Assessment of Retinal Functional Abnormalities in Diabetic Patients Without Retinopathy|NEURODIAB|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2005|May 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|56|||Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|For diabetic patients :        age between 20 and 55 type 1 or type 2 diabetes mellitus diabetes duration of more than 5        years no diabetic retinopathy on fundus examination or fundus photographs        For control subjects :        sex and age matching with the diabetic patients no diabetes, no familial or personal        history of elevated blood sugar|June 2009|September 16, 2011|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839150||143766|
NCT00839462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12039|Efficacy of Dexpanthenol in Thermic Erythema|Evaluation of the Effect of Bepanthen Burn Relief Foam Spray New Formula on a Thermic Erythema. Equivalence Trial. Intra-individual Design.||Bayer|No|Completed|September 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 18, 2013|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839462||143743|
NCT00839475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1|Investigation of the Uterine Cervix Using CervicalMD|Investigational Study: Imaging the Uterine Cervix Using C30 Investigational Device||STI-Medical Systems|No|Completed|June 2008|July 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|26|Samples Without DNA|LEEP specimens|Female|18 Years|65 Years|No|Non-Probability Sample|Women identified with an abnormal Pap smear|March 2010|March 22, 2010|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00839475||143742|
NCT00839852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-17|The Purpose of the Study is to Determine Whether Cariprazine is a Safe and Tolerated Long-term Treatment in Patients With Chronic Stable Schizophrenia|A Long-Term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia||Forest Laboratories||Completed|May 2009|||August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|61 Years|No|||September 2011|September 13, 2011|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839852||143714|
NCT00839826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10942|ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial|Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement. ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial|ODiXaHip|Bayer|No|Completed|December 2002|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|641|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00839826||143716|
NCT00839839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 0120080226|Egg Freezing Pilot Study|Oocyte Cryopreservation in Assisted Reproduction||University Reproductive Associates|No|Completed|February 2009|February 2011|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|35 Years|No|||December 2015|December 1, 2015|February 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839839||143715|
NCT00838929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08D.522|Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases|Phase I Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases||Thomas Jefferson University|Yes|Active, not recruiting|March 2009|February 2016|Anticipated|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|February 6, 2009||No||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00838929||143783|
NCT00839202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-06-0069-CR002|Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay|PK Analysis of a Novel Immunoassay in Hemophilia A||Children's Hospital Los Angeles|No|Completed|September 2006|February 2009|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|7|||Male|18 Years|N/A|No|||February 2009|February 6, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839202||143762|
NCT00840762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-118|A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication|A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication||Ruth M. Rothstein CORE Center|No|Recruiting|March 2009|July 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|756|||Both|N/A|N/A|No|||January 2010|January 25, 2010|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840762||143646|
NCT00841100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080675|Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response|Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response||University of Miami|Yes|Recruiting|December 2008|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|N/A|No|||February 2009|March 10, 2009|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841100||143620|
NCT00840463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-300-0126|Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan|Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction||University of Texas Southwestern Medical Center|Yes|Terminated|January 2009|January 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|3|||Both|18 Years|70 Years|No|||June 2015|June 10, 2015|February 6, 2009|Yes|Yes|Poor enrolment|No||https://clinicaltrials.gov/show/NCT00840463||143669|
NCT00840476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2824|Meloxicam 15 mg Tablets Under Fasting Conditions|A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Meloxicam 15 mg Tablets Versus Mobic® 15 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|February 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 6, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00840476||143668|
NCT00840801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700801|Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children|Single-blind, Randomized, Phase 3B Study in Children Aged 1 - 11 Years to Investigate the Immunogenicity, Safety and Interchangeability of Two Tick-borne Encephalitis (Tbe) Vaccines Administered According to a Conventional Schedule||Pfizer|Yes|Completed|February 2009|August 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|302|||Both|1 Year|11 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840801||143643|
NCT00837018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0520|Exercise Intolerance in Obstructive Sleep Apnea Syndrome Patients|Exercise Intolerance in Obstructive Sleep Apnea Syndrome Patients: Cardiovascular and Metabolic Characterisation During Exercise. Treatments Effect.|EXAOS|University Hospital, Grenoble|No|Completed|June 2005|May 2012|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|1||Actual|30|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00837018||143928|
NCT00838942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 010110|Life From Vision in Alzheimer Disease|Cataract Surgery Benefice in Improvement of Behaviour, Autonomy and Mood for Alzheimer Patients.|VIVA|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2004|April 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|50 Years|N/A|No|Non-Probability Sample|Patients studied are elderly people suffering from both Alzheimer's disease and low vision        due to a bilateral impeding cataract|June 2011|October 27, 2011|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00838942||143782|
NCT00835016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILL-LTP-0108|Early Psychosocial Stimulation Program for Children of Depressed Mothers|Early Psychosocial Stimulation (LTP) Program for Children of Depressed Mothers: An RCT|LTP|Pakistan Institute of Learning and Living|No|Completed|February 2009|January 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|260|||Female|16 Years|40 Years|No|||September 2015|September 19, 2015|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00835016||144080|
NCT00835029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111111|Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches|Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis||Hadassah Medical Organization|No|Completed|March 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|20 Years|80 Years|No|||March 2015|March 24, 2015|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00835029||144079|
NCT00824070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|575|Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects|An Open-Label, Randomized Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects After a Single Topical Dose||Bausch & Lomb Incorporated|No|Completed|February 2009|August 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|105|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|January 15, 2009|No|Yes||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00824070||144915|All drug concentrations were significantly below MIC90 values for relevant staphylococcal species.
NCT00824642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2004.362|Effect of Acu-Transcutaneous Electrical Nerve Stimulation (TENS) on Post-Exercise Expiratory Flow Rate in Subjects With Asthma|Effect of Acu-TENS on Post-Exercise Expiratory Flow Rate in Subjects With Asthma- A Randomized Controlled Trial||The Hong Kong Polytechnic University||Completed|May 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|30|||Both|18 Years|N/A|No|||January 2009|January 16, 2009|January 16, 2009||||No||https://clinicaltrials.gov/show/NCT00824642||144872|
NCT00837655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIR_CT_CLINTEC_01|Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)|Study of the Effect of Treatment With Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure|SIR|Karolinska Institutet|Yes|Withdrawn|January 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||January 2009|September 25, 2012|January 29, 2009||No|PI retired|No||https://clinicaltrials.gov/show/NCT00837655||143879|
NCT00837668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0018|Stromal Gene Expression During Pulmonary Sarcoidosis|Stromal Gene Expression During Pulmonary Sarcoidosis||Ohio State University|No|Suspended|April 2005|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|Samples With DNA|lung tissue|Both|18 Years|N/A|No|Non-Probability Sample|patients from sarcoidosis clinic|July 2010|July 21, 2010|February 4, 2009||No|Interim analysis|No||https://clinicaltrials.gov/show/NCT00837668||143878|
NCT00837148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-068|Sorafenib and Dacarbazine in Soft Tissue Sarcoma|Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma||Memorial Sloan Kettering Cancer Center|Yes|Completed|February 2009|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|February 4, 2009|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00837148||143918|
NCT00837915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA01111|Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D® 24 Hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in Healthy Adult Volunteers Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|June 2002|November 2002|Actual|August 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 5, 2009|January 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00837915||143859|
NCT00838188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920060356|Energy Expenditure in Breast and Bottle Feeding Preterm Infants Fed Their Mother's Breast Milk|Energy Expenditure in Breast and Bottle Feeding Preterm Infants Fed Their Mother's Breast Milk||Tel-Aviv Sourasky Medical Center|No|Completed|November 2007|March 2008|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||5|Actual|23|Samples Without DNA|Maternal breast milk|Both|34 Weeks|40 Weeks|No|Non-Probability Sample|Preterm infants born after 32 weeks of gestation, when they reached the corrected        gestational age of 34 weeks or more.|February 2009|February 5, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838188||143838|
NCT00838214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-38/AIH|Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis|Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-Blind, Randomized, Active-Controlled, Multicentre Study||Dr. Falk Pharma GmbH|Yes|Completed|March 2001|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|208|||Both|10 Years|70 Years|No|||February 2009|February 5, 2009|February 5, 2009||||No||https://clinicaltrials.gov/show/NCT00838214||143836|
NCT00838825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCVMC 2/8/08-10|Continuous Quality Improvement for Diabetes|Continuous Quality Improvement for Diabetes: Unique Care Delivery Design's Effect on Quality of Care and Utilization of Resources||Santa Clara Valley Health & Hospital System|Yes|Enrolling by invitation|April 2006|April 2010|Anticipated|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|10|||Both|30 Years|N/A|No|||December 2008|February 5, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838825||143791|
NCT00839488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-95-C-011|Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis|Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery||Far Eastern Memorial Hospital|Yes|Terminated|April 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||October 2013|October 12, 2013|February 6, 2009||No|the chief of GS left the hopsital and the successor did't want to keep on this study|No||https://clinicaltrials.gov/show/NCT00839488||143741|
NCT00841373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100,611|Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease|Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease||Southern New England Retina Associates|Yes|Completed|July 2007|January 2010|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841373||143599|
NCT00840099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-543|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions|An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|August 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 8, 2009|February 6, 2009|No|Yes||No|May 18, 2009|https://clinicaltrials.gov/show/NCT00840099||143696|
NCT00840112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU eirb# 4929|Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy|Vitamin E Treatment for LCHAD Associated Neuropathy||Oregon Health and Science University|No|Terminated|July 2010|October 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|7 Years|N/A|No|||July 2010|October 20, 2015|February 9, 2009||No|New data does not support a role of vitamin E in LCHAD associated neuropathy.|No||https://clinicaltrials.gov/show/NCT00840112||143695|
NCT00839878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3738|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia DiabCare Asia 2008 (Bangladesh)|DiabCare Asia|Novo Nordisk A/S|No|Completed|March 2009|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2092|Samples With DNA|Blood sample|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to inclusion        and exclusion criteria. Patients will be selected randomly from clinic record/ list to        avoid any bias.|July 2012|July 17, 2012|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839878||143712|
NCT00840138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kozicki321|A Comparison of Bile Duct Injuries Following Open Cholecystectomy Versus Laparoscopic Cholecystectomy|Comparison of Iatrogenic Common Bile Duct Injuries Following Open Cholecystectomy vs Laparoscopic Cholecystectomy||Medical Centre of Postgraduate Education, Poland|No|Active, not recruiting|January 1996|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|70|||Both|21 Years|90 Years|No|Probability Sample|Patients treated for common bile duct injuries following laparoscopic and open        cholecystectomy procedures.|February 2009|February 9, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840138||143693|
NCT00839501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5305|Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome|Therapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil Syndrome||University of Rochester|Yes|Terminated|December 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|3|||Both|10 Years|N/A|No|||January 2012|January 19, 2012|February 5, 2009|Yes|Yes|Unable to recruit sufficient number of participants|No||https://clinicaltrials.gov/show/NCT00839501||143740|
NCT00839514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0301|Trichloroethylene (TCE) Exposure in an Industrial Population|Evaluation of Parkinson Disease Symptoms in Trichloroethylene Exposed Patients in an Industrial Population|TCE|University of Kentucky|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|27|||Both|N/A|N/A|No|Non-Probability Sample|Follow-up with individuals who previously particpated in the research study entitled        "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"|June 2012|June 6, 2012|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839514||143739|
NCT00839527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112757|A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes|A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|February 2009|March 2013|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|685|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|February 5, 2009|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT00839527||143738|
NCT00841386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101365|Treatment of Keratoconus Using Collagen Cross-Linking|Treatment of Keratoconus Using Collagen Cross-Linking By Means of Topical Riboflavin and UV Light.||University at Buffalo|No|Recruiting|September 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|35 Years|Accepts Healthy Volunteers|||January 2009|February 10, 2009|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841386||143598|
NCT00837486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1626|Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression|Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression||MedtronicNeuro|Yes|Completed|February 2009|April 2013|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|February 3, 2009|No|Yes||No|March 13, 2015|https://clinicaltrials.gov/show/NCT00837486||143892|With this 30-subject cohort, and only 29 subjects completing the blinded-treatment phase per protocol, the comparisons of response rates and improvements were not adequately powered.
NCT00834652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH081150|Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight|Improving Depression Treatment Outcomes With an Insulin-Sensitizing Agent||Washington University School of Medicine|No|Completed|September 2007|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|20 Years|60 Years|No|||August 2015|August 6, 2015|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00834652||144108|
NCT00835042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036543|Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00835042||144078|
NCT00835055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43/05|Expression of Molecular Markers Before and After Neo-adjuvant Chemoradiotherapy in Rectal Cancer|||St. Claraspital AG||Recruiting|April 2005|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|group is selected from a single institution ( community hospital)|September 2009|September 21, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835055||144077|
NCT00835068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090X1-4409|Post Marketing Observational Study of Reformulated BeneFIX|Post Marketing Observational Study Of Reformulated BeneFIX||Pfizer|No|Completed|January 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Both|N/A|N/A|No|Non-Probability Sample|Hemophilia B patients already receiving or starting treatment with reformulated BeneFIX|September 2014|September 11, 2014|February 2, 2009|No|Yes||No|September 11, 2014|https://clinicaltrials.gov/show/NCT00835068||144076|
NCT00815828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392/2006|The Effects of Resistance Exercises in Glycemic Control of Women With Gestational Diabetes|The Effects of Resistance Exercises in Glycemic Control of Women With Gestational Diabetes - A Randomized Clinical Trial||University of Sao Paulo|Yes|Completed|October 2006|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|64|||Female|18 Years|45 Years|No|||November 2008|December 30, 2008|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00815828||145541|
NCT00815841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShaareZMC.ctil|Methylphenidate in Healthy Young Adults|||Shaare Zedek Medical Center|No|Not yet recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|50|||Both|20 Years|30 Years|No|||December 2008|December 30, 2008|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00815841||145540|
NCT00815854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH082784|Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects|Folate Pharmacogenomics and Risk of Atypical Antipsychotic Metabolic Side Effects||University of Michigan|Yes|Recruiting|October 2008|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Anticipated|150|||Both|18 Years|90 Years|No|||June 2015|June 11, 2015|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00815854||145539|
NCT00816140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200702009M|Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication|Comparative Study of the Levofloxacin-Based and Clarithromycin-Based Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication and Change of Gut Flora and Drug Susceptibility Before and After Treatment||National Taiwan University Hospital|No|Completed|June 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|432|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2011|April 21, 2011|August 6, 2007||No||No||https://clinicaltrials.gov/show/NCT00816140||145517|
NCT00837681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005C0058|Pulmonary Complications of Hematopoietic Stem Cell Transplantation|Pulmonary Complications of Hematopoietic Stem Cell Transplantation||Ohio State University|Yes|Active, not recruiting|October 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Blood draw will be 10cc of blood, analysis includes % of CD8+CD57+ and CD8+CD28-. On one      occasion, after the 6 mo. post transplant timepoint the subject will be asked to donate a      larger amount of blood (50cc) if they are not anemic.      ***Respiratory Specimens of extra BAL or biopsy specimens will be collected at any point a      study patient undergoes a clinically warranted bronchoscopy or lung biopsy procedure and the      diagnostic physician feels there is adequate specimen to use extra sample for research      purposes.|Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled to undergo hematopoietic stem cell transplantation (HSCT)|October 2015|October 13, 2015|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837681||143877|
NCT00838201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080537|Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer||Amgen|No|Completed|February 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|384|||Male|18 Years|N/A|No|||November 2013|November 1, 2013|February 5, 2009|Yes|Yes||No|July 23, 2013|https://clinicaltrials.gov/show/NCT00838201||143837|
NCT00838487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZODIAC|Evaluate Safety & Efficacy of Condroflex in Subjects With OA|Phase 3 Study, to Evaluate Safety & Efficacy of the Association Condroflex + Therapeutic Exercises Compared to Placebo + Therapeutic Exercises, in Subjects With Knee OA|ZD20108|Zodiac Produtos Farmaceuticos S.A.|Yes|Recruiting|March 2009|March 2010|Anticipated|July 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|40 Years|70 Years|No|||October 2009|October 9, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838487||143815|
NCT00838500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUF 1497|THERMES ET VEINES: Spa for Prevention of Leg Ulcers|Evaluation of the Efficacy of Spa Treatment for Prevention of Leg Ulcers in Advanced Chronic Venous Insufficiency.||Association Francaise pour la Recherche Thermale|Yes|Completed|May 2008|November 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|425|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838500||143814|
NCT00838513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-003A|Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)|An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)|aHUS|Alexion Pharmaceuticals|Yes|Completed|July 2009|December 2013|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|February 3, 2009|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT00838513||143813|
NCT00838838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13900|Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis|Nebido® Therapy in Hypogonadal Male Patients With Osteoporosis Associated With Paraplegia Compared With Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients With Osteoporosis Associated With Paraplegia||Bayer|No|Completed|September 2005|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Male|18 Years|N/A|No|Non-Probability Sample|Male patients > 18yrs in medical practices fulfilling all criteria for documentation.|April 2010|April 13, 2010|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838838||143790|
NCT00838851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-1523 (GCRC 2040)|Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults|Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adult||University of North Carolina, Chapel Hill|No|Terminated|August 2003|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 5, 2012|February 6, 2009|No|Yes|no further funding|No||https://clinicaltrials.gov/show/NCT00838851||143789|
NCT00839865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFL-2008-11|Trial of Herb Yuyang Ointment to Diabetic Foot Ulcer|Phase 1 Study of Herb Yuyang Ointment That Expressed Good Effect in Diabetic Foot Ulcer||Guiyang No.1 People's Hospital|Yes|Recruiting|November 2008|March 2011|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2009|February 9, 2009|February 9, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00839865||143713|
NCT00837239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0948|Huachansu & Gemcitabine in Pancreatic Cancer|A Randomized, Placebo-controlled, Blinded Phase II Study of Huachansu & Gemcitabine in Pancreatic Cancer||M.D. Anderson Cancer Center|Yes|Completed|June 2007|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837239||143911|
NCT00837759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090056|Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes|Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes||National Institutes of Health Clinical Center (CC)|No|Terminated|February 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|16 Years|30 Years|No|||December 2012|December 31, 2012|February 4, 2009|No|Yes|Changes to study personnel.|No|March 24, 2012|https://clinicaltrials.gov/show/NCT00837759||143871|
NCT00833339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3293-08-015|Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder|Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone||James J. Peters Veterans Affairs Medical Center|Yes|Recruiting|May 2008|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|80|||Male|18 Years|N/A|No|||March 2015|March 30, 2015|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833339||144209|
NCT00841139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-004965-14|Metabolic Manipulation in Chronic Heart Failure|Metabolic Manipulation in Chronic Heart Failure||University Hospital Birmingham NHS Foundation Trust|Yes|Completed|February 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|16 Years|90 Years|No|||November 2011|November 25, 2011|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00841139||143617|
NCT00837252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090075|Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2009|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2011|May 23, 2011|February 4, 2009|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00837252||143910|
NCT00837265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUGR-002|Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel|A Randomized Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel)|NEUGR-002|Teva Pharmaceutical Industries|Yes|Completed|August 2008|July 2010|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|334|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|February 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00837265||143909|
NCT00838006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074626|Psychophysiologic Predictors of Post-deployment Mental Health Outcomes|Identification of and At-Risk Interventions for Pre-deployment Psychophysiologic Predictors of Post-deployment Mental Health Outcomes||Biomedical Research Foundation|No|Completed|September 2008|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|426|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838006||143852|
NCT00838019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPH/SCU-IMed 01/08|Intrabone Cord Blood Transplantation|Pilot Study About Viability and Efficacy of Intrabone Administration of Umbilical Cord Blood for Allogeneic Stem Cell Transplantation||Hospital Clinic of Barcelona|No|Recruiting|February 2009|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||February 2009|February 5, 2009|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838019||143851|
NCT00834665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 13406 / GCC610|Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma|Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells||University of Pennsylvania|No|Active, not recruiting|December 2006|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|80 Years|No|||January 2013|January 31, 2013|January 3, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00834665||144107|
NCT00835081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2921|Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.|A Two-Way , Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.||Teva Pharmaceuticals USA|No|Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00835081||144075|
NCT00835094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02177|A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Study P02177)|A Randomized Trial Assessing the Chronobiology of Once Daily Administration of Mometasone Furoate DPI in Patients With Asthma||Merck Sharp & Dohme Corp.|No|Completed|October 2002|July 2003|Actual|July 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|12 Years|N/A|No|||April 2015|April 27, 2015|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00835094||144074|
NCT00835107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSIY-287-08|An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression|An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression||Queen's University|No|Completed|February 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835107||144073|
NCT00815867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI07-Pr CHOUKROUN|Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant|Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant|Neo-PDGF|Centre Hospitalier Universitaire, Amiens|Yes|Completed|October 2007|September 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|75 Years|No|||October 2011|October 19, 2011|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00815867||145538|
NCT00815880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO02291|C-Pulse IDE Feasibility Study- A Heart Assist System|C-Pulse Implantable Counterpulsation Pump (ICP) Feasibility Study - A Heart Assist System||Sunshine Heart Inc.|Yes|Completed|December 2008|October 2012|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||March 2015|March 31, 2015|December 30, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00815880||145537|
NCT00816153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/1|Pleth Variability Index and Fluid Management During Surgery|Is Pleth Variability Index Able to Guide Fluid Management During Surgery?||Université Catholique de Louvain|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||December 2008|December 30, 2008|December 30, 2008||No||No||https://clinicaltrials.gov/show/NCT00816153||145516|
NCT00816387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU01/07|Fallopian Tube Sperm Perfusion (FSP) Versus Intra-uterine Insemination (IUI) in Natural Cycle|Fallopian Tube Sperm Perfusion (FSP) Versus Intra-uterine Insemination (IUI) in Natural Cycle: a Prospective Randomized Study||IRCCS Burlo Garofolo|Yes|Completed|October 2007|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|24 Years|40 Years|No|||March 2009|December 2, 2010|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816387||145498|
NCT00837408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909071|Genetics of Type 2 Diabetes Among Han Chinese|Genetics of Type 2 Diabetes Among Han Chinese||National Institutes of Health Clinical Center (CC)||Completed|January 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3000|||Both|26 Years|N/A|No|||September 2015|October 3, 2015|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837408||143898|
NCT00837694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Temple1|Snack Food Reinforcement in Obese and Non-Obese Women|Differential Effects of Daily Snack Food Intake on Reinforcing Value of Food in Obese and Non-Obese Women.||State University of New York at Buffalo|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||6|||||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women ages 18 - 50 years who were obese (body mass index >/= 30) or non-obese (BMI < 30)|February 2009|February 4, 2009|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00837694||143876|
NCT00838253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 0614-202|Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled Staggered Dose-escalating Phase IIb Study of the Safety and Efficacy of Istaroxime Over 24 Hours at Three Doses in Acute Decompensated Heart Failure Patients (The IGNITE Trial)||Debiopharm International SA|Yes|Withdrawn|June 2009|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|February 5, 2009|Yes|Yes|The study was not started due to a re-evaluation of the istaroxime development program|No||https://clinicaltrials.gov/show/NCT00838253||143833|
NCT00838526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-G000-305|Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)|Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)||Eisai Inc.||Completed|August 2008|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|75 Years|No|||October 2015|October 15, 2015|February 5, 2009|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00838526||143812|
NCT00838864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-97-C-010|Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding|Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding||Far Eastern Memorial Hospital|Yes|Completed|March 2009|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|79|||Both|18 Years|N/A|No|||January 2009|August 28, 2015|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00838864||143788|
NCT00838877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2750C00001|Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid|Open Label Positron Emission Tomography Study With [18F]AZD4694 and [11C]AZD2184, Candidate Radioligands for AB Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease|PET|AstraZeneca|No|Completed|January 2009|October 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|26|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00838877||143787|
NCT00841126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT 401|Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate|An Open, Randomized, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate Together With a Randomized Placebo Controlled Double Blind Fermagate Comparison in Hemodialysis Patients With Hyperphosphatemia||Ineos Healthcare Limited|Yes|Terminated|July 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|657|||Both|18 Years|N/A|No|||October 2010|October 18, 2010|February 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00841126||143618|
NCT00838591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-221-CL-007|Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma|MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma||MediciNova|Yes|Completed|March 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|65 Years|No|||September 2013|September 4, 2013|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838591||143807|
NCT00838617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081243|Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS)|Muscle Ultrasound: A New Tool for Measuring Progression in ALS||Vanderbilt University|Yes|Completed|February 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with ALS (Amyotrophic Lateral Sclerosis)|December 2009|December 10, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838617||143806|
NCT00833118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004837|Tongue Pull Versus Jaw Thrust|Tongue Pull Versus Jaw Thrust||Mayo Clinic||Completed|November 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Male or female scheduled for surgery and undergoing intubation for general anesthesia        administration|February 2010|February 11, 2010|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833118||144226|
NCT00833352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPTAL CRT 0408|Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device|Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device|SEPTAL-CRT|Guidant Corporation|No|Completed|November 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|January 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833352||144208|
NCT00833612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00001|Counterpulsation Reduces Infarct Size Pre-PCI for AMI|A Multi-center, Randomized, Controlled Study of Mechanical Left Ventricular Unloading With Counterpulsation to Reduce Infarct Size Pre-PCI for Acute Myocardial Infarction - CRISP AMI|CRISP-AMI|Datascope Corp.|Yes|Completed|December 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|339|||Both|18 Years|90 Years|No|||June 2011|June 24, 2011|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00833612||144188|
NCT00833976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002219|Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia|Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia||Massachusetts General Hospital|No|Completed|July 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||April 2014|April 29, 2014|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833976||144160|
NCT00834262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3669|Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients|A Multi Centre, Open Label, Non-Randomized, Non Interventional, Observational Study on the Safety and Efficacy of Biphasic Insulin Aspart (NovoMix® 30, NovoMix® 50 and NovoMix® 70 or Combinations) in Type 2 Diabetes Mellitus Patients||Novo Nordisk A/S|No|Completed|April 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|339|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient with type 2 diabetes who has HbA1c greater than 7% on insulin with or without        OAD and who needs intensification of treatment with either NovoMix® 30, NovoMix® 50 or        NovoMix® 70 or combinations, will be eligible A nonrandomized sample of approximately 325        subjects with Type 2 diabetes mellitus will be enrolled.|June 2012|June 15, 2012|February 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00834262||144138|
NCT00834275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2920|Cefadroxil 500 mg Capsules Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose Fasting, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-smoking Male and Female Subjects.||Teva Pharmaceuticals USA|No|Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00834275||144137|
NCT00834678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08164|Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer|Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|April 2009|September 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|January 31, 2009|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00834678||144106|
NCT00835471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVALT10|2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study)|NVALT10|Dutch Society of Physicians for Pulmonology and Tuberculosis|No|Recruiting|March 2009|June 2014|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||July 2010|July 23, 2010|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835471||144045|
NCT00835484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-1122|Cefdinir Capsules 300 mg, Fasting|A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00835484||144044|
NCT00816166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISSIT CA-2007-01|VISSIT Intracranial Stent Study for Ischemic Therapy|Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease|VISSIT|Codman & Shurtleff|Yes|Terminated|October 2008|June 2014|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|85 Years|No|||February 2015|February 2, 2015|December 29, 2008|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT00816166||145515|Early termination of enrollment led to small numbers of subjects analyzed (less than 50% of the prospectively planned sample size). Various endpoints, subgroup and sensitivity analyses were not conducted because the study was not fully enrolled.
NCT00816686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007002|A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer|A Phase 1, Open-Label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M18 Given as Monotherapy in Subjects With Advanced Renal Cell Carcinoma||Astellas Pharma Inc|No|Terminated|October 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|7|||Both|18 Years|N/A|No|||May 2010|February 26, 2013|January 1, 2009|No|Yes|Trial was terminated due to the need to re-formulate the study drug.|No||https://clinicaltrials.gov/show/NCT00816686||145475|
NCT00837421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005H0029|The Ohio State University Sepsis Registry|The Ohio State University Sepsis Registry||Ohio State University|No|Suspended|December 2006|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|hospital intensive care unit|February 2011|February 8, 2011|February 4, 2009||No|Temporary hold on enrollment for interim analysis|No||https://clinicaltrials.gov/show/NCT00837421||143897|
NCT00838227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07I/C41-00|Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder|Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study||Manhattan Psychiatric Center|Yes|Withdrawn|February 2008|June 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|64 Years|No|||September 2014|September 16, 2014|February 5, 2009||No|This study was withdrawn because there was no source of funding to implement the study.|No||https://clinicaltrials.gov/show/NCT00838227||143835|
NCT00838240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06061|Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia|Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)|AML-14A|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|November 2008|||December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|60 Years|No|||July 2012|July 19, 2012|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00838240||143834|
NCT00837785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS101|A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS|A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With Multiple Sclerosis||Biogen|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|55 Years|No|||January 2011|January 27, 2011|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837785||143869|
NCT00837798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|374|RATE Registry - Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population|Registry of AT/AF Episodes in the CRM Device Population: RATE Registry|RATE|St. Jude Medical|No|Completed|October 2006|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5379|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a CRM device|December 2012|December 18, 2012|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00837798||143868|
NCT00838539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-2205|Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors|A Phase 1 Study Of Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors||Puma Biotechnology, Inc.|No|Completed|April 2009|December 2013|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|February 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00838539||143811|
NCT00838552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJ HS-2178|Markers of Airway Inflammation in BAL Fluid From Children With Asthma|Prospective Analysis of Markers of Airway Inflammation and Remodeling in Bronchoalveolar Lavage Fluid From Children With Asthma.||National Jewish Health|No|Recruiting|October 2007|January 2021|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|18 Years|No|Probability Sample|Patients undergoing bronchoscopy at National Jewish Health|April 2015|April 14, 2015|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00838552||143810|
NCT00839904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDR2-HMO-CTIL|Physical Activity and Health of Children With Cancer in Remission|The Effect of Physical Activity on the Mental and Physical Health of Children With Cancer in Remission||Hadassah Medical Organization|No|Completed|February 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|6 Years|16 Years|No|||July 2013|July 29, 2013|February 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00839904||143710|
NCT00840775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV103-01|PIONIR Study (Presillion™ and Presillion™ Plus Stent Systems)|Clinical Protocol Presillion™ and Presillion™ Plus Stent Systems||Medinol Ltd.|No|Completed|April 2009|June 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|278|||Both|18 Years|N/A|No|||August 2011|August 11, 2011|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840775||143645|
NCT00837005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOBU-STRESS01|Prognostic Value of High Dose Dobutamine Stress Magnetic Resonance Imaging|Prognostic Value of High Dose Dobutamine Stress Magnetic Resonance in Patients With Ischemic Heart Disease. Assessment of Myocardial Perfusion and Wall Motion.|DS-Prognosis|Heidelberg University|No|Completed|January 2005|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2500|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients referred to our institution for clinically indicated dobutamine        stress MRI due to suspected or known CAD (with/without prior revascularization and        with/without history of previous myocardial infarction).|March 2012|March 28, 2012|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00837005||143929|
NCT00832546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGX426CLP1003|A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers|A Double-Blind, Randomized, Placebo Controlled, Cross-Over, Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Volunteers||TorreyPines Therapeutics|Yes|Completed|May 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||January 2009|January 29, 2009|January 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00832546||144268|
NCT00837473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trial #3206|Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures|A Prospective Pilot Study on the Performance of The Plexur P™ Bone Void Filler||Osteotech, Inc|No|Completed|January 2009|October 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2012|September 14, 2012|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837473||143893|
NCT00832832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00021272|Eyelid Closure in Glaucoma Therapy|Eyelid Closure in Topical Glaucoma Therapy||Johns Hopkins University|No|Completed|January 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|N/A|No|||September 2012|September 19, 2012|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832832||144246|
NCT00833105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4649|Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury|Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury (SCI)||Oregon Health and Science University|Yes|Active, not recruiting|January 2009|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||April 2014|April 28, 2014|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833105||144227|
NCT00833365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31394|Early Versus Late Use of Ibuprofen for PDA Closure|Early vs. Late Use of Ibuprofen for PDA Closure and Pain/Stress Reduction||University of Utah|No|Terminated|January 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|N/A|96 Hours|No|||December 2014|December 10, 2014|January 29, 2009|No|Yes|Study drug not available|No||https://clinicaltrials.gov/show/NCT00833365||144207|
NCT00833378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111716|Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.|A Phase I, Open-label, Single Sequence, Crossover Study Evaluating the Safety and the Pharmacokinetics of Lopinavir/Ritonavir and Eltrombopag Given Alone and When Co-administered in Healthy Adult Subjects.||GlaxoSmithKline||Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|January 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00833378||144206|
NCT00833625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0752|FDG-PET-CT and Biomarkers in Esophageal Cancer|FDG-PET-CT and Biomarkers to Assess Pathologic Response in Surgical Specimens of Patients With Localized Esophageal Cancer After Chemoradiation||M.D. Anderson Cancer Center|No|Completed|February 2009|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00833625||144187|
NCT00833638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12719|A Study in Erectile Dysfunction|Tadalafil 2.5 mg and 5 mg Once a Day Compared to Placebo in Day of Onset of Efficacy||Eli Lilly and Company|No|Completed|February 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|372|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 18, 2010|January 30, 2009|Yes|Yes||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00833638||144186|
NCT00833989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111539|Safety Escalating Repeat IV, in Stroke Patients|A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke|MAG111539|GlaxoSmithKline|No|Completed|July 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|42|||Both|18 Years|90 Years|No|||October 2011|March 15, 2012|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833989||144159|
NCT00834288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT1-009|A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions|A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions||Labopharm Inc.||Completed|June 2003|||August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|January 30, 2009||No||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00834288||144136|
NCT00834301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0801|An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients|An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients||Nephrian|No|Recruiting|January 2009|September 2009|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||February 2009|February 2, 2009|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00834301||144135|
NCT00834327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aplindore-250|Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome|A Randomized, Double-Blind, Placebo-Controlled Four Week Study of the Efficacy and Safety of Four Doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of Aplindore MR Tablets vs. Placebo in Idiopathic Restless Legs Syndrome.||Neurogen Corporation|No|Terminated|February 2009|December 2009|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|230|||Both|18 Years|N/A|No|||October 2009|October 12, 2009|January 30, 2009|Yes|Yes|Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety    concerns identified.|No||https://clinicaltrials.gov/show/NCT00834327||144133|
NCT00835120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08-24|Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance|Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance||University Hospital Case Medical Center|Yes|Completed|March 2009|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|70 Years|No|||October 2014|October 10, 2014|February 2, 2009|No|Yes||No|October 10, 2014|https://clinicaltrials.gov/show/NCT00835120||144072|
NCT00836576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01002|Benazepril HCl 40 mg Tablets, Fasting|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Benazepril HCl (40 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Lotensin®, Novartis Pharmaceuticals Corporation) in 40 Fasted, Healthy, Adult Subjects||Teva Pharmaceuticals USA|No|Completed|February 2001|March 2001|Actual|March 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 3, 2009|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00836576||143961|
NCT00836849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02070|Sertraline Hydrochloride 100 mg Tablets, Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|March 2002|April 2002|Actual|April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|No|||February 2009|February 3, 2009|February 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00836849||143941|
NCT00836862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|482-08-EP|Arteriovenous Fistula Tissue Bank|Arteriovenous Fistula Tissue Bank||University of Nebraska|No|Recruiting|February 2009|||November 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Serum, Whole Blood, Tissue|Both|19 Years|N/A|No|Probability Sample|Patients will be eligible if they are 19 years of age or greater and have placement of an        arteriovenous fistula planned witin 30 days.|July 2010|July 15, 2010|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00836862||143940|
NCT00816400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP187|A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.|A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-derived Growth Factor Receptor Alpha (PDGFRα), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists|MEDI-575|MedImmune LLC|No|Completed|January 2009|April 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|December 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00816400||145497|
NCT00817258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-0701|Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma|Phase Ⅱ Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma||Fudan University|Yes|Recruiting|January 2007|December 2009|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|70 Years|No|||January 2009|January 5, 2009|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00817258||145431|
NCT00837954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0803|Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis|Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis|COBBANA|Aesculap AG|No|Completed|February 2009|April 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00837954||143856|
NCT00837967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589LC00003|Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients|A Comparison of Tolerability of 10 Inhalations of Symbicort® Turbuhaler® 160/4.5 μg and 10 Inhalations of Terbutaline Turbuhaler® 0.4 mg on Top of Symbicort® Turbuhaler® 160/4.5 μg 1 Inhalation Bid, Randomized, Double-blind, Cross Over, Phase III Study in Japanese Adults Asthma Patients||AstraZeneca|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|16 Years|65 Years|No|||August 2012|August 27, 2012|February 5, 2009|Yes|Yes||No|July 5, 2010|https://clinicaltrials.gov/show/NCT00837967||143855|
NCT00840164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812048R|Pathology of Skin, Nerve and Vasculature in the Amputated Limb of Diabetes|Pathology of Skin, Nerve and Vasculature in the Amputated Limb of Diabetes||National Taiwan University Hospital|No|Recruiting|February 2009|December 2013|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|After amputation, sural nerve, posterior tibial nerve, and the accompanying vasculature will      be harvested from the amputated leg. 3mm-puch skin will be taken from the amputated leg, 10      cm above the lateral malleolus.|Both|10 Years|90 Years|No|Non-Probability Sample|Diabetic foot wound patient who underwent below-knee amputation due to poor wound healing        and severe infection condition. The patient population often receives leg revasculariztion        surgery but poor response for wound healing.|August 2011|October 13, 2011|February 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00840164||143691|
NCT00839241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-ABT-0004|A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood ("Bank Blood")|An Open , Prospective, Randomized, Parallel Group Study to Investigate Whether Postoperatively Collected and Transfused Autologous Whole Blood Improves the Immunological Status in Comparison to Allogenic Blood Transfusion in Patients Undergoing Total Knee Replacement||Wellspect HealthCare|No|Completed|January 2009|||July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|February 6, 2009||No||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00839241||143760|
NCT00839553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95042|Intrapleural Minocycline After Aspiration of Spontaneous Pneumothorax|Intrapleural Minocycline After Manual Aspiration for the Prevention of Primary Spontaneous Pneumothorax. A Phase III Multicenter Prospective Randomized Controlled Trial||Far Eastern Memorial Hospital|Yes|Recruiting|April 2007|April 2009|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|||Anticipated|100|||Both|15 Years|50 Years|No|||February 2009|February 6, 2009|February 6, 2009||||No||https://clinicaltrials.gov/show/NCT00839553||143736|
NCT00840788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Episio- 01 - RCT|Comparison of Adhesive Glue With Skin Suture for Repair of Episiotomy|Skin Adhesive Versus Subcuticular Suture for Perineal Skin Repair After Episiotomy - a Randomized Controlled Trial.||Hospital Sao Joao|No|Completed|May 2005|January 2007|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Female|N/A|N/A|No|||February 2009|February 9, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840788||143644|
NCT00832260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR08004ES|IES-ACap: Influence of Atrial Pulse Width in the Behaviour of ACap™ Confirm Algorithm.|Influence of Atrial Pulse Width in the Behaviour of ACap™ Confirm Algorithm.|IES-ACap|St. Jude Medical|No|Completed|January 2009|September 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients whit a Zephyr™ pacemaker implanted, models 5826 and 5820.|September 2014|September 25, 2014|January 29, 2009||No||No|August 27, 2014|https://clinicaltrials.gov/show/NCT00832260||144290|
NCT00832819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-J081-110|E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)|E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)||Eisai Inc.||Completed|February 2009|October 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|74 Years|No|||February 2015|April 9, 2015|January 23, 2009||No||No|February 21, 2015|https://clinicaltrials.gov/show/NCT00832819||144247|
NCT00832273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-501|Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery|Use of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Liver Failure: Uncontrolled Treatment Protocol to Provide Expanded Access With Cost Recovery||Vital Therapies, Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|10 Years|70 Years||||September 2013|September 9, 2013|January 29, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00832273||144289|
NCT00832559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA X-06|A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients|A Phase I, Open-label, Dosage Escalation, Study of Multiple Doses of CAVATAKTM (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors||Viralytics||Terminated|January 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|January 29, 2009||No|Poor recruitment rate.|No||https://clinicaltrials.gov/show/NCT00832559||144267|
NCT00832572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 3042|Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy|A Double-blind, Placebo-controlled, Cross-over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy||Gilead Sciences|No|Terminated|January 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|January 28, 2009|Yes|Yes|Lack of enrollment|No|May 28, 2013|https://clinicaltrials.gov/show/NCT00832572||144266|The study was stopped after 5 participants were enrolled. No outcome measure analyses were performed. Adverse events were collected and reported to the study center's Institutional Review Board.
NCT00833391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110882|Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)|An Open-label, Randomized, Single Dose, Five-period Crossover Study to Evaluate the Relative Bioavailability of Different Formulations of GSK1838262 in Healthy Volunteers.||XenoPort, Inc.||Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2010|May 10, 2013|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833391||144205|
NCT00833664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10136025|Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions|The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|January 2002|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 11, 2009|January 30, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00833664||144184|
NCT00833651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024793|Protective Immunity Project 02|A Prospective Comparison of the Magnitude and Character of the Immune Response to Influenza Vaccine in Immunosuppressed Renal Transplant Patients and Healthy Age-matched Volunteers|PIP-02|Emory University|Yes|Completed|November 2006|October 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|97|Samples Without DNA|serum, PBMCs|Both|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult (ages 18-59) recipients of deceased or living donor renal transplants|November 2013|November 21, 2013|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00833651||144185|
NCT00834002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 5/6/29|Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission|Wilms Tumor Gene (WT1) mRNA-transfected Autologous Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia (AML): a Phase I Trial|CCRG 05-001|University Hospital, Antwerp|No|Completed|March 2005|December 2008|Actual|November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2009|February 5, 2010|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00834002||144158|
NCT00834314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-291 M-MA|Randomized Pilot Study Comparing Two Vacuum-wound-dressings for Open Abdomen Treatment|Vacuum-Therapy in Open Abdomen Treatment - Randomized Pilot-trial Comparing Fascial Closure and Survival With "Vacuum-Pack"-Technique vs. "Abdominal Dressing"|ABDOVAC|Universitätsmedizin Mannheim|Yes|Terminated|February 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 2, 2009||No|extended obligations of amended medical device law in Germany 2010 did not allow to continue    and complete the trial due to budget limitation|No||https://clinicaltrials.gov/show/NCT00834314||144134|
NCT00834691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-938|An Evaluation of the Causes of Anemia in Patients With Heart Failure|Anemia in Chronic Heart Failure: Etiology, Comparisons With Renal Disease, and Relationships With Biomarkers and Left Ventricular Remodeling.|ANCHOR|Montreal Heart Institute|No|Completed|January 2008|||February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|180|Samples Without DNA|Plasma and serum samples for analysis of biomarkers.|Both|18 Years|N/A|No|Probability Sample|One hundred and eighty (180) patients will be enrolled in three groups.        Group 1: This group will involve 80 patients with anemia (hemoglobin < 120g/L in women and        < 130 g/L in) and systolic heart failure (LVEF < or = 40%; New York Heart Association        -NYHA- functionnal class II-IV).        Group 2: This group will include 50 patients with systolic heart failure (LVEF < or = 40%;        New York Heart Association -NYHA- functionnal class II-IV), but without anemia (hemoglobin        > or = 120g/L in women and > or = 130 g/L in men).        Group 3 : 50 patients with at least moderate CRF (eGFR < 60ml/min/1,73m2), and LVEF > or =        50%, with or without anemia.|July 2010|July 30, 2010|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00834691||144105|
NCT00835497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-0476|5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting|A Relative Bioavailability Study of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|June 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 9, 2009|January 30, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00835497||144043|
NCT00835510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTNF-0708|Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis||Taro Pharmaceuticals USA|No|Completed|June 2008|December 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|548|||Both|12 Years|N/A|No|||January 2014|January 2, 2014|January 30, 2009|No|Yes||No|May 4, 2009|https://clinicaltrials.gov/show/NCT00835510||144042|
NCT00835900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 136208|An Alternative Dosing Schedule of Varenicline for Smoking Cessation|Extended Varenicline for Smoking Cessation: A Pilot Study||Roswell Park Cancer Institute|Yes|Completed|March 2009|July 2015|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00835900||144012|
NCT00836277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-161|Phase II Study of Irinotecan and Panitumumab|Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma||University of Pittsburgh|Yes|Completed|May 2009|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836277||143983|
NCT00840957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI07-DM / FAKIR|Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis|Pharmaco Kinetic and Pharmacokinetic-Pharmacodynamic Variability of Infliximab|FAKIR|University Hospital, Tours|No|Completed|November 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|Samples With DNA|whole blood and serum|Both|18 Years|N/A|No|Non-Probability Sample|Rheumatoid arthritis|April 2015|April 8, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00840957||143631|
NCT00840970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-0208|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2008|||||N/A|N/A|N/A||||||||||||||March 25, 2015|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840970||143630|
NCT00816998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-004364|Range of Motion and Patients With Distal Radius Fractures|The Effect of Early vs. Delayed Range of Motion in the Outcome of Patients With Distal Radius Fractures||Mayo Clinic|No|Completed|October 2006|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|85 Years|No|||April 2011|April 6, 2011|January 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00816998||145451|
NCT00816426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909061|Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis|Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery||National Institutes of Health Clinical Center (CC)||Completed|December 2008|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|25|||Both|20 Years|100 Years|No|||January 2016|February 3, 2016|December 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00816426||145495|
NCT00816439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090040|Imaging Cannabinoid CB1 Receptors in Alcohol Dependence|Imaging Cannabinoid CB1 Receptors in Alcohol Dependence||National Institutes of Health Clinical Center (CC)||Completed|December 2008|August 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|101|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|December 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00816439||145494|
NCT00816712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-064|A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)|A Randomized, Single-Blind, Placebo-Controlled, Single-dose, Parallel Design Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (FSR)||Merck Sharp & Dohme Corp.||Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|28|||Male|60 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|December 31, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00816712||145473|
NCT00816725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32MH077371|Effectiveness of a Web-based Prevention Program for Postpartum Depression|Using the Internet for English/Spanish Randomized Trials for Postpartum Depression||University of California, San Francisco|No|Completed|January 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|January 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00816725||145472|
NCT00837733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1551354|Endometrial Local Injury and Implantation Failure|Endometrial Local Injury Improves the Pregnancy Rate Among Recurrent Implantation Failure Patients Undergoing IVF/ICSI||Yazd Research & Clinical Center for Infertility|Yes|Completed|January 2008|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|115|||Female|15 Years|39 Years|Accepts Healthy Volunteers|||February 2009|February 4, 2009|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837733||143873|
NCT00841152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139/180/2008|Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute|A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects|BAGvsTCP|Turku University Hospital|No|Recruiting|March 2009|December 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00841152||143616|
NCT00838968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI|The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma|The Efficiency of Postoperative Interferon-alpha(IFNa) Treatment in p48 Positive Patients With Hepatocellular Carcinoma||Fudan University|Yes|Withdrawn|January 2008|January 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|75 Years|No|||August 2012|August 21, 2012|February 6, 2009||No|we have found another marker (microRNA26) which is more sensitive to evaluate the effect of    postoperative IFNa treatment in patients with HCC|No||https://clinicaltrials.gov/show/NCT00838968||143780|
NCT00838890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA198-001|A Study of BMS-863233 in Patients With Hematologic Cancer|A Phase 1/2, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Refractory Hematologic Malignancies||Bristol-Myers Squibb||Terminated|March 2009|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|February 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00838890||143786|
NCT00839566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEN_G_CA_9|PAF-HEFT (Permanent Atrial Fibrillation in Heart Failure Trial)|Permanent Atrial Fibrillation in Heart Failure Trial|PAF-HEFT|Medtronic Bakken Research Center|No|Terminated|November 2008|July 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|January 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00839566||143735|
NCT00839579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1x4min interval|Cardiovascular Treatment|How Little Pain for Cardiac Gain? A Pilot Study||Norwegian University of Science and Technology|Yes|Completed|January 2009|June 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|35 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839579||143734|
NCT00832533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0814|The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure|INST 0814: The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure||New Mexico Cancer Care Alliance|Yes|Completed|November 2008|January 2010|Actual|February 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|9|Samples With DNA|Blood samples and Buccal Smear|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|2 participants with Hispanic ethnicity are represented as well. Darker-skinned        individuals, such as African Americans, produce considerably less vitamin D. Inclusion of        African Americans will be critical. Asians and African Americans do develop melanoma, but        at a rate ten times less than Caucasians and it does not appear to be related to sun        exposure; thus, to include them at this time would not allow us to focus on the        medically-related issue.|September 2015|September 24, 2015|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832533||144269|
NCT00832598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-142|[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors|18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2009|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|January 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00832598||144264|
NCT00833131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGBRJG0109|The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer|Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study||Polish Colorectal Cancer Study Group|Yes|Recruiting|November 2008|November 2015|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|75 Years|No|||April 2010|April 14, 2010|January 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00833131||144225|
NCT00834379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B006511|Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2000|September 2000|Actual|September 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|58|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 30, 2009|January 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00834379||144129|
NCT00834392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2008:035|Exercise in Men With Prostate Cancer|A Pilot Study of Exercise in Men With Prostate Cancer Receiving Androgen Depletion Therapy||University of Manitoba|No|Completed|October 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|50 Years|N/A|No|||January 2011|January 31, 2011|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834392||144128|
NCT00834015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ksshp Dnro 4E/2008|Spinal Fusion and Rehabilitation Study|Outcome of Lumbar Spinal Fusion Patients and Significance of Postoperative Exercise Therapy: Randomized Controlled Trial and Spine Register Study||Jyväskylä Central Hospital|No|Completed|May 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|100|||Both|20 Years|N/A|No|||April 2015|April 13, 2015|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00834015||144157|
NCT00834340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036501|Glimepiride 4 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|June 22, 2009|https://clinicaltrials.gov/show/NCT00834340||144132|
NCT00834353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F.501(134)/02-EC/MC(Aca)/16713|Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis|Prospective Study of N-acetyltransferase2 (NAT2) Gene and Rifampicin Induced Cytochrome P-450 as Susceptible Risk Factors for Antituberculosis Drug Induced Hepatitis||Maulana Azad Medical College|Yes|Completed|September 2005|September 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|||||Both|10 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Cases are enrolled in the study from primary care clinic after they are diagnosed with        pulmonary tuberculosis.|February 2009|February 2, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834353||144131|
NCT00834366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT1-013|A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions|||Labopharm Inc.||Completed|February 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|January 30, 2009|Yes|Yes||No|April 6, 2009|https://clinicaltrials.gov/show/NCT00834366||144130|
NCT00835523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSS 2009|Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist|OHSS Prevention by GnRH-agonist Triggering of Final Oocyte Maturation and Cryoperservation of All Two-pronucleate Oocytes in Women Undergoing Stimulation for IVF With Gonadotrophins and GnRH-analogues: a Prospective, Observational, Multicentric, Clinical Cohort Study||University of Schleswig-Holstein|Yes|Completed|May 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|39 Years|No|Non-Probability Sample|IVF patients|June 2012|June 13, 2012|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00835523||144041|
NCT00840294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16368B|Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)|Randomized, Multi-Institution Trial of Ciprofloxacin Versus Observation for Men With an Elevated Prostate Specific Antigen (PSA)||University of Chicago|No|Terminated|January 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Male|18 Years|N/A|No|||July 2014|July 7, 2014|February 9, 2009|Yes|Yes|Combination of futility analysis and poor accrual|No|July 7, 2014|https://clinicaltrials.gov/show/NCT00840294||143681|Early termination due to poor accrual and interim futility analysis.
NCT00840593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5203037|A Prospective, Randomised Long-term Follow-up of Operative Versus Non-operative Treatment of Gr. 3 Acromioclavicular Dislocation|A Prospective, Randomised 18 -Year Follow-up Study of Operative and Non-operative Treatment of Acute, Total Acromioclavicular Dislocation.||Kuopio University Hospital|No|Completed|February 2009|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|N/A|N/A|No|||December 2011|December 7, 2011|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00840593||143659|
NCT00840606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-654|Buspirone Hydrochloride 30mg Tablets, Fasting|A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2001|April 2002|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 9, 2009|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00840606||143658|
NCT00840619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPS-GMC-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2008|||||N/A|N/A|N/A||||||||||||||February 9, 2009|February 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00840619||143657|
NCT00840983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mercer-K23-03|Effects of Delayed Cord Clamping in Very Low Birth Weight Infants|Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants||University of Rhode Island|Yes|Completed|August 2003|December 2006|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|72|||Female|N/A|N/A|No|||November 2015|November 27, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00840983||143629|
NCT00836914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-04|Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-101 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge||Gilead Sciences|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|55 Years|No|||January 2013|January 4, 2013|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00836914||143936|
NCT00816452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISED_L_04261|Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer|Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.|InoPro|Sanofi||Completed|January 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Male|60 Years|N/A|No|Non-Probability Sample|Male with Prostate Cancer suffering from Osteoporosis|November 2010|November 2, 2010|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816452||145493|
NCT00816738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801035R|Evaluation of the Treatment of Recurrent Corneal Erosions by Anterior Stromal Puncture With Nd: YAG Laser|Evaluation of the Treatment of Recurrent Corneal Erosions by Anterior Stromal Puncture With Nd: YAG Laser||National Taiwan University Hospital|Yes|Completed|January 2008|March 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|33|||Both|20 Years|71 Years|No|Non-Probability Sample|to evaluate the clinical outcomes after anterior stromal puncture with Nd:YAG laser in a        consecutive series of 33 eyes in 33 patients with unilaterally recurrent corneal erosion.|December 2008|January 2, 2009|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816738||145471|
NCT00816751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONG-08-1781|Paracervical Versus Intracervical Lidocaine|Paracervical Versus Intracervical Lidocaine for Suction Curettage: A Randomized Controlled Trial||University of California, San Diego|Yes|Completed|December 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2009|January 2, 2009|December 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00816751||145470|
NCT00838565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0151002|Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis|Phase I, Randomized, Patient and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PF-04236921 in Patients With Rheumatoid Arthritis Receiving Methotrexate||Pfizer|No|Completed|May 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|41|||Both|18 Years|70 Years|No|||March 2012|March 28, 2012|February 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00838565||143809|
NCT00838578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN330-US-02|Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer|Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer||Kyowa Hakko Kirin Pharma, Inc.|No|Terminated|March 2009|October 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|February 4, 2009|No|Yes|Per protocol, the study was terminated based on interim analysis results|No|March 19, 2014|https://clinicaltrials.gov/show/NCT00838578||143808|
NCT00837499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0551|Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.|Comparative Study of Breast Cancers and Their Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2008|||September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1825|Samples With DNA|One-time blood draw (about 3 tablespoons). If blood cannot be drawn or not enough blood can      be drawn, a saliva sample will be taken.|Female|18 Years|N/A|No|Non-Probability Sample|Woman, 18 years or older, of Mexican descent (Mexican or Mexican-American) or an        African-American woman, and have invasive breast cancer during past 12 months.|February 2016|February 3, 2016|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00837499||143891|
NCT00837512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348-2005|Insulin Delivery Using Microneedles in Type 1 Diabetes|Insulin Delivery Using Microneedles in Type 1 Diabetes||Emory University|Yes|Completed|September 2008|July 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|8 Years|18 Years|No|||November 2013|November 20, 2013|February 4, 2009||No||No|August 13, 2013|https://clinicaltrials.gov/show/NCT00837512||143890|
NCT00838903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112753|Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes|A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|February 2009|March 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1049|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|February 5, 2009|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT00838903||143785|
NCT00838916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112754|A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes|A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.||GlaxoSmithKline|Yes|Completed|February 2009|May 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|779|||Both|18 Years|N/A|No|||April 2014|May 22, 2014|February 5, 2009|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT00838916||143784|
NCT00836485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNJ-ALK201/08-003-11|Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|A Prospective, Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis||Senju USA, Inc.|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||May 2009|May 15, 2009|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836485||143967|
NCT00839163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11223|Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)|ODIXa-DVTA Prospective, Randomized, Multinational, Multicenter, Partially Blinded, Parallel-group, Open-label Active Comparator Controlled Phase II Dose Finding and Proof of Principle Trial.||Bayer|Yes|Completed|March 2004|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|613|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00839163||143765|
NCT00839176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-10100-P2A-002|Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)|A Double-blinded, Randomized, Placebo-controlled, Dose-Exploring Study of RX-10100 When Given for Eight Consecutive Weeks to Subjects With Major Depression Disorder (MDD)||Rexahn Pharmaceuticals, Inc.|No|Completed|January 2009|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|118|||Both|18 Years|65 Years|No|||November 2013|November 18, 2013|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00839176||143764|
NCT00839189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1518 (GCRC 1983)|Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults|Safety Study To Determine the Effect of a 10,000 EU Dose of Clinical Center Reference Endotoxin in Allergic and Mildly Asthmatic Adults||University of North Carolina, Chapel Hill|No|Completed|October 2002|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2009|December 8, 2009|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00839189||143763|
NCT00832312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080780|Intraarticular Ozone Therapy for Pain Control in Osteoarthritis of the Knee|Intraarticular Ozone Therapy for Pain Control in Osteoarthritis of the Knee||Ben-Gurion University of the Negev|No|Recruiting|August 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|75 Years|No|||June 2012|January 13, 2013|January 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00832312||144286|
NCT00832000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11050|Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia|Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia||University of Kansas Medical Center|Yes|Completed|December 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|16 Years|N/A|No|||August 2013|August 19, 2013|January 27, 2009|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT00832000||144309|
NCT00848094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-003|Radiation Dose Escalation Study for Advanced Liver Cancer|Phase I Trial of Radiation Dose Escalation for Locally Advanced Hepatocellular Carcinoma||Fudan University|Yes|Completed|April 2005|May 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848094||143088|
NCT00848107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-DU-202|Open-Label Study of Oral Treprostinil in Digital Ulcers|Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: An Open-label Multicenter Extension Study|DISTOL-EXT|United Therapeutics|No|Terminated|September 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|February 16, 2009|Yes|Yes|The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled    TDE-DU-201 study did not meet its primary efficacy objective.|No|July 12, 2013|https://clinicaltrials.gov/show/NCT00848107||143087|Interpretation of the change in digital ulcer status was limited by the lack of a control group and the discontinuation of the study prior to subjects completing all scheduled visits.
NCT00848653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELECTION|ELECTION - The Electrode Configuration Cardiac Resynchronization Therapy (CRT) Study (ELECTION)|The Electrode Configuration (ELECTION) CRT Study Including ELECTION Phrenic Nerve Stimulation (PNS) Sub-Study|ELECTION|Guidant Corporation|No|Completed|November 2004|December 2008|Actual|September 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|260|||Both|18 Years|N/A|No|Non-Probability Sample|patients indicated for CRT therapy|February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848653||143046|
NCT00848666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC 48-08|Safety and Efficacy of a Novel Topical Therapy for Tinea Pedis (Athlete's Foot)|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2009|||April 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2009|February 23, 2009|August 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00848666||143045|
NCT00848965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110341|A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber|A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purpose of Investigating the Sensitivity||GlaxoSmithKline||Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|59|||Both|18 Years|65 Years|No|||February 2011|August 23, 2012|February 12, 2009||No||No|August 23, 2012|https://clinicaltrials.gov/show/NCT00848965||143022|
NCT00848978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140|Strength Training in Nonagenarians|Health Enhancing Strength Training in Nonagenarians|STRONG|Hospital General Universitario Gregorio Marañon|Yes|Enrolling by invitation|March 2009|August 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|60|||Both|90 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 20, 2009|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00848978||143021|
NCT00849264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-004|Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients|a Randomized Controlled Study of Surgical Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|30 Years|60 Years|No|||December 2008|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00849264||143000|
NCT00849251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6817|Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma|Combination Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma (PLD-BCD)||University of Washington|Yes|Terminated|November 2008|June 2015|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|February 20, 2009|No|Yes|One of the study drugs is not available.|No||https://clinicaltrials.gov/show/NCT00849251||143001|
NCT00856323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|702632|Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men|Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM||Friends Research Institute, Inc.|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|53|||Male|18 Years|N/A|No|||March 2015|March 18, 2015|March 3, 2009|Yes|Yes||No|August 27, 2012|https://clinicaltrials.gov/show/NCT00856323||142466|
NCT00856336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DART|Phase I Safety Study of DMXAA in Refractory Tumors|5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.|DART|Antisoma Research|Yes|Completed|May 2003|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|15|||Both|18 Years|N/A|No|||March 2009|March 4, 2009|March 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00856336||142465|
NCT00850161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasulin™-BNT-US-100-PK009|Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin|Intranasal Insulin and Its Effect on Postprandial Glucose Metabolism in Comparison to Subcutaneous Insulin||CPEX Pharmaceuticals Inc.|No|Withdrawn|July 2009|September 2010|Anticipated|August 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|50 Years|No|||February 2016|February 12, 2016|February 23, 2009|Yes|Yes|Business purposes.|No||https://clinicaltrials.gov/show/NCT00850161||142934|
NCT00856947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007871-26|Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood|Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood: An Interventional Trial in the ABC (Asthma Begins in Childhood) Cohort|ABCvitaminD|Copenhagen Studies on Asthma in Childhood|Yes|Active, not recruiting|March 2009|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856947||142419|
NCT00857220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-247|Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia|A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia||Sunovion|Yes|Completed|May 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|304|||Both|6 Years|17 Years|No|||June 2013|June 18, 2013|March 4, 2009|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT00857220||142398|Designed to assess safety/tolerability. Efficacy endpoints evaluated w/ descriptive stats only, w/ no placebo group against which to assess the impact of therapy. ~40% completion rate typical for one year studies but limits interpretation of results.
NCT00848692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18257|Drug Intervention in Chronic Fatigue Syndrome|B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study.|KTS-1-2008|Haukeland University Hospital|No|Completed|June 2008|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||June 2011|June 1, 2011|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848692||143043|
NCT00857584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00058|Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy|Effectiveness of Quetiapine XR Versus Sertraline in Acute Depression as add-on Therapy to Previous Mood Stabilizer Treatment: a Pilot Study||AstraZeneca|No|Completed|May 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||March 2012|April 16, 2012|March 5, 2009|Yes|Yes||No|February 6, 2012|https://clinicaltrials.gov/show/NCT00857584||142371|
NCT00846625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34035|Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids|Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids Following a Periocular Steroid Injections in Patients on Steroid Sparing Agents or Low Dose Steroids|SURFING|University of Utah|Yes|Withdrawn|November 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|February 18, 2009|Yes|Yes|Insufficient enrollment (no subjects were enrolled)|No||https://clinicaltrials.gov/show/NCT00846625||143200|
NCT00846924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Embrace001|30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event|30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event: A Randomized Controlled Trial|EMBRACE|Sunnybrook Health Sciences Centre|No|Active, not recruiting|May 2009|December 2015|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|564|||Both|55 Years|N/A|No|||April 2015|April 1, 2015|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00846924||143177|
NCT00847522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI26818|Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma|Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma||University of Utah|Yes|Active, not recruiting|February 2009|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847522||143131|
NCT00859040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-266|Monthly SOM230C for Recurrent or Progressive Meningioma|Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|March 2009|March 2016|Anticipated|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|March 9, 2009|Yes|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00859040||142259|
NCT00848146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23522|NOTES-Assisted Laparoscopic Cholecystectomy Surgery|Natural Orifice Translumenal Endoscopic Surgery (NOTES)-Assisted Laparoscopic Cholecystectomy Surgery|TAS-NOTES|Northwestern University|No|Completed|February 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|85 Years|No|||July 2012|July 3, 2012|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848146||143084|
NCT00848341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREDIT|Canadian Registry of ICD Implant Testing Procedures|Canadian Registry of ICD Implant Testing Procedures||Guidant Corporation|Yes|Completed|January 2006|November 2008|Actual|April 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|261|||Both|18 Years|N/A|No|Non-Probability Sample|patients who are indicated for a market approved ICD|February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848341||143069|
NCT00848354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-4532|Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy|A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.||Pfizer|No|Completed|June 2009|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|429|||Both|18 Years|69 Years|No|||December 2015|December 11, 2015|February 18, 2009|Yes|Yes||No|February 2, 2012|https://clinicaltrials.gov/show/NCT00848354||143068|
NCT00855517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 06|A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma|A Partially Masked, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Withdrawn|March 2009|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|March 2, 2009|Yes|Yes|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT00855517||142526|
NCT00855530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS4848|Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder|A Fifty-Two-Week Multicenter, Open-Label, Study Evaluating the Long-Term Safety and Tolerability of SR58611A 350 mg q12 in Patients With Major Depressive Disorder.||Sanofi|No|Completed|September 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|527|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|March 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00855530||142525|
NCT00855829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|galmedics-HMO-CTIL|A Feasibility Study Designed to Assess the Efficacy of the ActiLady Device in Adult Female Subjects With Dysmenorrhea|A Single-Center, Randomized, Controlled, Double-Blind Feasibility Study Designed to Assess the Safety Performance of ActiLady Prototype in Adult Female Subjects With Dysmenorrhea.||Hadassah Medical Organization|No|Completed|May 2010|October 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|35 Years|No|||November 2013|November 10, 2013|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855829||142503|
NCT00856050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-341|Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma|Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma||Dana-Farber Cancer Institute|Yes|Completed|February 2009|March 2014|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||February 2014|April 24, 2014|March 4, 2009|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT00856050||142486|
NCT00849550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015605|Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.|A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors|COBRA|Duke University|Yes|Completed|July 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2012|December 21, 2012|February 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00849550||142980|
NCT00856609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909095|The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects|The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|March 2009|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856609||142445|
NCT00847860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurology-2008-VD|Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions|Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White|CAVAD|Peking University First Hospital|Yes|Completed|March 2008|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|40 Years|80 Years|No|||December 2009|May 5, 2015|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847860||143106|
NCT00856583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99824|Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use|Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study|SCoP|H. Lundbeck A/S|Yes|Completed|July 2002|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9809|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|March 5, 2009||No||No|May 4, 2011|https://clinicaltrials.gov/show/NCT00856583||142447|
NCT00848406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2009007|A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects|An Observational Study to Obtain Normal Values of Inflammatory Variables in Induced Sputum, Exhaled Breath, and Bronchial Biopsies From Healthy Smoking and Non-smoking Individuals|NORM|University Medical Center Groningen|No|Completed|April 2009|January 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|Samples With DNA|Blood, induced sputum, bronchial biopsies, brush and lining fluid, urine|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy individuals|January 2015|January 15, 2015|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848406||143064|
NCT00848705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK70026-01A2|Adolescent Self-Management of Type 1 Diabetes: an Intervention (Completed)|Adolescent Self-Management of Type 1 Diabetes: an Intervention|YourWay|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|October 2007|May 2009|Actual|January 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|72|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||January 2011|January 31, 2011|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848705||143042|
NCT00879580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-FR-001|Enterprise Stent Aneurysm Treatment (ESAT) Study - France|"Prospective Multicenter Observational Study for the Evaluation of the Efficacy of the Cordis Enterprise(TM) Self-expanding Intracranial Stent: Enterprise Stent Aneurysm Treatment (ESAT) Study|ESAT|Codman & Shurtleff|No|Completed|February 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|133|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects presenting with ruptured or non-ruptured aneurysms for whom simple or        balloon-assisted endovascular treatment is considered impossible or insufficient by the        interventional neuroradiologist.|October 2013|October 10, 2013|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00879580||140706|
NCT00846950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-3-075|Effects of H1-Antagonist on Cognition|Effects of H1-Antagonist on Stages of Human Information Processing||Maastricht University Medical Center|No|Completed|December 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846950||143175|
NCT00847262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOT-2|Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes|Hypertension With Obesity Trial: Diabetes Mellitus Branch|HOT-DM|Third Military Medical University|Yes|Completed|June 2008|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|30 Years|70 Years|No|||December 2013|December 15, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847262||143151|
NCT00850200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0806 - HL01|Proton Therapy for Hodgkin Lymphoma|Improving the Therapeutic Ratio by Using Proton Beam Radiation Therapy for Patients With Stage IA-IIIBX (Bulky/Non-bulky) Hodgkin Lymphoma Involving the Mediastinum Following Standard Chemotherapy|HL01|University of Florida|Yes|Active, not recruiting|August 2009|July 2020|Anticipated|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|6 Years|N/A|No|||June 2015|June 16, 2015|February 20, 2009|Yes|Yes||No|December 13, 2013|https://clinicaltrials.gov/show/NCT00850200||142931|
NCT00850213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-REDES1.7|Assessment of Clinical Performance and Costs of the Endeavor Resolute Stent "in Real Life" in Spain.|Registro Redes - Evaluación Del Comportamiento clínico y Del Coste Del Stent Coronario Endeavor Resolute de Medtronic "en el Mundo Real" en España|REDES|Medtronic Bakken Research Center|Yes|Completed|February 2009|February 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|448|||Both|18 Years|N/A|No|Probability Sample|Patients with an indication for an Endeavor Resolute coronary stent. The study will        include all consecutive patients who are appropriate candidates for at least one Endeavor        Resolute stent in at least one target lesion after angiography.|February 2012|February 14, 2012|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850213||142930|
NCT00858429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08I5|Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases|Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver||Northwestern University|Yes|Active, not recruiting|March 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|March 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858429||142306|
NCT00858728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/NIR03/64|Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly|Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly: a Randomised Controlled Trial|ADIT|Queen's University, Belfast|No|Completed|October 2006|September 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|83|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||July 2010|July 22, 2010|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858728||142283|
NCT00859053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-013|Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment|Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects||Bristol-Myers Squibb|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|46|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|March 6, 2009|No|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT00859053||142258|
NCT00859066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00026874|Evaluation of Radiology Resident Anxiety When Beginning Emergency Room (ER) Call|Evaluation of Radiology Resident Anxiety When Beginning ER Call||University of Michigan|Yes|Terminated|January 2009|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|19|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|First year radiology residents|April 2012|April 26, 2012|March 9, 2009||No|Original Principal Investigator (Andrew Trout M.D.) left the University.|No||https://clinicaltrials.gov/show/NCT00859066||142257|
NCT00859365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127/08|Acupuncture for Back and Neck Pain in an Emergency Room Setting|Efficacy of an Integrative Approach Utilizing Acupuncture as an add-on Therapy for the Treatment of Back and Neck Pain in an Emergency Department Setting - A Comparative Randomized Controlled Trial|ABNP|Assaf-Harofeh Medical Center|Yes|Completed|January 2009|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|60 Years|No|||January 2012|January 27, 2012|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859365||142236|
NCT00848367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007254-01H|Binge Eating Disorder Treatment Study|Optimizing Outcomes for Binge Eating, Depression and Weight Loss for Obese Women With Binge Eating Disorder by Matching to Group Psychological Treatments Based on Level of Attachment Anxiety||Ottawa Hospital Research Institute|No|Completed|April 2007|December 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|102|||Female|18 Years|N/A|No|||January 2014|January 10, 2014|February 19, 2009||No||No|June 4, 2013|https://clinicaltrials.gov/show/NCT00848367||143067|
NCT00848380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CCH-DUM-2008/2|Management of Cardiovascular Risk Factors|Management of Cardiovascular Risk Factors||AstraZeneca|No|Completed|February 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1492|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with hypertension and hyperlipidemia and other CV risk factors|November 2010|November 15, 2010|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848380||143066|
NCT00855543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-11-2097|Phospholipase A2 Producing Bacteria and Pre-Term Labor|Phospholipase A2 Producing Bacteria, Age at Gestation, Cervical Length Measurement and the Incidence of Pre-Term Labor||CAMC Health System|No|Completed|August 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obstetric patients in West Virginia|July 2011|July 14, 2011|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855543||142524|
NCT00846989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRKI983A2201|Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension|A 4-week Multi-center, Single-masked, Randomized, Latanoprost-controlled, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of RKI983 (0.05% and 0.10%) Ophthalmic Solution Given Twice a Day Versus Once Daily Latanoprost 0.005%, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.||Novartis||Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|276|||Male|18 Years|N/A|No|||February 2013|February 11, 2013|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00846989||143172|
NCT00855842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIS|Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion|Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion|DAIS|Boston University|No|Terminated|March 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|50 Years|No|||June 2011|June 10, 2011|March 2, 2009||No|inadequate enrollment|No|April 4, 2011|https://clinicaltrials.gov/show/NCT00855842||142502|The study was terminated early because the clinical facility changed and eligible patients were not seen at the facility.
NCT00856349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shock-Less|Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming|Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming||Medtronic Cardiac Rhythm Disease Management|No|Completed|April 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4384|||Both|N/A|N/A|No|Non-Probability Sample|Subjects implanted with a Medtronic market released single, dual, or triple chamber        defibrillator (US/Canada - Concerto®/Virtuoso® or newer model; AsiaPacific, Israel, Latin        America - EnTrust™, InSync Sentry®, or Concerto®/Virtuoso® or newer model) within the past        30 days are eligible for participation in the study.|July 2014|July 1, 2014|February 26, 2009||No||No|May 22, 2014|https://clinicaltrials.gov/show/NCT00856349||142464|
NCT00856596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08023|Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females|Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks||Jamaica Hospital Medical Center|Yes|Recruiting|March 2009|September 2009|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 3, 2009|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856596||142446|
NCT00847548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-KP-463|Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting|Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting||VU University of Amsterdam|No|Active, not recruiting|September 2010|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847548||143129|
NCT00847561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077312|Effectiveness of a Family-Based Treatment for Preventing Anxiety Disorders in At-Risk Children|Family-Based Prevention for Childhood Anxiety||Johns Hopkins University|Yes|Completed|August 2008|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|136|||Both|7 Years|12 Years|No|||May 2014|May 5, 2014|February 18, 2009||No||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00847561||143128|
NCT00848185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIMAD-MC-10-2008-01|Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors|Differential Regulation of VEGF, Cadherin and Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors: Try to Explain the Lower OHSS Incidence||IVI Madrid|Yes|Completed|June 2008|March 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|Samples With DNA|follicular fluid|Female|18 Years|34 Years|Accepts Healthy Volunteers|Non-Probability Sample|oocyte Donors|May 2015|May 4, 2015|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848185||143081|
NCT00848172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090084|Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor|Double-Blind, Placebo Controlled Pilot-Study of Octanoic Acid in Essential Tremor||National Institutes of Health Clinical Center (CC)|No|Completed|February 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|21 Years|N/A|No|||November 2012|November 22, 2012|February 19, 2009|No|Yes||No|August 6, 2012|https://clinicaltrials.gov/show/NCT00848172||143082|
NCT00848731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC_kline_iNO1.1|Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism|Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism||Carolinas Healthcare System|No|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||June 2011|June 23, 2011|February 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848731||143040|
NCT00879593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTADIR PTcCO2/SLA|Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)|Potential Role for Nocturnal PtcCO2 Monitoring in the Close Follow up of ALS Patients.||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|No|Active, not recruiting|April 2009|December 2015|Anticipated|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|80|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879593||140705|
NCT00849277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2414|Study of the Effect of Probiotics on Respiratory Morbidity After Influenza Vaccination of Elderly in Nursing Homes|An RCT in Nursing Homes: the Effect of a Probiotic Treatment With Lactobacillus Casei Shirota on Respiratory Morbidity After Influenza Vaccination of Elderly.||Universiteit Antwerpen||Completed|October 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|737|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 20, 2009|February 20, 2009||||No||https://clinicaltrials.gov/show/NCT00849277||142999|
NCT00849290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB01|Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)|||Dendreon|No|Completed|April 2004|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Male|18 Years|N/A|No|||March 2013|March 12, 2013|February 19, 2009|Yes|Yes||No|May 28, 2010|https://clinicaltrials.gov/show/NCT00849290||142998|
NCT00849576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject™-15J|Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.|||Biodel|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|15|||Both|40 Years|75 Years|No|||July 2015|July 30, 2015|February 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00849576||142978|
NCT00857870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWT-2008-1|Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects|Comparative Investigation of Efficacy and Safety of Insulin Glargine Versus Metformin as First Line Drug in Treatment of Early Type 2 Diabetes|GLORY|GWT-TUD GmbH||Completed|March 2009|December 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|35 Years|75 Years|No|||January 2012|January 10, 2012|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00857870||142349|
NCT00858169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09044|Assessment of Wrist Joint and Knee Joint Inflammation in Patients With Rheumatoid Arthritis by Quantitative Three Dimensional Power Doppler Ultrasonography|Taichung Veterans General Hospital|3D sono in RA|Taichung Veterans General Hospital|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Both|N/A|N/A|No|Non-Probability Sample|A total of 30 patients with RA who visit outpatient clinic of Rheumatology at Taichung        Veterans General Hospital (TCVGH) will be enrolled consecutively at if they met the study        inclusion criteria|February 2015|February 12, 2015|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858169||142326|
NCT00858182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-001-07|Study of Safety and Efficacy on New Peritoneal Dialysis Solutions|Evaluation of a New Peritoneal Dialysis Solutions Containing Glucose, Xylitol and L-carnitine Compared to Standard PD Solutions in End-stage Renal Disease (ESRD) Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)||Iperboreal Pharma Srl|No|Withdrawn|May 2009|January 2013|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858182||142325|
NCT00849927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|somos 12-04-01|Circumferential Lesions of the Glenoid Labrum|Circumferential Lesions of the Glenoid Labrum: A Prospective Cohort Study of Arthroscopic Repair With Minimum 2-Year Follow-up: A Multi-Center Study.||Society of Military Orthopedic Surgeons|No|Completed|January 2003|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|17 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|Department of Defense active duty members|February 2009|February 21, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00849927||142952|
NCT00850473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0813|PET/CT Study in the Diagnosis of Coronary Plaque|x Comparison of Cardiac Positron Emission Tomography/Computed Tomography (PET/CT) With Coronary Angiography (CA) in the Diagnosis and Characterization of Coronary Artery Plaque|PET/CT|Washington University School of Medicine|Yes|Completed|October 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00850473||142910|
NCT00850772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPEN|Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer|Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer|OPEN|Queensland Centre for Gynaecological Cancer|Yes|Completed|January 2009|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|109|||Female|18 Years|N/A|No|||June 2014|June 10, 2014|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850772||142888|
NCT00859378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5203038|Cemented vs Non-cemented Semiendoprosthesis in the Treatment of Proximal Femoral Fractures|A Prospective, Randomized Study Comparing Cemented and Non-cemented Semiendoprostheses in the Treatment of Proximal Femoral Fractures in the Elderly Patients||Kuopio University Hospital|No|Active, not recruiting|October 2008|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|No|||April 2015|April 3, 2015|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859378||142235|
NCT00859664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145/07|Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders|||Assaf-Harofeh Medical Center||Recruiting|March 2009|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|3 Years|18 Years|No|Probability Sample|Children over the age of 3, diagnosed with autism, treated with neuroleptics|March 2009|March 10, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859664||142214|
NCT00859937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01165|Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors|Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Malignant Salivary Tumors||National Cancer Institute (NCI)||Active, not recruiting|March 2009|||January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||June 2014|April 2, 2015|March 10, 2009|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT00859937||142195|
NCT00847002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWFT07312007|Flexitouch Treatment for Venous Ulcers|A Pilot Randomized Trial of Flexitouch as an Adjunctive Treatment for Venous Ulcers||Tactile Medical|No|Terminated|September 2007|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|February 18, 2009|No|Yes|Lack of Enrollment|No|May 31, 2012|https://clinicaltrials.gov/show/NCT00847002||143171|
NCT00847015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-159|Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer|Phase II Study of Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer||Memorial Sloan Kettering Cancer Center|Yes|Completed|February 2009|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 18, 2009|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00847015||143170|
NCT00847041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A109753|Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis.|Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis.||University of California, San Francisco|No|Completed||||||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|Probability Sample|Twenty total patients are being recruited: ten adult patients who meet the clinical        criteria for chronic rhinosinusitis requiring surgical therapy and ten adult patients        undergoing either orbital decompression for Graves' orbitopathy or maxillomandibular        advancement for obstructive sleep apnea, with no history of sinus disease.|February 2009|February 18, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847041||143168|
NCT00847288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OptiVol® Care Pathway|OptiVol® Care Pathway|OptiVol® Care Pathway||Medtronic Cardiac Rhythm Disease Management|No|Completed|March 2009|May 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1682|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|February 13, 2009||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00847288||143149|
NCT00847574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WORLD Study|The WORLD (Weight Optimization: Revamping Lifestyles Using the Dietary Guidelines) Study - Developing, Implementing, and Testing an Education Program|Development, Implementation, & Testing and Education Program to Teach Weight Loss Using the 2005 Dietary Guidelines to Pre-Menopausal Women|WORLD|Penn State University|No|Completed|March 2006|December 2010|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|101|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847574||143127|
NCT00847873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-KP-466|Treatment of Intimate Partner Violence and Substance Abuse in a Substance Abuse Treatment Facility|Treatment of Intimate Partner Violence and Substance Abuse in a Substance Abuse: a Randomized Controlled Trial||VU University of Amsterdam|No|Completed|October 2009|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2013|November 3, 2013|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847873||143105|
NCT00848432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004BA720A22|Risperidone Maintenance Treatment in Schizophrenia|Risperidone Maintenance Treatment for Relapse Prevention in Schizophrenia||Capital Medical University|Yes|Completed|December 2002|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|404|||Both|18 Years|65 Years|No|||February 2009|February 23, 2009|February 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848432||143062|
NCT00848419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exp pain 1-ginosar-HMO-CTIL|A Prospective Randomized Comparison of Fentanyl, Methadone and Morphine for Epidural Analgesia in an Experimental Pain Model|A Prospective Randomized Comparison of Fentanyl, Methadone and Morphine for Epidural Analgesia in an Experimental Pain Model||Hadassah Medical Organization|No|Not yet recruiting|April 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|70 Years|No|||February 2009|February 19, 2009|February 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848419||143063|
NCT00848718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206-003|A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5)|A Phase I Dose Escalation Study of MK-2206 in Combination With Standard Doses of Selected Chemotherapies or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|March 2009|May 2012|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|February 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00848718||143041|
NCT00849030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1033IL/0029|ATAC - Arimidex, Tamoxifen Alone or in Combination|A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer||AstraZeneca|Yes|Completed|July 1996|April 2010|Actual|June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|9358|||Female|45 Years|N/A|No|||June 2012|June 5, 2012|February 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00849030||143017|
NCT00849043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERO C009E|Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopnea|A Single Arm, Open-label Extension Study to Evaluate the Long-term Durability of Treatment Response and and Safety of the Provent Professional Sleep Apnea Therapy Device for the Non-invasive Treatment of Obstructive Sleep Apnea-hypopnea|AERO C009E|Ventus Medical, Inc.|No|Completed|February 2009|October 2010|Actual|August 2010|Actual|Phase 3|Observational|N/A||1|Anticipated|65|||Both|18 Years|N/A|No|Probability Sample|OSA subjects from C009 AERO study who were randomized to the Provent arm and completed the        study. All must continue to meet the C009 inclusion and exclusion criteria.|January 2011|January 25, 2011|February 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00849043||143016|
NCT00880113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008T034|The Dutch Acute Stroke Trial (DUST): Prediction of Outcome With Computed Tomography (CT) - Perfusion and CT-angiography|The Dutch Acute Stroke Trial (DUST): Prediction of Outcome With CT-perfusion and CT-angiography|DUST|UMC Utrecht||Recruiting|May 2009|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Patients 18 years or older with acute stroke symptoms who present in the hospital within 9        hours of onset of symptoms.|June 2012|June 4, 2012|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880113||140665|
NCT00849589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-07-406|Computerized Screening and Brief Physician Advice to Reduce Teen Drinking|Computerized Screening and Brief Physician Advice to Reduce Teen Drinking||Children's Hospital Boston|Yes|Withdrawn|January 2010|December 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|3100|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||March 2011|March 7, 2011|February 23, 2009||No|Grant application was not funded|No||https://clinicaltrials.gov/show/NCT00849589||142977|
NCT00849888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006109|Serum-Free Thymus Transplantation in DiGeorge Anomaly|Phase I Serum-Free Cultured Thymus Transplantation in DiGeorge Anomaly, IND9836|SerumFree|Duke University|Yes|Terminated|April 2008|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|N/A|2 Years|No|||October 2014|October 27, 2014|February 22, 2009|No|Yes|The sponsor decided to withdraw the study.|No||https://clinicaltrials.gov/show/NCT00849888||142955|
NCT00849901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6223|A Study in the Treatment of Children and Adolescents With Major Depressive Disorder|A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder||Eli Lilly and Company|No|Completed|March 2009|October 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|337|||Both|7 Years|17 Years|No|||March 2012|March 18, 2012|February 20, 2009|Yes|Yes||No|February 22, 2012|https://clinicaltrials.gov/show/NCT00849901||142954|
NCT00850499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-LYM-2033|Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab|A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab||Millennium Pharmaceuticals, Inc.|No|Terminated|September 2009|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|February 24, 2009|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00850499||142908|Early termination leading to small numbers of subjects analyzed
NCT00850512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOP21+R-Z|Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy||CHOP21+R-Z|University of Bologna||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|60 Years|N/A|No|||February 2009|February 24, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850512||142907|
NCT00850226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17111|Comparing Acceptance and Commitment Therapy (ACT) and Cognitive Therapy (CT) for Test Anxiety|Comparing Acceptance and Commitment Therapy Strategies to Cognitive Therapy Strategies in Reduction of Test Anxiety||Drexel University|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2010|May 28, 2010|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850226||142929|
NCT00850486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHZ_02|Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography|The Diagnostic Benefits of HyperQTM vs. Conventional ECG During Stress Test. A Comparison Study in Women Referred to Angiography.||BSP Biological Signal Processing Ltd.|No|Recruiting|August 2008|March 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|200|||Female|N/A|N/A|No|||February 2009|February 24, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850486||142909|
NCT00846352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007668|Early Versus Late Bronchoscopy in Bone Marrow Transplantation (BMT) Patients|Randomized Trial Comparing Early Versus Late Bronchoscopy in Hematopoietic Stem Cell Transplant Patients With Pulmonary Infiltrates.||Wake Forest Baptist Health|No|Recruiting|January 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2009|August 5, 2009|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00846352||143221|
NCT00859677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP -023|Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection|Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection|MRSA-2|Uniformed Services University of the Health Sciences|Yes|Suspended|March 2009|December 2015|Anticipated|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|60|Samples With DNA|Skin biopsy will be obtained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-positive and negative patients with a recent screen for MRSA colonization or a history        of MRSA infection will be asked to participate. Participants will be recruited by        providers within the infectious disease clinics at the sites. In addtion, MRSA isolates        will be monitored at the central laboratory and providers of patients with MRSA will be        notified and asked to notify their patients of the opportunity to participate in this        study.|May 2015|May 6, 2015|March 10, 2009||No|Enrollment was stopped due to staffing issues.|No||https://clinicaltrials.gov/show/NCT00859677||142213|
NCT00847301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.84|Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery|Observational Cohort Study to Evaluate Safety and Efficacy of Pradaxa (Dabigatran Etexilate) in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery||Boehringer Ingelheim||Completed|April 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|472|||Both|18 Years|N/A|No|Non-Probability Sample|Moderate renal insufficiency|August 2015|August 25, 2015|February 18, 2009||||No|June 30, 2015|https://clinicaltrials.gov/show/NCT00847301||143148|
NCT00847587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30291|Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant|Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant||University of Utah|Yes|Completed|January 2009|May 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|February 18, 2009||No||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00847587||143126|Limitations:Study was not blinded & early insertion was allowed as late as 3 days postpartum. Insertion on postpartum days 1-3 was allowed so long as lactogenesis had not already occurred to mimic normal clinical practice & improve generalizability.
NCT00847886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol LX3305.1-104-DDI|Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis||Lexicon Pharmaceuticals|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||June 2010|June 1, 2010|February 17, 2009|Yes|Yes||No|April 19, 2010|https://clinicaltrials.gov/show/NCT00847886||143104|
NCT00847899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR9281-CLN-003|Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance||Arete Therapeutics|No|Completed|January 2009|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Both|18 Years|75 Years|No|||November 2009|November 18, 2009|February 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847899||143103|
NCT00849056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112755|Safety and Efficacy of Albiglutide in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|January 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|February 19, 2009|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT00849056||143015|
NCT00849069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112350|Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine|An Observer-blind, Safety Study of GSK Biologicals' Haemophilus Influenzae and Streptococcus Pneumoniae Candidate Vaccine in Adults.||GlaxoSmithKline||Terminated|March 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|40 Years|80 Years|No|||October 2015|October 19, 2015|February 19, 2009|Yes|Yes|The study has been stopped for logistic reasons not related to the safety or efficacy of the    vaccine.|No||https://clinicaltrials.gov/show/NCT00849069||143014|
NCT00848744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-011008|Comparison of Two Salicylic Acid Formulations|A Split-Face, Paired-Comparison, Pilot Study to Evaluate Safety and Efficacy of Two Topical Salicylic Acid 1.0% Creams for Mild to Moderate Acne Vulgaris||Northwestern University|Yes|Completed|February 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|10|||Both|13 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|November 24, 2008||No||No|November 10, 2009|https://clinicaltrials.gov/show/NCT00848744||143039|
NCT00849641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR-ST9201/09|Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis|Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis||University of Regensburg|No|Not yet recruiting|March 2009|March 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|patients with decompensated liver cirrhosis|February 2009|February 20, 2009|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849641||142973|
NCT00849654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-04753|Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma|Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma|PCYC-04753|Pharmacyclics|No|Completed|February 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|February 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00849654||142972|
NCT00849966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09/10E|Celecoxib for Pediatric Adenotonsillectomy|Celecoxib for Pediatric Adenotonsillectomy: A Randomized Controlled Double Blinded Study||Children's Hospital of Eastern Ontario|Yes|Completed|August 2009|December 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|282|||Both|2 Years|18 Years|No|||April 2013|April 17, 2013|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849966||142949|
NCT00849004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97CT1018|Prevention of Hypertrophic Scars or Keloids|Comparison of the Effectiveness in Prevention of Hypertrophic Scars or Keloids Between Silicone Sheet, Silicone Gel and Paper Steri-strip-A Randomised Controlled Trial.|RCT|Kaohsiung Veterans General Hospital.|No|Active, not recruiting|March 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|75|||Both|N/A|N/A|No|||October 2012|October 19, 2012|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849004||143019|
NCT00849017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112756|Safety and Efficacy Study of Albiglutide in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|January 2009|January 2013|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|309|||Both|18 Years|N/A|No|||April 2014|May 29, 2014|February 19, 2009|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT00849017||143018|
NCT00849303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5772765|Multicenter Rehabilitation Study in Acute Stroke|Gait-Oriented Rehabilitation at Different Phases in Patients With Acute Stroke - Multicenter Randomized Controlled Trial.||University of Jyvaskyla|No|Recruiting|January 2009|||December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|55 Years|N/A|No|||February 2009|February 20, 2009|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849303||142997|
NCT00849602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BALF-01|The Effect of Chloroquine in the Treatment of Patients With Dengue|The Effect of Chloroquine in the Treatment of Patients With Dengue||University of Sao Paulo|Yes|Active, not recruiting|February 2008|June 2009|Anticipated|May 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||February 2009|February 23, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849602||142976|
NCT00849914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer|Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer||Ruhr University of Bochum|No|Completed|July 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|28|Samples With DNA|Punch biopsy from tumour, punch biopsy from healthy skin|Both|18 Years|N/A|No|Non-Probability Sample|dermatologic primary care clinic|October 2012|October 15, 2012|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849914||142953|
NCT00846417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009530|Implantable Cardioverter Defibrillator (ICD) Support Groups and Veterans|Impact of ICD Support Groups in Veterans Receiving Internal Cardioverter Defibrillators||Emory University|Yes|Terminated|July 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|3|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients of primary care cardiology clinics at the Atlanta VAMC|September 2013|September 10, 2013|February 16, 2009||No|No funding, lost support staff, no data collected/processed|No||https://clinicaltrials.gov/show/NCT00846417||143216|
NCT00846053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1219|FDG-PET Imaging in Young Cystic Fibrosis Patients|FDG-PET Imaging in Young Cystic Fibrosis Patients||Washington University School of Medicine|Yes|Recruiting|February 2009|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|28|||Both|12 Years|21 Years|No|Probability Sample|Our Pediatric Cystic Fibrosis Clinic currently has 124 patients between the ages of 12 and        21 years. We will need to recruit patients from this clinic population, plus new patients        that enter the clinic over the 2 to 3 year period.|March 2011|March 2, 2011|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00846053||143244|
NCT00846391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8245-005|A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)|A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK8245 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control||Merck Sharp & Dohme Corp.||Terminated|December 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|February 17, 2009|Yes|Yes|Study was terminated due to inability to recruit patients.|No|August 26, 2010|https://clinicaltrials.gov/show/NCT00846391||143218|This study was terminated due to the continuing inability to recruit patients. No efficacy analysis was performed because of insufficient sample size for meaningful analysis due to early study termination and insufficient sample size.
NCT00846404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|730-2006|Markers of Oxidative Stress Diastolic Dysfunction|Markers of Oxidative Stress Present in Blood in Patients With Diastolic Dysfunction|ODDS|Emory University|No|Active, not recruiting|July 2006|July 2010|Anticipated|May 2007|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients of primary care cardiology clinics at Emory University.|February 2009|February 17, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00846404||143217|
NCT00846365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491CLD_301|Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension|A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension||Takeda|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1085|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|February 13, 2009|Yes|Yes||No|January 4, 2012|https://clinicaltrials.gov/show/NCT00846365||143220|
NCT00846378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIRB07051803|Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction|The Mechanism of Ischemic Post-conditioning in Humans: Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction|PCinAMI|University of Cincinnati|Yes|Suspended|March 2008|||May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|April 16, 2008||No|Suspended for potential change in protocol to include different imaging modalities|No||https://clinicaltrials.gov/show/NCT00846378||143219|
NCT00846664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0112080162|Short Arc Multifidus Study|Increase in Multifidus Size By Short Arc Banding on the ATM Machine as Measure by Diagnostic Ultrasound||Logan College of Chiropractic|No|Recruiting|February 2009|March 2009|Anticipated|March 2009|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846664||143197|
NCT00846677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLB-D301|Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips|A Randomized, Open-label, Cross-over Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips.||McGill University|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||March 2012|March 1, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846677||143196|
NCT00847626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491CLD_302|Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension|A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension||Takeda|No|Completed|January 2009|July 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|1711|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|February 18, 2009|Yes|Yes||No|January 4, 2012|https://clinicaltrials.gov/show/NCT00847626||143123|
NCT00848445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFÉ|Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -|the Use of Atrial Fibrillation Pacing Therapies in Patients With no Previous History of Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -|CAFE|Guidant Corporation|No|Completed|October 2002|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|270|||Both|18 Years|N/A|No|||February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848445||143061|
NCT00848757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donaghue DF08-313|Changing Lifestyles for Better Health|Changing Lifestyles for Better Health: A Model Program for Community Health Centers||Yale University|No|Completed|March 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Female|18 Years|55 Years|No|||July 2015|July 20, 2015|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00848757||143038|
NCT00848458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI|Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma|Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma - An Open Randomized, Controlled, Prospective, Single Blinded Clinical Trial|AAI|Medical University of Vienna|Yes|Recruiting|January 2009|||December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||July 2010|July 14, 2010|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848458||143060|
NCT00849342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3708|Observational Study on Levemir® in Obese Diabetic Patients|A Prospective, Multicentre, Non-controlled, Observational, 52-weeks Study: the Evaluation of the Body Weight Progress During the Treatment With Insulin Detemir in Type 1 or 2 Diabetes Patients, Previously Treated With Other Basal Insulins|KILOS|Novo Nordisk A/S|No|Completed|December 2008|January 2013|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|580|||Both|6 Years|N/A|No|Non-Probability Sample|Patients from both general and speciality practice settings who have been deemed        appropriate to receive Levemir® because of weight increase on other insulin therapies, and        as part of routine out-patient care by the prescribing physician.|July 2014|August 13, 2014|February 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00849342||142994|
NCT00849628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI 150069-1|Use of Drugs and Constipation in Nursing Homes|Use of Drugs and Constipation in Nursing Homes||Norwegian University of Science and Technology|No|Completed|June 2008|February 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|270|||Both|60 Years|N/A|No|Non-Probability Sample|Residents in nursing homes|August 2011|August 29, 2011|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849628||142974|
NCT00849082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22863|Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer|Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy Plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis||European Organisation for Research and Treatment of Cancer - EORTC||Completed|May 1987|||November 1995|Actual|Phase 3|Interventional|Primary Purpose: Treatment|||||||Male|N/A|79 Years|No|||July 2012|July 10, 2012|February 20, 2009||||No||https://clinicaltrials.gov/show/NCT00849082||143013|
NCT00849355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOPEH-LINFMYO-2007|Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk|Phase II, Multicenter Trial to Evaluate the Efficacy and Safety of the Following Treatment Squeme:Ciclophosphamide, Vincristine, Lyposomal Doxorrubicine, Myocet and Prednisone,Combined With Rituximab in First Line Treatment for Patients With Aggresive No Hodgkin B Lymphoma and Cardiovascular Risk||Asociacion Doctor Peset Para el Estudio de la Hematología|No|Recruiting|August 2008|November 2010|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|70 Years|No|||February 2009|February 20, 2009|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849355||142993|
NCT00849615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S396 FLOT3|Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|FLOT3|Krankenhaus Nordwest|Yes|Completed|February 2009|January 2016|Actual|January 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|252|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849615||142975|
NCT00849940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009391|Validation of Brain Oxygenation Monitor on Pediatric Patients|Validation of the CAS Medical System, Inc. FORE-SIGHT Near-Infrared Spectroscopy (NIRS) Monitor in Pediatric Subjects for Viscerosomatic Applications||Duke University|No|Recruiting|February 2009|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|180|||Both|N/A|17 Years|No|||August 2014|November 3, 2014|January 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00849940||142951|
NCT00849953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1498-001|FinESS Registry Study|FinESS Registry Study||Entellus Medical, Inc.|No|Completed|March 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who in the investigator's opinion, require trans-antral treatment of the        maxillary sinus ostium and ethmoid infundibulum to remodel the bony sinus outflow tract        using balloon displacement of adjacent bone and paranasal sinus structures using FinESS        Sinus Treatment.|June 2011|June 27, 2011|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849953||142950|
NCT00850239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-PROT302|Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin||Phenomix|No|Terminated|May 2009|December 2010|Anticipated|October 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|85 Years|No|||August 2010|August 10, 2010|February 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850239||142928|
NCT00846066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 06 10-150E|Oral Health Training Program for Pediatric Residents|Effective Educational Instruction in Preventive Oral Health: Hands On Training (HOT)Versus Web Based Training (WBT): A Randomized Control Trial||Children's Mercy Hospital Kansas City|Yes|Completed|January 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|56|||Both|22 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|February 13, 2009||No||No|February 19, 2009|https://clinicaltrials.gov/show/NCT00846066||143243|
NCT00850551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35243-E/A|Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis|Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis||University of Washington|No|Completed|January 2009|December 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850551||142905|
NCT00846092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIR for Diabetic Maculopathy|Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study|Phase 1 Study To Determine the Effects of Short Term Near-infrared Light (NIR) Therapy on Anatomic and Functional Abnormalities of Diabetic Macular Edema, and Assess Safety of Short Term Near-infrared Light Therapy in Eyes With Diabetic Macular Edema.|NIR|Medical College of Wisconsin|No|Completed|November 2007|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00846092||143241|
NCT00847054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-004-001|A Study of of MORAb-004 in Subjects With Solid Tumors|A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-004, a Humanized Monoclonal Antibody, in Subjects With Solid Tumors||Morphotek|No|Completed|March 2009|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|February 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847054||143167|
NCT00847314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13899|Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients|Efficacy and Tolerability of Testogel® / Nebido in Combination With a Standardised Exercise and Diet Programme in Hypogonadal Male Patients With Abdominal Obesity Compared With Exercise and Diet Programme||Bayer|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Male|35 Years|64 Years|No|Non-Probability Sample|Male patients in medical practices > 35yrs fulfilling all criteria for documentation.|June 2013|June 19, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847314||143147|
NCT00846690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-DB-08-0484|Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel|Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel for Control of Pain of Dental Needle Insertion in the Palate||The University of Texas Health Science Center, Houston|No|Recruiting|January 2009|May 2009|Anticipated|March 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 18, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00846690||143195|
NCT00847028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHmol-001|Oral Glucose Solution as Pain Relief in Newborns: Results of a Clinical Trial|Oral Glucose Solution as Pain Relief in Newborns: Results of a Clinical Trial||Universiteit Antwerpen|Yes|Active, not recruiting|November 2007|April 2009|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|304|||Both|N/A|N/A|No|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847028||143169|
NCT00847340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol V profamilia|Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population|Prevalence of HPV Genotypes in Genital Warts in Colombian Male and Female Population Attending Medical Services.|GWprofamilia|La Fundacion para la Investigacion y el Desarrollo|Yes|Completed|December 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|342|Samples With DNA|Biopsies from genital warts will be taken through an excisional procedure. Homeostasis will      be obtained by using topications of Monssell solution. Biopsy sample will be splinted in      order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to      the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer      Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the      pathology laboratory for haematoxiline - eosine paint and lecture.|Both|18 Years|45 Years|No|Non-Probability Sample|Patients attending to gynecologic or STD consult in a mayor out patient clinic in Bogotá        (PROFAMILIA).        Female and male between 18 - 45 years of age living in Bogota, Colombia.|March 2012|March 19, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847340||143145|
NCT00848198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP00007 OTO|TearLab Core Validation Study|A Prospective Study to Establish Normative Values, Demographic Variations, Referent Diagnostic Values and Disease Severity Correlations for Dry Eye Disease and TearLab Osmometry.|CVS|TearLab Corporation|No|Enrolling by invitation|February 2009|July 2010|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ophthalmology and Optometry Clinics|February 2010|February 2, 2010|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00848198||143080|
NCT00848211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYMON-08001|Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects|Phase I/IIA Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects|THYMON-08001|Thymon, LLC|No|Completed|February 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|50 Years|No|||February 2011|February 17, 2011|February 13, 2009|Yes|Yes||No|June 12, 2010|https://clinicaltrials.gov/show/NCT00848211||143079|
NCT00848224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL66786|Improving Adherence to Pharmacological Treatment|Improving Adherence to Pharmacological Treatment|PACT|University of Massachusetts, Worcester|No|Completed|September 2000|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|689|||Both|30 Years|85 Years|No|||February 2009|February 19, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00848224||143078|
NCT00848471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.539|Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)|Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems) for Measuring Energy Expenditure at Rest and in Dynamic Phase After a Meal in Adult Healthy and Obese Volunteers|Protocol Quark|Hospices Civils de Lyon|No|Recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 18, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848471||143059|
NCT00848770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA 07-470|Manipulation of Arterial Pressure in Acute Ischemic Stroke|Manipulation of Arterial Pressure Early in Non Thrombolysed Acute Ischemic Stroke: Effects on Death and Neurological Disability|MAPAS|Hospital de Clinicas de Porto Alegre|No|Recruiting|January 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|December 30, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848770||143037|
NCT00849095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIFA-ASMA-BF-001|Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma|As Needed Budesonide/Formoterol Combination Versus Regular Budesonide/Formoterol Combination Plus as Needed Terbutaline in Mild-Moderate Persistent Asthma||Università degli Studi di Ferrara|Yes|Completed|April 2009|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|860|||Both|18 Years|65 Years|No|||May 2014|May 29, 2014|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849095||143012|
NCT00849368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHA-08-AZA/ALLO-01|Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients|Dose-effect Relationship Between Allopurinol, Azathioprine and 6-thioguanine Nucleotide Levels (6-TGN) in Inflammatory Bowel Disease Patients.||University of Zurich|Yes|Completed|January 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||February 2012|February 6, 2012|September 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00849368||142992|
NCT00849381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111758|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female Brazilian, Taiwanese and Thai Subjects Who Had Received Control Vaccine in Study 580299/008||GlaxoSmithKline||Completed|April 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1239|||Female|26 Years|N/A|Accepts Healthy Volunteers|||August 2014|September 4, 2014|February 19, 2009|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00849381||142991|
NCT00849394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-097|Evaluation of Protein in the Urine in Patients Receiving Bevacizumab|An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab||North Texas Veterans Healthcare System|No|Completed|November 2007|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|18 Years|N/A|No|Probability Sample|106 patients receiving bevacizumab doses of < 10 mg/kg at a rate of 0.5 mg/kg/min in        hematology/oncology outpatient clinic. Most of the patients are likely to have advanced        stage colon or rectal cancer.|February 2009|October 31, 2012|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849394||142990|
NCT00850252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cytograft A-V|Use of a Lifeline Graft in the A-V Shunt Model|Use of a Completely Autologous and Completely Biological Tissue Engineered Blood Vessel Lifeline as an Arteriovenous Fistula in Hemodialysis Patients - Safety and Efficacy Study.||Cytograft Tissue Engineering|Yes|Completed|September 2004|December 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|21 Years|N/A|No|||July 2013|July 15, 2013|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00850252||142927|
NCT00850538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEBH 2008-018|Role of Bone in Knee Osteoarthritis (OA)|The Role of Bone and Its Measurement in Knee Osteoarthritis||The New England Baptist Hospital|No|Completed|July 2008|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|Samples Without DNA|Tibial plateau patella fat pad synovial fluid and synovium|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male or female, over age 18, with scheduled primary total knee replacement surgery at        NEBH, with no contradindications for MRI|November 2015|November 2, 2015|February 23, 2009||No||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00850538||142906|
NCT00846079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THVI-101|Myocardial Perfusion Assessment With Multidetector Computed Tomography|Myocardial Perfusion Assessment With Multidetector Computed Tomography||Tennessee Heart and Vascular Institute, P.C.|No|Active, not recruiting|February 2009|September 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846079||143242|
NCT00850265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORM-DPB-extrafine|Effect of Spacer in Extrafine Formoterol-Beclomethasone Treatment to Asthma|Rol of Spacer in the Combined Treatment With Extrafine Beclomethasone-Formoterol in Stable Asthma||Hospital General de Requena|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||March 2009|March 26, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850265||142926|
NCT00850564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK63639B|Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men|Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men||Massachusetts General Hospital|No|Completed|February 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2011|April 15, 2011|February 23, 2009|Yes|Yes||No|March 3, 2011|https://clinicaltrials.gov/show/NCT00850564||142904|
NCT00846482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-10-376|Exploratory Study Of The ERCC-1 Gene|Exploratory Study Of The ERCC-1 Gene Expression In Colorectal Cancer Cell Lines And In Patients With Colorectal Cancer||Montefiore Medical Center|Yes|Recruiting|February 2008|August 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Biospecimens include blood and tumor samples.|Both|N/A|N/A|No|Non-Probability Sample|Metastatic colon or rectal cancer        Stage II or III colon or rectal cancer|February 2009|February 17, 2009|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00846482||143211|
NCT00846105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erasme-ULB-P2008/201|Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)|Two-Center Intervention Study to Evaluate the Impact of Rapid Molecular Screening on Nosocomial Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA).||Erasme University Hospital|No|Completed|February 2009|May 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|7400|||Both|18 Years|N/A|No|||June 2010|June 14, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846105||143240|
NCT00846703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007016|The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia|Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province||Sun Yat-sen University|Yes|Recruiting|July 2008|December 2018|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|N/A|16 Years|No|||March 2010|March 5, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846703||143194|
NCT00846716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.9.18 ver2-4|Shiga Progression of Diabetes, Nephropathy and Retinopathy|Exploratory Study to Investigate the Suppressive Effect of Oral Anti-Diabetic Drug (TZD) on Progression of Diabetic Nephropathy on|SHIP-DINER|Shiga University|Yes|Recruiting|March 2008|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|75 Years|No|||February 2009|February 18, 2009|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00846716||143193|
NCT00847067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004783|Chronic Post Breast Surgery Pain|A Prospective, Single-blinded, Randomized, Trial Evaluating the Use of Paravertebral Block to Decrease Chronic Post Breast Surgery Pain.||Mayo Clinic|No|Terminated|February 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|80 Years|No|||June 2010|June 10, 2010|February 18, 2009||No|Funding not renewed|No||https://clinicaltrials.gov/show/NCT00847067||143166|
NCT00847600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEN-8-11-08|Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia|Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-week, Randomized, Double-blind, Placebo-controlled Trial|PREG-2008|Sha’ar Menashe Mental Health Center|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|No|||December 2010|December 14, 2010|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847600||143125|
NCT00847613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921044|A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate|Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate||Pfizer|Yes|Completed|March 2009|February 2012|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|800|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|February 17, 2009|Yes|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT00847613||143124|Results include data of 1-year analysis.
NCT00847353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIN_01|Normal Values of High Frequency ECG (HyperQ™) in Apparently Healthy Individuals and in Young and Masters Athletes|Normal Values of High Frequency ECG (HyperQ™) in Asymptomatic, Apparently Healthy Normal Weight vs. Obese Individuals and in Young and Masters Athletes||BSP Biological Signal Processing Ltd.|No|Recruiting|February 2009|June 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample referred or self referred to stress testing|February 2010|February 3, 2010|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847353||143144|
NCT00847366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 534|Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma|An Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma||AEterna Zentaris|No|Active, not recruiting|May 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|N/A|No|||October 2011|May 28, 2012|February 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847366||143143|
NCT00847639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-REV|Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma|Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma|07-REV|Center for International Blood and Marrow Transplant Research|Yes|Completed|February 2009|March 2014|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||April 2014|April 2, 2014|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847639||143122|
NCT00847665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVN-2308-2008|Pressure Ulcer Prevention in Ventilated Patients Using Two Repositioning Regimens|Comparison of Two Turning Regimens (2 Versus Every 4 Hours) in the Prevention of Pressure Ulcers in Patients on Mechanical Ventilation That Use Alternating-pressure Air Mattresses.|PUPPAS|University Hospital Virgen de las Nieves|Yes|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|330|||Both|18 Years|N/A|No|||March 2013|March 9, 2013|February 18, 2009||No||No|June 28, 2012|https://clinicaltrials.gov/show/NCT00847665||143121|
NCT00847912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|562|CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial|CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial|VAKCCT|VA Office of Research and Development|Yes|Active, not recruiting|June 2009|July 2016|Anticipated|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|N/A|N/A|No|||October 2015|October 15, 2015|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847912||143102|
NCT00848237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-500|HALO Patient Registry: Ablation of Barrett's Esophagus|HALO Patient Registry: Ablation of Barrett's Esophagus, A Multi-Center Patient Registry||Medtronic - MITG|No|Completed|July 2007|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5521|||Both|N/A|N/A|No|||January 2016|January 5, 2016|December 20, 2007|No|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT00848237||143077|Endoscopic clearance rate for Barrett's esophagus-Percentage of patients with no endoscopically visible Barrett's esophagus at 1 year follow-up: This endpoint is a visual and not reliable or accurate.
NCT00848796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|southlake|Comparative Study of Two Brands of Heparin Already on the Market|Do Different Heparin Brands Influence Bleeding in Coronary Surgery||Southlake Regional Health Centre|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|90 Years|No|||February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848796||143035|
NCT00848783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-837|Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers|A Randomized Phase-II Study of Patients With Locally Advanced Gastric of Gastro-Esophageal Adenocarcinoma Treated With Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine, Followed by Prolonged Administration of Capecitabine||New York University School of Medicine|Yes|Terminated|May 2008|September 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|February 19, 2009|Yes|Yes|Due to slow accrual|No|November 9, 2012|https://clinicaltrials.gov/show/NCT00848783||143036|Early termination leading to small numbers of subjects analyzed.
NCT00849407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M3-I|Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma|Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma|M3|Medical University of Vienna|No|Recruiting|October 2008|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Our goal is to recruit at least one thousand melanoma patients of any stage and one        thousand controls in order to acquire a well sized cohort for identifying independent        molecular markers in multivariate analyses (for statistical considerations see        "Statistical analysis" on page 8). Patients who visit the out-door clinic of the        Department of Dermatology at the Medical University of Vienna with any other diseases than        melanoma, their spouses and spouses of melanoma patients will be asked to contribute as        controls.|April 2013|April 23, 2013|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849407||142989|
NCT00849693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7109|A Study in the Treatment of Children and Adolescents With Major Depressive Disorder|A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder||Eli Lilly and Company|No|Completed|March 2009|September 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|463|||Both|7 Years|17 Years|No|||March 2012|March 26, 2012|February 23, 2009|Yes|Yes||No|February 22, 2012|https://clinicaltrials.gov/show/NCT00849693||142969|
NCT00849706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481131-HMO-CTIL|Effect of Work Load and Sleep Deprivation on Medical Staff's Driving Skills|Effect of Work Load and Sleep Deprivation on Medical Staff's Driving Skills||Hadassah Medical Organization||Not yet recruiting|March 2009|||March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Medical staff (doctors and nurses) working night shifts.|February 2009|February 23, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00849706||142968|
NCT00850018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|633|Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease - Pilot Intervention Study|Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Disease - A Pilot Intervention Study||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|December 2004|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2009|December 17, 2010|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00850018||142945|
NCT00849667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb003-004|Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse|A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse||Morphotek|Yes|Completed|April 2009|April 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1100|||Female|18 Years|N/A|No|||November 2013|June 25, 2015|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00849667||142971|
NCT00849979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0228|Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy|M.D. Anderson Symptom Inventory (MDASI-GI) Validation and Clinical Utility in Patients With Gastrointestinal Cancers Being Treated or Followed by GI Medical Oncology||M.D. Anderson Cancer Center|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|184|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849979||142948|
NCT00849992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20115|Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy|Randomized Prospective Study Comparing 5% Imiquimod and Photodynamic Therapy for Actinic Cheilitis||Norwegian University of Science and Technology|No|Completed|March 2009|November 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849992||142947|
NCT00850278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-006265-32|Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors|Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors|FLT|University Hospital, Caen|Yes|Completed|October 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850278||142925|
NCT00850291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2907|Economisation of Whipple Resection Using Electrosurgical Sealing Device|Prospective, Controlled, Randomized Study of Economisation of the Preparation in Partial Duodenopancreatectomy Using an Electrosurgical Sealing Device Versus Traditional Methods|SEAL|Universitätsklinikum Hamburg-Eppendorf|No|Completed|May 2008|October 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|89|||Both|N/A|N/A|No|Non-Probability Sample|Patients planned for partial pancreatoduodenectomy for pancreatic head carcinoma,        periampullary carcinoma, chronic pancreatitis and other benign lesions.|December 2010|December 30, 2010|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850291||142924|
NCT00846495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Frova vs. Topiramate|Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine|A Randomized, Single-Blind Pilot Study to Compare the Efficacy and Cost-Effectiveness of Frovatriptan vs. Topiramate for the Prevention of Migraine||Cady, Roger, M.D.|No|Completed|August 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 11, 2012|February 17, 2009|Yes|Yes||No|June 9, 2011|https://clinicaltrials.gov/show/NCT00846495||143210|
NCT00846781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08642|Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)||DEFY|Merck Sharp & Dohme Corp.|Yes|Terminated|February 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|308|||Both|5 Years|N/A|No|||October 2015|October 15, 2015|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00846781||143188|
NCT00846755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE-1126-IT|Thyroid Disease in Pregnancy: Case Finding Versus Universal Screening|Impact of Treating Thyroid Hormone Dysfunction During Pregnancy: A Randomized Controlled Trial of Universal Screening Versus Case Finding||Ospedale V. Fazzi|No|Completed|March 2005|December 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4657|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 26, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00846755||143190|
NCT00846768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.26|BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD|Randomised, Double-Blind, Cross-over Study to Determine the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, Delivered With the Respimat Inhaler, After 3 Weeks of Once Daily or Twice Daily Administration in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|February 2009|||July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|||Actual|47|||Both|40 Years|N/A|No|||May 2014|May 29, 2014|February 18, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00846768||143189|
NCT00847106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-2893|Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients|Augmentation of Dendritic Cell Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells With an Anti-CD25 Monoclonal Antibody (Daclizumab). A Clinical Study.||Radboud University||Completed|March 2004|October 2005||October 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment||||15|||Both|18 Years|75 Years|No|||February 2009|February 18, 2009|February 18, 2009||||No||https://clinicaltrials.gov/show/NCT00847106||143163|
NCT00846430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-260|Medical Treatment of "High-Risk" Neurofibromas|Medical Treatment of "High-Risk" Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies||Spectrum Health Hospitals|No|Active, not recruiting|October 2008|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|30 Years|No|||May 2015|May 20, 2015|January 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00846430||143215|
NCT00846729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02092009-1778|Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors|Preserving Renal Longevity in Living Kidney Donors||Stanford University||Recruiting|March 2003|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|1. Blood samples are obtained throughout the kidney function study. These samples are           analyzed for Iothalamate and PAH (markers of kidney function) only.        2. Kidney tissue obtained by biopsy at the time of surgery are used to analyze the           structure of the kidney.      No Tissue or Blood is used for genetic analysis.|Both|18 Years|N/A|No|Non-Probability Sample|1. Men and Women who are undergoing surgery for kidney donation for transplantation who             are between the ages of 18 and 45, and 55 and above.          2. Men and women who are undergoing surgery for kidney donation for transplantation who             exhibit mild hypertension.          3. Men and women who donated a kidney for transplantation 10 to 20 years ago.|September 2010|September 3, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846729||143192|
NCT00847327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK80102|Parental Management of Young Children's Diabetes|Parenting and Control Among Young Children With Type 1 Diabetes|YCP|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|April 2008|March 2013|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|135|||Both|1 Year|6 Years|No|||February 2011|February 1, 2011|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847327||143146|
NCT00848263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADIUS-DVR-DNP|Unstable Fractures of the Distal Radius: Trial of Volar Plate Versus Dorsal Nail Plate Fixation|Unstable Fractures of the Distal Radius: Randomised Controlled Trial of Volar Plate Versus Dorsal Nail Plate Fixation.|RADIUS|Sykehuset Asker og Baerum|No|Completed|February 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|55 Years|N/A|No|||November 2014|November 17, 2014|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848263||143075|
NCT00847678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYC123A2201|Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS|A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS||Novartis||Terminated|August 2006|||November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|N/A|No|||February 2009|February 18, 2009|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847678||143120|
NCT00847925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-309-1002|Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects|A Double Blind, Placebo and Standard Care Controlled, Randomised Study to Investigate the Clinical Safety and Toleration, Wound Healing and Antiscarring Potential of Two Applications of Intradermal RN1001 (Avotermin) in Healthy Male Subjects||Renovo|No|Completed|November 2001|September 2003|Actual|September 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|9||Actual|103|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847925||143101|
NCT00848250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071078|Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children|Effects of Angiotensin Converting Enzyme Inhibition During and After Cardiopulmonary Bypass in Infants and Children With Congenital Heart Defects||Vanderbilt University|No|Completed|September 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|N/A|17 Years|No|||October 2010|October 25, 2010|February 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00848250||143076|
NCT00848484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5757-005|Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Add-On Therapy, 2-Period Cross-Over Clinical Trial to Evaluate the Safety and Efficacy of MK5757 for the Treatment of Cognitive Impairment in Men With Schizophrenia||Merck Sharp & Dohme Corp.||Completed|October 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Male|21 Years|55 Years|No|||October 2015|October 30, 2015|February 19, 2009|Yes|Yes||No|June 11, 2010|https://clinicaltrials.gov/show/NCT00848484||143058|
NCT00849433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2009008|Effects of Smoking on Bronchial Epithelium|Effects of Smoking on Airway Remodeling and Phenotypic Changes of the Airway Epithelium in Asthma and COPD: Strategies to Restore the Epithelial Barrier, Repair and Steroid Sensitivity.||University Medical Center Groningen|No|Completed|April 2009|April 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Bronchial biopsies Bronchial brushes Blood|Both|18 Years|75 Years|No|Probability Sample|30 patients with asthma; 30 patients with COPD|January 2015|January 15, 2015|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849433||142988|
NCT00849108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS747158-201|Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158|A Phase 2, Open-Label, Randomized Multicenter Study for the Development of One-Day Rest/Stress Cardiac Positron Emission Tomography (PET) Perfusion Imaging Protocols of BMS747158||Lantheus Medical Imaging|Yes|Completed|January 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|176|||Both|18 Years|75 Years|No|||April 2012|October 12, 2015|January 5, 2009|Yes|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT00849108||143011|
NCT00850044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-749|Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1|A Double-Blind, Randomized, Placebo-Controlled, Nonfasting Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Doses of ABT-450 With and Without Ritonavir||Abbott|No|Completed|February 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|87|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 14, 2010|February 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00850044||142943|
NCT00850057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-060201|Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|A Phase 1, Open Label, Dose-escalation, Pharmacodynamic Study of Intranodal Injection of Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||University of California, San Diego|Yes|Completed|February 2006|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||September 2010|March 31, 2011|February 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00850057||142942|
NCT00850317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-377|Fanconi Anemia Transplant Lacking Genotypically Identical Donor|Multicenter Phase II Trial-Hematopoietic Stem Cell Transplantation for Treatment of Patients With FA Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine||Children's Hospital Boston|No|Not yet recruiting|April 2009|||April 2012|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||February 2009|February 24, 2009|February 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850317||142922|
NCT00849680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V520-016|A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)|A Phase I Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in a Prime-Boost Regimen in Healthy Adults||Merck Sharp & Dohme Corp.|No|Completed|April 2003|February 2010|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|317|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|February 20, 2009|No|Yes||No|June 9, 2011|https://clinicaltrials.gov/show/NCT00849680||142970|An interim analysis of a related study, V520 Protocol 023 (NCT00095576), showed that the MRKAd5 vaccine used in Protocol 016 (NCT00849680) was not efficacious; therefore, only a high level summary of the safety data was performed.
NCT00850005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200434|Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain|IVIG for Treatment of Resistant Neuropathic Pain: a Preliminary Study||University of Calgary|No|Recruiting|February 2009|December 2010|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||February 2009|February 23, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00850005||142946|
NCT00846118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208-032|Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)|Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis.||Juntendo University Hospital|Yes|Active, not recruiting|February 2009|March 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1550|||Both|20 Years|80 Years|No|||September 2014|September 24, 2014|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846118||143239|
NCT00846131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU08I4|Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma|A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined With Therasphere in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation.||Northwestern University|Yes|Active, not recruiting|February 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|January 21, 2016|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00846131||143238|
NCT00846794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR1219080169|AcuGraph and Digestive Symptoms|Can AcuGraph Differentiate Between Participants With and Without Digestive Symptoms||Logan College of Chiropractic|No|Recruiting|February 2009|March 2009|Anticipated|March 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Logan students currently enrolled|February 2009|February 17, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00846794||143187|
NCT00847145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P13E1|Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers|A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13||Novartis||Completed|February 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|2249|||Both|365 Days|394 Days|Accepts Healthy Volunteers|||March 2015|March 2, 2015|February 18, 2009|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT00847145||143160|None reported.
NCT00847132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-001152|A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients|A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients||Massachusetts General Hospital|No|Completed|July 2007|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|175|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847132||143161|
NCT00847418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 351/08, 2009DR1015|Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine|Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine||University Hospital, Basel, Switzerland||Completed|February 2009|October 2009|Actual|||Phase 1|Interventional|N/A|1||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2010|February 18, 2009||||No||https://clinicaltrials.gov/show/NCT00847418||143139|
NCT00846443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCLC2009|Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer|A Phase I Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer.||Fudan University|Yes|Recruiting|January 2009|||January 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|N/A|No|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846443||143214|
NCT00846456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-CAST-GBM|Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma|Phase I/II Trial of Vaccine Therapy With Tumor Stem Cell Derived mRNA- Transfected Dendritic Cells in Patients Receiving Standard Therapy for Glioblastoma||Oslo University Hospital|Yes|Completed|January 2009|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||October 2015|October 19, 2015|February 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00846456||143213|
NCT00846469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 0000 7282|Coronary Computed Tomography (CT) Angiography Versus Standard Therapy in the Emergency Room|64 Slice Coronary CT Angiography vs. Standard Therapy in the Emergency Room: Determining Cost-effectiveness and Predicting Clinical Outcome in Patients With Low and Moderate Risk for Acute Coronary Syndrome.||University of Michigan|No|Completed|July 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|25 Years|N/A|No|||December 2012|December 4, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846469||143212|
NCT00846742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOD08|Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma|Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma||St. Jude Children's Research Hospital|Yes|Recruiting|February 2009|January 2027|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|21 Years|No|||February 2016|February 15, 2016|February 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00846742||143191|
NCT00847080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0431|Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism|Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|December 2008|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|No|||February 2009|April 22, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847080||143165|
NCT00847977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/3-J|Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic Acidosis|Intérêt d'Utiliser Des solutés de Remplissage équilibrés à la Phase précoce d'un Traumatisme crânien Grave Pour Limiter l'Acidose hyperchlorémique|IsoTC|Nantes University Hospital|No|Terminated|October 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847977||143097|
NCT00847990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-T21-301|Non-Invasive Screening for Fetal Aneuploidy|Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker||Sequenom, Inc.|No|Completed|March 2009|August 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|5000|Samples With DNA|plasma, PBMCs|Female|18 Years|N/A|No|Probability Sample|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will        receive the fetal FISH and/or karyotype results from the procedure.|September 2011|September 1, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847990||143096|
NCT00848497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21148|Testosterone for Penile Rehabilitation After Radical Prostatectomy|Efficacy of Testosterone Replacement Therapy in Penile Rehabilitation Following Radical Prostatectomy (#: 04-07-30-01)||Baylor College of Medicine|Yes|Terminated|November 2007|March 2013|Actual|March 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3|||Male|18 Years|N/A|No|||June 2015|June 2, 2015|February 19, 2009|Yes|Yes|Lack of volunteers who would consent to participate and lack of funding|No|March 18, 2013|https://clinicaltrials.gov/show/NCT00848497||143057|The subject that completed the study reported no adverse reactions or events.
NCT00847938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD066-08|Comparision of Different Dose of Neostigmine at Advanced Decurarization|Randomized, Controlled, Double-blind, Prospective Study, Comparing Different Doses of Neostigmine at Advanced Decurarization .|NEODEC|Centre Hospitalier Departemental Vendee|No|Completed|March 2009|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|72|||Both|18 Years|75 Years|No|||November 2009|November 30, 2009|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847938||143100|
NCT00849121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO08802|Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer|A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer||University of Wisconsin, Madison|Yes|Active, not recruiting|March 2009|July 2019|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|N/A|No|||October 2015|October 9, 2015|February 19, 2009|Yes|Yes||No|August 29, 2014|https://clinicaltrials.gov/show/NCT00849121||143010|Of the 17 participants enrolled, 16 received at least 6 initial immunizations with pTVG-HP vaccine and were deemed evaluable to be assessed for outcome measure 3.
NCT00849134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111383|First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.|A First-Time-in-Human Randomised, Single Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Escalating Doses of GSK1482160, in Male and Female Healthy Subjects, and to Make a Preliminary Assessment of the Effect of Food.||GlaxoSmithKline|No|Completed|November 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 12, 2010|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00849134||143009|
NCT00849147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0603|Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)|A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)||Medical College of Wisconsin|Yes|Completed|October 2008|November 2013|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|1 Year|70 Years|No|||August 2015|August 5, 2015|February 20, 2009|Yes|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT00849147||143008|
NCT00849719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-AW-0400-CTIL|Effects of a Combination of IV-PCA With Continuous IV Infusion of MO, Versus IV-PCA MO on Postoperative Pain|Effects of Combination of Continuous Intravenous (IV) Infusion Plus Patient-Controlled Analgesia (PCA) of Morphine (MO) vs. IV-PCA MO on Postoperative Pain Control||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|April 2009|June 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|80 Years|No|||February 2009|February 23, 2009|February 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00849719||142967|
NCT00850070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHC-0901|Sapropterin as a Treatment for Autistic Disorder|Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial||The Children's Health Council|Yes|Completed|March 2009|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|3 Years|6 Years|No|||January 2014|January 27, 2014|February 20, 2009|Yes|Yes||No|August 31, 2012|https://clinicaltrials.gov/show/NCT00850070||142941|
NCT00850330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iraci-01|Study for Early Detection of Drug Interactions in Older Hospitalized Patients Using on Line Software|Transversal, Multicentric Study for Early Detection of Drug Interactions in Older Hospitalized Patients Using on Line Software in Córdoba, Argentina|SEDDI|Universidad Nacional de Córdoba|No|Recruiting|June 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|65 Years|N/A|No|Non-Probability Sample|Hospitalized patients older than 65 years old|August 2009|August 3, 2009|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00850330||142921|
NCT00850616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V526-001|Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)|A Phase I Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and in Combination in Healthy Adults||Merck Sharp & Dohme Corp.||Completed|April 2005|March 2011|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|147|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|February 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00850616||142900|
NCT00850031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-P08-020A|Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes|A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay (ACI)™ ACI 7000PDT in Presbyopic Subjects (OUS Study)|ACI|AcuFocus, Inc.|No|Active, not recruiting|January 2009|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|45 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00850031||142944|
NCT00850304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-02-36-7242|Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide|Feasibility Study of Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide on Ambulatory Schedule||Tehran University of Medical Sciences|Yes|Completed|October 2007|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|60 Years|N/A|No|||February 2009|February 21, 2009|February 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00850304||142923|
NCT00850577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA196-005|Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer|A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology||Bristol-Myers Squibb|Yes|Terminated|June 2009|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|February 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850577||142903|
NCT00850590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-02/2008 (SUSD)|Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights|A Randomised, Placebo-controlled, Double-blind, Dose Escalation Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of Rectal Suppositories Containing Between 5 and 15 mg NRL001 or Matching Placebo for Two Different Sized Suppositories (1 g and 2 g).||Norgine|Yes|Completed|February 2009|||April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 21, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850590||142902|
NCT00846508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1166A3|Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis|Phase III Randomized Trial of Comparing CCRT vs. RT Alone for Cervical Cancer Patients Primarily Treated by Radiotherapy and With Clinically Defined Good-prognosis||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|February 2009|January 2013|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|208|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||February 2009|December 31, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00846508||143209|
NCT00847158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iStent Washout study|A Clinical Trial of Phacoemulsification Versus Phacoemulsification & the iStent Implantation in POAG Patients|A Randomized, Double-Masked Clinical Trial of Phacoemulsification Compared With Phacoemulsification and Micro-Bypass Stent Implantation in Patients With POAG||University of Turin, Italy|Yes|Completed|December 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||February 2009|February 18, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847158||143159|
NCT00847431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0354|Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease (PD)|Mapping Mood in the Subthalamic Nucleus in PD|MOOD-D|Washington University School of Medicine|No|Active, not recruiting|December 2008|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|103|||Both|40 Years|N/A|No|Non-Probability Sample|PD patients with and without STN DBS|June 2015|June 2, 2015|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847431||143138|
NCT00847171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0885 CDR0000634155|Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer|A Safety and Bioactivity Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of Patients With High Risk/ Metastatic HER-2/Neu- Overexpressing Breast Cancer With No Evidence of Disease||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|December 2008|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2013|May 24, 2013|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847171||143158|
NCT00847119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 20006. XEBERECTO/ICO/005|Xeloda and Bevacizumab to Treat Rectal Cancer|ESTUDIO FASE II DE BEVACIZUMAB EN COMBINACIÓN CON CAPECITABINA Y RADIOTERAPIA COMO TRATAMIENTO PREOPERATORIO EN PACIENTES CON CÁNCER RECTAL LOCALMENTE AVANZADO RESECABLE|xeberecto|Institut Català d'Oncologia|No|Active, not recruiting|September 2007|September 2013|Anticipated|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|75 Years|No|||June 2013|June 19, 2013|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847119||143162|
NCT00847691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSTIC GENSARC|GENSARC 2008 : Medical Economic Evaluation of the Molecular Detection by FISH (Fluorescent in Situ Hybridization) and by PCR (Polymerase Chain Reaction) of Sarcomas Specific Translocations and Amplifications .|GENSARC 2008 : Medical Economic Evaluation of the Molecular Detection by FISH (Fluorescent in Situ Hybridization) and by PCR (Polymerase Chain Reaction) of Sarcomas Specific Translocations and Amplifications .|GENSARC|Centre Hospitalier Universitaire de Nice|No|Completed|March 2009|July 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|350|Samples With DNA|sarcoma biopsy|Both|N/A|N/A|No|Probability Sample|Patients with a strong clinical and histological suspicion of sarcoma|February 2009|December 17, 2012|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847691||143119|
NCT00847704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4005|Clinic-Based AMES Treatment of Stroke|Clinic-Based Ames Treatment of the Lower Extremity in Chronic Stroke Subjects||Oregon Health and Science University|Yes|Terminated|April 2008|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||February 2009|December 17, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847704||143118|
NCT00847951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00021322|Ultrasound for Perfusion in Neonates|3D Ultrasound for Perfusion in Neonates||University of Michigan|No|Withdrawn||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|28 Days|Accepts Healthy Volunteers|||June 2012|June 20, 2012|February 17, 2009||No|Study terminated at this time by investigator. Will create new protocol.|No||https://clinicaltrials.gov/show/NCT00847951||143099|
NCT00847093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMX-944700|LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery|Post-Operative Pain Control in Children and Infants Undergoing Penoplasty: A Randomized Control Trial of a Local Anesthetic Cream Placebo.|LMX-4|Ferndale Laboratories, Inc.|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|50|||Male|3 Months|3 Years|No|||February 2009|June 30, 2011|February 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00847093||143164|
NCT00848536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-40|Efficacy Study of Travoprost APS Versus TRAVATAN|A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|March 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|371|||Both|18 Years|N/A|No|||April 2012|April 4, 2012|February 19, 2009|No|Yes||No|February 14, 2011|https://clinicaltrials.gov/show/NCT00848536||143054|
NCT00848549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-314|Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures|A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures||Eisai Inc.||Completed|October 2008|November 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|295|||Both|18 Years|78 Years|No|||November 2015|December 21, 2015|February 19, 2009||No||No|November 12, 2012|https://clinicaltrials.gov/show/NCT00848549||143053|
NCT00848276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008138-01H|Sex Hormones and Blood PCSK9 Levels|Human Studies On Gender Differences In PCSK9 Function In Lipoprotein Metabolism||Ottawa Hospital Research Institute|No|Completed|July 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|61|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|Primary care clincs|December 2010|December 7, 2010|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848276||143074|
NCT00848510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62242-003|EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases|A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With Liver Metastases After Failure of Standard Therapy||Merck KGaA||Completed|February 2009|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|February 19, 2009|No|Yes||No|July 24, 2015|https://clinicaltrials.gov/show/NCT00848510||143056|
NCT00848809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.073|Pharmacokinetics of Vancomycin in the ICU in Renal Replacement Therapy|Pharmacokinetics of Vancomycin in Various Modalities of Renal Replacement Therapy in the Intensive Care Unit||Avera McKennan Hospital & University Health Center|No|Withdrawn|December 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|0|None Retained|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients must be admitted to the intensive care unit at Avera McKennan Hospital in Sioux        Falls, SD.|April 2015|April 21, 2015|February 19, 2009||No|PI had difficult enrollment.|No||https://clinicaltrials.gov/show/NCT00848809||143034|
NCT00848822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1108-01|Sleep and Glucose Regulation in Youth With Type 1 Diabetes Mellitus|Sleep and Glucose Regulation in Youth With Type 1 Diabetes Mellitus||University of Arizona|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|10 Years|16 Years|No|Non-Probability Sample|Pariticipants will be recruited from the Angel Clinic for Children with Diabetes and        Endocrine Disorders which is part of University Medical Center in Tucson, Arizona|April 2011|April 14, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00848822||143033|
NCT00849173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090085|Global Study of Women's Health|Global Study of Women's Health||National Institutes of Health Clinical Center (CC)||Completed|February 2009|November 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|7|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|February 19, 2014|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849173||143006|
NCT00849732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V520-018|A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)|A Worldwide, Phase I, Dose-Escalating Study of Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Healthy Adults||Merck Sharp & Dohme Corp.|No|Completed|June 2003|February 2011|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|360|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|February 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00849732||142966|
NCT00850083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152/08|Accuracy of Measurement of Surface Body Temperature Using the Health e Pod Device (Card Guard) Compared to Gold Standard Equipment|Accuracy of Measurement of Surface Body Temperature Using the Health e Pod Device (Card Guard) Compared to Gold Standard Equipment||Assaf-Harofeh Medical Center|No|Not yet recruiting|March 2009|||December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|18 Years|No|Non-Probability Sample|Children visiting the pediatric emergency unit|February 2009|February 23, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850083||142940|
NCT00850343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDP870-275-08-004|Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients|A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered Without Coadministration of Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-003)||Astellas Pharma Inc|No|Completed|March 2009|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|20 Years|74 Years|No|||October 2014|October 27, 2014|February 23, 2009||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT00850343||142920|
NCT00850642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112046|GSK2190915 Moderate to Severe Asthma Study|The Efficacy of Orally Administered GSK2190915 as an add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils||GlaxoSmithKline|No|Terminated|June 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||March 2012|June 14, 2012|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850642||142898|
NCT00850603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPT01|Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®|Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135||Sanofi|No|Completed|October 2002|November 2004|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|170|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|February 24, 2009|Yes|Yes||No|March 13, 2009|https://clinicaltrials.gov/show/NCT00850603||142901|
NCT00846144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0136-08-HMO|The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients|This Study is a Small Preliminary Study to Evaluate the Possibility of Performing a Phase 1 Study.||Hadassah Medical Organization|No|Not yet recruiting|September 2009|December 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846144||143237|
NCT00846157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKMGI 4-06|Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients|R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail|NKCell|NKBio Co.Ltd.|No|Enrolling by invitation|September 2007|September 2014|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|276|||Both|20 Years|70 Years|No|||February 2009|June 26, 2011|February 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00846157||143236|
NCT00846170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-01-09|Probiotics in Irritable Bowel Syndrome|Double Blind Placebo Controlled Study of the Effect of Probiotics "Co-Biotic" (TM)on Symptoms and Fecal Bacterial Composition in IBS Patients||Meir Medical Center|No|Withdrawn|September 2010|||March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||May 2011|March 8, 2015|February 16, 2009||No|sponsor decided they are not interested in the study due to finacial reasons|No||https://clinicaltrials.gov/show/NCT00846170||143235|
NCT00846807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.85|Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery|Observational Cohort Study to Evaluate the Safety and Efficacy of Pradaxa (Dabigatran Etexilate) for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery in a Routine Clinical Setting.||Boehringer Ingelheim||Completed|February 2009|||July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5476|||Both|18 Years|75 Years|No|Non-Probability Sample|Subgroups of the general population|September 2012|September 13, 2012|February 13, 2009||||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00846807||143186|
NCT00846820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT07-30|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||November 21, 2014|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00846820||143185|
NCT00846833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0808-024-253|Haploidentical NK Cell Infusion in Malignant Melanoma|Phase I/II Study of Haploidentical Natural Killer Cell Infusion in Patients With Refractory or Relapsed Malignant Melanoma||Seoul National University Hospital|Yes|Completed|February 2009|April 2012|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||June 2012|June 6, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846833||143184|
NCT00847184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Airtraqnasal2009|Comparison of Airtraq Versus MacIntosh Intubation Via Nasal Approach|Comparison of Airtraq vs. MacIntosh Intubation Via Nasal Approach||Kliniken Essen-Mitte|No|Recruiting|February 2009|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2009|February 18, 2009|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00847184||143157|
NCT00847197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1903-004|A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK1903 in Patients With Dyslipidemia||Merck Sharp & Dohme Corp.|No|Completed|June 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|70 Years|No|||November 2015|November 19, 2015|February 18, 2009|Yes|Yes||No|August 27, 2010|https://clinicaltrials.gov/show/NCT00847197||143156|
NCT00847743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLRI-2007-03|Study on Whether Tart Cherry Juice Can Reduce Oxidative Stress and Inflammation|Effects of Tart Cherry Juice on Oxidative Stress and Inflammation in Older Men and Women||Kronos Longevity Research Institute|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|12|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 18, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847743||143115|
NCT00847964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM-08-001|Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery|SYM-08-001: A Pilot Study to Evaluate the Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With Dilated Cardiomyopathy Undergoing Open-heart Surgery||LoneStar Heart, Inc.|No|Completed|February 2009|November 2012|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||November 2012|November 29, 2012|February 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00847964||143098|
NCT00847717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SND_01|Trial of IIb Preserving Neck Dissection|Randomized Controlled Trial of IIb Preserving Neck Dissection VS Neck Dissections Involving IIb Removal (Selective/Functional) in Patients With N0 Neck With Oral Cavity Malignancies||Banaras Hindu University|No|Recruiting|August 2007|||September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||August 2009|August 10, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847717||143117|
NCT00848302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HLOBO247|Endothelial Function in Human Arteries|Endothelial Function in Human Arteries||The Cleveland Clinic|Yes|Completed|September 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|February 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848302||143072|
NCT00848835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAD LIFE|Long Term Integrity Follow-up Evaluation|Long Term Integrity Follow-up Evaluation|LEAD LIFE|Guidant Corporation|No|Completed|March 2002|January 2010|Actual|October 2009|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|372|||Both|18 Years|N/A|No|Non-Probability Sample|all patients who are indicated for a market released ICD|August 2010|August 30, 2010|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848835||143032|
NCT00848848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V104P3|Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older|A Phase Ib, Multi-Center, Randomized, Observer-Blind, Proof of Concept, Dose- and Formulation-Ranging Study to Evaluate Safety, Tolerability, and Immunogenicity of One Dose of Trivalent Inactivated Influenza Vaccine in Different Presentations (Intramuscular and Intradermal Delivery), Dosages (Regular or Higher A/H3N2 Content) and Doses of Adjuvant Administered to Healthy Elderly Aged ≥ 65 Years||Novartis||Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|10||Actual|450|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848848||143031|
NCT00848523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBTC-2008-1|Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors|Phase II Trial of LBH589 (Panobinostat) in Adult Patients With Recurrent Malignant Gliomas||Neurological Surgery, P.C.|Yes|Terminated|November 2008|April 2009|Actual|April 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|N/A|No|||September 2009|July 15, 2010|February 19, 2009|No|Yes|insufficient accrual|No||https://clinicaltrials.gov/show/NCT00848523||143055|
NCT00849186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634770|Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer|A Pilot Study of Neoadjuvant SUNITINIB MALATE (Sunitinib) in Patients With Renal Cell Carcinoma Undergoing Nephrectomy||Roswell Park Cancer Institute|Yes|Completed|August 2007|April 2010|Actual|July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|February 20, 2009|No|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT00849186||143005|
NCT00849446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTESIS-DepG-2009-1|Validity and Reliability of an Activity Monitor in Persons With a Cerebrovascular Accident|||University College of Antwerp|No|Completed|February 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Fifteen patients and fifteen healthy subjects will be included in the study following        written informed consent. The following demographic and clinical data were recorded: age,        gender, height, length, medication use, self-reported handedness, Edinburgh Handedness        Inventory, Rivermead Gross Function, Functional Ambulation Categories, medical and        surgical history.|February 2011|August 23, 2011|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849446||142987|
NCT00849459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000629819|Gene Therapy in Treating Women With Metastatic Breast Cancer|Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer||National Cancer Institute (NCI)||Recruiting|August 2008|||August 2010|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||June 2009|June 9, 2009|February 20, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00849459||142986|
NCT00849745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010324|Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases|Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases||Duke University|Yes|Terminated|January 2003|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|69 Years|No|||July 2015|July 20, 2015|February 22, 2009|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00849745||142965|
NCT00849758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51518|Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients|Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients.|EBS|Universitaire Ziekenhuizen Leuven|No|Completed|May 2009|September 2014|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|110|Samples With DNA|peripheral blood is collected for DNA, RNA, serum plasma, and lymphocytes|Female|70 Years|N/A|No|Probability Sample|70+, female, M0, all breast tumor types allowed (main goal is effect of chemo on the        patient; looking at ER pos only would lead to insufficient numbers).        80 patients receiving adjuvant TC (taxotere cyclophosphamide 75/600) q3w, 4x Nadir        systematically in first cycle (d10 and 15) to have idea on haematological toxicity grades        III-IV.        No primary prophylaxis at first cycle, but allowed for secondary prophylaxis (febrile        neutropenia or prolonged neutropenia = 5d < 500 neutrophils).        Herceptin preferably given in HER2 positive patients after chemo (HERA like) in order to        have similar treatment; but the investigator can also give concomitantly with chemo.        40 patients receiving 5y AI (control group).|December 2014|December 8, 2014|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849758||142964|
NCT00850096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-0100-CPEX011|Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus|Effects of Nasulin v.Placebo on Blood Glucose Control in Patients With Type 2 DM Treated With Basal Insulin & Oral Antidiabetic Meds, Excluding Secretagogues in Phase 2A, Randomized, Parallel, Double-Blind, Placebo-Controlled, Multi-Center Study|CPEX-011|CPEX Pharmaceuticals Inc.|No|Completed|January 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|90 Years|No|||November 2013|November 25, 2013|January 30, 2009|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00850096||142939|
NCT00850109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-00012|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||April 25, 2012|February 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850109||142938|
NCT00850356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#B-120208|Quality of Life Outcomes and Economic Impacts of Bariatric Surgery|Alberta Population-based, Prospective Evaluation of the Quality of Life Outcomes and Economic Impacts of Bariatric Surgery||University of Alberta||Completed|November 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|500|||Both|18 Years|60 Years|No|Non-Probability Sample|Three participant goups (n=500:)        Bariatric Surgery(Sx):150 participants. Patients approved for bariatric surgery in an        Adult Weight Management Clinic (AWMC) will be eligible (BMI ≥35 kg/m2 and a major medical        comorbidity or BMI ≥ 40 kg/m2). Contraindications to surgery are pregnancy, unstable        psychiatric disease, patients deemed too medically high-risk, age > 60 years, active        substance abuse, or an active eating disorder.        Medical Treatment(Mx):200 participants. Patients will be approached for the study upon        their first visit in the AWMC.        Both medical and surgical patients receive intensive lifestyle counseling (diets,        exercise, behavioral modification) delivered according to current recommendations. Other        than receiving extra education about surgery and post-operative diets, there is no        difference in care between the medical and surgical arms.        Community Wait-List Control(Wx):150 participants will be enrolled from the list of newly        referred patients to the AWMC.|May 2013|May 17, 2013|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850356||142919|
NCT00850629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/017/09|Hormonal Regulation of Body Weight Maintenance|Hormonal Regulation of Body Weight Maintenance||Charite University, Berlin, Germany|Yes|Active, not recruiting|October 2009|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|10 Years|90 Years|Accepts Healthy Volunteers|||January 2012|January 30, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00850629||142899|
NCT00846183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|local injury111|Effect of Local Injury on Implantation|Effect of Local Injury to Endometrium on the Day of Oocyte Retrieval in First IVF Cycle on Implantation Rate.||Yazd Research & Clinical Center for Infertility|Yes|Completed|June 2008|June 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Female|N/A|35 Years|Accepts Healthy Volunteers|||December 2013|December 20, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846183||143234|
NCT00846196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008119|A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects|A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations.||Warner Chilcott|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|538|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|February 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00846196||143233|
NCT00846521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603001202|Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity|Postprandial Glycemia in Association With Vascular Disease in Childhood Obesity||Yale University|No|Terminated|September 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|12 Years|25 Years|Accepts Healthy Volunteers|||April 2013|April 29, 2013|February 16, 2009|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT00846521||143208|
NCT00846534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0916|The Assessment of Oxidative Stress Markers and the Development of Atrial Fibrillation After Cardiac Surgery|The Assessment of Oxidative Stress Markers and the Development of Atrial Fibrillation After Cardiac Surgery|POAF|University of Illinois at Chicago|No|Terminated|April 2008|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Approximately 10- 15 ml of blood will be drawn from subjects. Blood samples will be      separated into plasma and serum to measure the oxidative stress markers.|Both|18 Years|N/A|No|Probability Sample|The target population of this study is all patients who will undergo cardiac surgery.        There is no particular age range, but subjects less than 18 years of age will be omitted        because of the rarity of AF in this population. The target number of subjects will be 100.|April 2014|April 21, 2014|January 14, 2009||No|Insufficient patient volume|No||https://clinicaltrials.gov/show/NCT00846534||143207|
NCT00846547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22003|Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders|An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders||Seaside Therapeutics, Inc.|Yes|Completed|February 2009|September 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|6 Years|17 Years|No|||May 2013|May 10, 2013|February 17, 2009|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT00846547||143206|
NCT00846560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS04CTIL|Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)|Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)||Rambam Health Care Campus|No|Enrolling by invitation|August 2008|||December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Amyotrophic lateral sclerosis and Healthy subjects|February 2009|February 17, 2009|February 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00846560||143205|
NCT00846859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOTABU-BO2|Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?|Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?||Sahlgrenska University Hospital, Sweden|No|Completed|March 2009|January 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|30 Years|70 Years|No|||July 2011|July 20, 2011|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846859||143182|
NCT00847210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-P107-163|Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease|A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease||Takeda|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|12 Years|17 Years|No|||January 2012|January 31, 2012|February 18, 2009|No|Yes||No|September 8, 2010|https://clinicaltrials.gov/show/NCT00847210||143155|For outcome measures #4, 5, 6, 7 and 8, outcomes could not be estimated for one participant in the 30 mg dose group.
NCT00847457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH075762|Depressed Adolescents Treated With Exercise (The DATE Study)|Exercise Treatment for Depressed Youth||University of Texas Southwestern Medical Center|Yes|Completed|January 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|12 Years|17 Years|No|||June 2013|June 26, 2013|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847457||143136|
NCT00847444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUCCESS-C Trial|Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention|Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention Strategies|SUCCESS-C|Ludwig-Maximilians - University of Munich|Yes|Active, not recruiting|February 2009|September 2016|Anticipated|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3547|||Female|18 Years|N/A|No|||April 2013|April 17, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847444||143137|
NCT00847379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-007e-DMD|Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)|A Phase 2b Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy||PTC Therapeutics|Yes|Terminated|January 2009|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|173|||Male|N/A|N/A|No|||August 2013|August 28, 2013|February 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00847379||143142|
NCT00847392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-BUS|Study to Determine Pediatric Bladder Volume Prior to Catheterization|Pediatric Volumetric Bladder Ultrasound Study|PV-BUS|McMaster University|No|Withdrawn|March 2009|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|36 Months|No|||June 2009|June 24, 2009|February 17, 2009||No|Inability to obtain grant funding|No||https://clinicaltrials.gov/show/NCT00847392||143141|
NCT00847405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2678|Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets Versus Imitrex® 100 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects||Teva Pharmaceuticals USA|No|Completed|March 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 17, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00847405||143140|
NCT00847730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACDrsg 2008-37|Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negatvie Pressure Wound Therapy|A Single Arm, Prospective Clinical Trial Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabectic Foot Ulcers Receiving VAC Negative Pressure Therapy||KCI USA, Inc.|No|Completed|February 2009|September 2009|Actual|June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|75|||Both|18 Years|N/A|No|||September 2011|September 8, 2011|February 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00847730||143116|
NCT00848289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-8577|Genetic Susceptibility to Bladder Cancer|H-8577:Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach||Baylor College of Medicine|No|Recruiting|July 2008|January 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|2200|Samples Without DNA|blood (about 40 cc or 8 teaspoons), urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any patient who have been diagnosed with bladder cancer or who is healthy is eligible to        participate without regard to age, sex, or ethnicity.|February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848289||143073|
NCT00848588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLP 6566|A Survey of Factors Associated With the Successful Recognition of Agonal Breathing and Cardiac Arrest.|A Survey of Factors Associated With the Successful Recognition of Agonal Breathing and Cardiac Arrest by 9-1-1 Call Takers.||Ottawa Hospital Research Institute|No|Completed|June 2009|September 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|409|||Both|N/A|N/A|No|Probability Sample|The survey will be sent to all full-time and part-time 9-1-1 call takers employed in the        Canadian provinces of Ontario, Nova Scotia and New Brunswick, as well as the city of        Montreal, Quebec, Canada.|March 2012|March 1, 2012|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848588||143050|
NCT00848601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-1776-01|Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma|Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Hormone and Docetaxel Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma||Astex Pharmaceuticals|No|Terminated|February 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|February 19, 2009|No|Yes|The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in    patients with refractory prostate and lymphoma|No||https://clinicaltrials.gov/show/NCT00848601||143049|
NCT00848562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICO-HDPCI-1|Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients|Oral Nicorandil to Reduce Cardiac Death After Coronary Revascularization in Hemodialysis Patients: A Randomized Trial||Toujinkai Hospital|Yes|Completed|January 2002|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|129|||Both|30 Years|N/A|No|||February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848562||143052|
NCT00848575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99075|A Preliminary Study Utilizing a Flexible Endoscope for Pelvic Culdoscopy|A Preliminary Study Utilizing a Flexible Endoscope for Pelvic Culdoscopy|Culdo|University of Arkansas|No|Terminated|February 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|N/A||1|Actual|2|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Participants will be selected from among women attending the gynecologic clinics or        gynecologic oncology clinic of UAMS. Subjects from all races and ethnicities may        participate. No children (aged <18 years) are to be enrolled.|September 2013|September 13, 2013|February 19, 2009|No|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT00848575||143051|
NCT00849160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREPATS 001|Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.|Non-comparative, Opened Study, Evaluating in HIV-1 Infected Patients With Undetectable Viral Load, Treated by an Antiretroviral Combination Including a Protease Inhibitor Boosted With Ritonavir and Administered by Oral Route Twice a Day, the Substitutability of the Current Protease Inhibitor Regimen by the Association Darunavir/Ritonavir 800/100 mg Once a Day to Maintain the Viral Load Under the 50 Copies/ml Limit of Detection After 24 Weeks of Treatment.|RADAR|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|No|Completed|May 2009|September 2011|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849160||143007|
NCT00849511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270472|Melatonin for Migraine Prevention|Melatonin for Migraine Prevention (The MMP-study): A Randomized, Double-blind, Cross-over, Placebo-controlled Study of Melatonin in Prophylactic Treatment of Migraine|MMP|Nordlandssykehuset HF|No|Completed|February 2009|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849511||142983|
NCT00849810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0002|Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate|Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study||University of Mississippi Medical Center|Yes|Terminated|January 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|February 2, 2009|Yes|Yes|Difficulty with recruiting willing participants.|No|March 18, 2013|https://clinicaltrials.gov/show/NCT00849810||142961|
NCT00849472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110264|Treatment With Pazopanib for Neoadjuvant Breast Cancer|A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer||GlaxoSmithKline|No|Completed|July 2009|April 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Female|18 Years|N/A|No|||December 2013|January 30, 2014|February 12, 2009|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00849472||142985|
NCT00849485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50277|Levetiracetam 750 mg Tablets Under Non-Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Levetiracetam 750 mg Tablet and Keppra® (Reference) Following a 750 mg Dose in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|November 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 20, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00849485||142984|
NCT00850122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012011|An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates|An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates||Duke University|No|Active, not recruiting|July 2013|August 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|120 Days|No|||February 2016|February 11, 2016|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00850122||142937|
NCT00850369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-HL79915-1|A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension|A Pilot Study of the Effects of Chronic Red Blood Cell Transfusion in Sickle Cell Disease On Pulmonary Hypertension in Patients With Sickle Cell Disease||University of North Carolina, Chapel Hill|Yes|Withdrawn|February 2005|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||July 2013|July 26, 2013|February 22, 2009||No|Slow accrual onto the study|No||https://clinicaltrials.gov/show/NCT00850369||142918|
NCT00850382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 11-08|Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)|Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)||University of Ulm|No|Completed|June 2009|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850382||142917|
NCT00850694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F061228001|Vitamin D Deficiency in Obese Adolescent Girls and Influence of Vitamin D on Insulin Secretion and Sensitivity|Assessment of Prevalence of Vitamin D Deficiency in Obese Adolescent Girls and Influence of Vitamin D on Insulin Secretion and Sensitivity||University of Alabama at Birmingham|No|Completed|February 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|114|||Female|10 Years|18 Years|No|Non-Probability Sample|Obese female adolescents|September 2011|September 9, 2011|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850694||142894|
NCT00850655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0607M88827|Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae|Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|March 2008|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|5 Years|10 Years|No|Non-Probability Sample|community sample|March 2014|March 12, 2014|October 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00850655||142897|
NCT00850668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CoFAR1|Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults|A Phase 1 Study of Heat/Phenol-Killed, E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP 123) in Healthy Volunteers Followed by Subjects Allergic to Peanuts (CoFAR 1)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|February 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00850668||142896|
NCT00846209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0923-010|Improving Prescription Drug Warning Labels|||Northwestern University|No|Completed|June 2007|February 2009|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 17, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00846209||143232|
NCT00846222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192/08|Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study|||Assaf-Harofeh Medical Center|No|Active, not recruiting|February 2009|July 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|88 Years|No|||February 2009|February 17, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00846222||143231|
NCT00846573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Docket # 12639|Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders|Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders||University of Massachusetts, Worcester|No|Terminated|November 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|14|||Both|5 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 8, 2012|February 16, 2009|Yes|Yes|The study was halted prematurely as the PI was no longer an employee of UMass Medical School.|No|August 21, 2012|https://clinicaltrials.gov/show/NCT00846573||143204|
NCT00846846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0, 29 October 2008|PROTECT Continued Access Post Marketing Surveillance Trial|Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial: PROTECT Continued Access Post Marketing Surveillance Trial|PROTECT-CA|Medtronic Vascular|No|Completed|January 2009|March 2015|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1018|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|February 18, 2009|Yes|Yes||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00846846||143183|
NCT00847223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL06-1|Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma|A Phase II Study Evaluating the Efficacy and Safety of the Farnesyl-transferase Inhibitor ZARNESTRA® in Patients With Relapsed, Refractory or Progressive Mantle Cell Lymphoma Not Appropriate for Autologous Bone Marrow Transplantation||Lymphoma Study Association|Yes|Terminated|June 2007|||March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|February 18, 2009||No|Inefficiency of treatment|No||https://clinicaltrials.gov/show/NCT00847223||143154|
NCT00847496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-333|Awbat Versus Biobrane in Partial Thickness Burns|The Treatment of Partial Thickness Burns: Awbat(r) Versus Biobrane(r)|Awbat|The University of Texas Medical Branch, Galveston|No|Withdrawn|December 2009|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|3 Months|18 Years|No|||December 2012|December 10, 2012|February 17, 2009|No|Yes|Company went out of business|No||https://clinicaltrials.gov/show/NCT00847496||143133|
NCT00847470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101883|DPBRN Reasons for Placing the First Restoration on Permanent Tooth Surfaces|Reasons for Placing the First Restoration on Permanent Tooth Surfaces||Dental Practice-Based Research Network|No|Completed|June 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|5810|||Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Practitioner investigators must have been enrolled in the DPBRN, completed the "Assessment        of caries diagnosis & caries treatment" study; and do at least some restorative dentistry        in their practices. The human subjects directly involved in this study were patients who        had sought treatment in the DPBRN practitioners' practices.|November 2014|November 17, 2014|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847470||143135|
NCT00847769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-08-00192|Ankle Sprains and Corticospinal Excitability|Effect of Manual Therapy Intervention on Corticospinal Excitability in Individuals With Post-Acute Ankle Sprains|ACE|University of Southern California|No|Recruiting|December 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|27|||Both|18 Years|60 Years|No|||December 2008|February 17, 2009|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00847769||143113|
NCT00847782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV198-001|An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism|An Experimental Medicine Study to Quantify PCSK9 Serum Concentrations and LDL Receptor Expression in Peripheral Blood Cells in Normal and Hypercholesterolemic Subjects||Bristol-Myers Squibb|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 4, 2009|February 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00847782||143112|
NCT00848003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003600-01A1|Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics|Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics|PHASE|Georgetown University|Yes|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|February 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00848003||143095|
NCT00848016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01160|Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery|A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)||National Cancer Institute (NCI)||Completed|February 2009|June 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2014|April 17, 2014|February 19, 2009|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00848016||143094|
NCT00848029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87P12|Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Shedules|||Novartis||Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|240|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848029||143093|
NCT00848042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-07-001|Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck|A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck||Nanospectra Biosciences, Inc.|Yes|Completed|April 2008|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|130 Years|No|||October 2015|October 5, 2015|February 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00848042||143092|
NCT00848055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1240.1|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single Rising, Open-label Doses of AbGn-168 Administered by Intravenous Infusion (1 Mcg/kg, 5 Mcg/kg, 25 Mcg/kg, 125 Mcg/kg, 625 Mcg/kg, 3 mg/kg, or 10 mg/kg) or Subcutaneous Injection (625 Mcg/kg) to Patients With Chronic Plaque Psoriasis||Boehringer Ingelheim||Completed|December 2008|||October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|8||Actual|40|||Both|18 Years|65 Years|No|||October 2013|October 31, 2013|February 18, 2009||||No||https://clinicaltrials.gov/show/NCT00848055||143091|
NCT00848068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-61|Evaluation of FID 114657 on Tear Film Lipid Layer Thickness|||Alcon Research|No|Completed|January 2009|||March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848068||143090|
NCT00848926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG035-0003|A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma|A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)||Seattle Genetics, Inc.|Yes|Completed|February 2009|May 2015|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|12 Years|N/A|No|||June 2015|November 6, 2015|February 18, 2009|Yes|Yes||No|September 15, 2011|https://clinicaltrials.gov/show/NCT00848926||143025|
NCT00848939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-DU-101|Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis|An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine (UT-15C) Sustained Release Tablets in Patients With Systemic Sclerosis|DISTOL-PK|United Therapeutics|No|Completed|December 2008|April 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2012|October 19, 2012|February 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00848939||143024|
NCT00848900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOAL2009|Guangzhou Outdoor Activity Longitudinal Study|A Controlled Clinical Trial of the Effect of Increases Time Outdoors in the Prevention of Juvenile-onset Myopia in Chinese Children||Sun Yat-sen University|Yes|Enrolling by invitation|April 2009|July 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|N/A|N/A|No|||October 2010|November 19, 2010|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848900||143027|
NCT00848913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2007-0127 + 37036|Strength Training After Hip Fracture Surgery|Effect of Rehabilitation With Versus Without Progressive Strength Training Implemented in the Acute Ward After Hip Fracture Surgery: A Randomized Controlled Trial||Hvidovre University Hospital|Yes|Completed|October 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|65 Years|N/A|No|||June 2015|June 2, 2015|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848913||143026|
NCT00848861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-kao|A Trial Comparing Propofol to Midazolam Plus Meperidine Sedation for Outpatient Colonoscopy|||University of Alberta|No|Completed|February 2006|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|92|||Both|18 Years|75 Years|No|||February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848861||143030|
NCT00848874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R41MH75162|Portable Visual Guidance System Phase II|Phase II Study of a Portable Visual Guidance System for Use by AS/HFA Students in Inclusion Settings|PVGS-II|SymTrend Inc.|No|Enrolling by invitation|September 2008|April 2010|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|11 Years|21 Years|No|||February 2009|February 19, 2009|April 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00848874||143029|
NCT00848887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V104P2|A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age|A Phase Ib, Randomized, Observer-Blind, Multicenter, Factorial-Design Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Injections of Trivalent Inactivated Influenza Vaccine With or Without a Second Influenza B Strain in Combination With or Without One of Three Different Doses of Adjuvant in Healthy Children, Aged 6 to <36 Months||Novartis||Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|410|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||January 2014|January 23, 2014|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848887||143028|
NCT00849537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8711|The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy|||hahid Beheshti University of Medical Sciences||Recruiting|April 2008|April 2009|Anticipated|April 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||February 2009|February 23, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849537||142981|
NCT00849836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCPD|Novel Biomarkers in Chronic Airway Diseases|The Study for The Identification of Novel Biomarkers in Chronic Airway Inflammatory Disorders||Chonbuk National University||Recruiting|February 2009|January 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with acute exacerbation of asthma or COPD, patients with stable status of those        disease, and the healthy control subjects|February 2009|February 23, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849836||142959|
NCT00849771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080160|Operative Versus Nonoperative Treatment for Scapula Fractures|Multicenter Prospective Study of Operative and Non-operative Treatment for Scapula Fractures||Vanderbilt University|No|Withdrawn|March 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The subject population will include patients seen at participating facilities for the care        of scapula fractures, who are 18 years of age or older, meet inclusion/exclusion criteria        and are willing to consent.|November 2015|November 10, 2015|February 20, 2009||No|Joined another larger group of same study|No||https://clinicaltrials.gov/show/NCT00849771||142963|
NCT00849797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50370|Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Oxcarbazepine 600 mg Tablet and Trileptal® Following a 600 mg Dose in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|February 20, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00849797||142962|
NCT00850408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|172502|Enhancing the Response to Rehabilitation After Stroke Using Repetitive Transcranial Magnetic Stimulation (rTMS)|Enhancing the Response to Rehabilitative Interventions After Stroke Using Transcranial Magnetic Stimulation||McGill University Health Center|Yes|Terminated|June 2008|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|19 Years|N/A|No|||April 2013|April 22, 2013|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850408||142915|
NCT00850707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASACC2009-02|Vascular Access for Hemodialysis and Inflammation|Artero-Venous Fistula, Prosthetic Polytetrafluoroethylene Grafts (AVG), Tunneled Cuffed Catheter (TCC): Impact of Vascular Access on HD Inflammation and Monocyte Activation||St. Orsola Hospital|Yes|Completed|January 2000|December 2008|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|458|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|The three groups of patients were homogeneous for: a) demographic characteristics; b)        dialysis adequacy; c) vascular access blood flow; d) white cell count.|February 2009|February 26, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850707||142893|
NCT00846261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z2-001|The Infected Bone Nonunion and Soft Tissue Defect of Long Bone Treated Simultaneously With Ilizarov Technique|The Infected Bone Nonunion and Soft Tissue Defect of Long Bone Treated Simultaneously With Ilizarov Technique||Zhejiang University|Yes|Completed|January 2002|January 2008|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2009|March 3, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846261||143228|
NCT00846274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKATIII_I_2007|Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III|Single-Dose, Open Label, Randomized Comparative Clinical Trial to Evaluate the Tolerability, Safety and PK/PD of Human ATIII Products, "SKATIII Injection" and"ATIII Injection" in Healthy Male Subjects||SK Chemicals Co.,Ltd.||Completed|October 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|19 Years|40 Years|Accepts Healthy Volunteers|||February 2009|February 17, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00846274||143227|
NCT00850681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-024|A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers|A Randomized, Controlled Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers Using an Open Application Photoallergic Test Design||Peplin|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2009|September 7, 2015|February 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850681||142895|
NCT00846235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2934004|Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis|Clinical Evaluation of the Effect of Moisturising Cream on Skin Moisture in Atopic Dermatitis||Orion Corporation, Orion Pharma|No|Completed|December 2008|May 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|No|||October 2009|October 7, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00846235||143230|
NCT00846872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65-08|Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance|Effect of Continuous Subcutaneous GHRP-3 Infusion at 2 Dose Levels on the Physiological Secretion of the GH-IGF-I System, Blood Pressure, Glucose, Inflammatory Markers and Endothelial Function in Subjects With Insulin Resistance||Tulane University Health Sciences Center|Yes|Terminated|July 2008|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|4|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|February 17, 2009|Yes|Yes|Inadequate subject recruitment|No||https://clinicaltrials.gov/show/NCT00846872||143181|
NCT00847509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT101|A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation|A Phase II/III, Open Label, Non-Randomized, Multi - Center Study Of Positron Emission Tomography (PET) Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation|FLT101|Siemens Molecular Imaging|No|Completed|February 2009|September 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|49|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|February 17, 2009|No|Yes||No|July 26, 2013|https://clinicaltrials.gov/show/NCT00847509||143132|
NCT00847821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3115A1-1125|Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene|RNA Expression Analysis Of Endometrial Biopsies Comparing Placebo, Bazedoxifene/ Conjugated Estrogens And Raloxifene||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|May 2009|August 2010|Actual|August 2010|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Retrospective||8|Actual|185|Samples With DNA|Endometrial biopsy blocks|Female|40 Years|75 Years|No|Non-Probability Sample|Postmenopausal women who participated in and completed the 3115A1-303 study, were at least        80% compliant with test article administration during the study, and have provided a new        signed and written informed consent for study 3115A1-1125.|September 2010|September 3, 2010|February 18, 2009||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00847821||143109|
NCT00847795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1005|Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.|A Trial to Investigate the Accelerated Wound Healing and Antiscarring Potential, Safety, Toleration and Systemic Exposure of Intradermal RN1001 (Avotermin) in Male and Female Subjects Aged 60 Years and Over.||Renovo|No|Completed|September 2002|June 2003|Actual|June 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|42|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 18, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847795||143111|
NCT00847808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-GD08-178|Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy|A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy||Takeda|No|Completed|February 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|178|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|February 18, 2009|Yes|Yes||No|April 5, 2011|https://clinicaltrials.gov/show/NCT00847808||143110|
NCT00847756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMVac clinical study|Host-pathogen Interaction in Otitis Media|Thorough Clinical Investigation of the Host-pathogen Interaction in Chronic and Recurrent Otitis Media|OMVac|Radboud University|No|Active, not recruiting|April 2008|July 2011|Anticipated|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|179|Samples With DNA|blood nasopharyngeal swab middle ear fluid|Both|N/A|5 Years|No|Probability Sample|Children up to 5 years of age suffering from rAOM, COME or CSOM waiting for tympanostomy        tube insertion|December 2010|July 19, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847756||143114|
NCT00848315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DK065985|Diabetes Management in Low-Income Hispanic Patients|Diabetes Management in Low-Income Hispanic Patients||University of Massachusetts, Worcester|No|Completed|July 2004|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|252|||Both|18 Years|N/A|No|||February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848315||143071|
NCT00849212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-J081-231|An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)|A Phase II, Open-label, Ascending High-dose, add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)||Eisai Inc.||Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|64 Years|No|||January 2013|January 3, 2013|February 20, 2009||No||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00849212||143003|
NCT00849238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2005-0291|Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation|Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation Following Campath-1H Induction||University of Wisconsin, Madison||Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|0|||Both|45 Years|N/A|No|||October 2015|October 6, 2015|December 14, 2007|||feasibility issues|No||https://clinicaltrials.gov/show/NCT00849238||143002|
NCT00849199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-60|Cancer Screening and Prevention Program for High Risk Women|Cancer Screening and Prevention Program for High Risk Women||New York University School of Medicine|No|Recruiting|July 2001|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Female|18 Years|N/A|No|Non-Probability Sample|Primarily disadvantaged women who have a family history of breast and or ovarian cancer or        who have had a personal history of breast and or ovarian cancer or who themselves or a        relative have positive genetic markers for breast or ovarian cancer.|July 2015|July 29, 2015|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00849199||143004|
NCT00849849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-08-11|Comprehensive Postpartum Screening Strategies for Women With Gestational Diabetes Mellitus (GDM)|Comprehensive Postpartum Screening Strategies for Women With Prior Gestational Diabetes (COPSS - GDM): Now is the Time for a Paradigm Shift in Clinical Practice|COPSS-GDM|Woman's|Yes|Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|214|Samples Without DNA|Blood samples for diabetes testing|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Postpartum women with GDM (before 12 weeks postpartum)|December 2014|December 17, 2014|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849849||142958|
NCT00850135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02052009-1738|Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes|Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes||Stanford University|No|Active, not recruiting|February 2009|July 2015|Anticipated|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|230|||Female|18 Years|50 Years|No|||March 2015|March 30, 2015|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00850135||142936|
NCT00850395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001070|Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection|Non-Interventional Study Of Celsentri® In Treatment Experienced Patients Infected With CCR5 Tropic HIV-1||ViiV Healthcare|No|Completed|July 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|79|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-1 infected, therapy-experienced patients, CCR5-tropic virus,|November 2012|November 5, 2012|February 23, 2009|No|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT00850395||142916|Designation of outcomes as primary and secondary was based on study team input as study did not specify primary or secondary outcome measures.
NCT00850148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8721|Comparison of Anwar and Melles Techniques in Deep Anterior Lamellar Keratoplasty (DALK) for Keratoconus Patients|||hahid Beheshti University of Medical Sciences||Completed|May 2008|September 2009|Actual|June 2009|Actual|N/A|Interventional|N/A|2||||||Both|15 Years|45 Years|No|||February 2009|January 4, 2012|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850148||142935|
NCT00850421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01837-04-C|Pilot Study of BOTOX for Migraine Headaches|A Single-Center Pharmacoeconomic Pilot Study of BOTOX® (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches||HealthPartners Institute|No|Terminated|April 2004|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2013|November 25, 2015|February 23, 2009|Yes|Yes|Recently published BOTOX efficacy data and study design deficits.|No|July 10, 2013|https://clinicaltrials.gov/show/NCT00850421||142914|
NCT00850434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA20041125|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2005|||||N/A|N/A|N/A||||||||||||||February 24, 2009|February 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850434||142913|
NCT00850720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007443|Study of Possible Brain Hormone Problems After Open Heart Surgery in Infants|Prevalence of Neuroendocrine Dysfunction in the Pediatric Cardiopulmonary Bypass Patient||Emory University|No|Terminated|March 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|N/A|1 Year|No|Non-Probability Sample|Patients at Childrens Healthcare of Atlanta at Egleston|November 2013|November 18, 2013|February 24, 2009||No|Inability to recruit / logistic problems.|No|January 15, 2010|https://clinicaltrials.gov/show/NCT00850720||142892|Early termination of study; Technical problems with measurement leading to unreliable or uninterpretable data.
NCT00846287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Docket # 12830|Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI|Assessment of Arformoterol for COPD Using Hyperpolarized 3He MRI||University of Massachusetts, Worcester|No|Completed|November 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|16|||Both|50 Years|N/A|No|||October 2012|October 3, 2012|February 16, 2009|Yes|Yes||No|June 19, 2012|https://clinicaltrials.gov/show/NCT00846287||143226|
NCT00846248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H847627262|Chromium and Insulin Resistance|Chromium and Insulin Resistance||University of California, San Francisco|No|Completed|January 2006|July 2011|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|75|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846248||143229|
NCT00846586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2341|Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease|INTRUST1|Novartis|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1134|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 15, 2009|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00846586||143203|
NCT00846885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04225|Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Sumatriptan Succinate, (100mg), Compared to and Equivalent Dose of a Commercially Available Reference Drug Product (Imitrex®, GlaxoSmithKline, USA) in 28 Fed, Healthy, Adult Subjects.||Teva Pharmaceuticals USA|No|Completed|August 2004|October 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 17, 2009|No|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00846885||143180|
NCT00847236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-078|Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica|Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica||Lahey Clinic|No|Active, not recruiting|January 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatients and Healthy volunteers from colleague referral and own practice|December 2015|December 15, 2015|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847236||143153|
NCT00847483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XALA-0091-157|Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US|A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-Week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan).|XLT|Pfizer|No|Completed|January 2002|August 2002|Actual|August 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|375|||Both|18 Years|N/A|No|||February 2009|February 17, 2009|February 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00847483||143134|
NCT00858715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vienna REACT|Resistance to Antithrombotic Therapy|Resistance to Antithrombotic Therapy in Patients Undergoing Angioplasty and Stenting for Cardiovascular Disease - Vienna REACT|Vienna REACT|Medical University of Vienna|No|Completed|May 2008|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858715||142284|
NCT00847834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9292|Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population|Multi-center Open Label, Non-comparative Observational Study of Irbesartan-Hydrochlorothiazide in the Treatment of Hypertension in Chinese Population||Sanofi|No|Completed|December 2003|||June 2004|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|968|||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00847834||143108|
NCT00859027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-062|Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer|The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men||University of Connecticut Health Center|No|Completed|January 2003|February 2009|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Male|55 Years|85 Years|No|||June 2013|June 28, 2013|March 7, 2009||No||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00859027||142260|Small number but otherwise no limitations.
NCT00848120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22074|A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis|An Open Label Study to Evaluate the Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis||Hoffmann-La Roche||Completed|December 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|February 19, 2009||No||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00848120||143086|
NCT00848133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bonutti_SV_MV_001|A Comparison of Subvastus and Midvastus Approaches in Minimally-Invasive Total Knee Arthroplasty|A Comparison of Subvastus and Midvastus Approaches in Minimally-Invasive Total Knee Arthroplasty||Sinai Hospital of Baltimore|No|Completed|July 2004|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|51|||Both|40 Years|N/A|No|||February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848133||143085|
NCT00848081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11668|A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1-Adrenergic Blocker Therapy||Eli Lilly and Company|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|318|||Male|45 Years|N/A|No|||August 2010|August 16, 2010|February 19, 2009|Yes|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT00848081||143089|
NCT00848328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634775|Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma|A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular NHL (RV 0163)||University of California, Davis|Yes|Active, not recruiting|March 2008|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|February 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848328||143070|
NCT00848627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20395|Screening for Bladder Cancer|Screening for Bladder Cancer||Baylor College of Medicine|No|Recruiting|March 2007|February 2015|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Male|60 Years|N/A|No|Probability Sample|MD Anderson Cancer Center, Baylor College of Medicine, University of Rochester Medical        Center and Laval University that contain within them county hospitals, Veterans        Administrations Hospitals, fee-for-service clinics, and tertiary care facilities will        enroll subjects. Each site will devise their own means of soliciting participants in the        study.|December 2010|December 9, 2010|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848627||143048|
NCT00848640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12594|Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma|Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug|MERITS|Egyptian Foundation For Cancer Research|Yes|Completed|October 2008|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|60 Years|No|||September 2009|May 25, 2010|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848640||143047|
NCT00848952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2008-01|Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis|Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis|CHIC|University Hospital, Angers||Not yet recruiting|March 2009|||March 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|450|||Both|18 Years|N/A|No|||February 2009|February 3, 2010|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00848952||143023|
NCT00849524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-101357 - prev 080497|Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma||University of California, San Diego|Yes|Terminated|January 2009|July 2014|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 20, 2009|Yes|Yes|drug supply became unavailable|No|August 24, 2015|https://clinicaltrials.gov/show/NCT00849524||142982|
NCT00849823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080666|HIV Prevention Program for African American Teen Males|A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males||University of Kentucky|Yes|Completed|February 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|840|||Male|15 Years|23 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00849823||142960|
NCT00850447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-08-045|Cognitive Remediation in Posttraumatic Stress Disorder (PTSD)|Cognitive Remediation in PTSD||Bronx VA Medical Center|No|Completed|October 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850447||142912|
NCT00856934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/03|Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing|A New Model to Enhance Wound Healing Using Autologous Keratinocytes in Platelet Concentrates - a Prospective Randomized Trial.||Centre Hospitalier Universitaire Vaudois|No|Completed|June 2005|||March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|80 Years|No|||February 2009|February 5, 2009|January 2, 2009||No||No|January 2, 2009|https://clinicaltrials.gov/show/NCT00856934||142420|
NCT00850733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071304|516-BOTOX Urinary Incontinence Detrusor|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Safety and Efficacy of a Single Treatment With 2 Dose Levels of BOTOX Purified Neurotoxin Complex Followed by a Treatment With BOTOX in Patients With…||Veterans Medical Research Foundation|Yes|Completed|August 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|N/A||1|||||Both|18 Years|80 Years|No|Non-Probability Sample|The study will recruit 260 patients nationwide with an expected recruitment of 6 patients        at the VA San Diego Healthcare System. Patients must be between 18-80 years of age and        will include patients with neurogenic detrusor overactivity as a result of spinal cord        injury or multiple sclerosis, with urinary incontinence, who have not been adequately        managed with anticholinergic therapy. 50% of the patients randomized will be of spinal        cord injury etiology and 50% of multiple sclerosis etiology.|September 2009|September 15, 2009|February 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850733||142891|
NCT00846300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP000016-01|A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas|An Intervention to Improve Medication Knowledge & Compliance Among Family Practice Patients in South Texas: An RRNEST Study.||The University of Texas Health Science Center at San Antonio|No|Completed|August 2001|May 2003|Actual|May 2003|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|99 Years|No|||October 2015|October 7, 2015|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846300||143225|
NCT00846313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002.127|Can Malnutrition be Prevented in Patient With Colorectal Cancer Stage Dukes D?|A Randomised Study of Dietary Counseling for Patients With Colorectal Cancer.|ColErn|Norwegian University of Science and Technology|No|Withdrawn|December 2003|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|February 16, 2009||No|Study was stopped due to lack of resources (clinical dietitians)|No||https://clinicaltrials.gov/show/NCT00846313||143224|
NCT00846638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Chang-AA014678|Women's Health Habits Study|Screening and Brief Intervention for Problem Drinking Women|WHHS|Brigham and Women's Hospital|No|Completed|January 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|611|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00846638||143199|
NCT00846937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3097|Plant Stanol Ester Beverage and Ileostoma Patients|Effects of a Plant Stanolester Beverage on Cholesterol Metabolism Among Human Subjects With Ileostoma|STOMA|Helsinki University|No|Completed|February 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2009|February 9, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00846937||143176|
NCT00846599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUB730|Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men|Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men|PERTH|Tufts University|No|Recruiting|January 2008|January 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|HIV-infected white males who have identified themselves with concerns about diet or        cardiovascular disease.|December 2009|December 2, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846599||143202|
NCT00846612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-948|Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer|Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer||New York University School of Medicine|Yes|Completed|January 2008|June 2012|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||October 2012|October 18, 2012|February 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00846612||143201|
NCT00846898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0717/47|Is There a Metabolic Effect of Cinnamon on HbA1c, Blood Pressure and Serum Lipids in Type 2 Diabetes Mellitus?|The Effect of Dietary Supplementation of Cinnamon (Cinnamon Cassia) on HbA1c, Blood Pressure and Serum Lipid Measurements in Patients With Type 2 Diabetes Mellitus: a Randomised Placebo Controlled, Double Blind Clinical Trial|cinnamon|Thames Valley University|Yes|Completed|March 2008|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|80 Years|No|||February 2009|November 11, 2011|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00846898||143179|
NCT00846911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14689|AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs|AVANTI - Avelox® in Acute Exacerbations of Chronic Bronchitis||Bayer|No|Completed|April 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2672|||Both|35 Years|N/A|No|Non-Probability Sample|Primary care clinic|July 2012|July 5, 2012|February 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00846911||143178|
NCT00847249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1882C00001|AZD9164 Single Ascending Dose Study in Healthy Male Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD9164 After Single Ascending Doses in Healthy Male Subjects||AstraZeneca|No|Completed|February 2009|April 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|65|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00847249||143152|
NCT00882856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09215-22/5.1. 22AUG2011|Treating Clozapine-induced Sinustachycardia With Bisoprolol|Treating Clozapine-induced Sinustachycardia With Bisoprolol - a Double Blinded Placebo Controlled Cross Over Study|Biscloz|University of Aarhus|Yes|Recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00882856||140457|
NCT00882869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-205|XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)||Aegera Therapeutics|No|Completed|March 2009|May 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00882869||140456|
NCT00879385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI31116|KRAS Wild-type Metastatic Colorectal Cancer Trial|Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab||University of Utah|Yes|Completed|December 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879385||140720|
NCT00879398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221075|Toviaz Post Marketing Surveillance Study|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Toviaz (Registered)||Pfizer|No|Completed|November 2009|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3000|||Both|18 Years|N/A|No|Non-Probability Sample|- Subjects who are diagnosed as Overactive Bladder (OAB) defined as urgency, with or        without urgency incontinence, usually with frequency and nocturia, in the absence of local        or metabolic factors explaining these factors.|September 2015|September 30, 2015|April 9, 2009||No||No|August 6, 2015|https://clinicaltrials.gov/show/NCT00879398||140719|
NCT00879372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-145|Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression|Double Blind,Randomized, Placebo Controlled Trial of Adjunctive Tianeptine in the Treatment of Bipolar Depression||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|March 2009|December 2013|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|13|||Both|18 Years|70 Years|No|||October 2013|October 5, 2013|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879372||140721|
NCT00879658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312A2201|Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis|A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.||Novartis||Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|296|||Both|18 Years|55 Years|No|||September 2012|September 19, 2012|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879658||140700|
NCT00879671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-100205|Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration|Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration||Medical University of Vienna|Yes|Completed|November 2006|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|126|||Both|50 Years|90 Years|No|||November 2014|November 13, 2014|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879671||140699|
NCT00880165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 04-021|Cost Effectiveness of Ambulatory Management for Veterans With Sleep Apnea|Cost Effective Strategy to Evaluate Veterans With Sleep Apnea|VSATT|VA Office of Research and Development|Yes|Completed|November 2006|January 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|296|||Both|18 Years|90 Years|No|||March 2014|March 18, 2014|April 10, 2009||No||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00880165||140661|
NCT00880477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/069|Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine|Immunogenicity and Safety of GSK Biological's DTPa-HBV-IPV/Hib Vaccine or DTPa-IPV/Hib co-Administered With HBV Vaccine as Primary and Booster Vaccination in Healthy Infants Born to Hepatitis B Surface Antigen Negative Mothers||GlaxoSmithKline||Completed|January 2001|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|140|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||April 2009|April 9, 2009|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880477||140638|
NCT00880490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT0050801|Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Five-period, Placebo and Active-controlled,Cross-over, Multi-centre, Study Evaluating Single Administration of Three Doses of Inhaled PT005 in Patients With Moderate-to-Severe COPD, Compared to Open- Label Marketed Formoterol (FORADIL® AEROLIZER®) as an Active Control||Pearl Therapeutics, Inc.|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|34|||Both|40 Years|80 Years|No|||October 2010|October 11, 2010|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880490||140637|
NCT00880802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST-TRAC|Finding Acute Coronary Syndromes (ACS) With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms|Finding ACS With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms|FAST-TRAC|Nanosphere, Inc.|No|Active, not recruiting|December 2008|March 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|Plasma samples.|Both|18 Years|N/A|No|Non-Probability Sample|This study is designed to evaluate cTnI in heparinized plasma at more frequent intervals        than most rapid rule-out or rule-in protocols from ED subjects who: 1) are experiencing        signs and symptoms consistent with ACS or ischemic heart disease in the ED, 2) have their        initial ECG analysis performed in the ED, and 3) are expected to have cTnI measured        serially in the ED.|January 2010|January 8, 2010|April 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00880802||140614|
NCT00880516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16749A|Genetic Factors in Chronic Sinusitis|Genetic Factors in Chronic Sinusitis||University of Chicago|No|Recruiting|April 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1200|Samples With DNA|peripheral blood for DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults with and without chronic sinusitis|August 2015|August 10, 2015|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00880516||140635|
NCT00880828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008WFCRC-02|Comparing Two Different Cervical Collars for the Treatment in Patient With Cervical Radiculopathy and Radicular Pain|A Single-Center, Prospective, Randomized, Active Controlled, Single Blind, Parallel Design, Three Arms Trial Comparing Two Different Cervical Collar Combine With Acetaminophen and Acetaminophen Along for the Treatment in Patient With Cervical Radiculopathy and Radicular Pain||Taipei Medical University WanFang Hospital|No|Active, not recruiting|August 2010|October 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|72|||Both|20 Years|N/A|No|||September 2010|September 23, 2010|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880828||140612|
NCT00853905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-827|Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?|The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery||Wills Eye|No|Completed|February 2009|January 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|21 Years|N/A|No|||March 2016|March 2, 2016|February 27, 2009|No|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT00853905||142650|
NCT00854282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812139R|The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between Clinical Prognosis and Regulatory T Cell Expression|The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between|Tregs|National Taiwan University Hospital|No|Recruiting|January 2009|December 2012|Anticipated|January 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Female|18 Years|80 Years|No|||March 2009|March 2, 2009|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854282||142621|
NCT00846963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC:127|Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates|Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates|URSONEONAT|St. Justine's Hospital|No|Completed|October 2008|March 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|N/A|N/A|No|||September 2013|September 16, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846963||143174|
NCT00846976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6874C00014|Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer|A Treatment Protocol to Monitor the Safety of a 200 mg Daily Dose of Bicalutamide (Casodex) in Patients With Advanced Prostate Cancer||AstraZeneca|No|Completed|December 1994|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Male|18 Years|N/A|No|||January 2015|January 20, 2015|February 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00846976||143173|
NCT00882778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3695|PROPACT: Retrospective Prophylaxis Patient Case Collection|Prophylactic Treatment With Recombinant Factor VIIa (rFVIIa, NovoSeven®) in Haemophilia Patients With Inhibitors|PROPACT|Novo Nordisk A/S|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|86|||Male|N/A|N/A|No|Non-Probability Sample|Haemophilia patients in specialist hospital clinic or private clinic settings|August 2014|August 6, 2014|April 14, 2009|No|Yes||No|May 11, 2011|https://clinicaltrials.gov/show/NCT00882778||140463|
NCT00883051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL MIG-202|Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment|A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine||CoLucid Pharmaceuticals|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|450|||Both|18 Years|65 Years|No|||April 2010|April 22, 2010|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883051||140442|
NCT00847535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006|An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence|Muscle Cell Mediated Therapy for Stress Urinary Incontinence: An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells.||Cook||Completed|September 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|18 Years|N/A|No|||July 2015|July 29, 2015|February 18, 2009|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT00847535||143130|
NCT00881868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10118|Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp|A Multi-Center, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Clobetasol Propionate Spray Versus Vehicle for the Management of Moderate to Severe Plaque Psoriasis of the Scalp||Galderma Laboratories, L.P.|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|April 13, 2009|Yes|Yes||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00881868||140532|
NCT00881881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-102388|Study Evaluating the Clinical and Therapeutic Management of Rheumatoid Arthritis in Spain|Clinical and Therapeutic Management of the Rheumatoid Arthritis in Spain||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|360|||Both|18 Years|N/A|No|Probability Sample|Patients with early RA and established RA treated in Rheumatology units in a real-world        setting|April 2009|April 14, 2009|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881881||140531|
NCT00881296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hamamatsu 20-34|Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer|Randomized Phase II Study of Biweekly Chemotherapy With Gemcitabine and Carboplatin in Elder Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer|GEEP|Hamamatsu University|Yes|Completed|March 2008|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|76 Years|N/A|No|||May 2010|September 5, 2011|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881296||140576|
NCT00882505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU8461|Comparison of 25-hydroxy Vitamin D Level in Caucasian Women Receiving Vitamin D Supplementation and Not Receiving Supplementation: a Randomized Controlled Trial.|Comparison of 25-hydroxy Vitamin D Level in Caucasian Women Receiving Vitamin D Supplementation and Not Receiving Supplementation: a Randomized Controlled Trial.||Northwestern University|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|67|||Female|18 Years|47 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882505||140484|
NCT00882518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00008|Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients|A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode|ESPRIT|AstraZeneca|No|Completed|April 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|388|||Both|18 Years|65 Years|No|||April 2012|April 16, 2012|April 14, 2009|Yes|Yes||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00882518||140483|
NCT00883168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP4006|A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1791|||Both|12 Years|N/A|No|||June 2013|June 17, 2013|April 16, 2009|Yes|Yes||No|May 21, 2012|https://clinicaltrials.gov/show/NCT00883168||140433|
NCT00878891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2007/01|Real-time Continuous Glucose Monitoring in Diabetic Cardiothoracic Surgery Patients|Real Time Continuous Glucose Monitoring With Glucoday® as an Assistant for Intensive Insulin Therapy in Diabetic Cardiothoracic Surgery Patients: a Randomized Study Comparing Blood Glucose Measurements Alone or Associated to Continue Glucose Monitoring|MARGE|University Hospital, Bordeaux|No|Terminated|April 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|45|||Both|20 Years|80 Years|No|||July 2015|July 30, 2015|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878891||140758|
NCT00879411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.582|Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients|24h BP Under Micardis in Daily Practice||Boehringer Ingelheim||Completed|April 2009|||January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|670|||Both|18 Years|95 Years|No|Non-Probability Sample|hypertensive patients|February 2014|February 28, 2014|April 9, 2009||||No|January 18, 2012|https://clinicaltrials.gov/show/NCT00879411||140718|
NCT00879424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeDAR-01|Vitamin D Supplementation in Childhood Atopic Dermatitis|Randomized Trial of Vitamin D Supplementation in Winter-related, Childhood Atopic Dermatitis||Massachusetts General Hospital|No|Completed|February 2009|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|2 Years|17 Years|No|||December 2013|December 16, 2013|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879424||140717|
NCT00879684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1131002|Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors||Pfizer|No|Completed|January 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|April 9, 2009|No|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT00879684||140698|Designation of outcomes as primary, secondary was based on study team’s input as study did not specify them as primary or secondary.
NCT00879892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT2009-009505-25|Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients|Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients|Xe-hypotheca|Turku University Hospital|Yes|Completed|May 2009|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|80 Years|No|||January 2015|January 16, 2015|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00879892||140682|
NCT00879905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSP990A2101|A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors|A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally in Adult Patients With Advanced Solid Malignancies||Novartis||Completed|May 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|April 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879905||140681|
NCT00879879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0108 Pilot|Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis|Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project||University of South Florida|Yes|Completed|March 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|N/A|No|||August 2013|August 9, 2013|April 10, 2009|No|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00879879||140683|
NCT00880178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630|Plaque Inflammation and Dysfunctional HDL Cholesterol in Participants Receiving Niacin and Statins in the AIM-HIGH Study (The HDL Proteomics Study)|Plaque Inflammation and Dysfunctional HDL in AIM-HIGH|HDL Proteomics|University of Washington|Yes|Completed|May 2008|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|324|Samples Without DNA|Plasma for HDL isolation|Both|45 Years|N/A|No|Probability Sample|Participants in the main AIM-HIGH study (NCT00120289)|December 2012|December 18, 2012|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880178||140660|
NCT00880191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N08C3|Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy|Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy||Alliance for Clinical Trials in Oncology|No|Completed|April 2009|May 2015|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|430|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|April 10, 2009|Yes|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT00880191||140659|
NCT00880854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO08807|Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer|Phase I Dose-escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) for Patients With BCG-resistant Localized Transitional Cell Carcinoma of the Bladder||University of Wisconsin, Madison|Yes|Withdrawn|June 2009|||February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|April 13, 2009|No|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00880854||140610|
NCT00881101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS- PH I -01-2009|Clinical Study of Liposomal Paclitaxel in Chinese Patients|Dose Escalation Study of Liposomal Paclitaxel in Chinese Patients With Advanced Solid Tumors||Nanjing Sike Pharmaceutical Co., Ltd.|No|Active, not recruiting|April 2009|December 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||April 2009|April 14, 2009|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881101||140591|
NCT00881426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA17499|To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fasting Conditions||Sandoz||Completed|March 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|54 Years|Accepts Healthy Volunteers|||April 2009|April 15, 2009|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881426||140566|
NCT00854295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-100|Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee|Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee||Zimmer, Inc.|No|Active, not recruiting|April 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00854295||142620|
NCT00879801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENFIEV|Genetic Physiopathology and Evolution of Type 2 Diabetes|Evaluation of Genetic, Biochemical and Clinical Determinants of Type 2 Diabetes Progression in Subjects at High Risk|GENFIEV|University of Pisa|Yes|Completed|January 2003|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1017|Samples With DNA|Serum and plasma sample, DNA|Both|30 Years|65 Years|No|Probability Sample|Subjects will be recruited from outpatients diabetic units located in different areas of        Italy.|April 2009|April 9, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879801||140689|
NCT00847275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/12-K|Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)|Behaviour and Cognitive Evaluation for Dialysis Elderly Patients|BCDE|Nantes University Hospital|Yes|Recruiting|July 2008|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Both|75 Years|N/A|No|||January 2010|January 25, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00847275||143150|
NCT00880373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 07/48/01|Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine|An Evaluation of the Effectiveness of Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease: a Double-blind, Placebo-controlled Randomised Trial|SWIM|London North West Healthcare NHS Trust|Yes|Terminated|March 2011|August 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|320|||Both|16 Years|N/A|No|||December 2012|December 3, 2012|April 9, 2009||No|The funding withdrawal and early termination of the trial is based upon lack of suitable    recruitment figures in order to reach the required trial endpoints.|No||https://clinicaltrials.gov/show/NCT00880373||140645|
NCT00881556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD5420|Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)|A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)|RDEB|Columbia University|Yes|Active, not recruiting|March 2009|July 2014|Anticipated|June 2014|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|21 Years|No|||February 2012|February 14, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881556||140556|
NCT00881569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-U102E|Extended Use Protocol for Subjects With Cancer to Receive Continued Treatment With CS-7017|Extended Use of CS 7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Subjects With Cancer||Daiichi Sankyo Inc.|No|Completed|March 2009|September 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||September 2012|September 5, 2012|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881569||140555|
NCT00881894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0951|Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.|Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm^2) From 2 Different Manufacturing Processes||UCB Pharma|No|Completed|October 2008|December 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|52|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|October 17, 2014|April 13, 2009|No|Yes||No|November 20, 2009|https://clinicaltrials.gov/show/NCT00881894||140530|
NCT00882180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-VSP02-001|Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement|A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients With Advanced Solid Tumors With Liver Involvement||Alnylam Pharmaceuticals|No|Completed|March 2009|August 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|April 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882180||140508|
NCT00882531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISOROS|Isotretinoin in Papular-Pustular Rosacea|Evaluation of the Efficacy of Isotretinoin Versus Placebo in Terms of Response Rate Among Patients Presenting Papular-pustular Rosacea Resistant to Standard Therapy|ISOROS|Laboratoires Bailleul-Biorga|Yes|Completed|February 2007|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||November 2009|November 16, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882531||140482|
NCT00882544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-112|Prospective Pediatric Pyeloplasty Robotic Surgical Database|Prospective Pediatric Pyeloplasty Robotic Surgical Database||Connecticut Children's Medical Center|No|Recruiting|March 2009|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|18 Years|No|Non-Probability Sample|Children 0-18 years of age who receive a robotic pyeloplasty procedure at Connecticut        Children's Medical Center|February 2012|February 9, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882544||140481|
NCT00882557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-RENID-08-06|Study to Evaluate Daptomycin Given During Dialysis and After Dialysis|A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis||Cubist Pharmaceuticals LLC|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|April 15, 2009|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00882557||140480|
NCT00879164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000640197|Stellate Ganglion Nerve Block in Treating Women With Hot Flashes|Pilot Evaluation of a Stellate Ganglion Block for the Treatment of Hot Flashes||Mayo Clinic|Yes|Completed|April 2009|December 2010|Actual|December 2010|Actual|Phase 0|Interventional|Primary Purpose: Supportive Care|||Anticipated|10|||Female|18 Years|N/A|No|||October 2014|October 15, 2014|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879164||140737|
NCT00879437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24549|Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma|A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas||Baylor College of Medicine|Yes|Active, not recruiting|July 2009|May 2019|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|3 Years|21 Years|No|||January 2016|January 20, 2016|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879437||140716|
NCT00879450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-08-035|Evaluating the Impact of a New Complement to Physiotherapy Intervention for Positional Torticollis in Infants|Evaluating the Impact of a New Complement to Physiotherapy Intervention for Positional Torticollis in Infants||McGill University Health Center|Yes|Terminated|May 2009|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|6 Months|No|||July 2011|July 19, 2011|April 7, 2009||No|Clinical department where study was held was unable to continue collaboration|No||https://clinicaltrials.gov/show/NCT00879450||140715|
NCT00879697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44444|Strength Training in Walking Tolerance in Intermittent Claudication Patients|Effects of Strength Training and Walking Training on Physical Fitness of Patients With Intermittent Claudication||University of Sao Paulo|Yes|Completed|July 2005|December 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|50 Years|85 Years|No|||April 2009|April 9, 2009|January 27, 2009||No||No|January 27, 2009|https://clinicaltrials.gov/show/NCT00879697||140697|Our sample was composed of patients with many diseases and taking different medications.
NCT00879918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00208|Pharmacogenetics of Nicotine Metabolism in African-Americans|Pharmacogenetics of Nicotine Metabolism in African-Americans|5075-AAPK1|University of California, San Francisco|No|Completed|December 2008|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|April 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879918||140680|
NCT00879931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/031|Influence of Corticoids on Renal Function in Cardiac Surgery|Influence of Corticoids on Renal Function in Cardiac Surgery||University Hospital, Ghent|No|Recruiting|January 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|80 Years|No|||December 2014|December 4, 2014|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00879931||140679|
NCT00880204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT2008|Evaluation of Essential Surgical Skills-Emergency Maternal and Child Health (ESS-EMCH) Training by Assessing the Doctors' Practices|Evaluation of Essential Surgical Skills-Emergency Maternal and Child Health (ESS-EMCH) Training by Assessing the Doctors' Practices in Pakistan||Child Advocacy International|Yes|Recruiting|May 2009|November 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|24|||Both|N/A|N/A|No|||May 2009|May 13, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00880204||140658|
NCT00880217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015964|A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|May 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|430|||Both|18 Years|55 Years|No|||February 2013|February 27, 2013|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880217||140657|
NCT00880230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-999|Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)|INTENSE: Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent|INTENSE|Medtronic Endovascular|Yes|Completed|March 2009|December 2012|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 10, 2009|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT00880230||140656|
NCT00880529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-118|Pain Relief for Ventilated Patients With Multiple Rib Fractures Using the ON-Q Pain Relief System|Does Continuous Subcutaneous Paravertebral Infusion of Bupivicaine With the ON-Q Pain Relief System vs. Standard IV Pain Management Decrease Ventilator Dependence in Trauma Patients With Multiple Rib Fractures|ON-Q|The Cooper Health System|No|Terminated|February 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|April 10, 2009|Yes|Yes|low enrollment, 2 pts enrolled no data every analyzed investigator left the institution|No||https://clinicaltrials.gov/show/NCT00880529||140634|
NCT00880841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-A93-AU|A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone|A Single-Dose, 1-Period, 1-Treatment Pilot Study of an Investigational Capsule Formulation of 2 mg/.05 mg Buprenorphine/Naloxone Under Fasting Conditions||Nanotherapeutics, Inc.|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|healthy normals between the ages of 18 and 55 (inclusive)|April 2015|April 13, 2015|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880841||140611|
NCT00880867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVCI-0838|Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma|A Phase I Study of Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma||Nevada Cancer Institute|Yes|Terminated|April 2009|April 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|April 10, 2009|No|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT00880867||140609|
NCT00880880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS17028|Improving Women's Health by Using an Electronic Pelvic Floor Questionnaire|Improving the Assessment of Women's Health Through the Use of a Computerized Pelvic Floor Questionnaire||University of Wisconsin, Madison|No|Completed|August 2007|||August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|284|||Female|40 Years|N/A|Accepts Healthy Volunteers|||April 2009|October 1, 2015|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880880||140608|
NCT00880893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD28|Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore|Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore||Sanofi|Yes|Completed|April 2009|June 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1198|||Both|2 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880893||140607|
NCT00881114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGx-SELECT|Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer|A Prospective Phase II Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer|PGx-SELECT|Georgetown University|Yes|Withdrawn|April 2009|June 2013|Anticipated|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2009|March 26, 2015|April 13, 2009|Yes|Yes|Investigator decided it was not feasible to conduct this study|No||https://clinicaltrials.gov/show/NCT00881114||140590|
NCT00881127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-983|To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release Tablets Under Fasting Conditions||Sandoz||Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|24 Years|54 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|April 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881127||140589|
NCT00854308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAM4558g|A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Activity of MetMAb, a Monovalent Antagonist Antibody to the Receptor Met, Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)||Genentech, Inc.||Completed|April 2009|January 2012|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|February 27, 2009|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT00854308||142619|
NCT00880386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0208|Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer|A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients With Non-Small Cell Lung Cancer||University of South Florida|No|Withdrawn|March 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|May 21, 2013|April 10, 2009||No|Study concept was not approved by NCI. Study was never activated. No enrollment|No||https://clinicaltrials.gov/show/NCT00880386||140644|
NCT00880100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT12CF08-01|Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)|Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old||Forest Laboratories|Yes|Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|2 Years|6 Years|No|||February 2015|February 17, 2015|April 9, 2009|Yes|Yes||No|March 5, 2014|https://clinicaltrials.gov/show/NCT00880100||140666|
NCT00880698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1072|Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers|Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|202|||Both|N/A|14 Weeks|Accepts Healthy Volunteers|||July 2015|July 17, 2015|April 10, 2009|Yes|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT00880698||140621|The study was closed to enrollment prematurely so statistical power to detect differences was reduced.
NCT00881023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CAIS-05|Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration|A Multicenter, Randomized, Pivotal Study to Evaluate the Safety and Efficacy of the Cartilage Autograft Implantation System (CAIS) for the Surgical Treatment of Articular Cartilage Lesions of the Knee|CAIS|DePuy Mitek|No|Completed|July 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|55 Years|No|||February 2015|February 26, 2015|April 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881023||140597|
NCT00881582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMH-01-09|Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients|Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients||King Abdulaziz Medical City|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|68 Years|No|||September 2012|September 13, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881582||140554|
NCT00881595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0803-SA02|Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas|A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas|SA02|University of Florida|Yes|Withdrawn|February 2009|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|55 Years|N/A|No|||March 2016|March 3, 2016|April 13, 2009||No|No patients accrued since study opened|No||https://clinicaltrials.gov/show/NCT00881595||140553|
NCT00881907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090152H|Tissue Characterization in Teeth Treated With a Regeneration Protocol|Tissue Characterization in Teeth Treated With a Regeneration Protocol||The University of Texas Health Science Center at San Antonio|Yes|Completed|March 2010|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|1|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881907||140529|
NCT00881920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23574-CHARKALL|Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL|Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With CLL, B-Cell Lymphoma or Multiple Myeloma|CHARKALL|Baylor College of Medicine|Yes|Active, not recruiting|July 2009|July 2034|Anticipated|July 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881920||140528|
NCT00882193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133-09|Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers|Pilot Therapy Using Betaine in Combination With Peginterferon Alpha-2a Plus Ribavirin in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Pegylated Interferon and Ribavirin||University of Nebraska|Yes|Terminated|May 2009|May 2011|Actual|May 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|N/A|No|||August 2011|August 8, 2011|April 15, 2009|Yes|Yes|new medications with improved response released, nonaccrual|No||https://clinicaltrials.gov/show/NCT00882193||140507|
NCT00882570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50040|To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 250mg/5 ml Cefdinir (Test Formulation) and Omnicel 250mg/5 ml Powder For Oral Suspension (Reference Formulation) Each Given as a Single Oral Dose to Forty Healthy Male and/or Female Volunteers in the Fasting State||Sandoz||Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|56 Years|Accepts Healthy Volunteers|||April 2009|April 15, 2009|April 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882570||140479|
NCT00882882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B013701|To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions|A Relative Bioavailability Study of Metformin HCL 500 mg XR Tablets Under Fasting Conditions||Sandoz||Completed|June 2001|June 2001|Actual|June 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||April 2009|April 16, 2009|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882882||140455|
NCT00882895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0042 / 201101864|Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma|Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma||Washington University School of Medicine|No|Recruiting|May 2009|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|70 Years|No|||January 2016|January 14, 2016|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882895||140454|
NCT00879177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-218|Smoking Study With Behavioral Therapy for Hypertensive Patients|Contingency Management for Initiating Smoking Abstinence in Patients With Hypertension|VANQUISH|University of Connecticut Health Center|No|Active, not recruiting|April 2009|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879177||140736|
NCT00879463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH 1969 TT|Brain Tissue Oxygen Saturation and Blood Transfusion in Cardiac Surgery|The Impact of Brain Tissue Oxygen Saturation Monitoring in Reducing the Use of Red Blood Cells in Cardiac Surgery|INVOS|Larissa University Hospital|No|Completed|June 2009|April 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|150|||Both|N/A|N/A|No|||July 2012|July 24, 2012|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879463||140714|
NCT00879710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00002485|Effect of Diabetes Mellitus on Cholesterol Metabolism|Effect of Diabetes Mellitus on Cholesterol Absorption, Synthesis and Statin Efficacy||Medical College of Wisconsin|No|Completed|August 2008|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879710||140696|
NCT00879957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090136H|Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates|Comparison of Heparin vs. no Heparin on Duration of Peripherally Inserted Central Catheter Patency in Neonates||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|January 2010|May 2011|Actual|March 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|N/A|1 Year|No|||April 2015|April 14, 2015|March 26, 2009||No|A study was published regarding the same question this study had.|No||https://clinicaltrials.gov/show/NCT00879957||140677|
NCT00879944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-2009-13793|Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index|Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis||Northwestern University|Yes|Completed|May 2009|July 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|409|||Both|5 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|1. Children ages 5 to 17 years old with either moderate or severe plaque type psoriasis          2. Children ages 5 to 17 years old with moderate or severe atopic dermatitis          3. Children ages 5 to 17 years old seen in dermatology clinic who are healthy and             without a systemic disorder.|April 2015|April 10, 2015|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00879944||140678|
NCT00880243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFA 9802|Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)|Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML||Acute Leukemia French Association|Yes|Completed|March 1999|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|473|||Both|15 Years|50 Years|No|||April 2009|April 10, 2009|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00880243||140655|
NCT00880542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633030|Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery|A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma||Jonsson Comprehensive Cancer Center|Yes|Terminated|August 2008|||November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|April 10, 2009|Yes|Yes|The study lost funding.|No|April 13, 2011|https://clinicaltrials.gov/show/NCT00880542||140633|This study lost funding and was not able to enroll enough participants to do a complete review.
NCT00880906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080741|Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis|Prospective, Single-Blinded, Randomized Controlled Trial With Sham Comparing Standard Therapy With or Without Esophageal Dilatation in Patients With Eosinophilic Esophagitis|EOE|Vanderbilt University|No|Completed|August 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||July 2013|April 29, 2014|August 25, 2008||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00880906||140606|
NCT00881140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bp001|Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids|The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa)||BioPro Medical Ltd|No|Completed|April 2009|July 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|30 Years|53 Years|No|||December 2012|December 18, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881140||140588|
NCT00881153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA17502|To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb Company (Cefzil) 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose In Healthy Adults Volunteers Under Fasting Conditions.||Sandoz||Completed|May 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881153||140587|
NCT00854581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070805|Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma|Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b||University of Miami|Yes|Terminated|November 2007|||November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|120 Years|No|||November 2015|November 23, 2015|February 28, 2009|No|Yes|Investigator Decision|No|December 22, 2014|https://clinicaltrials.gov/show/NCT00854581||142598|
NCT00854022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17150|Genetic Susceptibility to Kidney Cancer|Genetic Susceptibility to Renal Cell Carcinoma||Baylor College of Medicine|No|Recruiting|July 2008|July 2014|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1600|Samples With DNA|We will utilize the blood collected to run several laboratory analyses that will assess DNA      damage/repair, telomere length, telomerase activity, and other genetic instability as      predictors of RCC risk. All information linking this unique identifier to the participant      will be kept in a secure location under lock-and-key password protected.      In addition, RCC tumor and adjacent normal tissue samples may be obtained from the MDACC      Institutional Tissue Bank (ITB) for cases only. The samples obtained will be left over from      surgical procedures, so as to prevent any additional distress to the patient.|Both|18 Years|N/A|No|Probability Sample|Adult patients with newly diagnosed (diagnosed within the year of enrollment) with        possible Renal Cell Carcinoma (RCC)|December 2010|December 2, 2010|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00854022||142641|
NCT00881036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV from anti-HBc positive|Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients|Activation of HBV Under Immunosuppression in HBsAg-negative But Anti-HBc-positive Patients With Hematological Malignancies||Kyoto University|No|Completed|August 2006|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Probability Sample|HBsAg-negative but anti-HBc-positive patients with hematological malignancies treated at        Kyoto University Hospital|September 2015|September 2, 2015|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00881036||140596|
NCT00881335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDC12007211-O|Implemental Flutter Mucus Clearance Devices on Geriatric Lung Function|Implemental Flutter Mucus Clearance Devices on Geriatric Lung Function||Tongji University|Yes|Completed|April 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|60|||Both|85 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 25, 2012|April 14, 2009||No||No|June 17, 2009|https://clinicaltrials.gov/show/NCT00881335||140573|
NCT00880711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OAT-FAS-2009/1|Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)|Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer|FIONA|AstraZeneca|No|Completed|April 2009|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|57|||Female|N/A|N/A|No|Non-Probability Sample|Hospitals, office based specialists|November 2011|November 29, 2011|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880711||140620|
NCT00881348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04680|Dermacyd Infantile (Lactic Acid) - Photo Evaluation.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Infantile (Lactic Acid).||Sanofi||Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00881348||140572|
NCT00881361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z1071|Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer|A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women With Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|July 2009|||March 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|756|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881361||140571|
NCT00881608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-010|Study to Evaluate Menses Induction in Women Administered Proellex|An Open-Label, Escalating Dose, Single Center, Cross-over Design, Phase I Study to Evaluate Menses Induction in Women Administered Proellex||Repros Therapeutics Inc.|No|Terminated|February 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|11|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|April 14, 2009|Yes|Yes|Repros stopped study for safety and the FDA put the study on hold for safety.|No|June 26, 2014|https://clinicaltrials.gov/show/NCT00881608||140552|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00881621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011438|Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer|Phase II Study of Lapatinib and Capecitabine in 2nd Line Treatment of Locally Advanced/Metastatic Pancreatic Cancer||Georgetown University|Yes|Terminated|August 2009|June 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||March 2014|March 23, 2014|April 13, 2009|Yes|Yes|slow enrollment|No||https://clinicaltrials.gov/show/NCT00881621||140551|
NCT00882908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015799|A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin In Treatment-Naive Genotype 1 Hepatitis C-Infected Subjects|PILLAR|Tibotec Pharmaceuticals, Ireland|Yes|Completed|June 2009|April 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|386|||Both|18 Years|70 Years|No|||May 2014|May 19, 2014|April 16, 2009|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00882908||140453|
NCT00882206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS112|Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment|A Therapeutic Trial of Decitabine (Dacogen) and Vorinostat (SAHA) in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) MT2008-29R||Masonic Cancer Center, University of Minnesota|Yes|Completed|April 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|2 Years|60 Years|No|||January 2013|January 24, 2013|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882206||140506|
NCT00882219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|330704|Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period|XERES Trial: Clinical Evaluation of Patients With Everolimus-eluting Stent " Xience V® " Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period|XERES|Abbott Vascular|No|Completed|March 2009|July 2012|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00882219||140505|
NCT00878904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000639080|Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors|A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies||University of California, San Francisco|Yes|Active, not recruiting|June 2009|April 2015|Anticipated|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878904||140757|
NCT00879190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03192009-2018|Comparison of Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial|Comparison of Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial||Stanford University||Suspended|May 2009|May 2014|Anticipated|May 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|282|||Female|18 Years|55 Years|No|||September 2012|September 25, 2012|April 7, 2009||No|We are currently performing and interim analysis for possible neonatal organism resistance to    antibiotic regimens.|No||https://clinicaltrials.gov/show/NCT00879190||140735|
NCT00879723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-SIUSOM-09-002-1|Burn Micronutrient Repletion Pilot Study|Burn Micronutrient Repletion Pilot Study: Characterizing Relationships Between Vitamin and Mineral Supplementation and Health Outcomes of Adult Burn Patients||Southern Illinois University|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|19 Years|N/A|No|||August 2015|August 25, 2015|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879723||140695|
NCT00879970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111960|Thiazolidinedione Intervention With Vitamin D Evaluation|Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease|TIDE|GlaxoSmithKline|Yes|Terminated|May 2009|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1332|||Both|50 Years|N/A|No|||July 2013|April 9, 2015|April 2, 2009|Yes|Yes|FDA has placed the trial on full clinical hold.|No|November 10, 2011|https://clinicaltrials.gov/show/NCT00879970||140676|
NCT00880269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2213|Efficacy and Safety of Panobinostat (LBH5789) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)|A Phase II Study of Oral Single Agent Panobinostat in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)||Novartis|No|Completed|August 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|85 Years|No|||April 2013|April 18, 2013|March 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880269||140653|
NCT00880256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013|Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data|Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data||Seattle Institute for Biomedical and Clinical Research|No|Completed|September 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Male|18 Years|N/A|No|||January 2012|January 20, 2012|April 10, 2009||No||No|November 25, 2011|https://clinicaltrials.gov/show/NCT00880256||140654|
NCT00880555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6553-W|Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)|Semantic Memory, Financial Capacity and Brain Perfusion in MCI|CASL|VA Office of Research and Development|No|Completed|April 2009|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|78|None Retained|N/A- no biospecimens|Both|50 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|160 subjects are anticipated, with the expectation that initial cognitive evaluations will        exclude about 60 subjects. We intend to maintain and follow 100 subjects, 40 with        non-dementia memory impairment (meeting criteria for amnestic MCI) and 40 with no        cognitive impairment, and 20 with mild Alzheimer disease|February 2016|February 24, 2016|April 10, 2009||No||No|November 10, 2015|https://clinicaltrials.gov/show/NCT00880555||140632|This trial did not involve an intervention. Technical problems limited the analysis of the MRI scans. Lack of a designated rater for the study negatively impacted participant retention.
NCT00881166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-0470-02|Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors|Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens|SGI-0470-02|Astex Pharmaceuticals|No|Completed|November 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|101|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881166||140586|
NCT00881179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B013721|To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions||Sandoz||Completed|May 2002|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||April 2009|April 15, 2009|April 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881179||140585|
NCT00881751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101282|Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer|A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)||Medical University of South Carolina|Yes|Active, not recruiting|March 2009|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|116 Years|No|||October 2015|October 14, 2015|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881751||140541|
NCT00880724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-01576 AD|European Multi-Center Post Market Study of the IBV Valve System|European Post Market Study: A Prospective, Randomized, Controlled, Multicenter Study to Evaluate the Performance of the IBV Valve System for the Treatment of Severe Emphysema|IBV|Spiration, Inc.|No|Active, not recruiting|March 2007|June 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|40 Years|74 Years|No|||June 2009|June 25, 2009|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880724||140619|
NCT00880737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS 2008|Prognostic Value of Computed Tomography (CT) Scan in Hemodynamically Stable Patients With Acute Symptomatic Pulmonary Embolism||PROTECT|Carlos III Health Institute|Yes|Completed|February 2009|||June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|850|||Both|18 Years|N/A|No|Non-Probability Sample|Hemodynamically stable outpatients with suspicion of pulmonary embolism, confirmed by        objective testing|February 2010|June 14, 2011|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880737||140618|
NCT00880750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-127|Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults|A Phase I Pharmacodynamic Equivalence Study Comparing Urinary Phosphate Excretion and Plasma Lanthanum Pharmacokinetics for a Lanthanum Carbonate Granule Formulation and Chewable Tablets Administered to Healthy Adult Subjects||Shire|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|March 3, 2015|April 13, 2009|No|Yes||No|February 19, 2010|https://clinicaltrials.gov/show/NCT00880750||140617|
NCT00881049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BCN19T|Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma|Phase II Trial of Imatinib(Gleevec®) in Selected Patients With Metastatic Melanoma||Peking University|No|Completed|December 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|18 Years|85 Years|No|||January 2011|January 14, 2011|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00881049||140595|
NCT00881374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04679|Dermacyd Infantile (Lactic Acid)- Compatibility.|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermic Irritability, Dermic Sensitivity) of Dermacyd Infantile (Lactic Acid).||Sanofi||Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00881374||140570|
NCT00882583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J08101|A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC|A Phase I/II Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in Locally Advanced Squamous Cell Carcinoma of Head and Neck (HNSCC)|Dasatinib|Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|June 2009|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882583||140478|
NCT00882921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-ELA-042|An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients|A Multi-Center Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients Enrolled in the Hunter Outcome Survey (HOS) Receiving Idursulfase Enzyme Replacement Therapy||Shire|No|Completed|October 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|Blood and urine|Male|5 Years|N/A|No|Non-Probability Sample|Patients with Hunter syndrome|July 2014|August 4, 2014|April 16, 2009|Yes|Yes||No|June 23, 2014|https://clinicaltrials.gov/show/NCT00882921||140452|
NCT00882232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080064|Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer|Transperineal Injection of Cross-linked Hyaluronan Gel Into Anterior Perirectal Fat to Reduce Rectal Toxicity From High Dose Rate Brachytherapy and/or Intensity-Modulated Radiation Therapy for Prostate Cancer||Cancer Center of Irvine|Yes|Completed|September 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||February 2013|February 14, 2013|April 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882232||140504|
NCT00878930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OAR-FAS-2008/1|Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer|Non-interventional Report on Parameters of Acceptability, Efficacy and Compliance of Fulvestrant in Post-menopausal Patients With Advanced Breast Cancer HR Positive Who Progresses to One Prior Endocrine Therapy With Antiestrogens|FRAME|AstraZeneca|No|Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Post-menopausal women with advanced breast cancer hormone receptor-positive who have        progressed to a one prior hormone therapy.|January 2011|January 4, 2011|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878930||140755|
NCT00878943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481269|Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study|A Local, Multi-centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study In India Or Ongoing In A1481269 Study Who Continue To Receive Benefit From Sildenafil Therapy.|UK 92480|Pfizer||Temporarily not available|April 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Expanded Access|N/A|||||||Both|18 Years|100 Years|No|||January 2016|January 25, 2016|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878943||140754|
NCT00879203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1258|Glycemic Control, Brain Structure and Cognition in Youth With Type 1 Diabetes (T1DM)|Glycemic Control, Brain Structure and Cognition in Youth With T1DM|LO5/HY5|Washington University School of Medicine|No|Recruiting|November 2008|November 2016|Anticipated|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|285|||Both|7 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|LO5: Youth with type 1 diabetes (T1DM) between the ages of 7-16 who have been diagnosed        within the previous 3 months. Non-diabetic siblings of the participants with T1DM aged        7-16 years old.        HY5: Youth and young adults (ages 9-21) who have already completed an earlier study with        the lab.|January 2016|January 7, 2016|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00879203||140734|
NCT00879996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD0350908A|Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients|A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients||State University of New York at Buffalo|No|Completed|April 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 3, 2012|April 10, 2009||No||No|March 21, 2012|https://clinicaltrials.gov/show/NCT00879996||140674|small subject number not a double-blind study
NCT00880009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A6-2207|Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer|A Phase 2, Randomized, Open-Label Study Of Bosutinib Administered In Combination With Letrozole Versus Letrozole Alone As First Line Therapy In Post-Menopausal Women With Locally Advanced Or Metastatic ER+/PgR+/ErbB2- Breast Cancer||Pfizer|No|Terminated|July 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|N/A|No|||October 2012|October 4, 2012|April 8, 2009|Yes|Yes|See termination reason in detailed description.|No|October 4, 2012|https://clinicaltrials.gov/show/NCT00880009||140673|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.
NCT00880282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01910|Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment|A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|April 2009|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|1 Year|21 Years|No|||April 2013|April 28, 2014|April 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880282||140652|
NCT00880594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0013|Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine|The Modulation of Cerebral Pain Responses Using Desipramine in the Treatment of Irritable Bowel Syndrome (IBS)||Washington University School of Medicine|No|Recruiting|February 2009|||February 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||March 2010|March 15, 2010|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880594||140629|
NCT00880945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-no-emn|Conventional Bronchoscopy Plus Rose Versus Electromagnetic Navigation (EMN) Plus Rose in Small Peripheral Lesions|Comparison of the Electromagnetic Navigation System and Rapid on Site Evaluation Versus Conventional Bronchoscopy and Rapid on Site Evaluation: Improved Yield in Small Peripheral Lung Lesions(Original Investigation)||Azienda Ospedaliero Universitaria Maggiore della Carita|No|Not yet recruiting|May 2009|May 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with peripheral lesion suitable for surgery who need preoperative diagnosis will        be studied, at first, with conventional bronchoscopy under fluoroscopic guidance. In case        of non diagnostic procedure they will be candidates for ENB. All the patients will be        candidates to surgical procedure in case of malignant lesions.|April 2009|April 13, 2009|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880945||140603|
NCT00880568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1496-002|Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)|A Phase I Dose Escalation Study of MK1496 in Patients With Advanced Solid Tumor||Merck Sharp & Dohme Corp.|No|Completed|April 2009|January 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|27|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|April 10, 2009|No|Yes||No|September 25, 2012|https://clinicaltrials.gov/show/NCT00880568||140631|
NCT00880581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0064|A Phase II Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas|A Phase II Study of Intratumoral Injection PF-3512676 in Combination With Local Radiation in Low-Grade B-Cell Lymphomas||Stanford University|Yes|Active, not recruiting|January 2009|September 2013|Anticipated|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2012|December 30, 2012|April 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880581||140630|
NCT00880919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709M16844|Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)|Seroquel XR for the Management of Borderline Personality Disorder (BPD)||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|June 2008|December 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|45 Years|No|||February 2013|February 1, 2013|April 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880919||140605|
NCT00880932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803787|Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert|The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID||University of Pennsylvania|No|Completed|August 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|1865|||Both|N/A|N/A||||April 2009|April 13, 2009|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880932||140604|
NCT00880412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHT0202/002|A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease|A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)|EHT0202/002|Exonhit|Yes|Completed|April 2008|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|197|||Both|60 Years|90 Years|No|||September 2009|September 18, 2009|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880412||140642|
NCT00880425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/CDH/01|Do Patients With Chronic Daily Headache Have Continuous Headache or Moments of Headache Relief?|Do Patients With Chronic Daily Headache Have Continuous Headache or Moments of Headache Relief?||Thomas Jefferson University|No|Completed|April 2009|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Headache clinic patients with diagnosis of Chronic Migraine, New Daily Persistent        Headache, Chronic Tension type headache, or chronic post traumatic headache, over age 18.|January 2011|January 4, 2011|April 10, 2009||No||No|October 22, 2010|https://clinicaltrials.gov/show/NCT00880425||140641|
NCT00880763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-016|A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)|A Phase II Randomized Placebo-controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Japanese Treatment-Experienced Patients With Chronic Hepatitis C Infection||Merck Sharp & Dohme Corp.|No|Completed|April 2009|February 2012|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|90|||Both|20 Years|64 Years|No|||December 2015|December 22, 2015|April 10, 2009|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00880763||140616|
NCT00880789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23668-ACT CAT|Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus|Adoptive Transfer of Cord Blood T Cells To Prevent and Treat CMV and Adenovirus Infections After Transplantation|ACT-CAT|Baylor College of Medicine|Yes|Completed|May 2009|June 2014|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|90 Years|No|||October 2014|October 13, 2014|April 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880789||140615|
NCT00881062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-009|Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose Administration in Healthy Female Subjects||Repros Therapeutics Inc.|No|Completed|April 2009|June 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881062||140594|
NCT00882245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P441201CD|Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis|A Phase II, Double-Blind, Vehicle Controlled Study to Determine the Efficacy, Safety and Toleration of SRD441 Ointment in Patients With Atopic Dermatitis||Serentis Ltd.|No|Completed|April 2009|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||October 2009|October 29, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882245||140503|
NCT00882596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S07-002|Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer Patients|A Multi-Site, Prospective, Non-Randomized Study of the Contura™ Multi-Lumen Balloon (MLB) Catheter to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetry, Local Tumor Control, Cosmetic Outcome, and Toxicity||Cancer Center of Irvine|Yes|Completed|May 2008|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|50 Years|N/A|No|||July 2013|January 26, 2016|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882596||140477|
NCT00882934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAFA06|The Management of Erectile Dysfunction With Placebo Only|A Single-Blind, Controlled, Randomized, Parallel-Group Study of the Efficacy of Patients' Awareness on the Composition of the Experimental Drug in the Treatment of Erectile Dysfunction.|DAFA06|Rio de Janeiro State University|Yes|Completed|October 2006|January 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|123|||Male|18 Years|N/A|No|||April 2009|April 15, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882934||140451|
NCT00882947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14183|Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)|Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)||Bayer|No|Completed|February 2006|September 2008|Actual|September 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|None Retained|n.a.|Both|18 Years|65 Years|No|Non-Probability Sample|Adult Chinese patients (age 18-65 male and female) with Primary Pulmonary Hypertension|April 2009|April 16, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00882947||140450|
NCT00883181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060445|A Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy|A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy||Amgen|No|Completed|December 2007|September 2014|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1370|None Retained|This is an observational study. No bio-specimens are being collected.|Both|18 Years|N/A|No|Probability Sample|Subjects greater than or equal to 18 years old. Subjects with breast, ovarian or lung        cancer. Subjects receiving chemotherapy in any schedule, e.g. dose dense or standard        chemotherapy.        Subjects with Investigator assessed risk of febrile neutropenia (FN) ≥20% (based on 2006        European Organisation for Research and Treatment of Cancer (EORTC) G-CSF Guidelines).        Subjects with concurrent administration of radiotherapy are not eligible (previous        radiotherapy is permitted if terminated at least 2 weeks prior to commencing applicable        chemotherapy in this study).        Written subject consent (where required by local law).|February 2016|February 24, 2016|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883181||140432|
NCT00878956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2007/02808|Bicarbonate in Cardiac Surgery|A Phase IIb Multiple Blind Randomized Controlled Trial of Sodium Bicarbonate in Cardiac Surgery at High-risk of Acute Kidney Injury||Austin Health|Yes|Terminated|April 2009|January 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|427|||Both|70 Years|N/A|No|||July 2012|July 31, 2012|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878956||140753|
NCT00879476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|245_RAMIP_06|Bioequivalence Study of Ramipril 10 mg Capsules Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioavailability Study Comparing Ramipril 10 mg Capsules of OHM Laboratories Inc (a Subsidiary of Ranbaxy Pharmaceuticals Inc) With ALTACE® 10 mg Capsules (Containing Ramipril 10 mg) of King Pharmaceuticals Inc, in Healthy, Adult, Male Human Subjects Under Fasting Condition.||Ranbaxy Inc.|Yes|Completed|January 2007|March 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|68|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2009|April 9, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879476||140713|
NCT00879749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nexvax2-001|Safety Study of Nexvax2 in Subjects With Coeliac Disease|A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet||Nexpep Pty Ltd|No|Completed|April 2009|June 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||April 2011|April 5, 2011|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879749||140693|
NCT00880022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|supp930|Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer|Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer||Vanderbilt University|No|Completed|May 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|21 Years|N/A|No|||September 2012|September 12, 2012|April 10, 2009||No||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00880022||140672|
NCT00880295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24457|Patient Outcomes With Endoscopic Versus Open Carpal Tunnel Release|Endoscopic vs Open Carpal Tunnel Release: Comparison of Patient Satisfaction, Outcomes, and Complications||Penn State University|Yes|Recruiting||||||Phase 2|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|68|||Both|18 Years|75 Years|No|||April 2009|August 4, 2010|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880295||140651|
NCT00880308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225X2101|Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors||Novartis||Completed|March 2009|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||December 2014|December 27, 2014|April 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880308||140650|
NCT00881205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DDE18|Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment|A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase|EXCITING|Novartis||Terminated|April 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|65 Years|No|||March 2012|March 8, 2012|April 14, 2009||No|Termination of study due to low enrollment|No|January 20, 2012|https://clinicaltrials.gov/show/NCT00881205||140583|This study was terminated early due to low recruitment numbers. This study did not have the anticipated 80% power.
NCT00880958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-123|Effects of Supplement Containing Various Probiotics and Fermentation Products on Obesity|Effects of Supplement Containing Various Probiotics and Fermentation Products on Obesity: a Double-Blind, Randomized Controlled Trial||Hiroshima University|No|Completed|March 2009|September 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||October 2009|October 28, 2009|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880958||140602|
NCT00881192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IABPCABG|Perioperative Intra-Aortic Balloon Pump (IABP) in Coronary Artery Bypass Grafting (CABG) Operations in Patients With Severely Depressed Left Ventricular Function|Perioperative IABP in CABG Operations in Patients With Severely Depressed Left Ventricular Function: a Randomized, Controlled Trial||IRCCS Policlinico S. Donato|No|Completed|April 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|160|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881192||140584|
NCT00881764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC8756|PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study|Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study||Columbia University|No|Completed|May 2009|January 2016|Actual|April 2015|Actual|N/A|Observational|N/A||2|Actual|369|||Both|8 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will be a multi-center study based at Columbia University with the following        participating centers: Boston Children's (Harvard University), Children's Hospital of        Philadelphia (University of Pennsylvania), Monroe Carell Children's Hospital (Vanderbilt        University), and Morgan Stanley Children's Hospital of New York (Columbia University).        Children exposed to anesthesia prior to 36 months must be ages 8 yr, 0 mo to 15 yr, 0 mo        and have a sibling with no history of surgery or anesthesia prior to 36 months of age.|February 2016|February 1, 2016|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881764||140540|
NCT00882076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-096|Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias|Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias||Milton S. Hershey Medical Center|Yes|Completed|March 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||December 2014|December 4, 2014|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882076||140516|
NCT00881465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF-09-0155|Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder||University of South Florida|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|April 14, 2009||No||No|April 7, 2015|https://clinicaltrials.gov/show/NCT00881465||140563|Use of a non-active control condition.
NCT00881478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E22161|Family Intervention for Obese Children Using Portion Control Strategy for Weight Control|Family Intervention for Obese Children Using Portion Control Strategy (F.O.C.U.S.) for Weight Control- A Randomized Controlled Trial|FOCUS|University of Calgary|No|Completed|August 2009|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||October 2011|August 29, 2014|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00881478||140562|
NCT00880451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909027|Development and Decline of Brain and Cognition Through the Life Span|Development and Decline of Brain and Cognition Through the Life Span||National Institutes of Health Clinical Center (CC)||Completed|March 2009|||||N/A|Observational|Time Perspective: Retrospective|||||||Both|N/A|N/A|No|||October 2008|April 10, 2009|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880451||140640|
NCT00880464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-216|Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer|A Phase Ib Study of Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete GM-CSF Following Preoperative Chemotherapy in Women With Operable Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2009|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|April 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880464||140639|
NCT00881634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-984|To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release Tablets Under Fed Conditions||Sandoz||Completed|June 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|53 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|April 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881634||140550|
NCT00881647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077667|Treating People With Post-Traumatic Stress Disorder With Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Treatment of Insomnia in Posttraumatic Stress Disorder||University of California, San Francisco|Yes|Completed|November 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||February 2014|February 20, 2014|April 14, 2009||No||No|January 7, 2014|https://clinicaltrials.gov/show/NCT00881647||140549|
NCT00881400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA17503|To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb Company (Cefzil) 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose In Healthy Adults Volunteers Under Fed Conditions||Sandoz||Completed|June 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 15, 2009|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881400||140568|
NCT00881933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPHO-SCT0804|Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)|Phase I/II Study of Fludarabine, Cyclophosphamide Plus TBI Conditioning Regimen for Double Units Cord Blood Transplantation in Severe Aplastic Anemia||The Korean Society of Pediatric Hematology Oncology|Yes|Recruiting|November 2008|September 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|1 Year|21 Years|No|||March 2012|March 23, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881933||140527|
NCT00882258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-003|Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids|A Phase II, Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Selective Progesterone Receptor Modulator Proellex (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata||Repros Therapeutics Inc.|Yes|Completed|March 2006|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|144|||Female|18 Years|50 Years|No|||July 2014|July 3, 2014|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882258||140502|
NCT00882609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMI-2008-01|F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets|18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques||American College of Radiology - Image Metrix|No|Recruiting|January 2009|June 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|550|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882609||140476|
NCT00882960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104904-1|Intranasal Fentanyl for Pain Management|Atomization of Fentanyl: A Randomized Comparison Study of Intranasal Versus Intravenous Fentanyl for Pre-hospital Pain Management||Genesys||Recruiting|April 2009|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|14 Years|N/A|No|||May 2009|May 3, 2011|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882960||140449|
NCT00883194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRF108-POC99-09|A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunteers|A Single-center, Randomized, Placebo-controlled, Double-blind, Single-dose, Efficacy of PRF-108 4% and PRF-110 4% Versus Ropivacaine Solution 0.5% in an Experimental Pain Model||PainReform LTD|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883194||140431|
NCT00878917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOR/2008|Equivalence Study of Dorzolamide 2% Eye Drops Solution|Randomized, Double-Masked, Active Controlled, Crossover Phase III Equivalence Study of Dorzolamide 2% Eye Drops Solution In Subjects With Open Angle Glaucoma Or Ocular Hypertension||Alfred E. Tiefenbacher (GmbH & Co. KG)|Yes|Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2010|February 11, 2010|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878917||140756|
NCT00878969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrinolysis in Dialysis Aim 3|Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3|Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3||Vanderbilt University|Yes|Terminated|January 2010|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 18, 2016|April 8, 2009|Yes|Yes|insufficient enrollment and retention|No|November 20, 2015|https://clinicaltrials.gov/show/NCT00878969||140752|
NCT00878982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTSB001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||February 6, 2013|April 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00878982||140751|
NCT00879983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661179|An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects|An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects||Pfizer|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00879983||140675|
NCT00879515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH077554|Examining Social, Emotional, and Cognitive Functioning in People With Fragile X and Down Syndromes|Genetics and Physiology of Social Anxiety in Fragile X||University of California, Davis|Yes|Completed|October 2005|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|511|Samples With DNA|Saliva samples collected at four time periods|Both|5 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with fragile X syndrome, Down syndrome, the fragile X premutation, and normal        development|March 2013|March 5, 2013|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879515||140710|
NCT00880646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-124|Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity|Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity: a Double-Blind, Randomized Controlled Trial||Hiroshima University|No|Completed|March 2009|October 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2009|October 28, 2009|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880646||140625|
NCT00880659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-004|Bangladesh Secondary Transmission Handwashing Protocol|Prevention of Secondary Transmission of Human Influenza by Promoting Handwashing With Soap: The Bangladesh Interruption of Secondary Transmission of Influenza Study (BISTIS)||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|June 2009|December 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6600|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2010|December 29, 2010|April 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00880659||140624|
NCT00881491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090181H|Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste|Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste||The University of Texas Health Science Center at San Antonio|Yes|Completed|April 2009|January 2015|Actual|January 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|10|||Both|7 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881491||140561|
NCT00881504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-07-006|A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma|A Single-Center, Open-Labeled, Phase II Trial of Modified FOLFOX6 With Bevacizumab in Patients With Advanced Biliary System Carcinoma||Georgetown University|Yes|Terminated|June 2009|December 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||September 2014|October 16, 2014|April 13, 2009|Yes|Yes|It was not possible to get insurance companies to cover bevacizumab.|No|September 5, 2014|https://clinicaltrials.gov/show/NCT00881504||140560|
NCT00881777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01 Rev. C|Feasibility Study of Radiofrequency Heating of Cardiac Infarction Scar to Treat Heart Failure|Radiofrequency Energy Use in Cardiomyopathy and Ventricular Enlargement (RECOVER)|RECOVER|CoRepair, Inc.|No|Terminated|September 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|80 Years|No|||July 2011|July 12, 2011|April 13, 2009||No|Unable to recruit suitable subjects within a reasonable time period.|No||https://clinicaltrials.gov/show/NCT00881777||140539|
NCT00882102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0288|Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)|Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Completed|April 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|16 Years|N/A|No|||September 2013|September 3, 2013|April 15, 2009||No||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00882102||140514|
NCT00882089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1098987|Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients|Registry Study of the Contura™ Multi-Lumen Balloon (MLB) Applicator for Accelerated Partial Breast Irradiation in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients||Cancer Center of Irvine|Yes|Completed|October 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||July 2013|January 26, 2016|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882089||140515|
NCT00882336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CEU-DUM-2008/1|European Study of Cardiovascular Risk|Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice|EURIKA|AstraZeneca|No|Completed|May 2009|October 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|7200|Samples Without DNA|Whole blood Serum|Both|50 Years|N/A|No|Probability Sample|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV        event or hospitalisation for a CV event) from Primary Care or hospital outpatient        clinic.Participating investigators will belong either to PC centres or hospitals, in the        proportion representing the reality on where this kind of patient is managed in each        country.|October 2009|October 28, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882336||140496|
NCT00881387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20080919|Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment|A Pilot Study of Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma||University of Miami Sylvester Comprehensive Cancer Center|Yes|Withdrawn|February 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2013|July 25, 2014|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881387||140569|
NCT00881413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMCP98004|Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding|Clinical Effectiveness of Intravenous Esomeprazole Versus Pantoprazole in Preventing Peptic Ulcer Recurrent Bleeding: a Double-Blind Randomized Trial||Lotung Poh-Ai Hospital|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2009|April 7, 2015|April 13, 2009||No|problems in funding|No||https://clinicaltrials.gov/show/NCT00881413||140567|
NCT00881946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKB112835|Repeat Dose Safety Study for Compound to Treat Hematologic Cancer|A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy||Accenture|No|Completed|July 2009|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|73|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00881946||140526|
NCT00881959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-800|Study of Root Coverage With Acellular Dermal Matrix: Puros® Dermis Versus Alloderm®|Multi-center, Post-market, Prospective, Randomized, Examiner-Only-Masked Study of Root Coverage With Acellular Dermal Matrix: Puros® Dermis Versus Alloderm®||Zimmer, Inc.|No|Completed|August 2009|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|April 14, 2009||No||No|May 7, 2015|https://clinicaltrials.gov/show/NCT00881959||140525|
NCT00882271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCU-08-VINJ003|Fibromyalgia Acupuncture Study|Efficacy of Acupuncture to Improve Symptoms and Functionality for People With Fibromyalgia||Southern California University of Health Sciences|Yes|Completed|January 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00882271||140501|
NCT00882622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A165/08_2|Effect of Remote Ischemic Preconditioning on Cardiac Function After Cardiac Surgery|Effect of Remote Ischemic Preconditioning on Cardiac Function After Cardiac Surgery||University of Schleswig-Holstein|No|Withdrawn|February 2009|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|April 14, 2009||No|Endpoints were investigated in parallel in NCT00877305|No||https://clinicaltrials.gov/show/NCT00882622||140475|
NCT00882635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STREAMPCI|The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study|The STrategic Reperfusion Early After Myocardial Infarction (STREAM) Anticoagulation With Enoxaparin vs. Unfractionated Heparin in Primary PCI Sub-study.||University of Alberta|No|Completed|October 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882635||140474|
NCT00882648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19524|The Effect of Fetal Gender on Maternal Substance Abuse Treatment|The Effect of Fetal Gender on Maternal Substance Abuse Treatment||Johns Hopkins University|No|Completed|April 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|850|||Female|N/A|N/A|No|Non-Probability Sample|All women enrolled in comprehensive substance abuse treatment at the Center for Addiction        and Pregnancy (CAP) between 2004 and 2009|February 2013|February 19, 2013|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882648||140473|
NCT00882986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1121717|Cardiovascular and Metabolic Responses to a Mixed Meal|Role of Exercise Training and Body Weight on Cardiovascular and Metabolic Responses to a Mixed Meal Tolerance Test||University of Kansas Medical Center|No|Completed|January 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Male|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|young, lean, healthy men|September 2015|September 22, 2015|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00882986||140447|
NCT00883233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29085|Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris|Efficacy and Safety Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|FREE|Galderma|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|123|||Both|12 Years|35 Years|No|||November 2010|November 11, 2010|April 16, 2009||No||No|October 11, 2010|https://clinicaltrials.gov/show/NCT00883233||140428|
NCT00883207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DINADEP|Dialogical and Narrative Processes in Couple Therapy for Depression|Dialogical and Narrative Processes in Couple Therapy for Depression. Two Year Follow-up Study of the Effectiveness and Processes in Couple Therapy|DINADEP|University of Jyvaskyla|No|Recruiting|February 2006|October 2009|Anticipated|July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|65|||Both|15 Years|65 Years|No|||April 2009|April 16, 2009|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00883207||140430|
NCT00879216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-003|VA106483 and Alpha Blocker Interaction Study in Elderly Males|A Single Centre, Double-blind, Placebo Controlled Crossover Study in Elderly Male Subjects to Investigate the Plarmacodynamic Interaction of VA106483 Administered Concomitanctly With Alpha-blocker Therapy||Vantia Ltd|No|Completed|April 2009|July 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Male|65 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 24, 2009|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879216||140733|
NCT00879762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0040|High Dose IMVAMUNE® in Vaccinia-Naive Individuals|Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||January 2012|December 6, 2012|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879762||140692|
NCT00880607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0721|The Use of Intraoperative Intrathecal Morphine Versus Epidural Extended Release Morphine for Postoperative Pain Control in Pediatric Patients Undergoing Posterior Spinal Fusion|The Use of Intraoperative Intrathecal Morphine Versus Epidural Extended Release Morphine for Postoperative Pain Control in Pediatric Patients Undergoing Posterior Spinal Fusion|IT Morphine|University of Colorado, Denver|Yes|Completed|December 2008|September 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|8 Years|17 Years|No|||May 2015|May 26, 2015|April 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880607||140628|
NCT00880620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX066-B08-05|A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease|A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease|APEX-PD|IMPAX Laboratories, Inc.|No|Completed|April 2009|November 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|381|||Both|30 Years|N/A|No|||January 2016|January 25, 2016|April 3, 2009|Yes|Yes||No|December 7, 2015|https://clinicaltrials.gov/show/NCT00880620||140627|
NCT00880633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0703-58|Endoscopic Ultrasound Staging of Periampullary Neoplasms: Retrospective|EUS Staging Accuracy of Periampullary Neoplasms: a Retrospective Review||Indiana University|No|Completed|April 2007|February 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|Retrospective review of patients who have already undergone an EUS at this institution.|February 2011|February 16, 2011|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880633||140626|
NCT00849862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50276|Levetiracetam 750 mg Tablets Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Levetiracetam 750 mg Tablet and Keppra® (Reference) Following a 750 mg Dose in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|February 20, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00849862||142957|
NCT00849875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111714|A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients|Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma||GlaxoSmithKline||Terminated|May 2009|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||March 2015|September 24, 2015|February 2, 2009|Yes|Yes|Early end of trial notification after termination of long term follow up due to lack of    scientific justification to continue collect information.|No||https://clinicaltrials.gov/show/NCT00849875||142956|
NCT00850174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-917|Oxcarbazepine 600 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Oxcarbazepine 600 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|February 20, 2009|No|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00850174||142933|
NCT00880971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-L-015|To Evaluate Postoperative 3D Conform Radiotherapy in Patients With IIIA (N2) Non-small Cell Lung Cancer|Phase III Comparison of Postoperative 3D Conform Radiotherapy After Chemotherapy and Chemotherapy Alone in Patients With Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2009|July 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|70 Years|No|||December 2011|December 15, 2011|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880971||140601|
NCT00881218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGADENOSON.MRI.WUSTL|Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson|Feasibility of Detecting Myocardial Ischemia by First-pass Contrast MRI Using Regadenoson||Washington University School of Medicine|Yes|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||April 2012|April 8, 2012|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881218||140582|
NCT00881231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA17524|To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Eon and Otsuka (Pletal) 50 mg Cilostazol Tablets In Healthy Adults Volunteers Under Fasting Conditions||Sandoz||Completed|January 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|April 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881231||140581|
NCT00881517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM7J4HCH|Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection|Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection|CHIP|IRCCS Policlinico S. Matteo|No|Completed|June 2009|October 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|124|||Female|18 Years|N/A|No|||December 2011|December 7, 2011|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881517||140559|
NCT00881790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEHAVE01|The Behaviour of Dental Nurses Applying Fluoride Varnish to Young Children|The Behavioural Engagement of Dental Nurses Applying the Fluoride Varnish to Young Children: the BEHAVE Study|BEHAVE|University of St Andrews|Yes|Completed|April 2009|December 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|509|||Both|3 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nursery school children from designated nursery schools (from under resourced communities)        in East Scotland.        Health Boards involved include: Fife, Forth Valley and Tayside|January 2013|January 9, 2013|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881790||140538|
NCT00846326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAI01|Preventing Tolerance to Oxymetazoline in Allergic Rhinitis|A Proof of Concept Study to Evaluate if Concomitant Topical Intranasal Steroid Prevents Tolerance and Rebound Congestion Due to Regular Oxymetazoline in Persistent Allergic Rhinitis.||University of Dundee|No|Not yet recruiting|April 2010|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||December 2009|January 11, 2010|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00846326||143223|
NCT00882375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431111|Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy|Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy. A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 52 Week Study in Smokers Motivated to Quit.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|479|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882375||140494|
NCT00881088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTECT|Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures|Prophylaxis of Venous Thromboembolism in Patients With a Nonsurgical Fracture of the Lower Extremity Immobilised in a Below-Knee Plaster Cast|PROTECT|Red Cross Hospital Beverwijk|No|Recruiting|April 2009|April 2013|Anticipated|April 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|669|||Both|18 Years|N/A|No|||May 2009|December 15, 2012|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881088||140592|
NCT00881972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1116098|Physical Activity and Glycemic Control|Physical Activity and Glycemic Control||University of Kansas Medical Center|No|Completed|February 2009|July 2010|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881972||140524|
NCT00881985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 09-051|Effect of Continuous Positive Airway Pressure for Treatment of Obstructive Sleep Apnea on Resistant Hypertension|Effect of Continuous Positive Airway Pressure for Treatment of Obstructive Sleep Apnea on Drug-resistant Hypertension : A Randomized Controlled Trial||The University of Hong Kong||Recruiting|March 2009|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|65 Years|No|||January 2016|January 17, 2016|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881985||140523|
NCT00882284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0040|Hypotension in Neonates|Hydrocortisone Treatment of Hypotension in Term and Late Preterm Infants: An Observational Study||NICHD Neonatal Research Network|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|820|||Both|N/A|72 Hours|No|Non-Probability Sample|All newborn infants born at ≥34 0/7 weeks gestational age admitted to NICU Network centers        who are intubated and mechanically ventilated within 72 hours of postnatal age|July 2015|July 21, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00882284||140500|
NCT00882674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22002|A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer|An Exploratory Study to Evaluate the Biological Activity of R1507, a Human Monoclonal Antibody Antagonist of the Insulin-like Growth Factor Receptor (IGF-1R) in Women With Operable Breast Cancer||Hoffmann-La Roche||Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882674||140471|
NCT00882973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPMPC202|Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer|||Samyang Biopharmaceuticals Corporation||Active, not recruiting||||||Phase 1/Phase 2|Interventional|N/A|||||||Both|18 Years|N/A|No|||April 2009|April 16, 2009|April 16, 2009||||No||https://clinicaltrials.gov/show/NCT00882973||140448|
NCT00883220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR010553-01|Self Management in Urinary Catheter Users|Self-management of Urine Flow in Long-term Urinary Catheter Users||University of Rochester|Yes|Completed|June 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|202|||Both|18 Years|N/A|No|||July 2011|September 17, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883220||140429|
NCT00883246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEFINITIVE LE|Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE)|Determination of Effectiveness of SilverHawk Peripheral Plaque Excision (SilverHawk Device) for the Treatment of Infrainguinal Vessels/Lower Extremities||Medtronic Endovascular|Yes|Completed|April 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|800|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 16, 2009|Yes|Yes||No|January 23, 2015|https://clinicaltrials.gov/show/NCT00883246||140427|The study’s principal limitations include a lack of randomization and follow-up beyond 12 months.
NCT00879502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH078041|Examining Physiology and Brain Function in People With the Fragile X Premutation|Limbic System Function in Carriers of the Fragile X Premutation||University of California, Davis|Yes|Completed|June 2007|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|110|Samples With DNA|Saliva and blood samples|Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Members of the general population, those with the fragile X premutation, and the brothers        of those with the fragile X premutation|March 2013|March 5, 2013|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879502||140711|
NCT00879736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THT in practice|A Study of the Effect of Patient Education (Talking Health Together) in Improving Doctor-patient Communication|A Multi-centre, Randomised Trial in Ontario to Evaluate the Efficacy of Talking Health Together T.M. (T.H.T. in Practice), a Communication Education Intervention for Primary Care Patients With Chronic Disease.||AstraZeneca|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|322|||Both|40 Years|N/A|No|||October 2010|August 19, 2011|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879736||140694|
NCT00880048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110833|A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|Orvepitant MDD|GlaxoSmithKline|Yes|Terminated|March 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|346|||Both|18 Years|64 Years|No|||September 2012|September 13, 2012|April 9, 2009|Yes|Yes|To allow assessment of isolated events of seizure during program|No||https://clinicaltrials.gov/show/NCT00880048||140670|
NCT00880061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090117|An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma|An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma||National Institutes of Health Clinical Center (CC)||Terminated|April 2009|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|17 Years|No|||June 2015|June 6, 2015|April 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880061||140669|
NCT00880334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-116|Randomized Study of Docetaxel +/- ZD6474 in Metastatic TCC|Randomized Study of Docetaxel +/- ZD6474 in Metastatic TCC||Dana-Farber Cancer Institute|Yes|Completed|September 2006|May 2015|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||August 2015|January 22, 2016|April 10, 2009|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT00880334||140648|
NCT00880347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHTAD/002|Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia|Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia : A Prospective Study for a Blood Diagnostic Test in Alzheimer's Disease - (Protocol n° EHTAD/002).||Exonhit|No|Completed|February 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|550|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 30, 2011|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880347||140647|
NCT00882414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THROMBOVIT|Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)|A Multi-centre, Randomized, Controlled, Single-blinded, Phase II Study to Investigate the Safety and Efficacy of Intravenous Infusions of FERINJECT® Versus Placebo in Patients With Thrombocytosis Secondary to Iron Deficiency and Chronic Inflammatory Bowel Disease||Vifor Inc.|No|Terminated|December 2006|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|60 Years|No|||April 2010|April 7, 2010|April 15, 2009||No|Main objective of study was met. Further recruitment was difficult.|No||https://clinicaltrials.gov/show/NCT00882414||140491|
NCT00882427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0807|Blood Glucose Control Over an Extended Glucose Control Range in Postoperative Cardiac Surgery Patients in the Intensive Care Unit|Single-center, Open Study on the Performance of the Software eMPC Algorithm Used for Blood Glucose Control Over an Extended Glucose Control Range (4.4 to 8.3 mmol/L) for a Maximum of 48 Hours in Postoperative Cardiac Surgery Patients in the Intensive Care Unit|Aldea_02|B. Braun Melsungen AG|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882427||140490|
NCT00880984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CAR-07-Gr-01|Compression Anastomosis Using the Compression Anastomosis Ring (CAR™ 27)|Compression Anastomosis Using the CAR™ 27||Aristotle University Of Thessaloniki|No|Completed|June 2008|||September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2009|January 6, 2010|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880984||140600|
NCT00881244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1411-C-101|Study of AS1411 in Advanced Solid Tumours|Phase I Open Label Study of AS1411 in Advanced Solid Tumours||Antisoma Research|Yes|Completed|September 2003|February 2007|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2009|April 14, 2009|April 14, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00881244||140580|
NCT00881257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR0148|Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System|Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System||Vessix Vascular, Inc|Yes|Terminated|August 2007|May 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|April 13, 2009||No|Data was inconclusive|No||https://clinicaltrials.gov/show/NCT00881257||140579|
NCT00850746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443-CL-048|A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults|A Phase 1, Randomized, Double-Blind, Placebo- and Active- Controlled, Crossover Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Male and Female Adult Subjects||Astellas Pharma Inc|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 21, 2014|February 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00850746||142890|
NCT00850759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080715010|Using Virtual Reality to Train Children in Pedestrian Safety|Using Virtual Reality to Train Children in Pedestrian Safety||University of Alabama at Birmingham|Yes|Completed|October 2009|March 2014|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|240|||Both|7 Years|8 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|February 24, 2009||No||No|June 17, 2013|https://clinicaltrials.gov/show/NCT00850759||142889|
NCT00846339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT08_BUP1|PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration|[11C] Raclopride PET Imaging Study That Investigates Relation Between Occupancy of Dopamine D2 Receptors and Genotypes of DRD2 After Bupropion Administration||Seoul National University Hospital|No|Completed|November 2008|June 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|20 Years|50 Years|No|||February 2011|February 19, 2011|February 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00846339||143222|
NCT00882115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AADCRC-UCLA-01|Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose|Broccoli Sprout Extract Effects on the Inflammatory Response to Diesel Exhaust Particles in the Nose||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882115||140513|
NCT00881439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIANA|Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment|A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction|ARIANA-CHF-RD|University Medical Center Groningen|Yes|Terminated|April 2009|December 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|April 14, 2009||No|Futility|No||https://clinicaltrials.gov/show/NCT00881439||140565|
NCT00881660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28021|Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia|A Prospective Study of the Effectiveness of Fetal Endotracheal Occlusion (FETO) in the Management of Severe and Extremely Severe Congenital Diaphragmatic Hernia|FETO|Baylor College of Medicine|Yes|Recruiting|March 2010|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Female|18 Years|45 Years|No|||January 2016|January 11, 2016|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881660||140548|
NCT00881673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-005|To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge|A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge (CAC)||Alcon Research|Yes|Withdrawn|May 2009|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|March 3, 2012|April 14, 2009|Yes|Yes|Management decision|No||https://clinicaltrials.gov/show/NCT00881673||140547|
NCT00881686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xinzangwaike0002|Myocardial Protection With Adenosine Preconditioning|Study of Myocardial Protection in Pediatric Cardiac Surgery With Adenosine Preconditioning||Xijing Hospital|Yes|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|238|||Both|N/A|24 Months|No|||March 2009|April 14, 2009|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881686||140546|
NCT00881998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIUWHOZ-09-02|Study of Two Surgical Approaches for Total Hip Arthroplasty|Prospective, Randomized Study of Two Surgical Approaches for Total Hip Arthroplasty||Rothman Institute Orthopaedics|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||April 2009|April 15, 2009|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881998||140522|
NCT00882297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/06|Subclavian Vein Ultrasound Guided Cannulation in Adult|Subclavian Vein Ultrasound Guided Cannulation in Adult: Transversal and Longitudinal Approach Comparison|CATETEL|University Hospital, Bordeaux|No|Completed|April 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882297||140499|
NCT00882661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPR002|SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study|A Prospective Randomized Clinical Investigation of the SECURE-C Cervical Artificial Disc: A Pivotal Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study||Globus Medical Inc||Active, not recruiting|July 2005|September 2015|Anticipated|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|380|||Both|18 Years|60 Years|No|||May 2013|May 10, 2013|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882661||140472|
NCT00879528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL-HD0802|Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory|Consolidation PET-based and Donor-based After Salvage Therapy in Patients With Hodgkin Lymphoma in Relapse or Refractory||Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|May 2009|September 2015|Anticipated|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients confirmed Hodgkin's lymphoma at refractory at first line therapy or relapse|September 2015|September 14, 2015|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879528||140709|
NCT00878995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-073|Testosterone for Treating Cachexia in Patients With Advanced or Recurrent Cervical Cancer|Nutrition and Anabolic Interventions in Cancer Cachexia||The University of Texas Medical Branch, Galveston|No|Completed|April 2008|June 2015|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Female|18 Years|65 Years|No|||October 2015|October 6, 2015|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878995||140750|
NCT00879008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12629|SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)|SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB|SYMPROVE III|Bayer|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|345|None Retained|n.a.|Both|18 Years|N/A|No|Non-Probability Sample|It is a multicentre study in the ambulatory sector. Every primary care physician or        pulmologist should inclose the first 5 patients with AECB from Anthonisen type I or II|June 2014|June 20, 2014|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879008||140749|
NCT00879229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-300-0128|ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension|ARTEMIS-PH|Gilead Sciences|Yes|Terminated|July 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|80 Years|No|||May 2014|May 5, 2014|April 8, 2009|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00879229||140732|Study GS-US-300-0128 was terminated early with enrollment of 40 of 225 planned subjects.
NCT00879242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AIT07|Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec|Multicenter, Open Label, Prospective Study to Evaluate the Efficacy and Safety of Deferasirox 30 mg/kg/Day for 52 Weeks, in Transfusion-dependent Beta-thalassemic Patients With Cardiac MRI T2* < 20 Msec||Novartis||Completed|February 2009|||May 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|10 Years|N/A|No|||November 2011|November 14, 2011|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879242||140731|
NCT00879489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00715832|Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer|Phase I/II Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer||Quantum Immunologics, Inc.|No|Active, not recruiting|May 2008|September 2011|Anticipated|March 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|85 Years|No|||April 2009|February 23, 2011|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879489||140712|
NCT00879255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHI 07-259|Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With Posttraumatic Stress Disorder|Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With PTSD|CPTVTEL|VA Office of Research and Development|No|Completed|October 2008|June 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Male|18 Years|N/A|No|||April 2015|April 23, 2015|April 7, 2009||No||No|November 12, 2014|https://clinicaltrials.gov/show/NCT00879255||140730|For patients in rural areas, their local mental health facilities may not have access to videoteleconferencing technology.There were no women veterans as study participants. Participants with acute safety concerns or current substances were excluded.
NCT00848991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Comparison of Propofol to Precedex With Propofol for Emergence and Recovery in Patients Having Craniotomy Surgery|Comparison of Propofol Standard Anesthetic to Precedex With Propofol for Emergence and Recovery in Patients Having Craniotomy Surgery||The Cooper Health System|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|February 9, 2012|December 17, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848991||143020|
NCT00881803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-6|Iron & Vitamin C Study|Implications of Concurrent Iron and Ascorbic Acid Supplementation on Iron Status in Persons With Spinal Cord Injury||VA Office of Research and Development|No|Completed|June 2008|June 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Blood samples will be obtained for analysis.|Male|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|US Veterans with spinal cord injuries greater than 6 months who are located near Bronx, NY|May 2012|May 21, 2012|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00881803||140537|
NCT00849563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011592|Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes|Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes|TDE|Duke University|No|Completed|April 2009|June 2013|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|450|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|February 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00849563||142979|
NCT00883090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI71023_2002|A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency|A 12 Week, Multicenter, Pharmacokinetic and Safety Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency||CSL Behring|No|Completed|May 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|N/A|N/A|No|||December 2011|December 7, 2011|April 16, 2009|Yes|Yes||No|December 7, 2011|https://clinicaltrials.gov/show/NCT00883090||140439|
NCT00850187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan - Bone - 001|Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage|Treatment of Full-thickness Articular Cartilage Defects in the Knee of Patients With Autologous Bone-marrow Mesenchymal Stem Cells and Scaffold||Royan Institute|Yes|Completed|August 2008|December 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|45 Years|60 Years|No|||April 2010|January 2, 2012|February 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00850187||142932|
NCT00850460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAM-0655|Quality of Life in Patients With Statin-Associated Myopathy|Quality of Life and Metabolic Alterations in Patients With Statin-Associated Myopathy||Rockefeller University|No|Terminated|February 2009|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|14|||Both|40 Years|60 Years|No|||February 2013|March 17, 2015|February 23, 2009|Yes|Yes|Investigator left institution and no PI has been found to continue the study|No||https://clinicaltrials.gov/show/NCT00850460||142911|
NCT00883337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10891|A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis|A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period|TENERE|Sanofi|Yes|Completed|April 2009|May 2015|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|324|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 16, 2009|Yes|Yes||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00883337||140420|
NCT00879060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL086745-01A1|Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy|Clinical and Therapeutic Implications of Fibrosis in Hypertrophic||Tufts Medical Center|Yes|Recruiting|November 2007|November 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|95|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2009|April 8, 2009|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879060||140745|
NCT00846651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #29595|Spinal Anesthesia Induced Hypotension During Cesarean Section|Comparison of Phenylephrine Infusion With Colloids vs. Crystalloids for Reduction of Spinal-induced Hypotension During Cesarean Section||Penn State University|No|Completed|February 2009|February 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|35 Years|No|||July 2013|July 3, 2013|February 18, 2009||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT00846651||143198|technical problems for analysing fetal pH in all newborns
NCT00881452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00101|A Trial of CM-AT in Children With Autism|A Phase III Randomized Double Blind Placebo Controlled Trial of CM-AT in Children With Autism|CM-AT|Curemark|No|Completed|May 2009|September 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|182|||Both|3 Years|8 Years|No|||March 2013|March 11, 2013|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881452||140564|
NCT00882024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3003RA|Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)|A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast With Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients With Active Rheumatoid Arthritis (RA)||Nuon Therapeutics, Inc.|Yes|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|75 Years|No|||January 2011|January 5, 2011|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882024||140520|
NCT00881699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5264|Testing an HIV Prevention Intervention for Psychiatric Patients in Brazil|Randomized Clinical Trial of a Brazilian HIV Prevention Intervention for the Severely Mentally Ill||New York State Psychiatric Institute|Yes|Completed|September 2006|August 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|460|||Both|18 Years|80 Years|No|||March 2012|March 8, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881699||140545|
NCT00881712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0802-LU02|Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)|A Phase II Trial of 3 Dimensional Proton Radiotherapy With Concomitant Chemotherapy for Patients With Initially Unresectable Stage III Non-Small Cell Lung Cancer|LU02|University of Florida|Yes|Terminated|June 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|April 13, 2009|Yes|Yes|projected enrollment rate not feasible|No|May 28, 2015|https://clinicaltrials.gov/show/NCT00881712||140544|
NCT00882011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL-LY_01|Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters|Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy-pathological Parameters||Fondazione Italiana Linfomi ONLUS|No|Recruiting|April 2009|April 2019|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Involved lymph nodes biopsy; biopsies performed in other areas affected by lymphoma; bone      marrow blood; peripheral blood.|Both|15 Years|N/A|No|Probability Sample|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or        intensive chemotherapy followed by transplant.|October 2011|October 12, 2011|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882011||140521|
NCT00882999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12778|A Study of Patients With Relapsing Remitting Multiple Sclerosis|Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis||Eli Lilly and Company|Yes|Completed|April 2009|June 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|245|||Both|18 Years|64 Years|No|||June 2012|June 22, 2012|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882999||140446|
NCT00879021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pregabalin and SCI-Short|Study of Pregabalin in the Prevention of Central Neuropathic Pain in Acute Spinal Cord Injury|Can Pregabalin Prevent the Development of Neuropathic Pain Following Spinal Cord Injury? A Double-Blind, Randomized, Placebo Controlled Trial.||Nova Scotia Health Authority|No|Terminated|September 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|70 Years|No|||July 2013|July 29, 2013|April 8, 2009||No|lack of funding and patients|No||https://clinicaltrials.gov/show/NCT00879021||140748|
NCT00880321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112680|A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors|A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|June 2009|March 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||June 2013|April 10, 2014|April 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00880321||140649|
NCT00879788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135_RAMIP_06|Bioequivalence Study of Ramipril 10 mg Capsules Under Fed Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study Comparing Ramipril 10 mg Capsules of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc.), With Altace® Capsule 10 mg (Containing Ramipril 10 mg) of Monarch Pharmaceuticals Inc, USA in Healthy, Adult, Male, Human Subjects Under Fed Conditions.||Ranbaxy Inc.|Yes|Completed|October 2006|March 2007|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2009|April 9, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879788||140690|
NCT00881816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-GC-02-2008|Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma|Phase I Clinical Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma||Nanjing Sike Pharmaceutical Co., Ltd.|No|Active, not recruiting|April 2009|December 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||April 2009|April 14, 2009|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881816||140536|
NCT00882440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-011|A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)|A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954)||Merck Sharp & Dohme Corp.||Completed|December 1990|January 1992|Actual|August 1991|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|576|||Both|21 Years|N/A|No|||August 2015|August 17, 2015|April 14, 2009|Yes|Yes||No|April 17, 2009|https://clinicaltrials.gov/show/NCT00882440||140489|
NCT00882128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RFR-DUM-2008/2|Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)|Evaluation of the Control Level (GINA) of Asthmatic Patients Consulting Their General Practitioner for a Seasonal Increase of Respiratory Symptoms (High and / or Low), Whether an Inhaled Corticotherapy is Taken or Not|SAISON|AstraZeneca|No|Completed|May 2009|October 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|3300|||Both|18 Years|N/A|No|Probability Sample|The first 3 consecutive adult and asthmatic patients consulting their general practitioner        for a seasonal increase of respiratory symptoms (high and / or low) and treated with PRN        fast acting bronchodilatator alone or associated with inhaled IGCS, excluding all other        treatments for asthma.|November 2009|November 13, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882128||140512|
NCT00882141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0116|Race, Menopause and Metabolism After Exercise and Diet|Menopause, Genes and Metabolism After Weight Loss and Exercise||National Institute on Aging (NIA)|Yes|Completed|March 2002|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||January 2010|January 11, 2010|April 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882141||140511|
NCT00882154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50039|To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and/or Female Volunteers in the Fed State||Sandoz||Completed|April 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|56 Years|Accepts Healthy Volunteers|||April 2009|April 15, 2009|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882154||140510|
NCT00879320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002056|Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder|Healthy Lifestyle in Adults With ADHD||Massachusetts General Hospital|No|Completed|February 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|253|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults ages 18-55 who have ADHD (for ADHD group) Healthy adult volunteers ages 18-55 who        do not have ADHD (control group)|October 2013|October 21, 2013|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879320||140725|
NCT00882791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU2538|Basal Cell Carcinoma Recurrence After Mohs Surgery|Basal Cell Carcinoma Recurrence||Northwestern University|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|115|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be selected from Northwestern University - Department of Dermatology,        Chicago, IL and from DuPage Medical Group Dermatology, Naperville, IL.|September 2012|September 14, 2012|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00882791||140462|
NCT00883077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009SDU-QILU-G01|Assessment of Colonic Permeability by Confocal Laser Endomicroscopy|Combined Assessment of Colonic Permeability by Real Time Confocal Laser Endomicroscopy and Sucralose Absorption Test||Shandong University|Yes|Recruiting|April 2009|December 2009|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples With DNA|Biopsies during colonoscopy.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with indications for colonoscopy in Qilu Hospital outpatient and inpatient        department are the study population of this study.|October 2009|October 13, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883077||140440|
NCT00879606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-836-01-08|Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome|Efficacy and Safety Evaluation of ALT-836 in Patients With Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome||Altor Bioscience Corporation|Yes|Completed|April 2009|January 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|April 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879606||140704|
NCT00879814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6108A1-1004|Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults|A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects||Pfizer|No|Completed|April 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|40 Years|No|||July 2015|July 15, 2015|April 10, 2009|No|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT00879814||140688|
NCT00879294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR1_IRB00005677|The Effect of Gum Chewing on Postoperative Ileus|The Effect of Gum Chewing on Postoperative Ileus||Wake Forest School of Medicine|No|Not yet recruiting||||June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|6 Years|18 Years|No|||June 2010|June 24, 2010|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879294||140727|
NCT00882037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|335-08-FB|Risk and Protective Factors for Rural Methamphetamine Dependence|Risk and Protective Factors for Rural Methamphetamine Dependence||University of Nebraska|No|Enrolling by invitation|August 2008|July 2010|Anticipated|August 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a study of 150 rural and urban persons in treatment for methamphetamine        dependence. We propose to enroll 150 participants (75 rural and 75 urban) over a two year        period. Of these 150 participants, 75 will be Latino and 75 non-Latino (approximately 37        rural and 37 urban for each group).|April 2009|April 15, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882037||140519|
NCT00882050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808104|Intravenous Exenatide (Byetta) During Surgery|Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial||University of Pennsylvania|Yes|Recruiting|March 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882050||140518|
NCT00881725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-ANIMATE-001|A Study of Pre-operative Metformin in Prostate Cancer|A Phase II, Open Label Assessment of Neoadjuvant Intervention With Metformin Against Tumour Expression of Signaling|ANIMATE|University Health Network, Toronto|Yes|Terminated|June 2009|June 2012|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|75 Years|No|||June 2012|June 18, 2012|April 14, 2009||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00881725||140543|
NCT00881738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B013720|To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions|A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions||Sandoz||Completed|June 2002|July 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|19 Years|54 Years|Accepts Healthy Volunteers|||April 2009|April 15, 2009|April 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881738||140542|
NCT00882700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50038|To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and/or Female Volunteers in the Fasting State||Sandoz||Completed|April 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|56 Years|Accepts Healthy Volunteers|||April 2009|December 30, 2009|April 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882700||140469|
NCT00882713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21797|A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once- Monthly Administration of Subcutaneous CERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anemia||Hoffmann-La Roche||Completed|February 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00882713||140468|
NCT00883012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paediatric influenza vax|Influenza Vaccine in HIV Infected Children|Immunogenicity, Safety and Efficacy of Influenza Vaccine in HIV Infected Children||University of Witwatersrand, South Africa|No|Completed|February 2009|June 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|412|||Both|6 Months|5 Years|No|||April 2012|April 2, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883012||140445|
NCT00879268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G030132|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Phase 1 Study of Liver Machine Preservation With Vasosol Solution||Polyak, Maximilian||Completed|July 2004|February 2009|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||April 2009|April 7, 2009|April 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879268||140729|
NCT00879034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02-0074|A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria|A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies||Children's Hospital Boston|Yes|Completed|March 2009|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||April 2010|April 20, 2010|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879034||140747|
NCT00883259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/2008|Metformin and Gestational Diabetes in High-risk Patients: a RCTs|Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients||University Magna Graecia|Yes|Not yet recruiting|September 2013|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|40 Years|No|||April 2013|April 5, 2013|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883259||140426|
NCT00883272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0670-0|Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women|Assessment of Femarelle (DT56a), a Novel SERM, Effect on the Clotting Time in Normal and Thrombophililic Postmenopausal Women||New York University School of Medicine|No|Completed|January 2007|June 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|Samples Without DNA|Blood samples were collected in evacuated tubes (Vacutainer, Becton Dickinson) at baseline,      eight weeks, and one year.|Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Peri- and postmenopausal women aged 40-67. Menopause defined as a FSH > 40 and no menses        for > 1 year.|October 2015|October 20, 2015|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883272||140425|
NCT00880035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-105-R2|Efficacy of Music on Reduction of Sedative Drugs in Mechanically Ventilated Intensive Care Unit Patients|M.U.S.I.C (MUSicotherapy in the Intensive Care) Interventional, Pilot, Cross-Over, in Mechanically-Ventilated Patients on ICU Ward|MUSIC|Université de Sherbrooke|Yes|Recruiting|December 2008|December 2010|Anticipated|July 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2009|April 20, 2009|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880035||140671|
NCT00848679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACET3-ginosar-HMO-CTIL|Investigating the Novel Observation of Right-Left Difference in Uterine Artery Vascular Resistance in Pre-Eclampsia|Investigating the Novel Observation of Right-Left Difference in Uterine Artery Vascular Resistance in Pre-Eclampsia: A Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Dose-Dependent Effect of Epidural Lidocaine on Right-Left Uterine Artery Blood Flow Differences in Pre-Eclampsia, With Healthy Term Pregnant and Non-Pregnant Controls||Hadassah Medical Organization|No|Not yet recruiting|March 2009|October 2009|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|No|||February 2009|February 19, 2009|February 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848679||143044|
NCT00882453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13853|Physical Activity and Fatigue in Early Multiple Sclerosis (MS)|Betaferon Treatment and Exercise Data Gathering IN Early MS|BEGIN|Bayer|No|Completed|August 2006|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1739|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Patients after a first demyelinating event suggestive of MS as well as patients with        recently diagnosed RRMS (< 12 months)|May 2012|May 28, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882453||140488|
NCT00883103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-091|Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test|Double Blinded Randomized Trial Between Lidocaine Jelly And Plain Aqueous Gel For Urethral Straight Catheterization And The Q-Tip Test||Baystate Medical Center|Yes|Completed|November 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|137|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 10, 2011|April 15, 2009||No||No|July 18, 2011|https://clinicaltrials.gov/show/NCT00883103||140438|
NCT00883116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-196|A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer|A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy|IXAMPLE2|Bristol-Myers Squibb|Yes|Terminated|August 2009|December 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Female|18 Years|N/A|No|||June 2015|June 16, 2015|April 16, 2009|Yes|Yes|Interim analysis results showed that ixabepilone did not improve survival compared with    control chemotherapies.|No|December 6, 2013|https://clinicaltrials.gov/show/NCT00883116||140437|This study was terminated per Data Monitoring Committee. Results from an interim analysis showed that there was no favorable benefit/risk ratio with ixabepilone and that ixabepilone did not improve survival compared with control chemotherapies.
NCT00882804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000230|Hemin in Healthy Subjects|Effect of Hemin on Heme-Oxygenase-1 Activity in Healthy Subjects||Mayo Clinic||Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2009|April 16, 2009|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882804||140461|
NCT00879099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73654|Interaction Study of Timolol Eye Drops and Paroxetine Capsules|The Effect of Paroxetine on the Plasma Levels of Timolol Using Ophthalmic 0.5% Timolol Eye Drops and 0.1% Timolol Eye Gel in Healthy Volunteers||Santen Oy|No|Completed|April 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2009|January 27, 2010|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00879099||140742|
NCT00883350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 28023|Evaluation of the Remote Intervention for Diet and Exercise (RIDE)|Design and Evaluation of the Remote Intervention for Diet and Exercise (RIDE)|RIDE|Pennington Biomedical Research Center|Yes|Completed|May 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883350||140419|
NCT00879073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15690|Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors|Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|April 2009|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|April 8, 2009|No|Yes|Principal Investigator is leaving Moffitt|No||https://clinicaltrials.gov/show/NCT00879073||140744|
NCT00879307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07455|Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR|Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR||Hospital de Clinicas de Porto Alegre|No|Recruiting|March 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||February 2011|February 15, 2011|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879307||140726|
NCT00880126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 MH076158|Community Development Teams to Scale-Up Multidimensional Treatment Foster Care (MTFC) in California|Community Development Teams to Scale-Up MTFC in California||Center for Research to Practice|Yes|Enrolling by invitation|September 2006|August 2011|Anticipated|August 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2009|April 10, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00880126||140664|
NCT00880399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111733|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|orvepitant MDD|GlaxoSmithKline|Yes|Terminated|March 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|328|||Both|18 Years|64 Years|No|||September 2013|September 12, 2013|April 9, 2009|Yes|Yes|To allow assessment of isolated events of seizure during program|No||https://clinicaltrials.gov/show/NCT00880399||140643|
NCT00882063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/15/07|Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma|An Open Label, Multicenter Phase I/II Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Relapsed and/or Relapsed/Refractory Multiple Myeloma||Piramal Enterprises Limited|Yes|Completed|January 2008|May 2012|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882063||140517|
NCT00882362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-08-002|Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder|Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder||Otsuka Pharmaceutical Co., Ltd.|No|Completed|March 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|20 Years|N/A|No|||December 2013|December 20, 2013|April 2, 2009||No||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00882362||140495|
NCT00882310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB4460|A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer|A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer||Columbia University|Yes|Completed|September 2006|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|75 Years|No|||November 2014|November 12, 2014|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882310||140498|
NCT00882687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118-ACJ-100|Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis|A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model||Shire|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|60|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882687||140470|
NCT00882726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015562|A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus|A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Intravenous and Subcutaneous Single-Dose Study in Healthy Subjects and Ascending Subcutaneous Multiple-Dose Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immune Response of CNTO 3649||Centocor, Inc.|No|Completed|February 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|133|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00882726||140467|
NCT00883285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|255/08|Incidence and Severity of Silent and Apparent Cerebral Embolism After Conventional and Minimal-invasive Transfemoral Aortic Valve Replacement|Incidence and Severity of Silent and Apparent Cerebral Embolism After Conventional and Minimal-invasive Transfemoral Aortic Valve Replacement||University Hospital, Bonn|No|Completed|April 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients with aortic valve disease|January 2014|January 31, 2014|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883285||140424|
NCT00879047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA018001|Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection|Interaction of Alcohol & HAART in HIV/AIDS and HIV/AIDS With HCV Co-Infection||University of California, San Francisco|Yes|Completed|April 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 2, 2014|March 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879047||140746|
NCT00847847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080404|Neuromuscular Transmission in Amyotrophic Lateral Sclerosis|Neuromuscular Transmission in Amyotrophic Lateral Sclerosis|NETALS|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|75 Years|No|||December 2009|November 16, 2012|February 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00847847||143107|
NCT00879775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E00058|Efficacy of Caffeine Injection as an Adjuvant to Opioid Therapy in Cancer Pain|Efficacy of Caffeine as an Adjuvant to Opioid Therapy in Cancer Pain: a Randomized, Double-blind, Placebo-controlled Trial||Korea Research Foundation|No|Completed|April 2009|September 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|41|||Both|18 Years|N/A|No|||September 2009|March 3, 2011|April 9, 2009||No||No|January 11, 2011|https://clinicaltrials.gov/show/NCT00879775||140691|
NCT00879541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-BIO-07-47|Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A|A Phase II, Multicentre, Double-blinded, Randomised, Cross-over Study to Evaluate Efficacy, Safety and Pharmacokinetics of Biostate® in Subjects With Haemophilia A.||CSL Behring|Yes|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|81|||Male|12 Years|N/A|No|||February 2011|February 10, 2011|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879541||140708|
NCT00879554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1121003|A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors|A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors|CVX-045-101|Pfizer|No|Completed|February 2007|November 2010|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|April 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00879554||140707|
NCT00881530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.24|Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension|A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients||Boehringer Ingelheim||Completed|March 2009|||May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|660|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|April 14, 2009||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00881530||140558|
NCT00881829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1000-000-001REV7|Study of Spectro-photometric Based Systems Measuring Pulse Oximetry and Other Analytes and Physiological Parameters|Study of Spectro-photometric Based Systems Measuring Pulse Oximetry and Other Analytes and Physiological Parameters||Clinimark, LLC|Yes|Recruiting|March 2005|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of the Denver metropolitan area.|March 2015|March 4, 2015|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00881829||140535|
NCT00878839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09-016|Investigation of Corneal Aberrations and Visual Outcomes in Patients Implanted With an AcrySof Toric Intraocular Lens (IOL)|||Alcon Research|No|Withdrawn|March 2009|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||June 2012|July 31, 2012|April 7, 2009|No|Yes|Product availability|No||https://clinicaltrials.gov/show/NCT00878839||140762|
NCT00883129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|632|Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)|Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)|SLSII|University of California, Los Angeles|Yes|Active, not recruiting|September 2009|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||September 2009|April 20, 2013|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00883129||140436|
NCT00879086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-209|A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer|A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer||Eisai Inc.||Completed|March 2009|April 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|N/A|No|||July 2014|July 22, 2014|April 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879086||140743|
NCT00879112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB07811-201|Study of MB07811 in Subjects With Hypercholesterolemia|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of MB07811 for 12 Weeks Followed by a 6-Week Off Drug Phase in Subjects With Primary Hypercholesterolemia||Ligand Pharmaceuticals|No|Withdrawn|April 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|65 Years|No|||August 2011|August 10, 2011|April 8, 2009|No|Yes|Study terminated prior to initiation|No||https://clinicaltrials.gov/show/NCT00879112||140741|
NCT00879125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080368|Effect of Gastric Bypass on Patients With Type 2 Diabetes and/or Dyslipidemia|Effect of Gastric Bypass on Type 2 Diabetes and/or Dyslipidemia||Vanderbilt University|No|Completed|November 1999|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|219|||Both|17 Years|66 Years|No|Non-Probability Sample|Patients with Type 2 diabetes with a BMI over 35kg/m2|September 2009|September 10, 2009|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879125||140740|
NCT00879619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 07-64|Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients|A Pilot Phase I/II Study to Evaluate the Effects of Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients With Biochemical Relapse||University of California, Irvine|Yes|Terminated|July 2009|November 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||April 2013|April 19, 2013|April 8, 2009|Yes|Yes|Terminated due to slow accrual.|No|April 19, 2013|https://clinicaltrials.gov/show/NCT00879619||140703|The study was terminated due to slow accrual. Zero subjects were analyzed.
NCT00879827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/049|Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants|Immunogenicity and Reactogenicity of GSK Biologicals' DTPa-HBV-IPV and Hib Vaccines When Administered Concomitantly to Healthy Infants Administered as a Three-Dose Primary Vaccination Course at the Age of 1.5, 3.5 and 6 Months||GlaxoSmithKline||Completed|September 2000|May 2001|Actual|May 2001|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||April 2009|April 9, 2009|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879827||140687|
NCT00879840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909121|Assessment of Screening Modalities for Gynecologic Cancers|Assessment of Screening Modalities for Gynecologic Cancers||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 2009|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|170|||Female|50 Years|120 Years|No|||October 2015|November 5, 2015|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00879840||140686|
NCT00880139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-171008|Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes|A Cross-sectional Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes||Medical University of Vienna||Terminated|June 2009|September 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients|November 2014|November 13, 2014|December 18, 2008||No||No||https://clinicaltrials.gov/show/NCT00880139||140663|
NCT00860457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-CLL-PI-089|Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)|Lenalidomide Following Rituximab and Fludarabine in Untreated Chronic Lymphocytic Leukemia||Georgetown University|Yes|Completed|February 2008|February 2012|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|March 10, 2009|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT00860457||142155|
NCT00882739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo002|Safety and Efficacy of Three Different Loading Doses of Clopidogrel, in Patients With Acute Myocardial Infarction|Safety and Efficacy of Three Different Loading Doses of Clopidogrel, Administered at First Medical Contact in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. The LOAD & GO Trial|Load & Go|Ospedale San Donato|No|Completed|April 2009|||July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|168|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882739||140466|
NCT00882323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPHO-SCT 0802|Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)|Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia||The Korean Society of Pediatric Hematology Oncology|Yes|Recruiting|November 2008|October 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|1 Year|21 Years|No|||March 2012|March 23, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882323||140497|
NCT00883298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4514s|Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme|Phase II Study of Bi-Weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme||Center for Neurosciences, Tucson|Yes|Active, not recruiting|April 2009|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|83 Years|No|||April 2014|April 1, 2014|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00883298||140423|
NCT00880074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0106|Clinical Response to Chemotherapy With Fluoro-L-Thymidine With Positron Emission Tomography (FLT-PET)|Early Prediction of Clinical Response to Chemotherapy With FLT-PET {[F-18]-Fluoro-L-thymidine (FLT) With Positron Emission Tomography (PET)}||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2009|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|16|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880074||140668|
NCT00880087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|620|Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial|Therapeutic Hypothermia After Pediatric Cardiac Arrest (In Hospital)|THAPCA-IH|University of Michigan|Yes|Active, not recruiting|September 2009|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|N/A|18 Years|No|||December 2015|December 2, 2015|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880087||140667|
NCT00880360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070042H|A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer|A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy|ONTAK|The University of Texas Health Science Center at San Antonio|Yes|Completed|February 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||January 2013|January 7, 2013|April 10, 2009|Yes|Yes||No|August 13, 2012|https://clinicaltrials.gov/show/NCT00880360||140646|
NCT00880672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHKu1|Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate|Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride||Seoul National University Hospital|Yes|Completed|January 2008|April 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|50 Years|N/A|No|||April 2009|June 10, 2013|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880672||140623|
NCT00879281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OND1333118|Action Plan to Enhance Self-management and Early Detection of Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients|Action Plan to Enhance Self-management and Early Detection of Exacerbations in COPD Patients; A Multicenter RCT (ACZiE)|ACZiE|UMC Utrecht|Yes|Completed|December 2008|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|233|||Both|40 Years|N/A|No|||April 2009|February 23, 2011|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00879281||140728|
NCT00848393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB08-00029|Measures to Lower the Stress Response in Pediatric Cardiac Surgery|Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl, Low Dose Fentanyl Plus Dexmedetomidine and High Dose Fentanyl.||Nationwide Children's Hospital|Yes|Completed|November 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|52|||Both|1 Month|3 Years|No|||June 2015|June 26, 2015|February 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00848393||143065|
NCT00881270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04678|Dermacyd Infantile - Acceptability.|Safety Dermatological Evaluation: Acceptability With Paediatric Follow up Dermacyd Infantile (Lactic Acid).||Sanofi||Completed|March 2009|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Both|N/A|12 Years|Accepts Healthy Volunteers|||September 2009|September 25, 2009|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00881270||140578|
NCT00882167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-RTB-0001|Cine-magnetic Resonance Imaging (MRI) Detecting Intra Abdominal Adhesions|Sensitivity and Predictive Value of Functional Cine Magnetic Resonance Imaging (MRI) Detecting Intra-abdominal Adhesions||Radboud University|No|Recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patient who will undergo elective abdominal surgery|November 2014|November 4, 2014|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882167||140509|
NCT00883142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-11|Functional and Physiological Responses to Lokomat Therapy (Pilot Study)|Functional and Physiological Responses to Lokomat Therapy (Pilot Study)||VA Office of Research and Development|No|Completed|October 2006|March 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|Samples With DNA|Serum, plasma and for some muscle biopsy samples|Both|18 Years|N/A|No|Non-Probability Sample|Lokomat Rehabilitation Clinic|June 2013|June 10, 2013|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883142||140435|
NCT00883155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-09018|To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions|To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions.||Sandoz||Completed|October 1998|October 1998|Actual|October 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2009|April 16, 2009|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00883155||140434|
NCT00878852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08/90331|Efficacy of Contingency Management in the Treatment of Adolescents With Cannabis Use Disorders|Efficacy of a Contingency Management Program in the Treatment of Adolescents With Cannabis Use Disorders in a Child and Adolescent Psychiatry and Psychology Department||Hospital Clinic of Barcelona|No|Recruiting|April 2009|||December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|18 Years|No|||May 2009|May 20, 2009|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878852||140761|
NCT00879866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62235-002|EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)|An Open-label, Phase Ib, Dose-escalation Trial on the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Biological Effects and Antitumor Activity of EMD 521873 in Combination With Local Irradiation (20 Gy) of Primary Tumors or Metastases in Subjects With Non-small Cell Lung Cancer Stage IIIb With Malignant Pleural Effusion or Stage IV With Disease Control (Partial Response or Stable Disease) After Application of 4 Cycles of Platinum-based, First-line Chemotherapy||Merck KGaA||Completed|April 2009|September 2012|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00879866||140684|
NCT00879333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001R2301|Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)|A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy|GRANITE-1|Novartis|Yes|Completed|July 2009|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|656|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|April 8, 2009|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00879333||140724|4 randomized patients, 2 patients each from the everolimus and placebo arms were excluded from the safety analyses as they did not receive any dose of study treatment.
NCT00879346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00011|A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets|A Randomised, Open-label, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets in Healthy Subjects||AstraZeneca|No|Completed|March 2009|July 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 22, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00879346||140723|
NCT00879632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07456|Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania|Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up Study||Hospital de Clinicas de Porto Alegre|No|Recruiting|March 2009|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|SERUM, DNA, PLASMA|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Bipolar disorders patients during acute mania or depression using treatment as usual|February 2011|February 15, 2011|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879632||140702|
NCT00879853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Academic Senate Grant|Trial of Mental Health Treatment for Darfur Refugees in Cairo|Randomized Controlled Trial of Mental Health Treatment for Darfur Refugees in Cairo||University of California, San Francisco|No|Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 10, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00879853||140685|
NCT00880152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34622|Mindfulness Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study|Mindfulness-Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study|MBSRforPTSD|Seattle Institute for Biomedical and Clinical Research|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880152||140662|
NCT00852722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00004555|Low Fat Diet and Multiple Sclerosis|A Randomized, Controlled Study of Diet and Multiple Sclerosis|MS|Oregon Health and Science University|Yes|Completed|February 2009|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852722||142740|
NCT00882765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000639616|Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|A Pre-Surgical, Randomized Clinical Trial of Genistein in Resectable Pancreatic Adenocarcinoma||Jonsson Comprehensive Cancer Center|Yes|Withdrawn|May 2009|||January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||July 2012|October 28, 2015|April 15, 2009||No|Study has been closed due to no accrual.|No||https://clinicaltrials.gov/show/NCT00882765||140464|
NCT00882752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-009|Report of a New Method Used to Identify the Bacteria Present in a Human Colon Biopsy Sample|Retrospective Study Protocol: Report of a New Method Used to Identify the Bacteria Present in a Human Colon Biopsy||Southwest Regional Wound Care Center|Yes|Completed|January 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|Samples With DNA|colon biopsy|Female|18 Years|N/A|No|Probability Sample|People with ulcerative colitis.|September 2011|September 6, 2011|September 29, 2008||No||No||https://clinicaltrials.gov/show/NCT00882752||140465|
NCT00883025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP ISCML 113/08|Correlation Between Friedman Classification and the Apnea Hypopnea Index (AIH) in a Population With Obstructive Sleep Apnea Syndrome (OSAS)|Correlation Between Friedman Classification Ande ApneaHypopnea Index in a Population With OSAS|FriedmAIH|Irmandade da Santa Casa de Misericoridia de Limeira|No|Completed|February 2007|October 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|147|||Both|21 Years|N/A|Accepts Healthy Volunteers||Patients of Ambulatory of Sleep Respiratory Disorders of Santa Casa de Limeira|April 2009|April 16, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883025||140444|
NCT00883311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRT-C09-C017|A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis|A Clinical Usage Study to Evaluate the Safety and Efficacy of BRT-FC-83C in the Management of Mild to Moderate Atopic Dermatitis||Biomed Research & Technologies, Inc.|Yes|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|50 Years|No|||August 2010|August 29, 2010|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00883311||140422|
NCT00883064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00102|To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions.||Sandoz||Completed|March 2000|April 2000|Actual|April 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|54 Years|Accepts Healthy Volunteers|||March 2009|April 16, 2009|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00883064||140441|
NCT00880685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901M56882|Memantine in the Treatment of Kleptomania|Memantine Treatment of Kleptomania: An Open-Label Study||University of Chicago|Yes|Completed|March 2009|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||January 2014|January 17, 2014|March 18, 2009|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00880685||140622|
NCT00881010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0380|Automated Pain Intervention for Underserved Minority Breast Cancer Patients|Automated Pain Intervention for Underserved Minority Breast Cancer Patients||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2009|||February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Disadvantaged African American or Hispanic females diagnosed with breast cancer aged 18        years or older with access to telephones.|November 2015|November 23, 2015|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00881010||140598|
NCT00848159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041/07|Postural Assessment by Photogrammetry|Evaluation of Thoracic Kyphosis in Elderly Women Affected by Osteoporosis Through Computerized Photogrammetry||Universidade de Franca|Yes|Completed|April 2007|February 2009|Actual|November 2007|Actual|N/A|Observational|N/A||2||12||The two groups were photographed in the sagittal plane with right column markers fixed on      two anatomical points. The selected images were quantified by computerized photogrametry,      using the program Autocad-2006|Female|65 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators evaluated 12 women with mean age of 68.5 years (range 65 to 74 years),        divided into two groups. Group 1 consists of six women with a densitometric diagnosis of        osteoporosis in column (SD: -2.70 to -4.97) and group 2 consists of six women with a        densitometric diagnosis of osteopenia in column (DP: 1.07 to -2 , 09), both compared with        young adults.|February 2009|February 19, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00848159||143083|
NCT00881283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-p-001379|Long-term Cardiovascular Risk in Cured Cushing's Patients|Role of Adipokines in Long-term Cardiovascular Risk in Cured Cushing's Patients||Massachusetts General Hospital|No|Withdrawn|October 2008|October 2010|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|serum, urine|Female|35 Years|55 Years|No|Probability Sample|Cured Cushing's disease|April 2015|April 29, 2015|April 13, 2009||No|No patients were enrolled.|No||https://clinicaltrials.gov/show/NCT00881283||140577|
NCT00881543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaoPauloGH|"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"|"Effect of Dipeptidyl Peptidase IV Inhibitors on Glycemia, Insulin, Glucagon, C Peptide, Glp 1 and Lipids After Isocaloric Meals With Different Nutritional Composition in Patients With Type 2 Diabetes näive of Treatment"||University of Sao Paulo General Hospital|No|Completed|June 2009|October 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|40 Years|70 Years|No|||May 2012|May 24, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881543||140557|
NCT00882817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220095560|Pulmonary Rehabilitation in Interstitial Lung Diseases|Effects of Pulmonary Rehabilitation in Interstitial Lung Diseases: a Prospective Randomized Controlled Trial||Katholieke Universiteit Leuven|No|Completed|April 2009|November 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||July 2013|July 31, 2013|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882817||140460|
NCT00882830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNCT050253|Electrical Muscle Stimulation (EMS), a Preventive and Therapeutic Tool for Critical Illness Polyneuromyopathy (CIPNM)|Electrical Muscle Stimulation (EMS), a Preventive and Therapeutic Tool for Critical Illness Polyneuromyopathy (CIPNM)- A Randomized Controlled Parallel Intervention Trial.||University of Athens|No|Active, not recruiting|September 2007|September 2015|Anticipated|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|90 Years|No|||March 2015|March 12, 2015|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00882830||140459|
NCT00879138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-001|Efficacy and Safety of VA106483 in Elderly Males|A Double-Blind, Placebo-Controlled Dose Response Study to Investigate Pharmacodynamics and Pharmacokinetics of Single and Repeated Oral Doses of VA106483 in Elderly Male Subjects||Vantia Ltd|No|Completed|August 2008|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|27|||Male|65 Years|N/A|No|||April 2009|April 8, 2009|February 18, 2009||||No||https://clinicaltrials.gov/show/NCT00879138||140739|
NCT00879151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02272009-1878|Study of Treatment for Adolescents With Bulimia Nervosa|Treatment of Bulimic Adolescents||Stanford University|Yes|Completed|January 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|12 Years|18 Years|No|||May 2015|May 21, 2015|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00879151||140738|
NCT00878865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0228014|Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets|Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets; an Open, Randomised, Single Centre, Single Dose Study With Crossover Design in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878865||140760|
NCT00878878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-191-004|Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).|A Phase 4, Placebo Controlled, Single-blind, Cross-over Safety Study to Evaluate the Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR) as Measured by Right Heart Catheterization||GE Healthcare|Yes|Completed|March 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|April 8, 2009|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00878878||140759|
NCT00879359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20806|Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer|A Phase II Trial of a Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody, AVASTIN, in Combination With Cytotoxic Chemotherapy CARBOPLATIN and PACLITAXEL for Recurrent/Advanced Endometrial Cancer||The Cleveland Clinic|Yes|Completed|December 2007|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 9, 2013|April 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00879359||140722|
NCT00879645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S103|Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function|A Phase I Study to Assess the Pharmacokinetics of IK-1001 (Sodium Sulfide) in Subjects With Impaired Renal Function Following a Continuous 3-hour Intravenous Infusion||Ikaria|Yes|Terminated|August 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|April 9, 2009|Yes|Yes|unable to develop a rapid & reliable assay to detect sulfide concentrations|No|October 7, 2010|https://clinicaltrials.gov/show/NCT00879645||140701|
NCT00880815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0246|Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies|Fludarabine, Bendamustine and Rituximab (FBR) Non-myeloablative Allogeneic Conditioning for Patients With Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|February 2009|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00880815||140613|
NCT00880503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904067|Collection of Tissue Samples for Study of Multidrug Resistance|Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute||National Institutes of Health Clinical Center (CC)||Completed|December 2003|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|9999|||Both|18 Years|99 Years|No|||February 2016|February 18, 2016|April 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00880503||140636|
NCT00881075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001-1:201|Safety and Efficacy of SeeMore (TM) in Heart Patients|An Open-label, Baseline-Controlled Study of the Safety and Efficacy of SeeMore (TM) (EVP 1001-1 Injection) in Heart Patients||Eagle Vision Pharmaceutical Corp.|No|Completed|June 2008|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|April 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00881075||140593|
NCT00853593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116|Model 4396 Left Ventricular (LV) Lead Study|Model 4396 Left Ventricular Lead Study|4396|Medtronic Cardiac Rhythm Disease Management|No|Completed|March 2009|August 2010|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|197|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|February 26, 2009|Yes|Yes||No|August 25, 2011|https://clinicaltrials.gov/show/NCT00853593||142674|
NCT00882388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COREA-volunteer|The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers|Phase 4 Study of the Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel||Seoul National University Hospital|Yes|Completed|March 2005|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 15, 2013|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882388||140493|
NCT00882401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008745-38|Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation|The Effect of Vitamin D on the Microcirculation of Patients With Chronic Kidney Disease (CKD) and Vitamin D Deficiency||Barts & The London NHS Trust|No|Completed|April 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2011|March 21, 2011|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882401||140492|
NCT00883038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|785206|Does a Low-Fat Vegetarian Diet Improve Insulin Resistance in Individuals With Type 2 Diabetes?|Does a Low-Fat Vegetarian Diet Improve Insulin Resistance in Individuals With Type 2 Diabetes?||Institute for Clinical and Experimental Medicine|Yes|Completed|July 2008|March 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|70|||Both|30 Years|70 Years|No|||April 2009|April 15, 2009|July 15, 2008||No||No||https://clinicaltrials.gov/show/NCT00883038||140443|
NCT00883324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0108001|Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum|A Phase IIIB Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum|SpecOp|Hologic, Inc.|No|Completed|March 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|329|||Female|18 Years|N/A|No|Non-Probability Sample|Labor and delivery triage, prenatal clinic|June 2011|June 16, 2011|April 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00883324||140421|
NCT00881309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0902|To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis|To Compare the Efficacy and Safety of Tripterygium (TW) vs Aza in the Maintenance Therapy for Lupus Nephritis||Nanjing University School of Medicine|Yes|Completed|March 2009|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|60 Years|No|||April 2009|May 17, 2011|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881309||140575|
NCT00881322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAN-2008|A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult|A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Effects of Gas Defense On Intestinal Gas Symptoms in Otherwise Healthy Adults||Miami Research Associates|No|Completed|June 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|61|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2009|September 29, 2009|April 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00881322||140574|
NCT00881842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201.3.128|Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2009/2010. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects||Abbott|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 24, 2011|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00881842||140534|
NCT00881855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA17501|To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fed Conditions.||Sandoz||Completed|March 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 14, 2009|April 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00881855||140533|
NCT00880997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18197-4|The Efficacy of Doxazosin for Cocaine Users|Doxazosin, An Alpha-1 Adrenergic Antagonist, for Cocaine Dependence: Pilot Study||Baylor College of Medicine|Yes|Completed|September 2009|December 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|64 Years|No|||October 2012|October 22, 2012|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00880997||140599|
NCT00882466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO in AMI|The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction|Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction||Seoul National University Bundang Hospital|Yes|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||April 2009|April 16, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00882466||140487|
NCT00882479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SHIS-09-0047|Formalizing a Conceptual Framework of Work Domain Knowledge|Formalizing a Conceptual Framework of Work Domain Knowledge||The University of Texas Health Science Center, Houston|No|Completed|April 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|51|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Inclusion Criteria:          1. Subjects must be over 21 years old          2. Subjects must be a student or employee in University of Texas          3. Subjects must be able to read and write in English          4. Subjects must be able to give signed informed consent|June 2012|June 12, 2012|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00882479||140486|
NCT00882492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP 1 01|GLP 1 for Intraoperative Glycemic Control|Identifying a Novel Mechanism for Perioperative Hyperglycemia Identifying a Novel Mechanism for Perioperative Hyperglycemia in Cardiac Surgery: A Role for Incretins|GLP|University of Pennsylvania|Yes|Completed|December 2008|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00882492||140485|
NCT00882843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-9|Feasibility Study for the Use of Low-magnitude, High Frequency Mechanical Stimulation of Bone in Persons With Spinal Cord Injury (SCI)|Feasibility Study for the Use of Low-magnitude, High Frequency Mechanical Stimulation of Bone in Persons With SCI||VA Office of Research and Development|No|Completed|September 2006|February 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ten ambulatory able-bodied and Twelve non-ambulatory subjects with SCI will be enrolled to        participate|June 2012|June 21, 2012|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00882843||140458|
NCT00852631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00060|Seroquel XR in Adults With Schizophrenia|Open-label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia||AstraZeneca|No|Terminated|February 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|June 12, 2012|February 26, 2009|Yes|Yes|The study was prematurely terminated due to insufficient recruitment.|No|May 18, 2011|https://clinicaltrials.gov/show/NCT00852631||142747|
NCT00852904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909083|National Children s Health Study|Vanguard Phase of the National Children s Study||National Institutes of Health Clinical Center (CC)||Completed|February 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|13700|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|October 6, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852904||142726|
NCT00852345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 5347|Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy|Clofazamine in the Long Term Treatment of Leprosy, Phase III||Kaiser Permanente||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2015|April 2, 2015|February 26, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00852345||142769|
NCT00852917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT3-003|A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee (With 7-Day Follow-up)|||Labopharm Inc.||Completed|January 2003|||August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|552|||Both|40 Years|75 Years|No|||April 2012|April 25, 2012|January 29, 2009|Yes|Yes||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00852917||142725|
NCT00852930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090118|Low Level Laser Treatment and Breast Cancer Related Lymphedema|Low Level Laser Treatment and Breast Cancer Related Lymphedema||Vanderbilt University|No|Completed|September 2009|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Female|21 Years|N/A|No|||November 2015|November 30, 2015|February 26, 2009||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT00852930||142724|
NCT00853216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8530-02-768|Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (30 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Roxicodone™, 30 mg Tablet, Roxane Laboratories, Inc.) in Normal Human Subjects Under Fasting Conditions||Mallinckrodt|No|Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 26, 2009|February 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00853216||142702|
NCT00853515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001757|Goal-directed Fluid Resuscitation in Acute Pancreatitis|A Randomized-controlled Trial of a Targeted Approach to Fluid Resuscitation in Acute Pancreatitis||Brigham and Women's Hospital|Yes|Terminated|March 2009|June 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|No|||July 2010|July 7, 2010|February 27, 2009||No|interim analysis incidence primary endpoint lower than anticipated. Sigicant finding based on    secondary endpoint.|No||https://clinicaltrials.gov/show/NCT00853515||142680|
NCT00853502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-001902|The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa|The Effect of Testosterone Replacement on Bone Mineral Density and Bone Microarchitecture in Teenage Boys and Young Adult Men With Anorexia Nervosa||Massachusetts General Hospital|Yes|Suspended|December 2008|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Male|14 Years|30 Years|No|||July 2011|July 5, 2011|February 26, 2009||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT00853502||142681|
NCT00854191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804030R|Effect of Simulator Practice on Trainees' Endoscopic Retrograde Cholangiopancreatography (ERCP) Performance in the Early Learning Period|A RCT of Mechanical Simulator Practice and Usual Training vs. Usual Training on Novice Trainee Clinical ERCP Performance||National Taiwan University Hospital|Yes|Completed|July 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|8|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2009|March 2, 2009|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854191||142628|
NCT00854178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-20|Toxicogenomic and Immunocytotoxic Effects of Propofol and Isoflurane Anesthetics in Patients Undergoing Elective Surgery|Toxicogenomic and Immunocytotoxic Effects of Propofol and Isoflurane Anesthetics in Patients Undergoing Elective Surgery||UPECLIN HC FM Botucatu Unesp|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Anticipated|26|||Both|18 Years|50 Years|No|||January 2010|January 5, 2010|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854178||142629|
NCT00854412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL1|The Effect of Weight Loss on Serum Mannose-Binding Lectin(MBL) Levels|The Effect of Weight Loss on Serum Mannose-Binding Lectin (MBL) Levels|WLMBL|University of Aarhus|No|Completed|March 1995|June 1995|Actual|June 1995|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|36|||Both|18 Years|N/A|No|||March 2009|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854412||142611|
NCT00854698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4199|Long-Term Effects of Aortic Valve Mismatch|Long-Term Effects of Aortic Valve Mismatch on Functional Ability and Remodeling the Left Ventricular After Aortic Valve Replacement Mechanics||University Hospital, Strasbourg, France|No|Completed|June 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|77|||Both|18 Years|60 Years|No|||June 2014|June 20, 2014|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854698||142589|
NCT00869557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0104|Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Atripla® (Efavirenz 600 mg/Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults||Gilead Sciences|Yes|Completed|April 2009|September 2013|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|March 24, 2009|Yes|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT00869557||141465|
NCT00854542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001437|Effectiveness of Telepsychiatry-based Culturally Sensitive Collaborative Treatment of Depressed Chinese Americans|Effectiveness of Telepsychiatry-based Culturally Sensitive Collaborative Treatment of Depressed Chinese Americans||Massachusetts General Hospital|Yes|Active, not recruiting|January 2009|April 2015|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00854542||142601|
NCT00855101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501092|A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults|An Open-Label, Intravenous (6/4 Mg/Kg Q12h) To Oral Switch (200 Mg Q12h), Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Healthy Male And Female Adults||Pfizer|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|March 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855101||142558|
NCT00854867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP1501|Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.|Phase I Randomised Multi-centre Study to Demonstrate the Safety of WBRT Concomitant to Intrathecal Liposomal Cytarabine (DepoCyte®) Versus WBRT & Sequential Intrathecal Liposomal Cytarabine (DepoCyte®) for Treatment of STNM With or Without Brain Metastasis.||Mundipharma Research Limited|Yes|Completed|February 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||February 2013|February 21, 2014|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854867||142576|
NCT00855114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS029|Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery|A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|July 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|March 3, 2009|Yes|Yes|Withdrawn due to no accrual|No||https://clinicaltrials.gov/show/NCT00855114||142557|
NCT00850863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23437|Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)|Acute and Chronic Inflammatory Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD: From Specific Disease Phenotyping Towards Novel Therapy (Study 2).||Top Institute Pharma|Yes|Recruiting|February 2009|January 2015|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||9|Anticipated|240|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuels and COPD patients. For detail description see Groups/Cohorts.|February 2009|February 24, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850863||142881|
NCT00851500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-604-2.01US|A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis|||Kowa Research Institute, Inc.|No|Completed|February 2009|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|75 Years|No|||August 2011|August 15, 2011|February 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851500||142834|
NCT00852072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090121002|Randomized Trial Comparing Spincteroplasty and Lithotripsy for Extraction of Large Bile Duct Stones|Randomized Trial Comparing Spincteroplasty and Lithotripsy for Extraction of Large Bile Duct Stones||University of Alabama at Birmingham|No|Terminated|February 2009|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|19 Years|90 Years|No|||October 2011|October 7, 2011|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852072||142790|
NCT00852085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R49CE000544-03|Reducing Youthful Dangerous Driving||RYDD|Rhode Island Hospital|Yes|Active, not recruiting|October 2005|June 2009|Anticipated|June 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|482|||Both|16 Years|20 Years|No|||February 2009|February 25, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852085||142789|
NCT00851812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8029NCI|Exercise for Breast Cancer Patients (EXCAP)|Aerobic and Resistance Exercise for Cancer Treatment-Related Fatigue||University of Rochester|Yes|Active, not recruiting|May 2007|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|114|||Female|21 Years|N/A|No|||December 2014|May 26, 2015|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851812||142810|
NCT00852371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRVG49|Intermittent Preventive Treatment of Malaria in Schoolchildren|IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda||Gates Malaria Partnership|Yes|Completed|February 2008|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|760|||Both|8 Years|13 Years|No|||February 2009|February 26, 2009|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT00852371||142767|
NCT00852644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635119|Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer||Boston Medical Center|Yes|Active, not recruiting|January 2009|March 2018|Anticipated|June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00852644||142746|
NCT00852943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090086|Screening Protocol for Genetic Diseases of Mast Cell Homeostasis and Activation|Screening Protocol for Genetic Diseases of Allergic Inflammation and Mast Cell Homeostasis and Activation||National Institutes of Health Clinical Center (CC)||Recruiting|February 2009|||||N/A|Observational|N/A|||Anticipated|500|||Both|1 Year|80 Years|No|||September 2015|October 6, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852943||142723|
NCT00863746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13266|A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).|A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease|MISSION|Bayer|Yes|Completed|April 2009|April 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|703|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|March 17, 2009|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00863746||141907|
NCT00853801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetSyn-PDM|Integrating Lifestyle Therapy for Diabetes Prevention Into Primary Care|Detecting and Managing Metabolic Syndrome and Pre-Diabetes in General Medicine Clinic (Feasibility)||John H. Stroger Hospital|Yes|Completed|February 2006|December 2010|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|1||Anticipated|112|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853801||142658|
NCT00864396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513298-2|Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux|Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux: A Double-Blind, Placebo Controlled, Randomized Clinical Trial||University of California, Davis|Yes|Completed|July 2005|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||March 2009|March 17, 2009|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00864396||141857|
NCT00864409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-2006-4062|Local Infiltration Analgesia With Ropivacaine Versus Placebo in Bilateral Hip Arthroplasty|||Hvidovre University Hospital||Recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|N/A|N/A|No|||March 2009|March 17, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864409||141856|
NCT00854438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110|Reduction of Adverse Events of Anticholinergic Drugs by Multidisciplinary Medical Reviews in Norwegian Nursing Homes|Pharmacist-initiated Reduction of Anticholinergic Drug Activity|PRADA|Oslo University Hospital|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|87|||Both|N/A|N/A|No|||June 2015|June 18, 2015|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00854438||142609|
NCT00860158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GU07-124|Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer|A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer||Hoosier Cancer Research Network|Yes|Terminated|March 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|N/A|No|||February 2016|February 4, 2016|March 11, 2009|No|Yes|Slow accrual; closed by funder|No|January 7, 2016|https://clinicaltrials.gov/show/NCT00860158||142178|This study was terminated due to slow accrual and no results were analyzed.
NCT00878826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03172009-2003|Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.|Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.||Stanford University|No|Completed|May 2009|October 2014|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|11|||Female|18 Years|55 Years|No|||November 2014|November 17, 2014|April 7, 2009||No||No|June 21, 2013|https://clinicaltrials.gov/show/NCT00878826||140763|Small numbers of subjects
NCT00854555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980924076|The ATLET Study: Can Subjects With Incomplete Spinal Cord Injury Learn to Walk?|The ATLET Study: Can Subjects With Incomplete Spinal Cord Injury Learn to Walk? A Randomized Clinical Trial|ATLET|North Norway Rehabilitation Center|No|Recruiting|August 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2015|January 16, 2015|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854555||142600|
NCT00854594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-414|Interprofessional Training to Improve Diabetes Care: The ReSPECT Trial|Interprofessional Training for Improving Diabetes Care|ReSPECT|VA Office of Research and Development|No|Completed|September 2010|September 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|117|||Both|25 Years|85 Years|No|||September 2015|September 2, 2015|February 27, 2009||No||No|June 11, 2015|https://clinicaltrials.gov/show/NCT00854594||142597|IRB-related delays were so significant that aspects of the research plan could not be completed. Delays have also been experienced in the collection and analysis of clinical endpoints.
NCT00855140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT004429-01A1|Acupuncture for the Treatment of Insomnia|Acupuncture for the Treatment of Insomnia - A Pilot Study||University of Pittsburgh|Yes|Completed|March 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|60 Years|No|||January 2016|January 7, 2016|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855140||142555|
NCT00850876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOA-12008|Heated Humidified Continuous Positive Airway Pressure and Nasal Physiology|Randomized Cross-over Trials of the Effect of Heated Humidified CPAP Versus Non-humidified CPAP on Nasal Physiology||University of Athens|No|Completed|September 2008|June 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|20|Samples Without DNA|Nasal wash will be performed using a technique adapted by Hurst et al. Briefly, a 12-French      Foley catheter (Bard, Crawley, UK), modified by removal of the tip distal to the balloon,      was inserted into the nostril and inflated with sufficient air to form a comfortable seal      (typically 7-10ml). With the patients head flexed 45o forward, 7ml of warmed 0.9% saline      will be instilled through the catheter and washed in and out of the nasal cavity three      times. A portion of the pooled wash from both nostrils will be centrifuged to yield a      supernatant for analysis of inflammatory cytokines (IL-6, IL-8, TNF-a, IL-10).|Both|18 Years|80 Years|No|Non-Probability Sample|Subjects who refer to the Center of Sleep Disorders of "Evangelismos" General Hospital of        Athens for suspected sleep disordered breathing.|April 2010|April 8, 2010|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850876||142880|
NCT00850837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Keller 069551 AF020|Safety of Acidform Lubricant in HIV-Uninfected Women|Safety of Acidform Lubricant (Amphora) in Women at Low Risk for HIV-1 Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2009|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|February 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00850837||142883|
NCT00850850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-002497-22|Physostigmine After General Anesthesia|The Use of Physostigmine in Elderly Patients in the Postoperative Recovery-phase After General Anesthesia||Bispebjerg Hospital|Yes|Recruiting|December 2009|May 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|N/A|No|||May 2010|May 26, 2010|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850850||142882|
NCT00851136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APM4566g|A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)|A Phase Ib Study of the Safety and Pharmacokinetics of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer||Genentech, Inc.||Completed|May 2009|June 2010|Actual|||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|February 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851136||142862|
NCT00851201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK075981|Family Weight Management Study|Comprehensive Approach to Family Weight Management||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|August 2009|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|506|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00851201||142857|
NCT00851461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID11-50-17|Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy|Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai Patients||Ramathibodi Hospital|No|Completed|April 2008|November 2013|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|20 Years|N/A|No|||February 2009|May 20, 2015|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851461||142837|
NCT00851864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05161977|Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing|Weight-Adjusted Dosing of Tinzaparin in Pregnancy||University of Calgary|Yes|Completed|October 2007|May 2011|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 14, 2013|November 18, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851864||142806|
NCT00852358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRC-002|A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I|A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I||Dickson, Patricia I., M.D.|Yes|Completed|June 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|6 Years|N/A|No|||January 2016|January 22, 2016|February 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00852358||142768|
NCT00852384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0046|Non Invasive Pressure Support Ventilation (NIPPV) Versus Recruitment Maneuver (RM) and Preoxygenation|Non Invasive Pressure Support Ventilation (NIPPV) Versus Conventionnal Approach and Early Recruitment Maneuver (RM) for Preoxygenation of Morbidly Obese Patient||University Hospital, Clermont-Ferrand||Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2009|August 27, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852384||142766|
NCT00852657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|430-04149 (REK)|Comparison of Tendon Repair and Physiotherapy in the Treatment of Small and Medium-sized Tears of the Rotator Cuff|Comparison of Surgical Treatment by Tendon Repair and Physiotherapy in the Treatment of Small and Medium-sized Tears of the Rotator Cuff||Martina Hansen's Hospital|No|Active, not recruiting|September 2004|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852657||142745|
NCT00863369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04115|Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma|A Phase I/II Study of VELCADE in Combination With Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma||City of Hope Medical Center|Yes|Active, not recruiting|June 2005|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863369||141935|
NCT00864110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-05-233|Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)|A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)||Cell>Point LLC|Yes|Completed|April 2010|December 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|4|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00864110||141879|
NCT00864760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P99-228|A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Versus 400 mg Gabapentin Capsules Under Fasting Conditions||Actavis Inc.|No|Completed|June 1999|June 1999|Actual|June 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864760||141829|
NCT00864084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:007|Does Pulmonary Rehabilitation Improve Balance in People With Respiratory Disease?|Does a Pulmonary Rehabilitation Program Improve Balance in Individuals With Respiratory Disease?||University of Manitoba|No|Completed|April 2009|December 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|N/A|No|||August 2014|August 26, 2014|March 17, 2009||No||No|September 30, 2013|https://clinicaltrials.gov/show/NCT00864084||141881|This sample size in this study was small. Study participants received an individualised exercise program which means that exercises given and number of pulmonary rehabilitation sessions attended were not standardized between study participants.
NCT00864097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091017|Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip|A Phase 3, Randomized, Double-Blind, Controlled, Multi-Center Study Of The Analgesic Efficacy And Safety Of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip||Pfizer|Yes|Terminated|August 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|607|||Both|18 Years|N/A|No|||February 2012|March 4, 2015|March 17, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00864097||141880|
NCT00864734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02-995|A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|November 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864734||141831|
NCT00864747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-1384|A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 160 mg Propranolol Hydrochloride Extended Release Capsules Under Non-Fasting Conditions||Actavis Inc.|No|Completed|May 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864747||141830|
NCT00864708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3252-R|Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008|Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008||VA Office of Research and Development|Yes|Terminated|December 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|21 Years|N/A|No|||May 2014|May 7, 2014|March 17, 2009|No|Yes|The enrollment period/study duration had exceeded The Alfred Mann Foundation's timeline.|No|November 25, 2013|https://clinicaltrials.gov/show/NCT00864708||141833|Study sponsor, Alfred Mann foundation (AMF) stopped study because “enrollment period/study duration has exceeded the AMF’s timeline”.
NCT00878540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L2/2008|Short-term Metabolic Effects of Mirtazapine in Healthy Subjects|Phase 1 Study of Mirtazapine in Healthy Subjects|SMMS|Max-Planck-Institute of Psychiatry|No|Completed|September 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Male|20 Years|25 Years|Accepts Healthy Volunteers|||September 2010|September 15, 2010|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878540||140785|
NCT00874159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3712|A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in Philippines|DiabCare Asia 2008 Philippines A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Philippines & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Philippines|DiabCare Asia|Novo Nordisk A/S|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|770|Samples With DNA|Capillary or venous blood will be drawn for analysing HbA1c.|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to inclusion        and exclusion criteria.|August 2014|August 12, 2014|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00874159||141118|
NCT00874445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 475|Comparison of 50% Tilt and Tuned Waveforms in Single-Coil Active Can Configuration|Prospective Comparison of 50/50% Tilt and Tuned Defibrillation Waveforms in a Single Coil Active Can Configuration|PROMISE|St. Jude Medical|No|Completed|March 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|77|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with ICD/CRT-D indications|June 2015|June 3, 2015|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874445||141096|
NCT00854841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-257|The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder|Randomized, Open Label Study of Dasatinib (100mg qd) vs. High-Dose Imatinib (600mg) in Patients With Chronic Phase CML Who Have Had Suboptimal Response After 3-18 Months of Therapy With Imatinib (400mg)||Pusan National University Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2009|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854841||142578|
NCT00854854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BX-TK-001|Efficacy Study of TKcell in Advanced Gastric Cancer|Evaluating the Safety and Efficacy of Combination Therapy With FOLFOX-4 and TKcell Therapy Versus FOLFOX-4 Alone in Patients With Recurrent, Unresectable and Advanced Gastric Cancer||Binex|No|Enrolling by invitation|January 2009|July 2010|Anticipated|January 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|19 Years|N/A|No|||March 2009|May 15, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00854854||142577|
NCT00854607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-089|An Observational Study of Fungal Biomarkers (MK-0000-089)|A Prospective, Non-Intervention, Observational Assessment of the Correlation Between Circulating Biomarkers of Fungal Bioburden and Clinical Outcome in the Setting of Invasive Aspergillosis||Merck Sharp & Dohme Corp.|No|Completed|March 2009|August 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|Samples With DNA|Blood samples are collected for 12 weeks to evaluate levels of fungal biomarkers.|Both|16 Years|N/A|No|Non-Probability Sample|Participants will be selected through collaborations with clinicians.|August 2015|August 4, 2015|February 27, 2009||No||No|July 24, 2012|https://clinicaltrials.gov/show/NCT00854607||142596|
NCT00854620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-04988|Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer|A Phase 2 Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma at Stanford University||Stanford University|Yes|Completed|December 2007|January 2011|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|No|||May 2015|May 20, 2015|February 27, 2009|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT00854620||142595|
NCT00855127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0769|New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients|Early Biomarkers of Acute Kidney Injury in Liver Transplant Patients||University of Colorado, Denver|No|Withdrawn|January 2009|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Urine supernatent Serum|Both|18 Years|90 Years|No|Non-Probability Sample|All patients presenting to the University of Colorado Hospital or the University of        Washington Medical Center for a liver transplant operation|May 2015|May 28, 2015|March 3, 2009||No|no enrollment|No||https://clinicaltrials.gov/show/NCT00855127||142556|
NCT00850889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-JULIDO-0801|Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nasolabial Folds|||Allergan||Completed|November 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|October 6, 2014|February 23, 2009|Yes|Yes||No|February 24, 2011|https://clinicaltrials.gov/show/NCT00850889||142879|
NCT00851175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rosucaff2|Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?|Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?||Radboud University|No|Completed|March 2009|September 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2009|September 30, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851175||142859|
NCT00851214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFH DEM 001|Use of Non Invasive Hemodynamic Cardiovascular Monitoring to Evaluate Emergency Department Patients|Assessments of Early Hemodynamics in Emergency Department Patients and Evaluation of Trends and Variability in Prediction of Life-saving Interventions||Henry Ford Health System|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Acutely ill or injured Emergency Department patients|March 2009|February 17, 2010|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851214||142856|
NCT00851227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-086|Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function|A Phase 1, Open-Label Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan||Cumberland Pharmaceuticals|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|26|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|February 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00851227||142855|
NCT00851877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634258|Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer|A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma||University of Texas Southwestern Medical Center||Active, not recruiting|March 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851877||142805|
NCT00852098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1069/06|Laparoscopic Nissen Fundoplication Comparing Division Versus Non-Division of Short Gastric Vessels|Randomized Clinic Trial of Total Fundoplication and Fundal Mobilization With or Without Division of Short Gastric Vessels: Long-Term Endoscopic Evaluation||Federal University of São Paulo|Yes|Completed|November 1997|May 2008|Actual|January 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2009|February 25, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852098||142788|
NCT00862719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812-15; IUCRO-0223|Sitagliptin Umbilical Cord Blood Transplant Study|A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies||Indiana University|Yes|Completed|March 2009|February 2015|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|59 Years|No|||February 2016|February 26, 2016|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862719||141984|
NCT00862732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRD/03-08|Study to Prevent Negative Thoughts of Life|A Randomised Controlled Trial With Cognitive Behavioural Therapy for Persons With Active Suicidal Ideations||Institute for Research & Development Sri Lanka|No|Not yet recruiting|March 2009|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|68|||Both|18 Years|64 Years|No|||March 2009|March 16, 2009|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862732||141983|
NCT00863057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5252|Combination Pain Therapy in HIV Neuropathy|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|15|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|March 16, 2009|Yes|Yes||No|December 14, 2011|https://clinicaltrials.gov/show/NCT00863057||141959|The results should be interpreted with caution since the total sample size was much lower than planned.
NCT00863031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-497|A Trial on the Effectiveness of Screening and Brief Problem-Solving Therapy (PST) for Elderly Patients With Psychological Problems|A Randomised Controlled Trail on the Effectiveness of Screening and Brief Counselling (Problem-Solving Therapy) for Elderly Patients With Psychological Problems in Primary Care.||The University of Hong Kong|No|Completed|November 2002|June 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|299|||Both|60 Years|N/A|No|||March 2009|March 16, 2009|March 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00863031||141961|
NCT00863044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1032|High Frequency Ventilation During Off Pump Coronary Artery Bypass Graft (CABG)|Impact of High Frequency Ventilation During Coronary Anastomosis in Off Pump Coronary Artery Bypass.|VHF|Montreal Heart Institute|No|Completed|November 2009|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|19 Years|N/A|No|||March 2016|March 15, 2016|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863044||141960|
NCT00863759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|656/06|Wavefront Analysis and Contrast Sensitivity After Cataract Surgery With Akreos Advanced Optics Intraocular Lens Implantation|Wavefront Analysis and Contrast Sensitivity After Cataract Surgery With Akreos AO Intraocular Lens Implantation: Clinical Comparative Study||University of Sao Paulo|No|Completed|March 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||March 2009|July 1, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863759||141906|
NCT00864773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-3-16|The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy|Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab||Hallym University Medical Center|Yes|Enrolling by invitation|March 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|60 Years|No|||March 2009|March 18, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864773||141828|
NCT00864422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC-ID351656|Changes in Motor Cortex Following Exercises for Chronic Low Back Pain|Driving Plasticity in the Motor Brain in Chronic Back Pain||The University of Queensland|No|Completed|October 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|55 Years|No|||March 2009|March 17, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864422||141855|
NCT00864721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-135|Sunitinib Non Small Cell Lung Cancer Patients Over 70|Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70||US Oncology Research|No|Completed|February 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|70 Years|N/A|No|||May 2014|May 19, 2014|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00864721||141832|
NCT00852176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Best PMA Post-approval Study|Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System|Best Vascular P000018 Post-approval Study: Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System||Best Vascular, Inc.|Yes|Recruiting|May 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated on-label with the Beta-Cath™ 3.5F System at Washington Hospital Center|March 2010|March 31, 2010|February 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00852176||142782|
NCT00860171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2238.00|Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma|A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies||Fred Hutchinson Cancer Research Center|Yes|Recruiting|February 2009|||September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|March 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00860171||142177|
NCT00874744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cerof-001|Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema|Phase 2 Study of Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema.|Tribeva-DME|Universidade Federal de Goias|No|Completed|March 2008|October 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|40 Years|90 Years|No|||March 2009|March 31, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874744||141074|
NCT00874757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088-09|Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects|Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of||University of Nebraska|No|Recruiting|July 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|19 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 healthy subjects|August 2011|August 2, 2011|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874757||141073|
NCT00875043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120070324|Determine the Effect of Intraocular Pressure (IOP), Optic Nerve Imaging, Venous Congestion in Volunteers Prone Position 5 Hours|A Pilot Study to Determine the Effect on Intraocular Pressure, Optic Nerve Imaging and Other Markers of Venous Congestion of Volunteer Subjects in the Prone Position for a Period of Five Hours||Rutgers, The State University of New Jersey|No|Completed|March 2008|July 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|April 2009|April 2, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00875043||141051|
NCT00854334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neat-OSA-001|Co-existent Obstructive Sleep Apnea (OSA) and Obesity: Finding Non-exercise Activity Thermogenesis (NEAT) Targets for Intervention|Co-existent OSA and Obesity: Finding NEAT Targets for Intervention||Katz, Sherri Lynne, M.D.|No|Recruiting|September 2010|December 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples Without DNA|urine|Both|10 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited from those scheduled to undergo polysomnography in the sleep        laboratory at the Children's Hospital of Eastern Ontario|July 2011|July 18, 2011|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854334||142617|
NCT00854880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|921105|A Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Comparative Phase II Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis||National Taiwan University Hospital||Completed|March 2005|February 2006|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|69|||Both|20 Years|N/A|No|||March 2005|March 2, 2009|September 12, 2005||||No||https://clinicaltrials.gov/show/NCT00854880||142575|
NCT00854893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV3128|Enhance of Language Learning With Neurostimulation|Enhance of Language Learning With Neurostimulation (Transcranial Direct Current Stimulation)||Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|October 2009|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|86 Years|Accepts Healthy Volunteers|||March 2011|March 18, 2011|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854893||142574|
NCT00851188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU-vandenBout|Internet Delivered Self-help for Insomnia|||Utrecht University|Yes|Completed|January 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|626|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 12, 2012|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851188||142858|
NCT00850902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-049|Humidity Strategy to Decrease Morbidity and Mortality in Extremely Low Birth Weight Infants|Application of a Different Incubator Humidity Strategy at Birth to Decrease Morbidity and Mortality in Extremely Low Birth (1000 g or Less) Infants||King Fahad Medical City|Yes|Not yet recruiting|March 2009|April 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|700|||Both|N/A|N/A|No|||March 2009|March 9, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850902||142878|
NCT00850915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR-01-2009-IPT-KENYA|Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya|Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya|IPT|KNCV Tuberculosis Foundation|No|Completed|April 2009|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1259|||Both|15 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 17, 2013|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850915||142877|
NCT00851825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-435|Heart Rate Variability During Weaning From Mechanical Ventilation|The Effect of T-Tube and Pressure Support on Cardiorespiratory Variables and Heart Rate Variability During Weaning From Mechanical Ventilation||Hospital de Clinicas de Porto Alegre|No|Completed|March 2003|June 2007|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with respiratory failure receiving MV for more than 48 hours, who had been        admitted to the Intensive Care Unit (ICU) of the Hospital de Clínicas de Porto Alegre, and        who met the criteria for weaning from MV according to the parameters previously defined        were selected to participate in this study.|May 2009|May 7, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851825||142809|
NCT00851838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-001-06|L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis|Phase 2 Study of Dialysis Efficiency and Tolerability of Peritoneal Dialysis Solution Containing Glucose Plus L-Carnitine in APD (Automated Peritoneal Dialysis) Treated Uremic Patients||Iperboreal Pharma Srl|No|Completed|June 2009|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851838||142808|
NCT00862043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBHGM-SIOVAC|Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease|Sildenafil for Improving Outcomes After Valvular Correction|SIOVAC|Hospital General Universitario Gregorio Marañon|Yes|Active, not recruiting|April 2009|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862043||142034|
NCT00852111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090088|Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy|Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|February 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|292|||Male|18 Years|N/A|No|||May 2014|July 30, 2015|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852111||142787|
NCT00862394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0705-PR-0027|A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma|A 12-week, Multinational, Randomised, Double Blind, Double Dummy, 4-arm Parallel-group Study Comparing the Efficacy and Safety of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation, Via HFA Pressurised Inhalation Solution, in Moderate to Severe Symptomatic Asthmatic Patients Aged ≥ 12 Years Under Treatment With Inhaled Corticosteroids||Chiesi Farmaceutici S.p.A.|No|Completed|February 2009|January 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|783|||Both|12 Years|N/A|No|||October 2009|August 24, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862394||142009|
NCT00863070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003|Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy|Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy|Gait|Connecticut Children's Medical Center|No|Recruiting|April 2009|June 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|8|||Both|4 Years|65 Years|No|Non-Probability Sample|Bladder exstrophy patients receiving follow-up services at Connecticutcmc Urology clinic.|June 2011|June 14, 2011|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00863070||141958|
NCT00863382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11566|Comparison of External Event Recorders for Atrial Fibrillation Monitoring|Comparison of External Event Recorders With Implantable Monitor for Post Atrial Fibrillation Monitoring: Assessment of Cost and Efficacy||University of Kansas Medical Center|No|Withdrawn|January 2009|January 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00863382||141934|
NCT00864435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3159|A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single Dose, Fasting, Bioequivalence Study of Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets in Normal, Healthy, Non-Smoking Male and Female Subjects||Actavis Inc.|No|Completed|October 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864435||141854|
NCT00864448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-677-1G|A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Under Fasting Conditions||Actavis Inc.|No|Completed|October 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864448||141853|
NCT00852189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-0489-01|Study of EC0489 for the Treatment of Refractory or Metastatic Tumors|A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle||Endocyte|No|Completed|April 2009|April 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|February 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00852189||142781|
NCT00860184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPD2008A|SmartRisk Stroke Prediction by MRI of Carotid Disease|Assessment of MRI-based Prediction of Stroke and Other Cerebrovascular Symptoms Arising From Carotid Atherosclerotic Disease in Asymptomatic Individuals|SmartRisk|VPDiagnostics|Yes|Recruiting|November 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patient referred for ultrasound assessment of carotid artery disease|April 2011|April 13, 2011|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860184||142176|
NCT00853008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-AR/2003|Treatment of High Risk Adult Acute Lymphoblastic Leukemia|Treatment of High Risk Adult Acute Lymphoblastic Leukemia|LAL-AR/2003|PETHEMA Foundation|Yes|Active, not recruiting|January 2003|January 2016|Anticipated|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|16 Years|N/A|No|||October 2015|October 12, 2015|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853008||142718|
NCT00852436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dao-Watson Pregabalin|Pregabalin and Orofacial Neuropathic Pain|Efficacy of Pregabalin in the Treatment of Orofacial Neuropathic Pain|Pregabalin-Dao|University of Toronto|No|Terminated|February 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||November 2010|June 1, 2015|November 6, 2008||No|difficulty to recruit patients|No||https://clinicaltrials.gov/show/NCT00852436||142762|
NCT00853268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0595-05-813|Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Controlled-Release Test Tablet Formulation of Oxycodone Hydrochloride (40 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (OxyContin® 40 mg, Purdue Pharma L.P.) in Normal Human Subjects Under Fed Conditions||Mallinckrodt|No|Completed|April 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853268||142698|
NCT00874783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0599-08-HMO-CTIL|Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases|Derivation of Induced Pluripotent Stem Cells From Somatic Cells Donated by Patients With Neurological Diseases for the Study of the Pathogenesis of the Disorders and Development of Novel Therapies||Hadassah Medical Organization|No|Active, not recruiting|April 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|donation of a skin specimen of up to 10mm in diameter from skin which will be removed in a      surgical operation from a patient who is scheduled to undergo an operation for medical      reasons and with no relation to the study at hand.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|120 donors to cover 10 different neurodegenerative disorders (previously specified) based        on 10 donors per disorder and 20 healthy control donors.|February 2016|February 28, 2016|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00874783||141071|
NCT00854035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5435-15|MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus|A Phase III, Randomized, Placebo-Controlled, Double-Blind Clinical Trial and Subsequent Open-Label, Extension Clinical Trial to Study the Efficacy and Safety of Addition of MK-0431/ONO-5435 in Japansese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Insulin Monotherapy||Ono Pharmaceutical Co. Ltd||Completed|February 2009|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00854035||142640|
NCT00854048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M112|The Performance of Pulse Oximeters in Pediatric Patients With Low Oxygen Saturation Levels|The Performance of Nellcor OxiMax N-560 and Masimo SET Radical Pulse Oximeters in Pediatric Patients With Low Oxygen Saturation Levels||Medtronic - MITG|Yes|Completed|December 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|66|||Both|N/A|N/A|No|Probability Sample|Pediatric patients after cardiopulmonary by-pass in the PICU.|February 2009|February 27, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00854048||142639|
NCT00854061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PKT-0415083-P|Study of T-PRED(TM) Compared to Pred Forte(R) II|||Bausch & Lomb Incorporated|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|135|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854061||142638|
NCT00854347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Albert|Hyperglycemia in the Intensive Care Unit, a Prevalence Study|Hyperglycemia in the Intensive Care Unit Marker of Diabetes or Pre-Diabetes ?||Université de Montréal|No|Completed|November 2005|February 2007|Actual|August 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|All adults patients with an expected stay of 24 hours or more who are admitted to our 28        beds ICU tertiary center Sacré-Coeur Hospital ICU.|November 2008|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854347||142616|
NCT00854360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-201|Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Range-Finding Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Adult and Adolescent Patients (12 Years and Older) With Seasonal Allergic Rhinitis (SAR)||Teva Pharmaceutical Industries|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|487|||Both|12 Years|N/A|No|||April 2012|April 23, 2012|March 2, 2009|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00854360||142615|
NCT00855153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-09-012|Virtual Reality and D-Cycloserine in Combat Related Psycological Trauma in Burn Service Members|A Pilot Study Using Gradual Virtual Reality Exposure Therapy and D-Cycloserine (DCS) for Treatment of Combat Related Psychological Trauma in Burn Service Members||United States Army Institute of Surgical Research|No|Withdrawn|May 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|45 Years|No|||December 2011|December 19, 2011|March 3, 2009||No|Investigator was not able to maintain IRB approval. Study never accrued subjects.|No||https://clinicaltrials.gov/show/NCT00855153||142554|
NCT00855166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00012|Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes|A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone||AstraZeneca|Yes|Completed|February 2009|December 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|30 Years|75 Years|No|||August 2013|August 9, 2013|March 3, 2009|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT00855166||142553|For participants who did not complete 24 weeks, last observation carried forward (LOCF) was used.
NCT00855179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1138.11|Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency|A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 720 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency||Boehringer Ingelheim||Completed|March 2009|||November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|March 3, 2009||||No||https://clinicaltrials.gov/show/NCT00855179||142552|
NCT00851240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT12-CD015|BTT-1023 in Rheumatoid Arthritis|A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Rheumatoid Arthritis - a Double-blind Randomized Placebo-controlled Sequential Group Trial||Biotie Therapies Corp.||Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||February 2012|February 2, 2012|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00851240||142854|
NCT00851253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635094|Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer|The Feasibility and Outcome of Cyberknife® Stereotactic Radiosurgical Boost and Salvage Therapy for Head and Neck Cancer||Boston Medical Center|Yes|Active, not recruiting|January 2009|February 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|February 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851253||142853|
NCT00851513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD08/6-B|Therapeutic Effects Analysis of Pudendal Nerve Infiltrations After 3 Months, in Patients Suffering of Pudendal Neuralgia||INFILTHERA|Nantes University Hospital||Completed|November 2008|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|202|||Both|18 Years|N/A|No|||September 2013|September 2, 2013|February 25, 2009||||No||https://clinicaltrials.gov/show/NCT00851513||142833|
NCT00851539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-443|Evaluating Post-test HIV Counseling Videos for Teens|Educational Effectiveness of an HIV Pretest Video for Adolescents: A Randomized Controlled Trial|Control|North Bronx Healthcare Network|Yes|Completed|June 2008|April 2011|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|200|||Both|15 Years|21 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851539||142831|
NCT00851851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1104|New Non-invasive Methods for Real-time Monitoring of Organ Function.|New Non-invasive Methods for Real-time Monitoring of Organ Function.|RTMKF|Washington University School of Medicine|No|Active, not recruiting|January 2009|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Urine and blood samples|Both|18 Years|N/A|No|Probability Sample|Surgical patients.|August 2015|August 13, 2015|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851851||142807|
NCT00862420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY10810|Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease|A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg/Day Versus Ticlopidine 200 mg/Day in Patients With Peripheral Arterial Disease - With Extended Treatment of Clopidogrel 75 mg/Day for 40 Weeks||Sanofi|Yes|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|431|||Both|20 Years|N/A|No|||July 2012|July 16, 2012|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00862420||142007|
NCT00862433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090097|Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women|Vitamin E Pharmacokinetics and Biomarkers in Women||National Institutes of Health Clinical Center (CC)||Recruiting|March 2009|December 2019|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|326|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862433||142006|
NCT00862407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19299|Impact of Pulsatile Cardio-Pulmonary Bypass (CPB) on Vital Organ Recovery|Impact of Pulsatile CPB on Vital Organ Recovery||Penn State University|Yes|Recruiting|October 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|Samples Without DNA|Blood and plasma samples|Both|N/A|17 Years|No|Non-Probability Sample|300 children (150 per perfusion system) ages 1 year to < 18 years requiring CPB for        cardiac surgery.|May 2012|May 8, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00862407||142008|
NCT00862706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AUS06|Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks|An Open-label, Single-arm, Multicenter, Study of Telbivudine in Nucleos(t)Ide-naïve Subjects of Black/African American or Hispanic/Latino Origin With Compensated Chronic Hepatitis B Virus (HBV) Infection||Novartis||Terminated|April 2009|||December 2011|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|16 Years|70 Years|No|||November 2011|November 1, 2011|March 16, 2009|Yes|Yes|Stopped with Patients|No||https://clinicaltrials.gov/show/NCT00862706||141985|
NCT00862745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA0221IX|Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)|A Multi-center, Randomized, Placebo-controlled Clinical Trial Comparing Fesoterodine to Placebo in Women Diagnosed With Urge Urinary Incontinence by the 3 Incontinence Questions (3IQ). Followed by a Multi-center Open Label Clinical Cohort Study of Long-term Effects of Treatment With Fesoterodine.|BRIDGES|University of California, San Francisco|Yes|Completed|January 2009|May 2011|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|645|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 19, 2011|March 13, 2009|Yes|Yes||No|September 14, 2011|https://clinicaltrials.gov/show/NCT00862745||141982|
NCT00863772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091026|Tanezumab and Nerve Function In Arthritis Patients|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of Tanezumab On Peripheral Nerve Function In Patients With Osteoarthritis||Pfizer|No|Terminated|May 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|220|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|March 17, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00863772||141905|
NCT00864123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH076775|D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder|D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder||University of South Florida|No|Completed|January 2008|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|March 17, 2009||No||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00864123||141878|
NCT00851604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052508-HMO-CTIL|ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors|Evaluation of Serological Markers ProGRP, CgA, NSE and TUM2-PK in Patients With Malignant Neuroendocrine Tumors||Hadassah Medical Organization|No|Recruiting|March 2009|January 2011|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Serum and plasma|Both|18 Years|90 Years|No|Non-Probability Sample|The patients with neuroendocrine tumors|May 2010|June 2, 2010|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851604||142826|
NCT00852449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0045|Intraoperative Hypovolemia and Fluid Therapy|Restrictive Versus Liberal Intraoperative Goal-directed Fluid Management During Major Abdominal Surgery:a Prospective Randomized Study||University Hospital, Clermont-Ferrand||Terminated|May 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|70|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852449||142761|
NCT00853281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLIH|A Cluster Randomized Trial to Evaluate Long Lasting Insecticidal Hammocks to Prevent Forest Malaria in Vietnam|A Cluster Randomized Trial to Evaluate the Effectiveness of Long Lasting Insecticidal Hammocks for Controlling Forest Malaria in Central Vietnam||Institute of Tropical Medicine, Belgium|No|Completed|March 2004|June 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18646|||Both|N/A|N/A|No|||September 2010|September 12, 2010|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853281||142697|
NCT00853307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14006|MLN8237 for Treatment of Patients With Ovarian, Fallopian Tube, or Peritoneal Carcinoma|A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients With Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Millennium Pharmaceuticals, Inc.|No|Completed|March 2009|June 2011|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||November 2013|November 15, 2013|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853307||142695|
NCT00853580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X080929007|A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1|A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1|STARS|University of Alabama at Birmingham|Yes|Active, not recruiting|July 2009|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853580||142675|
NCT00853606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-314|Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction|An Open-Label, Long-Term Evaluation of the Safety and Efficacy of Avanafil in Men With Erectile Dysfunction||VIVUS, Inc.|No|Completed|March 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|712|||Male|18 Years|N/A|No|||August 2012|August 10, 2012|February 27, 2009|Yes|Yes||No|May 25, 2012|https://clinicaltrials.gov/show/NCT00853606||142673|
NCT00874796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-227-0106|Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection|A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106)||Gilead Sciences|Yes|Terminated|May 2009|July 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|307|||Both|18 Years|65 Years|No|||January 2014|January 3, 2014|April 2, 2009|Yes|Yes|Reports of significant laboratory abnormalities and adverse events in a number of clinical    study participants.|No||https://clinicaltrials.gov/show/NCT00874796||141070|
NCT00875069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0050|Efficacy and Safety of Ethanol Lock Solution in Prevention of Catheter Related Bloodstream Infection for Patients Suffering Acute Renal Failure, and Hospitalized in Intensive Care Unit. A Multi-Center, Randomized, Versus Placebo, Double Blinded Clinical Trial|Efficacy and Safety of Ethanol Lock Solution in Prevention of Catheter Related Bloodstream Infection for Patients Suffering Acute Renal Failure, and Hospitalized in Intensive Care Unit. A Multi-Center, Randomized, Versus Placebo, Double Blinded Clinical Trial.|ELVIS|University Hospital, Clermont-Ferrand||Completed|April 2009|February 2013|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|1460|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875069||141049|
NCT00854074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL - 01|Neurostimulation for the Treatment of Post-Operative Ileus|Neurostimulation for the Treatment of Post-Operative Ileus||ElectroCore LLC|No|Withdrawn|July 2009|January 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||February 2016|February 15, 2016|February 26, 2009|Yes|Yes|Withdrawn: study halted prematurely, prior to enrollment of first participant|No||https://clinicaltrials.gov/show/NCT00854074||142637|
NCT00854633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-0901|Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants|Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants||Agennix|Yes|Recruiting|June 2009|December 2012|Anticipated|March 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|24 Hours|No|||March 2012|March 13, 2012|March 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854633||142594|
NCT00854646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-05|Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)|Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS||Onconova Therapeutics, Inc.|No|Completed|October 2008|December 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|February 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00854646||142593|
NCT00855218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12918|A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).|A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).||Bayer|Yes|Completed|March 2009|February 2013|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|March 3, 2009|Yes|Yes||No|August 23, 2012|https://clinicaltrials.gov/show/NCT00855218||142549|
NCT00851266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V512-002|A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults|A Dose-Escalation, Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of a Bivalent Influenza Peptide Conjugate Vaccine Formulated With Aluminum- and ISCOMATRIX(TM) Containing Adjuvants (BIPCV/IMX) Evaluated in Healthy Adults 18 to 35 Years of Age||Merck Sharp & Dohme Corp.||Completed|October 2006|January 2009|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|187|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|February 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00851266||142852|
NCT00851526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-04-042|Coronary Bifurcation Stenting (COBIS) Registry in South Korea|Coronary Bifurcation Stenting (COBIS) Registry in South Korea|COBIS|Samsung Medical Center||Completed|January 2004|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1919|||Both|18 Years|N/A|No|Probability Sample|Patients with coronary bifurcation lesion treated with drug-eluting stents|July 2012|July 15, 2012|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851526||142832|
NCT00851552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635486|Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment|A Phase II Study of VDR (VELCADE™, DOXIL® and RITUXAN™) in Relapsed/Refractory Diffuse Large B-cell Lymphoma||Roswell Park Cancer Institute|Yes|Terminated|January 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|February 25, 2009|Yes|Yes|Lack of sponsor support|No|June 23, 2014|https://clinicaltrials.gov/show/NCT00851552||142830|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.
NCT00863083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/101|Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity|Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity||Medical College of Wisconsin|No|Terminated|February 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|8 Years|17 Years|No|||June 2010|June 17, 2010|March 16, 2009||No|Study was terminated due to poor enrollment.|No||https://clinicaltrials.gov/show/NCT00863083||141957|
NCT00863096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAT.1246-04-07527-GRT|Human Papillomavirus Screening and Vaccine Readiness Program|Human Papillomavirus Screening and Vaccine Readiness Program||Public Health Research Institute, India|No|Withdrawn|June 2009|December 2010|Anticipated|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young women who participated in the formative study on acceptability of HPV vaccine in        Mysore, India|March 2009|March 2, 2011|March 16, 2009||No|Unable to get the vaccine on time to offer it to the study population.|No||https://clinicaltrials.gov/show/NCT00863096||141956|
NCT00862758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14524|Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab|Emergency IND for Provision of Tocilizumab||University of Oklahoma|No|No longer available|February 2009|October 2010|Actual|October 2010|Actual|N/A|Expanded Access|N/A|||||||Male|11 Years|12 Years|No|||December 2013|December 9, 2013|March 16, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00862758||141981|
NCT00863395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0705M09523|Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma|Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma|CTCL|University of Minnesota - Clinical and Translational Science Institute|No|Terminated|December 2008|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 28, 2014|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00863395||141933|
NCT00851032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0885|Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol|An Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial. A Molecular Profile-Based Study in Patients With Advanced Cancer Treated in the Investigational Cancer Therapeutics Program||M.D. Anderson Cancer Center|No|Recruiting|February 2009|||February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|5000|Samples With DNA|Specimen obtained from MDACC Tissue Bank.|Both|N/A|N/A|No|Non-Probability Sample|Patients with Advanced Cancer Treated in the Investigational Cancer Therapeutics Program        Registered on MDACC tissue bank protocol (LAB07-0817).|January 2016|January 14, 2016|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00851032||142869|
NCT00851331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3391|Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits|Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits||University Hospital, Strasbourg, France||Not yet recruiting||||||N/A|Interventional|N/A|||||||Both|4 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 24, 2009|February 24, 2009||||No||https://clinicaltrials.gov/show/NCT00851331||142847|
NCT00852462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-404|Lung Cancer Symptom Assessment and Management Intervention|Lung Cancer Symptom Assessment and Management Intervention||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2008|June 2016|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|179|||Both|21 Years|N/A|No|||October 2014|October 26, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852462||142760|
NCT00852475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARA-006-08F|Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome|Comparative Effects of Two Popular Diets in Veterans With the Metabolic Syndrome|MUFA PUFA|VA Office of Research and Development|No|Completed|February 2010|April 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852475||142759|
NCT00852735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0047|Effect of the Antioxidant Micronutrients of Rapeseed Oil on the Prevention of Cardiovascular Diseases (Optim'Oils)|Effect of the Antioxidant Micronutrients of Rapeseed Oil on the Prevention of Cardiovascular Diseases||University Hospital, Clermont-Ferrand||Completed|December 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|60|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 9, 2010|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852735||142739|
NCT00852748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFEMC 08.520|Validation of Venogenic Hypothesis for Cough, Exertional and Sexual Headaches|||French Society for the Study of Migraine Headache|No|Completed|January 2009|September 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|patients suffering of cough, exertional and sexual headaches|February 2009|October 7, 2010|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852748||142738|
NCT00853021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8804|Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney|Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma||Case Comprehensive Cancer Center|Yes|Completed|December 2005|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|February 26, 2009|Yes|Yes||No|July 28, 2015|https://clinicaltrials.gov/show/NCT00853021||142717|
NCT00853034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXOS 001|Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects|Effects of Arabinoxylan-Oligosaccharides on Colonic Metabolism and Microbial Composition Compared to Other Prebiotics in Healthy Subjects||Katholieke Universiteit Leuven|Yes|Completed|October 2006|September 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 26, 2009|February 25, 2009||||No||https://clinicaltrials.gov/show/NCT00853034||142716|
NCT00853320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8515-02-779|Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (15 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Roxicodone™, 15 mg Tablet, Roxane Laboratories, Inc.) in Normal Human Subjects Under Fasting Conditions||Mallinckrodt|No|Completed|February 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853320||142694|
NCT00853619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSA290200810010|Clinical Decision Support Consortium|Clinical Decision Support Consortium for AHRQ CDS Research|CDSC|Brigham and Women's Hospital|No|Enrolling by invitation|March 2008|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 27, 2012|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853619||142672|
NCT00853918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS-17632|Clinical Practice Intensity: Comparing Veterans Affairs (VA) to Private Sector Physicians|Clinical Practice Intensity: Comparing VA to Private Sector Physicians||White River Junction VAMC|No|Active, not recruiting|June 2009|December 2010|Anticipated|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|1000|||Both|N/A|N/A|No|||June 2010|June 4, 2010|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853918||142649|
NCT00874510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-429|A Randomized Controlled Trial of Mandatory Naps for Physicians in Training|Interventions to Improve Fatigue Management Among Physician Trainees||VA Office of Research and Development|Yes|Completed|June 2009|December 2013|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|352|||Both|N/A|N/A|No|||January 2016|January 22, 2016|March 31, 2009||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT00874510||141091|
NCT00854373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-9999|Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial|Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial||University of California, San Francisco|Yes|Completed|June 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Female|18 Years|N/A|No|||August 2013|August 1, 2013|March 2, 2009||No||No|May 29, 2013|https://clinicaltrials.gov/show/NCT00854373||142614|This study was powered to detect difference in fertilization instead of pregnancy outcomes, because the number of patients required to detect a 10% absolute difference in pregnancy rates was too large to be completed at our center (n=387 per group).
NCT00855192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beh #07-10|Antenatal Relaxation Group for Anxiety and Depression Management|Antenatal Depression Group Research Project: The Effectiveness of Mindfulness-based Relaxation and Interpersonal Therapy to Relieve Anxiety and Depression Symptoms in Pregnant Women.|ARG|University of Saskatchewan|No|Enrolling by invitation|October 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|16 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 17, 2010|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855192||142551|
NCT00855205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14889A|Rituximab for Pulmonary Sarcoidosis|Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open-|RIPS|University of Cincinnati|Yes|Completed|July 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|March 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00855205||142550|
NCT00850980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-766|Selective AV Nodal Vagal Stimulation For Reduction of the Ventricular Rate During Atrial Fibrillation|Selective AV Nodal Vagal Stimulation For Reduction of the Ventricular Rate During Atrial Fibrillation||The Cleveland Clinic|No|Withdrawn|February 2009|December 2009|Anticipated|||Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing open heart surgery          -  Able to give Informed Consent and          -  Permanent/Persistent or currently in Atrial Fibrillation 18 years or older|February 2010|May 24, 2010|February 23, 2009||No|unable to recruit|No||https://clinicaltrials.gov/show/NCT00850980||142873|
NCT00850928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-658|Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids|Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids.||New York University School of Medicine|No|Completed|December 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|Samples With DNA|Serum and plasma will be collected and stored at baseline, intra-operatively, and one day      post-operative for analysis of markers of inflammation. Plasma will be collected and stored      at baseline, three months, and six months for analysis of Beta Amyloid levels. DNA will be      collected and stored at baseline for analysis of Apolipoprotein E.|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|65 years and older scheduled for major spinal surgery.|March 2016|March 15, 2016|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850928||142876|
NCT00850941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0254|Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy|Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy||M.D. Anderson Cancer Center|No|Recruiting|January 2009|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|Samples With DNA|Leftover tissue from prostate surgery to be used for biomarker research.|Male|18 Years|N/A|No|Probability Sample|Patients having a rising prostate-specific antigen (PSA) level after prostate was        surgically removed, meaning prostate cancer return.|February 2016|February 4, 2016|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850941||142875|
NCT00851279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-CLIN-013|Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia|Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia: Data Collection of Clinical Scar-related VT Cases|STOP-VT|Stereotaxis|No|Completed|June 2009|April 2013|Actual|October 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|80 Years|No|||July 2015|July 27, 2015|February 24, 2009|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00851279||142851|
NCT00861783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-08|Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma|A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors||Onconova Therapeutics, Inc.|No|Completed|June 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||December 2011|December 29, 2011|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861783||142054|
NCT00861796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYR-101C01|Study of CYR-101 in Patients With Schizophrenia|A Multi-center, Inpatient and Ambulatory, Phase 2, Double Blind, Randomized, Placebo-controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia||Cyrenaic Pharmaceuticals|No|Completed|March 2008|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||May 2011|June 6, 2011|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00861796||142053|
NCT00854750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTHAR version 1.0|Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis|Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis||University of Texas Southwestern Medical Center|Yes|Terminated|May 2009|July 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 19, 2013|February 27, 2009|Yes|Yes|Poor Enrollment- schedule of assessments too complex and time-consuming.|No||https://clinicaltrials.gov/show/NCT00854750||142585|
NCT00863408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909093|Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali|Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali (Village of Thierola in the District of Banamba)||National Institutes of Health Clinical Center (CC)||Completed|March 2009|March 2010||||N/A|Observational|Time Perspective: Prospective|||||||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00863408||141932|
NCT00855010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112008-047|Pioglitazone on Pancreatic Steatosis and Bone Health|Effect of Pioglitazone on Pancreatic Steatosis and Bone Health||University of Texas Southwestern Medical Center|Yes|Completed|February 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|No|||November 2014|November 14, 2014|February 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00855010||142565|
NCT00852215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-014|Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion?|Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion? (COPE Study): Long-Term Follow-up Study|COPE|Samsung Medical Center||Recruiting|August 2008|July 2010|Anticipated|July 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2009|February 25, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852215||142779|
NCT00852488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#080906|Medium-term Venous Access in Congenital Heart Surgery|A Medium-term Venous Access Alternative in Infants Undergoing Congenital Heart Surgery||Vanderbilt University|No|Completed|March 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|365 Days|No|||February 2010|February 12, 2010|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00852488||142758|
NCT00852501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-044|Characterization of Receptors in Non-functioning Pituitary Macroadenomas|Characterization of Receptors Present in Non-functioning Pituitary Macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR)||John H. Stroger Hospital|No|Recruiting|March 2006|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|A small piece of the pituitary macradenoma removed at surgery will be frozen to perform      RT-PCR|Both|18 Years|N/A|No|Probability Sample|All subjects who are diagnosed with a non-functioning pituitary macroadenoma who are        scheduled for surgery.|April 2013|April 8, 2013|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852501||142757|
NCT00852761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114569|A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis|A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects.||GlaxoSmithKline|No|Completed|March 2009|August 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|February 25, 2009|Yes|Yes||No|November 4, 2010|https://clinicaltrials.gov/show/NCT00852761||142737|
NCT00853047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol LX1606.1-202-CS|Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy|||Lexicon Pharmaceuticals|No|Completed|March 2009|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|23|||Both|18 Years|N/A|No|||July 2014|February 4, 2016|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853047||142715|
NCT00853294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8867-03-790|Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Extended Release Test Capsule Formulation of Chlorpheniramine Polistirex and Hydrocodone Polistirex Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in Normal Human Subjects Under Fasting Conditions||Mallinckrodt|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853294||142696|
NCT00853333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F081016014|Sedation and Pain (The Effect of IV Sedation on Pain Perception)|Sedation and Pain (The Effect of IV Sedation on Pain Perception)||University of Alabama at Birmingham|Yes|Completed|November 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|86|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 24, 2014|February 26, 2009|Yes|Yes||No|August 23, 2013|https://clinicaltrials.gov/show/NCT00853333||142693|
NCT00853346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH076037-01|Psychosocial Treatment of Depression in Parkinson's Disease|Psychosocial Treatment of Depression in Parkinson's Disease||Massachusetts General Hospital|Yes|Active, not recruiting|April 2007|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|80 Years|No|||November 2012|November 15, 2012|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853346||142692|
NCT00853931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-2008-0012|Biomarker - Panitumumab Response With KRAS Wild Type MCC|An Exploratory Trial of Biomarkers for Panitumumab Response Among Previously Treated Patients With KRAS Wild Type Metastatic Colorectal Cancer.||British Columbia Cancer Agency|No|Completed|October 2009|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853931||142648|
NCT00874822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212-09-EP|Prevalence of Sleep Apnea in Patients Presenting for Hip or Knee Replacement Surgery|Prevalence of Sleep Apnea in Patients Presenting for Hip or Knee Replacement Surgery||University of Nebraska|No|Completed|September 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|216|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects are all patients referred to an academic internal medicicine preoperative        evaluation clinic prior to hip or knee arthroplasty.|January 2012|January 18, 2012|March 26, 2009||No||No|October 27, 2011|https://clinicaltrials.gov/show/NCT00874822||141068|Obstructive sleep apnea was diagnosed in only four patients due to a high rate of failure to undergo PSG by patients for whom it was indicated. A second major weakness is the use of a literature control group.
NCT00874835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo33171|Corneal Endothelium Delivery Instrument|Endothelial Graft Injector Versus Folding Forceps Insertion During Descemet's Stripping Endothelial Keratoplasty (DSEK)||Ocular Systems, Inc.|Yes|Active, not recruiting|March 2009|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|45 Years|N/A|No|||May 2010|May 6, 2010|April 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00874835||141067|
NCT00854906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109338|Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time|Comparison of Keratometric Tear Break Up Time (KTBUT) to Fluorescein Tear Break Up Time (FTBUT)||University of Arkansas|No|Completed|February 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Jones Eye Clinic, Department of Ophthalmology, University of Arkansas        for Medical Sciences|October 2014|October 22, 2014|March 2, 2009||No||No|July 7, 2010|https://clinicaltrials.gov/show/NCT00854906||142573|
NCT00854932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoPInS|Neonatal Procalcitonin Intervention Study|Effect of Procalcitonin-guided Decision Making on Duration of Antibiotic Therapy in Suspected Neonatal Early-onset Sepsis: Multicenter Prospective Randomized Intervention Study|NeoPInS|Luzerner Kantonsspital|Yes|Active, not recruiting|June 2009|August 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Both|N/A|3 Days|No|||March 2016|March 4, 2016|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854932||142571|
NCT00861211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-17043-17|Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess The Safety and Efficacy of Two Weeks of Oral Senicapoc Administration on Allergen Challenge in Atopic Asthmatic Subjects||Icagen|No|Completed|October 2008|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|No|||July 2011|July 8, 2011|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861211||142097|
NCT00861237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2342|Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery|Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery||Medical University of Vienna|No|Terminated|July 2008|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|March 12, 2009||No|Number of patients to be recruited to small, missing cooperation of study members|No||https://clinicaltrials.gov/show/NCT00861237||142095|
NCT00850954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0440|Project CASA: Promoting Smoke-Free Indoor Air Policy in Mexican American Households|Project CASA: Promoting Smoke-Free Indoor Air Policy in Mexican American Households||M.D. Anderson Cancer Center|No|Recruiting|August 2006|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Study smoke-free indoor air policy of Mexican American households in Houston Metropolitan        area.|March 2016|March 14, 2016|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00850954||142874|
NCT00851292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROE-3|The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing|The BIOPRES Trial; Transrectal BIOpsies of the PRostate: End Versus Side-firing|BIOPRES|Amphia Hospital|No|Recruiting|October 2009|September 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|800|||Male|N/A|N/A|No|||June 2011|June 21, 2011|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851292||142850|
NCT00861523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0101-08-EMC|Does Thiamine Help Vomiting and Nausea in Pregnancy?|Comparison Between the Treatment of Thiamine and Promethazine for Improving Vomiting and Nausea in Pregnancy||HaEmek Medical Center, Israel||Terminated|February 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||June 2015|June 21, 2015|February 18, 2009||No|Difficulties in recruiting patients|No||https://clinicaltrials.gov/show/NCT00861523||142074|
NCT00861536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82/06|Comparison of ATG to Thymoglobuline in Renal Transplantation|An Open, Multicenter, Randomised, Parallel Group Pilot Study to Investigate Two Different Polyclonal Rabbit Immunoglobulin Preparations for Safety and Efficacy:A Comparison of ATG-Fresenius S to Thymoglobulin in Prophylaxis for Immunological High Risk Patients Following Renal Transplantation||University Hospital, Basel, Switzerland|No|Completed|January 2009|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861536||142073|
NCT00862082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-2002|Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|A Randomized Phase I/II, Multi-Center, Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma||Proacta, Incorporated||Terminated|March 2009|May 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|March 12, 2009|Yes|Yes|PR104 plus sorafenib was poorly tolerated in patients with advanced HCC|No|May 31, 2011|https://clinicaltrials.gov/show/NCT00862082||142032|Early termination leading to small numbers of subjects analyzed. Phase II part of study never initiated.
NCT00862784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13897|A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer|An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients With Metastatic Colorectal Cancer||Eli Lilly and Company|Yes|Completed|April 2009|August 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|March 16, 2009|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00862784||141980|
NCT00851617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-391|Does Threshold IMT Influence Weaning?|Is Threshold IMT Useful To Accelerate Weaning From Mechanical Ventilation?||Hospital de Clinicas de Porto Alegre|No|Completed|August 2004|July 2007|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|92|||Both|18 Years|N/A|No|||February 2009|March 5, 2009|February 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00851617||142825|
NCT00855270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6884-JZ-CTIL|Efficacy of Single Dose IV Hydrocortisone in Post Traumatic Stress Disorder (PTSD) Prevention|The Efficacy of a Single Dose IV Hydrocortisone Given Within 6 Hours of Exposure to a Traumatic Event in PTSD Prevention||Sheba Medical Center|No|Recruiting|April 2009|August 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 22, 2011|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855270||142545|
NCT00851630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013131|Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)|A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST)|THIRST|Duke University|Yes|Completed|June 2004|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|13 Years|N/A|No|||May 2010|May 2, 2010|February 25, 2009|Yes|Yes||No|March 15, 2009|https://clinicaltrials.gov/show/NCT00851630||142824|
NCT00851929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17747|Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension|Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension||Medical University of South Carolina|No|Recruiting|November 2008|June 2010|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2009|February 25, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851929||142801|
NCT00851942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON 431-07|Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test|Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test||Cardiff University|No|Active, not recruiting|September 2008|July 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|240|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2009|February 24, 2010|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851942||142800|
NCT00852202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-52|Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression|A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression||Forest Laboratories|No|Completed|June 2009|||June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|234|||Both|18 Years|65 Years|No|||July 2011|July 6, 2011|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00852202||142780|
NCT00852228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTILIV07|Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy|Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial|OPTILIV|Association pour la Recherche sur le Temps Biologique et la Chronothérapie|Yes|Active, not recruiting|July 2008|December 2015|Anticipated|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852228||142778|
NCT00852241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF4|Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study|||The Cleveland Clinic||Completed|February 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 15, 2010|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852241||142777|
NCT00852787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0115|Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease|Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease||National Institute on Aging (NIA)|No|Active, not recruiting|April 2009|May 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|75 Years|No|||December 2009|May 23, 2012|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852787||142735|
NCT00852774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08159|Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery for Endometrial Robotics Versus Laparotomy|Effects of Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery For Endometrial Cancer: Robotics Versus Laparotomy||Ohio State University Comprehensive Cancer Center|No|Withdrawn|May 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Endometrial Cancer Surgical Candidates|July 2014|July 25, 2014|February 25, 2009||No|terminated due to low staffing|No||https://clinicaltrials.gov/show/NCT00852774||142736|
NCT00853073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-867|Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?|Does a New Add on (or Adjunctive) Therapy Used in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?|Avastin|Wills Eye|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|February 26, 2009|No|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT00853073||142713|
NCT00853060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-415|Energy Expenditure in Weaning From Mechanical Ventilation|Energy Expenditure During Weaning From Mechanical Ventilation: Is There Any Difference Between Pressure Support and T-Tube?||Hospital de Clinicas de Porto Alegre|No|Completed|March 2006|March 2008|Actual|March 2007|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with respiratory failure receiving MV fore more than 24 hours, who had been        admitted to the Intensive Care Unit (ICU) of the Hospital de Clínicas de Porto Alegre and        who met the criteria for weaning from MV according to the parameters previously defined        were selected to participate in the study.|February 2009|February 26, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00853060||142714|
NCT00853944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01947|Effect of Sitagliptin on Graft Function Following Islet Transplantation|A Randomized Controlled Trial to Determine if Sitagliptin Will Enhance Islet Graft Function When Given for 1 Year Following Transplantation||University of British Columbia|No|Recruiting|July 2009|July 2011|Anticipated|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|20 Years|65 Years|No|||February 2011|February 15, 2011|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853944||142647|
NCT00853957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100AUS01|Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension|An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension|AACESS|Novartis|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|443|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|February 26, 2009|Yes|Yes||No|December 6, 2010|https://clinicaltrials.gov/show/NCT00853957||142646|
NCT00853970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-S&E-1205081-P|Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery|||Bausch & Lomb Incorporated||Completed|February 2009|December 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|February 26, 2009|Yes|Yes||No|November 15, 2010|https://clinicaltrials.gov/show/NCT00853970||142645|
NCT00875121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB#2220|Peer Interactions and Food Are Substitutable in Youth|Peer Interactions and Food Are Substitutable in Youth||University at Buffalo|No|Completed|October 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A||1|||||Both|9 Years|11 Years|No|Probability Sample|Boys and girls ages 9-11.|April 2009|May 11, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875121||141045|
NCT00875134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-06-54|Testing of the Apnea Prevention Device|Testing of the Apnea Prevention Device||Oregon Health and Science University|No|Active, not recruiting|March 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|21 Years|N/A|No|||April 2009|April 2, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875134||141044|
NCT00854919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18591305|Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder|An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder|OCDDRUG|Osaka City University||Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|N/A|3||||||Both|20 Years|50 Years|No|||December 2005|March 2, 2009|March 2, 2009||||No||https://clinicaltrials.gov/show/NCT00854919||142572|
NCT00855231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27903-D|Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain|Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain - Assessment of Chest Pain Utilizing a Triple Rule Out Evaluation With Computed Tomography (ACUTE CT) Trial|ACUTE CT|University of Washington|No|Completed|July 2006|September 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|30 Years|N/A|No|Non-Probability Sample|Alll patients presenting to the University of Washington Medical Center Emergency        Department with possible acute coronary syndrome|September 2011|September 9, 2011|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855231||142548|
NCT00861835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMCROSE|Trial of Rapid On-Site Evaluation of Transbronchial Needle Aspirate (TBNA)|A Randomized Prospective Trial of Rapid On-Site Evaluation of Transbronchial Needle Aspirate Specimens||Maine Medical Center|Yes|Completed|November 2004|December 2007|Actual|November 2007|Actual|N/A|Interventional|Primary Purpose: Diagnostic|2||||||Both|N/A|N/A|No|||March 2009|March 12, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861835||142050|
NCT00861549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP005|Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers|Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers||PhytoHealth Corporation|No|Completed|August 2008|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2011|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00861549||142072|
NCT00861809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111809|The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis|A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis||GlaxoSmithKline|No|Completed|June 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|11|||Both|18 Years|70 Years|No|||July 2012|August 2, 2012|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00861809||142052|
NCT00861822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1083-B|Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study|Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study||University Health Network, Toronto|Yes|Completed|July 2009|July 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00861822||142051|
NCT00862056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH08012|Detection of Subclinical Atherosclerosis in Asymptomatic Individuals|Prospective Detection of Subclinical Atherosclerosis in Asymptomatic Individuals With High Likelihood of Coronary Artery Disease With a Novel, Low-Radiation Volumetric Computed Tomography Approach|Decide CTA|Piedmont Healthcare|No|Recruiting|January 2009|December 2014|Anticipated|July 2014|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Whole blood for DNA and RNA analysis for genetics and genomics|Both|35 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Coronary Artery Disease|April 2014|April 14, 2014|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00862056||142033|
NCT00862797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273/07|Pressure Course in the Tube Cuff During Swallowing|Pressure Course in the Tube Cuff During Swallowing||University Hospital Freiburg|No|Completed|January 2008|||May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients recovering from general anaesthesia or intensive care patients both intubated        with cuffed endotracheal tubes|March 2009|February 1, 2010|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00862797||141979|
NCT00854490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO-002|Follow-up Study of Small-intestinal Mucosal Injuries in Chronic Non-steroidal Anti-inflammatory Drugs (NSAIDs)-Users|||Nagoya University||Not yet recruiting|October 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|80 Years|No|Non-Probability Sample|Chronic NSAID users|September 2009|September 18, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854490||142605|
NCT00851643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V502-002|Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)|A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX)||Merck Sharp & Dohme Corp.|Yes|Completed|April 2006|November 2009|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|158|||Female|18 Years|24 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|February 24, 2009|No|Yes||No|February 10, 2011|https://clinicaltrials.gov/show/NCT00851643||142823|
NCT00851955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-000099|Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer|Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer||Mayo Clinic||Completed|May 2007|November 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|150|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Primary Care|January 2016|January 11, 2016|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851955||142799|
NCT00852514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 95-08-28A|The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis|The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis||Taipei Veterans General Hospital, Taiwan|Yes|Completed|September 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|80 Years|No|||February 2009|February 26, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852514||142756|
NCT00853099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-447|A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis|A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.||AbbVie|No|Completed|February 2009|August 2013|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|274|||Both|15 Years|N/A|No|||September 2014|September 3, 2014|February 27, 2009||No||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00853099||142711|
NCT00853086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3537|Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database|United Kingdom Haemophilia Centre Doctor's Organisation (UKHCDO) - Novo Nordisk Collaboration on NovoSeven® Post Marketing Follow-up Measures||Novo Nordisk A/S|No|Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|139|||Male|N/A|N/A|No|Non-Probability Sample|Patients from speciality practice settings|August 2014|August 8, 2014|February 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00853086||142712|
NCT00853372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080579|AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib|Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma||Amgen|No|Active, not recruiting|April 2009|March 2016|Anticipated|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853372||142691|
NCT00853671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSCTSTRESS|Myocardial Stress Perfusion Imaging With Dual Source CT|Myocardial Stress Perfusion Imaging With Dual Source CT||Massachusetts General Hospital|No|Recruiting|April 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|40 Years|90 Years|No|||April 2010|April 30, 2010|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853671||142668|
NCT00853684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902024|Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer|Phase II Study of Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer|OXCE|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|February 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|75 Years|No|||September 2009|September 17, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853684||142667|
NCT00853632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study# 2006-05|Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol|Carpentier-Edwards® Perimount Magna® Mitral Pericardial Bioprostheses Models 7000/7000 TFX and Carpentier-Edwards® Perimount Magna® Mitral Ease™ Pericardial Bioprostheses Models 7200TFX and 7300/7300TFX||Edwards Lifesciences|No|Active, not recruiting|August 2007|December 2023|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853632||142671|
NCT00853645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-11398|Initial Chronic Human Validation Study: Subcutaneous Implantable (S-ICD) System|Initial Chronic Human Validation Study: Subcutaneous Implantable (S-ICD) System|Chronic II|Boston Scientific Corporation|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|||||||Both|18 Years|N/A|No|||February 2009|February 27, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853645||142670|
NCT00853658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100F2301|Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV).|ATMOSPHERE|Novartis|No|Completed|March 2009|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|7120|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853658||142669|
NCT00854321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KuoRituxi1|Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital|One Centre Follow-up Study on Safety and Efficacy|KuoRituxi1|Kuopio University Hospital|No|Completed|November 2004|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|49|||Both|18 Years|N/A|No|Non-Probability Sample|patients with active RA in one centre|March 2009|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854321||142618|
NCT00854568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 09-01|Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL|A Randomized Phase III Study Comparing CHOP Versus CEOP-induced Cardiotoxicity in Patients With Aggressive B-cell Lymphoma||Fudan University|No|Completed|March 2009|February 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|398|||Both|18 Years|75 Years|No|||August 2014|August 19, 2014|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854568||142599|
NCT00875147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 12-2009|Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases|Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases A Case Matched Control Study||University of Zurich|Yes|Completed|April 2009|September 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|0|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients, who underwent liver resection due to CRLM between 2005 and 2007, were        retrospectively assessed for eligibility. Patients with chemotherapy containing Bev prior        to surgery are identified consequtively. This group of patient with preoperative Bev is        matched to patients without Bev. Consecutive patients with neoadjuvant application of        Bevacizumab will be matched to patients without Bevacizumab. Results are statistically        adjusted according to potential confounders.|January 2010|January 22, 2010|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875147||141043|
NCT00854685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART621-223|Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate|A Factorial-design, Randomised, Double-blind, Placebo-controlled, Dose Optimisation Study to Investigate the Safety, Efficacy, Immunogenicity and Pharmacokinetics of ART621 Following Multiple Dose Administration in Subjects Diagnosed With Rheumatoid Arthritis Concomitantly Taking Methotrexate||Arana Therapeutics Ltd|Yes|Completed|February 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|27|||Both|18 Years|80 Years|No|||March 2009|January 4, 2010|March 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854685||142590|
NCT00854945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-15|Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML|A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)||Onconova Therapeutics, Inc.|No|Completed|January 2009|February 2014|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|March 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854945||142570|
NCT00860951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0002 - AT P300 Keyboard Study|P300 Brain Computer Interface Keyboard to Operate Assistive Technology|||University of Michigan|No|Completed|September 2008|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 10, 2015|March 11, 2009||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00860951||142117|
NCT00853567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-304|Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids|A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids||Repros Therapeutics Inc.|Yes|Terminated|February 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|71|||Female|18 Years|48 Years|No|||August 2014|August 5, 2014|February 27, 2009|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00853567||142676|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00862095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208075|Medical Therapies for Chronic Post-Traumatic Headaches|A Randomized Controlled Trial of Medical Therapies for Chronic Post-Traumatic Headaches||Madigan Army Medical Center|Yes|Terminated|June 2008|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|50 Years|No|||April 2013|April 22, 2013|March 12, 2009|Yes|Yes|inadequate enrollment, insufficient funds to continue enrollment|No||https://clinicaltrials.gov/show/NCT00862095||142031|
NCT00862108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A080054|Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)|Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD||Seoul National University Hospital|Yes|Recruiting|September 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|6 Years|18 Years|No|||September 2009|September 20, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00862108||142030|
NCT00862446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080887|Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease|Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease||Vanderbilt University|Yes|Recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|24 Months|No|||June 2015|June 1, 2015|March 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00862446||142005|
NCT00862459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91400|Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)|Multi-center, Double-blind, Randomized, Controlled, Parallel Group, Dose Comparison Study With Corresponding Blinded Image Evaluation Following a Single Intravenous Injection of Three Different Doses of Gadobutrol 1.0 Molar (Gadavist) in Patients With Known or Suspected Focal Blood Brain Barrier Disturbances and/or Abnormal Vascularity of the Central Nervous System||Bayer|No|Completed|August 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|237|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|November 26, 2008|No|Yes||No|September 14, 2011|https://clinicaltrials.gov/show/NCT00862459||142004|OptiMARK was used as a standard of reference in this study. A formal comparison of the efficacy of gadobutrol and OptiMARK was not specified prospectively in the statistical analysis plan. For completeness, the safety data of OptiMARK is presented.
NCT00854503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131/08|Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients|||University of Rome Tor Vergata||Completed|September 2008|December 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|75 Years|No|||January 2011|May 11, 2011|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854503||142604|
NCT00850785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-76|Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer|A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer|DRibble|Providence Health & Services|No|Active, not recruiting|January 2009|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|February 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850785||142887|
NCT00851071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 08-913|Interventional Study of Anxiety Symptoms in the Implantable Cardioverter Defibrillator (ICD) Patient|Bakken Heart Brain Institute's "An Observational and Interventional Study of Anxiety Symptoms in the Implantable Cardioverter Defibrillator (ICD) Patient."||The Cleveland Clinic|No|Recruiting|February 2009|||March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||February 2010|February 1, 2010|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00851071||142866|
NCT00851656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4001-001|MilkScreen Home Test for Alcohol in Breast Milk|MilkScreen Home Test for Alcohol in Breast Milk Clinical Study||UpSpring Baby, Ltd.|No|Completed|May 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Lactating women, 21 years and older.|February 2009|February 25, 2009|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851656||142822|
NCT00851669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00023495|The MEADOW PROJECT (Mending the Effects of Alcohol and Depression on Women) and The Bridge Program (Connecting Recovery Treatment and Behavioral Health)|Behavioral Treatment for Alcohol Dependent Women With Co-occurring Depression|MEADOW/Bridge|University of Rochester|Yes|Completed|April 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|65 Years|No|||July 2013|July 12, 2013|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851669||142821|
NCT00851968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2008-008|A Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy|A Prospective Randomized Controlled Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy||Eastern Hepatobiliary Surgery Hospital|Yes|Active, not recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|320|||Both|18 Years|70 Years|No|||February 2009|February 25, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851968||142798|
NCT00852800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-352|Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study|Effect of Intravenous Albumin (Standard vs Dose Reduced Regimen) On Renal Impairment and Mortality in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis: A Double Blind Randomized Clinical Trial|ALTERNATE|Hospital de Clinicas de Porto Alegre|No|Enrolling by invitation|March 2006|March 2011|Anticipated|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||June 2010|June 4, 2010|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852800||142734|
NCT00852813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXOS 002|Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects|Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects: a Randomized, Placebo-Controlled Cross-Over Study||Katholieke Universiteit Leuven|Yes|Completed|October 2007|June 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|February 26, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852813||142733|
NCT00852553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200311379|Neurohumoral Control of Intestinal Electrical and Mechanical Activity|Neurohumoral Control of Intestinal Electrical and Mechanical Activity||University of California, Davis|No|Completed|February 2003|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|Samples Without DNA|jejunum|Both|N/A|N/A|No|Non-Probability Sample|All patients having elective bowel resections|July 2012|July 23, 2012|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852553||142753|
NCT00852566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-004106-13|Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia|An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid|NordCML006|Norwegian University of Science and Technology|No|Completed|March 2009|December 2015|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852566||142752|
NCT00853385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921064|A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis|Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate||Pfizer|Yes|Completed|May 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|717|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|February 27, 2009|Yes|Yes||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00853385||142690|
NCT00853112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7331009|A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension|A Phase 2a, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study Investigating The Dose-Response Of PF-00489791 On Acute Hemodynamics In Subjects With Idiopathic And Familial Pulmonary Hypertension||Pfizer|Yes|Terminated|April 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|44|||Both|18 Years|N/A|No|||March 2012|March 27, 2012|February 27, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00853112||142710|
NCT00853983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8180C00013|Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers|An Open-Label, Phase I Study to Assess Absorption, Metabolism and Excretion of a Single Oral Dose of [14C]AZD0530 in Healthy Male Volunteers||AstraZeneca|No|Completed|March 2009|April 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|50 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 20, 2009|February 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00853983||142644|
NCT00853996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01116|Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer|Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer||National Cancer Institute (NCI)|No|Completed|February 2009|||August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|44|||Female|30 Years|55 Years|No|||May 2013|May 31, 2013|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853996||142643|
NCT00854009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3219K1-1004|Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|February 2009|April 2009|Anticipated|April 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00854009||142642|
NCT00853697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008|Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer|Phase II Trial of Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer||Memorial Sloan Kettering Cancer Center|Yes|Completed|March 2009|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|N/A|No|||October 2015|October 28, 2015|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853697||142666|
NCT00853710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB 2008-A01497-48|Test Semiquantitative Prostate Specific Antigen (PSA)|Validation of a Semiquantitative Screening Assay for PSA||Centre Rene Huguenin|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|94|||Male|18 Years|N/A|No|||June 2009|August 4, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00853710||142665|
NCT00875420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD1901-002|A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women|A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2, Multi-Center, Dose-Finding Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women||Radius Health, Inc.|No|Completed|March 2009|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|100|||Female|40 Years|75 Years|No|||October 2011|February 22, 2012|March 6, 2009|Yes|Yes||No|February 16, 2011|https://clinicaltrials.gov/show/NCT00875420||141022|
NCT00875433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.24|Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours|Phase II Open Label Trial to Assess the Efficacy and the Impact on QTcF of Continuous Oral BIBW 2992 at a Daily Dose of 50mg in Patients With Relapsed or Refractory Solid Tumours Including Patients With Brain Metastases and Those With Glioblastoma Not Amenable to Other Therapy||Boehringer Ingelheim||Completed|March 2009|||April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||October 2013|December 5, 2013|April 2, 2009||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00875433||141021|
NCT00860730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V10801|PERCEVAL Pivotal Trial|PERCEVAL Pivotal Trial||LivaNova|Yes|Active, not recruiting|January 2009|September 2015|Anticipated|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|75 Years|N/A|No|||May 2014|May 21, 2015|March 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00860730||142134|
NCT00860964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMB 97-667|A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women|A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women||Peking Union Medical College|No|Completed|February 1998|December 2006|Actual|February 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|221|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 16, 2009|March 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00860964||142116|
NCT00861224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050123|Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology|The Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)||Amgen||Completed|August 2005|May 2007|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|None Retained|No biospecimen samples were retained.|Both|18 Years|N/A|No|Non-Probability Sample|Splenectomized or nonsplenectomized subjects with a primary diagnosis of ITP from either        of the phase 3 studies (20030105 or 20030212) or the open-label extension study 20030213;        pretreatment bone marrow biopsy within 1 year of enrollment into the phase 3 study;        separate written informed consent for the follow-up bone marrow.|July 2010|July 15, 2010|March 12, 2009||||No||https://clinicaltrials.gov/show/NCT00861224||142096|
NCT00855023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08-229-147|Knee Alignment Contributions to Anterior Cruciate Ligament (ACL) Injury|Tibiofemoral Alignment: Contributing Factors to Noncontact Anterior Cruciate Ligament Injury||The Orthopaedic Center, Maryland|No|Suspended|November 2007|October 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteer athletes and excluded those who had any of the following criteria: 1)        counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical        hardware [plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.]); (2) relevant        medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid        obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the        knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the        knee that required medical attention; (5) previous surgery on the knee; or (6) current        pain in the knee.|March 2009|March 2, 2009|March 2, 2009||No|May continue recruiting only if required by journal reviewers|No||https://clinicaltrials.gov/show/NCT00855023||142564|
NCT00853866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-00160436-36|Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation|Entwicklung Neuronaler Repräsentationen Nach Schlaganfall: Verbesserung Motorischer Leistungen Durch Transkranielle Gleichstromstimulation Und Noradrenerge Co-Stimulation|STIMBOX|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|January 2009|June 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|12|||Both|18 Years|86 Years|No|||December 2010|December 1, 2010|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853866||142653|
NCT00854230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJ0007|Pharmacotherapy for HIV Infected Patients With Alcohol Problems|Pharmacotherapy for HIV Infected Patients With Alcohol Problems||VA Connecticut Healthcare System|Yes|Withdrawn|January 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 27, 2012|March 2, 2009|Yes|Yes|We expanded to a bigger, multi-site study & decided to close this study.|No||https://clinicaltrials.gov/show/NCT00854230||142625|
NCT00851344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110163|Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo|A Randomised, Double-Blind, Placebo-Controlled, 4-Period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis||GlaxoSmithKline||Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|54|||Male|18 Years|60 Years|No|||June 2009|June 18, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851344||142846|
NCT00851981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55302|Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease|Effect of Oral S-Adenosylmethionine Administration on Abnormalities of Hepatic Methionine Metabolism and Disease Progression in Alcoholic Liver Disease. A Randomized, Double Blind, Placebo-controlled Trial|RCT SAMe|Loma Linda University|No|Completed|October 2008|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|September 9, 2010|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851981||142797|
NCT00851994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0458|Urine Proteome of Patients Having Surgery|Urine Proteome of Patients Undergoing Surgery||Washington University School of Medicine|No|Active, not recruiting|July 2008|August 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|274|Samples With DNA|We are collecting urine and blood samples.|Both|19 Years|N/A|No|Non-Probability Sample|Patients having surgery.|November 2015|November 9, 2015|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851994||142796|
NCT00852254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-C-COSTATUS-6A-H|Validation of Minimally Invasive Ultrasound Indicator Dilution Technique in Critically Ill Children|Validation of a Novel, Minimally Invasive Ultrasound Indicator Dilution Technique for Measuring Cardiac Index in Critically Ill Children||Transonic Systems Inc.|No|Recruiting|June 2008|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric patients (less than 18 years of age) with in situ arterial and central venous        catheters.|April 2010|April 9, 2010|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852254||142776|
NCT00852280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-6-24-1|Effects of Pulsed-Dyed Laser on Scar Formation|Effects of Pulsed-Dyed Laser on Scar Formation||Shriners Hospitals for Children|No|Completed|December 2008|June 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|17|||Both|9 Years|N/A|No|||July 2010|June 6, 2012|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852280||142774|
NCT00852293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481132-HMO-CTIL|The Connection Between Liver Disease and Chitinase Proteins|The Connection Between Liver Disease and Chitinase Proteins||Hadassah Medical Organization||Not yet recruiting|March 2009|March 2014|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood tests are taken to determin Chitinase 3 like-1 protein levels.|Both|18 Years|N/A|No|Non-Probability Sample|The study will include patients with liver disease followed at the liver unit, Hadassah        Medical Center, Jerusalem Israel.|February 2009|February 25, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852293||142773|
NCT00852579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR010|Effects of Macrolides on Asthma Control|Effects of Macrolides on Asthma Control, Airway Inflammation and Bacterial Colonisation in Smokers With Asthma.||University of Glasgow|Yes|Completed|March 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 18, 2011|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852579||142751|
NCT00852826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFN001/08|Evaluation of a Hemostatic and Sealing Agent to Prevent Surgical Complications After Axillary Lymphadenectomy|Value of a Hemostatic and Sealing Agent for Preventing Seroma After Axillary Lymphadenectomy||Hospital Universitario Virgen de la Arrixaca||Completed|January 2008|November 2008||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||February 2009|February 26, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852826||142732|
NCT00852839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552-207S|A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Arm Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome||Parion Sciences|No|Completed|February 2009|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|80 Years|No|||July 2014|July 11, 2014|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00852839||142731|
NCT00853125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080708|Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer|Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)||Rutgers, The State University of New Jersey|Yes|Active, not recruiting|February 2009|||February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||September 2014|September 26, 2014|February 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853125||142709|
NCT00853424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02859|A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease|A Comparison of Islet Cell Transplantation With Medical Therapy on the Risk of Progression of Diabetic Retinopathy and Diabetic Macular Edema||University of British Columbia|No|Withdrawn|December 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|65 Years|No|||November 2011|March 14, 2014|February 26, 2009||No|"We were unable to enroll any subjects in this study due to lack of interest."|No||https://clinicaltrials.gov/show/NCT00853424||142687|
NCT00853398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS_GEN_II_6112003|MINIMALLY INVASIVE SURGERY in Total Knee Arthroplasty|A Prospective (Non)-Randomized Controlled Multicenter Clinical Study Of the Genesis ii Total Knee System in Minimally Invasive Total Knee Arthroplasty|MIS GEN II|Smith & Nephew, Inc.||Terminated|October 2004|December 2007|Actual|October 2007|Actual|Phase 4|Interventional|N/A|2||||||Both|18 Years|80 Years|No|||May 2014|May 22, 2014|February 27, 2009||No|The results obtained 1 year after surgery were clearly indicative of the outcome and the    investigators decided to terminate follow-up at that point.|No||https://clinicaltrials.gov/show/NCT00853398||142689|
NCT00853411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08010052|Asthma Exacerbation Study|Th2 Effects on Eicosanoid Pathways: Implications for Altered Innate Responses in Asthma||University of Pittsburgh||Withdrawn|December 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|February 27, 2009||No|Terminated by Investigator due to lack of eligible subjects.|No||https://clinicaltrials.gov/show/NCT00853411||142688|
NCT00853723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08100148|Comparison Study of PTHrP and PTH to Treat Osteoporosis|Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis||University of Pittsburgh|Yes|Completed|May 2009|June 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|105|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|February 27, 2009|Yes|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT00853723||142664|This study was not double-blinded. There was no placebo group in this study. Subjects had higher than anticipated calcium intake and baseline vitamin D levels.
NCT00853736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8530-02-783|Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (30 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Roxicodone™, 30 mg Tablet, Roxane Laboratories, Inc.) in Normal Human Subjects Under Fed Conditions||Mallinckrodt|No|Completed|February 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853736||142663|
NCT00875459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject™-07J|An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus|||Biodel|No|Completed|April 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|233|||Both|18 Years|70 Years|No|||July 2015|July 28, 2015|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875459||141019|
NCT00875472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB#2306|Social Influences on Adolescents' Snack Purchases|Social Influences on Adolescents' Snack Purchases||University at Buffalo|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|N/A||1|||||Both|12 Years|14 Years|No|||April 2009|April 2, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875472||141018|
NCT00860743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULM-014-08F|Respiratory and Autonomic Plasticity Following Intermittent Hypoxia|Respiratory and Autonomic Plasticity Following Intermittent Hypoxia|RAP-IH|VA Office of Research and Development|Yes|Completed|September 2009|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|63|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|March 10, 2009|No|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT00860743||142133|The primary limitation of this trial was the number of participants that required screening to recruit the participants that met the inclusion criteria for the study. However, once the participants were recruited few withdrew.
NCT00853255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 260|Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults|Phase 1 Inpatient Study of the Safety and Immunogenicity of One Dose of Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N3 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|July 2010|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|February 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00853255||142699|
NCT00855283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-2|Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI|Intranasal Administration of Neostigmine and Glycopyrrolate for Bowel Evacuation|IN NEO|VA Office of Research and Development|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855283||142544|
NCT00851045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA196-004|Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer|A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer||Bristol-Myers Squibb|Yes|Completed|October 2009|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|February 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851045||142868|
NCT00851058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AA15708-3|Reducing Driving Offenses of Adolescent Drinkers|A Randomized Control Trial of the Effectiveness of of Group Motivational Counseling and an Emergency Department Experience in Reducing Risky Alcohol Use and Driving Behaviors.|ROAD|Rhode Island Hospital|Yes|Active, not recruiting|May 2007|April 2012|Anticipated|March 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|786|||Both|16 Years|20 Years|No|||February 2011|February 24, 2011|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851058||142867|
NCT00851396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080221001|Assessment of Influence of Vitamin D on Insulin Secretion and Sensitivity in Obese Teenage Girls|Assessment of Influence of Vitamin D on Insulin Secretion and Sensitivity in Obese Teenage Girls (Assessment of Prevalence of Vitamin D Deficiency in Obese Teenage Girls and Influence of Vitamin D on Insulin Secretion and Sensitivity)||University of Alabama at Birmingham|No|Completed|April 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Female|13 Years|18 Years|No|Non-Probability Sample|Female adolescents who are menarchal BMI is 95th centile, for age and sex|September 2011|September 9, 2011|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00851396||142842|
NCT00851695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1399|Examining the Role of Vitamin D in Asthma and Chronic Obstructive Pulmonary Disease (COPD)|Vitamin D in Obstructive Lung Diseases||Brigham and Women's Hospital|No|Completed|July 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|2266|Samples With DNA|Serum samples|Both|5 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|For the Childhood Asthma Management Program, the study population was children with mild        to moderate asthma, 5 to 12 years of age, living across the United States. For the Genetic        Epidemiology of Asthma in Costa Rica study, the study population was children with asthma,        5 to 12 years of age, living in Costa Rica. For the Normative Aging Study, the study        population was a community sample of men living in the Boston area.|August 2012|August 10, 2012|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00851695||142819|
NCT00851357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDPH 05-45834|Telephone Counseling and the Distribution of Nicotine Patches to Smokers|The Efficacy of Telephone Counseling and the Centralized Distribution of Nicotine Replacement Therapy Through a Smoking Cessation Quitline||University of California, San Diego|No|Completed|February 2009|December 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|4200|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851357||142845|
NCT00851370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJ-241|Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels|Exploratory Study of Xolair (Omalizumab)to Improve Outcomes in Patients With COPD and Elevated IgE Levels, and Positive RAST or Skin Prick Tests||National Jewish Health|Yes|Withdrawn|January 2009|February 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|40 Years|70 Years|No|||April 2015|April 14, 2015|February 4, 2009|Yes|Yes|Unable to find eligible subjects- study closed|No||https://clinicaltrials.gov/show/NCT00851370||142844|
NCT00851383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI B001|A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers|A Phase I Placebo-controlled, Double-blinded (in Terms of Vaccine or Placebo), Randomized Dose-escalation Trial to Evaluate the Safety and Immunogenicity of Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers. (IAVI B001)||International AIDS Vaccine Initiative|Yes|Completed|March 2009|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|February 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00851383||142843|
NCT00852267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-068|Lipoprotein Effects of Substituting Beef Protein for Carbohydrate|Lipoprotein Effects of Substituting Beef Protein for Carbohydrate||Children's Hospital & Research Center Oakland|No|Completed|January 2008|December 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00852267||142775|
NCT00852527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 08-377|Evaluation of VA's Traumatic Brain Injury (TBI) Clinical Reminder and Comprehensive TBI Evaluation (CTBIE)|Evaluation of VA's TBI Clinical Reminder And Secondary Level Evaluation|TBI|VA Office of Research and Development|No|Completed|June 2009|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|456|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Operation Enduring Freedom/ Operation Iraqi Freedom (OEF/OIF) Veterans|August 2014|April 6, 2015|February 25, 2009||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT00852527||142755|
NCT00852540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110978|Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA|A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus||GlaxoSmithKline|No|Completed|April 2009|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|410|||Both|2 Months|N/A|No|||July 2012|February 25, 2016|February 26, 2009|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00852540||142754|
NCT00852306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-265|A Comparison of Two Freezing Techniques|A Comparison of Two Freezing Techniques||Northwell Health|No|Completed|February 2009|October 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|18|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 8, 2012|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852306||142772|
NCT00852319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0017|Interpregnancy Care Project-Mississippi (IPC-M)|Interpregnancy Care Project-Mississippi|IPC-M|University of Mississippi Medical Center|No|Completed|February 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|264|||Female|13 Years|44 Years|No|||January 2016|January 13, 2016|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852319||142771|
NCT00852878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPSC IRB #5275|The Treatment of Recurrent Abdominal Pain in Children|The Treatment of Recurrent Abdominal Pain in Children: A Comparison of Biofeedback and Behavioral Intervention||Kaiser Permanente|No|Withdrawn|March 2009|||January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|17 Years|No|||December 2010|June 19, 2015|February 26, 2009||No|Not enough interested participants|No||https://clinicaltrials.gov/show/NCT00852878||142728|
NCT00852852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-284|Computerized Assessment for Patients With Cancer|Computerized Assessment for Patients With Cancer-ESRA-C II|ESRA-C_II|Dana-Farber Cancer Institute|Yes|Completed|October 2008|December 2013|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|779|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852852||142730|
NCT00853450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1700C00004|Bleeding Time Study With AZD6482, Clopidogrel and ASA|A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared With Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA||AstraZeneca|No|Completed|February 2009|July 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 18, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853450||142685|
NCT00853463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001083|Discharge ALERT: Quality Improvement Initiative|Multi-centered Discharge Alert to Prevent DVT and PE at Hospital Discharge|Discharge|Brigham and Women's Hospital|No|Completed|April 2009|May 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2515|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853463||142684|
NCT00853437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-COSTATUS-2A-H|Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Pediatric Patients|Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Pediatric Patients|GCH|Transonic Systems Inc.|No|Recruiting|January 2009|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|16 Years|No|Non-Probability Sample|Pediatric patients (up to 16 years of age ) in the ICU with in situ central venous and        arterial catheters.|May 2012|May 30, 2012|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853437||142686|
NCT00854100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-71|Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder|A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder||Forest Laboratories|No|Completed|June 2009|||December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|232|||Both|18 Years|65 Years|No|||February 2012|February 6, 2012|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854100||142635|
NCT00854386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-IM-0502-CTIL|Effect of Intraoperative Fluid Restriction on Postoperative Outcomes in Video-assisted Thoracic Surgery (VATS)|The Effect of Intraoperative Fluid Restriction on Postoperative Outcomes in Video-assisted Thoracic Surgery (VATS) for Lung Resection||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|May 2009|September 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Months|80 Years|No|||October 2009|October 14, 2009|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854386||142613|
NCT00875498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00558-47|Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia|Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia||Hôpital le Vinatier|Yes|Completed|November 2008|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|No|||January 2016|January 26, 2016|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875498||141016|
NCT00852995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-015|Dose Finding Study of HP802-247 in Venous Leg Ulcers|A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in Venous Leg Ulcers||Healthpoint|No|Completed|February 2009|July 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|228|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|February 26, 2009|Yes|Yes||No|February 15, 2016|https://clinicaltrials.gov/show/NCT00852995||142719|
NCT00854243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA1|Role of Greyscale and Power Doppler Sonography in Therapy Monitoring in Early Rheumatoid Arthritis (RA)|Therapy Monitoring in Early Rheumatoid Arthritis: The Role of Greyscale and Power Doppler Sonography A Prospective Study Of 20 Egyptian Rheumatoid Arthritis Patients||Cairo University|No|Not yet recruiting|April 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|50 Years|No|Probability Sample|Adult onset Rheumatoia Arthritis patients with a disease duration of less than 3 months|March 2009|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854243||142624|
NCT00854763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091036M|Olmesartan on Ambulatory Blood Pressure Change|Phase 4 Study on Olmesartan, an Angiotensin Receptor Blocker, on Ambulatory Blood Pressure Change, Vitamin D Levels and Urinary Sodium Excretion of Patients With Hypertension||National Taiwan University Hospital|No|Not yet recruiting|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|200 patients with hypertension who received an angiotensin receptor antagonist,        Olmesartan, for 12 weeks' treatment|February 2009|March 1, 2009|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854763||142584|
NCT00854516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU Study No-05-000007|Open Label Clinical Study to Assess the Clinical Safety of a New Compression Device in Subjects With Peripheral Arterial Vascular Disease|Open Label Clinical Study to Assess the Clinical Safety of a New Compression Procedure in Subjects With Peripheral Arterial Vascular Disease||3M|Yes|Completed|February 2009|January 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2010|January 20, 2012|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00854516||142603|
NCT00854776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98C1-051|Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor|The Occurrence of Peptic Ulcer Disease and Its Complications in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Co-prescription of Proton Pump Inhibitor||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|January 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|40 Years|90 Years|No|||June 2010|June 6, 2010|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854776||142583|
NCT00855036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 07 110|Prospective Evaluation of Blunt Renal Injury in Children|Prospective Evaluation of Blunt Renal Injury in Children||Children's Mercy Hospital Kansas City|No|Recruiting|August 2008|August 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|1 Month|17 Years|No|Probability Sample|Patients under 18 who have an identifiable renal parenchymal injury on CT after blunt        trauma|January 2016|January 27, 2016|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855036||142563|
NCT00851084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10668|Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer|Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer|AFFIRM|Sanofi|Yes|Completed|February 2009|January 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|268|||Both|18 Years|N/A|No|||May 2013|June 21, 2013|February 24, 2009|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00851084||142865|The overall survival (OS) data are severely limited due to the low number of events (<50%) in both arms, therefore median OS cannot be accurately estimated due to limitations of available data.
NCT00851708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC vs DKT|Impact of N-Acetylcysteine on Oxidative Stress and Renal Function in Deceased Kidney Transplant Recipients|Oxidative Stress and Postoperatory Renal Function in Deceased Kidney Transplantation||University of Sao Paulo|No|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Both|18 Years|N/A|No|||February 2009|February 27, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851708||142818|
NCT00851721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090701|Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor|FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor||Baxalta US Inc.|Yes|Completed|March 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|4 Years|65 Years|No|||January 2014|June 26, 2015|February 25, 2009|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00851721||142817|
NCT00851422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-C-COSTATUS-5A-H|Accurate Measurement of Cardiac Output Using the Ultrasound Dilution Technique|Accurate Measurement of Cardiac Output Using the Ultrasound Dilution Technique|BCM|Transonic Systems Inc.|No|Completed|February 2008|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|||Both|N/A|18 Years|No|Non-Probability Sample|Any pediatric patient (aged < 18 years) who has undergone cardiac transplantation and is        already scheduled for a biopsy will be offered the opportunity to participate.|May 2012|May 30, 2012|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851422||142840|
NCT00851682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO#03-0535|Feasibility Study of Prostate Tumor Localization for Focal Cryoablation of Prostate Carcinoma|Feasibility Study of Prostate Tumor Localization for Focal Cryoablation of Prostate Carcinoma||Washington University School of Medicine|No|Terminated|January 2009|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|65|||Male|20 Years|85 Years|No|||October 2015|October 14, 2015|February 25, 2009|Yes|Yes|Enrollment was stopped and will not resume. Participants are no longer being examined.|No|September 8, 2015|https://clinicaltrials.gov/show/NCT00851682||142820|
NCT00851747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF2|A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal|||The Cleveland Clinic||Terminated|February 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Female|25 Years|70 Years|Accepts Healthy Volunteers|||January 2010|January 15, 2010|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851747||142815|
NCT00851773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3633|Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects|A Randomised, Double Blind, Placebo-controlled, Parallel-group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.||Novo Nordisk A/S|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|84|||Male|20 Years|45 Years|No|||February 2015|February 20, 2015|February 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00851773||142813|
NCT00852020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCSU-002-CFS|Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients|Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in CHF and COPD Patients. A Randomised, Double-blind and Controlled Pilot Study.||Fresenius Kabi||Completed|April 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|75 Years|No|||June 2011|June 1, 2011|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00852020||142794|
NCT00852592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09020546|Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial|Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial||University of Pittsburgh|Yes|Completed|May 2009|February 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852592||142750|
NCT00852865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 08-17|Lactobacillus Farciminis and Hyperalgesia|Effect of a Dialy Consumption of a Probiotic (Lactobacillus Farciminis) on Hyperalgesia in Response to Thermal Stimulation||Lallemand SAS|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 30, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852865||142729|
NCT00852891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004341 UFRGS|Cardiorespiratory Changes in Patients Being Weaned Off Mechanical Ventilation|Cardiorespiratory Changes in Patients Being Weaned Off Mechanical Ventilation: a Randomized Crossover Clinical Trial||Hospital de Clinicas de Porto Alegre|No|Completed|December 2005|August 2007|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving MV for more than 48 hours, who had been admitted to the Intensive Care        Unit (ICU), and who met the criteria for weaning from MV according to the parameters        previously defined were selected to participate in this study.|February 2009|February 26, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852891||142727|
NCT00853138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD050674|Web-based CBT for Children With Chronic Pain|Web-based CBT for Children With Chronic Pain||Seattle Children's Hospital|No|Completed|May 2007|May 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|12 Years|18 Years|No|||May 2015|May 26, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853138||142708|
NCT00853151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12758|A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes|A Proof of Concept Study to Evaluate the Coadministration of TT223 Given Daily and LY2428757 Given Once-Weekly for Four Weeks in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|February 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|131|||Both|18 Years|70 Years|No|||March 2012|March 19, 2012|February 26, 2009|No|Yes||No|September 15, 2011|https://clinicaltrials.gov/show/NCT00853151||142707|
NCT00853476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 001/09|The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test|The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test||Chulalongkorn University|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult Healthy Volunteers|February 2011|February 16, 2011|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853476||142683|
NCT00853762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28851|Atacicept in Multiple Sclerosis Extension Study, Phase II|An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)|ATAMS ext|EMD Serono||Terminated|February 2009|February 2011|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|60 Years|No|||February 2012|February 3, 2012|February 26, 2009|No|Yes|EMD Serono voluntarily decided to terminate this trial after observing increased MS disease    activity in trial 28063 ATAMS [Please refer to ATAMS]|No||https://clinicaltrials.gov/show/NCT00853762||142661|
NCT00853749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3013|Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine|Revaccination With Pneumococcal Conjugate Vaccine - Characterization Of The Immune Response After Polysaccharide|REPLAY|Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|89|||Both|5 Years|8 Years|No|||December 2010|December 16, 2010|February 19, 2009|Yes|Yes||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00853749||142662|In protocol, primary analysis based on All Available Immunogenicity Population and later modified to Evaluable Immunogenicity Population in Statistical Analysis Plan based on subsequent similar studies and suitability for primary objective.
NCT00854087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fuzheng Huayu S-USIIT-01 Study|Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis|A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis||SCTI Research Foundation|Yes|Completed|August 2010|August 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|70 Years|No|||June 2014|June 18, 2014|February 26, 2009|No|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT00854087||142636|
NCT00854659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-613|A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of ABT-102 in Healthy Subjects||Abbott|No|Completed|March 2009|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|November 1, 2010|March 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00854659||142592|
NCT00853879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0143|An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease|An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease||Northwell Health|No|Terminated|December 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|30 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853879||142652|
NCT00853892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0595-05-812|Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Controlled-Release Test Tablet Formulation of Oxycodone Hydrochloride (40 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (OxyContin® 40 mg, Purdue Pharma L.P.) in Normal Human Subjects Under Fasting Conditions||Mallinckrodt|No|Completed|April 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853892||142651|
NCT00854789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-20012|Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer|Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients||Walter Reed Army Medical Center|No|Completed|December 2002|March 2013|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|95|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|March 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00854789||142582|
NCT00855049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052008-076|A Randomized Crossover Study to Determine the Pharmacokinetics of Intranasally Administered Acetaminophen in Healthy Adults|A Randomized Crossover Study to Determine the Pharmacokinetics of Intranasally Administered Acetaminophen in Healthy Adults||University of Texas Southwestern Medical Center|No|Withdrawn|April 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|February 27, 2009||No|Unable to obtain FDA approval|No||https://clinicaltrials.gov/show/NCT00855049||142562|
NCT00850798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 97-12-04|The Benefits of Intensive Glycemic Control in Elderly Patients With Type 2 Diabetes|||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|February 2009|December 2020|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|80 Years|N/A|No|||June 2010|July 23, 2010|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850798||142886|
NCT00851110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc 2004/110|Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors|A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.||University Medical Center Groningen||Terminated|October 2004|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|50|||Female|18 Years|50 Years|No|||February 2009|February 24, 2009|February 23, 2009||||No||https://clinicaltrials.gov/show/NCT00851110||142864|
NCT00851435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB-101-002|Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa|A Non-comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa||Kenta Biotech Ltd|No|Completed|February 2008|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2009|July 29, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851435||142839|
NCT00852007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-ONC-001 CAN|A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1|A Phase I/II Study Evaluating the Safety and Efficacy of Vaccination With Autologous Dendritic Cells Loaded With Tn-MUC1 Peptide in Patients With Non-Metastatic Androgen Independent Prostatic Adenocarcinoma.|MUC1|McMaster University|No|Active, not recruiting|February 2009|March 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Male|19 Years|N/A|No|||December 2013|December 4, 2013|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852007||142795|
NCT00851734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX214-01|A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)|A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca||Lux Biosciences, Inc.|No|Completed|February 2009|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|February 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00851734||142816|
NCT00851786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5247|Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy|A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX® (Zoster Vaccine Live) in Human Immunodeficiency Virus (HIV)-1-Infected Adults on Potent Combination ART With Conserved Immune Function||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2009|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|395|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|February 25, 2009|Yes|Yes||No|September 7, 2012|https://clinicaltrials.gov/show/NCT00851786||142812|
NCT00852033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Wood-AA013919|Alcohol Early Intervention for Freshmen|Alcohol Early Intervention for Freshmen|Transitions|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Active, not recruiting|January 2004|July 2009|Anticipated|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1014|||Both|17 Years|20 Years|Accepts Healthy Volunteers|||February 2009|February 24, 2009|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00852033||142793|
NCT00852605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV2001|Acute Lung Injury After Allogeneic Transplantation - Diagnosis and Early Treatment|A Randomized Clinical Trial on the Use of Early Intermittent Non-Invasive Ventilation in Patients Suffering From Acute Lung Injury After Allogeneic Transplantation||Technische Universität Dresden||Completed|December 2001|||August 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Open Label|2||Actual|86|||Both|18 Years|N/A|No|||February 2009|February 26, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852605||142749|
NCT00852618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5249s|Intensive Viral Dynamics Substudy of A5248|Intensive Viral Dynamics Substudy of A5248||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2008|September 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|11|Samples Without DNA|Plasma samples will be collected throughout the study|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected participants currently enrolled in study A5248|June 2015|June 8, 2015|February 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00852618||142748|
NCT00853489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-20108|rhBMP-2 Versus Autograft in Critical Size Tibial Defects|RhBMP-2 vs. Autograft for Critical Size Tibial Defects: A Multicenter Randomized Trial||St. Louis University|Yes|Recruiting|August 2011|August 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|February 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853489||142682|
NCT00853164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0318|A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)|A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy|MAP-P|Washington University School of Medicine|No|Active, not recruiting|July 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Male|40 Years|80 Years|No|||November 2009|November 17, 2009|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853164||142706|
NCT00854139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKD01|Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)|Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure||Massachusetts General Hospital|Yes|Completed|August 2001|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|February 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00854139||142632|
NCT00854152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4604g|A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma|An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma||Genentech, Inc.||Completed|March 2009|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854152||142631|
NCT00854113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-1474-C-328|Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers|A Phase I , Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of EGT0001474 In Healthy Volunteers||Theracos|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|February 27, 2009|No|Yes||No|October 25, 2010|https://clinicaltrials.gov/show/NCT00854113||142634|
NCT00854126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4605g|A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma|An Open-label, Phase I, Dose-escalation Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors and Non-hodgkin's Lymphoma||Genentech, Inc.||Completed|May 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854126||142633|
NCT00854672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-4-007|Muscle Strength and Exercise Capacity in Sarcoidosis Patients|Exercise Capacity, Muscle Strength and Fatigue in Sarcoidosis: a Two-year Follow-up Study||Maastricht University Medical Center|Yes|Completed|January 2009|September 2011|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|124|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the        department of Respiratory Medicine of the Maastricht University Medical Centre (MUMC) a        tertiary referral center in the Netherlands will be included in this study|April 2012|April 5, 2012|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00854672||142591|
NCT00867620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707055R|Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma|Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma||National Taiwan University Hospital|Yes|Enrolling by invitation|August 2008|July 2010|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|82|Samples With DNA|These biospecimens will be keep in low-temperature (-80 degree)and then genomic DNA will be      extracted from blood/urine samples until the detection of DNA methylation profiles.|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects from the Department of Urology of NTUH. Those with urothelial        carcinoma(bladder, renal pelvis and ureter) will be recruited in this study period. After        they signed the informed consent,we will ask them some questions through face-to-face        interview and collect 6-8ml blood and 50c.c. urine. Then genomic DNA will be extracted        from these biospecimens to perform a non-invasive DNA methylation-based assay.|February 2009|March 22, 2009|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867620||141613|
NCT00867633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804011R|Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan|Observational Study of Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan||National Taiwan University Hospital|No|Recruiting|March 2009|March 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|100|Samples With DNA|DNA extracted from the resected tissue samples|Both|N/A|N/A|No|Probability Sample|The patients who received nephrectomies|February 2012|February 20, 2012|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867633||141612|
NCT00854256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iScience-022-CG|Trabeculectomy Versus Canaloplasty to Treat Glaucoma|Comparison of Canaloplasty and Trabeculectomy in Patients With Open Angle Glaucoma and Inadequate Local Eye Pressure Lowering Therapy - a Prospective, Randomized Study||University of Cologne|No|Recruiting|April 2009|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854256||142623|
NCT00854269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705075R|Screening and Identification of Biomarkers on Cervical Cancers|Screening and Identification of Novel Diagnostic and Prognosis Biomarkers on Cervical Cancers||National Taiwan University Hospital|No|Recruiting|January 2007|January 2011|Anticipated|May 2008|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|250|||Female|25 Years|80 Years|No|||March 2009|March 22, 2009|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00854269||142622|
NCT00854802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 025-HCV-205|A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients|A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients||Debiopharm International SA|Yes|Completed|January 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|290|||Both|18 Years|65 Years|No|||February 2016|February 12, 2016|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854802||142581|
NCT00854815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 11 181|Irrigation Versus No Irrigation for Perforated Appendicitis|Irrigation Versus No Irrigation for Perforated Appendicitis||Children's Mercy Hospital Kansas City|No|Completed|December 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|1 Month|17 Years|No|||July 2012|July 31, 2012|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854815||142580|
NCT00855062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uganda minocycline study|Minocycline for HIV+ Cognitive Impairment in Uganda|Minocycline in the Treatment of HIV-Associated Cognitive Impairment in Uganda||Johns Hopkins University|Yes|Terminated|April 2008|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||January 2011|January 28, 2011|March 2, 2009||No|The Neurologic AIDS Research Consortium Data Safety and Monitoring Board committee recommended    to terminate the study early due to futility on 11/6/2009.|No|December 17, 2010|https://clinicaltrials.gov/show/NCT00855062||142561|The estimated sample size was 100; however, due to early termination of the study, the total number of randomized participants was 73.
NCT00850811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-023|A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers|A 4-Day, Randomized, Controlled, Open Application Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers, Using a Phototoxicity Test Design||Peplin|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2009|September 7, 2015|February 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00850811||142885|
NCT00850824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18 DK075371-DCAS|Community Health Workers in Diabetes Care in American Samoa|Diabetes Care in American Samoa|DCAS|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2007|July 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|268|||Both|21 Years|75 Years|No|||October 2015|October 5, 2015|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00850824||142884|
NCT00851409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1207|A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration|An Open-label Exploratory Phase II Study of the Safety and Immunogenicity of Repeated "rhC1INH" Administration of 50 U/Kg in Patients With Hereditary C1 Inhibitor Deficiency ("HAE")|OPERA|Pharming Technologies B.V.|No|Completed|June 2009|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|February 25, 2009||No||No|November 9, 2012|https://clinicaltrials.gov/show/NCT00851409||142841|
NCT00851162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009762|Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions|Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions||Emory University|No|Withdrawn|March 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|11 Years|N/A|No|||November 2012|November 27, 2012|February 24, 2009|Yes|Yes|Study was not continued due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00851162||142860|
NCT00851448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCSU-001-CFS|Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients|Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients. A Randomised, Double-blind, Controlled Pilot Study||Fresenius Kabi||Terminated|October 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|17|||Both|18 Years|75 Years|No|||May 2011|June 1, 2011|February 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00851448||142838|
NCT00851760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU Dijon OPH 01|Epiretinal Macular Membrane and Cataract Extraction|Idiopathic Epiretinal Macular Membrane and Cataract Extraction : Combined vs Consecutive Surgery||Centre Hospitalier Universitaire Dijon|Yes|Completed|January 2005|September 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|50 Years|90 Years|No|||August 2009|August 3, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851760||142814|
NCT00852046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2008.071|Adjunct Dexmedetomidine (Precedex®) Therapy Impact on Sedative and Analgesic Requirement|Adjunct Dexmedetomidine Therapy Impact on Sedative and Analgesic||Avera McKennan Hospital & University Health Center|Yes|Withdrawn|February 2009|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|No|||July 2011|October 5, 2011|February 24, 2009|Yes|Yes|PI resigned.|No||https://clinicaltrials.gov/show/NCT00852046||142792|
NCT00852332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635901|Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer|An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.||National Cancer Institute (NCI)||Recruiting|August 2009|||September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2009|September 17, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852332||142770|
NCT00853177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070304|MEOPA Breathing Analgesia for Oocyte Retrieval(KALOVAL)|MEOPA Breathing Analgesia vs Local Anesthesia for Oocyte Retrieval in ART: a Prospective, Randomized Controlled Study|KALOVAL|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Female|18 Years|42 Years|No|||May 2011|September 15, 2012|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00853177||142705|
NCT00853190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8867-03-791|Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Extended Release Test Capsule Formulation of Chlorpheniramine Polistirex and Hydrocodone Polistirex Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in Normal Human Subjects Under Fed Conditions||Mallinckrodt|No|Completed|September 2003|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853190||142704|
NCT00853203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-1028|Expressive Disclosure and Colorectal Cancer|Expressive Disclosure Program for Colorectal Cancer Patients||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2009|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|174|||Both|18 Years|N/A|No|Non-Probability Sample|Study population of 174 participants diagnosed with colorectal cancer.|October 2015|October 28, 2015|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00853203||142703|
NCT00853775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816533-2|Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups|Regulation of Lipoprotein(a) Metabolism in Humans With Reference to Ethnicity||University of California, Davis|Yes|Completed|February 2009|December 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Actual|325|Samples With DNA|plasma, DNA, white blood cell|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are recruiting 100 African American and 100 Caucasian families. The families that will        be recruited will have two natural parents and two natural offspring.|February 2015|February 6, 2015|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00853775||142660|
NCT00853788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00004428|Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil|Genomic and Histological Analysis of Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|skin biopsy samples|Both|19 Years|90 Years|No|Non-Probability Sample|patients with diffuse cutaneous systemic sclerosis|February 2012|February 15, 2012|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853788||142659|
NCT00854165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901015R|Lung Transplantation in Respiratory Failure Patients|Extracorporeal Membrane Oxygenation Support for Bilateral Sequential Lung Transplantation in Respiratory Failure Patients.||National Taiwan University Hospital|No|Active, not recruiting|February 2009|June 2009|Anticipated|April 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|10|||Both|N/A|N/A|No|Probability Sample|Between July 2006 and July 2008, we performed bilateral sequential lung transplantation        under venoarterious ECMO support in 10 respiratory failure patients with various lung        diseases. This study wanted to report the preoperative condition, postoperative        complications, and short-term outcome after lung transplantation.|March 2009|March 2, 2009|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854165||142630|
NCT00854399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706002R|Screening and Identification of Ovarian Cancers|Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Ovarian Cancers||National Taiwan University Hospital|No|Recruiting|January 2006|December 2011|Anticipated|January 2006|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|250|||Female|15 Years|80 Years|No|||March 2009|March 2, 2009|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00854399||142612|
NCT00854425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-asp-NK/T|L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma|Phase II Study of L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma||Fudan University|No|Completed|June 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||February 2012|February 16, 2012|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854425||142610|
NCT00868478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMC-07-0080-CTIL|The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)|Phase I-II Trial of the Anti CD74 Monoclonal Antibody-Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia||Kaplan Medical Center|No|Recruiting|April 2009|April 2012|Anticipated|April 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||September 2009|June 1, 2010|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868478||141548|
NCT00854529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005285|Subconjunctival Bevacizumab Effect on Bleb Vascularity|Subconjunctival Bevacizumab Injection for the Prevention of Bleb Vascularization Post Trabeculectomy||Rabin Medical Center|Yes|Not yet recruiting|April 2009|October 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2009|March 2, 2009|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854529||142602|
NCT00854828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR055176-01A2|A Multicenter Prospective Study of Quality of Life in Adult Scoliosis|A Multicenter Prospective Study of Quality of Life in Adult Scoliosis|ASLS|Washington University School of Medicine|Yes|Active, not recruiting|January 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|80 Years|No|||December 2015|December 7, 2015|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854828||142579|
NCT00855088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC IRB 08-0419|Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue|A Phase IV, Open Label Study in Healthy Male Subjects to Investigate the Extent of Darunavir/Ritonavir and Etravirine Exposure in Blood, Seminal Fluid, and Rectal Mucosal Tissue Following Single and Multiple Dosing of Darunavir/Ritonavir and Etravirine|DESeRT|University of North Carolina, Chapel Hill|No|Completed|July 2009|February 2011|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||May 2011|May 11, 2011|March 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00855088||142559|
NCT00855075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-03-2038|Correlation of Cerebral State Index With the Richmond Agitation-Sedation Scale in Mechanically Ventilated ICU Patients|Correlation of the Cerebral State Index With the Richmond Agitation-Sedation Scale in ICU Patients Who Are Sedated and Mechanically Ventilated: A Pilot Study||CAMC Health System|No|Terminated|May 2008|February 2010|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|85 Years|No|Probability Sample|Critically ill adults admitted to the surgical-trauma unit at Charleston Area Medical        Center with an anticipated duration of mechanical ventilation of at least 72 hours.|July 2015|July 27, 2015|January 15, 2009||No|Technology used to obtain/measure cerebral state index is no longer manufactured|No||https://clinicaltrials.gov/show/NCT00855075||142560|
NCT00851123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UiB24126|Modified Constrained - Induced Movement Therapy Compared to Intensive Bimanual Training|Modified Constrained - Induced Movement Therapy Compared to Intensive Bimanual Training for Subacute Stroke Patients. A Randomized Controlled Trial||University of Bergen|Yes|Terminated|February 2009|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|February 23, 2009||No|Due to recruitment difficulties the trial was stopped after an interim analysis at 30    patients.|No||https://clinicaltrials.gov/show/NCT00851123||142863|
NCT00851149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2009.36|Pro-inflammatory Cytokines in Blood From Orthopedic Surgery Compared to Abdominal Aneurysm Repair|Pro-inflammatory Cytokines (IL-1beta,IL-6, IL-8 and TNF-α) and Complement Activation (C3a) in Blood Collected From Surgery Field From Patients Undergoing Orthopedic Surgery Compared to Patients Undergoing Abdominal Aneurysm Repair.|KEEP-HB|Sykehuset i Vestfold HF|No|Active, not recruiting|November 2009|May 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Blood|Both|18 Years|N/A|No|Probability Sample|Primary care clinic|June 2010|June 10, 2010|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00851149||142861|
NCT00851474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-C-COSTATUS-7A-H|Measurement of Cardiac Output and Blood Volumes|Measurement of Cardiac Output and Blood Volumes|WSU|Transonic Systems Inc.|No|Suspended|March 2009|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (older than 18 years of age) in the Intensive Care Unit with arterial and        central venous catheters in place.|May 2012|May 30, 2012|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851474||142836|
NCT00851487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARIMA Study Group|Trial of Amoxicillin Compared With Placebo for Pneumonia in Children Aged 2-59 Months|A Randomized Multicentre Double Blind Trial of Amoxicillin Compared With Placebo for Treatment of WHO Defined Non-Severe Pneumonia in Children Aged 2-59 Months: NARIMA Study Group||Pakistan Institute of Medical Sciences|Yes|Completed|January 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|900|||Both|2 Months|59 Months|No|||February 2009|February 25, 2009|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851487||142835|
NCT00851799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5260s|Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters|Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Substudy of A5257||AIDS Clinical Trials Group||Completed|June 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|334|Samples Without DNA|Blood and urine samples will be collected and stored|Both|18 Years|N/A|No|Non-Probability Sample|Antiretroviral naïve, HIV-infected men and women with HIV-1 RNA level >1000 copies/ml        initiating treatment for HIV-1 infection.|December 2015|December 9, 2015|February 24, 2009|No|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00851799||142811|
NCT00852059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JoGu_KJP_ASTA-3285-26|Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA)|Effect of Methylphenidate Formulation on ADHD-patients` Adherence to Medical Treatment. A Comparison of Medikinet Retard® (ER) Once Daily and Medikinet® (IR) Twice Daily in Children and Adolescents Diagnosed With ADHD|ASTA|Johannes Gutenberg University Mainz|No|Terminated|March 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|6 Years|17 Years|No|||May 2014|May 6, 2014|February 25, 2009||No|Diffculties to recruit anticipated study size, now analysis|No||https://clinicaltrials.gov/show/NCT00852059||142791|
NCT00858013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-CRO-08-197|Study of the Durability of Glycemic Control With Nateglinide|Multi-center, Randomized, Open Label Study of the Durability of Glycemic Control With Nateglinide Versus Glimepiride as Monotherapy in Type 2 Diabetic Patients||Ajou University School of Medicine|Yes|Recruiting|April 2009|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858013||142338|
NCT00858286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109780|A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.|Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.||GlaxoSmithKline|No|Completed|February 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00858286||142317|
NCT00858559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS047|Follow-up of Patients With Implantable Cardioverter Defibrillators by Home Monitoring (ANVITE)|Follow-up of Patients With Implantable Cardioverter Defibrillators by Home Monitoring (ANVITE)|ANVITE|Biotronik SE & Co. KG|No|Terminated|March 2009|December 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|110|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|March 9, 2009||No|Stopped due to low enrollment. Patients will be followed up for 3 months.|No||https://clinicaltrials.gov/show/NCT00858559||142296|
NCT00858572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-03|STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies||Synta Pharmaceuticals Corp.|No|Completed|March 2009|February 2013|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|March 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858572||142295|
NCT00855400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMN/ELA|Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis|Phase I/II Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis|CMN/ELA|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Completed|February 2007|February 2010|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|20 Years|65 Years|No|||December 2010|December 1, 2010|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855400||142535|
NCT00855413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 0821|Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine|CID 0821 - Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected Antiretroviral Naïve Patients Treated With Darunavir/Ritonavir and Etravirine||University of North Carolina, Chapel Hill|Yes|Completed|March 2009|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|March 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00855413||142534|
NCT00855439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H80-US-X012|Evaluation of Exenatide in Patients With Diabetic Neuropathy|A Single-center,Proof of Concept,Randomized,Controlled Parallel Group Clinical Trial of the Effects of Exenatide vs. a Long Acting Insulin Analog to Evaluate the Efficacy of Exenatide in Patients With Diabetic Neuropathy and Type 2 Diabetes||University of Michigan|No|Completed|June 2008|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|70 Years|No|||April 2015|April 23, 2015|March 3, 2009||No||No|April 23, 2015|https://clinicaltrials.gov/show/NCT00855439||142532|
NCT00855972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03022009-1918|Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome|Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome||Stanford University||Withdrawn|August 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||December 2015|December 9, 2015|March 3, 2009|Yes|Yes|The FDA IND application is paused due to additional required testing. The IRB protocol was    closed prior to research starting.|No||https://clinicaltrials.gov/show/NCT00855972||142492|
NCT00855959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5259C00001|Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients|An Evaluation of Efficacy and Safety of Corresponding Doses of Pulmicort Turbuhaler® and Pulmicort Respules® in Japanese Asthmatic Adult Patients (Open, Multicenter, Phase III Study)||AstraZeneca|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|16 Years|N/A|No|||February 2011|February 16, 2011|March 4, 2009|Yes|Yes||No|August 17, 2010|https://clinicaltrials.gov/show/NCT00855959||142493|
NCT00856232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220080056|Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department|Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department||Rutgers, The State University of New Jersey|No|Completed|January 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|91|||Both|21 Years|N/A|No|||March 2013|March 22, 2013|March 4, 2009||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT00856232||142473|Limited number of subjects due to difficulty with recruitment
NCT00856505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00557|Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation|Everolimus and Mycophenolate Sodium as GvHD Prophylaxis in Allogeneic Stem Cell Transplantation||University Hospital Freiburg|Yes|Recruiting|March 2008|March 2011|Anticipated|March 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|65 Years|No|||March 2009|March 4, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856505||142453|
NCT00859417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.485/28|Study Evaluating the Effectiveness of the Use of Prosthesis With Trans-Obturator Way for the Correction of Anterior Prolapse|PERIGEE :Randomized Study Evaluating the Effectiveness of the Use of Prosthesis With Trans-obturator Way for the Correction of Anterior Prolapse.||Hospices Civils de Lyon|Yes|Completed|September 2008|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Female|18 Years|90 Years|No|||November 2013|November 29, 2013|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859417||142232|
NCT00855621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRHF-PD-01|Effects of Deep Brain Stimulation in Parkinson's Disease|Prognostic Factors in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) - a Prospective Randomized Double-blind Study (The NORSTIM Study)||Oslo University Hospital|Yes|Active, not recruiting|March 2009|December 2023|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||January 2015|January 7, 2015|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855621||142518|
NCT00855907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-NM-593-CTIL|Fatty Liver in Inflammatory Bowel Disease (IBD) Patients|Prevalence of Fatty Liver in Inflammatory Bowel Disease (IBD) Patients and Mechanisms Related to Inflammation and Fatty Liver||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2009|March 2011|Anticipated|March 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|Blood count and biochemistry tests (such as: Liver and thyroid enzimes,cholesterol,      immunology, glucose)|Both|18 Years|N/A|No|Non-Probability Sample|One hundred consecutive IBD patients treated at the Tel Aviv Sourasky Medical Center will        be recruited.|March 2009|March 4, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00855907||142497|
NCT00856440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-1|Safety and Efficacy of Routine Colonoscopy Preparations|Safety and Efficacy of Routine Colonoscopy Preparations||VA Office of Research and Development|No|Completed|June 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|330|Samples Without DNA|Serum and urine samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Veterans, SCI and able-bodied|July 2010|July 15, 2010|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00856440||142457|
NCT00856726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080669|Racial Differences in Phosphorus Metabolism|Racial Differences in Phosphorus Metabolism||University of Miami|No|Completed|February 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|June 30, 2011|March 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00856726||142436|
NCT00856427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11284|Implantation of Markers for the Radiotherapy of Lung Cancer Patients|Implantation of Markers for the Radiotherapy of Lung Cancer Patients||Virginia Commonwealth University|Yes|Terminated|February 2008|August 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|March 4, 2009||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00856427||142458|
NCT00856687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0281002|A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects|A Randomized, Double-Blind (3rd Party Open), Double-Dummy, Placebo- And Active Controlled, 3-Way Crossover Study To Determine The Effects Of Oral PF-03893787 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.||Pfizer|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|60 Years|No|||January 2010|January 21, 2010|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00856687||142439|
NCT00857051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM.HO.04|Postpartum Support: Can we Facilitate the Transition to Motherhood?|Postpartum Support: Can we Facilitate the Transition to Motherhood?||American University of Beirut Medical Center|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|552|||Female|N/A|N/A|No|||March 2009|September 24, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857051||142411|
NCT00857064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NGR-DUM-2008/2|Subjective Well Being of Schizophrenic Patients in Greece|Subjective Well Being of Schizophrenic Patients in Greece|AURA|AstraZeneca|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|600|||Both|18 Years|65 Years|No|Non-Probability Sample|Target Group:Patients suffering from Schizophrenia treated in private practice|December 2010|December 7, 2010|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00857064||142410|
NCT00857077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFID-R7602|Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana|Evaluation of the Safety and Effectiveness of EPI-Linked Malaria Intermittent Chemotherapy and Iron Supplementation||Gates Malaria Partnership|Yes|Completed|September 2000|June 2004|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2485|||Both|2 Months|24 Months|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857077||142409|
NCT00857350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709003082|The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment|The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment||Yale University|No|Completed|June 2008|September 2012|Actual|June 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|90 Years|No|Non-Probability Sample|HIV+, opioid dependent|July 2013|July 19, 2013|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00857350||142389|
NCT00857662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G000296|Study Comparing Onyx and TRUFILL in Brain Arteriovenous Malformations (AVMs)|U.S. Multicenter, Randomized Controlled Study Comparing the Performance fo Onyx(EVOH) and TRUFILL® (n-BCA)in Presurgical Embolization of Brain Arteriovenous Malformations (BAVMs)||ev3|Yes|Completed|May 2001|December 2007|Actual|April 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|N/A|N/A|No|||March 2009|March 6, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857662||142365|
NCT00859222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-342|LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma|Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|March 2009|December 2014|Anticipated|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|March 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859222||142245|
NCT00858299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-089|The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria|The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria||Samsung Medical Center|Yes|Not yet recruiting|March 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|70 Years|No|||March 2009|March 6, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00858299||142316|
NCT00858312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL49|Dairy Foods and Weight Loss|Role of Dairy Foods to Enhance Central Fat and Weight Loss With Moderate Energy Restriction in Overweight and Obesity Individuals||USDA, Western Human Nutrition Research Center|No|Completed|October 2006|August 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|72|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2009|October 22, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00858312||142315|
NCT00859833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31431|Effects of Body Mass Index on the Hyperemic Response to Regadenoson|Effects of Body Mass Index on the Hyperemic Response to Regadenoson||University of Utah|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||May 2011|May 20, 2011|March 10, 2009|Yes|Yes||No|November 1, 2010|https://clinicaltrials.gov/show/NCT00859833||142202|Due to technical problems, data from two of the 30 subjects was not usable.
NCT00859846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2340|Ultrasound Guided Arterial Line Placement in Long Axis Versus Short Axis in Pediatric Patients|Comparison of Ultrasound Guided Arterial Line Placement in Long Axis Versus Short Axis in Pediatric Patients.||University of Oklahoma|Yes|Recruiting|March 2009|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|74|||Both|N/A|14 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859846||142201|
NCT00855699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RED 740|Alcohol Detoxification in Primary Care Treatment (ADEPT)|Alcohol Detoxification in Primary Care Treatment (ADEPT) - a Feasibility Study of Conducting a Randomised Trial in Primary Care Comparing Two Pharmacological Regimens.|ADEPT|University of Bristol|No|Completed|November 2009|November 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|No|||January 2011|January 18, 2011|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855699||142512|
NCT00855712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR-05-2008|Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation|Prospective, Multicenter, Randomized, Clinical Investigation of TransMedics Organ Care System (OCS) for Cardiac Use|PROCEEDII|TransMedics|Yes|Completed|March 2009|November 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855712||142511|
NCT00855725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0246|Affective Processing in Depression and Epilepsy|Affective Processing in Depression and Epilepsy; An fMRI Study||Northwell Health|No|Terminated|June 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There are four study groups.          1. Healthy Controls          2. Subjects with epilepsy only          3. Subjects with primary depression only          4. Subjects with epilepsy and depressive symptoms.|July 2009|July 8, 2009|March 3, 2009||No|PI wanted to discontinue study.|No||https://clinicaltrials.gov/show/NCT00855725||142510|
NCT00855985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Anastomotic Techniques in Pancreaticoduodenectomy|A Randomised Controlled Trial of Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Pancreaticoduodenectomy for Cancer|PG/PJ|Lakeshore Hospital|No|Active, not recruiting|July 2004|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|312|||Both|20 Years|80 Years|No|||September 2011|September 24, 2011|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00855985||142491|
NCT00856245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11571|Evaluate Rituximab in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma|Role of Rituximab Containing Salvage Chemotherapy and in Vivo Purging in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma or Transplant Eligible Mantle Cell Lymphoma||University of Kansas Medical Center|Yes|Active, not recruiting|February 2009|January 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2013|March 31, 2015|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856245||142472|
NCT00856830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080929010|Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer|Phase I/IIa Study of the Novel Combination of Bendamustine With Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients With Extensive Stage Small Cell Lung Cancer||University of Alabama at Birmingham|Yes|Active, not recruiting|March 2009|May 2016|Anticipated|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|79 Years|No|||February 2016|February 22, 2016|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856830||142428|
NCT00856843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI800-303|BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects||Braintree Laboratories|No|Completed|February 2009|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|N/A|No|||October 2010|October 15, 2010|March 5, 2009|Yes|Yes||No|September 3, 2010|https://clinicaltrials.gov/show/NCT00856843||142427|As prespecified in the study protocol, expected prep related side effects (nausea, vomiting, cramping, bloating and overall discomfort) were only documented as AEs if patients rated them severely distressing on the study questionnaire.
NCT00855322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAEx-0809|Study Examining the Effect of Exercise in People With Rheumatoid Arthritis Taking Anti-TNFalpha Medication|Randomized Controlled Trial Examining The Effect Of Exercise In People With Rheumatoid Arthritis Taking Anti-TNFalpha Medication||University College Dublin|No|Active, not recruiting|January 2008|July 2009|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|70 Years|No|||February 2009|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855322||142541|
NCT00856180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-148|Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies|Pilot Study of Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2009|||September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856180||142477|
NCT00856193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2207|A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study to Investigate the Bronchodilatory Effect of 50 µg NVA237 Inhaled Once Daily in Patient With Chronic Obstructive Pulmonary Disease (COPD).||Novartis||Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|40 Years|N/A|No|||June 2011|June 8, 2011|March 4, 2009|Yes|Yes||No|January 20, 2011|https://clinicaltrials.gov/show/NCT00856193||142476|
NCT00855920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-GA-0814|Study Utilizing Rilonacept in Gout Exacerbations|A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare|SURGE|Regeneron Pharmaceuticals|Yes|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|70 Years|No|||June 2011|September 27, 2013|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855920||142496|
NCT00856739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6650-R|Obesity and the Initiation of Knee Osteoarthritis|Obesity and Initiation of Osteoarthritis||VA Office of Research and Development|No|Completed|March 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community||1|Actual|177|Samples Without DNA|One tube of blood identified with a unique number.|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults aged 20-60, of varying weights.|December 2014|December 10, 2014|March 5, 2009||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00856739||142435|
NCT00856700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/08|Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome|Effect of GLP-1 on Endothelial Function and Glucose Uptake in Patients With Metabolic Syndrome||University of Rome Tor Vergata|Yes|Completed|November 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00856700||142438|
NCT00856713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-01/2005 (ACPS)|Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers|A Study in Healthy Volunteers and Patients With Liver Cirrhosis to Assess the Effects of Age, Gender, and Stable Liver Disease on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) as an in-Vivo Marker of Liver Function in Man||Norgine|No|Completed|March 2006|||August 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|6||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856713||142437|
NCT00857376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00016646|Dose Ranging Study of the Effects of Alpha Lipoic Acid on Oxidative Stress|Dose Ranging Study of the Effects of Alpha Lipoic Acid on Oxidative Stress|Alpha|Johns Hopkins University|No|Completed|March 2008|September 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|77|||Both|40 Years|N/A|No|||September 2012|September 27, 2012|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00857376||142387|
NCT00857389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0363|Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies|Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2009|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|60 Years|No|||November 2015|November 17, 2015|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857389||142386|
NCT00857363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120508|Colonic Transit Time Validation Study|SmartPill Colonic Transit Time Validation Study in Patients With Chronic Constipation|CTT|The SmartPill Corporation|No|Recruiting|March 2009|June 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|210|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with constipation referred to a tertiary motility center|January 2010|January 14, 2010|March 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857363||142388|
NCT00858910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/077|Comparison of Embedded and Added Motor Imagery Training in Patients After Stroke|Comparison of Embedded and Added Motor Imagery Training to Improve a Motor Skill in Patients After Stroke: a Pilot Randomised Controlled Trial Using a Mixed Methods Approach||Reha Rheinfelden|No|Completed|March 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||July 2010|October 24, 2013|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858910||142269|
NCT00858923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080104|Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)|Phase 1 Study of the HemoModulator System for the Treatment of Human Immunodeficiency Virus (HIV)||Energex Systems, Inc.|Yes|Enrolling by invitation|July 2008|November 2009|Anticipated|July 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||March 2009|April 7, 2009|March 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858923||142268|
NCT00859547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499H01|Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants|A Phase 4, Open-Label, Single-Group Safety and Immunogenicity Study of RECOTHROM® (rThrombin) in Pediatric Subjects Undergoing Synchronous Burn Wound Excision and Skin Grafting||ZymoGenetics|Yes|Completed|March 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|17 Years|No|||January 2012|January 25, 2012|March 9, 2009|No|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT00859547||142223|
NCT00859560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OJP-ARI-2007/1|Retrospective Survey of Bone Fracture in Patients With Arimidex 1mg|Retrospective Survey of Bone Fracture in Post-Menopausal Breast Cancer Patients With Arimidex 1 mg as Adjuvant Therapy||AstraZeneca||Completed|January 2008|December 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2205|||Female|N/A|N/A|No|Non-Probability Sample|Post-menoposal breast cancer patients who were previousely registered in clinical        experience investigation with Arimidex 1mg as adjuvant therapy.|March 2009|March 10, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859560||142222|
NCT00859573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 DA018197-104386|Modafinil for Methamphetamine Dependence|Clinical Efficacy of Modafinil in Recently-Abstinent Methamphetamine-Dependent Volunteers||University of Arkansas|Yes|Terminated|April 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||June 2011|June 17, 2011|March 10, 2009|Yes|Yes|Terminated due to lack of funding.|No|April 15, 2011|https://clinicaltrials.gov/show/NCT00859573||142221|Early termination leading to small numbers of subjects analyzed. Small number of completers leading to small numbers of subjects analyzed.
NCT00859859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0137|Vagus Nerve Stimulation in Rheumatoid Arthritis|Vagus Nerve Stimulation in Rheumatoid Arthritis||Northwell Health|No|Terminated|October 2006|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 19, 2011|March 10, 2009|Yes|Yes|The protocol was terminated early (prior to complete enrollment) after interim analysis proved    data to be statistically insignificant|No||https://clinicaltrials.gov/show/NCT00859859||142200|
NCT00859300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.463|MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction|MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction. A Case Control Study|MAP-IDM|Hospices Civils de Lyon|No|Completed|December 2007|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1011|||Both|18 Years|N/A|No|Non-Probability Sample|Cases: 500 patients with ventricular fibrillation at the acute phase of myocardial        infarct, Controls: 500 patients without ventricular fibrillation at the acute phase of        myocardial infarct.|March 2016|March 15, 2016|March 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00859300||142240|
NCT00859313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARX-C-004|An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement|An Open-Label Functionality, Safety, and Efficacy Study of the NanoTab® Delivery System/ARX-F01 15 Mcg in Patients Undergoing Elective Unilateral Knee Replacement||AcelRx Pharmaceuticals, Inc.|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|March 9, 2009|Yes|Yes||No|January 25, 2012|https://clinicaltrials.gov/show/NCT00859313||142239|
NCT00859339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GU07-123|Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC|A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123||Hoosier Cancer Research Network|Yes|Terminated|March 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|March 9, 2009||No|Patient Toxicities|No||https://clinicaltrials.gov/show/NCT00859339||142238|
NCT00855738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081144|A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice|Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice||Pfizer|Yes|Completed|May 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||November 2010|November 23, 2010|March 3, 2009|Yes|Yes||No|June 23, 2010|https://clinicaltrials.gov/show/NCT00855738||142509|This study was cancelled with 111 patients enrolled due to lack of recruitment, and inability to analyze the study by treatment groups. Seizures were analyzed by 3 month data instead of 2 month data as originally planned.
NCT00855764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-388|Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer|Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer||Bristol-Myers Squibb|Yes|Completed|October 2005|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|20 Years|74 Years|No|||October 2009|February 2, 2010|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855764||142508|
NCT00855998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044608-HMO-CTIL|Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer|Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer||Hadassah Medical Organization|No|Recruiting|March 2009|March 2011|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Serum|Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|women visiting the outpatient oncology clinic for genetic/familial high-risk assessments|March 2009|June 2, 2010|February 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00855998||142490|
NCT00856258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0171002|Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845|A Phase 1, Double Blind (Sponsor Open), Randomized, Placebo Controlled, Parallel Group, Oral Multiple Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF 03882845 In Healthy Volunteers||Pfizer|No|Terminated|March 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 22, 2009|March 3, 2009|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00856258||142471|
NCT00858416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC-01|Combined Vibrations, Passive Motion and Thermotherapy for Knee Osteoarthritis|Efficacy of Combined Local Mechanical Vibrations, Continuous Passive Motion and Thermotherapy in the Management of Osteoarthritis of the Knee|KC-01|Kineticure|No|Completed|April 2006|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|71|||Both|45 Years|80 Years|No|||March 2009|March 6, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00858416||142307|
NCT00858702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLM004-071|Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension|Add-on Study of CCBs or Diuretics in Essential Hypertension Not Achieving Target Blood Pressure on Olmesartan Medoxomil Alone||Daiichi Sankyo Inc.|No|Completed|February 2005|November 2005|Actual|July 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|20 Years|74 Years|No|||September 2009|September 18, 2009|March 9, 2009|No|Yes||No|July 16, 2009|https://clinicaltrials.gov/show/NCT00858702||142285|
NCT00858975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709063R|Study of Cryotherapy for Renal Tumors|Study of Cryotherapy for Renal Tumors||National Taiwan University Hospital|No|Withdrawn|October 2007|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||December 2012|August 12, 2013|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858975||142264|
NCT00855335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015442|A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women|A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women||Janssen Scientific Affairs, LLC|No|Recruiting|April 2009|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|90|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|March 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855335||142540|
NCT00856206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-GA-0815|Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy||Regeneron Pharmaceuticals|Yes|Completed|March 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1274|||Both|18 Years|80 Years|No|||December 2011|December 1, 2011|February 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856206||142475|
NCT00856219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220044983|Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects|Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects|Feeding|Rutgers, The State University of New Jersey|No|Completed|February 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856219||142474|
NCT00856453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632845|Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer|Restorative Yoga for Women With Ovarian Cancer Undergoing Chemotherapy||Comprehensive Cancer Center of Wake Forest University|No|Terminated|May 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2|||Female|18 Years|N/A|No|||July 2012|February 27, 2013|March 4, 2009|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT00856453||142456|
NCT00857714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812-11|Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast|Lapatinib in the Treatment of Ductal Carcinoma in Situ of the Breast||Indiana University|Yes|Terminated|April 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1|||Female|18 Years|N/A|No|||June 2015|June 16, 2015|March 6, 2009|Yes|Yes|Terminated due to low accrual|No|June 16, 2015|https://clinicaltrials.gov/show/NCT00857714||142361|
NCT00857090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-001|Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones|Double-Blind, Placebo-Controlled, Concentration-Escalating, Pharmacokinetic Study Evaluating the Systemic Absorption, Safety, and Efficacy of OMS201 in Subjects Undergoing Ureteroscopic Treatment of Ureteral- or Renal Collecting System-Located Stones||Omeros Corporation|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||October 2012|October 10, 2012|March 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857090||142408|
NCT00858585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.066|Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study|Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study||University of Michigan Cancer Center|Yes|Active, not recruiting|March 2009|November 2016|Anticipated|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Retained samples will consist of a portion of the specimens collected for this concordance      study: peripheral blood leukocytes, lymph nodes, and tumor tissue. All retained samples will      be completely de-identified and re-numbered.|Female|18 Years|N/A|No|Probability Sample|breast cancer patients|March 2016|March 10, 2016|March 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00858585||142294|
NCT00858598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US 6|Pro Osteon Bone Void Filler Study|Pro Osteon Bone Void Filler Data Collection|PO|Biomet, Inc.|No|Withdrawn|December 2009|January 2014|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who fit within the inclusion / exclusion criteria of the FDA cleared indications        for use.|February 2012|February 29, 2012|March 9, 2009|No|Yes|Study never started. Study suspended indefinitely.|No||https://clinicaltrials.gov/show/NCT00858598||142293|
NCT00858611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090090|VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...|VRC 307: A D/B Randomized Ph. I Study of Safety/Immunogenicity of a Prime-Boost Schedule of an Investigational DNA Influenza Vaccine, Followed by the Seasonal Influenza Trivalent Inactivated Vaccine (TIV), Compared to TIV Alone in Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|51|||Both|18 Years|70 Years|No|||June 2010|June 22, 2010|March 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00858611||142292|
NCT00857688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNPEMS0209|Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration|Randomized Clinical Study to Evaluate the Effectiveness and Safety of the Drug Topic Bismu-Jet ® (Bismuth Tartrate, Neomycin Sulphate and Procaine Hydrochloride) Compared to Placebo in Improvement of Signs and Symptoms of Ulcerations Caused Disease.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Completed|May 2011|November 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|12 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 22, 2013|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00857688||142363|
NCT00857701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.009|Dynamic Splinting After Total Knee Arthroplasty|Dynamic Splinting After Total Knee Arthroplasty: a Randomized, Controlled Trial||Dynasplint Systems, Inc.|Yes|Terminated|January 2009|||May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|90 Years|No|||August 2013|August 8, 2013|March 6, 2009||No|Unrelated to trial|No||https://clinicaltrials.gov/show/NCT00857701||142362|
NCT00858936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201|Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of IK-1001 to Evaluate Safety, Pharmacokinetics and Proof-of-concept Efficacy for Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft(CABG)Surgery||Ikaria|Yes|Terminated|May 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|85 Years|No|||April 2015|April 3, 2015|March 9, 2009||No|Study Terminated - Company decision|No||https://clinicaltrials.gov/show/NCT00858936||142267|
NCT00859235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY022009|The Influence of Oral Hygiene on Local Wound and Systemic Infection in Patients With Percutaneous Endoscopic Gastrostomy Placement|Predicting Oral Care Before Percutaneous Endoscopic Gastrostomy (PEG). The Influence of Oral Hygiene on Local Wound and Systemic Infection in Patients With PEG Placement|PEG|Hillel Yaffe Medical Center|Yes|Not yet recruiting|May 2009|December 2009|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|50|||Both|45 Years|80 Years|No|||March 2009|March 10, 2009|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859235||142244|
NCT00859261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 15464|Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound|2D Silicon Transducer-Compression Plates for Breast Ultrasound||University of Michigan|Yes|Active, not recruiting|March 2009|March 2016|Anticipated|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|21|||Female|30 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859261||142243|
NCT00859586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090087|Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation|Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)|Yes|Completed|February 2009|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|8 Years|75 Years|No|||August 2014|October 5, 2015|March 10, 2009|Yes|Yes||No|October 5, 2015|https://clinicaltrials.gov/show/NCT00859586||142220|
NCT00859599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-039|Monochromatic Phototherapy on Diabetic Foot Ulcers|Monochromatic Phototherapy on Diabetic Foot Ulcers. A Twenty Weeks Prospective, Randomised, Double Blind, Multi-centre, Placebo Controlled Study||Biolight AB|No|Recruiting|August 2008|April 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|107|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00859599||142219|
NCT00858676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGU-75|Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)|Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation||Aichi Gakuin University|Yes|Recruiting|April 2009|March 2013|Anticipated|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|20 Years|N/A|No|||July 2012|July 17, 2012|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858676||142287|
NCT00858689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010308|Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome|Add-on Pilot Trial of Minocycline in Fragile X Syndrome||FRAXA Research Foundation|No|Completed|October 2007|January 2009|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|13 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|March 9, 2009||No||No|September 1, 2013|https://clinicaltrials.gov/show/NCT00858689||142286|This was an open-label trial. Further study in a randomized controlled trial is warranted.
NCT00859885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117/08|International PFO Consortium|Secondary Stroke Prevention In Patients With Patent Foramen Ovale: International PFO Consortium||University Hospital Inselspital, Berne|No|Recruiting|January 2009|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with ischemic stroke or transient ischemic attacks, in whom a patent foramen        ovale has been diagnosed by means of a transesophageal echocardiography|September 2014|September 8, 2014|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00859885||142198|
NCT00855777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Verona - CE1597|Etoricoxib Versus Ibuprofen in Third Molar Extraction Pain|Evaluation of Analgesic Efficacy of Etoricoxib Compared With Ibuprofen in Third Molar Extraction Pain.||Universita di Verona|No|Not yet recruiting|April 2009|April 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||March 2009|March 3, 2009|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855777||142507|
NCT00856544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921046|A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications|Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS||Pfizer|Yes|Completed|May 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|795|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|March 3, 2009|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00856544||142450|
NCT00856271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-866/01|Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension||Daiichi Sankyo Inc.|No|Completed|August 2004|April 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|287|||Both|18 Years|75 Years|No|||September 2010|September 28, 2010|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00856271||142470|
NCT00856284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322_305|Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes|ENDURE|Takeda|Yes|Completed|March 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2639|||Both|18 Years|80 Years|No|||September 2013|September 25, 2013|March 4, 2009|Yes|Yes||No|September 25, 2013|https://clinicaltrials.gov/show/NCT00856284||142469|The Week 52 results summarized in herein differ from the Week 52 results summarized in an interim analysis, because the per protocol set (PPS) defined for the final analysis included fewer subjects than the PPS defined for the interim analysis.
NCT00849316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-3702|Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease|A Multicenter, Open Label, Nonrandomized, Non Interventional, Observational, Safety and Efficacy Study of NovoRapid™(Insulin Aspart) in Patients With Coexisting Diabetes and Kidney Disease in India. The NovoRapid™ Nephropathy Study||Novo Nordisk A/S|No|Withdrawn|February 2009|November 2009|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Patients from both speciality practice settings who have been deemed appropriate to        receive NovoRapid™ as new treatment and as part of routine out-patient care by the        prescribing physician.|January 2013|January 18, 2013|February 20, 2009|No|Yes|Due to company decision to focus resources on the finalisation of three ongoing studies in the    region|No||https://clinicaltrials.gov/show/NCT00849316||142996|
NCT00849329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109275|A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer|An Open-Label, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer||GlaxoSmithKline||Completed|March 2009|February 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||March 2011|May 17, 2012|February 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00849329||142995|
NCT00855933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008110|A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing|A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing||Procter and Gamble|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 7, 2013|March 3, 2009|Yes|Yes||No|December 3, 2012|https://clinicaltrials.gov/show/NCT00855933||142495|
NCT00857103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCN 177500/V50|Effect of Interactive Tailored Assessment on Patient-provider Communication|Improving Patient-Provider Communication in Cancer Care||Oslo University Hospital|No|Completed|August 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857103||142407|
NCT00857402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArgII|Arginine as an Adjuvant Treatment Against Tuberculosis|Arginine Rich Food Supplementation as an Adjuvant Treatment Against Tuberculosis||Linkoeping University|No|Completed|February 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|180|||Both|15 Years|60 Years|No|||March 2009|March 5, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857402||142385|
NCT00857415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A07|Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain|A Phase III Study of the Correlation Between Florbetapir F 18 (18F-AV-45) PET Imaging and Amyloid Pathology||Avid Radiopharmaceuticals|No|Completed|December 2008|May 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|226|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 17, 2012|March 5, 2009|Yes|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT00857415||142384|
NCT00857727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dex Peds 08-088|Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children|Use of Dexmedetomidine for Emergence Delirium in Children Undergoing General Anesthesia for Endovascular Interventional Neuroradiologic Procedures|DexPeds|St. Luke's-Roosevelt Hospital Center|Yes|Completed|August 2009|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|6 Months|17 Years|No|||January 2015|March 3, 2015|March 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857727||142360|
NCT00857740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUN B14320084324|Influence of Painphysiolgy Education on the Pain Inhibition in Fibromyalgia|Influence of Painphysiolgy Education on the Pain Inhibition in Fibromyalgia||Vrije Universiteit Brussel||Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||March 2009|July 7, 2010|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00857740||142359|
NCT00857753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10613401|Relative Bioavailability of a Fentanyl Patch|A Study to Evaluate the Relative Bioavailability of a Fentanyl PAtch Transdermal Delivery System (25 ug/hr) (Sandoz) Compared to Duragesic (Fentanyl Transdermal SYstem 25 ug/hr Patches (Alza)||Sandoz||Completed|September 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 6, 2009|March 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00857753||142358|
NCT00858026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL009|Impact of a Fermented Infant Formula in Weaning Babies|Impact of a Fermented Infant Formula in Weaning Babies||Bledina|No|Completed|April 2006|June 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|91|||Both|54 Days|68 Days|No|||March 2009|March 6, 2009|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858026||142337|
NCT00858325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1790C00002|Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China|A Two Cohort, Open Label, Single and Multiple Dose Pharmacokinetic Study of 4mg/Kg and 6mg/Kg Doses of Daptomycin in Healthy Chinese Subjects Living in China||AstraZeneca|No|Completed|February 2009|March 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|March 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858325||142314|
NCT00858338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-51 (H 10610)|Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer|Phase-II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma (R0 Resection and at Least D1 Lymph-node Dissection)||New York University School of Medicine|Yes|Completed|December 2002|February 2012|Actual|March 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858338||142313|
NCT00858897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF 1-2006-627-A|Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A|Regulation of Glutathione Homeostasis in Adolescents With Type 1 Diabetes - Study A||Nemours Children's Clinic|No|Completed|June 2007|February 2009|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|14 Years|18 Years|No|||July 2009|July 14, 2009|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858897||142270|
NCT00856297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P13E1|Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine|An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercially Available MenACWY Conjugate Vaccine||Novartis||Completed|February 2009|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|389|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|March 2, 2009|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00856297||142468|
NCT00859274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5801112|Saline Challenge in Monitoring Asthma Control|Saline Challenge in Monitoring Asthma Control||Kuopio University Hospital|No|Completed|March 2009|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|90 Years|No|||October 2013|October 9, 2013|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859274||142242|
NCT00859287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GJP-DUM-2007/1|Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis|Omepral® Tablets Mega-study to Investigate the Efficacy on Various Type of Acid Reflux Related Symptoms and QOL, and Epidemiology in Patients With Erosive Esophagitis in Daily Medical Practice|OMAREE|AstraZeneca|No|Completed|June 2007|July 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10703|||Both|N/A|N/A|No|Non-Probability Sample|Patients endoscopically diagnosed as erosive esophagitis accompanied with either two days        or more heartburn or acid taste in the mouth of any severity|July 2009|July 14, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859287||142241|
NCT00857805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58348|Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma|Randomized Controlled Trial of Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma||Loma Linda University|No|Recruiting|January 2009|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857805||142354|
NCT00859638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-177|I Am Able: Population Based Rehabilitation in a Family Health Team|I Am Able: Population Based Rehabilitation in a Family Health Team||McMaster University|No|Completed|May 2008|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|124|||Both|44 Years|N/A|No|||September 2009|June 17, 2010|March 10, 2009||No||No|September 29, 2009|https://clinicaltrials.gov/show/NCT00859638||142216|The limited duration of the study period may not allow sufficient time to show the difference in outcome measures such as self-rated health and health care utilization.
NCT00855803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 072010-134|Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis|Phase II Study of Stereotactic Body Radiation Therapy and Vertebroplasty for Localized Spinal Metastasis (SBRT Spine)||University of Texas Southwestern Medical Center|Yes|Recruiting|February 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855803||142505|
NCT00855478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-FR-002|French Post-Marketing Surveillance Survey|French Post-Marketing Surveillance Survey|FR E-REGISTRY|Cordis Corporation|Yes|Terminated|May 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4080|||Both|18 Years|N/A|No|||November 2010|November 25, 2010|March 3, 2009|Yes|Yes|Early termination of patient enrollment based on business decision|No||https://clinicaltrials.gov/show/NCT00855478||142529|
NCT00855491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-009|Posterior Capsule Opacification (PCO) With AcrySof Single-Piece IOL|Prospective Evaluation of Posterior Capsule Opacification in Myopic Eyes 4 Years After AcrySof Single-Piece IOL Implantation||Iladevi Cataract and IOL Research Center|Yes|Completed|July 2003|November 2008|Actual|September 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 3, 2009|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855491||142528|
NCT00857181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLC-2009-01|Cytokines and the Risk of Infection in Liver Cirrhosis|A Single-center, Open Study to Investigate Cytokine Levels in Patients With Hepatic Cirrhosis Before the Development of Significant Infection|CLC-2009|Medical University of Graz|No|Terminated|March 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples Without DNA|Serum and plasma samples.|Both|18 Years|N/A|No|Non-Probability Sample|150 patients with biopsy proven or clinically evident liver cirrhosis|March 2012|March 2, 2012|March 5, 2009||No|Finding to be unable to reach the primary endpoint|No||https://clinicaltrials.gov/show/NCT00857181||142401|
NCT00857545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0255|OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission|A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission||Gynecologic Oncology Group|Yes|Active, not recruiting|July 2010|||February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|163|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857545||142374|
NCT00834821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077671|Effectiveness of a Behavioral Treatment Program for Attention Deficit Hyperactivity Disorder, Inattentive Type|Integrated Multi-setting Psychosocial Treatment for ADHD-Inattentive Type||University of California, San Francisco|No|Active, not recruiting|November 2008|June 2014|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|7 Years|11 Years|No|||January 2014|January 17, 2014|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00834821||144095|
NCT00834834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5752/6777R|Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder|Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change||New York State Psychiatric Institute|Yes|Recruiting|March 2009|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||September 2013|September 25, 2013|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00834834||144094|
NCT00834847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B006512|Pravastatin Sodium 40 mg Tablets Food Challenge Study|A Relative Bioavailability Food Challenge Study of Pravastatin Sodium 40 mg Tablets||Teva Pharmaceuticals USA|No|Completed|August 2000|September 2000|Actual|September 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2009|January 30, 2009|January 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00834847||144093|
NCT00855946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX - 2008/25|Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy|Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy|PROTEORECTUM|University Hospital, Bordeaux|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|Samples With DNA|whole blood|Both|18 Years|80 Years|No|Non-Probability Sample|patient with rectal carcinoma|May 2013|May 7, 2013|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00855946||142494|
NCT00857116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALBP|Deworming Against Tuberculosis|The Impact of Deworming on Host Immunity and Clinical Outcome in Patients With Pulmonary Tuberculosis||Linkoeping University|Yes|Completed|March 2009|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|140|||Both|18 Years|65 Years|No|||August 2013|August 28, 2013|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857116||142406|
NCT00857428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10713409|Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions|A Study to Evaluate the Relative Bioavailability of Oxymorphone 40 mg Extended-Release Tablets (Sandoz, Inc.) Compared to Opana ER (Oxymorphone Hydrochloride) Extended-Release Tablets, 40 mg (Endo Pharmaceuticals, Inc.) in Healthy Volunteers Under Fasted Conditions||Sandoz|No|Completed|November 2007|December 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00857428||142383|
NCT00857441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRF8025|Drug-eluting Balloon in Bifurcations Trial|A Prospective Three-arm Multi-center Study to Investigate Procedural, Clinical and Angiographic Outcomes Using a Drug Eluting Balloon Versus a Standard Balloon in Combination With a Bare Metal Stent and a DES Stent, Following the Provisional Side Branch T-stenting Approach, in Patients With Complex Lesions|DEBIUT|UMC Utrecht|Yes|Completed|January 2008|January 2015|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857441||142382|
NCT00857454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14273|A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations|A Phase III Open-label Extension of the MTE08 Trial (A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion® (Cutaneous Solution) in Hypogonadal Men) to Evaluate Skin-safety||Eli Lilly and Company|No|Completed|October 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Male|18 Years|N/A|No|||December 2010|December 15, 2010|March 4, 2009|Yes|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00857454||142381|
NCT00857467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-01/2008 (SUM)|Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.|Randomised, Double-blind, Single Dose, Three-way, Cross-over Study to Investigate the Safety and Response to 1g or 2g Rectal Suppositories Containing 5 mg or 10 mg 1R,2S-methoxamine Hydrochloride [NRL001] or Matching Placebo||Norgine|No|Completed|February 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2009|December 21, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857467||142380|
NCT00857766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112355|A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|249|||Both|50 Years|N/A|No|||December 2011|October 18, 2012|March 5, 2009|No|Yes||No|December 16, 2010|https://clinicaltrials.gov/show/NCT00857766||142357|
NCT00858039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X08-0296|Cardiotoxicity of Adjuvant Trastuzumab|Prediction of Cardiotoxicity Using Serum N-terminal Pro-B-type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab|CATS|Royal Prince Alfred Hospital, Sydney, Australia|No|Completed|February 2009|June 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|Samples With DNA|Human serum Human whole blood|Female|18 Years|N/A|No|Non-Probability Sample|Patients presenting to tertiary referral medical oncology clinics|November 2014|November 4, 2014|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858039||142336|
NCT00858351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200.97PY|Thermal Biofeedback for the Treatment of Diabetic Neuropathy|A Placebo-Controlled Trial of Thermal Biofeedback Assisted Relaxation for the Treatment of Diabetic Neuropathy: An Evaluation of Outcomes and Mechanisms||Rosalind Franklin University of Medicine and Science|No|Completed|November 2007|April 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858351||142312|
NCT00858364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070782|Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy||Amgen|Yes|Recruiting|June 2009|June 2019|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|3000|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858364||142311|
NCT00858624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H1004/142|Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity|Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity||University of Manchester|No|Completed|February 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858624||142291|
NCT00856856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-370 Cohort B|ABSORB Clinical Investigation, Cohort B|A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With de Novo Native Coronary Artery Lesions.|ABSORB B|Abbott Vascular|Yes|Active, not recruiting|March 2009|April 2016|Anticipated|October 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00856856||142426|
NCT00856869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-02/2003(ACPS)|Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers|A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.||Norgine|No|Completed|August 2004|April 2005|Actual|February 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|7||Actual|52|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856869||142425|
NCT00856882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK4450/06M|The Effects of Soy Protein and Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors|The Effects of Soy Protein and/or Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors-a Six Months RCT Among Postmenopausal Women||Chinese University of Hong Kong|Yes|Completed|October 2007|||April 2008|Actual|N/A|Interventional|N/A|3||||||Female|46 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00856882||142424|
NCT00858403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15656|Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation|Phase II Study of Dasatinib in Advanced Non-small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|March 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|March 5, 2009|Yes|Yes|Slow Accrual|No|July 12, 2011|https://clinicaltrials.gov/show/NCT00858403||142308|The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.
NCT00853528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635267|Stereotactic Radiosurgery in Treating Patients With Spinal Metastases|Cyberknife Radiosurgery for Improving Palliation of Metastatic Tumors of the Spine||Boston Medical Center|Yes|Active, not recruiting|January 2009|June 2016|Anticipated|June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|February 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853528||142679|
NCT00853814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD055270|Increasing Youth Physical Activity: Neighborhood Environment Influences|Increasing Youth Physical Activity: Neighborhood Environment Influences||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|September 2007|September 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00853814||142657|
NCT00853827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2366|Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients|A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy|AQUARIUS|Novartis|No|Completed|March 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|613|||Both|35 Years|N/A|No|||May 2014|May 20, 2014|February 26, 2009|No|Yes||No|January 23, 2014|https://clinicaltrials.gov/show/NCT00853827||142656|
NCT00856310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-0817|A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Tolerability of REGN475 in Healthy Subjects||Regeneron Pharmaceuticals|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|56|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|February 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00856310||142467|
NCT00857818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-564|Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome|A 16-Week, Randomized, Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Non-HDL Cholesterol Among Patients With Schizophrenia and Bipolar I Disorder Who Have Pre-existing Metabolic Syndrome||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Terminated|April 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||July 2011|November 7, 2013|March 6, 2009|Yes|Yes|Slow Accrual|No|May 17, 2011|https://clinicaltrials.gov/show/NCT00857818||142353|The study terminated early due to low enrollment. Mean changes from baseline in: the Clinical Global Impression-Severity Scale and the Impact of Weight on Quality of Life scores were not analyzed due to insufficient data for meaningful conclusions.
NCT00857831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-8|Vitamin D and Calcium Study|Vitamin D and Calcium Replacement/Supplementation in Subjects With Chronic Spinal Cord Injury||VA Office of Research and Development|No|Completed|January 2008|August 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857831||142352|
NCT00858130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2143Veinoplus|Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome|Optimal Intensity and Frequency of a Portable Electrical Muscle Stimulator (VeinoPlus) to Improve Symptoms of Postthrombotic Syndrome|VeinoPlus|University of North Carolina, Chapel Hill|Yes|Completed|March 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|March 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858130||142329|
NCT00834509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807416|Biomarkers for Obstructive Sleep Apnea|Towards a Blood Test for Diagnosis of Obstructive Sleep Apnea|BOSA|University of Pennsylvania|Yes|Active, not recruiting|April 2008|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|30 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|OSA patients with moderate to severe disease as confirmed by apnea-hypopnea index (AHI >        15) in a polysomnography. Healthy controls, both snorers and nonsnorers, with an        apnea-hypopnea index (AHI < 5) in a polysomnography.|May 2015|May 27, 2015|February 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00834509||144119|
NCT00834522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1021|Granisetron 1 mg Tablets, Non-fasting|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Granisetron 1 mg Tablets Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 1, 2009|January 30, 2009|No|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00834522||144118|
NCT00856765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 08-255|Drug-eluting Balloon in Acute Myocardial Infarction|Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction|DEB-AMI|UMC Utrecht|Yes|Active, not recruiting|March 2009|November 2015|Anticipated|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|80 Years|No|||July 2015|July 14, 2015|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00856765||142433|
NCT00856791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-12|Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients|Phase II Single-arm Study of ON 01910.Na by 2-hr Infusion in Patients With Recurring Platinum-resistant Ovarian Cancer||Onconova Therapeutics, Inc.|No|Completed|March 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|N/A|No|||January 2013|January 7, 2013|March 4, 2009|Yes|Yes||No|November 27, 2012|https://clinicaltrials.gov/show/NCT00856791||142431|
NCT00857129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100|Can Differentiated Birth Care Improve the Service?|Differentiated Birth Service- an Improvement?||Ostfold Hospital Trust|No|Completed|September 2006|December 2013|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1111|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 17, 2014|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857129||142405|
NCT00857142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10713410|Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions|A Study to Evaluate the Relative Bioavaility of Oxymorphone Hydrochloride 40 mg Extended-Release Tablets(Sandoz, Inc. Compared to Opana ER (Oxymorphone Hydrochloride) Extended-Release Tablets, 40 mg (Edo Pharmaceuticals Inc.) in Healthy Volunteers Under Non-Fasted COnditions||Sandoz||Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00857142||142404|
NCT00857480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-05/2005 (IN-B)|Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin|A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part B: Interaction With Ursodeoxycholic Acid and Cloxacillin||Norgine|No|Completed|June 2006|October 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|12|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||March 2009|March 6, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857480||142379|
NCT00857493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-024|A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects|A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects||Bavarian Nordic|Yes|Completed|June 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|56 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 28, 2015|March 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00857493||142378|
NCT00855816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-019-08F|Post Traumatic Stress Disorder (PTSD) Hyperarousal Symptoms Treated With Physiological Stress Management|PTSD Hyperarousal Symptoms Treated With Physiological Stress Management|BaRT|VA Office of Research and Development|Yes|Completed|February 2010|July 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|March 3, 2009||No||No|October 7, 2014|https://clinicaltrials.gov/show/NCT00855816||142504|Higher than anticipated withdrawal rate limited power of statistical analyses.
NCT00857194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-5|Cardiovascular Disease Study|Risk Factors for Coronary Heart Disease in Spinal Cord Injury: Conventional and Emerging||VA Office of Research and Development|No|Recruiting|March 2007|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|serum and plasma|Both|45 Years|75 Years|No|Non-Probability Sample|Subjects will be recruited from hospital clinics, through advertisements, and referral        from primary care physicians.|January 2016|January 6, 2016|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857194||142400|
NCT00857207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0902-W|Metacognitive Training to Enhance Strategy Use in Blast-Related TBI|Metacognitive Training to Enhance Strategy Use in Blast Related TBI||VA Office of Research and Development|No|Recruiting|October 2013|September 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|55 Years|No|||January 2016|January 14, 2016|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857207||142399|
NCT00858052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G 080055|Core Study of the Safety and Effectiveness of IDEAL IMPLANT(R) Saline-filled Breast Implants|Core Study of the Safety and Effectiveness of IDEAL IMPLANT(R) Saline-filled Breast Implants in Women Who Are Undergoing Primary Breast Augmentation or Replacement of Existing Augmentation Implants||Ideal Implant Incorporated|No|Active, not recruiting|February 2009|February 2020|Anticipated|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 4, 2014|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858052||142335|
NCT00858065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-BMiller-AA015323|Adolescent Family-Based Alcohol Prevention|Adolescent Family-Based Alcohol Prevention||Pacific Institute for Research and Evaluation|Yes|Completed|April 2005|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|1228|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00858065||142334|
NCT00858377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080016|A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors|A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors||Amgen|Yes|Active, not recruiting|April 2009|May 2017|Anticipated|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858377||142310|
NCT00858390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R38OT10585|Nutritional Status and Enteral Absorption Capability After Brain Death|Clinical Interventions to Increase Organ Procurement Nutritional Status and Enteral Absorption Capability After Brain Death (R38OT10585)|HRSA Nutrition|The University of Texas Health Science Center, Houston|Yes|Completed|February 2009|December 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|14 Years|65 Years|No|||June 2014|June 13, 2014|March 6, 2009||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT00858390||142309|
NCT00858637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI-196-E11|Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis|A Phase III, Multicentre, Double-blind, Double-dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 Versus Simvastatin for the Treatment of Dyslipidaemia in Subjects With Chronic Kidney Disease on Dialysis (Incorporating a Placebo-controlled Withdrawal Phase)||Mitsubishi Tanabe Pharma Corporation|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|260|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|March 9, 2009||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT00858637||142290|
NCT00856518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6576-R|Expiratory Muscle Training for Persons With Neurodegenerative Disease|Expiratory Muscle Training for Persons With Neurodegenerative Disease|EMST|VA Office of Research and Development|No|Completed|March 2009|August 2014|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00856518||142452|
NCT00856531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mobius syndrome|Impairments of Oral Language in Mobius Syndrome|Impairments of Oral Language in Subjects With the Möbius Sequence|Mobius|Fortaleza University|No|Completed|January 2002|January 2003|Actual|January 2003|Actual|N/A|Observational|Time Perspective: Cross-Sectional||15|||||Both|3 Years|16 Years|No|Non-Probability Sample|fifteen subjects with Möbius syndrome with age ranging from two to thirteen years old,        from both sexes, seen in one of the three main center for genetic diagnosis in the state        of Ceará, Brazil.|March 2009|March 4, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856531||142451|
NCT00857519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-885|A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma|Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma|IAC-RB|Wills Eye|No|Recruiting|January 2009|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||June 2013|June 12, 2013|March 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857519||142376|
NCT00857532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A12|Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients|A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment||Avid Radiopharmaceuticals|No|Completed|January 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|31|||Both|60 Years|N/A|No|||February 2013|February 1, 2013|March 5, 2009|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00857532||142375|
NCT00858962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811004456|Buprenorphine/Raltegravir Pharmacokinetic Interaction Study|A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Raltegravir (Isentress) and Buprenorphine||Yale University|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|March 6, 2009|No|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT00858962||142265|The sample size was small, though within the range of similar drug-drug interaction studies. This study utilized a within-subject design with patients acting as their own controls (thereby resulting in less intra-patient variability).
NCT00853554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3249-02-769|Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Hydromorphone Hydrochloride (8 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (DILAUDID®, 8 mg Tablet, Knoll Pharmaceutical Company) in Normal Human Subjects Under Fasting Conditions||Mallinckrodt|No|Completed|December 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2009|February 26, 2009|February 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00853554||142677|
NCT00853840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001074|Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc|A Randomized, Single-Blinded, Placebo-Controlled Two-Way Crossover Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc||ViiV Healthcare|No|Completed|April 2008|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|February 27, 2009|No|Yes||No|May 5, 2009|https://clinicaltrials.gov/show/NCT00853840||142655|
NCT00853853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2048-08|EnSeal Device Versus Ferguson Technique in Hemorrhoidectomy|Randomized Trial Comparing Standard Ferguson Technique With the EnSeal Device During Hemorrhoidectomy||The Miriam Hospital|Yes|Active, not recruiting|March 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|February 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00853853||142654|
NCT00856895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU14943 (2689-001)|Quality of Life in Pre and Post Renal Transplant in Hispanic and Non-Hispanic Recipients|Evaluation of Quality of Life Pre and Post Renal Transplant in Hispanic and Non-Hispanic Recipients|QOL|Northwestern University|No|Enrolling by invitation|October 2007|December 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 1779 kidney transplants have been performed in the last 10 years in NMH, and        220 of those kidney transplants were done in Hispanics recipients. Informed consent will        be required to participate in the study.|October 2015|October 6, 2015|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00856895||142423|
NCT00854711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-AH-7009-CTIL|Randomized Placebo-Controlled Trial of Inhaled iNO in Acute ST-Segment Elevation MI Treated by Primary Angioplasty|Randomized Placebo-Controlled Trial of Inhaled iNO in Acute ST-Segment Elevation MI Treated by Primary Angioplasty|ENAMOR|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|August 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2009|May 7, 2009|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00854711||142588|
NCT00854724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-000726|Puerarin Effects on Alcohol Drinking|Puerarin (NPI-031G) Effects on Alcohol Drinking - A Natural Settings Study|PAD|Mclean Hospital|No|Completed|February 2009|July 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 1, 2011|February 27, 2009|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT00854724||142587|
NCT00859651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD3638|Vitamin D in Postmenopausal Women at High Risk for Breast Cancer|Effects of High-Dose Vitamin D on Circulating Vitamin D Levels and Breast Density in Postmenopausal Women at High Risk for Breast Cancer Development||Columbia University|Yes|Completed|June 2009|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Female|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859651||142215|
NCT00834535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-1123|Cefdinir Capsules 300 mg, Non-fasting|A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Non-fasting Conditions||Teva Pharmaceuticals USA|No|Completed|July 2005|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|January 30, 2009|No|Yes||No|June 18, 2009|https://clinicaltrials.gov/show/NCT00834535||144117|
NCT00834899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HL091265-01A1|A Safety Study of Eptifibatide in Patients With Sickle Cell Disease|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease||University of North Carolina, Chapel Hill|Yes|Terminated|January 2009|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|55 Years|No|||February 2013|May 22, 2013|January 31, 2009|Yes|Yes|Slow accrual and no cost extension not approved by NHLBI|No|February 24, 2013|https://clinicaltrials.gov/show/NCT00834899||144089|The study was terminated early resulting in small numbers of subjects analyzed.
NCT00834912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT1-016|Study of Two Tramadol Contramid® OAD 300 mg Controlled-Release Tablets From Two Different Manufacturing Sites Following a 300 mg Dose in Healthy Subjects Under Fasting and Fed Conditions|||Labopharm Inc.||Completed|February 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|January 30, 2009||Yes||No|April 9, 2009|https://clinicaltrials.gov/show/NCT00834912||144088|
NCT00856804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRITAL|Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance|Usefulness of Adding Thalidomide to Peginterferon and Ribavirin in Patients With Hepatitis C and Resistance to Interferon. Phase II|TRITAL|Valme University Hospital|No|Recruiting|March 2009|June 2012|Anticipated|June 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|45 Years|80 Years|No|||March 2009|March 5, 2009|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00856804||142430|
NCT00856817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOADO|Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation|||Radboud University||Terminated|March 2009|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|August 10, 2011|March 5, 2009||No|Recruitment faillure. Similar study published by others. Not yet entered treatment phase.|No||https://clinicaltrials.gov/show/NCT00856817||142429|
NCT00859352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9831C00008|AZD1981 Midazolam CYP4503A Induction Study|A Phase I, Open, Randomised, Non-Comparative, Parallel Group Study of a Potential Cytochrome P450 3A Induction After Repeat Twice Daily Oral Dosing With 100 and 500 mg AZD1981 Tablets for 14 Days to Healthy Male Volunteers With Single Oral Doses of Midazolam 7.5 mg.||AstraZeneca|No|Completed|March 2009|April 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|April 9, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859352||142237|
NCT00858143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6291014|Non Interventional Study For Patients Treated With Somavert®|German Non Interventional Study For Patients Treated With Somavert®|GPOS|Pfizer|Yes|Completed|January 2004|January 2008|Actual|January 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|311|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with diagnosed acromegaly who were already being treated with Somavert® or were        to start treatment with Somavert® were included in the study.|March 2009|August 24, 2009|March 6, 2009|No|Yes||No|June 25, 2009|https://clinicaltrials.gov/show/NCT00858143||142328|
NCT00858156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161HI101|BG9928 in Subjects With Hepatic Impairment|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Oral BG9928 in Subjects With Mild and Moderate Hepatic Impairment and in Healthy Subjects||Biogen|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2010|January 26, 2010|March 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858156||142327|
NCT00857558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-08-001|A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes|A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes||Kyowa Hakko Kirin Company, Limited|No|Completed|January 2009|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|280|||Both|20 Years|75 Years|No|||January 2014|January 6, 2014|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00857558||142373|
NCT00857571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0461003|A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.|An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.||Pfizer|No|Terminated|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857571||142372|
NCT00857844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU8309 0773-018|Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers|Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers||Northwestern University|No|Completed|July 2007|May 2012|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|207|Samples With DNA|-  Urine will be collected from all patients in the 3 groups and analyzed for biomarkers           of interstitial fibrosis and proximal tubule injury. Specific biomarkers that will be           tested are: urinary TGF-beta1, kidney injury molecule-1 and angiotensinogen. Urinary           biomarkers will be normalized to creatinine and analyzed using an ELISA assay.        -  An additional 18mls of blood will be collected. This blood will be used to study organ           transplant tolerance in subjects who are currently using immunosuppressant medications.|Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted in liver transplant recipients. We are planning to collect        data and genotyping in 650 liver transplant recipients. Patients who satisfy the following        inclusion/exclusion criteria will be eligible for the study:|May 2013|May 1, 2013|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00857844||142351|
NCT00857857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110762|A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics|A Randomised, Placebo-controlled, Incomplete Block, Three-way Cross-over Study to Evaluate the Effect of Treatment With Repeat Inhaled Doses of GW870086X on the Allergen-induced Early and Late Asthmatic Response in Subjects With Mild Asthma||GlaxoSmithKline|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|65 Years|No|||March 2012|March 22, 2012|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857857||142350|
NCT00859612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1Ro1DK080770-01A1|Renal Osteodystrophy: A Fresh Approach|Renal Osteodystrophy: A Fresh Approach||University of Kentucky|No|Completed|March 2009|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|464|Samples Without DNA|blood samples and bone biopsy samples|Both|18 Years|N/A|No|Non-Probability Sample|patients from dialysis clinics|June 2015|June 3, 2015|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859612||142218|
NCT00859625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0809004192|The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy|The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy||Yale University|No|Completed|November 2008|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|500|||Both|30 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 20, 2015|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859625||142217|
NCT00859872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-0801|Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia|Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia||Central South University|Yes|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|45 Years|No|||July 2009|July 31, 2009|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859872||142199|
NCT00857168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTE10|To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion|A Phase I Trial to Determine the Impact of Application of Antiperspirant and Deodorant as Well as Washing the Application Site, on the Pharmacokinetics of Testosterone Following Single Dose Applications of 2% Testosterone MD-Lotion® (Cutaneous Solution)|MTE10|Acrux DDS Pty Ltd|No|Completed|January 2009|April 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|6||Anticipated|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 12, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857168||142402|
NCT00852397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0661004|A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients|A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg BID Apixaban In Combination With Standard Therapy In Patients With Recent (≤7 Days) Acute Coronary Syndrome (ACS)||Pfizer|Yes|Terminated|April 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|151|||Both|20 Years|N/A|No|||August 2013|August 27, 2013|February 26, 2009||No|See termination reason in detailed description.|No|June 4, 2013|https://clinicaltrials.gov/show/NCT00852397||142765|
NCT00858117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 04H6|A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL|A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL||Northwestern University|Yes|Active, not recruiting|March 2005|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|March 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858117||142330|
NCT00852670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058A200|ACT-128800 in Psoriasis|Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis||Actelion|Yes|Completed|October 2008|September 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|60 Years|No|||November 2009|November 11, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852670||142744|
NCT00852956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBE 209|Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects|Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects||OBEcure Ltd.|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 3, 2009|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00852956||142722|
NCT00852969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21DK077368|Niacin and Endothelial Function in Early CKD|Does Raising HDL-C With Niacin Improve Endothelial Function in Early CKD?||Tufts Medical Center|Yes|Completed|August 2008|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|21 Years|80 Years|No|||April 2014|April 3, 2014|February 26, 2009|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00852969||142721|
NCT00857233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10252|Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease|An Open-label Extension Study Examining the Safety and Tolerability of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type Having Completed Study 10158||H. Lundbeck A/S|No|Terminated|June 2004|October 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|297|||Both|50 Years|N/A|No|||July 2012|July 26, 2012|March 5, 2009||No|Please see explanation in the Detailed Description field.|No|July 26, 2012|https://clinicaltrials.gov/show/NCT00857233||142397|Long recruitment, premature termination.
NCT00857597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D00668-01C|Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment|A Randomized Controlled Trial of Transoral Incisionless Fundoplication (TIF) Versus Proton Pump Inhibitors (PPIs) for Treatment of GERD: The TIF vs. PPIs Study|TvP|University of Pittsburgh|Yes|Recruiting|March 2009|March 2011|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||April 2009|April 17, 2009|March 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857597||142370|
NCT00854451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC86-2314-B002-169|Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection|Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study||National Taiwan University Hospital|No|Completed|August 1996|February 1998|Actual|December 1997|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|128|||Both|20 Years|75 Years|No|||July 1996|March 1, 2009|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00854451||142608|
NCT00854464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200809019R|Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma|Arsenic Methylation, Cigarette Smoking Exposure, Individual DNA Susceptibility Factors and Urothelial Carcinoma||National Taiwan University Hospital|No|Recruiting|August 2008|||July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|420|||Both|N/A|N/A|No|Non-Probability Sample|project recruited 420 UC patients in Taiwan University Hospital|March 2009|March 2, 2009|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00854464||142607|
NCT00854958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0404/38|The Diagnosis of Oral Allergy Syndrome Through the Use of a Structured Questionnaire|The Diagnosis of Oral Allergy Syndrome Through the Use of a Structured Questionnaire||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|May 2005|September 2007|Actual|September 2006|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|123|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult subjects aged over 18 years recruited from the general population|February 2009|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854958||142569|
NCT00854971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BX-TK-002|Efficacy Study of TKcell in Advanced Colorectal Cancer|Evaluating the Safety and Efficacy of Combination Therapy With FOLFOX-4 and TKcell Therapy Versus FOLFOX-4 Alone in Patients With Recurrent, Unresectable and Advanced Colorectal Cancer||Binex|No|Active, not recruiting|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|19 Years|80 Years|No|||March 2009|May 15, 2009|February 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00854971||142568|
NCT00834925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diltiazem Af|Low Dose of Diltiazem for Rate Control of Atrial Fibrillation|||Seoul National University Hospital||Recruiting|August 2009|August 2011|Anticipated|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|February 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00834925||144087|
NCT00857155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 1464|Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to Coronary Artery Bypass Graft (CABG)||TARGET-CABG|LifeBridge Health|No|Recruiting|January 2009|February 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|85 Years|No|||March 2009|March 5, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00857155||142403|
NCT00858988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJM-rifaximin|Trial of Rifaximin in the Treatment of Tropical Enteropathy|A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Non-Absorbable Antibiotic, in the Treatment of Tropical Enteropathy||Washington University School of Medicine|No|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||||||Both|3 Years|5 Years|Accepts Healthy Volunteers|||March 2009|March 9, 2009|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858988||142263|
NCT00855504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34-499/2008(SR)|Association of Periodontitis and Preeclampsia During Pregnancy|Role of Cytokines in Association Between Periodontitis and Preeclampsia During Pregnancy||Maulana Azad Medical College|No|Completed|February 2009|January 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|528|||Female|18 Years|35 Years|No|Probability Sample|primigravidae women with 14-20 weeks of gestation.|April 2015|April 10, 2015|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855504||142527|
NCT00856908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00020|Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes|A Randomised, Single-Blind, Placebo-Controlled, Phase IIa Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 During Four Weeks in T2DM Subjects Treated With Insulin||AstraZeneca|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|75 Years|No|||November 2012|November 27, 2012|March 5, 2009|Yes|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT00856908||142422|The primary objective of the study was to assess safety and tolerability and hence the study was not sized based on statistical considerations. The most import outcome, "no safety or tolerability concerns were identified", is not a numerical variable
NCT00856921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAASachalasia|Genetic Evaluation of AAAS Gene in Early-Onset Achalasia and Alacrima Patients|To Find Out the Genetic Relationship Between the Early-Onset Achalasia and AAAS Gene|AAAS|Asan Medical Center|Yes|Completed|April 2008|March 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective|||Actual|19|Samples With DNA|DNA and genetic analysis|Both|N/A|N/A|No|Non-Probability Sample|Early age onset achalasia|March 2009|March 5, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00856921||142421|
NCT00857779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-H-01|Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients|A Multicentre Randomised Phase II Clinical Trial to Demonstrate Equivalent Pharmacodynamic Efficacy and Tolerability of Two Updosing Schedules for ALK-Flex SQ||ALK-Abelló A/S|Yes|Completed|February 2009|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|473|||Both|18 Years|65 Years|No|||February 2013|February 7, 2013|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857779||142356|
NCT00857792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15237B|Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging|Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging||University of Chicago|No|Completed|March 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|March 5, 2009|Yes|Yes||No|November 18, 2014|https://clinicaltrials.gov/show/NCT00857792||142355|
NCT00858078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909074|A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women|A Qualitative Exploration of the Impact of Positive BRCA 1/2 Mutation Status on the Lives of Young Women||National Institutes of Health Clinical Center (CC)||Completed|January 2009|||||N/A|Observational|N/A|||Anticipated|126|||Female|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|March 8, 2016|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858078||142333|
NCT00858091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||April 6, 2015|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858091||142332|
NCT00858104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IALT-07|Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results|Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results||Elesta S.R.L.|Yes|Completed|November 2008|May 2013|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858104||142331|
NCT00855452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-08-HMO-CTIL|Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors|rIL-2 Activated Allogeneic Lymphocytes for the Induction of Graft Versus Tumor Effect (GVT) in Metastatic Solid Tumors|rIL-2(LAK)|Hadassah Medical Organization|Yes|Completed|January 2009|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|70 Years|No|||October 2008|June 10, 2015|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00855452||142531|
NCT00855465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11348|A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.|Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|CHEST-1|Bayer|Yes|Completed|February 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|80 Years|No|||October 2014|October 24, 2014|December 15, 2008|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00855465||142530|
NCT00855790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colon polypectomy|Comparison of Two Types of Biopsy Forceps for Obtaining Cold Biopsy Polypectomy for Small Sessile Colorectal Polyps Less Than 6 mm in Diameter|Comparison of Two Types of Biopsy Forceps for Obtaining Cold Biopsy Polypectomy for Small Sessile Colorectal Polyps Less Than 6 mm in Diameter||University of Florida|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855790||142506|
NCT00856011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU 508-03 (2003)|Nerve Morphology in Diabetic Patients|Posterior Interosseous Nerve Pathology May Provide Novel Insights Into Both Predisposition and Potential Vascular Basis for the Development of Carpal Tunnel Syndrome in Diabetic Patients.||Skane University Hospital|No|Completed|December 2003|April 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|46|Samples Without DNA|Biopsies of the posterior interosseous nerve|Both|18 Years|80 Years|No|Probability Sample|Patients referred to a specialized hand clinic|March 2009|March 4, 2009|March 4, 2009||||No||https://clinicaltrials.gov/show/NCT00856011||142489|
NCT00852410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0001-A|The Hemostatic and Hemodynamic Effects of Adrenaline During Endoscopic Sinus Surgery|The Hemostatic and Hemodynamic Effects of Adrenaline During Endoscopic Sinus Surgery: Randomized Clinical Trial||University of Toronto|No|Not yet recruiting|March 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2010|June 29, 2010|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852410||142764|
NCT00852683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2007-374|The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study|||Nova Scotia Health Authority||Completed|May 2008|December 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|60 Years|No|||March 2014|March 5, 2014|March 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00852683||142743|
NCT00856986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1842|The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes|The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extension||Novo Nordisk A/S|No|Completed|March 2009|November 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|987|||Both|18 Years|80 Years|No|||November 2014|November 17, 2014|March 5, 2009|Yes|Yes||No|April 19, 2011|https://clinicaltrials.gov/show/NCT00856986||142416|
NCT00857610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00026851/ Derm 604|Retinol-induced Dermatitis in Aged Skin|Molecular Analyses of Retinoid-induced Dermatitis in Aged/Photoaged Human Skin||University of Michigan|No|Recruiting|April 2009|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|200|Samples With DNA|Skin biopsies will be taken; however, they are not intended to be used for DNA extraction.|Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be between the ages of 21-60 years of age, with moderate clinical        photodamage, and either gender.|September 2015|September 22, 2015|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857610||142369|
NCT00857883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111314|A First-Time-In-Human Study in Healthy Subjects|A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects|FTIH|GlaxoSmithKline|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00857883||142348|
NCT00858195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-0547|A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules|A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules Under Fasting Conditions||Sandoz||Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 6, 2009|March 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858195||142324|
NCT00854204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015763|Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629|Phase I, Open-label, 3-way Crossover Trial in Healthy Male Volunteers to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629||Tibotec Pharmaceuticals, Ireland||Completed|November 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|January 15, 2009||||No||https://clinicaltrials.gov/show/NCT00854204||142627|
NCT00854217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/03FEV/047|Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Completed|March 2009|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||March 2011|March 2, 2011|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854217||142626|
NCT00854477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP001|Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma|A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma||Cambridge University Hospitals NHS Foundation Trust|No|Completed|November 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00854477||142606|
NCT00836134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS_Rectus_sheath|Ultrasound-guided Rectus Sheath Block for Post-operative Pain Control Following Umbilical Hernia Repair|Ultrasound-guided Rectus Sheath Block for Post-operative Pain Control Following Umbilical Hernia Repair||Seattle Children's Hospital|Yes|Completed|February 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|1 Year|17 Years|No|||June 2014|June 10, 2014|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836134||143994|
NCT00859001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM+R-Z|Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy|A Phase II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy.|FM+R-Z|University of Bologna||Completed||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859001||142262|
NCT00859014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01-HB-37163-05|Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients|Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients||The University of Texas Health Science Center, Houston|Yes|Completed|January 2009|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|83 Years|No|||December 2014|December 31, 2014|March 9, 2009|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00859014||142261|This is a Phase I safety and feasibility study, designed without a control group. Small sample size and inclusion of selected patients warrants caution in interpretation of findings. A randomized controlled study is needed.
NCT00857506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A11|Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)|Longitudinal Study of Long-term (36 Month) Cognitive Outcomes in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Who Have Previously Had PET Imaging With 18F-AV-45 Injection.||Avid Radiopharmaceuticals|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|152|||Both|50 Years|N/A|No|||March 2013|March 26, 2013|March 5, 2009|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00857506||142377|
NCT00858650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHyMe|Registry of Hypogonadism in Men|Registry of Hypogonadism in Men|RHyMe|New England Research Institutes|No|Enrolling by invitation|March 2009|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|999|||Male|18 Years|N/A|No|Non-Probability Sample|Hypogonadal men|February 2015|March 13, 2015|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858650||142289|
NCT00858663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-138|Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer|A Phase I Study of Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer||Memorial Sloan Kettering Cancer Center|Yes|Completed|March 2009|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|March 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858663||142288|
NCT00858949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-415|Costs of Postoperative Nausea and Vomiting in Ambulatory Surgery Patients|Time-Motion Study of PONV Costs in Ambulatory Surgery||Outcomes Research Consortium|No|Completed|August 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients undergoing elective surgery with anesthesia that is expected to last one hour        and to require significant postoperative opioids|March 2010|March 17, 2010|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858949||142266|
NCT00851890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-380|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|70 Years|No|||December 2014|December 29, 2014|February 24, 2009|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT00851890||142804|
NCT00852124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040151|Safety of VSL#3 in Adult Asthmatics|Safety of VSL#3 for Adult Asthmatics||University of Maryland|Yes|Terminated|February 2007|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|February 13, 2009|No|Yes|Inadequate recruitment|No|December 2, 2014|https://clinicaltrials.gov/show/NCT00852124||142786|Early termination due to small number of persons recruited before PI relocated.
NCT00852982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALF 2006 03 25|Exercise Effects on Cardiovascular Risk Factors, Quality of Life, Muscle Function in Type 2 Diabetes and Healthy Persons|Exercise - Effects on Health Related Quality of Life, Cardiovascular Risk Factors, and Cellular Functions With Respect to Glucose Metabolism, in Type 2 Diabetes Mellitus, Impaired Glucose Tolerance and in Healthy Individuals.|SMIDIG|Karolinska Institutet|No|Active, not recruiting|April 2006|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|213|||Both|45 Years|69 Years|Accepts Healthy Volunteers|||February 2009|February 27, 2009|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852982||142720|
NCT00856622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96TIPG004|A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients|A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension.||Pfizer|No|Completed|August 1997|June 1999|Actual|June 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|436|||Both|18 Years|N/A|No|||June 2009|June 3, 2009|March 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856622||142444|
NCT00853229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 08-195|Pregabalin for the Treatment of Vulvodynia|Pregabalin (Lyrica) for the Treatment of Vulvodynia: A Randomized, Double-blinded, Placebo-controlled Cross-over Study||The Cleveland Clinic|No|Terminated|February 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|N/A|No|||August 2013|August 22, 2013|February 27, 2009|Yes|Yes|Not feasible due to low accrual|No||https://clinicaltrials.gov/show/NCT00853229||142701|
NCT00853242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APB00108|Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis|LEAP|Sanofi|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|349|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|February 27, 2009|Yes|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT00853242||142700|
NCT00853541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001164|Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study|Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study|CAPRICORN|Massachusetts General Hospital|No|Withdrawn|March 2009|October 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|blood samples are taken|Both|18 Years|N/A|No|Non-Probability Sample|150 heart failure patients|September 2015|September 22, 2015|February 26, 2009||No|No patients enrolled.|No||https://clinicaltrials.gov/show/NCT00853541||142678|
NCT00858234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-098|Phase I Study of MK0683 in Combination With Bortezomib in Multiple Myeloma Patients (0683-098)|A Multicenter, Open-Label, Phase I Study of MK0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma||Merck Sharp & Dohme Corp.|No|Completed|March 2009|April 2012|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||January 2016|January 21, 2016|March 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858234||142321|
NCT00858481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-201-05|A Pilot Dose Ranging Study of Spinosad Creme Rinse|Efficacy and Safety of Different Strengths of Spinosad Topical Creme (0%, 0.5%, 1.0% or 2%) in Subjects With Pediculosis Capitis - a Dose Ranging Study||ParaPRO LLC|No|Completed|September 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|2 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858481||142302|
NCT00858494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35537-D|Homeopathic Cold Medicine for Children|Homeopathic Cold Medicine for Children||University of Washington|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|24 Months|59 Months|No|||March 2011|March 1, 2011|March 5, 2009||No||No|December 27, 2010|https://clinicaltrials.gov/show/NCT00858494||142301|
NCT00857896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221066|Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years|An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years.||Pfizer|Yes|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|8 Years|17 Years|No|||November 2011|November 20, 2011|February 26, 2009|Yes|Yes||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00857896||142347|
NCT00857909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES:HOS:SKM.02.2009|The Effect of Amiloride and Spironolactone in Healthy Persons|The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study|SPAS|Regional Hospital Holstebro|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 7, 2011|March 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857909||142346|
NCT00858208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751028|Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.|Long-Term Non-Interventional Study To Investigate The Efficacy And Safety Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice.|MACULA|Pfizer|No|Completed|March 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with Age-related Macula degeneration|September 2011|March 14, 2012|February 26, 2009||No||No|March 14, 2012|https://clinicaltrials.gov/show/NCT00858208||142323|
NCT00858442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Quezada|Platelet-Rich Plasma (PRP) in Reconstructive Surgery on Children With Retractable Burn Sequelae on Extremities|PRP on Children With Retractable Burn Sequelae Who Have Submitted Release of Burn Contractures and Skin Graft on Their Limbs. A Double-Blind Randomized Clinical Trial||Corporation for the Aid of Burned Children|No|Completed|March 2009|November 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|5 Years|21 Years|No|||January 2015|January 28, 2015|March 5, 2009||No||No|April 18, 2013|https://clinicaltrials.gov/show/NCT00858442||142305|Loss cases: PRP group: 3/23 and group without PRP: 1/21
NCT00858741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMEMA - BONE METASTASES|Palliative Radiotherapy for Bone Metastases: Single Versus Multiple Fractions.|Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions.||Marilia Medicine School|No|Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||March 2009|March 9, 2009|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858741||142282|
NCT00858455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111602|A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572|A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Maalox® Advanced Maximum Strength and One A Day® Maximum on Pharmacokinetics of GSK1349572 in Healthy Adult Subjects|DDI|GlaxoSmithKline||Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|June 4, 2009|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00858455||142304|
NCT00835770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS303|BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)|A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis|ENDORSE|Biogen|No|Active, not recruiting|February 2009|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1738|||Both|19 Years|58 Years|No|||October 2015|October 16, 2015|February 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00835770||144022|
NCT00836147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-0107|Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids|A Single-centre, Double Blind, Randomised, Exploratory Study to Explore the Efficacy and Safety of Juvista 250ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids.||Renovo|No|Completed|February 2009|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||September 2010|September 27, 2010|February 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00836147||143993|
NCT00859898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-034|Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control||Bristol-Myers Squibb|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1093|||Both|18 Years|77 Years|No|||February 2014|February 4, 2014|March 10, 2009|Yes|Yes||No|February 4, 2014|https://clinicaltrials.gov/show/NCT00859898||142197|
NCT00859911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCBD01|The Effectiveness of Micronutrient Supplements on Growth and Educational Achievement of Schoolchildren in Bangladesh|The Effectiveness of Multiple Micronutrient Supplements Given by Teachers to School-Age Children on Growth and Educational Achievement||Save the Children|No|Active, not recruiting|March 2008|October 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2300|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2009|March 9, 2009|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859911||142196|
NCT00856024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05632|ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)|ATHENAS - Retrospective Analysis of Compliance to Treatment of Chronic Hepatitis C With Pegylated Interferon Alpha 2b Associated to Ribavirin Until Week 12 and Correlation With Virological Response in Brazil Health Centers|ATHENAS|Merck Sharp & Dohme Corp.|No|Terminated|July 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|902|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with confirmed chronic hepatitis C and who completed 12 weeks of treatment with        peginterferon alfa-2b and ribavirin. Patients will come from approximately 65 Brazilian        sites and should satisfy all inclusion criteria and none of the exclusion criteria.|June 2015|June 4, 2015|March 4, 2009||No||No|October 14, 2011|https://clinicaltrials.gov/show/NCT00856024||142488|
NCT00856037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|508-08|Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment|A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)||University of Nebraska|Yes|Recruiting|February 2009|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|19 Years|N/A|No|||August 2015|August 12, 2015|March 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00856037||142487|
NCT00851305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008SDU-QILU-G01|Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy|Comparison Confocal Laser Endomicroscopy With Conventional Endoscopy for the Detection of Early Gastric Cancers|CLE|Shandong University|Yes|Completed|August 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1786|||Both|45 Years|80 Years|No|||July 2012|July 16, 2012|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851305||142849|
NCT00851578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST1056|ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology|ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology|ASAP|Boston Scientific Corporation|Yes|Completed|January 2009|December 2013|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||September 2013|January 26, 2015|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851578||142828|
NCT00851903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXT_LANTU_C_02761|Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial|Combination Therapy of Insulin Glargine and Sitagliptin in Patients With Type 2 Diabetes Not Adequately Controlled by a Previous Treatment With Metformin and Either Insulin Glargine or Sitagliptin||Sanofi||Completed|June 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|35 Years|71 Years|No|||September 2012|September 3, 2012|February 25, 2009|Yes|Yes||No|September 3, 2012|https://clinicaltrials.gov/show/NCT00851903||142803|
NCT00852137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-017|A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis|A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis||Peplin|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||April 2012|February 18, 2015|February 22, 2009|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00852137||142785|
NCT00851565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01MA|Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy|Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy||Copenhagen University Hospital at Herlev|Yes|Active, not recruiting|June 2009|February 2014|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2011|November 24, 2011|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00851565||142829|
NCT00852423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMP0308|Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria|Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria|PREGACT|Institute of Tropical Medicine, Belgium|Yes|Completed|June 2010|April 2015|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3428|||Female|15 Years|N/A|No|||March 2016|March 11, 2016|February 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00852423||142763|
NCT00852696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8867|Over Active Bladder Patients Having Sling Surgery|A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures.||Cleveland Clinic Florida|No|Completed|February 2008|February 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00852696||142742|
NCT00852709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0715|Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias|Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias|POE07-01|Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|September 2007|||January 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|1 Year|21 Years|No|||September 2010|September 21, 2010|February 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00852709||142741|
NCT00852163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-150|Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen|Phase II Trial of Clofarabine With Parenteral Busulfan (Busulfex®) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases||Baylor Research Institute|Yes|Completed|March 2007|December 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|February 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00852163||142783|
NCT00856362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3110A1-1004|Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects|An Open-label, Single-Dose, 4-Period, Sequential Study to Determine the Effect of Moxidectin on CYP3A4 Activity in Healthy Subjects Using Midazolam as a Probe Substrate||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 15, 2010|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856362||142463|
NCT00856375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PIR-03|NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer|A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naive, KRAS-Mutant, Metastatic Colorectal Cancer (mCRC)||Nektar Therapeutics|Yes|Completed|December 2008|December 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||January 2015|February 6, 2015|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856375||142462|
NCT00856960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-127|The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)|A Randomized, Double-Blind, Placebo-Controlled, 4-Treatment, 3-Period, Incomplete Block, Balanced Crossover Study to Evaluate the Effects of a Single Dose of Aliskiren and Losartan on Renal Blood Flow Measurements in Healthy Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|January 2010|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|12|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00856960||142418|
NCT00856973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-246|Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia|A Randomized, Placebo Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia||Sunovion|Yes|Completed|May 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|486|||Both|6 Years|17 Years|No|||May 2013|June 7, 2013|March 4, 2009|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT00856973||142417|Per protocol, study did not have PSG adaptation nights at baseline and contained one PSG assessment post randomization visit
NCT00857935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-203-07|A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse|A Pilot Study to Test the Operational Elements of an Actual Use Study Designed to Compare the Safety and Efficacy of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months of Age or Older With Pediculosis Capitis||ParaPRO LLC|No|Completed|March 2007|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|6 Months|N/A|Accepts Healthy Volunteers|||March 2009|March 6, 2009|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00857935||142344|
NCT00857948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP003|Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation|A Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of 3 Strengths of Ivermectin Treatment Conditioner and Placebo in Subjects With Pediculus Humanus Capitis (Head Lice) Infestation||Topaz Pharmaceuticals Inc|No|Completed|March 2009|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|78|||Both|6 Months|N/A|No|||March 2012|March 1, 2012|March 6, 2009|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00857948||142343|
NCT00858507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-184|Engaging Homeless Veterans in Primary Care|Engaging Homeless Veterans in Primary Care||VA Office of Research and Development|No|Completed|October 2009|March 2014|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|221|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 10, 2014|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00858507||142300|
NCT00858780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881K1-4500|Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA|Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA)|DOSERA|Pfizer|No|Completed|January 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|91|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|March 6, 2009||No||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00858780||142279|
NCT00858767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-064|Arabic Gum-Absorption Study|Comparison of Absorption and Efficacy of 3 Different Menaquinone-7 Delivery Systems; Casein Powder, Arabic Gum Powder, or Linseed Oil||Maastricht University Medical Center|No|Completed|October 2008|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|69|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2010|December 15, 2010|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858767||142280|
NCT00858793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARL-GT 2005|High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT|High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT||Universitätsklinikum Hamburg-Eppendorf|Yes|Suspended|October 2008|October 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||May 2015|May 12, 2015|March 9, 2009||No|A leukaemia case was reported in patient treated with a similar vector. For safety risk we    stopped recruitment|No||https://clinicaltrials.gov/show/NCT00858793||142278|
NCT00858221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-08-107PLIN|Association of Genes to Resistance to Weight Loss in Obese Patients|Association of Genetic Variants in Obesity Genes to Resistance to Weight Loss and Susceptibility to Metabolic Syndrome in Morbidly Obese Patients: A Single Center, Blinded, Retrospective Clinical Study||Interleukin Genetics, Inc.|No|Completed|August 2008|July 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|824|Samples With DNA|DNA to be analyzed by genotyping|Both|21 Years|70 Years|No|Probability Sample|Caucasian adults between the age of 21 and 70 years, inclusive, who fit the criteria for        patients undergoing bariatric surgery at the Geisinger Clinic.|October 2009|October 19, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00858221||142322|
NCT00858468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC27|Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age|Proof of Concept Study of the Safety and Immunogenicity of Influenza Virus Vaccine Fluzone® 2004-2005 Among Healthy Children 2 Months vs 6 Months of Age||Sanofi|No|Completed|April 2005|December 2006|Actual|June 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|394|||Both|2 Months|9 Months|Accepts Healthy Volunteers|||January 2014|January 16, 2014|March 5, 2009|Yes|Yes||No|April 20, 2009|https://clinicaltrials.gov/show/NCT00858468||142303|
NCT00859118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08905|Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies|Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies||University of Wisconsin, Madison|Yes|Completed|February 2009|December 2014|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2014|March 4, 2015|March 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00859118||142253|
NCT00835783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-K20|Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation|PET/CT in Infection and Inflammation Imaging: Current Utility and Future Perspectives (The PIN-UP Study)|PIN-UP|Odense University Hospital|No|Terminated|November 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|N/A|No|Probability Sample|Patients are referred for FDG-PET/CT at the Department of Nuclear Medicine, Odense        University Hospital. Patients are recruited for part project A from the entire hospital        through a project nurse at the Department of Infectious Diseases. Patients are recruited        for part project B and part project C among all patients referred for FDG-PET/CT as per        usual guidelines.|October 2014|October 26, 2014|February 3, 2009|No|Yes|Study logistics proved difficult and enrollment never moved beyond the pilot phase.|No||https://clinicaltrials.gov/show/NCT00835783||144021|
NCT00855244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00023|Metabolic Syndrome in Bone Marrow Transplant Survivors|Metabolic Syndrome in Bone Marrow Transplant Survivors||Nationwide Children's Hospital|No|Terminated|March 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|9 Years|23 Years|No|||May 2015|May 14, 2015|March 3, 2009||No|Principal Investigator left the institution|No||https://clinicaltrials.gov/show/NCT00855244||142547|
NCT00856557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-430|Intervening to Prevent Contextual Errors in Medical Decision Making|Intervening to Prevent Contextual Errors in Medical Decision Making||VA Office of Research and Development|No|Completed|October 2009|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|138|||Both|N/A|N/A|No|||October 2014|April 6, 2015|March 3, 2009||No||No|October 27, 2014|https://clinicaltrials.gov/show/NCT00856557||142449|
NCT00856570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-040|A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects|An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects||Astellas Pharma Inc|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|March 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00856570||142448|
NCT00851006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33465|Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram|Adjunctive Creatine Treatment for Adolescent Females With Major Depressive Disorder Who Are Non-Responders to Fluoxetine or Escitalopram: A Magnetic Resonance Spectroscopy Study||University of Utah|Yes|Completed|April 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|February 23, 2009|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT00851006||142871|
NCT00851019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08-2177|Dance Dance Revolution (DDR) in Type 2 Diabetes|Dance Dance Revolution (DDR) Exergaming in Adults With Type 2 Diabetes Mellitus||Charles Drew University of Medicine and Science|Yes|Completed|February 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|65 Years|No|||March 2013|March 25, 2013|February 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00851019||142870|
NCT00851318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDP870-275-08-002|Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients|A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered in Combination With Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-001)||Astellas Pharma Inc|No|Completed|March 2009|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Both|20 Years|74 Years|No|||October 2014|October 27, 2014|February 23, 2009||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT00851318||142848|
NCT00852150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC 2008-083|Is a Reporting System for Gastritis or Duodenitis (Modified Lanza Scale) Reproducible?|Reproducibility of Modified Lanza Scale for the Reporting of Gastritis and Duodenitis||Ruttonjee Hospital|No|Completed|March 2009|December 2011|Actual|December 2011|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|all patient undergoing upper endoscopy after informed consent is obtained|June 2012|June 5, 2012|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00852150||142784|
NCT00855556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0171|Parkinson's Disease Genetics Database|Parkinson's Disease Genetics Database||Northwell Health|No|Terminated|February 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples With DNA|DNA stored in TE buffer solution|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with a diagnosis of Parkinson's Disease as determined by standard neurological        criteria.|September 2015|September 15, 2015|February 25, 2009||No|Enrollment into this registry was not as robust as investigator envisioned. Thus, the registry    was closed.|No||https://clinicaltrials.gov/show/NCT00855556||142523|
NCT00851916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK Recurrent Prostate SD|CyberKnife Radiosurgery for Locally Recurrent Prostate CA|VIRTUAL HDR CYBERKNIFE RADIOSURGERY FOR LOCALLY RECURRENT PROSTATIC CARCINOMA: A PHASE II STUDY||CyberKnife Centers of San Diego|No|Recruiting|February 2009|||February 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||March 2014|March 13, 2014|February 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00851916||142802|
NCT00856635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM030|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON)||Teva Pharmaceutical Industries||Completed|February 2009|February 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|45 Years|No|||September 2013|September 20, 2013|March 4, 2009|Yes|Yes||No|July 11, 2013|https://clinicaltrials.gov/show/NCT00856635||142443|
NCT00857623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00009|Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy|A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy||AstraZeneca||Completed|February 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|80 Years|No|||November 2012|November 8, 2012|February 27, 2009|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00857623||142368|
NCT00857922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0413|Neurosciences Research Repository|Neurosciences Research Repository|NRR|The University of Texas Health Science Center, Houston|Yes|Recruiting|March 2009|August 2029|Anticipated|March 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|5000|Samples With DNA|whole blood, plasma, white cells, saliva, tissue, CSF|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients admitted to the Neurosurgery service (Mischer Neuroscience Institute/UT        Department of Neurosurgery or Neurosurgical Critical Care service) are eligible for this        study. Family members of those with select conditions will be approached for enrollment at        a future date.|November 2015|November 30, 2015|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00857922||142345|
NCT00858520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220072389|Serum, Plasma, DNA and Tissue Bank in Chronic Obstructive Pulmonary Disease and Lung Cancer|Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.||Katholieke Universiteit Leuven|No|Recruiting|October 2007|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|2000|Samples With DNA|Germline DNA, serum and plasma, Peripheral blood mononuclear cells, Lung tissue biopsies|Both|25 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with Chronic Obstructive Pulmonary Disease and smoking controls.|September 2013|September 2, 2013|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858520||142299|
NCT00859131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thymo vs IL2|Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists|Rabbit Anti-thymocyte Globulin Versus IL2 Receptor Antagonists in Combination With Tacrolimus, Corticosteroids and Mycophenolate Mofetil in a Predominantly High Risk Kidney Transplant Population.||Medical University of South Carolina|No|Active, not recruiting|March 2009|July 2014|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|75 Years|No|||February 2014|February 28, 2014|March 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859131||142252|
NCT00859144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 03-0888|Training Community Members to Deliver HIV Prevention Programs to Urban Youth|Community Partnerships to Prevent Urban Youth Health Risks (CHAMPions)||Icahn School of Medicine at Mount Sinai|No|Completed|March 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|901|||Both|12 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00859144||142251|
NCT00859105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIQ-TOCR-01RB01-CE|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis|A Multicenter, Double-Blind, Vehical-Controlled Study Comparing Imiquimod Cream, 5% (Apotex Inc.) to Aldara™ Cream, 5%(3M Pharmaceutials, U.S.) and Aldara™ Cream, 5%(3M Pharmaceuticals, Canada) in the Treatments of Actinic Keratosis.||Apotex Inc.|Yes|Completed|February 2008|||November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|497|||Both|N/A|N/A|No|||March 2009|March 9, 2009|March 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859105||142254|
NCT00859430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-117-SA|Levetiracetam 1000 mg Under Non-Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Levetiracetam 1000 mg Tablet Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|January 2007|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 9, 2009|March 9, 2009|No|Yes||No|July 9, 2009|https://clinicaltrials.gov/show/NCT00859430||142231|
NCT00859742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTS-06-211|Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Mediastinal Re-Staging of Non-Small Cell Lung Cancer (NSCLC)|Endobronchial Ultrasound Guided Transbronchial Needle Aspiration for the Mediastinal Re-Staging After Induction Therapy in Non-Small Cell Lung Cancer. A Prospective Study||National Cancer Center, Korea|Yes|Active, not recruiting|March 2009|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2009|March 10, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859742||142208|
NCT00845624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12213|Time Outside Target Oxygen Saturation Range in Preterm Infants and Long Term Outcomes and Preterm Infants|DURATION OF TIME OUTSIDE, BELOW, AND ABOVE THE TARGETED Oxygen SATURATION RANGE In Preterm Infants|SAT01ROP|University of Virginia|Yes|Completed|January 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|N/A|12 Months|Accepts Healthy Volunteers|Probability Sample|NICU patients at risk for ROP|February 2009|June 13, 2012|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00845624||143277|
NCT00854984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/462|Pilot Study of a Self-help Intervention for Depression in Patients With a Chronic Disease|Pilot Study of a Practice Nurse Supported Psychological Self-help Intervention for Patients With Diabetes or Coronary Heart Disease and Co-morbid Depression||University of Edinburgh|No|Recruiting|February 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|49|||Both|35 Years|N/A|No|||April 2010|April 7, 2010|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00854984||142567|
NCT00854997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812080R|The Impact of Obstructive Sleep Apnea on the Outcomes in Patients of First-Time Acute Myocardial Infarction|The Impact of Obstructive Sleep Apnea on the Outcomes in Patients of First-Time Acute Myocardial Infarction||National Taiwan University Hospital|Yes|Recruiting|January 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|serum, plasma, RNA, DNA|Both|18 Years|N/A|No|Probability Sample|first-time, Killip I-II, post primary PCI within 5th -7th day of AMI|February 2009|March 1, 2009|January 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00854997||142566|
NCT00850993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64,185-202|A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia|A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia||InfaCare Pharmaceuticals Corporation|Yes|Terminated|August 2008|May 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|N/A|48 Hours|No|||August 2014|August 19, 2014|February 24, 2009|Yes|Yes|To redefine study population|No|December 6, 2013|https://clinicaltrials.gov/show/NCT00850993||142872|It should be noted that the study was discontinued before enrollment of the full 4.5 mg/kg cohort,and therefore, the stannsoporfin 4.5 mg/kg treatment group included 8 patients and the placebo group included 15 patients.
NCT00855582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11667|A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men With Both Erectile Dysfunction and Benign Prostatic Hyperplasia|COMORBID©|Eli Lilly and Company|No|Completed|March 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|606|||Male|45 Years|N/A|No|||July 2011|July 26, 2011|March 3, 2009|Yes|Yes||No|June 1, 2011|https://clinicaltrials.gov/show/NCT00855582||142521|P-values for the peak urine flow rate outcome were corrected in this record after an error was identified.
NCT00855868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN PA 4003|Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals|Evaluation of the Ability of a Novel [18F] Amyloid Ligand ([18F]-AV-45) to Distinguish Patients With a Clinical Diagnosis of Alzheimer's Disease From Cognitively Normal Elderly Individuals||Avid Radiopharmaceuticals|Yes|Completed|March 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|28|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|March 2, 2009|Yes|Yes||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00855868||142500|
NCT00855569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREN-101|Hemostatic Textile to Control Bleeding at Donor Graft Sites|Use of a HemostaticTextile (StasilonTM) to Control Bleeding at Skin Graft Donor Sites (Randomized, Single-Blind)|Stasilon|University of North Carolina, Chapel Hill|No|Completed|June 2008|December 2010|Actual|September 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the UNC Jaycee Burn Center|June 2012|June 15, 2012|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855569||142522|
NCT00851591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A08-3479|Effect of Fenugreek on Milk Production|Effect of Fenugreek on Milk Production|fenugreek|Texas Tech University Health Sciences Center|Yes|Terminated|September 2008|August 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|45 Years|No|||June 2014|June 30, 2014|February 24, 2009|Yes|Yes|Low enrollment; investigator chose not to continue study|No|January 24, 2014|https://clinicaltrials.gov/show/NCT00851591||142827|
NCT00856999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGNR-08-0093|Botox Cosmetic and the Young Patient With Glabellar Furrows|Botox Cosmetic and the Young Patient With Glabellar Furrows||Oregon Health and Science University|No|Completed||||||Phase 4|Interventional|Primary Purpose: Treatment|1||||||Female|30 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 4, 2009|March 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856999||142415|
NCT00856063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTREC JG - 08|Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD)|Feasibility and Utility of Autonomic Correlates of Impulsivity in Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD): Extending Translational Research Skills||University of Arizona|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|5|||Both|48 Months|70 Months|No|||July 2012|July 5, 2012|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856063||142485|
NCT00856076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP-study|Venous Thromboembolism in Pregnancy Study|Venous Thromboembolism and Intrauterine Fetal Death in Pregnancy - Epidemiology and Pathogenic Mechanisms|VIP|Oslo University Hospital|No|Recruiting|January 2005|December 2023|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||10|Anticipated|1200|Samples With DNA|Serum, EDTA and citrated plasma, whole blood and processed DNA|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases: women with first-time validated venous thromboembolism in pregnancy or women who        had experienced intrauterine fetal death, either all cases with validated data from        medical records or cases meeting for blood sampling.        Controls: women from the source population; either population based with data from the        Norwegian Patient Registry or Norwegian Birth Registry, or hospital-based and randomly        drawn from the source population and with validated data, or subset of the latter group        meeting for blood sampling|March 2009|October 17, 2011|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856076||142484|
NCT00856089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT112759|Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization|Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization||Ochsner Health System|Yes|Withdrawn|May 2009|October 2009|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|May 28, 2013|March 4, 2009|Yes|Yes|Study is withdrawn and no one enrolled due to changes in personnel|No||https://clinicaltrials.gov/show/NCT00856089||142483|
NCT00857246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-72 (H12637)|Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer|Neoadjuvant Therapy of Gastric Cancer With Irinotecan, Cisplatin and Cetuximab Followed by Surgical Resection and Adjuvant Chemoradiation||New York University School of Medicine|Yes|Completed|July 2005|October 2015|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|March 4, 2009|Yes|Yes||No|March 2, 2015|https://clinicaltrials.gov/show/NCT00857246||142396|
NCT00857259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2203|The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration|A Randomized, Double-masked, Parallel Group Study to Assess the Efficacy of Oral Everolimus, Either Alone or Added to Lucentis, in Patients With Neovascular Age-related Macular Degeneration||Novartis||Terminated|February 2009|||July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|50 Years|N/A|No|||July 2011|July 22, 2011|March 4, 2009|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00857259||142395|
NCT00857272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F38-27|F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects||Braintree Laboratories|No|Completed|February 2009|||May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|March 5, 2009|Yes|Yes||No|August 9, 2010|https://clinicaltrials.gov/show/NCT00857272||142394|Total number of patients experiencing a non-serious adverse event is based on all adverse events, not just those events above the reporting threshold of 3%
NCT00857285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSP-866/01|Olmesartan Medoxomil Versus Losartan in Patients With Hypertension|A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker "Olmesartan Medoxomil" Versus "Losartan" in Patients With Mild to Moderate Essential Hypertension||Daiichi Sankyo Inc.|No|Completed|May 2002|September 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|20 Years|75 Years|No|||July 2009|July 22, 2009|March 5, 2009|No|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00857285||142393|
NCT00857636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA129060|Behavioral Intervention Study for Better Breast and Cervical Cancer Control for Korean American Women|Better Breast and Cervical Cancer Control for Korean American Women||Johns Hopkins University|Yes|Completed|November 2009|November 2014|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|560|||Female|21 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857636||142367|
NCT00858247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008743|Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents|Significance of Vitamin D Status in Obese Adolescents- A Pilot Study to Examine the Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors||Mayo Clinic|Yes|Completed|April 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|51|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|March 5, 2009|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00858247||142320|
NCT00858260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.471/14|Arnogene: A Phosphocalcic Study in Dialysis|Genetic Determinants of Phosphocalcic Metabolism in Hemodialysis Patients|ARNOGENE|Hospices Civils de Lyon|No|Completed|November 2008|February 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Searching for high morbi-mortality risk Klotho variants|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients undergoing maintenance dialysis since at leat three months|September 2009|September 3, 2009|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858260||142319|
NCT00858806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005102-42|Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy|Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients With Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) With Standard IM Therapy|INTERIM0407|Università degli Studi di Brescia|Yes|Completed|April 2008|December 2014|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|65 Years|N/A|No|||December 2014|December 2, 2014|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858806||142277|
NCT00858819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUREG11961|Clinical Trial of Osteoporosis in Ankylosing Spondylitis|Clinical Trial of Osteoporosis in Ankylosing Spondylitis||Göteborg University|No|Completed|March 2009|December 2014|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|250|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Probability Sample|Patients with definitive ankylosing spondylitis attending three rheumatology clinics in        Western Sweden.|May 2015|May 28, 2015|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858819||142276|
NCT00859456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC2308|Sunitinib in Soft Tissue Sarcoma|A Phase II, Open-label, Non-randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas||Columbia University|No|Active, not recruiting|April 2007|December 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|March 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00859456||142230|
NCT00859729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pVAX/rhPSA -EP 2006|Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer|DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients With Relapsed Prostate Cancer. A Phase I/II Study||Uppsala University|Yes|Completed|December 2008|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|15|||Male|18 Years|N/A|No|||March 2014|March 14, 2014|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859729||142209|
NCT00859755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-403-101|A Safety Study of ARRY-403 in Patients With Type 2 Diabetes|||Array BioPharma||Completed|March 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||August 2012|August 29, 2012|March 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00859755||142207|
NCT00855634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUM-Chir-001/2009|Resection in Pancreatic Cancer With Minimal Metastatic Disease or Venous Infiltration Trial at Technische Universität München|Extended Versus Standard Resection in Two Cohorts of Patients With Adenocarcinoma of the Pancreas: Minimal Metastatic Disease or Venous Infiltration - a Randomized Trial|PaMeViTUM|Technische Universität München|Yes|Terminated|August 2009|March 2012|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|355|||Both|18 Years|N/A|No|||July 2009|September 5, 2012|March 3, 2009||No|Protocol planned interim analysis after two years showed very low recruitment in cohort 1 and    low recruitment in cohort 2.|No||https://clinicaltrials.gov/show/NCT00855634||142517|
NCT00845650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS.AIG.001|Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)|A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV)||Emergent BioSolutions|Yes|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|February 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00845650||143275|
NCT00845949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95034|Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes|Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes||Far Eastern Memorial Hospital|Yes|Withdrawn|November 2006|June 2008|Anticipated|June 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Synovial tissue|Both|18 Years|90 Years|No|Probability Sample|Synovial tissue from patient with rheumatoid arthritis who underwent total knee        replacement surgery after informed consent.|May 2012|May 18, 2012|March 3, 2008||No|NO available budget and difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT00845949||143252|
NCT00859391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV0801|Effects of Gluten Digestion With ALV003|A Phase 0 Study in Subjects With Well Controlled Celiac Disease to Assess the Effects of Gluten Digestion With ALV003 (a Protease Enzyme) in Vitro|0801|Alvine Pharmaceuticals Inc.|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|Samples With DNA|The enzyme linked immunospot (ELISPOT) assay is used in vaccine development, cancer      research, infectious disease diagnosis and monitoring, autoimmune disease studies and      allergy and transplantation research. The ELISPOT enables determination of the frequency of      cytokine secreting cells. The ELISPOT is a combination of both immunoassay and bioassay      because live cells are cultured in plates. This enables a very high sensitivity to detect      cytokine secretion at a single cell level as secreted cytokine does not diffuse into media      but is immediately membrane bound.|Both|18 Years|75 Years|No|Probability Sample|The target population for this study is patients with celiac disease with HLA DQ2        phenotype who have well controlled celiac disease without significant co-morbidities and        are previously on a gluten free diet for at least 8 weeks prior to study entry.|June 2009|June 9, 2009|January 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00859391||142234|
NCT00855257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-07|Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome|Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Patients Presenting a Recent Acute Coronary Syndrome.|EVANACS|French Cardiology Society|Yes|Completed|June 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|75 Years|No|||July 2009|July 8, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855257||142546|
NCT00855595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14366|Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea|An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily in Subjects With Moderate Papulopustular Rosacea||Bayer|No|Completed|February 2009|July 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|March 3, 2009|Yes|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00855595||142520|
NCT00859950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811010102|Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea|Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea||Weill Medical College of Cornell University|Yes|Completed|April 2009|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|70|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 29, 2015|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859950||142194|
NCT00856388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 118807|Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders|A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation||Roswell Park Cancer Institute|Yes|Active, not recruiting|January 2009|||May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|3 Years|75 Years|No|||September 2013|September 16, 2013|March 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00856388||142461|
NCT00856401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFDA 93.103|ADD-ON Study to Existing Hypoparathyroidism Studies|Phase II Trial of Parathyroid Hormone for the Treatment of Hypoparathyroidism||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|September 2010|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|62|||Both|18 Years|85 Years|No|||June 2014|June 12, 2014|March 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856401||142460|
NCT00855855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5A15|Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease|Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines||Sanofi|No|Active, not recruiting|February 2009|December 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|520000|||Both|N/A|59 Months|Accepts Healthy Volunteers|Non-Probability Sample|5.2 million person years over the 6 year study period|August 2015|August 17, 2015|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855855||142501|
NCT00856661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12649A|Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)|A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke||H. Lundbeck A/S|Yes|Terminated|April 2009|||October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|85 Years|No|||November 2015|November 18, 2015|March 5, 2009|Yes|Yes|The recruitment into DIAS4 has been stopped as the result of DIAS 3 indicates that the study    is unlikely to reach its primary endpoint with the current protocol|No|October 6, 2015|https://clinicaltrials.gov/show/NCT00856661||142441|
NCT00857012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ODE-ARI-2008/1|Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)|Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT): An in Practice Assessment of Arthralgias and Related Costs as Well as Compliance in the First Year of Anastrozole Therapy|COMPACT|AstraZeneca|No|Completed|April 2009|February 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2313|||Female|18 Years|N/A|No|Probability Sample|The patient population will include postmenopausal women with hormone-receptor positive        primary breast cancer receiving adjuvant endocrine treatment with anastrozole upfront or        following two to three years of tamoxifen therapy ("switch") according to the current SmPC        (Appendix C). Patients will have received anastrozole treatment for at least 3 months and        up to 6 months before the start of the study.|November 2012|November 9, 2012|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857012||142414|
NCT00857298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-08-0628|Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome|Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome||Washington University School of Medicine|No|Completed|February 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Female|18 Years|60 Years|No|||February 2015|February 13, 2015|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00857298||142392|
NCT00857961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14271|A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations|A Phase II, Randomised, Four-way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered Dose (MD) Lotion® Formulations and Doses in Hypogonadal Men||Eli Lilly and Company|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Male|18 Years|70 Years|No|||January 2011|January 6, 2011|March 4, 2009|Yes|Yes||No|December 15, 2010|https://clinicaltrials.gov/show/NCT00857961||142342|
NCT00858832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106202|Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine|Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine||University of South Florida|No|Completed|December 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|March 9, 2009||No||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00858832||142275|Early termination due to lack of feasibility in completing project; full analysis was not conducted;
NCT00858845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|641|Using Clonidine to Improve Leg Weakness in People With Heart Failure|Clonidine and the Skeletal Myopathy of Heart Failure||University of California, Los Angeles|Yes|Completed|May 2008|December 2012|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|11|||Both|21 Years|65 Years|No|||September 2013|September 4, 2013|March 6, 2009|Yes|Yes||No|June 19, 2013|https://clinicaltrials.gov/show/NCT00858845||142274|This is a small trial, but it was not terminated early, and there were no technical issues.
NCT00859183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S01101|Oral Sirolimus for In-Stent Restenosis|A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Impact of Oral Sirolimus on Restenosis Prevention in Patients With In-Stent Restenosis.|OSIRIS|Deutsches Herzzentrum Muenchen|Yes|Completed|October 2001|March 2004|Actual|February 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|N/A|No|||March 2009|March 9, 2009|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00859183||142248|
NCT00859157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633754|Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer|Tumescent Mastectomy: A Prospective Comparison to Standard Mastectomy Technique||University of California, Davis|No|Recruiting|October 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|74|||Female|18 Years|N/A|No|Non-Probability Sample|Adult (age 18 or more) women with histologic diagnosis of stage 0, I, II, III breast        cancer undergoing mastectomy.|January 2013|January 15, 2013|March 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00859157||142250|
NCT00859170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001|Use of Antiretropulsion Device in Laser Lithotripsy|Use of the Accordion Stone Management Device in Laser Lithotripsy||Percutaneous Systems, Inc.|No|Terminated|February 2009|August 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||January 2010|January 6, 2010|March 5, 2009||No|Change in priorities occurred|No||https://clinicaltrials.gov/show/NCT00859170||142249|
NCT00859482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ntz-Tregs1|Differential Immune Effects of Natalizumab|A Phase IV Study to Investigate Differential Immune Effects of Natalizumab||Cantonal Hospital of St. Gallen|No|Completed|July 2006|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|Samples Without DNA|full blodd|Both|18 Years|65 Years|No|Probability Sample|Patients initiating natalizumab for treatment of relapsing remitting MS|March 2009|March 10, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859482||142228|
NCT00859768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB254|The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients|The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients Treated With Radiotherapy.||Netherlands Open University|No|Completed|April 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|568|||Both|18 Years|N/A|No|||March 2009|March 7, 2011|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859768||142206|
NCT00859469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA2861 (Final)|Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma|Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial||Columbia University|Yes|Active, not recruiting|April 2004|March 2013|Anticipated|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|March 9, 2009|No|Yes||No|January 20, 2012|https://clinicaltrials.gov/show/NCT00859469||142229|
NCT00855647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11022007-792|Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)|Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)||Stanford University||Completed|August 2003|July 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99999|||Male|18 Years|N/A|No|||June 2010|June 1, 2010|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855647||142516|
NCT00855660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13790|Effect of Riociguat on Bone Metabolism|Investigation of the Effect of Riociguat, Administered as 2.5 mg IR-tablets TID Over 14 Days, on Bone Metabolism in a Randomized, Placebo-controlled, Double-blind, 2-fold Cross-over Design in Healthy Male Subjects||Bayer|No|Completed|March 2009|July 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855660||142515|
NCT00855673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-S1|Intermittent Mechanical Compression For Peripheral Arterial Disease|Intermittent Mechanical Compression For Peripheral Arterial Disease|FM-S1|Hospital Universitario Getafe|No|Completed|January 2001|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|75 Years|No|||February 2009|March 2, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855673||142514|
NCT00854737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000149|Cytidine and Omega-3 Fatty Acids in Bipolar Disorder|A Combination of Cytidine and Omega-3 Fatty Acids in Bipolar Disorder: Are There Additive or Synergistic Mood Stabilizing Effects?||Mclean Hospital|No|Completed|July 2004|July 2010|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|55 Years|No|||April 2012|April 19, 2012|February 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00854737||142586|
NCT00859404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 3886-201|A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma|A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma||Glenmark Pharmaceuticals Europe Ltd. (R&D)|Yes|Active, not recruiting|October 2008|January 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|282|||Both|18 Years|65 Years|No|||September 2009|September 23, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859404||142233|
NCT00859690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901010175|Regulation of Vascular Thrombosis in Sleep Apnea|Regulation of Vascular Thrombosis in Sleep Apnea||Weill Medical College of Cornell University|No|Completed|March 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|14|Samples With DNA|A total of 15ml (approximately 1 tablespoon) of whole blood will be collected from each      subject during his or her out-patient office visit. This sample will be retained for genomic      analysis|Both|21 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from patients presenting for sleep disorders at the Weill        Cornell Pulmonary Associates / Cornell Center for Sleep Medicine practices at New        York-Presbyterian Hospital in New York City.|July 2013|July 25, 2013|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859690||142212|
NCT00856141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-036|Set up for in-Vivo Measurement of Dynamic Intraocular Pressure (IOP)|In Vivo Evaluation of Dynamic IOP Measuring Device During Phacoemulsifcation: A Prospective Randomised Clinical Trial||Iladevi Cataract and IOL Research Center|Yes|Completed|January 2006|May 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 4, 2009|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856141||142480|
NCT00859963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.ROWG2 (US 25)|Regenerex Tibial Tray Multi-Center Data Collection|Regenerex Tibial Tray Multi-Center Data Collection||Biomet, Inc.|No|Enrolling by invitation|March 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients|February 2014|July 2, 2015|March 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00859963||142193|
NCT00856115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4208|Differences in Timely Cancer Diagnosis in African American and Caucasian Patients With Newly Diagnosed Colorectal Cancer|Appraisal Delay and Disparities in Timely Cancer Diagnosis||Case Comprehensive Cancer Center|Yes|Completed|November 2008|January 2014|Actual|October 2010|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|84|||Both|21 Years|N/A|No|Probability Sample|African American patients and Caucasian patients with newly diagnosed colorectal cancer.|July 2014|July 14, 2014|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856115||142481|
NCT00856648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-3|SmartPill Monitoring for Assessment of GI Function in SCI|SmartPill Monitoring for Assessment of GI Function in SCI||VA Office of Research and Development|No|Completed|April 2009|December 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|None Retained|No Biospecimens will be collected.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|SCI and able-bodied individuals, 18-75 years of age|May 2012|May 21, 2012|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00856648||142442|
NCT00857311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V520-022|MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection||Merck Sharp & Dohme Corp.|Yes|Completed|May 2004|May 2010|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|17|||Both|18 Years|55 Years|No|||August 2015|August 11, 2015|March 4, 2009|No|Yes||No|June 9, 2011|https://clinicaltrials.gov/show/NCT00857311||142391|An interim analysis of a related study, V520 Protocol 023 (NCT00095576), showed that the MRKAd5 vaccine used in Protocol 022 (NCT00857311) was not efficacious; therefore, only a high level summary of the safety data was performed.
NCT00857324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMP-1|Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients|A Phase I/II, Multi-Center, Open Label Study of Vorinostat Plus Melphalan and Prednisone (ZMP) in Advanced, Refractory Multiple Myeloma Patients||University of Turin, Italy|Yes|Terminated|March 2009|March 2014|Anticipated|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|March 4, 2009||No|The Phase I of the study was completed, but Phase 2 has not been activated|No||https://clinicaltrials.gov/show/NCT00857324||142390|
NCT00857649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10158|Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease|A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type||H. Lundbeck A/S|No|Terminated|December 2003|September 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|369|||Both|50 Years|N/A|No|||November 2013|November 12, 2013|March 5, 2009||No||No|October 26, 2011|https://clinicaltrials.gov/show/NCT00857649||142366|Long recruitment, premature termination, substantial protocol changes; baseline imbalances (concomitant medication and severity of agitation). Variability across sites in reported events frequency (50% of agitation reports from a single site)
NCT00857974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00001451|Physical Activity Program for Older Renal Transplant Candidates|Impact of a Physical Activity Intervention on Physical Function and Quality of Life in Aging Candidates for Renal Transplantation: The PART Study|PART|Wake Forest School of Medicine|No|Active, not recruiting|July 2007|December 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|60 Years|N/A|No|||March 2009|March 6, 2009|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00857974||142341|
NCT00858533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BER10457|Trial of Health at Work Workplace Health Intervention|A Pilot Controlled Feasibility Trial of Early Health at Work Workplace Intervention|H@W|University of Liverpool|Yes|Completed|June 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|63|||Both|18 Years|65 Years|No|||January 2010|July 26, 2010|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858533||142298|
NCT00858858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAST-002-08F|Clinical Studies on Bile Acids in Barrett's Esophagus|Clinical Studies on Bile Acids in Barrett's Esophagus||VA Office of Research and Development|Yes|Completed|March 2009|February 2015|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|March 9, 2009||No||No|November 7, 2014|https://clinicaltrials.gov/show/NCT00858858||142273|
NCT00858871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-033|First Line Hepato Cellular Carcinoma (HCC)|A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma|BRISK FL|Bristol-Myers Squibb|Yes|Completed|May 2009|September 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1714|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00858871||142272|
NCT00859196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13069|Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries|A Randomized, Double-blind, Single Centre, Placebo-controlled Pilot Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Previously Injured Skin by Investigation of Skin Biopsies||Bayer|No|Completed|February 2009|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859196||142247|
NCT00859209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68/08|Capnography in Infants Ventilated With High Frequency Ventilation|Capnography in Infants Ventilated With High Frequency Ventilation: Prospective, Observational, Multi-Center Study||Bnai Zion Medical Center|No|Completed|December 2008|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|N/A|2 Months|No|Non-Probability Sample|Infants in NICU ventilated with HFV|March 2009|August 11, 2015|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859209||142246|
NCT00859521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-116-SA|Levetiracetam 1000 mg Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Levetiracetam 1000 mg Tablet Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|January 2007|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 9, 2009|March 9, 2009|No|Yes||No|July 9, 2009|https://clinicaltrials.gov/show/NCT00859521||142225|
NCT00859495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB9658 (A6)|Trimodal Lung-Sparing Treatment of Pleural Mesothelioma|Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol||Columbia University|Yes|Recruiting|February 2008|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||October 2011|October 28, 2011|March 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00859495||142227|
NCT00859508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SyntheCel|Study of SyntheCelTM Dura Replacement to Other Dura Replacements|A Prospective, Multi-Center, Randomized, Controlled Clinical Study Comparing SyntheCelTM Dura Replacement to Other Dura Replacements in Patients Requiring Dura Repair Following Cranial Surgery||Synthes USA HQ, Inc.||Completed|February 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|75 Years|No|||March 2012|March 6, 2012|March 6, 2009|Yes|Yes||No|February 3, 2012|https://clinicaltrials.gov/show/NCT00859508||142226|
NCT00859781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810010067|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer|A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy||Weill Medical College of Cornell University|Yes|Recruiting|June 2009|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Male|18 Years|N/A|No|||December 2015|December 10, 2015|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859781||142205|
NCT00855348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epigenomics_SPR0006|PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening|PRESEPT Study: Prospective Evaluation of Septin 9 Performance for Colorectal Cancer Screening|PRESEPT|Epigenomics, Inc|Yes|Completed|June 2008|April 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7929|Samples With DNA|Eligible consented Subjects meeting inclusion / exclusion criteria will have 40 ml of blood      drawn prior to undergoing bowel cleansing in preparation for screening colonoscopy. Subject      blood specimens will be processed according to Epigenomics' plasma preparation procedure      (Blood Collection and Plasma Preparation SOP.|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted in Subjects scheduled for screening colonoscopy according to        current U.S. CRC screening guidelines.|August 2014|August 1, 2014|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00855348||142539|
NCT00855686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11018|Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies|A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies||H. Lundbeck A/S|No|Completed|January 2007|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|199|||Both|50 Years|N/A|No|||September 2013|September 19, 2013|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855686||142513|
NCT00856479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infuse Study|A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures|A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures|Infuse|Nova Scotia Health Authority|Yes|Withdrawn|March 2009|March 2013|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2009|May 14, 2015|February 26, 2009||No|Study never started|No||https://clinicaltrials.gov/show/NCT00856479||142455|
NCT00859079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCW-GLP1-1|Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients|Efficacy of a Continuous GLP-1 Infusion in Comparison to a Structured Insulin Infusion Protocol to Reach Normoglycemia in Non-Fasted Type 2 Diabetic Patients||Medical University of Graz|Yes|Completed|June 2006|January 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|No|||March 2009|March 9, 2009|March 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00859079||142256|
NCT00859716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE393-103|ACE393-103 Vaccination Challenge Study|A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of ACE393 to Determine Efficacy Against the Symptoms of Moderate to Severe Campylobacter Jejuni Infection in Normal Healthy Volunteers|ACE393-103VC|TD Vaccines A/S|Yes|Active, not recruiting|October 2008|July 2009|Anticipated|March 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2009|March 10, 2009|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859716||142210|
NCT00859703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.45346|Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer|Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer.|RISAROS|Hospices Civils de Lyon|No|Completed|November 2009|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||October 2013|October 30, 2013|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859703||142211|
NCT00855296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050182|Thrombin Regulated Platelet Activation|Thrombin Regulated Platelet Activation||Vanderbilt University|Yes|Recruiting|September 2006|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing angioplasty|June 2011|June 29, 2011|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855296||142543|
NCT00856154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT2006-000102-22|Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection|Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection. Phase I Trial|HIVDCVac|Statens Serum Institut|Yes|Completed|January 2007|October 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|50 Years|No|||March 2009|April 7, 2009|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00856154||142479|
NCT00856167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0289-01|Traditional Chinese Medicine (TCM) for Temporomandibular Dysfunction (TMD): A Whole Systems Multi-site Trial|TCM for TMD: A Multi-Site Whole Systems Trial|TCM-TMD|University of Arizona|Yes|Completed|September 2006|December 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|70 Years|No|||May 2015|May 26, 2015|March 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856167||142478|
NCT00856102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2008:318|Exercise and Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy|Efficacy of Exercise in Promotion Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy||University of Manitoba|Yes|Completed|March 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|50 Years|N/A|No|||January 2011|January 31, 2011|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00856102||142482|
NCT00856674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPL01-CCL2|Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy|A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy||Osprey Pharmaceuticals USA, Inc.|No|Terminated|March 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2010|June 1, 2010|March 4, 2009||No|Study terminated due to resources and slow enrollment; not due to safety|No||https://clinicaltrials.gov/show/NCT00856674||142440|
NCT00856414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-BTX-0806|Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines|||Allergan||Completed|March 2009|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|35 Years|55 Years|No|||November 2011|November 8, 2011|March 4, 2009||No||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00856414||142459|
NCT00857987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GADEMS0109|Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections.|Randomized , Placebo-controlled, Clinical Trial of Efficacy and Safety Evaluation of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improving the Signs and Symptoms of Infections of Way Upper (URI)||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Recruiting|April 2010|December 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|174|||Both|12 Years|N/A|No|||January 2011|January 27, 2011|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00857987||142340|
NCT00858273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF 1-2006-627-B|Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B|Regulation of Glutathione Homeostasis in Adolescents With Type 1 Diabetes - Study B||Nemours Children's Clinic|No|Completed|March 2008|August 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|12 Years|21 Years|No|||May 2012|May 2, 2012|March 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00858273||142318|
NCT00858546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6874-OC-CTIL|The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease|The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease||Sheba Medical Center|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|40 Years|N/A|No|||October 2009|October 15, 2009|March 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00858546||142297|
NCT00858884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC# 06-117|Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus|Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus||University of New Mexico|No|Completed|August 2006|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|68|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00858884||142271|
NCT00855426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF03-HMO-CTIL|Diagnostic Protocol Of Painful Hip|||Hadassah Medical Organization|No|Suspended||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|40 Years|85 Years|No|Non-Probability Sample|patients that are admitted to the ER after trauma.|October 2010|November 28, 2010|March 3, 2009||No|the research is on susoension beacause the lack of manpower|No||https://clinicaltrials.gov/show/NCT00855426||142533|
NCT00859534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV016|Phase II Solar Urticaria (SU) Pilot Study|A Phase II, Open Label Pilot Study to Evaluate the Safety and Efficacy of A Bioresorbable Subcutaneous Implant of CUV1647 in Patients With Solar Urticaria (SU)||Clinuvel Pharmaceuticals Limited|No|Completed|December 2008|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 13, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00859534||142224|
NCT00859794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0258|An Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy|An Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy Using Electrophysiology, Cortical Mapping, and fMRI||Northwell Health|Yes|Enrolling by invitation|November 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|5 Years|N/A|No|Non-Probability Sample|Subjects who are excellent candidates for resective surgery selected on the basis of        intractability of their seizures to medical intervention by antiepileptic drugs and        following a noninvasive workup.|November 2015|November 12, 2015|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00859794||142204|
NCT00859807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0731001|A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects|A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects||Pfizer|No|Completed|May 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 20, 2010|March 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00859807||142203|
NCT00855387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 5-2009|Severe Complications Triplicate the Costs of Major Surgical Procedures|Surgical Complications Dramatically Influence Overall Cost of Major Surgical Procedures||University of Zurich|No|Completed|March 2009|November 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1235|||Both|12 Years|90 Years|No|Non-Probability Sample|A cohort study with 1235 patients including consecutive patients undergoing major surgery        (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) in a        single tertiary care center|November 2009|November 25, 2009|March 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00855387||142536|
NCT00855361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014824|A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)|A Pharmacokinetic, Pharmacodynamic and Short-term Safety Study of Single and Multiple Day Doses of Rabeprazole Sodium in Neonates and Pre-term Infants With a Corrected Age of Less Than 44 Weeks With a Presumptive Diagnosis of GERD||Janssen Research & Development, LLC||Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|N/A|44 Weeks|No|||April 2013|April 26, 2013|March 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00855361||142538|
NCT00855374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070474|PAR Regulation of Platelet Function in Diabetic Patients|PAR Regulation of Platelet Function in Diabetic Patients||Vanderbilt University|Yes|Recruiting|June 2008|June 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Diabetic patients in the Vanderbilt General Clinical Research Center|June 2011|June 29, 2011|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00855374||142537|
NCT00856752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-04A/2005 (IN-A)|Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine|A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part A: Interaction With Rifampicin and Cyclosporine||Norgine|No|Completed|June 2006|August 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|12|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||March 2009|March 5, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00856752||142434|
NCT00856492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636131|S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer|A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|April 2010|December 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Female|18 Years|N/A|No|||May 2015|May 8, 2015|March 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00856492||142454|
NCT00856778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP001SU|Virtue® Male Incontinence Sling Study|Virtue® Male Incontinence Sling Study||Coloplast A/S|Yes|Completed|January 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Male|18 Years|N/A|No|||April 2014|April 11, 2014|March 5, 2009|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT00856778||142432|
NCT00858754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200K1-4006|Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects|A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain||Valeant Pharmaceuticals International, Inc.|No|Withdrawn|March 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|90 Years|No|||July 2011|July 22, 2011|March 9, 2009|Yes|Yes|Withdrawn [This study was terminated early by Wyeth, prior to dosing any subjects, for    business reasons not related to safety.|No||https://clinicaltrials.gov/show/NCT00858754||142281|
NCT00859092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-12-FB-0305|Promotion of Thickened Feeds to Manage Newborns With Feeding Difficulties|Promotion of Thickened Feeds to Manage Newborns With Feeding Difficulties||Eastern Virginia Medical School|No|Completed|March 2008|September 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|N/A|3 Months|No|||March 2012|March 7, 2012|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00859092||142255|
NCT00855608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHUH|Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study|The Safety and Tolerability of Intravitreal Adalimumab in Patients With Refractory Diabetic Macular Retinopathy or Choroidal Neovascularization or Uveitis: A Pilot Study|ADA01|Rafic Hariri University Hospital|Yes|Recruiting|March 2009|March 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|17 Years|88 Years|No|||September 2009|July 20, 2011|March 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00855608||142519|
NCT00855309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633817|Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia|Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|November 2008|||November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|112|||Both|18 Years|120 Years|No|||September 2014|October 22, 2015|March 3, 2009|Yes|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT00855309||142542|per the protocol, only nephrotoxicities (as measured by Creatinine increase over baseline were observed.
NCT00855881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|376|Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma|A Trial of Metronomic Chemotherapy With Tegafur/Uracil for Patients With Locally Advanced (Stage III~IVB) Head and Neck Squamous Cell Carcinoma (HNSCC)||Mackay Memorial Hospital|Yes|Recruiting|December 2008|December 2016|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|20 Years|N/A|No|||August 2010|July 25, 2011|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00855881||142499|
NCT00855894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOC4603g|A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer|An Open-label Phase II Multicenter Study of the Safety and Activity (as Measured by FDG-PET Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer|PENGUIN|Genentech, Inc.||Completed|March 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|March 4, 2009|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00855894||142498|
NCT00857038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-046|Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)|Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.||Medical Center Alkmaar|No|Not yet recruiting|April 2009|January 2010|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|41 Years|N/A|No|||March 2009|March 5, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857038||142412|
NCT00857025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07243|Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase I Study of MM-10-001 In Advanced Non Small Lung Cancer||City of Hope Medical Center|Yes|Active, not recruiting|November 2008|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00857025||142413|
NCT00857675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADF30001|A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B|A Multi-Centre, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients With HBeAg Positive Chronic Hepatitis B Followed by Long-Term (5 Years Total) Adefovir Dipivoxil Treatment. (Report on Year 1 and Year 2 Data)||GlaxoSmithKline||Completed|December 2002|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|65 Years|No|||April 2009|April 2, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00857675||142364|
NCT00858000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111722|Analysis of Expression of Specific Markers in Hepatocellular Carcinoma|Analysis of the Incidence of Expression of a Specific Set of Genes and of Tumor Antigens in Cancer Tissue From Patients With Hepatocellular Carcinoma||GlaxoSmithKline||Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|None Retained|This retrospective study is based upon the analysis of archived samples and patient-related      data already available at the investigational site|Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic|December 2009|December 23, 2009|March 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00858000||142339|
NCT00866307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL08P1|Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)|Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study||Children's Oncology Group||Active, not recruiting|February 2009|||March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|1 Year|30 Years|No|||April 2015|April 10, 2015|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866307||141711|
NCT00866320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11805|Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab|A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy||Case Comprehensive Cancer Center|Yes|Completed|February 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|March 19, 2009|Yes|Yes||No|December 27, 2011|https://clinicaltrials.gov/show/NCT00866320||141710|
NCT00866333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0501|A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma|A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma||Syndax Pharmaceuticals|No|Active, not recruiting|March 2009|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866333||141709|
NCT00866944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT201-204|Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases|A Randomized, Open-label, Controlled, Multi-center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases|MT201-204|Amgen Research (Munich) GmbH|Yes|Completed|March 2009|November 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||November 2011|November 10, 2011|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00866944||141664|
NCT00866957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU8344 1530-004|Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)|Human Liver Explants for HIF-1 Alpha- Analysis/Comparison||Northwestern University|No|Recruiting|February 2006|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Both, samples with DNA and without: serum, plasma, genomic samples, & liver biopsy specimens|Both|18 Years|N/A|No|Non-Probability Sample|Subject must have hepatocellular carcinoma, or had hepatocellular carcinoma|January 2016|January 21, 2016|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866957||141663|
NCT00867581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30725019-2|Magnetic Resonance Imaging (MRI) Study of the Hippocampus After Infarction in the Territory of the Middle Cerebral Artery|To Observe Delayed Neuronal Death of Hippocampus After Middle Cerebral Artery Infarction Through Magnetic Resonance Imaging(MRI) Volume Measurement and Magnetic Resonance Spectroscopy(MRS) Study of Hippocampus||Huazhong University of Science and Technology|Yes|Recruiting|September 2008|||July 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|chronic-stage patients of unilateral middle cerebral artery infarction|March 2009|March 23, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867581||141616|
NCT00867867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-009|Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries|The Usefulness of Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|October 2003|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|235|||Both|9 Months|24 Months|Accepts Healthy Volunteers|||March 2009|July 13, 2013|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867867||141594|
NCT00867880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-011|Pharmacokinetic Study Of Ibuprofen Injection (IVIb) In Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Crossover Study of the Pharmacokinetics, Safety and Tolerability of Ibuprofen Inejction (IVIb) In Healthy Adult Volunteers||Cumberland Pharmaceuticals|Yes|Completed|March 2009|June 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867880||141593|
NCT00868972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMPF-01|Renal Stenting With Distal Atheroembolic Protection|Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection||Universita di Verona|No|Recruiting|March 2009|September 2011|Anticipated|March 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2010|January 22, 2010|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868972||141510|
NCT00868985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-01/2007(ELE)|Effects of Oral PEG 3350 on Electrolyte Balance|Effects of Oral PEG 3350 on the Electrolyte Balance in Patient Volunteers With Chronic Constipation:Pharmacokinetic Evaluation||Norgine|No|Completed|January 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868985||141509|
NCT00868998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB3329|GTX Regimen for Biliary Cancers|Phase II Study of the Gemzar, Taxotere and Xeloda Regimen (GTX) for Inoperable or Metastatic Adenocarcinoma of the Biliary System||Columbia University|Yes|Terminated|August 2005|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|March 23, 2009|Yes|Yes|Poor patient accrual|No||https://clinicaltrials.gov/show/NCT00868998||141508|
NCT00867906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP003|Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma|A Double-blind, Randomised, Placebo-controlled Study to Assess the Safety of Cat-PAD in Cat Allergic Subjects With Controlled Asthma||Circassia Limited|No|Completed|March 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|65 Years|No|||May 2010|May 5, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00867906||141591|
NCT00900601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUS nr: 28125409|Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma|Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma - A Study to Measure Effect of Surgery, Analysis of Clinical Tests and Detection of Sacroiliac Instability Using RSA.||Oslo University Hospital|Yes|Completed|January 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||August 2011|August 8, 2011|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900601||139142|
NCT00900614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR-246-01|Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer|An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma||Aprea AB|Yes|Completed|May 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900614||139141|
NCT00891943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phpepw71|A Trial of One to One Weight Management in Primary Care|A Randomised Controlled Trial of a One to One Weight Management Intervention in Primary Care||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|June 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 8, 2010|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891943||139767|
NCT00899821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000280490|Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer|Head And Neck Cancer Immunotherapy Using Biodegradable Microspheres||New York University School of Medicine||Completed|June 2000|||December 2004|Actual|N/A|Interventional|N/A|||||||Both|20 Years|80 Years|No|||December 2008|November 8, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899821||139197|
NCT00869271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01|Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer|Postoperative folfox4 Only vs folfox4 Plus TAC in the Treatment Unresectable Liver Metastasis of Colorectal Cancer: a Randomized,Prospective,Control Trial||Fudan University|No|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869271||141487|
NCT00869284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS 073|Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas|Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas|073|French Innovative Leukemia Organisation|Yes|Completed|October 1994|February 2009|Actual|July 1999|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|15 Years|60 Years|No|||March 2009|March 24, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00869284||141486|
NCT00869297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:135|Goal Directed Fluid Therapy in Free Flap Patients|Goal Directed Fluid Therapy for Microvascular Free Flap Reconstruction Following Mastectomy: A Pilot Study||University of Manitoba|No|Completed|March 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|80 Years|No|||April 2011|April 18, 2011|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869297||141485|
NCT00869245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008247|Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain|Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain||Wake Forest Baptist Health|No|Completed|March 2009|October 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|124|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869245||141489|
NCT00865046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6614-R|Periosteal Stimulation for Knee Osteoarthritis|Efficacy of Periosteal Stimulation and Boosters for Advanced Knee OA Pain|PST|VA Office of Research and Development|No|Completed|November 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|190|||Both|50 Years|89 Years|No|||January 2015|January 22, 2015|March 17, 2009||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT00865046||141807|
NCT00865774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006734|The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients|The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients|TM|Wake Forest Baptist Health|No|Completed|January 2009|December 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|333|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865774||141751|
NCT00866697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110655|Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||GlaxoSmithKline|Yes|Active, not recruiting|May 2009|November 2017|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|940|||Female|18 Years|N/A|No|||February 2015|February 5, 2015|March 19, 2009|Yes|Yes||No|July 3, 2013|https://clinicaltrials.gov/show/NCT00866697||141682|
NCT00865722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RemPostConditioning|Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI)|Pilot Study to Test Feasibility, Safety, Molecular Mediators and Preliminary Efficacy of Remote Myocardial Postconditioning Provided With Extrinsic Cuff Compression of Lower Limb During Primary PCI|RemPostCon|IRCCS Policlinico S. Matteo|No|Completed|March 2009|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|80 Years|No|||August 2012|August 16, 2012|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865722||141755|
NCT00865735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001Ver4|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 1993|||||N/A|N/A|N/A||||||||||||||April 16, 2012|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865735||141754|
NCT00866346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0564|PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation|A Phase I Study of PR1-Specific Cytotoxic T-Lymphocyte Infusion for Patients With Recurrent CML After Allogeneic Hematopoietic Transplantation||M.D. Anderson Cancer Center|No|Withdrawn|March 2008|||March 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||March 2014|March 3, 2014|March 18, 2009|No|Yes|Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell    production.|No||https://clinicaltrials.gov/show/NCT00866346||141708|
NCT00866684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROSKIN 01|Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|PROSKIN|Charite University, Berlin, Germany|No|Terminated|January 2007|July 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|March 19, 2009||No|Insufficient patient recruitment|No||https://clinicaltrials.gov/show/NCT00866684||141683|
NCT00868465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANSACT09|Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)||TRANSACT|Radboud University|Yes|Completed|April 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|6 Months|10 Years|No|||April 2009|June 4, 2010|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868465||141549|
NCT00867282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0871003|A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers.|B0871003|Pfizer|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 27, 2009|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867282||141639|
NCT00867295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/22|Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device|A Randomized, Double-blind, Placebo-controlled Trial to Determine Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device.|TIVAD|Istanbul University|Yes|Completed|September 2008|March 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||March 2009|June 1, 2010|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867295||141638|
NCT00899600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100674|Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain|Intra-operative Ketamine Infusions in Patients With Chronic Lower Back Discomfort Undergoing Laminectomies.||Dartmouth-Hitchcock Medical Center|Yes|Completed|February 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|May 8, 2009||No||No|November 27, 2012|https://clinicaltrials.gov/show/NCT00899600||139213|
NCT00869310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGAR-01-2009|Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis|Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial||S. Maria Hospital, Terni|No|Terminated|September 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|March 24, 2009||No|we terminated the study before enrolling 303/560 due to a slow accrual|No||https://clinicaltrials.gov/show/NCT00869310||141484|
NCT00891956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909132|The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome|The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome||National Institutes of Health Clinical Center (CC)||Completed|April 2009|January 2016||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891956||139766|
NCT00892216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-188|Does Acupressure Decrease Post-operative Nausea and Vomiting (PONV) After the Pectus Excavatum Correction (NUSS) Procedure?|Does Acupressure Decrease Post-operative Nausea and Vomiting After the NUSS Procedure?||McMaster University|No|Terminated|April 2005|October 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|8 Years|40 Years|No|||April 2015|April 7, 2015|April 30, 2009||No|Not enough participants for study to be completed|No||https://clinicaltrials.gov/show/NCT00892216||139748|
NCT00892229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS - 1769|Buccal Versus Vaginal Misoprostol in Surgical Termination of the First Trimester Missed Abortion in Erbil|Buccal Versus Vaginal Misoprostol for Cervical Ripening Prior to Surgical Termination of the First Trimester Missed Abortion in Erbil||Hawler Medical University|No|Completed|March 2007|March 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Female|19 Years|35 Years|Accepts Healthy Volunteers|||May 2009|May 1, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892229||139747|
NCT00869531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B223|Effect of Wholegrain Wheat on Body Weight and Composition and Cardiovascular Risk|Healthgrain WP 4.4.3: Effects of Whole Grain on Weight Maintenance/Weight Reduction in Overweight Subjects|HEALTHGRAIN|University of Copenhagen|No|Completed|August 2007|December 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||March 2009|March 25, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869531||141467|
NCT00865436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-0248|A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|April 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865436||141777|
NCT00869518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08033578|Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults|Randomized, Double-Blinded Evaluation of Rifabutin Based Therapy for Eradication of Staphylococcus Aureus Carriage in HIV Infected Individuals With Prior Skin and Skin Structure Infections||University of California, San Francisco|No|Terminated|July 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|March 24, 2009||No|Poor enrollment|No|March 13, 2014|https://clinicaltrials.gov/show/NCT00869518||141468|
NCT00865059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-080|A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|February 2001|March 2001|Actual|February 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865059||141806|
NCT00865397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3699|Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment|Observational Study of Glycaemic Control in Type 2 Diabetic Patients Uncontrolled on Oral Antidiabetic Agents and Starting With Once Daily Levemir® (Insulin Detemir) - 24 Weeks, Prospective, Multicentre Observational Study in Hungary|HA-BOT|Novo Nordisk A/S|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1032|||Both|18 Years|N/A|No|Non-Probability Sample|A non-randomised sample of approximately 1000 subjects with OAD failure from specialists -        diabetologists practice who have been deemed appropriate to receive insulin detemir as        add-on to OAD therapy as part of routine out-patient care by the prescribing physician.|March 2012|June 28, 2012|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00865397||141780|
NCT00865410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0646-009|A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Extended-Released Tablets Formulation in Fasted, Normal, Healthy Subjects.||Actavis Inc.|No|Completed|August 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865410||141779|
NCT00898014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574195|Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer|Study Evaluating the Prognostic and Predictive Value of Response to First-Line Chemotherapy by Detection of Circulating Tumor Cells (CTC) in Patients With Metastatic Breast Cancer||National Cancer Institute (NCI)||Completed|May 2007|||April 2010|Actual|N/A|Observational|N/A|||Anticipated|216|||Both|N/A|N/A|No|||July 2009|May 12, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898014||139321|
NCT00865345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 218|An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance|An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance|6-DayFU|Medtronic Diabetes|Yes|Completed|March 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|75 Years|No|||November 2012|November 5, 2012|March 18, 2009|Yes|Yes||No|April 19, 2011|https://clinicaltrials.gov/show/NCT00865345||141784|
NCT00865358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT002915|Yoga for Chronic Low Back Pain|Yoga for Chronic Low Back Pain in a Predominantly Minority Population: A Pilot Randomized Controlled Trial||Boston Medical Center|No|Completed|February 2007|January 2008|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|64 Years|No|||December 2012|December 4, 2012|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00865358||141783|
NCT00867308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0882|Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Trilineage Dysplasia (AML-TLD)|Protocol Title: Phase II Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (AML-TLD)||Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|March 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|March 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867308||141637|
NCT00867321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0745|Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer|Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma||Alliance for Clinical Trials in Oncology|Yes|Completed|April 2009|May 2013|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867321||141636|
NCT00867919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH076966|Designing and Testing a Family Therapy for Adolescent Depression|Family Therapy for Adolescent Depression: Deployment Focused Development, Phase 1||Oregon Research Institute|No|Completed|April 2009|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|14 Years|18 Years|No|||April 2013|April 16, 2013|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867919||141590|
NCT00868166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO19622 CL E Q 1015-1|Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)|Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole|MITOTARGET|Trophos|Yes|Completed|April 2009|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|512|||Both|18 Years|80 Years|No|||March 2012|March 27, 2012|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868166||141571|
NCT00868738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24134|Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Children|Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Healthy Children 4 to 8 Years of Age||Baylor College of Medicine|No|Completed|March 2009|October 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||November 2011|November 1, 2011|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868738||141528|
NCT00900120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592848|Collecting and Storing Blood Samples From Patients With Cancer|Banking DNA for Analysis of Genetic Polymorphisms in Patients With Cancer||Rutgers, The State University of New Jersey|No|Withdrawn|March 2004|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Patients seen at CINJ who have a diagnosis of cancer and plan to be treated at CINJ will        be asked to participate in this DNA banking resource|December 2011|December 8, 2011|May 9, 2009||No|Will be replaced by honest broker program|No||https://clinicaltrials.gov/show/NCT00900120||139177|
NCT00899834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBTP02-SJ|DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma|Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study||St. Jude Children's Research Hospital|No|Recruiting|June 2006|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|tumor and constitutional tissue samples from patients with diffuse brainstem glioma and      other types of brainstem gliomas|Both|N/A|18 Years|No|Non-Probability Sample|Fresh-frozen and fixed tumor samples and correspondent normal tissue from patients        affected with this tumor (peripheral blood is applicable only to patients with focal        brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at        diagnosis)|October 2015|October 29, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899834||139196|
NCT00900107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMW 02|Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals|Time Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals.||University of Leipzig|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2009|May 11, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00900107||139178|
NCT00900328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150607|Study of Tumor Samples From Patients With Lung Cancer|A Pilot Project to Study the Expression of c-MET and p53 in Resected Lung Adenocarcinoma Specimens||Alliance for Clinical Trials in Oncology|No|Recruiting|September 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|280|Samples With DNA|Tissue, serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-small cell lung adenocarcinoma enrolled on CALCB 140202|July 2015|July 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900328||139162|
NCT00900341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0509-04|Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma|LABORATORY STUDIES OF SOFT TISSUE SARCOMAS||University of Arizona||Completed|August 2005|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|N/A|N/A|No|Probability Sample|Patients undergoing surgical treatment for soft tissue sarcomas removal or core needle        biopsy for medically indicated diagnostic or therapeutic purposes.|March 2014|March 20, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900341||139161|
NCT00887627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-094|Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function|A Phase 1, Open-Label Study to Assess the Effects of Renal Impairment on the Pharmacokinetics of Intravenous Conivaptan||Cumberland Pharmaceuticals|No|Completed|April 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|25|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00887627||140094|
NCT00887640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016256|Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer|Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer||Duke University|Yes|Terminated|July 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|18 Years|N/A|No|||January 2013|January 24, 2014|April 23, 2009|Yes|Yes||No|September 4, 2013|https://clinicaltrials.gov/show/NCT00887640||140093|
NCT00892242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0589 / 201109094|Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer|Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer||Washington University School of Medicine|Yes|Terminated|December 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|May 1, 2009|Yes|Yes|Principal Investigator decided to close the study early.|No||https://clinicaltrials.gov/show/NCT00892242||139746|
NCT00865449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-590|Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis|Role of Renin Angiotensin Blockade in Peritoneal Fibrosis in Peritoneal Dialysis Patients||Instituto Nacional de Cardiologia Ignacio Chavez|No|Completed|July 2008|March 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||March 2009|October 23, 2012|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865449||141776|
NCT00865072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-372|A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 750 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|August 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865072||141805|
NCT00865085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-P2-259|A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting Conditions|Single Dose Crossover Comparative Bioavailability Study of Citalopram 40 mg Tablets in Healthy Male Volunteers/Fasting State||Actavis Inc.|No|Completed|June 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865085||141804|
NCT00897793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC RAD 0576|Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer|A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury||Vanderbilt-Ingram Cancer Center|No|Completed|January 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples With DNA|venous blood|Both|18 Years|N/A|No|Probability Sample|People who have epithelial cancers and who will undergo radiation therapy|April 2013|April 10, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897793||139337|
NCT00867646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080418R|Comparison Study of CoaguChek XS PT and Laboratory Innovin PT by NTUH Lab Medicine|Comparison Study of CoaguChek XS Prothrombin Time and Laboratory Innovin PT by NTUH Lab Medicine||National Taiwan University Hospital|Yes|Completed|May 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|75 Years|No|Non-Probability Sample|70 Warfarin teated patients|December 2009|December 14, 2009|August 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00867646||141611|
NCT00866073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00331|Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia|Phase II Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia Who Are Not Eligible for Standard Induction Chemotherapy||University Hospital Freiburg|No|Completed|April 2003|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|238|||Both|60 Years|N/A|No|||March 2009|March 19, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866073||141729|
NCT00866398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008|Economic Evaluation German Drug-Eluting Stent Registry|Economic Evaluation German Drug-Eluting Stent Registry||Charite University, Berlin, Germany|No|Completed|December 2005|March 2008|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3973|||Both|N/A|N/A|No|Non-Probability Sample|Patients with coronary heart disease, eligible for stent implantation.|January 2011|January 14, 2011|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866398||141705|
NCT00898274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11807|Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants|Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer||Case Comprehensive Cancer Center|Yes|Completed|January 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples With DNA|Blood samples from patients at high risk of developing prostate cancer and from healthy male      participants.|Male|45 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Primary Care Clinic|March 2016|March 8, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898274||139304|
NCT00898287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/28/08|Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer|A Phase I/II Study to Evaluate Safety and Efficacy of P276-00 in Combination With Gemcitabine in Patients With Cancer of Pancreas|SAVIOR|Piramal Enterprises Limited|Yes|Completed|May 2009|||December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00898287||139303|
NCT00866710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-38941|Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease|Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease|BETTUR PD|Atlanta VA Medical Center|No|Completed|October 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|50 Years|N/A|No|||January 2012|January 10, 2012|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866710||141681|
NCT00866060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/123|Donepezil and Memantine in Moderate to Severe Alzheimer's Disease|Donepezil and Memantine in Moderate to Severe Alzheimer's Disease|DOMINO-AD|King's College London|Yes|Recruiting|February 2008|June 2013|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|800|||Both|N/A|N/A|No|||March 2009|March 19, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866060||141730|
NCT00898794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSGR-GR-01-07|Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer|Influence of Bevacizumab and VEGF on Platelet Aggregation||National Cancer Institute (NCI)||Recruiting|October 2007|||May 2009|Anticipated|N/A|Observational|N/A|||Anticipated|20|||Both|N/A|N/A|No|||June 2011|August 6, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898794||139269|
NCT00898807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0155|Citalopram for Agitation in Alzheimer's Disease|A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease|CitAD|JHSPH Center for Clinical Trials|Yes|Completed|July 2009|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|N/A|N/A|No|||June 2014|June 26, 2014|May 11, 2009||No||No|March 19, 2014|https://clinicaltrials.gov/show/NCT00898807||139268|
NCT00899340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0624|Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx|Protein Expression Profiles in Oropharyngeal Squamous Cell Carcinoma||Vanderbilt-Ingram Cancer Center|Yes|Completed|May 2006|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|54|||Both|N/A|N/A|No|Probability Sample|community sample|March 2013|March 29, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899340||139232|
NCT00899028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584223|Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants|Identification and Validation of Molecular Markers in Lung Cancer||National Cancer Institute (NCI)||Recruiting|May 2001|||May 2011|Anticipated|N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|August 11, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899028||139251|
NCT00899041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-FK-08/02|Functional Evaluation of a Standard and a High-flexion Knee Prosthesis Using Thigh-calf Contact Force Measurements|In-vivo Study Investigating the Difference in Functional Outcome Between Two Types of Knee Prostheses: the Sigma FB (Depuy, J&J, UK; Standard Implant) and the Sigma RP-F (Depuy, J&J, UK; High-flexion Implant)||Radboud University||Completed|October 2008|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|67|||Both|N/A|N/A|No|||December 2011|November 7, 2013|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00899041||139250|
NCT00899054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/31/08|Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer|An Open Label, Multicenter Phase I/II Study Of Selective Cyclin Dependent Kinase Inhibitor P276-00 In Combination With Radiation In Subjects With Recurrent And/Or Locally Advanced Squamous Cell Carcinoma Of Head And Neck|SPARK|Piramal Enterprises Limited|Yes|Completed|August 2009|November 2012|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00899054||139249|
NCT00899327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595855|Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants|Molecular and Functional Characterisation of Bone Marrow Function in Normal Subjects, Myelodysplastic Syndromes (MDS) and Secondary Disorders of Heamatopoiesis||National Cancer Institute (NCI)||Recruiting|January 2007|||December 2011|Anticipated|N/A|Observational|N/A|||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 7, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899327||139233|
NCT00865488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-GYN-002|Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery|A Prospective, Controlled, Randomized, Multi-Center, Pivotal Study Evaluating the Safety and Efficacy of AdhexilTM in Prevention And/Or Reduction of Adhesions in Gynecology Surgery||OMRIX Biopharmaceuticals|Yes|Suspended|May 2009|April 2010|Anticipated|February 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|45 Years|No|||December 2009|December 20, 2009|March 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865488||141773|
NCT00865501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFO-TP5-I|Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease|Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease||University of Erlangen-Nürnberg Medical School|Yes|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|40 Years|No|||July 2012|July 6, 2012|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865501||141772|
NCT00865839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-593|A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|March 2002|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865839||141747|
NCT00865852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-373|A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 750 mg Metformin Hydrochloride Extended Release Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|August 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865852||141746|
NCT00866099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS No: 49287|Dementia Early Recognition and Response in Primary Care|Evidence-based Interventions In Dementia EVIDEM-ED: Early Recognition and Response in Primary Care|EVIDEM-ED|University College, London|Yes|Recruiting|July 2009|September 2012|Anticipated|May 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|125|||Both|N/A|N/A|No|||March 2009|April 16, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866099||141727|
NCT00900640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCP Contrast 144-09|Reactions to Contrast Media (CM) Administered at the Time of the Endoscopic Retrograde Cholangiopancreatography (ERCP)|Reactions to Contrast Media (CM) Administered at the Time of Endoscopic Retrograde Cholangiopancreatography (ERCP)||University of Florida|No|Recruiting|May 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|780|||Both|18 Years|N/A|No|Probability Sample|All patients who medically need an ERCP to further evaluate or treat their medical        condition.|March 2016|March 9, 2016|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900640||139139|
NCT00887978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-308|Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension|A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension|FREEDOM-C2|United Therapeutics|Yes|Completed|June 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|75 Years|No|||December 2012|December 7, 2012|April 23, 2009|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT00887978||140068|
NCT00897312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL0651|Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease|Title: Evaluation of Systemic IDO Levels After Various Immunotherapeutics||Vanderbilt-Ingram Cancer Center|Yes|Completed|August 2006|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|Samples Without DNA|-  Serum/plasma samples will be collected from patients being treated for untreated acute           and chronic Hepatitis C with pegylated IFN-α and ribavirin        -  Serum/plasma samples will be collected from patients being treated for metastatic           melanoma with CYP-206,675        -  Serum/plasma samples previously collected|Both|N/A|N/A|No|Probability Sample|patients with Hepatitis C; Anti-TNF in patients with active inflammatory bowel        disease(IBD); anti-CTLA Ig in patients with metastatic melanoma|April 2011|April 6, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897312||139370|
NCT00865787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002656|Effects of EGCG-Enhanced Extra Virgin Olive Oil on Endothelial Function|Effects of EGCG-Enhanced Extra Virgin Olive Oil on Endothelial Function||Mayo Clinic|No|Completed|February 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|83|Samples Without DNA|blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mayo Clinic Patients|August 2011|August 10, 2011|February 29, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00865787||141750|
NCT00865813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1143/07|Biopsy Incisional With Trepan in Periocular Lesions|Biopsy Incisional With Trepan in Periocular Lesions||University of Sao Paulo|No|Active, not recruiting|December 2008|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865813||141749|
NCT00867659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRM2|The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors|The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome in Oocyte Donors||Virginia Center for Reproductive Medicine|Yes|Completed|March 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Female|19 Years|32 Years|No|||March 2013|March 26, 2013|March 21, 2009||No||No|December 27, 2012|https://clinicaltrials.gov/show/NCT00867659||141610|Only 20 donors were recruited because this was a pilot study to assess the benefit of Cetrotide acetate in oocyte donors in the prevention of ovarian hyperstimulation syndrome.
NCT00867672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00332/AMLSG14-09|Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia|Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy|DECIDER|University Hospital Freiburg|Yes|Recruiting|August 2011|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|60 Years|N/A|No|||August 2014|August 27, 2014|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867672||141609|
NCT00898027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0615|Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer|Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on Magnesium Homeostasis||Vanderbilt-Ingram Cancer Center|Yes|Terminated|May 2006|February 2009|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Probability Sample|Individuals with the diagnosis of a malignancy for which they are considering therapy with        an inhibitor of the EGFR pathway, have received an inhibitor of the EGFR pathway prior to        study start, have no severe underlying renal dysfunction as defined as estimated GFR<60 by        MDRD equation and must be ≥ 18 years of age.|January 2013|January 28, 2013|May 9, 2009||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00898027||139320|
NCT00868192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0508 / 201102272|Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma|Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma||Washington University School of Medicine|Yes|Completed|May 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Female|18 Years|N/A|No|||October 2014|October 10, 2014|March 18, 2009|Yes|Yes||No|October 2, 2014|https://clinicaltrials.gov/show/NCT00868192||141569|
NCT00868491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR-62202-717|Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer|Induction Chemotherapy Followed by Chemoradiation With Cetuximab and Cisplatin for Inoperable Squamous Cell Carcinoma of the Head and Neck||Institute of Oncology Ljubljana|Yes|Completed|March 2008|October 2011|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2011|October 23, 2011|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868491||141547|
NCT00898261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000526268|Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia|Genetic Risk Classes in Adult Acute Lymphocytic Leukemia||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|137|||Both|15 Years|65 Years|No|||June 2007|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898261||139305|
NCT00866970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD518-CLIN-004|Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia|A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia||Alder Biopharmaceuticals, Inc.|Yes|Completed|September 2008|December 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|124|||Both|18 Years|N/A|No|||September 2010|September 10, 2010|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00866970||141662|
NCT00899080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600320|Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide|Screening of Cathepsin G Levels in Multiple Myeloma Patients Receiving Treatment With Thalidomide/Lenalidomide Within the ECOG Trials E1A00 and E4A03||National Cancer Institute (NCI)||Not yet recruiting|August 2008|||September 2008|Anticipated|N/A|Observational|N/A|||||||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|September 3, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899080||139248|
NCT00869349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001762|Living Well With Rheumatoid Arthritis|Brigham Rheumatoid Arthritis Sequential Study B.R.A.S.S.||Brigham and Women's Hospital|No|Active, not recruiting|September 2008|December 2014|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|100|||Both|18 Years|81 Years|No|||February 2013|February 4, 2013|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869349||141481|
NCT00899613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000564050|Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia|Study Aiming at Researching Diagnostic Markers for the Recognition of Precancerous States, Tracking, Follow-up, and the Identification of New Therapeutic Targets for Mesothelioma in Patients With Atypical Mesothelial Hyperplasia.||National Cancer Institute (NCI)||Recruiting|April 2007|||January 2010|Anticipated|N/A|Observational|N/A|||Anticipated|270|||Both|N/A|N/A|No|||July 2009|December 13, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899613||139212|
NCT00899847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT201|Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG|A Phase II Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients||Stanford University||Active, not recruiting|May 2009|November 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|75 Years|No|||October 2013|October 29, 2013|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00899847||139195|
NCT00865163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASER Registry|LASER: Real Life Antithrombotic Stent Evaluation Registry|LASER: Real Life Antithrombotic Stent Evaluation Registry|LASER|Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|November 2008|||November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with significant symptomatic coronary artery disease who for this reason undergo        PCI with implantation of one or more drug eluting stent(s) (DES) or bare metal stent(s)        and requiring Vitamin K Antagonist based full anticoagulation therapy (target INR 2-4,5)        for any clinical indication.        The LASER Registry will collect the data of 1000 patients with the need for oral        anticoagulation and 1000 matched control patients without the need for oral        anticoagulation.|September 2010|September 7, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865163||141798|
NCT00865514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14617-CP-001|Pharmacotoxicology of Trichloroethylene Metabolites|Pharmacotoxicology of Trichloroethylene Metabolites: Short-term Effect of DCA on in Vivo Tyrosine Catabolism and MAAI Expression||University of Florida|No|Terminated|August 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Both|22 Years|60 Years|Accepts Healthy Volunteers|||July 2013|June 2, 2015|March 17, 2009|Yes|Yes|Difficulty in obtaining the solution from the compounding pharmacies caused a two year delay    in start-up; the funding ended prior to study completion.|No|March 21, 2013|https://clinicaltrials.gov/show/NCT00865514||141771|
NCT00865865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#48/2006|Computer Aided Gap Balancing Improves Sagittal Stability and Outcomes for Cruciate-Retaining Total Knee Arthroplasty|Computer Aided Gap Balancing Improves Sagittal Stability and Outcomes for Cruciate-Retaining Total Knee Arthroplasty- 2-Year Results of a Prospective Randomised Trial||Singapore General Hospital|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865865||141745|
NCT00866112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10053|A Randomized Exercise Trial for Wheelchair Users|A Randomized Exercise Trial for Wheelchair Users||University of Kansas Medical Center|No|Completed|May 2008|June 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|135|||Both|18 Years|65 Years|No|||April 2010|June 13, 2012|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866112||141726|
NCT00866463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481265|A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects|An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of An Experimental Tablet Of Sildenafil With Or Without Water Relative To Viagra® Conventional Oral Tablet With Water.||Pfizer|No|Completed|October 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866463||141700|
NCT00897832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0666|Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer|Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer||Vanderbilt-Ingram Cancer Center|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients with pancreatic cancer|March 2013|March 2, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897832||139334|
NCT00865124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000564|Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease|Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease||Brigham and Women's Hospital|Yes|Completed|September 2008|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|70 Years|No|||July 2013|July 31, 2013|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865124||141801|
NCT00865423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-079|A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|February 2001|March 2001|Actual|February 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865423||141778|
NCT00897117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0136|Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer|Molecular Fingerprinting of Lung Cancer||Vanderbilt-Ingram Cancer Center|No|Recruiting|May 2001|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Both prospective and retrospectives samples of blood and tissue.|Both|18 Years|120 Years|No|Probability Sample|People who have clinical stage I and II non-small cell lung cancer|December 2015|December 31, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897117||139383|
NCT00897520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000585297|Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy|PILOT-high Throughput-protein Profiling Analysis of Sera Collected From E1694 Patients Undergoing HDI (Arm B)||National Cancer Institute (NCI)||Not yet recruiting|November 2007|||July 2008|Anticipated|N/A|Observational|N/A|||Anticipated|40|||Both|N/A|N/A|No|||May 2008|December 23, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897520||139354|
NCT00867685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0970C00008|Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation|A Phase I, Randomized, Open Label, 2-Way Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of AZD2624 (Tablet Versus Liquid Suspension) Followed by an Additional Period to Assess the Food Effect on the Tablet||AstraZeneca||Completed|March 2009|April 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2009|April 29, 2009|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867685||141608|
NCT00868218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANFLUVAC-2008, Version 2|Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults|Preparing for an Influenza Pandemic: A Phase I Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults|PANFLUVAC|University of Bergen|No|Active, not recruiting|March 2009|November 2013|Anticipated|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|60|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868218||141567|
NCT00898521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW2008-09-03|Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns|Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns (Children & Adults)- Protocol MW2008-09-03||MediWound Ltd|Yes|Recruiting|June 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|4 Years|55 Years|No|||April 2011|May 8, 2011|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00898521||139286|
NCT00898534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-07-121|Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus|Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus||Children's Hospital Boston|No|Completed|November 2003|January 2006|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|234|||Both|2 Years|18 Years|No|||May 2009|May 11, 2009|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00898534||139285|
NCT00898508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04125|Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease|Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up||City of Hope Medical Center|Yes|Active, not recruiting|August 2005|||November 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|910|Samples With DNA|Peripheral blood sample and biopsy tissue|Female|20 Years|N/A|No|Probability Sample|City of Hope New patients|November 2015|November 4, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898508||139287|
NCT00869024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pending|Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement|AsseSsment of Efficacy, Safety and Utility of intRa myocardiAl iNjection of Stem Cells in Patients With End Stage Heart Failure Undergoing LVAD Implantation (ASSURANCE)|ASSURANCE|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|November 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||May 2015|May 4, 2015|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869024||141506|
NCT00869037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:123|Analgesia After Total Knee Arthroplasty|Analgesia After Total Knee Arthroplasty: Randomized Controlled Trial Comparing (a) Periarticular Multimodal Technique With (B) Continuous Femoral Nerve Block + Posterior Capsular Injection||University of Manitoba||Recruiting|March 2009|February 2012|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||January 2010|March 23, 2011|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869037||141505|
NCT00869050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB3348|Capecitabine and Temozolomide for Neuroendocrine Cancers|Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers||Columbia University|Yes|Completed|August 2005|October 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869050||141504|
NCT00869570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 41/08|External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer|Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|March 2009|October 2016|Anticipated|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|120 Years|No|||September 2015|September 28, 2015|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869570||141464|
NCT00865150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-001-08|Amino Acid and Acylcarnitine Profiles in Premature Neonates|How Illness and Nutritional Support Influence Amino Acid and Acylcarnitine Profiles in Premature Neonates||Mednax Center for Research, Education and Quality|Yes|Completed|April 2009|February 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1003|||Both|23 Weeks|31 Weeks|Accepts Healthy Volunteers|Probability Sample|Hospital|February 2012|February 28, 2012|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865150||141799|
NCT00865878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUSA-CP0104|ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients|A Randomized, Evaluator-Blinded, Parallel Group Comparison of PDT With Levulan Topical Solution + Blue Light vs Levulan Topical Solution Vehicle + Blue Light for the Treatment of AK and Reduction of New NMSC in Organ Transplant Recipients||DUSA Pharmaceuticals, Inc.|No|Terminated|May 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|March 18, 2009|No|Yes|Orphan Drug Designation for this indication not granted|No||https://clinicaltrials.gov/show/NCT00865878||141744|
NCT00866125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-078|Hand Function in Patients With Poly- or Dermatomyositis|Hand Function, Health Related Quality of Life and Activity Performance in Patients With Polymyositis or Dermatomyositis.||Karolinska Institutet|No|Completed|April 2002|August 2002|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 50 patients diagnosed with polymyositis or dermatomyositis were identified        through the myositis registry at the rheumatology clinic at Karolinska University        Hospital, Stockholm, Sweden.|March 2009|March 19, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866125||141725|
NCT00897559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600323|Study of Bone Marrow Samples From Patients With Acute Leukemia|Identifying the Genetic Basis of Adult AMKL||Eastern Cooperative Oncology Group|No|Active, not recruiting|July 2008|||August 2099|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Acute Leukemia|August 2015|August 6, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897559||139351|
NCT00898079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTR01B1|Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer|A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors||Children's Oncology Group|No|Recruiting|March 2003|||January 2100|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|3000|Samples With DNA|solid tissue (malignant and normal)|Both|N/A|30 Years|No|Non-Probability Sample|Any patient diagnosed with primary neoplasm, who developed a second malignant neoplasm,        any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the        International Classification of Disease for Oncology, Third Edition.|November 2015|November 12, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898079||139316|
NCT00897104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-029|MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)|A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine||Merck Sharp & Dohme Corp.||Completed|August 1995|September 1996|Actual|May 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|933|||Both|18 Years|65 Years|No|||February 2015|February 13, 2015|May 8, 2009|Yes|Yes||No|September 26, 2009|https://clinicaltrials.gov/show/NCT00897104||139384|No limitations were encountered in this study.
NCT00900952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074X1-4489|Epidemiologic Study Evaluating Infections in Elderly Patients|Epidemiologic Study of Infections in Elderly Patients||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|||Both|65 Years|N/A|No|Non-Probability Sample|Infected elderly patients treated at Internal Medicine wards in Spanish hospitals|October 2009|October 8, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00900952||139116|
NCT00867022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESTSYMPIS|Autonomic Nervous Activity in Women With Gestational Diabetes|Autonomic Nervous Activity in Women With Gestational Diabetes||Helsinki University|No|Completed|August 2004|March 2009|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Gestational diabetic women having or not hypertension with two control groups, one        pregnant on non-pregnant. All the women are studied during night time to study the arousal        of the sympathetic activity in the early morning hours|March 2009|March 20, 2009|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867022||141658|
NCT00867399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-717|A Safety and Tolerability Study of ABT-126 in Elderly|A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects||Abbott||Completed|March 2009|||May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2010|October 31, 2010|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867399||141630|
NCT00897325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL05B1|Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma|A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens||Children's Oncology Group|Yes|Recruiting|September 2006|||September 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Bone marrow, blood|Both|N/A|30 Years|No|Non-Probability Sample|Patients with relapsed ALL or prior history of non-Hodgkin lymphoma|September 2015|September 28, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897325||139369|
NCT00867958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CAR-07-IL-01|Compression Anastomosis Using the CAR™ 27|Compression Anastomosis Using the CAR™ 27||HaEmek Medical Center, Israel|No|Completed|September 2008|December 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||May 2009|February 20, 2011|March 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867958||141587|
NCT00867971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162/08|Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?|||Assaf-Harofeh Medical Center||Active, not recruiting|February 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|6 Years|18 Years|No|Probability Sample|Children age 6-18 treated with growth hormone|February 2009|March 22, 2009|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867971||141586|
NCT00868231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/23|Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients|||Almirall, S.A.||Completed|March 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|40 Years|N/A|No|||May 2015|May 29, 2015|March 23, 2009||No||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00868231||141566|
NCT00868244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMDleoncarlos|Relationship of Facial Pattern With Bruxism|Relationship of Facial Pattern With Bruxism|BRUXISM|Universidad de Guanajuato|Yes|Recruiting|June 2008|August 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|300|||Both|12 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|radiographs, photographs and dental plaster models of people who come to orthodontic        treatment|March 2009|March 23, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868244||141565|
NCT00868530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-3316|Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects|An Evaluation Of The Safety And Efficacy Of On-Demand Treatment With Xyntha (B Domain Deleted Recombinant Factor VIII, Albumin Free) In Chinese Subjects With Hemophilia A||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|6 Years|N/A|No|||April 2011|April 1, 2011|March 19, 2009||No||No|December 3, 2010|https://clinicaltrials.gov/show/NCT00868530||141544|
NCT00867945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35811-A|Pregnancy-Induced Analgesia - A Longitudinal Study of DNIC|Pregnancy-Induced Analgesia - A Longitudinal Study of DNIC||University of Washington|No|Recruiting|March 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|maternity clinic - Pregnant Cohort community sample - Non-pregnant Control Cohort|June 2013|June 17, 2013|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867945||141588|
NCT00868205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P8353|Coffee and In-vivo Oxidative Stress|The Relationship Between Short- and Mid-term Intake of Coffee on in Vivo Levels of Oxidative Stress Parameters in Healthy Adults.||TNO|No|Completed|March 2009|March 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|180|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868205||141568|
NCT00898820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC0527|Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524|Predictive Markers of Response to Pemetrexed (Companion Study to RC0524)||Mayo Clinic|Yes|Completed|November 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|N/A|||Anticipated|80|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|May 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00898820||139267|
NCT00868777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00017520|The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures|The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures||University of Michigan|No|Completed|January 2008|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|85 Years|No|||March 2009|September 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868777||141525|
NCT00864851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKT028|Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease|A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease||Shire|Yes|Completed|December 2008|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|N/A|No|||May 2014|March 3, 2015|March 18, 2009||No||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00864851||141822|
NCT00865176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1DX06002|Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting Conditions|Comparative Bioavailability Study of Eplerenone 50 mg Tablets (Sandoz Inc., USA) and Inspra 50 mg Tablets (GD Searle LLC, USA) in Healthy Male and/or Female Volunteers Under Fasting Conditions.||Sandoz||Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00865176||141797|
NCT00869362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-001439|Effect of Inpatient Diabetes Management on Outpatient Glycemic Control|Effect of Inpatient Diabetes Management on Outpatient Glycemic Control||Massachusetts General Hospital|Yes|Completed|March 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|March 25, 2009||No||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00869362||141480|
NCT00864825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6893-MW-CTIL|Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia|Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia||Sheba Medical Center|No|Completed|August 2009|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|65 Years|No|||May 2012|May 6, 2012|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864825||141824|
NCT00864838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4429/2008|Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab|Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection||University of Sao Paulo|Yes|Completed|June 2008|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|N/A|No|||March 2009|March 18, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864838||141823|
NCT00865891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0099|A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|96|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865891||141743|
NCT00866138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04019|A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3|Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3||AB Science|No|Active, not recruiting|February 2005|December 2015|Anticipated|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866138||141724|
NCT00897845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598872|Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer|Molecular Profiling of E2197 FFPE Samples Using a Custom 512 Breast Cancer Gene Set on the DASL Platform: Towards the Development of Predictive Gene Sets for Risk of Recurrence in Patients With Operable Breast Cancer Treated With Adjuvant Therapy||National Cancer Institute (NCI)||Not yet recruiting|January 2009|||July 2011|Anticipated|N/A|Observational|N/A|||Anticipated|2541|||Female|18 Years|N/A|No|||October 2008|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897845||139333|
NCT00898612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000588925|Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant|Using the Transcriptome for Early Detection of Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation||Mayo Clinic|Yes|Withdrawn|March 2008|||December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing allogeneic bone marrow transplantation at participating institutions.|March 2014|March 6, 2014|May 9, 2009||No|No Patients enrolled|No||https://clinicaltrials.gov/show/NCT00898612||139280|
NCT00866749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0375|Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma|Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2006|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|12 Years|40 Years|No|||November 2015|November 5, 2015|March 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866749||141678|
NCT00867412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERALUST|Randomized Study of Positron Emission Tomography - Computed Tomography (PET/CT) in Pre-Operative Staging of Lung Cancer|Randomized Study of PET/CT in Pre-Operative Staging of Lung Cancer||Rigshospitalet, Denmark|No|Completed|January 2002|February 2008|Actual|February 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|189|||Both|18 Years|80 Years|No|Probability Sample|Patients with non-small cell lung cancer|March 2009|March 20, 2009|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867412||141629|
NCT00867386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 14940|Desensitization for Highly Sensitized Recipients of Pancreas Transplantation|Desensitization for Highly Sensitized Recipients of Pancreas Transplantation||Northwestern University|No|Completed|December 2006|October 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of type 1 diabetes who are highly sensitized (defined as having        panel reactive antibody (PRA) level >50%) who underwent successful desensitization        treatment followed by a deceased donor pancreas transplantation at NMH .|March 2014|March 11, 2014|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00867386||141631|
NCT00867984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7345220000|Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders|Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders (TORSION). A Randomized Comparison of Torsion-imaging Guided Optimization vs. Usual Settings.|TORSION|University of Calgary|Yes|Active, not recruiting|March 2009|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867984||141585|
NCT00868257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH083306|Measurement of Adherence to ART in HIV-Infected Children in Uganda (The CHARTA Study)|Measurement of Adherence to ART in HIV-Infected School-Aged Children in Uganda||Massachusetts General Hospital|No|Completed|July 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|Plasma samples to repeat HIV viral load testing, in the case of processing errors. If these      samples are not needed, they may be used for immunologic or viral resistance testing at a      future date.|Both|1 Year|10 Years|No|Non-Probability Sample|Children recruited from the outpatient Children's HIV/AIDS Care Clinic at the Mbarara        University Teaching Hospital in rural, southwestern Uganda|January 2012|January 11, 2012|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868257||141564|
NCT00868270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY55-08|Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis|||Hillel Yaffe Medical Center||Not yet recruiting|May 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|N/A|7 Years|No|Probability Sample|Hospitalized children with UTIs|March 2009|March 22, 2009|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00868270||141563|
NCT00868517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 08-121|Examining the Effect of Acupuncture on Sleep Difficulties Related to Post Traumatic Stress Disorder|The Effect of Acupuncture on PTSD-Related Insomnia||VA Office of Research and Development|No|Completed|October 2009|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||September 2014|April 6, 2015|March 23, 2009||No||No|September 22, 2014|https://clinicaltrials.gov/show/NCT00868517||141545|
NCT00868790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3577-009|A Study of the Safety and Efficacy of MK3577 in Patients With Type 2 Diabetes Mellitus (MK-3577-009)|A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK3577 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|Yes|Terminated|March 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|118|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|March 24, 2009|Yes|Yes|Upon interim analysis, sufficient data was accrued to assess study hypotheses.|No||https://clinicaltrials.gov/show/NCT00868790||141524|
NCT00869375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEARWAY-CLI|Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia|Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia: A Randomized Controlled Trial||University of Oklahoma|Yes|Terminated|April 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|85 Years|No|||June 2014|June 26, 2014|March 25, 2009|Yes|Yes|very low enrollment due to low access to study population|No|April 4, 2014|https://clinicaltrials.gov/show/NCT00869375||141479|The main limitation of this trial was slow enrollment. This led to early termination leading to small numbers of subjects analyzed. This makes the results uninterpretable.
NCT00864864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-307|Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma|Pilot Study of Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma||Massachusetts General Hospital|Yes|Active, not recruiting|May 2007|May 2012|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2011|September 2, 2011|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00864864||141821|
NCT00865189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19202|A Study of Avastin (Bevacizumab) in Patients With Newly Diagnosed Locally Advanced Rectal Cancer.|A Randomized, Open-label Study to Assess the Effect on Tumor Response, and the Safety, of Two Neo-adjuvant Approaches With Avastin in Newly-diagnosed Patients With High Risk Locally-advanced Rectal Cancer||Hoffmann-La Roche||Active, not recruiting|November 2007|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865189||141796|
NCT00865527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC1.0|Pilot Study of Colon Cancer Screening Tests|Randomized Comparison of Virtual Colonoscopy, Optical Colonoscopy, and Fecal Occult Blood Testing for Colorectal Cancer Screening: a Pilot Study||McMaster University|No|Terminated|March 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|198|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 31, 2012|March 18, 2009||No|Lack of ongoing funding|No||https://clinicaltrials.gov/show/NCT00865527||141770|
NCT00865904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-809-101|Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the ∆F508-CFTR Gene Mutation||Vertex Pharmaceuticals Incorporated|Yes|Completed|March 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|93|||Both|18 Years|N/A|No|||June 2015|August 1, 2015|March 18, 2009|Yes|Yes||No|August 1, 2015|https://clinicaltrials.gov/show/NCT00865904||141742|
NCT00866151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-08-108WMGTP|A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs|A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs||Interleukin Genetics, Inc.|No|Enrolling by invitation|August 2008|September 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Buccal swabs are collected by Stanford and sent to Interleukin Genetics for genotyping.|Female|25 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|The study population for the A to Z study are premenopausal women who are overweight (BMI        27-40 kg/m2) but in otherwise good general health. Overweight participants with        potentially confounding health conditions are excluded (eg., hypertension, diabetes, heart        disease, cancer). Children were not included in this study. The participants were asked to        agree to a random assignment to dietary plans.|March 2009|March 19, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866151||141723|
NCT00898378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808-24; IUCRO-0221|Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps|Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study||Indiana University|Yes|Completed|January 2009|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|551|Samples With DNA|Biospecimens will be analyzed to study metabolimics, lipidomics, genomics, glycoproteomics,      global proteomics and Vitamin D status.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited via oncology, gastroenterology and surgical oncology clinics at        Indiana University Medical Center. Healthy controls will be subjects without any        abnormalities after a colonoscopy. Subjects with polyps will be those whose colonoscopy        identifies adenomatous polyps (informed consent will be signed first and samples will be        collected; after colonoscopy the samples will be identified as "healthy" or "polyps").|September 2014|September 17, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898378||139297|
NCT00898638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546682|Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants|Head and Neck Tumor Tissue Repository and Clinical Database||Vanderbilt University||Recruiting|February 2003|||||N/A|Observational|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|March 28, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898638||139279|
NCT00867035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGP1|Bad Breath Response to Tongue Scraper and Rinses|Bad Breath Response to Tongue Scraper and Rinses, a Double-blind, Randomized, Parallel Group Clinical Trial.||University of California, San Francisco|Yes|Completed|March 2008|June 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 15, 2013|March 20, 2009|Yes|Yes||No|July 1, 2009|https://clinicaltrials.gov/show/NCT00867035||141657|Total number of subjects is less than the desired 50 persons; dimethyl sulfide measures distorted by materials in syringes; accuracy of portable gas chromatograph a concern.
NCT00867048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603M83587|Strategic Timing of Antiretroviral Treatment|Strategic Timing of AntiRetroviral Treatment|START|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|March 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4688|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867048||141656|
NCT00867425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08030183|Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program|Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program: A Pilot Study in a Military Community||University of Pittsburgh|Yes|Completed|April 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|62 Years|No|||April 2012|April 26, 2012|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867425||141628|
NCT00867438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-01-05/04|Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy|Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium (CB-01-05-MMX™), Administered as Add-on Therapy to Oral Mesalazine or Other 5-ASA Derivatives, in Patients With Active, Left-Sided, Mild to Moderate Ulcerative Colitis. A Multicentre Randomized, Double-Blind, Comparative Study Versus Placebo.||Cosmo Technologies Ltd|No|Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|70 Years|No|||March 2009|March 24, 2009|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867438||141627|
NCT00867698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST-MHE201|AST-120 Used to Treat Mild Hepatic Encephalopathy|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy|ASTUTE|Ocera Therapeutics|No|Completed|March 2009|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|148|||Both|18 Years|70 Years|No|||June 2014|June 2, 2014|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867698||141607|
NCT00868010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD055525|Enhancing Rehabilitation After Stroke|Donepezil to Promote Functional Recovery Post-stroke|Enhance|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|March 2009|November 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|March 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868010||141583|
NCT00868569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-03|Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer|TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial||Fudan University|Yes|Recruiting|January 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868569||141541|
NCT00868582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPR|The National Oncologic PET Registry|The National Oncologic PET Registry|NOPR|American College of Radiology Imaging Network|No|Recruiting|May 2006|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|333000|||Both|N/A|N/A|No|Non-Probability Sample|Medicare beneficiaries who are referred for NaF-18 PET (the FDG-PET arm of NOPR has        completed enrollment)|January 2016|January 15, 2016|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868582||141540|
NCT00868543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-37|Long or Very Long-Limb Gastric Bypass in Superobese|Long or Very Long-Limb Gastric Bypass in Superobese||Kaunas University of Medicine|No|Recruiting|July 2008|December 2015|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868543||141543|
NCT00868803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCID1995-014|Aberrant Gene Expression Prostate Carcinoma|Identification of Aberant Gene Expression in Human Prostatic Carcinoma||Lahey Clinic|No|Active, not recruiting|April 1995|April 2025|Anticipated|April 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Surplus tissue following pathologic review requirements will be snap frozen and processed      for extraction of RNA. mRNA will be reversed transcribed to make cDNA with the prime      5'TCCTTAGAAC, followed by 40 cycles of palindromic PCR using the sam eprimer. Amplified cDNA      (35 S-labled) will be analysed on a 4% polyacrylamide gel. Comparative analysis of cDNA      amplified products will serve to identify aberrantly expressed candidate genes. Such      products will be isolated, sequenced and evaluated as to their role in establishing the      neoplastic pheotype and the potential utility as a marker of prostatic neoplastic      progression.|Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients diagnosed with prostate cancer patients undergoing surgery for suspected prostate        cancer but have negative biopsy healthy volunteers - blood sample only|March 2015|March 30, 2015|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868803||141523|
NCT00869089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102652|Safety and Efficacy of CC-10004 for Prurigo Nodularis|An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis||University Hospital Case Medical Center|No|Completed|September 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|March 23, 2009|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT00869089||141501|
NCT00868751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-PRHEU-TCZ-01|Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis|Single Patient Use of Tocilizumab for Treatment of Steroid Dependent, Active Systemic Onset Juvenile Idiopathic Arthritis||Tufts Medical Center|No|Terminated|March 2009|June 2010|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|2 Years|16 Years|No|||December 2012|December 6, 2012|March 24, 2009|No|Yes|Hyperintensities of unclear etiology on brain MRI. Follow up revealed no progression.|No||https://clinicaltrials.gov/show/NCT00868751||141527|
NCT00868764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/40/C|An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron|An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron||Prostrakan Pharmaceuticals|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 5, 2009|March 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00868764||141526|
NCT00868504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6887-AO-CTIL|Measuring Temperatures of Tissues During Endoscopy|Measuring Temperatures of Tumors and Normal Tissues in the GI Tract, Using a Thermocouple Sheathed in a Catheter, in the Work Canal of an Endoscope||Sheba Medical Center|No|Recruiting|April 2009|November 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who undergo endoscopy or colonoscopy.|September 2009|September 29, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868504||141546|
NCT00869388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0961|A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors|A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors||Washington University School of Medicine|Yes|Completed|October 2008|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|March 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00869388||141478|
NCT00864877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D355 - 001|Comparison of Biodegradable & Metal Plates for Fixing Ankle Fracture|A Randomised, Prospective Clinical Investigation to Compare Post-Operative Fracture Healing and Complication Rate After the Fixation of Ankle Fractures Using the Inion OTPS FreedomPlate Biodegradable Fixation System Versus Conventional Metal Screws and Plates.||Inion Oy|No|Not yet recruiting|May 2009|||April 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|No|||March 2009|March 18, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864877||141820|
NCT00864890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-P2-260|A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditions|Single Dose Crossover Comparative Bioavailability Study of Citalopram 40 mg Tablets in Healthy Male Volunteers/Fed State||Actavis Inc.|No|Completed|June 2003|July 2003|Actual|July 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864890||141819|
NCT00865202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0543|A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium|A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium||University of Colorado, Denver|Yes|Completed|December 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|325|||Both|60 Years|N/A|No|||March 2013|March 27, 2013|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865202||141795|
NCT00865540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMB NO:0925-0586|Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies|Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies||Clinica Oftamologica Zona Sul|Yes|Active, not recruiting|March 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|50 Years|80 Years|No|||March 2009|May 23, 2011|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865540||141769|
NCT00866164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060192/S019|Prometra's Utilization in Mitigating Pain II|Prometra's Utilization in Mitigating Pain II|(PUMP 2)|Flowonix Medical||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2012|March 2, 2012|March 18, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00866164||141722|
NCT00866554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT112661|Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy|Phase II Study of Bicalutamide and Dutasteride for Prostate Cytoreduction Prior to Permanent Implant I-125 Prostate Brachytherapy||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|March 2009|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Male|18 Years|N/A|No|||April 2015|April 14, 2015|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866554||141693|
NCT00898391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL07B1|Study of DNA in Blood Samples From Patients With Neuroblastoma|Analysis of Circulating MYCN DNA in Serum Samples Obtained From Patients With Neuroblastoma||Children's Oncology Group|No|Recruiting|June 2007|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|329|||Both|N/A|N/A|No|Probability Sample|Patients with neuroblastoma treated at a COG participating site.|November 2015|November 16, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898391||139296|
NCT00898664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0625|DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer|Genetic Analysis of Head and Neck Squamous Cell Carcinoma||Vanderbilt-Ingram Cancer Center|Yes|Completed|June 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|74|Samples With DNA|Assess common genetic mutations in tumor and germline DNAs from HNSCCs and search for viral      DNAs and relate this information to demographics, tumor characteristics and patient      prognosis.|Both|18 Years|N/A|No|Probability Sample|Nonsmoking patients less than 40 years of age at first diagnosis of HNSCC.|March 2013|March 29, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898664||139278|
NCT00867061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-11|Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)|A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 5-day Continuous Intravenous Dosing Of ON 01910.Na Administered Every 2 Weeks in Patients With Intermediate-1, Intermediate-2, or High Risk Myelodysplastic Syndrome (MDS)||Onconova Therapeutics, Inc.|No|Withdrawn|March 2009|September 2010|Anticipated|June 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|March 19, 2009|Yes|Yes|Mutual decision by site and sponsor because of difficulty recruiting Patients.|No||https://clinicaltrials.gov/show/NCT00867061||141655|
NCT00867087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K5-2005|Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma|An Open-Label, Single-Arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible For Autologous Stem Cell Transplantation||Pfizer|No|Completed|June 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867087||141654|
NCT00867451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC IRB# 2008-1287|Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)|A Pilot Study Designed To Improve Sleep and Subsequent Daytime Functioning in Children Diagnosed With ADHD||Children's Hospital Medical Center, Cincinnati|No|Completed|January 2010|July 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|6 Years|12 Years|No|||March 2012|March 15, 2012|March 20, 2009|Yes|Yes||No|September 28, 2011|https://clinicaltrials.gov/show/NCT00867451||141626|
NCT00867464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909106|Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls|Extended Follow-up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|10000|||Female|24 Years|32 Years|No|||May 2015|March 10, 2016|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867464||141625|
NCT00867711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-04/2008|Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients|Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma Patients||Istituto Clinico Humanitas|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|121|Samples With DNA|The paraffin-embedded tumor specimens of patients will be collected. The tumor RNA and DNA      will be extracted and genotyping, gene expression and gene copy number analyses will be      performed with validated PCR and array-CGH techniques.|Both|18 Years|N/A|No|Non-Probability Sample|Malignant Pleural Mesothelioma patients treated with carboplatin and pemetrexed|November 2014|December 1, 2014|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867711||141606|
NCT00868283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBE-CN-050823|The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke|CASTA|Ever Neuro Pharma GmbH|Yes|Completed|September 2006|February 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1071|||Both|18 Years|85 Years|No|||July 2011|July 6, 2011|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868283||141562|
NCT00868296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001B3-335|Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)|A Muliticenter, Open Label Safety Study of 2 Doses of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed GERD||Wyeth is now a wholly owned subsidiary of Pfizer||Completed|March 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|N/A|12 Months|No|||April 2010|April 29, 2010|March 20, 2009|Yes|Yes||No|November 30, 2009|https://clinicaltrials.gov/show/NCT00868296||141561|
NCT00869167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-052R|Ramelteon for Insomnia Comorbid With Asthma|Ramelteon for Insomnia Comorbid With Asthma||Northwestern University|No|Terminated|March 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|60 Years|No|||April 2013|April 26, 2013|March 19, 2009||No||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00869167||141495|Recruitment difficulties led to only 3 participants in the study. Only 2 participants finished the study.
NCT00869180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCF-004|Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain|SUPPORT 2|Cerimon Pharmaceuticals|No|Completed|February 2009|August 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|17 Years|75 Years|No|||January 2010|January 26, 2010|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869180||141494|
NCT00868556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V81708|fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?|fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?||The Cleveland Clinic|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|11 episodic migraine sufferers, 11 chronic migraine sufferers, 11 non-migraine sufferers|March 2009|January 4, 2010|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868556||141542|
NCT00868816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02|Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles|A Prospective, Randomized, Control Trial of Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles vs 12 Cycles||Fudan University|Yes|Completed|January 2005|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|75 Years|No|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868816||141522|
NCT00869115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 0614-106|Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure|A Randomized, Double-blind, Placebo-controlled Escalating Dose Phase I Interaction Study to Evaluate the Pharmacokinetics, Tolerability and Pharmacodynamics of Three Dose Levels of Debio 0614 (Istaroxime) as a 24-hour Constant Rate IV Infusion in Combination With Chronic Oral Digoxin Treatment in Patients With Controlled Cardiac Failure and Decreased Left Ventricular Systolic Function||Debiopharm International SA|Yes|Withdrawn|June 2009|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|March 24, 2009|No|Yes|The study was not started due to a re-evaluation of the istaroxime development program|No||https://clinicaltrials.gov/show/NCT00869115||141499|
NCT00869063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCF-005|Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion|WIND|Cerimon Pharmaceuticals|No|Completed|February 2009|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Both|17 Years|75 Years|No|||January 2010|January 26, 2010|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869063||141503|
NCT00869076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PharmacistDiabetesJameson|Pharmacists Management of Diabetes|Pharmacist Management of Diabetes Mellitus: A Randomized Controlled Trial.||Advantage Health Physician Network|No|Completed|May 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|102|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00869076||141502|
NCT00869401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0877|Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|June 2009|||October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|217|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869401||141477|
NCT00865241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02-994|A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|November 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865241||141792|
NCT00865254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA021839A|Prize Reinforcement for Smoking Cessation|Prize Reinforcement for Smoking Cessation||Wayne State University|Yes|Completed|August 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|84|||Both|13 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 27, 2013|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865254||141791|
NCT00865215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-1383|A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 160 mg Propranolol Hydrochloride Extended Release Capsules Under Fasting Conditions||Actavis Inc.|No|Completed|April 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865215||141794|
NCT00865228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-475_201|Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia|A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia||Takeda|No|Terminated|July 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|224|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|March 18, 2009|Yes|Yes|Overall profile of the compound does not offer significant clinical advantage to patients over    currently available lipid lowering agents|No||https://clinicaltrials.gov/show/NCT00865228||141793|
NCT00865553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000629824|Computer-Assisted Stop-Smoking Program in Helping Doctors Counsel Patients Who Smoke Cigarettes|Clinical Testing of a Decision Support System for Tobacco Use Treatment||National Cancer Institute (NCI)||Recruiting|March 2009|||August 2010|Anticipated|Phase 2|Interventional|Primary Purpose: Health Services Research|1||Anticipated|630|||Both|18 Years|N/A|No|||March 2011|September 19, 2013|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865553||141768|
NCT00865566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 505|Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men|Phase 2b, Randomized, Placebo-Controlled Test-of-Concept Trial to Evaluate the Safety and Efficacy of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|May 2009|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|2504|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865566||141767|
NCT00866853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015949|TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.|A Phase I, Open Label, 2-period, Randomized, Crossover Trial in 16 Healthy Subjects to Assess the Drug Interaction Potential of TMC435 With Oral Midazolam and With a Drug Cocktail Representative of CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP2C19 Substrates.||Tibotec Pharmaceuticals, Ireland||Completed|March 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866853||141670|
NCT00866866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21571|The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms|The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial||University of Calgary|No|Recruiting|March 2009|May 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2009|March 20, 2009|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00866866||141669|
NCT00898404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL04B1|Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate|Molecular Correlates of Methotrexate in Childhood ALL||Children's Oncology Group|No|Recruiting|November 2003|||January 2100|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|17 Years|No|Non-Probability Sample|Newly Diagnosed Patients with ALL treated with Methotrexate|November 2015|November 2, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898404||139295|
NCT00898677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-030|Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)|A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine||Merck Sharp & Dohme Corp.||Completed|September 1995|September 1996|Actual|May 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1268|||Both|18 Years|65 Years|No|||February 2015|February 13, 2015|May 8, 2009|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00898677||139277|
NCT00867100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060279|Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis|A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis||Amgen||Completed|December 2007|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 19, 2010|March 20, 2009||||No||https://clinicaltrials.gov/show/NCT00867100||141653|
NCT00867737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT112430|Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)|Onset of Action of Advair HFA 115/21 in Comparison to Symbicort pMDI 160/4.5 Measured by Impulse Oscillometry, IOS.||Allergy and Asthma Center of El Paso|No|Recruiting|September 2008|September 2009|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|45 Years|No|||March 2009|March 23, 2009|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867737||141604|
NCT00867724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-CLD-AOS|Clinical Study-evaluate Performance&Safety "Aer-O-Scope" in Colon of Low Risk Patients|A Clinical Study to Evaluate the Performance & Safety of the "Aer-O-Scope" Traveling Through the Colon in Low Risk Subjects||GI View Ltd.|No|Recruiting|September 2009|March 2012|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867724||141605|
NCT00867997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRL0707|Noncarious Cervical Lesion Treatment Outcomes|Noncarious Cervical Lesion Treatment Outcomes: Randomized Clinical Trial||Pearl Network|Yes|Completed|March 2009|February 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|304|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867997||141584|
NCT00868842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM10870|Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis|Open-label, Single-center Study of Whether Oral Penicillin Desensitization of Healthy Sensitive Subjects Results in Allergen Cross-desensitization of Mast Cells by Skin Testing and Desensitization of Peripheral Blood Basophils.||Virginia Commonwealth University|Yes|Completed|January 2009|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Clinical and community recruitment|April 2014|April 10, 2014|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868842||141520|
NCT00868621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8848|Urinary Cytokines in Patients With Overactive Bladder (OAB)|Identification of Urinary Cytokines in Patients With Overactive Bladder (OAB)||Cleveland Clinic Florida|Yes|Active, not recruiting|March 2007|June 2009|Anticipated|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|56|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Twenty healthy women (control), 20 women suffering from overactive bladder and other 20        women suffering from UTI will be selected for the study. Each control will be age matched        within +/- 5 years to patients.|March 2009|March 23, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868621||141537|
NCT00868634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-080-2|Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer|Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients|CARIN|iOMEDICO AG|No|Completed|February 2009|October 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868634||141536|
NCT00868829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPMFB22009|Firebird2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent Registry Trial|Firebird2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent Registry Trial|FOCUS|Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Recruiting|April 2009|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5000|||Both|18 Years|N/A|No|||August 2011|August 9, 2011|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868829||141521|
NCT00869141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB#08-10-110-01|Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma|Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma||University of California, Los Angeles|No|Completed|March 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|85 Years|No|||July 2015|November 30, 2015|March 24, 2009||No||No|June 1, 2015|https://clinicaltrials.gov/show/NCT00869141||141497|
NCT00869154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD 20425|Multidisciplinary Treatment in Patients With Mild Traumatic Brain Injury|Effect of Multidisciplinary Treatment in Patients With Mild Traumatic Brain Injury - a Randomized Controlled Trial||Haukeland University Hospital|Yes|Active, not recruiting|March 2009|January 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|16 Years|55 Years|No|||December 2015|December 1, 2015|February 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869154||141496|
NCT00869102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BET-001|Characterization of Beta Cell Failure|||University Hospital Tuebingen||Withdrawn|May 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2009|July 30, 2014|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00869102||141500|
NCT00869128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu951005|A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia|A Randomized Double-Blind, Crossover Study Comparing the Efficacy of Prolonged-Release Melatonin Versus Placebo in a 3 Week Treatment of Diabetic Patients Suffering From Insomnia||Neurim Pharmaceuticals Ltd.|No|Completed|November 1995|March 1997|Actual|March 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|N/A|N/A|No|||March 2009|March 30, 2009|December 8, 2008||No||No|December 8, 2008|https://clinicaltrials.gov/show/NCT00869128||141498|
NCT00864903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZMC|A New Enzymatic Assay for Rapid Diagnosing of Central Nervous System Enteroviral Infection|A Comparison Between a New Experimental Enzymatic Assay to Real Time PCR for the Diagnosing of Central Nervous System Enteroviral Infection||Shaare Zedek Medical Center|No|Active, not recruiting|April 2009|November 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Cerebrospinal Fluid|Both|N/A|16 Years|No|Non-Probability Sample|children age 0-16 years who undergo a spinal tap at the pediatric ER due to suspected        meningitis.|March 2009|September 17, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864903||141818|
NCT00864916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|646|Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People|A Randomized, Placebo-Controlled Trial of Pentoxifylline Plus Combination ART vs. Combination ART Alone to Improve Endothelial Dysfunction in HIV-Infected Patients||Indiana University|Yes|Completed|March 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|March 17, 2009|Yes|Yes||No|March 10, 2014|https://clinicaltrials.gov/show/NCT00864916||141817|
NCT00865943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03-381|A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions|A Relative Bioavailability of 10 mg Citalopram Hydrobromide Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|July 2003|August 2003|Actual|August 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865943||141739|
NCT00865956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00015261|A Comprehensive Disease Management Program for Medically-Complex Substance Users|A Comprehensive Disease Management Program for Medically-Complex Substance Users||Johns Hopkins University|No|Recruiting|March 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2009|November 3, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00865956||141738|
NCT00865618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1DX06003|Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed Conditions|Comparative Bioavailability Study of Eplerenone 50 mg Tablets (Sandoz Inc., USA) and Inspra 50 mg Tablets (GD Searle LLC, USA) in Healthy Male and/or Female Volunteers Under Fed Conditions.||Sandoz||Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00865618||141763|
NCT00865579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28850|Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients|Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients||Newron||Completed|March 2009|||July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|965|||Both|30 Years|N/A|No|||July 2012|March 28, 2013|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865579||141766|
NCT00865917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCB-CRC-07-02|Cardiovascular Effects of Selective I(f)-Channel Blockade|Einfluss Selektiver I(f)-Blockade Auf Orthostase-Toleranz Und Sympathikusaktivität Bei Gesunden||Hannover Medical School|No|Recruiting|November 2008|December 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865917||141741|
NCT00865930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-35|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||March 18, 2009|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865930||141740|
NCT00866606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090A1-3305|Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects|An Evaluation Of The Safety And Efficacy Of On-Demand Treatment With BeneFIX (Nonacog Alfa, Recombinant Factor IX) In Chinese Subjects With Hemophilia B||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|6 Years|N/A|No|||April 2011|April 1, 2011|March 19, 2009|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00866606||141689|
NCT00867178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03167|Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System|A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System||National Cancer Institute (NCI)||Active, not recruiting|February 2009|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|2 Months|47 Months|No|||October 2015|March 11, 2016|March 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867178||141647|
NCT00867191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P02836|Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)|A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen||Merck Sharp & Dohme Corp.|No|Completed|February 2002|April 2003|Actual|April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|233|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867191||141646|
NCT00867204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCP systems|Short Versus Long Wire ERCP Systems|Prospective Randomized Blinded Comparison of a Short-wire ERCP System to Traditional Long-wire Devices|ERCP systems|University of Florida|No|Completed|October 2004|January 2009|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|71|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with the clinical indication for an ERCP.|March 2009|September 16, 2011|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00867204||141645|
NCT00898417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592948|Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab|Development of a Serum Proteomic Classifier for the Prediction of Benefit From Bevacizumab in Combination With Carboplatin and Paclitaxel||National Cancer Institute (NCI)||Not yet recruiting|March 2008|||April 2009|Anticipated|N/A|Observational|N/A|||Anticipated|90|||Both|18 Years|N/A|No|||August 2008|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898417||139294|
NCT00898950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-001418-14|Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes|The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk||University of Portsmouth|No|Completed|August 2004|July 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|21|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2009|May 11, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00898950||139257|
NCT00867113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BUS282|Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)|A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)||Novartis||Active, not recruiting|July 2009|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867113||141652|
NCT00867477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0632|PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide|A Biomarker Study Comparing the Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide in Patients Who Receive Thoracic Radiotherapy||M.D. Anderson Cancer Center|No|Completed|March 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|163|||Both|N/A|N/A|No|||August 2014|August 27, 2014|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867477||141624|
NCT00868049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADRIANABF1|Study of Stomatognathic System of the Obese Subjects|Study of Stomatognathic System,Chewing and Deglutition Functions in the Obese Subjects|SSSCDFO|University of Sao Paulo|No|Completed|May 2007|February 2009|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|40|||Both|18 Years|58 Years|Accepts Healthy Volunteers|Non-Probability Sample|twenty obese patients (6 Male /14 Female, mean age 32.2 ± 9.9, mean BMI 43,3 ± 9.6 Kg/m2)        and twenty lean volunteer (4 Male / 16 Female mean age 30.7 ±6.7, mean BMI 22.3 ± 1.9        Kg/m2)|March 2009|March 23, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868049||141580|
NCT00868595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-PC-001|MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer|A Phase I, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Castrate Resistant Prostate Cancer||Bellicum Pharmaceuticals|Yes|Completed|April 2009|March 2012|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|N/A|No|||February 2015|February 10, 2015|March 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00868595||141539|
NCT00868023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0809-PR-0038|Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients|A Phase II, Multinational, Multicentre, Double Blind, Double Dummy, Randomised, 5-way Cross-over, Placebo and Active Controlled Clinical Study to Test the Non-inferiority of a Single Dose of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg Dry Powder) Via NEXT™ DPI 1 or 4 Inhalations Versus CHF 1535 (Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg) pMDI With HFA-134a Propellant 1 or 4 Puffs on FEV1 AUC0-12h in Partly Controlled Adult Asthmatic Patients||Chiesi Farmaceutici S.p.A.|No|Completed|February 2009|October 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|69|||Both|18 Years|N/A|No|||December 2010|December 22, 2010|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868023||141582|
NCT00868036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Contact Urticaria|Evaluating for Contact Allergies in Patients With Chronic Urticaria|Contact Allergens Causing Chronic Urticaria in a New England-Area Population||Tufts Medical Center|No|Recruiting|December 2008|March 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||February 2010|February 1, 2010|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868036||141581|
NCT00869427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|545-07286a 1.2007.2483 (REK)|Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured|Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured||Sunnaas Rehabilitation Hospital|No|Terminated|March 2009|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2010|July 2, 2010|March 25, 2009||No|Inability to recruit sufficient number of patients|No||https://clinicaltrials.gov/show/NCT00869427||141475|
NCT00864929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-IVN-DUM-2008/1|An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice|An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice||AstraZeneca|No|Completed|November 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Patient was diagnosed as nosocomial infection|February 2011|February 15, 2011|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864929||141816|
NCT00865267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP03-685|The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects|A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Dose Ranging Study||Actavis Inc.|No|Completed|December 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865267||141790|
NCT00869414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00024168|Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes|Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring||Johns Hopkins University|Yes|Not yet recruiting|March 2009|May 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|25|||Both|18 Years|90 Years|No|||March 2009|March 25, 2009|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869414||141476|
NCT00865592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-PROT300E|Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus|An Open Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety of PHX1149T/Dutogliptin in Subjects With Type 2 Diabetes Mellitus||Phenomix|No|Terminated|March 2009|March 2011|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|18 Years|85 Years|No|||August 2010|August 10, 2010|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865592||141765|
NCT00865605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP03-689|Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects|A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Pivotal Bioequivalence Study||Actavis Inc.|No|Completed|December 2003|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|71|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865605||141764|
NCT00865631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P99-229|A Limited Food Effect Study of Gabapentin 800 mg Tablets|A Limited Food Effect Study of 800 mg Gabapentin Tablets Versus 400 mg Gabapentin Capsules||Actavis Inc.|No|Completed|June 1999|June 1999|Actual|June 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865631||141762|
NCT00865982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract-CT-2008-001849-26|Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer|Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal Esophagus|DCXAIOCHARITE|Charite University, Berlin, Germany|Yes|Active, not recruiting|September 2008|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||August 2011|August 4, 2011|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00865982||141736|
NCT00865995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/26|Pepsin As A Biomarker For Aspiration|Pepsin as a Biomarker for Aspiration Due to Gastroesophageal Reflux||Medical College of Wisconsin|No|Completed|February 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|76|Samples Without DNA|Tracheal fluid|Both|1 Year|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal children undergoing general endotracheal anesthesia Children with tracheostomies        Children undergoing bronchoscopy Intubated children in PICU|October 2013|October 22, 2013|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00865995||141735|
NCT00866177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01164|MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma|Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas||National Cancer Institute (NCI)||Completed|March 2009|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Both|18 Years|N/A|No|||June 2013|July 16, 2015|March 19, 2009|Yes|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT00866177||141721|
NCT00866190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0048|Dose Escalation Study of SQ109 in Healthy Adult Volunteers|A Phase 1B, Randomized, Placebo-Controlled, Double-Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single-Daily Doses of SQ109 in Normal, Healthy Male and Female Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|November 3, 2011|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866190||141720|
NCT00866567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MatPed 08-017|Defects in Opsonophagocytosis in Premature Infants|Defects in Opsonophagocytosis in Premature Infants as a Factor for the Development of Neonatal Sepsis||University Hospital, Geneva|No|Completed|October 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|Samples With DNA|Serum cDNA|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All premature infants delivered at the University Hospitals of Geneva|March 2009|February 2, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866567||141692|
NCT00866580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112865|A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine|Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1562902A.||GlaxoSmithKline||Withdrawn|May 2010|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|61 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 19, 2015|March 19, 2009|Yes|Yes|Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|No||https://clinicaltrials.gov/show/NCT00866580||141691|
NCT00866879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU8308 0773-017|Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients|Randomized Conversion of Calcineurin-Inhibitors(Tacrolimus to Sirolimus),6-24 Months Post Transplant Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection,Renal Allograft Function & Lymphocytes Function||Northwestern University|No|Active, not recruiting|June 2007|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|275|||Both|18 Years|70 Years|No|||January 2016|January 6, 2016|March 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866879||141668|
NCT00867815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12912|PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men With Erectile Dysfunction Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)||Bayer|No|Recruiting|July 2009|February 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|284|||Male|40 Years|N/A|No|||March 2016|March 9, 2016|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867815||141598|
NCT00867828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBP-4209AD|Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)|Multi-Center, Double-Blind, Placebo-Controlled, Monotherapy Study of Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease|MNEMOSYNE|NeuroBioPharm Inc.|No|Completed|May 2009|January 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|175|||Both|50 Years|N/A|No|||September 2011|September 30, 2011|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867828||141597|
NCT00898690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000355163|Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer|Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol||National Cancer Institute (NCI)||Active, not recruiting|March 2003|||||N/A|Observational|N/A|||Anticipated|120|||Both|18 Years|N/A|No|||May 2006|December 17, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898690||139276|
NCT00898963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000544400|Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496|Identification of Biomarkers in Follicular Lymphoma||National Cancer Institute (NCI)||Active, not recruiting|April 2007|||||N/A|Observational|N/A|||Anticipated|175|||Both|18 Years|N/A|No|||January 2010|June 21, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898963||139256|
NCT00867750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SX-PHCC-001|SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma|Radioembolisation (RE) With SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC). A Comparative, Prospective, Randomised, Open, Pilot Study.|SIRTACE|Sirtex Medical|Yes|Completed|March 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|March 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867750||141603|
NCT00867763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939|In Vitro Maturation With in Vitro Fertilization (IVF) Compared to Mild in Vitro Fertilization|Clinical Research Study on in Vitro Maturation With IVF Compared to Mild Stimulation IVF|IVM vs IVF|Batzofin Fertility Services|Yes|Suspended|March 2009|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1440|||Female|21 Years|41 Years|Accepts Healthy Volunteers|||March 2009|August 10, 2010|March 23, 2009||No|investigator changed location, requires new training effort|No||https://clinicaltrials.gov/show/NCT00867763||141602|
NCT00868062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08101 colloidAug08|Responses to Colloid Infusions|Do 100 kiloDaltons Matter? A Prospective Randomised Double-blind Study on the Blood Volume Expanding Effects of Two Different Colloids in Patients Undergoing Laparoscopic Cholecystectomy||University of Nottingham|No|Completed|April 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 15, 2011|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868062||141579|
NCT00868608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K7-2001|Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma|A Phase 2 Study Of Inotuzumab Ozogamicin (CMC-544) In Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) That Is Refractory To Or Has Relapsed After Rituximab And Chemotherapy Or Radioimmunotherapy||Pfizer|No|Completed|July 2009|June 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868608||141538|
NCT00868309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-03/02|A Comparison of Crotalinae (Pit Viper) Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab, Ovine Antivenom (CroFab) in the Treatment of Pit Viper Envenomation|A Comparison of Anavip and CroFab in the Treatment of Subjects With Crotalinae (Pit Viper) Envenomation: A Randomized, Prospective, Open-Label, Controlled, Comparative, Multicenter Study||Instituto Bioclon S.A. de C.V.|No|Completed|January 2005|February 2007|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|70 Years|No|||April 2009|April 3, 2009|November 6, 2008|Yes|Yes||No|November 6, 2008|https://clinicaltrials.gov/show/NCT00868309||141560|
NCT00868855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 030473|Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-Critical Coronary Artery Disease|The Intracoronary Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events in Patients With Non-Critical Coronary Artery Disease||Vanderbilt University|Yes|Enrolling by invitation|December 2003|||December 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||March 2009|March 24, 2009|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00868855||141519|
NCT00869206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-70604|Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement|A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|March 2009|||May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1758|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869206||141492|
NCT00869193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08050V|Effect of Grape Seed Extract on Blood Pressure|Effect of Grape Seed Extract High in Polyphenols on Blood Pressure in Subjects With Elevated Blood Pressure Levels||Unilever R&D|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|70|||Both|35 Years|75 Years|No|||August 2009|August 27, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869193||141493|
NCT00869440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS 7056-003|Dose-Finding Safety Study Evaluating CNS 7056 in Patients Undergoing Diagnostic Upper GI Endoscopy|A Phase IIa, Randomized, Controlled, Double-Blind, Dose-Finding Study Evaluating the Safety and Pharmacodynamics of CNS 7056 in Patients Undergoing Diagnostic Upper GI Endoscopy||Paion UK Ltd.|Yes|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|102|||Both|18 Years|65 Years|No|||September 2010|September 8, 2010|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869440||141474|
NCT00865280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTK 0796 CSSI-0804|Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)|A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection|CSSI|Paratek Pharmaceuticals Inc|No|Terminated|March 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|March 17, 2009|Yes|Yes|Terminated|No||https://clinicaltrials.gov/show/NCT00865280||141789|
NCT00865293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obesity MCA 2009|Expiratory Airflow Limitation in Subjects With Obesity|Obesity and Expiratory Flow Limitation (EFL)|EFL|Medical Center Alkmaar|No|Active, not recruiting|July 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healty volunteers|July 2009|July 13, 2009|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865293||141788|
NCT00866008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOSTrial|A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)|The Impact of the Heterogeneity of the Recruited Cohort of Follicles During Ovarian Hyperstimulation for IVF on Aneuploidy Rates of Generated Embryos.||UMC Utrecht|No|Terminated|October 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||July 2013|July 19, 2013|March 19, 2009||No|Due to a very slow inclusion rate.|No||https://clinicaltrials.gov/show/NCT00866008||141734|
NCT00865969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-19|Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma|A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma|PTCL|Spectrum Pharmaceuticals, Inc|Yes|Completed|December 2008|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|March 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865969||141737|
NCT00866203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA05|HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy|A Prospective, Randomized, Multicenter Trial Comparing a Modified HDS Therapy Supported by PBPC Transplant With Additional 4 Courses of Front-Line Therapy in Adult Aggressive NHL With PR After Short Course of Up-Front Chemotherapy||Gruppo Italiano Studio Linfomi|No|Completed|October 2000|April 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|441|||Both|18 Years|65 Years|No|||March 2009|March 19, 2009|March 13, 2007||No||No||https://clinicaltrials.gov/show/NCT00866203||141719|
NCT00866216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA02511|Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Geneva 600mg Azithromycin Monohydrate Tablets and Pfizer Inc. (Zithromax) 600mg Azithromycin Dihydrate Tablets in Healthy Adult Volunteers Under Fasting Conditions||Sandoz||Completed|August 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 19, 2009|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866216||141718|
NCT00866593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004L04118|A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression|A Randomized Double-blind Parallel Innovator-Controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram Oxalate Tablets in the Treatment of Chinese Patients With Depression||Shanghai Mental Health Center|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|65 Years|No|||April 2013|April 1, 2013|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00866593||141690|
NCT00868400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECALICS|Clinical Value of Preoperative Oral Carbohydrate Loading in Colorectal Surgery|Multi-centre Double-blind Randomized Trial of the Clinical Value of Preoperative Oral Carbohydrate Loading in Colorectal Surgery.||Gulhane School of Medicine|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|215|||Both|16 Years|80 Years|No|||March 2015|March 9, 2015|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868400||141554|
NCT00868413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-458|Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia||AbbVie||Completed|November 2009|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||May 2013|June 5, 2013|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868413||141553|
NCT00898703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597587|Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer|QUANTIFICATION OF CIRCULATING ENDOTHELIAL CELLS (CEC) AND PLASMA ANGIOGENIC FACTORS IN PATIENTS WITH BREAST CANCER||University of Arizona||Completed|August 2001|March 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Female|N/A|N/A|No|Probability Sample|women with breast cancer or a history of breast cancer|December 2012|December 13, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898703||139275|
NCT00899782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-140202|Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer|The CALGB Lung Cancer Tissue Bank||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|July 2004|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Tumor, blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected or histologically documented previously untreated lung cancer        undergoing surgical resection at a CALGB Lung Cancer Tissue Bank-approved institution.|November 2015|November 10, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899782||139200|
NCT00867776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005105|Creating African-American Wellness Through Exercise|Creating African-American Wellness Through Exercise: Community Driven Strategies to Improve Health||Oregon Health and Science University|No|Terminated|June 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|22|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|March 23, 2009||No|We decided to alter the intervention.|No||https://clinicaltrials.gov/show/NCT00867776||141601|
NCT00868335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWK-Tracking01|Cervical Spine; Movement Before and After Anterior Cervical Discectomy, With or Without a Cervical Disc Prosthesis|Cervical Spine; Movement Before and After Anterior Cervical Discectomy, With or Without an Activ-C Cervical Disc Prosthesis.||Maastricht University Medical Center|Yes|Completed|December 2007|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|No|||March 2016|March 20, 2016|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868335||141559|
NCT00868348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-003180-39|A Comparison of Naropin and Ketorolac for Postoperative Analgesia After Total Knee Arthroplasty|Local Infiltration Analgesia for Total Knee Arthroplasty: Should Ketorolac be Added||University of Aarhus|Yes|Completed|May 2009|September 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||July 2013|January 22, 2014|March 24, 2009||No||No|July 10, 2013|https://clinicaltrials.gov/show/NCT00868348||141558|
NCT00868647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFAII|Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood|Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood: A Phase II Study||Seattle Children's Hospital|Yes|Suspended|June 2007|||June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||August 2009|August 28, 2009|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868647||141535|
NCT00869466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCGPC-B-AHEAD|Weight Control Programs in Women Who Have Undergone Surgery for Early Stage Breast Cancer|B- AHEAD Study (Breast - Activity & Healthy Eating After Diagnosis) Randomised Comparison of 3 Weight Control Programmes During Adjuvant Treatment for Early Breast Cancer.||National Cancer Institute (NCI)||Completed|August 2008|February 2011|Actual|||N/A|Observational|N/A|||Actual|409|||Female|18 Years|N/A|No|||March 2009|April 2, 2013|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869466||141472|
NCT00864981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B052005|A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions||Sandoz||Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00864981||141812|
NCT00865319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-05-232 Amendment 1|Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)|A Multicenter Phase 2 Study Comparing 99m Tc EC-DG SPECT/CT With 18F FDG PET/CT in the Evaluation of Patients With Non-small Cell Lung Cancer (NSCLC)||Cell>Point LLC|Yes|Completed|June 2009|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|22|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|March 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00865319||141786|
NCT00869219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMisericordiaSantos|Comparison of Pain Sensation During Single Use of Two Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)|Phase 4 Study of Topical NSAID for Ophthalmologic Use: Pain Measurement After First Drop.||Santa Casa de Misericordia de Santos|No|Recruiting|March 2009|August 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||March 2009|March 25, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00869219||141491|
NCT00869453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162/08/CE/FBM|Gut Hormone Secretion and Macronutrients|Gut Hormone Secretion Pattern in Response to Different Macronutrients in Healthy Volunteers||University of Lausanne|No|Completed|March 2009|December 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male volunteers|June 2012|June 29, 2012|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869453||141473|
NCT00865332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080437|Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates|Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates||National Institutes of Health Clinical Center (CC)||Withdrawn|December 2007|December 2010||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|50 Years|No|||December 2010|December 30, 2011|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865332||141785|
NCT00864955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 08 13|Cutaneous DNA Damage Caused by UV-A Irradiation|Damage to DNA Caused by UV-A Irradiation: Photochemical Mechanism and Cutaneous Parameters Involved in the Formation of Cyclobutane Pyrimidine Dimers|DIMUVA|University Hospital, Grenoble|Yes|Completed|March 2009|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||September 2009|September 2, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00864955||141814|
NCT00864968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-493|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers||Actavis Inc.|No|Completed|February 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864968||141813|
NCT00864942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-CLL-NHL-PI-356|Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)|Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-Cell Lymphoid Malignancies|Phase I BLR|Georgetown University|Yes|Completed|February 2009|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||June 2014|March 12, 2015|March 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00864942||141815|
NCT00865644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-347|Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1|Pilot Study of Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1||Massachusetts General Hospital|Yes|Active, not recruiting|March 2009|December 2013|Anticipated|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865644||141761|
NCT00865657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0852|A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|September 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865657||141760|
NCT00866892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808-081|Pediatric Pilot Study: Irrigation and Scrubbing in Facial and Scalp Wounds|A Pilot Study of Noncontaminated Facial and Scalp Wounds in the Pediatric Population: Getting Away Without Irrigation and Scrubbing||Children's Hospitals and Clinics of Minnesota|No|Withdrawn|April 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Month|20 Years|No|||July 2015|July 13, 2015|March 19, 2009||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT00866892||141667|
NCT00866229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-51-15|Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level|Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level||Ramathibodi Hospital|Yes|Recruiting|April 2008|June 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||March 2009|March 19, 2009|March 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866229||141717|
NCT00866242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040710 Phase IIb|Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb|Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study||University of Maryland|Yes|Terminated|January 2010|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|March 19, 2009|Yes|Yes|Reactogenicity met study halting criteria|No||https://clinicaltrials.gov/show/NCT00866242||141716|
NCT00866619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110021|Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa|Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa||GlaxoSmithKline||Completed|March 2009|January 2014|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|15459|||Both|6 Weeks|17 Months|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866619||141688|
NCT00867529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2226.00|Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma|Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|February 2009|||March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||November 2015|November 23, 2015|March 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867529||141620|
NCT00867542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iugr2009HMO-CTIL|Dental and Oral Finding in Israeli Children With Past Intrauterine Growth Retardation (IUGR)|Dental and Oral Findings in Israeli Children With Past IUGR - a Comprehensive Study||Hadassah Medical Organization|No|Not yet recruiting|June 2009|February 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|45|||Female|3 Years|4 Years|Accepts Healthy Volunteers|Probability Sample|15 children aged 3-4 y old with IUGR in the past, 30 healthy children sex and age matched|March 2009|March 23, 2009|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867542||141619|
NCT00867555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-052|Green Tea, High in Epigallocatechin Gallate (EGCG) and Postprandial Fat Oxidation|Effects of the Green Tea Extract TEAVIGO High in EGCG, on Postprandial Fat Oxidation in Overweight Volunteers||Maastricht University Medical Center|Yes|Completed|October 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|March 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867555||141618|
NCT00868426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103001|Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler|Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler, Symbicort Turbuhaler; an Open, Single Center, Single Dose Study With 3-way Crossover Design in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|August 12, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868426||141552|
NCT00868439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLY5016-202|Evaluation of Patiromer in Heart Failure Patients|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients|PEARL-HF|Relypsa, Inc.|No|Completed|April 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 23, 2009|Yes|Yes||No|November 11, 2015|https://clinicaltrials.gov/show/NCT00868439||141551|
NCT00899522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445453|Tissue Sample Collection From Patients With Fanconi Anemia|Fanconi Anemia Cancer Cell Repository||OHSU Knight Cancer Institute||Completed|August 2005|May 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|8|||Both|1 Year|55 Years|No|Probability Sample|To recruit participants into this project, an announcement will be posted on the Fanconi        Anemia Research Fund website (http://www.fanconi.org/) after IRB approval is obtained.|May 2014|May 16, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899522||139219|
NCT00899535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617514|Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030|The Cancer Genome Atlas (TCGA) Utilizing Z0030 NSCLC Patient Samples||Alliance for Clinical Trials in Oncology||Withdrawn|October 2008|||October 2010|Anticipated|N/A|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899535||139218|
NCT00867789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810-162|Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department|Trimethoprim-sulfamethoxazole Versus Placebo in the Treatment of Cutaneous Abscesses in the Emergency Department||Children's Mercy Hospital Kansas City|No|Recruiting|March 2009|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|3 Months|17 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867789||141600|
NCT00868075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/S1102/40|Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis|Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis||NHS Lothian|No|Completed|March 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|75 Years|No|||November 2011|November 4, 2011|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00868075||141578|
NCT00868868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-990-0340|Pedometer and Exercise Study in Prostate Cancer Patients With Hormonal Therapy|Pedometer and Exercise Study: A Randomized Trial Evaluating the Use of a Pedometer and Brief Exercise Coaching in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.||Groupe de recherche en Urologie de la Mauricie|No|Recruiting|June 2008|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male subjects aged 18 years or older with histological confirmed prostate cancer.|March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868868||141518|
NCT00869232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106952|UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission|UARK 2008-02, A Phase II Trial for High-risk Myeloma Evaluation Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-host-exhausting and Timely Dose-reduced MEL-80-VRD-PACE Tandem Transplants||University of Arkansas|No|Enrolling by invitation|October 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|75 Years|No|||October 2015|October 1, 2015|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869232||141490|
NCT00864994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23475|Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)|COPD: Transition of Systemic Inflammation Into Multiorgan Pathology (Study 3). (De Effecten Van Ontsteking op Skeletspieren Bij COPD)||Top Institute Pharma|Yes|Not yet recruiting|September 2010|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Blood will be retained to investigate differences in candidate genes (SNPs) for COPD and CVD      between the different groups.|Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Totally 60 subjects will be included          -  30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75             years)          -  30 COPD patients with GOLD stage II (age 40-75 years)|September 2010|March 26, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00864994||141811|
NCT00865696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00-435|A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 15 mg Mirtazapine Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|September 2001|September 2001|Actual|September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865696||141757|
NCT00865709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13162|Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects|Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease||Bayer|Yes|Completed|March 2009|February 2012|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|February 2, 2009|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT00865709||141756|
NCT00865748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-052|A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|January 2004|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865748||141753|
NCT00865670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA03414|To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Geneva 600 mg Azithromycin Monohydrate Tablets and Pfizer Inc. (Zithromax) 600 mg Azithromycin Dihydrate Tablets in Healthy Adult Volunteers Under Fed Conditions||Sandoz||Completed|August 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00865670||141759|
NCT00865683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|618|DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)|DHA, Inflammation, and Insulin Sensitivity||National Heart, Lung, and Blood Institute (NHLBI)|No|Recruiting|April 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2009|July 14, 2009|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865683||141758|
NCT00866021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA-5506|Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r|A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent.|PEKARI|Fundacion SEIMC-GESIDA|No|Completed|February 2008|October 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00866021||141733|
NCT00866034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETRO Trial|Cetrotide Treatment Optimization|Prospective, Multicenter,Randomized Controlled Trial Towards Identifying the Optimal GnRH Antagonist Treatment Protocol||UMC Utrecht|Yes|Terminated|February 2009|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|617|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||February 2014|February 4, 2014|March 19, 2009||No|Due to limited rate of patient inclusion|No|October 17, 2013|https://clinicaltrials.gov/show/NCT00866034||141732|The study was terminated prematurely because no significant difference was observed in clinical outcome after 617 inclusions. A much larger population would be needed to detect a small significant difference in favour of either study arm.
NCT00866255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237/06|Continuous Measurement of Intratracheal Pressure|Continuous Measurement of Intratracheal Pressure in Mechanically Ventilated Infants||University Hospital Freiburg|No|Completed|January 2008|||May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|10 Years|No|||March 2009|February 1, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866255||141715|
NCT00865306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000P000305|Early Intervention for Children at Risk for Anxiety|Early Intervention for Children at Risk for Anxiety||Massachusetts General Hospital|No|Completed|March 1998|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|4 Years|7 Years|No|||September 2010|September 22, 2010|March 17, 2009||No||No|July 20, 2010|https://clinicaltrials.gov/show/NCT00865306||141787|Wait-list control condition Use of parent report in diagnostic interviews (necessary in this young age range) Small sample size
NCT00866268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRENAJE50MMHG/1|Low Versus High Pressure Suction Drainage After Total Knee Arthroplasty|"Low Versus High Pressure Suction Drainage After Total Knee Arthroplasty: a Double Blind Randomized Controlled Trial"||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|May 2006|March 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866268||141714|
NCT00866645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004L03556|A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia|A Randomized Blind Parallel Intramuscular Haloperidol-Controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Intramuscular Levosulpiride in the Treatment of Chinese Patients With Agitation Of Schizophrenia||Shanghai Mental Health Center|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||December 2010|December 2, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866645||141686|
NCT00866905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 133|Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer|Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer||SCRI Development Innovations, LLC|No|Completed|April 2009|October 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Female|18 Years|N/A|No|||December 2014|December 5, 2014|March 19, 2009|No|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00866905||141666|
NCT00867243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU12442 1963-002|Prediction of Hepatitis C Recurrence in Liver Transplant Recipients|Prediction of Hepatitis C Recurrence in Liver Transplant Recipients||Northwestern University|No|Terminated|October 2005|May 2011|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|24|Samples With DNA|Recipient specimens: Peripheral blood draws at baseline and follow-up clinic visits.      Donor specimens: Donor cells will be isolated from lymph nodes obtained at time of harvest;      if living donor - blood taken at time of liver resection surgery.|Both|18 Years|N/A|No|Probability Sample|The target population is males/females over the age of 18 that require liver        transplantation, and their donors|June 2013|June 10, 2013|March 19, 2009||No|This project is no longer being adequately supported to allow completion|No||https://clinicaltrials.gov/show/NCT00867243||141642|
NCT00867256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDMOM|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2004|||||N/A|N/A|N/A||||||||||||||March 19, 2009|April 7, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867256||141641|
NCT00867217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11548|Vitamin D3 for Aromatase Inhibitor Induced Arthralgias|A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).|VITAL|University of Kansas Medical Center|Yes|Active, not recruiting|March 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Female|18 Years|N/A|No|||August 2010|August 17, 2010|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867217||141644|
NCT00867230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0201|FTS Study in Patients With Advanced Hematologic Malignancies|A Phase I Open-Label Study of S-Trans, Trans-Farnesylthiosalicylic Acid (FTS) Administered on Days 1 to 21 of a 28 Day Cycle in Patients With Advanced Hematologic Malignancies||M.D. Anderson Cancer Center|No|Completed|May 2006|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|March 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867230||141643|
NCT00867841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEO-ID-001|A Polymerase Chain Reaction (PCR) - Based Method to Improve Antibiotic Prescribing for Pneumonia|A Polymerase Chain Reaction-based Method to Improve Antibiotic Prescribing for Children and Adolescents With Community-Acquired Pneumonia - a Pilot Study||Children's Hospital of Eastern Ontario|No|Withdrawn||||||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|0|Samples With DNA|nasopharyngeal swabs blood samples (for pneumococcal PCR)|Both|180 Days|N/A|Accepts Healthy Volunteers|Non-Probability Sample|children with community-acquired pneumonia presenting to the Children's Hospital of        Eastern Ontario emergency department|February 2016|February 24, 2016|March 23, 2009||No|funding issues and procedural problems|No||https://clinicaltrials.gov/show/NCT00867841||141596|
NCT00867854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 081|Treatment De-Intensification and Residual HIV-1 in Youth|Treatment De-Intensification and Residual HIV-1 in Adolescents and Young Adults: A Sub-Study of ATN 061 and ATN 071.||Westat|Yes|Completed|February 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|34|Samples With DNA|Whole blood|Both|18 Years|24 Years|No|Non-Probability Sample|Twenty-five subjects enrolled in Arm A of ATN 061 who started highly-active antiretroviral        therapy (HAART) at CD4+ T cells > 350 cells/cubic millimeter (mm3) and are undergoing        treatment de-intensification at week 48 of HAART.        Twenty-five "control" subjects initiating HAART based on current Department of Health and        Human Services (DHHS) guidelines at CD4+ T cell levels < 350 cells/mm3 and maintained on        standard HAART.|March 2016|March 1, 2016|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867854||141595|
NCT00868127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-04-TL-475-010|Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia|An Open-Label Extension Study to Evaluate the Safety and Tolerability of Lapaquistat Acetate in Subjects With Hypercholesterolemia||Takeda|No|Completed|December 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|574|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|March 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868127||141574|
NCT00868153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14494|Mirena in Idiopathic Menorrhagia|Levonorgestrel Releasing Intrauterine Device (Mirena) in Idiopathic Menorrhagia||Bayer|No|Completed|August 2004|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1125|None Retained|Serum|Female|30 Years|45 Years|No|Non-Probability Sample|Women diagnosed with idiopathic menorrhagia, age 30-45, BMI 18-34|February 2015|February 16, 2015|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00868153||141572|
NCT00899275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST06B1|Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma|A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens||Children's Oncology Group|No|Recruiting|February 2008|||January 2100|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|Samples With DNA|serum, plasma and blood|Both|N/A|120 Years|No|Non-Probability Sample|All osteosarcoma patients seen at COG institutions|May 2015|September 28, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899275||139236|
NCT00868374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-07-29|Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder|Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder|MDD/GAD|University Hospital Case Medical Center|Yes|Terminated|June 2008|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||December 2013|December 23, 2013|March 24, 2009|Yes|Yes|Study terminated due to low enrollment|No|November 1, 2013|https://clinicaltrials.gov/show/NCT00868374||141556|
NCT00868660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP08-216|Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose|A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission||Zealand Pharma|Yes|Completed|January 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|60 Years|No|||November 2010|November 1, 2010|March 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00868660||141534|
NCT00868881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CES-DUM-2008/2|Treatment of Hypertension in Primary Care in Spain|Treatment of Hypertension in Primary Care in Spain|TAPAS|AstraZeneca|No|Completed|March 2009|July 2009|Actual|||N/A|Observational|Time Perspective: Retrospective||6|Anticipated|2160|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 years or older who has been diagnosed of primary hypertension and/or        treated for hypertension.|July 2009|July 10, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868881||141517|
NCT00868894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27-003|Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension|A Randomized, Double-masked, Placebo- and Active-controlled, Multi-Center, Dose Escalation Trial of DE-104 Ophthalmic Solution in Japanese and Non-Japanese Subjects With Primary Open-angle Glaucoma or Ocular Hypertension||Santen Inc.||Completed|March 2009|June 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|49|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868894||141516|
NCT00869479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002371|Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis|Validation of a Questionnaire as a Screening Tool to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis||Massachusetts General Hospital|Yes|Completed|March 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Massachusetts General Hospital Dermatology and Rheumatology clinics|December 2010|December 14, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00869479||141471|
NCT00869492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mar-der1|Comparison of Nadifloxacin Cream Alone and With Benzoyl Peroxide Solution in the Treatment of Acne|A Double Blind Randomised Comparison of Nadifloxacin 1% Cream Alone and Nadifloxacine %1 Cream With Benzoyl Peroxide 5% Solution in the Treatment of Mild to Moderate Facial Acne Vulgaris||Marmara University|No|Active, not recruiting|August 2008|June 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|14 Years|40 Years|No|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869492||141470|
NCT00865020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2408|Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal|A Twelve-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Prolonged Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg in Mild to Moderate Hypertensive Patients With the 24-hour Ambulatory Blood Pressure Measurement After 1 Week of Treatment Withdrawal Study Acronym: ASSERTIVE - AliSkiren Study of Profound antihypERtensive Efficacy in hyperTensIVE Patients|ASSERTIVE|Novartis||Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|822|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|March 17, 2009||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00865020||141809|
NCT00865033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B053709|A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions|A Relative Bioavailability Study of Metformin HCL 1000 mg Tablets Under Fasting Conditions||Sandoz||Completed|November 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 18, 2009|March 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00865033||141808|
NCT00865761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-0851|A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|September 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865761||141752|
NCT00866359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-BCT-001|A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease||Celgene|Yes|Completed|October 2009|July 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|March 18, 2009|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00866359||141707|Planned sample size not reached; slow enrollment
NCT00866385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1320C00011|AZD8566 Food Effect/Microtracer Study|An Open, Randomised, Phase I, 2-Period Crossover Trial to Investigate the Absolute Bioavailability and the Effect of Food on the Oral Bioavailability of AZD8566 in Healthy Volunteers||AstraZeneca|No|Completed|March 2009|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 8, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866385||141706|
NCT00866047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG035-0004|A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma|A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)||Seattle Genetics, Inc.|Yes|Active, not recruiting|March 2009|June 2016|Anticipated|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|12 Years|N/A|No|||January 2016|January 26, 2016|March 19, 2009|Yes|Yes||No|September 15, 2011|https://clinicaltrials.gov/show/NCT00866047||141731|Maximum duration of follow-up was 17.5 months; 9 participants were continuing on treatment and 31 participants remained in survival follow-up at the time of the efficacy analyses.
NCT00866281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPKC412A2114|A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia|A Phase I/II, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients With Relapsed or Refractory Leukemia||Novartis||Terminated|September 2009|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|3 Months|18 Years|No|||November 2015|November 18, 2015|March 19, 2009|Yes|Yes|Despite considerable efforts to boost recruitment during the final year of the study, no new    patients were enrolled.|No|September 8, 2015|https://clinicaltrials.gov/show/NCT00866281||141713|The study was terminated early since despite considerable efforts to boost recruitment, no new participants were enrolled in the final year of this study.
NCT00866294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112810|Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)|A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder||GlaxoSmithKline|No|Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|416|||Both|20 Years|N/A|No|||February 2013|May 29, 2014|March 19, 2009||No||No|October 14, 2010|https://clinicaltrials.gov/show/NCT00866294||141712|
NCT00866632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-ABI-COP-538|Improving Psychological Wellness After Acquired Brain Injury|Improving Mood, Adjustment and Coping in People With Acquired Brain Injury: A Randomized Controlled Trial to Examine the Efficacy of a Cognitive Behaviour Therapy Protocol Adapted for Brain Injury and Remote Administration of Services.||Toronto Rehabilitation Institute|No|Recruiting|June 2008|||December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|75|||Both|18 Years|65 Years|No|||September 2010|September 9, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866632||141687|
NCT00866658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10887|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)|A Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea|GETGOAL-L-ASIA|Sanofi|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|311|||Both|19 Years|N/A|No|||March 2014|March 14, 2014|March 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866658||141685|
NCT00866918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML0631|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia|Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation||Children's Oncology Group|Yes|Active, not recruiting|March 2009|||June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|2 Years|21 Years|No|||July 2015|August 21, 2015|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866918||141665|
NCT00866671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111081|Observational Study of Nelarabine in Children and Young Adults|A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma||GlaxoSmithKline|No|Completed|February 2009|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|N/A|21 Years|No|Probability Sample|Male or Female 21 years or younger with Relapsed or refractory T-lineage Acute        Lymphoblastic Leukaemia (T-ALL) or lymphoblastic lymphoma (T-LBL)|January 2015|January 12, 2015|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866671||141684|
NCT00867269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090102|Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia|Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia||National Institutes of Health Clinical Center (CC)||Recruiting|March 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|March 12, 2016|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867269||141640|
NCT00867568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-287|TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma|A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma||Spectrum Health Hospitals|Yes|Completed|March 2009|February 2016|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|12 Months|21 Years|No|||February 2016|February 4, 2016|March 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867568||141617|
NCT00867893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sit-AUG|Suggested Immobilization Test (SIT) Test for Early Detection of Restless Legs Syndrome (RLS) Augmentation - Proof of Concept|d Immobilization Test (SIT) Test for Early Detection of Restless Legs Syndrome (RLS) Augmentation - Proof of Concept||Johns Hopkins University|No|Completed|February 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|68|||Both|18 Years|N/A|No|Non-Probability Sample|RLS patients treated with medication|August 2012|August 13, 2012|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00867893||141592|
NCT00867594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0566-08-HMO-CTIL|Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients|A Single Blind, Open-Label Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral Insulin Formulation in Type 1 Subjects||Hadassah Medical Organization||Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|50 Years|No|||March 2008|August 10, 2011|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867594||141615|
NCT00867607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX6-201ver4-HMO-CTIL|Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis|A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm||Hadassah Medical Organization|Yes|Completed|March 2011|March 2014|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|65 Years|No|||March 2012|April 19, 2015|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00867607||141614|
NCT00868140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCUIRB4480|Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)|Determination if Indirectly Reducing Circulating Insulin by Improving Insulin Sensitivity With Pioglitazone, Decreases Renal Clearance of DCI, Increases the Circulating Concentration of DCI, and Enhances Insulin-stimulated Release of the DCI-IPG Mediator in Obese Women With PCOS|PCOS|Virginia Commonwealth University|Yes|Terminated|February 2009|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|36|||Female|18 Years|40 Years|No|||August 2014|August 1, 2014|March 22, 2009|Yes|Yes|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00868140||141573|
NCT00869544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0606151|Pneumocystis in Pathogenesis of HIV-associated Emphysema|Pneumocystis in Pathogenesis of HIV-associated Emphysema|PACT|University of Pittsburgh|Yes|Completed|August 2007|July 2013|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|Samples With DNA|oral wash blood sputum BAL|Both|18 Years|N/A|No|Probability Sample|patients who have been determined to attend the UPMC HIV/AIDS program and/or participants        in the Pitt Mens study.|September 2014|September 4, 2014|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869544||141466|
NCT00899574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 09-0225|Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases|Phase II Evaluation of Imiquimod, a Topical Toll-like Receptor 7 (TLR7) Agonist in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases||New York University School of Medicine|Yes|Completed|May 2009|June 2013|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|May 11, 2009|Yes|Yes||No|April 12, 2012|https://clinicaltrials.gov/show/NCT00899574||139215|The 20% response rate would have justified to continue; but the study was concluded and a new trial of imiquimod and local radiotherapy (NCT01421017) is open, based on preclinical findings indicating that the combination was more effective.
NCT00899587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8753|Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia|Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia||hahid Beheshti University of Medical Sciences|Yes|Recruiting||||||Phase 1|Interventional|N/A|3||||||Both|N/A|N/A||||May 2009|May 11, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00899587||139214|
NCT00899795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445436|Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers|Stromal Injury and Clonal Adaptation in Myelodysplasia||OHSU Knight Cancer Institute|Yes|Terminated|June 2002|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|35|||Both|5 Years|120 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inpatient, outpatient, and normal volunteers|February 2016|February 2, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899795||139199|
NCT00899808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000609|Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer|Molecular and Genetic Markers in the Local-regional Management of Patients Undergoing Radiation Therapy||Rutgers, The State University of New Jersey|No|Withdrawn|May 2006|||May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing radiation therapy for malignant disease will be eligible for these        studies. Initially we will focus on specific disease sites, such as breast, prostate and        lung, but ultimately we will expand this to include any disease site. Patients who met        standard criteria for radiation therapy but ultimately did not receive radiation therapy        will be used as a control arm if needed.|May 2015|May 27, 2015|May 9, 2009||No|not "applicable clinical trial"|No||https://clinicaltrials.gov/show/NCT00899808||139198|
NCT00868673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRUCTOSE 09-630|The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome|The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome||Instituto Nacional de Cardiologia Ignacio Chavez|No|Completed|March 2009|February 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|120|||Both|18 Years|60 Years|No|||November 2009|July 8, 2010|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868673||141533|
NCT00869505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000461|Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder|A Chart Review of Memantine Use in the Treatment of Obsessive-Compulsive Disorder at the OCD Institute||Massachusetts General Hospital|No|Completed|March 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|||||Both|18 Years|N/A|No|Non-Probability Sample|The study population comprised 44 subjects who received standard treatment at the MGH/        McLean Hospital OCD Institute Intensive Residential Treatment (IRT) program, admitted        between May 1999 and December 2007.|March 2009|March 25, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869505||141469|
NCT00865007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA-6008|Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy|A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir|KRETA|Fundacion SEIMC-GESIDA|No|Completed|December 2008|September 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|88|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865007||141810|
NCT00865371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0646-010|A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Extended-Released Tablets Formulation in Normal, Healthy Man Following a Standard Meal||Actavis Inc.|No|Completed|September 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865371||141782|
NCT00865384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00-436|A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 15 mg Mirtazapine Tablets Under Non-Fasting Conditions||Actavis Inc.|No|Completed|September 2001|September 2001|Actual|September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865384||141781|
NCT00890058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-547|A Case Control Study to Define Clinical, Immunologic and Radiographic Features of the Aromatase Inhibitor Arthralgia Syndrome|A Case Control Study to Define Clinical, Immunologic and Radiographic Features of the Aromatase Inhibitor Arthralgia Syndrome|CIRAS|Georgetown University|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|48|Samples Without DNA|Blood samples for cytokine measurements|Female|18 Years|N/A|No|Non-Probability Sample|Postmenopausal women with stage I-III breast cancer currently undergoing treatment at the        Lombardi Cancer Center will be screened for the presence of joint and hand        symptoms.Patients with symptoms who are receiving aromatase inhibitors will be considered        to be cases, while those with symptoms who are not receiving aromatase inhibitors will be        considered to be controls.|April 2009|July 14, 2010|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890058||139909|
NCT00890305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-2008-01|Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone|Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease||Medivation, Inc.|Yes|Completed|May 2009|March 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890305||139890|
NCT00890318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-705|A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C|||Abbott||Completed|April 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 19, 2010|April 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890318||139889|
NCT00899873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617494|Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997|Proposed Study of CLL Samples||National Cancer Institute (NCI)||Not yet recruiting|August 2008|||November 2009|Anticipated|N/A|Observational|N/A|||Anticipated|225|||Both|18 Years|N/A|No|||May 2009|February 10, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899873||139193|
NCT00900146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885I2202|Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients|Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study||Novartis||Terminated|April 2009|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|556|||Both|18 Years|74 Years|No|||January 2012|January 17, 2012|May 6, 2009|Yes|Yes|Numerically modest lowering of HbA1c with canakinumab in combination with metformin was    inadequate to continue patients with T2DM into Period IV of this study.|No|November 22, 2011|https://clinicaltrials.gov/show/NCT00900146||139175|
NCT00891137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT 2008-38|Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy|A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies||Cellerant Therapeutics|No|Completed|April 2009|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|30|||Both|12 Years|65 Years|No|||October 2014|October 23, 2014|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891137||139827|
NCT00899860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000550079|Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer|Renal Cell Cancer Tumor Markers||Comprehensive Cancer Center of Wake Forest University|Yes|Terminated|September 2003|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|N/A|120 Years|No|Non-Probability Sample|Those wiht histologically confirmed renal cell cancer who have underwent nephrectomy for        renal cell cancer.|June 2012|September 29, 2015|May 9, 2009||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00899860||139194|
NCT00900133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7104|Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer|A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|January 2005|December 2006|Actual|April 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|60|Samples With DNA|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor      markers.|Both|18 Years|N/A|No|Probability Sample|Patients With Newly Diagnosed Stage I,II,III Breast Cancer. Primary care clinic|October 2015|October 1, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900133||139176|
NCT00900354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-PK-2006-07|Pharmacokinetics of Dactinomycin in Young Patients With Cancer|Pharmacokinetics of Actinomycin D in Children With Cancer||National Cancer Institute (NCI)||Recruiting|June 2006|||||N/A|Observational|N/A|||Anticipated|50|||Both|N/A|21 Years|No|||June 2009|August 9, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900354||139160|
NCT00870987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1550|Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria|Clinical Trial on Safety, Immunogenicity, and Efficacy of a Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium Falciparum Circumsporozoite Protein and Apical Membrane Antigen 1 in Healthy Malaria-Naïve Adults in the US|DNA-Ad|U.S. Army Medical Research and Materiel Command|No|Active, not recruiting|May 2009|November 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|December 28, 2015|March 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00870987||141357|
NCT00871000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111815|Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.|Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 5 to 6-year-old Children.||GlaxoSmithKline||Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|303|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||January 2011|January 22, 2011|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871000||141356|
NCT00871273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP002|Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma|A Pharmacokinetic Study of Capecitabine in Patients Undergoing Peri-operative Chemotherapy and a Total Gastrectomy for Adenocarcinoma of the Stomach||Cambridge University Hospitals NHS Foundation Trust|No|Terminated|November 2009|October 2014|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||July 2015|July 18, 2015|March 27, 2009||No|1. Slow recruitment; 2. Change to clinical environment reducing the pool of potentially    eligible patients; 3. Availability of data from another similar study|No||https://clinicaltrials.gov/show/NCT00871273||141336|
NCT00900094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000276589|UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer|Proteomics Biomarker Development Laboratory (Aka IRB 1999-514)|IRB 2000-294|University of Michigan Cancer Center|Yes|Completed|June 2000|October 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The laboratory will apply technologies for protein analysis to the detection and        identification of proteins secreted by tumor cells and protein antigens that induce a        humoral response in tumors. The initial targeted tumor types for the identification of        potential biomarker proteins are: Colon, esophagus, ovary, lung, breast and liver|February 2012|February 5, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900094||139179|
NCT00888277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL IRB # 09.0167|Bayer/Cognitive Assessments With Multiple Sclerosis Subjects|Neuropsychological Assessments in the Multiple Sclerosis Clinic||University of Louisville|No|Completed|May 2009|January 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|55 Years|No|Non-Probability Sample|Subjects will be recruited from patients diagnosed with MS at the University of Louisville        Neurologists PCS.|October 2013|October 31, 2013|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00888277||140046|
NCT00888563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090131|Fatigue in Healthy Individuals|Fatigue in Healthy Individuals||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 12, 2015|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888563||140024|
NCT00888862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHCC2008-3|Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women|Desvenlafaxine Succinate in Major Depressive Disorder: Effects on Structural and Functional Imaging, Cognition, and Functional Outcomes in Midlife Women and Men|DVS|McMaster University|No|Recruiting|June 2009|October 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||April 2009|February 7, 2012|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888862||140001|
NCT00889174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090128|The Nosology and Etiology of Leukodystrophies of Unknown Causes|Leukodystrophies of Unknown Cause||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|||||N/A|Observational|N/A|||Anticipated|500|||Both|1 Month|99 Years|Accepts Healthy Volunteers|||August 2015|March 3, 2016|April 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00889174||139977|
NCT00889447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00013323|Screening Evaluation for Studies of Chronic Obstructive Pulmonary Disease (COPD)|Screening Evaluation for Studies of COPD||Johns Hopkins University|Yes|Active, not recruiting|January 2008|||July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples Without DNA|blood|Both|40 Years|N/A|No|Non-Probability Sample|Both Male and Female 40 years and older|April 2013|April 1, 2013|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889447||139956|
NCT00889720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051113|A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery|A Multicenter, Open Label Study To Investigate The Feasibility And Efficacy Of A Smoking Cessation Program With Varenicline In Patients Undergoing Elective Surgery||Pfizer|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2011|October 12, 2011|April 28, 2009|Yes|Yes||No|July 27, 2011|https://clinicaltrials.gov/show/NCT00889720||139935|This study was terminated after 16 of 100 planned subjects were enrolled due to slow recruitment and non-compliance with the protocol; only selected efficacy listings of the surgical population and key safety data were reported.
NCT00889733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVHM-01|Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer|A Phase I/II Trial of Intraperitoneal (IP) Cisplatin Combined With IV Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Their Initial Surgery Performed Following Neoadjuvant Intravenous Chemotherapy|OVHM-01|University Health Network, Toronto|Yes|Terminated|February 2007|||July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|75 Years|No|||October 2011|October 6, 2011|April 27, 2009||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00889733||139934|
NCT00889746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001v4|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2008|||||N/A|N/A|N/A||||||||||||||May 5, 2009|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889746||139933|
NCT00898833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000321397|Plasma and Urine Biomarkers in Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy|Laboratory Studies in Hormone Refractory Prostate Cancer - A Companion Study to CALGB 9480||Alliance for Clinical Trials in Oncology||Withdrawn|July 2003|||||N/A|Observational|N/A|||Actual|0|||Male|18 Years|N/A|No|||July 2013|July 15, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898833||139266|
NCT00899093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0235|YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy|A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy||Gynecologic Oncology Group||Active, not recruiting|September 2007|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Female|18 Years|N/A|No|Non-Probability Sample|Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity,        or Fallopian Tube Cancer Receiving Chemotherapy|February 2016|February 19, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899093||139247|
NCT00900666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFB2008.08|Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury|Randomized Controlled Trial on the Effects of Botulinum Toxin Injections in the Rectus Femoris on Gait Function in Stiff Knee Gait Following Acquired Brain Injury||Mary Free Bed Rehabilitation Hospital|No|Terminated|January 2009|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|May 12, 2009|Yes|Yes|Original subject recruitment goal was unrealistic. Study was terminated at N=19.|No|May 2, 2013|https://clinicaltrials.gov/show/NCT00900666||139137|Early termination due to difficulty identifying and recruiting participants.
NCT00900679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08032|Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer|A Standardized Nursing Intervention Protocol for Ovarian Cancer as a Chronic Illness||City of Hope Medical Center|Yes|Completed|July 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|N/A|1||Anticipated|110|||Female|18 Years|N/A|No|||August 2010|August 9, 2010|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00900679||139136|
NCT00899626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000584214|Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Patients and Healthy Participants Undergoing Colonoscopy, Endoscopy, or Surgery|Novel Colon Cancer Markers in Gastrointestinal Tissue and Biofluids||Vanderbilt University|Yes|Recruiting|June 2002|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood, Tissue, Body Fluids|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with GI malignancy|January 2013|January 21, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899626||139211|
NCT00900653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0022|Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women|Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study||Yonsei University|No|Enrolling by invitation|May 2009|July 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|142|||Female|40 Years|N/A|No|||May 2009|May 29, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00900653||139138|
NCT00896896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0668|Immunoreactivity to Cetuximab in Cancer Patients|Immunoreactivity to Cetuximab in Cancer Patients||Vanderbilt-Ingram Cancer Center|No|Completed|November 2006|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|538|||Both|18 Years|75 Years|No|Non-Probability Sample|Head and neck cancer or colorectal cancer patients who were treated with cetuximab|March 2013|March 29, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896896||139398|
NCT00897143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1507|Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer|Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens||Case Comprehensive Cancer Center|Yes|Withdrawn|June 2007|||||N/A|Observational|Time Perspective: Retrospective||1|Actual|0|Samples With DNA|Malignant pleural effusion specimens from patients with primary lung cancer obtained from      the Pathology Department at the University Hospitals of Cleveland.|Both|N/A|N/A|No|Probability Sample|Malignant pleural effusion samples from patients with primary lung cancer.|October 2015|October 8, 2015|May 9, 2009||No|PI Left|No||https://clinicaltrials.gov/show/NCT00897143||139381|
NCT00897351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600985|Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803|Evaluation of Polymorphisms, Mutations, and Protein Expression by Automated Quantitative Immunohistochemistry (AQUA) in the LapatinibTargets and Metabolic Pathway in Samples From E5803||National Cancer Institute (NCI)||Not yet recruiting|August 2008|||February 2009|Anticipated|N/A|Observational|N/A|||Anticipated|37|||Male|18 Years|N/A|No|||March 2009|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897351||139367|
NCT00871013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108053|UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)|Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)||University of Arkansas|Yes|Recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||October 2015|October 2, 2015|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871013||141355|
NCT00871286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 8997|Point-of-Care Computed Tomography (CT) Chronic Rhinosinusitis Study|Role of Point-of-Care CT Scanning in Patients Presenting With Symptoms of Chronic Rhinosinusitis||Northwestern University|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|70 Years|No|||January 2012|January 17, 2012|March 26, 2009||No||No|August 29, 2011|https://clinicaltrials.gov/show/NCT00871286||141335|
NCT00887939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090126|Pathogenesis of Physical Induced Urticarial Syndromes|Pathogenesis of Physical Induced Urticarial Syndromes||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|2 Years|90 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887939||140071|
NCT00888602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009001|Study to Evaluate the Effects of Psyllium on Blood Glucose|An Open Label, Randomized, 4-Period Cross-over Study to Evaluate the Effects of Psyllium Taken Before a Meal on Postprandial Blood Glucose in Healthy Males||Procter and Gamble|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|49|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888602||140021|
NCT00888615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0260|Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian,Fallopian Tube or Primary Peritoneal Cancer||Gynecologic Oncology Group|Yes|Recruiting|December 2010|||January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|April 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888615||140020|
NCT00888576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-4445|Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan|A Registry Study to Describe the Implications of Therapeutic Management of Etanercept in Patients With Rheumatoid Arthritis||Pfizer|No|Completed|December 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|441|||Both|20 Years|N/A|No|Non-Probability Sample|clinic|February 2012|February 7, 2012|April 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888576||140023|
NCT00888589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001022|Detection of Aggressive Breast Tumors Using Tc-99m-NC100692|Improved Sensitivity for the Detection of Aggressive Breast Tumors Using 99mTc-NC100692 and a Dual-headed Small Field of View CZT Gamma Camera.||Mayo Clinic|No|Completed|May 2008|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Female|18 Years|90 Years|No|Non-Probability Sample|Patients that are scheduled for a biopsy at the Mayo Clinic in Rochester, MN. The patients        must have a suspicious lesion|March 2014|March 25, 2014|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888589||140022|
NCT00888875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fast igel1|ILMA Fastrach Versus I-gel for Fiberoptic Tracheal Intubation|Is Fiberoptic Intubation Through the I-gel™ Equal to Fiberoptic Intubation Through the Intubating Laryngeal Mask (Fastrach)™ ?||University Hospital Inselspital, Berne|No|Completed|July 2008|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|85 Years|No|||March 2014|March 11, 2014|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888875||140000|
NCT00889187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-375|Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer|Phase I/II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer||Dana-Farber Cancer Institute|Yes|Terminated|August 2009|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2012|August 15, 2012|April 27, 2009|Yes|Yes|Excess toxicity was identified intraoperatively|No||https://clinicaltrials.gov/show/NCT00889187||139976|
NCT00898300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0514|Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer|Establishment of a Head and Neck Cancer Tissue/Specimen Bank||Radiation Therapy Oncology Group|No|Completed|September 2005|November 2013|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|351|Samples Without DNA|1. Fresh frozen specimens of normal squamous mucosa, tumors, and pre-malignant lesions of      the upper aerodigestive tract. 2. Paraffin-embedded tissue sections from head and neck      premalignant and malignant lesions. 3. Serum, plasma and isolate lymphocytes from blood      drawn from patients with head and neck cancer. 4. Buccal scrapings and saliva samples from      patients with head and neck cancer.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with confirmed or suspected head and neck cancer|November 2015|November 11, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898300||139302|
NCT00898547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150509|Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107|Additional Circulating Markers of Angiogenesis and Disease in Mesothelioma Patients Treated on CALGB 30107||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|November 2005|||March 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|47|Samples With DNA|Samples retained from patients participating on CALGB-30107.|Both|18 Years|N/A|No|Non-Probability Sample|Patients previously enrolled on CALGB-30107 diagnosed with malignant mesothelioma.|July 2015|July 31, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898547||139284|
NCT00899119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000487602|Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia|Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia||National Cancer Institute (NCI)||Recruiting|November 2005|||||N/A|Observational|N/A|||Anticipated|40|||Both|18 Years|N/A|No|||January 2008|December 17, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899119||139246|
NCT00899366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529758|DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia|Molecular Mechanisms of NOTCH Induced Transformation in T-ALL||National Cancer Institute (NCI)||Not yet recruiting|December 2006|||||N/A|Observational|N/A|||Anticipated|48|||Both|N/A|N/A|No|||June 2007|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899366||139230|
NCT00899639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000809|Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer|Correlation of Oncotype Dx With Image Features and Molecular Characteristics of Breast Cancer||Rutgers, The State University of New Jersey|Yes|Withdrawn|May 2008|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients with ER+ breast cancer with associated Oncotype Dx scores|May 2015|May 27, 2015|May 9, 2009|No|Yes|not "applicable clinical trial"|No||https://clinicaltrials.gov/show/NCT00899639||139210|
NCT00896922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000530630|Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911|Assessment of MUM1 Expression, Lymphoma-Associated Macrophages, and Regulatory T-Cells in Follicular Lymphoma: Prognostic Markers in SWOG S8809 and S9800/S9911 Trials Representing Pre-and Post-Monoclonal Antibody Therapy Protocols||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|349|||Both|16 Years|N/A|No|||June 2007|November 21, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896922||139396|
NCT00900367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583255|Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women|Nutrition Modulated Metabolism as a Disease Risk Factor||Brigham and Women's Hospital|No|Active, not recruiting|July 2005|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|1500|Samples Without DNA|we have only plasma, NHS has DNA samples.      Study is nested case control, so retrospective with respect to individual inclusion,      prospective with respect to sample collected before disease. Enrollment is approximate as it      includes samples that will be drpped, eg for QC resons|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women enrolled in the NHS I study; Group selected by Drs. Willett and Hankinson|February 2013|February 14, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900367||139159|
NCT00897364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-413|Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers|Analysis of Intermediate Endpoint Biomarkers in the Respiratory Epithelium of Smokers Compared to Non-Smoking Controls||University of Colorado, Denver|No|Active, not recruiting|May 2000|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|78|Samples With DNA|endobronchial biopsies, blood, sputum, urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|High risk for lung cancer/normal volunters|January 2016|January 13, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897364||139366|
NCT00897611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0402 CDR0000462562|Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma|Identification of Hypermethylated Serum Tumor DNA in High Grade Glioma Patients and Correlation With Magnetic Resonance Imaging Findings||Sidney Kimmel Comprehensive Cancer Center||Completed|April 2005|||August 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|42|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897611||139350|
NCT00870675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-P-00842/6|Magnetic Resonance Imaging (MRI) of Ventriculomegaly: Morphology and Outcome|MRI of Ventriculomegaly: Morphology and Outcome||National Institute for Biomedical Imaging and Bioengineering (NIBIB)|No|Completed|January 1996|June 2011|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|434|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women carrying a fetus diagnosed by ultrasound as having ventriculomegaly.|September 2014|September 23, 2014|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870675||141381|
NCT00870688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPA 044/K|Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening|Non Interventional Trial of Valproate Sustained Release Minitablets Once Daily in the Evening||Desitin Arzneimittel GmbH|No|Completed|January 2005|April 2006|Actual|April 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|82|||Both|12 Years|N/A|No|Non-Probability Sample|community sample outpatients|February 2009|May 19, 2009|January 9, 2009||No||No|January 9, 2009|https://clinicaltrials.gov/show/NCT00870688||141380|
NCT00871026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JO 207/4-1-5|Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM) - Based Planning and Creation of Orthodontic Appliances|Randomized Controlled Clinical Study Comparing Conventional and CAD/CAM-Based Treatment With Fixed Orthodontic Appliances||Charite University, Berlin, Germany|No|Active, not recruiting|March 2007|October 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|160|||Both|11 Years|30 Years|No|||March 2009|March 27, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871026||141354|
NCT00871299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT004572-O1A1|Practicing Alternative Techniques to Heal From Depression: The PATH-D Study|Applying Mindfulness-Based Cognitive Therapy to Treatment Resistant Depression|PATH-D|University of California, San Francisco|Yes|Completed|September 2009|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871299||141334|
NCT00887952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FO UFRGS|Partial Removal of Caries Dentines|Alternative Treatment of Deep Caries Lesions Based on Biological Evidences|PRCD|Federal University of Rio Grande do Sul|No|Active, not recruiting|August 2005|November 2010|Anticipated|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|329|||Both|9 Years|45 Years|No|||April 2009|December 29, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887952||140070|
NCT00887965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080287|A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab|A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab||Amgen|No|Completed|June 2009|August 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Female|N/A|N/A|No|||October 2013|October 23, 2013|April 23, 2009|Yes|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00887965||140069|
NCT00897546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000489213|Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma|Multiplex Analysis of Serum Biomarkers for Prediction Interferon Therapy Response in Melanoma Patients||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|1716|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2007|August 20, 2010|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897546||139352|
NCT00897533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000543981|Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer|Development of a Model to Predict Progression Free Survival After Treatment With Erlotinib in E3503||National Cancer Institute (NCI)||Active, not recruiting|April 2007|||||N/A|Observational|N/A|||Anticipated|137|||Both|N/A|N/A|No|||June 2007|June 21, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897533||139353|
NCT00897806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-408|Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Feasibility of Measuring Gene Expression Patterns Using Tissue Acquisition of Primary Stage 3 & 4 Epithelial Ovarian Cx or Primary Peritoneal Cx & Gene Expression Array Technology for Predicting Paclitaxel Chemotherapy||M.D. Anderson Cancer Center|No|Terminated|February 2002|February 2009|Actual|February 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|Samples With DNA|Tumor samples undergo transcriptional profiling using cDNA microarrays.|Both|N/A|N/A|No|Non-Probability Sample|Patients with newly diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary        Peritoneal Cancer.|July 2012|July 27, 2012|May 9, 2009||No|Terminated due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00897806||139336|
NCT00898040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000495284|Study of DNA Samples From Patients With Multiple Myeloma|Proposal for Combining ECOG Myeloma Trial SNP Data||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|N/A|No|||February 2009|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898040||139319|
NCT00898560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-128|Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive|Effect of Repeated Administration of Eslicarbazepine Acetate (BIA 2-093) 800mg Once-daily on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Subjects||Bial - Portela C S.A.|Yes|Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|May 11, 2009||No||No|December 5, 2014|https://clinicaltrials.gov/show/NCT00898560||139283|
NCT00898846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551714|Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery|Identification of the Prognostic Factors of Stage II Colon Cancer Patients Receiving Adjuvant Chemotherapy With UFT||National Cancer Institute (NCI)||Active, not recruiting|October 2006|||||N/A|Observational|N/A|||Anticipated|1000|||Both|20 Years|80 Years|No|||August 2011|December 17, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898846||139265|
NCT00900159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESRC-977|Effects of Daytime Eszopiclone Administration in Shift Workers|Effects of Daytime Eszopiclone Administration in Shift Workers on Overnight Wakefulness During a Subsequent Simulated Nightshift||Brigham and Women's Hospital|No|Completed|May 2009|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|April 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900159||139174|
NCT00900380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000478869|Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia|Comparison of P-gp Efflux and Accumulation Assay Results With ECOG 3999 Leukemia Samples||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|40|||Both|18 Years|N/A|No|||October 2007|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900380||139158|
NCT00900692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.001|Dynamic Splinting for Excessive Pronation Following CVA|Dynamic Splinting for Excessive Pronation Following CVA: A Randomized, Controlled Tial|SupPro Botox|Dynasplint Systems, Inc.|Yes|Withdrawn|May 2009|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00900692||139135|
NCT00900705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-2009-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2009|||||N/A|N/A|N/A||||||||||||||May 12, 2009|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900705||139134|
NCT00897637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN03B1|Gene Expression Profiles to Categorize Wilms Tumors|Categorization of Wilms Tumors by Genetic Expression||Children's Oncology Group|No|Recruiting|February 2004|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Specimens from patients previously enrolled as "On Study" or "Followed Biology Only" on        protocol NWTSG-5 (COG-Q9401)|November 2015|November 5, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897637||139348|
NCT00896909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000476582|HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598|Evaluation of HER2 Mutations in Patient Tumors From E2598||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|44|||Both|18 Years|N/A|No|||December 2006|July 6, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896909||139397|
NCT00897169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3662|A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects|A Trial Investigating the Possible Difference in the Development of Type 2 Diabetes in Caucasian and Japanese Subjects by a Model-based Analysis||Novo Nordisk A/S|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|271|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|February 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00897169||139380|
NCT00897377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YP2008009|Treatment Strategy for Low-grade Gliomas|Treatment Strategy for Low-grade Gliomas||Sun Yat-sen University|Yes|Terminated|December 2007|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|500|||Both|18 Years|60 Years|No|||May 2009|August 4, 2014|May 8, 2009||No|Difficulty in recruiting patients|No||https://clinicaltrials.gov/show/NCT00897377||139365|
NCT00897624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633500|Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma|Evaluation of the Detection of Tumor Cells in Bone Marrow and Blood in Patients With Choroid Melanoma||National Cancer Institute (NCI)||Completed|November 2007|||May 2011|Actual|N/A|Observational|N/A|||Anticipated|15|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|May 9, 2009||||No||https://clinicaltrials.gov/show/NCT00897624||139349|
NCT00898092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-20502|Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia|Molecular Genetic Studies of Acute Myeloid Leukemia (AML) With Normal Cytogenetics. A CALGB Leukemia Tissue Bank Project||Alliance for Clinical Trials in Oncology||Active, not recruiting|May 2006|||December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|735|||Both|15 Years|59 Years|No|Non-Probability Sample|Patients enrolled on CALGB 19808 with tissue previously submitted to the CALGB Leukemia        Tissue Bank|July 2015|July 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898092||139315|
NCT00870701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08SARC01|Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma|Randomised Multicentric Phase III Study Comparing Observation Versus Post-surgery Radiotherapy After Complete Exeresis With Margins Greater Than or Equal to 1 cm in Soft Tissues Members Sarcoma.||Institut Claudius Regaud|Yes|Recruiting|March 2009|March 2021|Anticipated|March 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|570|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870701||141379|
NCT00870714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sanofi-Aventis IST 16167|Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study|Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study|IST 16167|Kansas City Veteran Affairs Medical Center|Yes|Active, not recruiting|September 2004|||September 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||March 2009|March 25, 2009|July 24, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00870714||141378|
NCT00871039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB HM12035|Pilot Study Evaluating Stress Response and Immune Function in Mechanically Ventilated Patients With Alcohol Use Disorders Treated With Propofol or Midazolam|Randomized Clinical Trial Comparing Propofol and Midazolam in Mechanically Ventilated Critically Ill Patients With Alcohol Use Disorders: An Open Label Pilot Study||Virginia Commonwealth University|No|Withdrawn|March 2009|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|March 26, 2009|Yes|Yes|Due to logistical purposes|No||https://clinicaltrials.gov/show/NCT00871039||141353|
NCT00871312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOTI-001|Evaluation of Topical Wound Oxygen (two2) Therapy|A Randomized, Double-blinded, Parallel Group, Placebo-Controlled, Multi-Center Trial of Topical Wound Oxygen Therapy in the Treatment of Diabetic Lower Extremity Ulcers||AOTI Ltd.|Yes|Terminated|May 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 8, 2014|March 26, 2009||No|Low recruitment rate meaning unable to complete the study in a timely manner|No||https://clinicaltrials.gov/show/NCT00871312||141333|
NCT00871325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100CPT1|Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans|Effect of Gastrointestinal Nerve Modulation With DAIKENCHUTO (TU-100) on Gastrointestinal and Colonic Transit in Humans||Tsumura USA|No|Completed|June 2009|January 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871325||141332|
NCT00871338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111709|Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants|Study in Healthy Children of GSK Biologicals' DTPa-IPV/Hib-MenC-TT Vaccine, GSK2197870A, Co-administered With Prevenar™ as a Three-dose Primary Vaccination Course in Infancy Followed by a Booster Dose of Menitorix™ at 12 Months of Age||GlaxoSmithKline||Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|284|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2014|July 24, 2014|March 26, 2009|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00871338||141331|
NCT00871611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIE190109|Viennese Prevalence Study of Anderson-Fabry Disease|Prevalence of Anderson - Fabry Disease in Patients With Left Ventricular Hypertrophy|VIEPAF|Medical University of Vienna|No|Active, not recruiting|January 2009|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples Without DNA|Urine|Both|18 Years|90 Years|No|Probability Sample|Patients with left ventricular hypertrophy diagnosed by echocardiography|July 2011|July 27, 2011|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871611||141310|
NCT00888290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI#2008-376|Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects|Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects||Albert Einstein College of Medicine of Yeshiva University|No|Completed|March 2009|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|N/A|No|||February 2015|February 12, 2015|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888290||140045|
NCT00888303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD123|Single Dose Steroid Before Thyroidectomy for Benign Disease to Improve Postoperative Nausea, Pain, and Vocal Function|Randomized Controlled Trial on Efficacy of Preemptive 8 mg of Dexamethasone for Reducing Pain and Postoperative Nausea and Vomit After Thyroidectomy for Benign Disease.||Ospedale Misericordia e Dolce|Yes|Recruiting|January 2009|October 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2012|September 1, 2012|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888303||140044|
NCT00898573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE15107|Lapatinib Resistance in Patients With Breast Cancer|Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers||Case Comprehensive Cancer Center|Yes|Withdrawn|July 2008|||||Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|Previously collected tumor tissue samples are obtained for genetic analysis studies.      Patients also undergo blood sample collection for extraction of DNA.|Both|N/A|N/A|No|Probability Sample|Primary care clinic|October 2015|October 1, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898573||139282|
NCT00897819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000534281|Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200|Evaluation of the Association Between DNA Methylation and Shortened Survival in Patients With Advanced Colorectal Cancer Treated With 5-FU/Oxaliplatin-Based Regimens in E3200||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|350|||Both|18 Years|N/A|No|||March 2007|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897819||139335|
NCT00898053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS08B1|Study of Tumor Samples From Patients With Ewing Sarcoma|Observational - Prognostic Value of p53 and/or p16 Alterations in Ewing Sarcoma||Children's Oncology Group|No|Recruiting|September 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|tumor samples|Both|N/A|50 Years|No|Non-Probability Sample|Diagnosis of Ewing sarcoma|November 2015|November 6, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898053||139318|
NCT00898313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0398|Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer|Molecular Predictors of Lung Cancer Behavior||Vanderbilt-Ingram Cancer Center|No|Recruiting|December 2003|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Blood, urine, nasal cells, sputum, bronchal epithelial cells, airway tissue, and lung tissue|Both|18 Years|120 Years|No|Non-Probability Sample|People who may have lung cancer.|December 2015|December 31, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898313||139301|
NCT00899652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B945|DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|The Molecular Epidemiology of de Novo and Treatment Related 11q23 Leukemia in the Young||Children's Oncology Group|No|Completed|January 1997|September 2006|Actual|September 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|149|Samples With DNA|marrow, blood, pheresis bag|Both|N/A|21 Years|No|||February 2014|February 11, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899652||139209|
NCT00899899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B977|Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission|A Study of the Mechanisms of Intrinsic and Acquired Methotrexate Resistance in Acute Lymphocytic Leukemia||Children's Oncology Group|No|Completed|June 1998|April 2006|Actual|March 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|135|||Both|N/A|120 Years|No|Non-Probability Sample|Acute lymphoblastic leukemia (ALL) in relapse|May 2015|September 28, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899899||139192|
NCT00900406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 0664|Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant|Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD)||Vanderbilt-Ingram Cancer Center||Completed|January 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|190|Samples Without DNA|Blood collection|Both|18 Years|N/A|No|Non-Probability Sample|People who have received a stem cell transplant and are being treated for graft versus        host disease or are at risk of graft versus host disease.|November 2012|November 4, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900406||139157|
NCT00900718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 03/05|Comparison of Straumann Bone Ceramic and Bio-Oss With Guided Tissue Regeneration for Alveolar Ridge Preservation|Comparison of Straumann Bone Ceramic (SBC) and Bio-Oss in Combination With Guided Tissue Regeneration (GTR) for Volume Preservation of Alveolar Ridge After Tooth Extraction: a Randomised, Single Blind, Controlled Clinical Trial||Institut Straumann AG|No|Completed|February 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900718||139133|
NCT00897182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000595708|Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia|Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray||Alliance for Clinical Trials in Oncology||Withdrawn|May 2008|||May 2009|Anticipated|N/A|Observational|N/A|||Actual|0|||Both|N/A|N/A|No|||July 2013|July 15, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897182||139379|
NCT00897858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000481330|Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors|Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children With Newly Diagnosed Central Nervous System Tumors||Pediatric Brain Tumor Consortium|No|Withdrawn|August 2006|||January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|21 Years|No|Non-Probability Sample|The study population consists of newly diagnosed pediatric patients with a CNS tumor and        no prior irradiation or chemotherapy. Cerebrospinal fluid (CSF) is withdrawn as part of        initial diagnosis/staging, the administration of intrathecal therapy, or CSF diversion.|April 2013|April 18, 2013|May 9, 2009||No|This non-therapeutic study was registered in error. The PRS team doesn't delete studies once    registered, so they recommended changing the status to Withdrawn|No||https://clinicaltrials.gov/show/NCT00897858||139332|
NCT00898118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWOG-MDS-SCT RC RIC-06|Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant|Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC)||National Cancer Institute (NCI)||Recruiting|April 2007|||March 2013|Anticipated|N/A|Observational|N/A|||Anticipated|125|||Both|N/A|17 Years|No|||April 2008|August 9, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898118||139314|
NCT00870727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0805-26|Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders|Pharmacotherapy of Pervasive Developmental Disorders||Indiana University|Yes|Completed|February 2009|May 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|5 Years|17 Years|No|||May 2015|May 14, 2015|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00870727||141377|
NCT00871351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06027|Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)|Ezetimibe Phase IV Clinical Study in Patients With Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|February 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|125|||Both|20 Years|N/A|No|||September 2015|September 28, 2015|March 26, 2009|No|Yes||No|May 16, 2011|https://clinicaltrials.gov/show/NCT00871351||141330|
NCT00871624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TuftsMedicalCenter 8533|Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation|Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation for Patients With Acute Respiratory Failure: A Randomized, Double-blind, Placebo-controlled Pilot Study||Tufts Medical Center|Yes|Completed|March 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|85 Years|No|||November 2015|November 3, 2015|March 27, 2009|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00871624||141309|
NCT00896883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA2008-02|Evaluation of the Middle Turbinate Implant for Affixing the Middle Turbinate to the Nasal Septum|A Prospective, Non-Randomized, Limited-Use Evaluation of the Middle Turbinate Implant for Affixing the Middle Turbinate to the Nasal Septum|MTI|ENTrigue Surgical, Inc.|No|Completed|April 2009|May 2010|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|65 Years|No|||August 2012|August 21, 2012|May 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896883||139399|
NCT00897130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003943-55|5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)|Clinical and Biological Effects of 5-Azacitidine Five Days/Monthly Schedule in Symptomatic Low-risk Myelodysplastic Syndromes (MDSs)|MDSAZA0706|Università degli Studi di Brescia|Yes|Completed|August 2008|December 2014|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00897130||139382|
NCT00897338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0737 CDR0000571962|Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer|A Feasibility Study of a Novel Technique to Identify Circulating Breast Cancer Cells in Patients With Metastatic Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Completed|August 2007|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples With DNA|DNA|Female|18 Years|N/A|No|Probability Sample|Metastatic breast cancer patients|October 2015|October 9, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897338||139368|
NCT00898872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000455162|SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial|Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease||Southwest Oncology Group|No|Completed|March 1993|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who consented to SWOG 9245 for banking|May 2013|May 17, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898872||139263|
NCT00898859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2009086|Role of A Disintegrin and Metalloproteinase (ADAM) in Epithelial Dysfunction|Role of ADAMs in Epithelial Dysregulation in COPD. Differences Between From Non-smokers, Healthy Smokers and Patients With COPD.||University Medical Center Groningen|No|Completed|May 2009|December 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|50|Samples Without DNA|Bronchial brushes|Both|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects and subjects with COPD|January 2015|January 15, 2015|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00898859||139264|
NCT00899132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5Y06|Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer|The Role of TAB3 Protein in Tumorigenesis||Case Comprehensive Cancer Center|No|Terminated|February 2007|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|180|Samples With DNA|Tumor tissue samples from paraffin-embedded tissue blocks.|Both|N/A|N/A|No|Probability Sample|Primary care center|September 2015|September 28, 2015|May 9, 2009||No|Study due for continuing review|No||https://clinicaltrials.gov/show/NCT00899132||139245|
NCT00899392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6-6053|Improving Informed Consent in Pediatric Endoscopy|Improving Informed Consent and Assent in Pediatric Endoscopy||Children's Hospital of Philadelphia|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 24, 2013|May 8, 2009||No||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00899392||139228|Subjects of study did not all complete secondary outcome measures hence some pilot data was included in 2ndary outcome analysis, New instrument used attempting to validate. Largely female, educated cohort. >60% college educated in both groups.
NCT00899379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-025|Treatment of Multiple Attacks of Acute Migraine (0462-025)|A Randomized, Triple-Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of MK462 10 mg p.o. in the Treatment of Multiple Attacks of Migraine Headache||Merck Sharp & Dohme Corp.||Completed|April 1995|April 1996|Actual|January 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|473|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|May 8, 2009|Yes|Yes||No|September 26, 2009|https://clinicaltrials.gov/show/NCT00899379||139229|Pooled Extension data for PN022- NCT00897949; PN025- NCT00899379 and PN029- NCT00897104 appears in NCT00897949
NCT00899912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0612|Changes in DNA After Radiation Therapy in Patients With Prostate Cancer|Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study||Radiation Therapy Oncology Group|Yes|Completed|June 2006|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|Samples With DNA|Frozen tissue cores of prostatic biopsy specimens|Male|18 Years|N/A|No|Non-Probability Sample|Intermediate risk prostate cancer patients|November 2015|November 14, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899912||139191|
NCT00900172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592945|Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel|Angiogenesis Pathway Gene Polymorphisms Associated With Clinical Outcome in Patients Enrolled in ECOG 4599||National Cancer Institute (NCI)||Not yet recruiting|March 2008|||April 2009|Anticipated|N/A|Observational|N/A|||Anticipated|180|||Both|18 Years|N/A|No|||August 2008|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900172||139173|
NCT00896935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597579|Arizona Cancer Center Biospecimen Repository|Arizona Cancer Center Biospecimen Repository||University of Arizona|Yes|Recruiting|July 2006|||July 2020|Anticipated|N/A|Observational|N/A||1|Anticipated|10000|Samples With DNA|Tissue will be collected and preserved from the primary organ site, from the metastases,      from patient blood (serum and lymphocytes), from patient urine, and from related samples of      other tissues/fluids removed by the surgeon left over after diagnostic testing.|Both|18 Years|N/A|No|Non-Probability Sample|The goal of this protocol is to provide cancer investigators access to a wide variety of        tissues and biospecimens for translational studies in cancer by collecting and preserving        tissue from the primary organ site, from the metastases, from patient blood (serum and        lymphocytes), from patient urine, and from related samples of other tissues/fluids removed        by the surgeon left over after diagnostic testing. No additional tissue will be taken at        the time of surgery other than that required for patient care, but additional blood and        urine samples will be obtained at that time. This protocol is not limited to certain types        of cancer.|November 2015|November 30, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896935||139395|
NCT00897390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-092|Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 1000 mg Metformin Immediate Release (IR) Tablet Relative to 2.5 mg Saxagliptin Tablet and 1000 mg Metformin IR Tablet Co-administered to Healthy Subjects in a Fasted and in a Fed State||AstraZeneca|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|May 8, 2009|No|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00897390||139364|
NCT00897208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-2005|Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer|Estrogen-DNA Adducts in Breast, Urine and Serum as Biomarkers of Breast Cancer Risk||Mayo Clinic|Yes|Active, not recruiting|May 2005|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|19 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The target population is adult women, ages 19 to 80 years of age. In 2003, there were        approximately 2000 new and 3000 established patient visits in the Breast Diagnostic Clinic        (BDC) and Breast Cancer Clinic (BCC) Our new patients include those seen in the BDC with        new breast concerns and those at seeking counseling regarding a family history or at high        risk for developing breast cancer, as well as those women seen in the BCC with a new        diagnosis of invasive or non-invasive breast cancer.|March 2015|January 7, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897208||139378|
NCT00897403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546530|Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy|Discovery of Candidate Biomarkers in Colon Cancer and Precancers Repository||National Cancer Institute (NCI)||Recruiting|February 2007|||||N/A|Observational|N/A|||Anticipated|3000|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||October 2008|August 11, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897403||139363|
NCT00897650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0547|Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer|Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy||Vanderbilt-Ingram Cancer Center|No|Recruiting|December 2005|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Lung tumor tissue and blood samples will be collected.|Both|N/A|N/A|No|Non-Probability Sample|People who have or may have lung cancer.|June 2014|June 18, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897650||139347|
NCT00897871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-PK-2006-09|Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer|Pharmacokinetics and Pharmacogenetics of Anticancer Drugs in Infants and Young Children||National Cancer Institute (NCI)||Recruiting|February 2007|||||N/A|Observational|N/A|||Anticipated|60|||Both|N/A|2 Years|No|||June 2009|August 9, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897871||139331|
NCT00897884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METFORMIN|Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer|Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer||Mount Sinai Hospital, Canada|No|Completed|October 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|70 Years|No|||January 2012|January 18, 2012|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00897884||139330|
NCT00898131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 01X1|Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer|Specialized Program of Research Excellence (SPORE) in Breast Cancer: Tissue and Specimen Collection||Northwestern University|No|Recruiting|August 2001|January 2020|Anticipated|January 2020|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples Without DNA|Tissue from diagnostic biopsies, as well as initial or follow-up surgical procedures for the      treatment or prevention of breast cancer. No extra tissue is taken, only what is left over      following clinical use will be retained for banking purposes.|Female|N/A|N/A|No|Non-Probability Sample|Women undergoing biopsy or surgical procedures for the diagnosis, treatment, or prevention        of breast cancer.|June 2015|October 14, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898131||139313|
NCT00871364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA32215|A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Actavis Group hf 50 mg Venlafaxine Hydrochloride Tablets and Wyeth Pharmaceuticals (Effexor®) 50 mg Venlafaxine Hydrochloride Tablets||Actavis Inc.|No|Completed|April 2006|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871364||141329|
NCT00871650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH083035-01|Neurobiological Correlates of Post Traumatic Stress Disorder (PTSD) During Rapid Eye Movement (REM) Sleep|Neurobiological Correlates of PTSD During REM Sleep (REM-P)|REM-P|University of Pittsburgh|Yes|Completed|March 2009|November 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF),        ages 18-50, with combat experience, who are not on medication.|January 2013|January 14, 2013|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871650||141307|
NCT00871975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C001-C0015 TETRA-NIRS|Diagnostic Utility of Tetra-NIRS in Conjunction With Urodynamic Studies|The Purpose of This Experiment is to Validate the Previous Clinical Study Results Using the Tetra-NIRS (Near Infrared Spectroscopy) as Compared to the Conventional UDS in the Voiding Procedure. This Evaluation Will Use a Commercially Available Tetra-NIRS Device.||Laborie Medical Technologies Inc.|No|Terminated|April 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|155|||Both|18 Years|N/A|No|||April 2015|August 31, 2015|March 26, 2009|No|Yes|Low enrollment exceeding trial deadlines|No||https://clinicaltrials.gov/show/NCT00871975||141282|
NCT00898066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0334|S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease|Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma||Southwest Oncology Group|No|Completed|September 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|N/A||1|Actual|37|||Both|N/A|N/A|No|Non-Probability Sample|pts from S0115, S0232, S0340, S0417 and all new SWOG MM SM, WM, MGUS studies after 9/1/05        before closure|March 2015|March 5, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898066||139317|
NCT00898326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUSMH-TRIGU0709|PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer|Analysis of Biopsy Results at 36 Months After Permanent I-125 Implantation Therapy Plus LHRH-agonist Therapy for Patients With Untreated Intermediate Prostate Cancer.||National Cancer Institute (NCI)||Recruiting|April 2008|||September 2014|Anticipated|N/A|Observational|N/A|||Anticipated|420|||Male|20 Years|75 Years|No|||July 2009|August 9, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898326||139300|
NCT00899418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000472065|Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100|Differential Response of Breast Cancer Patients on E2100 Treated With Bevacizumab as a Function of Genetic Polymorphisms of VEGF and KDR||Eastern Cooperative Oncology Group||Completed|May 2006|||November 2006|Actual|N/A|Observational|Time Perspective: Retrospective|||Anticipated|500|||Female|18 Years|N/A|No|||October 2008|April 2, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899418||139226|
NCT00899145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0246|Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers|Genetic Modifiers of BRCA1/BRCA2-Related Breast Cancer Risk in BRCA1/BRCA2 Mutation Carriers||Gynecologic Oncology Group||Withdrawn|May 2008|||January 2010|Actual|N/A|Observational|N/A||1|Actual|0|||Female|18 Years|80 Years|No|Probability Sample||May 2015|May 7, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899145||139244|
NCT00899405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583056|Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer|EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood||University of California, Davis|Yes|Recruiting|May 2005|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Archival tissue specimens and blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with lung cancer|May 2015|May 7, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899405||139227|
NCT00899951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J06129 CDR0000600337|Studying Fentanyl in Patients With Cancer|Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|October 2007|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|No|Probability Sample|cancer pts|April 2013|April 16, 2013|May 9, 2009|No|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00899951||139190|
NCT00899665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000483773|Proteases in Patients With Prostate Cancer That Has Spread to the Bone|Proteases in Prostate Cancer Bone Metastasis||Barbara Ann Karmanos Cancer Institute|No|Completed|July 2001|January 2008|Actual|September 2006|Actual|N/A|Observational|N/A|||Actual|31|||Male|40 Years|N/A|No|||February 2014|February 10, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899665||139208|
NCT00899678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C87035|The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents|A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)|NURTURE|UCB Pharma|Yes|Terminated|April 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|6 Years|17 Years|No|||March 2015|March 3, 2015|April 29, 2009|Yes|Yes|higher than projected discontinuation rate during Maintenance Phase|No|June 28, 2013|https://clinicaltrials.gov/show/NCT00899678||139207|
NCT00900419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-1108|Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers|Biomarkers and Dysplastic Respiratory Epithelium||University of Colorado, Denver|No|Recruiting|March 2002|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Sputum sample,Endobronchial biopsy, bronchial secretions, pulmonary labage, blood and urine,      buccal smears,exhaled breath collection.|Both|21 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|High Risk for Lung Cancer, suspected lung cancer, lung cancer.|December 2015|December 9, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900419||139156|
NCT00900445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL0631|Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia|Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|Yes|Withdrawn|June 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|0|||Both|10 Years|19 Years|No|Non-Probability Sample|Newly diagnosed with acute lymphoblastic leukemia and the intended induction treatment        must contain prednisone/prednisolone, vincristine and daunorubicin in the doses and        schedule as per the current COG AALL0232 protocol.|May 2013|May 30, 2013|May 9, 2009||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00900445||139154|
NCT00900731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2350|A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD|INTENSITY|Novartis||Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1598|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|May 12, 2009|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00900731||139132|
NCT00896948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558974|Study of Proteins in Head and Neck Cancer Cells|Novel Protein Regulator of Tumor Suppressor ARF & NF-κB||Vanderbilt University||Completed|May 2005|||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||October 2008|May 14, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896948||139394|
NCT00897221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA29-EXT|A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia|An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia||ApoPharma|Yes|Completed|June 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|7 Years|35 Years|No|||June 2011|June 24, 2011|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00897221||139377|
NCT00897416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5518|Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer|Validation of a Serum Marker Panel for Early Detection of Breast Cancer in High-Risk Women||Fred Hutchinson Cancer Research Center||Completed|October 2001|June 2007|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1452|||Female|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women undergoing screening mammography or breast biopsy.|November 2010|November 5, 2010|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897416||139362|
NCT00897663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0477|Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies|Optimizing EGFR Inhibitor-Based Therapies for GBM||Alliance for Clinical Trials in Oncology||Withdrawn|November 2006|||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||January 2013|July 26, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897663||139346|
NCT00897897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|996233|Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids|Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids||Philips Healthcare|Yes|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|59 Years|No|||December 2012|December 3, 2012|May 11, 2009||No||No|July 5, 2011|https://clinicaltrials.gov/show/NCT00897897||139329|
NCT00898144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600575|Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171|Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS)||National Cancer Institute (NCI)||Not yet recruiting|February 2008|||June 2009|Anticipated|N/A|Observational|N/A|||Anticipated|55|||Female|N/A|N/A|No|||November 2010|November 5, 2010|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898144||139312|
NCT00872014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080580|A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer|Phase 2 Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma||Amgen||Completed|August 2009|July 2015|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2016|February 5, 2016|March 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872014||141280|
NCT00872248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-200903-MZ005|Neuraxial Anesthesia and Restless Leg Syndromes in Cesarean|Correlation of Neuraxial Anesthesia and Restless Leg Syndromes in Cesarean Delivery|NARELESS|Nanjing Medical University|Yes|Completed|February 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Female|18 Years|50 Years|No|||May 2011|July 26, 2011|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872248||141262|
NCT00872261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH086160|Determining Characteristics and Behaviors of Adolescent Women Regarding HIV Risk and Microbicide Trial Participation|Adolescent Women & Microbicide Trials: Assessing the Challenges & Opportunities to Their Participation||FHI 360|No|Completed|March 2010|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Female|15 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Formative research will recruit adolescents and other participants from community samples        in Pune, India and Dar es Salaam, Tanzania.        Pilot clinical study will recruit adolescents from India and Tanzania through healthcare        facilities, nongovernmental organizations, and other mechanisms.|April 2013|April 29, 2013|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872261||141261|
NCT00898352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000070950|Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes|Phase III Radiation Therapy vs Pelvic Node Resection for Previously Untreated Invasive Squamous Cell Carcinoma of the Vulva With Positive Groin Nodes||Gynecologic Oncology Group||Completed||||November 1990|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|1||||||Female|N/A|N/A|No|||October 2009|May 24, 2013|May 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00898352||139299|
NCT00898365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN03B2|Study of Kidney Tumors in Younger Patients|Renal Tumors Classification, Biology, and Banking Study||Children's Oncology Group|Yes|Recruiting|February 2006|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Tumor tissue, blood, and urine.|Both|N/A|29 Years|No|Non-Probability Sample|Patients with the first occurrence of any tumor of the kidney identified on CT scan or        MRI.|November 2015|November 16, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898365||139298|
NCT00898599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMNUT0055|Prebiotics and Immune Function in Middle Aged Humans|Investigation of the Effects of a Prebiotic Supplement on Immune Function in Healthy Human Adults||University Hospital Southampton NHS Foundation Trust.|No|Completed|April 2009|July 2010|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|49|||Both|45 Years|66 Years|Accepts Healthy Volunteers|||July 2010|November 26, 2014|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00898599||139281|
NCT00899431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0871|Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)|Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|May 2009|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00899431||139225|
NCT00899457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0734|Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants|Molecular Predictors of Lung Cancer Behavior: Controls||Vanderbilt-Ingram Cancer Center||Completed|April 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy, non-smokers.|April 2013|June 23, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899457||139224|
NCT00899691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040138|Study of Hair Samples From Patients With Cancer|Detection and Quantification of Changes in Levels of Protein Expression and Phosphorylation Status Using Human Hair Samples||National Institutes of Health Clinical Center (CC)||Completed|March 2005|October 2008|Actual|||N/A|Observational|N/A|||Anticipated|190|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899691||139206|
NCT00899964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2372/09|IT-based Training in Obesity|Influence of a Combined Personal and IT-based Physical Activity Intervention in an Obese, Sedentary Population on Daily Activity and Metabolic Risk Profile||Technische Universität München|No|Completed|May 2009|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|184|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|May 5, 2009||||No||https://clinicaltrials.gov/show/NCT00899964||139189|
NCT00899977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5214-23-CRD-002|TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension|A Double-blind, Randomized, Placebo-controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension||Targacept Inc.|No|Terminated|May 2009|December 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1|||Both|18 Years|65 Years|No|||September 2013|September 3, 2013|May 8, 2009|Yes|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT00899977||139188|
NCT00900185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000304552|Study of a Polymorphism in Patients With Prostate Cancer|Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer||National Cancer Institute (NCI)||Completed||||||N/A|Observational|N/A|||Anticipated|750|||Male|N/A|N/A|Accepts Healthy Volunteers|||February 2007|April 29, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900185||139172|
NCT00900458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|exercise and pre-eclampsia|Exercise Induced Improvement of the Venous Reserve Capacity in Formerly Pre-eclamptic Women|Adjustment of the Venous Reserve Capacity by Aerobic Exercise in Women at Increased Risk of Hypertensive Pregnancy Complications||Radboud University|No|Completed|March 2009|April 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|50|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900458||139153|
NCT00900744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 08-1373|A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6|A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6||Icahn School of Medicine at Mount Sinai|No|Recruiting|January 2009|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2009|May 12, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900744||139131|
NCT00896961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02489|EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer|Does Hypoxia Predict Radiation/Surgical Tumor Response/A Correlative Trial of EF5, an Agent for the Detection of Tumor Hypoxia||National Cancer Institute (NCI)||Terminated|August 2001|||September 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|May 9, 2009|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00896961||139393|
NCT00897429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150705|Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581|Correlative Science Studies in Colon Cancer a Companion Study to CALGB 9581 and 89803||Alliance for Clinical Trials in Oncology|No|Recruiting|July 2007|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|902|Samples With DNA|Tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with colon cancer registered to CALGB 9581 or 89803|July 2015|July 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897429||139361|
NCT00897442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078647|Collecting Tumor Samples From Patients With Gynecological Tumors|Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer||National Cancer Institute (NCI)||Recruiting|June 1992|||||N/A|Observational|N/A|||||||Female|N/A|N/A|No|||December 2011|August 30, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897442||139360|
NCT00897676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-10-6255|Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity|Role of GLP-1 in Congenital Hyperinsulinism:Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity||Children's Hospital of Philadelphia|No|Recruiting|May 2009|April 2017|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|6 Months|18 Years|No|||March 2016|March 7, 2016|May 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00897676||139345|
NCT00897923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529768|Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma|In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy||Mayo Clinic||Active, not recruiting|September 2003|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|March 2015|March 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897923||139327|
NCT00897910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000597015|Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma|Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|April 2008|September 2012|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|Samples Without DNA|Data from flow cytometry, and Cytokine release assays for B cells and T cells from      peripheral blood mononuclear cells (PBMCs) will be obtained.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of multiple myeloma identified from the outpatient clinics or        inpatient service of Karmanos Cancer Center by physicians in the Department of Hematology        and Medical Oncology.|December 2015|December 9, 2015|May 9, 2009||No|Funding unavailable|No|October 22, 2013|https://clinicaltrials.gov/show/NCT00897910||139328|Tis study was closed due to technical laboratory difficulty in performing the experiments proposed.
NCT00898430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0392|Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy|Biomarkers of Survival in HNSCC||Vanderbilt-Ingram Cancer Center|Yes|Terminated|November 2003|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|||Both|N/A|N/A|No|Non-Probability Sample|Head and Neck cancer patients who are uniformly treated with concurrent        carboplatin/paclitaxel and radiation.|March 2013|March 29, 2013|May 9, 2009||No|Study closed prematurely upon PI's departure|No||https://clinicaltrials.gov/show/NCT00898430||139293|
NCT00872027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH082156|Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit|Feasibility Study to Prevent Post-ICU Depression||National Institute of Mental Health (NIMH)|No|Not yet recruiting|April 2009|July 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|25 Years|N/A|No|||April 2009|April 3, 2009|March 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872027||141279|
NCT00872274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220_SUMAT_08|Bioequivalence Study of Sumatriptan 100mg Tablets Under Fed Conditions|An Open Label, Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets (Containing 140 mg of Sumatriptan Succinate Equivalent to 100 mg Sumatriptan) Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|July 2008|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 30, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00872274||141260|
NCT00872287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1948-01|Pain in Single Incision Laparoscopic Surgery Cholecystectomy|Randomized Controlled Study of Different Pain Scores in Single Transumbilical Incision Laparoscopic Cholecystectomy Versus Classic Laparoscopic Cholecystectomy||G. Hatzikosta General Hospital|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|28 Years|75 Years|No|||March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872287||141259|
NCT00898885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPPSSS1|Analysis of the Clinical and Histological Correlation of Oral Graft-Versus-Host-Disease (GVHD)|Clinical and Histological Evaluation of Chronic Graft-Versus Host Disease (cGVHD) in Oral Mucosa|ORALGVHD|University of Sao Paulo|Yes|Completed|January 2008|April 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|41|Samples Without DNA|samples of oral mucosa and minor salivary glands stained with hematoxylin and eosin for      visualization of the layers in optical microscope|Both|N/A|N/A|No|Probability Sample|patients underwent bone marrow transplantation with clinical signs of oral        Graft-versus-host Disease|May 2009|May 11, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00898885||139262|
NCT00899158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3204|Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss|Role of Caspase-3, Phosphatidylinositol-3 Kinase (PI3K), and 3-methylhistidine (3-MH) in the Pathophysiology of Skeletal Muscle Loss in Weight-losing Pancreas Cancer Patients||Case Comprehensive Cancer Center|Yes|Completed|June 2005|December 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|44|Samples With DNA|During surgery, a muscle biopsy is performed and approximately 1 cm of rectus abdominous      muscle is obtained for analysis.|Both|18 Years|N/A|No|Probability Sample|Primary care clinic|September 2015|September 29, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899158||139243|
NCT00899470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-081|Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Immediate Release (IR) Tablet Relative to 2.5 mg Saxagliptin Tablet and 500 mg Metformin IR Tablet Co-administered to Healthy Subjects in a Fasted and in a Fed State||AstraZeneca|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 8, 2015|May 8, 2009|No|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT00899470||139223|
NCT00899704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z3081|Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer|Molecular Mechanisms of OSCC Tumor Invasion||Alliance for Clinical Trials in Oncology|No|Recruiting|March 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|161|||Both|N/A|N/A|No|Probability Sample|Patient tissue samples are screened using polymerase chain reaction (PCR) for human        papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis        signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to        quantify expression levels for targeted genes. Initial data analysis is performed using        Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes. are|July 2015|July 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899704||139205|
NCT00899990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS07B1|Collecting and Storing Biological Samples From Patients With Ewing Sarcoma|A COG Study for Collecting and Banking Ewing Sarcoma Specimens||Children's Oncology Group|Yes|Recruiting|February 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|Samples With DNA|tumor specimens, bone marrow and peripheral blood|Both|N/A|21 Years|No|Non-Probability Sample|Patients with a diagnosis of Ewing sarcoma.|November 2015|November 12, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899990||139187|
NCT00900198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060213|Collection of Tissue Samples for Cancer Research|Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)||National Institutes of Health Clinical Center (CC)||Recruiting|September 2006|December 2019|Anticipated|||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|3000|||Both|18 Years|110 Years|No|||January 2016|March 4, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900198||139171|
NCT00900432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0331-01|Immune Response in Peripheral Blood of Patients With Colon Cancer|Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract||University of Arizona|Yes|Completed|July 2004|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|67|||Both|N/A|N/A|No|Probability Sample|colon cancer|August 2012|December 2, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900432||139155|
NCT00900471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01403|Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors|Advanced Tumor Bank Project||Comprehensive Cancer Center of Wake Forest University|Yes|Recruiting|May 2004|||May 2020|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|2500|||Both|18 Years|120 Years|No|Non-Probability Sample|Those with a clinically suspected solid tumor and scheduled for surgical resection and/or        biopsy|September 2015|September 22, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900471||139152|
NCT00900757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015573|Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide|Phase II Study to Evaluate the Efficacy and Safety of Intravenous Palonosetron in Primary Glioma Patients Receiving Standard Radiotherapy and Concomitant Temozolomide||Duke University|No|Completed|August 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|57|||Both|18 Years|90 Years|No|||March 2014|November 3, 2014|May 11, 2009|Yes|Yes||No|December 30, 2013|https://clinicaltrials.gov/show/NCT00900757||139130|
NCT00897234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008NTLS094|Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers|Plasma Quantification of Cathepsin D and FAS in Non-Small Cell Lung Cancer||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|December 2008|October 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|84|Samples With DNA|Blood sample collection, one 10 ml purple top EDTA tube, will be collected from each patient      and control via venipuncture or from a central line.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects who have non-small cell lung cancer (NSCLC) will be recruited from the Masonic        Cancer Center at the University of Minnesota. Controls will be non-smoking individuals,        age matched to the NSCLC subjects recruited through advertising. Normal controls should        not be regularly exposed to second hand smoke.|August 2014|August 21, 2014|May 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00897234||139376|
NCT00897455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000598427|Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers|Genetic Modifiers of BRCA1/BRCA2-Related Breast Cancer Risk in BRCA1/BRCA2 Mutation Carriers - CIMBA 5||National Cancer Institute (NCI)||Recruiting|April 2008|||December 2009|Anticipated|N/A|Observational|N/A|||Anticipated|10000|||Female|18 Years|80 Years|No|||March 2011|March 22, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897455||139359|
NCT00897702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-163|Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer|Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|January 2007|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|tissue and blood|Both|N/A|N/A|No|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment        team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer        Center (MSKCC).|February 2016|February 11, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897702||139344|
NCT00897715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-031-09S|Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)|Inflammation in CKD and CVD - The Role of Genetics and IL-1ra||VA Office of Research and Development|Yes|Completed|January 2013|May 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|May 8, 2009||No||No|February 18, 2016|https://clinicaltrials.gov/show/NCT00897715||139343|
NCT00897936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000476571|DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia|A Pilot Study to Characterize the Genomic and Epigenomic Signature of NPM Positive Vs. NPM Negative NCL||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||Anticipated|32|||Both|18 Years|N/A|No|||March 2007|July 6, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897936||139326|
NCT00898157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000571530|Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494|Analysis of E4494 Tissues to Determine the Prognostic Significance of Biomarkers in Diffuse Large B Cell Lymphoma (DLBCL) Treated With Standard Chemotherapy (CHOP) Plus Rituximab ®)1||National Cancer Institute (NCI)||Not yet recruiting|September 2007|||||N/A|Observational|N/A|||Anticipated|1600|||Both|60 Years|N/A|No|||December 2007|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898157||139311|
NCT00898443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080829007|Continuous Labor Epidural Catheter for Tubal Ligation Study|Success Rate, Efficiency, and Predictors of Reactivation of a Continuous Labor Epidural Catheter for Postpartum Tubal Ligation||University of Alabama at Birmingham|Yes|Terminated|October 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|18|||Female|19 Years|45 Years|No|||June 2012|June 26, 2012|May 8, 2009||No||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00898443||139292|
NCT00872573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT03/14|A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stem™ AMT in a Total Primary Hip Replacement|Prospective, Uncontrolled, Two-centre, RSA, Post-market Surveillance Study to Evaluate the Stability of the C-Stem™ AMT Femoral Component in Primary Total Hip Arthroplasty.||DePuy International|No|Terminated|July 2006|||October 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|60 Years|80 Years|No|||September 2015|September 21, 2015|March 30, 2009|No|Yes|Technical issues with RSA at main site and departure of Principal Investigator|No||https://clinicaltrials.gov/show/NCT00872573||141238|
NCT00872859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26658|The BREASTrial:Breast Reconstruction Evaluation Using Acellular Dermal Matrix as a Sling Trial|The BREASTrial: Breast Reconstruction Evaluation Using Acellular Dermal Matrix as a Sling Trial||University of Utah|Yes|Active, not recruiting|October 2008|October 2013|Anticipated|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|196|||Female|18 Years|80 Years|No|||June 2012|June 1, 2012|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872859||141217|
NCT00898898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG N9831-ICSC|Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831|Analyses of c-Myc (MYC) and Topoisomerase II Alpha (TOP2A) Copy Number Aberrations; MYC, Insulin-like Growth Factor Receptor-1 (IGF-1R) and PTEN Protein Expressions; and Phosphatidylinositol 3' Kinase (PIK3) Gene Mutations in N9831 Primary Breast Tumors||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|May 2000|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1649|Samples With DNA|Tissue (FFPE whole block sections and TMA sections)|Female|18 Years|N/A|No|Non-Probability Sample|Female patients with primary HER2 positive breast cancer which received doxorubicin and        cyclophosphamide (AC) followed by paclitaxel with or without trastuzumab.|July 2015|July 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898898||139261|
NCT00899171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9031-S9126-S9333-S9500-A|S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia|S9031-S9126-S9333-S9500-A, Examination of the Prognostic Significance of AML-Specific and Age-Associated Genes in AML Patients||Southwest Oncology Group|No|Completed|November 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|251|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled on S9031, S9333, S0106 or S0112 that consented to use of specimens for        future research|March 2015|March 5, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899171||139242|
NCT00899483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3545|Can Enhanced Glycemic Control in Type II Diabetics Improve Myocardial Protection During Coronary Artery Bypass Grafting?|Can Enhanced Glycaemic Control in Type II Diabetics Improve Myocardial Protection During Coronary Artery Bypass Grafting?|GUIDE|University Hospital Birmingham||Not yet recruiting|July 2009|||July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2009|May 11, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00899483||139222|
NCT00899756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491609|Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer|Study of Mutations of Epidermal Growth Factor Receptor in the Blood of Patients With Advanced Non Small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|June 2006|||||N/A|Observational|N/A|||Anticipated|50|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899756||139202|
NCT00899717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/017|Occlusal Adjustment as Treatment for Chronic Orofacial Pain|Basis for an Etiological Diagnosis and Treatment of the Chronic TMD-pain: RCT Study||University of Santiago de Compostela|Yes|Completed|May 2009|April 2010|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||July 2013|July 21, 2013|May 11, 2009||No||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00899717||139204|
NCT00900003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0717|Studying Biomarkers in Patients With Pancreatic Cancer|Developing Biomarkers in Pancreatic Cancer||Vanderbilt-Ingram Cancer Center|No|Completed|May 2007|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|||Both|N/A|N/A|No|Non-Probability Sample|patients with cancer of the pancreas|December 2013|December 10, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900003||139186|
NCT00900211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000581165|Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX|VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK]||National Cancer Institute (NCI)||Recruiting|August 2007|||March 2012|Anticipated|N/A|Observational|N/A|||Anticipated|400|||Both|16 Years|N/A|No|||April 2008|August 23, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900211||139170|
NCT00896974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00907|Study of 9cUAB30 in Healthy Participants|A Pilot Study of the Novel Retinoid, 9cUAB30 to Determine Preliminary Pharmacokinetics||National Cancer Institute (NCI)||Completed|August 2008|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|June 17, 2015|May 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00896974||139392|
NCT00896987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106172|Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies|An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine or Carbamazepine for Cognitive Function as Initial Monotherapy in Adult Untreated Epilepsies||Korean Epilepsy Society|No|Completed|May 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|16 Years|60 Years|No|||May 2009|May 11, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00896987||139391|
NCT00897247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000518348|Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite|Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations||Barbara Ann Karmanos Cancer Institute|No|Completed|January 2007|October 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|494|||Both|25 Years|80 Years|No|Non-Probability Sample|Clinic|March 2014|March 4, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897247||139375|
NCT00897728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599189|Study of Tumor and Blood Samples From Women With Breast Cancer|Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast.||National Cancer Institute (NCI)||Recruiting|February 2008|||February 2010|Anticipated|N/A|Observational|N/A|||Anticipated|180|||Female|18 Years|N/A|No|||July 2009|November 30, 2010|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897728||139342|
NCT00897949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-022|MK0462 in Treatment of Migraine With Recurrence (MK0462-022)|A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence||Merck Sharp & Dohme Corp.||Completed|March 1995|July 1996|Actual|January 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1473|||Both|18 Years|65 Years|No|||February 2015|February 13, 2015|May 8, 2009|Yes|Yes||No|September 26, 2009|https://clinicaltrials.gov/show/NCT00897949||139325|Pooled Extension data for PN022- NCT00897949; PN025- NCT00899379 and PN029- NCT00897104 appears in NCT01286207
NCT00898456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-20501|Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia|Multidrug Resistance Protein Gene Polymorphisms in Acute Myeloid Leukemia. A CALGB Leukemia Tissue Bank Project||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|October 2006|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|600|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with acute myeloid leukemia enrolled on CALGB-9621, CALGB-9720, or CALGB-19808|July 2015|July 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898456||139291|
NCT00898716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA191-003|Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan|Phase 1 Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan||Bristol-Myers Squibb|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||July 2010|November 29, 2011|May 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00898716||139274|
NCT00898170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-2505|Effect of Myoma Removal on Blood Pressure and Erythropoetin Level|Effect of Myoma Removal on Blood Pressure and Erythropoetin Level||Shiraz University of Medical Sciences||Completed|May 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|28|||Female|22 Years|55 Years|No|||May 2009|May 11, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00898170||139310|
NCT00899262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000599372|Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy Volunteers|Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG)||National Cancer Institute (NCI)||Recruiting|April 2008|||April 2011|Anticipated|N/A|Observational|N/A|||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2009|August 23, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899262||139237|
NCT00872586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-866 CMB/01|Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy||Daiichi Sankyo Inc.|No|Completed|August 2006|August 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|75 Years|No|||September 2010|September 28, 2010|March 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872586||141237|
NCT00872872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 094|Nevirapine Clearance After Short-term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT)|Nevirapine Plasma Level After Discontinuation of Short-term Antiretroviral Treatment for the Prevention of Mother-to-child Transmission of HIV and Development of Drug Resistant HIV-1 Variants With 1 or 2 Weeks Continuation of Zidovudine/Lamivudine in Women After Delivery||Thai Red Cross AIDS Research Centre|No|Recruiting|May 2008|||April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Female|18 Years|45 Years|No|||September 2009|May 11, 2015|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872872||141216|
NCT00898911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000600560|Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer|Prediction of Overall Survival Using Mass Spectrometry Profiling in Head and Neck Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitors||National Cancer Institute (NCI)||Not yet recruiting|August 2008|||December 2008|Anticipated|N/A|Observational|N/A|||Anticipated|30|||Both|18 Years|N/A|No|||February 2009|May 9, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898911||139260|
NCT00899184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000492784|DNA Changes in Patients With Prostate Cancer|Assessment of SNP Genotypes in Men With Prostate Cancer||National Cancer Institute (NCI)||Not yet recruiting|July 2006|||||N/A|Observational|N/A|||Anticipated|646|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|February 18, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899184||139241|
NCT00900029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-016|Safety Follow-Up to HP 802-247-09-015|A Twenty-Four Week Non-Interventional Safety Follow-Up to HP 802-247-09-015||Healthpoint|No|Completed|June 2009|January 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|206|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who participated in Study No. 802-247-09-015 - "A Phase II Randomized, Double        Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in        Venous Leg Ulcers" and agreed to continue with the follow-up study.|January 2012|January 5, 2012|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900029||139184|
NCT00899769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000546781|Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers|Serum Biomarkers for Head and Neck Cancer||National Cancer Institute (NCI)||Recruiting|April 2005|||||N/A|Observational|N/A|||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2008|August 11, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899769||139201|
NCT00899743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9333A|S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia|Determining the Clinicopathological Significance of CaMKIIgamma Activation in AML||Southwest Oncology Group|Yes|Completed|August 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|132|||Both|56 Years|N/A|No|Non-Probability Sample|specimens from S9333|March 2015|March 5, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899743||139203|
NCT00900016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000579635|Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery|Pharmacodynamic Study of Fibroblast Activity Protein in Patients With Localized Pancreas Cancer Undergoing Surgical Resection||Fox Chase Cancer Center|No|Active, not recruiting|August 2007|||December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|Samples Without DNA|peripheral blood sample|Both|N/A|N/A|No|Non-Probability Sample|Surgury patients scheduled to undergo a resection or exploration of their pancreatic tumor|March 2016|March 1, 2016|May 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900016||139185|
NCT00900224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617738|Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia|Assessment of Novel Molecular Markers in Acute Myeloid Leukemia||Alliance for Clinical Trials in Oncology||Withdrawn|June 2008|||December 2018|Anticipated|N/A|Observational|N/A|||Actual|0|||Both|N/A|N/A|No|||July 2013|July 15, 2013|May 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00900224||139169|
NCT00900237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-127|Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine|A Phase I, Single Centre, Open, Randomised, Parallel Study to Evaluate the Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine in Healthy Subject||Bial - Portela C S.A.|Yes|Completed|November 2008|February 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|May 11, 2009||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00900237||139168|
NCT00900770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0158|Implications of Amyloid Pathology|Implications of Amyloid Deposition in Clinically Normal Older Individuals||National Institute on Aging (NIA)||Recruiting|November 2008|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Longitudinal cohort of the Massachusetts Alzheimer's Disease Research Center and community        volunteers|December 2009|December 23, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900770||139129|
NCT00900783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INH-FV1-005|A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients With Herpes Zoster||Bristol-Myers Squibb|No|Completed|May 2009|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|350|||Both|50 Years|N/A|No|||September 2015|September 23, 2015|May 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900783||139128|
NCT00897026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9741A-ICSC|Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344|ER/HER2/Ki67 Breast Cancer Subtypes as Predictive Factors for Response to Adjuvant Dose-dense Therapy, and Basal Subtypes of Double-negative Breast Cancer as Prognostic Factors in Intergroup Trial C9741||Alliance for Clinical Trials in Oncology|No|Recruiting|July 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1195|||Female|18 Years|N/A|No|Non-Probability Sample|Women aged 18 years and older diagnosed with node-positive breast cancer.|July 2015|July 23, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897026||139390|
NCT00897468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0704|Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer|Developing In-Vivo Models of Human Breast Cancer||Vanderbilt-Ingram Cancer Center|No|Recruiting|February 2007|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Female|18 Years|N/A|No|Non-Probability Sample|breast cancer patients|August 2015|August 24, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897468||139358|
NCT00898482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0533 CDR0000452792|Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants|Pancreatic Cancer Serum and Peripheral Blood Lymphocyte Repository||Sidney Kimmel Comprehensive Cancer Center|No|Completed|May 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only||3|Actual|88|||Both|18 Years|120 Years|Accepts Healthy Volunteers|Probability Sample|The three cohorts are: 1) Healthy individuals, 2) At risk individuals and 3) Cancer        patients.|November 2015|November 17, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898482||139289|
NCT00898755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTR04B1|Collecting and Storing Tissue From Young Patients With Cancer|Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies||Children's Oncology Group|No|Recruiting|March 2007|||January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||17|Anticipated|500|Samples With DNA|tumor tissue|Both|N/A|21 Years|No|Non-Probability Sample|Any patient that has been enrolled on a COG therapeutic, biology, or tissue banking        protocol that allows collection of tissue for research and submission to a COG-designated        resource laboratory is eligible for this study.|November 2015|November 16, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898755||139272|
NCT00898469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL03B2|Identifying Risk Factors for Bone Tissue Death in Young Patients With Acute Lymphoblastic Leukemia Treated on Clinical Trial CCG-1882|Study Of Pharmacogenetic Risk Factors For Avascular Necrosis CCG 1882||Children's Oncology Group|No|Active, not recruiting|March 2005|||March 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|671|||Both|10 Years|120 Months|No|Non-Probability Sample|Pediatric patients who received intensive therapy for acute lymphoblastic leukemia on        clinical trial CCG-1882.|August 2015|September 25, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898469||139290|
NCT00898976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-97-95-51|Biomarkers in Native American Women With Breast Cancer|Molecular Markers in Native American Women With Breast Cancer||Alliance for Clinical Trials in Oncology|No|Completed|August 1998|May 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|Samples With DNA|tissue samples|Female|18 Years|N/A|No|Non-Probability Sample|Native American women with primary adenocarcinoma of the breast with prior surgical        treatment for breast cancer within the Aberdeen or Phoenix areas of the Indian Health        Service or the Alaska area of the Native Health Service between 1990-2000.|July 2015|July 7, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898976||139255|
NCT00898989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-a00055-52|Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis|Evaluation of Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis|IBMan|Institut de Myologie, France|No|Completed|April 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|December 2010|December 18, 2010|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00898989||139254|
NCT00899002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0611|Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer|Molecular Analysis of Liver Cancer||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn|July 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|Samples With DNA|DNA will be extracted from the tissue samples and analyzed for molecular signatures, i.e.,      genomic and proteomic analyses.|Both|N/A|N/A|No|Probability Sample|Sample collection: 20 cases of fibrolamellar carcinoma and 20 hepatocellular carcinomas.|April 2013|April 8, 2013|May 9, 2009||No|slow accrual|No||https://clinicaltrials.gov/show/NCT00899002||139253|
NCT00872599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPAR Alpha Agonist|The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans|The Effect of a PPAR Alpha Agonist on CYP Monooxygenase Activity in Humans||Vanderbilt University|Yes|Completed|September 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|March 26, 2009|No|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT00872599||141236|
NCT00872885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|425965|Bunionectomy Trial With GRT6005|A Randomized, Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Moderate to Severe Pain Following Bunionectomy.||Grünenthal GmbH|No|Completed|March 2009|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|258|||Both|18 Years|75 Years|No|||June 2010|June 21, 2010|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872885||141215|
NCT00898924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491128|Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer|Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106||Alliance for Clinical Trials in Oncology|No|Completed|November 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|N/A|||Anticipated|49|||Both|18 Years|N/A|No|||September 2013|October 16, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898924||139259|
NCT00898937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000377341|Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast|Pilot Study for Analysis of Tumor Gene Expression by DNA Microarray Analysis in Patients Undergoing Breast Cancer Surgery or Core Biopsy Sampling||Georgetown University|No|Terminated|September 1999|December 2015|Anticipated|December 2014|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Female|18 Years|N/A|No|Non-Probability Sample|Any woman undergoing a breast biopsy or breast surgery|January 2015|January 27, 2015|May 9, 2009||No|Funding ended|No||https://clinicaltrials.gov/show/NCT00898937||139258|
NCT00899197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000547204|Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer|Tamoxifen Resistance in Breast Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Terminated|May 2007|||March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Female|18 Years|120 Years|No|Non-Probability Sample|Female >/= 18 years old with confirmed invasive breast cancer|September 2015|September 29, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899197||139240|
NCT00900250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD04B1|Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma|Hodgkin Disease (HD) Banking Study||Children's Oncology Group|No|Active, not recruiting|October 2006|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1272|||Both|N/A|N/A|No|Non-Probability Sample|Patients With Hodgkin's Lymphoma.|May 2015|May 12, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900250||139167|
NCT00900484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078649|SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma|Central Lymphoma Repository Tissue Procurement Protocol||Southwest Oncology Group|No|Completed|February 1989|October 2011|Actual|July 2011|Actual|N/A|Observational|N/A||1|Actual|458|Samples With DNA|Tissue collected for patients consenting to banking on SWOG lymphoma protocols|Both|16 Years|N/A|No|Non-Probability Sample|Patients consenting to SWOG 8819 banking protocol|May 2013|May 17, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900484||139151|
NCT00900796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-4452|Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis|Success and Failure of Biological Therapy: Predictors of Response in Patients With Active Ankylosing Spondylitis|PRETEA|Pfizer|No|Completed|March 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|132|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with active ankylosing spondylitis treated in rheumatology units|May 2012|May 7, 2012|May 11, 2009||No||No|May 7, 2012|https://clinicaltrials.gov/show/NCT00900796||139127|
NCT00900809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 12-151|Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia|Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia||NantKwest, Inc.|Yes|Active, not recruiting|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900809||139126|
NCT00897039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000491440|Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas||National Cancer Institute (NCI)||Recruiting|March 2006|||||N/A|Observational|N/A|||Anticipated|60|||Female|N/A|N/A|No|||July 2009|September 19, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897039||139389|
NCT00897260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02813|Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders|Umbilical Cord Blood Transplantation as Treatment of Adult Patients With Hematologic Disorders||University of British Columbia|No|Recruiting|May 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|N/A|No|||November 2011|November 21, 2011|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00897260||139374|
NCT00897962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000583066|Blood Glycan Biomarkers in Women With Stage IV Breast Cancer|Serum Glycan Analysis in Breast Cancer||University of California, Davis|Yes|Active, not recruiting|September 2006|December 2014|Anticipated|February 2011|Actual|N/A|Observational|N/A||3|Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with metastatic breast cancer receiving active chemotherapy, endocrine therapy or        targeted therapy Healthy age matched controls without chronic diseases and not on regular        prescription medications Patients seen at Internal Medicine Clinic for any reason other        than active, metastatic cancer|February 2014|February 28, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897962||139324|
NCT00897988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000558955|DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx|Effect of PI3K Inhibition in HPV-Associated HNSCC||National Cancer Institute (NCI)||Recruiting|April 2006|||||N/A|Observational|N/A|||Anticipated|40|||Both|N/A|N/A|No|||October 2008|August 11, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897988||139322|
NCT00898183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078645|S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma|Cytogenetic, Molecular and Cellular Biology Studies in Metastatic Melanoma Patients, Ancillary||Southwest Oncology Group|No|Completed|November 1996|February 2007|Actual|February 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|91|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898183||139309|
NCT00898209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0332|Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)|Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|April 2003|December 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|564|Samples With DNA|Peripheral blood lymphocyte DNA, and Exhaled breath condensate|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers as well as patients at risk or already identified as having lung        cancer.|April 2013|June 23, 2014|May 9, 2009||No|This study competed with another VICC study|No||https://clinicaltrials.gov/show/NCT00898209||139308|
NCT00899015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907221|Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J|Sample Analysis for Terminated Protocol 00-C-0070, Pediatric Phase I Trial of Arsenic Trioxide||National Institutes of Health Clinical Center (CC)||Completed||February 2008|Actual|||N/A|Observational|N/A|||Anticipated|23|||Both|2 Years|21 Years|No|||March 2012|March 14, 2012|May 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00899015||139252|
NCT00898742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0715|Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer|Molecular Signatures of HNSCC in Response to Targeted Therapies||Vanderbilt-Ingram Cancer Center||Terminated|April 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|58|||Both|N/A|N/A|No|Non-Probability Sample|head and neck cancer patients|March 2013|March 29, 2013|May 9, 2009||No|study closed prematurely upon PI's departure from VICC|No||https://clinicaltrials.gov/show/NCT00898742||139273|
NCT00899548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0524, CDR0000509417|DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer|DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|September 2006|June 2016|Anticipated|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Serum, plasma, DNA, RNA, whole blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Metastatic breast cancer patients and women without a history of breast cancer (ie,        healthy women or "normals')|October 2015|October 9, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899548||139217|
NCT00899561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc|Computed Tomography (CT) Score and Histopathology of the Middle Turbinate in Chronic Rhinosinusitis|Correlation Between Middle Turbinate Histopathology and Computed Tomography Staging in Chronic Rhinosinusitis|CT|Meir Medical Center|Yes|Recruiting|December 2008|December 2012|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples Without DNA|Middle turbinate samples of patients with limited, intermediate, and extensive chronic sinus      disease.|Both|18 Years|N/A|No|Non-Probability Sample|patients with a limited (of 1-8), intermediate (9-16), and extensive (17-24) sinus        disease.|March 2012|March 16, 2012|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00899561||139216|
NCT00872612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMC-GRANULOMA|Trial for the Diagnosis of Sarcoidosis|Endosonography (EUS and EBUS) vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis: a Randomized Trial|GRANULOMA|Leiden University Medical Center|Yes|Completed|March 2009|May 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|304|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872612||141235|
NCT00872898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-57A|Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism|An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism||Forest Laboratories|No|Completed|April 2009|||August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|6 Years|18 Years|No|||November 2013|November 26, 2013|March 30, 2009|Yes|Yes||No|August 1, 2013|https://clinicaltrials.gov/show/NCT00872898||141214|
NCT00899210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000574192|Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer|Study of Diagnostic Tests Studying Kinetic Variation of Serum Matrix Metalloproteases After Surgical Treatment and/or Destruction by Radiofrequency in Patients With Hepatic Metastases From Colorectal Cancer||National Cancer Institute (NCI)||Completed|September 2003|||May 2011|Actual|N/A|Observational|N/A|||Anticipated|75|||Both|18 Years|N/A|No|||May 2011|May 14, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899210||139239|
NCT00899496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 95A05|Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants|Pilot Study of Cancer Resistance in Humans||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|September 2005|||December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|48|||Both|N/A|120 Years|Accepts Healthy Volunteers|Non-Probability Sample|Those with metastatic cancer OR healthy individuals with no prior cancer diagnosis and who        are over the age of 50.|December 2015|December 28, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899496||139221|
NCT00900263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0120|S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma|S0120, A Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasmaproliferative Disorders||Southwest Oncology Group|Yes|Active, not recruiting|June 2002|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Bone marrow/peripheral blood|Both|N/A|N/A|No|Non-Probability Sample|plasmaproliferative disease not requiring therapy|March 2015|March 5, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900263||139166|
NCT00900523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GYN 0648|Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer|Urine Prostaglandin-M(PGE-M) in Ovarian Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|November 2006|July 2008|Actual|July 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Female|17 Years|N/A|No|Probability Sample|Women with known or suspected ovarian cancer who are greater than 17 years in age.|April 2013|April 17, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900523||139148|
NCT00900042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000502305|SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer|Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949||Southwest Oncology Group||Completed|July 1993|January 2003|Actual|December 2002|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|34|Samples With DNA|Tumor diagnostic tissue|Both|N/A|N/A|No|||February 2014|February 21, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900042||139183|
NCT00900497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08001-BMSCTI|A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers|A Phase I/II Study For the Use of White Blood Cells From Healthy Donor-participants To Treat Subjects With Solid Cancers||South Florida Bone Marrow/Stem Cell Transplant Institute|No|Enrolling by invitation|April 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900497||139150|
NCT00900510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008450|Antibiotic Therapy After Incision and Drainage for Abscess|The Use of Adjuvant Antibiotic Therapy After Incision and Drainage for Pediatric Abscess: A Prospective, Randomized, Double-blinded, Placebo-Controlled Trial||Wake Forest School of Medicine|Yes|Withdrawn|May 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|18 Years|No|||December 2014|December 8, 2014|May 11, 2009||No|Recruitment of this population in the hospital setting not practical.|No||https://clinicaltrials.gov/show/NCT00900510||139149|
NCT00897273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHOC-J0729, CDR0000554422|Human Papillomavirus Infection of the Mouth in Young Men and Risk Factors for Oropharyngeal Cancer|Oral HPV Infection in Young Men||Sidney Kimmel Comprehensive Cancer Center||Completed|May 2007|||May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Laboratory Methods:      Oral rinse sample:      Standard, well-validated assays will be used to detect HPV genomic DNA in oral exfoliated      cells from the Scope oral rinse sample.      Serum sample:      Standard laboratory assays will be used to detect antibodies to HPV16 L1 viral capsid      protein.|Male|18 Years|21 Years|Accepts Healthy Volunteers|Probability Sample|A convenience sample of 500 men recruited from Baltimore-area college health centers        (Johns Hopkins University, University of Maryland, or Towson University).|September 2010|September 15, 2010|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897273||139373|
NCT00897481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-LCC-06/Q1206/149|Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy|A Retrospective Case-Control Study of Melanoma Patients Who Have Undergone Sentinel Lymph Node Biopsy||National Cancer Institute (NCI)||Recruiting|January 2007|||September 2011|Anticipated|N/A|Observational|N/A|||Anticipated|1000|||Both|N/A|N/A|No|||April 2008|August 9, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897481||139357|
NCT00897741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000482353|Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer|Gene Expression Profiles in Primary and Metastatic Pancreatic Cancer||Barbara Ann Karmanos Cancer Institute|No|Completed|December 2004|March 2009|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Cancer clinic|February 2014|February 10, 2014|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897741||139341|
NCT00897754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000560986|Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab|Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy||National Cancer Institute (NCI)||Active, not recruiting|July 2007|||||N/A|Observational|N/A|||Anticipated|200|||Both|18 Years|N/A|No|||September 2007|May 16, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897754||139340|
NCT00898222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC ASA Normal|Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects|Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects||Brigham and Women's Hospital|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|May 8, 2009||No||No|July 16, 2014|https://clinicaltrials.gov/show/NCT00898222||139307|
NCT00890565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/39/C|Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)|A Single-Blind, Randomized, Parallel Trial to Define the ECG Effects of Sancuso® (Granisetron Transdermal System) Compared to Placebo and Moxifloxacin in Healthy Men and Women||Prostrakan Pharmaceuticals|No|Completed|May 2009|September 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|240|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2009|September 24, 2010|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890565||139870|
NCT00898768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELSIUS|Capsule Endoscopy to Screen for Small Bowel Neoplasia in Lynch Syndrome|Capsule Endoscopy in Lynch Syndrome for Small Intestinal Tumor Screening|CELSIUS|University Medical Center Groningen|No|Completed|May 2009|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|200|||Both|35 Years|70 Years|No|||December 2014|December 8, 2014|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00898768||139271|
NCT00898495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000551712|Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery|Single Nucleotide Polymorphisms (SNP) in Platinum-/Radiation Pathway Genes to Predict Outcome in Patients With Esophageal Adenocarcinoma Treated With Cisplatin-Based Chemoradiotherapy Followed by Surgical Resection||National Cancer Institute (NCI)||Active, not recruiting|May 2007|||||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||September 2007|May 16, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898495||139288|
NCT00899288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000482403|Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98|Investigating the Chemical Properties of Fingernails to Determine the Efficacy of Nail Structure for Evaluating Bone Fragility||International Breast Cancer Study Group|Yes|Terminated|April 2005|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Female|30 Years|N/A|No|||July 2012|July 26, 2012|May 9, 2009||No|Insufficient accrual|No||https://clinicaltrials.gov/show/NCT00899288||139235|
NCT00899301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 03103|Collecting and Storing Tissue Samples From Women With or Without Breast Cancer|Breast Tissue/Body Fluids Repository||Vanderbilt-Ingram Cancer Center|No|Recruiting|January 2004|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|4000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with and without breast cancer.|April 2015|August 24, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899301||139234|
NCT00873197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/41/C|PK, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and IV Granisetron|A Study to Assess the Pharmacokinetics, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and Intravenous Granisetron in Healthy Subjects||Prostrakan Pharmaceuticals|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2009|May 1, 2009|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00873197||141191|
NCT00873509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10888|Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder|A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder|B-ACE|Chugani, Diane C.|Yes|Active, not recruiting|May 2009|January 2016|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|166|||Both|2 Years|6 Years|No|||February 2015|February 12, 2015|March 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00873509||141167|
NCT00873769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-106|Staccato Loxapine PK in Smokers and Nonsmokers|Pharmacokinetics of Staccato® Loxapine for Inhalation in Smokers Compared to Nonsmokers||Alexza Pharmaceuticals, Inc.|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 18, 2009|April 1, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00873769||141147|
NCT00899223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000271412|Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes|The CALGB Leukemia Tissue Bank||Alliance for Clinical Trials in Oncology||Withdrawn|May 1996|||||N/A|Observational|N/A|||Actual|0|||Both|N/A|N/A|No|||February 2013|July 11, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899223||139238|
NCT00899509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-159905|Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer|Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|October 2000|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1500|Samples With DNA|Tissue|Female|N/A|N/A|No|Non-Probability Sample|Patients with breast cancer enrolled on Cancer and Leukemia Group B (CALGB) 9344 or 9741.|June 2015|June 22, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00899509||139220|
NCT00900848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHQ-0905-A|Posterior Tibial Artery Bypass for Iliofemoral Artery Injury Associated With Massive Blood Loss and Shock|Traumatic Disruption of Iliofemoral Arterial Segment is Often Associated With Multiple Injuries, Massive Hemorrhage, State of Shock, and Loss of Blood Supply to the Ipsilateral Lower Extremity, as Well as With High Mortality||The Second Hospital of Qinhuangdao|Yes|Completed|January 2009|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|8|||Both|20 Years|60 Years|No|Non-Probability Sample|8 patients|May 2009|May 11, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900848||139123|
NCT00900861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RHU-DUM-2009/1|Asthma Control and Clinical Practice in Hungary 2009|Asthma Control and Clinical Practice in Hungary 2009||AstraZeneca|No|Completed|April 2009|November 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Pulmonology outpatient clinics|December 2009|December 3, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00900861||139122|
NCT00900822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 02/05|Straumann Bone Ceramic Versus BioOss in Sinus Elevation|Randomized, Controlled Clinical Study to Compare Bone Formation Around Micro-implants in the Maxilla After Sinus Floor Augmentation With Straumann Bone Ceramic or Bio-Oss in a Split Mouth Design||Institut Straumann AG|No|Completed|November 2005|December 2008|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|80 Years|No|||July 2012|July 31, 2012|May 11, 2009||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00900822||139125|
NCT00900835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04140|Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer|Reducing Barriers to Pain and Fatigue Management||City of Hope Medical Center|No|Completed|June 2005|August 2010|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|470|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00900835||139124|
NCT00897052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0511|Gene Expression Profiles in Predicting Survival of Patients With Head and Neck Cancer|Survival Prediction in HNSCC Based on Gene Expression Profiles From FFPE Tissues||Vanderbilt-Ingram Cancer Center|Yes|Completed|February 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|29|Samples With DNA|To identify gene expression profile associated with survival from formalin-fixed paraffin      embedded tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Prior patients who participated on clinical trial RTOG-9501|September 2012|September 7, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897052||139388|
NCT00897494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000479140|Identification of Biomarkers for Early Detection of Pancreatic Cancer|Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project||Barbara Ann Karmanos Cancer Institute|No|Completed|February 2005|April 2011|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|Samples Without DNA|Venous blood|Both|18 Years|120 Years|No|Non-Probability Sample|Venous blood collection samples from newly dianosed|March 2016|March 7, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897494||139356|
NCT00897767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000357586|Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial|Ancillary Laboratory Protocol For the Collection of Diagnostic Material On Patients Considered For ECOG Treatment Trials For Leukemia Or Related Hematologic Disorders||National Cancer Institute (NCI)||Recruiting|July 2004|||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||December 2012|December 5, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897767||139339|
NCT00897975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00005390 Chestnut HillHC|Red Yeast Rice and Phytosterols In Statin Intolerance|Red Yeast Rice and Phytosterols Versus Red Yeast Rice and Placebo for the Treatment of Hyperlipidemia in Patients With Statin Intolerance: A Multi-Center Randomized Double-blind Study||Chestnut Hill Health System|Yes|Completed|July 2009|July 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2009|July 14, 2011|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00897975||139323|
NCT00897780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-0445-08|Combined Biofeedback With Virtual Reality in the Treatment of Pediatric Headache||VR|Hadassah Medical Organization|Yes|Not yet recruiting|September 2009|December 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|9 Years|18 Years|No|||May 2009|May 11, 2009|May 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00897780||139338|
NCT00890578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007642|HISTOACRYL: A Study of Its Efficacy in Final Scar Formation|It is Our Intent to Conduct a Prospective Randomized Controlled Trial Examining the Use of Histoacryl© in the Closure of Surgical Incisions in Comparison to Subcuticular Suture and to Dermabond©.||Mayo Clinic||Completed|April 2009|February 2011|Actual|February 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|21|||Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|1) and 2): Reduction Mammoplasty or mastopexy patients: Patients who present to the        plastic surgery clinic and are scheduled for breast procedures will be recruited and        consented by a clinical studies co-ordinator. This will include patients undergoing a        standard Wise pattern reduction mammoplasty (reduction and lift) or a standard Wise        pattern mastopexy (lift only). See exclusion criteria below.        1) and 2): Abdominoplasty or panniculectomy patients: Patients who present to the plastic        surgery clinic and are scheduled for abdominal procedures will be recruited and consented        by a clinical studies coordinator. See exclusion criteria below.|June 2012|June 19, 2012|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890578||139869|
NCT00890591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPB-OM-0106|Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension|National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine Besylate|Benibest|Daiichi Sankyo Inc.|No|Completed|August 2006|August 2007|Actual|June 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|30 Years|70 Years|No|||May 2009|May 27, 2009|February 11, 2009||No||No|February 11, 2009|https://clinicaltrials.gov/show/NCT00890591||139868|
NCT00898235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632869|Collecting Samples From Patients With Primary Systemic Amyloidosis|Data, Tissue, Blood, and Urine Repository for Amyloid Diseases||Boston Medical Center|No|Recruiting|January 2000|February 2037|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|blood, urine, and tissue|Both|18 Years|N/A|No|Probability Sample|Participants diagnosed, or with suspicion of having, primary systemic amyloidosis|January 2016|January 14, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00898235||139306|
NCT00891098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Hoffart|Comparing Imaginal Exposure and Imagery Rescripting in Treatment of Posttraumatic Stress Disorder (PTSD)|Comparing Imaginal Exposure (IE) and Imagery Rescripting and Reprocessing Therapy (IRRT) in the Treatment of Posttraumatic Stress Disorder (PTSD)||Modum Bad|No|Completed|November 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|20 Years|65 Years|No|||June 2013|June 4, 2013|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891098||139830|
NCT00898781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000582085|Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer|Molecular Detection of Circulating Cancer Cells in Breast, Ovarian, Colon and Pancreatic Cancer||Mayo Clinic|Yes|Terminated|November 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|80|||Both|N/A|N/A|No|Probability Sample|Registration - Inclusion Criteria          -  Radiographic or marker evidence of metastatic ovarian, breast, pancreatic, or colon             disease or pre-operative clinically staged 3 ovarian cancer or locally advanced or             metastatic pancreatic cancer.          -  Not received prior therapy for metastatic disease.        Registration - Exclusion Criteria:        -History of any prior cancer|July 2011|July 18, 2011|May 9, 2009||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT00898781||139270|
NCT00891683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG33773-201|Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy||Aegera Therapeutics|Yes|Completed|March 2009|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|75 Years|No|||May 2010|May 28, 2010|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891683||139787|
NCT00874068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL1|The Effects of Dietary Palmitic Acid Triacylglyceride Position on Bone Strength Parameters in Infants|The Effects of Dietary Palmitic Acid Triacylglyceride Position on Anthropometric Measures, Bone Strength Parameters, Stool Characteristics and Stool Biochemistry in Preterm and Term Infants|InFat_002|Enzymotec|No|Completed|February 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|94|||Both|N/A|1 Month|Accepts Healthy Volunteers|||February 2011|February 23, 2011|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874068||141124|
NCT00869804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|478-08-FB|Heading Off Peripheral Neuropathy With Exercise|Pilot Randomized Study of Aerobic and Resistance Exercise for Women Undergoing Treatment for Breast Cancer With Taxanes.|HOPE|University of Nebraska|Yes|Not yet recruiting|April 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|19 Years|N/A|No|||March 2009|March 25, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869804||141446|
NCT00900055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445231|Research Study in Healthy Volunteers or Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma|Dysregulation of Hematopoiesis in Fanconi Anemia||OHSU Knight Cancer Institute||Active, not recruiting|June 1975|||March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|1 Year|55 Years|Accepts Healthy Volunteers|Probability Sample|The Center for Hematologic Malignancies, the Knight Cancer Institute at OHSU, and the Bone        Marrow Failure clinic at Doernbecher Children's Hospital at OHSU will be centers for        recruitment.|April 2015|April 22, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900055||139182|
NCT00900536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-RE05-TRANSORCE|DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE|TRANSORCE (A Sub-study of SORCE)||National Cancer Institute (NCI)||Completed|July 2007|June 2012|Actual|||N/A|Observational|N/A|||||||Both|18 Years|N/A|No|||November 2008|August 9, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900536||139147|
NCT00897065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-MA.17ICSC|Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17|Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort||National Cancer Institute (NCI)||Recruiting|June 2006|||||N/A|Observational|N/A|||Anticipated|957|||Female|N/A|N/A|No|||April 2008|July 9, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897065||139387|
NCT00897286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBTP01|Study of Stored Tumor Samples in Young Patients With Brain Tumors|Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas, Medulloblastoma/PNET and Gliomas of the Pediatric CNS||St. Jude Children's Research Hospital|No|Active, not recruiting|November 2004|February 2026|Anticipated|February 2026|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|139|Samples With DNA|Fresh frozen, fixed and cultured tumor cells collected prospectively from a clinically well      characterized patient cohort.|Both|N/A|21 Years|No|Non-Probability Sample|Participants will have ATRT, CPC, medulloblastoma/PNET, ependymoma or glioma of the CNS as        documented by the local neuropathologist. All studies will be conducted using tumor        material collected prospectively from a clinically well characterized patient cohort.|February 2016|February 1, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897286||139372|
NCT00897078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635797|Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy Siblings|Health Effects After Leukemia (HEAL) Research Study||Vanderbilt University|Yes|Completed|January 2009|October 2011|Actual|October 2011|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|Samples With DNA|Banked DNA|Both|8 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|A minimum target accrual at each institution is 25 subjects for each treatment modality        and 25 siblings, for a total of 75 study participants at VCH. An attempt will be made to        approach equal numbers of male and female survivors.|June 2013|June 11, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897078||139386|
NCT00897299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000456426|Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy|Identifying Genomic Predictors of Recurrence After Adjuvant Chemotherapy||National Cancer Institute (NCI)||Completed||||||N/A|Observational|N/A|||Anticipated|900|||Female|18 Years|N/A|No|||June 2007|May 16, 2009|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897299||139371|
NCT00897507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL04B2|DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia|Single Nucleotide Polymorphisms and Relapse Risk in Standard Risk ALL||Children's Oncology Group|No|Active, not recruiting|March 2005|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|800|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric patients with acute lymphoblastic leukemia|August 2015|August 24, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897507||139355|
NCT00890279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPKDhypertension|Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)|Phase II Study for the Second-Line Treatment of Hypertension in Patients With Autosomal Dominant Polycystic Kidney Disease; ACEI vs. CCB||Ministry of Health, Labour and Welfare, Japan|No|Recruiting|July 2009|November 2012|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|60 Years|No|||December 2009|December 1, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890279||139892|
NCT00890877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/012/08|OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma|Dose Finding Study in Patients With Mild to Moderate Persistent Asthma: A Parallel Group, Randomised, Placebo Controlled, Double Blind Assessment of Oral Oc000459 Dosed At Three Dose Schedules for Twelve Weeks Finding Study In Patients With Mild To Moderate Persistent Asthma||Oxagen Ltd|No|Completed|April 2009|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|480|||Both|18 Years|55 Years|No|||September 2010|September 1, 2010|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890877||139847|
NCT00890838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMS/2008/Omegaven/Surgery/02|Preoperative Intravenous Omega 3 Fatty Acids Administration in Valvular Surgery Patients|Preoperative Intravenous Omega 3 Fatty Acids Administration in Valvular Surgery Patients: A Prospective, Randomized, Open-label, Comparative Clinical Trial|IVFO-Valvular|Nizam's Institute of Medical Sciences University, India|No|Completed|April 2009|December 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|50 Years|No|||October 2014|October 1, 2014|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890838||139850|
NCT00890851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050302|Procedure Transurethral Needle Ablation (TUNA) and Hospitalization of Short Duration|Evaluation of Procedure Tuna Within the Framework of a Hospitalization of Short Duration|EPURE|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2006|March 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Male|45 Years|85 Years|No|||April 2009|September 30, 2009|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890851||139849|
NCT00891111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUHS08613|Incentives for Preventative Health Care: Increasing Completion of Health Risk Assessments|Incentives for Preventative Health Care: Increasing Completion of Health Risk Assessments||Carnegie Mellon University|No|Not yet recruiting|May 2009|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|634|||Both|18 Years|N/A|No|||April 2009|April 30, 2009|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891111||139829|
NCT00891384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LenaMain-Trial|Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma|A Randomised Comparison of Daily 25 mg Versus 5 mg Lenalidomide as Maintenance Therapy After High-dose Therapy and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma||Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Yes|Active, not recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|194|||Both|18 Years|75 Years|No|||August 2015|August 19, 2015|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00891384||139809|
NCT00891696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-306|Nutritional and Contractile Regulation of Muscle Growth|Nutritional and Contractile Regulation of Muscle Growth (Cycle 2)||The University of Texas Medical Branch, Galveston|No|Completed|April 2009|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|14||Actual|144|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891696||139786|
NCT00874094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.01|Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds|Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds||The New York Eye & Ear Infirmary|No|Completed|April 2008|July 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|25 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|April 1, 2009||No||No|July 18, 2011|https://clinicaltrials.gov/show/NCT00874094||141123|
NCT00874107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CL-PGG-LCA0821|Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination With Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer||Biothera|Yes|Active, not recruiting|June 2009|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||May 2015|May 5, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874107||141122|
NCT00874120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18121|Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)|Randomized, Placebo-Controlled, Double-Blind, Two-Way Crossover Study to Evaluate the Effects of Phenylephrine HCl Extended-Release Tablets 30 mg Compared to Placebo on Ambulatory Blood Pressure||Bayer|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|April 1, 2009|Yes|Yes||No|June 2, 2010|https://clinicaltrials.gov/show/NCT00874120||141121|
NCT00869817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0147|Dominantly Inherited Alzheimer Network (DIAN)|Dominantly Inherited Alzheimer Network (DIAN)|DIAN|Washington University School of Medicine|Yes|Recruiting|January 2009|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|serum, plasma, cerebral spinal fluid|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mutation carriers and non-carriers from families with a mutation (which is different from        the genetic risk factor Apo-E4) known to cause Alzheimer's disease.|February 2016|February 1, 2016|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869817||141445|
NCT00870077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protobese|A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver Disease|Effect of a Whey Protein Supplementation on Intrahepatic Lipids in Obese Patients With Non-alcoholic Fatty Liver Disease|PROTOB|University of Lausanne|No|Completed|April 2009|April 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|50 Years|No|||February 2012|February 23, 2012|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870077||141425|
NCT00900068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617385|Blood Samples From Patients With Cancer Treated on a Clinical Trial to Control Nausea and Vomiting During Donor Stem Cell Transplant|Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation||OHSU Knight Cancer Institute||Terminated|August 2008|October 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|9|||Both|18 Years|120 Years|No|Non-Probability Sample|During the pilot study, serum samples were collected from a subgroup of patients in both        the placebo and the aprepitant arms|February 2016|February 11, 2016|May 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00900068||139181|
NCT00900302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000443230|OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer|Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer||OHSU Knight Cancer Institute||Completed|April 2005|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|98|||Both|N/A|120 Years|No|Non-Probability Sample|De-identified tissue samples will be obtained from the OHSU Pathology Department|February 2016|February 9, 2016|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900302||139163|
NCT00900276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000550059|Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants|BARC: A Secreted Marker of Kidney Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|June 2006|April 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|120 Years|Accepts Healthy Volunteers|Non-Probability Sample|Those with a diagnosis of renal cell carcinoma or a diagnosis of transitional cell        carcinoma of the urothelium.|October 2015|October 22, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900276||139165|
NCT00900289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000577616|Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer|DNA Methylation as a Predictor for Response and Progression-Free Survival in Patients With Ovarian Cancer||Cancer Research UK, Glasgow|No|Recruiting|March 2002|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Tissue and whole blood|Female|18 Years|N/A|No|Probability Sample|Patients eligible for this study will be patients with clinically suspected FIGO stages        Ic-IV epithelial ovarian cancer that are about to undergo surgery for confirmatory biopsy        and attempted cytoreductive surgery.|February 2013|February 12, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00900289||139164|
NCT00900575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008173|Cervical Cancer Detection Using Optical Spectroscopy|Cervical Cancer Detection Using Optical Spectroscopy||Duke University|No|Recruiting|May 2006|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|310|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900575||139144|
NCT00900549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCT67914 (Lesser Earth)|Evaluation of Resynchronization Therapy for Heart Failure|EvaluAtion of Resynchronization Therapy for Heart Failure (EARTH)|EARTH|Montreal Heart Institute|Yes|Terminated|October 2003|July 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|May 12, 2009||No|Futility reason, no difference between study groups|No||https://clinicaltrials.gov/show/NCT00900549||139146|
NCT00900562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM104-B-001-09|Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy|Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy||PharmaMar|No|Terminated|August 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||January 2013|January 14, 2013|May 12, 2009|Yes|Yes|Slow and poor recruitment.|No||https://clinicaltrials.gov/show/NCT00900562||139145|
NCT00900874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIIIMS|Rapid Onset Action of Salbutamol Versus Formoterol|Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|January 2009|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|5 Years|15 Years|No|||May 2009|May 12, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00900874||139121|
NCT00889408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS075|DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma|A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|April 2009|June 2016|Anticipated|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|12 Years|N/A|No|||January 2016|January 22, 2016|April 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889408||139959|
NCT00889681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP PS-024|Continued Access Protocol|CAP-AF: Continued Access Protocol for the Evaluation of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation|CAP-AF|Medtronic Atrial Fibrillation Solutions|Yes|Completed|March 2009|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|75 Years|No|||March 2014|March 26, 2014|April 24, 2009|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00889681||139938|
NCT00890019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC033|A Study of AdCh63 ME−TRAP Alone and With MVA ME−TRAP|A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidate AdCh63 ME-TRAP, Alone and With MVA ME-TRAP, Using a Prime-boost Delivery Schedule||University of Oxford|Yes|Completed|July 2007|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890019||139912|
NCT00890292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016186|A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-Label, Multi-Center, Sequential Group, Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of JNJ-31001074 After a Single Dose Administration in Pediatric Subjects With Attention-Deficit/Hyperactivity Disorder, 12 to 17 Years Old||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|18|||Both|12 Years|17 Years|No|||April 2010|April 15, 2010|April 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890292||139891|
NCT00899353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU9230|Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)|Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies||Marshall University|No|Terminated|August 2008|October 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|May 8, 2009||No|Original Principal Investigator left the institution.|No|April 29, 2013|https://clinicaltrials.gov/show/NCT00899353||139231|
NCT00890864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0710/2|Pilot Study: Age Extension of NHS Breast Screening Programme|Pilot Study of the Feasibility and Acceptability of Randomising the phasing-in of the Age Extension of the NHS Breast Screening Programme in England||University of Oxford|No|Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|36000|||Female|47 Years|73 Years|Accepts Healthy Volunteers|||July 2010|July 16, 2010|January 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00890864||139848|
NCT00891124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2009/2|Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).|A Multi-center, Prospective, Observational Study to Assess the Effect of Patient Education Related to CV Risk Factors in Type 2 Diabetes Mellitus|PATROL|AstraZeneca|No|Completed|May 2009|October 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4045|||Both|18 Years|N/A|No|Non-Probability Sample|Type II DM and Hypertension and/or Hyperlipidemia|November 2009|November 2, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00891124||139828|
NCT00891423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2008/03406|A Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Unit (ICU) Patients|A Randomised Controlled Crossover Pilot Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Patients|MERO001|Austin Health|No|Completed|April 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891423||139807|
NCT00891397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-181|Pregabalin Versus Placebo as an Add on for Complex Regional Pain Syndrome (CPRS) of the Upper Limb Managed by Stellate Ganglion Block (The PREGA Study)|Pregabalin vs. Placebo as an Add on for Complex Regional Pain Syndrome of the Upper Limb Managed by Stellate Ganglion Block|PREGA|McMaster University|No|Terminated|November 2007|October 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|April 28, 2009||No|Unable to recruit patients|No||https://clinicaltrials.gov/show/NCT00891397||139808|
NCT00891709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 29102-C01|LEO 29102 Single and Multiple Dose Study by Dermal Application|A Phase 1, First in Man, Safety, Tolerability and Pharmacokinetic Study of Single Ascending and Multiple Cutaneous Doses of LEO 29102 2.5 mg/g Cream or LEO 29102 Cream Vehicle in Healthy Male Subjects||LEO Pharma|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|64|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|March 2, 2016|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891709||139785|
NCT00891969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040810|Treatment Decision Making Between Oncologists and Women With Newly Diagnosed Breast Cancer and Their Healthy Companions|The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients||Rutgers, The State University of New Jersey|Yes|Terminated|February 2009|March 2013|Actual|May 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|||Female|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed, early-stage, female, breast-cancer patients who are scheduled to see a        participating surgical oncologist for an initial treatment decision making visit|November 2015|November 5, 2015|April 30, 2009||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00891969||139765|
NCT00878813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 001/09|Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study|Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk-study|CoRisk|University Hospital Inselspital, Berne|No|Completed|March 2009|October 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1102|Samples Without DNA|In all patients: 5 ml serum      In patients undergoing intra-arterial revascularisation: 10 ml serum|Both|N/A|N/A|No|Probability Sample|All consecutive patients who are admitted to the emergency department of the Inselspital        Bern - Switzerland with a clinical diagnosis of acute ischemic stroke within 24 hours of        symptom onset. Inselspital Bern is a university based hospital with a catchment area of        about 1.000.000 people|November 2011|November 9, 2011|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00878813||140764|
NCT00870974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPEB|A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions|Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions|FPEB|Institute for Neurodegenerative Disorders|No|Recruiting|March 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|155|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00870974||141358|
NCT00874419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20981|Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation|A Randomized, Open-label, Multi-center Phase III Study of Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With EGFR Exon 19 or 21 Mutation (Optimal)|ML20981|Tongji University|Yes|Completed|August 2008|July 2012|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874419||141098|
NCT00900081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000550067|Cyclooxygenase-2 Expression in Tissue Samples From Patients With a Normal Cervix, Cervical Intraepithelial Neoplasia, or Early Invasive Cervical Cancer|Evaluation of Cyclooxygenase-2 Expression in Normal Cervix, Cervical Intraepithelial Neoplasia and Early Invasive Squamous Cell Carcinoma With Correlation to Parameters of Invasion and Angiogenesis||Comprehensive Cancer Center of Wake Forest University|No|Withdrawn|May 2003|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|120 Years|No|Non-Probability Sample|patients with Cervical Intraepithelial Neoplasia|October 2015|October 22, 2015|May 9, 2009||No|no accrual, PI left institution|No||https://clinicaltrials.gov/show/NCT00900081||139180|
NCT00888264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NBE-SER-2008/1|A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder|A 6 Month Observational Multicentric Prospective Study Observing the Use of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder, in the Course of a Major Depressive Episode|HARMONY|AstraZeneca|No|Completed|May 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|152|||Both|18 Years|65 Years|No|Non-Probability Sample|Outpatients (male or female), diagnosed with Bipolar I or II disorder, having presented or        presenting a major depressive episode (according to DSM-IV-TR) with starting date of 6        months maximum before the inclusion.|December 2010|December 21, 2010|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888264||140047|
NCT00900588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-sPanFlu-2001|Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents|Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescent||Sinovac Biotech Co., Ltd|Yes|Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||||||Both|12 Years|17 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2009|May 12, 2009||||No||https://clinicaltrials.gov/show/NCT00900588||139143|
NCT00900887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM 1470/08.03.18|Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema|Efficacy of Topic Antiinflammatory Therapy Treatment in Center Point Thickness Secondary to Selective Photocoagulation in Diabetic Macular Edema||Hospital Juarez de Mexico|No|Completed|April 2008|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|84|||Both|40 Years|80 Years|No|||March 2015|March 18, 2015|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900887||139120|
NCT00897091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000528264|S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil|Molecular Predictors of Outcome on CAF Plus Tamoxifen Versus Tamoxifen Alone in Postmenopausal Women With Node Positive, Receptor Positive Breast Cancer [NCI Correlative Science Reference No. # 8814A-ICSC]||Southwest Oncology Group|No|Completed|July 2006|October 2007|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|750|||Female|18 Years|N/A|No|Non-Probability Sample|Patients consenting to banking in S8814|May 2013|May 28, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00897091||139385|
NCT00889161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curcumin-1|Curcumin in Pediatric Inflammatory Bowel Disease|Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study||Seattle Children's Hospital||Completed|May 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|8 Years|18 Years|No|||June 2010|June 16, 2010|April 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889161||139978|
NCT00889421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e4235|Apremilast in the Treatment of Uveitis|An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.||Oregon Health and Science University||Terminated|November 2009|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|April 24, 2009|Yes|Yes|Investigator discretion due to lack of efficacy in three subjects enrolled|No|June 6, 2014|https://clinicaltrials.gov/show/NCT00889421||139958|Study was terminated prematurely due to inefficacy in the three initial patients enrolled. Endpoints were not analyzed as participants did not make it to the 6 month time frame before discontinuing the study.
NCT00889434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECGC-TOC-HMO-CTIL|Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)|Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CF||Hadassah Medical Organization|No|Recruiting|September 2009|June 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||November 2012|November 11, 2012|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00889434||139957|
NCT00889694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2008]2-4|Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis|Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis: a 12-Week, Multiple Centers, Randomized Double-Blind, Positive Drug and Placebo Controlled Clinical Trial||Sun Yat-sen University|Yes|Enrolling by invitation|October 2008|August 2009|Anticipated|July 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|No|||April 2009|April 27, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889694||139937|
NCT00889707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX302-2-03|Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia|A Randomized, Double-blind, Placebo-controlled Phase II Study of Transperineal Intraprostatic Injection of PRX302 for the Treatment of Benign Prostatic Hyperplasia|TRIUMPH-1|Sophiris Bio Corp|No|Completed|January 2009|September 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|92|||Male|40 Years|80 Years|No|||August 2013|August 19, 2013|April 27, 2009||No||No|May 28, 2013|https://clinicaltrials.gov/show/NCT00889707||139936|
NCT00890032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006677|Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme|Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial||Duke University|Yes|Active, not recruiting|September 2009|January 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|April 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890032||139911|
NCT00890045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0004|Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study|A Comparison Between the HeRO® Graft and Conventional Arteriovenous Grafts in Hemodialysis Patients||Hemosphere, Inc.|Yes|Completed|July 2004|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890045||139910|
NCT00869622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VABHS IRB#1889|Antiepileptic Drugs and Osteoporotic Prevention Trial|Antiepileptic Drugs and Osteoporotic Prevention Trial|ADOPT|Boston VA Research Institute, Inc.|Yes|Completed|June 2006|January 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Male|18 Years|85 Years|No|||July 2015|July 23, 2015|March 25, 2009|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00869622||141460|
NCT00869635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0056|S-1 and Photodynamic Therapy in Cholangiocarcinoma|Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control||Asan Medical Center|Yes|Completed|February 2009|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|90 Years|No|||February 2014|February 5, 2014|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869635||141459|
NCT00869921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4195 Chronic Performance|Model 4195 Left Ventricular (LV) Lead Chronic Performance Study|Attain StarFix® Model 4195 Left Ventricular Lead Chronic Performance Post Approval Study||Medtronic|No|Active, not recruiting|March 2009|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|1322|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with a 4195 LV Lead within the past 30 days. All patients must meet        Inclusion criteria and none of the Exclusion criteria.|October 2015|October 29, 2015|March 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00869921||141437|
NCT00869934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH079188-02|Cognitive-Behavior Therapy for Insomnia|Cognitive-Behavior Therapy for Insomnia: Component Analysis and Treatment||Laval University|No|Completed|April 2008|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|186|||Both|25 Years|N/A|No|||June 2013|June 28, 2013|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00869934||141436|
NCT00870181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009HGG-01|ADV-TK Improves Outcome of Recurrent High-Grade Glioma|Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma|HGG-01|Huazhong University of Science and Technology|Yes|Completed|January 2008|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||June 2013|June 22, 2013|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870181||141418|
NCT00870194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-CR-GWDK|A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin|A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin||AstraZeneca|No|Completed|March 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|75 Years|No|||March 2015|March 20, 2015|March 25, 2009|Yes|Yes||No|April 11, 2011|https://clinicaltrials.gov/show/NCT00870194||141417|
NCT00870753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2006.1243|Yoga in Treatment of Eating Disorders|Yoga in Treatment of Eating Disorders||Norwegian School of Sport Sciences|No|Recruiting|March 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2009|March 26, 2009|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870753||141375|
NCT00871052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Graz IRB 19-129 ex 07/08|Calcipotriol and Polymorphic Light Eruption|Calcipotriol in the Prevention of Polymorphic Light Eruption||Medical University of Graz|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|N/A|No|||October 2009|October 2, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871052||141352|
NCT00896584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK-40/3|Exercise Pulseoximetry for Pre-flight Evaluation of Chronic Obstructive Pulmonary Disease (COPD) Patients|May Pulseoximetry During Physical Exercise Predict Hypoxemia in COPD Patients During Air Travel?||LHL Helse|No|Completed|May 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|40 Years|80 Years|No|Probability Sample|COPD patients|November 2010|November 17, 2010|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896584||139420|
NCT00896844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Meads|A Trial on the Effect of Emotional Disclosure of Traumatic Life Events on Physical Health|A Randomised Controlled Trial on the Effect of Emotional Disclosure of Traumatic Life Events on Physical Health||University Hospital Birmingham|No|Completed|September 2001|May 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 11, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00896844||139401|
NCT00891358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 073|Empowerment Intervention for Young Women - Phase I|A Secondary Prevention Empowerment Intervention for Young Women Living With HIV||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|November 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Female|16 Years|24 Years|No|||December 2014|February 12, 2015|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891358||139811|
NCT00891371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-48-52030-223|Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea|A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhea|MEDARD|Ipsen|No|Completed|July 2009|August 2013|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|April 30, 2009|No|Yes||No|July 17, 2015|https://clinicaltrials.gov/show/NCT00891371||139810|
NCT00891657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN-08-002|Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy|A Randomised, Prospective, Multi-Centre Clinical Study of SprayShield™ Adhesion Barrier System as a Barrier for the Prevention of Adhesion Formation After Laparoscopic Myomectomy||Integra LifeSciences Corporation|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|15|||Female|18 Years|N/A|No|||September 2014|September 4, 2014|April 30, 2009||No||No|July 13, 2010|https://clinicaltrials.gov/show/NCT00891657||139789|The very small sample size makes it difficult to detect any real differences between the treatments, if such differences exist.
NCT00891670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS-0901-D|Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism|Validation of Adjunctive Cilostazol According to CYP2C19 Polymorphism: Prospective, Randomized, Single-Center Trial:|ACCEL2C19|Gyeongsang National University Hospital|Yes|Not yet recruiting|May 2009|July 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2009|April 30, 2009|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891670||139788|
NCT00871598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT12-CD016|BTT1023 in Psoriasis|A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Plaque Psoriasis - a Double-blind Randomized Placebo-controlled Sequential Group Trial||Biotie Therapies Corp.|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|26|||Both|18 Years|75 Years|No|||November 2010|November 15, 2010|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871598||141311|
NCT00871936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLx-4090-09-07|A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes||Kadmon Corporation, LLC|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|75 Years|No|||February 2015|February 2, 2015|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871936||141285|
NCT00872209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-001-00|Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa|Bioequivalence of Ciprofloxacin 0.3%: a Randomized, Multicenter, Parallel, Comparative Study on the Safety and Efficacy of Ciprofloxacin 0.3% in a Standard Solution or Foam Solution, in Patients With Acute External Otitis.||Otic Pharma|Yes|Completed|May 2009|November 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2009|December 23, 2009|March 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00872209||141265|
NCT00872196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-605|A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies|A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-072 After Discontinuation of ABT-072 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-072 Clinical Studies||AbbVie||Completed|April 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|65 Years|No|||January 2013|March 22, 2013|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872196||141266|
NCT00872443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/8-J|Interest of Occlusion of Permeable Foramen Ovale After a Cryptogenic Cerebrovascular Accident (CVA)|Interest of Occlusion of Permeable Foramen Ovale After a Cryptogenic Cerebrovacular Accident.|FOPasa|Nantes University Hospital|No|Completed|November 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|72|||Both|18 Years|55 Years|No|Probability Sample|patient who had an occlusion of POF after CVA, younger than 55 years and without        thromboembolic events.|April 2010|April 27, 2010|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872443||141247|
NCT00873340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14173|Physical Disability in Patients Treated With Betaferon|Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice||Bayer|No|Completed|October 2007|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|83|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|MS community sample|June 2014|June 25, 2014|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873340||141180|
NCT00873353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21154|Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients|An Open Non-randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer|XELTA|Grupo Gallego de Investigaciones Oncologicas|No|Completed|March 2008|August 2010|Actual|August 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||August 2010|August 17, 2010|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873353||141179|
NCT00873327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020476|Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates|Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates||Duke University|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|32|||Both|N/A|60 Days|No|||May 2013|May 29, 2013|March 30, 2009|No|Yes||No|November 25, 2012|https://clinicaltrials.gov/show/NCT00873327||141181|
NCT00873613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006900|Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine?|Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine?||Emory University|No|Completed|April 2009|July 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|705|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873613||141159|
NCT00873899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFPS-2006-2-335243-UO RL|Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators||EVOLVO|Regione Lombardia|No|Recruiting|May 2008|September 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with left ventricular systolic dysfunction implanted wih ICD|April 2009|April 1, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00873899||141137|
NCT00870220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15327B|Initiating Transdermal Estradiol Therapy in Turner's Syndrome|Initiating Transdermal Estradiol Therapy in Turner's Syndrome||University of Chicago|Yes|Terminated|April 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|1|||Female|138 Months|13 Years|No|||March 2014|March 10, 2014|March 5, 2009|No|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT00870220||141415|
NCT00870519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-168-01|Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Evaluation of [123I] MNI-168 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Institute for Neurodegenerative Disorders|No|Terminated|January 2009|January 2011|Actual|January 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 24, 2011|March 26, 2009|Yes|Yes|Assessment of data shows inadequate brain uptake, suggesting the tracer is inadequate as an    imaging biomarker of brain amyloid.|No||https://clinicaltrials.gov/show/NCT00870519||141393|
NCT00870207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-09-0023|Tu Salud Si Cuenta Worksite: Pilot Intervention Study|Tu Salud Si Cuenta Worksite: Pilot Intervention Study|TSSC Worksite|The University of Texas Health Science Center, Houston|No|Completed|November 2010|April 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 29, 2011|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870207||141416|
NCT00870506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60MD002265DT1|Community Trial to Enhance Organ Donation|Community-based Intervention to Enhance Signing of Organ Donor Cards||Case Western Reserve University|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|973|||Both|15 Years|N/A|Accepts Healthy Volunteers|||March 2010|July 9, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870506||141394|
NCT00871377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003420-01A2|Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures|Pilot Randomized Double Blind Crossover Study Of Fish Oil [Eicosapentaenoic Acid (EPA) And Docosahexaenoic Acid (DHA)] For Intractable Partial Seizures|FOS|National Center for Complementary and Integrative Health (NCCIH)|Yes|Completed|May 2008|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|24|||Both|18 Years|70 Years|No|||January 2014|January 9, 2014|March 27, 2009|Yes|Yes||No|October 31, 2013|https://clinicaltrials.gov/show/NCT00871377||141328|
NCT00871390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|628|Organization of Excitation in People With Atrial Fibrillation|Complex Electrograms in Atrial Fibrillation: Spatiotemporal Organization and Mechanistic Insights and Organization in Acute Atrial Fibrillation Post Open Heart Surgery||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|September 2006|August 2011|Anticipated|August 2011|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with paroxysmal and chronic atrial fibrilation (AF).|August 2009|August 6, 2009|March 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871390||141327|
NCT00871403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111128|Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer|An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Cell Lung Cancer||GlaxoSmithKline|No|Completed|July 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||March 2012|June 12, 2013|March 26, 2009|Yes|Yes||No|January 26, 2012|https://clinicaltrials.gov/show/NCT00871403||141326|Efficacy data were only summarized for the pazopanib (pazo.) 800 mg + pemetrexed (peme.) 500 mg/m^2 and the cisplatin 75 mg/m^2 + peme. 500 mg/m^2 arms due to the small sample size/short treatment duration in the pazo. 600 mg + peme. 500 mg/m^2 arm.
NCT00871663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04629|Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Weekly in Subjects With Advanced Malignancies||Merck Sharp & Dohme Corp.|No|Completed|August 2006|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|123|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871663||141306|
NCT00871078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRA-713/06|Anatomic and Visual Function Assessments on Asymptomatic HIV-positive Patients|Anatomic and Visual Function Assessments on Asymptomatic HIV-positive Patients Using Optical Coherence Tomography and Frequency Doubling Technology Perimetry||Federal University of São Paulo|No|Completed|June 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV infected patients|September 2009|September 28, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871078||141350|
NCT00871637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222-08-FB|Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction|Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction||University of Nebraska|Yes|Recruiting|August 2008|June 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Three groups Group One : Healthy non-smoking controls Group Two : Smoking adults with        chronic bronchitis/COPD Group Three: Non-smoking adults with chronic bronchitis/COPD|March 2009|March 26, 2009|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871637||141308|
NCT00896857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU-74A04|Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer|Breast Cancer Prevention by Inducing Apoptosis in DCIS Using Breast Ductal Lavage||Comprehensive Cancer Center of Wake Forest University||Completed|April 2004|||February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Female|N/A|120 Years|No|Non-Probability Sample|Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer|October 2015|October 22, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896857||139400|
NCT00896818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000592728|Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends|The British Breast Cancer Study - National Cancer Research Network Cohort (BBC-NCRN)||National Cancer Institute (NCI)||Recruiting|January 2005|||January 2009|Anticipated|N/A|Observational|N/A|||||||Female|N/A|70 Years|Accepts Healthy Volunteers|||June 2009|August 23, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896818||139403|
NCT00896831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08461|Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy|Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study|PORTOALEGRE|Hospital de Clinicas de Porto Alegre|Yes|Enrolling by invitation|November 2008|September 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|70 Years|No|||June 2009|June 5, 2009|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896831||139402|
NCT00892463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00072|Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder|Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder||Sunnybrook Health Sciences Centre|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|65 Years|No|||July 2011|July 27, 2011|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892463||139730|
NCT00871949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1171001|Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults|A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PNU-100480 (PF-02341272) After First Time Administration Of Ascending Oral Doses To Healthy Adult Subjects Under Fed And Fasted Conditions||Sequella, Inc.|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|19|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|March 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871949||141284|
NCT00872469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN76912190|World Maternal Antifibrinolytic Trial|Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial|WOMAN|London School of Hygiene and Tropical Medicine|Yes|Recruiting|May 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20000|||Female|16 Years|N/A|No|||September 2015|September 7, 2015|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872469||141245|
NCT00872456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC 08-0090CTIL|Associations Between Diabetes Care and Haptoglobin Genotype On outComes|The ADHOC Project: Associations Between Diabetes Care and Haptoglobin Genotype On outComes|ADHOC|Clalit Health Services|Yes|Active, not recruiting|March 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3054|||Both|55 Years|N/A|No|Probability Sample|Patients recruited from primary care clinics. All are diabetic patients 55 years old or        older at the time of ICARE initiation (2005).|June 2015|June 20, 2015|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872456||141246|
NCT00873652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2008/5|Observational Study of Immune Response to Hepatitis B Childhood Booster|An Observational Study of Children Immunised in Infancy Against Hepatitis B Virus, Evaluating the Persistence of Immunity and the Immune Response to a Scheduled Booster Dose of Hepatitis B Vaccine||University of Oxford|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|28|Samples Without DNA|Serum|Both|41 Months|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children have been recorded as having commenced an accelerated course of HBV vaccine        between the years 2000 and 2006|May 2013|May 7, 2013|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00873652||141156|
NCT00873639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3721|Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoRapid® (Insulin Aspart) and Levemir® (Insulin Detemir) in a Basal-bolus Regimen for Treatment of Type 1 Diabetes Mellitus in Romania||Novo Nordisk A/S|No|Completed|April 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|417|||Both|6 Years|75 Years|No|Probability Sample|Type 1 diabetes patients from diabetes centres who have been deemed appropriate to receive        NovoRapid® and Levemir® as new treatment in basal-balus regimen and as part of routine        care by the prescribing physician.|July 2012|July 17, 2012|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00873639||141157|
NCT00873912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA205|A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a New 6:2 Influenza Virus Reassortant in Healthy Adults|MI-MA205|MedImmune LLC|No|Completed|May 2009|December 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2011|July 12, 2011|April 1, 2009|Yes|Yes||No|October 8, 2010|https://clinicaltrials.gov/show/NCT00873912||141136|
NCT00873626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071208|Treatment's Duration of Acute Uncomplicated Pyelonephritis|Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis.|DTP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|310|||Female|18 Years|65 Years|No|||June 2011|November 5, 2014|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873626||141158|
NCT00869648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UN3371|Head Positions to Open the Upper Airway|Head Positions to Open the Upper Airway- a Pilot Study||Medical University Innsbruck|No|Completed|April 2009|August 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 29, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869648||141458|
NCT00869947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6749-M|Effects of Wearing a Powered Ankle-Foot Prosthesis on Amputee Walking|Effects of Wearing a Powered Ankle-Foot Prosthesis on Amputee Walking||VA Office of Research and Development|No|Completed|March 2009|January 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|March 24, 2009||No||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00869947||141435|
NCT00870233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-155|Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life|Electronic Patient-Reported Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2009|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Female|18 Years|N/A|No|Non-Probability Sample|Patients undergoing laparotomy for presumed or confirmed gynecologic malignancy at MSKCC.|March 2016|March 11, 2016|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870233||141414|
NCT00870532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-LUN|Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer|A Prospective Study of Metronomic Oral Vinorelbine in Combination With Sorafenib in Advanced Non-small Cell Lung Cancer a) A Phase I Dose-finding Study of the Combination of Metronomic Oral Vinorelbine and Sorafenib b) Pharmacokinetics Profiling of the Combination of Metronomic Oral Vinorelbine and Sorafenib at MTD||National Cancer Centre, Singapore|No|Completed|June 2008|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|21 Years|N/A|No|||November 2013|November 1, 2013|June 9, 2008||No||No||https://clinicaltrials.gov/show/NCT00870532||141392|
NCT00871091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JO 207/4-1-4|Study Investigating Tooth Movements With Conventional and Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM) Supported Fixed Appliances|Pilot Study Investigating Tooth Movements With Conventional and CAD/CAM Supported Fixed Appliances||Charite University, Berlin, Germany|No|Active, not recruiting|January 2007|June 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|35 Years|No|||March 2009|March 27, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871091||141349|
NCT00870779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS 0711|Fluorescence Guided Resection of Brain Tumors|Co-registered Fluorescence-Enhanced Resection of Brain Tumors Stage I: Correlation With MR and Biopsy|FGR|Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|May 2007|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|234|||Both|21 Years|N/A|No|||August 2014|August 28, 2014|March 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00870779||141373|
NCT00870792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ibwadhrct88$|Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals|Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals|MAP|National Institute on Drug Abuse (NIDA)|No|Completed|November 2002|February 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|156|||Both|18 Years|N/A|No|||March 2009|April 6, 2009|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870792||141372|
NCT00871104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOSIMI|Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis|Evaluation of the Efficacy and Safety of Fosfomycin Plus Imipenem for the Treatment of Methicillin-resistant Staphylococcus Aureus (MRSA) Infective Endocarditis.||Hospital Clinic of Barcelona|Yes|Recruiting|July 2009|December 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871104||141348|
NCT00871416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEEDLEN/DCD/3/DK|Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles|Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles. Furthermore, the Thickness of Cutis/Subcutis Is Measured on Recommended Insulin Injection Sites||Novo Nordisk A/S|No|Completed|April 1997|July 1997|Actual|July 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|65 Years|No|||June 2012|June 28, 2012|March 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871416||141325|
NCT00871676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804361|Use of Chewing Gum to Facilitate Appetite Control and Weight Loss|Use of Chewing Gum to Facilitate Appetite Control and Weight Loss in Overweight Individuals Treated by Lifestyle Modification||University of Pennsylvania|No|Active, not recruiting|May 2006|December 2008|Anticipated|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|21 Years|75 Years|No|||March 2009|March 27, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871676||141305|
NCT00872001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05633|The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)|The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG)|RED-CABG|Merck Sharp & Dohme Corp.|Yes|Terminated|April 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3080|||Both|50 Years|N/A|No|||October 2015|October 28, 2015|March 27, 2009|Yes|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT00872001||141281|
NCT00892476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F010613009|Prevention of Myopia of Prematurity by Calcium Supplementation|Prevention of Myopia of Prematurity by Calcium Supplementation in a Randomized Controlled Pilot Trial||University of Alabama at Birmingham|Yes|Completed|February 2002|December 2008|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|99|||Both|N/A|14 Days|No|||July 2010|December 4, 2012|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00892476||139729|
NCT00892489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004213|A Bioequivalence Study of 15 mg ER OROS Paliperidone|Pivotal Bioequivalence Study With 15 mg ER OROS Paliperidone Comparing the Phase 3 Formulation With the To-be-marketed Formulation and Evaluation of Food Effect on the to be Marketed Formulation in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2004|December 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|80|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|December 18, 2008||||||https://clinicaltrials.gov/show/NCT00892489||139728|
NCT00892255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008 Microwave Ablation|Microwave Ablation of Resectable Liver Tumors|Microwave Ablation of Resectable Liver Tumors||St. Joseph Hospital of Orange|No|Recruiting|April 2009|||April 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for liver resection, either for primary or metastatic disease|September 2012|September 12, 2012|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892255||139745|
NCT00892502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-007652-34|Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?|Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? A Clinical, Prospective, Randomized, Blinded Examination of Patients Suffering From Hematological Malignancies Treated With Intensive Chemotherapy and/or Radiotherapy.|Bismuth-PBH|Copenhagen University Hospital at Herlev|No|Completed|May 2009|February 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||September 2013|September 9, 2013|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892502||139727|
NCT00872222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT03/39|A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle™ Acetabular Cup Prosthesis With a Ceramic-on-ceramic Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement||DePuy International|No|Terminated|November 2006|||September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|70 Years|No|||August 2014|August 13, 2014|March 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872222||141264|
NCT00872820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH081299|Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder|Neural Mediators of Behavior Therapy for Anxiety||University of California, Los Angeles|No|Completed|October 2008|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|45 Years|No|||December 2014|December 9, 2014|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872820||141220|
NCT00873080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSantaMaria|Reliability of the Angle Measurement of the Software for Photogrammetry Postural Assessment (SAPO)|Reliability of the Angle Measurement of the Software for Photogrammetry Postural Assessment|SAPO|Universidade Federal de Santa Maria|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|24|||Female|20 Years|35 Years|No|Probability Sample|24 subjects with temporomandibular disorder|March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873080||141200|
NCT00872794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT03/29|A Single Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery|Prospective Single-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy ASR™ Hip in Subjects With Suitable Indications for a Primary Resurfacing Hip Arthroplasty||DePuy International|No|Terminated|November 2003|||February 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||September 2011|September 1, 2011|March 19, 2009|Yes|Yes|DePuy discontinued this product in 4Q 2009.At the time of this decision DePuy reviewed all    clinical studies for this product and decided to close this Study.|No||https://clinicaltrials.gov/show/NCT00872794||141222|
NCT00872807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/5.2006.3473 (REK)|The Activity School in Finnmark for Overweight Children|The Activity School in Finnmark for Overweight and Obese Children and Their Families||University Hospital of North Norway|No|Completed|April 2009|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|6 Years|12 Years|No|||December 2012|December 11, 2014|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872807||141221|
NCT00873938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/GD/70|Compliance to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana||Compliance|Kintampo Health Research Centre, Ghana|No|Completed|October 2005|September 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|411|||Both|10 Years|N/A|No|Probability Sample|A rural population in the middle belt of Ghana|April 2009|April 29, 2010|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873938||141134|
NCT00873925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF IRB 696-2008|Cord Blood Plus Vitamin D and Omega 3s in T1D|Transfusion of Autologous Umbilical Cord Blood Plus Vitamin D and Omega 3 Fatty Acids to Preserve Beta Cell Function in Children With Recent Onset Type 1 Diabetes - A Pilot Study||University of Florida|Yes|Completed|March 2009|October 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|1 Year|18 Years|No|||April 2013|April 1, 2013|April 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00873925||141135|
NCT00869661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV20536|A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4|A Randomized, Double-blind, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination With Pegasys® and Ribavirin® (SOC) Versus SOC in Treatment-Naïve Patients With HCV Genotype 1 or 4 Infection||Hoffmann-La Roche||Completed|February 2001|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|413|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869661||141457|
NCT00869960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080428014|Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women|Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women||University of Alabama at Birmingham|Yes|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 17, 2013|March 25, 2009||No||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00869960||141434|
NCT00870805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNSW HREC 08322|Ultrabrief Pulsewidth Electroconvulsive Therapy (ECT)|A Controlled Study of Ultrabrief Pulsewidth ECT (Electroconvulsive Therapy)|UB ECT|The University of New South Wales|Yes|Completed|January 2009|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|150|||Both|18 Years|N/A|No|||September 2011|February 26, 2013|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870805||141371|
NCT00871117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111852|Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years|Immunogenicity and Safety Study of Kinrix® Co-administered With Varivax®||GlaxoSmithKline||Completed|March 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|478|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|March 26, 2009|Yes|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00871117||141347|
NCT00871429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL080108|Skin Care for Cancer Patients: A Product Satisfaction Survey|Selected Skin Products for Cancer Patients: A Product Satisfaction Survey||Northwestern University|No|Completed|March 2009|August 2010|Actual|November 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|99|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|March 26, 2009|Yes|Yes||No|May 5, 2010|https://clinicaltrials.gov/show/NCT00871429||141324|No limitations of the trial identified.
NCT00871702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0744 / 201103095|Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease|Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity||Washington University School of Medicine|Yes|Completed|October 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|March 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871702||141303|
NCT00872040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-5177-MA-CTIL|The Effect of Delivery Mode on Inter - Couple Relationship, Sexual Function and Pelvic Floor Activity|Observational Study on the Effect of Delivery Mode on Inter Personal Relationship, Sexual Function and Pelvic Floor Activity||Sheba Medical Center|No|Recruiting|October 2008|October 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who attend primary care antenatal clinic|March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872040||141278|
NCT00871689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS110|Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML|Haploidentical Donor NK Cell Adoptive Therapy and Double T Cell Depleted Umbilical Cord Blood Transplantation With Post-Transplant IL-2 Immune Therapy For Refractory Acute Myeloid Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Terminated|January 2009|October 2011|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|45 Years|No|||July 2012|July 18, 2012|March 27, 2009|Yes|Yes|Due to graft failure.|No|June 11, 2012|https://clinicaltrials.gov/show/NCT00871689||141304|Quantitative, phenotypic and functional assessment of the in vivo expanded UCB-derived NK cells on Day 72 were not performed. Patients were not well enough to provide research samples.
NCT00896051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016045|TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients|TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects||Janssen R&D Ireland|Yes|Completed|August 2009|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|May 7, 2009|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00896051||139458|
NCT00896064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112993|Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults|A Study to Evaluate Safety & Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults||GlaxoSmithKline||Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|43|||Both|18 Years|41 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896064||139457|
NCT00896077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DT-002|Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes|A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (12 mg/kg) Administration in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus||DiaKine Therapeutics, Inc.||Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|8|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00896077||139456|
NCT00896337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2020|EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries|A Boston Scientific Trial of the EPIC™ Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries|ORION|Boston Scientific Corporation|Yes|Completed|May 2009|December 2013|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|May 8, 2009|Yes|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00896337||139438|
NCT00896623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000529126|DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer|Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897||National Cancer Institute (NCI)||Completed|December 2006|||||N/A|Observational|N/A|||Anticipated|1577|||Female|N/A|N/A|No|||June 2007|January 14, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896623||139417|
NCT00872482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMB1000-018|A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases|A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer||YM BioSciences|No|Terminated|April 2009|July 2011|Anticipated|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|March 26, 2009|Yes|Yes|Study closed due to low enrollment|No||https://clinicaltrials.gov/show/NCT00872482||141244|
NCT00872495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-061|Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer|Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney||Lahey Clinic|No|Recruiting|September 2002|November 2025|Anticipated|October 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Lahey Clinic patients presenting to the Department of Urology and Primary Care Referrals|December 2015|December 18, 2015|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00872495||141243|
NCT00873093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01908|Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)||National Cancer Institute (NCI)|Yes|Active, not recruiting|March 2009|||September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|151|||Both|1 Year|31 Years|No|||April 2014|September 30, 2014|March 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00873093||141199|
NCT00873119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-17|Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary|An Open-label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary||Onxeo||Completed|February 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|March 31, 2009|Yes|Yes||No|July 1, 2014|https://clinicaltrials.gov/show/NCT00873119||141197|
NCT00873379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-314|Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly|Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly: a Randomized, Double Blind, Placebo-Controlled Trial||Lawson Health Research Institute|Yes|Completed|October 2007|March 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|122|||Both|65 Years|N/A|No|||July 2009|July 6, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873379||141177|
NCT00873067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCP/08/207-4495-CFAE|Benefit of Complex Fractionated Atrial Electrograms Elimination in Atrial Fibrillation Ablation|Benefit of Complex Fractionated Atrial Electrograms Elimination in Atrial Fibrillation Ablation||Hospital Clinic of Barcelona|Yes|Completed|January 2009|September 2013|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|70 Years|No|||September 2011|February 26, 2014|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873067||141201|
NCT00869739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634536|Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer|Prostate Cancer Recovery Enhancement for African American Men and Their Intimate Partners||East Carolina University||Completed|August 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|||Actual|112|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2013|February 21, 2013|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869739||141451|
NCT00869752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I190|MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I-II Trial of MK-0646, a Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor, in Combination With Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer||Canadian Cancer Trials Group|Yes|Completed|January 2009|July 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2012|March 6, 2014|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869752||141450|
NCT00869687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLYL_L_02888|Biopsy Study for Sculptra (Poly-L-Lactic Acid)|A Single Group Study for the Characterization of Human Tissue Response to Injectable Poly-L-Lactic Acid (Sculptra) in Healthy Volunteers||Sanofi|No|Completed|March 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|35 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 22, 2012|March 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00869687||141455|
NCT00869700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEACAT 2_4_2|Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults|Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults|SEACAT 2_4_2|University of Cape Town|Yes|Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 25, 2010|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869700||141454|
NCT00869674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD-200804|GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study|一项比较GeneSearch 乳腺淋巴结（BLN）检测试剂盒和永久病理切片检测乳腺癌患者腋窝前哨淋巴结转移的前瞻性、多中心临床试验 A Prospective and Multi-center Clinical Trial By Comparing GeneSearch™ Breast Lymph Node (BLN) Test Kit To Permanent Pathological Section On Detecting Axillary Sentinel Lymph Node Metastases In Breast Cancer Patients||Johnson & Johnson Medical, China|No|Terminated|February 2009|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|540|||Both|18 Years|N/A|No|||June 2009|May 29, 2013|March 25, 2009||No|Investigational products has been suspended from the US market|No||https://clinicaltrials.gov/show/NCT00869674||141456|
NCT00870545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074804|Reintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study|Reintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study||Memphis VA Medical Center|No|Completed|September 2009|November 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|N/A|N/A|No|||June 2013|June 3, 2013|March 25, 2009||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00870545||141391|Small sample size, some of the Wounded Warrior Project spouses knew each other, pilot feasibility study and not a randomized controlled trial.
NCT00870818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA031-02|Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)|An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus||MacroGenics|No|Terminated|February 2009|May 2011|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|219|||Both|10 Years|37 Years|No|||March 2012|March 5, 2012|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00870818||141370|
NCT00870831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-0870|Islet Function and Clinical Analyses of Transplant Recipients|Islet Function and Clinical Analyses if Transplant Recipients (Project 2 of JDFI Washington University Center For Islet Transplantation) (Please Note That the JDRFI Funded Has Ended|Islet OGTT|Washington University School of Medicine|No|Terminated|October 2000|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|8|Samples Without DNA|Serum samples are obtained during the OGTT and stored in a -20degree freezer. They are      tested for Insulin C-peptide and glucose.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 diabetics that have successfully received and maintained an islet transplant here        at Washington University. Loss of transplant function is an exclusion criteria.|December 2014|December 8, 2014|March 26, 2009||No|PI left University|No||https://clinicaltrials.gov/show/NCT00870831||141369|
NCT00871130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_13_01_09|The Effect of Bariatric Surgery on Thyroid Function and Morphology|The Effect of Bariatric Surgery on Thyroid Function and Morphology, a Retrospective Study||University Hospital Inselspital, Berne|No|Completed|January 1998|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who have received a surgical procedure to result in desired weight reduction        (gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a        combination of any)|March 2009|March 27, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00871130||141346|
NCT00871442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-017|Parturient Controlled Epidural Analgesia (PCEA) With or Without a Basal Infusion for Early Labor|Parturient Controlled Epidural Analgesia (PCEA) With or Without a Basal Infusion for Early Labor||Baystate Medical Center|No|Withdrawn|May 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|November 17, 2015|March 27, 2009||No|would not substantially add to existing contributions in the literature|No||https://clinicaltrials.gov/show/NCT00871442||141323|
NCT00871455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-7|Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study|Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study||VA Office of Research and Development|No|Completed|April 2003|December 2011|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871455||141322|
NCT00871715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS056256|Arm Rehabilitation Study After Stroke|Interdisciplinary Comprehensive Arm Rehab Evaluation (ICARE) Stroke Initiative|ICARE|University of Southern California|Yes|Completed|June 2009|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|361|||Both|21 Years|N/A|No|||October 2014|October 27, 2014|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871715||141302|
NCT00872053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4125K-1|Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis|Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis||VA Office of Research and Development|No|Completed|February 2009|January 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|75 Years|No|||September 2013|September 18, 2013|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00872053||141277|
NCT00872300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AURA-6202-011|PHA-739358 for the Treatment of Multiple Myeloma|An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression||Nerviano Medical Sciences||Terminated|October 2008|September 2010|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|7|||Both|18 Years|75 Years|No|||May 2014|May 13, 2014|March 30, 2009|Yes|Yes|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT00872300||141258|
NCT00872313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-200903-MZ003|Risk Factors for Postpartum Psychosis|Potential Risk Factors for Postpartum Psychosis|RIFPP|Nanjing Medical University|Yes|Completed|February 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|4000|||Female|18 Years|50 Years|No|Probability Sample|Parturients undergoing spontaneous or induced labor or cesarean delivery|January 2014|January 11, 2014|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872313||141257|
NCT00896636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08B2|Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration|Gene Methylation and Estradiol Levels in Random FNA Samples as Biomarkers for Breast Cancer Risk||Northwestern University|Yes|Active, not recruiting|May 2008|September 2021|Anticipated|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|385|Samples Without DNA|Breast tissue random fine needle aspiration (rFNA) samples will be collected and levels of      methylation and hormones will be measured in each.|Female|35 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women coming in for screening mammography, for diagnostic imaging, for evaluation of        benign breast problems, and for breast cancer risk evaluation who have no history of        breast cancer.|September 2015|September 24, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896636||139416|
NCT00892541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004150|A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone|Investigation of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2004|November 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00892541||139725|
NCT00892554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002447|The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)|The Impact of Docosahexaenoic Acid on Neuropsychological Status in Females With Phenylketonuria|PKU&DHA|Emory University|Yes|Completed|June 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Female|12 Years|50 Years|No|||December 2015|December 9, 2015|May 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892554||139724|
NCT00871962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTADIR 2009 - COHORTE|Long-term Oxygen Treatment (LTOT) in Chronic Obstructive Pulmonary Disease: Factors Influencing Survival|Long-term Oxygen Treatment (LTOT) in Chronic Obstructive Pulmonary Disease: Factors Influencing Survival: Survival Factors in COPD Treated by Long-term Oxygen Therapy||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|Yes|Active, not recruiting|June 2009|May 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|Samples Without DNA|Blood gaz analysis|Both|40 Years|75 Years|No|Probability Sample|COPD patients on necessity of long-term oxygen therapy|June 2015|June 22, 2015|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871962||141283|
NCT00872833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|640|Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions|Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles||New England Research Institutes|Yes|Completed|July 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|People with transfusion-dependent thalassemia who receive care at sites funded by the        Thalassemia Clinical Research Network and their satellites.|April 2012|October 5, 2015|March 30, 2009||No||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00872833||141219|
NCT00873392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 051031|Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease|Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients.|NICOPARK2|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2009|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|70 Years|No|||December 2013|December 29, 2013|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873392||141176|
NCT00873678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051079|Assessment of the Prevalence of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome|Assessment of the Prevalence and Mutational Spectrum of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome and Cerebello-oculo-renal Syndromes|JSCORS|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|80|Samples With DNA|Whole blood sample (10 ml)|Both|N/A|N/A|No|Non-Probability Sample|Children or adult patients affected with JS/CORS|March 2010|June 2, 2010|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873678||141154|
NCT00873366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC083C|Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer|¹³C - Dextromethorphan (DM) Breath Test for Determination of CYP2D6 Enzyme Activity in Patients Receiving Tamoxifen||Mayo Clinic|Yes|Terminated|May 2009|||December 2015|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|210|||Female|18 Years|N/A|No|||March 2015|March 23, 2015|March 31, 2009|Yes|Yes|Funding issues|No||https://clinicaltrials.gov/show/NCT00873366||141178|
NCT00873405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|049/06|Banded Sleeve Gastrectomy Versus Banded Ring Gastric Bypass in Morbidly Obese Patients|Banded Sleeve Gastrectomy Versus Banded Ring Gastric Bypass in Morbidly Obese Patients: a Prospective Controlled Trial.||Federal University of Espirito Santo|Yes|Active, not recruiting|June 2006|||June 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Female|20 Years|60 Years|No|||March 2009|March 31, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873405||141175|
NCT00869765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09052|Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression|An Open Pilot Trial of Transcranial Direct Current Stimulation (tDCS) Augmented by D-Cycloserine as a Treatment for Depression.||The University of New South Wales|Yes|Completed|April 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|90 Years|No|||September 2010|September 9, 2010|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869765||141449|
NCT00870246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|914/04|Diaphragmatic Mobility and Chronic Obstructive Pulmonary Disease|Influence of Diaphragmatic Mobility on the Exercise Capacity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease|DMCOPD|University of Sao Paulo|No|Completed|February 2008|November 2008|Actual|May 2008|Actual|N/A|Observational|N/A||2|Actual|50|||Both|50 Years|75 Years|No|Non-Probability Sample|Sixty patients with moderate or severe COPD were evaluated.|May 2009|May 5, 2009|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870246||141413|
NCT00870558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626727|Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer|Adjuvant Treatment by Intra-arterial Injection of Lipiodol-labeled Iodine-131 in Preventing Recurrence of Hepatocellular Carcinoma After Curative Treatment||National Cancer Institute (NCI)||Completed|June 2005|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2009|August 13, 2011|March 26, 2009||||No||https://clinicaltrials.gov/show/NCT00870558||141390|
NCT00870844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12053A|Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke|A Randomised, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Patients With Acute Ischemic Stroke||H. Lundbeck A/S|Yes|Completed|May 2009|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|50 Years|90 Years|No|||April 2011|April 19, 2011|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870844||141368|
NCT00871143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAXKAYR|Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)|Efficacy of Cognitive Behaviour Therapy -v- Anxiety Management for Body Dysmorphic Disorder: a Randomised Controlled Trial||Institute of Psychiatry, London|No|Completed|April 2009|September 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|17 Years|65 Years|No|||September 2015|September 4, 2015|March 27, 2009||No||No|April 15, 2015|https://clinicaltrials.gov/show/NCT00871143||141345|Small sample size: may have led to difficulty in identifying predictors of outcome.Investigator bias: but testing blinding would be biased as it may be influenced by her rating of the outcome.Treatment too brief to achieve sig. changes in BDD.
NCT00871468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-08-003|Plating Clavicle Fractures|Does Anterior-Inferior Clavicle Plating Have a Lower Rate of Soft Tissue Irritation Compared to Superior Plating? A Prospective Randomized Trial||United States Army Institute of Surgical Research|No|Active, not recruiting|October 2008|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871468||141321|
NCT00871728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013837|Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules|Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules||Janssen Korea, Ltd., Korea|No|Completed|January 2007|December 2009|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|20 Years|70 Years|No|||June 2013|June 24, 2013|February 13, 2009|Yes|Yes||No|April 29, 2013|https://clinicaltrials.gov/show/NCT00871728||141301|Initially it was planned to assess clinical cure rate but analysis for clinical cure rate following the administration of the study drug was replaced by change in SCIO scores which was the primary endpoint.
NCT00872066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT02/11|A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement|A Prospective, Randomised, Uncontrolled, Single-Centre, Post-Market Surveillance Study To Evaluate The Performance Of SmartSet® HV and SmartSet® GHV Bone Cements In Primary Cemented Total Hip Arthroplasty(THA)||DePuy International|No|Active, not recruiting|March 2006|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|75 Years|No|||September 2014|September 4, 2014|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872066||141276|
NCT00872326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/ICPD/2007|Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia|Phase I/II Study of Regenerative Cell Therapy in Treating Diabetic Patients With Critical Limb Ischemia||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|December 2007|May 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||November 2014|November 13, 2014|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872326||141256|
NCT00896649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000640404|Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer|Impact of Dedicated Breast PET Imaging vs. Conventional Two-View Digital Mammography on Recall Rates and Cancer Detection as a Screening Examination in Underserved Women||Boston Medical Center|Yes|Active, not recruiting|February 2009|January 2016|Anticipated|July 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|260|||Female|35 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 28, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896649||139415|
NCT00892307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 10928/11143|Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)|Coronary Anatomy and Physiology Using Multidetector Dual Source Computed Tomography With Adenosine Enhancement: Comparative Study With SPECT Imaging: Pilot Studies I/II||Cedars-Sinai Medical Center|No|Completed|February 2007|May 2011|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Coronary Artery Disease|November 2013|November 11, 2013|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00892307||139742|
NCT00892905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-467|Comparing Point of Care Clotting Tests in the OR Versus Standard Laboratory Clotting Tests|Comparison Between Point of Care INR and aPTT Hemochron Jr Whole Blood Measurement With Standard Laboratory in Patients Having Elective First Time on Pump Coronary Artery Bypass Grafting (CABG)||McMaster University|No|Completed|January 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult patient undergoing elective on pump CABG|January 2011|February 28, 2011|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00892905||139698|
NCT00872235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPU-M-024/QUINH-45/05|Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Fixed-Dose Combination of Quinapril 20 mg and Hydrochlorothiazide 25 mg Tablets of OHM Laboratories Inc.(Division of Ranbaxy Laboratories Limited) With Accuretic 20-25 mg Tablets (Fixed Dose Combination of Quinapril 20 mg and Hydrochlorothiazide 25 mg) of Parke-Davis (Division of Pfizer Inc.) in Healthy, Adult, Human, Male Subjects Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|June 2005|November 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872235||141263|
NCT00872846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|598500|Balance System Study in Type 2 Diabetic Patients|Evaluation of the BALANCE System in Type 2 Diabetic Patients||Beta-Stim Ltd.|Yes|Completed|February 2009|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||January 2012|January 23, 2012|March 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00872846||141218|
NCT00873106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT comparison|Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography|Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography||Glostrup University Hospital, Copenhagen|No|Completed|February 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A group of diabetic and healthy participants|September 2012|September 5, 2012|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00873106||141198|
NCT00873951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEGLAIRE CT|Influence of Protein Hydrolysis on Dietary Protein Digestibility and Metabolism in Healthy Subjects|Influence of Protein Hydrolysis on Dietary Protein Digestibility and Metabolism in Healthy Subjects||Institut National de la Recherche Agronomique|Yes|Completed|January 2006|January 2008|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|3||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2009|April 1, 2009|April 1, 2009||||No||https://clinicaltrials.gov/show/NCT00873951||141133|
NCT00873691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 442|Comparison of Fixed Tilt and Tuned Waveforms in Right-sided Implants|Prospective Comparison of 50/50% Tilt and Tuned Defibrillation Waveforms in Right-Sided Implants|Tilt & Tune|St. Jude Medical|No|Completed|March 2009|November 2011|Actual|November 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with approved ICD/CRT-D indications|June 2015|June 3, 2015|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873691||141153|
NCT00873665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011329|Erectile Dysfunction Study|Exercise Training, Erectile Dysfunction, and Prostate Cancer Study.||Duke University|No|Completed|December 2008|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|N/A|No|||July 2013|October 25, 2013|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873665||141155|
NCT00869713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15322|Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated|Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults|RVF|U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|June 2009|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869713||141453|
NCT00869778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71006.01|Therapeutic Hepatitis B Vaccine (Synthesized Peptide) in Treating Chronic Hepatitis B Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Synthesized Peptide) in Treating Chronic Hepatitis B Patients||Chongqing Jiachen Biotechnology Ltd.|Yes|Active, not recruiting|June 2009|June 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|18 Years|65 Years|No|||June 2012|June 14, 2012|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869778||141448|
NCT00869973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGAR-02-2009|Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients|Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study||S. Maria Hospital, Terni|No|Terminated|September 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|580|||Female|18 Years|N/A|No|||October 2009|January 22, 2013|March 25, 2009||No|We terminated the study after enrolling 580/900 patients due to a slow accrual|No||https://clinicaltrials.gov/show/NCT00869973||141433|
NCT00869986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12791|A Study for Patients With Relapsing Remitting Multiple Sclerosis|A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis|MINDSET01|Eli Lilly and Company|Yes|Completed|November 2006|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|50 Years|No|||September 2010|September 7, 2010|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869986||141432|
NCT00870259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP 508920|Investigating Physiological Adaptations to Weight Loss|An Investigation of Physiological Adaptations Contributing to Weight Regain After Weight Loss||University of Melbourne|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 3, 2014|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870259||141412|
NCT00870272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2.0|Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP)|A Randomized Study of Sublingual and Buccal Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation||Gynuity Health Projects|No|Completed|July 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|550|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 26, 2009|March 26, 2009||||No||https://clinicaltrials.gov/show/NCT00870272||141411|
NCT00870571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24309|A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions|Comparative, Randomized, Single Dose, 2-way Crossover Bioavailability Study of Actavis Group hf and Pfizer Inc. (Norvasc®)10 mg Amlodipine Besylate Tablets in Healthy Adult Volunteers Under Fed Conditions.||Actavis Inc.|No|Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870571||141389|
NCT00870584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AUS33|Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma|A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma||Novartis||Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|271|||Both|12 Years|N/A|No|||October 2011|October 12, 2011|March 25, 2009|Yes|Yes||No|October 12, 2011|https://clinicaltrials.gov/show/NCT00870584||141388|
NCT00870857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08050145|Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center|Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center|MACS|University of Pittsburgh|Yes|Active, not recruiting|January 2009|June 2016|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|blood oral wash sputum BAL|Both|18 Years|N/A|No|Probability Sample|Subjects will be recruited from the University of Pittsburgh and the University of        California Los Angles MACS sites. The University of California San Francisco will serve as        the recruiting center for the WIHS cohort.|December 2015|December 2, 2015|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870857||141367|
NCT00871156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106491|Tafenoquine/Chloroquine DDI Study|Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers||GlaxoSmithKline||Completed|March 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 15, 2009|March 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871156||141344|
NCT00871169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0802|Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer|INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer||New Mexico Cancer Care Alliance|Yes|Completed|October 2008|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871169||141343|
NCT00871481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2225.00|Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma|Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 For Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center|Yes|Completed|February 2009|October 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|March 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871481||141320|
NCT00871741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111761|Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.|Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.||GlaxoSmithKline||Terminated|April 2009|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|8 Weeks|16 Weeks|Accepts Healthy Volunteers|||November 2012|November 16, 2012|March 26, 2009|Yes|Yes|Study stopped due to non-approval of IEC to proposed change in locations. Study    discontinuation not due to safety/efficacy reasons related to the vaccine.|No||https://clinicaltrials.gov/show/NCT00871741||141300|
NCT00871754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-009A|Molecular Analysis Of Bladder Cancer|Molecular Analysis Of Bladder Cancer||Lahey Clinic|No|Active, not recruiting|April 1988|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|patient's undergoing removal of a malignant bladder tumor|March 2016|March 2, 2016|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871754||141299|
NCT00871767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00019|AZD5672 Bioavailability Study in Healthy Male and Female Subjects|An Open-Label, Randomized, 4 Period Crossover, Replicate Study to Assess the Relative Bioavailability of the Phase III and Phase IIb Formulations of AZD5672 in Healthy Male and Female Subjects||AstraZeneca|No|Completed|March 2009|May 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871767||141298|
NCT00872079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMM-04-07S|Personalized Warfarin Dosing by Genomics and Computational Intelligence|Personalized Warfarin Dosing Using Genomics and Computational Intelligence||VA Office of Research and Development|No|Terminated|September 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|175|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|March 27, 2009||No|Lack of Funding|No|February 21, 2014|https://clinicaltrials.gov/show/NCT00872079||141275|
NCT00872092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTO-0001|Validation of Breath Tests in Diagnosing Small Bowel Bacterial Overgrowth|Validation of Breath Tests in Diagnosing Small Bowel Bacterial Overgrowth|BTO|University Hospital, Bonn|No|Completed|October 1997|September 1998|Actual|September 1998|Actual|N/A|Observational|N/A||1|Actual|22|Samples Without DNA|Breath samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected small bowel bacterial overgrowth|March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872092||141274|
NCT00872339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|639|Assessment of Pain in People With Thalassemia|Assessment of Pain in People With Thalassemia|Pain|New England Research Institutes|Yes|Completed|March 2009|December 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|252|||Both|12 Years|90 Years|No|Non-Probability Sample|Thalassemia patients who receive regular blood transfusions and those who do not receive        regular blood transfusions.|January 2014|May 27, 2014|March 30, 2009||No||No|January 2, 2014|https://clinicaltrials.gov/show/NCT00872339||141255|
NCT00896662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC PHI0433|Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202|Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202||Vanderbilt-Ingram Cancer Center|Yes|Completed|January 2005|August 2008|Actual|October 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|50cc of peripheral blood will be collected in CPT tubes for mononuclear cell isolation and      10cc in SST tubes for plasma collection.|Both|18 Years|N/A|No|Probability Sample|Up to 25 patients; three at each dose level achieved in order to gain additional        information regarding safety, pharmacokinetics, and biological effect of VEGF Trap given        intravenously.        Patients with a solid tumor and is consented and eligible for enrollment onto        VGFT-ST-0202. Patients who are willing to undergo phlebotomy prior to treatment, and 14        and 28 and 57 days following initial dose of VEGF-Trap. Patients with an Hgb ≥10gm at the        time of blood draw.|April 2011|April 20, 2011|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896662||139414|
NCT00872521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015640|A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma|A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance||Janssen-Cilag Pty Ltd|No|Completed|January 2009|November 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|March 27, 2009||No||No|December 14, 2012|https://clinicaltrials.gov/show/NCT00872521||141242|
NCT00872534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-ASA-002|Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers|A Randomized, Single-Blind, Endoscopic Evaluation Of Upper GI Mucosal Damage Induced By PL-2200 Versus Aspirin In Healthy Volunteers||PLx Pharma|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|204|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|March 10, 2009|Yes|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT00872534||141241|
NCT00873418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009707|Coping Skills and Heart Failure: Outcomes and Mechanisms|Coping Skills Training in Heart Failure: Outcomes and Mechanisms|COPE-HF|Duke University|Yes|Completed|March 2009|February 2016|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|190|||Both|21 Years|N/A|No|||March 2016|March 16, 2016|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873418||141174|
NCT00873704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-Surg-003|Supplemental Oxygen in Vascular Surgery|Supplemental Postoperative Oxygen and the Risk of Surgical Wound Infection in a Vascular Surgery Population: A Randomized Controlled Trial||North Karelia Central Hospital|No|Completed|March 2009|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|110 Years|No|||October 2015|October 11, 2015|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873704||141152|
NCT00873717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM07055|Improvement of Nutritional Status in Elderly Residents of Long-term Facilities|Improvement of Nutritional Status in Elderly Residents of Long-term Facilities: Impact of Two Strategies (Oral Care and Dietary Control)|Nutrident|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|114|||Both|70 Years|N/A|No|||April 2009|July 25, 2012|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00873717||141151|
NCT00873730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-406|Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain|A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis|Loadet|Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|70 Years|No|||April 2010|April 23, 2010|April 1, 2009|Yes|Yes||No|June 30, 2009|https://clinicaltrials.gov/show/NCT00873730||141150|
NCT00869726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12788|A Study for Patients With Secondary Progressive Multiple Sclerosis|A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis|MAESTRO-01|Eli Lilly and Company|Yes|Completed|December 2004|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|596|||Both|18 Years|65 Years|No|||May 2010|May 27, 2010|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869726||141452|
NCT00873964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11534|Metabolic Syndrome in an Elderly Population is More Linked to Insulin Resistance Than to Obesity|Metabolic Syndrome in an Elderly Population is More Linked to Insulin Resistance Than to Obesity||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Active, not recruiting|March 2009|July 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|156|Samples Without DNA|Serum collected.|Both|60 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Approximately 156 obese (BMI 30-34 kg/m2), non-diabetic men and women between the ages of        60-80 years of age will be eligible to enroll in the study if they meet the following        inclusion criteria: (1) BMI 30-34 kg/m2. (2) Ability and willingness to provide signed,        witnessed informed consent.|April 2012|April 26, 2012|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00873964||141132|
NCT00870623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|540-08-FB|Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections|Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections||University of Nebraska|No|Recruiting|June 2009|||June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|136|Samples Without DNA|Blood (maximum 40mL) will be collected for future use or for purposes that are not integral      to the current research.|Both|19 Years|N/A|No|Probability Sample|Hospitalized adult patients with positive blood cultures|March 2011|March 1, 2011|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870623||141385|
NCT00869999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002|Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma|Everolimus in Combination With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma||Massachusetts General Hospital|Yes|Completed|May 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2013|October 23, 2014|March 25, 2009|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT00869999||141431|
NCT00870285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Graz IRB 20-253 ex 08/09|Ustekinumab Plus UVB-311nm in Psoriasis|Ustekinumab Plus UVB-311nm Half-side Phototherapy in Patients With Psoriasis||Medical University of Graz|No|Completed|March 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870285||141410|
NCT00870298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803788|Computer Stop Order Alert to Prevent Concurrent Prescribing of Trimethoprim/Sulfamethoxazole and Warfarin|Randomized Controlled Study of a Computer Stop Order Versus Routine Practice When Trimethoprim/Sulfamethoxazole is Ordered Concurrently With Warfarin|warf-tmp/smx|University of Pennsylvania|No|Terminated|August 2006|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|1971|||Both|N/A|N/A|No|||December 2015|December 7, 2015|March 26, 2009|No|Yes|four adverse events encountered|No||https://clinicaltrials.gov/show/NCT00870298||141409|
NCT00870597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOB-03|Transconjunctival Sutureless 25-Gauge Vitrectomy|Transconjunctival Sutureless 25-Gauge Vitrectomy for Visually Significant Vitreous Floaters in Patients With Multifocal Intraocular Lens|TSV-25G|Hospital Oftalmologico de Brasilia|Yes|Completed|January 2007|December 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|N/A|No|||March 2009|March 26, 2009|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870597||141387|
NCT00871195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-RHD-301|A Noninvasive Test for Fetal RHD Genotype|Evaluation Of The Performance Of A Noninvasive Test For Fetal RHD Genotype On The Sequenom MassARRAY System|NAFTnet RHD|Sequenom, Inc.|No|Completed|April 2009|April 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|520|Samples With DNA|Plasma and buffy coat.|Female|18 Years|N/A|No|Probability Sample|Pregnant women who are known to be serologically RhD negative.|May 2012|May 9, 2012|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871195||141341|
NCT00871494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661192|Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan|A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Pelvic Inflammatory Disease (PID) Requiring Initial Intravenous Therapy||Pfizer|No|Completed|May 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Female|16 Years|80 Years|No|||September 2011|September 28, 2011|March 27, 2009|Yes|Yes||No|September 28, 2011|https://clinicaltrials.gov/show/NCT00871494||141319|
NCT00871780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYS-IMA-08-11|A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients|A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients "TIMER" Study|TIMER|Biogen|No|Completed|August 2009|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|18 Years|60 Years|No|||November 2014|November 11, 2014|March 26, 2009|Yes|Yes||No|November 11, 2014|https://clinicaltrials.gov/show/NCT00871780||141297|
NCT00872105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Distal Clavicle Study|Conservative Treatment Versus Operative Plate Fixation for Acute, Displaced Fractures of the Distal Clavicle|A Multicentre, Randomized Trial of Conservative Treatment Versus Operative Plate Fixation for Acute, Displaced Fractures of the Distal Clavicle||St. Michael's Hospital, Toronto|No|Recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|89|||Both|16 Years|60 Years|No|||November 2015|November 16, 2015|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872105||141273|
NCT00872118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Tran-AA014014|Brief Intervention for Socially Anxious College Drinkers|Brief Intervention for Socially Anxious Alcohol Abusers|BISAD|University of Cincinnati|No|Completed|April 2004|March 2008|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|26 Years|No|||September 2010|September 15, 2010|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00872118||141272|
NCT00872365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colciencias 110645921540|Effect of Micronutrients and Exercise During Pregnancy on Factors Related With Non-Transmissible Chronic Diseases|Effect of Micronutrients and Exercise During Pregnancy on Factors Related With Non-Transmissible Chronic Diseases||Universidad del Valle, Colombia|Yes|Not yet recruiting|March 2011|May 2012|Anticipated|November 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|320|||Female|16 Years|30 Years|Accepts Healthy Volunteers|||January 2011|January 8, 2011|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00872365||141253|
NCT00872625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633331|Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer|Phase I Study - Hypofractionated Cyberknife Radiotherapy Combined With Neoadjuvant Chemotherapy for Breast Tumors||Centre Antoine Lacassagne||Completed|April 2007|December 2010|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||February 2015|February 8, 2015|March 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00872625||141234|
NCT00872352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.1|Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients|Phase 3 Study to Evaluate Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients.||Wolfson Medical Center|No|Not yet recruiting|April 2009|August 2009|Anticipated|July 2009|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872352||141254|
NCT00892619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|h-22378|Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel|Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel.||Michael Debakey Veterans Affairs Medical Center|No|Recruiting|December 2008|May 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||||||Both|19 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 30, 2009|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00892619||139719|
NCT00892957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550801|FS VH S/D 500 S-apr in Vascular Surgery|Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-apr for Hemostasis in Subjects Undergoing Vascular Surgery||Baxter Healthcare Corporation|No|Completed|July 2009|November 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|176|||Both|N/A|N/A|No|||October 2012|October 26, 2012|May 4, 2009|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT00892957||139694|
NCT00892593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-FIT|Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing|Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing|ASC-FIT|Forsyth Medical Center|No|Recruiting|May 2009|May 2020|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|4100|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892593||139721|
NCT00892606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL IRB # 08.0200|Methadone Versus Morphine for Orthopedic Surgery Patients|Effectiveness of Pre-Operative Methadone Versus Morphine for Post-Operative Analgesia in Orthopedic Surgery Patients||University of Louisville|No|Recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||June 2012|June 14, 2012|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892606||139720|
NCT00872547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT05/18|Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement|Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of a Large Metal-on-Metal (MoM) Bearing Comprising a DePuy ASR™ Cup in Conjunction With Either a DePuy ASR™ Hip Resurfacing Femoral Component or a DePuy ASR™ XL Head in Subjects With Indications Suitable for Either a Primary Resurfacing Arthroplasty or Primary Total Hip Arthroplasty||DePuy International|No|Terminated|September 2006|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|329|||Both|18 Years|65 Years|No|||September 2015|December 14, 2015|March 30, 2009|No|Yes|DePuy discontinued this product in 4Q2009. At the time of this decision DePuy reviewed all    clinical studies for this product and decided to close this Study|No||https://clinicaltrials.gov/show/NCT00872547||141240|
NCT00872560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEEDLEN/DCD/4/I|Comparison of 2 NovoFine® Needles on the Reflux of Insulin|Insulin Leakage and Pain Perception in IDDM Children or Adolescents, Where the Injections Are Performed With NovoFine™ 6 x 0.30 mm Needles and NovoFine® 8 x 0.30 mm Needles: An Open, Randomized, Two-period Cross-over, Multi-centre, Phase IIIb Trial at 4 Centres||Novo Nordisk A/S|No|Completed|January 1998|July 1998|Actual|July 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|10 Years|18 Years|No|||January 2012|January 23, 2012|March 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872560||141239|
NCT00873431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC47-101|Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47|An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.||Valneva Austria GmbH|Yes|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873431||141173|
NCT00873444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT00/37|A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing|Randomised, Controlled, Prospective, Multi-Centre, Post Market Surveillance Study Comparing a Ceramic-on-Metal Bearing and a Metal-on-Metal Bearing in Subjects Requiring Primary Total Hip Arthroplasty for Non-Inflammatory Degenerative Joint Disease||DePuy International|No|Terminated|July 2006|||January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|20 Years|75 Years|No|||September 2011|December 17, 2015|March 19, 2009|No|Yes|Study progress very slow therefore terminated as other projects underway to investigate the    same research question which will deliver results earlier|No||https://clinicaltrials.gov/show/NCT00873444||141172|
NCT00873743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31121976-3|Analgesia and Antihyperalgesia of Tramadol and Acetaminophen Per Oral After Caesarean Section|Postoperative Analgesia and Antihyperalgesia of Tramadol and Acetaminophen Per Oral After Caesarean Section -A Randomised Controlled Trial in Female O-Desmethyl 1 Metabolizers Identified by the Respective Gene-||Medical University of Vienna|Yes|Suspended|October 2008|October 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|CYP P450 2D6 metabolizer status|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Female patients postoperatively after cesarian section|April 2009|April 1, 2009|April 1, 2009||No|Study was stopped because of ineffectiveness of one investigated Drug|No||https://clinicaltrials.gov/show/NCT00873743||141149|
NCT00873756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APO4565g|A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer|A Phase Ib Study of the Safety and Pharmacokinetics of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer||Genentech, Inc.||Completed|May 2009|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00873756||141148|
NCT00874003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOTABU-BO1|The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers|The Effects of Mirtazapine vs Placebo on Alcohol Consumption in Male Alcohol High Consumers; a Randomized Controlled Trial||Sahlgrenska University Hospital, Sweden|No|Completed|April 2004|February 2009|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Male|18 Years|65 Years|No|||March 2009|April 1, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874003||141129|
NCT00873977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-285|Treatment Adherence and Outcomes in Three Modalities of Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea|Comparison of Three Modalities of Continuous Positive Pressure Airway Treatment for Obstructive Sleep Apnea Syndrome||Kyoto University, Graduate School of Medicine|Yes|Completed|April 2009|July 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|93|||Both|20 Years|N/A|No|||November 2011|November 30, 2011|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00873977||141131|
NCT00873990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07GS028SUR|Fissure Sealant Retention Trial|Split Mouth Clinical Trial of Fissure Sealant Retention With Self Etching and Total Etch Bonding Agent|FSRT|Aga Khan University|Yes|Recruiting|January 2009|October 2009|Anticipated|July 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|93|||Both|6 Years|25 Years|Accepts Healthy Volunteers|||March 2009|April 1, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00873990||141130|
NCT00870012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD-GUT#2|Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics|||Chinese University of Hong Kong|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|20|||Both|18 Years|70 Years|No|||February 2014|February 20, 2014|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870012||141430|
NCT00870025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIMAD-LO-09-2008-01|Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients|hCG Priming Prior to COH in Poor Responder IVF Patients|APPE|IVI Madrid||Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|41 Years|No|||April 2015|April 21, 2015|October 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00870025||141429|
NCT00870311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-48-95|Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients|Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients||Wayne State University|No|Completed|March 1996|April 2004|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|65 Years|No|||March 2009|March 25, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870311||141408|
NCT00870324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD459|OptiSense™ Performance in Detecting Atrial Episodes|OptiSense Performance in Detecting Atrial Episodes in CRMD Device Patient Population|SENSE-AF|St. Jude Medical|Yes|Completed|March 2009|September 2010|Actual|September 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Patients with approved pacemaker indications.|June 2015|June 3, 2015|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870324||141407|
NCT00870883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR208621|N-acetylcysteine Plus Deferoxamine for Patients With Hypotension|Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure||Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude|Yes|Completed|March 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870883||141365|
NCT00870896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P65201|The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Tiotropium on the Cough Reflex in Patients With COPD||University of South Florida|Yes|Completed|February 2008|June 2012|Actual|February 2009|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|40 Years|80 Years|No|||September 2014|September 29, 2014|March 25, 2009|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00870896||141364|
NCT00871182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT0010801|Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Single Dose, Four-period, Six-treatment, Placebo-controlled, Balanced, Incomplete Block, Cross-over, Study of Four Doses of Inhaled PT001 in Patients With Mild to Moderate COPD, Compared to Open Label Tiotropium||Pearl Therapeutics, Inc.|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|33|||Both|40 Years|75 Years|No|||June 2013|June 12, 2013|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871182||141342|
NCT00872378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-AGREE Study|The Effects of Exenatide After Gastric Restriction|A Pilot Study of the Effects of BYETTA® (Exenatide) on Weight Loss in Morbidly Obese Non Diabetic Patients Following Adjustable Gastric Banding|AGREE|Advanced Specialty Care|Yes|Recruiting|February 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|March 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872378||141252|
NCT00872638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20076828|The Effect of Wound Edge Eversion on Cosmesis|The Effect of Wound Edge Eversion on Cosmesis||Stony Brook University|No|Withdrawn|January 2008|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|March 28, 2009||No|lack of participation|No||https://clinicaltrials.gov/show/NCT00872638||141233|
NCT00872651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-074|Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension|||Alcon Research|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|February 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872651||141232|
NCT00872664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31886|Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids|Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids||University of Utah|No|Completed|September 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|36|||Both|N/A|21 Days|No|||December 2013|December 3, 2013|March 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872664||141231|
NCT00872924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219_SUMAT_08|Bioequivalence Study of Sumatriptan 100mg Tablets Under Fasting Conditions|An Open Label, Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets (Containing 140 mg of Sumatriptan Succinate Equivalent to 100 mg Sumatriptan) Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|July 2008|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 30, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00872924||141212|
NCT00873210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181185|Study In Patients With Kidney Cancer Treated With Sutent|Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent||Pfizer|No|Completed|May 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|121|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or        2nd line anticancer therapy.|November 2012|November 7, 2012|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873210||141190|
NCT00873223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3673|Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir|Insulin Detemir Co-administered With Liraglutide: An Open Label Trial to Assess Insulin Detemir and Liraglutide Pharmacokinetics and Pharmacodynamics Following Liraglutide Therapy in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00873223||141189|
NCT00872937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812138R|Retrospective Study of the Relationship Between Human Papillomavirus Genotype and Cervical Epithelial Lesions|Retrospective Study of the Relationship Between Human Papillomavirus Genotype and Cervical Epithelial Lesions||National Taiwan University Hospital|No|Recruiting|March 2009|December 2012|Anticipated|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|800|||Female|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|cervical cancer patients with HPVinfection|March 2012|May 16, 2012|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872937||141211|
NCT00873522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08012|Microbiology and Clinical Outcome of Pneumonia|Microbiology and Clinical Outcome of Community Acquired Pneumonia and Health-Care-Associated Pneumonia in Taiwan: a Multi-Center Study||Taichung Veterans General Hospital|No|Recruiting|March 2008|March 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2600|||Both|18 Years|N/A|No|Non-Probability Sample|Those adult patients (age ≥ 18 y/o) met the criteria of pneumonia are evaluated. The        patients are enrolled if they meet the following criteria [9] .          -  The diagnosis of pneumonia is established within 48h of hospitalization (including             time of emergency room).          -  Pneumonia is defined as clinical suspicion of pneumonia (cough, short of breath,             expectorant) with new-onset pulmonary infiltrates plus at least one of the following             criteria:               -  Fever (≥38.3C) or hypothermia (＜36.0C) (axillary temp - 0.5)               -  Leukocytosis (increase of total WBC > 10,000/cumm); or leukopenia (<4000/cumm)                  or band > 10%               -  Purulent airway secretion (tracheal aspirates, or sputum)|March 2009|March 31, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873522||141166|
NCT00873236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTVERNHOSP-RD2007-114|MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer|Dynamic Contrast Enhanced MRI (DCE-MRI) Assessment of the Vascular Changes Induced With Bevacizumab Alone and in Combination With Interferon-α in Patients With Advanced Renal Cell Carcinoma||National Cancer Institute (NCI)||Recruiting|April 2008|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|N/A|No|||March 2009|August 9, 2013|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873236||141188|
NCT00872911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-085|Nutrition and Exercise for Sarcopenia|Nutrition and Exercise to Improve Protein Metabolism and Prevent Sarcopenia in Aging||The University of Texas Medical Branch, Galveston|No|Active, not recruiting|March 2009|August 2017|Anticipated|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|108|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|March 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872911||141213|
NCT00892983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105891.01.P.NH|Prevention of Overweight in Infancy|Primary Prevention of Rapid Weight Gain in Early Childhood: a Randomised Controlled Trial|POInz|University of Otago|Yes|Active, not recruiting|May 2009|April 2017|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|800|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||May 2011|August 2, 2011|May 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00892983||139692|
NCT00892970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044-101|The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period|||Merck Sharp & Dohme Corp.||Completed|April 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|313|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|May 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892970||139693|
NCT00893295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635953|Increasing Colorectal Cancer Screening in African Americans|Increasing Colon Cancer Screening in Primary Care Among African Americans||National Cancer Institute (NCI)||Recruiting|February 2008|||December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|896|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||July 2009|December 17, 2013|May 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893295||139670|
NCT00873132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012450|BTC Neuropsychological Database|BTC Neuropsychological Database:Prospective Study||Duke University|No|Withdrawn|April 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|For those patients enrolled, we will conduct analysis on data that is gathered during        neuropsychological testing visits to better describe the pattern of neurocognitive        deficits typically seen in our patient population and to publish our findings with the        goal of informing a larger scientific community.|June 2013|June 17, 2013|March 30, 2009||No|No Funding|No||https://clinicaltrials.gov/show/NCT00873132||141196|
NCT00873145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|funovics1|Management of Bone Defects Around the Elbow|Modular Prosthetic Reconstruction of Major Bone Defects of the Distal Humerus.||Medical University of Vienna|No|Completed|December 2008|January 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients with major bone defects around the elbow and/or distal humerus due to cancer or        failed arthroplasty.|March 2009|April 14, 2015|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873145||141195|
NCT00873457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015060|Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Duke University|No|Completed|August 2009|April 2013|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2013|May 19, 2013|March 30, 2009|Yes|Yes||No|December 15, 2012|https://clinicaltrials.gov/show/NCT00873457||141171|Early termination leading to small numbers of subjects analyzed. All patients were heavily pretreated and had aggressive disease.
NCT00873470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/9-I|Wolff-Parkinson-White Syndrome Anterograde Refractory Period of Accessory Duct|Long Term Evolution of the Anterograde Refractory Period of Accessory Duct in the Wolff-Parkinson-White Syndrome|WPW|Nantes University Hospital|No|Terminated|February 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Both|21 Years|64 Years|No|||February 2013|February 7, 2013|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873470||141170|
NCT00870051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P#888|Endurant Stent Graft Natural Selection Global Postmarket Registry|Endurant Stent Graft Natural Selection Global Postmarket Registry|ENGAGE|Medtronic Endovascular|No|Active, not recruiting|March 2009|October 2021|Anticipated|October 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with an AAA who are considered candidates for endovascular|January 2016|January 26, 2016|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870051||141427|
NCT00874016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Airtraq 4469|Airtraq Versus Standard Direct Laryngoscopy in the Pediatric Airway|A Comparison of the Airtraq and Standard Direct Laryngoscopy in the Pediatric Airway - A Randomized Trial.||IWK Health Centre|Yes|Completed|April 2009|December 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|6 Years|Accepts Healthy Volunteers|||April 2009|December 15, 2010|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874016||141128|
NCT00874029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0004|Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids|Evaluation of the Halt System for Laparoscopic Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation|Halt|Halt Medical, Inc|Yes|Completed|March 2009|March 2014|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Female|25 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 3, 2014|April 1, 2009|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00874029||141127|
NCT00871208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR08-057-111672|Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy|Randomized, Placebo-Controlled Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids vs. Low-Potency Corticosteroid Mono-therapy||St. Luke's-Roosevelt Hospital Center|Yes|Withdrawn|May 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|9 Months|17 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|March 27, 2009|Yes|Yes|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT00871208||141340|
NCT00871234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812-18 (TMC125HIV4003)|Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study|Effects of Etravirine (INTELENCETM) on Endothelial Function in HIV-uninfected Adults: A Pilot Study||Indiana University|Yes|Completed|April 2009|July 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|January 5, 2011|March 27, 2009||No||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00871234||141339|
NCT00871247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40398|A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fed Conditions||Actavis Inc.|No|Completed|November 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871247||141338|
NCT00870038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bernard1|To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study|Early Re-Endothelialization Might Not be the Unique Solution to Prevent Restenosis. The EREMUS Study|EREMUS|Ospedale della Misericordia|No|Not yet recruiting|December 2010|January 2012|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|85 Years|No|||March 2009|July 21, 2010|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870038||141428|
NCT00870337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633321|Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer|Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer|ENDORAD|ARCAGY/ GINECO GROUP|Yes|Completed|March 2008|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||October 2014|October 28, 2014|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870337||141406|
NCT00870610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010|Jugular Venous Oxygen Saturation During Therapeutic Hypothermia After Cardiac Arrest|Cerebral Metabolism During Therapeutic Hypothermia for Cardiac Arrest|SjO2|Policlinico Hospital|No|Completed|November 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|Samples With DNA|whole blood|Both|18 Years|85 Years|No|Non-Probability Sample|Adult patients who are in coma after cardiac arrest, admitted to the Intensive Care Unit        of a University Teaching Hospital and undergoing therapeutic hypothermia|April 2015|April 27, 2015|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00870610||141386|
NCT00870870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13930|A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Patients With Lung Cancer Who Have Not Received Chemotherapy Before|Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer||ImClone LLC|No|Completed|March 2009|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00870870||141366|
NCT00871793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEF-24801|Effect of Occupational Therapy on the Function and Mobility of Elbow Fractures|Effect of Occupational Therapy on the Function and Mobility in Supracondylar Humerus Fractures: A Randomized Controlled Trial||Seattle Children's Hospital|No|Completed|March 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|5 Years|12 Years|No|||June 2012|June 28, 2012|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871793||141296|
NCT00871806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1601122|Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water|Phase 1, Open-Label, Randomized, Single-Dose, 5-Way Crossover Pilot Bioavailability Study Comparing Eletriptan Oral Disintegrating Tablet Formulations A And B Administered With Or Without Water To Relpax® Commercial Tablets Administered With Water||Pfizer|No|Completed|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|20|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 22, 2010|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871806||141295|
NCT00872391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 017/2009|Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma|Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea||Medical University of Vienna||Recruiting|March 2009|||March 2024|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|155|||Both|18 Years|N/A|No|||March 2009|March 30, 2009|March 30, 2009||||No||https://clinicaltrials.gov/show/NCT00872391||141251|
NCT00872677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612147|Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors|A Culturally-Tailored Weight Loss Program||Barbara Ann Karmanos Cancer Institute|No|Completed|May 2004|November 2008|Actual|October 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|31|||Female|18 Years|70 Years|No|Probability Sample|Two groups to participate:        Group 1: Dietitian led counseling and Weight Watchers groups for 18 months Group 2:        Dietitian led counseling and Weight Watchers groups for 18 months with Spirituality        counseling from 6 to 18 months.|April 2013|April 25, 2013|March 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00872677||141230|
NCT00872950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-040|3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)|Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)|LEMS|Lahey Clinic|No|Recruiting|June 2001|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|March 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872950||141210|
NCT00877305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A165/08|Effect of Remote Ischemic Preconditioning on Cognitive Function After Cardiac Surgery|||University of Schleswig-Holstein|No|Completed|October 2008|||November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877305||140878|
NCT00877318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B80908-20|Cardiac Rehabilitation of Heart Failure Patients by Telemedicine|Cardiac Rehabilitation of Heart Failure Patients by Telemedicine: a Randomized Multicenter Study.|READ|University Hospital, Caen|Yes|Terminated|March 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|80 Years|No|||March 2016|March 17, 2016|April 6, 2009||No|insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00877318||140877|
NCT00873249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2007/3|Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia|Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia|SMS|AstraZeneca|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|339|||Both|18 Years|N/A|No|Non-Probability Sample|Stabilized outpatients with a diagnosis of schizophrenia|March 2010|March 23, 2010|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873249||141187|
NCT00878189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8641014|A Trial In Patients With Advanced Cancer And Leukemia|A Phase I Trial Of PF-03084014 In Patients With Advanced Solid Tumor Malignancy And T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma||Pfizer|No|Terminated|June 2009|March 2016|Anticipated|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|16 Years|N/A|No|||March 2016|March 10, 2016|April 6, 2009|Yes|Yes|The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014    development. There were no safety/efficacy concerns behind the decision.|No||https://clinicaltrials.gov/show/NCT00878189||140810|
NCT00873795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09603-001|Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression|Efficacy and Safety of Aripiprazole 2.5mg Combine Sertraline 50mg in Major Depression||Chimei Medical Center|Yes|Completed|April 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||April 2009|April 1, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873795||141145|
NCT00893334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#4463|Evaluation of Limb-Girdle Muscular Dystrophy|Evaluation of Limb-Girdle Muscular Dystrophy||Cooperative International Neuromuscular Research Group|Yes|Completed|April 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|60|Samples With DNA|Blood samples will be collected one time for DNA analysis.Only to confirm genotype if      results are not available prior enrollement|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The subject population will include all patients diagnosed LGMD2I, LGMD2A, LGMD2B, and        BMD. BMD is an X-linked recessive condition that only affects males. It has been described        in all ethnic backgrounds. LGMD2I, LGMD2A and LGMD2B are autosomal recessive conditions        affecting both males and females of all ethnic backgrounds equally, both sexes and all        ethnicities are expected to be equally represented. Clinical symptoms manifest in the        second decade of life, therefore all participants will be over the age of 18. Healthy        controls will be recruited to match the study population based on age, sex, and ethnicity.|March 2014|March 6, 2014|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893334||139667|
NCT00893321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8701|Comparison of Inferior Oblique Muscle Recession and Myectomy|Comparison of Inferior Oblique Muscle Recession and Myectomy||hahid Beheshti University of Medical Sciences|Yes|Active, not recruiting|May 2008|September 2009|Anticipated|May 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|2|||Both|N/A|N/A|No|||May 2009|May 4, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893321||139668|
NCT00893607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-01/2006 (SUPP)|Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum|Proof of Concept Study in Healthy Volunteers to Investigate the Safety and Response to a Single Dose of 10mg Methoxamine (NRL001) Applied Locally Using a Suppository to the Anal Canal or Rectum||Norgine|No|Completed|April 2007|December 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2009|May 5, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893607||139646|
NCT00893620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007|Zenith(R) Connection Endovascular Covered Stent Clinical Study|||Cook||Terminated|January 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2012|January 23, 2012|April 27, 2009||No|Due to less than expected enrollment rates, Cook has reevaluated the need for this clinical    study.|No||https://clinicaltrials.gov/show/NCT00893620||139645|
NCT00873158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shoulder 100|Dynamic Splinting for Patients With Adhesive Capsulitis|Outcomes Following Dynamic Splinting and/or Physical Therapy for Patients With Adhesive Capsulitis|DS-SDH|Dynasplint Systems, Inc.|Yes|Terminated|January 2006|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|40 Years|64 Years|No|||August 2013|August 8, 2013|March 31, 2009||No|Unrelated to trial|No||https://clinicaltrials.gov/show/NCT00873158||141194|
NCT00873483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13871|US Ovulation Inhibition Study in Obese Women|Multicenter, Open-Label, Uncontrolled Study to Investigate the Impact of Weight and BMI on Inhibition of Ovulation of a Transdermal Patch Formulation Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene in Young Female Volunteers Stratified by BMI Over a Period of 3 Treatment Cycles||Bayer|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|173|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00873483||141169|
NCT00873496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAlpoz 1|Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients|Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study.||Ege University|No|Completed|January 2005|January 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Female|N/A|N/A|No|Probability Sample|The study group consisted of 30 female patients recently diagnosed as Sjögren's syndrome.|March 2009|March 31, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873496||141168|
NCT00870922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR0204090171|Effects of Masseter Manual Therapy on Temporomandibular Dysfunction|Effects of Masseter Manual Therapy on Temporomandibular Dysfunction: A Pilot Study||Logan College of Chiropractic|No|Recruiting|March 2009|May 2009|Anticipated|May 2009|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2009|March 25, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870922||141362|
NCT00870350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008195-13|An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster|An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age|Tdap Booster|Swedish Institute for Infectious Disease Control|Yes|Active, not recruiting|April 2009|June 2010|Anticipated|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|400|||Both|14 Years|15 Years|Accepts Healthy Volunteers|||March 2009|June 4, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870350||141405|
NCT00870935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU02/07|A Trial to Compare Three Methods of Performing Hysterosalpingography|A Prospective, Randomized Study to Compare the Efficacy and the Tolerability of Three Methods of Performing Hysterosalpingography||IRCCS Burlo Garofolo|No|Completed|August 2007|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|222|||Female|25 Years|42 Years|No|||March 2009|December 2, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870935||141361|
NCT00870948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-220|Phase 1 BA Study, Single Center With Healthy Volunteers|||Abbott|No|Completed|January 2009|||April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|November 4, 2010|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00870948||141360|
NCT00870909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01226-49|Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia|Anodal & Cathodal tDCS for Treatment of Resistant Auditory Hallucinations in Schizophrenia||Hôpital le Vinatier|No|Recruiting|January 2009|November 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||October 2014|October 3, 2014|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870909||141363|
NCT00871507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016048|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus|SD in Subjects With T2DM||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|25|||Both|25 Years|60 Years|No|||May 2014|May 21, 2014|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871507||141318|
NCT00876083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14692|PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination|Post-marketing Surveillance Study Ultravist®-IMAGE IoproMide (UltrAvist®) to Gain Further Information on Tolerability and Safety in X-ray Examination|IMAGE|Bayer|No|Completed|March 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44920|||Both|N/A|N/A|No|Non-Probability Sample|The study population will consist of female and male patients who require an X-ray        examination with contrast enhancement. Physicians should consult the full prescribing        information for Ultravist before enrolling patients and familiarize themselves with the        safety information in the product package label.|February 2011|February 25, 2011|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876083||140971|
NCT00876096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-API-03|Interest of Real-Time Polymerase Chain Reaction (PCR) in the Diagnosis of Fungal Infections|Development and Validation of Fungal Extraction and Real -Time PCR Assay for the Diagnosis of Medically Important Fungal Infections in Blood Samples.||Centre Hospitalier Universitaire de Nice|No|Enrolling by invitation|February 2007|March 2010|Anticipated|July 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|480|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2009|April 3, 2009|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876096||140970|
NCT00876109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4255g|A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable|An Open-Label, Phase I, Dose-Escalation Study Evaluating Two Dosing Schedules of PI3-Kinase Inhibitor (GDC-0941) in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable||Genentech, Inc.||Completed|October 2007|November 2013|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876109||140969|
NCT00872131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH076198|Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder|Neuro-Genetic Markers of SSRI Treatment Response in Social Anxiety Disorder||University of Michigan|No|Completed|March 2008|August 2011|Actual|May 2011|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|Samples With DNA|Saliva samples|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community and outpatient clinic samples|November 2011|November 21, 2011|March 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872131||141271|
NCT00876473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|590|Evaluation of Different Continuous Positive Airway Pressure (CPAP) Systems in Patients With Acute Respiratory Failure|The CPAP in Patients Affected by Acute Respiratory Failure||Policlinico Hospital|No|Completed|April 2009|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Critically ill patients affected by Acute Respiratory Failure|April 2015|April 27, 2015|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876473||140942|
NCT00876746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Supra / Infra Catheters|Optimization of Catheter Insertion Site for Continuous Peripheral Nerve Blocks|Optimization of Catheter Insertion Site for Continuous Peripheral Nerve Blocks||University of California, San Diego|No|Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2009|June 14, 2010|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876746||140921|
NCT00876759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tomo0701|Whole-Brain Radiotherapy (WBRT) Versus WBRT and Integrated Boost Using Helical Tomotherapy for Multiple Brain Metastases|Whole-Brain Radiotherapy (WBRT) vs. WBRT and Integrated Boost Using Helical Tomotherapy for Patients With Multiple Brain Metastases - a Multicentre Randomized Phase II Trial||University Hospital, Essen|Yes|Recruiting|April 2009|July 2013|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876759||140920|
NCT00877019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Time Dependent Professional Toothbrushing Study|Time Dependent Professional Toothbrushing Study Comparing Sonicare With Manual Toothbrushes|timebrush|University of Erlangen-Nürnberg Medical School|No|Completed|August 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Investigator), Primary Purpose: Treatment|||Actual|90|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2009|April 6, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877019||140900|
NCT00877032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1181001|Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration|A Phase I, Double-masked, Placebo-controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Single Escalating Doses Of Rn6g In Patients With Dry, Age-related Macular Degeneration (Amd)||Pfizer|No|Completed|April 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|57|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|April 6, 2009|Yes|Yes||No|March 20, 2015|https://clinicaltrials.gov/show/NCT00877032||140899|Results for pharmacodynamic parameters [Cmax, Tmax and AUC (0-65d) of A beta(1-X)], are presented as absolute values at specified time points and not as change from baseline as planned.
NCT00877929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.21|Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus|An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.||Boehringer Ingelheim||Completed|February 2009|||May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|706|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|February 6, 2009||||No|May 13, 2011|https://clinicaltrials.gov/show/NCT00877929||140830|
NCT00873821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-012|A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration in Subjects With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|December 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||February 2015|February 24, 2015|March 31, 2009|No|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00873821||141143|
NCT00878202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B80909-60|Therapeutic Education by Telemedicine in Chronic Heart Failure|Impact of Clinical Follow-up and Therapeutic Education by Telemedicine in Chronic Heart Failure: a Randomized Multicenter Study.|SEDIC|University Hospital, Caen|Yes|Terminated|March 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|65 Years|95 Years|No|||February 2013|February 19, 2013|April 6, 2009||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00878202||140809|
NCT00873535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/2008|Effect of Varenicline on Reactivity to Smoking and Drinking Cues|Effect of Varenicline on Reactivity to Smoking and Drinking Cues in Individuals With Concurrent Tobacco Dependence and Alcohol Use||Centre for Addiction and Mental Health|No|Completed|October 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873535||141165|
NCT00873808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000614118|S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307|Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)||Southwest Oncology Group|Yes|Withdrawn|October 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|N/A|||Actual|0|||Female|18 Years|N/A|No|||April 2013|April 9, 2013|April 1, 2009||No|lack of accrual|No||https://clinicaltrials.gov/show/NCT00873808||141144|
NCT00895674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14686|Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar|Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar||Bayer|No|Completed|July 2006|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2840|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of advanced RCC|September 2010|September 29, 2010|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895674||139487|
NCT00895687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0554|Study of Erlotinib in Combination With Bortezomib|A Phase I Dose-Escalation Study of Erlotinib in Combination With Bortezomib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.||M.D. Anderson Cancer Center|No|Completed|April 2009|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|N/A|No|||July 2015|July 10, 2015|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895687||139486|
NCT00895947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-113|Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu|Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia||Amarillo Biosciences, Inc.|Yes|Completed|April 2009|March 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|May 6, 2009|Yes|Yes||No|November 16, 2010|https://clinicaltrials.gov/show/NCT00895947||139466|
NCT00873171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-04-2046|Osteopathic Manipulation Therapy in the Treatment of Interstitial Cystitis|Osteopathic Manipulation Therapy in the Treatment of Interstitial Cystitis||CAMC Health System|No|Completed|January 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|24|||Female|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|A sample of 60 patients that have a confirmed diagnosis of Interstitial Cystitis as        patients of Urological Surgical Associates and Charleston Area Medical Center (CAMC) based        on current diagnostic recommendations. The patients will be selected based on their        clinical history of interstitial cystitis.|April 2010|April 15, 2010|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873171||141193|
NCT00874055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB2213|The Presence of Friends Increases Food Intake in Youth|The Presence of Friends Increases Food Intake in Youth||University at Buffalo|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|N/A||1|Actual|72|||Both|9 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|Boys and girls between the ages of 9-15.|April 2009|April 1, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874055||141125|
NCT00869791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX066-B08-11|A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa|A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa||IMPAX Laboratories, Inc.|No|Completed|February 2009|August 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|30 Years|N/A|No|||October 2010|October 29, 2010|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869791||141447|
NCT00870649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT05-01|Efficacy of Vaccine Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical Recurrences of Schistosoma Haematobium Pathology|Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children|Bilhvax|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|February 2009|December 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|6 Years|9 Years|No|||January 2012|January 9, 2012|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870649||141383|
NCT00871845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07090035|Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients|Effects of Dietary and Behavioral Intervention and Orlistat for Management of Obesity and Metabolic Syndrome on Response to Hepatitis C Therapy||University of Pittsburgh|Yes|Recruiting|September 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|222|||Both|18 Years|N/A|No|||March 2009|March 26, 2009|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871845||141292|
NCT00872716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00051|Quetiapine in Specific Phobia|Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia|QUISS|University Hospital Muenster|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|60|||Both|18 Years|70 Years|No|||March 2011|March 30, 2011|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872716||141227|
NCT00871520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro-08|Prognosis and Survival Estimates in Palliative Therapy|Prognosis in Palliative Therapy - a Prospective Study on Survival Prognostication in Advanced Stage Cancer Patients||Heinrich-Heine University, Duesseldorf|No|Active, not recruiting|April 2008|December 2015|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|612|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive unselected cancer patients referred for palliative treatment to one of the        participating institutions.|April 2015|April 7, 2015|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871520||141317|
NCT00871819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2008|Optimized Programming in Spinal Cord Stimulation (SCS) System|Optimized Programming in a Multiple-Independent Current Sources Spinal Cord Stimulation (SCS) System|OP|Boston Scientific Corporation|No|Completed|March 2009|September 2009|Actual|August 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 5, 2013|March 27, 2009||No||No|February 13, 2012|https://clinicaltrials.gov/show/NCT00871819||141294|Small number of subjects; technical outcomes not necessarily predictive of therapeutic effectiveness.
NCT00871832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-020|Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality|To Evaluate if Pre-admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit||Northwell Health|No|Completed|May 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older        and speak English that give consent.|June 2013|June 5, 2013|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00871832||141293|
NCT00872703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-907|Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?|Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?||Wolfson Medical Center|No|Completed|January 2008|February 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|42|||Both|1 Year|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children of woman with CMV proved intrauterine infections|March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872703||141228|
NCT00876486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPMBC301|Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer|A Open-label, Randomized, Parallel, Phase III Trial to Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol®(Conventional Paclitaxel With Cremorphor EL) in Subjects With Recurrent or Metastatic Breast Cancer||Samyang Biopharmaceuticals Corporation|No|Recruiting|December 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Female|18 Years|N/A|No|||June 2012|June 10, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876486||140941|
NCT00873262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVE-2008-03|Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS)|A Phase II Randomized, Two-arms, Single-blind, Cross Controlled Study for Evaluation the Safety and Efficacy of Diagnosis and Treatment of Premenstrual Syndrome by Detecting Skin Reactions Followed by Desensitization to Sex Hormones||EVE Medical Systems Ltd.|Yes|Recruiting|April 2009|November 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Female|20 Years|45 Years|No|||February 2010|June 15, 2010|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873262||141186|
NCT00873548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFNA_Asia|Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation (PFNA)-Asia|Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation Asia - A Prospective Multicenter Case Series||AO Clinical Investigation and Documentation|No|Completed|November 2007|March 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|245|||Both|65 Years|N/A|No|Non-Probability Sample|Patients with acute trochanteric fractures at surgery/ orthopedic departments|January 2013|January 24, 2013|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873548||141164|
NCT00869830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFT in IPD|The Effectiveness of Biofeedback Treatment in Constipated Patients With Idiopathic Parkinson's Disease|The Effectiveness of Biofeedback Treatment in Constipated Patients With Idiopathic Parkinson's Disease||Asan Medical Center|Yes|Completed|January 2007|||August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||March 2009|March 25, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869830||141444|
NCT00869843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0343|Study of Saline Linked Monopolar Surface Radiofrequency (RF) Ablation of Hepatic Tumors|Phase I Study of Saline Linked Monopolar Surface Radiofrequency (RF) Ablation of Hepatic Tumors||Washington University School of Medicine|No|Completed|October 2002|March 2009|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869843||141443|
NCT00870402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA08I20032|Aldosterone in Diabetic Nephropathy|Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.|ALDODN|Universidad Los Andes, Chile|Yes|Recruiting|March 2009|March 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|30 Years|70 Years|No|||March 2009|March 25, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870402||141402|
NCT00878501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00019|Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee|A Phase II Randomised, Double-blind, Parallel Group, 4-week Treatment, Adaptive Dose Finding, Multi-centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee|OA19|AstraZeneca|No|Terminated|March 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|241|||Both|40 Years|80 Years|No|||May 2012|May 28, 2012|April 8, 2009|Yes|Yes|The study was terminated after the planned interim analysis.|No|January 27, 2011|https://clinicaltrials.gov/show/NCT00878501||140788|
NCT00878514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0228015|Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions|Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions; an Open, Randomised, Single Centre, Single Dose Study With Crossover Design in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|May 2009|July 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878514||140787|
NCT00896220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0157-AE|Towards RECOVER: Outcomes and Needs Assessment in Intensive Care Unit (ICU) Survivors of Prolonged Mechanical Ventilation and Their Caregivers|Towards RECOVER - Rehabilitation and Recovery in Survivors of Critical Illness. Long-Term Outcomes and Needs Assessment in ICU Survivors of Prolonged Mechanical Ventilation and Their Caregivers|RECOVER|University Health Network, Toronto|No|Recruiting|April 2006|October 2012|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|16 Years|N/A|No|Non-Probability Sample|Critically ill individuals who require mechanical ventilation for one week or greater and        their primary family caregiver|May 2009|October 8, 2009|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896220||139447|
NCT00896467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-0701|Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy|Psychological and Emotional Impacts of Participation in Randomized Clinical Studies in Medical Oncology||National Cancer Institute (NCI)||Terminated|September 2007|November 2010|Actual|September 2010|Actual|N/A|Observational|N/A|||Anticipated|200|||Both|18 Years|N/A|No|||July 2009|July 9, 2013|May 8, 2009||||No||https://clinicaltrials.gov/show/NCT00896467||139428|
NCT00873184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010000|Study of Massage Therapy Within a Brain Tumor Setting|Feasibility Study of Massage Therapy Within a Brain Tumor Setting||Duke University|Yes|Completed|September 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2012|May 29, 2013|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873184||141192|
NCT00873782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54AR056953|Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy|Safety and Feasibility of Transvenous Limb Perfusion With Normal Saline in Human Muscular Dystrophy||University of North Carolina, Chapel Hill|Yes|Completed|March 2009|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|21 Years|N/A|No|||January 2015|February 27, 2015|April 1, 2009|No|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT00873782||141146|
NCT00870636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-00044|Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)|Compassionate Use Pan-VEGF Blockade for the Treatment of ROP (Compassionate Use BLOCK-ROP) Trial||Children's Hospital Los Angeles||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|30 Weeks|N/A||||March 2009|March 27, 2009|March 26, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00870636||141384|
NCT00870363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816535|A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy|A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy||University of California, Davis|No|Completed|April 2009|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 15, 2013|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00870363||141404|
NCT00870376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97109|Studies of Biomarkers in Different Urodynamic Diagnoses of Female Patients With Lower Urinary Tract Symptoms|Studies of Biomarkers in Different Urodynamic Diagnoses of Female Patients With Lower Urinary Tract Symptoms||Far Eastern Memorial Hospital||Suspended|April 2009|||April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|330|||Female|20 Years|N/A|No|Non-Probability Sample|female patients with LUTS|July 2015|July 4, 2015|March 26, 2009||No|no budget|No||https://clinicaltrials.gov/show/NCT00870376||141403|
NCT00871260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16570B|Stress Testing and Cardiac Magnetic Resonance|Stress Testing and Cardiac Magnetic Resonance||University of Chicago|No|Recruiting|April 2009|April 2020|Anticipated|April 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|525|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871260||141337|
NCT00872729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP103-01|Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis|A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis||Raptor Pharmaceuticals Inc.|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|N/A|N/A|No|||June 2015|June 10, 2015|March 27, 2009|Yes|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT00872729||141226|
NCT00875550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-08-05|Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects|A Phase III Randomized, Double-blind, Dose-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit Subjects||Hospira, Inc.|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|1 Month|16 Years|No|||July 2015|July 23, 2015|March 31, 2009|Yes|Yes||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00875550||141012|
NCT00875836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA026782|Buspirone Treatment for Marijuana Dependence|Buspirone Treatment for Marijuana Dependence||Medical University of South Carolina|Yes|Active, not recruiting|September 2009|May 2016|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|April 2, 2009|Yes|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT00875836||140990|Limitations included significant attrition during the course of the 12-week trial, difficulty with UCT interpretation due to the long excretion half-life of marijuana in urine, and likelihood that the genetic analysis was underpowered.
NCT00873834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030901|Fluoxetine Essay in Children With Autism|Fluoxetine : Clinical and Anatomy-functional Therapeutic Effects in Children With Autism|FAIR|Assistance Publique - Hôpitaux de Paris|Yes|Withdrawn|September 2009|November 2011|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|12 Years|No|||April 2009|January 9, 2012|April 1, 2009||No|Withdrawn for problem of logistics with the associated laboratories|No||https://clinicaltrials.gov/show/NCT00873834||141142|
NCT00872963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC 1512|An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial|An Extended Follow up of a Phase 2b Vaccine Trial With RTS,S/AS01E in Kilifi District, Kenya.|MAL059|KEMRI-Wellcome Trust Collaborative Research Program|Yes|Active, not recruiting|February 2009|August 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|Samples Without DNA|Yearly cross sectional bleeds to collect blood samples.|Both|19 Months|35 Months|Accepts Healthy Volunteers|Non-Probability Sample|The local population is predominantly from Mijikenda ethnic group. The study area is        within Kilifi District at the Kenyan coast and majority are subsistence farmers.Kilifi        District experiences long rains in May-July and short rains in November/December. Measured        Entomological Inoculation Rates in the area vary from 10-50 per year.|December 2015|December 4, 2015|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00872963||141209|
NCT00869856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX575-304|Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)|An Open Label, Single-arm, Baseline-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 Administered Once a Week (qw) and Once Every Two Weeks (q2w) in the Treatment of Anemia Associated With Chronic Kidney Disease in Pre-dialysis and Dialysis Subjects|SWEEP|Sandoz|Yes|Withdrawn|April 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|March 25, 2009||No|investigation of adverse events in a related clinical study|No||https://clinicaltrials.gov/show/NCT00869856||141442|
NCT00870155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12789|A Study for Patients With Multiple Sclerosis|An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis|MAESTRO-02|Eli Lilly and Company|No|Terminated|February 2007|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|546|||Both|18 Years|65 Years|No|||September 2010|September 7, 2010|March 26, 2009|Yes|Yes|Negative efficacy results of the MAESTRO-01 trial|No||https://clinicaltrials.gov/show/NCT00870155||141420|
NCT00870662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-AAR-001|A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal|A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal||NovaShunt AG|No|Completed|December 2008|||December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2011|December 16, 2011|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870662||141382|
NCT00889967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-3100-0901|Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"|An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin for Inhalation Compared With Placebo for Inhalation in the Management of Pseudomonas Aeruginosa in Patients With Non Cystic Fibrosis Bronchiectasis||Aradigm Corporation|No|Completed|February 2010|June 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|80 Years|No|||August 2012|August 27, 2012|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889967||139916|
NCT00896740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000445212|Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants|Analysis of Fanconi Anemia Gene Function by Microarray Analysis of Bone Marrow Cells||OHSU Knight Cancer Institute|Yes|Terminated|March 2002|September 2007|Actual|September 2007||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|90|||Both|1 Year|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|FA Patients are recruited from OHSU Clinics. Healthy Normal donors are recruited with an        IRB approved advertisement which runs in the Outlook and is posted on bulletin boards        around campus|October 2007|November 20, 2012|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896740||139408|
NCT00874042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-117|Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors||ArQule|No|Completed|March 2009|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|April 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00874042||141126|
NCT00870064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-13763|The Treatment of Type I Open Fractures in Pediatrics|The Treatment of Type I Open Fractures in Pediatrics: Evaluating the Necessity of Formal Irrigation and Debridement|PROOF|Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|March 2010|October 2018|Anticipated|October 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|3 Years|14 Years|No|||July 2015|July 29, 2015|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870064||141426|
NCT00874991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709009426|Cardiac Deformation: Correlation With Conventional Echocardiographic Hemodynamic Variables (An Intraoperative Study)|Cardiac Deformation: Correlation With Conventional Echocardiographic Hemodynamic Variables. An Intraoperative Study.||Weill Medical College of Cornell University|No|Recruiting|June 2008|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|198|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery with general anesthesia.|June 2015|June 10, 2015|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00874991||141055|
NCT00875277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLQ-003|A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products|A Psoriasis Plaque Test Comparing LEO 29102 Cream and Its Different Combinations to Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris||LEO Pharma|No|Completed|April 2009|July 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|1||Actual|24|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875277||141033|
NCT00870961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08I3|Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps|Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study||Northwestern University||Terminated|February 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|22|||Both|50 Years|N/A|No|||September 2013|September 13, 2013|March 26, 2009||No|PI changed institutions and accrual was not completed.|No||https://clinicaltrials.gov/show/NCT00870961||141359|
NCT00872417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACT0810|Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients|Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients||Peking Union Medical College|Yes|Not yet recruiting|March 2009|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|750|||Both|18 Years|65 Years|No|||March 2009|March 30, 2009|March 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872417||141249|
NCT00872430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02121|Laxative Effectiveness of a Phytotherapeutic Tea|Laxative Effectiveness of a Phytotherapeutic Tea: A Randomized Placebo-Controlled Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Completed|July 2002|June 2003|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|No|||June 2009|June 16, 2009|November 6, 2008||No||No|November 6, 2008|https://clinicaltrials.gov/show/NCT00872430||141248|
NCT00872144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2009-316|Sativex for Treatment of Chemotherapy Induced Neuropathic Pain|A Double Blind Placebo Controlled Crossover Pilot Trial of Sativex With Open Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain||Nova Scotia Health Authority|No|Completed|June 2010|March 2013|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00872144||141270|
NCT00872157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0395|BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets|A Limited, First-in-Man, Phase IB Evaluation of BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With High-Volume Osseous Metastases and no Standard Treatment Options||M.D. Anderson Cancer Center|No|Completed|March 2009|||October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||October 2015|October 22, 2015|March 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00872157||141269|
NCT00872404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2008/02|A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma|A Phase II Study of CP-751,871 in Patients With Recurrent and/or Metastatic Squamous Head and Neck Carcinoma||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Terminated|January 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|March 30, 2009||No|lack of efficacy|No||https://clinicaltrials.gov/show/NCT00872404||141250|
NCT00872690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6661-R|Factors Affecting Return to Work Among OEF/OIF Veterans With Polytrauma|Factors Affecting Return to Work Among OEF/OIF Veterans With Polytrauma||VA Office of Research and Development|No|Completed|October 2010|September 2014|Actual|September 2013|Actual|N/A|Observational|N/A||2|Actual|7|||Both|18 Years|75 Years|No|Non-Probability Sample|Community sample|March 2015|March 13, 2015|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00872690||141229|
NCT00873847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0042|Cerebral Function Monitoring in Premature Infants|Cerebral Function Monitoring and Brain Injury in Preterm Infants: Correlation With Neuroimaging Abnormalities and Neurodevelopmental Impairment - a Pilot Study||NICHD Neonatal Research Network|Yes|Completed|July 2009|August 2012|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|N/A|72 Hours|No|Non-Probability Sample|Infants born at NRN centers and admitted to the NICU that are between 401 grams and 1,000        grams OR between 23 0/7 and 28 6/7 weeks gestational age. Infants must be enrolled by the        time they are 72 hours old.|July 2015|July 27, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00873847||141141|
NCT00874133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004589|The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis|The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis||Rabin Medical Center|Yes|Terminated|March 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|80 Years|No|||December 2013|December 5, 2013|March 25, 2009|Yes|Yes|Completed due to low number of eligible patients|No||https://clinicaltrials.gov/show/NCT00874133||141120|
NCT00874146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-03-2008|Level of HER2-neu Gene Amplification an Response to Trastuzumab|Retrospective Study of the Level of HER2-neu Gene Amplification as Predictive Factor of Response in Patients With HER2-positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.||Istituto Clinico Humanitas|No|Recruiting|March 2009|December 2009|Anticipated|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|Samples With DNA|FISH test performed on paraffine embedded tumor sections.|Female|18 Years|N/A|No|Non-Probability Sample|Patients with HER2-positive advanced breast cancer treated with trastuzumab-containing        regimen.|September 2010|September 1, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00874146||141119|
NCT00869869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMF-Scheer|Melatonin Supplementation to Improve Sleep in Patients With Heart Failure|Restoration of Sleep in Heart Failure Patients||Brigham and Women's Hospital|No|Withdrawn|March 2009|March 2011|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|35 Years|75 Years|No|||June 2011|June 27, 2011|March 25, 2009|Yes|Yes|No subjects were enrolled in this study. Funding ran out.|No||https://clinicaltrials.gov/show/NCT00869869||141441|
NCT00870142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24308|A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions|Comparative, Randomized, Single Dose, 2-way Crossover Bioavailability Study of Actavis Group hf and Pfizer Inc. (Norvasc®)10 mg Amlodipine Besylate Tablets in Healthy Adult Volunteers Under Fasting Conditions.||Actavis Inc.|No|Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870142||141421|
NCT00870168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626717|Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer|Modifications of Hormone Receptors and Biological Parameters of Metastatic Breast Cancer Treated With First-line Chemotherapy. Prospective Biological Study.||National Cancer Institute (NCI)||Completed|January 2006|||May 2011|Actual|N/A|Interventional|Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||July 2009|May 13, 2011|March 26, 2009||||No||https://clinicaltrials.gov/show/NCT00870168||141419|
NCT00870116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBRT CNPC|Stereotactic Body Radio Therapy (SBRT) for Early-stage Non Small Cell Lung Cancer (NSCLC)|SBRT Radiotherapy for Non-operated Non-small-cell Lung Cancer (NSCLC), T1-T2, N0, M0|SBRT-NSCLC|Centre Leon Berard|Yes|Active, not recruiting|April 2009|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||February 2013|March 5, 2013|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00870116||141423|
NCT00870129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-009|Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors|Using Advanced MR Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans: A Pilot Study, and to Examine Metabolite Changes in Gliomas and Other Solid Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870129||141422|
NCT00870415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633327|Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer|Multicenter (Phase II) Study of Oncoplastic Surgical Techniques for Breast Conservation in Breast Cancers||National Cancer Institute (NCI)||Recruiting|April 2007|||April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|352|||Female|18 Years|N/A|No|||July 2009|January 7, 2011|March 26, 2009||||No||https://clinicaltrials.gov/show/NCT00870415||141401|
NCT00890526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC004678|Intervention for Reduced Sound Tolerance|Intervention for Reduced Sound Tolerance||University of Alabama, Tuscaloosa|No|Completed|July 2002|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|N/A|N/A|No|||June 2012|June 20, 2012|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890526||139873|
NCT00890227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORC_KMK_08_006|Incidence of Proximal Junctional Kyphosis (PJK) in Long Posterior Spinal Fusion: A Study Comparing Traditional Open Surgery to Minimally Invasive Percutaneous Technique at the Proximal Fusion Levels|Incidence of Proximal Junctional Kyphosis (PJK) in Long Posterior Spinal Fusion: A Prospective Controlled Randomized Study Comparing Traditional Open Surgery to Minimally Invasive Percutaneous Technique at the Proximal Fusion Levels/Levels||Johns Hopkins University|No|Not yet recruiting|June 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|68|||Both|18 Years|N/A|No|||April 2009|April 27, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890227||139896|
NCT00890474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moxibustion_siege|Moxibustion for Fetus in Breech Presentation|Moxibustion for Fetus in Breech Presentation||University Hospital, Geneva|No|Completed|October 2004|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|212|||Female|N/A|N/A|No|||April 2009|April 28, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890474||139877|
NCT00870103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-08-05|Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery|An Evaluation of the Prophylactic Efficacy and Safety of the Administration of the Combination Formulation of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops in Inflammation and Infection Post-cataract Surgery||Alcon Research|No|Completed|September 2008|||February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||March 2010|March 3, 2010|September 26, 2008|No|Yes||No|January 14, 2010|https://clinicaltrials.gov/show/NCT00870103||141424|
NCT00874679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12805|REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy|REal-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra® Therapy||Bayer|No|Completed|March 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7293|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment|November 2011|November 9, 2011|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874679||141078|
NCT00872170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|638|Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension|Pilot of Oral Sildenafil for the Treatment of Pulmonary Hypertension in Thalassemia With Comparison to Controls||New England Research Institutes|Yes|Completed|March 2009|November 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|7 Years|N/A|No|||January 2014|January 2, 2014|March 30, 2009|Yes|Yes||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00872170||141268|Of 14 patients in the Sildenafil arm, 4 patients with discrepant TRVs between the local site, core lab and NHLBI readings were excluded for the main analyses.
NCT00872183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090098|Exploring a Motor Learning Technique Based on the Mirror Motor Neuron System|Exploring a Motor Learning Technique Based on the Mirror Motor Neuron System||National Institutes of Health Clinical Center (CC)||Completed|March 2009|May 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|76|||Both|18 Years|50 Years|No|||May 2012|May 4, 2012|March 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00872183||141267|
NCT00872976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-182|Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia|Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia||Bristol-Myers Squibb|No|Withdrawn|May 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|March 31, 2009|No|Yes|Business Objectives Changed|No||https://clinicaltrials.gov/show/NCT00872976||141208|
NCT00873561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI 6024-0101|A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel, Dose-Ranging Study to Evaluate The Efficacy, Safety, Tolerability, and Pharmacodynamics of NBI-6024 In Adult and Adolescent Patients With New Onset Type 1 Diabetes Mellitus||Neurocrine Biosciences|Yes|Completed|December 2001|July 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|188|||Both|10 Years|35 Years|No|||March 2009|March 30, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00873561||141163|
NCT00873574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 07014|JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders|Molecular Study of Factors Involved in JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders|SMP|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2008|September 2012|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|234|Samples With DNA|Peripheral blood samples (35 ml) and buccal swabs|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population of familial patients with MPD and controls|March 2013|March 7, 2013|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873574||141162|
NCT00873275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08005|Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer|Phase I Study of Ursodeoxycholic Acid (Ursodiol)in Combination With 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Cancer||City of Hope Medical Center|Yes|Active, not recruiting|November 2008|||September 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00873275||141185|
NCT00873587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F081016009|Clinical Trial Evaluating the Optimal Technique for Chest Tube Removal|Randomized Clinical Trial Evaluating the Optimal Technique for Chest Tube Removal||University of Alabama at Birmingham|No|Completed|March 2009|September 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|342|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2013|October 11, 2015|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873587||141161|
NCT00873860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP199|Study to Evaluate the Safety and Efficacy of CAT-354|A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, on Asthma Control in Adults||MedImmune LLC|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|194|||Both|18 Years|65 Years|No|||August 2012|August 29, 2012|April 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00873860||141140|
NCT00873873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|645|Progression of Airway Obstruction in Childhood Asthma|Progression of Airway Obstruction in Childhood Asthma||National Jewish Health|Yes|Completed|September 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|55|Samples Without DNA|Induced sputum, urine, blood, and exhaled breath condensates|Both|16 Years|40 Years|No|Non-Probability Sample|Participants enrolled in CAMPCS/3 from various CAMP sites will be invited to participate        in this study.|September 2014|September 28, 2014|April 1, 2009||No||No|November 27, 2011|https://clinicaltrials.gov/show/NCT00873873||141139|We had planned to extend invitations to the remaining 55 participants in a streamlined version of this protocol after analyzing the preliminary data and an additional cycle of CAMP was funded in 2007.
NCT00869583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|642|Increasing Physical Activity Among Mexican American Women (The Enlace Study)|Enlace: A Partnership to Promote Physical Activity Among Mexican Immigrant Women||The University of Texas Health Science Center at San Antonio|No|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|117|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 6, 2014|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869583||141463|
NCT00869882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/33|SPONGIT: Comparison of Two Surgical Approaches in the Treatment of Degenerative Spondylolysthesis|Comparison of 2 Surgical Approaches in the Treatment of Degenerative Spondylolysthesis: Posterolateral Fusion With Instrumentation (GPLI) Plus or Minus Transforaminal Lumbar Interbody Fusion (TLIF)|SPONGIT|University Hospital, Bordeaux|No|Completed|June 2009|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|74 Years|No|||October 2014|October 29, 2014|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869882||141440|
NCT00869895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-E044-101|A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors|A Phase I Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors||Eisai Inc.||Completed|March 2009|||August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||November 2012|January 27, 2016|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00869895||141439|
NCT00870740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205-MS-202|Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis.|A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)|SELECTION|Biogen|Yes|Completed|February 2009|October 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|520|||Both|18 Years|56 Years|No|||October 2014|October 13, 2014|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00870740||141376|
NCT00870428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|584-08|Predicitve Use of Spot Urine Protein/Creatinine Ratios in Preeclampsia|The Predictive Use of Spot Urine Protein/Creatinine Ratios and Decreased Sample Collection Time in the Diagnosis of Preeclampsia||MemorialCare|No|Recruiting|March 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|117|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women between 24-42 weeks who are being evaluated for preeclampsia.|March 2009|March 26, 2009|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870428||141400|
NCT00870441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15L-CL-019|Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Multiple Dose, Multi-Center Study to Compare the Safety of ASP2151 to Valacylcovir and Placebo in Healthy Male and Female Subjects||Astellas Pharma Inc|No|Terminated|March 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|442|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|February 27, 2013|March 25, 2009|No|Yes|Study terminated due to treatment-emergent serious adverse events|No||https://clinicaltrials.gov/show/NCT00870441||141399|
NCT00870454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015973|An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase||SK Life Science||Completed|May 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|386|||Both|18 Years|75 Years|No|||January 2013|January 15, 2013|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00870454||141398|
NCT00890240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016183|A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-Label, Multi-Center, Sequential Group, Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of JNJ-31001074 After a Single Dose Administration in Pediatric Subjects With Attention-Deficit/Hyperactivity Disorder, 6 to 11 Years Old||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|18|||Both|6 Years|11 Years|No|||April 2010|April 15, 2010|April 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890240||139895|
NCT00890513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK_180/06|Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment|Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment|Swiss-BEAN|University Hospital Inselspital, Berne|No|Completed|April 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1200|||Both|16 Years|N/A|No|Non-Probability Sample|Next of kin of patients cared for in one of the 42 ICU's located in german-speaking        Switzerland (ICU recognized by Swiss Society of Intensive Care Medicine).|November 2009|November 19, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890513||139874|
NCT00891072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03109|Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors||National Cancer Institute (NCI)||Completed|July 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891072||139832|
NCT00890799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-20090315|Transcatheter Closure Versus Surgery of Perimembranous Ventricular Septal Defects|Clinical Evaluation of Transcatheter Closure and Surgery of Perimembranous Ventricular Septal Defects||Xijing Hospital|Yes|Completed|June 2007|July 2012|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|200|||Both|2 Years|80 Years|No|||February 2013|February 2, 2013|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00890799||139853|
NCT00891059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISKUS-01|The Role Of Cognitive Impairment In The Use Of The Diskus Inhaler|The Role Of Cognitive Impairment In The Use Of The Diskus Inhaler|Cognitive|Synergy Health Solutions|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Nursing Home Residents with Mini Mental Status Exam (MMSE) score between 10 and 24        inclusive with convenience sampling or invitation to volunteer|November 2010|November 22, 2010|April 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891059||139833|
NCT00874978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04CC06|The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality|The Efficacy and Safety of Lenalidomide (Revlimid®) Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome Associated With Del (5q) Cytogenetic Abnormality||King's College Hospital NHS Trust|No|Active, not recruiting|January 2005|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00874978||141056|
NCT00871559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R421-ST-0804|A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies|A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies||Regeneron Pharmaceuticals|No|Completed|June 2009|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|March 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871559||141314|
NCT00871533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-067|Pilot Study of IFN α2b for Melanoma Patients|Pilot Analysis of the Effects of IFN α2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes||University of Pittsburgh|Yes|Recruiting|September 2009|April 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871533||141316|
NCT00871546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04715|SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)|A Randomized Phase 2 Study of SCH 727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL)||Merck Sharp & Dohme Corp.|No|Terminated|March 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|8|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871546||141315|
NCT00872781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|255_QUIHY_07|Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study Comparing Fixed Dose Combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg Tablets of OHM Laboratories Inc (a Subsidiary of Ranbaxy Pharmaceuticals Inc) With ACCURETICTM Tablets (Containing Fixed Dose Combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg) of Parke Davis, in Healthy, Adult, Human, Male Subjects Under Fasting Condition.||Ranbaxy Inc.|Yes|Completed|October 2007|December 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872781||141223|
NCT00872742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH080966|Testing a New Therapy for Trichotillomania|Acceptance Enhanced Behavior Therapy for Trichotillomania||University of Wisconsin, Milwaukee|No|Active, not recruiting|March 2009|October 2014|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|65 Years|No|||April 2014|April 8, 2014|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872742||141225|
NCT00872755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1948-02|Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD)|Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease||G. Hatzikosta General Hospital|No|Completed|January 2002|December 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||March 2009|March 30, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00872755||141224|
NCT00873002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6208|Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery|Phase I Study of Combination of Sorafenib and LBH589 in Hepatocellular Carcinoma||Case Comprehensive Cancer Center|Yes|Terminated|March 2009|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|March 31, 2009|No|Yes|Dose Limiting Toxicity|No||https://clinicaltrials.gov/show/NCT00873002||141206|
NCT00872989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000638595|S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Southwest Oncology Group|Yes|Active, not recruiting|March 2010|October 2016|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||May 2014|May 12, 2014|March 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00872989||141207|
NCT00873288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626557|Personalized Letter With Cancer Information Service Support or a Standard Reminder Letter in Women Scheduled for Colposcopy After an Abnormal Pap Test|Activating Collaborative CIS Support Via Targeted Provider Mailing||National Cancer Institute (NCI)||Recruiting|October 2006|||September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Health Services Research|||Anticipated|500|||Female|18 Years|N/A|No|||March 2009|January 27, 2010|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873288||141184|
NCT00873301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB 13-08-2008|The Effectiveness of Vestibulectomy|||Western Galilee Hospital-Nahariya|No|Completed|January 2009|February 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|50 Years|No|||March 2012|March 29, 2012|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873301||141183|
NCT00873600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4Y07|Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer|A Randomized Controlled Trial of Outpatient Geriatric Evaluation and Management Among Older Patients With Breast and Colon Cancer||Case Comprehensive Cancer Center|Yes|Withdrawn|October 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|||Both|65 Years|N/A|No|Probability Sample|Primary care clinic|March 2015|March 17, 2015|March 31, 2009||No|No accrual|No||https://clinicaltrials.gov/show/NCT00873600||141160|
NCT00869908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3693|Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication|The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study|A1chieve®|Novo Nordisk A/S|No|Completed|November 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|66726|||Both|N/A|N/A|No|Non-Probability Sample|Only people with type 2 diabetes treated by general practitioners and specialists who        prescribe insulin analogues in their routine practice will be included|August 2014|August 6, 2014|March 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00869908||141438|
NCT00869596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-128|Study of Biomarkers of Airway Inflammation (0000-128)|A Randomized Clinical Trial to Assess the Effects of Inhaled Fluticasone on Sputum Neutrophils After Low-dose Inhaled Endotoxin Challenge in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|March 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00869596||141462|
NCT00870480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40397|A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fasting Conditions.||Actavis Inc.|No|Completed|November 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870480||141396|
NCT00870493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIgA|Aliskiren for Immunoglobulin A (IgA) Nephropathy|The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study||Chinese University of Hong Kong|No|Completed|April 2009|July 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||December 2012|December 3, 2012|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870493||141395|
NCT00870766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5200617|Computer Tomography (CT) Trial of Acute Abdomen||PRACTA|Kuopio University Hospital||Completed|January 2009|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2010|September 13, 2010|March 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00870766||141374|
NCT00871065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-08-FB|Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm|Safety and Efficacy Trial of Sildenafil Citrate in Attenuation of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage||University of Nebraska|Yes|Withdrawn|July 2009|January 2011|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Both|19 Years|N/A|No|||March 2009|March 26, 2009|March 26, 2009|Yes|Yes|PI decision|No||https://clinicaltrials.gov/show/NCT00871065||141351|
NCT00870467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-859|A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis|A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis||Abbott||Completed|March 2009|August 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|334|||Both|20 Years|N/A|No|||August 2012|August 1, 2012|March 26, 2009||No||No|March 9, 2012|https://clinicaltrials.gov/show/NCT00870467||141397|
NCT00890812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14363|Factor XI Levels in Acute Ischemic Stroke|Factor XI Levels in Acute Ischemic Stroke||University of Utah|No|Completed|May 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|450|Samples With DNA|A small 2ml vial of spun plasma|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients presenting to the University of Utah Health Sciences Center Emergency        Department.|August 2011|August 2, 2011|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890812||139852|
NCT00891644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 066b|Linkage to Care - Part II|HIV-Related Care Engagement: Linkage to Care and Care-Seeking for HIV-Infected Adolescents, Phase II||Westat|Yes|Completed|June 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|59|||Both|14 Years|24 Years|No|Non-Probability Sample|1. Behaviorally-infected, HIV positive adolescents, informed of their HIV diagnosis             within 6-18 months of the protocol screening date, who provide consent for study             participation;          2. Ages 14-24 years, inclusive at the time of protocol screening;          3. Males and females; and          4. English- or Spanish-speaking        Group 1 - HIV positive adolescents who never initiated care within 6 months of receipt of        HIV positive results; Group 2 - HIV positive adolescents who initiated care, but did not        follow up with care within 12 months of the initial care visit. Also included in this        group are those who initiated and followed-up with care, but have dropped out of care for        12 or more months; and Group 3 - HIV positive adolescents who initiated care and        maintained care. These youth are currently in care.|February 2016|February 29, 2016|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891644||139790|
NCT00871572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11095|A Study for Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of LY2409021 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|87|||Both|18 Years|70 Years|No|||December 2010|December 9, 2010|March 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871572||141313|
NCT00871585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OHR-CAS-2008/1|Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide|Non-interventional Observational Study to Evaluate Change of PSA Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide in Combination With Medical or Surgical Castration||AstraZeneca|No|Completed|March 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|340|||Male|40 Years|N/A|No|Non-Probability Sample|400 advanced prostate cancer patients (outpatients or hospitalized) treated with        bicalutamide in combination with medical or surgical castration according to standard        clinical practice|April 2010|April 14, 2010|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871585||141312|
NCT00871910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04630|Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies||Merck Sharp & Dohme Corp.|No|Completed|October 2006|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|81|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00871910||141287|
NCT00871923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0170|Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer|A Phase II Study to Determine the Efficacy of Tarceva® (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2009|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||November 2015|November 3, 2015|March 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00871923||141286|
NCT00871858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633329|Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer|Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response||National Cancer Institute (NCI)||Recruiting|January 2008|||September 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Female|N/A|84 Years|No|||July 2009|January 7, 2011|March 27, 2009||||No||https://clinicaltrials.gov/show/NCT00871858||141291|
NCT00871871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-117|Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)|A Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Evaluate the Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis in Obese Patients With Hypertension||Merck Sharp & Dohme Corp.|No|Completed|March 2009|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|35 Years|75 Years|No|||July 2015|July 22, 2015|March 27, 2009|No|Yes||No|February 22, 2011|https://clinicaltrials.gov/show/NCT00871871||141290|
NCT00871884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234567|Evaluation of Two Treatments for Chronic Post Concussion Syndrome|The Role of Anxiety Sensitivity in the Maintenance of Chronic Post Concussion Symptoms||Simon Fraser University|Yes|Terminated|April 2008|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|March 27, 2009||No|Poor enrollment, low recruitment.|No||https://clinicaltrials.gov/show/NCT00871884||141289|
NCT00871897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|649|Examining the Cognitive Benefits of Cardiac Rehabilitation in People With Heart Failure (The CHF CaRe Study)|Cognitive Benefits of Cardiac Rehabilitation in Heart Failure|CHF CaRe|National Heart, Lung, and Blood Institute (NHLBI)|No|Enrolling by invitation|April 2009|June 2013|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|50 Years|85 Years|No|Non-Probability Sample|Patients with heart failure|December 2009|December 11, 2009|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00871897||141288|
NCT00873054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08-2078|Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy|Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy||CAMC Health System|No|Completed|October 2008|January 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|32|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Community patients who present to Charleston Area Medical Center (CAMC) or the private        urology clinics of Drs. Tierney, Martinez or Davalos with kidney stones between 10 and 20        mm in size would be screened based on inclusion criteria for possible enrollment in the        study.|January 2014|January 30, 2014|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00873054||141202|
NCT00873028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1CRh|Evaluation of Inspiratory Muscle Strength Early After Coronary Artery Bypass|Inspiratory Muscle Strength as a Determinant of Functional Capacity Early After Coronary Artery Bypass Graft Surgery||Hospital de Clinicas de Porto Alegre|No|Completed|August 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|75 Years|No|||March 2009|March 31, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873028||141204|
NCT00873041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2209|Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study|A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload|THALASSA|Novartis||Completed|November 2008|June 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|166|||Both|10 Years|N/A|No|||May 2013|May 20, 2013|March 30, 2009|Yes|Yes||No|June 20, 2012|https://clinicaltrials.gov/show/NCT00873041||141203|
NCT00873015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14024|Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm|Safety and Pharmacokinetic Evaluation of Sodium Nitrite Injection for the Prevention of Post-Subarachnoid Hemorrhage Induced Vasospasm||Hope Pharmaceuticals|Yes|Completed|April 2010|August 2012|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|80 Years|No|||July 2013|July 28, 2013|March 31, 2009|Yes|Yes||No|January 26, 2013|https://clinicaltrials.gov/show/NCT00873015||141205|
NCT00873314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR01-2003|Bed Rest for Threatened Preterm Labor. Pilot Study|Bed Rest for Arrested Threatened Preterm Labor. Pilot Study for the Design of a Randomized Controlled Clinical Trial.||Institute for Clinical Effectiveness and Health Policy|No|Completed|July 2006|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Female|N/A|N/A|No|||March 2009|March 31, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00873314||141182|
NCT00873886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #PRO07080362|A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy|A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy||University of Pittsburgh|Yes|Withdrawn|April 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Female|18 Years|N/A|No|||September 2015|September 28, 2015|April 1, 2009|Yes|Yes|We will focus on other Tamiflu research studies. No subjects were enrolled.|No||https://clinicaltrials.gov/show/NCT00873886||141138|
NCT00869609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08120047|Evaluation of Group Lifestyle Balance Maintenance Strategies|Evaluation of Group Lifestyle Balance Maintenance Strategies||University of Pittsburgh|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|March 24, 2009||No||No|January 11, 2016|https://clinicaltrials.gov/show/NCT00869609||141461|The sample size was small and included primarily white individuals, so these results may not be generalizable to other groups. The CPC was not carbohydrate restricted and may not be directly comparable to studies that focus on carbohydrate reduction.
NCT00877396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT 88113|Hutterite Influenza Prevention Study|Does Vaccinating Health Hutterite Children Against Influenza Prevent Influenza in Other Hutterite Colony Members: A Randomized Cluster Trial||McMaster University|Yes|Completed|September 2008|July 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4771|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 27, 2011|January 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00877396||140871|
NCT00877409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAA461-08/v8|Safety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II|A Monocentric, Single-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of the Topical Drug Acnase Creme in the Treatment of Acne Vulgaris I and II|ACNASE|Zurita Laboratorio Farmaceutico Ltda.|No|Not yet recruiting|April 2009|July 2009|Anticipated|July 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|12 Years|35 Years|No|||April 2009|April 6, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877409||140870|
NCT00877994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0236|Nurture: A Program for Mothers With Histories of Disordered Eating|Breaking the Cycle of Risk: Intervention for Mothers With Eating Disorders||University of North Carolina, Chapel Hill|No|Completed|April 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|N/A|No|||December 2011|March 8, 2013|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877994||140825|
NCT00877747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-PET-intens-retr|Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma|Early Chemotherapy Intensification With BEACOPP in High-risk, Interim-PET Positive Advanced-stage Hodgkin Lymphoma:a GITIL Retrospective Multicenter Clinical Study||Ospedale Santa Croce-Carle Cuneo|No|Active, not recruiting|January 2006|October 2015|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|160|||Both|16 Years|80 Years|No|Non-Probability Sample|Patients with advanced stage Hodgkin's lymphoma (IIB to IVB) or in stage IIA with adverse        prognostic factors (more than 3 nodal sites, ESR > 50 mm, bulky lesion)|October 2015|October 16, 2015|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877747||140844|
NCT00877760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV 09-01|Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B|Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a add-on Strategy for the Treatment of HBeAg-positive Chronic Hepatitis B|ARES|Foundation for Liver Research|No|Completed|August 2009|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877760||140843|
NCT00878254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080803|Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma|Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma||University of Miami|Yes|Recruiting|March 2009|||December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|64 Years|No|||February 2016|February 1, 2016|April 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00878254||140805|
NCT00878267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0840|Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: A Qualitative Study|A Qualitative Study of Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: Integrating PROs and Decision Support Into an Electronic Record||M.D. Anderson Cancer Center|No|Completed|March 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|UT MD Anderson Cancer Center (MDACC) cancer patients, 21 years of age or older, receiving        palliative care, their caregivers, and UT MDACC physicians and nurses who work in        palliative care.|September 2011|September 20, 2011|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878267||140804|
NCT00878592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08010154|Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity|Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity||University of Pittsburgh|Yes|Recruiting|October 2008|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 8, 2009|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878592||140781|
NCT00878280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712102R-1|Copy Number Variations, Inflammatory Cytokines and the Risk of Dementia|Copy Number Variations, Expression of Inflammatory Cytokines and the Risk of Dementia - A Two-stage Genome-wide Association Study||National Taiwan University Hospital|No|Recruiting|August 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|700|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|hospital recruited dementia patients and controls|April 2011|April 21, 2011|August 31, 2008||No||No||https://clinicaltrials.gov/show/NCT00878280||140803|
NCT00878605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-010-08F|Development of A Novel Anti-Hyperglycemic Agent|Development of A Novel Anti-Hyperglycemic Agent||VA Office of Research and Development|Yes|Terminated|April 2010|September 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|38|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|April 7, 2009|Yes|Yes|Unable to reach accrual target.|No|December 17, 2014|https://clinicaltrials.gov/show/NCT00878605||140780|This subject was terminated early and data was not analyzed due to inability to recruit and therefore small numbers of subjects to analyze leading to uninterpretable data.
NCT00878618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1250C00056|Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837|A Phase I, Single-Centre, Open, Randomized, Two-Way Crossover Study to Evaluate the Pharmacokinetics of the Extended-Release Test Formulation of AZD0837 Compared to the Extended-Release AZD0837 Reference Formulation After Repeated Dosing in Healthy Volunteers||AstraZeneca|No|Completed|April 2009|May 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 2, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00878618||140779|
NCT00874237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-107|Staccato Loxapine Thorough QT/QTc|Thorough QT/QTc Study of Staccato® Loxapine for Inhalation in Healthy Volunteers||Alexza Pharmaceuticals, Inc.|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 18, 2009|April 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00874237||141112|
NCT00874250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAG 08-03|Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic|An Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for the Primary Treatment of Aneurysm of the Descending Thoracic Aortic||W.L.Gore & Associates|Yes|Active, not recruiting|June 2009|December 2016|Anticipated|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|21 Years|N/A|No|||June 2015|June 1, 2015|March 31, 2009|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00874250||141111|
NCT00867802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28934 (HP-00041191)|Mindfulness Intervention For Child Abuse Survivors (MICAS)|Mindfulness Intervention For Child Abuse Survivors|MICAS|University of Maryland|No|Active, not recruiting|May 2007|March 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|21 Years|65 Years|No|||March 2009|March 20, 2009|December 8, 2008||No||No||https://clinicaltrials.gov/show/NCT00867802||141599|
NCT00868387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Macronutrient Relations and Weight Loss in Obese Subjects|Effects of Macronutrient Relations on Body Weight, Body Composition, and Cardiovascular Risk Markers in Overweight Patients Attending a Telemedically Guided Weight Loss Program||Heart and Diabetes Center North-Rhine Westfalia|No|Completed|November 2005|December 2007|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868387||141555|
NCT00868907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008138|Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food|A Crossover Study to Assess the Relative BA of Delayed-release Risedronate Compared When Dosed With Either Dinner, Breakfast or Breakfast Plus a Calcium/Vitamin D Tablet||Warner Chilcott|No|Completed|March 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|March 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00868907||141515|
NCT00874432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0221|Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease|Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease||University of Wisconsin, Madison|Yes|Completed|March 2009|December 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|90|||Both|60 Years|89 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874432||141097|
NCT00875030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0551002|A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects|A Single-Dose Bioequivalence Study Comparing Artesunate Sachets (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects||Pfizer|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 7, 2010|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875030||141052|
NCT00875329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 08-411|Traumatic Brain Injury (TBI) Screening Instruments|TBI Screening Instruments and Processes for Clinical Follow-Up||VA Office of Research and Development|No|Completed|September 2010|February 2015|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|97|None Retained|As there are no biospecimans, there is no biospeciman description.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All those who have served in OEF/OIF who have been or need to be screened using the TBI        Clinical Reminder|June 2015|June 4, 2015|April 1, 2009||No||No|June 10, 2014|https://clinicaltrials.gov/show/NCT00875329||141029|
NCT00875316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P58/07CL/ST/08/01|Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients|A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month||Phytopharm|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|36|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2009|August 20, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875316||141030|
NCT00876551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spongebop01|Endoscopic-vacuum Assisted Closure of Intrathoracic Postsurgical Leaks|Endoscopic - Vacuum Assisted Closure of Intrathoracic Postsurgical Leaks|EVACoIL|Hannover Medical School|No|Recruiting|January 2008|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2009|May 25, 2010|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876551||140936|
NCT00876824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSV-AMBE III-KA-0908|To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar|A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar)||Bharat Serums and Vaccines Limited|Yes|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|5 Years|65 Years|No|||June 2011|June 1, 2011|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876824||140915|
NCT00877084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.5.139.06KAN|Exacerbation and Training in Patients With Chronic Obstructive Pulmonary Disease|Exacerbation and Training - Study; a Randomized Controlled Study of the Effect of Resistance Training in Acute Exacerbations of COPD|EXTRA|Katholieke Universiteit Leuven|No|Completed|January 2004|December 2008|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|80 Years|No|||April 2009|April 6, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877084||140895|
NCT00877136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-029 TheraSphere®|A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®|A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®||St. Joseph Hospital of Orange|No|Recruiting|February 2009|February 2016|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from St. Joseph Hospital of Orange, community members in the St. Joseph Hospital        service area and surrounding areas|October 2014|October 14, 2014|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00877136||140891|
NCT00877721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR483209CTIL|Self Mobility Improvement in the Elderly by Counteracting Falls (SMILING)|||Soroka University Medical Center|Yes|Completed|April 2010|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2009|September 19, 2010|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877721||140846|
NCT00877422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDAC-VD-01|Vitamin D Supplementation Prevents Elderly Pneumonia|Vitamin D Supplementation Prevents Pneumonia in Institutionalized Elderly Subjects||Tohoku University|No|Completed|August 2008|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|100|||Both|65 Years|N/A|No|||April 2009|April 7, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877422||140869|
NCT00878644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|619|Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial|Therapeutic Hypothermia After Pediatric Cardiac Arrest (Out of Hospital)|THAPCA-OH|University of Michigan|Yes|Completed|September 2009|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|295|||Both|N/A|18 Years|No|||December 2015|December 2, 2015|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878644||140777|
NCT00878657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000639635|Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer|Phase I/II Radiotherapy Dose Escalation Study in Locally Advanced Pancreatic Cancer, Using a Simultaneous Intensity Modulated Boost With Concurrent Gemcitabine||Rutgers, The State University of New Jersey|No|Terminated|April 2009|October 2013|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2014|May 1, 2014|April 8, 2009|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00878657||140776|
NCT00878007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5503|Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren|Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren||London School of Hygiene and Tropical Medicine|Yes|Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|5177|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878007||140824|
NCT00878020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB123-001|Safety Study to Evaluate BMS-830216 in Healthy Subjects|Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-830216 (Pro-Drug of BMS-819881) in Healthy Subjects||Bristol-Myers Squibb|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|February 22, 2011|April 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878020||140823|
NCT00878293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|449723|Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic|A Randomized Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Pain Due to Diabetic Polyneuropathy||Grünenthal GmbH|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Actual|90|||Both|18 Years|75 Years|No|||August 2010|August 19, 2010|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00878293||140802|
NCT00878306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA024982|Disulfiram Interactions With HIV Medications: Clinical Implications|Disulfiram Interactions With HIV Medications: Clinical Implications||University of California, San Francisco|No|Completed|November 2008|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 4, 2014|April 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878306||140801|
NCT00878631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPHR HIT|Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline|The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial|TOPHR HIT|St. Michael's Hospital, Toronto|No|Completed|September 2004|December 2008|Actual|January 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|16 Years|N/A|No|||April 2009|April 8, 2009|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878631||140778|
NCT00874263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007521|Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies|The Role of Endoscopic Confocal Microscopy in Diagnosing Colorectal Cancer and Other Gastrointestinal Pathologies in Vivo|ASGE-FNDT-1|Mayo Clinic|Yes|Completed|March 2008|June 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|225|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients presenting to Mayo Clinic, Jacksonville, Florida for a screening,        surveillance colonoscopy, and/or a diagnostic and surveillance upper endoscopy, will be        eligible based on inclusion and exclusion criteria. Eligible patients will be offered        entry into the study on the day of the procedure in the hospital GI or Mayo Clinic        Jacksonville endoscopy suites.|June 2012|June 21, 2012|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874263||141110|
NCT00868101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP01|The Effect of Remote Ischemic Preconditioning Applied in Children the Day Before Open Heart Surgery|The Use of Remote Ischemic Preconditioning Applied in Child the Day Before Open Heart Surgery With Extracorporeal Circulation to Correct Congenital Heart Diseases (the Second Window Effect)||University of Sao Paulo|Yes|Completed|January 2008|December 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|22|||Both|1 Month|2 Years|No|||December 2011|December 2, 2011|March 23, 2009||No||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00868101||141576|Small number of subjects
NCT00868114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJCC 09-01|Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer|A Phase II Study of Apoptosis Induction Through Direct Tumor Injection of TNFerade(TM)or Radiation Alone Followed by KLH-Pulsed Autologous Dendritic Cells in Patients With Unresectable Pancreatic Cancer||Leo W. Jenkins Cancer Center|Yes|Active, not recruiting|July 2006|December 2015|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868114||141575|
NCT00868920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806514|Patient-Controlled Sedation Versus Anesthesiologist-Administered Sedation|A Phase IV, Randomized, Double-Blind, Controlled Study of the Effects of Patient-Controlled Sedation vs. Anesthesiologist-Administered Sedation With Propofol and Remifentanil on Rate of Disordered Breathing in Subjects Undergoing Elective Colonoscopy||University of Pennsylvania|Yes|Completed|January 2008|March 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868920||141514|
NCT00874718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007755|Impact in Life Quality of a Educational Program for Prevention of Occupational Musculoskeletal Disorders in Workers|Impact in Life Quality of a Educational Program for Prevention of Occupational Musculoskeletal Disorders in Workers.||Federal University of Rio Grande do Sul|Yes|Completed|October 2007|March 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|April 1, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874718||141076|
NCT00874731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-037|A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037 AM1)|A Clinical Trial to Assess the Effect of Deforolimus (AP23573; MK-8669) on QTc Interval in Patients (Protocol 037)||Merck Sharp & Dohme Corp.|No|Completed|April 2009|April 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00874731||141075|
NCT00875862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adhesive Capsulitis|Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks|Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks: A Randomized, Triple-Masked, Placebo-Controlled Study||University of California, San Diego|No|Terminated|September 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||October 2009|April 21, 2011|April 3, 2009|Yes|Yes|procedure no longer being done|No||https://clinicaltrials.gov/show/NCT00875862||140988|
NCT00875875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ericsson-001|Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea|Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea|Rifaximin 600|The University of Texas Health Science Center, Houston|No|Withdrawn|June 2009|June 2009|Anticipated|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|April 3, 2009||No|No study population in Mexico (H1N1). Study withdrawn from IRB consideration.|No||https://clinicaltrials.gov/show/NCT00875875||140987|
NCT00876187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091012|A Study of Tanezumab in Adults With Chronic Low Back Pain|A Randomized, Double-Blind, Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effects of Tanezumab in Adult Patients With Chronic Low Back Pain||Pfizer|Yes|Completed|June 2009|February 2011|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1359|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876187||140963|
NCT00876161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAS181-1-02|DAS181 Single Dose Escalation Study in Healthy Adults|Phase 1 Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study in Healthy Adults||Ansun Biopharma, Inc.|Yes|Completed|April 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 2, 2010|April 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00876161||140965|
NCT00876174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143-09-EP|Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C|Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C||University of Nebraska|No|Terminated|May 2009|January 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|20 ml blood for peripheral mononuclear cells|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults with genotype 1, chronic hepatitis C who are to undergo antiviral therapy and their        healthy family member or significant other|January 2010|January 11, 2010|April 2, 2009||No|no accrual|No||https://clinicaltrials.gov/show/NCT00876174||140964|
NCT00876837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC-SCI-LT|Long-term Outcomes and Life Satisfaction of Adults With Pediatric-Onset Spinal Cord Injuries|Long-term Outcomes and Life Satisfaction of Adults With Pediatric-Onset Spinal Cord Injuries||Shriners Hospitals for Children|No|Recruiting|March 1998|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|19 Years|100 Years|No|Non-Probability Sample|The subjects for this study are adults who have received care in the SCI Programs of the        Shriners Hospitals in Chicago, Philadelphia, or Northern California, who are 19 years of        age and older and who were injured at age 18 years or younger.|December 2015|December 1, 2015|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876837||140914|
NCT00877097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5302410|Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women|Randomized Clinical Trial on the Effectts of Estradiol 2 mg + NETA 1 mg With or Without Clodronate on Bone Mineral Density and Bone Markers of Osteoporotic Postmenopausal 167 Finnish Women.|Osteo|Kuopio University Hospital|No|Completed|July 1996|February 2009|Actual|December 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|167|||Female|50 Years|70 Years|No|||April 2009|April 6, 2009|April 2, 2009||||No||https://clinicaltrials.gov/show/NCT00877097||140894|
NCT00877110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-011|Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma|Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|April 2009|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|N/A|N/A|No|||October 2015|October 28, 2015|April 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00877110||140893|
NCT00877383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2351|Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease|INTRUST2|Novartis||Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1142|||Both|40 Years|N/A|No|||August 2011|August 23, 2011|April 6, 2009|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00877383||140872|
NCT00878059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD R01|Alzheimer's Family Research|Proxy Decision Making for Alzheimer Disease Research||University of California, San Francisco|No|Completed|July 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be adult men and women who, under California law (AB2328), would be legally        eligible to serve as proxy decision makers for Alzheimer's Disease patients for research.        These will be spouses or adult children of people with Alzheimer's Disease.|October 2013|October 14, 2013|March 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00878059||140820|
NCT00878072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAM810B2305|Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis|A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis||Novartis||Completed|March 2009|||June 2010|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|12 Years|18 Years|No|||May 2012|May 1, 2012|April 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878072||140819|
NCT00877435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF-105314-120675|Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial|Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial||University Hospital, Basel, Switzerland|Yes|Completed|September 2008|October 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||January 2015|January 28, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877435||140868|
NCT00877448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVX002|A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)|A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose Safety Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers||BiondVax Pharmaceuticals ltd.|Yes|Completed|June 2009|November 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|7||Actual|63|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|January 28, 2009||No||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00877448||140867|
NCT00878345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colegroenersterni|Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation|Dexmedetomidine Versus Pentobarbital Sedation Protocol for Non-painful Procedural Sedation in Pediatrics||Washington University School of Medicine|Yes|Withdrawn||June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|120|||Both|6 Months|6 Years|No|||November 2009|November 6, 2009|April 7, 2009||No|Study was never opened|No||https://clinicaltrials.gov/show/NCT00878345||140798|
NCT00878358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydrotherapy-HMO-CTIL|Hydrotherapy Versus Physiotherapy for Short-term Rehabilitation After Primary TKR|Hydrotherapy Versus Physiotherapy for Short-term Rehabilitation After Primary TKR||Hadassah Medical Organization|No|Completed|June 2009|June 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2009|April 27, 2011|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878358||140797|
NCT00878033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKH-KIMII-001-09|Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients|Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients||Martin-Luther-Universität Halle-Wittenberg|No|Completed|April 2009|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|45|Samples Without DNA|Serum Samples will be frozen for later Cytokine Sampling.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Diabetic and Non-diabetic Dialysis Patients. Healthy Controls.|January 2012|January 17, 2012|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878033||140822|
NCT00878046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT05/01|Multi-centre Study to Assess Long-term Safety and Efficacy of the Silent™ Hip Prosthesis in Primary THR|A Non-comparative, Multi-centre Study to Evaluate the Safety and Efficacy of the DePuy Silent™ Hip Prosthesis in Primary Total Hip Replacement||DePuy International|No|Terminated|May 2005|June 2014|Actual|October 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|N/A|No|||August 2014|January 5, 2015|April 7, 2009||No|The Silent Hip has been rationalized for business reasons only|No||https://clinicaltrials.gov/show/NCT00878046||140821|
NCT00878319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-08-055|Operative and Nonoperative Treatment of Humeral Shaft Fractures|A Randomized Prospective Trial Comparing Operative and Nonoperative Treatment of Humeral Shaft Fractures||McGill University Health Center|No|Recruiting|August 2009|December 2020|Anticipated|May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878319||140800|
NCT00874848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CL-PGG-LCA0822|Efficacy/Safety of Imprime PGG® Injection With Cetuximab and Paclitaxel/Carboplatin Therapy in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)|Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer||Biothera|Yes|Completed|August 2009|September 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||March 2014|March 3, 2014|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874848||141066|
NCT00874861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-135|HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas|A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With Recurrent WHO Grade II Gliomas||University of Pittsburgh|Yes|Completed|April 2009|November 2013|Actual|May 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|April 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00874861||141065|
NCT00868686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-50193|Clinical Trial Comparing Volar, Dorsal, and Custom Thermoplastic Splinting in the Treatment of Acute Mallet Finger|Blinded, Prospective, Randomized Clinical Trial Comparing Volar, Dorsal, and Custom Thermoplastic Splinting in the Treatment of Acute Mallet Finger||St. Paul's Hospital, Canada||Completed|October 2005|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|65 Years|No|||March 2009|March 24, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868686||141532|
NCT00868699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050236|Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)|A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression||Sunovion|Yes|Completed|April 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|505|||Both|18 Years|75 Years|No|||March 2014|March 31, 2014|March 23, 2009|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT00868699||141531|
NCT00868933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD-Diet|Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease|Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial||Chinese University of Hong Kong||Completed|February 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|159|||Both|18 Years|70 Years|No|||February 2014|February 20, 2014|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868933||141513|
NCT00869258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8630|Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar|Phase II Study for Inoperable Non-Metastatic Pancreatic Cancer (Stage IVA) With Neoadjuvant Gemzar, Taxotere and Xeloda (GTX), and Radiation With Gemzar||Columbia University|Yes|Active, not recruiting|June 2005|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869258||141488|
NCT00875615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20080793|Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients||University of Miami Sylvester Comprehensive Cancer Center||Completed|December 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||November 2013|July 25, 2014|April 2, 2009|Yes|Yes||No|July 18, 2013|https://clinicaltrials.gov/show/NCT00875615||141007|
NCT00875342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0802009646|Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)|D-cycloserine Enhanced Imaginal ExposureTherapy for Posttraumatic Stress Disorder (PTSD)||Weill Medical College of Cornell University|Yes|Recruiting|May 2008|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|70 Years|No|||September 2015|September 25, 2015|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875342||141028|
NCT00875628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121018|A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers|A Phase 1, Randomized, Double Blind (Sponsor-Open), Placebo Controlled, Dose Escalation, Multiple Dose Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers||Pfizer|No|Terminated|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|April 1, 2009|No|Yes|See Detailed Description|No||https://clinicaltrials.gov/show/NCT00875628||141006|
NCT00875641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112229|Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States|Safety Study of GSK Biologicals' Rotarix® (Rotavirus Vaccine, Live, Oral) Administered to a Birth Cohort in United States Health Insurance Plans||GlaxoSmithKline||Active, not recruiting|April 2009|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Actual|127120|||Both|N/A|1 Year|Accepts Healthy Volunteers|Non-Probability Sample|Children affiliated to two participating health insurance plans.|June 2015|June 25, 2015|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875641||141005|
NCT00876564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/228-CAG(REK)|Rogaland Trauma System Study|Trauma System Evolution. A Quality Improvement Study of the Trauma System at Stavanger University Hospital, Norway.|RTSS|Norwegian Air Ambulance Foundation|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1812|||Both|N/A|N/A|No|||May 2013|May 7, 2013|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876564||140935|
NCT00876200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.437/30|Efficacy of Minoxidil in Children With Williams-Beuren Syndrome|The Efficacy of Minoxidil in Children With Williams-Beuren Syndrome: a Randomized Clinical Trial.|Williams|Hospices Civils de Lyon|Yes|Completed|March 2009|August 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|6 Years|18 Years|No|||January 2016|January 20, 2016|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876200||140962|
NCT00876577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14495|VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis|VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis|VICTOR|Bayer|No|Completed|May 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1206|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Adult female and male patients with AECB, who are at least 18 years of age and are        scheduled to be treated with Moxifloxacin injection, independent of the duration and        severity of the underlying chronic bronchitis, can be documented after the therapy        decision has been made.|September 2012|September 7, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876577||140934|
NCT00876850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTK 0796-CSSI-0805|Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)|A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection||Paratek Pharmaceuticals Inc|No|Withdrawn|July 2009|August 2010|Anticipated|July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|April 6, 2009|Yes|Yes|Terminated|No||https://clinicaltrials.gov/show/NCT00876850||140913|
NCT00877123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-09-43-CTIL|Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose|Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Effect of Vitamin D Supplementation on Fasting Glucose and IL-10 in Arab Women With Impaired Fasting Glucose.||Clalit Health Services|No|Completed|June 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Female|40 Years|65 Years|No|||October 2009|November 9, 2011|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877123||140892|
NCT00877799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR845-CLIN2001|Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 During the Post-Operative Period in Subjects Undergoing Laparoscopic-Assisted Hysterectomy||Cara Therapeutics, Inc.|No|Completed|March 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|114|||Female|21 Years|60 Years|No|||April 2015|April 23, 2015|April 6, 2009|Yes|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT00877799||140840|
NCT00877812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 D072398|Vitamin B6 Dependence of One-Carbon Metabolism|Vitamin B6 Dependence of One-Carbon Metabolism||University of Florida|No|Completed|January 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 25, 2013|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00877812||140839|
NCT00878332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sandwich osteotomy-HMO-CTIL|Histologic Evaluation of Bone Formation After Alveolar Augmentation by "Sandwich Osteotomy" Procedure for Dental Implants Insertion|"Sandwich Osteotomy" Histologic Evaluation||Hadassah Medical Organization|Yes|Active, not recruiting|February 2009|April 2011|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Histologic slides|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients refered to the oral and maxillofacial clinic for bone augmentation (because of        insufficient bone height) and fixed rehabilitation using dental implants|March 2009|April 7, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878332||140799|
NCT00878683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11525|Novel Device for Reducing Catheter-Related Infections|Exploring the Use of a Novel Device for Reducing Catheter-Related Bloodstream Infections||University of Kansas Medical Center|No|Withdrawn|July 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|April 7, 2009|Yes|Yes|Never received IRB approval; Withdrawn before enrollment ever started|No||https://clinicaltrials.gov/show/NCT00878683||140774|
NCT00878696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITBTMS|Influence of Tonic and Burst Transcranial Magnetic Stimulation (TMS) Characteristics on Acute Inhibition of Subjective Tinnitus|Influence of Tonic and Burst TMS Characteristics on Acute Inhibition of Subjective Tinnitus||University Hospital, Antwerp|No|Completed|January 2007|April 2008|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|64|||Both|18 Years|78 Years|No|Probability Sample|Patients presented to our Multidisciplinary Tinnitus Clinic with tinnitus as a main        complaint.|April 2009|April 8, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878696||140773|
NCT00874276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14617-CP-004|Pharmacotoxicology of Trichloroethylene Metabolites|Pharmacotoxicology of Trichloroethylene Metabolites||University of Florida|Yes|Completed|August 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|21|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2013|June 3, 2015|April 1, 2009|Yes|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT00874276||141109|
NCT00874289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01/08|Utility of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Predicting Renal Impairment, Further Decompensation and Rehospitalization in Acutely Decompensated and Chronic Heart Failure Patients|Utility of NGAL in Predicting Renal Impairment, Further Decompensation & Rehospitalization in Acutely Decompensated & Chronic Heart Failure Patients|ANGLE-HF|The Alfred|No|Completed|December 2008|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|106|Samples Without DNA|Blood and urine samples are being collected.|Both|18 Years|N/A|No|Non-Probability Sample|Acute and chronic heart failure|January 2015|January 20, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874289||141108|
NCT00874523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARTA|Raltegravir and Atazanavir Dosing Strategy Study|A Randomised, Open-label, Cross-over Study to Examine the Pharmacokinetics and Short-term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-infected Patients|SPARTA|Kirby Institute|No|Completed|July 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||April 2010|April 10, 2012|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874523||141090|
NCT00874536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDR3-HMO-CTIL|Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)|The Effect of Omega-3 Fatty Acid Supplementation on Behavior of Children With ADHD||Hadassah Medical Organization|No|Completed|April 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|6 Years|16 Years|No|||July 2013|July 29, 2013|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874536||141089|
NCT00874549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA29|Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years|A Safety and Immunogenicity Evaluation of a Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) and a Meningococcal Polysaccharide Vaccine Groups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in Subjects 56 Years of Age or Older||Sanofi|No|Completed|October 2007|October 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|216|||Both|56 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 12, 2013|March 31, 2009|Yes|Yes||No|March 8, 2010|https://clinicaltrials.gov/show/NCT00874549||141088|
NCT00874874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633547|Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery|Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery||National Cancer Institute (NCI)||Recruiting|May 2008|||May 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||July 2009|December 23, 2009|April 2, 2009||||No||https://clinicaltrials.gov/show/NCT00874874||141064|
NCT00874887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-ZYM-08-001|A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms|||Allergan||Completed|March 2009|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|66|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 16, 2011|April 1, 2009|Yes|Yes||No|November 16, 2011|https://clinicaltrials.gov/show/NCT00874887||141063|Only a small number of resistant species were obtained at the study endpoints. Therefore, some outcome measures were not able to be analyzed.
NCT00868712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU# 04-12020|Warfarin and Coronary Calcification Project|Warfarin and Coronary Calcification Project|WACC|Walter Reed Army Medical Center|Yes|Completed|May 2004|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients without known coronary heart disease, disorders of calcium metabolism or chronic        kidney disease aged > 18 years who are referred to take or currently taking warfarin and        are followed in the Anticoagulation Management Clinic at Walter Reed Army Medical Center        (WRAMC).|August 2012|August 23, 2012|March 24, 2009||No||No|February 2, 2010|https://clinicaltrials.gov/show/NCT00868712||141530|Cross-sectional nature, small sample size. Initially powered for sample size of 100 subjects, our trial was stopped early after an interim analysis at 70 subjects demonstrated no trend for effect of warfarin after adjusting for standard risk factors.
NCT00868452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050235|Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)|A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression||Sunovion|Yes|Completed|April 2009|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|348|||Both|18 Years|75 Years|No|||March 2014|March 31, 2014|March 23, 2009|Yes|Yes||No|January 11, 2013|https://clinicaltrials.gov/show/NCT00868452||141550|
NCT00868946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15314|Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany|A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in Landstuhl Regional Medical Center (Landstuhl, Germany) IND 16,666|HFRS|U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|October 2009|June 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|17 Years|65 Years|No|||December 2015|December 28, 2015|March 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868946||141512|
NCT00868959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050256|Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression|A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression||Sunovion|Yes|Completed|April 2009|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|813|||Both|18 Years|75 Years|No|||April 2014|April 9, 2014|March 23, 2009|Yes|Yes||No|February 17, 2014|https://clinicaltrials.gov/show/NCT00868959||141511|
NCT00875654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 06 25|Intravenous Stem Cells After Ischemic Stroke|Cell Therapy by Intravenous Injection of Mesenchymal Stem Cells After Stroke|ISIS|University Hospital, Grenoble|Yes|Active, not recruiting|August 2010|July 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|70 Years|No|||February 2015|February 12, 2015|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875654||141004|
NCT00875368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-283|Maraviroc Immune Recovery Study|Maraviroc Immune Recovery Study, A Multicenter, Randomized, Placebo-controlled, Exploratory Mechanistic Study Into the Role of Maraviroc on Immune Recovery|MIRS|UMC Utrecht|Yes|Completed|February 2009|August 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875368||141026|
NCT00875693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812010140|A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)|A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT)for Primary Refractory and Relapsed Acute Myelogenous Leukemia||Weill Medical College of Cornell University||Recruiting|June 2009|||March 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|30|||Both|18 Years|70 Years|No|||January 2011|January 3, 2011|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875693||141001|
NCT00875914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. C00909|Magnetically Navigated vs. Manually Guided Radiofrequency in Atrioventricular-Node-Reentry-Tachycardia|Randomized Comparison Between Magnetically Navigated vs Manually Guided Radiofrequency in AV-Node-Reentry-Tachycardia|MAGMA-AVNRT|Deutsches Herzzentrum Muenchen|No|Recruiting|April 2009|February 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||May 2009|May 18, 2009|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00875914||140984|
NCT00875927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCHS|Effects of Breezy Candy on Halitosis|Breezy Candy Halitosis Study|BCHS|Breezy Industries Ltd.|No|Not yet recruiting|May 2009|July 2009|Anticipated|June 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|75|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2009|April 5, 2009|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875927||140983|
NCT00876213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060095|Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans|Amylin and GLP-1: Influence on Gastric Emptying, Appetite and Food Intake in Humans.||Hvidovre University Hospital|No|Completed|March 2007|June 2008|Actual|||N/A|Observational|Observational Model: Case Control||2|Actual|23|||Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with type 1 diabetes and matched healthy control subjects|April 2009|April 3, 2009|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876213||140961|
NCT00876226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|479-07-FB|Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome|Study to Determine Steady-state Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome||University of Nebraska|Yes|Withdrawn|May 2010|April 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|19 Years|65 Years|No|||May 2014|May 19, 2014|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876226||140960|
NCT00876590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701248|Glucose Monitor Accuracy Investigation (Ⅱ)|Glucose Monitor Accuracy Investigation (Ⅱ)||National Taiwan University Hospital|Yes|Completed|April 2006|December 2006|Actual|October 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|319|||Both|15 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The glucose concentrations of volunteer shall be distributed as specified in ISO15197        Table 3|April 2009|April 7, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876590||140933|
NCT00876603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A Vs P Decompression for CSM|Anterior Vs Posterior Procedures for Cervical Spondylotic Myelopathy: Prospective Randomized Clinical Trial|A Comparison of Anterior and Posterior Procedures for the Surgical Management of Cervical Spondylotic Myelopathy: Prospective Randomized Clinical Trial|CSM|The University of Hong Kong|Yes|Recruiting|May 2001|December 2020|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|40 Years|80 Years|No|Probability Sample|Patients suffer from cervical spondylotic myelopathy requiring surgery.|January 2010|January 12, 2010|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876603||140932|
NCT00876863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERE-110-03|Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease|A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease||Ceregene|Yes|Active, not recruiting|September 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|80 Years|No|||December 2012|December 10, 2012|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876863||140912|
NCT00876876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-LX3422|International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia|International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia||CardioKine Inc.||Withdrawn|July 2009|December 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||November 2010|November 19, 2010|April 3, 2009|Yes|Yes|Created Extension study - This study was no longer feasible|No||https://clinicaltrials.gov/show/NCT00876876||140911|
NCT00877825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB235U|The Influence of Soy Isoflavnoids on the Hypocholesterolemic Effects of Soy|The Influence of Soy Isoflavnoids on the Hypocholesterolemic Effects of Soy||University of Toronto||Completed||April 2000|Actual|||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 7, 2009|April 3, 2009||||No||https://clinicaltrials.gov/show/NCT00877825||140838|
NCT00877838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXN-188-202|Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura|A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura||Danish Headache Center|Yes|Recruiting|May 2009|December 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||July 2009|July 27, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877838||140837|
NCT00878085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR|Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living|fMRI and Robot-Assisted Practice of Activities of Daily Living||Medical College of Wisconsin|Yes|Completed|November 2008|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|61|||Both|30 Years|85 Years|Accepts Healthy Volunteers|||February 2014|February 3, 2014|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00878085||140818|
NCT00874328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-08-333|A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Study of TS-1, Irinotecan and Cisplatin for Patients With Advanced or Metastatic NSLC||National Cancer Center, Korea|Yes|Recruiting|October 2008|December 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|18 Years|N/A|No|||July 2010|October 22, 2010|December 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00874328||141105|
NCT00874588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVT-L0901|Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer|Phase I Trial in Studying Peptide Vaccine Therapy Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer||Fukushima Medical University|Yes|Completed|March 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||August 2013|August 13, 2013|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874588||141085|
NCT00878670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ze 358 2008.01|Investigation of Efficacy and Safety of EPOGAM|Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study)||Max Zeller Soehne AG|No|Completed|March 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|2 Years|45 Years|No|||January 2012|January 25, 2012|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878670||140775|
NCT00874575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2008-CS01|Nutritional Intervention for Age-related Muscular Function and Strength Losses|A Double Blind Study on the Efficacy of a Combination of Beta-hydroxy-beta-methylbutyrate and Vitamin D on Muscular Strength and Functionality in Older Adults.||Metabolic Technologies Inc.|Yes|Completed|November 2008|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|76|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 16, 2014|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00874575||141086|
NCT00874562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-429|Rapamycin in Relapsed Acute Lymphoblastic Leukemia|Rapamycin in Relapsed Acute Lymphoblastic Leukemia||Dana-Farber Cancer Institute|Yes|Active, not recruiting|July 2007|April 2016|Anticipated|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|14|||Both|365 Days|N/A|No|||February 2016|February 12, 2016|April 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00874562||141087|
NCT00875160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAU-CL-104|A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101|An Open-Label Study to Assess the Pharmacokinetics, Safety, and Pharmacodynamics of Repeated Doses of Orally Administered AT2101 in Adult Patients With Type 1 Gaucher Disease||Amicus Therapeutics|No|Terminated|April 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||August 2010|August 17, 2010|April 2, 2009|Yes|Yes|Subject Recruitment|No||https://clinicaltrials.gov/show/NCT00875160||141042|
NCT00875173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oswaldo Cruz|Selenium Treatment and Chagasic Cardiopathy (STCC)|Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease|STCC|Oswaldo Cruz Foundation|Yes|Recruiting|October 2008|December 2020|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT00875173||141041|
NCT00868725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6870-AO-CTIL|Detecting Lesions in the Oral Cavity With Thermal Imaging|Detecting Lesions in the Oral Cavity With Thermal Imaging||Sheba Medical Center|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients reporting for oral cavity examination under the possibility of presenting with        oral cavity lesions|September 2009|September 30, 2009|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00868725||141529|
NCT00865098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62241-053|Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Open-label, Non-randomized, Non-controlled, Multicenter Phase II Study Investigating Cetuximab in Combination With Concomitant-boost Radiotherapy as First-line Treatment for Japanese Patients With Newly Diagnosed Locally Advanced SCCHN.||Merck KGaA||Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|20 Years|N/A|No|||February 2014|February 10, 2014|March 18, 2009||No||No|June 23, 2011|https://clinicaltrials.gov/show/NCT00865098||141803|
NCT00865111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0646-001|A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Sustained Release Tablets in Fasted, Normal, Healthy Men.||Actavis Inc.|No|Completed|March 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865111||141802|
NCT00875056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-103|Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103)|A Phase II Study of MK0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL)||Merck Sharp & Dohme Corp.|No|Active, not recruiting|April 2009|January 2017|Anticipated|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|20 Years|74 Years|No|||May 2015|May 8, 2015|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875056||141050|
NCT00875082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVAB-02|Effect of Montelukast on Remodelling Markers in Asthmatic Children|Effect of Montelukast on Metalloproteinase (MMP)-9, MMP-12, Tissue Inhibitor Metalloproteinase-1 (TIMP-1), Procollagen Type I C-terminal Peptide (PICP) and TGF-beta1 Levels in Sputum From Mild Intermittent Asthmatic Children: a Pilot Study|MORACH|Universita di Verona|No|Completed|February 2010|April 2013|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|6 Years|14 Years|No|||June 2013|June 18, 2013|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875082||141048|
NCT00875940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 08-01-24-02|Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis|Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis Between Tc-99m Tetrofosmin SPECT Adn Echocardiography||University of Cincinnati|Yes|Completed|February 2008|||January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hospital population having diagnostic testing.|April 2009|April 3, 2009|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00875940||140982|
NCT00876265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 90028-0622/1|Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.|A Randomized, Blinded, Controlled, Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®, After Mid-to-Deep Dermal Implantation for Correction of Moderate to Severe Facial Wrinkles||Merz Pharmaceuticals, LLC|No|Completed|December 2006|December 2008|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 19, 2013|April 3, 2009|No|Yes||No|December 13, 2011|https://clinicaltrials.gov/show/NCT00876265||140958|
NCT00875888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000050|High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock|High Cut-off Continuous Venovenous Hemodialysis (CVVHD) to Improve Hemodynamic Stability and Organ Function Scores in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock|HICOSS|Gambro Dialysatoren GmbH|No|Terminated|February 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||January 2010|August 23, 2015|January 9, 2009||No|based on interim analysis statistical significance in primary endpoint cannot be achieved with    planned sample size, no safety concerns|No||https://clinicaltrials.gov/show/NCT00875888||140986|
NCT00875901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0901 - LU03|Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)|Hypofractionated, Image-Guided Radiation Therapy With Proton Therapy for Stage I Non-Small Cell Lung Cancer|LU03|University of Florida|Yes|Recruiting|September 2009|April 2032|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|23|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875901||140985|
NCT00876629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.529|Renal Magnetic Resonance (MR) Elastography in Healthy Volunteers|Renal MR Elastography: Normal Findings and Variability of Stiffness Measurements|MRE_Rénale|Hospices Civils de Lyon|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2009|August 18, 2009|March 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00876629||140930|
NCT00876889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002029|Safety of Riluzole in Patients With Acute Spinal Cord Injury|Safety and Pharmacokinetics of Riluzole in Patients With Traumatic Acute Spinal Cord Injury||The Methodist Hospital System|No|Completed|April 2010|April 2012|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|36|Samples Without DNA|plasma and cerebral spinal fluid|Both|18 Years|70 Years|No|Non-Probability Sample|Admitted to a NACTN hospital|July 2013|July 29, 2013|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00876889||140910|
NCT00876252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC43-201|Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients|A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients||Valneva Austria GmbH|Yes|Completed|December 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|400|||Both|18 Years|80 Years|No|||October 2012|October 18, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876252||140959|
NCT00877474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-001-08|Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors|Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors||PharmaMar|No|Completed|March 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|April 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00877474||140865|
NCT00877773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0827|Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients|Histology-Independent Study of the mTOR Inhibitor, Temsirolimus, in Patients With Advanced Cancer||M.D. Anderson Cancer Center|No|Terminated|April 2009|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|N/A|N/A|No|||July 2014|July 8, 2014|April 7, 2009||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00877773||140842|
NCT00877786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2002|Online Cognitive Behavioral Therapy for Bulimia Nervosa|Optimizing Technology in the Treatment of Bulimia Nervosa|CBT4BN|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|April 2008|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877786||140841|
NCT00877500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0435|Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease|A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-negative Breast Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|April 2009|||April 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Female|18 Years|N/A|No|||July 2015|July 14, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877500||140863|
NCT00878371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hall Morphine TAA-01|Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier|Identification and Quantification of the Effects of a Surgery-induced Peripheral Inflammatory Response on Changes in Drug Efflux Transporter Function in the Brain||Nova Scotia Health Authority|No|Completed|May 2009|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|N/A|No|||March 2014|March 12, 2014|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878371||140796|
NCT00878735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sesshin|The Effects of a Meditation Retreat on Healthy Volunteers and Cancer Patients: an fMRI Study|The Effects of an Intensive Mindfulness Practice (Sesshin) on Neural Systems: an fMRI Evaluation of Healthy Volunteers and Cancer Patients|Sesshin|Hospital Israelita Albert Einstein|Yes|Completed|January 2008|||January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|96|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 6, 2014|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878735||140770|
NCT00874302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-306|Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms|A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids||Repros Therapeutics Inc.|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||June 2014|June 26, 2014|March 31, 2009|Yes|Yes|Study terminated for safety and the FDA put the study on hold for safety.|No||https://clinicaltrials.gov/show/NCT00874302||141107|
NCT00875186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AET 1|The Influence of Aerobic Endurance Training After Roux-en-Y-Gastric Bypass|Impact of Aerobic Physical Exercising on Body Composition and co-Morbidities in Patients After Laparoscopic Roux-en-Y Gastric Bypass|AET|Universitätsmedizin Mannheim|No|Recruiting|October 2006|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|morbidly obese patients underwent laparoscopic Roux-en-Y gastric bypass as a primary        procedure for morbid obesity|April 2009|April 2, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875186||141040|
NCT00875199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-108-2|Contingency Management to Promote Weight Loss in Low Income Adults|Contingency Management to Promote Weight Loss in Low Income Adults||University of Connecticut Health Center|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|No|||November 2011|November 17, 2011|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00875199||141039|
NCT00874900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALP12526|Asthma Learning Project|Asthma Learning Project: Randomized Trial of a Computerized Asthma Game in a Pediatric Emergency Department|ALP|Seattle Children's Hospital|No|Recruiting|December 2008|May 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|7 Years|15 Years|No|||July 2011|July 7, 2011|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874900||141062|
NCT00875771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-08-03|Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients|Phase II Study of Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients|AVAXIRI|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|April 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00875771||140995|
NCT00875784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103629|An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)|An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate) Injection 4mg Administered Using the IMITREX STATdose System® and a TREXIMA Tablet Followed by IMI||GlaxoSmithKline|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 30, 2010|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00875784||140994|
NCT00900900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008225|The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers|The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers|DHEA|Duke University|Yes|Completed|July 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|22|||Male|18 Years|65 Years|No|||September 2012|September 14, 2012|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900900||139119|
NCT00900913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 24-2008|Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral Nerve Excitability|Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral||University of Zurich|Yes|Completed|January 2010|July 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|34|||Male|18 Years|65 Years|No|||August 2011|August 5, 2011|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00900913||139118|
NCT00875355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633496|Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer|Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer||National Cancer Institute (NCI)||Recruiting|November 2007|||November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||July 2009|August 25, 2009|April 2, 2009||||No||https://clinicaltrials.gov/show/NCT00875355||141027|
NCT00875381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002038|Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin|Immunohistochemical Analysis of Melanocytes in Sun-Exposed Skin||Mayo Clinic|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|The proposed dog-ears excised, that were to be discarded during reconstruction, were      evaluated for the presence of any visible lesions (i.e. ephelid, lentigo, seborrheic      keratosis, nevi). Dog-ears with any skin lesions were excluded. The specimens were inked by      the surgeon on the side to be cut by the histotechnician. The specimens were placed in      formalin bottles and submitted to the pathology department at Mayo Clinic Rochester for      processing. The tissue was cut (4 microns) along its long access and stained with routine H&      E and Mart-1 (MelanA) immunostains.|Both|18 Years|N/A|No|Non-Probability Sample|A total of 50 patients from Mayo Clinic Jacksonville and 50 Mayo Clinic Rochester will be        enrolled in this study.|March 2011|March 14, 2011|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875381||141025|
NCT00875680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTADIR CMTS autoPPC 2009|Efficacy of autoPPC for the Treatment of Obstructive Sleep Apnea Syndrome (OSAS)|Evaluation of the Efficacy of Autoadjusted Positive Pressure Devices for the Treatment of Obstructive Sleep Apnea Syndrome||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|No|Recruiting|May 2009|June 2014|Anticipated|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|75 Years|No|||February 2012|February 9, 2012|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875680||141002|
NCT00875953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCENT003|Use of the Harmonic Scalpel in Neck Dissection|Harmonic Scalpel vs. Electrocautery in Modified Radical Neck Dissection: A Single Blinded Prospective Randomized Trial||University of Calgary|No|Completed|January 2009|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||April 2009|December 13, 2010|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00875953||140981|
NCT00875667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MCL-002|A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)|A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma|Sprint|Celgene|Yes|Active, not recruiting|April 2009|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00875667||141003|
NCT00876642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oncoclinica-2009-02|Trial Comparing Best Supportive Care to Aloe Vera Gel|Phase III Trial Comparing Best Supportive Care to Aloe Vera Gel as a Prophylactic Agent for Radiation Induced Skin Toxicity||Marilia Medicine School|Yes|Completed|March 2007|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|137|||Both|18 Years|85 Years|No|||April 2009|April 6, 2009|April 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00876642||140929|
NCT00877149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600ACN04E1|Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B|A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B||Novartis||Completed|March 2009|||April 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|16 Years|N/A|No|||May 2012|May 3, 2012|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877149||140890|
NCT00877461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461700317|Glucose Monitor Accuracy Investigation (Ⅰ)|Glucose Monitor Accuracy Investigation (Ⅰ)||National Taiwan University Hospital|Yes|Completed|May 2005|December 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|308|||Both|15 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The glucose concentrations of volunteer shall be distributed as specified in ISO15197        Table 3|April 2009|April 7, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877461||140866|
NCT00877162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00757|The Rocky Sleep Study|Night Waking Reduction in Canadian Infants: A Randomized Controlled Clinical Trial of a Parent-based Cognitive and Behavioural Intervention in Community Health Units.||University of British Columbia|Yes|Completed|June 2009|September 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|235|||Both|6 Months|8 Months|Accepts Healthy Volunteers|||June 2012|June 18, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00877162||140889|
NCT00877487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-401|Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder|A Phase 4, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire||Completed|April 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|55 Years|No|||July 2012|July 31, 2012|March 19, 2009|Yes|Yes||No|July 6, 2011|https://clinicaltrials.gov/show/NCT00877487||140864|
NCT00877513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-02-2165|Insulin Resistance in Smokers Undergoing Smoking Cessation|Insulin Resistance in Smokers Undergoing Smoking Cessation||Charles Drew University of Medicine and Science|Yes|Terminated|February 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|103|||Both|25 Years|70 Years|No|||February 2014|February 7, 2014|February 23, 2009||No|Funding expired|No||https://clinicaltrials.gov/show/NCT00877513||140862|
NCT00877526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3723|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia|DiabCare Asia 2008 (Malaysia): A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia|DiabCare Asia|Novo Nordisk A/S|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1670|Samples With DNA|Capillary or venous blood will be drawn for analysing HbA1c.|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to the        inclusion and exclusion criteria.|July 2012|July 17, 2012|April 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00877526||140861|
NCT00878098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909115|Study of DDT and Loss of Clinically-Recognized Pregnancies in South Africa|Study of DDT and Loss of Clinically Recognized Pregnancies in South Africa||National Institutes of Health Clinical Center (CC)||Completed|April 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2805|||Female|20 Years|34 Years|Accepts Healthy Volunteers|||August 2015|December 12, 2015|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878098||140817|
NCT00878709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A2-3004|Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer|ExteNET|Puma Biotechnology, Inc.|Yes|Active, not recruiting|July 2009|November 2016|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2840|||Female|18 Years|N/A|No|||August 2015|August 20, 2015|April 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00878709||140772|
NCT00878722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-15|Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy|A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy||Onxeo||Completed|August 2007|April 2012|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|April 7, 2009|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT00878722||140771|
NCT00874315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636111|Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.|A Multicenter Pilot Study of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation With In-vivo T-cell Depletion to Evaluate the Role of NK Cells and KIR Mis-matches in Relapsed or Refractory High-risk Neuroblastoma.||Nationwide Children's Hospital|Yes|Withdrawn|September 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|18 Years|No|||October 2015|October 14, 2015|April 1, 2009|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00874315||141106|
NCT00878748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600X1-4434|Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder|An Open Label, Prospective and Multi-center Recurrence Prevention Study With Effexor XR in MDD Patients in China||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Withdrawn|April 2009|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|0|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878748||140769|
NCT00878761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STX-002|Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)|Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)||Stromedix, Inc.|Yes|Withdrawn|September 2010|December 2011|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|65 Years|No|||May 2011|May 20, 2011|April 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00878761||140768|
NCT00874601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VENTURE|Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke|Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke|VENTURE|Hallym University Medical Center|Yes|Recruiting|October 2008|July 2012|Anticipated|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|578|||Both|18 Years|N/A|No|||October 2011|October 4, 2011|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874601||141084|
NCT00874913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2006/0052|Study of Ocular Blood Flow in Patients With Glaucoma and/or Obstructive Sleep Apnea Syndrome (OSAS)|Study of Ocular Blood Flow Using Laser Doppler Flowmetry in Patients With Glaucoma and/or OSAS||University Hospital, Grenoble|No|Recruiting|September 2006|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2012|October 8, 2012|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00874913||141061|
NCT00874614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-IB12B|A Study Evaluating Ultratrace Iobenguane I 131 (MIBG) in Patients With Malignant Pheochromocytoma/Paraganglioma|A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma||Molecular Insight Pharmaceuticals, Inc.|Yes|Active, not recruiting|June 2009|June 2021|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|12 Years|N/A|No|||October 2015|January 5, 2016|April 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00874614||141083|
NCT00875446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111330|First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis|A Single and Repeat Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of GSK1223249 in Patients With ALS.||GlaxoSmithKline|No|Completed|May 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|80 Years|No|||November 2011|November 10, 2011|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875446||141020|
NCT00875212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPB-CAPES_2005|Effect of Calcium Glycerophosphate (CaGP) - Fluoride Dentifrice on Dental Biofilm pH|Effect of a Dentifrice Containing Calcium Glycerophosphate and Fluoride on the pH of Dental Biofilm in Vivo|CAGP-F|Federal University of Paraíba|No|Completed|January 2006|July 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|12|||Both|19 Years|30 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|April 2, 2009||No||No|April 2, 2009|https://clinicaltrials.gov/show/NCT00875212||141038|pH measurements of dental biofilms were difficult after continuous use of dentifrice because of reduced biofilm mass in contrast to baseline measurements.
NCT00900627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00003|Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)|A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer|THYME|AstraZeneca|Yes|Completed|June 2009|February 2015|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|150 Years|No|||January 2016|January 15, 2016|May 12, 2009||No||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00900627||139140|The primary statistical analysis of PFS was performed, but the planned analyses of overall survival at 50% maturity, and of PFS at 50% OS maturity, were not performed.AEs were coded using MedDRA v14.0 (part A) and MedDRA v15.0 (part B).
NCT00900939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acne001|Plant-based Dietary Intervention for Treatment of Acne|Plant-based Dietary Intervention for Treatment of Acne||Physicians Committee for Responsible Medicine|No|Completed|July 2009|March 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 6, 2012|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00900939||139117|
NCT00874809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1799|Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study|A Pilot Study to Explore Basal Insulin Dosing Requirements in Patients With Type 2 Diabetes Treated With Insulin Pump Therapy||Diabetes Care Center|No|Completed|March 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874809||141069|
NCT00875095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.08.118|Impact of Sperm DNA Integrity on Artificial Reproductive Treatment (ART)|Impact of Sperm DNA Integrity on ART Treatment||Northwell Health|No|Terminated|October 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|8|Samples Without DNA|Smears of semen samples will be stained and stored.|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patient population at the Center for Human Reproduction.|September 2015|September 9, 2015|April 2, 2009||No|Study funding was withdrawn by the sponsor following agreement that slow patient recruitment    warranted a new approach.|No||https://clinicaltrials.gov/show/NCT00875095||141047|
NCT00875706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-427|Training and Coaching to Promote High Performance in Veteran Affairs (VA) Nursing Home Care|Training and Coaching to Promote High Performance in VA Nursing Home Care||VA Office of Research and Development|No|Completed|October 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|45|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|April 1, 2009||No||No|October 10, 2014|https://clinicaltrials.gov/show/NCT00875706||141000|
NCT00875979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO22495|A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab|A Phase Ib/II, Open-label Study of the Safety, Tolerability, and Efficacy of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab||Hoffmann-La Roche||Completed|May 2009|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||December 2013|December 20, 2013|April 2, 2009|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00875979||140979|
NCT00876304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0911004|Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia|Phase 1, Investigator And Subject-Blind, Placebo-Controlled, Randomized, Sequential Group, Multiple Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04802540 In Patients With Schizophrenia||Taisho Pharmaceutical Co., Ltd.|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|39|||Both|18 Years|55 Years|No|||October 2009|March 17, 2010|April 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00876304||140955|
NCT00876278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46LC HEN 401-08|Night Driving Pilot|Prospective Clinical Study to Evaluate Usability of Mesotest II for Assessment of Night Driving Capacity of Pseudophakic Patients Implanted With Monofocal IOL *AT.Smart 46LC||Carl Zeiss Meditec AG|No|Withdrawn|June 2009|February 2010|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|50 Years|75 Years|No|||November 2013|November 27, 2013|April 3, 2009||No|Due to internal reasons study was not performed.|No||https://clinicaltrials.gov/show/NCT00876278||140957|
NCT00876616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0901|Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis|An Multi-site, Open, Prospective Study to Assess the Efficacy and Safety of Multi-target Therapy in the Treatment of Class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis||Nanjing University School of Medicine|Yes|Completed|April 2009|February 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|362|||Both|18 Years|65 Years|No|||August 2013|August 28, 2013|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876616||140931|
NCT00876655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-108|Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate|An Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Sequence, Crossover, Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of TR-701 (Torezolid Phosphate) in Normal Healthy Adults||Trius Therapeutics LLC|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|April 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00876655||140928|
NCT00876902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSPSL-0003-PF.3|YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation|A Controlled, Prospective, Blinded, Randomized, Single-Center, Study of YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation|YSPSL|Y's Therapeutics, Inc.|Yes|Active, not recruiting|May 2008|October 2009|Anticipated|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876902||140909|
NCT00877175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I50221|Comparison of Instillation and Packing in Mydriasis for Premature Infants|Comparison of Conventional Instillation and Lower Conjunctival Fornix Packing in Mydriasis for Premature Infants||Khon Kaen University|Yes|Completed|March 2009|June 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|25|||Both|1 Month|4 Months|No|||March 2012|March 7, 2012|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877175||140888|
NCT00878111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR013|Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour|NGR013: Phase I and Pharmacodynamic Study of NGR-hTNF Administered at High Doses in Patients With Advanced or Metastatic Solid Tumour||MolMed S.p.A.|No|Active, not recruiting|April 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878111||140816|
NCT00878124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoQ10 - 08-0205-A|How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome|The Influence of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome in Intrauterine Insemination|CoQ10|University of Toronto|No|Terminated|June 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|100|||Female|38 Years|43 Years|Accepts Healthy Volunteers|||January 2010|January 11, 2010|April 7, 2009||No|Very low recruitment rate|No||https://clinicaltrials.gov/show/NCT00878124||140815|
NCT00878137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC Comparison 08-1883|Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin|INR Determined by Plasma-based Methods Versus Newer Point-of-care Instruments in Patients With Antiphospholipid-antibody Syndrome Treated With Anticoagulants||University of North Carolina, Chapel Hill|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|APLA patients will be identified through the UNC Thrombophilia Program database. Control        patients will be recruited at UNC Anticoagulation Clinic visits.|October 2012|October 12, 2012|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00878137||140814|
NCT00878176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-005|Sacral Neuromodulation Test With Bilateral First Stage Tined Lead Procedure in Patients With Non-obstructive Urinary Retention: A Pilot Study|Sacral Neuromodulation Test With Bilateral First Stage Tined Lead Procedure in Patients With Non-obstructive Urinary Retention: A Pilot Study||Maastricht University Medical Center|No|Recruiting|June 2009|December 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|April 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878176||140811|
NCT00874341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSA study N02042|Effect of Fruit and Vegetables on Insulin Resistance|Dose−Response Effect of Fruit and Vegetables on Insulin Resistance in Healthy People Who Are Overweight and at High Risk of Cardiovascular Disease|FIRST|Queen's University, Belfast|No|Completed|January 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 7, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874341||141104|
NCT00874627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K070602|Sublingual Milk Immunotherapy in Children|Sublingual Milk Immunotherapy in Children With IgE-mediated Cow Milk Protein Allergy|Lactaide|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2008|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|5 Years|17 Years|No|||December 2012|December 10, 2012|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874627||141082|
NCT00874640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14317|Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)|Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)||Bayer|No|Completed|March 2009|November 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3711|||Both|7 Years|N/A|No|Non-Probability Sample|Radiological practice|February 2014|February 19, 2014|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874640||141081|
NCT00874926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13405|EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS|Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS||Bayer|No|Completed|June 2008|April 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|405|||Male|N/A|N/A|No|Non-Probability Sample|Haemophilia A patients, no specific study population|January 2014|January 28, 2014|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00874926||141060|
NCT00875225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59741 - Finding Answers|Using Multimedia Technology for Hypertension Control for Low-Income African Americans|Culturally Sensitive Intervention: CSI Birmingham|CSI Birmingham|Cooper Green Mercy Hospital|Yes|Active, not recruiting|December 2006|May 2009|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 2, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875225||141037|
NCT00875485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110699|Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™|Study to Evaluate Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™||GlaxoSmithKline||Completed|May 2009|July 2013|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|210|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|April 2, 2009|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00875485||141017|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).The table shows updated results following complete retesting and reanalysis.
NCT00866450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWP-0658|Effects of a Western-type Diet on Colorectal Inflammation|Effects of a Western-type Diet on Colorectal Inflammation, Gut Permeability and Systemic Endotoxemia||Rockefeller University|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|5|||Both|50 Years|72 Years|No|||January 2012|January 10, 2012|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866450||141701|
NCT00875108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject™-09J|An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus|||Biodel|No|Completed|July 2007|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|30 Years|70 Years|No|||July 2015|July 28, 2015|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00875108||141046|
NCT00875394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-189|Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)|A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin||Merck Sharp & Dohme Corp.|No|Completed|February 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|68|||Both|30 Years|78 Years|No|||August 2015|August 26, 2015|April 1, 2009|No|Yes||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00875394||141024|A limited number of participants were recruited into this open-label study. This study was conducted at a single site.Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.
NCT00875732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELD001|Choosing the Right Pacing Mode in Heart Failure - The CHOICE Trial|CHOosing the rIght paCing Mode in Heart failurE : Should Heart Failure Patients With Bradycardia Receive Biventricular Pacemakers Rather Than Conventional Pacemakers?|CHOICE|University of Dundee|No|Recruiting|September 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2009|June 24, 2010|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00875732||140998|
NCT00875966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA17045|Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Eon and Pfizer Inc. (ZITHROMAX) 200mg/5mL Azithromycin Suspension Following a 600mg Dose in Healthy Adult Volunteers Under Fed Conditions||Sandoz||Completed|August 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 3, 2009|April 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00875966||140980|
NCT00876343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-08-001|Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder|Placebo-Controlled, Double-Blind, Parallel Group-Comparison Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder||Otsuka Pharmaceutical Co., Ltd.|No|Completed|March 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|586|||Both|20 Years|74 Years|No|||December 2013|December 20, 2013|April 2, 2009||No||No|December 20, 2013|https://clinicaltrials.gov/show/NCT00876343||140952|
NCT00876668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAG II|Evaluation of the Clinical Significance of Fluorescence Videoangiography With Indocyanine-Green|Pilot-Study to Evaluate the Clinical Significance of the Fluorescence Videoangiography With Indocyanine-Green in Patients With PAD, Rutherford Classification II-V, and Relation to Common Diagnostics.||Johann Wolfgang Goethe University Hospitals|No|Active, not recruiting|June 2007|December 2009|Anticipated|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Probability Sample|Patients with PAD, Rutherford classification II-V, not requiring surgery|April 2009|April 6, 2009|January 16, 2008||No||No||https://clinicaltrials.gov/show/NCT00876668||140927|
NCT00876291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UB2712|Efficacy of Lactobacillus GG (LGG) in Children With Abdominal Pain|The Use of Lactobacillus gg in Functional Abdominal Pain in Children: a Double-blind Randomized Control Trial|LGGDAR|University of Bari|Yes|Completed|December 2004|August 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|4 Years|14 Years|No|||April 2009|January 31, 2011|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00876291||140956|
NCT00877188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808034R|Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors|Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors: Upper Extremity Function, Quality of Life and Fitness Outcomes||National Taiwan University Hospital|Yes|Completed|January 2009|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|70 Years|No|||November 2012|December 20, 2012|March 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00877188||140887|
NCT00877201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ryogoku6886|Improvement of Accommodation With Anti-Oxidant Supplementation in Visual Display Terminal Users|||Ryogoku Eye Clinic|Yes|Completed|March 2007|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|||||||Both|40 Years|49 Years|Accepts Healthy Volunteers|||April 2009|April 7, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877201||140886|
NCT00876915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25387|A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients|A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients|PHACS|University of Rochester|Yes|Terminated|July 2009|December 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|218|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|March 31, 2009|Yes|Yes|slow enrollment and lack of continuing funds|No|July 24, 2015|https://clinicaltrials.gov/show/NCT00876915||140908|
NCT00877851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/NIR01/97|Evaluation of an Interactive CD-ROM for People With Type 2 Diabetes|Development and Evaluation of an Interactive CD-ROM for People With Type 2 Diabetes (Evaluation Phase)|LWD|Queen's University, Belfast|No|Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2011|August 19, 2011|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877851||140836|
NCT00877877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111375|Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.|Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of a HPV Vaccine (GSK 580299) in Healthy Female Subjects||GlaxoSmithKline||Completed|May 2009|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|632|||Female|15 Years|24 Years|Accepts Healthy Volunteers|||June 2015|September 10, 2015|March 26, 2009|No|Yes||No|March 31, 2011|https://clinicaltrials.gov/show/NCT00877877||140834|
NCT00876733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1524|Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients|Non-Interventional Observational Study With Viramune Plus ARV in HIV Infected Patients||Boehringer Ingelheim||Completed|March 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|605|||Both|18 Years|N/A|No|Non-Probability Sample|patients|January 2015|January 14, 2015|March 20, 2009||||No|December 27, 2014|https://clinicaltrials.gov/show/NCT00876733||140922|
NCT00878384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008CI008B|Catheter Ablation Versus Medical Rate Control for Atrial Fibrillation in Patients With Heart Failure|A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure|ARC-HF|Royal Brompton & Harefield NHS Foundation Trust|Yes|Completed|April 2009|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|80 Years|No|||July 2012|July 11, 2012|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878384||140795|
NCT00878397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5482|Impact of School-based Delivery of Long Lasting Insecticide Nets|Evaluating the Impact of Delivering Long Lasting Insecticide Nets Through Schools on Household Access and the Health of School Children in North Eastern Kenya||London School of Hygiene and Tropical Medicine|No|Completed|May 2009|November 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5113|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878397||140794|
NCT00878423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT13387/0001|Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors|A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors||Astex Pharmaceuticals|No|Completed|May 2008|March 2014|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|62|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|April 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878423||140793|
NCT00878787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03162009-1999|Theta-burst Transcranial Magnetic Stimulation|Theta-burst Transcranial Magnetic Stimulation for the Treatment of Childhood Dystonia and Spasticity||University of Southern California||Completed|January 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|2 Years|29 Years|No|||May 2014|May 28, 2014|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00878787||140766|
NCT00878800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-14|A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas|A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas||Onxeo||Completed|December 2006|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|April 7, 2009|Yes|Yes||No|July 7, 2014|https://clinicaltrials.gov/show/NCT00878800||140765|
NCT00874354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4441|Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction|REVITALIZE: Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction|REVITALIZE|Cedars-Sinai Medical Center|Yes|Active, not recruiting|July 2005|December 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||April 2011|April 13, 2011|December 26, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00874354||141103|
NCT00875251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE - 0292.0.008.000-05|Growth and Body Composition in Preterm Infants|Growth and Body Composition of Very Low Birth Weight Infants Compared With Infants Birth at Term|Crescer|Oswaldo Cruz Foundation|Yes|Recruiting|April 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|6 Months|No|Non-Probability Sample|Preterm infants with birth weight less than 1500g        Term infants without IUGR|July 2015|July 21, 2015|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875251||141035|
NCT00875264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11981/1047/ON/US|Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer|An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer||Teva Pharmaceutical Industries|No|Completed|September 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|April 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00875264||141034|
NCT00874939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0249-023|A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)|A Randomized Clinical Trial To Evaluate the Single Dose Acute Effects of MK-0249 and Donepezil On Cognitive Function In Adult Patients With Alzheimer's Disease||Merck Sharp & Dohme Corp.|No|Terminated|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|4|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|April 2, 2009|No|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT00874939||141059|
NCT00866476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040710 Phase IIa|Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa|Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study||University of Maryland|Yes|Terminated|January 2010|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|March 19, 2009|Yes|Yes|Reactogenicity met study halting criteria|No||https://clinicaltrials.gov/show/NCT00866476||141699|
NCT00866762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-0683/092-0|A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia|A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia.||Copenhagen University Hospital at Herlev|Yes|Active, not recruiting|February 2009|December 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2011|December 9, 2011|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00866762||141677|
NCT00866775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093-045|Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs|Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs||Sunovion|No|Completed|April 2009|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|16 Years|70 Years|No|||February 2016|February 9, 2016|March 18, 2009|Yes|Yes||No|October 6, 2015|https://clinicaltrials.gov/show/NCT00866775||141676|The comparison of active treatment to control which was used in this trial is based on a pooled analysis of comparator groups from 8 earlier trials of similar design. Limitations related to use of historical control groups are applicable.
NCT00875407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/09|Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot|||Assistance Publique Hopitaux De Marseille|No|Completed|February 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00875407||141023|
NCT00875719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTADIR CMTS OXYGEN 2009|Oxygen Portable Concentrator During Exercises in Patients With COPD|Comparing Effectiveness of Oxygen Supplementation From a Portable Concentrator and a Liquid Oxygen Source During Walking Test in COPD Patients With Respiratory Failure||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|Yes|Completed|February 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|45 Years|80 Years|No|||February 2011|February 15, 2011|March 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00875719||140999|
NCT00876356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-0180|The Health Benefits of Conjugated Linoleic Acid (CLA) for Asthma & Allergy|Conjugated Linoleic Acid (CLA) as Adjunctive Therapy in Mild Asthmatics: A Pilot Study.||University of British Columbia|No|Completed|May 2002|September 2004|Actual|May 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2009|April 3, 2009|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876356||140951|
NCT00876681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Popliteal Catheter: US vs. NS|Ultrasound Guidance Versus Electrical Stimulation for Continuous Popliteal-Sciatic Nerve Blocks|Ultrasound Guidance Versus Electrical Stimulation for Continuous Popliteal-Sciatic Nerve Blocks: A Randomized, Controlled Trial||University of California, San Diego|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2009|October 7, 2009|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876681||140926|
NCT00876317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36459|Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder|Efficacy and Safety of Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder||Clinica Virgen Milagrosa|Yes|Terminated|November 2009|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||June 2012|June 29, 2012|April 2, 2009||No|Change in current areas of research interest of the collaborator|No||https://clinicaltrials.gov/show/NCT00876317||140954|
NCT00876330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U18HS016970-01|Improving Antihypertensive and Lipid-Lowering Therapy|CERT-HIT: A Multimodal Intervention to Improve Antihypertensive and Lipid-lowering Therapy|CERT2|VA Boston Healthcare System|No|Active, not recruiting|May 2009|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6000|||Both|18 Years|89 Years|No|||September 2012|September 19, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876330||140953|
NCT00877214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL 7-2008|Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas|Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas|MAINTAIN|University of Giessen|Yes|Recruiting|April 2009|April 2022|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1272|||Both|18 Years|80 Years|No|||June 2015|June 17, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877214||140885|
NCT00877227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010-0237|Does B Vitamin Supplementation Decrease Homocysteine Concentrations in Newborns|Does Folinic Acid Supplementation Decrease Homocysteine Concentrations in Newborns||Radboud University|No|Completed|January 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|37|||Both|N/A|2 Weeks|Accepts Healthy Volunteers|||April 2009|May 5, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877227||140884|
NCT00877539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9291002|A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects|A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.||Pfizer|No|Completed|June 2009|July 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|60 Years|No|||September 2010|September 27, 2010|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877539||140860|
NCT00877552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH064065-07|Prospective Studies of the Pathogenesis of Schizophrenia|Prospective Studies of the Pathogenesis of Schizophrenia (Center Title) Early Brain Development in High Risk Children (Project Title) Early Brain Development in One and Two Year Olds (Associated Grant Title)||University of North Carolina, Chapel Hill|No|Active, not recruiting|August 2002|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|600|Samples With DNA|MRIs, buccal swabs, prenatal ultrasounds|Both|N/A|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|medical center and community clinics|December 2015|December 3, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877552||140859|
NCT00877864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEAL- 22251|Diabetes Exercise and Lifestyle Trial|Diabetes Exercise and Lifestyle Trial|DEAL|University of Calgary|No|Active, not recruiting|February 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|6||Actual|26|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877864||140835|
NCT00875823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1605-03|International Registry for Primary Hyperoxaluria|International Registry for Hereditary Calcium Stone Diseases||Mayo Clinic|Yes|Withdrawn|September 2003|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Any patient with a confirmed diagnosis of primary hyperoxaluria (PH)|April 2015|April 6, 2015|April 2, 2009||No|Study was combined with Mayo protocol 07-003476|No||https://clinicaltrials.gov/show/NCT00875823||140991|
NCT00877292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0004|A New Prenatal Blood Test for Down Syndrome|The RNA (RNA-Based Noninvasive Aneuploidy) Study|RNA|Women and Infants Hospital of Rhode Island|No|Completed|February 2009|May 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|4664|Samples With DNA|Fetal RNA and DNA in maternal plasma|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women between about 10 weeks and 21 weeks 6 days gestation who are undergoing a        diagnostic procedure (i.e., chorionic villus sampling or amniocentesis) for karyotype        analysis.|June 2015|June 1, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877292||140879|
NCT00878436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 08-479|Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration|Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-resistant Prostate Cancer||New York University School of Medicine|Yes|Completed|June 2009|July 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Male|18 Years|N/A|No|||August 2015|August 21, 2015|April 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00878436||140792|
NCT00878449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-234|A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer|A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer||AbbVie||Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|April 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878449||140791|
NCT00874666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT004236|Allicin Bioavailability From Garlic Supplements and Garlic Foods|Allicin Bioavailability of Garlic Products||Silliker, Inc.|Yes|Active, not recruiting|April 2009|April 2011|Anticipated|April 2011|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874666||141079|
NCT00874393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0041|Early Blood Pressure Management in Extremely Premature Infants|Early Blood Pressure Management in Extremely Preterm Infants Feasibility Pilot Study|ELGAN BP|NICHD Neonatal Research Network|Yes|Completed|July 2009|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|10|||Both|N/A|24 Hours|No|||October 2015|November 6, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874393||141100|
NCT00874406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-04|Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer|Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer||Fudan University|Yes|Recruiting|January 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||April 2009|April 1, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874406||141099|
NCT00866411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2007.147|Cranial Electrotherapy Stimulation (CES) for Soldiers With Combat-Related Symptoms|Outcomes of Cranial Electrotherapy Stimulation (CES) With Soldiers for Combat-Related Symptoms|CES|Brooke Army Medical Center|Yes|Recruiting|May 2007|January 2010|Anticipated|May 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2009|March 19, 2009|March 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866411||141704|
NCT00866983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481270|Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil|A Local, Multi-Centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy For Patients Who Completed A1481244 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil , Prior To Reimbursement And Availability For Patients In Brazil.||Pfizer|No|No longer available|October 2009|September 2012|Actual|September 2012|Actual|Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||February 2013|February 11, 2013|March 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866983||141661|
NCT00866723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-323|Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer|Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin||Dana-Farber Cancer Institute|Yes|Terminated|March 2009|June 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|March 19, 2009|Yes|Yes|Recruitment has been terminated prematurely because of poor enrollment.|No|November 19, 2014|https://clinicaltrials.gov/show/NCT00866723||141680|Early termination leading to small numbers of subjects analyzed.
NCT00866489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DONG2008RPC|The Neuroprotective Effects of RPC on the Neurosurgery|Clinical Trial Cencer, Xijing Hospital, Fourth Military Medical University||Xijing Hospital|Yes|Completed|September 2008|September 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|20 Years|70 Years|No|||March 2009|December 26, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866489||141698|
NCT00866788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4577g|A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)||Genentech, Inc.||Completed|March 2009|||January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|90|||Both|12 Years|75 Years|No|||September 2011|September 16, 2011|March 20, 2009|Yes|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00866788||141675|The laboratory and vital signs were not reported because no imbalance or abnormality were found."
NCT00875745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902-08; IUCRO-0234|Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)|Phase I, Open-label, Dose-escalation Study of the Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)||Indiana University|Yes|Completed|April 2009|October 2013|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875745||140997|
NCT00875758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LETAP-09-0380|Optimizing Treatment of Post-hemorrhagic Ventricular Dilation in Preterm Infants|Phase II Study of Late- Versus Early Treatment of Post-hemorrhagic Ventricular Dilation in Preterm Infants.|LETAP|Washington University School of Medicine|Yes|Active, not recruiting|May 2009|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|34 Weeks|No|||December 2015|December 7, 2015|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875758||140996|
NCT00876369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|045-09-EP|Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema|Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema||University of Nebraska|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|19 Years|N/A|No|Non-Probability Sample|Subjects at subspeciality clinic (allergy/immunology) at tertiary care medical center|December 2009|December 17, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00876369||140950|
NCT00876382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI OUTCOMES 06|Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma|Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma||SCRI Development Innovations, LLC|No|Completed|May 2009|August 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|47|||Both|18 Years|N/A|No|Non-Probability Sample|Two hundred plus patients treated with Nexavar as first or second line therapy for        advanced renal cell carcinoma.|November 2013|November 12, 2013|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876382||140949|
NCT00876395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001J2301|Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer|A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer|BOLERO-1|Novartis||Active, not recruiting|September 2009|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|719|||Female|18 Years|N/A|No|||February 2016|February 2, 2016|April 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876395||140948|
NCT00876928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D-Prediabetes|Vitamin D in Minorities With Prediabetes|Effect of Vitamin D Supplementation on Pre-Diabetes in a Minority Population||Charles Drew University of Medicine and Science|Yes|Completed|March 2009|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|117|||Both|18 Years|90 Years|No|||April 2013|April 17, 2013|April 6, 2009||No||No|July 3, 2012|https://clinicaltrials.gov/show/NCT00876928||140907|
NCT00876954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreopHypertherm1|Preoperative Hyperthermia in Major Abdominal Surgery Patients|Preoperative Whole-Body Hyperthermia in Patients Undergoing Major Abdominal Cancer Surgery: A Randomized Pilot Study||Medical University of Vienna|No|Completed|April 2009|July 2011|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876954||140905|
NCT00876967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laryngotest|Comparison of Three Laryngoscope Blades for Orotracheal Intubation in the Operating Room|Comparison of Performance of Three Laryngoscope Blades: Plastic Single Use, Metallic Single Use and Metallic Reusable Blades.|Laryngotest|University Hospital, Caen|Yes|Completed|January 2008|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|1040|||Both|18 Years|N/A|No|||March 2010|March 30, 2010|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876967||140904|
NCT00877565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VI_echo_01_2009|Global Longitudinal Peak Systolic Strain (GLPSS) Derived From Transesophageal Echocardiography - A Reliable Measure of Systolic Function?|Is Global Longitudinal Peak Systolic Strain (GLPSS) Derived From Transesophageal Echocardiography a Reliable Measure of Systolic Function? A Multicenter-Study to Compare GLPSS With Ejection Fraction Derived From Biplane Simpson´s Method on TTE and TEE in Patients Undergoing Elective Cardiac and Non-Cardiac Surgery|2DSonTOEcho|Medical University of Vienna|No|Recruiting|February 2009|||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|19 Years|90 Years|No|Probability Sample|Patients undergoing cardiac and non-cardiac surgery|April 2009|April 7, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877565||140858|
NCT00877240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|735-2008|The Influence of an Intervention Program on Altering Health Behavioral Patterns Among IDF's Staff|||Medical Corps, Israel Defense Force||Withdrawn|August 2008|August 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|0|||Both|26 Years|55 Years|No|||March 2016|March 15, 2016|April 6, 2009||No|lack of complaince|No||https://clinicaltrials.gov/show/NCT00877240||140883|
NCT00877578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/023/HP|Efficacy of a Special Oral Nutritional Supplement on Nutritional Status of Malnourished Elderly Patients|Efficacy of a Special Oral Nutritional Supplement on Nutritional Status of Malnourished Elderly Patients|Nutri-PA|University Hospital, Rouen|No|Completed|April 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|60 Years|95 Years|No|||October 2013|October 15, 2013|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877578||140857|
NCT00876447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-094|A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis|||Allergan|No|Completed|January 2009|September 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|April 1, 2009|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00876447||140944|
NCT00876460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.29|BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I|A Phase I Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Docetaxel - a Phase I, Open-label, Dose-escalation Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy||Boehringer Ingelheim||Completed|March 2009|July 2015|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|20 Years|74 Years|No|||September 2015|September 23, 2015|March 3, 2009||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00876460||140943|
NCT00877903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403|Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)|A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction||Mesoblast, Ltd.|Yes|Active, not recruiting|March 2009|February 2016|Anticipated|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|21 Years|85 Years|No|||May 2015|May 19, 2015|April 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00877903||140832|
NCT00877916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2009|||||N/A|N/A|N/A||||||||||||||June 15, 2010|April 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00877916||140831|
NCT00874965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER20105|Electrostimulation, Skeletal Muscle Function, and Exercise Capacity in Chronic Obstructive Pulmonary Disease (COPD)|Study of the Benefits of Lower Limb Electrostimulation Training on Muscular Parameters and Minute Ventilation During Exercise in Severe and Deconditioned COPD Patients.|ESTIM|Laval University|No|Completed|December 2006|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|55 Years|80 Years|No|||October 2012|October 9, 2012|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00874965||141057|
NCT00867334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BUS278T|New Individualized Therapy Trial for Metastatic Colorectal Cancer|A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay|NITMEC|Inova Health Care Services|No|Completed|June 2009|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00867334||141635|
NCT00867347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633526|Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer|Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study||National Cancer Institute (NCI)||Active, not recruiting|December 2006|||March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|1015|||Both|18 Years|N/A|No|||March 2009|July 9, 2011|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867347||141634|
NCT00867360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02262009-1838|Treatment of Psychotic Major Depression With Mifepristone|Hypothalamic-Pituitary-Adrenal (HPA)/Dopamine Axis in Psychotic Depression||Stanford University||Terminated|August 2005|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|85 Years|No|||June 2009|June 10, 2009|March 20, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00867360||141633|
NCT00866502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0031-001|A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease|A Randomized, Double-blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed® II Pump.||Newron Sweden AB|Yes|Completed|March 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|30 Years|75 Years|No|||January 2015|January 9, 2015|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00866502||141697|
NCT00866515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112205|Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole|A Double-blind, Placebo-controlled, Randomised, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Co-administration of GW642444M With Ketoconazole||GlaxoSmithKline|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 3, 2010|January 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00866515||141696|
NCT00866801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES 2008-12|Coronary Blood Flow Regulation During General Anesthesia|Cardiac Sympathetic Innervation and Coronary Blood Flow Regulation During General Anesthesia||VU University Medical Center|No|Completed|April 2009|October 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|45|Samples Without DNA|Frozen plasma will be retained|Male|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The study population consists patients scheduled for surgery and general anesthesia.        Patients will be recruited from the preoperative screening clinic in the four,        aforementioned, groups of patients.|October 2015|October 12, 2015|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00866801||141674|
NCT00876018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 001/2008|Nutrition, Physical Performance & Fitness in Indian School Children|A Double Blind Randomized Controlled Trial in School Going Children, to Evaluate the Impact of a Multiple Micronutrient Fortified Nutritional Powder on Physical Performance Measures||GlaxoSmithKline|No|Completed|July 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|300|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876018||140976|
NCT00866424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080327-1|Clinical Trial of Hyperbaric Oxygen Treatment in Trigeminal Neuralgia Patients|A Prospective Study on Efficacy of Hyperbaric Oxygenation Treatment for Patients With Trigeminal Neuralgia: a Randomized, Double-Blind, Mock Hyperbaric Chamber -Controlled, Parallel-Group Trial||Xijing Hospital|Yes|Enrolling by invitation|April 2008|April 2009|Anticipated|January 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2009|March 19, 2009|January 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866424||141703|
NCT00866437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EveMS-0908|Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel|Prospective, Controlled, Single-blinded, Longitudinal, Two-arms, Clinical Study Evaluation of Efficacy/Safety of EVE-PMS Skin-Test Panel -Detecting Sensitivity to Sex Hormones in Women With Premenstrual Syndrome||EVE Medical Systems Ltd.|Yes|Recruiting|April 2009|November 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|40|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||February 2010|June 15, 2010|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866437||141702|
NCT00876941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA025068|Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use|Efficacy/Effectiveness of Unhealthy Drug Use Screening/Brief Intervention Models|ASPIRE|Boston Medical Center|No|Completed|April 2009|September 2014|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|589|||Both|18 Years|N/A|No|||February 2012|October 1, 2014|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876941||140906|
NCT00876720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-rTMS-Tinnitus-01|Effectiveness Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Chronic Tinnitus|Effectiveness of Combined Frontal and Temporal Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Chronic Tinnitus||University of Regensburg|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2010|November 12, 2010|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876720||140923|
NCT00877890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB108 (DURATION-5)|A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)|A Randomized, Open-Label, Parallel-Group, Comparator-Controlled, Multicenter Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|March 2009|January 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|April 6, 2009|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00877890||140833|
NCT00877253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPMOC201|Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer|Open-label, Multicenter, Phase I Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin as a Firstline Treatment in Subjects With Advanced Ovarian Cancer||Samyang Biopharmaceuticals Corporation|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Female|18 Years|N/A|No|||June 2012|June 11, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00877253||140882|
NCT00878163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01400|GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery|Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine||National Cancer Institute (NCI)||Active, not recruiting|March 2009|||April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||September 2015|March 11, 2016|April 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00878163||140812|
NCT00874653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14175|Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding|Levonorgestrel Releasing Intrauterine System (MIRENA) in Idiopathic Menorrhagia||Bayer|No|Completed|April 2008|December 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Female|30 Years|49 Years|No|Non-Probability Sample|Women with a diagnosis of idiopathic menorrhagia and Mirena inserted for a period no        longer than three months according to the assessment of the investigator will be included        in the study|June 2014|June 20, 2014|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874653||141080|
NCT00876993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-CNS-001|Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors|A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System Tumors||All Children’s Hospital Johns Hopkins Medicine|Yes|Active, not recruiting|September 2008|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Months|23 Years|No|||January 2015|January 22, 2015|April 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876993||140902|
NCT00877006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/3064/NL/MN|Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study|An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)||Teva Pharmaceutical Industries|Yes|Active, not recruiting|April 2009|March 2017|Anticipated|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 3, 2009|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT00877006||140901|
NCT00877591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA013004|Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications|Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications||University of California, San Francisco|No|Completed|April 2008|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 2, 2014|April 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00877591||140856|
NCT00877604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUDCA200701|Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis|A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis|TUDCA-ALS|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Yes|Completed|June 2008|April 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|75 Years|No|||November 2014|November 19, 2014|April 7, 2009||No||No|October 31, 2014|https://clinicaltrials.gov/show/NCT00877604||140855|
NCT00878475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|grmec62|Dyspnea and Biomarkers in a Prehospital Setting|Quantitative Capnometry and Nt-proBNP in Differentiating of Acute Dyspnea in Pre-Hospital Emergency Setting||Health Care Center Maribor|No|Completed|January 2005|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|546|||Both|N/A|N/A|No|Non-Probability Sample|During the period of the study, 546 consecutive patients with acute dyspnea were treated        by emergency teams (emergency physician, register nurse, and medical technician/driver in        an ambulance-car or at pre-hospital emergency medical center). After pre-hospital care,        all patients were admitted to the University Clinical Center Maribor and followed until        discharge.        To be eligible for the study, a patient had to present with shortness of breath as the        primary complaint (defined as either the sudden onset of dyspnea without history of        chronic dyspnea or an increase in the severity of chronic dyspnea).|April 2009|April 8, 2009|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878475||140789|
NCT00877617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0305|Quality of Life in Men With High Risk Localized Prostate Cancer|Assessment of Quality of Life in Men With High Risk Localized Prostate Cancer Undergoing Neoadjuvant Investigational Therapy||M.D. Anderson Cancer Center|No|Withdrawn|May 2006|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Male|18 Years|N/A|No|Non-Probability Sample|M.D.Anderson Cancer Center prostate cancer patients who have received neoadjuvant        investigational therapies prior to radical prostatectomy for high risk clinically        localized prostate cancer.|July 2012|July 26, 2012|April 6, 2009||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00877617||140854|
NCT00877630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMMU-2-2009-2|Minimal Invasiveness of Endoscopic Thyroidectomy|Minimal Invasiveness of Endoscopic Thyroidectomy||Second Military Medical University||Completed|September 2006|May 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|N/A|N/A|No|Non-Probability Sample|patients admitted in the ward who are diagnosed with thyroid nodule and will undergo        thyroidectomy|April 2009|April 9, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877630||140853|
NCT00875537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-118|Neurogenic Mechanisms in Burning Mouth Syndrome|Neurogenic Mechanisms in Burning Mouth Syndrome With Focus on Localization and Desensibilization of Vanilloid Receptor TRPV1|BMS17|University of Copenhagen|Yes|Completed|January 2009|June 2010|Actual|April 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||June 2010|February 22, 2011|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875537||141013|
NCT00878215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104308|Clinical Application of Image Guided Liver Surgery|Clinical Application of Image Guided Liver Surgery||Washington University School of Medicine|Yes|Recruiting|December 2002|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|66|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00878215||140808|
NCT00868179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pradax|A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days|A Cohort (Follow Up) Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax (Tablet) Post Discharge for Ten Days, Without the Need for Routine Coagulation Monitoring and Dose Adjustment||Nova Scotia Health Authority|Yes|Withdrawn|April 2009|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|95 Years|No|||May 2009|May 14, 2015|March 23, 2009||No|study never started|No||https://clinicaltrials.gov/show/NCT00868179||141570|
NCT00866528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111109|Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer|An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer||GlaxoSmithKline|No|Completed|July 2009|October 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|March 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866528||141695|
NCT00866541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|327/07|Flow Proportional Pressure Support in Volunteers|Flow Proportional Pressure Support as a New Mode of Spontaneous Breathing Assist - Evaluation of Objective and Subjective Measured Data in Volunteers||University Hospital Freiburg|No|Recruiting|January 2009|||December 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2009|March 19, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866541||141694|
NCT00866814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE004|Study Of Hernia Repair Utilizing The Bard Ventrio Hernia Patch|A Prospective, Single Arm, Multi-Center Study Of Open Ventral Hernia Repair Utilizing The Bard Ventrio Hernia Patch||C. R. Bard|No|Completed|March 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|119|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with a diagnosis of ventral hernia will be screened for eligibility against the        study protocol inclusion and exclusion criteria utilizing standard preoperative criteria        (e.g. physical examination, blood work, medical evaluation, etc) which occurred within 30        days of the date of consent.|October 2012|October 10, 2012|March 20, 2009|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00866814||141673|This study was designed as a single arm observational trial without predefined statistical hypotheses (theories) to test; therefore, data can only be described and no treatment comparisons or conclusions can be made.
NCT00866827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20969|Airway Vascular Lesions|Airway Vascular Lesions||University of Arkansas||Active, not recruiting|December 2002|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|75|||Both|N/A|N/A|No|Non-Probability Sample|All patients in the ACH database that have been treated in the last ten years for airway        vascular lesions.|January 2016|January 21, 2016|December 17, 2007||No||No||https://clinicaltrials.gov/show/NCT00866827||141672|
NCT00875992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLS RCT 09|Trial to Evaluate the Effectiveness of Angular Stable Locking System (ASLS) in Patients With Distal Tibial Fractures|A Randomized Controlled Trial to Evaluate the Effectiveness of Angular Stable Locking System (ASLS) in Patients With Distal Tibial Fractures Treated With Expert Tibial Nails (ETN)||AO Clinical Investigation and Documentation|No|Completed|June 2009|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00875992||140978|
NCT00876005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/11/07-04|Supplemental Oxygen and the Risk of Surgical Site Infection|Perioperative Supplemental Oxygen and the Risk of Surgical Site Infection|PORSSI|Santa Clara Valley Health & Hospital System|Yes|Recruiting|August 2006|August 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1202|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 3, 2009|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876005||140977|
NCT00875797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P4-0092: onko|Enteral Versus Parenteral Glutamine Supplement|Comparison of Effect of Enteral Versus Parenteral Glutamine Supplement on Intestinal Permeability and Outcome of Critically Ill Patients||University Medical Centre Ljubljana|Yes|Terminated|October 2004|March 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|80 Years|No|||December 2013|December 1, 2013|April 2, 2009||No|Termination due to interim analysis results, inclusion problems in small ICUs.|No|June 27, 2013|https://clinicaltrials.gov/show/NCT00875797||140993|Termination due to small sample size for nutritional pilot study.
NCT00869323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS043|Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders|Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)||Masonic Cancer Center, University of Minnesota|Yes|Terminated|March 2009|December 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|March 25, 2009|Yes|Yes|Funding unavailable|No||https://clinicaltrials.gov/show/NCT00869323||141483|
NCT00869336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-0801|Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)|Phase 2 Study - A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration Finding Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Luliconazole Cream 1% in Patients With Tinea Pedis||Tinea Pharmaceuticals|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|147|||Both|12 Years|N/A|No|||June 2011|June 6, 2011|March 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00869336||141482|
NCT00866736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-01|A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia|A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia||Kanto CML Study Group|Yes|Completed|March 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|15 Years|N/A|No|||December 2010|September 14, 2015|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00866736||141679|
NCT00876031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWS-2007-HR|Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma|A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults|CWS-2007-HR|University Hospital Tuebingen|Yes|Recruiting|July 2009|July 2024|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|6 Months|21 Years|No|||July 2015|July 9, 2015|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00876031||140975|
NCT00876694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B1303|Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Efficacy of Indacaterol (300 µg o.d.) Using Salmeterol (50 µg b.i.d.) as an Active Control in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|March 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|186|||Both|40 Years|N/A|No|||October 2011|October 4, 2011|April 3, 2009||No||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00876694||140925|
NCT00876707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0088/09|Wavefront Analyzes and Visual Performance of Three Multifocal Intra-ocular Lenses|Phase 1 Study of Ocular Aberrations and Visual Performance of Eyes Implanted With Three Multifocal Intra-ocular Lenses|IOL|University of Sao Paulo||Completed|March 2009|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|40 Years|70 Years|No|||April 2009|July 1, 2010|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876707||140924|
NCT00878150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40378 G|Life Improvement Following Traumatic Brain Injury|Cognitive Behavioral Therapy for Depression After Traumatic Brain Injury|LIFT|University of Washington|No|Completed|September 2007|September 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00878150||140813|
NCT00878462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07010|An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)|A Randomized, Crossover Study Evaluating the Acceptability of Unflavored Asenapine and Raspberry Flavored Asenapine in Stable Subjects With A Psychotic Disorder||Merck Sharp & Dohme Corp.|No|Completed|June 2005|October 2005|Actual|October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|174|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|April 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00878462||140790|
NCT00874367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0035|Early-Onset Sepsis Surveillance Study|Early-Onset Sepsis: an NICHD/CDC Surveillance Study|EOS|NICHD Neonatal Research Network|Yes|Completed|February 2006|May 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|615|Samples Without DNA|Samples of the isolated pathogens|Both|N/A|72 Hours|Accepts Healthy Volunteers|Non-Probability Sample|All live born infants >400g birth weight delivered at NICHD Neonatal Research Network        participating hospitals|October 2015|November 6, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874367||141102|
NCT00875511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study #3480|Effects of a Computer Game on Activity Choices|||University at Buffalo|No|Completed|November 2008|September 2009|Actual|||N/A|Observational|N/A||1|Anticipated|40|||Both|18 Years|50 Years|No|Probability Sample|Adults between the ages of 18-50|April 2009|June 25, 2010|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875511||141015|
NCT00875524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD22|Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects|Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam||Sanofi|No|Completed|March 2009|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|180|||Both|2 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875524||141014|
NCT00877045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI OUTCOMES 01|Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting|Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting||SCRI Development Innovations, LLC|No|Completed|January 2008|February 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be        eligible. This will include current active patients as well as patients who have expired        and have medical chart available. Estimate reviewing approximately 300 charts total.|August 2010|August 3, 2010|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00877045||140898|
NCT00877331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34892-C|Brief Intervention in Primary Care for Problem Drug Use and Abuse|Brief Intervention in Primary Care for Problem Drug Use and Abuse||University of Washington|Yes|Completed|April 2009|September 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|868|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 17, 2014|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877331||140876|
NCT00876785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI829|Effect of Rye Bread Breakfasts on Eight Hour Satiety Ratings|Effect of Rye Bread Breakfasts on Subjective Hunger and Satiety||Swedish University of Agricultural Sciences|No|Completed|September 2007|May 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|32|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 13, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876785||140918|
NCT00876798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-LX3430|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia||CardioKine Inc.|Yes|Completed|June 2009|||November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||November 2010|June 20, 2011|April 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876798||140917|
NCT00877058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G213 194/08|SUPPORT FOR FRAIL ELDERLY PERSONS - From Prevention to Palliation|Elderly Persons at the Risk Zone - a Randomized Controlled Trial of a Community Based Preventive Multiprofessional Program for Old Persons at Risk of Frailty||Vardalinstitutet The Swedish Institute for Health Sciences|No|Completed|January 2008|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|459|||Both|80 Years|N/A|No|||June 2014|June 11, 2014|April 6, 2009||No||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00877058||140897|
NCT00877942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH083045-01|Sex Differences in Early Brain Development; Brain Development in Turner Syndrome|Sex Differences in Early Brain Development; Brain Development in Turner Syndrome||University of North Carolina, Chapel Hill|No|Completed|October 2006|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|295|Samples With DNA|For participating children with Turner Syndrome, subjects may participate in an optional      blood draw for DNA extraction and hormone assays.|Both|N/A|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|Control subjects are recruited from the Prenatal Diagnostic Clinic at UNC-Chapel Hill,        which performs over 12,000 prenatal ultrasound scans a year. Please note that all pregnant        women in North Carolina are referred for an ultrasound at gestational age 18 weeks as part        of routine prenatal care. Subjects with Turner syndrome are identified through the UNC        Turner Syndrome clinic, through advertisements with relevant local and national support        groups such as the Turner Syndrome Society, and through genetic counselors and other        relevant health professionals throughout the United States.|May 2014|May 1, 2014|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877942||140829|
NCT00877643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHS B 2008 035|Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure|Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3|RACE 3|University Medical Center Groningen|Yes|Recruiting|May 2009|July 2019|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|40 Years|N/A|No|||July 2015|July 27, 2015|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877643||140852|
NCT00877656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hx-CD4-109|HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma|An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma||Emergent BioSolutions|No|Completed|August 2005|December 2008|Actual|January 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2009|November 20, 2012|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00877656||140851|
NCT00878527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CircuLite CRP-001|Safety and Performance Evaluation of CircuLite Synergy|Safety and Performance Evaluation of the CircuLite Synergy Pocket Circulatory Assist Device||HeartWare, Inc.|Yes|Active, not recruiting|June 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2016|March 22, 2016|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878527||140786|
NCT00866840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000637646|Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Phase II Trial of Riluzole in Patients With Advanced Melanoma||Rutgers, The State University of New Jersey|No|Completed|April 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00866840||141671|
NCT00867490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPH100ADE01|Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothiazide 25 mg|AMAZING|Novartis||Completed|March 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|186|||Both|18 Years|N/A|No|||May 2011|May 4, 2011|March 20, 2009||No||No|January 7, 2011|https://clinicaltrials.gov/show/NCT00867490||141623|The Phases of this study were entered in separate tables for outcomes and the Phases for SAEs and the AEs were entered all in one table.
NCT00867932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-005|Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects|An Open Label Multi Center Study of Eculizumab in Children and Adolescents With Diagnosis of Paroxysmal Nocturnal Hemoglobinuria||Alexion Pharmaceuticals|No|Completed|May 2009|November 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|2 Years|17 Years|No|||November 2009|May 5, 2014|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00867932||141589|
NCT00867373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0329|Parent Perceptions of Weight Status: Impact of a Pilot Intervention|Parent Perceptions of Weight Status: Impact of a Pilot Intervention to Enhance Awareness of Risk for Overweight Parents and Their Children||University of Colorado, Denver|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|222|||Both|3 Years|13 Years|No|||April 2013|April 24, 2013|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00867373||141632|
NCT00876044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TES10897|A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients|A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc Interval in Cancer Patients Treated With Docetaxel|QUTIE|Sanofi|No|Completed|April 2009|November 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||December 2011|December 13, 2011|April 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00876044||140974|
NCT00866996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR008329|Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder|A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder||McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||Completed||December 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|1323|||Both|6 Years|12 Years|No|||March 2010|May 20, 2011|March 19, 2009||||No||https://clinicaltrials.gov/show/NCT00866996||141660|
NCT00867009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10726|A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer|A Phase 2 Study of Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) Other Than Predominantly Squamous Cell Histology||Eli Lilly and Company|No|Completed|April 2009|September 2014|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|No|||September 2014|May 20, 2015|March 20, 2009||No||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00867009||141659|
NCT00878774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR001|Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis|An Escalating, Multiple-dose Study in Ragweed Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Ragweed||Circassia Limited|No|Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|65 Years|No|||November 2010|November 9, 2010|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878774||140767|
NCT00874380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-036|Fiber Intake in an End Stage Renal Disease (ESRD) Population Followed Over 2 Years|Fiber Content of Hemodialysis Patients' Diet and it's Cardiovascular Implications.||Northwell Health|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|N/A|N/A|No|Non-Probability Sample|ESRD|May 2013|May 14, 2013|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874380||141101|
NCT00874952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIT-DUM-2007/1|Regional Observation of the Metabolic Syndrome|Regional Observation of the Metabolic Syndrome|ORSA|AstraZeneca|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1600|||Both|40 Years|74 Years|No|Non-Probability Sample|Primary care clinic|February 2010|February 16, 2010|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00874952||141058|
NCT00876057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0102|Psychological Well-being, Recovery and Sexuality After Total and Subtotal Hysterectomy|Subtotal Versus Total Abdominal Hysterectomy- a Prospective Randomised Comparison of Medical , Psychological and Sexual Effects.||University Hospital, Linkoeping|No|Completed|March 1998|April 2005|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|N/A|No|||June 2012|June 8, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876057||140973|
NCT00876070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI OUTCOMES 02|Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer|Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|November 2008|February 2011|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|198|||Female|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Metastatic Breast Cancer from January 2005 to three months prior        to site-specific protocol initiation will be eligible. This will include current/actively        being treated patients as well as patients who have previously completed therapy.|November 2011|November 18, 2011|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00876070||140972|
NCT00876135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|proto nage 2|Role of Airway Hyperresponsiveness on Performance in Elite Swimmers.|Role of Airway Hyperresponsiveness on Performance in Elite Swimmers: Efficiency of a Bronchodilator to Prevent an Exercise-induced Bronchoconstriction||Laval University|Yes|Completed|December 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|57|||Both|14 Years|N/A|No|||May 2013|May 9, 2013|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876135||140967|
NCT00876148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM Allo SCT|Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting|Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting||Azienda Ospedaliera San Giovanni Battista||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|18 Years|75 Years|No|Probability Sample|A cohort of patients undergoing allografting for hematological malignancies|April 2009|April 3, 2009|April 3, 2009||||No||https://clinicaltrials.gov/show/NCT00876148||140966|
NCT00876512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0124|CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study|CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study|CALDERA-PCI|Kumamoto University|No|Completed|December 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|Samples With DNA|CYP2C19 gene alteration is measured by using whole blood in patients with stable effort      angina undergoing PCI.|Both|20 Years|N/A|No|Probability Sample|Kumamoto University Hospital, Kumamoto Chuo Hospital and Saisekai Kumamoto Hospital|September 2014|September 8, 2014|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876512||140939|
NCT00876525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V10604|Clinical Investigation of the Freedom SOLO Stentless Heart Valve|Clinical Investigation of the Freedom SOLO Stentless Heart Valve||LivaNova|Yes|Active, not recruiting|March 2009|September 2017|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|700|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876525||140938|
NCT00877968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:017|Glycemic Responses and Sensory Characteristics of Whole Yellow Pea Flour Added to Novel Functional Foods|Glycemic Responses and Sensory Characteristics of Whole Yellow Pea Flour Added to Novel Functional Foods||University of Manitoba|No|Completed|March 2008|||May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Actual|23|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2009|April 7, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877968||140827|
NCT00878241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CAR-07-IL-01|Compression Anastomosis Using the CAR™ 27|||Bnai Zion Medical Center|No|Completed|June 2008|November 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2009|February 23, 2011|April 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00878241||140806|
NCT00877344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00363|Better Contraceptive Choices: Immediate or Delayed Insertion of IUC After Second Trimester Abortion|Better Contraceptive Choices: Immediate vs. Delayed Insertion of Intrauterine Contraception After Second Trimester Abortion||University of British Columbia|No|Active, not recruiting|June 2009|December 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|534|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 29, 2015|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00877344||140875|
NCT00874172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070605-OST07010|Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy|New Analgesic Strategy Combining Nitrous Oxide, Nefopam, Acetaminophen and Morphine Compared to the Usal Antalgic Strategy (Acetaminophen and Morphine) for the Treatment of Acute Sickle Cell Disease Pain in the Emergency Room|DREPANOX|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2009|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Male|18 Years|N/A|No|||November 2012|December 17, 2012|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874172||141117|
NCT00874185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481256|Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk|Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.|TIERRA|Pfizer|No|Completed|December 2007|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|720|||Male|18 Years|N/A|No|Non-Probability Sample|People with cv risk|February 2013|February 12, 2013|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874185||141116|
NCT00877955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131019|Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation|Open-label, Randomized, Single-dose, 2-way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet||Pfizer|No|Withdrawn|September 2012|October 2012|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|April 7, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00877955||140828|
NCT00878228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29015|Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy|Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy|PDNV|Hospital for Special Surgery, New York|Yes|Completed|April 2009|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|65 Years|No|||January 2013|January 28, 2013|April 7, 2009||No||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00878228||140807|
NCT00867503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1137-04|Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer|Open Label Phase II Trial of Bendamustine Hydrochloride (HCL) in Women With Advanced Ovarian Cancer||University of Arizona|Yes|Completed|February 2009|April 2013|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|March 20, 2009|Yes|Yes||No|October 1, 2012|https://clinicaltrials.gov/show/NCT00867503||141622|The team was not able to collect fresh tumor tissue at the time of the study, so we could not examine patient tumors to determine their DNA repair capabilities.
NCT00869011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUIR8687|Exercise for Patients With Renal Cell Cancer Receiving Sunitinib|Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)||Charite University, Berlin, Germany|No|Recruiting|December 2009|||June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|75 Years|No|||December 2009|December 21, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00869011||141507|
NCT00865137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG-506E-04-32|An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients|An Open-label, Single-centre Study to Assess the Effect of Food on the Relative Bioavailability of Orally Administered Tacrolimus Modified Release Formulation, FK506E (MR4), in Stable Kidney Transplant Recipients||Astellas Pharma Inc|Yes|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|March 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00865137||141800|
NCT00866086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634652|Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors|Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors||National Cancer Institute (NCI)||Recruiting|February 2009|||February 2010|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2009|April 18, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00866086||141728|
NCT00876980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-676|Obstructive Sleep Apnea and Diabetes Mellitus|The Effect of Nasal Continuous Positive Airway Pressure Treatment on Glycemic Control and Vascular Function in Patients With Obstructive Sleep Apnea and Type II Diabetes Mellitus.||The University of Hong Kong|Yes|Completed|May 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|25 Years|70 Years|No|||October 2013|October 15, 2013|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00876980||140903|
NCT00876408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI OUTCOMES 08|Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer|Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer: Role in Clinical Management and Primary Site Prediction||SCRI Development Innovations, LLC|No|Completed|May 2009|November 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 30 patients at Tennessee Oncology with unknown primary cancer have had        commercially available RT-PCR assays done on their tissue biopsy since the assay became        available in 2007. These patients are the subjects of this review.|December 2013|December 3, 2013|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876408||140947|
NCT00876421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-8539POE004|Study of ONO-8539 in Patients With Overactive Bladder|A Randomised, Multi-Centre, Double-Blind, Placebo and Active-Controlled, 5-Way Parallel Group Study to Investigate the Efficacy, Safety and Tolerability of ONO-8539 in Patients With Overactive Bladder||Ono Pharmaceutical Co. Ltd||Completed|April 2009|||April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|435|||Both|18 Years|80 Years|No|||June 2012|June 12, 2012|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00876421||140946|
NCT00876434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090116|Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti|Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveitis||National Institutes of Health Clinical Center (CC)||Completed|April 2009|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2011|September 26, 2015|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876434||140945|
NCT00875563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-541|Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study|Evaluation of the Safety and Effectiveness of the Zenith(R) Fenestrated AAA Endovascular Graft||Cook||Completed|January 2005|September 2015|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 19, 2009|Yes|Yes||No|June 30, 2015|https://clinicaltrials.gov/show/NCT00875563||141011|
NCT00876122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4254g|A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable|An Open-Label, Phase I, Dose-Escalation Study of PI3-Kinase Inhibitor (GDC-0941) in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable||Genentech, Inc.||Completed|March 2008|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00876122||140968|
NCT00875238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000613213|Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab|Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)|PACE in BC|Vanderbilt University|Yes|Recruiting|June 2008|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Serum, Plasma, Mononuclear Cells|Both|18 Years|85 Years|No|Non-Probability Sample|Persons with newly diagnosed breast cancer with planned anthracycline-based chemotherapy.|December 2014|December 1, 2014|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875238||141036|
NCT00876772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLN-ALS01|Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)|Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS)||Charite University, Berlin, Germany|No|Recruiting|March 2011|||July 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||March 2011|March 23, 2011|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00876772||140919|
NCT00877357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL/DTPwHBHib/WHOCON/2008/0100|Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine|Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants||Shantha Biotechnics Limited|No|Recruiting|January 2009|February 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3000|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||April 2009|May 5, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877357||140874|
NCT00877669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-10-038|Efficacy Study of HoLEP and TURP on LUTS Secondary to BPH|The Comparison of Efficacy Between Holmium Laser Enucleation of the Prostate (HoLEP) and Transurethral Resection of the Prostate (TURP) on the Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostate Hyperplasia (BPH)||Samsung Medical Center|No|Recruiting|October 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Male|50 Years|80 Years|No|||January 2014|February 12, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877669||140850|
NCT00877682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0244|Prostate Conformal Cryotherapy|Regional Cryoablation for Localized Adenocarcinoma of the Prostate||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2009|||April 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|N/A|N/A|No|||February 2016|February 12, 2016|April 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00877682||140849|
NCT00877981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPT02|Open Versus Video-Assisted Minimal-Invasive Parathyroid Surgery|Open Compared to Video-Assisted Minimal-Invasive Parathyroid Surgery in Primary Hyperparathyroidism||Uppsala University|No|Completed|February 2003|October 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|143|||Both|N/A|N/A|No|||April 2009|April 7, 2009|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877981||140826|
NCT00878566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005300|Alberta Clinical Trial in Optimizing Hypertension|Alberta Clinical Trial in Optimizing Hypertension: The RxAction Study|RxAction|University of Alberta|No|Completed|November 2009|March 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 25, 2015|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00878566||140783|
NCT00878553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOM201|Study of Sleep-maintenance Activity of 3 Doses of SKP-1041|A Phase 2, Double-Blind, Placebo-Controlled, Double-Dummy, Cross-Over Study to Investigate the Hypnotic Activity of Three Doses (10mg, 15mg, 20mg) of a New Zaleplon Prototype, SKP-1041, in Adults With Primary Insomnia||Somnus Therapeutics, Inc.|No|Completed|May 2010|August 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|67|||Both|21 Years|64 Years|No|||January 2013|January 30, 2013|March 19, 2009|Yes|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT00878553||140784|Questionnaires focused on initial insomnia as opposed to middle of the night awakening, short exposure to each dose, and lengthy washout periods between doses, may not allow for ideal assessment of subjective response to treatment.
NCT00874198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|european-nph-study-01|European Study on Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus|European Multicenter Study on the Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus||International Neuroscience Institute Hannover|No|Active, not recruiting|October 2004|June 2009|Anticipated|March 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|156|||Both|18 Years|N/A|No|||April 2009|April 2, 2009|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874198||141115|
NCT00874471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01EY015858|Uveitis Gene-Expression Profiling|||Oregon Health and Science University|No|Completed|June 2005|||July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||10|Actual|280|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals suffering from selected subtypes of uveitis, individuals suffering from        selected autoimmune disease and healthy individuals.|April 2014|April 7, 2014|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874471||141094|
NCT00874458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633336|MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ|Ductal Carcinoma in Situ: Protocol Evaluating the Assessment of Extension of Disease by MRI||Centre Antoine Lacassagne|No|Completed|April 2007|December 2013|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Female|18 Years|N/A|No|||July 2009|November 20, 2014|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874458||141095|
NCT00874770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-014|Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)|A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|June 2009|January 2011|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|April 2, 2009|Yes|Yes||No|August 6, 2015|https://clinicaltrials.gov/show/NCT00874770||141072|
NCT00867126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000637622|Pioglitazone as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Treatment With Gemcitabine|A Pilot Study of Pioglitazone as Second Line Therapy for Patients With Previously Treated Metastatic Adenocarcinoma of the Pancreas With Disease Progression After Gemcitabine Based Chemotherapy||National Cancer Institute (NCI)||Recruiting|February 2009|||February 2013|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2009|April 2, 2009|March 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867126||141651|
NCT00867139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2323.00|TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients|A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients||Fred Hutchinson Cancer Research Center|Yes|Completed|March 2009|January 2010|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Both|1 Year|N/A|No|||August 2013|August 8, 2013|March 20, 2009|No|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT00867139||141650|Study was terminated. Limitations of this study include: small sample size pilot study; inability to enroll the projected number of patients for full analysis before the study was terminated.
NCT00867152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112934|GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir|A Phase I, Open Label, Randomized, Three Period, One-way, Two Cohort, Adaptive Crossover Study to Evaluate the Effect of Darunavir/Ritonavir Plus Etravirine and Lopinavir/Ritonavir Plus Etravirine on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING112934)||ViiV Healthcare||Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|March 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00867152||141649|
NCT00867516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD518-CLIN-003|Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis|A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|ALD518-003|Alder Biopharmaceuticals, Inc.|No|Completed|October 2008|December 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|127|||Both|18 Years|80 Years|No|||September 2010|September 10, 2010|March 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00867516||141621|
NCT00865462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0646-004|A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Normal, Healthy Man Following a Standard Meal||Actavis Inc.|No|Completed|July 2004|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865462||141775|
NCT00865475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA 6108|Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC|A Randomized Comparative Clinical Trial of ZDV + 3TC + ABC (Trizivir) vs Monotherapy With Lopinavir/R (Kaletra) in Patients With Viral Suppression on Previous Treatment With ZDV + 3TC + ABC (Trizivir) for Preventing Lipoatrophy|KALIPO|Fundacion SEIMC-GESIDA|No|Completed|December 2008|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|March 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00865475||141774|
NCT00875810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESTIGE Observational Study|PRESTIGE Observational Study|PRESTIGE Observational Study||Medtronic Spinal and Biologics|No|Completed|April 2008|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|194|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with degenerative disc disease (DDD) who are scheduled to receive a cervical        arthroplasty.|January 2016|January 26, 2016|April 1, 2009||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00875810||140992|Low patient compliance at the 6 and 12 months follow up visits
NCT00875004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633325|Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors|Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy||National Cancer Institute (NCI)||Recruiting|December 2007|||November 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Supportive Care|1||Anticipated|300|||Both|18 Years|N/A|No|||July 2009|December 13, 2009|April 2, 2009||||No||https://clinicaltrials.gov/show/NCT00875004||141054|
NCT00875017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-128|Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers|An Open-label, Phase I, One-dose, One-meal, Balance Study Comparing the Absorption of Dietary Phosphorus When Administering FOSRENOL® (Lanthanum Carbonate) or RENVELA® (Sevelamer Carbonate) in Healthy Adult Volunteers||Shire|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|January 22, 2009|No|Yes||No|March 3, 2010|https://clinicaltrials.gov/show/NCT00875017||141053|
NCT00877266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US vs. NS Perineural Catheter|Ultrasound Guidance Versus Electrical Stimulation for Perineural Catheter Insertion|Ultrasound Guidance vs. Electrical Stimulation for Perineural Catheter Insertion: A Randomized, Controlled Trial||University of California, San Diego|No|Completed|August 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||April 2009|April 6, 2009|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00877266||140881|
NCT00877279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 90028-0717/1|Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft|A Randomized,Blinded,Controlled,Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero® Soft, After Superficial to Mid Dermal Implantation for Correction of Mild Facial Wrinkles Over 4 Weeks.||Merz Pharmaceuticals, LLC|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2013|October 23, 2013|April 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00877279||140880|
NCT00875576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB# 2354|Influence of Parents and Friends on Children and Adolescents|Influence of Parents and Friends on Children and Adolescents||University at Buffalo|No|Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|N/A||1|Anticipated|40|||Both|5 Years|14 Years|No|Probability Sample|Boys and girls ages 5-6 yrs and 12-14 yrs and their mothers.|April 2009|June 25, 2010|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875576||141010|
NCT00876499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0747|Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients|Relationship Among Fatigue, Symptoms, Melatonin and Sleep in PBT Patients Undergoing Radiation Therapy||M.D. Anderson Cancer Center|No|Completed|January 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals over 18 years of age with a primary brain tumor scheduled for radiation        therapy.|January 2015|January 7, 2015|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876499||140940|
NCT00877370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00022460|Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis|Pharmacokinetics of Invanz® (Ertapenem) in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis||University of Michigan|No|Completed|February 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|April 3, 2009||No||No|August 29, 2012|https://clinicaltrials.gov/show/NCT00877370||140873|
NCT00877695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Entre Culturas|Motiv82Change: an HIV Prevention Study for Young Latino Men|Young Hispanic Men "Entre Culturas": Navigating Culture, Identity and HIV Risk|Motiv82Change|Nova Southeastern University|Yes|Completed|August 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|200|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||February 2013|March 1, 2013|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00877695||140848|
NCT00877734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|baclofen-unc-0507|Efficacy and Tolerability of Baclofen for Alcohol Dependence|Phase IIIa Trial of Baclofen for Alcohol Dependence||University of North Carolina, Chapel Hill|No|Completed|April 2005|June 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|21 Years|65 Years|No|||April 2011|September 13, 2012|February 7, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00877734||140845|
NCT00874211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0702|S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases|S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment||Southwest Oncology Group|Yes|Active, not recruiting|December 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|Samples With DNA|Serum for banking & whole blood for DNA analysis and banking.|Both|N/A|N/A|No|Non-Probability Sample|SWOG membership and CCOP participants through CTSU.|March 2015|March 4, 2015|April 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00874211||141114|
NCT00878579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS-002-DDD|Percutaneous Dynamic Stabilization (PDS) System Versus Fusion for Treating Degenerative Disc Disease|A Study to Evaluate the Safety and Effectiveness of the PDS System to Treat Back Pain Associated With Degenerative Disc Disease||Interventional Spine, Inc.|No|Terminated|March 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||February 2013|February 19, 2013|April 7, 2009|Yes|Yes|Sponsor Termination|No||https://clinicaltrials.gov/show/NCT00878579||140782|
NCT00874224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-110|Surgical Recovery After Left Lateral Hepatic Sectionectomy: Laparoscopic Versus Open Surgery.|The ORANGE II Trial: An International Multicenter Randomised Controlled Trial of Optimised Surgical Recovery After Left Lateral Hepatic Sectionectomy: Open Versus Laparoscopic Surgery Within an Enhanced Recovery Programme|ORANGE II|Maastricht University Medical Center|Yes|Completed|January 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|110|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00874224||141113|
NCT00874484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB 2409|Enoxaparin as Treatment for Vulvodynia|Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia||Western Galilee Hospital-Nahariya|No|Completed|March 2009|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|19 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00874484||141093|
NCT00874497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-08-250|Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema|A Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Pharmacodynamics, Efficacy and Safety of 50 mg Tetomilast Administered as Oral Tablets in Patients With Chronic Obstructive Pulmonary Disease Associated With Emphysema THIS STUDY IS CLOSED TO ENROLLMENT AND NEW SITES|EMPHASIS|Otsuka Pharmaceutical Development & Commercialization, Inc.||Terminated|March 2009|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|40 Years|75 Years|No|||August 2015|August 6, 2015|March 31, 2009|Yes|Yes|Sponsor Terminated|No||https://clinicaltrials.gov/show/NCT00874497||141092|
NCT00867165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05522|Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) (Phase 3, Protocol No. P05522)||Merck Sharp & Dohme Corp.|Yes|Completed|May 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|6 Years|10 Years|No|||April 2015|April 20, 2015|March 20, 2009|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00867165||141648|
NCT00868088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT for Lip|Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip|A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip.||Tufts Medical Center|No|Completed|July 2009|September 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|March 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00868088||141577|
NCT00868361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAL-MB-100|A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel|A Phase 1 Open-label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male||Teva Pharmaceutical Industries|No|Terminated|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 15, 2009|March 24, 2009|No|Yes|Poor recruitment of fast and slow acetylators|No||https://clinicaltrials.gov/show/NCT00868361||141557|
NCT00865826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5253|Observational Study of Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals|Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals||AIDS Clinical Trials Group||Completed|December 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|801|Samples With DNA|Sputum samples and blood collection|Both|13 Years|N/A|No|Probability Sample|HIV-infected males and females who are not currently receiving ART|March 2015|March 17, 2015|March 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00865826||141748|
NCT00874692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPNPPT84|Health and Environmental Effects of Boiler Management Systems in Social Housing|Randomised Controlled Trial of Boiler Management Systems in Social Housing in Camden: An Assessment of Health, Environmental and Economic Outcomes||London School of Hygiene and Tropical Medicine|No|Completed|April 2009|November 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 1, 2010|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00874692||141077|
NCT00875589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6403-R|Eye Movement Recordings in the Diagnosis of Traumatic Brain Injury|Eye-movement Recordings in the Diagnosis of Traumatic Brain Injury||VA Office of Research and Development|No|Completed|April 2011|June 2014|Actual|December 2013|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult betwenn 18 and 55 years old with and without a diagnosis of MTBI|October 2015|October 15, 2015|April 1, 2009||No||No|September 10, 2015|https://clinicaltrials.gov/show/NCT00875589||141009|
NCT00875602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW ES-MRK-PROT-6|Evaluation of EverOn™ - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion|Evaluation of EverOn™ - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion||EarlySense Ltd.|No|Completed|April 2009|September 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2314|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875602||141008|
NCT00875290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GerberPumpStudy|The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children|Gerber Pump Trial: Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Real-Time Sensor Augmentation (RTSA) in 0-3 Years Old Diabetes Patients; A One Year Randomized Controlled Clinical Trial.|Gerber RTSA|Seattle Children's Hospital|No|Recruiting|November 2008|November 2014|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Months|3 Years|No|||August 2011|August 4, 2011|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875290||141032|
NCT00875303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN Feb 2008|Brief Primary Care Intervention Helps Parents With Discipline|Brief Primary Care Intervention Helps Parents With Discipline||Vanderbilt University|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|258|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00875303||141031|
NCT00876538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO19622 CL E Q 1204-1|Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy|A Double Blind, Placebo Controlled Study of the Effect of 330 mg QD of TRO19622 in the Treatment of Chemotherapy Induced Peripheral Neuropathy|CIPN|Trophos|No|Completed|March 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|80 Years|No|||December 2012|December 27, 2012|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00876538||140937|
NCT00876811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22069|Effect of Red Raspberry Consumption on Fasting Oxidative Stress Biomarkers|Raspberries and Human Health: A Short-term Intervention Trial Investigating the Effect of Daily Red Raspberry Consumption on Fasting Oxidative Stress Biomarkers||University of Toronto|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|24|||Both|18 Years|43 Years|Accepts Healthy Volunteers|||October 2010|October 28, 2010|April 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00876811||140916|
NCT00875849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633474|Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer|Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor Prognosis After Complete Surgical Resection||Centre Antoine Lacassagne|Yes|Completed|March 2008|December 2013|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||August 2012|November 20, 2014|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00875849||140989|
NCT00877071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08070016|LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed|LC Drug Eluting Bead for Regional Chemoembolization to Downstage Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation|HCC|University of Pittsburgh|Yes|Completed|November 2008|April 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|April 4, 2009||No||No|January 8, 2016|https://clinicaltrials.gov/show/NCT00877071||140896|
NCT00877708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#PRO08100393|Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol|Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol||University of Pittsburgh|Yes|Active, not recruiting|March 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Biologic samples (isolates) will be under the control of the principal investigator of this      research project. All samples provided to the investigator are de-identified by the honest      broker and will be coded with numbers. The information linking these code numbers to the      corresponding subjects' identities will be kept in a separate, secure location that only the      honest broker has access to. The investigator on this study will keep the samples      indefinitely. Samples will be kept in the investigator's laboratory located in Scaife Hall,      room 839, 3550 Terrace Street. At no time with the research investigators have access to any      patient identifers. Medical record information and bacteria samples from facilities outside      of UPMC will be provided to the PI de-identified. At not time will anyone on the research      team have access to patient identifiers. All information and bacteria are collected as part      of the patient's clinical treatment.|Both|18 Years|N/A|No|Probability Sample|patients with E. coli infections at UPMC|December 2015|December 16, 2015|April 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00877708||140847|
NCT00885586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuZoster Effectiveness 2006|Acupuncture in Herpes Zoster Neuralgia (ACUZoster)|Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia|ACUZoster|Ludwig-Maximilians - University of Munich|Yes|Recruiting|November 2008|December 2016|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|336|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885586||140250|
NCT00885014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCUPsychiatry002|Telephone Cognitive-Behavioral Therapy (CBT) for Subthreshold Depression and Presenteeism in Workplace|Telephone Cognitive-behavioral Therapy for Subthreshold Depression and Presenteeism in Workplace: a Randomized Controlled Trial||Kyoto University|Yes|Completed|April 2009|September 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|20 Years|57 Years|No|||March 2012|March 15, 2012|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885014||140294|
NCT00885287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMR/HQ/R.8a/Vol.IX/794|Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania|Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania|InterACT|University of Copenhagen|Yes|Completed|July 2009|January 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|830|||Both|15 Years|60 Years|No|||January 2013|January 15, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885287||140273|
NCT00885300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3705|Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients|Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients||Shiraz University of Medical Sciences|Yes|Completed|January 2008|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2009|April 20, 2009|April 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00885300||140272|
NCT00886392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM 1449/08.02.13|Diabetic Macular Edema Severity at Diagnosis|Distribution of Macular Edema Severity Level at the Moment of Diagnosis||Hospital Juarez de Mexico|No|Completed|June 2006|April 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|118|||Both|40 Years|70 Years|No|Non-Probability Sample|Target population were type 2 diabetic patients with CSME who attended general hospitals        of Mexico City and its metropolitan area; available population were patients with CSME        evaluated at a general hospital|April 2009|April 21, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886392||140188|
NCT00886626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902M59181|GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children|GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children: A Randomized, Controlled, Pilot Study||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|May 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|8 Years|19 Years|No|||October 2012|October 22, 2012|April 22, 2009|Yes|Yes||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00886626||140170|Small sample size; un-blinded; crossover study design
NCT00886873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mife_Fibroids_02|Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids|Mifepristone 5 mg Versus 10 mg During 6 Months for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial.|Mifemyo_2|Mediterranea Medica S. L.|Yes|Completed|May 2008|May 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|50 Years|No|||October 2014|October 16, 2014|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886873||140151|
NCT00892008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081094|A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin|Pregabalin (Lyrica) Action In Neuropathic Pain Syndrome (PAINS): A Post Marketing Surveillance Study On Efficacy, Safety And Tolerability Of Pregabalin|PAINS|Pfizer|No|Completed|September 2006|August 2008|Actual|August 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2278|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female, 18 years and above diagnosed with neuropathic pain.|January 2010|January 8, 2010|April 30, 2009||Yes||No|August 27, 2009|https://clinicaltrials.gov/show/NCT00892008||139762|
NCT00892021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3230A1-1003|Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder|An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Subjects With Schizophrenia or Schizoaffective Disorder||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|May 2009|October 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Anticipated|24|||Both|18 Years|50 Years|No|||July 2009|July 17, 2009|May 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892021||139761|
NCT00887679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011288|Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS|Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder, Adherence to Antiretroviral Therapy,Cognition, and Immune Status Among Patients With HIV and AIDS: A 6-week Open-label, Prospective, Pilot Trial.||Duke University|No|Completed|May 2009|September 2010|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||March 2014|October 23, 2014|April 23, 2009|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT00887679||140090|
NCT00888693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-752|A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia|||Abbott|No|Completed|November 2008|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|81|||Both|18 Years|60 Years|No|||October 2010|December 5, 2010|April 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888693||140014|
NCT00883974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preterm Sensitivity Training|Sensitivity Training For Parents of Preterm Infants|Early Sensitivity Training for Parents of Preterm Infants: Impact on the Developing Brain||University of Melbourne|No|Completed|April 2004|September 2005|Actual|August 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Female|N/A|N/A|No|||October 2009|October 28, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883974||140371|
NCT00883961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/029/09|Exercise Following Autologous Peripheral Blood Stem Cell Transplantation|||Charite University, Berlin, Germany|No|Recruiting|December 2009|September 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2009|December 21, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883961||140372|
NCT00885378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-080|Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, Twice Daily, in Combination With Metformin IR in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin IR Alone||AstraZeneca|No|Completed|May 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|78 Years|No|||May 2015|May 8, 2015|April 21, 2009|Yes|Yes||No|November 2, 2011|https://clinicaltrials.gov/show/NCT00885378||140266|
NCT00884494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#090362|Ghrelin and Insulin Resistance|Role of Ghrelin in the Improvement of Insulin Resistance After Roux-en-Y Gastric Bypass Surgery||Vanderbilt University|No|Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Plasma, DNA|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be selected from the Center for Surgical Weight loss at Vanderbilt        University Medical Center (Nashville, TN) after approval for Roux-en-Y gastric bypass        surgery. Control participants will be recruited via advertisements|March 2016|March 2, 2016|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884494||140332|
NCT00884507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN22018|A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease|A Dose-ranging, Randomized, Double-blind , Placebo-controlled Study of the Effect of RO5313534, Used as add-on Therapy to Donepezil, on Cognitive Function in Patients With Mild to Moderate Symptoms of Alzheimer's Disease||Hoffmann-La Roche||Completed|May 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|389|||Both|50 Years|N/A|No|||March 2016|March 1, 2016|April 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00884507||140331|
NCT00885937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13941|Comparative Safety Study of New Sinecort Formulation Versus Positive Control|Single-blind, Randomized, Controlled, Single Center Trial to Evaluate the Skin Irritation Potential of a New Topical Formulation by Means of an Occlusive Patch Test in Healthy Subjects.||Bayer|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 20, 2014|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885937||140223|
NCT00884169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-EU03|Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients|||Maruho Co., Ltd.||Completed|July 2009|December 2009||||Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind|||||||Both|18 Years|65 Years||||November 2010|November 2, 2010|April 17, 2009||||No||https://clinicaltrials.gov/show/NCT00884169||140357|
NCT00884182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPA12|Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children|Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children||Sanofi|No|Completed|April 2009|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|350|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00884182||140356|
NCT00884741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01670|Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma|Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2009|||March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|978|||Both|18 Years|N/A|No|||February 2015|July 29, 2015|April 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884741||140314|
NCT00884754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-594|Comparison of GlideScope-Specific Rigid Stylet to Standard Malleable Stylet for GlideScope Intubation by Novice Operators|Comparison of GlideScope-Specific Rigid Stylet to Standard Malleable Stylet for GlideScope Intubation by Novice Operators||Lawson Health Research Institute|No|Completed|March 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|60|||Both|18 Years|85 Years|No|||December 2010|December 13, 2010|April 20, 2009||No||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00884754||140313|
NCT00885898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40/11/04 UGoettingen|Out-of-Hospital Non-Invasive Ventilation for Patients With Acute Respiratory Failure|Out-of-Hospital Non-Invasive Ventilation in Patients With Acute Respiratory Insufficiency|NIV|University of Göttingen|No|Completed|March 2005|April 2009|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885898||140226|
NCT00885612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OKR-DUM-2009/1|10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)|10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors||AstraZeneca|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1114|||Female|50 Years|N/A|No|Probability Sample|Postmenopausal patients with early breast cancer, who are taking aromatase inhibitors no        longer than 6 months as an adjuvant treatment after surgery|June 2010|June 28, 2010|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885612||140248|
NCT00885313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1406-18-4|Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)|Study of Efficacy and Tolerability of Docosahexaenoic Acid (DHA) on Children Affected by Nonalcoholic Fatty Liver Disease (NAFLD).|EDACN|Bambino Gesù Hospital and Research Institute|Yes|Completed|March 2009|March 2011|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|4 Years|16 Years|No|||May 2011|May 12, 2011|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885313||140271|
NCT00886405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB332/08|Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer|Phase II Study That Evaluates Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer||National Institute of Cancerología|No|Recruiting|July 2006|January 2010|Anticipated|April 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2009|April 21, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886405||140187|
NCT00886912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-160/2008|Training in Hypoxia to Prevent Acute Mountain Sickness|Prevention of Acute Mountain Sickness (AMS) by Intermittent Hypoxic Training||Heidelberg University|No|Recruiting|June 2008|October 2009|Anticipated|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2009|June 24, 2010|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886912||140148|
NCT00883480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLAT|Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma|Tratamiento Individualizado en función de Las Mutaciones en EGFR y Del Nivel de expresión de BRCA1 en Pacientes Con Adenocarcinoma de pulmón Avanzado|SLAT|Spanish Lung Cancer Group|No|Completed|June 2005|November 2008|Actual|January 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|153|||Both|18 Years|N/A|No|||April 2009|April 16, 2009|December 22, 2008||No||No||https://clinicaltrials.gov/show/NCT00883480||140409|
NCT00886886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB373/08|Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)|Pharmacological Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacological Effects and Pharmacokinetics||University Hospital, Basel, Switzerland|Yes|Completed|April 2009|March 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886886||140150|
NCT00886899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-0002|Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)|Facilitated Antegrade Steering Technique in Chronic Total Occlusions|FAST-CTOs|BridgePoint Medical|Yes|Completed|March 2009|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|April 21, 2009|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00886899||140149|
NCT00892047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH083660-01A1|Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)|Incomplete Response in Late Life Depression: Getting to Remission|IRL GREY|University of Pittsburgh|No|Completed|August 2009|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|468|||Both|60 Years|N/A|No|||December 2015|December 16, 2015|April 29, 2009||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00892047||139760|limited number of participants older than 75, or members of racial/ethnic minority groups; limited follow-up period
NCT00888030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWW-0003|P-cresol: Correlation With Glomerular Filtration Rate and Outcome in Chronic Kidney Disease|||Chang Gung Memorial Hospital|Yes|Completed|May 2006|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|300|Samples Without DNA|Serum level of p-cresol and indoxyl sulfate|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|All CKD patients attended at out-patient department of nephrology were included for        analysis. The inclusion criteria were adults aged > 18 y/o or < 80 y/o; estimated GFR or        CCR < 60 ml/min; no spontaneous renal improvement or progression in past 3 months.|September 2012|September 5, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00888030||140064|
NCT00888043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004929|Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors|A Phase I/Biomarker Study of Bevacizumab in Combination With CNTO 95 in Patients With Refractory Solid Tumors|CNTO95/Avastin|Duke University|No|Completed|March 2009|January 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888043||140063|
NCT00888056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-01|Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease|Effect of Deep Brain Stimulation of the Hypothalamus/ Fornix on Memory Impairment in Patients With Alzheimer's Disease||Centre Hospitalier Universitaire de Nice|Yes|Recruiting|June 2009|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|50 Years|65 Years|No|||April 2009|June 26, 2012|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888056||140062|
NCT00889876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000461-28|Effect of Exercise or Metformin on Nocturnal Blood Pressure and Other Risk Factors for CVD Among Obese Adolescents|Effect of Exercise or Metformin on Nocturnal Blood Pressure and Other Risk Factors for Cardiovascular Disease (CVD) Among Obese Adolescents||Karolinska Institutet|Yes|Recruiting|February 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|13 Years|19 Years|No|||February 2011|February 3, 2011|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889876||139923|
NCT00889889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S203.2.004|Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.||Abbott|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1270|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2013|September 27, 2013|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889889||139922|
NCT00884832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005892|A Placebo-Controlled Study of Clonidine for Fecal Incontinence.|A Placebo-Controlled Study of Clonidine for Fecal Incontinence.||Mayo Clinic|No|Completed|October 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|75 Years|No|||January 2014|January 20, 2014|April 17, 2009|Yes|Yes||No|October 16, 2013|https://clinicaltrials.gov/show/NCT00884832||140307|
NCT00884234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL011LCL|Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Repeat Dose, Single Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines In Adults||Revance Therapeutics, Inc.|No|Completed|February 2009|June 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 25, 2013|April 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884234||140352|
NCT00885391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060908|QT Variability Pre and Post Cardioversion|QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation|DCCV|Vanderbilt University|No|Completed|January 2007|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|219|Samples With DNA|Blood sample|Both|21 Years|N/A|No|Probability Sample|Cardiology Clinic Hospital inpatient|December 2014|December 9, 2014|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885391||140265|
NCT00885664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC 30|Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection|Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection||University of Cincinnati|No|Active, not recruiting|October 2005|December 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2009|May 14, 2009|April 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00885664||140244|
NCT00884819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-573|Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome|Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial||Lawson Health Research Institute|No|Terminated|December 2008|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|45 Years|No|||April 2015|April 1, 2015|April 20, 2009|Yes|Yes|Poor recruitment|No||https://clinicaltrials.gov/show/NCT00884819||140308|
NCT00886184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0821|Intra-arrest Therapeutic Hypothermia in Prehospital Cardiac Arrest|Intra-arrest Therapeutic Hypothermia in Prehospital Cardiac Arrest. Impact on Biomarker of Brain Damage.|HITUPPAC-BIO|University Hospital, Grenoble|Yes|Completed|February 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886184||140204|
NCT00886444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMINI-1|Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran|Comparative Evaluation of Various CMR Pulse-Sequences for Macrophage Imaging Using Ferucarbotran as Molecular Contrast Agent in Human Myocardial Infarction||Robert Bosch Gesellschaft für Medizinische Forschung mbH|No|Completed|March 2009|||March 2010|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|80 Years|No|||November 2014|November 6, 2014|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886444||140184|
NCT00884780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 01-020E|Development of a New Electronic Measure of Pediatric Pain: A Pilot Study|Development of a New Electronic Measure of Pediatric Pain: A Pilot Study||Children's Mercy Hospital Kansas City|No|Completed|April 2009|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|8 Years|17 Years|No|Probability Sample|Presentation to either Abdominal Pain Clinic or Integrative Pain Management Clinic. A        total of ten patients from each clinic, five (5) aged 8-12 and five (5) aged 13-17.|July 2013|July 30, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884780||140311|
NCT00885040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090118|Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders|Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|95|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|April 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00885040||140292|
NCT00884455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AATD Tissue Bank|Alpha-1 Foundation DNA and Tissue Bank|Alpha-1 Foundation DNA and Tissue Bank||University of Florida|No|Enrolling by invitation|December 2002|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|blood, liver and lung|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|subjects with alpha-1-antitrypsin deficiency, carriers of deficient alleles and interested        individuals|April 2015|April 14, 2015|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884455||140335|
NCT00884468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A5-4468|Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis|Anxiety and Depression in Patients With Psoriatic Arthritis: Prevalence and Characteristics||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|384|||Both|18 Years|N/A|No|Probability Sample|Patients with PsA from outpatient's surgery or primary health care centres|May 2009|May 26, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00884468||140334|
NCT00885326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000638257|N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma|A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma||New Approaches to Neuroblastoma Therapy Consortium|Yes|Active, not recruiting|December 2009|May 2016|Anticipated|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|30 Years|No|||December 2015|December 11, 2015|April 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00885326||140270|
NCT00885339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-109|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure||Given Imaging Ltd.|No|Completed|February 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients that are indicated for colonoscopy, who are suspected or known to suffer from        colonic diseases|March 2010|March 10, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885339||140269|
NCT00885599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gingival-ST2|Efficacy of a Naturally-derived Mouthrinse for Gingival Inflammation|A Randomized Multi-treatment/Controlled Double-blinded Study to Evaluate the Efficacy of a Naturally-derived Mouthrinse in the Treatment of Gingival Inflammation.||Shaare Zedek Medical Center|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|94|||Both|14 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885599||140249|
NCT00885911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01196|Evaluation of the Intubating Laryngeal Airway in Children|Evaluation of the Intubating Laryngeal Airway in Children - Phase 1||University of British Columbia|No|Completed|March 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|N/A|16 Years|Accepts Healthy Volunteers|Probability Sample|Perioperative safety for children. A device that would be an invaluable addition to        difficult pediatric airway management plans, increasing the likelihood of quickly and        effectively securing the difficult airway, and decreasing the risk of catastrophic        hypoxemia.|September 2012|September 27, 2012|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885911||140225|
NCT00886132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC-Siu 2006|A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands|A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands||University Health Network, Toronto|Yes|Completed|January 2007|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 22, 2015|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886132||140208|
NCT00887224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-3360|Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder|A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder||Pfizer|No|Completed|June 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|874|||Both|18 Years|N/A|No|||May 2012|November 6, 2014|April 22, 2009|Yes|Yes||No|March 6, 2012|https://clinicaltrials.gov/show/NCT00887224||140125|P-value from the primary analysis is different from the one testing equality of relapse rates on Double-blind day 185. Estimated percentages were provided as representative descriptive measures. Medians were not estimable due to low relapse rates.
NCT00884026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-03019|Can Augmentation Index (AIx) be Used to Predict Hypotension After Spinal Anesthesia?|Pulse Wave Analysis and Augmentation Index Changes Associated With Neuraxial Anesthesia in the Parturient||University of British Columbia|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|56|||Female|19 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00884026||140367|
NCT00888368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHMC07-0387|Accuracy of the Transpatellar Tendon Approach to Knee Arthrocentesis|||Denver Health and Hospital Authority||Completed|January 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||July 2012|July 11, 2012|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888368||140039|
NCT00888381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-NHF-09-57|A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2009/2010 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged ≥ 18 to < 60 Years) and 'Older Adults' (Aged ≥ 60 Years).||CSL Limited||Completed|May 2009|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 27, 2015|April 24, 2009|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00888381||140038|
NCT00888069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP101-CL-2004|Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects|A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT||OPKO Health, Inc.|No|Completed|May 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|80 Years|No|||February 2010|September 29, 2014|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888069||140061|
NCT00888966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAM 2009-2|Oxidative Stress and Cardiac Arrest|Evaluation of Oxidative Stress After Out of Hospital Cardiac Arrest Treated With Moderate Hypothermia||Institut d'Anesthesiologie des Alpes Maritimes|No|Completed|April 2006|December 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Plasma|Both|18 Years|80 Years|No|Non-Probability Sample|community sample|June 2011|June 30, 2011|April 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00888966||139993|
NCT00884845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM2734-A-003-08|Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors|Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors||PharmaMar|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884845||140306|
NCT00885079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037E-08-001|Confirmatory Study of OPC-12759 Ophthalmic Suspension|Confirmatory Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients||Otsuka Pharmaceutical Co., Ltd.|No|Completed|May 2009|April 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Both|20 Years|N/A|No|||November 2013|November 18, 2013|April 19, 2009||No||No|September 12, 2013|https://clinicaltrials.gov/show/NCT00885079||140289|
NCT00885092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-082|Single Site Study of the Wettability of Contact Lenses With an Investigational Multi-Purpose Disinfecting Solution vs. a Marketed Multi-Purpose Solution|Wettability of Silicone Hydrogel Lenses With SiH MPDS FID 114675A vs. A Marketed Multi-Purpose Solution||Alcon Research|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|April 17, 2009|Yes|Yes||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00885092||140288|
NCT00886678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH01|A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)|A Phase II Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer|NSCLC|Zhejiang Cancer Hospital|Yes|Active, not recruiting|July 2008|July 2010|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|70 Years|No|||March 2010|February 23, 2011|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00886678||140166|
NCT00885651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-5-23-9-3-8-15|Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines|A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects.|MEXICHO|Rigshospitalet, Denmark|Yes|Enrolling by invitation|September 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2009|April 21, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885651||140245|
NCT00887263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUM-5/GVH|Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)|Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD||Dr. Falk Pharma GmbH|Yes|Completed|March 2009|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887263||140122|
NCT00885053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADIPOMEGA|Fish Oil and Inflammation in Overweight Subjects|The Effect of Acute and Short-term Intervention With Fish Oil on Overweight Subjects - Focus on Inflammation|ADIPOMEGA|Aalborg Universitetshospital|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||December 2009|January 25, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885053||140291|
NCT00885027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527.80|MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment|Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment||Boehringer Ingelheim||Completed|March 2009|||April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1342|||Male|40 Years|N/A|No|Probability Sample|men >=40 years old with BPH|November 2013|November 13, 2013|January 20, 2009||||No||https://clinicaltrials.gov/show/NCT00885027||140293|
NCT00885924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.947|Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery|Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery||St. Olavs Hospital|No|Terminated|March 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|April 2, 2009||No|to include required number of patients took too much time|No||https://clinicaltrials.gov/show/NCT00885924||140224|
NCT00886158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Viral PTLD|Virus Surveillance in Pediatric Solid Organ Transplant Recipients|Virus Surveillance in Pediatric Solid Organ Transplant Recipients: Identifying Risk Factors for PTLD and Other Complications Post-Transplant||Seattle Children's Hospital|No|Recruiting|June 2001|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood, urine, kidney biopsy tissue|Both|N/A|21 Years|No|Non-Probability Sample|Solid organ transplant recipients receiving their care at Seattle Children's Hospital|July 2011|July 20, 2011|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00886158||140206|
NCT00886145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-10|Effect of Vibration Therapy on Bone in Persons With Sub-acute Spinal Cord Injury|Effect of Using Low-magnitude High Frequency Mechanical Stimulation of Bone in Persons With Subacute SCI||James J. Peters Veterans Affairs Medical Center|No|Completed|June 2009|December 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1|||Male|18 Years|65 Years|No|||March 2015|March 30, 2015|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886145||140207|
NCT00887471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-095|Comparison of Sleep Study Results After Partial Intracapsular Tonsillectomy Versus Total Tonsillectomy|Comparison of Polysomnography Outcomes for Microdebrider-assisted Partial Intracapsular Tonsillectomy Versus Total Tonsillectomy||State University of New York - Downstate Medical Center|No|Completed|August 2006|January 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|6 Months|14 Years|No|Non-Probability Sample|Children treated at the SUNY Downstate Medical Center or the Long Island College Hospital        in Brooklyn, NY for sleep-disordered breathing documented by positive polysomnography by        either Partial Intracapsular Tonsillectomy and Adenoidectomy or complete Tonsillectomy and        Adenoidectomy between 2003 and 2008.|June 2012|December 20, 2013|March 28, 2008||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00887471||140106|Selection bias, sample size limitation as it the study was not powered to detect small differences between the groups, and the use of unattended home PSG instead of laboratory-based PSG.
NCT00885144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iLiNS-ACCEPT-M|Trial on the Acceptability of Modified Lipid Based Nutrient Supplements Among Malawian Infants|Differential Acceptability of New Lipid Based Nutrient Supplement (LNS) Formulations for Prevention of Moderate Malnutrition|iLiNS-ACCEPT-M|University of Tampere|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|19|||Both|8 Months|12 Months|Accepts Healthy Volunteers|||June 2009|June 23, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885144||140284|
NCT00887458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0932|A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy|A Randomized Phase II Clinical Trial of Two Dose-levels of Itraconazole in Patients With Metastatic Castration-resistant Prostate Cancer||Johns Hopkins University|Yes|Completed|July 2009|December 2013|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Male|18 Years|N/A|No|||January 2014|January 28, 2014|April 23, 2009||No||No|December 11, 2013|https://clinicaltrials.gov/show/NCT00887458||140107|
NCT00883467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC in MRI 040908|The Effects of Preconditioning on Intramuscular High-Energy Phosphate Levels During Ischemia|The Effects of Preconditioning on Intramuscular High-Energy Phosphate Levels During Ischemia|IPC in MRI|Medical University of Vienna||Active, not recruiting|May 2008|||June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2009|April 16, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883467||140410|
NCT00888407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614458-3|Community-based Hepatitis B Interventions for Hmong Adults|Community-based Hepatitis B Interventions for Hmong Adults||University of California, Davis|No|Completed|September 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1500|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888407||140036|
NCT00888979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCK002885HU|Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy|Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy||Hartford Hospital|No|Recruiting|April 2009|November 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 23, 2010|April 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888979||139992|
NCT00888992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812-77B|Technology-Enhanced Quitline Services to Prevent Smoking Relapse|Technology-Enhanced Quitline Services to Prevent Smoking Relapse|TEQ|Indiana University|No|Completed|April 2010|March 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1785|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888992||139991|
NCT00889278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0748|Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation|Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|February 2008|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|Samples With DNA|10cc Peripheral Blood|Both|18 Years|N/A|No|Non-Probability Sample|Lymphoma patients of Dartmouth Hitchcock Medical Center's Norris Cotton Cancer Center        schedule to receive APBSCT.|September 2015|September 16, 2015|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00889278||139969|
NCT00889291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Abbs|HeRO Vascular Access Device Post Market Procedural Survey Protocol|HeRO Vascular Access Device Post Market Procedural Survey Protocol|PPS|Hemosphere, Inc.|No|Completed|December 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|77|||Both|N/A|N/A|No|Non-Probability Sample|End stage renal disease patients requiring vascular access|April 2009|April 28, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00889291||139968|
NCT00889304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-O-H-0702|Position HTO Multicenter NIS|Study on Quality of Life in Patients With Unicompartmental Arthrosis After High Tibial Osteotomy With the Position HTO(R) System|Position HTO|Aesculap AG|No|Completed|July 2007|June 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|221|||Both|18 Years|N/A|No|Probability Sample|adult patients|July 2011|July 21, 2011|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889304||139967|
NCT00886197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707042R|Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease|Diagnostic Efficacy of Narrow Band Imaging (NBI) in Patients With Gastroesophageal Reflux Disease (GERD)||National Taiwan University Hospital|No|Completed|September 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|20 Years|70 Years|No|Non-Probability Sample|1. Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years             old.          2. Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least             3 times per week in recent 4 months.|April 2009|April 21, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886197||140203|
NCT00885105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC32|Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age|Evaluation of Serologic Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® Vaccine at 2 Months of Age||Sanofi|No|Completed|October 2005|September 2007|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|242|||Both|6 Months|11 Months|Accepts Healthy Volunteers|||January 2014|January 17, 2014|April 20, 2009|Yes|Yes||No|September 2, 2009|https://clinicaltrials.gov/show/NCT00885105||140287|
NCT00885118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.15|4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)|A Phase II, Randomised, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Once Daily Oral Administration of BI 10773 (1 mg, 5 mg, 10 mg, and 25 mg) for 28 Days in Japanese Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Completed|April 2009|||October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|100|||Both|20 Years|70 Years|No|||November 2014|November 13, 2014|April 20, 2009||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT00885118||140286|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information”.
NCT00887523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/184|Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis|Randomized Controlled Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis||University Hospital, Ghent|No|Recruiting|July 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|N/A|No|||June 2015|June 2, 2015|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887523||140102|
NCT00887536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-46-I|A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer|A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer||NSABP Foundation Inc|Yes|Active, not recruiting|May 2009|January 2022|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3900|||Female|18 Years|70 Years|No|||June 2015|June 24, 2015|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887536||140101|
NCT00885950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-4-076|Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants|Prevention of the Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-based Neoadjuvant Chemotherapy for Colorectal Liver Metastases by Means of Anticoagulants||Maastricht University Medical Center|Yes|Completed|January 2008|June 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|80|Samples Without DNA|Paraffin embedded liver tissue|Both|18 Years|N/A|No|Probability Sample|Patients suffering from colorectal liver metastases who have undergone a partial hepatic        resection|February 2014|February 3, 2014|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885950||140222|
NCT00885963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC682-08|A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer|A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer||Cyclacel Pharmaceuticals, Inc.|No|Terminated|December 2008|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|March 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00885963||140221|
NCT00885352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-128|Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and Pioglitazone||Merck Sharp & Dohme Corp.|No|Completed|April 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|313|||Both|18 Years|78 Years|No|||July 2015|July 27, 2015|April 20, 2009|Yes|Yes||No|November 4, 2011|https://clinicaltrials.gov/show/NCT00885352||140268|
NCT00885365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMA-0631-PR-0010 Core|A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®|A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa|CT03 Core|Chiesi Farmaceutici S.p.A.|No|Completed|April 2009|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|324|||Both|6 Years|N/A|No|||June 2014|June 19, 2014|April 20, 2009||No||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00885365||140267|
NCT00885625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200805005M|7-valent Pneumococcal Conjugated Vaccination|1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection|PCV|National Taiwan University Hospital|Yes|Recruiting|March 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|350|||Both|18 Years|N/A|No|||June 2010|July 14, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885625||140247|
NCT00885638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lund University Diabetes 001|Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion|Study of the Effect of Sitagliptin on the Hormonal Responses to Macronutrient Ingestion in Healthy Volunteers||Lund University|No|Completed|August 2009|September 2012|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 25, 2013|April 21, 2009||No||No|September 21, 2012|https://clinicaltrials.gov/show/NCT00885638||140246|
NCT00886652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIS-301/08|An Aerobic Exercising Program on Respiratory Muscle Strength in Patients With Adolescent Idiopathic Scoliosis|Results of an Aerobic Exercising Program on Respiratory Muscle Strength in Patients With Adolescent Idiopathic Scoliosis: a Randomized, Controlled Trial||Irmandade da Santa Casa de Misericordia de Sao Paulo|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|10 Years|20 Years|No|||April 2009|February 25, 2016|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886652||140168|
NCT00886925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFAE|Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis|Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy.|ALFAE|Hospital Universitari Vall d'Hebron Research Institute|No|Completed|March 2009|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|85 Years|No|||April 2012|December 14, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886925||140147|
NCT00886938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0551|rTMS To The Dorsolateral Prefrontal Cortex For Patients With Subjective Idiopathic Tinnitus. A Pilot Study|rTMS To The Dorsolateral Prefrontal Cortex For Patients With Subjective Idiopathic Tinnitus. A Pilot Study||Washington University School of Medicine|Yes|Completed|June 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|No|||May 2014|May 7, 2014|April 22, 2009||No||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00886938||140146|Open label study.
NCT00886418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/28|Influence of Muscle Relaxation on a Closed-loop Anesthesia System|Effect of Continuous Myorelaxation on the Need for Hypnotic Agent During Surgical Procedures Which do Not Require it (Multicenter, Randomized and Prospective Study)|Drone-Curare|Hopital Foch|No|Recruiting|December 2009|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|April 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00886418||140186|
NCT00886639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGL O2|Effect of Oxygen-supply on 6-Minute-Walking-Distance of COPD III/IV-patients|Effect Of Oxygen-Supply On The 6-Minute-Walking-Distance in Patients With Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage III/IV Before And After A Multimodal Rehabilitation||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|December 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|127|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|April 21, 2009||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00886639||140169|
NCT00883753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA22460|An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy|An Extension Phase of the Multi-National Open-Label Study (MA21573) to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.||Hoffmann-La Roche||Completed|March 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|934|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|April 17, 2009||No||No|June 18, 2014|https://clinicaltrials.gov/show/NCT00883753||140388|
NCT00886223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSA-RobPex1|Laparoscopic Sacropexy With Robot-Assisted Surgical System|Laparoscopic Sacropexy: Clinical Prospective Study With Robot-Assisted Technique(da Vinci®-System)|RobPex|Kantonsspital Aarau|No|Recruiting|April 2009|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 23, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886223||140201|
NCT00883727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRPL/AMI/07-08/001|Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI|A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intravenous ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With st Elevated Acute Myocardial Infarction (Stemi)||Stempeutics Research Pvt Ltd|Yes|Completed|April 2009|August 2012|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|70 Years|No|||March 2013|March 4, 2013|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883727||140390|
NCT00888745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[]4623g|A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis||Genentech, Inc.||Completed|May 2009|||June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|75 Years|No|||November 2010|November 29, 2010|April 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888745||140010|
NCT00885976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F081114005|The Predictors and Patient Versus Parental Perceptions of Health-Related Quality of Life in Pediatric Chronic Pain|The Predictors and Patient Versus Parental Perceptions of Health-Related Quality of Life in Pediatric Chronic Pain||University of Alabama at Birmingham||Completed|September 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|||Both|8 Years|18 Years|No|Non-Probability Sample|Participants will come from those patients evaluated and treated in the Pediatric Chronic        Pain Medicine Clinic at the Children's Hospital facilities. The likely study population        includes essentially the pediatric population of the entire state of Alabama and        immediately adjacent states (i.e., the geographic catchment area of the Children's        Hospital of Alabama).|June 2013|June 25, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885976||140220|
NCT00885989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S338.1.002|Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers|A Placebo-Controlled, Combined Single and Multiple Rising Dose Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV338 After Intravenous Administration in Healthy Male Subjects||Solvay Pharmaceuticals|No|Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 28, 2010|January 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00885989||140219|
NCT00886977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YAM80-01|Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)|Pilot-Study of YAM80 in Amyotrophic Lateral Sclerosis. Evaluation of the Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)||Yoshino Neurology Clinic|No|Active, not recruiting|April 2009|||December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|25 Years|65 Years|No|||April 2009|October 22, 2010|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886977||140143|
NCT00886990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 086|Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens|Comparing the Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens for Children Failing Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Treatment||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|240|||Both|1 Year|18 Years|No|Non-Probability Sample|Data of children who satisfy the following eligibility criteria will be included.|April 2009|May 14, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886990||140142|
NCT00886470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCS-PT-09.001|ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns|Phase I/II Randomized Blinded Safety and Dose-determining Efficacy Trial Comparing Accs (Amnion-derived Cellular Cytokine Solution) in 3 Different Regimens With Standardized Care 0.9% Nacl in the Topical Treatment of Partial-thickness Burns||Stemnion, Inc.|Yes|Terminated|June 2009|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|17|||Both|18 Years|65 Years|No|||October 2012|October 11, 2012|April 22, 2009|Yes|Yes|This study was terminated early due to slow accrual of patients.|No||https://clinicaltrials.gov/show/NCT00886470||140182|
NCT00894855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14598|Skin Cancer Screening and Education at Beaches|Skin Cancer Screening and Education Program at Beaches|SHADE|Dana-Farber Cancer Institute|No|Completed|January 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|634|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 30, 2014|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894855||139550|
NCT00894868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23118|Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure|A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure||Novartis||Completed|May 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|798|||Both|18 Years|85 Years|No|||April 2014|April 24, 2014|May 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00894868||139549|
NCT00894881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-NV-0080-CTIL|The Effect of Colonoscopy on Resting Energy Expenditure|The Effect of Colonoscopy on Resting Energy Expenditure||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals before colonoscopy|May 2009|May 6, 2009|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894881||139548|
NCT00886964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 107|Hepatitis B Vaccination (HBV) in HIV Infected Children|Immunogenicity and Safety of Intradermal Compare to Intramuscular Hepatitis B Vaccination in HIV Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|1 Year|18 Years|No|||June 2010|June 4, 2010|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886964||140144|
NCT00883519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5758|The Efficacy of Parent Involvement in the Treatment of Adolescent Depression|The Efficacy of Parent Involvement in the Treatment of Adolescent Depression||New York State Psychiatric Institute|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|12 Years|17 Years|No|||April 2012|April 12, 2012|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883519||140406|
NCT00883779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22201|A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer||Hoffmann-La Roche||Completed|April 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|451|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|April 15, 2009||No||No|November 10, 2015|https://clinicaltrials.gov/show/NCT00883779||140386|
NCT00886171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB#2175|Effects of Social Skills and Physical Activity Training on Recreational Activities in Youth|Effects of Social Skills and Physical Activity Training on Recreational Activities in Youth||University at Buffalo|No|Completed|September 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|12 Years|14 Years|No|||September 2011|September 28, 2011|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886171||140205|
NCT00886457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVCI-0725|5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates|Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-Deoxycytidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron): A Phase I Study With Molecular Correlates||Nevada Cancer Institute|Yes|Terminated|April 2009|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|April 21, 2009|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00886457||140183|
NCT00886431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitrification study|Vitrification Versus Slow Cooling of Human Cleavage Stage Embryos|A Double Blinded, Randomised Controlled Trial Comparing the Effectiveness of Vitrification to Slow Cooling in Cryopreserving Human Preimplantation Embryos||UMC Utrecht|No|Terminated|May 2009|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886431||140185|
NCT00887250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_580|A Study to Investigate the Antihypertensive Efficacy of MK0954|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan (MK954, DuP753) in Patients With Mild to||Merck Sharp & Dohme Corp.||Completed|December 1991|November 1992|Actual|August 1992|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|366|||Both|21 Years|N/A|No|||July 2009|July 8, 2009|April 22, 2009|Yes|Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00887250||140123|Safety has been reported in the literature.
NCT00887484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114544|A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne|A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris||GlaxoSmithKline|No|Completed|February 2009|July 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|21 Years|N/A|No|||November 2012|November 6, 2012|April 23, 2009||No||No|September 22, 2010|https://clinicaltrials.gov/show/NCT00887484||140105|
NCT00887497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6618|Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery|Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery||University of California, Irvine|Yes|Terminated|April 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|April 22, 2009||No|terminated due to failure to enroll patients after two years of approval|No||https://clinicaltrials.gov/show/NCT00887497||140104|
NCT00883493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00055|Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression|A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination With Lithium in the Treatment of Patients With Acute Bipolar Depression|QUALITY|AstraZeneca|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|65 Years|No|||July 2012|July 2, 2012|April 16, 2009|Yes|Yes||No|February 29, 2012|https://clinicaltrials.gov/show/NCT00883493||140408|
NCT00887237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIV|Triple Site Ventricular Stimulation for Cardiac Resynchronization Therapy (CRT) Candidates|Triple Site Ventricular Stimulation for CRT Candidates|TRIV|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|May 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887237||140124|
NCT00893672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCR06006|Comparison of Two Chest Radiograph Prescription Strategies in Intensive Care Unit|A Cluster-Randomized Two-Period Cross-Over Study Comparing Routine and on-Demand Prescription of Chest Radiographs in Mechanically Ventilated Adults : the RARE Study|RARE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2006|April 2009|Actual|August 2007|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|849|||Both|18 Years|N/A|No|Probability Sample|All newly admitted adult patients receiving mechanical ventilation at the time of the        morning visit in ICU|May 2009|May 5, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893672||139641|
NCT00894244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU1178|Quantitative Evaluation of Skin Shrinkage Caused by a Non-invasive Tightening Device|Quantitative Evaluation of Skin Shrinkage Caused by a Non-invasive Tightening Device||Northwestern University|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|May 5, 2009|Yes|Yes||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00894244||139597|
NCT00884286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-B-013-02|Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma|A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma||PharmaMar|No|Completed|December 2004|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||February 2011|February 10, 2011|April 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884286||140348|
NCT00884585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192371-016|Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis|||Allergan|No|Completed|May 2009|July 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|176|||Both|12 Years|N/A|No|||November 2012|November 2, 2012|April 17, 2009|Yes|Yes||No|September 27, 2012|https://clinicaltrials.gov/show/NCT00884585||140326|
NCT00888095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBS in the caudal Zona incerta|Deep Brain Stimulation (DBS) For Parkinson's Disease: Caudal Zona Incerta Versus Subthalamic Nucleus|The Clinical Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) Versus Bilateral Deep Brain Stimulation of the Caudal Zona Incerta (cZI-DBS) in Patients With Idiopathic Parkinson's Disease||Charite University, Berlin, Germany|Yes|Not yet recruiting|July 2010|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||July 2009|July 21, 2009|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888095||140059|
NCT00888108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-338|Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer|A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere® (Docetaxel) in the Treatment of Subjects With Solid Tumors||Abbott||Completed|July 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888108||140058|
NCT00888134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00576|Selumetinib in Cancers With BRAF Mutations|Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Cancers With BRAF Mutations Identified by Prospective Genotypic Analysis||National Cancer Institute (NCI)|Yes|Completed|July 2009|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||July 2015|December 10, 2015|April 23, 2009|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT00888134||140057|
NCT00890747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02208|Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy|A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy||National Cancer Institute (NCI)||Completed|August 2009|||May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2013|March 14, 2014|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890747||139856|
NCT00886691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0186G|Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Gynecologic Oncology Group|Yes|Active, not recruiting|December 2010|||June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||May 2013|May 28, 2013|April 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00886691||140165|
NCT00887289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.659|Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)|Non-interventional Observational Study on the Influence of Pramipexole (PPX) on Sensory Symptoms of Restless Legs Syndrome (RLS)||Boehringer Ingelheim||Completed|April 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1504|||Both|18 Years|N/A|No|Non-Probability Sample|RLS patients|March 2014|June 17, 2014|July 29, 2008||||No|October 12, 2010|https://clinicaltrials.gov/show/NCT00887289||140120|
NCT00887276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2005-000771-18|Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia|Prospective, Doubleblind, Randomized Multicenter Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia|PENCAP|University of Ulm|No|Terminated|November 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|290|||Both|18 Years|N/A|No|||January 2010|December 16, 2014|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887276||140121|
NCT00896766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL06B1|Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia|Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk ALL Pilot Project: Application of Array-Based Methods and Gene Re-Sequencing to Identify Candidate Molecular Targets for High-Risk Pediatric Acute Lymphoblastic Leukemia||Children's Oncology Group|No|Recruiting|July 2006|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Both|1 Year|21 Years|No|Non-Probability Sample|Targets for High-Risk Pediatric Acute Lymphoblastic Leukemia|November 2015|November 2, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896766||139406|
NCT00895128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0555|Study of Erlotinib in Combination With Dasatinib|A Phase I Dose-Escalation Study of Erlotinib in Combination With Dasatinib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.||M.D. Anderson Cancer Center|No|Completed|April 2009|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895128||139529|
NCT00895427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2709|A Study Comparing Skin Fluorescence to Coronary Artery Calcification|A Cross-Sectional Study Comparing Noninvasive Skin Fluorescence to Coronary Artery Calcification Measured by Rapid Computed Tomography|CACS|VeraLight, Inc.|No|Completed|February 2009|September 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||12|Anticipated|240|||Both|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects are sorted into the follwoing categories for age (years): men:45-54,55-64,65+,        women: 50-59, 60-69, 70+. In addition, subjects will be sorted into the follwoing        categories for CACS:0-10, 11-100, 101-400, 401-1000, >1000 and absence/presence of        diagnosed diabetes (type 1 or type 2)|October 2011|October 7, 2011|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895427||139506|
NCT00895700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVT-MP-001|Internet-based Intervention in Cardioverter-defibrillator Patients to Enhance Quality of Life|WEB-based Distress Management Program for Implantable CARdioverter dEfibrillator Patients (WEBCARE) Trial|WEBCARE|University of Tilburg|No|Recruiting|March 2010|February 2014|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|350|||Both|18 Years|75 Years|No|||June 2012|June 18, 2012|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895700||139485|
NCT00895713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG302|Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation|Efficacy and Safety of Intramuscular Hepatitis B Virus Immune Globulin Grifols for the Prevention of Hepatitis B Virus Recurrence After Orthotopic Liver Transplantation.||Grifols Biologicals Inc.|No|Completed|November 2004|July 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|70 Years|No|||May 2009|May 7, 2009|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895713||139484|
NCT00886665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|grb03484777|The Evaluation of Safety and Efficacy of JWHGWT on Diabetic Neuropathy|The Evaluation of Safety and Efficacy of JWHGWT on Diabetic Neuropathy||Taichung Veterans General Hospital|Yes|Recruiting|July 2008|July 2009|Anticipated|June 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||April 2009|June 17, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886665||140167|
NCT00886951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-388/390-01|Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease|Evaluation of [123I] MNI-388 and 123-I MNI-390 and SPECT as Markers of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Institute for Neurodegenerative Disorders|No|Terminated|March 2009|||March 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 20, 2010|April 22, 2009|No|Yes|There did not appear to be uptake of the ligand in the areas of the brain expected for    individuals with amyloid.|No||https://clinicaltrials.gov/show/NCT00886951||140145|
NCT00884299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK19021970DM|Nutritional Enhancement in Chronic Obstructive Pulmonary Disease (COPD)|Nutritional Enhancement in COPD: Randomized, Controlled Trial||University of Thessaly|Yes|Completed|January 2004|April 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|90 Years|No|||April 2009|April 20, 2009|April 16, 2009||||No||https://clinicaltrials.gov/show/NCT00884299||140347|
NCT00884598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636508|Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer|Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer - a Single-center, Open-label Phase I Study|CIRAB|Universitätsmedizin Mannheim|Yes|Recruiting|December 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||April 2010|April 27, 2010|April 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00884598||140325|
NCT00883506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00104|To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed|Randomized, 3-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions Under Fasting and Fed Conditions.||Sandoz||Completed|May 2000|June 2000|Actual|June 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2009|April 16, 2009|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00883506||140407|
NCT00883740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081165|Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia|Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study||Pfizer|Yes|Completed|June 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|April 17, 2009|Yes|Yes||No|May 16, 2011|https://clinicaltrials.gov/show/NCT00883740||140389|The protocol specified analyses of secondary outcome measures (OMs) indicated OMs would use PP population; however all secondary OMs were analyzed using the ITT population in accordance with the statistical analysis plan.
NCT00885430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hookey Pico-Salax Volunteers|Pico-Salax Colonic Preparation Study: Quantifying Electrolyte and Volume Status Changes|Pico-Salax Colonic Preparation Study: Quantifying Electrolyte and Volume Status Changes||Queen's University|No|Completed|July 2008|September 2008|Actual|July 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|45 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885430||140262|
NCT00884858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS/MVC01/2008|Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects|Use of Maraviroc (MVC) in Immunological Non-responder HIV-1-infected Patients.||Ospedale L. Sacco – Polo Universitario|No|Completed|April 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884858||140305|
NCT00884871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071113|Study of Surgically-Induced Weight Loss on Pelvic Floor Disorders|A Prospective Cohort Study of the Impact of Surgically-Induced Weight Loss on Pelvic Floor Disorders||University of California, San Diego|No|Completed|September 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 obese women who have met surgical eligibility for laparoscopic adjustable gastric        banding at the Center for the Treatment of Obesity at UCSD|November 2009|November 10, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884871||140304|
NCT00893932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeptinHadassahMO|Leptin: a Therapeutic Option for Treating Catabolic States and Malnutrition in Critically Ill Patients|||Hadassah Medical Organization|No|Recruiting|August 2008|December 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples Without DNA|Blood samples for leptin levels|Both|18 Years|N/A|No|Probability Sample|Patients admitted to the Medical ICU and diagnosed with SIRS|April 2009|May 5, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893932||139621|
NCT00885417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901041M|The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study|The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study||National Taiwan University Hospital|Yes|Completed|April 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|142|||Both|20 Years|N/A|No|||March 2011|April 21, 2011|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885417||140263|
NCT00888758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06042006|Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction|Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up.|ROBUST|Masaryk University|Yes|Not yet recruiting|May 2009|May 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|85 Years|No|||April 2009|April 30, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888758||140009|
NCT00891722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000614912|Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma|Translation Study for Children and Adolescents With Low Grade Glioma||National Cancer Institute (NCI)||Recruiting|August 2008|||||N/A|Observational|N/A|||Anticipated|900|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2009|August 23, 2013|April 30, 2009||||No||https://clinicaltrials.gov/show/NCT00891722||139784|
NCT00887029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCC1023|A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma|A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study)|DVX|Ophthalmic Consultants Centres, Canada|Yes|Completed|January 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00887029||140140|
NCT00895739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMS-ALESAA|Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure|Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients||National Cancer Institute (NCI)||Recruiting|June 2006|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2009|August 9, 2013|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895739||139482|
NCT00896259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2007-057|Effects of a Late Phase Exercise Program Following Total Hip Arthroplasty|Effects of a Late Phase Education and Exercise Program Following Total Hip Arthroplasty: A Pilot Project||Nova Scotia Health Authority|No|Completed|March 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|orthopedic clinic outpatients (of one clinic)|August 2012|August 28, 2012|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896259||139444|
NCT00894231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS071108|Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis|Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis||AAADRS Clinical Research Center|Yes|Completed|January 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00894231||139598|
NCT00894530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08638|The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)|||Merck Sharp & Dohme Corp.||Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|314|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|May 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00894530||139575|
NCT00895986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA 7-08-CR-62|Using Conversation Maps to Reinforce Self-Care|Achieving and Maintaining Glycemic Control: Using Conversation Maps to Reinforce Self-Care||Joslin Diabetes Center|No|Completed|December 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|134|||Both|25 Years|75 Years|No|||October 2012|October 17, 2012|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895986||139463|
NCT00895999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Poleshuck K23|Psychosocial Treatment for Women With Depression and Pain|Psychosocial Treatment for Gynecology Patients With Comorbid Depression and Pain||University of Rochester|Yes|Completed|March 2007|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00895999||139462|
NCT00896272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909142|Adaptation Among Adolescents and Adults With Klinefelter Syndrome|Adaptation Among Adolescents and Adults With Klinefelter Syndrome||National Institutes of Health Clinical Center (CC)||Completed|May 2009|January 2015||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|600|||Male|14 Years|80 Years|No|||January 2015|January 14, 2015|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896272||139443|
NCT00887510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|650|Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)|Metabolic Effects of Antihypertensive Drugs|MEAD|University of Florida|No|Completed|May 2007|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||June 2014|June 12, 2014|April 23, 2009|Yes|Yes||No|June 10, 2013|https://clinicaltrials.gov/show/NCT00887510||140103|
NCT00883766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX002|Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1|PCOS and IVF: A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1||Institut Universitari Dexeus|No|Terminated|April 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Female|18 Years|37 Years|No|||October 2010|July 19, 2012|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883766||140387|
NCT00884039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-12|Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients|Compassionate Use of Anecortave Acetate: Clinical Protocol for the Treatment of Corticosteroid-induced Intraocular Pressure (IOP) Increases After Corneal Transplantation||Cornea Research Foundation of America|Yes|Terminated|May 2009|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|April 17, 2009|Yes|Yes|Preliminary data analysis showed insufficient efficacy to justify continuation.|No|September 20, 2010|https://clinicaltrials.gov/show/NCT00884039||140366|
NCT00884884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Swift-AA015753|Aripiprazole and Topiramate on Free-Choice Alcohol Use|Aripiprazole and Topiramate on Free-Choice Alcohol Use|AT|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|No|Completed|September 2007|October 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|90|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|April 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884884||140303|
NCT00896480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111473|Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma|Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma||GlaxoSmithKline||Completed|May 2009|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2014|September 24, 2015|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896480||139427|
NCT00885157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV26|Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly|Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines||Sanofi|No|Completed|April 2009|December 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|225|||Both|15 Months|18 Months|Accepts Healthy Volunteers|||January 2014|January 20, 2014|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885157||140283|
NCT00885170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-042|A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (0822-042)(COMPLETED)|A Phase IIa Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Odanacatib (MK0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate||Merck Sharp & Dohme Corp.|Yes|Completed|April 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|247|||Female|60 Years|N/A|No|||February 2015|February 12, 2015|April 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00885170||140282|
NCT00885443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02470|Emergence Delirium in Children: Total Intravenous Anesthesia With Propofol and Remifentanil Versus Inhalational Sevoflurane Anesthesia|Emergence Delirium in Children: Total Intravenous Anesthesia With Propofol and Remifentanil Versus Inhalational Sevoflurane Anesthesia||University of British Columbia|No|Completed|February 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885443||140261|
NCT00885716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIF2168-1764.1|A Shared Decision Making Training for Inpatients With Schizophrenia|Shared Decision Making: Ein Kommunikationstraining für Patienten Mit Schizophrenie||Technische Universität München|No|Recruiting|May 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|60 Years|No|||April 2010|April 7, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885716||140240|
NCT00885729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-0738c 2009|Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects|Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects||University Hospital, Akershus|No|Active, not recruiting|April 2009|July 2018|Anticipated|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00885729||140239|
NCT00893945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA-0611|Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors|A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors||Rockefeller University|Yes|Completed|June 2007|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|19|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|December 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00893945||139620|
NCT00893958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCO-T500-PVFD-1|Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|January 2006|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 9, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893958||139619|
NCT00894543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MsFLASH-01|MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women|Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women||Fred Hutchinson Cancer Research Center|Yes|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|205|||Female|40 Years|62 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|May 5, 2009|Yes|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00894543||139574|Although this was a community-based sample, the volunteers may be a select group motivated to seek treatment. An 8-week trial is brief, but data indicate that this interval is sufficient to determine long-term efficacy of a nonhormonal compound.
NCT00891150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGY.LB.01|Oxytocin to Decrease Blood Loss During Cesarean Section|Intravenous Oxytocin Use to Decrease Blood Loss During Cesarean Section. What is the Optimal Dose: A Randomized Blinded Trial||American University of Beirut Medical Center|Yes|Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|200|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891150||139826|
NCT00891163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3274-101|Evaluate the Depth and Duration of Anesthesia|A Randomized, Double-Blind, Two-Period, Crossover Study to Evaluate the Depth and Duration of Anesthesia of Synera™ Patches Compared to Placebo Patches Applied to Healthy Adult Volunteers||ZARS Pharma Inc.|No|Completed|December 2006|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 30, 2009|April 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891163||139825|
NCT00888017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29104|Proton Pump Inhibitor Therapy and Bone Density in Premature Infants|Proton Pump Inhibitor Therapy and Bone Density in Premature Infants|PPI|University of Utah|No|Terminated|April 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Infants born between 24 and 34 weeks gestation and 600g to 2000g birth weight.|January 2013|January 22, 2013|April 8, 2009||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00888017||140065|
NCT00895973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072008-053|A Trial of Bed Versus Stirrups Delivery in Nulliparous Women for Prevention of Perineal Lacerations|A Randomized Trial of Bed Versus Stirrups Delivery in Nulliparous Women for Prevention of Perineal Lacerations||University of Texas Southwestern Medical Center|No|Recruiting|March 2009|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|194|||Female|16 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 8, 2009|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00895973||139464|
NCT00896532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060326|Phase 2 Study of AMG 785 in Postmenopausal Women With Low Bone Mineral Density|A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density||Amgen|No|Completed|June 2009|February 2016|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|419|||Female|55 Years|85 Years|No|||February 2016|February 24, 2016|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896532||139424|
NCT00896571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14287|Transdermal Contraceptive Patch - Endometrial Effects Study|Single-center,Open-label, Uncontrolled Study to Investigate the Effects of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene on the Endometrium in a 21-day Regimen for 13 Cycles in 80 Healthy Women||Bayer|No|Completed|July 2009|August 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|92|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896571||139421|
NCT00887354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12400|A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture|Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine BMD (Bone Mineral Density) in Men and Postmenopausal Women With Low Bone Mass and a Recent Pertrochanteric Hip Fracture|MOVE|Eli Lilly and Company|No|Completed|April 2009|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|50 Years|N/A|No|||September 2015|September 3, 2015|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887354||140115|
NCT00887601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134-006|BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)|A 4-Period, Placebo-Controlled, Crossover Study to Evaluate the Utility and Feasibility of BOLD fMRI and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (Donepezil and MK3134)||Merck Sharp & Dohme Corp.|No|Completed|August 2007|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00887601||140096|
NCT00892398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ACA04T|Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab|Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab||Maisonneuve-Rosemont Hospital|Yes|Completed|March 2009|March 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|75 Years|No|||April 2014|April 8, 2014|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892398||139735|
NCT00892411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 103/08|Prognostic Value of Measures of the Central Hypersensitivity in Patients With Acute Low Back Pain|Prognostic Value of Measures of Central Hypersensitivity in Patients With Low Back Pain||University Hospital Inselspital, Berne|No|Completed|February 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|154|||Both|18 Years|80 Years|No|Probability Sample|Patients with acute low back pain referred from primary care.|July 2015|July 16, 2015|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892411||139734|
NCT00892762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-001|Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health|||Alcon Research|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|434|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892762||139709|
NCT00884312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-010|A Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols|An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols||Onyx Pharmaceuticals|No|Active, not recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884312||140346|
NCT00884325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XYZ0801|Management of Pruritus With Xyzal in Atopic Dermatitis|Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study||Derm Research, PLLC|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|April 17, 2009|Yes|Yes||No|April 23, 2013|https://clinicaltrials.gov/show/NCT00884325||140345|Small number of subjects. Of 40 subjects enrolled, only 33 completed the 4 week study.
NCT00884611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10162008-1321|Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study|Development of Algorithms for a Hypoglycemic Prevention Alarm||Stanford University|No|Completed|May 2007|August 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|12 Years|46 Years|No|||March 2015|March 5, 2015|April 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884611||140324|
NCT00884624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-200|Evaluation of the PillCam™ Colon Capsule -2 System|Evaluation of the PillCam™ Colon Capsule -2 System||Given Imaging Ltd.|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|255|||Both|18 Years|57 Years|No|Non-Probability Sample|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from        large bowel diseases.|March 2010|March 10, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884624||140323|
NCT00896493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT206|Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma|A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma||Stanford University|Yes|Recruiting|May 2009|December 2022|Anticipated|December 2022|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00896493||139426|
NCT00896519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS-FL2008-RCHOP-GM|GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma|An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine®) Associated With RCHOP Chemotherapy and Rituximab (MabThera®) Maintenance in Patients With First-line Advanced Follicular Non Hodgkin's Lymphoma||National Cancer Institute (NCI)||Not yet recruiting|March 2009|||March 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2009|August 1, 2013|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896519||139425|
NCT00896753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000550060|Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum|Gene Expression Profiling of Metastatic Colon Cancer (CCCWFU 89B03)||Comprehensive Cancer Center of Wake Forest University|No|Completed|September 2003|May 2008|Actual|September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|||Both|N/A|120 Years|No|Non-Probability Sample|patients with metastatic colen cancer|September 2015|September 30, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896753||139407|
NCT00892736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01472|Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy|A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2-Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2009|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|19 Years|N/A|No|||December 2015|February 11, 2016|May 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892736||139711|
NCT00892749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0004|Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis|A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis||Astellas Pharma Inc|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|248|||Both|20 Years|N/A|No|||April 2015|April 30, 2015|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892749||139710|
NCT00893386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StarFix Extraction|Attain StarFix® 4195 Lead Extraction Study|Attain StarFix® Model 4195 LV Lead Extraction Study||Medtronic Cardiac Rhythm Disease Management|No|Completed|July 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|227|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be chosen by investigators participating in the study at up to 25        experienced extraction centers throughout the United States and Canada. Patients of both        genders that are indicated for a Model 4195 or a non-Model 4195 Medtronic lead extraction        who meet all inclusion criteria may be in the study.|January 2016|January 29, 2016|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893386||139663|
NCT00893399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 09-09|Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation|Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation||University of Ulm|Yes|Recruiting|February 2010|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|588|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893399||139662|
NCT00894270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novofine002|Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees|Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees||Liggins Institute|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|6 Years|N/A|No|||May 2009|May 7, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894270||139595|
NCT00894257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-PP-06|Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population|Trends in Risk of Mother-to-child Transmission of Hepatitis C Through Analysis of Prevalence of Risk Factors for Maternal Infection Among a Southern European Population|EPIALHICE B|Centre Hospitalier Universitaire de Nice|No|Recruiting|May 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|128|||Female|15 Years|55 Years|No|Non-Probability Sample|HCV/HIV infected pregnant women|March 2010|April 2, 2010|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894257||139596|
NCT00891995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirecNet 012|Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes|Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|September 2010|November 2015|Anticipated|November 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|6 Years|45 Years|No|||November 2011|April 30, 2013|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891995||139763|
NCT00888342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK-61|Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in COPD Patients|A Study of Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in Patients With COPD in Different Stages of the Disease, and the Effect of Alcohol, Supplementary Oxygen and Zopiclone on These Changes.||LHL Helse|No|Completed|May 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|150|||Both|N/A|N/A|No|||May 2012|May 15, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00888342||140041|
NCT00895765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zoucc1|The Follow up of Chinese Young Children With Melamine-Related-Calculus|Part 1 The Outcome of Children With Melamine-Related-Calculus||Zhejiang University|Yes|Enrolling by invitation|September 2008|October 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Blood and Urine|Both|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|young children with melamine-related-calculus|May 2009|May 7, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895765||139480|
NCT00895440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuropad01|Role of Indicator Test (Neuropad) in Detecting Diabetic Neuropathy|Neuropad Test for Detection of Sudomotor Dysfunction in Patients With Painful and Painless Diabetic Neuropathy and Charcot Neuroarthropathy||Tameside Hospital NHS Foundation Trust|No|Completed|July 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||5|Actual|139|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 1 and type 2 diabetic patients with and without peripheral neuropathy (painless and        painful) and Charcot neuroarthropathy; and non-diabetic subjects|November 2013|November 25, 2013|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895440||139505|
NCT00895453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/2000|Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)|Monthly Itraconazole Versus Classic Homeopathy for the Treatment of Recurrent Vulvovaginal Candidiasis: a Randomised Trial||Medical University of Vienna|No|Completed|May 2000|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|144|||Female|18 Years|60 Years|No|||May 2009|May 7, 2009|January 16, 2009||No||No|January 16, 2009|https://clinicaltrials.gov/show/NCT00895453||139504|
NCT00895752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809-11|Riluzole in Fragile X Syndrome|Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay||Indiana University|Yes|Completed|April 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895752||139481|
NCT00887367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106591|EtOH Interaction Study|A Study to Investigate Potential Interactions Between GSK598809 and Ethanol in Healthy Subjects||GlaxoSmithKline||Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 3, 2010|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887367||140114|
NCT00896545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04072009-2158|Early Childhood Prevention of Childhood Overweight|Development of an Early Intervention for the Prevention of Childhood Obesity||Stanford University|Yes|Completed|November 2008|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896545||139423|
NCT00896558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112668|A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects||GlaxoSmithKline|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 27, 2011|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00896558||139422|
NCT00895726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC10004|Pilot Study of APD209 in Cancer Cachexia|Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of APD209 in Patients With Cachexia and Advanced Malignancy||Acacia Pharma Ltd|No|Completed|March 2009|January 2012|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895726||139483|
NCT00895960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0318|Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma|Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma||M.D. Anderson Cancer Center|No|Terminated|May 2009|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 7, 2009|No|Yes|Sponsor withdrew support; Study did not progress to Phase II.|No||https://clinicaltrials.gov/show/NCT00895960||139465|
NCT00896233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-132|Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)|Test-Retest Repeatability Study of Magnetic Resonance Elastography (MRE) for Liver Fibrosis Assessment in Healthy Volunteers and Hepatitis C Virus-Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|May 7, 2009|No|Yes||No|January 18, 2011|https://clinicaltrials.gov/show/NCT00896233||139446|Since both primary objectives were met based on the Part 1 analysis, a decision was made to stop the study and not proceed to Part 2. Therefore, data from Part 1 of the study were used for outcome measures 3 and 4 instead of data from Part 2.
NCT00896246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL994-01/2007 (GLO)|Scintigraphic Assessment Following Klean-Prep® or Moviprep®|Scintigraphic Assessment of Gastrointestinal Transit Following Administration of Klean-Prep® (4L) or Moviprep® (2L) to Healthy Volunteers.||Norgine|No|Completed|September 2006|November 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 11, 2009|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896246||139445|
NCT00893412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/191|Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography|Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography : a Randomized, Controlled, Double Blinded Study||Universitair Ziekenhuis Brussel|Yes|Completed|November 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|128|||Female|18 Years|45 Years|No|||May 2009|May 4, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893412||139661|
NCT00893685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|European Commission|Randomized Controlled Trial of Home Telemonitoring for Elderly People|Elderly Friendly Alarm Handling and Monitoring (DREAMING)|Dreaming|Health Information Management, Belgium|Yes|Not yet recruiting|May 2009|December 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 7, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00893685||139640|
NCT00893984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pre001|Alternative in Beta Blocker Intolerance: The ABBI Trial|Alternative in Beta Blocker Intolerance; the ABBI Trial|ABBI|Minneapolis Heart Institute Foundation|No|Terminated|May 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|21 Years|N/A|No|||December 2013|December 6, 2013|May 5, 2009||No|Lack of patient recruitment|No||https://clinicaltrials.gov/show/NCT00893984||139617|
NCT00884936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-08-112-USKAG|Identification of Gene Biomarkers in Aging Skin|Identification of Gene Biomarkers in Aging Skin; a Blinded, Prospective, Single-center, Clinical Study||Interleukin Genetics, Inc.|Yes|Completed|August 2008|April 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|121|Samples With DNA|A 4 mm punch biopsy taken from exposed and unexposed skin.|Female|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asian female subjects between the ages of 20 to 75 years old who are non-smokers with no        history of prior alcoholism.|October 2009|March 30, 2015|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884936||140300|
NCT00884949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-002|A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA|A Phase 1/2, Multicenter, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)||BioMarin Pharmaceutical|No|Completed|April 2009|March 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|5 Years|18 Years|No|||May 2014|May 28, 2014|April 10, 2009||No||No|March 13, 2014|https://clinicaltrials.gov/show/NCT00884949||140299|
NCT00891449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-06-2770|Space Flight Simulation to Study Effects of Micro-gravity Through Bed Rest|Countermeasure and Functional Testing Study (CFT-70)|FAP|National Aeronautics and Space Administration (NASA)|Yes|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Blood, Urine|Both|24 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|November 2015|November 13, 2015|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891449||139805|
NCT00891462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-MD-33|Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)|Efficacy and Safety of Aclidinium Bromide at Two Dose Levels (200 μg Twice Daily, 400 μg Twice Daily) vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Forest Laboratories|No|Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|561|||Both|40 Years|N/A|No|||August 2012|August 14, 2012|April 30, 2009|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00891462||139804|
NCT00887692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/185|Comparison of Set-up Reproducibility Between Prone and Supine Intensity Modulated Radiotherapy (IMRT) for the Adjuvant Treatment of Breast Carcinoma After Lumpectomy|Comparison of Set-up Reproducibility Between Prone and Supine Intensity Modulated Radiotherapy (IMRT) for the Adjuvant Treatment of Breast Carcinoma After Lumpectomy||University Hospital, Ghent|No|Completed|July 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||October 2010|October 18, 2010|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887692||140089|
NCT00887705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK-63|ADL- Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Activities of Daily Living (ADL)-Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)||LHL Helse|No|Completed|May 2009|June 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|24|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|April 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00887705||140088|
NCT00888355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_582|MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension|A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Losartan Given Once or Twice Daily in Patients With Mild to Moderate Hypertension||Merck Sharp & Dohme Corp.||Completed|May 1992|February 1993|Actual|January 1993|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|428|||Both|21 Years|N/A|No|||July 2009|July 2, 2009|April 24, 2009|Yes|Yes||No|May 7, 2009|https://clinicaltrials.gov/show/NCT00888355||140040|Note that deaths are not entered under "drop reasons" in the participant flow panel because the patients who died are already counted as dropped due to adverse event.
NCT00886288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.521|TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium|A Comparison of Telmisartan Effectiveness in Hypertensive Patients With and Without Albuminuria.||Boehringer Ingelheim||Completed|September 2006|||April 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|2874|||Both|19 Years|N/A|No|Probability Sample|hypertensive patients|June 2014|June 12, 2014|April 21, 2009||||No|August 27, 2009|https://clinicaltrials.gov/show/NCT00886288||140196|Observational study of daily medical practice, a lot of patients did not return to their GP for the second visit during the time period of 10 to 14 weeks after the first visit
NCT00896012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AUS59|Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal|Phase 4 Study: Comparison of Myfortic and Early Rapamycin Conversion vs. Low-Dose Tacrolimus in Preventing Acute Rejection and Chronic Allograft Fibrosis: A Protocol Biopsy Directed Approach||University at Buffalo|Yes|Enrolling by invitation|January 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2009|May 8, 2009|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896012||139461|
NCT00896285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816478|The First Therapeutic Intervention in Malignant Pleural Effusion Trial|TIME1: A 2 X 2 Factorial Trial to Assess Whether Non-steroidal Anti-inflammatory Analgesics and Small-bore Chest Tubes Are Less Painful Than Opiate Analgesics and Large-bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion.|TIME-1|University of California, Davis|Yes|Completed|April 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|4|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896285||139442|
NCT00886730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15836A|Primary Care Patients With Depression for Internet-Based Social Support|Feasibility Study of Methods of Referral Primary Care Patients With Depression for Internet-Based Social Support|Psychobabble|University of Chicago|Yes|Completed|October 2008|May 2011|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|49|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886730||140162|
NCT00886743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3067K1-2213|Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia|Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy||Pfizer|No|Terminated|September 2009|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||February 2016|February 5, 2016|April 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00886743||140161|
NCT00887380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 08.06|STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)|A Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Anti-oestrogen Therapy Delayed Until After Radiotherapy.|STARS|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Recruiting|September 2009|December 2024|Anticipated|December 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887380||140113|
NCT00883363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE_RAAA_PRECON_01|Reduction of Myocardial Infarction by Preconditioning in Patients With Ruptured Abdominal Aortic Aneurysm|Reduction of Myocardial Infarction by Preconditioning in Patients With Ruptured Abdominal Aortic Aneurysm|PreconRAAA|Aarhus University Hospital|No|Completed|April 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883363||140418|
NCT00892775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108760|Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds|Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds||GlaxoSmithKline||Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|501|||Both|11 Months|21 Months|Accepts Healthy Volunteers|||May 2011|June 1, 2011|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892775||139708|
NCT00892788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-128-1|A Behavioral Intervention for Reducing Obesity|A Behavioral Intervention for Reducing Obesity||University of Connecticut Health Center|No|Completed|April 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||November 2011|November 17, 2011|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00892788||139707|
NCT00892801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0772|Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer|A Phase I/II Study of RAD001 and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)||Vanderbilt-Ingram Cancer Center|Yes|Terminated|May 2009|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2012|March 9, 2012|May 2, 2009|Yes|Yes|Terminated due to low accrual. Study was closed to accrual prematurely and did not continue on    to Phase II.|No||https://clinicaltrials.gov/show/NCT00892801||139706|
NCT00893061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635986|Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer|A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer.||National Cancer Institute (NCI)||Recruiting|February 2009|||July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|N/A|70 Years|No|||July 2009|January 20, 2011|May 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00893061||139687|
NCT00893074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00026278|The Effect of Prescription Medications in Marijuana Users|The Effect of Prescription Medications in Marijuana Users||Johns Hopkins University|No|Recruiting|April 2009|October 2011|Anticipated|October 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|July 15, 2011|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00893074||139686|
NCT00893425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATARAMCD9509|Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria|Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria||Gulhane School of Medicine||Completed|January 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 2, 2009|April 28, 2009||||No||https://clinicaltrials.gov/show/NCT00893425||139660|
NCT00893698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/17|Bilateral Allotransplantation of Upper Limbs|||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2009|||January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|5|||Both|18 Years|50 Years|No|||August 2014|August 28, 2014|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893698||139639|
NCT00893971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT0030901|Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects|A Randomized, Double-blind, Single Dose, Four-period, Four-treatment, Cross-over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects||Pearl Therapeutics, Inc.|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893971||139618|
NCT00884676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080376|Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors|A Phase I Trial of Weekly and Every Three Weeks Ixabepilone and Sunitinib in Solid Tumor Patients||University of Miami|Yes|Completed|November 2008|July 2015|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|120 Years|No|||July 2015|October 8, 2015|April 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00884676||140319|
NCT00891748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001:CD40L|Safety Study on AdCD40L Gene Therapy for Bladder Cancer|A Phase I/IIa Study of Dose-escalating Intravesical AdCD40L Instillation in Urinary Bladder Carcinoma||Uppsala University|No|Completed|November 2006|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||April 2009|January 15, 2010|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891748||139782|
NCT00887718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 07-0235-C|Positron Emission Tomography(PET) in Lymphoma Assessment|Positron Emission Tomography for Staging, and Treatment Assessment of Response in Lymphomas (the Pet-star Lymphoma Study)||University Health Network, Toronto|Yes|Completed|August 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|103|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887718||140087|
NCT00889538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glutathione-KCPCRU-01|Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems|Double-Blind, Placebo-Controlled, Crossover Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems||University of Louisville|No|Completed|April 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|5 Years|16 Years|No|||January 2016|January 29, 2016|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889538||139949|
NCT00886314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Clown Doctors and a Sedative Premedicant for Children Undergoing Surgery|||Shaare Zedek Medical Center||Not yet recruiting|June 2009|||September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|2 Years|12 Years|No|||February 2009|October 18, 2009|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00886314||140194|
NCT00886548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL-20091|Echocardiographic Examination Performed by Nurses in Cardiac Intensive Care Unit|Echocardiographic Examination Performed by Nurses in Cardiac Intensive Care Unit. Is it Clinical Useful?||Levanger Hospital|No|Withdrawn|April 2009|May 2010||May 2010||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|16 Years|N/A|No|Non-Probability Sample|Patients hospitalized at Cardiac Intensive Care Unit at Levanger Hospital|May 2009|January 11, 2016|April 21, 2009||No|Delayed inclusion|No||https://clinicaltrials.gov/show/NCT00886548||140176|
NCT00886535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-047|Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity|An Observational Trial of the Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity||Milton S. Hershey Medical Center|No|Suspended|February 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|N/A|No|Probability Sample|Females, age 18 years of age and above. Patients receiving tamoxifen for adjuvant therapy        of breast cancer or ductal carcinoma in situ or as chemoprevention.|January 2013|January 8, 2013|April 22, 2009||No|interim analysis|No||https://clinicaltrials.gov/show/NCT00886535||140177|
NCT00886782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA198-002|A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors|A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Terminated|May 2009|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00886782||140158|
NCT00886795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tahoe-001|Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy|A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.|TAHOE|Johns Hopkins University|Yes|Completed|May 2009|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|70 Years|No|||December 2015|December 17, 2015|April 22, 2009|No|Yes||No|August 31, 2015|https://clinicaltrials.gov/show/NCT00886795||140157|Open Label study. Small number of patients. Outcome measures for urticaria not standardized.
NCT00886808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-007-01-DME|Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema||iCo Therapeutics Inc.|Yes|Completed|February 2008|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|15|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|April 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00886808||140156|
NCT00884143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OIT-ARI-2008/1|Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer|Retrospective Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer in Two Successive Time Periods|TIME 2 CHANGE|AstraZeneca|No|Completed|July 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|515|||Female|N/A|N/A|No|Non-Probability Sample|Post-menopausal patients with breast cancer already treated with advjuvant hormonal        therapy.|April 2010|April 19, 2010|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884143||140358|
NCT00896779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04202009-2338|Lucentis in Advanced Macular Degeneration|Lucentis in Advanced Macular Degeneration||Stanford University|No|Completed|October 2009|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|N/A|No|||June 2015|June 1, 2015|May 8, 2009|No|Yes||No|May 7, 2015|https://clinicaltrials.gov/show/NCT00896779||139405|Limitations include small number of subjects analyzed and no control group that were untreated.
NCT00896792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000615562|Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers|The Pilot Palliative ARNP (Advanced Registered Nurse Practitioner) Liaison Program (The PAL Program): Improving Communication Between Patients, Oncologists, and Hospice, Promoting Timely Hospice Referrals and Bringing Education and Research Efforts to Hospice and Palliative Care||Mayo Clinic|Yes|Active, not recruiting|October 2008|||September 2015|Anticipated|N/A|Interventional|N/A|||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00896792||139404|
NCT00892424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0598-C|Sorafenib-RT Treatment for Liver Metastasis (SLIM)|Phase I/II Trial of Radiation Therapy and Sorafenib for Treatment of Unresectable Liver Metastases||University Health Network, Toronto|Yes|Active, not recruiting|November 2008|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892424||139733|
NCT00892814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBCG PBI protocol|Partial Breast Versus Whole Breast Irradiation in Elderly Women Operated on for Early Breast Cancer|Partial Breast Versus Whole Breast Irradiation to Women ≥ 60 Years Operated With Breast Conservation for Early Breast Cancer: a Randomized Fase II Trial||Danish Breast Cancer Cooperative Group|Yes|Recruiting|May 2009|May 2022|Anticipated|May 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|628|||Female|60 Years|N/A|No|||January 2016|January 21, 2016|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00892814||139705|
NCT00893113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURA-RT-002|An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms|A Phase 3, Double Blind, Placebo-COntrolled, Crossover Study to Evaluate the Efficacy of Alfuzosin in Treating Men With ED and Mild LUTS.||Chesapeake Urology Research Associates|Yes|Completed|June 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Male|30 Years|69 Years|Accepts Healthy Volunteers|||April 2013|April 12, 2013|April 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893113||139683|
NCT00893087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK:122/2008|Comparison of Pressure-, Flow- and Neurally Adjusted Ventilatory Assistance (NAVA)-Triggering in Pediatric and Neonatal Ventilatory Care|Comparison of Pressure-, Flow- and NAVA-triggering in Pediatric and Neonatal Ventilatory Care||University of Oulu|No|Completed|February 2009|August 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|N/A|17 Years|No|||January 2010|January 19, 2010|May 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00893087||139685|
NCT00893100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|724|Evaluation of Pain Reduction After Hemorrhoidectomy With Use of Diltiazim Ointment 2%|Evaluation of Pain Reduction After Hemorrhoidectomy With Use of Diltiazim Ointment 2%||Tehran University of Medical Sciences|Yes|Completed|October 2007|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|1|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2009|May 2, 2009|April 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00893100||139684|
NCT00893438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMW-56100004|Efficacy of Web-based Cognitive Behavioural Treatment for Adolescents With Chronic Fatigue Syndrome|Fatigue in Teenagers on the Internet (FitNet); Efficacy of Web-based Cognitive Behavioural Treatment for Adolescents With the Chronic Fatigue Syndrome|FitNet|UMC Utrecht|Yes|Completed|January 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893438||139659|
NCT00893711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS-2009|Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic|Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic: a Clinical and Microbiological, Double-blind, Prospective, Randomised, Controlled Study||Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna|Yes|Recruiting|March 2008|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|155|||Both|N/A|16 Weeks|No|||June 2014|June 24, 2014|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893711||139638|
NCT00884975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM19021970DM|Exacerbations and Health Related Quality of Life in Chronic Obstructive Pulmonary Disease|Exacerbations and Health Related Quality of Life in Chronic Obstructive Pulmonary Disease: CRECOPD Study||University of Thessaly|Yes|Active, not recruiting|May 2002|June 2009|Anticipated|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with a diagnosis of Chronic Obstructive Lung Disease according to the GOLD        definition (Pauwels RA, Buist AS, Calverley PM, et al; GOLD Scientific Committee. Global        strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary        disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop        summary. Am J Respir Crit Care Med. 2001;163(5):1256-76.), who attend outpatient clinics        at Chania General Hospital on the island of Crete, Greece|April 2009|April 20, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884975||140297|
NCT00885222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eitan-DBS-PD-MDD-HMO-CTIL|Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease Patients|Antidepressant Effect of Deep Brain Stimulation (DBS) in Parkinson's Disease (PD) Patients: Relationship of Stimulation Parameters to Improvement in the Clinical Features of Depression in PD Patients.||Hadassah Medical Organization||Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|40 Years|75 Years|No|||May 2010|June 2, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885222||140278|
NCT00885235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-101|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure||Given Imaging Ltd.|No|Completed|October 2008|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Subjects that are indicated for colonoscopy who are suspected or known to suffer from        large bowel diseases.        The study population will consist of subjects who fulfill at least one of the inclusion        criteria and none of the exclusion criteria.|August 2009|August 2, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885235||140277|
NCT00885248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0623|Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer|Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer||Asan Medical Center|Yes|Active, not recruiting|January 2009|December 2009|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|75 Years|No|Probability Sample|The suspects of pancreatic cancer to visit Asan Medical Center in South Korea|April 2009|April 20, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885248||140276|
NCT00891774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP101 US-04|Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI|An Open-label, Multi-Center, Prospective, Post Market Study to Assess the Safety and Effectiveness of EVOLENCE® in Facial Augmentation of Subjects With Fitzpatrick Skin Color Types IV, V, and VI||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|April 30, 2009|No|Yes||No|April 15, 2011|https://clinicaltrials.gov/show/NCT00891774||139780|This was not a controlled trial and the company made a business decision to discontinue marketing the product in the US, so the program has been terminated. No analysis will be performed on Secondary Outcome Measures.
NCT00888706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR007771|Effect of Activities and Exercise on Sleep in Elderly Persons With Dementia|Effect of Activities and Exercise on Sleep in Dementia||National Institute of Nursing Research (NINR)|Yes|Completed|August 2002|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|355|||Both|55 Years|N/A|No|||April 2009|April 27, 2009|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888706||140013|
NCT00888719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-SKD-201|Therapeutic Exploratory Study of CWP-0403|A Prospective, Randomized, Double Blinded, Multicenter and Therapeutic Exploratory Study to Comparatively Assess Efficacy and Safety of CWP-0403 in Type 2 Diabetes Patients Who Are Insufficiently Controlled by Diet and Exercise.||JW Pharmaceutical|No|Completed|February 2009|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|145|||Both|25 Years|75 Years|No|||November 2010|November 3, 2010|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888719||140012|
NCT00889005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shalev_Phone_2009|Prevention of Post-traumatic Stress Disorder by Telephone Based Cognitive Behavioral Therapy|Prevention of Post-traumatic Stress Disorder by Telephone Based Cognitive Behavioral Therapy||Hadassah Medical Organization|No|Completed|May 2009|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|65 Years|No|||December 2012|December 3, 2012|April 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00889005||139990|
NCT00886327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-001|Detecting Postoperative Recurrence in Crohn's Disease|Detection of Postoperative Recurrence of Crohn's Disease by Colonic Capsule-Endoscopy||Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|May 2009|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients who are operated for CD in any of the participating study centers        are eligible. Included are patients with segmental small bowel, ileocecal or segmental        colonic resection. All patients have to give written informed consent before participating        in the study.|April 2009|May 30, 2012|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886327||140193|
NCT00886756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1960C00003|AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects|A Phase I, Single-Centre, Randomised, Double-Blind, Placebo Controlled Single-Ascending Dose, Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD8529 in Healthy Male Japanese Subjects|JSAD|AstraZeneca|No|Completed|April 2009|July 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 18, 2009|April 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00886756||140160|
NCT00886769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885G2305|Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)|A Randomized, Double-blind, Placebo Controlled, Single-dose Study to Assess the Initial Efficacy of Canakinumab (ACZ885) With Respect to the Adapted ACR Pediatric 30 Criteria in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations|β-SPECIFIC 1|Novartis||Terminated|July 2009|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|2 Years|19 Years|No|||March 2012|March 13, 2012|April 22, 2009|Yes|Yes|recommendation by Data Monitoring Committee|No|November 21, 2011|https://clinicaltrials.gov/show/NCT00886769||140159|
NCT00883389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041163|Med-alert Bracelet in Chronic Kidney Disease|Safe Kidney Care Med-Alert Bracelet/Keytag||University of Maryland|No|Completed|May 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic kidney disease and impaired kidney function|December 2014|December 1, 2014|April 16, 2009||No||No|July 31, 2011|https://clinicaltrials.gov/show/NCT00883389||140416|
NCT00883623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001405-41|A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis|A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis|LEOMEX|Heidelberg University|Yes|Completed|April 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|74 Years|No|||November 2013|November 21, 2013|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883623||140398|
NCT00887081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOVCervello1|Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies|Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C|IFNRIBAHE|Azienda Ospedaliera V. Cervello|Yes|Recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|150|||Both|18 Years|60 Years|No|||April 2009|April 22, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00887081||140136|
NCT00887094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-180|Aerobic Training, Aerobic-resistance Training and Glucose Profile (CGMS) in Type 2 Diabetes|Acute and Subacute Effects of Aerobic Training vs Aerobic/Resistance Training Upon Glucose Profile Evaluated Through Continuous Glucose Monitoring System in Type 2 Diabetes|CGMSexercise|Hospital de Clinicas de Porto Alegre|Yes|Completed|June 2009|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|35 Years|65 Years|No|||August 2011|August 3, 2011|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887094||140135|
NCT00883922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-12-078-03|Central Venous Saturation (ScvO2) Monitoring in Pediatric Patients Undergoing Cardiac Surgery|Central Venous Saturation (ScvO2) Monitoring in Pediatric Patients Undergoing Cardiac Surgery||University of California, Los Angeles|No|Recruiting|January 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|12 Years|No|Probability Sample|Patients scheduled for cardiac surgery|April 2009|April 17, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883922||140375|
NCT00883584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD-10412003-1|IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study|A Phase IIa, Proof of Concept Study to Evaluate the Reduction in Inflammatory Biomarkers and Assess Airway Function Following Administration of IMD-1041 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|COPD|Institute of Medicinal Molecular Design, Inc.|No|Active, not recruiting|July 2008|May 2009|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|80 Years|No|||April 2009|April 22, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883584||140401|
NCT00892437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-216-0105|Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9350-boosted Atazanavir (ATV/GS-9350) Compared to Ritonavir-boosted Atazanavir (ATV/r) in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults||Gilead Sciences|Yes|Completed|May 2009|January 2015|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|April 30, 2009|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT00892437||139732|There were no limitations affecting the analysis or results.
NCT00892450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01143|Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease|Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot Study||VA Office of Research and Development|No|Completed|May 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||October 2014|October 2, 2014|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00892450||139731|
NCT00884104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMK-3|A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks|A Prospective, Open-label, Observational, Multi-center Study for the Identification of Predictive Factors for the Solifenacin Treatment in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks and Evaluation of Efficacy and Persistency of Add on Solifenacin in Men With Residual Overactive Bladder Symptoms After Previous Monotherapy With Tamsulosin.||Samsung Medical Center|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|307|||Male|45 Years|N/A|No|||January 2016|January 6, 2016|March 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00884104||140361|
NCT00893126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00020514|Premature Coronary Artery Disease (CAD) in Severe Psoriasis|Premature Coronary Artery Disease (CAD) in Severe Psoriasis||University of Michigan|No|Active, not recruiting|November 2009|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|31 ml of blood will be drawn in conjunction with this study.Lipid, Glucose and Lipoprotein      will be drawn in one SST tube = 7 ml. Insulin (INS) will be collected in one Green top tube      = 7 ml. HSCRP- will be collected in on SSS tube = 7 ml. IL-6 will be collected in Red or      Lavender top tube = 7 ml. An additional 3 ml will be drawn for ICAM testing. (The blood for      the ICAM testing and IL- 6 will be drawn and frozen until funding has been obtained to run      these tests). Specimens will be be properly disposed of after testing is completed.|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with severe psoriasis will be selected prospectively from the clinics of the        University of Michigan, Dept. of Dermatology.        The comparison group (subjects without psoriasis) will be targeted in the Dermatology        clinic by screening for matching variables before enrollment. This group will be matched        by age and gender to the psoriasis population, and on Framingham risk score.|December 2015|December 21, 2015|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00893126||139682|
NCT00884689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RDE-SYM-2009/1|A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®|A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART® 1-2 Inhalations b.i.d. as Maintenance Therapy Plus Additional Inhalations As-needed, Compared to Patients Treated With a Free Combination of an Inhaled Glucocorticosteroid and an Inhaled Long Acting ß2-agonist Plus as Needed Inhalations of a Short Acting ß2 Agonist.||AstraZeneca|No|Completed|April 2009|June 2010|Actual|||N/A|Observational|Observational Model: Case-Only||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Asthma treatment will not be assigned randomly, but will be administered at the discretion        of the physicians according to standard medical practice. Each site should enrol 5        patients using the Symbicort® SMART® principle and 5 patients being prescribed a free        combination GCS / LABA treatment.|March 2011|March 30, 2011|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884689||140318|
NCT00884702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090123|Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation|Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|580|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||May 2015|February 9, 2016|April 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00884702||140317|
NCT00884962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C08-003PLV|A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema|||Aeris Therapeutics||Completed|December 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|40 Years|N/A|No|||October 2011|October 20, 2011|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884962||140298|
NCT00884715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP107-002|Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome|Open Label Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome||Endo Pharmaceuticals|No|Terminated|July 2009|December 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||September 2013|September 17, 2013|April 20, 2009|Yes|Yes|Program was terminated for business reasons|No||https://clinicaltrials.gov/show/NCT00884715||140316|
NCT00884988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYM.ANKLE.09|Lymphomyosot for Ankle Edema Following Fracture|The Efficacy of Lymphomyosot in the Treatment of Posttraumatic Edema Following Ankle Fracture, Pending Surgery: a Randomized, Double-blind, Placebo-controlled Study.||Shaare Zedek Medical Center|No|Suspended|February 2010|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2012|February 19, 2012|April 19, 2009||No|Study recruiter withdrew from study. Suspended until replacement found.|No||https://clinicaltrials.gov/show/NCT00884988||140296|
NCT00885261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-SB-096-CTIL|The Prevalence of Metabolic Syndrome in Patients Suffering From Chronic Pain|The Prevalence of Metabolic Syndrome in Patients Suffering From Chronic Pain||Tel-Aviv Sourasky Medical Center|No|Completed|May 2009|April 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over 18 that suffer from chronic pain and are being treated at the pain medicine        unit|April 2009|March 26, 2014|April 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00885261||140275|
NCT00885274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hookey Pico-Salax Timing|A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy|A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy.||Queen's University|No|Completed|November 2008|August 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|250|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885274||140274|
NCT00888082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8664L00012|Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy|Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study|PROOF|AstraZeneca|No|Withdrawn||April 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|102|||Female|18 Years|45 Years|No|||December 2010|December 9, 2010|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888082||140060|
NCT00888732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asp-BIAsp-HI-2008|A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin|A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin in Patients With Type 1 Diabetes, A Randomised, Quadruple Crossover Trial||University of Aarhus|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2011|April 27, 2011|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888732||140011|
NCT00889018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RACHNAMEEL|Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma|Randomized Control Trial Comparing Carboplatin 560mg/m2 With 750mg/m2 for Ocular Salvage in Groups C and D Intraocular Retinoblastoma||All India Institute of Medical Sciences, New Delhi|No|Active, not recruiting|April 2009|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||February 2012|February 7, 2012|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889018||139989|
NCT00889031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0905|Protocol to Obtain Blood Samples for Leukemia Research|Protocol to Obtain Blood Samples for Leukemia Research||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|April 2009|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|10cc of peripheral blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center|October 2015|October 8, 2015|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00889031||139988|
NCT00887133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-477|Effectiveness of Western Medicine Outpatient Consultations in Primary Care|Effectiveness of Western Medicine Outpatient Consultations in Primary Care - A Comparison With Chinese Medicine Consultations||The University of Hong Kong|No|Completed|November 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1469|||Both|18 Years|N/A|No|Non-Probability Sample||April 2009|April 22, 2009|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00887133||140132|
NCT00887146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alliance N0577|Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma|Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma||Alliance for Clinical Trials in Oncology|Yes|Recruiting|September 2009|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|April 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887146||140131|
NCT00886561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0126-2005|HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia|HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia||Emory University|No|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 21, 2013|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886561||140175|
NCT00883402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACST-2|Carotid Endarterectomy Versus Carotid Artery Stenting in Asymptomatic Patients|Asymptomatic Carotid Surgery Trial-2 (ACST-2): an International Randomised Trial to Compare Carotid Endarterectomy With Carotid Artery Stenting to Prevent Stroke|ACST-2|University of Oxford|Yes|Recruiting|January 2008|||December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3600|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883402||140415|
NCT00887107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL17727.058.07|Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma|Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma||Leiden University Medical Center|No|Completed|October 2007|||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|80 Years|No|||April 2009|April 22, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887107||140134|
NCT00887120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT045|Dose Reduction of Lopinavir in Children|Pharmacokinetics and Efficacy of Low- or Standard-Dose of Lopinavir/Ritonavir (Kaletra®) in PI-naïve HIV-1 Infected Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|April 2007|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|2 Years|18 Years|No|||April 2009|April 22, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00887120||140133|
NCT00884481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008065-35|Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS|A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months|TYNERGY|Biogen|No|Completed|March 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects diagnosed with Relapsing Remitting Multiple Sclerosis initiating treatment with        Tysabri|July 2015|July 9, 2015|April 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00884481||140333|
NCT00887614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002861|Mindfulness, Emotional Well-being, and Sleep Quality|Mechanisms of Mindfulness: Effects on Sleep Quality, Stress Physiology and CVD Risk||Duke University|Yes|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|372|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 1, 2011|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887614||140095|
NCT00883831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI0904|The Effectiveness and the Safety of Acupuncture for Symptomatic Care of Hemodialysis Patients: A Case-series|Acupuncture for Symptomatic Care of Hemodialysis Patients: a Case-series||Korea Institute of Oriental Medicine|No|Completed|April 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|N/A|No|||April 2009|January 22, 2010|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883831||140382|
NCT00883857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-04-090-03|Comparison Endotracheal Cardiac Output Monitor (ECOM) to a Standard Device in Measuring Heart Blood Volume|Comparison Endotracheal Cardiac Output Monitor (ECOM) to a Standard Device in Measuring Heart Blood Volume||University of California, Los Angeles|No|Recruiting|October 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for cardiac surgery|April 2009|April 17, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883857||140380|
NCT00883870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRPL/CLI/07-08/001|Mesenchymal Stem Cells in Critical Limb Ischemia|A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)||Stempeutics Research Pvt Ltd|Yes|Completed|April 2009|August 2012|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||March 2013|March 4, 2013|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883870||140379|
NCT00883883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50041|To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 250mg/5 ml Cefdinir (Test Formulation) and Omnicel 250mg/5 ml Powder For Oral Suspension (Reference Formulation) Each Given as a Single Oral Dose to Forty Healthy Male and/or Female Volunteers in the Fed State||Sandoz||Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|56 Years|Accepts Healthy Volunteers|||April 2009|April 17, 2009|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00883883||140378|
NCT00884390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-4432|Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings|A Postauthorization Safety Surveillance Study Of Patients Switching To ReFacto AF From ReFacto Or Other Factor VIII Products In Usual Care Settings||Pfizer|No|Terminated|May 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|208|||Male|12 Years|N/A|No|||August 2014|August 20, 2014|April 16, 2009|Yes|Yes|See termination reason in detailed description.|No|March 20, 2014|https://clinicaltrials.gov/show/NCT00884390||140340|The study was terminated early by agreement with the EMA before full recruitment was attained, but this is not considered to affect the overall results and the ability of the study to address its objectives.
NCT00884403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01332|Gestational Age is Underestimated by Menstrual Dating Compared to Ultrasound Dating in Those Undergoing Abortion up to 20 Weeks|Gestational Age is Underestimated by Menstrual Dating Compared to Ultrasound Dating in Those Undergoing Abortion up to 20 Weeks||University of British Columbia|No|Completed|September 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|415|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|women in British Columbia who obtained abortion up to twenty weeks gestational age.|March 2014|March 14, 2014|April 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00884403||140339|
NCT00884728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41 17May2004|Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory|East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities|EAHSP|Menzies School of Health Research|No|Completed|September 2004|August 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|2329|Samples Without DNA|throat swabs, pyoderma swabs and skin scrapings for tinea where individual consent was      obtained within selected participating communities|Both|N/A|15 Years|No|Non-Probability Sample|Residents aged <15 years of participating communities in a remote region of the Northern        Territory|April 2009|April 20, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884728||140315|
NCT00885846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H77B11|Effects of Qigong on Type 2 Diabetic Patients|A Pilot Study: The Effects of Qigong Therapy on Type 2 Diabetic Patients||Bastyr University||Completed|June 2007|May 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|65 Years|No|||April 2015|October 23, 2015|February 5, 2009||No||No|February 5, 2009|https://clinicaltrials.gov/show/NCT00885846||140230|Limitations to this study include high withdrawal rate from PRT group, especially during the first cohort. Also, participants from both Qigong and PRT group changed or discontinued medications. Consequently, their results were excluded from analysis.
NCT00885859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-025|Transcutaneous Electrical Nerve Stimulation (TENS) in Chronic Pain, Responders and Non-Responders?|Is Transcutaneous Electrical Nerve Stimulation (TENS) an Effective Method to Modulate Pain Transmission and Pain Perception in Patients Suffering From Chronic Non-Specific Pain Syndromes?||Maastricht University Medical Center|No|Not yet recruiting|June 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|62|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with chronic musculoskeltal pain will be recruted from the Pain Clinic of the        University Hospital Maastricht (MUMC)|April 2009|April 21, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885859||140229|
NCT00885534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-017|Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma|Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma||Memorial Sloan Kettering Cancer Center|Yes|Completed|April 2009|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|April 21, 2009|No|Yes||No|April 7, 2015|https://clinicaltrials.gov/show/NCT00885534||140254|
NCT00885547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0904|Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis|Prospective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis.||Nanjing University School of Medicine|No|Terminated|March 2009|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|60 Years|No|||March 2015|March 31, 2015|April 20, 2009||No|low-rate of enrollment|No||https://clinicaltrials.gov/show/NCT00885547||140253|
NCT00887744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-0001-AP|Intermittent Neurogenic Claudication Treatment With APERIUS®|A Multicenter, Post Marketing Clinical Follow-up Study to Evaluate the Safety and Effectiveness of the Minimally Invasive Device APERIUS® in Degenerative Lumbar Spinal Stenosis With Symptomatic Neurogenic Intermittent Claudication|INCA|Medtronic Spinal and Biologics|No|Completed|November 2006|March 2010|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|21 Years|N/A|No|||January 2016|January 26, 2016|April 23, 2009||No||No|April 11, 2011|https://clinicaltrials.gov/show/NCT00887744||140085|
NCT00887757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-588|Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors|A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Gemzar® (Gemcitabine) in the Treatment of Subjects With Solid Tumors||Abbott||Completed|September 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00887757||140084|
NCT00888394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173908909-8909-4-9|Effectiveness of Podiatry on Plantar Pain|Clinical Effectiveness of Quiropodiatry and Orthesis on Heel and Plantar Pain: Randomized Control Trial|EPOPLAPAIN|University of Malaga|Yes|Completed|September 2009|February 2013|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|312|||Both|18 Years|65 Years|No|||January 2013|July 23, 2013|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00888394||140037|
NCT00888420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X080201003|The Application of Performance Improvement Principles to the Patient Throughput Process in an Adult Outpatient Pain Treatment Clinic|The Application of Performance Improvement Principles to the Patient Throughput Process in an Adult Outpatient Pain Treatment Clinic||University of Alabama at Birmingham||Completed|February 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1221|||Both|19 Years|N/A|No|Non-Probability Sample|Outpatient pain clinic patients|October 2015|October 19, 2015|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888420||140035|
NCT00888433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-058|Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)|Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)|HTN-2|Medtronic Vascular|Yes|Completed|June 2009|May 2015|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|85 Years|No|||May 2015|May 4, 2015|April 24, 2009|Yes|Yes||No|September 13, 2013|https://clinicaltrials.gov/show/NCT00888433||140034|
NCT00891982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114679|A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash|A Phase 3, Multicenter, Assessor-Blinded Study Of The Tolerability Of a Topical Antibiotic and Retinoid Used In Conjunction With Benzoyl Peroxide Wash In Subjects With Mild-To-Moderate Facial Acne Vulgaris||GlaxoSmithKline|No|Completed|April 2009|July 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|12 Years|45 Years|No|||April 2015|May 7, 2015|April 29, 2009|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00891982||139764|
NCT00887653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-09|Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy|Changes in Lipid Profiles and Safety of Raltegravir Based Antiretroviral Therapy in HIV-1-infected Patients With Hyperlipidemia While on Current Standard Therapy||The Miriam Hospital|Yes|Completed|May 2009|April 2014|Actual|June 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|April 23, 2009|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00887653||140092|
NCT00887159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01917|Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|July 2009|||September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|168|||Both|18 Years|N/A|No|||May 2015|July 1, 2015|April 22, 2009|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT00887159||140130|
NCT00887393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCRU 2462|Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates|Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates||University of Michigan|No|Completed|April 2009|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|55 Years|No|||June 2013|June 17, 2013|April 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00887393||140112|
NCT00883935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111854|GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir|Phase I, Open Label, Randomized, Drug-Drug Interaction Study in Healthy Subjects to Investigate the Effects of Co-Administered Atazanavir/Ritonavir (300mg/100mg) or Atazanavir 400mg Administered Once Daily on the Steady-State Plasma Pharmacokinetics of GSK1349572 30mg Administered Once Daily||GlaxoSmithKline||Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 18, 2009|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00883935||140374|
NCT00884208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903-07|Fall Risk Prediction and Reduction in Community Ambulators 65 Years of Age or Older|Fall Risk Prediction and Reduction in Community Ambulators 65 Years of Age or Older||Guthrie Healthcare System|No|Recruiting|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults 65 years or older who are community ambulators.|April 2009|April 17, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884208||140354|
NCT00883909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103094|ARI103094-Follow-Up Study for REDUCE Study Subjects|ARI103094-Follow-Up Study for REDUCE Study Subjects||GlaxoSmithKline|No|Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2795|Samples With DNA|PART B: Collection of tissue blocks or unstained slides from positive biopsies.|Male|50 Years|N/A|No|Probability Sample|Patients with or without prostate cancer that participated in the REDUCE trial|February 2013|February 21, 2013|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00883909||140376|
NCT00884793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLUS1|Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut|A Prospective Longitudinal Pilot Study to Measure the Effect of Intensification With Raltegravir +/- a Protease Inhibitor (PI) or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) on HIV-1 Levels in the Gut|PLUS|University of California, San Francisco|Yes|Completed|September 2008|December 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|65 Years|No|||June 2012|June 18, 2012|April 20, 2009|Yes|Yes||No|August 8, 2011|https://clinicaltrials.gov/show/NCT00884793||140310|1) relatively small number of participants; 2) intensification may have been too short; 3)the biopsies themselves can cause inflammation/microbial leakage; 4) sampling may miss viral replication if it occurs in temporally and spatially-discrete foci
NCT00884806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-081|7-Day, Multi-Site Study of an Investigational Multi-Purpose Disinfecting Solution for Contact Lens Wearers|Corneal Staining Evaluation of SiH MPDS FID 114675A||Alcon Research|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|110|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|April 17, 2009|Yes|Yes||No|February 20, 2012|https://clinicaltrials.gov/show/NCT00884806||140309|
NCT00883376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP ISCML 114/08|Classification of Stanford for Snore as Factor of Aggravation of the Apnea Hypopnea Index (AIH) in Patients With Obstructive Sleep Apnea Syndrome (OSAS)|Classification of Stanford for Snore as Factor of Aggravation of the AIH in Patients With OSAS.|StanforAIH|Irmandade da Santa Casa de Misericoridia de Limeira|No|Completed|January 2007|December 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|159|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients of ambulatory of Sleep Respiratory Disorders of Santa Casa de Limeira|April 2009|April 16, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883376||140417|
NCT00883597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2009-311|Sidestream Dark-Field (SDF) Imaging of the Intestinal Microcirculation|Sidestream Dark-Field Imaging of the Intestinal Microcirculation in Clinical Sepsis: The Impact of Activated Protein C Therapy||Nova Scotia Health Authority|No|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|36|||Both|19 Years|N/A|No|Non-Probability Sample|Patients presenting to ICU with sepsis and ileostomy|March 2015|July 27, 2015|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883597||140400|
NCT00883844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV09-03|PEG-IFN in HBV Patients With Incomplete Response to NA|Lowering Viral Load With Nucleos(t)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B - a Pilot Study|PADD|Foundation for Liver Research|No|Completed|April 2009|August 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||April 2013|April 18, 2013|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883844||140381|
NCT00883896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3199K1-2001|Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis|A Randomized, Parallel, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of ILV-094 Administered Subcutaneously To Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate||Pfizer|No|Completed|June 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|195|||Both|18 Years|N/A|No|||November 2012|November 12, 2012|April 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00883896||140377|
NCT00885001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0311090179|The Effects of Short Arc Banding|The Effects of Short Arc Banding: A Novel Exercise Intervention in Patients With Chronic Low Back Pain||Logan College of Chiropractic|No|Recruiting|April 2009|May 2009|Anticipated|May 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|No|||April 2009|April 20, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00885001||140295|
NCT00884117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV20237|An Influenza Resistance Information Study (IRIS)|An Open Label Study to Examine Natural Prevalence and/or Emergence of Resistance to Antivirals Among Influenza Virus Isolates, and of the Clinical Outcome of Patients With Influenza: Influenza Resistance Information Study (IRIS)||Hoffmann-La Roche||Completed|January 2009|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|4184|||Both|1 Year|N/A|No|Non-Probability Sample|Patients presenting with clinical signs and symptoms of influenza during the local        influenza season|March 2016|March 15, 2016|April 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00884117||140360|
NCT00884416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-122|Sorafenib in Newly Diagnosed High Grade Glioma|Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma||University Hospital, Geneva|Yes|Completed|March 2009|March 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884416||140338|
NCT00884429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHSL|Effectiveness of Chest Physiotherapy in Infants With Acute Viral Bronchiolitis|Effectiveness of Chest Physiotherapy Actual Versus Conventional Techniques in Infants With Acute Viral Bronchiolitis. Random Clinical Trial|ECPAVB|Hospital Sirio-Libanes|Yes|Completed|April 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|N/A|24 Months|No|||January 2012|August 28, 2012|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884429||140337|
NCT00885560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70410|SNAP 25 Gene Study|Do People With ADHD, Who Respond Well to Amphetamine Medication But Not to Methylphenidate, Have Allelic Variants of the SNAP 25 Gene?||University of British Columbia|No|Terminated|July 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|19|Samples With DNA|Whole blood for genetic analysis.|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|ADHD patients from 6 years of age|September 2012|September 14, 2012|April 20, 2009||No|Collecting data for the population involved was very difficult. Over 3 years, only 19    participants were recruited.|No||https://clinicaltrials.gov/show/NCT00885560||140252|
NCT00885872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACH|Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)|A 104-week, Open-label, Single-group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)|REACH|Chinese PLA General Hospital|No|Recruiting|March 2009|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||April 2009|May 26, 2010|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885872||140228|
NCT00885885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-08-04|Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases|An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-only Metastases.|PLANET|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|May 2009|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||September 2015|September 14, 2015|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885885||140227|
NCT00886106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RemiAnes 1|The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers|The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers|RemiAnes 1|Medical University of Vienna|No|Recruiting|June 2009|March 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886106||140210|
NCT00888446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI A002|Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid|Phase II, Placebo-controlled, Double-blind, Dose-escalation/Dose-optimization Trial to Evaluate Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-associated Virus (AAV) Capsid|TGC14F|International AIDS Vaccine Initiative|Yes|Completed|October 2005|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|91|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888446||140033|
NCT00890461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07080211|Reconstruction of 12-Lead Electrogram From Intracardiac Signals From Defibrillators During or After Implantation|Reconstruction of 12-Lead Electrogram From Intracardiac Signals From Defibrillators During or After Implantation||University of Pittsburgh|No|Active, not recruiting|November 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Subjects will be identified by their cardiologist who is also an investigator on this        study at the time they are evaluated for an ICD implantation. Once it has been determined        during the course of the patient's regular clinical care that he or she requires an ICD,        they will be approached for enrollment into the study by the physician investigator and        the clinical research coordinator.|January 2016|January 8, 2016|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890461||139878|
NCT00888329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005478|Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy|Prevention of Postoperative Nausea and Vomiting in a Gynecologic Surgery Population: A Randomized Placebo Controlled Trial of Aprepitant NK-1-receptor Antagonist||Mayo Clinic|No|Terminated|July 2007|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|256|||Female|18 Years|N/A|No|||March 2012|March 5, 2012|April 24, 2009|Yes|Yes|Slow accrual.|No|February 1, 2012|https://clinicaltrials.gov/show/NCT00888329||140042|Results might have been influenced by selection bias.
NCT00883415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041025|Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease|A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease||University of Maryland|No|Completed|May 2008|November 2012|Actual|November 2012|Actual|Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of individuals being followed for their chronic kidney        disease (CKD) at one of the Nephrology/Early Renal Insufficiency Clinics at the Baltimore,        Maryland VA Medical Center and are being considered for erthropoietin therapy for anemia        related to CKD.|December 2014|December 1, 2014|April 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00883415||140414|
NCT00883649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBH2005-01|Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye|A Randomized, Parallel-Group, Placebo-Control, Double-Blind Trial Comparing the Efficacy and Safety of Nutritional Supplementation Containing Omega 3 Fatty Acids and Gamma Linoleic Acid, for Treatment of Keratoconjunctivitis Sicca in Post-Menopausal Females||Virginia Eye Consultants||Completed|September 2008|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|62|||Female|40 Years|N/A|No|||February 2012|February 16, 2012|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883649||140396|
NCT00887406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104865|Study of GSK961081 in Healthy Volunteer Subjects|A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetic Profile and Pharmacodynamics of Single and Repeat Inhaled Doses of GSK961081 in Healthy Subjects||GlaxoSmithKline||Completed|November 2005|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|46|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887406||140111|
NCT00887419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000226|Spinal Cord Stimulator Implant Study|Pain Coping Skills Training for Spinal Cord Stimulator Implant Candidates|SCS|Duke University|No|Completed|November 2008|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887419||140110|
NCT00884221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999906 CS08|MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer|A Randomized, Open-label, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy of MENOPUR Versus Recombinant FSH in Controlled Ovarian Stimulation Following a GnRH Antagonist Protocol and Single Embryo Transfer|MEGASET|Ferring Pharmaceuticals|No|Completed|July 2009|January 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|749|||Female|21 Years|34 Years|No|||April 2012|April 18, 2012|April 17, 2009||No||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00884221||140353|
NCT00884520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVM4000|An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037|An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037|VM4-037|Siemens Molecular Imaging|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 15, 2010|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00884520||140330|
NCT00883636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0245|Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis|Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis||Northwell Health|No|Terminated|October 2008|October 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4|Samples With DNA|Blood Serum, plasma|Both|6 Months|21 Years|No|Non-Probability Sample|Focal Segmental Glomerulosclerosis Patients and Non Focal Segmental Glomerulosclerosis        SRNS patients|June 2013|June 18, 2013|April 17, 2009||No|study stopped due to lack of activity|No||https://clinicaltrials.gov/show/NCT00883636||140397|
NCT00885066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633338|Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer|Phase I Study of Gemcitabine, Capecitabine, and Erlotinib Together in Advanced Pancreatic Cancers||Centre Antoine Lacassagne||Completed|May 2008|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||February 2015|February 8, 2015|April 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00885066||140290|
NCT00884442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1215ni09ct|Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions|Randomized, Non-blind, 4-fold Crossover Study on Safety, Tolerability and Pharmacokinetics of Nifedipine After Single Oral Doses of Adalat® LA 60 mg or of a Marketed Generic Version of Nifedipine Retard 60 mg After an Overnight Fasting or Immediately After a High-fat American Breakfast in Healthy Male Volunteers||SocraTec R&D GmbH|No|Completed|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 20, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884442||140336|
NCT00883610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070070|Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers|Modulation of QT Interval by Rapid Atrial Pacing in Patients With Dual Chamber Pacemakers||Vanderbilt University|Yes|Completed|April 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|21 Years|N/A|No|Probability Sample|Cardiology Clinic|December 2014|December 9, 2014|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883610||140399|
NCT00884767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633477|Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin|Characterization and Research of Predictive Markers of Neurotoxicity During Treatment With Oxaliplatin in Colorectal Carcinoma: a Genetic and Proteomic Approach. Phase II Multicenter Study||National Cancer Institute (NCI)||Recruiting|September 2007|||August 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|206|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|April 18, 2009||||No||https://clinicaltrials.gov/show/NCT00884767||140312|
NCT00884130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q1909/74|Cost Effectiveness of Laparoscopic Colorectal Surgery|Cost Effectiveness of Laparoscopic Colorectal Surgery||University of Surrey|Yes|Completed|January 2006|October 2007|Actual|August 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|All patients requiring a colorectal resection between January 2006 and August 2007 at The        Royal Surrey County Hospital, UK.|April 2009|April 16, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00884130||140359|
NCT00885573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808|Pharyngeal Sensitivity in Diagnosis Algorithm for Sleep Apnea Syndrome|Measurement of Pharyngeal Sensitivity With the SENSITEST Device: Validation of the Diagnosis Algorithm for Sleep Disordered Breathing|SENSITEST|University Hospital, Grenoble|No|Completed|December 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|52|||Male|30 Years|65 Years|No|||May 2014|May 2, 2014|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885573||140251|
NCT00886613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-003|A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)|A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate Biomarkers of Immunity to Varicella Zoster Virus Following Immunization With V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine or With ZOSTAVAX in Healthy Volunteers||Merck Sharp & Dohme Corp.|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|120|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|April 22, 2009|No|Yes||No|March 22, 2011|https://clinicaltrials.gov/show/NCT00886613||140171|
NCT00886119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-319-C-005 sub 8|Comparison of a Multifocal Contact Lens to a Traditional Multifocal Contact Lens|Lotrafilcon B Multifocal Evaluations - Comparison to a Traditional Multifocal in Higher Spectacle Adds||Alcon Research||Completed|April 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|35 Years|N/A|No|||January 2012|June 26, 2012|April 10, 2009|Yes|Yes||No|September 14, 2010|https://clinicaltrials.gov/show/NCT00886119||140209|
NCT00886366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1920C00001|Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD6714 in Healthy Male Volunteers and Male Type II Diabetic Patients||AstraZeneca||Terminated|April 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|26|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|April 17, 2009|No|Yes|Part A reached a predefined stopping criteria. Relevant doses for part B could not be    established based on A and subsequently study was stopped.|No||https://clinicaltrials.gov/show/NCT00886366||140190|
NCT00890890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-018|A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease||Bristol-Myers Squibb|Yes|Terminated|May 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|45 Years|90 Years|No|||September 2015|September 23, 2015|April 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890890||139846|
NCT00891735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4579g|A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)|A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration|HARBOR|Genentech, Inc.||Completed|July 2009|August 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1097|||Both|50 Years|N/A|No|||December 2012|December 11, 2012|April 29, 2009|Yes|Yes||No|September 18, 2012|https://clinicaltrials.gov/show/NCT00891735||139783|
NCT00891436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUMCgsk 113002|Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms|Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy||Rush University Medical Center|No|Completed|April 2009|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|April 30, 2009||No||No|September 14, 2012|https://clinicaltrials.gov/show/NCT00891436||139806|
NCT00888667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV001|Optimal EGM Configuration for Morphology Discrimination|Optimal EGM Configuration for Morphology Discrimination|SVT Morphology|St. Jude Medical|No|Terminated|April 2009|May 2010|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Probability Sample|Patients with a dual chamber ICD and frequent PVCs|June 2013|June 7, 2013|April 24, 2009||No|Patient population was not available|No||https://clinicaltrials.gov/show/NCT00888667||140016|
NCT00888680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGC20-1531-06|Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine|A Multinational, Multi-centre, Randomised, Double-blind, Placebo-controlled, 3-way Crossover Study in Migraine Patients, Treated With Two Doses of BGC20-1531 and Placebo||BTG International Inc.|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|April 27, 2009||No|No patients enrolled. Delay due to optimisation of drug product formulation.|No||https://clinicaltrials.gov/show/NCT00888680||140015|
NCT00883441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCO-CT-2004-517708-WP4|Implementation Research of New Dengue Vector Control Tools|Implementation Research of New Dengue Vector Control Tools||Institute of Tropical Medicine, Belgium|No|Completed|July 2006|December 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|22|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 7, 2013|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883441||140412|
NCT00883675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC#08-002|Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer|Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer||Maestro Clinical, Inc.|Yes|Completed|May 2009|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|133|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|April 17, 2009|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00883675||140394|
NCT00883662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14474|Mirena Observational Program|Mirena Observational Program||Bayer|No|Completed|June 2009|November 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2680|None Retained|n.a|Female|18 Years|N/A|No|Non-Probability Sample|Patients older than 18 years with previously taken decision of their gynecologist to        insert Mirena according to registered indications|January 2016|January 27, 2016|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883662||140395|
NCT00883688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN08-01|Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma|A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma||M.D. Anderson Cancer Center|No|Completed|July 2009|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|21 Years|No|||November 2015|November 17, 2015|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883688||140393|
NCT00883948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|651|Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)|Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)|EDEN|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|December 2007|May 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1000|||Both|13 Years|N/A|No|||February 2012|February 9, 2012|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883948||140373|
NCT00884533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111802|QTc Study of Rosi XR in Healthy Volunteers|A Study to Evaluate the Effect of Extended Release Rosiglitazone (RSG XR) on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin|Rosi XR|GlaxoSmithKline||Withdrawn|June 2009|August 2009|Anticipated|August 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|April 16, 2009|Yes|Yes|The whole project was terminated|No||https://clinicaltrials.gov/show/NCT00884533||140329|
NCT00884195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816667-1|Journaling and Weight Loss|Journaling and Weight Loss||University of California, Davis|No|Active, not recruiting|January 2009|December 2011|Anticipated|September 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||May 2011|May 25, 2011|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884195||140355|
NCT00915616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melatonin and reflux|The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease|The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease||Mansoura University||Withdrawn||||||Phase 3|Interventional|Primary Purpose: Treatment|4||||||Both|42 Years|56 Years|Accepts Healthy Volunteers|||June 2009|June 5, 2009|June 1, 2009||||No||https://clinicaltrials.gov/show/NCT00915616||138006|
NCT00915837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRDX- 001|Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema|Phase 1 Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema|STRIDE|SurModics, Inc.|No|Completed|June 2005|May 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||June 2009|June 4, 2009|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915837||137989|
NCT00906412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0732|Ventrointermediate Nucleus (VIM DBS) and Working Memory|VIM DBS and Working Memory|WMVIM|Washington University School of Medicine|No|Enrolling by invitation|September 2006|December 2016|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Washington University School of Medicine Movement Disorder Clinic|January 2016|January 7, 2016|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906412||138704|
NCT00906425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 05/05|Clinical Study Comparing Submerged Versus Trans-mucosal Healing of P.004 Implants in the Anterior Mandible and Maxilla|Randomized, Controlled Clinical Study Comparing Submerged vs. Trans-mucosal Placement of P.004 Implants in the Anterior Maxilla and Mandible by Evaluation of the Change in Bone Level Between 1st Stage Surgery and 6 Months Post Surgery||Institut Straumann AG|No|Completed|October 2006|October 2013|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|May 19, 2009||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00906425||138703|
NCT00915824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT2006029|Prevention of Potentially Inappropriate Prescribing in Late Life Using Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) and Screening Tool to Alert Doctors to Right Treatment (START) Criteria|Prevention of Potentially Inappropriate Prescribing in Late Life Using STOPP (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) and START (Screening Tool to Alert Doctors to Right i.e. Appropriate Indicated Treatment): A Randomized Controlled Trial.||Cork University Hospital|No|Active, not recruiting|November 2007|June 2009|Anticipated|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|400|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 28, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915824||137990|
NCT00916110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3242K1-1001|Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects|Ascending Single Dose Study Of The Safety, Tolerability, PK And PD Of ATN-103 Administered SC Or IV To Healthy Japanese Male Subjects|ATN-103|Ablynx|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Actual|72|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00916110||137968|
NCT00916071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002374|Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders|Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders||Massachusetts General Hospital|No|Completed|October 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|64|||Both|18 Years|55 Years|No|Non-Probability Sample|Male and female outpatients between, and including, 18 and 55 years of age with a history        of eating disorder diagnosis.|January 2013|March 7, 2013|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916071||137971|
NCT00916084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|behnaz1357|Comparative Results of Maxillary Deficiency Treatment by Fixed Tongue Appliance and Fixed Facemask in Growing Patients|This Study is to Apply the Tongue Force to Correct the Dentofacial Deformities||Shahid Beheshti University|Yes|Recruiting|June 2009|August 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||December 2009|July 26, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916084||137970|
NCT00916643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBMI_HELP_Secura|Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy|Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy|Secura|B. Braun Medical Inc.|No|Completed|December 1999|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|N/A|N/A|No|||January 2014|January 29, 2014|June 8, 2009|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT00916643||137927|
NCT00917163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SES/RCT/01|SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent|A Randomized Comparison of the Supralimus® Stent With the Xience V™ Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions||Sahajanand Medical Technologies Pvt. Ltd.|Yes|Terminated|July 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|June 8, 2009||No|due to unavoidable circumstances relating to logistic issues and regulatory processes in    various countries causing unacceptable delays.|No||https://clinicaltrials.gov/show/NCT00917163||137887|
NCT00917176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMS_ONS_01|Occipital Nerve Stimulation in Fibromyalgia|Subcutaneous C2 Stimulation: Treatment of Fibromyalgia||University Hospital, Antwerp||Completed||||||Phase 2|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Female|18 Years|65 Years|No|||June 2009|June 9, 2009|June 9, 2009||||No||https://clinicaltrials.gov/show/NCT00917176||137886|
NCT00917475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904054R|Socio-Emotional Development in Preterm Infants|Socio-Emotional Development in Preterm Infants||National Taiwan University Hospital|No|Recruiting|January 2010|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Infants born prematurely with no significant congenital problems (e.g., cleft palate,        cardiac malformations) and their mothers ages 18 to 40.|January 2010|January 27, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917475||137863|
NCT00918034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSO-OL012|Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|A Phase 2 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy||Light Sciences Oncology|No|Completed|May 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|50 Years|N/A|No|||November 2012|November 14, 2012|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918034||137821|
NCT00918047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804P107|Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oxcarbazepine Extended Release (OXC XR) as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy|Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy||Supernus Pharmaceuticals, Inc.|No|Completed|June 2009|November 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|4 Years|17 Years|No|||May 2013|May 10, 2013|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918047||137820|
NCT00918892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1108|Assessment of Candidate Protein Expression in Breast Cancer Specimens|Assessment of Candidate Protein Expression in Human Breast Cancer Specimens||Case Comprehensive Cancer Center|No|Recruiting|April 2008|||March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|80|Samples With DNA|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal      adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.|Both|N/A|N/A|No|Probability Sample|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal        adjacent tissue are used for immunohistochemistry studies of expression of candidate        genes.|September 2015|September 28, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918892||137755|
NCT00918905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telekol-1|Nurse Tele-Consultations With Discharged COPD Patients Reduce the Numbers of Readmissions|KOL-Fyn - an Explorative Study Wtih Telemedicine in COPD Patients at Home||Svendborg Hospital|No|Completed|June 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|40 Years|N/A|No|||June 2009|June 10, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00918905||137754|
NCT00889239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRG 4780066|Clinical Performance and Wear Mechanism of Hot-Pressed Ceramic Crowns|Clinical Performance and Wear Mechanism of Hot-Pressed Ceramic Crowns||Mahidol University|No|Completed|May 2004|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00889239||139972|
NCT00889252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-4539|Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers|A Single-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers||Vistakon Pharmaceuticals|No|Completed|April 2009|||July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|8 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 18, 2015|April 24, 2009|Yes|Yes||No|October 4, 2010|https://clinicaltrials.gov/show/NCT00889252||139971|
NCT00889824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0600|Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability|Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability||Washington University School of Medicine|No|Completed|February 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|85 Years|No|||January 2016|January 13, 2016|April 27, 2009||No||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00889824||139927|
NCT00889837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-108|Staccato Loxapine Pulmonary Safety in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease||Alexza Pharmaceuticals, Inc.|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|53|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 28, 2009|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889837||139926|
NCT00890669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234/07|Treadmill Training and Quality of Life in Parkinson's Disease|Treadmill Walking Training With Additional Body Load Improves Quality of Life in Subjects With Parkinson's Disease||Universidade Federal de Sao Carlos|No|Completed|August 2007|December 2008|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|51 Years|81 Years|No|||May 2009|May 1, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890669||139862|
NCT00890682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C317|Study of Postoperative Analgesia in Bunionectomy|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing First Metatarsal Osteotomy (Bunionectomy)||Pacira Pharmaceuticals, Inc|Yes|Completed|April 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|April 28, 2009|Yes|Yes||No|November 21, 2011|https://clinicaltrials.gov/show/NCT00890682||139861|
NCT00891267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSE-866/46|Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome|Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome|VAMOS|Daiichi Sankyo Inc.|No|Completed|October 2008|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00891267||139818|
NCT00906360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-00279|Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck|A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer||National Cancer Institute (NCI)||Terminated|July 2008|||September 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|May 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00906360||138708|
NCT00908817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST|Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat|Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat||Soonchunhyang University Hospital||Completed|May 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|20 Years|70 Years||||May 2009|May 26, 2009|May 21, 2009||||No||https://clinicaltrials.gov/show/NCT00908817||138523|
NCT00909090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGA-2009-10141-1|Macular Pigment and Glare Disability|Effects of Lutein and Zeaxanthin Upon MPOD and Its Effects Upon Glare Disability, Photostress Recovery, and Contrast Enhancement in Healthy Subjects: A Randomized, Double-blind Placebo-controlled Study|MP-GD|University of Georgia|Yes|Active, not recruiting|May 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2011|August 10, 2011|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00909090||138502|
NCT00916123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812010139|Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer|A Phase I Trial of Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Anti-prostate-specific Membrane Antigen Monoclonal Antibody in Patients With Metastatic, Castrate-resistant Prostate Cancer||Weill Medical College of Cornell University|Yes|Active, not recruiting|May 2009|May 2016|Anticipated|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Anticipated|30|||Male|18 Years|N/A|No|||May 2015|May 4, 2015|June 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00916123||137967|
NCT00916656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI3023_3001|Fibrinogen Concentrate (Human) − Efficacy and Safety Study|Efficacy and Safety of Fibrinogen Concentrate (Human) (FCH) for On-demand Treatment of Acute Bleeding in Subjects With Congenital Fibrinogen Deficiency||CSL Behring|No|Withdrawn|October 2009|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||May 2014|May 6, 2014|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916656||137926|
NCT00906906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122007-025|Validation of Venous Cannulae Flow Ratings|Validation of Venous Cannulae Flow Ratings of the DLP Right Angle Cannulaes Utilizing Ultrasound Transit Time Technology||University of Texas Southwestern Medical Center|No|Recruiting|January 2008|June 2009|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|Children who undergo heart-lung bypass during surgical correction of their congenital or        acquired heart disease.|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906906||138667|
NCT00906919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM03-0095|The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes|The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes||University of Victoria|Yes|Completed|April 2004|April 2009|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|321|||Both|19 Years|N/A|No|||May 2009|May 19, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906919||138666|
NCT00916370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-373|SPIRIT PRIME Clinical Trial|SPIRIT PRIME Clinical Trial.|SPIRIT PRIME|Abbott Vascular|Yes|Completed|June 2009|February 2014|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|525|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|June 5, 2009|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT00916370||137948|
NCT00917202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-237/2007|Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8 Project of the SFB 544|Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8||Heidelberg University||Completed||||||Phase 2|Interventional|N/A|3||||||Male|17 Years|55 Years||||June 2009|June 9, 2009|June 9, 2009||||No||https://clinicaltrials.gov/show/NCT00917202||137884|
NCT00916383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAD-US02-0810|Study in Elderly Alzheimer's Subjects 3 Consecutive 7-Day Applications of 350mg DTP-Donepezil Transdermal Patch-System|Randomized, Placebo-Controlled Study in Elderly Alzheimer's Subjects on Established/Well Tolerated Dose of Aricept to Assess Skin Tolerability, Skin Irritation and Adhesion (3 Consecutive 7-Day Applications of 350mg DTP-System|DTP-System|Teikoku Pharma USA|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|48|||Both|65 Years|N/A|No|||June 2012|June 15, 2012|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916383||137947|
NCT00917774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-6-10|A Gender-Specific Posterior Cruciate-Substituting High-Flexion Knee Prosthesis Does Not Improve Fit and Function|A Gender-Specific Posterior Cruciate-Substituting High-Flexion Knee Prosthesis Does Not Improve Fit and Function Compared With a Standard Posterior Cruciate-Substituting High-Flexion Knee Prostheis A Prospective, Randomized Study||Ewha Womans University|Yes|Completed|November 2006|May 2009|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Female|N/A|N/A|No|||June 2009|June 11, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917774||137840|
NCT00917761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950924|Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B|Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Negative Chronic Hepatitis B||National Taiwan University Hospital|Yes|Recruiting|February 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917761||137841|
NCT00918060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COA. No. MU-IRB 2008/153.0511|Clinical Effects of Locally-delivered Gel Containing Camella Sinensis Extracts as an Adjunct in Peridontitis Treatment|Clinical Effects of Locally-delivered Gel Containing Camella Sinensis Extracts||Mahidol University|Yes|Active, not recruiting|February 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|34 Years|74 Years|Accepts Healthy Volunteers|||October 2010|October 9, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918060||137819|
NCT00918359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|782-2008-IDF-CTIL|Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes|Following Study: Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes||Medical Corps, Israel Defense Force||Recruiting|May 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|Whole blood|Male|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Blood samples of HT and HI subjects will be collected from volunteers who experienced heat        exhaustion or heat stroke in their past and participating in heat tolerance test (HTT).        The test, using conservative criteria discriminates between HI and HT groups. The        distinction between HI and HT groups occurs only following analyses of the HTT.|June 2011|June 28, 2011|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918359||137796|
NCT00918645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000628784|Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis|Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease|UCDCC#217|University of California, Davis|Yes|Completed|September 2009|June 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Male|18 Years|N/A|No|||June 2013|June 19, 2013|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918645||137774|
NCT00918918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P8600|Effect of Alcohol Consumption on Markers of Inflammation|The Effect of Moderate Alcohol Consumption on a Human in Vivo Model of Low-grade Systemic Inflammation in Young, Normal-weight Men|AR23|TNO|Yes|Completed|August 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918918||137753|
NCT00918931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0792|Obatoclax for Systemic Mastocytosis|Evaluation of Obatoclax Mesylate as Therapy for Patients With Systemic Mastocytosis||M.D. Anderson Cancer Center|No|Terminated|June 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|June 9, 2009|Yes|Yes||No|March 30, 2011|https://clinicaltrials.gov/show/NCT00918931||137752|
NCT00889265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-801|CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation|Prospective, Multi-Center Study of CopiOs® Pericardium Membrane With Puros® Cancellous Particulate Allograft for Localized Alveolar Ridge Augmentation||Zimmer, Inc.|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|April 26, 2009||No||No|May 5, 2014|https://clinicaltrials.gov/show/NCT00889265||139970|
NCT00889525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/104/2005|Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor|Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor||Seth Gordhandas Sunderdas Medical College||Completed|November 2007|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|12 Years|N/A|No|||April 2009|April 28, 2009|April 27, 2009||||No||https://clinicaltrials.gov/show/NCT00889525||139950|
NCT00890136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00017777|Chronic Obstructive Pulmonary Disease (COPD) and Domestic Endotoxin (CODE)|COpd and Domestic Endotoxin (CODE)|CODE|Johns Hopkins University|Yes|Completed|July 2008|November 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|84|Samples Without DNA|blood, sputum|Both|40 Years|N/A|No|Non-Probability Sample|Both Male and Female 40 years and older|April 2015|April 15, 2015|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890136||139903|
NCT00890994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005522|Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)|Evaluation of Molecular Breast Imaging in Patients With a High Likelihood of Ductal Carcinoma in Situ||Mayo Clinic|No|Enrolling by invitation|December 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Female|25 Years|90 Years|No|Non-Probability Sample|Prospective patients will be identified by the radiologist based on findings in their        mammographic, ultrasound or MRI studies. Patients who are suspected to have DCIS based on        mammographic findings will be invited to participate in this study.|March 2016|March 18, 2016|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890994||139838|
NCT00891800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCI023|Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver|A Phase II Feasibility Study to Assess the Use of SIR-Sphere in Patients With Breast Cancer Who Have Chemotherapy-Resistant Disease in the Liver|SIRT|St. Joseph's Hospital, Florida|No|Terminated|July 2007|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|85 Years|No|||July 2010|June 6, 2011|April 29, 2009|Yes|Yes|Lack of study patients|No||https://clinicaltrials.gov/show/NCT00891800||139778|
NCT00892073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008879|Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy|Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study||The Hospital for Sick Children|Yes|Completed|May 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|9 Years|22 Years|No|||August 2013|August 14, 2013|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00892073||139759|
NCT00892086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I52109|Prevalence and Recognition of Geriatric Syndrome in Outpatient Clinic at Srinagarind Hospital|Prevalence and Recognition of Geriatric Syndrome in Outpatient Clinic at Srinagarind Hospital||Khon Kaen University|No|Recruiting|May 2009|May 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|internal medicine outpatient clinic|May 2009|May 1, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892086||139758|
NCT00906074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1811046|Study Evaluating Severe Surgical Site Infections (SSIs) Following Contaminated Or Dirty-infected Abdominal Surgery|A Multicenter, Surgeon-Matched Case-Control Study of Severe Surgical Site Infections (SSIs) Following Contaminated Or Dirty-infected Abdominal Surgery|EURIDICE|Pfizer|No|Completed|February 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|180|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with or without surgical site infections (SSI) after surgery, treated in major        hospitals with general surgical units selected from all over Spain|May 2012|May 9, 2012|May 19, 2009||No||No|March 9, 2012|https://clinicaltrials.gov/show/NCT00906074||138729|Adverse events and serious adverse events were not collected for this epidemiology study.
NCT00906087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP#31911|Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions|The Effect of Myocilin Genetic Variants on Intraocular Pressure and Blood Pressure Variation in Sitting and Supine Positions.|Myoc Gene|University of Michigan|Yes|Completed|May 2009|||December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906087||138728|
NCT00906633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEIFEMcombo0509|Seifem Surveillance of Antifungal Combination Therapy In Hematologic Italian Centers|Seifem Observational Study of Antifungal Combination Therapy In Hematologic Italian Centers|SEIFEM COMBO|University Hospital, Udine, Italy|Yes|Completed|January 2009|January 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Haematologic patients with proven or probable invasive fungal infectious|May 2009|January 25, 2010|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906633||138688|
NCT00909428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109248|Validation of a Real-Time Urodynamic Measure of Urinary Urgency|Validation of a Real-Time Urodynamic Measure of Urinary Urgency as a Measure of the Success of Drug Treatment||Loyola University|No|Completed|January 2007|February 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||May 2009|May 27, 2009|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909428||138477|
NCT00915850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMU-EC01|Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)|Phase I/II Trial of Combination Chemotherapy With Docetaxel, Cisplatin and 5-FU for Unresectable Advanced Esophageal Cancer.||Wakayama Medical University|Yes|Recruiting|August 2007|August 2015|Anticipated|August 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|20 Years|N/A|No|||September 2010|September 8, 2010|June 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915850||137988|
NCT00916097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP6976F_2502|NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)|A Multicenter Phase II Trial of Docetaxel Combined With Cisplatin (CDDP) as a Neo-Adjuvant Chemotherapy in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)||Sanofi||Completed|July 2002|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|20 Years|75 Years|No|||June 2009|June 23, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916097||137969|
NCT00917215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KE0802|Effectiveness of Acupuncture for Asthma|Effectiveness of Acupuncture for Asthma: A Randomized, Sham-acupuncture and Waiting-list Controlled Trial||Korea Institute of Oriental Medicine||Completed|September 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|19 Years|70 Years|No|||July 2009|July 29, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917215||137883|
NCT00917228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prevesc0001|A Wireless Lingual Feedback Device to Reduce Overpressures in Seated Posture: A Feasibility Study|A Wireless Lingual Feedback Device to Reduce Overpressures in Seated Posture: A Feasibility Study|prevesc0001|TIMC-IMAG||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|||||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young healthy subjects|June 2009|June 9, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917228||137882|
NCT00917488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108-PR-PRI-147|Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).|Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).||Laboratorios Leti, S.L.|No|Completed|May 2009|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|27|||Both|18 Years|50 Years|No|||June 2011|June 17, 2011|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917488||137862|
NCT00918086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014641|Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment|Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment: Building Translational Research Capacity in Nutrition and Infectious Diseases in the Republic of Georgia||Emory University|No|Completed|July 2009|July 2014|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|199|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 10, 2014|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918086||137817|
NCT00918073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT-GCRC CIMT HIV smokers|Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Patients|Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Infected Patients||The University of Texas Health Science Center, Houston|No|Completed|November 2007|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|16 Years|N/A|No|Non-Probability Sample|HIV positive smokers who enroll in a smoking cessation trial who elect to participate in        this substudy|May 2013|May 6, 2013|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918073||137818|
NCT00918372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|img001|Coronary Artery Disease (CAD) in Women Marathon Runners|Coronary Atherosclerosis in Women Athletes: Asymptomatic Twin Cities Marathon Women Studied by MSCT Angiography||Minneapolis Heart Institute Foundation|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female long distance runners as compared to age and risk-matched controls from both        sedentary and fitness activity groups who have never been significant runners, derived        from the Minneapolis Heart Institute Foundation's (MHIF) Cross-Sectional Imaging database.|September 2010|September 10, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918372||137795|
NCT00918671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2007.2192|Medication-overuse Headache: 4 Years Follow up|Treatment of Medication-overuse Headache: 4 Years Follow up|MOHfollowup|Norwegian University of Science and Technology|Yes|Completed|January 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|22 Years|74 Years|No|Non-Probability Sample|Patients aged 18-70 years remitted to the out-patient clinics of the neuroloical        departments of five University Hospitals in Norway with probable medication overuse        headache included in a 1-year open-labeled trial during 2004-2006.|September 2010|November 30, 2010|June 9, 2009||No||No|June 3, 2010|https://clinicaltrials.gov/show/NCT00918671||137772|
NCT00918658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Z08|Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer|Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity||Case Comprehensive Cancer Center|No|Terminated|April 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|34|Samples With DNA|To collect normal and malignant cells in bone marrow and peripheral blood samples from      patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous      leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in      cytotoxicity assays.|Both|N/A|N/A|No|Probability Sample|Primary care clinic|October 2015|October 8, 2015|June 10, 2009||No|PI closed lab|No||https://clinicaltrials.gov/show/NCT00918658||137773|
NCT00919269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9902|Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma|A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol||Children's Oncology Group|No|Recruiting|March 1999|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|human tumor tissue and other biological specimens (blood, serum, and bone marrow)|Both|N/A|50 Years|No|Non-Probability Sample|Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study,        patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study and        patients NOT planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study.|March 2016|March 18, 2016|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919269||137727|
NCT00919282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONKO 002 pilot|Gemcitabine (GFF) in Patients With Pancreatic Cancer|A Multi Center Phase II Study of 5-Fluorouracil/ Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.|GFF|CONKO-Studiengruppe|No|Completed|September 1997|December 2002|Actual|July 2000|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||June 2009|June 11, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00919282||137726|
NCT00890422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASOKLIF 0608/MI|Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine|Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine|immunisation|Elisabethinen Hospital|No|Active, not recruiting|March 2007|July 2010|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|99|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||April 2009|April 28, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890422||139881|
NCT00890968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC-202|Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis|A Multi-Center Randomized, Double-Blind, Placebo Controlled, Parallel Group Comparison Study of Once Daily Triamcinolone Acetonide 0.5% DuraPeel™ Versus Placebo DuraPeel in the Treatment of Hand Dermatitis|TAC-202|ZARS Pharma Inc.|No|Completed|April 2009|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890968||139840|
NCT00890981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080747|A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab|A HR-pQCT Study in Postmenopausal Women Previously Treated With Denosumab||Amgen|No|Completed|July 2009|August 2010|Actual|June 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|79|||Female|N/A|N/A|No|||March 2014|March 5, 2014|April 23, 2009|Yes|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00890981||139839|
NCT00891553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112792|CR9112792, a Follow-up of Study CR9108963|Study CR9112792, a Study to Assess Bone Mineral Density Changes in Post-menopausal Osteoporotic Women Following Discontinuation of Ronacaleret or Placebo Treatment in Study CR9108963||GlaxoSmithKline|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|171|||Female|N/A|N/A|No|Probability Sample|The study population for CR9112792 will include approximately 145 postmenopausal women of        those enrolled in study CR9108963, identified from subjects willing to participate and        meeting eligibility criteria at pre-specified sites.|February 2013|February 21, 2013|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00891553||139797|
NCT00891527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07060249|Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis|Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis|PVS|Children's Hospital Boston|Yes|Active, not recruiting|October 2008|April 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||February 2016|February 23, 2016|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891527||139799|
NCT00891540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2009-019|Local Infiltration Analgesia With Ropivacaine Versus Placebo in Caesarean Section|Lokal Infiltrations Analgesi Med Ropivakain 0,5 % Versus Ropivakain 0,2 % Versus Placebo Efter Sectio Caesarea: et Prospektivt, Dobbeltblindet, Placebokontrolleret Studie.||Hvidovre University Hospital|No|Completed|July 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|90|||Female|18 Years|40 Years|No|||April 2009|June 22, 2011|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891540||139798|
NCT00892099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000398|DIVINE: Dialysis Infection and Vitamin D In New England|DIVINE: Dialysis Infection and Vitamin D In New England||Massachusetts General Hospital|Yes|Completed|November 2009|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|105|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|April 30, 2009||No||No|May 22, 2015|https://clinicaltrials.gov/show/NCT00892099||139757|
NCT00887770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1710C00006|A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart|A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers||AstraZeneca|No|Completed|April 2009|July 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 15, 2009|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887770||140083|
NCT00906646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91/04|Preparation of Patients for Cardiac Surgery|Preparation of Patients for Cardiac Surgery|MPM|Bayside Health|No|Completed|April 2004|December 2008|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|N/A|N/A|No|||May 2009|May 20, 2009|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906646||138687|
NCT00909727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-770-103|Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation|A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years With Cystic Fibrosis and the G551D Mutation|ENVISION|Vertex Pharmaceuticals Incorporated|Yes|Completed|August 2009|April 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|6 Years|11 Years|No|||July 2012|July 18, 2012|May 26, 2009|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00909727||138456|
NCT00916396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tasmc-09-MB-158-ctil|Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder|Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder: Modulation of Sexual Libido by Androgens and Neurosteroids||Tel-Aviv Sourasky Medical Center||Recruiting|June 2005|December 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||November 2009|November 29, 2009|June 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916396||137946|
NCT00916409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-14|Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)|A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.||NovoCure Ltd.|Yes|Active, not recruiting|June 2009|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||May 2015|December 28, 2015|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916409||137945|
NCT00916669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-097|A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)|A Randomized Phase II Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy (Cisplatin Plus Etoposide) With Respect to Time to Tumor Progression (TTP) in Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (SCLC) Without Underlying Venous Thromboembolism||Massachusetts General Hospital|Yes|Withdrawn|July 2008|||July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||July 2010|May 7, 2013|June 5, 2009|Yes|Yes|sponsor withdrew funding prior to patient enrollment|No||https://clinicaltrials.gov/show/NCT00916669||137925|
NCT00916890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-SM-1-Op-Cancer|Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain|Chronic Administration of Opioids in Cancer Chronic Pain:an Open Prospective Study on Efficacy, Safety and Pharmacogenetic Factors Influence.||IRCCS Policlinico S. Matteo|No|Suspended|February 2009|December 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|June 9, 2009||No|difficulties in patients enrolment|No||https://clinicaltrials.gov/show/NCT00916890||137908|
NCT00917189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R33MH085901|Computerized Cognitive Skills Training for Adolescents With Velocardiofacial Syndrome|Computer-Based Cognitive Remediation in Adolescents With VCFS||State University of New York - Upstate Medical University|Yes|Active, not recruiting|September 2009|April 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|12 Years|16 Years|No|||February 2014|February 4, 2014|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917189||137885|
NCT00917241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanjingMU|Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone|Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone||Nanjing Medical University|No|Completed|June 2004|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|65 Years|No|||June 2009|May 2, 2013|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917241||137881|
NCT00917501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Del/McNa OMega 3|Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania|Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania||University of Cincinnati|Yes|Completed|June 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|63|||Both|10 Years|21 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917501||137861|
NCT00918411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-500|A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome|Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome||Astellas Pharma Inc|No|Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|98|||Male|20 Years|64 Years|No|||October 2015|October 9, 2015|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918411||137792|
NCT00918424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804P303|Long Term Study to Evaluate the Safety and Tolerability of Oxcarbazepine Extended Release (OXC XR) as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy|Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy||Supernus Pharmaceuticals, Inc.|Yes|Completed|June 2009|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|4 Years|17 Years|No|||November 2012|November 6, 2012|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918424||137791|
NCT00918697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8713|Mechanical Versus Alcohol Epithelial Debridement During Hotorefractive Keratectomy (PRK)|Mechanical Versus Alcohol-Assisted Epithelial Debridement During Photorefractive Keratectomy: A Confocal Microscopic Clinical Trial||hahid Beheshti University of Medical Sciences||Completed|July 2009|March 2010|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Both|20 Years|40 Years|No|||April 2010|October 12, 2010|June 10, 2009||||No||https://clinicaltrials.gov/show/NCT00918697||137770|
NCT00918385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012159|Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer|A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer|ARS|Duke University|Yes|Terminated|May 2009|August 2013|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Male|18 Years|N/A|No|||September 2014|October 28, 2014|June 10, 2009|Yes|Yes|Permanent closure of trial to further accrual based on IDE disapproval|No|September 11, 2014|https://clinicaltrials.gov/show/NCT00918385||137794|
NCT00918398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9831C00003|AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations|An Open, Single-dose, Phase I, 4-period Partly Crossover Study in Healthy Men or Women to Assess Relative Bioavailability of Oral Administration of AZD1981 Via Tablets Compared With Suspension and Basic Systemic Pharmacokinetic Parameters After Intravenous Administration||AstraZeneca|No|Completed|June 2009|July 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 29, 2009|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918398||137793|
NCT00918684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065653-01A1|Aging Brain Changes, Executive Dysfunction and Depression|Aging White Matter Changes, Executive Dysfunction and Depression|FA|Weill Medical College of Cornell University|Yes|Active, not recruiting|August 2002|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|60 Years|85 Years|No|||February 2011|February 18, 2011|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918684||137771|
NCT00918970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708045|Interest of Real Time Measurement of Autonomous Nervous System for the Detection of Brain Death|Interest of Real Time Measurement of Autonomous Nervous System for the Detection of Brain Death: the MEANS Study|MEANS|Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|August 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|N/A|No|Probability Sample|subjects with severe cerebral lesions admitted in intensive care units|June 2009|June 12, 2009|June 8, 2009||No|Angioscanners in excess of the SNA group because of use of thiopental|No||https://clinicaltrials.gov/show/NCT00918970||137749|
NCT00918944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-11-4596|Electronic Health Record (EHR) Decision Support to Improve Outpatient Asthma Care|EHR Decision Support to Improve Outpatient Asthma Care||Children's Hospital of Philadelphia|No|Completed|January 2006|August 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Both|N/A|N/A|No|||December 2011|December 22, 2011|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918944||137751|
NCT00918957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2303|A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).|EDIT|Novartis||Completed|June 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|6 Years|21 Years|No|||October 2012|October 1, 2012|June 4, 2009|Yes|Yes||No|May 5, 2012|https://clinicaltrials.gov/show/NCT00918957||137750|
NCT00915122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0396-C|Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate|A Phase I/II Study of Dose Escalated Intensity Modulated Radiation Therapy (IMRT) for the Treatment of Pelvic Lymph Nodes and Primary Tumour in Patients With Carcinoma of the Prostate||University Health Network, Toronto||Active, not recruiting|November 2005|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Male|N/A|80 Years|No|||June 2015|June 16, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00915122||138043|
NCT00889902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320.6740|Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis|Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis||Wuhan University|Yes|Not yet recruiting|April 2009|July 2011|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Cervical exfoliated cells|Female|25 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|residents of a certain town|April 2009|April 27, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889902||139921|
NCT00889915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014075|Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)|A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD||Duke University|Yes|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|228|||Both|6 Years|17 Years|No|||July 2013|July 30, 2013|April 27, 2009|Yes|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00889915||139920|
NCT00889928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-08-0004|A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance|A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance|NOTES|Ethicon Endo-Surgery|No|Completed|April 2009|August 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|N/A|No|||November 2011|November 1, 2011|April 28, 2009|No|Yes||No|November 1, 2011|https://clinicaltrials.gov/show/NCT00889928||139919|No significant limitations. Small sample size limits inference to a larger population, however it did allow to assess whether the procedure was feasible.
NCT00890435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL08N1|Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial|A Pharmacokinetic Participation Questionnaire Study||Children's Oncology Group|Yes|Completed|July 2008|January 2011|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A patient (family) who has consented to participate in a Phase I trial.|February 2014|October 20, 2015|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890435||139880|
NCT00889460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO58.07 DK|Safety and Tolerability Study of rBet v1 SLIT Tablets|Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen||Stallergenes|No|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|60 Years|No|||April 2009|April 28, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889460||139955|
NCT00892112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD2009.01|Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy|Immunoglobulin Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Parvovirus B19 Persistence - a Prospective, Double-blind, Randomized, Placebo-controlled Clinical Trial||Sanquin|No|Recruiting|November 2009|November 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892112||139756|
NCT00888147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005304|Fiber Formula Study Among Radiation Oncology Patients|Pilot Study: "Does Using a Fiber Containing Enteral Tube Feeding Formula Increase Constipation and the Use of Stool Softeners in Patients Undergoing Radiation Therapy and Have a Percutaneous Endoscopic Gastrostomy (PEG) Placed?"||Mayo Clinic|Yes|Completed|April 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|N/A|No|Probability Sample|These participants have head and neck cancer, are undergoing radiaiton therapy and will        have a percutaneous endoscopic gastrostomy (PEG) placed.|September 2011|September 23, 2011|April 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888147||140056|
NCT00908570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5.1|Topical Estriol for Vaginal Health|Topical Estriol for Vaginal Health||Gynuity Health Projects|No|Completed|June 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|104|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2011|March 3, 2011|May 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00908570||138542|
NCT00908804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-surg-004|Open Versus Laparoscopic Appendectomy|Open Versus Laparoscopic Appendectomy in Suspected Acute Appendicitis - a Prospective Randomised Clinical Trial With With 10-Year Follow-up||North Karelia Central Hospital||Completed||||||N/A|Interventional|N/A|2||||||Both|15 Years|N/A|No|||May 2009|May 26, 2009|May 26, 2009||||No||https://clinicaltrials.gov/show/NCT00908804||138524|
NCT00915343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2006-0007084-89|Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency|A, Randomised, Controlled, Two-armed, Two-period Cross-over, Multi-centre Phase II/III Study to Assess the Safety and Pharmacokinetics of Once-daily Oral Modified-release Hydrocortisone in Patients With Adrenal Insufficiency|DC 06/02|Shire|No|Completed|August 2007|January 2009|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||March 2014|July 16, 2015|June 5, 2009||No||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00915343||138026|
NCT00916682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X07-03-0142|Structure and Function of Salivary Proteins|Structure and Function of Salivary Proteins||Children's Hospital Boston|No|Recruiting|November 2007|||February 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|6 Years|N/A|No|Non-Probability Sample|Subjects will be approached during their pulmonary clinic appointment or while they are        inpatient at Children's Hospital, Boston.|June 2009|June 8, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916682||137924|
NCT00916695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XV02RS|Everolimus-Eluting Stent for Bifurcation Coronary Lesions: Comparison of Simple Versus Complex Techniques|Everolimus-Eluting Stent in the Treatment of Bifurcation Lesions: Comparison of Main Vessel Stent to Main Vessel and Side Branch Stent||Spanish Society of Cardiology|Yes|Recruiting|June 2009|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|332|||Both|18 Years|N/A|No|||July 2009|July 22, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00916695||137923|
NCT00916903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBPHS#4280F|Genetic Disease Gene Identification|Genetic Disease Gene Identification||State University of New York - Upstate Medical University|No|Enrolling by invitation|October 2005|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||2|Anticipated|200|Samples With DNA|DNA will be isolated from peripheral blood or cheek scraoes.|Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients and their families identified by physicians.|June 2009|June 9, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916903||137907|
NCT00916916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15070|Lanreotide Levels in Acromegaly|Lanreotide Levels in Acromegaly||Cedars-Sinai Medical Center||Recruiting||||||N/A|Observational|N/A||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients from Cedars-Sinai Pituitary Center|June 2009|June 9, 2009|June 9, 2009||||No||https://clinicaltrials.gov/show/NCT00916916||137906|
NCT00917514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-01|An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen|An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen During Azathioprine Treatment in Patients With Crohn's Disease or Ulcerative Colitis||Medicpen AB|Yes|Completed|June 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Chrohn's disease or Ulcerative Colitis. Male or Female above 18 years of        age. Ability to provide written informed consent. Must have been on Azathioprine treatment        for at least 6 months prior to study start.|June 2009|February 25, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917514||137860|
NCT00917527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090615|Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease|Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease||Yonsei University|Yes|Recruiting|June 2009|June 2013|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|77|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917527||137859|
NCT00917813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD-1002|A Study of Anti-HIV Monoclonal Antibody KD-247|A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy||The Chemo-Sero-Therapeutic Research Institute|Yes|Completed|September 2007|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|27|||Both|18 Years|64 Years|No|||November 2012|November 16, 2012|June 8, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00917813||137837|
NCT00917826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2 L-D AB|Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies|A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies||HemaQuest Pharmaceuticals Inc.|No|Terminated|September 2008|||September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|3 Years|N/A|No|||July 2011|July 28, 2011|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917826||137836|
NCT00918710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 08104|Human Papillomavirus and Oropharynx Carcinoma|Impact of the Human Papillomavirus (HPV) Status in Carcinologic Prognosis of Oropharynx Squamous Cell Carcinoma.|Papillophar|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2009|May 2017|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|362|Samples With DNA|Pieces of Oropharyngeal squamous cell carcinomas biopsies|Both|18 Years|N/A|No|Non-Probability Sample|Patients with squamous cell carcinoma of oropharynx followed by the participating centers|November 2015|November 19, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918710||137769|
NCT00918437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OES-002|Postoperative Pain Course After Uvulopalatoplasty|Characterization of the Postoperative Pain Course and Intensity After Uvulopalatoplasty With Radiofrequency Knife (RAUP)||Oslo University Hospital|No|Completed|June 2005|June 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients of either sex, of Caucasian origin, between the age of 18 and 80, who are        referred to the hospital for snoring that have been subjected to a sleep study indicating        that uvulopalatoplasty might have a considerable affect on the snoring.|June 2005|July 3, 2011|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918437||137790|
NCT00919295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|323/2551(EC4)|Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome|Study of Anti-nociceptive Biogenic Amine Status, Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Thai Fibromyalgia Syndrome Patients.||Mahidol University|No|Completed|December 2008|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 24, 2012|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919295||137725|
NCT00889317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0824|Sensorimotor Maps of Vowel Perception and Production|Les Cartes Sensori-motrices De La Parole : Corrélats Neuroanatomiques Des Systèmes De Perception Et De Production Des Voyelles Du Français|SPIM|University Hospital, Grenoble|No|Completed|March 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults|January 2013|January 15, 2013|April 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00889317||139966|
NCT00889941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02082009-1758|Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK|Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK||Stanford University|Yes|Completed|May 2004|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|N/A|N/A|No|||April 2009|April 28, 2009|February 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00889941||139918|
NCT00890201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-2704009-02|Pancreaticobiliary Reflux in Patients Without Cholelithiasis|Is Pancreaticobiliary Reflux in Patients With Cholelithiasis and Without Cholelithiasis a Normal Phenomenon?||Cirujanos la Serena|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|197|||Both|15 Years|N/A|No|Non-Probability Sample|1. Patients with gallstones (symptomatic cholelithiasis) submitted to elective surgery.          2. Patients without gallstones submitted to elective surgery for benign or malignant             gastroesophageal diseases|September 2010|December 1, 2010|April 28, 2009||No||No|July 27, 2009|https://clinicaltrials.gov/show/NCT00890201||139898|
NCT00890734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT003-QbG10 11|CYT003-QbG10 for Treatment of Allergic Asthma Bronchial|A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial||Cytos Biotechnology AG|No|Completed|April 2009|November 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|65 Years|No|||February 2012|February 10, 2012|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890734||139857|
NCT00891007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEA-HFN-002|Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years|Partially Randomized, Controlled Phase II Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years||Bavarian Nordic|No|Completed|June 2009|August 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|90|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00891007||139837|
NCT00889785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090076|Situational Problem Solving in Adolescents With Type 2 Diabetes: Enhancing a Randomized Controlled Trial (RCT)|Situational Problem Solving in Adolescents With Type 2 Diabetes: Enhancing an RCT||Vanderbilt University|No|Completed|June 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|43|||Both|12 Years|19 Years|No|||December 2013|December 16, 2013|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889785||139930|
NCT00889798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-TLN|Tumor Registry of Lymphatic Neoplasia|Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.|TLN-Registry|iOMEDICO AG|No|Active, not recruiting|April 2009|December 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3750|||Both|18 Years|N/A|No|Non-Probability Sample|patients with a malignant lymphatic disease requiring therapy|February 2016|February 26, 2016|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889798||139929|
NCT00890071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIE-SCCU-200902|Brachial Artery Peak Velocity Variation to Predict Fluid Responsiveness|Brachial Artery Peak Velocity Variation to Predict Fluid Responsiveness in Mechanically Ventilated Patients||Hospital del SAS de Jerez|No|Completed|December 2008|April 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|Critical ill patients with controlled mechanical ventilation and acute circulatory        failure.|April 2009|April 28, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890071||139908|
NCT00890084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.581|Telmisartan Tab Hypertension|RESPECT: Observational, Prospective, Open-label, Multi-center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.||Boehringer Ingelheim||Completed|April 2009|||December 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2913|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|February 2014|February 28, 2014|April 28, 2009||||No|December 30, 2011|https://clinicaltrials.gov/show/NCT00890084||139907|
NCT00890604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34140-B|Outcomes Associated With Application of a Normothermia Protocol in Patients With Severe Neurological Insult and Fever|Outcomes Associated With the Application of the Normothermia Protocol in Patients With Severe Neurological Insult and Fever|SNIF|University of Washington|No|Terminated|July 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|85 Years|No|||June 2012|June 19, 2012|April 28, 2009||No|Practice change created contamination of usual care arm|No||https://clinicaltrials.gov/show/NCT00890604||139867|
NCT00909103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS-EG001|Endoscopic Ultrasound Elastography in Pancreatic Masses|Computer-aided Diagnosis of Endoscopic Ultrasound Elastography Used in the Differentiation of Focal Pancreatic Masses|EUS-EG|University of Medicine and Pharmacy Craiova|Yes|Completed|June 2008|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|285|Samples Without DNA|Pathology samples obtained from duodeno-pancreatectomies or caudal pancreatectomies done      with curative intent, as well as microhistological fragments obtained through EUS-FNA biopsy      processed by paraffin embedding|Both|18 Years|80 Years|No|Non-Probability Sample|The diagnosis of chronic pancreatitis will be based on the clinical information (history        of alcohol abuse, previous diagnosis of chronic pancreatitis or diabetes mellitus), as        well as a combination of imaging methods (ultrasound, CT and EUS). At least four criteria        of chronic pancreatitis during EUS will be considered for the positive diagnosis.        A positive cytological diagnosis will be taken as a final proof of malignancy of the        pancreas mass. The diagnoses obtained by EUS-FNA will be further verified either by        surgery or during a clinical follow-up of at least 6 months.|January 2010|January 11, 2010|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00909103||138501|
NCT00915018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A2-3005|Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer|A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer|NEFERTT|Puma Biotechnology, Inc.|Yes|Active, not recruiting|August 2009|December 2017|Anticipated|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Female|18 Years|N/A|No|||May 2015|October 21, 2015|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915018||138051|
NCT00915863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP-0901|Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy|A Prospective Randomized Controlled Trial Comparing Isolated Roux-en-Y Reconstruction With Billroth-II-type Reconstruction After Pancreaticoduodenectomy||Wakayama Medical University|Yes|Recruiting|June 2009|March 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|20 Years|N/A|No|||January 2010|January 25, 2010|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00915863||137987|
NCT00917540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-CLL1|Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia|Prospective Collection of Biological Data of Prognostic Relevance in Patients||Gruppo Italiano Studio Linfomi|No|Recruiting|February 2007|April 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|495|Samples With DNA|Peripheral blood|Both|18 Years|80 Years|No|Non-Probability Sample|Previously untreated Binet stage A B-CLL patients, who do not necessitate therapy        according to NCI guidelines|April 2013|April 5, 2013|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917540||137858|
NCT00916929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40006062/D|Detect Fluid Early From Intra-thoracic Impedance Monitoring|Detect Fluid Early From Intra-thoracic Impedance Monitoring|DEFEAT-PE|St. Jude Medical|No|Completed|May 2009|March 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|162|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|June 8, 2009|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00916929||137905|There were no limitations of the trial.
NCT00916942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C123|Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)|An Open-Label Study Of The Use Of Topical Lidocaine (2.5%)/Prilocaine (2.5%) Cream As Pre-Treatment For NGX-4010 In Subjects With Postherpetic Neuralgia (PHN)||NeurogesX||Completed|June 2009|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||September 2009|September 3, 2009|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916942||137904|
NCT00917787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6788-34128-01|Analysis of Blood-based Biomarkers of Asthma|Analysis of Blood-based Biomarkers of Asthma|ABBA|University of California, San Francisco|No|Completed|June 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|127|Samples With DNA|sputum, saliva, DNA, RNA, Plasma, serum|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asthmatics and Non-asthmatics|September 2011|September 20, 2011|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917787||137839|
NCT00917800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Essen 09-3981|Comparison of the HyperQ Versus Conventional Electrocardiogram (ECG) to Detect Ischemia|Diagnostic Benefits of HyperQ™ vs. Conventional ECG During Stress Test. A Comparison Study in Patients Referred for Angiography||West German Heart Center Essen|No|Active, not recruiting|May 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients referred to the West German Heart Center in Essen for coronary angiography|June 2013|June 11, 2013|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917800||137838|
NCT00918099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avaulta|The Use of Avaulta for Anterior Repair|The Use of Avaulta for Anterior Repair. A Multicenter Randomised Prospective Controlled Study||Roskilde County Hospital|Yes|Recruiting|October 2008|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|130|||Female|55 Years|N/A|No|||June 2009|June 10, 2009|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918099||137816|
NCT00918112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0841|Development of a Face Valid Executive Functioning Task|Development of a Face Valid Executive Functioning Task|MedTask|Washington University School of Medicine|No|Active, not recruiting|September 2004|November 2016|Anticipated|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruit participants through Volunteer for Health, word of mouth, and from a clinical        population at the Washington University in St Louis School of Medicine's Neurological        Clinical Research Unit (NCRU).|January 2016|January 7, 2016|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00918112||137815|
NCT00917553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30791|Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy|Proof-of-Concept 2 (POC2): Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients With Mild to Moderate Non-Proliferative Diabetic Retinopathy|POC2|Penn State University|Yes|Completed|July 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|June 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917553||137857|
NCT00918736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC96-2314-B-075B-006|Efficacy of 3 Weekly Injections of Hyaluronate in Patients With Ankle Osteoarthritis|Hyaluronans in the Treatment of Ankle Osteoarthritis||Kaohsiung Veterans General Hospital.|Yes|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|75 Years|No|||June 2009|June 11, 2009|March 16, 2009||No||No|March 16, 2009|https://clinicaltrials.gov/show/NCT00918736||137767|One limitation includes the absence of a control group, thus the placebo effects associated with joint injections were not investigated.
NCT00919022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14556|Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate|Prospective Observational Non-interventional Study of Correlation of Treatment With Androcur, Disease Stage, Testosterone Level, Age With Sexual Function and Erectile Dysfunction (Measured by IIEF-5 Validated Questionnaire)|ANES|Bayer|No|Terminated|August 2009|August 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|194|None Retained|n.a.|Male|18 Years|N/A|No|Non-Probability Sample|Random sample of cancer patients visiting oncologist or urologist ambulance who are        suitable for standard Cyproterone treatment.|October 2012|October 30, 2012|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00919022||137745|
NCT00918125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011117|Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use|The Use of Educational Videos to Improve Patient Decision Making and Racial Disparities in the Implantation of Implantable Cardioverter Defibrillators (ICDs)|VIVID-01|Duke University|No|Completed|November 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|59|||Both|19 Years|N/A|No|Non-Probability Sample|Patients eligible for an implantable cardioverter defibrillator (ICD) for the primary        prevention of sudden cardiac death.|April 2013|October 15, 2015|June 10, 2009||No||No|January 22, 2013|https://clinicaltrials.gov/show/NCT00918125||137814|Study terminated early and thus only 59 out of the proposed 90 patients were enrolled.
NCT00918723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 2401|Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|May 2009|||March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918723||137768|
NCT00889330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003-05|Safety and Efficacy Study of a Eye Drop for Eye Allergy|||Vistakon Pharmaceuticals||Completed|April 2009|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|10 Years|N/A|No|||February 2015|February 18, 2015|April 24, 2009|Yes|Yes||No|June 24, 2011|https://clinicaltrials.gov/show/NCT00889330||139965|
NCT00889343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO KRK 0307|Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer|A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma|FOSCO|AIO-Studien-gGmbH|Yes|Terminated|March 2009|December 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00889343||139964|
NCT00889954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24486-HERCREEM|Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy|Administration of Her2 Chimeric Receptor and TGFbeta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced Her2 Positive Malignancy (HERCREEM)|HERCREEM|Baylor College of Medicine|Yes|Active, not recruiting|May 2009|June 2030|Anticipated|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|3 Years|N/A|No|||February 2016|February 26, 2016|April 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00889954||139917|
NCT00888888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-2604009-01|Colonic Resections in Patients With Suspected Appendicitis|Risk Factors for Colonic Resections in Patients With Suspected Acute Appendicitis||Cirujanos la Serena|No|Completed|April 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|87|||Both|15 Years|N/A|No|Non-Probability Sample|Patients submitted to appendectomy for suspected acute appendicitis and in whom the        surgeon takes the decision to convert to right colectomy based on operative findings and        other factors the we aim to identify|October 2012|October 29, 2012|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888888||139999|
NCT00890630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3265|Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term|Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term: A Pilot Study.|IC-PROM|McMaster University|No|Terminated|April 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Female|N/A|N/A|No|||July 2011|July 19, 2011|April 27, 2009||No|Inadequate Patient Recruitment.|No||https://clinicaltrials.gov/show/NCT00890630||139865|
NCT00890344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD08/7-P|Body Composition Assessment in Healthy Full-term Neonates by Anthropometry, Air Displacement Plethysmography and Multiple-frequency Bio-impedance Analysis|"Body Composition Assessment in Healthy Full-term Neonates by Anthropometry, Air Displacement Plethysmography (PeaPod) and Multiple-frequency Bio-impedance Analysis (BIA)"||Nantes University Hospital|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|1 Day|Accepts Healthy Volunteers|Non-Probability Sample|Full-term infants 10th percentile for gestational age, according to the Audipog's growth        chart|September 2011|September 29, 2011|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890344||139887|
NCT00890357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0111|Identifying Factors Underlying the Discontinuation of Triptans|Identifying Factors Underlying the Discontinuation of Triptans||Mayo Clinic|Yes|Completed|August 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|292|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Specialty Headache Clinics|March 2013|March 27, 2013|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890357||139886|
NCT00891176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112830|Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines|Persistence of Antibodies After Full Vaccination Course With GSK Biologicals' Menitorix or MenC Conjugate Vaccine, Co-administered With DTPa or DTPa/Hib Containing Vaccine and Pneumococcal Conjugate Vaccine, in Children up to 6 Years of Age||GlaxoSmithKline||Completed|May 2009|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|582|||Both|36 Months|76 Months|Accepts Healthy Volunteers|||February 2014|February 13, 2014|April 30, 2009|Yes|Yes||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00891176||139824|
NCT00891189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|637|Determine the Relationship Between Circadian Rhythms and Nocturnal Asthma|Circadian Rhythms and Nocturnal Asthma||Northwestern University|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy and asthmatic participants|September 2014|November 11, 2014|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891189||139823|
NCT00915031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6397|Use of Hypothermia During Robotic Prostatectomy|Hypothermic Nerve Sparing Radical Prostatectomy||University of California, Irvine|Yes|Enrolling by invitation|August 2008|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Male|18 Years|N/A|No|||June 2013|June 24, 2013|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915031||138050|
NCT00915044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-07-ID-153-CTIL|Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in Inflammatory Bowel Disease (IBD)|Characterization of Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in IBD|IBD|Tel-Aviv Sourasky Medical Center|No|Recruiting|July 2007|||July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples Without DNA|15 ml peripheral blood will be obtained from all participants.|Both|10 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults and children aged 10-80. Research group: Approximately 40 patients (adults and        children) suffering from IBD will be enrolled.        Control group: Approximately 100 controls will be enrolled in the research.|June 2009|June 4, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915044||138049|
NCT00916422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005868-10|Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen|Clinical, Multi-centre,Randomized, Double-blind, Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerised Extract of Phleum Pratense Pollen on Patients With Hypersensitivity to Grass Pollen||Laboratorios Leti, S.L.|No|Completed|June 2008|October 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|55 Years|No|||August 2012|January 28, 2014|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916422||137944|
NCT00916981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ref:2006-73|Treatment of Atrophic Nonunion by Preosteoblast Cells|Treatment of Refractory Non-union Fractures by Pre-osteoblast Cells Grafting : a Pilot Study.||University Hospital of Liege|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00916981||137901|
NCT00917839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT.01|The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis|Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis.||Cantonal Hospital of St. Gallen|Yes|Recruiting|June 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|50 Years|No|||June 2009|June 9, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917839||137835|
NCT00917280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#E07-117|Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without Dementia|Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in PD Without Dementia|Lab2Life|Washington University School of Medicine|No|Completed|December 2008|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|174|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Controls:        Recruited from community, VFH.|June 2015|June 1, 2015|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917280||137878|
NCT00917293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08030|Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia|A Randomized, Double-Blind, Placebo-Controlled, Comparative Study to Evaluate the Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia in Patients With Schizophrenia and Schizoaffective Disorders||Medicure|No|Terminated|May 2009|August 2014|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|June 8, 2009|Yes|Yes|modified formulation under investigation|No||https://clinicaltrials.gov/show/NCT00917293||137877|
NCT00917566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 0909|Evaluation of Airtraq in Pediatric|Evaluation of Airtraq in Pediatric Population: A Prospective Randomized Study||King Khaled Eye Specialist Hospital|Yes|Completed|April 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|10 Years|No|||November 2009|November 18, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917566||137856|
NCT00917579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581166|Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet In Healthy Subjects||Pfizer|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|October 16, 2009|June 8, 2009|Yes|Yes||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00917579||137855|
NCT00918450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-738|Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen|A Phase 2b Monotherapy Study of ABT-263 in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia||Abbott||Withdrawn|March 2010|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2010|February 25, 2010|May 22, 2009|Yes|Yes|Sponsor has decided to not proceed with this study.|No||https://clinicaltrials.gov/show/NCT00918450||137789|
NCT00918749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009003|Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women|Study Assessing the Efficacy, Safety, and Pharmacokinetics of 75 and 100 mg Once-a-month Delayed-release Risedronate Formulations Compared to 150 mg Once-a-month Immediate-release Risedronate for 3 Months in Postmenopausal Women Age 45-80||Warner Chilcott|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|205|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|June 10, 2009|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT00918749||137766|
NCT00919035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSRI 0901|Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients|Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients||Oncology Specialists, S.C.|Yes|Completed|June 2009|October 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||June 2014|June 19, 2014|June 10, 2009|No|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT00919035||137744|
NCT00919048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25597|Uroflow Measurements in Urogynecology Patients Compared to Healthy Female Volunteers|Uroflow Measurements in Urogynecology Patients Compared to Healthy Female Volunteers||University of Rochester|No|Completed|September 2008|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|36|||Female|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Urogynecology clinic|December 2009|December 15, 2009|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919048||137743|
NCT00919308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U18HS016725-02|Simulation Training for Ultrasound Guided Central Venous Catheter Insertion|Simulation Training for Ultrasound Guided Central Venous Catheter Insertion||Yale University|No|Completed|August 2006|June 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|184|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|PGY-1 or PGY-2 resident status in the Yale-New Haven Hospital Emergency Medicine, Internal        Medicine, General Surgery, Obstetric and Gynecology and Anesthesia residency programs.|June 2009|June 11, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00919308||137724|
NCT00919321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09082M|The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL||KLL2|Tampere University Hospital|No|Completed|June 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|32|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||March 2012|February 17, 2014|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919321||137723|
NCT00915148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StaHF500804|Ultrasound and Prolonged Labour|First Stage 3D-ultrasound During Prolonged Labour.||Helse Stavanger HF|No|Completed|November 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Female|N/A|N/A|No|Non-Probability Sample|Primi gravidae, with one fetus, after the 37th week. Cephalic presentation. Prolonged        first stage according to WHO definitions.|October 2010|July 27, 2015|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915148||138041|
NCT00887666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-121|Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure|Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure||State University of New York - Downstate Medical Center|No|Recruiting|October 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|People with congestive heart failure|April 2009|April 23, 2009|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887666||140091|
NCT00887991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09NT02|A Trial Comparing Two Breast Pumps in Mothers Expressing Milk for Their Preterm Infants|Randomised Trial Comparing the Efficacy of the ISIS Duo iQ Electric Breast Pump and the Medela Symphony Electric Breast Pump in Mothers Expressing Breast Milk for Preterm Infants||Institute of Child Health||Recruiting|February 2009|February 2010|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|176|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|This is a parallel trial where subjects (mother of preterm infants) will be allocated to        use one of two electric breast pumps to express milk.|April 2009|April 23, 2009|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887991||140067|
NCT00888628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAK|Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients|Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients||Massachusetts General Hospital|Yes|Active, not recruiting|May 2009|August 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|70 Years|No|||April 2015|April 6, 2015|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888628||140019|
NCT00889213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08D.229|An Evaluation of a New Technique Utilizing a Biologic Glue and Tissue Patch to Seal the Cut Edge of the Pancreas Following Removal of the Tail of the Pancreas|A Prospective Randomized Comparison of Pancreatic Stump Closure Techniques Utilizing an Autologous Falciform Patch and Fibrin Glue Compared to Standard Closure Following Distal Pancreatectomy With or Without Splenectomy||Thomas Jefferson University|Yes|Recruiting|August 2008|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|190|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 5, 2014|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889213||139974|
NCT00890643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-018-08S|Effect of Prazosin on Neurophysiology and Cognition in Post-Traumatic Stress Disorder (PTSD)|Effect of Prazosin on Neurophysiologic Responses and Cognitive Performance in PTSD||VA Office of Research and Development|Yes|Withdrawn|December 2009|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|65 Years|No|||September 2013|September 20, 2013|April 28, 2009||No|Primary investigator left VA employment|No||https://clinicaltrials.gov/show/NCT00890643||139864|
NCT00890656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0166|Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage|Phase II Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage||M.D. Anderson Cancer Center|No|Completed|June 2003|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|N/A|N/A|No|||February 2012|February 17, 2012|April 29, 2009||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00890656||139863|
NCT00891202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD02507|A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)||Sanofi|Yes|Active, not recruiting|November 2009|November 2015|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|N/A|No|||October 2015|October 16, 2015|April 30, 2009|Yes|Yes||No|August 22, 2014|https://clinicaltrials.gov/show/NCT00891202||139822|The results include data up to the end of double-blind primary analysis period (Week 39).
NCT00891228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSN275200800042U|Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men|A Multicenter, Randomized, Double-Blind Comparator Trial of the Safety and Sperm and Gonadotropin Suppression Resulting From Combined Use of Nestorone® Gel (0, 8 or 12 mg NES) and Testosterone Gel (10 g) Compared With Testosterone Gel in Normal Men|CCN007|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|May 2009|November 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|99|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|December 14, 2012|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891228||139821|
NCT00915057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-09/2008 (CHBC)|Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.|An Open Study to Investigate the Effects of Chronic Viral Hepatitis B or C on the Pharmacokinetics of Cholyl-lysyl-fluorescein (NRL972) Before, During and After Standard Treatment.||Norgine|No|Completed|March 2009|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|65 Years|No|||December 2009|December 21, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915057||138048|
NCT00915356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3191C00009|Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305|A Double-blind, Randomised, Placebo-controlled, Multicentre, Dose-escalating Study of AZD1305 Given Intravenously for Cardioversion of Atrial Fibrillation||AstraZeneca|Yes|Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|228|||Both|20 Years|80 Years|No|||January 2012|January 2, 2012|June 5, 2009|Yes|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT00915356||138025|
NCT00915629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01513-52|Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®|||Pileje|No|Terminated|June 2009|July 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|134|||Female|18 Years|65 Years|No|||October 2011|October 5, 2011|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915629||138005|
NCT00917267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWCK|A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects|A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications||AstraZeneca|No|Completed|July 2009|April 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|691|||Both|20 Years|N/A|No|||March 2015|March 20, 2015|June 8, 2009|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00917267||137879|
NCT00917306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-020|A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)|A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)||Peplin|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917306||137876|
NCT00917319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siriraj CEU 52-001|Prevention and Control of Healthcare-Associated Infections|Randomized Controlled Study on Effectiveness of Implementing Bundling Infection Control Interventions for Prevention and Control of Healthcare-Associated Infections in General Medical Wards at Siriraj Hospital, Bangkok, Thailand||Mahidol University|No|Active, not recruiting|January 2009|||July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2000|||Both|18 Years|N/A|No|||June 2009|June 16, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00917319||137875|
NCT00916708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTEM|Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients|Appropriateness Evaluation of Follow up Procedures in Gynaecology Oncology TOTEM Study: Multicentric Randomized Controlled Clinical Trial Between Two Follow up Regimens With Different Tests Intensity in Endometrial Cancer Treated Patients.|TOTEM|Azienda Ospedaliera San Giovanni Battista|Yes|Recruiting|September 2008|December 2019|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2300|||Female|18 Years|N/A|No|||January 2016|January 2, 2016|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916708||137922|
NCT00916721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-001903|Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence|Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence|SCP|Massachusetts General Hospital|Yes|Completed|April 2008|January 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|June 5, 2009|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00916721||137921|Subjects were asked to not smoke for 12 hrs prior propranolol.Then were permitted to smoke throughout the week prior physiologic testing.Possibly each smoking experience presented a potential opportunity for the creation of new smoking memories.
NCT00917852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAG 08-02|Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection|Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Traumatic Transection of the Descending Thoracic Aorta||W.L.Gore & Associates|Yes|Active, not recruiting|November 2009|November 2016|Anticipated|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|June 8, 2009|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT00917852||137834|
NCT00918138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-085|Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg|A 4-Week, Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy of Saxagliptin in Combination With Metformin XR 1500 mg Versus Up-titrated Metformin XR to 2000 mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise and a Stable Dose of Metformin XR 1500 mg||AstraZeneca|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|78 Years|No|||May 2015|May 4, 2015|June 9, 2009|Yes|Yes||No|September 2, 2011|https://clinicaltrials.gov/show/NCT00918138||137813|
NCT00918151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3781|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Korea|DiabCare Asia 2008 (Korea): A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia|DiabCare Asia|Novo Nordisk A/S|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1932|Samples With DNA|Capillary or venous blood will be drawn for analysing HbA1c|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to the        inclusion and exclusion criteria.|August 2014|August 12, 2014|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918151||137812|
NCT00918463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809009979|A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase II, Single-Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma||Weill Medical College of Cornell University|No|Recruiting|June 2009|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2011|January 3, 2011|March 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918463||137788|
NCT00918476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121008|Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)|A Phase 1, Open Label Fixed Sequence Study To Investigate The Effects Of Multiple Oral Doses Of Filibuvir On The Steady State Pharmacokinetics Of Oral Contraceptive Steroids In Healthy Female Subjects||Pfizer|No|Completed|June 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|14|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918476||137787|
NCT00919061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-029|Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy|A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naïve to Systemic Therapy||Memorial Sloan Kettering Cancer Center||Completed|August 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 11, 2009|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00919061||137742|
NCT00919074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0831|Comparison of Double Wire Technique With Pancreatic Duct Stent Placement for Difficult Bile Duct Cannulation|Comparison of Double Wire Technique With Pancreatic Duct Stent Placement for Difficult Bile Duct Cannulation: a Randomized Clinical Trial||Washington University School of Medicine|Yes|Completed|September 2008|December 2014|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|90 Years|No|||December 2014|December 8, 2014|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919074||137741|
NCT00919347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080909006|The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction|The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction in Diabetic Patients Undergoing Retinal Surgery||University of Alabama at Birmingham|Yes|Completed|June 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|19 Years|70 Years|No|Non-Probability Sample|The study population will consist of patiented from the Callahan Eye Foundation.|May 2012|May 25, 2012|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00919347||137721|
NCT00915174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/1005|Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects|||Merz Pharmaceuticals GmbH||Completed|June 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 5, 2011|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915174||138039|
NCT00919334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRF5438/06M|Myopia Control With Simultaneous Vision Approach|Control of Myopia Progression in Myopic Children Using Simultaneous Vision Approach||The Hong Kong Polytechnic University|Yes|Completed|July 2007|June 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919334||137722|
NCT00915161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC-07/H0505/197|Sustained Effects of Thoracocentesis in Mechanically Ventilated Patients|Sustained Effects of Thoracocentesis in Mechanically Ventilated Patients: an Observational Single Centre Cohort Study||Oxford University Hospitals NHS Trust|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients on Mechanical ventilation with evidence of pleural effusion on CXR confirmed with        bedside ultrasound|June 2009|June 4, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915161||138040|
NCT00888641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007979|A Pilot Study of Renal Hypothermia During Partial Nephrectomy|A Pilot Study of Renal Hypothermia During Partial Nephrectomy||Mayo Clinic|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888641||140018|
NCT00888654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000641168|Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy|Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy||Barbara Ann Karmanos Cancer Institute|No|Completed|August 2009|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Male|18 Years|N/A|No|||March 2015|March 23, 2015|April 24, 2009|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT00888654||140017|There were no significant limitations.
NCT00889226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP_PTV4_704|Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia|A Randomized, Open Label, Dose Titration Study to Evaluate the Efficacy and Safety of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia|ESPRIT|JW Pharmaceutical|Yes|Completed|April 2008|January 2010|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|25 Years|75 Years|No|||April 2013|April 2, 2013|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889226||139973|
NCT00889499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 146/04|Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron|Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron||University Hospital Inselspital, Berne|No|Completed|March 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889499||139952|
NCT00890110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCC- vac-sut-1|Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib|Phase1/2 Study of Vaccination With DNP Modified Autologous Renal Cell Carcinoma in Combination With Sunitinib in Stage 4 RCC|rcc|Hadassah Medical Organization|No|Not yet recruiting|June 2009|December 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|15 Years|70 Years|No|||April 2009|April 28, 2009|April 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890110||139905|
NCT00890955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LUN07-130|Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies|A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies||Hoosier Cancer Research Network|Yes|Completed|March 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890955||139841|
NCT00891241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMI 1195 -101|A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure|A Multi-Center, Single Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure||Lantheus Medical Imaging|Yes|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2011|August 17, 2011|April 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891241||139820|
NCT00891254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-2904009-03|Long-term Follow-up of Incisional Hernia Repaired With Intraperitoneal Mesh|Randomized Study of Long-term Follow-up of Incisional Hernia Repaired With Intraperitoneal Mesh Versus On-lay Mesh Repair||Cirujanos la Serena|No|Completed|January 2009|July 2012|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|35 Years|75 Years|No|||October 2012|October 29, 2012|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891254||139819|
NCT00915876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paricalcitol-AMC2443|Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo|Effects of 19-nor-1α-dihydroxyvitamin D2 (Paricalcitol) Versus Placebo on Oxidative Stress and Vascular Reactivity in CKD Patients||Albany College of Pharmacy and Health Sciences|No|Completed|March 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915876||137986|
NCT00916136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081299|Skeletal Versus Cutaneous Traction For Treatment of Femur Fractures|Evaluation of Skeletal Versus Cutaneous Traction for Diaphyseal Femur Fractures||Vanderbilt University|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 5, 2009||No||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00916136||137966|
NCT00917332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0256-09-HMO|Effects of Relaxation and Guided Imagery Training on Pain at Childbirth|Effects of Relaxation and Guided Imagery Training on Rate and Time of Receiving Regional Anesthesia (Epidural), and on the Experience of Childbirth||Hadassah Medical Organization||Not yet recruiting|August 2009|November 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 9, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917332||137874|
NCT00917345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904076R|Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity|||National Taiwan University Hospital|No|Recruiting|January 2008|May 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients were referred to the hypertension clinics for suspicious of aldosteronism after        an initial evaluation, and recorded in the Taiwan Primary Aldosteronism Investigation        (TAIPAI). The initial evaluation included (1) age at onset younger than 35 years, (2)        hypertension that is difficult to control after initiating therapy, (3) clinical        occurrence of a hypertensive crisis, (4) the presence of hypokaliemia or metabolic        alkalosis, or a random aldosterone-renin ration (ARR) >30, and (5) evidence of adrenal        incidentaloma and hypertension or hypokalemia. All patients with intention to confirm and        received captopril test were recruited and data were prospectively collected.|June 2009|June 9, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917345||137873|
NCT00917592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANC-05|Trial Assessing the Efficacy of a Short Course of Intravenous Antibiotic Followed by Oral Antibiotic in Uncomplicated Acute Diverticulitis|Prospective Randomized Clinical Trial Assessing the Efficacy of a Short Course of Intravenous Amoxicillin Plus Clavulanic Acid Followed by Oral Antibiotic in Patients With Uncomplicated Acute Diverticulitis|DANC-05|Consorci Sanitari de Terrassa|Yes|Completed|December 2005|October 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||June 2009|June 8, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917592||137854|
NCT00917865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008094|FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer|Anti-[18F]FACBC PET-CT for the Characterization of Primary Prostate Cancer||Emory University|Yes|Terminated|April 2008|January 2013|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Male|18 Years|N/A|No|||November 2013|November 18, 2013|June 5, 2009|No|Yes|Optimal histolgic verification support such as whole mount analysis could not be made    available.|No|May 8, 2013|https://clinicaltrials.gov/show/NCT00917865||137833|A major limitation of our study is lack of step section whole mount histology at our institution which restricted the ability to ensure an exact correlation of histology to imaging.
NCT00918164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0541005|Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects|A Randomized, Open-Label, Single Dose, Crossover Study To Evaluate The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And To Assess Food Effect In Healthy Subjects||Pfizer|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 9, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00918164||137811|
NCT00918177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 09 004|An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease|Dual Release Gastric Retentive AP09004, Vs. Active Control; a Pharmacokinetic/Pharmacodynamic, Comparative, Safety Evaluation in Parkinson's Patients||Intec Pharma Ltd.|Yes|Completed|July 2009|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||February 2010|May 25, 2014|June 1, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00918177||137810|
NCT00918190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 0917|Late Onset Postoperative Nausea and Vomiting|Late Onset Postoperative Nausea and Vomiting Following Strabismus Surgery in Pediatric.What Combination is Better||King Khaled Eye Specialist Hospital|Yes|Completed|June 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|75|||Both|4 Years|12 Years|No|||February 2010|January 6, 2011|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918190||137809|
NCT00918489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHA-I|Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)|A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma|SAHA-I|Heidelberg University|Yes|Completed|May 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918489||137786|
NCT00918502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2009-004|Monitor Patients With Sleep Apnea|Adherent Respiratory Monitoring for Apnea Detection and Evaluation Study|ARMADA|Corventis, Inc.|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|sleep study|February 2010|February 2, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918502||137785|
NCT00907400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00024|Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E|Phase I, Open-label, Randomized, 2-way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Naprosyn E Under Fasting and Fed Conditions in Healthy Volunteers||AstraZeneca|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907400||138629|
NCT00907686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014684|TT-CMV Observational Birth Cohort Study|Prevention of Transfusion-transmitted CMV (TT-CMV) in Lowbirth Weight Infants (LBWI; ≤1500 Grams) Using CMV Seronegative and Leukoreduced Transfusions.|TT-CMV|Emory University|Yes|Completed|January 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|600|Samples Without DNA|Whole Blood, Urine, Breast Milk|Both|N/A|5 Days|No|Non-Probability Sample|Low birthweight infants in NICU.|June 2015|June 25, 2015|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907686||138609|
NCT00908193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051080|Laparoscopic "DA VINCI" Robot Assisted Abdominal Wall Hernia Repair|Assistance Robotics for the Surgical Treatment of the Abdominal Wall Hernia|ARTE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2007|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2013|August 1, 2013|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908193||138570|
NCT00915187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX09-4|Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly|A Phase II Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly, a Double-blind Randomized, Controlled Single Center Study||NasVax Ltd|Yes|Completed|October 2009|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|65 Years|N/A|No|||October 2011|October 18, 2011|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915187||138038|
NCT00907101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10127|Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes|Evaluation of the Effectiveness of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) in Reducing Antibiotic Sensitive and Resistant Strains of P Acnes||Galderma Laboratories, L.P.|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 20, 2009||No||No|August 12, 2014|https://clinicaltrials.gov/show/NCT00907101||138652|
NCT00888927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW-0761-001|Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma|Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects With Previously Treated Peripheral T-Cell Lymphoma||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|May 2009|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2013|August 26, 2013|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888927||139996|
NCT00888940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECAL-CCPB-08-07|Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery|CONSERV - 2 (Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) - A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding|CONSERV-2|Cubist Pharmaceuticals LLC|Yes|Completed|June 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|243|||Both|18 Years|85 Years|No|||July 2015|July 21, 2015|April 26, 2009|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT00888940||139995|
NCT00889512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120080358|The Luveris In Vitro Fertilization Trial|The Luveris® In Vitro Fertilization Trial: The Effect of Recombinant Luteinizing Hormone on Follicular Response, Oocyte Quality, and Pregnancy in In-Vitro Fertilization Treatment Cycles in Women Without Endogenous LH Activity.||University Reproductive Associates|No|Terminated|April 2009|November 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|38 Years|No|||October 2014|October 22, 2014|April 28, 2009|Yes|Yes|Drug no longer available by manufacturer|No|January 8, 2014|https://clinicaltrials.gov/show/NCT00889512||139951|
NCT00890123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMS/2008/Omegaven/Surgery/01|Preoperative Intravenous Omega 3 Fatty Acids Administration in Elderly Patients Undergoing Hip Surgery|Preoperative Intravenous Omega 3 Fatty Acids Administration in Elderly Patients Undergoing Hip Surgery: A Prospective, Randomized, Open-label, Comparative Clinical Trial||Nizam's Institute of Medical Sciences University, India|No|Completed|April 2009|December 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|60 Years|80 Years|No|||October 2014|October 1, 2014|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890123||139904|
NCT00891787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090135|Probiotic Ingestion and Isoagglutinin Titers|Probiotic Ingestion and Isoagglutinin Titers||National Institutes of Health Clinical Center (CC)||Completed|April 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Both|18 Years|70 Years|No|||April 2014|April 11, 2014|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891787||139779|
NCT00891813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W10-677|Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose|Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose||Abbott||Completed|May 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|April 29, 2009||No||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00891813||139777|
NCT00915889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06081|Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors|Cervical Cancer Survivorship Among African-, European-, and Latina-American Survivors||City of Hope Medical Center|Yes|Completed|November 2006|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|340|||Female|18 Years|65 Years|No|||June 2015|June 3, 2015|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915889||137985|
NCT00916149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMC111754|Cognitive Effects of Treatment of Interictal Discharges|Cognitive Effects of Treatment of Interictal Discharges||Massachusetts General Hospital|Yes|Recruiting|January 2007|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|June 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00916149||137965|
NCT00909909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040807|Radiation Therapy in Treating Women With Early Stage Breast Cancer|Safety and Feasibility of Accelerated, Hypofractionated Radiotherapy in Women With Breast Cancer: A Phase II Trial||Rutgers, The State University of New Jersey|Yes|Recruiting|May 2009|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|120 Years|No|||March 2016|March 10, 2016|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909909||138442|
NCT00910221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2007/02810|Cardiopulmonary-bypass and Reno-protective Effect of Atorvastatin Trial|A Phase II Randomised, Double-blind, Placebo-controlled Study of the Effect of Atorvastatin on Postoperative Renal Function in Patients Undergoing Elective Cardiopulmonary Bypass.|CREAT|Austin Health|Yes|Completed|March 2008|September 2011|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||August 2009|September 9, 2012|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910221||138418|
NCT00917605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903080R|Robot-Assisted Therapy in Stroke Patients|Robot-Assisted Upper Limb Rehabilitation in Stroke||National Taiwan University Hospital||Recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|120|||Both|N/A|N/A|No|||March 2012|July 8, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917605||137853|
NCT00917878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-096|Postprandial Effects of Milk and Milk Constituents|The Effects of Milk and Milk Constituents on Postprandial Inflammation in Overweight Subjects||Maastricht University Medical Center||Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|16|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917878||137832|
NCT00917891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 014A|An Expanded Safety Study of Dapivirine Gel 4759 in Africa|A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4759, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.||International Partnership for Microbicides, Inc.|Yes|Completed|November 2009|September 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|280|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 9, 2011|June 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00917891||137831|
NCT00918203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13900|A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Eli Lilly and Company|Yes|Active, not recruiting|January 2010|March 2016|Anticipated|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918203||137808|
NCT00918216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8107|Spectroscopy of Breast Tissue|Spectroscopy of Breast Tissue||Case Comprehensive Cancer Center|No|Completed|March 2008|October 2013|Actual|October 2013|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|141|Samples With DNA|This study will involve up to 200 female patients already undergoing needle biopsy or      surgical excision of a breast lesion identified clinically.|Female|N/A|N/A|No|Non-Probability Sample|This study will involve up to 200 female patients already undergoing needle biopsy or        surgical excision of a breast lesion identified clinically. The patients will be recruited        from the General Surgery and Radiology practices of the co-investigators.|July 2014|July 14, 2014|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918216||137807|
NCT00918515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0510C00001|Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043|A Phase I, Single-Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After Single Ascending Doses in Healthy Male Volunteers||AstraZeneca|No|Completed|May 2009|August 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918515||137784|
NCT00918528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-09-HYMC|Effect of Mitomycin C on Urethral Stricture Recurrence After Internal Urethrotomy|||Hillel Yaffe Medical Center||Not yet recruiting|June 2009|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Male|18 Years|85 Years|No|||June 2009|June 10, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918528||137783|
NCT00908219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21728|A Study of Bevacizumab to Prevent Malignant Ascites|A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites||Baylor College of Medicine|Yes|Withdrawn|July 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||February 2012|June 2, 2015|May 21, 2009|Yes|Yes|Accrual closed by sponsor due to lack of accrual and study progress|No||https://clinicaltrials.gov/show/NCT00908219||138568|
NCT00908505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTX- HMO-CTIL|Comparison Between RTX (Biphasic Cuirass Ventilator) and Physiotherapy in Cystic Fibrosis Patients|Comparison Between bi-Phasic Negative Pressure Ventilator Therapy and Physiotherapy in Cystic Fibrosis Patients|RTX|Hadassah Medical Organization|No|Not yet recruiting|July 2009|December 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|7 Years|N/A|No|||May 2009|May 26, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00908505||138547|
NCT00908479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00665|The Effect of an Inpatient Home-work Exercise Program on Leg Function After Stroke|Exercise Programs for Stroke: Effect of an Inpatient Supplementary Practice Program on Lower Extremity Function||University of British Columbia|No|Completed|September 2009|April 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|142|||Both|19 Years|N/A|No|||June 2014|June 16, 2014|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908479||138549|
NCT00908492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC1050|Supporting Caregivers of Persons With Dementia: A Pilot Study|Pilot Study of the Environmental Skill Building Program for Dementia Caregivers||McMaster University|No|Completed|November 2009|September 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908492||138548|
NCT00888953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FICE09041|Nursing Homes Study of Fall Risk Assessment Oriented to Intervention|Estudio de Medida Del Riesgo de Caídas Orientada a la Intervención en Residencias|EMERCOIR|Fundacio Salut i Envelliment UAB|No|Completed|May 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|331|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 12, 2013|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888953||139994|
NCT00889850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO 001.2009|Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted and Fed Administration|Open, Randomised, Single-Dose, 2x2-Way Cross-Over Comparative Oral Bioavailability Study in Healthy Adult Male Subjects Under Fasted Conditions (Block I) and Under Fed Conditions (Block II); Comparison of 40 mg Esomeprazole Mepha Capsules (Test) With 40 mg Esomeprazole INexium MUPS Tablets (Reference)||Mepha Ltd.|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|100|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 22, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889850||139925|
NCT00889863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885G2301|Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations|β-SPECIFIC 2|Novartis||Completed|July 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|2 Years|19 Years|No|||September 2012|September 13, 2012|April 21, 2009|Yes|Yes||No|September 12, 2012|https://clinicaltrials.gov/show/NCT00889863||139924|
NCT00890396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|647|Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)|Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Study||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Enrolling by invitation|September 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Observational|Observational Model: Cohort||2|Anticipated|167|Samples With DNA|Stored blood and urine|Both|2 Years|7 Years|No|Non-Probability Sample|Children from the initial BABY HUG study who agree to participate in this follow-up study.|July 2009|July 24, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890396||139883|
NCT00890409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Engineering 211|Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy|Selective Head Cooling With Mild Systemic Hypothermia After Neonatal Hypoxic-Ischemic Encephalopathy: A Multi-Center Randomized Controlled Trial in China||Fudan University|Yes|Completed|May 2002|August 2005|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|256|||Both|N/A|6 Hours|No|||May 2009|May 1, 2009|January 2, 2009||No||No|January 2, 2009|https://clinicaltrials.gov/show/NCT00890409||139882|
NCT00891501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amgad|The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects|The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects||Cairo University|No|Recruiting|November 2006|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|15 Years|55 Years|No|||April 2009|April 30, 2009|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891501||139801|
NCT00891514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0118|Inflammation and Exercise in Stroke|Aging, Inflammation and Exercise in Chronic Stroke||National Institute on Aging (NIA)|Yes|Recruiting|May 2009|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|75 Years|No|||September 2009|September 29, 2009|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891514||139800|
NCT00891826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAX 103|Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability|Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability: the "BIPO-3" Trial||Ludwig-Maximilians - University of Munich|Yes|Completed|April 2009|April 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||April 2013|April 11, 2013|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00891826||139776|
NCT00916435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K99HL094665-01 (in review)|Study of the Implantable Cardioverter Defibrillator (ICD) Intracardiac Electrograms|Prospective Observational Study of the ICD Intracardiac Electrograms for Prediction of Ventricular Tachyarrhythmias and Congestive Heart Failure|ICD-EGMs|Johns Hopkins University|No|Completed|March 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|630|||Both|18 Years|N/A|No|Probability Sample|Patients with ischemic or non-ischemic cardiomyopathy undergoing ICD implantation for        primary or secondary prevention of sudden cardiac death|April 2015|April 19, 2015|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916435||137943|
NCT00916955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3669FF|Genetic Modifiers for 22q11.2 Syndrome|Genetic Modifiers for 22q11.2 Syndrome|VCFS|State University of New York - Upstate Medical University|No|Recruiting|March 2008|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|peripheral blood|Both|N/A|N/A|No|Non-Probability Sample|All individuals with velo-cardio-facial syndrome confirmed by FISH|August 2010|January 5, 2015|March 24, 2008||No||No||https://clinicaltrials.gov/show/NCT00916955||137903|
NCT00916968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-6-9|Comparison of Function and Fit of Standard and Gender-Specific CR High-Flex Total Knee Prostheses|Comparison of Function and Fit of Standard Posterior Cruciate-Retaining High-Flexion and Gender-Specific Posterior Cruciate-Retaining High-Flexion Total Knee Prostheses A Prospective, Randomized Study|CR|Ewha Womans University|Yes|Completed|February 2007|May 2009|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|N/A|N/A|No|||June 2009|July 1, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00916968||137902|
NCT00917254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-031|Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery|Phase II/III Study of YM150 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients Undergoing Elective Total Knee Replacement Surgery -||Astellas Pharma Inc|No|Completed|May 2009|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|369|||Both|20 Years|N/A|No|||June 2010|June 14, 2010|June 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00917254||137880|
NCT00906568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-32/09|Evaluation of Bronchial Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)|Clinical Presentation and Bronchial Inflammation of Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients With Cystic Fibrosis|ABPA|Johann Wolfgang Goethe University Hospitals|No|Completed|April 2009|August 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|40|Samples With DNA|serum: total Ig-E and RAST, sputum|Both|4 Years|45 Years|No|Non-Probability Sample|Outpatients of Department of cystic fibrosis, Goethe University, Frankfurt, Germany|October 2010|February 15, 2011|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906568||138693|
NCT00917618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|The Effects of Group Cycling (Spinning®) With Knee Osteoarthritis: A Randomized Control Trial|The Effects of Group Cycling (Spinning®) On Gait and Pain-Related Disability in Persons With Knee Osteoarthritis: A Randomized Control Trial||Mercy Hospital, Pittsburgh, PA|No|Completed|January 2005|September 2006|Actual|May 2006|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|45 Years|75 Years|No|||June 2009|June 9, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917618||137852|
NCT00917631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#4382|Co-Bedding as a Comfort Measure for Twins Undergoing Painful Procedures|Co-Bedding as a Comfort Measure for Twins Undergoing Painful Procedures|CComforT|IWK Health Centre|No|Recruiting|December 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|N/A|N/A|No|||June 2009|June 9, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917631||137851|
NCT00906334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-17|Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk|A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk||Onconova Therapeutics, Inc.|No|Completed|May 2009|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||October 2014|October 11, 2014|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906334||138710|
NCT00906854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0061/08|Urinary Incontinence and Practice of Physical Exercises|Urinary Incontinence and Practice of Physical Exercises Among Nulliparous and Nulligest Women||Universidade de Franca|Yes|Completed|March 2008|October 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|108|||Female|18 Years|30 Years|No|Non-Probability Sample|108 women, nulliparous and nulligest, average age 23.9 years old (from 18 to 30 years old)        who exercise regularly. They were divided into 3 groups according to the regular practice        of exercise forms, they are (G1) weight training, (G2) aerobic exercises, included jump,        step and dancing classes, and (G3) swimming. All participants were questioned about the        perception of leakage of urine during the practice of exercises.|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906854||138671|
NCT00907114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM 1667/09.03.24|Topic Ketorolac Added to Panphotocoagulation in Proliferative Diabetic Retinopathy|Efficacy and Safety of Topic Ketorolac to Treat Center Point Thickness Secondary to Panphotocoagulation in Proliferative Diabetic Retinopathy||Hospital Juarez de Mexico|No|Completed|June 2009|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|44|||Both|40 Years|75 Years|No|||March 2015|March 18, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00907114||138651|
NCT00907127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-5428|Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome|Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome|CAN|University of Michigan|No|Completed|January 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907127||138650|
NCT00908232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013165|Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD|Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD|SEQUENTIAL|Janssen-Cilag International NV|Yes|Completed|May 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|163|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|May 21, 2009|Yes|Yes||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00908232||138567|The response rate of bortezomib in combination with dexamethasone after 4 cycles was much higher than originally assumed. Therefore the sample size of the randomized groups is too small for further statistical analysis.
NCT00907972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 08-30|The Effects of Vitamin D and Bone Loss in Parkinson's Disease|Effect of Vitamin D3 Supplementation in Parkinson's Disease Patients - A Pilot Study|PDVD3|Memorial Medical Center|No|Completed|September 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||July 2013|July 11, 2013|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00907972||138587|
NCT00907985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112676|A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects|Double Blind, Double-dummy, Randomised, Placebo Controlled Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects||GlaxoSmithKline|No|Terminated|May 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 31, 2011|May 7, 2009||No|Slow recruitment; trial unlikely to reach completion|No||https://clinicaltrials.gov/show/NCT00907985||138586|
NCT00908206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109709|Effects of GSK598809 on Brain Activation in Abstinent Alcoholics|A Placebo-controlled, Single-blind, Cross-over, Randomised, fMRI Study Comparing Cue-induced Brain Activation Patterns After a Single Oral Dose of GSK598809 or Placebo in Abstinent Alcoholic Subjects||GlaxoSmithKline|No|Withdrawn|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||April 2015|April 15, 2015|May 21, 2009||No|Study not approved by BfARM|No||https://clinicaltrials.gov/show/NCT00908206||138569|
NCT00909350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005272|Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue|Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue: A Potential Target for Understanding and Preventing the Progression of Barrett's Esophagus||Mayo Clinic|No|Completed|April 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|biopsy tissue from proximal and distal esophagus, stomach and duodenum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects identified from individuals referred for upper endoscopy at Mayo Clinic in        Jacksonville, Florida|February 2015|February 11, 2015|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00909350||138483|
NCT00909363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801009600|Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients|Pathobiology of Thrombocytopenia and Bleeding in Patients With Wiskott-Aldrich Syndrome||Weill Medical College of Cornell University|No|Recruiting|June 2009|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|3 Months|80 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909363||138482|
NCT00890149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13610|Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults|Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults||University of Maryland|Yes|Active, not recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|25 Years|No|||December 2015|December 3, 2015|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890149||139902|
NCT00890162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090129|A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis|A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||July 2015|February 2, 2016|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890162||139901|
NCT00890695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC 1415|Effectiveness of Supplementary Feeding During Infection Among Moderately Malnourished Children|Randomized Controlled Trial of an Outpatient Strategy of Ready to Use Supplementary Food (RUSF) Among Moderately Malnourished Children With Acute Infection|MODMAL|University of Oxford|No|Terminated|May 2009|November 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|6 Months|5 Years|No|||June 2013|June 17, 2013|April 29, 2009||No|New provision of supplementary feeds for moderately malnourished children in the study area.|No|January 15, 2013|https://clinicaltrials.gov/show/NCT00890695||139860|The trial was forced to stop early, 65 recruited. Analysis was inadequately powered to detect the changes in WHZ score and MUAC, the analysis of which had been originally planned for a sample size of 400.
NCT00891280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4-08-001|Dose-escalation Study of Oral CX-4945|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma||Cylene Pharmaceuticals|No|Recruiting|February 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891280||139817|
NCT00890708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0808-057-254|Therapeutic Drug Monitoring of Voriconazole|Influence of Therapeutic Drug Monitoring of Voriconazole on Incidence of Drug Adverse Reaction||Seoul National University Hospital|Yes|Completed|November 2008|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|110|||Both|16 Years|N/A|No|||February 2012|February 18, 2012|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890708||139859|
NCT00891293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111821|A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™|A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™||GlaxoSmithKline|No|Completed|March 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|79 Years|No|||November 2010|January 22, 2011|April 30, 2009|Yes|Yes||No|May 6, 2009|https://clinicaltrials.gov/show/NCT00891293||139816|LOV111821/OM5XX was terminated due to the lack of substantial incremental change in the primary endpoint lipid values above that reached in either the original study (LOV111859/OM5) or the first extension study (LOV111860/OM5X).
NCT00887783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.01|Navelbine And Radiotherapy in Locally Advanced Lung Cancer|Induction Chemotherapy With Carboplatin and Navelbine Oral(R) Followed by Concomitant Navelbine Oral(R) and Irradiation in Local-regionally Advanced Non-small Cell Lung Cancer. A Randomized Phase II Study.|NARLAL|Odense University Hospital|Yes|Active, not recruiting|May 2009|September 2018|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|75 Years|No|||January 2015|January 20, 2015|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887783||140082|
NCT00887809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-015|Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes|Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes||Memorial Sloan Kettering Cancer Center|Yes|Completed|April 2009|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|April 23, 2009|Yes|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT00887809||140081|
NCT00916175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN_LC_P134|Metabolic Syndrome and Functional Food|Randomized Double Blind Factorial Assay, Aloe Vera (AV) And/Or Cnidoscolus Chayamansa (CC) Versus Placebo, Reduction Of High Blood Glucose In Women With Metabolic Syndrome||Universidad Autonoma de Nuevo Leon|Yes|Completed|October 2008|February 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|125|||Female|20 Years|70 Years|No|||July 2009|June 28, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916175||137963|
NCT00916448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATV LPS study|The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia|The Effects of Atazanavir-induced Hyperbilirubinemia on the Innate Immune Response During Human Endotoxemia. A Parallel Double Blind Placebo Controlled Pilot Study.||Radboud University|Yes|Completed|May 2009|July 2015|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|August 13, 2015|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916448||137942|
NCT00906581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-000281/2|Self-Guided Depression Treatment on Long-Duration Spaceflights: A Continuation Study|Self-Guided Depression Treatment on Long-Duration Spaceflights: A Continuation Study||Beth Israel Deaconess Medical Center|No|Active, not recruiting|April 2009|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|30 Years|60 Years|No|||March 2009|May 20, 2009|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906581||138692|
NCT00906594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-USP-01|Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure|Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure: a Prospective, Four-week, Open-label, Randomized, Controlled Clinical Trial.||University of Sao Paulo||Completed|September 2007|July 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||August 2015|August 15, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00906594||138691|
NCT00910234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-98|Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants|Early Treatment With Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants: Comparison of High and Low Dose||China Medical University Hospital|Yes|Not yet recruiting|August 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|100|||Both|N/A|6 Hours|No|||May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910234||138417|
NCT00906035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706469|The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)|The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)||University of Pennsylvania|No|Terminated|September 2002|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|79 Years|No|||November 2011|January 31, 2013|May 20, 2009|Yes|Yes|Difficulty finding subjects who met the inclusion/exclusion criteria.|No||https://clinicaltrials.gov/show/NCT00906035||138732|
NCT00907140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0804|Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study|Assessment of Changes in Pattern and Magnitude of Tumor FDG Uptake During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer||Washington University School of Medicine|Yes|Active, not recruiting|August 2008|August 2016|Anticipated|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Female|18 Years|100 Years|No|||December 2015|December 7, 2015|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907140||138649|
NCT00907413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13898|Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma|Photodynamic Therapy for Palliation of Unresectable Cholangiocarcinoma A Multicenter, Open Label, Randomized, Controlled Phase III Trial|PDT|Weill Medical College of Cornell University|Yes|Terminated|May 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|May 21, 2009||No|PI relocated and reopened trial in new university|No||https://clinicaltrials.gov/show/NCT00907413||138628|
NCT00907699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9507|Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507|Study of Epithelial Growth Factor Receptor Mutations in Tumor Specimens and Blood Samples From Patients With Non-Small Cell Lung Cancer Enrolled on Clinical Trial CASE-2507||Case Comprehensive Cancer Center|Yes|Withdrawn|August 2008|||February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|This laboratory study is looking at biomarkers in tumor tissue and blood samples from      patients with non-small cell lung cancer.|Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|July 2014|July 23, 2014|May 21, 2009||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00907699||138608|
NCT00908518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-RF-514-CTIL|The Difference in Postoperative Cognitive Dysfunction and Myocardial Ischemia Between Propofol and Isoflurane|Postoperative Cognitive Dysfunction and Perioperative Myocardial Ischemia: Comparing Total IV Anesthesia and Inhalation Anesthesia.|POCD|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|June 2009|July 2011|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|65 Years|N/A|No|Non-Probability Sample|500 patients older then 65 year, scheduled for elective non-cardiac, non-neuro surgery|May 2009|May 26, 2009|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908518||138546|
NCT00908752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-037|Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC|A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)|BRISK TA|Bristol-Myers Squibb|Yes|Active, not recruiting|July 2009|December 2015|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|870|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|May 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908752||138528|
NCT00909025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-IMAB-001|Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer|Clinical First-in-human Single-dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-center, Phase I, Open-label, i.v. Infusion Study||Ganymed Pharmaceuticals AG|Yes|Completed|May 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|No|||October 2012|March 11, 2014|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00909025||138507|
NCT00909376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Ledmore|Is Early Second Trimester Vaginal Ultrasound Scan Associated With Adverse Perinatal Outcomes?|Is Early Second Trimester Vaginal Ultrasound Scan Associated With Adverse Perinatal Outcomes?||Shaare Zedek Medical Center|No|Not yet recruiting|July 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|450|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women with one fetus who has no malformations.|May 2009|May 27, 2009|April 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00909376||138481|
NCT00909389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05647|Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)|Post - Marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients||Merck Sharp & Dohme Corp.|No|Completed|November 2006|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4748|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years old and above seen in the outpatient clinic who were diagnosed to have        hypercholesterolemia. Patients with primary (heterozygous familial and non - familial)        hypercholesterolemia or homozygous familial hypercholesterolemia were also included.|May 2015|May 27, 2015|May 20, 2009||No||No|June 24, 2009|https://clinicaltrials.gov/show/NCT00909389||138480|
NCT00889551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPFM 022/2003|Pregnancy and Growth of Adolescent Mothers and Their Child|Pregnancy and Growth of Adolescent Mothers and Their Child||University of Brasilia||Active, not recruiting||||||N/A|Observational|N/A||1|||||Female|12 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|adolescent mothers and their child that are in the ambulatory of growth and development in        the pediatrics center of Braslia University Hospital - HUB|April 2009|April 28, 2009|April 28, 2009||||No||https://clinicaltrials.gov/show/NCT00889551||139948|
NCT00889564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0050|HeRO Vascular Access Device Bacteremia Study|HeRO Vascular Access Device Bacteremia Study||Hemosphere, Inc.|Yes|Completed|March 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||April 2009|April 28, 2009|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889564||139947|
NCT00889577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-018|Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons|Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons||Uniformed Services University of the Health Sciences|Yes|Completed|December 2008|December 2013|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|233|Samples With DNA|Blood samples will be obtained|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive patients who had participated in our previous Liver Study at NMCSD will be        given the opportunity to participate in this study, as well as HIV patients who did not        participate in the Liver Study.|May 2015|May 6, 2015|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889577||139946|
NCT00890175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDC-004-105|Staccato Loxapine Pulmonary Safety in Patients With Asthma|Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma||Alexza Pharmaceuticals, Inc.|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 28, 2009|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890175||139900|
NCT00890188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-97-035|Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer|The Feasibility of Combing THALIDOMIDE and UFUR in the Treatment of Advanced Colorectal Cancer After Oxaliplatin-Contained Chemotherapy|UFUR|National Cheng-Kung University Hospital|No|Recruiting|January 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|80 Years|No|||May 2009|May 5, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00890188||139899|
NCT00890721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402C316|Study of Pain Control in Hemorrhoidectomy|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy||Pacira Pharmaceuticals, Inc|No|Completed|May 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|April 28, 2009|Yes|Yes||No|November 22, 2011|https://clinicaltrials.gov/show/NCT00890721||139858|
NCT00891306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-AMT-011-02|Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects|An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects||Amsterdam Molecular Therapeutics|Yes|Completed|February 2009|April 2011|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891306||139815|
NCT00891839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/2039/NL/US-CA|Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma|An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma||Teva Pharmaceutical Industries|No|Completed|June 2009|May 2014|Actual|December 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|April 29, 2009|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT00891839||139775|
NCT00891852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110106-1|Non-Invasive Determination of Fetal Chromosome Abnormalities|Non-Invasive Determination of Fetal Chromosome Abnormalities||Lenetix Medical Screening Laboratory|Yes|Recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|Plasma|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The investigators anticipate enrolling 1000 subjects who are presenting for prenatal        diagnosis by CVS or genetic amniocentesis for increased risk for fetal aneuploidy.|April 2009|April 30, 2009|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00891852||139774|
NCT00891865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-03|Viral Triggers in Pediatric Lung Transplantation|Viral Triggers of Alloimmunity and Autoimmunity in Pediatric Lung Transplantation (CTOTC-03)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|61|Samples With DNA|Blood and nasopharyngeal samples|Both|N/A|21 Years|No|Non-Probability Sample|Pediatric patients undergoing lung transplantation|May 2015|May 26, 2015|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891865||139773|
NCT00890331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK70917|Prevention of Self-care Deterioration in Early Adolescents With Diabetes|Family Teamwork and Coping Skills Prevention Program||Virginia Commonwealth University|No|Completed|April 2007|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|285|||Both|11 Years|14 Years|No|||January 2016|January 6, 2016|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00890331||139888|
NCT00916734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOCH/IRB/0614|Assessing Patient Response to Therapeutic Exercise Based on Clinical Prediction Rule (CPR) for Spinal Manipulation|Assessing Patient Response to Therapeutic Exercise Based on the Clinical Prediction Rule for Spinal Manipulation||Daemen College|Yes|Completed|November 2007|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|80 Years|No|||December 2011|December 2, 2011|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916734||137920|
NCT00916994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-04|Prospective Study for Safety and Efficacy of InSpace™ in Rotator Cuff Tear Subjects|One-arm, International, Multi-center With Competitive Recruitment, Prospective Study to Assess the Safety and Efficacy of OrthoSpace's InSpace™ in Rotator Cuff Tear Subjects Scheduled for Surgery of the Rotator Cuff||OrthoSpace Ltd.|No|Completed|July 2009|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||June 2013|March 10, 2015|June 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00916994||137900|
NCT00906880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAT0208|Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase|Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage|NECT-FIELD|Drugs for Neglected Diseases|Yes|Completed|April 2009|January 2013|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|630|||Both|N/A|N/A|No|||May 2013|May 30, 2013|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906880||138669|
NCT00906867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-62/09|Pulmonary Function Test, Bronchial Hyperresponsiveness and Quality of Life in Patients With Vocal Cord Dysfunction (VCD)|Pulmonary Function Test, Bronchial Hyperresponsiveness and Quality of Life in Patients With Vocal Cord Dysfunction (VCD)|VCD|Johann Wolfgang Goethe University Hospitals|No|Completed|April 2009|March 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|Samples Without DNA|Serum, total IgE|Both|7 Years|30 Years|No|Non-Probability Sample|Outpatients of departement of Pediatric Pulmonology and Allergology.|October 2011|October 7, 2011|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906867||138670|
NCT00907426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-038|Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin|||Allergan|No|Completed|August 2009|May 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|368|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|May 20, 2009|Yes|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT00907426||138627|
NCT00907712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-09|Cardiovascular Assessment Before and After Limb Amputation|||HaEmek Medical Center, Israel|Yes|Withdrawn|May 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|May 18, 2009||No|Department difficulties|No||https://clinicaltrials.gov/show/NCT00907712||138607|
NCT00907725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p000363|Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?|Follow-up With Serum BhCG Simplify Medical Abortion: A Randomized Controlled Trial||Planned Parenthood League of Massachusetts|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|376|||Female|18 Years|64 Years|No|||May 2012|May 8, 2012|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00907725||138606|
NCT00907998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPL180A2210B|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study in Patients With Coronary Heart Disease (CHD) to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of APL180||Novartis|No|Completed|June 2009|||October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|104|||Both|18 Years|75 Years|No|||November 2009|November 19, 2009|May 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907998||138585|
NCT00908011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-00287|Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets|A Prospective, Randomized Study to Determine the Effect of Ezetimibe in Addition to Rosuvastatin on Lipids in Participants With the Hypercholesterolemia Associated With HIV Antiretroviral Therapy||University of British Columbia|No|Completed|June 2009|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|19 Years|N/A|No|||November 2015|November 30, 2015|May 21, 2009||No||No|November 30, 2015|https://clinicaltrials.gov/show/NCT00908011||138584|
NCT00908531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBCG 07-REAL|Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer|Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.|REAL|Danish Breast Cancer Cooperative Group|No|Terminated|May 2009|June 2024|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Female|60 Years|N/A|No|||February 2015|February 13, 2015|May 26, 2009|Yes|Yes|Poor recruitement|No||https://clinicaltrials.gov/show/NCT00908531||138545|
NCT00908544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUC_NewEra_3.3|New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients|NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0|NewEra|MUC Research GmbH|Yes|Active, not recruiting|May 2009|November 2019|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908544||138544|
NCT00908765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42008754|Effects of Aerobe Interval Training and Moderate Continuous Training in Chronic Obstructive Pulmonary Disease Patients|Effects of Aerobe Interval Training and Moderate Continuous Training in COPD Patients||Norwegian University of Science and Technology|Yes|Completed|August 2008|September 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|45 Years|80 Years|No|||January 2013|January 2, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00908765||138527|
NCT00909038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.574|Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study|A Descriptive Pharmaco-epidemiological Study of a Hypertensive Patient Population Treated With a Fixed-dose Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg and of Conditions for the Management of Arterial Hypertension||Boehringer Ingelheim||Completed|May 2009|||November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2411|||Both|18 Years|N/A|No|Probability Sample|3440|May 2014|May 14, 2014|May 26, 2009||||No|March 23, 2011|https://clinicaltrials.gov/show/NCT00909038||138506|
NCT00909051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14284|GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups|Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups||Bayer|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15729|||Both|18 Years|N/A|No|Non-Probability Sample|-  Patients with untreated or pretreated diabetes mellitus type 2          -  No Glucobay® intake within the last 3 months before documentation of initial visit          -  Exclusion Criteria: contraindication stated in the local Glucobay® product             information; warnings and precautions must be considered.|January 2012|January 18, 2012|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909051||138505|
NCT00905827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-424|Patient and Provider Outcomes of E-Learning Training in Collaborative Assessment and Management of Suicidality|Patient and Provider Outcomes of E-Learning Training in Collaborative Assessment and Management of Suicidality|CAMS|VA Office of Research and Development|Yes|Completed|July 2010|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|212|||Both|22 Years|80 Years|Accepts Healthy Volunteers|||October 2014|April 6, 2015|May 19, 2009||No||No|December 29, 2014|https://clinicaltrials.gov/show/NCT00905827||138748|Providers in this VISN may not be representative of providers in other VAMCs.
NCT00905840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 04/07|A Study to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Diameter Bone Level Implants|A Randomized, Controlled, Double Blind, Clinical Trial to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Ø Bone Level Implants Which Will be Restored With a Removable Prosthesis by Comparing Two Different Implant Alloys in Split Mouth Design||Institut Straumann AG|No|Completed|November 2007|September 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|May 20, 2009||No||No|August 14, 2014|https://clinicaltrials.gov/show/NCT00905840||138747|
NCT00889590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08.185|Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)|Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study|HR-GCT|Leiden University Medical Center|No|Terminated|December 2008|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 28, 2009||No|low recruitment with registration denosumab|No||https://clinicaltrials.gov/show/NCT00889590||139945|
NCT00890448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-475_310|Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate|A Modified Case Control Study to Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate||Takeda|No|Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control||1|Anticipated|66|Samples With DNA|Pharmacogenomic whole blood sample|Both|N/A|N/A|No|Non-Probability Sample|Subjects who participated in lapaquistat acetate phase 2 and phase 3 clinical studies|May 2012|May 23, 2012|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890448||139879|
NCT00889200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608-002|Eszopiclone Treatment & Cortisol Responsivity|Eszopiclone Treatment & Cortisol Response to HPA Axis Tests||Butler Hospital|No|Completed|May 2007|August 2009|Actual|December 2008|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|No|||November 2014|November 3, 2014|April 23, 2009|Yes|Yes||No|August 21, 2013|https://clinicaltrials.gov/show/NCT00889200||139975|
NCT00889759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBoutbreak|The Role of High Resolution-Computed Tomography (CT) in Tuberculosis (TB) Outbreak Investigation|The Role of Addition of High Resolution-CT in Outbreak Investigation of Tuberculosis||Armed Forces Capital Hospital, Republic of Korea|No|Completed|December 2007|April 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A military unit in South Korean Army|September 2009|September 22, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889759||139932|
NCT00889772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008726|Lung Injury Prediction Study|Identifying Patients at Risk of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) at the Time of Hospital Admission: External Validation of a Lung Injury Prediction Score (LIPS)|USCTG-LIPS1|Mayo Clinic|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients >18 years of age with one or more predisposing conditions for        ALI/ARDS (pneumonia, sepsis, shock, pancreatitis, aspiration, high risk trauma and high        risk surgery) at the time of hospital admission|June 2012|September 22, 2015|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889772||139931|
NCT00890617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000640304|Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis|A Pilot Study of Percutaneous Cryotherapy as Treatment for Stage I Lung Cancer or Solitary Metastatic Lung Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|March 2009|||April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|120 Years|No|||March 2016|March 15, 2016|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890617||139866|
NCT00890903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-155|Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)|Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer||Pierre Fabre Pharma GmbH|No|Completed|March 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|62|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced non-small cell lung cancer (NSCLC) or metastatic,        Antracycline-resistant breast cancer, treated with Navelbine capsules|June 2012|June 28, 2012|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890903||139845|
NCT00916474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-950-112|Virology Follow up Study in Subjects Previously Treated With Telaprevir|EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies||Vertex Pharmaceuticals Incorporated|No|Completed|June 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|408|||Both|18 Years|70 Years|No|Non-Probability Sample|Subjects who have previously received at least 1 dose of telaprevir-based treatment        (telaprevir plus peginterferon alfa 2a [Peg IFN-alfa-2a] with or without ribavirin [RBV])        in 1 of the following clinical studies: VX05-950-104, VX05 950-104EU, VX06-950-106,        VX06-950-107, VX07-950-108, VX08-950-111, and VX-950-TiDP24-C216.|February 2014|February 26, 2014|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916474||137940|
NCT00916747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progeria Efficacy|Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria|An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies||Children's Hospital Boston|Yes|Active, not recruiting|August 2009|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||December 2015|December 22, 2015|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916747||137919|
NCT00917007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBPHS #5803|Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis|Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis in ABO-compatible and Incompatible Healthy Term Newborn Infants.||State University of New York - Upstate Medical University|No|Recruiting|June 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|Samples With DNA|whole blood|Both|N/A|28 Days|No|Non-Probability Sample|healthy term newborn infants of mothers with type O blood type|August 2010|August 4, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917007||137899|
NCT00906620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5277|Saving and Empowering Young Lives in Europe (Israel)|Saving and Empowering Young Lives in Europe in Israel, Evaluation, Intervention and Prevention|SEYLE-ISRAEL|Rabin Medical Center|Yes|Completed|September 2009|January 2012|Actual|January 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1247|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906620||138689|
NCT00907153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29714|Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)|Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial.||Milton S. Hershey Medical Center|No|Completed|May 2009|September 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|45 Years|No|||September 2014|September 17, 2014|May 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00907153||138648|
NCT00907166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-CPI-613-004|A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients|A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients||Cornerstone Pharmaceuticals, Inc.|No|Active, not recruiting|May 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||January 2014|January 27, 2014|May 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907166||138647|
NCT00907179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-036|Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer|Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer||University of Pittsburgh|Yes|Terminated|July 2009|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 20, 2009|No|Yes|Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..|No||https://clinicaltrials.gov/show/NCT00907179||138646|
NCT00907439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU-HRPO-07-0551|Study of the Effect of Inhaled Anesthetics on Diastolic Heart Function Using a Doppler-derived Efficiency Index|Changes in Diastolic Dysfunction With the Onset of Volatile Anesthesia in Patients Undergoing Coronary Artery Bypass Grafting as Determined by a Load-independent Efficiency Index Derived From the Parameterized Doppler Analysis of Left Ventricular Filling||Washington University School of Medicine|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing non-emergent coronary artery bypass grafting surgery at a tertiary        care center|November 2010|November 3, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907439||138626|
NCT00907738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0683-007|A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)|A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers||Merck Sharp & Dohme Corp.|No|Completed|August 2005|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|May 21, 2009|Yes|Yes||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00907738||138605|Non-serious adverse events were only collected if they caused drug interruption, discontinuation, or dose reduction.
NCT00908024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA191-006|Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors|A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Terminated|October 2009|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00908024||138583|
NCT00908778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVD- 302|A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects|A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.||Vitreoretinal Technologies, Inc.|No|Recruiting|October 2008|||July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|160|||Both|50 Years|N/A|No|||October 2009|October 19, 2009|May 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908778||138526|
NCT00908791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0906|Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue|An in Vivo Proof of Principle Trial to Determine Whether the Nutritional Supplement Conjugated Linoleic Acid (CLA, Clarinol™) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|May 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Female|18 Years|N/A|No|||June 2012|June 8, 2012|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908791||138525|
NCT00909064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816251-2|The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty|The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty||University of California, Davis||Not yet recruiting|June 2009|December 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|91|||Both|18 Years|80 Years|No|||May 2009|May 26, 2009|May 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909064||138504|
NCT00909077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Rituximab-DXM|The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)|A Randomised Phase III Study of the Efficacy of High Dose Dexamethasone Versus High Dose Dexamethasone in Combination With Rituximab (MabThera®)in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)||Copenhagen University Hospital at Herlev|No|Active, not recruiting|August 2004|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909077||138503|
NCT00909714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETS Trial|Neuroregeneration Enhanced by Transcranial Direct Current Stimulation (TDCS) in Stroke|Neuroregeneration Enhanced by TDCS in Stroke|NETS|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|July 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00909714||138457|
NCT00906113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0058-09-HMO|Intra-arterial Chemotherapy for Children With Retinoblastoma|Phase 1-2 Study of Injection of Melphalan Into the Ophthalmic Artery in Children With Retinoblastoma||Hadassah Medical Organization|No|Recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Months|10 Years|No|||March 2015|March 17, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906113||138726|
NCT00906126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122006051|Oral Misoprostol for Labor Augmentation: A Pilot Study|Oral Misoprostol for Labor Augmentation: A Dose-Finding Pilot Study||University of Texas Southwestern Medical Center|No|Completed|April 2007|May 2009|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|46|||Female|18 Years|45 Years|No|||May 2009|May 20, 2009|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906126||138725|
NCT00889603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2501065|Non-Interventional Study With Aricept® Evess|Non-Interventional Study With Aricept® Evess In Patients Diagnosed With Mild And Moderate Alzheimer's Disease Or Vascular Dementia||Pfizer|Yes|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|370|||Both|50 Years|N/A|No|Non-Probability Sample|The patients will be selected from those addressing psychiatrists on an outpatient bases,        male / female, older than 50 years, being diagnosed with Alzheimer's Disease and Vascular        Dementia, with MMSE score between 12 - 24.|March 2011|March 4, 2011|April 27, 2009||No||No|January 26, 2011|https://clinicaltrials.gov/show/NCT00889603||139944|FAQ Change from baseline not analyzed, a note to file was issued stating it was removed from protocol but erroneously remained in statistical analysis section. Patient Domain of Benefit, Week 24 LOCF not analyzed; endpoint only collected at Week 24.
NCT00888004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2206|Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias||Novartis||Completed|March 2009|||August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|30 Years|85 Years|No|||October 2009|October 22, 2009|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888004||140066|
NCT00890214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AABR-0609|Prostacyclin's Effect on Platelet Responsiveness|Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.||Catholic University of the Sacred Heart|No|Completed|September 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|N/A|No|||April 2009|April 28, 2009|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00890214||139897|
NCT00889473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1001-006 Part B|Study of the Efficacy of AT1001 (Larazotide Acetate) to Treat Celiac Disease|A Phase IIb, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of AT-1001 in Celiac Disease Subjects During a Gluten Challenge||Alba Therapeutics|No|Completed|April 2009|April 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|72 Years|No|||January 2010|July 12, 2012|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889473||139954|
NCT00889486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-102-CL-G002|Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus||Tranzyme, Inc.|No|Completed|April 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|92|||Both|18 Years|80 Years|No|||December 2012|December 7, 2012|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889486||139953|
NCT00890097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-36|Geographic Atrophy Treatment Evaluation|The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)|GATE|Alcon Research|Yes|Terminated|April 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|772|||Both|55 Years|N/A|No|||June 2014|June 4, 2014|April 27, 2009|Yes|Yes|Treatment ineffective|No|June 4, 2014|https://clinicaltrials.gov/show/NCT00890097||139906|
NCT00891475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCRB-003|Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients|Phase II Trial of Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients With Small Primary Tumor||Kidney Cancer Research Bureau|Yes|Completed|May 2008|January 2011|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|85 Years|No|||February 2014|February 11, 2014|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891475||139803|
NCT00916760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-005871-17|Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica|Clinical, Multi-centre, Randomised, Double-blind Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerized Extract of Parietaria Judaica Pollen on Patients With Hypersensitivity to This Pollen||Laboratorios Leti, S.L.|No|Completed|February 2008|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|55 Years|No|||August 2012|November 8, 2013|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916760||137918|
NCT00909298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP889-202|Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)|A Randomized Clinical Trial of Intrinsic Pathway Antagonists in Patients Undergoing Implantation of Left Ventricular Assist Devices||vTv Therapeutics|Yes|Terminated|June 2009|||June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909298||138487|
NCT00917020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C216|The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis||Capnia, Inc.|No|Completed|July 2009|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||August 2012|August 6, 2012|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917020||137898|
NCT00917033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHA GS 01|Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy|Orotracheal Intubation of Morbidly Obese Patients. A Randomised Controlled Trial Comparing the GlideScope Videolaryngoscope to the Macintosh Direct Laryngoscope.||Glostrup University Hospital, Copenhagen|No|Completed|September 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||February 2010|February 23, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917033||137897|
NCT00910039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1308|Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases|SUNDANCE Trial: Phase II Trial of Sunitinib as Maintenance Therapy After Stereotactic Radiosurgery in Patients With 1-3 Newly Diagnosed Brain Metastases||Case Comprehensive Cancer Center|Yes|Terminated|April 2009|April 2014|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|May 28, 2009|Yes|Yes|Slow Accrual|No|July 18, 2013|https://clinicaltrials.gov/show/NCT00910039||138432|
NCT00906945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0910 / 201106039|Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia|Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia||Washington University School of Medicine|Yes|Active, not recruiting|February 2011|September 2015|Anticipated|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|39|||Both|18 Years|70 Years|No|||March 2015|March 18, 2015|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906945||138664|
NCT00906893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2008/31|Evaluation of [18F]-FMISO for Non Operated Glioblastoma|Methodological Evaluation of Fluor 18 Labelled Fluoromisonidazole ([18F]-FMISO) Positon Emission Tomography-Computed Tomography (PET-CT) for Non Operated Glioblastoma|MISOGLIO|University Hospital, Bordeaux|No|Completed|June 2009|January 2013|Actual|January 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|14|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906893||138668|
NCT00906672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/26|Medico Economic Evaluation of Dermal Substitute Integra® for Coverage of Inferior Limb Traumatic Skin Loss||INTEGRA®|University Hospital, Bordeaux|Yes|Completed|June 2009|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|15 Years|80 Years|No|||May 2014|May 7, 2014|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906672||138685|
NCT00906685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRVO|Bevacizumab for Central Retinal Vein Occlusion Study|A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO)||St. Erik Eye Hospital|No|Completed|May 2009|September 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||November 2011|November 21, 2011|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906685||138684|
NCT00907452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFM 2007-03|Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone|Pharmacogenomic Study to Predict Survival, Best Response and Toxicity in Newly Diagnosed Myeloma Patients Above the Age of 65 Treated With Either a Combination of Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone||Intergroupe Francophone du Myelome|No|Active, not recruiting|April 2009|||September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1555|||Both|65 Years|N/A|No|||June 2011|June 18, 2011|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907452||138625|
NCT00908245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR01010|Ischemic Preconditioning in Major Hepatectomy|Evaluation of Ischemic Preconditioning in Patients Undergoing Major Liver Resection With Intermittent Pedicular Clamping: A Multicentric Randomized Trial|HECLA|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2003|December 2008|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||July 2011|December 15, 2011|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908245||138566|
NCT00908271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-059|Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects|Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects||AstraZeneca|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|May 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00908271||138565|
NCT00916617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133L1-2204|Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab|A Multicenter, Open-Label, Multiple Dose, Parallel Group Investigation Of The Long-Term Safety, Tolerability, Reactogenicity And Efficacy Of Bapineuzumab Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer Disease||Pfizer|Yes|Terminated|June 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|50 Years|90 Years|No|||November 2012|November 28, 2012|June 4, 2009|Yes|Yes|The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical    benefit. This decision was not based on any new safety concerns.|No||https://clinicaltrials.gov/show/NCT00916617||137929|
NCT00916630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-097|Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)|A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate||Massachusetts General Hospital|Yes|Completed|January 2009|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916630||137928|
NCT00909402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA194-004|A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas|Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas||Bristol-Myers Squibb|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|May 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909402||138479|
NCT00909415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0171|Urodynamic Evaluation in Patients With Anorectal Malformation According to Spinal Cord Abnormalities|Urodynamic Evaluation in Patients With Anorectal Malformation According to Spinal Cord Abnormalities||Yonsei University||Completed|May 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|53|||Both|1 Month|11 Years|No|Non-Probability Sample|patients with anorectal malformation|January 2012|January 26, 2012|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909415||138478|
NCT00916864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEFAST!-1|Biomarker for Rapid Diagnosis of Hemispheric Stroke|Biomarker for Rapid Diagnosis of Hemispheric Stroke|BE FAST!|Johann Wolfgang Goethe University Hospitals|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Human plasma|Both|18 Years|N/A|No|Probability Sample|Patients admitted with symptoms suspicious of acute hemispheric stroke to primary,        secondary and tertiary care hospitals in Europe.|June 2011|June 22, 2011|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00916864||137910|
NCT00910013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-340|Femoral Block With or Without Ropivacaine for Analgesia After Total Knee Replacement (TKR)|A Randomized Trial Comparing the Efficacy on Post-operative Analgesia of Intra-articular Ropivacaine Added to a Femoral Block After Total Knee Replacement|TKR|Hopital de l'Enfant-Jesus|No|Completed|April 2006|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||May 2009|February 25, 2011|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910013||138434|
NCT00910026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4163/02-09-2008|Study of the Influence of Various Tidal Volumes on Exhaled Breath Condensate (EBC) in Mechanically Ventilated Patients|Exhaled Breath Condensate (EBC) Collection and Analysis in Mechanically Ventilated ICU Patients: Monitoring of the Influence of Various Tidal Volumes on Lung Inflammatory Biomarkers|TDEBC|Larissa University Hospital|No|Completed|May 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2009|October 24, 2013|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910026||138433|
NCT00917748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_04203|Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)|A Prospective, Randomised, Double-Blind, Placebo-Controlled Phase III Study of Modafinil to Improve Fatigue and Quality of Life in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer||Sanofi||Completed|June 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917748||137842|
NCT00888316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008NTLS103|Iron Overload in Patients Undergoing Donor Stem Cell Transplant|Iron Overload in Allogeneic Hematopoietic Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Completed|December 2008|June 2012|Actual|June 2012|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|112|||Both|18 Years|75 Years|No|Probability Sample|Allogeneic Hematopoietic Cell Transplantation|June 2013|June 11, 2013|April 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00888316||140043|
NCT00888901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-001|Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag|Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag.|PLATEFUN|Medical University of Vienna|No|Completed|May 2009|May 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|30|||Both|18 Years|90 Years|No|||April 2012|April 19, 2012|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888901||139998|
NCT00890370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998CF004B|Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis?|A Comparison of Five Airway Clearance Techniques in the Treatment of Adults With Cystic Fibrosis|ACT|Royal Brompton & Harefield NHS Foundation Trust|No|Completed|July 1999|September 2003|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|75|||Both|16 Years|N/A|No|||April 2009|April 28, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890370||139885|
NCT00890916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6027-R|Hand Function for Tetraplegia|Hand Function for Tetraplegia Using a Wireless Neuroprosthesis||VA Office of Research and Development|No|Active, not recruiting|January 2012|December 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|April 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00890916||139844|
NCT00891488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0119|Stress Resilience Study|Systemic and Localized Stress Resilience in Aging: Effects of Physical Fitness||Kronos Longevity Research Institute|No|Completed|July 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Blood, saliva, and urine samples|Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|July 2010|August 2, 2010|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891488||139802|
NCT00891761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112512|A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy|A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Cisplatin-Induced Nausea and Vomiting||GlaxoSmithKline||Withdrawn|September 2009|July 2010|Anticipated|July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|April 30, 2009|Yes|Yes|This study has been cancelled prior to enrollment.|No||https://clinicaltrials.gov/show/NCT00891761||139781|
NCT00909311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-923|Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir|Randomized, Open-label, 2-period Cross-over Study in Healthy Adults to Evaluate the Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir||Abbott|No|Completed|May 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|October 11, 2010|May 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909311||138486|
NCT00909597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC21893|A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety , Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea||Hoffmann-La Roche||Completed|May 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|756|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909597||138464|
NCT00909610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1283|Ursodiol Tablets 500 mg Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 26, 2009|No|Yes||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00909610||138463|
NCT00909636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-031|A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet|A Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 in Healthy Adults||Abbott|No|Completed|May 2009|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 11, 2010|May 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909636||138462|
NCT00906958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08177-0608|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2009|||||N/A|N/A|N/A||||||||||||||May 20, 2009|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906958||138663|
NCT00906971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|posca-832|Physiotherapeutic Intervention in Children With Chronic Functional Constipation|Physiotherapeutic Intervention in Children With Chronic Functional Constipation||Universidade Federal de Pernambuco|Yes|Completed|March 2009|April 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|72|||Both|4 Years|18 Years|No|||November 2012|November 6, 2012|May 19, 2009||No||No|September 14, 2012|https://clinicaltrials.gov/show/NCT00906971||138662|The study was not designed to assess if a longer period of physiotherapy using these exercises could bring more clinical benefits to bowel habits, therefore, further studies should be undertaken to assess longer treatment periods, of 6 to 12 months.
NCT00906139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCorreia|Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients|Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients||Federal University of São Paulo|Yes|Active, not recruiting|March 2008|November 2009|Anticipated|February 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|75 Years|No|||May 2009|May 22, 2009|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906139||138724|
NCT00907192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0019|Self Reported Deviations From Opioid Analgesic Prescription|The Influence of Patients' Knowledge, Attitudes and Beliefs on Self Reported Deviations From Opioid Analgesic Prescription: an Exploratory Survey||M.D. Anderson Cancer Center|No|Completed|May 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|201|||Both|18 Years|N/A|No|Non-Probability Sample|Patients least 18 years old, diagnosised advanced cancer, and are taking narcotic pain        drugs (opioids).|June 2013|June 14, 2013|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907192||138645|
NCT00915811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06CC12|Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin|Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin|FB-ATG|King's College Hospital NHS Trust|No|Terminated|June 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2011|August 16, 2011|June 5, 2009||No|FB ATG is now a standard for sib allo MDS patients|No||https://clinicaltrials.gov/show/NCT00915811||137991|
NCT00908037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108062|Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)|A Three Part, Staggered Cohort, Open-label and Double Blind, Randomized, Placebo Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Eltrombopag, a Thrombopoietin Receptor Agonist, in Previously Treated Pediatric Patients With Chronic ITP.|PETIT|GlaxoSmithKline|Yes|Completed|September 2009|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|1 Year|17 Years|No|||October 2014|March 19, 2015|May 21, 2009|Yes|Yes||No|September 29, 2014|https://clinicaltrials.gov/show/NCT00908037||138582|
NCT00916344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38-1|Master Study for the Investigation of Safety and Efficacy of the EVIA Pacemaker|Master Study of the EVIA DR-T/DR/SR-T/SR Pacemaker||Biotronik SE & Co. KG||Completed|June 2009|March 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|175|||Both|N/A|N/A|No|||October 2011|October 4, 2011|June 4, 2009||No||No|July 27, 2011|https://clinicaltrials.gov/show/NCT00916344||137950|
NCT00916357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-117-204|Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)|Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM||Halozyme Therapeutics|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|23|||Both|18 Years|70 Years|No|||July 2014|July 30, 2014|June 5, 2009|Yes|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT00916357||137949|
NCT00916877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inhouse|Prophylactic Cranial Irradiation in Patients With HER-2-Positive Metastatic Breast Cancer|Prophylactic Cranial Irradiation in Patients With HER-2-Positive Metastatic Breast Cancer||AHS Cancer Control Alberta|No|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Female|18 Years|N/A|No|||August 2011|August 4, 2011|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916877||137909|
NCT00917150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-08-801|To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Dose-comparison Trial of OPC-6535 in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Otsuka Pharmaceutical Co., Ltd.|No|Completed|March 2009|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|771|||Both|40 Years|75 Years|No|||June 2014|June 9, 2014|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917150||137888|
NCT00917449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-004639-24|Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome|Interventional Pharmacological Study With L-Arginine in the Prevention of Type 2 Diabetes Mellitus in Patients With Metabolic Syndrome|L-arginine|IRCCS San Raffaele|Yes|Completed|December 2005|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|142|||Both|35 Years|N/A|No|||June 2009|June 9, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917449||137865|
NCT00917462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-016|Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer|Phase II Trial of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917462||137864|
NCT00918346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77550|Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation|Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation in Patients With Open-angle Glaucoma or Ocular Hypertension||Santen Oy|No|Completed|September 2005|April 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|June 9, 2009||No||No|August 4, 2009|https://clinicaltrials.gov/show/NCT00918346||137797|
NCT00918879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00008|Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control|A 24-Week National, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase IIIb Study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise||AstraZeneca|No|Completed|May 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|June 5, 2009|Yes|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00918879||137756|
NCT00888914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL006LCL|Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, to Treat Moderate to Severe Lateral Canthal Lines in Adults.||Revance Therapeutics, Inc.|No|Completed|November 2008|February 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|30 Years|55 Years|No|||October 2013|October 25, 2013|April 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888914||139997|
NCT00889811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0806-060-247|Effect of Remote Preconditioning in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery|Effect of Lower Limb Remote Preconditioning on Myocardial Injury in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery||Seoul National University Hospital|Yes|Completed|March 2009|August 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|68|||Both|18 Years|80 Years|No|||October 2009|October 7, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889811||139928|
NCT00890383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS Sur 2007-030|Colloids in Severe Trauma|Colloids in Severe Trauma: A Multi-Center Pilot Study of "Crystalloid Only" or "Crystalloid + Colloid" Volume Resuscitation in Trauma Patients (CIST)|CIST|University of the Philippines|Yes|Completed|May 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||November 2009|November 23, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890383||139884|
NCT00890929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-15611|Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)|A Phase 1-2 Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia||Stanford University|Yes|Completed|April 2009|June 2012|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|60 Years|N/A|No|||October 2014|October 13, 2014|April 28, 2009|Yes|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT00890929||139843|
NCT00890942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si146/2009|Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal Morphine Induced Pruritus After Cesarean Section|Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal||Mahidol University|No|Completed|May 2009|May 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|40 Years|No|||July 2011|July 22, 2011|April 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00890942||139842|
NCT00887731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30125|Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care|Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care||University of Utah|No|Terminated|August 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|20|||Both|N/A|3 Months|No|Non-Probability Sample|Any neonatal intensive care patient who is requiring oxygen therapy as part of their        respiratory treatment course will be eligible for this study.|September 2013|September 10, 2013|April 22, 2009|Yes|Yes|slow enrollment|No||https://clinicaltrials.gov/show/NCT00887731||140086|
NCT00906347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102008-030|A Trial of Oral Misoprostol for Labor Augmentation|A Randomized, Controlled Trial of Oral Misoprostol for Labor Augmentation||University of Texas Southwestern Medical Center|Yes|Completed|December 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Female|16 Years|N/A|Accepts Healthy Volunteers|||May 2009|November 8, 2012|May 19, 2009|Yes|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT00906347||138709|
NCT00906607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0077/08|Prevalence of Urinary Incontinence in Different Age Categories|Prevalence of the Urinary Incontinence in Adolescents, Young, Adults and Aged||Universidade de Franca|Yes|Completed|February 2008|October 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort||4|Actual|78|||Female|10 Years|75 Years|No|Non-Probability Sample|The study included 78 nulliparous and nulligest women of different ages living in the city        of Franca, and these are divided into: G1 (10-18 years), G2 (20-35 years), G3 (45-60        years) and G4 (65-75 years).        Women with a history of cancer or surgery of the lower urinary tract, urinary tract        infection, cognitive changes, pregnancy and obesity, were excluded from this study.|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906607||138690|
NCT00906373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13931|A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver|A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)||Eli Lilly and Company|No|Completed|May 2009|May 2014|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906373||138707|
NCT00905853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sapp001|Ventricular Tachycardia (VT) Ablation Versus Enhanced Drug Therapy|Ventricular Tachycardia Ablation vs. Enhanced Drug Therapy in Structural Heart Disease|VANISH|Nova Scotia Health Authority|Yes|Completed|May 2009|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00905853||138746|
NCT00908687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA201|A/H5N1/LT Dose Ranging Study|A Randomized Blinded, LT Dose-ranging Study to Assess the Immunogenicity and Safety of Different Doses of LT Adjuvant Patch Administered in Conjunction With Different Doses of Inactivated Influenza A/H5N1 Vaccine in Healthy Adults||Intercell USA, Inc.|Yes|Completed|May 2009|July 2011|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|500|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|May 22, 2009|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT00908687||138533|
NCT00908947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-08-001|CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs|CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs|CONTINUUM|C. R. Bard|Yes|Enrolling by invitation|February 2011|July 2019|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|234|||Both|21 Years|N/A|No|||November 2015|November 23, 2015|May 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908947||138513|
NCT00909233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13930|LEVITRA® 20mg Special Drug Use Investigation (Long-term)|LEVITRA® 20mg Special Drug Use Investigation (Long-term)||Bayer|No|Completed|August 2007|December 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1221|||Male|18 Years|64 Years|No|Non-Probability Sample|Primary care clinic|December 2014|December 12, 2014|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00909233||138491|
NCT00909896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08155|Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy|Prospective, Double Arm, Comparative Study for the Evaluation of Postoperative Pain, QOL, and Determination of Inflammatory Markers In Patients Undergoing Robotics Versus Open Laparotomy Approach for Staging of Endometrial Cancer||Ohio State University Comprehensive Cancer Center|No|Active, not recruiting|April 2009|||January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|||Female|18 Years|85 Years|No|Probability Sample|Female subjects ages 18-85 years old, Pre operative diagnosis of clinical stage I or II        endometrial cancer, Subject able to tolerate use of opioids for pain management, Eastern        Cooperative Oncology Group (ECOG)0-3.|October 2015|October 13, 2015|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909896||138443|
NCT00910208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-448|Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department|Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|April 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|211|||Both|18 Years|65 Years|No|||July 2012|July 12, 2012|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910208||138419|
NCT00914576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-101108|Effect of Antioxidants on Oxygen Induced Vasoconstriction in Lipopolysaccharide (LPS) Induced Inflammatory Model in Humans|Effect of Antioxidants on Oxygen Induced Vasoconstriction in LPS Induced Inflammatory Model in Humans||Medical University of Vienna|Yes|Completed|April 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914576||138085|
NCT00914888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074K4-3340|Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia|Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Withdrawn|January 2011|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|17 Years|No|||June 2012|June 5, 2012|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914888||138061|
NCT00914901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL2009JE|Concentrations of Salmeterol in Blood and Urine|Blood and Urinary Concentrations of Inhaled Salmeterol in Asthmatic Subjects and Elite Athletes With Asthma.||Bispebjerg Hospital|Yes|Not yet recruiting|July 2009|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914901||138060|
NCT00906555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08dz1900501-a|The Effect of Different Dosages of Solute Clearance on Outcome in Twice Weekly Hemodialysis Patients|The Effect of Different Dosages of Solute Clearance on Outcome in Twice Weekly Hemodialysis Patients-A Prospective, Randomized, Multi-Center Intervention Study||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|June 2009|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||May 2009|May 20, 2009|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906555||138694|
NCT00906828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DuoCOMT|Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors|Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors|DuoCOMT|Uppsala University|Yes|Completed|October 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|10|||Both|30 Years|90 Years|No|||January 2010|January 15, 2010|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906828||138673|
NCT00906841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIT90Y-DOTA-hLL2|Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma|Phase II Study of Evaluation of Fractionated Radio-immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-cell Lymphoma||French Innovative Leukemia Organisation|Yes|Terminated|October 2007|July 2018|Anticipated|March 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|60 Years|80 Years|No|||March 2016|March 15, 2016|May 18, 2009||No|completed recruitment of patients on 15 december 2010|No||https://clinicaltrials.gov/show/NCT00906841||138672|
NCT00911183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636032|Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma|Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life||National Cancer Institute (NCI)||Recruiting|October 2008|||October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|120|||Both|70 Years|N/A|No|||July 2009|July 21, 2009|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911183||138344|
NCT00911196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111726|Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma|Analysis of the Incidence of Expression of Tumor Antigens and Tumor Marker in Cancer Tissue From Asian Patients With Hepatocellular Carcinoma and Evaluation of Prognostic Significance of These Tumor Antigens.||GlaxoSmithKline||Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|200|None Retained|This retrospective study is based upon the analysis of archived samples and patient-related      data already available at the investigational site|Both|N/A|N/A|No|Probability Sample|Primary care clinic|September 2011|September 29, 2011|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911196||138343|
NCT00919230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D/2003/21|Randomised Trial Comparing Iron Supplementation Versus Placebo in the Treatment of Anaemia After Hip Fracture|Randomised Trial Comparing Iron Supplementation Versus Placebo in the Treatment of Anaemia After Hip Fracture||Peterborough and Stamford Hospitals NHS Foundation Trust|Yes|Completed|July 2004|August 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|60 Years|N/A|No|||December 2012|December 7, 2012|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919230||137729|
NCT00919243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hebmu 08-12|Prednisone for Heart Failure Patients With Hyperuricemia|Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia||Hebei Medical University|Yes|Completed|February 2009|August 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||June 2009|August 31, 2010|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919243||137728|
NCT00915070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-320708|Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans|Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans||Medical University of Vienna|Yes|Completed|October 2010|December 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00915070||138047|
NCT00915083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR PH US 2008 PK002|A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.|A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.||Celgene|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||March 2013|March 26, 2013|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915083||138046|
NCT00915382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOS|Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer|Phase III Trial of 3-weekly vs. 5-weekly Schedule of S-1 Plus Cisplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer.|SOS|Asan Medical Center|Yes|Completed|January 2009|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|625|||Both|18 Years|74 Years|No|||January 2014|January 13, 2014|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915382||138023|
NCT00915408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05CC15|A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma|A Phase I Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma|CRD|King's College Hospital NHS Trust|No|Completed|September 2006|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2013|September 1, 2015|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915408||138022|
NCT00915655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016312|A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents|A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years|DIONE|Tibotec Pharmaceuticals, Ireland|Yes|Completed|July 2009|March 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|12 Years|18 Years|No|||August 2012|August 28, 2012|June 4, 2009|No|Yes||No|November 25, 2011|https://clinicaltrials.gov/show/NCT00915655||138003|
NCT00907855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU DASI 08-713|Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests|Clinical Role of the Duke Activity Status Index in the Selection of the Optimal Type of Stress Myocardial Perfusion Imaging Study in Patients With Known or Suspected Ischemic Heart Disease|DASI-08-713|New York University School of Medicine|No|Completed|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred by their primary physician to the Nuclear Lab at NYU School of Medicine        for stress myocardial perfusion imaging testing.|November 2011|November 29, 2011|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00907855||138596|
NCT00908115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208355/128|Post Market Surveillance for Infanrix™|Evaluation of Safety and Efficacy Through Post Market Surveillance for Infanrix™, the DTaP Mixed Vaccine||GlaxoSmithKline||Completed|August 2003|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1258|||Both|N/A|N/A|No|||October 2011|October 13, 2011|May 21, 2009|Yes|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00908115||138576|
NCT00908661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)116/2006|Effectiveness of a Lightweight Mesh in the Laparoscopic Prevention of Parastomal Hernia|Study of the Effectiveness of a Lightweight Mesh (Polypropylene and Poliglecaprone 25 and Oxidized Cellulose) in the Prevention of Parastomal Hernia in Patients Requiring a Permanent Ostomy. Laparoscopic Approach||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|November 2007|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|34|||Both|18 Years|N/A|No|||March 2011|March 14, 2011|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00908661||138535|
NCT00908895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-206|Non-bridging Fixator Versus Percutaneous Pinning for Distal Radius Fractures|Non-bridging Radio-radial Fixator Compared to Percutaneous Pinning for Unstable Distal Radius Fracture. A Prospective Randomized Trial.||Hopital de l'Enfant-Jesus|No|Completed|April 2003|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2009|February 25, 2011|May 26, 2009||No||No|November 12, 2009|https://clinicaltrials.gov/show/NCT00908895||138517|Very long time between the end of the study and the manuscript preparation due to temporarily lack of statistician and the need for some national associations that the study is not published before presentation.
NCT00908908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-E044-103|A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors|An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors||Eisai Inc.||Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|May 20, 2009||No||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00908908||138516|
NCT00908700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAAOSII|Left Atrial Appendage Occlusion Study II|Phase III Pilot Study - Left Atrial Appendage Occlusion Study|LAAOSII|Population Health Research Institute|No|Completed|August 2009|November 2012|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|51|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908700||138532|
NCT00909571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-08-04-KOR|Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus|A Phase 3 Pilot Study to Describe the Pharmacokinetics of Tacrolimus in Patients Undergoing Primary Liver Donor Liver Transplantation Treated With Prograf Injection and Modified Release Tacrolimus Based Immunosuppressive Regimen||Astellas Pharma Inc|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|N/A|No|||April 2010|April 15, 2010|May 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909571||138466|
NCT00909584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.2103|Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia|Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia||Telik|No|Terminated|April 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|May 26, 2009|No|Yes|Study TLK199.2103 was terminated for business reasons.|No||https://clinicaltrials.gov/show/NCT00909584||138465|
NCT00914355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 07-0346-C|Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2)|Phase II Trial of Stereotactic Body Radiation Therapy for Unresectable Hepatocellular Carcinoma||University Health Network, Toronto|Yes|Active, not recruiting|August 2007|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914355||138102|
NCT00914368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-08-002|Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis|TOPAS-1, A Pharmacodynamic Phase II Study of Clopidogrel P2Y12 Platelet Inhibition|TOPAS-1|Uppsala University|No|Completed|January 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|450|||Both|18 Years|N/A|No|||September 2009|April 12, 2010|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00914368||138101|
NCT00914927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-202|Once-Daily Oral E5501 Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures|A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures||Eisai Inc.||Completed|May 2009|||January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|N/A|No|||January 2012|May 21, 2013|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914927||138058|
NCT00914940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2222.00|Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD|A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|October 2009|August 2020|Anticipated|August 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|14 Years|55 Years|No|||January 2016|January 25, 2016|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914940||138057|
NCT00910546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPCRT002|Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer|Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer||Rigshospitalet, Denmark|No|Completed|February 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|40 Years|N/A|No|||December 2012|December 27, 2012|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910546||138393|
NCT00910858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-PK-002|A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes|A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes||Celgene|Yes|Completed|January 2005|May 2009|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|May 28, 2009|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT00910858||138369|
NCT00910520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-520|Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence|||Allergan|No|Completed|September 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|548|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|May 28, 2009|Yes|Yes||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00910520||138395|
NCT00910533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNB-0509|Study on Early Lyme Neuroborreliosis|Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis||University Medical Centre Ljubljana|No|Recruiting|June 2009|||June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|15 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 30, 2014|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910533||138394|
NCT00910819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM TKK|Colorectal Cancer Registry|Prospective and Retrospective Observation of the Adjuvant and Palliative Treatment Strategies in the Therapy of Colorectal Cancer in Germany||iOMEDICO AG|No|Recruiting|September 2006|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6500|||Both|18 Years|N/A|No|Non-Probability Sample|Colorectal cancer patients undergoing antineoplastic treatment.|November 2015|February 26, 2016|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910819||138372|
NCT00910832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-EDU-01|Efficacy of Eductyl® Versus Placebo for Treatment of Dyschesia|Comparative, Randomized, Double-blind Study of the Efficacy of Eductyl® Versus Placebo for Treatment of Patients With Dyschesia Treated by Rectal Rehabilitation|Eductyl|Laboratoires Techni Pharma|No|Completed|May 2009|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910832||138371|
NCT00910845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-095|Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence|||Allergan|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|557|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|May 28, 2009|Yes|Yes||No|January 29, 2013|https://clinicaltrials.gov/show/NCT00910845||138370|
NCT00911508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004616|Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial|Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial|CABANA|Mayo Clinic|Yes|Recruiting|August 2009|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2200|||Both|18 Years|90 Years|No|||September 2015|September 14, 2015|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911508||138319|
NCT00915109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS-2010-026|Gait Stability of People With Lower-limb Amputations|Gait Stability of People With Lower-limb Amputations||Nova Scotia Health Authority|No|Completed|June 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prosthetic outpatient clinic of one rehabilitation centre|September 2012|September 18, 2012|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915109||138044|
NCT00915434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016180|A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Characterize the Pharmacokinetics and the Effect of Food of JNJ-31001074 in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2009|November 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 22, 2010|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915434||138020|
NCT00915096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-FOL|Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma|High Tumor Burden Follicular Lymphoma: Impact of [18F]-FDG Positron Emission Tomography (PET) in the Assessment of Treatment Response||Lymphoma Study Association|No|Active, not recruiting|September 2007|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Burden tissue sample|Both|18 Years|80 Years|No|Non-Probability Sample|High Tumor Burden Follicular Lymphoma patients|March 2010|March 14, 2010|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915096||138045|
NCT00915668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016261|A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women|An Open-Label, Randomized, Crossover Drug-Drug Interaction Study to Assess the Effects of Multiple Doses of JNJ-31001074 on the Pharmacokinetics of a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Withdrawn||March 2011|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|||Anticipated|32|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 24, 2010|June 4, 2009|No|Yes|The trial is postponed pending the completion of other ongoing pre-clinical and clinical work.|No||https://clinicaltrials.gov/show/NCT00915668||138002|
NCT00916162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-091|Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy|A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy||Massachusetts General Hospital|Yes|Completed|August 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Female|35 Years|N/A|No|Non-Probability Sample|Participants will be recruited from hopsitals and clinics of the Dana-Farber/Harvard        Cancer Center.|May 2013|May 7, 2013|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916162||137964|
NCT00908401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICreteil|Analgesic Effect of Breastmilk for Procedural Pain in Preterm Infants|Breastmilk or Oral Sucrose Solution in Preterm Neonates for Procedural Pain: a Randomized, Controlled Study|BMoS|Centre Hospitalier Intercommunal Creteil|No|Recruiting|April 2009|July 2009|Anticipated|July 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|N/A|10 Days|No|||May 2009|May 22, 2009|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908401||138555|
NCT00908154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107727|Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.|Single-Blind, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers||GlaxoSmithKline||Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 29, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00908154||138573|
NCT00908414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016195|PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.|Phase I, Double-blind, Randomized, Placebo-controlled Trial in Healthy Volunteers to Examine Safety, Tolerability, Plasma Pharmacokinetics of TMC589337&TMC589354 After Increasing Single Oral Doses & in an Open-label Part After Different Repeated Doses in Combination With Single Oral Dose of TMC310911||Tibotec Pharmaceuticals, Ireland|No|Terminated|May 2009|October 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|May 21, 2009|No|Yes|The premature end of this trial was a business decision and not due to safety or efficacy    concerns of the compounds.|No||https://clinicaltrials.gov/show/NCT00908414||138554|
NCT00909272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-039-D|Ultrasound Guided Diagnostic Lumbar Medial Branch Blocks|Ultrasound Guided Diagnostic Lumbar Medial Branch Blocks||McMaster University|No|Withdrawn|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|0|||Both|18 Years|65 Years|No|Non-Probability Sample|Primary care pain clinic|April 2015|April 7, 2015|May 22, 2009||No|One of the investigators has left the institution|No||https://clinicaltrials.gov/show/NCT00909272||138489|
NCT00909285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX -NC-01|Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients|Testing the Effects of TMS Stimulation and Cognitive Training for Alzheimer Patients: A Pilot Study||Assaf-Harofeh Medical Center|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|85 Years|No|||July 2010|July 11, 2010|May 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00909285||138488|
NCT00914043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-45.1|Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45|Biobehavioral Mechanisms of Fatigue in Patients Treated on NSABP B-45: A Phase III Clinical Trial Comparing Adjuvant Sunitinib Malate to Placebo in Women With Residual Invasive Breast Cancer Following Neoadjuvant Chemotherapy||NSABP Foundation Inc||Withdrawn||June 2010|Actual|June 2010|Actual|N/A|Observational|N/A|||Actual|0|||Female|N/A|N/A|No|||January 2013|January 10, 2013|June 3, 2009||No|Withdrawn as NCI rescinded approval for parent study NSABP-B-45|No||https://clinicaltrials.gov/show/NCT00914043||138126|
NCT00914381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA06915|Behavioral Treatment for Cocaine Dependent Women|Behavioral Treatment for Cocaine Dependent Women||Yale University|No|Completed|December 1994|March 2002|Actual|March 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|145|||Female|18 Years|50 Years|No|||June 2009|June 3, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914381||138100|
NCT00914329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 08 20|Gelsemium Sempervirens in Anticipatory Anxiety|Randomized Controlled Study Versus Placebo Evaluating Effectiveness of Gelsemium Sempervirens (5CH et 15CH) on Provoked Anticipatory Anxiety, in Healthy Volunteers|ANXIHOMEV|University Hospital, Grenoble|No|Completed|June 2009|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2010|June 2, 2010|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00914329||138104|
NCT00914342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GGR-DUM-2009/1|Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ|A Cross-sectional Study on the Prevalence and Impact in Work Productivity of GERD in Primary Care Patients With Upper GI Symptoms Using the Novel Questionnaire GERD-Q. The Greek GERD-Q Study|GerdQ-Greece|AstraZeneca|No|Completed|July 2009|December 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|889|||Both|18 Years|N/A|No|Probability Sample|Patients who consult their primary care physician and have experienced upper-GI symptoms        during the last week prior their consultation|December 2009|December 24, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914342||138103|
NCT00910260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000|Impact on UVB Narrow Band and UVA1 Therapy on Serum 25-hydroxyvitamin D Levels|Impact on UVB Narrow Band and UVA1 Therapy on Serum 25-hydroxyvitamin D Levels||University of Zurich|No|Completed|March 2009|February 2011|Actual|February 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|Samples Without DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|dermatology clinic|May 2014|May 18, 2014|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00910260||138415|
NCT00910559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-05-075|Phenotypic and Genetic Factors in Autism Spectrum Disorders|Phenotypic and Genetic Factors in Autism Spectrum Disorders||Children's Hospital Boston|Yes|Recruiting|July 2008|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples With DNA|Whole blood|Both|18 Months|N/A|No|Non-Probability Sample|Individuals with ASDs and their parents and/or siblings|September 2011|September 13, 2011|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910559||138392|
NCT00910871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012352|To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.|A Phase II, Open-label Trial With TMC207 as Part of a Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Subjects With Sputum Smear-positive Pulmonary Infection With MDR-TB.||Janssen Infectious Diseases BVBA|Yes|Completed|September 2009|January 2013|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|May 28, 2009|No|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT00910871||138368|In Participant Flow, the 12 deaths shown are restricted to those that occurred during the trial and do not include 4 deaths reported after discontinuation in long-term survival follow-up.
NCT00911209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0328|Weight Loss in Pre-Hypertensive Patients With Diastolic Dysfunction|Impact of Weight Loss on Diastolic Dysfunction in Overweight Pre-Hypertensives||Ohio State University|Yes|Terminated|July 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|21 Years|N/A|No|||October 2012|October 11, 2012|May 28, 2009||No|Terminated because funding was not found|No||https://clinicaltrials.gov/show/NCT00911209||138342|
NCT00911521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTWC/CREC/704/09|Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study|Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study||Tuen Mun Hospital|Yes|Completed|October 2009|June 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Female|N/A|35 Years|Accepts Healthy Volunteers|||October 2011|October 9, 2011|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911521||138318|
NCT00915447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 07-10-025|Diesel Exhaust Particles and Leukotriene Production|Diesel Exhaust Particles and Leukotriene Production||University of California, Los Angeles||Active, not recruiting|January 2008|October 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Urine, Nasal Lavage|Both|18 Years|65 Years|No|Non-Probability Sample|Community sample|August 2010|August 19, 2010|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915447||138019|
NCT00915135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375-CCT-001|Efficacy and Safety of Ramelteon on Chronic Insomnia|A Double-Blind, Dose-Response, Cross-Over Study of TAK-375 With Chronic Insomnia (Phase II Study) -- Polysomnographic Evaluation||Takeda|Yes|Completed|May 2002|December 2003|Actual|December 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|66|||Both|20 Years|65 Years|No|||May 2010|May 31, 2010|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915135||138042|
NCT00915421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCK-KVK-001|Pre-Hospital Cooling in Cardiac Arrest Patients|Pre-Hospital Cooling in Cardiac Arrest Patients - Feasibility Pilot Study|PRE-COOL|Emergency Medical Service of the Central Bohemian Region, Czech Republic|Yes|Recruiting|July 2007|August 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Probability Sample|Out-of-hospital cardiac arrest patients|June 2009|June 5, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915421||138021|
NCT00916188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/25/47/4564|Effects of Black Tea on Type 2 Diabetes|Effects of Black Tea Consumption on Oxidative Stress, Serum Lipid Profile and Insulin Sensitivity in Patients With Type 2 Diabetes||National Nutrition and Food Technology Institute|Yes|Completed|October 2006|November 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|45|||Both|N/A|N/A|No|||June 2009|July 26, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916188||137962|
NCT00908167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELHEM|Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies|A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies||St. Jude Children's Research Hospital|No|Completed|September 2009|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|N/A|31 Years|No|||July 2015|July 10, 2015|May 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00908167||138572|
NCT00908427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-05-09|Impact of 80 W KTP Laser Vaporization Prostatectomy on Severity of Obstruction in Benign Prostatic Hyperplasia|Impact of 80 Watt KTP Photoselective Laser Vaporization Prostatectomy on Severity of Obstruction in Benign Prostatic Hyperplasia: 6-Month Results of a Nonrandomized Prospective Trial||Samsung Medical Center|No|Completed|June 2004|September 2007|Actual|May 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Male|50 Years|N/A|No|||May 2009|May 22, 2009|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908427||138553|
NCT00913744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-005|Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion|A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (AMD)|MIVI-5|ThromboGenics|Yes|Completed|January 2010|April 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|N/A|No|||April 2014|December 2, 2014|June 2, 2009||No||No|April 2, 2014|https://clinicaltrials.gov/show/NCT00913744||138149|
NCT00913757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909149|A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area|A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area||National Institutes of Health Clinical Center (CC)||Recruiting|May 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1850|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||July 2015|August 12, 2015|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913757||138148|
NCT00914056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bajaj 006|A Study of Controlled Lactulose Withdrawal|Is Continuous Lactulose Therapy Necessary for Patients With Hepatic Encephalopathy? A Prospective Study of Controlled Lactulose Withdrawal||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Completed|September 2008|May 2012|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|75 Years|No|||March 2013|March 19, 2013|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914056||138125|
NCT00914394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-310708|Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans|Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans||Medical University of Vienna|Yes|Terminated|October 2010|||July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00914394||138099|
NCT00914589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1810-3540|Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery|A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment With Two Different Doses of Recombinant Factor XIII Following Cardiopulmonary Bypass Surgery||Novo Nordisk A/S|Yes|Completed|July 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|479|||Both|18 Years|80 Years|No|||November 2014|November 12, 2014|June 3, 2009|Yes|Yes||No|September 22, 2014|https://clinicaltrials.gov/show/NCT00914589||138084|
NCT00914914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDGTI-p28-001|Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment|A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors||CDG Therapeutics, Inc.|Yes|Completed|April 2009|June 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|June 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914914||138059|
NCT00910273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-4458|Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients|Effects of Etanercept on Endothelial Function and Carotid Intima-media Thickness (IMT) in Patients With Active AS|CREST|Pfizer|No|Terminated|July 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 27, 2009||No||No|October 3, 2012|https://clinicaltrials.gov/show/NCT00910273||138414|Due to early termination and few participants attending visits after Week 12, statistical analysis limited to Week 12.
NCT00910286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Two cycling off modes in psv|Two Cycling Off Modes in Pressure Support: Study of Respiratory Mechanics, Breathing Comfort and Asynchrony Patterns|VENTILAÇÃO MECÂNICA COM PRESSÃO SUPORTE: ESTUDO DA ASSINCRONIA EXPIRATÓRIA (in Portughese)||Hospital de Clinicas de Porto Alegre|No|Completed|December 2004|June 2008|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|1||Actual|18|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910286||138413|
NCT00910910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CLL-008|Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)|A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS CHLORAMBUCIL AS FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|ORIGIN|Celgene|Yes|Active, not recruiting|October 2009|April 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|450|||Both|65 Years|N/A|No|||May 2015|May 12, 2015|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910910||138365|
NCT00910884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643461|Natural Supplements and a Special Diet in Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Prostate Cancer, Breast Cancer, or Uterine Cancer|Gene Expression Control Using Micro-Trace Element Compounds During C.A.M. and Conventional Cancer Protocols||Brabant Research|Yes|Not yet recruiting|April 2016|February 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910884||138367|
NCT00910897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFM 2007-02|Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)|A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma||Intergroupe Francophone du Myelome|No|Active, not recruiting|March 2008|||August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|65 Years|No|||May 2009|May 29, 2009|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910897||138366|
NCT00911222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-143|Epidemiological EMESIS-Registry|Epidemiologic Registry for the Description of Antiemetic Strategies Under Real-life Conditions.|EMESIS|iOMEDICO AG||Completed|October 2008|August 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1035|||Both|18 Years|N/A|No|Non-Probability Sample|Practitioners specialized in oncology, hematology and/or gynaecology|December 2014|December 23, 2014|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911222||138341|
NCT00911235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221080|The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects|An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Effect Of Fluconazole, A Moderate CYP3A4 Inhibitor, On The Single-Dose Pharmacokinetics Of Fesoterodine In Healthy Subjects.||Pfizer|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00911235||138340|
NCT00911807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBE-031010|Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease|A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)|Combi|Ever Neuro Pharma GmbH|No|Completed|October 2004|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|217|||Both|51 Years|N/A|No|||June 2009|June 4, 2009|April 7, 2009||No||No|April 7, 2009|https://clinicaltrials.gov/show/NCT00911807||138296|
NCT00915460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-98-838|Open-Label Safety Extension Study of Avonex|An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830||Biogen|Yes|Completed|September 1999|July 2003|Actual|June 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|408|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2009|June 5, 2009|June 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915460||138018|
NCT00915681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB16A1.07|Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning|Prevention and Treatment of Amatoxin Induced Hepatic Failure With Intravenous Silibinin ( Legalon® SIL): An Open Multicenter Clinical Trial||Madaus Inc|No|Recruiting|February 2010|December 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|N/A|No|||March 2016|March 18, 2016|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915681||138001|
NCT00915473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008203|Greater Occipital Nerve Block for Migraine Prophylaxis|Greater Occipital Nerve Block for Migraine Prophylaxis||Mayo Clinic|No|Completed|June 2009|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||February 2014|February 24, 2014|June 5, 2009|Yes|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT00915473||138017|
NCT00915941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-000550|Exploratory Study of Potential Pulmonary Aspiration Markers From Bronchoalveolar Lavage Fluid|Exploratory Study of Potential Pulmonary Aspiration Markers From Bronchoalveolar Lavage Fluid"|Pepsin|Mayo Clinic|Yes|Completed|January 2009|November 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|Samples Without DNA|BALF specimens will be collected by the MCF Biospecimen Facility at the time of the      bronchoscopy. A minimum of 5 mL will be collected. Specimen processing will include      centrifugation to separate the cell pellet from the supernatant. The supernatant will be      stored in 2 mL cryovials, and stored at -70°C until time of testing for the pepsin-ELISA.      Storage will allow retesting at another date if the assay is modified or if another      substance of interest arises in the course of the study that requires re-testing of the      specimens. The clinical sample will also be tested through the Mayo Clinic medical      laboratory for bilirubin, pepsinogen, amylase, and lipase.|Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects will be recruited from the Mayo Clinic Jacksonville site. As defined in the        inclusion criteria, patients will only be identified once they are scheduled for a        bronchoscopy for clinical indications. Only adult patients will be considered, and there        will be no regard to gender or ethnicity in the screening or selection. The BAL procedure        may or may not be requested by the referring clinician as part of the patient's        bronchoscopy. In those subjects where the BAL is not requested for clinical indications,        that means the BAL will be an additional procedure to be added to the patient's        bronchoscopy for research purposes. Both patients in the inpatient and outpatient settings        will be recruited, but emergent or operating room based bronchoscopies will be excluded.        The specific inclusion and exclusion criteria are listed below.|November 2011|November 10, 2011|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915941||137981|
NCT00915902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIDDING|Fish Oil Study for High Triglyceride Levels in Children|Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents||Nemours Children's Clinic|No|Completed|July 2009|September 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|10 Years|17 Years|No|||November 2015|November 4, 2015|June 4, 2009|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT00915902||137984|Intrinsic variability of triglycerides is large and may have confounded analyses; 4-week washout between treatment periods may have been too short; a reduction of triglycerides in the corn oil placebo group may have compromised the results.
NCT00915915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14348|Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)|Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol and Either 1.05 or 2.1 mg Gestodene in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles||Bayer|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00915915||137983|
NCT00907868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636007|Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ|A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS||National Cancer Institute (NCI)||Recruiting|November 2008|||May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1950|||Female|18 Years|N/A|No|||July 2009|July 7, 2009|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00907868||138595|
NCT00907881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-158|The OBSTACLE Hypoglycemia Study (MK-0000-158)|Prospective Observational Study to Assess Correlation Between Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes Treated With Sulfonylurea||Merck Sharp & Dohme Corp.||Completed|August 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1069|||Both|18 Years|75 Years|No|Non-Probability Sample|Diabetic clinic patients|April 2015|April 1, 2015|May 21, 2009||No||No|October 20, 2011|https://clinicaltrials.gov/show/NCT00907881||138594|
NCT00908713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS 2003-CA|Corticoids in Severe Community-Acquired Pneumonia (CAP)|Corticoids in Severe Community-acquired Pneumonia||Hospital Clinic of Barcelona|No|Completed|January 2004|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908713||138531|
NCT00908960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-378|Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles|A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles|MicroTEC|Dana-Farber Cancer Institute|Yes|Completed|May 2009|October 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|70|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|May 26, 2009|Yes|Yes||No|July 22, 2013|https://clinicaltrials.gov/show/NCT00908960||138512|
NCT00913484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA012979|Disulfiram for Cocaine Abuse in Buprenorphine Treatment|Disulfiram for Cocaine Abuse in Buprenorphine Treatment||Yale University||Completed|October 2000|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|45 Years|No|||June 2009|June 3, 2009|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00913484||138169|
NCT00913770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA025991-01|Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department|Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department||Yale University|No|Completed|September 2008|December 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|329|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|June 1, 2009||No||No|May 11, 2015|https://clinicaltrials.gov/show/NCT00913770||138147|
NCT00913783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920256|To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions|Comparative, Randomized, 2-Way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fasted Conditions||Sandoz||Completed|November 1992|December 1992|Actual|December 1992|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913783||138146|
NCT00914069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62009123|Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter|Evaluation of the Safety and Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter for Peripheral Intravenous (PIV) Insertion in Children, Oncology Patients and Elderly: a Controlled Randomized Trial||Vascular Pathways, Inc.|Yes|Terminated|June 2009|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|175|||Both|5 Years|90 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|June 1, 2009||No|Funding Stopped|No||https://clinicaltrials.gov/show/NCT00914069||138124|
NCT00914628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK008|TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia|TK008 Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia||MolMed S.p.A.|Yes|Recruiting|February 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914628||138081|
NCT00914641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0661007|Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers|A Randomized, Open-Label, Single Dose, Four Way Cross-Over Bioavailability Study Comparing Three Modified Release Formulations Of Apixaban Tablets To Apixaban Immediate Release Tablets In Healthy Volunteers||Pfizer|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|June 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914641||138080|
NCT00914602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-C-058|An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects|An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations||XenoPort, Inc.||Completed|May 2009|||January 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|30 Years|75 Years|No|||May 2011|May 18, 2011|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914602||138083|
NCT00910949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-059b|Sensory Perception After Thoracotomy|Chronic Pain After Thoracotomy||Rigshospitalet, Denmark|No|Completed|June 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Anticipated|48|||Both|19 Years|N/A|No|Non-Probability Sample|Lung cancer patients|January 2010|February 1, 2010|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910949||138362|
NCT00910962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111810|A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation|Solstice|GlaxoSmithKline|Yes|Completed|October 2009|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|540|||Both|45 Years|N/A|No|||October 2014|October 30, 2014|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910962||138361|
NCT00911300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111418|Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm|An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Pilot Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients With Atrial Fibrillation Undergoing Electric Cardioversion Following Transesophageal Echocardiography||GlaxoSmithKline||Completed|August 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|349|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|May 28, 2009||No||No|August 2, 2012|https://clinicaltrials.gov/show/NCT00911300||138335|
NCT00911248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC299-ONC-007-NF2|PTC299 for Treatment of Neurofibromatosis Type 2|A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2||PTC Therapeutics|No|Suspended|July 2009|May 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2012|April 6, 2012|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00911248||138339|
NCT00911534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-A001-307|Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)|A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)||Eisai Inc.||Completed|January 2009|October 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|75 Years|No|||November 2015|January 4, 2016|May 29, 2009|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT00911534||138317|
NCT00911547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-029|The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Parallel-Group Study to Assess the Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients||Merck Sharp & Dohme Corp.||Completed|March 1995|May 1996|Actual|April 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|642|||Both|15 Years|85 Years|No|||March 2015|March 13, 2015|May 29, 2009|Yes|Yes||No|July 24, 2009|https://clinicaltrials.gov/show/NCT00911547||138316|Efficacy over 16 weeks of treatment for Beclo and MK+Beclo groups, and last 10 weeks for Placebo and MK groups to minimize confounding effect of beclo in 1st 4 weeks of treatment and to allow beclo washout.
NCT00918983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX02-0017|Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)|Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017||Nymox Corporation|No|Completed|April 2009|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|500|||Male|45 Years|N/A|No|||April 2014|April 1, 2014|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918983||137748|
NCT00918996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO # 09-0173|The Bladder Flap at Cesarean Section: A Randomized Controlled Trial|The Bladder Flap at Cesarean Delivery: Establishing Evidence for Practice||Washington University School of Medicine|Yes|Completed|March 2010|September 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|258|||Female|18 Years|42 Years|No|||October 2015|October 8, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918996||137747|
NCT00919009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COTSUN Korea Trial|Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)|A Phase II Study of the Combination of TACE and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma in National Cancer Center Korea (COTSUN Korea Trial)||National Cancer Center, Korea|No|Completed|June 2009|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|20 Years|N/A|No|||June 2009|May 29, 2012|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00919009||137746|
NCT00915720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILR 1208|Implanted Loop Recorder Post Atrial Fibrillation Ablation|Implanted Loop Recorder Surveillance of Recurrent Atrial Fibrillation After Atrial Fibrillation Ablation||Thoracic & Cardiovascular Healthcare Foundation|No|Active, not recruiting|August 2008|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing surgical atrial fibrillation|July 2010|July 19, 2011|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915720||137998|
NCT00915928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic Subdural Hematoma|Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors|Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors|KSDH|Odense University Hospital|Yes|Terminated|July 2009|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|June 3, 2009||No|No effect of the ACE inhibitor evaluated halfway in the study|No||https://clinicaltrials.gov/show/NCT00915928||137982|
NCT00916227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-614-111|A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome|||Array BioPharma||Completed|June 2009|||January 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2014|December 27, 2014|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916227||137959|
NCT00916461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI 04T-583|Role of Minocycline in First Episode Psychosis|A Randomised, Double Blind Pilot Study of Minocycline and Placebo Added to Treatment-as-Usual (TAU) in First-Episode Psychosis||Stanley Medical Research Institute|No|Completed|May 2006|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|65 Years|No|||June 2009|June 12, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916461||137941|
NCT00907920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL09B1|Studying Tumor Samples From Young Patients With Neuroblastoma|Observational - Characterizing the Frequency and Spectrum of ALK Mutations in Neuroblastoma||Children's Oncology Group|No|Completed|December 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1500|Samples With DNA|Tumor Samples|Both|N/A|30 Years|No|Non-Probability Sample|Patients with newly diagnosed neuroblastoma previously enrolled on clinical trial        COG-ANBL00B1.|May 2015|May 12, 2015|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00907920||138591|
NCT00913094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07001-M2-1-2-3|Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension|Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)|BETTER-HTN|CardioDynamics|Yes|Recruiting|January 2009|June 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Participants will be recruited form a population of subjects presenting to a specialty        hypertension clinic|June 2009|June 9, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00913094||138199|
NCT00913458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4524|Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis|A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate||Pfizer|No|Completed|September 2009|December 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|306|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|May 26, 2009||No||No|June 10, 2013|https://clinicaltrials.gov/show/NCT00913458||138171|
NCT00913718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960380|To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fasting Conditions Following Administration of a 40 mg Dose||Sandoz||Completed|June 1996|July 1996|Actual|July 1996|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913718||138151|
NCT00913731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NSE-DUM-2008/1|Quality Project to Evaluate and Validate the FAST-O Rating Scale|Quality Project to Evaluate and Validate the FAST-O Rating Scale (Fast ASessment in Acute Treatment of Psychosis-Observation)|FAST-O|AstraZeneca|No|Completed|May 2009|October 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|111|||Both|N/A|N/A|No|Non-Probability Sample|Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive        care unit|October 2009|October 28, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913731||138150|
NCT00913796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200B0-112299|Metabolic Acidosis in Renal Transplant Patients|Metabolic Acidosis and Its Impact on Mineral Metabolism and Physical Performance in Renal Transplant Patients|MART|University of Zurich|Yes|Completed|December 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|65 Years|No|||June 2009|October 21, 2010|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00913796||138145|
NCT00913809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870609-D|To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets|A Two-Way Single Dose Crossover Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets||Sandoz||Completed|December 1987|December 1987|Actual|December 1987|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913809||138144|
NCT00914082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080200|Mental Training and Childbirth|The Effect of Mental Training on Childbirth Measured on Pain Experience and Other Birth Outcomes||University of Aarhus|No|Completed|April 2009|March 2013|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1222|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 15, 2013|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00914082||138123|
NCT00914095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005801-20|Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)|Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial|PARKGAIT-II|University Hospital, Lille|Yes|Completed|October 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|30 Years|80 Years|No|||June 2009|April 23, 2012|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00914095||138122|
NCT00914654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOR2009JE|Concentrations of Formoterol in Blood and Urine|Blood and Urinary Concentrations of Inhaled Formoterol in Asthmatic Subjects and Elite Athletes With Asthma||Bispebjerg Hospital|Yes|Not yet recruiting|July 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914654||138079|
NCT00914667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221079|The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects|An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Fesoterodine On The Pharmacokinetics And Pharmacodynamics Of A Single Supratherapeutic Dose Of Warfarin In Healthy Subjects.||Pfizer|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|June 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914667||138078|
NCT00914615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 07-0348-C|Stereotactic Body Radiation Therapy (SBRT) in Liver Metastasis (COLD 3)|Phase II Trial of Stereotactic Body Radiation Therapy for Unresectable Liver Metastases From Colorectal Carcinoma||University Health Network, Toronto|Yes|Active, not recruiting|August 2007|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914615||138082|
NCT00910572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 30/90|Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma|Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced HCC (Hepatocellular Carcinoma) Not Eligible to Curative Approach. A Phase II-b Study.||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|July 2007|May 2010|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||May 2009|June 30, 2011|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910572||138391|
NCT00910585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES08711|Coaching in Childhood Asthma|Phase 4 Study of Case Management and Environmental Control in Asthma|Coach|Washington University School of Medicine|No|Completed|January 1997|January 2002|Actual|January 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|191|||Both|N/A|N/A|No|||May 2009|May 29, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910585||138390|
NCT00910923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015703|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers|Single Ascending Dose||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|37|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 2, 2009|March 19, 2009||||No||https://clinicaltrials.gov/show/NCT00910923||138364|
NCT00911261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202-029|Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain|An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain||Endo Pharmaceuticals|Yes|Completed|August 2003|May 2005|Actual|March 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|223|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911261||138338|
NCT00911274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-982-AU|Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 28, 2009|No|Yes||No|June 1, 2009|https://clinicaltrials.gov/show/NCT00911274||138337|
NCT00911287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202-028|Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain|An Open-Label Effectiveness and Safety Study of Oxymorphone Extended Release in Opioid-Naive Patients With Chronic Pain.||Endo Pharmaceuticals|No|Completed|June 2003|March 2004|Actual|January 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911287||138336|
NCT00915486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS I-020201/01|A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers|A Randomized, Multi-center, Controlled, Parallel Group, Dose Finding Study of the Efficacy and Safety of Topically Applied I-020201 as an Adjunct to Good Standard-of-care Versus Good Standard-of-care Alone in Patients With Chronic Diabetic Foot Ulcers|DFU|Kuros Biosurgery AG|Yes|Completed|May 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|211|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915486||138016|
NCT00907673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-CHF-001|The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure|||NovaShunt AG|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2011|December 16, 2011|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907673||138610|
NCT00907959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZL-101-003|A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer|A Phase 2 Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer||Bionovo|Yes|Not yet recruiting|January 2012|July 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|N/A|No|||February 2012|February 6, 2012|May 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907959||138588|
NCT00916201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EICAS|Evaluation Study of New Compounds With Potential Use in Schizophrenia|Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.|EICAS|Central Institute of Mental Health, Mannheim|No|Not yet recruiting|December 2015|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|86|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916201||137961|
NCT00916214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLA Trial|Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program|Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program||Ringkobing Love Apotek|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Both|65 Years|N/A|No|||September 2009|June 13, 2011|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00916214||137960|
NCT00908440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-266|Decision Aid in Veterans With Posttraumatic Stress Disorder|Decision Aid in Veterans With Posttraumatic Stress Disorder||White River Junction VAMC|Yes|Not yet recruiting|June 2009|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||May 2009|May 22, 2009|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00908440||138552|
NCT00913120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-027|Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery|Phase II/III Study of YM150 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients Undergoing Elective Total Hip Replacement Surgery||Astellas Pharma Inc|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|610|||Both|20 Years|N/A|No|||June 2010|June 8, 2010|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913120||138197|
NCT00912873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hip Concentration Study|Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks|Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks||University of California, San Diego|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|June 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912873||138215|
NCT00913471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0452|Biomarkers for Pain in Spinal Cord Injury (SCI) Patients|Biomarkers for Pain in Spinal Cord Injury (SCI) Patients|SCI Pain|The University of Texas Health Science Center, Houston|No|Active, not recruiting|June 2009|December 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|Samples Without DNA|blood samples (120 subjects) and skin tissue biopsy (20 subjects)|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Acute and Chronic traumatic spinal cord injury patients and healthy volunteers|December 2015|December 10, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913471||138170|
NCT00914108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X03-10-072R|Severe Intrauterine Growth Retardation: Developmental Newborn Intensive Care Unit (NICU) Care|Family-Centered Neuropsychoeducational In-NICU Intervention for Preterm Infants With Severe Intrauterine Growth Retardation and for Their Families||Children's Hospital Boston|No|Completed|October 1996|July 2002|Actual|July 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|N/A|36 Weeks|No|||June 2009|June 3, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914108||138121|
NCT00914121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-105|Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)|A Single Dose, Crossover, Placebo- and Moxifloxacin- Controlled Study of the Effects of Bosutinib on Cardiac Repolarization in Healthy Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914121||138120|
NCT00914407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-030209|Measurement of Retinal Blood Flow, Retinal Oxygenation and Retinal Oxygen Extraction in Healthy Subjects During Normoxia and Systemic Hyperoxia|Measurement of Retinal Blood Flow, Retinal Oxygenation and Retinal Oxygen Extraction in Healthy Subjects During Normoxia and Systemic Hyperoxia||Medical University of Vienna|Yes|Recruiting|April 2010|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|48|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914407||138098|
NCT00910325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008p001938|Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy||Massachusetts General Hospital|Yes|Terminated|November 2008|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|26 Years|64 Years|No|||October 2012|October 29, 2012|May 27, 2009||No|The alternative laparoscopic chole, has so little morbidity very few patients opt for a    transvaginal approach when presented with the alternative|No||https://clinicaltrials.gov/show/NCT00910325||138410|
NCT00907491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIM-CC 01|Accuracy of Cough Detection in Healthy Adults|Use of Objective Cough Counting Device to Assess the Accuracy of Cough Detection in Healthy Adults Simulating Cough in Different Postures, Mobility and Environmental Conditions||KarmelSonix Ltd.|No|Completed|February 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|54|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults 21 years and above|May 2009|June 8, 2011|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907491||138622|
NCT00910299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12323|Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)|Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent|TRIGGER-PCI|Eli Lilly and Company|Yes|Terminated|July 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|423|||Both|18 Years|80 Years|No|||April 2012|May 8, 2012|May 28, 2009|Yes|Yes|Due to the low rate of primary endpoint events experienced in the study to date|No|April 10, 2012|https://clinicaltrials.gov/show/NCT00910299||138412|The study was terminated early, and no formal statistical time-to-event analysis was performed.
NCT00910598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT|Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)|A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS|OCTIMS|Amphia Hospital|No|Recruiting|September 2009|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||February 2010|February 9, 2010|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910598||138389|
NCT00910611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-028|A Test of the Effectiveness of a Device for Pediatric Immunization Pain|Relieving Pediatric Immunization Pain Using A Reusable Personal Device|Buzzy|MMJ Labs LLC|No|Active, not recruiting|January 2009|July 2010|Anticipated|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||June 2010|June 24, 2010|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00910611||138388|
NCT00911313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU- 059|Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome|Letrozole Versus Combined Metformin and Clomiphene Citrate for Ovulation Induction in Clomiphene-Resistant Women With Polycystic Ovary Syndrome||Mansoura University|Yes|Completed|June 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|20 Years|36 Years|No|||May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911313||138334|
NCT00911573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074K4-3339|Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects|A Phase 3, Multicenter, Randomized, Double-Blind Study To Evaluate The Safety And Efficacy Of Tigecycline Versus Comparator (Clindamycin Or Vancomycin) For The Treatment Of Complicated Skin And Skin Structure Infections, Including Those Due To MRSA, In Pediatric Subject Ages 8 To 17 Years Old||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Withdrawn|August 2011|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|17 Years|No|||June 2012|June 5, 2012|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911573||138314|
NCT00911326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO3-06|Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma|A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma||Navidea Biopharmaceuticals|Yes|Terminated|May 2009|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|101|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|May 28, 2009|Yes|Yes|The trial was terminated early based on an interim review by the Data and Safety Monitoring    Committee for positive efficacy outcome and no safety concerns.|No|July 8, 2014|https://clinicaltrials.gov/show/NCT00911326||138333|The study was prospectively structured to include an interim analysis at 33.3% enrollment. The trial was terminated early based on an interim review by the Data and Safety Monitoring Committee for positive efficacy outcome and lack of safety concern.
NCT00911833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909153|The Roles of Trust and Respect in Patient Reactions to Race-based and Personalized Medicine Vignettes: An Experimental Study|The Roles of Trust and Respect in Patient Reactions to Race-Based and Personalized Medicine Vignettes: An Experimental Study||National Institutes of Health Clinical Center (CC)||Completed|May 2009|March 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|September 26, 2015|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911833||138294|
NCT00915499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-01-08|Complex Sleep Apnea Syndrome (CompSAS) Resolution Study|Is Adaptive Servo-Ventilation Therapeutically More Effective Than Continuous Positive Airway Pressure In Treating Complex Sleep Apnea Syndrome?|CompSAS|ResMed|No|Completed|May 2009|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|June 4, 2009|Yes|Yes||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00915499||138015|
NCT00908999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-2008-0090|Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)|FMRI of Anosognosia in Amnestic MCI and AD: Focus on Cortical Midline Structures||University of Wisconsin, Madison||Completed|April 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|60 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|MCI and AD patients are referred from memory clinics at the UW hospital, William S.        Middleton Memorial Veterans Hospital (Madison, WI) and the statewide clinics offered        through the Wisconsin Alzheimer's Institute (WAI).|September 2011|September 27, 2011|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908999||138509|
NCT00915694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000644278|Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme|A Phase I Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|April 2009|||July 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|120 Years|No|||February 2016|February 9, 2016|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915694||138000|
NCT00915707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14916B|Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk|Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk||University of Chicago|No|Completed|January 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|23|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915707||137999|
NCT00908180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-PAIReD|Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma||National Cancer Institute (NCI)||Not yet recruiting|July 2009|||July 2014|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|16 Years|65 Years|No|||June 2009|August 1, 2013|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908180||138571|
NCT00908453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-06-2|The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin|||Nobelpharma|Yes|Completed|May 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|2 Years|N/A|No|||May 2010|May 21, 2010|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00908453||138551|
NCT00916487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fructo001|Efficacy of Fructose Metabolizing Enzymatic Product in Fructose Malabsorption|Efficacy of Fructose Metabolizing Enzymatic Product Fructosin(R) in Patients With Fructose Malabsorption||Sciotec Diagnostic Technologies GmbH|No|Completed|June 2009|August 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|80 Years|No|||December 2010|December 17, 2010|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916487||137939|
NCT00908466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00028588|Sirolimus as Therapeutic Approach to Uveitis|A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis|SAVE|Johns Hopkins University|No|Recruiting|July 2009|February 2013|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00908466||138550|
NCT00912834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97088|Study of Prevalence of Proteinuria, Urinary Tract Infection or Hematuria in Athletes|Urine Analysis in Different Types of Athletes||Far Eastern Memorial Hospital|No|Active, not recruiting|December 2008|November 2009|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||7|Actual|300|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|In some types exercise, including basketball, swimming, tract & field, tennis, football        athletes, we make a study analysis of their urine data to find any abnormality such as        microhematuria, proteinuria or pyuria.|June 2009|September 22, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912834||138218|
NCT00912847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHCC002|Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma|Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma||Chinese University of Hong Kong|No|Completed|October 1997|April 2004|Actual|April 2004|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1018|||Both|40 Years|70 Years|No|Non-Probability Sample|HBV carriers between age 40 and 70 years|June 2009|June 1, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912847||138217|
NCT00913146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMEA5982FAU90|Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria?|Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria? A School-Based Prospective, Exposed/Non Exposed to Fever, Study in Benin.||Institut de Recherche pour le Developpement|No|Completed|February 2008|March 2009|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|484|Samples With DNA|whole blood dried on filter papers|Both|5 Years|15 Years|No|Non-Probability Sample|2600 schoolchildren of 5 years-old and above|June 2009|June 3, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913146||138195|
NCT00913159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alana Desai HM3 vs F2|A Trial Comparing Efficacy of HM3 Versus F2 Lithotripters for Stone Fragmentation|A Randomized Controlled Trial Comparing Efficacy of HM3 vs F2 Lithotripters for Stone Fragmentation||Washington University School of Medicine|No|Terminated|November 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|90 Years|No|||October 2010|October 15, 2010|June 1, 2009||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00913159||138194|
NCT00913133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DES-09-02|Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis|Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)|DESIR-ABLE|Canyon Pharmaceuticals, Inc.|Yes|Completed|March 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|516|||Both|18 Years|N/A|No|||January 2013|January 6, 2013|May 26, 2009|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00913133||138196|This was a multi-center, single-arm, observational safety trial. The lack of an active comparator does not allow us to make conclusions about the relative safety and efficacy of the product.
NCT00914134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDAUT2009|Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease|Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease||Helsinki University|No|Completed|April 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|40 Years|80 Years|No|||February 2011|February 23, 2011|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00914134||138119|
NCT00914420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST10|Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™|OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™|OISTER|Clearstream Technologies Ltd.|Yes|Recruiting|June 2009|October 2012|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2010|April 16, 2010|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914420||138097|
NCT00907504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021017|Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer|Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer|ADVIGO1017|Pfizer|Yes|Withdrawn|July 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907504||138621|
NCT00910312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-03|ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial|Evaluation of Safety and Feasibility of the ICE-SENSE™, a Cryotherapy Device for Office-based Ultrasound-guided Treatment of Breast Fibroadenoma|ICE-CRYSTAL|IceCure Medical Ltd.|No|Completed|April 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||February 2013|February 7, 2013|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910312||138411|
NCT00910936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA04/050/07|Exercise for Patients With HIV Infections|Effects of an Exercise Program on Metabolic Parameters of Patients With a HIV Infection.||Charite University, Berlin, Germany|No|Recruiting|May 2009|February 2010|Anticipated|January 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2009|December 18, 2009|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910936||138363|
NCT00907790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32722|Nursing Management of Irritable Bowel Syndrome (IBS) 2008|Nursing Management of IBS:Improving Outcomes||University of Washington|Yes|Completed|March 2009|January 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|70 Years|No|||January 2013|January 14, 2013|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907790||138601|
NCT00908583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05295|Desensitization in Kidney Transplantation|Desensitization for Preformed Anti-HLA Antibodies in Kidney Transplantation||University of Cincinnati|No|Completed|May 2009|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|44|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|May 26, 2009|Yes|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT00908583||138541|
NCT00910975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTG1_081119|Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C|Tailored Treatment of Hepatitis C Genotype 1|TTG1|Göteborg University|Yes|Completed|November 2007|September 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2012|September 3, 2012|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910975||138360|
NCT00911339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atorvastatin-CD34+|Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents|Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents||IRCCS Policlinico S. Matteo|No|Enrolling by invitation|January 2009|April 2010|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||May 2009|May 29, 2009|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911339||138332|
NCT00911586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-09009|Pharmacokinetic Study to Determine Time to Steady-state|Pharmacokinetic Study to Determine Time to Steady-state of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men.||Clarus Therapeutics, Inc.|No|Completed|July 2009|January 2010|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|75 Years|No|||August 2010|August 17, 2010|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911586||138313|
NCT00911599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-506|RCT Comparing Ion Levels and Clinical Outcomes of A-Class BFH to Metal on Polyethylene Total Hip Replacement|A Prospective Randomized Clinical Trial Comparing Ion Levels and Clinical Outcomes of the CONSERVE® A-Class Total Hip System With BFH® Technology to Metal on Polyethylene Total Hip Replacement|RCT|Ottawa Hospital Research Institute|No|Completed|August 2006|May 2013|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|70 Years|No|||January 2014|January 21, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911599||138312|
NCT00907387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL010LCL|Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment Lateral Canthal Lines in Adults||Revance Therapeutics, Inc.|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907387||138630|
NCT00909012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|455-08|Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria|Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria||Ludwig-Maximilians - University of Munich|No|Completed|May 2009|March 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|114|||Both|5 Years|13 Years|No|||June 2014|June 19, 2014|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00909012||138508|
NCT00915954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17015|Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)|Growth Hormone Feedback In Patients With Acromegaly, Type 2 Diabetes Mellitus, And Healthy Adults||Cedars-Sinai Medical Center||Recruiting|December 2008|||||Phase 4|Interventional|Masking: Single Blind (Subject)|||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 28, 2009|June 5, 2009||||No||https://clinicaltrials.gov/show/NCT00915954||137980|
NCT00915967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_5170|Prevention of Neurosurgical Wound Infections|Pilot Project: Prevention of Neurosurgical Wound Infections|POWI|Oregon Health and Science University|Yes|Active, not recruiting|July 2009|July 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2012|September 3, 2012|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915967||137979|
NCT00909922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3019.02|Musculoskeletal Measurements in Transfemoral Amputees|Musculoskeletal Measurements in Transfemoral Amputees||Miami VA Healthcare System|Yes|Recruiting|January 2006|December 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Unilateral Transfemoral and Knee Disarticulation Amputees|May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909922||138441|
NCT00908973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RnonR|Gut Hormone Response, Appetite and Intestinal Transit Time in Good and Poor Weight Responders After Gastric Bypass|Gut Hormone Response, Appetite and Intestinal Transit Time in Good and Poor Weight Responders 1-2 Years After Gastric Bypass|RnonR|Hvidovre University Hospital|No|Completed|May 2009|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|46|Samples Without DNA|Plasma and serum specimens are retained|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Case subjects are recruited from the outpatient clinic of endocrinology at Hvidovre        University Hospital. Control subjects are recruited through announcement in local        newspapers.|March 2012|March 19, 2012|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908973||138511|
NCT00908986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2971g|Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis|Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis||Northwell Health|Yes|Withdrawn|December 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|May 22, 2009|Yes|Yes|Terminated by sponsor|No||https://clinicaltrials.gov/show/NCT00908986||138510|
NCT00910247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093-050|Eslicarbazepine Acetate Monotherapy Long Term Study|Long Term Eslicarbazepine Acetate Extension Study||Sunovion|No|Active, not recruiting|August 2009|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|348|||Both|16 Years|70 Years|No|||September 2015|September 25, 2015|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910247||138416|
NCT00912860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-867|Immunogenicity and Safety Study of Serum-Free Avonex|A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis||Biogen|No|Completed|January 2003|January 2005|Actual|December 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|155|||Both|18 Years|60 Years|No|||June 2009|June 5, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912860||138216|
NCT00913107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS287-2007B|Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia|Lamotrigine in Trigeminal Neuralgia: Efficacy and Safety in Comparison With Carbamazepine||University of Malaya|No|Completed|September 2007|June 2008|Actual|February 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|N/A|N/A|No|||June 2010|June 27, 2010|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00913107||138198|
NCT00913510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-MSP-0001|Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction|Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis||Wellspect HealthCare|No|Terminated|December 2009|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|June 3, 2009|Yes|Yes||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00913510||138167|
NCT00913497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-089|The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children|Phase 4 Crossover Study Comparing the Effect of Insulin Glulisine to Insulin Aspart on Breakfast Post Prandial Blood Glucose Levels in Prepubertal Children With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy||Spectrum Health Hospitals|No|Completed|June 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|4 Years|11 Years|No|||April 2014|April 3, 2014|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913497||138168|
NCT00914433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI 1100-101|Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers|A Phase 1,Randomized, Double--blind, Placebo-controlled Study Assessing the Safety and Tolerability, the Pharmacodynamics and Pharmacokinetics of Single-ascending and Repeated Doses of Inhaled TPI 1100 in Healthy Subjects||Pharmaxis|Yes|Withdrawn|April 2009|April 2010|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|June 2, 2009||No|Drug development suspended|No||https://clinicaltrials.gov/show/NCT00914433||138096|
NCT00914680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEMAST1|Berlin Magnetic Seizure Therapy Depression Trial 01|Investigation of Efficacy and Tolerability of Magnetic Seizure Therapy in the Treatment of Depression||Charite University, Berlin, Germany|No|Recruiting|June 2009|May 2013|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|25 Years|80 Years|No|||June 2009|July 20, 2011|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914680||138077|
NCT00914693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91554|EU/LA Pearl Index Study - Transdermal Contraceptive Patch|Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects||Bayer|No|Completed|April 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1694|||Female|18 Years|35 Years|No|||December 2014|December 4, 2014|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00914693||138076|
NCT00908310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-041-075|Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)|A Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive OMNISCAN (Gadodiamide Injection) for Contrast-enhanced Magnetic Resonance Imaging.||GE Healthcare|Yes|Completed|May 2009|September 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|213|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|May 13, 2009|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT00908310||138562|As a result of the FDA reference ID: #2954949, subject enrolment was terminated at 213 subjects. All subjects (202 subjects) who received any dose of Omniscan were followed as per protocol until study completion, withdrawal, or lost-to-follow-up.
NCT00908596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13701|Primovist / Eovist in Renally Impaired Patients|Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Primovist/Eovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information.|PERI|Bayer|No|Completed|May 2009|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|357|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|May 26, 2009|No|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT00908596||138540|The study was stopped early since the FDA released the sponsor from completing enrollment because the NSF incidence estimate was lower than the original literature–based estimate, and since enrollment quota were not feasible.
NCT00908830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM 20989|Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients|Pharmacokinetics of Mycophenolic Acid in Cystic Fibrosis Lung Transplant Recipients||University of Michigan|Yes|Active, not recruiting|June 2009|March 2012|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|10|||Both|18 Years|70 Years|No|||August 2011|August 3, 2011|May 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908830||138522|
NCT00909116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CME-08-001|International Multicenter Prospective Transtar Registry|International Transtar Registry - Stapled Transanal Rectal Resection Performed With Contour Transtar Stapler in the Treatment of Obstructed Defecation Syndrome (ODS)||Ethicon Endo-Surgery (Europe) GmbH|Yes|Completed|January 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|16 Years|N/A|No|Non-Probability Sample|Consecutive male and female patients of at least 16 years with symptoms of chronic        constipation due to ODS associated with anatomical changes, such as internal rectal        prolapse and rectocele|April 2014|April 15, 2014|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909116||138500|
NCT00909129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-541|Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment|Hepatitis C Virus Dynamic and Immune Activation in HIV-1 Coinfected Patients Treated With Pegylated Interferon Alfa-2a and Ribavirin|DICO|Karolinska Institutet|Yes|Completed||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|N/A|No|||May 2009|May 26, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00909129||138499|
NCT00909441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 08.224|Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer|Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer: A Multi-institutional Prospective Study Furthering the Treatment of Breast Cancer|SN-FNAC|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Completed|February 2009|December 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Female|18 Years|N/A|No|||June 2011|February 9, 2015|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00909441||138476|
NCT00909324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGET980AIN03|Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery|Efficacy, Tolerability and Comfort of 0.3% Hypromellose Eyedrops in the Pre- and Post-Operative Treatment of Patients Undergoing LASIK Surgery||Novartis||Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|21 Years|35 Years|No|||February 2011|February 24, 2011|May 26, 2009||No||No|January 12, 2011|https://clinicaltrials.gov/show/NCT00909324||138485|
NCT00909649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|seroma in breast surgery|Influence of Fibrin Glue on Seroma Formation After Modified Radical Mastectomy|Influence of Fibrin Glue on Seroma Formation After Modified Radical|MRM|Mansoura University|Yes|Completed|January 2005|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Female|N/A|N/A|No|||April 2009|May 27, 2009|December 5, 2008||No||No|December 5, 2008|https://clinicaltrials.gov/show/NCT00909649||138461|
NCT00909935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02-0067|The Pharmacokinetics of Dexmedetomidine in Children|The Pharmacokinetics of Dexmedetomidine in Children||Children's Hospital Boston|Yes|Active, not recruiting|April 2011|December 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Plasma|Both|3 Years|12 Years|No|Non-Probability Sample|Children requiring sedation for MRI scanning|January 2016|January 26, 2016|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909935||138440|
NCT00909948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 07-068|Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant|Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant|RLI|Massachusetts General Hospital|Yes|Suspended|November 2008|November 2012|Anticipated|November 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||July 2010|July 21, 2010|May 27, 2009|No|Yes|Temprorary closure to new accrual because the Baxter Isolex was withdrawn. Will reopen when    new device is available.|No||https://clinicaltrials.gov/show/NCT00909948||138439|
NCT00906048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVOF_L_03815|LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection|A National, Multicenter, Non-comparative Study Evaluating the Efficacy of the Combination of Levofloxacin (500 mg) and Rifampicin (600 or 900 mg Depending on Weight) Administered Once Daily by Oral Route, as Replacement of Empirical Antibiotic Therapy Given Intravenously With a Total Duration of 6 Weeks of the Antibiotic Therapy, in the Treatment of OsteoArticular Prosthetic Infections (OAPI), With a Two-stage Revision of the Prosthesis.||Sanofi||Terminated|April 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|50 Years|N/A|No|||February 2011|February 4, 2011|May 20, 2009||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT00906048||138731|
NCT00912639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG004|A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer|A Clinical Trial of Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) in Patients With Taxane-Pretreated Recurrent Breast Cancer||Korean Breast Cancer Study Group|Yes|Enrolling by invitation|May 2009|May 2011|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Female|18 Years|N/A|No|||June 2009|June 15, 2009|May 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00912639||138233|
NCT00912652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RuralLITE|Rural Lifestyle Intervention Treatment Effectiveness Trial|Rural Lifestyle Intervention Treatment Effectiveness Trial|RuralLITE|University of Florida|Yes|Completed|June 2008|June 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|612|||Both|21 Years|75 Years|No|||July 2014|July 17, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00912652||138232|
NCT00913211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704M06701|Repetitive Transcranial Magnetic Stimulation (rTMS) to Promote Hand Recovery in Stroke|rTMS and Motor Learning Training to Promote Recovery From Hemiparesis|rTMS|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|40|||Both|21 Years|90 Years|No|||August 2011|August 30, 2011|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00913211||138190|
NCT00913224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-03113|To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets|A Relative Bioavailability Study of Diclofenac Sodium 50 mg Enteric-Coated Tablets||Sandoz||Completed|April 1993|April 1993|Actual|April 1993|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Male|18 Years|41 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913224||138189|
NCT00913237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860520D|To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets|Randomized, 2-Way Crossover Bioavailability Study of Desipramine Hydrochloride 50 mg Tablets||Sandoz||Completed|July 1987|August 1987|Actual|August 1987|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913237||138188|
NCT00913822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|870609D|To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets|Bioavailability of Desipramine Hydrochloride Tablets||Sandoz||Completed|December 1987|December 1987|Actual|December 1987|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913822||138143|
NCT00913835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13899|A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer|Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti-Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer||Eli Lilly and Company|Yes|Completed|June 2009|February 2014|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Female|18 Years|N/A|No|||February 2014|February 13, 2014|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00913835||138142|
NCT00913848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1050|To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions||Sandoz||Completed|October 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|21 Years|47 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913848||138141|
NCT00914446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-APR-05|Identification of Protective and Worsening Steatohepatitis (NASH) Factors|Identification of Protective and Worsening Steatohepatitis (NASH) Factors by Microarray in Morbid Obesity Patients||Centre Hospitalier Universitaire de Nice|No|Recruiting|April 2008|April 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|150|||Both|18 Years|60 Years|No|||June 2009|June 4, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00914446||138095|
NCT00914459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-4433|Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients|A Non-randomized, Open-label Study To Evaluate The Pharmacokinetics, Safety And Efficacy Of Refacto Af In Previously Treated Pediatric Subjects Less Than Twelve Years Of Age With Severe Hemophilia A (Fviii:c <1%).||Pfizer|No|Active, not recruiting|December 2009|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|N/A|11 Years|No|||February 2016|February 11, 2016|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914459||138094|
NCT00907231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0112|Evaluation of Serial Troponin and Cardiac Multimarkers at the Point of Care in the Emergency Department||ESTIMATE|Biosite|No|Withdrawn|February 2010|May 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 400 adults presenting to the ED with possible AMI will be enrolled.|July 2015|July 20, 2015|May 20, 2009||No|Business Decision|No||https://clinicaltrials.gov/show/NCT00907231||138642|
NCT00908063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX-CL-II-005|Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI)|A Randomized, Placebo Controlled, Double-Blind, Single Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of Oxycyte in Patients With Severe Non-Penetrating Traumatic Brain Injury|STOP-TBI|Tenax Therapeutics, Inc.|Yes|Terminated|October 2009|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|70 Years|No|||March 2014|November 11, 2014|May 22, 2009||No|futility|No||https://clinicaltrials.gov/show/NCT00908063||138580|
NCT00908076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H21192|Amitiza in Constipation Associated With PD (Parkinson's Disease)|RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF LUBIPROSTONE IN THE TREATMENT OF CONSTIPATION ASSOCIATED WITH PARKINSON'S DISEASE.|AMITIZA|Baylor College of Medicine|No|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|85 Years|No|||September 2010|April 5, 2011|May 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908076||138579|
NCT00908323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 908|Early Immune Responses to Vaccination - A Substudy to HVTN 205|Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|47|Samples With DNA|Blood samples 30 - 90 mL per visit|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants enrolled in HVTN 205|March 2015|March 25, 2015|May 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00908323||138561|
NCT00908336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25033|Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen|Phase II, Multicenter, Randomized, Open Label Study of a Sequential Treatment of Intermittent Erlotinib and Docetaxel Versus Erlotinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer After Failure of a Prior Chemotherapy Regimen||Hospital Arnau de Vilanova|No|Recruiting|March 2009|December 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||May 2009|May 22, 2009|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00908336||138560|
NCT00909467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-097 ex 08/09|Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases|Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases||Medical University of Graz|No|Completed|April 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|86|Samples With DNA|Samples with DNA will be retained for later examinations at the Department for Genetics, if      the patient agrees with it (specific question at the patient information).|Both|18 Years|95 Years|No|Probability Sample|patients with known myeloproliferative or myelodysplastic disease as a risk factor for        pulmonary hypertension|March 2012|March 8, 2012|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00909467||138474|
NCT00908843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIC2117|Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration|Comparative Efficacy of the Application of an Oral/iv Hydration Protocol in the Prevention of Contrast Induced Nephropathy|NIC|Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|September 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|167|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00908843||138521|
NCT00909142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14236|Bonefos and the Consumption of Analgesics|Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis|BICAM|Bayer|No|Completed|April 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|149|||Both|18 Years|N/A|No|Non-Probability Sample|Random sample of cancer patients visting oncologist or urologist ambulance who are        suitable for standard clodronate treatment.|April 2012|April 5, 2012|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00909142||138498|
NCT00909454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901159|Vitamin D Supplement Study for Adolescents|V.I.P. Feasibility Study (Vitamin D Intake Project)|VIP|Georgia Regents University|No|Completed|February 2009|June 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|45|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00909454||138475|
NCT00909779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091-080|Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects|A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease||Sunovion|Yes|Completed|June 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|841|||Both|40 Years|N/A|No|||September 2013|September 12, 2013|May 26, 2009|Yes|Yes||No|June 21, 2013|https://clinicaltrials.gov/show/NCT00909779||138452|Although LABAs other than study medication were discontinued, other medications were not controlled for. A large number of subjects discontinued after a primary event and their eventual outcomes are unknown.
NCT00909792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-319-C-013|Clinical Evaluation of Two New Silicone Hydrogel Multifocal Products|Clinical Evaluation of Two New Silicone Hydrogel Multifocal Products||Alcon Research||Completed|May 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|259|||Both|35 Years|N/A|No|||January 2012|June 26, 2012|May 27, 2009|Yes|Yes||No|September 16, 2010|https://clinicaltrials.gov/show/NCT00909792||138451|
NCT00908726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microemulsion Phase 1|Population Pharmacokinetics/Pharmacodynamics (PK/PD) of Microemulsion Propofol in Healthy Volunteers|Population Pharmacokinetic and Pharmacodynamic Modeling of Microemulsion Propofol in Healthy Volunteers: Comparison With Lipid Emulsion Propofol||Asan Medical Center|No|Completed|May 2009|June 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|63|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 18, 2012|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908726||138530|
NCT00909662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7107|Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers|Physiology of Chemotherapy Induced Fatigue and Cognitive Dysfunction in Early Stage Breast Cancer||Case Comprehensive Cancer Center|Yes|Terminated|July 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|18|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy        will be enrolled from the outpatient oncology clinics of the Case Comprehensive Cancer        Center.        Twenty female control subjects will be recruited, consisting predominantly of age-matched        (i.e.        +/- 10 years of age) friends or family members of the patients.|October 2015|October 1, 2015|May 27, 2009||No|Funding unavailable|No||https://clinicaltrials.gov/show/NCT00909662||138460|
NCT00909688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3219K1-1001|Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses|Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|June 2009|October 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|May 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909688||138459|
NCT00909337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-295 ex 06/07|Early Therapy of Pulmonary Arterial Hypertension|Early Therapy of Pulmonary Arterial Hypertension||Medical University of Graz|No|Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|90 Years|No|||September 2011|September 22, 2011|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00909337||138484|
NCT00906100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW IRB 122007-040|Prevalence of Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients With Biventricular (BiV) Device|Prevalence of Prolonged Inter/Intra-Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients Undergoing Biventricular (BiV) Device Placement||University of Texas Southwestern Medical Center|No|Recruiting|May 2008|May 2010|Anticipated|May 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for biventricular ICD placement|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906100||138727|
NCT00906061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPNM-PS2-07|Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients|Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2||Hospital Arnau de Vilanova|No|Recruiting|October 2007|October 2011|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||May 2009|May 19, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906061||138730|
NCT00912886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071237|Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease|Neuroactive Steroids and Cognition in Humans: Pregnenolone Sulfate an Early Marker of the Memory Loss Associated With Alzheimer's Disease|STERMEM|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|90|Samples With DNA|Plasma and serum from AD patients and from Controls|Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  AD Patients will be recruited among the new patients from the consultations of the             geriatric centres involved in the study          -  Controls will be recruited from the consultations, associations of aged persons or             among the relatives of the patient|April 2013|April 10, 2013|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912886||138214|
NCT00913861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-238|Non-pharmacological Intervention for Colonoscopy|Does Non-pharmacological Intervention Reduce Consumption of Propofol During Colonoscopy?||University Hospital, Geneva|No|Terminated|May 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|May 22, 2009||No|affiliation's change of the principal investigator need a new review bord|No||https://clinicaltrials.gov/show/NCT00913861||138140|
NCT00913874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1049|To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions||Sandoz||Completed|October 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913874||138139|
NCT00907803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIGA-246-004|Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246|Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Assess Safety, Tolerability, and PK of the Anti-Orthopoxvirus Compound ST-246 When Administered as a Single Daily Oral Dose for 14 Days in Volunteers in the Fed State|246-Safety|SIGA Technologies|Yes|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|107|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2010|September 15, 2010|May 21, 2009|Yes|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT00907803||138600|
NCT00908609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-064S-2|Optical Tomography With Ultrasound Guidance|3-D Simultaneous Ultrasound and NIR Imaging for Breast Cancer Detection||University of Connecticut Health Center|Yes|Active, not recruiting|April 2007|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|340|||Female|18 Years|N/A|No|Non-Probability Sample|1. Women undergo ultrasound guided biopsy          2. Breast cancer patients undergo neoadjuvant thermotherapy treatment|September 2012|September 7, 2012|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908609||138539|
NCT00908856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-3040|Autologous Cell Therapy After Stroke|Safety of IV Autologous Mononuclear Cells and Marrow Stromal Cells After Stroke||University of California, Irvine|No|Withdrawn|January 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|May 26, 2009|No|Yes|Not funded|No||https://clinicaltrials.gov/show/NCT00908856||138520|
NCT00909155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600B-100953|Brain Imaging Techniques That Predict Antidepressant Responsiveness|Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine|WyethKolden|University of Wisconsin, Madison|No|Completed|July 2002|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|May 18, 2009||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00909155||138497|Relatively small number of subjects. Not powered statistically to determine if either treatment arm (fluoxetine or venlafaxine) is superior.
NCT00909480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1768|Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes|A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes|EFFICACY|Novo Nordisk A/S|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|457|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|May 27, 2009|Yes|Yes||No|June 10, 2011|https://clinicaltrials.gov/show/NCT00909480||138473|
NCT00909805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-10|Interest of 2-octyl-cyanoacrylate (Dermabond®) in Closing Surgical Incisions in Children Before Acquisition of Continence|Interest of 2-octyl-cyanoacrylate (Dermabond®) in Closing Surgical Incisions in Children Before Acquisition of Continence. Randomised, Prospective, Non-inferiority Study.||Centre Hospitalier Universitaire de Nice|No|Recruiting|September 2009|September 2012|Anticipated|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|248|||Both|N/A|24 Months|No|||March 2010|March 23, 2012|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909805||138450|
NCT00910078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sFLC r, KLR and IFIX|Serum Free Light Change in Multiple Myeloma|Serum Free Light Chain Ratio, Total Kappa/Lambda Ratio, and Immunofixation as Prognostic Factors in Multiple Myeloma.||Azienda Ospedaliera San Giovanni Battista||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|18 Years|75 Years|No|Probability Sample|A cohort of patients undergoing autolog transplantatio|May 2009|May 28, 2009|May 28, 2009||||No||https://clinicaltrials.gov/show/NCT00910078||138429|
NCT00910091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-55-58064-004|The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer|A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer||Ipsen|No|Completed|August 2009|July 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Female|18 Years|N/A|No|||August 2015|August 28, 2015|May 21, 2009||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT00910091||138428|
NCT00910104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-04-048|Cholestasis Reversal: Efficacy of IV Fish Oil|Cholestasis Reversal: Efficacy of IV Fish Oil|Reversal|Children's Hospital Boston|Yes|Recruiting|September 2004|September 2020|Anticipated|September 2020|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|N/A|17 Years|No|||February 2016|February 26, 2016|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910104||138427|
NCT00905905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMI|Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction|Additive Effect of Ezetimibe Upon Simvastatin Treatment on Systemic Inflammatory Activity and Endothelial Function During Myocardial Infarction||Brasilia Heart Study Group|No|Completed|May 2009|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|40 Years|70 Years|No|||March 2010|March 23, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00905905||138742|
NCT00908739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1808|Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer|Assessment of Patterns of Expression of VEGF, Matrix Metalloproteinase 2, 9 Activity, E-Cadherin Regulation and CA-9 Activity as Predictors of Aggressive Renal Cell Carcinoma Behavior||Case Comprehensive Cancer Center|Yes|Withdrawn|May 2008|||September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Previously collected tumor tissue samples are examined by immunohistochemistry for levels of      expression of five different factors related to aggressive tumor behavior (i.e., VEGF      expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic      anhydrase 9 activity.|Both|N/A|N/A|No|Probability Sample|Primary care clinic|September 2015|September 29, 2015|May 23, 2009|No|Yes|PI left|No||https://clinicaltrials.gov/show/NCT00908739||138529|
NCT00909987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-0801|Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum|Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy With Selective Radiotherapy Use in Patients With Intermediate-Risk Cancer of the Rectum Defined by Magnetic Resonance Imaging||Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Completed|March 2009|June 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||September 2013|October 10, 2013|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00909987||138436|
NCT00910000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-026|Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer|Phase IB/II Study of Combination Vorinostat, Carboplatin and Gemcitabine + Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer||Dana-Farber Cancer Institute|Yes|Terminated|June 2009|June 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Female|18 Years|N/A|No|||June 2015|June 12, 2015|May 26, 2009|Yes|Yes|Terminated due to unacceptable toxicity|No||https://clinicaltrials.gov/show/NCT00910000||138435|
NCT00909961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HTR04|A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years|A One Year, Local, Open Label, Multicentre Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on BMD and Biochemical Markers of Bone in PMO Pts Between the Ages of 50 and 65 Years||Novartis||Completed|November 2009|||December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Female|50 Years|65 Years|No|||June 2012|June 29, 2012|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909961||138438|
NCT00909974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEIN2004PR298|Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso|Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso|MISAME2|Institute of Tropical Medicine, Belgium|Yes|Completed|February 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1302|||Female|15 Years|45 Years|No|||September 2010|September 12, 2010|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909974||138437|
NCT00905775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-22|Renal Function in Patients Submitted to Myocardial Revascularization Surgery|Evaluation of Renal Function and Oxidative Stress in Patients Submitted to Myocardial Revascularization Surgery, With Extracorporeal Circulation, and Anesthesia With Isoflurane or Propofol||UPECLIN HC FM Botucatu Unesp|Yes|Terminated|December 2008|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|75 Years|No|Probability Sample|Included in present study will be patients of both sexes, aged from 18 to 75 years,        submitted to revascularization surgery of the myocardium with the use of extracorporeal        circulation, who had consented to participation by signing the Terms of Free and Clear        Consent.        Patients excluded will be those with a history of hepatic or renal dysfunction, or a        history involving acute myocardial infarct; patients that made use of vitamin C and E;        patients presenting other cardiac pathologies (valvular, congenital, corrected or not in        the same operational act).|May 2009|June 24, 2015|April 28, 2009||No|Failure of recruitment|No||https://clinicaltrials.gov/show/NCT00905775||138752|
NCT00913172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000001|Cost and Cost-effectiveness of PTB+ Treatment in Southern Ethiopia|Improving Community Based TB Care in Southern Ethiopia Cost and Cost Effectiveness||University of Bergen|No|Completed|September 2006|April 2008|Actual|March 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|229|||Both|N/A|N/A|No|Probability Sample|This study was conducted along a CRT to find out if involving HEWs improves the treatment        success rate of smear-positive patients. For both treatment alternatives, smear-positive        patients who were diagnosed (from September 2006 to September 2007) and started treatment        were prospectively enrolled until the end of treatment. The detail of the study are given        elsewhere|May 2009|May 14, 2010|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00913172||138193|
NCT00913185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1021|Comparison Study of Topical Acne Regimens|Acne Free vs. Proactiv for the Treatment of Moderately Severe Acne Vulgaris||MedDerm Associates|Yes|Completed|December 2006|February 2008|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|128|||Both|13 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|March 1, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00913185||138192|
NCT00913523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-101|Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora|Vaginal Lactobacillus and Other Key Microflora During and After Menses in Women Using Tampons Containing Glycerol Monolaurate (GML) and Women Using Tampons Without GML||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|482|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 19, 2011|June 3, 2009|No|Yes||No|April 12, 2011|https://clinicaltrials.gov/show/NCT00913523||138166|
NCT00913887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-04124|To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions||Sandoz||Completed|April 1994|May 1994|Actual|May 1994|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913887||138138|
NCT00914147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642265|Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors|Pulmonary Function Tests (PFT) in a Phase I Patient Population||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|May 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|18 Years|120 Years|No|||February 2016|February 8, 2016|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914147||138118|
NCT00914160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-08133|To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions||Sandoz||Completed|August 1993|September 1993|Actual|September 1993|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914160||138117|
NCT00908349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804P302|Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy|Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy on up to Three Concomitant Antiepileptic Medications||Supernus Pharmaceuticals, Inc.|Yes|Completed|June 2009|June 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|18 Years|66 Years|No|||June 2012|June 18, 2012|May 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908349||138559|
NCT00908622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIO/REG/PERCUTÁNEO|Study of the Efficacy of Percutaneous Implantation of Autologous Myoblasts in Patients With Old Infarction|Phase II, Blind, Controlled, Randomised Study of the Efficacy of Percutaneous Implantation of Autologous Myoblasts in Patients With Old Infarction|PERCUTANEO|Clinica Universidad de Navarra, Universidad de Navarra|No|Terminated|March 2007|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|30 Years|80 Years|No|||September 2015|September 10, 2015|May 25, 2009||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00908622||138538|
NCT00908869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METRO1/IPC2005-001|Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm|Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm|METRO1|Institut Paoli-Calmettes|Yes|Completed|May 2006|May 2011|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2012|January 26, 2012|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00908869||138519|
NCT00909168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYFLAI07|Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)|Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)|MYFLAI07|University Hospital, Udine, Italy|Yes|Completed|March 2008|March 2013|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|18 Years|65 Years|No|||May 2014|May 5, 2014|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909168||138496|
NCT00909181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070060|Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence|A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multicenter Study Evaluating the Effect of Treatment With Topically Administered Oxybutynin Gel in Patients With Urinary Frequency, and Urge and Mixed Urinary Incontinence With a Predominance of Urge Incontinence Episodes With an Open-Label Extension||Antares Pharma Inc.|Yes|Completed|March 2009|November 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|626|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|May 25, 2009|Yes|Yes||No|November 29, 2010|https://clinicaltrials.gov/show/NCT00909181||138495|
NCT00910143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 08-05-09|Introduction and Influence of Total Mesorectal Excision (TME) in the Treatment of Rectal Cancer|Introduction of Total Mesorectal Excision (TME) in the Treatment of Rectal Cancer. Influence of This New Operation Technique on Local Recurrence and Long-Time Survival. Retrospective Study: 1993-2001||University Hospital Inselspital, Berne|No|Completed|January 1993|December 2001|Actual|December 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|194|||Both|16 Years|N/A|No|Non-Probability Sample|all adult patients with adenocarcinoma of the rectum who underwent colorectal surgery at        Bern University Hospital between January 1993 and December 2001|May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910143||138424|
NCT00910156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01|Indirect Laryngoscopy for Nasal Intubation|Indirect Versus Direct Laryngoscopy for Routine Nasotracheal Intubation: a Pilot Study||General Hospital Linz||Completed||||||Phase 4|Interventional|N/A|3||||||Both|18 Years|80 Years||||May 2009|May 28, 2009|May 28, 2009||||No||https://clinicaltrials.gov/show/NCT00910156||138423|
NCT00909818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBCG hypo protocol|Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients|Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients: a Randomized Phase II Trial, CIRRO (The Lundbeck Foundation Center for International Research in Radiation Oncology)||Danish Breast Cancer Cooperative Group|Yes|Active, not recruiting|May 2009|May 2022|Anticipated|May 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|976|||Female|41 Years|N/A|No|||August 2015|August 18, 2015|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909818||138449|
NCT00910117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNTG 09-01|Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase II Study of Nimotuzumab Plus PF as Induction Chemotherapy in Patients With Locally Advanced HNSCC||Fudan University|No|Completed|May 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||February 2012|February 16, 2012|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910117||138426|
NCT00910130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBP4|Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4|Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4||IRCCS Policlinico S. Matteo||Recruiting|July 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|Samples With DNA|Serum Subcutaneous adipose tissue|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ambulatory patients or primary care clinic for "End Stage Renal Disease group;" Blood        donors or primary care clinic for "Control group"|May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910130||138425|
NCT00905918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120901|Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer|A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Colon||Rutgers, The State University of New Jersey|No|Completed|June 2009|May 2014|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|May 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00905918||138741|
NCT00906217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hookey Picosalax Elderly Trial|Safety, Efficacy, and Tolerance of Pico-Salax for Colon Cleansing Prior to Colonoscopy in an Elderly Population|Safety, Efficacy, and Tolerance of Pico-Salax for Colon Cleansing Prior to Colonoscopy in an Elderly Population||Queen's University|No|Completed|January 2009|September 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|70 Years|N/A|No|Non-Probability Sample|patients older than 70 scheduled for colonoscopy|September 2011|September 14, 2011|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906217||138718|
NCT00909701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B/12/2008|Metabolic Response Following Intake of 2 Metabolic Preconditioning Drinks|Investigating the Metabolic Response Following Intake of 2 Metabolic Preconditioning Drinks: a Randomized Double-blind Crossover Healthy Volunteer Study||University of Nottingham|No|Completed|May 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|15|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2009|July 17, 2009|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00909701||138458|
NCT00906932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 022004-040|Comparison Study of a New Fiberoptic Intubation Device to Standard Intubation Techniques|A Prospective Study Comparing the Trachview Videoscope to Standard Direct Laryngoscopy for Orotracheal Intubation||University of Texas Southwestern Medical Center|No|Completed|March 2004|September 2004|Actual|September 2004|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|159|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Medical students with no prior intubation experience and patients requiring intubation for        elective surgery|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906932||138665|
NCT00905801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-149|Computed Tomography (CT) Perfusion Imaging of Lung Cancer|CTP (Computed Tomography Perfusion) Imaging of Lung Cancer||University of Pittsburgh|Yes|Terminated|June 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|16|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 15, 2009|No|Yes|Co-PI left institution, PI not pursuing|No||https://clinicaltrials.gov/show/NCT00905801||138750|
NCT00905814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061052|A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers|A Phase I Bioequivalence Study To Compare The Plasma Pharmacokinetics Of Five 1-mg And One 5-mg AG-013736 Tablets In Healthy Volunteers||Pfizer|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|21 Years|47 Years|Accepts Healthy Volunteers|||November 2009|November 13, 2009|May 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00905814||138749|
NCT00907751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060801|Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura|Association of Rituximab to Plasma Exchange in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura|PTTritux|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00907751||138604|
NCT00907764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT 5127|Stress Echocardiography Study With Regadenoson|An Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 ug Regadenoson Bolus for Pharmacological Stress Echocardiography||Gilead Sciences|Yes|Terminated|April 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|22|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|May 20, 2009|No|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT00907764||138603|
NCT00907777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112807|Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™|Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine||GlaxoSmithKline||Completed|June 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Both|46 Months|50 Months|Accepts Healthy Volunteers|||March 2011|January 19, 2012|May 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907777||138602|
NCT00905788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-001|Embryo Transfer: Embryo Expulsion and Outcome|Embryo Transfer: Embryo Expulsion and Outcome||Royan Institute|Yes|Completed|February 2008|December 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Female|18 Years|40 Years|No|||April 2010|April 17, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00905788||138751|
NCT00912925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALID-003-99|Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational, Clinical Study of Recombinant Human Alpha L-Iduronidase In Patients With Mucopolysaccharidosis I||Sanofi|No|Completed|December 2000|September 2001|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|5 Years|N/A|No|||March 2015|March 19, 2015|June 2, 2009|Yes|Yes||No|July 2, 2009|https://clinicaltrials.gov/show/NCT00912925||138211|Rare disease with limited sample size, FVC calculations less reliable for patients whose height is below the 3rd% for general population.
NCT00913198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4126-201|A Study of CP-4126 in Patients With Advanced Pancreatic Cancer|A Phase II Study of CP-4126 in Patients With Advanced Pancreatic Cancer.||Clavis Pharma|No|Completed|April 2009|September 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00913198||138191|
NCT00913900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0008|Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease|Stem Cell Revascularization in Patients With Critical Limb Ischemia|SCRIPT-CLI|University of Wisconsin, Madison|Yes|Terminated|May 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|21 Years|90 Years|No|||December 2014|December 4, 2014|June 2, 2009|No|Yes|Failure to mobilize adequate CD34+ stem cells for minimum study treatment dose.|No||https://clinicaltrials.gov/show/NCT00913900||138137|
NCT00914173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medasense001|Pain Monitoring Using Plurality of Non-invasive Physiological Measurement|A Single-blind Randomized Clinical Trial to Assess the Efficacy of the Medasense's Non-Invasive Pain Monitor in Estimating the Pain Level Comparing to the Pain Stimuli and the Reported Pain Level on Healthy Subjects.||Medasense Biometrics Ltd|No|Completed|November 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2010|January 27, 2010|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914173||138116|
NCT00907530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-123|Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain|Phase IV, Double-Blind, Multi-Center, Randomized, Crossover Study to Compare 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF GADOVIST® in Magnetic Resonance Imaging (MRI) of the Brain|MERIT|Bracco Diagnostics, Inc||Completed|September 2009|July 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|121|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907530||138619|
NCT00908362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-0003|Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers|Investigator Initiated, Placebo Controlled, Randomized Pilot Trial on the Influence of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers With COPD Stage GOLD 0 or 1.||University of Rostock|No|Completed|May 2009|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|45|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||May 2009|January 12, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00908362||138558|
NCT00909194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBRO1|Juvenile Primary Fibromyalgia Syndrome (JPFS) in an Adolescent Psychiatric Population|Juvenile Primary Fibromyalgia in a Female Adolescent Psychiatric Population||University of Kentucky|No|Completed|July 2007|December 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||May 2009|May 26, 2009|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909194||138494|
NCT00909493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2008-006|Chronic Pain Care Network|Nova Scotia Chronic Pain Collaborative Care Network: A Pilot Study|NSCPCCN|Nova Scotia Health Authority|No|Completed|June 2008|May 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|19 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 31, 2011|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00909493||138472|
NCT00909831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643294|Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment|A Phase I Trial of Hydroxychloroquine in Combination With Temsirolimus in Patients With Refractory Solid Tumors||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|October 2008|||May 2012|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|120 Years|No|||February 2016|February 9, 2016|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909831||138448|
NCT00906256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV689-103|Clinical Pharmacology Study of AZD7295 in Healthy Subjects|A Clinical Pharmacology Study to Determine the Pharmacokinetic, Safety and Tolerability Profile of Oral Doses of AZD7295 in Healthy Subjects||Arrow Therapeutics|Yes|Completed|April 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 11, 2010|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00906256||138716|
NCT00906269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAF001982HU|Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer|Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy|HBOT|Hartford Hospital|No|Recruiting|July 2009|January 2013|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|40 Years|65 Years|No|||April 2011|May 18, 2012|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906269||138715|
NCT00905931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASH 3|Lycopene Following Aneurysmal Subarachnoid Haemorrhage|Acute Oral Lycopene Therapy on Cerebral Autoregulation and Delayed Ischaemic Deficits Following Aneurysmal Subarachnoid Haemorrhage (LASH): A Randomized Controlled Trial|LASH|University of Cambridge|Yes|Not yet recruiting|September 2010|October 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|124|||Both|19 Years|N/A|No|||June 2010|June 10, 2010|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905931||138740|
NCT00905944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/063/07|Exercise in Patients With a Biventricular Pacemaker|Effects of an Exercise Program on the Tendance to Severe Arrhythmias in Patients With Severely Impaired Left Ventricular Function and Cardial Re-synchronisation Therapy||Charite University, Berlin, Germany|No|Recruiting|December 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|75 Years|No|||December 2009|December 21, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905944||138739|
NCT00906243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-9103-002|RNActive®-Derived Therapeutic Vaccine|Phase I/IIa Study of RNActive®-Derived Therapeutic Vaccine in Advanced or Metastatic Hormone Refractory Prostate Cancer||University of Florida|No|Terminated|May 2009|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|75 Years|No|||February 2012|March 29, 2012|May 14, 2009|No|Yes|Study Closed after completion of Phase I|No|February 29, 2012|https://clinicaltrials.gov/show/NCT00906243||138717|This study was terminated early by decision of the Sponsor after 6 subjects had been enrolled in the Phase I part of the study. No efficacy evaluations were planned during the Phase I part of the study.
NCT00906503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642256|Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules|Does Ultra Short-term Steroid Therapy Increase the Accuracy of FDG-PET/CT in Evaluation of Pulmonary Nodules?||Barbara Ann Karmanos Cancer Institute|No|Completed|April 2009|April 2012|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|May 20, 2009|No|Yes||No|September 23, 2014|https://clinicaltrials.gov/show/NCT00906503||138698|Small number of subjects.
NCT00906399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105MS301|Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis|ADVANCE|Biogen|Yes|Completed|June 2009|October 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1516|||Both|18 Years|65 Years|No|||September 2014|September 15, 2014|May 20, 2009|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00906399||138705|
NCT00907205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF1126-001-06|A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors|A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors|SF112600106|Semafore Pharmaceuticals|No|Completed|April 2007|April 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|May 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00907205||138644|
NCT00907218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000444|Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)|An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking||Massachusetts General Hospital|No|Terminated|April 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|60 Years|No|||July 2013|July 31, 2013|May 20, 2009|Yes|Yes|extremely slow enrollment|No|May 9, 2013|https://clinicaltrials.gov/show/NCT00907218||138643|Extremely slow enrollment so the study was terminated early.
NCT00918320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 2008/1378|Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours|Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours|TOTEM2|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Completed|June 2009|August 2015|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|6 Months|20 Years|No|||January 2016|January 25, 2016|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00918320||137799|
NCT00907465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27013|Sedentary Behavior in African Americans|Measurement of Sedentary Behavior in African American Adults|SeBA|Pennington Biomedical Research Center|No|Completed|July 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community members of Baton Rouge, LA.|December 2012|December 2, 2012|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00907465||138624|
NCT00907478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080009|Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)|A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)||Amgen|No|Completed|August 2009|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|May 21, 2009|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00907478||138623|
NCT00908050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22737|Study of the Safety and Efficacy of Botox in Bruxism|DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF BOTULINUM TOXIN TYPE A (BOTOX) IN BRUXISM||Baylor College of Medicine|No|Recruiting|April 2009|July 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|80 Years|No|||September 2010|June 23, 2011|May 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00908050||138581|
NCT00908284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20030814|Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV|Atherosclerotic Risk and Response to Exercise Intervention in HIV+ Children||University of Miami|Yes|Completed|December 2008|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|N/A|25 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908284||138564|
NCT00906386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60409|Methadone Maintenance Treatment and Smoking Cessation|An Examination of the Efficacy, Safety, and Gender Differences in Using Varenicline as an Aid to Smoking Cessation in a Population of Methadone Maintained Opioid Dependent Patients (Pilot Trial)|MMTASC|Vancouver Coastal Health|No|Enrolling by invitation|May 2009|February 2011|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|112|||Both|19 Years|75 Years|No|||May 2009|March 1, 2010|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00906386||138706|
NCT00913536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 05-0620-CE|Cone Beam Computed Tomography (CT) Bladder|Cone-Beam Computed Tomography in Image-Guided Radiotherapy for Patients With Bladder Cancer||University Health Network, Toronto|No|Active, not recruiting|October 2005|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913536||138165|
NCT00907244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHP 901 ASL|Arterial Spin Labeling Perfusion Magnetic Resonance (MR) Imaging in Pediatric Brain Tumors|CHP-901:Arterial Spin Labeling Perfusion MR Imaging in Pediatric Brain Tumors||Children's Hospital of Philadelphia|No|Completed|April 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|N/A|18 Years|No|Non-Probability Sample|Patients between 0-18 years who are diagnosed with primary brain tumor, undergoing MRI for        clinical purpose are eligible for the study.|January 2012|October 26, 2012|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907244||138641|
NCT00907517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05247|A Phase 1 Dose-escalation Study of a Cell Cycle Inhibitor With and Without Cytarabine in Patients With Acute Leukemias (Study P05247)|A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias||Merck Sharp & Dohme Corp.|No|Terminated|July 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00907517||138620|
NCT00907829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6302-W|Source of Hand Weakness After Stroke|Source of Neurally-Mediated Hand Weakness After Stroke||VA Office of Research and Development|No|Withdrawn|February 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|80 Years|No|||May 2014|May 1, 2014|May 21, 2009||No|Methods unexpectedly required additional refinement that precluded subject enrollment.|No||https://clinicaltrials.gov/show/NCT00907829||138598|
NCT00908089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-RACo|TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis|Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis|NEO-RACo|Helsinki University|Yes|Active, not recruiting|March 2003|December 2015|Anticipated|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||March 2015|March 31, 2015|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908089||138578|
NCT00908882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 08-117|Tobacco Cessation for Veterans With Post Traumatic Stress Disorder (PTSD)|Telehealth Care Management and Tobacco Cessation for Veterans With PTSD||VA Office of Research and Development|Yes|Completed|July 2009|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|178|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|May 22, 2009||No||No|April 20, 2015|https://clinicaltrials.gov/show/NCT00908882||138518|
NCT00909844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-54-52014-159|Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study|Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With Precocious Puberty|DECAPUB|Ipsen|No|Completed|April 2008|January 2016|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|N/A|No|||February 2016|February 29, 2016|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00909844||138447|
NCT00909857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91781|Effect on Primary Dysmenorrhea|A Multi-center, Double-blind, Double-dummy, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of SH T00658ID Compared to SH D593B in the Treatment of Primary Dysmenorrhea||Bayer|No|Completed|April 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|507|||Female|14 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|April 24, 2009|Yes|Yes||No|November 15, 2011|https://clinicaltrials.gov/show/NCT00909857||138446|
NCT00910169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract: 2007 -A01110-53|Evaluation of Hospitalization for Anorexia Nervosa (EVALuation de l'Apport de l'HOSPITalisation Pour Anorexie Mentale : EVALHOSPITAM)|Evaluation of Hospitalization for Anorexia Nervosa: Efficacy of Treatment and Predictive Factors of Outcome.|EVHAN|Institut Mutualiste Montsouris|Yes|Active, not recruiting|March 2009|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|all biological analysis during hospitalisation, serotonin , tryptophan, CD4/CD8|Both|8 Years|65 Years|No|Non-Probability Sample|All patients hospitalisied in 11 tertiary centers for eating disorders in france|May 2009|August 6, 2012|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00910169||138422|
NCT00905957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3818|Transversus Abdominis Plane Block For Renal Transplant Recipients|Transversus Abdominis Plane Block For Renal Transplant Recipients: A Randomized Controlled Double-blinded Study||Royal Liverpool and Broadgreen University Hospitals NHS Trust|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||October 2010|August 17, 2011|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905957||138738|
NCT00905970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPDYN|Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection|Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection|HYPDYN|Germans Trias i Pujol Hospital|Yes|Recruiting|May 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|105|Samples With DNA|Whole blood collected on QuantiFeron-Gold-In Tube tubes. Exhaled breath collected on R-Tube|Both|18 Years|N/A|No|Non-Probability Sample|Latent Tuberculosis Infected people|November 2009|July 8, 2011|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905970||138737|
NCT00910182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 07-05-09|Outcome After Conservative and Surgical Treatment of Splenic Injuries After Blunt Abdominal Trauma.|Outcome After Conservative and Surgical Treatment of Splenic Injuries After Blunt Abdominal Trauma. Retrospective Study 2002-2008.||University Hospital Inselspital, Berne|No|Completed|January 2002|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|200|||Both|16 Years|N/A|No|Non-Probability Sample|all patients suffering from traumatic splenic rupture admitted to Bern University Hospital        between January 2002 and December 2008|May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910182||138421|
NCT00906516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAD-302|Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme|A Phase II Protocol for the Use of Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme||Bradmer Pharmaceuticals Inc.|No|Not yet recruiting|May 2009|December 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2009|May 20, 2009|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906516||138697|
NCT00906763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK284112008|Effects of Chocolate on Motor Symptoms of Parkinson's Disease|Effects of Chocolate on Motor Symptoms of Parkinson's Disease - A Monocenter, Prospective, Observer-blinded Interventional Trial|ChocoPD|Technische Universität Dresden|No|Recruiting|May 2009|October 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|23|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906763||138678|
NCT00906776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 01/05|Emdogain and Straumann Bone Ceramic in Infrabony Defects|Randomised, Controlled, Clinical Study to Compare the Effect of a Combination of Enamel Matrix Proteins and Straumann Bone Ceramic With Autogenous Bone in Deep-wide Intrabony Defects||Institut Straumann AG|No|Terminated|April 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||November 2012|November 20, 2012|May 19, 2009||No|Difficulty to recruit patients fulfilling inclusion criteria|No|August 30, 2012|https://clinicaltrials.gov/show/NCT00906776||138677|
NCT00906282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 186|Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer|Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients With Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|June 2009|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906282||138714|
NCT00906529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novo 092|Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin|RAndomized SubCutaneous Insulin in INpatients (RASCIN) Trial: Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin|RASCIN|University of Texas Southwestern Medical Center|Yes|Recruiting|May 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|65 Years|No|||May 2009|May 19, 2009|May 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906529||138696|
NCT00906659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM 1453/08.02.26|Visual Function, Center Point Thickness and Macular Volume After Photocoagulation|Correlation of Visual Function, Center Point Thickness and Macular Volume Changes Three Weeks After Focal Photocoagulation for Diabetic Macular Edema||Hospital Juarez de Mexico|No|Completed|January 2006|March 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|89|||Both|40 Years|70 Years|No|Non-Probability Sample|Target population were type 2 diabetics from Mexico City and its metropolitan area,        accessible population were the patients who attended a General Hospital in Mexico City|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906659||138686|
NCT00918333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0886|Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma|A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma||Mayo Clinic||Active, not recruiting|June 2009|||January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|148|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|June 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918333||137798|
NCT00918853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRP/IPC 2007-005|Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas|Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas.|MRP|Institut Paoli-Calmettes|No|Completed|August 2008|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|18 Years|N/A|No|||March 2013|March 19, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918853||137758|
NCT00919178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 256|Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus|Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers.||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|June 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00919178||137733|
NCT00919191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-6805|Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face|An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model||Valeant Pharmaceuticals International, Inc.|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|June 10, 2009|Yes|Yes||No|December 28, 2009|https://clinicaltrials.gov/show/NCT00919191||137732|
NCT00908297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35580-D|Safety and Tolerability of Coenzyme Q10 in Hemodialysis Patients|Safety, Tolerability and Efficacy of Coenzyme Q10 in Hemodialysis Patients: Aim 1||University of Washington|Yes|Completed|February 2010|November 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|85 Years|No|||April 2012|April 20, 2012|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00908297||138563|
NCT00908557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 08 15|Impact of Readability Improvements on the Comprehension of Written Information Given to Clinical Trial Patients: a RCT|Multicenter RCT to Assess the Impact of Improvements in Lexico-syntactic Readability and Good Practice in Writing on the Comprehension of Written Information Given to Patients Participating in Clinical Trials.|LISYCOM|University Hospital, Grenoble|No|Completed|April 2009|March 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908557||138543|
NCT00906984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 01-61|TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma|A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma|TheraSphere|University of California, Irvine|Yes|Recruiting|May 2002|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|December 27, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00906984||138661|
NCT00907543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-025|Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial|Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy (Cisplatin, 5-FU and Radiotherapy Followed by Surgery) to Surgery Followed by Postoperative Chemoradiation (Cisplatin, Epirubicin, 5-FU, Radiotherapy) for Esophageal Cancer|QUINTETT|Lawson Health Research Institute|Yes|Recruiting|April 2009|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907543||138618|
NCT00907816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC Study 2009P-000611|Concurrent Electronic Order Entry Variation Reporting Impact on Ordering Behavior|Concurrent Electronic Order Entry Variation Reporting Impact on Ordering||Massachusetts General Hospital|No|Enrolling by invitation|April 2009|April 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|72|||Both|N/A|N/A|No|Non-Probability Sample|PCPs at MGH|May 2009|May 22, 2009|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907816||138599|
NCT00908102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A18/01|Managing Non-acute Low Back Symptoms in Occupational Health: Two Trials|The Prevalence of Low Back Symptoms in a Finnish Forestry Company - Effectiveness of Primary Care Interventions for Non-acute Low Back Symptoms in Occupational Health. Two Separate Randomised Controlled Trials (RCT) of Various Levels.||Helsinki University|No|Active, not recruiting|September 2001|December 2016|Anticipated|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|505|||Both|18 Years|56 Years|No|||March 2015|March 17, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00908102||138577|
NCT00909506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|adjuvant metformin for BC|Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients|||Seoul National University Hospital||Completed|June 2009|December 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|105|||Female|20 Years|N/A|No|||September 2010|July 27, 2015|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909506||138471|
NCT00909519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT3012-X-113|Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide|A Phase 1, Single-Center, Randomized, Parallel-group, Placebo- and Naproxen- Controlled, Double-blind Study to Evaluate the Effect of Naproxcinod 750 mg Bid Administered for 8 Days on the Renal Hemodynamics, Natriuretic and Renin Responses to a Single Bolus IV Dose of Furosemide 40 mg in Male Healthy Normotensive Volunteers||NicOx|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|31|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00909519||138470|
NCT00909220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH082133|Using Affective Differences to Predict Response to Behavioral Treatment for Major Depressive Disorder|Translating Affective Science to Predict Outcomes of Behavioral Treatment for MDD||Northwestern University|Yes|Completed|May 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|77|||Both|18 Years|72 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants are drawn from the general population through on-line advertisements for the        study.|July 2015|July 20, 2015|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00909220||138492|
NCT00909532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-770-102|Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation|STRIVE|Vertex Pharmaceuticals Incorporated|Yes|Completed|June 2009|November 2012|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|167|||Both|12 Years|N/A|No|||January 2013|January 14, 2013|May 26, 2009|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT00909532||138469|
NCT00909870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABH-Dermagraft-001-08|Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers|A Prospective, Multi-Center, Randomized, Controlled Clinical Investigation of Dermagraft(R) in Subjects With Venous Leg Ulcers DEVO-Trial|DEVO|Shire Regenerative Medicine, Inc.|No|Completed|June 2009|August 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|537|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|May 28, 2009|Yes|Yes||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00909870||138445|
NCT00910195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_BiLevel APAP_34/2008|Validation of a New Automatic Bi-level Algorithm in the Treatment of Sleep-disordered Breathing|Validation of a New Automatic Bi-level Algorithm in the Treatment of Sleep-disordered Breathing||Wissenschaftliches Institut Bethanien e.V|No|Completed|June 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||August 2011|August 8, 2011|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910195||138420|
NCT00905983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPNM-ANC-07|Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients|Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non Small Cell Lung Cancer (NSCLC) Patients.||Hospital Arnau de Vilanova|No|Active, not recruiting|October 2007|September 2011|Anticipated|September 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|70 Years|N/A|No|||May 2009|May 19, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905983||138736|
NCT00906295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2009-024|Establishment of Optimal Transfusion Threshold After Major Orthopedic Surgery|Establishment of Optimal Transfusion Threshold After Major Orthopedic Surgery||Rigshospitalet, Denmark|No|Completed|June 2009|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||June 2011|June 3, 2011|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906295||138713|
NCT00906542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECAST-01|Predictors of Early Chest Infection in Acute Ischemic Stroke|Predictors of Early Chest Infection in Acute Ischemic Stroke|PRECAST|University of Rostock|No|Completed|May 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|530|||Both|18 Years|N/A|No|Probability Sample|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke        unit within 24 hours after stroke onset|February 2010|February 18, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906542||138695|
NCT00906802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPD Study|Benefit of Roux-en-Y (R-Y) Reconstruction After Pancreaticoduodenectomy|Benefit of R-Y Reconstruction After Pancreaticoduodenectomy||Kochi University|Yes|Recruiting|April 2003|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|30 Years|80 Years|No|||July 2009|July 22, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906802||138675|
NCT00918008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-054|A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer|A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer||Memorial Sloan Kettering Cancer Center||Terminated|June 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples With DNA|single blood sample|Male|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from the Department of Urology, New York Presbyterian Hospital,        Weill Medical College of Cornell University, and from the Department of Surgery, Urology        Service at Memorial Sloan-Kettering Cancer Center.|March 2015|March 4, 2015|June 10, 2009||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00918008||137823|
NCT00918021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011307-22|Polypharmacy in Clozapine-resistant Schizophrenia|Olanzapine Augmentation in Clozapine-resistant Schizophrenia: a Randomized Double-blind Study|CLOZANS|Niuvanniemi Hospital|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918021||137822|
NCT00918866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMP 115-416|A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure|A Phase IV, Open-Label Safety Evaluation of the Effect of DEFINITY® on Pulmonary Artery Hemodynamics in Patients With Normal and Increased Pulmonary Artery Pressure||Lantheus Medical Imaging|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|No|||October 2011|March 30, 2015|June 4, 2009|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00918866||137757|
NCT00919204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061050|Axitinib Pharmacokinetics in Chinese Healthy Volunteers|An Open Label Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Healthy Chinese Volunteers||Pfizer|No|Completed|August 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|June 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00919204||137731|
NCT00906997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLONPREV|Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy|Colorectal Cancer Screening in Average-risk Population: a Multicenter, Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy.||Hospital Clinic of Barcelona|Yes|Active, not recruiting|November 2008|November 2021|Anticipated|November 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|55498|||Both|50 Years|69 Years|No|||March 2015|March 31, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906997||138660|
NCT00907257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-6270|A Study of Different Use Regimens Using Two Acne Treatments|A Clinical Assessment of the Use of RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser and a 5% Benzoyl Peroxide Wash Used in the Morning Compared to the Use of RETIN-A MICRO 0.04% Pump Nightly and a 5% Benzoyl Peroxide Wash in the Morning For the Treatment of Facial Acne Vulgaris||Valeant Pharmaceuticals International, Inc.|No|Completed|February 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|247|||Both|12 Years|N/A|No|||February 2012|February 14, 2012|May 20, 2009|Yes|Yes||No|December 22, 2010|https://clinicaltrials.gov/show/NCT00907257||138640|
NCT00907842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC09-2-052|Hernia Prevention in Stomas|Prevention of Parastomal Hernias and Incisional Hernias in Old Stoma Wounds: a Pilot Study||Academisch Ziekenhuis Maastricht|No|Completed|April 2010|April 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907842||138597|
NCT00908635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-1483B|The Role of Angiopoietin, Tie-2, and Vascular Endothelial Growth Factor (VEGF) in Sepsis-Induced Multiple Organ Dysfunction Syndrome (MODS)|The Role of Angiopoietin, Angiopoietin Receptor Tie-2, and Vascular Endothelial Growth Factor in Sepsis-Induced Multi-Organ Dysfunction Syndrome||Chang Gung Memorial Hospital|Yes|Recruiting|July 2008|August 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|whole blood|Both|18 Years|90 Years|No|Probability Sample|patients admitted to ICU due to sepsis|May 2009|May 26, 2009|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00908635||138537|
NCT00908648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-01|The Use of Narrow Band Imaging in Screening Colonoscopy|The Impact of Narrow Band Imaging in Screening Colonoscopy: a Randomized Controlled Trial.||Valduce Hospital|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|2||Actual|206|||Both|50 Years|69 Years|No|||April 2009|April 2, 2009|January 22, 2009||No||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00908648||138536|
NCT00908921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIME_L_04409|Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)|Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM)|GREAT|Sanofi||Completed|April 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|391|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00908921||138515|
NCT00908934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1520C00004|AZD9056 Relative Bioavailability Study|An Open-label, Randomized, 2 Cohort, 2 Period Crossover Study to Assess the Relative Bioavailability of the Phase III to the Phase IIb Formulation of AZD9056 in Healthy Male and Female Subjects||AstraZeneca|No|Completed|May 2009|July 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 22, 2009|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00908934||138514|
NCT00909259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-Feasibility|Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing|Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing||Respicardia, Inc.|No|Completed|October 2007|December 2013|Actual|September 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|May 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909259||138490|
NCT00909545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCC Protocol #124|Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease|A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease|STEADY-PD|Northwestern University|Yes|Completed|July 2009|February 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|99|||Both|30 Years|N/A|No|||April 2013|April 16, 2013|May 26, 2009||No||No|October 2, 2012|https://clinicaltrials.gov/show/NCT00909545||138468|
NCT00909558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E001-08|Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer|A Phase I Open Label, Single Site, Safety and Efficacy Study of the Effects of Autologous Natural Killer and Natural Killer T Cell Immunotherapy on Malignant Disease||Envita Medical Center, Inc.|Yes|Suspended|May 2009|||June 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||February 2010|February 23, 2010|May 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909558||138467|
NCT00909883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0051|Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)|Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)|RBHP 2008|University Hospital, Clermont-Ferrand||Recruiting|September 2009|September 2012|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|45|||Both|30 Years|75 Years|No|||March 2011|March 24, 2011|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00909883||138444|
NCT00906022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0801|Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND)|EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months.|EXPAND|Biotronik AG|Yes|Completed|May 2009|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|51 Years|N/A|No|||February 2015|February 6, 2015|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906022||138733|
NCT00906321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909150|Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk|Facilitating Web-Based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk||National Institutes of Health Clinical Center (CC)||Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|64|||Female|35 Years|N/A|No|||May 2010|June 5, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906321||138711|
NCT00905996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM04|Primary Prophylaxis of Gastric Varix Bleed|A Randomized Controlled Trial Comparing Cyanoacrylate Injection Versus Beta-Blockers Versus No Treatment for Primary Prophylaxis of Gastric Variceal Bleed||Govind Ballabh Pant Hospital|No|Completed|August 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|74|||Both|12 Years|75 Years|No|||May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905996||138735|
NCT00906009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-01837|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2009|||||N/A|N/A|N/A||||||||||||||May 20, 2009|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906009||138734|
NCT00906308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-101-004|A Study of MF101 in Postmenopausal Women|A Phase 3, Double-blind, Placebo-Controlled, Randomized Clinical Trial, Assessing Safety and Efficacy of MF101 for Hot Flushes and Menopausal Symptoms in Postmenopausal Women|HERBA|Bionovo|Yes|Recruiting|October 2011|||February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1200|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906308||138712|
NCT00907088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000007781|Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years|Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years: a Randomized Controlled Trial||The Hospital for Sick Children|No|Completed|January 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|251|||Both|9 Months|9 Months|Accepts Healthy Volunteers|||March 2014|March 12, 2014|May 21, 2009||No||No|December 2, 2013|https://clinicaltrials.gov/show/NCT00907088||138653|
NCT00919217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.0172|Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms|Exploratory Study on the Timing of MS Symptoms||University of Louisville|Yes|Recruiting|August 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|50 Years|No|Non-Probability Sample|Females with relapsing-remitting multiple sclerosis, not menopausal, neither pregnant nor        nursing, not treated with steroids in the last 30 days and not on experimental medications|July 2013|July 30, 2013|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919217||137730|
NCT00918619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0804|Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection|Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-bound Fibrin Sealant During Liver Resection (ESSCALIVER)|ESSCALIVER|Aesculap AG|No|Completed|January 2010|January 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918619||137776|
NCT00918632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061053|Food Effect Study Of AG-013736 In Healthy Volunteers|A Phase I Open-Label Study In Healthy Volunteers To Compare The Plasma Pharmacokinetics of Polymorph Form XLI AG-013736 In The Fasted And Fed State||Pfizer|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 1, 2009|June 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918632||137775|
NCT00915369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO/NDR/02/2008/01|A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer|A Multicentre Phase I Study Of Cremophor FreePaclitaxel Nanoparticle In Advanced Breast Cancer||Fresenius Kabi Oncology Ltd.|No|Recruiting|March 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|65 Years|No|||February 2010|February 5, 2010|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915369||138024|
NCT00915642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1516/07|Overnight Weight Loss and Sleep Structure|Overnight Weight Loss, Sleep Structure and the Endocrine System|weightsleep|Associacao Fundo de Incentivo a Psicofarmcologia|Yes|Recruiting|September 2007|May 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Male|21 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal and obese volunteers|July 2009|July 31, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915642||138004|
NCT00907270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69770|Supplementation With Vitamin D Improves Leptin Resistance|Effect of Vitamin D Supplementation on Leptin Resistance, Hunger, Body Weight and Resting Energy Expenditure in Obese Women.||Mexican National Institute of Public Health|Yes|Not yet recruiting|September 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|45 Years|65 Years|No|||May 2009|May 20, 2009|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907270||138639|
NCT00907569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24762|Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer|A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer||AHS Cancer Control Alberta|Yes|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2011|February 18, 2016|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907569||138617|
NCT00908128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1264|Mycophenolate Mofetil Tablets Under Fed Conditions|A Single-Dose, Replicate, Comparative Bioavailability Study of Two Formulations of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|August 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 22, 2009|No|Yes||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00908128||138575|
NCT00908375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA7057|Efficacy of Pregabalin in Patients With Radicular Pain|Efficacy of Pregabalin in Patients With Radicular Pain||Northwestern University|No|Completed|May 2009|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|64 Years|No|||September 2014|October 2, 2014|May 21, 2009||No||No|May 29, 2014|https://clinicaltrials.gov/show/NCT00908375||138557|Early subject withdrawal and lost to follow-up leading to small numbers of subjects analyzed.
NCT00908388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAG 08-01|Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection|Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection||W.L.Gore & Associates|Yes|Active, not recruiting|October 2009|June 2017|Anticipated|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||May 2015|May 19, 2015|April 3, 2009|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT00908388||138556|
NCT00909207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0182|Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing|Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing||M.D. Anderson Cancer Center|No|Completed|July 2009|||June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals, age 18 years or older, receiving chemotherapy and/or radiation therapy.|July 2014|July 10, 2014|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00909207||138493|
NCT00908674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14166|Androcur Effects on Quality of Life|Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients||Bayer|No|Completed|June 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|245|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with advanced prostate cancer|April 2010|April 12, 2010|March 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00908674||138534|
NCT00894985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV0109_BLA2|Efficacy and Safety of Sodium Heparin|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|June 2009|December 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894985||139540|
NCT00894699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARX-C-007|A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs™ in Patients Undergoing an Elective Abdominal Liposuction Procedure||AcelRx Pharmaceuticals, Inc.|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||May 2014|May 23, 2014|May 5, 2009|Yes|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT00894699||139562|
NCT00895245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6862|Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head & Neck Cancer Undergoing Concurrent Chemotherapy and Radiation||University of Washington|No|Terminated|February 2009|||September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|6|||Both|18 Years|70 Years|No|||May 2013|May 7, 2013|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895245||139520|
NCT00895258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH080150|Cognitive Training to Improve Work Outcomes in Severe Mental Illness|Cognitive Training to Improve Work Outcomes in Severe Mental Illness||University of California, San Diego|Yes|Completed|April 2008|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895258||139519|
NCT00895518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009260|Examining the Effectiveness of an Early Psychological Intervention to Prevent Post-Traumatic Stress Disorder|Effects of Early Psychological Intervention to Prevent PTSD||Emory University|Yes|Completed|April 2008|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|139|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895518||139499|
NCT00895531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL OICN 091095|Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement|Comparison of Peripheral Nerve Blocks vs. Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement: A Prospective, Randomized Study||University of Louisville|No|Recruiting|December 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||June 2012|June 14, 2012|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895531||139498|
NCT00895544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810802|Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults|An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years||Nanotherapeutics, Inc.|Yes|Completed|May 2009|June 2011|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|231|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||July 2011|October 7, 2015|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895544||139497|
NCT00895830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10002|Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)|Randomised, Double-blind, Placebo-controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-operative Nausea and Vomiting||Acacia Pharma Ltd|No|Completed|May 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|257|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|May 7, 2009|Yes|Yes||No|February 24, 2011|https://clinicaltrials.gov/show/NCT00895830||139475|
NCT00895843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9938|Protective Analgesia for Postoperative Pain Relief Following Day Case Oral Surgery|Protective Analgesia Using Bupivacaine and Conventional Release Ibuprofen Versus Bupivacaine and Sustained Release Ibuprofen for Postoperative Pain Relief in Patients Undergoing Third Molar Surgery: a Randomised Controlled Trial||University of Manchester|Yes|Completed|November 2006|January 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|122|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 7, 2009|March 24, 2009||No||No|March 24, 2009|https://clinicaltrials.gov/show/NCT00895843||139474|
NCT00896090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD|Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder|Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder||University of Texas Southwestern Medical Center|No|Recruiting|April 2009|December 2011|Anticipated|June 2011|Anticipated|Phase 1|Observational|N/A||2|||||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient psychiatry clinic, community|May 2009|May 8, 2009|May 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896090||139455|
NCT00896363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109035|Safety and Efficacy Study in Patients With Major Depressive Disorder|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects With Major Depressive Disorder||GlaxoSmithKline|No|Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|64 Years|No|||March 2012|March 29, 2012|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00896363||139436|
NCT00887198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016927|Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer||Janssen Research & Development, LLC|Yes|Active, not recruiting|April 2009|May 2017|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1088|||Male|18 Years|N/A|No|||January 2016|January 25, 2016|April 18, 2009|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT00887198||140127|These results are up to clinical cutoff (CCO) date (that is, 31 March 2014).
NCT00887211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostent|ProStent Coronary Drug-Eluting Stent|Clinical Trial Program of a Medical Instrument Product|Prostent|CCRF Consulting Co., Ltd.|Yes|Recruiting|October 2008|March 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|75 Years|No|||April 2009|April 29, 2009|April 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887211||140126|
NCT00883454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHE-HCC|Estimation of Functional Liver Reserve Using Cholinesterases|Estimation of Functional Liver Reserve in Patients With Hepatocellular Carcinoma in Cirrhosis: the Value of Preoperative Cholinesterases||University of Milan|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|181|||Both|18 Years|90 Years|No|Non-Probability Sample|The records of approximately 245 consecutive patients who were referred at our Unit        because of HCC were reviewed. Among those, 191 (78%) were submitted to surgery, and 181        (74%) were resected. The patients excluded from surgery were addressed to symptomatic        treatments because of advanced disease or impaired liver functional reserve, or to        percutaneous ablation therapy according to our policy. Among resected patients, there were        145 (80%) men and 36 (20%) women, with median age of 67 years (range 36-87 years).|April 2009|April 16, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883454||140411|
NCT00887432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 128308|Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation|Randomized Placebo-Controlled, Double-Blind Study of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer||Roswell Park Cancer Institute|Yes|Recruiting|April 2009|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||October 2015|October 9, 2015|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887432||140109|
NCT00887445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S341.1.001|First in Man Study With SLV341|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects||Solvay Pharmaceuticals|No|Terminated|July 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 27, 2010|January 30, 2009|No|Yes|The study was terminated on June 25th, 2009 due to strategic decision|No||https://clinicaltrials.gov/show/NCT00887445||140108|
NCT00883428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK 28|Prevalence of Low Back and Pelvic Pain in Pregnant Women|Prevalence of Low Back and Pelvic Pain in Pregnant Women and Factors Associated With a Greater Risk of Having it||Kovacs Foundation|Yes|Completed|June 2009|June 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1158|||Female|18 Years|48 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who are 28 weeks pregnant or more (in the third trimester of the        pregnancy).|March 2014|March 11, 2014|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883428||140413|
NCT00893451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitaD-CKD1|Study of Vitamin D3 Supplementation in Patients With Chronic Kidney Disease|Does Vitamin D3 (Cholecalciferol) Supplementation Change Insulin Resistance in Patients With Chronic Kidney Disease?|VitaD-CKD1|Sahlgrenska University Hospital, Sweden|Yes|Completed|September 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893451||139658|
NCT00893464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16002|A Study of IXAZOMIB in Adult Patients With Lymphoma|An Open-Label, Dose-Escalation, Phase 1 Study of IXAZOMIB (MLN9708), A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma||Millennium Pharmaceuticals, Inc.|No|Completed|August 2009|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|May 4, 2009|No|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT00893464||139657|
NCT00893750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE1390/2.1_UKon|Trauma and Truth Interventions (NET) Versus Conflict Resolution and Social Skills Trainings for Vulnerable Youths in Northern Uganda|Effects of Trauma-Therapy and Truth Education, Conflict Resolution and Social Skills Trainings and Traditional Ways of Coping in Northern Uganda||University of Konstanz|No|Completed|May 2009|||June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|12 Years|30 Years|Accepts Healthy Volunteers|||June 2010|June 30, 2010|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893750||139635|
NCT00893477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS-FL2008-RGM|GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma|An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine®) Associated With Rituximab (MabThera®) in Patients With Follicular Non Hodgkin's Lymphoma With no Prior Treatment||National Cancer Institute (NCI)||Not yet recruiting|March 2009|||March 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2009|August 1, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893477||139656|
NCT00893490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8756|Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma|Ahmed Glaucoma Valve Alone,With Amniotic Membrane or With MMC for Treatment of Refractory Glaucoma||hahid Beheshti University of Medical Sciences|Yes|Recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|3||||||Both|7 Years|75 Years|No|||May 2009|May 4, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893490||139655|
NCT00894647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW01-0901|Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery|A Phase 3b Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses||Graceway Pharmaceuticals, LLC|No|Completed|May 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|247|||Both|18 Years|N/A|No|||August 2010|August 23, 2010|May 5, 2009|Yes|Yes||No|July 28, 2010|https://clinicaltrials.gov/show/NCT00894647||139566|A treatment-emergent AE (TEAE) was an AE that began or worsened in severity after the first application of study drug. TEAEs were summarized for each treatment group by overall incidence, descending order, relationship to study drug, and severity.
NCT00894660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0731004|A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects|A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects||Pfizer|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|38|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 20, 2010|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894660||139565|
NCT00894712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-0838|Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis|Effect of Topical Application of Sulforaphane- Containing Broccoli Sprout Extracts on Radiation Dermatitis During External-beam Radiation Therapy for Breast Cancer||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|April 2009|November 2015|Anticipated|November 2012|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|32|||Female|18 Years|N/A|No|Non-Probability Sample|Breast Cancer|October 2014|October 2, 2014|May 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00894712||139561|
NCT00895271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090133|Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders|Establishing Fibroblast-derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|73|||Both|2 Years|85 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895271||139518|
NCT00895557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807134|Assessing the Impact of Varenicline on Brain-Behavior Vulnerability|Assessing the Impact of Varenicline on Brain-Behavior Vulnerability in Cocaine Dependence||University of Pennsylvania|No|Active, not recruiting|December 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|30|||Male|18 Years|55 Years|No|||April 2012|April 11, 2012|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895557||139496|
NCT00895583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468E8-4500|Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients|Planned Transition To Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy In Renal Allograft Recipients||Pfizer|No|Completed|June 2009|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|254|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|April 29, 2009|Yes|Yes||No|July 23, 2014|https://clinicaltrials.gov/show/NCT00895583||139494|
NCT00895856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP - 414/2008|Functional Capacity in Institutionalized Elders|Evaluation of the Functional Capacity in Institutionalized Elders Who Do Not Receive Physiotherapic Assistance||Centro de Estudos Superiores de Maceio|No|Completed|March 2008|December 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3|||Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample, eder people.|May 2009|May 8, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895856||139473|
NCT00896129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QOL-CML0208|Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy|Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia Patients With Complete Cytogenetic Response Treated With Imatinib as First Line Therapy: Health-Related Quality of Life, Symptom Burden and Adherence to Therapy Issues.||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|448|||Both|18 Years|N/A|No|Non-Probability Sample|Adult CML patiens under Imatinib treatment for at least three years|January 2014|January 21, 2014|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896129||139454|
NCT00896376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626782|Trastuzumab in Treating Women With Metastatic Breast Cancer|Prospective Multicenter Study of Genetic Factors Predictive of the Pharmacodynamics of Trastuzumab in Patients With Metastatic Breast Cancer||Centre Antoine Lacassagne||Completed|December 2005|September 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Female|18 Years|N/A|No|||February 2015|February 8, 2015|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896376||139435|
NCT00883714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/030/09|Exercise During the Allogeneic Stem Cell Transplantation|Exercise During the Allogeneic Stem Cell Transplantation||Charite University, Berlin, Germany|No|Recruiting|May 2009|August 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2009|December 21, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883714||140391|
NCT00883987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2009-366|Osteopathic Treatment of Low Back Pain|A Pilot Project to Study the Effect of Four Osteopathic Treatments on Trunk Muscle Firing Patterns and Temporospatial Parameters of Gait in Persons With Chronic Low Back Pain||Nova Scotia Health Authority|No|Completed|June 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|19 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with chronic mechanical low back pain (Chronic low back pain is defined as having        "pain between the lower ribs and gluteal folds, with minimal radiation to the thigh and        never below the knee, present for a minimum of seven weeks"|March 2014|March 5, 2014|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883987||140370|
NCT00884000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999905 CS07|A Study of Zomacton in Children With Growth Hormone Deficiency|A Randomised, Open-label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety for 12 Months of Zomacton to Genotropin in Children With Idiopathic Growth Hormone Deficiency||Ferring Pharmaceuticals|No|Completed|January 2010|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|3 Years|11 Years|No|||July 2012|July 16, 2012|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884000||140369|
NCT00884247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GSE-DUM-2009/1|Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity|A Prospective, Non Interventional Study to Evaluate the Effects on Quality of Life, Symptoms and Productivity in Patients With Gastroesophageal Reflux Disease (GERD) After 6 Weeks Structured Treatment in a Company Health Care Setting||AstraZeneca|No|Completed|April 2009|June 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Probability Sample|Company health care setting|December 2010|December 6, 2010|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884247||140351|
NCT00883701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL19021970DM|Granzymes and Perforin at the Onset of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Granzymes and Perforin at the Onset of COPD Exacerbations||University of Thessaly|Yes|Completed|December 2002|September 2009|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|sputum cells and supernatant|Both|18 Years|90 Years|No|Non-Probability Sample|COPD patients        Subjects are recruited from a community based outpatient primary medical clinic by        consecutive sampling.        Control subjects        Subjects who seek medical assistance for symptoms suggesting acute bronchitis (dyspnea,        sputum production, purulence, wheeze, cough) are recruited from a community based        outpatient primary medical clinic by consecutive sampling.|August 2009|April 28, 2010|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883701||140392|
NCT00892827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK- 01|Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia|The Efficacy and Safety of Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia. Single-arm Phase II Study. Analysis of Complement Activation Pathways.||Wolfson Medical Center|No|Recruiting|April 2009|December 2010|Anticipated|July 2009|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2010|September 12, 2010|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00892827||139704|
NCT00892515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000617105|Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer|Women In Steady Exercise Research (WISER) Sister||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|October 2008|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Masking: Single Blind|1||Actual|183|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892515||139726|
NCT00892840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN162-002|Multiple-Ascending Dose Study|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-820836 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|May 2009|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|57|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|May 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892840||139703|
NCT00893165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM2H-2009-01|Does Moderate Physical Activity in Hemodialysis Patients Reduce Inflammation?|Does Moderate Physical Activity in Chronic Hemodialysis Patients Reduce Inflammation Via Inhibition of Proinflammatory Monocyte Activity?||Martin-Luther-Universität Halle-Wittenberg||Completed|January 2010|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|16|Samples With DNA|Serum and DNA samples|Both|18 Years|75 Years|No|Non-Probability Sample|End-stage renal disease patients on chronic hemodialysis therapy|January 2012|January 13, 2012|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00893165||139679|
NCT00893802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP102/2002/FOB|Influence of Periodontal Treatment During Pregnancy in Adverse Pregnant Outcomes|Influence of Periodontal Treatment in Pregnant Women Attending Antenatal Care at a Public Health Center in Adverse Pregnant Outcomes: a Controlled Clinical Trial||University of Sao Paulo|No|Completed|August 2001|September 2002|Actual|August 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|33|||Female|16 Years|39 Years|Accepts Healthy Volunteers|||May 2009|May 4, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893802||139631|
NCT00894127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODA-001|Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer|Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer||Biomoda Inc.|Yes|Completed|March 2009|March 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 19, 2014|May 4, 2009||No||No|August 19, 2014|https://clinicaltrials.gov/show/NCT00894127||139606|
NCT00894140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT01/27|Study to Assess the Stability, Efficacy and Safety of the Silent™ Hip Prosthesis in Primary Total Hip Replacement|A Non-comparative, Two Centre, EN540, RSA, Pilot Study to Evaluate the Stability, Efficacy and Safety of the Silent Hip Prosthesis in Primary Total Hip Replacement||DePuy International|No|Completed|January 2003|June 2014|Actual|November 2004|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|25 Years|65 Years|No|||August 2014|January 30, 2015|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894140||139605|
NCT00894439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3219K1-1002|Study Evaluating BLI-489 and Piperacillin in Healthy Subjects|A Randomized, Open-label, Single-dose, 3-period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone.||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 16, 2009|May 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00894439||139582|
NCT00894075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-004-09|Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)|Single-Center, Case-Control Study of Safety, Efficacy and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) for Treatment of Hypophosphatasia in Children||Alexion Pharma GmbH|Yes|Withdrawn|July 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|5 Years|12 Years|No|||April 2012|January 24, 2013|May 4, 2009|Yes|Yes|Withdrawn pending further review of clinical design.|No||https://clinicaltrials.gov/show/NCT00894075||139610|
NCT00894088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCO-T500-PVFS-1|Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|January 2006|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 9, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894088||139609|
NCT00894101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS# 2009-6857|Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation|A Phase II/III, Open Label, Non-Randomized, Multi-Center Study of Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation||University of California, Irvine|No|Withdrawn|May 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|7|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|May 4, 2009|Yes|Yes|The main sponsor of this multi-center trial has submitted this protocol. A single    participating site should not register this study.|No||https://clinicaltrials.gov/show/NCT00894101||139608|
NCT00894114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V520-019|A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)|A Probe Study of the Safety, Tolerability, and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5, or Placebo in Merck V520 Protocols 007 or 012||Merck Sharp & Dohme Corp.||Completed|May 2003|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00894114||139607|
NCT00894673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV0109_HIP|Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass|HEPSBCCV0109|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|July 2009|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894673||139564|
NCT00894686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700802|Tick-Borne Encephalitis (TBE) Seropersistence After First Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)|Open-label Phase 4 Study to Investigate the Seropersistence of Tick-Borne Encephalitis (TBE) Virus Antibodies After the First Booster Vaccination and the Response to a Second Booster Vaccination With FSME-IMMUN in Children, Adolescents and Young Adults (Follow-Up to Study 700401)||Baxter Healthcare Corporation|Yes|Active, not recruiting|May 2009|November 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|160|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 11, 2012|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00894686||139563|
NCT00895596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVCL004|Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B|A PhaseII, Open-Label, Multinational, Multi-Centre, Sequential Group, Dose-Escalation Study to Assess the Safety and Antiviral Activity of LB80380 for 12 Weeks in Patients With Lamivudine-Refractory Chronic Hepatitis B||LG Life Sciences|No|Completed|March 2004|December 2007|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|5||Actual|65|||Both|18 Years|65 Years|No|||May 2009|May 7, 2009|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895596||139493|
NCT00894998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV0109_CRI|Efficacy and Safety of Sodium Heparin in Patients (Cristália)|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|June 2009|December 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894998||139539|
NCT00895011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-303|Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy||VIVUS, Inc.|No|Completed|April 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|298|||Male|18 Years|70 Years|No|||September 2012|September 14, 2012|May 5, 2009|Yes|Yes||No|May 25, 2012|https://clinicaltrials.gov/show/NCT00895011||139538|
NCT00895284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-008892|A Trial on Laparoscopic Hysterectomy Versus Robotic Hysterectomy|Laparoscopic Hysterectomy With and Without Robotic Assistance: a Randomized Prospective Trial||Mayo Clinic|No|Terminated|March 2007|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|N/A|No|||May 2013|May 9, 2013|May 6, 2009|Yes|Yes|Lack of funding|No|May 9, 2013|https://clinicaltrials.gov/show/NCT00895284||139517|The study was terminated due to lack of funding.
NCT00895297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001361-29|Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia|Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation|Dasatinib|European Group for Blood and Marrow Transplantation|Yes|Terminated|February 2010|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|May 6, 2009||No|Slow recruitment. No safety concerns during this study.|No||https://clinicaltrials.gov/show/NCT00895297||139516|
NCT00895570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1538/6032/ES/US|The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction|Sleep Restriction, Impaired Glucose Metabolism, and Performance: The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction||Brigham and Women's Hospital|No|Completed|January 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||May 2009|May 7, 2009|May 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895570||139495|
NCT00896389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040712|Salt Loading and Thiazide Intervention Study|The Relationship Between STK39 Genotypes, Salt Sensitivity, Thiazide Diuretics-induced Blood Pressure Response|SALTI|University of Maryland|Yes|Completed|October 2009|March 2013|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00896389||139434|
NCT00896142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601112|Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)|Optima CAD (Optimal Mechanical Evaluation)||University of Pittsburgh||Completed|October 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|18+ years of age must be patients of UPMC Cardiovascular Institute|November 2011|November 21, 2011|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896142||139453|
NCT00892320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004936|A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers|A Randomized, Open-label, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2004|May 2004|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|45 Years|No|||April 2010|June 6, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00892320||139741|
NCT00896688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-575-D|Ultrasound Guided Diagnostic Cervical Medial Branch Block|Ultrasound Guided Diagnostic Cervical Medial Branch Block||McMaster University|No|Suspended|January 2016|May 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|August 2014|August 20, 2014|April 30, 2009||No|The PI has been unable to continue with the study.|No||https://clinicaltrials.gov/show/NCT00896688||139412|
NCT00884013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCIP001|New York City (NYC) Health eHearts Pay for Quality Pilot|Program Evaluation of New York City Health eHearts Pay for Quality Program|ehearts|New York City Department of Health and Mental Hygiene|No|Completed|January 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|84|||Male|22 Years|N/A||Non-Probability Sample|Adult Primary Care Providers that have adopted an electronic health record in New York        City in non-hospital based practices.|April 2009|April 17, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00884013||140368|
NCT00885131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090124|Effect of Reward on Learning in Motor Cortex|Effects of Reward on Learning in the Motor Cortex||National Institutes of Health Clinical Center (CC)||Completed|April 2009|January 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|64|||Both|18 Years|50 Years|No|||January 2013|February 19, 2014|April 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00885131||140285|
NCT00884273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS31|Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients|A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration||Ferring Pharmaceuticals|No|Completed|August 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Male|18 Years|N/A|No|||October 2013|October 21, 2013|April 17, 2009||No||No|February 1, 2012|https://clinicaltrials.gov/show/NCT00884273||140349|
NCT00884260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91775|GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China|Multi-center, Open Label, Single Arm Study to Assess Efficacy, Safety, Bleeding Pattern and Pharmacokinetics of the Ultra Low Dose Levonorgestrel Intrauterine Contraceptive System (LCS) for a Maximum of 3 Years in Women 18 to 40 Years of Age||Bayer|No|Completed|April 2009|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|918|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00884260||140350|
NCT00884546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA194-003|Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma|A Phase Ib Multiple Ascending Dose Study of BMS-833923 Alone or in Combination With Lenalidomide (Revlimid) Plus Dexamethasone or in Combination With Bortezomib (Velcade) in Subjects With Relapsed or Refractory Multiple Myeloma||Bristol-Myers Squibb|No|Completed|July 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|April 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00884546||140328|
NCT00892853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00022370|Association of Bone Quality and Quantity With Vascular Calcification|Association of Bone Quality and Quantity With Vascular Calcification.||University of Michigan|No|Withdrawn|February 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|30 Years|N/A|No|||June 2014|June 11, 2014|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892853||139702|
NCT00893178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMW 03|Impact of Polymorphism on Pulmonary Pressure in Subjects With Pulmonary Hypertension of Different Cause|Impact of Different Genetic Polymorphism on the Pulmonary Pressure in Patients With Pulmonary Hypertension of Different Cause With Special Focus on Patients With Chronic Heart Failure||University of Leipzig|No|Recruiting|December 2007|December 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|600|Samples With DNA|EDTA Blood, Serum|Both|18 Years|N/A|No|Probability Sample|CHF elevated pulmonary hypertension|September 2011|September 2, 2011|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00893178||139678|
NCT00893191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39/09|The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction|The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction||Assaf-Harofeh Medical Center||Recruiting|May 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Male|40 Years|65 Years|No|Non-Probability Sample|50 healthy males aged 40 - 65 years|May 2009|May 4, 2009|May 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00893191||139677|
NCT00893503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS-160408-SP|Scope Pilot Research Study|Stop Colorectal Cancer Through Prevention and Screening|SCOPE|University of Alberta|No|Completed|April 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1248|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Family practitoners will refer patients to Gastroenterologist physicians for consideration        into the SCOPE Pilot Research program. They will be evaluated for suitability initially by        gastroenterologists who will then refer them directly to the SCOPE Pilot research program        to further assess suitability. Those patients who meet the inclusion criteria with no        exclusion criteria present will be invited to an education session and invited to partake        in the research program if willing.|March 2011|March 7, 2011|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893503||139654|
NCT00893516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN112|CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma|A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.||Emergent BioSolutions|No|Terminated|May 2007|December 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|May 5, 2009||No|Portfolio consolidation.|No||https://clinicaltrials.gov/show/NCT00893516||139653|
NCT00894426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RKR-DUM-2009/1|Patient's Perception in Symptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease|Prospective, Observational, Multi-center, Non-interventional Study to Assess Patients Perception in SYmptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease|SYMBOL|AstraZeneca|No|Completed|May 2009|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|45 Years|N/A|No|Non-Probability Sample|The inclusion/exclusion criteria are designed to select subjects suffering from severe        COPD (according to spirometric classification, GOLD stage III and IV) and in a stable        state|December 2010|December 2, 2010|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00894426||139583|
NCT00895024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0031|Caregiver Assessments of the Quality of Home Hospice Care|Caregiver Assessments of the Quality of Home Hospice Care: A Comparison Across 3 Ethnic Groups (A Preliminary Study)||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2009|||April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bereaved family caregivers who completed their participation in the UT MDACC parent        protocol (2006-0494) and have lost their loved one within 3-23 months. Caregivers who        participated in the parent grant met the inclusion/exclusion criteria of the parent grant.|July 2015|July 14, 2015|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00895024||139537|
NCT00894374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0551003|Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects|A Single-Dose Bioequivalence Study Comparing Artesunate Tablet (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects||Pfizer|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 24, 2010|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894374||139587|
NCT00894387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2368|Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure|ASTRONAUT|Novartis||Completed|May 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1639|||Both|18 Years|N/A|No|||October 2013|October 15, 2013|May 5, 2009|Yes|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00894387||139586|
NCT00894400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0703/6|Characterisation of Fractionated Electrograms Critical for Maintenance of Atrial Fibrillation (AF)|Characterisation of Fractionated Electrograms Critical for Maintenance of AF|CAFE AF|Barts & The London NHS Trust|No|Completed|April 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894400||139585|
NCT00895323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636332|Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer|Phase I Study of Preoperative Detection of Colorectal Carcinoma With Bispecific Antibody Pretargeting||National Cancer Institute (NCI)||Recruiting|November 2008|||March 2010|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|9|||Both|18 Years|N/A|No|||July 2009|September 16, 2013|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895323||139514|
NCT00895336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0443|Lactobacillus GG in Pediatric Ulcerative Colitis (UC)|An Open Label Pilot Study of Lactobacillus GG in Pediatric Ulcerative Colitis||Children's Hospital Medical Center, Cincinnati|Yes|Withdrawn|March 2011|October 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|5 Years|18 Years|No|||February 2011|February 8, 2011|April 27, 2009|Yes|Yes|IND for this study remained on clinical hold|No||https://clinicaltrials.gov/show/NCT00895336||139513|
NCT00895869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BF01|Pain in Neonates During Screening for Retinopathy of Prematurity Using Two Methods|Pain in Neonates During Screening for Retinopathy of Prematurity Using Binocular Indirect Ophthalmoscopy and Wide-field Digital Retinal Imaging: a Randomized Comparison|RETCAM|NHS Lothian|No|Completed|April 2004|February 2008|Actual|January 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|76|||Both|N/A|32 Weeks|No|Non-Probability Sample|Premature infants|February 2010|February 24, 2010|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895869||139472|
NCT00896155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|349|Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients|A Randomized Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy to Assess the Extent of Pulmonary Fibrosis and Disease Related Control and Survival in Breast Cancer Patients|CONSET|Tata Memorial Hospital|Yes|Recruiting|December 2008|December 2013|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Female|N/A|N/A|No|||August 2011|August 27, 2011|May 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896155||139452|
NCT00896168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015460|An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis|A Multi-Center, Pre-Marketing Clinical Trial to Evaluate the Efficacy and Safety of Infliximab Treatment on Rheumatoid Arthritis||Xian-Janssen Pharmaceutical Ltd.|No|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|65 Years|No|||September 2013|September 11, 2013|May 7, 2009|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00896168||139451|
NCT00896675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC HN 0744|Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer|Proteomic Prediction of Clinical Benefit in HNSCC||Vanderbilt-Ingram Cancer Center|Yes|Completed|June 2007|December 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|352|||Both|N/A|N/A|No|Non-Probability Sample|Head and Neck cancer patients|March 2013|March 29, 2013|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896675||139413|
NCT00892333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEI-002|Large Abdominal Hernia Repair With SurgiMend 3.0|Repair of Large Abdominal Hernia Defects By A Novel Biologic Mesh: A Prospective Multi-Center Observational Study|BRIDGE|Integra LifeSciences Corporation|No|Completed|April 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|122|||Both|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with surgical conditions such as i) open abdomen after a damage control operation        for a traumatic or non-traumatic surgical emergency, ii) removal of infected prosthetic        materials from a previous abdominal hernia repair, iii) iatrogenic injury of the bowel        during adhisiolysis for repair of a large abdominal hernia, iv) contaminated operative        field due to presence of an ostomy or the need for additional surgical procedures.|September 2013|November 13, 2014|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00892333||139740|
NCT00885404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/03445|Chloride High Level Of Resuscitation Infusion Chloride High Level Of Resuscitation Infusion Delivered Evaluation|A Prospective, Before and After Study of the Impact of Lower Chloride Intravenous Fluid Management on Patients' Acid-base Status, Renal Profile,Length of Stay and Mortality.|CHLORIDE|Austin Health|No|Active, not recruiting|February 2009|August 2010|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7000|||Both|N/A|N/A|No|||February 2010|February 24, 2010|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885404||140264|
NCT00885677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-MORE-CARE|MOnitoring REsynchronization deviCes and cARdiac patiEnts|MOnitoring REsynchronization deviCes and cARdiac patiEnts|MORE-CARE|Medtronic Bakken Research Center|Yes|Terminated|June 2009|April 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|918|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 21, 2009||No|Low enrollment rate|No||https://clinicaltrials.gov/show/NCT00885677||140243|
NCT00884559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ekbb_SH_103|Leadership Instructions Improve Cardiopulmonary Resuscitation in a High Fidelity Simulation|Brief Leadership Instructions Improve Cardiopulmonary Resuscitation in a High Fidelity Simulation: a Randomised Controlled Trial||University Hospital, Basel, Switzerland|No|Completed|November 2005|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|237|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884559||140327|
NCT00892866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0237|CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells|Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)||Gynecologic Oncology Group|Yes|Recruiting|February 2009|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|877|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with abnormal cervical cancer cells|February 2016|February 9, 2016|May 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00892866||139701|
NCT00893217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91232|BEYOND Pilot Study|Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS||Bayer|No|Completed|November 2002|June 2003|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|55 Years|No|||November 2009|November 6, 2009|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893217||139676|
NCT00893230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 7403-179|A Study of a Probiotic in Atopic Dermatitis|A Double-Blind, Randomized, Placebo-Controlled Intervention Study of the Efficacy and Safety of "NFM proBio65" in the Atopic and Allergic Volunteers||Chungbuk National University|Yes|Completed|January 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|2 Years|10 Years|No|||May 2009|May 4, 2009|May 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00893230||139675|
NCT00892892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Re-No. 3186|Sympathetic Nerve Activity in Renal Failure|Role of the Sympathetic Nerve System for the Pathogenesis and Progression of Chronic Kidney Failure|SNS in CRF|University of Erlangen-Nürnberg Medical School|No|Withdrawn|November 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||March 2015|March 16, 2015|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892892||139699|
NCT00893529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZONMW120520010-NHS2008B096|A Study of the Effect of Replacing Sugary Drinks by Low-sugar Alternatives on Body Weight and Fat Mass in Children|A Double-blind, Randomized Trial of the Efficacy of Replacing Sugary Drinks by Low-sugar Alternatives on Body Weight and Fat Mass in School Children|DRINK|VU University of Amsterdam|No|Completed|May 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|641|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893529||139652|
NCT00893542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCO-C250-PVFS-1|Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions||Roxane Laboratories|No|Completed|November 2005|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|37|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 9, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893542||139651|
NCT00894764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU_09-2007|The Study of Chest Infections in Infants Living in a Refugee Camp on the Thai-Burmese Border|A Clinical and Microbiological Study of Acute Respiratory Infections in Refugee Infants Living on the Thai-Burmese Border|ARI|University of Oxford|No|Completed|September 2007|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Maela is a densely populated camp predominantly inhabited by refugees of the Karen ethnic        group. It is located in hills adjoining the Burmese border 50 km north of Mae Sot. It is        the largest of the camps on the Thai-Burmese border, housing around one-third of the total        refugee population. Maela has a population of approximately 43,000 people, of which 20%        are females of child bearing age. Women presenting for antenatal care at SMRU's clinic        will be asked to take part in the study.|May 2012|May 4, 2012|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894764||139557|
NCT00894777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-4577|Study Evaluating Management of Patients With Moderate and Severe Psoriasis|Management of Patients With Moderate and Severe Psoriasis Under Treatment With Topical and/or Systemic Drugs||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|469|||Both|18 Years|N/A|No|Probability Sample|Patients with moderate and severe psoriasis under treatment with topical and/or systemic        drugs in usual clinical practice|November 2010|November 19, 2010|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894777||139556|
NCT00894452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070603|Variance of Oral Methadone Dosage: Description of Implicated Factors|Factors Associated With the Variance of Oral Methadone Dosage at Steady State of Maintenance Treatment: Description of Bio-markers of Phenotype and Genotype.|METHADOSE|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2008|May 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|210|Samples With DNA|serum: orosomucoid, methadone dosage, OH midazolam/midazola ratio      DNA: CYPs, MDR1, OPRM1, COMT|Both|18 Years|N/A|No|Non-Probability Sample|Defined population: participants or population are selected based on predefined criteria|January 2015|January 20, 2015|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00894452||139581|
NCT00894751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0281|Two Anesthetic Techniques in Magnetic Resonance Imaging (MRI)|A Qualitative Comparison of Two Anesthetic Techniques in Children Undergoing Magnetic Resonance Imaging||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|January 2009|||January 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|12 Months|7 Years|Accepts Healthy Volunteers|||May 2009|May 6, 2009|May 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00894751||139558|
NCT00895310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200916901|Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy|Assessing PSA Response in Low Dose Ketoconazole in Hormone Refractory Prostate Cancer Patients Who Have Failed at Least One Prior Systemic Chemotherapy Regimen||University of California, Davis|Yes|Completed|May 2009|May 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Male|18 Years|N/A|No|||May 2015|May 7, 2015|May 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895310||139515|
NCT00895037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-4420|Study Evaluating Pharmacovigilance Of Refacto AF|Refacto Af (Registered) Pharmacovigilance Study||Pfizer|No|Recruiting|July 2009|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|N/A|N/A|No|Non-Probability Sample|Patients with hemophilia A|March 2016|March 24, 2016|May 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895037||139536|
NCT00895895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-2005|Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease|A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease||Pfizer|Yes|Terminated|May 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|526|||Both|50 Years|N/A|No|||December 2012|December 21, 2012|May 7, 2009|Yes|Yes|See termination reason in detailed description.|No|December 21, 2012|https://clinicaltrials.gov/show/NCT00895895||139470|Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.
NCT00895609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNDRO|Sugammadex and Neostigmine at Shallow Neuromuscular Blockade|Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.5)|SUNDRO|Technische Universität München|Yes|Completed|March 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|64 Years|No|||March 2013|March 18, 2013|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00895609||139492|
NCT00895882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-019|Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)|A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Virus Infection||Merck Sharp & Dohme Corp.|Yes|Withdrawn|November 2010|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|65 Years|No|||October 2015|October 21, 2015|May 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895882||139471|
NCT00896701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-20206|Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2|A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project||Alliance for Clinical Trials in Oncology|No|Completed|January 2004|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|451|Samples With DNA|bone marrow blast cells peripheral blood mononuclear cells|Both|15 Years|N/A|No|Non-Probability Sample|This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who        have previously provided their consent. Diagnostic and follow-up samples from acute        myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who        have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665        will be used.|July 2015|July 6, 2015|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896701||139411|
NCT00896402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1989mdmd|Chlorhexidine Versus Betadine in Preventing Colonization of Femoral Nerve Catheters After Total Joint Arthroplasty (TJA)|Chlorhexidine vs. Betadine in Preventing Colonization of Continuous Femoral Catheters After Total Joint Arthroplasty||Northwell Health|No|Withdrawn|July 2014|June 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|May 7, 2009||No|Funding inadequate|No||https://clinicaltrials.gov/show/NCT00896402||139433|
NCT00892632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008669|Confocal Endomicroscopy for Biliary Strictures -Phase I|A Pilot Study of Confocal Endomicroscopy for Biliary Strictures - Phase I||Mayo Clinic|Yes|Terminated|April 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|May 1, 2009||No|Difficult (slow) Enrollment|No||https://clinicaltrials.gov/show/NCT00892632||139718|
NCT00885690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.1 - 01-25-09|Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)|A Multicentre Double-blinded Randomized Head-to-head Study|SEROLA|University of Aarhus|Yes|Terminated|April 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|April 20, 2009||No|Due to recruitment problems|No||https://clinicaltrials.gov/show/NCT00885690||140242|
NCT00885703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5225 (HiFLAC)|High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals|A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|February 2010|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|168|||Both|16 Years|N/A|No|||January 2016|January 6, 2016|April 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00885703||140241|
NCT00886002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002443|Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers.|Explorative, Double-blind Study on Dose Effectiveness of DUROGESIC D-Trans 12 Mcg/h and 25mcg/h Compared to Transtec and Placebo in Acute Pain Models in Healthy Volunteers.||Janssen-Cilag A.G., Switzerland||Completed|November 2004|January 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|20|||Both|18 Years|40 Years|No|||June 2010|June 18, 2010|April 20, 2009||||No||https://clinicaltrials.gov/show/NCT00886002||140218|
NCT00886210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abdominal drainage|Clinical Impact of Routine Abdominal Drainage After Laparoscopic Cholecystectomy|Clinical Impact of Routine Abdominal Drainage After Laparoscopic Cholecystectomy. A Prospective Randomized Study||Mansoura University|Yes|Completed|October 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|100|||Both|21 Years|80 Years|No|||April 2009|April 21, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886210||140202|
NCT00892268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000629150|Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain|Acupuncture for the Treatment of Aromatase Inhibitor Associated Joint Pain in Post-Menopausal Breast Cancer Patients||University of Arizona|Yes|Terminated|January 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|68|||Female|N/A|N/A|No|||May 2009|April 23, 2010|May 1, 2009|Yes|Yes|Poor accural|No||https://clinicaltrials.gov/show/NCT00892268||139744|
NCT00892281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10120|ORCA - Oracea® for Rosacea: A Community-based Assessment|A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea||Galderma Laboratories, L.P.|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1421|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|April 30, 2009||No||No|October 26, 2010|https://clinicaltrials.gov/show/NCT00892281||139743|
NCT00892567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12911|Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer|Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine|Breast 37|University of Virginia|Yes|Completed|May 2009|February 2012|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892567||139723|
NCT00892580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22003A|Biomarker and DNA Collection in Subjects Participating in Protocol 22003|Biomarker Testing and DNA Collection in Subjects Participating in an Open-Label, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Autism Spectrum Disorders||Seaside Therapeutics, Inc.|No|Completed|May 2009|||June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples With DNA|DNA from blood, plasma|Both|6 Years|17 Years|No|Non-Probability Sample|Autism Spectrum Disorder subjects|July 2013|July 30, 2013|May 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892580||139722|
NCT00892879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS IRB # 09-14A|A Trial of Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy|A Randomized Trial of Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy||Providence Health & Services|No|Completed|February 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||May 2011|May 17, 2011|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892879||139700|
NCT00893243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSS-01-08|Efficacy Comparative Study Between Tears Again®, Opticol® and Optive®|Efficacy Comparative Study Between Tears Again®, o Opticol® e o Optive® in Clinical and Symptomatology Treatment of Dry Eye Syndrome in Contact Lens Wearers and/or Computers Users||Hospital de Sao Sebastiao|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Administrative staff of the hospital with more than 4 hours/day computer use and contact        lens wearers|May 2009|May 4, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893243||139674|
NCT00893815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-016|Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients|Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients||Uniformed Services University of the Health Sciences|Yes|Active, not recruiting|April 2009|December 2016|Anticipated|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|250|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of 50 HIV-negative patients and at least 200        HIV-positive patients who are 18-50 years of age and current participants of "A        Retrospective and Prospective Observational Study of the Natural History of HIV Infection        in Active Duty U.S. Military Personnel and Department of Defense Beneficiaries"(RV168).|May 2015|May 7, 2015|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893815||139630|
NCT00894413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0813, NA_00012749|A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract|A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|January 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|May 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00894413||139584|
NCT00894478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013137|Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using Diffusion Tensor Imaging|Improving Lesion Detection in Children With MRI-negative Partial Epilepsy Using Diffusion Tensor Imaging||The Hospital for Sick Children|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|64|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be identified from the epilepsy clinic and seizure rounds and who have had        previous MRI in an outside institution or prior MRI at least two years ago at the Hospital        for Sick Children.        Control children will be recruited through hospital publications and from families        participating in the study (healthy siblings)|September 2013|September 9, 2013|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894478||139579|
NCT00894491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-4872|Complementary and Alternative Medical Trends: A Patient Survey in a University Based Clinic|Complementary and Alternative Medical Therapy Trends: A Patient Survey in a University Based Clinic||University of California, Irvine|Yes|Recruiting|January 2006|December 2010|Anticipated|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|33|||Both|41 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|14 male, 19 female white non-Hispanic, college educated over the age of 41|October 2010|October 14, 2010|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894491||139578|
NCT00895063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOTOXEX|Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia|Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia||New York University School of Medicine|Yes|Terminated|December 2007|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 2, 2016|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895063||139534|
NCT00895076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2019|Study to Compare the Pharmacokinetics of a Dexamethasone Iontophoretic Patch to a Dexamethasone Injection|A Randomized, Open-Label, Single Dose, Two-Way Crossover Study to Evaluate the Pharmacokinetics and Safety of a Dexamethasone Iontophoretic Transdermal Patch Compared to Dexamethasone Injection in Healthy Adult Volunteers||Travanti Pharma Inc.||Active, not recruiting|May 2009|May 2009|Anticipated|May 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 6, 2009|May 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895076||139533|
NCT00895050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4576|Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients|Impact of the Use of a Computer-based Tools on the Clinical Management and Evolution of Patients With Rheumatoid Arthritis.||Pfizer|No|Completed|March 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|321|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with RA treated in rheumatology offices|July 2011|July 13, 2011|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895050||139535|
NCT00896194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01NR010949-PRO08050004|Self-Efficacy in Weight Loss Treatment|Self-Efficacy in Weight Loss Treatment|SELF|University of Pittsburgh|No|Completed|May 2009|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 2, 2015|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00896194||139449|
NCT00896181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0025-|Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)|A Phase 2 Study of Sequential and Concurrent Chemoradiation for Patients With Advanced Nasopharyngeal Carcinoma (NPC)||Stanford University||Recruiting|January 2009|||January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|120 Years|No|||October 2015|October 15, 2015|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896181||139450|
NCT00896415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inter-scanner study|Interscanner Variation in Musculoskeletal Computed Tomography (CT) Measures|Inter-scanner Comparison of Muscle Attenuation Measures|Interscanner|University of California, San Francisco||Completed|May 2009|November 2009|Actual|||N/A|Observational|Observational Model: Ecologic or Community||1|Anticipated|20|||Female|60 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|In this project we will study women 60-70 years old because they have the highest risk of        bone fractures resulting from falls.|May 2009|June 28, 2010|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896415||139432|
NCT00892359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1 - Leitner|Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)|The Pharmacokinetics of Anidulafungin During Continuous Venovenous Hemofiltration||Medical University of Vienna|No|Recruiting|April 2009|||April 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|70 Years|No|||April 2009|May 1, 2009|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00892359||139738|
NCT00892346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHOPES-myeloma09|Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma|Phase III Study of Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|May 2009|December 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|No|||November 2014|November 26, 2014|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892346||139739|
NCT00892996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 9091/2552(EC2)|Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section|Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section: a Randomized Comparison of Metoclopramide or Ondansetron Alone or in the Combination With Dexamethasone.||Mahidol University|Yes|Active, not recruiting|May 2009|April 2011|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 3, 2009|May 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00892996||139691|
NCT00886704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|477-08|Omega-3 Fatty Acids, the Omega-3 Index, and Atherosclerosis|Influence of Dietary Omega-3 Fatty Acids in a Convenience Drink (Smartfish) on the Omega-3 Index in Patients With Atherosclerotic Disease||Ludwig-Maximilians - University of Munich|No|Completed|April 2009|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|30 Years|75 Years|No|||July 2009|September 29, 2011|April 21, 2009||No||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00886704||140164|Single center study, too small to detect rare side effects, 8 week intervention period relatively short.
NCT00887003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-392|Epidural Study of Patients With Chronic Lower Back Pain|Effects of Volume and Dose of Local Anaesthetic Solution in Epidural Steroidal Injections for Patients With Chronic Lower Back Pain||McMaster University|No|Completed|May 2005|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|252|||Both|18 Years|75 Years|No|||July 2011|February 7, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887003||140141|
NCT00892918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVZ-001|Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision|A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity.||Meir Medical Center|No|Not yet recruiting|June 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2009|May 4, 2009|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892918||139697|
NCT00892931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-6827-019|Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme|Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme||Myrexis Inc.|No|Completed|April 2009|September 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||October 2011|October 13, 2011|May 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892931||139696|
NCT00893256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFRPA/006/2004|Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia|Prospective Double-Blind Randomized Comparison Study of Improvement in Negative Symptoms With Risperidone vs Risperidone +Citalopram Combination Therapy in Schizophrenia--a Clinical Study|RIS-CIT-SCH|National Institute of Mental Health and Neuro Sciences, India|Yes|Completed|December 2004|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|17 Years|50 Years|No|||May 2009|May 4, 2009|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893256||139673|
NCT00893555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VORI911|Pharmacologic Optimization of Voriconazole|Pharmacologic Optimization of Voriconazole - a Prospective Clustered Group-randomized Cross-over Trial of Therapeutic Drug Monitoring|VORI911|University Medical Center Groningen|Yes|Recruiting|April 2009|January 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893555||139650|
NCT00893828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rev. B, 29-Sep-08|Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (PAPIRUS III)|Monitoring Pulmonary Artery Pressure by Implanted Device Responding to Ultrasonic Signal|PAPIRUS III|Boston Scientific Corporation|Yes|Active, not recruiting|March 2009|||September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|None Retained|Whole Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients previously implanted with a RemonCHF device|March 2014|March 3, 2014|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893828||139629|
NCT00894465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO # 06-0665|Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)|A Randomized, Double-Blind, Placebo-Controlled Study Examining the Efficacy of Oral Midazolam in Reducing Anxiety in Children Undergoing Voiding Cystourethrogram||Washington University School of Medicine|No|Terminated|August 2006|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|44|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||March 2011|March 9, 2011|May 4, 2009||No|Most pts requested to be treated with versed. It was difficult to randomize pts.|No||https://clinicaltrials.gov/show/NCT00894465||139580|
NCT00894816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELEFANT|Probiotics in Prevention of Allergies, Obesity and Caries|Effects of Feeding Lactobacillus F19 to Infants During Weaning on Allergies, Immune Programming, Gut Microbiota, Overweight and Oral Health|ELEFANT|Umeå University|No|Active, not recruiting|August 2000|December 2016|Anticipated|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|171|||Both|4 Months|4 Months|Accepts Healthy Volunteers|||February 2016|February 12, 2016|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894816||139553|
NCT00891566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-04-051|Duration of Immobilization After Rotator Cuff Repair: Its Clinical Impact|Prolonged Versus Conventional Immobilization After Arthroscopic Repair for Medium to Large Size Rotator Cuff Tear. A Prospective Randomized Controlled Trial||Samsung Medical Center|No|Completed|April 2008|April 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|medium to large size rotator cuff tears|May 2011|May 23, 2011|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00891566||139796|
NCT00895349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2009-PETLACE|Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)|The Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer|PET LACE|Ontario Clinical Oncology Group (OCOG)|Yes|Terminated|April 2010|October 2017|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|171|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|May 6, 2009||No|On 30-Jun-2014 as per recommendations from Steering Committee; due to low recruitment rate.|No||https://clinicaltrials.gov/show/NCT00895349||139512|
NCT00895362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0553|Erlotinib in Combination With Cetuximab|A Phase I Dose-Escalation Study of Erlotinib in Combination With Cetuximab in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.||M.D. Anderson Cancer Center|No|Completed|April 2009|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||July 2015|July 10, 2015|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895362||139511|
NCT00895375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 08-0087|Prevalence of Sleep Disturbances in Psoriasis|Prevalence of Sleep Disturbances in Psoriasis||Wake Forest School of Medicine|No|Active, not recruiting|October 2009|March 2016|Anticipated|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from the Wake Forest University Physicians outpatient clinics|December 2015|December 9, 2015|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895375||139510|
NCT00895388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P REK NORD 105/2007|Effects of Structured Rehabilitation Program on Quality of Life in Rectal Cancer Patients- a Randomized Controlled Trial|Effects of Structured Rehabilitation Program on Quality of Life After Surgical Treatment for Rectal Cancer- a Randomized Controlled Clinical Trial||University Hospital of North Norway|Yes|Recruiting|May 2009|November 2013|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 2, 2011|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895388||139509|
NCT00895635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|631|Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study)|Exercise Training to Reduce Claudication: Arm Ergometry Versus Treadmill Walking|EXERT|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2009|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|90 Years|No|||September 2014|September 5, 2014|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895635||139490|
NCT00895648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0815-C|Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma|Phase II Study of Neo-adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Malignant Pleural Mesothelioma||University Health Network, Toronto|No|Terminated|January 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|May 6, 2009||No|low accrual due to competing study for same group of patients|No||https://clinicaltrials.gov/show/NCT00895648||139489|
NCT00895622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0539|Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma|Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas||Radiation Therapy Oncology Group|Yes|Active, not recruiting|June 2009|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|244|||Both|18 Years|120 Years|No|||March 2016|March 3, 2016|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895622||139491|
NCT00892372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bwhba1c|Relationship Between Body Weight and Glycohemoglobin|Relationship Between Changes in Body Weight and Glycohemoglobin Levels in Patients With Type 2 Diabetes Treated With Diet or Pioglitazone.||Saitama Medical University|Yes|Completed|April 2009|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|100|||Both|32 Years|76 Years|No|Probability Sample|primary care clinic|May 2009|May 1, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892372||139737|
NCT00892684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA-013|Does Omega-3 Fatty Acid Supplementation in Pregnancy and During Lactation Protect the Child From Allergic Disease?|Omega-3 Fatty Acid Supplementation in Pregnancy and During Lactation: a Randomized, Double-Blind, Placebo Controlled Trial.||Linkoeping University|No|Active, not recruiting|March 2003|September 2011|Anticipated|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|146|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2009|May 1, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892684||139715|
NCT00896428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2008/09|Effects of Gallopamil in Severe Asthma|Effects of Gallopamil on Bronchial Smooth Muscle Remodelling in Severe Asthma: a Double Blind Study.|REMODEL'ASTHME|University Hospital, Bordeaux|Yes|Completed|December 2009|November 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00896428||139431|
NCT00896714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/44|Factors Influencing Anesthetic Drug Requirement|Impact of Environmental and Demographic Factors on Pre-operative Doses of Anesthetic Agents (Prospective Multicenter Study)|PosoAnes|Hopital Foch|No|Recruiting|May 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4500|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896714||139410|
NCT00894192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH-2005-0516|Comprehensive Evaluation of Visual Function|Comprehensive Evaluation of Visual Function||The Chicago Lighthouse for People Who Are Blind or Visually Impaired|No|Recruiting|February 2009|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2009|May 5, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894192||139601|
NCT00894205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2078|Neuropsychological Effects of Strengthening Exercise for Older Adults|Neuropsychological and Physiological Effects of Low-Impact Exercise for Older Adults||Union College, New York|No|Completed|June 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 9, 2015|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894205||139600|
NCT00892658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0761-C|Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)|A Phase I Study of Sorafenib and Radiation Therapy in Patients With Hepatocellular Carcinoma||University Health Network, Toronto|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892658||139717|
NCT00892671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E080829003|Airway Management and Vascular Access Simulation|Airway Management and Vascular Access Simulation||University of Alabama at Birmingham|No|Completed|October 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|N/A||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|third and fourth year medical studens enrolling in the UAB Department of Anesthesiology        rotation|August 2010|August 27, 2010|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00892671||139716|
NCT00895414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008NTLS060|Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer|The Effect of Enalapril on Doxorubicin Exposure in Adjuvant Breast Cancer Treatment||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|April 2009|December 2015|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|17|||Female|18 Years|N/A|No|||April 2015|April 23, 2015|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895414||139507|
NCT00886483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0019-A|Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)|Pilot Explorations of Neurofeedback Issues in ADHD||Ohio State University|No|Completed|August 2008|June 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|6 Years|12 Years|No|||September 2013|September 26, 2013|April 22, 2009||No||No|July 2, 2012|https://clinicaltrials.gov/show/NCT00886483||140181|Small sample.Self-selection families willing to stop/delay meds.Failure to select for high TBR.Small/medium pre-post ES suggests particular Tx technology may not have been the most effective.Sham NF may not have been inert.
NCT00886496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000523819|Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia|A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia||Enzon Pharmaceuticals, Inc.||Withdrawn|November 2006|April 2011|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Supportive Care|||Actual|0|||Both|2 Years|17 Years|No|||August 2007|June 19, 2012|April 21, 2009|No|Yes|No participants enrolled. IND withdrawn.|||https://clinicaltrials.gov/show/NCT00886496||140180|
NCT00895141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM3355|Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)|Changes in LDL and HDL With Increased Intake of Saturated Fat From Dairy Foods in Individuals With Atherogenic Dyslipidemia and LDL Subclass Pattern B||Children's Hospital & Research Center Oakland|No|Completed|April 2009|April 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|53|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895141||139528|
NCT00892944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2080C00009|An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516|An Open Label Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2516 After Oral Administration to Healthy Subjects||AstraZeneca|No|Completed|April 2009|October 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 27, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00892944||139695|
NCT00893308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481133- HMO-CTIL|Metabolic Viral Host Properties|||Hadassah Medical Organization||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|||||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Both male and female volunteers were recruited. with and without HCV infection, with and        without Gaucher disease.|May 2009|May 10, 2009|April 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00893308||139669|
NCT00893269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00017909|The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep|The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep||Johns Hopkins University|No|Completed|October 2008|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00893269||139672|
NCT00893282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTP-001|Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy|A Randomized, Controlled, Prospective, Single Blind Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy.||Pluromed, Inc.|No|Completed|February 2008|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|68|||Both|18 Years|N/A|No|||May 2009|May 4, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00893282||139671|
NCT00893568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/01|Post Traumatic Stress Disorder and Neural Mechanisms Involved in Its Treatment|Post Traumatic Stress Disorder and Neural Mechanisms Involved in Its Treatment||Assistance Publique Hopitaux De Marseille|No|Completed|April 2009|||May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|62|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893568||139649|
NCT00895089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS98-CT2-20|Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess|Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study||Kaohsiung Veterans General Hospital.|No|Completed|May 2009|December 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|N/A|No|||December 2015|December 1, 2015|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895089||139532|
NCT00891579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG0806|Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations|Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations||Chinese Society of Lung Cancer||Completed|February 2009|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|80 Years|No|||December 2012|December 7, 2012|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891579||139795|
NCT00891592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02707|Umbilical Cord Blood Transplant for Hematological Malignancies|A Phase 1 Dose Escalation Study of Infusion of ex Vivo cd3/cd28 Costimulated Umbilical Cord Blood-derived t Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies|UCB|University of Pennsylvania|No|Active, not recruiting|January 2009|January 2013|Anticipated|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|50 Years|No|||January 2013|January 31, 2013|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891592||139794|
NCT00895102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-032|Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers|An Open-Label Randomized, Crossover Study to Evaluate the Bioavailability of ABT-333 Tablets Versus Capsules, and A Double-blind, Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending Doses of ABT-333 Tablets Versus Placebo in Healthy Volunteers||Abbott|No|Completed|April 2009|||June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 12, 2010|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895102||139531|
NCT00895401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-001|DaVita Assessment of Nutritional Supplement Effects (DANSE)|DaVita Assessment of Nutritional Supplement Effects|DANSE|Davita Clinical Research|Yes|Completed|April 2009|||January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||February 2011|February 5, 2011|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895401||139508|
NCT00895921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH082805|Examining the Effects of Antipsychotic Medications on Insulin Sensitivity|Acute Impact of Antipsychotics on Insulin Sensitivity: A Novel Human Model||Veterans Medical Research Foundation|No|Completed|November 2008|June 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895921||139468|
NCT00895934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01147|Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML|A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)|No|Completed|May 2009|September 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|50 Years|N/A|No|||July 2012|January 22, 2015|May 7, 2009|Yes|Yes||No|August 6, 2014|https://clinicaltrials.gov/show/NCT00895934||139467|
NCT00895908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH085889|Reducing Attention Deficit Hyperactivity Disorder in Kindergarten and Pre-Kindergarten Children|Reducing ADHD by Promoting Social Collaboration and Self-Regulation Skills||National Institute of Mental Health (NIMH)|No|Not yet recruiting|January 2010|April 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|178|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||June 2009|June 25, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895908||139469|
NCT00892697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810010040|Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)|#0810010040: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus Infection: A Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C||Weill Medical College of Cornell University|Yes|Completed|May 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||December 2014|March 9, 2015|April 30, 2009|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00892697||139714|
NCT00893009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/09|The Effect on Small Airways of Addition of Theophylline as Inducer of Histone Deacilase Activity for Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Treated With Inhaled Steroids and Long Acting Beta Agonists||COPD|Assaf-Harofeh Medical Center|No|Not yet recruiting|July 2009|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|45 Years|75 Years|No|||April 2009|April 4, 2011|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893009||139690|
NCT00893035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2005 DA|Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients|Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.||Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|June 2006|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|862|||Both|18 Years|80 Years|No|Non-Probability Sample|patients treated in a cancer center|March 2015|March 2, 2015|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893035||139689|
NCT00893646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09025|Effects of Weight Reduction on Sleep and Alertness in Long-distance Truck and Bus Drivers|Effects of Weight Reduction and Lifestyle Changes on Sleep, Alertness and Cardiometabolic Risk Factors in Overweight Professional Long-distance Drivers|SF-Truck|UKK Institute|No|Completed|May 2009|January 2015|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Male|30 Years|62 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893646||139643|
NCT00894504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 126|Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer|A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|February 2010|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Female|18 Years|N/A|No|||April 2015|April 28, 2015|May 5, 2009|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00894504||139577|
NCT00894517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-091|A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia|||Allergan|No|Completed|August 2009|August 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Male|45 Years|70 Years|No|||July 2013|July 30, 2013|May 5, 2009|Yes|Yes||No|July 30, 2013|https://clinicaltrials.gov/show/NCT00894517||139576|
NCT00894829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV0109_EUR|Efficacy and Safety of Sodium Heparin (Eurofarma)|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|June 2009|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894829||139552|
NCT00894842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCR-NS-003|Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia|A 10-week, Randomized, Double-Blind, Placebo-Controlled Trial of a Neurocognition Enhancing Agent(Pregnenolone) in Patients With Schizophrenia.||National Research Foundation, Singapore|Yes|Completed|June 2009|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|21 Years|65 Years|No|||October 2011|October 4, 2011|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894842||139551|
NCT00894556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-087|A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders||Merck Sharp & Dohme Corp.|No|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|109|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|May 5, 2009|Yes|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00894556||139573|
NCT00894894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-0470-01|Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies|Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies||Astex Pharmaceuticals|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|70 Years|No|||December 2011|December 1, 2011|May 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00894894||139547|
NCT00895154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|653|A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study|A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study||Washington University School of Medicine|No|Completed|September 2003|December 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|8 Years|18 Years|No|||December 2014|December 10, 2014|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895154||139527|
NCT00895167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT - 2008-004900-30|The Effects of Oral Curcumin on Heme Oxygenase-1 (HO-1) in Healthy Male Subjects|The Effects of Oral Curcumin on Heme Oxygenase-1 (HO-1) in Healthy Male Subjects|CUMAHS|Medical University of Vienna|No|Completed|January 2009|August 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895167||139526|
NCT00893581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DelBello MM NeuroImaging Study|Multimodal Neuroimaging of Treatment Effects in Adolescent Mania|Multimodal Neuroimaging of Treatment Effects in Adolescent Mania||University of Cincinnati|Yes|Recruiting|March 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Anticipated|180|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893581||139648|
NCT00893594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113010|Efficacy of Sumatriptan With Naprosyn in Migraine With Aura|A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura||Dent Neurologic Institute|No|Recruiting|October 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893594||139647|
NCT00893841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00032|Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride|A Randomized, Double-Blind, Placebo Controlled Exploratory Study of Augmentation of Seroquel XR With Pramipexole Dihydrochloride for Bipolar Depression||Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.|No|Completed|February 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|65 Years|No|||February 2013|February 1, 2013|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893841||139628|
NCT00894153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53-001|p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage|Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage||Shenzhen SiBiono GeneTech Co.,Ltd|No|Recruiting|May 2009|June 2013|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1200|||Both|18 Years|65 Years|No|||February 2010|April 6, 2012|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894153||139604|
NCT00894179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGA-9B04|Safety and Accuracy Study of Regadenoson Atropine Combination for Stress Echocardiography in Identification of Coronary Artery Disease|Feasibility, Safety and Accuracy of Regadenoson-Atropine ( REGAT) Stress Echocardiography for the Diagnosis of Coronary Artery Disease: An Angiographic Correlative Study|REGAT|Henry Ford Health System|No|Recruiting|May 2009|December 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|85 Years|No|Probability Sample|This will be a prospective study evaluating stable outpatients with no prior diagnosis of        coronary disease who may or may not have had a prior functional stress imaging test and        are going for a clinically indicated cardiac catheterization as deemed by their physician        due to suspected coronary artery disease either based on symptoms or based on results for        prior functional testing|May 2010|June 21, 2011|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894179||139602|
NCT00891605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-589|Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors|A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Paclitaxel in the Treatment of Subjects With Solid Tumors||Abbott||Completed|July 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2012|August 7, 2012|April 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00891605||139793|
NCT00887874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3722|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan|DiabCare Asia 2008. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia.|DiabCare Asia|Novo Nordisk A/S|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2370|Samples With DNA|Capillary or venous blood will be drawn for analysing HbA1c.|Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to the        inclusion and exclusion criteria.|July 2012|July 17, 2012|April 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00887874||140076|
NCT00895661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-054|High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas|Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas||Massachusetts General Hospital|Yes|Active, not recruiting|July 2009|December 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895661||139488|
NCT00896207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01106|Studying Different Formulations of SR13668 in Healthy Volunteers|Single-Dose Phase 0 Exploratory Pharmacokinetic Clinical Trial Comparing Five Oral Formulations of SR13668, an Orally Active AKT Pathway Inhibitor||National Cancer Institute (NCI)||Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|20|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2014|May 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00896207||139448|
NCT00896441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04202009-2339|Functional MRI Before and After Treatment for Depression|Functional MRI Before and After Treatment for Depression||Stanford University||Recruiting|February 2009|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 25, 2011|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00896441||139430|
NCT00896454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070315|Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium|A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates||Amgen|No|Completed|November 2009|August 2013|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|May 7, 2009|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00896454||139429|
NCT00888160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB06-00089|Timing of Orthopaedic Surgery in the Multiply-injured Patient: Development of a Protocol for Early Appropriate Care|Timing of Orthopaedic Surgery in the Multiply-injured Patient: Development of a Protocol for Early Appropriate Care||MetroHealth Medical Center|No|Active, not recruiting|September 2010|||September 2030|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Both|16 Years|N/A|No|Probability Sample|All patients at least 16 years of age treated at a major urban level 1 trauma center        between the years 2000 and 2006, who had any of the following musculoskeletal injuries:        unstable pelvic ring fracture, unstable acetabulum fracture, or femur fracture.|March 2016|March 15, 2016|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888160||140055|
NCT00893347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02595|An Intervention Program to Reduce to the Risk of Persistent Symptoms After Concussion|Prevention of Persistent Post-concussion Syndrome With Cognitive-behavioural Therapy in At-risk Patients||University of British Columbia|No|Completed|June 2009|October 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|65 Years|No|||November 2012|November 22, 2012|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893347||139666|
NCT00893906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIV-SEN-01|Inactivated Influenza Vaccine Effectiveness in Tropical Africa|Assessment of the Effectiveness of Seasonal Trivalent Influenza Vaccine Among Children in Senegal||PATH|No|Completed|May 2009|April 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|10000|||Both|6 Months|10 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|May 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00893906||139623|
NCT00889044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08 -5397-SM-CTIL|Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI|Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI||Sheba Medical Center|No|Recruiting|April 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2009|April 26, 2009|April 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00889044||139987|
NCT00889057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGosteo-BAY|Sorafenib in Relapsed High Grade Osteosarcoma|Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.||Italian Sarcoma Group||Completed|January 2008|June 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|15 Years|75 Years|No|||March 2013|March 26, 2013|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889057||139986|
NCT00889356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZD 002-08|Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis|Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis)||Zodiac Produtos Farmaceuticos S.A.|Yes|Not yet recruiting|September 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|50 Years|No|||April 2009|April 27, 2009|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00889356||139963|
NCT00895115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120802|Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer|A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Prostate||Rutgers, The State University of New Jersey|No|Completed|April 2009|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|65|||Male|18 Years|N/A|No|||June 2012|June 12, 2012|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00895115||139530|
NCT00894569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2008-003174-18|Paclitaxel/Carboplatin With or Without Cetuximab in CUP|Open-Labeled, Randomized Multi-Center Phase II Study Evaluating the Efficacy and Safety of Paclitaxel/ Carboplatin With and Without Cetuximab as First-Line Treatment of Adeno- and Undifferentiated Carcinoma of Unknown Primary (CUP)|PACET-CUP|Heidelberg University|Yes|Not yet recruiting|July 2009|August 2011|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894569||139572|
NCT00894920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3114301|Biotin Status in Pregnancy|Biotin Status in Pregnancy||University of Arkansas|No|Completed|August 2009|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|124|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894920||139545|
NCT00894907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG: HU 1707/2-1|Early Goal-directed Volume Resuscitation in Severe Acute Pancreatitis|EAGLE: Early Goal-directed Volume Resuscitation in Severe Acute Pancreatitis: A Randomised Multi-centre Study|EAGLE|Technische Universität München|Yes|Recruiting|August 2009|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894907||139546|
NCT00895466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP223-NL-0701|Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients|A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.||Pepscan Therapeutics|Yes|Recruiting|October 2008|||December 2009||Phase 1/Phase 2|Interventional|N/A|||Anticipated|12|||Male|N/A|N/A|No|||May 2009|May 7, 2009|May 6, 2009||||No||https://clinicaltrials.gov/show/NCT00895466||139503|
NCT00893854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8727|The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema|The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema||hahid Beheshti University of Medical Sciences|No|Recruiting||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|N/A|N/A|No|||May 2009|May 4, 2009|May 4, 2009||||No||https://clinicaltrials.gov/show/NCT00893854||139627|
NCT00894166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013846|Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype|Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype|ConNic3|Duke University|Yes|Completed|May 2009|October 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|606|||Both|18 Years|65 Years|No|||September 2013|September 19, 2013|May 4, 2009|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT00894166||139603|The group sizes for the post quit date randomization groups was relatively small. Second, the study used a tailored dose of pre-cessation nicotine patch therapy that is not in accordance with current product labeling in the US.
NCT00894790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191352|Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident|A Phase IV Open Label Randomized Multicenter Comparative Study Of Celecoxib Efficacy And Safety Versus Standard Doses Of Oral Diclofenac In Acute Pain Due To Cervical Sprain Related To Motor Vehicle Accident||Pfizer|Yes|Terminated|November 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||February 2011|February 25, 2011|March 27, 2009||No|See termination reason in detailed description.|No|January 28, 2011|https://clinicaltrials.gov/show/NCT00894790||139555|
NCT00894803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50NS04483-06|Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke|The "Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Enhanced Regimen" (CLEAR-ER Stroke Trial)|CLEAR-ER|University of Cincinnati|Yes|Completed|July 2009|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|85 Years|No|||March 2014|March 26, 2014|May 6, 2009|Yes|Yes||No|November 27, 2013|https://clinicaltrials.gov/show/NCT00894803||139554|
NCT00891319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD059814|Electrical Stimulation for Recovery of Hand Function in Chronic Stroke Survivors|Contralaterally Controlled FES for Chronic Arm/Hand Hemiplegia: Single-Site RCT||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|January 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|September 25, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891319||139814|
NCT00888199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Rifkin|Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis|Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis||Tensegrity Prosthetics|Yes|Not yet recruiting|January 2010|June 2010|Anticipated|June 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2009|April 24, 2009|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888199||140052|
NCT00888524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|857 IAC 0630041300|Plus Deep Water Running on Low Back Pain|Evidence-Based Physiotherapy With and Without Deep Water Running on Non-Specific Low Back Pain. A Randomized Controlled Trial|+DWR|University of Malaga|Yes|Completed|January 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||April 2009|April 24, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00888524||140027|
NCT00891878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0747|Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction|A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction||Alliance for Clinical Trials in Oncology|No|Completed|August 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891878||139772|
NCT00892125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011440|A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder|Evaluation of the Effect of Carbamazepine on the Steady-state Pharmacokinetics of Paliperidone Extended Release in Clinically Stable Subjects With Schizophrenia or Bipolar I Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2006|March 2007|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|64|||Both|18 Years|55 Years|No|||April 2010|May 17, 2011|November 20, 2008||||||https://clinicaltrials.gov/show/NCT00892125||139755|
NCT00896727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000467801|Protein Expression in Predicting Response to Treatment Using Tumor Tissue Samples From Women With Stage I, Stage II, or Stage IIIA Breast Cancer Treated on Clinical Trial SWOG-9313|Prediction of Therapeutic Response Using AQUA™ Quantitative Protein Expression Analysis of ER, PgR, and HER2 of Breast Cancer Tissue Microarrays From SWOG Protocol 9313||National Cancer Institute (NCI)||Recruiting|July 2006|||||N/A|Observational|N/A|||Anticipated|2100|||Female|18 Years|N/A|No|||July 2007|October 14, 2010|May 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00896727||139409|
NCT00888485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRK97|Randomized Trial of Behavioral Intervention Versus Standard Treatment|Secondary Prevention in Uppsala Primary Health Care After Myocardial Infarction, Coronary Artery CABG and PCI. Secondary Prevention After CHD (SUPRIM).|SUPRIM|Uppsala University|No|Completed|May 1996|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|362|||Both|N/A|75 Years|No|||April 2009|April 24, 2009|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888485||140030|
NCT00888797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6994-OZ-CTIL|β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence|Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial.||Sheba Medical Center|No|Recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|75 Years|No|||July 2011|July 10, 2011|April 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00888797||140006|
NCT00888810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005706-44|Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer|A Phase II Study Evaluating the Association of Topotecan and Lapatinib in Early Recurrent (Less Than 12 Months)Ovarian or Peritoneal Cancer Patients After First Line of Platinum-Based Chemotherapy|TOPO-LAPA|Centre Francois Baclesse|Yes|Terminated|March 2008|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||April 2009|April 27, 2009|April 27, 2009||No|lack of efficacy (intermediate analysis)|No||https://clinicaltrials.gov/show/NCT00888810||140005|
NCT00888459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-008574|A Pilot Study Evaluating Nicotine Lozenges and Self Help|A Pilot Study to Assess the Effectiveness of the Nicotine Lozenge for Smokeless Tobacco Users||Mayo Clinic|No|Completed|April 2008|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 14, 2011|April 24, 2009|Yes|Yes||No|October 4, 2010|https://clinicaltrials.gov/show/NCT00888459||140032|
NCT00888771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0405/121/1|Discard:Characterisation of Colonic Polyps in Vivo|Characterisation of Small Colonic Polyps in Vivo|DISCARD|Imperial College London|No|Completed|August 2008|June 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study group therefore would comprise those presenting for 3 yearly follow up or sooner        i.e. those with a resected colorectal cancer or those with ≥ three adenomas or one        advanced ≥10mm adenoma or those with a positive faecal occult blood test|July 2010|February 11, 2016|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888771||140008|
NCT00888784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM03|Secondary Prophylaxis Gastric Variceal Bleed|Endoscopic Cyanoacrylate Injection Versus Beta-Blockers for Secondary Prophylaxis of Gastric Variceal Bleed||Govind Ballabh Pant Hospital|No|Completed|August 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|64|||Both|10 Years|70 Years|No|||April 2009|April 27, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888784||140007|
NCT00889629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-080|Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients|Pilot Study: Effects of Hectorol (Doxercalciferol) Vitamin D Replacement on Proteinuria, PTH Level and Bone Turnover in Stable Kidney Transplant Recipients: a Single-Blind, Placebo-Controlled Study in Patients Receiving 25-OH Vitamin D3||State University of New York - Downstate Medical Center|No|Recruiting|November 2008|January 2010|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||April 2009|April 28, 2009|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889629||139942|
NCT00889616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909134|Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali|Phase 1 Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and in Bancoumana, Mali||National Institutes of Health Clinical Center (CC)||Completed|April 2009|July 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|50 Years|No|||July 2012|October 23, 2014|April 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00889616||139943|
NCT00885482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009−011273−32|Atazanavir and Lamivudine for Treatment Simplification|Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Atazanavir/Ritonavir + Lamivudine in Patients Stably Treated With Two NRTIs + Atazanavir/Ritonavir With Optimal Virologic Response.|AtLaS|Catholic University of the Sacred Heart|No|Completed|May 2009|May 2011|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|April 20, 2009||No||No|February 4, 2015|https://clinicaltrials.gov/show/NCT00885482||140258|
NCT00895180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTC-0901 CDR0000641230|Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme|An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2010|||December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00895180||139525|
NCT00886054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901010R|The Prediction of Intracranial Pressure and Clinical Outcome by Transcranial Doppler in Neurocritical Patients|The Prediction of Intracranial Pressure and Clinical Outcome by Transcranial Doppler in Neurocritical Patients||National Taiwan University Hospital|No|Active, not recruiting|December 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|16 Years|80 Years|No|Probability Sample|Patients admitted via emergency room for neurosurgical emergency, such as trauma, stroke,        etc.|December 2009|December 20, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886054||140214|
NCT00892385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1Y05|Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors|A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors||Case Comprehensive Cancer Center|Yes|Active, not recruiting|August 2007|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892385||139736|
NCT00893919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYCO-C250-PVFD-1|Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions||Roxane Laboratories|No|Completed|November 2005|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|37|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 9, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893919||139622|
NCT00893048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8876|The Use of Oral Steroids in the Treatment of Cellulitis|Utility of Prednisone in the Treatment of Cellulitis||Penn State University|No|Not yet recruiting|September 2009|July 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|70 Years|No|||May 2009|May 4, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00893048||139688|
NCT00893360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 13930|CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction|A Phase I Randomized, Dose Escalation Study of the Safety and Efficacy of Intracoronary Delivery of Cardiosphere-Derived Stem Cells in Patients With Ischemic Left Ventricular Dysfunction and a Recent Myocardial Infarction|CADUCEUS|Cedars-Sinai Medical Center|Yes|Completed|May 2009|February 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|80 Years|No|||February 2012|February 10, 2014|May 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893360||139665|
NCT00893659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAR-GLUCAN-1|Beta-glucan on Fecal Microflora in Polypectomized Patients|The Effect of Beta-glucan on Faecal Microflora in Polypectomized Patients||Harokopio University|Yes|Completed|January 2009|July 2015|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|69|||Both|20 Years|75 Years|No|||July 2015|July 23, 2015|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893659||139642|
NCT00891332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taiho10020400|Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer|Phase II Study of S-1 Plus LV (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic Colorectal Cancer||Taiho Pharmaceutical Co., Ltd.|No|Completed|October 2008|November 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|20 Years|N/A|No|||January 2012|January 16, 2012|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891332||139813|
NCT00888537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000748|Wiser Choices in Acute Myocardial Infarction|Wiser Choices in Acute Myocardial Infarction||Mayo Clinic|No|Completed|March 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|90 Years|No|||March 2016|March 18, 2016|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888537||140026|
NCT00888550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHMC07-0216|Splinting Versus Not Splinting of the Distal Lower Extremity After Intramedullary Nailing for Tibial Fractures|A Randomized Trial of Post-Operative Outcomes: Splinting Versus Not Splinting of the Distal Lower Extremity After Intramedullary Nailing for Tibial Fractures||Denver Health and Hospital Authority||Completed|August 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||September 2010|September 28, 2010|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00888550||140025|
NCT00891891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD R01 HD048629|Psychosocial Adjustment of Adolescents With Spina Bifida|Psychosocial Adjustment of Adolescents With Spina Bifida|CHATS|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Active, not recruiting|September 2005|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|8 Years|15 Years|No|Non-Probability Sample|Children with spina bifida (ages 8-15) and their families and close friends|October 2015|October 8, 2015|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891891||139771|
NCT00892138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/4352 Norw Medical Assoc|Mindfulness Training for Stress Management|Mindfulness Training for Stress Management: A Two-centre Randomised Controlled Study of Medical and Psychology Students With Long-term Follow up||Norwegian Knowledge Centre for the Health Services|No|Active, not recruiting|September 2009|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|290|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892138||139754|
NCT00887848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeLoGAIT_2009|Effectiveness of Robotic Assisted Gait Training in Children With Cerebral Palsy|Effectiveness of Robotic Assisted Gait Training in Children With Cerebral Palsy: A Randomized Controlled Clinical Trial Including 3D Gait Analysis|PeLoGAIT|University Children's Hospital, Zurich|No|Recruiting|May 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Both|6 Years|18 Years|No|||January 2016|January 18, 2016|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887848||140078|
NCT00887861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2202|Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery|A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Parallel-group Study of BGG492 as Monotherapy in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery||Novartis|No|Completed|March 2009|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|No|||February 2011|February 22, 2011|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887861||140077|
NCT00888173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0229I|Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma||Gynecologic Oncology Group|Yes|Active, not recruiting|July 2009|||January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|April 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00888173||140054|
NCT00887822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22367|A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer|A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Chinese Patients With Advanced Gastric Cancer.||Hoffmann-La Roche||Completed|March 2009|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887822||140080|
NCT00887835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLS-007-FUS|A Post-Market Study of Transfacet Lumbar Spine Fixation and Fusion Utilizing the PERPOS™ PLS System|A Post-Market Study of Transfacet Lumbar Spine Fixation and Fusion Utilizing the PERPOS™ PLS System||Interventional Spine, Inc.|No|Withdrawn|April 2009|||October 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2009|April 25, 2012|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887835||140079|
NCT00889109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7068-AO-CTIL|Shoulder Proprioception Following Open and Arthroscopic Instability Repair|Proprioception of the Glenohumeral Joint Following Open and Arthroscopic Repair for Anterior Shoulder Instability||Sheba Medical Center|Yes|Not yet recruiting|July 2009|||December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients treated in our shoulder outpatients clinic will be candidates for inclusion        in this study.|April 2009|April 27, 2009|April 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00889109||139982|
NCT00889382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-202|A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)|A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)||Astellas Pharma Inc|No|Completed|July 2009|January 2014|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|152|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|April 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889382||139961|
NCT00889070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA192|Respiratory Events Among Premature Infants|Respiratory Events Among Premature Infants (32-<36 w/GA) - Outcomes & Risk Tracking Study (The REPORT Study)||MedImmune LLC|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|6 Months|No|Non-Probability Sample|Male or female preterm infants 32-≤36 wGA|August 2009|August 6, 2009|April 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00889070||139985|
NCT00889083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAM-2009-1|Hepatic Mitochondrial Function in Sepsis|Evaluation of Hepatic Mitochondrial Function in Sepsis||Institut d'Anesthesiologie des Alpes Maritimes|No|Recruiting|April 2009|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Liver biopsies|Both|18 Years|80 Years|No|Non-Probability Sample|Community sample|June 2011|June 30, 2011|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00889083||139984|
NCT00889369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHCC2008-2|Duloxetine for Major Depression in Peri-/Postmenopausal Women|Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life||McMaster University|No|Recruiting|May 2009|June 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||June 2009|February 7, 2012|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889369||139962|
NCT00890253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILT08|Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation|A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free De-novo Immunosuppression After Liver Transplantation|CILT|University Medical Center Goettingen|Yes|Recruiting|January 2010|January 2013|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||January 2010|September 14, 2011|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890253||139894|
NCT00889980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-133|Melanoma Molecular Profiling Analysis|Sentinel Node and Non-Sentinel Lymph Nodes (SLN and Non-SLN) Procurement From Melanoma Subjects for Molecular Profiling Analysis||University of Pittsburgh|Yes|Recruiting|May 2008|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|Lymph nodes (less than 20% of any node), blood will be drawn at the pre study visit (serum      and peripheral blood mononuclear cells) and appropriate lineage control tissue will be      collected.|Both|12 Years|N/A|No|Non-Probability Sample|Melanoma patients|December 2015|December 3, 2015|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889980||139915|
NCT00885495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC 40|Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study|The Effects of Darunavir Plus Ritonavir on the Pharmacokinetics and Pharmacodynamics of Rosuvastatin||University of Cincinnati|No|Active, not recruiting|January 2009|August 2009|Anticipated|June 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2009|April 21, 2009|April 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00885495||140257|
NCT00885508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-Chimio-Rev-08|A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q|A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q|GFM-Chimio-Rev|Groupe Francophone des Myelodysplasies|Yes|Active, not recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|N/A|N/A|No|||April 2015|April 23, 2015|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885508||140256|
NCT00885781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803090M|Efficacy and Safety Comparison Between SMOFlipid and Lipovenoes MCT|Clinical Study Comparing Safety and Efficacy of SMOFlipid, the New Generation Fat Emulsion, in Comparison With the Current Fat Emulsion Lipovenoes MCT at the Hospital||National Taiwan University Hospital|No|Completed|November 2008|December 2010|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|25 Years|75 Years|No|||May 2011|October 13, 2011|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885781||140235|
NCT00886067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00004|Positron Emission Tomography (PET) Study|An Open-label Positron Emission Tomography (PET) Study Using 2 [18F] F A85380 to Determine α4β2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-fertile Female (Non-nicotine Users) Healthy Volunteers||AstraZeneca|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 9, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886067||140213|
NCT00886301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PP-08|Fatty Liver and Ectopic Fat in Overweight and Obese Patients|Fatty Liver and Ectopic Fat in Overweight and Obese Patients||Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|70 Years|No|||March 2010|March 29, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886301||140195|
NCT00894218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-26|New Tool of Subjective and Objective Functional Evaluation and the Quality of Life After Arthroplastic Surgery of the Hip and the Knee Assisted or Not by Computer and Mini-invasive Arthroplasty|||Assistance Publique Hopitaux De Marseille|No|Terminated|April 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|1|||Both|20 Years|80 Years|No|||February 2014|February 24, 2014|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894218||139599|
NCT00892710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 196|Trial of Poor Performance Status Patients (ToPPS)|Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2|ToPPS|SCRI Development Innovations, LLC|No|Completed|June 2009|May 2015|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|172|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 30, 2009|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT00892710||139713|
NCT00893373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-SORAML-034|Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age|A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age|SORAML|Technische Universität Dresden|Yes|Completed|March 2009|September 2014|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|60 Years|No|||February 2016|February 4, 2016|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893373||139664|
NCT00893867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ptcl-01373|Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke|A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset|MACSI|D-Pharm Ltd.|Yes|Terminated|December 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|85 Years|No|||October 2012|October 23, 2012|May 4, 2009|Yes|Yes|The result of a pre-planned interim futility analysis|No||https://clinicaltrials.gov/show/NCT00893867||139626|
NCT00893880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP8|A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis|A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis||Nitric BioTherapeutics, Inc|No|Completed|June 2009|May 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|92|||Both|19 Years|N/A|No|||October 2012|October 18, 2012|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893880||139625|
NCT00893893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-0003|Very-low-density-lipoprotein Triglyceride (VLDL-TG) Uptake in Visceral Fat|Very-low-density-lipoprotein Triglyceride(VLDL-TG) Uptake in Visceral Fat||University of Aarhus|Yes|Completed|May 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|16|Samples With DNA|Blood samples Adipose tissue samples|Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|August 2011|August 24, 2011|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893893||139624|
NCT00892151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2009-01|Evaluation of GLUCOFACTS® Deluxe Diabetes Management System|Evaluation of GLUCOFACTS® Deluxe Diabetes Management System In a Clinical Setting||Ascensia Diabetes Care|No|Completed|April 2009|April 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 1, 2009|Yes|Yes||No|April 15, 2010|https://clinicaltrials.gov/show/NCT00892151||139753|
NCT00888849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-07-0008|An Open-label, Randomized, Prospective Study of the Effectiveness, Safety, and Clinical Outcomes of Stapled Anastomoses Versus Hand-Sutured Anastomoses in Patients Undergoing Gastrointestinal End to End or Side to Side Anastomoses|An Open-label, Randomized, Prospective Study of the Effectiveness, Safety, and Clinical Outcomes of Stapled Anastomoses Versus Hand-Sutured Anastomoses in Patients Undergoing Gastrointestinal End to End or Side to Side Anastomoses|Tiger|Ethicon Endo-Surgery||Completed|April 2009|February 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|280|||Both|18 Years|75 Years|No|||November 2011|November 30, 2011|April 20, 2009||No||No|October 18, 2011|https://clinicaltrials.gov/show/NCT00888849||140002|
NCT00894296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0027-08-SHA|Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on Treatments|Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on Treatments||Shalvata Mental Health Center|Yes|Recruiting|March 2009|January 2013|Anticipated|January 2013|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|schizophrenia patients and healthy subjects between the ages 18-65|January 2012|January 4, 2012|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894296||139593|
NCT00888212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/069|Minimally Invasive Techniques Or Surgery In the Diagnosis of Sarcoidosis|Minimally Invasive Techniques Or Surgery In the Diagnosis of Sarcoidosis (MITOSIS-Trial)|MITOSIS|University Hospital, Ghent|No|Completed|June 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|No|||June 2009|June 19, 2009|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888212||140051|
NCT00888498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPacific|Ankle Manual Therapy for Ankle Sprains|Ankle Manual Therapy for Individuals With Post-Acute Ankle Sprains: A Randomized, Placebo-Controlled Trial|AMT|University of the Pacific|No|Suspended|January 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|189|||Both|16 Years|60 Years|No|||July 2015|July 1, 2015|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888498||140029|
NCT00888511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.02|Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer|Concomitant Tarceva® and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study|TARLAL|Odense University Hospital|Yes|Recruiting|May 2009|December 2020|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|90 Years|No|||January 2015|January 20, 2015|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888511||140028|
NCT00889122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3459|Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families|Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families||Maine Medical Center|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|213|||Both|9 Years|17 Years|Accepts Healthy Volunteers|||July 2010|August 3, 2010|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889122||139981|
NCT00888186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYSK-PD-2007|Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics|Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics|DYSK-PD-2007|Uppsala University|Yes|Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|5|||Both|30 Years|90 Years|No|||April 2009|April 24, 2009|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888186||140053|
NCT00888472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00101626|Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Refractory Asthma|Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Patients With Refractory Asthma||Gunma University|No|Completed|November 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|No|||February 2013|February 3, 2013|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888472||140031|
NCT00889668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-01-001 CTIL|Evaluation of the Performance and Use of Non-Invasive Glucose Monitoring Device|Evaluation of the Performance and Use of GlucoTrack Model DF-F Non-Invasive Glucose Monitoring Device.|CR-01-001|Integrity Applications Ltd.|Yes|Recruiting|May 2009|October 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|180|||Both|10 Years|N/A|No|||April 2012|April 29, 2012|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00889668||139939|
NCT00889642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dharma-NSCO3|Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers|A Multicenter Double-Blind Randomized Placebo Controlled Two-Arm Study Evaluating the Safety and Efficacy of the Iontophoretic Administration of Lidocaine and Epinephrine Using Lidocaine Iontophoretic Drug Delivery System (IDDS) to Provide Local Anesthesia for Venipuncture in Healthy Adult Volunteer Subjects||Dharma Therapeutics Inc.|No|Completed|May 2009|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 22, 2009|April 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889642||139941|
NCT00889655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005072|A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely|A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of MiraLAX (PEG 3350) vs Golytely as Bowel Preparation for Screening Colonoscopy||Oregon Health and Science University|Yes|Not yet recruiting|May 2009|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|432|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||April 2009|April 28, 2009|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889655||139940|
NCT00889993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701M00265|Satiety Response After Mixed Fiber Doses|Effect of Four Doses of Mixed Fiber on Satiety, Food Intake, Glucose, Insulin, and Gut Hormone Release||University of Minnesota - Clinical and Translational Science Institute|No|Completed|November 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889993||139914|
NCT00890825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00016|Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients|A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic Non Small Cell Lung Cancer (Stage IIIB- IV)||AstraZeneca|No|Active, not recruiting|April 2009|December 2016|Anticipated|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|422|||Both|18 Years|130 Years|No|||January 2016|January 7, 2016|April 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890825||139851|
NCT00890539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC08-247|Methacholine Challenge: Comparison of Doubling and Quadrupling Methacholine Dose Regimes Using the Tidal Volume Method|Methacholine Challenge: Comparison of Doubling and Quadrupling Methacholine Dose Regimes Using the Tidal Volume Method||University of Saskatchewan|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|15|||Both|18 Years|N/A|No|||November 2009|November 23, 2009|March 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00890539||139872|
NCT00885521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|348/08|Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis|Exercise Training in Patients With Non-CF Bronchiectasis - a Multi-centre Randomized Controlled Trial||Bayside Health|Yes|Completed|February 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|20 Years|80 Years|No|||March 2014|March 10, 2014|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885521||140255|
NCT00885794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 08-069-0508|Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)|Microperimetry and High-Definition-OCT in Ranibizumab Treatment for Diabetic Macular Edema (MORE-Study)|MORE|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Active, not recruiting|May 2008|May 2012|Anticipated|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|51 Years|N/A|No|||June 2011|June 23, 2011|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885794||140234|
NCT00886080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF 178|The Effect of Arrhythmia Surgery on Quality of Life in Patients With Atrial Fibrillation Undergoing Cardiac Surgery|A Prospective Randomised Multicentre Comparison on Health Related Quality of Life: the Value of Add-on Arrhythmia Surgery in Patients With Atrial Fibrillation Undergoing Valvular and/or Coronary Bypass Surgery||Maastricht University Medical Center|No|Completed|October 2002|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|150|||Both|N/A|N/A|No|||April 2009|April 21, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886080||140212|
NCT00892723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OL-ASCAR-05|A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars|A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids||Capstone Therapeutics|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|59|||Both|18 Years|65 Years|No|||September 2012|September 10, 2012|April 30, 2009|Yes|Yes||No|May 17, 2012|https://clinicaltrials.gov/show/NCT00892723||139712|
NCT00890487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30031978|Hyaluronic Acid and Vaginal Distress|Effects of Hyaluronic Acid Oral Supplementation on the Vaginal Epithelium: a Prospective, Randomized, Double-Blind, Placebo Controlled Study||University of Messina|No|Not yet recruiting|May 2009|December 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|70|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||April 2009|April 27, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890487||139876|
NCT00890500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT1050-01|Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.|A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies.||Fate Therapeutics|Yes|Completed|January 2011|October 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||October 2013|October 7, 2013|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00890500||139875|
NCT00893633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINMAs-2004|Critical Illness Neuromuscular Abnormalities in Neurocritical Care Patients|Prospective Case-Only Study of Neuromuscular Pathology in Patients on Mechanical Ventilation in the Neurosurgical Intensive Care Unit||Clinical Institute of the Brain, Russia|No|Completed|March 2004|January 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|135|||Both|16 Years|N/A|No|Non-Probability Sample|Patients from neurosurgical ICU in city clinical hospital|July 2009|July 9, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00893633||139644|
NCT00891020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22533|A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)|Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs||Hoffmann-La Roche||Completed|May 2009|March 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|886|||Both|18 Years|N/A|No|||October 2012|October 19, 2012|April 29, 2009|Yes|Yes||No|February 28, 2012|https://clinicaltrials.gov/show/NCT00891020||139836|
NCT00888225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR K2005|Tennis Elbow Trial|Chronic Lateral Epicondylitis. A Randomized Controlled Clinical Trial of Two Physical Training Concepts With Special Reference to Etiology and Treatment Effect|Epi-X|Uppsala University|No|Completed|October 2003|December 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|205|||Both|20 Years|75 Years|No|||April 2009|April 24, 2009|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888225||140050|
NCT00894049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITAC02-01|A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation|A Multicenter Prospective Randomized Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation|ITAC02-01|Institut Paoli-Calmettes|Yes|Completed|November 2002|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|65 Years|No|||December 2013|December 31, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894049||139612|
NCT00888836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC-2009-1|Diet and Medical Therapy Versus Bariatric Surgery in Type 2 Diabetes|Prospective Randomized Controlled Trial on the Effect of Gastric Bypass and Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI > 35 vs. Medical Therapy|DIBASY|Catholic University of the Sacred Heart|No|Completed|April 2009|November 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|30 Years|60 Years|No|||July 2014|July 28, 2014|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888836||140003|
NCT00889135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041037|Long Term Treatment With L-DOPS|Long Term Treatment With L-DOPS||Vanderbilt University|No|Enrolling by invitation|September 2004|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2011|January 3, 2013|April 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00889135||139980|
NCT00893724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF0901|Supplemental Adjuvants for Intracellular Nutrition and Treatment|The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration|SAINTS|Mid-Atlantic Retina Consultations, Inc.||Active, not recruiting|June 2009|September 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|N/A|N/A|No|||July 2011|July 19, 2011|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00893724||139637|
NCT00888823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24541/ethics24761|Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer|Multicentre, Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Early Stage Non-Small Cell Lung Cancer (NSCLC)||AHS Cancer Control Alberta|No|Completed|March 2010|June 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00888823||140004|
NCT00889096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBEmoMem|Effects of Propranolol on the Encoding and Retrieval of Emotional Material After Single Dose Administration in Healthy Young Subjects|Effects of Propranolol on the Encoding and Retrieval of Emotional Material After Single Dose Administration in Healthy Young Subjects||University Medicine Greifswald|No|Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|46|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2009|June 26, 2015|April 27, 2009||||No||https://clinicaltrials.gov/show/NCT00889096||139983|
NCT00894283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00025492|A Pilot Study Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients|A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily With Respect to Preventing VTE After Bariatric Surgery in Obese Patients||Johns Hopkins University|Yes|Completed|June 2009|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|198|||Both|18 Years|70 Years|No|||August 2014|August 6, 2014|May 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00894283||139594|
NCT00890006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 06-0520-C|Advanced Imaging for Radiotherapy Treatment Planning and Guidance for Low-Intermediate Risk Prostate Cancer (Margin)|Low-Intermediate Risk Prostate Cancer: Improving Acute Toxicity Outcomes of Radiotherapy With the Integration of Advanced Imaging for Treatment Planning and Guidance||University Health Network, Toronto|Yes|Active, not recruiting|September 2006|September 2016|Anticipated|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|99|||Male|18 Years|N/A|No|||June 2015|June 12, 2015|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890006||139913|
NCT00890266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAR1006|Corneal Collagen Cross-linking With Hypotonic Riboflavin in Corneas Thinner Than 400 Microns|Collagen Cross-linking With Riboflavin in a Hypotonic Solution, With UV Light, on Corneas Less Than 400 Microns Thick: an Exploratory Study.|HypotonicRibo|Moorfields Eye Hospital NHS Foundation Trust|Yes|Active, not recruiting|April 2009|July 2010|Anticipated|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|18 Years|60 Years|No|||April 2009|May 6, 2010|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00890266||139893|
NCT00890552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM0010|A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis|A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis||Stanford University|Yes|Completed|April 2009|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00890552||139871|
NCT00896025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012009-011|Study of N-Acetylcysteine in Acute Liver Failure (ALF)|A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study|ONAC|University of Texas Southwestern Medical Center|Yes|Terminated|December 2008|December 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||January 2014|January 29, 2014|May 8, 2009|Yes|Yes|The low enrollment did not provide statistical power for any meaningful results.|No|December 11, 2013|https://clinicaltrials.gov/show/NCT00896025||139460|Early termination lead to zero subjects analyzed.
NCT00896038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090136|The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD|The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD||National Institutes of Health Clinical Center (CC)|No|Completed|May 2009|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|21 Years|50 Years|No|||October 2015|October 5, 2015|May 8, 2009|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT00896038||139459|
NCT00891085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-302|Synchronized Intermittent Mechanical Ventilation Versus Open Lung Ventilation With Spontaneous Respiration|Synchronized Intermittent Mechanical Ventilation vs Open Lung Ventilation With Spontaneous Respiration|SOLV|University of New Mexico|Yes|Recruiting|October 2007|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|198|||Both|18 Years|N/A|No|Probability Sample|Adult Trauma Patients with ISS>/=25|April 2009|April 29, 2009|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00891085||139831|
NCT00885833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPHO-S0701|Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)|Phase I/II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome||The Korean Society of Pediatric Hematology Oncology|No|Completed|February 2007|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|1 Year|25 Years|No|||July 2014|July 11, 2014|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885833||140231|
NCT00885807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-70402|A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale)|Psychometric Validation of the Weiss Functional Impairment Rating Scale and the Weiss Symptom Record in Patients With Attention-Deficit Hyperactivity Disorder||University of British Columbia|No|Completed|July 2006|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|220|||Both|7 Years|N/A|Accepts Healthy Volunteers|Probability Sample|People with ADHD from 7 years of age|June 2011|June 17, 2011|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885807||140233|
NCT00885820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-008|Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection|The Effects of Treatment of Subclinical Rejection on Renal Histology and Graft Function in Renal Transplant Patients Receiving Tacrolimus and Mycophenolate Mofetil||Astellas Pharma Inc|Yes|Completed|September 2001|January 2006|Actual|July 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|April 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00885820||140232|
NCT00886574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY-2009-11|Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events|Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients|CAPPA|Hanyang University|Yes|Active, not recruiting|April 2009|February 2014|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|40 Years|N/A|No|||May 2010|June 3, 2010|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886574||140174|
NCT00886821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1111001|A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of CVX-096 In Type 2 Diabetic Adult Subjects||Pfizer|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|70 Years|No|||July 2015|July 30, 2015|April 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00886821||140155|
NCT00891345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV001|Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy|A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Prostate Cancer Patients - a First Dose in Man Study|ALECSAT|CytoVac A/S|No|Completed|April 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||April 2012|April 26, 2012|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891345||139812|
NCT00891618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0679|Acupuncture for Chemo-Induced Peripheral Neuropathy|Acupuncture for Chemo-induced Peripheral Neuropathy in Multiple Myeloma and Lymphoma Patients||M.D. Anderson Cancer Center|No|Completed|April 2009|||April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00891618||139792|
NCT00890760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAL 034|A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites|Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP||University of Oxford|Yes|Completed|March 2009|February 2011|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|10||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890760||139855|
NCT00890786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGG|A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas|A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|May 2009|June 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|3 Years|30 Years|No|||January 2016|January 26, 2016|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00890786||139854|
NCT00891033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI32829|Panobinostat/Velcade in Multiple Myeloma|Phase I Exploratory Study of Panobinostat IV in Combination With Bortezomib in Relapsed/Refractory Multiple Myeloma Patients||University of Arkansas|Yes|Terminated|April 2009|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|April 28, 2009|No|Yes|This study was terminated because the drug company stopped making the study drug|No||https://clinicaltrials.gov/show/NCT00891033||139835|
NCT00891046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885G2301E1|An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.|An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever|β-SPECIFIC 3|Novartis||Completed|September 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|295|||Both|2 Years|19 Years|No|||April 2015|April 14, 2015|April 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891046||139834|
NCT00888238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-179|A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)|A Randomized Clinical Trial to Evaluate Glucose-Dependent Insulinotropic Effects of a Single Dose of a DPP-4 Inhibitor in Lean Healthy Males||Merck Sharp & Dohme Corp.|No|Completed|May 2009|July 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|April 24, 2009|No|Yes||No|May 24, 2010|https://clinicaltrials.gov/show/NCT00888238||140049|
NCT00888251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.27.CLI|Evaluation of a Weight Management Program|A Multicenter, Retrospective Study to Evaluate the Effectiveness of the OPTIFAST Weight Management Program||Nestlé|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|153|||Both|N/A|N/A|No|Non-Probability Sample|OPTIFAST Program participants|September 2011|September 21, 2011|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00888251||140048|
NCT00894062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0483|Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent|ComparisiOn of Neointimal coVerage betwEen zotaRolimus Eluting Stent and Everolimus Eluting Stent Using Optical Coherence Tomography at 9 Months (COVER OCT)|COVER OCT|Yonsei University|Yes|Completed|December 2008|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|80 Years|No|||July 2009|March 23, 2010|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894062||139611|
NCT00889148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-215-THR|Morphine COnsumption in Joint Replacement Patients, With and Without GaBapentin Treatment, a RandomIzed ControlLEd Study|Multiple Doses of Gabapentin and Postoperative Morphine Consumption in Primary Hip Arthroplasty|MOBILE|McMaster University|No|Completed|October 2007|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|19 Years|90 Years|No|||April 2009|February 28, 2011|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889148||139979|
NCT00893737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110211|"Completeness of Response" Following Treatment With Treximet™ for Migraine|An Open-label Study to Evaluate "Completeness of Response" Following Treatment With Treximet™ for Migraine||Cady, Roger, M.D.|No|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|147|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 4, 2011|May 5, 2009|Yes|Yes||No|September 22, 2010|https://clinicaltrials.gov/show/NCT00893737||139636|
NCT00889395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH082663-02|Cognitive and Psychosocial Benefits of MISC Training for Ugandan Children|Cognitive and Psychosocial Benefits of Caregiver Training for Ugandan HIV Children||Makerere University|No|Recruiting|September 2008|June 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Both|16 Months|6 Years|No|||April 2009|May 14, 2009|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00889395||139960|
NCT00895193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11627|Alternative Options to Minimize Niacin-Induced Flushing|Alternative Options to Minimize Niacin-Induced Flushing||University of Kansas Medical Center|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|100|||Both|21 Years|70 Years|No|||May 2014|May 22, 2014|May 6, 2009||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00895193||139524|Limitations include: pilot design, small sample size, short duration of a one-time niacin dose, utilization of only one niacin formulation.
NCT00895479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ark 103|Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence|A Phase III, Randomized, Controlled, Open Label, Multicenter Study of the Efficacy and Safety of Trinam® (EG004); an Assessment of Primary Unassisted Patency and Survival of Vascular Access Grafts in Hemodialysis Patients With End Stage Renal Disease|AdV-VANTAGE|Ark Therapeutics Ltd|Yes|Terminated|April 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|May 7, 2009|Yes|Yes|Strategic reasons. Seeking partner for future development.|No||https://clinicaltrials.gov/show/NCT00895479||139502|
NCT00895778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISCO|Neuromuscular Blockade Improves Surgical Conditions|Neuromuscular Blockade Improves Surgical Conditions|NISCO|Technische Universität München|Yes|Completed|March 2009|December 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|64 Years|No|||March 2013|March 18, 2013|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00895778||139479|
NCT00896311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVERT-01|Intravenous (IV) Nitroglycerin for Versions in Nulliparous Women|INVERT: IV Nitroglycerin for Versions Trial - a Randomized Placebo-controlled Trial in Nulliparous Women|INVERT (01)|University of Calgary|No|Completed|March 2003|February 2008|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Female|N/A|N/A|No|||August 2013|August 27, 2013|May 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00896311||139440|
NCT00896324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0002|Intellectual Impairment in Women With Breast Cancer|Assessment and Treatment of Cognitive Deficits in Breast Cancer||Stanford University|Yes|Completed|March 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Female|40 Years|65 Years|No|||May 2014|May 29, 2014|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00896324||139439|
NCT00896298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502-294|Trial of Leptin Replacement Therapy in Patients With Lipodystrophy|Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With Lipodystrophy||University of Texas Southwestern Medical Center|No|Completed|April 2006|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|6 Years|70 Years|No|||December 2015|December 3, 2015|May 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00896298||139441|
NCT00886353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APN01-1-01|Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)|Double-blind, Placebo-controlled Dose-escalation Phase I Study With Recombinant Human Soluble Angiotensin Converting Enzyme 2 (rhACE2) APN01 in Healthy Volunteers||Apeiron Biologics|Yes|Completed|April 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 30, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886353||140191|
NCT00886093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401006|A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants|A Phase 1, Open Label, Randomized, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On PF-04447943 Pharmacokinetics In Healthy Adult Subjects||Pfizer|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|April 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00886093||140211|
NCT00886340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK70594 (completed)|A Lifestyle Change Program to Prevent Type 2 Diabetes|A Lifestyle Change Program to Prevent Type 2 Diabetes||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|September 2005|August 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Both|21 Years|N/A|No|||April 2012|April 4, 2012|January 22, 2009||No||No|January 22, 2009|https://clinicaltrials.gov/show/NCT00886340||140192|
NCT00886834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24403|Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol vs. Placebo Prior to IUD Insertion in Nulliparous Women|MPIIN|University of Utah|Yes|Completed|April 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|108|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 22, 2009|Yes|Yes||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00886834||140154|
NCT00891917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-4|Liq-NOL Efficacy in Pediatric Patients With Down Syndrome|Evaluation of Coenzyme q10 (Liq-nol®) Efficacy in Pediatric Patients With Down Syndrome||Children's Hospital Medical Center, Cincinnati|Yes|Completed|January 2005|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|6 Years|16 Years|No|||January 2014|January 27, 2014|April 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00891917||139769|
NCT00891631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iSBIRT RFA-od-09-003|Primary Care iSBIRT to Reduce Serious Teen Health Risks|Primary Care Internet/Intranet-based Screening, Brief Intervention, and Referral to Treatment (iSBIRT) System to Reduce Serious Teen Health Risks||Children's Hospital Boston|Yes|Withdrawn|September 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|699|||Both|12 Years|21 Years|No|||March 2011|March 7, 2011|April 30, 2009||No|Grant application was not funded|No||https://clinicaltrials.gov/show/NCT00891631||139791|
NCT00892164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|642|Thyroid Surgery With the New Harmonic Scalpel or the Electrothermal Bipolar Vessel Sealer|Thyroid Surgery With the New Harmonic Scalpel or the Electrothermal Bipolar Vessel Sealer: a Prospective Randomized Study||Hippocration General Hospital|Yes|Completed|August 2008|April 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||May 2009|May 1, 2009|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00892164||139752|
NCT00891904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000640992|Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer|A Feasibility Study of Re-irradiation Using Stereotactic Body Radiation Therapy (SBRT) and Cetuximab for Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Roswell Park Cancer Institute|Yes|Terminated|April 2009|||July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|120 Years|No|||September 2015|September 29, 2015|April 30, 2009|No|Yes|Low accrual|No|January 29, 2014|https://clinicaltrials.gov/show/NCT00891904||139770|Trial terminated early. Too few patients to analyze.
NCT00894036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MatPed 08-002R|The Burden and Genetic Variability of Extended-Spectrum ß-Lactamase (ESBL) - Producing Pathogens in Swiss Children|Epidemiology of Extended-spectrum ß-lactamase (ESBL)-Producing Enteric Gram-negative Bacilli in Swiss Children||University Hospital, Geneva|Yes|Recruiting|July 2008|December 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|15 Years|No|Non-Probability Sample|All children hospitalized in a pediatric hospital or a pediatric unit in Switzerland|May 2009|September 24, 2009|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894036||139613|
NCT00894309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRI-1|Validation of the Fluid Responsiveness Index in Critically Ill Patients|Evaluation of the Validity of a New Index Provided by the PiCCO2 Device for Predicting Fluid Responsiveness in Critically Ill Patients|FRI|Bicetre Hospital|No|Not yet recruiting|May 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|90 Years|No|Probability Sample|Patients with an acute circulatory failure|May 2009|May 5, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894309||139592|
NCT00893997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0913|PR1 Vaccination in Myelodysplastic Syndrome (MDS)|Phase 2 Study of Proteinase 3 PR1 Peptide Vaccine in Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Terminated|July 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|May 4, 2009|Yes|Yes|The trial was ended per sponsor due to slow accrual rates.|No|March 17, 2011|https://clinicaltrials.gov/show/NCT00893997||139616|
NCT00894010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESC-001|Photosensitivity Proof of Concept Trial|Assessment of Marketed AEDs in the Human Photosensitivity Proof of Concept Trial||The Epilepsy Study Consortium|No|Completed|May 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|6|||Both|18 Years|60 Years|No|||March 2012|March 1, 2012|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894010||139615|
NCT00894023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARD03|Intracoronary Abciximab With Clearway Catheter|IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis|IC-CLEARLY|University of Roma La Sapienza|No|Terminated|June 2009|June 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||January 2013|January 3, 2013|May 4, 2009||No|the study was stopped because the sample size was very difficult to achieve.|No||https://clinicaltrials.gov/show/NCT00894023||139614|
NCT00894933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE0814|Performance Evaluation of the AMS CONTINUUM™ Device|Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy||American Medical Systems|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Male|40 Years|N/A|No|||June 2011|June 6, 2011|May 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00894933||139544|
NCT00894946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF-LUBE|The In Vitro Fertilization - Lipiodol Uterine Bathing Effect Study|The in Vitro Fertilisation - Lipiodol Uterine Bathing Effect Study||University of Auckland, New Zealand|Yes|Recruiting|May 2009|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|39 Years|No|||May 2009|May 6, 2009|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894946||139543|
NCT00895206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/640|Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study|Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study|CD4-01|University Hospital, Ghent|No|Recruiting|May 2009|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895206||139523|
NCT00895492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck 2009|Two-year Surveillance of Rotavirus Genotypes Causing Acute Diarrhea in Children Younger Than 5 Years Requiring Emergency Room (ER) and Hospital Admission in Chile|Two Year (2009-2010) Surveillance of Rotavirus Genotypes Causing Acute Diarrhea in Children Younger Than 5 Years of Age Requiring Emergency Room and Hospital Admission in Two Large Cities in Chile.||University of Chile|No|Completed|May 2009|April 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|967|Samples With DNA|stool|Both|1 Month|5 Years|No|Non-Probability Sample|Children younger than 5 years of age with acute diarrhea or related diagnosis requiring        emergency room and hospital admission in two large cities in Chile|April 2014|April 30, 2014|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00895492||139501|
NCT00896597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-11/2008 (PAIR)|Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis|An Open, Randomised Study to Compare the Reproducibility of CTP Rating and NRL972 Pharmacokinetics in Patient Volunteers With Hepatic Cirrhosis.||Norgine|No|Completed|April 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|240|||Both|18 Years|80 Years|No|||August 2010|August 6, 2010|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896597||139419|
NCT00896610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090140|Natural History of Autoimmune Diabetes and Its Complications|Natural History of Autoimmune Diabetes and Its Complications||National Institutes of Health Clinical Center (CC)||Recruiting|May 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|2 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 24, 2015|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896610||139418|
NCT00886379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSS-103306|Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health|Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health|BSS|Brigham and Women's Hospital|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|6||Actual|744|||Both|9 Years|11 Years|Accepts Healthy Volunteers|||April 2009|April 21, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886379||140189|
NCT00886600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-021|A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)|A Double-blind, Randomized, Parallel-group, Placebo-controlled Pilot Study to Investigate the Magnitude and Duration of Response and the Safety of MK0954 (50 mg Given Once or Twice Daily, or 100 mg Given Once Daily) Compared to Placebo Using Ambulatory Blood Pressure Monitoring||Merck Sharp & Dohme Corp.||Completed|May 1991|August 1992|Actual|May 1992|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|122|||Both|21 Years|N/A|No|||August 2015|August 17, 2015|April 22, 2009|Yes|Yes||No|May 21, 2009|https://clinicaltrials.gov/show/NCT00886600||140172|Safety has been reported in the literature.
NCT00886587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMOECZ0002|To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children|A Double-Blind, Randomized, Active-Controlled Clinical Trial To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|April 2009|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|108|||Both|2 Years|12 Years|No|||June 2014|June 4, 2014|April 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00886587||140173|
NCT00887172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-6|Trial of Chinese Herbal Medicine in the Treatment of Upper Respiratory Tract Infections (URTIs)|A Randomized Double Blind, Placebo-Controlled Clinical Trial of Chinese Herbal Medicine (CHM) in the Treatment of Acute Upper Respiratory Tract Infections||The University of Hong Kong|Yes|Completed|June 2005|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|327|||Both|18 Years|N/A|No|||April 2009|April 22, 2009|April 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887172||140129|
NCT00891930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070820|Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab|Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin-or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab||Amgen|No|Completed|May 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|March 12, 2009|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT00891930||139768|
NCT00893139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-077|A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye|||Alcon Research|Yes|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|765|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00893139||139681|
NCT00892177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0872|Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme|Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|October 2009|||November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|May 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00892177||139751|
NCT00887887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-4-022|The Association Between Gene Polymorphisms and Infectious Complications After Liver Surgery|The Association Between Gene Polymorphisms in the Innate Immune Response and the Risk of Infectious Complications and Liver Failure After Partial Hepatic Resection||Maastricht University Medical Center|Yes|Completed|January 2008|January 2014|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|whole blood, fresh frozen liver tissue|Both|18 Years|N/A|No|Probability Sample|Patients with benign or malignant liver disease requiring partial hepatic resection at the        Maastricht University Medical Centre|October 2014|October 13, 2014|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887887||140075|
NCT00893763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01NR007652|Strategies To Prevent Pneumonia 2 (SToPP2)|Oral Care Intervention in Mechanically Ventilated Adults|SToPP2|University of South Florida|Yes|Completed|September 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|314|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 4, 2009||No||No|June 11, 2015|https://clinicaltrials.gov/show/NCT00893763||139634|
NCT00893776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1134397|Bilateral Versus Unilateral Task Retraining Using the SaeboFlex Orthosis|The Effectiveness of Bilateral Versus Unilateral Task Retraining Using the SaeboFlex Orthosis in Individuals With Subacute and Chronic Stroke.||University of Missouri-Columbia|No|Suspended|June 2009|December 2014|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|May 4, 2009||No|Insufficient time for study extenuating personal circumstances of PI|No||https://clinicaltrials.gov/show/NCT00893776||139633|
NCT00893789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3067/ES/MN|Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (50, 150, and 250 mg/Day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury||Teva Pharmaceutical Industries||Terminated|April 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|117|||Both|18 Years|65 Years|No|||August 2013|August 14, 2013|May 4, 2009|Yes|Yes|Study has been stopped by sponsor decision.|No|May 9, 2013|https://clinicaltrials.gov/show/NCT00893789||139632|The sponsor’s decision to terminate the study early resulted in a small number of study participants and related limitations to the interpretation of the study results.
NCT00894322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB110|A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension|A Two-Cohort, Single- and Repeat Dose Study to Examine the Pharmacokinetics, Tolerability, and Safety of Ready to Use Exenatide Once Weekly in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|65|||Both|19 Years|75 Years|No|||August 2015|September 3, 2015|May 5, 2009|Yes|Yes||No|April 16, 2014|https://clinicaltrials.gov/show/NCT00894322||139591|
NCT00894335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|retroper adrenal|Anesthesia Management of Retroperitoneal Adrenalectomies|Anesthesiological Management of Hemodynamics and Gas Exchange for Retroperitoneal Adrenalectomies||Kliniken Essen-Mitte|No|Recruiting|May 2008|July 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|500|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with adrenal tumors scheduled for retroperitoneal adrenalectomies|May 2009|June 27, 2011|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894335||139590|
NCT00894348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-032|Factors Predicting Positive Yields on Biliary Brush Cytology During Endoscopic Retrograde Cholangiopancreatography|EXEMPT: Prospective Factors Predicting Positive Yields on Biliary Brush Cytology During Endoscopic Retrograde Cholangio-pancreatography (ERCP)|ERCP|The Cleveland Clinic|Yes|Recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing an ERCP for evaluation of biliary strictures|July 2013|July 29, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894348||139589|
NCT00894582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0678-010|Prospective Study of Ventral Hernia Repair|Prospective Measurements of Intra-Abdominal Volume and Pulmonary Function After Repair of Massive Ventral Hernias With the Components Separation Technique||Northwestern University|Yes|Completed|January 2007|December 2008||December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2009|May 5, 2009|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894582||139571|
NCT00894595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M197-08|Preventing Knee Injuries in Adolescent Female Football Players|Preventing Knee Injuries in Adolescent Female Football Players - Protocol of a Cluster-randomized Controlled Trial||Region Skane|No|Completed|August 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4564|||Female|13 Years|17 Years|Accepts Healthy Volunteers|||December 2010|January 3, 2011|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894595||139570|
NCT00894608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a00949200|Letrozole Combined With Gonadotropins (Gn) for Ovarian Stimulation Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) in Patients With Polycystic Ovary Syndrome (PCOS)|Letrozole Combined With Gn for Ovarian Hyperstimulation Undergoing IVF/ICSI in Patients With PCOS||Yunyang Medical College|Yes|Enrolling by invitation|January 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|N/A|N/A|No|||May 2009|May 5, 2009|May 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00894608||139569|
NCT00894959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV0109_BLA1|Efficacy and Safety of Sodium Heparin in Patients|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|July 2009|December 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894959||139542|
NCT00895219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0404/64|Physiotherapy and Dysfunctional Breathing|A Comparison of the Effects of Respiratory Physiotherapy Alone and Respiratory Physiotherapy Combined With Musculoskeletal Techniques in the Management of Dysfunctional Breathing|HVS|Royal Brompton & Harefield NHS Foundation Trust|No|Active, not recruiting|July 2007|December 2009|Anticipated|July 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|N/A|No|||April 2009|May 7, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895219||139522|
NCT00895232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN03032|Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments|Iron Sucrose In The Treatment of Restless Legs Syndrome (RLS): The Safety of Three Dose Regimens as Evaluated by Clinical Assessments||Luitpold Pharmaceuticals|No|Completed|November 2003|November 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|19 Years|N/A|No|||May 2015|June 8, 2015|May 7, 2009|Yes|Yes||No|June 29, 2009|https://clinicaltrials.gov/show/NCT00895232||139521|
NCT00895505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDOAT2006|D-Dimer Guided Oral Anticoagulant Treatment (OAT)|Safety and Efficacy of a D-Dimer-Guided Strategy for Extension of Secondary Prophylaxis of Venous Thromboembolism - a Prospective and Randomized Management Trial|DDOAT2006|University Hospital, Bonn|Yes|Recruiting|February 2008|February 2012|Anticipated|February 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|18 Years|85 Years|No|||May 2009|May 7, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895505||139500|
NCT00895817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-14045|Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis|Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis||Walter Reed Army Medical Center|Yes|Completed|April 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2013|March 11, 2013|May 6, 2009||No||No|December 28, 2012|https://clinicaltrials.gov/show/NCT00895817||139476|
NCT00895791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract: 2009-010879-24|COmplex BifuRcation Lesions: A Comparison Between the AXXESS Device and Culotte Stenting: An Optical Coherence Tomography (OCT) Study|Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With the AXXESS Biolimus A9 Eluting Stent Versus Culotte Technique Using Everolimus-Eluting Stents: an Optical Coherence Tomography Analysis.|COBRA|University Hospital, Gasthuisberg||Not yet recruiting|June 2009|December 2015|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2009|May 7, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895791||139478|
NCT00895804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-003/2001|Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)|Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)||University Hospital, Basel, Switzerland|Yes|Completed|June 2001|March 2002|Actual|March 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 12, 2009|May 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00895804||139477|
NCT00896350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000637640|Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer|Predicting Treatment Response Based on Hypoxia in Head and Neck Cancers Using Non-Invasive Oxygen Sensitive MRI||National Cancer Institute (NCI)||Recruiting|October 2008|||April 2010|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2009|February 26, 2011|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00896350||139437|
NCT00887185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006H0194|Validation/Dissemination Of A Temporal Bone Dissection Simulator|Validation/Dissemination Of A Temporal Bone Dissection Simulator||Ohio State University|Yes|Completed|October 2006|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 26, 2011|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00887185||140128|
NCT00886847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0051|Comparison of Endobronchial Ultrasound-Guided Biopsy Using Fine Needle Aspiration Versus Fine Needle Capillary Sampling|Specimen Adequacy and Diagnostic Agreement of Fine Needle Aspiration (FNA) VS. Fine Needle Capillary Sampling (FNC) of Endobronchial Ultrasound-Guided Biopsy of Mediastinal Lymph Nodes||M.D. Anderson Cancer Center|No|Completed|April 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|18 Years|N/A|No|||August 2012|February 17, 2016|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886847||140153|
NCT00886860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091/2552(EC2)|The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol|The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol||Mahidol University|Yes|Completed|May 2009|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|64|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 12, 2010|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886860||140152|
NCT00893152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHI 08-097|Family Involvement in Treatment for PTSD|Perspectives on Enhancing Family Involvement in Treatment for PTSD||VA Office of Research and Development|No|Completed|November 2009|March 2012|Actual|October 2011|Actual|N/A|Observational|N/A||3|Actual|83|||Both|18 Years|65 Years|No|Non-Probability Sample|Veteran participants were OIF/OEF veterans receiving outpatient treatment for PTSD at the        Little Rock or Oklahoma City VAMCs. Each veteran participant was asked to designate an        adult family member/friend to participate in a separate interview.|March 2015|March 24, 2015|May 1, 2009||No||No|February 17, 2015|https://clinicaltrials.gov/show/NCT00893152||139680|
NCT00892190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 08-160|Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome|A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome||University of Pittsburgh|Yes|Completed|April 2011|February 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00892190||139750|
NCT00892203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2204|Efficacy and Safety of BGG492 in the Treatment of Migraine|A Multi-centre, Randomized, Double-blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492||Novartis|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|60 Years|No|||May 2012|May 4, 2012|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00892203||139749|
NCT00887900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALK|Deep Anterior Lamellar Keratoplasty (DALK)|Deep Anterior Lamellar Keratoplasty by Big-Bubble Technique: Results and Complications|DALK|Hospital Oftalmologico de Brasilia|Yes|Completed|January 2006|December 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||April 2009|April 23, 2009|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00887900||140074|
NCT00887913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Matrix RF_Facial Tx|Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction|Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction||Syneron Medical|No|Completed|April 2008|October 2009|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 2, 2010|April 23, 2009||No||No|October 6, 2010|https://clinicaltrials.gov/show/NCT00887913||140073|
NCT00887926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13959|Study of EB10 in Patients With Leukemia|An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia||ImClone LLC|No|Terminated|June 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2012|February 24, 2012|April 23, 2009|No|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT00887926||140072|
NCT00894725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hmsxLPS09|Laparoscopic Versus Open Left Colonic Resection|Laparoscopic vs. Open Left Colonic Resection: a Randomized Monocentric Trial||Università Vita-Salute San Raffaele|No|Completed|February 2000|December 2008|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|268|||Both|18 Years|N/A|No|||May 2009|May 6, 2009|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894725||139560|
NCT00894738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56790|Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures|Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures||Washington University School of Medicine|No|Completed|January 2010|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00894738||139559|
NCT00894361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVA-3028|Comparison of Mobile-Bearing and Fixed-Bearing All-Polyethylene Tibia Total Knee Designs|A Randomized Prospective Comparison of Mobile-Bearing and Fixed-Bearing (All-Polyethylene Tibia) Cruciate-Substituting Total Knee Arthroplasty (TKA) Designs||Minneapolis Veterans Affairs Medical Center|Yes|Completed|October 2001|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|400|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|March 24, 2009||No||No|March 24, 2009|https://clinicaltrials.gov/show/NCT00894361||139588|Mean 43 month followup with minimum 2 year followup; survival analysis will follow at long-term followup; multiple outcome measures also recorded other than range of motion (ROM)
NCT00894621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Noradrenalina precoce em UTIP|Norepinephrine as Early Vasopressor Therapy in Children Undergoing Mechanical Ventilation|Norepinephrine as Early Vasopressor Therapy in Children Undergoing Mechanical Ventilation||Unidade de Terapia Intensiva||Active, not recruiting|November 2008|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|1 Month|12 Years|No|||May 2009|May 6, 2009|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00894621||139568|
NCT00894634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BF-08-06|Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents|A Single-Dose, Open-Label, Pharmacokinetic Study of Brompheniramine Maleate Liquid in Children and Adolescents||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|17 Years|No|||February 2013|February 21, 2013|May 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00894634||139567|
NCT00894972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32474|Rehabilitation Following Lumbar Disc Surgery|Examining the Effectiveness of a Post-operative Rehabilitation Program Emphasizing Restoration of Multifidus Muscle Function for Individuals Undergoing Lumbar Discectomy: a Randomized Clinical Trial||University of Utah|No|Completed|April 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||November 2012|November 5, 2012|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00894972||139541|
NCT00934063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3709|An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®|A 24-month Prospective, Non-interventional, Observational Study on the Composite Clinical Endpoint (GET-Score) Reflecting Quality of Life, Body Composition and Cholesterol Metabolism in Patients Treated With Norditropin® (Somatropin)|GET|Novo Nordisk A/S|No|Completed|July 2009|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|121|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with acquired growth hormone deficiency who have been deemed appropriate to        receive Norditropin® as treatment and as part of routine out-patient care by the        prescribing physician.|April 2015|April 28, 2015|July 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00934063||136615|
NCT00934076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090218006|Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer|Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||University of Alabama at Birmingham|Yes|Withdrawn|February 2010|June 2015|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|N/A|No|||January 2011|May 6, 2015|July 6, 2009|No|Yes|Study was never activated|No||https://clinicaltrials.gov/show/NCT00934076||136614|
NCT00934635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015277|A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls|The "Therapeutic Window" of the "Atypical" Antipsychotic Paliperidone Extended Release (ER)-A Positron Emission Tomography Study With [18F]Fallypride as the Radiotracer||Janssen-Cilag G.m.b.H|No|Terminated|September 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|2|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|July 6, 2009|Yes|Yes||No|December 13, 2010|https://clinicaltrials.gov/show/NCT00934635||136571|Two subjects enrolled, both completed study per protocol. Study was prematurely terminated, data obtained were not submitted to further statistical analysis and will not be applicable for scientific analysis due to the low number of subjects.
NCT00935701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00026158|Acupressure and Acupuncture as an Intervention With Children With Autism II|Investigating the Use of Acupressure and Acupuncture With Children With Autism II||Johns Hopkins University|No|Completed|July 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|3 Years|10 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|July 8, 2009||No||No|March 10, 2014|https://clinicaltrials.gov/show/NCT00935701||136490|There were no limitations to this study.
NCT00935714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0023-09-HYMC|Exercise and Breast Cancer Related Lymphedema: Influence of Muscle Group and Sequence on Volume Change in Swollen and Normal Arms|||Hillel Yaffe Medical Center||Recruiting|August 2009|||January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Female|18 Years|N/A|No|||August 2009|August 18, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935714||136489|
NCT00936494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1137500|Inferior Turbinate Reduction in Pediatric Population Failing Tonsillectomy and Adenoidectomy for Sleep Disordered Breathing|Inferior Turbinate Reduction in Pediatric Population Failing Tonsillectomy and Adenoidectomy for Sleep Disordered Breathing (Randomized, Prospective, Controlled Study)||University of Missouri-Columbia|Yes|Terminated|June 2009|||May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|N/A|18 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|July 9, 2009||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00936494||136429|
NCT00936819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-872|The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial|A Phase IIb, Randomized, Double-blind, Placebo Controlled Study Using Transplantation of Autologous Early Endothelial Progenitor Cells(EPCs) for Patients Who Have Suffered Acute Myocardial Infarction|ENACT-AMI|Ottawa Hospital Research Institute|Yes|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936819||136404|
NCT00902720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54RR024347|Ovarian Tissue Freezing For Fertility Preservation|Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University||Oregon Health and Science University|Yes|Recruiting|May 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|25|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|May 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00902720||138981|
NCT00902733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08033|Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer|A Standardized Nursing Intervention Protocol for Pancreatic Cancer as a Chronic Illness||City of Hope Medical Center||Completed|July 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Primary Purpose: Health Services Research|1||Anticipated|125|||Both|18 Years|N/A|No|||September 2010|September 29, 2010|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902733||138980|
NCT00902746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-01-1|Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis|Phase3, Open-Label, Long-Term, NSAID-Add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea Associated With Endometriosis.||Nobelpharma|Yes|Completed|May 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Female|18 Years|N/A|No|||May 2014|May 15, 2014|May 7, 2009||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT00902746||138979|
NCT00936325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090184|Studies in the Pathogenesis of Systemic Capillary Leak Syndrome|Studies in the Pathogenesis of Systemic Capillary Leak Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|July 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|210|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||October 2015|January 16, 2016|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936325||136442|
NCT00936910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ambisome Locks at CHP|Antifungal Locks to Treat Fungal-related Central Line Infections|The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients||University of Pittsburgh|No|Completed|September 2006|September 2010|Actual|August 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|21 Years|No|||January 2016|January 12, 2016|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00936910||136397|
NCT00933621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-03|Intracoronary Injection of Autologous Bone Marrow Cells in Patients With Chronic Heart Failure: Five Years Follow up|Intracoronary Injection of Autologous Bone Marrow Cells in Patients With Chronic Heart Failure: Five Years Follow up||Assaf-Harofeh Medical Center|No|Completed|April 2003|December 2003|Actual|May 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|88 Years|No|||July 2009|July 6, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00933621||136648|
NCT00933634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECVPCV-001|Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation|Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation: a Randomized Controlled Trial||Valduce Hospital|Yes|Completed|January 2006|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|247|||Both|18 Years|85 Years|No|||July 2009|July 2, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933634||136647|
NCT00933907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04807|Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal|Study Title: Study for Dermatological Evaluation of Topic Compatibility Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd PH_DESILSTY_FR (Lactic Acid) .||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933907||136627|
NCT00933920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2110|Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension|A Randomized, Single-blind, Parallel Group, Multiple Oral Dose Study to Evaluate the Effect of a Light Meal on the Pharmacokinetics and Pharmacodynamics of Aliskiren Using Market 300 mg Tablet Formulation in Subjects With Mild to Moderate Hypertension||Novartis||Completed|June 2009|||December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|124|||Both|18 Years|65 Years|No|||February 2010|February 3, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933920||136626|
NCT00904098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3266-401|Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine|Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment)Of Menstrual Migraine||Endo Pharmaceuticals|No|Completed|September 2005|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Female|18 Years|N/A|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904098||138879|
NCT00904111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3261-001|A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain|A Randomized, Double-blind Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain||Endo Pharmaceuticals||Completed|August 2004|||October 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|N/A|No|||February 2010|December 5, 2013|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904111||138878|
NCT00904410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIMTEP 0402|Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET|Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET|CHIMTEP|Centre Oscar Lambret|No|Completed|May 2005|January 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|63|||Female|18 Years|N/A|No|||July 2012|July 20, 2012|March 15, 2007||No||No||https://clinicaltrials.gov/show/NCT00904410||138856|
NCT00904423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0014|Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption|A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.||Stanford University|Yes|Terminated|April 2009|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|85 Years|No|||October 2011|October 6, 2011|May 13, 2009|No|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT00904423||138855|
NCT00904956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANLATHU|Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner|Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner|GRANLATHU|Germans Trias i Pujol Hospital|No|Recruiting|November 2009|December 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Only a single population is going to be studied: the LTBI, thus people with proof to be M.        tuberculosis infected but demonstrating not having active disease.        As the first approach to demonstrate the Dynamic Hypothesis in humans, up to 6 people will        be included as controls.|November 2009|July 8, 2011|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904956||138814|
NCT00905619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5050W-1|Functional and Cognitive Impairment in Advanced Kidney Disease|Functional and Cognitive Impairment in Advanced Kidney Disease||VA Office of Research and Development|No|Active, not recruiting|December 2006|June 2016|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Anticipated|190|Samples Without DNA|Serum obtained and kept until end of study.|Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Veterans at the Bronx VA Renal Clinic, Hemodialysis Unit, and Primary Care Clinic|October 2015|October 13, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905619||138764|
NCT00901108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAKD-001|Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma|Prospective Randomized Controlled Trial of Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma||University of Alberta|Yes|Terminated|November 2009|October 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|40 Years|85 Years|No|||February 2016|February 23, 2016|May 11, 2009|No|Yes|Slow study recruitment and lack of clinical equipoise over time|No||https://clinicaltrials.gov/show/NCT00901108||139104|
NCT00901121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 09/04|Maxillary Sinus Elevation With Bio-Oss or Straumann BoneCeramic|Maxillary Sinus Grafting With Bio-Oss or Straumann Bone Ceramic Followed by Delayed Placement of Straumann Dental Implants: A Comparative Histomorphometric and Clinical Study||Institut Straumann AG|No|Completed|July 2005|March 2011|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|70 Years|No|||March 2016|March 2, 2016|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901121||139103|
NCT00933244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0055|Treatment of Vitamin D Insufficiency|Treatment of Vitamin D Insufficiency||University of Wisconsin, Madison|No|Completed|April 2010|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|230|||Female|N/A|75 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|July 2, 2009||No||No|June 16, 2015|https://clinicaltrials.gov/show/NCT00933244||136677|
NCT00933777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORAVE|SORAVE - Sorafenib and Everolimus in Solid Tumors|SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors.||Lung Cancer Group Cologne|Yes|Recruiting|July 2009|June 2013|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||July 2011|July 1, 2011|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933777||136636|
NCT00934882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11656|Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI|Phase I, Open-label, Non-placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI as First or Second Line Therapy in Patients With Metastatic Colorectal.||Bayer|No|Completed|August 2009|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00934882||136552|
NCT00902434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903|Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era|Retrospective Analysis of Histologies, Pattern of Care, and Outcomes of Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era: A Report From the Chicago Lymphoma Consortium||Oncology Specialists, S.C.|No|Completed|May 2009|April 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|50|||Both|80 Years|80 Years|No|Probability Sample|This study is looking at retrospectively evaluating patients with NHL who are over the age        of 80 at our institution between 2001-2007.|June 2014|June 30, 2014|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902434||139003|
NCT00902135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14543|Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)|Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH)||Bayer|No|Completed|May 2009|August 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|702|||Both|18 Years|N/A|No|Non-Probability Sample|Adult female and male Clinically Isolated Syndrome (CIS) and relapsing-remitting multiple        sclerosis (RRMS) patients who are at least 18 years of age, have started a treatment with        Betaferon based on clinical decision by the treating neurologist and have completed the        dose titration, will be documented after the therapy decision has been made.        The prescription of the medicine must be clearly independent from the decision to include        the patient in the study.|July 2015|July 15, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902135||139025|
NCT00902148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20031124|Evaluation of Bioresorbable Sheet to Prevent Intra-Abdominal Adhesions in Colorectal Surgeries|Evaluation of Intra-Abdominal Adhesions in Ileostomy Procedures When Using a Resorbable Polylactide Film (SurgiWrap) in Colorectal Surgeries||MAST Biosurgery, AG|No|Completed|December 2003|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|19|||Both|18 Years|78 Years|No|||May 2009|May 14, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902148||139024|
NCT00902447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-202|Human Blood Cell Disorders Tissue Bank|Human Blood Cell Disorders Tissue Bank||Northwell Health|No|Recruiting|April 2009|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|10000|Samples With DNA|cells, tissue, serum, saliva, etc|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|October 2015|October 5, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902447||139002|
NCT00902460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921059|CP-690,550 and Midazolam Drug-Drug Interaction Study|A Phase 1, Randomized, 2-Way Crossover, Multiple Dose, Open Label Study Of The Effect Of CP-690,550 On Midazolam Pharmacokinetics In Healthy Volunteers||Pfizer|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 12, 2009|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902460||139001|
NCT00936923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGPD-diuretics|Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients|Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients||Sun Yat-sen University|Yes|Withdrawn|June 2008|December 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|70 Years|No|||May 2015|May 19, 2015|July 9, 2009||No|The study was withdrawn prior to enrollment of first participant.|No||https://clinicaltrials.gov/show/NCT00936923||136396|
NCT00937443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vanderbilt_University|Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure|Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure|EPCCHFWalk|Vanderbilt University|No|Recruiting|July 2009|July 2011|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|60 ml of blood will be used to measure baseline levels of EPC's, NRG-1, VEGF, and SDF-1.      Repeat venipuncture will be done at Week 12. Approximately 60 ml of blood for the      measurement of EPC's, NRG1, VEGF, and SDF-1.|Both|30 Years|65 Years|No|Probability Sample|Cardiac Heart Failure Patients|August 2009|August 11, 2009|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937443||136357|
NCT00937456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_24/0904|Open Versus Laparoscopically-assisted Esophagectomy for Cancer|Open vs Laparoscopically-assisted Esophagectomy for Cancer: A Multicentric Phase III Prospective Randomized Controlled Trial||University Hospital, Lille|Yes|Completed|October 2009|July 2015|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|75 Years|No|||August 2015|August 13, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937456||136356|
NCT00933361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG 294/08|Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study|Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: a Phase I/II Study||Cantonal Hospital of St. Gallen|No|Recruiting|June 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2009|August 26, 2011|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00933361||136668|
NCT00933647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Projeto Chimarrão|Cardioprotective Effects of Green Tea Versus Maté Intake|Effects of Yerba Mate and Green Tea Consumption on Cardiovascular Risk Factors in Dyslipidemic and Overweight Subjects||Instituto de Cardiologia do Rio Grande do Sul|Yes|Recruiting|November 2007|December 2009|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|195|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00933647||136646|
NCT00904124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902-face|The Effect of Different Types of Dietary Fiber on Satiation|Determination of the Effect of Different Types of Isolated Dietary Fiber on ad Libitum Food Intake in Healthy Human Subjects||Wageningen University|No|Completed|May 2009|May 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|123|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 10, 2010|May 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00904124||138877|
NCT00904969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMS051|A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence|A Pre-Market Study of the AMS Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence|AMS051|American Medical Systems|No|Completed|September 2005|November 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Male|40 Years|N/A|No|||March 2011|March 31, 2011|May 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00904969||138813|
NCT00905281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSS|Study of Impact of Routine "Clinical Cancer Department/Supportive Care Department" Consultation on the Prescription of an Additional Line of Chemotherapy|Randomized Controlled Trial Assessing the Impact of Routine "Oncologist-supportive Care Team" Consultation on the Use of an Additional Line of Chemotherapy in Metastatic Breast Cancer Patients||Centre Leon Berard|No|Completed|November 2008|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Female|18 Years|N/A|No|||February 2015|February 6, 2015|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00905281||138790|
NCT00905294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFACTs 2009-001|Study of ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Coronary Artery Disease|ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Patients Undergoing Percutaneous Coronary Intervention|ADVANCE-PCI|University College Cork|No|Terminated|August 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|Samples Without DNA|serum, plasma|Both|18 Years|N/A|No|Probability Sample|Patients with coronary artery disease undergoing percutaneous coronary intervention|June 2013|June 17, 2013|May 19, 2009||No|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT00905294||138789|
NCT00905632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.7|4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients|Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA Administered in Combination With Peg-IFN and Ribavirin in Chronic HCV-infected Patients for 4 Weeks, a Randomised, Double-blind, Placebo Controlled Study||Boehringer Ingelheim||Completed|May 2009|||March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|75|||Both|18 Years|70 Years|No|||November 2014|November 21, 2014|May 19, 2009||||No||https://clinicaltrials.gov/show/NCT00905632||138763|
NCT00901147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGH651|Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma|An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy||Singapore General Hospital|Yes|Completed|November 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|21 Years|N/A|No|||June 2014|June 26, 2014|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901147||139101|
NCT00901134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCVC-JPULSE-H|Multicenter Registry Study With Therapeutic Hypothermia After Cardiac Arrest in Japan|Multicenter Registry Study With Therapeutic Hypothermia After Cardiac Arrest in Japan|J-PULSE-HYPO|National Cerebral and Cardiovascular Center|No|Completed|June 2008|July 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|452|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with therapeutic hypothermia after cardiac arrest from 2005 to 2009 in each        hospitals.|July 2011|July 21, 2011|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901134||139102|
NCT00901446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0112|Study of Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Combination Coronary Catheter|Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study|SAVOIR|InfraReDx|Yes|Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the patients presenting to the cardiac catheterization        laboratory for elective cardiac catheterization.|September 2010|September 13, 2010|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901446||139078|
NCT00933790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRC25|Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis|A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis||Tuberculosis Research Centre, India|Yes|Active, not recruiting|September 2009|September 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|331|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933790||136635|
NCT00901732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603EUSA03|Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer|Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer||Jazz Pharmaceuticals|Yes|Recruiting|May 2009|November 2010|Anticipated|November 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2009|May 13, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901732||139056|
NCT00902122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53-003|rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors|Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors||Shenzhen SiBiono GeneTech Co.,Ltd|No|Recruiting|May 2009|August 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|85 Years|No|||February 2010|April 6, 2012|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00902122||139026|
NCT00901758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVERT-02|Intravenous (IV) Nitroglycerin for Versions in Multiparous Women|Intravenous (IV) Nitroglycerin for Versions in Multiparous Women|INVERT (02)|University of Calgary|No|Completed|March 2003|February 2008|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Female|N/A|N/A|No|||August 2013|August 27, 2013|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901758||139054|
NCT00901771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ventus C020|Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP|A Non-randomized, Case Series Study of the Effectiveness of Provent Treatment of Obstructive Sleep Apnea Patients Who Are Non-compliant or Minimally Adherent With Positive Airway Pressure Therapy||St. Luke's Hospital, Chesterfield, Missouri|No|Completed|May 2009|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2010|June 14, 2010|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901771||139053|
NCT00902772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00008|Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users|A Single-Centre, Single-Dose, Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the AbusePotential of AZD7325 in Healthy Recreational CNS Depressant Users||AstraZeneca|No|Completed|May 2009|September 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|7||Anticipated|100|||Both|18 Months|55 Years|No|||September 2009|September 22, 2009|May 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00902772||138977|
NCT00902785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011051|A Study Of Early Markers Of Choroidal Neovascularization|A Two-Year Exploratory, Observational, Non-Interventional Multicenter Study To Identify Early Markers Of Choroidal Neovascularization In Fellow Eyes Of Patients With Neovascular AMD In One Eye||Pfizer|No|Terminated|March 2008|May 2010|Actual|May 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|50 Years|N/A|No|Non-Probability Sample|-  age-related macular degeneration (AMD)          -  choroidal neovascularization (CNV)|November 2010|November 9, 2010|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902785||138976|
NCT00903071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-090|Personalized Physician Learning to Improve Hypertension Care|Personalized Physician Learning Intervention to Improve Hypertension Care|PPL|HealthPartners Institute|Yes|Completed|March 2010|May 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|130|||Both|22 Years|N/A|No|||June 2014|June 12, 2014|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00903071||138954|
NCT00903084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH085598|Examining Hair to Determine Tenofovir Exposure|A Phase 1 Pharmacokinetic Study of Varying Dosing Patterns on Tenofovir Concentrations in Hair||Public Health Foundation Enterprises, Inc.|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|May 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00903084||138953|
NCT00933387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1309|A Study of Neoadjuvant Bio-chemotherapy (Bio-C/T) Followed by Concurrent Bio-radiotherapy (Bio-R/T) in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC)|A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC)||National Health Research Institutes, Taiwan|Yes|Recruiting|September 2009|March 2013|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|70 Years|No|||October 2009|October 29, 2009|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933387||136666|
NCT00933660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081203_Ed-web|Retention and Retrieval for Three Different Training Methods|Do we Need an Instructor, or a Manikin to Learn BLS/AED, or is Web Based Training as Good as Instructor Based Training?||Doczero|Yes|Enrolling by invitation|October 2007|September 2009|Anticipated|March 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Anticipated|280|||Both|15 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933660||136645|
NCT00925782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX-353-001|A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|A Phase IIA Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation||Spectrum Pharmaceuticals, Inc|Yes|Completed|January 2010|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|June 18, 2009|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00925782||137241|
NCT00933374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001L DE 17T|Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma|A Single Arm, Multi-center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-based Chemotherapy|RAD001|Heinrich-Heine University, Duesseldorf|Yes|Terminated|July 2009|September 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|July 3, 2009||No|delayed recruitment|No||https://clinicaltrials.gov/show/NCT00933374||136667|
NCT00926276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERD-BPD|The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia|The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD).|GERD-BPD|The University of Texas Health Science Center, Houston|No|Completed|June 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|24 Weeks|1 Year|No|||December 2014|December 9, 2014|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926276||137203|
NCT00926289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.550|Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension|A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (Systolic Blood Pressure (SBP) >=160 mmHg and Diastolic Blood Pressure (DBP) >=100 mmHg)||Boehringer Ingelheim||Completed|June 2009|||April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|894|||Both|18 Years|N/A|No|||December 2013|June 17, 2014|June 22, 2009||||No|April 20, 2011|https://clinicaltrials.gov/show/NCT00926289||137202|
NCT00934219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TgLL8506|Triglyceride Lowering Study|Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza.|TGLL|Jewish Hospital, Cincinnati, Ohio|Yes|Recruiting|July 2009|December 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||June 2009|July 7, 2009|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00934219||136603|
NCT00934232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32857|Busulfan in Multiple Myeloma|A Phase I/II Open Label Study of IV Busulfan (Busulfex®) in Multiple Myeloma Patients 65 Years of Age or Older, or With Renal Insufficiency Undergoing Autologous Transplantation||University of Iowa|Yes|Terminated|August 2009|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|June 4, 2009|Yes|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT00934232||136602|
NCT00904995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0443|Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis|Kinetics of 1, 3 Beta-d- Glucan Assay in Patients With Hematologic Malignancies Receiving Voriconazole Prophylaxis||M.D. Anderson Cancer Center|No|Completed|May 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|May 18, 2009|Yes|Yes||No|April 18, 2011|https://clinicaltrials.gov/show/NCT00904995||138811|
NCT00905333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2452L00021|Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal|Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine in a Combination Package Compared to the Separate Intake of the Reference Brands Atacand and Splendil After a Fasting Period.||AstraZeneca|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905333||138786|
NCT00904696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E/08/532|Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome|Assessment of Tolerability & Effectiveness of Progut in Treatment of Irritable Bowel Syndrome||National University Hospital, Singapore|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|The study subjects will be patients aged 18 years and older, diagnosed with IBS by their        own physicians, and determined to be eligible to receive a prescription for Progut. In        addition, they must satisfy the inclusion criteria stated below, be able to communicate        well, provide written informed consent required by local regulations and willing to        participate in the entire study.|April 2014|April 24, 2014|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904696||138834|
NCT00905346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02136|Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Capsules Administered as the Content of 2 x 25 mg Capsules Mixed With Applesauce in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2002|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 18, 2009|No|Yes||No|June 1, 2009|https://clinicaltrials.gov/show/NCT00905346||138785|
NCT00904982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809166|Randomized Trial of Interventions to Improve Warfarin Adherence|Randomized Trial of Interventions to Improve Warfarin Adherence|WIN3|University of Pennsylvania|Yes|Completed|October 2009|December 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|268|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904982||138812|
NCT00905307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-07-203|Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia|A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients With Acute Schizophrenia|STEP 203|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|July 2009|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|459|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|May 19, 2009|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT00905307||138788|
NCT00905320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803-15|Hernia Repair With or Without Sutures|Sutures or No Sutures (SONS)|SONS|Indiana University|Yes|Recruiting|September 2009|August 2021|Anticipated|August 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905320||138787|
NCT00905645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010193|Sientra Sponsored Silimed Gel-Filled Breast Implant Core Clinical Study|Sientra Sponsored Silimed Gel-Filled Mammary Implant Clinical Study Protocol: Core Clinical Investigation||Sientra, Inc.|No|Active, not recruiting|November 2002|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1788|||Female|18 Years|N/A|No|||November 2014|November 18, 2014|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905645||138762|
NCT00901459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002339|A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers|A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers|rTMS|Duke University|Yes|Completed|May 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|50 Years|No|||December 2012|December 17, 2012|May 11, 2009|Yes|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT00901459||139077|
NCT00901745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS/09/019/26905 - 1b|Interaction of Apelin and Angiotensin in the Human Forearm Circulation|Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man||University of Edinburgh|No|Completed|May 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2009|August 9, 2010|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901745||139055|
NCT00902473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011973|Bioequivalence Study of Topiramate Tablets 25mg Under Fed Conditions|Comparative, Randomized, Single Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Ortho-Mcneil Pharmaceutical (Topamax®) 25 mg Topiramate Tablets Following a 50 mg Dose in Healthy Adult Males Under Fed Conditions||Ranbaxy Inc.|Yes|Completed|September 2001|October 2001|Actual|September 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2009|May 14, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902473||139000|
NCT00902486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 28050-201|INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs|A Randomized, Double-blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients With Active RA With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs (DMARD) Therapy Including Biologics||Incyte Corporation|No|Completed|May 2009|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|127|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902486||138999|
NCT00903110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-79-52800-002|European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry|European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database: a European Registry for Monitoring Long Term Safety and Efficacy of Increlex®. Eu-IGFD|EuIGFD|Ipsen|Yes|Recruiting|December 2008|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|330|None Retained|Study Design Time Perspective: Retrospective and Prospective|Both|N/A|N/A|No|Non-Probability Sample|Children with Growth Failure due to Severe Primary IGF-1 Deficiency|December 2015|December 21, 2015|April 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00903110||138952|
NCT00903344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11711|Impact of Vitamin D Supplementation on Lactation Associated Bone Loss|Impact of Vitamin D Supplementation on Lactation Associated Bone Loss||University of Kansas Medical Center|No|Completed|December 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|May 14, 2009|Yes|Yes||No|May 22, 2014|https://clinicaltrials.gov/show/NCT00903344||138935|
NCT00925496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D10054|Patient Benefit From the New Modular Shoulder Prosthesis PROMOS|Patient Benefit From the New Modular Shoulder Prosthesis PROMOS - a Multicentre Cohort Study|Promos|Smith & Nephew, Inc.|Yes|Active, not recruiting|June 2009|December 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|March 2015|March 31, 2015|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925496||137263|
NCT00926016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2006.152|Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects|Assessment of the Efficacy of Pioglitazone on Viral Kinetics, Cytokines, and Innate Immunity in a Group of Insulin Resistant, Treatment Naïve, Chronic Hepatitis C, Genotype 1 Patients||Brooke Army Medical Center|Yes|Completed|June 2006|September 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|23|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926016||137223|
NCT00926042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-007|Genotype and Phenotype Registry: Enrollment of Normal Control Subjects for Current and Future Research|TAP0307: Enrollment of Normal Control Subjects for Current and Future Research||Northwell Health|No|Completed|February 2004|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4511|Samples With DNA|Cheek cell DNA sample will be collected|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York City/ Long Island metropolitan community|September 2015|September 9, 2015|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926042||137221|
NCT00933933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7B5-02-06R01|Evaluation of Diagnostic HIV Ag/Ab Combo Assay|Evaluation of ARCHITECT HIV Ag/Ab Combo Assay||Abbott Diagnostics Division|No|Completed|June 2009|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|635|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2011|July 5, 2011|July 2, 2009|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT00933933||136625|
NCT00926562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14147|A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients|A Randomized, Double-blinded Comparison of Iopromide and Iodixanol in Renally Impaired Patients Undergoing Cardiac Catheterization|DIRECT|Chinese PLA General Hospital|No|Completed|February 2009|May 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|592|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|June 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00926562||137181|
NCT00926575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-GVHD-03|Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD|SUPPORTS|Soligenix|Yes|Terminated|October 2009|May 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||August 2013|October 10, 2013|June 19, 2009|Yes|Yes|An independent Data Safety Monitoring Board recommended the study be stopped due to futility|No|July 12, 2013|https://clinicaltrials.gov/show/NCT00926575||137180|DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.
NCT00926536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05122009-2518|Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance|Impact of C-arm CT in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transhepatic Arterial Chemoembolization (TACE): Optimal Imaging Guidance||Stanford University|Yes|Completed|April 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|83|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926536||137183|
NCT00926549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2008-0048|Ocular Imaging With Spectral Domain Optical Coherence Tomography|Posterior and Anterior Ocular Imaging With Spectral Domain Optical Coherence Tomography||Yonsei University|Yes|Recruiting|May 2009|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|16 Years|85 Years|Accepts Healthy Volunteers|||June 2009|June 19, 2009|May 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926549||137182|
NCT00905359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 0002 AP|Neurogenic Intermittent Claudication Evaluation Study|A Multicenter Prospective Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Aperius™ PercLID™ System Versus Standalone Decompressive Surgery in Degenerative Lumbar Spinal Stenosis With Neurogenic Intermittent Claudication|NICE|Medtronic Spinal and Biologics|Yes|Completed|January 2010|April 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|21 Years|N/A|No|||January 2016|January 26, 2016|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905359||138784|
NCT00905671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102|Intravascular Near Infrared Spectroscopy (NIRS) Bifurcation - Lipid Core Plaque Shift Study|Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation||InfraReDx|No|Completed|June 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|40 Years|N/A|No|||September 2014|September 3, 2014|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00905671||138760|
NCT00905658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633553|Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer|Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study||National Cancer Institute (NCI)||Recruiting|June 2008|||November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|3||Anticipated|120|||Female|18 Years|65 Years|No|||July 2009|July 28, 2009|May 19, 2009||||No||https://clinicaltrials.gov/show/NCT00905658||138761|
NCT00901186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DES01|Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema|A Randomized, Open Label, Multicenter, Laser-controlled Phase II Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) vs. Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema|RED-ES|Novartis||Completed|November 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||July 2014|July 3, 2014|May 11, 2009||No||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00901186||139098|
NCT00901199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS24T|Combo Chelation Trial|Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload||Children's Hospital & Research Center Oakland|Yes|Completed|September 2007|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|8 Years|N/A|No|||August 2013|August 5, 2013|May 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00901199||139097|
NCT00901485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0708/16|Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Newly Diagnosed Patients|Autotitrating Non-invasive Ventilation (NIV) Versus Standard NIV; a Randomised Crossover Trial in Patients With Newly Diagnosed Hypoventilation||ResMed||Completed|April 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2011|March 21, 2012|January 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00901485||139075|
NCT00901160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-468|Thromboelastography (TEG®) and Platelet Function in Patients on Anti-platelet Agents|Pilot Study for the Prediction of Post-operative Thrombotic and Bleeding Complications in Non-cardiac Surgery Using Thromboelastography (TEG®) and Platelet Mapping Assay (PMA™) in Patients on Anti-platelet Agents||McMaster University|No|Terminated|January 2008|June 2011|Actual|March 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|40 Years|85 Years|No|Non-Probability Sample|Patients who are having non-ambulatory, non-cardiac, elective surgery|April 2015|April 7, 2015|May 11, 2009||No|Unable to get funding|No||https://clinicaltrials.gov/show/NCT00901160||139100|
NCT00901173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909141|A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya|The THINKER Study: A Pilot for a Case-Control of Esophageal Squamous Cell Carcinoma in Western Kenya||National Institutes of Health Clinical Center (CC)||Recruiting|May 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Both|7 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 30, 2015|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901173||139099|
NCT00901784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011972|Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions|Comparative, Randomized, Single Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Ortho-McNeil Pharmaceutical (Topamax®) 25 mg Topiramate Tablets Following a 50 mg Dose in Healthy Adult Males Under Fasting Conditions||Ranbaxy Inc.|Yes|Completed|September 2001|October 2001|Actual|September 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2009|June 17, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901784||139052|
NCT00901420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0384|Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients|Comparison of Urodynamic Evaluation in Post-Radiation Salvage Prostatectomy Versus Prostatectomy-only Patients||M.D. Anderson Cancer Center|No|Terminated|June 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2|||Male|N/A|N/A|No|Non-Probability Sample|Men, seen at MD Anderson Cancer Center, who underwent radical prostatectomy as the        first-line treatment for their prostate cancer or underwent salvage prostatectomy for        recurrence after first-line radiation treatment; or underwent prostatectomy at least one        year prior to study entry date or received perioperative (or peri-XRT) chemotherapy or        hormone therapy.|July 2012|July 27, 2012|May 12, 2009||No|Terminated due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00901420||139080|
NCT00901433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSI-PW-US-01|Self Operating of the Personal WheezoMeter by Intended Users - A Usability Study|Self Operating of the Personal WheezoMeter by Intended Users - A Usability Study||KarmelSonix Ltd.|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male/Female participants ages 18 and up that were either diagnosed as an asthmatic or are        parent/guardian of an asthmatic child age under 18 years.|May 2009|June 23, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901433||139079|
NCT00902161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0893-019|A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Crossover Study to Assess the Safety and Tolerability of MK0893 Coadministered With Propranolol Hydrochloride in Patients With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|May 2009|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|60 Years|No|||June 2015|June 8, 2015|May 13, 2009|No|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00902161||139023|
NCT00902499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0159|Evolution of Memory Related Activity|Evolution of Memory-related fMRI Activation Over the Course of MCI and AD||National Institute on Aging (NIA)||Recruiting|May 2006|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|160|||Both|55 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Memory Disorders Unit at Brigham and Women's Hospital, the Gerontology Research Unit at        Massachusetts General Hospital, Alzheimer's Association, area physicians, and community        dwelling adults|July 2010|July 23, 2010|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902499||138998|
NCT00903357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|schallergy|The Effectiveness of Montelukast on Atopic Dermatitis in Koreans|A Double Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Koreans||Soonchunhyang University Hospital|Yes|Completed|August 2009|April 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|2 Years|6 Years|No|||November 2015|November 16, 2015|May 14, 2009||No||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00903357||138934|
NCT00925795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHID-01|Effect of Extra Virgin Olive Oil on Atherosclerosis Biomarkers in HIV-infected Patients|Effect of Extra Virgin Olive Oil on Atherosclerosis Biomarkers in Patients Treated With Combination Antiretroviral Therapy: a Randomized, Crossover Trial|EVOO_HIV|University Hospital for Infectious Diseases, Croatia|Yes|Completed|September 2009|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|75 Years|No|||November 2010|November 22, 2010|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925795||137240|
NCT00926055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-2007-000-20546-0|Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)|Effects on Atherosclerosis Regression of Ezetimibe Monotherapy or Ezetimibe Plus Simvastatin Combination Therapy: Evaluation by Fluorodeoxyglucose Positron Emission Tomography||Korea University|Yes|Withdrawn|September 2011|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2010|March 17, 2015|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926055||137220|
NCT00926029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2007-GIN-06-RR|Compare the Clinical Efficacy of Prototype Toothpastes|Compare the Clinical Efficacy of Prototype Toothpastes||Colgate Palmolive|No|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|February 16, 2012|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT00926029||137222|
NCT00904709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2009-341|The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders|The Assessment of the Minimal Effective and Tolerated Dose of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders||Nova Scotia Health Authority|No|Not yet recruiting|June 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|149|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||May 2009|May 19, 2009|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904709||138833|
NCT00904722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0163|Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma|Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma||M.D. Anderson Cancer Center|Yes|Completed|January 2010|||April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904722||138832|
NCT00905684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14565|Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)|Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC))||Bayer|No|Completed|June 2009|December 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5446|||Female|18 Years|N/A|No|Non-Probability Sample|Women who have been found eligible for OC use and have newly been prescribed an OC in        accordance with the terms of the respective marketing authorization Starter (first-ever        user of an OC) and switcher from another OC (incl. women with a history of OC use)|March 2012|March 6, 2012|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905684||138759|
NCT00905697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E561kyoto|Patient Reported Outcomes in Living Donor Lung Transplantation|Analysis of Patient Reported Outcomes in Living Donor Lung Transplantation||Kyoto University, Graduate School of Medicine|No|Recruiting|April 2009|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Probability Sample|Kyoto University Hospital Clinic for Lung Transplantation|April 2015|April 1, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905697||138758|
NCT00901225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014563|Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant|Plerixafor Rescue Mobilization For Autologous Stem Cell Transplant Patients With Inadequate Response to G-CSF||Duke University|Yes|Completed|May 2009|May 2013|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||April 2014|April 8, 2014|May 4, 2009|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT00901225||139095|
NCT00901212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCT-67914 (Greater Earth)|Evaluation of Resynchronization Therapy for Heart Failure (EARTH)|Evaluation fo Resynchronization Therapy for Heart Failure (EARTH)|EARTH|Montreal Heart Institute|Yes|Completed|October 2003|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2012|May 6, 2012|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901212||139096|
NCT00901498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-004|Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease|A Bioavailability Study of Four Experimental BMS-708163 Formulations Relative to Solubilized Capsule Formulation in Healthy Young Male Subjects||Bristol-Myers Squibb|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|January 6, 2011|May 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00901498||139074|
NCT00901511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM7MCPK4|Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)|Whole Lung Lavage Followed by Inhaled Sargramostim in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis||IRCCS Policlinico S. Matteo|No|Enrolling by invitation|July 2009|July 2013|Anticipated|July 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||July 2009|July 27, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901511||139073|
NCT00901862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105/06|Magnetic Therapy in Migraine Prophylaxis|Magnetic Therapy in Migraine Prophylaxis; Placebo-Controlled, Double-Blind, Crossed Study||El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|Yes|Completed|March 2007|April 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|19|||Both|18 Years|55 Years|No|||May 2009|May 12, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901862||139046|
NCT00901875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU0808|Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan|An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects||Indivior Inc.|No|Completed|March 2009|January 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|127|||Both|20 Years|N/A|No|||January 2010|November 28, 2012|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901875||139045|
NCT00902226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12133A|Escitalopram in Patients With Social Anxiety Disorder|Efficacy and Safety of Escitalopram in Patients With Social Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia||H. Lundbeck A/S|No|Completed|March 2009|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||May 2011|May 11, 2011|May 14, 2009||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT00902226||139018|
NCT00901823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK010|Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline|A Randomized, Open-Label, Single- and Multiple-Dose, Four-Way Parallel Study Comparing the Fed and Fasted Pharmacokinetics of Two Dose Levels of Diazoxide Choline Controlled-Release Tablet (DCCR) in Healthy VolunteersVOLUNTEERS||Essentialis, Inc.|No|Not yet recruiting|March 2011|March 2011|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2010|November 4, 2010|May 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901823||139049|
NCT00901836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0805-SA03|Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma|A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma|SA03|University of Florida|Yes|Terminated|May 2009|November 2012|Actual|November 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|May 13, 2009||No|Study closed due to feasability|No||https://clinicaltrials.gov/show/NCT00901836||139048|
NCT00901849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4104|Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)|Phase 1 Study of Tarceva and Rapamycin For Recurrent Low-Grad Gliomas in Children With or Without Neurofibromatosis Type 1 (NF1)||Children's Research Institute|Yes|Completed|May 2007|October 2012|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|21 Years|No|||September 2014|September 12, 2014|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901849||139047|
NCT00901472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#14903B|Sleep Disordered Breathing and Diabetes|Sleep Disordered Breathing and Blood Glucose Control in Type 2 Diabetes||University of Chicago|No|Completed|February 2007|December 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|105|None Retained|Blood was taken for HbA1C|Both|18 Years|N/A|No|Non-Probability Sample|Adult female and male patients with type 2 diabetes who are followed by University of        Chicago physicians in the endocrinology or primary care clinic will self-identify        themselves for participation in response to flyers posted at the check-in desk.|September 2013|September 4, 2013|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901472||139076|
NCT00901797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dr. Maman|Arthroscopic Rotator Interval Closure in Shoulder Instability Repair|||Tel-Aviv Sourasky Medical Center|No|Recruiting|May 2009|May 2011|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|40 Years|No|||May 2009|February 10, 2010|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901797||139051|
NCT00902174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQTI571A2301|Imatinib (QTI571) in Pulmonary Arterial Hypertension|A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)|IMPRES|Novartis||Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||June 2013|February 16, 2016|May 13, 2009|Yes|Yes||No|April 16, 2013|https://clinicaltrials.gov/show/NCT00902174||139022|
NCT00902187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221081|A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects|An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.||Pfizer|No|Completed|May 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 24, 2010|May 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00902187||139021|
NCT00901810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sums316|Clinical Evaluation of Working Length Determination by Electronic Apex-Locator or Radiography on Adequacy of Final Working Length|Clinical Evaluation of Working Length Determination by Electronic Apex-Locator or Radiography on Adequacy of Final Working Length||Shiraz University of Medical Sciences|Yes|Recruiting|April 2009|August 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|12 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 12, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901810||139050|
NCT00902798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH085851/MH106450|Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder|Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder|Perspectives|University of Pittsburgh|No|Recruiting|April 2009|March 2020|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|169|||Both|16 Years|45 Years|No|||December 2015|December 16, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902798||138975|
NCT00903656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_MBC-5|Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy|Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Terminated|May 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|May 14, 2009||No|Caelyx was not available anymore|No||https://clinicaltrials.gov/show/NCT00903656||138913|
NCT00926315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMUSPIBCCVD2009|Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation|Influence of Vitamin D on Gene Expression Profile of Breast Cancer Samples From Post-menopausal Patients||University of Sao Paulo General Hospital|No|Active, not recruiting|July 2007|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Female|40 Years|70 Years|No|||October 2012|October 31, 2012|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926315||137200|
NCT00926588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-119|Stepped Care to Optimize Pain Care Effectiveness|Stepped Care to Optimize Pain Care Effectiveness (SCOPE)|SCOPE|VA Office of Research and Development|Yes|Completed|October 2009|June 2015|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|65 Years|No|||July 2015|July 17, 2015|June 18, 2009||No||No|November 7, 2014|https://clinicaltrials.gov/show/NCT00926588||137179|
NCT00926302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPE08034M1|A Bioequivalence Study of Levetiracetam Versus Keppra|A Randomized, Single, Two-Way Crossover Pivotal Study to Assess the Bioequivalence Study of Levetiracetam vs. Keppra Administered Under Fasting Conditions to Healthy Adult Subject||Tri-Service General Hospital|Yes|Completed|January 2008|April 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 22, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00926302||137201|
NCT00926874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401|Comparative Study of Arterial Properties After an Ischaemic Stroke or an Acute Coronary Syndrome|A Comparative Study of Structural and Functional Arterial Properties After an Ischaemic Stroke or an Acute Coronary Syndrome|AVC/SCA|University Hospital, Grenoble|No|Recruiting|November 2005|October 2009|Anticipated|October 2009|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|whole blood, serum|Both|40 Years|70 Years|No|Non-Probability Sample|Patients who presented an acute vascular event :an ischaemic stroke (either a full stroke        or a transitory ischaemic attack (TIA)) or an acute coronary syndrome (ACS).|August 2009|August 21, 2009|March 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00926874||137159|
NCT00926887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBA-001|Low Level Laser Therapy to Reduce Pain After Breast Augmentation Surgery|A Double-Blind, Randomized, Placebo-Controlled Evaluation of the Effect of the Erchonia(R) EML Laser on Reducing Pain Following Breast Augmentation Surgery||Erchonia Corporation|No|Completed|September 2005|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|June 22, 2009|Yes|Yes||No|June 26, 2009|https://clinicaltrials.gov/show/NCT00926887||137158|
NCT00905008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRIST_GH0102|Long-Term Safety of Drug Eluting Stents in the "Real World" (FReIburger STent Registry)|Long-Term Safety and Efficacy of Drug Eluting Stents in "Real World" - Results From the FReIburger STent Registry|FRIST|University Hospital Freiburg|Yes|Active, not recruiting|October 2006|||May 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1502|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|FRIST (FReIburger STent) is a single-centre, long-term stent registry in a high volume        tertiary referral cardiovascular centre. FRIST included patients treated with drug-eluting        stents and uncoated stents at the University Hospital of Freiburg, Germany, according to        non-restrictive inclusion criterions, in which virtually all consecutive patient subsets        were considered eligible.|May 2009|May 19, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00905008||138810|
NCT00905021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 24786 / EXTENT|Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer|EXTENT: Exemestane (AROMASIN®) in Combination With Sunitinib (SUTENT®) in Hormone Receptor Positive Metastatic Breast Cancer|EXTENT|Baylor Breast Care Center|Yes|Terminated|March 2010|February 2012|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|May 18, 2009|Yes|Yes|Sponsor withdrew support|No|February 6, 2012|https://clinicaltrials.gov/show/NCT00905021||138809|
NCT00905723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0759/08|The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women|Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women||Federal University of São Paulo|No|Recruiting|May 2009|||May 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||May 2009|May 19, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905723||138756|
NCT00901238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTB1|Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma|Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma|Chemosurgery|Weill Medical College of Cornell University|No|Completed|May 2006|July 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Month|N/A|No|||December 2009|December 16, 2009|May 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00901238||139094|
NCT00901251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VESOABCN02|Reproducibility Study of Over Active Bladder Symptom Score [OABSS]|Reproducibility Study of OABSS and Its Response to Treatment - Part 1: Reproducibility -|RESORT|Astellas Pharma Inc|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Symptomatic OAB patients having urgency episodes|March 2011|March 13, 2011|May 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00901251||139093|
NCT00901264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Master Study DiaTech Oncology|Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients|Correlation of the Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients|MiCK|DiaTech Oncology|No|Completed|December 2008|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|||Both|N/A|N/A|No|Non-Probability Sample|Cancer Patients for whom chemotherapy is planned.|November 2012|November 12, 2012|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901264||139092|
NCT00901524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000859-10|ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV|ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360μg/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, With Accompanying Measures) on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV.|ETOC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|June 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||October 2012|March 28, 2013|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00901524||139072|
NCT00901888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS/09/019/26905 - 1a|Interaction of Apelin and Angiotensin in the Human Forearm Circulation|Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man||University of Edinburgh|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2010|August 9, 2010|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00901888||139044|
NCT00901901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12917|Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma|A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)|SEARCH|Bayer|Yes|Active, not recruiting|May 2009|December 2016|Anticipated|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|732|||Both|18 Years|N/A|No|||January 2016|March 17, 2016|May 13, 2009|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00901901||139043|
NCT00901914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO59.08|Study of rBet v1 Tablets|A Multi-national, Randomised, DBPC, Phase II Study to Assess the Efficacy and Safety of Three Doses of SLIT Administered as rBet v 1 Tablets Once Daily to Patients Suffering From Birch Pollen Rhinoconjunctivitis||Stallergenes|No|Completed|October 2008|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|483|||Both|18 Years|65 Years|No|||February 2010|June 26, 2013|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00901914||139042|
NCT00902252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0196-08-A720|Multi-National Phase III Vitala™ 12-Hour Wear Test|Multi-National Phase III Vitala™ 12-Hour Wear Test||ConvaTec Inc.|No|Completed|April 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902252||139017|
NCT00902265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS33|Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)|Efficacy and Safety of Nocturin 0.1 mg Tablets in Treatment of Nocturia in Patients With Nocturnal Polyuria, Lower Urinary Tract Symptoms (LUTS) and Benign Prostate Syndrome (BPS).||Ferring Pharmaceuticals|No|Completed|February 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|138|||Male|18 Years|65 Years|No|Non-Probability Sample|private practices|April 2011|April 15, 2011|May 14, 2009||No||No|March 15, 2011|https://clinicaltrials.gov/show/NCT00902265||139016|
NCT00902538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8635-A-E303|Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension|Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone||Daiichi Sankyo Inc.|No|Completed|April 2009|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|2204|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|May 13, 2009|Yes|Yes||No|September 6, 2011|https://clinicaltrials.gov/show/NCT00902538||138995|
NCT00902551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-200703-FC012|DNA Cytometry for Cervical Cancer Screening in China|Comparison of DNA Image Cytometry and Conventional Cytology for Cervical Cancer Screening in China|DNACIC|Nanjing Medical University|Yes|Completed|January 2007|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25000|Samples With DNA|Cervical samples were taken through cervical brush. Feulgen method is used to determine the      amount of DNA.|Female|20 Years|65 Years|No|Probability Sample|Healthy women|November 2009|November 9, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902551||138994|
NCT00902213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAQOL|Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia|Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia: A Nursing Trial|PAQOL|St. Jude Children's Research Hospital|Yes|Completed|November 2009|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|4 Years|18 Years|No|||November 2015|November 16, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902213||139019|
NCT00902200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-12286-CS201|A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)|A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 Ophthalmic Solution 0.05%, 0.1% and 0.25% in Patients With Elevated Intraocular Pressure||Aerie Pharmaceuticals|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|89|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902200||139020|
NCT00902512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481267|Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations|Relative Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations In Healthy Volunteers Under Fasting Conditions.||Pfizer|No|Completed|April 2009|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 30, 2011|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902512||138997|
NCT00903136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000641937|Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus|Screening for Barrett's Esophagus With an Ultrathin Scanning Fiber Endoscope||National Cancer Institute (NCI)||Recruiting|May 2009|||December 2011|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Screening|||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2010|January 9, 2014|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903136||138951|
NCT00903149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|977468299|Long-term Effect of The Mother Infant Transaction Program (MITP)|Long-term Effect of The Mother Infant Transaction Program (MITP)|2007/2/0150|Oslo University Hospital|Yes|Active, not recruiting|January 2007|December 2011|Anticipated|February 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|||Both|35 Months|37 Months|Accepts Healthy Volunteers|Probability Sample|The cohort is 42 preterm infants in the intervention group, 40 preterm and 40 full term in        control groups.|July 2011|July 20, 2011|May 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00903149||138950|
NCT00903370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078 0004|Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery|Surgical Ablation Versus No Surgical Ablation for Patients With Persistent or Longstanding Persistent Atrial Fibrillation (AF) Undergoing Mitral Valve Surgery||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|January 2010|September 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903370||138933|
NCT00903916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3024-04003|Effect of Antipsychotics on Appetite Regulation|Effect of Weight-increasing Psychotropic Medications on Appetite Regulation|ADAPT|University of North Carolina, Chapel Hill|No|Completed|August 2007|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|Samples With DNA|whole blood, serum, plasma|Both|18 Years|40 Years|No|Non-Probability Sample|patients ages 18 to 40 years of age who are early in treatment (i.e., started treatment in        the past month) with 1 of 4 antipsychotic medications (olanzapine, risperidone,        ziprasidone, aripiprazole)|April 2012|April 2, 2012|May 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00903916||138893|
NCT00926081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK056/2007|Exercise Training Versus Best Medical Treatment Only in Peripheral Artery Disease|Exercise Training Versus Best Medical Treatment Only in Peripheral Artery Disease||Medical University of Vienna|No|Recruiting|November 2007|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2011|December 30, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926081||137218|
NCT00926328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0507-PL-SP-CT-BS|Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis|Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis||Colgate Palmolive|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 8, 2013|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT00926328||137199|
NCT00926601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0906-006-281|Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis|Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis||Seoul National University Hospital|No|Enrolling by invitation|June 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Sera of TB patient|Both|18 Years|N/A|No|Non-Probability Sample|Pulmonary tuberculosis|June 2012|June 13, 2012|June 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00926601||137178|
NCT00926900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB636 D6 2006-007090-72|The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes|The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes|SFB636D6|Central Institute of Mental Health, Mannheim|Yes|Recruiting|March 2009|||April 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|65 Years|No|||November 2011|November 24, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926900||137157|
NCT00927199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:071|Efficacy of High-oleic Canola and Flaxseed Oils for Hypercholesterolemia and Cardiovascular Disease Risk Factors|Efficacy of Consumption of High-oleic Canola and Flaxseed Oils in the Management of Hypercholesterolemia and Other Cardiovascular Risk Factors||University of Manitoba|Yes|Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|36|||Both|18 Years|65 Years|No|||January 2013|January 31, 2013|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00927199||137134|
NCT00927472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALG-0817|Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice|A Multi-Center Phase III Study to Evaluate Ovide Lotion 0.5% Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects With Pediculosis Capitis||Taro Pharmaceuticals USA|No|Completed|August 2009|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|254|||Both|2 Years|N/A|No|||July 2014|July 9, 2014|June 23, 2009|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT00927472||137113|
NCT00905372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6747|Effect of LY2062430 on the Progression of Alzheimer's Disease|Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo|EXPEDITION|Eli Lilly and Company|Yes|Completed|May 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|55 Years|N/A|No|||May 2012|September 18, 2012|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905372||138783|
NCT00936975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-01292|Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases|A Phase 2, Multicenter Evaluation of 18F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant Prostate Cancer and Bone Metastases (BMS #180-279)||National Cancer Institute (NCI)||Completed|September 2009|December 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Male|18 Years|N/A|No|||December 2014|June 22, 2015|July 9, 2009|Yes|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT00936975||136392|
NCT00937248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0086-CE|Cone Beam Computed Tomography (CT) (CBCT) With and Without a Customized Vacuum Immobilization Device (CVID)|A Randomized Study Evaluating Set-up Reproducibility Using Cone Beam CT (CBCT) With and Without a Customized Vacuum Immobilization Device (CVID) in Rectal Cancer Patients Treated With Preoperative Pelvic Radiation Therapy||University Health Network, Toronto|No|Active, not recruiting|April 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00937248||136372|
NCT00901537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58358|Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer|Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck||Loma Linda University|No|Terminated|February 2009|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|May 12, 2009|No|Yes|Sponsor terminated due to no enrollments within last 4 months.|No||https://clinicaltrials.gov/show/NCT00901537||139071|
NCT00901927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0204|Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma|A Phase II Study of Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma||M.D. Anderson Cancer Center|No|Completed|May 2009|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|May 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901927||139041|
NCT00901940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/04|Understanding the Immune Response to Meningitis Vaccines|Single Centre Open-Label Randomised Trial of Meningococcal Serogroup ACYW-135 B Cell Response to Primary & Booster Doses of ACWY Conjugate Vaccine & Primary Dose of ACWY Polysaccharide With Booster Dose of ACWY Conjugate in Adults||University of Oxford|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|December 4, 2014|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901940||139040|
NCT00901953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2006.3376|Vestibular System in Migrainous Vertigo Patients|Do Migrainous Vertigo Patients Have More Hypersensitivity in Their Vestibular System Than Migraine Patients Without Vertigo?||University of Bergen|Yes|Enrolling by invitation|May 2007|September 2009|Anticipated|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|65|||Both|16 Years|61 Years|Accepts Healthy Volunteers|Non-Probability Sample|Migraine patients: primary care clinic        Migrainous vertigo patients: Neurological outpatients clinic, Sorlandet Hospital HF,        Kristiansand and Spesialistsenteret, Tollbodgata 4, Kristiansand.|May 2009|May 14, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901953||139039|
NCT00901966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909143|Sun Exposure and Melanoma in Agricultural Workers|Sun Exposure and Melanoma in Agricultural Workers||National Institutes of Health Clinical Center (CC)||Completed|May 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|892|||Both|18 Years|100 Years|No|||January 2016|January 29, 2016|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901966||139038|
NCT00902278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 13000|Immune Responses Induced by Different Licensed Influenza Vaccines|Immune Response Induced by Different Manufacturers of Influenza Vaccines||University of Massachusetts, Worcester|No|Active, not recruiting|October 2008|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902278||139015|
NCT00902564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12132A|Escitalopram in Patients With Generalized Anxiety Disorder|Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia||H. Lundbeck A/S|No|Completed|March 2009|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||May 2011|May 11, 2011|May 14, 2009||No||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00902564||138993|
NCT00902824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI P002|Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine|Phase I Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TBC-M4 (MVA Based HIV Vaccine) Alone or in a Prime-Boost Regimen With ADVAX, DNA HIV Vaccine||International AIDS Vaccine Initiative|Yes|Completed|November 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 8, 2013|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902824||138973|
NCT00902811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YNG0901|Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria|Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria|ACT|Medecins Sans Frontieres|No|Recruiting|December 2008|December 2009|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|600|||Both|6 Years|N/A|No|||May 2009|May 14, 2009|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00902811||138974|
NCT00902525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZETAL07|Zevalin Twice in Aggressive Non-Hodgkin Lymphoma|Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.||Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie|Yes|Terminated|January 2008|September 2011|Actual|January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||December 2012|December 28, 2012|May 14, 2009||No|After enrolling 25 patients an interim analysis was done.The study was discontinued in the    absence of the minimum number of 6 patients free of events|No||https://clinicaltrials.gov/show/NCT00902525||138996|
NCT00903383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol LX3305.1-201-RA|Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate|A Phase 2, Multi-center, Randomized, Double Blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy||Lexicon Pharmaceuticals|No|Completed|July 2009|||September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|208|||Both|18 Years|75 Years|No|||November 2011|November 11, 2011|May 14, 2009|Yes|Yes||No|October 3, 2011|https://clinicaltrials.gov/show/NCT00903383||138932|
NCT00903669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATessitore|Anthropometric Angular Measurement to Determine Muscle Tonus in Patients With Peripheral Facial Paralysis|Anthropometric Angular Measurement to Determine Muscle Tonus in Patients With Peripheral Facial Paralysis|PF|University of Campinas, Brazil|No|Completed|January 2005|February 2006|Actual|September 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|20 Years|70 Years|No|Non-Probability Sample|Patients diagnosed with PFP treated in the Hospital of Unicamp|May 2009|May 14, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903669||138912|
NCT00935337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34556|Follow-up of a Study Examining Sleep Management in United States Veterans|A Pilot Study of Two Contrasting Intervention Programs for Sleep Management - Part II||University of Utah|Yes|Completed|April 2009|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 23, 2011|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00935337||136518|
NCT00935571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090708|Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia|Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia||Asan Medical Center|No|Active, not recruiting|October 2007|September 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled to undergo elective thoracotomy of lung surgery|July 2009|July 8, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935571||136500|
NCT00903929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00028043|Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation|Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation||University of Rochester|Yes|Active, not recruiting|December 2009|||December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||April 2012|October 26, 2015|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903929||138892|
NCT00903942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00022397|Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)|A Modified Two Stage Phase II Study of Combination Abraxane and Radiation for Stage III Non-Small Cell Lung Cancer||University of Rochester|No|Withdrawn|March 2008|||March 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|May 15, 2009|Yes|Yes|funding was withdrawn from Drug company|No||https://clinicaltrials.gov/show/NCT00903942||138891|
NCT00904202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3220-009|A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions||Endo Pharmaceuticals|No|Completed|January 2003|||June 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904202||138871|
NCT00926913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7002-R|Investigating Optical and Neural Causes of Vision Loss|Investigating Optical and Neural Causes of Vision Loss||VA Office of Research and Development|No|Withdrawn|December 2014|July 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy subjects and patients diagnosed with age-related macular degeneration and        central vision loss will participate in the study.|April 2015|April 3, 2015|June 22, 2009||No|Project has ended|No||https://clinicaltrials.gov/show/NCT00926913||137156|
NCT00927212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#76 REV 00|Topical Application of AS101 for the Treatment of Atopic Dermatitis|Randomized Double Blind Uncontrolled Pilot Study to Compare 2% and 4% AS101 Ointment for the Treatment of Atopic Dermatitis||BioMAS Ltd|No|Terminated|June 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||June 2011|July 16, 2014|June 23, 2009||No|The trial started and halted due sponsor's considerations.|No||https://clinicaltrials.gov/show/NCT00927212||137133|
NCT00927485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol A2210108-UPR|Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)|Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)||University of Puerto Rico|Yes|Recruiting|November 2007|November 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|85 Years|No|||December 2014|December 3, 2014|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927485||137112|
NCT00927771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-01-01|Azelaic Acid Versus Hydroquinone in Melasma|Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma||Callender Center for Clinical Research|No|Recruiting|June 2009|December 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|89 Years|No|||June 2009|June 24, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927771||137090|
NCT00927784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1093|Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD|The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Bridge to Transplant Patients||Icahn School of Medicine at Mount Sinai|Yes|Terminated|August 2009|February 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|June 23, 2009|No|Yes|The enrollment has been terminated by the NHLBI for administrative reasons.|No||https://clinicaltrials.gov/show/NCT00927784||137089|
NCT00905385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0091|Nontypeable H. Influenzae in Healthy Adults|Phase I/II Single-Site, Randomized and Double-Blinded Trial to Further Characterize the HCD50, HCD90 and Transmissibility of Nontypeable Haemophilus Influenzae in a Human Colonization Model in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|15|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||July 2010|April 4, 2013|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905385||138782|
NCT00905710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChromoLynch|Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome|Chromoendoscopy in Lynch Syndrome Patients|ChromoLynch|University Medical Center Groningen|Yes|Active, not recruiting|September 2008|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|20 Years|70 Years|No|||December 2014|December 8, 2014|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905710||138757|
NCT00936988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000159|A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism|A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism||Amgen||Completed|November 2000|December 2005|Actual|June 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|June 4, 2009||||No||https://clinicaltrials.gov/show/NCT00936988||136391|
NCT00937261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIRN 2008-6382|Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning|Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning||University of California, Irvine|Yes|Recruiting|July 2009|January 2011|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|60 Years|No|||October 2010|October 27, 2010|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937261||136371|
NCT00937508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0585-AE|Smoking Cessation Program in the Preadmission Clinic|A Double Blind Randomized Placebo Controlled Study, for Smoking Cessation in Preadmission Clinic. the Use of a Teachable Moment||University Health Network, Toronto|Yes|Recruiting|June 2008|June 2011|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|N/A|No|||January 2010|April 7, 2010|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937508||136352|
NCT00937521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P16|Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants|A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants||Novartis||Completed|July 2009|February 2012|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|1507|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||March 2015|March 17, 2015|June 29, 2009||No||No|February 13, 2015|https://clinicaltrials.gov/show/NCT00937521||136351|
NCT00933426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0606|Lenalidomide and Paclitaxel in Prostate Cancer|A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases||M.D. Anderson Cancer Center|No|Terminated|August 2009|||December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|18 Years|N/A|No|||December 2015|December 10, 2015|July 3, 2009|Yes|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00933426||136663|
NCT00933439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duloxetine|Assessment of Cognitive Functioning Before and After Treatment With Duloxetine|Assessment of Cognitive Functioning Before and After Treatment With Duloxetine|DULOX|University of Texas Southwestern Medical Center|No|Completed|February 2005|September 2007|Actual|September 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|45 Years|No|||August 2013|August 9, 2013|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933439||136662|
NCT00902577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01912|MRI and PET Scan Using 18F-Fluoromisonidazole In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme|Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI||National Cancer Institute (NCI)||Active, not recruiting|August 2009|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902577||138992|
NCT00902837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3503|OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects|Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee &/or Hip Taking Oxycodone Equivalent of 20 - 80 mg/Day as Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Subjects Taking Oxycodone Prolonged Release Tablets (OxyPR) Alone.||Mundipharma Research GmbH & Co KG|No|Completed|May 2009|July 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902837||138972|
NCT00934778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0708/18|Minimally Invasive Endoscopy in Diffuse Lung Disease|Evaluation of Two Minimally Invasive Endoscopic Techniques for the Diagnosis of the Diffuse Lung Diseases.||Royal Brompton & Harefield NHS Foundation Trust|No|Enrolling by invitation|June 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|16 Years|N/A|No|||February 2012|February 3, 2012|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00934778||136560|
NCT00935064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29011|The Effect of Renin Inhibition on Nerve Function in Diabetes|Effect of Renin Inhibition on Cardiovascular Autonomic Nerve Function in Diabetes||Christiana Care Health Services|No|Completed|June 2009|April 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 7, 2009||No||No|December 31, 2012|https://clinicaltrials.gov/show/NCT00935064||136539|
NCT00934791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004315|Polycystic Liver Disease in Kidney Transplant|Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease||Mayo Clinic|No|Terminated|February 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|July 6, 2009|Yes|Yes|Terminated due to inadequate enrollment|No|February 4, 2013|https://clinicaltrials.gov/show/NCT00934791||136559|This study was terminated due to inadequate enrollment, no data was collected on the participant.
NCT00934804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19183|Accuracy of the Galilei Analyzer to Calculate the Effective Corneal Power After Corneal Refractive Surgery|Accuracy of the Galilei Analyzer to Calculate the Effective Corneal Power After Corneal Refractive Surgery|Galilei|Medical University of South Carolina|No|Terminated|June 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||October 2009|August 4, 2011|July 6, 2009||No|Principal Investigator separating employment from University.|No||https://clinicaltrials.gov/show/NCT00934804||136558|
NCT00935584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-196|Patient Centered Evaluation of Computerized Patient Records System|Patient Centered Evaluation of Computerized Patient Records System|PACECPRS|VA Office of Research and Development|No|Completed|May 2010|April 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|151|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 7, 2009||No||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00935584||136499|Study limitations include inability to capture EHR activity outside the visit, study only primary care providers at a single organization (VA) and only one EHR system, this limits generalizability of the findings to other setting.
NCT00935870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005-3|Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study|Bioactive Glass (S53P4) as Bone Graft Substitute in Operative Treatment of Depressed Lateral Condyle Fractures, Benign Bone Tumour Cavities and in Spinal Fusion - a 10 Years Follow-up and Bone Density Study.||Vivoxid Ltd|No|Completed|January 2008|February 2009|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|63|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who participated to previous clinical investigations with bioactive glass about        10 years ago.|July 2009|July 8, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935870||136477|
NCT00926939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA023469|Technological Innovations in Behavioral Treatments for Cigarette Smoking|Technological Innovations in Behavioral Treatments for Cigarette Smoking||National Development and Research Institutes, Inc.|No|Completed|June 2009|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00926939||137154|
NCT00927225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-104|Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic|Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic.||Hvidovre University Hospital|No|Completed|September 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||June 2009|June 23, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927225||137132|
NCT00927238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA-LTDR-0701|XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)|A Pivotal, Multi-Center, Clinical Trial Evaluating The Safety And Effectiveness of The Lumbar TDR Device In Patients With Single-Level Lumbar Degenerative Disc Disease|XL TDR|NuVasive|Yes|Completed|July 2009|July 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|246|||Both|18 Years|70 Years|No|||July 2015|July 28, 2015|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927238||137131|
NCT00927498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFA 0701|A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old|A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old.||Acute Leukemia French Association||Completed|December 2007|July 2013|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|50 Years|70 Years|No|||July 2013|July 10, 2013|April 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00927498||137111|
NCT00927511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIDeS|A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)|A Phase II Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) (Fulvestrant Intensity Density Study - Studio FIDeS)|FIDeS|Regina Elena Cancer Institute|No|Recruiting|October 2008|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Female|45 Years|85 Years|No|||June 2009|July 21, 2011|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927511||137110|
NCT00927797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-278/2004|Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)|Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas|PERLL|Heidelberg University|Yes|Active, not recruiting|February 2005|January 2012|Anticipated|January 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|185|||Both|18 Years|N/A|No|||June 2009|June 24, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927797||137088|
NCT00936676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/501|ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects|An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study||Teva Pharmaceutical Industries|No|Completed|July 2009|March 2013|Actual|March 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|684|||Both|N/A|N/A|No|Non-Probability Sample|Only those who participated in the ADAGIO trial, and who sign an approved informed consent        form, will be included in the follow-up study|May 2014|May 8, 2014|July 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00936676||136415|
NCT00936689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD01|Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE|Treatment of Hepatocellular Carcinoma (HCC)by Selective Traditional Chemoembolization(TACE)Versus Selective TACE Via Microspheres Loaded With Doxorubicin: a Multicentre,Randomized,Open Label,Controlled Study.|PRECISION-IT|University of Bologna|No|Completed|March 2008|December 2012|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||December 2012|December 21, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936689||136414|
NCT00937001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081235|Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness|Investigating the Histopathological and Clinical Significance of Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness|MUSIC Plus|Vanderbilt University|Yes|Active, not recruiting|November 2008|December 2016|Anticipated|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00937001||136390|
NCT00937274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.11.INF|Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution|Randomized, Double Blind Placebo-controlled Studies to Evaluate the Effect of an Orally-fed Escherichia Coli (E. Coli) Phage in the Management of ETEC and EPEC Induced Diarrhea in Children||Nestlé|No|Terminated|August 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Male|6 Months|24 Months|No|||November 2013|November 12, 2013|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00937274||136370|
NCT00937287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP 36701|Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters|Understanding HPV Vaccination Among Rural African American Primary Caregivers and Daughters||University of Georgia|No|Completed|July 2009|July 2012|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|410|||Female|13 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|The sample will include rural, female African American youth aged 13-17 (n=200) and their        primary caregivers (n=200) who reside in the same household.|August 2013|August 12, 2013|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937287||136369|
NCT00937534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-104|Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers|An Open Label, Single-dosing, and Parallel Study in Healthy Elderly and Young Male Volunteers.|Fimasartan|Boryung Pharmaceutical Co., Ltd|No|Completed|January 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Male|19 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 2, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00937534||136350|
NCT00933452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006L01603|A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects|A Open Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Safety of Duloxetine in Chinese Han Healthy Subjects||Shanghai Mental Health Center|Yes|Completed|July 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|July 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00933452||136661|
NCT00933400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN PA 4005|CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS|Randomized Controlled Study of a Rapid "Rule Out" Strategy Using CT Coronary Angiogram Versus Traditional Care for Low- to Intermediate-Risk ED Patients With Potential Acute Coronary Syndromes||American College of Radiology Imaging Network|Yes|Active, not recruiting|July 2009|April 2012|Anticipated|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1365|||Both|30 Years|N/A|No|||March 2012|March 13, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933400||136665|
NCT00933413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04841|Dermacyd Silver Frutal (Lactic Acid) - Acceptability.|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow-up (Dermacyd Silver Frutal (Lactic Acid)).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933413||136664|
NCT00933673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 09-02|New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma|Phase II Study of L-asparaginase Plus DICE Regimen in Patients With Stage I/II NK/T-cell Lymphoma||Fudan University|No|Recruiting|June 2009|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|14 Years|75 Years|No|||February 2012|February 16, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00933673||136644|
NCT00933686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27560|Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome|Growth Hormone Treatment of Severe Fibromyalgia Syndrome Associated With Functional Failure of Somatotropic Axis. A Multicentre, Randomized, Double-blind, Placebo-controlled Study.||Merck KGaA|No|Completed|December 2007|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|113|||Female|18 Years|N/A|No|||August 2013|August 1, 2013|July 2, 2009||No||No|April 15, 2013|https://clinicaltrials.gov/show/NCT00933686||136643|
NCT00934505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB08-02|Predictive Value of Pet Scan With Fdg Performed During Irradiation in Patients Treated for Oesaphagus Carcinoma|Predictive Value of FDG-TEP During Exclusive Chemo-Radiotherapy (CRT) in Patients With Oesophageal Carcinoma Cancer on the One-Year Survival (RTEP3)|RTEP3|Centre Henri Becquerel|Yes|Recruiting|May 2009|April 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Diagnosed patients a carcinoma of the oesophagus histologiquement proved|March 2011|May 24, 2012|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934505||136581|
NCT00934518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-066|Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma|Image Guided Intensity Modulated Reirradiation With Concurrent Cetuximab in the Treatment of Locoregionally Confined Relapsed Squamous Cell Carcinoma of the Head and Neck||Penn State University|Yes|Terminated|July 2009|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2009|July 28, 2010|July 7, 2009|Yes|Yes|Inadequate patient accrual|No||https://clinicaltrials.gov/show/NCT00934518||136580|
NCT00934245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090422004|Direct and Indirect Protection by Influenza Vaccine Given to Children in India|Direct and Indirect Protection by Influenza Vaccine Given to Children in India||University of Alabama at Birmingham|Yes|Completed|September 2009|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|4598|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2013|February 21, 2013|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934245||136601|
NCT00934531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-427|Donepezil and the Risk of Falls in Seniors With Cognitive Impairment|Can Cognitive Enhancers Reduce the Risk of Falls in Older People With Mild Cognitive Impairment? A Randomized Controled Trial||Lawson Health Research Institute|No|Active, not recruiting|September 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|65 Years|N/A|No|||March 2016|March 1, 2016|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934531||136579|
NCT00935090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000647210|3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer|Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|September 2009|September 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|120 Years|No|||February 2016|February 3, 2016|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935090||136537|
NCT00935103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117|The Effectiveness of Skill-Based HIV Psychoeducation in IV-Drug Abuser for Reducing High-risk Behavior|The Effectiveness of Skill-Based HIV Psychoeducation in IV-Drug Abuser for Reducing High-risk Behavior||Iran University of Medical Sciences|Yes|Completed|March 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|120|||Both|18 Years|N/A|No|||July 2009|August 24, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935103||136536|
NCT00935077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL091841|A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities|A Collaborative Model to Improve BP Control and Minimize Racial Disparities-CCC||University of Iowa|Yes|Completed|January 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|1441|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00935077||136538|
NCT00926640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090173|A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers|A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin||National Institutes of Health Clinical Center (CC)||Suspended|June 2009|March 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|99 Years|No|||July 2015|February 20, 2016|June 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00926640||137175|
NCT00927563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901M58441|Tolcapone Treatment of Pathological Gambling|Tolcapone Treatment of Pathological Gambling: An Open-Label Study||University of Chicago|Yes|Completed|June 2009|July 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|21 Years|75 Years|No|||January 2014|January 17, 2014|June 12, 2009|No|Yes||No|September 11, 2013|https://clinicaltrials.gov/show/NCT00927563||137106|This study did not assess treatment effects beyond an 8-week treatment period and these results may not generalize to the larger population of people with PG.
NCT00926952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6010|Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion|Safety and Efficacy of Photodynamic Therapy With Short Incubation Methylaminolevulinate Without Occlusion in the Treatment of Actinic Keratoses.||Innovaderm Research Inc.|No|Completed|July 2009|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2011|September 1, 2011|June 23, 2009||No||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00926952||137153|
NCT00927251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4296|Model 4296 Left Ventricular (LV) Lead Study|Model 4296 Left Ventricular Lead Study|4296|Medtronic Cardiac Rhythm Disease Management|No|Completed|June 2009|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|N/A|N/A|No|||June 2010|December 1, 2010|June 23, 2009|No|Yes||No|June 7, 2010|https://clinicaltrials.gov/show/NCT00927251||137130|
NCT00928135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xylitol, IND 66,427|Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects|Randomized Controlled Study of Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Hospitalized Patients With Exacerbation of Cystic Fibrosis||University of Iowa|Yes|Active, not recruiting|June 2009|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|12 Years|N/A|No|||June 2015|June 4, 2015|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928135||137062|
NCT00928382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090113|A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression|A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression||National Institutes of Health Clinical Center (CC)||Completed|March 2009|April 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|30|||Both|18 Years|90 Years|No|||April 2012|April 11, 2012|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00928382||137043|
NCT00936702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0871|Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary|A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)||Alliance for Clinical Trials in Oncology|Yes|Completed|September 2009|August 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936702||136413|
NCT00937014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.35.INF|Assessment of Growth of Infants Fed a New Formula|Assessment of Growth of Infants Fed a Starter Formula With a Whey-Isolate Enriched in Lactoferrin||Nestlé|No|Completed|February 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|180|||Both|N/A|17 Days|Accepts Healthy Volunteers|||June 2013|June 24, 2013|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937014||136389|
NCT00937027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Syntrix-AMT-PSO-101|Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis|A Randomized Phase 1 Study Comparing The Safety and Oral Pharmacokinetics Of 0.25 mg and 1.0 mg Aminopterin Tablets In Human Subjects With Psoriasis||Syntrix Biosystems, Inc.|Yes|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|21 Years|59 Years|No|||November 2012|November 1, 2012|July 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00937027||136388|
NCT00937300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH0908|T-cell Based Immunotherapy for Head and Neck Cancer|T-cell Based Immunotherapy for Treatment of Patients Squamous Cell Carcinoma in the Oral Cavity. A Pilot Study.||Herlev Hospital|Yes|Withdrawn|June 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||November 2011|November 22, 2011|July 10, 2009||No|The patients eligible for this trial do not exist anymore due to change in procedures.|No||https://clinicaltrials.gov/show/NCT00937300||136368|
NCT00933166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-335-C-014v2|Assessing the Performance of Lotrafilcon A Lenses During a Three Month Period|Assessing the Performance of Lotrafilcon A Lenses During a Three Month Period||Alcon Research|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Both|N/A|N/A|No|||January 2012|June 26, 2012|July 2, 2009|Yes|Yes||No|December 2, 2010|https://clinicaltrials.gov/show/NCT00933166||136683|
NCT00933465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMMED0874|Imodium Syrup Versus Imodium Tablets for Faecal Incontinence|Single Blinded Randomised Cross-over Study of Imodium Tablets Versus Imodium Syrup for the Treatment of Faecal Incontinence||University Hospital Southampton NHS Foundation Trust.|No|Withdrawn|October 2009|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||November 2014|November 17, 2014|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933465||136660|
NCT00933478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clark Bartlett|A Trial of Clay Weight on the Ear Drum for Patulous Eustachian Tube|A Trial of Clay Weight on the Ear Drum for Patulous Eustachian Tube||Nova Scotia Health Authority|Yes|Not yet recruiting|July 2009|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|5 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients will be selected if they meet the diagnostic criteria for patulous eustachian        tube.|July 2009|July 7, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00933478||136659|
NCT00933699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04803|Dermacyd PH_DESILSTY_FL (Lactic Acid) - Acceptability - Stay on Floral.|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up - Dermacyd PH_DESILSTY_FL (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|32|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933699||136642|
NCT00933959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27522|Pilot Study on Sleep Management for US Veterans|A Pilot Study of Two Contrasting Intervention Programs for Sleep Management||University of Utah|Yes|Completed|March 2008|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2009|July 6, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00933959||136623|
NCT00933946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04842|Dermacyd Silver Frutal (Lactic Acid) - Compatibility.|Study for Dermatological Evaluation of Topic Compatibility Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd Silver Frutal (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933946||136624|
NCT00934544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2352|Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial|A Randomized Study of INC424 (INCB018424) Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis||Novartis|Yes|Completed|July 2009|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 6, 2009|Yes|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT00934544||136578|
NCT00934817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIME_L_02279|Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg|An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M 1mg/500mg and 2mg/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Subjects||Handok Pharmaceuticals Co., Ltd.|No|Completed|March 2007|August 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 7, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934817||136557|
NCT00935116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR001cl|Etoricoxib for Postoperative Pain After Thyroid Surgery|Effect of the Administration of Etoricoxib on Postoperative Pain and Quality of Recovery in Patients Undergoing Thyroid Surgery||Hospital Padre Hurtado|No|Not yet recruiting|July 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|75 Years|No|||July 2009|July 7, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935116||136535|
NCT00935363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlyburideOATP2C9|Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK)|||University of California, San Francisco|No|Withdrawn|February 2010|April 2010|Anticipated|March 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935363||136516|
NCT00927836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX200-101|AXIS 2: AX200 for the Treatment of Ischemic Stroke|AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-controlled Phase II Trial|AXIS-2|Sygnis Bioscience GmbH & Co KG|Yes|Completed|May 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|85 Years|No|||August 2011|December 12, 2011|June 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927836||137085|
NCT00927303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-086-0609|The Spectralis-Cirrus Study|Comparison of Quality and Reproducibility of Retinal Thickness Measurements in Two Spectral Domain OCT- Machines||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|110|None Retained|male or femal persons age over 50 years with exudative age-related macular degeneration|Both|50 Years|N/A|No|Probability Sample|male or female persons aged more than 50 years with exudative age related macular        degeneration|June 2010|June 8, 2010|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927303||137126|
NCT00927810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2251E1|Long Term Study of Canakinumab (ACZ885) in Patients With Gout|A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Are Given Canakinumab at the Time of Gout Flare||Novartis||Completed|July 2009|||August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|80 Years|No|||May 2012|May 31, 2012|June 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927810||137087|
NCT00927823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1271001|A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients|A Phase 1, Open-Label, Dose-Escalation Study To Evaluate Safety, Pharmacokinetics, And Pharmacodynamics Of The PI3K/MTOR Inhibitor PF-04691502 In Adult Patients With Advanced Malignant Solid Tumors||Pfizer|No|Completed|December 2009|April 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|June 23, 2009|No|Yes||No|July 18, 2014|https://clinicaltrials.gov/show/NCT00927823||137086|
NCT00924313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080226|Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer|A Pilot Study of 11C-Acetate Positron Emission Tomography (PET) and 3 Telsa Magnetic Resonance Imaging (MRI) in Men With Prostate Cancer Undergoing Prostatectomy||National Institutes of Health Clinical Center (CC)|No|Completed|September 2008|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|June 17, 2009|Yes|Yes||No|July 12, 2012|https://clinicaltrials.gov/show/NCT00924313||137353|
NCT00936715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-203-0109|Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Subjects in United States|A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study||Gilead Sciences|No|Completed|August 2009|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||December 2015|December 11, 2015|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936715||136412|
NCT00936728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08C6|White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer|White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial||Mayo Clinic|Yes|Active, not recruiting|July 2009|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|21 Years|N/A|No|||March 2015|January 7, 2016|July 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00936728||136411|
NCT00937313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoR 07/16|The Pharmacokinetics and Potential Health Effects of Champagne Wine in Human Subjects|The Pharmacokinetics and Potential Health Effects of Champagne Wine in Human Subjects||University of Reading|No|Completed|July 2007|September 2008|Actual|February 2008|Actual|N/A|Observational|N/A||2|Actual|15|Samples Without DNA|plasma serum urine|Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|July 2009|July 10, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937313||136367|
NCT00933205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.16|An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.|An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.||Boehringer Ingelheim||No longer available|May 2004|||June 2008|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||October 2013|October 30, 2013|July 3, 2009||||No||https://clinicaltrials.gov/show/NCT00933205||136680|
NCT00933179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91557|FC Patch Low: Metabolism Study|A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (0.03mg/0.15mg) in a 21-day Regimen on Hemostatic Parameters in 30 Women Aged 18 182 35 Years Over 3 Treatment Cycles in Each Period||Bayer|Yes|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933179||136682|
NCT00933192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|muscle ultrasound|The Relationship Between Muscle Morphology and Muscle Strength|The Relationship Between Muscle Morphology and Muscle Strength||Karl Landsteiner Institute of Remobilization and Functional Health||Completed|July 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|52|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|outpatients or inpatients of the institute of physical medicine and rehabilitaion|April 2010|April 15, 2010|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933192||136681|
NCT00933738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0120.a|Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)||ECLIPSE 03|Biosite|No|Completed|December 2009|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Plasma samples to be retained for reference testing and banking.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing heparin bridging onto OAT with warfarin.|June 2011|June 21, 2011|July 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00933738||136639|
NCT00933712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04839|Dermacyd Silver Floral (Lactic Acid) - Compatibility.|Study for Dermatological Evaluation of Topic Compatibility. Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd Silver Floral (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933712||136641|
NCT00933972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22321|A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment|Effect of Renal Impairment on Pharmacodynamics and Pharmacokinetics of RO4998452: A Multiple-center, Open-label, Parallel Group Study Following Single Oral Dosing of RO4998452 to Type 2 Diabetes Patients With Varying Degrees of Renal Impairment.||Hoffmann-La Roche||Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|40 Years|80 Years|No|||March 2016|March 1, 2016|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00933972||136622|
NCT00933985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01936|Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia|A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination With Vincristine/Doxorubicin/Dexrazoxane, in Children With Relapsed/Refractory Solid Tumors or Leukemia||National Cancer Institute (NCI)||Terminated|June 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|21 Years|No|||April 2013|April 30, 2014|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00933985||136621|
NCT00934258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812111R|Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia|Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia||National Taiwan University Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|20 Years|79 Years||||November 2012|December 20, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934258||136600|
NCT00934557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProfGVHD1|Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation|Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation|ATG FRES|IRCCS Policlinico S. Matteo|Yes|Recruiting|March 2008|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Prevention|8|||42|||Both|1 Year|19 Years|No|||July 2009|July 7, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934557||136577|
NCT00934830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELI-107-04(REK)|Antibiotics Versus Therapeutic Ultrasound for Sinusitis|Antibiotics Versus Therapeutic Ultrasound for Treatment of Sinusitis: a Randomized Clinical Trial||Norwegian University of Science and Technology|No|Completed|January 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|15 Years|N/A|No|||October 2013|October 28, 2013|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934830||136556|
NCT00935129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005431ctil|Treatment Satisfaction of Using OmniPod System Compared With Conventional Insulin Pump in Adults With Type 1 Diabetes|Treatment Satisfaction of Using OmniPod System Compared With Conventional Insulin Pump in Adults With Type 1 Diabetes||Rabin Medical Center|No|Completed|August 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|35 Years|No|||February 2011|May 6, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00935129||136534|
NCT00935376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33669|Sleep Management in Cancer Survivors|A Pilot Study of Three Short-term Intervention Programs for Sleep Management in Cancer Survivors||University of Utah|Yes|Completed|May 2009|July 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 19, 2013|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00935376||136515|
NCT00935623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1518|Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans|Development of a Safe and Reproducible Human Sporozoite Challenge Model for Plasmodium Vivax in Healthy Adults in the United States|Pvivax|U.S. Army Medical Research and Materiel Command|No|Completed|April 2009|September 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00935623||136496|
NCT00927316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTP-A2003|E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)|Induced Asymptomatic E. Coli 83972 Bacteriuria in Patients With Recurrent Urinary Tract Infections and Bladder Dysfunction- is There a Protective Effect Against Recurrent Symptomatic Infections? A Blinded Placebo Controlled Cross-over Study.||Region Skane|No|Completed|March 2003|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|30|||Both|20 Years|85 Years|No|||November 2009|November 9, 2009|June 22, 2009||||No||https://clinicaltrials.gov/show/NCT00927316||137125|
NCT00927524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050116|Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls|An Open-Label, Randomized, Two-Period, Crossover Study to Characterize the Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls||Vanderbilt University|No|Completed|April 2005|December 2010|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927524||137109|
NCT00927537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13599|Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®|Data Collection on Hypertension and Its Treatment With Kinzal®/ Kinzalplus®||Bayer|No|Completed|April 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2052|||Both|18 Years|N/A|No|Non-Probability Sample|Community|September 2013|September 1, 2013|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927537||137108|
NCT00927550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAST_RD_FARM77Z3BL-5.1_132009|Lithium and Standard Therapy in Resistant Depression|Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial|LAST|Universita di Verona|Yes|Recruiting|June 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||September 2009|September 15, 2009|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927550||137107|
NCT00928408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070363|PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice|PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice||Amgen|No|Completed|October 2009|February 2012|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|305|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with primary HPT receiving cinacalcet in clinical practice|July 2014|July 18, 2014|June 25, 2009||No||No|February 5, 2013|https://clinicaltrials.gov/show/NCT00928408||137041|
NCT00928421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV014|An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins|An Open-label, Single-dose Pilot Study to Evaluate the Efficacy and Safety of Varisolve® (Polidocanol Endovenous Microfoam) 0.125% [0.2%] for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence||BTG International Inc.|No|Completed|June 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|75 Years|No|||February 2014|February 19, 2014|June 24, 2009|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT00928421||137040|
NCT00928434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS37|A Study of Degarelix in Patients With Prostate Cancer|A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment||Ferring Pharmaceuticals|No|Completed|May 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|405|||Male|18 Years|N/A|No|||September 2013|September 27, 2013|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928434||137039|
NCT00928161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0944|Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy|Evaluation and Treatment of Reflux Disease in Patients With Head and Neck Cancer Undergoing Radiation Therapy That Causes Significant Mucositis in the Reflux Field and Xerostomia||M.D. Anderson Cancer Center|No|Withdrawn|November 2012|||November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928161||137060|
NCT00936741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1073-415|An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome|An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome||Corcept Therapeutics|No|Completed|July 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|July 9, 2009|No|Yes||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00936741||136410|
NCT00936754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-RD-10-CLN2|Safety and Efficacy of a Single Dose of a Polyphenol-enriched Brown Seaweed Powder in Human|Safety and Efficacy of a Unique Dose of a Brown Seaweeds Powder Enriched in Polyphenols on Human|ICAST|innoVactiv Inc.|No|Completed|July 2009|January 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|23|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2010|January 18, 2010|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936754||136409|
NCT00934037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Core320|Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320 Detector Computed Tomography|Multi Center Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320-Detector Computed Tomography|Core320|Johns Hopkins University|Yes|Active, not recruiting|December 2009|September 2016|Anticipated|September 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|444|||Both|45 Years|85 Years|No|||September 2015|September 1, 2015|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00934037||136617|
NCT00934050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND005-AD251|ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease|A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease||Transition Therapeutics Ireland Limited|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|N/A|N/A|No|||May 2015|May 12, 2015|June 29, 2009|No|Yes||No|April 22, 2015|https://clinicaltrials.gov/show/NCT00934050||136616|
NCT00933491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-03|Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus|Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus: A Feasibility Cohort Study||University of Michigan|No|Completed|November 2008|December 2010|Actual|June 2010|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|Samples Without DNA|saliva and plaque biofilm|Both|40 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Type II diabetics and non diabetics with dental implants|October 2015|October 7, 2015|July 2, 2009||No||No|July 30, 2015|https://clinicaltrials.gov/show/NCT00933491||136658|
NCT00935688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT Consortium|Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area|An Examination of ACT Strategy in South-central Asia on Falciparum Malaria in a Context Where Vivax is the Major Species||London School of Hygiene and Tropical Medicine|Yes|Completed|May 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|4200|||Both|N/A|N/A|No|||February 2014|February 6, 2014|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935688||136491|
NCT00933725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007BAI20B014|Efficacy and Safety of Traditional Chinese Medicine Intervention for Women With Menopausal Syndrome|Efficacy and Safety of Combined Treatment of Herbs and TCM Emotion Treatment for Women With Menopausal Syndrome: A Multiple-centered Randomized Controlled Trial||Guangzhou University of Traditional Chinese Medicine|Yes|Completed|August 2009|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Female|41 Years|60 Years|No|||May 2010|June 15, 2012|July 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00933725||136640|
NCT00933998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMI-01|Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®|Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®||Carolina Musculoskeletal Institute|No|Completed|June 2006|||October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 28, 2014|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00933998||136620|
NCT00934271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSRT-SR-UFR|Fractionated Stereotactic Radiotherapy in Patients With Acromegaly|Fractionated Stereotactic Radiotherapy in Patients With Acromegaly. Single Centre Experience||Rigshospitalet, Denmark|No|Completed|January 2002|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|34|||Both|18 Years|N/A|No|Probability Sample|34 patients with active acromegaly despite medical therapy|October 2014|October 26, 2014|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934271||136599|
NCT00934570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-259|Activity and Metformin Intervention in Obese Adolescents|Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease|REACH|Lawson Health Research Institute|No|Completed|April 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|60|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||October 2012|October 3, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934570||136576|
NCT00934843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 17030|Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass|Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass||Medical University of South Carolina|No|Completed|March 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|N/A|30 Days|No|||September 2011|November 7, 2011|July 6, 2009||No||No|September 29, 2011|https://clinicaltrials.gov/show/NCT00934843||136555|Limitations of the current study include the lack of a true placebo group. Thus recommendations for or against intraoperative MP can not be made. The results of our trial do not preclude the efficacy of other glucocorticoid regimens.
NCT00935402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL091352-01A1|Sleep Deprivation and Energy Balance|Sleep Deprivation and Energy Balance|Sleep|St. Luke's-Roosevelt Hospital Center|No|Completed|November 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|30 Years|45 Years|Accepts Healthy Volunteers|||May 2010|February 22, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935402||136513|
NCT00936260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|individual reseacher|Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis|Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis||Ciudad Universitaria, Spain|No|Completed|January 1998|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|228|||Female|N/A|N/A|No|||January 1998|July 9, 2009|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936260||136447|
NCT00935389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-0903|Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria|Prospective Control Study of TW in the Treatment of LN Type V With Gross Proteinuria||Nanjing University School of Medicine|No|Completed|April 2009|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|60 Years|No|||July 2009|August 1, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935389||136514|
NCT00935662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2350C00001|A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses|A Randomised, Single-blind, Placebo-controlled, Two-centre Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD8329 After Single Ascending Oral Doses||AstraZeneca|No|Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|119|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 10, 2010|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935662||136493|
NCT00936052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBTC-2008-2|Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma|Phase II Pilot Trial of Hyperbaric Hyperoxygenation in Conjunction With Radiotherapy and Temozolomide In Adults With Newly Diagnosed Glioblastomas|HBO|Neurological Surgery, P.C.|Yes|Recruiting|December 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2010|July 15, 2010|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936052||136463|
NCT00927849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hypertensive anal canal|Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy|Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy||Mansoura University|Yes|Completed|September 2002|May 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|61 Years|Accepts Healthy Volunteers|||May 2009|May 7, 2009|March 23, 2009||No||No|March 23, 2009|https://clinicaltrials.gov/show/NCT00927849||137084|
NCT00928148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD465-201|The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo- and Active-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder||Shire||Completed|March 2004|October 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|86|||Both|18 Years|55 Years|No|||June 2009|June 23, 2009|June 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00928148||137061|
NCT00927862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154-001|Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin|The Clinical Impact of Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin in Patients Being Initiated on Oral Anticoagulation|Coumagen-II|Intermountain Health Care, Inc.|Yes|Completed|August 2008|June 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|2415|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|June 23, 2009||No||No|April 9, 2012|https://clinicaltrials.gov/show/NCT00927862||137083|
NCT00936871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271032|The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects|A Phase 1, Randomized, Single Dose, Placebo And Active Controlled, 3-Way Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects||Pfizer|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 1, 2010|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936871||136400|
NCT00937105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Daily Wear Corneal Infiltrative Event Study|Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study)|DWCIE|University Hospital Case Medical Center|Yes|Completed|November 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|218|||Both|15 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 27, 2014|July 9, 2009||No||No|July 1, 2013|https://clinicaltrials.gov/show/NCT00937105||136382|Mostly asymptomatic CIE events occurred which limited the ability to retrieve the lens worn (for culture) precisely at the time of CIE development; this may have hindered our ability to capture bioburden at the time of the adverse event.
NCT00937040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015058|Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate||Ortho-McNeil Janssen Scientific Affairs, LLC|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|65 Years|No|||July 2013|July 23, 2013|June 29, 2009|Yes|Yes||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00937040||136387|
NCT00936767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL0901|Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia|Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western|AMOS|University of Oxford|Yes|Withdrawn|October 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|16 Years|N/A|No|||October 2010|October 8, 2010|July 9, 2009||No|Did not get approval|No||https://clinicaltrials.gov/show/NCT00936767||136408|
NCT00936780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC001: V1.1|Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions|Safety and Efficacy of the Infinnium-Core™ Paclitaxel-Eluting Coronary Stent System for the Treatment of Patients With De Novo Coronary Lesions||Sahajanand Medical Technologies Pvt. Ltd.|No|Terminated|July 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|July 8, 2009||No|market demand from paclitaxel to sirolimus drug-eluting stent|No||https://clinicaltrials.gov/show/NCT00936780||136407|
NCT00936793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090186|Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers|Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|July 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|53|||Both|18 Years|60 Years|No|||February 2012|May 10, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936793||136406|
NCT00937326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113160|Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects|A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects||GlaxoSmithKline|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|225|||Both|30 Years|70 Years|No|||November 2011|December 1, 2011|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937326||136366|
NCT00934596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lund de-airing technique|CO2 Versus Lund De-airing Technique in Heart Surgery|CO2 Insufflation vs Lund De-airing Technique For Open Left Heart Surgery - Safety and Efficacy||Lund University|No|Completed|June 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|90 Years|No|||October 2013|October 7, 2013|July 7, 2009||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00934596||136574|This study included a total of 20 patients randomized to one of two groups with ten patients in each arms. The small number of study objects might be a potential limitation.
NCT00934609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-01SaarlandU|Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure|Effects of 12-weeks Endurance Training in Patients With Chronic Heart Failure Due to Dilated Cardiomyopathy|CHF|Saarland University|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|80 Years|No|||September 2009|September 17, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934609||136573|
NCT00934869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUR01-CTIL -HMO|Swelling or Malrotation of Metacarpal Shaft Fractures in the Evaluation of Rotational Deformity|Swelling or Malrotation of Metacarpal Shaft Fractures in the Evaluation of Rotational Deformity||Hadassah Medical Organization|No|Recruiting|August 2009|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|75 Years|No|Non-Probability Sample|Men and Women with isolated metacarpal fractures|March 2013|March 21, 2013|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934869||136553|
NCT00936247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0514|Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)|Prospective, Controlled, Single-blind, Bicentric, Randomized Study on the Safety of HES 130/0.42 Combined With a Bal. Electr. Sol. vs 5% Albumin Comb. With an Unbal. Electr. Sol. (NaCl 0.9%) in Pat. With Compensated Renal Failure||B. Braun Melsungen AG|No|Terminated|November 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2|||Both|50 Years|80 Years|No|||September 2010|September 27, 2010|July 8, 2009||No|organizational reasons at sites: low recruitment|No||https://clinicaltrials.gov/show/NCT00936247||136448|
NCT00934011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO_Protocol01|Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections|Comparative Study of C-reactive Protein vs. Procalcitonin to Guide Antibiotic Therapy in Patients With Severe Sepsis and Septic Shock Admitted to the Intensive Care Unit.||Federal University of Minas Gerais|Yes|Completed|September 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||June 2012|February 1, 2016|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934011||136619|
NCT00934024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#18521|Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers|Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers (GRAND)|GRAND|Medical University of South Carolina|Yes|Completed|April 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|21 Years|60 Years|No|||May 2010|October 31, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934024||136618|
NCT00934297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|049-2009|Visualization Tool for Investigation of Breast Lesions|Evaluation of a New Multi-modality Visualization Tool for Investigation of Breast Lesions||Sunnybrook Health Sciences Centre|No|Terminated|July 2009|July 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Female|21 Years|80 Years|No|Non-Probability Sample|Patients clinically suspicious for breast cancer will undergo the standard bilateral MRI        protocol, with the patient in the prone position and both breasts immobilized. Patients        with a BIRADS reading of 4 or 5 based on the initial MRI are called back for a second-look        US examination to determine if the lesion can be found using US imaging. If the lesion is        occult to US during this second-look examination, the radiologist may recommend a        follow-up high-resolution unilateral MRI to further characterize the lesion.        For this feasibility study, 10 patients with MRI-identified lesions that cannot be        visualized under the second-look ultrasound examination, and who will undergo the        recommended unilateral MRI follow-up will be asked to participate in our research study.|July 2011|July 27, 2011|July 6, 2009||No|The study was terminated as the PI left the institution.|No||https://clinicaltrials.gov/show/NCT00934297||136597|
NCT00934284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00014476|Effectiveness Study of Physical Therapy as an Adjunct to a Lumbar Therapeutic Selective Nerve Root Block|Effectiveness of Physical Therapy as an Adjunct to a Selective Nerve Root Block in the Treatment of Lumbar Radicular Pain From Disk Herniation||University of Utah|No|Completed|January 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|60 Years|No|||July 2009|July 7, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934284||136598|
NCT00934856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22572|A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer|An Open-label, Multi-center Study of the Safety and Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) With Docetaxel, and Potentially Pertuzumab, for Treatment for Patients With Advanced Breast Cancer||Hoffmann-La Roche||Completed|July 2009|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934856||136554|
NCT00935142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[18F]VM4-037|Non-invasive Imaging With [18F]VM4-037|Non Invasive Imaging of [18F]VM4-037 With Positron-Emission-Tomography (PET): A Phase I Trial|[18F]VM4-037|Maastricht Radiation Oncology|Yes|Withdrawn|January 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|June 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935142||136533|
NCT00936273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Double loop gain MCA 2009|Sleep Apnea and Periodic Breathing|Screening for Sleep Apnea Using Home Recording of the Double Loop Gain as a Measure of Periodic Breathing|DLI|Medical Center Alkmaar|No|Recruiting|June 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients suspected for sleep apnea syndrome|July 2009|July 9, 2009|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936273||136446|
NCT00936832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000637832|Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery|Front-line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study. (SUREMETS)||Federation Francophone de Cancerologie Digestive||Withdrawn|April 2009|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2009|March 3, 2014|July 8, 2009||No|because the sunitinib showed futility in anotehr trial|No||https://clinicaltrials.gov/show/NCT00936832||136403|
NCT00935675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TADDOR|Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment|||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||July 2009|September 1, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935675||136492|
NCT00936533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBSBTXA09|Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita|Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita - a Double-blind Placebo-controlled Phase II Proof of Concept Study||Uppsala University|No|Recruiting|May 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|N/A|No|||March 2011|March 8, 2011|July 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936533||136426|
NCT00936546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/183|A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy|A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy||University Hospital, Ghent|No|Active, not recruiting|June 2009|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936546||136425|
NCT00927576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6119-R|PC-Based Cognitive Rehabilitation for Traumatic Brain Injury (TBI)|PC-Based Cognitive Rehabilitation for TBI||VA Office of Research and Development|No|Completed|July 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|265|||Both|18 Years|78 Years|Accepts Healthy Volunteers|Non-Probability Sample|Controls subjects of various ages (approximately 230), and TBI patients (approximately        30).|July 2015|July 28, 2015|June 23, 2009||No||No|March 5, 2015|https://clinicaltrials.gov/show/NCT00927576||137105|Relatively small TBI group limits strength of conclusions. Not all of the results have yet been fully analyzed and subjected to peer-review.
NCT00936520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00029830|SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy|A Phase 1b, Randomized, Uncontrolled, Single-masked, Safety, Tolerability, and Pharmacokinetic Study of Multiple Doses of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Human Subjects Undergoing Elective Pars Plana Vitrectomy (PPV)||Johns Hopkins University|No|Recruiting|August 2009|September 2010|Anticipated|August 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||July 2009|December 7, 2009|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936520||136427|
NCT00936858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-049|RAD001 for Patients With Radioiodine Refractory Thyroid Cancer|A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|July 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936858||136401|
NCT00937417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0716|S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors||Southwest Oncology Group||Withdrawn|September 2008|||September 2009|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 10, 2009|No|Yes|Withdrawn because SWOG no longer pursuing this study at this time|No||https://clinicaltrials.gov/show/NCT00937417||136359|
NCT00936507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Smith|Does Portion Size Influence Intake of Low-Energy-Dense Foods in Preschool-Aged Children?|||University of Tennessee||Completed||||||Phase 0|Interventional|Intervention Model: Crossover Assignment|1||||||Both|3 Years|N/A||||July 2009|July 9, 2009|July 8, 2009||||No||https://clinicaltrials.gov/show/NCT00936507||136428|
NCT00933751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100/09|Changes of Oxygen Saturation in Inferior Vena Cava (IVC) in Patients During and After High Risk Abdominal Surgery and Relationship to the Outcome|Changes of Oxygen Saturation in Inferior Vena Cava (IVC) in Patients During and After High Risk Abdominal Surgery and Relationship to the Outcome.||Assaf-Harofeh Medical Center||Not yet recruiting|July 2009|||August 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients before emergent high risk abdominal surgery|July 2009|April 4, 2011|July 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00933751||136638|
NCT00933764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0113|Clinical Performance Evaluation of the Cholestech LDX Cardiac hsCRP Test (CLEAR)||CLEAR|Biosite|No|Withdrawn|August 2009|November 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Plasma and Serum samples will be retained for reference testing and banking.|Both|18 Years|N/A|No|Non-Probability Sample|Individuals being assessed of their risk of cardiovascular disease. Patients can currently        be diagnosed with cardiovascular disease.|July 2015|July 20, 2015|July 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00933764||136637|
NCT00935155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIFAB-727-44-2007|Effectiveness of Acupuncture as an Adjunct to Rehabilitation After Knee Arthroplasty|Effectiveness of Acupuncture as an Adjunct to Rehabilitation After Knee Arthroplasty. A Randomized Controlled Trial.||Back and Rehabilitation Center, Copenhagen|No|Recruiting|January 2009|March 2012|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|70 Years|No|||February 2012|February 7, 2012|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935155||136532|
NCT00935168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-CCT24378|Crystalloid Versus Hydroxyethyl Starch Trials|A Multi-centre Randomized Controlled Trial of Fluid Resuscitation With Starch (6%Hydroxyethyl Starch 130/0.4) Compared to Saline (0.9% Sodium Chloride) in Intensive Care Patients on Mortality|CHEST|The George Institute|Yes|Completed|December 2009|September 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7000|||Both|18 Years|N/A|No|||February 2012|November 14, 2012|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00935168||136531|
NCT00935415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPDD1962|Time-Effect of Montelukast Protection|Time-Effect of Montelukast on Protection Against Exercise-Induced Bronchoconstriction|TEMPE|Universita di Verona|No|Completed|January 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|6 Years|14 Years|No|||July 2009|July 8, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935415||136512|
NCT00935961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-028|RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer|A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer||Memorial Sloan Kettering Cancer Center|Yes|Completed|July 2009|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935961||136470|
NCT00935974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0119-11|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2008|||||N/A|N/A|N/A||||||||||||||July 7, 2009|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00935974||136469|
NCT00936806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/666|Observational Study of the Differences in Characteristics of the Spontaneous Electroencephalogram, Derived From the Left and Right Hemisphere in Patients With Unilateral Intracranial Tumor During Routine Anesthesia: Comparison With a Control Group Without Intracranial Pathology|Observational Study of the Differences in Characteristics of the Spontaneous Electroencephalogram, Derived From the Left and Right Hemisphere in Patients With Unilateral Intracranial Tumor During Routine Anesthesia. Comparison With a Control Group Without Intracranial Pathology.|VISTA|University Hospital, Ghent|No|Completed|January 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with unilateral intracranial tumor during routine anesthesia at the University        Hospital Ghent|January 2014|January 27, 2014|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936806||136405|
NCT00936481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090265|Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea|Variability of Fibrinolytic Markers and Endothelial Function in Obstructive Sleep Apnea||Vanderbilt University|No|Completed|February 2008|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|34|Samples With DNA|Blood samples to measure plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen      activator (t-PA)levels, endothelial function,fasting lipid profile and glucose levels.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are looking for adults over age 18 years without significnt medical or psychiatric        conditions (other than sleep apnea).|August 2013|August 19, 2013|July 8, 2009||No||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00936481||136430|
NCT00934583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH081124|Testing an Internet-Based Intervention for Preventing Eating Disorders|Preventing Eating Disorders and Reducing Comorbidity||Stanford University|Yes|Completed|August 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|549|||Female|18 Years|25 Years|No|||May 2012|June 5, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934583||136575|
NCT00934336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01036-47|Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention|Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention|ITOPOS|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|November 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|August 5, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934336||136594|
NCT00934622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCONsur002.07|Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL|Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric Intraocular Lens (IOL)||Alcon Research|No|Completed|November 2007|||March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|21 Years|N/A|No|||May 2010|May 5, 2010|July 7, 2009|Yes|Yes||No|March 25, 2010|https://clinicaltrials.gov/show/NCT00934622||136572|
NCT00935428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB e4084|Causes and Circumstances of Horse Related Injuries and Impact on Quality of Life|Causes and Circumstances of Horse Related Injuries and Impact on Quality of Life||Oregon Health and Science University|Yes|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Subjects will be identified through the OHSU Trauma Registry. Patients who were treated        from January 1, 2001 through September 30, 2008 for any horse related injury will be        invited to participate in the survey.|March 2011|June 7, 2011|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00935428||136511|
NCT00933556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0023|A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE|A Pilot Randomized Trial to Determine the Efficacy of a Probiotic, VSL#3 for Reducing Colonization by Vancomycin-resistant Enterococcus (VRE)|PROVE|University of Wisconsin, Madison|Yes|Completed|October 2008|March 2012|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933556||136653|
NCT00937079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS-01778-1|Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients|The Physiology of Glucagon-like-peptide-1 Receptor Expression in Patients With Endogenous Hyperinsulinism - Correlation With Histopathology||University Hospital, Basel, Switzerland|Yes|Completed|November 2007|December 2011|Actual|December 2011|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Tumor tissue|Both|18 Years|90 Years|No|Probability Sample|residents of Switzerland|January 2015|January 8, 2015|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00937079||136384|
NCT00936559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3202V1-1001|Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair|Randomized, Single-Blind, Standard Of Care Control, Dose-Escalating, Multicenter, Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Full Thickness Rotator Cuff Tears Treated By Means Of An Open Surgical Procedure||Pfizer|No|Terminated|September 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|13|||Both|25 Years|75 Years|No|||April 2012|April 12, 2012|July 2, 2009||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00936559||136424|
NCT00936299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0178|Bupropion for ADHD in Adolescents With Substance Use Disorder|Bupropion for ADHD in Adolescents With Substance Use Disorder||University of Colorado, Denver|Yes|Completed|January 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|13 Years|19 Years|No|||May 2013|May 28, 2013|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936299||136444|
NCT00937144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA123-CTIL|Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil|||The Baruch Padeh Medical Center, Poriya|Yes|Withdrawn|September 2009|February 2010|Anticipated|September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|60 Years|No|||July 2009|February 28, 2010|September 24, 2008||No|we didnt recieved the medicine|No||https://clinicaltrials.gov/show/NCT00937144||136379|
NCT00937430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09001|Bowel Preparation and Pelvic Organ Prolapse Surgery|Bowel Preparation and Return of Bowel Function After Pelvic Organ Prolapse Surgery.||TriHealth Inc.|Yes|Completed|March 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Female|21 Years|90 Years|No|||February 2014|February 17, 2014|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937430||136358|
NCT00933335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/023|Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab|Fludarabine Monophosphate Followed by Iodine I 131 Tositumomab for Untreated Low-grade and Follicular Non-Hodgkin's Lymphoma||GlaxoSmithKline||Completed|August 1998|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|July 2, 2009|Yes|Yes||No|December 1, 2011|https://clinicaltrials.gov/show/NCT00933335||136670|
NCT00933504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04804|Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral|Study for Dermatological Evaluation of Topic Compatibility. Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd PH_DESILSTY_FL (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933504||136657|
NCT00933517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Getna7/CJP1.0|Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.|Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study|TVA|Centre Jean Perrin|Yes|Completed|September 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|18 Years|N/A|No|||March 2014|March 20, 2014|July 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00933517||136656|
NCT00934310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0017-E|Introduction of the Surgical Safety Checklist|Patient Safety: Introduction of the Surgical Safety Checklist and Patient Outcome Assessment in an Academic Ambulatory Hospital||Sunnybrook Health Sciences Centre|No|Completed|May 2009|April 2012|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1000|||Both|16 Years|90 Years|No|Non-Probability Sample|Ambulatory surgical patients|January 2015|January 5, 2015|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934310||136596|
NCT00934323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M_SR_001|Dose Proportionality Study About Amaryl M Slow Release (SR) 1/500 mg|An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M SR 1/500mg and 2/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Male Subjects||Handok Pharmaceuticals Co., Ltd.|No|Completed|October 2008|April 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|33|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 7, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934323||136595|
NCT00904943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02135|Topiramate 25 mg Capsules Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Capsules Administered as 2 x 25 mg Capsules in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|June 2002|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 18, 2009|No|Yes||No|June 1, 2009|https://clinicaltrials.gov/show/NCT00904943||138815|
NCT00935987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCL09101|Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)|A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.||Gilead Sciences||Completed|November 2009|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00935987||136468|
NCT00936000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0622|Antioxidant Replacement Therapy in Patients With Alcohol Abuse|Double Blinded Placebo Controlled Trial of Protandim for Individuals With a History of Alcohol Abuse||University of Colorado, Denver|Yes|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|38|||Both|21 Years|55 Years|No|||July 2009|February 5, 2013|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936000||136467|
NCT00905593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AMX01|Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-label, Multicenter Study Providing Continuation of Nilotinib in Adult Patients With Imatinib-(Glivec®/Gleevec®) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|ENACT|Novartis||Approved for marketing|September 2008|||April 2011|Anticipated|Phase 3|Expanded Access|N/A|||||||Both|18 Years|60 Years|No|||July 2012|July 17, 2012|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905593||138766|
NCT00905606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01179|Topiramate 25 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Tablets and Topamax® 25 mg Tablets Administered as 2 x 25 mg Tablets in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2001|June 2001|Actual|June 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 18, 2009|No|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00905606||138765|
NCT00937339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20090520002-01|Effects of Whole Body Vibration in People With Chronic Stroke|The Effects of Exercise and Whole Body Vibration Training on Bone Health, Physical Fitness, and Neuromotor Performance in Individuals With Chronic Stroke: A Randomized Controlled Trial.||The Hong Kong Polytechnic University|Yes|Completed|July 2009|July 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937339||136365|
NCT00937053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9967|Maintaining a Higher Level of Haemoglobin: Effect on the White Cells After Bone Marrow Transplantation in Children.|The Effect of Maintaining a Higher Haemoglobin Level on Neutropenia Duration After Bone Marrow Transplantation in Children.||St. Justine's Hospital|Yes|Terminated|June 2009|June 2015|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|1 Year|18 Years|No|||May 2009|August 3, 2010|July 9, 2009||No|3 unexpected Serious Adverse Events (veno-occlusive disease (VOD))|No||https://clinicaltrials.gov/show/NCT00937053||136386|
NCT00937066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RC0-SYM-2007/1|Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)|Management of Patients With Moderate to Severe Asthma Uncontrolled When Treated With Low Dose Inhaled Corticosteroids: Cost-effectiveness of Three Therapeutics Alternatives||AstraZeneca|No|Completed||||||N/A|Observational|Observational Model: Cohort||1|Actual|1000|||Both|18 Years|65 Years|No|Non-Probability Sample|Primary care|January 2011|January 21, 2011|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937066||136385|
NCT00933231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-014|Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts|A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response||Astellas Pharma Inc|Yes|Active, not recruiting|June 2009|March 2018|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|281|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|July 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00933231||136678|
NCT00933530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113259|A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers|A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers||GlaxoSmithKline|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Actual|43|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933530||136655|
NCT00933543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC TA204/09|Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)|A Double Blinded, Prospective, Randomized, Stratified, Placebo-controlled, Multi-center Study of Photodynamic Therapy With VisonacTM Cream in Patients With Moderate to Severe Acne Vulgaris.||Photocure|No|Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|9 Years|35 Years|No|||November 2013|November 15, 2013|July 2, 2009|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT00933543||136654|
NCT00935181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3145/06|Respiratory Muscle Stretching in Chronic Obstructive Pulmonary Disease (COPD)|Respiratory Muscle Stretching in Patients With Chronic Obstructive Pulmonary Disease Submitted a Pulmonary Rehabilitation Program||Faculdade Evangelica do Parana|No|Completed|January 2006|December 2008|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|26|||Both|40 Years|75 Years|No|||July 2009|July 7, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00935181||136530|
NCT00936013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z09000700090903－2|Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study|Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Pneumonia: Multi-centre, Prospective, Randomized Controlled Study||Capital Medical University|Yes|Recruiting|August 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|14 Years|70 Years|No|||November 2009|November 1, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936013||136466|
NCT00936312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intl Female Hemophilia Study|Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study|Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study||Weill Medical College of Cornell University|No|Completed|March 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|200|||Female|N/A|N/A|No|Non-Probability Sample|Females with severe or moderate Hemophilia A (less than or equal to 5%) Females with        severe or moderate Hemophilia B (less than or equal to 5%)|December 2012|December 6, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936312||136443|
NCT00937170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-036C-2|Study Comparing Traditional and Gender-specific Total Knee Replacement Designs|A Prospective, Randomized, Control Trial Comparing Total Knee Arthroplasty With Traditional and Gender-Specific Designs||University of Connecticut Health Center|No|Withdrawn|June 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|0|||Female|40 Years|85 Years|No|||January 2011|January 20, 2011|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937170||136377|
NCT00936884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3200K1-3361|Study Evaluating The Efficacy And Safety Of Subcutaneous MOA-728 For The Treatment Of Opioid-Induced-Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, And Parallel-Group Study Of Subcutaneous MOA-728 For The Treatment Of Opioid-Induced Constipation In Adult Subjects||Valeant Pharmaceuticals International, Inc.|No|Completed|July 2009|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936884||136399|
NCT00936897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080562|A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates|A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates||Amgen|No|Completed|July 2009|January 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|833|||Female|55 Years|N/A|No|||February 2013|February 5, 2013|July 9, 2009|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT00936897||136398|
NCT00937131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/05/011|The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)|A Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) in Combination With Plasma Exchange (PEX) in Patients With Acute Thrombotic Thrombocytopenic Purpura (TTP)||University College, London|No|Active, not recruiting|March 2006|June 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||July 2009|July 9, 2009|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937131||136380|
NCT00937157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNAC/GA/01|Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)|Comparison of Standard 1.5 Versus 3T Optimized Protocols in Patients Treated With Glatiramer Acetate. A Conventional and Non-conventional MRI Study||University at Buffalo|No|Completed|September 2007|April 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|July 9, 2009|No|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT00937157||136378|
NCT00933881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28143|Gestational Diabetes and Sleep-Disordered Breathing|A Pilot Study to Evaluate the Association Between Gestational Diabetes, Heart Rate Variability and Sleep-Disordered Breathing||Christiana Care Health Services|No|Active, not recruiting|November 2008|July 2016|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|30|||Female|18 Years|40 Years|No|Non-Probability Sample|Women with Gestational Diabetes Mellitus (GDM)|December 2015|December 28, 2015|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00933881||136629|
NCT00933894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016303|VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram|A Phase I, Open-label, Randomized, Crossover Trial in 16 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Escitalopram at Steady-state||Tibotec BVBA||Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 16, 2010|July 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00933894||136628|
NCT00904384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB956/08 IP|Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients|Prevalencia, Factores de Riesgo y características patogénicas Diferenciales de EPOC y Enfisema en Pacientes Con infección VIH.|HIV&COPD|Cimera|No|Completed|July 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|350|||Both|40 Years|69 Years|No|Probability Sample|Patients will be recruited from the HIV outpatient consultation of the Internal Medicine        Department of Hospital Universitario Son Dureta (HUSD), in Mallorca, Spain. The HUSD is        the tertiary, reference hospital in the CAIB.|June 2011|June 9, 2011|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00904384||138858|
NCT00904397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3220-013|Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain|A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Chronic Axial Low Back Pain||Endo Pharmaceuticals||Terminated|July 2004|||November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes|Rofecoxib was withdrawn from the market due to safety concerns.|No||https://clinicaltrials.gov/show/NCT00904397||138857|
NCT00904670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWP06-ADD-100|Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)|NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study||Pfizer|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|6 Years|12 Years|No|||May 2014|May 27, 2014|May 18, 2009|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT00904670||138836|Results for primary outcome is presented as absolute values and not as change from pre-dose and the secondary outcomes are presented at each post-dose time-point and not pre-dose, as planned.
NCT00904930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-WCS1-WCS2-Hu|Evaluation of the Periotest Method in Dental Traumatology|Evaluation of the Periotest Method as a Tool for Tooth Mobility Monitoring and Splint Rigidity Assessment in Dental Traumatology||University of Erlangen-Nürnberg Medical School|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Both|19 Years|36 Years||Non-Probability Sample|Dental students Dental Clinic 1 and 2|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904930||138816|
NCT00904683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11934|Effect of LY2062430 on the Progression of Alzheimer's Disease|Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo|EXPEDITION2|Eli Lilly and Company|Yes|Completed|May 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1040|||Both|55 Years|N/A|No|||December 2012|December 11, 2012|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904683||138835|
NCT00905268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-III-001|A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients|A Phase III Double-blind, Randomised, Placebo-controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|MICONOS|Santhera Pharmaceuticals|Yes|Completed|April 2006|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|232|||Both|8 Years|N/A|No|||August 2010|August 20, 2010|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905268||138791|
NCT00936637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVA Growth Study|Effects on Growth of an Extensively Hydrolyzed Formula Fed to Term|A 16-Week Growth Study of an Extensively Hydrolyzed Infant Formula, 3 Months Treatment and 1 Month Follow-up for a Duration of 4 Months.||Perrigo Nutritionals|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver)|1||Actual|35|||Both|N/A|21 Days|Accepts Healthy Volunteers|||July 2009|July 9, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936637||136418|
NCT00936650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990120|A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Dose-Titration Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)||Amgen||Completed|November 1999|June 2001|Actual|March 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|June 4, 2009||||No||https://clinicaltrials.gov/show/NCT00936650||136417|
NCT00936962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-02175|Evaluation of Meningococcal C Vaccine Programmes in Canadian Children|Evaluation of Meningococcal C Vaccine Programmes in Canadian (BC, NS, Alta.) Children During Peak Years of Risk (0-<5 Years of Age)||University of British Columbia|No|Completed|July 2009|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|452|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||July 2015|July 14, 2015|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936962||136393|
NCT00937196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-DZ-06|Placebo Effects on Blood Pressure Induced by Expectancy Manipulation|Effects of Placebos and Verbal Suggestions on Blood Pressure - Randomized Controlled Trial||Ludwig-Maximilians - University of Munich|No|Completed|August 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|45|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937196||136375|
NCT00937222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59049|Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes|Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults Ith Type 2 Diabetes||Loma Linda University|Yes|Completed|June 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00937222||136374|
NCT00937495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03810|Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma|A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas||National Cancer Institute (NCI)||Completed|June 2009|June 2011|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||September 2013|April 25, 2014|July 10, 2009|Yes|Yes||No|September 11, 2013|https://clinicaltrials.gov/show/NCT00937495||136353|
NCT00932854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMEDY 09/0090|A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY)|A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of Isolated MEDiastinal lymphadenopathY (REMEDY)|REMEDY|University College London Hospitals|No|Active, not recruiting|July 2009|October 2011|Anticipated|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||October 2011|October 17, 2011|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932854||136707|
NCT00933140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25758|Anal HPV Infection and Abnormal Cytology in HIV-infected Women|Anal HPV Infection and Abnormal Cytology in HIV-infected Women||Boston Medical Center|Yes|Completed|October 2006|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Female|18 Years|64 Years|No|Non-Probability Sample|HIV infected women aged between 18-64 years presenting for cervical cytologic screening.|November 2015|November 16, 2015|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933140||136685|
NCT00928564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-6784|Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia|Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia: A Randomized Controlled Cross-over Trial||University of California, Irvine|Yes|Recruiting|April 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|140|||Female|18 Years|N/A|No|||June 2015|July 8, 2015|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00928564||137029|
NCT00928577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-406-004|Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)|A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel||Sanofi|No|Completed|December 2008|December 2015|Actual|December 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|14108|||Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants in Cohort 1 are vaccinia vaccine naive and had received ACAM2000® vaccine as        part of their Service Member readiness.        Participants in Cohort 2 did not receive ACAM2000® vaccine as part of their Service Member        readiness process because they are still protected by previous vaccinia vaccination or are        ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia        vaccination or for reasons solely attributable to conditions or characteristics of their        contacts (such as a healthy soldier who is married to someone with a contraindicated        condition).|February 2016|February 18, 2016|June 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00928577||137028|
NCT00929500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p-000121|Exercise Program in Women With Metabolic Syndrome|The Effect of Mixed Aerobic and Strength Training Program on Physical Fitness and Cerebrovascular Function in Older Women With Metabolic Syndrome: A Pilot Study With Randomized Control Trial (RCT) Design||Beth Israel Deaconess Medical Center||Completed|July 2009|December 2013|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|28|||Female|50 Years|N/A|No|||July 2014|July 17, 2014|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929500||136958|
NCT00934206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2009|Predictors of Individual Training Effectiveness in Preventive Exercise|Pilot Study to Find Predictors of Individual Training Effectiveness in Preventive Exercise||Saarland University|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||June 2011|August 25, 2011|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934206||136604|
NCT00933608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM-MD-68|Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease|Effects of Memantine on the Magnetic Resonance Spectroscopy (MRS) Measures of Neuronal Integrity in Subjects at Risk for Alzheimer's Disease||New York University School of Medicine||Completed|July 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|17|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|July 2, 2009|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00933608||136649|
NCT00935051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00155-50|Matrix Metalloproteinase-1/Tissue Inhibitor of Metalloproteinase-1 (MMP-1/TIMP-1) Ratio and Diabetic Foot Ulcers|Assessment of the MMP-1/TIMP-1 Ratio as a Predictor of Wound Healing in Diabetic Foot Ulcers|DIAB-MMP2|University Hospital, Grenoble|No|Completed|May 2009|November 2013|Actual|July 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|59|||Both|18 Years|40 Years|No|||December 2013|December 17, 2013|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00935051||136540|
NCT00928018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-073|Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma|A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma||Dana-Farber Cancer Institute|Yes|Completed|June 2009|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|72 Years|No|||December 2015|December 17, 2015|June 24, 2009|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT00928018||137071|
NCT00935831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112843|Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment|A Phase I, Single-Dose, Randomized and Single-Blind (Part 1), Fixed Sequence and Open-Label (Part 2), Studyto Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of 1278863A in Subjects With RenalImpairment and Matched Healthy Volunteers||GlaxoSmithKline|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|65 Years|No|||April 2012|April 12, 2012|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935831||136480|
NCT00935844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C19001|Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma|An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma||Millennium Pharmaceuticals, Inc.|No|Completed|October 2009|November 2011|Actual|August 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00935844||136479|
NCT00936130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 29004|Bariatric Surgery and Weight Loss on Energy Metabolism and Insulin Sensitivity|Effect of Bariatric Surgery and Weight Loss on Energy Metabolism and Insulin Sensitivity "BARIA"|BARIA|Pennington Biomedical Research Center|No|Completed|September 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|48|Samples Without DNA|Blood draw, urine, stool, fat and muscle biopsies.|Both|18 Years|65 Years|No|Probability Sample|Medically qualified for obesity surgery by Drs LeBlanc or Hausmann|December 2015|December 3, 2015|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00936130||136457|
NCT00936364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-08-9|Short-Term Fasting: Impact on Toxicity|Short-Term Fasting Prior To Platinum-based Chemotherapy: Feasibility and Impact on Toxicity||University of Southern California|Yes|Recruiting|July 2009|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|70|||Both|19 Years|N/A|No|||October 2015|October 24, 2015|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936364||136439|
NCT00936624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOTB07_AST_II_2008|Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma|A 12 Week, Multi-center,Randomized, Double Blinded, Parallel Group, Placebo-controlled, 4-arm, Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma||SK Chemicals Co.,Ltd.|Yes|Completed|July 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|245|||Both|15 Years|N/A|No|||December 2013|December 17, 2013|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936624||136419|
NCT00936663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254-09FB|Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation|A Randomized, Placebo-Controlled Double-Blind Trial Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation: A Pilot Study||University of Nebraska|Yes|Enrolling by invitation|July 2009|June 2011|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|19 Years|70 Years|No|||July 2009|July 20, 2009|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936663||136416|
NCT00924963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0922|J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion|Comparison of J-Tip® Jet Injection of 1% Buffered Lidocaine, 4% Lidocaine Topical Cream, and J-Tip® Jet Injection of Placebo Prior to Venipuncture and Peripheral Intravenous Catheter Insertion in a Pediatric Emergency Department||Children's Hospital Medical Center, Cincinnati|Yes|Terminated|June 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|132|||Both|7 Years|21 Years|Accepts Healthy Volunteers|||June 2009|October 17, 2011|June 18, 2009||No|Study ended due to lack of funding.|No||https://clinicaltrials.gov/show/NCT00924963||137304|
NCT00937235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA023507|Treatment of Smoking Among Individuals With PTSD|Treatment of Smoking Among Individuals With PTSD: A Phase II, Randomized Study of Varenicline and Cognitive Behavioral Therapy||University of Pennsylvania|Yes|Active, not recruiting|January 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|75 Years|No|||February 2012|December 12, 2014|July 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937235||136373|
NCT00925509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET2006-032|Application of Medical Imaging Procedures in Surgery Implanting in Cancerology With the Aim to Reduce Invasive Acts|Application of Medical Imaging Procedures in Surgery Implanting in Cancerology With the Aim to Reduce Invasive Acts|ATIM|Centre Leon Berard|No|Terminated|September 2007|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|53|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|June 2, 2009||No|Insufficient recruitment, too much selective inclusion criteria, feasibility problems|No||https://clinicaltrials.gov/show/NCT00925509||137262|
NCT00932555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14344|EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan|EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan||Bayer|No|Completed|April 2009|December 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Male|N/A|N/A|No|Non-Probability Sample|The study population will consist of patients with a diagnosis of hemophilia A. Physicians        should consult the full prescribing information for KOGENATE® FS before enrolling patients        and familiarize themselves with the safety information in the product package label.|March 2012|March 13, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932555||136728|
NCT00932581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM105|Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties|Investigation of the Psychometric Properties of the Bradykinesia Subscale When Administered Alone Versus as a Component of the Entire Motor Examination Section of the Unified Parkinson's Disease Rating Scale|Bravura|Teva Pharmaceutical Industries|No|Completed|June 2009|December 2009|Actual|November 2009|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|110|||Both|30 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of idiopathic Parkinsons disease (PD) who also presented with        bradykinesia and one other cardinal sign at the time of assessment.|November 2010|November 1, 2010|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932581||136727|
NCT00928889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDJN608ACN06|Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors|A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients|ENERGY|Novartis||Completed|July 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|June 25, 2009||No||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00928889||137004|
NCT00928902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8515|Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma|Pilot Phase II Trial for the Evaluation of the Effect of Systemic Low-dose IL-2 on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant, in Patients With High Risk Melanoma|MEL36|University of Virginia|Yes|Completed|November 1999|March 2005|Actual|April 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|85 Years|No|||October 2010|October 20, 2010|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928902||137003|
NCT00929799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA 6280012|Growth Hormone and Glucose Metabolism|Effects of Treatment With Human Growth Hormone on Insulin Resistance and Insulin Secretion in Adults With Growth Hormone Deficiency|GHGMS|Charite University, Berlin, Germany|No|Completed|November 2003|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929799||136936|
NCT00929812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GluGhr-study 01082005|Glucagon Modulation of Ghrelin Secretion|The Mechanisms Underlying the Glucagon-Induced Suppression of Ghrelin Secretion||Charite University, Berlin, Germany|No|Active, not recruiting|June 2006|December 2009|Anticipated|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2009|June 29, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929812||136935|
NCT00929227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090164|Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease|Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|109|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929227||136979|
NCT00929240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22223|A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer|A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy||Hoffmann-La Roche||Completed|July 2009|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|287|||Female|18 Years|N/A|No|||March 2015|March 2, 2015|June 16, 2009||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00929240||136978|
NCT00929253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 31695|Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)|Efficacy of Computer Delivered CRA (Bup II)|CAT|Virginia Polytechnic Institute and State University|Yes|Completed|September 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929253||136977|
NCT00929526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112949|Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study|Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693||GlaxoSmithKline||Completed|June 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|752|||Female|20 Years|25 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|June 26, 2009|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00929526||136957|
NCT00934479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001281|Intestinal Microecology in Chronic Constipation|The Intestinal Microecology in Chronic Constipation||Mayo Clinic|No|Completed|April 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00934479||136583|
NCT00934453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8996|Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Healthy Volunteers|A Phase I, Randomized Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Healthy Volunteers||Massachusetts General Hospital|Yes|Completed|December 2009|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00934453||136585|
NCT00934466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2637-008|Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)|A Randomized Clinical Trial to Assess the Effects of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|5||Actual|15|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|July 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00934466||136584|
NCT00927680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03CA130034 NCI|Familial Colorectal Cancer Registry in Hispanics|Familial Colorectal Cancer In Puerto Rico: A Feasibility Study|PURIFICAR|University of Puerto Rico|No|Recruiting|July 2007|July 2020|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|5000|Samples With DNA|Tumor blocks (colorectal tumors) and blood samples|Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Probands will be ascertained from the Puerto Rico Central Cancer Registry (PRCCR),             from the monthly report of incident colorectal cancer cases. Eligible cases were             persons (1) with pathologic diagnosis of colorectal cancer; (2) who were 15 years of             age or older, and (3) without previous history of colorectal cancer.          2. Probands will be ascertained from the Oncology Hospital, UDH Hospital and the Ashford             Presbyterian Community Hospital.|December 2014|December 3, 2014|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927680||137097|
NCT00928031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX010-28|Long-term Data Collection for Subjects in MDX-010 Studies|Collection of Long-Term Outcome Data for Subjects Who Have Previously Participated in Selected Ipilimumab (MDX-010) Studies in Metastatic Melanoma|MDX010-28|Bristol-Myers Squibb|No|Completed|June 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|160|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who received any dose of ipilimumab (MDX-010) in MDX010-02, MDX010-08, and        MDX010-15 and were alive at the time of study completion.|April 2010|April 23, 2010|June 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00928031||137070|
NCT00935558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA 0822|Dendritic Cell Based Therapy for Breast Cancer Patients|Evaluation of p53peptide-pulsed Dendritic Cells in Combination With an Aromatase Inhibitor as a Treatment for Patients With Breast Cancer With Disease Recurrence After Adjuvant or First Line Endocrine Therapy.||Herlev Hospital|Yes|Withdrawn|July 2009|||May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||May 2012|May 30, 2012|July 8, 2009||No|no patients enrolled|No||https://clinicaltrials.gov/show/NCT00935558||136501|
NCT00935857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00008540|Balloon Colonoscopy for Incomplete Colonoscopy|Balloon Colonoscopy Versus Repeat Standard Colonoscopy for Prior Incomplete Colonoscopy: A Randomized Controlled Trial||Northwestern University|No|Terminated|April 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||September 2014|September 23, 2014|July 7, 2009||No|Significant difference at interim analysis|No|December 3, 2012|https://clinicaltrials.gov/show/NCT00935857||136478|Early termination due to interim analysis showing statistical difference; single operator.
NCT00936143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REM-CHN-IIS-01|Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis|An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis||Sun Yat-sen University|Yes|Completed|January 2008|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|16 Years|65 Years|No|||January 2016|January 24, 2016|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936143||136456|
NCT00936156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNET HR+ 5|Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years|||Gustave Roussy, Cancer Campus, Grand Paris||Recruiting||||||Phase 2|Interventional|Primary Purpose: Treatment|1||||||Both|N/A|5 Years||||July 2009|December 23, 2009|July 7, 2009||||No||https://clinicaltrials.gov/show/NCT00936156||136455|
NCT00924742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPEM08026M1|A Single-Dose Pharmacokinetics Study of Tapimycin Injection|A Single-Dose Pharmacokinetics Study of Tapimycin Injection(Piperacillin 4 g + Tazobactam 0.5 g Powder for Injection) Administered Under Fasting Conditions to Healthy Adult Subjects||Tri-Service General Hospital|Yes|Completed|March 2009|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 18, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924742||137321|
NCT00924976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G070058|Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families|Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families||University of North Carolina, Chapel Hill|No|Completed|May 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|303|||Both|18 Years|65 Years|No|||May 2011|May 10, 2011|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924976||137303|
NCT00925249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6950|Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy|Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy||Walter Reed Army Medical Center|Yes|Recruiting|May 2009|June 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients in the US government tricare health system|June 2009|December 11, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00925249||137282|
NCT00925262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BoltonP-1|Controlled Trial of Mental Health Interventions for Torture Survivors in Kurdistan|A Controlled Trial of Mental Health Interventions for Common Mental Health Problems Experienced by Torture Survivors Living in Kurdistan, Iraq.||Johns Hopkins Bloomberg School of Public Health|No|Completed|June 2009|October 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|530|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00925262||137281|
NCT00925808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0026|Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans|A Prospective Study of Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2009|||June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1187|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include cancer outpatients, 18 years or older, scheduled for        routine CT scan of the chest, abdomen and/or pelvis at UT MD Anderson Cancer Center.|January 2016|January 14, 2016|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925808||137239|
NCT00926068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO-09-01|Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers|Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers (Truheal)|Truheal|HealOr|Yes|Active, not recruiting|February 2010|||August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|80 Years|No|||April 2013|April 3, 2013|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926068||137219|
NCT00928629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00089|Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease|Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease. A Cross-sectional Multi-centre Clinical Study in Subjects With Cardiovascular Disease Risk Factors.|ACHILLES|AstraZeneca|No|Completed|June 2009|October 2009|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Both|45 Years|N/A|No|||November 2009|November 11, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928629||137024|
NCT00929279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS-07-I|Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time|Facilitation Through Abciximab By drOpping Infusion Line in Patients Undergoing Coronary Stenting. SYNergy With Clopidogrel at High Loading dOse Regimen|FABOLUS|Università degli Studi di Ferrara|Yes|Completed|November 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||June 2009|June 26, 2009|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929279||136975|
NCT00932867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14010|Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment|Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment|SONAR|Bayer|No|Completed|December 2007|August 2009|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3114|None Retained|n.a.|Both|18 Years|N/A|No|Non-Probability Sample|-  Any patient with a diagnosis of arterial hypertension, who do not tolerated ACE             inhibitor treatment treated by the drug PRITOR          -  Exclusion criteria for the patients treated by the drug PRITOR must be read in             conjunction with the local product information|April 2010|April 19, 2010|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932867||136706|
NCT00932880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-061-SA|Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects|An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets [Torrent Pharmaceuticals Limited,India] Compared to a 10 mg Dose of Norvasc®, [Pfizer, USA] in 18 Fed, Healthy Adult Subjects||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|45 Years||||July 2009|July 15, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932880||136705|
NCT00929565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14455|Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy|Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.||University of Oklahoma|No|Completed|June 2009|October 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|80 Years|No|Probability Sample|Patients from the VAMC in Oklahoma city|April 2012|April 5, 2012|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00929565||136954|
NCT00929578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-CL2|Fluphenazine Hydrochloride for Psoriasis|Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis|FP-CL2|Tufts Medical Center|No|Completed|November 2008|January 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||July 2012|July 20, 2012|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929578||136953|
NCT00930085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTEOHSEPS/IPC 2005-011|Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients|Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients|PROTEOHSEPS|Institut Paoli-Calmettes|No|Completed|August 2008|May 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00930085||136914|
NCT00930098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOV-111|A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia|A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia||Sanofi|No|Completed|December 2003|July 2007|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|N/A|21 Years|No|||February 2014|February 10, 2014|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00930098||136913|
NCT00930397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 07049|Observational Study in UTERO - Placental 3D Doppler Examination: Interest for Pre-eclampsia Screening During Pregnancy|The Evaluation of UTERO - Placental 3D Doppler Examination Potential Interest for Pre- Eclampsia Screening During Pregnancy. Observational Study in 100 Women at High Risk for Pre- Eclampsia and 70 Low Risk Women.|PLACENTA3D|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|146|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|100 women high risk of pre-eclampsia and 70 women low risk women of pre-eclampsia|May 2013|May 24, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930397||136890|
NCT00934492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC 1562|Cotrimoxazole Prophylaxis in Severely Malnourished Children|Randomized, Placebo Controlled Trial of Cotrimoxazole Prophylaxis Amongst HIV-uninfected Children With Severe Malnutrition|CTX|University of Oxford|Yes|Completed|November 2009|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1781|||Both|2 Months|5 Years|No|||August 2014|August 15, 2014|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934492||136582|
NCT00934739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1306|A Study of High-Risk Oral Cavity Cancer|Multicentre，A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer||National Health Research Institutes, Taiwan|Yes|Terminated|June 2007|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|N/A|70 Years|No|||July 2009|February 23, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934739||136563|
NCT00927693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3351|Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER)|Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER)|EISNER|Cedars-Sinai Medical Center||Completed|February 2001|August 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2137|||Both|45 Years|80 Years|No|||September 2011|September 28, 2011|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927693||137096|
NCT00928291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT febrile neutropenia|Procalcitonin Protocol to Shorten the Antibiotic Therapy in Febrile Neutropenia|The Use of a Procalcitonin (PCT)-Guided Protocol to Shorten the Duration of Antibiotic Therapy in Febrile Neutropenic Patients. An Interventional Study.||Federal University of Minas Gerais|Yes|Completed|January 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2009|June 22, 2011|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928291||137050|
NCT00928265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENAT|Safety and Efficacy of Neuroform3TM for Intracranial Aneurysm Treatment|Safety and Efficacy of Neuroform3TM for Intracranial Aneurysm Treatment|SENAT|Stryker Neurovascular|No|Completed|July 2008|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|116|||Both|18 Years|N/A|No|Probability Sample|Patient coming to the hospital to get an endovascular treatment of the aneurysm|May 2013|May 31, 2013|June 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928265||137052|
NCT00928590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-032|Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Twelve-Month Open-Label Safety Study of Polyquaternium-Preserved DuoTrav APS Dosed Once Daily in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928590||137027|
NCT00924443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOV-121|A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable|A Phase II Trial of Clofarabine in Older Patients With Acute Myeloid Leukemia for Whom Intensive Chemotherapy is Not Considered Suitable||Sanofi|No|Completed|June 2004|March 2008|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|65 Years|N/A|No|||March 2015|March 30, 2015|June 17, 2009||No||No|March 20, 2015|https://clinicaltrials.gov/show/NCT00924443||137344|
NCT00924755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMX-2008-03|Study of Surgical Mesh for Inguinal Hernia Repair|Early Outcome of Inguinal Hernia Repair With Biomerix Surgical Mesh Using the Lichtenstein Technique||Biomerix|No|Active, not recruiting|June 2009|November 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|19 Years|N/A|No|||October 2010|October 1, 2010|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924755||137320|
NCT00924989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-301|A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma|GALACCTIC|Astellas Pharma Inc|Yes|Completed|September 2009|October 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924989||137302|
NCT00925288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP 35706|Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers|Acceptability and Feasibility of a Modified HPV Vaccine Schedule in Brothel Based Female Sex Workers in Peru|Girasol|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|October 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||September 2012|September 10, 2012|June 3, 2009||No||No|July 3, 2012|https://clinicaltrials.gov/show/NCT00925288||137279|Small time difference between study arms (0,2,6 and 0,3,6 months); We cannot distinguish between antibodies resulting from vaccination and antibodies resulting from natural HPV infection;
NCT00925275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCL-08-001|Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors|A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists||Cellectar, Inc|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|9|||Both|18 Years|N/A|No|||April 2010|April 30, 2010|June 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00925275||137280|
NCT00925522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080076|Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT)|Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT)|Ablate-VT|St. Jude Medical|No|Completed|June 2009|July 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2011|January 3, 2014|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925522||137261|
NCT00925821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSMM XII|Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma|Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD)as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance - A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myeloma (DSMM XII)||Wuerzburg University Hospital|Yes|Completed|June 2009|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|65 Years|No|||June 2012|June 27, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00925821||137238|
NCT00929539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT130-G-08-006|Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients|A Phase II, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety and Tolerability of JTT-130 in Treatment-naïve, Metformin Only or Metformin Plus Sulfonylurea-treated Obese Type 2 Diabetic Patients||Akros Pharma Inc.|No|Completed|June 2009|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|496|||Both|18 Years|70 Years|No|||January 2013|January 31, 2013|June 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929539||136956|
NCT00929552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D202|Effect of Fish Oil on Markers of the Metabolic Syndrome in Overweight Adolescent Boys|Effect of n-3 LCPUFAs on Weight Reduction and Metabolic Syndrome.|TeenFisk|University of Copenhagen|No|Completed|November 2007|June 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|78|||Male|13 Years|15 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929552||136955|
NCT00928941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7009-M|Neural Correlates of Cognitive Rehabilitation in Post-Traumatic Stress Disorder (PTSD)|Neural Correlates of Cognitive Rehabilitation in PTSD||VA Office of Research and Development|No|Terminated|May 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|June 22, 2009||No|The PI has left the project and the VA, as of 3/2011|No||https://clinicaltrials.gov/show/NCT00928941||137000|
NCT00929305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-002|Low Level Laser Light Therapy and Chronic Neck and Shoulder Pain|Study of the Effect of Low Level Laser Therapy on the Reduction of Chronic Pain Associated With Neck and Shoulder Pain of Musculoskeletal Origin.||Erchonia Corporation|No|Completed|January 2001|June 2001|Actual|June 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||April 2014|April 2, 2014|June 25, 2009|Yes|Yes||No|July 7, 2009|https://clinicaltrials.gov/show/NCT00929305||136973|
NCT00929825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0520|Therapies for Salivary Flux Stimulation in Patients Transplanted With Hematopoietic Stem Cells|Effects of Mechanical and Electrical Sialogogues in Stimulation of the Flow and Biochemical Composition of Saliva in Patients Transplanted With Hematopoietic Stem Cells||Federal University of Minas Gerais|Yes|Withdrawn|February 2008|August 2011|Anticipated|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|60|||Both|16 Years|N/A|Accepts Healthy Volunteers|||July 2009|June 24, 2011|June 4, 2009||No|The Hospital had the Unit of Stem cells Tranplantion suspended|No||https://clinicaltrials.gov/show/NCT00929825||136934|
NCT00930111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cooker 533|Inpatient Attending Physician Rotation Duration Study|Inpatient Attending Physician Rotation Duration Study||John H. Stroger Hospital|No|Completed|June 2009|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|62|||Both|N/A|N/A|No|||August 2015|August 31, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930111||136912|
NCT00930124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP_DOvsCO|Cleft Orthognathic Surgery Versus Distraction Osteogenesis - Which is Better?|Distraction Versus Orthognathic Surgery - Which One is Better for Cleft Palate Patients||The University of Hong Kong|No|Completed|June 2002|January 2008|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 12, 2011|January 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00930124||136911|
NCT00926861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-052-0409|Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD|Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative AMD to Develop Exudative AMD|PAM|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Recruiting|July 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|||Both|50 Years|N/A|No|Probability Sample|male or female persons aged over 50 years with dry AMD|June 2010|June 8, 2010|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00926861||137160|
NCT00927420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2009/1|Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study|Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study||AstraZeneca|No|Completed|July 2009|October 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings|October 2009|October 29, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927420||137117|
NCT00934752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0013-01|De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions|An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions.||C. R. Bard|Yes|Completed|July 2009|January 2012|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934752||136562|
NCT00934765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiO 08/220b|Effect of Weight Loss on Reproductive Function in Overweight Men|Effect of Weight Loss on Reproductive Function in Overweight Men.||Oslo University College|No|Recruiting|September 2008|||June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Whole blood, semen|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Obese and overweight men that are planing to loss weight by diet and/or lifestyle changes        or gastric by-pass surgery.|March 2014|April 20, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934765||136561|
NCT00927433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intervention, cancer fatigue|Cancer Patients' Knowledge About Fatigue|Development and Implementation of a Structured Educational Programme to Increase Patients Knowledge About Fatigue and to Evaluate the Effect of Increased Knowledge on Cancer Patients Experience of Fatigue||Oslo University Hospital|No|Active, not recruiting|October 2007|December 2011|Anticipated|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|160|||Both|N/A|N/A|No|||June 2011|June 29, 2011|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927433||137116|
NCT00928044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-01-050|The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH)|The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone||Samsung Medical Center|No|Active, not recruiting|January 2008|July 2009|Anticipated|January 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|330|Samples Without DNA|Blood sample was taken before and in 1 week, 1 month and 3 months after surgery for      operation group or at the time of screening for control group, and transvaginal      ultrasonography was performed with AMH sampling.      After collection of blood, serum was stored at -70ºC until the measurement of AMH level.      Serum levels of AMH were determined by an enzyme-linked immunosorbent assay using commercial      kit (Beckman Coulter Inc., Paris, France)|Female|20 Years|49 Years|Accepts Healthy Volunteers|Probability Sample|Premenopausal women were enrolled and were allocated into two groups; operation and        control group. Operations were performed for benign ovarian tumors, leiomyoma or        adenomyosis. All eligible women were identified from the Samsung Medical Center. Written        informed consent was obtained from all subjects and the study was approved by the        Institutional Review Board of Samsung Medical Center.        A complete medical history was taken, and physical and gynecological examinations were        performed at baseline. Data included information on age, menstrual cycle, parity, weight,        height, and BMI. The follow-up length was 3 months. Blood sample was taken before and in 1        week, 1 month and 3 months after surgery for operation group or at the time of screening        for control group, and transvaginal ultrasonography was performed with AMH sampling.|June 2009|June 24, 2009|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00928044||137069|
NCT00924781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2578-003|A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)|A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease Who Are on Hemodialysis.||Merck Sharp & Dohme Corp.|No|Terminated|June 2009|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|39|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|June 18, 2009|Yes|Yes||No|October 25, 2011|https://clinicaltrials.gov/show/NCT00924781||137318|Cohort 3 (MK2578 1mcg/200U) was not initiated because the study was prematurelyterminated by the sponsor. All randomized participants received at least one dose of study medication. Data presented are for Cohort 1 and Cohort 2, where applicable.
NCT00928278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1691001|A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers.||Pfizer|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 18, 2009|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00928278||137051|
NCT00924183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00014|Measuring Response to Depression Treatment|Measuring Response to Depression Treatment: A Study Comparing the Sensitivity of Multiple Outcome Measures to Change||Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.|No|Active, not recruiting|June 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Plasma and white blood cells will be isolated from whole blood samples and will be stored      for future analysis.|Both|19 Years|65 Years|No|Non-Probability Sample|All subjects will diagnosed with a current major depressive episode. They will be        recruited from a community healthcare centre.|March 2011|March 22, 2011|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00924183||137362|
NCT00928603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-HSR-VT-001|Investigative Study of the Role of Focal Therapy for Prostate Cancer Treatment|Focal Therapy for Organ Confined Prostate Cancer: an Investigative Prospective Pilot Study||Università Vita-Salute San Raffaele|Yes|Enrolling by invitation|September 2009|September 2014|Anticipated|September 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|76 Years|No|||September 2009|September 14, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928603||137026|
NCT00924456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-0001|A Clinical Trial of the Transcendental Meditation (TM) Program on Blood Pressure, Psychological Distress, and Coping|A Randomized Controlled Trial of the Transcendental Meditation Program on Blood Pressure, Psychological Distress, and Coping in Young Adults||Maharishi University of Management|No|Completed|January 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|296|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|November 27, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924456||137343|
NCT00925002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX1A-303|Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis|Open-label Safety And Efficacy Evaluation Of Fx-1006a In Subjects With Transthyretin (Ttr) Amyloidosis (fx1a-303)||Pfizer|No|Recruiting|August 2009|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|75 Years|No|||March 2016|March 22, 2016|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925002||137301|
NCT00926094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF04-HMO-CTIL|Prevalence of Impaired Glucose Tolerance (IGT) in Patients With Frozen Shoulder|||Hadassah Medical Organization||Completed|April 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|30 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|people that were diagnosed with frozen shoulder at the last three years and are not        diabetic.|April 2011|May 11, 2011|June 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00926094||137217|
NCT00926107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 4/09|Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse|Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.||Hellenic Cooperative Oncology Group|No|Terminated|June 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||November 2011|November 9, 2011|June 22, 2009||No|The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in    the first two years of patients enrolment|No||https://clinicaltrials.gov/show/NCT00926107||137216|
NCT00925535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271043|Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)|Open-Label, Randomized, 3-Way Crossover Study To Estimate The Interaction Between Multiple Dose Rifabutin And Lersivirine (UK-453,061) In Healthy Subjects||Pfizer|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 17, 2010|June 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925535||137260|
NCT00925548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200038-010|STRIDE - STimulating Immune Response In aDvanced brEast Cancer|A Randomized, Double-blind, Controlled Phase III Study of Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Post-menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer|STRIDE|EMD Serono|Yes|Terminated|September 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|N/A|No|||July 2014|July 23, 2014|June 17, 2009|Yes|Yes|See termination reason in the below Purpose statement|No|June 24, 2014|https://clinicaltrials.gov/show/NCT00925548||137259|Efficacy data were not analyzed as the trial was prematurely terminated following the clinical hold on the investigational new drug application for tecemotide (L-BLP25)
NCT00926614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2008.153|Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba|48 Week Pilot Trial Assessing the Efficacy of Pioglitazone, Atorvastatin, Pegasys and Weight Based Ribavirin in Chronic Hepatitis C, Genotype 1 Patients Who Have Previously Relapsed or Did Not Respond to PegInterferon /Ribavirin Therapy||Brooke Army Medical Center|No|Completed|September 2008|December 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926614||137177|
NCT00928980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFN-2009-2013|Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression|The Clinical and Cost-effectiveness of Mindfulness Based Cognitive Therapy, Maintenance Antidepressant Medication and Its Combination in the Prevention of Relapse in Patients With Recurrent Depression||Radboud University|No|Completed|May 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|317|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928980||136997|
NCT00929292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAH-CL3-001|Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic|Study of Growth and Gastrointestinal Tolerance of an Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic.||Sodilac|No|Completed|November 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|66|||Both|N/A|3 Months|No|||June 2009|June 26, 2009|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929292||136974|
NCT00929318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-THY-WH-09|Influence of Thyroid Hormones on the Woundhealing Process|Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound||Hannover Medical School|No|Recruiting|June 2009|April 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|N/A|No|||June 2009|June 26, 2009|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929318||136972|
NCT00929331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110586|Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years.||GlaxoSmithKline||Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|January 5, 2012|June 25, 2009|Yes|Yes||No|July 15, 2010|https://clinicaltrials.gov/show/NCT00929331||136971|
NCT00929591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000075692|SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer|Phase III Comparison of Adjuvant Chemoendocrine Therapy With CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients With Involved Axillary Lymph Nodes and Positive Receptors||Southwest Oncology Group|Yes|Completed|May 1989|March 2010|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1558|||Female|18 Years|N/A|No|||January 2013|January 23, 2013|June 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929591||136952|
NCT00929851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0906-PR-0016|BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)|a 48-week, Double Blind, Randomized, Multinational, Multicentre, "Fixed Combination" Beclomethasone Dipropionate Plus Formoterol Fumarate Versus Formoterol in Patients With Severe Chronic Obstructive Pulmonary Disease||Chiesi Farmaceutici S.p.A.|Yes|Completed|October 2009|July 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1199|||Both|40 Years|N/A|No|||August 2013|August 2, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929851||136932|
NCT00927173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0001-00|Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder|A Prospective Multicenter Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Major Depression Disorder (MDD)||Brainsway|Yes|Completed|September 2009|June 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|233|||Both|22 Years|68 Years|No|||February 2013|October 14, 2014|June 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927173||137136|
NCT00927186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13032|Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women|Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy||Eli Lilly and Company|No|Completed|July 2009|April 2012|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|69|||Female|55 Years|89 Years|No|||February 2013|February 21, 2013|June 22, 2009|Yes|Yes||No|October 7, 2011|https://clinicaltrials.gov/show/NCT00927186||137135|
NCT00927446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMCP-98-006|Endoscopy Screening for Esophageal Cancer|Endoscopy Screening for Esophageal Neoplasm With Narrow Band Imaging in Patients With Head and Neck Cancer: A Controlled Tandem Endoscopy Trial||Lotung Poh-Ai Hospital|Yes|Terminated|June 2009|April 2010|Actual|April 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|Samples Without DNA|endoscopic biopsy for histopathological examination|Both|18 Years|N/A|No|Non-Probability Sample|Patients with tissue diagnosis of head and neck carcinoma|October 2010|October 18, 2010|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00927446||137115|
NCT00924495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5960429|Study Comparing Cortical Function and Dysfunction Tests in Low Back Pain|Regulatory Central Mechanisms in Chronic Nonspecific Low Back Pain With Lumbar Dysfunction||Kuopio University Hospital||Completed|June 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|80|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||September 2012|February 10, 2013|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924495||137340|
NCT00924508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydrogel for Eczema|Hydrogel Patch for the Treatment of Eczema|A Study to Compare the Efficacy of Triamcinolone 0.1% Cream Occluded With Hydrogel Patch to Triamcinolone 0.1% Cream Without Occlusion in the Treatment of Eczema||University of California, San Francisco|No|Terminated|July 2008|July 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2013|December 30, 2013|June 17, 2009||No|Loss of Funding|No|September 18, 2013|https://clinicaltrials.gov/show/NCT00924508||137339|Due to loss of funding, enrollment was terminated prior to intended accrual of 30 participants.
NCT00924794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112674|Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway|A Retrospective Epidemiological Study of Natural History of HPV Infections in Women Aged 18 Years and Above With Recurrent Conization Following a Primary Conization for High Grade Lesions/ Microinvasive Cervical Carcinomas, in Norway||GlaxoSmithKline||Terminated|June 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|410|||Female|18 Years|N/A|No|Probability Sample|Women aged 18 years and above registered in the Cancer Registry of Norway.|April 2015|April 16, 2015|June 18, 2009||No|This complex study included a pilot and a main part. As the results of the pilot study were    satisfying and conclusive, the main study was not performed.|No||https://clinicaltrials.gov/show/NCT00924794||137317|
NCT00925041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avedro T1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2009|||||N/A|N/A|N/A||||||||||||||June 22, 2015|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925041||137298|
NCT00924196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080079|Natural History Study of Patients With Neurofibromatosis Type I|Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1||National Institutes of Health Clinical Center (CC)||Recruiting|February 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|N/A|100 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924196||137361|
NCT00924209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090107|A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer|Phase II Study of Neoadjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2), Non-Squamous Cell Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)|No|Terminated|March 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||August 2012|August 21, 2012|June 17, 2009|Yes|Yes|Study was terminated due to poor accrual.|No|July 19, 2012|https://clinicaltrials.gov/show/NCT00924209||137360|No primary or secondary goals were met because of low accrual for which the study was closed.
NCT00925015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-016|Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients (0646-016)|A Phase I Study of MK0646 in Combination With Cetuximab and Irinotecan in Patients With Advanced or Metastatic Colorectal Cancer||Merck Sharp & Dohme Corp.||Completed|June 2009|December 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|20 Years|N/A|No|||January 2015|January 29, 2015|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00925015||137300|
NCT00924469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016936|A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer|A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer||Janssen Research & Development, LLC|No|Completed|November 2009|March 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Male|18 Years|N/A|No|||March 2013|March 6, 2013|June 17, 2009|Yes|Yes||No|March 6, 2013|https://clinicaltrials.gov/show/NCT00924469||137342|
NCT00924482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7565-14654|Impedance Cardiography: Clinical Evaluation of Endotracheal Cardiac Output Monitor (ECOM)|Impedance Cardiography: Clinical Evaluation of Endotracheal Cardiac Output Monitor (ECOM)|ECOM|University of California, San Francisco|Yes|Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|261|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|June 17, 2009|Yes|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00924482||137341|
NCT00924768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB9998 Protocol 14|A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers|A Study of Inhalation of 20,000 EU CCRE and MCC in Otherwise Healthy Individuals Who Are Current Cigarette Smokers|IRB 09-0259|University of North Carolina, Chapel Hill|No|Completed|May 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 3, 2013|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00924768||137319|
NCT00925834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUGOKO|Suggestive Effects on the Diameter of Coronary Arteries|Effects of Suggestive Components of Therapeutical Interventions on the Diameter of Coronary Arteries|SUGO-KO|Technische Universität München|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|60|||Both|18 Years|80 Years|No|||June 2009|June 19, 2009|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925834||137237|
NCT00926120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2008.193|The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC|A Phase II, Open-label, Efficacy and Safety Study to Evaluate the Effects of Mogroside Sweetener "PureLo" on Viral Load in Treatment Naïve, Genotype 1 Subjects With Chronic Hepatitis C|PureLo|Brooke Army Medical Center|No|Completed|December 2008|January 2010|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||February 2012|February 13, 2012|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926120||137215|
NCT00926133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSØ-123|Type 2 Diabetes and Acute Myocardial Infarction|Impaired Glucose Tolerance in Patients With Acute Myocardial Infarction.||Ullevaal University Hospital|No|Active, not recruiting|November 2005|December 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|224|Samples Without DNA|Blood samples (serum,plasma) including PaxGene tubes for mRNA sampling|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with acute ST-elevation myocardial infarction without known type 2-diabetes.|June 2009|June 22, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926133||137214|
NCT00926341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFH-CASR-FMD-06|The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome|A Study on the Effects of Peroxisome Proliferators Activated Receptor-γ Agonists on Certain Biochemical and Inflammatory Markers in Patients With Metabolic Syndrome||Aligarh Muslim University|No|Completed|October 2006|September 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|110|||Both|30 Years|70 Years|No|||June 2009|June 23, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926341||137198|
NCT00926627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT - 2007-005117-18|Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis|A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis|BOPSAC|Medical University of Vienna|No|Terminated|April 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|No|||June 2009|August 10, 2010|June 22, 2009||No|Not enough patients with the specified criteria could not|No||https://clinicaltrials.gov/show/NCT00926627||137176|
NCT00926926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTG0901|Effects of Oxybutynin Topical Gel on Gastric Emptying|Effect of Oxybutynin Chloride Topical Gel on Gastric Emptying, Using the Acetaminophen Absorption Test||Watson Pharmaceuticals|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|23|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 5, 2012|June 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00926926||137155|
NCT00928694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0767-031|Fenofibrate Bioequivalence Study (0767-031)|An Open-Label, Randomized, 2-Period, Crossover Study to Determine Definitive Bioequivalence After Administration of Single 160 mg Doses of the U.S. and UK Formulations of Fenofibrate in Healthy Adult Subjects||Merck Sharp & Dohme Corp.||Completed|February 2003|April 2004|Actual|April 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|June 25, 2009|No|Yes||No|November 10, 2009|https://clinicaltrials.gov/show/NCT00928694||137019|
NCT00928707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/08/2357/38|Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera|Phase II Study of the Histone-deacetylase Inhibitor GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Patients With JAK2V617F Positive Polycythemia Vera Non-responder to Hydroxyurea Monotherapy.|PV|Italfarmaco|No|Completed|June 2009|October 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|80 Years|No|||September 2012|September 17, 2012|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928707||137018|
NCT00928993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005369|An Evaluation of Actigraphy as an Indicator of Sleep and Wake in Children|An Evaluation of Actigraphy as an Indicator of Sleep and Wake in Children||Oregon Health and Science University|No|Not yet recruiting|June 2009|June 2012|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|6 Months|18 Years|No|Probability Sample|pediatric patients receiving sleep study as part of their standard medical care|September 2009|September 14, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928993||136996|
NCT00929630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SICCR 10/2006|Seton or Glue for Trans-sphincteric Anal Fistulas|Seton or Glue for Trans-sphincteric Anal Fistulas. A Prospective Randomised Clinical Trial||Societa Italiana di Chirurgia ColoRettale|Yes|Terminated|January 2006|June 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|70 Years|No|||September 2009|September 15, 2009|March 30, 2009||No|Evident advantages of one treatment (seton) over the other (Tissucol Glue)|No||https://clinicaltrials.gov/show/NCT00929630||136949|
NCT00929864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-235|Abatacept Versus Adalimumab Head-to-Head|A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis||Bristol-Myers Squibb|No|Completed|October 2009|November 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|869|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|June 29, 2009|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT00929864||136931|
NCT00928057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDDC-08-011|Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles|Comparison of Glycemic Control Among Diabetics Using the 4mm x 32G BD Pen Needle Versus the 8mm x 31G BD Pen Needle and the 5mm x 31G BD Pen Needle||Becton, Dickinson and Company|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|173|||Both|18 Years|75 Years|No|||September 2010|September 24, 2010|June 24, 2009|Yes|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00928057||137068|
NCT00927147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-BPA-01-2008|Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer|Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) Combined With Anti-erbB1 Antibody Therapy in the Treatment of Locally Recurred Head and Neck Cancer: A Phase I/II Study.||Boneca Corporation|No|Terminated|June 2009|June 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|June 21, 2009||No|The neutron facility closed down for financial reasons.|No||https://clinicaltrials.gov/show/NCT00927147||137138|
NCT00927160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0272|Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit|Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit||Icahn School of Medicine at Mount Sinai|No|Completed|June 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|346|||Both|75 Years|N/A|No|Probability Sample|Older adults hospitalized with a general medical condition in a tertiary hospital in an        urban setting|August 2013|August 13, 2013|June 22, 2009||No||No|June 7, 2013|https://clinicaltrials.gov/show/NCT00927160||137137|
NCT00927706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIUM-8317|Experimental Control Investigation of the Impact of Assistive Technology on the User-caregiver Dyad: a Multi-site Trial|Experimental Control Investigation of the Impact of an Assistive Technology Updating and Tune up Intervention on the User-caregiver Dyad: a Multi-site Trial|ATUTI|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|No|Completed|June 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|65 Years|N/A|No|||February 2014|February 14, 2014|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927706||137095|
NCT00927719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-406-005|Safety Surveillance Study of ACAM2000® Vaccinia Vaccine|A Phase IV Enhanced Safety Surveillance Study of ACAM2000® in Military Personnel||Sanofi|No|Recruiting|December 2008|September 2016|Anticipated|April 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200000|||Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants that had received ACAM2000®, vaccinia virus Smallpox vaccine.|March 2016|March 16, 2016|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927719||137094|
NCT00924261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10101|Age-Related Gait Changes and Hip Flexibility|Age-Related Gait Changes and Hip Flexibility||University of Virginia|Yes|Active, not recruiting|February 2007|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|250|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2009|September 3, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00924261||137357|
NCT00925028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00754|Warfarin Patient Self-Monitoring|THE FEASIBILITY OF PATIENT SELF-MANAGEMENT OF WARFARIN THERAPY IN THE CANADIAN PRIMARY CARE SETTING||University of British Columbia|No|Completed|July 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 4, 2010|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00925028||137299|
NCT00925301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-011|Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations||Amicus Therapeutics|Yes|Completed|August 2009|January 2014|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|16 Years|74 Years|No|||March 2014|March 20, 2014|June 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925301||137278|
NCT00925314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-10-01-02|A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma|A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma||Cosmo Bioscience|No|Active, not recruiting|June 2007|July 2014|Anticipated|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925314||137277|
NCT00925561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|643|Examining the Genetic Predictors of Coronary Artery Calcification in African Americans|Predictors of Coronary Artery Calcification in an African American Cohort||University of Michigan|No|Completed|January 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|752|Samples With DNA|Blood to measure risk factors and stored DNA for genetic studies|Both|20 Years|N/A|No|Non-Probability Sample|The study population will come from Jackson, MS and will include all men and women        belonging to sibships that previously participated in the second GENOA exam. The sampling        frame includes 1482 African Americans in 627 sibships providing 1552 sibling pairs from        Jackson, Mississippi.|June 2013|June 18, 2013|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925561||137258|
NCT00925847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080401|Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis|Open Multicenter Study of Lithium in Patients With Amyotrophic Lateral Sclerosis LISLA|LISLA|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2009|October 30, 2012|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925847||137236|
NCT00925860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCS-2009-1|Non-Positive Pressure Ventilation in Hypoxemic Patients|Non-Positive Pressure Ventilation in Hypoxemic Patients. A Randomized Study||Hospital Provincial de Castellon|Yes|Completed|June 2001|June 2007|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|80 Years|No|||June 2009|June 19, 2009|June 19, 2009||||No||https://clinicaltrials.gov/show/NCT00925860||137235|
NCT00926354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#71 REV 00|Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients|Phase II Open Study to Evaluate Safety and Efficacy of AS101 for the Treatment of Thrombocytopenia in Solid Tumor||BioMAS Ltd|No|Terminated|August 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2011|June 19, 2011|June 17, 2009||No|Sponsor's considerations|No||https://clinicaltrials.gov/show/NCT00926354||137197|
NCT00926367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0000-405|Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications|Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Topical Antibiotic and Benzoyl Peroxide to Benzoyl Peroxide and Adapalene Topical Gel Acne Medications||GlaxoSmithKline|No|Completed|May 2009|July 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|45 Years|No|||May 2015|May 1, 2015|June 21, 2009||No||No|September 7, 2010|https://clinicaltrials.gov/show/NCT00926367||137196|
NCT00926380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080723|Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis|The Denosumab And Teriparatide Administration Study (DATA)|DATA|Massachusetts General Hospital|Yes|Active, not recruiting|June 2009|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|45 Years|N/A|No|||September 2015|September 22, 2015|June 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926380||137195|
NCT00928720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14203|Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia|Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia||University of Virginia|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|57|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|June 24, 2009|No|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT00928720||137017|
NCT00929006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13717|Time Course of Waking Versus Sleep-associated Luteinizing Hormone (LH) Pulse Frequency Suppression in Response to Progesterone in Late Pubertal Girls With and Without Hyperandrogenemia|Time Course of Waking vs. Sleep-associated LH Pulse Frequency Suppression in Response to Progesterone in Late Pubertal Girls With and Without Hyperandrogenemia|CRM003|University of Virginia|Yes|Recruiting|June 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|36|||Female|10 Years|17 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|June 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929006||136995|
NCT00930215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00008|Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males|Open Label, Randomized, Single Center, 2-way Crossover Bioequivalence Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule 40 mg D961H After Repeated Oral Administration in Japanese Healthy Male Subjects||AstraZeneca|No|Completed|June 2009|August 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 9, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930215||136904|
NCT00930228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14067|Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome|Influence of Hyperandrogenemia on the Sleep-associated Slowing of Follicular LH Frequency in Adult Polycystic Ovary Syndrome|CRM004|University of Virginia|Yes|Recruiting|January 2009|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|72|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930228||136903|
NCT00930501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111222|Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients|Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients|Ovrescancer|Hadassah Medical Organization|No|Recruiting|June 2009|December 2013|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|bloods|Female|5 Years|45 Years|No|Non-Probability Sample|females 5-45 years old|June 2009|June 29, 2009|June 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00930501||136882|
NCT00927459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKM-ApoB-001|Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol|A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia||Arbutus Biopharma Corporation|Yes|Terminated|June 2009|January 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|June 23, 2009|Yes|Yes|Potential for immune stimulation to interfere with further dose escalation.|No||https://clinicaltrials.gov/show/NCT00927459||137114|
NCT00924222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFA-5-2007|Organ Protection With Sevoflurane Postconditioning After Cardiac Surgery With Cardiopulmonary Bypass|||University of Zurich|No|Completed|October 2007|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|90 Years|No|||October 2011|October 11, 2011|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924222||137359|
NCT00924248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14332|Primovist Regulatory Post Marketing Surveillance (PMS)|Primovist Regulatory Post Marketing Surveillance||Bayer|No|Completed|October 2007|May 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4358|None Retained|n.a.|Both|N/A|N/A|No|Non-Probability Sample|Korean who take Primovist for liver MRI|September 2012|September 18, 2012|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924248||137358|
NCT00928330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4627g|Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy|A Phase Ib, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Activity of Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy||Genentech, Inc.||Completed|July 2009|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00928330||137047|
NCT00924820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0122|A Pilot Study of Bevacizumab for Neoplastic Meningitis|A Pilot Study of Systemically Administered Bevacizumab in Patients With Neoplastic Meningitis (NM)||M.D. Anderson Cancer Center|No|Completed|June 2009|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2015|November 17, 2015|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924820||137315|
NCT00925106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191355|Pharmacokinetics Of Celecoxib Test Formulations|A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Celecoxib Formulations D1, D2 And D3 In Healthy Volunteers||Pfizer|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 19, 2010|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925106||137293|
NCT00924521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE GRAIN|Grains Reduce Adiposity and Improve Nutrition Study|Grains Reduce Adiposity and Improve Nutrition Study (GRAINS) Increased Whole Grain Intake - Beneficial Effects on Visceral Adiposity, Vascular Function and Glucose Metabolism/Insulin Resistance|GRAIN|Penn State University|No|Completed|March 2009|August 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|35 Years|55 Years|No|||November 2012|November 29, 2012|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924521||137338|
NCT00924534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S337.2.001|A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes|A Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV337 in Patients With Type 2 Diabetes on Metformin Monotherapy||Abbott|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|61|||Both|18 Years|75 Years|No|||August 2011|December 30, 2011|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924534||137337|
NCT00925054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-002|Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU|Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous (SC) Doses of rAvPAL-PEG in Subjects With PKU||BioMarin Pharmaceutical|Yes|Completed|September 2009|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|16 Years|55 Years|No|||July 2015|July 23, 2015|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925054||137297|
NCT00925327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVX-004|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus||CXL|Peschke Meditrade, GmbH|Yes|Not yet recruiting||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|6 Years|18 Years|No|||June 2009|June 19, 2009|June 19, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00925327||137276|
NCT00925067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G.0457.04N|Effects of Lightweight Meshes in Laparoscopic Inguinal Hernia Repair on Quality of Life and Male Fertility Aspects|Effects of Lightweight Meshes in Laparoscopic Inguinal Hernia Repair on Quality of Life and Male Fertility Aspects||Universitaire Ziekenhuizen Leuven|No|Completed|April 2003|June 2009|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|59|||Male|18 Years|50 Years|No|||June 2009|June 18, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925067||137296|
NCT00925574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015817|A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects and in Subjects With Moderate to Severe Psoriasis||Centocor, Inc.|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|71|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|June 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00925574||137257|
NCT00925587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060163|Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease|A Multicenter, Randomised, Double-Blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving Dialysis||Amgen|No|Completed|June 2009|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|358|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|May 28, 2009||No||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00925587||137256|
NCT00926653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH074818|Assessing Anterior Cingulate Brain Activity in People With Late-Life Depression|Anterior Cingulate Activation in Geriatric Depression||Weill Medical College of Cornell University|No|Completed|July 2005|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|76|||Both|60 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Depressed and control participants are recruited from the community, with additional        depressed participants recruited from a geriatric outpatient clinic at New York        Presbyterian/Weill Cornell Medical College.|August 2015|August 10, 2015|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926653||137174|
NCT00926666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW001|A Dose Finding Study for Pain Relief of a Broken Hip|A Dose Finding Study for Ultrasound Guided Anterior Psoas Compartment Blocks in Patients With a Fractured Neck of Femur?||NHS Greater Glasgow and Clyde|Yes|Not yet recruiting|October 2009|April 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Anticipated|48|||Both|35 Years|95 Years|No|||August 2009|August 3, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926666||137173|
NCT00926146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090602901|Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV|HBV Prevention for Homeless at Risk for HBV/HCV/HIV|HBV|University of California, Los Angeles|Yes|Completed|July 2009|February 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|451|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926146||137213|
NCT00927264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|664|PRIDE: Preventing Respiratory Illnesses During Childhood Study|A+ Head Start Intervention for Smoke Free Homes|PRIDE|Johns Hopkins University|Yes|Completed|January 2009|June 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|350|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927264||137129|
NCT00927277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELIPO-001|Low Level Laser Light Therapy as an Aid to Liposuction|Erchonia Medical, Inc., Erchonia EML Laser Liposuction Clinical Study V Protocol||Erchonia Corporation|No|Completed|March 2003|March 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 25, 2009|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927277||137128|
NCT00929019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL22553.000.08|Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients|mRNA Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients||Radboud University|No|Active, not recruiting|June 2009|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||September 2015|September 24, 2015|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929019||136994|
NCT00929344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA014028|Duloxetine Versus Pregabalin for Alcohol Dependence|Duloxetine Versus Pregabalin for Alcohol Dependence||The Scripps Research Institute|Yes|Active, not recruiting|July 2009|November 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929344||136970|
NCT00928174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2009-009|Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer|Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer||Queen's Medical Centre|No|Completed|June 2009|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|27|||Male|18 Years|120 Years|No|||October 2015|October 13, 2015|June 24, 2009|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00928174||137059|
NCT00928187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12169 2LADY|Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)|Multicentric, Non-inferiority, Randomized, Non-blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal)|2LADY|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|November 2009|September 2015|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|454|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928187||137058|
NCT00929604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLS|HIV Viral Load Monitoring in Resource-Poor Settings|Effectiveness of HIV Viral Load Monitoring of Patient Outcome in Resource-Poor Settings||University of Alabama at Birmingham|Yes|Completed|December 2006|June 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2112|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929604||136951|
NCT00929617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROG-SCCI 09-003-2|Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)|Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)|BEAT|University of Alabama at Birmingham|Yes|Active, not recruiting|June 2009|December 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|356|||Female|18 Years|70 Years|No|||August 2015|February 15, 2016|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929617||136950|
NCT00927732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2-D|Hydroquinidine Versus Placebo in Patients With Brugada Syndrome|BRD 06/2-D (Quidam) "Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator"|Quidam|Nantes University Hospital|Yes|Terminated|February 2009|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|June 24, 2009||No|insufficient recruitment, a lot of premature study discontinuations|No||https://clinicaltrials.gov/show/NCT00927732||137093|
NCT00927745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFON study|Clinical Evaluation of AutoFlow Mode During Mechanical Ventilation|Long Term Clinical Evaluation of AutoFlow Mode During Assist-Controlled Ventilation in ICU Patients|AFON|Centre Hospitalier Victor Dupouy|No|Completed|December 2002|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|N/A|No|||June 2009|June 24, 2009|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927745||137092|
NCT00927758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-Sandoz-2009-PilotFP|Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair|Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair||Sandoz Inc.||Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|105|||Both|18 Years|65 Years|No|||April 2014|August 29, 2014|June 23, 2009|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00927758||137091|
NCT00928304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14311|Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.|An Open-Label, Non-Randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection of Cerebral ß-Amyloid in Individuals With Down Syndrome Compared to Individuals Without Down Syndrome||Piramal Imaging SA|No|Completed|June 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|109|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 29, 2014|June 24, 2009|Yes|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT00928304||137049|
NCT00928317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART621-221|Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate|Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate||Arana Therapeutics Ltd|Yes|Terminated|April 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|80 Years|No|||January 2010|January 4, 2010|June 24, 2009|Yes|Yes|Corporate re-prioritization|No||https://clinicaltrials.gov/show/NCT00928317||137048|
NCT00928343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0187-CL-101|First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Subcutaneous and Oral Doses of GLPG0187 in Healthy Subjects.||Galapagos NV|No|Completed|June 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928343||137046|
NCT00924274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EROSO|Effect of Rapeseed Oil and Sunflower Oil|Effect of a Diet With Rapeseed Oil /Sunflower Oil on Lipoprotein in Children and Adolescents With Familial Hypercholesterolemia||Medical University of Vienna|Yes|Recruiting|March 2008|December 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|6 Years|18 Years|No|||June 2009|June 17, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924274||137356|
NCT00925353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSTMRI-002|The Pharmacokinetics of 4% Lidocaine Gel When Applied Topically to the Breasts|The Pharmacokinetics of 4% Lidocaine Gel When Applied Topically to the Breasts||Mountain States Tumor and Medical Research Institute|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|35 Years|N/A|No|||December 2013|December 20, 2013|June 18, 2009||No||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00925353||137274|No placebo comparison group; limited sample size; healthy subjects; lack of variation in doses.
NCT00924807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 004-08|Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer|Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer||Beth Israel Medical Center|No|Terminated|September 2008|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||March 2015|March 4, 2015|June 17, 2009||No|Sponsor closed the trial|No|January 13, 2015|https://clinicaltrials.gov/show/NCT00924807||137316|Data of zero ("0") participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study. Early termination leading to small number of subjects analyzed.
NCT00925080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-900193, Rev01|Pivotal Study of the Intravenous Blood Glucose (IVBG) System, In-Clinic Setting|||DexCom, Inc.|No|Completed|June 2009|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with insulin-requiring diabetes mellitus|February 2010|February 2, 2010|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00925080||137295|
NCT00925093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-MGP-AB-CSV-2009-1|Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection|Antibiotics in Cerebrospinal Fluid Following Intravenous Injection||Aarhus University Hospital|No|Withdrawn|September 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|January 23, 2015|June 18, 2009||No|Primary investigator left institution|No||https://clinicaltrials.gov/show/NCT00925093||137294|
NCT00925340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Spirito-AA017659|Family Check-Up for Adolescents and Siblings|Effects of the Family Check-Up on Adolescents With Alcohol-Related Events and Their Siblings||Brown University|Yes|Completed|September 2008|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|12 Years|18 Years|No|||July 2014|July 28, 2014|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925340||137275|
NCT00926406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-1455C|Environmental Exposure to Lead and Its Health Effects on Patients With Maintenance Hemodialysis|||Chang Gung Memorial Hospital||Recruiting|April 2010|December 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|90 Years|No|||April 2010|April 5, 2010|June 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00926406||137193|
NCT00926692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0266|Investigations Regarding B-cell Subsets in Humans|Investigations Regarding B-cell Subsets in Humans||Northwell Health|Yes|Completed|April 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|249|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Control Population|August 2015|August 24, 2015|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926692||137172|
NCT00926965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD|Tardive Dyskinesia and Cognitive Function|Tardive Dyskinesia and Cognitive Function|TD|Taipei Veterans General Hospital, Taiwan|No|Completed|January 2003|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|65 Years|No|||June 2009|June 23, 2009|March 2, 2008||No||No||https://clinicaltrials.gov/show/NCT00926965||137152|
NCT00927290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-006225-14|Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance|ANRS HC 22, PEGLIST-C, Multicenter, Randomized Controlled Trial of Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C, Non 2 or 3 Genotypes and Insulin Resistance|PEGLIST C|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Active, not recruiting|December 2009|June 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00927290||137127|
NCT00929032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NanospheresLiverEdinburgh09|Liver Transplantation and Reticuloendothelial Clearance Capacity|The Impact of Liver Transplantation on Reticuloendothelial Clearance Capacity||University of Edinburgh|No|Completed|September 2009|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients on the waiting list for liver transplantation will be invited to participate in        the study and written informed consent will be obtained from each participant. Patients        who are undergoing transplantation will be studied before operation, 24 hours after        transplantation and 7 days after transplantation.|October 2010|October 19, 2010|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00929032||136993|
NCT00929357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4617|Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment|A Retrospective Evaluation of the Radiographic Efficacy of Different Conventional Systemic Therapies and Biologics in Patients With Rheumatoid Arthritis in Routine Practice.||Pfizer||Completed|August 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|156|||Both|18 Years|N/A|No|Non-Probability Sample|200|August 2011|August 4, 2011|June 25, 2009||No||No|June 6, 2011|https://clinicaltrials.gov/show/NCT00929357||136969|
NCT00929643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-102311|Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections|The Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|203|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized for complicated intra-abdominal infections|August 2012|August 6, 2012|June 26, 2009||No||No|June 27, 2012|https://clinicaltrials.gov/show/NCT00929643||136948|
NCT00929903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01929|Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment|A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|June 2009|||April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|2 Years|25 Years|No|||September 2013|September 27, 2013|June 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00929903||136928|
NCT00928096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-gating-001|Breathing Adapted Radiotherapy for Mediastinal Lymphoma|Breathing Adapted Radiotherapy for Mediastinal Lymphoma||Rigshospitalet, Denmark|No|Completed|June 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|20 consecutive patients with mediastinal Hodgkin lymphoma and aggressive non-Hodgkin        lymphomas refered to Hematological Clinic, Copenhagen University Hospital, Rigshospitalet|October 2014|October 18, 2014|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928096||137065|
NCT00928070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221049|A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.||Pfizer|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|566|||Both|65 Years|N/A|No|||December 2012|December 10, 2012|June 24, 2009|Yes|Yes||No|December 10, 2012|https://clinicaltrials.gov/show/NCT00928070||137067|
NCT00928083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_09_001|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects|A Phase I Study To Investigate The Safety, Tolerability And Pharmacokinetic Profile Of OZ439 In Healthy Male and Female Subjects||Medicines for Malaria Venture|No|Completed|April 2009|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|17||Actual|63|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|June 24, 2009|No|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT00928083||137066|
NCT00924287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090041|Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)|Yes|Terminated|November 2008|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 17, 2009|No|Yes|This study was terminated after the first patient treated on study died as a result of the    treatment.|No|January 5, 2012|https://clinicaltrials.gov/show/NCT00924287||137355|This study was terminated after the first patient on study died as a result of the treatment.
NCT00924547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081363|Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis|Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma||Vanderbilt University|No|Completed|November 2013|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|6 Years|N/A|No|||July 2015|July 20, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924547||137336|
NCT00924560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-105-202|A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females|A Multicenter, Open-Label, Randomized, Controlled Study to Compare the Effects on Bone Mineral Density of DR-105 and a 28-Day Cycle Oral Contraceptive Regimen in Healthy, Postmenarchal, Adolescent Females||Teva Pharmaceutical Industries|No|Completed|June 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1361|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|June 18, 2009|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT00924560||137335|
NCT00924833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09F602|Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.|Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects.||Istituto Auxologico Italiano|Yes|Completed|May 2006|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2009|September 1, 2009|February 19, 2009||No||No|February 19, 2009|https://clinicaltrials.gov/show/NCT00924833||137314|We used standard doses of both beta blockers and observed similar HR reductions. We could not individually titrate drug doses. The degree of beta blockade might have been different in each subject.
NCT00925600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080560|A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy|A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy||Amgen|Yes|Active, not recruiting|November 2009|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|760|||Male|30 Years|N/A|No|||June 2015|June 25, 2015|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925600||137255|
NCT00925873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS SA4|GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly|A Randomized Study of Fludarabine in Part of Induction and Postremission Treatment for de Novo Acute Myeloid Leukaemia in Elderly Patients||French Innovative Leukemia Organisation|Yes|Completed|June 1996|November 2004|Actual|April 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|60 Years|75 Years|No|||June 2009|June 19, 2009|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00925873||137234|
NCT00926159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version # 3, December 4, 2009|Assessment of Appropriate ICD Implantation for Primary Prevention of Sudden Cardiac Death|"Assessment of Appropriate ICD Implantation for Primary Prevention of Sudden Cardiac Death"||University of Minnesota Physicians Heart at Fairview|No|Completed|March 2008|November 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|549|||Both|18 Years|N/A|No|Non-Probability Sample|Minnesota Heart Clinic Patients with an ejection fraction of 35% or less as identified        from cardiac echocardiogram and/or cardiac nuclear scan.|January 2011|August 3, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926159||137212|
NCT00926393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00040|Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression|A Phase IV, Multi-center, Double-blind, Double-dummy, Randomized, Parallel-group Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (Seroquel IR) With Quetiapine Fumarate Extended Release (Seroquel XR) During Initial Dose Escalation in Patients With Bipolar Depression||AstraZeneca|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|139|||Both|18 Years|50 Years|No|||May 2011|May 10, 2011|June 19, 2009|Yes|Yes||No|May 4, 2010|https://clinicaltrials.gov/show/NCT00926393||137194|
NCT00926172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASC1|Screening Intracranial Aneurysms With Magnetic Resonance Angiography (MRA) in China|Epidemiology of Cerebral Aneurysms With MRA in China in Middle-aged or Elder Person: a Population-based Survey||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|June 2007|June 2010|Anticipated|December 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|4500|||Both|35 Years|75 Years|No|Probability Sample|The investigators recruited 4500-5000 native inhabitants aged 35-75 years lived in China        according to China census-tract data from the year 2005. The gender was accordance with        China census-tract data, and the population aged 35-75 years has a higher incident of        intracranial aneurysm in the literature. Assuming an 8 percent prevalence of intracranial        aneurysm in the general population and using a two-sided alpha value of 0.05, the        investigators estimated that 4500-5000 native inhabitants would need to be enrolled for        the study.|December 2009|December 11, 2009|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926172||137211|
NCT00926978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-292|Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics|Comparison of I-124 and I-131 Radiopharmacokinetics in Patients Who Have Well-differentiated Thyroid Cancer and Are Prepared With Recombinant Human TSH Injection (rhTSH)||Washington Hospital Center|Yes|Recruiting|December 2008|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2011|August 15, 2011|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00926978||137151|
NCT00926718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCMC_09_021|The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy|The Effect of Rocuronium on the Response of CVI to Laryngoscopy||St. Vincent's Medical Center|No|Recruiting|June 2009|||June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|80|||Both|18 Years|75 Years|No|||June 2009|June 22, 2009|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926718||137170|
NCT00926991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute chest wall injuries|Chest Wall Repair of Rib Fractures After Trauma|Chest Wall Stabilization for Traumatic Chest Wall Injuries: An Observational Study||Vanderbilt University|No|Completed|August 2009|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Vanderbilt University Trauma Center.|March 2011|March 21, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926991||137150|
NCT00929370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110791|A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.|A 4-Part Parallel Group, Randomized, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Repeat Doses of GSK1018921 in Healthy Volunteers and Stable Patients With Schizophrenia and to Evaluate Its Effects on Pharmacokinetics of Midazolam.|GT1110791|GlaxoSmithKline||Terminated|July 2008|March 2009|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 25, 2009|June 25, 2009|No|Yes|Study has now been terminated due to changes in project strategy. Current available data will    be analysed and reported in a synoptic study report.|No||https://clinicaltrials.gov/show/NCT00929370||136968|
NCT00929916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#08C.251|Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy|Efficacy of a Low Volume PEG Purgative (MoviPrep®) Administered Entirely in the Morning Compared to Split Dose (PM/AM) Administration||Thomas Jefferson University|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|125|||Both|18 Years|N/A|No|Probability Sample|out-patients scheduled for afternoon colonoscopy in the Thomas Jefferson GI group|March 2013|March 11, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929916||136927|
NCT00925171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009RESP05|Maintenance Schedules Following Pulmonary Rehabilitation|The Effects of Maintenance Schedules Following Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease||University of East Anglia|No|Active, not recruiting|June 2009|June 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|128|||Both|35 Years|65 Years|No|||August 2011|August 3, 2011|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925171||137288|
NCT00930748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-4965-OP-CTIL|Evaluation of MRI for Prostate Cancer|Evaluation of the Potential of Endorectal MRI for the Staging and Recurrence of Prostate Cancer||Sheba Medical Center|No|Terminated|November 2008|June 2011|Actual|June 2011|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|18 Years|80 Years|No|Non-Probability Sample|patients with prostate cancer|June 2011|June 24, 2011|June 22, 2009||No|The MRI company forbidded additional scans with endorectal colil in this machine|No||https://clinicaltrials.gov/show/NCT00930748||136864|
NCT00928473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250609|The Danish Childhood Obesity Biobank|The Danish Childhood Obesity Biobank||Roskilde County Hospital|Yes|Recruiting|January 2009|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|5000|||Both|5 Years|22 Years|No|||November 2015|November 18, 2015|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928473||137036|
NCT00928109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1429|UCAN: Uniting Couples in the Treatment of Anorexia Nervosa|Innovative Trial for the Treatment of Anorexia Nervosa in Late Adolescence and Adulthood|UCAN|University of North Carolina, Chapel Hill|Yes|Completed|April 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928109||137064|
NCT00928122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCAF|Intrastromal Correction of Ametropia by a Femtosecond Laser|Intrastromal Correction of Ametropia by a Femtosecond Laser|ISCAF|20/10 Perfect Vision|No|Recruiting|July 2008|December 2012|Anticipated|January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Both|18 Years|N/A|No|||February 2010|February 7, 2010|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00928122||137063|
NCT00928356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Same Sitting Robotic CABG/PCI|A Single Center Clinical Evaluation of Same Sitting Hybrid Revascularization: Robotic Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Coronary Artery Disease|A Single Center Clinical Evaluation of Same Sitting Hybrid Revascularization: Robotic Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Coronary Artery Disease||Pinnacle Health Cardiovascular Institute|Yes|Recruiting|September 2008|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|N/A|N/A|No|||May 2013|May 2, 2013|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928356||137045|
NCT00925132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807728|Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat|Phase Ib/II: Epigenetic Modification of Chemosensitivity and Apoptosis in Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine, Temozolomide and Panobinostat||University of Iowa|Yes|Active, not recruiting|January 2010|June 2016|Anticipated|November 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925132||137291|
NCT00933569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04838|Dermacyd Silver Floral (Lactic Acid) - Acceptability.|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up Dermacyd Silver Floral (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933569||136652|
NCT00925119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|660|Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes|Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|December 2009|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|N/A|No|||September 2010|September 10, 2010|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00925119||137292|
NCT00925613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proseal08083|Benefits of Exchanging a Double Lumen Tube to a Proseal Laryngeal Mask or a Single Lumen Tube After a Thoracic Surgery|Exchange of a Double Lumen Tube With a Proseal Laryngeal Mask or Single Lumen Endotracheal Tube Before Emergence Following a Thoracic Surgery: a Randomized-controlled Trial.||Université de Montréal|Yes|Completed|April 2009|December 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 21, 2014|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925613||137254|
NCT00925626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/256|Sub-Vastus Versus Mid-Vastus Arthrotomy for Total Knee Arthroplasty: a Randomized Clinical Trial|Sub-Vastus Versus Mid-Vastus Arthrotomy for Total Knee Arthroplasty: a Randomized Clinical Trial With One Year Follow-up||University Hospital, Ghent|No|Suspended|June 2009|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|45 Years|N/A|No|||June 2015|June 3, 2015|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925626||137253|
NCT00925886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01|Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism|Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism||Asociación para Evitar la Ceguera en México|Yes|Completed|July 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|40 Years|80 Years|No|||June 2009|June 19, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925886||137233|
NCT00925899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feldt-01|Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer|Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer||Bispebjerg Hospital|Yes|Completed|October 2009|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925899||137232|
NCT00934908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Green Tea and Olanzapine|Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine|Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine||Medical University of South Carolina|No|Recruiting|March 2009|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|55 Years|No|||July 2009|July 7, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934908||136550|
NCT00934921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B026528|Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 8 mg Orally Disintegrating Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|February 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 8, 2009|July 6, 2009|No|Yes||No|July 8, 2009|https://clinicaltrials.gov/show/NCT00934921||136549|
NCT00926419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0911/08|Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery|Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery|InjHepAVar|University of Sao Paulo General Hospital|No|Not yet recruiting|June 2009|May 2010|Anticipated|November 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|10||Anticipated|600|||Both|13 Months|30 Months|Accepts Healthy Volunteers|||May 2009|June 22, 2009|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926419||137192|
NCT00926432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/32|Postural Balance of the Adult|3D Evaluation of Postural Balance of the Adult Affected by Postural Trouble, Using EOS™ Images and 3D-reconstructions With Regard to Gravity Line.|POSTURADULT|University Hospital, Bordeaux|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 6, 2013|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00926432||137191|
NCT00926705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alghanem2|Dexmedetomidine Infusion in Hypospadias Surgery|An Intraoperative Infusion of Dexmedetomidine Reduces the Opioid Requirements for Pediatric Patients Undergoing Hypospadias Surgery||University of Jordan|Yes|Completed|June 2008|January 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|48|||Male|1 Year|12 Years|No|||June 2009|June 22, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926705||137171|
NCT00926731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00018|Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)|A Phase I, Open-label, Multi-centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML)||AstraZeneca||Completed|June 2009|May 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|60 Years|N/A|No|||June 2011|June 15, 2011|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926731||137169|
NCT00935220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.55|Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients|An Open Label, Phase I Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Linagliptin (BI 1356) 5 mg After Single and Multiple Oral Administration in Patients With Type 2 Diabetes Mellitus of African American Origin for 7 Days||Boehringer Ingelheim||Completed|June 2009|||August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|21 Years|65 Years|No|||February 2014|June 17, 2014|July 1, 2009||||No|August 22, 2011|https://clinicaltrials.gov/show/NCT00935220||136527|
NCT00935740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5809-96|Tissue Factor Expression in Stage C Heart Failure|Tissue Factor Expression in Stage C Heart Failure|TFHF|University of Utah|No|Completed|December 1996|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|75|Samples Without DNA|50 ml of Serum|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Heart failure|July 2009|July 7, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00935740||136487|
NCT00935753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WLN01|Trial of Kuvan in Lesch-Nyhan Disease|Trial of Kuvan™ (Sapropterin) Treatment in Patients With Lesch Nyhan Disease||University of California, San Diego|No|Withdrawn||||||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|4 Years|N/A|No|||March 2010|March 15, 2010|July 8, 2009|Yes|Yes|Contractual issues|No||https://clinicaltrials.gov/show/NCT00935753||136486|
NCT00927329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0196|Evaluation of a Nasal Allergen Challenge Procedure Using Dust Mite Extract|Evaluation of the Safety and Effect of an Allergen Challenge Procedure on Nasal Airway Inflammation in Allergic Individuals Using a Dermatophagoides Farinae Extract Nasal Allergen Challenge Protocol|Dusty|University of North Carolina, Chapel Hill|No|Not yet recruiting|October 2016|April 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927329||137124|
NCT00927589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4613g|A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer|A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer||Genentech, Inc.||Completed|July 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|June 24, 2009|No|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT00927589||137104|
NCT00927875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA194-005|A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer|A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer||Bristol-Myers Squibb|No|Completed|February 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927875||137082|
NCT00927888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05072009-2478|Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery|The Effect of Preemptive Sphenopalatine Ganglion Block on Anesthetic Requirements, Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery||Stanford University|No|Completed|August 2007|August 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||November 2015|November 16, 2015|June 23, 2009||No||No|December 18, 2012|https://clinicaltrials.gov/show/NCT00927888||137081|
NCT00928486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-022|A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Subjects With Previously Treated Multiple Myeloma|A Safety Confirmation Study On Lenalidomide With Dexamethasone In Japanese Subjects With Previously Treated Multiple Myeloma||Celgene||Completed|May 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|N/A|No|||January 2011|January 26, 2011|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928486||137035|
NCT00924365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070087|Natural History Study of HIV Acquired in Infancy or Childhood|A Natural History Study of HIV Acquired in Infancy or Childhood||National Institutes of Health Clinical Center (CC)||Completed|February 2007|April 2014||||N/A|Observational|N/A|||Actual|54|||Both|6 Years|N/A|Accepts Healthy Volunteers|||April 2014|October 23, 2014|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924365||137349|
NCT00928395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPC121908|Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms|Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation|STEP|Uroplasty, Inc||Completed|January 2009|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|June 24, 2009|No|Yes||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00928395||137042|
NCT00928369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-04-053|Clinical Characteristics of Patients Under the Age 21 Years Who Underwent Gynecological Surgery|Clinical Characteristics of Adnexal Masses in Korean Pediatric and Adolescent Patients Under the Age 21 Years||Samsung Medical Center|No|Active, not recruiting|May 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|494|||Female|1 Year|20 Years|No|Non-Probability Sample|The incidence of gynecologic surgery during the pediatric and adolescent period remains        low. In this age group, the causes of gynecologic surgery were usually divided into three        parts, congenital anomalies, genital traumas, and pathologic lesions of genital tract        including uterine bady and cervix, ovaries, fallopian tubes, vagina, and vulva. Among        these, adnexal masses generally have been the most common cause of gynecologic surgery in        the pediatric and adolescent patients.|June 2009|June 24, 2009|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00928369||137044|
NCT00933283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015931|A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State|A Phase I, Open-Label, Single-Sequence Drug-Drug Interaction Trial in Subjects on Stable Methadone Maintenance Therapy, to Investigate the Potential Interaction Between Telaprevir 750 mg q8h and Methadone, at Steady-State||Tibotec BVBA|No|Completed|July 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933283||136674|
NCT00933296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4350|Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors|Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic||University Hospital, Strasbourg, France|No|Recruiting|July 2009|March 2016|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|Samples With DNA|White cells Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|University hospitals|November 2012|November 16, 2012|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933296||136673|
NCT00933842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04805|Dermacyd PH_DESILSTY_FL (Lactic Acid) - Photo Evaluation - Stay on Floral|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DESILSTY_FL (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933842||136632|
NCT00925366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020909|Which is the Most Reliable Radiologic Examination for the Diagnosis of Rotator Cuff Tendon Tear?|Comparative Performances of CT-arthrography, MRI and MR-arthrography in the Preoperative Assessment of the Rotator Cuff Tendon Tears, Surgical Observations Being Used as a Standard.|COIFFE|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2003|June 2009|Actual|September 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|64|||Both|18 Years|N/A|No|||June 2009|July 28, 2009|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925366||137273|
NCT00925379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070151|Renal HYPODYSPLASIA : Genetic and Familial Assessment|Renal HYPODYSPLASIA;Study of Familial Cases and Search for Predisposing Genes|HDR|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2009|July 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|342|Samples With DNA|DNA collection from the propositus and its parents and in case of families with more than      one affected member, collection of DNA from the all family.|Both|3 Months|18 Years|No|Non-Probability Sample|Children with a bilateral renal hypodysplasia|July 2014|July 25, 2014|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925379||137272|
NCT00925639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/UNIFESP 0728/08|Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause|Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause||Federal University of São Paulo|No|Not yet recruiting|August 2009|August 2010|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 19, 2009|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925639||137252|
NCT00925652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-134|Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer|ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer|ABCDE|Dana-Farber Cancer Institute|Yes|Terminated|September 2010|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|55|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|June 19, 2009|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00925652||137251|
NCT00934128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0164|High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer|An Exploratory Trial of Bilevel Positive Airway Pressure Device and High Flow Oxygen for Persistent Dyspnea in Advanced Cancer Patients||M.D. Anderson Cancer Center|Yes|Completed|August 2009|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 7, 2009||No||No|June 10, 2013|https://clinicaltrials.gov/show/NCT00934128||136610|
NCT00925912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s023h/49|A Trial of Closed Hemorrhoidectomy Under Local Perianal Block Versus Spinal Anesthesia|A Randomized Clinical Trial of Closed Hemorrhoidectomy Under Local Perianal Block Versus Spinal Anesthesia||Phramongkutklao College of Medicine and Hospital|Yes|Completed|December 2006|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2009|June 19, 2009|June 18, 2009||||No||https://clinicaltrials.gov/show/NCT00925912||137231|
NCT00926185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118-KCS-100|A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye|A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model||Shire|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|230|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|June 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926185||137210|
NCT00935233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-ICICLE|Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy Volunteers|ICICLE- A Study to Investigate the genetiCs of In Situ Carcinoma of the ductaL subtypE||National Cancer Institute (NCI)||Recruiting|July 2008|||July 2010|Anticipated|N/A|Observational|N/A|||Anticipated|6000|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2009|August 9, 2013|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935233||136526|
NCT00934934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANTREAT|Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment|Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study|CANTREAT|Clinical Evaluation Research Unit at Kingston General Hospital|No|Terminated|April 2010|December 2013|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|60|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|July 7, 2009||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT00934934||136548|
NCT00935207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0054|Study of the Impact of a Pain Diary in Pediatric Patients|The Impact of a Pain Diary on the Communication of Pain in Pediatric Patients||University of Mississippi Medical Center|No|Terminated|June 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|8|||Both|3 Years|19 Years|No|Non-Probability Sample|Inpatients at the Blair E. Batson Hospital for Children 3-19 years of age, receiving        regular controlled substance analgesic defined as: codeine with acetaminophen, fentanyl,        hydromorphone, meperidine, morphine, oxycodone with acetaminophen, propoxyphene with        acetaminophen, and hydrocodone with acetaminophen.|May 2013|May 2, 2013|June 17, 2009||No|Poor enrollment and data collection|No||https://clinicaltrials.gov/show/NCT00935207||136528|
NCT00935467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-091|Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects|A Study to Characterize the Steady-State Pharmacokinetics and Pharmacodynamics of 2.5 mg Saxagliptin Administered Twice Daily With Meals to Healthy Subjects||AstraZeneca|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|July 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935467||136508|
NCT00935766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0722 LUCHAR AIM 4|Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries|Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation||Denver Health and Hospital Authority|No|Terminated|September 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|76|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|July 8, 2009|Yes|Yes|The study was discontinued early due to lack of funding and slow enrollment|No|February 11, 2014|https://clinicaltrials.gov/show/NCT00935766||136485|The study was discontinued early due to lack of funding and slow enrollment
NCT00936065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-4625|Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis|A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis||Pfizer|No|Completed|July 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||March 2012|March 12, 2012|July 7, 2009|No|Yes||No|March 12, 2012|https://clinicaltrials.gov/show/NCT00936065||136462|One of the protocol-defined endpoints was change from baseline in the participant's assessment of general health, however data was collected and analyzed for change from baseline in the participant's assessment of joint pain.
NCT00936078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-117|Living Kidney Donor Study|Long-term Effects of Becoming a Living Kidney Donor Study|LKD|Lawson Health Research Institute|Yes|Recruiting|June 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Serum Urine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The donors will come from the identified population of people who will be donating their        kidney at the hospital sites participating in this study.        The non-donor population will be people who the donors identify and ask to act as their        control person. As well, controls will also be found using pamphlet and poster board        advertising.|January 2016|January 25, 2016|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936078||136461|
NCT00924885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitrolife-needle-01|Experience of Pain During Oocyte Retrieval- a Comparison Between Two Aspiration Needles|Experience of Pain During Oocyte Retrieval- a Comparison Between Two Aspiration Needles||Vitrolife|No|Completed|June 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Female|N/A|N/A|No|||October 2013|October 28, 2013|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924885||137310|
NCT00924391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WWB2007:110|Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans|Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans Study 1||University of Manitoba|Yes|Completed|September 2007|August 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||June 2009|June 17, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00924391||137348|
NCT00928499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-6736|Trial of Continuous Versus Cyclic Stimulation in Interstim Therapy|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy||University of California, Irvine|Yes|Recruiting|April 2009|June 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||November 2010|November 16, 2010|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928499||137034|
NCT00928512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2201|Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)|A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate||Novartis|No|Completed|July 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|237|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 25, 2009|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT00928512||137033|
NCT00924924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1141037|Act Healthy! A Controlled Trial of Worksite Health Promotion|Act Healthy! A Controlled Trial of Worksite Health Promotion||University of Missouri-Columbia|No|Active, not recruiting|August 2009|July 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 30, 2010|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924924||137307|
NCT00924573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10846|Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride|Double-blinded Comparative Study to Investigate the Efficacy and Safety of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride in Patients With T2DM Inadequately Treated With Constant Dose of Glimepiride||Sanofi|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|189|||Both|20 Years|74 Years|No|||August 2011|August 30, 2011|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924573||137334|
NCT00924586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-1101-27|Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT)|Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT), a Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study||Ono Pharmaceutical Co. Ltd||Completed|June 2009|||February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|258|||Both|20 Years|N/A|No|||June 2012|June 12, 2012|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924586||137333|
NCT00924300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217-09-FB|Study to Test the Usefulness of Magnetoencephalography (MEG) Imaging of Cognition in Children and Adolescents|Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) Studies of Typical and Atypical Cognitive Processes in Children and Adolescents||University of Nebraska|No|Recruiting|July 2009|June 2020|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|150|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|children and adolescents with or without a psychiatric disorder|December 2014|January 30, 2015|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00924300||137354|
NCT00933582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016420|A Clinical Study to Investigate the Effect on Pain Relief of a Single Dose of JNJ-39439335 in Patients With Chronic Osteoarthritis Pain of the Knee|A Randomized, Double-Blind, Placebo-Controlled Clinical Study of Single Doses of JNJ-39439335 Versus Single and Multiple Doses of Naproxen Versus Placebo in the Treatment of Painful Osteoarthritis of the Knee: Focus on Treatment Effects and Methodological Advances||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Actual|33|||Both|21 Years|65 Years|No|||July 2010|July 29, 2010|July 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00933582||136651|
NCT00934154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMSG-2005-001|Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma|Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma||Erkim Ilac A.S.|Yes|Completed|March 2006|September 2012|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|55 Years|N/A|No|||August 2013|August 14, 2013|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934154||136608|
NCT00934401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903755|Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer|Positron Emission Mammography With 3'-Deoxy-3'-[18F] Fluorothymidine (FLT PEM) for Evaluation of Response to Neoadjuvant Chemotherapy in Breast Cancer||University of Iowa|Yes|Terminated|July 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|N/A|No|Non-Probability Sample|Women diagnosed with breast cancer whose recommended treatment is neoadjuvant chemotherapy        followed by surgical resection.|June 2010|June 1, 2010|July 6, 2009|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT00934401||136589|
NCT00933829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12177|Comparison of Cosmetic Outcomes of Lacerations Repaired Using Absorbable Versus Non-absorbable Sutures|Comparison of Cosmetic Outcomes of Lacerations of the Trunk and Extremity Repaired Using Absorbable Versus Non-absorbable Sutures||Temple University|No|Completed|April 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|1 Year|65 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933829||136633|
NCT00934115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0061-07-RMC|Epidemiology of Infections in Pediatric Cancer Patients|Epidemiology of Infections in Pediatric Cancer Patients: A Prospective Multicenter Study in Israel||Rabin Medical Center|No|Active, not recruiting|January 2008|||||N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|N/A|20 Years|No|Probability Sample|Pediatric cancer patients|July 2009|July 15, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934115||136611|
NCT00934362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0795|Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease|A Double Blind, Cross-Over Study Comparing Aerosolized Lucinactant and Vehicle on Mucociliary Clearance for Cystic Fibrosis Lung Disease||University of North Carolina, Chapel Hill|Yes|Completed|October 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|14 Years|N/A|No|||January 2013|January 17, 2013|July 6, 2009|Yes|Yes||No|June 11, 2012|https://clinicaltrials.gov/show/NCT00934362||136592|
NCT00934375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-414|A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment|A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment||Eisai Inc.||Completed|February 2006|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|45 Years|90 Years||||December 2013|December 12, 2013|May 14, 2009|Yes|Yes||No|July 25, 2011|https://clinicaltrials.gov/show/NCT00934375||136591|
NCT00934674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1115|Study Comparing Two Different Tablet Formulations Of Bosutinib|A Single Dose Bioequivalence Study Comparing the Commercial Tablet Formulation to the Clinical Tablet of Bosutinib in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|July 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00934674||136568|
NCT00934661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006969|Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing|Low Dose Extended-release Epidural Morphine in Conjunction With Lumbar Plexus Block Versus Lumbar Plexus Block Alone for Total Hip Resurfacing Arthroplasty: A Randomized Controlled Trial.||Wake Forest School of Medicine|No|Recruiting|January 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2011|May 18, 2011|July 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934661||136569|
NCT00935493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0805003881|Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects|Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects||Yale University|Yes|Completed|June 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|154|||Both|75 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 10, 2014|July 7, 2009||No||No|June 18, 2014|https://clinicaltrials.gov/show/NCT00935493||136506|
NCT00935480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-2009.01|IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients|IMPACT OF THERAPY INTENSIFICATION BY AN INTEGRASE INHIBITOR +/- CCR5 INHIBITOR ON THE LYMPHOID RESERVOIR FOR HIV-1 IN CHRONICALLY INFECTED PATIENTS|IntensVIH|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|No|Completed|July 2010|February 2013|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935480||136507|
NCT00936091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS178-2007B, PS178-2007B|Effects of Vitamin A Supplementation on Intestinal Parasitic Reinfections|Effects of Vitamin A Supplementation on Intestinal Parasitic Reinfections, Growth, Iron Status and Educational Achievement Among Orang Asli Schoolchildren in Pos Betau, Pahang, Malaysia||Sana'a University|No|Completed|May 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|250|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||July 2009|August 3, 2009|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00936091||136460|
NCT00924638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYSTAL-AF|Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke|CRYptogenic STroke And underLying AF Trial|CRYSTAL-AF|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|June 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|447|||Both|40 Years|N/A|No|||January 2014|June 26, 2014|June 17, 2009|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00924638||137329|
NCT00928213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|972-07-024|PP13 and Doppler Study to Predict Preeclampsia|Combined Sonographic Examination and Placenta Protein 13 (PP13) to Compare the Risk for Development of Preeclampsia Among Among Pregnant Women With and Without a History of Preterm Delivery and Those Treated by Progesterone or Clexane||Ben-Gurion University of the Negev|No|Not yet recruiting|August 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|1000|||Female|16 Years|45 Years|No|||June 2009|June 24, 2009|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928213||137056|
NCT00924690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-CCEP|Colon Cancer Prevention Study|Disparities in Colorectal Cancer Prevention Behaviors||University of North Carolina, Chapel Hill|No|Completed|June 2009|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|207|||Female|50 Years|80 Years|Accepts Healthy Volunteers|||July 2010|July 6, 2010|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00924690||137325|
NCT00924703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-003|Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)|Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU||BioMarin Pharmaceutical|Yes|Active, not recruiting|January 2010|August 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|16 Years|55 Years|No|||May 2015|May 7, 2015|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924703||137324|
NCT00924677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN0901|The Effect of Therapeutic Methods for Chronic Knee Osteoarthritis Pain|Phase 1 Study of Therapeutic Methods for Chronic Knee Osteoarthritis Pain||Asan Medical Center|Yes|Completed|January 2009|June 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2009|June 18, 2009|June 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924677||137326|
NCT00924911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112034|Relative Bioavailability Study in Healthy Subjects|A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects|PDF112034|GlaxoSmithKline|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|June 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00924911||137308|
NCT00925210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22176|Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach|Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach Using Peripheral Endobronchial Ultrasonography and Electromagnetic Navigation Bronchoscopy||University of Calgary|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|16 Years|N/A|No|||September 2010|September 10, 2010|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925210||137285|
NCT00937092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUH-DC-101-FT|Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial|Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure|DAD-HF|Larissa University Hospital|No|Recruiting|January 2009|July 2012|Anticipated|January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|90 Years|No|||May 2010|May 25, 2010|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00937092||136383|
NCT00924846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-26|High-Frequency Oscillatory Ventilation Associated With Inhaled Nitric Oxide in Children|High-Frequency Oscillatory Ventilation Associated With Inhaled Nitric Oxide in Children: Randomized, Crossover Study||UPECLIN HC FM Botucatu Unesp|No|Completed|April 2005|June 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|1 Month|14 Years|No|||June 2009|June 19, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924846||137313|
NCT00933855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-148|Patient Communication Training Intervention|A Feasibility Study of a Patient Communication Training Intervention||Memorial Sloan Kettering Cancer Center||Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the Queen Cancer Center Clinic waiting room.|November 2011|November 22, 2011|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00933855||136631|
NCT00934167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPHIP0509_PRO|Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients|NON CLINICAL INFERIORITY OF HEPARIN SODIUM PRODUCED BY HIPOLABOR FARMACEUTICA LTDA COMPARED TO THE HEPARIN SODIUM PRODUCED BY APP PHARMACEUTICALS IN VENOUS THROMBOEMBOLISM PROPHYLAXIS, IN SURGICAL PATIENTS WITH MEDIUM RISK FOR DEVELOPMENT OF THROMBOEMBOLISM.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Active, not recruiting|May 2010|September 2011|Anticipated|November 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2010|October 26, 2010|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934167||136607|
NCT00934180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B026527|Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 8 mg Orally Disintegrating Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 8, 2009|July 6, 2009|No|Yes||No|July 8, 2009|https://clinicaltrials.gov/show/NCT00934180||136606|
NCT00934141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA020832|Evaluating Improvement Strategies in Addiction Treatment|Randomized Control Trial (RCT) Evaluating Improvement Strategies in Addiction Treatment|NIATx 200|University of Wisconsin, Madison|Yes|Completed|October 2006|January 2011|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|201|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2013|July 29, 2013|July 6, 2009||No||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00934141||136609|
NCT00934388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRW 001|A Randomised, Blinded Study on Laparoscopic Mesh Reinforcement for Chronic Groin Pain|A Randomised, Blinded Study on Laparoscopic Mesh Reinforcement for Chronic Groin Pain.||Royal Hobart Hospital|No|Not yet recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|50 Years|No|||March 2010|March 15, 2010|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934388||136590|
NCT00934687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009DR2125|Botulinum Toxin for the Treatment of Depression|Clostridium Botulinum Type A Neurotoxin Complex for Adjuvant Treatment of Depressive Disorders - a Randomized Controlled Pilot Study||University Hospital, Basel, Switzerland|Yes|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|25 Years|65 Years|No|||August 2013|August 13, 2013|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934687||136567|
NCT00934947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0681|Burn Healing and Analgesia With Propranolol|The BURN HELP Trial: BURN Healing and AnaLgesia With Propranolol|BURN HELP|University of North Carolina, Chapel Hill|Yes|Completed|July 2009|June 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|59 Years|No|||October 2014|October 7, 2014|July 6, 2009|Yes|Yes||No|May 7, 2012|https://clinicaltrials.gov/show/NCT00934947||136547|
NCT00935805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06260|Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy|ANALYSIS OF THE EFFECTIVENESS OF A STAGED MANAGEMENT PROGRAM AIMED AT CONTROLLING BLOOD PRESSURE AND BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENTS USING EXCLUSIVELY THE RESOURCES AVAILABLE IN A PRIMARY CARE SETTING IN BRAZIL||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|July 2006|July 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|124|||Both|30 Years|85 Years|No|Probability Sample|Type 2 diabetic patients attending a primary care outpatient facility|July 2011|October 25, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935805||136482|
NCT00936104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-PDAC-SP|Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)|Prognostic and Therapeutic Relevance of the 'Side Population' in Pancreatic Cancer||University Hospital, Gasthuisberg||Completed|August 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Pancreatic cancer tissue specimen|Both|18 Years|85 Years|No|Probability Sample|SP cells will be identified through incubation with vital dye Hoechst 33342 of cell        suspensions that are obtained from fresh human pancreatic cancer resection specimens.|July 2012|July 1, 2012|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936104||136459|
NCT00935779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAIC 043/02|Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer|Ultra Structure of Peritoneum at Electronic Microscopy in Control Subjects and Patients With Gastric Cancer||University of Chile|No|Completed|October 2002|December 2004|Actual|July 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|18|||Both|18 Years|N/A|No|Non-Probability Sample|patients with operable local gastric adenocarcinoma consulting to Hospital Clinico,        University of Chile during study period.|July 2009|July 8, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935779||136484|
NCT00935792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC088C|Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study||Mayo Clinic|Yes|Completed|July 2009|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|120 Years|No|||January 2016|January 6, 2016|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00935792||136483|
NCT00936572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.06.CLI|Probiotics In Colorectal Cancer Patients|A Randomized Double-Blind Trial of Perioperative Administration of Probiotics in Colorectal Cancer Patients.||University of Milano Bicocca|Yes|Completed|October 2006|October 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|80 Years|No|||July 2009|July 9, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936572||136423|
NCT00936585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090175|NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease|NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease||National Institutes of Health Clinical Center (CC)|Yes|Terminated|July 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|July 9, 2009|Yes|Yes|Study halted by the sponsor|No|April 24, 2013|https://clinicaltrials.gov/show/NCT00936585||136422|The NIH sub study ended earlier than anticipated as the Novartis main study was terminated for futility. As a result, not enough patients were enrolled to perform any analysis of data.
NCT00927927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8555-3618|First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Dose-escalation, Single and Multiple Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0142-0002 Administered Subcutaneously to Subjects With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|15||Actual|65|||Both|18 Years|75 Years|No|||October 2013|October 21, 2013|June 24, 2009|No|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT00927927||137078|Maximum tolerated dose was not reached.
NCT00927940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT2-07-03|RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent|The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries|RJ|Medtronic Vascular|Yes|Completed|March 2009|February 2015|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|20 Years|N/A|No|||April 2015|April 14, 2015|June 23, 2009||No||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00927940||137077|
NCT00928538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|832|Nurse Family Partnership (NFP) Contraceptive Study|Effectiveness of Home Based Distribution of Hormonal Contraceptives for Women at Risk for Unintended Pregnancy|NFP2|Oregon Health and Science University|No|Recruiting|September 2009|May 2015|Anticipated|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Female|15 Years|45 Years|No|||April 2015|April 20, 2015|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928538||137031|
NCT00928551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3153B3-1128|Comparative Formulation Study of Vabicaserin|A Randomized, Open-Label, Single-Dose, 3-Period Crossover, Comparative Study of a Modified Formulation of Vabicaserin (SCA-136) Versus the Reference Formulation in Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|September 10, 2009|June 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00928551||137030|
NCT00924417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRCIRB#2008-13630|A Distraction Protocol for Peripheral Intravenous (IV) Placement in the Pediatric Emergency Department|A Distraction Protocol for Peripheral IV Placement in the Pediatric Emergency Department||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Enrolling by invitation|January 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|4 Years|9 Years|No|||June 2009|June 18, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924417||137346|
NCT00924430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S337.1.002|Interaction Study SLV337/Simvastatin|A Drug Interaction Study to Investigate the Effects of SLV337 on the Pharmacokinetics of Simvastatin and Simvastatin Acid in Healthy Male Volunteers||Solvay Pharmaceuticals|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 4, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00924430||137345|
NCT00924716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVX-0601|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2009|||||N/A|N/A|N/A||||||||||||||June 18, 2009|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924716||137323|
NCT00924937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORDIOPREV|CORonary Diet Intervention With Olive Oil and Cardiovascular PREVention|Randomized Clinical Trial on the Effects of Mediterranean Diet (Rich on Olive Oil) in the Reduction of Coronary Events of Patients With Coronary Disease|CORDIOPREV|Hospital Universitario Reina Sofia|Yes|Active, not recruiting|November 2009|September 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|1002|||Both|20 Years|75 Years|No|||March 2016|March 2, 2016|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924937||137306|
NCT00924950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5939-31328-02|Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis|An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Taclonex Ointment With Hydrogel Patch Occlusion to Taclonex Ointment Without Occlusion in the Treatment of Plaque-Type Psoriasis||University of California, San Francisco|No|Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|June 17, 2009|Yes|Yes||No|August 4, 2011|https://clinicaltrials.gov/show/NCT00924950||137305|
NCT00937118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 5128|Damage Control for Duodenal and Combined Duodenal-Pancreatic Injuries|Damage Control for Severe Duodenal and Combined Duodenal-Pancreatic Injuries: A Retrospective Review||Oregon Health and Science University|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|43|||Both|N/A|N/A|No|Non-Probability Sample|Trauma patients who received a trauma laparotomy for a duodenal or combined        duodenal/pancreatic injury|May 2013|May 13, 2013|July 9, 2009||No||No|May 4, 2012|https://clinicaltrials.gov/show/NCT00937118||136381|
NCT00937378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC-SER120-DB2-200902|Treatment of Patients With Nocturia (Non-PK Study)|A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)||Serenity Pharmaceuticals, Inc.|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|326|||Both|50 Years|N/A|No|||April 2014|April 17, 2014|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937378||136362|
NCT00937365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5033|Pregnancy-Related Low Back Pain and Complementary and Alternative Medicine (CAM) Treatment|A Pilot Randomized Controlled Trial for Complementary and Alternative Medicine Treatment of Pregnancy-Related Low Back Pain.||Oregon Health and Science University|No|Recruiting|July 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|20 Years|49 Years|Accepts Healthy Volunteers|||July 2009|July 21, 2010|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937365||136363|
NCT00933868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-R001|Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke|Comparison of Magnesium Chloride Infusions Versus Placebo Administered Concomitantly With 100% Oxygen Given to Patients Who Have Residual Muscle Weakness From a Stroke That Occurred Three Months to Four Years Ago||Relox Medical, LLC|No|Completed|April 2009|July 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|90 Years|No|||September 2010|May 23, 2012|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00933868||136630|
NCT00934999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007334|Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy|A Randomized Comparison of Concomitant Incontinence Procedures Performed With Abdominal Sacral Colpopexy: the Burch Versus Mid-urethral Sling Trial||Mayo Clinic|No|Completed|June 2009|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|113|||Female|21 Years|N/A|No|||March 2016|March 18, 2016|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00934999||136543|
NCT00935012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX1B-303|Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy|Open-label Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-type Transthyretin (Ttr) Amyloid Cardiomyopathy||Pfizer|Yes|Active, not recruiting|September 2009|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|40 Years|N/A|No|||March 2016|March 24, 2016|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00935012||136542|
NCT00934414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-016|Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes|A Parallel, Controlled, Multi-Center, Single-Dose, One-Period Euglycemic Clamp Study Comparing Prandial Inhalation of Technosphere Insulin in Smokers and Non-Smokers With Type 2 Diabetes||Mannkind Corporation|No|Completed|August 2004|September 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|65 Years|No|||July 2009|July 7, 2009|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934414||136588|
NCT00934700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prot-002-2009|Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia|Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia|TOBYXe|Imperial College London|Yes|Completed|February 2012|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|N/A|12 Hours|No|||April 2012|October 27, 2014|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934700||136566|
NCT00934960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC 09-001|Multifocals and Accommodating/Bilateral Implantation of Different Multifocal Intraocular Lens (IOLs)|Distance, Intermediate and Near Visual Outcomes, Range of Vision and Patient Satisfaction After Bilateral Implantation of Different Multifocal IOLs||Medical University of South Carolina|No|Terminated|March 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|9|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|A total of 50 patients of both sexes and any race or ethnic background who underwent        uneventful routine bilateral cataract extraction and multifocal or accomodating        intraocular lens implantation will be included. Subjects will be divided in 5 groups of 10        subjects each based on the IOL implanted as follows: ReSTOR +4.0 D, ReSTOR +3.0 D,        Crystalens, ReZoom, and Mix-and-match (patients implanted with ReSTOR in one eye and        ReZoom in the fellow eye).|November 2009|November 17, 2009|July 6, 2009||No|PI separated employment from the university.|No||https://clinicaltrials.gov/show/NCT00934960||136546|
NCT00934973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5953|Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)|Management of Irritable Bowel Syndrome in Primary Care: Feasibility Randomised Controlled Trial of Mebeverine, Methylcellulose, Placebo and a Patient Self-management Cognitive Behavioural Therapy Website. (MIBS Trial)|MIBS|University of Southampton|No|Completed|April 2010|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|135|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00934973||136545|
NCT00935246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-12-042|Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning|Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning||Samsung Medical Center|Yes|Active, not recruiting|December 2008|December 2016|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|202|||Both|19 Years|89 Years|No|||December 2015|December 30, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935246||136525|
NCT00935272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1300-15|Safety/Efficacy Study of Restylane® in Lip Augmentation|A Randomized, Evaluator-Blinded, No-Treatment-Controlled Study of the Effectiveness and Safety of Restylane® in the Augmentation of Soft Tissue Fullness of the Lips||Medicis Global Service Corporation|No|Completed|July 2009|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|65 Years|No|||December 2011|December 22, 2011|July 7, 2009|No|Yes||No|November 2, 2011|https://clinicaltrials.gov/show/NCT00935272||136523|
NCT00936351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4786-W|Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia|Mindfulness as a Rehabilitation Strategy in Schizophrenia||VA Office of Research and Development|No|Completed|December 2007|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|July 8, 2009||No||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00936351||136440|The sample was middle-aged males with chronic schizophrenia, not representative of the broader population. Raters of work quality were not blinded to condition. Mindfulness and support conditions were not equally matched on intensity of intervention.
NCT00936598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09040160|Sleep and Endometrial Cancer|Surgery for Endometrial Cancer: Biobehavioral Analysis of Sleep, Stress and Pain||University of Pittsburgh|Yes|Terminated|July 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|6|||Female|18 Years|N/A|No|||April 2014|April 4, 2014|July 8, 2009|Yes|Yes|Investigator-initiated termination of approval due to problems with recruitment.|No|June 15, 2012|https://clinicaltrials.gov/show/NCT00936598||136421|
NCT00936338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191|Randomized Clinical Trial of Treatment for Temporomandibular Joint (TMJ) Disc Displacement|||Tokyo Medical and Dental University||Completed|January 2006|December 2006|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A||||July 2009|July 9, 2009|July 9, 2009||||No||https://clinicaltrials.gov/show/NCT00936338||136441|
NCT00937183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCMI-40-2003|Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma|Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates||National Cancer Institute (NCI)||Recruiting|September 2003|||June 2010|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2011|August 6, 2013|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00937183||136376|
NCT00928226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRN0010|Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases|A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases||Stanford University|Yes|Active, not recruiting|April 2009|February 2016|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928226||137055|
NCT00928525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571 Basket 1|Imatinib in Patients With Desmoid Tumor and Chondrosarcoma|Open-label Trial of Imatinib in Patients With Desmoid Tumor and Chondrosarcoma|Basket 1|Italian Sarcoma Group|Yes|Recruiting|May 2007|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|80 Years|No|||September 2014|September 3, 2014|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928525||137032|
NCT00924404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol #200903757|Xylitol Versus Saline in Chronic Sinusitis|Randomized Controlled Trial of Xylitol Versus Saline Rinse For Chronic Sinusitis||University of Iowa|No|Recruiting|May 2009|January 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924404||137347|
NCT00929201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-080|Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)|An Open-Label, Randomized, Two-Period Crossover Definitive Bioequivalence Study With the Final Marketed Image (FMI) Sitagliptin/Metformin Fixed-Dose Combination (FDC) Tablet and Co-Administration of the Sitagliptin and Metformin Individual Tablets After Consumption of a High-Fat Meal in Healthy Adult Subjects||Merck Sharp & Dohme Corp.|No|Completed|January 2008|May 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|June 25, 2009|No|Yes||No|January 5, 2010|https://clinicaltrials.gov/show/NCT00929201||136981|
NCT00929214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0319|Aggressive Local Therapy for Limited Bone-only Metastasis|Aggressive Local Therapy for Limited Bone-only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients||M.D. Anderson Cancer Center|No|Recruiting|June 2009|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|N/A|N/A|No|||October 2015|October 26, 2015|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929214||136980|
NCT00924729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_28692|Study of Ocular Penetration of Topically Administered Fluoroquinolones|Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery||Johns Hopkins University|No|Completed|September 2009|November 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|50|||Both|21 Years|N/A|No|||November 2009|May 25, 2010|June 5, 2009|No|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00924729||137322|
NCT00933322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 124/09|Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans|Randomized-controlled Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans||University Hospital Inselspital, Berne|Yes|Terminated|July 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|142|||Both|45 Years|69 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|July 2, 2009||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT00933322||136671|
NCT00937391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91784|Contrast-enhanced MRI in Children 2 Months to <2 Years|Open-label, Multi-center, Two-stage, Age Stratified, Pharmacokinetic, Safety, and Efficacy Study in Children 2 Months to < 2 Years of Age Undergoing Magnevist Injection Enhanced MRI||Bayer|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|54|||Both|2 Months|23 Months|No|||October 2015|October 19, 2015|July 10, 2009|Yes|Yes||No|September 8, 2011|https://clinicaltrials.gov/show/NCT00937391||136361|
NCT00937404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112581|Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix™) in Infants|Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix™) in Infants||GlaxoSmithKline||Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||March 2010|March 4, 2010|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937404||136360|
NCT00933309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0284|The Impact of Obesity and Obesity Treatments on Breast Cancer|The Impact of Obesity and Obesity Treatments on Breast Cancer: A Phase I Trial of Exemestane With Metformin and Rosiglitazone for Postmenopausal Obese Women With ER+ Metastatic Breast Cancer||M.D. Anderson Cancer Center|Yes|Completed|July 2009|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|N/A|No|||August 2012|February 17, 2016|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933309||136672|
NCT00934726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NAT-SER-2008/1|Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia|Patient Satisfaction and Quality of Life Under Treatment With Seroquel XR|PASQAL|AstraZeneca|No|Completed|July 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|The psychiatrists according to inclusion criteria select patients.|September 2011|September 22, 2011|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934726||136564|
NCT00935311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-063|Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction|A Randomized, Multicenter, Single-blind, Placebo-controlled Study Comparing the Analgesic Efficacy and Safety of Hydrocodone/ Acetaminophen Extended-release Tablets and Hydrocodone/Acetaminophen (NORCO) to Placebo in Subjects With Acute Pain Following Third Molar Tooth Extraction||AbbVie|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|122|||Both|18 Years|65 Years|No|||March 2014|March 10, 2014|June 29, 2009|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00935311||136520|
NCT00935545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1017|Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors|A Phase I Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide ISA-51VG in Pediatric Patients With Recurrent or Refractory Central Nervous System Tumors||New York University School of Medicine|Yes|Completed|July 2009|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|21 Years|No|||January 2016|January 25, 2016|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935545||136502|
NCT00934427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001|Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms|A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon||MediQuest Therapeutics|No|Active, not recruiting|June 2009|July 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||July 2010|July 19, 2010|June 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934427||136587|
NCT00934440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11570|A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma|A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma|5-AZ|University of Kansas Medical Center|Yes|Active, not recruiting|June 2009|June 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|June 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934440||136586|
NCT00934713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33902|The Effect of Montelukast Treatment in Wheezy Infants|The Effect of Montelukast Therapy on Respiratory Symptoms, Lung Function and Airway Responsiveness in Wheezy Very Young Children|Montelukast|Helsinki University|No|Completed|September 2004|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|112|||Both|6 Months|24 Months|No|||October 2003|July 7, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00934713||136565|
NCT00934986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC-NK/IPC 2007-004|Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia|Study of Natural Killer Cells Function in Untreated Patients With Chronic Lymphocytic Leukemia|LLC-NK|Institut Paoli-Calmettes|No|Completed|March 2008|September 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|70|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00934986||136544|
NCT00935259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-140|Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)|A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia||Merck Sharp & Dohme Corp.|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Male|30 Years|70 Years|No|||October 2015|October 7, 2015|July 7, 2009|No|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00935259||136524|
NCT00935506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV197-004|Ex Vivo Human Thrombosis Chamber Study|Evaluation of an Experimental EX Vivo Thrombosis Chamber Model in Healthy Male Subjects||Bristol-Myers Squibb|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|February 22, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935506||136505|
NCT00935519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNU 09-01|Cementless New Alumina-zirconia Ceramic Bearing Total Hip Arthroplasty (THA) in Asian Patients|Cementless New Alumina-zirconia(4th Generation Ceramic Bearing) Composite Ceramic Bearing Total Hip Arthroplasty (THA) in Asian Patients : a 5 Year Minimum Follow-up Study||Seoul National University Bundang Hospital|Yes|Active, not recruiting|May 2009|December 2030|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|310|||Both|N/A|N/A|No|||May 2015|May 18, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935519||136504|
NCT00936949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNU 03-01|Posterolateral Surgical Approach Compared With Modified Lateral Approach|Posterolateral Surgical Approach Compared With Modified Lateral Approach: A Prospective, Randomised Trial||Seoul National University Bundang Hospital|Yes|Completed|July 2003|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|196|||Both|N/A|N/A|No|||July 2009|March 7, 2013|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936949||136394|
NCT00936611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-071|LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia|Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Active, not recruiting|June 2009|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936611||136420|
NCT00936936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0378|High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors|High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors||M.D. Anderson Cancer Center|No|Recruiting|June 2009|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|67|||Both|12 Years|65 Years|No|||December 2015|December 16, 2015|July 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936936||136395|
NCT00937469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOSTRA-BU/REGIONSJ.1|Social Skills Training and Standard Treatment Versus Standard Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|Social Skills Training and Standard Treatment Versus Standard Treatment of Children With ADHD - Attention Deficit Hyperactivity Disorder. Attachment Problems Among Children With ADHD|SOSTRA-ADHD|Region Zealand|Yes|Completed|August 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|8 Years|13 Years|No|||July 2011|August 4, 2011|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937469||136355|
NCT00937482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00575|Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer|A Phase 1 Study of AZD2171 and WBRT in Patients With Brain Metastases||National Cancer Institute (NCI)||Terminated|August 2009|||March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|July 9, 2009|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT00937482||136354|
NCT00928239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSA-MeshPlace|Laparoscopic Sacropexy: Comparison of Mesh Attachment|Laparoscopic Sacropexy: Randomized Clinical Trial to Compare Two Different Attachment Sites of the Dorsal Mesh at the Vaginal Insertion(MeshPlace)|MeshPlace|Kantonsspital Aarau|No|Recruiting|June 2009|June 2014|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 24, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928239||137054|
NCT00933153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCUMOW1|Effectiveness of Oral Nutritional Supplements (ONS) in a Meals-on-Wheels Population|Validation of the Malnutrition Screening Tool (MST) and Effectiveness of Oral Nutritional Supplements (ONS) on Weight, Nutritional Status and Quality of Life in a Meals-on-Wheels Population||Texas Christian University|Yes|Completed|October 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|60 Years|N/A|No|||June 2014|June 12, 2014|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933153||136684|
NCT00928915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFmu-344/2008|International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage|Multicenter, Prospective Randomized Trial on the Use of Prothrombin Complex and Fresh Frozen Plasma in Patients With Intracerebral Hemorrhage Related to Vitamin K Antagonists|INCH|Heidelberg University|Yes|Terminated|July 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|June 25, 2009||No|Review by official authorities|No||https://clinicaltrials.gov/show/NCT00928915||137002|
NCT00928928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1948-03|Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer|Study of the Oxidative Stress in Patients With Colorectal Cancer. Open vs Laparoscopic Approach||G. Hatzikosta General Hospital|Yes|Completed|January 2008|||June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|40|||Both|N/A|N/A|No|||June 2009|June 25, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928928||137001|
NCT00929474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD466|BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement|BOOST: Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement||St. Jude Medical||Terminated|June 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|June 25, 2009|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT00929474||136960|
NCT00929487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-14/RDG-11-152|Acute Clinical Evaluation of Multi-purpose Solutions (MPS) in Soft Contact Lens Wearers|Acute Clinical Evaluation of MPS in Soft Contact Lens Wearers||Alcon Research|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|278|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|June 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00929487||136959|
NCT00933348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPAL A-1001|Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers|A Randomised, Double-blind, Placebo-controlled Study of the Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers.||Phoenix Eagle Company|No|Suspended|January 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|July 5, 2009||No|Slow recruitment caused rethink on the study design|No||https://clinicaltrials.gov/show/NCT00933348||136669|
NCT00934193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220081131|Does Peri-Operative Gabapentin Reduce Chronic Post-Thoracotomy Pain?|Does Peri-Operative Gabapentin Reduce Chronic Post-Thoracotomy Pain?||University of Kansas Medical Center||Withdrawn|July 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934193||136605|
NCT00933595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652|Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)|Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|September 2007|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|365|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|August 14, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933595||136650|
NCT00935025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00015|AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects|A Single-center, Single-blind, Randomized, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Oral Doses of AZD1305 Extended-release Capsules in Healthy Male Japanese and Caucasian Subjects|JMAD|AstraZeneca|No|Terminated|July 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|45|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|July 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935025||136541|
NCT00935324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD/R-01|The Role of CK18F in Predicting Graft-Versus-Host Disease (GvHD)|CK18-Fragments as Tools for Evaluating Diagnosis, Biological Activity, and Prognosis of Graft-Versus-Host Disease||Heidelberg University|Yes|Recruiting|February 2009|May 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Group A (patients scheduled for allo-SCT): 5ml serum (~25 times), 7,5ml EDTA (~25 times)      Group B (healthy volunteers): 30ml blood once|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients scheduled for allo-SCT|July 2009|July 8, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935324||136519|
NCT00935285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1692UT|Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)|Immune Response in Patients Who Develop Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU) and the Role of Toll-Like Receptors(TLR2,TLR4,TLR9).||University of Thessaly|No|Active, not recruiting|July 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|14 Years|N/A|No|Non-Probability Sample|This study will include ICU patients who receive mechanical ventilation <48h and have no        history of ΑRDS or other respiratory disease.|July 2009|July 8, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935285||136522|
NCT00935298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071016|Initial Dosage Range of Tacrolimus by Genotyping in Chinese Renal Transplantation|Prospective Study:Clinical Trial on the Tacrolimus Dosage Range in Chinese Renal Transplant Recipients With Different Genetic Phenotypes of Drug Metabolizing Enzymes(CYP3A5)|PSIDRTG|The Second Artillery General Hospital|Yes|Completed|July 2009|June 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|18 Years|65 Years|No|||December 2011|December 21, 2011|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935298||136521|
NCT00935532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-JE-GWBX|Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus|Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s)||AstraZeneca|No|Completed|July 2009|July 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|427|||Both|20 Years|N/A|No|||May 2015|May 21, 2015|July 8, 2009|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00935532||136503|
NCT00935818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003598|Varenicline and Bupropion for Smoking Cessation|Combination Therapy With Varenicline and Bupropion for Smoking Cessation|CHANBAN|Mayo Clinic|Yes|Completed|September 2009|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|506|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 25, 2014|July 6, 2009|Yes|Yes||No|March 21, 2014|https://clinicaltrials.gov/show/NCT00935818||136481|
NCT00936117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0793|Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia|Phase II Study of the Pharmacokinetics of Posaconazole Prophylaxis in Relapsed or Refractory Patients With Acute Leukemia||M.D. Anderson Cancer Center|No|Completed|September 2009|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2015|August 24, 2015|July 7, 2009||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00936117||136458|
NCT00932035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11130|Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer|Reducing Extremity Lymphedema Through Axillary Lymphatic Preservation Surgery||City of Hope Medical Center|Yes|Completed|June 2009|||May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|19|||Female|N/A|N/A|No|||May 2014|May 28, 2014|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932035||136768|
NCT00932282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2306|Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy|Peanut OIT & Anti-IgE: Peanut Oral Immunotherapy and Anti-IgE Treatment for Peanut Allergy {NIH R21 Combined Peanut Oral Immunotherapy and Anti-IgE: Mechanistic Studies}|PAIE/Xolair|University of North Carolina, Chapel Hill|Yes|Completed|July 2009|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|12 Years|N/A|No|||October 2015|October 6, 2015|June 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932282||136749|
NCT00932919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF-70343-AUIR-2|Thought Field Therapy and Cognitive Therapy for Agoraphobia|Thought Field Therapy and Cognitive Therapy for Agoraphobia - a Randomized Controlled Intervention Study Where the Efficacy of Thought Field Therapy is to be Compared to Cognitive Therapy||Sorlandet Hospital HF|No|Completed|October 2006|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00932919||136702|
NCT00932932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 01-014|Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls|11 Beta Hydroxysteroid Dehydrogenase 1 (11-beta HSD 1) Activity in Patients With Prader-Willi Syndrome and in Healthy Controls||Children's Mercy Hospital Kansas City|Yes|Completed|February 2009|August 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|36|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Defined population|June 2011|June 23, 2011|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932932||136701|
NCT00928967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14168|Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients|Prospective Multicenter, Non-interventional Study to Evaluate the Impact of the Introduction of Interferon Beta-1 b Treatment on Daily Life Activities in Patients at High Risk of Developing Multiple Sclerosis After a First Clinical Demyelinating Event or Having Received a Confirmed Diagnosis of RRMS||Bayer|No|Completed|May 2007|November 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|None Retained|n.a.|Both|18 Years|N/A|No|Non-Probability Sample|Males or females aged 18 years or over, having received a confirmed diagnosis of RRMS as        defined by the MacDonald or Poser criteria or after a first clinical demyelinating event        suggestive of Multiple Sclerosis, and meeting the requirements of the study inclusion        criteria.The choice of treatment must be clearly dissociated from the decision to include        the patient in the study.|October 2015|October 7, 2015|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928967||136998|
NCT00929266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-AO0625-50|Cultured Red Blood Cells : Life Span in Vivo Study|First Pilot Study Evaluating the Life Span of Autologous Cultured Red Blood Cells (cRBC) Generated From Peripheral Stem Cells in Three Healthy Volunteers - Feasibility Study|GRc2008|Etablissement Français du Sang|Yes|Completed|May 2010|February 2012|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 9, 2012|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929266||136976|
NCT00914316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-051|Supervised Treadmill Exercise And Ranolazine For Intermittent Claudication Of Lower Extremities|Supervised Treadmill Exercise And Ranolazine For Intermittent Claudication Of Lower Extremities. THE STERILE TRIAL.|STERILE|William Beaumont Hospitals|Yes|Completed|May 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|40 Years|N/A|No|||May 2013|May 21, 2013|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00914316||138105|
NCT00914550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107003-3|Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia|Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia||Winthrop University Hospital|No|Completed|June 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|47|None Retained|Serum Procalcitonin|Both|18 Years|N/A|No|Non-Probability Sample|Adults admitted to Winthrop University Hospital with Lung Infiltrates undergoing        antibiotic therapy|December 2014|December 12, 2014|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914550||138087|
NCT00914849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0713 / 201103429|Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies|A Phase II Study Evaluating the Safety and Efficacy of Intravenous AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies||Washington University School of Medicine|No|Completed|August 2009|February 2012|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|65 Years|No|||July 2013|July 22, 2013|June 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914849||138064|
NCT00914862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375_110|Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults|A Comparative Single Dose Pharmacokinetic and Safety Study of 4 mg or 8 mg Ramelteon in Adolescents With Insomnia Characterized by Difficulty With Sleep Onset, Children With Insomnia Associated With ADHD, and Healthy Adults.||Takeda|No|Completed|November 2009|April 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|56|||Both|6 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|June 3, 2009|No|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00914862||138063|
NCT00910507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCA IRB 07-070|The Impact of Exercise Counseling on Exercise Behavior in People With Type 2 Diabetes: A Randomized Clinical Trial|The Impact of Physical Therapist-Directed Exercise Counseling Combined With Fitness Center-Based Exercise Training on Stage of Exercise Behavior in People With Type 2 Diabetes: A Randomized Clinical Trial||University of Central Arkansas|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910507||138396|
NCT00901576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-114|A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers|A Phase 1, Open-label, Randomized, Three-period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and CONCERTA, Administered Alone and in Combination in Healthy Adult Volunteers||Shire||Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|May 12, 2009|No|Yes||No|April 16, 2010|https://clinicaltrials.gov/show/NCT00901576||139068|
NCT00901589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Petra Witt|Marine n-3 Polyunsaturated Fatty Acids in Pre- and Postmenopausal Women|The Incorporation of Marine n-3 Polyunsaturated Fatty Acids in Pre- and Postmenopausal Women: a Randomized Double-Blinded Placebo-Controlled Clinical Trial||Aalborg Universitetshospital|No|Completed|August 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|92|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||May 2009|May 13, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901589||139067|
NCT00929773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-001|Low Level Laser Therapy to Reduce Chronic Pain|Study of the Effect of Low Level Laser Light Therapy on the Reduction of Chronic Pain of the Neck and Shoulders||Erchonia Corporation|No|Completed|July 2000|September 2000|Actual|September 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||April 2014|April 2, 2014|June 25, 2009|Yes|Yes||No|July 6, 2009|https://clinicaltrials.gov/show/NCT00929773||136938|
NCT00930046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-11-0506|The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine|The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine for the Management of Pain After Surgical Correction of Ureteropelvic Junction Stenosis||Children's Hospital Boston|Yes|Completed|May 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|3 Months|14 Years|No|||February 2015|February 12, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930046||136917|
NCT00930631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS747158-103|Study of [3H] BMS747158 in Healthy Male Subjects|Pharmacokinetics, Metabolism and Elimination of Tritiated [3H] BMS747158 in Healthy Male Subjects|PPA103|Lantheus Medical Imaging|No|Completed|June 2009|January 2010|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930631||136873|
NCT00930644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0600-021|Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)|A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome||Shire|Yes|Completed|September 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||January 2015|November 10, 2015|June 26, 2009|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT00930644||136872|
NCT00931216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KE.07.0055|Integration of HIV Care and Treatment Into Antenatal Care in Migori District, Kenya|Integration of HIV Care and Treatment Into Antenatal Care in Migori District, Kenya||University of California, San Francisco|No|Completed|June 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1172|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 6, 2012|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931216||136829|
NCT00930891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0802|Bevacizumab in Extensive Small Cell Lung Cancer|Randomized Phase II-III Study of Bevacizumab 7,5 mg/kg in Combination With Chemotherapy Versus Chemotherapy in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy : PCDE (cisPlatin - Cyclophosphamide - epiDoxorubicin - Etoposide) or PE (cisPlatin - Etoposide)|CPC|Intergroupe Francophone de Cancerologie Thoracique|Yes|Completed|September 2009|July 2013|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00930891||136853|
NCT00930904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4196 Chronic Performance|Model 4196 Left Ventricular (LV) Lead Chronic Performance Study|Attain Ability® Model 4196 Left Ventricular Lead Chronic Performance Post Approval Study||Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|June 2009|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1778|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with a 4196 LV Lead within the past 30 days. All patients must meet        Inclusion criteria and none of the Exclusion criteria.|June 2014|June 4, 2014|June 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00930904||136852|
NCT00931749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIUSKOA-09-218|Effects of Ultrasound Therapy on Cartilage Healing in Patients With Knee Osteoarthritis|The Effects of Low Intensity Ultrasound on Medial Tibial Cartilage Morphology in Patients With Mild or Moderate Knee Osteoarthritis: A Double Blind, Randomized Placebo-controlled Study.||McMaster University|No|Completed|September 2009|June 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|45 Years|N/A|No|||June 2010|June 8, 2010|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931749||136790|
NCT00931762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BUS58|Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis|Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis||Novartis|No|Completed|July 2009|||August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|July 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931762||136789|
NCT00931463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SECOND-LINE|A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen|A Randomised Open-label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-line NNRTI/2N(t)RTI Therapy|SECOND-LINE|Kirby Institute|Yes|Completed|September 2009|August 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|558|||Both|16 Years|N/A|No|||February 2014|February 12, 2014|July 1, 2009||No||No|October 14, 2013|https://clinicaltrials.gov/show/NCT00931463||136810|
NCT00932607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB/0027|SUBLIVAC® Birch PROBE Study|SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study||HAL Allergy|Yes|Completed|July 2009|||February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932607||136725|
NCT00932620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)|THE EFFECT OF SIMVASTATIN VERSUS COMBINED SIMVASTATIN/EZETIMIBE TREATMENT ON THE CONCENTRATION OF SMALL DENSE LOW-DENSITY LIPOPROTEIN PARTICLES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA||University of Ioannina|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||June 2011|August 17, 2011|July 2, 2009||No||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00932620||136724|Limitations of our study include its open-label design and the lack of clinical endpoints. However, all laboratory determinations were performed blindly with regard to treatment allocation.
NCT00932906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ed-2008-06|Comparison of Different Automated External Defibrillation (AED) Training Methods|Comparison of Four Different AED Training Methods in Three Different Age Groups||Doczero|Yes|Enrolling by invitation|July 2008|December 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|12||Anticipated|396|||Both|15 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00932906||136703|
NCT00928655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1522A#1-4|Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude|Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude||University of Zurich|Yes|Completed|June 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|20 Years|80 Years|No|||May 2014|May 18, 2014|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00928655||137022|
NCT00928668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.4|Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma|Randomised, Double-Blind, Placebo-Controlled, 5-Way Cross-Over Study to Assess the Efficacy (Bronchoprotection) and Safety of a Single Dose of Orally Inhaled BI 1744 CL (2, 5, 10 and 20ug) in Patients With Intermittent Asthma||Boehringer Ingelheim||Completed|January 2006|||October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|June 25, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00928668||137021|
NCT00914030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4371 (2008-A01459-46)|Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders|Visual Exploration and Attention : Studies in Patients With Schizophrenia and Autism Spectrum Disorders||University Hospital, Strasbourg, France|No|Recruiting|June 2009|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Anticipated|140|||Both|7 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Psychiatry clinic in Strasbourg and Brumath. Pedopsychiatry Clinic in Strasbourg.        Residents of Strasbourg and Brumath|June 2015|September 29, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00914030||138127|
NCT00914563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH Kralovske Vinohrady|An Upgrading of the Resuscitative Patterns by Utilization of the Balanced Crystalloids and Synthetic Colloids and the Non-Invasive Hemodynamic Monitoring During Burn Shock|An Optimizing of the Resuscitative Patterns by Use of Balanced Crystalloids and Colloids and the Non-Invasive Hemodynamic Monitoring|FACT in BURNS|Faculty Hospital Kralovske Vinohrady|No|Enrolling by invitation|June 2009|December 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||June 2009|June 4, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00914563||138086|
NCT00914875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-25|Kidney Function After Pneumoperitoneum and Analgesia|Kidney Function After Laparoscopic Cholecystectomy and Tramadol Anesthesia Plus Dipyrone or Ketorolac||UPECLIN HC FM Botucatu Unesp|Yes|Completed|February 2007|December 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|126|||Both|18 Years|60 Years|No|Probability Sample|adult patients submitted to laparoscopic cholecystectomy and analgesia from tramadol plus        ketorolac or dypirone|June 2009|June 4, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914875||138062|
NCT00905736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPEC/03/09/74|Influence of Microcurrent Parameters on Effectiveness in Treatment of Chronic Tennis Elbow|Influence of Microcurrent Parameters on Effectiveness of Treatment of Chronic Tennis Elbow - a Preliminary Trial||University of Hertfordshire|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||August 2009|June 18, 2010|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00905736||138755|
NCT00905749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endotec TMJ|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 1997|||||N/A|N/A|N/A||||||||||||||April 6, 2015|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905749||138754|
NCT00902005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-07377b|Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment|Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in RA and Spondyloarthritis Patients, Treated With TNFalpha-inhibitors in Combination With Methotrexate or Methotrexate or TNFalpha-inhibitors Alone - a Prospective Study|PSARA|Revmatismesykehuset AS|Yes|Completed|April 2008|August 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|Samples With DNA|Whole blood|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with RA and spondyloarthritis starting with either combination therapy of        TNFalpha-inhibitor and methotrexate or methotrexate or TNFalpha-inhibitor alone, at        Lillehammer Hospital for Rheumatic diseases.Decision about treatment modality will be        based on conventional clinial judgement.|November 2013|November 20, 2013|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902005||139035|
NCT00929786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/DIH/01|Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity|Measurement of Drug Levels and Their Correlation With Hepatotoxicity During Antituberculosis Treatment||All India Institute of Medical Sciences, New Delhi|No|Completed|November 2007|June 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|72|Samples Without DNA|Plasma|Both|16 Years|65 Years|No|Non-Probability Sample|Subjects: Patients with diagnosis of CatI/CatIII Tuberculosis attending the out-patient        department of the All India Institute of Medical Sciences, New Delhi, will form the study        population.        Cases - those patients who develop DIH while on regular treatment with anti-TB drugs        Controls - age, sex matched patients who do not develop DIH while on regular treatment        with anti-TB drugs|November 2009|November 9, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929786||136937|
NCT00930059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401005|A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease|A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|55 Years|85 Years|No|||April 2013|April 9, 2013|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930059||136916|
NCT00931229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1408|Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients|Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Who Receive Rituximab-containing Chemotherapy and Are Previously Infected With Hepatitis B Virus||National Health Research Institutes, Taiwan|Yes|Active, not recruiting|June 2009|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|18 Years|75 Years|No|||December 2011|December 6, 2011|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00931229||136828|
NCT00931203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2207|Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer|A Phase II Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer||National Health Research Institutes, Taiwan|Yes|Recruiting|July 2008|July 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|80 Years|No|||July 2009|July 1, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931203||136830|
NCT00931775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIT-PIN_01-0C3|Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder|Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder|CIT-PIN|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|December 2002|November 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||July 2009|July 1, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931775||136788|
NCT00931736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-94831|Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness|A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness||McGill University|Yes|Active, not recruiting|August 2009|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5720|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931736||136791|
NCT00932308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHO-0588|Colorectal Inflammatory Response to a Western-Style Diet|Colorectal Inflammatory Response to a Western-Style Diet||Rockefeller University|No|Completed|September 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|5|||Both|50 Years|72 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|December 11, 2008||No||No||https://clinicaltrials.gov/show/NCT00932308||136747|
NCT00932633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00017965|Magnetic Resonance Imaging (MRI) to Evaluate Brain Injury in Congenital Heart Disease|Role of Inflammatory Response in Brain Injury Following Neonatal Cardiac Surgery|CHD Brain|Emory University|Yes|Completed|August 2009|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|Samples With DNA|dried blood spot sample|Both|N/A|30 Days|No|Non-Probability Sample|newborns with congenital heart disease requiring surgery during the first 30 days of life|February 2016|February 8, 2016|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932633||136723|
NCT00932945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04806|Dermacyd PH_DESILSTY_FR (Lactic Acid) - Acceptability - Stay on Frutal|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up - Dermacyd PH_DESILSTY_FR (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|32|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00932945||136700|
NCT00932958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bigPICTURE|Physicians International Coronary Computed Tomography Angiography (CCTA) Utilization Registry|Physicians International CCTA Utilization Registry|BIGPICTURE|MDDX LLC|Yes|Completed|May 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6000|||Both|18 Years|N/A|No|Probability Sample|Adults (18 or older) who are scheduled to undergo a CCTA imaging procedure.|December 2012|December 8, 2012|July 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00932958||136699|
NCT00928681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7281001|A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis|A Randomized, Double-Blind (Sponsor Open), Placebo Controlled, Dose Escalating, Parallel Group, Multi-Centre Study To Investigate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous/Sub-Cutaneous Doses Of PF-00547659 In Patients With Active Ulcerative Colitis.||Pfizer|No|Completed|September 2005|October 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|80|||Both|18 Years|70 Years|No|||June 2009|June 25, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00928681||137020|
NCT00904514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000573913|Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial|Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol||National Institutes of Health Clinical Center (CC)||Completed|October 2007|October 2007|Actual|October 2007|Actual|N/A|Observational|N/A|||Anticipated|241|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|May 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00904514||138848|
NCT00904527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601001b|Interest of Relaxation From Patients With Pain Due to Migraine|Interest of Relaxation From Patients With Pain Due to Migraine|MIGREL|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2006|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904527||138847|
NCT00904800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1250C00055|AZD0837 Extended Release (ER) Japan Study|A Single-blind, Randomised, Placebo-controlled, Parallel-group, Single Centre Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended-release Tablets AZD0837 After Single and Repeated Oral Administration to Young Healthy Male Japanese Subjects|ER J ph I|AstraZeneca|No|Completed|May 2009|June 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00904800||138826|
NCT00905073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10988|Low Dose Cyclosporin and Methotrexate Therapy in Diabetes|Low Dose Cyclosporin and Methotrexate Therapy in New Onset Diabetes Mellitus||Georgetown University|No|Completed|February 1990|June 1994|Actual|June 1994|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|8 Years|18 Years|No|||May 2009|April 12, 2011|May 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00905073||138805|
NCT00905398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrALL 01-08|Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Estudo da eficácia do Nilotinibe Concomitante à Quimioterapia no Tratamento de Pacientes Com Leucemia linfoblástica Aguda Filadélfia Positiva recém-diagnosticada|ALLPhi|Universidade Federal do Rio de Janeiro|Yes|Terminated|May 2009|July 2015|Anticipated|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||July 2015|July 7, 2015|May 15, 2009||No|The study was terminated due to excessive toxicity and low compliance to the protocol scheme.|No||https://clinicaltrials.gov/show/NCT00905398||138781|
NCT00905411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-55215-18821|Pacific Kids DASH for Health|Pacific Kids DASH for Health|PacDASH|Kaiser Permanente|No|Completed|February 2008|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|88|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||November 2011|June 13, 2013|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905411||138780|
NCT00905762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|608|Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation|A Single-Center, Randomized, Masked Study Comparing the Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After a Single Topical Instillation||Bausch & Lomb Incorporated|No|Completed|March 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|3||Actual|119|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 7, 2011|April 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00905762||138753|
NCT00901290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00018|Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects|A Randomized, Open-Label, Two-way Crossover Study to Determine the Effects of Co-administration of AZD7325 and a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects||AstraZeneca|No|Suspended|May 2009|September 2009|Anticipated|September 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|56|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|December 8, 2010|May 12, 2009|No|Yes|suspended pending data analysis|No||https://clinicaltrials.gov/show/NCT00901290||139090|
NCT00902655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-04-05|Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity|Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity||Samsung Medical Center|No|Completed|April 2004|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902655||138986|
NCT00930072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34225-D|Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage|Safety and Efficacy of Cervical Sympathetic Block in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage - Pilot Study||University of Washington|Yes|Recruiting|April 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00930072||136915|
NCT00930657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090177|CO2 Inhalation and Risk for Panic Disorder|CO2 Inhalation and Risk for Panic Disorder||National Institutes of Health Clinical Center (CC)||Completed|June 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|13|||Both|9 Years|20 Years|No|||September 2015|September 12, 2015|June 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00930657||136871|
NCT00930384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 030940|A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis|A Case Control Study to Evaluate the Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Among Patients With Psoriasis||George Washington University|No|Recruiting|November 2009|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|370|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be selected from the Dermatology Clinic at George Washington University        Hospital, Medical Faculty Associates.|February 2016|February 9, 2016|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930384||136891|
NCT00930930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0904|Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer|A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.||Vanderbilt-Ingram Cancer Center|Yes|Completed|June 2009|October 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|July 1, 2009|Yes|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT00930930||136850|The number of participants in each arm will not necessarily coincide with the number of participants affected in the respective arm. Some participants my have more than one event and/or some participants may not have an event at all.
NCT00930943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-133A|Effect of Extended-release Oxymorphone Taking With or Without Food on Cognitive Functioning|Effect of Extended-release Oxymorphone Hydrochloride (Opana® ER), Taken Fasting Versus With Food, on Cognitive Functioning in Opioid-tolerant Subjects: a Randomized, Single-blinded, Cross-over Study||MedVadis Research Corporation|No|Completed|May 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||September 2011|September 8, 2011|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930943||136849|
NCT00931242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD / CD|Study of Apremilast in Atopic or Contact Dermatitis|A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis||Tufts Medical Center|No|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2010|November 23, 2010|June 30, 2009|Yes|Yes||No|October 28, 2010|https://clinicaltrials.gov/show/NCT00931242||136827|This was a small, single-arm open-label study with no placebo or comparison group to serve as a control.
NCT00931255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042201|Tacrolimus to Sirolimus Conversion for Delayed Graft Function|Delayed Tacrolimus to Sirolimus Conversion in Renal Transplant Recipients With Delayed Graft Function|RAPA|University of Maryland|Yes|Recruiting|April 2009|February 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||December 2009|December 14, 2009|June 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931255||136826|
NCT00931502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816184|Stent Thrombosis In Acute Coronary Syndromes|Contemporary Treatment Of Stent Thrombosis In Acute Coronary Syndromes||University of California, Davis|No|Enrolling by invitation|April 2008|||||N/A|Observational|Observational Model: Case-Only||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have had a heart attack or almost have had a heart attack due to blood clots        forming within previously placed stents.|June 2009|June 30, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00931502||136807|
NCT00931788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPICORE 2009-003|Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack|Preventing Recurrent Vascular Events and Neurological Worsening Through Intensive Organized Case-Management (PREVENTION) Trial|PREVENTION|University of Alberta|No|Completed|January 2009|November 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|279|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00931788||136787|
NCT00932295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11820|Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.|Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.||Virginia Commonwealth University|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932295||136748|
NCT00932048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0709211|Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes|Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography||Korea University|Yes|Withdrawn|August 2011|March 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|35 Years|80 Years|No|||July 2009|September 5, 2013|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932048||136767|
NCT00932061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hum 00010061|Developing Biomarkers for Fibromyalgia|Developing Biomarkers for Fibromyalgia|Biomarkers|University of Michigan|No|Completed|June 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|105|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00932061||136766|
NCT00932321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-03903|Study of Safety and Efficacy of an Oral Contraceptive|Open Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate (NA) and Ethinyl Estradiol (EE)||Warner Chilcott|No|Completed|January 2004|November 2004|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|938|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|June 30, 2009|Yes|Yes||No|February 22, 2011|https://clinicaltrials.gov/show/NCT00932321||136746|
NCT00932360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C9366|Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)|Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)|TENS&FM|University of Iowa|Yes|Recruiting|June 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|50|||Both|18 Years|90 Years|No|||April 2010|April 21, 2010|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00932360||136743|
NCT00932646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.25|Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease|Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|June 2009|||May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|100|||Both|40 Years|N/A|No|||January 2016|January 11, 2016|July 2, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00932646||136722|Safety assessments are potentially confounded by both crossover and long washout periodsComparisons of active groups for the 12 to 24 hr period overestimate the effect of Foradil (sleeping period causing an overestimation of AUC)
NCT00932971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hep-Net-HIDIT-II|HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis|A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II)|HIDIT-II|HepNet Study House, German Liverfoundation|No|Active, not recruiting|June 2009|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00932971||136698|
NCT00932984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04840|Dermacyd Silver Floral (Lactic Acid) - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Silver Floral (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00932984||136697|
NCT00904813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98/240|The Stockholm III Trial on Different Preoperative Radiotherapy Regimens in Rectal Cancer|A Prospective Randomized Trial on Different Preoperative Radiotherapy Regimens in Rectal Cancer, Stockholm III.|Stockholm III|Karolinska Institutet|Yes|Active, not recruiting|November 1998|January 2018|Anticipated|January 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|840|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904813||138825|
NCT00904826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001240|An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica|An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica||Mayo Clinic|No|Completed|April 2009|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|May 18, 2009|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT00904826||138824|
NCT00905086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3Z08|Psychosocial Adjustment After Radiation Therapy in Patients With Cancer|Psychosocial Adjustment During the Post-Radiation Treatment Transition||Case Comprehensive Cancer Center|Yes|Completed|August 2008|May 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic|September 2015|September 29, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905086||138804|
NCT00905424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-203|Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant|A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 Years With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant||Shire|No|Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|246|||Both|18 Years|55 Years|No|||August 2013|August 26, 2013|May 18, 2009|Yes|Yes||No|June 15, 2011|https://clinicaltrials.gov/show/NCT00905424||138779|
NCT00905437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081229|Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement|Randomized Double-Blind, Multi-Center Study Of Efficacy And Tolerability Of Pregabalin Versus Placebo As An Adjunct To Standard Of Care For Perioperative Management Of Patients Undergoing Total Hip Arthroplasty||Pfizer|No|Terminated|November 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|72|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|May 19, 2009|Yes|Yes|The Study was terminated on May 24th 2012 due to a slow recruitment rate. The study was not    terminated for reasons of safety or efficacy.|No|April 25, 2013|https://clinicaltrials.gov/show/NCT00905437||138778|As the enrollment rate was very low, the study was prematurely terminated. The number of enrolled participants was too low for meaningful formal statistical conclusions.
NCT00901602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNEUMOSurv1LIPSP|Lebanese Interhospital Pneumococcal Surveillance Program|Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)|LIPSP|American University of Beirut Medical Center|No|Recruiting|October 2004|October 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Bacterial isolates|Both|N/A|N/A|No|Non-Probability Sample|patients with invasive pneumococcal disease with positive culture of S. pneumoniae from a        normally sterile site (blood, CSF, etc.)|January 2013|January 31, 2013|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00901602||139066|
NCT00901615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2CHOP-1|Lenalidomide and R-CHOP in B-cell Lymphoma|A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma|R2CHOP-1|Lymphoma Study Association|Yes|Active, not recruiting|January 2009|January 2012|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||March 2011|March 3, 2011|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901615||139065|
NCT00902668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12044|Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer|A Phase II Study Using Lovastatin to Improve Cosmetic Outcome After Radiation Therapy for Breast Cancer||Virginia Commonwealth University|Yes|Terminated|April 2009|April 2013|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|3|||Female|18 Years|N/A|No|||May 2013|June 11, 2013|May 14, 2009|Yes|Yes|Slow accrual|No|April 11, 2013|https://clinicaltrials.gov/show/NCT00902668||138985|Early termination leading to no subjects analyzed.
NCT00902681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221082|A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects|An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.||Pfizer|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|May 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00902681||138984|
NCT00930410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMID/IPC 2008-001|Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor|Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor|EMID|Institut Paoli-Calmettes|No|Completed|September 2008|May 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|June 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00930410||136889|
NCT00930670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPICE|Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects|Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects|SPICE|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|320|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930670||136870|
NCT00930956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSUHML09-RS|Comparison of Different Types of Resistant Starch|Resistant Starch Type 2 and Cross Linked Resistant Starch Type 4 on Blood Glucose||Kansas State University|No|Completed|May 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|11|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2009|July 28, 2010|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00930956||136848|
NCT00930683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP180|A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma|A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma|MEDI-546|MedImmune LLC|No|Completed|September 2009|July 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|34|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|June 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00930683||136869|
NCT00930982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12965|Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis|Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis||Bayer|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||November 2014|November 28, 2014|June 30, 2009|Yes|Yes||No|September 19, 2011|https://clinicaltrials.gov/show/NCT00930982||136846|
NCT00931515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N012009|Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty|A Prospective, Multi-center, Randomized, Controlled Clinical Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty||Pioneer Surgical Technology, Inc.|Yes|Completed|February 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|June 29, 2009|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT00931515||136806|Because the study was stopped after a total of 30 patients, demonstration of non-inferiority was impossible. Results from the 2 groups were compared using the Fisher exact test for categorical variables and ANOVA for continuous variables.
NCT00931528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0831|Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy|A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer||Radiation Therapy Oncology Group|Yes|Completed|November 2009|November 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|242|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 17, 2015|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931528||136805|
NCT00931554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DREN-01|Randomized Trial of Early Versus Standard Drainage Removal After Pancreatic Resections|Early Versus Standard Drainage Removal After Pancreatic Resections: Results of a Prospective Randomized Clinical Trial||Universita di Verona|No|Completed|March 2007|April 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|114|||Both|N/A|N/A|No|||July 2009|July 1, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00931554||136803|
NCT00932074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-KP413-P2-01|A Study to Determine the Safety, Tolerability and Efficacy of KP‑413 in Subjects With Atopic Dermatitis(AD)|A Phase 1/2 Study Evaluating the Safety, Tolerability and Efficacy of KP-413 Topical Ointment in Subjects With Atopic Dermatitis||Kaken Pharmaceutical|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|58|||Both|18 Years|64 Years|No|||April 2012|April 4, 2012|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932074||136765|
NCT00932087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.516|Characterization of Low Density Lipoprotein and Mechanism of the Pro Aggregant Effect Through Oxidant Stress and Lipid Exchange|Characterization of Low Density Lipoprotein and Mechanism of the Pro Aggregant Effect Through Oxidant Stress and Lipid Exchange|ECLIPSE|Hospices Civils de Lyon|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|48|||Male|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|group 1: type 2 diabetics with metabolic syndrome group 2: metabolic syndrome without        diabetes group 3: subjects with type 1 diabetes group 4: controls|April 2010|April 12, 2010|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00932087||136764|
NCT00932334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00006752|Culturally Sensitive Behavioral Interventions to Enhance Living Kidney Donation / Living Kidney Transplantation|Culturally Sensitive Behavioral Interventions to Enhance Living Kidney Donation / Living Kidney Transplantation|TALK|Johns Hopkins University|No|Completed|February 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|145|||Both|18 Years|70 Years|No|||March 2012|March 26, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932334||136745|
NCT00932100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG-CLIN211|A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome|A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome|RADAR|Regado Biosciences, Inc.|Yes|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|640|||Both|18 Years|80 Years|No|||March 2012|March 1, 2012|July 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932100||136763|
NCT00932659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012031|Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients|Characterization of Cardiac Arrhythmias in End Stage Kidney Disease Patients on Hemodialysis Using an Implantable Continuous Cardiac Rhythm Monitoring Device: A Pilot Study|CARE-ESRD|Duke University|Yes|Completed|June 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Duke hemodialysis patients with end stage renal disease|February 2013|April 11, 2013|July 2, 2009|No|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT00932659||136721|This is the 1st study of an implantable cardiac monitor in HD patients. Despite minimally invasive device implantation,collaboration between cardiology and nephrology, a large population of available subjects, we were able to enroll only 8 patients.
NCT00932997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06102|Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors|Reducing the Burden of Breast Cancer Among African American and Latina Survivors||City of Hope Medical Center|Yes|Completed|October 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Female|18 Years|N/A|No|||June 2015|June 3, 2015|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00932997||136696|
NCT00933010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIT-DUM-2008/1|Metabolic Syndrome Observation on a Regional Basis|Osservatorio Regionale Sulla Sindrome metabolicA|ORSA Umbria|AstraZeneca|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1600|||Both|18 Years|75 Years|No|Non-Probability Sample|Primary care clinic|October 2010|October 12, 2010|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933010||136695|
NCT00928733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3-026|Effects of Ethanol on Intestinal Permeability and Integrity|The Effect of Ethanol on Intestinal Permeability and Integrity in Healthy Individuals||Maastricht University Medical Center|Yes|Completed|September 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|3||Actual|17|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928733||137016|
NCT00905450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|588|Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery|||Bausch & Lomb Incorporated|No|Completed|June 2009|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|415|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905450||138777|
NCT00905463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E554kyoto|Prognosis of Lung Transplant Candidates|Analysis of Prognosis and Patient Reported Outcomes in Lung Transplant Candidates||Kyoto University, Graduate School of Medicine|No|Recruiting|April 2009|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|16 Years|N/A|No|Probability Sample|University hospital clinic for lung transplantation|April 2015|April 1, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905463||138776|
NCT00900965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS_FBM|Effect of Electroacupuncture in Patients With Irritable Bowel Syndrome|A Pilot Study on the Effect of Electroacupuncture on Functional Brain Mapping in Patients With Irritable Bowel Syndrome|IBS_FBM|Chinese University of Hong Kong|Yes|Completed|April 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||June 2009|June 30, 2009|May 12, 2009||||No||https://clinicaltrials.gov/show/NCT00900965||139115|
NCT00900978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4611|Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Jordanian Infants|Impact of the 7 Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of S. Pneumoniae in Healthy Jordanian Infants.|7vPCV|German-Jordanian University|Yes|Active, not recruiting|May 2009|October 2010|Anticipated|August 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|377|||Both|2 Months|2 Years|Accepts Healthy Volunteers|||September 2009|September 29, 2009|March 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00900978||139114|
NCT00901303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810010015|Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma|Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography in Hodgkin Lymphoma||Weill Medical College of Cornell University|No|Recruiting|May 2010|||April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2010|September 8, 2010|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00901303||139089|
NCT00902343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-158|Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection|A Prospective Randomized Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection||Memorial Sloan Kettering Cancer Center||Completed|May 2009|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902343||139010|
NCT00902356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080049|A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women|A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women||Amgen||Completed|May 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||April 2010|April 1, 2010|May 14, 2009||||No||https://clinicaltrials.gov/show/NCT00902356||139009|
NCT00929838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK81121|Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM|Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM|DM-TBSI|Medical University of South Carolina|Yes|Active, not recruiting|August 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|232|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929838||136933|
NCT00930150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01 MH090001-07|Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network|Cognitive Remediation in the Schizophrenia Trials Network||National Institute of Mental Health (NIMH)|Yes|Completed|July 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|55 Years|No|||November 2010|April 15, 2011|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00930150||136909|
NCT00930137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2009-084|Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women|Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women|TRANSW|Laval University|No|Completed|September 2009|September 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|64|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930137||136910|
NCT00930423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/270|Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease|Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease.||University Hospital, Ghent|No|Recruiting|August 2009|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|Samples With DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|patients with endstage renal failure treated in het University Hospital of Ghent|December 2014|December 4, 2014|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930423||136888|
NCT00930436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS001|Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease|Evaluation of Sodium Bicarbonate to Reduce Chronic Kidney Injury in Subjects With Advanced Chronic Kidney Disease (CKD) Who Are Undergoing Angiography|BOSS|MD Scientific|Yes|Terminated|January 2010|September 2012|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|391|||Both|18 Years|N/A|No|||February 2012|August 22, 2012|June 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930436||136887|
NCT00930969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST Detect|ST Segment Detection Study|ST Segment Detection Study|ST Detect|Medtronic Cardiac Rhythm Disease Management|No|Terminated|April 2008|March 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|175|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects coming into the hospital or the emergency room needing a defibrillator device        having had coronary artery disease as outlined in the inclusion criteria.|January 2012|March 27, 2012|June 29, 2009|No|Yes|Low observed spontaneous coronary event rate among enrolled subjects|No|October 27, 2011|https://clinicaltrials.gov/show/NCT00930969||136847|
NCT00931281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-861|Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir|A Blinded, Randomized, Nonfasting, Placebo-Controlled Study in Healthy Adults to Evaluate Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Ascending Doses of ABT-450 With Ritonavir||Abbott|No|Completed|June 2009|||September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 11, 2010|June 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931281||136824|
NCT00931541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0840C00007|AZD6088 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD6088 After Single Ascending Doses in Healthy Male and Non-Fertile Female Volunteers||AstraZeneca|No|Completed|June 2009|August 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931541||136804|
NCT00931827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14688|Acceptability of Long-term Progestin-only Contraception in Europe|Acceptability of Long-term Progestin-only Contraception in Europe||Bayer|No|Completed|January 2008|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|436|||Female|20 Years|35 Years|No|Non-Probability Sample|Women aged 20-35 years switching from short-acting hormonal contraception|December 2013|December 22, 2013|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931827||136784|
NCT00931801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-102|BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.|A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine|BATAR|Community Research Initiative of New England|Yes|Completed|December 2009|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|June 30, 2009|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT00931801||136786|
NCT00931814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701114|Effects of Exercise on Depression Symptoms, Physical Function, and Quality of Life in Community-Dwelling Elderly|Effects of Exercise on Depression Symptoms, Physical Function, and Quality of Life in Community-Dwelling Elderly||National Taiwan University Hospital|Yes|Completed|December 2005|June 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 6, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931814||136785|
NCT00932347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COA. No. MU-IRB 2008/177.1211|Effect of Mouthwash Containing Camellia Sinensis Extracts on Oral Malodor|Effect of Mouthwash Containing Camellia Sinensis Extracts on Oral Malodor, Plaque and Papillary Bleeding Indices in Gingivitis Patients.||Mahidol University|Yes|Completed|January 2008|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 21, 2011|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932347||136744|
NCT00932386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090056|Effects of Dexmedetomidine on Tourniquet Pain Associated With Lower Extremity Surgeries Under General Anesthesia|The Effects of Dexmedetomidine on Tourniquet Pain Associated With Lower Extremity Surgeries Under General Anesthesia in Same Day Elective Patients||Rutgers, The State University of New Jersey|No|Withdrawn|July 2009|||July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||April 2015|April 23, 2015|July 1, 2009|Yes|Yes|unable to secure funding for analysis of laboratory data.|No||https://clinicaltrials.gov/show/NCT00932386||136741|
NCT00932399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F6982-W|Longitudinal Study of Weight Change Following Lower Limb Amputation|Weight Change, Physical Activity and Health Promotion in Veteran Amputees||VA Office of Research and Development|No|Completed|March 2010|January 2016|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|4549|||Male|27 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|Veterans who received care at a VISN20 medical facility between 1997 and 2008|January 2016|January 13, 2016|July 1, 2009||No||No|October 2, 2014|https://clinicaltrials.gov/show/NCT00932399||136740|
NCT00932672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010519|Atkins Diet and Prostate Cancer Clinical Trial|Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer||Duke University|No|Terminated|June 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|45|||Male|18 Years|N/A|No|||December 2015|December 4, 2015|July 2, 2009||No|slow recruitment, lack of funding and PI transferred|No||https://clinicaltrials.gov/show/NCT00932672||136720|
NCT00933023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TopSteP|Mild Versus Potent Corticosteroids as Treatment for Phimosis in Children|A Randomised Controlled Trial of Mild Versus Potent Topical Corticosteroids as Primary Treatment for Non-retractile Foreskin in Children.|TopSteP|Chelsea and Westminster NHS Foundation Trust|Yes|Withdrawn|August 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|2 Years|16 Years|No|||July 2015|July 28, 2015|July 6, 2009||No|Patient numbers estimated to be too low to complete the trial in less than 10 years|No||https://clinicaltrials.gov/show/NCT00933023||136694|
NCT00928746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244.2507|Actuation Indicator Trial in Patients With COPD|ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|June 2009|||August 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|1||Actual|142|||Both|40 Years|N/A|No|||January 2014|June 23, 2014|June 25, 2009||||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00928746||137015|
NCT00901316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrasher21631|Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children|Prevention of Recurrent Infections Caused by Community-Acquired Staphylococcus in Children 3 Months to 18 Years||Baylor College of Medicine|Yes|Enrolling by invitation|June 2009|June 2012|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|3 Months|18 Years|No|||May 2009|May 12, 2009|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901316||139088|
NCT00901628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0804/056-021|Periarticular Multimodal Drug Injections in Total Knee Arthroplasty|Efficacy and Safety of Periarticular Multimodal Drug Injections in Total Knee Arthroplasty||Seoul National University Hospital|No|Completed|April 2008|April 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|81 Years|No|||December 2012|December 15, 2012|May 13, 2009||No||No|May 15, 2009|https://clinicaltrials.gov/show/NCT00901628||139064|
NCT00902018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809009980|Eltrombopag and the Bcl-xL Pathway in Idiopathic Thrombocytopenic Purpura (ITP)|The Effect of Eltrombopag on Platelet Survival: the Role of the BcL-xL Pathway||Weill Medical College of Cornell University|No|Active, not recruiting|May 2009|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 14, 2012|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00902018||139034|
NCT00902031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G599001036|Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients|Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate for Preventing/Treating Constipation in Palliative Care Patients.||University of Alberta|No|Completed|April 2006|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902031||139033|
NCT00902369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK106 II-01|A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)|||Asahi Kasei Pharma Corporation||Completed|May 2009|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|130|||Both|18 Years|65 Years|No|||July 2010|July 7, 2010|May 14, 2009||||No||https://clinicaltrials.gov/show/NCT00902369||139008|
NCT00902382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMN-PregReg|Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications|Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications||Yale University|Yes|Active, not recruiting|May 2009|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1650|Samples With DNA|Mothers of newborn infants will be asked to consent to the collection of buccal cells from      their infants for DNA testing. Fathers will also be asked to provide buccal cells via buccal      swab smears, if blood has not been obtained from them in the course of an RMN trial. The DNA      specimens will be available for use in other vetted studies to enable study of independent      genetic and environmental factors and gene-environment interactions for a broad range of      birth defects and infertility.|Female|18 Years|40 Years|No|Non-Probability Sample|The population will include women with infertility who receive ovulation stimulation drugs        within the context of a Reproductive Medicine Network sponsored trial as well as their        infants.|November 2015|November 17, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902382||139007|
NCT00930163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILR4646g|A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids|MILLY|Genentech, Inc.||Completed|July 2009|September 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|65 Years|No|||June 2011|June 30, 2011|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930163||136908|
NCT00930176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ten01|A Study Investigating Treatment Factor X in People With Factor X Deficiency|A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.||Bio Products Laboratory|No|Completed|January 2010|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|12 Years|N/A|No|||December 2014|December 8, 2014|June 10, 2009|Yes|Yes||No|November 25, 2014|https://clinicaltrials.gov/show/NCT00930176||136907|
NCT00930449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013779|Effects Of A Computerized Working Memory Training Program On Attention, Working Memory, And Academics, In Adolescents With Severe ADHD/LD|Effects Of A Computerized Working Memory Training Program On Attention, Working Memory, And Academics, In Adolescents With Severe ADHD/LD||The Hospital for Sick Children|No|Completed|November 2008|January 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|12 Years|17 Years|No|||May 2015|May 25, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930449||136886|
NCT00930709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVO1122|Botulinum Toxin Versus Active Strength Training in the Treatment of Lateral Epicondylitis|Botulinum Toxin Versus Active Strength Training in Treatment of the Lateral Epicondylitis - A Single-Blinded, Randomized, Controlled Trial|BooST|Seinajoki Central Hospital|No|Completed|March 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|20 Years|65 Years|No|||December 2014|December 30, 2014|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930709||136867|
NCT00930696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|trial_lavage_01/endometriosis|Effects of Extensive Abdominal Lavage on Postoperative Inflammation Following Full Thickness Excision of Deep Endometriosis|Extensive Abdominal Lavage Following Laparoscopic Full Thickness Resection of Deep Endometriosis Involving the Bowel, Effects on Post-Operative Inflammation: a Randomised Controlled Trial||Katholieke Universiteit Leuven|No|Completed|May 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|50 Years|No|||June 2009|June 29, 2009|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00930696||136868|
NCT00931008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SID530_2009|Study to Evaluate SID 530 Compared to Taxotere|A Randomized, Double-Blind, Two-Way Crossover, Bioequivalence Study of SID530 and Taxotere® in Study Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Therapy Failure or Study Participants With Locally Advanced or Metastatic Breast Cancer Who Have Failed At Least One Prior Chemotherapeutic Regimen||SK Chemicals Co.,Ltd.||Completed|October 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|42|||Both|18 Years|N/A|No|||August 2010|January 22, 2013|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931008||136844|
NCT00931268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GC0804|Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane|Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Stabilized Hyaluronic Acid of Non-animal Origin (Macrolane); a Baseline-controlled Single-centre Study.||Q-Med AB|No|Completed|August 2009|May 2012|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||November 2013|November 22, 2013|July 1, 2009||No||No|July 12, 2013|https://clinicaltrials.gov/show/NCT00931268||136825|
NCT00931580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD57126-01A2 UGA|Vitamin D Needs of Early Adolescent Children|Supplemental Vitamin D and Functional Outcomes in Early Adolescence||University of Georgia|Yes|Completed|October 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|323|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||September 2015|September 23, 2015|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931580||136801|
NCT00932113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOA|Mechanism of Action Study for Psoriasis|An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis.|MOA|Tufts Medical Center|No|Active, not recruiting|June 2009|June 2014|Anticipated|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|33|||Both|18 Years|85 Years|No|||April 2014|April 2, 2014|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00932113||136762|
NCT00932373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM3569g|A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Trastuzumab-MCC-DM1 (PRO132365) Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen||Genentech, Inc.||Completed|April 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|N/A|N/A|No|||August 2015|August 13, 2015|June 30, 2009|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT00932373||136742|
NCT00932126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1301001|This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors|Phase 1, Open Label, Dose-Escalation, Safety, Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309, An Oral PAK4 Inhibitor, In Patients With Advanced Solid Tumors||Pfizer|No|Terminated|September 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 30, 2009|No|Yes|See termination reason in detailed description.|No|December 11, 2012|https://clinicaltrials.gov/show/NCT00932126||136761|The study was closed due to pharmacokinetic (PK) issues observed from initial PK data. Individual plasma concentration versus time were listed but final PK analysis and pharmacodynamic analyses were not conducted.
NCT00933036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080175|Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients|Clinical Evaluation of the Crosstrees® System for PVA in Symptomatic Adult Patients With Acute Vertebral Body Compression Fractures at T4-L5||Crosstrees Medical Inc.|Yes|Completed|June 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|50 Years|N/A|No|||January 2014|January 21, 2014|July 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00933036||136693|
NCT00928759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13552|Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls|Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls|CRM002|University of Virginia|No|Recruiting|March 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Female|8 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Generally healthy peripubertal girls ages 8 - 16 years with a BMI of > or = to 95th        percentile will be recruited from the general population of the surrounding area.|November 2015|November 11, 2015|October 28, 2008||No||No||https://clinicaltrials.gov/show/NCT00928759||137014|
NCT00928772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14694|Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety|The Effect of Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety for Patients Undergoing First Eye Cataract Surgery||University of Oklahoma|No|Completed|July 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|116|||Both|50 Years|90 Years|No|||December 2013|December 19, 2013|June 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00928772||137013|
NCT00929045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13239|Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Development|Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Recovery||University of Virginia|No|Recruiting|July 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|8 Years|21 Years|Accepts Healthy Volunteers|||April 2010|April 12, 2010|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00929045||136992|
NCT00929058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVZ1|Bevacizumab and Vasoconstriction|Bevacizumab and Vasoconstriction|BVZ1|Radboud University||Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2009|May 17, 2010|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929058||136991|
NCT00901329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD2007-0123|NexGen Gender Fixed Bearing Knee Versus NexGen Legacy Knee Posterior Stabilized (LPS) - Flex Fixed Bearing Knee: A Study Comparing Two Different Knee Prostheses|NEXGEN Gender Fixed Bearing Knee Versus NEXGEN LPS-Flex Fixed Bearing Knee - a Prospective Randomized Study Comparing Two Different Knee Prostheses||Hvidovre University Hospital|Yes|Enrolling by invitation|May 2007|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|N/A|No|||May 2009|May 12, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901329||139087|
NCT00901641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emek123-08|Computer-Based Cognitive Training and Sleep Quality in Older Adult Insomniacs|Computer-Based Cognitive Training and Sleep Quality in Older Adult Insomniacs||The Max Stern Academic College Of Emek Yezreel|No|Active, not recruiting|May 2003|||April 2009|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|65 Years|N/A|No|||May 2009|May 13, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901641||139063|
NCT00902044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24489-HEROS|Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma|Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS)||Baylor College of Medicine|Yes|Recruiting|July 2009|July 2030|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|N/A|N/A|No|||October 2015|October 30, 2015|May 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00902044||139032|
NCT00902057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 09-088|Desmopressin for Bleeding Related to Low Body Temperature|Effect of Desmopressin on Platelet Dysfunction Associated With Mild Hypothermia in Healthy Volunteers||The University of Hong Kong||Not yet recruiting|June 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2009|May 13, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902057||139031|
NCT00903253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNK754-0901-1A|A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers|A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers||Link Medicine Corporation|Yes|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind|||Anticipated|40|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||September 2009|September 8, 2009|May 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00903253||138942|
NCT00929877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETOP_C_03968|KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges|A Randomised Double Blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of 2 Doses of Ketoprofen Lysinate Lozenges (6.25 mg & 12.5 mg) in Patients With Sore Throat||Sanofi||Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|801|||Both|18 Years|N/A|No|||May 2010|May 17, 2010|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929877||136930|
NCT00929890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08282|Additional Metabolic and Vascular Effects of Exercise in Patients on Diet-based Weight Loss Programs|Effect of Weight Loss Through Dietary Energy Restriction With or Without Exercise on Vascular and Metabolic Parameters in Subjects With Obesity||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|February 2009|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|20 Years|45 Years|No|||July 2011|October 25, 2011|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929890||136929|
NCT00930189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-0031|Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization|Randomized, Double Blind, Controlled Study With Verteporfin Photodynamic Therapy And Intravitreal Triamcinolone(IVTA) Vs Triple Therapy With Verteporfin Photodynamic Therapy, Intravitreal Triamcinolone And Intravitreal Ranibizumab In Patients With Subfoveal Choroidal Neovascularization(CNV) Secondary To Age-Related Macular Degeneration(AMD)||Asociación para Evitar la Ceguera en México||Recruiting|April 2006|September 2006|Anticipated|||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|100|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||December 2006|June 29, 2009|December 1, 2006||||No||https://clinicaltrials.gov/show/NCT00930189||136906|
NCT00930462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPCOLON|Evaluation of the Use of Cap in Improving the Performance of Colonoscopy|A Prospective Randomised Controlled Trial Comparing Cap-Assisted Colonoscopy Versus Standard Colonoscopy||Royal Prince Alfred Hospital, Sydney, Australia|No|Completed|March 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|400|||Both|18 Years|N/A|No|||June 2009|June 29, 2009|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00930462||136885|
NCT00930995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-05SBala-01-B|Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C|Angiotensin Receptor Blockade an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C||Kaiser Permanente|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|65 Years|No|||April 2012|April 23, 2012|July 1, 2009|Yes|Yes|Not Awarded|No||https://clinicaltrials.gov/show/NCT00930995||136845|
NCT00931320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2009/3|Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients|Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients|RACHEL|AstraZeneca|No|Completed|July 2009|September 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Who have at least made 1 visit to the outpatient clinic within previous 6 months .|October 2009|October 23, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931320||136821|
NCT00931593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.546/47|Transient Lower Esophageal Sphincter Relaxations and High Resolution Manometry|Transient Lower Esophageal Sphincter Relaxations Detection Using High Resolution Manometry. Validation in Healthy Volunteers.||Hospices Civils de Lyon|No|Recruiting|May 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2009|July 1, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931593||136800|
NCT00931567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-APR-07|Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing|Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing||Centre Hospitalier Universitaire de Nice|No|Completed|August 2007|February 2010|Actual|February 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931567||136802|
NCT00932139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-2222|Effect of Electro-Acupuncture on Blood Pressure|Neural Mechanism of the Effect of Acupuncture on Myocardial Ischemia||University of California, Irvine|No|Recruiting|February 2003|December 2010|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|94|||Both|18 Years|70 Years|No|||October 2010|October 14, 2010|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932139||136760|
NCT00931840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2208-04|A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma|A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)||Enzon Pharmaceuticals, Inc.|Yes|Active, not recruiting|June 2009|January 2012|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|220|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931840||136783|
NCT00931853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENCA_L_04392|Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).|National Study, Phase III, Parallel, Double Blind, Placebo Comparative and Randomized to Evaluate the Therapeutic Efficacy and Tolerability of the Combination Naturetti® (Cassia Fistula + Senna Alexandrina Miller) in the Chronic Functional Constipation||Sanofi||Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931853||136782|
NCT00932685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120030315A|Does Distraction With a Hand Held Video Game Reduce Preoperative and Emergence Anxiety in Children?|Is Preoperative Distraction With a Hand Held Video Game Boy as Effective as Midazolam in Reducing Preoperative Anxiety Levels in Children as Weel as Emergence Agitation?||Rutgers, The State University of New Jersey|No|Completed|December 2005|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|119|||Both|4 Years|12 Years|No|||July 2009|July 2, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932685||136719|
NCT00932698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16003|Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma||Millennium Pharmaceuticals, Inc.|No|Completed|June 2009|March 2013|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|July 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932698||136718|
NCT00926445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-177|Neonatal Pain- and Distress Experiences and Later Pain Behavior of Former Preterm and Critically Ill Newborn Infants|Effect of Neonatal Pain- and Distress Experiences on Later Pain Behaviour of Former Preterm and Critically Ill Newborn Infants||University of Cologne|No|Recruiting|November 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120||Saliva for measuring cortisol levels|Both|N/A|7 Days|No|Non-Probability Sample|Premature, critically ill term infants are recruited from the NICU of the University        hospital of Cologne. Healthy newborns are recruited from the nursery of the University        hospital of Cologne.|June 2009|June 22, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926445||137190|
NCT00926744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qde402mm|Nutrition and Exercise Intervention Study|Large-Scale Randomized Intervention Trial of Effects of Physical Activity on Incidence and Risk Factors of Cardiovascular Diseases in Healthy People|NEXIS|National Institute of Health and Nutrition|Yes|Active, not recruiting|April 2006|March 2018|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1085|||Both|30 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00926744||137168|
NCT00926757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHUST98-P1-07|Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B|Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial|HBVNHL|Taipei Veterans General Hospital, Taiwan|Yes|Completed|April 2009|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|16 Years|N/A|No|||May 2013|May 27, 2013|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926757||137167|
NCT00927004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moss IISP#36409|Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis|A Randomised Placebo-controlled Trail of Mechanical and Cold Hyperalgesia in Subjects With Painful Knee Osteoarthritis, Compared With Matched Controls, & Whether This Hyperalgesia Can be Modified by a 2-week Course of Etoricoxib 60mg.||Curtin University of Technology|No|Completed|August 2010|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 1, 2012|June 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927004||137149|
NCT00927017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lakritsi-2|The Effect of Liquorice on Plasma Potassium|Lakritsin Vaikutus Kaliumpitoisuuteen||University of Oulu|No|Terminated|June 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|9|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2010|April 6, 2010|June 22, 2009||No|When 9 subjects of targeted 12 subjects had been studied, no changes in plasma potassium were    detected and it was deemed futile to continue with enrolment.|No||https://clinicaltrials.gov/show/NCT00927017||137148|
NCT00902395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFG SAP 18189|Efficacy of Moderate Sedation for Dental Treatment of Young Children|Randomized Controlled Trial of Oral Sedatives for Moderate Sedation in Young Children||Universidade Federal de Goias|No|Completed|June 2008|May 2012|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|12 Months|36 Months|Accepts Healthy Volunteers|||January 2015|January 15, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902395||139006|
NCT00902694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH080964|Randomized Trial Of Achieving Healthy Lifestyles In Psych Rehabilitation|Randomized Trial Of Achieving Healthy Lifestyles In Psychiatric Rehabilitation|ACHIEVE|Johns Hopkins University|Yes|Completed|April 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|291|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902694||138983|
NCT00902967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU 1|Study To Check The Analgesic And Anti-Inflammatory Effects Of Atorvastatin In Patients Undergoing Abdominal Surgery|A Randomized Double Blind Study Of The Evaluation Of The Potential Analgesic And Anti-Inflammatory Effects Of Atorvastatin In Patients Undergoing Abdominal Surgery|A4S|B. J. Medical College, Pune|No|Not yet recruiting|July 2009|February 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|55 Years|No|||June 2009|June 1, 2009|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902967||138962|
NCT00903786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-J081-233|A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)|A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)||Eisai Inc.||Active, not recruiting|June 2009|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|64 Years|No|||February 2016|February 4, 2016|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903786||138903|
NCT00903799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/046/HP|Medico-economic Evaluation of ENTERRA Therapy|Clinical Efficacy and Efficiency of Gastric Electrical Stimulation (Enterra®) for Refractory Nausea and/or Vomiting|ENTERRA|University Hospital, Rouen|No|Active, not recruiting|June 2009|February 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|70 Years|No|||March 2015|March 10, 2015|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903799||138902|
NCT00930202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35774-A|Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury|Open Label Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury||University of Washington|Yes|Completed|August 2009|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||September 2010|September 8, 2010|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00930202||136905|
NCT00930475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001JDE15T|Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer|Everolimus (RAD001) in Combination With Intravenous Carboplatin in Taxane- and Anthracycline-pretreated Patients With Progressive Metastatic Breast Cancer||Charite University, Berlin, Germany|Yes|Recruiting|February 2009|||December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Female|18 Years|N/A|No|||June 2010|January 25, 2011|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00930475||136884|
NCT00930488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12803|Treatment of Patients With Acute Sinusitis|Treatment of Patients With Acute Sinusitis in Daily Practice||Bayer|No|Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6777|None Retained|n.a.|Both|N/A|N/A|No|Non-Probability Sample|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin|November 2012|November 19, 2012|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930488||136883|
NCT00930735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/0904|The Prognostic Significance of Fibrosis Detection in Cardiomyopathy|The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy||Royal Brompton & Harefield NHS Foundation Trust|No|Active, not recruiting|January 2000|July 2016|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Serum and plasma and myocardium|Both|18 Years|80 Years|No|Probability Sample|Consecutive referrals for CMR from tertiary and nontertiary referral hospitals scanned to        evaluate presence and amount of myocardial scarring.|February 2015|February 5, 2015|June 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00930735||136865|
NCT00931021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903004910|Smoking Cessation Treatment for Head and Neck Cancer Patients|Smoking Cessation Treatment for Head and Neck Cancer Patients||Yale University|No|Terminated|July 2009|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|June 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931021||136843|
NCT00930722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9061066|A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population|ASSET (Acupil® Non Interventional Study For Evaluation Of Safety Effectiveness And Tolerability)|ASSET|Pfizer|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|329|||Both|18 Years|N/A|No|Non-Probability Sample|400 patients will be included in this non-interventional study. Only hypertensive        subjects, over the age of 18 years, and who have already been receiving Acupil® for a        minimum duration of 4 weeks will be included in the study.|April 2011|April 7, 2011|June 29, 2009||No||No|April 7, 2011|https://clinicaltrials.gov/show/NCT00930722||136866|
NCT00931034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07SWHK|Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women|The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to the American Diabetic Association Diabetes Meal Plan on Body Weight and Satiety in Overweight Diabetic Women||Mondelēz International, Inc.|No|Completed|March 2007|July 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|55 Years|No|||June 2009|June 30, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00931034||136842|
NCT00925158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-UNIFESP 1515/07|Dissector Assisted Malar Elevation for Rhytidoplasty|Non-randomized Clinical Trial for Evaluation of the Dissector Assisted Malar Elevation in Videoendoscopic Rhytidoplasty.|DAME|Federal University of São Paulo|No|Active, not recruiting|December 2007|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Female|30 Years|59 Years|No|||July 2012|July 23, 2012|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925158||137289|
NCT00926770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-131|Cerebral Near Infrared Spectroscopy During Blood Sampling From a Peripheral Artery Catheter in Preterm Infants|Measurement of Cerebral Oxygenation With Near Infrared Spectroscopy During Blood Sampling From a Peripheral Artery Catheter in Preterm Infants With Gestational Age <37+0||University of Cologne|No|Recruiting|November 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|7 Days|No|Non-Probability Sample|Preterm infants (Gestational Age <37+0)|June 2009|June 23, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00926770||137166|
NCT00931294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI 5.1 2007-17|Saliva Testosterone Increases in Irritable Bowel Syndrome (IBS) Patients Beginning Choir Singing|Saliva Testosterone Increases in Choir Singer Beginners: a Randomised Controlled Trial to Test the Efficacy of Choir Singing in Irritable Bowel Syndrome (IBS) Patients||Stockholm University|No|Completed|May 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|55|||Both|N/A|N/A|No|||July 2009|July 1, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931294||136823|
NCT00925665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OdoAbGldscp|Intubation of Patients With Odontogenic Abcesses|Intubation of Patients With Odontogenic Abcesses Glidescope vs. Macintosh Technique||Kliniken Essen-Mitte|No|Completed|January 2009|June 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|We want to study patients, who present with a odontogenic abscess for surgical treatment.|June 2009|June 27, 2011|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925665||137250|
NCT00925678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7002013|DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season|A Double-blind, Placebo-controlled, Randomised Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DSP-3025 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season||Sumitomo Dainippon Pharma Co., Ltd.||Completed|June 2009|||||Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind|2||Anticipated|72|||Male|20 Years|39 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925678||137249|
NCT00932412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.456/50|The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)|A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA)Versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML).|CLARA|Hospices Civils de Lyon|Yes|Recruiting|March 2009|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|60 Years|No|||April 2013|April 28, 2013|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932412||136739|
NCT00926198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU- 31/09|Investigation of Clinical Spectrum, Bacterial Pathogens and Immune Response in Acute Pharyngotonsillitis|Frequency, Pathogen Spectrum and Specific Immune Response in Acute Pharyngotonsillitis in Children and Adolescents||Johann Wolfgang Goethe University Hospitals|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|4500|Samples Without DNA|throat culture, blood sample|Both|3 Months|18 Years|No|Non-Probability Sample|Patients aged 3 months to 18 years who will present clinical signs of tonsillopharyngitis.|September 2010|September 7, 2010|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926198||137209|
NCT00928200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2006-002|Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)|Intravenous Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia and Allergy to E. Coli Asparaginase (IND 104224)||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|May 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|21 Years|No|||August 2010|August 18, 2010|June 24, 2009|Yes|Yes|Study was terminated due to lack of accrual.|No||https://clinicaltrials.gov/show/NCT00928200||137057|
NCT00927615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807|Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)|Coronary Versus Intravenous abCiximab Administration During Emergency Reperfusion Of ST-segment Elevation Myocardial Infarction - the CICERO Trial|CICERO|University Medical Center Groningen|No|Active, not recruiting|September 2008|April 2011|Anticipated|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|534|||Both|18 Years|N/A|No|||March 2010|September 7, 2010|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927615||137102|
NCT00902980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-010|Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics|Regional Transplant Programs Study of Immunosuppressive Therapy Related Toxicities in Renal Transplant Recipients Managed at Regional or Satellite Community Nephrology Clinics||Astellas Pharma Inc|No|Completed|April 2005|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|264|||Both|18 Years|N/A|No|Probability Sample|Canadian subjects post renal transplant, currently being treated with immunosuppressive        therapy|September 2014|September 17, 2014|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902980||138961|
NCT00902993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00002|Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Male and Non-fertile Female, Young and Elderly Healthy Volunteers, After Oral Multiple Ascending Doses||AstraZeneca|No|Completed|April 2009|September 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 30, 2009|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00902993||138960|
NCT00903266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC008796|Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia|Behavioral and Neural Correlates of Melodic-Intonation-Therapy (MIT) and Speech-Repetition-Therapy (SRT) for Patients With Non-fluent Aphasia||Beth Israel Deaconess Medical Center|No|Recruiting|February 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|21 Years|80 Years|No|||January 2016|January 24, 2016|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903266||138941|
NCT00903526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3423/CE|Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital|Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital||University of Modena and Reggio Emilia||Active, not recruiting|March 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|patients diagnosed with a nosocomial candidaemia at the University Hospital of Modena,        Italy, between January 1998 and March 2008|May 2009|May 15, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903526||138923|
NCT00904085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3203-008|Post-operative Efficacy and Safety Study|A Randomized, Double-blind Evaluation of the Analgesic Efficacy and Safety of a Low Dose Oxymorphone Immediate Release in Patients Following Ambulatory Arthroscopic Knee Surgery||Endo Pharmaceuticals|No|Completed|April 2003|June 2003|Actual|June 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904085||138880|
NCT00928447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-114-201|Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis||Halozyme Therapeutics|No|Completed|June 2009|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|60 Years|No|||September 2012|September 10, 2012|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928447||137038|
NCT00928460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECGtrial|Efficacy of Preoperative Electrocardiography|The Efficacy of Routine Preoperative Electrocardiography in Patients Undergoing Non-cardiac Surgery||UMC Utrecht|Yes|Withdrawn||||||N/A|Observational|Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Probability Sample|All patients aged over 60 years, or younger patients with cardiovascular risk factors,        scheduled for non-cardiac surgery with an expected postoperative hospital length of stay        of at least 2 days.|July 2013|July 30, 2013|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928460||137037|
NCT00924326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090082|CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma|Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2009|December 2020|Anticipated|December 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|70 Years|No|||February 2016|March 8, 2016|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00924326||137352|
NCT00924599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-GDPP|A Pilot Study Using Weightloss and Exercise to Prevent Recurring Gestational Diabetes in Obese Women|Prevention of Gestational Diabetes Pilot Study||California Polytechnic State University-San Luis Obispo|No|Enrolling by invitation|June 2009|August 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Female|18 Years|40 Years|No|||January 2016|January 26, 2016|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00924599||137332|
NCT00924612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-09008|Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation|Phase II Study of the Effect of Food With Various Levels of Fat on the Pharmacokinetics of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men||Clarus Therapeutics, Inc.|No|Completed|July 2009|July 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|16|||Male|18 Years|65 Years|No|||August 2010|August 23, 2010|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924612||137331|
NCT00931307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-335-C-013|Evaluation of Lotrafilcon A Lenses Over a Three Month Period|Evaluation of Lotrafilcon A Lenses Over a Three Month Period||Alcon Research||Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|N/A|No|||October 2010|June 26, 2012|July 1, 2009|Yes|Yes||No|September 16, 2010|https://clinicaltrials.gov/show/NCT00931307||136822|Due to the small number of subjects successfully completing this trial, the results should be interpreted with caution.
NCT00926783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SELECT-AF|Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation|Selective CFAE Targeting for Atrial Fibrillation (SELECT-AF)|SELECT-AF|Biosense Webster, Inc.|No|Completed|August 2009|September 2013|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 22, 2009||No||No|March 24, 2014|https://clinicaltrials.gov/show/NCT00926783||137165|
NCT00931866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCF-006|Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries||Cerimon Pharmaceuticals|No|Completed|April 2009|December 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|407|||Both|18 Years|75 Years|No|||August 2010|August 12, 2010|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931866||136781|
NCT00927342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005LS001B|BioGlue or Vivostat in the Control of Air Leak in Thoracic Surgery|A Comparison of BioGlue and Vivostat in the Prevention of Air Leak in Thoracic Surgery||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|103|||Both|18 Years|N/A|No|||June 2009|June 23, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00927342||137123|
NCT00925925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35580|Epigenetic Markers of B-Cell Function in Low Birth Weight Infants|Epigenetic Markers of B-Cell Function in Low Birth Weight Infants||University of Utah|No|Completed|June 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|64|Samples With DNA|Blood will be stored as frozen mRNA isolates if parents consent to tissue banking.|Both|N/A|2 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Term or near-term infants born at less than or equal to 10% normal birth weight for        gestation.|June 2012|May 11, 2015|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925925||137230|
NCT00927914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS3201-G000-291|Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy|A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy||Eisai Inc.||Completed|July 2009|February 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|800|||Both|18 Years|75 Years|No|||November 2015|November 17, 2015|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927914||137079|
NCT00927043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-4433|Study Evaluating Renal Cell Carcinoma Risk Factors|Prospective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma|MICRA|Pfizer|No|Completed|May 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Treatment naive patients with proven advanced RCC|November 2011|November 4, 2011|June 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927043||137146|
NCT00927355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014509|Effect of Thiazolidinediones on Human Bone|Effects of Thiazolidinediones on Human Bone Marrow Stromal Cell Differentiation Capacity:In Vitro and In Vivo- A Pilot Study||Emory University|Yes|Completed|April 2009|July 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|10|||Both|18 Years|80 Years|No|||June 2014|June 2, 2014|June 24, 2009||No||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00927355||137122|
NCT00927953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGAWN1-02|Treatment of West Nile Virus With MGAWN1|Phase 2, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MGAWN1 in Subjects With Laboratory-documented West Nile Fever or Suspected Central Nervous System Infection Due to West Nile Virus|PARADIGM|MacroGenics|Yes|Terminated|May 2009|May 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|June 24, 2009|Yes|Yes|Early termination due to the inability to enroll (13 of 120 subjects enrolled)|Yes|April 10, 2012|https://clinicaltrials.gov/show/NCT00927953||137076|Early termination due to the inability to enroll (only 13 of 120 subjects enrolled); leading to small numbers of subjects analyzed and therefore many pre-specified analyses were not performed.
NCT00927966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-091|RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms|Phase I Clinical Trial of RAD001 in Combination With CP-751,871 in Patients With Advanced Sarcomas and Other Malignant Neoplasms||Dana-Farber Cancer Institute|Yes|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|June 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927966||137075|
NCT00924339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOYFIT|Soy Food Intervention Trial|The Soy Food Intervention Trial (SOY FIT) for the Treatment of Children and Adolescents With Familial Hypercholesterolaemia - Beneficial Effect of a Soy-Substituted Diet Confirmed by Assessment of Urinary Isoflavone Excretion as Compliance Markers|SOYFIT|Medical University of Vienna|Yes|Not yet recruiting|September 2009|September 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|4 Years|18 Years|No|||June 2009|June 17, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00924339||137351|
NCT00924352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSSMBC0804|Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer|Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer||Accelerated Community Oncology Research Network|No|Completed|June 2009|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|June 16, 2009|Yes|Yes||No|September 22, 2014|https://clinicaltrials.gov/show/NCT00924352||137350|
NCT00903279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPS2009|Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery|Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery (TOPS-MRSA)|TOPS-MRSA|Bay Pines VA Healthcare System|Yes|Withdrawn|August 2009|December 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2009|October 7, 2010|May 14, 2009|Yes|Yes|Funding|No||https://clinicaltrials.gov/show/NCT00903279||138940|
NCT00903539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180-001|Prospective SecurAcath Subcutaneous Securement Trial|Prospective SecurAcath Subcutaneous Securement Clinical Trial|SecurAcath|Interrad Medical|No|Completed|January 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|217|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated to have a central catheter placed at a hospital or private practice        clinic are included in the study population.|January 2012|January 26, 2012|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903539||138922|
NCT00903552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX 755.203|Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)|A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults||Novavax|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|221|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903552||138921|
NCT00903812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060297|IMPACT Non Hodgkins Lymphoma (NHL) Study|A Retrospective and Prospective Observational Study Reviewing Supportive Care Management of NHL Patients Treated With CHOP-14 or 21 Chemotherapy(With or Without Rituximab) (CHOP = Cyclophosphamide, Hydroxyrubicin (Adriamycin), Oncovin (Vincristine), Prednisone Chemotherapy )||Amgen||Completed|February 2007|March 2014|Actual|December 2008|Actual|N/A|Observational|N/A||1|Actual|1837|None Retained|This is an observational study. No bio-specimens are being collected.      Time perspective - this study enrolls both retrospective and prospective subjects|Both|18 Years|N/A|No|Probability Sample|Subjects greater than or equal to 18 years old. Subjects diagnosed with any histological        type of NHL (including both chemotherapy naïve and pre-treated subjects). Subjects planned        to receive a minimum of 3 cycles of CHOP-14 or CHOP-21 with or without Rituximab (for        subjects enrolled retrospectively, eligibility should be assessed on the profile at time        of planning treatment, where treatment initiates on or after 01 Jan 2005, with specific        focus on planned chemotherapy and not outcome or number of delivered cycles) . Before any        study-specific procedure, the appropriate written informed consent must be obtained for        countries where this is required|July 2014|July 14, 2014|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903812||138901|
NCT00914745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-HPB-001|Place Controlled Study to Treat Recurrent Herpes Labialis.|Single Center Phase I/II, Placebo Controlled, Randomized, Double-Blind Study to Treat Recurrent Herpes Labialis by Topical Treatment With Hydroxypropyl-Beta-Cyclodextrin-Ointment (HPßCD-20% Ointment)||University of Zurich|No|Completed|April 2009|May 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|50 Years|No|||May 2011|August 5, 2011|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00914745||138072|
NCT00924625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01HD058035-01|The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis|The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis||University of Pittsburgh|No|Completed|June 2009|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|21 Years|N/A|No|||September 2014|September 9, 2014|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924625||137330|
NCT00924872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS-2008-45|Power Mobility Training for Persons With Stroke|Power Mobility Training for Persons With Stroke: A Randomized Control Trial||Nova Scotia Health Authority|No|Completed|June 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|27|||Both|N/A|N/A|No|||August 2012|August 31, 2012|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924872||137311|
NCT00925704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-129|The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers|A Phase I, Randomized, Open-Label, Three Period Cross-Over Study to Assess the Pharmacokinetics of Oral Calcitriol (ROCALTROL®) in Healthy Volunteers When Administered Alone or When Co-Administered With Lanthanum Carbonate (FOSRENOL®) or Sevelamer Carbonate (RENVELA®)||Shire||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|41|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|June 19, 2009|No|Yes||No|March 19, 2010|https://clinicaltrials.gov/show/NCT00925704||137247|
NCT00925691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB : 2008-A01027-48|Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing|Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing|SEPTAL-PM|Rennes University Hospital|No|Active, not recruiting|April 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925691||137248|
NCT00924859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/09|The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis (CVT)|The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis||University Hospital Inselspital, Berne|No|Recruiting|September 2009|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Probability Sample|Consecutive patients with clinical suspicion of CVT at the emergency department of the        University Hospital (tertiary care clinic)|September 2014|September 23, 2014|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00924859||137312|
NCT00925145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00937|Single Incision Laparoscopic Appendectomy in the Community Utilizing Conventional Instruments|Single Incision Laparoscopic Appendectomy in the Community Utilizing Conventional Instruments||University of British Columbia|No|Completed|July 2009|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|32|||Both|N/A|N/A|No|Non-Probability Sample|All patients presenting to a community hospital (RGH) with a working diagnosis of acute        appendicitis when the investigator (myself) and co-investigator (Dr. Bloom) are on call        for general surgery emergencies.|June 2011|June 1, 2011|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925145||137290|
NCT00925392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DORICPK4002|Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects|Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects||University of Illinois at Chicago|No|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 12, 2013|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00925392||137271|
NCT00927602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005234-79|Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency|The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency||Università degli Studi dell'Insubria|Yes|Terminated|April 2009|March 2012|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|206|||Both|60 Years|N/A|No|||April 2012|April 23, 2012|June 24, 2009||No|study was stopped after enrolment of about 200 patients for slow recruitment|No||https://clinicaltrials.gov/show/NCT00927602||137103|
NCT00927901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149D2301|Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 4-way Crossover Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Indacaterol Salts (Maleate, Xinafoate, and Acetate) in Patients With Persistent Asthma||Novartis||Completed|June 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|75 Years|No|||August 2013|August 26, 2013|June 24, 2009||No||No|July 29, 2011|https://clinicaltrials.gov/show/NCT00927901||137080|
NCT00927056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2006:186|Evaluation of Minimally Invasive Microdiscectomy Versus Conventional Open Microdiscectomy For Lumbar Herniated Disc|Early Activity Monitoring and Pain Assessment in Minimally Invasive Microdiscectomy Versus Conventional Open Microdiscectomy For The Treatment of Lumbar Herniated Disc||University of Manitoba||Enrolling by invitation|June 2009|||June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||August 2011|August 13, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00927056||137145|
NCT00927069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6002|Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept|Open Label Study to Evaluate the Efficacy and Safety of Adalimumab in Patients With Plaque Psoriasis Who Showed an Unsatisfactory Response to Etanercept||Innovaderm Research Inc.|No|Completed|March 2007|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|85|||Both|18 Years|80 Years|No|||September 2011|September 1, 2011|June 22, 2009||No||No|January 18, 2010|https://clinicaltrials.gov/show/NCT00927069||137144|This was an open label uncontrolled study.
NCT00927628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShinjoOI|Macular Hole Reopening|Incidence and Factors Related to Macular Hole Reopening||Shinjo Ophthalmologic Institute|Yes|Completed|October 1990|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|831|||Both|40 Years|80 Years||Non-Probability Sample|Eight hundred seventy-seven eyes of 831 patients with a mean age of 64.9 ± 8.0 years were        studied.|June 2009|June 24, 2009|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927628||137101|
NCT00927641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKT-500-US17|HKT-500 in the Treatment of Adult Patients With Ankle Sprain|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Mild to Moderate Ankle Sprain||Hisamitsu Pharmaceutical Co., Inc.|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927641||137100|
NCT00927979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC090074CTIL|Pain Relief by Intra-Peritoneal Nebulization of Ropivacaine Under Remifentanil Anesthesia for Gynecological Laparoscopy|Phase 3 Prospective, Randomized, Controlled and Double-blinded Second Trial on Pain Relief by Continuous Intra-peritoneal Nebulization of Ropivacaine Under Remifentanil Anesthesia, During Gynecological Laparoscopic Surgery|PSDR|Carmel Medical Center|Yes|Completed|June 2009|October 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 26, 2011|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927979||137074|
NCT00927992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1831011|Study Evaluating Liver Transplantation in Haemophilia Patients in Spain|Liver Transplantation in Haemophilia Patients in Spain||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|11|||Both|N/A|N/A|No|Probability Sample|Patients with haemophilia who underwent liver transplantation and who have been        followed-up at any site in Spain.|December 2012|December 20, 2012|June 24, 2009||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00927992||137073|No outcomes were specified in the study protocol. Designation of outcomes as primary and secondary was based on study team’s input as study neither specifies nor prioritizes the outcomes.
NCT00913289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|675|Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells|Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells||Kanazawa University||Terminated|February 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|80 Years|No|||October 2012|October 16, 2012|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913289||138184|
NCT00913913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0708|Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients|A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-α-2b (IFNα-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)||Dartmouth-Hitchcock Medical Center|Yes|Terminated|February 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2014|October 28, 2015|June 2, 2009|Yes|Yes|low accrual not allowing site to meeting statistical endpoints|No|February 19, 2014|https://clinicaltrials.gov/show/NCT00913913||138136|This study closed early due to difficulty enrolling patients with enrollment limited due to new competing therapies. Though enrollment numbers per statistical design were not met, the primary objective may still be reviewed.
NCT00914186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS022-US201|Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of TS-022 in Adult Patients With a Diagnosis of Atopic Dermatitis (AD) With Moderate to Very Severe Pruritus||Taisho Pharmaceutical R&D Inc.|No|Completed|June 2009|October 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|122|||Both|18 Years|65 Years|No|||November 2011|November 30, 2011|May 28, 2009|Yes|Yes||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00914186||138115|Slower than expected enrollment and a higher than expected screen failure rate.
NCT00914472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPHIP0509|Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure.|A Randomized Non-inferiority Clinical Trial of Heparin Produced by Hipolabor Laboratory(PARINEX®) in Comparation With Heparin Produced by APP PHARMACEUTICALS in Patients With Chronic Renal Failure.|HEPHIP0509|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Active, not recruiting|April 2010|||March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2009|October 26, 2010|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914472||138093|
NCT00911651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_0801|Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients|Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients||University Hospital, Antwerp|Yes|Completed|June 2008|August 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|40 Years|85 Years|No|||May 2009|June 1, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911651||138308|
NCT00925717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2009/1|of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).|of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).|DART|AstraZeneca|No|Completed|May 2009|October 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4045|||Both|18 Years|N/A|No|Non-Probability Sample|Who have records of clinic visit with endocrine internal medicines of nationwide        secondary/tertiary hospitals within the last six months.|January 2010|January 25, 2010|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925717||137246|
NCT00925951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI0905|The Effectiveness of Wet Cupping on Persistent Non-specific Low Back Pain|The Effectiveness of Wet Cupping on Persistent Non-specific Low Back Pain: A Randomized, Waiting-list Controlled, Open-label, Parallel-group Pilot Study||Korea Institute of Oriental Medicine|Yes|Completed|June 2009|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|37|||Both|20 Years|60 Years|No|||June 2009|January 4, 2010|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925951||137228|
NCT00925938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso-Gyn-201|Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy|A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of the Misoprostol Vaginal Priming Insert for Women Requiring Cervical Priming Prior to a Hysteroscopy||Ferring Pharmaceuticals|Yes|Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Female|18 Years|80 Years|No|||January 2014|January 20, 2014|June 19, 2009|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00925938||137229|
NCT00926211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR-09-0002|Computer-Assisted Versus Manual Hair Harvest Comparative Study|Safety and Efficacy of Computer-Assisted vs. Manual Hair Follicle Harvest: A Comparative Hair Count Study||Restoration Robotics, Inc.|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Male|30 Years|59 Years|Accepts Healthy Volunteers|||September 2011|January 3, 2012|June 19, 2009|Yes|Yes||No|September 23, 2011|https://clinicaltrials.gov/show/NCT00926211||137208|
NCT00926224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M111|Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients|Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients||Echosens||Completed|July 2009|September 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||November 2010|November 15, 2010|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926224||137207|
NCT00927030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071269|Melatonin for Sleep in Children With Autism|Melatonin for Sleep in Children With Autism: Safety Tolerability and Dose|NICHD|Vanderbilt University|Yes|Completed|January 2008|October 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|17|||Both|4 Years|10 Years|No|||June 2012|June 28, 2012|June 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927030||137147|
NCT00926458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NONCAD|NON-Invasive Examinations of Coronary Artery Disease|NON-Invasive Examinations of Coronary Artery Disease|NONCAD|Herning Hospital|No|Recruiting|January 2009|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All patients referred for coronary angiography at Region Hospital Herning are screened for        the study and all patients complying with the in-/exclusion criteria are invited to        participate in the study.|June 2009|June 22, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926458||137189|
NCT00926471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01MH079945|Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders|A Cognitive-Behavioral Intervention for Children With Autism Spectrum Disorders||Virginia Polytechnic Institute and State University|No|Completed|September 2008|January 2013|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|17 Years|No|||November 2013|November 6, 2013|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926471||137188|
NCT00926796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0042|Efficacy of Combination Therapies for Gonorrhea Treatment|Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2010|May 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|614|||Both|15 Years|60 Years|No|||June 2013|July 23, 2015|June 23, 2009|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00926796||137164|After the SMC meeting held during August 2012, the SMC recommended halting trial enrollment because continued participant accrual to targeted enrollment of 500 infected participants would be highly unlikely to alter the results.
NCT00926809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009KHR001|H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection|Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial||Korean College of Helicobacter and Upper Gastrointestinal Research|Yes|Recruiting|September 2008|December 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|232|||Both|30 Years|75 Years|No|||June 2009|June 24, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00926809||137163|
NCT00927368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-340|Ultrasound Guided Femoral Nerve Block and Ultrasound Guided Femoral Nerve Block With Peripheral Nerve Stimulation in Knee Replacement Surgery|Comparison Between Ultrasound Guided Femoral Nerve Block Versus Ultrasound Guided Femoral Nerve Block With the Use of Peripheral Nerve Stimulation for Patients Undergoing Total Knee Replacement.||The Cleveland Clinic|No|Active, not recruiting|July 2009|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|420|||Both|18 Years|80 Years|No|||January 2013|December 18, 2013|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00927368||137121|
NCT00927654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002090-12|Iloprost in High Risk Cardiac Surgical Patients|Effect of Iloprost Inhalation Before and During Extracorporeal Circulation (ECC) on Perioperative Morbidity and Outcome in High Risk Cardiac Surgical Patients|Ilocard|Ludwig-Maximilians - University of Munich|Yes|Completed|June 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|80 Years|No|||January 2013|January 4, 2013|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00927654||137099|
NCT00928005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|666|Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study)|Diet and Exercise in Type 2 Diabetes and Prediabetes|SHAPE3|Johns Hopkins University|Yes|Completed|July 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|77|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 1, 2013|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00928005||137072|
NCT00928252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2008-069|Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer|Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer||Queen's Medical Centre|No|Active, not recruiting|June 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Male|18 Years|N/A|No|||February 2016|February 16, 2016|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928252||137053|
NCT00910403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901|Multicenter Evaluation of Safety and Effectiveness of Presbyopic LASIK for Hyperopes|A Prospective Multicenter, Study to Evaluate the Safety and Effectiveness of the Presbyopia Algorithm for Hyperopia and Hyperopic Astigmatism Using LASIK|PresbyLASIK|Technolas Perfect Vision GmbH|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00910403||138404|
NCT00910416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/22|The Comparability of Bispectral Index and Neurosense During Anesthesia|The Comparability of Bispectral Index and Neurosense During Total Intravenous Anesthesia and Balanced Anesthesia||Hopital Foch|No|Terminated|May 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Surgical patients|January 2011|January 22, 2011|May 27, 2009||No|Differences between BIS and Neurosense are important. This study can be terminated.|No||https://clinicaltrials.gov/show/NCT00910416||138403|
NCT00913588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960379|To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions|Comparative, Randomized, Single-Dose, 3-Way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fed and Fasted Conditions Following Administration of a 40 mg Dose||Sandoz||Completed|May 1996|August 1996|Actual|August 1996|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913588||138161|
NCT00913926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14575|Effects of Wellnara on Climacteric Symptoms|Multicenter Non-interventional Study on Efficacy, Tolerability, and Acceptance of Wellnara Containing 1.03 mg Estradiol Hemihydrate (Equivalent to 1 mg Estradiol) and 0.04 mg Levonorgestrel for Treatment of Hormone Deficiency Symptoms in Postmenopausal Women During 6 Cycles of 28 Days.||Bayer|No|Completed|September 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|749|||Female|N/A|N/A|No|Non-Probability Sample|The target population of this study are women who have received a prescription of Wellnara        on the basis of the decision of the treating gynecologist. The study is expected to        collect data of up to 2,400 women in about 700 gynecological practices in Germany.|April 2015|April 21, 2015|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913926||138135|
NCT00914199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070005|The Nordic Bifurcation Study III|Stenting of Coronary Artery Stenoses With Significant Side Branches. Should we, or Should we Not, Perform Dilatation of the Side Branch Through the Main Vessel Stent, if There is Acceptable Blood Flow in the Side Branch?|BIF III|Aarhus University Hospital Skejby|Yes|Active, not recruiting|April 2007|December 2016|Anticipated|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|477|||Both|N/A|N/A|No|||March 2015|March 12, 2015|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914199||138114|
NCT00914212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-103|A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)|A Functional Magnetic Resonance Imaging (fMRI) Study of the Reproducibility and the Effect of Sibutramine During Fasted and Fed Conditions in Healthy Overweight and Obese Men||Merck Sharp & Dohme Corp.|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|June 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914212||138113|
NCT00914485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 07-194|Using Multimedia Patient Feedback to Reduce Disparities in VA Healthcare|Using Multimedia Patient Feedback to Reduce Disparities in VA Healthcare||VA Office of Research and Development|No|Completed|December 2009|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|369|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|June 3, 2009||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT00914485||138092|
NCT00914732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0002|Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally|Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|524|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||January 2011|December 4, 2014|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914732||138073|
NCT00910429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11349|BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension|Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).|CHEST-2|Bayer|Yes|Active, not recruiting|July 2009|April 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|237|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910429||138402|
NCT00925405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0050|Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy|Breast MRI Screening in High-Risk Women After Mantle Radiation Therapy for Lymphoma||M.D. Anderson Cancer Center|No|Terminated|June 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Female|N/A|N/A|No|Non-Probability Sample|Women, breast cancer patients diagnosed with Hodgkin's lymphoma prior to 1995, who        underwent mantle-field irradiation between 1970-1995 at M. D. Anderson Cancer Center.|November 2011|November 7, 2011|June 18, 2009||No|Low accrual|No||https://clinicaltrials.gov/show/NCT00925405||137270|
NCT00925418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYO 1/IPC 2005-007|Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer|Randomized Trial Evaluating the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Patient Treated for Breast or Prostate Cancer.|CRYO1|Institut Paoli-Calmettes|No|Completed|September 2006|July 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|168|||Female|18 Years|N/A|No|||September 2011|September 13, 2011|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925418||137269|
NCT00924898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 0805 (PHI 02)|Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)|CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis||University of North Carolina, Chapel Hill|No|Completed|January 2005|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00924898||137309|
NCT00925184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WF-R-CWP-97-001|Students' View: Survey of Medical Education in Taiwan|Students' View: Survey of Medical Education in Taiwan||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|July 2008|November 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|370|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|medical students at their graduate year will be invited to participated in this study.        students who are willing to participate need to help us to fill out a questionnaire about        their educational experience in medical school.|November 2010|November 18, 2010|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925184||137287|
NCT00925431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21744|Nutrition and Coping Education for Symptom and Weight Management for Fibromyalgia|Lifestyle Modification Program for Overweight and Obese Fibromyalgia Patients||University of Utah|Yes|Completed|August 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|21 Years|65 Years|No|||May 2015|May 26, 2015|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925431||137268|
NCT00925730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASM981C2313|Open-Label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion|Non-Comparative Open-Label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion||Novartis||Completed|March 2004|||January 2006|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|2 Years|18 Years|No|||June 2009|June 19, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00925730||137245|
NCT00925964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07029|Systolic Pressure Index in Assessing the Risk of Cardiovascular Events|Interest of Measuring the Systolic Pressure Index in Assessing the Risk of Cardiovascular Events Peri-operatively in the Surgery, Settled Out of Cardiovascular Surgery|IPS|University Hospital, Limoges|No|Completed|January 2008|September 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|504|Samples Without DNA|Blood sample to evaluate Troponin, a Cardiac biomarker|Both|40 Years|N/A|No|Non-Probability Sample|All patients from thoracic surgery, cardiovascular surgery and transplantation,urologic        surgery, gastrointestinal surgery and orthopedic surgery services and coming to a        preoperative anesthesia consultation are concerned with the study.|June 2009|March 14, 2012|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00925964||137227|
NCT00926237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109033|Effect of rTMS on Resting State Brain Activity in Tinnitus|Effect of rTMS on Resting State Brain Activity in Tinnitus||University of Arkansas|No|Recruiting|January 2009|March 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|89 Years|No|||January 2016|January 4, 2016|June 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00926237||137206|
NCT00926484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF87330244|Tooth Mousse and Fluoride in Dentin Hypersensitivity Treatment|Combined Tooth Mousse and Fluoride Varnish in Dentin Hypersensitivity Treatment||Huazhong University of Science and Technology|No|Completed|January 2007|June 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|30|||Both|26 Years|66 Years|No|Probability Sample|primary care clinic|June 2009|June 22, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926484||137187|
NCT00927082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV22430|A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B|A Follow-up Study to Evaluate the Long-term Post Treatment Effects of Peginterferon Alfa-2a (PEG-IFN) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study WV19432(NEPTUNE).||Hoffmann-La Roche||Completed|April 2009|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|383|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 16, 2009||No||No|February 10, 2016|https://clinicaltrials.gov/show/NCT00927082||137143|Of the responders at FU Year 5, the proportion of patients who were receiving additional anti-HBV treatment after FU Week 24 varied between groups.The frequency of missing values (counted as non-response) was unevenly distributed between groups.
NCT00927095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH081837|Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)|Continuous OC Treatment in PMDD: Steroid Hormone Mechanisms|PMDD|University of North Carolina, Chapel Hill|Yes|Completed|July 2008|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|58|||Female|18 Years|52 Years|No|||June 2015|June 11, 2015|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00927095||137142|
NCT00927394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPV100AUS02|Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus|An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus|ViVID|Novartis||Completed|May 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1143|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|June 24, 2009|Yes|Yes||No|October 1, 2012|https://clinicaltrials.gov/show/NCT00927394||137119|
NCT00927667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12948|Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens|A Diagnostic Interventional, Controlled, Cross-sectional Evaluation of Joint Status Using Magnetic Resonance Imaging in Subjects With Severe Hemophilia A Treated With Primary Prophylaxis, Secondary Prophylaxis, or On-demand Therapy||Bayer|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|5||Actual|156|||Male|12 Years|35 Years|No|||February 2013|February 16, 2013|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927667||137098|
NCT00932542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT054|Eutectic Mixture for Hemorrhoidectomy Postoperative|"Topic Effects of Eutectic Mixture Use in Local Anesthetics on Hemorrhoidectomy Postoperative (Prospective Study, Randomized, Triple Blind, Placebo-controlled)"|CRT054|Federal University of São Paulo|Yes|Active, not recruiting|April 2010|November 2012|Anticipated|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|144|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00932542||136729|
NCT00932841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-007|The Use of VSL#3 in Irritable Bowel Syndrome in Children|The Use of VSL#3 in Irritable Bowel Syndrome in Children|VSL#3|Dayton Children's Hospital|Yes|Terminated|January 2008|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|13 Years|18 Years|No|||March 2012|March 16, 2012|July 2, 2009|Yes|Yes|PI has re-located. PI terminated FDA IND # and closed study.|No||https://clinicaltrials.gov/show/NCT00932841||136708|
NCT00910702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISBOR-61165995|The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body|The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body||GuangZhou WeiShiBo Biotechnology Co., ltd|Yes|Completed|May 2009|March 2013|Actual|December 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|10 Years|65 Years|No|||April 2013|April 29, 2013|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910702||138381|
NCT00910715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-0509|Duration of Antibiotic Treatment of Erythema Migrans|Duration of Antibiotic Treatment of Erythema Migrans. A Randomized Clinical Trial.||University Medical Centre Ljubljana|No|Completed|June 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|306|||Both|15 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 28, 2009||No||No|October 5, 2011|https://clinicaltrials.gov/show/NCT00910715||138380|
NCT00911053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01EY018312|Melatonin for Circadian Sleep Disorders in the Blind|Melatonin for Circadian Sleep Disorders in the Blind||Oregon Health and Science University||Recruiting|June 1997|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|40|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00911053||138354|
NCT00911404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC-670|Carbohydrate Restriction for Gestational Diabetes Mellitus|Comparison of Two Different Diets Containing Different Proportions of Carbohydrates in the Treatment of Gestational Diabetes Mellitus: A Randomized Clinical Trial|LO-CA|Hospital Arnau de Vilanova|No|Completed|January 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|152|||Female|18 Years|45 Years|No|||July 2012|July 15, 2012|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911404||138327|
NCT00914771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V87_17|Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects|A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects||Novartis||Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|722|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914771||138070|
NCT00910442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-24|Glutathione and Its Precursors in HIV-Infected Patients|The Effect of Substrate Supply on Modulating Plasma GSH Levels in Treated HIV+ Patients||UPECLIN HC FM Botucatu Unesp|Yes|Completed|February 2002|February 2009|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||May 2009|May 28, 2009|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910442||138401|
NCT00924651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCO08106; URCC0701|Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy|A Study of the Effects of Exercise on Cancer-Related Fatigue|EXCAP|University of Rochester|Yes|Active, not recruiting|September 2009|May 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|692|||Both|21 Years|N/A|No|||March 2016|March 16, 2016|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00924651||137328|
NCT00924664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091039|Long Term Safety Study of Tanezumab in Chronic Low Back Pain|A Randomized, Multicenter, Long Term Study of the Safety of Tanezumab in Patients With Chronic Low Back Pain||Pfizer|Yes|Terminated|August 2009|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|849|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|June 18, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00924664||137327|
NCT00925444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080204|Staple-line Reinforcement for Prevention of Pulmonary Air Leakage|Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer.|SPIRAL|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|85 Years|No|||January 2009|September 17, 2013|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925444||137267|
NCT00925743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD10870|A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer|A Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Cabazitaxel In Combination With Cisplatin Administered Every 3 Weeks In Subjects With Advanced Solid Malignancies||Sanofi|No|Completed|June 2009|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|June 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00925743||137244|
NCT00925977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005275ctil|Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents|Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents||Rabin Medical Center|No|Terminated|July 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|7 Years|20 Years|No|||June 2012|June 4, 2012|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00925977||137226|
NCT00926497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCTStocker|Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis|Use of Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis: Prospective Randomized Intervention Trial||Luzerner Kantonsspital|Yes|Completed|June 2005|January 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|N/A|3 Days|No|||May 2009|May 4, 2009|January 16, 2009||No||No|January 16, 2009|https://clinicaltrials.gov/show/NCT00926497||137186|The samll sample size does not allow to prove the safety of our Procalcitonin-guided strategy. Second, because of our single center setting, our results cannot be easily be extrapolated.
NCT00926510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0549|The Use of a Language Toolkit for Toddlers|Two to Talk: The Use of a Language Toolkit for Toddlers||University of North Carolina, Chapel Hill|No|Completed|August 2009|September 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|14 Months|19 Months|No|||October 2011|October 10, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926510||137185|
NCT00926523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0274|Biomarkers in the Evaluation of Chronic Lung Disease|Biomarkers in the Evaluation of Chronic Lung Disease||Northwell Health|Yes|Completed|June 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|67|Samples Without DNA|Exhaled breathe condensate.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are either a healthy volunteer, or someone who has confirmed Pulmonary        Hypertension and Interstitial Lung Disease|May 2011|May 26, 2011|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00926523||137184|
NCT00930865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-057|Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects|A Randomized, Open-Label, Parallel-group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects||AstraZeneca|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|June 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00930865||136855|
NCT00927108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-CMR-005|Rajavtihi Neuronal Adult Stem Cells Project|Adult Neuronal Progenitor Stem Cell Project|RNASc|Rajavithi Hospital|Yes|Not yet recruiting|July 2009|||December 2011|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|20 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 23, 2009|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00927108||137141|
NCT00927381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC03/03/05|Retrospective Evaluation of CroFab - Efficacy in Severe Envenomation|Retrospective Evaluation of Treatments and Outcomes Associated With Antivenom Therapy For Crotaline Snakebite - A Comparison Of Severe To Mild/Moderate Envenomations||BTG International Inc.|No|Completed|January 2005|December 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|247|||Both|N/A|N/A|No|Non-Probability Sample|All patients bitten by a pit viper and treated with CroFab between January 1, 2002 and        December 31 2004.|June 2009|June 24, 2009|June 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00927381||137120|
NCT00927407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALG-0603|Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice|A Randomized, Single-Dose, Parallel Group, Comparative Pharmacokinetic (PK) Study to Evaluate Malathion Gel 0.5% Versus Ovide (Malathion) Lotion 0.5% in Patients With Pediculosis Capitis||Taro Pharmaceuticals USA|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2013|December 21, 2013|June 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00927407||137118|
NCT00931996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-0522|Oculomotor and Spatial Cognition Deficits in Schizophrenia|Clinical and Computational Studies of Dopamine Function in Schizophrenia||University of Illinois at Chicago|No|Terminated|June 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|15 Years|64 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|June 25, 2009|Yes|Yes|Study was terminated due to low accrual.|No|November 8, 2011|https://clinicaltrials.gov/show/NCT00931996||136771|Early termination leading to small numbers of subjects analyzed
NCT00932009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV IISP #36113|Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men|Prevalence and Type Distribution of Genital Human Papillomavirus (HPV) in Tanzanian Men||Danish Cancer Society|No|Completed|March 2009|December 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1933|Samples With DNA|cell scrapes from penis|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Tanzanian men from an urban setting (Dar es Sallam)(factories, University, college)and men        from an rural setting (Muhesa, Mwanga, Bagamoyo)|August 2015|August 7, 2015|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00932009||136770|
NCT00913939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0026-C|High-Dose-Rate Brachytherapy|MRI-Guided HDR Brachytherapy for Prostate Cancer||University Health Network, Toronto|Yes|Recruiting|May 2009|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|N/A|No|||January 2016|January 28, 2016|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913939||138134|
NCT00913952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940155|To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions|Comparative, Randomized, 3-Way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fed and Fasted Conditions||Sandoz||Completed|April 1994|June 1994|Actual|June 1994|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913952||138133|
NCT00913965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9103B|To Demonstrate the Relative Bioavailability of Atenolol Tablets|Bioavailability of Atenolol Tablets||Sandoz||Completed|July 1989|August 1989|Actual|August 1989|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913965||138132|
NCT00914238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danish OPUS II trial|Extended Specialized Assertive Intervention for First Episode Psychosis|A Randomized Clinical Trial of the Effect of Five-years Versus Two-years Specialized Assertive Intervention for First Episode Psychosis - the OPUS II Trial|OPUSII|University of Copenhagen|Yes|Active, not recruiting|July 2009|January 2017|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|37 Years|No|||January 2014|January 24, 2014|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00914238||138111|
NCT00914251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|073/09|Vascular Effects of Hesperidin in Metabolic Syndrome|Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome||University of Rome Tor Vergata||Recruiting|November 2008|December 2010|Anticipated|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|55 Years|No|||June 2009|June 16, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914251||138110|
NCT00914511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-014|A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects|A Phase I, Single-Center, Open-Label, Non-Randomized, Two-Cohort Study to Assess the Effect of Age on the Pharmacokinetics of Avanafil And To Determine Avanafil Semen Exposure and the Acute Effect of Avanafil on Sperm Function in Healthy Young Male Subjects Following a Single Oral Dose of 200 mg||VIVUS, Inc.|No|Completed|May 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 5, 2011|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914511||138090|
NCT00914784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-IM-0295-CTIL|The Incidence of TRALI in Patients Undergoing Orthopedic-Oncology Surgery|The Incidence of Transfusion-Related Acute Lung Injury (TRALI) Following Blood Product Transfusion in Patients Undergoing Elective Orthopedic-Oncology Procedures||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|August 2009|September 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|550|Samples With DNA|blood from arterial line to test for PaO2|Both|18 Years|90 Years|No|Probability Sample|Patients aged >18 years old, with ASA I-III, undergoing elective orthopedic-oncology        procedures in the Sourasky Medical Center, and receiving blood products pre-, intra-, or        post-operatively.|June 2009|June 4, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914784||138069|
NCT00914810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4129-A|Effect of Supplemental Vitamin D on Skeletal Muscle Function in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effect of Supplemental Vitamin D on Skeletal Muscle Function in COPD Patients.||Minneapolis Veterans Affairs Medical Center|No|Completed|June 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|40 Years|N/A|No|||June 2013|June 7, 2013|June 4, 2009||No||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00914810||138067|
NCT00910481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN40553718|Balloon Pump Assisted Coronary Intervention Study|Balloon Pump Assisted Coronary Intervention Study|BCIS-1|British Cardiovascular Intervention Society|Yes|Active, not recruiting|December 2005|September 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|301|||Both|18 Years|N/A|No|||May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910481||138398|
NCT00910793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_0802|Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients|Open-Label, Prospective Study to Assess the Effects of Formoterol and Beclometasone Dipropionate Combination Therapy on Central and Peripheral Airway Dimensions in Asthmatic Patients||University Hospital, Antwerp|No|Completed|August 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910793||138374|
NCT00925197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0054|Patient International Normalised Ratio (INR) Self-Testing Program|Patient INR Self-Testing Program Improves the Quality of Oral Anticoagulant Therapy After Mechanical Heart Valve Replacement||University Hospital, Clermont-Ferrand||Completed|May 2004|January 2009|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label|||Actual|206|||Both|18 Years|N/A||||June 2009|June 19, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925197||137286|
NCT00925756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 590|CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery|The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression||California Collaborative Treatment Group|No|Completed|June 2009|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925756||137243|
NCT00925769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20784|ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer|An Open Label Study to Evaluate the Safety and Effect on Disease Progression of Triple Combination Treatment With Erlotinib (Tarceva), Bevacizumab (Avastin), and Capecitabine (Xeloda) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer (REBECA-Trial).||Hoffmann-La Roche||Completed|January 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|April 15, 2009||No||No|July 13, 2015|https://clinicaltrials.gov/show/NCT00925769||137242|Planned Part 2 of the study was not implemented and outcome measures related to Part 2 were not analyzed.
NCT00925990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-1027-03|CTS-1027 in Interferon-Naive Hepatitis C Patients|A Trial of CTS-1027 in Interferon-Naive Hepatitis C Patients||Conatus Pharmaceuticals Inc.|Yes|Completed|June 2009|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|June 19, 2009|No|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00925990||137225|
NCT00926003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIRB 07-709|Cognitive Rehabilitation in Ugandan Children With HIV|Neuropsychological Benefits of Cognitive Training in Ugandan HIV Children|HIV CCRT|Michigan State University|No|Suspended|October 2009|October 2012|Anticipated|October 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||June 2009|June 22, 2009|June 22, 2009||No|awaiting additional funding|No||https://clinicaltrials.gov/show/NCT00926003||137224|
NCT00930358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060240|Safety Study of Colonoscopy Under Sedation|Tolerance and Acceptability of Colonoscopy Under Sedation by an Equimolar Mixture of Oxygen and Nitrous Oxide. Comparison With General Anesthesia in a Randomized, Multicentric Study.|KALINAG|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|February 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|75 Years|No|||April 2011|April 5, 2011|June 29, 2009||No|This study was stopped due to low inclusion|No||https://clinicaltrials.gov/show/NCT00930358||136893|
NCT00930878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2213|Comparative Registry of the PROmus™, ENdeavor™ and CYpher™ Drug Eluting Stents|A Comparative Registry of the PROmus™, ENdeavor™ and CYpher™ Drug Eluting Coronary Stent Systems for the Treatment of Coronary Lesions|ProEnCy|Boston Scientific Corporation|Yes|Completed|February 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1934|||Both|18 Years|N/A|No|Probability Sample|All patients eligible and planned for percutaneous coronary intervention (PCI) with any of        the three stents and willing to give consent to allow for collection of their clinical        data. Patients also need to express willingness to comply with all standard of care        follow-up evaluations and medical therapies.|September 2011|October 24, 2011|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00930878||136854|
NCT00931190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-240|Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia|Evaluation of the Use of Human Papillomavirus Persistence for Determination of the Treatment Efficacy Among Women With Cervical Intraepithelial Neoplasia, and for Prediction of Recurrence of Cervical Disease||Lund University|No|Completed|February 2001|November 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|195|Samples With DNA|Cervical smear samples in physiologic saline.|Female|N/A|N/A|No|Non-Probability Sample|195 women referred for treatment of cervical intraepithelial neoplasia in the cathment        area of Umeå university hospital. All women had abnormal smears at enrollment.|September 2009|September 14, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931190||136831|
NCT00926835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIHWAF-CRCD-K-01|Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients|A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients||Ministry of Health & Welfare, Korea|Yes|Terminated|May 2009|July 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|9||Actual|692|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|June 23, 2009||No|due to patient recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00926835||137162|
NCT00927121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/1525|Clinical Investigation on the Acoustic Stimulation in the Treatment of Chronic Tinnitus|l Prospective Clinical Investigation on the Acoustic Stimulation With the "Coordinated Reset of Neural Subpopulations" in the Treatment of Chronic Tinnitus||ANM Adaptive Neuromodulation GmbH|Yes|Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|63|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00927121||137140|
NCT00927134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PedsZürich_GT05|Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children|Phase I/II Gene Therapy Study for X-linked Chronic Granulomatous Disease in Children|XCGDinChildren|University of Zurich|No|Completed|June 2004|September 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|1 Year|18 Years|No|||September 2011|September 26, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00927134||137139|
NCT00931710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVEA489AUS01|Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension|A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension|EXALT|Novartis||Completed|July 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|488|||Both|18 Years|N/A|No|||March 2011|March 1, 2011|July 1, 2009|Yes|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT00931710||136793|
NCT00932594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-5010|The New Serial Treatment of Temporomandibular Disorders|Create the New Serial Treatment of Temporomandibular Disorders||Sun Yat-sen University|Yes|Recruiting|January 2006|December 2026|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|4|||Both|16 Years|60 Years|No|||May 2015|May 19, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00932594||136726|
NCT00932256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAHIST IND 105781|Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients|STAHIST IND 105781 Phase 1 Clinical Trial||Magna Pharmaceuticals, Inc.|Yes|Completed|October 2009|December 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|No|||December 2010|December 6, 2010|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932256||136751|
NCT00932269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/132-31/4//2008/164-32|Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease|Seroimmunity 2007. Serological Study of the Swedish Population Regarding Vaccine Preventable Diseases Within the National Immunization Program (NIP), and a Sub Study Focusing on Foreign Born 14-16 Year-Olds.|Sero 2007|Swedish Institute for Infectious Disease Control|Yes|Active, not recruiting|March 2007|September 2011|Anticipated|May 2008|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|5400|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Seroimmunity 2007: the Swedish population.        Sub study: foreign born children between 14-16 years of age.|July 2009|July 1, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00932269||136750|
NCT00913978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00006131|An Evaluation of the Impact of Perioperative Warming on Maintenance of Normothermia and Outcome After Abdominal Surgery|A Prospective Randomized Evaluation of the Impact of Perioperative Warming on Maintenance of Normothermia and Outcome After Abdominal Surgery||Northwestern University|No|Active, not recruiting||||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913978||138131|
NCT00914264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|972246B|The Effects of Continuous Positive Airway Pressure on Overlap Syndrome|The Continuous Positive Airway Pressure Effects on Chronic Obstructive Pulmonary Disease Patients With Obstructive Sleep Apnea||Chang Gung Memorial Hospital|Yes|Recruiting|December 2008|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|N/A|No|Probability Sample|from outpatient clinic of CGMH and those in COPD cohort|August 2010|February 3, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00914264||138109|
NCT00914524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0866-C-J201|Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy|An Open-label Study of Olmesartan Medoxomil (CS-866) in Normotensive Patients With Chronic Glomerulonephritis or Diabetic Nephropathy||Daiichi Sankyo Inc.|No|Completed|January 2005|October 2006|Actual|April 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|20 Years|70 Years|No|||September 2010|September 28, 2010|June 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914524||138089|
NCT00914797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TER2009JE|Terbutaline Concentrations in Blood and Urine|Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration.||Bispebjerg Hospital|Yes|Not yet recruiting|July 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914797||138068|
NCT00910455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN005|Study of SRX246 Capsules in Healthy Adult Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers|AVN005|Azevan Pharmaceuticals|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 16, 2010|May 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910455||138400|
NCT00910468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSD08-00631|Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids|Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids||Ascher-Walsh, Charles, M.D.||Completed|July 2005|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|150|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with fibroid uterus desiring surgical management|May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910468||138399|
NCT00910806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015793|TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)|A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects.||Tibotec BVBA|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||April 2014|April 1, 2014|May 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00910806||138373|
NCT00911144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112933|Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine|Booster Vaccination With Pneumococcal Vaccine GSK1024850A or Prevenar™ Co-administered With Hiberix™ in Children Primed With the Same Vaccines||GlaxoSmithKline||Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|450|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||November 2011|November 10, 2011|May 28, 2009|Yes|Yes||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00911144||138347|
NCT00925457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016396|Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone|Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed||December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|1608|||Both|N/A|N/A|No|Probability Sample|Saskachewan residents who received domperidone or a proton pump inhibitor (PPI) between        January 1, 1990, and December 31, 2005|March 2012|March 15, 2012|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925457||137266|
NCT00925470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2009/1|Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure|Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure Without Known Cardio Vascular or Renal Disease, Stratified on Blood Pressure Control.|PREVENTA|AstraZeneca|No|Completed|June 2009|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1200|||Both|18 Years|N/A|No|Probability Sample|First 2 consecutive adults with hypertension, without known cardio vascular or renal        disease,seen by Cardiologists|December 2009|December 17, 2009|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925470||137265|
NCT00925483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#04-050|Decreasing Dialysis Cardiovascular Risk: Daily Versus Longer Treatments|Decreasing Dialysis Cardiovascular Risk: Daily Versus Longer Treatments||Dallas VA Medical Center||Recruiting|August 2004|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|21 Years|N/A|No|||February 2010|February 24, 2010|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925483||137264|
NCT00930007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13950|Sleep-wake Changes of Luteinizing Hormone Frequency in Pubertal Girls With and Without High Testosterone|Comparison of Sleep-wake LH Frequency in Peripubertal Girls With and Without Hyperandrogenemia|CRM005|University of Virginia|Yes|Active, not recruiting|October 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|90|Samples Without DNA|Serum obtained during frequent sampling will be stored (in case repeat measurements are      required), but will be discarded at the end of the study|Female|8 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample and patients from local clinics|November 2015|November 11, 2015|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00930007||136920|
NCT00930618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071212|Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies|NOCETER, a Multicenter Double Blind Placebo-controlled Randomized Trial: Reduction of CEsareans in Post TERm Pregnancies: Impact of Outpatient Cervical Ripening With NO Donors|NOCETER|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2009|April 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1409|||Female|18 Years|N/A|No|||June 2014|June 25, 2014|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930618||136874|
NCT00926250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109167|Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults|Effects of Pro-Stat Immuno-Protein Complex (PS-IPC) Supplementation on Muscle Mass and Function, Inflammatory Markers, and Immune Function in Older Adults|PS-IPC|University of Arkansas|No|Terminated|June 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||January 2012|January 17, 2012|June 22, 2009||No|Sponsor changed their study product and halted study.|No||https://clinicaltrials.gov/show/NCT00926250||137205|
NCT00926263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021037|A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects|A Phase 1, Open Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, And Effect On QT/QTc Interval For CP-751,871 Following Single Intravenous Administration To Healthy Adult Subjects||Pfizer|No|Terminated|July 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|June 21, 2009|No|Yes|See termination reason in detailed description.|No|January 18, 2013|https://clinicaltrials.gov/show/NCT00926263||137204|This study was terminated prior to enrollment of participants into Cohort 3 (2 doses of 20 mg/kg on consecutive days). Therefore, endpoints relating to that cohort were not assessed.
NCT00931450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-SUT-EXE-08|Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer|Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer.||National Cancer Institute (NCI)||Recruiting|March 2009|||October 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|70|||Female|N/A|N/A|No|||July 2009|August 9, 2013|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931450||136811|
NCT00931476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHKIN-1253|A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin|A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group, Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Norditropin® (Norditropin® PenSet® 24)||Novo Nordisk A/S|No|Completed|April 2000|June 2000|Actual|June 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|86|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 28, 2012|June 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931476||136809|
NCT00926848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|544-08|Reducing Risk in Cardiac Rehabilitation: Partners Together in Health (PaTH) Intervention Study|Reducing Risk in Cardiac Rehabilitation: Partners Together in Health (PaTH) Intervention Study|PaTH|University of Nebraska|No|Recruiting|July 2009|December 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|120|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 11, 2010|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00926848||137161|
NCT00931424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008001|The Clinical Trial for Primary Chronic Venous Insufficiency|The Clinical Research of Surgery on Primary Chronic Venous Insufficiency||Sun Yat-sen University|Yes|Recruiting|January 2006|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|15 Years|70 Years|No|||May 2009|June 30, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931424||136813|
NCT00931437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-086|Vitamin K-absorption From Dairy|Absorption of Different Forms of Vitamin K From Dairy Products||Maastricht University Medical Center|No|Completed|April 2009|November 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 15, 2010|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931437||136812|
NCT00932022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-SXR-09-003|Trospium Chloride XR in Obese Female Patients With Overactive Bladder|||Allergan|No|Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Female|18 Years|75 Years|No|||December 2012|December 14, 2012|July 1, 2009|Yes|Yes||No|December 14, 2012|https://clinicaltrials.gov/show/NCT00932022||136769|Due to lack of evaluable data, analysis for the secondary outcome measures was not performed.
NCT00928642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BUS241|Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer|A Phase II Trial of Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer Who Have Failed at Least Two Prior Therapies||Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Completed|June 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||October 2014|October 20, 2014|June 25, 2009|Yes|Yes||No|April 5, 2013|https://clinicaltrials.gov/show/NCT00928642||137023|This study was terminated due to a combination of poor accrual and lack of evidence of benefit.
NCT00928954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHR01EY06717|Cross-Over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus|Investigation and Treatment of Ocular Motor Disorders: Cross-Over Comparison of Gabapentin and Memantine as Treatment for Nystagmus||Case Western Reserve University|Yes|Completed|February 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||June 2009|June 25, 2009|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00928954||136999|
NCT00932893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081007|An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene|Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of PF-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus||Pfizer|Yes|Completed|September 2009|January 2016|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|347|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|June 30, 2009|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00932893||136704|These results are from a preliminary clinical study report including final results for PFS and interim results for OS.
NCT00928616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108/07|Differential Effects of a Diet Supplementation With Plant Sterol Esters on Human Monocytes|Differential Effects of "Functional Foods" Supplemented With Plant Sterol Esters on Blood Cells and Serum Parameters.|PSE-MO|University Hospital, Saarland|No|Active, not recruiting|April 2009|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 25, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928616||137025|
NCT00914277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT10775|SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction|Randomized, Double-blind, Placebo and Active Controlled Study of the Activity of SAR407899A Single-dose on the Ability to Increase Duration of Penile Rigidity, Under Experimental Condition, in Patients With Mild to Moderate Erectile Dysfunction (ED).|RHOKET|Sanofi|No|Completed|May 2009|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Male|18 Years|60 Years|No|||April 2011|April 29, 2011|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914277||138108|
NCT00914290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX056-B09-01|A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis|A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis||IMPAX Laboratories, Inc.|No|Completed|April 2009|February 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2013|September 8, 2015|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914290||138107|
NCT00914303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0490C00002|Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect||AstraZeneca|Yes|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|77|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2010|April 5, 2010|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00914303||138106|
NCT00914537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909158|Anal Cancer Screening Study|Anal Cancer Screening Study||National Institutes of Health Clinical Center (CC)||Completed|May 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Male|18 Years|N/A|No|||August 2015|September 16, 2015|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914537||138088|
NCT00914823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002486|Administration of Kisspeptin to Subjects With Reproductive Disorders|Kisspeptin Administration in the Adult||Massachusetts General Hospital|Yes|Recruiting|March 2009|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914823||138066|
NCT00914836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-09|Comparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful Shoulder|||HaEmek Medical Center, Israel|Yes|Withdrawn|June 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|35 Years|N/A|No|||June 2015|June 21, 2015|May 17, 2009||No|difficulties in the department|No||https://clinicaltrials.gov/show/NCT00914836||138065|
NCT00910494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB/JK/LET/LN1277|Intraoperative Radiotherapy for Rectal Cancer Using the Photon Radiosurgery System|Intraoperative Radiotherapy (IORT) for Rectal Cancer Using the Photon Radiosurgery System (PRS): A Phase I Clinical Trial||University of Dundee|No|Recruiting|January 2010|January 2017|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||June 2010|June 24, 2010|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910494||138397|
NCT00910780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0858|Metabolic Effects of Antipsychotic Substitution in Children|Metabolic Effects of Antipsychotic Substitution in Children|SMEAC|Washington University School of Medicine|Yes|Withdrawn|November 2009|November 2009|Anticipated|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|6 Years|18 Years|No|||March 2014|March 12, 2014|May 28, 2009||No|Study was not funded.|No||https://clinicaltrials.gov/show/NCT00910780||138375|
NCT00901277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010063|Supporting Post Myocardial Infarction (MI) Risk Modification Intervention Via Telemedicine Evaluation|Supporting Post MI Risk Modification Intervention Via Telemedicine Evaluation|SPRITE|Duke University|No|Completed|June 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|416|||Both|N/A|N/A|No|||September 2014|September 5, 2014|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901277||139091|
NCT00925223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009SDU-QILU-G02|Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients|Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients||Shandong University|Yes|Enrolling by invitation|June 2009|November 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|30|Samples With DNA|two mucosal biospecimens will be obtained from the rectosigmoid junction from each patient.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder        characterized by recurrent abdominal pain or discomfort associated with altered bowel        habits in the absence of structural and biochemical abnormalities.|October 2009|October 13, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00925223||137284|
NCT00925236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070110|Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia|Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia|MAGIC-MYH9|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2009|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|360|Samples With DNA|Blood sample|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|defined population|July 2015|July 27, 2015|June 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00925236||137283|
NCT00930020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHF/CTG016/2008|Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial|Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial, A Double-Blind, Randomized, Placebo-controlled, Multi-center Study|NeuMAST|Singhealth Foundation|Yes|Terminated|July 2009|November 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|21 Years|80 Years|No|||May 2013|May 30, 2013|June 29, 2009||No|interim analysis shows futility|No||https://clinicaltrials.gov/show/NCT00930020||136919|
NCT00930033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070144|Clinical Trial to Assess the Importance of Nephrectomy|Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib|CARMENA|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2009|February 2020|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|576|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930033||136918|
NCT00930371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35016-D|Effect of Diet Composition on Liver Fat and Glucose Metabolism|Effect of Diet Composition on Liver Fat and Glucose Metabolism|DietLFAT|University of Washington|No|Completed|June 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00930371||136892|
NCT00930917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA8|Heat Loss Prevention in Delivery Room Using a Polyethylene Cap|Heat Loss Prevention in Delivery Room: a Prospective, Randomised, Controlled Trial of Polyethylene Caps in Very Preterm Infants||University of Padova|No|Completed|December 2007|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|96|||Both|N/A|3 Minutes|No|||June 2009|June 30, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00930917||136851|
NCT00930605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH011001|The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)|A Phase II Study of Alemtuzumab in Combination With CHOP and ESHAP as First-Line Treatment in Peripheral T-Cell Lymphoma|C+CHOP/ESHAP|King Chulalongkorn Memorial Hospital|No|Completed|January 2005|July 2008|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|15 Years|65 Years|No|||October 2011|October 4, 2011|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930605||136875|
NCT00931489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217330|Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) - Correlation With Lucentis(R) Therapy|Retinal and RPE Autoimmunity in AMD: Assessment of Correlation With Degree of Response to Ranibizumab Therapy|Antibody|University of California, Davis|No|Completed|August 2009|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|131|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 26, 2014|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931489||136808|
NCT00931164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32164|Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)|Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial)|AHC-SO|University of Utah|Yes|Completed|August 2009|September 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|6 Months|25 Years|No|||March 2014|March 3, 2014|June 30, 2009|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00931164||136833|
NCT00931177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDSS|Validation of a Dehydration Scoring System|Validation of a Dehydration Scoring System|VDSS|Phoenix Children's Hospital|No|Completed|June 2009|November 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|1 Month|15 Years|No|Non-Probability Sample|Dehydrated children|September 2011|September 2, 2011|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931177||136832|
NCT00931723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D144AC00003|Adult Bipolar Mania|An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium Versus Placebo as an Add on to SEROQUEL XR (Quetiapine Fumarate) in Adult Patients With Acute Mania||AstraZeneca|No|Completed|June 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|65 Years|No|||March 2012|March 27, 2012|June 29, 2009|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT00931723||136792|
NCT00918554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070140|Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis|Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE|UVEXATE|Assistance Publique - Hôpitaux de Paris|No|Terminated|September 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||June 2013|May 30, 2014|June 9, 2009||No|insufficient number of inclusion|No||https://clinicaltrials.gov/show/NCT00918554||137781|
NCT00919113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR08004|Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome|A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome||Watson Pharmaceuticals|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Female|18 Years|N/A|No|||May 2013|May 1, 2013|June 11, 2009|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT00919113||137738|
NCT00915239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS/KUS2|Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers|Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers||Sahlgrenska University Hospital, Sweden|Yes|Completed|January 2006|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915239||138034|
NCT00915226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-310505-2|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure.||Medical University of Vienna||Withdrawn|September 2009|October 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915226||138035|
NCT00916305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gilbert deafness 1|TUNE! Teaching the UK About Noise Exposure: A Pilot Study|Pilot Study of an Intervention Among Young People to Prevent Noise-induced Hearing Loss and Tinnitus|gildeaf1|London School of Hygiene and Tropical Medicine|Yes|Enrolling by invitation|July 2009|November 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|164|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916305||137953|
NCT00916318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obesity-Chrildren Vardal|Childhood Overweight|Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health||Vardalinstitutet The Swedish Institute for Health Sciences||Recruiting|August 2008|November 2015|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|260|||Both|4 Years|5 Years|No|||May 2009|June 8, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916318||137952|
NCT00916565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3378-3|Evaluation of Cow Milk-Based Formulas - Functional Proteins|The Evaluation of Cow Milk-Based Formulas - Functional Proteins||Mead Johnson Nutrition||Completed|July 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|139|||Both|N/A|18 Days|Accepts Healthy Volunteers|Probability Sample|formula-fed and breastfed infants|August 2011|August 31, 2011|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916565||137933|
NCT00916838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1012|Neurocognitive Impact of Hypoglycemia in Type 1 Diabetes|Neurocognitive Impact of Hypoglycemia in Type 1 Diabetes|HYPO|Washington University School of Medicine|No|Active, not recruiting|January 2003|March 2016|Anticipated|March 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|187|||Both|4 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|125 children with Type 1 Diabetes Mellitus (T1DM) between 4 and 16 were recruited from the        Diabetes Clinic at St. Louis Children's Hospital. 62 healthy siblings between 4 and 16        also enrolled in the study.|June 2015|June 2, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00916838||137912|
NCT00933816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLOG0901|Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy|Phase I/II Study of Sorafenib In Combination With Low-dose FP Intraarterial Infusion Chemotherapy|SILIUS|Japan Liver Oncology Group|Yes|Completed|July 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|20 Years|N/A|No|||November 2010|November 24, 2010|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00933816||136634|
NCT00934648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20546|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate||Hoffmann-La Roche||Completed|October 2007|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|July 6, 2009||No||No|May 7, 2014|https://clinicaltrials.gov/show/NCT00934648||136570|
NCT00935194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z09000700090903|Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study|Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Infection: Multi-centre, Prospective, Randomized Controlled Study||Capital Medical University|Yes|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|102|||Both|14 Years|70 Years|No|||November 2009|November 30, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935194||136529|
NCT00903565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-060-CR|A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint|A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint|PARSC|Agendia|No|Recruiting|September 2008|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients recruited from participating hospitals worldwide|January 2016|January 28, 2016|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903565||138920|
NCT00903578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KT-1|Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients|Impact of FGF-23 and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients||Ramathibodi Hospital|No|Active, not recruiting|May 2009|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Kidney transplant recipients|December 2009|December 16, 2009|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00903578||138919|
NCT00903825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44/27-2-09|Duplex Guided Application of Local Anesthetic Before Femoral Artery Catheterization|Optimization of Local Anesthetic Effect With Duplex Ultrasound Guided Injection of Lidocaine Before Femoral Artery Catheterization: A Prospective Randomized Controlled Trial||University of Patras|No|Completed|January 2009|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|85 Years|No|||May 2009|January 13, 2010|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903825||138900|
NCT00911729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1970|Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma|Content Validation of the EORTC QLQ-C30 Version 3.0, and NIH Quality of Life and Symptoms Questionnaire for Pheochromocytoma and Paraganglioma||Molecular Insight Pharmaceuticals, Inc.|No|Terminated|April 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a documented (medical record) diagnosis of either pheochromocytoma or        paraganglioma with active symptoms or who are within 60 days of curative therapy|June 2013|June 7, 2013|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911729||138302|
NCT00912041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-BG2-TP-001|BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia|BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia|BrainGate2|Massachusetts General Hospital|Yes|Recruiting|May 2009|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|75 Years|No|||October 2015|October 2, 2015|June 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912041||138279|
NCT00912054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-007|DuoTrav APS Versus XALACOM® in Ocular Surface Health|||Alcon Research|No|Terminated|March 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||January 2012|July 17, 2012|June 1, 2009|No|Yes|poor enrollment|No||https://clinicaltrials.gov/show/NCT00912054||138278|
NCT00912327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CL-PGG-CRC0821|Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer|A Phase 2 Efficacy and Safety, Open-label, Multicenter Study of Imprime PGG® Injection in Combination With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer||Biothera|Yes|Completed|June 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|18|Samples With DNA|Tumor tissue samples from previous biopsies and blood plasma will be collected.|Both|18 Years|N/A|No|Probability Sample|Approximately 56 patients with Stage IV Kras-mutated colorectal cancer.|February 2012|February 14, 2012|June 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912327||138257|
NCT00912899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COU-NOS-001|A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma||Cougar Biotechnology, Inc.|No|Completed|November 2007|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2009|February 15, 2011|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912899||138213|
NCT00912912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0685|Sunitinib Malate in Refractory Germ Cell Tumors|Phase II Study of Sunitinib Malate in Refractory Germ Cell Tumors||M.D. Anderson Cancer Center|No|Terminated|May 2009|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||December 2015|December 21, 2015|June 1, 2009|Yes|Yes|Slow Accrual|No|December 21, 2015|https://clinicaltrials.gov/show/NCT00912912||138212|
NCT00917046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090309|The SMARTEX Heart Failure Study|Study of Myocardial Recovery After Exercise Training in Heart Failure|SMARTEX|Norwegian University of Science and Technology|Yes|Completed|January 2009|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|268|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917046||137896|
NCT00918567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4Z-US-X053|Effects of Strattera and Behavior Therapy on the School and Home Functioning of Elementary School Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|Effects of Strattera and Behavior Therapy on the School and Home Functioning of Elementary School Children With Attention-Deficit/Hyperactivity Disorder (ADHD)||State University of New York at Buffalo|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|6 Years|12 Years|No|||June 2009|June 10, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918567||137780|
NCT00918580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3014|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease|A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine||Pfizer|Yes|Completed|November 2009|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|158|||Both|6 Years|17 Years|No|||March 2014|March 17, 2014|June 9, 2009|Yes|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT00918580||137779|
NCT00919126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-07-C3-007|General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.|An International Phase III Randomised Trial Comparing the Propofol Consumption During General Anaesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia Alone in ASA III Patients With Increased Risk of Perioperative Cardiac Complications.||Air Liquide SA|No|Terminated|June 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|102|||Both|50 Years|N/A|No|||September 2014|September 15, 2014|June 11, 2009||No|Enrollment rate|No|June 4, 2014|https://clinicaltrials.gov/show/NCT00919126||137737|The study has been terminated earlier due to difficulties to find patients meeting the inclusion criteria.
NCT00915252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101010|Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML|AML-AZA|University Hospital Muenster|Yes|Completed|July 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|214|||Both|61 Years|N/A|No|||December 2012|December 13, 2012|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915252||138033|
NCT00915759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-6961|Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy|Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy||Walter Reed National Military Medical Center||Active, not recruiting|June 2009|December 2014|Anticipated|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|June 5, 2009||No||No|May 15, 2013|https://clinicaltrials.gov/show/NCT00915759||137995|
NCT00884637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORESEE HOME-POST-01|Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects|Correlation Between Visual Field Defects on Home Macular Perimeter (FORESEE HOME) and on OCT in Eyes of Patients With CNV Before and After Treatment||Notal Vision Ltd|No|Completed|June 2009|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|50 Years|N/A|No|Non-Probability Sample|Subjects suspected to have CNV secondary to AMD in at least one eye|October 2014|October 2, 2014|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884637||140322|
NCT00903032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 08-302|Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization|Patient-Centered Adherence Intervention After ACS Hospitalization|MEDICATION|VA Office of Research and Development|Yes|Completed|July 2010|August 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|253|||Both|18 Years|90 Years|No|||September 2014|April 6, 2015|May 13, 2009||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00903032||138957|
NCT00903292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR98004|Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma|Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma||National Cheng-Kung University Hospital|No|Recruiting|March 2009|December 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|52|||Both|20 Years|80 Years|No|||May 2009|May 15, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903292||138939|
NCT00903591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-040|Study of Radiation Exposure and Bilateral Breast Cancer|Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2009|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1699|Samples With DNA|blood sample or saliva sample|Female|18 Years|54 Years|No|Non-Probability Sample|All of the WECARE:GWA Study participants (new cases and individually matched controls)        will be identified, recruited, and interviewed by investigative teams in the five        population-based cancer registries (NCC, OCR, FHCRC, Iowa, and DCS).|April 2015|April 15, 2015|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903591||138918|
NCT00903604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP214-CS005|Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery||Action Pharma A/S|Yes|Completed|May 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|N/A|No|||May 2011|May 16, 2011|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903604||138917|
NCT00903838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S308.2.008|A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.|A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.||Abbott|No|Terminated|September 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|30 Years|N/A|No|||August 2011|August 25, 2011|May 14, 2009||No|The study was terminated on 31 May, 2011, due to strategic considerations.|No||https://clinicaltrials.gov/show/NCT00903838||138899|
NCT00911495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI-1070-103|Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease|Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease||Pfizer|No|Completed|May 2009|September 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|45 Years|No|||May 2013|January 31, 2014|May 27, 2009|No|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT00911495||138320|
NCT00911755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02826|Videolaryngoscopy in the Critically Ill|Randomized Controlled Trial to Evaluate the Efficacy of Video-laryngoscopy vs. Direct Laryngoscopy for Endotracheal Intubation in the Critically Ill Patients: A Pilot Study|VICI|University of British Columbia|No|Completed|July 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|N/A|No|||February 2014|February 18, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911755||138300|
NCT00912080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA02/IPC 2006-003|Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer|Utilisation of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer: A Prospective Cohort Study.|SA02|Institut Paoli-Calmettes|No|Active, not recruiting|April 2007|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|375|||Female|18 Years|70 Years|No|||March 2013|March 19, 2013|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00912080||138276|
NCT00912678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESP-2004-1|Minimizing Immunosuppression in Old for Old Kidney Transplantation|Prospective Randomized Controlled Trial to Compare a Calcineurin Inhibitor Free Immunosuppression With a Low Dose Tacrolimus Based Immunosuppression in "Old for Old" Kidney Transplantation.|ESP-CNI|University of Luebeck|Yes|Completed|March 2002|October 2008|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|65 Years|N/A|No|||June 2009|June 2, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912678||138230|
NCT00912691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00102/Autism|A Trial of CM-AT in Children With Autism- Open Label Extension Study|A Phase III Open Label Extension Study of CM-AT in Children With Autism|CM-AT|Curemark|Yes|Active, not recruiting|January 2010|May 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|9 Years|12 Years|No|||July 2015|January 26, 2016|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912691||138229|
NCT00917059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH085925|Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)|Personalized Response Indicators of SSRI Effectiveness in Major Depression||University of California, Los Angeles|Yes|Completed|May 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|172|||Both|21 Years|75 Years|No|||February 2013|February 4, 2013|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917059||137895|
NCT00917072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFH-4694|Innovative Strategies Which Improve the Clinical Handoff (I-SWITCH)|Innovative Strategies Which Improve the Clinical Handoff (I-SWITCH) Phase II: Randomized Controlled Trial Evaluating Educational Modalities Including Cognitive Simulation|I-SWITCH|Henry Ford Health System|No|Completed|September 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|39|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2009|June 9, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917072||137894|
NCT00917358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940215|Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C|Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C||National Taiwan University Hospital|Yes|Completed|July 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||December 2012|December 19, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917358||137872|
NCT00917371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903059M|The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults With Attention Deficit/Hyperactivity Disorder|The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults With Attention Deficit/Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|August 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|N/A||3|Anticipated|60|||Both|18 Years|50 Years|No|Non-Probability Sample|We will recruit 60 adults, aged 18 to 50, who are diagnosed with ADHD at the PI Gau's        Adult ADHD clinic at the Department of Psychiatry, National Taiwan University Hospital.|November 2010|November 23, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917371||137871|
NCT00918801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0786|Pilot Study of Hippocampal Function in Type 1 Diabetes Mellitus (T1DM)|Pilot Study of Hippocampal Function in T1DM|ASSET|Washington University School of Medicine|No|Active, not recruiting|April 2007|December 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|91|||Both|13 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young adults will be piloted in a sample of diabetic and non-diabetic adolescents ages        13-18.|January 2016|January 7, 2016|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00918801||137762|
NCT00915577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-872|Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe|An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects||Biogen|No|Completed|August 2005|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|74|||Both|18 Years|65 Years|No|||June 2009|June 5, 2009|June 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915577||138009|
NCT00914966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-400|A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE|A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE® (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks||Shire|No|Completed|July 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|6 Years|N/A|No|||March 2014|March 19, 2014|June 3, 2009|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT00914966||138055|
NCT00915564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015934|A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone|A Phase I, Open-Label, Single-Sequence Drug-Drug Interaction Trial in Subjects On Stable Methadone Maintenance Therapy, to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone, at Steady-State||Tibotec Pharmaceuticals, Ireland|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|55 Years|No|||October 2013|October 11, 2013|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915564||138010|
NCT00916032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060801|Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A|Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study||Baxalta US Inc.|Yes|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Male|18 Years|65 Years|No|||September 2013|June 26, 2015|June 5, 2009||No||No|March 31, 2013|https://clinicaltrials.gov/show/NCT00916032||137974|
NCT00916045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07CC12|Pilot Study of Unrelated Cord Blood Transplantation|Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies||King's College Hospital NHS Trust|No|Terminated|September 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|70 Years|No|||March 2012|February 10, 2015|June 5, 2009||No|Recruitment issues|No||https://clinicaltrials.gov/show/NCT00916045||137973|
NCT00917137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-Trisolini|Transbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy|Transbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy: Yield and Predictors of a Positive Aspirate||Maggiore Bellaria Hospital, Bologna|No|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|76 Years|No|Probability Sample|Adult patients with pulmonary nodule or mass referred for bronchoscopy to the Thoracic        Endoscopy Unit of Maggiore Hospital (Bologna Italy)|June 2010|June 22, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917137||137889|
NCT00884052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrasher 02825-1|Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures|Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures|Keppra|University of California, San Diego|Yes|Completed|April 2007|October 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|14 Days|No|||October 2012|October 21, 2012|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884052||140365|
NCT00884065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Idiap08/187|Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder|Effectiveness of Diacutaneous Fibrolysis on Pain and Mobility in Patients Suffering From Painful Shoulder. A Randomized Pilot Study.||Jordi Gol i Gurina Foundation||Completed|June 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 9, 2009||No||No|February 9, 2009|https://clinicaltrials.gov/show/NCT00884065||140364|
NCT00884650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040981|Managing Post-operative Pain in Children With Cerebral Palsy Using a Pain Pump|Comparing the Effectiveness of an Anesthetic Continuous-infusion Device to Oral Analgesia in Orthopedic Postoperative Pain Control of Children With Cerebral Palsy||Children's Hospital Colorado|No|Completed|June 2005|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|3 Years|17 Years|No|||June 2011|June 20, 2011|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00884650||140321|
NCT00903045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-01-08|Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder|Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder: PRopiverine Study on Overactive Bladder Including Urgency Data (PROUD)||Samsung Medical Center|Yes|Completed|January 2005|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903045||138956|
NCT00903058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2009|||||N/A|N/A|N/A||||||||||||||May 14, 2009|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903058||138955|
NCT00903305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000629408|Nurse-Provided Care or Standard Care in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer|A Standard Nursing Intervention Protocol for Breast Cancer as a Chronic Illness||City of Hope Medical Center||Withdrawn|July 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903305||138938|
NCT00903318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0742|Male:Female Birth Ratios and Phthalate Levels|Male:Female Birth Ratios and Phthalate Levels Along The Rural Lower Rio Grande Valley (Hidalgo County) and in Baytown, Texas||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2009|||April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Urine sample.|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and Women of Mexican American origin ages 18 to 40 years, residing in Baytown or the        lower Rio Grande Valley in Hidalgo County, Texas for at least 45 years.|June 2015|June 30, 2015|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903318||138937|
NCT00904449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202-022|Open Label Assessment of Long-Term Safety and Utility|An Open-Label Assessment of the Long-Term Safety and Utility of Numorphan® for the Relief of Moderate to Severe Pain in Patients With Cancer||Endo Pharmaceuticals|No|Completed|April 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904449||138853|
NCT00904462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3260-001|Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee|A Randomized, Double-Blind, Pilot Study Comparing the Efficacy and Safety of Lidocaine 5% Patch With Placebo in Patients With Pain From Osteoarthritis of the Knee||Endo Pharmaceuticals||Completed|August 2004|||September 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904462||138852|
NCT00911768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2007-007|Effect of Korean Red Ginseng (KRG) on Dry Mouth|PMS Clinical Study of Korean Red Ginseng Powder on Dry Mouth and Salivary Flow Rates in Xerostomatic Populations||The Korean Society of Ginseng|No|Completed|September 2007|December 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|76 Years|No|||August 2009|August 3, 2009|March 3, 2009||No||No|March 3, 2009|https://clinicaltrials.gov/show/NCT00911768||138299|
NCT00911781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hemangioma photo study|Hemangioma Growth During the First 6 Months of Life|Hemangioma Growth During the First 6 Months of Life||University of California, San Francisco|No|Completed|February 2009|December 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|36|||Both|3 Months|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients are being recruited from a national hemangioma support website (NOVA)and from        community clinics atthe University of California, San Francisco. We hope to reach more        interested parents through registering our protocol.|February 2013|February 4, 2013|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911781||138298|
NCT00912340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012495|Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer|Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer||Emory University|Yes|Active, not recruiting|May 2009|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912340||138256|
NCT00912353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1151C00002|AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects|A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7268 in Healthy Japanese Subjects|JSAD|AstraZeneca|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|56|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||August 2010|January 28, 2013|June 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912353||138255|
NCT00912366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS08015|Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy|A Prospective, Single Center, Observational Study Comparing the Safety and Efficacy of CVATS, HVATS and Open Surgery for Subjects Diagnosed With NSCLC Scheduled to Undergo a Lobectomy||Medtronic - MITG|No|Terminated|May 2009|December 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|39|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects referred for lobectomies at the hospital.|July 2015|July 23, 2015|June 1, 2009||No|Slow Enrollment|No||https://clinicaltrials.gov/show/NCT00912366||138254|
NCT00913250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-869|A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers|A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of AVONEX® (Interferon Beta-1a) Solutions for Injection Produced by a Serum-Containing Manufacturing Process and by a Serum-Free Manufacturing Process||Biogen|No|Completed|August 2003|October 2003|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|96|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913250||138187|
NCT00917085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01NR002444-04A1|Is Skin-to-Skin Care Helpful for Preterm Infants and Their Mothers After Birth?|Self-Regulatory Preterm Infant Care: Adaptation Postbirth||National Institute of Nursing Research (NINR)|No|Completed|July 1996|December 2001|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|N/A|N/A|No|||August 2009|August 7, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917085||137893|
NCT00917709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/34|Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies|In Vivo SPECT Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies: Applying in Diagnostic and Identification of Pathological Subtypes.|IBVM/DATSCAN|University Hospital, Bordeaux|No|Completed|May 2009|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|34|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00917709||137845|
NCT00916058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812010147|Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma|A Phase 1 Pilot Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma||Weill Medical College of Cornell University|Yes|Recruiting|March 2009|March 2012|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Anticipated|35|||Both|18 Years|N/A|No|||November 2010|November 4, 2010|June 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00916058||137972|
NCT00916591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZBrussels|Prokinetic Drugs and Enteral Nutrition|Effect of Prokinetic Drugs During the Administration of Enteral Nutrition|prokinetics|Universitair Ziekenhuis Brussel|Yes|Not yet recruiting|September 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients, intubated and mechanically ventilated, 18 years or older|June 2009|June 5, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916591||137931|
NCT00916604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00004|To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients|A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients|JMAD|AstraZeneca||Completed|May 2009|October 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|75 Years|No|||November 2009|November 2, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916604||137930|
NCT00883792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NordICC|The Northern-European Initiative on Colorectal Cancer|NordICC The Northern-European Initiative on Colorectal Cancer|NordICC|Norwegian Department of Health and Social Affairs|Yes|Recruiting|May 2009|July 2036|Anticipated|June 2026|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|66000|||Both|55 Years|64 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00883792||140385|
NCT00884078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H1013/6|Self Harm in Females of South Asian Family Origin|Exploratory RCT of Culturally Adapted Manual Assisted Problem Solving Training (C-MAP) for Self Harm in Females of South Asian Family Origin||Lancashire Care NHS Foundation Trust||Not yet recruiting|May 2009|December 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Female|16 Years|65 Years|No|||April 2009|April 17, 2009|February 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00884078||140363|
NCT00902759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08D.574|Fatigue and Pancreas and Bile Duct Cancer Study|Fatigue, Physical Functioning, and Quality of Life in Patients With Pancreatic and Periampullary Cancers Following Surgery, Chemotherapy, and/or Radiation Therapy||Thomas Jefferson University|No|Active, not recruiting|February 2009|December 2015|Anticipated|January 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902759||138978|
NCT00903851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3220-005|Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy|A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy.||Endo Pharmaceuticals||Completed|April 2002|||June 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|90 Years|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903851||138898|
NCT00903864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth1|Blood Pressure Monitor Clinical Test (Cuff Range: 22 cm-30 cm)|Blood Pressure Monitor Clinical Test (Cuff Range: 22 cm-30 cm)||Andon Health Co., Ltd||Completed|February 2009|||April 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|85|||Both|25 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|People whose arm range is 22 cm-30 cm|May 2009|May 18, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903864||138897|
NCT00904137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02904|Treatment of Type I Supracondylar Fractures of the Humerus|Taping Versus Splinting Versus Above Elbow Casting for Type I Supracondylar Fractures of the Humerus in Children: A Randomized Controlled Trial||University of British Columbia|No|Suspended|May 2009|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|87|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|May 15, 2009||No|Protocol modification is in progress due to low enrollment|No||https://clinicaltrials.gov/show/NCT00904137||138876|
NCT00904735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRSI-GICNO-08-002|Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma|IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study||National Cancer Institute (NCI)||Recruiting|June 2009|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|75 Years|No|||July 2009|August 9, 2013|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904735||138831|
NCT00904436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2648C-1|Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia|Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia||VA Office of Research and Development|No|Completed|December 1999|January 2001|Actual|January 2001|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|No|||May 2009|May 18, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00904436||138854|
NCT00911794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07300|Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease|Pulmonary Therapy and Supplemental Written Disclosure Therapy for Chronic Lung Disease||Winthrop University Hospital|No|Completed|January 2007|March 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|90 Years|No|||June 2009|June 1, 2009|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911794||138297|
NCT00912093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-FIR-054|A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)|A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)||Shire|No|Completed|June 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||July 2014|September 11, 2014|June 2, 2009|Yes|Yes||No|July 11, 2014|https://clinicaltrials.gov/show/NCT00912093||138275|
NCT00912106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96024|Analyzing Composition and Lubrication Properties of Synovial Fluid|Boundary Lubrication of Synovial Fluid Molecules and Its Effect on the Surrounding Cells and Tissues|SFCL|Far Eastern Memorial Hospital|No|Completed|April 2008|June 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|synovial fluid from knee joint|Both|N/A|N/A|No|Probability Sample|Patients who are going to receive HA injection of one or two knees|June 2009|June 2, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912106||138274|
NCT00912938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG001|Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients|A Phase IV, Multi-center, Open Label, Single Arm Clinical Trial to Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients||Korean Breast Cancer Study Group|Yes|Active, not recruiting|December 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|237|||Female|18 Years|N/A|No|||February 2010|February 14, 2010|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912938||138210|
NCT00913263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPC-002|An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate|An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer|2-HOF|Lidds AB|No|Completed|June 2009|July 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|45 Years|N/A|No|||April 2013|January 15, 2015|June 3, 2009||No||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00913263||138186|There were no limitations of the trial
NCT00917722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0045|Deep Brain Stimulation of the Subthalamic Nucleus (STN) and Cognitive Control|Deep Brain Stimulation of the STN and Cognitive Control: A Pilot Study|COVOLT|Washington University School of Medicine|No|Completed|March 2006|December 2013|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|Only patients who already have implants will be invited to participate in this study, and        no changes to stimulator settings are made for the purposes of this study.|January 2016|January 7, 2016|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917722||137844|
NCT00917423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5544/#6624R|Characteristics and Importance of Physical Activity in Women With Anorexia Nervosa|Physical Activity in Anorexia Nervosa: Characteristics and Clinical Significance||New York State Psychiatric Institute|Yes|Active, not recruiting|February 2009|June 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Blood samples|Female|16 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with anorexia nervosa participating in an inpatient treatment program|April 2014|March 24, 2015|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917423||137867|
NCT00918268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_10S|Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, When Administered to Non-elderly Adult and Elderly Subjects||Novartis||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 20, 2012|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918268||137803|
NCT00918281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-135-004|Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection|A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.||GE Healthcare|Yes|Completed|June 2009|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|June 9, 2009|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00918281||137802|
NCT00918593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA0906|Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy|Palliative Treatment of Ulcerated Cutaneous Metastases: Randomised Trial Between Electrochemotherapy and Radiotherapy||Copenhagen University Hospital at Herlev|Yes|Withdrawn|December 2009|February 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|June 9, 2009||No|No recruitment of patients|No||https://clinicaltrials.gov/show/NCT00918593||137778|
NCT00918606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-102-CL-01|An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers|||Neothetics, Inc||Completed|February 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|June 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918606||137777|
NCT00919165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-286|Assessment of Cognitive Function in Patients Undergoing Carotid Artery Stent Placement|Assessment of Cognitive Function in Patients Undergoing Carotid Artery Stent Placement: Cognitive Function in Carotid Stenting||Spectrum Health Hospitals|No|Active, not recruiting|December 2007|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|40 Years|80 Years|No|Probability Sample|Patients with severe carotid artery stenosis|June 2013|June 3, 2013|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919165||137734|
NCT00887549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13069|A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer|An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression||Eli Lilly and Company|No|Completed|April 2009|June 2011|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|April 23, 2009|Yes|Yes||No|July 29, 2011|https://clinicaltrials.gov/show/NCT00887549||140100|
NCT00883545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1045|Study of Adherence to Colonoscopy in Women|The Effect of a Woman Endoscopist on Adherence to Screening Colonoscopy in Women||University of Colorado, Denver|Yes|Completed|October 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|625|||Female|50 Years|70 Years|No|||September 2012|January 3, 2013|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883545||140404|
NCT00916240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|648|Multisystemic Therapy to Reduce Health Disparities in Adolescents With Asthma|Multisystemic Therapy to Reduce Health Disparities in Adolescents With Asthma||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Recruiting|September 2008|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|12 Years|16 Years|No|||July 2009|July 28, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916240||137958|
NCT00903331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055B201|Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study|A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis|MUSIC|Actelion|Yes|Completed|May 2009|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|May 14, 2009|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT00903331||138936|
NCT00903617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112795|Study to Test GSK256073 in Patients With Dyslipidemia|A Two Part, Multicenter Phase IIa, Placebo Controlled Study, to Examine the Safety, Tolerability, and Effects of GSK256073 on Lipids in Subjects With Dyslipidemia||GlaxoSmithKline|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|81|||Both|18 Years|75 Years|No|||March 2011|March 17, 2011|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903617||138916|
NCT00903877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04272009-2419|Study of T3 for the Treatment of Fibromyalgia|T3 for Fibromyalgia: a Pilot Double-blind Non-randomized Clinical Trial||Stanford University||Completed|May 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|50 Years|No|||June 2012|June 21, 2012|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903877||138896|
NCT00903890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULYM07056|Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma|Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma After Radiation Therapy/Anthracycline Chemotherapy||University of Rochester|No|Terminated|August 2008|November 2015|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Patients previously treated at the University of Rochester Department of Radiation        Oncology.|May 2015|May 29, 2015|May 15, 2009|No|Yes|not enough eligible patients|No||https://clinicaltrials.gov/show/NCT00903890||138895|
NCT00904150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLMC-GEN-2007|Study of the Molecular Genetics of Menstrual Migraine|A Case-control Study of the Molecular Genetics of Menstrual Migraine (Pure Menstrual and Menstrually-related Migraine)||The City of London Migraine Clinic|No|Completed|November 2007|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|585|Samples With DNA|Saliva Whole Blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Caucasian women|February 2014|February 18, 2014|May 17, 2009||No||No|September 8, 2013|https://clinicaltrials.gov/show/NCT00904150||138875|
NCT00905034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0267|Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage|Phase II Study of Methotrexate, Vincristine, Pegylated L-asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage||M.D. Anderson Cancer Center|No|Completed|March 2009|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|1 Year|N/A|No|||June 2015|June 9, 2015|May 18, 2009||No||No|June 9, 2015|https://clinicaltrials.gov/show/NCT00905034||138808|
NCT00911560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-075|Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma|Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma||Memorial Sloan Kettering Cancer Center||Recruiting|May 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Both|N/A|21 Years|No|||December 2015|December 22, 2015|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911560||138315|
NCT00911820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-039|Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer|A Randomized, Multicenter, Phase II Trial of Cisplatin, Irinotecan and Bevacizumab (PCA) vs. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|July 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|May 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00911820||138295|
NCT00912704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098001-3|Development of Early Diagnostic Techniques and Setup of Local Therapeutic Guidelines and Standards|Prevention and Treatment of Chronic Kidney Disease in Taiwan - Development of Early Diagnostic Techniques and Setup of Local Therapeutic Guidelines and Standards|Hmodialysis|Far Eastern Memorial Hospital|Yes|Completed|March 1998|December 1998|Actual|March 1998|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Not limited to the patient himself, as soon as the patient or family members decide to        enter or removed after dialysis can be done by patients themselves or family members as        well as the main decision-depth interviews with relevant medical and nursing staff.        Recently, a relative of reference are as follows:          1. Spouse.          2. Adult direct blood relatives of British Columbia.          3. Parents.          4. Brothers and sisters.          5. Grandparents.          6. Three pro-grandparents or extended family, such as blood.          7. Pro-marriage and so immediate.|April 1998|June 2, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912704||138228|
NCT00912964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-074|A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder|CAPRICORN|Astellas Pharma Inc|No|Completed|April 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2030|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|June 1, 2009|Yes|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT00912964||138209|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT00912977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e5348|Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia|Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia||Oregon Health and Science University|No|Enrolling by invitation|June 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Anticipated|14|||Both|18 Years|N/A|No|Non-Probability Sample|Parkinsons disease patients with levodopa-induced dyskinesia|June 2009|June 2, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912977||138208|
NCT00906438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-RD-05-CLN1|Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects|Effects of 2006-RD-05 on Salivary and Serum IgA Levels in Healthy Subjects||innoVactiv Inc.||Completed|May 2009|October 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2009|October 28, 2009|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906438||138702|
NCT00906698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.69|Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2|Phase I Open Label Trial to Assess Safety of BIBW 2992 With Vinorelbine in Solid Tumors Known to Overexpress HER2 and/or EGFR||Boehringer Ingelheim||Completed|June 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||March 2014|June 3, 2014|May 14, 2009||||No|January 10, 2014|https://clinicaltrials.gov/show/NCT00906698||138683|
NCT00918294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QuickOpt Study Asia|QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization|QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization|QuickOpt|St. Jude Medical|No|Completed|September 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2011|February 22, 2011|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00918294||137801|
NCT00919152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|245-09-EX|Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)|Correlates of Economic Outcomes of Enteral and Parenteral PPI Use in the ICU and After Discharge||University of Nebraska|No|Completed|July 2009|January 2012|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|534|||Both|19 Years|N/A|No|Non-Probability Sample|All patients greater than 18 years admitted to the ICU during 2006-2008 (January 2006        through December 2008; 3-year period)|May 2015|May 27, 2015|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919152||137735|
NCT00914979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033 - 08 - EMC|AngioSculpt Scoring Balloon Catheter For Bifurcation Coronary Lesions (ABC Study)|AngioSculpt Scoring Balloon Catheter For Bifurcation Coronary Lesions (ABC Study) Prospective, Multi-center, Non-randomized, Single-arm Registry|ABC|HaEmek Medical Center, Israel|Yes|Terminated|September 2008|September 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|June 4, 2009|Yes|Yes|Difficulties in recruiting patients|No||https://clinicaltrials.gov/show/NCT00914979||138054|
NCT00886509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/2008|Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients|Subcutaneous Administration of Pegylated Granulocyte-Colony Stimulating Factor for Long-Term Promotion of Collateral Growth in Patients With Coronary Artery Disease||University Hospital Inselspital, Berne|Yes|Completed|March 2009|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||December 2015|December 15, 2015|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886509||140179|
NCT00887042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPHO-S0501|Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML|Phase II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric Acute Myeloid Leukemia||The Korean Society of Pediatric Hematology Oncology|No|Active, not recruiting|June 2006|May 2012|Anticipated|May 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|1 Year|21 Years|No|||March 2012|March 23, 2012|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00887042||140139|
NCT00884091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-01-48A|A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects|A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects|IC-1-V1|Taipei Veterans General Hospital, Taiwan|No|Completed|April 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|21|Samples Without DNA|Plasma samples retained, with no potential for DNA extraction from any retained samples. The      retained samples will be destroyed after the results published.|Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Invited normal healthy volunteers from a research clinic|December 2011|December 5, 2011|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00884091||140362|
NCT00884377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-12364|Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis|A Phase I/II Randomized Comparison of Localized Heat Therapy Versus Sodium Stibogluconate (Pentostam) for the Treatment of Old World Cutaneous Leishmaniasis (HSRRB Log No. A-12364)||U.S. Army Medical Research and Materiel Command|Yes|Completed|February 2004|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||April 2009|April 17, 2009|April 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884377||140341|
NCT00916253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/37|Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies|Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.|AUTOSOP|University Hospital, Bordeaux|No|Completed|March 2010|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 24, 2013|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00916253||137957|
NCT00903630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS047|Lenalidomide and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|WCC #50 - Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer||Masonic Cancer Center, University of Minnesota|Yes|Suspended|April 2009|June 2014|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Female|18 Years|N/A|No|||August 2011|August 22, 2011|May 15, 2009|Yes|Yes|Due to national shortage of Doxil.|No||https://clinicaltrials.gov/show/NCT00903630||138915|
NCT00903903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB TCVGH No:C09048|Computer-Assisted Quantification of the Synovial Perfusion in Patients With Arthritis Using Two-Dimensional and Three-Dimensional Power Doppler Ultrasonography|Computer-Assisted Quantification of the Synovial Perfusion in Patients With Arthritis Using Two-Dimensional and Three-Dimensional Power Doppler Ultrasonography||Taichung Veterans General Hospital|Yes|Recruiting|April 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Arthritis patients who visited the Rheumatology out patient clinic in Taichung Veterans        General Hospital|May 2009|May 18, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903903||138894|
NCT00904163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04232009-2383|Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa|Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa||Stanford University||Completed|April 2009|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|Samples With DNA|Skin biopsies, serum|Both|18 Years|N/A|No|Non-Probability Sample|Adults (18 years of age or older) with RDEB diagnosis by a local dermatologist, who can        travel to Stanford University Medical Center.|May 2014|May 15, 2014|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00904163||138874|
NCT00904176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-058|Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects|Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects||AstraZeneca|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|May 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00904176||138873|
NCT00904475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3220-011|Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain|A Prospective, Prospective, Double-blind, Randomized, Placebo-Controlled, Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain||Endo Pharmaceuticals||Completed|April 2003|||April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904475||138851|
NCT00905047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLOCROSS|Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer|Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer|COLOCROSS|Centre Oscar Lambret|No|Completed|September 2005|September 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905047||138807|
NCT00905060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081010|HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM|PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|HeatShock|University of California, San Francisco|Yes|Completed|June 2009|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905060||138806|
NCT00912119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007017|Amicar Pharmacokinetics of Children Having Craniofacial Surgery|Pharmacokinetics of Epsilon-Aminocaproic Acid in Children Undergoing Craniofacial Reconstruction Surgery||Children's Hospital of Philadelphia|No|Completed|May 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|2 Months|24 Months|No|||October 2012|October 31, 2012|June 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912119||138273|
NCT00912379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/10|Hemoglobin MASIMO and Laboratory Measurement|Comparison of the Hemoglobin Results Obtained With the Masimo SpHb™ and the Clinical Laboratory Measurement||Hopital Foch|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|emergency unit patients and ICU patients requiring an hemoglobin determination|April 2010|April 19, 2010|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912379||138253|
NCT00912392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-69|Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)|Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study||Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd|No|Completed|May 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|75 Years|No|||August 2014|August 31, 2014|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912392||138252|
NCT00912717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030072|Pancreatic Adenocarcinoma Gene Environment Risk Study|The Pancreatic Adenocarcinoma Gene Environment Risk Study -A Prospective Cohort Study of Patients at Risk or Having Pancreatic Disease|PAGER|University of Pittsburgh|Yes|Recruiting|January 2004|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10000|Samples With DNA|Blood and urine specimens|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants who are diagnosed with pancreatic cancer, who are undergoing a procedure to        evaluate their pancreas, and who have a family history of pancreatic cancer are recruited        during appointments at the University of Pittsburgh Medical Center (e.g. Pancreas        Specialty Care Center, GI laboratory, Hereditary GI Program)|January 2016|January 14, 2016|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912717||138227|
NCT00912730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13565|A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma|A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma|MEL50|University of Virginia|Yes|Completed|August 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with melanoma scheduled to undergo sentinel node biopsy as part of recommended        clinical care, age 18 years or older.|October 2009|October 20, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912730||138226|
NCT00906152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-29|Association Between Low Back Pain and Quality of Sleep|Study of the Association Between Low Back Pain and the Quality of Sleep||Kovacs Foundation|Yes|Completed|September 2009|May 2013|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|437|||Both|N/A|N/A|No|Non-Probability Sample|Patients seen for low back pain in the primary care centers participating in the study.|March 2014|March 11, 2014|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906152||138723|
NCT00906165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 05/07|The Role of Immediate Provisional Restorations on Bone Level Implants|The Role of Immediate Provisional Restorations on Bone Level Implants. A Randomised, Single Blind Controlled Clinical Trial||Institut Straumann AG|No|Active, not recruiting|June 2008|June 2016|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906165||138722|
NCT00906711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0081/08|Analysis of Balance in the Aging Process|Analysis of Balance in the Aging Process||Universidade de Franca|Yes|Completed|February 2008|October 2008|Actual|August 2008|Actual|N/A|Observational|N/A||4|Actual|48||The evaluation instruments are the Berg Balance Scale (BBS), the Performance Oriented      Mobility Assessment (POMA), the Unipodal Support Test, the Functional Reach Test and the      Romberg's Test.|Both|10 Years|85 Years|No|Non-Probability Sample|The participants were selected in dependency of Unifran (University of France) and the        homes of the neighborhood. The choice of groups was based according to the degree of        functionality and independence in order to analyze the lack of balance in the process of        aging.|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906711||138682|
NCT00918307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007948-34|Efficacy and Safety of Varenicline Among HIV-infected Patients|Comparison of the Efficacy and Safety of Varenicline Versus Placebo for Smoking Cessation Among HIV-infected Patients. A Randomized Double Blind Controlled Trial|Inter-ACTIV|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|October 2009|July 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918307||137800|
NCT00915590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-017|Topical IL-1-Ra for Treatment of Corneal Neovascularization|Topical IL-1-Ra for Treatment of Corneal Neovascularization||Massachusetts Eye and Ear Infirmary||Completed|April 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915590||138008|
NCT00915603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 154|Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)||SCRI Development Innovations, LLC|No|Completed|July 2009|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|June 4, 2009|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00915603||138007|
NCT00886015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00019216|Modified Instrumentation for Surgery to Correct Trichiasis|PRET Clinical Trial of Evaluation of Modified Instrumentation for Surgery to Correct Trichiasis||Johns Hopkins University|Yes|Active, not recruiting|May 2009|December 2011|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1876|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|April 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00886015||140217|
NCT00886028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB/304/06|Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma|"Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma "||National Institute of Cancerología||Active, not recruiting|September 2006|June 2009|Anticipated|April 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|80 Years|No|||April 2009|April 21, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886028||140216|
NCT00919087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2009-002|Non Invasive Arrhythmia Detection in Hospital Settings|Evaluating Ventricular Events With Adherent Patient Monitoring Study|EVE|Corventis, Inc.|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|electrophysiology (EP) study or implantable cardioverter defibrillator (ICD) implant        Patients|February 2010|February 2, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919087||137740|
NCT00919100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08007|Buzzy Versus Vapocoolant Spray: Pediatric Needle Pain Relief|Buzzy: An Integration of Vibration, Cold, and Distraction for Pediatric Needle Pain Relief||Georgia State University|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|81|||Both|4 Years|18 Years|No|||June 2009|March 9, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919100||137739|
NCT00883558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-117-203|Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus|A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes||Halozyme Therapeutics|No|Completed|May 2009|April 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|48|||Both|18 Years|65 Years|No|||August 2014|August 28, 2014|April 15, 2009|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00883558||140403|
NCT00883571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anal stenosis|Comparative Study of the House Advancement Flap, Rhomboid Flap, and Y-V Anoplasty|Comparative Study of the House Advancement Flap, Rhomboid Flap, and Y-V Anoplasty in Treatment of Anal Stenosis: A Prospective Randomized Study||Mansoura University|Yes|Completed|April 2002|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|66 Years|No|||April 2009|December 28, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883571||140402|
NCT00915733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCEL-AMI-2C19|Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism|Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism|ACCELAMI2C19|Gyeongsang National University Hospital|Yes|Completed|May 2009|November 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||November 2009|November 9, 2009|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915733||137997|
NCT00915525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-096|Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence|||Allergan|No|Completed|February 2010|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|829|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|May 28, 2009|Yes|Yes||No|October 2, 2015|https://clinicaltrials.gov/show/NCT00915525||138013|
NCT00915993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643287|MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer|An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)||Recruiting|May 2009|||May 2011|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2009|June 5, 2009|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915993||137977|
NCT00916266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stem cells in Epilepsy|Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy|Phase 1 Study of Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy||Instituto do Cerebro de Brasilia|Yes|Completed|July 2008|May 2012|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|64 Years|No|||July 2015|July 29, 2015|April 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00916266||137956|
NCT00903643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F08047007|Sensory Processing in Subjects With Painful Bladder Syndrome|Sensory Processing in Subjects With Painful Bladder Syndrome||University of Alabama at Birmingham|Yes|Completed|May 2008|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|34|||Both|19 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with condition will be from Kirklin Clinic Urology Clinic and the Highlands Pain        Treatment Clinic. Healthy subjects will be recruited via advertisements.|July 2014|July 19, 2014|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903643||138914|
NCT00904488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1292|Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure|Addition of Oral Metolazone to Intermittent Intravenous Furosemide Versus Transition to Continuous Infusion Furosemide in Acute Decompensated Heart Failure Patients Experiencing an Inadequate Response to Therapy||University of North Carolina, Chapel Hill|No|Recruiting|October 2008|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|May 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904488||138850|
NCT00904748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481272|A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate|A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate In Healthy Male Subjects, Fasting Dosing, Being The Test Formulation Sildenafil Citrate 100 Mg CT , And The Reference Formulation Sildenafil Citrate 100 Mg Film-Coated Tablets (Viagra®), Both Formulations Manufactured By Laboratórios Pfizer Ltda.|A1481272|Pfizer|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|47|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 17, 2011|May 19, 2009|No|Yes||No|March 7, 2011|https://clinicaltrials.gov/show/NCT00904748||138830|
NCT00904761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25670|Effects of Physical Training on Heart Rate Variability and Exercise Capacity in Diabetes With Autonomic Neuropathy|Effects of Physical Training on Heart Rate Variability and Exercise Capacity in Diabetes With Autonomic Neuropathy||National Taiwan University Hospital|Yes|Completed|October 2001|May 2002|Actual|May 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||||||Both|20 Years|65 Years|No|||November 2012|December 27, 2012|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904761||138829|
NCT00911846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-10/2009|Attitudes Towards Buprenorphine and Methadone|Attitudes of Patients With Opioid-Substitution and Their Therapists Towards and Buprenorphine and Methadone|Att-1|Psychiatric University Hospital, Zurich|No|Recruiting|May 2009|June 2010|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|180|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients of therapeutic communities, in- and out-patients and their therapists|May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911846||138293|
NCT00912405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-0209|Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis|A Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis||Intersect ENT|No|Completed|March 2009|December 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|June 1, 2009|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT00912405||138251|
NCT00912418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8577|Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma|Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus GM-CSF-in-adjuvant, Followed by Systemic Low-dose-IL-2 Administration, in Patients With High Risk Melanoma.|MEL37|University of Virginia|No|Completed|January 2000|||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|85 Years|No|||June 2013|June 17, 2013|June 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912418||138250|
NCT00910052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20032206|Fibrin Sealant in Renal Transplantation|Routine Use of Fibrin Sealant Does Not Reduce Postoperative Wound Complications in Patients Undergoing Renal Transplantation: A Randomized Controlled Trial||Hennepin County Medical Center, Minneapolis|Yes|Completed|May 2003|September 2008|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|141|||Both|N/A|N/A|No|||May 2009|May 28, 2009|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910052||138431|
NCT00905866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-591|Quality of Life in Patients Undergoing Parathyroidectomy|Evaluation of Quality of Life in Patients Undergoing Parathyroidectomy||Mackay Memorial Hospital|Yes|Completed|August 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|All patients underwent parathyroidectomy|July 2011|July 20, 2011|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905866||138745|
NCT00906451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simvastatin Post-MI|Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction|Phase 4 Study of the Effect of Simvastatin Treatment on Inflammatory Response and Endothelial Function After Myocardial Infarction||Brasilia Heart Study Group|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|58|||Both|45 Years|70 Years|No|||May 2009|June 21, 2011|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906451||138701|
NCT00884910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N07VEGA Amendment 22.5|Long Term Use of the Provox Vega 22.5|Amendment on Phase 1 Trial N07VEG "Assessment of a Next Generation Indwelling Provox Voice Rehabilitation System (Vega)". Amendment 3: Long-term Use of the Provox Vega||Atos Medical AB|No|Completed|February 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|33|||Both|N/A|N/A|No|||July 2012|July 12, 2012|April 20, 2009|Yes|Yes||No|August 2, 2010|https://clinicaltrials.gov/show/NCT00884910||140301|
NCT00885183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK NORD 77/08|Adjuvant Acupuncture Care for Breast Cancer Patients Experiencing Side Effects From Chemotherapy|Adjuvant Acupuncture Care for Breast Cancer Patients Experiencing Side Effects From Chemotherapy. A Randomised Controlled Pilot and Feasibility Study|Acubreast|University Hospital of North Norway|No|Recruiting|April 2009|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Female|18 Years|N/A|No|||May 2012|May 11, 2012|April 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00885183||140281|
NCT00885755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22004|A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer|A Prospective Study to Evaluate Alterations in Molecular Biomarkers in HER2 Neu Positive Metastatic Breast Cancer Together With Assessment of Trastuzumab Use Beyond Progression After Initial Response to Trastuzumab-taxane Based Treatment||Hoffmann-La Roche||Completed|August 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|March 16, 2009||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT00885755||140237|The study was prematurely terminated on December 31, 2012. The end of study follow-up was February 18, 2013.
NCT00887055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMA|OPTIMA Bi-ventricular Capture Verification Study|Bi-ventricular Capture Verification Study||Guidant Corporation||Withdrawn||||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|April 22, 2009|||never started|No||https://clinicaltrials.gov/show/NCT00887055||140138|
NCT00887068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0503|Randomized Allogeneic Azacitidine Study|Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse||M.D. Anderson Cancer Center|Yes|Recruiting|April 2009|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|April 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887068||140137|
NCT00887328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTA0901|Extending the Time for Thrombolysis in Emergency Neurological Deficits|Extending the Time for Thrombolysis in Emergency Neurological Deficits|EXTEND|Neuroscience Trials Australia|Yes|Recruiting|June 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887328||140117|
NCT00918775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0038|Metastasectomy Study in Renal Cell Carcinoma (RCC)|A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma.||M.D. Anderson Cancer Center|No|Recruiting|June 2009|||June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|Patients with metastatic renal cell carcinoma (mRCC) and will be undergoing a surgical        resection of tumor.|March 2016|March 11, 2016|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918775||137764|
NCT00915213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6418|Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy|Incidence of Fluoroquinolone Resistant Enterobacteraciae in Patients Undergoing Repeat Ultrasound Guided Prostate Biopsy||University of California, Irvine|No|Active, not recruiting|October 2008|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Rectal Swab|Male|18 Years|N/A|No|Non-Probability Sample|Men undergoing repeat prostate biopsy|June 2013|June 24, 2013|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00915213||138036|
NCT00915538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSMR 2008-2|Comparing Bronchodilation of Symbicort With and With Out Valved Holding Chamber (Aerochamber Plus)|A Comparison of the Bronchodilating Activity of Symbicort pMDI 160/4.5 Used in the Conventional Manner and With a Valved Spacer Holding Chamber (Aerochamber Plus)|WSMR2|Western Sky Medical Research|No|Recruiting|May 2008|September 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2009|June 5, 2009|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915538||138012|
NCT00916006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-016|A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIa)||Peplin|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|June 4, 2009|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00916006||137976|
NCT00916825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RvF01 - 135/07|Effectiveness of a Rehabilitation Programme for Mothers With Breast Cancer and Their Children|Effectiveness of a Family-oriented Rehabilitation Programme for Mothers With Breast Cancer and Their Children - Quality of Life and Psychological Health of Mothers and Their Children||Philipps University Marburg Medical Center|No|Active, not recruiting|January 2009|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|750|||Female|N/A|N/A|No|||February 2010|February 2, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00916825||137913|
NCT00904189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U4706|Measurement of the Radiation Dose Cuticles Using Electron Paramagnetic Resonance (EPR)|Measurement of the Radiation Dose Cuticles Using Electron Paramagnetic Resonance (EPR) Spectroscopy||University of Rochester|No|Terminated|November 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|May 15, 2009||No|PI has relocated|No|December 24, 2014|https://clinicaltrials.gov/show/NCT00904189||138872|
NCT00904501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC2007- N11-02|Bone Marrow Autograft in Limb Ischemia|Cell Therapy in Critical Limb Ischemia|BALI|CHU de Reims|Yes|Completed|March 2009|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904501||138849|
NCT00904774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 07 018|Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants|Polymorphisms of Genes Controlling Alveolar Development and Risk of Bronchopulmonary Dysplasia|GENBPD|Centre Hospitalier Intercommunal Creteil||Enrolling by invitation|May 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|8 Weeks|No|Non-Probability Sample|Premature neonates|May 2009|May 19, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904774||138828|
NCT00904787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-CL-003|Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies|A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies||CASI Pharmaceuticals, Inc.||Completed|April 2009|May 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|May 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00904787||138827|
NCT00936377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0406|Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal|A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal|DATA|University of Colorado, Denver|No|Completed|September 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|85 Years|No|||July 2009|November 20, 2012|July 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936377||136438|
NCT00936390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0815|Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer|A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|September 2009|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1538|||Male|18 Years|N/A|No|||March 2016|March 8, 2016|July 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936390||136437|
NCT00936403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8630-1824|A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone|A Randomised, Open-labelled, Single Dose, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin NordiFlex® in Growth Hormone Deficient Children||Novo Nordisk A/S|No|Completed|August 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|6 Years|12 Years|No|||August 2012|August 2, 2012|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936403||136436|
NCT00909740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEF4693g|A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEGF0444A, Administered Intravenously to Patients With Advanced Solid Tumors||Genentech, Inc.||Completed|May 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|May 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00909740||138455|
NCT00909753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1284|Ursodiol 500 mg Tablets Under Fed Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500 mg Tablets Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|September 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|92|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 26, 2009|No|Yes||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00909753||138454|
NCT00909766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB123-002|Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects|Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose and Parallel Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-830216 (Prodrug of BMS-819881) in Obese Subjects||Bristol-Myers Squibb|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|113|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|May 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00909766||138453|
NCT00905879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13926|Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging|Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients||Bayer|No|Completed|June 2009|January 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|None Retained|n.a.|Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years old and above who will undergo contrast enhanced MRI with Gadobutrol        (Gadovist)|April 2013|April 25, 2013|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00905879||138744|
NCT00905892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRNHRA-09-002|Metabolic Fate Modifications of Saturated Fats After an Overfeeding|Metabolic Fate Modifications of Saturated Fats After an Overfeeding|SURNUT|Centre de Recherche en Nutrition Humaine Rhone-Alpe|Yes|Completed|September 2005|March 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00905892||138743|
NCT00906178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISK-NIH-MH080662|CyberSenga: Internet-based HIV Prevention in Uganda|CyberSenga: Harnessing the Power of the Internet to Prevent HIV in Ugandan Youth||Center for Innovative Public Health Research|No|Completed|August 2007|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|374|||Both|N/A|18 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906178||138721|
NCT00907010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088/08|Sarcopenia and Aging|Sarcopenia and Aging||Universidade de Franca|Yes|Completed|February 2008|October 2008|Actual|August 2008|Actual|N/A|Observational|N/A||4|Actual|48||The evaluation instruments used were: (1) Esfigmomanômetro (EM), (2) Trunk flexor in the      supine position,, (3) Jamar Dinamômetro and (4) Preston Pinch Gauge Dinamômetro.|Both|11 Years|82 Years|No|Non-Probability Sample|48 individuals participated in this study, being divided into four groups according to the        age: (G1) 11to 18 years old, (G2) 20 to 26 years old, (G3) 45 to 60 years old and (G4) 66        - 82 years old.|May 2009|May 20, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00907010||138659|
NCT00916773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712118R|Pulmonary Disorders During Exercise in Patients With Obstructive Sleep Apnea|Exercised-Induced Bronchoconstriction in Patients With Severe Obstructive Sleep Apnea||National Taiwan University Hospital|Yes|Recruiting|April 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 9, 2009|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916773||137917|
NCT00885469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-76|PillCam® ESO 2 in Esophageal Pathologies|Evaluation of PillCam® ESO 2 in Patients With Suspected Esophageal Pathologies|MA-76|Given Imaging Ltd.|No|Completed|December 2007|April 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|||Both|18 Years|N/A|No|Probability Sample|Patients with known Barrett's Esophagus or chronic GERD|August 2009|August 3, 2009|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885469||140259|
NCT00886275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901037M|Comparing the Effect of Dexmedetomidine With Midazolam on Sedation, Oxidative Stress, and Microcirculation in Intensive Care Unit|Comparing the Effect of Dexmedetomidine With Midazolam on Sedation, Oxidative Stress, and Microcirculation in Intensive Care Unit||National Taiwan University Hospital||Completed|July 2010|||April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|80 Years|No|||November 2012|November 15, 2012|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00886275||140197|
NCT00918242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090616|Prevalence of Coronary Artery Disease in the Siblings of Premature Coronary Heart Disease|Assessment of Occult CAD: Premature CAD Sibling Study (PreCASS)||Yonsei University|Yes|Recruiting|June 2009|||September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|87|||Both|18 Years|N/A|No|Non-Probability Sample|the siblings of premature coronary heart disease (male<55years old, female<65yeasrs old:        Framingham Heart Study) patients admitted relevant hospital within 1 year|July 2012|July 20, 2012|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00918242||137805|
NCT00914953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-R21AG029871|Oxytocin and Social Behavior Over the Lifespan|Oxytocin and Social Behavior Over the Lifespan: Interventional Study||Claremont Graduate University|No|Completed|February 2010|December 2011|Actual|December 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|41|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 29, 2012|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914953||138056|
NCT00919373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T46|Substrate Modification in Stable Ventricular Tachycardia in Addition to Implantable Cardioverter Defibrillator (ICD) Therapy|Substrate Modification in Stable Ventricular Tachycardia in Addition to ICD Therapy|VTACH|St. Jude Medical|No|Completed|July 2002|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|80 Years|No|||July 2013|July 26, 2013|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919373||137719|
NCT00916019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19200049|Investigation of the Effects of Exercise on Gene Expression|Investigation on Gene Expression and Gene Marker Accompanied by a Single Bout of Exercise and Exercise Training||Fukuoka University|Yes|Completed|July 2002|December 2007|Actual|December 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|19 Years|32 Years|Accepts Healthy Volunteers|||June 2009|June 15, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00916019||137975|
NCT00916578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0087|Xeloda (Capecitabine) and External Beam Radiation|A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Inflammatory or Non-Inflammatory Breast Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2009|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||July 2015|July 13, 2015|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916578||137932|
NCT00904215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.487|An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension|A Post Marketing Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension||Boehringer Ingelheim||Completed|February 2005|||May 2007|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1095|||Both|18 Years|80 Years|No|Probability Sample|Patients from clinics and hospitals in Korea|April 2014|April 3, 2014|May 18, 2009||||No|May 22, 2009|https://clinicaltrials.gov/show/NCT00904215||138870|
NCT00936169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVIO|Angiography Versus (vs) IVUS Optimisation|Angiography vs. IVUS Optimisation: A Multi-Centre European Study of Drug Eluting Stent Implantation|AVIO|Fondazione Mediolanum per Attività e Ricerche Cardiovascolari Onlus|No|Completed|May 2008|July 2011|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|284|||Both|18 Years|N/A|No|||July 2009|February 20, 2012|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936169||136454|
NCT00936182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0901|Study of Fluconazole in Children With Autism Spectrum Disorder|A Double-Blind, Placebo-Controlled Study of the Efficacy of Fluconazole as a Treatment for Autism Spectrum Disorder||The Center for Autism and Related Disorders||Recruiting|July 2009|July 2011|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|3 Years|10 Years|No|||July 2009|July 8, 2009|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936182||136453|
NCT00936416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN09-0096B|Assessment of Renal Physiology by Magnetic Resonance Imaging (MRI) in Normal Volunteers|Assessment of Renal Physiology (Glomerular Filtration Rate and Blood Flow) by MRI With Validation by Inulin and Para-Aminohippuric Acid Clearance in Normal Volunteers||University Health Network, Toronto|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 13, 2012|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936416||136435|
NCT00910065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12946|BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)|A Prospective, Randomized, Verum Controlled, Open Label, Parallel Group Multi-center Phase III Clinical Trial to Demonstrate the Superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) Treatment Versus 300 mg Aspirin® N Tablets p.o. (BAY e4465A) in Patients With Acute Coronary Syndrome, Measured by Time Dependent Thromboxane Inhibition|ACUTE|Bayer|No|Completed|March 2011|July 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910065||138430|
NCT00906477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Helse Nord SAT 544-06|Norwegian Constraint-Induced (CI) Therapy Multisite Trial|Intensive Training of Arm and Hand Function in People With Stroke - A Randomized Controlled Multisite Trial.|NORCIMT|University Hospital of North Norway|No|Terminated|October 2008|June 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|May 19, 2009||No|The study was extended for 2.5 years. A further extension could not be funded. When the study    was halted in June 2012, 47 subjects were included.|No||https://clinicaltrials.gov/show/NCT00906477||138700|
NCT00906737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0002|Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities|Targeted Lower Extremity Joint Training Effects on MS Gait Abnormalities||Mount Sinai Rehabilitation Hospital|No|Completed|April 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|25 Years|65 Years|No|||April 2014|April 7, 2014|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00906737||138680|
NCT00906724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U10HD030447|An Exercise Intervention Study in Insulin-Resistant Adolescents|An Exercise Intervention in Insulin-Resistant Minority Adolescents|3290|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|March 2005|December 2009|Anticipated|June 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|14 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Insulin-Resistant Minority Adolescents|January 2009|May 19, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00906724||138681|
NCT00907582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHOPES-APL09|ASCT for Relapsed APL After Molecular Remission|Autologous Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia After Relapse With Idarubicin and Busulfan Conditioning||Shanghai Jiao Tong University School of Medicine|No|Terminated|June 2009|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|60 Years|No|||November 2014|December 1, 2014|May 21, 2009||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00907582||138616|
NCT00916786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812153M|Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder|Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|August 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|240|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|7 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The sample will consist of 160 drug-naïve ADHD patients and 80 matched normal controls,        aged 7-18. The patients will be randomly assigned to two treatment groups, the        OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.|April 2012|July 8, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916786||137916|
NCT00916799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00576|VISN 23 Chronic Obstructive Pulmonary Disease (COPD) Case Management Using Home Telehealth Equipment|VISN 23 COPD Case Management Using Home Telehealth Equipment||VA Nebraska Western Iowa Health Care System|No|Recruiting|March 2009|May 2010|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|N/A|N/A|No|||June 2009|June 10, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00916799||137915|
NCT00917644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581167|Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet In Healthy Subjects||Pfizer|No|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2009|October 15, 2009|June 8, 2009|Yes|Yes||No|September 11, 2009|https://clinicaltrials.gov/show/NCT00917644||137850|
NCT00917657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1183/07|Photorefractive Keratectomy (PRK) for Hyperopia After Radial Keratotomy|Corneal Wavefront-Guided PRK With Adjunctive Mitomycin-C for the Treatment of Hyperopia After Radial Keratotomy||University of Sao Paulo|Yes|Completed|February 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|30 Years|70 Years|No|||June 2009|June 9, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917657||137849|
NCT00917670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-200-f-S-|Ultrastructural Changes of Trabeculectomy Specimens in Patients With Uveitic Secondary Glaucoma|||St. Franziskus Hospital|No|Completed|May 2009|December 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|trabeculectomy specimens including trabecular meshwork and Schlemms canal|Both|N/A|N/A|No|Non-Probability Sample|Patients with uveitic secondary glaucoma in need of surgical intervention.|July 2010|July 21, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917670||137848|
NCT00918229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPI-01 (USA)|Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects|One-arm, Multi-center, International Prospective Study to Assess the Safety and Efficacy of BioProtect Biodegradable Implantable Balloon in Prostate Cancer Subjects Undergoing Radiotherapy||BioProtect|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Male|45 Years|85 Years|No|||September 2011|September 4, 2011|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918229||137806|
NCT00918788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE9107|Laser Spectroscopy of Breast Tissue Through a Needle Device|Laser Spectroscopy of Breast Tissue Through a Needle Device||Case Comprehensive Cancer Center|No|Completed|April 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|17|Samples With DNA|This laboratory study is looking at samples of breast tissue from women who have undergone      breast biopsy or surgery.|Female|N/A|N/A|No|Probability Sample|Primary Care Clinic|August 2013|August 20, 2013|June 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918788||137763|
NCT00918814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-102-CL-03|Dose Ranging and Dose Frequency of LIPO-102|A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue||Neothetics, Inc|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|June 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00918814||137761|
NCT00915265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0052|Continuous Preperitoneal Infusion of Local Anesthetic (CPA) Versus Epidural Infusion of Local Anesthetic (EA) in Fast-Track Open Colorectal Surgery|Continuous Preperitoneal Versus Epidural Infusion of Local Anesthetic for Enhanced Postoperative Recovery Following Open Colorectal Surgery||University Hospital, Clermont-Ferrand||Completed|October 2009|May 2012|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915265||138032|
NCT00915278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1001001|A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors|A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors||Pfizer|No|Terminated|September 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|June 3, 2009|No|Yes|The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive    and does not support further development|No|February 25, 2014|https://clinicaltrials.gov/show/NCT00915278||138031|This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.
NCT00915551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-025|A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIb)||Peplin|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|N/A|No|||November 2013|February 18, 2015|June 4, 2009|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00915551||138011|
NCT00917436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L_9826|Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain|Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain||Sanofi||Completed|December 2004|July 2005|Actual|July 2005|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Actual|183|||Both|18 Years|70 Years|No|||January 2010|January 14, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917436||137866|
NCT00935883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090055|Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)|Eculizumab for the Treatment of Non-Exudative Age-Related Macular Degeneration: An Exploratory Study to Evaluate the Effects of C5 Inhibition on Drusen and Geographic Atrophy|COMPLETE|University of Miami|No|Completed|July 2009|August 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|N/A|No|||January 2015|January 20, 2015|July 7, 2009|Yes|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00935883||136476|
NCT00935896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|normal lung - V1|High Tidal Volume Induces Inflammation In Normal Lungs|Mechanical Ventilation With High Tidal Volume Induces Inflammation In Patients Without Lung Disease|Normallung|Federal University of Rio Grande do Sul|No|Completed||||||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|16 Years|N/A|No|||July 2009|July 8, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935896||136475|
NCT00936195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12200 UMA|Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial|Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial|UMA|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Withdrawn|January 2010|June 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|No|||February 2012|February 14, 2012|July 8, 2009||No|faillure to obtain insurance because of refusal from insurance companies|No||https://clinicaltrials.gov/show/NCT00936195||136452|
NCT00936429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV-001-C-101|Study of HBV-001 D1 in Healthy Adults|Phase 1, Placebo-Controlled, Double-Blind, Safety Study of HBV-001 D1 in Healthy Adults||Hawaii Biotech, Inc.|Yes|Completed|July 2009|January 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|July 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00936429||136434|
NCT00906191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-1114|Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects|An Open-Label, Single-Dose, Nonrandomized Study Of The Mass Balance And Metabolic Disposition Of Orally Administered 14C-Labeled SAM-531 In Healthy Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 25, 2009|May 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00906191||138720|
NCT00906204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183-09-FB|Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation|Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Trial to Assess Safety of Single Dose vs. Traditional Administration of Thymoglobulin Induction for Renal Transplantation|STAT|Wright State University|Yes|Completed|March 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|May 19, 2009|Yes|Yes||No|September 11, 2015|https://clinicaltrials.gov/show/NCT00906204||138719|After an interim analysis at the trial mid-point, the trial was terminated because a futility trend analysis showed a >1.72% chance of the primary endpoint rates between the two groups achieving a significant difference with further enrollment.
NCT00907023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 09/10|Transition From Hospital to Home in Solid Organ Transplant (SOT)|The Transition From Hospital to Home in Parents of Solid Organ Transplant Recipients||Medical College of Wisconsin|No|Completed|January 2009|May 2011|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|37|||Both|N/A|18 Years|No|Non-Probability Sample|Three Pediatric Transplant Hospitals|November 2011|November 8, 2011|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907023||138658|
NCT00907283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deferiprone08|Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)|Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA)||Ente Ospedaliero Ospedali Galliera|No|Active, not recruiting|November 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|80 Years|No|||August 2015|August 3, 2015|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907283||138638|
NCT00907595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-043R|Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon|Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial||Massachusetts General Hospital|Yes|Withdrawn|May 2009|July 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|90 Years|No|||November 2012|November 2, 2012|May 20, 2009|Yes|Yes|unable to recruit subjects for study.Collaborator stopped funding for study as of 3/31/2010|No||https://clinicaltrials.gov/show/NCT00907595||138615|
NCT00908141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6805|GM-CSF in Treating Patients With Relapsed Prostate Cancer|Immunologic Effects of GM-CSF (Sargramostim, Leukine®) in Patients With Biochemically-relapsed Prostate Cancer||Case Comprehensive Cancer Center|Yes|Completed|June 2006|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|N/A|No|||August 2013|August 15, 2013|May 22, 2009|Yes|Yes||No|May 20, 2013|https://clinicaltrials.gov/show/NCT00908141||138574|
NCT00916526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808078|Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough|Measurement of Exhaled NO and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough|MANOTOUX|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||November 2010|November 23, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916526||137936|
NCT00916812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH 0901|Sensitivity of Hyomental Distance Ratio as a Single Predictor of Difficult Intubation in Obstetrics|Hyomental Distance Ratio as a Predictor for Difficult Intubation in Elective and Emergency Cesarean Section.|HMDR|King Khaled Eye Specialist Hospital|Yes|Completed|May 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|188|||Female|18 Years|45 Years|No|Non-Probability Sample|Patients presenting for cesarean section under general anesthesia.|January 2015|January 13, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00916812||137914|
NCT00917384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13893|Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma|A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy||Eli Lilly and Company|Yes|Completed|August 2009|December 2015|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|355|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|June 8, 2009|Yes|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT00917384||137870|
NCT00917683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#5811|Investigation of Neuroserpin as an Autism Candidate Gene|Investigation of Neuroserpin as an Autism Candidate Gene||State University of New York - Upstate Medical University|No|Not yet recruiting|June 2009|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|DNA will be isolated from peripheral blood samples.|Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Autistic patients and their first degree relatives|February 2010|February 26, 2010|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917683||137847|
NCT00917696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-118|Study to Evaluate ATP-induced Pain and ATP-induced Dermal Vasodilation by Iontophoresis (0000-118)(COMPLETED)|A Randomized, Double Blind, Placebo Controlled, Crossover Clinical Trial to Evaluate the Effects of ATP-Induced Pain (AIP) and ATP-induced Dermal Vasodilation (AIDV) by Iontophoresis in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|44|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|June 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00917696||137846|
NCT00919139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0309|S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.|S0309, Myeloma Specimen Repository Protocol, Ancillary||Southwest Oncology Group|No|Completed|November 2003|November 2010|Actual|November 2010|Actual|N/A|Observational|N/A||1|Actual|190|Samples With DNA|bone marrow and peripheral blood|Both|N/A|N/A|No|Non-Probability Sample|patients enrolled on MM, SM, WM, amyloid or MGUS treatment/observation studies.|April 2015|April 1, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919139||137736|
NCT00916331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0606/034-008|Subcutaneous Indwelling of Vacuum Drainage in Total Knee Arthroplasty|Subcutaneous Indwelling of Vacuum Drainage in Total Knee Arthroplasty: Prospective Randomized Comparisons With Intraarticular Indwelling||Seoul National University Hospital|No|Completed|May 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|54 Years|85 Years|No|||June 2009|June 5, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00916331||137951|
NCT00915772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.52|Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid|Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid||Boehringer Ingelheim||Completed|June 2009|||June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|567|||Both|18 Years|80 Years|No|||April 2014|April 29, 2014|June 2, 2009||||No|June 13, 2012|https://clinicaltrials.gov/show/NCT00915772||137994|
NCT00915785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05CC12|Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities|Pilot Study of 5 Azacytidine in the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukaemia With High-risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities||King's College London|No|Completed|November 2005|||April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915785||137993|
NCT00883805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCRC 0163|Investigation of Systemic Metal Ion Concentration Following a Ceramic-on-metal Total Hip Arthroplasty|Investigation of Systemic Metal Ion Concentration Following a Ceramic-on-metal Total Hip Arthroplasty||Northwell Health|No|Withdrawn|April 2009|||April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|40 Years|80 Years|No|Non-Probability Sample|Subjects enrolled will have already undergone a total hip arthroplasty with either a        metal-on-metal articulation, or a ceramic-on-metal articulation.|September 2015|September 16, 2015|April 17, 2009||No|PI moved|No||https://clinicaltrials.gov/show/NCT00883805||140384|
NCT00917735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806M36121|Green Tea and Reduction of Breast Cancer Risk|Phase II, Randomized,Double-blind, Placebo-controlled, Study of the Efficacy of Green Tea Extract on Biomarkers of Breast Cancer Risk in High Risk Women With Differing Catechol-O-methyl Transferase (COMT) Genotypes||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2009|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1075|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|June 8, 2009|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT00917735||137843|We had limited success in recruiting minority populations.
NCT00884338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/028/09|Cognitive Function After Stem Cell Transplantation|Evaluation of the Cognitive Function of Patients After Stem Cell Transplantation||Charite University, Berlin, Germany|No|Recruiting|May 2009|September 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2009|December 18, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884338||140344|
NCT00935350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL-6033|Reduction of the Glycemic Index by a Novel Viscous Polysaccharide|Effect of Adding the Novel Fiber, PGX®,to Commonly Consumed Foods on Glycemic Response and Glycemic Index: A Practical and Effective Strategy for Reducing Post Prandial Blood Glucose Levels.||Glycemic Index Laboratories, Inc|No|Completed|May 2006|August 2006|Actual|June 2006|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|15||Actual|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00935350||136517|
NCT00935597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0906|Host Dendritic Cells in Allograft Patients|A Phase I Trial of Host Dendritic Cell Infusion After Allogeneic Stem Cell Transplant for Prevention or for Treatment of Relapsed Disease in Patients With Advanced Hematologic Malignancies||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|August 2009|||July 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|70 Years|No|||October 2010|October 28, 2010|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00935597||136498|
NCT00935909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112008-014|Use of Vein Viewer for Insertion of Peripheral Venous Cannula in Pediatric Patients With Difficult Intravenous Access|Use of Vein Viewer for Insertion of Peripheral Venous Cannula in Pediatric Patients With Difficult Intravenous Access.||University of Texas Southwestern Medical Center|No|Completed|January 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|603|||Both|N/A|18 Years|No|Probability Sample|The floor patients meeting the inclusion/exclusion criteria that need an IV|June 2013|June 19, 2013|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00935909||136474|
NCT00936208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.584|PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg|To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-vascular Risk Factor||Boehringer Ingelheim||Completed|May 2009|||November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3184|||Both|20 Years|80 Years|No|Non-Probability Sample|Hypertensive patients in the Kingdom of Saudi Arabia, Egypt and United Arab Emirates|March 2014|March 12, 2014|July 8, 2009||||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00936208||136451|
NCT00936442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5390L00076|Arimidex Therapy Compliance Electronic Monitoring System|ARimidex Therapy Compliance Electronic MonitorIng System. A Study to Evaluate the Impact of Educational Material on the Adherence to Treatment With Adjuvant Anastrozole for Postmenopausal Women With Hormone Sensitive Early Breast Cancer|ARTEMIS|AstraZeneca|No|Completed|June 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|104|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women with hormone sensitive early breast cancer|February 2012|February 13, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00936442||136433|
NCT00906490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-11|Clinical Study of the Intravenous Blood Glucose System in Hospitalized Adult Elective or Non-Emergent Surgery and Medical/Surgical Intensive Care Unit Patients|Observational Clinical Study of the Intravenous Blood Glucose System in Hospitalized Adult Elective or Non-Emergent Surgery and Medical/Surgical Intensive Care Unit Patients||Edwards Lifesciences|No|Completed|June 2009|May 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Acute care facility patient with a minimum of 24 hour ICU stay.|August 2013|August 16, 2013|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906490||138699|
NCT00907296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062017|Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing|A Multi-center, Randomized, Double Blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults With a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation With an Intramedullary Nail||Amgen|No|Completed|September 2009|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|402|||Both|18 Years|85 Years|No|||May 2013|May 22, 2013|May 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907296||138637|
NCT00907309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iMET RFA-OD-09-003|Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use|Dental and Medical Office Internet/Intranet Motivational Enhancement Therapy to Reduce Teen Tobacco, Alcohol, and Drug Use||Children's Hospital Boston|Yes|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Both|12 Years|21 Years|No|||January 2013|January 2, 2013|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907309||138636|
NCT00907608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWH-2008-darbe|A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy|A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy||Chinese University of Hong Kong|No|Terminated|December 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|N/A|No|||May 2009|May 21, 2009|May 21, 2009||No|Due to difficulty in patient recruitment|No||https://clinicaltrials.gov/show/NCT00907608||138614|
NCT00907634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00013078|Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™|Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™||Emory University|No|Withdrawn|February 2009|||August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Female|N/A|N/A|No|Non-Probability Sample|Stage IB-IV Cervical cancer patients|October 2013|October 23, 2013|May 21, 2009||No|Study closed by IRB because a Continuing Review and/or Close-Out have not been submitted.    Study closed by IRB|No||https://clinicaltrials.gov/show/NCT00907634||138612|
NCT00907894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2104|Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B|A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LDT600) in Children and Adolescents With Chronic Hepatitis B||Novartis||Completed|February 2009|||March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|22|||Both|2 Years|18 Years|No|||September 2012|September 26, 2012|May 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907894||138593|
NCT00907907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1263|Mycophenolate Mofetil Tablets Under Fasting Conditions|A Single-Dose, Replicate, Comparative Bioavailability Study of Two Formulations of Mycophenolate Mofetil 500 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|July 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 22, 2009|No|Yes||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00907907||138592|
NCT00917397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTF1|The Outcome of Treatment of Traumatised Refugees With Psychotherapy and/or Antidepressants|The Outcome of Treatment of Traumatised Refugees With Trauma-Focused Cognitive Behavioural Therapy and / or Antidepressants - a Randomised Controlled Trial||Psykiatrisk Center Gentofte|Yes|Completed|June 2009|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|280|||Both|18 Years|65 Years|No|||June 2014|June 17, 2014|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917397||137869|
NCT00917410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-SMS-01|Mobile Phone Text for Optimizing Asthma Treatment|Assessment of the Health Related Effects of Compliance Optimization in Asthma Through Use of SMS (Short Message System) - A Controlled Trial||University of Copenhagen|Yes|Completed|November 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|244|||Both|18 Years|45 Years|No|||June 2009|June 9, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00917410||137868|
NCT00917943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004337|Preventing Postpartum Return to Smoking|Smoking Resumption-Prevention is Postpartum Women|Quit for Two|Duke University|No|Completed|April 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|386|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 9, 2013|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00917943||137827|
NCT00917930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090505|Evaluation Rehabilitation on Glycometabolic State in Non-Diabetic Coronary Artery Disease (CAD) Patients|Effect of Cardiac Rehabilitation on Glucometabolic State in Non-Diabetic Patients With Chronic Ischemic Heart Disease||IRCCS San Raffaele|No|Completed|January 2006|January 2007|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|||||Both|N/A|N/A||Probability Sample|non diabetes patients with coronary artery disease|June 2009|June 10, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00917930||137828|
NCT00915291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA-ES62|Evaluating Effectiveness of Educational Intervention to Help Physicians Address Inappropriate Patient Requests for Direct-to-Consumer Advertised Prescription Medications|Sound Prescribing Study - Assessing the Impact of Pharmaceutical Marketing and Promotional Practices on Physician Prescribing||American Medical Association|No|Completed|May 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|133|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2009|June 5, 2009|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915291||138030|
NCT00915798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 2009-6740|Association Between Smoking, Brain Activity, Genes, and ADHD|Smoking, Neurocircuitry and Genes in Adult ADHD||University of California, Irvine|Yes|Active, not recruiting|April 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||4|Anticipated|80|Samples With DNA|Blood samples for genotyping|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Commuity sample|January 2015|August 5, 2015|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915798||137992|
NCT00914992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-310505|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure.||Medical University of Vienna|Yes|Withdrawn|July 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||November 2014|December 5, 2014|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914992||138053|
NCT00915005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0133|Image-Guided Adaptive Conformal Photon Versus Proton Therapy|A Bayesian Randomized Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence||M.D. Anderson Cancer Center|Yes|Active, not recruiting|June 2009|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|250|||Both|18 Years|85 Years|No|||August 2015|August 6, 2015|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00915005||138052|
NCT00916851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903062R|Clinical, Environmental, Neurocognitive, Brain Imaging, and Genetic Validity of Autism and ADHD|Clinical, Environmental, Neurocognitive, Brain Imaging, and Genetic Validity of Autism and Attention-deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|August 2010|July 2013|Anticipated|||N/A|Observational|Observational Model: Case Control||3|Anticipated|300|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments|Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|This 3-year program project consists of three projects investigating a sample, aged 8-17        years, of 100 normally developing children and adolescents, 100 ADHD, and 100 ASD.|April 2012|July 8, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916851||137911|
NCT00884663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-47-7006-2008|Candesartan Versus Propranolol for Migraine Prevention|Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study||Norwegian University of Science and Technology|Yes|Completed|April 2009|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|65 Years|No|||December 2013|December 22, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00884663||140320|
NCT00884351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090125|Magnetoencephalography in Absence Seizures|Magnetoencephalography in Absence Seizures||National Institutes of Health Clinical Center (CC)||Completed|April 2009|June 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|5|||Both|7 Years|35 Years|No|||June 2011|June 16, 2011|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884351||140343|
NCT00884364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/031/09|Exercise During Chemotherapy for Patients With Hematological Malignancies|Exercise During Chemotherapy for Patients With Hematological Malignancies||Charite University, Berlin, Germany|No|Recruiting|May 2009|September 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2009|December 21, 2009|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00884364||140342|
NCT00935610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGING-IMM08|Effect of Immunocal® With Exercise Versus Casein With Exercise on Aging Processes in Elderly Persons|Effect of the Cysteine-rich Whey Protein Isolate (Immunocal®) in Combination With Physical Exercise on Muscle Function, Body Composition and Inflammatory Cytokine Levels in Elderly Persons: A Randomized, Double-blind Study||Immunotec Inc.|No|Completed|June 2009|March 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|99|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2011|January 16, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935610||136497|
NCT00935922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816799-1|CCRC: Understanding the Effects of Omega-3 Fatty Acids Versus Lignans in Flaxseed on Metabolic and Inflammatory Markers Leading to Diabetes and Cardiovascular Disease|CCRC: Understanding the Effects of Omega-3 Fatty Acids vs. Lignans in Flaxseed on Metabolic and Inflammatory Markers Leading to Diabetes and Cardiovascular Disease.||University of California, Davis|Yes|Completed|February 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|36|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2009|October 25, 2012|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00935922||136473|
NCT00936221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00006|Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients|A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma||AstraZeneca||Completed|July 2009|November 2014|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|385|||Both|18 Years|130 Years|No|||February 2016|February 11, 2016|July 8, 2009|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00936221||136450|
NCT00936455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRokE DOC-LTO|Stroke Team Remote Evaluation Using a Digital Observation Camera- Long Term Outcomes(STRokE DOC-LTO)|An Observational Study to Evaluate the Long Term Outcomes of Patients Previously Enrolled in the STRokE DOC ("STRokE DOC Trial (NCT00283868)") Telemedicine Clinical Trial.|STRokE DOC-LTO|University of California, San Diego|No|Completed|June 2009|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|75|||Both|18 Years|90 Years|No|Probability Sample|Inclusion Criteria are:          1. Male or female subjects, age > 18 years.          2. Prior enrollment into the STRokE DOC ("STRokE DOC Trial (NCT00283868)") clinical             research trial.|April 2012|April 24, 2012|July 9, 2009||No||No|August 29, 2011|https://clinicaltrials.gov/show/NCT00936455||136432|This is an observational trial where patients were contacted by telephone for data collection only. No adverse event information was collected.
NCT00906750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRESP|A Study of a Live Intranasal Influenza Vaccine in Children With Cancer|A Pilot Study of Flumist, a Live Attenuated Intranasal Influenza Vaccine, and Inactivated Influenza Vaccine in Children With Cancer|FMRESP|St. Jude Children's Research Hospital|No|Completed|October 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|56|||Both|2 Years|21 Years|No|||October 2011|October 12, 2011|January 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00906750||138679|
NCT00907322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451036|A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults|A Phase 1, Investigator- And Subject-Blind (Sponsor-Open), Randomized, Crossover, Placebo-Controlled Trial To Assess The Safety, Tolerability, And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon [PF-01913539] In Healthy Adult Subjects||Pfizer|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 20, 2009|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907322||138635|
NCT00907335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-6397|A Study of Acne Treatment in Children Ages 9 to 11|A Multi-Center, Double Blind, Vehicle Controlled, Study of Retin-A Micro 0.04% in the Treatment of Pediatric Acne Vulgaris in Children, Ages 9 to 11 Years of Age||Valeant Pharmaceuticals International, Inc.|No|Completed|February 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|9 Years|11 Years|No|||February 2012|February 14, 2012|May 20, 2009|Yes|Yes||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00907335||138634|
NCT00907621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|infant colic|Effects of Acupuncture in the Treatment of Infant Colic|Effects of Acupuncture in the Treatment of Infant Colic: A Prospective Multi-center Single Blinded Randomized Controlled Study||University of Oslo|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Both|N/A|3 Months|Accepts Healthy Volunteers|||March 2015|March 15, 2015|May 21, 2009||No||No|November 22, 2013|https://clinicaltrials.gov/show/NCT00907621||138613|Our choice of acupuncture points and technique could be inferior to other more potent acupuncture approaches.
NCT00907946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alana Desai PCNL Study|Comparing Previously Placed Nephrostomy Tract (NT) Versus Single Stage Percutaneous Nephrolithotomy (PCNL)|A Prospective, Randomized Trial Comparing Previously Placed Nephrostomy Tract and Single Stage Percutaneous Nephrolithotomy and Its Effects on Infection and Bleeding Related Complications||Washington University School of Medicine|No|Terminated|December 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|90 Years|No|||February 2011|February 9, 2011|May 21, 2009||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT00907946||138589|
NCT00917124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-AKA01|Cerebral Oximetry and Neurocognitive Functions in Cardiosurgical Patients|Influence of Intraoperative Monitoring of Cerebral Oximetry on Neurocognitive Function After Coronary Artery Bypass Surgery: Randomized, Prospective Study||University of Zagreb|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|200|||Both|40 Years|80 Years|No|||June 2015|June 9, 2015|June 9, 2009||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT00917124||137890|number and selection of performed neurocognitive tests. MMSE test is not part of "Statement of consensus on assessment of neurobehavioral outcomes after cardiac surgery"lack of blind monitoring of cerebral oximetry in control group
NCT00918827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642386|Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy|Study of Biomarkers in Tissue Samples of Patients With Stage III Colon Cancer Treated With Adjuvant Chemotherapy Comprising Fluorouracil-Based Regimens(B-CAST)||Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Active, not recruiting|April 2009|||March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2128|||Both|N/A|N/A|No|Non-Probability Sample|Pathologically confirmed stage III colon adenocarcinoma patients who are given treatment        with fluorouracil-based post-opeartive adjuvant chemotherapy|October 2015|October 15, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00918827||137760|
NCT00915304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBMeDS-40344-06|Evidence-Based Medicine Electronic Decision Support Study|Patient Specific Automatic Reminders in Primary Care - the EBMeDS Randomised Trial|EBMeDS|University of Tampere|No|Completed|June 2009|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|1||Actual|12101|||Both|N/A|N/A|No|||December 2012|December 17, 2012|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915304||138029|
NCT00886522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152/2008/U/Sper|Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies|Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.|IBCB|St. Orsola Hospital|No|Recruiting|April 2009|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|65 Years|No|||June 2012|June 7, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886522||140178|
NCT00918840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPC-02|Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)|Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy Followed by Analytical Treatment Interruption|PHPC-02|Genetic Immunity|Yes|Completed|April 2009|June 2011|Actual|June 2011|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|16|Samples With DNA|peripheral blood mononuclear cells (PBMC) and plasma|Both|18 Years|55 Years|No|Probability Sample|Primary care clinic|February 2013|February 7, 2013|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00918840||137759|
NCT00886717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-UUCM-GPMOC201|Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer|Open-label, Multicenter, Phase I/II Trial to Evaluate Efficacy Safety of the Combination Therapy of Genexol-PM and Carboplatin as a Firstline Treatment in Subjects With Advanced Ovarian Cancer||National Cancer Institute (NCI)||Recruiting|May 2008|||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Female|18 Years|N/A|No|||December 2009|August 1, 2013|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00886717||140163|
NCT00883532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yeh 2009 (CMU)|Prevention of Chronic Lung Disease (CLD) in Preterm Infants|Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen||China Medical University, China|Yes|Recruiting|April 2009|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|N/A|4 Hours|No|||April 2009|August 7, 2012|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00883532||140405|
NCT00915980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2007-0108|Meal Stimulating After Roux-en Y Gastric Bypass|Meal Stimulating After Roux-en Y Gastric Bypass||Hvidovre University Hospital|Yes|Completed|January 2008|October 2010|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|Samples Without DNA|plasma and serum sampels for analysis of primarily intestinal hormones|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese with BMI > 40 undergoing gastric bypass surgery or obese with BMI > 35 with        complications of their obesity in form of high blood pressure or other related        complications undergoing gastric bypass surgery.|July 2011|July 6, 2011|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915980||137978|
NCT00916500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCCH GY 1001|Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer|A Phase II Trial of Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer Patients||Korea Cancer Center Hospital|No|Completed|March 2006|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Female|20 Years|75 Years|No|||April 2014|April 29, 2014|June 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00916500||137938|
NCT00935636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042009-046|An Evaluation of Efficacy of the GlideScope Cobalt Video Baton for Intubation on Children Weighing Less Than 10 Kilograms|An Evaluation of Efficacy of the GlideScope Cobalt Video Baton for Intubation on Children Weighing Less Than 10 Kilograms||University of Texas Southwestern Medical Center|No|Completed|May 2009|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|N/A|2 Years|No|Non-Probability Sample|Neonates and infants requiring endotracheal intubation under 10 kilograms and in which the        attending anesthesiologist decided to use the CGS-CVB will be included in this        observational study.|June 2013|June 19, 2013|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00935636||136495|
NCT00935935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bone2009|Study of Bone Disease in Older HIV-infected Adults|A Pilot Study on the Immunopathogenesis of Bone Disease in Older HIV-infected Adults||Ruth M. Rothstein CORE Center|No|Completed|December 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|101|Samples Without DNA|Serum and plasma|Both|50 Years|70 Years|No|Non-Probability Sample|100 HIV-infected adults, age 50 years or older, on HAART with undetectable viral loads,        who are randomly sampled from 6 strata defined by ethnicity (Black:White:Hispanic; 2:1:1)        and sex (male:female; 1:1).        100 HIV+ adults, age ≥ 50 yr (50 ♂, 50 ♀; 50 AA, 25 W, 25 H).|August 2012|August 1, 2012|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935935||136472|
NCT00934349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00348-49|Study of Dry Beriberi in Mayotte, Comoro Archipelago|Determination Study of Dry Beriberi in Patients Native to the Comoro Archipelago, in Mayotte (MABECO).|MABECO|Groupe Hospitalier Sud Reunion|Yes|Recruiting|June 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Blood samples drawn for thiamine status, vit B1 dosage will be centrifuged and a serum      sample will be frozen at -20°C, transferred to Regional Hospital of Reunion Island - GHSR      and retained in virology laboratory of Dr MICHAULT after end of study for further      explorations on beriberi|Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli)        fulfilling the clinical definition of the dry beriberi. 3 controls fullfilling inclusion        criteria will be recruited within the houshold by drawing lots.among|July 2009|July 7, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00934349||136593|
NCT00935727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-06-0255|Elastographic Imaging of Renal Transplants|Pilot Study to Define Parameters of Elastography Compared to Color Flow Doppler Ultrasound in Renal Transplants|Elastorenal|The University of Texas Health Science Center, Houston|No|Terminated|June 2006|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|10|||Both|18 Years|N/A|No|||July 2009|July 7, 2009|May 8, 2009||No|images obtained were non-diagnostic|No||https://clinicaltrials.gov/show/NCT00935727||136488|
NCT00936026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/1002|Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane|||Merz Pharmaceuticals GmbH||Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Masking: Open Label|1||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|February 7, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936026||136465|
NCT00907062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHPD#-137767|Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents|Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents: an Open Label Pilot Clinical Trial||University of Toronto|Yes|Completed|May 2009|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2010|July 7, 2010|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907062||138655|
NCT00907348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL_REAL07|Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma|Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)|REAL07|Fondazione Italiana Linfomi ONLUS|No|Active, not recruiting|October 2007|January 2012|Anticipated|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|60 Years|80 Years|No|||October 2011|October 12, 2011|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907348||138633|
NCT00907361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MagnaSafe-095151|The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)|The MagnaSafe Registry: Determining the Risks of MRI in the Presence of Pacemakers and Implantable Cardioverter Defibrillators|MagnaSafe|Scripps Health|No|Completed|April 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2039|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patient with pacemaker or ICD that is scheduled for a clinically indicated MRI.|November 2015|November 20, 2015|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00907361||138632|
NCT00912600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 03 035|Intensive Care Unit (ICU) Admission Decisions in the Elderly : the ICE-CUB Study|A Prospective Multicenter Study Examining the Criteria That Determine ICU Admission of Patients Over 80 Who Present to an Emergency Department and Evaluating the Impact of ICU Admission on Short and Mid-term Vital and Functional Outcome|IceCub|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2004|February 2009|Actual|January 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2643|||Both|80 Years|N/A|No|Non-Probability Sample|Old patients arriving to the emergency department of 15 French hospitals with conditions        that potentially warrant ICU admission.|May 2009|July 25, 2012|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912600||138236|
NCT00912613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q1502/127|Intensive Care Unit (ICU) Diaries as a Therapeutic Intervention for Post Traumatic Stress Disorder (PTSD) Following Critical Illness|ICU Diaries as a Therapeutic Intervention for Post Traumatic Stress Disorder Following Critical Illness|RACHEL II|University of Liverpool|Yes|Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|352|||Both|18 Years|N/A|No|||June 2009|June 1, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912613||138235|
NCT00915317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5125|Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency|Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency||Kaiser Permanente||Withdrawn|October 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|All hemodialysis patients at the Kaiser Permanente Los Angeles Medical Center with vitamin        D deficiency [defined by 25-hydroxyvitamin D level less than 30 ng/ml].|March 2015|March 10, 2015|October 15, 2008||No|Before we could start the study, we realized that many of the patients were already getting    ergocalciferol. Therefore, the study was closed.|No||https://clinicaltrials.gov/show/NCT00915317||138028|
NCT00915330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-Trisolini|Rapid On-site Cytopathologic Evaluation in the Diagnosis of Hilar/Mediastinal Adenopathy|Transbronchial Needle Aspiration With and Without Rapid On-site Cytopathologic Evaluation in the Diagnostic Approach to Hilar/Mediastinal Adenopathy: A Randomized Controlled Trial.||Maggiore Bellaria Hospital, Bologna|No|Completed|May 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Diagnostic|2|||164|||Both|18 Years|90 Years|No|||February 2010|February 18, 2010|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00915330||138027|
NCT00918541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CarotidMRI|Natural History of Atherosclerosis|Natural 1-year History of Atherosclerosis in Asymptomatic Patients With Mild to Moderate Carotid Stenosis||University of Zurich|No|Completed|January 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|Patients of the districthospital Bellinzona|December 2011|December 22, 2011|November 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00918541||137782|
NCT00886236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 18041 Gaba Bariatric|Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting|The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients||Medical University of South Carolina|No|Enrolling by invitation|July 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||April 2009|April 21, 2009|April 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00886236||140200|
NCT00886249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#29924|Depth of Focus Comparison Between Acrysof IQ and Acrysof Natural IOLs|Depth of Focus Comparison Between Acrysof IQ and Acrysof Natural IOLs||Medical University of South Carolina|No|Withdrawn|March 2009|October 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A total of 50 patients of both sexes and any race undergoing routine bilateral        phacoemulsification and intraocular lens implantation will be included.|October 2009|October 9, 2009|April 21, 2009|No|Yes|The PI has determined not to continue the study.|No||https://clinicaltrials.gov/show/NCT00886249||140199|
NCT00886262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasopressin HR #17345|Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant|Low Dose Vasopressin for Renal Protection During Liver Transplantation||Medical University of South Carolina|Yes|Enrolling by invitation|July 2007|January 2010|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2009|April 21, 2009|April 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00886262||140198|
NCT00887302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J&J Ethicon|Metabolics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy|Johnson and Johnson Ethicon Metabolics of RYGB With Gastrostomy|J&J Ethicon|East Carolina University|No|Not yet recruiting|May 2009|||June 2010|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|120|||Female|18 Years|60 Years|No|Non-Probability Sample|Obese caucasian females between the ages of 18-60 who have had bariatric surgery.|April 2009|April 22, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00887302||140119|
NCT00887315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16574B|The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Trial of Docetaxel, Cisplatin, and Hypofractionated Radiotherapy Versus Docetaxel and Cisplatin for Limited Volume Stage IV Non-small Cell Lung Cancer: The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial|SMART|University of Chicago|Yes|Terminated|April 2009|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|April 22, 2009|Yes|Yes|Slow accrual and loss of sponsor|No|June 24, 2013|https://clinicaltrials.gov/show/NCT00887315||140118|Funding was withdrawn before conclusions were reached so the study was terminated and no data was collected and analyzed.
NCT00915746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016342|A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of JNJ-31001074 in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2009|December 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 29, 2010|June 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00915746||137996|
NCT00916539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P-001424|Cast Immobilization for Non-Displaced Scaphoid Fractures|Non-displaced Scaphoid Fractures: A Clinical Trial of Cast Immobilization Including vs. Excluding the Thumb||Massachusetts General Hospital|No|Active, not recruiting|July 2007|January 2016|Anticipated|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Orthopaedic Hand Clinic|September 2015|September 22, 2015|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916539||137935|
NCT00916513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CEU-DUM-2008/2|Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey|Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey|PANORAMA|AstraZeneca|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|5926|||Both|40 Years|N/A|No|Probability Sample|To be recruited in Primary Care Centres mainly, but hospitals will be allowed in some        countries|April 2010|April 26, 2010|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00916513||137937|
NCT00916279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0010-01|PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis|A Prospective, Multicenter, European Registry Investigating the Lutonix Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis Within Bare-Metal Stents|PERVIDEO I|C. R. Bard|Yes|Completed|June 2009|December 2011|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 4, 2009||No||No|August 5, 2014|https://clinicaltrials.gov/show/NCT00916279||137955|
NCT00935649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0001.p.A|PinPointe FootLaser for the Treatment of Onychomycosis|Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis)||PathoLase, Inc.|Yes|Completed|June 2009|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|80 Years|No|||November 2010|April 8, 2013|July 7, 2009||No||No|April 8, 2013|https://clinicaltrials.gov/show/NCT00935649||136494|
NCT00933257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04808|Dermacyd PH_DESILSTY_FR (Lactic Acid) - Photo Evaluation - Stay on Frutal|Study Title: Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DESILSTY_FR.||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933257||136676|
NCT00933270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA-1 US/EU|Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery|Comparison of the SUpera® PERipheral System to a Performance Goal Derived From Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery|SUPERB|IDev Technologies, Inc.|Yes|Completed|July 2009|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|325|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|July 2, 2009|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT00933270||136675|
NCT00936845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Females with Hemophilia|Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study|Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study||Weill Medical College of Cornell University|No|Completed|April 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|22|||Female|1 Month|N/A|No|Non-Probability Sample|Females with severe or moderate (less than 5%) hemophilia A or B.|December 2012|December 6, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00936845||136402|
NCT00936039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-09-3-011|Effects of Unloading on Muscle Mass|The Effect of Immobilization on Myocellular Characteristics in Healthy, Young Males||Maastricht University Medical Center|No|Completed|October 2009|June 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00936039||136464|
NCT00936286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_SpiroTiger_87/2008|Respiratory Muscle Training in Obstructive Sleep Apnea Syndrome (OSAS) Patients|The Impact of Respiratory Muscle Training on the Therapy of Obstructive Sleep Apnea Syndrome (OSAS) Patients||Idiag AG|No|Completed|January 2009|March 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|75 Years|No|||March 2010|March 9, 2010|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00936286||136445|
NCT00907036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-ReACH|Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma|A Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET-positive Hodgkin Lymphoma||National Cancer Institute (NCI)||Not yet recruiting|July 2009|||July 2015|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|49|||Both|16 Years|65 Years|No|||June 2009|August 1, 2013|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907036||138657|
NCT00907049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-30|Association Between Neck Pain and Quality of Sleep|Study of the Association Between Neck Pain and the Quality of Sleep||Kovacs Foundation|Yes|Completed|September 2009|June 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|424|||Both|N/A|N/A|No|Non-Probability Sample|Patients seen for neck pain in the primary care centers participating in the study.|March 2014|March 11, 2014|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907049||138656|
NCT00907374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 04-09-772|Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria|Early Nephropathy Study in Diabetes With Inhibitory Renin-Angiotensin-Aldosterone System Therapy (END-IT)|END-IT|Charles Drew University of Medicine and Science|Yes|Completed|July 2005|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|70 Years|No|||March 2012|March 28, 2012|May 21, 2009||No||No|February 9, 2012|https://clinicaltrials.gov/show/NCT00907374||138631|
NCT00907660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0054|A Randomized Trial Comparing Two Doses of Portion-Controlled Foods Within a Primary Care Weight Loss Program|A Randomized Trial Comparing Two Doses of Portion-Controlled Foods Within a Primary Care Weight Loss Program|PCPCWLS|University of Colorado, Denver|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2010|February 1, 2013|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00907660||138611|
NCT00907933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111610|Intranasal SB-705498 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Examine the Safety, Tolerability and Pharmacokinetics of a) Single, Ascending and b) Twice-daily Repeat Doses of Intranasal SB-705498||GlaxoSmithKline|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|44|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|May 19, 2011|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00907933||138590|
NCT00912301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001003|Cheno Effect on Transit in Health and IBS-C|Effect of Chenodeoxycholic Acid on Gastrointestinal Transit and Colonic Functions in Health and Constipation-predominant Irritable Bowel Syndrome (IBS-C)|Chenotransit|Mayo Clinic|No|Completed|April 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 29, 2012|May 29, 2009||No||No|May 29, 2012|https://clinicaltrials.gov/show/NCT00912301||138259|
NCT00912626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-2-6426|Family Functioning and Child Behavior When a Sibling is Critically Ill|Family Functioning and Child Behavior When a Sibling is Critically Ill||Children's Hospital of Philadelphia|No|Completed|June 2009|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|90|||Both|18 Years|N/A|No|||April 2014|March 11, 2015|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912626||138234|
NCT00917956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB #: 20071696|Lithium in Inclusion Body Myositis (IBM)|A Pilot Trial of Lithium in Inclusion Body Myositis (IBM)|Li-IBM|Phoenix Neurological Associates, LTD|Yes|Completed|June 2008|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Muscle Biopsies will be taken at baseline and at the end of 6 months. Tissue will be frozen      then sent out for anaylsis.|Both|30 Years|88 Years|No|Probability Sample|Patients who fit criteria diagnosed with IBM|February 2010|February 25, 2010|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917956||137826|
NCT00917982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8801|The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients|The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7||hahid Beheshti University of Medical Sciences||Recruiting||||||Phase 1|Interventional|N/A|1||||||Both|3 Years|7 Years||||June 2009|June 10, 2009|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00917982||137825|
NCT00917995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-081M|Trial Concerning the Frequency of Parastomal Hernia With or Without a Mesh|STOMAMESH Prospective Randomised Multicenter Trial Concerning the Frequency of Parastomal Hernia With or Without a Mesh|STOMAMESH|Norrbottens Lans Landsting|No|Completed|January 2008|September 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|241|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917995||137824|
NCT00885456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVENT Trial|Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT|Effectiveness of a Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke: A Multi-site RCT|PREVENT|Nova Scotia Health Authority|Yes|Enrolling by invitation|December 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|250|||Both|17 Years|N/A|No|||October 2014|October 29, 2014|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00885456||140260|
NCT00885742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI71023_3001|A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency|A Prospective, Multicenter, Open-label, Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency||CSL Behring|No|Completed|August 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|41|||Both|N/A|N/A|No|||June 2012|July 10, 2012|April 21, 2009|Yes|Yes||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00885742||140238|
NCT00917917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0053|Effect of Physical Activity and Diet on the Treatment of Metabolic Syndrome|Role of Combined Intervention of Physical Activity and Nutrition in Metabolic Syndrome Treatment on Cardio-vascular Risk and Muscular- Skeletal Functions in Human Subject. Analysis of Patient's Compliance in Patient's Follow-up.||University Hospital, Clermont-Ferrand||Completed|May 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00917917||137829|
NCT00887341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22254|A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis|Phase II Multi-centre, Randomized, Parallel Group, Pilot Trial to Compare the Incidence of Tocilizumab Related Infusion Reactions in Moderate to Severe RA Patients When Infusion is Made Over 1 Hour Against 31 Minutes||Hoffmann-La Roche||Completed|May 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|April 22, 2009||No||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00887341||140116|
NCT00887562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC9240|Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes|A Phase IIa Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis and Stroke-like Episodes|MELAS|Columbia University|No|Active, not recruiting|May 2009|February 2014|Anticipated|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Both|8 Years|65 Years|No|||February 2013|February 13, 2013|April 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00887562||140099|
NCT00887575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 122|Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer|Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer||SCRI Development Innovations, LLC|No|Completed|June 2009|September 2014|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Female|18 Years|N/A|No|||April 2015|April 30, 2015|April 22, 2009|No|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00887575||140098|
NCT00887588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2214|LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction|A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction||Novartis|Yes|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|307|||Both|40 Years|N/A|No|||August 2015|August 12, 2015|April 22, 2009|Yes|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT00887588||140097|
NCT00883818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-12-027|Microorganism in Overactive Bladder Patients|Detection and Treatment Benefit of Microorganism (Chlamydia Trachomatis, Mycoplasma Hominis, Ureaplasma Urealyticum) in Overactive Bladder Patients||Samsung Medical Center|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Female|20 Years|80 Years|No|||June 2009|July 5, 2009|April 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00883818||140383|
NCT00916552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO1|Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder|The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study||Rigshospitalet, Denmark|Yes|Completed|September 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|65 Years|No|||November 2012|November 8, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00916552||137934|
NCT00916292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phage-W2009-01-1a|Safety Study of Topical Human FGF-1 for Wound Healing|A Phase 1a, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Normal Volunteers Given Punch Skin Biopsies||Phage Pharmaceuticals, Inc.|No|Not yet recruiting|November 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|June 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00916292||137954|
NCT00917098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077197|Examining Behavior Therapy for Trichotillomania in Children and Adolescents|Behavior Therapy for Pediatric Trichotillomania||University of Pennsylvania|Yes|Recruiting|October 2008|January 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|10 Years|17 Years|No|||February 2012|February 14, 2012|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00917098||137892|
NCT00935948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04497|Efficacy and Safety Evaluation of the Imescard Compound Water Smartweed Ointment|Phase 3 Clinical Trial - Efficacy and Safety Evaluation of the Drug Imescard Compound Water Smartweed, Adrenalin and Hamamelis Ointment||Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|April 2008|||May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2009|July 8, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935948||136471|
NCT00934089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0191002|A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329|A Phase 2, Single-Masked, Randomized, Crossover Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 Alone and In Combination With Latanoprost||Pfizer|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934089||136613|
NCT00934102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-368-C-103|Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses|Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses (P/318/08/C)|QUINCE|Alcon Research|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|57|||Both|17 Years|N/A|No|||November 2010|June 26, 2012|July 6, 2009|Yes|Yes||No|November 1, 2010|https://clinicaltrials.gov/show/NCT00934102||136612|
NCT00935441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4127-B|Effect of Case-Management Using Home Monitoring on Diabetes and Blood Pressure Outcomes|Effect of Nurse-Based, Protocol-Driven, Case-Management Utilizing Home Telemonitoring and Home HbA1c Measurement on Diabetes and Blood Pressure Outcomes||Minneapolis Veterans Affairs Medical Center||Completed|June 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2011|September 14, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935441||136510|
NCT00935454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baermed-001|Hepatocyte Matrix Implant Study|Intracorporeal Autologous Hepatocyte Matrix Implant: A New Tissue Engineering Procedure for Treatment of Hepatic Disease.|HMI|Baermed|Yes|Recruiting|July 2009|March 2012|Anticipated|September 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2009|April 11, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00935454||136509|
NCT00936468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-100-002|Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects|Randomized, Double Blind, Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With and Without JVRS-100 Adjuvant in Subjects 65 Years and Older||Colby Pharmaceutical Company|Yes|Completed|September 2009|September 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|472|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 10, 2011|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00936468||136431|
NCT00906789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Riverain SV 2.0.1 and OG5.0|Testing of Computer Aided Detection Software for Riverain Medical Group|Testing of Computer Aided Detection Software for Riverain Medical Group||Georgetown University|No|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|N/A||1|Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Radiologists in active clinical practice who are not subspecialists in chest radiology|August 2014|August 20, 2014|May 5, 2008|No|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT00906789||138676|No adverse events occurred. Study was subject to the following potential biases: Sample bias; Majority rule bias; Referral Bias, bias from knowledge that this is an experiment; reader order bias; learning bias; Bias from use of new technology, et al
NCT00906815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-1100-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2009|||||N/A|N/A|N/A||||||||||||||October 14, 2009|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00906815||138674|
NCT00912002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-016|A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)|A Study to Investigate the Absorption, Metabolism, Excretion and Mass Balance After Administration of a Single Dose of [14C]MK-0941||Merck Sharp & Dohme Corp.|No|Completed|October 2008|January 2009|Actual|November 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|65 Years|No|||June 2015|June 8, 2015|June 1, 2009|No|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00912002||138282|
NCT00912015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT3-001-E1-A1|A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up|A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up||Labopharm Inc.|No|Completed|March 2002|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|238|||Both|40 Years|75 Years|No|||April 2012|April 25, 2012|April 9, 2009||No||No|April 9, 2009|https://clinicaltrials.gov/show/NCT00912015||138281|
NCT00912275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200811019M|Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer|Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer||National Taiwan University Hospital|Yes|Recruiting|May 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Female|20 Years|N/A|No|||November 2012|November 15, 2012|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912275||138261|
NCT00912288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451006|A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease||Pfizer|Yes|Terminated|September 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|50 Years|N/A|No|||August 2012|August 30, 2012|June 1, 2009|Yes|Yes|See termination reason in detailed description.|No|July 30, 2012|https://clinicaltrials.gov/show/NCT00912288||138260|Results are not summarized because of early termination of the study due to modification in the development plan of the study medication following lack of demonstration of efficacy in the completed DIM14 CONNECTION (B1451002/NCT00675623) study.
NCT00912314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0818191|Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder|A Randomized Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder||University of California, San Diego||Suspended|February 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Female|18 Years|N/A|No|||June 2009|March 19, 2010|June 1, 2009|No|Yes|low recruitment|No||https://clinicaltrials.gov/show/NCT00912314||138258|
NCT00884897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041024|Oxytocin and Social Cognition in Schizophrenia|Oxytocin and Social Cognition in Schizophrenia||University of Maryland|Yes|Completed|January 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|No|||April 2013|April 2, 2013|April 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00884897||140302|
NCT00885768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAS001|Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization|Prevalence of Renal Artery Stenosis in Patients Refered for Cardiac Catheterization to Heart Center Hospital in July-September 2008|RAS|Imam Khomeini Hospital|Yes|Completed|July 2008|April 2009|Actual|September 2008|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|146|||Both|18 Years|N/A|No|Non-Probability Sample|All patients reffered to the Tehran Heart center for coronary angiography|April 2009|May 11, 2011|July 11, 2008||No||No|March 9, 2010|https://clinicaltrials.gov/show/NCT00885768||140236|
NCT00886041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mansoura university|Role of Laparoscopy in Unexplained Infertility|Role of Laparoscopy in Unexplained Infertility||Mansoura University|No|Completed|January 2003|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|512|||Female|18 Years|40 Years|No|||April 2009|April 21, 2009|April 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00886041||140215|
NCT00918255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-467|Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa|A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa||Abbott|No|Completed|April 2009|November 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|N/A|No|||April 2011|April 14, 2011|April 30, 2009|Yes|Yes||No|March 2, 2011|https://clinicaltrials.gov/show/NCT00918255||137804|
NCT00919360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB# 22086|Gene Expression In Pregnancies Complicated by Preeclampsia|Expression of Vascular Endothelial Growth Factor and Its Effectors in Preeclampsia||University of Rochester|No|Terminated|June 2008|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|125|Samples With DNA|serum, placental and decidual tissue|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Gravidas at 32-42 weeks gestation who present to Labor and Delivery units at University of        Rochester, Strong Memorial Hospital|October 2015|October 19, 2015|June 10, 2009||No|PI is no longer at University of Rochester, has moved to University of Florida, Gainesville.    PI email now homonq@ufl.edu. Phone is 352-273-7675|No||https://clinicaltrials.gov/show/NCT00919360||137720|
NCT00915200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 1R21AT004490|N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy|N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy.||The University of Texas Health Science Center at San Antonio|Yes|Active, not recruiting|October 2009|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|225|||Both|18 Years|70 Years|No|||March 2015|March 29, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00915200||138037|
NCT00915512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016543|A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia|An Open-label, Single-arm, Multicenter, Phase IV Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-release Paliperidone in Patients With Schizophrenia||Janssen-Cilag Turkey|No|Completed|May 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|65 Years|No|||October 2013|October 9, 2013|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00915512||138014|
NCT00917111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C218|The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used Four Times a Day in the Symptomatic Treatment of Seasonal Allergic Rhinitis||Capnia, Inc.|No|Completed|July 2009|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||August 2012|August 6, 2012|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00917111||137891|
NCT00937352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN115727-351|A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease|A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.||JANSSEN Alzheimer Immunotherapy Research & Development, LLC||Terminated|July 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|896|||Both|51 Years|N/A|No|||November 2013|November 26, 2013|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937352||136364|
NCT00934895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040803|Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca|Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)||Rutgers, The State University of New Jersey|No|Active, not recruiting|July 2009|||August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|18 Years|N/A|No|||May 2015|May 21, 2015|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00934895||136551|
NCT00936234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINNjA-DM|Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).|Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).|FINNjA-DM|Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|July 2009|November 2012|Anticipated|September 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|80 Years|No|||July 2009|June 21, 2011|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00936234||136449|
NCT00933218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2384/09|Beer, Marathon, Genetics, Inflammation and the Cardiovascular System: Be-MaGIC-Trial|Effects of Polyphenols on Changes of Inflammatory and Cardiovascular Status After a Marathon Run|Be-MaGIC|Technische Universität München|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||July 2009|October 19, 2010|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00933218||136679|
NCT00907075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-08012|Pilot Study to Assess Adherence to a Novel Eating System in Men and Women With Type 2 Diabetes Mellitus|Pilot Study to Assess Adherence to a Novel Eating System in Men and Women With Type 2 Diabetes Mellitus||Mondelēz International, Inc.|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|79 Years|No|||August 2012|August 21, 2012|May 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00907075||138654|
NCT00911742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT1-012|Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg|Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg OAD Formulation Versus Zytram® 200 mg||Labopharm Inc.||Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|April 8, 2009|Yes|Yes||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00911742||138301|
NCT00912028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOH--BRA-001|Clinical Performance Comparison of Several Different Contact Lenses|Multicenter, Single-masked, Randomized, Parallel, Controlled Study to Compare Senofilcon A Contact Lenses to Currently Used Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|May 2009|||February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|71|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|May 29, 2009|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT00912028||138280|
NCT00912067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7085-IB-CTIL|Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults|Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults||Sheba Medical Center|No|Enrolling by invitation|July 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|adults after hematopoietic stem cell transplantation done at sheba medical center Israel        during the last 3 years|June 2009|June 1, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912067||138277|
NCT00912665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-150808|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure||Medical University of Vienna|Yes|Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912665||138231|
NCT00885196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071C2201|A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis|A Double Blind, Randomized, Placebo Controlled, Multicenter, Dose Finding Study of Oral AEB071 Assessing Psoriasis Area and Severity Index (PASI) Response and a Function of Dose and Treatment Duration (Primary Outcome) in Patients With Plaque Psoriasis||Novartis||Completed|April 2009|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|336|||Both|18 Years|75 Years|No|||August 2012|August 31, 2012|April 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00885196||140280|
NCT00885209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-108|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure||Given Imaging Ltd.|No|Completed|February 2008|March 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|127|||Both|18 Years|50 Years|No|Non-Probability Sample|Patients that are indicated for colonoscopy, who are suspected or known to suffer from        colonic diseases|March 2010|March 10, 2010|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00885209||140279|
NCT00917904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 014B|An Expanded Safety Study of Dapivirine Gel 4789 in Africa|A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4789, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.||International Partnership for Microbicides, Inc.|Yes|Completed|July 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 13, 2011|June 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00917904||137830|
NCT00918762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642940|Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx|A Pilot Study Assessing the Use of DA VINCI® Robotic Surgical System in Laryngeal and Pharyngeal Surgeries||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 2009|October 2010|Actual|February 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|June 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00918762||137765|
NCT00920413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-044|Oral Vitamin C for Correction of Anemia in Patients Receiving Peritoneal Dialysis|Randomized, Double-Blind, Placebo-Controlled Trial of Oral Vitamin C on Correction of Anemia in Patients Receiving Peritoneal Dialysis||St. Michael's Hospital, Toronto|No|Completed|March 2002|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||June 2009|June 12, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920413||137641|
NCT00920426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112929|Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)|A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)||GlaxoSmithKline|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||March 2011|March 10, 2011|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920426||137640|
NCT00920439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112683|Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers|Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (Poliorix™) in Toddlers||GlaxoSmithKline||Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|26|||Both|18 Months|24 Months|Accepts Healthy Volunteers|||September 2013|September 5, 2013|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920439||137639|
NCT00920114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/04|Estimate of the Activity and the Forecast of the Lupus Disease of the Adult by a Transcriptomic Score (STUDY LU-PUCE)||LU-PUCE|Assistance Publique Hopitaux De Marseille|No|Completed|May 2009|March 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 12, 2012|June 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00920114||137664|
NCT00953992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2009-107|Etiology, Epidemiology and Prognostics of Acute Kidney Injury (AKI)|The Study of Etiology, Epidemiology and Prognostic Factors of Acute Kidney Injury||Huashan Hospital|Yes|Recruiting|April 2009|August 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|1ml whole blood and 1ml serum will obtained within 24 hour after AKI for hematological and      biochemistry analyze.|Both|16 Years|88 Years|No|Non-Probability Sample|Patients selected from a university-affiliated hospital in Shanghai, China.|August 2009|June 9, 2010|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953992||135092|
NCT00921102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEST-OST-01|Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia for Caesarean Section|Intrathecal Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia With Morphine for Elective Caesarean Section: a Randomized Controlled Trial||University of Parma|No|Completed|May 2007|May 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|216|||Female|18 Years|N/A|No|||June 2009|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921102||137588|
NCT00954369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W372000|Exploratory and Safety Study of [F-18]W372|A Phase 0, Open Label, Non-randomized, Multi-center, Exploratory and Safety Study of [F-18]W372||Siemens Molecular Imaging|No|Completed|August 2009|February 2010|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|24|||Both|55 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 21, 2012|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00954369||135064|
NCT00954902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G264|Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)|Development of a Dynamic Model of Inflammation for Studying the Anti-inflammatory Effects of Culinary Spices in Human Participants|Spice|Penn State University|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|32|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2011|August 16, 2011|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954902||135023|
NCT00943072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0819|Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)|A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion||Regeneron Pharmaceuticals|Yes|Completed|July 2009|April 2012|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|July 10, 2009|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT00943072||135927|
NCT00943852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-317|The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)|A Double-Blind, Randomized, Placebo-Controlled, 5-Period Crossover Study to Evaluate the Effects of a Single Dose of Losartan, a Single Dose of Isosorbide Mononitrate (ISMN), and Single Doses of Losartan + ISMN on Central Blood Pressure Measurements in Mildly Hypertensive Patients||Merck Sharp & Dohme Corp.||Completed|August 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|5||Actual|13|||Both|45 Years|70 Years|No|||April 2015|April 6, 2015|July 21, 2009|No|Yes||No|April 27, 2010|https://clinicaltrials.gov/show/NCT00943852||135867|Due to lower than expected Blood Pressure's in individual patients, an interim analysis was undertaken after 11 patients had completed 3 to 5 of the study periods; enough data was already collected to meet objectives, so the trial was stopped early.
NCT00943319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0132|Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies|A Phase I-II Study of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies||University of Chicago|Yes|Active, not recruiting|March 2012|March 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|124|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|July 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943319||135908|
NCT00943592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14341B|Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies|Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies||University of Chicago|Yes|Completed|March 2006|November 2013|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|75 Years|No|||January 2014|January 9, 2014|July 20, 2009|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT00943592||135887|
NCT00944411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082901|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2009|||||N/A|N/A|N/A||||||||||||||September 1, 2010|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00944411||135824|
NCT00944424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC # 2091-009|Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca|GORG - 002 Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer|GORG-002|King Faisal Specialist Hospital & Research Center|No|Recruiting|July 2009|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Female|18 Years|N/A|No|||December 2011|December 11, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944424||135823|
NCT00923065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040165|Cancer Care in the National Cancer Institute Center for Cancer Research|Care of the Adult Oncology Patient, CCR, NCI||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2004|||||N/A|Observational|N/A|||Actual|591|||Both|18 Years|100 Years|No|||December 2015|December 30, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923065||137438|
NCT00923078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7008-W|Neurophysiological Targets for Cognitive Training in Schizophrenia|Neurophysiological Targets for Cognitive Training in Schizophrenia||VA Office of Research and Development|No|Completed|November 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923078||137437|
NCT00923416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0136-CE|Trans-Rectal Ultrasound-Guided (TRUS) Adverse Events|A Prospective Quantification of Patient-Reported Adverse Events Following Trans-Rectal Ultrasound-Guided Intra-Prostatic Marker Insertion||University Health Network, Toronto|No|Completed|September 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|||Male|18 Years|N/A|No|Probability Sample|Prostate Cancer Patients who has trans-rectal ultrasound-guided implantation of        intra-prostatic markers for radiotherapy treatment|December 2012|December 18, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923416||137414|
NCT00923052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090079|The Natural History of Solid Organ Cancer Stem Cells (SOCSC)|The Natural History of Solid Organ Cancer Stem Cells (SOCSC)||National Institutes of Health Clinical Center (CC)||Terminated|February 2009|May 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|190|||Both|16 Years|N/A|No|||May 2015|May 8, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923052||137439|
NCT00923403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|555-210|Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II|Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II||University of Manitoba|Yes|Completed|August 2008|January 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2009|June 17, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923403||137415|
NCT00923793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CustomBone vs. Titanium|Comparison of Individual Computer Aided Design/Manufactured (CAD/CAM) - Based Implants Consisting on Hydroxylapatite and Titanium to be Used in Cranioplasty|Comparison of Individual CAD/CAM-based Implants Consisting on Hydroxylapatite and Titanium to be Used in Cranioplasty - a Randomized Multicenter Clinical Trial||University of Leipzig|No|Terminated|June 2009|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|June 17, 2009||No|Recruitment was stopped, due to slow recruitment rate|No||https://clinicaltrials.gov/show/NCT00923793||137391|
NCT00924040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090076|Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia|Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia||National Institutes of Health Clinical Center (CC)|No|Terminated|February 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 17, 2009||No|The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any    new supply.|No|September 20, 2011|https://clinicaltrials.gov/show/NCT00924040||137372|The study of BL22 has expired and MedImmune, the sponsor, is not interested in producing any new supply. All data has been analyzed and reviewed. All patients have been taken off study.
NCT00919867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-115|A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers|A Phase 1, Open-label, Randomized, Three-period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and VYVANSE, Administered Alone and in Combination in Healthy Adult Volunteers||Shire||Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|June 10, 2009|No|Yes||No|July 1, 2010|https://clinicaltrials.gov/show/NCT00919867||137683|
NCT00919880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B04|Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer|A Phase II Randomized Clinical Trial of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer||Peking University|Yes|Completed|July 2009|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Female|18 Years|65 Years|No|||August 2014|August 12, 2014|June 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00919880||137682|
NCT00920088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113045|Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs|A Phase I Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 Pharmacokinetics and to Assess the Effect of GSK2248761 on CYP450 Probe Drugs in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 2, 2010|June 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00920088||137666|
NCT00920140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111759|Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias|An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias||GlaxoSmithKline|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|June 12, 2009|No|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT00920140||137662|
NCT00920153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633503|Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma|Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrene at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma||National Cancer Institute (NCI)||Recruiting|May 2008|||May 2015|Anticipated|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|810|||Both|18 Years|65 Years|No|||April 2010|February 23, 2011|June 12, 2009||||No||https://clinicaltrials.gov/show/NCT00920153||137661|
NCT00919893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4015497|Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)|Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome||University of Giessen|Yes|Completed|December 1999|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|139|||Male|18 Years|65 Years|No|||June 2009|June 15, 2009|February 10, 2009||No||No|February 10, 2009|https://clinicaltrials.gov/show/NCT00919893||137681|
NCT00920127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32227/0001/001|Treatment With AKL1 in Obstructive Airways Disease (The TAKL Study)|An Investigation of the Safety and Efficacy of Oral AKL1 in Patients Diagnosed With Obstructive Lung Disease|TAKL|University of East Anglia|Yes|Active, not recruiting|June 2009|February 2012|Anticipated|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|80 Years|No|||August 2011|August 4, 2011|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920127||137663|
NCT00920842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 7141|Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant|Metabolic Syndrome Following Transplant for Leukemia||Fred Hutchinson Cancer Research Center|Yes|Completed|April 2005|November 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|244|||Both|9 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Childhood leukemia survivors and healthy siblings, 9-21 years of age.|November 2012|November 29, 2012|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920842||137608|
NCT00920751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBIRE-GI-003|Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance|Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance||East Bay Institute for Research and Education|Yes|Recruiting|March 2009|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|100|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2009|June 12, 2009|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920751||137615|
NCT00920764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-815|A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors|A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor||AbbVie|No|Completed|June 2009|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|92|||Both|18 Years|N/A|No|||January 2013|March 26, 2013|June 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920764||137614|
NCT00920777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21592|Survey and Cognitive Behavior Therapy for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|A RCT Study on the Effect of Short and Long Cognitive Behaviour Therapy (CBT) in CFS/ME Patients||Norwegian University of Science and Technology|Yes|Completed|May 2009|May 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|234|||Both|18 Years|62 Years|No|||June 2015|June 9, 2015|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920777||137613|
NCT00921115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11595|Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.|Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer||University of Kansas Medical Center|Yes|Recruiting|May 2009|December 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Female|18 Years|N/A|No|||December 2013|March 31, 2015|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921115||137587|
NCT00921128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090160|Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease|Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Not yet recruiting|June 2009|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|June 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921128||137586|
NCT00954070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E/09/026|Detection of Minimal Change Esophagitis Using Confocal Laser Endomicroscopy|Detection of Minimal Change Esophagitis Using Confocal Laser Endomicroscopy||National University Hospital, Singapore|No|Terminated|August 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|6|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hosipital patients with typical clinical manifestations of gastroesophageal reflux disease        but no endoscopy evidence of esophagitis.|December 2012|December 26, 2012|July 8, 2009||No|Difficulty in recruiting subjects for study|No||https://clinicaltrials.gov/show/NCT00954070||135086|
NCT00954083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194/2550 (EC2)|A Pilot Trial of a Developmental, Individual-Difference, Relationship-Bases (DIR)/Floortime for Children With Autistic Spectrum Disorders|A Pilot Randomized Controlled Trial of a DIR/ Floortime Parent Training Intervention for Pre-school Children With Autistic Spectrum Disorders|DIR|Mahidol University|No|Completed|June 2007|April 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||August 2009|August 5, 2009|August 4, 2009||||No||https://clinicaltrials.gov/show/NCT00954083||135085|
NCT00954668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEAL NSTEMI 1|ImmeDiate Versus EArLy Invasive Approach in Non-ST-Elevation Myocardial Infarction (IDEAL NSTEMI)|ImmeDiate Versus EArLy Invasive Approach in Non-ST-Elevation Myocardial Infarction (IDEAL NSTEMI)|IDEAL NSTEMI|University of Leipzig|Yes|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2100|||Both|18 Years|90 Years|No|||September 2009|June 24, 2010|August 6, 2009||No|No funding|No||https://clinicaltrials.gov/show/NCT00954668||135041|
NCT00954681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5911|Study of Quetiapine Treatment for Cannabis Dependence|Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence|STUC|New York State Psychiatric Institute|Yes|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||December 2012|January 15, 2014|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954681||135040|
NCT00944112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZB/4/698|Restrictive and Liberal Transfusion Strategies in Intensive Care|A Feasibility Randomized Trial Comparing Restrictive and Liberal Blood Transfusion Strategies in Patients Requiring Four or More Days in Intensive Care|RELIEVE|University of Edinburgh|No|Completed|August 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|55 Years|N/A|No|||March 2011|March 7, 2011|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944112||135847|
NCT00944437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICU-ICU-02|Continuous Positive Airway Pressure (CPAP) Ventilation Using a Novel Full-Face Mask Versus Conventional Helmet|Noninvasive Ventilation For Postoperative Acute Respiratory Failure: Comparison of Conventional Helmet With a Novel Full-Face Mask.||University of Parma|No|Terminated|May 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|89 Years|No|||November 2013|November 4, 2013|July 21, 2009||No|Failed to reach expected enrollment by anticipated dates.|No||https://clinicaltrials.gov/show/NCT00944437||135822|
NCT00944125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-08-166|Dual Site Left Ventricular (LV) Pacing|Dual Site LV Pacing Study: Prospective Randomized Blinded Crossover Study of Patients Meeting Current CRT-D Indication to be Implanted With Dual LV Pacing Leads and Paced Chronically for at Least 6 Months Post-implant.|DIVA|Aurora Health Care|No|Terminated|June 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|N/A|No|||March 2016|March 2, 2016|July 17, 2009|No|Yes|for administrative reasons (no safety concerns), no analysis completed|No|February 25, 2015|https://clinicaltrials.gov/show/NCT00944125||135846|Study terminated early form administrative reasons (no safety concerns), no analysis was completed.
NCT00923104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090120|An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin|An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|84|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2016|March 12, 2016|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923104||137435|
NCT00923429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Justina|Trial on Subacute Low Back Pain|A Randomized Controlled Clinical Trial of Stay-Active Care and Manual Therapy Versus Stay-Active Care Only in Subacute Low Back Pain in a Primary Health Care Setting. The Gotland Low Back Pain Study|Justina|Uppsala University|No|Completed|January 1994|December 2000|Actual|December 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|20 Years|55 Years|No|||June 2009|June 17, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923429||137413|
NCT00923806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090047|Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)|Yes|Terminated|December 2008|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|June 17, 2009|Yes|Yes|Study was terminated due to poor accrual.|No||https://clinicaltrials.gov/show/NCT00923806||137390|
NCT00924066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090037|Ixabepilone to Treat Cervical Cancer|A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|November 2008|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|80 Years|No|||May 2014|May 12, 2014|June 17, 2009|Yes|Yes||No|March 13, 2014|https://clinicaltrials.gov/show/NCT00924066||137370|
NCT00919906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|My Scrivener® - Measuring Effectiveness and Dose Response in Children|My Scrivener® - Measuring Effectiveness and Dose Response in Children||Obslap Research LLC|No|Completed|April 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Both|5 Years|19 Years|No|||October 2010|October 27, 2010|June 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00919906||137680|
NCT00920478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN09RH196|Targeting Synovitis in Early Rheumatoid Arthritis|Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments|TaSER|NHS Greater Glasgow and Clyde|No|Recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920478||137636|
NCT00920855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/1063/MM/US|Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma|An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma||Teva Pharmaceutical Industries||Completed|June 2009|December 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|June 11, 2009|Yes|Yes||No|August 15, 2012|https://clinicaltrials.gov/show/NCT00920855||137607|
NCT00920868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010354|XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib|A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.|XAD|Duke University|Yes|Completed|May 2009|August 2014|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00920868||137606|
NCT00920790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-002|Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma|Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma||Kyowa Hakko Kirin Company, Limited|No|Completed|June 2009|November 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|20 Years|N/A|No|||August 2012|August 24, 2012|June 9, 2009||No||No|July 9, 2012|https://clinicaltrials.gov/show/NCT00920790||137612|
NCT00920803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113221|A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases|A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases||GlaxoSmithKline|No|Completed|August 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|N/A|No|||August 2011|August 4, 2011|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920803||137611|
NCT00920816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061051|Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer|AG-013736 (Axitinib) For The Treatment Of Metastatic Renal Cell Cancer||Pfizer|Yes|Active, not recruiting|August 2009|February 2017|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|492|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|June 11, 2009|Yes|Yes||No|July 26, 2013|https://clinicaltrials.gov/show/NCT00920816||137610|The objective of the statistical analysis for secondary endpoints was to summarize data using descriptive statistics without performing any hypothesis testing.
NCT00920829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTON-1R01AA017633-01A1|Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism|Genetic and Brain Mechanisms of Naltrexone?s Treatment Efficacy for Alcoholism||Medical University of South Carolina|Yes|Active, not recruiting|June 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||June 2015|June 4, 2015|June 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920829||137609|
NCT00946335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03177|ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors|A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors||National Cancer Institute (NCI)||Completed|July 2009|June 2014|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|21 Years|No|||June 2014|July 7, 2014|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946335||135676|
NCT00946348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA013196|Cannabis and Schizophrenia: Self-Medication and Agonist Treatment|Cannabis and Schizophrenia: Self-Medication and Agonist Treatment||Dartmouth-Hitchcock Medical Center|Yes|Completed|December 2009|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 26, 2014|July 24, 2009|No|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT00946348||135675|
NCT00954421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461-2006|Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor|Use of Two DBS Electrodes to Treat Post-Traumatic Tremor||University of Florida|Yes|Completed|November 2006|December 2013|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|79 Years|No|||July 2014|July 21, 2014|July 27, 2009|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT00954421||135060|
NCT00954434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M246-08|Effects of Red Wine on Cardiovascular Risk Factors in Humans|||University Hospital, Linkoeping|No|Completed|September 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|44|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||August 2009|June 2, 2015|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954434||135059|
NCT00942773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT09_Vori2C19_A|Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole|Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part A)||Seoul National University Hospital||Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 2, 2010|July 14, 2009||||No||https://clinicaltrials.gov/show/NCT00942773||135950|
NCT00943865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07033|Three Lifestyle Interventions on Endothelial Function and Cardiometabolic Risk in Obese Patients With Metabolic Syndrome|Effect of Three Lifestyle Interventions on Endothelial Function, Anthropometric Parameters and Cardiometabolic Profile in Obese Patients With Metabolic Syndrome: a Randomized Controlled Trial .||Hospital de Clinicas de Porto Alegre|No|Completed|June 2007|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|76|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 21, 2009|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943865||135866|
NCT00943878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0039|Sanofi H1N1 + TIV - Adults and Elderly|Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Healthy Adult and Elderly Populations||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|805|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|July 26, 2012|July 21, 2009|Yes|Yes||No|April 14, 2011|https://clinicaltrials.gov/show/NCT00943878||135865|
NCT00943891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC01/09/08|A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer|A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer||National University Hospital, Singapore|No|Active, not recruiting|July 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1||500|Samples With DNA|CRC and NPC tumor specimens will be obtained.|Both|21 Years|N/A|No|Non-Probability Sample|Colorectal and nasopharyngeal cancer.|January 2014|January 21, 2014|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943891||135864|
NCT00944138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMISE#0001|8-week Pilot Study of Relaxation for Weight Loss in Adults With Chronic Kidney Disease|Randomized 8-week Pilot Study of Relaxation Methods for Weight Loss in Adults With Chronic Kidney Disease||Edward Hines Jr. VA Hospital||Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|88 Years|No|||July 2009|July 26, 2010|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944138||135845|
NCT00922805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMG-108061|Fiber Use in Pediatric Short Bowel Syndrome|Soluble Fiber Use in Pediatric Short Bowel Syndrome||Arkansas Children's Hospital Research Institute|No|Withdrawn|January 2009|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|1 Year|No|||January 2014|January 14, 2014|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922805||137458|
NCT00923117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080168|Sunitinib to Treat Recurrent Brain Cancer|A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas||National Institutes of Health Clinical Center (CC)|Yes|Terminated|June 2008|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||July 2014|September 29, 2015|June 17, 2009|Yes|Yes|The study was terminated based on results of an interim analysis for futility.|No|May 3, 2013|https://clinicaltrials.gov/show/NCT00923117||137434|The study was terminated based on results of an interim analysis for futility.
NCT00923130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090057|Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer|A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|December 2008|April 2016|Anticipated|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|99 Years|No|||June 2015|March 2, 2016|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00923130||137433|
NCT00923819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4XL-2009|4XL Study - Obesity Surgery in Adolescence|4XL-Study - Obesity Surgery in Adolescence|4XL|Sykehuset i Vestfold HF|No|Recruiting|June 2009|December 2027|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|13 Years|18 Years|No|||November 2015|November 16, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923819||137389|
NCT00924079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAL001|The Development of Oral Nalbuphine Dosage Form|Pharmacokinetic Study of Oral Nalbuphine in Normal Healthy Subjects|NAL|Tri-Service General Hospital|Yes|Recruiting|September 2008|||November 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|60|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 18, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924079||137369|
NCT00924092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090101|An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...|Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma||National Institutes of Health Clinical Center (CC)||Completed|March 2009|August 2012|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00924092||137368|
NCT00955227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:054|Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels|Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels||University of Manitoba|No|Active, not recruiting|July 2009|December 2015|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|60|||Both|18 Years|80 Years|No|||December 2014|December 2, 2014|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955227||134998|
NCT00919620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jcep-rct|Stage-specific Case Management for Early Psychosis|Outcome of Stage-specific Early Intervention for Psychosis in Hong Kong: A Randomized Controlled Study||The University of Hong Kong|No|Recruiting|June 2009|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Both|25 Years|55 Years|No|||January 2010|January 13, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919620||137701|
NCT00919633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4316001|Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C|COPE-HCV: Continuous Interferon Delivery Via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV|COPE-HCV|Medtronic Corporate Technologies and New Ventures|Yes|Completed|June 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|116|||Both|18 Years|65 Years|No|||March 2014|March 28, 2014|June 10, 2009|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00919633||137700|
NCT00919919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fr003|Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen|Efficacy & Tolerability of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Replacement Therapy - Phase II Comparative Study||Rabin Medical Center|No|Not yet recruiting|June 2009|November 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|45 Years|60 Years|No|||June 2009|June 11, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00919919||137679|
NCT00920166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-CL3-001|Evaluation of Safety, Growth, Tolerance and Effects on the Intestinal Fora of a New Milk for Healthy Infants|Growth and Tolerance in New Born Fed Formula Supplemented With Alpha-Lactalbumin and Containing a Symbiotic|Pétunia|Sodilac|No|Completed|February 2007|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|97|||Both|N/A|8 Days|No|||June 2009|June 12, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920166||137660|
NCT00920452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-SITE FF 0209|The 4-SITE Field Following Study (4-SITE FF)|RELIANCE QUADRIPOLAR DEFIBRILLATION LEADS (4-SITE)FIELD FOLLOWING The 4-SITE Field Following Study (4-SITE FF)|4-SITE FF|Guidant Corporation|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|430|||Both|18 Years|N/A|No|Probability Sample|Study Population: Patients should be selected from the investigator's general population        indicated for an ICD or CRT-D Implantation. The investigator has the responsibility of        screening all potential patients and selecting those who meet study eligibility criteria.|November 2010|December 3, 2012|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920452||137638|
NCT00920465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-10-2007|Treatment Regimens for Mifegyne and Cytotec|Comparison of the Effectiveness of Abortive Measures From the Administration of Mifegyne and Cytotec at One and Two Visits||Western Galilee Hospital-Nahariya|No|Recruiting|June 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|50 Years|No|||November 2010|May 24, 2011|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920465||137637|
NCT00921414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manteau 2007 SJ "LYMA"|Mantel Cell Lymphoma Efficacy of Rituximab Maintenance|Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL||French Innovative Leukemia Organisation|Yes|Completed|September 2008|March 2016|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|299|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00921414||137564|
NCT00920881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS05-066|Clinical Evaluation of the Accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System|Protocol #TS05-066 Clinical Evaluation of the Accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System||Abbott Diabetes Care|No|Completed|November 2005|December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects recruited from clinical research centers which specialize in diabetes-related        therapies.|June 2009|June 11, 2009|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920881||137605|
NCT00942799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ28200108|Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors|A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors||Sanofi|No|Completed|July 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|July 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942799||135948|
NCT00946647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589H2101|A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).|A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).||Novartis||Recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|111|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|July 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946647||135652|
NCT00942474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#1632|Nerve Access Tool Study|A Prospective, Non Randomized, Single-center, Non-blinded Feasibility Study Examining the Use of a Nerve Access Tool||MedtronicNeuro|No|Withdrawn|October 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Female|18 Years|N/A|No|||February 2014|February 18, 2014|July 20, 2009|No|Yes|Medtronic made a business decision to discontinue the study and withdraw the IDE.|No||https://clinicaltrials.gov/show/NCT00942474||135972|
NCT00943332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0819|Pediatric Femur Research Project|Pediatric Femur Research Project||Washington University School of Medicine|No|Active, not recruiting|June 2009|June 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|145|||Both|2 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will have undergone of the following interventions for the treatment of the femur        fracture: spica casting, nancy nailing, or submuscular plating, by a participating        physician in the trial. All of these treatments are considered standard of care for this        pediatric population.|June 2015|June 10, 2015|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00943332||135907|
NCT00944164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-06-C40|Primary Care Obesity Prevention and Treatment|Test the Feasibility of Primary Care Obesity Prevention and Treatment - Pilot Study||University of Washington|Yes|Completed|September 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|176|||Both|5 Years|9 Years|No|||July 2009|July 21, 2009|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00944164||135843|
NCT00944177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40483|Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects|||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|N/A||||July 2009|July 22, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944177||135842|
NCT00945282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113020|Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.|A Proof of Concept Study for GSK2248761 (An Extension of NV-05A-002: A Phase I/IIa Double-Blind Study to Evaluate the Safety and Tolerability, Antiretroviral Activity, Pharmacokinetics and Pharmacodynamics of IDX12899 in Antiretroviral Treatment-Naive HIV-1 Infected Subjects, Completed by Idenix)||ViiV Healthcare|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|21 Years|65 Years|No|||March 2012|May 30, 2013|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945282||135757|
NCT00943605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK VP-00074|PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Mastectomy|A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade™ 4.0 in Mastectomy|PRECISE|Medtronic Surgical Technologies|No|Terminated|June 2009|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Female|20 Years|70 Years|No|||January 2013|January 3, 2013|July 21, 2009|Yes|Yes|Termination due to acquisition of PEAK Surgical by Medtronic|No|November 29, 2012|https://clinicaltrials.gov/show/NCT00943605||135886|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.
NCT00943618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0850|Combining Varenicline and Bupropion for Smoking Cessation|Effectiveness of Varenicline vs. Varenicline Plus Bupropion or Placebo for Smoking Cessation||M.D. Anderson Cancer Center|Yes|Active, not recruiting|May 2010|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|385|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|July 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00943618||135885|
NCT00944463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-065|Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients|Randomized Double-blinded, Placebo-controlled Phase II Trial of Simvastatin and Gemcitabine in Advanced Pancreatic Cancer Patients||Samsung Medical Center|No|Active, not recruiting|October 2008|March 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944463||135820|
NCT00923468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080223|Pharmacokinetic Studies Participation Survey|ADVL08N1: A Pharmacokinetic Participation Questionnaire Study||National Institutes of Health Clinical Center (CC)||Completed|September 2008|||August 2009|Actual|N/A|Observational|Time Perspective: Prospective||||25|||Both|18 Years|N/A|No|||August 2009|September 2, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923468||137411|
NCT00923481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090138|A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...|A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors||National Institutes of Health Clinical Center (CC)|No|Completed|April 2009|January 2012|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2012|September 29, 2015|June 17, 2009|Yes|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00923481||137410|
NCT00954447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.36|Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy||Boehringer Ingelheim||Completed|August 2009|||September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1263|||Both|18 Years|N/A|No|||October 2012|December 4, 2013|August 6, 2009||||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00954447||135058|
NCT00923442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040102|Biology Studies of Hematologic Cancers|Hematologic Malignancy Biology Study||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|January 2004|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|148|||Both|N/A|75 Years|No|||November 2015|December 15, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923442||137412|
NCT00924105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT013-IL1bQb 01|Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes|A Two-Stage Randomized Placebo-controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 Beta Vaccine (CYT013-IL1bQb) in Patients With Type 2 Diabetes Mellitus||Cytos Biotechnology AG|Yes|Completed|June 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|69 Years|No|||February 2012|February 10, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00924105||137367|
NCT00951704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08116|Evaluation of the Quality of Cardio-Pulmonary Resuscitation (CPR) in Cardiac Arrest Patients|Evaluating the Quality of Prehospital and In-hospital Cardio-pulmonary Resuscitation by Reviewing Defibrillator Records - Comparing the Compressions to Concurrent Vital Signs (Invasive Blood Pressure, Cerebral Oxygen Saturation, EtCO2) and Iatrogenic Injuries Associated to Chest Compressions.||Tampere University Hospital|Yes|Recruiting|November 2008|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Adult population >18 years of age with cardiac arrest|April 2013|April 15, 2013|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951704||135263|
NCT00951717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1062|Using a Preparation and Education Intervention to Reduce Postpartum Depression Among New Mothers (The MADE IT 2 Study)|Preparation and Patient Education to Reduce Postpartum Depressive Symptoms||Icahn School of Medicine at Mount Sinai|Yes|Completed|July 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|590|||Female|18 Years|N/A|No|||November 2011|November 18, 2011|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951717||135262|
NCT00955500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(HG)61/2002|Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy|Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|January 2003|January 2009|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|116|||Both|18 Years|85 Years|No|||August 2009|August 7, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00955500||134977|
NCT00951392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.547|Implication of Metabolic and Genomic Modifications in Elderly Subjects|Implication of Metabolic and Genomic Modifications in Elderly Subjects|COMPALICLAMP|Hospices Civils de Lyon|No|Completed|May 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|35|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 8, 2010|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951392||135287|
NCT00951691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH083868|Enhanced Medical Rehabilitation for Disablement|Enhanced Acute Medical Rehabilitation for Disablement||Washington University School of Medicine||Completed|August 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|60 Years|N/A|No|||September 2012|March 18, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951691||135264|
NCT00921167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCST-L-0006|A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas|A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme||Clinical Research Center for Solid Tumor, Korea|No|Completed|June 2009|December 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|June 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00921167||137583|
NCT00952419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUF15|A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years|Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years||Sanofi|No|Completed|August 2009|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|474|||Both|6 Months|9 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|August 3, 2009|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00952419||135208|
NCT00952445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-131-004|A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus||InteKrin Therapeutics, Inc.|No|Completed|December 2003|June 2004|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|30 Years|75 Years|No|||August 2009|August 5, 2009|August 4, 2009||Yes||||https://clinicaltrials.gov/show/NCT00952445||135206|
NCT00942812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235-Ped/ERC-09|Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack|A Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack(Comprising of Low Osmolality ORS, Zinc Tablets, Water Purification Tablets and Pictorial Chart) on Childhood Diarrhea.||Aga Khan University|Yes|Completed|July 2009|September 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7200|||Both|2 Months|59 Months|No|||July 2009|August 9, 2011|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942812||135947|
NCT00942825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBP08-02|Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)|Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Locally Advanced (Stage IIIB With Malignant Pleural Effusion or Pericardial Effusion) or Metastatic (Stage IV) Non-squamous Non Small Cell Lung Cancer (NSCLC)|CBP08-02|CanBas Co. Ltd.|No|Completed|April 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942825||135946|
NCT00943085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077856|Early Family-Focused Treatment for Youth at Risk for Bipolar Disorder|Family-Focused Therapy as Early Treatment for Youth at Risk for Bipolar Disorder||University of California, Los Angeles|No|Completed|April 2007|August 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|52|||Both|9 Years|17 Years|No|||March 2014|March 24, 2014|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943085||135926|
NCT00943345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-034|Validation of New Tests for Gastrointestinal (GI) Permeability|Dubbelblind Crossover Study for Validation of New Tests for Gastrointestinal (GI) Permeability|Permeability|Maastricht University Medical Center|Yes|Enrolling by invitation|September 2009|February 2012|Anticipated|February 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|34|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|July 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00943345||135906|
NCT00945295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allergan-100808|Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity|Open-label, Parallel Study to Determine the Efficacy and Safety of Botulinum Neurotoxin A Paired With Rehabilitation Therapy vs. Botulinum Neurotoxin A Alone for the Treatment of Post-stroke Upper Limb Spasticity||Biomedical Research Institute of New Mexico|No|Completed|January 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|March 30, 2009||No||No|August 20, 2013|https://clinicaltrials.gov/show/NCT00945295||135756|This has a single-blind design. Admittedly, a double-blind design is best, but the participants could not be blind to the assignment of rehabilitation. Secondly, the study involved a relatively small sample size and limited follow-up duration.
NCT00945035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-070|Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)|An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of the 20% and 30% Etoricoxib (MK0663) Formulations||Merck Sharp & Dohme Corp.||Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|July 22, 2009|No|Yes||No|October 13, 2009|https://clinicaltrials.gov/show/NCT00945035||135776|
NCT00943631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0053|Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|406|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|October 25, 2012|July 21, 2009|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00943631||135884|
NCT00922519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-FLU-001/ethics 24765|Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body Positron Emission Tomography (PET) Scans for Imaging Bone|An Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body PET Scans in Patients for Whom 99m Tc MDP Bone Scans Would Normally be Indicated.||AHS Cancer Control Alberta|No|Recruiting|June 2009|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9999|||Both|15 Years|N/A|No|Non-Probability Sample|Patients for whom 99mTc MDP bone scans would normally be indicated|October 2014|October 1, 2014|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922519||137480|
NCT00954096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|707275|Nicotine Patch, Blood Flow and Oxidative Stress Study|The Effect Of Nicotine On Indices Of Arterial Function And Oxidative Stress||University of Pennsylvania|No|Completed|October 2002|December 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|55|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 23, 2009|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954096||135084|
NCT00955240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642638|Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer|Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 2009|||||Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|||Anticipated|77|||Both|18 Years|80 Years|No|||July 2011|July 8, 2011|August 7, 2009||||No||https://clinicaltrials.gov/show/NCT00955240||134997|
NCT00924118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00023049|Sodium Nitrite in Acute Myocardial Infarction|A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Prevention of Ischemia-Reperfusion Injury Associated With Acute Myocardial Infarction.||Johns Hopkins University|Yes|Recruiting|July 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|75 Years|No|||March 2016|March 24, 2016|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924118||137366|
NCT00951951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0001|Gait Analysis of Anterior Versus Posterior Approach in Performance of Total Hip Arthroplasty|Gait Analysis of Anterior vs. Posterior Approach in Performance of Total Hip Arthroplasty: A Multi-Centre, Prospective Trial||Medacta USA|Yes|Completed|June 2009|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|40 Years|N/A|No|||June 2015|June 25, 2015|July 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951951||135244|
NCT00951938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01005A|Trinity Evolution in Anterior Cervical Disectomy and Fusion (ACDF)|A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells (Trinity Evolution™ Viable Cryopreserved Cellular Bone Matrix) in Patients Undergoing Anterior Cervical Discectomy and Fusion||Orthofix Inc.|No|Completed|August 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subject selection will be conducted by patient's neurosurgeon or orthopedic surgeon.|April 2014|April 7, 2014|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951938||135245|
NCT00952484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-006-09|Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)|A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)||Alexion Pharma GmbH|Yes|Completed|September 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|5 Years|12 Years|No|||May 2014|May 27, 2014|August 3, 2009|Yes|Yes||No|May 14, 2011|https://clinicaltrials.gov/show/NCT00952484||135203|
NCT00920491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED UHBS|Biomarker-enhanced ED Disposition Decisions|BANC4 (BASEL NON - SPECIFIC COMPLAINTS 4) Biomarker-enhanced Disposition Decisions|BANC4|University Hospital, Basel, Switzerland|Yes|Completed|July 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|400|Samples Without DNA|whole blood (MR-proADM)|Both|18 Years|N/A|No|Non-Probability Sample|The protocol of the BANC study specifies that patients are consecutively enrolled in order        to obtain a random sample of the source population of ED self-referred and referred        patients with UC|December 2014|December 12, 2014|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920491||137635|
NCT00952458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2094/08|Bispectral Index Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography|Bispectral Index Monitoring as an Adjunct to Standard Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography|EndoBISs|Technische Universität München|No|Completed|July 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|144|||Both|18 Years|N/A|No|||May 2010|August 23, 2012|August 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00952458||135205|
NCT00953017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2009.209|A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy|A Randomized, Blinded Trial Comparing Miralax With Amitiza Pretreatment Versus Miralax With Dulcolax Pretreatment Versus Miralax Alone Without Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy||Brooke Army Medical Center|Yes|Completed|July 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Actual|425|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 1, 2012|August 5, 2009||No||No|September 6, 2012|https://clinicaltrials.gov/show/NCT00953017||135163|Indication for colonoscopy was restricted to colorectal cancer screening. Patients admitted to the hospital were not included. Polyp detection rates could have been influenced by unequal randomization of high-risk and low-risk patients for adenomas.
NCT00943371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6349-002|A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)|A Double-Blind, Randomized, Placebo-Controlled, Single and Divided Rising-Dose, Sequential Panel Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK6349 in Subjects With Type 2 Diabetes||Merck Sharp & Dohme Corp.||Terminated|August 2007|May 2009|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|No|||August 2015|August 26, 2015|July 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00943371||135904|
NCT00943644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17-05|Pre-biopsy With Dynamic Acquisitions|Determination of Sensitivity of a Dual-Headed Small Field of View Gamma Camera for the Detection of Small Breast Lesions||Mayo Clinic|Yes|Completed|August 2005|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|185|||Female|18 Years|N/A|No|Non-Probability Sample|Patients that are scheduled to have a biopsy at the Mayo Clinic in Rochester, MN and have        a lesion less the 2 cm|December 2011|December 14, 2011|November 10, 2008||No||No||https://clinicaltrials.gov/show/NCT00943644||135883|
NCT00943098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09PUK-DCsc05|Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery|Efficacy and Safety of a Single s.c. Diclofenac HPBCD 75mg/1ml Injection as Compared to a Single i.m. Voltarol® 75mg/3ml, in the Treatment of Acute Moderate-to-severe Post-surgical Pain Following Dental Surgery (Impacted 3rd Molar Removal).||IBSA Institut Biochimique SA|No|Completed|September 2009|May 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|65 Years|No|||December 2012|December 17, 2012|July 21, 2009||No||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00943098||135925|
NCT00943657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|720901|Yearly Strain Variation Study, 2009/2010|An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult and Elderly Population||Nanotherapeutics, Inc.|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 7, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943657||135882|
NCT00943683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-176|Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 6 to 24 Months With Asthma||Merck Sharp & Dohme Corp.||Completed|August 2000|February 2001|Actual|February 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|6 Months|24 Months|No|||June 2015|June 22, 2015|July 21, 2009|No|Yes||No|July 27, 2009|https://clinicaltrials.gov/show/NCT00943683||135880|
NCT00943904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-6799|Comparison of Motor and Sensory Response With Interstim Stimulation|Comparison of Motor and Sensory Response With Interstim Stimulation for Overactive Bladder and Urgency-Frequency Syndrome||University of California, Irvine|Yes|Completed|July 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Female|18 Years|N/A|No|||July 2013|July 18, 2013|July 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943904||135863|
NCT00945048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-MA|Non-Invasive Determination of Cardiac Output by Electrical Velocimetry|Non-Invasive Determination of Cardiac Output by Electrical Velocimetry Compared With Magnetic Resonance Tomography and Inert Gas Rebreathing Method||Universitätsmedizin Mannheim||Completed|June 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients with indication for CMR|January 2013|January 15, 2013|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00945048||135775|
NCT00945880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIG-101|Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive|A Phase 1b, Open Label Study of the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of 100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days Immediately Prior to Initiation of Treatment With HCV Standard of Care Therapy in Treatment-Naïve Subjects Chronically Infected With HCV|CLEAN-1|Eiger BioPharmaceuticals|No|Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|55 Years|No|||February 2011|February 24, 2011|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945880||135711|
NCT00944151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP Catheter|Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia|Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia: A Randomized, Triple-Masked, Placebo-Controlled Study||University of California, San Diego|No|Terminated|July 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2009|May 19, 2014|July 21, 2009|Yes|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT00944151||135844|
NCT00923156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2252|Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure|ESCAPE-SHF: A Double-blind, Double-dummy, Randomized, Multicenter, Parallel Group Study to Evaluate the Effects of Aliskiren, Ramipril and Combination Treatment on Plasma Concentration of Angiotensin II in Patients With Decompensated Systolic Heart Failure|ESCAPE-SHF|Novartis||Completed|May 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|123|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|June 17, 2009|Yes|Yes||No|February 1, 2012|https://clinicaltrials.gov/show/NCT00923156||137432|
NCT00923169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060200|Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)|A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti-Transforming Growth Factor-Beta (TGFBeta) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma||National Institutes of Health Clinical Center (CC)||Completed|July 2006|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2012|October 9, 2014|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00923169||137431|
NCT00954707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-6301|CYPRESS - CYPHER for Evaluating Sustained Safety|A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)||Cordis Corporation|Yes|Active, not recruiting|August 2009|March 2016|Anticipated|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2509|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|August 6, 2009|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT00954707||135038|
NCT00954941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0615|Ondansetron Versus Aprepitant Plus Ondansetron for Emesis|Comparative Trial Ondansetron Alone Versus Combination of Ondansetron Plus Aprepitant for Prevention of Nausea and Vomiting With Hematologic Malignancies Receiving Regimens Containing High-dose Cytarabine||M.D. Anderson Cancer Center|Yes|Completed|November 2009|May 2015|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|August 6, 2009||No||No|November 26, 2013|https://clinicaltrials.gov/show/NCT00954941||135020|
NCT00954954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHOSKNEE01-RPRPF|Outcomes After Standard and High-Flexion Posterior Stabilized Rotating-Platform Mobile-Bearing Total Knee Arthroplasty|Outcomes After Standard and High-Flexion Posterior Stabilized Rotating-Platform Mobile-Bearing Total Knee Arthroplasty: A Prospective Randomized Comparative Study||Seoul National University Hospital|No|Completed|October 2006|July 2009|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|170|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2009|August 6, 2009|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954954||135019|
NCT00951171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO_IUI|Effect of Cervical Occlusion During Intrauterine Insemination (IUI)|Evaluation of the Effect of Cervical Occlusion During Infertility Treatment by Intrauterine Insemination||Women and Infants Hospital of Rhode Island|No|Terminated|February 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|July 31, 2009||No|Randomization flawed. Results were poor in the innovative catheter group|No|July 10, 2012|https://clinicaltrials.gov/show/NCT00951171||135304|Randomization method found to be faulty
NCT00923832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090109|Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis|Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis||National Institutes of Health Clinical Center (CC)||Completed|March 2009|November 2009||||N/A|Observational|Time Perspective: Prospective|||||||Both|1 Year|N/A|No|||November 2009|November 25, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923832||137388|
NCT00923845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080088|Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer|Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells||National Institutes of Health Clinical Center (CC)|Yes|Active, not recruiting|March 2008|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|June 17, 2009|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT00923845||137387|Because the primary objective was not achieved, further accrual to the protocol was stopped at this point.
NCT00954928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0567|The Safety of Hand Surgery in the Anticoagulated Patient|The Safety of Hand Surgery in the Anticoagulated Patient||Washington University School of Medicine|No|Completed|June 2009|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|398|||Both|18 Years|N/A|No|Non-Probability Sample|Adults over 18 years of age having hand surgery while on anti-coagulant medication.        Control subjects undergoing hand and wrist surgery without anticoagulant medications will        be enrolled if they are over 18 years of age and able to consent to research        participation. Patients on Coumadin with INR values less than or equal to 3.5 will be        eligible for study inclusion.|June 2015|June 26, 2015|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954928||135021|
NCT00951457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT CLL-6 BendAlem|Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)|Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) - A Phase I/II Trial With Concomitant Evaluation of Safety and Efficacy||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Active, not recruiting|March 2009|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951457||135282|
NCT00952198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-403-102|A Safety Study of ARRY-403 in Patients With Type 2 Diabetes|||Array BioPharma|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|70 Years|No|||August 2012|August 29, 2012|August 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00952198||135225|
NCT00952211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL091848|Burden of Obstructive Sleep Apnea in Stroke (BOSAST)|Burden of Obstructive Sleep Apnea in Stroke (BOSAST)|BOSAST|University of California, San Diego|Yes|Terminated|August 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|10|||Both|45 Years|85 Years|No|||December 2015|December 16, 2015|August 3, 2009||No|problems with recruitment|No||https://clinicaltrials.gov/show/NCT00952211||135224|
NCT00951964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-APN-01|Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)|Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)||Centre Hospitalier Universitaire de Nice|No|Completed|October 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|2 Years|N/A|No|||May 2014|May 6, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951964||135243|
NCT00952224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leipzig MR 1|Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome|Prognostic Significance and Determinants of Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance in Acute Reperfused Myocardial Infarction||University of Leipzig|No|Completed|November 2006|March 2009|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|267|||Both|18 Years|N/A|No|Probability Sample|Cohort of patients with ST-elevation myocardial infarction undergoing primary percutaneous        coronary intervention|August 2009|August 4, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952224||135223|
NCT00952172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-2314-B-182-032-MY3|Stair Stepping Exercise Training in Patients With Obstructive Sleep Apnea Syndrome|Effectiveness of Stair Stepping Exercise Training on Cardiopulmonary Fitness and Sleep Situation in Patients With Obstructive Sleep Apnea Syndrome||Chang Gung Memorial Hospital|Yes|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|47|||Both|19 Years|60 Years|No|||August 2009|August 4, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952172||135227|
NCT00951925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0529|Protocol to Obtain Bone Marrow for Research|Protocol to Obtain Bone Marrow for Research||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|June 2005|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples With DNA|5cc of bone marrow aspirate|Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Patients undergoing diagnostic bone marrow biopsies at the Norris Cotton Cancer             Center of Dartmouth Hitchcock Medical Center (DHMC).          -  Patients undergoing bone marrow harvesting for autologous bone marrow             transplantation.|October 2015|October 8, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951925||135246|
NCT00953329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002474|Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy|An Open-Label Study to Determine the Safety and Efficacy of Alefacept as Monotherapy in Subjects With Chronic Plaque Psoriasis Who Have Failed to Respond to Anti-TNF Therapy||Duke University|No|Terminated|February 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||February 2013|February 20, 2013|July 22, 2009|Yes|Yes|Subjects declined enrollment; sponsor/PI elected to close study.|No|October 18, 2012|https://clinicaltrials.gov/show/NCT00953329||135142|Early termination due to one patient enrolled . The patient stopped the study because she was not improved and desired alternative treatment.
NCT00943137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK01/06/09|The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer|The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer||National University Hospital, Singapore|No|Active, not recruiting|June 2009|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|21 Years|80 Years|No|||June 2015|June 17, 2015|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00943137||135922|
NCT00943384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chronOS-050709|Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate|Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate Plus Local Bone for Posterolateral Lumbar Interbody Fusion or Lumbosacral Interbody Fusion||Synthes USA HQ, Inc.|No|Completed|July 2009|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|July 21, 2009|No|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT00943384||135903|Limitations included lack of control arm, no hypothesis for primary endpoint, & qualitative sample size estimate. chronOS Strip was used according to its FDA-cleared labeling; other usage was outside the study scope and was not evaluated clinically.
NCT00943397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-232|Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)|A Multicenter, Open-Label, Controlled, Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma||Merck Sharp & Dohme Corp.||Completed|April 2001|November 2001|Actual|October 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|6 Months|2 Years|No|||July 2015|July 1, 2015|July 21, 2009|Yes|Yes||No|July 27, 2009|https://clinicaltrials.gov/show/NCT00943397||135902|
NCT00943670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM4688g|Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression|A Phase II, Open-Label Study to Evaluate Corrected QT Interval Effects of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and to Evaluate the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression While Receiving T-DM1 Alone||Genentech, Inc.||Completed|July 2009|August 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||May 2013|May 23, 2013|July 19, 2009|Yes|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00943670||135881|
NCT00945009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN0534|Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor|Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor||Children's Oncology Group|Yes|Suspended|July 2009|||October 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|260|||Both|N/A|29 Years|No|||July 2015|July 27, 2015|July 22, 2009|Yes|Yes|Temporarily stopped for assessment|No||https://clinicaltrials.gov/show/NCT00945009||135778|
NCT00945022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL - 01|Evaluation of Safety and Efficacy of Using Lipsus Device for Oral Wetting|Evaluation of Safety and Efficacy of Using Lipsus Device for Oral Wetting||IMD Tech Ltd|No|Not yet recruiting|October 2011|April 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2009|June 8, 2011|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00945022||135777|
NCT00945893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP215|A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of MEDI3414 in Adults|MI-CP215|MedImmune LLC|Yes|Completed|August 2009|March 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|July 23, 2009|Yes|Yes||No|June 17, 2011|https://clinicaltrials.gov/show/NCT00945893||135710|
NCT00944476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-078|Application of Magnetic Resonance Fat-Free Imaging|Application of Magnetic Resonance Fat-Free Imaging||Memorial Sloan Kettering Cancer Center||Terminated|July 2009|||May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential research participants from those patients who are/will be scheduled for MRI        examination as part of their routine clinical care at MSKCC. Dr. Singer will also identify        four volunteers with no history of sarcoma to participate in this study.|May 2014|May 13, 2014|July 22, 2009||No|Software issues not resolved.|No||https://clinicaltrials.gov/show/NCT00944476||135819|
NCT00953797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4112|Role of Enhanced External Counterpulsation (EECP) Therapy in Patients With Resistant Hypertension|Role of EECP Therapy in Patients With Resistant Hypertension|EECP|Albert Einstein Healthcare Network|No|Withdrawn|May 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||January 2012|January 25, 2012|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00953797||135106|
NCT00953810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/115/2003/101/1304|Educational Intervention in Heart Failure Patients|RandomiZed AmbulatOry Interventional ProgrAm in Heart Failure PatieNts (ZOPAN)|ZOPAN|Institute of Cardiology, Warsaw, Poland|No|Completed|April 2004|January 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|822|||Both|18 Years|N/A|No|||August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953810||135105|
NCT00954720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-413|Observational Study of Iron Overload in Stem Cell Transplantation|A Prospective Observational Study of Iron Overload in Patients With Acute Leukemia or Myelodysplastic Syndromes Undergoing Myeloablative Allogeneic Stem Cell Transplantation||Dana-Farber Cancer Institute|No|Completed|March 2008|May 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|Samples With DNA|Banked serum and mononuclear cells|Both|18 Years|65 Years|No|Probability Sample|Patient's who are 18 years or older with acute leukema or MDS underdoing a myeloablative        allogeneic stem cell transplant|February 2013|February 26, 2013|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954720||135037|
NCT00954694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328-09-FB|Analysis of the NuStep as an Introductory Fitness Regimen|Assessing the Impact of an Introductory Exercise Regimen: An Analysis of the Consequent Effects of NuStep in Relation to Physical Activity and Lifestyle Adjustment in Adults With Type 1 and Type 2 Diabetes||University of Nebraska|No|Not yet recruiting|August 2009|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|19 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 6, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954694||135039|
NCT00951418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.5-15 July 2008|Serum Clozapine and Cognition|Serum Clozapine and Cognition||University of Aarhus|No|Completed|June 2009|September 2013|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|65 Years|No|Non-Probability Sample|ICD-10 Schizophrenia (f20.0-3; F20.9) treated with clozapine|August 2013|September 11, 2013|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951418||135285|
NCT00951197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2008/13|Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects|Estimation of Microstructure Alteration by MRI in Dementia Among Elderly Subjects Retired From Agricultural Profession and Living in Rural Area in Gironde - Participants From the AMI Cohort.|AMIMAGE|University Hospital, Bordeaux|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|318|||Both|65 Years|N/A|No|Non-Probability Sample|population retired from agricultural profession and living in rural area in Gironde|April 2012|April 27, 2012|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00951197||135302|
NCT00951990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vffr-37|Ergometer Cycling After Replacement of the Hip or Knee Joint|A Multicenter Randomized Controlled Trail of Ergometer Cycling After Hip and Knee Replacement Surgery||Verein zur Förderung der Rehabilitationsforschung in Schleswig-Holstein|Yes|Completed|January 2005|August 2008|Actual|April 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|457|||Both|18 Years|N/A|No|||April 2010|April 6, 2010|August 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00951990||135241|
NCT00951743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID Laboratories 001|Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)|Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in the Blood Cellular Reservoir (PBMCs) of HIV Patients With Suppressed Plasma Viral Load.||Rapid Laboratories Inc.||Recruiting|July 2009|July 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|July 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951743||135260|
NCT00951756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK83981|Controlled Feeding Experiment|Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Composition|CaFE|University of Pennsylvania|No|Completed|July 2009|August 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 22, 2013|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951756||135259|
NCT00951769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1001/3|Algorithms in a Simulated Difficult Intubation Scenario|A Comparison of the Difficult Airway Society (UK) and Australian Patient Safety Foundation Crisis Algorithms for Difficult Intubation in a Simulated Difficult Intubation Scenario||Aintree University Hospitals NHS Foundation Trust|No|Completed|March 2009|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Trainee anaesthetists in for 2 years of training|August 2009|January 14, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951769||135258|
NCT00952185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08121|Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers|Clinical Correlates of Immunologic Responses to the Flu Vaccine||City of Hope Medical Center|Yes|Terminated|November 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|August 4, 2009|No|Yes|Very low enrollment and follow-up, cannot meet study objectives|No||https://clinicaltrials.gov/show/NCT00952185||135226|
NCT00952471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11-34|Reduction in Clinical Variance Using Targeted Design Changes in Computerized Provider Order Entry Order (CPOE) Sets|Reduction in Clinical Variance Using Targeted Design Changes in Computerized Provider Order Entry Order (CPOE) Sets||Children's Research Institute|No|Completed|September 2004|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|458|||Both|N/A|N/A|No|||May 2015|May 19, 2015|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00952471||135204|
NCT00952731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWU07-9-02|4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ|Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast||Northwestern University|Yes|Completed|December 2009|||September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|N/A|No|||July 2015|July 18, 2015|August 4, 2009|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT00952731||135184|The study was originally designed to enroll 112 participants, unfortunately, the shelf-life of the study drug expired which resulted in early closure of the study after only 31 participants.
NCT00952757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00008|Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine|Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine: a Naturalistic, Prospective, Multicentric Observational Study of 6 Months Follow-up||Investigaciones Médicas Montejo S.L.|Yes|Completed|June 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|50 Years|No|Non-Probability Sample|Adult patients diagnosed with schizophrenia or bipolar disorder who developed APS-related        hyperprolactinaemia and were switched to quetiapine based on the clinician's judgement|August 2009|August 5, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952757||135182|
NCT00944489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAR-ATA-2009/1|To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension|Hypertension and Health-Related Quality of Life Adherence: Cross- Sectional Observational Study in Ambulatory Patients|ADHERENCE|AstraZeneca|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1150|||Both|21 Years|N/A|No|Probability Sample|clinic and private practice|December 2010|December 6, 2010|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00944489||135818|
NCT00944775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenalRehab|Exercise and Cardiac Measures in Dialysis Patients|Effects of Exercise Training on Non-invasive Cardiac Measures in Patients Undergoing Long-term Hemodialysis: A Randomized Controlled Trial||Aristotle University Of Thessaloniki|Yes|Completed|August 2007|June 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|63|||Both|18 Years|70 Years|No|||June 2009|July 22, 2009|April 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00944775||135796|
NCT00944788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FICE09071|A Structured Qi-gong Program for Hospitalized Older Adults|Feasibility and Impact on Quality of Life and Depressive Symptoms of a Structured Qi-gong Program for Hospitalized Older Adults. A Pilot Study.||Fundacio Salut i Envelliment UAB||Completed|July 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|58|||Both|50 Years|N/A|No|||June 2013|June 12, 2013|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944788||135795|
NCT00944801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNOP-09|Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma|RNOP-09: Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma - a Phase II Study||University of Regensburg|Yes|Completed|July 2002|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|70 Years|No|||July 2009|July 21, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00944801||135794|
NCT00945347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIG-99|Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?|Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind Placebo-controlled Study.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|July 2009|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|10|||Both|14 Years|N/A|No|||August 2011|August 9, 2011|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945347||135752|
NCT00945568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEN-0901|Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life|Preoperative Oral Supplementation With Carbohydrate and Branched-chain Amino Acid-enriched Nutrient Improves Postoperative Quality of Life in Patients Undergoing a Hepatectomy|KMS|Kochi University|Yes|Completed|May 2007|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|N/A|N/A|No|||July 2009|July 23, 2009|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945568||135735|
NCT00945581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK37|Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery|Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery||Abbott Nutrition|Yes|Completed|November 2009|March 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||March 2011|March 28, 2011|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945581||135734|
NCT00954109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-051-07S|Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals With Insulin Resistance|Physical Inactivity and Insulin Resistance in Skeletal Muscle||VA Office of Research and Development|No|Completed|August 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|30 Years|65 Years|No|||April 2015|April 3, 2015|August 4, 2009||No||No|January 8, 2015|https://clinicaltrials.gov/show/NCT00954109||135083|
NCT00954122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00074|Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia|A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia||AstraZeneca|No|Completed|September 2009|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|65 Years|No|||January 2013|January 7, 2013|August 6, 2009|Yes|Yes||No|May 18, 2011|https://clinicaltrials.gov/show/NCT00954122||135082|
NCT00955253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1234|Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance|A Trial of Guanfacine, an Alpha 2 Adrenergic Agonist, for Spatial Neglect and Impaired Vigilance Following Stroke and Focal Brain Damage|GASNIV|Imperial College London|Yes|Completed|April 2010|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2011|June 3, 2015|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955253||134996|
NCT00955266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000052|A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass|A Randomized Double-Blind Placebo-Controlled Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass||Brigham and Women's Hospital|Yes|Terminated|July 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|July 30, 2009||No|Inadequate recruitment|No||https://clinicaltrials.gov/show/NCT00955266||134995|
NCT00955513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOPO-P-307|Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Placebo-controlled, 3-treatment Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain||Novartis|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|242|||Both|18 Years|N/A|No|||January 2011|April 18, 2012|August 7, 2009|Yes|Yes||No|December 1, 2010|https://clinicaltrials.gov/show/NCT00955513||134976|
NCT00951405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7128-1907|Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors|An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of Prophylactic Administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients With Inhibitors||Novo Nordisk A/S|Yes|Completed|September 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|23|||Male|12 Years|65 Years|No|||June 2014|June 26, 2014|August 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951405||135286|
NCT00951730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808017|Evaluation of a Simplified Method for Diagnosis of Sleep Apnea in Children and Adults With Down Syndrome|Evaluation of a Simplified Method for Diagnosis of Sleep Apnea in Children and Adults With Down Syndrome|SAOS/T21|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2010|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|97|||Both|2 Years|N/A|No|Non-Probability Sample|Patients with Down syndrome|July 2015|July 3, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951730||135261|
NCT00951444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0823|Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without MK-0646 as First-Line Therapy in Advanced Squamous Non-Small Cell Lung Carcinoma||Alliance for Clinical Trials in Oncology||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|August 1, 2009|Yes|Yes|The study was not activated.|No||https://clinicaltrials.gov/show/NCT00951444||135283|
NCT00951795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0510|Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts|Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts||Biosite|No|Withdrawn|September 2009|September 2009||September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The intended study population is individuals with confirmed diagnosis of HIV infection ≥        12 years of age presenting to a physician's office or outpatient clinic.|July 2015|July 20, 2015|August 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951795||135256|
NCT00951470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0363|Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema|Lymphedema in Patients With Oral Cavity and Oropharyngeal Cancer: Prevalence, Functional Effects, and Treatment Outcomes||M.D. Anderson Cancer Center|No|Withdrawn|October 2012|||October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951470||135281|
NCT00952536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHAM-NSA-05-001 vs 11|Effect of Dietary Intake of Dried Whole Food Concentrates (Juice Plus) on Clinical Outcomes Following Periodontal Therapy: A Pilot Study|The Effect of Daily Dietary Intake of Dried Whole Food Concentrates of Fruit, Vegetables and Berries (Juice Plus+) in Improving Clinical Outcomes Following Non-surgical Periodontal Therapy: a Pilot Study.|BHAM-NSA-05-01|Birmingham Community Healthcare NHS|No|Completed|February 2005|December 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952536||135199|
NCT00952744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOPIN|Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction|Copeptin Helps in the Early Detection Of Patients With Acute Myocardial|CHOPIN|Brahms AG|No|Completed|August 2009|October 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2071|Samples Without DNA|Plasma samples|Both|18 Years|N/A|No|Probability Sample|Patients presenting to the ED with symptoms consistent with acute coronary syndromes.|January 2012|January 16, 2012|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00952744||135183|
NCT00953030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DP000094|Cost Effective Health Promotion for Older Adults|Cost Effective Health Promotion for Older Adults||University of Illinois at Chicago|No|Completed|September 2004|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label|3||Actual|423|||Both|40 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953030||135162|
NCT00953043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001438|Lubiprostone, Colonic Motility and Sensation|The Effect of Lubiprostone, a Chloride Channel Activator, on Colonic Sensorimotor Functions in Healthy Subjects. A Phase IV, Placebo-Controlled, Parallel Group Study||Mayo Clinic|Yes|Completed|September 2007|July 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|August 4, 2009|Yes|Yes||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00953043||135161|This study was conducted in healthy subjects and needs replication in patients with Irritable Bowel Syndrome.
NCT00952523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-7190|Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face|An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products (Retin-A Micro Gel, 0.04% Pump and Epiduo Gel) Using a Split-Face Model||Valeant Pharmaceuticals International, Inc.|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|August 4, 2009|Yes|Yes||No|January 26, 2010|https://clinicaltrials.gov/show/NCT00952523||135200|
NCT00944203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMEC09-031|Efficacy of Ipomea Pes-caprae Ointment as an add-on Therapy in Patient With Jellyfish Dermatitis|Efficacy of Ipomea Pes-caprae Ointment as an add-on Therapy in Patient With Jellyfish Dermatitis||Mahidol University|No|Recruiting|July 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944203||135840|
NCT00944216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP|Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study|Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study||Wright State University|Yes|Terminated|June 2009|January 2010||January 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|January 19, 2010|July 21, 2009|||terminated due to administrative reasons.|No||https://clinicaltrials.gov/show/NCT00944216||135839|
NCT00944502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E03-BUN-VITD-02/07|To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins|Multicenter Clinical Study, Phase III, Prospective, Randomized, Double-blind, Comparative to Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins||Bunker Industria Farmaceutica Ltda.|Yes|Not yet recruiting|October 2009|December 2009|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||July 2009|July 23, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944502||135817|
NCT00944515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|394/2551(EC4)|Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children|Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children : A Prospective, Randomized, Double-blind, Placebo Controlled Trial.||Mahidol University|Yes|Completed|August 2009|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|5 Years|15 Years|No|||March 2016|March 15, 2016|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944515||135816|
NCT00945607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-IM-01|Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer|Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer|09-IM-01|Trinitas Comprehensive Cancer Center|No|Active, not recruiting|July 2009|||July 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Female|18 Years|75 Years|No|||July 2011|July 21, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945607||135732|
NCT00945087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTF-1|Experimental Phage Therapy of Bacterial Infections|Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections||Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences||Recruiting|December 2005|||||N/A|Interventional|N/A|||||||Both|18 Years|N/A|No|||August 2013|September 5, 2013|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00945087||135772|
NCT00945308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97/09|Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients|Effectiveness of Intracoronary Injection of Eptifibatide as Adjunctive Antiplatelet Therapy in Primary Coronary Intervention in Patients With ST Segment Elevation Acute Myocardial Infarction.|ICE|Assaf-Harofeh Medical Center|No|Not yet recruiting|August 2009|February 2010|Anticipated|February 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||July 2009|July 23, 2009|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00945308||135755|
NCT00954486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-15270|Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia|An Open-Label, Single-Arm Pilot Study of the Efficacy of Erythropoietin Alfa in Improving Peak Oxygen Consumption in Elderly Subjects With Unexplained Anemia||Stanford University|No|Withdrawn|December 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||March 2016|March 23, 2016|August 5, 2009|No|Yes|Difficulty in identifying interested subjects.|No||https://clinicaltrials.gov/show/NCT00954486||135055|
NCT00954499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0019|Reducing Pain in Four- to Six-month Old Infants Undergoing Immunization Using a Multi-modal Approach|Reducing Pain in Four- to Six-month Old Infants Undergoing Immunization Using a Multi-modal Approach||Women's College Hospital|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|4 Months|6 Months|Accepts Healthy Volunteers|||February 2011|February 28, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00954499||135054|
NCT00954746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-860|Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859|CORDLESS- Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study||Endo Pharmaceuticals|No|Completed|July 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|645|Samples Without DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with Advanced Dupuytren's Disease Previously Treated with AA4500 in Studies        AUX-CC-854, AUX-CC-856, AUX-CC-857/AUX-CC-858, and AUX-CC-859|June 2015|June 12, 2015|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954746||135035|
NCT00954993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-029|Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)|A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK-7009 in Hepatitis C Infected Patients||Merck Sharp & Dohme Corp.|No|Terminated|January 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|40 Years|65 Years|No|||September 2015|September 1, 2015|August 6, 2009|No|Yes|This study was stopped for business and program changes. At no time was the safety of any    participants at risk.|No|September 26, 2014|https://clinicaltrials.gov/show/NCT00954993||135016|
NCT00951431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFP|Gastric Functions & Proton Pump Inhibitor( PPI) Study|Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia||Chinese University of Hong Kong|No|Recruiting|December 2009|December 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2011|February 18, 2011|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951431||135284|
NCT00955279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016405|A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis|A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis||Centocor, Inc.|Yes|Completed|November 2009|August 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|173|||Both|18 Years|85 Years|No|||June 2014|June 18, 2014|August 6, 2009|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT00955279||134994|
NCT00955292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3-07-002|Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas|A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Quarfloxin Administered Intravenously Weekly for Three Weeks of a Four Week Cycle in Patients With Advanced Solid Tumors or Lymphomas||Cylene Pharmaceuticals|No|Terminated|July 2007|December 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|August 7, 2009|Yes|Yes|Modified dose schedule presented no advantage over previously studied schedule|No||https://clinicaltrials.gov/show/NCT00955292||134993|
NCT00951509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6035-R|Virtual Reality Based Testing of Power Wheelchair Driving Skills|Computer-based and Virtual Assessment of Power Wheelchair Mobility||VA Office of Research and Development|No|Completed|August 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|31|||Both|18 Years|80 Years|No|Non-Probability Sample|People with physical disabilities who have a mobility impairment due to any any spinal        cord disease condition (e.g. Spinal Cord Injury, Spina Bifida)|July 2015|July 28, 2015|August 3, 2009||No||No|November 7, 2014|https://clinicaltrials.gov/show/NCT00951509||135278|
NCT00952263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-HCV1-09-01|Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C|Open-Label, Dose Escalation Phase I Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (MBL-HCV1) Against Hepatitis C E2 Glycoprotein|MBL-HCV1|MassBiologics|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 23, 2009|August 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00952263||135220|
NCT00952276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUF16|A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly|Immunogenicity and Safety of Multiple Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects||Sanofi|No|Completed|October 2009|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|548|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 26, 2011|August 3, 2009|Yes|Yes||No|August 26, 2011|https://clinicaltrials.gov/show/NCT00952276||135219|
NCT00952289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 18424-351|COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial|A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis||Incyte Corporation|Yes|Completed|August 2009|October 2015|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|309|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|August 4, 2009|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT00952289||135218|
NCT00952237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0227|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF||Dartmouth-Hitchcock Medical Center|Yes|Completed|January 2003|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00952237||135222|
NCT00952497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEL0805|A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer|A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer||ACT Biotech, Inc|No|Completed|June 2009|January 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00952497||135202|
NCT00952510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-069|Maastricht Neck Study: Cervical Range of Motion in Whiplash Patients|MaNeS (Maastricht Neck Study): Development of Chronic Disability in Neck Pain Patients After a Motor Vehicle Accident|MaNeS|Maastricht University Medical Center|Yes|Terminated|September 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|The population is based on 100 whiplash patients which underwent a measurment of the        cervical movements and gave permission to recontact them for further research.|April 2011|April 19, 2011|August 4, 2009||No|Respond was to low.|No||https://clinicaltrials.gov/show/NCT00952510||135201|
NCT00945061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11107|Radiation Therapy in Treating Patients With Recurrent Breast Cancer|Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation||Case Comprehensive Cancer Center|Yes|Active, not recruiting|September 2008|||May 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945061||135774|
NCT00945321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-165|A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)|A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects||Merck Sharp & Dohme Corp.||Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|July 23, 2009|No|Yes||No|April 22, 2010|https://clinicaltrials.gov/show/NCT00945321||135754|
NCT00945334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18709|Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome|Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome|C-IBS|Cedars-Sinai Medical Center|Yes|Completed|August 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|75 Years|No|||July 2015|July 17, 2015|July 23, 2009|Yes|Yes||No|February 25, 2015|https://clinicaltrials.gov/show/NCT00945334||135753|
NCT00945074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7833948|Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)|Protocol- vs. Patient-Oriented TCM Practices: A RCT for IBS Symptom Management|Acu/MoxaIBS|New York University|No|Active, not recruiting|July 2009|December 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|171|||Both|18 Years|70 Years|No|||September 2014|September 24, 2014|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00945074||135773|
NCT00946218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DENGEN|Diagnosis and Characterization of Dengue Fever in Children|Diagnosis and Characterization of Dengue Fever in Children||St. Jude Children's Research Hospital|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|258|||Both|6 Months|11 Years|No|Probability Sample|Children subject presenting to Benjamin Bloom Children's Hospital in San Salvador, El        Salvador.|October 2011|October 3, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00946218||135685|
NCT00954460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-GCB-058|Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease|Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease||Shire||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|3 Years|N/A||||February 2014|February 19, 2014|August 5, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00954460||135057|
NCT00954473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST08B1|Study of Blood Samples From Patients With Osteosarcoma|Retrospective Study of Genetic Risk Factors for Osteosarcoma||Children's Oncology Group|No|Recruiting|January 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1000|Samples With DNA|blood|Both|N/A|N/A|No|Probability Sample|All osteosarcoma patients seen at COG institutions are eligible|November 2015|November 16, 2015|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954473||135056|
NCT00954980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14632|Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins|Evaluation of Clinical Characteristics of Endovenous Sclerotherapy of Varicose Veins||University of Oklahoma|No|Active, not recruiting|May 2009|December 2014|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood samples will be obtained for measurement of D-dimer, fibrin monomer, and total      microparticles.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Vascular or primary care clinic patients who have been scheduled to undergo an endovenous        sclerotherapy procedure|December 2014|December 2, 2014|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954980||135017|
NCT00955305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01960|Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer|A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-squamous, Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 2010|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||July 2015|December 31, 2015|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955305||134992|
NCT00955318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6500-003|Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease|Phase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's Disease||Kyowa Hakko Kirin Company, Limited||Completed|July 2009|March 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|N/A|No|||August 2012|August 30, 2012|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955318||134991|
NCT00951210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202-2|Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)|Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.||Pluristem Ltd.|Yes|Completed|August 2009|October 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|81 Years|No|||November 2011|May 24, 2015|August 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00951210||135301|
NCT00951223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIFN 003|Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C|Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen® (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus|REACHSVR|Kadmon Pharmaceuticals|Yes|Withdrawn|August 2009|April 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from Community Gastrointestinal Practices as well as Academic Centers will be        asked to participate|September 2015|September 1, 2015|August 3, 2009||No|Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT00951223||135300|
NCT00951184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0841|Depression Screening in Patients Undergoing Radiation Therapy For Cancer|Efficiency of Screening for Depression in Cancer Patients Receiving Radiotherapy||Radiation Therapy Oncology Group|Yes|Completed|May 2009|November 2014|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|463|||Both|21 Years|N/A|No|Non-Probability Sample|Adult (at least age 21) cancer patients who are undergoing radiation therapy for their        first diagnosis of cancer with no mental incompetence which would preclude completion of        questionnaires, who is not considered suicidal or psychotic or otherwise unfit for study        participation. Patient must provide study-specific consent prior to screening.|March 2015|March 17, 2015|August 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00951184||135303|
NCT00951782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234-CTIL|Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation|Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease (COPD)|TMS|BeerYaakov Mental Health Center|No|Completed|October 2009|May 2013|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|115|||Both|21 Years|70 Years|No|||December 2013|December 19, 2013|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00951782||135257|
NCT00954564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650647|Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors|Arthralgia and Medication Adherence in Women With Early Stage Breast Cancer Taking Aromatase Inhibitors: The Breast Cancer Adjuvant Therapy (BCAT) Longitudinal Cohort Study.||Vanderbilt University|No|Recruiting|June 2009|June 2017|Anticipated|June 2014|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|580|||Female|35 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Postmenopausal women with breast cancer initiating aromatase inhibitor therapy|June 2013|June 11, 2013|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954564||135049|
NCT00952003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT GASTRIC-3|Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients|Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Active, not recruiting|July 2009|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952003||135240|
NCT00952016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3107|Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency|A Non-randomised Phase II Trial of Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency|MESH|Royal Marsden NHS Foundation Trust|Yes|Recruiting|February 2009|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||August 2009|December 3, 2013|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00952016||135239|
NCT00951977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELIVE-04|Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study|Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|7029|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants who have either donated a kidney or control subjects who are matched to have        similar demographics and health condition a donor in the study.|September 2012|September 12, 2012|July 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00951977||135242|
NCT00952250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010526|Targeted Feedback Reports to Improve Acute Coronary Syndromes (ACS) Care|Personalized and Targeted Feedback in the ACTION-Registry-GWTG||Duke University|No|Completed|February 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|149|||Both|18 Years|90 Years|No|||December 2011|December 1, 2011|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00952250||135221|
NCT00953095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G09-02-016-01|Social and Communication Outcomes for Young Children With Autism|Optimizing Social and Communication Outcomes for Young Children With Autism||Health Resources and Services Administration (HRSA)|No|Completed|April 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|112|||Both|24 Months|60 Months|No|||September 2014|September 22, 2014|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953095||135159|
NCT00944827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-22/846/06-2007|Combination Treatment With Green Tea Extract and Statins in Patients With Hypercholesterolemia|The Effects of Catechin Supplementation (Green Tea Extract), in Combination With the Classic Treatment for the Reduction of Hypercholesterolemia (Statin Therapy) on the Treatment's Effectiveness and in the Reduction of Classic Side Effects.|GTE-Stat|University of Thessaly|No|Completed|September 2007|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|65 Years|No|||July 2009|December 2, 2010|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944827||135792|
NCT00944840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1124|Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia|A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia||Gates Malaria Partnership|No|Completed|September 2008|August 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1312|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||July 2010|July 1, 2010|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944840||135791|
NCT00945633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27036|Dietary, Physiological, Genetic, and Behavioral Predictors of Health in a Young, Ethnically-Mixed Population|Dietary, Physiological, Genetic, and Behavioral Predictors of Health in a Young, Ethnically-Mixed Population|InSight|Pennington Biomedical Research Center|No|Active, not recruiting|June 2008|August 2023|Anticipated|August 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||12|Anticipated|1200|Samples With DNA|Archival repository|Both|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The 1200, free-living participants age 20-35 will be equally divided by gender and race        (Caucasian and African-American). Among the participants, 1/3 will have no obese parent,        1/3 will have one obese parent, and 1/3 will have two obese (body mass index, BMI > 30        kg/m2) parents.|February 2016|February 4, 2016|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945633||135730|
NCT00945646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FST201-AFOE-02|FST-201 In The Treatment of Acute Fungal Otitis Externa|A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Clinical Study Evaluating the Efficacy Of FST-201 (Dexamethasone 0.1%) Otic Suspension in Subjects With Acute Fungal Otitis Externa||Shire|No|Terminated|July 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||September 2012|September 14, 2015|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945646||135729|
NCT00945984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LESSRNx|Laparoendoscopic Single-site Radical Nephrectomy for Localized Renal Cell Carcinoma|Comparison of Laparoendoscopic Single-site Radical Nephrectomy With Conventional Laparoscopic Radical Nephrectomy for Localized Renal Cell Carcinoma|LESS|Seoul National University Hospital|Yes|Active, not recruiting|March 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|36|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Tertiary care center|July 2009|July 25, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945984||135703|
NCT00945620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC01TAP|Trans-Abdominis Plane Block Efficacy for Post-Cesarean Section Pain|Trans-Abdominis Plane Block Efficacy for Post-Cesarean Section Pain: A Randomized Double-Blinded Case Control Trial||Vanderbilt University|No|Withdrawn|September 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|40 Years|No|||June 2015|June 4, 2015|July 22, 2009||No|PI was unable to locate appropriate population|No||https://clinicaltrials.gov/show/NCT00945620||135731|
NCT00954512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04722|Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)|A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722)||Merck Sharp & Dohme Corp.|No|Terminated|September 2009|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 23, 2009|No|Yes|This study was terminated for business reasons.|No|November 18, 2015|https://clinicaltrials.gov/show/NCT00954512||135053|
NCT00955019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-002322|Novel Method of Surveillance in Barrett's Esophagus|Novel Method of Surveillance in Barrett's Esophagus||Mayo Clinic|Yes|Completed|October 2007|September 2009|Actual|August 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples Without DNA|cytology specimens|Both|18 Years|90 Years|No|Non-Probability Sample|patients with barretts esophagus|September 2009|September 14, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00955019||135014|
NCT00955344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K22CA133186-01|Increasing Primary Care Physician Colorectal Cancer Screening Rates|Increasing Primary Care Physician Colorectal Cancer Screening Rates||University of Pennsylvania|No|Not yet recruiting|September 2009|August 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|134|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2009|August 7, 2009|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955344||134989|
NCT00955006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 076|Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals|A Phase 1b Clinical Trial to Evaluate Mucosal Immune Responses to a DNA Plasmid Vaccine Prime Followed by an HIV-1 Adenoviral Vector Boost in Healthy Adenovirus Type 5 Seronegative HIV-1-uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|May 2011|||September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955006||135015|
NCT00951496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01956|Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma||National Cancer Institute (NCI)|No|Active, not recruiting|July 2009|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1500|||Female|18 Years|N/A|No|||January 2016|March 22, 2016|August 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951496||135279|
NCT00955097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Definity 08.0119|Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors|Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors|Definity®|University of Louisville|No|Terminated|May 2008|May 2010|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|August 6, 2009|Yes|Yes|No funding for this study|No||https://clinicaltrials.gov/show/NCT00955097||135008|
NCT00955110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202-402|Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)|An Exploratory, Single-Dose, Double-Blind, Randomized, Placebo-Controlled Crossover Study to Evaluate The Subjective and Objective Effects of Extended-Release Oxymorphone Compared to Controlled-Release Oxycodone in Healthy Non-Dependent Recreational Opioid Users||Endo Pharmaceuticals|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|78|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|August 5, 2009|No|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00955110||135007|
NCT00951808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|668|Preventing Acute Chest Syndrome by Transfusion Feasibility Study|Preventing Acute Chest Syndrome by Transfusion Feasibility Study( PROACTIVE Feasibility Study)|PROACTIVE|New England Research Institutes|Yes|Completed|July 2009|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|237|||Both|2 Years|N/A|No|||April 2013|April 16, 2013|July 31, 2009||No||No|April 25, 2012|https://clinicaltrials.gov/show/NCT00951808||135255|The feasibility study has been completed, but the randomization trial has been terminated early due to the lack of enrollment. Therefore, the results were reported with the subjects who completed the feasibility study and were not reported by Arm.
NCT00955383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112359|GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects|A Single Centre, Randomised, Double-blind, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2190915 in Healthy Japanese Subjects.||GlaxoSmithKline||Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 19, 2010|August 6, 2009||||No||https://clinicaltrials.gov/show/NCT00955383||134986|
NCT00951834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-AK|Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease|Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease|SUN-AK|Charite University, Berlin, Germany|No|Completed|October 2009|February 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|60 Years|N/A|No|||January 2016|January 20, 2016|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951834||135253|
NCT00952783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-031|A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study|A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Areas (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-020||Peplin|No|Completed|July 2009|October 2010|Actual|October 2010|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have achieved complete clearance of AK lesions (lesion count of 0) at Day 57        in study PEP005-020|March 2015|March 25, 2015|August 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00952783||135180|
NCT00952796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMU-IRB-970389|A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections|A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections||Kaohsiung Medical University Chung-Ho Memorial Hospital||Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||January 2009|August 1, 2011|March 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00952796||135179|
NCT00952822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060702|Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection|A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients||Baxalta US Inc.|Yes|Completed|September 2008|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|2 Years|65 Years|No|||June 2011|June 26, 2015|August 4, 2009|No|Yes||No|October 28, 2010|https://clinicaltrials.gov/show/NCT00952822||135178|
NCT00952835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOV-1716|Evaluation of Different Disease Control Indices in Children With Asthma and Rhinitis|Evaluation of Different Disease Control Indices in Children With Asthma and Rhinitis||Universita di Verona|No|Recruiting|July 2009|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|5 Years|N/A|No|Probability Sample|children with asthma and/or rhinitis visited at the outpatients clinic at the University        of Verona will be invited to participate to the study|June 2013|June 18, 2013|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952835||135177|
NCT00952575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADNC-0726|Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers|A Phase II, Open-label, Randomised, Dose-finding Study to Compare the Efficacy (in Terms of Clearance of RhD-positive RBCs) and Safety of LFB-R593, a Monoclonal Anti-RhD Antibody vs a Polyclonal Anti-RhD Immunoglobulin in Healthy RhD Negative Volunteers||Laboratoire français de Fractionnement et de Biotechnologies|Yes|Completed|August 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|78|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952575||135196|
NCT00953108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUE/09|Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients|Impact of Quetiapine Prolong and Escitalopram on the Hypothalamic-pituitary-adrenocortical (HPA)-Axis Activity in Depressed Patients||Ludwig-Maximilians - University of Munich|No|Completed|September 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953108||135158|
NCT00953121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016712|Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)|Phase II Study of Bevacizumab Plus Irinotecan and Carboplatin for Recurrent Malignant Glioma Patients||Duke University|No|Completed|September 2009|January 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|August 4, 2009|Yes|Yes||No|June 21, 2013|https://clinicaltrials.gov/show/NCT00953121||135157|
NCT00944229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD7501|The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure|Salutary Effects of Dietary Supplementation With OMEGA 3 on Exercise Performance and Endothelial Function in Patients With Congestive Heart Failure. A Matter of Lipid Oxidation ?||Columbia University|No|Terminated|January 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|February 12, 2009|Yes|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT00944229||135838|
NCT00944541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011171-76|Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration|Pilot Study Evaluating Maraviroc (Celsentri®)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO|145 MARIMUNO|French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|September 2009|January 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944541||135814|
NCT00944554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00019900|Relapse Prevention With Varenicline|Relapse Prevention With Varenicline|0815|Johns Hopkins University|Yes|Completed|October 2008|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2009|May 31, 2012|July 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00944554||135813|
NCT00944567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG26|A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma|A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma||International Extranodal Lymphoma Study Group (IELSG)|No|Completed|January 2007|||May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125||tissue|Both|18 Years|N/A|No|Non-Probability Sample|patient must have histological confirmation of the diagnodis of primary mediastinal        diffuse large B cell lymphoma and have a dominant mass within the anterior mediastinum|November 2013|November 5, 2013|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944567||135812|
NCT00945659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK080831|Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control|Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control|CGM-Teens|Nemours Children's Clinic|Yes|Completed|August 2009|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|121|||Both|11 Years|16 Years|No|||December 2015|December 3, 2015|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945659||135728|
NCT00945971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc010-09CTIL|Exercise Effects in Children With Attention Deficit Hyperactivity Disorder|Catecholamine and Cognitive Response to Exercise in Children With Attention Deficit Hyperactivity Disorder||Meir Medical Center|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||October 2015|October 25, 2015|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00945971||135704|
NCT00945997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00.0427L|Misoprostol for Second Trimester Termination of Pregnancy|Mifepristone (RU 486) and Misoprostol for Second Trimester Termination of Pregnancy. A Comparison of Two Different Dose Regimens.|MIMIS|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|October 2000|March 2005|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|176|||Female|16 Years|60 Years|No|||July 2009|July 23, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945997||135702|
NCT00954616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07033|Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly|Inappropriate Medications and Alzheimer Disease: Prevalence and Associated Factors in Elderly Patients Treated With Anticholinesterase and/or Memantine. MIDA Study.|MIDA|University Hospital, Limoges|No|Completed|January 2009|January 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|636|||Both|75 Years|N/A|No|Probability Sample|Patient of 75 and more years old affected by the Alzheimer's disease|August 2009|March 19, 2014|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00954616||135045|
NCT00945360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGY.AN.08|Aromatase Inhibitors for Treatment of Uterine Leiomyomas|Aromatase Inhibitors for the Prevention of the Growth of Uterine Leiomyomas in Perimenopausal Women: A Pilot Study||American University of Beirut Medical Center|Yes|Withdrawn|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|50 Years|55 Years|No|||July 2009|July 12, 2012|July 23, 2009|No|Yes|Inability to recruit patients|No||https://clinicaltrials.gov/show/NCT00945360||135751|
NCT00945373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 09-0839|Combination Therapy for the Treatment of Rosacea|Combination Therapy for the Treatment of Erythematotelangiectatic Rosacea||Marmur, Ellen, M.D.|No|Completed|July 2009|October 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945373||135750|
NCT00954785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP 34251|Etoricoxib in Acute Ankle Ligament Sprains|The Efficacy and Safety of Administration of the COX-2 Selective NSAID, Etoricoxib (120mg od. for 7 Days) Compared to Diclofenac (50 mg Tds. for 7 Days) and Placebo as Adjunct Treatment in the First 7 Days of Treatment of Acute Grade II Lateral Ankle Ligaments Sprains: A Clinical Trial||University of Cape Town|Yes|Withdrawn|November 2009|July 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|June 19, 2013|August 6, 2009|Yes|Yes|The study was terminated by Merck USA. The company did not supply drugs for the study.|No||https://clinicaltrials.gov/show/NCT00954785||135032|
NCT00954798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF07|A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly|Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly Subjects||Sanofi|No|Completed|August 2009|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00954798||135031|
NCT00954759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT Colic|The Effect of Chiropractic Treatment on Infantile Colic A Randomized, Controlled Trial|The Effect of Chiropractic Treatment on Infantile Colic A Randomized, Controlled Trial||Nordic Institute of Chiropractic and Clinical Biomechanics|No|Terminated|September 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|N/A|10 Weeks|No|||November 2012|November 6, 2012|August 6, 2009||No|Abandoned due to poor recruitment|No||https://clinicaltrials.gov/show/NCT00954759||135034|
NCT00954772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00056229|Mood and Subthalamic Nucleus (STN) Deep Brain Stimulation|Mood and STN Deep Brain Stimulation|MOST|University of Florida|No|Completed|July 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|91|||Both|18 Years|90 Years|No|Non-Probability Sample|Parkinson's patients who undergo STN DBS|August 2009|November 30, 2011|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954772||135033|
NCT00955331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETeMP|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2015|||||N/A|N/A|N/A||||||||||||||January 12, 2015|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955331||134990|
NCT00951483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201880|Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients|Cardiovascular Biomarkers During Quetiapine Treatment of Depression||Loyola University|No|Completed|July 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|65 Years|No|||October 2012|October 29, 2012|July 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951483||135280|
NCT00951236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIUCLEI 09-01|Study Comparing One Versus Two Cortisone Injections for Trigger Finger|A Prospective, Randomized Study Comparing One vs. Two Cortisone Injections for Trigger Finger||Rothman Institute Orthopaedics|No|Recruiting|May 2009|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|392|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|July 31, 2009||||No||https://clinicaltrials.gov/show/NCT00951236||135299|
NCT00951262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20090205002|Intervention Study on Life Review Among Advanced Cancer Patients in Fuzhou, China|Development and Evaluation of a Life Review Program for Advanced Cancer Patients in Fuzhou, China||The Hong Kong Polytechnic University|Yes|Completed|February 2009|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|N/A|No|||August 2009|February 10, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951262||135297|
NCT00951288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SafAMD|Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration|Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration|safAMD|Catholic University of the Sacred Heart|No|Enrolling by invitation|June 2009|December 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|55 Years|N/A|No|||July 2015|July 31, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951288||135295|
NCT00955396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113210|Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure|A Randomized, Double-blind, Placebo-controlled Cross-over Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure||GlaxoSmithKline||Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 7, 2010|August 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955396||134985|
NCT00951548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL-UC-03|Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis|Food Supplementation With the Probiotic Preparation VSL#3 as a Support to Standard Pharmaceutical Therapy in Patients With Mild to Moderate Active Ulcerative Colitis. A Double-blind, Randomized, Placebo Controlled Study||VSL Pharmaceuticals|Yes|Completed|October 2006|October 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|144|||Both|18 Years|N/A|No|||August 2009|August 3, 2009|August 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00951548||135275|
NCT00952328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H49316-34032-01|Effect of Early Limited Formula Use on Breastfeeding Outcomes|Effect of Early Limited Formula Use on Breastfeeding Outcomes|ELF|University of California, San Francisco|No|Completed|August 2009|April 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||April 2014|April 9, 2014|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00952328||135215|
NCT00952549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FYTP|Facial Yoga Toning Program - A Pilot Study|Facial Yoga Toning Program - A Pilot Study||The Cleveland Clinic|Yes|Terminated|August 2009|September 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 15, 2010|August 4, 2009||No|Investigator no longer at Cleveland Clinic|No||https://clinicaltrials.gov/show/NCT00952549||135198|
NCT00952562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7. juli 2009, version 1|The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals|The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals. A Randomised Double Blinded Placebo Controlled Trial.||Roskilde County Hospital|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 23, 2011|August 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00952562||135197|
NCT00952588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00009|Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients|A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)|SPARK-AML1|AstraZeneca||Completed|July 2009|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|60 Years|N/A|No|||February 2014|February 13, 2014|August 4, 2009|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT00952588||135195|
NCT00952848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000644516|Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy|The Efficacy of MC5-A ("Scrambler") Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial||Virginia Commonwealth University|Yes|Completed|June 2009|June 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|18 Years|N/A|No|||April 2013|April 26, 2013|August 4, 2009|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT00952848||135176|
NCT00944242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40485|Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fasting Conditions|||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|N/A||||July 2009|July 22, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944242||135837|
NCT00945386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005418|The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission|The Effect of Continuous, Various Dosages of Furosemide Drip on Hearing as Measured by Acoustic Emission||Rabin Medical Center|No|Not yet recruiting|August 2009|August 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|1 Month|18 Years|No|Non-Probability Sample|critically ill children in pediatric ICU.|July 2009|July 23, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945386||135749|
NCT00954343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2456/09|Shockwave Treatment of Diabetic Foot Ulcer: Step I|Shockwave Treatment of Diabetic Foot Ulcer. A Prospective, Controlled, Randomized Trial. Step 1|STUF|Technische Universität München|No|Withdrawn|August 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00954343||135066|
NCT00954629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PX-OA-03|A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee|A 26 Week Placebo-controlled, Randomised, Double-blind, Parallel Group Study of the Efficacy and Safety of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Pain Due to Osteoarthritis of the Knee||Smerud Medical Research International AS|No|Recruiting|June 2009|May 2010|Anticipated|May 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|N/A|No|||March 2010|March 22, 2010|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954629||135044|
NCT00954642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANP4667g|A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Completed|August 2009|||December 2011|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00954642||135043|
NCT00954603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedCMU Que vs Halo - 2008|A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium|Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium|QHdelirium|Chiang Mai University|Yes|Terminated|June 2009|July 2012|Anticipated|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||August 2009|June 22, 2011|August 6, 2009||No|few delirious patients were enrolled.|No||https://clinicaltrials.gov/show/NCT00954603||135046|
NCT00954226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0137|Erlotinib Prior to Surgery in Patients With Head and Neck Cancer|Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2009|||August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954226||135074|
NCT00954551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000909|Serum Procalcitonin|Utility of Serum Procalcitonin Levels to Distinguish Systemic Inflammatory Response From Systemic Infection in Febrile Subarachnoid Hemorrhage Patients||Mayo Clinic|No|Completed|July 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month        period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively        evaluated.|June 2011|June 6, 2011|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954551||135050|
NCT00951275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22462|A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Single Arm, Open-label Study of Early Improvement of Anemia and Fatigue During Treatment With Tocilizumab (TCZ) in Combination With DMARDs, in Adult Patients With Moderate to Severe Active Rheumatoid Arthritis.||Hoffmann-La Roche||Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|July 30, 2009||No||No|June 4, 2014|https://clinicaltrials.gov/show/NCT00951275||135296|
NCT00951522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-221-0102|A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers||Gilead Sciences|No|Completed|September 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951522||135277|
NCT00955032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0004762006|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease.|ReStore|University of Florida|No|Completed|April 2007|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|N/A|No|||September 2012|April 19, 2013|August 5, 2009||No||No|December 5, 2011|https://clinicaltrials.gov/show/NCT00955032||135013|Due to recruiting difficulties, only 24 participants completed study participation. Despite this, the investigators still had significant power to examine effects of interest.
NCT00955045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-US-007|A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy|A Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy||Kyowa Hakko Kirin Pharma, Inc.||Completed|August 2002|October 2003|Actual|||Phase 2/Phase 3|Interventional|N/A|1||||||Both|30 Years|N/A|No|||August 2009|August 5, 2009|August 4, 2009||||||https://clinicaltrials.gov/show/NCT00955045||135012|
NCT00955058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSA|Evaluation of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients|Study of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients|PSA|Shahid Beheshti University|Yes|Enrolling by invitation|February 2007|December 2010|Anticipated|February 2007|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|22 Years|25 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00955058||135011|
NCT00951249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 061|Feasibility Study of a Multi-Component Intervention for Black Men Who Have Sex With Men|Feasibility Study of a Community-Level, Multi-Component Intervention for Black Men Who Have Sex With Men||HIV Prevention Trials Network||Completed|July 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1553|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 9, 2012|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951249||135298|
NCT00955357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0954|Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures|An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures||UCB Pharma|No|Completed|August 2009|August 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|461|||Both|17 Years|N/A|No|||June 2014|October 17, 2014|August 6, 2009|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00955357||134988|This study was intended to assess the efficacy outcomes in the First Add-On Group and the Later Add-On Group individually relative to historical data. Comparisons between the 2 groups should not be attempted and conclusions should not be drawn.
NCT00953693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-iPS-001|Patient Specific Induced Pluripotency Stem Cells (PSiPS)|Patient Specific Induced Pluripotency Stem Cells (PSiPS)||Royan Institute|Yes|Completed|April 2009|July 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|12 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patient who suffering from metabolic disorders|April 2010|December 25, 2012|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00953693||135114|
NCT00953966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/069/07|Metabolic Changes Induced by Genetically Modified Potatoes|||Charite University, Berlin, Germany|No|Recruiting|June 2007|December 2009|Anticipated|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Anticipated|50|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953966||135094|
NCT00919568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2009-005|Monitoring Arrhythmia Patients (IMPACT)|Arrhythmia Detection With Adherent Patient Monitoring||Corventis, Inc.|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Remote cardiac monitoring|February 2010|February 2, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919568||137705|
NCT00920101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDMC570|Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging|Effect of Atorvastatin on Inflammatory Atherosclerotic Plaques Assessed by FDG-PET Imaging||National Defense Medical College, Japan|No|Recruiting|June 2009|December 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||March 2013|March 11, 2013|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920101||137665|
NCT00951561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWP01-01|A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen|A Randomized Four-Way Crossover Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen||Another Way Products|No|Completed|November 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 14, 2011|July 31, 2009||No||No|September 30, 2010|https://clinicaltrials.gov/show/NCT00951561||135274|
NCT00952874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCA/HIV|Molecular Biology of Anal Cancer in HIV-Positive Patients|Microsatellite Instability in Anal Squamous Cell Carcinomas of HIV-Positive Versus HIV-Negative Patients||University Hospital, Geneva|Yes|Completed|July 2009|June 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|30|Samples With DNA|Biosie of anal cancer|Both|20 Years|80 Years|No|Non-Probability Sample|HIV positive and negative patients with biopsy proven squamous cell carcinoma of the anal        canal|August 2009|June 24, 2010|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952874||135174|
NCT00952302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxford-Peru-2008|Study of the Effects of Iron Levels on the Lungs at High Altitude|Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension||University of Oxford|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|33|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 4, 2009|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00952302||135217|
NCT00953433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endoflex-Stylet|Laryngeal Morbidity After Endotracheal Intubation - Endoflex-tube Versus Use of Stylet|Laryngeal Morbidity After Endotracheal Intubation - Endoflex-tube Versus Use of Stylet||Rigshospitalet, Denmark|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953433||135134|
NCT00954577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|amdecroad|Reduce Obesity and Diabetes|The Pathogenesis of Type 2 Diabetes in Children and Utility of a School-based Intervention to Reduce Obesity and Diabetes in Children|ROAD|Academy for Medical Development and Collaboration, New York|Yes|Recruiting|July 2006|June 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|serum|Both|10 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children in 6th-8th grade.|August 2009|August 6, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954577||135048|
NCT00954590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM19|A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease|CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease|CONTACT|Medivation, Inc.|Yes|Terminated|October 2009|||August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|50 Years|N/A|No|||August 2012|August 27, 2012|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954590||135047|
NCT00945100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-143|Increasing Patching for Amblyopia in Children 3 to < 8 Years Old|Increasing Patching for Amblyopia in Children 3 to < 8 Years Old|ATS15|Jaeb Center for Health Research|Yes|Completed|August 2009|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|3 Years|7 Years|No|||February 2016|February 22, 2016|July 21, 2009||No||No|September 6, 2013|https://clinicaltrials.gov/show/NCT00945100||135771|A potential study limitation is that compliance with patching was based on discussions with the parent and by reviewing study calendars maintained by the parent, which not an objective measure of compliance.
NCT00945399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003481-18|Comparison of Microfracture Treatment and CARTIPATCH® Chondrocyte Graft Treatment in Femoral Condyle Lesions|Phase III Protocol Comparing a Microfracture Treatment to a CARTIPATCH® Chondrocyte Graft Treatment in Femoral Condyle Lesions||TBF Genie Tissulaire||Terminated|October 2008|September 2014|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|No|||April 2015|April 25, 2015|July 23, 2009||No|Manufacturing stopped|No||https://clinicaltrials.gov/show/NCT00945399||135748|
NCT00954889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-05-004|Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg|Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg||Samsung Medical Center||Active, not recruiting|August 2009|||November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Male|45 Years|N/A|No|||October 2011|October 31, 2011|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954889||135024|
NCT00955175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-09 ICORG|Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09|Radiation Dose Escalation For Non-Small Cell Lung Cancer Using Hypofractionated 3-Dimensional Conformal Radiation Therapy||ICORG- All Ireland Cooperative Oncology Research Group||Completed|November 2000|||June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|N/A|120 Years|No|||February 2016|February 15, 2016|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955175||135002|
NCT00954876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-P02-07003|Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer|Phase II, Multi-Center, Open-Label, Prospective Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type KRAS Colorectal Cancer Who Are Considered Nonoptimal Candidates or Are Intolerant to a First-Line Oxaliplatin/Irinotecan Regimen||Translational Drug Development|No|Withdrawn|August 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 27, 2012|July 17, 2009|Yes|Yes|Study has been terminated due to lack of accrual.|No||https://clinicaltrials.gov/show/NCT00954876||135025|
NCT00955370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909206|The Experience of Uncertainty in Parents of Children With an Undiagnosed Medical Condition|The Experience of Uncertainty in Parents of Children With an Undiagnosed Medical Condition||National Institutes of Health Clinical Center (CC)||Completed|August 2009|April 2012||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|500|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955370||134987|
NCT00951821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH082211|Concurrent Treatment for Depressed Parents and DepressedAdolescents|Concurrent Treatment for Parents and Adolescents Who Attempt Suicide||Brown University|Yes|Completed|July 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|12 Years|17 Years|No|||March 2015|August 4, 2015|August 3, 2009||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT00951821||135254|The outcome data from this study must be considered within the context of its limitations including the small sample size which reduces both the power to detect differences between groups as well as the stability of findings.
NCT00952029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636983|Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer|Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer||Federation Francophone de Cancerologie Digestive|Yes|Active, not recruiting|March 2010|July 2016|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|492|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|August 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00952029||135238|
NCT00952042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kongsgaard2|Resistance Training as Treatment of Achilles Tendinopathy|Heavy Slow Resistance Versus Eccentric Training in the Treatment of Achilles Tendinopathy. A Randomized Controlled Trial.||University of Copenhagen|Yes|Completed|July 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|60 Years|No|||July 2014|July 18, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952042||135237|
NCT00952861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH-INF-1|Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)|Antibiotic Treatment of Patients Admitted to Hospital With Acute Exacerbation of COPD. Effect of 1 Day of Antibiotic Therapy Compared to 6 Days of Therapy in Patients Who Are Stable After 24 Hours|TAExaCOP|Odense University Hospital|No|Withdrawn|October 2009|December 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|50 Years|N/A|No|||June 2010|August 10, 2010|July 24, 2009||No|Stopped due to poor recruitment|No||https://clinicaltrials.gov/show/NCT00952861||135175|
NCT00954265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rec-HCG 002|Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)|Phase III Study on the Effects of Recombinant HCG Ovulation Triggering on Stimulation, Embryonic and Pregnancy Parameters in an IVF Program||Universitair Ziekenhuis Brussel|Yes|Active, not recruiting|August 2005|September 2010|Anticipated|December 2007|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Female|20 Years|36 Years|No|||August 2009|December 23, 2009|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954265||135072|
NCT00954837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB 2008-A00839-46|Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer|Utility of a Second Ultrasound-guided Fine Needle Aspiration for the Detection of Thyroid Cancer in the Management of Single Thyroid Nodules or Multinodular Goitre.|CYT2THYR|Assistance Publique - Hôpitaux de Paris|No|Withdrawn|April 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 24, 2013|July 30, 2009||No|administrative delays too long|No||https://clinicaltrials.gov/show/NCT00954837||135028|
NCT00919581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0268|Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury|Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury||Northwell Health|No|Active, not recruiting|May 2009|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|287|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with spinal cord injury, uninjured controls|December 2015|December 15, 2015|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919581||137704|
NCT00952055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03028|Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin|Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin||Winthrop University Hospital|No|Terminated|July 2003|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|||Both|19 Years|N/A|No|Non-Probability Sample|Acute cornary syndrome|January 2015|January 15, 2015|July 31, 2009||No|1) A delay in obtaining immunoassays to measure serum neopterin 2)altered relevance of the    expected experimental results to clinical practice|No||https://clinicaltrials.gov/show/NCT00952055||135236|
NCT00920075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01FD001847-05 REVISED|Alendronate in Juvenile Osteoporosis|Phase II Study of Alendronate Sodium in Juvenile Osteoporosis (IND# 60,017)-Post Study Evaluation of Participants From Phase IIa and Phase IIb Clinical Study.||Medical University of South Carolina|Yes|Completed|July 2009|October 2010|Actual|September 2009|Actual|N/A|Observational|N/A||1|Actual|11|||Both|8 Years|21 Years|No|Non-Probability Sample|Available male and female children who have participated and Completed in our earlier open        label or double blind clinical trial.|November 2010|November 9, 2010|June 11, 2009|Yes|Yes||No|November 9, 2010|https://clinicaltrials.gov/show/NCT00920075||137667|
NCT00952614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007284|A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion|A Pilot Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion||Duke University|No|Completed|October 2002|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|August 4, 2009|Yes|Yes||No|August 6, 2013|https://clinicaltrials.gov/show/NCT00952614||135193|
NCT00953173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERO Study|HERO Study: Helping Evaluate Reduction in Obesity|||Apollo Endosurgery, Inc.|No|Active, not recruiting|December 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1106|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have already made a decision, independent of the study, to proceed with        LAP-BAND AP® implantation.|September 2015|September 16, 2015|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953173||135153|
NCT00954278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO08511|Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer|A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC)||University of Wisconsin, Madison|Yes|Active, not recruiting|July 2009|January 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|July 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00954278||135071|
NCT00954291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L27GRA14-1|An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects|An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects|Granisetron|Taipei Medical University WanFang Hospital|No|Recruiting|July 2009|August 2009|Anticipated|August 2009|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|8|Samples Without DNA|plasma|Male|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Health subjects|September 2010|September 3, 2010|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954291||135070|
NCT00954304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OXL-104|Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet|Clinical Trial to Investigate the Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet in Healthy Male Subjects : An Open, Parallel Dose Group Design|PGP inhibitor|Hanmi Pharmaceutical Company Limited|No|Completed|June 2009|September 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 10, 2010|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954304||135069|
NCT00953758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371001|A Study Of PF-04449913 In Select Hematologic Malignancies|A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies||Pfizer|No|Completed|March 2010|February 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|August 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00953758||135109|
NCT00954057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-102-CL-06|Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)|A Single-masked, Placebo Controlled, Multi-center Pilot Study to Determine the Safety and Efficacy of Orbital Injections of a Fixed Dose of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease||Neothetics, Inc|No|Completed|September 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954057||135087|
NCT00954356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPF-001-201|Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction|Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Safety, PK, & Efficacy of a Single Oral Dose of XPF-001 in the Treatment of Pain Related to Third Molar/Wisdom Tooth Extraction.||Xenon Pharmaceuticals Inc.|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|July 22, 2009|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT00954356||135065|This model is best suited for drugs with rapid onset of action (e.g. NSAIDs). XPF-001 does not have a rapid onset.
NCT00945113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4565|Pilot: Group Therapy for Children Who Stammer|A Pilot Randomised Controlled Trial of the Effectiveness of Intensive Group Speech and Language Therapy as a Treatment for Older Children Who Stammer||Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|June 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|6|||Both|8 Years|15 Years|No|||October 2015|October 7, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00945113||135770|
NCT00954031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/9-W|Impact of Anti-inflammatory and Antibiotic Therapy on the Emergence of Peri-tonsillar Abscess|Impact of Anti-inflammatory and Antibiotic Therapy on the Emergence of Peri-tonsillar Abscess|APA|Nantes University Hospital|No|Terminated|March 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|711|||Both|N/A|N/A|No|Non-Probability Sample|Patients, adult or child, including the diagnosis of APA was made, after consulting their        physician|January 2013|January 30, 2013|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954031||135089|
NCT00954044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5366|Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses|Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses||Oregon Health and Science University|Yes|Completed|January 2010|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|128|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954044||135088|
NCT00955188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632080|Computer-Based Tailored or Standard Information for Colorectal Cancer Screening|Evaluating a Preference-tailored Intervention to Increase CRC Screening in Primary Care Settings||University of Michigan Cancer Center|Yes|Completed|August 2004|May 2008|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|345|||Both|50 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Kelsey-Seybold Clinic, Houston, Tx        Study Coordinator: Bettencourt , Judy ( ) Email: Judith.L.Bettencourt@uth.tmc.e Phone:        713-500-9754|December 2012|December 19, 2012|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955188||135001|
NCT00955461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C66-07-F|Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System|Post-Market, Randomized, Single Blind, Split-Faced Comparison of the RevLite Nd:YAG Laser System Versus a Non-Ablative, Mid Infra-red, Fractionated Type Laser System for Skin Rejuvenation||Cynosure, Inc.|No|Completed|December 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Both|25 Years|65 Years|No|||November 2012|November 27, 2012|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955461||134980|
NCT00955474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001022|Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms|The Efficacy and Tolerability of Seroquel XR Combined With a Selective Serotonin Re-Uptake Inhibitor Versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder With Psychotic Features|Seroquel|Massachusetts General Hospital|No|Terminated|September 2008|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|85 Years|No|||March 2013|March 26, 2013|August 6, 2009||No|Seroquel went generic and AstraZeneca halted funding.|No||https://clinicaltrials.gov/show/NCT00955474||134979|
NCT00951366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X08-07-0335|Bronchopulmonary Disease (BPD) Patient Registry|The Center for Healthy Infant Development (Child) Clinic Patient Registry|CHILD|Children's Hospital Boston|No|Recruiting|June 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|360|||Both|N/A|12 Years|No|Non-Probability Sample|Bronchopulmonary Dysplasia (BPD) patients will be approached during clinical visit and        inpatient hospitalizations.|August 2009|August 3, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951366||135289|
NCT00951535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-17 ICORG|A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17|A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0M0 Prostate Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|June 2008|September 2026|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Male|18 Years|N/A|No|||October 2015|October 20, 2015|August 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00951535||135276|
NCT00952315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-045|Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery|Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy||Indiana Kidney Stone Institute|No|Active, not recruiting|August 2009|April 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952315||135216|
NCT00952601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AtkinsTourette|Pilot Study of the Modified Atkins Diet for Tourette Syndrome|Pilot Study of the Modified Atkins Diet for Tourette Syndrome||Johns Hopkins University|No|Terminated|September 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|65 Years|No|||July 2010|July 14, 2010|August 3, 2009||No|Insufficient interest and recruitment - study ended prematurely by investigators|No||https://clinicaltrials.gov/show/NCT00952601||135194|
NCT00953420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25145-CADEN|Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes|Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients With Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma(CADEN)|CADEN|Baylor College of Medicine|Yes|Completed|November 2009|July 2015|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|10 Years|N/A|No|||August 2015|August 26, 2015|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953420||135135|
NCT00924053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-1474-C-396|Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes|A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of EGT0001474 in Subjects With Type 2 Diabetes||Theracos|Yes|Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||March 2015|March 4, 2015|June 16, 2009|No|Yes||No|October 25, 2010|https://clinicaltrials.gov/show/NCT00924053||137371|
NCT00919594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08100448|Psychotherapy for Depressed Mothers of Psychiatrically Ill Children|Psychotherapy for Depressed Mothers of Psychiatrically Ill|IPT Moms|University of Pittsburgh|No|Completed|August 2009|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|7 Years|65 Years|No|||January 2016|January 28, 2016|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919594||137703|
NCT00919607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00007|Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients|||AstraZeneca|No|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|31|||Both|18 Years|60 Years|No|||March 2010|March 25, 2010|June 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00919607||137702|
NCT00919854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012553|A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children|A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age||Tibotec Pharmaceuticals, Ireland|Yes|Completed|September 2009|February 2011|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|3 Years|6 Years|No|||April 2014|April 3, 2014|June 11, 2009|No|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00919854||137684|
NCT00953186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z012094|Hyperbaric Oxygen Therapy as Adjunctive Treatment of Chronic Diabetic Foot Ulcers|Hyperbaric Oxygen Therapy as Adjunctive Treatment in Diabetics With Chronic Foot Ulcers|HODFU|Mrs. Thelma Zoegas Foundation|Yes|Completed|June 2002|June 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||August 2009|November 7, 2011|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953186||135152|
NCT00951574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS/02/SELE/01|Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)|Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.||Italfarmaco|Yes|Completed|October 2003|July 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1166|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951574||135273|
NCT00951587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-104|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure||Given Imaging Ltd.|No|Completed|February 2008|March 2010|Actual|February 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|49|||Both|18 Years|50 Years|No|||March 2010|March 10, 2010|August 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00951587||135272|
NCT00921089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1926|Vascular Calcification, Inflammation and Coronary Flow Velocity in Hemodialysis Patients|The Association Among Vascular Calcification, Inflammation and Coronary Flow Velocity in Hemodialysis Patients||Istanbul University|No|Completed|April 2008|December 2008|Actual|July 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|103|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|End stage renal disease patients and normotensive healthy controls were studied for the        assessment of coronary artery calcification score by electron-beam computerized tomography        and coronary flow reserve trans-thoracic Doppler harmonic echocardiographyby.|June 2009|June 16, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921089||137589|
NCT00954382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904037R|Trends in Intellectual Development in Down Syndrome|Trends in Intellectual Development, and Diverging Verbal and Non-verbal Abilities in the Down Syndrome Phenotype||National Taiwan University Hospital|No|Recruiting|May 2009|December 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|60|||Both|3 Months|40 Years|No|Non-Probability Sample|Down syndrome|March 2010|March 16, 2010|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954382||135063|
NCT00954395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DULCIS|DULCIS (D-dimer and ULtrasonography in Combination Italian Study)|Optimizing the Duration of Anticoagulation in Venous Thromboembolism: the DULCIS Study|DULCIS|St. Orsola Hospital|Yes|Completed|September 2008|June 2012|Actual|December 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1100|Samples With DNA|platelet poor plasma and whole blood for Dna|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a first episode of venous thromboembolism attending anticoagulation clinics        or general practitioners|August 2012|August 31, 2012|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954395||135062|
NCT00954408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108-2008|Fatigue in Dystonia (a Single Session, Questionnaire-based Study of Fatigue in Dystonia)|Fatigue in Dystonia (IRB No. 108-2008)|FID|University of Florida|No|Completed|July 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|123|||Both|21 Years|N/A|No|Non-Probability Sample|Current dystonia patients in our clinic between the ages of 21 and 100.|August 2011|September 16, 2011|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954408||135061|
NCT00953745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0419|Neuroimaging Of Treatment Effects in Treatment-Resistant Depression|Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression: A Raclopride/F-DOPA Positron Emission Tomography and Functional MRI Study.||Washington University School of Medicine|No|Recruiting|May 2009|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 8, 2011|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953745||135110|
NCT00954655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z9081|Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001|Genetic Risk Factors for Gastrointestinal Stromal Tumors (GIST)||Alliance for Clinical Trials in Oncology||Recruiting|December 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|374|||Both|18 Years|N/A|No|Non-Probability Sample|Tumor samples from patients with gastrointestinal stromal tumors enrolled on clinical        trial ACOSOG-Z9001|July 2015|July 23, 2015|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954655||135042|
NCT00954915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA031-04|Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis|A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis||MacroGenics|No|Terminated|December 2009|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|70 Years|No|||August 2012|August 20, 2012|August 4, 2009|Yes|Yes|Injection site reaction met protocol-defined stopping criteria.|No|March 27, 2012|https://clinicaltrials.gov/show/NCT00954915||135022|This study was terminated, with only 1 subject enrolled, due to meeting the study criteria for discontinuation regarding local or regional injection site reactions.
NCT00955201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6954-R|Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy|Exercise-Facilitated NeuroRehabilitation in Diabetic Neuropathy||VA Office of Research and Development|No|Active, not recruiting|December 2009|December 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|45 Years|80 Years|No|||April 2015|April 10, 2015|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955201||135000|
NCT00955214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SACRA1|Small Coronary Artery Treated by TAXUS Liberté Registry in Japan|Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease|SACRA|Society for Advancement of Coronary Intervention Research|Yes|Enrolling by invitation|April 2009|August 2012|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|20 Years|80 Years|No|||June 2010|June 9, 2010|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955214||134999|
NCT00955487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0124|Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns|Non-invasive Inhaled Nitric Oxide in Premature Newborns||University of Colorado, Denver|Yes|Active, not recruiting|January 2007|August 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|124|||Both|N/A|72 Hours|No|||September 2015|September 29, 2015|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955487||134978|
NCT00922480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-301|Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients|A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension||Boryung Pharmaceutical Co., Ltd|Yes|Completed|December 2008|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|506|||Both|18 Years|70 Years|No|||October 2009|October 7, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922480||137483|
NCT00922753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06109|Inspiratory Support Improves Preoxygenation in Healthy Subjects|The Efficacy and Tolerability of Different Levels of Inspiratory Support and PEEP During Preoxygenation. A Randomized Controlled Trial.||Maisonneuve-Rosemont Hospital|No|Completed|February 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|20|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 17, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922753||137462|
NCT00923039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 304|The Early Origins of Cardiovascular Disease|The Early Origins of Cardiovascular Disease : the Consequence of Growth Restriction During Foetal Life and Infancy on Cardiovascular Structure and Function in Adulthood||Danone Institute International||Not yet recruiting|June 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|200 Young adult students will be recruited at the Preventive Medicine Centre at Université        de la Méditerranée during their annual routine medical examination|June 2009|June 17, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923039||137440|
NCT00953147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-633|A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older|A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older||Sunovion|No|Completed|August 2009|May 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1110|||Both|12 Years|N/A|No|||June 2012|June 7, 2012|August 4, 2009|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT00953147||135155|This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg
NCT00953160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-TF-02|Radio Frequency (RF) Device for Reduction in Size of Localized Areas of the Body|Pilot Study to Evaluate the Cutera RF Device for Reduction in Size of Localized Areas of the Body, Including, But Not Limited to, Areas on the Abdomen, Leg, and Arm||Cutera Inc.|No|Terminated|April 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|August 4, 2009|Yes|Yes|The preliminary data from this pilot study did not indicate efficacy.|No|February 25, 2011|https://clinicaltrials.gov/show/NCT00953160||135154|Early termination of the study resulting in analysis of small numbers of subjects, and technical issues with repeatability and reproducibility of circumference measurements leading to termination.
NCT00953979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-2|Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis|A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial||Sun Yat-sen University|Yes|Completed|January 2008|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|65 Years|No|||January 2012|January 18, 2012|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953979||135093|
NCT00954252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0814-PR-0008|Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects|CT01|CERESPIR|Yes|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|84|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|July 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00954252||135073|
NCT00943943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0501|Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations|G-CSF and Plerixafor With Sorafenib for Acute Myelogenous Leukemia With FLT3 Mutations||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2010|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00943943||135860|
NCT00943956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000639358|Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer|A Phase I Trial to Evaluate Acute and Late Toxicities of Concurrent Treatment With Everolimus (RAD001) and Radio-Hormonotherapy in High-risk Prostate Cancer.||Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Completed|January 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|N/A|80 Years|No|||August 2015|August 3, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943956||135859|
NCT00944528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015617|Single Dose Partial Breast Radiotherapy|Single Dose Partial Breast Radiotherapy Using Extra-cranial Radiosurgery in Patients With Early Stage Breast Cancer - a Phase I Dose Escalation Study|RSU|Duke University|No|Active, not recruiting|January 2010|May 2016|Anticipated|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Female|55 Years|80 Years|No|||June 2015|June 25, 2015|July 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00944528||135815|
NCT00943930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA DA026761|Marijuana Drug Discrimination and Self-Administration|Smoked Marijuana Discrimination and Marijuana Choice in Humans: A Laboratory Mode|DDC|Wayne State University||Completed|April 2009|December 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|21 Years|45 Years|No|Non-Probability Sample|Marijuana dependent volunteers|July 2015|July 29, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943930||135861|
NCT00947336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-PHT-01|Evaluation of Safety & Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis (SBP) in Cirrhotics|Evaluation of Safety and Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis in Cirrhotics: A Randomized, Double Blind Placebo Controlled Trial||Govind Ballabh Pant Hospital||Completed|April 2005|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|110|||Both|12 Years|75 Years|No|||July 2009|July 27, 2009|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947336||135599|
NCT00948298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#08-05-2170-01|Effect of Vitamin D3 on Vascular Function|The Effect of Cholecalciferol (Vitamin D3) on Vascular Function and Cardiovascular Risk Factors||Charles Drew University of Medicine and Science|Yes|Active, not recruiting|July 2009|April 2012|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|130|||Both|18 Years|70 Years|No|||January 2012|January 22, 2012|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948298||135525|
NCT00947960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-103|Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease|A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study||Baylor Research Institute|No|Completed|June 2009|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|75 Years|No|||January 2016|January 12, 2016|July 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00947960||135551|
NCT00948844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC - 09 - NG - 521 - CTIL|Automatic Detection of Falls and Near Falls|Automatic Detection of Falls and Near Falls||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|August 2009|August 2011|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|90|||Female|50 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Healthy Older Adults          -  Parkinson's Disease Patients          -  Idiopathic Fallers|July 2009|July 28, 2009|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948844||135483|
NCT00948870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHTCM-002|Trial of Chinese Prescription Shugan Decoction on Irritable Bowel Syndrome（Diarrhea Type）|||Shanghai University of Traditional Chinese Medicine|Yes|Completed|August 2009|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||August 2009|March 6, 2013|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948870||135481|
NCT00949156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMUneurosurgery|Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma|Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma||Southern Medical University, China|Yes|Active, not recruiting|September 1997|December 2015|Anticipated|October 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|238|||Both|1 Year|70 Years|No|Probability Sample|The clinical data of 198 patients who underwent primary microsurgery for        craniopharyngiomas at our institute since July, 1997 until now was analysed        retrospectively. The anticipated 40 CP patients in the following two years were recurited        in the prospective cohort, who will be surgical treated according to the standard process.|September 2010|September 14, 2010|July 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949156||135459|
NCT00949403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0621|Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease|An Interdisciplinary Approach to the Study of Non-alcoholic Fatty Liver Disease|Liver|Washington University School of Medicine|Yes|Active, not recruiting|July 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood Samples.|Female|18 Years|45 Years|No|Probability Sample|Obese females between the ages of 18 and 45, with a BMI of greater then or equal to 45,        who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital.|January 2016|January 27, 2016|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949403||135440|
NCT00949416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD007|Risk Factors of Incidence of Type 2 Diabetes and Cardiovascular Diseases---Shanghai Baoshan Study|Risk Factors of Incidence of Type 2 Diabetes and Cardiovascular Diseases|SBSS|Shanghai Jiao Tong University School of Medicine|Yes|Enrolling by invitation|June 2009|September 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|1000 Type 2 diabetic patients, 1200 subjects with IGR and 1440 subjects with normal        glucose metabolism (aged above 40 years old, both men and women)were selected as target        population of this study by random sampling.|July 2009|July 29, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949416||135439|
NCT00951678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106983|Determination of Anatomic Variations of the Internal Jugular and Femoral Veins Using Ultrasound in the Emergency Department|Determination of Anatomic Variations of the Internal Jugular and Femoral Veins Using Ultrasound in the Emergency Department||Tampa General Hospital|No|Recruiting|May 2009|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Emergency room patients who fit inclusion criteria and consent to participation in the        study.|April 2015|April 29, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951678||135265|
NCT00944099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA 09PRE2020150|Lifestyle, Eating, and Activity Patterns|Eating Frequency Prescription for a Behavioral Weigh Loss Intervention|LEAP|University of Tennessee|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|65 Years|No|||November 2012|November 14, 2012|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944099||135848|
NCT00943826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21990|A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma|||Hoffmann-La Roche||Completed|June 2009|September 2015|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|921|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|July 17, 2009|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00943826||135869|
NCT00944372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0050-02-763|Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors|An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patients Referred for Scintigraphy of All Solid Tumors With a High Suspicion of Containing Somatostatin Receptor Positive Tissue||Mallinckrodt|No|Terminated|July 2003|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|10||Actual|150|||Both|18 Years|N/A|No|||July 2009|July 22, 2009|July 21, 2009|Yes|Yes|Enrollment was difficult|No||https://clinicaltrials.gov/show/NCT00944372||135827|
NCT00944073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0054|Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels|A Phase II Study in Infants (Greater Than or Equal to 6 - Less Than 36 Months), Children (Greater Than or Equal to 36 Months - 9 Years) and Adolescents (10 - 17 Years) to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|583|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||March 2010|January 29, 2015|July 21, 2009|Yes|Yes||No|March 17, 2011|https://clinicaltrials.gov/show/NCT00944073||135850|To limit blood draws, the younger 2 age strata were assigned varying blood draw schedules and there were deviations from the schedules, reducing the size of subsets on the same schedule, such uniformity being optimal for longitudinal comparisons.
NCT00944086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akaratas|Oxygen Concentration Should be Kept at the Lowest Possible Level During Recruitment|A Prospective Randomized Clinical Study:Oxygen Concentration Should be Kept at the Lowest Possible Level During Recruitment Manoeuvres||Istanbul University||Completed|May 2008|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|27 Years|61 Years|Accepts Healthy Volunteers|Probability Sample|This study has been applied on 32 cases which have undergone laparoscopic cholecystectomy.|August 2009|August 3, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944086||135849|
NCT00945763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1539-02|Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Adaptive Design, Single-Dose Study of Intravenous N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery||Alkermes, Inc.|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|230|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 28, 2011|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945763||135720|
NCT00945776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-04-2047|Weekly Phone Calls Versus Brief Patient Education to Improve Continuous Positive Airway Pressure (CPAP) Compliance|Weekly Phone Calls vs. Brief Patient Education to Improve CPAP Compliance: A Randomized Controlled Trial||CAMC Health System|No|Completed|April 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|N/A|No|||July 2009|July 23, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945776||135719|
NCT00942253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3745/EPE/2006|Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)|The Effects of Exercise Training in Combination With Dopamine Agonist to Physical Fitness Parameters and Quality of Life in Dialysis Patients With the Restless Legs Syndrome.|HDRLS|University of Thessaly|No|Completed|September 2006|July 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|65 Years|No|||July 2010|July 2, 2010|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942253||135988|
NCT00943150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK VP-00055|PEAK PlasmaBlade™ vs. Traditional Electrosurgery in Abdominoplasty|A Prospective, Randomized, Controlled Two-arm Superiority Study to Evaluate Use of the PEAK PlasmaBlade™ 4.0 in Abdominoplasty|PRECISE|Medtronic Surgical Technologies|No|Completed|December 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|25 Years|60 Years|No|||November 2012|November 29, 2012|July 20, 2009|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00943150||135921|
NCT00943163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906095R|Evaluation of Position-induced Cyclorotation Between Wavefront Measurement and Refractive Surgery by the Iris Registration Method|Evaluation of Position-induced Cyclorotation Between Wavefront Measurement and Refractive Surgery by the Iris Registration Method||National Taiwan University Hospital|No|Completed|January 2008|October 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|93|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ninety-three consecutive patients undergoing bilateral wavefront-guided laser refractive        surgery in the Department of Ophthalmology of the National Taiwan University Hospital        between September 2004 and December 2007.|July 2009|July 21, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943163||135920|
NCT00943969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP 0911965|Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass|Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass|OBEMO|Hopital Lariboisière|No|Completed|April 2009|January 2010|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943969||135858|
NCT00943982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090191|The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma|The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma||National Institutes of Health Clinical Center (CC)||Completed|July 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2010|September 26, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943982||135857|
NCT00944814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917273|Acceptability of Zinc-fortified Lipid-based Nutrient Supplements|Assessment of the Acceptability of Zinc-fortified Lipid Based Nutrient (LNS) Prepared for Young Burkinabe Children||University of California, Davis|Yes|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|9 Months|15 Months|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944814||135793|
NCT00947973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH082865|Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder|Multisite Study of School Based Treatment Approaches for ADHD Adolescents||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|July 2010|July 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|315|||Both|11 Years|15 Years|No|||February 2012|July 29, 2013|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947973||135550|
NCT00947986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0305|Mucociliary Clearance Time in Chronic Rhinosinusitis (CRS) Patients After Sinus Surgery|Effect of Baby Shampoo Nasal Irrigation on Mucociliary Clearance Time in Patients After Sinus Surgery||The University of Texas Health Science Center, Houston|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||March 2010|March 18, 2010|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00947986||135549|
NCT00948883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCD CANC 0701|Study of Cancers After Solid Organs Transplants|Epidemiological, Immunological, Pathological and Pharmacogenetic Study of Cancers Occuring After Solid Organs Transplants|K-GREF|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|330|Samples With DNA|Whole blood, frozen tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with solid organ transplant who have developed a cancer. Patients with solid        organ transplant who have not developed a cancer.|April 2013|April 3, 2013|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948883||135480|
NCT00948558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2009-108|Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT|Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).||Huashan Hospital|No|Recruiting|March 2009|September 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|the subjects will be selected from a university teaching hospital in Shanghai, China.|August 2009|August 4, 2009|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948558||135505|
NCT00948571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-3085|Influence of Posture and Gas Insufflation on Perioperative Lung Function|Influence of Posture, Anesthesia and Surgical Technique on Airway Resistance of the Upper and Lower Airway and Lung Function.||Kliniken Essen-Mitte|No|Recruiting|April 2009|February 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|20 patients scheduled for "robotic" prostatectomies 20 patients scheduled for open        prostatectomies 20 patients scheduled for open hemicolectomies|June 2011|June 27, 2011|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948571||135504|
NCT00949442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_C_02762|Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment|Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled|LANCELOT|Sanofi||Completed|July 2009|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|708|||Both|30 Years|70 Years|No|||August 2012|August 20, 2012|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00949442||135437|
NCT00949702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22657|A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma|An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma||Hoffmann-La Roche||Active, not recruiting|October 2009|October 2013|Anticipated|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|July 28, 2009|Yes|Yes||No|July 29, 2011|https://clinicaltrials.gov/show/NCT00949702||135417|
NCT00949949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0812|Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy|Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy||Mayo Clinic|Yes|Active, not recruiting|September 2009|||September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|52|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949949||135398|
NCT00950222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061014|Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic|Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic|IMPACT|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2009|January 2012|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00950222||135377|
NCT00951379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03152|Pioglitazone for Oral Premalignant Lesions|Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions an Inter-consortium Collaborative Study||National Cancer Institute (NCI)||Completed|February 2010|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||June 2014|September 19, 2014|July 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951379||135288|
NCT00944957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC 09-087|Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz|Patient Preference, Sleep Quality, and Anxiety/Depression: Comparison of Raltegravir and Efavirenz|Switch-ER|University Hospital, Geneva|Yes|Recruiting|November 2009|April 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2009|January 11, 2010|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944957||135782|
NCT00944385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0079|Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement|Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement||Yonsei University||Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|N/A|2||||||Both|20 Years|75 Years|No|||May 2011|May 26, 2011|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944385||135826|
NCT00944398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200817275|Impact of Targeted Zinc Fortification Programs on Plasma Zinc Concentration|Evaluation of the Use of Plasma Zinc Concentration for Assessing the Impact of Targeted and Mass Zinc Fortification Programs||University of California, Davis|No|Completed|January 2009|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|98|||Both|12 Months|17 Months|Accepts Healthy Volunteers|||February 2010|February 18, 2010|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944398||135825|
NCT00944684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091/07|High Dose Ribavirin in the Treatment of Chronic Hepatitis C|Prospective, Open-label, Randomised Controlled Trial on Efficacy and Tolerability of PegIFN-alpha 2a + Serum Level-adapted RBV vs. PegIFN-alpha 2a + Weight-based RBV in Treatment-naive Patients With Chronic Hepatitis C Genotype 1||University of Bern|No|Completed|November 2007|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||November 2011|November 10, 2011|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00944684||135803|
NCT00945789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102007|Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)|Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial||Tanta University|Yes|Completed|October 2007|June 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|N/A|24 Hours|No|||September 2009|September 24, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945789||135718|
NCT00945802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FST201-AOE-02|FST-201 In The Treatment of Acute Otitis Externa|A Multi-Center, Randomized, Double-Masked Clinical Study Evaluating the Efficacy Of FST-201 (Dexamethasone 0.1%) Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex (Ciprofloxacin 0.3%, Dexamethasone 0.1%) Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa||Shire||Terminated|July 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||September 2012|September 14, 2015|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945802||135717|
NCT00942890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSNRP Grant HU0001-08-1-TS10|Strength, Pain and Function in Operation Iraqi Freedom/Operation Enduring Freedom Amputees: A Nurse-Managed Program|Strength, Pain and Function in Operation Iraqi Freedom/Operation Enduring Freedom Amputees: A Nurse-Managed Program||University of Tennessee|Yes|Completed|April 2009|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|55 Years|No|||October 2015|October 13, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942890||135941|
NCT00943176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007692|Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)|Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis|PBC|Mayo Clinic|No|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|75 Years|No|||January 2012|January 13, 2012|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943176||135919|
NCT00943189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-4934-LG-CTIL|Fetal Anomalies Scan at the Time of Nuchal Translucency Study|Fetal Anomalies Scan at the Time of Nuchal Translucency Study||Sheba Medical Center|No|Recruiting|June 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All pregnant women at 12-14 weeks of gestation that are coming for nuchal translucency        examination and willing to participate in the study.|November 2009|November 19, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943189||135918|
NCT00943722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-002|A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)|A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|August 2009|December 2020|Anticipated|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|3074|||Both|9 Years|26 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|July 21, 2009|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00943722||135877|
NCT00943735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221078|This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder|A 13-Week, Single-Arm, Open-Label, Multicenter Study To Evaluate Refill Adherence And Satisfaction With Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder.||Pfizer|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|774|||Both|18 Years|N/A|No|Non-Probability Sample|fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician        visits|February 2012|February 10, 2012|July 20, 2009|Yes|Yes||No|November 16, 2011|https://clinicaltrials.gov/show/NCT00943735||135876|
NCT00943748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-006842-25|Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease|Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease|FAIR-PARK-I|University Hospital, Lille|Yes|Completed|October 2009|October 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|80 Years|No|||July 2009|August 31, 2012|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943748||135875|
NCT00943995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|907-M02R|Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis|TIW Growth Hormone Therapy in Children on Hemodialysis||Nationwide Children's Hospital|Yes|Completed|July 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|1 Month|16 Years|No|||May 2015|May 4, 2015|July 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943995||135856|
NCT00947999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36292-D Phase I|Neurofeedback Treatment of Pain in Persons With Spinal Cord Injury (SCI)|Neurofeedback Treatment of Pain in Persons With SCI: Phase 1||University of Washington|No|Completed|July 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|93|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited primarily from a previous survey study conducted by the        principal investigator, as well as a data registry maintained by the principal        investigator. Individuals recruited for these studies were recruited primarily from        rehabilitation clinics. Interested individuals may also learn about the study from        advertisements in newsletters and magazines from consumer organizations, physician        referrals, recruitment descriptions on University of Washington websites, and study        brochures in clinics.        In addition, SCI subjects participating in the study will give friends and relatives who        do not have a spinal cord injury or chronic pain a brochure informing them about the        study.|October 2011|June 4, 2013|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947999||135548|
NCT00949455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000640393|A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium|A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB]|LaMB|Queen Mary University of London|Yes|Active, not recruiting|March 2009|||July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949455||135436|
NCT00949468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opht2009|Microbiological Keratitis in a Countryside City of Brazil|Epidemiologic Characteristics, Predisposing Factors and Microbiological Profile of Infectious Corneal Ulcers in Two Referral Centers in a Countryside City of Brazil||Sao Jose do Rio Preto University|No|Completed|June 2008|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|74|Samples With DNA|Corneal scrapes|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|37 patients admitted in two referral ophthalmology centers in a countryside city of        Brazil. 37 volunteers were used as a control group.|July 2009|July 29, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949468||135435|
NCT00948584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-I038|Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix|Insulin Dose Titration System in Diabetic Patients Using a Short Messaging Service Automatically Produced by a Knowledge Matrix||Hallym University Medical Center|No|Completed|November 2007|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|70 Years|No|||July 2009|July 28, 2009|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948584||135503|
NCT00948857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092508-01|Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)|A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Premature Ovarian Failure (POF).|DHEAFert2|Center for Human Reproduction|No|Terminated|June 2009|October 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Female|21 Years|39 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|July 28, 2009||No|Lack of recruitment.|No|August 2, 2012|https://clinicaltrials.gov/show/NCT00948857||135482|Termination due to lack of consenting participants.
NCT00950235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD058061-01A1|Weight Management for Improved Pregnancy Outcomes|Weight Management for Improved Pregnancy Outcomes|Healthy Moms|Kaiser Permanente|Yes|Completed|October 2009|March 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|118|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|July 29, 2009||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT00950235||135376|
NCT00950248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090197|Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS)|Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2009|August 2018|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|65 Years|No|||August 2015|October 3, 2015|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950248||135375|
NCT00950482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 16997|Pilot Study - Impact of Traditional Acupuncture on Menopause|Pilot Study - The Impact of Traditional Acupuncture on Menopausal Vasomotor Symptoms, Psychological Stress and the Hypothalamic Pituitary Adrenal (HPA) - Sympathetic Nervous System (SNS) Axis: A Randomized, Controlled Trial||Cedars-Sinai Medical Center|No|Completed|January 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|45|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950482||135357|
NCT00950781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 17569|Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997|Cortisol Levels on Menopausal Vasomotor Symptoms - an Ancillary (Addendum) Study to the "Impact of Traditional Acupuncture on Menopausal Vasomotor Symptoms, Psychological Stress and the Hypothalamic Pituitary Adrenal (HPA) - Sympathetic Nervous System (SNS) Axis: A Randomized, Controlled Trial"||Cedars-Sinai Medical Center|No|Completed|January 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|45|||Female|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Menopausal women|August 2012|August 24, 2012|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00950781||135334|
NCT00943839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000638415|Sunitinib Malate in Treating Patients With Kidney Cancer|Effects of Sunitinib in the Expression of VEGF and of Interleukin 8: Explanation of Anti-angiogenic Effects.||Centre Antoine Lacassagne|Yes|Completed|February 2009|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943839||135868|
NCT00944970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRE0470P-305|Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia|Vasodilator Induced Stress In CONcordance With Adenosine (VISION-305)|VISION-305|Pfizer|Yes|Completed|October 2005|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Actual|578|||Both|30 Years|N/A|No|||May 2012|May 24, 2012|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00944970||135781|
NCT00945217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-01-63A|The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women|Genetic Probes of Atherogenic Dyslipidemia: The Roles of the SAH Gene Family (Study 2. Postmenopausal Women)|MOSAH-S2|Taipei Veterans General Hospital, Taiwan|No|Recruiting|October 2009|July 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|660|Samples With DNA|Samples With DNA - samples retained, with potential for extraction of DNA from buffy coats|Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers with natural menopause from a research clinic|December 2011|December 5, 2011|April 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00945217||135762|
NCT00945477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILCC #1|Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade|A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.||Illinois CancerCare, P.C.|No|Terminated|July 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|18 Years|85 Years|No|||October 2013|October 25, 2013|July 22, 2009|Yes|Yes|Slow enrollment|No|October 24, 2012|https://clinicaltrials.gov/show/NCT00945477||135742|Because of slow enrollment, the study was terminated. The study planned enrollment of 34 subjects, 11 were enrolled.
NCT00946140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-132|Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study|Motion Correction in Dynamic Contrast Enhanced MRI in Ovarian Cancer: A Pilot Study||Memorial Sloan Kettering Cancer Center||Completed|July 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Female|21 Years|N/A|No|Non-Probability Sample|The patients will be recruited from the existing patient population at Gynecologic Medical        Oncology Service at MSKCC. The patients meeting the eligibility criteria will be referred        to DCE-MRI study by a physician in the GMO service at MSKCC.|October 2013|October 23, 2013|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946140||135691|
NCT00943215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 29012|How Participants Behave and Respond on Their Own After Completing a 2-year Intervention of Calorie Restriction|The Proposed Study Entails a Follow-up of All the Completers for 2 Years With Visits Timed 3, 6, 12 and 24 Months After Completion of the 2-year CALERIE II Intervention.|CALERIE2-FU|Pennington Biomedical Research Center|No|Completed|July 2009|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|42|||Both|21 Years|50 Years|No|Non-Probability Sample|Participants that completeded the CALERIE II study at Pennington Biomedical Research        Center.|January 2016|January 13, 2016|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943215||135916|
NCT00943449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4SC-201-1-2009|4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma|A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment|Shelter|4SC AG||Completed|July 2009|September 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943449||135898|
NCT00944580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 30761|A Vaccine Study for High Risk Cancers|A Phase 1 Study to Determine the Immunologic Effects of a MAGE- A1, MAGE- A3, NY-ESO-1 Vaccine in Patients With High Risk Neuroblastoma, Osteogenic Sarcoma, and Rhabdomyosarcoma||Penn State University|Yes|Terminated|June 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|70 Years|No|||August 2010|July 26, 2011|July 21, 2009|No|Yes|unexpectedly low screening results leading to poor accrual|No||https://clinicaltrials.gov/show/NCT00944580||135811|
NCT00944593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 320030-120597|Gastric vs Jejunal Feeding in Diabetic Gastroparesis|A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers||University of Zurich||Withdrawn||January 2011||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||April 2012|April 2, 2012|July 20, 2009||No|Principle Investigator moved to another institution. Research funds transferred. Study to be    performed at new institution|No||https://clinicaltrials.gov/show/NCT00944593||135810|
NCT00944853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917272|Effects of Liquid Zinc Supplementation and Dispersible Zinc Tablets on Plasma Zinc Concentration|The Effect of Zinc Supplementation, Provided as Either a Liquid Zinc Solution or Dispersible Tablets, on Plasma Zinc Concentration Among Young Burkinabe Children||University of California, Davis|Yes|Completed|August 2009|February 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|462|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||February 2010|February 18, 2010|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944853||135790|
NCT00944866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07146|Effects of Cox-II Inhibitor on Biochemical Markers in Cardiovascular-related Adverse Effects|||National Chung Hsing University||Active, not recruiting|March 2008|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Arthritis|July 2009|July 22, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944866||135789|
NCT00948597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0721|Development of PK/PD Model for Individualized Propofol Dosing|A Non-Interventional Study to Develop a Pharmacokinetic - Pharmacodynamic Model for Individualized Propofol Dosing||Children's Hospital Medical Center, Cincinnati|Yes|Completed|July 2009|December 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|Samples With DNA|Participation involves the collection of one blood sample (3.0 ml) in an EDTA (lavender top)      tube for pharmacogenetic testing. Genomic DNA will be extracted using standard procedures.      Participation in pharmacogenetic testing is optional and requires additional consent;      subjects who refuse pharmacogenetifc testing may still be enrolled in this study.|Both|5 Years|18 Years|No|Non-Probability Sample|Patients will be recruited from the Cincinnati Children's Hospital Medical Center Surgical        Weight Loss Program for Teens (Thomas Inge, Director), supplemented with general surgery        patients who are overweight and have a Body Mass Index (BMI) of more than 30.|January 2014|January 8, 2014|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948597||135502|
NCT00949741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFM|Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients|Observational Retrospective Multicenter Study for the Citofluorimetric Analysis of Cerebrospinal Fluid Vs Conventional Method in Patients With Aggressive Non-Hodgkin's Lymphoma Without Leptomeningeal Disease|CFM|Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie|No|Completed|July 2009|October 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|175|||Both|18 Years|N/A|No|Probability Sample|Patients affected by aggressive non-Hodgkin's lymphoma at diagnosis|July 2009|October 21, 2013|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949741||135414|
NCT00949169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eulji07-34|Carotid Intima-media Thickness (IMT) and Large-vessel Atherosclerosis by Multidetector Computed Tomography (MDCT)|Association of Carotid IMT and Large-vessel Atherosclerosis by MDCT in Korean Type 2 Diabetic Patients||Eulji University Hospital|Yes|Completed|April 2006|July 2007|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|71|||Both|40 Years|80 Years|No|Non-Probability Sample|type 2 diabetic patients who had multiple cardiovascular risk factors|July 2009|July 29, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949169||135458|
NCT00949429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si306/2009|Quality of Postoperative Pain Management in Cardiac Surgical Patients|Quality of Postoperative Pain Management in Cardiac Surgical Patients||Mahidol University|Yes|Completed|July 2009|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled for cardiac surgery in Siriraj Hospital|July 2011|July 21, 2011|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949429||135438|
NCT00946257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112438|Subcutaneous Administration of Otelixizumab to T1DM Patients|A Randomised, Single-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Ascending Administration of Otelixizumab in Subjects With Type 1 Diabetes Mellitus|RAO112438|GlaxoSmithKline|No|Completed|July 2009|June 2013|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|33|||Both|18 Years|65 Years|No|||May 2014|May 29, 2014|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946257||135682|
NCT00946569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016423|A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Exploratory Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults With Persistent Asthma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|65 Years|No|||March 2014|March 31, 2014|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946569||135658|
NCT00944697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN2502|A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy|An Exploratory, Randomised, Double-blind, Single-dummy, Placebo Controlled, Parallel Group Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy||Mundipharma Research GmbH & Co KG|No|Completed|July 2009|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|98|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|July 22, 2009||No||No|November 22, 2011|https://clinicaltrials.gov/show/NCT00944697||135802|
NCT00944710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-144|Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old|Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old|ATS16|Jaeb Center for Health Research|Yes|Completed|August 2009|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|3 Years|7 Years|No|||February 2016|February 22, 2016|July 21, 2009|Yes|Yes||No|October 9, 2014|https://clinicaltrials.gov/show/NCT00944710||135801|A potential study limitation is that compliance with patching was based on discussions with the parent and by reviewing study calendars maintained by the parent, which not an objective measure of compliance.
NCT00944983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT09-00420-XP|Clinical Validation of the Tiba Medical Ambulo 2400 ABPM According to the ISO 80601-2-30 Standard in Adults, Adolescents, and Children|Clinical Validation of the Tiba Medical Ambulo 2400 ABPM According to the ISO 80601-2-30 Standard in Adults, Adolescents, and Children||Tiba Medical, Inc.|Yes|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|N/A||1|Actual|105|None Retained|Only blood pressure measurements are retained|Both|3 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults, Adolescents, and Children of different genders, ages, races & sizes (height,        weight & particularly arm size) plus blood pressure ranges (normatensive, hypotensive and        hypertensive).|May 2014|May 6, 2014|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944983||135780|
NCT00945256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-213|Muscle Perfusion and Protein Metabolism in Elderly|A Phase I Trial Examining Muscle Perfusion and Protein Metabolism in Elderly and Young||The University of Texas Medical Branch, Galveston|No|Completed|May 2003|May 2009|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|5||Actual|62|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2014|January 5, 2016|July 22, 2009|No|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT00945256||135759|
NCT00945230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Act2NS|Actigraphic Measurement of a Neurosurgical Procedure|Analysis of Post Surgical Response in A Fifty-Six Year Old Female With An Incidental Large Left Anterior Cranial Fossa Meningioma||Child Psychopharmacology Institute|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1|||Female|21 Years|75 Years|No|||July 2009|July 23, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945230||135761|
NCT00945243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZeroP-021109|Clinical Outcomes Study Evaluating the Zero-P PEEK|Prospective, Multi-Center Clinical Outcomes Study Evaluating the Zero-P PEEK for Anterior Cervical Interbody Fusion in the Treatment of Cervical Degenerative Disc Disease||Synthes USA HQ, Inc.|No|Terminated|July 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|70 Years|No|||January 2014|January 29, 2014|July 22, 2009|No|Yes|This study was terminated early due to lower than expected enrollment rates.|No||https://clinicaltrials.gov/show/NCT00945243||135760|
NCT00945516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0233|Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture|Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture: Prospective Randomized Study||Asan Medical Center|Yes|Completed|January 2009|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||October 2010|October 18, 2010|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00945516||135739|
NCT00945490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX02-0018|Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018|Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018||Nymox Corporation|No|Completed|May 2009|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Male|45 Years|N/A|No|||September 2014|September 24, 2014|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945490||135741|
NCT00945503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109731|Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.|An Adaptive PET Study in Healthy Volunteers Using [11C]GSK931145 to Establish the Relationship of Glycine Transporter 1 Occupancy by GSK1018921 to Plasma Concentrations Over Time.||GlaxoSmithKline||Completed|May 2008|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 30, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945503||135740|
NCT00946426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00160|Insulin Resistance in Type I Diabetes in Pediatric Care|Insulin Resistance in Type I Diabetes in Pediatric Care||Nationwide Children's Hospital|No|Withdrawn|July 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|9 Years|23 Years|No|Non-Probability Sample|Endocrinology clinic patients|May 2015|May 14, 2015|July 24, 2009||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00946426||135669|
NCT00946439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Revital123|Wheel Assisted Running Training (WART) in Children With Cerebral Palsy|Wheel Assisted Running Training in Children With Cerebral Palsy: A Controlled Clinical Trial|WART|Israel Sport Center for the Disabled|Yes|Completed|September 2004|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|||Actual|30|||Both|6 Years|19 Years|No|||July 2009|July 24, 2009|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946439||135668|
NCT00943423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03_DOG05_07|PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma|A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease|RAPID|University College, London|Yes|Active, not recruiting|July 2003|December 2015|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|602|||Both|16 Years|75 Years|No|||December 2014|December 3, 2014|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943423||135900|
NCT00943436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Univ. of Tennessee IRB:7679B|The Effects of Exercise on Dietary Intake|The Effects of Exercise on Energy Balance and Macronutrient Intake in College-aged Males||University of Tennessee|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2011|June 13, 2011|July 20, 2009||No||No|July 2, 2010|https://clinicaltrials.gov/show/NCT00943436||135899|
NCT00944008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODECYTE|PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia|PROCEDYTE: An Open, Prospective, Multicentre Clinical Trial With Historic Control to Determine Efficacy and Safety of Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration of Patients Between 16 and 30 Years Old With Standard Risk Acute Lymphoblastic Leukemia (ALL|2009-009422-92|PETHEMA Foundation|Yes|Terminated|September 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7|||Both|16 Years|30 Years|No|||April 2014|May 7, 2015|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00944008||135855|
NCT00944255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06289|Pharmacogenetics of Antifolate Drugs in Autoimmune Diseases in Taiwan|||National Chung Hsing University||Completed|February 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Both|18 Years|N/A||Probability Sample|A cross-sectional study involving 150 patients with RA were enrolled from TCVGH.|July 2009|July 22, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944255||135836|
NCT00944268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E01-AT-CAL-03-08|Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety|Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety|E01ATCAL0308|Ativus Farmaceutica Ltda|Yes|Not yet recruiting|September 2009|January 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|124|||Both|18 Years|N/A|No|||July 2009|July 23, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944268||135835|
NCT00944281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236850|Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS)|A Randomized, Double-blind, Controlled Trial in Rural Burkina Faso to Determine the Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS). Part of the iLiNS Study||University of California, Davis|No|Completed|May 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|3220|||Both|9 Months|9 Months|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944281||135834|
NCT00944606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 09-167|Vitamin D Versus Placebo in the Treatment of Vague Musculoskeletal Pain in Children|Vitamin D vs Placebo in the Treatment of Vague Musculoskeletal Pain in Children||University of New Mexico|Yes|Withdrawn|July 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|14 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|July 21, 2009||No|inability to recruit subjects|No||https://clinicaltrials.gov/show/NCT00944606||135809|
NCT00944879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35384|Preparing for Adolescent HIV Vaccine Trials in South Africa:|Preparing for Adolescent HIV Vaccine Trials in South Africa: a Multi-centre Study to Evaluate Acceptability of the HPV Vaccine in Adolescents|CATSA|Desmond Tutu HIV Centre|Yes|Not yet recruiting|August 2009|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1400|Samples Without DNA|Blood for HIV, syphilis and pregnancy testing|Both|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|South African adolescents aged 12 to 17|July 2009|August 14, 2009|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00944879||135788|
NCT00949182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649008|Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery|Micro and Macro Arteriolar Blockade of Hepatocellular Carcinoma (HCC): Treatment With Sorafenib Before and After Hepatic Arterial Embolization (HAE) Therapy for Liver Cancer.||Rutgers, The State University of New Jersey|No|Completed|July 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949182||135457|
NCT00949481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10083|Increasing Family Planning Uptake Among Postpartum Women|Increasing Family Planning Uptake Among Postpartum Women: Testing Supply and Demand Solutions||FHI 360|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|14050|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2012|August 15, 2012|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949481||135434|
NCT00945412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04-031|Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding|Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding||Massachusetts Eye and Ear Infirmary|No|Withdrawn|July 2009|September 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|5 Years|18 Years|No|||December 2010|December 6, 2010|July 23, 2009|Yes|Yes|PI moving to another institution|No||https://clinicaltrials.gov/show/NCT00945412||135747|
NCT00945425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00015|AZD7325 Japan Multiple Ascending Dose (MAD) Study|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7325 When Given in Multiple Ascending Oral Doses in Healthy Male Japanese Subjects|JMAD|AstraZeneca||Terminated|July 2009|November 2009|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 15, 2011|July 23, 2009|No|Yes|Decided to stop development of this compound globally|No||https://clinicaltrials.gov/show/NCT00945425||135746|
NCT00949715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optimize RV Follow-Up|Optimize RV Follow-up Selective Site Pacing Clinical Trial|Optimize RV Follow-up Selective Site Pacing Clinical Trial|ORVFUP|Medtronic Cardiac Rhythm Disease Management|No|Completed|September 2009|December 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|67|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|July 28, 2009||No||No|March 11, 2013|https://clinicaltrials.gov/show/NCT00949715||135416|Since the enrollment goal of the study (n=160) was not met (it was decided to stop enrollments after 67 due to slow enrollments), the results of the study were not powered and the results for the primary objective are inconclusive at this time.
NCT00949728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cola106|Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia|Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia||Hospital de Olhos Sadalla Amin Ghanem|Yes|Completed|October 2006|July 2009|Actual|August 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2009|July 29, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00949728||135415|
NCT00949962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22043-30041|Post-operative or Early Salvage XRT and ADT for High Risk PCa|Immediate or Early Salvage Post-operative External Radiotherapy Combined With Concomitant and Adjuvant Hormonal Treatment Versus Immediate or Early Salvage Postoperative External Radiotherapy Alone in pT3a-b R0-1 cN0M0 / pT2R1 cN0M0, Gleason Score 5-10 Prostatic Carcinoma. A Phase III Study||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Terminated|October 2009|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Male|N/A|80 Years|No|||July 2014|July 3, 2014|July 30, 2009||No|Poorly recruiting|No||https://clinicaltrials.gov/show/NCT00949962||135397|
NCT00949975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00012|A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium|A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium||AstraZeneca|Yes|Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|838|||Both|40 Years|80 Years|No|||June 2012|June 19, 2012|July 21, 2009|Yes|Yes||No|January 24, 2012|https://clinicaltrials.gov/show/NCT00949975||135396|
NCT00946010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801059R|Investigation of Hepatitis B and Hepatitis C in Taiwan|Investigation of Hepatitis B and Hepatitis C in Taiwan||National Taiwan University Hospital|Yes|Completed|April 2008|January 2011|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|6228|Samples With DNA|10ml blood was sampled and then serum was be retained.|Both|23 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People Born before 1985/01/01 who live in Taiwan are HBV or HCV pateints.|January 2011|January 20, 2011|April 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00946010||135701|
NCT00946270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0199|Pomalidomide for Myelofibrosis Patients|A Phase II, Prospective, Open Label Study to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2009|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946270||135681|
NCT00946283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060802|Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome|Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)||Rutgers, The State University of New Jersey|Yes|Active, not recruiting|March 2010|September 2015|Anticipated|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|July 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946283||135680|
NCT00944762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30MH085943|Ecosystem Focused Therapy for Treating Older Depressed Stroke Survivors|Ecosystem Focused Therapy for Depressed Stroke Survivors||Weill Medical College of Cornell University|Yes|Completed|May 2009|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|N/A|No|||June 2015|June 10, 2015|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944762||135797|
NCT00944450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-027|Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)|An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of Tablet Formulations Containing the Anhydrous and Monohydrate (FMI) Forms of MK0431||Merck Sharp & Dohme Corp.||Completed|August 2004|November 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|July 21, 2009|No|Yes||No|February 24, 2010|https://clinicaltrials.gov/show/NCT00944450||135821|
NCT00944723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107008-2|Impact of Mass Zinc Fortification Programs on Plasma Zinc Concentration|Evaluation of the Use of Plasma Zinc Concentration for Assessing the Impact of Targeted and Mass Zinc Fortification Programs||University of California, Davis|No|Completed|August 2009|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|132|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 18, 2010|July 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00944723||135800|
NCT00945269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2271.00|Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma|Phase I/II Study To Evaluate The Safety Of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following CD25 Lymphodepletion For Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center|Yes|Terminated|July 2009|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|75 Years|No|||December 2011|December 2, 2011|July 23, 2009|Yes|Yes|ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer    be supporting clinical trials that utilize this drug.|No||https://clinicaltrials.gov/show/NCT00945269||135758|
NCT00945529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPURE1|The Effects of Inhaled Nitric Oxide After Fontan Operation|The Effects of Inhaled Nitric Oxide on Patient Morbidity and Length of Hospital Stay Following Fontan Operation||Nemours Children's Clinic|Yes|Completed|August 2006|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|1 Year|5 Years|No|||May 2012|May 2, 2012|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945529||135738|
NCT00945542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461-2008|The Trauma- Formula-Driven Versus Lab-Guided Study (TRFL Study)|Formula-driven vs Laboratory-guided Transfusion Practices in Bleeding Trauma Patients: A Feasibility Randomized Controlled Study|TRFL|Sunnybrook Health Sciences Centre|Yes|Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|N/A|No|||December 2011|December 1, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945542||135737|
NCT00945555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1891006|Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options|Multi-Center, Non-Interventional, Observational Study To Evaluate The Antibacterial Therapeutical Options In Febrile Neutropenia Patients||Pfizer|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|264|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with febrile neutropenia who were planning to take antibacterial treatment.|November 2011|November 14, 2011|July 23, 2009|No|Yes||No|September 23, 2011|https://clinicaltrials.gov/show/NCT00945555||135736|
NCT00945815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0910|S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia||Southwest Oncology Group|Yes|Active, not recruiting|September 2010|August 2017|Anticipated|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|16 Years|N/A|No|||March 2015|March 5, 2015|July 23, 2009|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT00945815||135716|
NCT00945841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V44_13S|Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010 When Administered to Adult and Elderly Subjects||Novartis||Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 23, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945841||135714|
NCT00942877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090192|Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma|Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma||National Institutes of Health Clinical Center (CC)||Recruiting|July 2009|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|73|||Both|N/A|16 Years|No|||July 2015|February 25, 2016|July 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942877||135942|
NCT00942955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUEMS200801|Point-Of-Care Chemistry Test (POCT) Effect on the Emergency Department (ED)|A Randomized Controlled Multi-center Trial of a Point-Of-Care Chemistry Test for Reduction of Turnaround and Clinical Decision Time in the Emergency Department||Seoul National University Hospital|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|15 Years|N/A||Probability Sample|This study was performed in five EDs. Three were urban EDs with 30,000 to 45,000 annual        visits, and two were suburban EDs with 15,000 to 25,000 annual visits. Each hospital has        its own central laboratory which can test the same emergency chemistry tests, including        liver panel (alkaline phosphatase, protein, albumin, total bilirubin, direct bilirubin,        GOT, and GPT), renal panel (BUN, creatinine, calcium, and phosphorus), pancreas enzymes        (amylase, lipase), electrolytes (sodium, potassium, chloride, total CO2), lipid panel        (total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol), and blood gases (pH,        pO2, pCO2, and bicarbonate).|July 2009|July 20, 2009|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942955||135936|
NCT00943761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-028|A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)|A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials||Merck Sharp & Dohme Corp.|No|Completed|October 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|July 21, 2009|No|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT00943761||135874|
NCT00943475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE:0101.0.180.000-08|Assessment of Hemodynamic Response in Surgery of Circumcision in Children|Assessment of Hemodynamic Response and Pos-operatory Pain in Surgery of Circumcision in Children||Federal University of Juiz de Fora|Yes|Completed|March 2009|June 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Male|3 Years|13 Years|Accepts Healthy Volunteers|||March 2009|July 21, 2009|July 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943475||135896|
NCT00943488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0043|CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted CSL H1N1 Influenza Vaccine Administered at Two Dose Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|408|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|October 25, 2012|July 21, 2009|Yes|Yes||No|March 10, 2011|https://clinicaltrials.gov/show/NCT00943488||135895|
NCT00943774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-004352|High Resolution Phenotyping in Healthy Humans|Blood Pressure Variability, Baroreflex Sensitivity, and Cardiovascular Responses to Sympathoexcitation in Healthy Normotensive Humans||Mayo Clinic|Yes|Completed|April 2006|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|Samples With DNA|serum, white cells|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Southeast Minnesota|January 2016|January 5, 2016|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943774||135873|
NCT00944021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-824-CL-010|Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)|A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis||Global Alliance for TB Drug Development|No|Completed|August 2009|May 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|69|||Both|18 Years|64 Years|No|||February 2014|February 11, 2016|July 21, 2009|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT00944021||135854|
NCT00953212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-3514|Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery|A Randomized Controlled Trial to Compare Prophylaxis With Oral Ascorbic Acid, Oral Amiodarone or Both in Combination With Beta Blockers to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery||Maine Medical Center|Yes|Completed|August 2009|February 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|304|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953212||135150|
NCT00953459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08061|Sunitinib Malate in Treating Patients With Small Cell Lung Cancer|Phase II Study of Sunitinib (SU011248) in Patients With Small Cell Lung Cancer Who Are Either Chemo-naïve (Extensive Disease) or Have a "Sensitive" Relapse||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|February 2009|September 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|August 5, 2009||No|poorly recruiting|No||https://clinicaltrials.gov/show/NCT00953459||135132|
NCT00949494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH 06-159|Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)|Pilot Trial of Effects of Intra-articular Synvisc Therapy on Cartilage Determined by dGEMRIC in Patients With OA of the Knee||NorthShore University HealthSystem Research Institute|No|Completed|September 2006|February 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|40 Years|80 Years|No|||July 2009|July 29, 2009|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949494||135433|
NCT00946296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11597|Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease|Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease||University of Massachusetts, Worcester|No|Completed|April 2005|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|July 22, 2009||No||No|October 9, 2015|https://clinicaltrials.gov/show/NCT00946296||135679|Difficulty in enrolling subjects related to national shortages of potassium iodine which limited drug availability and contributed to delayed accrual as did decreased eligible patients and waning interest over time.
NCT00945672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951007|A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease|A Phase 2 Double-Blinded, Randomized, Placebo-Controlled, Multicenter Study Evaluating The Safety, Tolerability And Pharmacokinetics/ Pharmacodynamics Of PF-04360365 In Mild To Moderate Alzheimer's Disease Patients||Pfizer|Yes|Completed|August 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|50 Years|N/A|No|||June 2011|June 17, 2011|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945672||135727|
NCT00945685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN-IOP - 01|Evaluation of Safety and Efficacy of Using Imagine™ Computerized Radiofrequency System for Skin Tightening|Evaluation of Safety and Efficacy of Using Imagine™ Computerized Radiofrequency System for Skin Tightening||Endymion Medical Ltd|No|Completed|July 2008|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|30 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 23, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945685||135726|
NCT00946023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0941|Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab|Nonmyeloablative BMT With Post-transplant Cyclophosphamide, Rituximab and Optimized Donor Selection for B-cell Lymphomas||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|July 2009|August 2015|Anticipated|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|1 Year|75 Years|No|||September 2013|September 20, 2013|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00946023||135700|
NCT00942461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1948-04|Inflammatory Response in Laparoscopic and Open Colectomy|Contribution to the Study of Inflammatory Response in Laparoscopic vs Open Colon Cancer Surgery||G. Hatzikosta General Hospital|Yes|Completed|October 2008|||June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|40|||Both|N/A|N/A||||July 2009|July 20, 2009|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942461||135973|
NCT00942734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0567|Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma|Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck||M.D. Anderson Cancer Center|No|Completed|July 2009|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 20, 2009|Yes|Yes||No|November 24, 2015|https://clinicaltrials.gov/show/NCT00942734||135953|
NCT00942747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TemPCNSL|Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma|Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma||Charite University, Berlin, Germany|No|Recruiting|July 2009|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|75 Years|No|||April 2013|April 15, 2013|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942747||135952|
NCT00945854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04022009|Wholegrain Cereal Diet and Insulin Sensitivity|Effect of Whole Grain Rich Diet on Insulin Sensitivity in Individuals With Metabolic Syndrome||Federico II University|No|Completed|March 2008|December 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|70 Years|No|||May 2014|May 26, 2014|July 22, 2009||No||No|April 17, 2014|https://clinicaltrials.gov/show/NCT00945854||135713|
NCT00946179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT86|Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intramuscular Route)||Sanofi|No|Completed|May 2009|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 16, 2014|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00946179||135688|
NCT00944736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 06-115|Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease|Effect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in Remission||Children's Mercy Hospital Kansas City|Yes|Completed|July 2009|July 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|11 Years|17 Years|No|||March 2014|March 6, 2014|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944736||135799|
NCT00944749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090183|Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment|Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2009|December 2020|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|2 Years|82 Years|No|||January 2016|January 14, 2016|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00944749||135798|
NCT00946478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSDMED|Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema|A Three-week, Double-blind, Randomized Study to Evaluate the Effect of Pimecrolimus Cream 1% on Cathelicidin Expression in the Skin of Subjects With Atopic Dermatitis||University of California, San Diego|No|Completed|October 2009|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||January 2014|January 27, 2014|July 24, 2009|Yes|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT00946478||135665|
NCT00945828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGPB PBP 105184|Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors|Assessing Implementation and Effectiveness of Individual Education Plans for Children With Chronic Illness||University of Miami|No|Completed|January 2003|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|62|||Both|6 Years|12 Years|No|||March 2012|March 6, 2012|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945828||135715|
NCT00946153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-J081-202|Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)|Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)||Eisai Inc.||Completed|July 2009|December 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|20 Years|80 Years|No|||June 2015|June 19, 2015|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946153||135690|
NCT00946166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2009-183H|Impact of Statins on Cytokine Expression in Pneumonia|Impact of Statins on Cytokine Expression in Pneumonia||The University of Texas Health Science Center at San Antonio|No|Withdrawn|July 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|July 22, 2009||No|Investigator left institution.|No||https://clinicaltrials.gov/show/NCT00946166||135689|
NCT00942604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-028|A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05%, In Patients With Actinic Keratoses on Non-head Locations (REGION-Ib)||Peplin|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||November 2013|February 18, 2015|July 19, 2009|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT00942604||135963|
NCT00942929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/08|Lung Function Tests in Adolescents With Anorexia Nervosa|Lung Function Tests in Adolescents With Anorexia Nervosa||Bnai Zion Medical Center|Yes|Recruiting|September 2008|December 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|15|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents 12-18 years old hospitalized to a pediatric ward|July 2009|July 20, 2009|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942929||135938|
NCT00942942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-45|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2009|||||N/A|N/A|N/A||||||||||||||January 31, 2011|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942942||135937|
NCT00943241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001046|Screening in Myocardial Perfusion Patients|Screening for Breast Cancer in Patients Undergoing Myocardial Perfusion Imaging||Mayo Clinic|No|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|322|||Female|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female subjects who are undergoing Myocardial Perfusion imaging in the Nuclear Cardiology        laboratory at the Mayo Clinic in Rochester, MN.|February 2013|February 12, 2013|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943241||135914|
NCT00952354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|473492/2007-5|Oral Language in Children With Down Syndrome|Oral Language in Children With Down Syndrome: Lexical, Syntactic and Semantic Aspects||University of Sao Paulo|Yes|Active, not recruiting|August 2007|August 2009|Anticipated|April 2009|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|3 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 children with Down syndrome aged from 3 to 10 years|August 2009|August 4, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952354||135213|
NCT00952640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitA_PP|Making Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and Inflammation|Making Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and Inflammation.||Institut de Recherche pour le Developpement|No|Completed|June 2010|October 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|400|||Female|18 Years|50 Years||||October 2012|October 9, 2012|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952640||135191|
NCT00952913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1108|Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects|A Study to Examine The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib When Administered Concomitantly To Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|August 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00952913||135171|
NCT00953225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-004-09S|Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer|Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer|vit D & PCa|VA Office of Research and Development|Yes|Completed|January 2010|October 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Male|19 Years|85 Years|No|||March 2015|March 23, 2015|August 4, 2009|No|Yes||No|February 10, 2015|https://clinicaltrials.gov/show/NCT00953225||135149|
NCT00953472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003032|B-type Natriuretic Peptide (BNP) in Human Hypertension|Clinical Proteomics and Protein Therapeutics in Human Hypertension (BNP in Human Hypertension - Phase 1)||Mayo Clinic|Yes|Terminated|February 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|90 Years|No|||October 2011|October 10, 2011|April 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00953472||135131|
NCT00945126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKI-SCT-HAPLO-0106|Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk Diseases|Allogeneic Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells of Related or Unrelated Haploidentical Donors in Pediatric Patients With Malignant and Non-malignant Diseases||Johann Wolfgang Goethe University Hospitals|No|Recruiting|December 2006|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|N/A|30 Years|No|||April 2015|February 24, 2016|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00945126||135769|
NCT00946309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS 2333.00|Effects of Sulforaphane on Normal Prostate Tissue|In Vivo Effects of Sulforaphane Supplementation on Normal Human Prostate|PHASE|Fred Hutchinson Cancer Research Center|Yes|Enrolling by invitation|July 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Male|40 Years|75 Years|No|||March 2014|March 28, 2014|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946309||135678|
NCT00946322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-019-09S|Couple-Based Treatment for Alcohol Use Disorders and Post-Traumatic Stress Disorder|Couple-Based Treatment for Alcohol Use Disorders and PTSD|CTAP|VA Office of Research and Development|No|Completed|August 2010|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|July 23, 2009||No||No|December 8, 2015|https://clinicaltrials.gov/show/NCT00946322||135677|Study was an initial open-trial pilot study. A causal relationship cannot be determined between study interventions and outcomes due to lack of a comparison condition.
NCT00946595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-009776-13|Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients|A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL|ANRS 140 DREAM|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|November 2009|January 2014|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946595||135656|
NCT00942435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-042|A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery|A Randomized, Open Label Parallel Group Mechanical Prophylaxis Controlled Comparison Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery||Astellas Pharma Inc|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|156|||Both|40 Years|N/A|No|||June 2010|June 14, 2010|July 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942435||135975|
NCT00947479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMLodz OSA-AKI|Effect of Obstructive Sleep Apnea on Central Blood Pressure and Kidney and Endothelial Function|Effect of Correction of Obstructive Sleep Apnea With Positive Airway Pressure on Central Blood Pressure and Kidney and Endothelial Function|OSA-AKI|Medical Universtity of Lodz|Yes|Recruiting|February 2009|July 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Male|18 Years|70 Years|No|||July 2009|July 27, 2009|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947479||135588|
NCT00945594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cystoscopy|Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females|Randomized Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females||University of Oklahoma|Yes|Completed|July 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 29, 2013|July 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00945594||135733|
NCT00944996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|akparl08|Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression|Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression||Tirat Carmel Mental Health Center|Yes|Completed|June 2009|July 2012|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|July 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00944996||135779|
NCT00946205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lap rectopexy 200660096|Laparoscopic Rectopexy for Rectal Prolapse|Laparoscopic Posterior Rectopexy Without Mesh vs. Laparoscopic Anterior Mesh Rectopexy for Rectal Prolapse - a Prospective, Double-blind, Randomised Study||Aarhus University Hospital|No|Completed|September 2006|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00946205||135686|
NCT00942266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 142808|Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment|A Randomized Phase II Study of Two Dose-Levels of Vorinostat in Combination With 5-FU and Leucovorin in Patients With Refractory Metastatic Colorectal Cancer||Roswell Park Cancer Institute|Yes|Completed|July 2009|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|July 17, 2009|Yes|Yes||No|December 26, 2013|https://clinicaltrials.gov/show/NCT00942266||135987|
NCT00942578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090195|A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer|A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2009|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Male|18 Years|100 Years|No|||September 2015|October 8, 2015|July 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942578||135965|
NCT00942591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17/05|Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b|Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.|SWABIMS|University Hospital Inselspital, Berne|Yes|Completed|May 2005|May 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|55 Years|No|||July 2009|July 20, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942591||135964|
NCT00943462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-08-234|Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM|Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme||Centre hospitalier de l'Université de Montréal (CHUM)|No|Withdrawn|June 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Non-Probability Sample|GBM patients seen at the neuro-oncology clinic of Centre hospitalier de l'Université de        Montréal (CHUM)|April 2011|April 26, 2011|July 20, 2009||No|No eligible patients could be recruited.|No||https://clinicaltrials.gov/show/NCT00943462||135897|
NCT00952094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT09_KRN1493|Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493|Randomized, Open Clinical Trial to Evaluate Pharmacokinetic, Pharmacodynamic and Safety Profiles After Single Oral Administration of KRN1493 in Healthy Korean Male Subjects||Seoul National University Hospital||Completed|November 2008|June 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||August 2009|August 3, 2009|August 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00952094||135233|
NCT00952367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4602|Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China|Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children Aged 12-18 Months in Six Cities of China||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3641|Samples Without DNA|Nasopharyngeal swab|Both|12 Months|18 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Children 12 to 18 months old|March 2012|March 12, 2012|August 3, 2009||No||No|March 12, 2012|https://clinicaltrials.gov/show/NCT00952367||135212|
NCT00952653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-1205|Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam|An Open-Label, Two-Period, Sequential Drug Interaction Study to Evaluate the Effect of Multiple Doses of Desvenlafaxine Succinate Sustained Release (DVS SR) on the Pharmacokinetics of Midazolam When Coadministered in Healthy Subjects||Pfizer|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 9, 2011|August 3, 2009|Yes|Yes||No|July 6, 2011|https://clinicaltrials.gov/show/NCT00952653||135190|
NCT00952926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20090063|Watchful Waiting. An Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy|A Prospective Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy||Vejle Hospital|Yes|Active, not recruiting|September 2009|December 2018|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients referred from surgical departments in Denmark.|May 2015|May 20, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952926||135170|
NCT00953771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-08|Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura|Phase II Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura|TTP|Beth Israel Medical Center|No|Recruiting|October 2008|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|60 Years|No|||July 2015|July 17, 2015|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953771||135108|
NCT00945698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iLiNS-DOSE|Prevention of Linear Growth Failure in Infants and Young Children With Lipid-based Nutrient Supplements (iLiNS-DOSE)|A Two-centre, Randomised, Single-blind, Parallel Group Controlled Trial, Testing the Growth Promoting Effect of Long-term Complementary Feeding of Infants With Different Doses and Formulations of Lipid-based Nutrient Supplements (LNS)|iLiNS-DOSE|University of Tampere|Yes|Completed|November 2009|August 2014|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|1920|||Both|167 Days|197 Days|Accepts Healthy Volunteers|||May 2015|May 26, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00945698||135725|
NCT00946036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40486|Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed Conditions|||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|N/A|N/A||||July 2009|July 23, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00946036||135699|
NCT00946608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA27842|To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets|Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Sandoz Inc. and Schering (Claritin) 10 mg Loratadine Tablets In Healthy Adult Male Volunteers Under Fed and Fasting Conditions||Sandoz||Completed|June 2005|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946608||135655|
NCT00946621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B043724|To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions|A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions||Sandoz||Completed|October 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946621||135654|
NCT00946634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 154/06|Ozone Therapy in Endodontic Practice, in Vivo Study|Phase 4 - Ozone Therapy in Endodontic Practice, in Vivo Study||University of Sao Paulo|Yes|Completed|January 2009|March 2011|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|13 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 2, 2011|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946634||135653|
NCT00942448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09PUK-DCsc04|Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery|Efficacy and Safety Study of Diclofenac HPBCD 25, 50 mg/ml Administered as Single s.c. Dose, in the Treatment of Acute Moderate-to-severe Post-surgical Pain From Dental Surgery (Impacted 3rd Molar Extraction)||IBSA Institut Biochimique SA|No|Completed|September 2009|April 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|306|||Both|18 Years|65 Years|No|||February 2011|December 17, 2012|July 17, 2009||No||No|November 16, 2012|https://clinicaltrials.gov/show/NCT00942448||135974|No limitations of the trial have been detected
NCT00946517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00224|Impaired Family Dynamics Leads to Non Compliance in Type I Diabetes|Impaired Family Dynamics Leads to Non Compliance in Type I Diabetes||Nationwide Children's Hospital|No|Terminated|July 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Actual|20|||Both|9 Years|18 Years|No|Non-Probability Sample|Endocrinology clinic patients|May 2015|May 14, 2015|July 24, 2009||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT00946517||135662|
NCT00946192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000353|Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes|Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes||Massachusetts General Hospital|Yes|Recruiting|May 2009|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|230|||Female|14 Years|21 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946192||135687|
NCT00946452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RMY-SYM-2009/1|Symbicort SMART Satisfaction From Patient Perspective 2009|Symbicort SMART Satisfaction From Patient Perspective 2009||AstraZeneca|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|205|||Both|18 Years|59 Years|No|Non-Probability Sample|Primary care clinic|March 2010|March 17, 2010|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946452||135667|
NCT00946465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B043723|To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions|A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions||Sandoz||Completed|October 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946465||135666|
NCT00942617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 080895|Measurement of Platelet Dense Granule Release in Healthy Volunteers|Measurement of Platelet Dense Granule Release in Healthy Volunteers||Vanderbilt University|No|Withdrawn|July 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|July 17, 2009||No|funding issue|No||https://clinicaltrials.gov/show/NCT00942617||135962|
NCT00946491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-01|To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers|An Open-Label, Single-Dose, Crossover Study to Determine the Bioequivalency of Generic Haloperidol Tablets vs. Haldol in Normal Volunteers.||Sandoz||Completed|April 1987|May 1987|Actual|May 1987|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946491||135664|
NCT00946504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9208525-G2|To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets|A Two-Way Crossover Bioequivalence Study Comparing Single 10 mg Doses of Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets||Sandoz||Completed|October 1992|October 1992|Actual|October 1992|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946504||135663|
NCT00942903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD781_3CHME|Short-term Clinical Feasibility of the Provox XtraHMEs for Pulmonary Rehabilitation After Total Laryngectomy|Phase 1 Study. Short-term Feasibility of the Next Generation Provox HMEs for Pulmonary Rehabilitation After Total Laryngectomy|N08HME|Atos Medical AB|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|N/A|No|||October 2010|October 13, 2010|July 20, 2009|Yes|Yes||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00942903||135940|
NCT00942292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10097|The Effect of Fish Oils on Human Hepatic Colorectal Metastases|Randomised Controlled Trial of the Effects of Fish Oil Emulsion in Total Parenteral Nutrition Upon Tumour Vascularity in Patients With Hepatic Colorectal Metastases||University Hospitals, Leicester|Yes|Completed|May 2007|October 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||June 2013|June 24, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00942292||135986|
NCT00942305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-201|Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients||Chimerix|Yes|Completed|October 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942305||135985|
NCT00942994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100AUS02|Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension|An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension|ASCENT|Novartis||Completed|June 2009|||March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|412|||Both|18 Years|N/A|No|||May 2011|May 16, 2011|July 19, 2009|Yes|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT00942994||135933|
NCT00952380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAG-A001-201|Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients|A Three Month Prospective Open Label Study Of Therapy With Fragmin (Registered) (Dalteparin Sodium Injection) In Children With Venous Thromboembolism With Or Without Malignancies||Pfizer|No|Recruiting|August 2009|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|18 Years|No|||March 2016|March 24, 2016|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00952380||135211|
NCT00953251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TnT hs 2|TnThs Predicting Evolving Non-STEMI|High Sensitive Cardiac Troponin T for Early Prediction of Evolving Non-ST Segment Elevation Myocardial Infarction in Patients With Suspected Acute Coronary Syndrome and Negative Troponin Result on Admission||Heidelberg University|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|115|Samples Without DNA|Blood samples were collected on admission and ideally every hour within the initial 6 hours      after admission, unless the patient refused the blood draw, or venipuncture was not feasible      due to technical reasons.      After collection, blood samples were centrifuged immediately and serum stored at -80°C until      analysis. The laboratory staff responsible for measurements was blinded to patient data.|Both|18 Years|N/A|No|Probability Sample|Between May 2008 and December 2008, 115 consecutive patients were enrolled with symptoms        suggestive of ACS. All patients received a 12-lead electrocardiogram recording on        admission, and a second 12-lead ECG after 6 hours. Blood samples were collected on        admission and ideally every hour within the initial 6 hours after admission.|August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953251||135148|
NCT00953485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJGLYY002|Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)|Clinical Trial of Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome - Phase Ⅰ/Ⅱ||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|June 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|70 Years|No|||August 2009|August 19, 2009|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953485||135130|
NCT00945711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03802-08-C|Characteristics of Persons With an Eating Disorder and Type 1 Diabetes|Characteristics of Persons With an Eating Disorder and Type 1 Diabetes and Psychological Comparisons to Persons With an Eating Disorder and No Diabetes||HealthPartners Institute|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|154|||Both|N/A|N/A|No|Non-Probability Sample|Park Nicollet Eating Disorder Institute patient and International Diabetes Center type 1        diabetes patients|August 2013|November 30, 2015|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945711||135724|
NCT00945724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG30|This Trial is a Safety and Feasibility Study of Combination of State of the Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Testicular Diffuse Large B-cell Lymphoma|A Phase II Study of R-CHOP With Intensive CNS Prophylaxis and Scrotal Irradiation in Patients With Primary Testicular Diffuse Large B-cell Lymphoma|IELSG30|International Extranodal Lymphoma Study Group (IELSG)||Recruiting|April 2009|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|18 Years|80 Years|No|||June 2015|June 3, 2015|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945724||135723|
NCT00946049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|323/05|Oral Bacteria on Suture Materials - Clinical Comparison of an Antibacterial-coated and a Non-coated Suture Material|Oral Bacteria on Suture Materials - Clinical Comparison of an Antibacterial-coated and a Non-coated Suture Material (VICRYL PLUS® vs. VICRYL®, Ethicon) in Intraoral Dentoalveolar Surgery||University Hospital Freiburg|No|Completed|March 2005|February 2008|Actual|June 2007|Actual|N/A|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|50 Years|No|||July 2009|July 23, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00946049||135698|
NCT00946062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-3-057.5/pl|Evaluation of a Standardised Orientation and Mobility Training in Older Adults With Low Vision|The Impact of Orientation and Mobility Training on Mobility, Participation and Quality of Life in Older Adults With Visual Impairments: a Randomised Controlled Trial||Maastricht University Medical Center|No|Completed|November 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|55 Years|N/A|No|||November 2013|November 14, 2013|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946062||135697|
NCT00950820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO KRK 0107|Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer|An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study)|VOXEL|AIO-Studien-gGmbH|Yes|Terminated|September 2009|March 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|July 31, 2009||No|Recruitment rate to low; changed environment made protocol in its current state obsolete|No||https://clinicaltrials.gov/show/NCT00950820||135331|
NCT00950833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112801|Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children|Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children||GlaxoSmithKline||Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|467|||Both|31 Months|44 Months|Accepts Healthy Volunteers|||January 2012|January 19, 2012|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950833||135330|
NCT00950846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25064-UCB|Umbilical Cord Blood Transplant for Congenital Pediatric Disorders|Umbilical Cord Blood Transplant for Congenital Pediatric Disorders|UCB|Baylor College of Medicine|Yes|Recruiting|July 2009|January 2025|Anticipated|January 2025|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|17 Years|No|||September 2015|September 1, 2015|July 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00950846||135329|
NCT00951132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHUSPP0651|Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy|Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy|DECAMERONE|University Hospital, Akershus|Yes|Recruiting|September 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|70 Years|No|||September 2009|September 8, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951132||135307|
NCT00951145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIFJPAR 09-01|Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem|Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem||Rothman Institute Orthopaedics|No|Active, not recruiting||||||N/A|Observational|Observational Model: Case-Only||1|||||Both|N/A|N/A|No|Probability Sample|All patients undergoing THA prior to 1/1/2003 using Accolade femoral stem|April 2013|April 8, 2013|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951145||135306|
NCT00946933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSS-16198|Effects of Chronic Acid-Base Changes on Ventilatory and Perceptual Responses|Effects of Chronic Acid-Base Changes on the Ventilatory and Perceptual Response to Hypercapnia, Hypoxia and Exercise in Healthy Older Adults||Queen's University|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946933||135630|
NCT00946946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZT-2/CDP|Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine|Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study on the Efficacy and Safety of Azathioprine Versus Mesalazine for Prevention of Clinical Relapses in Crohn's Disease Patients With Postoperative Moderate or Severe Endoscopic Recurrence||Dr. Falk Pharma GmbH|No|Completed|February 2002|July 2009|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|78|||Both|18 Years|70 Years|No|||June 2012|June 25, 2012|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946946||135629|
NCT00947232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36020-J|inMotion Clinical Study: Using Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI|The Effectiveness of Physical Activity for Major Depression in People Aging With Multiple Sclerosis or Spinal Cord Injury|inMotion|University of Washington|No|Completed|October 2009|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|45 Years|N/A|No|||June 2014|June 10, 2014|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947232||135607|
NCT00947245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-011|Japanese Bridging Study Conducted in the United States|A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects||Bristol-Myers Squibb|No|Withdrawn|October 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|6||Actual|0|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||July 2013|July 17, 2013|July 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947245||135606|
NCT00945906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI71023_3002|An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency|A Prospective, Multicenter, Open Enrollment Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency||CSL Behring|No|Completed|September 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|61|||Both|N/A|N/A|No|||September 2012|September 12, 2012|July 23, 2009|Yes|Yes||No|September 12, 2012|https://clinicaltrials.gov/show/NCT00945906||135709|
NCT00945867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111/09|Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy|The Use of CYP 450 2D6 Genotype as a Predictor of Flecainide Efficacy in the Treatment of Patients With Atrial Fibrillation||Assaf-Harofeh Medical Center|No|Not yet recruiting|September 2009|August 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with atrial fibrillation and a normal heart.|July 2009|April 4, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945867||135712|
NCT00946530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06302009-2840|Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease|Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease||Stanford University||Active, not recruiting|September 2004|December 2010|Anticipated|December 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|55 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 13, 2010|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946530||135661|
NCT00942916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903008R|Serum Inflammatory Marker in Patients With Diagnosis of Nontuberculous Mycobacterial Pulmonary Infection|Serum Inflammatory Marker in Patients With Diagnosis of Nontuberculous Mycobacterial Pulmonary Infection||National Taiwan University Hospital|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|The patient was diagnosed as NTM pulmonary disease. They had satisfied at least        microbiological, radiographical and clinical criteria.|June 2012|August 28, 2012|July 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00942916||135939|
NCT00943202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0047|Sanofi Pasteur, TIV + H1N1, Pediatric Population|Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Previously Primed Infants and Toddlers (Greater Than or Equal to 6 - <36 Months), Children (Greater Than or Equal to 36 Months - 9 Years), and Adolescents (10 - 17 Years)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|531|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||December 2010|April 11, 2013|July 21, 2009|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00943202||135917|Due to difficulties identifying children in the youngest age stratum who were previously primed, enrollment in this stratum was closed prior to meeting the planned number of participants.
NCT00942630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-ENDO-0709|Value of Percutaneous Cholangioscopy After Placement of a Percutaneous Transhepatic Biliary Drainage|Percutaneous Cholangioscopy After Placement of a Percutaneous Transhepatic Biliary Drainage (PTBD) - a Prospective Study on Endoscopic Findings and Clinical Impact||Hannover Medical School|No|Completed|March 2008|April 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|1 Year|N/A|No|Non-Probability Sample|All patients receiving a PTBD|October 2011|October 7, 2011|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942630||135961|
NCT00951860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908020|Assessment of Autonomic Maturation in Neonatal Period and Early Neural Development From a Longitudinal Prospective Cohort|Assessment of Autonomic Maturation in Neonatal Period and Early Neural Development From a Longitudinal Prospective Cohort : the AuBE Study|AUBE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|302|||Both|N/A|1 Week|Accepts Healthy Volunteers|Non-Probability Sample|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the        hospital neonatal unit at the time of registration (after 37 weeks corrected for        prematurity) or in the maternity|September 2014|September 22, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951860||135251|
NCT00952939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5608|Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye|Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH)||Case Comprehensive Cancer Center|Yes|Completed|March 2009|February 2014|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|January 2015|January 28, 2015|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00952939||135169|
NCT00953498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS A70516-50|Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins|Influence of Glitazones on the Vasodilatory Effect of HDL Lipoproteins and on Phospholipase A2||Centre Hospitalier Universitaire Dijon|Yes|Completed|October 2007|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953498||135129|
NCT00953784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-025|Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery|Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery||Dallas VA Medical Center|No|Completed|April 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|197|||Both|18 Years|N/A|No|||May 2010|June 29, 2010|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953784||135107|
NCT00945451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000639362|Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer|Study of Doses Escalation on Efficacy on Cyberknife After Docetaxel-Cisplatin Concomitant Radiotherapy for Non Small Cells Lung Cancer Stage III||Centre Antoine Lacassagne|No|Recruiting|January 2009|December 2021|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|120 Years|No|||February 2016|February 2, 2016|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945451||135744|
NCT00945737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-08009|A Study on the Effects of Soy Protein on Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia|A Randomized, Controlled Parallel Study to Evaluate the Effects of a Non-Commercial Soy Protein Product on Fecal Bile Acids and Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia|PRV-08009|Solae, LLC|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|79 Years|No|||June 2012|June 6, 2012|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00945737||135722|
NCT00946075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2001|||||N/A|N/A|N/A||||||||||||||October 1, 2014|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946075||135696|
NCT00950573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOCTX|Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis|Is Progression of Arteriosclerosis in ESRD Patients Inhibited by Nocturnal Hemodialysis or Renal Transplantation?|NOCTX|Dianet Dialysis Centers|No|Recruiting|January 2010|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|160|Samples Without DNA|1x 4,5 ml citrate plasma      1x 10 ml EDTA plasma|Both|18 Years|75 Years|No|Non-Probability Sample|Patients with ESRD|August 2015|August 11, 2015|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00950573||135350|
NCT00950859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112961|A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir|A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance||ViiV Healthcare|No|Completed|August 2009|January 2015|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||September 2015|November 5, 2015|July 23, 2009|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT00950859||135328|
NCT00951158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0914|A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors|A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors||Dartmouth-Hitchcock Medical Center|Yes|Terminated|March 2010|June 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|N/A|No|||March 2012|May 11, 2015|August 3, 2009|No|Yes|Administrative suspension. PI/grant holder transferred to new institution.|No||https://clinicaltrials.gov/show/NCT00951158||135305|
NCT00946959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_0724|Characterization of Factors Influencing the Cognitive Decline in Patients With Coronary Artery Disease|Characterization of Factors Influencing the Occurrence of Cognitive Decline in Patients With Coronary Artery Disease and Undergoing Cardiac Surgery and Coronary Angioplasty|COGCAR|University Hospital, Lille|No|Recruiting|June 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946959||135628|
NCT00947505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7 2009-M-01|Treatment of Androgenetic Alopecia in Males|A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 7 Beam Model: For the Treatment of Androgenetic Alopecia in Males||Lexington International, LLC|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Male|25 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|July 27, 2009|No|Yes||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00947505||135586|
NCT00947518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/2004|Safety of Skin Cleansing With Chlorhexidine in Preterm Low Birth Weight Infants|Does Skin Cleansing With Chlorhexidine Affect Skin Condition, Temperature and Colonization in Hospitalized Preterm Low Birth Weight Infants?: A Randomized Clinical Trial||All India Institute of Medical Sciences, New Delhi|No|Completed|August 2005|February 2006|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|N/A|3 Hours|No|||June 2009|July 27, 2009|April 20, 2009||No||No|April 20, 2009|https://clinicaltrials.gov/show/NCT00947518||135585|
NCT00947843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOPRE-DM/CAD|Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents|Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial||Seoul National University Hospital||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|306|||Both|20 Years|85 Years|No|||July 2009|July 27, 2009|July 25, 2009||||No||https://clinicaltrials.gov/show/NCT00947843||135560|
NCT00946543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000601695|Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer|A Phase I Dose Escalation Study of the Use of Intensity Modulated Radiotherapy (IMRT) to Treat Prostate and Pelvic Nodes in Patients With Prostate Cancer - Pelvic IMRT for Prostate Cancer||National Cancer Institute (NCI)||Recruiting|March 2000|||March 2010|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|1||Anticipated|198|||Male|N/A|N/A|No|||July 2009|August 23, 2013|July 24, 2009||||No||https://clinicaltrials.gov/show/NCT00946543||135660|
NCT00942318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0816202|Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes|Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes: a One Year, Randomised, Parallel Study||University Hospital, Toulouse|No|Completed|March 2009|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00942318||135984|
NCT00942357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0258|Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer|A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma||Gynecologic Oncology Group|Yes|Active, not recruiting|June 2009|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|804|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942357||135981|
NCT00942656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-293|Effect of Trans Fatty Acids From Ruminant Sources on Risk Factors for Cardiovascular Disease|Effect of Trans Fatty Acids From Ruminant Sources on Risk Factors for Cardiovascular Disease||USDA Beltsville Human Nutrition Research Center|Yes|Completed|February 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Anticipated|120|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942656||135959|
NCT00942968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAG-A001-401|Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer|FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism||Eisai Inc.|No|Completed|June 2009|June 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|338|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|July 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942968||135935|
NCT00942331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01952|Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer|A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|July 2009|||June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2015|March 24, 2016|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942331||135983|
NCT00942643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-772|Endothelial Damage and Atherosclerosis in Obstructive Sleep Apnea|Endothelial Damage and Atherosclerosis in Obstructive Sleep Apnea: the Role of Advanced Glycation End-products||The University of Hong Kong|Yes|Terminated|May 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|July 20, 2009||No|Poor patient recruitment|No||https://clinicaltrials.gov/show/NCT00942643||135960|
NCT00943228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDOC001|Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation|Intensified Dosing of Cellcept in Kidney Transplantation Trial||Nova Scotia Health Authority|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00943228||135915|
NCT00952107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000095/1; BIDMC|Objective Flap Assessment During Reconstructive Surgery|Objective Flap Assessment During Reconstructive Surgery||Beth Israel Deaconess Medical Center|No|Completed|June 2009|February 2012|Actual|February 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|21 Years|N/A|No|||June 2012|June 11, 2012|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00952107||135232|
NCT00953264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/042/07|Hormonal and Metabolic Effects of Weight Loss|Hormonal and Metabolic Effects of Weight Loss||Charite University, Berlin, Germany|No|Recruiting|December 2007|||December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953264||135147|
NCT00953277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG-CP-003|Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer|A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy||AxoGen, Inc|No|Completed|August 2009|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|70 Years|No|||May 2015|May 20, 2015|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953277||135146|
NCT00945165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3-028|Exercise and Glycemic Control in Type 2 Diabetes|Defining the Optimal Exercise Program to Improve Glycemic Control in Various Stages of Type 2 Diabetes.||Maastricht University Medical Center|No|Completed|July 2009|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Male|40 Years|65 Years|No|||October 2012|October 24, 2012|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945165||135766|
NCT00945178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00021|Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Two-part Study to Assess Safety, Tolerability, Pharmacokinetics of Orally Administered AZD1386||AstraZeneca|Yes|Terminated|August 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|11|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 8, 2010|July 17, 2009||No|The study was terminated due to results in another study (NCT00878501).|No||https://clinicaltrials.gov/show/NCT00945178||135765|
NCT00946088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03312009-2078|Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial|Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial||Stanford University|No|Active, not recruiting|October 2009|October 2015|Anticipated|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|55 Years|No|||November 2014|November 19, 2014|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00946088||135695|
NCT00946361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00036|Impaired Insulin-like Growth Factor-1 (IGF-1) Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease|Impaired IGF-1 Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease||Nationwide Children's Hospital|No|Terminated|July 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|5 Years|15 Years|No|Non-Probability Sample|GI clinic patients|July 2009|May 14, 2015|July 24, 2009||No|PI left institution|No||https://clinicaltrials.gov/show/NCT00946361||135674|
NCT00942786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-077 ex 07/08|Natriuretic Peptides - Predictors of In-hospital and Long-term Major Adverse Cardiac Events After Emergency Surgery?|Prospective Study to Evaluate the Predictive Value of Brain Natriuretic Peptides for Adverse Long-term Cardiac Outcome||Medical University of Graz|Yes|Completed|February 2008|February 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|297|Samples Without DNA|one vial of serum per patient is retained|Both|50 Years|N/A|No|Non-Probability Sample|Consecutive patients undergoing emergency non-cardiac surgery|June 2015|June 9, 2015|July 18, 2009||No||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00942786||135949|
NCT00950586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110792|Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702|A Placebo-controlled, Single-blind, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Drug Interaction of GSK1034702 After Repeat Doses in Healthy Subjects||GlaxoSmithKline|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2011|August 23, 2012|July 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00950586||135349|
NCT00950599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-008|Study of Multiple Doses of Saxagliptin (BMS-477118)|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-477118 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||AstraZeneca|Yes|Completed|May 2003|May 2004|Actual|May 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|423|||Both|21 Years|70 Years|No|||March 2015|March 16, 2015|July 31, 2009|Yes|Yes||No|August 28, 2009|https://clinicaltrials.gov/show/NCT00950599||135348|
NCT00946699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP200|A Study of the Safety and Tolerability of MEDI-551 in Scleroderma|A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma||MedImmune LLC|Yes|Completed|March 2010|March 2014|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|50|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|July 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946699||135648|
NCT00946712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0819|Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer|A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||Southwest Oncology Group|Yes|Active, not recruiting|July 2009|||February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1546|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|July 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946712||135647|
NCT00946725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11627|To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg|A Comparative Bioavailability Study of Atenolol Tablets, 100 mg||Sandoz||Completed|November 2000|November 2000|Actual|November 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946725||135646|
NCT00946972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016447|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus|Multiple Dose Study in T2DM||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|July 2009|November 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|33|||Both|25 Years|60 Years|No|||March 2010|March 4, 2010|July 23, 2009|No|Yes|No safety signals were noted. The study completed the main phase, additional potential study    cohorts not required.|No||https://clinicaltrials.gov/show/NCT00946972||135627|
NCT00947258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Influence of Stretching on Muscle Performance|Influence of Stretching Hamstring and Quadriceps Femoral Muscles on Peak Torque and the Maximum Power of the Knee||Fortaleza University|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention||||15|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||July 2009|July 27, 2009|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947258||135605|
NCT00947531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBE-RU-051201|A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia|VascDem|Ever Neuro Pharma GmbH|No|Completed|October 2006|August 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|242|||Both|50 Years|85 Years|No|||September 2009|September 24, 2009|April 20, 2009||No||No|April 20, 2009|https://clinicaltrials.gov/show/NCT00947531||135584|
NCT00947856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-006|A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study|Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study||Seattle Genetics, Inc.|No|Completed|July 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|6 Years|N/A|No|||May 2014|November 17, 2015|July 24, 2009|Yes|Yes||Yes|March 21, 2014|https://clinicaltrials.gov/show/NCT00947856||135559|
NCT00946231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0108|Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home|HF Assessment With BNP In The Home|HABIT|Biosite|No|Completed|July 2009|October 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|187|Samples Without DNA|Plasma and Urine|Both|18 Years|N/A|No|Non-Probability Sample|Subjects admitted to the hospital with decompensated Heart Failure. Subjects may be        enrolled while still in the hospital or within 3 days post-discharge through a heart        failure clinic or other type of outpatient clinic.|August 2012|August 30, 2012|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946231||135684|
NCT00942981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090176|Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography|Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography||National Institutes of Health Clinical Center (CC)||Recruiting|July 2009|||||N/A|Observational|N/A|||Anticipated|330|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|December 2, 2015|July 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942981||135934|
NCT00942370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 0904|Electromyographic (EMG) and Mechanomyographic (MMG) Comparison|Comparison of Electromyographic With Mechanomyographic Signals of Rectus Abdominis|EMG-MMG|University Hospital, Grenoble|Yes|Completed|July 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|July 2009|July 31, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00942370||135980|
NCT00942669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-OTC-346 CTIL|Comparing the Sleep Strip OTC™ Accuracy in Screening for Sleep Apnea Syndrome Against the Reference Method, an In-lab Full Night Polysomnographic (PSG)|A Prospective, Single Center, Open, Equivalence, Two Phase Study Comparing the Sleep Strip OTC™ Accuracy in Screening for Sleep Apnea Syndrome Against the Reference Method, an In-lab Full Night Polysomnographic (PSG) Study.||Scientific Laboratory Products, Ltd.|Yes|Completed|August 2009|February 2012|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|July 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00942669||135958|
NCT00952666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00014120|Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy|Transrectal Ultrasound (TRUS) Imaging of the Prostate Gland and Neurovascular Bundles (NVB) During Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP)||Johns Hopkins University|Yes|Terminated|November 2008|December 2009|Actual|December 2009|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|35 Years|75 Years|No|||August 2009|September 10, 2010|August 4, 2009||No|The number of participants needed for this study has been met.|No||https://clinicaltrials.gov/show/NCT00952666||135189|
NCT00944931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090196|High-Density Direct Current Brain Polarization|High-Density Direct Current Brain Polarization||National Institutes of Health Clinical Center (CC)||Completed|July 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2012|September 26, 2015|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944931||135784|
NCT00945750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0208-144|A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)|A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine 20 mg Film-Coated Tablets (FCT) Compared to Famotidine 20 mg Chewable Tablets (CT) Without Water and Famotidine 20 mg Chewable Tablets (CTw) With Water (Protocol 144)||Merck Sharp & Dohme Corp.|No|Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|July 22, 2009|No|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT00945750||135721|
NCT00942838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI28777|Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity|Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity: A Phase I Trial|WAR|University of Utah|Yes|Withdrawn|July 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||July 2013|July 23, 2013|July 17, 2009||No|PI decision due to under accrual.|No||https://clinicaltrials.gov/show/NCT00942838||135945|
NCT00943111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD02607|A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)|A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)|ENCORE|Sanofi|Yes|Active, not recruiting|September 2009|May 2015|Anticipated|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||August 2014|August 22, 2014|July 20, 2009|Yes|Yes||No|August 22, 2014|https://clinicaltrials.gov/show/NCT00943111||135924|The results include data up to the end of primary analysis period (Week 52).
NCT00950612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112898|Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents|Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy HIV-negative Adolescents Living in a TB Endemic Region||GlaxoSmithKline||Completed|December 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950612||135347|
NCT00950872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS08016|Safety and Efficacy Study of Duet TRS|A Prospective, Single-Center Investigation of the Safety and Performance of the ENDO GIA Staplers With ENDO GIA Single Use Loading Units With DUET TRS TM in a Gastric Bypass Procedure||Medtronic - MITG|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 31, 2014|July 30, 2009||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT00950872||135327|
NCT00946738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA 1/100/05|The Effect of Physical Therapy on Raynaud`s Phenomenon Secondary to Systemic Sclerosis|A Prospective Randomized Controlled Study Analyzing the Effect of Biofeedback and Deep Oscillation on Raynaud´s Phenomenon Secondary to Systemic Sclerosis||Charite University, Berlin, Germany|Yes|Completed|October 2004|||March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2|||28|||Both|18 Years|80 Years|No|||July 2009|July 24, 2009|July 24, 2009||||No||https://clinicaltrials.gov/show/NCT00946738||135645|
NCT00946751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA15241|To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions||Sandoz||Completed|March 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946751||135644|
NCT00946764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA28312|To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions||Sandoz||Completed|July 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|19 Years|54 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946764||135643|
NCT00946660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-DA026861|Non-Treatment Study of Factors Affecting Cocaine Drug Choice|Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis: Study 1|CTA|Wayne State University|Yes|Completed|July 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|Samples With DNA|Whole Blood|Both|18 Years|55 Years|No|Non-Probability Sample|Cocaine abusing or dependent research volunteers|June 2012|June 1, 2012|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946660||135651|
NCT00946673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0036|Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer|A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer||Stanford University||Active, not recruiting|June 2009|July 2015|Anticipated|July 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|July 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946673||135650|
NCT00946686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B023709|To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions|A Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions||Sandoz||Completed|September 2002|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946686||135649|
NCT00947271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068171-06|Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic|HIV Prevention for STD Clinic Patients||The Miriam Hospital|No|Completed|October 2009|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1010|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 10, 2014|July 27, 2009||No||No|August 25, 2014|https://clinicaltrials.gov/show/NCT00947271||135604|
NCT00947544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-005|Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders|A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age With Urea Cycle Disorders, With a Long-Term Safety Extension||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|March 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|6 Years|17 Years|No|||June 2015|June 8, 2015|July 24, 2009|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00947544||135583|
NCT00947557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT-MD-303|Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin|A Phase III, Randomized, Double-Blind, Placebo-controlled, Multicenter Study To Evaluate The Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Glimepiride With or Without Metformin||Forest Laboratories|No|Terminated|July 2009|||July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|677|||Both|18 Years|85 Years|No|||September 2011|September 9, 2011|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00947557||135582|
NCT00947869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG-SFB539-H|Contrast Sensitivity in Glaucoma|Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)||University of Erlangen-Nürnberg Medical School||Recruiting|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|July 2009|July 27, 2009|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947869||135558|
NCT00947882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS36|A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)|A Dose-Finding, Multi-Centre, Double-Blind, Randomised, Parallel, Placebo-Controlled Trial to Investigate Efficacy and Safety of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)|DELUTS|Ferring Pharmaceuticals|Yes|Completed|August 2009|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|404|||Male|50 Years|N/A|No|||May 2015|May 13, 2015|July 27, 2009|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT00947882||135557|Following the planned 6-month interim analysis when all patients had completed the visit scheduled 6 months after dosing, a decision was taken to stop the trial since the primary efficacy endpoint was not met.
NCT00947895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q1001|Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone|Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study|RECLAIM|Neurologique Foundation, Inc.|No|Terminated|October 2009|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 2, 2009|Yes|Yes|Study reached halfway point in approximately one year time period and was halted to analyze    data.|No||https://clinicaltrials.gov/show/NCT00947895||135556|
NCT00945919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 08-1423|A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone|A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone||Icahn School of Medicine at Mount Sinai|No|Recruiting|July 2009|May 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2009|July 23, 2009|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945919||135708|
NCT00945932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112851|A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate Asthmatics|A Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Determine the Efficacy of Repeat Inhaled Doses of GW870086X on FEV1 in Mild to Moderate Asthmatics||GlaxoSmithKline|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|65 Years|No|||March 2012|March 22, 2012|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00945932||135707|
NCT00945945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13214|A Study of Duloxetine in Patients With Osteoarthritis Knee Pain|A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by Osteoarthritis of the Knee, in a 13-week, Double-blind, Randomized Study||Eli Lilly and Company|No|Completed|July 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|424|||Both|40 Years|N/A|No|||February 2011|February 11, 2011|July 23, 2009|Yes|Yes||No|February 11, 2011|https://clinicaltrials.gov/show/NCT00945945||135706|Due to a package labeling error, study drug was incorrectly administered to all patients in both treatment groups. This compromised the integrity of the entire study and rendered planned comparisons between duloxetine and placebo invalid.
NCT00945958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_09_13|Evaluation of Safety of Latanoprost Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension|A Clinical Evaluation of Safety of Latanoprost Ophthalmic Solution When Administered Once Daily in Subjects With Open Angle Glaucoma or Ocular Hypertension: an Open Label Study||Sun Pharma Advanced Research Company Limited|No|Completed|November 2010|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945958||135705|
NCT00942344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ALOS-201|Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension|An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension.||Hanmi Pharmaceutical Company Limited|No|Completed|May 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|320|||Both|18 Years|75 Years|No|||July 2009|July 17, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942344||135982|
NCT00946244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812114R|A Longitudinal Study of Effectiveness of Early Intervention for Preterm Infants|A Longitudinal Study of Effectiveness of Early Intervention for Preterm Infants||National Taiwan University Hospital|Yes|Enrolling by invitation|August 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|240|||Both|3 Years|4 Years|Accepts Healthy Volunteers|Probability Sample|Term and VLBW preterm children were born at the National Taiwan University Hospital and        the Mackay Memorial Hospital (MMH)|November 2009|November 16, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00946244||135683|
NCT00946556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HET-85518|Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix|Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix.||University of Toronto|No|Completed|April 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946556||135659|
NCT00942383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0765|Freehand Ultrasound Elasticity Imaging in Liver Surgery|Application of Novel, High Resolution, and Freehand Ultrasound Elasticity Imaging in Liver Surgery|IOUS|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2007|September 2013|Anticipated|September 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2011|August 5, 2011|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942383||135979|
NCT00951600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228_OXCAR_06|Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Oxcarbazepine 300 mg/5mL Oral Suspension of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc) With Trileptal® 300 mg/5mL Oral Suspension (Containing Oxcarbazepine 300 mg/5mL) of Novartis Pharmaceutical Corporation in Healthy, Adult, Male, Human Subjects Under Fasting Condition.||Ranbaxy Inc.|Yes|Completed|September 2006|December 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 3, 2009|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951600||135271|
NCT00951613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6012212US|A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC)||Nippon Kayaku Co.,Ltd.|Yes|Completed|July 2009|||January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|May 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951613||135270|
NCT00952952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-003637|Trial of Mesalamine for the Treatment of Active Microscopic Colitis|A Randomized, Dose Ranging Trial of Mesalmine for the Treatment of Active Microscopic Colitis.||Mayo Clinic||Completed|February 2007|November 2007|Actual|November 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|70|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|August 4, 2009||||||https://clinicaltrials.gov/show/NCT00952952||135168|
NCT00952965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth2|Wrist-used Blood Pressure Monitor Clinical Test (Cuff Range: 14cm-25cm)|Clinical Testing Report for Wrist-used Electronic Blood Pressure Monitor|WBPMCT|Andon Health Co., Ltd|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|86|||Both|23 Years|81 Years|Accepts Healthy Volunteers|Non-Probability Sample|resident of a community.|August 2009|August 5, 2009|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00952965||135167|
NCT00945464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAJ 08-8001|Scripps Polster Breast Care Center Investigational GeneBank|Scripps Polster Breast Care Center Investigational GeneBank|PINK|Scripps Translational Science Institute|No|Completed|July 2008|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1136|Samples With DNA|Approximately 19.5 mls of blood will be collected from volunteers. The blood from each      subject will be collected via venipuncture. If subject is unable/unwilling to provide blood      sample, we can also collect 2 mls of saliva.|Female|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care        Center.|October 2015|October 14, 2015|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945464||135743|
NCT00942201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080453|Comparison of Oral Dexamethasone Doses in Asthma Exacerbation|Comparison of Single Dose Versus Two Doses of Oral Dexamethasone in the Management of Acute Asthma Exacerbations in the Pediatric Emergency Department.||Rady Children's Hospital, San Diego|No|Completed|August 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||July 2009|July 17, 2009|June 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942201||135992|
NCT00942526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806035R|Oral Anti-Infective Agent for Esophageal Anastomotic Leakage|The Correlation of Oral Anti-Infective Agent With Anastomotic Leakage in Reconstruction Surgery for Esophageal Cancer||National Taiwan University Hospital|Yes|Recruiting|June 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|40 Years|85 Years|No|||July 2009|July 20, 2009|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942526||135968|
NCT00942487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeRo/04/Neb-LVD/003|Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol|Effects of NEbivolol on Subclinical Left Ventricular dYSfunction. A Comparative Study Against Metoprolol. The ENESYS Study. A Phase 3, Randomised, Parallel, Active-controlled, Open Label Study|ENESYS|Berlin-Chemie Menarini|No|Completed|April 2005|July 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||July 2009|July 20, 2009|July 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00942487||135971|
NCT00942500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02-007|Effects of Postconditioning On Myocardial Reperfusion|Effects of Postconditioning On Myocardial Reperfusion in Patients With ST-segment Elevation Myocardial Infarction|POST|Samsung Medical Center|Yes|Completed|July 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|700|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00942500||135970|
NCT00950885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL093279|Melatonin Treatment for Induced Transient Insomnia|Efficacy of Melatonin Treatment in a Phase Advance Model of Transient Insomnia||Brigham and Women's Hospital|Yes|Recruiting|September 2009|August 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950885||135326|
NCT00947011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00018441|Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)|The Effect of Dipeptidyl Peptidase-4 Inhibition on GLP-1 Induced Insulin Secretion and Glucose Turnover During Mild Stable Hyperglycemia in Young and Old Normal Volunteers||Johns Hopkins University|No|Active, not recruiting|March 2009|May 2011|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|64|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|July 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00947011||135624|
NCT00947024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9301813|To Demonstrate the Effect of Food on the Bioavailability of Glipizide|The Effect of Food on the Bioavailability of Glipizide||Sandoz||Completed|November 1993|November 1993|Actual|November 1993|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947024||135623|
NCT00946985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015646|28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years|A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate With Oral Risperidone in Adults With Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse||Ortho-McNeil Janssen Scientific Affairs, LLC|Yes|Terminated|June 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|163|||Both|18 Years|35 Years|No|||September 2012|September 3, 2012|July 2, 2009|Yes|Yes|The recruitment rate for the study was inadequate to achieve its enrollment goals.|No|March 8, 2011|https://clinicaltrials.gov/show/NCT00946985||135626|No efficacy analysis was performed due to early termination of the study (only 2 patients were randomized at the time of study termination).
NCT00947284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NIDCR R01 DE018526-2|Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity|Effect of Kappa Opioid Agonist-Antagonists in the Heat/Capsaicin Sensitization Model||University of California, San Francisco|Yes|Terminated|January 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|3|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|July 1, 2009|Yes|Yes|Experimental pain model didn't work as anticipated.|No|August 14, 2013|https://clinicaltrials.gov/show/NCT00947284||135603|The lead investigator passed away and co-investigators could not find complete data on his computer. The experimental model for skin sensitivity did not work in the first 3 participants, and the study was terminated without collecting outcomes data.
NCT00947908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-0004|Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy|Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy||University of Rostock|No|Active, not recruiting|June 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|16 Years|80 Years|No|||July 2009|January 12, 2010|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947908||135555|
NCT00947921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-01|Plasty or Prosthesis to Treat Functional Mitral Regurgitation|POP Study: Plasty or Prosthesis to Treat Functional Mitral Regurgitation in Low Ejection Fraction Patients; a Randomized Prospective Controlled Study|POP|Cardiochirurgia E.H.|Yes|Suspended|August 2009|August 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||May 2013|May 20, 2013|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00947921||135554|
NCT00948220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSTEO|Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C|Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1||University of Ulm|No|Completed|July 2003|March 2008|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Male|18 Years|65 Years|No|||May 2011|June 6, 2011|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00948220||135531|
NCT00948233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0222|Project COMBAT: Combating Tobacco Use in the United States Army|Combating Tobacco Use in the United States Army||M.D. Anderson Cancer Center|No|Recruiting|June 2009|||June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|2050|Samples Without DNA|Saliva samples at the 12-month follow-up visit to measure level of cotinine, a chemical      related to tobacco use.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Soldiers stationed at Fort Hood, Texas, who are not scheduled to be mobilized for a        13-month period.|November 2015|November 13, 2015|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00948233||135530|
NCT00954863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905045R|Genotypic Resistant HIV Strains in Taiwan|Identification and Characterization of Genotypic Resistant HIV Strains in Taiwan||National Taiwan University Hospital|Yes|Recruiting|August 2009|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected individuals receiving clinical care at National Taiwan University Hospital|August 2009|September 28, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954863||135026|
NCT00955136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286-09-FB|Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes|Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes||University of Nebraska|No|Withdrawn|July 2012|April 2015|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|30 Years|N/A|No|||June 2014|June 26, 2014|August 5, 2009|Yes|Yes|The study was withdrawn due to many implementation difficulties.|No||https://clinicaltrials.gov/show/NCT00955136||135005|
NCT00955149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000516|Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)|An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7||Mayo Clinic|Yes|Completed|August 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00955149||135004|
NCT00951301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007749|Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation|Mangosteen Effects on Inflammatory Markers in Atrial Fibrillation Trial|MRI-AF|Mayo Clinic|Yes|Terminated|July 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 31, 2009|Yes|Yes|Significantly lower accrual rate than anticipated, time constraints.|No||https://clinicaltrials.gov/show/NCT00951301||135294|
NCT00951314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090188|Brain Glutamate Receptors and Cocaine Dependence|Cocaine Dependence, Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Density, Genetics and Craving||National Institutes of Health Clinical Center (CC)||Terminated|July 2009|March 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|30|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2013|June 5, 2014|August 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00951314||135293|
NCT00951873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7129-3754|A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers|A Single-centre, Randomised, Placebo-controlled, Double-blind Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Local Tolerability of Ascending Subcutaneous Doses of Long Acting-rFVIIa in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|July 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|38|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|July 4, 2012|July 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00951873||135250|
NCT00951886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5418-OE-CTIL|The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally|The Validity of Forced Expiratory Maneuvers in Ataxia Teleangiectasia Studied Longitudinally||Sheba Medical Center|No|Active, not recruiting|July 2009|July 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|28|||Both|3 Years|20 Years|No|Non-Probability Sample|Patients with Ataxia Telangiectasia who are followed and treated in the National A-T        center at Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel|August 2009|August 3, 2009|August 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00951886||135249|
NCT00944671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0208C-145|A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)|A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets (FACT) Compared to Famotidine/Antacid EZ Chew Tablet Without Water and Famotidine/Antacid EZ Chew Tablet With Water||Johnson & Johnson Consumer and Personal Products Worldwide||Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|July 22, 2009|No|Yes||No|October 27, 2014|https://clinicaltrials.gov/show/NCT00944671||135804|
NCT00945204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICCD/NIHR SDO|Evaluation of Intermediate Care Clinics for Diabetes|Evaluation of Intermediate Care Clinics for Diabetes|ICCD|University Hospitals, Leicester|No|Completed|May 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1997|||Both|N/A|N/A|No|||August 2012|August 7, 2012|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00945204||135763|
NCT00946374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-149/2003|Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma|A Prospective Phase II Trial on R-CHOP Followed by High-dose BEAM and Autologous SCT and HLA-identical Allogenic SCT After Dose-reduced Conditioning in Patients Age < 55 Years With Primary Mantle-Cell-Lymphoma|HD-MCL2003|Heidelberg University|Yes|Recruiting|July 2004|June 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||July 2009|July 24, 2009|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946374||135673|
NCT00942513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-342|Effect of Lactose, Fructose, Sucrose, Whey Protein, and Soy Protein on Substrate Absorption and Oxidation: a Pilot Study|Effect of Lactose, Fructose, Sucrose, Whey Protein, and Soy Protein on Substrate Absorption and Oxidation: a Pilot Study||USDA Beltsville Human Nutrition Research Center|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|||Actual|9|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942513||135969|
NCT00943917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-02|Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus|Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus||Intarcia Therapeutics|No|Completed|August 2009|February 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|155|||Both|18 Years|70 Years|No|||March 2015|March 23, 2015|July 20, 2009|Yes|Yes||No|February 24, 2012|https://clinicaltrials.gov/show/NCT00943917||135862|8 subjects (4 in 20, 1 in 40 and 3 in ex inj)completed StI but not randomized to St II; 3 subjects (2 in 20/20 & 1 in 40/80) who completed St I, randomized to St II but not given study drug. St II Cont was optional, so not all pts elected to continue
NCT00943124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524B-070|MK0524B Bioequivalence Study (0524B-070)|An Open-Label, Definitive Bioequivalence Study to Compare the Pharmacokinetics of the Simvastatin, Nicotinic Acid, and MK0524 (Laropiprant) Components of a Formulation of MK0524B With That of Zocor™ and MK0524A Tablets||Merck Sharp & Dohme Corp.||Completed|July 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|July 21, 2009|No|Yes||No|October 9, 2009|https://clinicaltrials.gov/show/NCT00943124||135923|
NCT00943358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL10763|Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults|Safety and Immunogenicity of Cell-culture Non-adjuvanted and MF59-adjuvanted Influenza H1N1 Vaccines in Healthy Adults||University Hospitals, Leicester|Yes|Completed|July 2009|December 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|175|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943358||135905|
NCT00950898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-020|The Acute Effects of Coffee on Glucose Metabolism|Human Trial of the Acute Effects of Coffee on Glucose Metabolism||Brooklyn College of the City University of New York|No|Completed|November 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|11|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2009|July 31, 2009|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00950898||135325|
NCT00950911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080540|Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma||Amgen||Completed|July 2009|April 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|July 30, 2009||||No|December 17, 2012|https://clinicaltrials.gov/show/NCT00950911||135324|
NCT00947596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07030057|A Study of Inhaled Atropine Sulfate in Healthy Adults|Development of an Inhaled, Dry Powder Delivery System for the Administration of Atropine Sulfate||MicroDose Defense Products L.L.C.|Yes|Completed|August 2009|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2010|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00947596||135579|
NCT00947934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 - APN - 04|Study of the Brain Stimulation Effect on Memory Impairment in Alzheimer Disease|Study of the Effect of the Chronic Electric Stimulation of the Hypothalamus/Fornix on Memory Impairment in Alzheimer Disease.||Centre Hospitalier Universitaire de Nice|Yes|Recruiting|August 2009|August 2012|Anticipated|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|50 Years|70 Years|No|||July 2009|December 7, 2011|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947934||135553|
NCT00947947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH077507|Computerized HIV/Sexually Transmitted Disease (STD) Prevention Program|Enhancing Message Design in Tailored, Computerized HIV/STI Interventions|TIPSS|University of North Carolina, Chapel Hill|No|Completed|February 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|274|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947947||135552|
NCT00946998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-008-09S|Chronic Kidney Disease Antidepressant Sertraline Trial|Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease|CAST|VA Office of Research and Development|Yes|Recruiting|February 2010|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|N/A|No|||October 2015|October 27, 2015|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946998||135625|
NCT00947570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH065413|Neural Functioning Underlying Anxiety and Its Treatment (The INSULA Study)|Neural Substrates of Anticipation and Interoception in Anxiety Disorders||University of California, San Diego|No|Completed|October 2007|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 27, 2012|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947570||135581|
NCT00947583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.OC-0804|Osteocel® Plus in Transforaminal Lumbar Interbody Fusion (TLIF)|Osteocel® Plus in Transforaminal Lumbar Interbody Fusion (TLIF): Evaluation of Radiographic and Patient Outcomes||NuVasive|No|Completed|May 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|70 Years|No|Non-Probability Sample|Existing clinic patients|January 2014|January 7, 2014|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947583||135580|
NCT00948792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14626|Study of the Effect of Differing Platelet Transfusion Times in Neonates|The Effect of Variable Platelet Transfusion Durations on Platelet Count in Thrombocytopenic Newborns||University of Oklahoma|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|N/A|N/A|No|||June 2011|June 13, 2011|July 27, 2009||No||No|February 21, 2011|https://clinicaltrials.gov/show/NCT00948792||135487|
NCT00948805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0555/09|Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment|Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment||University of Sao Paulo|Yes|Recruiting|January 2009|July 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Female|21 Years|38 Years|Accepts Healthy Volunteers|||July 2009|July 28, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00948805||135486|
NCT00949091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_102|Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes|A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes||Takeda|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|68 Years|No|||June 2010|June 9, 2010|July 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949091||135464|
NCT00955162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU0902|Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")|A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France|RIME|Indivior Inc.|No|Completed|August 2009|May 2011|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||January 2010|November 28, 2012|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955162||135003|
NCT00951353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-02|Immune Development in Pediatric Transplantation (IMPACT)|Immune Development and Alloimmunity in Pediatric Renal Transplant Recipients||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2009|March 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|1 Year|20 Years|No|Non-Probability Sample|Pediatric end-stage renal disease patients needing a kidney transplant|February 2014|February 27, 2014|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951353||135290|
NCT00951652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH058593-02|Efficacy of Adding Interpersonal and Emotional Processing Therapy Techniques to Cognitive Behavioral Therapy to Treat Generalized Anxiety Disorder|Cognitive and Interpersonal Therapies for Generalized Anxiety||Penn State University||Completed|July 1998|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|65 Years|No|||November 2015|November 3, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951652||135267|
NCT00955422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090198|Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease|Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease||National Institutes of Health Clinical Center (CC)||Recruiting|July 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|550|||Both|45 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 24, 2015|August 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955422||134983|
NCT00951327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006221|Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)|Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing ERCP.||Mayo Clinic|No|Completed|November 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients presenting for ERCP with history of Primary Sclerosing Cholangitis|August 2010|August 3, 2010|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951327||135292|
NCT00951340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH039172-02|Feasibility of Adding Interpersonal and Emotional Processing Techniques to Cognitive Behavioral Therapy to Treat Generalized Anxiety Disorder|Desensitization and Cognitive Therapy in General Anxiety.||Penn State University|No|Completed|July 1996|December 1998|Actual|July 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years||||August 2009|November 4, 2013|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951340||135291|
NCT00951626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05081|A Standardized Nursing Intervention Protocol for HCT Patients|A Standardized Nursing Intervention Protocol for HCT Patients||City of Hope Medical Center|Yes|Completed|September 2005|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|282|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|August 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00951626||135269|
NCT00951639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BaylorU_Cassia_Women|Cassia Cinnamon for Glucose Uptake in Young Women|Cassia Cinnamon and Acute Endurance Exercise for the Enhancement of Glucose Uptake in Healthy Young Women||Baylor University|No|Completed|February 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|10|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||August 2009|August 3, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951639||135268|
NCT00952393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-005-09S|Nicotinic Receptors and Schizophrenia|Nicotinic Receptors and Schizophrenia||VA Office of Research and Development|Yes|Completed|January 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|August 3, 2009|No|Yes||No|November 25, 2015|https://clinicaltrials.gov/show/NCT00952393||135210|
NCT00952679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCW001|Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients|Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients||Fudan University|No|Recruiting|January 2009|December 2011|Anticipated|January 2009|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|70 Years|No|||August 2009|August 4, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952679||135188|
NCT00946101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP217|A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of MEDI3414 in Children|MI-CP217|MedImmune LLC|Yes|Completed|August 2009|March 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|326|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||July 2011|July 15, 2011|July 23, 2009|Yes|Yes||No|June 9, 2010|https://clinicaltrials.gov/show/NCT00946101||135694|
NCT00946114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481242|To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks|A Local, Multi-Centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For One Hundred Twelve Weeks / Prior To Reimbursement And Availability For Patients In Poland.||Pfizer|No|Completed|June 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Expanded access|February 2013|February 12, 2013|July 22, 2009|No|Yes||No|March 29, 2010|https://clinicaltrials.gov/show/NCT00946114||135693|
NCT00946400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-202|Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)|Prospectively Validating the 4Ts and Chong Score for Heparin Induced Thrombocytopenia||Washington Hospital Center|No|Not yet recruiting|August 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Serum will be collected to perform a serotonin release assay as confirmatory testing for the      presence of HIT.|Both|18 Years|N/A|No|Non-Probability Sample|For this study, patients already admitted to the hospital whose physician suspects the        presence of HIT will be recruited for this study. Specifically, the trigger for        recruitment include patients who have a HIT antibody test ordered.|July 2009|July 24, 2009|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946400||135671|
NCT00942539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2958CTIL|Midazolam Sedation for Neonatal Lumbar Puncture|Midazolam Sedation for Neonatal Lumbar Puncture in the Emergency Department: A Randomized Controlled Trial||Rambam Health Care Campus|No|Terminated|July 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Both|N/A|30 Days|No|||July 2010|May 5, 2014|July 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00942539||135967|
NCT00942851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090193|A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm|A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm||National Institutes of Health Clinical Center (CC)||Completed|July 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|July 18, 2009|No|Yes||No|May 29, 2012|https://clinicaltrials.gov/show/NCT00942851||135944|
NCT00946777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-04|Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days|Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days||Alcon Research|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946777||135642|
NCT00946790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-14-10551|To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets|Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets||Sandoz||Completed|July 1993|December 1993|Actual|December 1993|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946790||135641|
NCT00947609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH TB Px|Improving Latent Tuberculosis (TB) Diagnosis in Thai Children|Improving the Diagnosis and Management of Latent Tuberculosis in Thai Children|TB Px|South East Asia Research Collaboration with Hawaii|No|Completed|August 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|||Both|2 Months|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thai children between the ages of 2 months and 16 years with exposure to active TB adult        cases will be referred to the two study sites for eligibility screening.|June 2012|June 5, 2012|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947609||135578|
NCT00947297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-007|Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)|A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|November 2009|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|6 Years|N/A|No|||June 2015|June 8, 2015|July 24, 2009|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT00947297||135602|
NCT00947310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADIT-RIT|Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy|IDE-Exempt: Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy|MADIT-RIT|Boston Scientific Corporation|Yes|Completed|September 2009|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|1500|||Both|21 Years|N/A|No|||March 2013|March 4, 2013|July 27, 2009||No||No|March 4, 2013|https://clinicaltrials.gov/show/NCT00947310||135601|
NCT00948532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.OC.0801|Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®)|Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®): Evaluation of Radiographic and Patient Outcomes||NuVasive|No|Completed|March 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|80 Years|No|Non-Probability Sample|Existing clinic patients|April 2015|April 17, 2015|July 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00948532||135507|
NCT00948545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29092|Autonomic Nervous System Function Following Bariatric Surgery|Autonomic Nervous System Function and Novel Determinants of Glucose Homeostasis Following Bariatric Surgery||Christiana Care Health Services|No|Completed|July 2009|April 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|37|Samples Without DNA|Serum, plasma, urine|Both|18 Years|60 Years|No|Non-Probability Sample|Individuals having bariatric surgery|November 2012|November 6, 2012|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948545||135506|
NCT00948818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-31|Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation||Forest Laboratories|No|Completed|July 2009|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|803|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|July 28, 2009|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00948818||135485|
NCT00949377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|064-09|Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?|Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?||Beth Israel Medical Center|No|Withdrawn|September 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||April 2015|October 13, 2015|July 29, 2009|Yes|Yes|Unable to recruit enough patients at a single center.|No||https://clinicaltrials.gov/show/NCT00949377||135442|
NCT00951912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yanbinye|The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids|The Study of the Effects of Soy Isoflavones on the Metabolism of Glucose and Lipids in Postmenopausal Chinese Women With Impaired Glucose Regulation||Sun Yat-sen University|Yes|Completed|August 2009|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|165|||Female|30 Years|70 Years|No|||October 2012|October 16, 2012|August 3, 2009|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00951912||135247|A relative long time of recruitment leading to a little different in dietary intakes among subjects;The menstrual period will leading to different estradiol;The different severity of the diabetes leading to the different dropout percentage.
NCT00951665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM4652g|A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer|A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer||Genentech, Inc.||Completed|August 2009|June 2013|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|August 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00951665||135266|
NCT00951899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008284|The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics|The Effect of Colesevelam Hydrochloride on Disposition Index and Incretin Concentrations in Subjects With Type 2 Diabetes Using a Double-blind, Placebo-controlled, Parallel-group Study Design||Mayo Clinic|Yes|Completed|August 2009|December 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|38|||Both|35 Years|70 Years|No|||October 2013|October 17, 2013|July 31, 2009|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT00951899||135248|
NCT00952120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16863B|Comparison of Two Methods of Securing Skin Grafts Using Negative Pressure Wound Therapy: Vacuum Assisted Closure (VAC) and Gauze Suction (GSUC)|Comparison of Two Methods of Securing Skin Grafts Using Negative Pressure Wound Therapy: VAC and GSUC||University of Chicago|No|Completed|May 2009|July 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 24, 2015|July 31, 2009||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT00952120||135231|
NCT00952133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-605|Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV|Randomized Double Blind Study to Evaluate the Efficacy of IV Palo w/ IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed Post-Operative Nausea/Vomiting in Subj Undergoing Laparoscopic Surgeries w/a High Emetogenic Risk|PONV|New York University School of Medicine|No|Completed|July 2009|April 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|118|||Both|18 Years|55 Years|No|||March 2015|March 30, 2015|July 30, 2009|Yes|Yes||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00952133||135230|
NCT00944359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222218|Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children|Community-based Intervention Trial to Compare the Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children in Burkina Faso||University of California, Davis|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|7680|||Both|6 Months|27 Months|Accepts Healthy Volunteers|||December 2012|December 7, 2012|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944359||135828|
NCT00946127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00014030|ETV Versus Shunt Surgery in Normal Pressure Hydrocephalus|Endoscopic Third Ventriculostomy (ETV) Versus Ventriculoperitoneal Shunting (VPS) for the Surgical Management of Normal Pressure Hydrocephalus||Johns Hopkins University|No|Terminated|March 2009|October 2011|Actual|October 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|13|||Both|50 Years|N/A|No|Non-Probability Sample|Patients suspected of Normal pressure hydrocephalus i.e. - with gait disturbances and/ or        cognitive disturbances and/or urinary incontinence with dilation of ventricles on CT or        MRI.|October 2012|October 1, 2012|July 23, 2009||No|Unable to recruit patients and lack of efficacy in ETV arm|No||https://clinicaltrials.gov/show/NCT00946127||135692|
NCT00946387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B043712|To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions||Sandoz||Completed|September 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|22 Years|58 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946387||135672|
NCT00942565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 06-188 T/1213|Adjuvant Analgesic Effects of Low Dose Tramadol/Acetaminophen Combination After Open Gynaecological Surgery|||The University of Hong Kong||Completed|April 2007|December 2012|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|80 Years|No|||January 2013|January 31, 2013|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942565||135966|
NCT00942214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811001|Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment|Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study|Bionat2|University Hospital, Toulouse|No|Completed|June 2009|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|300|||Both|18 Years|55 Years|No|||March 2011|March 29, 2011|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00942214||135991|
NCT00942227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008586|The Value of Traction in Treatment of Lumbar Radiculopathy|The Value of Traction in Treatment of Lumbar Radiculopathy.||Intermountain Health Care, Inc.|No|Completed|July 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|60 Years|No|||January 2013|January 11, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00942227||135990|
NCT00942240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8211 725|Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects|A Phase I, Double-Masked, Multiple Rising Dose Study of ACU-4429 in Healthy Male and Female Subjects||Acucela Inc.|Yes|Completed|July 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|July 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942240||135989|
NCT00943410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9925|Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer|Phase II Trial of Herceptin Concurrent With External Beam Radiation Following Neoadjuvant Chemotherapy for the Treatment of HER2 Over-Expressing Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|March 2000|July 2009|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Female|18 Years|N/A|No|||August 2012|August 14, 2012|July 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943410||135901|
NCT00943709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060601|Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia|Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia||Rutgers, The State University of New Jersey|Yes|Withdrawn|May 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|July 21, 2009|Yes|Yes|lack of accrual|No||https://clinicaltrials.gov/show/NCT00943709||135878|
NCT00944190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36021-C|TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS)|Telephone Delivered Self-management Intervention for People With Multiple Sclerosis Addressing Pain, Fatigue, Depression, and Cognitive Difficulties|TakeCharge|University of Washington|No|Completed|October 2009|September 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944190||135841|
NCT00947050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/05|Prompt Human Coronary Collateral Vasomotor Function Induced by Dynamic Physical Exercise|Prompt Human Coronary Collateral Vasomotor Function Induced by Dynamic Physical Exercise||University Hospital Inselspital, Berne|Yes|Completed|April 2005|March 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|80 Years|No|||October 2010|October 25, 2010|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947050||135621|
NCT00947323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STED|Simvastatin for Treating Erectile Dysfunction|The Effect of Simvastatin in the Penile Erection: a Randomized, Double-blind Clinical Trial|STED|Santa Casa de Porto Alegre|Yes|Completed|January 2006|December 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|41|||Male|35 Years|70 Years|No|||September 2010|September 24, 2010|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947323||135600|
NCT00948285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A09-3519|Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer|Breast Cancer Staging MAgnetic Resonance for Treatment (B-SMART)|BSMART|Texas Tech University Health Sciences Center|No|Recruiting|July 2009|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Female|18 Years|99 Years|No|||October 2015|October 2, 2015|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948285||135526|
NCT00948246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP10088|European Union (EU) Post-Market Study on Easyband®|EU Post-Market Study on Easyband®||Allergan||Completed|April 2009|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|112|||Both|18 Years|N/A|No|Non-Probability Sample|Weight loss clinic and bariatric surgeon clinics within a hospital|October 2012|October 6, 2014|July 28, 2009||No||No|June 27, 2012|https://clinicaltrials.gov/show/NCT00948246||135529|
NCT00948259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP031112-08B03 (CR080901)|Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease|Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.||Noscira SA|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|60 Years|85 Years|No|||November 2009|November 10, 2009|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948259||135528|
NCT00948272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRV01|Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults|Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults||Sanofi|No|Completed|July 2009|August 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|384|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948272||135527|
NCT00948831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.OC-0803|Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF)|Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF): Evaluation of Radiographic and Patient Outcomes||NuVasive|No|Completed|April 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|70 Years|No|Non-Probability Sample|Existing clinic patients|April 2015|April 17, 2015|July 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00948831||135484|
NCT00949130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXL103/2002|Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|A Multicenter,Investigator-blinded,Randomized, Comparative Study to Evaluate the Efficacy and Safety of Oral NXL103 Versus Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)||Novexel Inc|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|80 Years|No|||March 2010|March 17, 2010|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949130||135461|
NCT00949143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS-2009-182|Effects of Axle Positions on Wheelchair Skills in Manual Wheelchair Users|Effects of Axle Positions on Wheelchair Skills in Manual Wheelchair Users||Nova Scotia Health Authority|No|Completed|May 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|15|||Both|17 Years|N/A|No|||March 2011|March 25, 2011|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949143||135460|
NCT00949390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0369|Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials|Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials||M.D. Anderson Cancer Center|No|Recruiting|August 2009|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Current participation in a UT MDACC Phase I Clinical trial with a clinical diagnosis of        advanced malignancy.|January 2016|January 14, 2016|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949390||135441|
NCT00955435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-15 ICORG|Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15|Proteomic Analysis of the Combined Hormonal Therapy and Radiation Therapy for Localized Prostate Cancer|ICORG 06-15|ICORG- All Ireland Cooperative Oncology Research Group||Active, not recruiting|September 2005|||October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Male|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with localised prostate cancer who will receive radiation therapy plus        hormonal therapy, for 4 - 8 months, are eligible for the trial. Patients will be eligible        to participate in the trial provided they have not received prior therapy for their        prostate cancer. It is planned that 60 patients will participate in the research study.        All patients will receive approx 4 months of induction hormone therapy (LHRH agonist and        Bicalutamide) prior to starting radiotherapy treatment.|February 2016|February 12, 2016|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955435||134982|
NCT00955448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anterior SIS 300609|Trial of Small Intestine Submucosa (SIS) Mesh for Anterior Repair: A Pilot Study|Randomized Controlled Trial of SIS Mesh for Anterior Repair: A Pilot Study|Anterior SIS|University of Calgary|No|Completed|December 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Female|N/A|N/A|No|||August 2013|August 14, 2013|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955448||134981|
NCT00943579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHC-0902|Open-Label Extension Study of Kuvan for Autism|Kuvan® (Sapropterin) as a Treatment for Autistic Disorder: An Open Label Extension Protocol||The Children's Health Council|No|Completed|August 2009|March 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|3 Years|6 Years|No|||July 2013|July 2, 2013|July 20, 2009|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT00943579||135888|
NCT00952146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|South Alvsborg Hospital|Transgastric Peritoneoscopy and Appendectomy|Transgastric Diagnostic Peritoneoscopy (Laparoscopy) and Appendectomy - A Pilot Study||Sodra Alvsborgs Hospital|No|Recruiting|November 2007|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2009|August 4, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00952146||135229|
NCT00952159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00380-57|CYTRAM (Cytochrome P450, Tramadol)|Validation of a New Method to Detect CYP2D6 Poor Metabolizers by Monitoring Seric Concentrations of O-demethyl-tramadol and Tramadol to Make a Ratio in Comparison With Genotyping in Post-operative Patients Treated With Intravenous Tramadol|CYTRAM|University Hospital, Caen|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|301|Samples With DNA|We propose to phenotype CYP2D6 in post-operative patients treated by tramadol by monitoring      seric concentrations of O-demethyl tramadol and tramadol to make a ratio in comparision with      genotype, and to find a threeshold to determine poor metabolizers. As already described,      genotyping CYP2D6 will use a rapid detection method of the alleles implicated in poor      metabolizer status (CYP2D6*3, *4, *5 et *6) in a caucasian population|Both|18 Years|N/A|No|Non-Probability Sample|Post-operative patients treated by tramadol|July 2011|July 1, 2011|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952159||135228|
NCT00952406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUGA -1 - 09|A Multi Center Study to Validate a Condition-specific Measure of Sexual Health in Women With Pelvic Floor Disorders|A Multi Center Study to Validate a Condition-specific Measure of Sexual Health in Women With Pelvic Floor Disorders||International Urogynecological Society|No|Completed|August 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|877|None Retained|No Biospecimens are to be retained.|Female|18 Years|100 Years|No|Non-Probability Sample|Goal to enroll approximately 800 women so that 600 surveys are available for evaluation of        the sexual health of women with pelvic floor disorders presenting for urogynecological        care in the United States or England|December 2015|December 10, 2015|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00952406||135209|
NCT00944944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-077|Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema|A Pilot Study Using the Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema||Memorial Sloan Kettering Cancer Center||Completed|July 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|58|||Female|21 Years|N/A|No|Non-Probability Sample|Potential GYN research subjects will be identified by a member of the patient's treatment        team, the protocol investigator, or research team at Memorial Sloan-Kettering Cancer        Center (MSKCC).|January 2010|January 29, 2010|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944944||135783|
NCT00945191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1008-A-U205|Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer|Phase 2 Study of CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or Metastatic Ovarian Cancer||Daiichi Sankyo Inc.|No|Completed|September 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||February 2013|February 1, 2013|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945191||135764|
NCT00946413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH95-TD-M-113-058|Application and Evaluation of Group Cognitive Intervention for Depressed Adolescents|Application and Evaluation of Group Cognitive Intervention for Depressed Adolescents||Taipei Medical University Hospital|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|31|||Both|14 Years|19 Years|No|||July 2009|July 24, 2009|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946413||135670|
NCT00942864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AKR07|Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)|An Open-label, Nonrandomized, Phase IIIb, Single Dose Study to Evaluated the Changes in Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) After Intravitreal Injection of Lucentis® in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)||Novartis Korea Ltd.||Enrolling by invitation|December 2008|||December 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||July 2009|July 21, 2009|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942864||135943|
NCT00943696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fonduestudie_EKGs|Effects of White Wine vs. Tea Intake During and an Alcoholic Digestive Following a High Fat, High Calorie Cheese Fondue Meal on Gastric Emptying and Abdominal Symptoms in Healthy Volunteers|||University of Zurich|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|12|||Both|19 Years|60 Years|No|||June 2010|June 24, 2010|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943696||135879|
NCT00948012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPSC01|Exercise-induced Pulmonary Hypertension in Patients With Sickle-cell Anemia|Exercise-induced Pulmonary Hypertension in Patients With Sickle-cell Anemia: an Echocardiographic Study.||Federal University of São Paulo|No|Completed|June 2006|November 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|44|||Both|17 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients with SCA, homozygous to hemoglobin S with preserved physical capacity, followed        at the Hematology and Blood Transfusion Division of the Federal University of Sao Paulo        (UNIFESP) or at the Hematology and Oncology Division of Santa Casa de Misericordia de Sao        Paulo Medical School.|July 2009|July 28, 2009|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948012||135547|
NCT00948025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG-CP-004|A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options|A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance Nerve Graft Evaluating Recovery Outcomes of Nerve Repair in the Hand. (CHANGE)|CHANGE|AxoGen, Inc||Completed|June 2009|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|70 Years|No|||May 2015|May 20, 2015|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00948025||135546|
NCT00948324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87755766|Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes|Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes||Sun Yat-sen University|Yes|Enrolling by invitation|June 2008|December 2018|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|25 Years|70 Years|No|||June 2013|June 4, 2013|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948324||135523|
NCT00948909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-984|Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease||AbbVie||Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|274|||Both|55 Years|90 Years|No|||January 2013|January 29, 2013|July 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948909||135478|
NCT00949195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZTE PULM-PAHP|Pulmonary Arterial Pressure Response During Exercise|Pulmonary Arterial Pressure Response During Exercise in COPD and Healthy Subjects|PAPCOPDHS|Szeged University|Yes|Recruiting|September 2009|December 2011|Anticipated|December 2009||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|80|None Retained|Blood sample is taken to analyse the systemic inflammatory marker (hsCRP) level from serum.      We measure the samples and than we don't store it.|Both|45 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|COPD patients (age between 45 and 70) with moderate to severe obstruction (FEV1<60%) and        healthy subjects (age between 45 and 70)|October 2009|July 20, 2011|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949195||135456|
NCT00919802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB0001|Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis|Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis||University of Alabama at Birmingham|Yes|Completed|June 2010|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|19 Years|65 Years|No|||December 2015|December 14, 2015|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00919802||137688|
NCT00920361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06130|Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)|Designated Drug Use Investigation 1 of Follistim Injection||Merck Sharp & Dohme Corp.|No|Completed|November 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1664|||Female|N/A|N/A|No|Non-Probability Sample|Japanese 1100 patients|February 2015|February 4, 2015|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920361||137645|
NCT00920374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113018|A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in People Aged 18 Years or Above||GlaxoSmithKline||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|118|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 14, 2013|June 12, 2009|Yes|Yes||No|April 22, 2010|https://clinicaltrials.gov/show/NCT00920374||137644|
NCT00920712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHTCM-001|Study of the Chinese Prescription Weiqi Decoction on Chronic Atrophic Gastritis|||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|August 2009|July 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||August 2009|August 20, 2009|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920712||137618|
NCT00920725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05012103|Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA|Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis|DKA|Rush University Medical Center|Yes|Completed|January 2005|December 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 14, 2012|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920725||137617|
NCT00921063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5361007|A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 5-Week Trial To Assess The Efficacy And Safety Of PD 0332334 Compared To Placebo And Alprazolam Extended-Release In Patients With Generalized Anxiety Disorder||Pfizer|No|Completed|November 2005|July 2006|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|222|||Both|18 Years|65 Years|No|||February 2010|February 17, 2010|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921063||137591|
NCT00921349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVL+Nadolol|A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis|A Randomized, Controlled Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis||National Science Council, Taiwan|Yes|Completed|December 2004|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|75 Years|No|||June 2009|June 15, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00921349||137569|
NCT00921856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOVA-1|Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)|Abnormal Coronary Vasomotion in Patients With Suspected CAD But Normal Coronary Arteries|ACOVA|Robert Bosch Medical Center|No|Recruiting|November 2007|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|320|||Both|35 Years|N/A|No|||November 2015|November 2, 2015|June 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00921856||137530|
NCT00949676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECIDE-HF|DECIDE-HF: Heart Rate Variability in Heart Failure Patients|DECIDE-HF - Heart Rate Variability in Heart Failure Patients|DECIDE-HF|Medtronic BRC|No|Active, not recruiting|September 2009|December 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Systolic Heart Failure Patients with NYHA class II or III and a ventricular ejection        fraction of less then 40%.|September 2013|September 20, 2013|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949676||135419|
NCT00949923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-08-1|Green Tea in Breast Cancer Patients|Green Tea Supplement in Women With Incident Breast Cancer||University of Southern California|No|Active, not recruiting|June 2008|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Female|18 Years|N/A|No|||October 2015|October 24, 2015|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949923||135400|
NCT00950209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/17|Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients|Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients||Assistance Publique Hopitaux De Marseille|No|Completed|April 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Male|30 Years|70 Years|No|||February 2014|February 24, 2014|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950209||135378|
NCT00951041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113574|Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years||GlaxoSmithKline||Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2011|March 24, 2011|July 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951041||135314|
NCT00947427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TrialNet-cana (IND)|Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes|Effects of Canakinumab On The Progression of Type 1 Diabetes In New Onset Subjects|anti IL-1|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|October 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|66|||Both|6 Years|45 Years|No|||May 2013|May 28, 2013|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947427||135592|
NCT00947401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234567|Fluid Management After Surgery in the Post-Anesthetic Care Unit (PACU)|The Practice of Fluid Management in the Post-anesthetic Care Unit (PACU) of Shaare Zedek Medical Center in Patients Undergoing Elective Surgery: an Observational Study||Shaare Zedek Medical Center|No|Not yet recruiting|September 2009|December 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (age > 18 yrs) after elective surgery|July 2009|July 27, 2009|July 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00947401||135594|
NCT00947414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELLUSHOCK-2009|Cellulite and Extracorporeal Shock Wave|Cellulite and Extracorporeal Shock Wave - a Randomized Trial||Hannover Medical School|No|Completed|June 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|65 Years|No|||December 2011|December 1, 2011|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947414||135593|
NCT00943787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12252|Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus|Counter-regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus|BPK003|University of Virginia||Completed|January 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|41|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|June 24, 2009||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT00943787||135872|
NCT00948350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-BR-34/08-1|Anesthesia for Awake Fiberoptic Intubation|Anesthesia for Awake Fiberoptic Intubation in Patients With Cervical Instability - Comparison of Translaryngeal Injection and "Spray as You go"-Technique||Klinikum St. Georg gGmbH|No|Completed|January 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948350||135521|
NCT00948636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-DON|Stem Cell Related Donor Safety Study|A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life|RDSafe|Center for International Blood and Marrow Transplant Research|Yes|Active, not recruiting|January 2010|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2300|||Both|N/A|N/A|No|Non-Probability Sample|participating institutions (transplant centers)|July 2014|July 16, 2015|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948636||135499|
NCT00944619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0306/44|Closing the Loop in Adults With Type 1 Diabetes - Alcohol Consumption|Randomised, Two-Period Crossover Study to Assess the Efficacy of Overnight Computer-based Glucose Control Compared With Conventional Pump Therapy Following the Consumption of Alcohol in Adults With Type 1 Diabetes|ANGELA02|University of Cambridge|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||January 2010|May 10, 2010|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944619||135808|
NCT00944892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-0901|A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee|A Randomized,Double Blind,Placebo-controlled,Parallel Group,Repeat Dose Study of the Safety and Efficacy of REGN475 in Patients With Osteoarthritis of the Knee||Regeneron Pharmaceuticals||Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|40 Years|75 Years|No|||December 2011|December 1, 2011|July 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00944892||135787|
NCT00920049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909165|Preventing Motor Vehicle Crashes Among Young Drivers: Evaluation of the Checkpoints Program Presented by the American Automobile Association|Preventing Motor Vehicle Crashes Among Young Drivers: Evaluation of the AAA Checkpoints Program||National Institutes of Health Clinical Center (CC)||Completed|June 2009|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|1||Anticipated|830|||Both|15 Years|N/A|Accepts Healthy Volunteers|||March 2012|September 26, 2015|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00920049||137669|
NCT00920348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRO-93326|The Canadian Cohort Obstructive Lung Disease|The Canadian Cohort Obstructive Lung Disease|CanCOLD|McGill University|Yes|Recruiting|January 2010|March 2017|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1500|Samples With DNA|Blood sampling        -  Biomarkers:IL-6, CRP, CC-16, SP-D"        -  DNA for genetics, epigenetic and RNA for transcriptomics        -  Markers for cardiovascular diseases: LDL, LDL and HDL sizes, Apo B, Apo A1, CRP, IL6,           TNF alpha, Adiponectine, Leptine, Glucose and Insulin.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects' selection and participation in CanCOLD- longitudinal cohort: Subjects will be        recruited from the study site participants (total from cross-sectional ≈5,000 subjects,        men and women).|November 2013|November 4, 2013|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920348||137646|
NCT00930514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22333|A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma|A Two Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Rituximab Subcutaneous (SC) Formulation in Patients With Follicular Lymphoma (FL) as Part of Maintenance Treatment||Hoffmann-La Roche||Completed|September 2009|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|6||Actual|281|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00930514||136881|
NCT00921583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 078/09|Long-term Examination of Titanium Dental Implants With a TPS Surface: A Prospective 20-year Case Series Study|Long-term Examination of Titanium Dental Implants With a TPS Surface: A Prospective 20-year Case Series Study||University of Bern|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|67|||Both|N/A|N/A|No|Non-Probability Sample|Partially edentulous patients provided with implants between 1986 and 1989 at the        Department of Oral Surgery and Stomatology at the University of Bern recruited for a        clinical and radiographic evaluation 20 years after implant installation. A total of 75        patients with 102 implants will be recalled for a clinical and radiographic examination.        All implants installed were hollow screw and hollow cylinder implants (Straumann,        Waldenburg, Switzerland) with a rough TPS surface. They were placed according to the        manufacturer's guidelines. The superstructures consistent in single crowns or fixed        partial dentures, which were incorporated 4-6 months postsurgically.|April 2012|April 12, 2012|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00921583||137551|
NCT00921869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-J081-102|A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors|A Phase I Dose-finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors.||Eisai Inc.||Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|74 Years|No|||April 2012|April 4, 2012|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921869||137529|
NCT00931060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15580|Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects|Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects||University of Aarhus|No|Completed|November 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|24|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 14, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931060||136841|
NCT00931333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/03|Efficacy and Safety Study of Non-percutaneous Vertebroplasty With Macroporous Calcium Phosphate Cement (MCPC)|Non Comparative, Monocentric, Prospective, Phase II, Study of Calcium Phosphate Cement MCPC Efficacy and Safety for Bone Filling in Vertebral Site|VERTEBRO-MCPC|University Hospital, Bordeaux|Yes|Completed|July 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||November 2011|November 23, 2011|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931333||136820|
NCT00931346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI E002|A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa|A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa||International AIDS Vaccine Initiative|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|72|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2011|August 24, 2011|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00931346||136819|
NCT00931918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05013|Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients|An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients||Millennium Pharmaceuticals, Inc.|No|Completed|October 2009|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|July 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931918||136777|
NCT00949689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH082034-01A1|Young Adult and Teen Sleep Study|Development and Piloting of CBT for Insomnia in Youth With Comorbid Depression|YATSS|Kaiser Permanente|No|Completed|September 2009|August 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|12 Years|20 Years|No|||October 2011|November 14, 2012|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949689||135418|
NCT00949936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ranier01/2008|Safety and Performance Study of the CAdiscTM-L Lumbar Spinal Disc Replacement Device For CE Marking|Debilitating Low Back paIn: Multi-centre Safety and performanCe invEstigation Of CAdiscTM-L, Total Disc ReplacemeNt Therapy|DISCERN|Ranier Technology Limited|No|Completed|October 2009|June 2010|Actual|||N/A|Interventional|Primary Purpose: Treatment|||||||Both|25 Years|65 Years|No|||October 2010|October 14, 2010|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00949936||135399|
NCT00950742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.68|Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.|Phase I Open Label Trial to Assess Safety of BIBW 2992 in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.||Boehringer Ingelheim||Completed|August 2009|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||July 2015|July 1, 2015|July 31, 2009||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00950742||135337|MTD was determined at 20mg afatinib when 1/6 pat. had DLT (3+3 design). Upon expansion of MTD cohort to 18 pat. recruitment was stopped when 4/13 pat. had DLT. No lower afatinib dose could be tested as 20mg was the lowest dose formulation available.
NCT00950755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104505|Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology|Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology||GlaxoSmithKline||Completed|June 1998|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||February 2012|July 26, 2012|July 30, 2009|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT00950755||135336|
NCT00951054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6012211US|A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer|A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients With Triple Negative Phenotype||Nippon Kayaku Co.,Ltd.|Yes|Completed|February 2009|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Female|18 Years|N/A|No|||February 2015|February 12, 2015|May 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951054||135313|
NCT00943267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEMM-APC-01|Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)|Effect of Intrapulmonary Administration of Recombinant Human Activated Protein C on Local Coagulation and Inflammation After Bronchial Instillation of Lipopolysaccharide in Humans||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|October 2008|March 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|52|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2009|March 15, 2011|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943267||135912|
NCT00947713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-002|Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome|Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With HMG in PCOs Patients With Previous Clomiphene Citrate (CC)-Resistant Anovulation||Royan Institute|Yes|Completed|August 2009|December 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|10|||Female|18 Years|30 Years|No|||April 2010|July 14, 2011|July 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00947713||135570|
NCT00944047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11368|Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression|Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)||University of Kansas Medical Center|Yes|Active, not recruiting|July 2009|September 2015|Anticipated|January 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||December 2013|March 31, 2015|July 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00944047||135852|
NCT00944307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0475|Effect of Antacids on the Pharmacokinetics of Raltegravir|Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers||University of Colorado, Denver|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|July 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00944307||135832|
NCT00944034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P12E1|Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12|A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12||Novartis||Completed|July 2009|January 2012|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|12||Actual|1588|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||October 2015|October 7, 2015|July 21, 2009|Yes|Yes||No|February 16, 2015|https://clinicaltrials.gov/show/NCT00944034||135853|None reported
NCT00944294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRE0470P-302|Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia|Vasodilator Induced Stress In CONcordance With Adenosine (VISION-302)|VISION-302|Pfizer|Yes|Completed|February 2004|April 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|419|||Both|30 Years|N/A|No|||May 2012|May 24, 2012|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00944294||135833|
NCT00944905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1203-01|Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)|A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma||Bristol-Myers Squibb|No|Completed|July 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|July 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00944905||135786|
NCT00945139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST AVF3911s|Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)|Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer||New Mexico Cancer Care Alliance|Yes|Completed|March 2007|August 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|18 Years|N/A|No|||July 2015|July 6, 2015|July 21, 2009|Yes|Yes||No|June 30, 2014|https://clinicaltrials.gov/show/NCT00945139||135768|
NCT00945438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID29|Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)||Sanofi|No|Completed|May 2009|July 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|131|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00945438||135745|
NCT00921362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NRO-SER-2006/2|Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme|Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme||AstraZeneca|No|Completed|May 2006|January 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1387|||Both|N/A|N/A|No|Probability Sample|Patients eligible for entry into the study will have a diagnosis of schizophrenia defined        by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria        and of a chronic or sub-chronic nature|June 2009|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921362||137568|
NCT00930527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD8300|Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors|Randomized Phase II Study of Omega-3-Fatty Acid on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients||Columbia University|Yes|Terminated|June 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Female|21 Years|N/A|No|||February 2013|July 22, 2014|June 29, 2009|No|Yes|Closed by sponsor.|No||https://clinicaltrials.gov/show/NCT00930527||136880|
NCT00930774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7054-R|Approaches to Auditory Rehabilitation for Mild Traumatic Brain Injury|Evaluation of Approaches to Auditory Rehabilitation for Mild TBI|mTBI|VA Office of Research and Development|No|Completed|October 2010|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|99|||Both|N/A|N/A|No|||June 2014|June 3, 2014|June 26, 2009||No||No|February 21, 2014|https://clinicaltrials.gov/show/NCT00930774||136862|
NCT00921596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xinzangwaike0003|Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass (CPB)|Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass, a Single Center's Experience|CPB|Xijing Hospital|Yes|Recruiting|January 2000|December 2009|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|2 Years|70 Years|No|||June 2009|June 14, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00921596||137550|
NCT00931073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451017|A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers|A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects||Pfizer|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|July 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931073||136840|
NCT00931632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-3001-BPD-301|Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants|Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth||INO Therapeutics|Yes|Completed|November 2009|May 2014|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|451|||Both|N/A|14 Days|No|||July 2015|January 27, 2016|July 1, 2009|Yes|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT00931632||136797|
NCT00931931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB13-00471|HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors|A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors||Nationwide Children's Hospital|Yes|Recruiting|March 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|7 Years|30 Years|No|||September 2015|September 24, 2015|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931931||136776|
NCT00932191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHCrush001|Endothelial Cell Loss After Cataract Surgery|Endothelial Cell Loss After Cataract Surgery: Comparison of a Reduced Ultrasound Technique Versus Standard Ultrasound Technique||University of California, San Francisco|No|Terminated|July 2009|July 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|40 Years|N/A|No|||August 2014|August 21, 2014|July 1, 2009||No|Stopped for lack of funds|No||https://clinicaltrials.gov/show/NCT00932191||136756|
NCT00950469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TnThs 1|TnThs for Identification Myocardial Infarction|Comparison of the New High Sensitive Cardiac Troponin T With the 4th Generation Troponin-T, Myoglobin, Heart-type Fatty Acid Binding Protein for Early Identification of Myocardial Necrosis in Patients With Suspected Acute Coronary Syndrome||Heidelberg University|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|Samples Without DNA|Blood samples (serum) were collected at presentation and after 6 hours. After collection,      serum was centrifuged immediately and stored at -80°C until analysis.      The laboratory staff responsible for measurements was blinded to patient data.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of        the University of Heidelberg were enrolled with symptoms suggestive of ACS.|July 2009|July 30, 2009|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950469||135358|
NCT00950768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISMM2001|Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients|GISMM2001: Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients: a Prospective, Multi-center Phase III Study||Azienda Ospedaliera San Giovanni Battista||Completed|February 2002|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|65 Years|No|||July 2009|July 31, 2009|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00950768||135335|
NCT00946881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN901 PCM202|Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer|A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer||Steba Biotech S.A.|Yes|Completed|July 2009|August 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||September 2012|February 21, 2013|July 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00946881||135634|
NCT00947180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24 DK67674 (completed)|Gastrointestinal Biopsychosocial Research Center|Randomized Controlled Trial Comparing Biofeedback, Electrogalvanic Stimulation, and Massage for the Treatment of Chronic Proctalgia||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|October 2000|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|157|||Both|18 Years|70 Years|No|||March 2010|March 17, 2010|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00947180||135611|
NCT00943514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090172|Natural History of Bronchiectasis|Natural History of Bronchiectasis & Bronchiectasis Patient Registry||National Institutes of Health Clinical Center (CC)||Recruiting|July 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|900|||Both|5 Years|N/A|No|||November 2015|December 15, 2015|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943514||135893|
NCT00943527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004850|Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast|Molecular Breast Imaging: Effect of Menstrual Cycle, Hormone Therapy, and Tamoxifen on Tc-99m Sestamibi Uptake in the Breast.||Mayo Clinic|No|Completed|January 2008|January 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|110|||Female|35 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|January 2012|January 23, 2012|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943527||135892|
NCT00943501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1800|Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes|Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability,Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes||Novo Nordisk A/S|Yes|Completed|November 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|21|||Both|10 Years|17 Years|No|||March 2015|March 13, 2015|July 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00943501||135894|
NCT00944333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Security|Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy|Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy||Fondazione Mediolanum per Attività e Ricerche Cardiovascolari Onlus|No|Terminated|July 2009|July 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1378|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|July 22, 2009||No|STOP due to recent data in literature questioning the need to continue DAP beyond six months    in patients with stable coronary artery stenting with DES.|No||https://clinicaltrials.gov/show/NCT00944333||135830|
NCT00944346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40484|Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects|||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|N/A||||July 2009|July 22, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00944346||135829|
NCT00944320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C05133|Pharmacogenetics of Antifolate Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis in Taiwan|||National Chung Hsing University|Yes|Completed|February 2006|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Both|18 Years|N/A||Probability Sample|A cross-sectional study involving 100 patients with RA were enrolled from TCVGH.|July 2009|July 22, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944320||135831|
NCT00944632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14501|Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis|Double-blind, Randomized, Dose Escalation Study of the Efficacy and Safety of ZK 245186 Ointment in Concentrations of 0.01%, 0.03%, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis||Bayer|No|Completed|July 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|55 Years|No|||February 2014|February 19, 2014|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944632||135807|
NCT00944645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-059|MK0524A Bioequivalence Study (0524A-059)|An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets||Merck Sharp & Dohme Corp.||Completed|October 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|July 21, 2009|No|Yes||No|October 20, 2009|https://clinicaltrials.gov/show/NCT00944645||135806|
NCT00944918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238UK/0005|Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)|A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-steroidal Aromatase Inhibitors||AstraZeneca|No|Completed|December 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|25|||Female|18 Years|N/A|No|||August 2011|August 26, 2011|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00944918||135785|
NCT00945152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB study # 1111446|Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)|Topical MRSA Bactericidal Gel to Eliminate MRSA and Promote Accelerated Healing of cSSTI of Open Wounds|Vancogel(R)|Robert S Berman MD|No|Recruiting|July 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00945152||135767|
NCT00929942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5237|Biodegradable Stents in Lung Transplantation|Treatment of Benign Bronchial Airway Stenoses in Patients After Lung Transplantation With a Biodegradable Stent - a Proof of Concept Study||Hannover Medical School|No|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2009|July 20, 2011|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929942||136925|
NCT00930241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5281M mono|Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation|Prospective Randomized Trial to Compare a Twice Daily to a Once Daily Administration of the Tacrolimus in Lung Transplanted Patients||Hannover Medical School|No|Terminated|July 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|70 Years|No|||March 2013|March 19, 2013|June 29, 2009||No|logistic reasons (insufficient funding, technical problems with MEMS)|No||https://clinicaltrials.gov/show/NCT00930241||136902|
NCT00931372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY10433|Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2|Restoration of First Phase Insulin Release in Subjects With Type 2 Diabetes Mellitus With Subcutaneous Injection of 20 µg AVE0010 in a Double-blind, Randomized, Placebo-controlled, Two-way Cross Over Intravenous Glucose Challenge Study.|RESTORE|Sanofi|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||February 2012|February 22, 2012|June 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931372||136817|
NCT00931385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.24|Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease|Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil Iin Patients With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|June 2009|||April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|99|||Both|40 Years|N/A|No|||May 2014|May 29, 2014|July 1, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00931385||136816|
NCT00930761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAME-21-2001|Effects of Music Therapy on Breastfeeding Among Mothers of Premature Newborns|A Randomized Controlled Trial to Evaluate the Effects of Music Therapy on Breastfeeding Rates Among Mothers of Premature Newborns||Universidade Federal do Rio de Janeiro|No|Completed|March 2004|October 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|101|||Female|N/A|N/A|No|||October 2009|October 13, 2009|June 29, 2009||No||No|July 8, 2009|https://clinicaltrials.gov/show/NCT00930761||136863|
NCT00930787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC2007.03.01|Hernia Repair in Multiply Morbid Patients|A Multicenter, Prospective, Randomized, Controlled, Single-Blinded Study of Strattice Reconstructive Tissue Matrix vs Proceed|RAM2P|LifeCell|Yes|Terminated|August 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|June 29, 2009||No|Stopped early|No|August 16, 2012|https://clinicaltrials.gov/show/NCT00930787||136861|
NCT00931359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0003|Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis|A Prospective, Multicenter, Parallel, Randomized, Blinded Study of the Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis|DRI-UP|Miramar Labs|Yes|Completed|June 2009|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|June 28, 2009|Yes|Yes||No|April 15, 2011|https://clinicaltrials.gov/show/NCT00931359||136818|Sham subjects exited the study at 6 months, so group comparisons are not possible for later timepoints.
NCT00932204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2006-0318|Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders|A Randomized, Controlled Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders||Severance Hospital|Yes|Completed|February 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|19 Years|60 Years|No|||July 2009|July 2, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932204||136755|
NCT00932490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015563|Tailored Intervention Protocol for Oral Chemotherapy Adherence|Tailored Intervention Protocol for Oral Chemotherapy Adherence||Duke University|Yes|Completed|August 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|48|||Both|18 Years|N/A|No|||November 2012|July 14, 2014|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932490||136733|
NCT00951067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQ-UE-LYMPHEDMA-PCD-RCT|Pneumatic Compression Treatment For Upper Extremity Acquired Lymphedema|Trial to Compare Pneumatic Compression Treatments for Upper Extremity Acquired Lymphedema|PCD-LYMPH|Children's Hospital Boston|No|Withdrawn|August 2009|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|August 3, 2009|No|Yes|Funding not available to continue with study.|No||https://clinicaltrials.gov/show/NCT00951067||135312|
NCT00951080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNP041609|SNaP Wound Care System Versus Traditional NPWT Device for Treatment of Chronic Wounds|Lower Extremity Venous and Diabetic Ulcer Negative Pressure Wound Therapy Trial.||Spiracur, Inc.|No|Completed|July 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|July 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00951080||135311|
NCT00942682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-094|Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors|Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors||Dana-Farber Cancer Institute|Yes|Completed|July 2009|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2014|April 27, 2014|July 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942682||135957|
NCT00942695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-109|Energy Value of Macronutrients From Pistachio Nuts and Mechanisms of Nutrient Action|Energy Value of Macronutrients From Pistachio Nuts and Mechanisms of Nutrient Action||USDA Beltsville Human Nutrition Research Center|Yes|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|15|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942695||135956|
NCT00943007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-2-055|Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors|Randomized Assessment of Conventional Neuronavigation Versus Intraoperative MRI for the Neurosurgical Treatment of Glioblastomas|RACING|Maastricht University Medical Center|Yes|Completed|February 2010|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|July 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943007||135932|
NCT00943254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006106|Metabolic Syndrome Diagnosis and Education Trial|Metabolic Syndrome: Impact of Receiving the Diagnosis and Education Intervention on Cardiovascular Risk Factor Modification and Willingness to Change||Mayo Clinic||Completed|October 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|74|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943254||135913|
NCT00943813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-043|Assessment of Comskil Training Through Videorecording and Patient Surveys|Assessment of Comskil Training Through Videorecording and Patient Surveys||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2009|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|19 Years|N/A|No|Non-Probability Sample|MSKCC new visits in clinic.|March 2016|March 7, 2016|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943813||135870|
NCT00943800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14736B|Combined Haploidentical-Cord Blood Transplantation for Adults and Children|Combined Haploidentical-Cord Blood Transplantation for Adults and Children||University of Chicago|Yes|Active, not recruiting|October 2006|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|1 Year|N/A|No|||October 2015|October 20, 2015|July 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943800||135871|
NCT00949533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22789|A Study on Emergence of Resistance With Tamiflu (Oseltamivir) in Patients With Seasonal Influenza|An Unblinded, Comparative, Randomized Study of Influenza A/H1N1 2009 Resistance in Patients With Standard and Double Dose Oseltamivir Treatment||Hoffmann-La Roche||Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|5 Years|N/A|No|||February 2016|February 1, 2016|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00949533||135430|
NCT00949546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20031168|Treatment of Hidradenitis Suppurativa Using Etanercept|Treatment of Hidradenitis Suppirativa With Etanercept Injection||Penn State University|No|Completed|April 2005|January 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with chronic HS|July 2009|July 29, 2009|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949546||135429|
NCT00944658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112008|Spondylitis Trial of Apremilast for Better Rheumatic Therapy|Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS)|START|Imperial College London|No|Completed|August 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00944658||135805|
NCT00950027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2006-006353-27|Study of Povidone Iodine to Reduce Pulmonary Infection in Head Trauma and Cerebral Hemorrhage in Intensive Care Unit|Prospective Randomized Double Blind Study Comparing the Effect of Oropharyngeal Decontamination by Povidone-iodine to Placebo on Ventilator-associated Pneumonia in Patients With Head Trauma or Cerebral Hemorrhage|SPIRIT-ICU|Rennes University Hospital|No|Terminated|April 2008|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|179|||Both|18 Years|N/A|No|||July 2012|July 4, 2012|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950027||135392|
NCT00950313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAHRC ED DIAB01|Assessment of Response Rates and Yields for Two Tools for Early Detection of Non-diabetic Hyperglycaemia and Diabetes|Assessment of Response Rates and Yields for Two Tools for Early Detection of Non-diabetic Hyperglycaemia and Diabetes|ATTEND|University of Leicester|Yes|Completed|April 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|432|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||July 2009|November 12, 2014|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950313||135370|
NCT00930800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712010R|Exercise Training in Children With Congenital Heart Defect|The Effect of Exercise Training on Exercise Capacity, Physical Activity, and Health-related Quality of Life in Children After Repair of Congenital Heart Defect||National Taiwan University Hospital|Yes|Completed|December 2007|November 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|60|||Both|7 Years|16 Years|Accepts Healthy Volunteers|||July 2009|July 19, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00930800||136860|
NCT00930813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0012-01|LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis|A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Catheter vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries With and Without Stenting.|LEVANT I|C. R. Bard|Yes|Completed|June 2009|December 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|June 30, 2009||No||No|August 5, 2014|https://clinicaltrials.gov/show/NCT00930813||136859|
NCT00930826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461956|Childhood Asthma and Schooling: The Truth Unveiled|Childhood Asthma and Schooling: The Truth Unveiled|CAS|Boushahri Clinic Medical Center|Yes|Completed|September 2006|August 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|450|||Both|6 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of a certain town|November 2008|July 16, 2010|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT00930826||136858|
NCT00930254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USV01|Peripheral Intravenous Puncture Guided by Vascular Ultrasound|Vascular Ultrasound During the Use of Peripheral Intravenous Catheters in Children: A Clinical, Randomized and Controlled Trial.||Federal University of São Paulo|Yes|Completed|February 2007|July 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|335|||Both|N/A|18 Years|No|||June 2009|June 29, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00930254||136901|
NCT00932217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pisa 01|Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma|Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma||University of Pisa|Yes|Active, not recruiting|December 2004|||April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|180|||Both|18 Years|70 Years|No|||February 2009|July 2, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932217||136754|
NCT00932230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD0206090175|The Effect of Kinesio Taping on Ankle Proprioception|The Effect of Kinesio Taping on Ankle Proprioception||Logan College of Chiropractic|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|65 Years|No|||May 2013|May 1, 2013|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932230||136753|
NCT00931086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1006-C1089|Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99|An Expanded Access Trial of Belimumab Antibody (Monoclonal Anti-BLyS Antibody) in Patients With Rheumatoid Arthritis (RA) Who Were Previously Treated Under HGS Protocol LBRA99|LBRA99|GlaxoSmithKline|No|No longer available|April 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||October 2012|October 29, 2012|June 30, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00931086||136839|
NCT00931944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNS-760704-CL211|Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)|An Open-Label, Safety and Tolerability, Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS)|CL211|Knopp Biosciences|No|Completed|July 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|21 Years|80 Years|No|||October 2014|October 13, 2014|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931944||136775|
NCT00931957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|860241-5807|Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease|Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease||Tehran University of Medical Sciences|Yes|Recruiting|October 2010|October 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|60 Years|No|||November 2010|November 19, 2010|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931957||136774|
NCT00933114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014784|Functional Imaging of Tumor and Normal Tissue|The Use of Functional Imaging to Quantify Tumor and Normal Tissue Physiology in Patients With Locally Advanced Head and Neck Cancer|FITT|Duke University|No|Terminated|October 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients presenting to Radiation Oncology for radiotherapy of the NH cancer.|April 2012|April 10, 2012|July 2, 2009||No|Funding ceased|No||https://clinicaltrials.gov/show/NCT00933114||136687|
NCT00946582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904005R|The Therapeutic Effects of Barkley's Parenting Management Program for Taiwanese School-Aged Children With Attention Deficit/Hyperactivity Disorder (ADHD)|The Therapeutic Effects of Barkley's Parenting Management Program for Taiwanese School-aged Children With Attention Deficit/Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|June 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946582||135657|
NCT00942409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-101358 - prev 081503|Study of Repeat Intranodal Injections of Ad-ISF35|A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD154 (Ad-ISF35) in Patients With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)||University of California, San Diego|Yes|Terminated|June 2009|July 2014|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 17, 2009|Yes|Yes|drug supply was no longer available|No|August 24, 2015|https://clinicaltrials.gov/show/NCT00942409||135977|
NCT00942396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK01007|Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography|Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography||Planmed Oy|No|Withdrawn|April 2008|March 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Female|40 Years|85 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|July 7, 2009|Yes|Yes|FDA changed classification of device and no longer requires this type of clinical data|No||https://clinicaltrials.gov/show/NCT00942396||135978|
NCT00943020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09026|Effects of Glutamine on Gastric Emptying|The Effects of Supplementing Glutamine on the Gastric Emptying Time of a Preoperative Metabolic Conditioning Drink in Healthy Volunteers: a Randomized Crossover Pilot Study||University of Nottingham|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Anticipated|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||November 2009|November 15, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00943020||135931|
NCT00943280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003642|Barrett's Esophagus in Olmsted County|Population Based Screening for Barrett's Esophagus in Olmsted County : A Pilot Study||Mayo Clinic|No|Completed|January 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|Samples With DNA|Gastric, GE junction and esophagus tissue samples collected.|Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Olmsted county residents|January 2012|January 4, 2012|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943280||135911|
NCT00948688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-114|Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas|Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas||Massachusetts General Hospital|Yes|Active, not recruiting|August 2009|August 2013|Anticipated|August 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|July 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948688||135495|
NCT00944060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK74511 (completed)|A Pilot Study of Diabetes Risk Reduction Program With WIC Mothers(The Special Supplemental Nutrition Program for Women, Infants, and Children) Overweight WIC Mothers|A Pilot Study of Diabetes Risk Reduction Program With Overweight WIC Mothers||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed||||||Phase 3|Interventional|Primary Purpose: Prevention|1||||||Female|18 Years|34 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00944060||135851|
NCT00949559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESP2009-001|Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors|A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumors||Esperance Pharmaceuticals Inc||Completed|July 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949559||135428|
NCT00949572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG09-EN01|Measuring Responses to Sublingual Antigens|Characterisation of Human Disseminated Cellular and Humoral Immune Responses Following Sublingual or Intramuscular Deposition of Antigens||St George's, University of London|No|Completed|September 2009|January 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|January 26, 2011|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949572||135427|
NCT00949793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002441|In Vivo Confocal Endomicroscopy of the Brain|In Vivo Confocal Endomicroscopy of the Brain||Carl Zeiss Surgical GmbH|No|Completed|March 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2009|November 9, 2009|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949793||135410|
NCT00950040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA017418|Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics|Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics|SUGAR|Rhode Island Hospital|Yes|Recruiting|July 2009|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||July 2009|May 6, 2015|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950040||135391|
NCT00950326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSF|A Comparison of Kneipp Hydrotherapy With Conventional Physiotherapy in the Treatment of Osteoarthritis of the Hip or Knee: Protocol of a Prospective Randomised Controlled Clinical Trial|A Comparison of Kneipp Hydrotherapy With Conventional Physiotherapy in the Treatment of Osteoarthritis of the Hip or Knee: Protocol of a Prospective Randomised Controlled Clinical Trial||Kneippsche Stiftungen|Yes|Recruiting|January 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||July 2009|July 30, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00950326||135369|
NCT00931125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AHU03T|Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone|Randomized, Double Blinded, Controlled, Two-center Study Assessing the Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone|VITARM|University of Debrecen|Yes|Active, not recruiting|March 2009|December 2013|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931125||136836|
NCT00931398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ConcertaATT4100|Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate|Treatment of College Students With ADHD Using OROS Methylphenidate||University of Pittsburgh|Yes|Withdrawn|April 2010|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|25 Years|No|||August 2012|August 23, 2012|June 30, 2009|Yes|Yes|Study was not initiated due to lack of funding by the sponsor|No||https://clinicaltrials.gov/show/NCT00931398||136815|
NCT00931099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-RT-244-CTIL|Fetal Outcome of Sleep Disordered Breathing During Pregnancy|Fetal Outcome of Sleep Disordered Breathing During Pregnancy||Tel-Aviv Sourasky Medical Center||Not yet recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|300 women in the third trimester of a singleton uncomplicated pregnancy, who attend a low        risk obstetric surveillance (group 1). 100 women hospitalized at the Antenatal department        due to pregnancy related hypertensive disorder, IUGR, diabetes mellitus, or premature        labor will also be recruited (group 2). 200 women of a singleton uncomplicated full term        pregnancy will be recruited during labor at the delivery room (group 3). Neonates born to        women from group 1 and 2 (group 4).|July 2009|July 1, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931099||136838|
NCT00932243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|845UT|Bacteremia in Intensive Care Unit (ICU)|Bacteremia in Intensive Care Unit (ICU) and the Role of Toll-Like-Receptors (TLRs)||University of Thessaly|No|Active, not recruiting|July 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|14 Years|N/A|No|Non-Probability Sample|Patients who will be nursed in ICU.|July 2009|July 2, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932243||136752|
NCT00932529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD-ID10591|Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting|Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.|BPP|University of Bergen|Yes|Completed|February 2003|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|226|||Both|18 Years|N/A|No|||December 2003|May 24, 2010|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932529||136730|
NCT00931645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFGMTC|Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia|Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia|Auto-LLC 2001|University Hospital, Caen|Yes|Completed|April 2001|December 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|241|||Both|18 Years|65 Years|No|||July 2009|July 1, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00931645||136796|
NCT00932802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12219|Greatest International Antiinfective Trial With Avelox|GIANT - Greatest International Antiinfective Trial With Avelox®|GIANT|Bayer|Yes|Completed|February 2004|November 2007|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50000|||Both|12 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of AECB who take moxifloxacin|November 2012|November 16, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932802||136710|
NCT00933127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000630578|S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone|Association of FC-Gamma Receptor Genotypes With Response and Clinical Benefit With Addition of Rituximab to CHOP Chemotherapy in Patients With Follicular Lymphoma (FL)||Southwest Oncology Group|No|Completed|December 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|142|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled to S8809 S9800 S9911 S9704 consenting to banking|July 2014|July 23, 2014|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933127||136686|
NCT00942422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000646899|Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma|The Clinical and Biologic Evaluation of Polyphenon E, an Extract of Green Tea Containing EGCG, in Plasma Cell Dyscrasias - Pilot Study||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|November 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|July 17, 2009|Yes|Yes|Low accrual and early termination|No|February 3, 2015|https://clinicaltrials.gov/show/NCT00942422||135976|Low accrual and early termination limits the conclusions one could draw. Although no pts on this trial met the primary endpoint of a 25% or greater M-protein reduction, the small number of pts enrolled prohibits formal statistical analysis.
NCT00943033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLI-FJVRF-08-SMB|Study of Mindfulness-Based Cognitive Therapy|Toward Identifying the Mechanisms of Action in Mindfulness-Based Cognitive Therapy|MBCT|Binghamton University|No|Completed|August 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00943033||135930|
NCT00943293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12175A|Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies|A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies||University of Chicago|Yes|Terminated|May 2003|January 2012|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|July 20, 2009|No|Yes|Poor accrual; did not enter phase 2|No||https://clinicaltrials.gov/show/NCT00943293||135910|
NCT00943566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STDS0901|A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer|A Multicenter, Open-label, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Sufentanil Transdermal System (TDS) With Sustained-Release Morphine Sulfate in Patients With Chronic Pain Due to Cancer||Labtec GmbH|No|Withdrawn|January 2010|February 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||June 2011|September 14, 2015|July 21, 2009|Yes|Yes|funding for project discontinued|No||https://clinicaltrials.gov/show/NCT00943566||135889|
NCT00943540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 08.07|Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients|Pharmacokinetic and Safety Pilotstudy of RAltegravir and Atazanavir in a Once DAily Dose Regimen in HIV-1 Infected Patients (PRADA)|PRADA|Radboud University|No|Completed|July 2009|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2011|January 7, 2011|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00943540||135891|
NCT00949234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQUAD|Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV|A Pilot Project to Operationalize the Prevention Strategy of Post Exposure Prophylaxis Following Sexual Exposure to HIV in Combination With Educational Programming and Behavioral Risk Reduction Strategies in Los Angeles County||University of California, Los Angeles|Yes|Recruiting|March 2010|March 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949234||135453|
NCT00949260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-01|Hemodynamic Assessment of Healthy and Hypertensive Pregnant Women by Non-Invasive Bio-Reactance|Hemodynamic Assessment of Healthy and Hypertensive Pregnant Women by Non-invasive Bio-reactance||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Our study population includes healthy non-pregnant and pregnant patients in their 3rd        trimester, as well as pregnant patients in their 3rd trimester with pregnancy-induced        hypertension (PIH). Both normal groups will be recruited from the outpatient day-unit        (healthy volunteers). Patients with PIH may be sent to labour and delivery for monitoring        by their obstetricians.|March 2010|March 25, 2010|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949260||135451|
NCT00949806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/35|Restless Legs Syndrome Treatment With Botulinum Toxin|Phase II Non Comparative, Open Study to Assess the Efficacy and Safety of the Botulinum Toxin Type A in Patients With Restless Legs Syndrome (RLS)|SOXIS|University Hospital, Bordeaux|No|Completed|August 2009|November 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949806||135409|
NCT00950053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120808A|Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer|Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer: A Prospective, Randomized, Controlled Trial||OrthoCarolina Research Institute, Inc.|Yes|Completed|December 2008|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|50 Years|N/A|No|||March 2013|March 11, 2013|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00950053||135390|
NCT00950066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBES_R_04320|Irbesartan and Amlodipine Combination in Controlling Blood Pressure|Study to Evaluate the Safety and Efficacy of Two Fixed Dose Combinations of Irbesartan / Amlodipine and Monotherapy After Eight Weeks of Treatment in Subjects With Uncomplicated Mild to Moderate Essential Hypertension|I-COMBO|Sanofi||Completed|July 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|270|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950066||135389|
NCT00950339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-SB-0196-09-TLV-CTIL|Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine|Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2009|July 30, 2009|April 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00950339||135368|
NCT00931697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-AD452-023|Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine|A Phase I Randomised, Double-Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine||Treague Ltd|Yes|Completed|June 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|July 30, 2010|June 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931697||136794|
NCT00931671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710039R|Task-Oriented Aerobic Exercise Training in Chronic Stroke Patients|Effects of Task-Oriented Aerobic Exercise Training on Cardiorespiratory Fitness and Cerebral Blood Flow in Chronic Stroke Patients||National Taiwan University Hospital|Yes|Completed|November 2007|May 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|40|||Both|30 Years|75 Years|No|||July 2009|July 6, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931671||136795|
NCT00931970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-01|Mode of Dialysis Therapy and Outcomes in End Stage Renal Disease (ESRD)|Comprehensive Prospective Study for Mode of Dialysis Therapy and Outcomes in ESRD||Clinical Research Center for End Stage Renal Disease, Korea|Yes|Recruiting|July 2009|April 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Serum Whole blood Urine Dialysate|Both|20 Years|N/A|No|Probability Sample|Incident dialysis patients in Korea|March 2015|March 30, 2015|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931970||136773|
NCT00923507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080105|Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)|Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lmphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)||National Institutes of Health Clinical Center (CC)||Recruiting|April 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|550|||Both|18 Years|100 Years|No|||August 2015|September 30, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923507||137408|
NCT00932503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vicryl plus 1|Antiseptic Sutures and Wound Infection|Do Triclosan Coated Sutures Reduce Wound Infections After Hepatobiliary Surgery? A Prospective Non Randomized Clinical Pathway Driven Study.||University Hospital, Saarland|No|Completed|October 2003|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|839|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932503||136732|
NCT00932516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07SWHK-NONDIABETIC|Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women|The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to a Traditional Calorie-Restricted Diet in Non-Diabetic Women||Mondelēz International, Inc.|No|Completed|March 2007|April 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|248|||Female|18 Years|55 Years|No|||July 2009|July 2, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00932516||136731|
NCT00932789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-3846-USC1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2008|||||N/A|N/A|N/A||||||||||||||July 16, 2010|January 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932789||136711|
NCT00932828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2307|Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study|Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study; Grant "Optimizing Tolerance Induction in Peanut Allergy: The DEVIL Study"|DEVIL|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|June 2009|June 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|9 Months|36 Months|No|||June 2015|July 13, 2015|July 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932828||136709|
NCT00919659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25.0|Parenteral Nutrition Support for Patients With Pancreatic Cancer|Parenteral Nutrition Support for Patients With Pancreatic Cancer. A Phase II Study.||CONKO-Studiengruppe|No|Completed|January 2002|May 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|32|||Both|18 Years|N/A|No|||June 2009|June 11, 2009|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00919659||137698|
NCT00924157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27820|Effect of Ile-Pro-Pro (IPP) on Endothelial Function in Patients With Coronary Artery Disease|Effect of a Protein Hydrolysate Rich in Lacto-tripeptide (IPP) on Hyperemic Blood Flow and Flow-mediated Dilation in Patients With Coronary Artery Disease||Boston University|No|Completed|July 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|54|||Both|21 Years|80 Years|No|||May 2012|May 23, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00924157||137364|
NCT00924170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090025|Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia|Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia||National Institutes of Health Clinical Center (CC)||Recruiting|October 2008|June 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|100 Years|No|||October 2015|November 10, 2015|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924170||137363|
NCT00942708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSA NIH Grant UL1-RR024982|Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension|Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension||University of Texas Southwestern Medical Center|Yes|Completed|September 2009|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|16 Years|75 Years|No|||June 2015|June 10, 2015|July 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942708||135955|
NCT00942721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH084931|Cognitive Behavioral Therapy Delivered Over the Internet for Women With Postpartum Depression|Web-Based Cognitive Behavioral Intervention for Women With Postpartum Depression||Oregon Research Institute|Yes|Completed|October 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|18 Years|N/A|No|||November 2013|November 21, 2013|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942721||135954|
NCT00943046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43-1|Master Study for the Investigation of Safety and Efficacy of the SIELLO Pacemaker Leads|Master Study of the SIELLO Pacemaker Leads||Biotronik SE & Co. KG||Recruiting|July 2009|December 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|N/A|N/A|No|||July 2009|February 12, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00943046||135929|
NCT00943306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|733-012|Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia|A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia||Aegerion Pharmaceuticals, Inc.|No|Completed|September 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|July 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00943306||135909|
NCT00948116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0703/29|Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes|Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing Coronary Revascularisation|BIOMARKERS|Barts & The London NHS Trust|Yes|Recruiting|July 2009|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Blood and urine samples will be retained for the duration of the study|Both|18 Years|N/A|No|Probability Sample|Patients with diabetes mellitus and renal impairment|March 2009|July 26, 2010|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948116||135539|
NCT00948389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-274|Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)|Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma||Bristol-Myers Squibb|No|Terminated|October 2009|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|July 28, 2009|Yes|Yes|Inability to meet protocol objectives|No|July 25, 2012|https://clinicaltrials.gov/show/NCT00948389||135518|
NCT00948402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-11|PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives|Effects of Metformin Versus Oral Contraceptives on PED/PEA-15 Protein Expression in Obese Women With Polycystic Ovary Syndrome||Federico II University|No|Completed|December 2006|January 2009|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|21 Years|28 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|July 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948402||135517|
NCT00948961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1401-01|A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1|A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1||Celldex Therapeutics|No|Completed|September 2009|February 2014|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948961||135474|
NCT00948974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18345|Variations of Cognitive Behavior Therapy for Social Anxiety Disorder|Variations of Cognitive Behavior Therapy for Social Anxiety Disorder||Drexel University|No|Completed|January 2010|December 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00948974||135473|
NCT00948987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|801907|Mechanism Based Resistance to Aspirin|Mechanism Based Resistance to Aspirin||University of Pennsylvania|Yes|Completed|September 2004|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 14, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00948987||135472|
NCT00949247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4108|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases|Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases||Case Comprehensive Cancer Center|Yes|Completed|December 2009|January 2013|Actual|January 2013|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||April 2013|April 17, 2013|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949247||135452|
NCT00949819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCaP|Active Surveillance for Cancer of the Prostate (ASCaP)|The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.|ASCaP|University of California, Los Angeles|Yes|Recruiting|June 2009|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|462|Samples With DNA|Serum, plasma, buffy coat, prostate tissue cores and urine.|Male|30 Years|85 Years|No|Non-Probability Sample|Community sample|November 2015|November 30, 2015|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949819||135408|
NCT00950352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32808|Citicoline Treatment of Methamphetamine Dependence|Citicoline Treatment of Methamphetamine Dependence||University of Utah|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|July 29, 2009|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT00950352||135367|
NCT00950625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091026SUR|Intraperitoneal Analgesia After Laparoscopic Cholecystectomy|Comparison of Analgesic Efficacy of Intra-peritoneal Lignocaine With Bupivacaine After Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial||Aga Khan University|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|14 Years|N/A|No|||July 2009|January 24, 2011|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00950625||135346|
NCT00922831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080514|Progression of Cognitive and Physical Symptoms in Multiple Sclerosis|Progression of Cognitive, Affective, and Physical Symptoms in Multiple Sclerosis.||MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute|No|Enrolling by invitation|August 2008|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Neurology Care Clinic|June 2009|June 16, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922831||137456|
NCT00923182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMCLL07709|A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Japanese Phase I Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Sanofi|Yes|Completed|February 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|75 Years|No|||April 2015|April 29, 2015|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00923182||137430|
NCT00931983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-38|The Effect of Locomotor Training on Children With Incomplete Spinal Cord Injuries|The Effect of Locomotor Training on Children With Incomplete Spinal Cord Injuries||McGill University|Yes|Withdrawn|March 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|4 Years|18 Years|No|Non-Probability Sample|community sample|July 2011|December 13, 2011|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931983||136772|
NCT00923221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070100|Collection of Blood From Patients With Prostate Cancer|Collection of Blood From Patients With Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|February 2007|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|1000|||Male|18 Years|100 Years|No|||October 2015|November 4, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923221||137428|
NCT00923520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090111|A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies|A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2009|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|99 Years|No|||May 2015|February 19, 2016|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00923520||137407|
NCT00923858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 201103230|The Natural History of Asymptomatic Rotator Cuff Tears|Asymptomatic Cuff Tears: A Model for Pain Development - Part B||Washington University School of Medicine|No|Enrolling by invitation|July 2005|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|405|||Both|18 Years|N/A|No|Non-Probability Sample|Patients are recruited from ultrasound and orthopaedic surgeon's clinic.|December 2015|December 7, 2015|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923858||137386|
NCT00924131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090127|Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial|Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial||National Institutes of Health Clinical Center (CC)||Completed|April 2009|May 2010||||N/A|Observational|N/A|||Anticipated|157|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924131||137365|
NCT00919646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2009-001|Monitoring Arrhythmia Patients in in Hospital Monitoring|Arrhythmia Detection With Adherent Patient Monitoring Study|ADAM|Corventis, Inc.|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Telemetry ward|February 2010|February 2, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919646||137699|
NCT00919958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX-PAD 1202-1|Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia|Phase I Study of Intramuscular (IM) Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-like Stromal Cells Derived From a Full Term Placenta. These Placental Adherent Stromal Cells (ASCs) Are Expanded in the Company's Proprietary PluriXTM 3D Bioreactor System. PLX Cells Are Immune Privileged and Possess Immunomodulatory Properties.||Pluristem Ltd.|Yes|Completed|June 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|40 Years|81 Years|No|||June 2012|June 17, 2012|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919958||137676|
NCT00942760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0901|Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas|DMS-0901: Multimodal Magnetic Resonance Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas||Dartmouth-Hitchcock Medical Center|Yes|Completed|April 2009|April 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Recurrent GBM patients|July 2012|May 7, 2013|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00942760||135951|
NCT00943059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-033|Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function|The Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function|ACP|Maastricht University Medical Center|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|31|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00943059||135928|
NCT00943553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7373-G000-201|A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects|A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects.||Eisai Inc.|No|Withdrawn|June 2010|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|16 Years|No|||April 2015|April 10, 2015|July 21, 2009|Yes|Yes|Terminated by Sponsor|No||https://clinicaltrials.gov/show/NCT00943553||135890|
NCT00948415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2097-07 Study 5|Evaluation of the Shape Up Rhode Island Campaign Study 5|Evaluation of the Shape Up Rhode Island Campaign Study 5: Does Adding Behavioral Weight Control Information to Shape-Up Rhode Island Improve Outcomes?||The Miriam Hospital|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 7, 2014|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948415||135516|
NCT00948428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D94-3101-07|Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis|A Multicenter, Double-Blind, Randomized, Parallel Group, Vehicle-Controlled Study to Determine the Clinical Equivalence of a Generic Imiquimod Cream, 5% and Aldara™ Cream in Subjects With Actinic Keratosis||Actavis Inc.|No|Completed|May 2008|April 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|462|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948428||135515|
NCT00949013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632885|S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313|Evaluation of the Expression of the Cancer Stem Cell Marker ALDH1 as a Predictor of Adjuvant Chemotherapy Response in Breast Cancers of High Risk Women in SWOG-9313||Southwest Oncology Group|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1600|||Female|18 Years|N/A|No|Non-Probability Sample|Patients enrolled to S9313 consenting to banking|May 2014|May 23, 2014|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949013||135470|
NCT00949000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR08018HV|AnalyST Treadmill Study|Clinical Evaluation of ST Segment Deviation Detection by SJM AnalyST and Analyst Accel Implantable Cardiac Defibrillators||St. Jude Medical|No|Completed|July 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2011|February 22, 2011|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949000||135471|
NCT00949585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA 0835162N|Potassium Intake in Patients With Chronic Kidney Disease|Potassium Intake in Patients With Chronic Kidney Disease|CKD-K|Johns Hopkins University|Yes|Completed|July 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949585||135426|
NCT00949832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006041|Vitamin D and Genetics in Nutritional Rickets|Vitamin D and Genetics in Nutritional Rickets||Mayo Clinic|No|Completed|January 2004|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|109|||Both|6 Months|16 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949832||135407|
NCT00950079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0180|Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography|Preventive Strategies of REnal Insufficiency in Patients With Diabetes Undergoing InterVENTion or Arteriography(PREVENT Trial)||CardioVascular Research Foundation, Korea|Yes|Recruiting|February 2008|January 2010|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|368|||Both|18 Years|N/A|No|||July 2009|July 30, 2009|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00950079||135388|
NCT00950365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pemetrexed/Erlotinib|Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed and Erlotinib Versus Single Agent Pemetrexed in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC)||Montefiore Medical Center|Yes|Recruiting|May 2006|||May 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||July 2009|July 30, 2009|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950365||135366|
NCT00950638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH2001|A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration|A Phase I Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration||Ophthotech Corporation|No|Completed|July 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|N/A|No|||November 2013|November 5, 2013|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950638||135345|
NCT00950651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT3-001-E1|A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee|A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee.||Labopharm Inc.||Completed|March 2002|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|431|||Both|40 Years|75 Years|No|||April 2012|April 25, 2012|April 14, 2009||No||No|April 14, 2009|https://clinicaltrials.gov/show/NCT00950651||135344|
NCT00922558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc068-09CTIL|Evaluation of Postural Control in Children Using Tetra Axial Posturography|Evaluation of Postural Control in Children Using Tetra Axial Posturography|tetrax1|Meir Medical Center|Yes|Recruiting|July 2010|June 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|480|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||June 2009|October 18, 2010|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922558||137477|
NCT00923195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090051|Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma|Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines||National Institutes of Health Clinical Center (CC)|Yes|Completed|December 2008|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|June 17, 2009|Yes|Yes||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00923195||137429|
NCT00923494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24506|Effectiveness of Ultrasound (US) Guided Supraclavicular Block|Effectiveness of Ultrasound Guided Supraclavicular Brachial Plexus Block With 20, 30, or 40 ml of Ropivacaine 0.5%||Baylor College of Medicine|Yes|Suspended|May 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|64 Years|No|||February 2013|February 5, 2013|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923494||137409|
NCT00923884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090103|Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer|Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|501|||Both|18 Years|N/A|No|||June 2015|July 23, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923884||137384|
NCT00923533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-103|A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers|An Open-label, Multiple-dosing, Crossover, and Parallel Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|March 2009|August 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|34|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923533||137406|
NCT00923871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0197-CE|Automating Breast Radiation Therapy (RT)|Automating the Breast Radiation Therapy Process to Improve Efficiency||University Health Network, Toronto|Yes|Active, not recruiting|June 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923871||137385|
NCT00920569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-HCE101-2A-H|Recirculation, Oxygenator Blood Volume and Cardiac Output Measurements During Extracorporeal Membrane Oxygenation|Measurement of Recirculation, Oxygenator Blood Volume and Cardiac Output in ECMO Using a Modified Transonic Systems (tm) HD02 Monitoring System||Transonic Systems Inc.|No|Terminated|May 2006|August 2008|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|N/A|N/A|No|||June 2012|June 4, 2012|June 11, 2009||No|Study site collaborators withdrew from participating due to time constraints.|No||https://clinicaltrials.gov/show/NCT00920569||137629|
NCT00920959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS30021|Advair Pediatric Once-Daily|A Stratified, Randomized, Double-blind, Placebo-controlled, Parallel-group, 12 Week Trial Evaluating the Safety and Efficacy of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg Once Daily Versus Fluticasone Propionate DISKUS 100mcg Once Daily and Placebo in Symptomatic Pediatric Subjects (4-11 Years) With Asthma||GlaxoSmithKline||Completed|November 2001|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|908|||Both|4 Years|11 Years|No|||December 2013|December 5, 2013|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920959||137599|
NCT00947791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1422|Treatment Study of Bipolar Depression|INTRAVENOUS KETAMINE IN TREATMENT-RESISTANT BIPOLAR DEPRESSION||Murrough, James, M.D.|Yes|Terminated|July 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|21 Years|70 Years|No|||September 2012|September 14, 2012|July 27, 2009|Yes|Yes|Change in available resources for study procedures|No||https://clinicaltrials.gov/show/NCT00947791||135564|
NCT00947804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS SACS Score SJH-01|Study to Validate Simple Acute Coronary Syndrome Score|Phase 1 - Pilot Study to Validate the Simple Acute Coronary Syndrome Score; an Acute Coronary Syndrome (ACS) Risk Stratification Tool|SACS Score|St. Joseph's Hospital, Florida|Yes|Enrolling by invitation|August 2009|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult patients presenting to the cardiac catherization suite whom have experienced ACS        symptoms within the past thirty days.|December 2012|April 5, 2013|July 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00947804||135563|
NCT00948129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0336|Smoking Cessation for Low-Income Adults|Enhancing Cancer Outreach for Low-income Adults With Innovative Smoking Cessation||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2010|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|756|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00948129||135538|
NCT00948142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE06-300|Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections|A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections||Cempra Inc|No|Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948142||135537|
NCT00948441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08010189|Pediatric Ethanol Lock Therapy Study.|Ethanol Lock Therapy for the Prevention of Catheter Related Blood Stream Infections||University of Pittsburgh|Yes|Completed|August 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Both|6 Months|21 Years|No|||February 2016|February 19, 2016|July 7, 2009||No||No|February 19, 2016|https://clinicaltrials.gov/show/NCT00948441||135514|
NCT00949026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008256|Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis|Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis||Emory University|Yes|Withdrawn|July 2009|May 2010||May 2010||Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|July 29, 2009||No|No accrual|No||https://clinicaltrials.gov/show/NCT00949026||135469|
NCT00949039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIP2|Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer|||Gustave Roussy, Cancer Campus, Grand Paris||Completed|February 2009|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|76 Years|No|||March 2015|March 11, 2015|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00949039||135468|
NCT00948701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206208|Community Volunteers Promoting Physical Activity Among Cancer Survivors|Community Volunteers Promoting Physical Activity Among Cancer Survivors|MFT2|The Miriam Hospital|Yes|Active, not recruiting|January 2010|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|108|||Female|21 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 3, 2012|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948701||135494|
NCT00948714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808214|Support for Cardiovascular Health in African American Primary Care Patients|Peer and Health Educator Support for Cardiovascular Health in African-American Primary Care Patients||University of Pennsylvania|Yes|Completed|May 2008|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|250|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 3, 2011|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948714||135493|
NCT00949598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000638373|Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer|Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment.||Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Completed|December 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|177|||Female|65 Years|N/A|No|||August 2015|August 3, 2015|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949598||135425|
NCT00949845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endotoxin|Cytokine-Associated Depression and Social Pain|An fMRI Study of Cytokine-Associated Depression and Social Pain||University of California, Los Angeles||Completed|January 2007|||||Phase 0|Interventional|Primary Purpose: Basic Science|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2009|July 29, 2009|July 29, 2009||Yes||||https://clinicaltrials.gov/show/NCT00949845||135406|
NCT00950092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-1116(C)|nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF|Numeris-AF Tethered Coagulation System With VisiTrax Indicated For Treatment of Persistent and Longstanding Persistent Atrial Fibrillation||nContact Surgical Inc.|Yes|Terminated|October 2009|October 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||September 2013|April 2, 2014|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950092||135387|
NCT00950664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0902-049-272|A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia|A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® (abobotulinumtoxinA) in the Clinical Efficacy and Safety in Comparison With Botox®(onabotulinumtoxinA), Assuming a Bioequivalence Ratio of 2.5:1 Units, in the Treatment of Cervical Dystonia||Seoul National University Hospital|Yes|Completed|August 2009|July 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|20 Years|80 Years|No|||August 2013|August 5, 2013|July 29, 2009|Yes|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT00950664||135343|
NCT00950924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT07312009|Optical Defocus to Stimulate Eye Elongation in Hyperopia|Use of Multifocal Contact Lenses to Stimulate Axial Elongation in Axial Hyperopia|ODSEEH|Aller, Thomas A., OD|Yes|Recruiting|January 2015|September 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950924||135323|
NCT00923234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-AZALE1-037|Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes|A Phase I Study of a Combination of 5-azacitidine Followed by Lenalidomide in High-risk MDS or Relapsed/Refractory AML Patients With Cytogenetic Abnormalities Including -5 or Del(5q)|AZALE|Technische Universität Dresden|Yes|Terminated|June 2009|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||December 2013|December 17, 2013|June 17, 2009||No|The primary objective has already been answered with the number of recruited patients.|No||https://clinicaltrials.gov/show/NCT00923234||137427|
NCT00923247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090089|A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)|A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|February 2009|May 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|80 Years|No|||June 2015|March 2, 2016|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00923247||137426|
NCT00923572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14339|Yasmin Post Marketing Surveillance|Yasmin Regulatory Post Marketing Surveillance||Bayer|No|Completed|December 2007|August 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|777|||Female|18 Years|N/A|No|Non-Probability Sample|Korean women who need oral contraceptive|November 2015|November 10, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923572||137404|
NCT00922844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL24375.041.08|The Effect of Sevoflurane Versus Isoflurane on Vasopressor Need|The Effect of Sevoflurane Versus Isoflurane on Vasopressor Need|ESIVAN|UMC Utrecht|Yes|Terminated|May 2009|December 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 18, 2015|June 12, 2009||No|too slow recruitment; lack of funding|No||https://clinicaltrials.gov/show/NCT00922844||137455|
NCT00919698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16938B|Delirium in Mechanically Ventilated Patients|An Assessment of Delirium in Mechanically Ventilated Patients Undergoing Daily Awakening From Sedation||University of Chicago|No|Completed|June 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|N/A|No|Probability Sample|Adult patients (> 18 years old) admitted to the intensive care unit who require mechanical        ventilation through an endotracheal tube with infusion of sedative or analgesic        medication.|December 2014|December 2, 2014|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919698||137695|
NCT00919711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080099|Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy|A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy||Amgen|No|Completed|September 2009|March 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|870|||Female|55 Years|N/A|No|||July 2014|July 14, 2014|June 11, 2009|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00919711||137694|
NCT00919386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-2137|Ureteral Stent Size Measurement Study|Three Methods of Ureteral Stent Measurement: Which Method Improves Quality of Life After Ureteral Stenting?||CAMC Health System|No|Completed|April 2009|May 2014|Actual|May 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|17|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Community patients who present to Charleston area Medical Center (CAMC) or the private        urology clinics of Drs. Davalos,Martinez,Tierney with the requirement of ureteral stent        would be screened for possible enrillment in the study.|July 2015|July 30, 2015|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00919386||137718|
NCT00919685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/03|Investigations of New Markers in Patients With Shock|Investigations of New Markers in Patients With Shock||Assistance Publique Hopitaux De Marseille|No|Completed|May 2009|||March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|80 Years|No|||August 2014|August 28, 2014|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919685||137696|
NCT00920985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91556|US Cycle Control and Blood Pressure Study|Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women||Bayer|No|Completed|June 2009|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|346|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|September 23, 2015|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920985||137597|
NCT00920998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|443-CL-503|Effect of Food Intake on Pharmacokinetic Profiles of Z-338|A Pharmacokinetics Study to Evaluate the Effect of Food Intake on PK Profile of Z-338 in Healthy Volunteers||Astellas Pharma Inc|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|30|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||July 2009|July 16, 2009|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00920998||137596|
NCT00947492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-07|Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs|Monitoring EBV Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs ; Orencia* (Abatacept) and RoActemra* (Tocilizumab).||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|June 2009|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947492||135587|
NCT00947817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008 07|Impact of Endothelial Cell Activation and Modifications of Haemostasis Induced by Infective Endocarditis on the Risk of Embolism|Impact of Endothelial Cell Activation and Modifications of Haemostasis Induced by Infective Endocarditis on the Risk of Embolism.||Assistance Publique Hopitaux De Marseille|No|Completed|September 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|77|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|August 21, 2015|January 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00947817||135562|
NCT00947830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT-1|Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia|A Study Investigating the Predictive Value of Intracellular and Plasma Imatinib Levels in Newly Diagnosed Patients With Chronic Myeloid Leukemia|OCT-1|McMaster University|No|Completed|July 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|Samples With DNA|Blood cells|Both|18 Years|N/A|No|Non-Probability Sample|newly diagnosed patients with chronic myeloid leukemia in chronic phase|January 2013|January 10, 2013|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947830||135561|
NCT00948727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P021004|Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation|Reduction of Acute and Chronic Graft-versus-host Disease After Allogeneic Hematopoietic Stem-cell Transplantation by Adapting Cyclosporine Doses According to Calcineurin Activity : a Proof-of-concept Trial|CALCICLO|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2004|June 2008|Actual|September 2006|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|39|||Both|12 Years|85 Years|No|||July 2009|September 30, 2009|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948727||135492|
NCT00949052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000640299|Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer|Radiation Sensitivity, DNA Repair, and Second Cancers.||National Cancer Institute (NCI)||Recruiting|January 2009|||January 2014|Anticipated|N/A|Observational|N/A|||Anticipated|1000|||Both|N/A|N/A|No|||April 2009|May 14, 2010|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949052||135467|
NCT00949299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stv 2/2009|Effects of Buprenorphine on Ulnar Nerve Motor Block|Effects of Buprenorphine on Ulnar Nerve Motor Block||University of Zurich|Yes|Terminated|January 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||August 2011|March 14, 2014|July 29, 2009||No|Not enough could be recruted|No||https://clinicaltrials.gov/show/NCT00949299||135448|
NCT00949273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPR0668|Safety and Efficacy Study of Cylindrical Abdominoperineal Resection to Treat Rectal Cancer|A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Cylindrical Abdominoperineal Resection in the Treatment of Advanced Very Low Rectal Cancer||Beijing Chao Yang Hospital|Yes|Recruiting|July 2009|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|circumferential resection margin; bowel perforation; cross sectional tissue area outside the      internal sphincter; mean distance from the internal sphincter to the anterior, posterior and      lateral circumferential resection margins|Both|18 Years|80 Years|No|Probability Sample|hospitalized patients with rectal cancer|November 2013|November 26, 2013|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949273||135450|
NCT00949624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5301005|CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors|Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors||Arog Pharmaceuticals, Inc.|No|Completed|December 2005|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|50|||Both|18 Years|N/A|No|||August 2011|January 18, 2012|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949624||135423|
NCT00949858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HL092347-01a1|New Data Analysis Methods for Actigraphy in Sleep Medicine|New Data Analysis Methods for Actigraphy in Sleep Medicine||Washington University School of Medicine|No|Enrolling by invitation|July 2009|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seen in clinic at the Washington University Sleep Medicine Center.|March 2014|March 19, 2014|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949858||135405|
NCT00950105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2364-CD-101|Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)|A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy Subjects||Ferring Pharmaceuticals|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950105||135386|
NCT00950378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27610|Non-Invasive Management of Chronic Venous Insufficiency|Non-Invasive Management of Chronic Venous Insufficiency||University of Utah|Yes|Completed|July 2009|December 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10|||Both|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|CVI subjects will be recruited from University of Utah vascular surgery service.Control        group will be recruited from the community.|May 2013|May 24, 2013|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950378||135365|
NCT00950937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06067|Exercise, Oxidative Stress and HIV|A Case-control Study to Test the Effects of a Bout of Aerobic Exercise Followed by Resistance Training on Antioxidant System in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV Subjects||Hospital de Clinicas de Porto Alegre|Yes|Completed|June 2006|July 2008|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|28|||Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants of the HIV group were recruited at the outpatient HIV/AIDS care unit of        the Hospital de Clínicas de Porto Alegre (HCPA), whereas the control group (non-HIV) was        formed by volunteers of the city of Porto Alegre, Rio Grande do Sul, Brazil|August 2009|August 4, 2009|February 16, 2009||No||No|February 16, 2009|https://clinicaltrials.gov/show/NCT00950937||135322|
NCT00950950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090153|A Study to Evaluate the Effect of AMG 785 on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Effect of AMG 785 on Parameters of Bone Quality of the Forearm Using pQCT in Postmenopausal Women With Low Bone Mineral Density||Amgen||Completed|September 2009|December 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Female|55 Years|80 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|July 30, 2009||||No||https://clinicaltrials.gov/show/NCT00950950||135321|
NCT00946803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO08316|A Patient-Controlled Cognitive-Behavioral Intervention for Cancer Symptoms|A Patient-Controlled Cognitive-Behavioral Intervention for Cancer Symptoms||University of Wisconsin, Madison|No|Completed|July 2009|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|86|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946803||135640|
NCT00947037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 12 005|Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study|An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects||Intec Pharma Ltd.|Yes|Withdrawn|August 2012|||August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|30 Years|95 Years|No|||September 2012|November 23, 2015|July 24, 2009||No|The sponsor decided to postpone the performance of this study to after phase 3|No||https://clinicaltrials.gov/show/NCT00947037||135622|
NCT00923598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cleveland TKA Study|Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks|Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks||University of California, San Diego|No|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00923598||137403|
NCT00923559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPPS-01|Mother-Infant Psychoanalysis Project of Stockholm|A Randomized Controlled Trial of Mother-Infant Psychoanalytic Treatment and Treatment As Usual at Child Health Centres|MIPPS|Karolinska Institutet|Yes|Completed|October 2005|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|N/A|18 Months|No|||June 2009|June 17, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923559||137405|
NCT00919724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|661|Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People|A Comparison of Endothelial Function Between HIV-infected Subjects Not Receiving Antiretroviral Therapy and Matched HIV-uninfected Control Subjects||Indiana University|Yes|Completed|May 2009|May 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|89|Samples Without DNA|Plasma, serum, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected people will be recruited from infectious diseases outpatient clinics of        Wishard Hospital and Indiana University Hospital. They will be enrolled in one of two        other HIV trials. HIV-uninfected people will be recruited from the Indianapolis general        population.|July 2014|July 1, 2014|June 11, 2009||No||No|May 28, 2014|https://clinicaltrials.gov/show/NCT00919724||137693|
NCT00919737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-08-1|Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme|A Phase 1/2, Multicenter, Non-Randomized, Open Label Clinical Trial of NPC-08 Implant in Patients Undergoing Surgery for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme.||Nobelpharma|Yes|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|64 Years|No|||October 2013|October 29, 2013|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919737||137692|
NCT00919971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHBIS|Bispectral Index (BIS) on Ventilated Patients in the Prehospital Setting|Use of Bispectral Index to Assess Depth of Sedation in Ventilated Patients in the Prehospital Setting|OHBIS|Beaujon Hospital|No|Completed|June 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Out of hospital ventilated patients, managed by EMS, aged > 18|October 2011|October 18, 2011|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00919971||137675|
NCT00920218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110258|Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A|Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A||GlaxoSmithKline||Completed|July 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|122|||Both|18 Years|N/A|No|||June 2011|May 7, 2015|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920218||137656|
NCT00920231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6731-R|Computer Vision System for the Blind Veteran|Computer Vision System for the Blind Veteran||VA Office of Research and Development|No|Completed|November 2011|September 2015|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Both|18 Years|80 Years|No|||December 2015|December 18, 2015|June 11, 2009||No||No|January 14, 2015|https://clinicaltrials.gov/show/NCT00920231||137655|
NCT00920556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113222|A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma|A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma||GlaxoSmithKline|No|Terminated|March 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|June 12, 2009||No|Study terminated.24 subjects enrolled;provided adequate data for decision making.|No||https://clinicaltrials.gov/show/NCT00920556||137630|
NCT00921011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0308|Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis|Iron and Atherosclerosis: Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis||Ohio State University|Yes|Active, not recruiting|May 2009|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum, plasma|Female|40 Years|N/A|No|Probability Sample|Perimenopausal women|October 2015|October 1, 2015|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921011||137595|
NCT00948155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808930|Measuring Smoking Behaviors While Using Varenicline|Assessment of Smoking Topography and Behaviors During Response to Varenicline||University of Pennsylvania|Yes|Completed|January 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|July 28, 2009|Yes|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00948155||135536|Attrition rates were high. The final sample consisted primarily of Caucasian males, which may limit the generalizability of the present findings.
NCT00948454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704074|Research Study on the Effects of Smoking on Arteries|The Dose Effect Of Cigarette-Smoking On Indices Of Arterial Function And Oxidative Stress||University of Pennsylvania|No|Completed|January 2003|June 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|105|Samples With DNA|Buffy coat from 4ml of blood will be stored for future genomic and proteomic analysis. Blood      will also be collected for telemore length. This will be performed at an outside      institution. Identifiers will be stripped from the samples prior to send out.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Chronic smokers (of between 4 and 20 years duration) and non-smokers will be recruited.        Smokers will be allocated to a "light" group, smoking 4-10 cigarettes per day and a        "heavy" smoking group who smoke 11-20 cigarettes per day. Non-smokers will be defined as        those with a life time consumption of no more than 20 cigarettes, do not live or work in a        smoky atmosphere. All individuals will have a normal history and clinical examination,        including a normal EKG, urinalysis and serum chemistry, haemogram and negative urinary        pregnancy test.|October 2009|October 23, 2009|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948454||135513|
NCT00948467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C20001|Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.||Completed|December 2009|June 2013|Actual|April 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||June 2013|July 1, 2013|July 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00948467||135512|
NCT00948740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000533|The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium|Phase III Study of the Effect of Vitamin D Repletion on Urinary Calcium Excretion in Kidney Stone Formers With Vitamin D Deficiency and High Urinary Calcium||Brigham and Women's Hospital|No|Active, not recruiting|August 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948740||135491|
NCT00949325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0963|Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma|Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas||Sidney Kimmel Comprehensive Cancer Center|No|Completed|September 2009|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|1 Year|N/A|No|||June 2014|November 25, 2014|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949325||135446|
NCT00949286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANCE-ON|Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study|Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study|ADVANCE-ON|The George Institute|No|Completed|January 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8494|||Both|N/A|N/A|No|Non-Probability Sample|All living participants who took part in the ADVANCE study|April 2014|May 15, 2014|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949286||135449|
NCT00949871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07170|Study of Support Groups for African-American Breast Cancer Survivors|Sister Survivor: African American Breast Cancer Coalition||City of Hope Medical Center|Yes|Completed|January 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Masking: Open Label|1||Actual|74|||Female|18 Years|N/A|No|||June 2015|June 3, 2015|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949871||135404|
NCT00950118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2063|Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science|Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science|DHREAMS|Columbia University|No|Recruiting|June 2005|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|2020|Samples With DNA|whole blood, tissue, saliva|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Children/neonates with an unrepaired congenital diaphragmatic hernia        Children/neonates with a reparied congenital diaphragmatic hernia        Women who are pregnant with a fetus diagnosed with congenital diaphragmatic hernia        Individuals with a family history of congenital diaphragmatic hernia|October 2015|October 2, 2015|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00950118||135385|
NCT00950131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16784|Testing the Effect of a Warning About New Drugs|Testing the Effect of a Warning About New Drugs||White River Junction VAMC|No|Completed|August 2009|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|2944|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|April 8, 2010|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950131||135384|
NCT00950391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK50600|Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus|Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus||Washington University School of Medicine|Yes|Not yet recruiting|August 2010|September 2015|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|50 Years|No|||January 2010|January 11, 2010|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950391||135364|
NCT00950404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481273|Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet|An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of Three Orally Disintegrating Tablet Formulations Of Sildenafil Without Water Relative To Viagra Conventional Oral Tablet With Water.||Pfizer|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 5, 2009|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950404||135363|
NCT00946816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 320030_1253331|The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity|The Effects of Dietary Intervention on Gastrointestinal Motility, Hormonal Feedback, Visceral Sensation and Satiety in Patients With Anorexia Nervosa and Obesity||University of Zurich||Completed|September 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|40 Years|No|||November 2012|November 13, 2012|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00946816||135639|
NCT00947063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B043722|To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions||Sandoz||Completed|July 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947063||135620|
NCT00947076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-49-11634|To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg|A Comparative Bioavailability Study of Fluoxetine Hydrochloride Capsules, 40 mg||Sandoz||Completed|February 2001|April 2001|Actual|April 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947076||135619|
NCT00947089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC 1|Role of Oxidized Regenerated Cellulose (ORC) Applied to "Dirty" Surgical Wounds|The Role of Oxidized Regenerated Cellulose in Preventing Infections at the Surgical Site: Prospective, Randomized Study in 98 Patients Affected by a Dirty Wound|ORC|Catholic University of the Sacred Heart|No|Completed|December 2003|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|98|||Both|N/A|N/A|No|||July 2009|July 24, 2009|July 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00947089||135618|
NCT00919399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 SEIN 03|Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant|Phase II Study Evaluating the Effectiveness of the Exemestane (Aromasin) With Tamoxifen on the Rate of Clinical Response Menopausal in Patients With Locally Advanced Breast Tumors|TAMARO|Institut Claudius Regaud|No|Completed|January 2002|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|60 Years|N/A|No|||June 2009|June 11, 2009|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919399||137717|
NCT00919412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101436-3|Non Invasive Biomarkers to Identify Subjects at Risk for Preterm Delivery|Non-Invasive Biomarkers To Identify Subjects At Risks For Preterm Delivery|PTMARKER|Winthrop University Hospital|No|Recruiting|June 2007|December 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Maternal blood Maternal cervical secretions Fetal umbilical cord blood Placenta|Female|18 Years|45 Years|No|Probability Sample|Pregnant women ages 18-45 with a diagnosis of preterm labor|February 2010|February 18, 2010|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919412||137716|
NCT00920244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2008.2402 (REK)|In-hospital Cardiac Arrest - Dynamics and State Transitions|Dynamics and State Transitions During Resuscitation in In-hospital Cardiac Arrest||St. Olavs Hospital|No|Completed|August 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|285|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with in-hospital cardiac arrest at St.Olavs Hospital (Trondheim, Norway) during        the study period.|April 2015|April 23, 2015|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920244||137654|
NCT00920257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112689|A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795|A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas||GlaxoSmithKline|No|Completed|June 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920257||137653|
NCT00920582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA031-03|Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus||MacroGenics|Yes|Completed|September 2009|July 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|254|||Both|8 Years|35 Years|No|||February 2013|February 28, 2013|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920582||137628|
NCT00920595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C9722/1065/PK/FR-UK|Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors|An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 Inhibitor) as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors||Teva Pharmaceutical Industries|No|Completed|June 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920595||137627|
NCT00920608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1520C00027|A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients|A Phase I, Multi-centre, Open-label, Fixed-sequence Study to Assess the Pharmacokinetics of Methotrexate Alone and When Co-administered With AZD9056 in Subjects With Rheumatoid Arthritis||AstraZeneca|No|Withdrawn|May 2009|September 2009|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|70 Years|No|||December 2010|December 2, 2010|June 12, 2009||||No||https://clinicaltrials.gov/show/NCT00920608||137626|
NCT00921024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625-001|Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections|A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis||Cubist Pharmaceuticals LLC|No|Completed|July 2009|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|90 Years|No|||January 2016|January 6, 2016|June 12, 2009|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT00921024||137594|
NCT00948168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-DIAB-01|Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes|6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|July 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|40 Years|80 Years|No|||July 2009|July 30, 2009|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948168||135535|
NCT00948181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009061|Evaluation of Plasma Catecholamine Concentration During Surgery|Evaluation of Stress Hormone Concentration During the Resection of Pheochromocytoma. Comparison of Surgeon - Anesthesiologist - Patient||Kliniken Essen-Mitte|No|Active, not recruiting|June 2009|September 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|8|Samples Without DNA|Venous blood will be drawn from the surgeon, anesthesiologist and from 8 patients to      determine plasma catecholamine concentrations. Only plasma will be used for measurements.|Both|18 Years|N/A|No|Non-Probability Sample|The population consists of 8 patients with pheochromocytoma scheduled for tumor resection,        one surgeon (with the experience of more than 50 pheochromocytoma resections) and one        anesthesiologist (with the experience of more than 50 pheochromocytoma resections).|July 2009|July 28, 2009|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948181||135534|
NCT00948480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00012064|Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells|Vaccine Biotherapy Of Cancer: Autologous Tumor Cells and Dendritic Cells as Active Specific Immunotherapy in Patients With Metastatic Melanoma|DCVaccineMel|Hoag Memorial Hospital Presbyterian|No|Completed|October 2000|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|16 Years|N/A|No|||May 2011|May 10, 2011|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948480||135511|
NCT00948753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04708|Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation|Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation||University of Pennsylvania|Yes|Completed|June 2009|January 2013|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||December 2011|February 6, 2013|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948753||135490|
NCT00948766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DUS44|Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44|A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44|ACTION|Novartis||Completed|July 2009|June 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|716|||Both|50 Years|N/A|No|||August 2013|August 19, 2013|July 28, 2009|Yes|Yes||No|January 8, 2013|https://clinicaltrials.gov/show/NCT00948766||135489|
NCT00950144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08131|Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer|Illness Perception, Pain and Symptom Distress in Gastrointestinal Cancers||City of Hope Medical Center|Yes|Completed|December 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|123|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving treatment at the City of Hope Medical Center.|February 2011|February 28, 2011|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950144||135383|
NCT00949312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649763|Studying Lymph Nodes in Patients With Stage II Colon Cancer|Ultrastaging of Early Colon Cancer||John Wayne Cancer Institute|Yes|Recruiting|May 2009|||May 2016|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Paraffin-embedded primary tumor and lymph node sections|Both|18 Years|85 Years|No|Non-Probability Sample|From the ambulatory cancer clinic, we will identify 300 stage II colon cancer patients        eligible for the study.|December 2015|December 24, 2015|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949312||135447|
NCT00949611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006070|Wiser Choices in Osteoporosis Choice II: A Decision Aid for Patients and Clinicians|Wiser Choices In Osteoporosis Choice II||Mayo Clinic|No|Completed|May 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|79|||Female|50 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949611||135424|
NCT00950703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00086|Primary Care Audit of Global Risk Management|Primary Care Audit of Global Risk Management|PARADIGM|Canadian Cardiovascular Research Network|No|Completed|March 2009|September 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3015|Samples Without DNA|Blood serum.|Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care clinics.|October 2015|October 13, 2015|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00950703||135340|
NCT00950963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-509|Nurse Telephone Management of Cholesterol in Diabetes|Nurse-run, Telephone-based Intervention to Improve Lipids in Diabetics|NATCHOS|Denver Health and Hospital Authority|No|Completed|September 2005|June 2008|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|762|||Both|17 Years|N/A|No|||April 2015|April 23, 2015|January 12, 2009||No||No|January 12, 2009|https://clinicaltrials.gov/show/NCT00950963||135320|
NCT00947349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.14|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients|Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naïve and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin||Boehringer Ingelheim||Completed|July 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|22|||Both|20 Years|70 Years|No|||July 2015|July 3, 2015|July 21, 2009||||No|January 22, 2015|https://clinicaltrials.gov/show/NCT00947349||135598|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information".
NCT00947362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169/04|Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul|Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055)|rtt-ACL|Waisenmedizin e. V. Promoting Access to Essential Medicine|Yes|Completed|August 2004|December 2007||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Both|5 Years|N/A||||July 2009|July 27, 2009|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947362||135597|
NCT00947622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCS_BP_FMS|Occipital Transcranial Direct Current Stimulation in Fibromyalgia|Occipital Transcranial Direct Current Stimulation in Fibromyalgia||University Hospital, Antwerp|No|Recruiting|July 2009|November 2009|Anticipated|October 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Female|18 Years|65 Years|No|||July 2009|July 27, 2009|July 27, 2009||||No||https://clinicaltrials.gov/show/NCT00947622||135577|
NCT00947635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Islet-Liver-MTC|Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention|Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention||University of Alberta|No|Completed|November 2005|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00947635||135576|
NCT00923897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 07-0020-CE|Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)|Phase II Trial of Palliative Radiotherapy for Locally Advanced Hepatocellular Carcinoma and Hepatic Metastases||University Health Network, Toronto|Yes|Completed|February 2007|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923897||137383|
NCT00923910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080051|Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood|A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2008|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|1 Year|74 Years|No|||April 2014|April 7, 2014|June 17, 2009|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00923910||137382|
NCT00919425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9910|S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer|S9910, Leukemia Centralized Reference Laboratories and Tissue Repositories - Ancillary||Southwest Oncology Group|No|Completed|April 1999|January 2012|Actual|January 2012|Actual|N/A|Observational|N/A||1|Actual|1294|Samples With DNA|Blood and bone marrow|Both|N/A|N/A|No|Non-Probability Sample|Patients participating on SWOG leukemia treatment studies|March 2015|March 5, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919425||137715|
NCT00919984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCCH GY 3001|Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer|Phase II Clinical Trial of Intravenous Paclitaxel and Carboplatin Plus Intraperitoneal Paclitaxel as an Adjuvant Chemotherapy in Patients With Optimally Debulked Advanced Epithelial Ovarian Carcinoma||Korea Cancer Center Hospital|No|Terminated|May 2007|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|20 Years|75 Years|No|||May 2014|May 7, 2014|June 7, 2009||No|This study stopped due to slow accrual.|No||https://clinicaltrials.gov/show/NCT00919984||137674|
NCT00920270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siriraj CEU 50-002|Nebulized Colistin for Hospital-Acquired Pneumonia|Efficacy and Safety of Nebulized Colistin for Adjunctive Therapy of Hospital-Acquired Pneumonia Caused by Gram Negative Bacteria||Mahidol University|No|Enrolling by invitation|June 2006|||March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||June 2006|June 11, 2009|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920270||137652|
NCT00920283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10901|COMPETE: A Clinical Evaluation of Chrono Carbostent Carbofilm™ Coated Stent|Randomized Comparison Between Two Cobalt-Chromium Balloon Expandable Stents for the Treatment of De Novo Coronary Artery Lesions|COMPETE|CID - Carbostent & Implantable Devices|Yes|Recruiting|July 2009|April 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920283||137651|
NCT00920621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655|Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)|Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)|VDAART|Brigham and Women's Hospital|Yes|Active, not recruiting|September 2009|June 2019|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|870|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|June 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920621||137625|
NCT00920634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06132|Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)|Protocol for Drug Use Investigation of Follistim Injection||Merck Sharp & Dohme Corp.|No|Completed|July 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|384|||Female|N/A|N/A|No|Non-Probability Sample|Japanese 300 patients|February 2015|February 4, 2015|June 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00920634||137624|
NCT00920647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-HIT-045|A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®|A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment||Shire|Yes|Completed|November 2009|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Male|3 Years|18 Years|No|||April 2014|October 6, 2015|June 12, 2009|Yes|Yes||No|October 31, 2013|https://clinicaltrials.gov/show/NCT00920647||137623|Untreated control group were not implanted with IDDD.Concentration of idursulfase in all CSF samples post single dose of idursulfase-IT were below LLOQ(Lower limit of quantitation) of the bioanalytical method therefore no results are reported.
NCT00921037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr: 128/2006|First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas|First Clinical Study of Erbium-YAG Laser Vaporisation of Cutaneous Neurofibromas||Medical University of Vienna|No|Recruiting|April 2006|November 2012|Anticipated|January 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|N/A|No|||June 2009|July 11, 2011|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921037||137593|
NCT00948194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0137|Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation|Investigation of the Effect of Nitric Oxide on Ischemic Reperfusion Injury During Extended Donor Criteria Liver Transplantation||University of Colorado, Denver|No|Active, not recruiting|October 2009|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|69 Years|No|||January 2016|January 13, 2016|July 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948194||135533|
NCT00948207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2009-1189|Online and Narrative Interventions for Advanced Cancer Patients|Online Narrative Interventions and Family Support for Advanced Cancer Patients||University of Wisconsin, Madison|Yes|Completed|February 2009|July 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|117|||Both|30 Years|60 Years|No|||February 2016|February 3, 2016|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948207||135532|
NCT00948493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-100-OL|Treatment Use of Generex Oral-lyn™ in Patients With Diabetes|An Open-Label Treatment Investigational New Drug (IND) for the Use of Generex Oral-lyn™ in Patients With Type 1 or Type 2 Diabetes Mellitus||Generex Biotechnology Corp.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||March 2013|March 18, 2013|July 27, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00948493||135510|
NCT00948506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809821|Trial of Topical Cidofovir for the Prevention of Hair Growth|A Phase II, Randomized, Double-blind, Placebo-controlled, Single-center Proof of Concept Study of Topical Cidofovir for the Prevention of Hair Growth||University of Pennsylvania|No|Completed|July 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 16, 2012|July 23, 2009|Yes|Yes||No|July 21, 2011|https://clinicaltrials.gov/show/NCT00948506||135509|
NCT00949065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-007794-23|Intravenous Immunoglobulins in Complex-regional Pain Syndrome|Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck)|PAINLESS|University of Giessen|Yes|Not yet recruiting|August 2009|April 2011|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|80 Years|No|||July 2009|July 29, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949065||135466|
NCT00949078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AADCRC-JHU-02|Omalizumab in the Treatment of Peanut Allergy|Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults||Johns Hopkins University|Yes|Active, not recruiting|July 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|50 Years|No|||July 2009|June 22, 2011|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949078||135465|
NCT00950157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16785|Testing the Effect of a Caution for Drugs Approved on Surrogate Outcomes Alone|Testing the Effect of a Caution for Drugs Approved on Surrogate Outcomes Alone||White River Junction VAMC|No|Completed|August 2009|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|2944|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 4, 2010|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950157||135382|
NCT00950170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3082B2-4434|Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting|An Open-label Study Of The Safety And Efficacy Of Refacto Af In Previously Untreated Patients In Usual Care Settings||Pfizer|No|Active, not recruiting|February 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label|1||Anticipated|50|||Male|N/A|6 Years|No|||March 2016|March 7, 2016|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00950170||135381|
NCT00949637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF SNAP y1|Scouting Nutrition and Activity Program|A Site-Randomized Controlled Trial for Health Promotion in Girl Scouts: Healthier Troops in a SNAP|SNAP|Kansas State University|No|Completed|October 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|76|||Female|8 Years|12 Years|Accepts Healthy Volunteers|||July 2009|July 29, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00949637||135422|
NCT00951002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-HADM-01|The Efficacy of Human Acellular Dermal Matrix in the Treatment of Anal Fistula|A Multicenter Clinical Trial to Evaluate the Efficacy of Human Acellular Dermal Matrix in the Treatment of Anal Fistula||Beijing Chao Yang Hospital|Yes|Recruiting|July 2009|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|80 Years|No|Probability Sample|hospitalized patients with complex anal fistula|November 2013|November 25, 2013|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951002||135317|
NCT00950677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22439|The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes|The Effect of the Glucagon Suppressors Pramlintide and Exenatide on Postprandial Glucose Metabolism in Children With Type 2 Diabetes Mellitus|T2DM|Baylor College of Medicine|Yes|Recruiting|July 2009|||December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|16|||Both|12 Years|21 Years|No|||December 2010|December 9, 2010|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950677||135342|
NCT00950690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111128|Efficacy and Tolerability of Xalatan in Patients|Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.|A6111128|Pfizer|No|Completed|July 2005|December 2007|Actual|December 2007|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|1289|||Both|18 Years|65 Years|No|Non-Probability Sample|adults with glauocma or ocular hypertension|February 2011|February 18, 2011|March 31, 2009||No||No|March 31, 2009|https://clinicaltrials.gov/show/NCT00950690||135341|Efficacy data were not summarized or analyzed because data collection did not permit clear identification of IOP & visual field data in this non-monitored observational study. Consequently, data were not sufficiently interpretable.
NCT00950976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACSC-CIT-04-06-US|Dose-response Enteral Citrulline for Normal Healthy Volunteers and Surgery Patients|Clinical Trial of Enteral Citrulline in Volunteers With Surgical Repair of Ventral Hernias||Nestlé|No|Completed|March 2008|August 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 24, 2012|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00950976||135319|
NCT00946829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.425|Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise|Study of Hypertensive Population Under Treatment With Micardis in Real Clinical Conditions With the Goal to Control the Early Morning BP Rise||Boehringer Ingelheim||Completed|January 2003|||May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18299|||Both|18 Years|80 Years|No|Non-Probability Sample|Primary Care Clinic|July 2009|July 24, 2009|July 24, 2009||||No||https://clinicaltrials.gov/show/NCT00946829||135638|
NCT00947102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gemcitabine1|Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer|Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma|GEMSTHER|Blood Transfusion Centre of Slovenia|No|Recruiting|February 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|30 Years|85 Years|No|Non-Probability Sample|Patients after resection of pancreatic tubular adenocarcinoma|July 2009|January 12, 2010|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947102||135617|
NCT00947375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nadir|Lamictal TM, Haloperidol Decanoate in Schizophrenia|The Effect of Lamictal TM Augmentation of Haloperidol Decanoate in the Treatment of Resistant Schizophrenia Predominantly by Verbal Resistant Hallucinosis: Randomized, Double-blind, Placebo-controlled, Study|CMCOBaku|Central Mental Clinic for Outpatients of Baku City|Yes|Terminated|January 2005|January 2007|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|335|||Both|18 Years|60 Years|No|||July 2009|July 27, 2009|July 20, 2009|Yes|Yes|All of the mentioned aim and objectives were achieved before the February 2007|No||https://clinicaltrials.gov/show/NCT00947375||135596|
NCT00947648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0369|Outpatient Neutropenic Diet Study|Are Neutropenic Diets Beneficial to Improve Outcome?||M.D. Anderson Cancer Center|Yes|Terminated|July 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|July 24, 2009||No|Slow Accrual|No||https://clinicaltrials.gov/show/NCT00947648||135575|
NCT00947661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_09_12|Efficacy and Safety of 2 Formulations of Latanoprost Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension|Comparison of the Efficacy and Safety of 2 Formulations of Latanoprost Ophthalmic Solution When Administered Once Daily in Subjects With Open Angle Glaucoma or Ocular Hypertension||Sun Pharma Advanced Research Company Limited||Completed|July 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|590|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00947661||135574|
NCT00919750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS02B3|Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors|A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens||Children's Oncology Group|No|Recruiting|March 2005|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|brain tumor tissue, blood|Both|N/A|18 Years|No|Non-Probability Sample|All patients treated for a brain tumor at a COG institution are eligible for participation        in this study.|November 2015|November 5, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919750||137691|
NCT00919763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18158|Efficacy and Safety Study of CD2027 Ointment 3 Mcg/g Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis|A Four-Week, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CD2027 Ointment 3 Mcg/g Twice Daily in the Treatment of Adults With at Least Moderate Atopic Dermatitis||Galderma|No|Completed|May 2009|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||May 2012|May 29, 2012|June 9, 2009|Yes|Yes||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00919763||137690|
NCT00919997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-060|Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men|HPV Infection in Indian HIV-Seropositive Men Who Have Sex With Men (MSM)||AIDS Malignancy Consortium|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|302|Samples With DNA|Anal cytology Penile cytology Saliva Blood|Male|18 Years|N/A|No|Non-Probability Sample|HIV-1 infected men who have sex with men from Mumbai and Vellore, India, who are age 18 or        older.|October 2015|October 1, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919997||137673|
NCT00920296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111839|DDI Study of Etravirine and GSK1265744|A Phase I, Open Label Crossover Study to Evaluate the Effect of Etravirine on GSK1265744 Pharmacokinetics in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 30, 2010|June 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00920296||137650|
NCT00920309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC#0903004934|Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy|Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy||Yale University|Yes|Terminated|June 2009|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|June 12, 2009|No|Yes|This study was stopped after larger studies published in the NEJM failed to show a benefit in    treating ADPKD|No|August 29, 2013|https://clinicaltrials.gov/show/NCT00920309||137649|
NCT00920660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113161|Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Multi-way Crossover Study to Assess the Effects of Single Oral Doses of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers||GlaxoSmithKline|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920660||137622|
NCT00920673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/06|Age Influence on the Modifications of the Oral, Pharyngeal and Laryngeal Axis Alignment in Children Induced by Head Extension: an MRI Study|Age Influence on the Modifications of the Oral, Pharyngeal and Laryngeal Axis Alignment in Children Induced by Head Extension: an MRI Study||Assistance Publique Hopitaux De Marseille|No|Completed|May 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|150|||Both|42 Weeks|18 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00920673||137621|
NCT00921336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2450-US-001|Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor|Open-Label, Sequential, Ascending, Multi-Dose, Phase 1 Study of KW-2450 as Monotherapy in Subjects With Previously Treated Advanced Solid Tumor||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||September 2010|September 9, 2010|May 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921336||137570|
NCT00921570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATA VALAMEX study|The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension|The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension||Gulhane School of Medicine||Completed|February 2008|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|70 Years|No|||June 2009|June 16, 2009|June 15, 2009||||No||https://clinicaltrials.gov/show/NCT00921570||137552|
NCT00948519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR 09-005|Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents|Laser Microbial Killing With Photo Activated Agents||New York Head & Neck Institute|No|Recruiting|May 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|July 21, 2011|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948519||135508|
NCT00948779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB 2008-A00892-53|Antibiotic Education for Children in an Emergency Care Unit|Therapeutic Education About Intake of Oral Solutions of Antibiotics in Children Under 6 Year-old at the Emergency Department in Robert Debré Hospital|ACHEEN|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|300|||Both|1 Month|6 Years|No|||July 2012|July 26, 2012|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948779||135488|
NCT00949897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120813B|Comparison Study of Biofoam Porous Metal Versus Allograft to Treat Adult Acquired Flatfoot|A Randomized, Prospective, Controlled Trial for Lateral Column Lengthening in Adult Acquired Flatfoot Using Biofoam Porous Metal Compared With Allograft||OrthoCarolina Research Institute, Inc.|Yes|Withdrawn|March 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|25 Years|75 Years|No|||March 2013|March 11, 2013|July 29, 2009|Yes|Yes|Funding terminated|No||https://clinicaltrials.gov/show/NCT00949897||135402|
NCT00950443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 080606|Acoustic Reflection Method and Work of Breathing|Acoustic Reflection Method and Work of Breathing : Two New Methods to Measure Children's Upper Airway Obstruction|MAVAS|Assistance Publique - Hôpitaux de Paris|No|Terminated|December 2009|November 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|38|||Both|N/A|15 Years|No|||August 2011|December 26, 2011|July 30, 2009||No|No inclusion|No||https://clinicaltrials.gov/show/NCT00950443||135360|
NCT00950417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-ESO-T-0901|Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer|Phase I Study of Nimotuzumab in Combination With Simultaneous Chemotherapy and Radiation for Patients With Locally Advanced Esophageal Cancer||Biotech Pharmaceutical Co., Ltd.|Yes|Completed|July 2009|November 2012|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||July 2009|August 17, 2015|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00950417||135362|
NCT00951015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112276|A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects|A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|ING112276|ViiV Healthcare|No|Active, not recruiting|July 2009|December 2014|Anticipated|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|208|||Both|18 Years|N/A|No|||October 2013|December 19, 2013|July 30, 2009|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00951015||135316|
NCT00951028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH084757|Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)|Efficacy of CBT for Adherence and Depression in HIV Care Settings||Massachusetts General Hospital|Yes|Completed|September 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951028||135315|
NCT00950989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090061|AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate|A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate||Amgen||Completed|December 2009|April 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|240|||Both|18 Years|70 Years|No|||January 2014|January 14, 2014|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950989||135318|
NCT00947115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112772|Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects|Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects||GlaxoSmithKline||Completed|September 2009|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|525|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|July 16, 2009|Yes|Yes||No|February 10, 2011|https://clinicaltrials.gov/show/NCT00947115||135616|
NCT00947388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1907|Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia||Case Comprehensive Cancer Center|Yes|Terminated|November 2008|March 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 20, 2013|July 24, 2009|Yes|Yes|No more eligible patients|No||https://clinicaltrials.gov/show/NCT00947388||135595|
NCT00947674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEWS80|A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)|Prospective, Randomized, Double-Blind, Sham Treatment Controlled Multicenter Study to Evaluate Efficacy and Safety of Cellsorba™EX Used for Leukocytapheresis (LCAP) in Patients With Steroid-Free, Active Ulcerative Colitis||Asahi Kasei Medical Co., Ltd.|No|Terminated|May 2009|October 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|July 27, 2009||No|short of enrollment|No||https://clinicaltrials.gov/show/NCT00947674||135573|
NCT00947687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-0001P-00|Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects|A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects||Pulmatrix Inc.|No|Completed|July 2009|October 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 27, 2010|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947687||135572|
NCT00948311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03798-08-A|Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.|Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes||HealthPartners Institute|Yes|Completed|December 2008|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|279|||Both|12 Years|N/A|No|Non-Probability Sample|International Diabetes Center patient with type 1 diabetes and an eating disorder.|February 2016|February 17, 2016|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948311||135524|
NCT00919464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-04-1803|Natural History of Anterior Compartment Pressures of the Thigh Following Femur Fracture|Natural History of Anterior Compartment Pressures of the Thigh Following Femur||CAMC Health System|No|Terminated|April 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|June 9, 2009||No|low enrollment|No||https://clinicaltrials.gov/show/NCT00919464||137712|
NCT00919477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OJP-CAS-2009/1|Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg|Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg|CAMON|AstraZeneca|No|Completed|May 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|712|||Male|N/A|N/A|No|Probability Sample|Prostate cancer patients who have no history of having received treatment by either        endocrine therapy (including surgical castration)|January 2013|January 21, 2013|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919477||137711|
NCT00919776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCCRBY24-ENLB|Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum|A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only.||London School of Hygiene and Tropical Medicine|Yes|Completed|August 2010|July 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||March 2015|March 25, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919776||137689|
NCT00920010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078624|S9925: Collecting and Storing Samples From Patients With Lung Cancer|Lung Cancer Specimen Repository Protocol, Ancillary||Southwest Oncology Group|No|Completed|September 2000|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2264|Samples With DNA|Fixed tissue in paraffin blocks or slides, slides of buccal brushings, fresh frozen tissue      peripheral blood, serum, plasma, white blood cells, and sputum.|Both|N/A|N/A|No|Non-Probability Sample|Lung cancer patients registered to SWOG lung protocols.|February 2015|February 5, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920010||137672|
NCT00920322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSG HREC 153|Repetitive Transcranial Magnetic Stimulation (rTMS) in Depression|A Randomised Study of rTMS in Depression||Northside Clinic, Australia|Yes|Terminated|May 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|June 11, 2009||No|Technical issues impeded recruitment.|No||https://clinicaltrials.gov/show/NCT00920322||137648|
NCT00920686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXN-188-203|Study of NXN 188 for the Treatment of Migraine With Aura|A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura||NeurAxon Inc.|No|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|239|||Both|18 Years|65 Years|No|||July 2014|July 20, 2014|June 12, 2009|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00920686||137620|
NCT00922142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|608-028|Cesarean Postoperative Pain Satisfaction|Cesarean Postoperative Pain Satisfaction With Intravenous Patient-Controlled Analgesia Intravenous, Oral, or Epidural Method||Saint Elizabeth Regional Medical Center|Yes|Completed|June 2009|December 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|120|Samples Without DNA|no biospecimens to be retained|Female|14 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|post-operative cesarean patients|July 2011|July 19, 2011|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922142||137508|
NCT00949338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-04 ICORG|Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04|A Randomised Trial Comparing The Bladder Volume Consistency Achieved With Two Bladder-Filling Protocols in Prostate Conformal Radiotherapy||ICORG- All Ireland Cooperative Oncology Research Group||Completed|March 2006|||June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|183|||Male|18 Years|N/A|No|||January 2014|December 30, 2014|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949338||135445|
NCT00949650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.32|BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation|A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation||Boehringer Ingelheim||Active, not recruiting|August 2009|April 2016|Anticipated|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|345|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 29, 2009||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00949650||135421|
NCT00949884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS0866-A-U452|Olmesartan Comparison to Losartan in Hypertensive Subjects|A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects||Daiichi Sankyo Inc.|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|941|||Both|18 Years|N/A|No|||March 2011|March 7, 2011|July 29, 2009|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT00949884||135403|
NCT00949663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0861B|Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function|Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function||Washington University School of Medicine|Yes|Completed|October 2009|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|July 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949663||135420|
NCT00949910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO18109|An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Expanded-access Study of the Effect of Tarceva on Treatment Response in Patients With Advanced Stage IIIB/IV Non-small-cell Lung Cancer||Hoffmann-La Roche||Completed|November 2004|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7040|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00949910||135401|
NCT00950456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820901|Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine|A Prospective Non-Interventional Observational Study to Assess the Safety of Two Vaccinations of a Vero Cell-Derived, Whole Virus H1N1 Pandemic Influenza Vaccine in Subjects Exposed to the Vaccine Through Policies by Governments or Health Authorities||Nanotherapeutics, Inc.|No|Completed|November 2009|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|3216|||Both|2 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The enrollment of subjects in this study will follow national vaccination policy decisions        in the UK.|May 2011|October 7, 2015|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950456||135359|
NCT00950430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005553|Imaging of Brain Amyloid Plaques in the Aging Population|Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia||Mayo Clinic|Yes|Enrolling by invitation|April 2008|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2500|||Both|30 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00950430||135361|
NCT00950716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2009-079|PEARL Program: Empowerment Program for Patients With Type 2 Diabetes (HK4)|Peer Support, Empowerment and Remote Communication Linked by Information Technology (PEARL): A Multi-Component Program to Improve Community-Based Diabetes Care|PEARL|Chinese University of Hong Kong|Yes|Completed|September 2009|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|632|||Both|18 Years|70 Years|No|||August 2015|August 23, 2015|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00950716||135339|
NCT00947700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32400-G|Early Connections, Early Detection and Intervention in Infants at Risk for Autism|UW ACE Project II, Early Detection and Intervention in Infants at Risk for Autism||University of Washington|No|Recruiting|January 2008|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|200|||Both|5 Months|12 Months|Accepts Healthy Volunteers|||September 2010|September 2, 2010|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947700||135571|
NCT00946842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR007504|A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants|A Phase I, Two-Panel, Open-Label, Randomized, 3-way Crossover Trial in Healthy Subjects to Determine the Relative Oral Bioavailability of TMC207 After Single Dose Administration of TMC207 100 mg as the Phase II Clinical Trial Tablet Formulation and as a Newly Developed Tablet Formulation, Under Fed and Fasted Conditions||Tibotec BVBA|No|Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|July 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00946842||135637|
NCT00947141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6077|Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)|Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring||University College, London|No|Completed|February 2003|February 2013|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00947141||135614|
NCT00948337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCS-09-266|A Study With Health Educational Material on Health Promotion in Cancer Survivors|A Randomized Controlled Trial on the Effect of Intervention With Health Educational Material on Knowledge, Attitude, and Behavior in Cancer Survivors||National Cancer Center, Korea|No|Active, not recruiting|August 2009|December 2010|Anticipated|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|326|||Both|18 Years|80 Years|No|||September 2009|February 25, 2010|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948337||135522|
NCT00948610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI RO1 HL079955|Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy|Sleep & Immune Mechanisms in Rheumatoid Arthritis: Remicade Substudy||University of California, Los Angeles|Yes|Completed|November 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|85 Years|No|||June 2012|June 26, 2012|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948610||135501|
NCT00948623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s06081980|Physical Activity Counseling During Pulmonary Rehabilitation|Physical Activity Counseling During Pulmonary Rehabilitation: Does it Improve Daily Physical Activity Levels|PAC|Katholieke Universiteit Leuven|No|Recruiting|April 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|N/A|No|||July 2009|July 29, 2009|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948623||135500|
NCT00948896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9926-33953|Chemopreventive Therapy for Malaria in Ugandan Children|A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria|PROMOTE-Chemop|University of California, San Francisco|Yes|Completed|June 2010|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|600|||Both|4 Months|5 Months|Accepts Healthy Volunteers|||October 2015|October 26, 2015|July 27, 2009|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT00948896||135479|
NCT00919490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-023|A Study of Single Dose of ABT-333 in Healthy Male Adults|A Double-blind, Randomized, Placebo-controlled Phase 1 Study in Healthy Male Adults to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Dose of ABT-333||Abbott||Completed|June 2009|||August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|39|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2010|October 22, 2010|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00919490||137710|
NCT00919503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2256.00|Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders|Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen||Fred Hutchinson Cancer Research Center|Yes|Recruiting|October 2010|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|54 Years|No|||February 2016|February 12, 2016|June 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00919503||137709|
NCT00920023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-085|Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)|Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)||Massachusetts General Hospital|Yes|Active, not recruiting|July 2008|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|June 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920023||137671|
NCT00920036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203987|Adjunctive Biofeedback Intervention for Operation Iraqi Freedom/Operation Enduring Freedom (OIF-OEF) Post Traumatic Stress Disorder (PTSD)|Adjunctive Biofeedback Intervention for OIF-OEF PTSD|ABIOP|Central Arkansas Veterans Healthcare System|No|Completed|February 2010|September 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|No|||July 2014|July 11, 2014|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00920036||137670|
NCT00920335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-25|Adult Intracranial Ependymoma|Adult Intracranial Ependydomas : Prognostic and Diagnostic Factors Assessment and Molecular Characterization||Assistance Publique Hopitaux De Marseille|No|Completed|March 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|192|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00920335||137647|
NCT00920699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREQUEL-01.00|Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)|A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease|PREQUEL|Huntington Study Group|Yes|Active, not recruiting|February 2010|June 2012|Anticipated|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920699||137619|
NCT00921050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN_LC_P136|Subclinical Hypothyroidism and Mind in the Elderly|Randomized Double Blind Levothyroxine vs Placebo, Mind (NEUROPSI) Improvement in Elderly With Persistent TSH 4-10 mUI/L||Universidad Autonoma de Nuevo Leon|Yes|Completed|June 2009|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|60 Years|95 Years|No|||June 2010|June 27, 2012|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921050||137592|
NCT00931606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A011-08|Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer|A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer||Celgene|Yes|Terminated|June 2009|April 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|30|||Female|18 Years|N/A|No|||February 2011|February 10, 2011|May 22, 2009|Yes|Yes|administrative reasons (slow patient enrollment)|No||https://clinicaltrials.gov/show/NCT00931606||136799|
NCT00949104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGTPAIN|Role of Oral Sucrose in Reducing the Pain to Orogastric Tube Insertion in Preterm Neonates|A Study to Assess the Role of Oral Sucrose in Reducing the Pain to Orogastric Tube Insertion in Preterm Neonates||Lady Hardinge Medical College|Yes|Completed|January 2008|April 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|N/A|167 Hours|No|||July 2009|July 29, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949104||135463|
NCT00949117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0802|Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer|An Open Label Randomized Phase II Study of an Appetite Stimulant, Cyproheptadine Hydrochloride, With and Without a Nutritional Supplement, in Children With Cancer/Treatment-Related Weight Loss||University of South Florida|Yes|Terminated|September 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|9|||Both|2 Years|17 Years|No|||March 2014|March 4, 2014|July 29, 2009|Yes|Yes|study not feasible with low accrual. DSMB recommended closure|No|July 8, 2013|https://clinicaltrials.gov/show/NCT00949117||135462|Study closed early due to slow accrual and lack of feasibility Only 1 subject completed protocol and considered in the outcome measures. Subject too young to complete PedsFAACT & did not have prealbumin drawn at 24 week visit so outcomes not assessed
NCT00949351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lerdsin 36/52|Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy|Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy||Lerdsin General Hospital|Yes|Not yet recruiting|September 2009|September 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Both|30 Years|70 Years|No|||July 2009|July 29, 2009|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949351||135444|
NCT00949364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPN-SG 01-09|Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage|Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage||University of Ulm|No|Active, not recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|50 Years|N/A|No|||September 2013|September 9, 2013|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949364||135443|
NCT00950183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020723E|Motorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures|Motorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures: An Evaluation of Narcotic Consumption, Pain, Wound Healing, and Patient Satisfaction||OrthoCarolina Research Institute, Inc.|Yes|Terminated|February 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|N/A|No|||October 2014|October 28, 2014|July 29, 2009||No|recruitment feasability|No|March 11, 2013|https://clinicaltrials.gov/show/NCT00950183||135380|The study was stopped due to poor enrollment. No results are available
NCT00950196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5196-AN-CTIL|Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia|The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia||Sheba Medical Center|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|50 Months|No|||June 2011|June 26, 2011|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950196||135379|
NCT00946868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0143/09|Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication|Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication||University of Sao Paulo|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|170|||Both|18 Years|N/A|No|Probability Sample|Adult patients of the Vascular and Endovascular Department (Intermittent Claudicantion        Group)|July 2009|July 23, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946868||135635|
NCT00947154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07172009-3320|Trial of Aripiprazole in Trichotillomania|Open Label Trial of Aripiprazole in Trichotillomania.||Stanford University|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||May 2015|May 31, 2015|July 23, 2009||No||No|April 19, 2015|https://clinicaltrials.gov/show/NCT00947154||135613|
NCT00950729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Socrate|The Effects of Lower Right Limb Orthopedic Immobilization on Driving Performance|The Effects of Lower Right Limb Orthopedic Immobilization on Driving Performance: an Experimental Study During Simulated Driving in Healthy Volunteers.||Université de Sherbrooke|No|Completed|March 2007|September 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|48|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 18, 2015|March 2, 2009||No||No|March 2, 2009|https://clinicaltrials.gov/show/NCT00950729||135338|
NCT00947167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|END0008|A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors|A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors||Stanford University|Yes|Terminated|March 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|N/A|No|||November 2011|November 9, 2011|July 23, 2009|No|Yes|Extreme toxicity of Pertuzumab and Erlotinib combination|No||https://clinicaltrials.gov/show/NCT00947167||135612|
NCT00948038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMI-033|Dairy Modulation of Oxidative and Inflammatory Stress in Overweight and Obese Subjects|||University of Tennessee|No|Completed|January 2007|May 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|50 Years|No|||July 2009|July 28, 2009|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948038||135545|
NCT00948051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOS_FOF08|Effects of follow-on Formula Enriched on Short-chain Fructooligosaccharides (scFOS) on Immune Response in Healthy Infants|A Placebo-controlled, Double-blind Randomized Study to Evaluate the Efficacy of a follow-on Milk Formula Supplemented With Fructo-oligosaccharides on Immune Response in Healthy Infants||Syral||Completed|March 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|4 Months|5 Months|Accepts Healthy Volunteers|||April 2011|April 12, 2011|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948051||135544|
NCT00946855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Soccer laboratory values|Effect of Elite Soccer Training on Routine Laboratory Parameters|Laboratory Values in Elite Soccer Players|SOCCERLAB|Saarland University|No|Completed|August 2008|July 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|467|Samples Without DNA|iced serum samples|Male|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|soccer players of the first two German professional soccer leagues|July 2009|July 24, 2009|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00946855||135636|
NCT00947128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B043713|To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions||Sandoz||Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|58 Years|Accepts Healthy Volunteers|||July 2009|July 24, 2009|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947128||135615|
NCT00904865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-08-145|Single Port Access (SPA) Cholecystectomy Versus Standard Laparoscopic Cholecystectomy|Single Port Access Cholecystectomy Versus Standard Laparoscopic Cholecystectomy - Randomized Study||University Hospital, Geneva|No|Recruiting|February 2009|||February 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2009|May 19, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904865||138821|
NCT00901342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-1|Open Label Study of Sipuleucel-T|An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer||Dendreon|No|Completed|August 2009|April 2015|Actual|December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Male|18 Years|N/A|No|||October 2015|October 5, 2015|May 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901342||139086|
NCT00901680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2008-180|Creation of the BioBank, Early Detection and Discovery Biomarkers|Creation of the BioBank,To Establish a Multidisciplinary Research Structure That Facilitates Projects That Bridge Specialties That Normally May or May Not Interact.||William Beaumont Hospitals|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3028|Samples With DNA|Biospecimens to be retained are tissue, blood, whole blood, DNA, RNA, urine saliva,cerebral      spinal fluid, amniotic fluid.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population male/female from inpatient and outpatient hospital settings or doctor offices..|August 2012|August 20, 2012|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901680||139060|
NCT00901693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-53|An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis|||Alcon Research|No|Terminated|June 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|452|||Both|6 Years|N/A|No|||May 2014|May 7, 2014|May 8, 2009|Yes|Yes|Internal business decision|No||https://clinicaltrials.gov/show/NCT00901693||139059|
NCT00901368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0806-PR-0032|FACTO Study (Foster® As Complete Treatment Option)|A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE® DISKUS®) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS.|FACTO|Chiesi Farmaceutici S.p.A.|No|Completed|May 2009|December 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|431|||Both|18 Years|65 Years|No|||April 2012|April 20, 2012|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901368||139084|
NCT00902408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-1-127|Effect of Lutein-enriched-egg Beverage on Age-Related Macular Degeneration (AMD)|The Effect of Lutein-enriched-egg Beverage on Progression of Age-related Macular Degeneration, a Randomized Trial||Maastricht University Medical Center|No|Completed|July 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|55 Years|85 Years|No|||November 2013|November 5, 2013|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902408||139005|
NCT00902707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-MUC-01|Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung|An Open-Label, 2-way Crossover Placebo-Controlled , Radio-Labeled Tracer Study Evaluating the Effect of MUCINEX® 1200 mg on Mucociliary and Cough Clearance From The Human Lung In Healthy, Non-Smoking Adults||University of North Carolina, Chapel Hill|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|June 8, 2012|May 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00902707||138982|
NCT00954850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAN Protocol|A National Program for Severe Asthma: The Canadian Severe Asthma Network|A National Program for Severe Asthma: The Canadian Severe Asthma Network|CSAN|University of Alberta|No|Withdrawn|June 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|If consented to by the patient, extra clinical specimens - sputum plugs, sputum supernatant,      blood and urine will be stored. If patients undergo a clinical bronchoscopy, mucosal      biopsies x 2 and bronchoalveolar lavage will be stored.|Both|18 Years|N/A|No|Non-Probability Sample|Severe asthmatics as the primary study group, mild-moderate asthmatics as the control        group|August 2012|August 23, 2012|August 5, 2009||No|Subjects not entered into electronic database due to current construct of database and    associated privacy legislations within Alberta.|No||https://clinicaltrials.gov/show/NCT00954850||135027|
NCT00952081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-745|A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients|A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients||New York University School of Medicine|Yes|Completed|July 2009|February 2010|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 26, 2015|July 29, 2009|Yes|Yes||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00952081||135234|
NCT00954317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-08-052|Do Epidurals Placed at a Lower Level Improve Labor Analgesia?|Do Epidurals Placed at a Lower Level Improve Labour Analgesia||Royal Victoria Hospital, Canada|No|Recruiting|September 2009|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 29, 2012|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954317||135068|
NCT00954330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|555555|Surgical Versus Functional Treatment for Acute Ruptures of the Lateral Ligament Complex of the Ankle in Young Males - A Randomized Controlled Trial With a Mean of 14 Years Follow-up|Surgical Versus Functional Treatment for Acute Ruptures of the Lateral Ligament Complex of the Ankle in Young Males - A Randomized Controlled Trial With a Mean of 14 Years Follow-up||Finnish Defense Forces|No|Completed|February 1991|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Male|19 Years|25 Years||||August 2009|August 6, 2009|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954330||135067|
NCT00953706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-770-104|Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation|DISCOVER|Vertex Pharmaceuticals Incorporated|Yes|Terminated|September 2009|May 2013|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|12 Years|N/A|No|||August 2015|August 27, 2015|August 4, 2009|Yes|Yes|Following review of results obtained from a pre-specified 6-month analysis of Part B data the    study was terminated on the basis of futility.|No|February 27, 2012|https://clinicaltrials.gov/show/NCT00953706||135113|In Part B, the treatment duration was 96 weeks; however, due to early study termination all analysis were performed up to Week 64, as planned.
NCT00953719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COC 36 mm|36 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement|Delta Ceramax 36 mm Ceramic-on-Ceramic Acetabular Cup Prosthesis Study||DePuy Orthopaedics|No|Completed|April 2003|July 2013|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|20 Years|75 Years|No|||August 2014|August 19, 2014|June 3, 2009|Yes|Yes||No|May 13, 2014|https://clinicaltrials.gov/show/NCT00953719||135112|At study inception, information on whether or not an adverse event was deemed to be serious was not collected. Because of this caveat, the Sponsor has reported all adverse events that occurred in this study.
NCT00953732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-030|A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies|A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on the Head (Face or Scalp) Who Have Completed Day 57 in Studies PEP005-016 or PEP005-025 (REGION IIa and IIb)||Peplin|No|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 3|Observational|Time Perspective: Prospective||1|Actual|117|||Both|18 Years|N/A|No|Non-Probability Sample|All patients must have achieved complete clearance of AK lesions at Day 57 visit in either        study PEP005-016 or PEP005-025 will be offered participation in this study.|March 2015|March 25, 2015|August 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00953732||135111|
NCT00955071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross 2009|Effects of Exercise on Abdominal Obesity and Risk Factors for Cardiovascular Disease|Dose-response Effects of Exercise on Abdominal Obesity and Risk Factors for CVD in Men and Women.||Queen's University|Yes|Completed|September 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|320|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00955071||135010|
NCT00955084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL999-900|Maintenance Study on the Long Term Safety of XL999|A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies||Symphony Evolution, Inc.|No|Completed|August 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955084||135009|
NCT00901992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIDAM-02-09|Evaluation of a Self-management Oriented Diabetes Education Program for Intensified Insulin Therapy in Type 2 Diabetes|Evaluation of a Self-management Oriented Diabetes Education Program for the Initiation of Intensive Insulin Therapy in Type 2 Diabetic Patients|MEDIAS-2-ICT|Forschungsinstitut der Diabetes Akademie Mergentheim|No|Completed|May 2009|August 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|75 Years|No|||August 2014|August 8, 2014|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901992||139036|
NCT00902902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-Liver surgery -GP73|A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark|A Clinical Study of GP73 as a HCC Early Tumor Mark||Peking Union Medical College Hospital|No|Recruiting|January 2008|July 2009|Anticipated|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|0|Samples With DNA|Human serum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The subjects were from different hospitals including: Peking Union Medical College        Hospital, The Cancer Hospital of PUMC, QiDong Cancer Institute, and Department of Surgery        University of Chicago from November of 2007 till the end of this study.|May 2009|May 14, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902902||138967|
NCT00903747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0001-C102|Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters|A Phase I Thorough QT/QTc Study To Evaluate The Effect of Therapeutic and Supratherapeutic Multiple Doses of Prucalopride on Cardiac Repolarisation in Healthy Male and Female Volunteers||Movetis|No|Completed|January 2009|May 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2009|May 15, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903747||138906|
NCT00903760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0092|Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)|A Randomized Study of Decitabine Alternating With Clofarabine Versus Decitabine Until Failure in Patients With Higher Risk Myelodysplastic Syndromes (MDS)||M.D. Anderson Cancer Center|Yes|Completed|January 2010|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903760||138905|
NCT00904033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00025478|Calcitriol, Physical Activity, and Bone Health in Cancer Survivors|A Pilot Study of the Effects of High-Dose Oral Calcitriol and Physical Activity on Bone Health in Breast Cancer Survivors||University of Rochester|Yes|Recruiting|December 2008|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|54|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00904033||138884|
NCT00904319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903762|Aquatic Power Training|Optimizing Mobility in Older Adults With Knee Osteoarthritis: Aquatic Power Training||University of Iowa|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|50 Years|N/A|No|||June 2010|June 24, 2010|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00904319||138863|
NCT00904332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090146|Changes in the Posterior Parietal Cortex - Primary Motor Cortex Pathway Induced by Motor Training|Changes in the Posterior Parietal Cortex - Primary Motor Cortex Pathway Induced by Motor Training||National Institutes of Health Clinical Center (CC)||Completed|May 2009|December 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|20|||Both|18 Years|50 Years|No|||December 2011|December 30, 2011|May 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00904332||138862|
NCT00905554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WW01|Warm Water for Unsedated Colonoscopy|Warm Water Irrigation Versus Standard Air Insufflation for Unsedated Colonoscopy: a Randomized Controlled Trial|WW|Valduce Hospital|No|Completed|April 2009|February 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|230|||Both|18 Years|80 Years|No|||September 2011|September 15, 2011|May 15, 2009||No||No|August 5, 2011|https://clinicaltrials.gov/show/NCT00905554||138769|
NCT00905567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01178|Topiramate 25 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Tablets Administered as 2 x 25 mg Tablets in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|June 2001|June 2001|Actual|June 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 18, 2009|No|Yes||No|May 28, 2009|https://clinicaltrials.gov/show/NCT00905567||138768|
NCT00901056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED-ESWT|Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction|Feasibility Study to Investigate the Effect of Low Intensity Shockwaves on Patients With Erectile Dysfunction Resulted From Vascular Origin||Medispec|No|Completed|November 2008|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||November 2010|January 23, 2011|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901056||139108|
NCT00901069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-NHL-06-UK/CC|Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma|Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial||University of Kentucky|Yes|Active, not recruiting|May 2009|August 2014|Anticipated|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901069||139107|
NCT00905515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-06-001|Optima: Optimizing Prograf Therapy in Maintenance Allografts II|Optima: Optimizing Prograf Therapy in Maintenance Allografts II|OPTIMAII|East Carolina University|No|Completed|August 2003|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|May 18, 2009||No||No|October 22, 2012|https://clinicaltrials.gov/show/NCT00905515||138772|
NCT00905528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Re.-No. 3204|TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus|Prospective Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus||University of Erlangen-Nürnberg Medical School|No|Completed|January 2002|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|69|||Both|30 Years|80 Years|No|Non-Probability Sample|Subjects with type 2 diabetes mellitus and normo or microalbuminuria|March 2015|March 24, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00905528||138771|
NCT00902096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009008|Predictors of Cord Blood Immunoglobin E (IgE) Levels|||Min-Sheng General Hospital||Recruiting|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|hospital and primary care clinic based study|May 2009|May 13, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902096||139028|
NCT00902109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCOPE-G-BETA|Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients|Pilot Study to Compare the Humphrey Field Analyzer (HFA) 30-2 Swedish Interactive Threshold Algorithm (SITA) Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE), Using a New Fast GATE (German Adaptive Threshold Estimation) in Glaucoma Patients Under Topic Therapy|TRASCO|University Hospital Tuebingen|No|Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Probability Sample|University Eye Hospital|January 2016|January 31, 2016|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00902109||139027|
NCT00902083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53-002|rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors|Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors|rAd-p53|Shenzhen SiBiono GeneTech Co.,Ltd|No|Recruiting|June 2009|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|85 Years|No|||February 2010|April 6, 2012|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00902083||139029|
NCT00903006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0336|Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer|A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer||M.D. Anderson Cancer Center|Yes|Terminated|November 2009|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|11|||Female|18 Years|N/A|No|||June 2014|January 21, 2015|May 13, 2009|Yes|Yes|Low Accrual|No|June 27, 2014|https://clinicaltrials.gov/show/NCT00903006||138959|Study terminated early due to small sample size.
NCT00903019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH083872|Feasibility of Telehealth Problem-Solving Therapy for Depressed Homebound Older Adults|Telehealth Problem-Solving Therapy for Depressed Homebound Older Adults||University of Texas at Austin|No|Completed|June 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|158|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 20, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00903019||138958|
NCT00951847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233_OXCAR_06|Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Oxcarbazepine 300 mg/5mL Oral Suspension of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc.) With Trileptal® 300 mg/5mL Oral Suspension (Containing Oxcarbazepine 300 mg/5mL) of Novartis Pharmaceutical Corporation in Healthy, Adult, Male, Human Subjects Under Fed Condition||Ranbaxy Inc.|Yes|Completed|October 2006|December 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 3, 2009|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00951847||135252|
NCT00952887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A031-02|A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ACE-031 (ActRIIB-IgG1) in Healthy Postmenopausal Women||Acceleron Pharma, Inc.|Yes|Completed|August 2009|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|August 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00952887||135173|
NCT00952900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DE010713|An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)|An Implementation and Biobehavioral Study of TMJMD||The University of Texas at Arlington|Yes|Completed|August 2008|July 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|456|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952900||135172|
NCT00953446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-105|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Suspended|August 2009|||August 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2010|November 18, 2010|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953446||135133|
NCT00953667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805670|The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study|The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study|GENE|University of Pennsylvania|Yes|Completed|June 2007|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|400|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|February 23, 2016|August 4, 2009|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT00953667||135116|
NCT00953680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-306|Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)|An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence After Administration of a Losartan 100-mg/Hydrochlorothiazide 12.5-mg Combination Tablet and the Coadministration of a Currently Marketed COZAAR™ 100-mg Tablet and MICROZIDE™ 12.5 mg Capsule in Healthy Adults||Merck Sharp & Dohme Corp.||Completed|April 2004|July 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|August 4, 2009|No|Yes||No|May 13, 2010|https://clinicaltrials.gov/show/NCT00953680||135115|PK analyses included complete data from 75 subjects. 3 losartan/E-3174 concentrations from 3 different subjects were excluded from analyses due to gross deviations; 75 minutes-Treatment B, 75 minutes-Treatment A, & 15 minutes-Treatment A.
NCT00922155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-0011B|Diagnosis of Lung Lesions by Endobronchial Ultrasound With an Alternative Guide Sheath|Clinical Effectiveness of a Balloon Covered Sheath as a Guide Sheath in Endobronchial Ultrasound Guided Diagnosis of Peripheral Lung Lesions||Chang Gung Memorial Hospital|Yes|Completed|April 2007|March 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|180|||Both|18 Years|N/A|No|||March 2007|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922155||137507|
NCT00902330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-11995|Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer|Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer||Virginia Commonwealth University|Yes|Completed|April 2009|May 2014|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|161|||Female|18 Years|N/A|No|||November 2015|November 19, 2015|May 14, 2009|Yes|Yes||No|May 15, 2014|https://clinicaltrials.gov/show/NCT00902330||139011|
NCT00902642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-127|What is the Effect of a Course for Treatment Providers on Their Patient Outcome|Does Training in Psychosocial Methods for Treatment Providers Improve Outcome for Pain Patients at Risk of Long-Term Disability? A Randomised Controlled Trail of a Course for Physical Therapists||Örebro County Council|No|Completed|September 2004|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|65 Years|No|||May 2009|May 13, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902642||138987|
NCT00903240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBS-001|Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer|Phase 3 Study of Bladder Cancer Recurrence Surveillance||Predictive Biosciences|No|Completed|May 2009|October 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|The specimens to be retained are urine only|Both|18 Years|N/A|No|Non-Probability Sample|The study population will be from urology and oncology practices|November 2009|June 7, 2011|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903240||138943|
NCT00903474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08061|Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors|Mindful Movement Program for Breast Cancer Survivors||City of Hope Medical Center|Yes|Completed|August 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|49|||Female|50 Years|N/A|No|||June 2015|June 3, 2015|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903474||138925|
NCT00903214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000641180|Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer|Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|May 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||April 2013|April 25, 2013|May 15, 2009|No|Yes|Funding ended|No||https://clinicaltrials.gov/show/NCT00903214||138945|
NCT00903227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAI03|Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis|A Proof Of Concept Study To Assess The Steroid Sparing Effect Of Combined Nasal And Inhaled Corticosteroid In Patients With Asthma And Persistent Rhinitis||University of Dundee|No|Completed|December 2006|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|65 Years|No|||May 2009|May 14, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903227||138944|
NCT00904904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539|Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery|||Bausch & Lomb Incorporated|No|Completed|April 2008|September 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|May 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00904904||138818|
NCT00905229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-09|Comparing Different Routes and Doses of Phytonadione (Vitamin K) for Reversing Warfarin Treated Patients With Hip Fracture Before Surgery|||HaEmek Medical Center, Israel|Yes|Withdrawn|May 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|May 18, 2009||No|Enrollment problems|No||https://clinicaltrials.gov/show/NCT00905229||138794|
NCT00905242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A-US41|Impact of Myfortic on Gastrointestinal (GI) Prophylaxis in Maintenance Renal Transplant Patients|Impact of Myfortic on GI Prophylaxis in Maintenance Renal Transplant Patients|MPACT|East Carolina University|No|Completed|March 2006|January 2007|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|61|||Both|18 Years|75 Years|No|||May 2009|May 18, 2009|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905242||138793|
NCT00905541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVS0001|Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion|Influence of Simvastatin on apoB-100 Secretion in Non-Obese Subjects With Moderate Hypercholesterolemia: A Stable Isotope Study|SVS|University Hospital, Bonn|No|Completed|November 1998|March 2000|Actual|March 1999|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|8|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 18, 2009|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905541||138770|
NCT00901082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN08-051|The Effectiveness of Information and Relaxation on Pre-procedural Block Anxiety and Procedural Discomfort During Medial Branch Block|The Effectiveness of Information and Relaxation on Pre-procedural Block Anxiety and Procedural Discomfort During Medial Branch Block: a Randomized Controlled Trial|TIRAP|McGill University Health Center|No|Completed|April 2009|February 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|70 Years|No|||October 2015|October 2, 2015|May 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00901082||139106|
NCT00901095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL094466|Can Diet- and Exercise-Induced Weight Loss Improve Asthma Control in Adults?|Can Diet- & Exercise-induced Weight Loss Improve Asthma Control in Adults||Palo Alto Medical Foundation|Yes|Completed|February 2010|March 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|330|||Both|18 Years|70 Years|No|||March 2014|March 17, 2014|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901095||139105|
NCT00901394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0074|Influence of Preoperative Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia|Influence of Preoperative Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia|Mini-VINO|Washington University School of Medicine|No|Completed|March 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|577|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00901394||139082|
NCT00901407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMC-R93|Lamotrigine Augmentation in Resistant Depression|Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression||Louisiana State University Health Sciences Center in New Orleans|Yes|Completed|December 2003|April 2007|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|65 Years|No|||May 2009|May 12, 2009|May 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901407||139081|
NCT00901381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GKSF-8|Granulocyte-colony Stimulating Factor for Stem Cells Therapy for Acute Ischemic Stroke|Open Prospective Randomized Controlled Trial of Efficacy and Safety of Granulocyte-colony Stimulating Factor Leukostim for Acute Ischemic Stroke.|STEMTHER|Clinical Institute of the Brain, Russia|Yes|Completed|June 2007|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|70 Years|No|||January 2014|January 6, 2014|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901381||139083|
NCT00912990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11672|Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet|Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet||Rady Children's Hospital, San Diego|No|Terminated|January 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|6 Months|17 Years||||September 2010|September 28, 2010|June 1, 2009|||Adequate subjects numbers not enrolled in study timeframe.|No||https://clinicaltrials.gov/show/NCT00912990||138207|
NCT00902421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-08-047|Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients|Efficacy and Safety of SSRI in Overactive Bladder Patients; a 3-month, Prospective, Open-label, Comparative Study||Samsung Medical Center|Yes|Completed|January 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|80 Years|No|||August 2010|August 24, 2010|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902421||139004|
NCT00913562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-040908|Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma|Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma||Medical University of Vienna|Yes|Withdrawn|June 2009|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913562||138163|
NCT00913575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/012|Effect of Pre-surgery Neuromuscular Physiotherapy (PT)|Effect of Pre-surgery Neuromuscular Physiotherapy (PT) on Functional Outcome After Total Knee Replacement (TKR): A Single-blinded Randomized Controlled Trial.|Omega|University of Zurich|Yes|Completed|June 2009|June 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|60 Years|85 Years|No|||May 2014|May 21, 2014|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00913575||138162|
NCT00952627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofAFRS 439130|Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects|Mechanism of the Anti-remodeling Activity of the Over-the-counter Dietary Supplement, Pycnogenol, on Age-dependent Process of Cardiac Fibrosis in Aged Hypertensive Subjects With Echocardiographic Evidence of Grade I/II Diastolic Dysfunction||University of Arizona|No|Terminated|July 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|50 Years|75 Years|No|||December 2013|December 14, 2013|August 3, 2009||No|Not able to recruit qualified patents|No||https://clinicaltrials.gov/show/NCT00952627||135192|
NCT00953199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lidocaine|Topical Pancreatic Duct Lidocaine for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis||Milton S. Hershey Medical Center||Completed|March 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|506|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953199||135151|
NCT00953407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-337-C-027|Comparative Clinical Evaluation of Daily Disposable Lenses in Symptomatic Lens Wearers|||Alcon Research||Completed|July 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|128|||Both|N/A|N/A|No|||January 2012|June 26, 2012|July 8, 2009|Yes|Yes||No|September 16, 2010|https://clinicaltrials.gov/show/NCT00953407||135136|
NCT00922168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pre-op PSG|Pre-operative Polysomnography Assessment of Cardiac Surgery Inpatients|Pre-operative PSG Assessment of Cardiac Surgery Inpatients||Cleveland Medical Devices Inc|No|Completed|March 2007|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|146|||Both|N/A|N/A|No|Non-Probability Sample|cardiac surgery patients|February 2014|February 5, 2014|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922168||137506|
NCT00954811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|recombinant LH 1505|Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)|A Phase IV Study on the Effect of Luteal Supplementation With Rec-LH on the Pregnancy Rate After Ovulation Triggering With GnRH-agonist Instead of HCG in IVF Protocol;Proof of Concept||Universitair Ziekenhuis Brussel|Yes|Recruiting|September 2005|December 2010|Anticipated|January 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|36 Years|No|||August 2009|January 7, 2010|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954811||135030|
NCT00954824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706771|Inflammation and the Metabolic Syndrome in Humans|Inflammation and the Metabolic Syndrome in Humans|LPS|University of Pennsylvania|No|Completed|August 2003|November 2007|Actual|November 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 21, 2015|August 5, 2009|Yes|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT00954824||135029|
NCT00922766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301088|Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice|Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice||Pfizer|Yes|Completed|May 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|618|||Both|18 Years|N/A|No|Non-Probability Sample|Patients management of non-ST segment elevated acute coronary syndromes in nursing home        who will be treated conservatively (without percutaneous corornary intervention [PCI] or        coronary artery bypass graft [CABG] within 48 hours).|January 2012|January 19, 2012|June 16, 2009||No||No|October 7, 2011|https://clinicaltrials.gov/show/NCT00922766||137461|
NCT00922779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16709|A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C|Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C||Hoffmann-La Roche||Completed|June 2002|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6661|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|June 16, 2009||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT00922779||137460|
NCT00902915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD|Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure|||Austrian Forum Against Cancer||Active, not recruiting|May 2009|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902915||138966|
NCT00902928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-040|A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery|A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 Bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery|ONYX-3|Astellas Pharma Inc|Yes|Completed|April 2009|August 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|1992|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|April 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902928||138965|
NCT00904046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK081423|Study of the Biological and Physical Manifestations of Spontaneous Uric Acid Kidney Stone Disease|Pathophysiology of Uric Acid Nephrolithiasis|IUAN|University of Texas Southwestern Medical Center|Yes|Recruiting|May 2009|December 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|21 Years|99 Years|No|||December 2015|December 11, 2015|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904046||138883|
NCT00904059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-009|Drug-Drug Interaction Study in Healthy Subjects|Open-Label, Randomized, Multiple-Dose, Drug-Drug Interaction Study to Assess the Pharmacokinetics and Safety of BMS-790052 and BMS-650032 Co-administered in Healthy Subjects||Bristol-Myers Squibb|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|28|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2010|January 6, 2011|April 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00904059||138882|
NCT00904631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/08|A Prospective, Open Label, Non Randomized, Clinical Study to Evaluate the Safety and Effectiveness of the Eraser Tattoo Removal Device|||Assaf-Harofeh Medical Center||Recruiting|May 2009|August 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 19, 2009|May 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00904631||138839|
NCT00904917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-10-4041|Preventing Depression in the Children of Depressed African American Mothers|Children of Depressed Mothers: Culture & Prevention||Children's Hospital of Philadelphia|Yes|Completed|February 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|34|||Both|8 Years|14 Years|No|||October 2014|October 17, 2014|May 19, 2009||No||No|September 26, 2013|https://clinicaltrials.gov/show/NCT00904917||138817|Small sample size; Inadequate power to detect changes between groups; No-intervention comparison group; Differential attrition in the two groups favoring the comparison group
NCT00905255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS10888|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)|A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes|GETGOAL-MONO|Sanofi|Yes|Completed|May 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|20 Years|N/A|No|||March 2014|March 14, 2014|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905255||138792|
NCT00905580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4-2009-0070|Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy|Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy||Severance Hospital|Yes|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|20 Years|65 Years|No|||October 2009|January 15, 2010|May 18, 2009||No||No|October 13, 2009|https://clinicaltrials.gov/show/NCT00905580||138767|
NCT00912431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-061|Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers|A Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in the Cerebrospinal Fluid (CSF) of Healthy Subjects||Abbott||Completed|June 2009|||August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|November 1, 2010|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912431||138249|
NCT00912444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATT|Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer|A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer|NATT|Shanghai Jiao Tong University School of Medicine|Yes|Terminated|July 2009|October 2015|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Female|18 Years|70 Years|No|||December 2015|December 29, 2015|June 1, 2009||No|TAC treatment was associated with better survial outcome compared with TC treatment, we    terminated recruiting and waiting for longer follow up period.|No||https://clinicaltrials.gov/show/NCT00912444||138248|
NCT00901706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0052|Multidimensional Assessment and Intervention for Elder Self-Neglect|Multidimensional Assessment and Intervention for Elder Self-Neglect||The University of Texas Health Science Center, Houston|Yes|Completed|August 2009|July 2012|Actual|February 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|100|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 17, 2013|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901706||139058|
NCT00901719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS/09/019/26905 - 3|Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation|Investigating the Interaction of Apelin and Systemic Angiotensin II Peripheral Resistance Vessels and Systemic Haemodynamics in Vivo in Man||University of Edinburgh|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Months|85 Years|Accepts Healthy Volunteers|||May 2009|August 9, 2010|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901719||139057|
NCT00912457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP0043/07|Donepezil Treatment for Sleep Apnea Patients|Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study|doneapnea|Associacao Fundo de Incentivo a Psicofarmcologia|Yes|Recruiting|March 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Male|30 Years|60 Years|No|||June 2009|June 2, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912457||138247|
NCT00913276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 15-2008|Conditioning With Volatile Anesthetics in Liver Transplantation|||University of Zurich|Yes|Completed|January 2009|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|98|||Both|18 Years|N/A|No|||November 2012|November 22, 2012|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00913276||138185|
NCT00913549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239-04|To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets|Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets||Sandoz||Completed|December 1989|January 1990|Actual|January 1990|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913549||138164|
NCT00913003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU0008753|Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery|Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery||Northwestern University|No|Terminated|May 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|22|||Female|18 Years|65 Years|No|||February 2015|February 2, 2015|June 2, 2009||No|PI terminated employment with the University|No|January 21, 2015|https://clinicaltrials.gov/show/NCT00913003||138206|This study was terminated early because the PI left the institution.
NCT00921375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB037/2007|Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia|Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia||Virchow Group|No|Completed|February 2010|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|1 Year|75 Years|No|||December 2014|December 11, 2014|May 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00921375||137567|
NCT00921609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8997|A Study Examining the Peri- and Post-operative Dynamics of the Growth Hormone (GH) - IGF-1 Axis in Subjects With Acromegaly During the First Year After Surgical Resection|A Study Examining the Peri- and Post-operative Dynamics of the GH-IGF-1 Axis in Subjects With Acromegaly During the First Year After Surgical Resection||Cedars-Sinai Medical Center||Recruiting|June 2006|October 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Enrollment will include subjects diagnosed with acromegaly caused by GH secreting adenomas        who undergo surgical treatment for their disease provided they meet all        inclusion/exclusion criteria.|December 2010|December 14, 2010|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921609||137549|
NCT00921882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-084|Is it Possible to Screen for Type 2 Diabetes at Day 2 in Gestational Diabetes Mellitus Patients Postpartum?|Is it Possible to Screen for Type 2 Diabetes at Day 2 Gestational Diabetes Mellitus Postpartum?|DG4|Université de Sherbrooke|No|Completed|June 2008|May 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Female|18 Years|45 Years|No|Non-Probability Sample|Women with gestational diabetes mellitus who delivered.|January 2016|January 4, 2016|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00921882||137528|
NCT00922181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kulasMWA1|Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer|Single-probe Microwave Ablation of Metastatic Liver Cancer is Highly Variable and Irreproducible|LiverMWA1|University Hospital, Gasthuisberg|No|Completed|August 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|90 Years|No|||November 2009|November 13, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00922181||137505|
NCT00922493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250525|Inspiratory Muscle Training in Weaning|Weaning Process in Elderly Intubated Patients Submitted to Inspiratory Muscle Training|IMT|Euro-American Network of Human Kinetics|No|Completed|December 2007|November 2008|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|||||||Both|60 Years|90 Years|No|||June 2009|June 17, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922493||137482|
NCT00922792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7128-3700|Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B|An Open, Non-Randomised Single and Multiple Dose Trial Investigating the Safety and Pharmacokinetics of Intravenous Administration of Long Acting rFVIIa (LA-rFVIIa) in Patients With Haemophilia A and B||Novo Nordisk A/S|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|55 Years|No|||November 2011|July 4, 2012|June 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00922792||137459|
NCT00923091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS8635-A-E302|Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension|Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension||Daiichi Sankyo Inc.|No|Completed|June 2009|March 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|2689|||Both|18 Years|N/A|No|||April 2012|April 6, 2012|June 16, 2009|Yes|Yes||No|January 30, 2012|https://clinicaltrials.gov/show/NCT00923091||137436|
NCT00902941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-Olfact-035|Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline|Reversibility of Olfactory Loss in Patients With Idiopathic Parkinson's Disease Following Treatment With Rasagiline||Technische Universität Dresden|Yes|Completed|May 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|64 Years|No|||February 2012|February 6, 2012|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902941||138964|
NCT00902954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHBCC0701|Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer|A Randomized Trial, Phase IIIb, Open Label Study of Exemestane After Two to Three Years of Anastrozole/Letrozole Treatment of Postmenopausal Women With Hormone Receptor Positive Breast Cancer|LEANEX|Fudan University|No|Recruiting|March 2008|June 2011|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Female|N/A|N/A|No|||May 2009|May 14, 2009|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902954||138963|
NCT00904345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2009.009|Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)|Phase II Study of RT Concurrent w/ Cetuximab in Patients w/ Locally Advanced Head & Neck SCC Who Do Not Qualify For Standard Chemotherapy Due To Age >70 Or Co-Morbidities||University of Michigan Cancer Center|Yes|Recruiting|February 2009|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|70 Years|N/A|No|||March 2016|March 17, 2016|May 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904345||138861|
NCT00904644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCS Project No 564|Raltegravir in the Swiss HIV Cohort Study|Raltegravir Use in the Swiss HIV Cohort Study (SHCS) - Evaluation of Efficacy, Safety, Plasma Levels and Evolution of Resistance||University of Zurich|No|Recruiting|April 2008|April 2012|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|200|Samples With DNA|Within the framework of the Swiss HIV Cohort Study samples are taken of all patients      regularly every 6 months. Plasma and frozen cells (www.shcs.ch)|Both|18 Years|N/A|No|Non-Probability Sample|The Swiss HIV Cohort study is a nationwide observational cohort existing for more than 20        years and is representative of the HIV-infected population in Switzerland (approx. 50% of        HIV-infected patients in Switzerland, participate in this study). All patients must sign        an informed consent to participate in this study.        The study population enrolled in the current "Raltegravir in the SHCS" study, is a        subgroup of patients, that has to go on Raltegravir within the Swiss HIV Cohort study.|May 2009|May 19, 2009|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904644||138838|
NCT00904657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1127|An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers|An Open-label One-way Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers||University of Cologne|Yes|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 3, 2009|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904657||138837|
NCT00911612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007454|Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?|A Phase IIB Study to Evaluate the Effects of Welchol (Colesevelam Hydrochloride) on Colonic Transit, Intestinal Permeability and Bowel Function in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)|welchol|Mayo Clinic|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||March 2012|March 29, 2012|May 29, 2009||No||No|February 10, 2012|https://clinicaltrials.gov/show/NCT00911612||138311|
NCT00911378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|weaning2009|Pressure Support Reduction Versus Spontaneous Breathing Trials in Weaning From Ventilation|A Randomized Controlled Trial on Weaning by Pressure Support Reduction Versus Spontaneous Breathing Trials in a Respiratory ICU||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|April 2008|September 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|130|||Both|10 Years|70 Years|No|||June 2009|June 19, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911378||138329|
NCT00911625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201463|Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency|Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency||Loyola University|No|Completed|May 2009|September 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||September 2015|September 20, 2015|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911625||138310|
NCT00912132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909152|The National Standard for Normal Fetal Growth|The National Standard for Normal Fetal Growth||National Institutes of Health Clinical Center (CC)||Completed|May 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3000|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|September 9, 2015|May 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00912132||138272|
NCT00912145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-35-11034|To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg|Bioavailability of Alprazolam Tablets, 2 mg.||Sandoz||Completed|February 1996|February 1996|Actual|February 1996|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|19 Years|49 Years|Accepts Healthy Volunteers|||June 2009|June 2, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912145||138271|
NCT00912158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RICU, Assiut University 1|Non Invasive Mechanical Ventilation in Acute Cardiogenic Pulmonary Edema|CPAP Versus BiPAP in Acute Cardiogenic Pulmonary Edema: Experience With 129 Patients||Assiut University|No|Completed|October 2003|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|129|||Both|18 Years|N/A|No|||August 2009|August 17, 2009|April 8, 2009||No||No|April 8, 2009|https://clinicaltrials.gov/show/NCT00912158||138270|
NCT00912743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9010C00008|Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status|A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status||AstraZeneca||Completed|May 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912743||138225|
NCT00914498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xylocaine CS Scar.CTIL|The Effect of Pre-incisional Local Xylocaine Injection on Post Operative Pain and Scar Formation After Cesarean Section|The Effect of Pre-incisional Local Xylocaine Injection on Post Operative Pain and Scar Formation After Cesarean Section||The Baruch Padeh Medical Center, Poriya|No|Recruiting|July 2009|||December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|45 Years|No|||August 2009|August 23, 2009|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914498||138091|
NCT00912756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOP-IC|Sufficient Treatment of Peripheral Intervention by Cilostazol|Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment|STOP-IC|Kansai Rosai Hospital|Yes|Recruiting|March 2009|September 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|20 Years|N/A|No|||July 2010|July 21, 2010|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912756||138224|
NCT00921388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-097-2|Exercise or Relaxation for Smoking Cessation|Exercise for Smoking Cessation in Postmenopausal Women||University of Connecticut Health Center|Yes|Active, not recruiting|March 2009|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|364|||Female|45 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921388||137566|
NCT00921622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-041|Vitamin Deficiency and Blood Pressure in Hospitalized Jewish General Hospital (JGH) Patients|Vitamin Deficiency and Blood Pressure in Hospitalized JGH Patients||Jewish General Hospital|No|Completed|June 2009|June 2011|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921622||137548|
NCT00921895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-003|A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis|A Comparison of the Sensitivity and Specificity of the RPS Adeno Detector IV™ at Detecting the Presence of Adenovirus to Viral Cell Culture.||Rapid Pathogen Screening|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|128|||Both|1 Year|N/A|No|||October 2015|October 26, 2015|June 14, 2009|Yes|Yes||No|August 22, 2012|https://clinicaltrials.gov/show/NCT00921895||137527|
NCT00922194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arsircar|Metformin in Overweight Type 2 Diabetes Mellitus|Metformin Monotherapy Significantly Improves Anthropometric and Glycemic Values in Overweight Type 2 Diabetes Mellitus: One Year or More Prospective Study.||Era's Lucknow Medical College|Yes|Completed|February 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|30 Years|70 Years|No|||July 2009|March 15, 2010|February 17, 2009||No||No|February 17, 2009|https://clinicaltrials.gov/show/NCT00922194||137504|
NCT00922506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-092|Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)|Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study"||Samsung Medical Center|No|Recruiting|May 2009|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Male|50 Years|80 Years|No|||January 2014|February 12, 2015|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922506||137481|
NCT00903500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/380|Controlled Outcome Evaluations of a Daily Physical Activity Intervention for Individuals With Type 2 Diabetes|Controlled Outcome Evaluations of a Daily Physical Activity Intervention for Individuals With Type 2 Diabetes||University Ghent|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|92|||Both|35 Years|75 Years|No|||May 2009|May 18, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903500||138924|
NCT00903773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016123|VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.|A Phase I Open-label Trial to Investigate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Telaprevir.||Tibotec BVBA||Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2010|December 16, 2010|May 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00903773||138904|
NCT00904358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si183/2009|Estimation of Internal Jugular Vein Central Venous Pressure (CVP) by Ultrasound|Validity and Reliability of Non-invasive Estimation of Central Venous Pressure by Measurement of Internal Jugular Size Using 2-dimensional Ultrasound||Mahidol University|Yes|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled for cardiac surgery in Siriraj Hospital|July 2011|July 21, 2011|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00904358||138860|
NCT00904371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.585|Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients|Evaluation of the Effect of Telmisartan on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients||Boehringer Ingelheim||Completed|December 2009|||January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|211|||Both|18 Years|N/A|No|Probability Sample|patients with arterial hypertension with moderate to very high cardiovascular risk|August 2012|August 16, 2012|May 18, 2009||||No|June 27, 2012|https://clinicaltrials.gov/show/NCT00904371||138859|
NCT00911352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/043|Cryotherapy Intervention for Docetaxel-induced Nail Toxicities|Nurse-initiated Cryotherapy Intervention for Docetaxel-induced Nail Toxicities: Case-control Study||Princess Alexandra Hospital, Brisbane, Australia|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911352||138331|
NCT00911365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0137|Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy|A Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy||Yonsei University||Completed|May 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|N/A|75 Years|No|||July 2011|August 2, 2011|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00911365||138330|
NCT00911638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHRI-2006724|Comparison of Ways to Prepare Patients for Decisions About Joint Replacement Surgery|Are Patient Decision Aids for Total Joint Replacement Cost-effective and do They Optimize the Surgical Referral Process From Primary Care?||Ottawa Hospital Research Institute|No|Active, not recruiting|May 2008|January 2016|Anticipated|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|340|||Both|N/A|N/A|No|||January 2015|February 8, 2015|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911638||138309|
NCT00912769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97025|Knee Muscle Force Recovery After Minimally Invasive Surgery (MIS) Total Knee Replacement (TKR)|Outcome and Benefit After Total Knee Arthroplasty: Natural History of Muscle Power Recovery and Difference Between Different Surgical Approach|MISTKR|Far Eastern Memorial Hospital|Yes|Completed|October 2003|March 2004|Actual|March 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|30|||Both|50 Years|80 Years|No|Non-Probability Sample|Patients after total knee replacement without severe systemic disorders|June 2009|June 2, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912769||138223|
NCT00913016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG002|Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy|Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole (Femara) as an Early Adjuvant Treatment||Korean Breast Cancer Study Group|Yes|Active, not recruiting|June 2007|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|897|||Female|45 Years|N/A|No|Non-Probability Sample|Patients recruited into the study are postmenopausal women who had undergone surgery for        primary breast cancer which was either estrogen receptor(ER) and/or progesteron        receptor(PgR)-positive or of both.|December 2009|February 14, 2010|May 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00913016||138205|
NCT00911859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015901|A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients|A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma||Janssen Research & Development, LLC|Yes|Completed|June 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|118|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|May 29, 2009|Yes|Yes||No|September 11, 2014|https://clinicaltrials.gov/show/NCT00911859||138292|
NCT00911872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-ART|EVOLENCE® Assessment of Recovery Time and Impact of Dermal Filler Selection: The E-ART™ Study|EVOLENCE® Assessment of Recovery Time and Impact of Dermal Filler Selection: The E-ART™ Study||Solish, Nowell, M.D.|No|Completed|January 2008|August 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|June 1, 2009|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911872||138291|
NCT00912171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/2007/O/Sper|Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children|Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children|SB-OSAS|University of Bologna|Yes|Completed|January 2009|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|2 Years|10 Years|No|||February 2013|February 14, 2013|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912171||138269|
NCT00914758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WNRG02|Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)|Comparison of Alemtuzumab (Campath®) and High Dose Interferon Beta-1a (Rebif®) Treatment on Cognition in Subjects With Relapsing Forms of MS||Washington Neuropsychology Research Group|No|Enrolling by invitation|March 2009|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1|||Both|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample diagnosed with relapsing remitting multiple sclerosis|June 2009|June 4, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914758||138071|
NCT00921141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI|Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports|Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports : Cohort and Prospective Study|CCI|Centre Oscar Lambret|No|Completed|May 2006|April 2009|Actual|April 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|815|||Both|18 Years|N/A|No|Non-Probability Sample|All the patients requiring the implementation of a catheter in an anticancerous center|July 2012|July 20, 2012|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921141||137585|
NCT00921154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO2704|Ivermectin Solution Bioequivalence Study - Fasted|A Single-dose, Randomised, Crossover Study to Compare the Rate and Extent of Absorption of Two Formulations of Ivermectin in Healthy, Fasting Male and Female Volunteers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2005|September 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921154||137584|
NCT00921401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662|Improving the Quality of Asthma Care Using the Internet|Improving the Quality of Asthma Care Using the Internet||Milton S. Hershey Medical Center|No|Completed|August 2009|February 2013|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|408|||Both|21 Years|60 Years|No|||May 2013|May 6, 2013|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921401||137565|
NCT00921635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZGOG0401|A Study to Evaluate the Impact of Maintaining Hemoglobin Levels in Anemic Patients With Carcinoma of the Cervix|A Phase III Study to Evaluate the Impact of Maintaining Haemoglobin Levels Above 120g/L Verses Above 100g/L in Anaemic Patients With Carcinoma of the Cervix Receiving Concurrent Cisplatin and Radiation Therapy|HOSTT|Tri-Service General Hospital|Yes|Suspended|April 2008|||May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2|||Female|18 Years|N/A|No|||June 2009|June 18, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921635||137547|
NCT00921648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080301|Clinical Findings in General Paresis|Xijing HOSPITAL, Fourth Military Medical University, China||Xijing Hospital|Yes|Completed|April 2008|January 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||5|Actual|6|||Both|30 Years|60 Years|No|Non-Probability Sample|6 cases|June 2009|June 15, 2009|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00921648||137546|
NCT00921908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-028|Multihole or Epidural Catheter for Local Anesthetic in the Wound|Multihole or Epidural Catheter for Local Anesthetic in the Wound||Hvidovre University Hospital|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|16|||Both|N/A|N/A|No|Non-Probability Sample|patients undergoing total hip arthoplasty|June 2009|June 16, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00921908||137526|
NCT00921921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAW002|Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?|Does Extra-fine HFA-BDP Suppress Small Airways Inflammation in COPD?||University of Dundee|No|Completed|June 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|40 Years|N/A|No|||June 2012|June 11, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00921921||137525|
NCT00922207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21827|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B|A Randomized, Open-label Study of the Effect of Peginterferon Alfa-2a (40KD)(PEGASYS) in Combination With Adefovir or Entecavir on HBeAg Seroconversion in Patients With HBeAg Positive Chronic Hepatitis B||Hoffmann-La Roche||Completed|May 2010|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|280|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|June 16, 2009||No||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00922207||137503|
NCT00922220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|343-2004|A Study of a Potential Mechanisms of Spinal Manipulation in the Treatment of Low Back Pain|Immediate Effect of Physical Interventions for Low Back Pain||University of Florida|No|Completed|October 2004|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2009|December 21, 2011|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922220||137502|
NCT00904072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080306OR|Integrated Novel Clinical Decision Support System (CDSS) in a Computerized Physician Order Entry System|Integrated a Novel Clinical Decision Support System (CDSS) in a Computerized Physician Order Entry System||National Taiwan University Hospital|No|Recruiting|February 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50000|||Both|N/A|N/A|No|Non-Probability Sample|The prescriptions which induced the alert windows pop out.|May 2009|May 18, 2009|May 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00904072||138881|
NCT00910338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-06-075|Efficacy and Safety of Extracorporeal Biofeedback|Efficacy and Safety of Extracorporeal Biofeedback Pelvic Floor Muscle Training to Treat Urodynamic Stress Incontinence||Samsung Medical Center|No|Completed|July 2007|December 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||April 2011|April 21, 2011|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910338||138409|
NCT00910624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05514|Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)|A Single-Arm Study to Provide Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies|PROVIDE|Merck Sharp & Dohme Corp.|Yes|Completed|June 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|May 28, 2009|No|Yes||No|September 18, 2013|https://clinicaltrials.gov/show/NCT00910624||138387|
NCT00910637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91555|Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles|Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects||Bayer|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1502|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 6, 2013|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910637||138386|
NCT00910650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001212|Study of Gene Modified Immune Cells in Patients With Advanced Melanoma|Adoptive Transfer of MART-1 F5 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of MART-126•35-Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Melanoma|F5|Jonsson Comprehensive Cancer Center|Yes|Recruiting|October 2009|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00910650||138385|
NCT00910988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0540|Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone|A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers||Washington University School of Medicine|No|Completed|February 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|46|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|February 3, 2009||No||No|April 11, 2013|https://clinicaltrials.gov/show/NCT00910988||138359|
NCT00910663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-983-AU|Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Mycophenolate Mofetil Capsules Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|October 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 28, 2010|May 28, 2009|No|Yes||No|June 1, 2009|https://clinicaltrials.gov/show/NCT00910663||138384|
NCT00911001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14343|SALTO - Epidemiological Study on Compliance and Treatment Satisfaction|Compliance and Treatment Satisfaction in Prophylaxis of Postsurgical Thromboembolism|SALTO|Bayer|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|480|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in antithrombotic prophylaxis treatment after total knee/hip replacement|September 2013|September 18, 2013|May 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00911001||138358|
NCT00911014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSD08-00564|Access to Healthcare, Patient Comprehension and Future Plans of Women Undergoing Surgery for a Vesicovaginal Fistula in Niamey, Niger|Access to Healthcare, Patient Comprehension and Future Plans of Women Undergoing Surgery for a Vesicovaginal Fistula in Niamey, Niger||Ascher-Walsh, Charles, M.D.|Yes|Completed|September 2005|January 2006|Actual|January 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|58|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who underwent surgery for repair of vesciovaginal fistula in Niamey, Niger|May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911014||138357|
NCT00911924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Synergy|A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma|A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma|SY|Glaukos Corporation|Yes|Completed|May 2009|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00911924||138287|
NCT00911937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221048|A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency.||Pfizer|No|Completed|August 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|963|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|June 1, 2009|Yes|Yes||No|July 9, 2012|https://clinicaltrials.gov/show/NCT00911937||138286|
NCT00913029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Second Line|Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)|A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma|SL|Glaukos Corporation|Yes|Completed|May 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00913029||138204|
NCT00913328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINGDEN-04-2002|Effect of Add-on Montelukast to Inhaled Corticosteroids on Airway Responsiveness|Effect of Add-on Montelukast to Inhaled Corticosteroids in Excessive Airway Narrowing in Adults With Asthma|SINGDEN|Hvidovre University Hospital|No|Completed|August 2002|October 2006|Actual|May 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|50 Years|No|||June 2009|June 3, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913328||138181|
NCT00913302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|746|Effects of Cardiovascular Training in Individuals With Ankylosing Spondylitis|Effects of Cardiovascular Training on Fitness, Cardiovascular Health, Bone Health and Quality of Life in Individuals With Ankylosing Spondylitis||University of Zurich|Yes|Completed|January 2008|November 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|106|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 4, 2013|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00913302||138183|
NCT00913315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQU023|Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis|Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms|ESTTFCP|Chongqing Medical University|Yes|Not yet recruiting|August 2009|January 2010|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|45 Years|No|||June 2009|June 4, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913315||138182|
NCT00914225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35464-B|Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya|Effect of Long-lasting Insecticide-treated Bednets and a Point-of-use Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya|ITN|University of Washington|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|500|Samples With DNA|Plasma HIV RNA Plasma for Malaria PCR|Both|18 Years|N/A|No|Non-Probability Sample|The study will compare markers of HIV disease progression among ART naive individuals        receiving LLIN and a simple microbiological water purification system to the control arm        of the randomized controlled trial being conducted at the same clinic settings        (NCT00507221).|May 2015|May 27, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00914225||138112|
NCT00913601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Treatment of Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Stimulation Bilaterally?|Treatment of Idiopathic Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Implantation and Stimulation of Permanent Electrodes Bilaterally - a Double-blinded Randomized Cross-over Trial|SNS|University of Aarhus|Yes|Terminated|May 2009|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|June 2, 2009||No|Prematurely stopped, as no beneficial effect was evident for bilateral stimulation after    interim analysis of the first 20 patients.|No||https://clinicaltrials.gov/show/NCT00913601||138160|
NCT00913614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD10491|Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia|Single Dose, Open Label Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Eplivanserin Doses in Children Aged 6-17 Years With Insomnia of Various Origins|PKiDs|Sanofi|Yes|Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|41|||Both|6 Years|17 Years|No|||November 2010|November 29, 2010|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913614||138159|
NCT00913640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0203|Prospective Memory in Parkinson's Disease|Prospective Memory in Parkinson's Disease|ProMem|Washington University School of Medicine|No|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Movement Disorder Clinic at Washington University St. Louis|July 2009|July 14, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00913640||138157|
NCT00921661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD10794|Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer|A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer||Sanofi|No|Completed|June 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|N/A|No|||November 2012|November 8, 2012|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921661||137545|
NCT00921934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168 A 08 VC|Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles|PASCORBIN 7.5g in the Treatment of Viral Infection, Especially Varicella Zoster Infection: An Observational Cohort Study|168|Pascoe Pharmazeutische Praeparate GmbH|No|Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|68|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort of adult patients suffering from acute viral infections, especially herpes zoster,        presenting themselves in Primary Care Centers or hospitals all over Germany.|August 2012|September 25, 2012|June 16, 2009||No||No|August 1, 2012|https://clinicaltrials.gov/show/NCT00921934||137524|
NCT00921947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX102-09|Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults|A Phase II, Randomized, Open-Label Study to Evaluate the Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) in Healthy Adults||VaxInnate Corporation|No|Completed|June 2009|August 2009|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|June 15, 2009|Yes|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00921947||137523|
NCT00922233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10139|Pericoital Oral Contraception With Levonorgestrel|Pericoital Oral Contraception With Levonorgestrel: A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Acceptability||FHI 360|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|72|||Female|N/A|45 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|June 10, 2009|Yes|Yes||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00922233||137501|
NCT00922246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55555|Insoles in Prevention of Lower Limb Injuries|Prevention of Lower Limb Overuse Injuries by Using Custom Made Insoles: A Randomized Controlled Trial of 230 Patients||Finnish Defense Forces|No|Completed|January 2007|May 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Male|18 Years|29 Years||||June 2009|June 16, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922246||137500|
NCT00922532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-3001-HRF-301|Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure|Inhaled Nitric Oxide For The Treatment Of Hypoxic Respiratory Failure With Pulmonary Hypertension In Preterm Infants||INO Therapeutics||Withdrawn|November 2009|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|48 Hours|No|||April 2015|April 3, 2015|June 16, 2009|Yes|Yes|Company decision not to pursue prior to submission|No||https://clinicaltrials.gov/show/NCT00922532||137479|
NCT00922818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-05-VA02|Study of Anatomic Nerve Sparing Radical Perineal Prostatectomy|Clinical Outcomes for Anatomic Nerve Sparing Radical Perineal Prostatectomy|RPP|Maimonides Medical Center|No|Recruiting|June 2009|June 2012|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Male|18 Years|N/A|No|Non-Probability Sample|Patients undergoing anatomic perineal prostatectomy at Maimonides Medical Center|May 2009|June 16, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922818||137457|
NCT00910351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12759|Cipro Inhaler for Cystic Fibrosis Children Ages 6-12|A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin in Adults and Children Aged 6 - 12 Years With Cystic Fibrosis Following Inhalation of Ciprofloxacin Dry Powder||Bayer|Yes|Completed|July 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|6 Years|12 Years|No|||November 2013|November 20, 2013|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00910351||138408|
NCT00910364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14181|Feasibility Study of Exercise in Patients With Leg Blood Clots|EXPERT Trial: Exercise to Prevent Post-thrombotic Syndrome Elicited by Recent Thrombosis|EXPERT|University of Oklahoma|Yes|Active, not recruiting|October 2008|December 2014|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910364||138407|
NCT00910676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-002913-38|Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors|Phase II Multicentric Study About Preventive Treatment of Folliculitis Induced by the EGF-R Inhibitors in Patients With Metastatic Colorectal Cancer and Treated by Cetuximab or With Non-small-cell Lung Carcinoma Treated by Erlotinib|DIPROCOL|Centre Oscar Lambret|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910676||138383|
NCT00911391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDFT RCT|Randomised Trial of Doppler-Optimised Fluid Balance in Elective Colectomy|Prospective, Double-Blinded, Randomised Controlled Trial of Doppler-Optimised Fluid Balance in Elective Colectomy Within an ERAS Protocol||University of Auckland, New Zealand|No|Completed|November 2009|October 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|90 Years|No|||November 2011|November 25, 2011|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911391||138328|
NCT00912470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-020706|Progressive Open Angle Glaucoma (OAG) and Ocular Blood Flow|Genetic Vascular Risk Factors and Ocular Blood Flow in Patients With Progressive Open Angle Glaucoma (OAG)-a Longitudinal Prospective Study||Medical University of Vienna|Yes|Withdrawn|May 2007|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|40 Years|N/A|No|||November 2014|November 20, 2014|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912470||138246|
NCT00912483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPBLA0409|Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients|Efficacy of Sodium Heparin 5.000 UI/0.25 mL (Blausiegel) Compared With Heparin Sodium 5.000 USP (APP Pharmaceuticals)for Venous Thromboembolism Prophylaxis In Surgical Patients With Medium Risk For The Thromboembolism Development||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Withdrawn|May 2010|January 2011|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912483||138245|
NCT00912496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0013|Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59|Phase I Randomized Study of the Safety, Dose Escalation, and Immunogenicity of Adjuvanted Influenza A/Anhui/05 Boosting in Subjects Previously Immunized With One or Two Doses of A/Vietnam/1203/04 or in Unprimed Individuals and Compared to Placebo||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|637|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2011|May 10, 2013|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912496||138244|
NCT00912795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISK-NIH-FIC7918|SMS Turkey: Harnessing the Power of Text Messaging to Promote Smoking Cessation|SMS Turkey: Harnessing the Power of TXT Messaging to Promote Smoking Cessation|SMS Turkey|Center for Innovative Public Health Research|No|Completed|January 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|151|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 31, 2012|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00912795||138221|
NCT00913341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9153A|To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg|Bioavailability of Alprazolam Tablets||Sandoz||Completed|November 1991|November 1991|Actual|November 1991|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913341||138180|
NCT00913042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 06021|Assessment of New Blood Culture Methods on the Microbiological Documentation of Febrile Neutropenia|Assessment of New Blood Culture Methods on the Microbiological Documentation of Febrile Neutropenia|HEMATOCPLUS|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|Samples With DNA|bacterial inoculum in the blood|Both|18 Years|N/A|No|Non-Probability Sample|Febrile neutropenia post-chemotherapy|April 2009|July 25, 2012|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913042||138203|
NCT00913354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acupuncture001|Acupuncture Versus Placebo Acupuncture During In Vitro Fertilization (IVF) Embryo Transfer|Acupuncture Versus Placebo Acupuncture During Ivf Embryo Transfer||Rigshospitalet, Denmark|No|Completed|November 2005|March 2009|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|635|||Female|18 Years|37 Years|No|||November 2005|June 3, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913354||138179|
NCT00913627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK-09-07|Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain|Ibuprofen 600 mg Extended Release (ER) Single-Dose Dental Pain Study||Pfizer|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|196|||Both|16 Years|40 Years|No|||November 2012|November 9, 2012|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00913627||138158|
NCT00913653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2117|Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure|An Open Label, Non-randomised Study to Explore Safety/Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure||Novartis||Completed|May 2009|||July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913653||138156|
NCT00913991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003315-01|Mechanisms of the Relaxation Response in Elderly Hypertensives|Mechanisms of the Relaxation Response in Elderly Hypertensives||National Center for Complementary and Integrative Health (NCCIH)|Yes|Recruiting|March 2009|December 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|90|||Both|55 Years|N/A|No|||February 2010|February 24, 2010|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913991||138130|
NCT00952432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008WFCRC-07|Compare the Efficacy of Acupuncture Therapy and Carbamazepine Oral Dosage in Patients With Carpal Tunnel Syndrome by Multiple Excitability Test|A Single-center, Prospective, Randomized, Positive Controlled, Parallel Design Trial to Compare the Efficacy of Acupuncture Therapy and Carbamazepine Oral Dosage in Patients With Carpal Tunnel Syndrome by Multiple Excitability Test||Taipei Medical University WanFang Hospital|No|Recruiting|May 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|N/A|No|||April 2011|April 11, 2011|August 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00952432||135207|
NCT00952692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016847|Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer|A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab||Duke University|No|Completed|July 2009|April 2012|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00952692||135187|
NCT00952705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP206|A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age|A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age|MI-CP206|MedImmune LLC|Yes|Completed|August 2009|March 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1800|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2011|December 9, 2011|August 3, 2009|Yes|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT00952705||135186|
NCT00952978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Livzon-IY-81149-03|Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)|Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China||Livzon Pharmaceutical Group Inc.|Yes|Completed|September 2005|May 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|496|||Both|18 Years|65 Years|No|||August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00952978||135166|
NCT00953290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCS002|Thigh Circumference Reduction Study|Cutera Radio Frequency Device for Thigh Circumference Reduction||Cutera Inc.|No|Terminated|January 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|70 Years|No|||May 2011|May 6, 2011|August 4, 2009|Yes|Yes|The study was terminated because the preliminary data did not indicate efficacy.|No|February 17, 2011|https://clinicaltrials.gov/show/NCT00953290||135145|Early termination of the study resulting in analysis of small numbers of subjects, and technical issues with repeatability and reproducibility of circumference measurements leading to termination.
NCT00953511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK-09-118|Cologne Esophageal Response Prediction Study (CERP-Study)|Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer|CERP|University of Cologne|Yes|Recruiting|August 2009|August 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00953511||135128|
NCT00953524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUF14|A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly|Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects||Sanofi|No|Completed|August 2009|December 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|849|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 6, 2014|August 3, 2009|Yes|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT00953524||135127|
NCT00910689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2RO1NS32374|Drug and Non-Drug Treatment Of Severe Migraine|Drug and Non-Drug Treatment of Severe Migraine|TSM|Ohio University|No|Completed|July 2001|November 2005|Actual|November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|232|||Both|18 Years|65 Years|No|||June 2009|June 4, 2009|November 24, 2008|Yes|Yes||No|November 24, 2008|https://clinicaltrials.gov/show/NCT00910689||138382|No side effect reached the 5% reporting threshold at either the Month 10 or the Month 16 assessment.
NCT00911027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR1-127|SonoVue Guided Prostate Biopsy|A Phase III Study to Compare SonoVue Guided Prostate Biopsy With Systematic Biopsy in the Detection of Prostate Malignant Lesions in Patients With Suspected Prostate Cancer||Bracco Diagnostics, Inc|No|Terminated|February 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|282|||Male|40 Years|N/A|No|||April 2012|April 24, 2012|May 7, 2009||No|Failure to meet primary objective|No||https://clinicaltrials.gov/show/NCT00911027||138356|
NCT00911040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2009|||||N/A|N/A|N/A||||||||||||||September 24, 2010|May 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911040||138355|
NCT00912197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1243|Effect of Oligofructose on Appetite in Overweight Subjects|Effect of Oligofructose on Appetite, Gut Hormones and Body Composition in Healthy Overweight Subjects||Imperial College London|Yes|Completed|June 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|22|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 22, 2011|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912197||138267|
NCT00912210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC IRB 07782|Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women|Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women||University of Illinois at Urbana-Champaign|No|Completed|April 2009|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|31|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||May 2009|May 29, 2009|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912210||138266|
NCT00912223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0701|Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)|A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN #0701)||Medical College of Wisconsin|Yes|Active, not recruiting|April 2009|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|1 Year|75 Years|No|||January 2016|January 11, 2016|June 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912223||138265|
NCT00912509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0143|Cross Linking for Treatment of Corneal Infection|A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis||Price Vision Group|Yes|Terminated|May 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|14 Years|N/A|No|||August 2014|August 21, 2014|May 30, 2009|No|Yes|insufficient efficacy|No|August 4, 2014|https://clinicaltrials.gov/show/NCT00912509||138243|
NCT00912522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0116-09-HMO-CTIL|Magnetic Prefrontal Stimulation for Studying the Role of the Cortex in High-level Cognition Processes and Reward System|Magnetic Prefrontal Stimulation for Studying the Role of the Cortex in High-level Cognition Processes and Reward System||Hadassah Medical Organization|No|Completed|June 2009|June 2014|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|91|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912522||138242|
NCT00912535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00026|Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms|Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms||Chang Gung Memorial Hospital||Completed|May 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|65 Years|No|||January 2012|January 3, 2012|May 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00912535||138241|
NCT00912808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e1784|Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease|A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's||Oregon Health and Science University|No|Completed|October 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|21 Years|N/A|No|||July 2011|July 20, 2011|June 2, 2009|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00912808||138220|Small number of subjects and lack of objective measurement to quantify falls. The most difficult condition to exclude was co-existing freezing of gait.
NCT00913367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HANDOK2008.10|Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus|A Multi-center, Open, Randomized, Parallel-group, 2 Arm Study to Compare the Efficacy and Safety of Amaryl®M 1/500mg Twice Daily Versus Amaryl® 4mg Both in Combination With Lantus® Once-daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control||Handok Pharmaceuticals Co., Ltd.|No|Completed|May 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|20 Years|N/A|No|||March 2013|March 26, 2013|May 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00913367||138178|
NCT00913666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-863|Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers|A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects||Biogen|No|Completed|November 2002|November 2004|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|121|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913666||138155|
NCT00914017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0407|Statins and Breast Cancer Biomarkers|Statins and Breast Cancer Biomarkers||University of Vermont|No|Recruiting|January 2005|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Female|35 Years|55 Years|No|||February 2010|February 10, 2010|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00914017||138128|
NCT00952718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRP-IRB-97-0458B|Effects of Inspiratory Muscle Training in Patients With Bronchiectasis|Effects of Inspiratory Muscle Training in Patients With Bronchiectasis||Chang Gung Memorial Hospital|No|Completed|January 2008|March 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|40 Years|80 Years|No|||August 2015|August 3, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00952718||135185|
NCT00952991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1721-04|The Effects of LAF237 on Gastric Function in Type 2 Diabetes|A Double Blind, Cross Over, Placebo Controlled, Multiple-dose Study to Evaluate the Effects of LAF237 on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes.||Mayo Clinic||Completed|May 2005|February 2006|Actual|February 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||18|||Both|35 Years|70 Years|No|||March 2011|March 22, 2011|August 4, 2009||||||https://clinicaltrials.gov/show/NCT00952991||135165|
NCT00953004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B245|Flax Mucilage and Apparent Nutrient Digestibility|Effect of Flaxseed and Flaxseed Mucilage on Energy Digestibility, Lipid Profile and Appetite|HØRFRØ|University of Copenhagen|No|Active, not recruiting|March 2009|December 2009|Anticipated|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2009|November 10, 2010|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00953004||135164|
NCT00953303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hebmu 08-12B|The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure|The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure||Hebei Medical University|Yes|Completed|January 2009|January 2012|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||February 2012|February 19, 2012|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00953303||135144|
NCT00953537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000638377|Predicting Response to Capecitabine in Women With Metastatic Breast Cancer|Multicentric Pilot Study of Dihydropyrimidine Dehydrogenase (DPD) Deficiency for Predicting Capecitabine Toxicity in Breast Cancer Patients||Centre Antoine Lacassagne||Completed|January 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|303|||Female|18 Years|N/A|No|||February 2015|February 8, 2015|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953537||135126|
NCT00954135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-006208-39|Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients|Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients||University of Turin, Italy|Yes|Active, not recruiting|September 2007|December 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Female|18 Years|N/A|No|||August 2009|August 6, 2009|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954135||135081|
NCT00953823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-031|The Prevalence of Thiamin Deficiency in Ambulatory Patients With Heart Failure|The Prevalence of Thiamin Deficiency in Ambulatory Patients With Heart Failure||St. Michael's Hospital, Toronto|No|Completed|May 2009|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|110|Samples Without DNA|Blood test|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiology Clinic (St Michael's Hospital)|December 2012|December 21, 2012|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953823||135104|
NCT00953836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/13/03/00/09|Plasma Pharmacokinetics of Alkylresorcinol Metabolites; New Candidate Biomarkers for Whole Grain Rye and Wheat Intake|Kinetic Study of Two Known Alkylresorcinol Metabolites in Human Subjects After the Intake of Rye Fiber, the Most Abundant Source of Alkylresorcinols in Diet.|Rye-kinetics|Helsinki University||Completed|March 2009|May 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy, free-living females and males|August 2009|August 5, 2009|August 5, 2009||||No||https://clinicaltrials.gov/show/NCT00953836||135103|
NCT00914706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEEAP-D0014a-2009-PTL|A Study of the Effect of a Chronic Disease Management System on Diabetes Care Within Multidisciplinary Primary Care Practices in Ontario|Challenging the Ontario Diabetes Care Quality Gap: Evaluation and Long-Term Cost-Utility Analysis of Using a Chronic Disease Management System (CDMS) in Primary Health Care Practices in Ontario (ODIAC-CDMS): A Prospective, Observational, Comparative Study of the Effect of a CDMS on Diabetes Care Within Multidisciplinary Primary Care Practices in Ontario.||St. Joseph's Healthcare Hamilton|No|Completed|June 2009|March 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The unit of evaluation or cluster for this study will be individual primary care        practitioners. The study will analyze aggregate practice level data from all rostered        diabetes patients within each practice. Between 33 and 61 primary care practitioners with        a total number of patients with diabetes across all practices of 2,376 from across Ontario        will be enrolled in the study.|May 2013|May 7, 2013|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00914706||138075|
NCT00914719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA013844-01|Alcohol Use and Sexual Risk: An Intervention|Alcohol Use and Sexual Risk: An Intervention||University of New Mexico||Completed|September 2002|August 2007|Actual|August 2007|Actual|N/A|Interventional|Intervention Model: Factorial Assignment, Primary Purpose: Prevention|3|||484|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||June 2009|June 4, 2009|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00914719||138074|
NCT00911417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC09030|A Study to Collect Intravascular Ultrasound Images Before and After Treatment With the Jetstream System|The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study||Pathway Medical Technologies Inc.|No|Completed|June 2009|August 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2011|September 2, 2011|May 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911417||138326|
NCT00911677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2004800-01H|Does APOE-e4 Predict Delirium and Cognitive Dysfunction After Surgery?|Does Apolipoprotein E Genotype Predict Delirium and Postoperative Cognitive Dysfunction?||Ottawa Hospital Research Institute|No|Completed|August 2005|May 2009|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|60 Years|N/A|No|Non-Probability Sample|Patients 60 years of age or greater undergoing open repair of the abdominal aorta at an        academic tertiary care hospital.|May 2009|May 29, 2009|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911677||138306|
NCT00912184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|High cut-off trial|Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure|Pilot Randomised Controlled Study Comparing The Effect of High Cut-off Point Haemofiltration With Standard Haemofiltration In Patients With Acute Renal Failure||Austin Health||Completed|May 2009|January 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||January 2012|January 26, 2012|June 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912184||138268|
NCT00911664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012867|Vitamin D Supplementation and CD4 Count in HIV-Infected Children|Vitamin D Supplementation and CD4 Count in HIV-Infected Children||The Hospital for Sick Children|No|Completed|February 2009|July 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Both|1 Year|18 Years|No|||June 2014|June 5, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911664||138307|
NCT00912236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-302|Evaluation of High-Density Lipoprotein in Obesity Study|Evaluation of High-Density Lipoprotein in Obesity Study||The Cleveland Clinic|No|Completed|June 2009|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|77|Samples Without DNA|Plasma and serum will be collected|Both|20 Years|80 Years|No|Non-Probability Sample|Study population will be selected from Cleveland Clinic outpatient departments|November 2012|November 29, 2012|May 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00912236||138264|
NCT00912249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098019-3|The Clinical Application of Horticulture Therapy in Psychiatric Rehabilitation|The Clinical Application of Horticulture Therapy in Psychiatric Rehabilitation||Far Eastern Memorial Hospital|No|Recruiting|April 2009|||December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|65 Years|No|||April 2009|June 2, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00912249||138263|
NCT00912548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG005|Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women|A Randomised Phase III Study for Evaluating the Role of the Addition of Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain in Premenopause or Regain Menstruation After Chemotherapy|ASTRRA|Korean Breast Cancer Study Group|Yes|Enrolling by invitation|May 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|1234|||Female|18 Years|45 Years|No|||June 2009|June 15, 2009|May 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00912548||138240|
NCT00912561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBF-Exercise|Effects of Intense Aerobic Exercise on the Cerebrovascular Reserve Capacity in Patients With Hemodynamically Relevant Intra- and Extracranial Stenoses|Effects of Intense Aerobic Exercise on the Cerebrovascular Reserve Capacity in Patients With Hemodynamically Relevant Intra- and Extracranial Stenoses|Exercise|Charite University, Berlin, Germany|No|Terminated|June 2009|December 2012|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2012|February 20, 2012|June 2, 2009||No|slow recruiting|No||https://clinicaltrials.gov/show/NCT00912561||138239|
NCT00912587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/119|Effect of Ghrelin on Sympathetic Nervous System|Effect of Ghrelin on Sympathetic Nervous System and Stress Reactivity||Baker IDI Heart and Diabetes Institute|No|Completed|June 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|46|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 19, 2011|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912587||138237|
NCT00912782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014859|Vitamin D and Arteriovenous Fistulae|Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients||Emory University|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|85 Years|No|||June 2014|June 2, 2014|June 1, 2009||No||No|November 2, 2013|https://clinicaltrials.gov/show/NCT00912782||138222|
NCT00913380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-LDCTinAPPY|Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT|Negative Appendectomy Rate Following Low-dose CT vs. Standard-dose CT||Seoul National University Bundang Hospital|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|891|||Both|15 Years|44 Years|No|||September 2011|September 2, 2011|May 15, 2009||No||No|June 27, 2011|https://clinicaltrials.gov/show/NCT00913380||138177|In this diagnostic trial, participants have a variety of abdominal diseases. Events with CTCAE v4 Grade 2 or less are not considered reportable according to the Study Protocol.
NCT00913393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-3019-032|Study of FG-3019 in Subjects With Type 2 DM and KD on ACEi and/or ARB Therapy|A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background ACEi and/or ARB Therapy||FibroGen|No|Terminated|February 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|34|||Both|18 Years|75 Years|No|||August 2012|August 30, 2012|June 2, 2009|Yes|Yes|Sub-optimal study design|No||https://clinicaltrials.gov/show/NCT00913393||138176|
NCT00913406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9041A1-902|Effect of Lutein in S-26 Gold On Growth And Safety|Effect of Lutein in S-26 Gold on Growth and Safety|S-26 Gold L|Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|November 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|232|||Both|N/A|14 Days|Accepts Healthy Volunteers|||June 2009|June 3, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00913406||138175|
NCT00913679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070082|A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty|A Comparison of Two Different Surgical Techniques to Preserve the Bony Supply and Improve Implant Longevity in Hip Resurfacing Arthroplasty||University of Aarhus|Yes|Recruiting|November 2008|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|60 Years|No|||November 2011|November 3, 2011|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913679||138154|
NCT00914004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8718-D|To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets|A Two-Way Crossover Bioequivalency Study Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets||Sandoz||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00914004||138129|
NCT00913692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090159|A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis|A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis||National Institutes of Health Clinical Center (CC)|Yes|Terminated|June 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|65 Years|No|||May 2012|May 3, 2012|June 3, 2009|No|Yes|Terminated due to slow recruitment.|No|February 29, 2012|https://clinicaltrials.gov/show/NCT00913692||138153|The protocol was terminated early due to slow recruitment.
NCT00913705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATCH - GECP 99/02|Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer|Randomized Trial of Surgery With or Without Paclitaxel Plus Carboplatin as Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable, Non-small-cell Lung Cancer|NATCH|Spanish Lung Cancer Group|Yes|Completed|September 1999|June 2009|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|624|||Both|18 Years|N/A|No|||June 2011|June 10, 2011|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913705||138152|
NCT00953316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X08-03-0176|Infant Transition From Car Bed to Car Safety Seat|A Prospective Examination of Infant Transition From Car Bed to Car Safety Seat||Children's Hospital Boston|No|Active, not recruiting|April 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|N/A|1 Year|No|Non-Probability Sample|At-risk infants, including all children born at less than 37 weeks gestation and other        high risk newborns such as those with a history of breathing problems and/or low tone.|August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953316||135143|
NCT00953550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-RSI-SU|Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine|Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine||Rigshospitalet, Denmark|Yes|Completed|September 2009|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|60 Years|No|||December 2010|March 1, 2011|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953550||135125|
NCT00953563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U0802|The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers|The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers||Synovis Surgical Innovations|No|Withdrawn|March 2009|||July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2011|December 12, 2012|July 24, 2009||No|Budgetary|No||https://clinicaltrials.gov/show/NCT00953563||135124|
NCT00953849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-003-09S|Vitamin D - Celecoxib Therapy|Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity||VA Office of Research and Development|Yes|Completed|November 2009|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|26|||Both|18 Years|85 Years|No|||January 2016|January 4, 2016|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953849||135102|
NCT00954148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-017|Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors|Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors||Dallas VA Medical Center|No|Terminated|September 2009|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|53|||Both|18 Years|90 Years|No|||May 2010|June 29, 2010|August 5, 2009||No|1st years Enrollment #s showed study was not going to meet criteria randomization.|No||https://clinicaltrials.gov/show/NCT00954148||135080|
NCT00954967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08/90345|Trial for Tobacco Cessation With Intensive Advice in Diabetic Patients: the ITADI Project|Community Intervention Trial for Smoking Cessation With Intensive Advice in Diabetic Patients in Primary Health Care|ITADI|Jordi Gol i Gurina Foundation|Yes|Not yet recruiting|September 2009|September 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|546|||Both|14 Years|N/A|No|||August 2009|August 6, 2009|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954967||135018|
NCT00910377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-389|Adolescent Mothers, Grandmothers, Breastfeeding and Complementary Feeding|Effect of Intervention About Breastfeeding and Complementary Feeding in Adolescent Mothers and Their Grandmothers||Hospital de Clinicas de Porto Alegre|Yes|Completed|May 2006|January 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|344|||Female|12 Years|19 Years|No|||May 2009|May 28, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910377||138406|
NCT00910390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITR-1-EMBRYOS|Comparison Between Three Freezing Protocols to Preserve Human Embryos|Randomized Comparison to Freeze Human Embryos by Either Vitrification or Slow Freezing Protocols||Erasme University Hospital|No|Recruiting|April 2009|May 2011|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|400|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||May 2009|July 7, 2010|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910390||138405|
NCT00911885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13075|A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome|A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome|CANDO|University of Massachusetts, Worcester|Yes|Completed|April 2009|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|21 Years|70 Years|No|||March 2015|March 16, 2015|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00911885||138290|
NCT00911898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-111-01-100|A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers|A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers|Monotherapy|Merrimack Pharmaceuticals|No|Completed|June 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|June 2, 2009|No|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT00911898||138289|
NCT00911911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAM 2006-10|Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy|Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy|SPAM|Centre Oscar Lambret|No|Completed|January 2007|July 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|66|||Female|18 Years|N/A|No|||July 2012|July 30, 2012|May 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00911911||138288|
NCT00911066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15003|MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia|An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia||Millennium Pharmaceuticals, Inc.|No|Completed|June 2009|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00911066||138353|
NCT00911963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCH-222-102|Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection|A Phase l b/II a, Multicenter, Randomized, Double-Blinded, and Placebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C-Infection||Vertex Pharmaceuticals Incorporated|Yes|Completed|April 2009|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|65 Years|No|||February 2014|February 6, 2014|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911963||138285|
NCT00911690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-065|Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders|Establishment of a Bank of Biospecimens for the Evaluation of New Methods Facilitating Early Diagnosis and the Monitoring of Progression and Therapy of Patients With Age-related Cognitive Disorders.||William Beaumont Hospitals|No|Enrolling by invitation|July 2009|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|Serum, Plasma, human platelet, urine (clarified), urine sediment, saliva|Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be obtained from individuals seen by the physicians affiliated with the        Division of Geriatric Medicine at Beaumont Hospital in the Geriatric Clinic.|October 2015|October 27, 2015|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911690||138305|
NCT00912574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8380|Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38|Evaluation of the Effects of Local GM-CSF-in-Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes|MEL38|University of Virginia|No|Completed|June 2004|||July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|85 Years|No|||June 2009|June 2, 2009|June 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00912574||138238|
NCT00913055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-07-000|Open Label Study of Octreotide Implant in Patients With Acromegaly|An Open-Label Study to Evaluate the Pharmacokinetic and Pharmacodynamic Response of a Hydrated and Non-Hydrated 84mg Octreotide Implant in Patients With Acromegaly||Endo Pharmaceuticals|No|Completed|February 2007|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||July 2011|July 13, 2011|May 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00913055||138202|
NCT00913081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #808911|Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)|Advancing Niacin by Inhibiting FLUSHing: (ANTI-FLUSH)|ANTI-FLUSH|University of Pennsylvania|No|Completed|February 2009|December 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|17|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||November 2011|February 19, 2015|May 29, 2009||No||No|January 29, 2015|https://clinicaltrials.gov/show/NCT00913081||138200|
NCT00913419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9038A|To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets|Bioavailability of Cyclobenzaprine HCl Tablets||Sandoz||Completed|November 1988|December 1988|Actual|December 1988|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||June 2009|June 3, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00913419||138174|
NCT00913432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB06010|A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis|A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open Label, Uncontrolled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of AB1010 at 3 and 6 mg/kg/Day in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including Anti TNF Alpha if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Anti TNF Alpha||AB Science|Yes|Active, not recruiting|March 2007|December 2012|Anticipated|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00913432||138173|
NCT00913445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09060|Wound Healing After Emergency Appendicectomy|Wound Healing and Cosmetic Result After Emergency Appendicectomy in Adult Patients: a Prospective, Randomised Trial Comparing Two Methods of Wound Closure||Tampere University Hospital|No|Completed|July 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2010|June 10, 2010|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00913445||138172|
NCT00904228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052008-049|Plastic Hat Trial to Prevent Hypothermia in Preterm Newborns in the Delivery Room|Effectiveness of Plastic Lined Hats for Prevention of Hypothermia in Premature Newborns in the Delivery Room||University of Texas Southwestern Medical Center|No|Recruiting|September 2008|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|260|||Both|N/A|1 Hour|Accepts Healthy Volunteers|||June 2010|June 24, 2010|February 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00904228||138869|
NCT00904241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL00B1|Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma|Neuroblastoma Biology Studies||Children's Oncology Group|Yes|Recruiting|November 2000|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|frozen tumor tissue, diagnostic bone marrow, diagnostic blood|Both|N/A|30 Years|No|Non-Probability Sample|Patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected        ganglioneuroma/maturing subtype.|November 2015|November 12, 2015|May 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00904241||138868|
NCT00953576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-374|Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer|A Phase I/II Trial of Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Castration Resistant Prostate Cancer With Pre- and Post-therapy Tumor Biopsies|KHLAD|Dana-Farber Cancer Institute|Yes|Terminated|August 2009|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|18 Years|N/A|No|||December 2015|December 16, 2015|August 4, 2009|Yes|Yes|drug toxicity|No||https://clinicaltrials.gov/show/NCT00953576||135123|
NCT00953862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#12233|Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility|Efficacy of Atomoxetine in Adults With ADHD and Substance Abuse Disorder Being Treated in a Residential Treatment Facility||New York University School of Medicine|No|Completed|July 2005|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|60 Years|No|||March 2013|March 11, 2013|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953862||135101|
NCT00954161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51742|Bystander Helping Behaviour for Myocardial Infarction Following First Aid Training|Bystander Helping Behaviour for Acute Myocardial Infarction Following a First Aid Training Programme That Draws Attention to the Barriers to Providing Help - Protocol for a Randomized Controlled Trial||Katholieke Universiteit Leuven|No|Completed|September 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 2, 2011|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00954161||135079|
NCT00954733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00004382|A Comparison of the Detection of Hypoventilation During Deep Sedation Utilizing Nasal End Title CO@ Versus Transcutaneous CO2 Measurement Techniques|A Comparison of the Detection of Hypoventilation During Deep Sedation Utilizing Nasal End Title CO@ Versus Transcutaneous CO2 Measurement Techniques||Northwestern University|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Female|18 Years|N/A|No|||June 2014|June 25, 2014|August 5, 2009||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00954733||135036|We only included healthy, female subjects without significant co-morbidities which limit our ability to generalize our findings to elderly and sicker patients who bay benefit the most from this monitoring.
NCT00954174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0261|Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer|A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary||Gynecologic Oncology Group|Yes|Active, not recruiting|August 2009|||November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|603|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00954174||135078|
NCT00910728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1060C00001|Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases|A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF||AstraZeneca|No|Completed|May 2009|August 2014|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|65|||Both|25 Years|N/A|No|||September 2014|September 11, 2014|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00910728||138379|
NCT00910741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-6004-002|NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia|Phase I/II Study of the Combination Therapy With NC-6004 and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer in Asian Countries||Nanocarrier Co., Ltd.|No|Completed|May 2009|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|75 Years|No|||January 2014|January 8, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00910741||138378|
NCT00911079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643085|Pilot Study of a Catheter-based Ultrasound Hyperthermia System|Pilot Study of a Catheter-based Ultrasound Hyperthermia System|08992|University of California, San Francisco|Yes|Active, not recruiting|April 2009|May 2018|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|May 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00911079||138352|
NCT00911105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-0810|Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone|Combined Application of Lenalidomide and Desamethasone in the Palliative Therapy of Patients With Multiple Myeloma||iOMEDICO AG|No|Active, not recruiting|May 2009|December 2015|Anticipated|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with mutiple myeloma receiving a combination therapy with Lenalidomide and        Dexamethasone.|August 2015|August 26, 2015|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00911105||138350|
NCT00911443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST1472DM01012|Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma|A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma||sigma-tau i.f.r. S.p.A.|No|Completed|July 2002|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|488|||Both|18 Years|75 Years|No|||July 2009|July 1, 2009|February 26, 2009||No||No|February 26, 2009|https://clinicaltrials.gov/show/NCT00911443||138324|
NCT00902590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-025|Familial and Atypical Urothelial Cancer Registry|Familial and Atypical Urothelial Cancer Registry||Memorial Sloan Kettering Cancer Center||Recruiting|May 2009|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|3200|Samples With DNA|Cases will be invited to provide a saliva sample and tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A member of the patient's treatment team, the protocol investigator, or a member of the        research team at Memorial Sloan-Kettering Cancer Center (MSKCC) will identify potential        research subjects. At MSKCC the following outpatient clinics will be used to recruit UC        cases: Urology and Genitourinary Oncology. Patients and families may also be directly        referred to the study team by any MSKCC physician, external physician, or by the family        itself.|October 2015|October 5, 2015|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902590||138991|
NCT00911976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-016|Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions|Prospective Evaluation of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: The Stenting Of Saphenous Vein Grafts Xience V Angiographic Study (SOS-Xience V)|SOS-Xience V|North Texas Veterans Healthcare System|Yes|Completed|May 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00911976||138284|
NCT00911989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-08-0008|Laparoscopic Sleeve Gastrectomy With Endoscopic Visualization|Endoscopic Visualization During a Laparoscopic Sleeve Gastrectomy Procedure||Ethicon Endo-Surgery|Yes|Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|21 Years|60 Years|No|||June 2012|June 19, 2012|May 31, 2009|No|Yes||No|October 4, 2011|https://clinicaltrials.gov/show/NCT00911989||138283|
NCT00912262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C203|A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers|A Randomized, Single Blind Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of Capsaicin Topical Liquid NGX-1998 in Healthy Volunteers||NeurogesX||Completed|June 2008|November 2008||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 2, 2009|June 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00912262||138262|
NCT00903162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-280|Extended Endocrine Therapy for Premenopausal Women With Breast Cancer|Extended Endocrine Therapy for Premenopausal Women With Breast Cancer||Dana-Farber Cancer Institute|Yes|Completed|May 2009|September 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|N/A|No|||January 2016|January 3, 2016|May 5, 2009|No|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT00903162||138949|
NCT00903175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001L2202|Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma|An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.|RECORD-3|Novartis||Completed|October 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|471|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|April 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903175||138948|
NCT00913068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 1September 102008|Postoperative Pain Control for Prostatectomy|Post Operative Analgesia Using the Transverse Abdominal Plan (TAP) Block in Patients Undergoing a Radical Retropubic Prostatectomy (RRP)|TAP|Nova Scotia Health Authority|No|Not yet recruiting|July 2009|November 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Male|N/A|80 Years|No|||May 2009|June 2, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00913068||138201|
NCT00903682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015751|A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients|A Phase IIb, Multi-centre, Randomised, Double-blind, Active-controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects|SENSE|Janssen-Cilag International NV|Yes|Completed|June 2009|January 2011|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|75 Years|No|||January 2013|January 7, 2013|May 14, 2009||No||No|February 10, 2011|https://clinicaltrials.gov/show/NCT00903682||138911|
NCT00903955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-2876|Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease|SCCOR in Host Factors in Chronic Lung Disease||University of North Carolina, Chapel Hill|Yes|Completed|September 2006|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|100|Samples With DNA|Blood|Both|18 Years|82 Years|No|Non-Probability Sample|Community members with a history of cigarette smoking and COPD/chronic bronchitis.|February 2013|February 6, 2013|May 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00903955||138890|
NCT00904553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URBT07099|Study of Resection Combined With Stereotactic Radiosurgery for 1 to 3 Brain Metastases|Pilot Study of Resection Combined With Stereotactic Radiosurgery in Patients With Limited (1-3) Brain Metastases||University of Rochester|Yes|Active, not recruiting|March 2008|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|brain tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients treated at the University of Rochester Medical Center|May 2015|May 29, 2015|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00904553||138845|
NCT00953056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-028|A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine in Chinese Healthy Adults, Children and Infants||Merck Sharp & Dohme Corp.|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|144|||Both|6 Weeks|47 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|August 4, 2009|No|Yes||No|March 25, 2011|https://clinicaltrials.gov/show/NCT00953056||135160|
NCT00953342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP93807|Impact of Aerobic Exercise on Asthma Morbidity|Impact of Aerobic Exercise on Asthma Morbidity|Ex-Asthma|Hopital du Sacre-Coeur de Montreal|No|Completed|January 2010|August 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953342||135141|
NCT00953589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLX883-204|480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)|480 STUDY: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin Given Bi-Weekly to PEG-Intron™ Plus Ribavirin Given Weekly|480S|Biolex Therapeutics, Inc.|Yes|Completed|July 2009|January 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|69 Years|No|||February 2012|February 1, 2012|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953589||135122|
NCT00953602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/011/09|Long Time Metabolic Changes Induced by Genetically Modified Potatoes|||Charite University, Berlin, Germany|No|Recruiting|April 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953602||135121|
NCT00953888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00001|Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Single Ascending Doses in Healthy Male and/or Female Subjects||AstraZeneca||Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|203|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953888||135100|
NCT00954187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59070|Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy|Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.||Loma Linda University|No|Terminated|November 2009|April 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 6, 2014|August 5, 2009|No|Yes|PI left institution|No|September 18, 2014|https://clinicaltrials.gov/show/NCT00954187||135077|
NCT00910754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016942|A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer|A QT/QTc and Multi-dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration- Resistant Prostate Cancer||Janssen Research & Development, LLC|No|Completed|May 2009|May 2012|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Male|18 Years|N/A|No|||April 2013|April 11, 2013|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00910754||138377|
NCT00911092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-13|Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer|Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer|COL06-13|Centre Oscar Lambret|No|Completed|October 2007|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|18 Years|N/A|No|||December 2011|December 30, 2011|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911092||138351|
NCT00911430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090157|Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection|Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection||National Institutes of Health Clinical Center (CC)||Terminated|May 2009|September 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|22|||Both|2 Years|N/A|No|||September 2014|September 18, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911430||138325|
NCT00911118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-035|Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer|A Phase I Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Male|18 Years|85 Years|No|||October 2015|October 7, 2015|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00911118||138349|
NCT00911703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|659|Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE Study)|Treatment Endpoints in Acute Decompensated Heart Failure|DECIDE|Vanderbilt University|No|Active, not recruiting|August 2008|December 2016|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department who fulfill the modified Framingham        criteria and are treated for acute heart failure.|December 2014|December 8, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911703||138304|
NCT00902603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-063A501|Ventavis® Registry Protocol|Registry to Prospectively Evaluate Use of Ventavis® in Patients With Pulmonary Arterial Hypertension|RESPIRE|Actelion|No|Terminated|March 2009|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|19 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|April 2015|April 9, 2015|May 13, 2009|No|Yes|low enrollment and difficulty recruiting eligible patients in adequate time|No||https://clinicaltrials.gov/show/NCT00902603||138990|
NCT00902850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROC2-08-169|One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens|One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to 1-Day Acuvue TruEye Lenses||Bausch & Lomb Incorporated|No|Completed|October 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|May 14, 2009|No|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT00902850||138971|
NCT00902863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-070|Impact of a Course on Stress Reduction|The Impact of a Course on Stress Reduction Techniques on Satisfaction, Stress, Performance, and Quality of Life in Patients With Chronic Pain|YOGA|McMaster University|No|Terminated|February 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|5|||Both|18 Years|75 Years|No|||May 2009|May 6, 2010|May 12, 2009||No|Unable to keep patients attending yoga sessions|No||https://clinicaltrials.gov/show/NCT00902863||138970|
NCT00903188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005844-26|Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation|Impact of Cyclosporine or Steroid Withdrawal at 3 Months Post Transplantation on Graft Function, Patient Survival and Cardiovascular Surrogate Markers the First 5 Years After Renal Transplantation.|CISTCERT|University Hospital, Antwerp|No|Recruiting|October 2008|April 2015|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||May 2009|May 15, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00903188||138947|
NCT00903409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111818|Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects|An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects||GlaxoSmithKline|No|Completed|November 2005|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|79 Years|No|||November 2012|November 8, 2012|May 14, 2009||||No|June 12, 2009|https://clinicaltrials.gov/show/NCT00903409||138930|Only Adverse Experience categories with a greater than 5% occurrence in any group were reported in the AE table.
NCT00912821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08dz1900501-b|Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients|Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients - A Prospective, Randomized, Controlled, Multi-Center Clinical Study||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|March 2009|July 2012|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||June 2009|June 1, 2009|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00912821||138219|
NCT00903968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-273|Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2009|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903968||138889|
NCT00904254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-Athero-040|The Use of Anti-CD4 mAb-Fragment for Imaging of Local Inflammation in Patients With Carotid Artery Stenosis|The Use of Anti-CD4 mAb-Fragment for Imaging of Local Inflammation in Patients With Asymptomatic and Symptomatic Carotid Artery Stenosis - an Open Proof of Concept Study.||Technische Universität Dresden|Yes|Not yet recruiting|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|21|||Both|50 Years|80 Years|No|||February 2012|February 2, 2012|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904254||138867|
NCT00904540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3220-006|Topical Lidocaine Patch in Low Back Pain|Open-Label Study Assessing the Efficacy of Topical Lidocaine Patch in Treatment of Low Back Pain||Endo Pharmaceuticals||Completed|March 2002|||October 2002|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||February 2010|February 8, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904540||138846|
NCT00905112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0998|Musculoskeletal and Obstetric Management Study|Musculoskeletal and Obstetric Management Study (MOMS)|MOMS|Logan College of Chiropractic|Yes|Active, not recruiting|October 2006|June 2009|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Female|15 Years|45 Years|No|||May 2009|May 19, 2009|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905112||138803|
NCT00905125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0033|Influenza Vaccine in Pregnant Women|A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Inactivated Trivalent Influenza Vaccine in Pregnant Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|102|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||March 2010|June 7, 2012|May 18, 2009|Yes|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00905125||138802|In September of 2009, the trial was closed to enrollment prior to accruing the intended 200 participants due to the availability of the 2009-2010 seasonal Influenza vaccine and onset of Influenza season.
NCT00952770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUH-09-07-60|Effect of Statins on the Radial Intima-media Thickness After Transradial Angioplasty|Effect of Statins on the Progression of the Intima-media Thickness of the Radial Artery After Radial Angioplasty||Chungnam National University|No|Recruiting|July 2009|||July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|75 Years|No|||August 2009|August 4, 2009|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00952770||135181|
NCT00953355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/009|Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients|Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome||University Magna Graecia|Yes|Completed|January 2004|May 2007|Actual|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|35 Years|No|||August 2009|November 2, 2010|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953355||135140|
NCT00953368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC-3862|Effect of Remote Ischemic Preconditioning on Cognitive Function After Off-Pump Coronary Artery Bypass Graft|Effect of Remote Ischemic Preconditioning on Cognitive Function After Off-Pump Coronary Artery Bypass Graft||Asan Medical Center|Yes|Not yet recruiting|October 2009|March 2012|Anticipated|March 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|270|||Both|40 Years|80 Years|No|||August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953368||135139|
NCT00953615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|342-06|Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)|Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis||Mayo Clinic|Yes|Terminated|April 2006|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|72 Years|No|||January 2012|January 24, 2012|August 4, 2009|Yes|Yes|Lack of enrollment|No|August 8, 2011|https://clinicaltrials.gov/show/NCT00953615||135120|Only one subject was enrolled, so study was terminated.
NCT00953628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|recHCG001|Endometrial Advancement After Rec or u-HCG Triggering|Endometrial Advancement After Rec or u-HCG Triggering||Universitair Ziekenhuis Brussel|No|Completed|August 2005|December 2008||December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|130|||Female|20 Years|36 Years|No|||December 2015|December 1, 2015|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953628||135119|
NCT00953901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2247-05|Is Plasma Transfusion Beneficial Prior to Low-Risk Procedures in Hospitalized Patients With Blood Clotting Abnormalities?|Restrictive Versus Liberal Fresh Frozen Plasma Transfusion Prior to Low-Risk Invasive Procedures in Hospitalized Patients.||Mayo Clinic||Completed|July 2006|December 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|2|||Both|1 Year|N/A|No|||November 2009|November 13, 2009|August 4, 2009||||No||https://clinicaltrials.gov/show/NCT00953901||135099|
NCT00954525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND77486|Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer|Phase I, Open Label, Dose Escalating Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer||Thomas Jefferson University|Yes|Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||January 2012|January 17, 2012|August 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00954525||135052|
NCT00910767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0308/297|Closing the Loop in Adults With Type 1 Diabetes|A Randomised, 2-period Cross-over Study to Assess the Feasibility of Overnight Computer-based Glucose Control Based on Continuous Subcutaneous Glucose Monitoring, and Compare it With Conventional Pump Therapy in Adults With Type 1 Diabetes|ANGELA01|University of Cambridge|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||September 2009|September 16, 2009|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00910767||138376|
NCT00911456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Can 3D Ultrasound Be Used Reproducibly by Radiation Therapists in Partial Breast Image-Guided Radiation Therapy|Can 3D Ultrasound Be Used Reproducibly by Radiation Therapists in Partial Breast Image-Guided Radiation Therapy?|IGRT|British Columbia Cancer Agency|Yes|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|80 Years|No|||October 2009|February 15, 2012|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911456||138323|
NCT00911716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-10 ICORG|TC Avastin. ICORG 08-10, V6|Pilot Evaluation of Bevacizumab, in Combination With Docetaxel and Cyclophosphamide in the Adjuvant Treatment of Patients With HER 2 Negative Breast Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Completed|October 2008|September 2015|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|May 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00911716||138303|
NCT00902889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Huntington|Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease|Single Centre (Pilot) Study for Deep Brain Stimulation (DBS) of the Globus Pallidus in Huntington's Disease (HD)||Heinrich-Heine University, Duesseldorf|No|Completed|May 2009|July 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902889||138968|
NCT00902876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10812-009|A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions|A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions.|MCT-Recession|Geistlich Pharma AG|Yes|Completed|March 2009|January 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|No|||February 2012|February 6, 2012|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00902876||138969|
NCT00903422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112509|Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)|Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)||GlaxoSmithKline|Yes|Completed|May 2009|December 2013|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903422||138929|
NCT00903708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0770|LY2275796 in Advanced Cancer|A Phase I Dose-Escalation, Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous LY2275796 in Patients With Advanced Cancer||M.D. Anderson Cancer Center|No|Completed|September 2006|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|May 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00903708||138909|
NCT00903721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05876|Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)|Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation||Merck Sharp & Dohme Corp.|No|Completed|November 2008|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3806|||Both|N/A|N/A|No|Non-Probability Sample|Japanese patients with perennial allergic rhinitis and/or seasonal allergic rhinitis|July 2015|July 29, 2015|May 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00903721||138908|
NCT00903981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-AVA-301|Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil|A Randomized, Placebo Controlled, Double Blind, Multicenter Therapeutic Confirmatory Clinical Study for the Evaluation of the Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction|ALERT|JW Pharmaceutical|No|Completed|March 2009|November 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|208|||Male|19 Years|70 Years|No|||February 2009|April 22, 2010|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00903981||138888|
NCT00903994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3269-201|A Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee|An Open-Label, Phase II, Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee|KTP|Endo Pharmaceuticals|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||May 2009|May 18, 2009|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903994||138887|
NCT00903396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N08C2|Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer|A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting||Alliance for Clinical Trials in Oncology|No|Terminated|September 2009|May 2013|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|7|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|May 15, 2009|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT00903396||138931|
NCT00904566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-107-RR|Validation of 70-gene MammaPrint Profile in Japanese Population|Validation 70-gene MammaPrint Profile in Japanese Population||Agendia|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|102|||Female|29 Years|70 Years|No|Probability Sample|Breast cancer patients, node-negative, treated with breast conserving therapy or        mastectomy with axilary lymph node dissection at Osaka Medical Center for Cancer and        Cardiovascular Diseases.|June 2015|June 22, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904566||138844|
NCT00905151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 8761|HIV and Kidney Function Study|Evaluation of the Performance of GFR Estimating Equations in HIV Positive Patients||Tufts Medical Center|No|Active, not recruiting|January 2009|October 2015|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|200|Samples Without DNA|Whole and urine will be retained for future testing.|Both|18 Years|N/A|No|Non-Probability Sample|Participants will be recruited from hospital based practices as well as from the        community.|September 2014|September 24, 2014|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00905151||138800|
NCT00904839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.51|BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer|A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients||Boehringer Ingelheim||Completed|May 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|May 18, 2009||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00904839||138823|
NCT00900991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-sPanFlu-2002|Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children|Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children||Sinovac Biotech Co., Ltd|Yes|Completed||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|3 Years|11 Years|Accepts Healthy Volunteers|||May 2009|May 13, 2009|May 12, 2009||||No||https://clinicaltrials.gov/show/NCT00900991||139113|
NCT00901004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GKR-DUM-2009/1|The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire|Non-interventional, Cross-sectional, Multi-center Study to Establish The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire (GerdQ)|MIGHT|AstraZeneca|No|Completed|April 2009|September 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1550|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who had shown the reflux esophageal minimal change in the endoscopic finding|December 2010|December 6, 2010|April 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00901004||139112|
NCT00901017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 04/05|Comparison of Synthetic Bone Substitute and a Bovine-derived Xenograft in Horizontal Bone Augmentation|A Randomised Controlled Spilt-mouth Clinical Study Comparing a Synthetic Bone Substitute and a Bovine-derived Xenograft in Primarily Horizontal Bone Augmentation Procedure During Placement of Straumann Oral Implants||Institut Straumann AG|No|Completed|March 2006|August 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|80 Years|No|||October 2012|October 4, 2012|May 11, 2009||No||No|August 30, 2012|https://clinicaltrials.gov/show/NCT00901017||139111|
NCT00953381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Livzon-IY-81149-01|Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)|Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase2 Trial in China||Livzon Pharmaceutical Group Inc.|Yes|Completed|October 2004|May 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|235|||Both|18 Years|65 Years|No|||August 2009|August 5, 2009|August 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00953381||135138|
NCT00953641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-134|Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy|Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy||University of Saskatchewan|No|Withdrawn|September 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Female|35 Years|N/A|No|||August 2012|August 11, 2012|August 26, 2008||No|Principle Investigator retired, Resident moved away|No||https://clinicaltrials.gov/show/NCT00953641||135118|
NCT00953914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04471|Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients|Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients With Autonomic Neuropathy||Hospital de Clinicas de Porto Alegre|No|Completed|March 2005|May 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||July 2011|July 6, 2011|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953914||135098|
NCT00954200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26.07.09.ctil|Ibuprofen as a Possible Preventer of Post Bronchoscopy Fever|Ibuprofen as a Possible Preventer of Post Bronchoscopy Fever||Shaare Zedek Medical Center||Recruiting||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|12 Years|No|||July 2009|July 24, 2011|July 26, 2009||||No||https://clinicaltrials.gov/show/NCT00954200||135076|
NCT00954538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3328-001|Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)|A Three Part Study to Evaluate the Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK-3328, a Radiotracer for Use in Positron Emission Tomography||Merck Sharp & Dohme Corp.|No|Completed|August 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|19|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|August 6, 2009|No|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00954538||135051|
NCT00911131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 8503|Enhancing Detection of Small Esophageal Varices by PillCam ESO|A New Technique to Enhance Detection of Small Esophageal Varices by PillCam ESO Capsule Endoscopy||Medical College of Wisconsin|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|May 29, 2009|Yes|Yes|Loss of funding|No||https://clinicaltrials.gov/show/NCT00911131||138348|
NCT00911469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27575|Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement|A Randomised, Double-blind, Placebo-controlled, Multicentre, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement.||Merck KGaA||Completed|November 2007|June 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|40 Years|N/A|No|||August 2014|August 4, 2014|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911469||138322|
NCT00911482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001493|Production of Free Fatty Acids From Blood Triglycerides|FFA Production From Triglyceride-Rich Lipoproteins||Mayo Clinic|No|Completed|June 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|16|Samples Without DNA|Plasma samples obtained during the study are stored for lipid analysis.|Both|35 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Volunteers from the region around Rochester, Minnesota who meet the inclusion criteria        will be recruited.|November 2012|November 6, 2012|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00911482||138321|
NCT00902304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489AAU01|Valsartan Intensified Primary Care Reduction of Blood Pressure Study|A Phase IV Clinical Trial of Intensified Blood Pressure Management in Primary Care Using Valsartan Alone and as Combination Anti-Hypertensive Therapy|VIPER-BP|Novartis|No|Completed|July 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2337|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|April 28, 2009||No||No|July 29, 2012|https://clinicaltrials.gov/show/NCT00902304||139013|
NCT00902616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arginine01|Effect of Arginine on Microcirculation in Patients With Diabetes|L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients||Tameside Hospital NHS Foundation Trust|No|Completed|June 2003|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|65 Years|No|||May 2009|November 26, 2013|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00902616||138989|
NCT00903734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0638|An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status|An Umbrella Protocol for Histology-Independent, Phase I Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status: Using Erlotinib Alone or in Combination With Cetuximab, Bortezomib, or Dasatinib to Overcome Resistance||M.D. Anderson Cancer Center|Yes|Completed|April 2009|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|May 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00903734||138907|
NCT00903201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110399|28 Day Repeat Dose in Cystic Fibrosis Patients|A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.||GlaxoSmithKline|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|N/A|No|||March 2012|May 31, 2012|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903201||138946|
NCT00904293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1644|Genotype-Guided Warfarin Therapy Trial|Randomized Controlled Trial of Genotype-Guided Dosing of Warfarin Therapy|WARFPGX|University of North Carolina, Chapel Hill|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||October 2013|June 2, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00904293||138865|
NCT00904579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906194|Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease|||National Institutes of Health Clinical Center (CC)||Recruiting|June 2006|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1929901|||Both|N/A|N/A|No|||August 2015|September 16, 2015|May 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00904579||138843|
NCT00903695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14594|MemoryXL Effects on Mild Cognitive Impairment Patients|Nutriceutical Effects on Cognitive Status in Mild Cognitive Impairment Patients|MemoryXL|University of Oklahoma|Yes|Terminated|June 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|10|||Both|55 Years|85 Years|No|||January 2012|January 25, 2012|May 14, 2009|Yes|Yes|Risk/benefit ratio did not indicate further study would be useful, or fair to future subjects.|No|July 26, 2011|https://clinicaltrials.gov/show/NCT00903695||138910|Benefits of study did not appear to outweigh subject inconvenience, so study was stopped prematurely. Also, very few 'healthy' MCI subjects were recruited from the clinic population; vast majority of MCI patients had exclusionary medical problems.
NCT00905164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02134|Topiramate 25 mg Capsules Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Sprinkle Capsules Administered as 2 x 25 mg Capsules in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2002|June 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 14, 2009|May 18, 2009|No|Yes||No|June 1, 2009|https://clinicaltrials.gov/show/NCT00905164||138799|
NCT00905177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700902|Predictors of Anticoagulation Control on Warfarin Therapy|Predictors of Anticoagulation Control on Warfarin Therapy||University of Pennsylvania|No|Recruiting|June 2009|April 2014|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1119|Samples With DNA|A one time blood sample will be collected for specific genetic testing and vitamin K assay|Both|21 Years|N/A|No|Non-Probability Sample|Study population will include all self-identified Caucasians and African Americans        initiating warfarin therapy.|December 2009|December 1, 2009|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905177||138798|
NCT00905190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODO-P8-689|Bioavailability Study of Anti Nausea Medication With and Without Food|Single Dose Crossover Comparative Bioavailability Study To Assess the Effect of Food on the Pharmacokinetics of Ondansetron Modified-Release Capsules (EUR1025) in Healthy Male and Female Volunteers|EUR-1025|Forest Laboratories|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2009|May 19, 2009|May 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00905190||138797|
NCT00905476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E552kyoto|Prognosis in Patients With Chronic Respiratory Failure Receiving Domiciliary Noninvasive Positive Pressure Ventilation (NPPV)|Analysis of the Prognosis and Clinical Course in Patients With Chronic Respiratory Failure Receiving Domiciliary NPPV||Kyoto University, Graduate School of Medicine|No|Completed|April 2009|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|N/A|No|Probability Sample|Outpatient clinic of respiratory medicine|April 2015|April 1, 2015|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905476||138775|
NCT00905489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1518|A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.|An Open-label, Multiple Dose, Cross-over Study to Evaluate the Steady-state Pharmacokinetic Parameters of Nevirapine Extended Release Tablets in HIV-1 Infected Children, With an Optional Extension Phase||Boehringer Ingelheim||Completed|June 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|3 Years|17 Years|No|||December 2015|December 2, 2015|May 6, 2009|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT00905489||138774|
NCT00901030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-066|Association Between Perioperative Platelet Function and Major Adverse Perioperative Events|The Association Between Perioperative Platelet Inhibition (Function) and Major Adverse Perioperative Cardiac Events in Post Percutaneous Coronary Intervention Patients Undergoing Non-cardiac Surgery||McMaster University|No|Completed|March 2009|September 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|30 Years|85 Years|No|Non-Probability Sample|Patients who have PCI have to stay on antiplatelet agents to prevent clotting of their        stents. These patients often require NCS at some stage after their PCI.|September 2015|September 21, 2015|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901030||139110|
NCT00953394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2004-003963-58|5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors|Continuous 5-fluorouracil Infusion Plus Long Acting Octreotide in Advanced Well Differentiated Neuroendocrine Carcinomas. A Phase II Trial of the Piemonte Oncology Network.||University of Turin, Italy|Yes|Completed|February 2002|December 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||August 2009|August 5, 2009|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00953394||135137|
NCT00953654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGA-2009-01913-1|Exercise Training for the Treatment of Generalized Anxiety Disorder|Exercise Training for the Treatment of Generalized Anxiety Disorder: A Randomized Controlled Trial Comparing Endurance and Strength Training Among Sedentary Women With Generalized Anxiety Disorder.||University of Georgia||Completed|August 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Female|18 Years|39 Years|No|||August 2010|August 3, 2011|August 4, 2009||No||No|August 17, 2010|https://clinicaltrials.gov/show/NCT00953654||135117|One limitation of this trial was the small sample size. Although the research design was sufficiently powered to detect a statistically significant effect for the primary outcome, a larger trial is warranted.
NCT00955123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHNC-KLT|Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Active Inflammatory Bowel Disease|Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Patients With Active Ulcerative Colitis and Crohn's Disease||University of Aarhus|No|Completed|January 2009|December 2011|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|Serum, plasma and urine.|Both|18 Years|50 Years|No|Probability Sample|Patients with active inflammatory bowel disease seen in the out-patients' clinic or        admitted to hospital for treatment.|October 2012|October 11, 2012|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00955123||135006|
NCT00953927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-020-485|A Study of MVA85A in Healthy Infants|Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants||Aeras|Yes|Completed|July 2009|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2797|||Both|126 Days|182 Days|Accepts Healthy Volunteers|||February 2014|February 4, 2014|July 31, 2009||No||No|October 23, 2013|https://clinicaltrials.gov/show/NCT00953927||135097|
NCT00954213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206/2551(EC1)|A Study of a Developmental,Individual-Difference,Relationship-Bases/Floortime Intervention for Children With Autistic|A One-year Prospective Follow-up Study of a DIR/ Floortime Parent Training Intervention for Pre-school Children With Autistic Spectrum Disorders|DIR|Mahidol University|No|Completed|May 2008|June 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||July 2010|July 22, 2010|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00954213||135075|
NCT00954005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma|Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma|R-GO|German Low Grade Lymphoma Study Group|No|Terminated|January 2003|June 2012|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 4, 2009||No|Predefined termination criterion of > 10 patients without CR or PR was matched.|No||https://clinicaltrials.gov/show/NCT00954005||135091|
NCT00954018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04-018|Microbial Community Composition and Metabolism in Cystic Fibrosis|Respiratory Microbial Community Composition and Metabolism in Cystic Fibrosis||Children's Hospital Boston|No|Recruiting|August 2009|||||N/A|Observational|Time Perspective: Prospective||3|Anticipated|120|Samples Without DNA|throat swabs or sputum|Both|2 Years|55 Years|No|Non-Probability Sample|Cystic fibrosis patients will be contacted during clinical care visits and inpatient        hospitalizations.|August 2009|August 5, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00954018||135090|
NCT00911157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111436|The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT)||GlaxoSmithKline||Completed|June 2008|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|20 Years|N/A|No|||March 2011|March 17, 2011|May 28, 2009||No||No|May 13, 2010|https://clinicaltrials.gov/show/NCT00911157||138346|
NCT00911170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080259|PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study|A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)||Amgen|Yes|Completed|November 2009|January 2015|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|847|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|May 21, 2009|Yes|Yes||No|November 19, 2013|https://clinicaltrials.gov/show/NCT00911170||138345|
NCT00901979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908A2203|A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)|||Novartis||Completed|April 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|693|||Both|18 Years|75 Years|No|||January 2013|January 3, 2013|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901979||139037|
NCT00902291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008002|A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer|A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer||Astellas Pharma Inc|Yes|Completed|April 2009|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00902291||139014|
NCT00902629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPITELL|Epiretinal Fibrosis, Effect of Early Surgery|Randomized Clinical Trial Investigating the Longterm Results of Early vs. Delayed Surgery for Epiretinal Fibrosis.|epitell|Glostrup University Hospital, Copenhagen|No|Completed|May 2008|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00902629||138988|
NCT00903435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F060505003|Quantitative Studies of Urinary Bladder Sensation|Quantitative Studies of Urinary Bladder Sensation||University of Alabama at Birmingham|Yes|Completed|May 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|19 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Non-healthy subjects will be recruited from Kirklin Clinic Urology Clinic and Pain        Treatment Center. Healthy subjects will be recruited via advertisements.|November 2011|November 30, 2011|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00903435||138928|
NCT00903461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-121|Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma|Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma||University of Pittsburgh|Yes|Recruiting|April 2012|September 2021|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|May 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00903461||138926|
NCT00904007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-422|Interactive Spaced Education to Optimize Hypertension Management|Interactive Spaced Education to Optimize Hypertension Management||VA Office of Research and Development|No|Completed|February 2010|September 2014|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|111|||Both|18 Years|N/A|No|||February 2015|April 6, 2015|May 15, 2009||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT00904007||138886|
NCT00904306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3062-04003|Binge Eating and Chromium Study|Chromium Picolinate in Binge Eating Disorder: A Feasibility Study|BEACh|University of North Carolina, Chapel Hill|Yes|Completed|July 2008|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|55 Years|No|||April 2012|April 2, 2012|May 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00904306||138864|
NCT00904592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A0401|A Study on Traditional Chinese Medicine (TCM) Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy|A Study on TCM Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy||Chengdu University of Traditional Chinese Medicine|Yes|Completed|September 2008|April 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|480|||Both|35 Years|75 Years|No|||August 2012|August 20, 2012|December 24, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904592||138842|
NCT00904280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3202-021|Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy|An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy of Numorphan® CR (Oxymorphone HCL Controlled Release) in Subjects With Cancer Pain or Chronic Lower Back Pain.||Endo Pharmaceuticals|No|Completed|March 2001|July 2003|Actual|July 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|239|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2009|May 18, 2009|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904280||138866|
NCT00905203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200811009R|Effects of Different Exercise Training Dose on Exercise Performance and Noninvasively Estimated Muscle Oxygen Extraction in Diabetic Postmenopausal Women|Effects of Different Exercise Training Dose on Exercise Performance and Noninvasively Estimated Muscle Oxygen Extraction in Diabetic Postmenopausal Women||National Taiwan University Hospital|Yes|Recruiting|February 2009|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|45|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||June 2010|July 14, 2010|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905203||138796|
NCT00901043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Griffin IRB # 2007-10|Effects of Walnut Consumption on Endothelial Function in Type 2 Diabetes|Effects of Walnut Consumption on Endothelial Function in Type 2 Diabetes: A Randomized, Controlled, Cross-over Trial|WALNUT|Griffin Hospital|No|Completed|October 2007|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|35 Years|75 Years|No|||December 2014|December 31, 2014|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901043||139109|
NCT00905502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-IM-38590207-CTIL|Intraoperative Fluid Management in Laparoscopic Bariatric Surgery|Intraoperative Fluid Management in Laparoscopic Bariatric Surgery - Does it Make a Difference?||Tel-Aviv Sourasky Medical Center|No|Completed|April 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|80 Years|No|||May 2009|May 19, 2009|May 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00905502||138773|
NCT00901355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-A00042-49|Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population|Morbidity and Mortality Based on Blood Pressure and Arterial Stiffness in Institutionalized Persons Aged 80 and Over: Study PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population).|PARTAGE|Central Hospital, Nancy, France|Yes|Completed|January 2007|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1130|||Both|80 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This population-based study included 1200 voluntary subjects aged 80 and older, living in        nursing home, included by four french university hospitals centre (Nancy, Dijon, Paris,        Toulouse) and two Italian (Cesena, Verona).|July 2015|July 29, 2015|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00901355||139085|
NCT00901654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE527-101|ACE527 Safety and Immunogenicity Study|A Phase I, Single Center, Double-Blind, Placebo-controlled Dose Finding Clinical Study to Evaluate the Safety and Immunogenicity of the Live Attenuated, Oral Vaccine ACE527||TD Vaccines A/S|Yes|Completed|June 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 28, 2010|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901654||139062|
NCT00901667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSRPAMD17|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||March 5, 2011|May 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901667||139061|
NCT00902070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06082|Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)|Protocol for Eslax Intravenous Drug Use Investigation||Merck Sharp & Dohme Corp.|No|Completed|November 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3969|||Both|N/A|N/A|No|Non-Probability Sample|Japanese 3000 patients|October 2015|October 29, 2015|May 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00902070||139030|
NCT00953134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Periconceptional_Fe|Periconceptional Iron Supplementation in Rural Bangladesh|Periconceptional Iron Supplementation on Iron and Folate Indicators Among Pregnant and Non-pregnant Women in Rural Bangladesh.||The Hospital for Sick Children|No|Completed|February 2007|March 2008|Actual|February 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|273|||Female|N/A|40 Years|Accepts Healthy Volunteers|||August 2009|April 14, 2010|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00953134||135156|
NCT00955409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134K1-2203|Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease|A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|November 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|N/A|N/A|No|||January 2014|January 29, 2014|August 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955409||134984|
NCT00952068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT2-002|A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day|A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day||Labopharm Inc.|No|Completed|January 2007|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|80 Years|No|||April 2012|April 25, 2012|April 16, 2009||No||No|April 16, 2009|https://clinicaltrials.gov/show/NCT00952068||135235|
NCT00952341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-169|Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)|A Phase III, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Safety, Tolerability and Efficacy of MK0869/Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With High-Dose Cisplatin||Merck Sharp & Dohme Corp.|No|Completed|August 2009|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|July 31, 2009|Yes|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00952341||135214|
NCT00953940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nefrane001|Prevention of Perioperative Acute Renal Failure|Prevention of Perioperative Acute Renal Failure in Abdominal Surgery||Hospital Universitario Ramon y Cajal|No|Terminated|June 2005|May 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||August 2009|June 30, 2011|August 4, 2009||No|An external board recommended to close the study for futility after the interin analysis|No||https://clinicaltrials.gov/show/NCT00953940||135096|
NCT00953953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 3052|Study of Left Ventricular Dyssynchrony in Heart Failure Patients|Study of the Phenomenon of Dynamic Left Ventricular Dyssynchrony in Heart Failure Patients and Its Clinical Significance.||Albert Einstein Healthcare Network|No|Completed|January 2007|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|16|||Both|18 Years|N/A|No|Probability Sample|Acutely Decompensated Systolic HF group: patients who are admitted to Albert Einstein        Medical Center on the HF service.        Chronic HF on Dialysis group: patients at the dialysis center at Albert Einstein Medical        Center.        Ambulatory Chronic HF group: patients who present to the Albert Einstein Medical Center HF        clinic.        Acutely Decompensated Diastolic HF group: patients who are admitted to Albert Einstein        Medical Center on the HF service.|January 2012|January 25, 2012|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00953953||135095|
NCT00901550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA_2008|The Chinese University of Hong Kong Early Arthritis Study|The Chinese University of Hong Kong Early Arthritis Study|ERA|Chinese University of Hong Kong|No|Completed|November 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||July 2012|July 31, 2012|May 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00901550||139070|
NCT00901563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZB/4/520/b|Gap Junction Potentiation of Endothelial Function With Rotigaptide|Gap Junction Potentiation of Endothelial Function With Rotigaptide in the Human Forearm Arterial Circulation - Effects of Ischaemia Induced Endothelial Dysfunction||University of Edinburgh|No|Recruiting|March 2009|||March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2009|May 13, 2009|May 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00901563||139069|
NCT00902317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1115|Prime Time for Superficial Femoral Artery (SFA) - The SFA Study|A Randomized Trial for Femoropopliteal Arteries|CLASE|Arizona Heart Institute|No|Terminated|November 2004|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|130|||Both|18 Years|N/A|No|||May 2009|May 14, 2009|May 14, 2009|No|Yes|No funding|No||https://clinicaltrials.gov/show/NCT00902317||139012|
NCT00903448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009010|Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression|Comparison of Prilosec OTC® Versus Prevacid ® for Gastric Acid Suppression||Procter and Gamble|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 22, 2010|May 14, 2009|Yes|Yes||No|August 4, 2010|https://clinicaltrials.gov/show/NCT00903448||138927|
NCT00904020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3220-008|A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain|A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain||Endo Pharmaceuticals||Completed|June 2002|||November 2002|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00904020||138885|
NCT00904605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3220-012|Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee|A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Pain From Osteoarthritis of the Knee||Endo Pharmaceuticals|No|Terminated|June 2004|November 2004|Actual|November 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||February 2010|February 12, 2010|May 15, 2009|Yes|Yes|Safety concerns with the COX-2 specific inhibitor class of drug.|No||https://clinicaltrials.gov/show/NCT00904605||138841|
NCT00904618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USherbrooke-001|Safety and Efficacy Study on the Implantation of the Tension-Free Vaginal Tape (TVT-Secur) Under Local Anesthesia|Better Short-Term Outcomes With The 'U-Method' Compared to the 'Hammock' Technique for the Implantation of the TVT-SECUR Under Local Anesthesia||Université de Sherbrooke|No|Completed|January 2007|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|N/A|N/A|No|||April 2009|May 18, 2009|March 11, 2009||No||No|March 11, 2009|https://clinicaltrials.gov/show/NCT00904618||138840|The single-surgeon single-center experience and the lack of objective outcome evaluation. A measurement bias of the 'U-Method' because of a learning curve for the cases using the ‘Hammock’ technique.
NCT00904878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFA Pregnancy Registry|A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease|A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease||University of California, San Francisco|No|Recruiting|August 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|||Female|18 Years|45 Years|No|Non-Probability Sample|Female patients with confirmed IBD diagnoses who are pregnant|January 2016|January 4, 2016|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00904878||138820|
NCT00904891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH080853|Testing the Effectiveness of Adolescent Depression Prevention Programs (The OregonBlues Study)|Effectiveness Trial of an Adolescent Depression Prevention Program||Oregon Research Institute|Yes|Completed|January 2009|November 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|390|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00904891||138819|
NCT00905216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV0109_BER|Efficacy and Safety of Sodium Heparin in Patients Submitted to Heart Surgery Using Bypass|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Recruiting|June 2009|December 2011|Anticipated|September 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|104|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|May 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00905216||138795|
NCT00904852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C03003|Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme|A Phase 1, Multicenter, Open-Label, Dose Escalation Study of Tandutinib (Formerly MLN518) in Combination With Temozolomide and Bevacizumab Following Concurrent Radiation Therapy and Temozolomide in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme.||Millennium Pharmaceuticals, Inc.|No|Withdrawn|June 2009|June 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2009|May 19, 2009|May 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00904852||138822|
NCT00905138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0259-CL-101|First-in-Human Single Ascending and Multiple Dose of GLPG0259|Double Blind, Placebo-controlled Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0259 in Healthy Subjects||Galapagos NV|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 17, 2012|May 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00905138||138801|
NCT00971126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCOGP-1209|Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)|A Phase I/II Study of Sorafenib With Combination of Thalidomide in Advanced or Metastatic Hepatocellular Carcinoma||National Health Research Institutes, Taiwan|Yes|Terminated|July 2009|December 2011|Anticipated|November 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|N/A|No|||September 2009|July 20, 2011|July 1, 2009||No|Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated    early this trial.|No||https://clinicaltrials.gov/show/NCT00971126||133794|
NCT00972075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRCADIN 1|Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects|A Double-Blind, Placebo-Controlled Study of Circadin™ for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects||Neurim Pharmaceuticals Ltd.|No|Completed|February 2006|October 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|20 Years|80 Years|No|||September 2009|September 6, 2009|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972075||133722|
NCT00963417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000637437|Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02|TEXT-Bone: A Substudy of the TEXT Trial to Evaluate Serial Bone Markers for Bone Remodeling, Serial Growth Factors, and Bone Mineral Density|TEXT-Bone|International Breast Cancer Study Group|Yes|Active, not recruiting|July 2009|December 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|120 Years|No|||February 2016|February 24, 2016|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963417||134379|
NCT00962845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090901|Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery|A Phase 0 Trial of Hydroxychloroquine, an Inhibitor of Autophagy, in Patients With Stage III or IV Resectable Melanoma||Rutgers, The State University of New Jersey|No|Active, not recruiting|September 2010|December 2015|Anticipated|May 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962845||134419|
NCT00963118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRGN52|Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability|Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability|Biogreen|Tufts University|No|Active, not recruiting|June 2009|December 2010|Anticipated|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|36|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 8, 2010|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963118||134400|
NCT00963404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRRO IP 070109 DaBlaCa-1|Image-Guided Tumorboost of Bladder Cancer|Image-guided Tumorboost of Localized Unifocal Bladder Cancer: A Phase I/II Study||University of Aarhus|No|Active, not recruiting|August 2009|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2015|December 4, 2015|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963404||134380|
NCT00963729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICCRU-NEOcent-C-21-07|Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery|A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal Patients With Primary Breast Cancer||National Cancer Institute (NCI)||Completed|September 2008|March 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|756|||Female|18 Years|70 Years|No|||August 2011|August 9, 2013|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963729||134356|
NCT00963950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902004771|Transvaginal Cholecystectomy Versus Laparoscopic Cholecystectomy in Patients With Biliary Colic|Transvaginal Cholecystectomy||Yale University|Yes|Enrolling by invitation|August 2009|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|65 Years|No|||April 2012|April 9, 2012|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963950||134339|
NCT00964522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI070141|Trial of the Effectiveness of a Nurse Education and Care Program for Breast Cancer Patients Treated With Chemotherapy|Randomized Trial of the Effectiveness of a Nurse Education and Care Program for Breast Cancer Patients Treated With Chemotherapy||Instituto de Salud Carlos III|No|Completed|January 2007|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|266|||Female|18 Years|N/A|No|||April 2010|June 21, 2011|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00964522||134296|
NCT00969800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA90811|Test of a Preventive Effect of a Deodorant Device Against Respiratory Infections|Double-blind Sham Device-controlled Multi-center Crossover Trial of Chlorine Dioxide Gas on the Protective Effect Against Respiratory Infections|Cleverin|Taiko Pharmaceutical Co., Ltd.|No|Active, not recruiting|October 2009|April 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1469|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 2, 2010|August 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00969800||133895|
NCT00969813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921015|A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function|A Phase 1, Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function||Pfizer|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2010|February 10, 2010|August 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00969813||133894|
NCT00974025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00029464|Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients|Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation||University of Michigan|No|Completed|June 2009|March 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|8 Years|25 Years|Accepts Healthy Volunteers|||September 2009|October 20, 2011|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974025||133574|
NCT00970021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ando-01|Agaricus Blazei Murill in Patients With Multiple Myeloma|Use of the Medicinal Mushroom Agaricus Blazei Murill in Addition to High Dose Chemotherapy in Patients With Multiple Myeloma.||Oslo University Hospital|No|Completed|June 2009|February 2014|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|N/A|N/A|No|||February 2014|February 22, 2014|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970021||133878|
NCT00970034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108S375|Gene Expression Profiles in Patients With Permanent Atrial Fibrillation (AF) Versus Sinus Rhythm (SR)|Comparative Gene Expression Profiles in Patients With Permanent Atrial Fibrillation and Normal Sinus Rhythm||Ankara University|No|Recruiting|December 2008|December 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Human atrial tissue|Both|18 Years|85 Years|No|Non-Probability Sample|Degenerative mitral valve regurgitation who require cardiac valve surgery|September 2009|September 2, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970034||133877|
NCT00970008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT004623-01|Exploring Massage Benefits for Arthritis of the Knee|Exploring Massage Benefits for Arthritis of the Knee|EMBARK|Rutgers, The State University of New Jersey|Yes|Completed|September 2009|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|125|||Both|35 Years|N/A|No|||April 2015|May 1, 2015|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00970008||133879|
NCT00970606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIP|STIP: Statin Trial for Influenza Patients|Randomized, Placebo Controlled Trial of the Effectiveness of Statins for Preventing Mortality Following ICU Admission for Influenza Complications|STIP|Vanderbilt University|Yes|Terminated|October 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|13 Years|N/A|No|||June 2013|June 28, 2013|August 31, 2009|Yes|Yes|Inability to recruit participants since H1N1 epidemic resolved.|No|March 12, 2013|https://clinicaltrials.gov/show/NCT00970606||133834|Only able to enroll only 7 participants of >2000 planned/anticipated, leading to early termination of the study and therefore unable to perform statistical analysis with such a small sample size.
NCT00970593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3283K1-1008|Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin|A Randomized, Double-Blind, Placebo-Controlled Study Of Multiple Doses Of OAP-189 To Determine The Safety, Tolerability, Pharmacodynamics, And Pharmacokinetics When Coadministered With Metformin In Type 2 Diabetic Subject|3283K1-1008-US|Pfizer|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|65 Years|No|||August 2011|August 11, 2011|September 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00970593||133835|
NCT00971178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807176008|Analgesic Effect of Peripheral Dexmedetomidine|Effectiveness of Peripheral Dexmedetomidine for Bilateral Third Molar Surgery Under General Anaesthesia||The University of Hong Kong|Yes|Completed|February 2006|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|50 Years|No|||June 2010|June 7, 2010|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00971178||133790|
NCT00971776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Voyager I: G80013/S001|Voyager I: Patient Discharge Using the AB5000 Portable Driver System|Voyager I: Patient Discharge Using the AB5000 Portable Driver System||Abiomed Inc.|Yes|Terminated|June 2008|September 2013|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|September 2, 2009|Yes|Yes|Terminated due to slow enrollment and change in business priority|No||https://clinicaltrials.gov/show/NCT00971776||133745|
NCT00971789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080151|Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes|A Pilot Study of Sirolimus (Rapamycin, Rapamune[Registered Trademark]) in Subjects With Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN||National Institutes of Health Clinical Center (CC)|No|Completed|July 2008|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||July 2013|September 29, 2015|September 3, 2009|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00971789||133744|
NCT00971802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0171008|A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers|A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo- Controlled, Parallel Group, Oral Multiple-Dose Trial to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-03882845 in Healthy Volunteers||Pfizer|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|50|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 22, 2010|September 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00971802||133743|
NCT00963430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0056|H1N1 Vaccine in Pregnant Women|A Phase II Study in Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||April 2010|November 29, 2012|August 20, 2009|Yes|Yes||No|April 21, 2011|https://clinicaltrials.gov/show/NCT00963430||134378|
NCT00963443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13700|Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold|A Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Acetylsalicylic Acid Combined With Pseudoephedrine, Compared With Acetylsalicylic Acid Alone, and Pseudoephedrine Alone, on Symptoms of Pain.||Bayer|No|Completed|September 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|833|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963443||134377|
NCT00963742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE G060058|Lenstec Softec HD Posterior Chamber Intraocular Lens Clinical Investigational Protocol|Lenstec Softec HD Posterior Chamber Intraocular Lens (PCIOL) Clinical Investigational Protocol||Lenstec Incorporated|No|Completed|December 2006|April 2010|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|390|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 17, 2014|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963742||134355|
NCT00963976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICHADAPT513000128|Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial|Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial|ICH ADAPT|University of Alberta|Yes|Completed|January 2007|February 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||February 2012|February 24, 2012|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00963976||134337|
NCT00964249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112017|Phase I Study of GW642444M in Healthy Japanese Male Subjects|Phase I Study of GW642444M - A Randomized, Double Blind, Placebo Controlled, Parallel-group, 7 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose of GW642444M From a Novel Dry Powder Device in Healthy Japanese Male Subjects -||GlaxoSmithKline||Completed|September 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||November 2009|November 25, 2009|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00964249||134316|
NCT00964262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PepE01|A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide|A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of SR Exenatide (PT302) After Subcutaneous Injection in Healthy Male Volunteers||Peptron, Inc.|Yes|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|34|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2013|July 18, 2013|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00964262||134315|
NCT00963963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD054297|Reducing HIV Risks in African American Teens|Reducing HIV Risks in African American Teens in High Poverty Urban Settings||Education Development Center, Inc.|No|Active, not recruiting|April 2006|April 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1200|||Both|11 Years|N/A|No|||June 2012|June 29, 2012|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00963963||134338|
NCT00960856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-028-07-1009|Four Arm Food Effect Study of Fenofibric Acid Tablets|A Four Arm, Single-Dose, Food Effect Evaluation With 105 mg Fenofibric Acid Tablets Administered in a Fasted State and Three Different Fed Conditions, Low-Fat/Low Calorie Meal, Standard Meal, and High-Fat/High Calorie Meal||Mutual Pharmaceutical Company, Inc.|No|Completed|November 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 16, 2009|August 14, 2009|No|Yes||No|August 27, 2009|https://clinicaltrials.gov/show/NCT00960856||134570|
NCT00960869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA32540-302|Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers|A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers||POZEN|Yes|Completed|October 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|519|||Both|55 Years|N/A|No|||January 2016|January 20, 2016|August 17, 2009|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00960869||134569|
NCT00960882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMMET 1011/07|Gastric Tolerability and Pharmacokinetics of DMMET-01|Gastric Tolerability and Pharmacokinetics of DMMET-01. Daily Intake for 30 Days, in Normal Alimentation Conditions, in Healthy Volunteers.||Laboratorios Silanes S.A. de C.V.|Yes|Completed|June 2007|April 2008|Actual|March 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960882||134568|
NCT00969462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1. NHL|Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma|Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients||Meir Medical Center|No|Completed|September 2009|December 2012|Actual|December 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2012|June 27, 2013|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00969462||133921|
NCT00969774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUC/SP 0021/2006|Facial Type Determination Through Cephalometry, Anthropometry and Facial Analysis|Facial Type Determination Through Ricketts Cephalometric Analysis, Anthropometric Measurements, Indices and Proportions and Facial Analysis Performed by Means of Photographs||Pontificia Universidade Catolica de Sao Paulo|Yes|Completed|February 2006|||November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|105|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|primary care orthodontic clinic|September 2009|September 1, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969774||133897|
NCT00969787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWP05195-P001|DWP05195 in Healthy Adult Male Volunteers|DWP05195 in Healthy Adult Male Volunteers||Daewoong Pharmaceutical Co. LTD.|Yes|Completed|April 2009|||November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|80|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|March 31, 2010|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00969787||133896|
NCT00970346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-1916|Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis|A Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy Volunteers||AlgiPharma AS|No|Completed|September 2009|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970346||133854|
NCT00970333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEPPA 001|Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions|Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions||Institute for Neurodegenerative Disorders|No|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970333||133855|
NCT00970619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-093|DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT.|Ultrasound Accelerated Catheter-directed Thrombolysis for Primary Iliofemoral Deep Vein Thrombosis (IFDVT) Compared to Non-invasive Conventional Anticoagulant Therapy Alone: a Dutch Randomized Controlled Multicenter Clinical Trial.|NL28394|Maastricht University Medical Center|Yes|Recruiting|May 2010|January 2015|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|September 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970619||133833|
NCT00970892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.ANK.0.20.05.04|VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management|Evaluation of VKORC1 and Cytochrome P450 CYP2C9 Gene Polymorphisms and Management of Warfarin Dose Using Pharmacogenetic Data||Ankara University|No|Recruiting|July 2009|December 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood|Both|18 Years|85 Years|No|Non-Probability Sample|Patients who require warfarin for at least 6 months under care of cardiovascular surgery,        cardiology and pulmonary disease.|September 2009|September 2, 2009|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00970892||133812|
NCT00970879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRD-Sidaction-01|Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine|Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomised Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine|PACOME|Institut de Recherche pour le Developpement|Yes|Completed|December 2009|December 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|430|||Female|18 Years|N/A|No|||January 2013|January 21, 2013|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00970879||133813|
NCT00971165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG08621-2|Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension|A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study|PREVER|Hospital de Clinicas de Porto Alegre|Yes|Completed|July 2010|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|655|||Both|40 Years|N/A|No|||February 2015|February 11, 2015|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971165||133791|
NCT00971529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhaotaoliang123|Smoking Cessation Effect of Tea Filter Through Inhibition of Nicotine Receptor|Phase 1 Study on Smoking Cessation Effect of Tea Filter||General Hospital of Beijing PLA Military Region|Yes|Completed|January 2009|July 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|159|Samples Without DNA|CO|Male|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups        (smoking with tea filters or regular filters).        The investigators then recruited 59 volunteers with longer smoking history and stronger        desire for quitting smoking for smoking cessation test using the tea filter.|September 2009|September 3, 2009|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00971529||133764|
NCT00971152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-GYN-08-02|Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle|Effect of a Higher Than Maximum 450IU Gonadotropin Dose on Patient Outcomes in an In-Vitro Fertilization Setting: a Randomized Controlled Non-infertility Trial||OVO R & D|No|Completed|September 2009|February 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|366|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971152||133792|
NCT00963989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 2480.A|Imaging Guided Patient Selection for Interventional Revascularization Therapy|The START Trial: Clinical Outcome in Acute Stroke Treatment After Imaging Guided Patient Selection for Interventional Revascularization Therapy|START|Penumbra Inc.|No|Completed|September 2009|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|146|||Both|18 Years|85 Years|No|||March 2016|March 14, 2016|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963989||134336|
NCT00964275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000639720|Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein|Study of Positron Emission Tomography With 18-fluorodeoxyglucose in Detecting Cancer in Patients With Idiopathic Venous Thromboembolism|MVTEP|University Hospital, Brest|Yes|Completed|March 2009|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|400|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00964275||134314|
NCT00960310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60111|Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions|Randomized, Open-Label, 1-Way Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex (Reference) Following a 50 mg Dose in Healthy Subjects Under Fed Conditions.||Sandoz||Completed|June 2006|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960310||134611|
NCT00960583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIL_PAPA|Economic Evaluation of an Exercise Program After Multidisciplinary Rehabilitation in Patients With Chronic Low Back Pain|Cost-utility Analysis of a 3-month Exercise Program vs. Routine Follow-up in Patients Having Completed Multidisciplinary Rehabilitation: a Randomized Controlled Trial||University of Lausanne|No|Completed|January 2005|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|60 Years|No|||August 2009|October 26, 2010|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960583||134591|
NCT00964535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103002|Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics|Bioequivalence Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 200/6 µg/Inhalation and Symbicort Turbohaler 200 µg/6 µg/Inhalation|KINECO|Orion Corporation, Orion Pharma|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|87|||Both|18 Years|60 Years|No|||February 2010|February 12, 2010|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964535||134295|
NCT00961441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01340|Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy|An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy||UCB Pharma|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|12 Years|55 Years|No|||July 2015|July 10, 2015|August 17, 2009|Yes|Yes||No|March 15, 2011|https://clinicaltrials.gov/show/NCT00961441||134525|
NCT00960284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000641309|Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer|Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil|PACT-7|IRCCS San Raffaele|No|Completed|June 2003|June 2009|Actual|June 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|75 Years|No|||January 2012|January 12, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960284||134613|
NCT00960297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 144|Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC|Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Terminated|August 2009|May 2013|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|August 13, 2009|Yes|Yes|Study was terminated due to slow accrual|No|August 27, 2013|https://clinicaltrials.gov/show/NCT00960297||134612|
NCT00969839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-001|NovaLign Intramedullary Fixation System (IFS) for the Treatment of Humeral Fractures|A Study to Evaluate the Safety and Effectiveness of the NovaLign Intramedullary Fixation System for the Treatment of Humeral Diaphysis Fractures||NovaLign Orthopaedics, Inc|No|Recruiting|September 2009|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2009|September 16, 2009|August 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969839||133892|
NCT00970047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-FS-101|Development of a Fetal Sex Assay From Maternal Whole Blood|Development of a Noninvasive Fetal Sex Determination Test Between 6 and 16 Weeks of Gestation||Sequenom, Inc.|No|Completed|June 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Plasma and PBMCs|Female|18 Years|64 Years|No|Non-Probability Sample|Pregnant women between 6 and 16 weeks of gestation.|October 2009|January 31, 2011|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00970047||133876|
NCT00970060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11385|Exercise and Nerve Function in Diabetes|Effectiveness of an Exercise Program on Nerve Function and Cutaneous Nerve Fibers in Adults With Type 2 Diabetes||University of Kansas Medical Center|No|Completed|June 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|40 Years|70 Years|No|||July 2013|July 3, 2013|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970060||133875|
NCT00970073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIRB 09-432|Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant|A Randomized Controlled Clinical Trial of Low Dose Thymoglobulin and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection After Liver Transplantation||The Cleveland Clinic|No|Active, not recruiting|August 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|70 Years|No|||July 2013|July 29, 2013|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970073||133874|
NCT00970632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12932|A Study of Tadalafil in Men With Benign Prostatic Hyperplasia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|October 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|511|||Male|45 Years|N/A|No|||March 2012|March 8, 2012|September 1, 2009|Yes|Yes||No|November 21, 2011|https://clinicaltrials.gov/show/NCT00970632||133832|
NCT00970359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-048|Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244|Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study||Memorial Sloan Kettering Cancer Center|Yes|Completed|September 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|September 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00970359||133853|
NCT00970372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSHF_815360|Dual-Diagnosis and Compulsory Treatment|Compulsory Treatment of Alcohol and Drug Dependent Patients and Dual Diagnosis in 5 Counties of Health Region South-East, Norway||Sorlandet Hospital HF|Yes|Completed|September 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|202|||Both|18 Years|N/A|No|Non-Probability Sample|In five counties there are a total of eight beds reserved for compulsory treatment        according to the LOST § 6.2 regulation. Of these, four are situated at the Addiction Unit        at Sørlandet Hospital (Kristiansand) and four at the Vestfold Clinic, part of the        psychiatric section in the county of Vestfold, Tønsberg. It will be necessary to include        both sites for two years of inclusion in this study to obtain sufficient samples, as there        are only approximately 35 patients in the compulsory committed category annually in this        region. All eligible patients compulsory committed to the two wards in Kristiansand and        Tønsberg during a twenty-four month period will be asked to participate during their        initial assessment.|April 2014|April 15, 2014|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970372||133852|
NCT00970645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002240|Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer|A Prospective Multicenter Study Comparing Endobronchial and Endoscopic Ultrasound-Guided FNA to Mediastinoscopy/Thoracoscopy in the Staging and Early Detection of Metastases in Lung Cancer||Mayo Clinic|No|Terminated|February 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2|||Both|21 Years|N/A|No|||July 2011|July 15, 2011|September 1, 2009||No|Similar study published results|No||https://clinicaltrials.gov/show/NCT00970645||133831|
NCT00971191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471031|A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804|A Presurgical Study To Evaluate Molecular Changes That Occur In Human Non-Small Cell Lung Cancer Tissue After Short Term Exposure To PF-00299804||Pfizer|No|Terminated|February 2010|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|September 2, 2009|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00971191||133789|
NCT00971204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-2734|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2009|||||N/A|N/A|N/A||||||||||||||July 30, 2015|September 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971204||133788|
NCT00971217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC/2009/096|Exploring the Effectiveness of the 'Back of the Net' Intervention on Indices of Physical and Psychological Measures|Exploring the Effectiveness of the 'Back of the Net' Intervention on Indices of Physical and Psychological Measures|BTN|Dublin City University|No|Completed|August 2010|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|140|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 29, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971217||133787|
NCT00971230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI E001|A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa|A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Kenya, Africa||International AIDS Vaccine Initiative||Completed|October 2009|July 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|72|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2010|August 5, 2010|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971230||133786|
NCT00971828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chinoy-001|A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy|A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy||Salford Royal NHS Foundation Trust|Yes|Recruiting|July 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Bloods, including fasting blood sugar, lipid profile and C-reactive protein, serum creatine      kinase, erythrocyte sedimentation rate, serology including antiphospholipid status.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|IIM patients will be recruited via the Adult Onset Myositis clinic, Salford Royal NHS        Foundation Trust. Suitable patients will be asked if they are willing to partake in the        study, via a letter, including a patient information leaflet. If willing, they will        contact our study co-ordinator, who will facilitate the visit to the WTCRF. The patient        will then sign a consent form and be able to enter the study.|October 2009|August 12, 2011|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971828||133741|
NCT00971503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM 02|Safety and Efficacy of Arterial Delivery of Autologous Bone Marrow Cells in the Treatment of Insulin-Dependent Diabetes|Método Para Regenerar el páncreas Con localización in Vivo de médula ósea Total Autologa en Pacientes diabéticos Tipo 1. Estudio Fase IIB.||University of Moron|Yes|Withdrawn|February 2011|February 2012|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|30 Years|No|||July 2011|July 26, 2011|September 1, 2009||No|Principal Investigator moved to Chile from Argentina|No||https://clinicaltrials.gov/show/NCT00971503||133766|
NCT00971516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPL900209-01|Healing Profile of Titanium Dental Implants Placed in Patients With Diabetes|Healing Profile of Titanium Dental Implants Placed in Patients With Type 2 Diabetes: a Prospective Osteoimmunological and Clinical Pilot Study||Escola Bahiana de Medicina e Saude Publica|Yes|Completed|October 2009|May 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 5, 2012|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971516||133765|
NCT00972140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-PR-3301-011-04|Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 3-month, Double-blind, Double-dummy, Randomised, Multinational, Multicenter, 2-arm Parallel-group Study Comparing the Efficacy and Safety of Formoterol-HFA pMDI 12µg Twice Daily and Formoterol-DPI 12µg Twice Daily, in Patients With Stable Chronic Obstructive Pulmonary Disease||Chiesi Farmaceutici S.p.A.|No|Completed|August 2005|October 2006|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|457|||Both|40 Years|N/A|No|||December 2011|December 12, 2011|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972140||133717|
NCT00964548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13076|Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage|Dantrolene in the Treatment of Cerebral Vasospasm After Subarachnoid Hemorrhage - a Phase 1 Study||University of Massachusetts, Worcester|No|Completed|July 2007|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|August 23, 2009||No||No|November 18, 2011|https://clinicaltrials.gov/show/NCT00964548||134294|Limitations of this trial include the small n. No power analysis was performed, but rather a convenience sample was chosen as this was a proof-of-concept study. Transcranial Doppler measurements are operator dependent.
NCT00964561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0036-08-05|Ph1 Study of Valortim and Ciprofloxacin in Humans|A Phase I, Single Blind, Randomized, Placebo Controlled, Drug Interaction Study of Intravenous (IV) Valortim® and Intravenous (IV) Ciprofloxacin in Healthy, Normal Subjects||PharmAthene, Inc.|Yes|Suspended|August 2009|July 2010|Anticipated|February 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|26|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||August 2009|August 9, 2010|August 22, 2009|No|Yes|On partial hold for clinical investigation into AE and SAE reported.|No||https://clinicaltrials.gov/show/NCT00964561||134293|
NCT00960323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1019|Drug-Drug Interaction Study Between Colchicine and Atorvastatin|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Atorvastatin on the Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 22, 2010|August 13, 2009|No|Yes||No|February 22, 2010|https://clinicaltrials.gov/show/NCT00960323||134610|
NCT00960596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902042R|Preventive Medicine Study of Childhood Atopic Diseases|Preventive Medicine Study of Childhood Atopic Diseases||National Taiwan University Hospital|Yes|Enrolling by invitation|July 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2009|August 24, 2009|August 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00960596||134590|
NCT00960895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERMOP-001|Pulmonary Hypertension in Lymphangioleiomyomatosis|Observational Study of Patients With Lymphangioleiomyomatosis and Pulmonary Hypertension|LAM-PH|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|No|Completed|August 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|||Female|18 Years|N/A|No|Non-Probability Sample|Lymphangioleiomyomatosis, either sporadic or associated with tuberous sclerosis        Precapillary pulmonary hypertension, as defined by right-sided heart catheterization (mean        pulmonary artery pressure higher than 25 mmHg, wedge capillary pulmonary pressure less        than 15 mmHg, pulmonary vascular resistance higher than 3 Wood units)|October 2011|October 26, 2011|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960895||134567|
NCT00960908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESOLUTE-KOREA|Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent|RESOLUTE-KOREA Registry - Registry to Evaluate the Efficacy of Zotarolimus-eluting Stent||Seoul National University Hospital|No|Recruiting|January 2009|||January 2012|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|Approximately 4000 patients derived from a population of patients receiving percutaneous        coronary intervention for ischemic heart disease will be enrolled in the present registry.|August 2009|August 17, 2009|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960908||134566|
NCT00960609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-HV|Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study|Communicating Veins Between Adjacent Hepatic Veins: Rare, Exceptional or Frequent? An Intra-operative Ultrasound Study||University of Milan||Completed|January 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Probability Sample|Patients with primary and metastatic liver tumors addressed to surgical treatment|August 2009|August 17, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960609||134589|
NCT00961766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103NS101|Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants|Phase 1: A Single-Center, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants||Biogen|Yes|Completed|August 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|70 Years|No|||October 2014|October 24, 2014|August 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00961766||134502|
NCT00961779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-HV-004|Safety Study of NNZ-2566 in Healthy Female Subjects|A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability and PK of NNZ-2566 in Healthy Females, When Administered as a Loading Dose (10-Min), and as a Loading Dose Followed by a Maintenance Dose (72-Hr).||Neuren Pharmaceuticals Limited|Yes|Completed|March 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|August 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00961779||134501|
NCT00970099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H6820-22194|Mechanism of Insulin-Resistant in Lean Non-Diabetics|Mechanism of Exercise Training in Lean Insulin-Resistant Non-Diabetics||University of California, San Francisco|No|Completed|February 2004|December 2009|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00970099||133872|
NCT00969826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT08_GCPGC|Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor|A Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of GCPGC After Single Subcutaneous Administration in Healthy Male Volunteers|GCPGC|Seoul National University Hospital|No|Completed|September 2008|September 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|38|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||January 2011|January 9, 2011|August 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00969826||133893|
NCT00970385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTP 95|Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma|Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP|LTP|University Hospital, Grenoble|Yes|Completed|January 1995|September 2008|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|70 Years|No|||September 2009|September 8, 2009|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00970385||133851|
NCT00970398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816609|Effect of an Infant Formula on Infant Growth, Health and Immune Functions|Effect of Infant Formula With Bovine Milk Osteopontin on Infant Growth, Health and Immune functions-a Double-blind Randomized Trial||Biostime, Inc.|Yes|Active, not recruiting|September 2009|July 2013|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|320|||Both|N/A|30 Days|Accepts Healthy Volunteers|||April 2013|April 18, 2013|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970398||133850|
NCT00970658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL-SIP-03/09|Efficacy and Safety of Salonsip Compared to Sabiá Plaster|Clinical Multicenter Study, Randomized, Open, to Evaluate the Efficacy and Safety of Salonsip Compared to Sabiá Plaster Relief of the Signs and Symptoms in Patients With Contusions, Sprains, Injuries and Muscular Injuries With Less Than 24 Hours Early or Holders of Myalgia, Pain and Tendonitis in Regions Miofasciais Articulated.|SAL-SIP-03/09|Hisamitsu Farmaceutica do Brasil Ltda|Yes|Not yet recruiting|December 2009|February 2010|Anticipated|January 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|12 Years|N/A|No|||September 2009|September 3, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970658||133830|
NCT00970931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG08621-1|Hypertension Prevention in Pre-Hypertensive Individuals|Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study|PREVER|Hospital de Clinicas de Porto Alegre|Yes|Completed|July 2010|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|730|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00970931||133809|
NCT00970944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A031713|Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)|A Multicenter Prospective Randomized Controlled Trial of the Effectiveness of Amantadine Hydrochloride in Promoting Recovery of Function Following Severe Traumatic Brain Injury||JFK Medical Center|Yes|Completed|February 2003|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|184|||Both|16 Years|65 Years|No|||September 2012|September 11, 2012|September 2, 2009|Yes|Yes||No|December 12, 2011|https://clinicaltrials.gov/show/NCT00970944||133808|
NCT00970905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 0908|Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy|Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen|AVERT|University of Vermont|Yes|Active, not recruiting|October 2009|August 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||December 2015|December 27, 2015|August 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970905||133811|
NCT00970918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00092|Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs|Prevalence of Atherosclerotic Disease in Asian Subjects Not on Lipid-lowering Agents, But With at Least Two CVD Risk Factors|CIMT|AstraZeneca|No|Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Screening|1||Actual|2609|||Both|30 Years|69 Years|No|||September 2010|September 22, 2010|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00970918||133810|
NCT00971568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-163|Urinary Biomarkers Characteristic to Interstitial Cystitis|Urinary Biomarkers Characteristic to Interstitial Cystitis- Proteomic Analysis of Urine||William Beaumont Hospitals|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|We will be examining urine already collected and in the Beaumont Biobank. The urine to be        examined is from patients with known severe Interstitial Cystitis (IC), mild IC or known        to not have the disease.|March 2012|March 15, 2012|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971568||133761|
NCT00971542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_03|Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age|A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Egg-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age||Novartis||Completed|September 2009|July 2011|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|778|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971542||133763|
NCT00971555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC#29111|Thyroid Function in Late Preterm Infants|Thyroid Function in Late Preterm Infants in Relation to Severity of Illness||Christiana Care Health Services|No|Completed|September 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Blood for total T4 and TSH testing will be done utilizing standardized filter paper used for      the State of Delaware Newborn Screening Program.|Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Late preterm infants|March 2011|March 22, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971555||133762|
NCT00972153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS001-0912403|Device to Reduce Surgery Site Contamination|Reduction of Airborne Particulate in the Surgical Field Using Directed Local Airflow||Nimbic Systems, LLC||Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|29|||Both|N/A|N/A|No|||March 2012|March 14, 2012|September 2, 2009|Yes|Yes||No|April 22, 2010|https://clinicaltrials.gov/show/NCT00972153||133716|
NCT00972179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080390|Safety Study of AMG 157 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 157 in Healthy Subjects||Amgen||Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 25, 2011|September 3, 2009||||No||https://clinicaltrials.gov/show/NCT00972179||133715|
NCT00964015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHSC|Starch or Saline After Cardiac Surgery|Short-term Outcomes of Fluid Replacement and Resuscitation Strategy in the Cardiac Surgery Patient: A Randomized, Controlled Trial|SSACS|London Health Sciences Centre|Yes|Active, not recruiting|August 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2011|January 3, 2012|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00964015||134334|
NCT00964028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112065|Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)|Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) in Infants||GlaxoSmithKline||Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||September 2013|September 5, 2013|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964028||134333|
NCT00964301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110807|Telemedicine Education for Rural Children With Asthma|Telemedicine Education for Rural Children With Asthma||Arkansas Children's Hospital Research Institute|Yes|Completed|August 2009|March 2015|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|August 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00964301||134312|
NCT00964574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_02483|Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus|Multicentre, Open, Non-randomised Controlled Phase IV Clinical Trial of Efficacy and Safety for Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine|PORTAL 1|Sanofi||Completed|July 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964574||134292|
NCT00960336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633600|Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer|Multicenter Study of PEGylated Liposomal Doxorubicin in Geriatric Oncology - Metastatic Breast Cancer - First-line Treatment PEGylated Liposomal Doxorubicin in Patients Older Than 70 Years, Breast Cancer Metastasis||ARCAGY/ GINECO GROUP|No|Completed|March 2008|||May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Female|70 Years|N/A|No|||October 2014|October 28, 2014|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960336||134609|
NCT00960622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRU|Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects|Effect of Substituting Truvada for Combivir or Trizivir vs Continuing Combivir or Trizivir on Physiologic Correlates of Mitochondrial Function in Subjects Infected With Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy|TRU|St. Luke's-Roosevelt Hospital Center|No|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||September 2012|January 25, 2013|August 17, 2009|Yes|Yes||No|September 21, 2011|https://clinicaltrials.gov/show/NCT00960622||134588|
NCT00960635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|336/00|Immunointervention With Calcitriol in New-Onset Type 1 Diabetes|Immunointervention With 1,25-dihydroxy-vitamin D3 in New-onset Type 1 Diabetes||Institut fur Diabetesforschung, Munich, Germany|No|Completed|June 2001|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Primary Purpose: Prevention|2||||||Both|18 Years|39 Years||||August 2009|August 17, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960635||134587|
NCT00961194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0730102|Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain|Evaluation of the Analgesic Effect of Orally Administrated Ketamine in Peripheral Neuropathic Pain Disease: Comparison of Three Doses Versus Placebo.|KETACLUD|University Hospital, Toulouse|No|Completed|March 2009|March 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|22|||Both|30 Years|90 Years|No|||December 2014|December 1, 2014|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961194||134544|
NCT00961207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHStrogerH09-083|Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients|Study of Triple Blockade of the Renin Angiotensin Aldosterone System (RAAS) in Diabetic (Type 1&2) Proteinuric Patients With (ACE-, ARB, DRI)||John H. Stroger Hospital|Yes|Terminated|August 2009|September 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|August 17, 2009||No|Altitude trial which used similar drugs was terminated due to increased ADR.|No||https://clinicaltrials.gov/show/NCT00961207||134543|
NCT00969488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pensa Rio - UERJ/FAPERJ|The Effect of a High Protein Diet on Body Weight Change During Post-partum|The Effect of a High Protein Diet on Body Weight Change and Body Composition During Post-partum: Randomized Clinical Trial Study||Rio de Janeiro State University|Yes|Completed|February 2009|July 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|180|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|July 19, 2011|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969488||133919|
NCT00969501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUF-SHO-0001|Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)|Investigator Initiated, Exploratory Case Study Three Injections of EUFLEXXA (Sodium Hyaluronate)Treatment of Chronic Shoulder Pain Associated With Osteoarthritis||Georgia Institute for Clinical Research, LLC|Yes|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|30 Years|79 Years|No|||March 2013|March 27, 2013|August 31, 2009|No|Yes||No|September 5, 2012|https://clinicaltrials.gov/show/NCT00969501||133918|
NCT00970684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4507|Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase II Study of Bevacizumab Plus Docetaxel and Gemcitabine in Subjects With Advanced, Previously Untreated, Non-Squamous Non-Small Cell Lung Cancer||Case Comprehensive Cancer Center|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|September 1, 2009|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00970684||133828|
NCT00970086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBB_ANA_TAP|Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Groin Surgery|Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Inguinal Surgical Procedures: How Does it Compare With the "Gold Standard" Caudal Blockade|TAP|University Hospital, Basel, Switzerland|No|Terminated|August 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|22|||Both|2 Years|8 Years|No|||December 2015|December 2, 2015|August 25, 2009||No|Groin surgery was changed to a laparoscopic technique; recruitable patients ceased.|No||https://clinicaltrials.gov/show/NCT00970086||133873|
NCT00970671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090690|Treatment of Surgical Scars Using the Pulsed Dye Laser|Treatment of Surgical Scars With the 595nm Pulsed Dye Laser Using Purpuric and Nonpurpuric Parameters: A Comparative Study||University of California, San Diego|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|80 Years|No|||October 2012|October 20, 2012|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970671||133829|
NCT00970957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOBA-03-2008|Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion|Study of the Safety and Efficacy of Bevacizumab Intravitreal Injections for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions|EBOVER|Instituto Universitario de Oftalmobiología Aplicada||Completed|September 2009|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|107|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00970957||133807|
NCT00971256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-144|Urine Cytology and Utility in Bladder Recurrence|Urine Cytology and Utility in Bladder Recurrence||William Beaumont Hospitals|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with bladder cancer.|November 2011|November 22, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971256||133784|
NCT00971581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETOM_L_04584|Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole|Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions||Sanofi||Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||June 2010|June 28, 2010|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971581||133760|
NCT00971594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG0120|Age, Lifestyle, Muscle Mechanisms in Insulin Resistance|Age, Lifestyle, Muscle Mechanisms in Insulin Resistance||National Institute on Aging (NIA)|Yes|Completed|June 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Male|50 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 2, 2009|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971594||133759|
NCT00971243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-513-E07|Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes|A Phase IIb, Double-blind, Parallel Group, Multi-center, Dose-finding Study to Investigate the Efficacy and Safety of 4 Doses of MP-513 When Added to Ongoing Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus, With an Open Label Extension||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|August 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|448|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|September 1, 2009||No||No|August 21, 2014|https://clinicaltrials.gov/show/NCT00971243||133785|
NCT00972231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0133-08-EMC|Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia|Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia||HaEmek Medical Center, Israel|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|93|||Both|5 Years|45 Years|No|Non-Probability Sample|150 patients suffering from hemoglobinopathies are treated at the Pediatric Hematology        Unit, Ha'Emek Medical Center. This include Thalassemia Major blood transfused and treated        by chelators, Thalassemia Intermedia patients ussualy not transfused, some of them treated        by Hydroxyurea, and two groups of Sickle cell patients, Sickkle cell homozygous and Sickle        cell thalassemia. Most of the Sickle cell patients are treated with Hydroxyurea.|August 2015|August 30, 2015|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972231||133711|
NCT00972543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28861|Raptiva in Palm and Sole Psoriasis|A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis Involving Palms and/or Soles, With or Without Pustules.||Merck KGaA|No|Terminated|September 2008|||May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|September 4, 2009||No|The study was terminated after the European Medicines Evaluation Agency recommended to suspend    the marketing authorisation of Raptiva in the European Union|No|June 28, 2010|https://clinicaltrials.gov/show/NCT00972543||133687|
NCT00971880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0039-09-EMC|Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects|Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects.||HaEmek Medical Center, Israel|No|Completed|May 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|1 Month|50 Years|No|Probability Sample|Patients receiving blood transfusions due to chronic hematologic disorders|August 2011|August 25, 2011|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971880||133737|
NCT00971841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-557|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer||Bristol-Myers Squibb|Yes|Completed|March 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|N/A|N/A|No|||July 2013|July 18, 2013|September 3, 2009|Yes|Yes||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00971841||133740|Upon completion of Study CA139-540 (NCT 00344552), one subject (who had received 7 courses paclitaxel) rolled over into Study CA139-557. During four years in Study CA139-557, subject received an additional 30 courses of paclitaxel.
NCT00971854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0603/11|Alteration of Deep Brain Stimulation Parameters for Dystonia|Alteration of Deep Brain Stimulation Parameters for Dystonia- A Double Blinded Randomised Controlled Trial||University of Oxford|Yes|Recruiting|September 2009|February 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|October 12, 2009|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971854||133739|
NCT00971867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-539|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer||Bristol-Myers Squibb|Yes|Completed|August 2006|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||September 2010|September 10, 2010|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971867||133738|
NCT00964041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001341|Once Weekly D-cycloserine for Schizophrenia|Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia.||Massachusetts General Hospital|No|Withdrawn|July 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||November 2013|November 19, 2013|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964041||134332|
NCT00964314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJB720603|Traditional Chinese Medicine Five Elements Music Therapy Improving Quality of Life in Patients With Advanced Cancer|Prospective Study With RCT Designed for Evaluation of TCM Five Elements Music Therapy Improving Quality of Life in Patients With Advanced Cancer||Ministry of Science and Technology of the People´s Republic of China|Yes|Completed|February 2009|October 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|146|||Both|18 Years|80 Years|No|||April 2012|April 19, 2012|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00964314||134311|
NCT00964587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL089751-01A1|Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes|Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics|DECIDE|Johns Hopkins University|Yes|Completed|August 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|382|||Both|25 Years|N/A|No|||May 2015|May 11, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964587||134291|
NCT00964600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|825|Bilateral Transversus Abdominis Plane Block and Postoperative Pain Intensity After Elective Cesarean Delivery|Evaluation of the Effect of Bilateral Transversus Abdominis Plane Block on Postoperative Pain Intensity and Analgesia Consumption After Elective Cesarean Delivery|TAP|Tehran University of Medical Sciences|Yes|Recruiting|September 2008|October 2009|Anticipated|September 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||November 2010|November 17, 2010|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00964600||134290|
NCT00960349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00066|Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients|A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric Cancer||AstraZeneca|No|Completed|August 2009|March 2011|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|N/A|No|||June 2011|June 13, 2011|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00960349||134608|
NCT00961246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11584-31742|Web-Based Active Balance Childhood Study in Chinese-American|Web-Based Active Balance Childhood Study in Chinese-American (Web ABC Study): A Randomized Clinical Trial|WEBABC|University of California, San Francisco|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|August 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00961246||134540|
NCT00960921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxford-Kyrgyzstan-2009|Study of the Effects of Iron on Lung Blood Pressure at High Altitude|Study of the Effects of Iron Supplementation on High Altitude Pulmonary Hypertension.||University of Oxford|No|Suspended|August 2009|||January 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 17, 2009||No|Study currently suspended at recruitment stage.|No||https://clinicaltrials.gov/show/NCT00960921||134565|
NCT00969852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT09_Sertraline|Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration|[11C] Sertraline PET Imaging Study That Investigates Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration||Seoul National University Hospital|No|Completed|July 2009|March 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 9, 2011|August 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00969852||133891|
NCT00970411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN951-001|Study of KRN951 in Patients With Solid Tumors|An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients With Solid Tumors||Kyowa Hakko Kirin Company, Limited|Yes|Active, not recruiting|August 2009|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||January 2016|February 22, 2016|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00970411||133849|
NCT00970424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT-MD-304|Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Pioglitazone||Forest Laboratories|No|Terminated|August 2009|||August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|85 Years|No|||September 2011|September 9, 2011|September 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970424||133848|
NCT00971269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2008/066|Pilot Study of NASHA/Dx Gel for Fecal Incontinence|A Pilot Study of Intersphincteric Injection of NASHA/Dx Gel for Fecal Incontinence||Uppsala University Hospital|No|Recruiting|January 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|80 Years|No|||September 2009|September 2, 2009|September 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971269||133783|
NCT00971282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29076|Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins|Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins||Galderma|No|Completed|December 2008|May 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 16, 2012|September 2, 2009||No||No|August 31, 2011|https://clinicaltrials.gov/show/NCT00971282||133782|
NCT00971607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-165|Sevoflurane In Acute Myocardial Infarction|Sevoflurane Sedation During Primary Percutaneous Coronary Intervention.|SIAMI|Lawson Health Research Institute|No|Completed|May 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||September 2014|September 8, 2014|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00971607||133758|
NCT00971620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090072|Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin|Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin||National Institutes of Health Clinical Center (CC)|No|Completed|January 2009|February 2015|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|September 3, 2009|Yes|Yes||No|December 11, 2014|https://clinicaltrials.gov/show/NCT00971620||133757|
NCT00971633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-095|A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)|An Open-Label, Randomized, Single Dose, 3-period Crossover Study to Determine the Bioequivalence of 3 Formulations of Ondansetron in Healthy Young Adult Male and Female Subjects||Merck Sharp & Dohme Corp.|No|Completed|November 2003|January 2004|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|September 3, 2009|No|Yes||No|July 30, 2010|https://clinicaltrials.gov/show/NCT00971633||133756|
NCT00971919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-20926|Chronic Pain in Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer|Prospective Cohort Study to Investigate Chronic Pain After Breast Cancer Surgery||National Cancer Institute (NCI)||Recruiting|March 2007|||May 2010|Anticipated|N/A|Observational|N/A|||Anticipated|284|||Female|18 Years|N/A|No|||September 2009|August 6, 2013|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971919||133734|
NCT00971893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0121003|A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients|A Prospective Study to Assess the Safety and Effectiveness of Medrol® in Acute Asthma in Indian Patients||Pfizer|No|Withdrawn|October 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients of Acute Asthma who have been prescribed oral Medrol tablets, will be enrolled|October 2009|October 29, 2009|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971893||133736|
NCT00971906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_02|Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age|A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of Age||Novartis||Completed|August 2009|April 2011|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|660|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 10, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971906||133735|
NCT00972816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V112_02|Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)|A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Pediatric Subjects 3 to < 9 Years of Age||Novartis|No|Completed|September 2009|October 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|1357|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|September 2, 2009|Yes|Yes||No|December 6, 2010|https://clinicaltrials.gov/show/NCT00972816||133666|
NCT00972257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5132|24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination|Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolol Fixed Combination (DTFC) Compared With the Brimonidine/Timolol Fixed Combination (BTFC) in Subjects With Primary Open-angle Glaucoma||Aristotle University Of Thessaloniki|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|29 Years|80 Years|No|||May 2014|May 9, 2014|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972257||133709|
NCT00972504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112864|723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover|A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000µg), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With Seasonal Allergic Rhinitis||GlaxoSmithKline|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|54|||Both|18 Years|65 Years|No|||February 2013|May 29, 2014|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00972504||133690|
NCT00972517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113638|Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years||GlaxoSmithKline||Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|245|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||June 2011|November 17, 2011|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972517||133689|
NCT00972218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-456|Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease|Efficacy of Adalimumab (Humira®) in Spondyloarthritis Related to Crohn's Disease||University of Alberta|No|Terminated|July 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2010|April 29, 2010|August 31, 2009||No|Difficulty with enrollment|No||https://clinicaltrials.gov/show/NCT00972218||133712|
NCT00964327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR006718|TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains|A Phase IIa Open-label, Randomized Trial to Determine the Antiviral Activity in 60 HIV Positive Subjects With Multiple PI Resistant Strains, Receiving Either Control Treatment or a Daily Dose of 800, 1600, 2400 or 3600 mg TMC114 (Darunavir) for 13 Days Followed by a Single Dose on Day 14||Tibotec Pharmaceuticals, Ireland||Completed|August 2001|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|42|||Both|18 Years|N/A|No|||April 2010|May 18, 2011|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00964327||134310|
NCT00964613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgical Capsulotomy|Pars Plana Surgical Capsulotomy for Posterior Capsular Opacification|Pars Plana Surgical Capsulotomy for Posterior Capsular Opacification|Capsulotomy|Dow University of Health Sciences|Yes|Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|176|||Both|1 Year|95 Years|No|Non-Probability Sample|Patients having posterior capsular opacification|August 2015|August 6, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964613||134289|
NCT00960362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-009-001|An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)|A Randomised, Double-blind, Placebo-controlled, and Single Dose-escalation Trial of AGS-009 Administered in Subjects With Systemic Lupus Erythematosus||Argos Therapeutics|No|Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|13|||Both|18 Years|65 Years|No|||January 2012|January 26, 2012|August 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960362||134607|
NCT00960648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCELLENT-REGISTRY|Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting|EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry||Seoul National University Hospital|No|Active, not recruiting|April 2009|||April 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|4000|||Both|N/A|N/A|No|Non-Probability Sample|Approximately 4000 patients derived from a population of patients receiving percutaneous        coronary intervention for ischemic heart disease will be enrolled in the present registry.|June 2010|June 28, 2010|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960648||134586|
NCT00960661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-EW-GWDM|A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes|A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea||AstraZeneca|No|Completed|September 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1036|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|August 17, 2009|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00960661||134585|
NCT00960960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4629g|A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent Or Metastatic Breast Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety And Pharmacology of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, And With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer||Genentech, Inc.||Active, not recruiting|August 2009|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960960||134562|
NCT00961857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-048|A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)|An Open-label, Randomized Two-Part, Two-Period Crossover Study to Demonstrate the Definitive Bioequivalence After Administration of Final Market Image (FMI) Sitagliptin /Metformin 50/500 mg and 50/1000 mg Fixed Dose Combination (FDC) and Concomitant Administration of 50 mg Doses of Sitagliptin and 500 or 1000 mg Doses of Metformin as Individual Tablets||Merck Sharp & Dohme Corp.|No|Completed|December 2005|January 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|August 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00961857||134495|
NCT00960934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5442-001|A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)|A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women With Osteoporosis||Merck Sharp & Dohme Corp.|No|Terminated|October 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|383|||Female|45 Years|85 Years|No|||February 2015|February 1, 2015|August 17, 2009|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00960934||134564|
NCT00960947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2009|||||N/A|N/A|N/A||||||||||||||August 15, 2009|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00960947||134563|
NCT00961233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSESOM0609|Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)|Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE): Esophageal Medication Distribution, Treatment Response, and Effect on the Adrenal Axis.||University of North Carolina, Chapel Hill|No|Completed|October 2009|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|August 14, 2009|Yes|Yes||No|September 4, 2012|https://clinicaltrials.gov/show/NCT00961233||134541|
NCT00961506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-08-145a|Prospective Evaluation of Laparoendoscopic Single Site Versus Laparoscopic Cholecystectomy|Prospective Evaluation of Laparoendoscopic Single Site Versus Laparoscopic Cholecystectomy||University Hospital, Geneva|No|Completed|March 2009|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2009|August 18, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961506||134520|
NCT00970112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08169/08|Dexamethasone and Etoricoxib for Pain Prevention Following Periodontal Surgery|O Uso de Dexametasona e Etoricoxibe Para a prevenção e Controle da Dor pós-operatória após Cirurgia Periodontal||Universidade Estadual de Ponta Grossa|Yes|Completed|November 2008|March 2010|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2010|May 17, 2010|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970112||133871|
NCT00970125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002156/2|Using Video Images to Improve Advance Care Planning in Patients With Cancer|Using Video Images to Improve Advance Care Planning in Patients With Cancer||Massachusetts General Hospital|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|80|||Both|21 Years|N/A|No|||April 2012|April 28, 2012|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00970125||133870|
NCT00970437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKF001906|A Comparison of Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and System of Supportive Psychotherapy (SYSP) for Early Onset Chronic Depression|A Comparison of Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and System of Supportive Psychotherapy (SYSP) for Early Onset Chronic Depression||University Hospital Freiburg|Yes|Completed|April 2010|December 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|268|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970437||133847|
NCT00970450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAAnaBaselParacetamol 2|The Central Analgesic Effects of Paracetamol on Serotonergic Pathways|The Central Analgesic Effects of Paracetamol on Serotonergic Pathways||University Hospital, Basel, Switzerland|Yes|Completed|November 2009|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|4||Actual|16|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00970450||133846|
NCT00970463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060035|Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly|Impact of Growth Hormone on Serum N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and on Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly||Herlev Hospital|Yes|Completed|January 2006|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|22|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with GHD based on an insufficient stimulation of GH-secretion during        Pyridostigmin-GHRH test.        Patients with acromegaly based on an insufficient supression of GH-secretion during oral        glucose tolerance test|September 2009|September 1, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970463||133845|
NCT00970970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2009.119|Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease|Visualizing VEGF Producing Lesions in Von Hippel-Lindau Disease|VHLimage|University Medical Center Groningen|No|Completed|September 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|Samples With DNA|Blood samples will be taken at day 1 and at the day of the MRI scan for analysis of VEGF      pathway related biomarkers (such as plasma VEGF, PDGF, placental growth factor (PlGF),      soluble VEGF receptors) and endothelial activation markers (such as Von Willebrand Factor      (VWF), plasminogen activator inhibitor type 1 antigen (PAI-1), tissue-type plasminogen      activator antigen (t-PA) and circulating endothelial cells (CECs)). DNA analysis for      evaluation of polymorphisms in genes involved in angiogenesis is optional. In available      biopsy or resection specimens, additional molecular staining of VEGF pathway related      proteins will be performed (such as VEGF, VEGF receptors, HIF).|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected from a tertiary referral center for Von Hippel-Lindau disease.|November 2012|November 5, 2012|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00970970||133806|
NCT00970983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO 185|Axillary Dissection Based on the Histological Result of the Sentinel Node, in Patients With Breast Carcinoma|Randomized Clinical Trial Comparing Axillary Dissection "by Principle" and Axillary Dissection Based on the Histological Result of the Sentinel Node, in Patients With Breast Carcinoma of Small Size||European Institute of Oncology|No|Completed|March 1998|April 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|532|||Female|40 Years|75 Years|No|||November 2011|November 28, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00970983||133805|
NCT00971295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-125|Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers|Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|October 2007|September 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|September 2, 2009||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT00971295||133781|
NCT00971308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI451-002|Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus|Open Label, Multiple-Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of BMS-824393 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|October 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|37|||Both|18 Years|60 Years|No|||January 2011|January 24, 2011|September 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00971308||133780|
NCT00971321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113462|Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 6 to 35 Months||GlaxoSmithKline||Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|157|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||June 2011|June 30, 2011|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971321||133779|
NCT00971646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1234567|Cohort Study: Perceptual Urge Sensation|Cohort Study: Perceptual Urge Sensation||Maastricht University Medical Center|No|Recruiting|June 2010|||December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|The study population consists of two groups: 1: patients with OAB; 2: patients with        osteoporosis.        The patients with OAB will be reqruited from the outpatient clinic and website designed        for patients with overactive bladder symptoms.        The patients with osteoporosis will be recruited from an electronic patient database.|July 2011|July 14, 2011|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971646||133755|
NCT00972244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692C00005|Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control||AstraZeneca|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|417|||Both|18 Years|79 Years|No|||August 2013|August 9, 2013|August 31, 2009|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT00972244||133710|If an efficacy measurement was unavailable at the time point for analysis, last observation was carried forward (LOCF).
NCT00972530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2005:362|Intra-articular Glucocorticoid Treatment of the Elbow|The Importance of Immobilisation After Intra-articular Glucocorticoid Treatment for Elbow Synovitis - a Randomised and Controlled Study||Department of Research and Development, County Council of Gavleborg and Uppsala University|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|N/A|N/A|No|||October 2009|October 9, 2009|September 3, 2009|Yes|Yes||No|September 10, 2009|https://clinicaltrials.gov/show/NCT00972530||133688|
NCT00972270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE: G080021|Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability|RECOVER II Trial: A Prospective Randomized Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability|RECOVER II|Abiomed Inc.|Yes|Terminated|July 2008|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|90 Years|No|||March 2011|March 18, 2011|September 2, 2009|Yes|Yes|Study closed due to insufficient enrollment|No||https://clinicaltrials.gov/show/NCT00972270||133708|
NCT00972829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAR-09-07|Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia|||Bronx VA Medical Center|No|Recruiting|September 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00972829||133665|
NCT00973089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSA001-HMO-CTIL|Alternative Treatment of Deep Carious Lesions Based on Biological Evidences|Alternative Treatment of Deep Carious Lesions Based on Biological Evidences||Hadassah Medical Organization|Yes|Withdrawn|May 2010|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|September 6, 2009||No|recruiting or enrolling participants has halted prematurely and will not resume|No||https://clinicaltrials.gov/show/NCT00973089||133645|
NCT00960375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-001-09S|Smoking Cessation for Veterans With Severe and Persistent Mental Illness|Randomized Trial of a Smoking Cessation Program for Persons With SMI||VA Office of Research and Development|Yes|Completed|April 2010|December 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|75 Years|No|||July 2015|July 28, 2015|August 14, 2009||No||No|June 5, 2015|https://clinicaltrials.gov/show/NCT00960375||134606|The sample was mostly male, African-American, and recruited at VAMCs; it is unclear if findings would generalize to community settings. Many declined to participate; the sample represents persons with SMI who are interested in quitting.
NCT00960674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/414-31/4|Tactile Massage in Type 2 Diabetes|Effects on Type 2 Diabetes by Tactile Massage Compared to Relaxation With Relaxation Tape||Karolinska Institutet|No|Completed|August 2007|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|35 Years|75 Years|No|||April 2013|April 17, 2013|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00960674||134584|
NCT00960973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin K|The Effect of Vitamin K Supplementation on Glucose Metabolism|The Effect of Vitamin K Supplementation on Glucose Metabolism||Seoul National University Hospital|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Male|20 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 9, 2011|August 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00960973||134561|
NCT00960986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9884|A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder|A Phase 4 Comparison of Duloxetine Dosing Strategies in the Treatment of Korean Patients With Major Depressive Disorder||Eli Lilly and Company|No|Completed|August 2009|April 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|249|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|August 17, 2009|Yes|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT00960986||134560|Large number of protocol violations; bias due to unblinded, open-label design (participants were predisposed to expect an outcome of nausea as the primary endpoint); use of emetogenic medications; incorrect reporting and intake of food and drug.
NCT00961558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-888|Canadian Varicocelectomy Initiative (CVI): Effects on Male Fertility and Testicular Function of Varicocelectomy|A Prospective, Multi-Centre, Randomized Controlled Study Comparing Varicocelectomy to Observation in Infertile Men With Clinical Varicoceles|CVI|Mount Sinai Hospital, Canada|Yes|Terminated||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Male|20 Years|65 Years|No|||August 2011|May 24, 2012|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961558||134517|
NCT00961870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGEAH FTR-2|Effect of Radius on Alpha Motor Neuron Excitability|Effect of Radius Subjecting to Mechanical Loading on Alpha Motor Neuron Excitability|ERAMNE|Vakif Gureba Training and Research Hospital|Yes|Completed|September 2009|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|80|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00961870||134494|
NCT00961519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|639-05 00|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2008|||||N/A|N/A|N/A||||||||||||||August 18, 2009|August 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00961519||134519|
NCT00961532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU8168|Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept|Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept|IMPACT|Northwestern University||Completed|December 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|85 Years|No|||July 2014|August 11, 2014|August 17, 2009|No|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT00961532||134518|
NCT00962130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0066|Glucose Monitoring in Tissue Transfers|Glucose Monitoring in Tissue Transfers||University of Wisconsin, Madison|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962130||134474|
NCT00962143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-044-CR|Acute Achilles Repair With or Without OrthADAPT Augmentation|Prospective, Randomized, Multi-center: Acute Achilles Repair With or Without OrthADAPT Augmentation||Synovis Surgical Innovations|No|Withdrawn|June 2008|January 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||December 2009|December 12, 2012|August 17, 2009|Yes|Yes|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT00962143||134473|
NCT00970151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 15251|Determinants of Fetal Inflammatory Exposure at Term|Determinants of Fetal Inflammatory Exposure at Term||Medical University of South Carolina|No|Completed|June 2005|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|618|Samples With DNA|Whole blood, blood serum, placenta, spinal fluid (for some subjects)|Female|14 Years|48 Years|Accepts Healthy Volunteers|Probability Sample|600 racially and ethnically diverse nulliparas who present to the Prenatal Wellness Center        at Cannon Place and Northwoods Clinic with a full term (>37 weeks) pregnancy and who        deliver in the Labor and Delivery Suite at MUSC Hospital|October 2009|October 9, 2009|February 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00970151||133868|
NCT00970177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110_03|Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age|A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of Age||Novartis||Completed|August 2009|March 2011|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|812|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 10, 2013|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970177||133867|
NCT00970476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-14344|Response To Cardiac Resynchronization Therapy In Heart Failure: Role Of Arterial Stiffness|Response To Cardiac Resynchronization Therapy In Heart Failure: Role Of Arterial Stiffness||Creighton University|No|Withdrawn|January 2007|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients, who are scheduled to undergo cardiac resynchronization therapy (CRT) at        Creighton University Cardiac Center will be included in this study.|August 2012|August 28, 2012|September 1, 2009||No|limited enrollment|No||https://clinicaltrials.gov/show/NCT00970476||133844|
NCT00970697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020706|Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers|Double Blind Randomized Controlled Trial of Recombinant Human Platelet Derived Growth Factor-BB Gel (Regranex Gel®) Versus Hydrogel (Duoderm Hydrogel®) for Healing of MARTORELL's Hypertensive Leg Ulcers. ERAN Trial.|ERAN|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2004|June 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||September 2011|October 3, 2011|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970697||133827|
NCT00971334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-T21-202|Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker||Sequenom, Inc.|No|Completed|August 2009|December 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2502|Samples With DNA|Plasma and PBMCs|Female|18 Years|N/A|No|Probability Sample|Pregnant women who are scheduled to undergo a CVS or amniocentesis procedure and will        receive the FISH, karyotype and/or QF-PCR results from the procedure.|February 2012|February 15, 2012|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00971334||133778|
NCT00971958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-002142|Infant Male Circumcision in Gaborone, Botswana, and Surrounding Areas: Feasibility, Safety and Acceptability|Infant Male Circumcision in Gaborone, Botswana, and Surrounding Areas: Feasibility, Safety and Acceptability||Brigham and Women's Hospital|Yes|Completed|May 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1235|||Male|N/A|28 Days|Accepts Healthy Volunteers|||August 2013|August 19, 2013|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971958||133731|
NCT00971971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10727-6|Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients|Assessment of a Protocol Aiming to Prevent Intradialytic Hypotension in Critically Ill Acute Kidney Injury Patients||Sao Jose do Rio Preto University|No|Completed|October 2005|September 2009|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971971||133730|
NCT00972283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3582|Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes|NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)|BEGIN™|Novo Nordisk A/S|No|Completed|September 2009|May 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1006|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|September 3, 2009|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT00972283||133707|
NCT00971932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62241-056|Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Open-label, Single-arm, Multicenter, Phase II Study Investigating Cetuximab in Combination With Chemotherapy in the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Japanese Subjects||Merck KGaA|Yes|Completed|July 2009|||March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|20 Years|N/A|No|||March 2014|March 10, 2014|September 3, 2009||No||No|July 4, 2012|https://clinicaltrials.gov/show/NCT00971932||133733|
NCT00971945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-387|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer||Bristol-Myers Squibb|Yes|Completed|June 2005|March 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|N/A|N/A|No|||November 2009|September 10, 2010|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971945||133732|
NCT00973115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-SIM-302|Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia|Efficacy and Safety of Morning Versus Evening Intake of Simvast CR Tablet in Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 3 Trial||Hanmi Pharmaceutical Company Limited|No|Completed|November 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|19 Years|75 Years|No|||September 2009|September 8, 2009|September 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00973115||133643|
NCT00972556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905028R|Comparison of Mineral Trioxide Aggregate (MTA) and 20% Formocresol (FC) in Pulpotomized Human Primary Molars|Comparison of Mineral Trioxide Aggregate and 20% Formocresol in Pulpotomized Human Primary Molars :A Long-Term Follow-Up Study||National Taiwan University Hospital|No|Recruiting|September 2009|July 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|30 Months|10 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972556||133686|
NCT00972842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_PTCL1|Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)|Phase I/II Trial of Lenalidomide in Combination With Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)|LenVoDex|Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Terminated|September 2009|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|September 7, 2009||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT00972842||133664|
NCT00972855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30063|Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions|Randomized, 1-Way, Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablets and Casodex® Administered as 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 8, 2009|September 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00972855||133663|
NCT00960414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01AT005013|Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons|Supporting Health by Integrating Nutrition and Exercise (SHINE)|SHINE|University of California, San Francisco|Yes|Completed|August 2009|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00960414||134604|
NCT00960999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0915|Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer|A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|November 2009|||August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 16, 2009||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT00960999||134559|
NCT00961597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MenisPRP-001|Assessment of Outcome of Meniscus Repair With or Without Platelet Rich Plasma|Repair of Human Meniscus Complex Red/White Tears With or Without Platelet-Rich Plasma||Cincinnati Sportsmedicine Research and Education Foundation|Yes|Withdrawn|September 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||December 2014|December 10, 2014|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961597||134515|
NCT00962169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw 80-007028-98-07309|Guideline Implementation in Physiotherapy|Development and Pilot Testing of an Implementation Strategy to Increase Physiotherapists'Adherence to Evidence-based Guideline for Patients With Low Back Pain: a Planned, Systematic and Theory-based Approach|GIPhT|Radboud University|No|Recruiting|July 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|N/A|N/A|No|||August 2009|August 18, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00962169||134471|
NCT00962156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-262|Scandinavian Starch for Severe Sepsis/Septic Shock Trial|Effects of Hydroxyethyl Starch 130/0.4 Compared With Balanced Crystalloid Solution on Mortality and Kidney Failure in Patients With Severe Sepsis|6S|Scandinavian Critical Care Trials Group|Yes|Completed|December 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|804|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962156||134472|
NCT00971022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0340|Discount Generic Prescription Study|Discount Generic Prescription Utilization in Low-income Populations||M.D. Anderson Cancer Center|No|Completed|August 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|574|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults or an adult's family member, over the age of 18, with a low-income (less than        $30,000/year) and a chronic health condition requiring prescriptions.|April 2012|April 16, 2012|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971022||133802|
NCT00971347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000354619|Chewing Gum for Weight Loss|Randomized Controlled Trial of Chewing Gum for Weight Loss||University of Alabama at Birmingham|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971347||133777|
NCT00970710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100454|Vaasa Childhood Obesity Primary Prevention Study|Vaasa Childhood Obesity Primary Prevention Study|VACOPP|University of Tampere|Yes|Active, not recruiting|January 2009|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|N/A|6 Years|Accepts Healthy Volunteers|||July 2011|August 4, 2011|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970710||133826|
NCT00970996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0124|Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma|Phase I Biochemotherapy With Cisplatin, Temozolomide, With Increasing Doses of Abraxane, Combined With Interleukin-2 and Interferon in Patients With Metastatic Melanoma|BCAA|M.D. Anderson Cancer Center|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||December 2012|December 31, 2012|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00970996||133804|
NCT00971009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009051|Effects of Internet Support for Cancer Patients|Effects of Internet Support for Cancer Patients on Health Outcomes, Health Care Utilization and Costs: A Randomized Clinical Trial|WebChoice 2|Oslo University Hospital|No|Completed|March 2010|July 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|200|||Female|18 Years|N/A|No|||October 2015|October 19, 2015|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00971009||133803|
NCT00971984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0074-09-EMC|Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel|Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel||HaEmek Medical Center, Israel|No|Completed|October 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|50|||Both|N/A|20 Years|No|Non-Probability Sample|A group of 50 children that underwent workup due to hemolytic anemia and were further        diagnosis as suffering from clinical alpha thalassemia.|August 2015|August 30, 2015|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971984||133729|
NCT00969943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10598|Gender Differences in Response to Cues in Cocaine Dependence|Gender Differences in Response to Cues in Cocaine Dependence||Medical University of South Carolina|No|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|||||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|There will be four primary sources of recruitment for cocaine dependent subjects: (1)        patients referred from the Center for Drug and Alcohol Programs (CDAP) intake coordinator,        (2) individuals presenting to CDAP for either inpatient or outpatient treatment, (3)        individuals presenting to the Charleston Center for inpatient or outpatient treatment, (4)        and individuals presenting to the Dorchester Alcohol and Drug Commission (DADC) for        treatment. Control subjects will be recruited from the Charleston community|September 2009|September 1, 2009|September 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969943||133884|
NCT00972296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOleson|Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia|Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia||Oregon Health and Science University|Yes|Active, not recruiting|September 2009|June 2015|Anticipated|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|27|||Both|5 Years|N/A|No|Non-Probability Sample|Patients followed at the Oregon Hemophilia Treatment Center|October 2014|October 28, 2014|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972296||133706|
NCT00972309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090139|A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer|A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|April 2009|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Male|18 Years|99 Years|No|||September 2015|October 6, 2015|September 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00972309||133705|
NCT00972868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000057|A Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Use of a Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients||Massachusetts General Hospital|No|Not yet recruiting|March 2013|March 2015|Anticipated|March 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2012|November 5, 2012|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00972868||133662|
NCT00973388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016417|VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers|A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects||Tibotec BVBA||Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 16, 2010|September 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00973388||133622|
NCT00973622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110881|Changing Thought and Action in Tobacco Dependence With Transcranial Magnetic Stimulation|Changing Thought and Action in Tobacco Dependence With Transcranial Magnetic Stimulation|rTMS|University of Arkansas|No|Completed|October 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|66|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|August 26, 2009|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT00973622||133604|We experienced significant subject attrition among smokers. We did not experience such attrition among nonsmokers. Also, six smokers were withdrawn because the MRI screen revealed brain abnormalities. No nonsmokers were withdrawn for this reason.
NCT00961012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01370|The Big Squeeze (Lessening the Big Squeeze: The Effect of the Trunk Release on Interface Pressures of Individuals Seated in a High Fowler's Positions)|Lessening the Big Squeeze: The Effect of the Trunk Release on Interface Pressures of Individuals Seated in a High Fowler's Positions||University of British Columbia|Yes|Completed|September 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|129|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 21, 2011|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00961012||134558|
NCT00961610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP-07024|Internet-based Support in Cancer Rehabilitation|Internet-based Support in the Rehabilitation of Danish Cancer Survivors||Danish Cancer Society|Yes|Completed|April 2004|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|794|||Both|18 Years|N/A||Probability Sample|A total of 66 scheduled rehabilitation course weeks were screened for eligibility between        19 April 2004 and 31 December 2005 from the Rehabilitation Centre Dallund in Denmark. All        58 eligible courses including 921 individuals were enrolled and randomized as 27 case        weeks (n = 416 persons) and 31 control weeks (n = 505 persons). Baseline assessments were        obtained from 799 individuals. Data from 10 individuals (5 from each treatment group) were        subsequently excluded, as they did not attend a rehabilitation course week as planned,        leaving final study population of 794 individuals analyzed by 'intention-to-treat' (case:        n = 361/794; control: n = 433/794). Participants were followed up for 12 months in        accordance with their dates of attendance of the rehabilitation course from 19 April 2004        till 31 December 2006.|August 2009|August 18, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961610||134514|
NCT00961259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-028-08-1017|Fasted Pharmacokinetic and Bioequivalency Study of Fenofibric Acid|Open-Label, Randomized, Single-Dose, 3-Arm, Crossover Pharmacokinetic and Bioequivalence Study of One 35 mg Fenofibric Acid Tablet and Three 35 mg Fenofibric Acid Tablets Versus One 105 mg Fenofibric Acid Tablet Under Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|February 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|August 14, 2009|No|Yes||No|August 20, 2009|https://clinicaltrials.gov/show/NCT00961259||134539|
NCT00961571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA61822D|Sunitinib and Capecitabine for First Line Colon Cancer|A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer||Georgetown University|Yes|Terminated|August 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|August 18, 2009|Yes|Yes|Unanticipated side effects and futility|No||https://clinicaltrials.gov/show/NCT00961571||134516|
NCT00962182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-03|Study of Enzyme Supplements to Treat Celiac Disease|Effect of a Cocktail of Two Common Enzyme Supplements on Celiac Disease Patients With Persistent Seropositivity||Heim Pal Children's Hospital|Yes|Active, not recruiting|August 2008|December 2015|Anticipated|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|12 Years|65 Years|No|||August 2015|August 17, 2015|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962182||134470|
NCT00962429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMT-Lou|Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy|Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study||Oregon Health and Science University|No|Completed|February 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|80 Years|No|||January 2013|January 30, 2013|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962429||134451|
NCT00971035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILR4660g|A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids|A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)|MOLLY|Genentech, Inc.||Completed|November 2009|February 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|210|||Both|18 Years|65 Years|No|||June 2011|June 30, 2011|September 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971035||133801|
NCT00971048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|828-101-09-013|Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds|Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds||Healthpoint|No|Completed|September 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|88|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|August 27, 2009|Yes|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00971048||133800|
NCT00971997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13329|A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients|The Study of Stepwise Introduction of Insulin Analog Mixture as a Post-marketing Clinical Trial of Lispro Mix 50/50 to Evaluate Efficacy and Safety in Type 2 Diabetic Patients With Inadequate Glycemic Control on Oral Therapy. (SIMPLE Study)|SIMPLE|Eli Lilly and Company|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|20 Years|80 Years|No|||March 2012|March 15, 2012|September 2, 2009|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT00971997||133728|
NCT00972894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTO/08/024|Group B Streptococcus (GBS) Polymerase Chain Reaction (PCR) Concordance Study|Prospective Evaluation of a Polymerase Chain Reaction (PCR) Assay (GenExpert DX™) for the Rapid Detection of Recto-vaginal Group B Streptococcus (GBS) Colonisation During Intrapartum Screening||HCA International Limited|No|Active, not recruiting|January 2010|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|None Retained|Vaginal culture swabs|Female|18 Years|70 Years|No|Non-Probability Sample|Pregnant females|September 2009|June 22, 2010|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00972894||133660|
NCT00971659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49/0316-Adjunct|Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes|Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily||Profil Institut für Stoffwechselforschung GmbH|No|Completed|January 2008|November 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|35 Years|70 Years|No|||September 2009|September 3, 2009|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971659||133754|
NCT00971672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0024/09-EMC|Incidence of Iron Deficiency Anemia in Toddlers|Incidence of Iron Deficiency Anemia in Toddlers||HaEmek Medical Center, Israel|No|Completed|February 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|260|||Both|18 Months|36 Months|Accepts Healthy Volunteers|Probability Sample|The purpose of this study is to analyze the frequency of Iron deficiency anemia in a group        of 400 toddles from age 18 months to 36 months.        Two groups of children will be included, 200 children from Jewish origin and 200 from non        Jewish origin, mostly Arabs.        Children that were previously diagnosed suffering from iron deficiency, children suffering        from chronic diseases or were born premature will not be included in the study.|August 2015|August 30, 2015|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971672||133753|
NCT00970515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K060214|Laparoscopic or Conventional Mesh Repair of Incisional and Umbilical Hernia|A Prospective, Multicenter, Randomized Trial Comparing Laparoscopy VS Conventional Mesh Repair of Incisional and Umbilical Hernia|EVENTRALAP|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|November 2009|March 2014|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|85 Years|No|||May 2011|October 27, 2011|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970515||133841|
NCT00970528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14081|Glucose Reduction by Early Acarbose Treatment in Basal Insulin|A Randomized, Parallel Group, Open-Label, Active-Controlled Study Comparing Acarbose With Voglibose in Patients Who Are Inadequately Controlled With Insulin Glargine Alone or in Combination With Metformin Based on Glycemic Control|GREAN|Bayer|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|79 Years|No|||February 2014|February 18, 2014|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970528||133840|
NCT00970749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09070184|Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis|Antigen-specific Cell Mediated Immune Response to Chlamydia Trachomatis||University of Pittsburgh|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|55|||Female|15 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 women with history of endocervical chlamydia and 10 women with no history of        endocervical chlamydia|July 2010|July 8, 2010|August 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00970749||133823|
NCT00970762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05975|Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)|Comparative Study of Org 9426 With Vecuronium Bromide (Phase III)||Merck Sharp & Dohme Corp.|Yes|Completed|February 2003|February 2004|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|90|||Both|20 Years|65 Years|No|||April 2015|April 16, 2015|July 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970762||133822|
NCT00971711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24041|Safety Study of Probiotics in Adults With Irritable Bowel Syndrome|Phase I, Open Label Safety Study of VSL#3 in Adults With Irritable Bowel Syndrome||Baylor College of Medicine|Yes|Completed|September 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|No|||March 2016|March 4, 2016|September 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00971711||133750|
NCT00972621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSCO-106-DISP|Clinical Evaluation of a New Viscoelastic for Cataract Surgery|Clinical Evaluation of a New Viscoelastic for Cataract Surgery||Abbott Medical Optics|No|Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 3, 2009|Yes|Yes||No|January 18, 2012|https://clinicaltrials.gov/show/NCT00972621||133681|
NCT00972569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003303|Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction|Specific Aims 3: Define in Hospitalized Decompensated CHF Patients With Renal Dysfunction, the Renal Actions of Low Dose Intravenous Infusion of BNP in the Presence and Absence of Acute PDE V Inhibition in Improving Renal Function|Aim 3 BNP/PDEV|Mayo Clinic|Yes|Enrolling by invitation|October 2009|July 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|69|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972569||133685|
NCT00972881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000648171|Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer|EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for Locally Advanced Rectal Cancer (North West Clinical Oncology Group-04 on Behalf of the NCRI Rectal Cancer Subgroup)|EXCITE|University College, London|Yes|Active, not recruiting|April 2009|December 2014|Anticipated|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|September 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00972881||133661|
NCT00973960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2|A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics|A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics||GI Dynamics|No|Completed|September 2009|December 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with Type 2 Diabetes|August 2011|August 5, 2011|September 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00973960||133579|
NCT00973128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMCSFAntimonyCL|Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis|Reduced Doses of Antimony Plus Recombinant Human GM-CSF Compared With Antimony in Standard Doses for Cutaneous Leishmaniasis: a Randomized, Single-blind, Placebo-controlled, Pilot Study|GMCSFSbv|Hospital Universitário Professor Edgard Santos|No|Completed|February 2004|May 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|50 Years|No|||September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973128||133642|
NCT00960687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-028-07-1008|Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate)|A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg TriCor® (Fenofibrate) Tablets Under Fed Conditions(Standard Meal)||Mutual Pharmaceutical Company, Inc.|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 16, 2009|August 14, 2009|No|Yes||No|August 27, 2009|https://clinicaltrials.gov/show/NCT00960687||134583|
NCT00960700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rayner-630F|A Multi Focal Visual Outcome Study Using Different Near Additions|Clinical Investigational Plan of the Rayner M-flex Multifocal Intraocular Lens (IOL) With Different Near Additions||Rayner Intraocular Lenses Limited|Yes|Terminated|September 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|Aphakic adults with potential for > 20/40 visual outcome to participate in a binocular        study. Subjects to be implanted bilaterally with study device.|February 2013|February 7, 2013|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960700||134582|
NCT00960713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0816002|The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders|The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders|RITAI|University Hospital, Toulouse|Yes|Completed|June 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples With DNA|A biological collection will be constituted to allow pharmaco- immunological studies.|Both|18 Years|N/A|No|Non-Probability Sample|Every patient treated by rituximab off -label for auto-immune diseases in the public        hospitals of the Midi-Pyrénées County (in the South of France) is eligible for the study|October 2012|October 22, 2012|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00960713||134581|
NCT00961272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0889|Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women|An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women||University of North Carolina, Chapel Hill|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Female|18 Years|49 Years|No|Non-Probability Sample|Six HIV-infected adult pre-menopausal women (> or equal to 18 and less than or equal to 49        years of age) currently undergoing treatment with raltegravir with an intact uterus and        cervix will be considered for enrollment. Pregnant women and women testing positive for        STDs (bacterial vaginosis, syphilis, gonorrhea, chlamydia, or trichomonas) will be        excluded. The six HIV-infected women enrolled in this study will come from the UNC-Chapel        Hill Infectious Diseases Clinic and associated clinics in local Health Departments.|February 2014|February 27, 2014|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00961272||134538|
NCT00966251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-2009-02|Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma|Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma||CureTech Ltd|No|Terminated|October 2009|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|August 25, 2009||No|The study was stopped because of slow accrual|No||https://clinicaltrials.gov/show/NCT00966251||134167|
NCT00961883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 078|Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults|A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime/Boost Vaccine Regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adult Participants||HIV Vaccine Trials Network|Yes|Completed|August 2009|||January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961883||134493|
NCT00970268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-MD-36|Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)|A Long-term, Randomized, Double-blind Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease||Forest Laboratories|No|Completed|January 2010|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|291|||Both|40 Years|N/A|No|||August 2012|August 14, 2012|September 1, 2009|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00970268||133860|
NCT00970281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13333|A Study of Olanzapine in Patients With Schizophrenia|A Double-Blind Confirmatory Study Comparing Rapid-Acting Intramuscular Olanzapine and Rapid-Acting Intramuscular Placebo in Patients With an Exacerbation of Schizophrenia With Acute Psychotic Agitation||Eli Lilly and Company|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|20 Years|64 Years|No|||March 2012|March 6, 2012|September 1, 2009|Yes|Yes||No|January 18, 2012|https://clinicaltrials.gov/show/NCT00970281||133859|
NCT00962442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAH-LYSO|N-Acetylcysteine in Severe Acute Alcoholic Hepatitis|N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial||Erasme University Hospital|Yes|Completed|September 2000|||January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||August 2009|August 19, 2009|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962442||134450|
NCT00962455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-CARA-0001113|Feedback Reports and e-Learning in Primary Care Spirometry|Feedback Reports and E-learning to Support Spirometry Test Performance in Dutch Family Practices|FRESCO|Radboud University|No|Completed|November 2007|April 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|1135|||Both|10 Years|N/A|No|||August 2009|August 19, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00962455||134449|
NCT00971685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2008-002|The Treatment of Lenalidomide in Patients With POEMS Syndrome|Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome||Istituto Clinico Humanitas|No|Recruiting|July 2009|July 2011|Anticipated|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971685||133752|
NCT00971698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0135-08-EMC|The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia|The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.||HaEmek Medical Center, Israel|No|Completed|February 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|50|||Both|1 Year|35 Years|No|Probability Sample|Two groups of patients: 25 patients with homozygous Sickle Cell Anemia and 25 patients        with Sickle Cell Thalassemia|August 2011|August 25, 2011|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971698||133751|
NCT00972595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-106|Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)|An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Determine the Bioequivalence of 2 Formulations of Ondansetron in Healthy Young Adult Male and Female Subjects||Merck Sharp & Dohme Corp.||Completed|June 2004|September 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|September 3, 2009|No|Yes||No|May 19, 2010|https://clinicaltrials.gov/show/NCT00972595||133683|
NCT00972608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014388|Surgical Planning for Reconstruction of Complex Heart Defects|Surgical Planning for Reconstruction of Complex Heart Defects||Emory University|No|Recruiting|August 2009|February 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|18 Years|No|Non-Probability Sample|Patients with complex congenital heart defects, such as Double Outlet Right Ventricle,        requiring surgical intervention, who are being treated at Children's Healthcare of        Atlanta.|January 2016|January 10, 2016|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972608||133682|
NCT00973427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPI-1001|DNA Chip Based Prognosis of Lung Cancer|DNA Chip Based Prognosis of Lung Cancer||Medical Prognosis Institute A/S|No|Completed|June 2008|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|144|Samples Without DNA|post resection specimen|Both|18 Years|75 Years|No|Non-Probability Sample|The population consist of subjects being examined for NSCLC at Roswell Park Cancer        Institute (US), University of Alabama (US), Copenhagen University (DK), Odense University        Hospital (DK) and Aarhus University Hospital (DK)|September 2015|September 22, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973427||133619|
NCT00973661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00013264|Electronic Tools to Assist With Identification of and Counseling for Overweight Patients|Electronic Tools to Assist With Identification of and Counseling for Overweight Patients||Northwestern University|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2600|||Both|18 Years|65 Years|No|||July 2011|July 26, 2011|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973661||133601|
NCT00971061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1465087|Ahmed Glaucoma Valve and Single-Plate Molteno Implants in Treatment of Refractory Glaucoma|||Vanak Eye Surgery Center|Yes|Completed|January 2003|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|40 Years|N/A|No|||September 2009|September 3, 2009|September 2, 2009||||No||https://clinicaltrials.gov/show/NCT00971061||133799|
NCT00971074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0156|Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy|The Use of Viscosupplementation for the Treatment of Patients With Persistent Non-mechanical Pain Status-post Partial Menisectomy||Ohio State University|Yes|Withdrawn|December 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||March 2012|March 27, 2012|September 2, 2009||No|Patients did not meet inclusion criteria.|No||https://clinicaltrials.gov/show/NCT00971074||133798|
NCT00971386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4025|Short Term Hemodynamic Effects of Controlled Slow Breathing With Biofeedback in Patients With Heart Failure|Short Term Hemodynamic Effects of Controlled Slow Breathing With Biofeedback in Patients With Heart Failure: Normal Healthy Subjects vs. Chronic Ambulatory Heart Failure Patients vs Acute Heart Failure||Albert Einstein Healthcare Network|No|Completed|February 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 9, 2011|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971386||133774|
NCT00971399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMS vs ODS for CRINV|Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting|Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer||Seoul National University Hospital|No|Completed|September 2009|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|172|||Both|20 Years|N/A|No|||February 2011|February 24, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971399||133773|
NCT00971425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113572|Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)|Immunogenicity and Safety of GSK Biologicals' Pandemic Influenza Candidate Vaccine GSK2340272A||GlaxoSmithKline||Completed|September 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|145|||Both|61 Years|N/A|Accepts Healthy Volunteers|||February 2011|March 15, 2011|August 27, 2009|Yes|Yes||No|February 10, 2011|https://clinicaltrials.gov/show/NCT00971425||133772|
NCT00972907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 104|An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects|An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects||RDD Pharma Ltd|No|Completed|December 2009|February 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||February 2011|February 15, 2011|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00972907||133659|
NCT00972582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012066|Upper Limit of Leucine Intake in Adults|Determination of the Tolerable Upper Limit of Leucine Intake in Adult Humans||The Hospital for Sick Children|No|Completed|May 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|5|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972582||133684|
NCT00969657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6050|Validation of a Predictive Model After Complete Response in Rectal Cancer|Prospective Validation of a Predictive Model for Pathologic Complete Response After Chemoradiotherapy in Rectal Cancer: A Prognostic Study|Thunder|Maastricht Radiation Oncology|Yes|Completed|August 2009|December 2014|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|serum,plasma|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|January 2015|January 12, 2015|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969657||133906|
NCT00970541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 29010|Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome|Phase 1 Study That Will Compare 12 Weeks of Supplementation With Cinnamon Extract on the Action of Insulin and Blood Sugar (Glucose) With 12 Weeks of Supplementation With a Placebo.|Eccentric|Pennington Biomedical Research Center|No|Terminated|August 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Female|20 Years|40 Years|No|||March 2016|March 23, 2016|August 31, 2009||No|Recruitment|No||https://clinicaltrials.gov/show/NCT00970541||133839|
NCT00961051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBR-105-9608|Evaluation of an Investigational Multi-Purpose Solution (MPS)|Evaluation of an Investigational MPS||Abbott Medical Optics|No|Completed|February 2009|November 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 6, 2013|July 27, 2009|Yes|Yes||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00961051||134555|
NCT00961064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090199|A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)|A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)||National Institutes of Health Clinical Center (CC)||Recruiting|July 2009|December 2021|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00961064||134554|
NCT00961285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENOTYPING ANALYSIS OF ALL|Genotyping Analysis of Acute Lymphoblastic Leukemia|High Resolution Genome Wide-Copy Number Profiling and Pharmacogenomic Analysis in Acute Lymphoblastic Leukemia by Single Nucleotide Polymorphism (SNP) Arrays|GALL|University of Bologna|No|Recruiting|March 2009|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|extracted DNA or cryopreserved cells in Guanidine isothiocyanate or fresh peripheral blood      (10 ml) and/or bone marrow samples (at least 2 ml) in EDTA.|Both|18 Years|N/A|No|Probability Sample|adult ALL patients|August 2009|November 29, 2010|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961285||134537|
NCT00961623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07292009-3441|Characterizing Knee Pain and Response to Surgery Using Local Biomarkers|Characterizing Knee Pain and Response to Surgery Using Local Biomarkers||Stanford University|Yes|Recruiting|July 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Synovial fluid lavage.|Both|18 Years|90 Years|No|Probability Sample|Our study population includes adult males and females presenting to a single orthopaedic        surgeon for arthroscopic management of acute or chronic knee pain due to a mechanical        derangement discernable by MRI.        Subjects are selected using a probability sampling scheme, such that every knee        arthroscopy patient that presents, without exclusionary criteria described above, is        offered enrollment in the study. To date, approximately 85% of patients consent to        enrollment, with no apparent sampling bias. Additionally, we are using repeated measures        (matched random sampling) to evaluate the role of mediators of knee pain, and to assess        the potential of utilizing expression profiles to monitor surgical outcome. For example,        clinical indicators and biomarker expression profiles taken peri-operatively are compared        to those obtained 12 weeks post-operatively in the same subject.|June 2011|June 10, 2011|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961623||134513|
NCT00961896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225B2203|A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients|A Double-blind, Randomized, Vehicle-controlled Proof of Concept (PoC) Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Topical Administrations of LDE225 (a Specific Smoothened Inhibitor) on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients Followed by an Open Label, Randomized Expansion Group to Test Two Different Strengths of an Improved LDE225 Formulation for Extended Treatment Durations||Novartis||Completed|July 2009|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|75 Years|No|||October 2015|October 5, 2015|August 18, 2009||No||No|August 19, 2015|https://clinicaltrials.gov/show/NCT00961896||134492|
NCT00962468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA-EQCP001|European Quality of Care Pathways Study on Chronic Obstructive Pulmonary Disease (COPD)|The European Quality of Care Pathways Study: The Impact of a Care Pathway for Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) : an International Cluster Randomized Controlled Trial."|EQCP-COPD|European Pathway Association|Yes|Enrolling by invitation|May 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|N/A|N/A|No|||August 2009|August 19, 2009|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962468||134448|
NCT00970554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000011712|Effectiveness of Telescopic Magnification in the Treatment of Amblyopia|Effectiveness of Telescopic Magnification in the Treatment of Amblyopia||The Hospital for Sick Children|No|Completed|December 2007|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|4 Years|17 Years|No|||August 2013|August 26, 2013|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970554||133838|
NCT00970567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/039/07|Ketoacidosis in Individuals With Type I Diabetes Mellitus (T1DM)|Ketoacidosis in Individuals With T1DM||Charite University, Berlin, Germany|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|19|||Both|18 Years|60 Years|No|||September 2009|September 1, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00970567||133837|
NCT00970801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-09-016|Study of Nontuberculous Mycobacterial Lung Disease|Identification of Host Susceptibility Factors and Development of Biomarkers for Diagnosis, Prognosis and Treatment of Nontuberculous Mycobacterial Lung Disease||Samsung Medical Center|No|Recruiting|January 2008|December 2019|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|90 Years|No|Non-Probability Sample|Patients visited Samsung Medical Hospital|November 2015|November 17, 2015|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970801||133819|
NCT00972322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8245-012|Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)|A Placebo-Controlled Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacokinetics of MK-8245 in Subjects With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||April 2015|April 23, 2015|September 3, 2009|No|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00972322||133704|
NCT00972335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CNS 12|Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma|A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma||SCRI Development Innovations, LLC|No|Terminated|January 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 2, 2009|Yes|Yes|Study terminated early due to slow accrual|No|January 5, 2015|https://clinicaltrials.gov/show/NCT00972335||133703|Enrollment closed early due to slow accrual, leading to small number of subjects analyzed - biomarker analysis outcome measure not analyzed or reported
NCT00973141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016471|A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee or Hip Pain From Osteoarthritis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|September 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|467|||Both|40 Years|80 Years|No|||April 2015|April 13, 2015|September 4, 2009|Yes|Yes|Logistic reasons associated with the FDA-imposed clinical hold.|No||https://clinicaltrials.gov/show/NCT00973141||133641|
NCT00973947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-09 ICORG|Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer|A Prospective Randomised Controlled Clinical Trial Investigating the Benefits of Patient-customised Headrests Versus Standard (Non-patient Specific) Headrests in the Immobilisation of Patients Receiving Radiotherapy for Head and Neck Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Completed|January 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2013|December 30, 2014|September 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00973947||133580|
NCT00969631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU- 012|Combined Metformin and Clomiphene Citrate (CC) or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome (PCOS)|Combined Metformin and Clomiphene Citrate Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome||Mansoura University|Yes|Completed|September 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|282|||Female|20 Years|36 Years|No|||August 2009|August 31, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969631||133908|
NCT00969644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-2009-049|The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons|The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons||Herlev Hospital|Yes|Enrolling by invitation|September 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969644||133907|
NCT00938860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400A2430|Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C|A Multi-center, Randomized, Open Label, Controlled Study to Compare the Sustained Virological Response During Treatment With Neoral or Tacrolimus in Maintenance Liver Transplant Recipients Treated With Pegylated Interferon and Ribavirin for Recurrent Hepatitis C|SUSTAIN|Novartis||Completed|September 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|70 Years|No|||May 2015|May 5, 2015|July 13, 2009||No||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00938860||136248|
NCT00938873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Lahtinen|Understanding the Impact of Meditative Homework on Metacognitive Processes in the Context of Mindfulness Based Cognitive Therapy (MBCT)|Understanding the Impact of Meditative Homework on Metacognitive Processes in the Context of Mindfulness Based Cognitive Therapy (MBCT)||Lahtinen, Marika|No|Completed|December 2009|April 2011|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|7|||Both|18 Years|65 Years|No|Non-Probability Sample|Eight participants will be recruited from South London and Maudsley NHS Trust, which is a        national health service site offering Mindfulness Based Cognitive Therapy (MBCT).|February 2012|February 27, 2012|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938873||136247|
NCT00972010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090314|Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade|A Prospective, Controlled Study To Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade Compared to Traditional Electrosurgery||University of California, San Diego|No|Completed|July 2009|November 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|21|Samples With DNA|Breast tissue|Female|N/A|N/A|No|Non-Probability Sample|Patients recruited from the Moores UCSD Cancer Center and the UCSD Medical Center|November 2010|November 9, 2010|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972010||133727|
NCT00972348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2598-33964|Trial Embedded in an Electronic Personal Medical Health Records|A Randomized Controlled Trial Embedded in an Electronic Medical Record (myHERO).||University of California, San Francisco|No|Completed|July 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|338|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972348||133702|
NCT00973440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-035|Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies|Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Colorectal, Breast or Lung Cancer||Dana-Farber Cancer Institute|Yes|Completed|March 2009|October 2013|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|59|||Both|70 Years|N/A|No|Non-Probability Sample|Participants are identified by review of the clinic visit schedule at the Dana-Farber        Cancer Institute, identifying individuals age 70 and older diagnosed with colon, rectal,        breast or lung cancer|October 2013|October 21, 2013|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973440||133618|
NCT00973154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEP|Corticosteroid Treatment for Community-Acquired Pneumonia - The STEP Trial|Corticosteroid Treatment for Community-Acquired Pneumonia A Randomized, Double-blind Study- The STEP Trial|STEP|University Hospital, Basel, Switzerland|Yes|Completed|December 2009|December 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|800|||Both|18 Years|N/A|No|||May 2014|April 20, 2015|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00973154||133640|
NCT00970229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-420-01|Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.|Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls|MNI-420|Institute for Neurodegenerative Disorders|No|Recruiting|July 2009|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|August 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00970229||133863|
NCT00970242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-4-053|Ambulatory Urodynamic Evaluation of Sacral Neuromodulation for Non-Obstructive Urinary Retention|Ambulatory Urodynamic Evaluation of Sacral Neuromodulation for Non-obstructive Urinary Retention||Maastricht University Medical Center|No|Enrolling by invitation|August 2009|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|N/A|No|Probability Sample|Patients with diminished or absent bladder contraction|September 2009|September 3, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970242||133862|
NCT00970255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-SD-0559-CTIL|Frenotomy of the Labial Frenulum in Infants With Breastfeeding Difficulties|Effect of Labial Frenulum Clipping on Nipple Pain and Latch Problems in Breastfeeding Infants||Tel-Aviv Sourasky Medical Center|No|Suspended|October 2009|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|6 Months|Accepts Healthy Volunteers|||August 2012|August 1, 2012|September 1, 2009||No|Difficulty in recruiting participants|No||https://clinicaltrials.gov/show/NCT00970255||133861|
NCT00961649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-038|Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination|Safety and IOP-Lowering Efficacy of Brinzolamide/Brimonidine Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma and/or Ocular Hypertension||Alcon Research|No|Terminated|October 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|195|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|August 18, 2009|Yes|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT00961649||134511|
NCT00973999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTO/09/032|Botulinum Toxin and Saliva Management in Tracheotomised Patients|A Randomised Placebo Controlled Trial to Explore the Effectiveness of Botulinum Toxin Injection at Reducing Oral Secretions and Frequency of Tracheal Suctioning in Tracheotomised Patients.||HCA International Limited|Yes|Withdrawn|September 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2009|September 5, 2012|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973999||133576|
NCT00961298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-4656|An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder|An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder||West Penn Allegheny Health System|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||June 2014|June 8, 2014|August 17, 2009||No||No|March 14, 2014|https://clinicaltrials.gov/show/NCT00961298||134536|A limitation of this pilot study was its small sample size and open label design. Another limitation may be that the patient sample is not representative of a true cross section of the GAD population as a whole.
NCT00961636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-102|A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia||Merck Sharp & Dohme Corp.|No|Completed|October 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1152|||Both|18 Years|75 Years|No|||January 2015|January 29, 2015|August 17, 2009|Yes|Yes||No|January 14, 2012|https://clinicaltrials.gov/show/NCT00961636||134512|
NCT00961909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22340|A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus|A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin||Hoffmann-La Roche||Completed|June 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|122|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00961909||134491|
NCT00966511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB041|Vibration Response Imaging (VRI) in Patients Who Are Potential Candidates for Surgical Resection|Vibration Response Imaging (VRI) in Patients Who Are Potential Candidates for Surgical Resection||Deep Breeze|Yes|Enrolling by invitation|June 2009|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|Study participants will be patients who are candidates for lung resection (lobectomy or        greater)|February 2011|February 8, 2011|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966511||134147|
NCT00963352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Knut2009|Colon Cancer Prognosis After Radical Surgery|Prognosis of Colon Cancer. Clinical and Pathological-anatomical Factors Concerned With Radical Surgery||Haraldsplass Deaconess Hospital|No|Recruiting|January 2007|December 2010|Anticipated|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Biopsies. 1) fresh frozen 2) sampled in RNA later 3) archival formalin|Both|N/A|N/A|No|Non-Probability Sample|Community patient population from hospital catchment area.|August 2010|August 26, 2010|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00963352||134383|
NCT00962780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3002|Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine|A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine||Pfizer|Yes|Completed|March 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|303|||Both|6 Years|N/A|No|||November 2014|November 13, 2014|August 18, 2009|Yes|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT00962780||134424|
NCT00962793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0187|Diagnosis of Latent Tuberculosis(TB) Infection in Health Care Workers Using TST and Whole Blood Interferon-γ Assay|||Yonsei University||Completed||||||N/A|Observational|Time Perspective: Prospective||1|||||Both|20 Years|N/A||Probability Sample|latent tuberculosis prevalence of health care workers|August 2009|August 19, 2009|August 19, 2009||||No||https://clinicaltrials.gov/show/NCT00962793||134423|
NCT00942110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-311|Alterations in Postprandial Glucose and Lipid Metabolism in Patients With Obstructive Sleep Apnea|Examination of Association Between Glucose, Lipid Metabolism and Obstructive Sleep Apnea||Kyoto University, Graduate School of Medicine|Yes|Completed|September 2009|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|20 Years|N/A|No|||March 2012|March 5, 2012|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942110||135999|
NCT00937742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE TOMATO|The Effect of Processed Tomato Products on CVD Risks|The Effect of Processed Tomatoes on Endothelium- and Platelet- Function|TOMATO|Penn State University|No|Completed|January 2008|April 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937742||136334|
NCT00937989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08092|Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer|Patient Navigation in Breast Cancer Care; Addressing Barriers to Treatment Initiation, Completion, and Follow Up||City of Hope Medical Center|Yes|Completed|November 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|52|||Both|50 Years|N/A|No|||June 2015|June 3, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937989||136315|
NCT00938262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-105|A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|An Open-label, Three-treatment, Three-period, One-sequence, Crossover Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|April 2009|August 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938262||136294|
NCT00938275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113261|A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers|A Phase I Randomized, Open-label, Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers||GlaxoSmithKline|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00938275||136293|
NCT00970216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMST-Y-1|Study of Telbivudine in Chronic Hepatitis B|A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.||Chang Gung Memorial Hospital|Yes|Completed|February 2009|January 2016|Actual|January 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|160|Samples With DNA|Serum will be stored at screening/baseline and complete study after corresponding with      inclusion/exclusion criteria.|Both|18 Years|N/A|No|Non-Probability Sample|Male or female patients, at least 18 years of age diagnosed with chronic hepatitis B with        liver disease and telbivudine is prescribed by physicians based on clinical justification.        And patients are able to communicate well, provide written informed consent, and willing        to participate in the entire study.|January 2016|January 31, 2016|September 1, 2009||No||No|January 31, 2016|https://clinicaltrials.gov/show/NCT00970216||133864|
NCT00938574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atu027-I-01|Study With Atu027 in Patients With Advanced Solid Cancer|A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer||Silence Therapeutics GmbH|Yes|Completed|June 2009|September 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||September 2012|April 8, 2013|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938574||136270|
NCT00938587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9391005|A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis|A Phase 2a, Randomized, Double-Blind, Active And Placebo-Controlled Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis||Pfizer|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|N/A|No|||October 2011|October 29, 2011|July 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938587||136269|
NCT00939185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661182|Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections|Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections|COMPAS|Pfizer|No|Completed|April 2007|January 2009|Actual|January 2009|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|400|||Both|1 Year|14 Years|No|Non-Probability Sample|ZITHROMAX® administration will be considered in children / adolescents from the first year        of life up to 14 years old with the following diagnoses: Acute otitis media, Sinusitis,        Pharyngitis/tonsillitis, Pneumonia, Bronchitis.|March 2010|March 25, 2010|July 13, 2009|No|Yes||No|December 17, 2009|https://clinicaltrials.gov/show/NCT00939185||136223|Only 1 subject received tablet; therefore, no suspension versus tablet efficacy data is displayed as initially planned.
NCT00939549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0840|High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis|Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis|HiCy|Sidney Kimmel Comprehensive Cancer Center|Yes|Suspended|March 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|70 Years|No|||November 2010|November 8, 2010|July 14, 2009||No|Suspended for revisions to the protocol.|No||https://clinicaltrials.gov/show/NCT00939549||136196|
NCT00939562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1901003|Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate|An Open-Label, Two-Treatment, Two-Period, Randomized Cross-Over Study To Assess The Bioequivalence Between Commercial Doxycycline Carragenate And Monohydrate Tablet Formulations In Normal Healthy Male Subjects||Pfizer|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 19, 2009|July 8, 2009|No|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT00939562||136195|
NCT00970840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917060-1|Acceptability of Lipid-Based Nutrient Supplements (LNS) for Women and Infants|Acceptability of Lipid-based Nutrient Supplements (LNS) for Women and Infants||University of California, Davis|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|46|||Both|6 Months|N/A|Accepts Healthy Volunteers|||September 2009|September 2, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970840||133816|
NCT00973674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCUE-TBI|Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Brain Injury|A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Severe Traumatic Brain Injury|RESCUE - TBI|University of Texas Southwestern Medical Center|Yes|Completed|July 2009|May 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||April 2014|April 4, 2014|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973674||133600|
NCT00971438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ryhov County Hospital|Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging|Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging|STRAPPSCORE|Ryhov County Hospital|No|Terminated|September 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1312|||Both|10 Years|N/A|No|||May 2015|May 4, 2015|September 1, 2009||No|Failing recruitement and more exclusions than anticipated.|No||https://clinicaltrials.gov/show/NCT00971438||133771|
NCT00961948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000196|Indigo Carmine Staining and Narrow Band Imaging (NBI) of Colonic Mucosa for Detection of Dysplasia in Ulcerative Colitis|A Pilot Study for the Determination of Inter-observer Variation for Abnormalities Detected by Indigo Carmine Staining and Narrow Band Imaging Among Patients Undergoing Surveillance Colonoscopy for Ulcerative Colitis||Mayo Clinic|No|Completed|June 2009|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Patients with clinically quiescent, histologically proven pan-ulcerative colitis for at        least 8 years will be recruited from the outpatient gastroenterology clinic of the Mayo        Clinic Florida and randomized to white light followed by NBI or white light followed by        indigo carmine staining to include confocal microscopy.|February 2013|February 26, 2013|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961948||134488|
NCT00961935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50MH077248-02|Pediatric Bipolar Disorder Study at UCLA|Examining Neurocognitive Profiles of Bipolar Disorder and Attention-Deficit Hyperactivity Disorder||University of California, Los Angeles|No|Completed|August 2008|September 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|50|||Both|7 Years|17 Years|No|Probability Sample|Bipolar Disorder|January 2016|January 12, 2016|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961935||134489|
NCT00961961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH080097|Prevention of Relapse & Recurrence of Bipolar Depression|Prevention of Relapse & Recurrence of Bipolar Depression||University of Pennsylvania|Yes|Active, not recruiting|July 2009|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00961961||134487|
NCT00962208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-ZG13|Retardation of Myopia in Orthokeratology|Orthokeratology for Myopic Control in Chinese Children - a Randomized Clinical Trial|ROMIO|The Hong Kong Polytechnic University|No|Completed|March 2008|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||July 2013|September 21, 2013|August 18, 2009||No||No|July 17, 2013|https://clinicaltrials.gov/show/NCT00962208||134468|
NCT00962481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R014|Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia|A Double-blind, Placebo Controlled, Randomized, Cross-over, Phase IIa Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia in Healthy Subjects||Revotar Biopharmaceuticals AG||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 5, 2010|August 19, 2009||||No||https://clinicaltrials.gov/show/NCT00962481||134447|
NCT00962806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK084118|Intensive Exercise to Improve Mitochondrial Dysfunction in Pediatric Obesity|Intensive Exercise to Improve Mitochondrial Dysfunction in Pediatric Obesity||Massachusetts General Hospital|Yes|Active, not recruiting|August 2009|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|18 Years|No|||April 2012|April 25, 2012|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962806||134422|
NCT00961922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVA 2008-4013|Pediatric Research on Improving Speed, Memory and Attention|The Efficacy of Neurofeedback to Improve Processing Speed, Attention and Memory in Childhood Brain Tumour Survivors: a Randomized Controlled Trial|PRISMA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Active, not recruiting|January 2010|July 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|105|||Both|8 Years|18 Years|No|||October 2012|October 3, 2012|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961922||134490|
NCT00962195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P8604|The Effect of Purple Sweet Potato (PSP)-Juice on Liver Enzymes and Blood Pressure|The Effect of Purple Sweet Potato (PSP)-Juice on Liver Enzymes and Blood Pressure||TNO|No|Completed|June 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||April 2010|April 13, 2010|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962195||134469|
NCT00963664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-MM-009|Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma|Phase 2 Study of Interferon Alfa-2b and Lovastatin Combination Therapy for Patients With High-risk Resected or Unresectable Malignant Melanoma||NeoPlas Innovation|No|Withdrawn|December 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|August 20, 2009|Yes|Yes|Modifications will be necessary before full IRB approval will be secured.|No||https://clinicaltrials.gov/show/NCT00963664||134361|
NCT00963677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-30700790|Nasotracheal Intubation Using Shikani Optical Stylet|Shikani Optical Stylet for Nasotracheal Intubation Undergoing Oral and Maxillofacial Surgery, a Prospective Evaluation|SOS|Central South University|Yes|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|70 Years|No|||March 2012|May 1, 2012|August 19, 2009||No||No|May 26, 2010|https://clinicaltrials.gov/show/NCT00963677||134360|
NCT00963690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-0100-01|Evaluation of the CloSys Closure System as an Adjunct to Standard Compression|CloSys Hemostatic Device U.S. Multi-Center Clinical Investigation||CloSys Corporation|Yes|Suspended|August 2009|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|130|||Both|18 Years|N/A|No|||April 2014|February 15, 2015|August 12, 2009|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT00963690||134359|
NCT00963651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-VORTEX|GE Healthcare VolumeRAD Lung Nodule Detection Study|GE Healthcare VolumeRAD Lung Nodule Detection Study||American College of Radiology - Image Metrix|No|Completed|August 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|187|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will include those referred for x-ray computed tomography (CT) of the chest        for suspicion of a pulmonary nodule or other unrelated reasons.|July 2013|July 23, 2013|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963651||134362|
NCT00942123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2551|Study On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis|On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Completed|January 2009|October 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Probability Sample|Patients with lactic acidosis and metformin intoxication (as documented by drug serum        measurement)|September 2013|September 26, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00942123||135998|
NCT00942136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112941|GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study|The Official Study Title Exceeds the 300 Character Limit for This Field. See Detailed Study Description Section for Official Study Title.||GlaxoSmithKline||Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 8, 2009|July 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942136||135997|
NCT00937755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F941101|The Study of Atypical Antipsychotics-induced Metabolic Disturbances|The Study of Atypical Antipsychotics-induced Metabolic Disturbances||Taipei Medical University Hospital|No|Completed|March 2006|May 2009|Actual|March 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|80|||Both|18 Years|60 Years|No|Non-Probability Sample|psychiatric outpatient clinic and inpatient units|July 2009|July 10, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937755||136333|
NCT00938002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0321|Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients|Rapid Bacterial Identification and Antibiotic Resistance Testing in Critically Ill Adults at Risk for Ventilator Acquired Pneumonia (VAP).||Denver Health and Hospital Authority|No|Enrolling by invitation|July 2009|July 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|DNA collected from whole blood|Both|18 Years|N/A|No|Probability Sample|Critically ill ventilated patients|July 2015|July 22, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938002||136314|
NCT00938548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4-2009-0186|Perioperative Administration of Pregabalin for Pain After Mastectomy|Perioperative Administration of Pregabalin for Pain After Mastectomy||Severance Hospital|Yes|Completed|June 2009|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Female|21 Years|69 Years|No|||July 2009|May 17, 2010|July 13, 2009||No||No|March 29, 2010|https://clinicaltrials.gov/show/NCT00938548||136272|
NCT00938561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 8608|Evaluation of New Markers to Assess Kidney Function|Validity and Reliability of a Novel GFR Marker||Tufts Medical Center|No|Withdrawn|September 2009|September 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|0||Blood and urine will be retained for future testing|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with CKD and without CKD will be recruited to participate in the study. Subjects        with CKD will be recruited primarily from the Kidney and Blood Pressure Center. Subjects        without CKD will be recruited from advertisements as well as the volunteer database at the        Jean Mayer Human Nutrition Research Center on Aging (HRNCA), which is located next to        Tufts Medical Center.|May 2012|May 31, 2012|July 8, 2009|Yes|Yes|Non availability of funding|No||https://clinicaltrials.gov/show/NCT00938561||136271|
NCT00970580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212-LC-101|A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer|A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer||Biogen|Yes|Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||November 2011|September 12, 2013|September 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970580||133836|
NCT00970853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007041|MOM Program 8-Year Follow-up|The MOM Program Continuation - 8 Year Follow-up||Children's Hospital of Philadelphia|No|Completed|March 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|187|||Both|94 Months|98 Months|No|||March 2014|March 20, 2014|September 2, 2009||No||No|December 7, 2011|https://clinicaltrials.gov/show/NCT00970853||133815|
NCT00938886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-17181-1|Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment|Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment||Brown University|Yes|Completed|October 2009|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938886||136246|
NCT00971477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009172431|Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis|Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis||University of California, Davis|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|64|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00971477||133768|
NCT00971490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2007.158-T|Effects of a 4-week Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) Program on Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD)|Effects of a 4-week Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) Program on Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD)||The Hong Kong Polytechnic University||Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|30|||Both|50 Years|N/A|No|||September 2009|September 2, 2009|July 28, 2009||||No||https://clinicaltrials.gov/show/NCT00971490||133767|
NCT00969956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTCOD|Time To Complications Occurs in Diabetes|Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur||Karolinska Institutet|No|Enrolling by invitation|April 2012|May 2027|Anticipated|May 2027|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|950|||Both|18 Years|N/A|No|Probability Sample|Typ 1, Typ 2 and LADA Diabetics from the diabetic clinic at Sophiahemmet, Stockholm,        Sweden|May 2012|April 8, 2015|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00969956||133883|
NCT00969969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC-0031|A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment of Osteoarthritis of the Great Toe|A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment of Osteoarthritis of the Great Toe||Cartiva, Inc.||Active, not recruiting|August 2009|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00969969||133882|
NCT00940082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|the south west Hospital|The Cardiopathic Features and Analysis of Risk Factors in the Elderly Diabetic|The Cardiopathic Features and Analysis of Risk Factors in the Elderly Diabetic||Third Military Medical University|Yes|Recruiting|June 2007|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|400|Samples Without DNA|Take the fasting blood more than 12 hours overnight|Both|18 Years|95 Years|No|Non-Probability Sample|type 1 and type 2 diabetic patients. They have been included in the standard diagnostic        criteria for WHO1999 years and those diabetic patients with acute and chronic infection,        high blood pressure, special and Gestational diabetic patients have been excluded.        (Judgment have been made according to the case history, physical examination, medication,        hormone history, blood routine etc) Those repeatedly hospitalized patients were recorded        according to the time they took their first related inspection|September 2011|September 11, 2011|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940082||136155|
NCT00962832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN4575g|A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus||Genentech, Inc.||Completed|September 2009|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|65 Years|No|||November 2014|November 4, 2014|August 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962832||134420|
NCT00962221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0099.09EMC|Lipids Profile in Subclinical Hypothyroidism|Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Subclinical Hypothyroidism|LPSH|HaEmek Medical Center, Israel|No|Not yet recruiting|October 2009|October 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|85 Years|No|Probability Sample|Patients followed at the Endocrine Institute, Haemek Medical Center, Afula, Israel|September 2009|September 9, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962221||134467|
NCT00962494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0044|Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors|Cancer Survivors Online Self-Management Workshop||Stanford University||Completed|July 2009|December 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|585|||Both|19 Years|N/A|No|||February 2013|February 5, 2013|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962494||134446|
NCT00962819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007373|Measles, Mumps, and Rubella (MMR) Immunity in College Students|Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine||Emory University|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 4|Observational|Time Perspective: Cross-Sectional||1|Actual|74|Samples With DNA|Whole blood|Both|18 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects for this study will be 18-22 year olds recruited from Emory University's student        population who have received two age-appropriate doses of the MMR-II vaccine.|March 2014|March 4, 2014|May 19, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00962819||134421|
NCT00963079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB 07-0008|Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients|Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients||Fertility Center of Las Vegas|No|Completed|July 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2010|July 12, 2010|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00963079||134403|
NCT00964223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114547|A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne|A Single-blind, Randomized, Comparative Split-face Study Evaluating the Tolerability of Clindamycin and Benzoyl Peroxide Gel to Benzoyl Peroxide/Adapalene Gel in the Treatment of Acne Vulgaris.||GlaxoSmithKline|No|Completed|July 2009|February 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||April 2015|May 14, 2015|August 20, 2009||No||No|September 7, 2010|https://clinicaltrials.gov/show/NCT00964223||134318|
NCT00963937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111035|Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents|A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents||GlaxoSmithKline|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|178|||Both|10 Years|17 Years|No|||July 2011|July 28, 2011|August 20, 2009||No||No|July 28, 2011|https://clinicaltrials.gov/show/NCT00963937||134340|
NCT00964210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCH CA27091|Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination|Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result|HPV|Murdoch Childrens Research Institute|Yes|Completed|March 2008|April 2011|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|240|||Female|12 Years|26 Years|No|||August 2009|April 14, 2011|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00964210||134319|
NCT00973739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0328|Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors|Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors||New York University School of Medicine|Yes|Completed|September 2009|November 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|4 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|September 3, 2009||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00973739||133595|
NCT00969995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-AM-197-CTIL|Identification of Inflammatory Markers in Migraine Patients|Identification of Inflammatory Markers in Migraine Patients||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2009|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|250|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|The patient group will consist of 200 subjects with various headache types treated at the        headache clinic at the Sourasky Medical Center, Tel-Aviv, ISRAEL, and 50 healthy controls.|September 2009|September 1, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00969995||133880|
NCT00938288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3357-EU-001|A Study of KW-3357 in Congenital Antithrombin Deficiency|A Phase I Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of a Single Dose (50IU/kg) of KW-3357 in Subjects With Congenital Antithrombin Deficiency.||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|April 2009|April 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|N/A|No|||March 2011|June 15, 2011|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938288||136292|
NCT00970320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3170|Prevalence and Treatment of Anal Incontinence in Primiparous Women|Prevalence and Treatment of Anal Incontinence in Primiparous Women||Ostfold Hospital Trust|No|Completed|May 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1571|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|February 10, 2016|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970320||133856|
NCT00971139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCN191008/V50|Implementing Online Patient-Provider Communication Into Clinical Practice|Implementing Online Patient-Provider Communication Into Clinical Practice: Implementation Research|OPPC|Oslo University Hospital|No|Completed|November 2009|December 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|199|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00971139||133793|
NCT00970866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917276-1|Efficacy of Lipid-Based Nutrient Supplements (LNS) for Pregnant and Lactating Women and Their Infants|Efficacy of Lipid-based Nutrient Supplements (LNS) for Pregnant and Lactating Women and Their Infants||University of California, Davis|Yes|Active, not recruiting|November 2009|December 2015|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|864|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970866||133814|
NCT00939848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-03 09/0193|Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers|Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers|ABC-03|University College, London|Yes|Completed|April 2011|September 2014|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||October 2012|October 24, 2014|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939848||136173|
NCT00971464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-683|Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation|A Randomized Controlled Trial of Eccentric Viewing Training vs. Closed Circuit Television Use for Visual Rehabilitation From Age-Related Macular Degeneration|AMD|Lawson Health Research Institute|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|10|||Both|50 Years|N/A|No|||September 2012|September 7, 2012|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971464||133769|
NCT00962533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-01|EFFicacy Optimization Research of Telbivudine Therapy|A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study)|EFFORT|Nanfang Hospital of Southern Medical University|Yes|Completed|August 2009|August 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|606|||Both|18 Years|65 Years|No|||March 2012|January 29, 2013|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962533||134443|
NCT00962546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO 09-0950|Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage|Computed Tomographic Perfusion and Computed Tomographic Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage||Washington University School of Medicine|Yes|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the neurological intensive care unit with subarachnoid hemorrhage due        to rupture of a cerebral aneurysm|December 2014|December 8, 2014|August 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962546||134442|
NCT00963105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-CLL-009|Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia||Celgene|Yes|Active, not recruiting|October 2009|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963105||134401|
NCT00963391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMPCOL298|"Alcohol Based Hand Sanitizers for the Prevention of Acute Diarrheal Disease and Acute Respiratory Infection in Children Under 5 Attending Childcare Centers in Bogotá, Cundinamarca and Tolima, in Colombia: a Cluster Randomized Control Trial"|"Alcohol Based Hand Sanitizers for the Prevention of Acute Diarrheal Disease and Acute Respiratory Infection in Children Under 5 Attending Childcare Centers in Bogotá, Cundinamarca and Tolima, in Colombia: a Cluster Randomized Control Trial"||Fundación Santa Fe de Bogota|No|Completed|February 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1727|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||August 2009|August 20, 2009|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963391||134381|
NCT00963703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:160|Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis|Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis Using Rituximab: A Pilot Study Evaluating Synovial Outcomes||University of Manitoba|Yes|Completed|December 2007|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963703||134358|
NCT00963716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Khan-1|Hot and Cold Biopsy Forceps in the Diagnosis of Endobronchial Lesions|Hot and Cold Biopsy Forceps in the Diagnosis of Endobronchial Lesions||Postgraduate Institute of Medical Education and Research|No|Completed|November 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|168|||Both|18 Years|N/A|No|||August 2009|August 20, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00963716||134357|
NCT00963092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-UC-SOCS-03-5-064|Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer|Stomach and Oesophageal Cancer Study (SOCS)||National Cancer Institute (NCI)||Recruiting|August 2002|||December 2010|Anticipated|N/A|Observational|N/A|||Anticipated|4000|||Both|16 Years|N/A|Accepts Healthy Volunteers|||July 2011|August 9, 2013|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963092||134402|
NCT00963365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6703C00001|AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)|Pt. A: Ph I, Sngl-Blind, Randomized, Pcbo-Controlled 3-Way Crossover Study Followed by an Open-label Food Effect Study to Assess the PK of IV and Oral AZD6765 in Healthy Male and Female Subjects Pt.B: Ph I, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and PK of AZD6765 When Administered in Multiple Ascending Doses to Healthy Subjects||AstraZeneca|No|Withdrawn|November 2008|March 2010|Anticipated|February 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|August 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00963365||134382|
NCT00964236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU/Kuvan/Christ|The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)|The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)||University of Missouri-Columbia|No|Enrolling by invitation|August 2009|August 2011|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic for phenylketonuria. Columbia, Missouri, community for control.|August 2009|August 21, 2009|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00964236||134317|
NCT00964496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk3015|Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation|Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study||Shanghai Jiao Tong University School of Medicine|No|Completed|November 2004|August 2009|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|40 Years|85 Years|No|||August 2009|November 17, 2015|August 24, 2009||No||No|August 26, 2009|https://clinicaltrials.gov/show/NCT00964496||134297|Single center, open-label study; lack of placebo pills, make it impossible on equality of dosages between two groups; lack of dose response assessment either in patients or assays of serum vascular endothelial growth factor.
NCT00969397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2009-7069|Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks|Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks||University of California, Irvine|Yes|Withdrawn|November 2009|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|N/A|No|||August 2015|August 5, 2015|August 31, 2009||No|We have decided not to pursue the study|No||https://clinicaltrials.gov/show/NCT00969397||133926|
NCT00969410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05670|A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases|A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670)||AVEO Pharmaceuticals, Inc.|No|Completed|August 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969410||133925|
NCT00969761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.6|BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour|A Phase I Dose Escalation Trial of BI 6727 in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumors||Boehringer Ingelheim||Completed|August 2009|||February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|August 31, 2009||||No||https://clinicaltrials.gov/show/NCT00969761||133898|
NCT00969696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905005104|Galantamine Effects on Cognitive Function in Marijuana Users|Galantamine Effects on Cognitive Function in Marijuana Users||Yale University|Yes|Completed|August 2009|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969696||133903|
NCT00969709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-01|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Fixed-Dose Study of F2695 SR in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|September 2009|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|724|||Both|18 Years|65 Years|No|||August 2013|August 22, 2013|August 31, 2009|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00969709||133902|
NCT00969722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3F8-NB-201|A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients|A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients||United Therapeutics|Yes|Terminated|August 2009|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Months|13 Years|No|||February 2013|February 28, 2013|August 31, 2009|Yes|Yes|Lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00969722||133901|
NCT00969735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-1|Cryoenergy Or Radiofrequency for Pulmonary Vein Isolation|Cryoenergy Or Radiofrequency for Pulmonary Vein Isolation (COR Trial)|COR|Hospital San Carlos, Madrid|No|Completed|July 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||April 2013|April 1, 2013|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00969735||133900|
NCT00969748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-VDF-RF|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2009|||||N/A|N/A|N/A||||||||||||||August 31, 2009|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969748||133899|
NCT00970294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10946|Pilot Project of Health Promotion for People With Diabetes|Feasibility and Effectiveness of a Health Promotion Program on Aerobic Fitness and Glycemic Control for Adults With Type 2 Diabetes||University of Kansas Medical Center|No|Completed|July 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|40 Years|70 Years|No|||July 2012|July 18, 2012|September 1, 2009||No||No|May 29, 2012|https://clinicaltrials.gov/show/NCT00970294||133858|
NCT00970307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112157|Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age||GlaxoSmithKline||Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|421|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2011|December 8, 2011|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970307||133857|
NCT00962871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP22512|A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both|An Open-label, Randomized Study to Evaluate the Acute Immunologic Responses in Asian Subjects With E Antigen Positive Chronic Hepatitis B Following Initiation of Therapy for Hepatitis B With Pegasys, Nucleoside Analogues, or Both.||Hoffmann-La Roche||Completed|August 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Male|18 Years|55 Years|No|||January 2016|January 14, 2016|August 19, 2009||No||No|December 9, 2015|https://clinicaltrials.gov/show/NCT00962871||134418|
NCT00963131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 47/362-023|High-dose Antioxidants for Central Serous Chorioretinopathy|High-dose Antioxidants for Central Serous Chorioretinopathy||Prince of Songkla University|Yes|Completed|December 2004|June 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|50 Years|No|||December 2009|December 29, 2009|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963131||134399|
NCT00963144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GMY-DUM-2009/1|Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study|Diagnosis and Response to Treatment Using a Reliable Gerd Questionnaire-an In Clinical Practise Study|GQS|AstraZeneca|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|79 Years|No|Probability Sample|Primary care clinic|October 2010|October 20, 2010|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00963144||134398|
NCT00967148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009121-01H|Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer|The Use of Extended Perioperative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Pilot Randomized Controlled Trial|PERI-OP|Ottawa Hospital Research Institute|Yes|Completed|June 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00967148||134099|
NCT00967434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006832-01H|Statin Drugs to Prevent Complications During Surgery|Short Term Atorvastatin Regime for Vasculopathic Surgical (STAR-VaS) Patients Study|STAR-VaS|Ottawa Hospital Research Institute|Yes|Active, not recruiting|December 2007|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|45 Years|N/A|No|||October 2011|October 24, 2011|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967434||134077|
NCT00967135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC 2010-001|Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.|Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|80 Years|No|||April 2012|April 11, 2012|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967135||134100|
NCT00968019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CR-001|Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion Stent|A Multicenter Postmarket Surveillance Registry Evaluating the Performance and Long Term Safety of the Presillion Stent in de Novo Native Coronary Artery Lesions. Iberian Registry||Johnson and Johnson, S.A.|Yes|Completed|April 2009|May 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|318|||Both|N/A|N/A|No|Probability Sample|All sujects treated with Presillion stent up to two de novo coronary artery lesions|March 2013|March 5, 2013|August 27, 2009||No||No|January 15, 2013|https://clinicaltrials.gov/show/NCT00968019||134032|since the difference with the performance goal is this large; the possibility of underreporting of adverse events is something that needs to be considered.
NCT00968032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09k003|Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System|Single-center Non-comparative, Prospective Interventional Clinical Investigation on the Procedural Success and Safety of the Nit-Occlud® PFO Closure Device and Its Application System.|09k003|pfm medical ag|No|Completed|July 2009|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|65 Years|No|||May 2011|May 30, 2011|August 27, 2009||No||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00968032||134031|
NCT00968279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/134/08|Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation|Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation||Charite University, Berlin, Germany|No|Completed|August 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with atrial fibrillation scheduled to undergo coronary angiography due to        suspected coronary artery disease.|April 2013|May 2, 2013|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00968279||134012|
NCT00968617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2578-002|A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)|A Phase IIb Randomized, Active Comparator-Controlled, Open-Label Clinical Trial to Study the Efficacy and Safety of MK2578 for the Treatment of Anemia in ESA (Erythropoiesis-Stimulating Agent)-Naive Patients With Chronic Kidney Disease Who Are Not on Dialysis.||Merck Sharp & Dohme Corp.|No|Terminated|November 2009|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|7|||Both|18 Years|75 Years|No|||October 2015|October 30, 2015|August 27, 2009|Yes|Yes||No|October 7, 2011|https://clinicaltrials.gov/show/NCT00968617||133986|Cohort 1 (MK2578 1.0 mcg/kg) was the only cohort initiated because the study was prematurely terminated by the sponsor. 7 participants received at least 1 dose of MK2578 & 2 participants received all 3 doses. Data presented are for Cohort 1.
NCT00968630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2212.00|Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer|Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV||Fred Hutchinson Cancer Research Center||Recruiting|December 2009|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||November 2015|November 13, 2015|August 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00968630||133985|
NCT00960271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/138/HP|Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC)|Medico-economic Evaluation of a Preoperative Algorithm Including EBUS for NSCLC Initial Staging|EVIEPEB|University Hospital, Rouen|Yes|Completed|September 2008|December 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|363|||Both|18 Years|N/A|No|Non-Probability Sample|This study will include non small cell lung cancer patients, stage III A (before PET        Scan), with resectable tumors.|January 2013|January 17, 2013|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960271||134614|
NCT00960531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134K1-2205|A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease|A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study to Determine Safety, Tolerability, and Immunogenicity of ACC-001 With QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease||Pfizer|Yes|Completed|July 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|111|||Both|N/A|N/A|No|||January 2014|January 29, 2014|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00960531||134595|
NCT00960830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS990|Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety|Mirtazapine Reduces ICD Appropriate Shocks in Cardioverter Implanted Patients With Depression and Anxiety||Universidad Nacional de Rosario|Yes|Completed|April 2007|November 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|65 Years|87 Years|No|||August 2009|August 17, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00960830||134572|
NCT00960843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-08-0009|Six-month Study to Compare the Effects of Volume- and Pressure-Guided Adjustments on Weight Loss and Satiety|A Randomized, Controlled, 6-month Study to Compare the Effects of Volume- and Pressure-guided Adjustments on Weight Loss and Satiety in Patients Implanted With the Swedish Adjustable Gastric Band||Ethicon Endo-Surgery|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|August 14, 2009||No||No|November 2, 2011|https://clinicaltrials.gov/show/NCT00960843||134571|
NCT00960804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091040|Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients|A Phase 3, Double-Blind, Placebo-Controlled, Multicenter, Long-Term Safety Study Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip||Pfizer|No|Terminated|February 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|August 17, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00960804||134574|
NCT00960817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC 02/2009|"Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up|"Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up||Hillel Yaffe Medical Center||Not yet recruiting||||||Phase 0|Interventional|N/A|2||||||Both|18 Years|80 Years|No|||August 2009|August 17, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960817||134573|
NCT00961415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22089|AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer|Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN®) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)||Hoffmann-La Roche||Completed|August 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|376|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|August 18, 2009||No||No|November 30, 2015|https://clinicaltrials.gov/show/NCT00961415||134527|
NCT00961727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009778|Implementation of Bedside Pediatric Early Warning Systems (PEWS)|Implementation of Bedside PEWS at Credit Valley Hospital||The Hospital for Sick Children|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|200|||Both|N/A|18 Years|No|Probability Sample|Patients admitted to the 22-bed paediatric inpatient unit and were less than 18 years of        age at hospital admission|May 2015|May 28, 2015|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961727||134505|
NCT00961740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911180- Helse Vest|Childhood Obesity- Characteristics and Treatment|Cognitive Behavioural Treatment for Childhood Obesity- A Clinical Trial.||University of Bergen|No|Completed|February 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||May 2014|May 25, 2014|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961740||134504|
NCT00962286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBEFUR|Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration|||Rabin Medical Center|No|Terminated|September 2009|July 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|18 Years|55 Years|No|||August 2009|August 3, 2011|August 18, 2009||No|The blood pressure did not decrease following furosemide administration|No||https://clinicaltrials.gov/show/NCT00962286||134462|
NCT00962585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-CT03|Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients|Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients||Ausio Pharmaceuticals, LLC|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|169|||Female|N/A|N/A|No|||March 2014|March 11, 2014|August 19, 2009|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT00962585||134439|Per-protocol, an ANOVA model was to be used for the primary efficacy analysis. However using statistical adjustment of baseline values, ANCOVA could be more a more powerful analysis (Vickers AJ. BMC Med Res Methodology. 2001;1:6. Epub 2001 Jun 28).
NCT00962598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1321|The Role Of Omega-3 Fatty Acids In Adolescent Depression|The Role Of Omega-3 Fatty Acids In Adolescent Depression||Icahn School of Medicine at Mount Sinai|Yes|Completed|February 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|12 Years|19 Years|No|||October 2015|October 23, 2015|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962598||134438|
NCT00962884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090600|Breathing Device for Orthostatic Hypotension (OH)|Assessment of Inspiratory Breathing Devices to Improve Orthostatic Tolerance in Neurogenic Orthostatic Hypotension||Vanderbilt University|No|Recruiting|December 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 22, 2015|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962884||134417|
NCT00963157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0058|Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a Sanofi Pasteur H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|789|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|December 4, 2014|August 20, 2009|Yes|Yes||No|November 10, 2011|https://clinicaltrials.gov/show/NCT00963157||134397|
NCT00963183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2340C00001|AZD5423 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD5423 After Single Ascending Doses in Healthy Male Subjects||AstraZeneca|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|72|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|January 13, 2015|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00963183||134396|
NCT00963781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-5248|Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)|A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent|SEASIDE|Scripps Health|Yes|Active, not recruiting|August 2009|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|900|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|August 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00963781||134352|
NCT00966888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-BIG2-04|Radiation Therapy or Standard Therapy in Treating Women With Stage II Breast Cancer Who Have Undergone Mastectomy|Selective Use of Postoperative Radiotherapy AftEr MastectOmy - SUPREMO||National Cancer Institute (NCI)||Recruiting|January 2006|||June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|3500|||Female|N/A|N/A|No|||August 2009|August 9, 2013|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966888||134119|
NCT00966901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431087|Photoirritation and Photoallergic Potential of a New Nicotine Patch|Assessment of Photoirritation and Photoallergic Potential of a Newly Developed Nicotine Transdermal Therapeutic System (TTS) After Single and Multiple Application and Multiple UV Exposure in Healthy Subjects. A Standard Photocontact Allergenicity Assay.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|August 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|1||Actual|43|||Both|18 Years|65 Years|No|||July 2012|July 6, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966901||134118|
NCT00968929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI01A06|Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)|Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China|RESUPEC|Beijing Chao Yang Hospital|No|Completed|June 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|75 Years|No|||August 2009|August 31, 2009|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968929||133962|
NCT00967421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES437291 VALIDAD|Development of a Valid Test Battery for Assessing Driving Ability When Influenced by Drugs.|Development of a Valid Test Battery for Assessing Driving Ability When Influenced by Drugs.|VALIDAD|St. Olavs Hospital|No|Completed|September 2009|November 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|20|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||November 2011|January 30, 2013|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967421||134078|
NCT00967694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005402|Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers|Effect of N2O on Intraocular Pressure in Healthy Volunteers||Oregon Health and Science University|No|Completed|August 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|August 27, 2009||No||No|April 24, 2014|https://clinicaltrials.gov/show/NCT00967694||134057|
NCT00968045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibro 01/07|Fibrinogen and Bleeding After Cardiac Surgery|Fibrinogen and Bleeding After Cardiac Surgery|Fibro-3|Sahlgrenska University Hospital, Sweden|Yes|Completed|April 2009|May 2015|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|85 Years|No|||May 2015|May 19, 2015|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00968045||134030|
NCT00968292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifkin-2|Stability and 3D Motion Study of an Experimental Prosthetic Foot|Stability & 3D Motion Study of an Experimental Prosthetic Foot||Tensegrity Prosthetics||Not yet recruiting|May 2010|August 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00968292||134011|
NCT00968643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-03 ICORG|Spinal Cord Compression. ICORG 05-03, V6|A Randomised Phase III Trial of Two Fractionation Schemes in the Treatment of Malignant Spinal Cord Compression||ICORG- All Ireland Cooperative Oncology Research Group|No|Completed|January 2006|||May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||August 2014|December 30, 2014|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968643||133984|
NCT00960544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0003|Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism|Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism Using a Limited Pharmacokinetic Sampling Plan||M.D. Anderson Cancer Center|Yes|Not yet recruiting|February 2016|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960544||134594|
NCT00960557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC101-100|Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden|A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden|OXi4503|OXiGENE|No|Completed|July 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||August 2011|August 22, 2011|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960557||134593|
NCT00961168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOBARDS|Work of Breathing and Mechanical Ventilation in Acute Lung Injury|Prospective Study on the Effects of Artificial Breathing Patterns on Work of Breathing in Patients With Acute Lung Injury.|WOBALI|University of California, San Francisco|No|Withdrawn|September 2009|September 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|85 Years|No|||March 2015|March 3, 2015|August 16, 2009||No|Budgetary restrictions|No||https://clinicaltrials.gov/show/NCT00961168||134546|
NCT00961181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0902|Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis|Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis A Prospective, Multi-centre, Non-randomized Clinical Trial With Follow-up Investigations at 1, 6 and 12 Months|PEPPER|Biotronik AG|Yes|Completed|August 2009|May 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|August 13, 2009||No||No|March 19, 2013|https://clinicaltrials.gov/show/NCT00961181||134545|Single arm design. Optimal time point for a quantitative angiographic follow up should be scheduled after 12 months, as recommended by the Academic Research Consortium guidelines for DES.
NCT00961155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/137/08/KE|Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma|Usefulness of Exhaled Breath Condensate and FENO for Evaluation of Markers of Airway Inflammation in Children With Asthma||Medical Universtity of Lodz|No|Recruiting|August 2009|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961155||134547|
NCT00961753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibuprofendosingstudy|Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates|Safety and Efficacy of an Optimized Ibuprofen Dosing Regimen Versus Standard Dosing for Pharmacologic Closure of Patent Ductus Arteriosus|OIDS|OSF Healthcare System|Yes|Terminated|August 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|29 Days|No|||January 2014|January 25, 2014|August 18, 2009|Yes|Yes|FDA drug recall on July 30, 2010|No||https://clinicaltrials.gov/show/NCT00961753||134503|
NCT00962026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-AI-1022|Rilonacept in Diabetes Mellitus Type 1: Safety Study|A Phase I, Open-label, Safety Study of Anti-inflammatory Therapy With Rilonacept in Adolescents and Adults With Type 1 Diabetes Mellitus|RID-A|University of Texas Southwestern Medical Center||Completed|February 2011|June 2013|Actual|March 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|16 Years|45 Years|No|||February 2014|February 21, 2014|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962026||134482|
NCT00963755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178/08|F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer|Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer||University of Lausanne Hospitals|No|Recruiting|August 2009|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Surgical specimen for total prostatectomy|Male|N/A|80 Years|No|Non-Probability Sample|Primary prostate cancer: Patients referred with a suspicion of prostate cancer based on        elevated PSA and rectal examination in whom a prostate biopsy is planned and radical        prostatectomy is envisioned in the event of a positive biopsy finding        Prostate cancer relapse: Patients previously treated for prostate cancer and being        investigated for biochemical relapse for whom surgical or radiation therapy is envisioned        in the event of a positive FCH-PET finding|January 2016|January 24, 2016|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963755||134354|
NCT00964002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000641767|Efavirenz in Treating Patients With Metastatic Prostate Cancer|A Phase II Trial to Assess the Efficacy of Efavirenz in Metastatic Patients With Androgen-independent Prostate Cancer||National Cancer Institute (NCI)||Recruiting|May 2008|||December 2009|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||September 2009|September 4, 2009|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00964002||134335|
NCT00964288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111676|Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects|A Double Blind, Double Dummy, Placebo Controlled Cross Over Study With a Positive Control to Investigate the Effect of a GSK Drug on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects||GlaxoSmithKline|No|Terminated|July 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|July 5, 2012|July 23, 2009||No|During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of    brainstem toxicity/encephalopathy during lidocaine/saline infusion|No||https://clinicaltrials.gov/show/NCT00964288||134313|
NCT00963495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS1.0|Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy|Phase 1 Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy||University Health Network, Toronto|Yes|Terminated|August 2009|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00963495||134374|
NCT00963794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-D176767|Diagnosis of Rectal Cancer by Electromagnetic Device|Clinical Investigation on a Device for the Diagnosis of Rectal Cancer||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|442|||Both|18 Years|95 Years|No|||August 2009|August 21, 2009|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963794||134351|
NCT00967174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431083|Cumulative Skin Irritation Potential of a New 25 mg Nicotine Patch|Study on the Cumulative Skin Irritation Potential of a Newly Developed 25 mg Nicotine Transdermal Therapeutic System. A Double Blind, Randomized, Repeat Patch Test, Single Center Study in 42 Healthy Male and Female Subjects||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|May 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|1||Actual|42|||Both|18 Years|65 Years|No|||July 2012|July 6, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00967174||134097|
NCT00967187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-4326-204|Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.|A Phase II Multicenter, Open-label, Randomized, Parallel Group, Study of Bevirimat in HIV-1 Positive Patients to Evaluate the Safety, Efficacy, and Pharmacokinetics of MPC-4326 Administered as Monotherapy for 14 Days and as Part of an Optimized Background Regimen for up to 72 Weeks.||Myrexis Inc.|Yes|Completed|May 2008|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2010|January 4, 2010|August 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967187||134096|
NCT00967733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-16261-101|Alpha-Linolenic Acid and Inflammatory Markers|Effect of Alpha-Linolenic Acid on Blood Markers of Inflammation||Harvard School of Public Health|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|130|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 18, 2013|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967733||134054|
NCT00967746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06060|An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)|A Randomized, Multicenter, Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Doses of an Etonogestrel-releasing Medicated Intrauterine System (ENG-MIUS) Versus a Copper-releasing Intrauterine Device (IUD)||Merck Sharp & Dohme Corp.|No|Completed|November 2009|July 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|84|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967746||134053|
NCT00967759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-DCN-03(05/08)|Study Comparing 3 Formulations to Evaluate the Efficacy and Safety of the Inflammatory Symptoms of the Upper Respiratory Tract, in Children Between 2 and 6 Years Old|A Double Blind, Randomized, Multicenter Phase III Study Comparing 3 Formulations: Dose Fixed Combination of Bronpheniramine and Fenilefrine, Bronpheniramine Isolated and Fenilefrine Isolated, to Evaluate the Efficacy and Safety of the Treatment of the Inflammatory Symptoms of Upper Respiratory Tract, in Children Between 2 and 6 Years Old.||Ache Laboratorios Farmaceuticos S.A.|No|Suspended||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|300|||Both|2 Years|6 Years|No|||July 2011|July 12, 2011|August 26, 2009||No|The study was designed again in compliance with the regulatory agency.|No||https://clinicaltrials.gov/show/NCT00967759||134052|
NCT00967707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBPPKPD-09|Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain|Population Pharmacokinetic and Pharmacodynamic Modeling of Gabapentin in Neuropathic Pain - Effect of Adjuvant Pharmacotherapy||Uppsala University|Yes|Completed|August 2009|September 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2011|October 11, 2011|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967707||134056|
NCT00967720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08021601|Barriers to Adherence to Asthma Controller Meds in Low Income Urban Minority Adolescents|Qualitative Analysis of the Barriers to Adherence With Asthma Controller Medication Among Inner City African American Adolescents as Identified Through Focus Group Data|ADEPT|Rush University Medical Center|No|Completed|March 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|4|||Both|12 Years|15 Years|No|Non-Probability Sample|four low income urban adolescents with uncontrolled moderate persistent asthma|August 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967720||134055|
NCT00968058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005347|Leak Pressure of Uncuffed Pediatric Endotracheal Tubes|Temporal Variation of the Leak Pressure of Uncuffed Pediatric Endotracheal Tubes Following Intubation: A Prospective Observational Study||Oregon Health and Science University||Completed|June 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|7 Years|No|Non-Probability Sample|Pediatric patients undergoing surgical procedures at Oregon Health & Science University|May 2012|May 3, 2012|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00968058||134029|
NCT00968305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L06121901|Interleukin (IL)-13 as a Marker in Pediatrics Asthma|Cytokine Production in Children With Asthma.||Rush University Medical Center|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|19|Samples Without DNA|Venous blood was obtained to measure total serum immunoglobulin E, radioallergosorbent test      for environmental aeroallergens, and for peripheral blood mononuclear cells isolation|Both|8 Years|15 Years|No|Non-Probability Sample|African-American children, ages 8 to 15 years, with clinically diagnosed asthma which had        been stable for at least 4 weeks prior to enrollment in the study.|August 2009|August 26, 2009|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00968305||134010|
NCT00968318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reduce seroma with expanders|Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders|Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders||Cairo University|No|Completed|May 2006|November 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|56|||Both|12 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 27, 2009|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968318||134009|
NCT00965185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000257|Statin Therapy to Improve Atherosclerosis in HIV Patients|Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients||Massachusetts General Hospital|Yes|Completed|September 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||February 2015|February 17, 2015|August 24, 2009|Yes|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT00965185||134248|FDG-PET scan data was interpretable in only a limited subset of participants as a result of technical problems with manual co-registration in assessing identical regions of aortic arterial inflammation in serial FDG-PET scans.
NCT00965198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00016682|Comparison of Infection Rates Among Patients Using Two Catheter Access Devices|Comparison of a Novel Silver-Coated Catheter Access Device and a Standard Catheter Access Device: A Dual Center Cross-Over Study||Emory University|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||4|Actual|10000|Samples Without DNA|Samples for biofilm analysis may be banked for further study.|Both|18 Years|N/A|No|Non-Probability Sample|Nearly all hospitalized patients require some form of indwelling IV catheter as part of        routine care, and approximately 20% of patient-days include central lines. All adult        patients admitted to 2 Emory affiliated hospitals (Emory University Hospital and Emory        University Hospital Midtown) during the study period will be included in the study        population.|November 2013|November 19, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00965198||134247|
NCT00965536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NFI-SER-2009/1|Nis Register Study Comparing Seroquel and Seroquel Prolong|A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.||AstraZeneca|No|Completed|August 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|South Karelia Central Hospital in-patients|February 2011|February 15, 2011|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965536||134221|
NCT00960570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-028-08-1018|Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz|An Open-Label Drug Interaction Study to Investigate the Effects of Steady State Fenofibric Acid on the Single-Dose Pharmacokinetics of Efavirenz in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|August 14, 2009|No|Yes||No|August 20, 2009|https://clinicaltrials.gov/show/NCT00960570||134592|
NCT00962299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL26689.075.09|Effectiveness of Inhaled Corticosteroids in Preschool Children With Acute Dyspnea and Wheeze|Effectiveness of Inhaled Corticosteroids in Preschool Children Following Hospital Admission for Acute Dyspnea and Wheeze|ICS@ADP|Princess Amalia Children's Clinic|No|Terminated|May 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|1 Year|4 Years|No|||October 2015|October 21, 2015|August 18, 2009||No|recruitment was unsuccesfull, only 7 patient have been included untill 2012|No||https://clinicaltrials.gov/show/NCT00962299||134461|
NCT00962611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12871|BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer|An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer||Bayer|Yes|Active, not recruiting|November 2009|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962611||134437|
NCT00961428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5544|Motivation to Exercise in People With Anorexia Nervosa|Behavioral Assessment of the Reinforcing Effects of Exercise in Patients With Anorexia Nervosa||New York State Psychiatric Institute|Yes|Completed|December 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|60|Samples Without DNA|fasting blood draws to measure cortison and leptin levels|Female|18 Years|45 Years|No|Probability Sample|Participants will be patients with anorexia nervosa on the inpatient unit at New York        State Psychiatric Institute|December 2012|December 4, 2012|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961428||134526|
NCT00963482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAG - 06.004264|Smoking Cessation in Alcoholics|Secondary Prevention of Tobacco Dependence in Alcohol-dependent Patients - a Randomized, Controlled Trial||University Hospital, Basel, Switzerland|No|Completed|July 2007|August 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|65 Years|No|||March 2015|March 9, 2015|August 20, 2009||No||No|February 1, 2012|https://clinicaltrials.gov/show/NCT00963482||134375|Originally two recruiting centers were planned, what failed. Though less subjects than expected.
NCT00962910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA-EQCP002|European Quality of Care Pathways Study on Proximal Femur Fracture (EQCP-PFF)|The European Quality of Care Pathways Study: The Impact of a Care Pathway for Proximal Femur Fracture (PFF) : an International Cluster Randomized Controlled Trial."||European Pathway Association|Yes|Enrolling by invitation|May 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|440|||Both|65 Years|N/A|No|||August 2009|August 19, 2009|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962910||134415|
NCT00963768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012451|A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of JNJ-28431754 in Type 2 Diabetes Mellitus Patients||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|116|||Both|25 Years|65 Years|No|||April 2014|April 22, 2014|August 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00963768||134353|
NCT00963508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALG-0816|Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice|A Multi-Center Phase III Study to Evaluate Malathion Gel 0.5% Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects With Pediculosis Capitis||Taro Pharmaceuticals USA|No|Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|403|||Both|2 Years|N/A|No|||May 2014|May 14, 2014|August 14, 2009|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT00963508||134373|
NCT00963807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02899|Trial Comparing the Use of FLT PET to Standard CT to Assess Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable NSCLC|Phase II Single-Arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess the Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Completed|September 2009|November 2014|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|19 Years|N/A|No|||June 2014|April 30, 2015|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963807||134350|
NCT00968682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-01 ICORG|CADY Study ICORG 08-01|Detection of Cardiac Dysfunction in Patients Treated With Trastuzumab for HER-2 Positive Breast Cancer. The CADY Study||ICORG- All Ireland Cooperative Oncology Research Group||Completed|April 2008|||April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|480|||Female|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with HER2 positive breast cancer, who are foreseen for neoadjuvant        and/or adjuvant treatment with chemotherapy and Trastuzumab either sequentially or in        combination or single agent Trastuzumab.        Patients enrolled on BETH or ALTTO are also eligible.|August 2014|December 30, 2014|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968682||133981|
NCT00968344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-121|Muscle Mass During Space Exploration|An Integrated Low-Volume Nutritional Countermeasure to Maintain Muscle Mass and Function During Space Exploration||The University of Texas Medical Branch, Galveston|Yes|Completed|August 2009|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|45 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968344||134007|
NCT00968357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-SCV-HCV-P2-001|Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed|A Phase 2, Multicenter, Multidose, Open-Label Study to Evaluate the Safety and Immunomodulatory Effects of SCV-07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Genotype 1 Chronic Hepatitis C Who Have Relapsed After a Response to a Course of at Least 44 Weeks Treatment With Pegylated Interferon and Ribavirin||SciClone Pharmaceuticals|Yes|Completed|September 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|40|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968357||134006|
NCT00969280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI0906|Acupuncture for Dry Eye Syndrome|Acupuncture for Dry Eye Syndrome : A Randomized, Patient-Assessor Blinded, Non-acupuncture Point Shallow Penetration-Controlled Study||Korea Institute of Oriental Medicine|Yes|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||September 2010|December 17, 2010|August 31, 2009||No||No|September 17, 2010|https://clinicaltrials.gov/show/NCT00969280||133935|
NCT00968071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0882|Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome|A Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Completed|February 2008|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|16 Years|N/A|No|||February 2013|February 4, 2013|August 26, 2009||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT00968071||134028|
NCT00968331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVLIRIT01|Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|||University of Bologna||Terminated|March 2009|December 2011|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|65 Years|N/A|No|||August 2012|August 24, 2012|August 28, 2009||No|The EC withdrawn the approval becuase of possible conflicts of interests between our Institute    and Supporter (Celgene)|No||https://clinicaltrials.gov/show/NCT00968331||134008|
NCT00968656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISO 08-1010|Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1|Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1|FISO PET/CT|Washington University School of Medicine|No|Completed|January 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968656||133983|
NCT00968669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP198|A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults|A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults With Uncontrolled Asthma||MedImmune LLC|Yes|Completed|December 2009|January 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|329|||Both|18 Years|65 Years|No|||May 2014|May 6, 2014|August 28, 2009|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT00968669||133982|
NCT00968916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10967|Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors|An Open-label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With AVE8062 Administered as a 30-minute Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.||Sanofi|No|Completed|September 2009|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|75 Years|No|||September 2014|September 18, 2014|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968916||133963|
NCT00969267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98001-62-020|The Effect of Auricular Point Stimulation on Obese Women|The Effect of Auricular Point Stimulation on Obese Women: a Randomized Controlled Trial||Taipei City Hospital|Yes|Completed|August 2009|July 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|90|||Female|16 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969267||133936|
NCT00964847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT004921-01A1|Lifestyle Modification and Blood Pressure Study|Lifestyle Modification and Blood Pressure Study|LIMBS|University of Pennsylvania|No|Recruiting|August 2009|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|75 Years|No|||August 2011|August 4, 2011|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964847||134271|
NCT00965172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0276|Caphosol in Sarcoma Patients With Mucositis|A Phase II Study to Evaluate the Preliminary Efficacy Assessment of Caphosol in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide or Cisplatin||M.D. Anderson Cancer Center|No|Completed|April 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|16 Years|65 Years|No|||March 2012|March 20, 2012|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00965172||134249|
NCT00965861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MISC 39|SCRI Tissue Testing Registry|SCRI Tissue Testing Registry||SCRI Development Innovations, LLC|No|Terminated|May 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|20|Samples With DNA|Potential retention of tissue blocks for future study.|Both|18 Years|N/A|No|Non-Probability Sample|The SCRI Oncology Research Consortium will collect written consent from patients allowing        the use of their tumor tissue sample(s) for testing/analysis at a future date.|August 2013|August 27, 2013|August 24, 2009||No|Replaced by a study with a similar design.|No||https://clinicaltrials.gov/show/NCT00965861||134197|
NCT00962039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH069715|Anxiety and Recurrent Abdominal Pain in Children|Anxiety and Recurrent Abdominal Pain in Children||National Institute of Mental Health (NIMH)|Yes|Recruiting|July 2004|April 2010|Anticipated|April 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|7 Years|18 Years|No|||March 2009|August 18, 2009|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962039||134481|
NCT00962052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDL0806|Biomarker Discovery and Application in Bladder Cancer|Biomarker Discovery and Application in Bladder Cancer: Identification and Detection of Gene Methylation, Tumor Specific Antigenes Markers of BCG Treatment.||Wolfson Medical Center|No|Recruiting|July 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|250|Samples With DNA|blood, first void urine, bladder tumors and healthy tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|1. Those currently diagnosed and undergoing treatment for bladder cancer (100).          2. Those currently diagnosed with other urogenital cancers including prostate cancer and             kidney cancer (50).          3. Those currently diagnosed with non-malignant urogenital conditions including urinary             tract infection, interstitial cystitis, and kidney stones for specificity analysis             (50).          4. Healthy control patients (50).|September 2010|September 12, 2010|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962052||134480|
NCT00962897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-198, Viabahn #2|Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusion|A Retrospective Review of Randomized Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusion With Four Years Followup||Texas Vascular Associates|Yes|Completed|September 2003|July 2009|Actual|May 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Vascular surgery clinic patients with ischemic symtpom of the lower extremities. Patients        were previously enrolled in a randomized prospective study comparing treatment of blockage        in the legs with a surgical bypass or percutaneous covered stent placemnt.|August 2009|August 19, 2009|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962897||134416|
NCT00963469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-240|Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001||Merck Sharp & Dohme Corp.||Completed|August 2001|November 2001|Actual|November 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1079|||Both|15 Years|85 Years|No|||June 2015|June 22, 2015|August 19, 2009|Yes|Yes||No|September 16, 2009|https://clinicaltrials.gov/show/NCT00963469||134376|
NCT00962624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MenOccy|Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults|A Phase 2, Open-label Study of the Safety, Tolerability and Immunogenicity of a Meningococcal B Vaccine When Administered at a 0, 2, 6 Months and of a Single Dose of Meningococcal ACWY Conjugate Vaccine in Healthy Adults Aged 18-65 Years|MenOccy|Public Health England|No|Completed|July 2010|March 2012|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962624||134436|
NCT00962637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-003|Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Open-Label, Active-Controlled Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism||Repros Therapeutics Inc.|No|Completed|March 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|194|||Male|18 Years|68 Years|No|||February 2010|February 10, 2010|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962637||134435|
NCT00962650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-08-0007|Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance|A Feasibility Trial to Evaluate Natural Orifice Transgastric Endoscopic Diagnostic Peritoneoscopy With Laparoscopic Assistance.|NOTES|Ethicon Endo-Surgery|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|August 12, 2009|No|Yes||No|December 20, 2010|https://clinicaltrials.gov/show/NCT00962650||134434|Ten male and female subjects indicated for Diagnostic Peritoneoscopy in advance of Roux-en Y Gastic Bypass procedure, who had a history of previous abdominal surgery, and met study Inclusion Criteria, were enrolled in the study.
NCT00962663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-105665-05|Effects of ICA-105665 Using the Intradermal Capsaicin and Ultraviolet B (UV-B) Models in Healthy Male Subjects|A Randomized, Placebo-Controlled, 3-way Crossover Study to Investigate the Pharmacodynamic Effects of ICA-105665 Using the Intradermal Capsaicin and UV-B Models in Healthy Male Subjects||Pfizer|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962663||134433|
NCT00962923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJGLYY003|Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)|||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|August 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|65 Years|No|||August 2009|August 19, 2009|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962923||134414|
NCT00963196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14503|Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response|Supplementation of Antidepressants With Fatty Acid Therapy|SADFAT|University of Virginia|No|Withdrawn|September 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|78|||Both|18 Years|N/A|No|||June 2010|June 2, 2010|August 20, 2009|Yes|Yes|End of allotted time for subject recruiting.|No||https://clinicaltrials.gov/show/NCT00963196||134395|
NCT00963521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000626786|Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission|Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission||National Cancer Institute (NCI)||Completed|June 2008|||May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||May 2011|May 12, 2011|August 20, 2009||||No||https://clinicaltrials.gov/show/NCT00963521||134372|
NCT00964054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH082153|Depression Outcomes Study of Exercise|Adapting Exercise Treatment for Depression to Adolescents: A Pilot Study|DOSE|National Institute of Mental Health (NIMH)|Yes|Completed|September 2012|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||April 2012|March 13, 2013|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00964054||134331|
NCT00964067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJERTEREHAB2009|Aerobic Interval Training in Cardiac Rehabilitation|Effect of High Intensity Aerobic Interval Training in Cardiac Rehabilitation||Norwegian University of Science and Technology|No|Completed|September 2009|July 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|80 Years|No|||February 2015|February 18, 2015|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00964067||134330|
NCT00968708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322_402|Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome|EXAMINE|Takeda|Yes|Completed|September 2009|June 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5380|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|August 28, 2009|Yes|Yes||No|March 8, 2014|https://clinicaltrials.gov/show/NCT00968708||133979|
NCT00968968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112515|Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone|A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer||Novartis||Active, not recruiting|January 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968968||133959|
NCT00968981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4610g|A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists|A Phase Ib, Open-Label, Dose-Scheduling Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists||Genentech, Inc.||Completed|September 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|August 28, 2009|No|Yes||No|July 9, 2015|https://clinicaltrials.gov/show/NCT00968981||133958|
NCT00968695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG0802|Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.|Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.||Instituto Grifols, S.A.|No|Completed|July 2009|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|80 Years|No|||April 2015|April 14, 2015|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968695||133980|
NCT00964860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009061|A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing|A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing||Procter and Gamble|No|Completed|August 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 2, 2012|August 20, 2009|Yes|Yes||No|June 28, 2012|https://clinicaltrials.gov/show/NCT00964860||134270|
NCT00968942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL015LCL|Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Repeat Dose, Single Center Study to Evaluate the Efficacy and Safety of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults||Revance Therapeutics, Inc.|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 25, 2013|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968942||133961|
NCT00965211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS HBDL|Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome|Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome.||Shalvata Mental Health Center|Yes|Recruiting|September 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||January 2012|January 4, 2012|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965211||134246|
NCT00965562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001011511|Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)|A Double-blind, Parallel Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)||Donaghue Medical Research Foundation|Yes|Completed|September 2000|October 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|49|||Female|18 Years|48 Years|No|||February 2015|March 3, 2015|August 24, 2009|Yes|Yes||No|July 2, 2013|https://clinicaltrials.gov/show/NCT00965562||134219|small sample size
NCT00961454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-000937|Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression|A Pilot Study to Evaluate the Ability of Photobiomodulation to Alter Cerebral Blood Flow in the Frontal Poles and to Affect the Emotional Status of Patients With Major Depression||Massachusetts General Hospital|Yes|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||August 2009|August 18, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961454||134524|
NCT00961792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12119a|Chicago Social Drinking Project|Individual Differences After Consumption of Alcohol and Other Common Substances and Long-Term Follow-Up of Social Drinking, Young Adults|CSDP|University of Chicago|Yes|Active, not recruiting|March 2004|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|5||Anticipated|400|||Both|21 Years|29 Years|No|||March 2015|March 4, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00961792||134500|
NCT00961805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1044/06|Effectiveness of Dance on Patients With Fibromyalgia|Effectiveness of Dance on Patients With Fibromyalgia||Federal University of São Paulo|No|Completed|August 2007|November 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|65 Years|No|||August 2009|August 19, 2009|April 30, 2009||No||No|April 30, 2009|https://clinicaltrials.gov/show/NCT00961805||134499|
NCT00962104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12107|Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder|A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)||Eli Lilly and Company|No|Completed|August 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|391|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|August 18, 2009|Yes|Yes||No|February 6, 2012|https://clinicaltrials.gov/show/NCT00962104||134476|
NCT00962312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-39 ICORG|Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Study of Lapatinib and Capecitabine in the Treatment of Metastatic Pancreatic Cancer.||ICORG- All Ireland Cooperative Oncology Research Group||Completed|January 2009|||December 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2012|December 30, 2014|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962312||134460|
NCT00962325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK83438|Increasing Physical Activity Among Inactive Bariatric Surgery Patients (Bari-Active)|Increasing Physical Activity Among Inactive Bariatric Surgery Patients||The Miriam Hospital|No|Completed|March 2009|June 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962325||134459|
NCT00962338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-125|Pain and Convalescence After Laparoscopic Groin Hernia Repair|Pain and Convalescence After Laparoscopic Groin Hernia Repair|Lap-Lyske|University Hospital Koge|Yes|Completed|August 2009|June 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|210|||Both|18 Years|85 Years|No|Probability Sample|The population are from Region Sjaelland and are planned for laparoscopic inguinal or        femoral herniorrhaphy. Single university hospital department i Denmark.|August 2011|August 19, 2011|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962338||134458|
NCT00962949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081398|The Renin-Aldosterone Axis in Postural Tachycardia Syndrome|The Renin-Aldosterone Axis in Postural Tachycardia Syndrome||Vanderbilt University|No|Recruiting|April 2009|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2009|August 19, 2009|August 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962949||134412|
NCT00963235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3017|Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS|A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine||Pfizer|Yes|Completed|November 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|331|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|August 20, 2009|Yes|Yes||No|April 17, 2013|https://clinicaltrials.gov/show/NCT00963235||134392|
NCT00963248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BToenshoff002|EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients|Surveillance of EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients - a Multicenter Prospective Study||Klinik für Kinder- und Jugendmedizin|Yes|Completed|July 2003|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|Samples Without DNA|EDTA plasma for EB viral load, serum for differentiated serology and sodium heparine      whole-blood for EBV-specific t cells|Both|N/A|N/A|No|Non-Probability Sample|pediatric (< 18 years) and adult (>= 18 years) kidney allograft recipients|April 2015|April 10, 2015|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963248||134391|
NCT00963209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650376|Tamoxifen Citrate in Patients With Breast Cancer|Tamoxifen Metabolism and the Impact of Tamoxifen Dose on the Level of the Active Metabolites in Endocrine Sensitive Breast Cancer Patients||Centre Hospitalier Universitaire Vaudois|No|Recruiting|June 2009|December 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963209||134394|
NCT00963820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16004|Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and Refractory Multiple Myeloma||Millennium Pharmaceuticals, Inc.|No|Completed|October 2009|January 2014|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|August 20, 2009|No|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00963820||134349|
NCT00964340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113312|A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days|A Randomized, Placebo-Controlled, Double-Blind, Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days||GlaxoSmithKline|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||December 2010|December 9, 2010|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00964340||134309|
NCT00964626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000641288|Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer|A Phase II Study of Efficacy and Safety of Paclitaxel and Cisplatin Every 2 Weeks as the First-line Treatment of Patients With Ovarian Cancer Stage Ic-IV.||National Cancer Institute (NCI)||Recruiting|April 2009|||April 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|72 Years|No|||August 2009|August 23, 2013|August 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00964626||134288|
NCT00968721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090527|Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use|Decisional Influences and IBD Patients' Medication Use||Vanderbilt University|No|Recruiting|June 2010|December 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|The Vanderbilt University Medical Center Research Recruitment Registry will be used to        identify the medical record and phone numbers of all VUMC patients recieving treatment for        IBD.|July 2011|July 14, 2011|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968721||133978|
NCT00965289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOELAMS 074|High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma|Front-line High-dose Chemotherapy (HDT) Combined With Rituximab for Adults With Aggressive Large B-cell Lymphoma (DLBCL) : Goelams 074 Trial.||Nantes University Hospital|Yes|Completed|April 2002|June 2009|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|60 Years|No|||August 2009|August 25, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965289||134240|
NCT00968994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-0004|Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites|A Randomized, Site-Matched, Controlled Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites||Exciton Technologies Inc.|No|Recruiting|December 2009|January 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||December 2009|December 22, 2009|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968994||133957|
NCT00969319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14285|Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America|Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America||Bayer|No|Completed|September 2009|February 2014|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|105|None Retained|n.a.|Male|N/A|N/A|No|Non-Probability Sample|The study population will consist of patients with a diagnosis of hemophilia A. Physicians        should consult the full prescribing information for KOGENATE® FS before enrolling patients        and familiarize themselves with the safety information in the product package label.|January 2015|January 16, 2015|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969319||133932|
NCT00964912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN162-001|Single Dose Study of BMS-820836|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|July 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|11||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 24, 2011|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00964912||134267|
NCT00968955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2009-079|Effect of Local Infiltration Analgesia in Total Hip Arthroplasty|Effect of Local Infiltration Analgesia With Ropivacaine in Total Hip Arthroplasty: a Prospective, Randomized, Double-blind, Placebo-controlled Trail||Hvidovre University Hospital|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968955||133960|
NCT00969293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOV2302/CLIN/101/P|Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion|An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion|FOV2302|Fovea Pharmaceuticals SA|Yes|Terminated|September 2009|March 2012|Anticipated|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969293||133934|
NCT00969306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chloroquine IV|Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients|Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial|Chloroquine IV|Maastricht Radiation Oncology||Recruiting|September 2013|||June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|208|||Both|18 Years|100 Years|No|||February 2016|February 29, 2016|August 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00969306||133933|
NCT00964873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-04|A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia||Synta Pharmaceuticals Corp.|No|Completed|August 2009|August 2011|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964873||134269|
NCT00964886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-019-09S|Efficacy of Antidepressants in Chronic Back Pain|Efficacy of Antidepressants in Chronic Back Pain||VA Office of Research and Development|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|70 Years|No|||July 2015|July 16, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964886||134268|
NCT00961220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02927|O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma|A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|January 2010|||April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|19 Years|N/A|No|||May 2014|March 11, 2015|August 16, 2009|Yes|Yes||No|March 11, 2015|https://clinicaltrials.gov/show/NCT00961220||134542|
NCT00961467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV MM PI 210|RMPT for Relapsed/Refractory Multiple Myeloma|Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma|RMPT|Fondazione Neoplasie Sangue Onlus|No|Active, not recruiting|February 2007|February 2011|Anticipated|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2010|March 17, 2010|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00961467||134523|
NCT00962351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2009-0100|Metal Ion Release From an FDA-Approved Metal-on-Metal Total Hip Replacement Implant|Metal Ion Release From an FDA Approved Metal-on-Metal Hip Replacement Implant: A Multi-Center, Randomized Clinical Trial||Anderson Orthopaedic Research Institute|Yes|Completed|October 2003|October 2013|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|120|||Both|40 Years|80 Years|No|||August 2015|August 14, 2015|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962351||134457|
NCT00962377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0007|A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation|Early Invasive Monitoring Attenuation Through Gene Expression (EIMAGE) Trial|EIMAGE|XDx|No|Active, not recruiting|August 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 20, 2010|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962377||134455|
NCT00962065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-201-DM|Study of LX4211 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX4211 in Subjects With Type 2 Diabetes Mellitus||Lexicon Pharmaceuticals|No|Completed|August 2009|||December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|No|||February 2011|February 4, 2011|August 10, 2009|Yes|Yes||No|February 4, 2011|https://clinicaltrials.gov/show/NCT00962065||134479|
NCT00962078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRÄ-LTX-08022|Pulmonary Rehabilitation in Patients Before Lung Transplantation (LTx)|Effects of a Complex Pulmonary Rehabilitation Program on Patients With End Stage Lung Diseases Undergoing Evaluation for Lung Transplantation (Pre-LTx)||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|July 2008|||October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||November 2011|November 10, 2011|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00962078||134478|
NCT00962676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0129|Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients|||Yonsei University||Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|N/A||2|Actual|140|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|suspicious of tuberculosis, immunocompromised patients such cancer patients on        chemotherapy, transplantation patients, patients with immunosuppressant|January 2012|January 31, 2012|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962676||134432|
NCT00962936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-2009-01|Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection|Phase I/II Study to Evaluate the Safety and Tolerability of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection||CureTech Ltd|No|Terminated|September 2009|January 2013|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|60 Years|No|||August 2014|August 28, 2014|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962936||134413|
NCT00963547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206-015|A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (2206-015)|A Phase I Investigation of the Combination of MK2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|September 2009|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00963547||134370|
NCT00963560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09-008|Presbyopia-Correcting Intraocular Lenses (IOLs)|A Randomized, Subject-masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting IOLs||Alcon Research|No|Completed|August 2009|||March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|132|||Both|21 Years|N/A|No|||July 2011|July 13, 2011|August 19, 2009|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00963560||134369|
NCT00963833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14438|Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis|Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis||Bayer|No|Active, not recruiting|December 2009|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|68|||Both|12 Years|16 Years|No|Non-Probability Sample|Treatment naive children and adolescents aged 12 to 16 years at inclusion diagnosed with        RRMS.|January 2016|January 11, 2016|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00963833||134348|
NCT00963846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomedisyn 200901|Huperzine for Cognitive and Functional Impairment in Schizophrenia|Huperzine for Cognitive and Functional Impairment in Schizophrenia||Biomedisyn Corporation|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|55 Years|No|||February 2013|February 28, 2013|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963846||134347|
NCT00963222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-04-27-6617|The Study of the Effects of Vitamin A on Immune System in Patients With Atherosclerosis|The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Atherosclerosis||Tehran University of Medical Sciences|Yes|Enrolling by invitation|September 2009|March 2013|Anticipated|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|60|||Both|35 Years|60 Years|No|||June 2012|June 2, 2012|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963222||134393|
NCT00964353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16738B|Clinical and Economic Implications of Genetic Testing for Warfarin Management|The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management||University of Chicago|Yes|Active, not recruiting|August 2009|December 2014|Anticipated|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|268|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|August 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00964353||134308|
NCT00964639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLACC2008|Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies|Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies. A Prospective, Randomized and Double-blinded Study||University of Aarhus|Yes|Completed|August 2009|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|N/A|18 Years|No|||January 2013|January 25, 2013|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964639||134287|
NCT00960401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05018|A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer|Pilot Study "A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer"|ABCART|Winthrop University Hospital|No|Active, not recruiting|August 2005|December 2012|Anticipated|May 2007|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|20|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|breast cancer patients after radiation treatment|August 2012|August 13, 2012|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00960401||134605|
NCT00965302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20090068H|Sleeve Gastrectomy Versus Medical Management for Remission of Diabetes in Mild to Moderately Obese Patients|Sleeve Gastrectomy vs Medical Management for Remission of Diabetes in Mild to Moderately Obese Patients||Wilford Hall Medical Center|Yes|Completed|August 2009|September 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||August 2009|January 12, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965302||134239|
NCT00965614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34MD01|To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia|To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia||National Taiwan University Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|80 Years||||November 2012|December 20, 2012|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965614||134215|
NCT00965627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-01/2008|Biology of Thymic Tumors|Biological Analysis of a Series of Thymoma and Thymic Carcinoma: Genetic Aberrations and Potential Therapy Targets.||Istituto Clinico Humanitas|No|Completed|June 2008|August 2009|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|134|Samples With DNA|paraffin-embedded tumor specimens of patients|Both|18 Years|N/A|No|Non-Probability Sample|Thymoma and thymic carcinoma patients will be retrospectively analyzed. Patients will be        selected based on the availability of tumor tissue.|August 2009|August 27, 2009|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00965627||134214|
NCT00964951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0060|CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a CSL H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||November 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|August 26, 2010|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964951||134265|
NCT00964964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3765|A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics|A Trial Assessing the Number of Hypoglycaemic Episodes and Glycaemic Variability During Two Different Regimens of SIBA 200 U/ml in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00964964||134264|
NCT00964938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSLV|Multisite Pacing With a Quadripolar Lead|Multisite Pacing With a Quadripolar Left Heart Lead in Cardiovascular Resynchronization Therapy (CRT) Patients||St. Jude Medical|No|Completed|August 2009|||April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|N/A|No|||March 2012|March 24, 2012|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00964938||134266|
NCT00965250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090212|Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy|Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy||National Institutes of Health Clinical Center (CC)|Yes|Active, not recruiting|August 2009|October 2021|Anticipated|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|August 24, 2009|Yes|Yes||No|October 12, 2012|https://clinicaltrials.gov/show/NCT00965250||134243|
NCT00965263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#3980|Therapeutic Cocaine Vaccine: Human Laboratory Study|Tests of a Therapeutic Cocaine Vaccine||New York State Psychiatric Institute|No|Completed|March 2003|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|15|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00965263||134242|
NCT00965926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-078|A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers|A Pharmacokinetic Study in Healthy Non-elderly Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of YM178||Astellas Pharma Inc|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|72|||Both|20 Years|54 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00965926||134192|
NCT00966199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBRACE|The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population|Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly|MBRACE|Radboud University|No|Not yet recruiting|September 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|70 Years|N/A|No|||August 2009|August 25, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00966199||134171|
NCT00961480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-095|A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)|A 3-Part, Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence After Administration of the FMI Sitagliptin/Metformin 50/500 mg, 50/850 mg and 50/1000 mg FDC Tablet and Co-administration of Corresponding Doses of Sitagliptin and Metformin as Individual Tablets||Merck Sharp & Dohme Corp.|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|August 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00961480||134522|
NCT00961493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074589|RCT of an Acceptance-based Behavior Therapy for GAD|Randomized Controlled Trial of an Acceptance-based Behavior Therapy for Generalized Anxiety Disorder||University of Massachusetts, Boston|Yes|Completed|March 2007|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961493||134521|
NCT00961818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTP|Immediate Effect Analysis of Vocal Techniques|Perceptual, Acoustic and Laryngological Analysis of Vocal Techniques Immediate Effect||Tuiuti University of Paraná|Yes|Completed|July 2008|December 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|32|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Were included in the study, female subjects with normal voices evidenced by the slightly        altered auditory-perceptual analysis, without vocal complaints, aged between 20 and 45        years.|August 2009|August 18, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961818||134498|
NCT00962091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14010|Study of MLN8237 in Patients With Advanced Solid Tumors|An Open-label, Phase 1 Study of the Relative Bioavailability, Food Effect, Safety and Tolerability of MLN8237 in Patients With Advanced Solid Tumors||Millennium Pharmaceuticals, Inc.|No|Completed|September 2009|April 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|August 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962091||134477|
NCT00962390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS CT04|Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia|Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia||Ausio Pharmaceuticals, LLC|No|Completed|June 2009|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|116|||Male|50 Years|N/A|No|||January 2016|January 8, 2016|August 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962390||134454|
NCT00962364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-01-BMC-Reg|Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease|Long-term Evaluation and Follow-up Care of Patients Receiving Intracoronary Bone Marrow-derived Cell Administration for Heart Disease|BMC registry|Johann Wolfgang Goethe University Hospitals|No|Recruiting|October 2001|December 2021|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|1500|Samples With DNA|Serum and plasma from peripheral blood and bone marrow may me retained|Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from heart disease with consecutive signs of heart failure, treated in        our clinic or being referred for cell therapy|September 2015|September 8, 2015|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962364||134456|
NCT00963261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO5098|Quality of Life and Psychological Well-being in Patients With Malignant Melanoma|Side-effect Management for Patients With Malignant Melanoma Undergoing Treatment With Interferon Alpha (IFN-α)- Diagnosis and Therapy -||University Hospital Freiburg|No|Recruiting|April 2009|April 2012|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Both|18 Years|N/A|No|||June 2010|June 24, 2010|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963261||134390|
NCT00963573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03428|Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)|Efficacy and Safety of Loratadine-Betamethasone Oral Solution (1 mg/0.05 mg/1 mL) for Initial Treatment of Severe Perennial Allergic Rhinitis in School Age Children||Merck Sharp & Dohme Corp.|No|Completed|September 2003|November 2006|Actual|November 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|6 Years|12 Years|No|||April 2015|April 20, 2015|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963573||134368|
NCT00963586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qol hn maastro umcg|Quality of Life in Patients Treated for Head and Neck Cancer|Quality of Life in Patients Treated for Head and Neck Cancer||Maastricht Radiation Oncology|No|Completed|June 2009|April 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|456|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated for head and neck cancer more than 6 months ago.|June 2010|June 24, 2010|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963586||134367|
NCT00963859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0441|Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder|Phase II Evaluation of Robotic-assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder||M.D. Anderson Cancer Center|No|Completed|October 2007|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|N/A|No|||April 2013|April 10, 2013|August 19, 2009||No||No|June 28, 2012|https://clinicaltrials.gov/show/NCT00963859||134346|
NCT00963534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG-MCL4|Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.|Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma - a Nordic Lymphoma Group Trial|LENA-BERIT|Lund University Hospital|No|Active, not recruiting|September 2009|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|65 Years|N/A|No|||April 2015|April 10, 2015|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963534||134371|
NCT00964652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234/2007|Treadmill Training With Additional Body Load: Effects on Gait of Subjects With Parkinson´s Disease|||Universidade Federal de Sao Carlos||Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|51 Years|81 Years|No|||August 2009|August 24, 2009|August 24, 2009||||No||https://clinicaltrials.gov/show/NCT00964652||134286|
NCT00961025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA1229_DM_I|A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1 Study to Investigate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of DA-1229 in Healthy Male Subjects||Dong-A ST Co., Ltd.||Recruiting|May 2009|March 2010|Anticipated|February 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|August 20, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00961025||134557|
NCT00961038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13014|Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Randomized, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLD II - III), Following Inhalation of Ciprofloxacin PulmoSphere® Inhalation Powder||Bayer|No|Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|19|||Both|40 Years|75 Years|No|||March 2014|March 31, 2014|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961038||134556|
NCT00965328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO 06044|Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration|Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates||Onze Lieve Vrouwe Gasthuis|Yes|Completed|February 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||August 2009|August 24, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965328||134237|
NCT00965640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPB-2002-01|Treatment of Male Pattern Baldness With Botulinum Toxin|A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia||The Crown Institute|No|Completed|December 2002|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Primary Purpose: Screening|||||||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965640||134213|
NCT00965653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22623|A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis|Open-label, Multicenter, Randomized, Parallel Study to Investigate pk, pd, Efficacy and Safety of Tocilizumab (TCZ, RO4877533) Following Subcutaneous Administration of TCZ 162 mg Weekly or Every Other Week in Combination With Methotrexate in Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|August 2009|July 2011||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00965653||134212|
NCT00965939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51257|An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients|Study to Assess Response to Tamoxifen in (cT3)/ Inoperable Locally Advanced / Metastatic ER-positive Breast Cancer by the 'Tamoxifen Activity Score' Based on Drug Interaction and Polymorphisms in Genes Coding for Tam. Metabolising Enzymes.|CYPTAMBRUT-2|Vlaamse Vereniging voor Obstetrie en Gynaecologie|Yes|Completed|February 2009|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Female|18 Years|N/A|No|Non-Probability Sample|Female, with ER-positive breast cancer|October 2015|October 27, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965939||134191|
NCT00965952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-08-009|A Surgical Simulation Study to Evaluate the Safety of a Device Mechanism as Treatment for Vaginal Apical Prolapse|A Prospective, Observational Surgical Simulation Study to Evaluate the Safety of the VFIX Device Mechanism as Treatment for Vaginal Apical Prolapse||Ethicon, Inc.|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|||Female|18 Years|N/A|No|Non-Probability Sample|hospital referrals|February 2010|February 9, 2010|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965952||134190|
NCT00965276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040088|Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer|Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival||National Institutes of Health Clinical Center (CC)||Completed|January 2004|December 2010||||N/A|Observational|N/A|||Actual|2500|||Both|N/A|N/A|No|||December 2010|September 23, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965276||134241|
NCT00965601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFR 080554|A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia|A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia|NFR|Indiana University|No|Completed|July 2008|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Female|18 Years|65 Years|No|||August 2009|April 5, 2012|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965601||134216|
NCT00965913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431082|Cumulative Skin Irritation Potential of a New 15 mg Nicotine Patch|Study on the Cumulative Skin Irritation Potential of a Newly Developed 15 mg Nicotine Transdermal Therapeutic System. A Double Blind, Randomized, Repeat Patch Test, Single Center Study in 42 Healthy Male and Female Subjects||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|May 2005|June 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|1||Actual|42|||Both|18 Years|65 Years|No|||June 2012|June 27, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965913||134193|
NCT00966732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yoga for Fibromyalgia|Yoga for Fibromyalgia|Yoga of Awareness Program for Fibromyalgia: A Randomized Clinical Trial||Oregon Health and Science University|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Female|21 Years|N/A|No|||October 2014|October 14, 2014|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966732||134130|
NCT00961831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13107|Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients|Open-label, Multicenter Study for an Evaluation of Radiation Dosimetry, Metabolism, Safety and Tolerability of the [F18] Labeled PET (Positron Emission Tomography) Tracer BAY 85-8050 Following a Single Intravenous Administration in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability and Diagnostic Performance of the Tracer in PET/CT (Computer Tomography) in Patients||Bayer|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 19, 2014|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961831||134497|
NCT00961844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-004|Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma|Phase I/II Trial for Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma||Oslo University Hospital|No|Terminated|August 2009|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2014|August 22, 2014|August 12, 2009||No|Logistical problems|No||https://clinicaltrials.gov/show/NCT00961844||134496|
NCT00962117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1066937|Relationship Between Dopamine Genetics, Food Reinforcement, Energy Intake and Obesity|Food Reinforcement Genotype Interactions and Eating||State University of New York at Buffalo|Yes|Completed|February 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|310|Samples With DNA|Saliva DNA samples will be collected from all participants|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited from newspaper ads, posters on campus and in community        settings, web based recruitment (ads on Craig's list and on the department's website) and        direct mail targeted to community residents between 18-50 years of age.|June 2012|June 12, 2012|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00962117||134475|
NCT00962962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012628|Exercise Dose-Response Effects in Prediabetes|Exercise Dose-Response Effects in Prediabetes: Responses and Mechanisms|STRRIDE-PD|Duke University|No|Completed|July 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|288|||Both|45 Years|75 Years|No|||September 2013|July 14, 2014|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962962||134411|
NCT00962975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP22612|A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies|||Hoffmann-La Roche||Completed|September 2009|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962975||134410|
NCT00963274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12215|Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma|Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma||Virginia Commonwealth University|Yes|Active, not recruiting|April 2010|March 2016|Anticipated|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00963274||134389|
NCT00963287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHTCM-003|Trial of Chinese Prescription on Ulcerative Colitis|||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|August 2009|August 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||August 2009|August 24, 2009|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00963287||134388|
NCT00963872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008UC097|Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer|MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)||Masonic Cancer Center, University of Minnesota|Yes|Terminated|March 2010|August 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||October 2015|October 13, 2015|August 21, 2009|Yes|Yes|Lack of efficacy after interim analysis|No|April 22, 2015|https://clinicaltrials.gov/show/NCT00963872||134345|
NCT00964119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0106|Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population|An Interdisciplinary Study of Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population||University of Wisconsin, Madison||Terminated|July 2008|August 2013|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|||Both|12 Years|21 Years|No|Non-Probability Sample|All subjects will be recruited from the UW-Madison, Department of Dermatology located at 1        South Park Street, Madison, Wisconsin. Study flyers and brochures will be posted in the        waiting areas and clinic rooms at the UW Dermatology clinics. UW Dermatologist will        identify patients that meet study criteria and ask if they are interested in research        participation, then they will be referred to study personnel for more information.|February 2015|February 11, 2015|August 21, 2009||No|Principal Investigator has left Sponsoring Instiution|No|December 5, 2014|https://clinicaltrials.gov/show/NCT00964119||134326|
NCT00964405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112016|Phase I Study of GSK233705 in Healthy Japanese Male Subjects|Phase I Study of GSK233705 - A Randomised, Double Blind, Placebo-controlled, 2-parts Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Inhaled Doses of GSK233705 From a Novel Dry Powder Device in Healthy Japanese Male Subjects -||GlaxoSmithKline||Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||February 2011|June 21, 2012|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00964405||134304|
NCT00964080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBP-426 201|Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma|A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma||Mebiopharm Co., Ltd|No|Active, not recruiting|May 2009|April 2015|Anticipated|October 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||April 2012|November 28, 2014|August 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964080||134329|
NCT00964093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baylor IRB # 008-299|The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants|The Efficacy of Silver Alginate (Algidex®) Dressing in Reducing Central Line Infections in Very Low Birth Weight (VLBW) Infants: A Multicenter Collaborative Randomized Controlled Trial.||Baylor Research Institute|Yes|Enrolling by invitation|March 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|N/A|3 Weeks|No|||March 2015|March 12, 2015|August 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964093||134328|
NCT00960739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIITOP-0607|Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma|Phase II Study of the Association of Iodobenzylguanidine Meta-I131 (I131 MIBG) and Topotecan in the Treatment of Refractory or Relapsed Metastatic Neuroblastoma|MIITOP|Centre Oscar Lambret|No|Active, not recruiting|November 2008|April 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|1 Year|20 Years|No|||February 2016|February 15, 2016|August 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00960739||134579|
NCT00956020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-01|Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation|Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation||The New York Eye & Ear Infirmary|No|Completed|October 2009|July 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|August 10, 2009||No||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00956020||134937|
NCT00956033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC2008-305|Skin Biopsies in Chemotherapy-Induced Neuropathy|Skin Biopsies in Chemotherapy-induced Neuropathy||Erasmus Medical Center|No|Completed|November 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|skin biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Patients with multiple myeloma receiving bortezomib in a large university hospital|December 2014|December 23, 2014|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956033||134936|
NCT00956306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8159_HI_I|A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function|A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function|udenafil|Dong-A ST Co., Ltd.|No|Completed|November 2007|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|18|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956306||134915|
NCT00956319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STCR-0802-TW|A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients|A Randomized, Open-Label, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Zolpidem Modified Release (MR) in Patients With Primary Insomnia||Astellas Pharma Inc|No|Completed|May 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|64 Years|No|||October 2011|October 5, 2011|August 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956319||134914|
NCT00956618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB10-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2009|||||N/A|N/A|N/A||||||||||||||May 17, 2010|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956618||134891|
NCT00965965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917361-1|Comprehensibility of Colorectal Cancer Screening Educational Materials: Effects on Patient Knowledge and Motivation|Effects of Comprehensibility of Colorectal Cancer Screening Educational Materials on Patient Knowledge and Motivation: A Randomized Controlled Trial||University of California, Davis|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|60|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00965965||134189|
NCT00956631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiDAS I|MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS I|Vertos Medical, Inc.|Yes|Completed|July 2008|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|August 7, 2009|Yes|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00956631||134890|
NCT00966212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6241|Parent Education for Young Teen Females|Reducing Alcohol & Risks Among Young Females||Education Development Center, Inc.|No|Completed|September 2003|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|12 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 29, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966212||134170|
NCT00966225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP-01-2009-1|LIP-01 in Hypercholesterolemia|An Open-label Dose-finding Study of LIP-01 in Otherwise Healthy Individuals With Hypercholesterolemia||Afexa Life Sciences Inc|No|Completed|September 2009|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00966225||134169|
NCT00966498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1023-2003|Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors|Peripheral Blood Stem Cell Transplantation in Children With High-Risk or Recurrent Solid Tumors||Emory University|Yes|Terminated|May 2003|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|35 Years|No|||December 2013|December 9, 2013|August 11, 2009||No|poor enrollment|No||https://clinicaltrials.gov/show/NCT00966498||134148|
NCT00957580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200066_002|Trial of Pimasertib in Hematological Malignancies|Phase II Trial With Safety-Run-In of MEK Inhibitor MSC1936369B in Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies||EMD Serono|Yes|Terminated|September 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|80|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|August 11, 2009|No|Yes|The trial has been terminated due to an estimated low probability of clinical benefit based on    limited anti-leukemic effects observed in safety run-in (Part 1).|No||https://clinicaltrials.gov/show/NCT00957580||134819|
NCT00957593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-20080907|Induction of Labor With Oxytocin: When Should Oxytocin be Held?|Induction of Labor With Oxytocin: When Should Oxytocin be Held?||Lehigh Valley Hospital|Yes|Completed|February 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|July 31, 2009||No||No|October 13, 2012|https://clinicaltrials.gov/show/NCT00957593||134818|
NCT00962403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000717|Evaluation of a Yoga Intervention for Post-Traumatic Stress Disorder|Evaluation of a Yoga Intervention for Post-Traumatic Stress Disorder|EYIPTSD|Brigham and Women's Hospital|Yes|Completed|August 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 19, 2013|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00962403||134453|
NCT00962728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090609|Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)|Assessment of Inspiratory Breathing Devices to Improve Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome||Vanderbilt University|No|Recruiting|October 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||December 2015|December 7, 2015|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962728||134428|
NCT00962689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0067|Clinical Study to Improve Diagnosis and Treatment of Sinusitis|Improving Patient Care Via Proteomics Based, Microbe-Specific Detection of Chronic Rhinosinusitis||Ohio State University|No|Recruiting|August 2009|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|whole blood nasal secretions nasal mucosa nasal polyps|Both|5 Years|90 Years|No|Non-Probability Sample|Patients from age 5 to 90 undergoing endoscopic sinus surgery for treatment of chronic        rhinosinusitis|October 2013|October 14, 2013|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962689||134431|
NCT00962702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAAx1DD20809|Exclusion of the Left Atrial Appendage (LAA) With the LAAx, Inc. TigerPaw System|Exclusion of the Left Atrial Appendage With the LAAx, Inc., TigerPaw™ System During Elective, Non-Endoscopic Cardiac Surgery Procedures||LAAx, Inc.|No|Recruiting|August 2009|October 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2009|August 19, 2009|August 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962702||134430|
NCT00962715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0145|Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia|A Randomized, Phase I/II Clinical Trial Evaluating the Safety, Reactogenicity, and Immunogenicity of Licensed Trivalent Influenza Vaccine Administered With Recombinant Interferon Alpha Among Patients With Chronic Lymphocytic Leukemia||M.D. Anderson Cancer Center|Yes|Withdrawn|April 2011|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962715||134429|
NCT00962988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPRC-6749|Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease|Efficacy and Cost-effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease||Ottawa Heart Institute Research Corporation|Yes|Completed|December 2009|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|194|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962988||134409|
NCT00963599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476A-117|Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Fall Study||Merck Sharp & Dohme Corp.||Completed|September 1999|November 1999|Actual|November 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|907|||Both|15 Years|85 Years|No|||February 2015|February 24, 2015|August 19, 2009|Yes|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00963599||134366|
NCT00963885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV21075|A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection|A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infectio||Hoffmann-La Roche||Completed|August 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|229|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963885||134344|
NCT00964145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14723 Nulliparous Women|Effects of Age on the Levator Ani Muscle of Nulliparous Women|Effects of Age on the Levator Ani Muscle of Nulliparous Women||University of Oklahoma|Yes|Completed|August 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|80|||Female|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community-dwelling nulliparous females, ages 21-70 years. Women are eligible for        participation if they are willing to undergo a physical examination regardless of race,        continence or prolapse status.|June 2011|June 27, 2011|August 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964145||134324|
NCT00964392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMA #P030031/S014|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation|AF Registry|Biosense Webster, Inc.||Active, not recruiting|September 2009|December 2018|Anticipated|September 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964392||134305|
NCT00964665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABF656A2206|Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects|A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.||Novartis||Terminated|July 2009|||November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|141|||Both|18 Years|75 Years|No|||January 2011|January 5, 2011|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964665||134285|
NCT00964106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112684|Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation|Validation Study of Simultaneous Administration of Multiple Cytochrome P450/Transporter Probes for Drug Interaction Evaluation in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|August 2009|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00964106||134327|
NCT00960427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649658|Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery|Colorectal Cancer Stem Cells Marker Expression in Rectal Cancer Patients Undergoing Chemoradiotherapy-A Pilot Study||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|June 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||April 2013|April 12, 2013|August 14, 2009||No|No surgeon available to perfrom gastroscopy|No||https://clinicaltrials.gov/show/NCT00960427||134603|
NCT00960440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921032|Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors|Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors||Pfizer|Yes|Completed|October 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|399|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|August 14, 2009|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT00960440||134602|
NCT00960726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0673|NOV-002 in Myelodysplastic Syndrome (MDS)|Phase 2 Study of NOV-002 in Low and Intermediate-1 Risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||July 2012|July 27, 2012|August 17, 2009|Yes|Yes|Study withdrawn at sponsor request.|No||https://clinicaltrials.gov/show/NCT00960726||134580|
NCT00973713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009/3522|Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol|Phase II Study of RAD001 in Advanced Cholangiocarcinoma|RADiChol|Austin Health|Yes|Recruiting|September 2009|March 2012|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973713||133597|
NCT00973986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YWLCSY-0900328|Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin|Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease|ECGPPA|Liuhuaqiao Hospital|Yes|Completed|June 2009|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Male|35 Years|65 Years|No|||September 2009|November 28, 2011|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00973986||133577|
NCT00965978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|529-CL-027|A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation|A Study to Evaluate Food Effect on Pharmacokinetics Parameters After Administration of ONO-5920/YM529 Intermittent Formulation||Astellas Pharma Inc|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|45 Years|81 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965978||134188|
NCT00965991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC#03-277|Metformin Compared to Glyburide in Gestational Diabetes|A Randomized Prospective Trial of Metformin Compared to Glyburide in Gestational Diabetes||University of New Mexico|No|Completed|July 2003|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Female|13 Years|N/A|Accepts Healthy Volunteers|||May 2008|June 23, 2010|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965991||134187|
NCT00966264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Finnish Academy-project 29168|Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia|Hysterectomy and Levonorgestrel-releasing IUS in the Treatment of Menorrhagia|VUOKKO|Helsinki University|No|Completed|October 1994|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Female|35 Years|49 Years|Accepts Healthy Volunteers|||August 2009|August 26, 2009|January 20, 2009||No||No|January 20, 2009|https://clinicaltrials.gov/show/NCT00966264||134166|
NCT00956644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBAM_R_04220|Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy|Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy|I-COMBINE|Sanofi||Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|406|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956644||134889|
NCT00966524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG 2010-001|Learning and Retention of Tracheal Intubation by Medical Students: Comparison of Standard Intubation Teaching Against Video-guided Intubation Teaching.|Learning and Retention of Tracheal Intubation by Medical Students: Comparison of Standard Intubation Teaching Against Video-guided Intubation Teaching.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|January 2010|June 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 10, 2010|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966524||134146|
NCT00966238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX125-02|Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age|A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults ≥65 Years of Age||VaxInnate Corporation|No|Completed|September 2009|March 2011|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 22, 2014|August 24, 2009|No|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00966238||134168|
NCT00956917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFG001|Comparison Study for Bioelectrical Impedance Device to Measure Human Body Composition|Comparison of Impedance Components and Estimated Body Composition Variables Determined by Using Bioelectrical Impedance Devices Manufactured by Akern SRL and RJL Systems||Akern USA LLC|No|Completed|May 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|109|||Both|16 Years|90 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2009|August 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956917||134868|
NCT00957255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-0803|Rotator Cuff Repair (RCR) With and Without OrthoADAPT Augmentation|Rotator Cuff Repair (RCR) With and Without OrthoADAPT Augmentation||Synovis Surgical Innovations|No|Withdrawn|March 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||May 2013|May 29, 2013|August 11, 2009|Yes|Yes|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT00957255||134843|
NCT00957268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322_104|Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus|A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults With Type 2 (Non-Insulin Dependent) Diabetes Mellitus||Takeda|No|Completed|September 2009|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|46|||Both|10 Years|65 Years|No|||January 2015|January 26, 2015|August 6, 2009|No|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00957268||134842|
NCT00967031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642631|Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases|A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer||UNICANCER|No|Completed|April 2009|||February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967031||134108|
NCT00962416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137/09|Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI)|Comparison of Biolimus Eluted From an Erodable Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction and In Vivo 3-Vessel Assessment of Time-Related Changes of Culprit and Non-Culprit Lesions by IVUS/OCT in AMI|COMFORTABLE|University Hospital Inselspital, Berne|Yes|Active, not recruiting|September 2009|December 2015|Anticipated|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1161|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962416||134452|
NCT00963027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-116|Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil|An Evaluation of Single Dose UT-15C SR (Treprostinil Diethanolamine) Pharmacokinetics Following Repeated Dosing With the Proton Pump Inhibitor Esomeprazole in Healthy Adult Volunteers||United Therapeutics|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 5, 2010|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00963027||134407|
NCT00963040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TI-004|Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache|The Effect of Intranasal Oxytocin on Headache Intensity and Headache-associated Symptoms in Patients Suffering From Chronic Daily Headache||MedVadis Research Corporation|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2011|September 8, 2011|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963040||134406|
NCT00963001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-115|Effect of Food on the Pharmacokinetics of Oral Treprostinil|Effect of Different Meal Types on the Pharmacokinetics of a Single 1 mg Oral Dose of UT-15C (Treprostinil Diethanolamine) Sustained Release Tablets in Healthy Volunteers||United Therapeutics|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 5, 2010|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00963001||134408|
NCT00963300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000652306|MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy|Hypoxia Assessment in Localized Prostate Cancer: A Companion Protocol to a Phase II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer||National Cancer Institute (NCI)||Not yet recruiting|September 2009|||September 2010|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||August 2009|February 18, 2011|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963300||134387|
NCT00964132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194204-203|Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|A Multiple-Center, Open-Label, Study of the Safety and Efficacy of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)||NuRx Pharmaceuticals, Inc.|No|Active, not recruiting|March 2009|June 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2009|September 2, 2009|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964132||134325|
NCT00963898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104mai|Accurate Controlled Dental Sedation|The Clinical Efficacy of the Combination Target Controlled Infusion With Bispectral Index Monitor in Propofol Sedation for Dental Patients With Mental Retardation|ACDS|Okayama University|No|Completed|April 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|40|||Both|16 Years|N/A|No|||August 2009|August 21, 2009|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963898||134343|
NCT00964171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000641759|Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas.||National Cancer Institute (NCI)||Recruiting|August 2008|||December 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||April 2010|April 6, 2010|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00964171||134322|
NCT00964418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1994|A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 in Young and Geriatric Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00964418||134303|
NCT00964431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND2-08-03|Phase 2 Study of Indomethacin Capsules to Treat Dental Pain|A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Indomethacin Test Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars||Iroko Pharmaceuticals, LLC|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|203|||Both|18 Years|50 Years|No|||March 2012|May 15, 2012|August 24, 2009|Yes|Yes||No|November 22, 2011|https://clinicaltrials.gov/show/NCT00964431||134302|
NCT00964366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114545|Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications|Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Clindamycin and Benzoyl Peroxide to Dapsone Gel Topical Acne Medications||GlaxoSmithKline|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|August 20, 2009||No||No|April 13, 2010|https://clinicaltrials.gov/show/NCT00964366||134307|
NCT00964379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|528-93|Intraperitoneal Versus Extraperitoneal Colostomy|Prospective Randomized Trial of Intraperitoneal Versus Extraperitoneal Techniques for Construction of Terminal Iliac Fossa Colostomies||Mayo Clinic|No|Completed|January 1988|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00964379||134306|
NCT00960453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT09_Sitagliptin|Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin|Multiple-dose, Dose Escalation Study to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin in Healthy Male Volunteers||Seoul National University Hospital|No|Completed|December 2008|||September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 19, 2011|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960453||134601|
NCT00961311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-111|Sprinter Legend Balloon Catheter|Evaluation of Acute Safety and Efficacy of the Medtronic Sprinter Legend 1.25mm Balloon Dilation Catheter Utilized for Enlarging Coronary Luminal Diameters During PCI Procedures||Medtronic Vascular|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||October 2011|October 21, 2011|July 14, 2009|Yes|Yes||No|January 27, 2011|https://clinicaltrials.gov/show/NCT00961311||134535|
NCT00961324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1991|A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes|A Randomised, Single-centre, Double-blind, Parallelgroup, Multiple Dose Trial Comparing the Within-subject Variability of SIBA and Insulin Glargine With Respect to Pharmacodynamic Response at Steady State Conditions in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|August 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00961324||134534|
NCT00966004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-048|A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder|Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder||Astellas Pharma Inc|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1139|||Both|20 Years|N/A|No|||July 2013|July 15, 2013|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00966004||134186|
NCT00966277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0487|Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients|Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.||M.D. Anderson Cancer Center|Yes|Completed|April 2010|||September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966277||134165|
NCT00966290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0200301|Anticoagulant Clinics and Vitamin K Antagonists|Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study|COMPARE|University Hospital, Toulouse|Yes|Completed|February 2003|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1006|||Both|18 Years|N/A|No|||August 2009|August 25, 2009|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00966290||134164|
NCT00966784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-NV-233-CTIL|The Effect of 2 Months Daily Supplementation of Orange Juice With Fibers|The Effect of 2 Months Daily Supplementation of Orange Juice With Fibers||Tel-Aviv Sourasky Medical Center||Not yet recruiting|September 2009|December 2010|Anticipated|September 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study|||Anticipated|50|||Both|18 Years|65 Years||||August 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966784||134126|
NCT00966537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-4936-LG-CTIL|The 3-Dimensional Ultrasound for Fetal Anomaly Scan|The 3-Dimensional Ultrasound for Fetal Anomaly Scan.||Sheba Medical Center|No|Recruiting|May 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pregnant woman|August 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966537||134145|
NCT00956930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 12339|Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery|An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial)||Northwestern University|Yes|Recruiting|August 2009|August 2020|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|120 Years|No|||October 2015|October 5, 2015|August 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00956930||134867|
NCT00966745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mil_living_liver_donor|Milrinone During Living Donor Hepatectomy|Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique||Seoul National University Hospital|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|19 Years|55 Years|No|||August 2009|August 26, 2009|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00966745||134129|
NCT00966758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_0901|Open, Prospective Pilot Study to Obtain Aerosol Distribution in Asthmatic Patients Using Single Photon Emission Computed Tomography (SPECT) for Comparison With Functional Imaging Using Computer Methods|Open, Prospective Pilot Study to Obtain Aerosol Distribution in Asthmatic Patients Using SPECT-CT for Comparison With Functional Imaging Using Computer Methods||University Hospital, Antwerp|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||September 2010|September 15, 2010|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966758||134128|
NCT00967304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008039-01H|Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism|REVERSEII: Validation of the "Men and HERDOO2"- A Clinical Decision Rule to Identify Patients With "Unprovoked" Venous Thromboembolism Who Can Discontinue Anticoagulants After 6 Months of Treatment.|REVERSEII|Ottawa Hospital Research Institute|Yes|Active, not recruiting|November 2008|January 2016|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|3312|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967304||134087|
NCT00962741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-3338|Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis|A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis|CLIPPER|Pfizer|Yes|Completed|September 2009|January 2013|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Both|2 Years|17 Years|No|||May 2014|May 29, 2014|August 13, 2009|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT00962741||134427|Results include data for Part 1 (up to Week 12) and Part 2 (up to week 96) of the study.
NCT00963053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|913-002|VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept|A Randomised, Double Blind, Placebo Controlled, Multicentre, Cross Over Proof of Concept Study to Investigate the Efficacy and Safety of Pre Emptive Administration of Repeated, Oral Doses of VA111913 TS for the Alleviation of Dysmenorrhoea||Vantia Ltd|No|Completed|August 2009|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Female|18 Years|35 Years|No|||May 2014|May 6, 2014|August 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00963053||134405|
NCT00963313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUE-ADA-2009-01|A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis|A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis||Instituto de Investigacion Biomedica de A Coruna|No|Completed|March 2010|June 2014|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|Samples Without DNA|Samples recollected for analysing IL6 and MMP3 from patients blood serum.|Both|18 Years|70 Years|No|Probability Sample|Patients with active axial forms of psoriatic arthritis|September 2014|September 22, 2014|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963313||134386|
NCT00963612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN09-0426-CE|Non-invasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)|Non-Invasive Prediction of Microvascular Invasion (MVI) in Hepatocellular Carcinoma (HCC) by Assessment of Tumor Oxygenation by Blood Oxygen Level-Dependent Magnetic Resonance Imaging (BOLD MRI)||University Health Network, Toronto|No|Recruiting|September 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00963612||134365|
NCT00964158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113528|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years||GlaxoSmithKline||Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|210|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964158||134323|
NCT00972374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-031D|Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function|||Allergan|Yes|Completed|November 2009|July 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|September 3, 2009|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT00972374||133700|
NCT00972660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDREC.[2009]008|Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease|A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Ex-Vivo Cultured Allogenic Mesenchymal Stem Cells For the Treatment of Extensive Chronic Graft Versus Host Disease||Guangdong General Hospital|Yes|Enrolling by invitation|September 2009|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|N/A|N/A|No|||May 2010|August 25, 2014|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972660||133678|
NCT00972673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112018|A Study of GW685698X in Healthy Japanese Male Subjects|Phase I Study of GW685698X-A Randomized, Double Blind, Placebo Controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose From a Novel Dry Powder Device in Healthy Japanese Male Subjects.||GlaxoSmithKline||Completed|September 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|48|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||February 2011|June 21, 2012|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972673||133677|
NCT00972946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/R/CAR/15.2|Cell Tracking Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI) - A Pilot Study|The Use of Magnetic Resonance Imaging and Superparamagnetic Particles of Iron Oxide in Cardiovascular Disease - a Pilot Study in Healthy Volunteers||University of Edinburgh|No|Recruiting|September 2009|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 8, 2009|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00972946||133656|
NCT00964678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM12120|Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension|Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension||Virginia Commonwealth University|No|Recruiting|June 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964678||134284|
NCT00973479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015784|An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Centocor, Inc.|Yes|Completed|September 2009|February 2013|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|592|||Both|18 Years|N/A|No|||November 2013|November 29, 2013|September 4, 2009|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT00973479||133615|
NCT00966017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0167|Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia|Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia||National Institute on Aging (NIA)|Yes|Recruiting|July 2009|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|108|||Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals will be identified and recruited using IRB approved flyers distributed to        treating clinicians, caregivers from Board and Care homes, sheltered workshop        administrators (where potential participants are employed), and representatives of County        Regional Centers (primary evaluation and treatment centers for developmentally delayed        individuals).|December 2009|December 23, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966017||134185|
NCT00966836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTECT 2008-006980-35|Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy|Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy|PROTECT|University of Bologna|No|Recruiting|April 2009|||April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Both|18 Years|70 Years|No|||August 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966836||134123|
NCT00967057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-ALLR3|Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL)||National Cancer Institute (NCI)||Completed|October 2002|December 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|470|||Both|1 Year|18 Years|No|||January 2011|August 9, 2013|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967057||134106|
NCT00966771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30937|The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception|Preventing Future Pregnancy After Choosing the Copper IUD vs. Oral Levonorgestrel for Emergency Contraception|IUD EC|University of Utah|Yes|Completed|October 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|548|||Female|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women presenting to family planning clinics for emergency contraception|February 2016|February 18, 2016|August 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00966771||134127|
NCT00967044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0805|Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma|Phase I/II of Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma||M.D. Anderson Cancer Center|No|Completed|November 2009|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|August 25, 2009|Yes|Yes||No|September 2, 2014|https://clinicaltrials.gov/show/NCT00967044||134107|Initially intended to proceed to phase II at MTD, treatment interruptions were frequently required in participants treated at MTD for Grade 3/4 Thrombocytopenia so study amended to obtain more detailed safety data at MTD in expanded phase I study.
NCT00967590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP22666|A Study of RO5036505 in Patients With Moderate to Severe Asthma|A Multi-center, Randomized, Double-Blind, Multiple-Dose, Placebo-controlled Asthma Control Study Evaluating the Efficacy, Safety, and Tolerability of RO5036505 in Subjects With Moderate-to-Severe Asthma||Hoffmann-La Roche||Withdrawn|September 2009|August 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||September 2009|September 1, 2009|August 21, 2009|Yes|Yes|No patients dosed|No||https://clinicaltrials.gov/show/NCT00967590||134065|
NCT00967954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000639017|Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer|A Study of Changes in the Prostate Following Androgen Deprivation to Investigate Therapy Response and Resistance in Clinical Prostate Cancer||National Cancer Institute (NCI)||Recruiting|September 2008|||August 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|120|||Male|N/A|N/A|No|||August 2009|January 9, 2014|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967954||134037|
NCT00962754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL26894.075.09|Fluid Balance Study in Sick Neonates|Reliability and Utility of Fluid Balance Charting in Neonates Admitted to the Pediatric Ward.||Princess Amalia Children's Clinic|No|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|170|||Both|N/A|28 Days|Accepts Healthy Volunteers|||April 2014|April 8, 2014|August 18, 2009||No||No|January 4, 2012|https://clinicaltrials.gov/show/NCT00962754||134426|lack of a more reliable assessment method of fluid status, for example central venous pressure or body impedance measurementsmoderate disease severityunequal distribution of premature infants amongst the study groups
NCT00962767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903X-101128|Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission|A Randomized Study of Two Doses Gemtuzumab Ozogamicin vs. A Two-year Maintenance With Atra Plus Chemotherapy as Post-consolidation Treatment for Intermediate and High-risk Adult Patients With Acute Promyelocytic Leukemia (Apl)||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|May 2002|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|61 Years|No|||August 2009|August 19, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00962767||134425|
NCT00971113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05PAV 363|Prebiotic Effect of a Jelly Containing Short Chain Fructo-Oligosaccharides and Sideritis Euboea Extract|Impact of a Jelly Containing Short Chain Fructo-oligosaccharides and Sideritis Euboea Extract on Human Gut Microflora||Harokopio University|No|Completed|April 2007|December 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|64|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 2, 2009|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971113||133795|
NCT00963326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000635996|Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer|Morphological and Molecular Characterization of Tumors of the Aero-digestive Tract in Patients Who Have no Risk Factors Such as Alcohol, Smoking, or Occupation||National Cancer Institute (NCI)||Recruiting|June 2008|||July 2010|Anticipated|N/A|Observational|N/A|||Anticipated|60|||Both|15 Years|N/A|No|||February 2011|February 25, 2011|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963326||134385|
NCT00963625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB 07-0014|Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients|Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients||Fertility Center of Las Vegas|No|Completed|October 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|October 8, 2010|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00963625||134364|
NCT00964444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6684165DP01|Demonstration of a New Device to Measure the Force of Delivering a Baby|Demonstration of a New Device to Measure the Force of Delivering a Baby||Pinnacle Health System|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|None Retained|No biospecimens|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with an uncomplicated singleton pregnancy at term in active labor, who are        anticipated to have a vaginal delivery.|July 2010|July 22, 2010|August 24, 2009||No||No|June 17, 2010|https://clinicaltrials.gov/show/NCT00964444||134301|The trial was limited to singleton term pregnancy (37-42 weeks) patients in active labor. The study was only designed to prove that the device works and not to determine the normal range of force exerted on a fetus as it was delivered.
NCT00964457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI0905|Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients|Treatment of Patient With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before Under and After Radiation and With Adding Cetuximab to K_RAS Wild-type Patients.||Copenhagen University Hospital at Herlev|Yes|Not yet recruiting|August 2009|July 2017|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2009|August 24, 2009|August 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964457||134300|
NCT00964691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2009|A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands|Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine Versus Weekly Chloroquine Prophylaxis During Pregnancy in Solomon Islands: a Randomized Controlled Trial|IPTpRCT|Ministry of Health and Medical Services, Solomon Islands|Yes|Terminated|August 2009|August 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2504|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||July 2010|July 5, 2010|August 24, 2009||No|Low prevalence of malaria, high prevalence of reported allergy to sulphur drugs, high    proportion of women not meeting the inclusion criterea.|No||https://clinicaltrials.gov/show/NCT00964691||134283|
NCT00960466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON/2007/2744|Distress Thermometer Intervention Trial|Evaluating the Effect of Monitoring Cancer Patients Using the Distress Thermometer on Levels of Distress and Health Service Costs - a Randomised Controlled Trial|DiTIT|University Hospitals Bristol NHS Foundation Trust|No|Completed|October 2009|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|220|||Both|18 Years|85 Years|No|||April 2014|April 1, 2014|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960466||134600|
NCT00973193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 09-001|Preoperative Panitumumab and Radiotherapy in Rectal Cancer|Phase II Study of Preoperative Panitumumab and External Beam Radiotherapy in Patients With Locally Advanced Rectal Cancer|PrePaRad|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Terminated|September 2009|December 2012|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|September 7, 2009||No|The intermediate analyses did not allowed to continue the clinical study.|No||https://clinicaltrials.gov/show/NCT00973193||133637|
NCT00961077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-HO-GC-01|Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer|A Prospective Phase II Study of Attenuated S-1 and Oxaliplatin(Attenuated SOX) as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer||Soonchunhyang University Hospital|Yes|Active, not recruiting|August 2009|August 2012|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|65 Years|80 Years|No|||August 2009|August 17, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961077||134553|
NCT00966316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707004|Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke|Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke|PAIS|Guangzhou University of Traditional Chinese Medicine|Yes|Completed|May 2009|January 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|314|||Both|18 Years|85 Years|No|||May 2011|May 14, 2011|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966316||134162|
NCT00966849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|inh051|Manicaland Cash Transfer Trial|The Scientific Evaluation of a Cash Transfer Pilot Project to Support Orphans and Vulnerable Children (OVC) in Manicaland, Zimbabwe||Imperial College London|No|Completed|August 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|4043|||Both|N/A|17 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966849||134122|
NCT00967109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2009-072|Establishment of Optimal Transfusion Threshold During Spine Surgery|Establishment of Optimal Transfusion Threshold During Spine Surgery||Rigshospitalet, Denmark|No|Completed|September 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00967109||134102|
NCT00966550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOM 2009-071|A Study of Tomato Products and Disease Risk|Tomato Products and Postprandial Oxidation and Inflammation: a Clinical Trial in Healthy Weight Men and Women|TOM|Institute for Food Safety and Health, United States|No|Completed|August 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|August 26, 2009||No||No|August 20, 2014|https://clinicaltrials.gov/show/NCT00966550||134144|Acute study; Chronic effect should be investigated.
NCT00966810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML ASCTCTIL|Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion|Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion and Preemptive Donor Lymphocyte Infusion.||Rambam Health Care Campus|No|Active, not recruiting|December 1999|January 2011|Anticipated|January 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||January 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966810||134125|
NCT00966823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080077|Fetal Tracheal Balloon Study in Diaphragmatic Hernia|Phase 2 Fetal Tracheal Balloon (IDE G080077) Study in Diaphragmatic Hernia||Rhode Island Hospital|Yes|Terminated|September 2008|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|N/A|No|||May 2015|May 4, 2015|August 26, 2009|No|Yes|Device no longer available|No||https://clinicaltrials.gov/show/NCT00966823||134124|
NCT00967317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E02-OSM-AS-01-08|Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.|Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.|E02OSMAS0108|Laboratorios Osorio de Moraes Ltda.|No|Not yet recruiting|December 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|6 Years|N/A|No|||August 2009|August 25, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00967317||134086|
NCT00967603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643632|Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer|Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer: a Phase II Randomized Trial.|PACT-12|IRCCS San Raffaele|No|Completed|February 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||December 2009|January 31, 2012|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967603||134064|
NCT00967330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21965|A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma|||Hoffmann-La Roche||Completed|June 2010|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|70 Years|No|||October 2015|October 20, 2015|June 16, 2009||No||No|October 20, 2015|https://clinicaltrials.gov/show/NCT00967330||134085|Data for time to treatment failure were not collected as this outcome was removed as per changes in planned analysis.
NCT00967629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-0976|Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy|Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy||Icahn School of Medicine at Mount Sinai|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967629||134062|
NCT00967967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 20389|Validation of the Rhinitis Control Scoring System (RCSS)|Validation of a Rhinitis Control Tool : the Rhinitis Control Scoring System (RCSS)|RCSS|Laval University|No|Suspended|March 2009|September 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||May 2013|May 24, 2013|August 26, 2009||No|Awaiting results from sub analysis to decide if study continuesé|No||https://clinicaltrials.gov/show/NCT00967967||134036|
NCT00970814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA_DTRR-2009-LITTEN-02|Levetiracetam XR in Very Heavy Drinkers|A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers|NCIG 002|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Completed|October 2009|October 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 20, 2014|September 1, 2009||No||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00970814||133818|
NCT00970827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-015|Remote Ischemic Postconditioning During Percutaneous Coronary Interventions|Remote Ischemic Postconditioning During Percutaneous Coronary Interventions.|RIP-PCI|Lawson Health Research Institute|No|Completed|May 2009|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|360|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00970827||133817|
NCT00963638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC #2008-287|Beneficial Effects of Magnesium Supplementation On Idiopathic Muscle Cramps|Beneficial Effects of Magnesium Supplementation On Idiopathic Muscle Cramps||William Beaumont Hospitals|No|Completed|April 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|85 Years|No|||September 2012|September 19, 2012|August 18, 2009|Yes|Yes||No|April 19, 2011|https://clinicaltrials.gov/show/NCT00963638||134363|
NCT00971451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13398|Quadriceps Function Prior to Anterior Cruciate Ligament Reconstruction|Quadriceps Function Prior to Anterior Cruciate Ligament Reconstruction||University of Virginia|No|Recruiting|November 2007|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|15 Years|55 Years|No|||March 2011|March 4, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971451||133770|
NCT00971750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-03-08-009|Laparoscopic Versus Transabdominal Ultrasound in Morbidly Obese Patients|Comparison of Laparoscopic Ultrasound to Transabdominal Ultrasound for the Detection of Gallbladder Pathology in the Bariatric Surgical Population.||Gundersen Lutheran Medical Foundation||Completed|October 2003|October 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|253|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will consist of patients undergoing laparoscopic gastric bypass at a        community-based teaching institution.|June 2012|June 29, 2012|September 3, 2009||No||No|March 23, 2012|https://clinicaltrials.gov/show/NCT00971750||133747|
NCT00972049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2080C00004|Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects|A Phase I, Single-centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics After Oral Single Ascending Doses of AZD2516 in Young and Elderly Japanese Healthy Subjects||AstraZeneca|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||March 2010|March 2, 2010|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972049||133724|
NCT00960492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-002|Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma|A Phase 1 Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination With Temozolomide and Radiation Therapy in the First Line Treatment of Subjects With Glioblastoma||Exelixis|No|Completed|September 2009|October 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960492||134598|
NCT00960778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#18333|Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes|Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes|BIRCWH|Medical University of South Carolina|Yes|Completed|March 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|21 Years|60 Years|No|||May 2010|October 31, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960778||134576|
NCT00961090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104974|Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.||Allegheny Singer Research Institute|Yes|Completed|September 2009|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|August 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00961090||134552|
NCT00961103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDGEE-SMA|Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)|Assessment of Motor Development Related to Use of Orthoses in SMA II and III||Arcispedale Santa Maria Nuova-IRCCS|Yes|Not yet recruiting|September 2009|December 2009|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|patients with SMA II and SMA III referred to UDGEE for rehabilitation consultation|August 2009|August 17, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961103||134551|
NCT00960752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0416|Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist|Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist||M.D. Anderson Cancer Center|Yes|Active, not recruiting|May 2010|||May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|71|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|August 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00960752||134578|
NCT00960765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPL200907A|Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics|Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus||CPL Associates|No|Completed|August 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|15|Samples Without DNA|Serum, urine, stool|Both|18 Years|95 Years|No|Non-Probability Sample|Morbidly obese (BMI > 40 kg/m2) patients with T2D|January 2016|January 27, 2016|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00960765||134577|
NCT00961662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70971-005|A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)|Dose Ranging Effects of Three Low-doses of Naturlose™ (Tagatose) on Glycemic Control and Safety of Naturlose™ (Tagatose) Over Six Months in Subjects With Mild Type 2 Diabetes Mellitus Under Control With Diet and Exercise.||Spherix Incorporated|No|Completed|February 2008|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|161|||Both|18 Years|75 Years|No|||November 2014|November 1, 2014|August 17, 2009|No|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00961662||134510|
NCT00966576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-22a|Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy|The Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (Azarga®) to Prostaglandin Monotherapy||Alcon Research|No|Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|21 Years|N/A|No|||April 2012|July 18, 2012|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966576||134142|
NCT00966862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-NV-237-CTIL|The Glycemic Effect of Taking a Supplementation of Orange Juice With Fibers|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|September 2009|May 2010||February 2010|Anticipated|Phase 1/Phase 2|Interventional|N/A|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966862||134121|
NCT00966563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANAMI PP01-09|Mangafodipir as an Adjunct to Percutaneous Coronary Intervention|Mangafodipir as an Adjunct to Percutaneous Coronary Intervention in Acute Myocardial Infarction (MANAMI)|MANAMI|PledPharma AB|No|Completed|December 2009|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|80 Years|No|||July 2013|July 15, 2013|August 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00966563||134143|
NCT00967343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-AIR-004|Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor|An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor||Kiadis Pharma|Yes|Terminated|August 2009|February 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|65 Years|No|||March 2013|March 22, 2013|August 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967343||134084|
NCT00967642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06036|Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI)|Intravenous Insulin for 24 Hours in Patients With Diabetes Mellitus Submitted to Percutaneous Coronary Intervention With Stent: Effects Upon Oxidative Stress and Inflammatory Markers||Hospital de Clinicas de Porto Alegre|Yes|Terminated|August 2006|April 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||70|||Both|18 Years|80 Years|No|||August 2009|August 27, 2009|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967642||134061|
NCT00967070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431084|Skin Sensitization Potential of a New Nicotine Patch|Study on the Skin Sensitization Potential of a New Nicotine Transdermal Therapeutic System (TTS). A Double Blind, Randomized, Repeat Patch Test, Single Center Phase I Study||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|May 2005|August 2005|Actual|August 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|1||Actual|257|||Both|18 Years|65 Years|No|||July 2012|July 6, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00967070||134105|
NCT00967083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-104|Support Needs and Preferences of Family Caregivers of Lung Cancer Patients|Support Needs and Preferences of Family Caregivers of Lung Cancer Patients||Memorial Sloan Kettering Cancer Center||Completed|August 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients whose family caregivers may be eligible for this study will be identified by a        member of the patient's treatment team, the protocol investigator, or research team at        Memorial Sloan-Kettering Cancer Center (MSKCC) or Queens Cancer Center (QCC).|December 2014|December 10, 2014|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967083||134104|
NCT00967616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-U203|Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy|Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy||Daiichi Sankyo Inc.|No|Completed|September 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967616||134063|
NCT00968240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901010185|Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)|Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma||Northwell Health|No|Completed|July 2009|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00968240||134015|
NCT00968565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 090717|Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)|Regional Citrate Anticoagulation in ECMO||Vanderbilt University|Yes|Completed|January 2010|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|1 Year|No|||June 2010|June 1, 2015|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968565||133990|
NCT00963066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00583-54|NAV-ALI: Neurally Adjusted Ventilatory Assist in Patients Recovering Spontaneous Breathing After Acute Lung Injury|NAV-ALI: Effects of Different Levels of Neurally Adjusted Ventilatory Assist (NAVA) in Patients Recovering Spontaneous Breathing After Acute Lung Injury: A Physiological Evaluation.||University Hospital, Caen|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|15|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00963066||134404|
NCT00963339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US02|Age-Related Macular Degeneration (AMD) - Usability Study|Age-Related Macular Degeneration (AMD) - Usability Study|AMD|Notal Vision Ltd|Yes|Completed|September 2009|September 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|50 Years|N/A|No|Probability Sample|Intermediate AMD|September 2010|September 22, 2010|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00963339||134384|
NCT00964197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FemmeJock|The Purpose of This Study is to Look at Pelvic Support Problems, Also Commonly Known as Pelvic Organ Prolapse|FemmeJock: A Pilot Study to Assess Patient Satisfaction and Improvement of Pelvic Floor Symptoms Using a Pelvic Floor Support Girdle in Women With Uterovaginal Prolapse.||University of Oklahoma|Yes|Completed|November 2008|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 5, 2014|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00964197||134320|
NCT00963911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000637122|Questionnaire in Screening Older Patients With Cancer|Validation of a Screening Tool in Geriatric Oncology||National Cancer Institute (NCI)||Completed|June 2008|||May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1650|||Both|70 Years|N/A|No|||May 2011|May 12, 2011|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00963911||134342|
NCT00964184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeanDM-01|Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population|||Diabetes Foundation, India|No|Completed|September 2009|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|14 Years|40 Years|No|||August 2015|August 5, 2015|August 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964184||134321|
NCT00961376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS IRB 06-55|Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)|Vaccination of Chemotherapy Induced Lymphopenic Unresectable Stage III or Stage IV Melanoma Patients Following Reconstitution With Total or CD25-depleted PBMC||Providence Health & Services|No|Terminated|July 2009|December 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|August 14, 2009|Yes|Yes|PI Discretion|No||https://clinicaltrials.gov/show/NCT00961376||134530|
NCT00961675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FST201-AOE-AS|FST-201 in the Treatment of Acute Otitis Externa|A Phase III Clinical Study Evaluating the Efficacy Of FST-201 Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa||Shire|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|75 Years|No|||September 2012|September 14, 2015|August 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00961675||134509|
NCT00961688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRS-3296|The Impact of Polycystic Ovary Syndrome (PCOS) on Quality of Life and Healthcare Beliefs|The Impact of PCOS on Quality of Life and Healthcare Beliefs|PCOS|Georgia Reproductive Specialists|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|N/A||1|Anticipated|600|||Female|18 Years|55 Years|No|Non-Probability Sample|Women with Polycystic Ovary Syndrome (PCOS) between the age of 18 and 55|February 2010|February 1, 2010|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00961688||134508|
NCT00961974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-06|Intensive Care Program for Youth With Diabetes|Intensive Care Program for Youth With Diabetes||Joslin Diabetes Center|Yes|Completed|April 2002|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|154|||Both|8 Years|16 Years|No|||August 2015|August 5, 2015|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961974||134486|
NCT00961987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1309|Innovation to Providing Interprofessional Maternity Care|Innovation to the Provision of Maternity Care in Hamilton: An Inter- and Intraprofessional Collaboration||McMaster University||Not yet recruiting|October 2009|||June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Female|16 Years|60 Years|No|||August 2009|August 18, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961987||134485|
NCT00961337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH97-DC-2003|Evaluation of a School-based Influenza Vaccination Program|Evaluation of a School-based Influenza Vaccination Program||Centers for Disease Control, Taiwan|Yes|Completed|October 2008|May 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|7854|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||August 2009|August 17, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00961337||134533|
NCT00961350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA32540-301|A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers|A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers||POZEN|Yes|Completed|October 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|530|||Both|55 Years|N/A|No|||January 2016|January 20, 2016|August 17, 2009|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00961350||134532|
NCT00961363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904052M|Effect of Sitagliptin in Impaired Glucose Tolerance|The Effect of Sitagliptin on Postprandial Glycemia and Endothelial Function in Chinese Subjects With Impaired Glucose Tolerance||National Taiwan University Hospital|No|Recruiting|December 2009|||June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|65 Years|No|||March 2010|March 19, 2010|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00961363||134531|
NCT00962507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08099|Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma|A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma||City of Hope Medical Center|Yes|Completed|July 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|August 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00962507||134445|
NCT00962520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-0534B|Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer|Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|April 2009|||April 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00962520||134444|
NCT00966589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5204519|Surgical or Conservative Treatment of Sportsman Hernia|Chronic Groin Pain and Sportsman Hernia of Athletes: Randomized Study Between Conservative Treatment and Laparoscopic Hernioplasty (TEP)||Kuopio University Hospital|Yes|Completed|January 2008|February 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||March 2010|March 10, 2010|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00966589||134141|
NCT00967408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49CE 8/08|Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients|Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke||Azienda Ospedaliero Universitaria Maggiore della Carita|No|Recruiting|July 2009|October 2011|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967408||134079|
NCT00967096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003578|Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)|Rifaximin for Preventing Acute Graft Versus Host Disease||Emory University|Yes|Completed|April 2007|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|N/A|No|||November 2013|November 26, 2013|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967096||134103|
NCT00967356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2300C00002|AZD5985 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD5985 in Healthy Male Subjects||AstraZeneca|No|Terminated|August 2009|November 2009|Anticipated|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|72|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 11, 2009|August 26, 2009||No|Terminated (halted prematurely) due to tolerability issues.|No||https://clinicaltrials.gov/show/NCT00967356||134083|
NCT00967369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0604|Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma|A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2009|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|N/A|No|||February 2016|February 18, 2016|August 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967369||134082|
NCT00967655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000652936|Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer|A Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Radiation in Combination With Capecitabine & Paniumumab With and Without Irinotecan in Patients With Localized Rectal Cancer||National Cancer Institute (NCI)||Recruiting|July 2009|||July 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||September 2009|January 9, 2014|August 27, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00967655||134060|
NCT00967993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-202|Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease|A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)||Keryx Biopharmaceuticals|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 2|Observational|Time Perspective: Retrospective||1|Actual|22|||Both|18 Years|N/A|No|Probability Sample|Patients selected from pool of dialysis patients at each clinic.|November 2014|November 19, 2014|August 27, 2009||No||No|October 4, 2014|https://clinicaltrials.gov/show/NCT00967993||134034|
NCT00968253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0100|RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia|Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)||M.D. Anderson Cancer Center|No|Completed|November 2009|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|10 Years|N/A|No|||December 2015|December 7, 2015|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968253||134014|
NCT00968266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR-56-BMQ|Improving Beliefs About Medication in Patients With Rheumatoid Arthritis|Improving Beliefs About Medication in Patients With Rheumatoid Arthritis: Randomized Controlled Study Into the Effect of a Motivational Patient-centered Intervention for Non-adherent Patients Compared to Usual Care Controls||Sint Maartenskliniek|Yes|Completed|September 2009|April 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00968266||134013|
NCT00963924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002237|D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia|A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia||Massachusetts General Hospital|No|Completed|August 2009|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||July 2014|July 31, 2014|August 20, 2009|Yes|Yes||No|June 23, 2014|https://clinicaltrials.gov/show/NCT00963924||134341|
NCT00960232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2009-1|Vitamin D, Blood Pressure, Lipids, Infection and Depression|Vitamin D, Blood Pressure, Lipids, Infection and Depression||University of Tromso|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 3, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960232||134617|
NCT00960245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRACS P94-102|Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions|A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.||Sandoz||Completed|July 1994|July 1994|Actual|July 1994|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960245||134616|
NCT00960258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13172|Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.|Phase I, Uncontrolled, Open-label, Non-randomized Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Advanced, Refractory Solid Tumors||Bayer|Yes|Completed|July 2009|October 2013|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00960258||134615|
NCT00964470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#AW-101008MC-DS|Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery|Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery|AWBAT-D|Aubrey Inc.|No|Recruiting|August 2009|||December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|June 21, 2010|August 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00964470||134299|
NCT00964704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22056|A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer|A Single Arm, Open-label Study to Evaluate the Efficacy on Tumor Response and the Safety of Bevacizumab and Trastuzumab Combination and Sequential Capecitabine in Patients With HER2 +Ive Locally Recurrent or Metastatic Breast Cancer After Early Relapse to Adjuvant Trastuzumab-containing Therapy||Hoffmann-La Roche||Withdrawn|March 2011|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 21, 2009||No|No patients have been recruited therefore study has been cancelled|No||https://clinicaltrials.gov/show/NCT00964704||134282|
NCT00960479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1BH00001|Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions|A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Fasting Conditions.||Sandoz||Completed|January 2001|February 2001|Actual|February 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960479||134599|
NCT00961389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/283-2|Validating a Delirium Prediction Model for Critically Ill Patients|Validating a Delirium Prediction Model for Critically Ill Patients||Radboud University|No|Recruiting|May 2009|October 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|650|Samples With DNA|blood, urine|Both|18 Years|N/A|No|Non-Probability Sample|tertiary care clinic|August 2009|October 26, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961389||134529|
NCT00961402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH085176|The Effect of Exercise on Preventing PostPartum Depression|Efficacy of an Exercise Intervention for the Prevention of PostPartum Depression||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 24, 2013|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961402||134528|
NCT00961701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0097.09EMC|Lipids Profile in Primary Hyperparathyroidism|Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Primary Hyperparathyroidism|LPHP|HaEmek Medical Center, Israel|No|Not yet recruiting|October 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|85 Years|No|Probability Sample|Patients followed at the Endocrine Institute|August 2009|August 18, 2009|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00961701||134507|
NCT00961714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-02-A|OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture|Evaluation of Safety and Effectiveness of the OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture|OsseoFix|Alphatec Spine, Inc.|Yes|Terminated|August 2009|July 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 7, 2014|August 17, 2009|Yes|Yes|Withdrew study|No||https://clinicaltrials.gov/show/NCT00961714||134506|
NCT00962234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR PIN 111846/ethics 24906|Metabolism of Lipids in Advanced Cancer|Metabolism of Lipids in Advanced Cancer||AHS Cancer Control Alberta|No|Terminated|October 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|12|Samples With DNA|Blood|Both|18 Years|85 Years|No|Non-Probability Sample|Lung cancer patients|April 2012|February 24, 2016|August 17, 2009||No|ethics approval not renewed by Study Group|No||https://clinicaltrials.gov/show/NCT00962234||134466|
NCT00962247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT1056365|Effect of Changing Sedentary Behavior in Youth|Effect of Changing Sedentary Behavior in Youth|Effects|State University of New York at Buffalo|Yes|Completed|July 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|61|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||August 2009|August 18, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00962247||134465|
NCT00962260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-06-004|Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease|An Open-label Expanded Access Trial of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease Who Require Enzyme Replacement Therapy||Protalix||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2013|August 13, 2013|August 18, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00962260||134464|
NCT00966602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-809-005|Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 2, 2010|August 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00966602||134140|
NCT00967161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2009-240-01H|Motion Analysis of EMP Knee Versus Posterior Stabilized Knee Arthroplasty for Osteoarthritis|3D Motion Analysis of Evolution Medial Pivot Knee VS Posterior Stabilized Knee Arthroplasty for Osteoarthritis of the Knee.Feasibility Pilot for a Prospective Randomized Controlled Trial.||Ottawa Hospital Research Institute|No|Completed|January 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967161||134098|
NCT00967122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYUSWLP-BH|Band Holiday Study|The Effect of Lap Band Adjustment on Satiety Peptides||New York University School of Medicine|No|Completed|July 2009|March 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00967122||134101|
NCT00967382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999210-01H|TIPPS: Thrombophilia in Pregnancy Prophylaxis Study|TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.|TIPPS|Ottawa Hospital Research Institute|Yes|Completed|July 2000|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|292|||Female|18 Years|N/A|No|||May 2014|May 16, 2014|May 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00967382||134081|
NCT00967395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(KF) 01-123/04|Effect of Healing on Rheumatoid Arthritis|Effect of Healing on Rheumatoid Arthritis: a Three-arm Double-blind, Randomized, Controlled Trial|RAhealing|Frederiksberg University Hospital|No|Completed|January 2008|September 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|90|||Female|18 Years|N/A|No|||January 2012|January 5, 2012|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967395||134080|
NCT00967668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBB 09-034|Coaching Veterans to Healthy Weights and Wellness|ASPIRE: Coaching Veterans to Healthy Weights and Wellness|ASPIRE|VA Office of Research and Development|Yes|Completed|January 2010|December 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|481|||Both|18 Years|N/A|No|||February 2014|April 6, 2015|August 26, 2009||No||No|July 29, 2014|https://clinicaltrials.gov/show/NCT00967668||134059|
NCT00967681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0901-CU|Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease|Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease||Catalysis SL|Yes|Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Female|20 Years|N/A|No|||May 2012|May 2, 2012|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967681||134058|
NCT00968006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sita-EPC|Effect of Sitagliptin on Endothelial Progenitor Cells|Effects of 4-week Sitagliptin Therapy on Endothelial Progenitor Cells in Type 2 Diabetic Patients. A Non-randomized Controlled Open-label Pilot Trial.||University of Padova|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|40 Years|80 Years|No|||April 2010|April 2, 2010|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00968006||134033|
NCT00968864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCH BMT 09-01|T-cell Depleted Alternative Donor Transplantation|A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients||Carolinas Healthcare System|Yes|Recruiting|August 2009|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|N/A|30 Years|No|||February 2016|February 5, 2016|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968864||133967|
NCT00964483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21HL091303-02|Translating Dietary Trials Into the Community|Translating the Dietary Approaches to Stop Hypertension (DASH)Diet Into an Urban, African-American Community in Winston-Salem, North Carolina||Wake Forest School of Medicine|No|Completed|January 2010|September 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|21 Years|99 Years|No|||December 2015|December 10, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964483||134298|
NCT00960518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHDSYY20090725|TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)|Combination Therapy With TACE and Adefovir Compared With TACE Alone for HBV-related Unresectable Hepatocellular Carcinoma|TACE|Tongji University|Yes|Recruiting|August 2009|August 2015|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Both|20 Years|75 Years|No|||August 2009|August 14, 2009|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960518||134596|
NCT00960505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0118|Alternate Day Fasting for Weight Loss, Weight Maintenance and Cardio-protection|Alternate Day Fasting for Weight Loss, Weight Maintenance and Cardio-protection||University of Illinois at Chicago|Yes|Completed|September 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960505||134597|
NCT00960791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00008|Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)|An Open, Single-centre, Single Group, Phase I Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of AZD1656 After Oral Administration of 14C-labelled AZD1656 to Type II Diabetes Mellitus Patients|ADME|AstraZeneca||Completed|July 2009|September 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|35 Years|65 Years|No|||September 2009|September 15, 2009|August 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960791||134575|
NCT00961116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-028-07-1007|Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)|A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg Tricor® (Fenofibrate) Tablets Under Fasting Conditions.||Mutual Pharmaceutical Company, Inc.|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 27, 2009|August 14, 2009|No|Yes||No|August 24, 2009|https://clinicaltrials.gov/show/NCT00961116||134550|
NCT00961129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902016R|The Continuing Care Needs in Colorectal Cancer Patients in Different Stages|The Continuing Care Needs From Receiving Treatment to Survival in Colorectal Cancer Patients in Different Stages||National Taiwan University Hospital|Yes|Recruiting|March 2009|December 2011|Anticipated|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|269|||Both|18 Years|N/A|No|Non-Probability Sample|recruit colon cancer inpatients and outpatients in clinics|April 2010|April 11, 2010|August 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00961129||134549|
NCT00961142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-006016-33|Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia|Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia|CD3/CD19 Haplo|University Hospital Tuebingen|Yes|Recruiting|June 2009|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||December 2014|December 3, 2014|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00961142||134548|
NCT00962013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53|Restoration® Modular Revision Hip System Post Market Study|A Prospective Open-Label Evaluation of the Restoration® Modular System||Stryker Orthopaedics|No|Completed|January 2004|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|18 Years|85 Years|No|||August 2014|August 14, 2014|August 13, 2009|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT00962013||134483|
NCT00962273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0133-E|The Pandemic Stress Vaccine: A Resource to Enhance the Resilience of Healthcare Workers Facing an Infectious Outbreak|The Pandemic Stress Vaccine: Randomized Controlled Trial of an Educational Resource to Enhance the Resilience of Healthcare Workers Facing an Infectious Outbreak||Mount Sinai Hospital, Canada|No|Terminated|October 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Actual|118|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2010|August 17, 2010|August 18, 2009||No|low participation and retention rates|No||https://clinicaltrials.gov/show/NCT00962273||134463|
NCT00962559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aSAH and Hypopituitarism 0815|Hypopituitarism After Aneurismal Subarachnoid Hemorrhage|Endocrine and Neuropsychological Changes After Aneurismal Subarachnoid Hemorrhage.||Universitätsmedizin Mannheim|No|Completed|February 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|26|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients diagnosed with aSAH with a clinical grade of I-IV according to Hunt and Hess are        included in the study.|February 2010|February 16, 2010|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00962559||134441|
NCT00962572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0093|The Effects of Aggressive Patient Management on Cancer Therapy Management|The Effects of Aggressive Patient Management on Cancer Therapy Management||University of Mississippi Medical Center|No|Withdrawn|January 2009|December 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|rural and minority patients who require radiation therapy|April 2012|April 6, 2012|August 18, 2009||No|Investigator decided not to pursue|No||https://clinicaltrials.gov/show/NCT00962572||134440|
NCT00962000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gambro PI 2009|Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate|Effect of Dialysate Flow Rate on Delivered Dose of Dialysis (Kt/Vurea)||Gambro Renal Products, Inc.|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|August 18, 2009||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT00962000||134484|
NCT00968110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Milk-01|Xolair Treatment for Milk Allergic Children|Xolair (Omalizumab) Enhances Oral Tolerance Induction in Milk Allergic Children||Children's Hospital Boston|Yes|Active, not recruiting|March 2009|July 2013|Anticipated|April 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|4 Years|18 Years|No|||January 2013|January 16, 2013|August 27, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00968110||134025|
NCT00968123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIUCLEI 09-02|Consecutive Series Outcomes Review of Patients Undergoing a New Single Portal Technique for Endoscopic Carpal Tunnel Release|Consecutive Series Outcomes Review of Patients Undergoing a New Single Portal Technique for Endoscopic Carpal Tunnel Release||Rothman Institute Orthopaedics|No|Active, not recruiting||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|N/A|N/A||Probability Sample|This is a consecutive series, retrospective review of the first 50 patients who have        undergone carpal tunnel release surgery using a new single portal endocopic technique.|April 2013|April 8, 2013|August 27, 2009||||No||https://clinicaltrials.gov/show/NCT00968123||134024|
NCT00968383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.50/V/09|Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment|Late Percutaneous Coronary Intervention of the Occluded Infarct-Related Artery in Patients With Preserved Infarct Zone Viability Determined With Magnetic Resonance Imaging|COAT|Institute of Cardiology, Warsaw, Poland|No|Terminated|September 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|85 Years|No|||May 2015|May 13, 2015|June 30, 2009||No|The study was prematurely terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT00968383||134004|
NCT00938405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSI-WCH-100|Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus|Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus||University of Colorado Denver School of Medicine Barbara Davis Center|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|July 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938405||136283|
NCT00937846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110771|Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study|An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [11C] GSK1034702 in Healthy Subjects||GlaxoSmithKline||Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||February 2011|August 23, 2012|June 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00937846||136326|
NCT00938106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0206-C|Optimized Magnetic Resonance Brachytherapy (MR BT) in Cervix Cancer|Implementation of Optimized Magnetic Resonance Image-guided Intra-uterine Brachytherapy in Cervical Cancer||University Health Network, Toronto|Yes|Active, not recruiting|May 2008|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||June 2015|June 12, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938106||136306|
NCT00939003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-791|Study of Adalimumab in Patients With Axial Spondyloarthritis|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis||AbbVie|No|Completed|July 2009|August 2013|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|July 10, 2009|Yes|Yes||No|February 2, 2012|https://clinicaltrials.gov/show/NCT00939003||136237|
NCT00939315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|196/08|Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy|Impact of Multimodal Diagnostic Assessment of Cerebral Gliomas With F-18-fluoroethyl-L-tyrosine PET/CT, F-18-fluorocholine PET/CT and Magnetic Resonance Imaging and Spectroscopy|Gliomes-FLP|University of Lausanne Hospitals|No|Completed|July 2009|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with glioma suspicion referred for biopsy to our university hospital|January 2016|January 24, 2016|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939315||136214|
NCT00939016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of TN IRB 7701 B|The Influence of Factors on Accuracy of Reported Dietary Intake|The Influence of Dietary Restraint, Social Desirability and Food Type on Accuracy of Reported Dietary Intake||University of Tennessee|No|Completed|September 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|40|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||November 2012|November 14, 2012|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00939016||136236|
NCT00940836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05492|Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome|Phase III Clinical Trial - Efficacy and Safety Assessment of a Compound Acetaminophen, Chlorpheniramine and Phenylephrine Combination in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome in Adults||Hospital de Clinicas de Porto Alegre|No|Recruiting|June 2009|||November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2009|July 15, 2009|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940836||136097|
NCT00969202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDRS0001|Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer|Phase 1 Study of Stereotactic Hypofractionated Radiosurgery of Low Grade Prostate Cancer/Early Stage||San Diego Radiosurgery|No|Recruiting|August 2009|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|99 Years|No|||November 2015|November 17, 2015|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00969202||133941|
NCT00969215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-02|Burn Scar Appearance After Treatment With Fractional Carbon Dioxide (CO2) Laser|Burn Scar Characteristics After Treatment With Fractional CO2 Laser: A Clinical and Histological Study||Moy-Fincher Medical Group|No|Completed|December 2009|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2011|July 24, 2011|August 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00969215||133940|
NCT00969228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112269|Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants|Immunogenicity, Reactogenicity and Safety Study to Evaluate Two Doses of the Lyophilised Formulation of the Human Rotavirus (HRV) Vaccine When Administered to Healthy Korean Infants Previously Uninfected With HRV||GlaxoSmithKline||Completed|August 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|684|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2011|December 2, 2011|August 20, 2009|Yes|Yes||No|June 16, 2011|https://clinicaltrials.gov/show/NCT00969228||133939|
NCT00964808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT2009-010539-41|Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur|Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur||Vejle Hospital|Yes|Completed|September 2009|August 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964808||134274|
NCT00964821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06157|Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant|Influenza Specific Humoral and Cellular Immunity After Vaccination in Recipients of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation||City of Hope Medical Center|Yes|Completed|January 2007|||May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|459|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 10, 2013|August 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00964821||134273|
NCT00965146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48|Scorpio® Cruciate Retaining (CR) Outcomes Study|An Open Label, Post-market, Non-randomized, Multi-center Study of the Outcomes of the Scorpio® Cruciate Retaining (CR) Total Knee System||Stryker Orthopaedics|No|Terminated|June 2001|||July 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|215|||Both|21 Years|80 Years|No|||April 2013|April 8, 2013|August 11, 2009|Yes|Yes|Terminated due to lagging follow-up.|No|November 9, 2012|https://clinicaltrials.gov/show/NCT00965146||134250|This study was terminated early due to lagging follow up prior to the 15 year endpoint.
NCT00965497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-113|Escitalopram (Lexapro) for Depression MS or ALS|An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis||University of South Carolina|Yes|Completed|July 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|70 Years|No|||August 2011|August 4, 2011|August 7, 2009||No||No|April 19, 2011|https://clinicaltrials.gov/show/NCT00965497||134224|
NCT00965510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9118277Downing306|SeaCare's Care Coordination for Diabetes Management in a Primary Care Office|Improved Management of Type II Diabetes in a Primary Care Office With Targeted Case Management||SeaCare Health Services|Yes|Terminated|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||September 2010|September 29, 2011|August 24, 2009||No|insufficient recruitment of control and study patients|No||https://clinicaltrials.gov/show/NCT00965510||134223|
NCT00965835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0166|Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome|Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome||National Institute on Aging (NIA)|Yes|Recruiting|August 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals will be identified and recruited using IRB approved flyers distributed to        treating clinicians, caregivers from Board and Care homes, sheltered workshop        administrators (where potential participants are employed), and representatives of County        Regional Centers (primary evaluation and treatment centers for developmentally delayed        individuals).|December 2009|December 23, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965835||134199|
NCT00966927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDGEE-SPINA BIFIDA|Assessment of Functional Independence and Quality of Life in Adolescents With Spina Bifid|Assessment of Functional Independence and Quality of Life in Italian Population of Adolescents With Spina Bifid||Arcispedale Santa Maria Nuova-IRCCS|Yes|Recruiting|July 2009|November 2009|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|14 Years|21 Years|No|Non-Probability Sample|subjects with spina bifid referred to primary care clinic|August 2009|August 26, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966927||134116|
NCT00967200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7745|Study of Tissue Samples From Patients With Glioma or Other Brain Tumors|Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis||University Hospital, Montpellier|No|Completed|November 2003|November 2015|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|180|||Both|18 Years|120 Years|No|Probability Sample|Pathophysiology of gliomas and identification of molecular markers that may predict        prognosis and progression or that could identify new therapeutic|November 2015|November 23, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967200||134095|
NCT00967811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 07|A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG|An Open-Label, Phase 2 Study of Different Formulations (E1 and E2) of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967811||134048|
NCT00968136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2006-0020|Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study|||Yonsei University||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|1 Month|5 Years||Non-Probability Sample|refractory infantile spasms|August 2009|August 27, 2009|August 27, 2009||||No||https://clinicaltrials.gov/show/NCT00968136||134023|
NCT00968149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-219|A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Age 2 Through 14 Years With Seasonal Allergic Rhinitis||Merck Sharp & Dohme Corp.|No|Completed|March 2001|July 2001|Actual|June 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|413|||Both|2 Years|14 Years|No|||February 2015|February 6, 2015|August 27, 2009|Yes|Yes||No|September 15, 2009|https://clinicaltrials.gov/show/NCT00968149||134022|Efficacy endpoints are exploratory.
NCT00938743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-004309-90|Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine|Driving Ability in Adults With ADHD Before and After 10-weeks of Treatment With 40-80mg Atomoxetine vs. Untreated Adults With ADHD|DrivPerfATX|Central Institute of Mental Health, Mannheim|Yes|Completed|January 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|No|||January 2011|January 19, 2011|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938743||136257|
NCT00938704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-OPT-09-002|Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms|||Allergan|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|July 10, 2009|Yes|Yes||No|September 22, 2011|https://clinicaltrials.gov/show/NCT00938704||136260|
NCT00938717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-103-302|Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 26 Weeks in Patients With Irritable Bowel Syndrome With Constipation||Ironwood Pharmaceuticals, Inc.||Completed|July 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|805|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|July 12, 2009|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00938717||136259|
NCT00939341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00035|Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia|Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy (SMART) in Asthma Patients Across Asia: SMARTASIA|SMARTASIA|AstraZeneca|No|Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|862|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|July 13, 2009||No||No|August 11, 2011|https://clinicaltrials.gov/show/NCT00939341||136212|The design of the study does not allow for any conclusion regarding the effect of Symbicort SMART, it being a within-group comparison
NCT00939354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R09-2839B|Asthma in the Elderly: The Role of Exhaled Nitric Oxide Measurements|Asthma in the Elderly: The Role of Exhaled Nitric Oxide Measurements||Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|No|Completed|July 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|65 Years|N/A|No|Non-Probability Sample|Subjects with asthma over the age of 65 who are currently followed in our practice|October 2015|October 28, 2015|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939354||136211|
NCT00939367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/05/004|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fed Conditions|Randomized, Two Period Crossover Studies in Fed Healthy, Normal Subjects to Compare the Single Dose Bioavailability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|||Actual|30|||Both|18 Years|45 Years||||October 2013|October 22, 2013|July 13, 2009||No||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00939367||136210|
NCT00938379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLAO1|Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR|Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR||London School of Hygiene and Tropical Medicine|Yes|Recruiting|July 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|5000|||Both|5 Years|70 Years|Accepts Healthy Volunteers|||July 2009|July 13, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938379||136285|
NCT00938392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112662|Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly|Immunogenicity & Safety Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Adults.||GlaxoSmithKline||Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|726|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2012|June 7, 2012|July 9, 2009|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT00938392||136284|
NCT00938691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASDS-45322|Optimal Suture Choice for Improved Scar Outcomes|||Dallas VA Medical Center|Yes|Active, not recruiting|April 2009|July 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|N/A|No|||July 2009|July 13, 2009|July 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938691||136261|
NCT00940524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-046|Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia|Phase I Study of Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): ALL-6 Protocol||Memorial Sloan Kettering Cancer Center|Yes|Completed|July 2009|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|July 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940524||136121|
NCT00940277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-65727|Couple-Focused Intervention for Breast Cancer Patients|Couple-Focused Group Intervention for Women With Early-Stage Breast Cancer||Fox Chase Cancer Center|Yes|Completed|December 2007|October 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|611|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940277||136140|
NCT00968877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vita-D3|Vitamin D and Chronic Renal Insufficiency|Vitamin D and Chronic Renal Insufficiency||Odense University Hospital|Yes|Completed|September 2009|January 2011|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||December 2009|January 25, 2011|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968877||133966|
NCT00969241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090018-YR.ctil|The Effect of Periodontal Treatment on the Level of Free Radicals in the Saliva|The Effect of Periodontal Treatment on the Level of Free Radicals in the Saliva||The Baruch Padeh Medical Center, Poriya|No|Recruiting|July 2009|||December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with periodontitis who visit the department and volunteers.|August 2009|December 22, 2010|August 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00969241||133938|
NCT00964834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0036-08-06|Ph1 Study of Valortim and Doxycycline in Humans|A Phase I, Single Blind, Randomized, Placebo Controlled, Drug Interaction Study of Intravenous (IV) Valortim® and Intravenous (IV) Doxycycline in Healthy Normal Subjects||PharmAthene, Inc.|Yes|Terminated|July 2009|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 9, 2010|August 24, 2009|No|Yes|Sister trial has SAE investigation underway - sponsor elected to withdraw as study expected to    be repeated later|No||https://clinicaltrials.gov/show/NCT00964834||134272|
NCT00965523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-J081-224|Study of E7389 for Advanced or Metastatic Breast Cancer|Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer||Eisai Inc.||Completed|January 2008|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Female|20 Years|74 Years|No|||July 2013|July 14, 2013|August 20, 2009||No||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00965523||134222|
NCT00966940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-08-16|Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension|The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients||Alcon Research|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|21 Years|N/A|No|||May 2012|May 18, 2012|August 26, 2009|Yes|Yes||No|February 9, 2011|https://clinicaltrials.gov/show/NCT00966940||134115|
NCT00967486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-11-1878|Selective Versus Routine Shunting in Carotid Endarterectomy Patients|Selective Shunting in Appropriately Selected Patients Undergoing Carotid Endarterectomy Based on Stump Pressure||CAMC Health System|No|Completed|December 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|August 27, 2009||No||No|July 31, 2012|https://clinicaltrials.gov/show/NCT00967486||134073|
NCT00967824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649906|Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer|Developing and Testing a Tamoxifen Prophylaxis Decision Aid||University of Michigan Cancer Center||Completed|October 2005|||August 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized|||Anticipated|1683|||Female|N/A|N/A|No|||March 2011|March 22, 2011|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967824||134047|
NCT00967837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-66|Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics|Effects of Pulsatile Intravenous Insulin Therapy on Diabetic Subjects With Non Healing Wounds|wounds|Florida Atlantic University|Yes|Terminated|January 2006|September 2012|Anticipated|January 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||August 2009|August 27, 2009|August 6, 2009||No|Administrative|No||https://clinicaltrials.gov/show/NCT00967837||134046|
NCT00969345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP-HRV|Effects of Respiratory Yoga Training on Heart Rate Variability and Baroreflex of Healthy Elderly Subjects|Effects of Respiratory Yoga Training (Bhastrika) on Heart Rate Variability and Baroreflex, and Quality of Life of Healthy Elderly Subjects||University of Sao Paulo|No|Completed|August 2007|December 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||August 2009|August 31, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969345||133930|
NCT00969332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02-079-02|A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease|Omegaven and Parenteral Nutrition Associated Cholestasis|FO|University of California, Los Angeles|Yes|Recruiting|August 2009|August 2024|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|18 Years|No|||February 2016|February 22, 2016|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969332||133931|
NCT00964977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOESAK-pN1-108399|Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.|Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state)||Johannes Gutenberg University Mainz|Yes|Recruiting|October 2009|December 2018|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00964977||134263|
NCT00938431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0847|A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures|A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures||UCB Pharma|No|Completed|November 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|47|||Both|1 Month|17 Years|No|||November 2015|November 10, 2015|July 2, 2009|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT00938431||136281|
NCT00938756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633542|Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome|Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer||National Cancer Institute (NCI)||Recruiting|April 2008|||May 2009|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||April 2010|April 6, 2010|July 11, 2009||||No||https://clinicaltrials.gov/show/NCT00938756||136256|
NCT00939419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3140-ET|The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis|A Randomised Control Trial on the Effectiveness of Three Modalities of Tuberculosis Treatment Supervision Under DOTS Strategy in Ethiopia.||University of Leeds|Yes|Completed|January 2005|February 2007|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|924|||Both|15 Years|N/A|No|||July 2009|July 15, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939419||136206|
NCT00939731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081008|Relative Drug Exposures Of Two Formulations of PF-02341066|A Phase I Relative Bioavailability Study To Compare The Powder-In-Capsule And Immediate Release Tablet Of PF-02341066 In Healthy Volunteers||Pfizer|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|July 14, 2009|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00939731||136182|
NCT00939978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0427|Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery|||Yonsei University||Completed|April 2009|July 2010|Actual|June 2010|Actual|N/A|Interventional|N/A|2||Actual|74|||Both|20 Years|N/A|No|||October 2010|October 6, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939978||136163|
NCT00939991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016446|Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas|Phase I/II Study of Bevacizumab Plus Daily Temozolomide and Vorinostat for Recurrent Malignant Glioma Patients||Duke University|No|Completed|October 2009|April 2013|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|July 14, 2009|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT00939991||136162|
NCT00940264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG08/060/2B|Laparoscopic Transvaginal Hybrid Cholecystectomy: a Prospective Data Collection.|||Cantonal Hospital of St. Gallen|No|Completed|September 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Female|18 Years|N/A|No|Non-Probability Sample|female patiens with given indication for cholcystectomy|February 2012|February 10, 2012|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940264||136141|
NCT00940004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL22750.000.08|Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients|TLR Ligand Matured Dendritic Cell Vaccination in Melanoma Patients: the Key Towards a More Potent Immune Induction?||Radboud University|No|Completed|June 2009|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||November 2014|November 4, 2014|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00940004||136161|
NCT00940550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 266|Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women|A Randomised, Double-Blind, Placebo-Controlled Four-Way Cross-Over Trial to Study the Effects of Prolonged-Release Melatonin, Temazepam and Zolpidem on the Spectral Composition of the EEG During Nocturnal Sleep in Healthy Middle-Aged Men and Women||University of Surrey|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Both|55 Years|64 Years|Accepts Healthy Volunteers|||November 2009|August 5, 2011|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940550||136119|
NCT00940563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BIT03|A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors|STI571 (Imatinib) in KIT-expressing Gastrointestinal Stromal Tumors (GIST): a Prospective, Open-label, Multicenter Study on Best Clinical Use in the Advanced Disease.||Novartis||Completed|March 2002|||August 2004|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00940563||136118|
NCT00968890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113525|Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza GSK2340272A and Fluarix™ 2009-2010 Vaccines When Co-administered in Elderly Subjects Aged 61 Years and Older||GlaxoSmithKline||Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|168|||Both|61 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 17, 2011|August 27, 2009|Yes|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00968890||133965|
NCT00968903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-030|Effects of Methylprednisolone After Total Hip Arthroplasty|Effects of Pre-operative Methylprednisolone (125mg iv) After Total Hip Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail||Hvidovre University Hospital|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|48|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968903||133964|
NCT00969254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E01-OSM-PLS-01-08|Study to Assess the Efficacy and Safety of "Pílulas de Lussen®" Compared to the Pyridium® in the Symptomatic Control of Dysuria|Phase III Clinical Study, Prospective, Multicenter, Double-blind, Randomized, Double-dummy to Assess the Efficacy and Safety of "Pílulas de Lussen®" Compared to the Pyridium® in the Symptomatic Control of Dysuria|E01OSMPLS0108|Laboratorios Osorio de Moraes Ltda.|No|Not yet recruiting|December 2009|March 2010|Anticipated|February 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2009|August 31, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969254||133937|
NCT00966667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130901|Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer|Health Behaviors Among Individuals Diagnosed With Colorectal Cancer||Rutgers, The State University of New Jersey|No|Active, not recruiting|November 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|222|||Both|21 Years|N/A|No|Probability Sample|colorectal cancer|December 2015|December 16, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966667||134135|
NCT00966680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01465|How Fast Are we? Speed of General Versus Spinal Anesthesia for Emergency Cesarean Delivery: A Simulation Based Study|Speed of General Versus Spinal Anesthesia for Emergency Cesarean Delivery: A Simulation Based Study||University of British Columbia|Yes|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|19|None Retained|16 anesthesiologists will be recruited for the simulation part. 100 women having elective      cesarean delivery will be timed in the clinical part.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consenting anesthesiologists, R5 residents and anesthesia fellows practicing at BC Women's        Hospital.|March 2014|March 14, 2014|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966680||134134|
NCT00966407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC IRB#3842|Assessing Inherited Markers of Metabolic Syndrome in the Young|Assessing Inherited Markers of Metabolic Syndrome in the Young|AIMM Young|Children's Research Institute|No|Recruiting|February 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples With DNA|Blood samples are obtained for DNA extraction and measuring various biomarkers (including      fasting glucose, insulin, lipid profile, and hemoglobin A1c)|Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|The population from which cohorts will be selected include students, residents, staff,        and/or faculty who are present on Howard University, East Carolina University, and/or        University of Massachusetts, Amherst campuses and surrounding areas.|February 2015|February 3, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966407||134155|
NCT00966420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJOG-01|Traction Assisted Polypectomy of the Intestine|Traction Assisted Endoscopic Mucosa Resection (TAEMR)|TAEMR|St John of God Hospital, Vienna|No|Completed|July 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|90 Years|No|||March 2010|March 27, 2010|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966420||134154|
NCT00966654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00013802|Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery|Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass Surgery|GLP-1 CABG|Johns Hopkins University|No|Active, not recruiting|September 2008|September 2012|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||March 2010|March 25, 2010|August 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00966654||134136|
NCT00967512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELP1020|Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course|Aezea (Cenersen) in Combination With Chemotherapy for Treatment of Acute Myelogenous Leukemia Subjects ≥55 Years of Age With No Response to Single Frontline Induction Course in a Randomized Double-Blind Placebo-Controlled Multi-Center Study||Eleos, Inc.|No|Withdrawn|January 2012|January 2012|Actual|January 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|55 Years|N/A|No|||September 2014|September 16, 2014|August 26, 2009|Yes|Yes|Study Was Terminated due to lack of Funding.|No||https://clinicaltrials.gov/show/NCT00967512||134071|
NCT00967850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOBA-002-2007|Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia|Phase III Study of Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia||Instituto Universitario de Oftalmobiología Aplicada|No|Completed|April 2008|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||August 2009|March 18, 2014|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00967850||134045|
NCT00959933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1BH01001|Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions|A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Non-Fasting Conditions.||Sandoz||Completed|April 2001|May 2001|Actual|May 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 14, 2009|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959933||134640|
NCT00960206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/45|ABC/Trident® Ceramic Post Approval Study|Post-Approval Study of the ABC and Trident® Systems||Stryker Orthopaedics|No|Completed|March 2003|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|413|||Both|21 Years|75 Years|No|||July 2014|July 24, 2014|August 5, 2009|Yes|Yes||No|June 7, 2013|https://clinicaltrials.gov/show/NCT00960206||134619|
NCT00964990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016474|A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-traumatic Neuralgia, Followed by a Double Blind Safety Extension and an Open-label Safety Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|September 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|August 21, 2009|Yes|Yes|Logistic reasons associated with the FDA-imposed clinical hold.|No||https://clinicaltrials.gov/show/NCT00964990||134262|
NCT00965315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200711014M|A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome|A Multicenter, Randomized, Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome||National Taiwan University Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|20 Years|79 Years||||November 2012|December 20, 2012|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965315||134238|
NCT00939081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2794|Community Based Obesity Prevention Among Blacks|Community Based Obesity Prevention Among Blacks||Duke University|No|Completed|May 2010|June 2014|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Female|25 Years|N/A|No|||July 2014|July 28, 2014|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00939081||136231|
NCT00939432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 453/2008|Taboo Perception of Incontinence, Depression and Cancer|The Greatest Taboo- Urinary Incontinence, Depression and Cancer||Medical University of Vienna|No|Completed|November 2005|April 2007|Actual|April 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||3|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of 150 test persons from waiting areas of a teaching hospital and in        private practices of general practitioners in Austria agreed to take part in the study,        with an additional 10 persons (6.2%) declining after being informed about the subject.|July 2009|July 14, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939432||136205|
NCT00939445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VJR-NEPHRO001|Short Daily Hemodialysis and Online HDF: Which One is Better?|Short Daily Hemodialysis and Online HDF: Which One is Better?|SHD|Bangkok Metropolitan Administration Medical College and Vajira Hospital|Yes|Completed|June 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|70 Years|No|||December 2015|December 13, 2015|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00939445||136204|
NCT00939029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002581|Highdose Nicotine Patch Therapy for Smokeless Tobacco Use|Highdose Nicotine Patch Therapy for Smokeless Tobacco Use||Mayo Clinic|Yes|Completed|July 2010|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|July 10, 2009|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT00939029||136235|
NCT00939042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1777|Alster Stem Cells - Intramyocardial Stem Therapy|Percutaneous Intramyocardial Cell Therapy After Acute Myocardial Infarction Using Bone Marrow Mononuclear Cells||Asklepios proresearch|No|Active, not recruiting|January 2009|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||April 2011|April 14, 2011|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00939042||136234|
NCT00939055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D00764|StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight|A Randomized Controlled Trial of StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight||EndoGastric Solutions|No|Terminated|July 2009|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|64 Years|No|||May 2014|May 28, 2014|July 10, 2009|Yes|Yes|Based on futility analysis, study would not meet primary endpoint.|No|March 24, 2014|https://clinicaltrials.gov/show/NCT00939055||136233|
NCT00939380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130906|Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial|Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial|P-SCIP|Rutgers, The State University of New Jersey|No|Completed|May 2010|May 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|212|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939380||136209|
NCT00939744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-040|Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation|Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation.|EAU2|Université de Sherbrooke|No|Recruiting|May 2009|October 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|130|Samples Without DNA|uterus biopsy|Female|18 Years|40 Years|No|Non-Probability Sample|women who will have a c-section at the CHUS|March 2015|March 3, 2015|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939744||136181|
NCT00940290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMBE-ITESM-1|Practice Guidelines Grading Systems|Different Grading Systems to Grade Evidence and Recommendations in Clinical Practice Guidelines: Does it Influence the Clinicians´ Behavior?||Instituto Tecnologico y de Estudios Superiores de Monterey|No|Completed|August 2009|November 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|216|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|January 12, 2010|July 13, 2009||No||No|December 9, 2009|https://clinicaltrials.gov/show/NCT00940290||136139|The outcome was measured in only one topic and could be not expanded to other areas of pediatrics or even other specialties in medicine.
NCT00940589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU AZ1|Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor|A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor||Neurim Pharmaceuticals Ltd.|No|Completed|September 2009|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|50 Years|85 Years|No|||July 2013|July 15, 2013|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940589||136116|
NCT00940888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60020938|SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients|SJ4 Post Approval Study||St. Jude Medical|No|Completed|June 2009|December 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1701|||Both|18 Years|N/A|No|Non-Probability Sample|ICD and CRTD indicated patients|February 2016|February 12, 2016|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940888||136093|
NCT00941187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808076|Evolution of Pulmonary Capillary Blood Volume|Evolution of Pulmonary Capillary Blood Volume (Vc) in Patients After a First Episode of Pulmonary Embolism.|VcEP|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|August 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patient with a first episode of symptomatic pulmonary embolism|November 2013|November 6, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941187||136070|
NCT00965549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04211|Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients|Comparison of a Basal Plus One Insulin Regimen (Insulin Glargine/Insulin Glulisine) With a Biphasic Insulin Regimen (Insulin Aspart/Insulin Aspart Protamine 30/70) in Type 2 Diabetes Patients Following Basal Insulin Optimisation|LanScape|Sanofi||Completed|July 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|75 Years|No|||January 2013|January 7, 2013|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965549||134220|
NCT00965848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015766|A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections|A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections||Janssen-Cilag Ltd.,Thailand|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|August 24, 2009||No||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00965848||134198|
NCT00966147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|meroz01- HMO-CTIL|Advanced Hemodynamic Monitoring for Goal-directed Hemodynamic Management During Radical Cystectomy|Advanced Hemodynamic Monitoring for Goal-directed Hemodynamic Management During Radical Cystectomy||Hadassah Medical Organization|No|Not yet recruiting|October 2009|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||||||Both|18 Years|N/A|No|||July 2009|August 25, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966147||134175|
NCT00966446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809899|Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community|Epidemiology and Prevention of MRSA Transmission in the Community||University of Pennsylvania|Yes|Completed|September 2009|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|972|||Both|6 Months|N/A|No|||February 2014|February 3, 2014|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966446||134152|
NCT00966953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERO-0907-PLA-16-RR|Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.|Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.||Colgate Palmolive|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 14, 2009|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT00966953||134114|
NCT00966693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0179|Lenalidomide, Thalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2009|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00966693||134133|
NCT00967213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952AKR03|Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration|Changes in Preferential Hyperacuity Perimeter (PHP) and Fundus Autofluorescence (FAF) in Patients With Neovascular Age-related Macular Degeneration Receiving Combination of Ranibizumab and Verteporfin Therapy||Novartis Korea Ltd.||Completed|August 2006|||February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|50 Years|N/A|No|||August 2009|August 26, 2009|August 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967213||134094|
NCT00967473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-062|ACRYSOF® Toric NATURAL T9 Intraocular Lens (IOL)|||Alcon Research|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|21 Years|N/A|No|||June 2011|June 23, 2011|August 25, 2009|Yes|Yes||No|June 23, 2011|https://clinicaltrials.gov/show/NCT00967473||134074|
NCT00967239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP MCO831|Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2|The Pharmacogenomics of Breast Cancer Prevention: A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2||NSABP Foundation Inc|No|Active, not recruiting|April 2009|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1881|None Retained|DNA extracted from stored lymphocytes|Female|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|breast cancer cases and matched controls from: participants in NSABP P-1 (tamoxifen or no        tamoxifen) participants in NSABP P-2 (raloxifene or no raloxifene; tamoxifen or no        tamoxifen)|May 2015|May 6, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967239||134092|
NCT00967252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008526-01H|Impact of Chronic Statin Use During Surgery on Inflammation and Infection Rates|An Observational Trial of Perioperative Atorvastatin on Inflammatory and Endothelial Function in Patients Undergoing Vascular Surgery (STAR-VaS 2)|STAR-VaS2|Ottawa Hospital Research Institute|Yes|Completed|November 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|50|||Both|45 Years|N/A|No|Probability Sample|Patients undergoing elective non-cardiac high-risk surgery as defined by the POISE        criteria|July 2011|July 19, 2011|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967252||134091|
NCT00969007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-083|Identification of Predictors of Success for Lifestyle Modifications in Overweight Pre-diabetic Subjects|Identification of Predictors of Success for Lifestyle Modifications in Overweight Pre-diabetic Subjects||Université de Sherbrooke|No|Completed|November 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00969007||133956|
NCT00969020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-RSI-RRS|A Telemedicine Solution for Remote Support of Rehabilitation, for Patients Undergoing, Total Hip Arthroplasty Surgery|The Effect of Remote Rehabilitation Support Via a Telemedicine Solution for Patients Undergoing an Optimized Fast-track Orthopedic Surgery Procedure With the Implementation of a Total Hip Arthroplasty.|RRS|Regionshospitalet Silkeborg|No|Completed|September 2009|August 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|72|||Both|N/A|N/A|No|||October 2012|October 22, 2012|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00969020||133955|
NCT00965003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0019|MRI Imaging of the Human Larynx|High Resolution MRI in the Evaluation of Laryngeal Neoplasia||Stanford University|Yes|Terminated|July 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|Laryngeal cancer patients at Stanford University|December 2013|December 12, 2013|August 21, 2009||No|Absence of key personnel to conduct study|No||https://clinicaltrials.gov/show/NCT00965003||134261|
NCT00965341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0262|Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients|A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer.||M.D. Anderson Cancer Center|Yes|Completed|September 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|53|||Male|18 Years|N/A|No|||June 2013|June 17, 2013|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00965341||134236|
NCT00955747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70971-004|Naturlose (D-Tagatose) Efficacy Evaluation Trial|Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects With Type 2 Diabetes Under Diet Control and Exercise|NEET|Spherix Incorporated|No|Completed|April 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|494|||Both|18 Years|75 Years|No|||November 2014|November 18, 2014|August 7, 2009|No|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00955747||134958|
NCT00955760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/1003|Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate|A Single Center, Open-Label, Three Periods, Fixed Sequence Design Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate||Merz Pharmaceuticals GmbH||Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Masking: Open Label|1||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2009|February 7, 2011|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955760||134957|
NCT00939783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451029|An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease|An Open Label Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon (PF 01913539) In Patients With Alzheimer's Disease||Pfizer|Yes|Terminated|September 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|649|||Both|50 Years|N/A|No|||October 2012|October 11, 2012|July 13, 2009|Yes|Yes|See termination reason in detailed description.|No|October 11, 2012|https://clinicaltrials.gov/show/NCT00939783||136178|This safety study did not specify primary or secondary outcome measures. Relevant summaries of all safety assessments are thus provided. Urine blood abnormalities seen are deemed due to interference with dipstick test by a metabolite of dimebon.
NCT00939796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005005|Clinical Study of the Tympanostomy Tube Delivery System|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System For the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media (inVENT)|inVENT|Acclarent|No|Completed|March 2009|July 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||September 2014|September 26, 2014|July 14, 2009|Yes|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT00939796||136177|
NCT00940316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 07I4|Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer|A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer||Northwestern University|Yes|Active, not recruiting|July 2009|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940316||136137|
NCT00939068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H200804|Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission|A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection||Southeast University, China|Yes|Enrolling by invitation|February 2008|November 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Female|20 Years|40 Years|No|||October 2009|October 13, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00939068||136232|
NCT00939393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005002|Balloon Sinus Dilation In Office or OR|ESS Performed in Operating Room Versus Clinician's Office|ORIOS|Acclarent|No|Completed|April 2008|July 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|72|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|July 14, 2009|Yes|Yes||No|May 6, 2014|https://clinicaltrials.gov/show/NCT00939393||136208|
NCT00939406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyalospine|Clinical Trial to Evaluate Safety and Efficacy of Hyalospine® in Lumbar Laminectomy or Laminotomy|A Multi-center Prospective Randomized Phase II Clinical Trial to Evaluate Safety and Efficacy of Hyalospine® in Lumbar Laminectomy or Laminotomy|Hyalospine|AO Clinical Investigation and Documentation|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|75 Years|No|||December 2012|December 19, 2012|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939406||136207|
NCT00939757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-041|Study of the Effect of Food on the Pharmacokinetics of Mirabegron|A Phase 1, Open-Label, Randomized, Single Oral Dose, Three-Way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Mirabegron||Astellas Pharma Inc|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|76|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|July 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00939757||136180|
NCT00940017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851020|A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects|A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects||Pfizer|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 5, 2010|July 13, 2009|No|Yes||No|October 20, 2009|https://clinicaltrials.gov/show/NCT00940017||136160|
NCT00940602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2302|Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study|A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload|TELESTO|Novartis|Yes|Active, not recruiting|March 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|N/A|No|||September 2015|September 27, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940602||136115|
NCT00940875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22429|A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Open-label Study of the Effect of First Line Treatment With Tarceva in Sequential Combination With Gemcitabine, Compared to Gemcitabine Monotherapy, on Progression-free Survival in Elderly or ECOG PS of 2 Patients With Advanced Non-small Cell Lung Cancer.||Hoffmann-La Roche||Terminated|June 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|July 6, 2009||No|Study was stopped due to slower than expected recruitment.|No|December 19, 2014|https://clinicaltrials.gov/show/NCT00940875||136094|Due to slower than expected recruitment, this study was stopped after 54 patients had been enrolled.
NCT00965224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG 09-003|Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma|Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial||University Hospital, Antwerp|No|Enrolling by invitation|January 2010|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2013|July 11, 2013|August 24, 2009||||No||https://clinicaltrials.gov/show/NCT00965224||134245|
NCT00965237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-368-C-101|Multifocal Contact Lens Use in Previous Contact Lens Wearers With Near Vision Demands|P/331/09/C: Multifocal Pilot Study: Refitting Drop Outs (GARM)|GARM|Alcon Research|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|N/A|N/A|No|||January 2012|June 26, 2012|August 24, 2009|Yes|Yes||No|January 21, 2011|https://clinicaltrials.gov/show/NCT00965237||134244|
NCT00966160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-1999-LRE|CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes|Phase 3, Single Center, Controlled, Investigator-blinded, Randomized Matched Pair Design Study of CD4 Cell Recovery in HIV-1 Patients With Sustained Virologic Response Comparing Protease Inhibitor and Non-nucleoside Reverse Transcriptase Inhibitor Based Treatment Regimes||University of Cologne||Completed|January 1999|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|215|||Both|20 Years|60 Years|No|||August 2009|September 28, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966160||134174|
NCT00966433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLMA study WFU|A Comparison of Different Ventilation Strategies in Children Using the Proseal™ Laryngeal Mask Airway|A Comparison of Different Ventilation Strategies in Children Using the Proseal™ Laryngeal Mask Airway||Wake Forest School of Medicine|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|33|||Both|12 Months|5 Years|No|||February 2016|February 10, 2016|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966433||134153|
NCT00966459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_0803|Computed Tomography (CT) and Lung Function Data Collection for Computational Fluid Dynamics (CFD) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Computed Tomography (CT) and Lung Function Data Collection for Computational Fluid Dynamics (CFD) in COPD Patients||University Hospital, Antwerp|No|Completed|November 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|40 Years|N/A|No|||August 2009|August 31, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966459||134151|
NCT00966472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007908-01H (OTT 08-07)|Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC|A Phase I, Dose Finding Study of the Combination of High-dose Statin Agent (Rosuvastatin) With Erlotinib in Patients With Advanced Solid Malignancies, With a Focus on Squamous Cell Carcinomas and NSCLC.||Ottawa Hospital Research Institute|Yes|Completed|March 2009|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||April 2015|April 21, 2015|August 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00966472||134150|
NCT00966966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3193A1-1109|Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered|An Open-Label, Nonrandomized Study To Evaluate The Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, A Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally To Healthy Young Adult Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 18, 2010|August 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00966966||134113|
NCT00966979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66|Triathlon® Partial Knee Replacement (PKR) Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Triathlon® Partial Knee Resurfacing (PKR) Unicondylar Knee System|PKR|Stryker Orthopaedics|No|Recruiting|December 2009|January 2027|Anticipated|January 2027|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|184|||Both|21 Years|75 Years|No|||January 2016|January 11, 2016|August 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00966979||134112|
NCT00967226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4502|Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas|Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study||Children's Research Institute|No|Terminated|July 2009|December 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|N/A|6 Months|No|||January 2016|January 27, 2016|August 26, 2009|Yes|Yes|Serious adverse events with prednisolone, primarily temporary growth retardation, <5th    percentile.|No|March 14, 2014|https://clinicaltrials.gov/show/NCT00967226||134093|Not every enrolled participant had an adverse event and some had more than one. The prednioslone participants who had adverse events warranting early withdrawal had severe failure to thrive (<5th percentile), a serious adverse event.
NCT00967499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-08-11|Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)|A Multi-Center, Open-Label, 2-Arm, Randomized, Stratified, Parallel, Pilot Study to Assess Palonosetron vs. Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)||Eisai Inc.||Completed|July 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2010|May 6, 2010|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967499||134072|
NCT00968734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIPE, CAPES|Vitamin D Status After Single Oral Dose of Cholecalciferol in Low Fat Meal Compared to High-fat Meal|Vitamin D Status After Single Oral Dose of Cholecalciferol in Low Fat Meal Compared to High-fat Meal|VITDAB_08606|Federal University of Rio Grande do Sul|Yes|Completed|August 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|40 Years|No|||August 2009|March 4, 2010|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968734||133977|
NCT00969046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPO906A2117|Dose-Escalation Study in Advanced Colon Cancer Patients|EPO906 Phase I 6-arm Trial to Optimize Administration Exploring Single Dose Bolus and Continuous Infusion Over 1 or 5 Days Every 3 or 4 Weeks in Patients With Pretreated Advanced Colon Cancer With Nutritional Support Treatment and Intensive Management of Diarrhea||Novartis||Completed|November 2003|||November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969046||133953|
NCT00966030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-042|Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)|An Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate Vs. a Single Dose of the Reference MK0974 Liquid Filled Capsule in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00966030||134184|
NCT00966303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR150091|Cardiac Rehabilitation in Cardiomyopathies|The Effectiveness of a Cardiac Rehabilitation in Patients With Cardiomyopathy||Fortaleza University|Yes|Completed|June 2008|June 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|60 Years|No|||October 2009|October 5, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966303||134163|
NCT00965354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1367|Mechanisms of Severe Acute Influenza Consortium (MOSAIC)|Mechanisms of Severe Acute Influenza Consortium (MOSAIC)|MOSAIC|Imperial College London|No|Completed|December 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|257|Samples With DNA|A) Swabs and secretions from the nose and throat B) Blood C) Sputum D) Urine E) Stool      In addition, if the patients are having further respiratory sample collection as part of      their routine care, for example tracheal aspirates, bronchial lavage and other samples then      we would like to take an additional amount of these samples for our research.|Both|N/A|N/A|No|Non-Probability Sample|Hospital admissions|June 2011|June 3, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965354||134235|
NCT00965666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-07-24|Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia|Etanercept (Enbrel) in Children With Fanconi Anemia and Early Bone Marrow Failure: A Pilot Study||Children's Hospital Medical Center, Cincinnati|Yes|Completed|October 2005|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|3|||Both|4 Years|N/A|No|||March 2012|March 7, 2012|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00965666||134211|
NCT00940329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/CP-059|Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol|Investigation on the Cardiovascular and Pharmacokinetic Interaction Between Oral Roflumilast and Inhaled Formoterol in Healthy Subjects||Nycomed||Completed|April 2004|December 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00940329||136136|
NCT00939770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0912|Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma|A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma||Children's Oncology Group|Yes|Active, not recruiting|September 2009|||May 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|1 Year|21 Years|No|||January 2016|January 14, 2016|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00939770||136179|
NCT00940030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S357/307|Comparison of Mechanical Bowel Preparation Versus Enema for Candidates to Colorectal Resection for Adenocarcinoma|Effect of Mechanical Bowel Preparation With Polyethylene Glycol Plus Bowel Enema (Glycerine 5%) vs Bowel Enema Alone in Patients Candidates to Colorectal Resection for Malignancy. Prospective, Randomized Clinical Trial|MBP|European Institute of Oncology|No|Recruiting|October 2007|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|80 Years|No|||December 2015|January 21, 2016|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940030||136159|
NCT00940303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20514|OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer|An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study)||Hoffmann-La Roche||Completed|June 2009|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00940303||136138|
NCT00940576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP_H08b-00|Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases|Dietetic Effects of Mare's Milk in Patients With Chronic Inflammatory Bowel Diseases (IBD) - a Double Blind Placebo Controlled Cross-over Study.||University of Jena|Yes|Completed|July 2000|February 2001|Actual|February 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|10 Years|50 Years|No|||May 2015|May 5, 2015|July 15, 2009||No||No|July 17, 2009|https://clinicaltrials.gov/show/NCT00940576||136117|
NCT00941473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J90067|Effect of Epidural Steroid Injection on Bone Mineral Density in Postmenopausal Women|Effect of Epidural Steroid Injection on Bone Mineral Density In Postmenopausal Women||Henry Ford Health System|Yes|Completed|July 2007|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Female|55 Years|80 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|July 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00941473||136048|
NCT00965874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOMAGHI|Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation|Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation : Randomised Controlled Double Blind Study (LOMAGHI Study)||University of Monastir|No|Recruiting|August 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965874||134196|
NCT00966173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6001|International Melanoma Algorithm Training Study - IMATS|An International, Multicenter, Prospective, Non-controlled, Non-randomised, Clinical Study to Collect Impedance Data of Potentially Malignant Pigmented Nevi and Histological Diagnoses||SciBase AB|No|Completed|December 2005|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1800|||Both|18 Years|N/A|No|||August 2010|August 10, 2010|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966173||134173|
NCT00966706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642240|Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer|PEXG (Cisplatin, Epirubicin, Capecitabine, Gemcitabine) Versus PDXG (Cisplatin, Docetaxel, Capecitabine, Gemcitabine) in Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial|PACT-9|IRCCS San Raffaele|No|Completed|June 2005|October 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|75 Years|No|||August 2009|January 31, 2012|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966706||134132|
NCT00966992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0811|Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer|Randomized Phase II Study of Zoledronic Acid vs Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer||Washington University School of Medicine|No|Terminated|August 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|N/A|No|||August 2015|August 10, 2015|August 18, 2009|Yes|Yes|Lack of enrollment|No|August 10, 2015|https://clinicaltrials.gov/show/NCT00966992||134111|
NCT00968747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000073|Regulation of FGF21 by Nutritional Challenges|The Effect of Acute Nutritional Challenges on FGF21 Levels in Humans||Beth Israel Deaconess Medical Center|No|Recruiting|July 2009|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|4||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|July 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00968747||133976|
NCT00969033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1008-A-E203|CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin|A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen||Daiichi Sankyo Inc.|No|Terminated|July 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969033||133954|
NCT00959660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005668|Exercise Intolerance in Elderly Patients With Diastolic Heart Failure|Study of the Effect of Caloric Restriction and Exercise Training in Patients With Heart Failure and a Normal Ejection Fraction.(SECRET)|SECRET|Wake Forest School of Medicine|Yes|Active, not recruiting|February 2009|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|60 Years|N/A|No|||November 2015|November 19, 2015|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00959660||134660|
NCT00966329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARAVI-SWITCH|Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects|Pilot Study to Assess the Safety and Efficacy of Switching the Nnrti or pi to Maraviroc in Hiv-1-infected Subjects With Persistent Viremia Suppression||Germans Trias i Pujol Hospital|No|Completed|October 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966329||134161|
NCT00940043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-072|Monitoring of the Inflammatory Response of Patients With Premature Rupture of Membranes With Bedside Tests|Monitoring of Women With Preterm Premature Rupture of Membranes (PPROM) Between 28 and 33 Weeks of Gestation With Repetitive Immunochromatographic Bedside Test to Detect Inflammatory Protein in Vaginal Secretions.|EFFARM|Université de Sherbrooke|No|Completed|September 2008|December 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|vaginal secretions|Female|18 Years|40 Years|No|Non-Probability Sample|women hospitalized for premature rupture of membranes at the CHUS|January 2013|January 15, 2013|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940043||136158|
NCT00940927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-41|Dose-response of Albuterol in Asthmatics|Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule||Nemours Children's Clinic|No|Completed|July 1993|October 1994|Actual|October 1994|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|8 Years|65 Years|No|||April 2015|April 14, 2015|June 27, 2008|Yes|Yes||No|February 3, 2009|https://clinicaltrials.gov/show/NCT00940927||136090|
NCT00940615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6859-M|The Effect of Aerobic Exercise on Mild Traumatic Brain Injury|Aerobic Exercise in TBI: White Matter Integrity and Cognition||VA Office of Research and Development|No|Terminated|September 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|50 Years|No|||June 2015|June 25, 2015|July 14, 2009||No|Primary Investigator is no longer employeed by the VA|No||https://clinicaltrials.gov/show/NCT00940615||136114|
NCT00940901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00017554|Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia|Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia||Johns Hopkins University|Yes|Terminated|June 2008|December 2013|Anticipated|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Male|14 Years|45 Years|No|||September 2013|September 20, 2013|July 16, 2009|Yes|Yes|funding was terminated|No||https://clinicaltrials.gov/show/NCT00940901||136092|
NCT00941213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1235|Monopolar Electrosurgery Versus Ultrasound Scissors in Thoracoscopic Ventral Spondylodesis|Comparison of the Quantity of Bleeding and the Duration of Operation in Thoracoscopic Ventral Spondylodesis During Preparation With Monopolar Electrosurgery Compared to Ultrasound Scissors.|Harmonic|University of Cologne|No|Recruiting|December 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2010|June 24, 2010|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941213||136068|
NCT00941486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FST100-AVC-02|FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis|||Shire||Terminated|June 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|3 Years|N/A|No|||September 2012|September 14, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00941486||136047|
NCT00941499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0023|Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab|Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Bevacizumab With/Without Cetuximab by K-RAS Mutational Status and Liver Function for Advanced Cancers Metastatic to the Liver||M.D. Anderson Cancer Center|No|Completed|July 2009|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|140|||Both|N/A|N/A|No|||November 2015|November 16, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941499||136046|
NCT00965575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1042|Pilot Study of Melatonin and Epilepsy|Melatonin and Sleep in Patients With Epilepsy||Children's Hospital Medical Center, Cincinnati|Yes|Completed|June 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|6 Years|11 Years|No|||June 2014|June 17, 2014|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00965575||134218|
NCT00965588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBI Protocol V118|Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease|A Phase I, Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of the UBITh AD Immunotherapeutic Vaccine (UB 311) in Patients With Mild to Moderate Alzheimer's Disease||United Biomedical|Yes|Completed|February 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|50 Years|80 Years|No|||August 2011|August 22, 2011|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965588||134217|
NCT00965887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-045|Bioequivalence of Two Tablet Forms of MK0974 (0974-045)|An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate vs. a Single Dose of a Tablet Form of MK0974 Hydrate in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00965887||134195|
NCT00965900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTPEBL|Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding|Randomized Controlled Trial Comparing Propranolol, Endoscopic Banding Ligation, and Combined Treatment to Prevent First Variceal Hemorrhage in Patients With Liver Cirrhosis||Korea University|No|Recruiting|September 2006|May 2014|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|288|||Both|18 Years|70 Years|No|||August 2009|August 25, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965900||134194|
NCT00966186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jungwon|The Rotational Insertion Technique for ProSeal Laryngeal Mask Airway|The 90-degree Rotational Insertion Technique for the Large Size ProSeal Laryngeal Mask Airway||Seoul National University Hospital|Yes|Completed|November 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|120|||Both|27 Years|75 Years|No|||July 2010|July 21, 2010|August 20, 2009||No||No|January 4, 2010|https://clinicaltrials.gov/show/NCT00966186||134172|First, as the PLMAs were inserted by two anesthesiologists who were experts in PLMA insertion, these results may not apply to novices. Second, the insertion technique was impossible to blind the anesthesiologists, which might be a source of bias.
NCT00967863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649028|Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer|Phase III Study Comparing Irradiation at a Dose of 80 Gy to Irradiation at 70 Gy in Unfavorable Prostate Cancers Associated With Prolonged Hormonal Therapy||National Cancer Institute (NCI)||Recruiting|October 2008|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Male|18 Years|80 Years|No|||August 2009|September 29, 2009|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967863||134044|
NCT00967876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/133/08|Coronary Artery Stent Evaluation With 320-slice Computed Tomography - The CArS 320 Study|Coronary Artery Stent Evaluation With 320-slice Computed Tomography - The CArS 320 Study|CARS-320|Charite University, Berlin, Germany||Completed|April 2009|||November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|40 Years|N/A|No|Non-Probability Sample|Patients who underwent coronary artery stent placement in the past and are clinically        indicated to undergo conventional coronary angiography.|July 2014|July 22, 2014|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967876||134043|
NCT00967889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-ProMPT|Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer|Molecular Mechanisms of Disease Progression and the Development of Novel Treatment Strategies in Advanced Prostate Cancer (Northern Prostate Cancer Collaborative (ProMPT))||National Cancer Institute (NCI)||Recruiting|January 2002|||June 2011|Anticipated|N/A|Observational|N/A|||||||Male|N/A|N/A|No|||August 2009|August 9, 2013|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967889||134042|
NCT00968162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00011048|Sickle Cell Disease Conditioning for Bone Marrow Transplant|Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study||Emory University|Yes|Suspended|February 2009|December 2016|Anticipated|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|18 Years|No|||March 2015|March 10, 2015|August 11, 2009||No|stopping rule has been met|No||https://clinicaltrials.gov/show/NCT00968162||134021|
NCT00968396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0886|Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts|Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts||M.D. Anderson Cancer Center|No|Withdrawn|February 2013|||February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||April 2013|April 4, 2013|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968396||134003|
NCT00969358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/12|Evaluation of a Rehabilitation Program After Lung Surgery|Evaluation of a Rehabilitation Program After Lung Surgery (Prospective Observational Study)||Hopital Foch|No|Completed|August 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|tertiary care clinic|January 2012|January 4, 2012|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00969358||133929|
NCT00969371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE G050048|Lenstec Tetraflex Accommodating Posterior Chamber Intraocular Lens (IOL) Clinical Investigation|Lenstec TetraFlex Accommodating Posterior Chamber Intraocular Lens (IOL)Clinical Investigation||Lenstec Incorporated|No|Completed|September 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|470|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 31, 2009|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969371||133928|
NCT00966342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01465|Rapid Evaluation of Seasonal Influenza Vaccine|Post-marketing Surveillance of Annual Influenza Vaccines: Extended Vaccine Safety and Immunogenicity Evaluation||University of British Columbia|No|Withdrawn|August 2009|November 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|August 24, 2009||No|New studies are being offered|No||https://clinicaltrials.gov/show/NCT00966342||134160|
NCT00965679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090211|X-ray Fluoroscopy Fused With Computed Tomography (XFC) Technical Development|X-ray Fluoroscopy Fused With Computed Tomography (XFC) Technical Development||National Institutes of Health Clinical Center (CC)||Completed|August 2009|May 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|1|||Both|18 Years|N/A|No|||May 2010|September 26, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965679||134210|
NCT00965705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20472|Stepped Care Treatment for Binge-Eating|Dialectical Behavior Therapy for Early Non-Responders to CBT||Temple University|Yes|Recruiting|June 2009|March 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|100|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965705||134209|
NCT00940654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSICM&KSCCM FACE|The Fever and Antipyretic in Critically Illness Evaluation Study|The Fever and Antipyretic in Critically Illness Evaluation Study|FACE|Japanese Society of Intensive Care Medicine|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1426|||Both|20 Years|N/A|No|Probability Sample|Adult non-neurological critically ill patients required intensive care for more than 48        hour.|September 2009|May 18, 2010|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940654||136111|
NCT00940667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ALOS-301|Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension|A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy||Hanmi Pharmaceutical Company Limited|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|N/A|No|||July 2009|July 15, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940667||136110|
NCT00940628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19569|A Study of Xenical (Orlistat) in Overweight and Obese Adolescents|Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents||Hoffmann-La Roche||Completed|April 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|12 Years|14 Years|No|||March 2016|March 1, 2016|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00940628||136113|
NCT00940641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1140C00017|Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration|A Phase 1, Open, Two Period, Single-Centre, Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After Intravenous and 14C-labelled Oral Administration of AZD7325 to Healthy Male Volunteers||AstraZeneca|No|Suspended|August 2009|October 2009|Anticipated|October 2009|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|8|||Male|35 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 21, 2011|July 15, 2009|No|Yes|Study withdrawn prior to enrollment due to AZ business decision unrelated to safety.|No||https://clinicaltrials.gov/show/NCT00940641||136112|
NCT00940914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0730302|Dopaminergic Loss and Pain in Parkinson's Disease|Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain||University Hospital, Toulouse|No|Completed|March 2009|July 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|30 Years|70 Years|No|||March 2011|March 29, 2011|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00940914||136091|
NCT00941226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|340/07|The Quality Of Life Of Cerebral Palsy Child Carers|Evaluation of the Quality of Life of Cerebral Palsy Child Carers||Centro de Estudos Superiores de Maceio|No|Completed|October 2007|December 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|2 Years|N/A|No|Non-Probability Sample|CP child carers attended in the physiotherapy sector of a philanthropic institution on        Maceió - AL|July 2009|July 17, 2009|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941226||136067|
NCT00941239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Met-LP 1007/06|Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)|Gastric Tolerability and Pharmacokinetics of an Extended Release Metformin and an Immediate Release Metformin||Laboratorios Silanes S.A. de C.V.|Yes|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941239||136066|
NCT00950495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U/1731/0326|Oral Appliance Therapy in Obstructive Sleep Apnea|Effects of an Oral Appliance on Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial||VU University of Amsterdam|Yes|Completed|October 2003|July 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||December 2014|December 24, 2014|July 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00950495||135356|
NCT00950508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMPET-001|A Study of the Effect of Plasmaexchange in Patients With Acute Liver Failure|European Multicenter Plasma Exchange Trial (Empet): A Controlled, Open, Randomised, Multicenter Study In Patients With Acute Liver Failure||Rigshospitalet, Denmark|No|Completed|June 1998|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00950508||135355|
NCT00966485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84-2230|Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting|||Shiraz University of Medical Sciences|Yes|Completed|October 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|40 Years|67 Years|No|||August 2009|August 25, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966485||134149|
NCT00966719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/23E|Breastfeeding Support Intervention in Jaundiced Infants|The Impact of a Breastfeeding Support Intervention on Breastfeeding Duration in Jaundiced Infants Admitted to a Tertiary Care Centre: a Randomized Controlled Trial.||Children's Hospital of Eastern Ontario|No|Completed|October 2009|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|99|||Both|N/A|1 Month|No|||January 2016|January 28, 2016|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966719||134131|
NCT00967005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908M70981|N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers|N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers||Yale University|Yes|Active, not recruiting|September 2009|September 2014|Anticipated|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||March 2014|March 10, 2014|August 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967005||134110|
NCT00967265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Introduction seminar|Introduction Seminar About Patient Participation and Treatment Options for Psychiatric Patients on Waiting List|Introduction Seminar About Patient Participation and Treatment Options for Patients on Waiting List in a Community Mental Health Centre - Development, Effect, Experiences and Costs||Norwegian University of Science and Technology|No|Completed|June 2009|July 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967265||134090|
NCT00958412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPE-201 EXT|Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study|A Randomized, Double-blind Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Premenopausal Women With Symptomatic Endometriosis-extension Study||Repros Therapeutics Inc.|Yes|Terminated|February 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|48 Years|No|||June 2014|June 23, 2014|August 11, 2009|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No||https://clinicaltrials.gov/show/NCT00958412||134755|
NCT00958802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-WF-PHD-05|Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies|Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies||Taipei Medical University WanFang Hospital|No|Completed|May 2009|September 2009|Actual|August 2009|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|N/A|N/A|No|||November 2010|November 18, 2010|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958802||134726|
NCT00959101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN4440-1963|Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers|A Randomised, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Male Volunteers||Novo Nordisk A/S|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959101||134703|
NCT00967525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000113|Intraosseous Infusion of Unrelated Cord Blood Grafts|A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts||Emory University|Yes|Terminated|March 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|36 Months|60 Years|No|||November 2013|November 26, 2013|August 11, 2009||No|poor enrollment|No||https://clinicaltrials.gov/show/NCT00967525||134070|
NCT00967538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6011|Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments|Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab||Innovaderm Research Inc.|No|Completed|September 2009|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|80 Years|No|||July 2014|July 23, 2014|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967538||134069|
NCT00968409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFNP 06-1034|Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)|Labeling of Receptor Ligands and Other Compounds With Halogen Radionuclides: Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using FFNP|FFNP|Washington University School of Medicine|Yes|Completed|January 2007|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968409||134002|
NCT00959361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003164|Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy|Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy - Randomized Clinical Trial|PC-HIV|Hospital de Clinicas de Porto Alegre|No|Completed|June 2006|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||August 2009|September 28, 2009|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959361||134683|
NCT00959374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN08003|Evaluation of Dermal Closure With an Absorbable Barbed Suture as Compared to a Conventional Absorbable Suture|A Prospective, Randomized Study to Evaluate Dermal Closure With an Absorbable Barbed Suture (V-Loc 180 Absorbable Wound Closure Device or V-Loc 90 Absorbable Wound Closure Device) as Compared to a Conventional Absorbable Suture||Medtronic - MITG|No|Completed|August 2009|February 2012|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|229|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 6, 2013|August 13, 2009||No||No|August 29, 2012|https://clinicaltrials.gov/show/NCT00959374||134682|
NCT00969059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112967|Study in Neuropathic Pain Patients With Peripheral Nerve Injury|A Randomised, Double Blind Study to Evaluate the Safety and Efficacy of the p38 Kinase Inhibitor, GW856553, in Subjects With Neuropathic Pain From Peripheral Nerve Injury|PNI|GlaxoSmithKline|No|Completed|August 2009|October 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|80 Years|No|||March 2012|August 14, 2014|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00969059||133952|
NCT00965367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125/2007|Postoperative Nausea and Vomiting and Acupuncture/Acupressure|Can Acustimulation Attenuate Postoperative Nausea and Vomiting in Children Who Have Undergone Tonsillectomy/Adenoidectomy?||National Research Centre of Complementary and Alternative Medicine, Norway|No|Completed|May 2008|November 2008|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|154|||Both|2 Years|12 Years|No|||August 2009|August 24, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965367||134234|
NCT00966355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPSTOT|Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding|RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide||Korea University|No|Recruiting|September 2006|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|822|||Both|16 Years|75 Years|No|||August 2009|August 25, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966355||134159|
NCT00966368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1988|Comparison of Two NN1250 Formulations in Healthy Volunteers|A Trial to Test for Bioequivalence Between Two NN1250 Formulations in Healthy Subjects||Novo Nordisk A/S|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|August 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00966368||134158|
NCT00950300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO22227|A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Trastuzumab (Herceptin) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer|A Randomized Open-Label Study to Compare the Pharmacokinetics, Efficacy, and Safety of Subcutaneous (SC) Herceptin (Trastuzumab) With Intravenous (IV) Herceptin (Trastuzumab) Administered in Women With HER2-Positive Early Breast Cancer||Hoffmann-La Roche||Active, not recruiting|October 2009|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|596|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950300||135371|
NCT00940355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICASSO 06-009|Secondary Prevention of Problems in Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Secondary Prevention of Problems in Health Status in Patients With COPD by Early Detection, Motivational Intervention to Engage in Treatment by the Patient, and by Individualized Treatment||Radboud University|No|Completed|September 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|303|||Both|18 Years|N/A|No|||July 2009|January 19, 2010|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940355||136134|
NCT00950287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00898-47|Detection of Neonatal Bradycardia|Early Detection of Severe Apnea-bradycardia in Preterm Infants Using Algorithm Fusion|INTEM|Rennes University Hospital|No|Completed|September 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|54|||Both|N/A|33 Weeks|No|Non-Probability Sample|Preterm infants born before 33 weeks of gestational age with a post conceptional age of        less than 36 weeks.|June 2012|March 7, 2013|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950287||135372|
NCT00941252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITIC1.0|ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial|Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia|ITIC|Medical University of Vienna|Yes|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|80 Years|No|||January 2011|January 21, 2011|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941252||136065|
NCT00941512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1|High Resolution Digital Imaging of the Uterine Cervix|Investigation to Correlate High Resolution Digital Images of the Uterine Cervix With Histopathology||STI-Medical Systems|No|Completed|April 2005|December 2005|Actual|December 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|112|Samples Without DNA|Uterine Cervix tissue|Female|18 Years|N/A|No|Non-Probability Sample|Women identified with an abnormal Pap smear|July 2009|July 15, 2009|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941512||136045|
NCT00941525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83155|Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure|Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure|CCT-IOP|Aristotle University Of Thessaloniki|No|Completed|September 2009|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|174|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941525||136044|
NCT00941850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL10707|A Study of Triple-site Ventricular Pacing in Patients Who Have Not Responded to Conventional Dual Ventricular Site Cardiac Resynchronization Therapy|TRIple-site VENTricular Pacing in Non-responders to Conventional Dual Ventricular Site Cardiac Resynchronization Therapy|TRIVENT|University Hospitals, Leicester||Completed|July 2009|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941850||136019|
NCT00941863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100375|Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)|Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors||Bayer|No|Completed|July 2002|April 2008|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|158|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|June 12, 2009|Yes|Yes||No|February 3, 2010|https://clinicaltrials.gov/show/NCT00941863||136018|
NCT00946907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERICARDITE|Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin|Benign Acute Pericarditis: Brief Versus Longer Treatment. Randomized, Multicentric, Double Blind, Non Inferiority Trial|pericardite|University Hospital, Brest|Yes|Terminated|July 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|July 24, 2009||No|This study was suspended by principal investigator's decision. All the sites were not opened,    and the recruitment was so slow.|No||https://clinicaltrials.gov/show/NCT00946907||135632|
NCT00967018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS34|A Long Term Safety Study of Degarelix in Patients With Prostate Cancer|A Phase IIIb, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients With Prostate Cancer||Ferring Pharmaceuticals|No|Completed|August 2009|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Male|18 Years|N/A|No|||January 2013|January 2, 2013|August 18, 2009||No||No|November 23, 2012|https://clinicaltrials.gov/show/NCT00967018||134109|
NCT00967278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 03/07092-6|Hemodynamic Changes in Off-pump Coronary Artery Bypass Grafting|Hemodynamic Changes in Off-pump Coronary Artery Bypass Grafting||University of Sao Paulo|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Both|N/A|80 Years|No|Non-Probability Sample|Patients with coronary artery disease indicated to elective surgical treatment|August 2009|August 31, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967278||134089|
NCT00967551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007903|Micronutrient Sprinkles in a Daycare Center|The Impact of the Use of Zinc Supplementation and Other Micronutrients on the Occurence of Diarrhea Diseases and Respiratory Infections in Children of Daycare Centers||Emory University|No|Completed|July 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|143|||Both|6 Months|4 Years|Accepts Healthy Volunteers|||April 2013|April 5, 2013|August 27, 2009||No||No|January 24, 2013|https://clinicaltrials.gov/show/NCT00967551||134068|
NCT00958425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2009-252|Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty|Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty: a Phase III Double-blinded, Single-centred, Randomized Controlled Study||Nova Scotia Health Authority|Yes|Suspended|January 2014|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|August 11, 2009|Yes|Yes|Failure of funding|No||https://clinicaltrials.gov/show/NCT00958425||134754|
NCT00967902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-0427|Safety and Effectiveness Study of Combo Bio-engineered Sirolimus Eluting Stent|The REMEDEE Study: A Prospective, Randomized Study to Evaluate the Safety and Efficacy of an Abluminal Sirolimus Coated Bio-engineered Stent (Combo Bio-engineered Sirolimus Eluting Stent)|REMEDEE|OrbusNeich|Yes|Active, not recruiting|November 2009|September 2015|Anticipated|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||April 2015|April 30, 2015|August 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967902||134041|
NCT00968188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0182|Internet-based HIV/STI Prevention for Young MSM Receiving HIV Testing|A Randomized Control Trial of an Internet-based HIV/STI Prevention for Young MSM Receiving HIV Testing.|KIU|University of Illinois at Chicago|No|Enrolling by invitation|August 2009|June 2011|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Male|18 Years|24 Years|Accepts Healthy Volunteers|||August 2009|September 28, 2009|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00968188||134019|
NCT00968461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0622|Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders|A Phase I Study of Phenethyl Isothiocyanate (PEITC) in Patients With Lymphoproliferative Disorders Previously Treated With Fludarabine||M.D. Anderson Cancer Center|No|Withdrawn|May 2013|||May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|August 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00968461||133998|
NCT00968175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090528002|Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer|EUS Guided-Celiac Plexus Neurolysis (CPN) for Patients With Unresectable Pancreatic Cancer: A Multi-Center, Randomized, Single-Blinded Controlled Trial||University of Alabama at Birmingham|No|Completed|June 2009|December 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|60|||Both|19 Years|N/A|No|||May 2014|June 2, 2014|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00968175||134020|
NCT00968760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0635|Autologous CD19-specific T Cells Infusion|CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Autologous Hematopoietic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2011|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|75 Years|No|||September 2015|September 14, 2015|August 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00968760||133975|
NCT00968773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rebound HRD|Rebound Hernia Repair Device Mesh Trial|Rebound Hernia Repair Device Trial||Minnesota Medical Development, Inc.|Yes|Active, not recruiting|September 2009|September 2013|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2009|March 14, 2016|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968773||133974|
NCT00969072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI30016|Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia|A Long-term Extension Study of GI198745 in Subjects With Benign Prostatic Hyperplasia||GlaxoSmithKline|No|Completed|August 2003|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|121|||Male|50 Years|N/A|No|||September 2010|September 9, 2010|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00969072||133951|
NCT00969085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0838|Trial of Curcumin in Cutaneous T-cell Lymphoma Patients|Phase II Trial of Curcumin in Cutaneous T-cell Lymphoma Patients||M.D. Anderson Cancer Center|No|Withdrawn|November 2012|||November 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||September 2012|September 5, 2012|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969085||133950|
NCT00965718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILC-IIT-01|Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer|Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Activated T-lymphocyte ("Immuncell-LC") Cell Therapy in Gemcitabine Refractory Advanced Pancreatic Cancer||Green Cross Cell Corporation|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||September 2014|September 16, 2014|August 24, 2009||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT00965718||134208|
NCT00965731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081002|Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer|Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.||Pfizer|No|Completed|January 2010|January 2014|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|August 24, 2009|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT00965731||134207|The sponsor terminated phase 2 of this study; no data was collected during phase 2, leading to phase 2 outcomes not analyzed. The decision was based on strategic considerations regarding the clinical program only; there were no safety concerns.
NCT00966875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12061|A Study in Patients With Rheumatoid Arthritis|A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy||Eli Lilly and Company|No|Completed|August 2009|June 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Anticipated|429|||Both|18 Years|75 Years|No|||June 2012|June 22, 2012|August 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00966875||134120|
NCT00941603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05675|Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Subjects With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)|A Phase 2 Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of SCH 900271 Compared to Placebo in Subjects With Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia||Merck Sharp & Dohme Corp.|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|619|||Both|18 Years|75 Years|No|||February 2015|February 24, 2015|July 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00941603||136038|
NCT00941902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0022-09 ZIV|A Potential Novel Marker for Liver Fibrosis in NASH: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor|A Potential Novel Marker for Liver Fibrosis in Nonalcoholic Steatohepatitis: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor Non-interventional Study.||Ziv Hospital|Yes|Completed|May 2009|February 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|148|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients who are scheduled to bariatric surgery will be enrolled.|May 2011|May 16, 2011|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941902||136015|
NCT00949988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 110054 - Prev 080422|A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia|A Phase I/II Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia|BMS-CA180105|University of California, San Diego|Yes|Active, not recruiting|May 2009|||June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||September 2010|May 2, 2011|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949988||135395|
NCT00951119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reperate3|Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients|The Effect of Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients With Hypertension (Resperate-3) A Randomized, Double-blind Controlled Trial|Reperate3|Medical Research Foundation, The Netherlands|No|Completed|September 2009|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00951119||135308|
NCT00940940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKUA-001|Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation|Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations||University of Alberta|No|Active, not recruiting|October 2009|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940940||136089|
NCT00940953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX313CT001|Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study Comparing Relative Efficacy of CE Budesonide+Azelastine & Rhinocort Aqua+Astelin Nasal Sprays Against Placebo in the Treatment of AR in an EEC Model||Ligand Pharmaceuticals|No|Completed|February 2008|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|65 Years|No|||October 2012|October 2, 2012|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940953||136088|
NCT00941265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 05-159 (NAC 05.051)|Effect of Dopaminergic Medication on Recovery of Aphasia|Effect of Dopaminergic Medication on Recovery of Aphasia||University Hospital, Geneva|Yes|Completed|February 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|25 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941265||136064|
NCT00950261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCCH GY 1002|Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients|Phase II Clinical Trial for Adjuvant Concurrent Chemoradiation Therapy in Post-operative Cervical Cancer Patients||Korea Cancer Center Hospital|No|Recruiting|January 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|N/A|N/A|No|||May 2014|May 7, 2014|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950261||135374|
NCT00950274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERFECT 001|Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery|Intramyocardial Transplantation of Bone Marrow Stem Cells for Improvement of Post-infarct Myocardial Regeneration in Addition to CABG Surgery: a Controlled, Prospective, Randomized, Double Blinded Multicenter Trial (PERFECT)|PERFECT|Miltenyi Biotec GmbH|Yes|Terminated|July 2009|October 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|79 Years|No|||March 2016|March 14, 2016|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950274||135373|
NCT00948090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273-08-201|PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients|A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|January 2010|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|207|||Both|18 Years|65 Years|No|||July 2014|July 1, 2014|July 28, 2009|No|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT00948090||135541|
NCT00948103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050701|The Interest of the Nitrous Oxide During Intravesical Injection of Botulinum Toxin A|Nitrous Oxide (KALINOX®) Inhalation and Tolerance of Intravesical Botulinum Neurotoxin A Injection: a Double-blind Randomized Controlled Study|PROTOTOX|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948103||135540|
NCT00939224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP1542|Study of Non-Invasive Regional Oxygen Saturations in Pediatric Patients Undergoing Cardiac Catheterization|Calibration and Validation of the a Non-Invasive Regional Oxygen Saturation Device in Neonates, Infants and Children Undergoing Cardiac Catheterization||Nonin Medical, Inc|No|Completed|July 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|N/A|12 Years|No|Non-Probability Sample|Patients with cardiovascular disease (acquired or congenital; cyanotic or acyanotic;        unrepaired, palliated or fully repaired) requiring cardiac catheterization to diagnose or        treat the disease will be eligible for study.|August 2011|August 23, 2011|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00939224||136220|
NCT00957840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36114|Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome|Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome||University of Utah|No|Completed|July 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|N/A|1 Year|No|||May 2015|May 5, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957840||134799|
NCT00958139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804M3101|Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes|Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|June 2008|October 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|61|||Both|14 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|August 12, 2009||No|After year 1, there was insufficient statistical power to detect a difference in the primary    outcome measure during planned study period.|No||https://clinicaltrials.gov/show/NCT00958139||134776|
NCT00958152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-222-002|Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential-group, Multiple-dose, Drug-drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects||Vertex Pharmaceuticals Incorporated|Yes|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 6, 2010|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00958152||134775|
NCT00967915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.0077|Efficacy of Neonatal Release of Ankyloglossia|Efficacy of Neonatal Release of Ankyloglossia||United States Naval Medical Center, Portsmouth|Yes|Completed|November 2007|||July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|58|||Both|N/A|14 Days|Accepts Healthy Volunteers|||August 2009|August 27, 2009|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967915||134040|
NCT00967928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATDTCC0801|Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer|Phase I Everolimus Dose Finding Study for the Treatment of Stage IV or Recurrent, Non-resectable, Cervical Cancer With Standard Whole Pelvic Radiation Therapy in Combination With Weekly Cisplatin and Daily Everolimus||Accelerated Community Oncology Research Network|No|Withdrawn|December 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2014|February 13, 2014|August 27, 2009|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT00967928||134039|
NCT00968474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00033|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2009|||||N/A|N/A|N/A||||||||||||||August 28, 2009|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968474||133997|
NCT00968786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTDM 01|Home Monitoring in the Management of Hypertension and Diabetes Mellitus|A Trial of the Use of Multiple Automated Measuring Devices in the Management of Patients With Hypertension and Type 2 Diabetes Mellitus||Shanghai Jiao Tong University School of Medicine|Yes|Enrolling by invitation|August 2008|September 2009|Anticipated|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|70 Years|No|||August 2009|August 28, 2009|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968786||133973|
NCT00959114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV003-0921|Safety and Efficacy of ALV003 for the Treatment of Celiac Disease|A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With ALV003 In Patients With Well-Controlled Celiac Disease||Alvine Pharmaceuticals Inc.|No|Completed|August 2009|October 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|75 Years|No|||July 2012|July 30, 2012|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959114||134702|
NCT00969384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3,3 270809|Physical Health of Residents in Psychiatric Institutions|Physical Health of Residents in Psychiatric Institutions||Aarhus University Hospital||Active, not recruiting|February 2009|||August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 31, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969384||133927|
NCT00965016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSEIRB0980106|Induced Hypothermia in Cardiac Arrest Patients Rescued by Extracorporeal Cardiopulmonary Resuscitation.|The Therapeutic Effect of Induced Hypothermia in Cardiac Arrest Patients Rescued by Extracorporeal Cardiopulmonary Resuscitation (ECPR).||Min-Sheng General Hospital|No|Recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|16 Years|N/A|No|||August 2009|August 23, 2009|August 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00965016||134260|
NCT00965744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCZH-0908-016|A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension|||Shanghai Changzheng Hospital|Yes|Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||August 2009|August 26, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965744||134206|
NCT00965757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T614-ADN|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate||Eisai Inc.||Completed|July 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|20 Years|69 Years|No|||November 2015|November 19, 2015|August 25, 2009||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT00965757||134205|
NCT00966628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/IGK-KAL/08|Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)|The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients||Innogene Kalbiotech Pte. Ltd|No|Active, not recruiting|May 2008|December 2009|Anticipated|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|2 Years|14 Years|No|||August 2009|August 27, 2009|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966628||134138|
NCT00941915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018266|Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer|A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Continuous Real-time Evaluation of Prostate Motion and IMRT Plan Reoptimization Based on the Anatomy of the Day|SMART|Duke University|No|Active, not recruiting|November 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|40 Years|82 Years|No|||December 2015|December 7, 2015|July 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00941915||136014|
NCT00950547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-02|ICU Cell Saver to Reduce Blood Transfusions in Cardiac|Routinely Use of CardioPAT Cell Saver in Cardiac Surgery: A Prospective Randomized Study Focused on Allogenic Blood Transfusion and Clinical Outcome||Cardiochirurgia E.H.|Yes|Completed|August 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Both|N/A|N/A|No|||January 2010|January 4, 2010|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950547||135352|
NCT00950560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WanFangH98043|An Empirical Study of Perceived Hospital Service Quality: A Comparison of Inpatient, Outpatient and Emergence Patient|An Empirical Study of Perceived Hospital Service Quality: A Comparison of Inpatient, Outpatient and Emergence Patient||Taipei Medical University WanFang Hospital|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|2|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|100 inpatient 100 outpatient 100 emergency patient|April 2011|April 22, 2011|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950560||135351|
NCT00937768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0852|Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy|Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy||Mayo Clinic|No|Terminated|July 2009|July 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|N/A|No|||October 2015|December 11, 2015|July 9, 2009|Yes|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00937768||136332|
NCT00950521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-96-IRB-145|Efficacy Study of CD34 Stem Cell in Chronic Stroke Patients|Phase II Study of Autologous Peripheral Blood CD34 Stem Cell Implantation in Chronic Stroke Patients||China Medical University Hospital|Yes|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|70 Years|No|||April 2011|April 20, 2011|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950521||135354|
NCT00950534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04264|Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care|A Randomised, Multicentre, Open-Label, Parallel-Group, 24-Week Phase IV Study Comparing the Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care: General Practitioner Initiation of Insulin Glargine Versus the Usual Standard of Care|RELIANCE|Sanofi||Terminated|July 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||November 2011|November 9, 2011|July 30, 2009||No|due to poor recruitment|No||https://clinicaltrials.gov/show/NCT00950534||135353|
NCT00950807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113073|GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects With COPD||GlaxoSmithKline|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|176|||Both|40 Years|80 Years|No|||January 2014|January 16, 2014|July 30, 2009|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT00950807||135332|
NCT00951106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR #719|Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon|Therapeutic Efficacy Study of Pyrimethamine / Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon||Walter Reed Army Institute of Research (WRAIR)|No|Completed|January 1998|August 2009|Actual|June 1999|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|6 Months|N/A|No|||July 2010|July 26, 2010|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00951106||135309|
NCT00967291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642574|Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer|Mitomycin and Ifosfamide (MI) as Salvage Therapy for Metastatic Pancreatic Adenocarcinoma: a Phase II Study.|PACT-11|IRCCS San Raffaele|No|Terminated|March 2006|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||August 2009|January 31, 2012|August 26, 2009||No|lack of activity and G3-4 toxicity at interim analysis|No||https://clinicaltrials.gov/show/NCT00967291||134088|
NCT00967564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013075|Survey on QUality of Life In myeloDisplasia (SQUID)|QUALITY OF LIFE ASSESSMENT IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME||Janssen-Cilag S.p.A.||Completed|March 2007|November 2009|Actual|November 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|18 Years|N/A|No|Probability Sample|outpatients|April 2014|April 24, 2014|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967564||134067|
NCT00968201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-072|Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )|A Multicenter, Double-Blind, Randomized, Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients||Merck Sharp & Dohme Corp.|No|Completed|December 1997|March 2001|Actual|March 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|689|||Both|2 Years|5 Years|No|||April 2015|April 23, 2015|August 27, 2009|Yes|Yes||No|September 15, 2009|https://clinicaltrials.gov/show/NCT00968201||134018|
NCT00968448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sportmed-Saarland-8/2009|Inspiratory Muscle Training (IMT) in Athletes|Inspiratory Muscle Training (IMT) in Athletes||Saarland University|No|Completed|August 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|January 4, 2011|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968448||133999|
NCT00969124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avantis TER 08-07|Impact of Experience on Results With the Third Eye Retroscope|Impact of Experience With the Third Eye Retroscope on Detection Rates and Withdrawal Times During Colonoscopy||Avantis Medical Systems|No|Completed|January 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|328|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 22, 2013|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969124||133947|
NCT00968422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-506|A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects|||Abbott||Completed|August 2009|||January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|28|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2010|November 1, 2010|August 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00968422||134001|
NCT00968435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-083|Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma|Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2009|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968435||134000|
NCT00965029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101/09|Spirometry in Mechanically Ventilated Chronic Obstructive Pulmonary Disease (COPD) Patients|Spirometry in Mechanically Ventilated COPD Patients: Correlation of Lung Function Tests to Successful Weaning From Mechanical Ventilation||Assaf-Harofeh Medical Center|No|Not yet recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|COPD patients with respiratory failure due to COPD exacerbation, and on mechanical        ventilation|August 2009|April 4, 2011|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965029||134259|
NCT00965380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01006B|Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)|A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells (Trinity Evolution™ Viable Cryopreserved Cellular Bone Matrix) in Posterior Lumbar or Transforaminal Lumbar Interbody Fusion (PLIF or TLIF)|TLF|Orthofix Inc.|No|Active, not recruiting|September 2009|November 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic lumbar degenerative disc disease scheduled to undergo PLIF or        TLIF.|April 2014|April 7, 2014|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00965380||134233|
NCT00966914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS32212R|Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin|Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin||BioNumerik Pharmaceuticals, Inc.|Yes|Completed|April 2010|June 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|540|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00966914||134117|
NCT00941928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0160|Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)|Adoptive Transfer of Haploidentical NK Cells in Combination With Epratuzumab for the Treatment of Relapsed Acute Lymphoblastic Leukemia||M.D. Anderson Cancer Center|No|Terminated|July 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||May 2014|May 19, 2014|July 16, 2009|Yes|Yes|Slow accrual|No|May 22, 2013|https://clinicaltrials.gov/show/NCT00941928||136013|
NCT00937547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERVICAL CANCER AND HPV|Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela|Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma.|HPI|Instituto Oncologico Luis Razetti|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|329|Samples With DNA|4.1. Collection of cervical samples:      1. Previous ethics committe approval (Instituto Venezolano de Investigaciones Cientificas      and Instituto de Oncología Luis Razetti), we are going to collect paraffin bloks of 300      patients with hystologic diagnosis of CIN 2/3 or Stage I cervical cancer.      The samples will be obtained from archives of the Pathology Units of the following medical      centers in Venezuela: Instituto de Oncología Luis Razetti, Anatomía Patológica Universidad      Central de Venezuela, Hospital Oncológico Pérez Carreño (Valencia), Maracaibo, Barquisimeto,      Ciudad Bolívar, Puerto La Cruz, Mérida and Barinas.|Female|N/A|N/A|No|Probability Sample|cervical samples|November 2012|November 30, 2012|July 10, 2009||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00937547||136349|
NCT00942149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019311|An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants|An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants||Duke University|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|120 Days|No|||June 2013|July 1, 2013|July 2, 2009|No|Yes||No|October 18, 2012|https://clinicaltrials.gov/show/NCT00942149||135996|
NCT00942162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111476|A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma|GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma|PREDICT|GlaxoSmithKline||Completed|August 2009|April 2015|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942162||135995|
NCT00937781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000631851|Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690|Molecular Prognostic Factor Analysis in Melanoma||National Cancer Institute (NCI)||Not yet recruiting|August 2008|||August 2010|Anticipated|N/A|Observational|N/A|||Anticipated|307|||Both|18 Years|70 Years|No|||July 2009|July 10, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937781||136331|
NCT00946920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS35|A Trial of Degarelix in Patients With Prostate Cancer|An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen With Goserelin Acetate in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy||Ferring Pharmaceuticals|Yes|Completed|June 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|859|||Male|18 Years|N/A|No|||May 2014|May 2, 2014|July 3, 2009|Yes|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT00946920||135631|
NCT00947219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.12 2009-M-02|Treatment of Androgenic Alopecia in Males|A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 9 & 12 Beam Models: For the Treatment of Androgenetic Alopecia in Males||Lexington International, LLC|Yes|Completed|July 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|79|||Male|25 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|July 27, 2009|Yes|Yes||No|January 6, 2011|https://clinicaltrials.gov/show/NCT00947219||135608|
NCT00947466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1501|A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain|A Multi Centre Open Label Single Therapy Dose Ranging Study to Characterise the Pharmacokinetics & Tolerability of BTDS 5-20 ug/h in Children Who Require Opioid Analgesia for Moderate to Severe Mouth Pain Secondary to Chemotherapy Induced Mucositis.|BUP1501|Mundipharma Research Limited|Yes|Terminated|February 2010|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|2 Years|16 Years|No|||September 2015|September 25, 2015|July 8, 2009||No|25 patients have been recruited and it was considered that further recruitment would add no    extra PK information|No||https://clinicaltrials.gov/show/NCT00947466||135589|
NCT00947778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-05|Analysis of Language and Auditory Abilities in Cochlear Implanted Children|Analysis of Language and Auditory Abilities in Cochlear Implanted Children: Assessment by an Auditory Learning Programmed Method||Assistance Publique Hopitaux De Marseille|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|22|||Both|4 Years|10 Years|No|||February 2014|February 24, 2014|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00947778||135565|
NCT00938600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU-1819|Antenatal Vitamin D3 Dose-finding and Safety Study|Antenatal Vitamin D Supplementation to Improve Neonatal Health Outcomes in Dhaka, Bangladesh: Preliminary Dose-finding and Safety Study|AViDD-1|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|July 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|75|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|July 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938600||136268|
NCT00938613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX947CT001|Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Compare the Relative Efficacy of Budesonide Administered Via CE Budesonide Nasal Solution & Rhinocort Aqua in the Treatment of the Symptoms of AR in an EEC Model||Ligand Pharmaceuticals|No|Completed|February 2007|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|65 Years|No|||October 2012|October 2, 2012|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938613||136267|
NCT00940186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMM-DMPK-080901|Clinical Pharmacokinetics Study on Pikamilone|Clinical Pharmacokinetics Study on Pikamilone||Chinese Academy of Sciences|Yes|Completed|March 2009|April 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|plasma|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|15 male subjects and 15 female subjects were enrolled in this study. They were divided        into three groups by random and each group contained 5 male and 5 female subjects.|July 2009|July 14, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940186||136147|
NCT00967577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902010212|177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors|177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study||Weill Medical College of Cornell University|Yes|Recruiting|July 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|August 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00967577||134066|
NCT00967941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-11-1879|Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis|Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis||CAMC Health System|No|Completed|August 2007|August 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|201|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2009|July 31, 2012|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00967941||134038|
NCT00968799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGOV01|Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study|Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study||Cantonal Hospital of St. Gallen|Yes|Terminated|February 2008|December 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|70 Years|No|||May 2013|May 13, 2013|February 12, 2008||No|poor patient accrual|No|March 26, 2013|https://clinicaltrials.gov/show/NCT00968799||133972|
NCT00969137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905005103|Sensitivity to Intravenous Nicotine: Genetic Moderators|Sensitivity to Intravenous Nicotine: Genetic Moderators||Yale University|Yes|Recruiting|June 2009|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969137||133946|
NCT00969098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-02/2009|Response Evaluation in Malignant Pleural Mesothelioma|Early Response Evaluation in Malignant Pleural Mesothelioma By Total Glycolytic Volume (TGV) Analysis of Serial FDG-PET Scans (Positron Emission Tomography Scans)||Istituto Clinico Humanitas|No|Active, not recruiting|June 2009|September 2015|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Histologically proven MALIGNANT PLEURAL MESOTHELIOMA and Patients not candidate to radical        surgery|August 2015|August 5, 2015|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00969098||133949|
NCT00969111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0902-PR06|Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy|Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy|PR06|University of Florida|Yes|Recruiting|August 2009|August 2050|Anticipated|August 2031|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|70|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969111||133948|
NCT00965042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016306|Effect of Ceftobiprole on Human Intestinal Microflora|Effect of Ceftobiprole on the Intestinal Human Microflora Following Multiple-dose Administration in Healthy Female and Male Subjects||Basilea Pharmaceutica|No|Completed|April 2009|June 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 27, 2012|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00965042||134258|
NCT00965393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP 5|The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway|The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway||University of Edinburgh|No|Completed|August 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00965393||134232|
NCT00965406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIKI2|Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone|Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone in the Early Management of Acute Coronary Syndrome: Randomised Controlled Study||University of Monastir|No|Completed|August 2010|June 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|772|||Both|18 Years|N/A|No|||November 2014|December 1, 2014|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965406||134231|
NCT00965419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11332|A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder|Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder||Eli Lilly and Company|No|Terminated|August 2014|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|266|||Both|6 Years|18 Years|No|||September 2015|September 3, 2015|August 24, 2009|Yes|Yes|Terminated due to low 5 year completer number and not meeting primary objective.|No||https://clinicaltrials.gov/show/NCT00965419||134230|
NCT00966043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract 2009-010059-28.|Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes|Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes, in Postmenopausal ER-positive Breast Cancer Patients According to Uterine and Biochemical Changes and Tolerability of Tamoxifen.|CYPTAMBRUT-3|Vlaamse Vereniging voor Obstetrie en Gynaecologie|Yes|Completed|June 2009|July 2011|Actual|July 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|||Female|18 Years|N/A|No|Non-Probability Sample|Postmenopausal female breast cancer patients starting adjuvant tamoxifen therapy.|October 2015|October 27, 2015|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966043||134183|
NCT00966056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01_M012_3210|Study of Mitomycin C and Nasal Splint to Treat Nasal Synechiae|Comparative Study of Mitomycin C and Internal Nasal Septal Splint in the Treatment of Nasal Synechiae||Karnataka Institute of Medical Sciences|Yes|Completed|October 2007|September 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2009|July 7, 2011|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966056||134182|
NCT00967772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLV100|The Safety/Tolerability and Pharmacokinetics (PKs) of Naftopidil in Korean Healthy Male Volunteers|A Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics of Naftopidil After Oral Administration in Korean Healthy Male Volunteers||Dong-A ST Co., Ltd.|No|Completed|September 2009|March 2010|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967772||134051|
NCT00967785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090200|A Phase I Study of Mozobil in the Treatment of Patients With WHIMS|A Phase I Study of Mozobil (TM) in the Treatment of Patients With WHIMS||National Institutes of Health Clinical Center (CC)||Recruiting|July 2009|December 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||February 2016|March 15, 2016|August 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00967785||134050|
NCT00967798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012724|Prevention of Cystic Fibrosis Diabetes|A Randomized, Double-blind, Placebo-controlled Study to Determine Whether Chronic Treatment of Cystic Fibrosis Subjects With Impaired Glucose Tolerance Using Sitagliptin (Januvia) Prevents the Development of Diabetes|Prevent|Emory University|Yes|Recruiting|May 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|118|||Both|13 Years|N/A|No|||October 2015|October 22, 2015|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967798||134049|
NCT00942175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR_101|A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.|A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects||Takeda|No|Completed|December 2009|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|160|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 1, 2012|July 16, 2009|No|Yes||No|May 31, 2011|https://clinicaltrials.gov/show/NCT00942175||135994|
NCT00942188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13286|A Study of LY2189102 in Patients With Type 2 Diabetes|Phase 2 Randomized, Double-blind, Placebo Controlled, Parallel Design Study in Patients With Type 2 Diabetes Mellitus Who Are Stable on Diet and Exercise, With or Without Metformin Monotherapy.||Eli Lilly and Company|No|Completed|June 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|109|||Both|20 Years|75 Years|No|||December 2010|April 5, 2011|July 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00942188||135993|
NCT00938626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000646891|Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma|Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).||Barbara Ann Karmanos Cancer Institute|Yes|Completed|October 2009|March 2013|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|July 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938626||136266|
NCT00938015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A-101698|Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis|A Post-Marketing Surveillance For Safety And Adherence To Treatment Of Enbrel In Adults With Psoriatic Arthritis In Belgium|PROVE|Pfizer|No|Completed|October 2004|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|303|||Both|18 Years|N/A|No|Non-Probability Sample|rheumatology centers|March 2013|March 27, 2013|July 10, 2009||No||No|March 27, 2013|https://clinicaltrials.gov/show/NCT00938015||136313|
NCT00938028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p-000636|Metabolome and Microbiomic in Fecal Samples|Fecal Samples for Metabolomic and Microbiomic Studies: Effects of Preparation and Storage|MicroMet|Massachusetts General Hospital|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4|None Retained|Stool samples|Both|12 Months|20 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy toddlers in a day care center|July 2009|July 17, 2009|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00938028||136312|
NCT00938301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1071001|A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers|A Phase 1, Placebo-Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects||Pfizer|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 15, 2009|July 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938301||136291|
NCT00938314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTx®-265-CP-202-IS|Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)|REGENESIS-LED|Stem Cell Therapeutics Corp.|Yes|Terminated|August 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|96|||Both|18 Years|85 Years|No|||November 2011|November 24, 2011|July 9, 2009|Yes|Yes|Slow Enrollment|No|September 1, 2011|https://clinicaltrials.gov/show/NCT00938314||136290|The trial was terminated after 96 of a planned 128 patients were enrolled, thus limiting opportunities to demonstrate a clear statistical benefit of active therapy compared to placebo.
NCT00938912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP848|An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy|An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy||UCB Pharma|No|Enrolling by invitation|December 2009|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|192|||Both|1 Month|17 Years|No|||March 2016|March 18, 2016|July 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938912||136244|
NCT00939211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1882C00003|The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease|A Double-blind, Double-dummy, Placebo-controlled, Randomised, Multi-centre, 5-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of Inhaled AZD9164 Compared to Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|LaCrossE|AstraZeneca|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|25|||Both|40 Years|N/A|No|||July 2011|July 8, 2011|July 13, 2009||No||No|July 8, 2011|https://clinicaltrials.gov/show/NCT00939211||136221|
NCT00940446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAF_PC000001|A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement|A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement||Orthopaedic Research Foundation|Yes|Completed|July 2007|July 2009|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 8, 2012|July 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940446||136127|
NCT00968214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBCI-MA.27A|Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27|A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.||Alliance for Clinical Trials in Oncology||Withdrawn|September 2008|||September 2012|Anticipated|N/A|Observational|N/A|||Actual|0|||Female|45 Years|N/A|No|||July 2013|July 11, 2013|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00968214||134017|
NCT00968487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-I-LyP-1|The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers|A Clinical Study of the Safety of Ascending Doses of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Normal Healthy Volunteers||HemCon Medical Technologies, Inc|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|August 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968487||133996|
NCT00968500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-107|Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer|Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bereaved parents will be identified through death records kept by the Department of        Pediatrics and cross-referenced with the deceased child's MSK medical record.|August 2015|August 14, 2015|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968500||133995|
NCT00968812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016480|CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride|A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy||Janssen Research & Development, LLC|Yes|Completed|September 2009|January 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1452|||Both|18 Years|80 Years|No|||April 2014|April 3, 2014|August 28, 2009|Yes|Yes||No|April 17, 2013|https://clinicaltrials.gov/show/NCT00968812||133971|No notable study limitations were identified by the Sponsor.
NCT00965055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090948|Ezetimibe in Patients Hypo-responsive to Statins|Atorvastatin vs. Atorvastatin/Ezetimibe in Patients With Hypo-response to Initial Dose Statin Therapy||University of California, San Diego|Yes|Terminated|September 2009|September 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|80 Years|No|||January 2013|January 25, 2013|August 24, 2009||No|The study was terminated due to inability to recruit subjects. A total of 2/100 anticipated    were radomized.|No||https://clinicaltrials.gov/show/NCT00965055||134257|
NCT00965068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090203|Cholesterol in ASD: Characterization and Treatment|Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment||National Institutes of Health Clinical Center (CC)||Completed|July 2009|November 2013|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|44|||Both|4 Years|12 Years|No|||June 2015|June 9, 2015|August 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00965068||134256|
NCT00964717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126/08|Chiropractic for Back and Neck Pain in an Emergency Department Setting|Efficacy of an Integrative Approach Utilizing Chiropractic as an Add On Therapy for the Treatment Back and Neck Pain in an Emergency Department Setting - A Comparative Randomized Controlled Trial|CBNP|Assaf-Harofeh Medical Center|Yes|Completed|May 2009|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|60 Years|No|||January 2012|January 27, 2012|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964717||134281|
NCT00964730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAL-TQT-101|A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm|A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers||Teva Pharmaceutical Industries|No|Completed|October 2009|February 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|135|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2010|April 6, 2010|August 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00964730||134280|
NCT00965770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01871|Post Abortion IUD & Recurrent Abortion 2001-2004|Preventing Repeat Abortion: Is the Immediate Insertion of Intrauterine Devices Post-abortion a Cost-effective Option Associated With Fewer Repeat Abortions? Findings From 2001-2004 Data||University of British Columbia|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1101|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female resident of Interior Health region seeking an abortion|June 2012|June 27, 2012|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965770||134204|
NCT00965783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#15207A|Predictors of the Metabolic Effect of Sleep Loss|Predictors of the Metabolic Effect of Sleep Loss|SDBO|University of Chicago|No|Completed|June 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965783||134203|
NCT00965796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IO-Lido|Intraoperative Intravenous Lidocaine|Effect of Intraoperative Intravenous Lidocaine on Pain After Hysterectomy||Federal University of São Paulo|No|Completed|May 2008|December 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|60 Years|No|||August 2009|August 25, 2009|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965796||134202|
NCT00966069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/09/QRCH/42|A Comparison of Respiratory Sample Collection by a Parent or by a Healthcare Worker|ReSPeCT: An Unblinded, Randomised, Controlled Trial to Compare Respiratory Sample Collection by a Parent or by a Healthcare Worker at a Home Visit|ReSPeCT|Queensland Children's Medical Research Institute|No|Completed|August 2009|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|64|||Both|N/A|2 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966069||134181|
NCT00938054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090171|Identification of Characteristics Associated With Symptom Remission in Autism|Characterization of Autism Spectrum Disorder in School Aged Children||National Institutes of Health Clinical Center (CC)||Completed|June 2009|October 2012||||N/A|Observational|N/A|||Actual|37|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||October 2012|November 27, 2013|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938054||136310|
NCT00938067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35970-C|Staying Connected: Trauma Center to Tribal Community Linkage for Physically Injured American Indian Patients|American Indian and Alaska Native Health Disparities Staying Connected: Trauma Center to Tribal Community Linkage for Physically Injured American Indian Patients||University of Washington|No|Completed|June 2009|December 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00938067||136309|
NCT00938080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG013-ODOM-101|Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck|A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck||ActoGeniX N.V.|Yes|Completed|September 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|6||Actual|25|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|July 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938080||136308|
NCT00937794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-HIT-050|Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®|A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®||Shire|No|Completed|July 2009|August 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Male|32 Months|18 Years|No|Non-Probability Sample|Initial patient eligibility will be based on patient age and gender. Patients must be        receiving weekly IV Elaprase infusions to be eligible for enrollment.|March 2014|March 6, 2014|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937794||136330|
NCT00938041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/010|Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody|Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody||GlaxoSmithKline||Completed|April 1998|June 2013|Actual|May 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2013|February 27, 2014|July 9, 2009|Yes|Yes||No|February 27, 2014|https://clinicaltrials.gov/show/NCT00938041||136311|
NCT00938327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112896|Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants|Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered According to the Prescribing Information to Indian Infants||GlaxoSmithKline||Completed|August 2009|April 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|332|||Both|6 Weeks|167 Days|Accepts Healthy Volunteers|Probability Sample|subjects from the age of 6 weeks at the time of the first Rotarix™ vaccination and less        than 24 weeks of age at the time of second Rotarix™ vaccination|February 2016|February 18, 2016|July 9, 2009|Yes|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00938327||136289|
NCT00939627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02847|Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab|Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||National Cancer Institute (NCI)||Completed|July 2009|January 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||December 2013|August 3, 2015|July 14, 2009|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00939627||136190|
NCT00939640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00025253|Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure|Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet on Ventriculovascular Function in Heart Failure With Preserved Systolic Function|DASH-DHF|University of Michigan|No|Recruiting|July 2009|March 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|N/A|No|||September 2010|September 7, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939640||136189|
NCT00939653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2007-002|T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)|T2007-002 A Phase II Study of Clofarabine With Etoposide and Cyclophosphamide in Relapsed/Refractory AML (IND 104,650)||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|July 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|1 Year|21 Years|No|||March 2012|March 7, 2012|July 13, 2009|No|Yes|Study lost funding and it was decided that it could not meet it's accrual goals.|No||https://clinicaltrials.gov/show/NCT00939653||136188|
NCT00939666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-034|Minimal Invasive Strategies for Good and Complete Response to Chemoradiation in Rectal Cancer|Minimal Invasive Treatment for Patients With Good Response to Chemoradiation With Selection and Follow-up by MRI: a Single Arm Phase-II Feasibility Study in Rectal Cancer||Maastricht University Medical Center|Yes|Recruiting|July 2009|||December 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939666||136187|
NCT00967980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Femoral vs. Psoas PNB Cath Hip|Femoral Versus Psoas Continuous Peripheral Nerve Blocks Following Hip Arthroplasty|Femoral Versus Psoas Continuous Peripheral Nerve Blocks Following Hip Arthroplasty||University of California, San Diego|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2010|September 23, 2010|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00967980||134035|
NCT00968227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0733|Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage|Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage||Washington University School of Medicine|No|Completed|November 2007|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00968227||134016|
NCT00968513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH083684|Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry|Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry||Stanford University|Yes|Active, not recruiting|September 2009|November 2015|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|956|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968513||133994|
NCT00968526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113459|Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above||GlaxoSmithKline||Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 1, 2011|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968526||133993|
NCT00968539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113456|Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years||GlaxoSmithKline||Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968539||133992|
NCT00968552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stents/ERCP|Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents|Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents||University of Florida|No|Recruiting|August 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Age 18 or older|March 2016|March 9, 2016|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968552||133991|
NCT00964769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-KF-05092341|Study of Evaluation Indexes for Antibody Production in Sera After Immunization|A Study of Evaluation Indexes for Antibody Production in Sera After Immunization||Ewha Womans University|Yes|Completed|April 2005|June 2005|Actual|May 2005|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|70|||Both|2 Years|90 Years|Accepts Healthy Volunteers|||August 2009|August 24, 2009|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964769||134277|
NCT00964782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31171|The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation|The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation||Penn State University|Yes|Recruiting|August 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|August 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00964782||134276|
NCT00964795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-0910|Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)|An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration||Regeneron Pharmaceuticals|No|Completed|December 2009|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|323|||Both|50 Years|N/A|No|||March 2015|March 10, 2015|August 20, 2009|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT00964795||134275|
NCT00965458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN045AI|Inducing Remission in Type 1 Diabetes With Alefacept|Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)|T1DAL|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|March 2011|April 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|12 Years|35 Years|No|||October 2015|October 29, 2015|August 22, 2009|Yes|Yes|Manufacturer discontinued production of Amevive®: business decision.|No|December 19, 2014|https://clinicaltrials.gov/show/NCT00965458||134227|Enrollment ended early with 49 subjects (instead of the planned 66) as a result of the decision, unrelated to safety reasons, made by Astellas Pharma US, Inc. to discontinue manufacturing Amevive® (alefacept).
NCT00964743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15783|Depocyt® With Sorafenib in Neoplastic Meningitis|A Single Arm Pilot Study of Intrathecally Administered DepoCyt® With Systemic Sorafenib in the Treatment of Neoplastic Meningitis From Solid Tumors||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|August 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2012|September 4, 2013|August 24, 2009|Yes|Yes|Low Accrual|No|January 19, 2012|https://clinicaltrials.gov/show/NCT00964743||134279|The study closed early due to low accrual of 2 of 10 expected patients. Neither patient completed 8 weeks of treatment as outlined in the protocol. Both patients expired before reaching the 6 month Progression Free Survival endpoint.
NCT00964756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080807013 (UAB 0821)|A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers|A Phase I Study of AD5.SSTR/TK.RGD; A Tropism Modified Adenovirus Vector for Intraperitoneal Delivery of Therapeutic Genes and Additional Capability of Noninvasive Imaging of Gene Transfer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (Infectivity Enhanced Adenoviral Vectors for Ovarian CA)||University of Alabama at Birmingham|Yes|Completed|August 2009|April 2012|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|19 Years|N/A|No|||February 2013|February 11, 2013|June 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00964756||134278|
NCT00965445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-IRB-96-0019B|The Comparison of Oxidative Stress Between Inhalation Anesthetics|The Comparison of Oxidative Stress Between Inhalation Anesthetics||Chang Gung Memorial Hospital|Yes|Completed|March 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|thirty milliliters of urine was collected from urine bag of patients at the following times:      baseline before anesthesia, 30 minutes before cardiopulmonary bypass, during cardiopulmonary      bypass, after the end of cardiopulmonary bypass.|Both|25 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients receiving cardiac valve surgery in Taipei Change Gung Memorial Hospital will be        invited to participate this study|August 2009|August 24, 2009|August 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00965445||134228|
NCT00966381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0259|Breastfeeding and Exercise for Healthy Infants and Postpartum Moms Too!|Breastfeeding and Exercise for Healthy Infants and Postpartum Moms Too!|BEHIP|University of North Carolina, Greensboro|Yes|Recruiting|October 2008|December 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Female|23 Years|37 Years|Accepts Healthy Volunteers|||August 2009|August 25, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966381||134157|
NCT00966615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Balance BCM|The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition|The Effect of Neutral Peritoneal Dialysis Solution With Minimal Glucose-Degradation-Product on the Fluid Status and Body Composition - A Randomized Control Trial||Chinese University of Hong Kong|No|Completed|September 2010|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|80 Years|No|||September 2014|September 4, 2014|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00966615||134139|
NCT00968084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090201|Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols|Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|August 2009|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|2 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00968084||134027|
NCT00968097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-340-01|Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition|Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Institute for Neurodegenerative Disorders|No|Terminated|April 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|12|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 27, 2009|April 25, 2008|No|Yes|Early Phase I study of [123I]MNI-340 did not evidence as marker of disease|No||https://clinicaltrials.gov/show/NCT00968097||134026|
NCT00938093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH65281|Treatment of Late-life Anxiety in Primary Care Settings|Treatment of Late-life Anxiety in Primary Care Settings||Wake Forest Baptist Health|No|Completed|March 2006|February 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|60 Years|N/A|No|||June 2015|June 15, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938093||136307|
NCT00938340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE 102|Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction|Postprandial Effects of Walnut Components vs Whole Walnuts on Oxidative Stress, Inflammation, Platelet Function, and Endothelial Function in Volunteers With Moderate Hypercholesterolemia||Penn State University|Yes|Completed|August 2007|May 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||July 2009|July 10, 2009|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00938340||136288|
NCT00938639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-CAL-09-59|A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults|A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.||CSL Limited|Yes|Completed|July 2009|March 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|July 13, 2009||No||No|July 24, 2013|https://clinicaltrials.gov/show/NCT00938639||136265|
NCT00938938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16782|Testing the Effect of Press Guides on Health Journalists|Testing the Effect of Press Guides on Health Journalists||White River Junction VAMC|No|Enrolling by invitation|June 2009|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 20, 2010|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00938938||136242|
NCT00938951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-22|Evaluate the Ability of Systane Ultra to Improve Subjective Symptoms of Ocular Irritation Post 60 Min. Athletic Performance.|||Alcon Research|No|Completed|June 2009|||July 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938951||136241|
NCT00939250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DK081031|A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care|A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|October 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|21 Years|70 Years|No|||September 2010|September 21, 2010|July 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00939250||136218|
NCT00939263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231/08|Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index|Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index: A Prospective Multicenter Study|EEsAI|University Hospital Inselspital, Berne|Yes|Recruiting|January 2011|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|650|||Both|N/A|N/A|No|Non-Probability Sample|Adult and pediatric patients with the diagnosis Eosinophilic Esophagitis, who are treated        in the participating hospitals|September 2015|September 15, 2015|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00939263||136217|
NCT00939276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-003|Macular Edema Incidence/Severity Reduction With Nevanac|||Alcon Research|No|Terminated|August 2009|August 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|July 10, 2009|Yes|Yes|Patient recruitment difficulties|No||https://clinicaltrials.gov/show/NCT00939276||136216|
NCT00939289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-900070, Rev01|Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)|Pilot Study of Concurrent Use of the SEVEN® and FreeStyle Navigator® Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus||DexCom, Inc.|No|Completed|July 2008|February 2009|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with type 1 diabetes mellitus|February 2010|February 2, 2010|July 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00939289||136215|
NCT00939939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP MSD 01-08|Effect of Sitagliptin on Postprandial Lipoprotein Metabolism|||Ludwig-Maximilians - University of Munich|No|Terminated|March 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|19 Years|70 Years|No|||July 2009|June 24, 2011|July 14, 2009|No|Yes|Recruitment failure|No||https://clinicaltrials.gov/show/NCT00939939||136166|
NCT00939952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35922|Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis|Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis||Albany College of Pharmacy and Health Sciences|No|Completed|June 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 22, 2013|July 14, 2009||No||No|July 25, 2012|https://clinicaltrials.gov/show/NCT00939952||136165|
NCT00968825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL012LCL|Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Administration of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults||Revance Therapeutics, Inc.|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 25, 2013|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968825||133970|
NCT00968838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0797|A Study for Leukemia Patients With Life-Threatening Infections|Comparative Study of Radiated and Unradiated Leukocyte Transfusions for Patients With Life-threatening Infections: A Collaborative Study by the Leukemia Department and Laboratory Medicine||M.D. Anderson Cancer Center|Yes|Completed|April 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|August 27, 2009||No||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00968838||133969|
NCT00969150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-02|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|September 2009|||November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|362|||Both|18 Years|80 Years|No|||August 2013|August 22, 2013|August 31, 2009|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT00969150||133945|
NCT00969163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-015|A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).|A Pilot Study to Investigate Biomarkers of Skin Androgenization Following Short-Term Testosterone Administration in Healthy Postmenopausal Women||Merck Sharp & Dohme Corp.||Completed|October 2004|June 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|30|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|August 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00969163||133944|
NCT00969176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51597|Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in Neonates|Single and Multiple Dose Trial to Evaluate Pharmacokinetics, -Dynamics and Safety of iv Paracetamol in Preterm and Term Neonates|PARANEO|Universitaire Ziekenhuizen Leuven|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|28 Days|No|||December 2010|December 21, 2010|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00969176||133943|
NCT00969189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/2008/2808|Evaluation of the Pediatric Igel Airway in 250 Children|A Cohort Evaluation of the Pediatric Igel Airway in 200 Children and in 50 Infants||University Hospitals Bristol NHS Foundation Trust|No|Terminated|August 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|N/A|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|children between 10 - 30 kgs infants between 5-10 kgs|December 2011|December 14, 2011|August 31, 2009||No|Initial number of 250 was not based on sample size. Most airway studies use n=100 therefore    trial stopped when 120 children recruited|No||https://clinicaltrials.gov/show/NCT00969189||133942|
NCT00965471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI04A01|Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease|Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease||Guangzhou University of Chinese Medicine|Yes|Completed|October 2006|June 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|940|||Both|40 Years|75 Years|No|||August 2009|August 24, 2009|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00965471||134226|
NCT00965133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shdir-08/4914|Endurance Training in Young Persons With Cerebral Palsy; Evaluation of Training Method and Effect|Enthusiasm - Sweat - Satisfaction! In Youngster With CP||Reidun Lauglo|No|Completed|September 2009|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|10 Years|17 Years|No|||June 2013|June 10, 2013|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965133||134251|
NCT00965432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22006|A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107|A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy, Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107||Seaside Therapeutics, Inc.|Yes|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2010|February 5, 2010|August 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00965432||134229|
NCT00965081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12873|A Study for Adult Patients With Fibromyalgia|A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia|HMGG|Eli Lilly and Company|No|Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|308|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|August 24, 2009|Yes|Yes||No|September 28, 2011|https://clinicaltrials.gov/show/NCT00965081||134255|
NCT00966082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBLPPL-2|Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding in Pts With Previous Variceal Treatment|RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment||Korea University|No|Recruiting|August 2008|July 2013|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|70 Years|No|||August 2009|August 25, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966082||134180|
NCT00966095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PReCISE|PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy|A Prospective, Multi-Center PRostate Cancer Individual Signature Evaluation Trial (PReCISE) in Patients Undergoing Scheduled Prostate Biopsy|PReCISE|Source MDx|No|Active, not recruiting|December 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1200|Samples Without DNA|whole blood for gene expression analysis      serum      plasma|Male|40 Years|N/A|No|Probability Sample|Men scheduled for a prostate biopsy|November 2010|November 23, 2010|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966095||134179|
NCT00966108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/02|SENSIMED Triggerfish Discomfort During IOP Monitoring|Evaluation of SENSIMED Triggerfish for 24 Hour IOP Monitoring in Healthy Subjects and Glaucoma Patients|09/02|Sensimed AG|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects and glaucoma patients|February 2010|February 3, 2010|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966108||134178|
NCT00966394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|adhd-hmo-ctil|Salivary Bacteria and Oral Health Status in Children With ADHD|Changes in Salivary Bacteria and Oral Health Status in Children With Attention Deficit Hyperactivity Disorder (ADHD)|ADHD|Hadassah Medical Organization|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|150|None Retained|saliva|Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with ADHD, treated by medications or not, treated in the neurologic clinic at        Hadassah.        The control are healthy children visiting the pediatric dental clinic at Hadassah.|August 2009|May 25, 2010|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966394||134156|
NCT00966641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-NAP-001|Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults|"A Single-Dose Crossover Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adult Volunteers in the Fasted State"||PLx Pharma|Yes|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|August 25, 2009|No|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT00966641||134137|
NCT00968370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-009|Trial in Childhood Pneumonia With Malnutrition|Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|November 2008|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|440|||Both|2 Months|59 Months|No|||August 2009|July 14, 2013|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968370||134005|
NCT00937612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGHN-0801|Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk|A Phase II Trial of Postoperative Concurrent Chemoradiation for Head and Neck Squamous Cell Carcinoma Patients With Multiple Risk Factors of Recurrence||Chang Gung Memorial Hospital|Yes|Terminated|June 2008|March 2014|Anticipated|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||February 2012|February 9, 2012|July 9, 2009||No|Study group showed better 2-yr overall survival than historical control (89% vs 66%)|No||https://clinicaltrials.gov/show/NCT00937612||136344|
NCT00938353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/1404/003/09|Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup|Multicentre, Randomized, Double-blind, Placebo-controlled, Two-arm Parallel Groups Study Design to Demonstrate the Efficacy and Tolerability of a Single Dose of BDP Suspension for Nebulisation 1600 µg vs Placebo in the Treatment of Children Aged 6 Months to 3 Years With a Clinical Diagnosis of Moderate Croup||Chiesi Farmaceutici S.p.A.|No|Terminated|April 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|6 Months|3 Years|No|||April 2011|April 28, 2011|July 10, 2009||No|possibility to discriminate the active drug from placebo|No||https://clinicaltrials.gov/show/NCT00938353||136287|
NCT00938366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27967|Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects|An Open-label, Cross Over Study, to Assess the Interactions of Pantoprazole (Proton Pump Inhibitor) With Oral Cladribine Administered in Subjects With Multiple Sclerosis||Merck KGaA|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||February 2015|September 21, 2015|July 9, 2009||No||No|September 21, 2015|https://clinicaltrials.gov/show/NCT00938366||136286|
NCT00938665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRP-1418|Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.|Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.|COGNISION™|Neuronetrix, Inc.|No|Completed|December 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|204|Samples Without DNA|1. These lab tests will be performed from a standard blood draw:             1. B12             2. TSH             3. CRP             4. ALT             5. HGB             6. Hgb1AC             7. T4             8. K             9. Cl            10. CO2            11. ApoE            12. Platelet Count            13. INR            14. PT        2. MRI- INCLUDING VOLUMETRY        3. CSF 5ML (Optional)|Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects between 60 and 90 years old meeting DSM-IV criteria for dementia of the        Alzheimer's type and NINCDS-ADRDA criteria for probable AD will be recruited in the AD        cohort. Matched cognitively healthy volunteers will be recruited for the Control group.|March 2014|March 6, 2014|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938665||136263|
NCT00938678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-09-01|Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers|A Phase I, Randomized, Single Dose, Crossover Study Evaluating the Pharmacokinetics and Pharmacodynamics of Pegfilgrastim Hospira Compared to Neulasta (Amgen) Following Subcutaneous Administration to Healthy Volunteers||Hospira, Inc.|No|Completed|June 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|71|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938678||136262|
NCT00938652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11486|A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer|A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer||Sanofi|Yes|Completed|July 2009|February 2012|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|519|||Female|18 Years|N/A|No|||September 2013|September 13, 2013|July 10, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT00938652||136264|
NCT00938990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4667 - ACH IRB|The Effect of Etomidate on Outcomes of Trauma Patients|The Effect of Etomidate on Outcomes of Trauma Patients||Advocate Hospital System|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|0|||Both|14 Years|N/A||||November 2011|November 30, 2011|July 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938990||136238|
NCT00938964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015641|Lidocaine For Neuroprotection During Cardiac Surgery|Lidocaine For Neuroprotection During Cardiac Surgery||Duke University|Yes|Recruiting|July 2009|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|476|||Both|50 Years|N/A|No|||August 2015|August 4, 2015|July 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938964||136240|
NCT00938977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HospitalSCSP|The Obesity-hypoventilation Syndrome Study of Clinical Characteristics and Predictive Factors of Response to Treatment|The Obesity-Hypoventilation Syndrome: A Study Of Clinical Characteristics And Predictive Factors Of Response To Treatment With Continuous Positive Airway Pressure (CPAP) And Non-Invasive Ventilation (NIV)||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|June 2003|||June 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|No|||July 2009|July 13, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938977||136239|
NCT00939679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B263|Effect of Gastric Bypass Surgery on Energy Metabolism|ERGEM: Effect of Roux-en-Y Gastric Bypass Surgery on Energy Metabolism.|ERGEM|University of Copenhagen|No|Completed|September 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|65 Years|No|||August 2013|August 1, 2013|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939679||136186|
NCT00939692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06TOR01|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions|Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Topiramate (2 x 25 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Topamax®, Ortho-McNeil Neurologics, Inc.)in Fasted, Healthy, Adult Subjects||Torrent Pharmaceuticals Limited||Completed|January 2007|April 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 12, 2013|July 13, 2009||No||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00939692||136185|
NCT00939705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06TOR02|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions|Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Topiramate (2 x 25 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Topamax®, Ortho-McNeil Neurologics, Inc.) in Fed, Healthy, Adult Subjects||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 8, 2011|July 13, 2009||No||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00939705||136184|
NCT00939328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0902|S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment|S0902, Phase II Study of Bendamustine Plus Rituximab for the Treatment of Refractory B-Cell Chronic Lymphocytic Leukemia||Southwest Oncology Group|Yes|Withdrawn|September 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|July 14, 2009|Yes|Yes|question was no longer committee priority|No||https://clinicaltrials.gov/show/NCT00939328||136213|
NCT00968578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-134|Effects of Methylprednisolone After Total Knee Arthroplasty|Effects of Pre-operative Methylprednisolone (125mg iv) After Total Knee Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail||Hvidovre University Hospital|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|48|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00968578||133989|
NCT00968591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001X2102|Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency|An Open-label, Single-dose Study to Assess the Pharmacokinetics of Oral Everolimus (Afinitor®) in Subjects With Impaired Hepatic Function||Novartis||Completed|November 2009|||November 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|34|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2011|February 23, 2011|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968591||133988|
NCT00968604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0762|C-VISA BikDD: Liposome in Advanced Pancreatic Cancer|A Phase I Open-Label Dose Escalation Study to Assess the Safety and Tolerability of the BikDD Nanoparticle in Patients With Advanced Pancreatic Cancer||M.D. Anderson Cancer Center|No|Withdrawn|March 2015|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|August 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00968604||133987|
NCT00968851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-009|Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia|A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy||FORUM Pharmaceuticals Inc|No|Completed|December 2009|March 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|317|||Both|18 Years|55 Years|No|||March 2012|March 28, 2014|August 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00968851||133968|
NCT00965107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1A-AGE/ONSET|Onset Time of Thiopental Versus Propofol in the Elderly|Onset Time of Thiopental Versus Propofol in the Elderly||Rigshospitalet, Denmark|Yes|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|60 Years|N/A|No|||February 2010|March 8, 2010|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00965107||134253|
NCT00965120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP 3|The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway|The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway||University of Edinburgh|No|Completed|August 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00965120||134252|
NCT00965484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281291|Genotropin Study Assessing Use of Injection Pen|Multicenter, Open-Label Study Assessing Dyad (Subject And Caregiver) Perception Of Convenience And Preference Of The Newly Developed Mark VII Injection Pen||Pfizer|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|8 Years|18 Years|No|||April 2010|January 26, 2011|August 21, 2009|Yes|Yes||No|December 2, 2010|https://clinicaltrials.gov/show/NCT00965484||134225|
NCT00965094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIL03|Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients|Efficacy and Safety of Certican® (Everolimus) in Combination With Myfortic® (EC-MPS, Enteric-coated Mycophenolate Sodium) After Early CNI Elimination Versus Myfortic® in Combination With Prograf® in Renal Transplant Recipients||Novartis||Completed|December 2009|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||August 2014|August 14, 2014|August 24, 2009||No||No|May 30, 2014|https://clinicaltrials.gov/show/NCT00965094||134254|
NCT00965809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC09|Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)|Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD|THC_PTSD|Hadassah Medical Organization||Active, not recruiting|October 2009|April 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|19 Years|60 Years|No|||September 2012|October 28, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965809||134201|
NCT00965822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-E002-2007-3|A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population|A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population||Afexa Life Sciences Inc|No|Completed|September 2009|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|293|||Both|3 Years|11 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00965822||134200|
NCT00966121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBLPPL-1|Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding|RCT Comparing the Efficacies of Endoscopic Variceal Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding||Korea University|No|Recruiting|August 2008|July 2013|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|70 Years|No|||August 2009|August 25, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00966121||134177|
NCT00966134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 411|Ghrelin, Growth Hormone and Growth Factors at High Altitude|||Medical University of Vienna||Completed|April 2002|September 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Caucasians from an Alpinist association|August 2009|February 22, 2010|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00966134||134176|
NCT00967447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.103|Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery|Incidence of Symptomatic Venous Thromboembolic Events and Major Bleeding Events After Dabigatran Etexilate in Patients Subject to Subject to Elective Total Hip or Knee Replacement Surgery.||Boehringer Ingelheim||Terminated|February 2009|||January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|74 Years|No|Non-Probability Sample|Primary Care Clinics|February 2014|February 24, 2014|August 13, 2009||||No|January 5, 2012|https://clinicaltrials.gov/show/NCT00967447||134076|
NCT00967460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88/09|Effect of a Physical-activity-promoting Environment on Motor Skills, Physical Activity and Quality of Life of Children in Childcare Settings|Effect of a Physical-activity-promoting Environment on Motor Skills, Physical Activity, Quality of Life and BMI of Children in Childcare Settings (Youp'là Bouge)|Youp'là bouge|University of Lausanne Hospitals|Yes|Completed|January 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|1764|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||August 2009|January 27, 2011|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00967460||134075|
NCT00929097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw 80-82315-98-09005|Implementation of Guidelines on Hereditary or Familial Colorectal Cancer|Implementation of Guidelines on Hereditary or Familial Colorectal Cancer Risk Calculation and Risk Communication|RISCO|Radboud University|No|Enrolling by invitation|October 2009|January 2012|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|70 Years|No|||June 2009|June 25, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929097||136988|
NCT00929110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2303|1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)|A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease|GLOW2|Novartis||Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1066|||Both|40 Years|N/A|No|||August 2012|August 9, 2012|June 25, 2009|Yes|Yes||No|June 22, 2012|https://clinicaltrials.gov/show/NCT00929110||136987|
NCT00929396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYB-02|A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers|A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)Administered in PPD Positive Volunteers at 0 and 2 Months|THYB-02|Statens Serum Institut|Yes|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929396||136966|
NCT00971763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000644293|Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma|A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy||University College, London|Yes|Completed|March 2006|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||September 2009|December 3, 2014|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00971763||133746|
NCT00972062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEVA 540837|Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis|Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis|MSSkin|University of North Carolina, Charlotte|Yes|Completed|June 2009|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00972062||133723|
NCT00940680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ALOS-302|Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension|A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 100mg Versus Losartan 100mg in Patients With Essential Hypertension Not Controlled on Losartan Monotherapy||Hanmi Pharmaceutical Company Limited|No|Completed|April 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||July 2009|July 15, 2009|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940680||136109|
NCT00973206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTH20090609|Factors Influencing Cardiovascular Prognosis|Factors Influencing Cardiovascular Prognosis in Hypertensive Patients (Pythia Study)|Pythia-GR|Aristotle University Of Thessaloniki|Yes|Not yet recruiting|January 2017|January 2027|Anticipated|January 2027|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers,community sample, residents of a certain town|June 2014|June 24, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973206||133636|
NCT00973219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTM16002|Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load|A Randomized Prospective Open-label Trial for Comparing Combination Therapy Peg-Interferon Alfa-2a/Adefovir Dipivoxil and Peg-Interferon Alfa-2a/Tenofovir Disoproxil Fumarate Versus no Treatment in HBeAg Negative Chronic Hepatitis B Patients With Low Viral Load.|LVL|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Active, not recruiting|September 2009|November 2018|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||January 2015|January 19, 2015|September 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00973219||133635|
NCT00941278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-10-PS-22|An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis|||Provectus Pharmaceuticals|No|Completed|July 2009|April 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2010|July 2, 2010|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00941278||136063|
NCT00973232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06CCL102|A Comparative Bioavailability/Food Effect Study of Immediate-Release and Extended-Release Tramadol HCl/Acetaminophen Combination Products Following Single-Dose and Multiple-Dose Administration in Healthy Adult Volunteers|A Single-Centre, Open-Label, Randomised Study to Compare the Single Dose (Including the Effect of Food) and Multiple Dose Pharmacokinetic Profiles of Acetram Contramid® BID Tablets vs the Immediate-Release Tablet Reference Products Zaldiar® and Ultracet®||Labopharm Inc.|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|7||Actual|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973232||133634|
NCT00973245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11866|BAY59-7939 in Atrial Fibrillation Once Daily (OD)|BAY 59-7939 (Factor Xa Inhibitor) Phase II Once Daily Dose Study in Patients With Atrial Fibrillation||Bayer|No|Completed|July 2006|January 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|102|||Both|20 Years|N/A|No|||December 2014|December 26, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973245||133633|
NCT00974012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-0442|Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Extended Release Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|September 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00974012||133575|
NCT00973505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN09021|CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)|Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)|AI-CYP19|Korea University Anam Hospital|No|Recruiting|March 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Serum|Female|18 Years|80 Years|No|Non-Probability Sample|Breast cancer patients taking the medication of AI (aromatase inhibitor) in post menopause        status.|September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973505||133613|
NCT00931879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVZ111903|Lovaza® and Microvascular Function in Type 2 Diabetes|The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes||Eastern Virginia Medical School|No|Completed|October 2009|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|80 Years|No|||August 2012|August 14, 2012|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00931879||136780|
NCT00932152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 08-131|Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer|A Phase II Randomized Trial of Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer Who Have Received First-line Platinum-based Chemotherapy With or Without Bevacizumab||University of Pittsburgh|Yes|Terminated|September 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3|||Female|18 Years|N/A|No|||February 2014|February 12, 2014|July 1, 2009|Yes|Yes|Poor enrollment/suspended to accrual; will close per AstraZeneca request|No||https://clinicaltrials.gov/show/NCT00932152||136759|
NCT00932165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991078|Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin|Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|December 2004|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|451|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A5991078 prescribes the Exemestane (Aromasin).|July 2010|July 13, 2010|June 30, 2009|No|Yes||No|November 13, 2009|https://clinicaltrials.gov/show/NCT00932165||136758|
NCT00931892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000280|Serum Markers in Gluten Challenge|Circulating Markers of Celiac Disease Activity During Gluten Challenge - a Pilot Study.||Beth Israel Deaconess Medical Center|No|Completed|April 2009|||August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|22|||Both|17 Years|72 Years|No|||July 2014|July 22, 2014|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931892||136779|
NCT00932178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRECC006|Calmer Life: A Worry Reduction Program for Older Adults|Calmer Life: A Worry Reduction Program for Older Adults||Baylor College of Medicine|No|Active, not recruiting|April 2009|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|No|||January 2015|July 21, 2015|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932178||136757|
NCT00932451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081005|An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene|Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus||Pfizer|Yes|Completed|January 2010|December 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1069|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932451||136736|
NCT00929409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2009.373|Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia|A 6-week Randomised, Open Comparative, Multi-centre Study of Intravenous Ferric Carboxymaltose (Ferinject) and Oral Iron (Duroferon) for Treatment of Post Partum Anemia||Norwegian University of Science and Technology|No|Terminated|June 2009|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|45 Years|No|||February 2012|February 15, 2012|June 26, 2009||No|Stopped prematurely because too few patients were recruited.|No||https://clinicaltrials.gov/show/NCT00929409||136965|
NCT00933075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04843|Dermacyd Silver Frutal (Lactic Acid) - Photo Evaluation.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Silver Frutal (Lactic Acid).||Sanofi||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|July 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00933075||136690|
NCT00929955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILL-UoM-0110|Role of Anti-Inflammatory Agents in Patients With Schizophrenia|Study of Role of Anti-Inflammatory Agents in Patients With Schizophrenia||Pakistan Institute of Learning and Living|No|Recruiting|June 2009|September 2009|Anticipated|September 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|65 Years|No|||June 2009|June 29, 2009|June 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00929955||136924|
NCT00930267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yael12-HMO-CTIL|Infections in Pediatric Cancer Patients|Epidemiology and Etiology of Infections in Pediatric Cancer Patients: A Prospective Study||Hadassah Medical Organization||Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|18 Years|No|Probability Sample|All newly diagnosed pediatric cancer patients age 0-18 years admitted with fever during or        following chemotherapy|June 2009|June 29, 2009|June 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00930267||136900|
NCT00930280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36695-3|Genetic and Environmental Risk Factors for Hemorrhagic Stroke-GERFHS III|Genetic and Environmental Risk Factors for Hemorrhagic Stroke|GERFHS-III|University of Cincinnati|No|Active, not recruiting|July 2008|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1260|Samples With DNA|whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will be limited to physician-reviewed cases of people who have had a        hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile        radius of the University of Cincinnati.|December 2015|December 8, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930280||136899|
NCT00930553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMMS03409|An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab|An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab||Sanofi|Yes|Completed|August 2009|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1322|||Both|N/A|N/A|No|||March 2016|March 11, 2016|June 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930553||136879|
NCT00930566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006.409|Extracorporal Photopheresis Pilot Study|Allogenic Hematopoietic Stem Cell Transplantation (HSCT) From a Genoidentical Donor After a Reduced Intensity Conditioning Transplantation (RICT) Followed by an Early Preventive Treatment (Day 21) With Extracorporal Photopheresis After Transplantation.|ECP|Hospices Civils de Lyon|Yes|Recruiting|April 2009|September 2015|Anticipated|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|65 Years|No|||April 2013|April 23, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930566||136878|
NCT00972088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peri Anal Study|Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease|Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease||Bikkur Holim Hospital|Yes|Completed|August 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|10 Years|80 Years|No|||May 2013|May 15, 2013|September 2, 2009||No||No|February 4, 2012|https://clinicaltrials.gov/show/NCT00972088||133721|
NCT00972101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0075|Infusion of Expanded Cord Blood T Cells|Infusion of Expanded Cord Blood T Cells Following Cord Blood Transplantation||M.D. Anderson Cancer Center|No|Withdrawn|September 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|55 Years|No|||October 2012|October 10, 2012|September 3, 2009|No|Yes|Development of other studies led to termination without recruitment.|No||https://clinicaltrials.gov/show/NCT00972101||133720|
NCT00972959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138MMY 2051|Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy|A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of the Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Mineral Density, Bone Metabolism, Radiographically-detected Osteolytic Bone Lesions, Skeletal-related Events and Bone Pain in Patients With Multiple Myeloma Who Have Relapsed After 1-3 Prior Lines of Therapy||University of Athens|No|Completed|July 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|September 8, 2009||No||No|January 15, 2014|https://clinicaltrials.gov/show/NCT00972959||133655|
NCT00973492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00903-50|Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes|Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes|VARIAFIT|Association Grenobloise pour le Developpement D'etudes et de Recherches en Physiopathologie Endocrinienne, Diabetologie et Maladies de la Nutrition|No|Active, not recruiting|September 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that have been prescribed functional insulinotherapy at University Hospital        Grenoble|September 2009|September 8, 2009|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00973492||133614|
NCT00973518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADD 09-02|Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)|Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction Test: A One-month Study||Orasi Medical, Inc.|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|||Both|50 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|The current study will include patients meeting DSM-IV-TR criteria for dementia of        Alzheimer's type, and age- and gender-matched healthy control subjects meeting criteria of        normal neurological function.|August 2010|August 12, 2010|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00973518||133612|
NCT00973752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-356|Treatment of Older Adults With Acute Lymphoblastic Leukemia|Treatment of Older Adults With Acute Lymphoblastic Leukemia||Massachusetts General Hospital|Yes|Active, not recruiting|August 2009|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|51 Years|75 Years|No|||March 2015|March 27, 2015|September 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973752||133594|
NCT00931619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090182|GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression|GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression||National Institutes of Health Clinical Center (CC)||Completed|June 2009|April 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|February 19, 2014|July 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00931619||136798|
NCT00931905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0632/02|Homeopathic Preparation Plumbum Metallicum for Lead Poisoning|Effectiveness of the Homeopathic Preparation Plumbum Metallicum in Decreasing Blood Levels in Exposed Workers.||Federal University of São Paulo|Yes|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2|||113|||Both|18 Years|N/A|No|||July 2009|July 31, 2009|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00931905||136778|
NCT00933088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 08-072|Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer|Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer||New York University School of Medicine|Yes|Terminated|June 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|43|||Female|13 Years|19 Years|No|Probability Sample|Adoelscent girls between the ages of 13 and 19 years; with a mother who was diagnosed with        localized breast cancer (Stage II,II), who is not more than one year past her diagnosis        and treatment, and attends the NYUMC or NYCHHC Cancer Center clinics.|June 2011|June 3, 2011|July 2, 2009||No|due to slow accrual and lack of funding|No||https://clinicaltrials.gov/show/NCT00933088||136689|
NCT00928824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KyorinU|Can Japanese Traditional Foods Lower Blood Pressure in Healthy Volunteers|Dietary Nitrate in Japanese Traditional Foods Lowers Diastolic Blood Pressure in Healthy Volunteers.|Horenso|Kyorin University|Yes|Completed|June 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|25|||Both|20 Years|N/A|Accepts Healthy Volunteers|||June 2009|June 25, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928824||137009|
NCT00929123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002796|Mechanisms of Neural Mobilization in the Treatment of Chronic Pain|Mechanisms of Neural Mobilization in the Treatment of Chronic Pain||University of Florida|No|Completed|May 2007|June 2009|Actual|July 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929123||136986|
NCT00929435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14684|Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Carriage Rates in Resident Physicians|The Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Nasal Carriage Among Resident Physicians||University of Oklahoma|No|Terminated|June 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All newly recruited residents will be eligible for enrollment.|April 2012|April 5, 2012|June 24, 2009||No|Minimal enrollment|No||https://clinicaltrials.gov/show/NCT00929435||136963|
NCT00929682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0055|Levobupivacaine for Epidural Analgesia in Labour|||University Hospital, Clermont-Ferrand||Completed|June 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|136|||Female|18 Years|N/A|No|||April 2013|April 2, 2013|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929682||136945|
NCT00929968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAK694A2201|Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis|A Randomized, Double-blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen||Novartis||Completed|June 2009|||February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|35|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929968||136923|
NCT00930293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH085874|Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety|Personalizing Treatment of Depression Complicated by Panic Features-Pilot Study||University of Pittsburgh|No|Completed|July 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|June 26, 2009|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT00930293||136898|
NCT00930306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00011|AZD2066 Cocktail Study|A Phase I, Open Label, Multi Centre Study in Healthy Volunteers to Estimate the Effect of Multiple Doses of AZD2066 on the Activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 by Administering a Cocktail of Caffeine, Bupropion, Tolbutamide, Omeprazole, Metoprolol and Midazolam||AstraZeneca|No|Completed|June 2009|September 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2009|October 23, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930306||136897|
NCT00930579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD6525|Metformin Pre-Surgical Pilot Study|Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation||Columbia University|Yes|Active, not recruiting|October 2009|March 2014|Anticipated|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|25 Years|N/A|No|||July 2013|July 30, 2013|June 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00930579||136877|
NCT00931112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709137|Effects of Individualized Exercise Training in Patients With Peripheral Arterial Disease|Effects of Individualized Exercise Training on Arterial Function, Walking Ability and Quality of Life in Patients With Peripheral Arterial Disease Post Surgery||National Taiwan University Hospital|Yes|Completed|November 2006|June 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|32|||Both|30 Years|N/A|No|||July 2009|July 21, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931112||136837|
NCT00971815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080132|Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight|Effects of 3 Months of SSRI-Treatment on Metabolism and HPA-axis in Young Men Born With Low Birth Weight - a Randomized, Double Blinded and Placebo-controlled Trial|LBW-SSRI|University of Aarhus|Yes|Completed|May 2009|April 2014|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||May 2013|July 7, 2014|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971815||133742|
NCT00972387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of TN IRB 7959-B|Carbohydrate-Protein Supplementation During Endurance Running|"Nutritional Ergogenic Aids: The Effects of Carbohydrate-Protein Supplementation During Endurance Exercise"||University of Tennessee|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972387||133699|
NCT00972400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000647658|Fatigue in Breast Cancer Survivors|Biological Mechanisms of Fatigue in Breast Cancer Survivors||National Cancer Institute (NCI)||Recruiting|January 2009|||January 2011|Anticipated|N/A|Observational|N/A|||Anticipated|96|||Female|N/A|N/A|No|||September 2009|August 23, 2013|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972400||133698|
NCT00972725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113165|Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose|A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.||GlaxoSmithKline||Completed|December 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|52 Years|Accepts Healthy Volunteers|||November 2010|January 22, 2011|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972725||133673|
NCT00972439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-07-00269|Oral Contraceptive (OC) Progestin Dose and Breast Proliferation|Evaluating the Effect of Oral Contraceptive Progestin Dose on Breast Epithelial Cell Proliferation||University of Southern California|No|Completed|August 2007|||November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||September 2009|September 4, 2009|September 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00972439||133695|
NCT00972686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112826|Dose-Escalation Study of GSK2126458|A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma|FTIH|GlaxoSmithKline||Completed|August 2009|March 2015|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||August 2015|March 10, 2016|September 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00972686||133676|
NCT00972699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077553|Mentor Mothers: A Sustainable Family Intervention in South African Townships|Mentor Mothers: A Sustainable Family Intervention in South African Townships||University of California, Los Angeles|Yes|Completed|July 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1200|||Female|18 Years|N/A|No|||May 2013|May 1, 2013|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972699||133675|
NCT00972972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|699|Effect of Bilberry (European Blueberries) and Grape Polyphenols on Cognition and Blood Parameters|Effect of Bilberry (European Blueberries) and Grape Polyphenols on Cognition and Blood Parameters in Normal, Aged Men With Subjective Memory Decline|BLUEBERRY|Ullevaal University Hospital|No|Active, not recruiting|December 2006|December 2009|Anticipated|July 2007|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|61|||Male|67 Years|77 Years|Accepts Healthy Volunteers|||September 2009|September 11, 2009|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972972||133654|
NCT00973765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20080055H_|Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses|Randomized Placebo-Controlled Trial of Bactrim on 7 Day Outcome in Emergency Department Patients With Uncomplicated Abscesses at Risk for Community Acquired Methicillin Resistant Staph Aureus||Wilford Hall Medical Center|Yes|Completed|November 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|212|||Both|16 Years|N/A|Accepts Healthy Volunteers|||September 2009|March 1, 2010|September 8, 2009||No||No|January 19, 2010|https://clinicaltrials.gov/show/NCT00973765||133593|
NCT00973778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJYY200907001|A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma|A Phase II Study for Short Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination With Capecitabine in Patients With Resectable Rectal Carcinoma|IMRT|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|July 2009|July 2012|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|75 Years|No|||September 2009|June 14, 2011|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973778||133592|
NCT00969423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2009-054|Chronic Pain After Video-assisted Thoracoscopic Surgery (VATS) Surgery for Pneumothorax|Chronic Pain After VATS Surgery for Pneumothorax||Rigshospitalet, Denmark|No|Terminated|October 2009|||December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|40 Years|No|||August 2011|August 17, 2011|August 31, 2009||No|unable to recruit|No||https://clinicaltrials.gov/show/NCT00969423||133924|
NCT00969436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109995|Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM|Non-inferiority of GSK Biologicals' Measles-mumps-rubella-varicella (MMRV) Vaccine 208136 vs Priorix™ and Priorix™ Coadministered With Varilrix™ (Comparator) and to Evaluate Non-inferiority of Priorix™ and MMRV Vaccine 208136 vs Comparator||GlaxoSmithKline||Completed|November 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|450|||Both|9 Months|10 Months|Accepts Healthy Volunteers|||April 2011|April 28, 2011|August 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00969436||133923|
NCT00969449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14566|Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan|An Open Label, Randomized, Two-Way Crossover Trial to Compare the Pharmacokinetic Parameters of an Extended- Release Naproxen Sodium Tablet Relative to Naprelan® Tablets Following Single Dose Administration Under Fasted Conditions||Bayer|No|Completed|April 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|August 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00969449||133922|
NCT00932464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A2-1112|Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib|An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study To Determine The Effect Of A High-Fat Meal On The Relative Bioavailability And Pharmacokinetics Of A Single Dose Of The 240 mg Formulation Of Neratinib In Healthy Subjects||Puma Biotechnology, Inc.|No|Withdrawn|August 2012|August 2012|Anticipated|August 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|July 1, 2009|No|Yes|Study withdrawn as it no longer is deemed necessary per project status.|No||https://clinicaltrials.gov/show/NCT00932464||136735|
NCT00932477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9965-001|Safety and Tolerability of Artificial Tears in Dry Eye Subjects|Safety and Tolerability of Artificial Tears in Dry Eye Subjects||Allergan|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|47|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|July 1, 2009||No||No|November 9, 2011|https://clinicaltrials.gov/show/NCT00932477||136734|
NCT00932750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-MOS-01|Study of Coffee Mannooligosaccharides for Weight Management|THE EFFECTS OF COFFEE MANNOOLIGOSACCHARIDES ON INDICES OF BODY WEIGHT, BODY COMPOSITION, AND SATIETY IN HUMANS|MOS|Mondelēz International, Inc.|No|Completed|September 2006|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932750||136714|
NCT00928837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primus Pharmaceuticals LOA-03P|Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee|A Double-Blind,Randomized, Placebo Controlled, Parallel Group, Multi-Center Study of Flavocoxid (Limbrel) Versuss Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee||Primus Pharmaceuticals|No|Completed|March 2006|September 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|350|||Both|35 Years|85 Years|No|||June 2009|June 25, 2009|November 12, 2008||No||No||https://clinicaltrials.gov/show/NCT00928837||137008|
NCT00928850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-051|Modifications to Radical Prostatectomy: Feasibility Study|A Randomized Trial of Modifications to Radical Prostatectomy: Feasibility Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Male|21 Years|N/A|No|||July 2015|July 21, 2015|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928850||137007|
NCT00929162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00036|ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer|A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 (Zibotentan) Plus Carboplatin and Paclitaxel or Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy||AstraZeneca|No|Terminated|June 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|N/A|No|||August 2012|August 3, 2012|June 25, 2009|Yes|Yes|Primary objective of the trial was not met and so there was no benefit in collecting further    information|No|April 26, 2012|https://clinicaltrials.gov/show/NCT00929162||136984|
NCT00929422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612018R|Positron Emission Tomography (PET) in Evaluating Cerebral Glucose Metabolism and Functional Change for Patients With Spinal Cord Injury|PET in Evaluating Cerebral Glucose Metabolism and Functional Change for Patients With Spinal Cord Injury||National Taiwan University Hospital|No|Recruiting|August 2007|December 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|160|||Male|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|right handed patients with spinal cord injury|November 2010|November 30, 2010|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929422||136964|
NCT00930592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peds Metabolic Syndrome|Peds Metabolic Syndrome in Psoriasis|Assessor-Blinded Study of the Metabolic Syndrome and Surrogate Markers of Increased Cardiovascular Risk in Children With Moderate to Severe Psoriasis Compared With Age Matched Population of Children With Warts||Tufts Medical Center|No|Completed|April 2009|December 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|42|Samples Without DNA|Whole blood and serum|Both|10 Years|17 Years|No|Non-Probability Sample|These subjects will be recruited from the pediatric Dermatology Clinic at Tufts Medical        Center, community physician referral, and advertisements.|September 2013|September 16, 2013|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930592||136876|
NCT00929695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2327.00|Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease|A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease||Fred Hutchinson Cancer Research Center||Completed|June 2009|||July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|164|||Both|N/A|N/A|No|||March 2015|March 3, 2015|June 25, 2009|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00929695||136944|
NCT00931138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFA 9801|Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2|Treatment of AML in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 26- ALFA 9801|ALFA 9801|Acute Leukemia French Association|Yes|Completed|December 1999|December 2006||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3|||420|||Both|50 Years|70 Years|No|||August 1999|June 30, 2009|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00931138||136835|
NCT00931151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURPROL 2|Effects of Dietary Protein on Undesirable Postprandial Events in Overweight Subjects|||Institut National de la Recherche Agronomique|Yes|Completed|April 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|August 22, 2011|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00931151||136834|
NCT00931411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRP07019|Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis|Double-Blind Study of Tolerance and Moisturizers Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis Under Normal Conditions of Use||Cosmetique Active International|No|Terminated|January 2009|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|3 Years|12 Years|No|||September 2011|September 18, 2011|June 29, 2009||No|Patients would improve naturally due to weather conditions|No|August 3, 2010|https://clinicaltrials.gov/show/NCT00931411||136814|
NCT00972452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUIRB1135317|Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes|Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals|OGTT|University of Kansas Medical Center|No|Completed|August 2009|September 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|30 Years|65 Years|No|||September 2015|September 23, 2015|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972452||133694|
NCT00972465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CRC-T|Study of Nimotuzumab to Treat Colorectal Cancer|Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras||Peking University|Yes|Recruiting|June 2009|April 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2009|September 4, 2009|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972465||133693|
NCT00972413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCT-001|Cone Beam Computed Tomography for Breast Imaging|Cone Beam Computed Tomography for Breast Imaging and IV Contrast Enhanced Cone Beam Computed Tomography Breast Imaging|CBCTBI|Koning Corporation|Yes|Completed|June 2008|May 2012|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|104|||Female|40 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 13, 2012|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972413||133697|
NCT00972426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-TWB-0901(n)|A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients|A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients||Taiwan Otsuka Pharm. Co., Ltd||Completed|October 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|20 Years|80 Years|No|||September 2011|September 1, 2011|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00972426||133696|
NCT00972712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000655|Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma|A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma||Emory University|Yes|Completed|December 2006|March 2015|Actual|December 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|September 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00972712||133674|
NCT00972738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-235|Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)|A Multi-Center, Double-blind, Randomized, Parallel-Group Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring 2001 Study||Merck Sharp & Dohme Corp.|No|Completed|April 2001|July 2001|Actual|July 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1214|||Both|15 Years|85 Years|No|||July 2015|July 1, 2015|September 4, 2009|Yes|Yes||No|September 15, 2009|https://clinicaltrials.gov/show/NCT00972738||133672|In the paper patients who withdrew for worsening allergic rhinitis/conjunctivitis were included under category of discontinued due to lack of efficacy rather than discontinued due to clinical Adverse Events
NCT00972985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADE 09-01|Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test|Acute Effect of Three Neuroactive Drugs on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction Test||Orasi Medical, Inc.|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972985||133653|
NCT00973258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/1108/2007|Randomized Controlled Trial of Community-based Nutritional, Physical and Cognitive Training Intervention Programmes for At Risk Frail Elderly|Randomized Controlled Trial of Community-based Nutritional, Physical and Cognitive Training Intervention Programmes for At Risk Frail Elderly|FIT|National Medical Research Council (NMRC), Singapore|Yes|Completed|December 2009|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|246|||Both|65 Years|89 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973258||133632|
NCT00973804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090210|Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders|Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders||National Institutes of Health Clinical Center (CC)||Terminated|August 2009|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|69 Years|No|||May 2013|September 6, 2014|September 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00973804||133590|
NCT00969475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-01|The Effects of Fractional Carbon Dioxide (CO2) Laser Treatment Prior to Wound Closure|The Effects of Fractional CO2 Resurfacing Prior to Complex Wound Closure||Moy-Fincher Medical Group|No|Not yet recruiting|October 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2009|September 13, 2009|August 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00969475||133920|
NCT00932763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-085-SA|Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 22 Fasted, Healthy Adult Subjects|An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited, India) Compared to a 10 mg Dose of Norvasc® (Pfizer, USA) in 22 Fasted, Healthy Adult Subjects||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|45 Years||||July 2009|July 15, 2009|July 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00932763||136713|
NCT00932776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 268|Tracheobronchial Secretion Removal|||University of Milano Bicocca||Completed||||||N/A|Interventional|N/A|2||||||Male|18 Years|N/A||||July 2009|July 2, 2009|July 2, 2009||||No||https://clinicaltrials.gov/show/NCT00932776||136712|
NCT00933101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 12-200E|Vascular Inflammation in Adolescents With Type 1 Diabetes|Prevalence of Oxidative Stress, Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness (cIMT) and Biomarkers of Vascular Inflammation in Adolescents With Type-1 Diabetes Mellitus (T1DM)||Children's Mercy Hospital Kansas City|Yes|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|51|Samples With DNA|Whole blood|Both|12 Years|18 Years|No|Non-Probability Sample|Pediatric Endocrinology clinic|June 2011|June 23, 2011|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00933101||136688|
NCT00929721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-4000|A Global Active Surveillance for Community Acquired Pneumonia|Global Active Surveillance for Community-Acquired Pneumonia (CAP) in Adults 50 Years and Older||Pfizer|No|Completed|December 2009|February 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5172|||Both|50 Years|N/A|No|||April 2012|April 12, 2012|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929721||136942|
NCT00929981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0121004|A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients|Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects||Pfizer|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have been prescribed oral Medrol Tablets (4 or 16 mg) for treatment of        contact dermatitis will be enrolled|November 2011|November 21, 2011|June 29, 2009|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT00929981||136922|
NCT00930319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS41|Effectiveness and Safety of Firmagon®|Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma|FAST|Ferring Pharmaceuticals|No|Completed|June 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|676|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with Advanced Hormone-dependent Prostate Carcinoma|March 2014|March 24, 2014|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930319||136896|
NCT00930332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC22|Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain|A Phase I Study to Determine the Dose of Methadone as a First Line Agent in the Treatment of Chronic Neuropathic Cancer Pain||Canadian Cancer Trials Group|Yes|Terminated|April 2009|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|8|||Both|18 Years|N/A|No|||July 2011|October 5, 2015|June 27, 2009||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT00930332||136895|
NCT00930345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070104|Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma|A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy|PREINSUT|Assistance Publique - Hôpitaux de Paris|No|Terminated|December 2008|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||May 2009|March 31, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00930345||136894|
NCT00921427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000241|The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy|||Beth Israel Deaconess Medical Center|No|Completed|November 2007|March 2012|Actual|December 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|June 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00921427||137563|
NCT00921674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO2804|Ivermectin Solution Bioequivalence Study - With Food|A Single-dose, Randomised, Crossover Study to Compare the Rate and Extent of Absorption of Two Formulations of Ivermectin in Healthy Male and Female Volunteers After Food||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921674||137544|
NCT00930839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-597|Role of Prostaglandins on Niacin-Induced Flushing|Exploring the Role of Prostaglandin D2 and the DP1 Receptor on Nicotinic Acid Induced Flushing||Eastern Virginia Medical School|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Skin biopsies and serum|Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal, healthy control subjects, males and females, ages 30-80|March 2010|March 9, 2010|June 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00930839||136857|
NCT00930852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1017/51|A Pilot Study of Migraine and Appetite Behaviour in Children|Migraine, Appetite Behaviour and Obesity: is There a Link?. A Pilot Study of Migraine and Appetite Behaviour in Children.||Alder Hey Children's NHS Foundation Trust|No|Completed|July 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|60|||Both|5 Years|16 Years|No|Non-Probability Sample|New referrals to outpatient general paediatric and paediatric neurology service (both        accepting primary care referrals) within a single multispecialty children's hospital.|February 2012|February 19, 2012|June 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00930852||136856|
NCT00922259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 10-003|Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7|Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H7N7 (6-2) AA ca Recombinant (A/Netherlands/219/03 (H7N7) x A/Ann Arbor/ 6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N7 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|May 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00922259||137499|
NCT00922272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-204|Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms|A Phase 2, Multicenter Study With Open-label & Randomized Double-blind Placebo-controlled Withdrawal Phases to Evaluate the Efficacy, Safety, & Tolerability of SPD489 in Adults With Schizophrenia & Predominant Negative Symptoms Who Are Clinically Stable & Taking Stable Doses of Atypical Antipsychotic Medication||Shire|No|Completed|September 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|55 Years|No|||June 2013|March 3, 2015|June 15, 2009|Yes|Yes||No|December 6, 2011|https://clinicaltrials.gov/show/NCT00922272||137498|
NCT00922545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550.62|Evaluation of a Combined Strategy Addressed to Practitioners and Chronic Obstructive Pulmonary Disease (COPD) Patients to Improve Clinical Control and Quality of Life|Evaluation of a Combined Strategy Addressed to Practitioners and COPD Patients: Information Feed-back and Health Education, to Improve Clinical Control and Quality of Life||Jordi Gol i Gurina Foundation|Yes|Active, not recruiting|April 2004|December 2010|Anticipated|December 2007|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|801|||Both|40 Years|N/A|No|||October 2009|October 8, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922545||137478|
NCT00972192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23193|Effectiveness of Inpatient Voluntary Counseling and Testing (VCT) in Uganda|Effectiveness of Inpatient HIV Voluntary Counseling and Testing in Uganda||Makerere University|No|Completed|February 2004|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|500|||Both|18 Years|N/A|No|||September 2009|September 3, 2009|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972192||133714|
NCT00972205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080035|Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors|A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1(Registered Trademark), Evaluating Pgp Inhibition in Tumors and Normal Tissues||National Institutes of Health Clinical Center (CC)|No|Completed|December 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|80 Years|No|||July 2012|July 13, 2012|September 3, 2009||No||No|September 20, 2011|https://clinicaltrials.gov/show/NCT00972205||133713|
NCT00972478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01964|Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)||National Cancer Institute (NCI)|No|Active, not recruiting|November 2010|||December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||September 2015|December 30, 2015|September 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972478||133692|
NCT00972114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090903|CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy|Coronary Artery Bypass Graft Surgery Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Patients With Ischemic Cardiomyopathy: a Prospective Randomized Controlled Clinical Trial||China National Center for Cardiovascular Diseases|Yes|Recruiting|October 2009|December 2011|Anticipated|June 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|20 Years|70 Years|No|||December 2009|December 9, 2009|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00972114||133719|
NCT00972127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/1004|Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen|Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Open-Label, Randomized, Single Center, Multiple Dose, 2-Period, 2-Sequence, Crossover Study With and Without Application of a Urinary pH Acidification Regimen||Merz Pharmaceuticals GmbH||Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|February 4, 2011|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972127||133718|
NCT00973011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD4711g|A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy|A Phase Ia, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy||Genentech, Inc.||Completed|September 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|50 Years|85 Years|No|||February 2012|February 2, 2012|September 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00973011||133651|
NCT00972998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 105|Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects|An Open Label Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects||RDD Pharma Ltd|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 28, 2009|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00972998||133652|
NCT00973271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV011|Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides|A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind Active-Controlled Extension Assessing Safety and Tolerability||Essentialis, Inc.|Yes|Not yet recruiting|March 2011|December 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|750|||Both|18 Years|N/A|No|||November 2010|November 4, 2010|September 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973271||133631|
NCT00973284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV01-103|Norwalk Vaccine Study|Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety and Efficacy Study in Healthy Adults of Intranasal Norwalk Virus-like Particle Vaccine in Experimental Human Norwalk Virus Infection||LigoCyte Pharmaceuticals, Inc.|Yes|Completed|September 2009|August 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|98|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|May 21, 2012|September 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973284||133630|
NCT00973531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4113|Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension|Effect of Treating Sleep Disorder Breathing Therapy in Patients With Resistant Hypertension||Albert Einstein Healthcare Network|No|Withdrawn|May 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||January 2012|January 25, 2012|September 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973531||133611|
NCT00973791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMU-08711MZ|Fluid Management for Cesarean Section II|Fluid Management for Cesarean Section Undergoing Spinal Anesthesia|FMCS-II|Nanjing Medical University|Yes|Completed|October 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|860|||Female|21 Years|40 Years|No|||September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973791||133591|
NCT00973817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-206|Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis|Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects With Acute On Chronic Hepatitis (AOCH)|SILVER|Vital Therapies, Inc.|Yes|Completed|September 2009|May 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|67 Years|No|||April 2013|April 1, 2013|September 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973817||133589|
NCT00928863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82315-98-09003|Haemorrhagia Postpartum: an Implementation Study on the NVOG Guidelines and MOET Instructions|Haemorrhagia Postpartum: an Implementation Study on the NVOG Guidelines and MOET Instructions|Fluxim|Radboud University|No|Active, not recruiting|January 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|320|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|women with a high risk for haemorrhagia postpartum delivering in a hospital|May 2013|May 22, 2013|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928863||137006|
NCT00929175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-020|Antihypertensive Effect of Continuous Positive Airway Pressure in Resistant Hypertensive Patients With Sleep Apnea|Antihypertensive Effect of Continuous Positive Airway Pressure (CPAP) in Resistant Hypertensive Patients With Sleep Apnea: Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Completed|February 2008|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|30 Years|70 Years|No|||April 2013|February 24, 2014|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00929175||136983|
NCT00929448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iTBI2009|The Predictive Value of Clinical and Immunological Factors in the Development of Pneumonia After Traumatic Brain Injury|The Predictive Value of Clinical and Immunological Factors in the Development of Pneumonia After Traumatic Brain Injury||Royal Alexandra Hospital|No|Completed|July 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive Care|December 2012|December 3, 2012|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929448||136962|
NCT00929461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.EGE.0.01.00.00/7EM/458|Impact of Omega-3 Fatty Acids on Lactate|Do Omega-3 Fatty Acids Have Any Impact On Serum Lactate Levels After Major Gastric Cancer Surgery?||Ege University|No|Completed||||||N/A|Interventional|Primary Purpose: Treatment|2||||||Both|25 Years|65 Years||||November 2009|November 24, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929461||136961|
NCT00929708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0570C00003|Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 4-week, Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group, Multi-centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 μg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD|GLAD|AstraZeneca|No|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|329|||Both|40 Years|N/A|No|||January 2014|January 22, 2014|June 26, 2009||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT00929708||136943|
NCT00929734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009A2|Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease|Effect of ROsuvastatin Therapy on Peripheral Vasodilator Function, Inflammatory Markers and Pulmonary Function in Patients With StablE Chronic Obstructive Pulmonary Disease|RODEO|University Hospital, Akershus|Yes|Completed|March 2010|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|40 Years|80 Years|No|||September 2015|September 7, 2015|June 26, 2009||No||No|July 9, 2015|https://clinicaltrials.gov/show/NCT00929734||136941|
NCT00929747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M08-008|Comparison of Corneal Aberrations and Visual Outcomes in AcrySof IQ Toric Patients Versus Limbal Relaxing Incision (LRI) Patients|Comparison of Corneal Aberrations and Visual Outcomes in AcrySof IQ Toric Patients Versus LRI Patients||Alcon Research|No|Withdrawn|June 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||October 2009|April 10, 2012|June 25, 2009|Yes|Yes|Management Decision|No||https://clinicaltrials.gov/show/NCT00929747||136940|
NCT00929760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-226|Impact of Specialised Renal Care in Patients With Chronic Kidney Disease|Impact of Specialised Renal Care in Patients With Chronic Kidney Disease Stage 3-5: A Prospective Randomised Study. "The Implicate Study"|IMPLICATE|University Hospital, Geneva|No|Recruiting|June 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||September 2009|September 15, 2009|June 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00929760||136939|
NCT00929994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brooks - 001|Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack|Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack||Toronto Rehabilitation Institute|No|Completed|March 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|100 Years|No|Probability Sample|TIA|November 2015|November 11, 2015|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929994||136921|
NCT00920894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kainuu PlantStanol Ester Study|Effect of Plant Stanol Esters on Blood Lipids|The Effect of Plant Stanol Esters on Serum Total and Lipoproteins Lipids, Non-cholesterol Sterols and Apolipoproteins in Subjects With Elevated Blood Lipid Concentration||Clinical Life Sciences Ltd.||Completed|January 2009|November 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|112|||Both|20 Years|70 Years|No|||November 2009|November 4, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920894||137604|
NCT00920907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-087|Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma|A Randomized, Parallel, Open-Label Study to Compare the Pharmacokinetics of Ipilimumab (BMS-734016) Process C to Process B in Subjects With Advanced Melanoma||Bristol-Myers Squibb|No|Completed|August 2009|October 2012|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|June 9, 2009|No|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00920907||137603|
NCT00921440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22462/2 - 2005-070|Computed Tomography Coronary Angiography (CTCA) and Coronary Flow in Stenosis Analysis|CT Coronary Angiography: Coronary Flow Quantification Supplements Morphological Stenosis Analysis||University of Cologne|Yes|Completed|August 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|51 Years|N/A|No|Probability Sample|people with suspected or known coronary artery disease (CAD)|June 2009|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921440||137562|
NCT00921960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVUH - HFU - 020|St. Vincent's Screening To Prevent Heart Failure Study|St. Vincent's Screening To Prevent Heart Failure (STOP-HF) Study Using Natriuretic Peptides to Identify and Prevent Progression of Left Ventricular Dysfunction in Community Based, Asymptomatic, At-risk Individuals.|STOP-HF|St Vincent's University Hospital, Ireland|Yes|Recruiting|January 2005|July 2017|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|40 Years|N/A|No|||December 2012|December 11, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00921960||137522|
NCT00921973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX102-07|Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults|A Multicenter, Double-Blinded, Randomized, Placebo Controlled Study to Investigate the Safety and Immunogenicity of VAX102 When Given in the Same Arm With the Standard Influenza Vaccine in Healthy Adults||VaxInnate Corporation|No|Completed|June 2009|September 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921973||137521|
NCT00921986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-176|Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic|Cleveland Clinic Arrhythmia Biospecimen Repository (Cleveland Clinic Arrhythmia BioBank)||The Cleveland Clinic|Yes|Recruiting|March 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|Biospecimens to be collected: DNA, RNA, plasma, & serum. Also tissue may be collected.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing arrhythmia procedures, cardiac surgery or inpatient or outpatient        evaluations for arrhythmias at the Cleveland Clinic or from outside collaborative        institutions or from other clinical trials.|June 2010|June 1, 2010|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921986||137520|
NCT00922285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08028|Art Therapy for Caregivers of Young Patients Undergoing Bone Marrow Transplant for Cancer|Art Therapy Interventions With Caregivers Supporting Pediatric Patients Who Are Undergoing Bone Marrow Transplantation for Cancer||City of Hope Medical Center|Yes|Completed|June 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922285||137497|
NCT00972491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-8910|The Optimal Time to Put Laryngeal Mask Airway in the Mouth Under General Anesthesia|The Optimal Time of Insertion of Laryngeal Mask Airway With Propofol Induction|LMA|Tufts Medical Center|No|Completed|September 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|198|||Both|18 Years|65 Years|No|||December 2013|December 3, 2013|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972491||133691|
NCT00973037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN09020|CYP2D6 Genotype on the Clinical Effect of Tamoxifen|Impact of CYP2D6 Genotype on the Clinical Effects of Tamoxifen Using With Samples From Prospective Randomized Multicenter Study|ASTRRA-CYP2D6|Korea University Anam Hospital|No|Recruiting|March 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|922|Samples With DNA|Serum|Female|18 Years|45 Years|No|Probability Sample|young women(≤45 years) with hormone-sensitive breast cancer who remain in premenopause or        regain menstruation after chemotherapy|September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973037||133649|
NCT00972751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000601255|S9304A Study of Protein Expression in Tumor Tissue Samples From Patients With Stage II or Stage III Rectal Cancer Enrolled in Clinical Trial SWOG-9304|Investigation of Thioredoxin-1 Family Protein Expression in Rectal Cancer||Southwest Oncology Group|No|Completed|February 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|220|||Both|18 Years|120 Years|No|Non-Probability Sample|Patients enrolled on SWOG-9304, adenocarcinoma of the recturm Stage II or III|September 2015|September 28, 2015|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972751||133671|
NCT00973024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016468|A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|September 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|389|||Both|18 Years|80 Years|No|||April 2015|April 28, 2015|September 4, 2009|Yes|Yes|Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial.|No||https://clinicaltrials.gov/show/NCT00973024||133650|
NCT00973297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151059-HMO-CTIL|A Targeted Falls Prevention Program in Rehabilitation In-Patients|A Targeted Falls Prevention Program in Rehabilitation In-Patients||Hadassah Medical Organization|No|Not yet recruiting|November 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|N/A|No|||September 2009|September 8, 2009|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00973297||133629|
NCT00973544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA -08-5530 -EW- CTIL|Do Closed Suction Drains Affect the Complications Rate of Breast Reconstruction With Silicone Prosthesis?|Complications of Breast Reconstruction With Silicone Prosthesis in Relation to Closed Suction Drains||Sheba Medical Center|No|Not yet recruiting|September 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|cultures of fluids from drain|Female|18 Years|N/A|No|Probability Sample|Patients that underwent breast reconstruction with silicone prosthesis and in which drains        were left in the surgical field. patients will signed an informed consent form|September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973544||133610|
NCT00973830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU0923013|The Missouri Health Literacy and Diabetes Communication Initiative|The Missouri Health Literacy and Diabetes Communication Initiative||Northwestern University||Recruiting|August 2008|July 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1080|||Both|25 Years|N/A|No|||September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973830||133588|
NCT00969514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-167|Robotic-Assisted Laparoscopic Cystectomy|Robotic-assisted Laparoscopic Cystectomy: Our Center's Clinical Experience||William Beaumont Hospitals|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|31|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing robotic cystectomy|September 2011|September 30, 2011|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969514||133917|
NCT00928876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN001|Interleukin-1 Receptor Antagonist and Insulin Sensitivity|Effect of Interleukin-1 Receptor Antagonist on Insulin Sensitivity in Obese, Insulin Resistant Individuals||Radboud University|No|Active, not recruiting|June 2009|July 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|December 16, 2010|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928876||137005|
NCT00929188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016057|A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Followed by an Open-Label Extension Phase||Janssen Research & Development, LLC|Yes|Completed|October 2009|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|99 Years|No|||December 2015|December 18, 2015|June 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00929188||136982|
NCT00920504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEINCA|Pilot Study to Test the Feasibility and the Efficacy of the German Language Adapted PRO-SELF© Plus Pain Control Program|Pilot Study to Test the Feasibility and the Efficacy of the German Language Adapted PRO-SELF© Plus Pain Control Program, an Educational Intervention Directed at Patients and Their Family Caregivers to Reduce Cancer Pain and Related Symptoms|PEINCA|University Hospital, Basel, Switzerland|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|39|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920504||137634|
NCT00920192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111645|Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer|A Phase 1/2, Open-Label, Multicenter Study of GSK1363089Gin Adult Subjects With Hepatocellular Carcinoma||GlaxoSmithKline|No|Completed|August 2009|March 2015|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920192||137658|
NCT00920920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMBRACE 1|An International Study on Magnetic Resonance Imaging (MRI)-Guided Brachytherapy in Locally Advanced Cervical Cancer|A International Study on MRI-Guided Brachytherapy in Locally Advanced Cervical Cancer|EMBRACE|Medical University of Vienna|No|Recruiting|July 2008|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|N/A|N/A|No|Probability Sample|Patients to be included:        Patients with newly biopsy proven squamous carcinoma, adenocarcinoma or adeno-squamous        carcinoma of the uterine cervix, FIGO stage IB, IIA, IIB, IIIA, IIIB and IVA in whom        definitive radiotherapy with curative intent is planned are qualified for the study.        Patients with para-aortic metastatic nodes (stage IVB) to the level of L2 are also        eligible but patients with further dissemination are not.        Staging should as a minimal include gynaecological examination, MRI of the pelvis,        abdominal CT or MRI and chest radiography. Further investigations are applied if necessary        (e.g. cystoscopy, rectoscopy) or normally done according to institutional practice (e.g.        PET-CT).|June 2009|June 15, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920920||137602|
NCT00921453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWDiss3000490-2|Tailored Internet Information Supply for Patients - Part 2|Quality of Self-Diagnosis by Headache Patients Getting Tailored Internet Information - Part 2||Health & Life Sciences University, Tryol|Yes|Completed|April 2009|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Students and employees of Bamberg University.|June 2009|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921453||137561|
NCT00921466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113235|Pilot Study to Assess Feasibility, Reliability and Validity of the e-SSRS-IVR|Pilot Study to Assess Feasibility, Reliability and Validity of the e-SSRS-IVR|e-SSRS-IVR|Rogers Center for Research & Training, Inc.|No|Enrolling by invitation|June 2009|August 2009|Anticipated|July 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Study subjects will be recruited from a single clinical site (Rogers Memorial Hospital,        Milwaukee WI). Half of the subjects will be recruited through public advertisement for        Rogers Hospital employees and the other half will be recruited from recent inpatient        psychiatric admissions.|June 2009|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921466||137560|
NCT00921180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950922|Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B|Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B||National Taiwan University Hospital|Yes|Recruiting|February 2007|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921180||137582|
NCT00921999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090170|Immune Response to Varicella-Zoster Vaccination and Infection|Immune Responses to Varicella-Zoster Virus Vaccination and Infection||National Institutes of Health Clinical Center (CC)||Completed|June 2009|January 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|19|||Both|5 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 9, 2015|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00921999||137519|
NCT00921687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSCVAMCCKD1|Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study|Chronic Kidney Disease Guideline Adherence - a Cluster Randomized Controlled Quality Improvement Study||Louis Stokes VA Medical Center|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|781|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|June 15, 2009||No||No|July 30, 2012|https://clinicaltrials.gov/show/NCT00921687||137543|
NCT00922571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-C-1.1|A Study of Cataract Surgery With the Femtosecond Laser|A Study of Cataract Surgery With the Assistance of the Femtosecond Laser||Abbott Medical Optics|No|Terminated|June 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|50 Years|80 Years|No|||July 2014|July 7, 2014|June 16, 2009|Yes|Yes|Sponsor decided not to pursue market release of prototype device used in this study|No||https://clinicaltrials.gov/show/NCT00922571||137476|
NCT00922584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG0805|Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor|A Phase II Study of Sorafenib (BAY 43-9006®) in Patients With Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)Treatment||Chinese Society of Lung Cancer|Yes|Completed|December 2008|April 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00922584||137475|
NCT00922857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408079|Influence of Muscular Atrophy on Biological and Functional Benefit of Respiratory Rehabilitation in Patients With Chronic Respiratory Failure|Influence of Muscular Atrophy on Biological and Functional Benefit of Respiratory Rehabilitation in Patients With Chronic Respiratory Failure|INSPIRE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|April 2005|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|40 Years|75 Years|No|||July 2014|July 23, 2014|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922857||137454|
NCT00972764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|461956 (BoushahriCMC)|Laryngomalacia No Longer An Ambiguity|Laryngomalacia No Longer An Ambiguity||Boushahri Clinic Medical Center|Yes|Completed|January 2006|September 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1500|||Both|N/A|2 Years|Accepts Healthy Volunteers|Probability Sample|Primary care clinics|September 2009|September 4, 2009|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972764||133670|
NCT00972777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603|Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.||Bausch & Lomb Incorporated|No|Completed|October 2009|February 2011|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|474|||Both|1 Year|N/A|No|||February 2012|February 14, 2012|September 4, 2009|Yes|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT00972777||133669|
NCT00973323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12024|BAY59-7939 Japanese in Atrial Fibrillation (2nd)|BAY 59-7939 (Factor Xa Inhibitor) Phase II Low Dose Study in Patients With Atrial Fibrillation||Bayer|No|Completed|September 2005|March 2006|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|100|||Both|20 Years|N/A|No|||December 2014|December 26, 2014|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00973323||133627|
NCT00973310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-L001|Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer|A Phase II Study on the Safety and Efficacy of Radiation Therapy and Concurrent Erlotinib in Locally Advanced Non-small-cell Lung Cancer||Tianjin Medical University Cancer Institute and Hospital|No|Recruiting|October 2009|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||December 2010|December 21, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973310||133628|
NCT00973856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09025|Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands|Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands||Akron General Medical Center||Completed|September 2009|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|75 Years|No|||June 2015|June 22, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973856||133587|
NCT00969527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0903-CU|Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis|Assessment of the Efficacy of Oncoxin+Viusid Administration in the Treatment of Rheumatoid Arthritis||Catalysis SL|Yes|Completed|September 2009|April 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||May 2011|May 6, 2011|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00969527||133916|
NCT00919932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA-08-001-UPMC|Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework|Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework.||University of Pittsburgh|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|13 Years|17 Years|No|||January 2016|January 18, 2016|June 11, 2009||No||No|January 18, 2016|https://clinicaltrials.gov/show/NCT00919932||137678|
NCT00920179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21071965|Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome|The Application of In Vivo Confocal Scanning Laser Microscopy in the Evaluation of the Secretory Glands in Patients With Sjögren's Syndrome||Keio University|No|Enrolling by invitation|October 2007|||December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with primary SS and healthy controls|June 2009|June 12, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920179||137659|
NCT00920517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 250|Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine|Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine With Boosting at 4 Versus 6 Months||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|June 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00920517||137633|
NCT00920933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2104|Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy Subjects|Double Blind, Placebo Controlled, Parallel Group Study With an Open Label Reference Arm to Assess the Effects of Intravenously Administered AIN457 on Ozone Induced Neutrophilia Compared to Placebo & Oral Corticosteroid in Healthy Volunteers||Novartis||Completed|January 2009|||November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920933||137601|
NCT00921193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-14-001|Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer|Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer||Navotek Medical, Ltd.|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Male|45 Years|N/A|No|||March 2011|March 29, 2011|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921193||137581|
NCT00921479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OE-001|Postoperative Course Following Wisdom Tooth Surgery|Postoperative Course and Quality of Life Following Surgical Removal of the Mandibular 3. Molar||Ullevaal University Hospital|No|Recruiting|June 2005|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|45 Years|No|Non-Probability Sample|Norwegian outpatients patients of Caucasian origin operated in a primary care clinic|March 2010|March 2, 2010|June 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00921479||137559|
NCT00921700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARIBU-022|Analgesic Effect of Paracetamol, Paracetamol + Codeine, Ibuprofen and Their Combination|Analgesic Effect of Ibuprofen 400 mg/Paracetamol 1000 mg, Ibuprofen 400 mg/ Paracetamol 1000 mg/60 mg Codeine, and Paracetamol 1000 mg/Codeine 60 mg: A Single-dose, Randomized, Placebo-controlled and Double-blind Study||Ullevaal University Hospital|No|Recruiting|June 2009|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|30 Years|No|||March 2010|March 2, 2010|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921700||137542|
NCT00922012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-08-064|Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome|Efficacy of Electromagnetic Stimulation Therapy for the Treatment of Chronic Prostatitis or Chronic Pelvic Pain Syndrome||Samsung Medical Center|No|Completed|November 2007|December 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||May 2011|May 10, 2011|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922012||137518|
NCT00922025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OTW-IRE-2009/1|Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients|A Multi-centre, Naturalistic Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of EGFR TKI in Male Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer of Adeno Histology Failed 1st Line Chemotherapy||AstraZeneca|No|Completed|August 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|186|||Male|20 Years|N/A|No|Probability Sample|Primary Care Clinic|September 2011|September 26, 2011|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922025||137517|
NCT00922311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis-ST-01|Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade|Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study||The University of Hong Kong|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|No|||July 2015|July 2, 2015|June 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00922311||137496|
NCT00922324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP206-001|Safety and Tolerability of STP206 in Healthy Adult Subjects|A Single-Center Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Assess the Safety and Tolerability of Single and Multiple Daily Oral Administration of STP206 Live Biotherapeutic in Healthy Adult Subjects||Sigma Tau Pharmaceuticals, Inc.|No|Completed|March 2010|November 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 16, 2013|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00922324||137495|
NCT00922597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13213|Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery|Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery - NO PEACKS|NO PEACKS|Bayer|No|Completed|August 2008|September 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Male|N/A|N/A|No|Non-Probability Sample|The study population will consist of patients with a diagnosis of severe haemophilia A.        Physicians should consult the full prescribing information for KOGENATE Bayer before        enrolling patients and familiarize themselves with the safety information in the product        information.|April 2015|April 17, 2015|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922597||137474|
NCT00922610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21983|A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients|An Open-label Study of the Effect of Mircera on Hemoglobin Levels in Filipino Chronic Kidney Disease Patients||Hoffmann-La Roche||Completed|February 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922610||137473|
NCT00922870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1450|Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock|Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock|Cascade|Gambro Lundia AB|No|Completed|April 2009|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|85 Years|No|||April 2013|April 9, 2013|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922870||137453|
NCT00923260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCMNSZ-1486|Omentectomy and Metabolic Syndrome|Effect of Omentectomy on Metabolic Syndrome, Acute Phase Reactants & Inflammatory Mediators in Patients Undergoing LRYGBP: A Randomized Trial||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|December 2005|July 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|65 Years|No|||November 2009|November 24, 2009|January 28, 2009||No||No|January 28, 2009|https://clinicaltrials.gov/show/NCT00923260||137425|An important limitation of our study is the small number of studied patients.
NCT00923273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080078|Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer|A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC||National Institutes of Health Clinical Center (CC)|No|Completed|February 2008|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|42|||Both|18 Years|N/A|No|||October 2013|October 1, 2015|June 17, 2009|Yes|Yes||No|May 24, 2013|https://clinicaltrials.gov/show/NCT00923273||137424|
NCT00972790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0041-GAP|Scalp Nerve Blocks for Post-Craniotomy Pain|Effect of Bilateral Scalp Nerve Blocks on Post-operative Pain and Discharge Times in Patients Undergoing Supra-tentorial Craniotomy and General Anaesthesia||St. Michael's Hospital, Toronto|No|Completed|March 2010|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||December 2011|February 29, 2012|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972790||133668|
NCT00972803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8660|The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms|The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms||Tabriz University|No|Completed|May 2008|May 2009|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|65 Years||||February 2007|September 8, 2009|September 8, 2009||||No||https://clinicaltrials.gov/show/NCT00972803||133667|
NCT00973050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30062|Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions|Randomized, 1-Way Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablets and Casodex® Administered as 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|September 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 8, 2009|September 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00973050||133648|
NCT00973063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-029-283|Effectiveness of Routine Sterile Gloving in Blood Culture|Influence of Routine Sterile Gloving on Contamination Rates in Blood Culture||Seoul National University Hospital|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1854|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00973063||133647|
NCT00973076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1600C00003|Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055|A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours||AstraZeneca|Yes|Completed|August 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|20 Years|N/A|No|||June 2011|June 14, 2011|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00973076||133646|
NCT00973570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-43|Smoking Cessation Program Among Adolescents in Vocational Training Centers|Evaluation of a Smoking Cessation Program Among ADOlescents in Vocational Training Centers|TABADO|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|15 Years|20 Years|Accepts Healthy Volunteers|||September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973570||133608|
NCT00973557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019830|The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function|The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function||Cedars-Sinai Medical Center|No|Completed|September 2009|January 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|6|Samples Without DNA|10 ml of whole blood will be collected to measure prolactin, growth hormone, IGF-I, TSH,      thyroxine, ACTH, and cortisol levels|Both|18 Years|N/A|No|Non-Probability Sample|Patients who have cancer and have been treated with the drug Bevacizumab for at least one        month.|February 2012|February 6, 2012|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973557||133609|
NCT00969540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mattress1|Trial on the Effect of Optically Modified Fiber Mattress Covers on Sleep Disturbances in Patients With Chronic Back Pain|Double Blind, Placebo Controlled, Crossover Pilot Trial on the Effect of Optically Modified Polyethylene Terephthalate Fiber Mattress Covers on Sleep Disturbances in Patients With Chronic Back Pain||University of California, Irvine|No|Completed|June 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 31, 2009|Yes|Yes||No|June 29, 2012|https://clinicaltrials.gov/show/NCT00969540||133915|This is a pilot study to determine the framework to study sleep, pain and mattress covers. The number of subjects is small. The observed data is evaluated in a descriptive (bar graph) presentation.
NCT00969553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.16|Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers|A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|August 2009|||September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|August 31, 2009||||No||https://clinicaltrials.gov/show/NCT00969553||133914|
NCT00969865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCARE|Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program|Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program|iCARE|Piedmont Healthcare|No|Recruiting|October 2011|||July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|670|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with no known coronary artery disease and who have an intermediate or high        Framingham Risk Score (10 year risk 10 percent or greater).|April 2014|April 14, 2014|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969865||133890|
NCT00919672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070218,JLF|Treatment of Irritable Bowel Syndrome (IBS) With Sacral Nerve Stimulation|Treatment of Irritable Bowel Syndrome (IBS) With Sacral Nerve Stimulation. A Blinded, Randomized Crossover Study||University of Aarhus|Yes|Active, not recruiting|April 2009|November 2013|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|May 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00919672||137697|
NCT00919945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012584|Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn|Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn||The Hospital for Sick Children|Yes|Terminated|January 2009|July 2014|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|N/A|30 Days|No|||May 2014|May 12, 2014|June 11, 2009||No|Reduced enrollment rate for SV patients due to high competition for studies|No||https://clinicaltrials.gov/show/NCT00919945||137677|
NCT00920946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM20|A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Huntington Disease|HORIZON|Medivation, Inc.|Yes|Completed||||||Phase 3|Interventional|Primary Purpose: Treatment|2||||||Both|30 Years|N/A|No|||April 2011|April 13, 2011|June 12, 2009||No||||https://clinicaltrials.gov/show/NCT00920946||137600|
NCT00921726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 003|Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults|Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2009|March 18, 2010|June 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921726||137540|
NCT00921206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX102-05|Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults|Open-label Study to Investigate the Humoral and Cellular Immune Response to Two Doses of VAX102 Influenza Vaccine in Healthy Adults||VaxInnate Corporation|No|Completed|June 2009|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921206||137580|
NCT00921219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO2005|Ivermectin Solution Bioequivalence Study - With Food (Repeat)|Ivermectin Solution Bioequivalence Study - With Food (Repeat)||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|September 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921219||137579|
NCT00922350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2525|Heliox and Posture in Patients With Asthma|Heliox and Posture Optimize Action of Nebulization With Bronchodilators for Asthma Attacks. Randomized Trial.||Universidade Federal de Pernambuco|Yes|Completed|June 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|65 Years|No|||June 2009|June 16, 2009|June 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00922350||137493|
NCT00921713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P20CA137219NN|Testing an Optimal Model of Patient-Centered Cancer Care|Testing an Optimal Model of Patient-Centered Cancer Care||Group Health Cooperative|No|Completed|September 2008|August 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00921713||137541|
NCT00922883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090154|A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia|A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2009|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|12 Years|N/A|No|||November 2015|November 26, 2015|June 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00922883||137452|
NCT00922337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD-05|The Israeli MGuard Registry|A Prospective, Observational, Multicenter Registry To Evaluate the 'Real World' Clinical Performance of the MGuard Coronary Stent System||InspireMD|Yes|Completed|July 2009|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an indication for coronary stent implantation according to the Israeli        regulatory approval of the MGuard Coronary Stent System. All patients who receive one or        more MGuard Coronary Stent System in one or more target lesions should be included.|March 2014|March 5, 2014|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922337||137494|
NCT00923611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-657-BR-CT-202|Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel Grouped, Clinical Study to Evaluate the Antihypertensive Efficacy and Tolerability and to Determine the Adequate Antihypertensive Dosage of Fimasartan(BR-A-657-K) in Patients With Mild to Moderate Essential Hypertension||Boryung Pharmaceutical Co., Ltd|Yes|Completed|September 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|182|||Both|18 Years|70 Years|No|||June 2009|June 17, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923611||137402|
NCT00919438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2008-001|Non Invasive External Monitoring in Dialysis Patients|Fluid Removal During Adherent Renal Monitoring|FARM|Corventis, Inc.|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care and kidney failure clinics|February 2010|February 2, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919438||137714|
NCT00919451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRBY24-T1RB|Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy|A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone.||London School of Hygiene and Tropical Medicine|Yes|Completed|August 2010|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||September 2014|March 24, 2015|June 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00919451||137713|
NCT00923936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090130|Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma|Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma||National Institutes of Health Clinical Center (CC)||Recruiting|April 2009|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|99 Years|No|||May 2015|November 7, 2015|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00923936||137380|
NCT00973349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V112_01|Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults|A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Adult Subjects 18 or More Years of Age||Novartis|No|Completed|September 2009|December 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|2719|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|September 2, 2009|Yes|Yes||No|December 7, 2010|https://clinicaltrials.gov/show/NCT00973349||133625|
NCT00973583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTampere-RO5125|Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infections|Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infections; a Randomized Double-blinded Trial in Young Finnish Men||University of Tampere|No|Completed|May 2005|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|164|||Male|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973583||133607|
NCT00973336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT02_2008|Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?|Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Successful Surgery in Patients Without Osteoporosis?||Medical University of Vienna|No|Recruiting|September 2009|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973336||133626|
NCT00973882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARBETOP|Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers|Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.||Centre Leon Berard|No|Completed|April 2005|January 2010|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|18 Years|N/A|No|||November 2011|November 2, 2011|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00973882||133585|
NCT00973895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090204|VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old|VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old||National Institutes of Health Clinical Center (CC)||Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|70 Years|No|||September 2010|September 4, 2010|September 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00973895||133584|
NCT00973869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000648267|Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery|A Pilot Study of Administration of Curcumin to Determine Colonic Curcumin Tissue Levels in Patients Awaiting Colorectal Endoscopy or Patients With Colorectal Cancer Awaiting Resection||National Cancer Institute (NCI)||Recruiting|July 2009|||January 2010|Anticipated|Phase 1|Interventional|Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|June 23, 2014|September 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00973869||133586|
NCT00969878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA025223|Multisite Controlled Trial of Cocaine Vaccine|A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence|TA-CD|Baylor College of Medicine|Yes|Completed|August 2010|July 2014|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|55 Years|No|||December 2014|December 11, 2014|August 31, 2009|Yes|Yes||No|July 17, 2014|https://clinicaltrials.gov/show/NCT00969878||133889|
NCT00969891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLPKPD-20081127|Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia|Population Based Pharmacokinetic and Pharmacodynamic Dosage Model for Cytarabine, Daunorubicin and Etoposide for Acute Myeloid Leukemia||University of Copenhagen||Completed|September 2009|August 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|Samples Without DNA|plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|adult patients with acute myeloid leukemia|August 2011|August 24, 2011|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00969891||133888|
NCT00970138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009APA-MGC|Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer|A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma||Fudan University|No|Completed|June 2009|December 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|141|||Both|18 Years|70 Years|No|||September 2010|July 11, 2011|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970138||133869|
NCT00920205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-3100-001|Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments|Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer||Myrexis Inc.|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|18 Years|N/A|No|||October 2011|October 13, 2011|June 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00920205||137657|
NCT00920530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808073|Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study|Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage at Delivery : a Medico-Economic and Feasibility Study|BBFAST|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2008|June 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|224|Samples Without DNA|Vaginal swab|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women having a pregnancy follow up with Streptococcus agalactiae monitoring        according with french recommandations.|June 2009|June 17, 2009|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00920530||137632|
NCT00920543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM40086|GSK BHR Study (Sont)|A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUSTM BID or Fluticasone Propionate DISK ...||GlaxoSmithKline||Completed|February 2003|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|464|||Both|12 Years|N/A|No|||March 2011|April 11, 2013|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920543||137631|
NCT00921739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017361|Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies|Phase I Dose Escalation Study of Accelerated Fractionation With Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esophageal Injury|ESIMRT|Duke University|No|Active, not recruiting|August 2009|June 2019|Anticipated|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921739||137539|
NCT00921752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CHU-DUM-2009/1|C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)|C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)|C2 -CORVUS|AstraZeneca|No|Completed|May 2009|November 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Ambulatory clinics|December 2009|December 3, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00921752||137538|
NCT00922038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025202|Rewarding Sexually Transmitted Infection (STI) Prevention and Control in Tanzania|Encouraging Safe Sexual Practices Among Youth Using Cash Rewards: A Randomized Trial in the Kilombero/Ulanga Districts, Tanzania|RESPECT|University of California, Berkeley|Yes|Completed|February 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2411|||Both|16 Years|N/A|No|||June 2009|June 16, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00922038||137516|
NCT00922051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20070305001|Acute Effects of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Forced Expiratory Flow Volume in One Second (FEV1) and Blood β-Endorphin Level in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Acute Effects of Acu-TENS on FEV1 and Blood β-Endorphin Level in Subjects With COPD||The Hong Kong Polytechnic University||Completed|March 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|44|||Both|45 Years|N/A|No|||June 2009|June 16, 2009|June 16, 2009||||No||https://clinicaltrials.gov/show/NCT00922051||137515|
NCT00922363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACAF01-01|Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers|An Open Phase I, Dose-escalating, Clinical Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers||Statens Serum Institut|Yes|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922363||137492|
NCT00922376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/0201|Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management|Assessment of the Clinical Efficacy and Acceptability of the Think Positive (T+) Diabetes Management System in Insulin Requiring Diabetes|T+|University College London Hospitals|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922376||137491|
NCT00922623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 90028-0622/1 Supplement|Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI|A Multicenter Study of The Safety and Effectiveness of Dermal Filler, Belotero®, After Mid-to-Deep Dermal Implantation for Correction of Moderate to Severe Facial Wrinkles (Such as Nasolabial Folds) Over 24 Weeks in Subjects With Fitzpatrick Phototype Scores of IV, V, and VI.||Merz Pharmaceuticals, LLC|No|Completed|May 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|75 Years|No|||April 2013|April 19, 2013|June 3, 2009|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00922623||137472|
NCT00922636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10925|A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder|A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder||Eli Lilly and Company|Yes|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|340|||Both|6 Years|17 Years|No|||July 2014|July 29, 2014|June 16, 2009|Yes|Yes||No|September 26, 2013|https://clinicaltrials.gov/show/NCT00922636||137471|Some sites may have received data with identifying information from the central lab; data from 69 participants were excluded from efficacy analyses. Data were excluded from efficacy analyses for a participant randomized before study site approval.
NCT00922649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANM002|Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes|Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes||Animas Corporation|No|Completed|February 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|58|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2009|June 16, 2009|March 13, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00922649||137470|
NCT00923312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-9201-003|Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|Safety and Efficacy Phase I/IIa Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)||CureVac AG|Yes|Completed|May 2009|May 2014|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|75 Years|No|||October 2013|November 11, 2014|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923312||137422|
NCT00923299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636018|Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine|Phase I-II Study Evaluating Combined Treatment of Cetuximab and Trastuzumab in Metastatic Pancreatic Cancer Patients Progressing After Gemcitabine Based Chemotherapy.||National Cancer Institute (NCI)||Recruiting|December 2008|||April 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|67|||Both|18 Years|N/A|No|||June 2009|June 20, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923299||137423|
NCT00923923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC # 0806003974|Stress Reactivity in Veterans Receiving Pharmacological Treatment for PTSD and Alcohol Dependence|Stress Reactivity in Veterans Receiving Pharmacological Treatment for Post-traumatic Stress Disorder (PTSD) and Alcohol Dependence||Yale University|Yes|Completed|January 2009|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|57|||Both|21 Years|65 Years|No|||September 2015|September 14, 2015|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00923923||137381|
NCT00923949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080208|Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer|Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)|No|Terminated|August 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2012|September 29, 2015|June 17, 2009||No|Study never published; terminated early due to low accrual.|No|January 11, 2012|https://clinicaltrials.gov/show/NCT00923949||137379|Study never published; terminated early due to low accrual.
NCT00973102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESCUE - Shock|Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Hemorrhagic Shock (RESCUE - Shock)|Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Hemorrhagic Shock (RESCUE - Shock): A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Patients With Hemorrhagic Shock|RESCUE - Shock|University of Texas Southwestern Medical Center|Yes|Completed|July 2009|May 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||April 2014|April 4, 2014|July 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973102||133644|
NCT00973596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33CSCO-122 659/139 470|The Swiss Venous Thromboembolism Cohort 65+|Swiss Venous Thromboembolism Cohort Study of Elderly Patients With Acute Venous Thromboembolism|SWITCO65+|University of Lausanne Hospitals|No|Completed|September 2009|December 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1003|||Both|65 Years|N/A|No|Non-Probability Sample|Outpatients and inpatients with acute venous thromboembolism from 9 Swiss university and        non-university hospitals|December 2014|December 1, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973596||133606|
NCT00973609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-KRK-0207|Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)|Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maintenance Treatment and Reinduction in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer||AIO-Studien-gGmbH|Yes|Completed|August 2009|August 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|853|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00973609||133605|
NCT00969566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_ENDO1|Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination|Predictive Parameters for Therapeutic Efficacy of Initial Combination Therapy With Sitagliptin and Metformin in Type 2 Diabetic Patients|COSMETIC|Seoul National University Bundang Hospital|Yes|Completed|January 2009|July 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|90 Years|No|||January 2012|January 5, 2012|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969566||133913|
NCT00969579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090194|Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer|Characterizing Lone Parenting: A Multi-Institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|28|||Both|18 Years|65 Years|No|||April 2015|March 16, 2016|August 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00969579||133912|
NCT00969904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_0804|Pilot Study to Assess the Effect of High Dose N-acetylcysteine (NAC) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Double Blind, Randomized, Placebo-controlled, Two-way Crossover, Pilot Study to Assess the Effect of High Dose N-acetylcysteine on Small Airways and on Inflammation and Oxidative Stress in COPD Patients.||University Hospital, Antwerp|No|Completed|March 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|N/A|No|||June 2012|June 29, 2012|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969904||133887|
NCT00920972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0923|Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases|A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime||Washington University School of Medicine|Yes|Recruiting|December 2001|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|220|||Both|N/A|20 Years|No|||December 2014|December 9, 2014|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920972||137598|
NCT00921232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPSODIE|Assessment of the Burden Within the Dyad Patient/Caregiver|Crossed Assessment of the Burden Within the Dyad Patient/Caregiver: Analysis of Explanatory Factors and Consequences for Return at Home of the Life-ending Patient|RAPSODIE|Centre Oscar Lambret|No|Completed|April 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|139|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|May 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00921232||137578|
NCT00921245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13027|FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period|First REal-life Evaluation of Darifenacin in Overactive Bladder Patients During 3 Months|FREEDOM|Bayer|No|Completed|June 2007|February 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Private Practice Patients|April 2015|April 17, 2015|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921245||137577|
NCT00921492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSLFEA-17611|Acupuncture and Gonadotropin-releasing Hormone Pulse Generator and Stress Axis in Polycystic Ovary Syndrome|Does Low-frequency Electro-acupuncture Restore Sensitivity of the Gonadotropin-releasing Hormone Pulse Generator and Stress Axis in Polycystic Ovary Syndrome|PCOSLFEA|Göteborg University|No|Completed|February 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Female|18 Years|39 Years|No|||October 2011|October 6, 2011|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00921492||137558|
NCT00921765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOK-018|Reversal of Ketamine Pharmacodynamic Effects With Naloxone|Naloxone Block of Low-dose (Analgetic Dose) Ketamine||Ullevaal University Hospital|No|Recruiting|June 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|64|||Female|18 Years|30 Years|No|||March 2010|March 2, 2010|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921765||137537|
NCT00922064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKT-20090219 Version 1.3|Effects of Electroconvulsive Therapy (ECT) on Serotonin-1A Receptor Binding|Effects of Electroconvulsive Therapy on Serotonin-1A Receptor Binding in Major Depression||Medical University of Vienna|Yes|Completed|June 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|60 Years|No|||November 2011|November 15, 2011|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922064||137514|
NCT00922389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-P0-V1|A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia|A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.||Beike Biotech India Pvt.ltd|Yes|Not yet recruiting|July 2009|January 2011|Anticipated|January 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|65 Years|No|||June 2009|June 16, 2009|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922389||137490|
NCT00922662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-021|Database of Patients Undergoing Cardiac Computed Tomographic Angiography at William Beaumont Hospital (CT DATABASE)|Database of Patients Undergoing Cardiac Computed Tomographic Angiography (CCTA)at William Beaumont Hospital|CTDATABASE|William Beaumont Hospitals|No|Recruiting|December 2008|June 2019|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|-  Both genders          -  Retrospective CCTA subjects who have undergone CCTA in the past 5 years at this             institution          -  Prospective subjects who will have a CCTA at this institution (ongoing)|April 2015|April 30, 2015|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922662||137469|
NCT00922896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gyeongsang-001|Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer|A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer||Gyeongsang National University Hospital|No|Completed|June 2009|May 2011|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|70 Years|No|||November 2012|November 18, 2012|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00922896||137451|
NCT00922909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/14|Executive Control Analysis in Patients Suffering From Parkinson Disease and Treated by Deep Brain Stimulation|Executive Control Analysis in Patients Suffering From Parkinson Disease and Treated by Deep Brain Stimulation (Chronometric and Electromyographic Approach During a Simon Task)||Assistance Publique Hopitaux De Marseille|No|Completed|June 2009|||June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922909||137450|
NCT00922922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136-09-EP|Duration and Direct Cost of Behavioral Health Concerns in Pediatric Primary Care|Duration and Direct Cost of Behavioral Health Concerns in Pediatric Primary Care|EI|University of Nebraska|No|Recruiting|April 2009|August 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 500 patients from a pediatricin office will be reviewed.|June 2009|June 17, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922922||137449|
NCT00923624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH081750|Patient Portal to Support Treatment Adherence|Patient Portal to Support Treatment Adherence||Group Health Cooperative|No|Completed|June 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923624||137401|
NCT00923637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20090601A|Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer|Feasibility of Administering Adjuvant Chemotherapy of Pemetrexed Followed by Pemetrexed/Oxaliplatin Immediately Post-VATS in Patients With Completely Resected NSCLC||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|June 2009|June 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||June 2009|June 17, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923637||137400|
NCT00923650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090052|Informed Consent in Pediatric Cancer Trials|Informed Consent in Pediatric Phase I Cancer Trials||National Institutes of Health Clinical Center (CC)||Completed|December 2008|February 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|1|||Both|N/A|21 Years|No|||February 2010|September 26, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923650||137399|
NCT00923663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEN-MALT|Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type||Medical University of Vienna||Recruiting|July 2009|June 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|80 Years|No|||September 2010|September 27, 2010|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923663||137398|
NCT00923962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-1 Coronary circulation 01|Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus|Endothelial and Metabolic Effects of GLP-1 in Coronary Circulation in Patients With Type 2 Diabetes Mellitus||University Hospital, Gentofte, Copenhagen|No|Completed|June 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923962||137378|
NCT00973921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paieon-Columbia-SO|Comparison of StentOptimizer With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography|Comparison of StentOptimizer - an Angiography-based Post Deployment Stent Analysis Application With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography for Post Deployment Stent Analysis||Paieon Inc.|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|40|||Both|40 Years|N/A|No|Non-Probability Sample|Consecutive patients that underwent IVUS guided stent implantation in the institution.|March 2014|March 6, 2014|September 6, 2009|Yes|Yes||No|June 5, 2012|https://clinicaltrials.gov/show/NCT00973921||133582|This is a relatively small study designed to evaluate the procedural decision about post-deployment dilatation not powered to evaluate the outcome of patients. The operator decision of his post-dilatation strategy was qualitative.
NCT00973362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007HPVASCUS30|Evaluation of the APTIMA® HPV Assay on the TIGRIS System in ASC-US and Negative for Intraepithelial Lesion/Malignancy (NILM) Population|Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens||Gen-Probe, Incorporated|No|Completed|March 2008|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|12982|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 14, 2013|September 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973362||133624|
NCT00973375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHQ09-003|Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals||AIFSIDDES|Liuhuaqiao Hospital|No|Recruiting|May 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|75 Years|No|Non-Probability Sample|These patients who received two kinds of drug-eluting stent (Endeavor and Excel) im        simultaneously.|September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973375||133623|
NCT00969917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-09|Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma|A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma||Infinity Pharmaceuticals, Inc.|No|Withdrawn|January 2010|December 2010||December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|September 1, 2009|Yes|Yes|Company decision not to start the study|No||https://clinicaltrials.gov/show/NCT00969917||133886|
NCT00973908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WWL - CDiff Prevention|Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea|Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea||National Health Service, United Kingdom|Yes|Completed|April 2010|December 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|231|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973908||133583|
NCT00970489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND-104364|Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation|(OPERA)Randomized Clinical Trial to Examine Whether Peri-operative Intake of n-3 Polyunsaturated Fatty Acids Will Reduce the Occurrence of Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery|OPERA|Brigham and Women's Hospital|Yes|Completed|August 2010|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1516|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|August 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970489||133843|
NCT00969670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-LF-242-CTIL|Correlation of Particulate Matter and Heme Oxygenase-1 Protein Activity in Asthmatic Children by Induced Sputum Analysis.|Correlation of Particulate Matter and Heme Oxygenase-1 Protein Activity in Asthmatic Children by Induced Sputum Analysis.||Tel-Aviv Sourasky Medical Center||Recruiting|October 2009|||||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|Samples of indused sputum|Both|5 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children, between 5-17 years, performing a routine diagnosis of asthma in Tel Aviv        Sourasky Medical Center|November 2009|November 21, 2009|August 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00969670||133905|
NCT00970723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071227-AOM 08077|High Blood Pressure and Sleep Apnea in Diabetic Macular Edema|Role of High Blood Pressure and Sleep Apnea in Type 2 Diabetic Macular Edema|OMHADIA|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970723||133825|
NCT00921258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0700043|Active Control of Prostatic Cancer With Criteria of Latence|Active Control of Prostatic Cancer With Criteria of Latence. Impact on Specific 10 Years Survival.|SURACAP|Clinique Mutualiste Chirurgicale de la Loire|No|Terminated|December 2007|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Male|18 Years|74 Years|No|Non-Probability Sample|patients with latent prostate cancer who agree to be controlled instead of to be        immediately treated for this cancer|June 2015|June 3, 2015|June 12, 2009||No|Financial problem (not enough budget to continue the study)|No||https://clinicaltrials.gov/show/NCT00921258||137576|
NCT00921505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARIBU-024|Effect of Ibuprofen, Paracetamol and Their Combination on Radical Oxygen Species (ROS) Production|The Effect of Ibuprofen, Paracetamol and Their Combination on Reactive Oxygen Species (ROS)- Production in Leukocytes and Platelet Activation||Oslo University Hospital|No|Completed|May 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|7|||Both|18 Years|35 Years|No|||March 2009|July 3, 2011|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921505||137557|
NCT00921778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSH-LAPCONE UUS|Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern|Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern|LSH-LAPCONE|Ullevaal University Hospital|No|Recruiting|September 2008|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|140|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2008|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921778||137536|
NCT00922077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-Nikodelis|Individualized Neurodevelopmental Treatment|Individualized Neurodevelopmental Treatment||Hellenic Society for Disabled Children|Yes|Completed|January 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|1|||Female|6 Years|9 Years||||June 2009|June 16, 2009|June 1, 2009||||No||https://clinicaltrials.gov/show/NCT00922077||137513|
NCT00922090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NKR-SER-2009/1|A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended|A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended-Release Tablets (SEROQUEL XRâ) in Subjects With Schizophrenia-An Observational, Multicentric Prospective Study|CLIMAX|AstraZeneca|No|Completed|July 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1494|||Both|18 Years|65 Years|No|Probability Sample|Adult diagnosed as Schizophrenia according to DSM-IV-TR criteria, the groups will be        selected selected from general hospital or mental hospital.|March 2010|March 11, 2010|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00922090||137512|
NCT00922402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart & Diabetes|Heart & Diabetes - Feasibility Study|Heart & Diabetes - Feasibility Study||Medtronic Bakken Research Center|No|Withdrawn|June 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922402||137489|
NCT00922675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Po 1506|Postconditioning in ST-elevation Myocardial Infarction|Postconditioning in ST-elevation Myocardial Infarction Treated With Primary PCI|POSTEMI|Oslo University Hospital|Yes|Recruiting|June 2009|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922675||137468|
NCT00922935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 02/04|Comparison of Early and Late Loading in the Edentulous Upper Jaw Using Cresco Prosthetic System on Straumann Implants|A 3 Arm Controlled Randomised Study: Comparison of Early and Late Loading Protocols in Full Arch Reconstructions in the Edentulous Maxilla, Using The Cresco Prosthetic System on Straumann Implants||Institut Straumann AG|No|Completed|October 2004|September 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||August 2011|July 31, 2012|June 16, 2009||No||No|June 13, 2011|https://clinicaltrials.gov/show/NCT00922935||137448|
NCT00922948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-001-09|Cryoablation Versus Radiofrequency Ablation for Small Renal Masses|A Prospective Randomized Pilot Trial of Cryoablation (CA) Versus Radio Frequency Ablation (RFA) for the Management of Small Renal Masses||St. Joseph's Healthcare Hamilton|No|Withdrawn|March 2010|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||December 2015|December 15, 2015|June 16, 2009||No|Cryoablation is no longer offered at our hospital, and likely won't be offered in the near    future.|No||https://clinicaltrials.gov/show/NCT00922948||137447|
NCT00923325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090054|Blood and Tissue Study of Patients in NIH Protocol 08-C-0800|A Group Wide Biology and Banking Study for Phase II Study of R1507||National Institutes of Health Clinical Center (CC)||Completed|December 2008|||||N/A|Observational|N/A|||Actual|8|||Both|2 Years|N/A|No|||August 2015|August 28, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923325||137421|
NCT00923676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGMM/03/2007|Treatment of Hyperlipidemia and Sexual Dysfunction|Effect of Fenofibrate and Rosuvastatin on Sexual Dysfunction in Hyperlipidemic Patients. A Randomized Trial||Second University of Naples|No|Active, not recruiting|April 2008|April 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00923676||137397|
NCT00919516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRANZ-07-0046|Autologous Bone Marrow Mononuclear Cell Implantation for Moderate to Severe Peripheral Arterial Disease|Use of Autologous Bone-Marrow Mononuclear Cell Implantation Therapy as a Limb Salvage Procedure in Patients With Moderate to Severe Peripheral Arterial Disease||The Vascular and Vein Center, Columbus, OH|No|Completed|December 2007|March 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919516||137708|
NCT00973401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Holfort|Retinal Function in Relation to Long Term Changes in the Glucose Level|||Glostrup University Hospital, Copenhagen|No|Recruiting|September 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|60 Years|No|Non-Probability Sample|30 type 1 diabetics without diabetic retinopathy, with dysregulated metabolic status that        is to be medically optimized.|September 2009|September 23, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973401||133621|
NCT00973414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMU-09053MZ|Fluid Management for Cesarean Section III|Fluid Management for Cesarean Section Undergoing Combined Spinal Epidural Anesthesia (CSEA)|FMCS-III|Nanjing Medical University|Yes|Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|850|||Female|21 Years|40 Years|No|||September 2009|September 8, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973414||133620|
NCT00969592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49-0361-GluAsp|Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers|Comparison of Pharmacodynamics and Pharmacokinetics of the Two Fast-acting Insulin Analogs Insulin Glulisine and Insulin Aspart in Healthy Volunteers||Profil Institut für Stoffwechselforschung GmbH|No|Completed|November 2007|June 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 1, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969592||133911|
NCT00972361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0134-08-EMC|Routine Preoperative Hemostatic Laboratory Evaluation Prior to Tonsillectomy or Adenoidectomy in Children|Routine Preoperative Hemostatic Laboratory Evaluation Prior to Tonsillectomy or Adenoidectomy in Children - a Necessity or Habitude?||HaEmek Medical Center, Israel|No|Completed|January 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|12 Months|18 Years|No|Non-Probability Sample|Data from about 200 children that were evaluated for abnormal coagulation tests performed        before minor surgery.        The data will include cause of referral, laboratory analysis performed and results.        If the data allows the outcome of the operation and bleeding complications, will also        recorded.|August 2011|August 25, 2011|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00972361||133701|
NCT00970190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36534-B|Olfactory Dysfunction of Rhinosinusitis - Cyclic Adenosine Monophosphate (cAMP)/Calcium Signaling Study|Olfactory Dysfunction of Rhinosinusitis - cAMP/Calcium Signaling Study|cAMP|University of Washington|No|Completed|August 2009|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|Samples Without DNA|Samples consist of discarded tissue resulting from the following clinical procedures:      endoscopic sinus surgery for chronic sinusitis, endoscopic transnasal approach to the      pituitary for pituitary tumor removal, endoscopic inferior turbinectomy or septoplasty for      nasal congestion and endoscopic repair of CSF leaks. Samples will only be retained for 1      year post-surgery and then destroyed.|Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the University of Washington Rhinology Clinic for evaluation of        sinus problems|December 2014|December 10, 2014|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00970190||133866|
NCT00969683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/21|Double-Lumen Tube With or Without a Carinal Hook|Comparison Between Left Double-lumen Tube With or Without a Carinal Hook During Lung Surgery||Hopital Foch|No|Completed|August 2009|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00969683||133904|
NCT00969605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGCEH-ICU-1|Adaptive Support Ventilation in the Weaning of COPD|Adaptive Support Ventilation for Faster Weaning in COPD: A Randomized Controlled Trial||Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital|No|Completed|April 2007|December 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|97|||Both|18 Years|N/A|No|||September 2009|May 26, 2010|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969605||133910|
NCT00969618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12397|A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder|Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)||Eli Lilly and Company|No|Completed|November 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|211|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|August 31, 2009|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00969618||133909|
NCT00969930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LICAVALGENE 2009|Genetic Association Study Between Single Nucleotide Polymorphisms (SNPs) and Cognitive Performance in Young Bipolar Type I Patients: LICAVALGENE|Genetic Association Study Between Single Nucleotide Polymorphisms (SNPs) and Cognitive Performance in Young Bipolar Type I Patients: LICAVALGENE|Licavalgene|University of Sao Paulo|No|Enrolling by invitation|August 2009|March 2012|Anticipated|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young bipolar disease patients in mania, depression, hypomania or mixed states without        medication use over the past 15 days.|September 2009|August 15, 2011|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00969930||133885|
NCT00921271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3786|The Application of Near Infrared Spectroscopy (NIRS) in the Detection of Lower Limb Compartment Syndrome|The Application of Near Infrared Spectroscopy (NIRS) in the Detection of Lower Limb Compartment Syndrome||University Hospital Birmingham NHS Foundation Trust|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|16 Years|N/A|No|Non-Probability Sample|All patients admitted to Selly Oak Hospital (Secondary care) meeting the study inclusion        criteria.|September 2011|September 20, 2011|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921271||137575|
NCT00921284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/41|Influence of Dexmedetomidine on a Closed-Loop Anesthesia System|Closed-Loop Delivery of Propofol and Remifentanil: Sparing Effect of Dexmedetomidine||Hopital Foch|No|Completed|June 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|66|||Male|18 Years|N/A|No|||December 2011|December 29, 2011|June 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00921284||137574|
NCT00921518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC AKICS|Prevention of Acute Kidney Injury in Cardiac Surgery Patients|Prevention of Acute Kidney Injury in Cardiac Surgery Patients||Community Medical Center, Scranton, PA|Yes|Completed|January 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|June 15, 2009||No||No|January 28, 2014|https://clinicaltrials.gov/show/NCT00921518||137556|
NCT00921791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG 04465|Efficacy of Home Blood Pressure Monitoring (MONITOR Study)|Efficacy of Home Blood Pressure Monitoring to Improve Blood Pressure Control: a Randomized Controlled Trial With Ambulatory Blood Pressure Measurement|MONITOR|Hospital de Clinicas de Porto Alegre|No|Completed|April 2006|June 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|136|||Both|18 Years|80 Years|No|||June 2009|June 15, 2009|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921791||137535|
NCT00922103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0426|A Study to Investigate the Ileo Neo Rectal Anastomosis Compared to the Ileo Pouch Anal Anastomosis for Patients With Ulcerative Colitis|A Historical Cohort Study, to Investigate Morbidity, Functional and Physiological Outcome, as Well as Endoscopic and Histological Aspects and the Quality of Life, of the Ileo Neo Rectal Anastomosis (INRA) Compared to the Ileo Pouch Anal Anastomosis (IPAA), for Patients With Ulcerative Colitis (UC)||Elisabeth-TweeSteden Ziekenhuis|No|Completed|June 2005|July 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|15 Years|80 Years|No|||September 2010|September 10, 2010|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00922103||137511|
NCT00922428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|157 A 07 PA|PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders|PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders: A Non-interventional Observational Study.|157|Pascoe Pharmazeutische Praeparate GmbH|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1389|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort of adult patients suffering from rheumatic diseases and relating symptoms who        present themselves in German Primary Care Centers.|April 2015|April 16, 2015|June 16, 2009||No||No|May 16, 2013|https://clinicaltrials.gov/show/NCT00922428||137487|
NCT00922688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIRCo05.02.2009/2|Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients|Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients|AIRCo|Medical Center Alkmaar|No|Recruiting|December 2010|May 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|30|||Male|18 Years|75 Years|No|||November 2010|July 20, 2011|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922688||137467|
NCT00922701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-001-04|L-Carnitine in Peritoneal Dialysis|Phase 2 Study of Dialysis Efficiency and Tolerability of Nocturnal Peritoneal Dialysis Solution Containing Glucose Plus L-carnitine||Iperboreal Pharma Srl|No|Completed|June 2004|December 2004|Actual|October 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2010|February 16, 2010|February 11, 2009||No||No|February 11, 2009|https://clinicaltrials.gov/show/NCT00922701||137466|
NCT00922974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0631|Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis|Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis||Radiation Therapy Oncology Group|Yes|Recruiting|November 2009|||November 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|352|||Both|18 Years|120 Years|No|||November 2015|November 19, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00922974||137445|
NCT00922987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081236|Clinical Study With Lyrica In Patients Suffering From Epilepsy|Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency||Pfizer|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|286|||Both|18 Years|N/A|No|Probability Sample|-  Adult patiens with partial seizures.          -  Other inclusion criteria according to Summary of Product Characteristics (SmPC).|July 2011|July 19, 2011|June 17, 2009|Yes|Yes||No|May 31, 2011|https://clinicaltrials.gov/show/NCT00922987||137444|On review of blinded data it was decided that an additional analysis set, MFAS was required. MFAS was created for analysis of seizure data. The outcomes related to seizure data were therefore analyzed for MFAS population and not FAS population.
NCT00923364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090096|Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC|Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2009|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|19|||Both|12 Years|60 Years|No|||June 2015|February 27, 2016|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00923364||137418|
NCT00923338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006|Clinical Evaluation of the Surgisis Biodesign Vesico-Vaginal Fistula Plug|Clinical Evaluation of the Surgisis Biodesign Vesico-Vaginal Fistula Plug|VVP|Cook||Completed|September 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|10 Years|N/A|No|||July 2012|December 29, 2015|June 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00923338||137420|
NCT00923351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070206|Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma|A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors||National Institutes of Health Clinical Center (CC)|Yes|Suspended|August 2007|July 2017|Anticipated|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|19 Months|35 Years|No|||April 2015|April 13, 2015|June 17, 2009|Yes|Yes|Principal investigator is negotiating to get access to rhIL-7. See Limitations.|No|July 9, 2013|https://clinicaltrials.gov/show/NCT00923351||137419|Re: Reason stopped: Of 30 pts who have received immunotherapy,12 remain on F/U, are stable or without evidence of disease,11 died of PD, 7 are currently receiving additional therapy (NOT ON THIS PROTOCOL) for PD.
NCT00923975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2009-08|Evaluation of DIDGET TM World Reports|Evaluation of Avatar Web Reports||Ascensia Diabetes Care|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 17, 2009|Yes|Yes||No|June 10, 2010|https://clinicaltrials.gov/show/NCT00923975||137377|
NCT00919815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRBY24-T1RA|Ciclosporin in the Management of New Type 1 Reactions in Leprosy|A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions||London School of Hygiene and Tropical Medicine|Yes|Completed|August 2010|July 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||March 2015|March 21, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919815||137687|
NCT00919828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2009-003|Monitor Patients With Acute Heart Failure|Adherent Monitoring of Congestive Heart Failure During Therapy for Excess Fluid Study|ACUTE|Corventis, Inc.|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients|February 2010|February 2, 2010|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00919828||137686|
NCT00970775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2600C00003|AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers|JSAD|AstraZeneca|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|32|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970775||133821|
NCT00970788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000826/6|A Pilot Study of Using Video Images in Advance Care Planning in Malignant Glioma Patients|A Pilot Study of Using Video Images in Advance Care Planning in Malignant Glioma Patients||Massachusetts General Hospital|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|21 Years|N/A|No|||April 2012|April 28, 2012|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00970788||133820|
NCT00971087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03|Multicenter Hologic Tomosynthesis Study|A Multicenter, Controlled Clinical Trial to Evaluate the Hologic Tomosynthesis Mammography||Hologic, Inc.|No|Active, not recruiting|September 2009|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3800|||Female|18 Years|N/A|No|||December 2012|December 5, 2012|September 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971087||133797|
NCT00971100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110_04|Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age|A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Cell-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age||Novartis||Completed|August 2009|August 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|752|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00971100||133796|
NCT00969982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.4.1|Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial||Gynuity Health Projects|No|Completed|June 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|238|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00969982||133881|
NCT00973466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK26/09|Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients|Prevalence of Asymptomatic and Symptomatic Infection of N. Gonorrheae and C. Trachomatis and Seroprevalence of HSV Typ 2 and Sexual Health Seeking Behaviour in People With HIV Infection in Bern|CTNG|University Hospital Inselspital, Berne|No|Completed|May 2009|June 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|All consecutive HIV-infected patients attending the Clinic for Infectious Diseases at Bern        University Hospital will be asked to participate in the study if they were sexually active        during the last 12 months|January 2011|January 12, 2011|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00973466||133616|
NCT00973700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V112_04|Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)|A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Children and Adults Ages 3 to 64 Years||Novartis||Completed|August 2009|October 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|784|||Both|3 Years|64 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|September 2, 2009|Yes|Yes||No|October 20, 2010|https://clinicaltrials.gov/show/NCT00973700||133598|
NCT00970502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 06-0509|Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer|Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation||Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2007|November 2010|Anticipated|November 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 1, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00970502||133842|
NCT00970736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6697-M|Stability of Motor Output in Aging Adults|Corticobulbar Motor Output in Aging Adults||VA Office of Research and Development|No|Completed|November 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults between 60 and 80 years of age|December 2014|March 5, 2015|September 1, 2009||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00970736||133824|
NCT00921297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-09-21|Cataract Removal and Alzheimer's Disease|Therapeutic Effects of Cataract Removal in Alzheimer's Disease||University Hospital Case Medical Center|Yes|Recruiting|June 2009|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|210|||Both|50 Years|90 Years|No|||December 2015|December 1, 2015|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921297||137573|
NCT00921531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-THALIDOMIDE|Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma|Phase Ⅲ Study of Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma||Fudan University|Yes|Recruiting|June 2009|April 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||June 2009|April 18, 2011|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921531||137555|
NCT00921804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1960C00004|Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients|A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Active-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD8529 in Adult Schizophrenia Patients||AstraZeneca||Completed|June 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|296|||Both|18 Years|65 Years|No|||June 2010|June 29, 2010|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921804||137534|
NCT00921817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109498|Body Composition in Infants and Children|Validation of a Body Composition Method for Infants and Children||Arkansas Children's Hospital Research Institute|Yes|Completed|May 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|two urine samples are collected during the study visit|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|healthy children weighing between 0 and 110 pounds|February 2010|February 10, 2010|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921817||137533|
NCT00922116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22285|A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera® for the Maintenance of Haemoglobin Levels in Patients With Chronic Renal Anaemia Who Are Not on Dialysis||Hoffmann-La Roche||Completed|April 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|191|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|June 16, 2009||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00922116||137510|
NCT00922415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-ID-255-CTIL|Fecal Calprotectin as a Marker for Macroscopic Recurrence of Crohn's Disease After Intestinal Resection|Use of Fecal Calprotectin as a Surrogate Marker for Macroscopic Recurrence of Disease in Patients With Crohn's Disease After Intestinal Resection||Tel-Aviv Sourasky Medical Center|No|Recruiting|August 2009|December 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|At all follow-up visits, they will undergo the following tests; CBC, ESR, CRP, and fecal      calprotectin. Sera will be stored for antibodies such as ASCA or anti glycan antibodies.      During colonoscopy, disease recurrence will be evaluated by two scores, the Rutgeerts score      and the CDEIS score, both containing 4 grades. Recurrence will be assessed by histological      findings as well.|Both|18 Years|N/A|No|Non-Probability Sample|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal        resection for complicated Crohn's disease|December 2010|December 15, 2010|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922415||137488|
NCT00923000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDI-001|Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs|Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs||Tri-Service General Hospital|Yes|Recruiting|December 2008|December 2009|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Anticipated|50|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||June 2009|June 18, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923000||137443|
NCT00923013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090005|Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia|Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease||National Institutes of Health Clinical Center (CC)||Recruiting|October 2008|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|177|||Both|18 Years|100 Years|No|||March 2016|March 19, 2016|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00923013||137442|
NCT00922714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scandinavian Glutamin Study|Scandinavian Intensive Care Unit (ICU) Glutamine Study|Glutamine to Intensive Care Patients - a Prospective, Double-Blind, Placebo-Controlled Multicenter Study in the Scandinavian Countries||Scandinavian Critical Care Trials Group|No|Terminated|October 2003|August 2009|Anticipated|May 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|85 Years|No|||June 2009|June 15, 2009|June 15, 2009||No|Slow recruitment, stopped after 4 years|No||https://clinicaltrials.gov/show/NCT00922714||137465|
NCT00922961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAMMOSITE2|Research for Predictive Biologic Parameters of Cutaneous Hypersensitivity After Brachytherapy in Breast Cancer|Research for Predictive Biologic Parameters of Cutaneous Hypersensitivity After Brachytherapy in Breast Cancer|MAMMOSITE2|Centre Oscar Lambret|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Female|60 Years|N/A|No|||July 2012|July 20, 2012|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00922961||137446|
NCT00923741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080166|Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer|An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC)||National Institutes of Health Clinical Center (CC)||Completed|June 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|90 Years|No|||November 2012|October 23, 2014|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00923741||137393|
NCT00923702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMGF48979|Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India|Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India||International Agency for Research on Cancer|Yes|Active, not recruiting|September 2009|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20000|||Female|10 Years|18 Years|Accepts Healthy Volunteers|||September 2013|September 10, 2013|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923702||137396|
NCT00923715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24391|Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia|Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia||Baylor College of Medicine|Yes|Enrolling by invitation|August 2009|May 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|63|||Both|12 Years|21 Years|No|||December 2010|December 7, 2010|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00923715||137395|
NCT00923728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090119|A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors|A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors||Vertex Pharmaceuticals Incorporated||Withdrawn|April 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2011|January 8, 2014|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923728||137394|
NCT00919542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCRBY24-ENLA|Ciclosporin in the Management of New Erythema Nodosum Leprosum|A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.||London School of Hygiene and Tropical Medicine|Yes|Completed|July 2010|July 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Female|18 Years|65 Years|No|||March 2015|March 21, 2015|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919542||137707|
NCT00921076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH 02-035|Gait Analysis of Ankle Arthroplasty and Arthrodesis|Gait Analysis of Patients Undergoing Total Ankle Arthroplasty, Ankle Arthrodesis, Tibiotalocalcaneal or Pantalar Fusion.||St. Michael's Hospital, Toronto|No|Recruiting|June 2002|||January 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|85 Years|No|||July 2009|December 12, 2012|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921076||137590|
NCT00971724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05888|Biomarkers of Prednisolone Treatment (P05888)|A Randomized, Placebo-controlled, Double-blind, Single-center Study Using Multiple Doses of Prednisolone to Quantify Effects on Selected Biomarkers and Assess Pharmacokinetics in Healthy Males||Merck Sharp & Dohme Corp.|No|Completed|May 2006|March 2008|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|72|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|September 3, 2009||||No||https://clinicaltrials.gov/show/NCT00971724||133749|
NCT00971737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0947 CDR0000653173|Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer|A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|July 2009|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|120 Years|No|||September 2015|September 23, 2015|September 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971737||133748|
NCT00972023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000653162|DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer|A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer||Barbara Ann Karmanos Cancer Institute||Terminated|February 2010|August 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|N/A|No|||July 2013|July 8, 2013|September 3, 2009||No||No|April 23, 2013|https://clinicaltrials.gov/show/NCT00972023||133726|
NCT00972036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-030|Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy|Phase I Study of Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy||Memorial Sloan Kettering Cancer Center|Yes|Completed|August 2009|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|September 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00972036||133725|
NCT00973687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2967|Dexamethasone Tolerability in the Treatment of Acute Asthma in Children|Dexamethasone Tolerability in the Treatment of Acute Asthma in Children||IWK Health Centre|No|Completed|September 2004|May 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|430|||Both|2 Years|14 Years|No|||September 2009|August 25, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973687||133599|
NCT00973635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00009658|The Web-Based Education of Beginning Interns on Handoffs|The Web-Based Education of Beginning Interns on Handoffs||Northwestern University|No|Withdrawn|July 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 12, 2013|August 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00973635||133603|
NCT00973973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-56418-0901|Efficacy and Safety Study of NBI-56418 Sodium in Subjects With Endometriosis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis||AbbVie|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Female|18 Years|49 Years|No|||January 2013|January 2, 2013|September 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00973973||133578|
NCT00941538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.2006BAI02A11|Screening for Nasopharyngeal Carcinoma in High Risk Populations|Screening for Nasopharyngeal Carcinoma (NPC) on the High Risk Area and Evaluation on the Project of Early Diagnosis and Treatment||Sun Yat-sen University|Yes|Recruiting|June 2009|July 2019|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|Samples With DNA|Whole blood, Serum, White cells, pathological tissue|Both|30 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cantonese Residents of Zhongshan City; Cantonese Residents of Sihui City|July 2009|July 21, 2009|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941538||136043|
NCT00971360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUTFEK 2009/173|Cytokine Levels in Conversion Disorder|Proinflammatory Cytokine Levels in Patients With Conversion Disorder||Trakya University|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|primary care clinic|September 2009|October 19, 2010|September 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00971360||133776|
NCT00971373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM12358|Pilot Study to Determine the Effectiveness of Antimicrobial Healthcare Worker's (HCW) Hands and Clothing|Pilot Study to Determine the Effectiveness of Antimicrobial Scrubs on Bacterial Burden of HCW's Hands and Clothing in a Clinical Setting||Virginia Commonwealth University|Yes|Enrolling by invitation|September 2009|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 2, 2009|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00971373||133775|
NCT00921310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0668 / 201105207|Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer|A Phase I/II Trial of Temsirolimus and Pemetrexed in Recurrent/Refractory Non Small Cell Lung Cancer (NSCLC)||Washington University School of Medicine|No|Active, not recruiting|September 2009|May 2015|Anticipated|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921310||137572|
NCT00921323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol No. 29778|The Use of Pedometers as an Adjunctive Tool in a School-based Pediatric Weight Management Program|The Use of Pedometers as an Adjunctive Tool in a School-based Pediatric Weight Management Program||Penn State University|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|June 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00921323||137571|
NCT00921544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coombesucrose|Sucrose Analgesia for the Reduction of Pain During Retinopathy of Prematurity Screening|Sucrose and Non Nutritive Suck as Analgesia for Babies Undergoing Retinopathy of Prematurity Screening; a Randomised Placebo Controlled Trial||Coombe Women and Infants University Hospital|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||June 2009|June 15, 2009|June 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00921544||137554|
NCT00921557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1076|Safety and Effectiveness of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density|Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|August 2009|||January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|51|||Both|11 Years|24 Years|No|||March 2016|March 2, 2016|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921557||137553|
NCT00922441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-203|A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Valsartan-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657•K) During 24hours by Dose in Patients With Mild to Moderate Essential Hypertension||Boryung Pharmaceutical Co., Ltd|Yes|Completed|December 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|70 Years|No|||December 2010|December 14, 2010|June 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00922441||137486|
NCT00922727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-MSC-08-0266|Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults|Phase I Safety and Tolerance of Lactobacillus Reuteri in Adults||The University of Texas Health Science Center, Houston|Yes|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|June 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00922727||137464|
NCT00924014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure|Comparative Effects of Conivaptan and Loop Diuretics on Plasma Neurohormones and Systemic and Renal Hemodynamics in Subjects With Chronic Congestive Heart Failure||Hennepin County Medical Center, Minneapolis|No|Not yet recruiting|July 2009|March 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|8|||Both|18 Years|80 Years|No|||June 2009|June 17, 2009|June 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00924014||137374|
NCT00924027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090100|A Study of Patients Receiving High-Dose Rate Brachytherapy|A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch||National Institutes of Health Clinical Center (CC)||Recruiting|March 2009|November 2025|Anticipated|November 2022|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|112|||Both|18 Years|90 Years|No|||December 2015|December 15, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00924027||137373|
NCT00923377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070123|Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer|Pilot Trial to Identify and Characterize Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer||National Institutes of Health Clinical Center (CC)||Completed|March 2007|May 2010||||N/A|Observational|Time Perspective: Prospective|||Actual|3|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|September 26, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923377||137417|
NCT00919841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 059/2551(EC3)|Sequential Volume Measurement of Postpartum Uterus Using 3-dimensional Sonographies|Sequential Volume Measurement of Postpartum Uterus Using 3-dimensional Sonographies|3DUT|Mahidol University|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who deliver a singleton vaginally will be invited to participate the study.|May 2010|May 1, 2010|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00919841||137685|
NCT00920062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-C-HCE101-3A-H|Measurement of Recirculation During Venovenous Extracorporeal Membrane Oxygenation (VV ECMO)|Ultrasound Dilution Measurement of Recirculation During Venovenous Extracorporeal Membrane Oxygenation||Transonic Systems Inc.|No|Enrolling by invitation|June 2007|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|N/A|21 Years|No|||June 2012|June 4, 2012|June 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00920062||137668|
NCT00923988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHS-EF|Effect of Passive Smoking on Platelet Function and Endothelial Function|Acute Effects of Short-term Exposure to Secondhand Smoke on Platelet Activation and Endothelial Function||Kantonsspital Graubünden||Completed|June 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2009|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923988||137376|
NCT00924001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070210|Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma|Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)|Yes|Terminated|August 2007|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|June 17, 2009|No|Yes|study was stopped due to low accrual|No|December 22, 2011|https://clinicaltrials.gov/show/NCT00924001||137375|
NCT00920387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDA1|Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety|LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study||Multidisciplinary Association for Psychedelic Studies|No|Completed|February 2008|September 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|June 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00920387||137643|
NCT00920738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003NT064|Metabolic Syndrome in Childhood Cancer Survivors|Metabolic Syndrome in Childhood Cancer Survivors||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|April 2005|June 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|512|Samples With DNA|A 22 gauge intravenous polyethylene catheter will be inserted into an antecubital vein of      one arm and the necessary blood for all baseline laboratory studies will be obtained and      processed as per standard protocol.|Both|9 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|The childhood cancer survivor (CCS) subjects for this study will be selected from        Pediatric Oncology databases at the University of Minnesota Medical Center and Children‟s        Hospitals and Clinics of Minneapolis and St. Paul as described previously. CCS will        complete a comprehensive evaluation in the Masonic Clinical Research Unit (MCRU) over a 2        day time period. The comparative data on normal children and adolescents will be obtained        from healthy siblings frequency matched by age and gender and who will be evaluated in a        manner similar to the CCS.|August 2014|August 21, 2014|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920738||137616|
NCT00929929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA_LEU-09|Study to Assess the Effect of Leucine Along With Resistance Exercise on Muscle Strength and Quality of Life in Elders|Randomized Double-blind, Placebo-controlled, Parallel Design, Pilot Study to Assess the Effect of a Nutritional Supplement With Leucine, Along With a Progressive Resistance Exercise Program, on Muscle Strength and Quality of Life in Elderly People.||Hospital Clinic of Barcelona|No|Completed|December 2009|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|70 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 8, 2014|June 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00929929||136926|
NCT00972634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000648077|Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer|The European Palliative Care Research Collaborative - Computerised Symptom Assessment and Classification of Pain, Depression and Physical Function (Cachexia) (EPCRC - CSA)||Norwegian University of Science and Technology|No|Completed|October 2008|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1051|||Both|18 Years|N/A|No|Non-Probability Sample|Patients|October 2015|October 5, 2015|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00972634||133680|
NCT00972647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59130|Radiation Exposure Using Laser Guided Fluoroscopy in Various Orthopaedic Procedures|Radiation Exposure Using Laser Guided Fluoroscopy in Various Orthopaedic Procedures||Loma Linda University|Yes|Withdrawn|August 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|89 Years|No|||September 2013|September 29, 2013|August 20, 2009||No|Lack of personnel|No||https://clinicaltrials.gov/show/NCT00972647||133679|
NCT00972920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/NIR03/45|TAP Block for Gynaecological Laparotomies - a Comparison of Ultrasound-guided Block and Blind Technique|Transversus Abdominis Plane (TAP) Block for Gynaecological Laparotomies - a Comparison of Ultrasound-guided Block and Blind Technique||Northern Health and Social Care Trust|No|Completed|August 2009|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|89 Years|No|||October 2015|October 20, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00972920||133658|
NCT00972933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-144|Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma|Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis||University of Pittsburgh|Yes|Active, not recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|September 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00972933||133657|
NCT00973648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0481|Exploring Voluntary Control of Tinnitus|Exploring Voluntary Control of Tinnitus: A Pilot Study||Washington University School of Medicine|No|Completed|August 2009|February 2012|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|17|||Both|18 Years|80 Years|No|Non-Probability Sample|Speciality clinic Community health centers Solicitation of participants from American        Tinnitus Association and Acoustic Neuroma Society Research database|June 2013|June 10, 2013|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973648||133602|
NCT00973934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4371|Magnetic Seizure Therapy (MST) for the Treatment of Major Depression|Magnetic Seizure Therapy (MST) for the Treatment of Major Depression|MST-2|Duke University|Yes|Completed|April 2002|December 2009|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||June 2014|June 9, 2014|September 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00973934||133581|
NCT00941551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN/501/ZKL/69/L|Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively|Five-year Follow up of a Randomized Clinical Trial of Unilateral Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively||Jagiellonian University|Yes|Completed|January 2000|December 2008|Actual|December 2003|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|150|||Both|18 Years|65 Years|No|Probability Sample|primary care clinic|July 2009|July 16, 2009|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941551||136042|
NCT00941564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK76|Comparative Ca Absorption and Tolerance in Healthy Term Infants Fed Milk-based Formulas With Different Fat Blends|"Comparative Calcium Absorption and Gastrointestinal Tolerance in Healthy Term Infants Fed Milk-based Formulas With Different Fat Blends"||Abbott Nutrition|Yes|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|84 Days|159 Days|Accepts Healthy Volunteers|||November 2010|November 24, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00941564||136041|
NCT00941876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10121|Integration of Family Planning and HIV Services in Tanzania|An Evaluation of Integration of Family Planning Into HIV/AIDS Care and Treatment Clinics in Tanzania||FHI 360|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|864|||Both|18 Years|45 Years|No|||August 2011|August 10, 2011|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00941876||136017|
NCT00921830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO2203|Pharmacokinetics of 3 Formulations of Ibuprofen Suppositories|A Single-dose, Randomised, Crossover Study to Compare the Rate and Extent of Absorption of Three Formulations of Ibuprofen in Healthy, Fasting Male and Female Volunteers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|April 2004|November 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|June 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00921830||137532|
NCT00921843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1195|Methadone in Pediatric Anesthesia|Methadone in Pediatric Anesthesia||Washington University School of Medicine|No|Active, not recruiting|May 2009|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|5 Years|18 Years|No|||January 2016|January 13, 2016|June 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00921843||137531|
NCT00922129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-002-09|Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer|A Prospective Randomized Pilot Study Examining the Role and Effectiveness of Conversion to Sirolimus Versus CNI Reduction in Renal Transplant Patients With Prostate Cancer||St. Joseph's Healthcare Hamilton|No|Withdrawn|September 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|50 Years|No|||January 2014|January 13, 2014|June 16, 2009||No|Study did not start up as planned.|No||https://clinicaltrials.gov/show/NCT00922129||137509|
NCT00923026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090161|Follow Up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies|Follow Up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|June 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|633|||Both|18 Years|N/A|No|||August 2015|September 9, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923026||137441|
NCT00923390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090092|Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor|Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor||National Institutes of Health Clinical Center (CC)||Terminated|March 2009|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||August 2012|February 19, 2014|June 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00923390||137416|
NCT00923780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070060|Evaluation of Blood Vessel Formation in Endocrine Tumors|Prospective Evaluation of Tumor Angiogenesis in Endocrine Neoplasms||National Institutes of Health Clinical Center (CC)||Completed|January 2007|||September 2009|Actual|N/A|Observational|Time Perspective: Prospective||||400|||Both|N/A|N/A|No|||September 2009|September 26, 2015|June 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00923780||137392|
NCT00932711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4140-B|Effect of Educational Intervention in Patients With Low-Risk Chronic Obstructive Pulmonary Disease|Limited Intervention in Low Risk(Tier 3) COPD Patients||Minneapolis Veterans Affairs Medical Center|No|Enrolling by invitation|July 2009|July 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|4000|||Both|N/A|N/A|No|||June 2009|July 2, 2009|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00932711||136717|
NCT00933049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005HD11/3472U|Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months|Clinical Efficacy of Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months Attending Mulago Hospital: A Randomized Clinical Trial.||Makerere University|Yes|Completed|July 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|505|||Both|2 Months|59 Months|No|||July 2009|July 6, 2009|July 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00933049||136692|
NCT00933062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113140|Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered as Single and Multiple Doses in the Fed State to Normal Healthy Male Volunteers||GlaxoSmithKline|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00933062||136691|
NCT00919555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071808|Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)|Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis|PNA|Phoenix Neurological Associates, LTD|Yes|Completed|June 2008|March 2012|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|85 Years|No|||November 2012|November 29, 2012|June 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00919555||137706|
NCT00929071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS DP101L - US - 02|Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®|Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®|AD-1016|Weinkle, Susan H., M.D.|No|Completed|January 2009|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|June 24, 2009||No||No|December 16, 2013|https://clinicaltrials.gov/show/NCT00929071||136990|
NCT00929084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000799|Survivor Stories: Impact on Cancer Patients' Quality of Life and Follow-up|Survivor Stories: Impact on Cancer Patients' Quality of Life and Follow-up||Washington University School of Medicine|Yes|Active, not recruiting|November 2009|December 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|220|||Female|30 Years|N/A|No|||December 2015|December 7, 2015|June 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00929084||136989|
NCT00920400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALPROTECT|Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract|Value of Fecal Calprotectin in Upper Gastrointestinal Disease||University Hospital, Basel, Switzerland|No|Completed|March 2008|December 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|287|Samples Without DNA|Biopsy samples (stomach, duodenum) will be stored by the Department of Pathology at the      University Hospital Basel|Both|18 Years|N/A|No|Non-Probability Sample|300 consecutive patients undergoing upper endoscopy at the Department of Gastroenterology        & Hepatology at the University Hospital Basel|January 2010|January 11, 2010|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00920400||137642|
NCT00929656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6862-W|Combined Neural and Behavioral Therapies to Enhance Stroke Recovery|Combining Neural and Behavioral Therapies to Enhance Stroke Recovery||VA Office of Research and Development|No|Active, not recruiting|August 2010|November 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|80 Years|No|||November 2015|November 13, 2015|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00929656||136947|
NCT00929669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809652|Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas|Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study|LAR|University of Pennsylvania|Yes|Terminated|June 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|June 23, 2009|Yes|Yes|unable to identify a third subject|No||https://clinicaltrials.gov/show/NCT00929669||136946|
NCT00940368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-10/27.02.2009|A Study to Assess the Anti-Emetic Efficacy of Ginger in Children and Adolescents Receiving Chemotherapy|A Study to Evaluate the Anti-Emetic Effect of Ginger Powder Vs Placebo as an Add-on Therapy in Children and Adolescents Receiving Chemotherapy : A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|June 2009|January 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|8 Years|21 Years|No|||July 2009|July 24, 2009|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940368||136133|
NCT00973167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|469508|Low-magnitude High-frequency Vibration Study on Fracture Rate in Community Elderly|The Efficacy of Low-magnitude, High-frequency Vibration Treatment on Reducing Fracture Risks and Fracture Incidences in the Community Elderly - a Prospective Randomized Trial||Chinese University of Hong Kong|No|Completed|January 2009|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|704|||Female|65 Years|85 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00973167||133639|
NCT00973180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-0923017|Enhanced Prescription Drug Label to Improve Patient Understanding and Use|Enhanced Prescription Drug Label to Improve Patient Understanding and Use||Northwestern University|No|Completed|May 2009|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|850|||Both|30 Years|N/A|No|||September 2014|September 25, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973180||133638|
NCT00973453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM/0028|Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients|Dose Tolerability Study With High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients||HAL Allergy|Yes|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|48|||Both|18 Years|N/A|No|||September 2011|September 9, 2011|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00973453||133617|
NCT00940966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-02-1776|A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome|A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome||CAMC Health System|No|Completed|July 2006|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|12 Years|18 Years|No|||February 2015|February 2, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940966||136087|
NCT00970203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-070|Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer|Feasibility, Safety and Efficacy Evaluation of Alpha-Type 1 Dendritic Cell(DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With PSA Progression After Local Therapy for Prostate Cancer||University of Pittsburgh|Yes|Recruiting|September 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Male|18 Years|N/A|No|||December 2015|December 23, 2015|September 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00970203||133865|
NCT00973726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stig Holfort|The Retinal Function in Relation to Glucose Changes|The Retinal Function in Relation to Glucose Changes||Glostrup University Hospital, Copenhagen|Yes|Recruiting|September 2009|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|80 Years|No|||September 2009|September 23, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00973726||133596|
NCT00941889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO 07-0648|The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata|The Effect of Human Papillomavirus Vaccination on Recurrence Rates in HIV Positive Patients Treated for Anal Condylomata||Washington University School of Medicine|No|Enrolling by invitation|July 2007|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2009|August 14, 2009|July 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00941889||136016|
NCT00922454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Acute Technical Outcomes of the Talent Abdominal Aortic Aneurysm (AAA) Stent-Graft Versus Cook Zenith Stent-Graft|Acute Technical Outcomes of the Talent AAA Stent -Graft vs. Cook Zenith Stent- Graft: A Case-Control Study||Center for Vascular Awareness, Albany, New York|No|Recruiting|June 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2009|June 16, 2009|June 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00922454||137485|
NCT00922467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/47|Influence of Esmolol on a Closed-Loop Anesthesia System|Closed-loop Delivery of Propofol and Remifentanil: Sparing Effect of Esmolol||Hopital Foch|No|Terminated|June 2009|December 2011|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|N/A|No|||January 2012|January 4, 2012|June 2, 2009||No|lack of effectiveness|No||https://clinicaltrials.gov/show/NCT00922467||137484|
NCT00922740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-002|VA106483 Dose Response Study in Elderly Males|An Open Label, Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Elderly Male Subjects||Vantia Ltd||Completed|June 2009|September 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|65 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 24, 2009|June 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00922740||137463|
NCT00932425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMACS|Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)|Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS): A Pilot Randomized Trial|CMACS|University of California, San Francisco|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|July 1, 2009|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT00932425||136738|
NCT00932724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY503C2|CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer|Phase II Double-blind Placebo-controlled Trial of CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Cancer|CY503C2|Cytavis Biopharma GmbH|Yes|Terminated|July 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||June 2011|July 9, 2013|June 25, 2009||No|The sponsor declared the early termination of the study due to poor recruitment of patients.|No||https://clinicaltrials.gov/show/NCT00932724||136716|
NCT00932438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBIRI # 09.0034|Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6|Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy|DEBIRI|University of Louisville|Yes|Completed|June 2009|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||November 2011|April 17, 2013|July 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00932438||136737|
NCT00932737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202.839|(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis|A Double-blind, Placebo-controlled, Randomized, Parallel-group Pilot Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used on Demand for the Treatment of Self-reported Functional Abdominal Pain Associated With Cramping||Boehringer Ingelheim||Completed|June 2009|||February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||October 2013|April 30, 2014|June 17, 2009||||No||https://clinicaltrials.gov/show/NCT00932737||136715|
NCT00929136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aarhus University Hospital|Peripheral Effects of Endotoxin on Insulin Resistance|The Effect of Regional Inflammation on Metabolism and Insulin Sensitivity in the Lower Extremity.||Aarhus University Hospital|No|Completed|June 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 1, 2010|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00929136||136985|
NCT00928785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPV02C|Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults|A Randomised, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Tdap-IPV Vaccine and a Tetanus Monovalent Vaccine in Healthy Adults 18 Years of Age and Older||Sanofi Pasteur MSD|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|456|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 3, 2009|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00928785||137012|
NCT00928798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2-058|Topical Rapamycin for Fibrofolliculomas|Topical Rapamycin to Treat Fibrofolliculomas in Birt-Hogg-Dubé Syndrome||Maastricht University Medical Center|No|Completed|January 2010|August 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|June 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00928798||137011|
NCT00928811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17718|Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant|One-year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-risk Kidney Transplant Recipients Treated With MPA|Simulect|Drexel University|Yes|Terminated|May 2009|April 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|June 25, 2009|Yes|Yes|Investigator left University 04/2010|No||https://clinicaltrials.gov/show/NCT00928811||137010|
NCT00929383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRISS|An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis|An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis|IRISS|Stryker Neurovascular|Yes|Completed|February 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|41 Years|N/A|No|Non-Probability Sample|Patients with symptomatic intracranial atherosclerotic stenosis. Patients will be included        who are eligible for endovascular treatment and for which treatment with the Wingspan™        Stent system has been judged necessary by the treating physician.|September 2012|May 15, 2014|June 26, 2009||No||No|March 14, 2014|https://clinicaltrials.gov/show/NCT00929383||136967|
NCT00982254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175A-C-02|Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes|A Comparison of the Pharmacodynamic and Pharmacokinetic Properties of Oral Insulin vs. s.c. Regular Insulin in Type 2 Diabetic Patients||Profil Institut für Stoffwechselforschung GmbH|No|Completed|October 2001|||November 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|35 Years|70 Years|No|||September 2009|September 22, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00982254||132962|
NCT00982527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSCPB-1|Fenoldopam in Pediatric Cardiac Surgery|Intraoperative Fenoldopam Infusion in Children Requiring Cardiopulmonary Bypass During Cardiac Surgery||Bambino Gesù Hospital and Research Institute|No|Completed|September 2009|November 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|365 Days|No|||June 2012|June 26, 2012|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982527||132941|
NCT00982787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3107|Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy|A Phase II Randomized, Placebo Controlled, Double-blind, Cross-over Clinical Trial to Test the Safety and Potential Anticonvulsant Efficacy of a Botanical Extract From Passiflora Incarnata, in Patients With Partial Onset Epilepsy.||Oregon Health and Science University|Yes|Active, not recruiting|September 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||November 2009|February 22, 2011|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00982787||132921|
NCT00982566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-069|Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer|A Phase 1 Study Evaluating the Relative Oral Bioavailability of New Formulations of ABT-263 in Subjects With Cancer||Abbott||Completed|October 2009|December 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|16||Actual|37|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00982566||132938|
NCT00982579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV001|Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers|An Open Randomized Phase I Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1/2-uninfected Mothers|PedVacc001|Medical Research Council|Yes|Completed|November 2009|September 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|N/A|3 Days|Accepts Healthy Volunteers|||September 2009|February 2, 2012|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982579||132937|
NCT00978562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005405|DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors|Imaging Vascular Properties of Pediatric Brain Tumors Using DSC-MRI With Ferumoxytol (Code 7228) and DCE-MRI With Gadolinium in a Single Imaging Session: An NCI Sponsored Exploratory Trial||OHSU Knight Cancer Institute|Yes|Active, not recruiting|August 2009|December 2017|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Both|5 Years|18 Years|No|||March 2016|March 21, 2016|September 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978562||133232|
NCT00980395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1071-04|Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma|A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas||University of Arizona|Yes|Active, not recruiting|July 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980395||133096|
NCT00978822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-0904-001|Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage|Clevidipine in Aneurysmal Subarachnoid Hemorrhage, A Pilot Study|CLASH|Henry Ford Health System|Yes|Recruiting|September 2009|June 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||September 2009|September 17, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978822||133212|
NCT00978835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002325|Tailored Case Management for Diabetes and Hypertension|Tailored Case Management for Diabetes and Hypertension|TEACH-DM|Duke University|Yes|Completed|May 2008|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|377|||Both|21 Years|N/A|No|||July 2014|July 14, 2014|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978835||133211|
NCT00979433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-74|Bubble Continuous Positive Airway Pressure (CPAP) With Conventional CPAP for Extubation in Preterm Infants|Bubble CPAP vs. Conventional CPAP Following Extubation in Preterm Very Low Birth Weight (VLBW) Infants: A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|No|Completed|September 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|N/A|7 Days|No|||February 2013|February 23, 2013|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979433||133166|
NCT00979420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1535|Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune|Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune||Boehringer Ingelheim||Completed|August 2009|||November 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|patients|June 2014|June 27, 2014|September 16, 2009||||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00979420||133167|
NCT00980655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3003|Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients|A Phase 3, Open-label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13vPnC Followed by 23vPS in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years and Older.||Pfizer|Yes|Completed|January 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|251|||Both|2 Years|N/A|No|||March 2014|March 17, 2014|September 18, 2009|Yes|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT00980655||133078|
NCT00980980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH000223K|Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)|Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal|REDUCE-MRSA|Harvard Pilgrim Health Care|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|3||Actual|74256|||Both|13 Years|N/A|No|||August 2014|August 18, 2014|September 19, 2009||No||No|May 14, 2014|https://clinicaltrials.gov/show/NCT00980980||133060|
NCT00981097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-064|Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma|Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas||AIDS Malignancy Consortium|No|Completed|August 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|Samples With DNA|5 tubes of peripheral blood collected along with available tissue blocks or fresh frozen      tissue collected at baseline.|Both|18 Years|N/A|No|Non-Probability Sample|Persons with HIV infection and a diagnosis of an untreated aggressive B-cell lymphoma.|August 2014|August 27, 2014|September 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00981097||133051|
NCT00981981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL8034|Effect of the Molecular Weight of Oat β-glucan on Its Ability to Lower Serum Cholesterol|Effect of Varying Dose and Molecular Weight on the Serum LDL-cholesterol-lowering Properties of Oat β-glucan|Bluebird|Glycemic Index Laboratories, Inc|No|Completed|November 2008|August 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|367|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 20, 2011|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00981981||132983|
NCT00989131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAS-07OVA|Study of Paclitaxel in Patients With Ovarian Cancer|An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL)||Oasmia Pharmaceutical AB|Yes|Completed|February 2009|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|789|||Female|18 Years|N/A|No|||February 2014|February 3, 2014|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00989131||132437|
NCT00989144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH004|Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort|Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort.|SEARCH004|Thai Red Cross AIDS Research Centre|No|Completed|January 2007|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|Samples With DNA|Pools will be made by aliquoting 40ul per subject into each pool, with a maximum of 20      subjects per pool, yielding a maximum pool volume of 800 ul. Samples will be run with the      Roche Amplicor ver 1.5 test in ultrasensitive mode with appropriate controls as per      manufacturer's instructions. Quality assurance will be per SOP. Pools testing positive will      be re-analyzed at the individual sample level. Positive samples will be confirmed by Bayer      bDNA NAT. Frequency of infection will be tabulated.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The client from the Voluntary Counseling and Testing (VCT) facilities at the Thai Red        Cross Anonymous Clinic in Bangkok, Thailand.|October 2009|October 28, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989144||132436|
NCT00989430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBarrett3|Prism Adaptation Therapy for Spatial Neglect|Prism Adaptation Therapy for Spatial Neglect: Theoretical and Practical Outcomes||Kessler Foundation|Yes|Active, not recruiting|October 2012|January 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989430||132414|
NCT00989716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04002|The Efficacy of Nitric Oxide in Stroke (ENOS) Trial|A Prospective, Collaborative, International, Multicentre, Randomised, Parallel-group, Single and Outcome Blinded, Controlled, Factorial Trial to Investigate the Safety and Efficacy of Treatment With Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, and of Continuing or Stopping Temporarily Pre-stroke Antihypertensive Therapy, in Patients With Acute Stroke|ENOS|University of Nottingham|Yes|Recruiting|July 2001|October 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|3500|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989716||132392|
NCT00982241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OABdrinkstudy|Overactive Bladder (OAB) Drink Advice Study|Prospective Intervention Study of Drink Advice in Overactive Bladder Syndrome (OAB)||Radboud University|Yes|Withdrawn|July 2009|||December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|0|||Both|18 Years|75 Years|No|||September 2009|July 23, 2012|September 22, 2009||No|Difficulty in enrolling participants|No||https://clinicaltrials.gov/show/NCT00982241||132963|
NCT00979069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6860-M|Aerobic Exercise to Improve Executive Language Function In Older Adults|Aerobic Exercise to Improve Executive Language Function in Older Adults||VA Office of Research and Development|No|Completed|September 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|65 Years|89 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|September 15, 2009||No||No|September 18, 2014|https://clinicaltrials.gov/show/NCT00979069||133193|
NCT00982306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN08OC202|Brief Interventions in General Hospital (BIG)|Brief Interventions for Heavy Alcohol Users Admitted to General Hospital|BIG|Partnerships in Care|Yes|Recruiting|February 2010|April 2012|Anticipated|February 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|1||Anticipated|294|||Both|18 Years|80 Years|No|||July 2010|July 28, 2010|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982306||132958|
NCT00979147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVA-3946B|Comparison of a Metal Backed Fixed-Bearing Tibial Baseplate and an All-Polyethylene Tibia in Total Knee Arthroplasty|A Randomized Prospective Level 1 Comparison of a Modular Polished Fixed-Bearing Tibial Baseplate and an All-Polyethylene Tibia in Total Knee Arthroplasty||Minneapolis Veterans Affairs Medical Center||Completed|November 2007|||May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|400|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979147||133188|
NCT00981032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0264|Improving Aspirin Use Among Adults at Risk for Cardiovascular Disease (CVD)|Improving Implementation of the US Preventive Service Task Force Recommendation for Prophylactic Aspirin Use Among Adults at Risk for Cardiovascular Disease||Geisinger Clinic|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|884|||Both|45 Years|70 Years|No|||February 2011|February 16, 2011|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00981032||133056|
NCT00979134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2610C00001|Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|October 2009|March 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|979|||Both|25 Years|N/A|No|||June 2015|June 25, 2015|September 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979134||133189|
NCT00980343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02922|GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery|A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)||Completed|February 2010|||May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2013|May 21, 2014|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980343||133100|
NCT00980642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-453|Accuracy of the Drager Dual-sensor Temperature Measurement System|Accuracy of the Draeger Dual-sensor Temperature Measurement System in The Perioperative Period||Outcomes Research Consortium|No|Completed|March 2010|August 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|75|||Both|6 Years|80 Years|No|||August 2012|August 27, 2012|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980642||133079|
NCT00981292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24Z1|Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults|Cerebral Blood Flow, Cerebro-electrical Activity and Behavioural Effects of Epigallocatechin Gallate (EGCG) Administration in Healthy, Young Adults||Northumbria University|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|32|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|September 21, 2009||No||No|June 25, 2010|https://clinicaltrials.gov/show/NCT00981292||133036|
NCT00981877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protrota2007|Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian Children|Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian Children: Randomized Double-blind, Controlled Trial Using Two Different Preparations||Centro Pediatrico Albina de Patino|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|76|||Both|1 Month|23 Months|No|||September 2009|September 21, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00981877||132991|
NCT00988533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP008|A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age|An Open-label Study to Assess the Bioavailability, Safety, Local Tolerance, and Efficacy of 0.5% Ivermectin Cream in Subjects 6 Months to 3 Years of Age With Pediculus Humanus Capitis (Head Lice) Infestation||Topaz Pharmaceuticals Inc|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|6 Months|3 Years|No|||March 2012|March 30, 2012|October 1, 2009|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT00988533||132483|
NCT00988546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSRD-000-00F|Evaluation of Computerized Template Entry for Compensation and Pension (C&P) Examinations|Evaluation of Computerized Template Entry for C&P Examinations||VA Office of Research and Development|Yes|Completed|May 2005|July 2005|Actual|July 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|37|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2009|October 1, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988546||132482|
NCT00988819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB C/09/022|To Investigate the Influence of Ethnicity in Metabolic Disease in Healthy, Overweight and Obese Subjects|Developmental Pathways to Metabolic Diseases: Metabolic Physiology, Epigenetics and Body Composition in Healthy Overweight and Obese Subjects With a Fixed Range of Body Mass Index in Singapore - To Investigate the Influence of Ethnicity|SAMS-1|National University Hospital, Singapore|No|Recruiting|July 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|plasma, serum, packed cells, blood clot, urine, buccal cells, muscle tissue|Male|21 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Singapore population|February 2010|February 28, 2010|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988819||132461|
NCT00989157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1J-US-X054|Effects of Gastric Bypass on Blood Levels of Duloxetine|A Preliminary Comparison of the Effect of Roux-en-Y Bariatric Surgery on Blood Levels of Duloxetine||Neuropsychiatric Research Institute, Fargo, North Dakota|No|Completed|September 2009|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|October 1, 2009|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT00989157||132435|
NCT00989170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1206|Family Program for Weight Gain Prevention|Family Program for Weight Gain Prevention||University of Colorado, Denver|No|Completed|July 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|418|||Both|3 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989170||132434|
NCT00989443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-COL-CI01|Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions|A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3)||Mithra Pharmaceuticals|No|Completed|May 2010|||September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Female|18 Years|50 Years|No|||October 2010|October 20, 2010|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989443||132413|
NCT00990028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28-09ROHI|Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury|Effect of Rosuvastatin on Immunological Markers After Traumatic Brain Injury: Clinical Randomized Double Blind Study Phase 2||Universidad Autonoma de San Luis Potosí|Yes|Completed|August 2009|August 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|60 Years|No|||October 2009|October 5, 2011|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990028||132368|
NCT00989690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRSI-HSRL-02-2007|Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer|Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer||National Cancer Institute (NCI)||Recruiting|February 2008|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|275|||Both|18 Years|N/A|No|||October 2009|August 9, 2013|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989690||132394|
NCT00989703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0259-CL-102|GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects|Double Blind, Placebo Controlled, Dose Ranging and Methotrexate Interaction Study for the Assessment of Safety, Tolerability and Pharmacokinetics (PK) of Multiple Oral Doses of GLPG0259 in Healthy Subjects||Galapagos NV|No|Completed|September 2009|January 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 17, 2012|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989703||132393|
NCT00990002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002|Investigation of A Children's Beverage Containing Different Probiotics|INVESTIGATION OF CHANGES IN LEUKOCYTE POPULATIONS AMONG CHILDREN RECEIVING A FOLLOW-ON COW'S MILK-BASED FORMULA CONTAINING DIFFERENT BIOACTIVE INGREDIENTS.||Mead Johnson Nutrition|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|||Both|2 Years|4 Years|Accepts Healthy Volunteers|Probability Sample|children 2-4 years of age|May 2011|May 9, 2011|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990002||132370|
NCT00989976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#16028A|Individual Differences in Diabetes Risk: Role of Sleep Disturbances|Individual Differences in Diabetes Risk: Role of Sleep Disturbances||University of Chicago|No|Completed|February 2009|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989976||132372|
NCT00989989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002D2303|Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema|A Randomized, Double-masked, Multicenter, Laser Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema|REVEAL|Novartis||Completed|September 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|396|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|October 2, 2009||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT00989989||132371|
NCT00978575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iron Gab|Iron Substitution After Upper Gastro-Intestinal Bleeding|Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial||University of Aarhus|Yes|Completed|April 2010|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|97|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978575||133231|
NCT00978588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0429|Comparison of 6% Hydroxyethyl Starch 130/0.4 With 5% Albumin as Priming Solution for Cardiopulmonary Bypass|||Yonsei University||Completed|February 2008|August 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|N/A|N/A|No|||February 2012|February 2, 2012|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978588||133230|
NCT00982839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK057100-08|Rectal Sensory Training - A Study of Two Techniques|Rectal Sensory Training - A Randomized Controlled Study of Two Techniques||Georgia Regents University|No|Completed|March 2004|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982839||132917|
NCT00980031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-14634|Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension|Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension|Aldosterone|Creighton University|No|Terminated|April 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|19 Years|N/A|No|||March 2014|March 27, 2014|September 11, 2009||No|Funding ended prior to study completion|No||https://clinicaltrials.gov/show/NCT00980031||133120|
NCT00980681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-047|Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)|Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Renal Arterial Disease||Guerbet|No|Terminated|September 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|220|||Both|18 Years|N/A|No|||September 2010|September 20, 2010|September 17, 2009|Yes|Yes|Lack of recruitment.|No||https://clinicaltrials.gov/show/NCT00980681||133077|
NCT00980993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00005606|Quantification of Respiratory-induced Prostate Motion|Pilot Study on the Quantification of Respiratory-induced Prostate Motion During Radiation Therapy Using Continuous Real-time Tracking||Oregon Health and Science University|No|Active, not recruiting|September 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Male|18 Years|N/A|No|Non-Probability Sample|Localized prostate cancer patients undergoing intensity-modulated radiation therapy.|September 2009|September 21, 2009|September 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00980993||133059|
NCT00981565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-Surg-005|Mild Carpal Tunnel Syndrome|Operative Versus Conservative Treatment in Mild Carpal Tunnel Syndrome, Randomized Prospective Multicenter Study||North Karelia Central Hospital||Completed|September 2009|June 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|65 Years|No|||October 2012|October 17, 2012|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00981565||133015|
NCT00981578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM010|ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Feasibility Study to Evaluate the Safety and Initial Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System||InSightec||Recruiting|September 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00981578||133014|
NCT00981890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0115-C|Stereotactic Radiosurgery With Sunitinib for Brain Metastases|A Phase I Study of Stereotactic Radiosurgery Concurrent With Sunitinib in Patients With Brain Metastases||University Health Network, Toronto|Yes|Active, not recruiting|July 2009|July 2016|Anticipated|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981890||132990|
NCT00988559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0866, NA_00020850|Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)|A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2009|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|39|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988559||132481|
NCT00988832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06066|An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)|A UK Retrospective Audit of Patients With Crohn's Disease Treated With Infliximab||Merck Sharp & Dohme Corp.|Yes|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|380|||Both|18 Years|N/A|No|Non-Probability Sample|All interested hospital physicians across the UK who prescribe infliximab as part of their        treatment of Crohn's Disease patients will be included. Physicians will record information        from the medical records of patients who meet the inclusion criteria.|September 2015|September 1, 2015|October 1, 2009|No|Yes||No|December 6, 2011|https://clinicaltrials.gov/show/NCT00988832||132460|
NCT00988845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0093|Indole-3-Carbinol Effects on Estrogen Metabolism|Effects of Dietary Indole-3-Carbinol on Estrogen Metabolites Across a Wide Range of Body Mass Index: Implications for the Prevention of Endometrial Cancer in Obese Women||University of Wisconsin, Madison|Yes|Terminated|September 2009|January 2014|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|October 1, 2009||No|Slow accrual in the high BMI group|No||https://clinicaltrials.gov/show/NCT00988845||132459|
NCT00989183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1964|Lifestyle Factors Study|Lifestyle Factors and Their Impact on Ovarian Reserve||University of Oklahoma|No|Recruiting|August 2009|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|65|Samples With DNA|Telomere length assay|Female|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will obtain whole ovaries (single or pairs) from 65 healthy females between the ages of        21 and 55 undergoing surgical oophorectomy for benign indications at the OU Medical        Center, Oklahoma City, Oklahoma.        *NOTE: Must be willing to travel to Oklahoma City to participate. Need to have the        transvaginal ultrasound and skin autofluorescence measurement at the OU Physicians        Reproductive Health Clinic in Oklahoma City, Oklahoma.|December 2014|December 2, 2014|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989183||132433|
NCT00989469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEXIRI|Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation|SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.|NEXIRI|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Completed|February 2009|February 2012|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989469||132411|
NCT00989456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|420082351|Well Being and Rehabilitation in Chronically Ill Patients: Structured Patient Education and Physical Exercise|Structured Patient Education in Combination With Physical Exercise as Part of the Integrated Care to Chronically Ill Patients With Chronic Obstructive Pulmonary Disease, Heart Failure and Stroke. A Randomized Controlled Intervention Trial.||Norwegian University of Science and Technology|No|Completed|September 2009|April 2013|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|54|||Both|45 Years|N/A|No|||April 2013|April 9, 2013|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00989456||132412|
NCT00990041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9002-10-04.PBMC|Release of Cytokines by Stimulated Peripheral Blood Mononuclear Cells (PBMC) From Chronic Periodontitis Subjects|||Escola Bahiana de Medicina e Saude Publica||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy humans|October 2009|October 5, 2009|October 5, 2009||||No||https://clinicaltrials.gov/show/NCT00990041||132367|
NCT00990054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ04808|Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia||Sanofi|Yes|Completed|December 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|70 Years|No|||March 2015|March 19, 2015|October 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990054||132366|
NCT00990015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0861001|A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single-Dose Escalation Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04308515 in Healthy Volunteers||Pfizer|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 29, 2010|October 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990015||132369|
NCT00990288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26078|The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery|The Role of a Topical Hemostatic Agent in Reducing Blood Loss in Unilateral Total Knee Arthroplasty||Hospital for Special Surgery, New York|Yes|Completed|October 2007|||August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Both|N/A|N/A|No|||October 2009|January 11, 2011|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990288||132348|
NCT00990275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268-07|Alcohol Exposure and Airway Hyperresponsiveness|Alcohol Exposure and Airway Hyperresponsiveness||University of Nebraska|No|Completed|October 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00990275||132349|
NCT00990509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-173|Albumin for Intracerebral Hemorrhage Intervention|Albumin for Intracerebral Hemorrhage Intervention|ACHIEVE|Georgetown University|No|Terminated|September 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|October 1, 2009|Yes|Yes|Enrollment was stopped due to low recruitment and the PI's move to a different institution.|No|July 22, 2014|https://clinicaltrials.gov/show/NCT00990509||132331|There was an insufficient number of subjects in each treatment arm to allow for a meaningful analysis of the effects of albumin on HARM status (blood brain barrier disruption).
NCT00990522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-014|Study of the Efficacy of Sharp Debridement for the Management of Chronic Wounds|A Prospective, Randomized, Controlled Study of the Efficacy of Sharp Debridement for the Management of Chronic Wounds||Southwest Regional Wound Care Center|No|Withdrawn|May 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 6, 2009||No|No participants enrolled, per PI discretion|No||https://clinicaltrials.gov/show/NCT00990522||132330|
NCT00979459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-010|A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)|A Single Dose Study to Compare the Pharmacokinetics of Two Probe Formulations of MK-1006||Merck Sharp & Dohme Corp.|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|September 17, 2009|No|Yes||No|July 12, 2012|https://clinicaltrials.gov/show/NCT00979459||133164|
NCT00979472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC-2009-0014|Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency|Comparison of the Effect of Flexible Dosage of Solifenacin Succinate Between Patients Who Have Frequent Micturition With and Without Urgency||Asan Medical Center|No|Completed|April 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|291|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979472||133163|
NCT00978874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654177|Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer|[F18]EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Carcinoma of the Cervix||National Cancer Institute (NCI)||Recruiting|May 2008|||May 2010|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||September 2009|October 17, 2009|September 16, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00978874||133208|
NCT00979745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV029|Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)|A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)||Clinuvel Pharmaceuticals Limited|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|70 Years|No|||August 2011|August 3, 2011|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979745||133142|
NCT00980044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0489|Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal|Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal||University of Kentucky|No|Completed|October 2009|March 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|September 17, 2009|Yes|Yes||No|June 10, 2013|https://clinicaltrials.gov/show/NCT00980044||133119|The study was designed to analyze only completers (12 subjects per group so the description of study participant characteristics and outcomes are from these a prior defined n=36 (12 per group) completers.
NCT00980057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adaptive CRT|Adaptive Cardiac Resynchronization Therapy Study|Adaptive Cardiac Resynchronization Therapy Study|aCRT|Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|November 2009|September 2012|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|522|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|September 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980057||133118|
NCT00980759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-209|Prophylactic Irradiation of the Para-Aortic Lymph Nodes in Locally Advanced Uterine Cervical Cancer|A Phase II Randomized Study of Prophylactic Irradiation of the Para-Aortic Lymph Nodes by 3-D Conformal Radiotherapy Technique With Concurrent Chemotherapy Based on the Hypoxic Status of Locally Advanced Uterine Cervical Cancer||National Cancer Center, Korea|No|Active, not recruiting|July 2006|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|312|||Female|18 Years|80 Years|No|||September 2015|September 7, 2015|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980759||133072|
NCT00981656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0926|Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer|A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging||Radiation Therapy Oncology Group|Yes|Recruiting|November 2009|||October 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|120 Years|No|||October 2015|October 13, 2015|September 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981656||133008|
NCT00980694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UQ01|Bioavailability of Ubiquinol in Huntington Disease|Bioavailability of Ubiquinol in Huntington Disease||University of Rochester|No|Recruiting|September 2009|May 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|N/A|No|||September 2009|September 18, 2009|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00980694||133076|
NCT00981305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH 0905-037-281|Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors|Impact of Lactate-containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors: Prospective Randomized Controlled Trial||Seoul National University Hospital|Yes|Active, not recruiting|September 2009|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Female|20 Years|60 Years|No|||April 2013|April 18, 2013|September 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00981305||133035|
NCT00981318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rodwick01|Pilot Assessment of Lopinavir/Ritonavir and Maraviroc|Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients|PALM|Rodwick, Barry M., M.D.|No|Terminated|December 2009|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2015|June 20, 2015|September 19, 2009|Yes|Yes|unable to enroll expected number of subjects|No||https://clinicaltrials.gov/show/NCT00981318||133034|
NCT00981604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 07 132|Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy|Single Incision Versus Laparoscopic Cholecystectomy|SILS|Children's Mercy Hospital Kansas City|No|Completed|August 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|18 Years|No|||December 2011|December 12, 2011|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981604||133012|
NCT00981903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-04-5|Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer|Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer||University of Southern California|No|Terminated|July 2005|October 2015|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|131|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 18, 2009|Yes|Yes|Tinzaparin will no longer be available in the United States|No||https://clinicaltrials.gov/show/NCT00981903||132989|
NCT00981916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16451A|Ultrasound Determination of Needle Depth in Epidurals in Adult Patients|Ultrasound Determination of Needle Depth in Lumbar and Thoracic Epidurals in Adult Non-Parturient Patients||University of Chicago|Yes|Completed|September 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population will include all non parturients above the age of 18 who are        candidates for epidural placement prior to surgery|September 2013|September 4, 2013|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981916||132988|
NCT00988286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK057100|Mechanism of Action of Biofeedback Therapy|Mechanism of Action of Biofeedback Therapy||Georgia Regents University|No|Active, not recruiting|August 2005|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00988286||132502|
NCT00988572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radius|Vestibular Rehabilitation for Patients With Fall-related Wrist Fractures|Vestibular Rehabilitation for Patients With Fall-related Wrist Fractures - a Randomized Controlled Trial||Lund University|No|Completed|March 2009|March 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|50 Years|N/A|No|||March 2015|March 30, 2015|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988572||132480|
NCT00988858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12092|A Study of Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer||Eli Lilly and Company|No|Completed|November 2009|November 2014|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988858||132458|
NCT00989495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dytfong|Comprehensive Cohort Study of Bracing for Adolescent Idiopathic Scoliosis (AIS): A Feasibility Study|Single-blind Comprehensive Cohort Study Incorporating a Randomized Controlled Design on Bracing in AIS: A Feasibility Study||The University of Hong Kong|No|Completed|October 2008|November 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|68|||Both|10 Years|N/A|No|||December 2014|December 1, 2014|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989495||132409|
NCT00989482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fulbright-Gonzales|Improving Antibiotic Prescribing Practices in Mexican Primary Care Clinics|Improving Antibiotic Prescribing Practices in Mexican Primary Care Clinics||University of California, San Francisco|No|Completed|January 2010|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|847|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00989482||132410|
NCT00989729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVAR-150-2009|Preoperative Methylprednisolone in Endovascular Aortic Repair|Preoperative Methylprednisolone in Endovascular Aortic Repair - a Randomized Double Blind Placebo Controlled Clinical Trial|POMEVAR|Rigshospitalet, Denmark|Yes|Completed|October 2009|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989729||132391|
NCT00990886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002878|The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women|The Effect of Ditropan XL on Vasomotor Symptoms in Healthy Postmenopausal Women: a Double-blind Placebo Controlled Pilot Study||Ortho-McNeil Janssen Scientific Affairs, LLC||Completed|April 2004|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990886||132302|
NCT00990301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10630201|A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide 15mg/25mg Tablets (Paddock Laboratories, Inc) and Uniretic® 15mg/25mg Tablets (Schwarz Pharma)(Moexipril HCl/Hydrochlorothiazide) in Healthy Adult Volunteers Under Fasting Conditions.||Paddock Laboratories, Inc.||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|October 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990301||132347|
NCT00990561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ultravate Lac-Hydrin Ranbaxy|Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis|A Clinical Study Comparing the Efficacy of Ultravate Ointment Once Daily vs. Twice Daily in Combination With Lac-Hydrin Lotion in the Treatment of Stable Plaque Psoriasis||University of California, San Francisco|Yes|Completed|July 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 4, 2012|October 5, 2009|Yes|Yes||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00990561||132327|
NCT00990574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10012009-4120|A Study Comparing Two Spinal Techniques for for Cesarean Delivery Anesthesia|Spinal Anesthesia for Cesarean Delivery: The Wiley Spinal Catheter Intermittent Bolus Technique Versus Single Shot Spinal Anesthesia||Stanford University|No|Withdrawn|October 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|45 Years|No|||October 2015|October 7, 2015|October 5, 2009||No|device not found to be adequate|No||https://clinicaltrials.gov/show/NCT00990574||132326|
NCT00990847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-IOA-0601|Nebulized Procaterol Versus Nebule Salbutamol for the Treatment of Moderate Acute Asthma|The Efficacy of Nebulized Procaterol Versus Nebulized Salbutamol for the Treatment of Moderate Acute Asthma: a Randomized, Double-blind, Parallel Group Study||PT Otsuka Indonesia|No|Completed|June 2007|August 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|15 Years|60 Years|No|||October 2009|October 6, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990847||132305|
NCT00990262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P000458|Rule Out Myocardial Infarction by Computer Assisted Tomography|Accuracy of Contrast Enhanced Multidetector Computed Tomography to Identify Cardiac Cause of Symptoms in Patients With Intermediate Likelihood of Acute Coronary Syndrome (ACS) - A Comparison to Standard Care|ROMICAT|Massachusetts General Hospital|No|Completed|May 2005|April 2009|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|368|Samples With DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients who presented to the emergency department at Massachusetts General Hospital, with        acute chest pain and with initial negative biomarkers and normal or non-ischemic ECG|October 2009|October 2, 2009|September 30, 2009||||No||https://clinicaltrials.gov/show/NCT00990262||132350|
NCT00990535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-6|High Dose Somatostatin Analogues in Neuroendocrine Tumors|Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study|HIDONET|Federico II University|Yes|Completed|January 2006|December 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|80 Years|No|||October 2009|October 6, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990535||132329|
NCT00979173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018751|Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma|A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants||Duke University|No|Completed|November 2009|June 2012|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2013|January 28, 2014|August 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979173||133186|
NCT00979485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-75|Microparticles in Pediatric Inflammatory Disease|Microparticles in Pediatric Inflammatory Bowel Disease||Indiana University|Yes|Terminated|August 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric GI clinic at Riley Hospital Pediatric well child clinic at Riley Hospital|June 2011|June 22, 2011|September 17, 2009||No|initial results suggest no significant trends will be observed with completion of study|No||https://clinicaltrials.gov/show/NCT00979485||133162|
NCT00979498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biel 003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld||||||N/A|N/A|N/A||||||||||||||September 17, 2009|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979498||133161|
NCT00979511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01|Effect of High-Calcium Milk and Weight-Bearing Exercise on Bone Mineral Status of Pre-Pubertal Girls|The Effect of a 10-month School-based Provision of High-calcium Milk and Weight-bearing Exercise Program on the Bone Mineral Status of 7 to 9 Year Old Pre-pubertal Girls|Bone Health|Nutrition Center of the Philippines|No|Completed|February 2009|September 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|120|||Female|7 Years|9 Years|Accepts Healthy Volunteers|||March 2012|March 14, 2012|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979511||133160|
NCT00980070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|329-09-FB|The Effectiveness of a Pediatric Lumbar Puncture Restraint Device|The Effectiveness of a Pediatric Lumbar Puncture Restraint Device|SNOWBOARD|University of Nebraska|No|Recruiting|October 2009|June 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|30|||Both|N/A|90 Days|No|||June 2012|June 19, 2012|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980070||133117|
NCT00980369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIstanbul|The Importance of Lateral Internal Sphincterotomy Incision: Parallel or Vertical|Incision Type for Lateral Internal Sphincterotomy||SB Istanbul Education and Research Hospital|Yes|Enrolling by invitation|October 2007|January 2010|Anticipated|March 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|52|||Both|18 Years|65 Years|No|Probability Sample|Primary care clinic|September 2009|September 18, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980369||133098|
NCT00981669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1242/06|Rotavirus Vaccine Produced by Butantan Institute|Evaluation of Rotavirus Vaccine Produced by Butantan Institute. Phase I - Safety, Tolerability and Immunogenicity Evaluation||Butantan Institute|Yes|Completed|March 2009|June 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 15, 2013|September 17, 2009||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT00981669||133007|The vaccine candidate needs to be evaluated further in larger trials, among the target population.
NCT00981006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICAD0910|AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA)|Hybrid Biotherapy Involving Autologous Human Cardiac Stem Cell Transplantation Combined With the Controlled Release of bFGF Using a Gelatin Hydrogel Sheet to Treat Severe Refractory Heart Failure With Chronic Ischemic Cardiomyopathy|ALCADIA|Kyoto Prefectural University of Medicine|Yes|Completed|April 2010|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|80 Years|No|||March 2015|March 31, 2015|September 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00981006||133058|
NCT00981019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPIB-01-SM|Doctors' Understanding of Survival Statistics|Study of Primary Care Physicians' Understanding and Use of Different Survival Measures|MPIB|Max Planck Institute for Human Development|Yes|Completed|December 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|778|||Both|30 Years|65 Years|No|Non-Probability Sample|301 primary care physicians (internal, general, and family medicine physicians)|July 2011|July 20, 2011|September 18, 2009||No||No|May 20, 2011|https://clinicaltrials.gov/show/NCT00981019||133057|Mistaken exclusion of "exclusively outpatient" physicians due to a programming mistake of the online survey screener
NCT00981591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIL-001-12806|Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients|A Randomized, Double Blind, Placebo-controlled Pilot Study of the Safety and Effective Dosing of Inhaled Iloprost in Pediatric Patients With Pulmonary Hypertension Treated With Inhaled Nitric Oxide||Seattle Children's Hospital|Yes|Withdrawn|September 2009|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|21 Years|No|||January 2015|January 15, 2015|September 18, 2009|Yes|Yes|No patients recruited|No||https://clinicaltrials.gov/show/NCT00981591||133013|
NCT00981617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33-005|ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Adaptive Study of the Safety and Efficacy of RDC-0313 in Adults With Alcohol Dependence||Alkermes, Inc.|No|Completed|October 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|406|||Both|18 Years|N/A|No|||August 2011|August 19, 2011|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981617||133011|
NCT00988299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0864|Energy Expenditure Responses to Acute Exercise in Older Women (Calorie Expenditure and Exercise)|Energy Expenditure Responses to Acute Exercise in Older Women|CEE|Washington University School of Medicine|No|Completed|October 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|26|||Female|60 Years|75 Years|Accepts Healthy Volunteers|||December 2011|December 2, 2011|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988299||132501|
NCT00988312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyelomVak|Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma|Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma||University Hospital Carl Gustav Carus|No|Completed|March 2002|March 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|70 Years|No|||October 2009|October 1, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988312||132500|
NCT00988585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dupont-0609|Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil|Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil|EPA|Cardiovascular Research Associates|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988585||132479|
NCT00988871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICC1342|Comparison of Central Venous Pressures (CVPs) Measured From Peripherally Inserted Central Catheters (PICC) and CICC in Liver Transplantation Recipients|Comparison of the Central Venous Pressures Measured From the Peripherally Inserted Antecubital Central Catheters and the Internal Jugular Vein Central Catheters in Liver Transplantation Recipients|PICC|National Cancer Center, Korea|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|N/A|N/A|No|Non-Probability Sample|Adult patients who had been scheduled for elective liver transplant surgery, and placed        with both PICC and CICC.|October 2009|October 1, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988871||132457|
NCT00990067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 253/09|Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)|Pharmacological Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacodynamics (PD) and Pharmacokinetics (PK)||University Hospital, Basel, Switzerland|Yes|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990067||132365|
NCT00990600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADONE|QoL and Adherence to One-pill Once-a-day HAART|Adherence to a One Pill, Once-a-day Antiretroviral Regimen|ADONE|A.O. Ospedale Papa Giovanni XXIII|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|212|||Both|18 Years|80 Years|No|||October 2009|October 28, 2009|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990600||132324|
NCT00989742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07061|Doxycycline In Lymphangioleiomyomatosis (LAM)|A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.||University of Nottingham|No|Completed|July 2009|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989742||132390|
NCT00990899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08025|Hypertension and Sleep Disordered Breathing in Pediatrics|Hypertension and Sleep Disordered Breathing in Pediatrics||Winthrop University Hospital|Yes|Recruiting|October 2008|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|10 Years|17 Years|No|Non-Probability Sample|children aged 10 to 17 years who have been diagnosed with primary hypertension|May 2010|May 11, 2010|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990899||132301|
NCT00990314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS-MR-PAH-204|Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients|An Open-label Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients||Lung Biotechnology PBC|No|Completed|November 2009|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||May 2014|May 19, 2014|October 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990314||132346|
NCT00990587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPX V001|Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy|Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy||University Health Network, Toronto|Yes|Completed|October 2009|||May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990587||132325|
NCT00990548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE1561|Family Cardiac Caregiver Investigation to Evaluate Outcomes|Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)|FIT-O|Columbia University|No|Completed|November 2009|July 2012|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4500|||Both|N/A|N/A|No|Non-Probability Sample|Cardiovascular Service Line inpatients at Columbia University Medical Center/New York        Presbyterian Hospital during a consecutive 11-month period.|May 2013|May 14, 2013|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990548||132328|
NCT00979784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMMA-FMRC01|Better Weight-Better Sleep (BWBS) Trial|The Better Weight-Better Sleep Study: A Pilot Intervention in Primary Care|BWBS|Summa Health System|No|Completed|April 2009|May 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|49|||Both|18 Years|84 Years|No|||June 2013|June 11, 2013|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979784||133139|
NCT00979797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-059|Community-Integrated Management of Childhood Illness (IMCI) Programme Evaluation|An Assessment of Public Health Effectiveness of Approaches to Promote Key Family & Community Behaviors for Child Survival||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|July 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|140000|||Both|N/A|49 Years|No|||September 2009|September 28, 2014|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979797||133138|
NCT00980083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSE|GLP-1 - Regulatory Mechanism of Postprandial Glycemia|Endogenous GLP-1 Regulates Postprandial Glycaemia in Human: Relative Contributions of Insulin, Glucagon, and Gastric Emptying||Ludwig-Maximilians - University of Munich|No|Completed|October 2004|December 2007|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00980083||133116|
NCT00980733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Global Alliance G#102512|Efficacy of Micronutrient Fortified Yoghurt in School Children for Health Benefits|Efficacy of Consumption of Micronutrient Fortified Yoghurt on Biochemical Markers, Cognitive Development, Morbidity and Physical Growth Among 6-9 Years School Going Children in Bangladesh - A Double Masked, Randomized Trial With a Concurrent Matched Control||Annamalai University|Yes|Recruiting|September 2008|August 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1325|||Both|6 Years|9 Years|No|||September 2009|September 18, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980733||133074|
NCT00980746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-206|Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) as Therapy for Patients With Painful Diabetic Neuropathy: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial||Bial - Portela C S.A.|No|Completed|November 2007|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|557|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|September 18, 2009||No||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00980746||133073|
NCT00981643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 08-950|Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy|The Effects of Meditation on Pain, Fatigue and Physical Functioning in Patients With Multiple Sclerosis and Peripheral Neuropathy||The Cleveland Clinic|No|Completed|February 2009|December 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|50|||Both|N/A|N/A|No|||September 2011|September 7, 2011|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981643||133009|
NCT00981929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-375|Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes|Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes||University of Southern Denmark|Yes|Terminated|September 2009|January 2011|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|412|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|June 24, 2010|September 21, 2009|||Unexpected non-serious adverse events|No||https://clinicaltrials.gov/show/NCT00981929||132987|
NCT00988598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401008|A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease|A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Mild To Moderate Alzheimer's Disease Subjects On Stable Donepezil Therapy||Pfizer|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|55 Years|85 Years|No|||August 2010|August 5, 2010|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988598||132478|
NCT00988910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14182|Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being|Observational Study on the Effects of DRSP-Containing Combined Oral Contraceptives (Yasmin,Yasminelle) and Other Combined Oral Contraceptives on the General and Sexual Well-Being in COC Users|COSME|Bayer|No|Completed|January 2008|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|632|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women using Combined Oral Contraceptive (COC)|June 2014|June 25, 2014|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988910||132454|
NCT00988884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-005|A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)|A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) Given Concomitantly With Menactra™ and Adacel™ in Preadolescents and Adolescents (11 to 15 Year Olds)||Merck Sharp & Dohme Corp.|Yes|Completed|October 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1241|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|October 1, 2009|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT00988884||132456|
NCT00988897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALI_L_03943|Colorectal Cancer RECHALLENGE|A Phase II Study of Modified FOLFOX-6 Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer in Patients Who Have Received Oxaliplatin-based Adjuvant Chemotherapy||Sanofi||Withdrawn|October 2009|May 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2009|December 21, 2009|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00988897||132455|
NCT00989196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENA-01|Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A|Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A||Octapharma|Yes|Completed|May 2010|September 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|12 Years|65 Years|No|||December 2013|December 16, 2013|September 30, 2009|Yes|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT00989196||132432|
NCT00989209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 890/04|Myofunctional Therapy in Facial Palsy|Improvement of Facial Symmetry With Myofunctional Therapy Combined to Botulinum Toxin Injections in Long Standing Facial Paralysis||University of Sao Paulo General Hospital|No|Completed|January 2005|December 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|16 Years|62 Years|Accepts Healthy Volunteers|||October 2009|October 2, 2009|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989209||132431|
NCT00989755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2008-1335|Center for Disease Control (CDC) Fax to Quit/Academic Detailing Grant|An Evaluation of the Fax to Quit Program and Wisconsin Tobacco Quitline Utilization by Southeastern Wisconsin Clinics|F2Q/EAD|University of Wisconsin, Madison||Completed|September 2008|August 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|49|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989755||132389|
NCT00990613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451038|A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin|A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults||Pfizer|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|19|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||February 2010|February 2, 2010|October 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990613||132323|
NCT00990626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NHU-SER-2009/1|Seroquel XR in Schizophrenia Relapse Prevention|Seroquel XR in Schizophrenia Relapse Prevention||AstraZeneca|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|||Both|18 Years|70 Years|No|Non-Probability Sample|Psychiatric outpatient clinics|November 2010|November 16, 2010|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990626||132322|
NCT00991549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-087|Diabetes Prevention In Estrie|Comparative Evaluation of the Effectiveness of 2 Available Resources in Estrie, for the Prevention of Type 2 Diabetes in High-risk Subjects||Université de Sherbrooke|No|Completed|December 2004|January 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|53|||Both|N/A|N/A|No|||October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991549||132251|
NCT00991172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-0908|A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Sciatic Pain||Regeneron Pharmaceuticals|Yes|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|65 Years|No|||December 2011|December 1, 2011|September 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991172||132280|
NCT00991510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116B8|Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients|Comparative Bioavailability of Myfenax® (Teva) and CellCept® (Roche) in Stable Patients After Renal Transplantation||Teva Pharmaceutical Industries|No|Terminated|August 2009|March 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|August 29, 2009||No|Slow recruitment and lack of time to product launch|No|May 13, 2013|https://clinicaltrials.gov/show/NCT00991510||132254|The study was designed to have a power of at least 80 % to show bioequivalence with 80 subjects. Only 43 subjects were included.
NCT00991523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-054|Overnight Post-Exercise Recovery After Protein Ingestion Prior to Sleep|Protein Ingestion Prior to Sleep as a Dietary Strategy to Improve Post-exercise, Overnight Recovery.||Maastricht University Medical Center|Yes|Completed|October 2009|December 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||April 2011|April 19, 2011|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991523||132253|
NCT00987428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080903|Early Endoscopic Ultrasound - Based Sphincterotomy or Conservative Treatment in Severe Biliary Pancreatitis|Randomised Multicenter Trial of Early EUS Followed by Endoscopic Sphincterotomy in Case of Bile Duct Stone vs Conservative Treatment in Severe Biliary Pancreatitis|EEPAB2|Assistance Publique - Hôpitaux de Paris|No|Terminated|August 2009|March 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|September 29, 2009||No|Insufficient number of participants|No||https://clinicaltrials.gov/show/NCT00987428||132568|
NCT00990860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS-13967|Study in Asia of the Combination of TACE With Sorafenib in HCC Patients|START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial|START|Taipei Veterans General Hospital, Taiwan|No|Active, not recruiting|February 2009|||February 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|N/A|No|||June 2010|January 3, 2011|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00990860||132304|
NCT00991120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPASS-HF Extension|Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study|Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study||Medtronic Cardiac Rhythm Disease Management|No|Enrolling by invitation|October 2009|March 2013|Anticipated|March 2013|Anticipated|Phase 2|Observational|N/A||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of all currently enrolled patients in the COMPASS-HF,        Chronicle IHM Phase I/II, REDUCEhf and PAH Pilot studies who provide written informed        consent for the Extension Phase.|January 2013|January 31, 2013|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991120||132284|
NCT00980122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC05/30/07|Aggressiveness of Care at the End of Life in Cancer Patients|Aggressiveness of Care at the End of Life in Cancer Patients||National University Hospital, Singapore||Completed|March 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|N/A|N/A|No|Probability Sample|All advanced cancer patients who passed away in the National University Hospital during a        defined 1 year period, will have a retrospective review of paper and electronic records.        Study subjects are identified from the weekly mortality lists that are sent to the        Department of Haemtology Oncology. We aim to include 250 patients in this retrospective        study.|April 2010|April 7, 2010|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00980122||133114|
NCT00980421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHN/NTF/82008-09|Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children|Effect of Mode of Delivery of Iron and/or Iron and Zinc Supplement on Iron Status Markers and Potential Markers of Iron Toxicity in Children Aged 24-36 Months||Annamalai University|No|Not yet recruiting|October 2009|August 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|240|||Both|24 Months|36 Months|No|||September 2009|September 18, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980421||133094|
NCT00979758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fuwai Hospital 2009|Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction|Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction|STEM-AMI|Chinese Academy of Medical Sciences, Fuwai Hospital|No|Enrolling by invitation|January 2009|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|30 Years|80 Years|No|||January 2016|January 26, 2016|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979758||133141|
NCT00979771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112145|A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Patients With Rheumatoid Arthritis||GlaxoSmithKline|No|Withdrawn|February 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|September 17, 2009||No|internal decision|No||https://clinicaltrials.gov/show/NCT00979771||133140|
NCT00980408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH999|The Influence of Glutamate on Memory in Humans|The NMDA Receptor Co-agonist D-cycloserine Accelerates Associative Learning in the Human Hippocampal CA Region||University Hospital, Bonn||Completed|June 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Actual|120|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980408||133095|
NCT00980785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0036|Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's|Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's|SEAIRA|University of Wisconsin, Madison|Yes|Completed|April 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|14|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|September 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00980785||133071|
NCT00980798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012601|Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee|Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Investigate the Analgesic Effect of OROS Hydromorphone Hydrochloride in Comparison With Placebo in Subjects With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee||Janssen-Cilag International NV|No|Completed|October 2007|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|288|||Both|40 Years|N/A|No|||April 2014|April 8, 2014|September 18, 2009|Yes|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT00980798||133070|Concomitant and rescue medication were permitted in the study. This may be why the results in the placebo arm so closely resemble those in the treatment arm. Patients were also less severely impacted by the underlying disease than in other studies.
NCT00981045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT09030|Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function|Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function|REPAIR-IDA|Luitpold Pharmaceuticals|Yes|Completed|August 2009|August 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2561|||Both|18 Years|N/A|No|||October 2013|October 22, 2013|September 21, 2009|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00981045||133055|
NCT00981331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092025|Changes in the Ankle Range of Motion Following Subtalar Joint Manipulation|Changes in the Ankle Range of Motion Following Subtalar Joint Manipulation in Patients With Sub-acute, Grade II, Ankle Inversion Sprains Quantified Using Quaternion Eigen Analysis.||Canadian Memorial Chiropractic College|No|Recruiting|May 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|16 Years|50 Years|No|||January 2016|January 26, 2016|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981331||133033|
NCT00981344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012299|Wheeled Mobility in Everyday Life|Wheeled Mobility in Everyday Life: Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|RERC-4a|Duke University|No|Completed|October 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Both|N/A|N/A|No|||August 2012|November 7, 2012|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00981344||133032|
NCT00981955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25AA1|The Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood|A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood.||Northumbria University|No|Completed|August 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2010|July 22, 2010|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981955||132985|
NCT00989222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/4:8|Volar Plating or External Fixation of Dorsally Displaced Fractures of the Distal Radius?|Volar Plating or External Fixation of Dorsally Displaced Fractures of the Distal Radius? A Prospective Randomized Study||Danderyd Hospital|No|Completed|January 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|20 Years|70 Years|No|||October 2009|October 2, 2009|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989222||132430|
NCT00989781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090560|Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome|Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome||University of California, San Diego|Yes|Completed|September 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|36|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|October 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989781||132387|
NCT00989235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-023 LT (Sub study)|Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis|A Phase 3B, Multi-Center, Randomized, Double-blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate-naïve Early Erosive Rheumatoid Arthritis Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate - Low Dose Sub-Study||Bristol-Myers Squibb|No|Completed|April 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||June 2011|June 18, 2011|October 2, 2009|Yes|Yes||No|May 12, 2011|https://clinicaltrials.gov/show/NCT00989235||132429|
NCT00989508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3535|Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy|Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy|HYPER|University Hospital Birmingham|Yes|Recruiting|October 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||April 2011|August 10, 2011|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989508||132408|
NCT00989768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-CBED06b|Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A|Field Effects of Two Commercial Preparations of Botulinum Toxin Type a Administered to the Frontalis Muscles||Brazilan Center for Studies in Dermatology|No|Completed|May 2005|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||October 2009|May 24, 2010|October 5, 2009||No||No|October 28, 2009|https://clinicaltrials.gov/show/NCT00989768||132388|The field of muscular effects of the studied toxins was objectively measured by EMG and it is not very precise. However, there is no more precise objective measurement to currently evaluate the field effects in muscles than EMG.
NCT00990652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08C5|Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide|A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-operatively||Northwestern University|Yes|Completed|May 2009|October 2012|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|October 6, 2009|Yes|Yes||No|December 11, 2013|https://clinicaltrials.gov/show/NCT00990652||132320|
NCT00990327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX-III-AP-001|Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI|The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)|ASPECT|Forest Laboratories|No|Terminated|November 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|863|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|October 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990327||132345|
NCT00990340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM201|Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method|Study to Compare Injection Anxiety Immediately Before the Administration of Each Dose of Tev-Tropin® Between a Needle-syringe Injection Method and a Needle-free Injection Method in Pediatric Subjects With Human Growth Hormone Deficiency|T-jet®|Teva Pharmaceutical Industries|No|Completed|September 2009|August 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Male|7 Years|17 Years|No|||June 2011|June 23, 2011|October 5, 2009|Yes|Yes||No|March 14, 2011|https://clinicaltrials.gov/show/NCT00990340||132344|
NCT00990353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-624-08|A Model to Identify Specific Predictors of Spatial Neglect Recovery|Comparing Prism Adaptation Therapy and Bromocriptine Medication for Spatial Neglect: Theoretical and Practical Outcomes||Kessler Foundation|Yes|Recruiting|January 2009|October 2020|Anticipated|January 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Stroke survivors with right brain stroke and evidence of a hidden disability of functional        vision (spatial neglect)|March 2015|March 31, 2015|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00990353||132343|
NCT00990639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YWhep091|Effect of Candesartan in Alcoholic Liver Fibrosis|Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial||Yonsei University|Yes|Completed|September 2005|March 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|70 Years|No|||October 2009|October 6, 2009|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990639||132321|
NCT00991198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFLOTDO002|The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage|The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial||Aria Aesthetics Inc.|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|49|||Female|25 Years|60 Years|No|||June 2011|June 6, 2011|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991198||132278|
NCT00991588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCLPL-001|Clinical Outcome of Posterior Cruciate Ligament (PCL) Posterolateral Reconstruction|Reconstruction of the Posterior Cruciate Ligament and Posterolateral Structures of the Knee||Cincinnati Sportsmedicine Research and Education Foundation|Yes|Enrolling by invitation|October 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||December 2014|December 10, 2014|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991588||132248|
NCT00991185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013132|Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children|CSF Pharmacokinetics of Antimicrobials in Children||Duke University|Yes|Completed|July 2009|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|8|Samples With DNA|CSF, Blood, urine, bronchial, salivary, peritoneal, wound/abscess|Both|N/A|18 Years|No|Non-Probability Sample|Children (<18) receiving antimicrobial agents and having cerebrospinal fluid collected as        part of standard of care|June 2014|July 23, 2014|October 6, 2009|No|Yes||No|June 13, 2014|https://clinicaltrials.gov/show/NCT00991185||132279|
NCT00991536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B40320084384|Impact of Non Invasive Ventilation on Quality of Sleep|Impact of Non Invasive Ventilation on Quality of Sleep||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|January 1987|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|95|||Both|10 Years|80 Years|No|Non-Probability Sample|Patients with respiratory failure due to predominantly restrictive disorders submitted to        NIV in preparation for long-term home ventilation and assessed between 1987 and 2008 at        the Sleep laboratory.|October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991536||132252|
NCT00990873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150803|Study of Tissue Samples From Patients With Stage I Non-Small Cell Lung Cancer Enrolled on Research Study CALGB-140202|A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202)||Alliance for Clinical Trials in Oncology|No|Completed|July 2009|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|Samples With DNA|Tissues and blood samples|Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with stage I non-small cell lung cancer and previously enrolled on        CALGB 140202.|July 2015|July 9, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990873||132303|
NCT00991146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2308|Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase|An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan||Novartis||Completed|October 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|2 Years|N/A|No|||March 2015|March 4, 2015|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991146||132282|
NCT00980447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPIP501-01a|Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults|A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults.||UMN Pharma Inc.|Yes|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||February 2010|February 5, 2010|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980447||133092|
NCT00980109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 004|Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir|A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteers for 16 Weeks|SEA 004|University of Oxford|Yes|Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|390|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 21, 2010|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980109||133115|
NCT00981370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS30T|Clinical Importance of Treating Iron Overload in Sickle Cell Disease|Clinical Importance of Treating Iron Overload in Sickle Cell Disease||Children's Hospital Los Angeles|No|Recruiting|April 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|14 Years|N/A|No|||September 2009|September 21, 2009|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981370||133030|
NCT00981942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22505 TRE|Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec|An Open Label Clinical Trial of Imatinib Mesylate(Glivec)in Patients With Moderate to Severe Nephrogenic Systemic Fibrosis|NSF|University of Aarhus|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981942||132986|
NCT00981357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0541004|A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee|A Phase 2a Randomized, Double-Blinded, Double Dummy, Placebo And Active Controlled, Two-Way Cross-Over, Flare-Enriched Multi-Centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 In Patients With Osteoarthritis Of The Knee||Pfizer|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|75 Years|No|||June 2011|June 2, 2011|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981357||133031|
NCT00981630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-040-007|Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine|Randomised, Double-blind, Placebo Controlled Phase II, Dose-ranging Study of the Safety, Tolerability and Immunogenicity of Live Attenuated ChimeriVax™-JE Vaccine (Lyophilised)||Sanofi|Yes|Completed|November 2004|November 2007|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|128|||Both|18 Years|48 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|September 21, 2009|Yes|Yes||No|November 6, 2012|https://clinicaltrials.gov/show/NCT00981630||133010|
NCT00982488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-188|Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis|START rollover|Bristol-Myers Squibb|No|Completed|October 2007|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|238|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 16, 2009|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00982488||132944|
NCT00989794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN 004-00|Study to Evaluate the Safety and Performance of Treatment of Articular Cartilage Lesions Located on the Femoral Condyle With gelrinC|Phase I/II Study for the Safety and Performance of GELRIN C||Regentis Biomaterials|Yes|Active, not recruiting|September 2009|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|October 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00989794||132386|
NCT00990080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP91|Interchangeability of Infanrix™ IPV/Hib and Pediacel® at 2,4 & 6 Months of Age|Safety and Immunogenicity of Two Mixed Primary Immunization Schedules: Pediacel® at 2 and 4 Months of Age Followed by One Dose of Infanrix™ IPV/Hib at 6 Months of Age; and, Infanrix™ IPV/Hib at 2 Months of Age, Followed by Pediacel® at 4 and 6 Months of Age||Dalhousie University|No|Completed|May 2010|January 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|253|||Both|42 Days|3 Months|Accepts Healthy Volunteers|||June 2011|June 14, 2011|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990080||132364|
NCT00990093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP062CC|A Randomised, Cross-over, Open-labelled Test Catheter Acceptance Study|A Randomised, Cross-over, Open-labelled Study Evaluating the Acceptance of Test Catheters Compared to SpeediCath Catheters||Coloplast A/S|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|N/A|No|||August 2012|August 2, 2012|October 5, 2009||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT00990093||132363|
NCT00990938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMO-2125-201|Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients|A Phase 1, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Safety Assessment Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients||Idera Pharmaceuticals, Inc.|Yes|Completed|September 2009|January 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||May 2012|May 15, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990938||132298|
NCT00990912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA124-003|A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)|A Study to Document Long-term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects 1 - 21 Years of Age With Refractory Solid Tumors Who Have Experienced Clinical Benefit Following a Minimum of 6 Cycles of Therapy on BMS Protocol CA124-001 or BMS Protocol CA124-002||Bristol-Myers Squibb|No|Completed|January 2004|November 2005|Actual|November 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|1 Year|18 Years|No|||October 2009|February 3, 2010|October 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990912||132300|
NCT00990925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903004806|Lifestyle Modification for Weight Loss in Schizophrenia|Lifestyle Modification for Weight Loss in Schizophrenia||Yale University|No|Completed|October 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|65 Years|No|||November 2015|November 4, 2015|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990925||132299|
NCT00991562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN0005|IMGN901 in Combination With Lenalidomide and Dexamethasone|An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma||ImmunoGen, Inc.|No|Completed|December 2009|October 2014|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991562||132250|
NCT00991575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|916501|Long Term Vascular Changes in Type 1 Diabetes|Long Term Vascular Changes in Type 1 Diabetes, Clinical Aspects and Biological Markers|DM09|Oslo University Hospital|Yes|Enrolling by invitation|April 2009|May 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|Samples With DNA|whole blood, serum, white cells, urine, tissue|Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|This project will be a continuation of the previous cohort performed originally from 1982.        The group or cohorts will be selected from primary care clinic.|October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991575||132249|
NCT00987662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTH170909|Irbesartan Versus Amlodipine: The OBI Study|Double Blind Study of Irbesartan vs. Amlodipine in Obese Hypertensive Subjects- The OBI Study|OBI|Aristotle University Of Thessaloniki|Yes|Withdrawn|January 2012|January 2014|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|60 Years|No|||September 2009|February 10, 2014|September 30, 2009||No|no funding|No||https://clinicaltrials.gov/show/NCT00987662||132550|
NCT00980148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0012|Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities|Randomized Clinical Trial Evaluating Treatment Failure Following Recommended Therapy (Azithromycin Versus Doxycycline) for Genital Chlamydial Infection in Males and Females in Youth Correctional Facilities||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2009|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|567|||Both|12 Years|21 Years|No|||June 2014|March 5, 2015|September 17, 2009|Yes|Yes||No|March 5, 2015|https://clinicaltrials.gov/show/NCT00980148||133112|The analysis of the secondary endpoint Demographical Characteristics and Clinical Parameters to Predict Treatment Outcome was limited by the small number of events and is not presented.
NCT00980434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wolf-4|S-100B and Neuron-specific Enolase (NSE) in Spinal Trauma|The Clinical Use of S-100B and NSE in Spinal Cord Injuries|WBS|Medical University of Vienna|No|Completed|February 2008|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|Samples Without DNA|Serum probe|Both|1 Year|N/A|No|Non-Probability Sample|patients from daily practice|July 2011|April 3, 2012|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980434||133093|
NCT00985998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-NSCLC-T-0902|Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer|Phase 1 Study of Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer||Biotech Pharmaceutical Co., Ltd.|No|Withdrawn|September 2009|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|September 27, 2009||No|no paticipants enrolled|No||https://clinicaltrials.gov/show/NCT00985998||132674|
NCT00981383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAROTID-2009|Treating Depression in Coronary Artery Disease With Omega-3 Fatty Acids|CAROTID: CAD Randomized Omega-3 Trial In Depression|CAROTID|Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|June 2010|May 2016|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|45 Years|80 Years|No|||February 2016|February 29, 2016|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981383||133029|
NCT00981708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-178|Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)|A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis||University of Athens|No|Active, not recruiting|February 2008|February 2015|Anticipated|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|September 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00981708||133004|
NCT00981071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QFTconversion|The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure|The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure||Armed Forces Capital Hospital, Republic of Korea|No|Completed|May 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A military unit in South Korean Army|April 2010|April 7, 2010|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981071||133053|
NCT00981682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC-SER120-OL1-200903|Long Term Safety Assessment of SER120 in Patients With Nocturia|A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902||Serenity Pharmaceuticals, Inc.||Completed|August 2009|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|376|||Both|50 Years|90 Years|No|||January 2014|January 27, 2014|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981682||133006|
NCT00982189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC-003|Cardiovascular Prevention for Persons With HIV|Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study|AHA pilot|Minneapolis Medical Research Foundation|No|Completed|September 2009|May 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|37|||Both|40 Years|N/A|No|||October 2012|October 10, 2012|September 22, 2009|Yes|Yes||No|January 16, 2012|https://clinicaltrials.gov/show/NCT00982189||132967|Study was small with limited power to detect differences.
NCT00987051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060229|Sentinel Node and Endometrial Cancer|Validation of the Sentinel Node in Endometrial Cancer|Senti-Endo|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2007|October 2011|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|133|||Female|18 Years|N/A|No|||December 2012|December 10, 2012|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987051||132597|
NCT00990106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074250|Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)|A Placebo-Controlled Augmentation Trial of Prazosin for PTSD||Seattle Institute for Biomedical and Clinical Research|Yes|Completed|September 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|October 2, 2009|Yes|Yes||No|April 16, 2014|https://clinicaltrials.gov/show/NCT00990106||132362|The sample was restricted to soldiers with frequent recalled combat trauma nightmares. More studies in civilian trauma PTSD are needed. Results cannot be extrapolated to persons with PTSD who do not recall trauma nightmares.
NCT00990366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/180/2009|Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve|Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve||Turku University Hospital|No|Terminated|October 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|89 Years|No|||October 2011|October 10, 2011|October 5, 2009||No|Interim analysis results, study terminated 5/2010|No||https://clinicaltrials.gov/show/NCT00990366||132342|
NCT00990379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6076|Using Heavy Water to Study Cell Dynamics in Parkinson's Disease|Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases||KineMed|No|Active, not recruiting|April 2009|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|45|Samples Without DNA|plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy controls, HIV positive (on or off ARVs), patients diagnosed with Parkinson's        Disease.        All subjects must be 18 years of age or older.|March 2015|March 30, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00990379||132341|
NCT00990418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013654|Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System|Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System||Alza Corporation, DE, USA||Completed|March 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|October 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990418||132338|
NCT00990678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH-JEBJ-HIVstudy|Study of Vitamin D Supplementation to Male HIV Sero-positive Patients|Study of Vitamin D Supplementation to Male HIV Sero-positive Patients||Hvidovre University Hospital|Yes|Completed|April 2008|January 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 13, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990678||132318|
NCT00991211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL 1-2003|Bendamustine Plus Rituximab Versus CHOP Plus Rituximab|Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas||University of Giessen|Yes|Completed|January 2004|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|549|||Both|18 Years|N/A|No|||October 2009|March 13, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991211||132277|
NCT00991224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810108|Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy|A Pilot, Open Label, Multi Arm, Single Ctr Study to Evaluate Safety & Tolerability of Escalating Doses of Autologous T Cells Modified With Lentiviral Vectors Expressing High Affinity Gag-specific TCRS in HLA-A02 Patients With HIV||University of Pennsylvania|Yes|Completed|November 2009|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|2|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|October 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00991224||132276|
NCT00991237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL28367.068.09|PRF Treatment for Patients With Chronic Lumbosacral Radicular Pain Compared to Conventional Medical Management|Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for Patients With Chronic Lumbosacral Radicular Pain||Maastricht University Medical Center|Yes|Completed|February 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 23, 2013|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991237||132275|
NCT00991250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mel-Swe-01 2009-12-17|SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma|A Multi-centre, Two-arm, Randomized, Open, Phase II Study Investigating SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma||SentoClone AB|Yes|Recruiting|October 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|N/A|No|||February 2010|February 4, 2010|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00991250||132274|
NCT00987467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010864|Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis|Long-term Results of Topical Cyclosporine 0.05% in the Treatment of Atopic Keratoconjunctivitis||Johns Hopkins University|No|Completed|August 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2013|October 4, 2013|September 30, 2009||No||No|April 15, 2013|https://clinicaltrials.gov/show/NCT00987467||132565|We were not able to have a control group and the treatment was not masked.
NCT00987454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC-RC/RB002|Erythropoietin in Traumatic Brain Injury (EPO-TBI)|A Randomised, Placebo-controlled Trial of Erythropoietin in ICU Patients With Traumatic Brain Injury|EPO-TBI|Australian and New Zealand Intensive Care Research Centre|Yes|Completed|May 2010|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|606|||Both|15 Years|65 Years|No|||July 2015|July 29, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987454||132566|
NCT00987675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650138|High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer|An Evaluation of Lesion Control Using Focal Ablation With High Intensity Focused Ultrasound in the Treatment of Non-Metastatic Progressive Prostate Cancer||National Cancer Institute (NCI)||Recruiting|July 2009|||July 2011|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|26|||Male|N/A|N/A|No|||March 2011|August 23, 2013|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987675||132549|
NCT00987688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DJC003|The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury|Multi-centre Randomised Trial to Evaluate the Effect of Early Hypothermia on Neurological Function in Patients With Severe Traumatic Brain Injury. Including Renal Sub Study|POLAR-RCT|Australian and New Zealand Intensive Care Research Centre|Yes|Recruiting|April 2010|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|60 Years|No|||February 2015|February 26, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987688||132548|
NCT00987441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMU-0933MZ|Epidural Labor Analgesia and Infant Neurobehavior|Epidural Analgesia for Labor Pain and Infant Neurobehavior|ELAIN|Nanjing Medical University|Yes|Completed|September 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|1200|||Female|19 Years|45 Years|No|||July 2011|July 26, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987441||132567|
NCT00980824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62060|ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients|ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Attending A&E Following a Suicide Attempt. A Pilot Study.|ENGAGE|University of Glasgow|No|Recruiting|November 2009|November 2010|Anticipated|September 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2010|June 25, 2010|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980824||133069|
NCT00981058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13909|First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin|A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)|SQUIRE|Eli Lilly and Company|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1093|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981058||133054|
NCT00986765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071211|Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia|Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial|HEPEPE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2009|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|257|||Female|18 Years|N/A|No|||January 2016|January 16, 2016|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986765||132618|
NCT00986219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RGR-DUM-2009/1|A Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms|A Cross Sectional Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms and the Limitations of Daily Activities in Primary Care. The " Asthma Language " Survey||AstraZeneca|No|Completed|September 2009|December 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|696|||Both|18 Years|N/A|No|Probability Sample|Primary care patients with persistent asthma treated with inhaled corticosteroid-based        maintenance treatment for at least 6 months and followed up by thep hysician for at least        the same period of time.|December 2009|December 16, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00986219||132657|
NCT00986232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-011|ProQuad Dose Selection Study (V221-011)(COMPLETED)|A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections||Merck Sharp & Dohme Corp.|No|Completed|April 1999|September 2000|Actual|April 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1551|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||March 2015|March 23, 2015|September 25, 2009|Yes|Yes||No|January 25, 2010|https://clinicaltrials.gov/show/NCT00986232||132656|Seven (7) participants received unknown clinical material and 1 participant received diluent only; they were considered to be protocol violators and weren't included in the efficacy/safety analyses.
NCT00981721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8480C00060|A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies|A Phase I, Randomised, Multi-centre, Open-label Study to Determine the Pharmacokinetics and Tolerability of Cediranib (RECENTIN™, AZD2171) Following a Single and Multiple Oral 20mg or 30 mg Doses in Chinese Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|September 2009|April 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2011|June 17, 2011|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981721||133003|
NCT00981968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321046|Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects|An Investigator- And Subjects- Blind Phase 1 Study To Investigate Pharmacokinetics, Safety And Tolerability Of Sitaxentan In Japanese Healthy Subjects Following Single And Multiple Doses And Western Healthy Subjects Following Single Dose||Pfizer|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981968||132984|
NCT00981695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV002|Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers|An Open Randomized Phase I/II Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1-infected Mothers|PedVacc002|Medical Research Council|Yes|Recruiting|November 2009|October 2011|Anticipated|July 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|72|||Both|N/A|3 Days|No|||September 2009|June 15, 2011|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981695||133005|
NCT00983541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI35306|Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma|Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma||University of Utah|Yes|Terminated|September 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|September 22, 2009|No|Yes|Low enrollment|No|June 21, 2013|https://clinicaltrials.gov/show/NCT00983541||132863|
NCT00990392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kerrie-333333|Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections|Pilot Study: Topical Antibiotics for Prevention of ICU Central Line Infections|ToPICL|Fraser Health|Yes|Withdrawn|November 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|N/A|N/A|No|||May 2015|May 28, 2015|October 5, 2009||No|Change of practice to antibiotic impregnated catheters and large study published showing their    efficacy. Made topical antibiotics obselete.|No||https://clinicaltrials.gov/show/NCT00990392||132340|
NCT00990405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreanCHUGR05|Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia|Phase 4 Study of Helicobacter Pylori Eradication Therapy||Korean College of Helicobacter and Upper Gastrointestinal Research|Yes|Active, not recruiting|October 2009|December 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|400|||Both|20 Years|70 Years|No|||October 2009|October 5, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990405||132339|
NCT00990665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60024498/E|Promote Q Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Quartet Left Ventricular Heart Lead Study|Promote Q CRT-D and Quartet Left Ventricular Heart Lead Study|Promote Q|St. Jude Medical|Yes|Completed|September 2009|July 2012|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990665||132319|
NCT00991276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081185|Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study Of Pregabalin And Pramipexole In Adults With Restless Legs Syndrome||Pfizer|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|October 6, 2009|Yes|Yes||No|May 18, 2012|https://clinicaltrials.gov/show/NCT00991276||132272|
NCT00991601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KA-05092|Ultra Sound Guided Fine Needle Aspiration Cytology (FNAC) of Liver and Pancreas Tumours|||Herlev Hospital|No|Suspended|July 2009|December 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||October 2010|October 12, 2010|October 7, 2009||No|New ultra sound technology have made this present study design less relevant and force us to    change the design of the study.|No||https://clinicaltrials.gov/show/NCT00991601||132247|
NCT00990951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJ 3001-09|Study of Efficacy of Association of Senna Alexandrina Mill and Associations on Functional Intestinal Constipation|Double-blind, Randomized, Placebo-controlled Study of Efficacy of Association of Senna Alexandrina, Cassia Fistula, Tamarindus Indica, Coriandrum Sativum, Periandra Mediterranea in Patients With Functional Intestinal Constipation||Marjan Industria e Comercio ltda|Yes|Suspended|June 2010|July 2014|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|65 Years|No|||July 2014|July 7, 2014|October 5, 2009||No|The study was interrupted by recruitment failure.|No||https://clinicaltrials.gov/show/NCT00990951||132297|
NCT00990964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Attain Success|Attain Success Clinical Trial|Attain Success Clinical Trial||Medtronic Cardiac Rhythm Disease Management|No|Completed|November 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2014|||Both|18 Years|N/A|No|Non-Probability Sample|Patient referral to a participating study center with practitioners experienced in        handling and implantation of the cardiac resynchronization therapy (CRT) device, the        left-heart lead, and the use of the delivery catheter.|August 2012|August 13, 2012|October 6, 2009||No||No|August 13, 2012|https://clinicaltrials.gov/show/NCT00990964||132296|
NCT00990977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DanishCS|Mindfulness and Cancer Mamma - Clinical Trial MBSR Among Women Operated for Breast Cancer|A Prospective, Randomized Controlled Trial of Mindfulness-based Stress Reduction (MBSR) Among Women Operated for Breast Cancer|MICA|Danish Cancer Society|No|Completed|March 2008|November 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|336|||Female|18 Years|75 Years|No|||June 2015|June 29, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00990977||132295|
NCT00987480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-031|Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 14, 2015|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987480||132564|
NCT00987506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F330702|Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France|Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France|Far XIENCE V®|Abbott Vascular|Yes|Completed|June 2008|December 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1165|||Both|18 Years|N/A|No|Non-Probability Sample|Study Population Description * Definition: For observational studies only, a description        of the population from which the groups or cohorts will be selected (e.g., primary care        clinic, community sample, residents of a certain town).|April 2012|April 17, 2012|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987506||132562|
NCT00987753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F990224004|Study Evaluating the Safety and Tolerability of L-377202|A PhaseI/II Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of L-377202 Administered Once Every 3 Weeks||University of Alabama at Birmingham|Yes|Completed|March 1999|November 2001|Actual|September 2000|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||June 2010|June 25, 2010|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987753||132543|
NCT00987714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R38OT10587|Monitoring Organ Donors to Increase Transplantation Results (MOnIToR)|Monitoring Organ Donors to Increase Transplantation Results|MOnIToR|University of Pittsburgh|No|Completed|August 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|556|||Both|16 Years|N/A|No|||April 2013|April 16, 2013|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987714||132546|
NCT00987701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMU-0932MZ|Perineuraxial Anesthesia Fluid Management and Infant Neurobehaviors|Correlation Between Perineuraxial Anesthesia Fluid Resuscitation in Cesarean Section and Infant Neurobehaviors|PAFUMIN|Nanjing Medical University|Yes|Completed|September 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5000|||Female|21 Years|40 Years|No|||July 2011|July 26, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987701||132547|
NCT00987922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-HUCH-220424|Mild Hypothermia in Acute Ischemic Stroke|Mild Hypothermia in Acute Ischemic Stroke After Thrombolytic Therapy: a Prospective,Open,Randomized,Single-center,Safety and Feasibility Study||Helsinki University|No|Completed|July 2007|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|85 Years|No|||September 2011|September 17, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987922||132530|
NCT00985491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1|Study for Short Term Weight Loss in Candidates for Bariatric Surgery|A Pilot Trial of the GI EndoBarrier Liner for Short Term Weight Loss in Subjects Who Are Candidates for Bariatric Surgery||GI Dynamics|No|Active, not recruiting|October 2008|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|55 Years|No|||December 2012|March 9, 2015|September 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985491||132713|
NCT00985725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-205|SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder|Phase 2, Multicenter, Randomized, Double-blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder||Shire|No|Completed|October 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|55 Years|No|||March 2012|March 3, 2015|September 25, 2009|Yes|Yes||No|February 7, 2012|https://clinicaltrials.gov/show/NCT00985725||132695|
NCT00980460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01975|Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer|Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment||National Cancer Institute (NCI)||Recruiting|September 2009|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|253|||Both|N/A|21 Years|No|||October 2015|March 24, 2016|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980460||133091|
NCT00980473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R399/57/2004|Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma|Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma: A Randomised Controlled Trial|ALPI|Singapore National Eye Centre|No|Recruiting|September 2007|||September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|N/A|No|||November 2009|June 16, 2011|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980473||133090|
NCT00980486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|587-08|Obesity and Antibiotic Tissue Concentration|Effects of Maternal Obesity on Tissue Concentrations of Prophylactic Antibiotics During Cesarean Delivery||MemorialCare|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|31|Samples Without DNA|Adipose, myometrial and blood serum samples|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients requiring cesarean delivery under non-emergent circumstances|September 2010|October 7, 2010|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980486||133089|
NCT00986778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-195|Entecavir Plus Adefovir in Lamivudine-Resistant Patients|A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects||Bristol-Myers Squibb|No|Withdrawn|December 2009|June 2014|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|16 Years|N/A|No|||December 2009|August 31, 2015|September 29, 2009|Yes|Yes|Business Objectives Changed|No||https://clinicaltrials.gov/show/NCT00986778||132617|
NCT00986791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scand-Ankle|Alcohol Cessation Intervention in an Acute Surgical Setting|Scand-Ankle: A Gold Standard Programme for Alcohol Cessation Intervention in Patients Undergoing Acute Fracture Surgery - A Randomised Clinical Multi-centre Study||Bispebjerg Hospital|Yes|Recruiting|November 2009|December 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986791||132616|
NCT00987064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Air 3-01|Clinical Effects of Temperature Controlled Laminar Airflow (TLA)|Clinical Effects of Purified Air Administered to the Breathing Zone in Allergic Asthma||Airsonett AB|No|Completed|October 2005|June 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|12 Years|28 Years|No|||September 2009|January 13, 2015|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00987064||132596|
NCT00986479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6702C00015|This is a Study to Determine the Antidepressant Effects of AZD6765|An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression||AstraZeneca|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||October 2014|October 15, 2014|September 24, 2009|No|Yes||No|October 15, 2014|https://clinicaltrials.gov/show/NCT00986479||132638|
NCT00986492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00297-50|Effects of Sleep Deprivation on Food Intake and Motor Activity in Man|Influence de la Privation Aigue de Sommeil Sur la Prise Alimentaire et l'activité Physique Chez l'Homme||University Hospital, Caen|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy normal subjects|September 2009|September 29, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00986492||132637|
NCT00982215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0057|Pilot Study of Pharmacology of Paracetamol Administered Per-oral Mucosa|Pilot Study of Pharmacology of Paracetamol Administered Per-oral Mucosa|PMB|University Hospital, Clermont-Ferrand||Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982215||132965|
NCT00983892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 08-309|Care Partners: Web-based Support for Caregivers of Veterans Undergoing Chemotherapy|Web-based Support for Caregivers of Veterans Undergoing Chemotherapy||VA Office of Research and Development|No|Completed|October 2009|February 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|134|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 22, 2009||No||No|February 2, 2016|https://clinicaltrials.gov/show/NCT00983892||132836|Recruitment rates were lower than expected.
NCT00984165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090224|Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation|Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)|No|Completed|September 2009|May 2015|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|September 24, 2009|No|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT00984165||132815|
NCT00989833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5890L00032|Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients|A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol "As-needed", or Terbutaline "As-needed" or Regular Use of Budesonide + Terbutaline "As-needed", in Patients With Mild Intermittent Asthma|MIA|AstraZeneca|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Both|12 Years|N/A|No|||July 2012|July 6, 2012|September 30, 2009|Yes|Yes||No|August 22, 2011|https://clinicaltrials.gov/show/NCT00989833||132383|
NCT00989846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK02|Biomarker in Lung Diseases|Feasibility Study on Establishing Biomarkers in Lung Diseases||Heidelberg University|No|Recruiting|October 2009|June 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Serum (blood)|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with acute or chronic lung diseases|October 2009|October 13, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00989846||132382|
NCT00990132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ1 09/N070|Study of the Efficacy of Home Mechanical Ventilation Post Acute Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Randomised Controlled Trial of Home Mechanical Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease Patients Post Acute Hypercapnic Exacerbation||Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|October 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990132||132360|
NCT00991289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5269|Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects|The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2010|January 2012|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|October 7, 2009|Yes|Yes||No|August 29, 2011|https://clinicaltrials.gov/show/NCT00991289||132271|
NCT00991302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5250|Durability of Adherence in Self-Management of HIV|Durability of Adherence in Self-Management of HIV|DASH|AIDS Clinical Trials Group|Yes|Completed|January 2010|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 12, 2015|October 7, 2009|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT00991302||132270|
NCT00991315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080809|Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate|Assessment of Tumor Resistance and Stem Cells in Prostate Cancer||Rutgers, The State University of New Jersey|No|Recruiting|December 2008|||May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Samples will be collected at time of TURP and will be deidentified and processed by standard      procedures.|Male|18 Years|N/A|No|Non-Probability Sample|Any patient undergoing a routine prostatectomy or TURP (transurethral resection of the        prostate) may be asked to participate|November 2015|November 5, 2015|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991315||132269|
NCT00991614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005|EVOLUTION® Duodenal Stent for Duodenal or Gastric Outlet Obstruction Caused by Malignant Neoplasms|Treatment of Duodenal or Gastric Outlet Obstruction and Duodenal Strictures Caused by Malignant Neoplasms With the EVOLUTION® Duodenal Stent||Cook|No|Completed|December 2009|March 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are referred into regional specialty centers for treatment of GI malignancy.|March 2012|March 28, 2012|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00991614||132246|
NCT00991627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEST-OST-02|Different Approaches to Maternal Hypotension During Cesarean Section|Pharmacological or Non-Pharmacological Management of Maternal Hypotension During Elective Cesarean Section Under Subarachnoid Anesthesia: a Randomized, Controlled Trial||University of Parma|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|50 Years|No|||August 2010|August 26, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991627||132245|
NCT00987766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0906|Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer|Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer.||Vanderbilt-Ingram Cancer Center|Yes|Completed|November 2009|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987766||132542|
NCT00988000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLICX07Q060519|Initial Specialist Telephone Consultation With New Patients in Secondary Care|Telephone Consultations for New Patients Being Referred to a Specialist Respiratory Outpatient Clinic||Imperial College London|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|100|||Both|18 Years|N/A|No|||May 2010|June 3, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988000||132524|
NCT00987727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF-AGN-OPH-DE-011|Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye|Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye||Allergan|No|Completed|November 2009|September 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|September 29, 2009|Yes|Yes||No|August 17, 2011|https://clinicaltrials.gov/show/NCT00987727||132545|
NCT00987740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-CA-2000|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2009|||||N/A|N/A|N/A||||||||||||||August 2, 2012|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987740||132544|
NCT00987974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD01|Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury|Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury||Radboud University|No|Completed|September 2009|March 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2001|April 27, 2010|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987974||132526|
NCT00987961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA026223|Linking Hospitalized Injection Drug Users to Buprenorphine|Linking Hospitalized Injection Drug Users to Buprenorphine||Butler Hospital|No|Completed|September 2009|September 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|75 Years|No|||November 2015|November 10, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987961||132527|
NCT00987935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.39|A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients|A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.||Boehringer Ingelheim||Completed|October 2009|January 2016|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 30, 2009||||No|June 3, 2015|https://clinicaltrials.gov/show/NCT00987935||132529|
NCT00987948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H005|Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels|Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA||University of Hawaii|No|Active, not recruiting|January 2010|March 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|September 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987948||132528|
NCT00986245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908-037-290|Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily|An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease||Seoul National University Hospital|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|30 Years|80 Years|No|||September 2013|September 4, 2013|September 24, 2009||No||No|July 7, 2012|https://clinicaltrials.gov/show/NCT00986245||132655|This study was designed to open-label study. We cannot exclude the psychological effect of each regimen.
NCT00981084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/6113|Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)|The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study||University of Missouri, Kansas City|Yes|Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|60 Years|No|||August 2013|August 6, 2013|September 18, 2009||No||No|April 22, 2013|https://clinicaltrials.gov/show/NCT00981084||133052|A small pilot trial with only one dose of drug administered. Limitations include the very small sample and the use of a single-dose cross-over design.
NCT00982553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-010005-36|The Raltegravir and Ribavirin Pharmacokinetics (PK) Study|A Prospective, Open-label, Three Phase Pharmacokinetic Study, to Assess the Pharmacokinetic Profile and Safety of Raltegravir 400 mg Twice Daily and Ribavirin 800 mg Once Daily, When Dosed Separately and Together in Healthy Volunteers||Imperial College London|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 4, 2011|September 22, 2009||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT00982553||132939|
NCT00983047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-IST-NSCLC-010|Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer|Phase II Study of Nimotuzumab Plus Docetaxel in Chemotherapy-refractory/Resistant Patients With Advanced Non-small-cell Lung Cancer||Biotech Pharmaceutical Co., Ltd.|Yes|Terminated|August 2009|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|September 21, 2009||No|The sponsor decide to terminate|No||https://clinicaltrials.gov/show/NCT00983047||132901|
NCT00987337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121014|Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Filibuvir Plus Pegylated Interferon Alfa-2a And Ribavirin In Treatment-Naive, HCV Genotype 1 Infected Subjects|FITNESS|Pfizer|Yes|Completed|November 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|288|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|September 29, 2009|Yes|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT00987337||132575|
NCT00987350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042669|Safety Study of Seasonal Influenza Vaccine by Jet Injection|A Clinical Study to Assess the Safety, Tolerability, and Immunogenicity of Licensed Seasonal Trivalent Influenza Vaccine Administered by Needle-free Jet Injection in One Intramuscular Dose to Healthy Young Adults||University of Maryland|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2010|September 3, 2010|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987350||132574|
NCT00983281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080598|Use of Hextend in Trauma|Use of Hextend in Trauma||University of Miami|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1714|||Both|18 Years|N/A|No|Probability Sample|Trauma patients|February 2013|February 20, 2013|September 23, 2009||No||No|January 15, 2013|https://clinicaltrials.gov/show/NCT00983281||132883|
NCT00986752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. B00101|Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease|Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease|ISAR-STATH|Deutsches Herzzentrum Muenchen|No|Recruiting|July 2009|March 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||January 2010|March 6, 2014|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986752||132619|
NCT00978510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB HGWA 2|Study of Health Personnel and the Assistance to Patients With Tuberculosis in Hospital Environment|Health Personnel and the Control of Tuberculosis in a Hospital Environment||Sociedade Cearense de Infectologia|No|Completed|January 2004|December 2006|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|159|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Health care professionals from a public hospital in Brazil|September 2009|September 16, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978510||133236|
NCT00990691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-37|Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome|Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome||Assistance Publique Hopitaux De Marseille|No|Completed|October 2008|||December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Female|4 Years|18 Years|No|||August 2015|August 6, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990691||132317|
NCT00990990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1171002|Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers|A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PNU-100480 (PF-02341272) After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects||Sequella, Inc.|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|7||Actual|59|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990990||132294|
NCT00991263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-159905C-ICSC|Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741|Intrinsic Breast Cancer Subtypes and Benefit of Paclitaxel in CALGB 9344 and Dose Dense Therapy in CALGB 9741||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|April 2009|||May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|3677|Samples With DNA|Tumor tissue samples|Female|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with breast cancer previously treated with paclitaxel and enrolled on        CALGB-9344 or CALGB-9741.|July 2015|July 9, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991263||132273|
NCT00991328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 07-0332|Role of Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery|Tailored Patient Management Guided With Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery.||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2009|December 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 7, 2009|October 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991328||132268|
NCT00991640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-022|Impact of an Integrated Obesity Management System on Patient's Care|Impact of an Integrated Obesity Management System on Patient's Care|ROGMF-2|Université de Sherbrooke|No|Active, not recruiting|November 2009|June 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|460|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991640||132244|
NCT00978770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTU-Neo-COMICE|MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer|Neo Comice Pilot; Efficacy of Advanced Semi-automated Functional Magnetic Resonance (MR) Imaging in the Early Prediction of Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy||National Cancer Institute (NCI)||Completed|August 2009|January 2010|Actual|||Phase 2|Interventional|Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||September 2009|August 6, 2013|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978770||133216|
NCT00979667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT2009-CS-6|A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection|Multicentre, Randomized, Controlled Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As The First Line Treatment For Human Swine Influenza (H1N1) Infection In Designated Flu Clinics During The Pandemic Influenza in Hong Kong||Chinese University of Hong Kong|No|Terminated|October 2009|October 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|N/A|No|||May 2010|April 8, 2011|September 17, 2009||No|Decreased Influenza activity; thus decrease/no eligible patient to recruit|No||https://clinicaltrials.gov/show/NCT00979667||133148|
NCT00979680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBR-2001|Sphincter-preserving Surgery After Preoperative Treatment of Ultra-low Rectal Carcinoma|Phase II Trial Comparing Two Neoadjuvant Treatments in Patients With Ultra-low Rectal Cancer: High-dose Radiotherapy Versus Radio-chemotherapy|GRECCAR1|Institut du Cancer de Montpellier - Val d'Aurelle|No|Completed|April 2001|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||September 2009|September 18, 2009|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979680||133147|
NCT00987987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040441|Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion|Amplifying Graft-versus-tumor Effect by Donor Regulatory T-cell Depletion Before Donor Lymphocytes Infusion: a Phase I/II Clinical Study|ILD-Treg|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2005|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|70 Years|No|||September 2009|January 21, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987987||132525|
NCT00988169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-026|Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations|A Phase II Trial of Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Activating Mutations||Memorial Sloan Kettering Cancer Center||Terminated|September 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 30, 2009|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00988169||132511|
NCT00988182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kraft_whey protein: study 2|The Effect of Whey Protein and Its Hydrolysate on Pre- and Post-Fixed Meal Glycemia and Insulin in Young Adults|The Effect of Whey Protein and Its Hydrolysate on Pre- and Post-Fixed Meal Glycemia and Insulin in Young Adults||University of Toronto|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|22|||Both|20 Years|27 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|September 30, 2009||||No||https://clinicaltrials.gov/show/NCT00988182||132510|
NCT00988156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-305|Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children|Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children||Bial - Portela C S.A.|No|Active, not recruiting|December 2007|June 2017|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|304|||Both|2 Years|16 Years|No|||July 2015|July 22, 2015|October 1, 2009||No||No|May 9, 2014|https://clinicaltrials.gov/show/NCT00988156||132512|
NCT00986024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460150|Resistance and/or Endurance Training, What is Most Effective in Prevention of Cardiovascular Diseases?|Strength Training Versus Aerobic Interval Training to Modify Risk Factors of the Metabolic Syndrome||Norwegian University of Science and Technology|No|Completed|August 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|20 Years|70 Years|No|||December 2012|December 12, 2012|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00986024||132672|
NCT00985738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0247|Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer|A Randomized Placebo-Controlled Double-Blind Clinical Trial to Assess the Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer|Dutasteride|University of Colorado, Denver|No|Terminated|September 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Male|40 Years|85 Years|No|||September 2009|January 15, 2013|September 11, 2009|Yes|Yes|low recruitment|No||https://clinicaltrials.gov/show/NCT00985738||132694|
NCT00986505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV lidocaine|Intravenous Lidocaine for Fibromyalgia|Effect of Intravenous Lidocaine on Manifestations of Fibromyalgia||Federal University of São Paulo|No|Completed|February 2005|December 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||September 2009|September 29, 2009|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00986505||132636|
NCT00978848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO8120077|Non-Invasive Sexually Transmitted Disease (STD) Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing: Meeting the Needs of an At-Risk Population|Non-Invasive STD Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing: Meeting the Needs of an At-Risk Population||University of Pittsburgh|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|305|Samples Without DNA|Any left over urine may be frozen for future use on infections in women|Female|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Females at least age 15 at time of enrollment who are presenting at Magee-Womens Hospital        for emergency contraception or urine pregnancy testing|July 2010|July 8, 2010|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978848||133210|
NCT00978861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE5|Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE|A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE|REMEWHITE|JDC Tech|Yes|Completed|October 2008|August 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|70|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 16, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00978861||133209|
NCT00983307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09G.104|A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer|A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer||Thomas Jefferson University|Yes|Completed|August 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983307||132881|
NCT00983320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00017|Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study|Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study||Université de Sherbrooke|No|Completed|April 2008|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Female|18 Years|65 Years|No|||October 2011|October 4, 2011|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983320||132880|
NCT00983294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1011|Drug-Drug Interaction Study of Colchicine and Azithromycin|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Azithromycin on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 20, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00983294||132882|
NCT00979381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO20084|Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor|Study to the Humoral and Cellular Immunoresponse After Influenza Vaccination in Patients With Metastasized RCC or GIST Treated With a Tyrosine Kinase Inhibitor(Sunitinib or Sorafenib)||Radboud University|No|Completed|October 2008|November 2009|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with metastasized renal cell carcinoma or GIST who have been treated with        sunitinib or sorafenib for at least 4 weeks, or patients with metastasized RCC who did not        receive a systemic treatment for their RCC (nephrectomy is allowed)          -  Patients who are indicated for influenza vaccination and and have been summoned for             this vaccination by their GP          -  healthy volunteers who have been summoned by theire GP to receive a influenza vaccin|September 2009|March 17, 2010|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979381||133170|
NCT00979394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAT-DUM-2009/1|Evaluation of Diabetes Care at Austrian GPs|Diabetes Care Austria 2009|DCA09|AstraZeneca|No|Terminated|October 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1513|||Both|N/A|N/A|No|Probability Sample|GPs|August 2010|August 16, 2010|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979394||133169|
NCT00990717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP04.NK92.01|Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies|A Dose Escalation Study of NK-92 Cell Infusions in Patients With Hematological Malignancies in Relapse After Autologous Stem Cell Transplantation.||University Health Network, Toronto|No|Recruiting|March 2005|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990717||132315|
NCT00991003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB25407|A New Method for Colorectal Cancer Screening: Colon Capsule Endoscopy Compared to Conventional Endoscopy|A New Method for Colorectal Cancer Screening: Colon Capsule Endoscopy Compared to Conventional Endoscopy||University Hospital, Basel, Switzerland|Yes|Completed|November 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|59|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2009|October 6, 2009|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991003||132293|
NCT00991016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1411001|Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers|A Phase 1 Randomized, Double Blind (3rd Party Open), Placebo Controlled Combined Single And Multiple Dose Safety, Tolerability And Pharmacokinetics Study Of Orally Administered PF-04805712 In Healthy Volunteers||Pfizer|No|Terminated|October 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|61|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 23, 2010|October 5, 2009||No|B1411001 was terminated after completion of 4 cohorts of the multiple ascending dose phase, as    additional data were deemed unnecessary. No safety concerns.|No||https://clinicaltrials.gov/show/NCT00991016||132292|
NCT00981734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0042/2008|Hiking Improves the Functional Autonomy|Effects of a Hiking Study About the Functional Autonomy Levels in Old Women Analyzed by the Family Health Program||Universidade Castelo Branco|Yes|Completed|September 2008|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|98|||Female|60 Years|N/A|No|||September 2009|September 21, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00981734||133002|
NCT00981747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPF-001|Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis|A Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis||University of Iowa|Yes|Active, not recruiting|September 2009|July 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|N/A|No|||August 2011|December 15, 2014|September 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00981747||133001|
NCT00991653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0201/35|Weight Fluctuation After Breast Cancer Treatment|Weight Fluctuation After Breast Cancer Treatment||The Royal Bournemouth Hospital|Yes|Active, not recruiting|August 2008|||January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|250|Samples With DNA|Fasting blood sample to determine participants genotype, insulin and glucose levels.|Female|18 Years|N/A|No|Non-Probability Sample|Females over 18 years diagnosed with breast cancer between 1/1/2003 and 31/12/2007.|December 2012|December 3, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991653||132243|
NCT00987493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 38/08|Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma|Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|September 2009|September 2016|Anticipated|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987493||132563|
NCT00979316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-020|Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects|Randomized, Double-Blinded, Placebo-Controlled, Open Label Positive- Controlled, Four-Way Crossover Study of the Electrocardiographic Effects of BMS-708163 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|62|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|January 6, 2011|September 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979316||133175|
NCT00979329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO20082|Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST|Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or GIST||Radboud University|No|Recruiting|May 2008|||December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients with metastatic renal cell cancer or GIST who will be treated with Sunitinib or        Sorafenib|October 2011|October 6, 2011|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979329||133174|
NCT00980200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113310|Efficacy and Safety Study in Subjects With Asthma|A Multi-center, Randomized, Double-blind, Placebo-controlled, Five Period Cross-over Study to Evaluate the Efficacy and Safety of Selected Doses and Dose Intervals of GW642444 Administered Via a Novel Dry Powder Inhaler (NDPI) in Subjects ≥18 Years of Age With Persistent Asthma||GlaxoSmithKline|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|75|||Both|18 Years|N/A|No|||June 2013|August 29, 2013|September 17, 2009|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT00980200||133108|
NCT00988208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-PC-002|Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer|A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)|Mainsail|Celgene|Yes|Active, not recruiting|November 2009|November 2016|Anticipated|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1059|||Male|18 Years|N/A|No|||December 2015|December 23, 2015|October 1, 2009|Yes|Yes||No|June 27, 2013|https://clinicaltrials.gov/show/NCT00988208||132508|The independent DMC concluded that it was unlikely the trial would achieve its primary endpoint of improved overall survival. The sponsor agreed and the experimental lenalidomide/placebo treatment arm of the study was discontinued.
NCT00980538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016408|TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents|Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents||Janssen R&D Ireland|No|Active, not recruiting|December 2009|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|169|||Both|6 Years|18 Years|No|||January 2016|January 20, 2016|September 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00980538||133086|
NCT00988195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-503|Study of Pegylated Human Recombinant Arginase for Liver Cancer|Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC): An Adaptive Design Dose Escalation Trial With Addition of Standard Doxorubicin Treatment||Bio-Cancer Treatment International Limited|Yes|Completed|May 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||March 2012|March 13, 2012|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988195||132509|
NCT00988416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810-11|Positron Emission Tomography-computed Tomography (PET-CT) for Main & Branch Intraductal Papillary Mucinous Neoplasm|PET-CT for Intraductal Papillary Mucinous Neoplasm (IPMN)||Indiana University|Yes|Recruiting|September 2009|September 2021|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|90 Years|No|Non-Probability Sample|Subjects are selected from group of patients in whom IPMN is suspected as they are seen in        the clinic for consultation with the surgeon regarding their surgical procedure.|July 2014|July 1, 2014|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00988416||132492|
NCT00988429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-304|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial||Bial - Portela C S.A.|No|Active, not recruiting|December 2008|October 2016|Anticipated|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|653|||Both|16 Years|N/A|No|||October 2015|October 14, 2015|October 1, 2009|Yes|Yes||No|December 3, 2013|https://clinicaltrials.gov/show/NCT00988429||132491|
NCT00986258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|835093|Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability||Grünenthal GmbH|No|Terminated|October 2009|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|September 28, 2009||No|This clinical trial was terminated early, due to slow recruitment and study drug shortages.|No|May 31, 2012|https://clinicaltrials.gov/show/NCT00986258||132654|The results of this trial have to be interpreted under the consideration that it was an open-label trial which was prematurely terminated.
NCT00986271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-0374B|Extravascular Lung Water Index in Severe Sepsis||EVLI in sepsis|Chang Gung Memorial Hospital||Completed||||||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|67|||Both|18 Years|N/A||||April 2008|September 28, 2009|September 27, 2009||||No||https://clinicaltrials.gov/show/NCT00986271||132653|
NCT00979446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-024S2|Passport to Brain Wellness in Sedentary Adults|Developing a Multi-Domain Intervention to Maintain Cognitive Health in Sedentary Adults Ages 60 - 80||HealthPartners Institute|Yes|Completed|June 2008|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|63|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979446||133165|
NCT00987077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRT_CSC_Kiel|Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy|Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial||University of Kiel|Yes|Completed|April 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|N/A|N/A|No|||September 2009|September 29, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987077||132595|
NCT00987090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/24|Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)|Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) : Variations of the Clinical Profile and Paraclinical Features Depending on the Age at the Onset of Clinical Signs||Assistance Publique Hopitaux De Marseille|No|Recruiting|October 2009|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|240|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987090||132594|
NCT00982540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD - IISP 36773|Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients|Empirical Antifungal Treatment in Neutropenic Patients Stratified by Risk: Prospective Validation of an Algorithm Based on the D-index|Dindexval|Universidade Federal do Rio de Janeiro|No|Terminated|February 2010|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|September 22, 2009||No|Low accrual|No||https://clinicaltrials.gov/show/NCT00982540||132940|
NCT00983554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK65038 (completed)|Metabolic Effects of Steroids in Obese Men|Metabolic Effects of Testosterone Alone or in Combination With Dutasteride or Anastrazole in Obese Men||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|June 2005|October 2009|Anticipated|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|57|||Male|24 Years|51 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00983554||132862|
NCT00979992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03811|Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer|A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2010|||May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||January 2016|March 4, 2016|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979992||133123|
NCT00980005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112999|Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children|Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children||GlaxoSmithKline||Completed|October 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2116|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|September 17, 2009|Yes|Yes||No|January 20, 2012|https://clinicaltrials.gov/show/NCT00980005||133122|
NCT00990730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11397-34652-01|Atherosclerosis in Rheumatoid Arthritis|Atherosclerosis in Rheumatoid Arthritis: Role of Inflammation, Lipoproteins, and Endothelial Dysfunction||University of California, San Francisco|Yes|Completed|September 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|80|Samples Without DNA|serum, plasma|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|RA subjects are from the UCSF RA cohort based at San Francisco General Hospital and UCSF        Medical Center. Controls will be selected from primary care clinics from these hospitals|January 2012|January 23, 2012|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00990730||132314|
NCT00991029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01S062835-01A1|Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial|Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial|POINT|University of California, San Francisco|Yes|Recruiting|October 2009|December 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|5840|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991029||132291|
NCT00982228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3583|Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes|NN1250-3583: A 52 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Parallel, Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: BB T1 LONG) / NN1250-3644: An Extension Trial to Trial NN1250-3583 Comparing Safety and Efficacy of NN1250 With Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin, in Type 1 Diabetes (BEGIN™: T1)|BEGIN™|Novo Nordisk A/S|No|Completed|September 2009|November 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|629|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|September 22, 2009|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT00982228||132964|
NCT00982501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501004.01.103|WS®1442 in Slightly Overweight Subjects|Investigation of Safety of WS®1442 in Slightly Overweight Subjects With Pilot Assessment of Pharmacodynamic Effects of WS®1442 on Endothelial Function||Dr. Willmar Schwabe GmbH & Co. KG|No|Completed|June 2008|February 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|60|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982501||132943|
NCT00982514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP NOPHO 2008|Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008|Thromboembolic Complications Related to Asparaginase in Children With ALL Treated According to NOPHO ALL 2008||Oslo University Hospital|Yes|Recruiting|September 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|1 Year|16 Years|No|Probability Sample|Oslo University Hospital, Department of Pediatrics|September 2012|September 11, 2012|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982514||132942|
NCT00979901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476A-162|Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis--Spring Study||Merck Sharp & Dohme Corp.|No|Completed|March 2000|May 2000|Actual|May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1577|||Both|15 Years|85 Years|No|||May 2015|May 4, 2015|September 17, 2009|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00979901||133130|Montelukast/loratadine arm was discontinued due to business decision by sponsor to focus development on montelukast monotherapy. There was no efficacy data reported for this treatment arm.
NCT00989950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cox002|Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD|Open Label Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children 6-12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)|Daytsleep|Cox Health Systems|Yes|Completed|December 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|26|||Both|6 Years|12 Years|No|||July 2012|July 16, 2012|September 30, 2009|Yes|Yes||No|March 12, 2012|https://clinicaltrials.gov/show/NCT00989950||132374|Small sample size, did not permit an examination of more specific differences among patch wear time conditions. Small sample size resulted in weaker randomization to patch wear time sequences that was not completely balanced in baseline covariates.
NCT00980863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LQ-bip|Effects of a Lifestyle Intervention on Body Mass Index in Patients With Bipolar Disorder|Effects of a Lifestyle Intervention on Body Mass Index in Patients With Bipolar Disorder||University of Zurich|No|Completed|March 2005|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||September 2009|September 18, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980863||133067|
NCT00980551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELRB1|Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma|A Pilot Study of Intravenous Topotecan and Vincristine in Combination With Subconjunctival Carboplatin for Patients With a History of Bilateral Retinoblastoma and Refractory/Recurrent Intraocular Disease (IND# 104,942)|RELRB1|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|March 2010|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|10 Years|No|||December 2010|December 10, 2010|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980551||133085|
NCT00981110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S402/208|Standard Versus Advanced Antimicrobial Dressing Containing Ionic Silver Following Colorectal Cancer Surgery|Surgical Sites Infections Following Colorectal Cancer Surgery. A Randomized Prospective Trial Comparing Standard and Advanced Antimicrobial Dressing Containing Ionic Silver.|AM|European Institute of Oncology|No|Completed|June 2008|December 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||September 2012|September 10, 2012|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00981110||133050|
NCT00988455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pdt bcc 2|Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up|||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2008|August 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2009|October 1, 2009|September 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988455||132489|
NCT00988741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-215|Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy|A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy||ArQule|No|Completed|September 2009|March 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988741||132467|
NCT00988442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5251|Telephone Support to Improve Adherence to Anti-HIV Medications|A Randomized Trial of Enhanced Nursing Telephone Support to Improve Medication Self-Management and Viral Outcomes of Antiretroviral Therapy-Experienced Patients||AIDS Clinical Trials Group|Yes|Completed|October 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988442||132490|
NCT00986518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080601|T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study|Controlled and Selective Depletion of Regulatory T-cell for Cancer Treatment, Efficacy and Safety Study|STARTREK|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||September 2013|November 21, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986518||132635|
NCT00986804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1126 / 201108378|Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant|Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome|AML MDS|Washington University School of Medicine|No|Completed|December 2009|February 2016|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00986804||132615|
NCT00982293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09109-01|The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes|A Randomized, Double Blind, Placebo Controlled Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes Mellitus, Pilot Study II||pico-tesla Magnetic Therapies, LLC|Yes|Terminated|September 2009|May 2011|Actual|May 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|165|||Both|21 Years|80 Years|No|||May 2011|May 4, 2011|September 21, 2009|No|Yes|Difficulty in Recruitment|No||https://clinicaltrials.gov/show/NCT00982293||132959|
NCT00980356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2009-14405-14|Vildagliptin in New Onset Diabetes After Transplantation|Vildagliptin in New Onset Diabetes After Transplantation - A Double-blind, Randomized, Placebo-controlled Trial|VINODAT|Medical University of Vienna|No|Completed|September 2009|December 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||August 2012|April 4, 2013|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980356||133099|
NCT00982826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-057|Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072|A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single and Multiple Doses (7 Days) of ABT-072 and an Open-label Study to Evaluate the Effect of Food on the Pharmacokinetic||Abbott|No|Completed|September 2009|January 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 19, 2010|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00982826||132918|
NCT00978523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARN-AR12-CT101|Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma|A Phase 1 Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma, for Which No Standard Therapy Is Available||Arno Therapeutics|No|Completed|August 2009|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978523||133235|
NCT00982800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-2005|Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?|Does Postoperative Gabapentin Reduce Pain, Opioid Consumption & Anxiety & Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?||Sunnybrook Health Sciences Centre|Yes|Completed|June 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|75 Years|No|||August 2010|August 4, 2010|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982800||132920|
NCT00982813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 09/4-G|Prospective Study of the Influence of Periodontal Diseases on Pre-term Birth: Observation in the Maternity Hospital of Nantes|Prospective Study of the Influence of Periodontal Diseases on Pre-term Birth: Observation in the Maternity Hospital of Nantes||Nantes University Hospital|No|Terminated|July 2009|September 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Female|18 Years|N/A|No|||October 2013|October 4, 2013|September 22, 2009||No|Difficulties of internal organization|No||https://clinicaltrials.gov/show/NCT00982813||132919|
NCT00979875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-117-104|A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone|Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic, 6-Way Crossover Study of Subcutaneously Administered Insulin Analogs With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Analogs Alone in Healthy Volunteers||Halozyme Therapeutics|No|Completed|September 2009|May 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|September 17, 2009|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT00979875||133132|
NCT00979888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649867|Study of How Caregivers Help Patients Cope With Respiratory and Other Symptoms Caused by Lung Cancer|A Non-pharmacological Supportive Care Intervention for Patients With Lung Cancer and Their Caregivers in the Management of the Respiratory Distress Symptom Cluster.||National Cancer Institute (NCI)||Recruiting|July 2009|||July 2010|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|80|||Both|N/A|N/A|No|||September 2009|August 23, 2013|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979888||133131|
NCT00980850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/08 H1N1|Swine Flu (Novel Influenza A H1N1) Vaccine Study|Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 Vaccine and GlaxoSmithKline H1N1 Vaccine in Children 6 Months to 12 Years of Age||University of Oxford|Yes|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|6 Months|12 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980850||133068|
NCT00982761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098012-3|Metabolic Syndrome of Occupational Drivers|Analysis of Health Status of Occupational Driver||Far Eastern Memorial Hospital|Yes|Completed|March 2009|May 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|50|||Both|25 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|This study is to understand the health status of occupational status. Occupational drivers        work in a sitting position for long durations, facing traffic stress, irregular mealtimes        and lack of exercise etc, and may impede their health. For passengers, their safety is        related to the occupational drivers' health status and should pay attention to the health        condition of the occupational drivers.|September 2009|July 21, 2010|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982761||132923|
NCT00982774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LVPTC-107|Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL|Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL||IDRI|Yes|Completed|April 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|42|||Both|7 Years|40 Years|No|||June 2011|June 23, 2011|September 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00982774||132922|
NCT00983008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-085B|Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts|A Prospective Cohort Study on the Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts||Providence Health & Services|No|Not yet recruiting|October 2009|November 2010|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|30|||Both|N/A|N/A|No|||September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983008||132904|
NCT00983021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-3632|Safety and Tolerability of NN9068 in Healthy Male Volunteers|A Trial to Test for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9068 and Compared With NN1250 and NN2211 in Healthy Subjects||Novo Nordisk A/S|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Male|18 Years|55 Years|No|||November 2014|November 3, 2014|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983021||132903|
NCT00989963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS-MR-PAH-203|Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)|A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)||Lung Biotechnology PBC|No|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|75 Years|No|||April 2013|April 16, 2013|October 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00989963||132373|
NCT00990236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-01|Thrombelastography Based Dosing of Enoxaparin|Thrombelastography Based Dosing of Enoxaparin for Thromboprophylaxis: a Prospective Randomized Trial||Oregon Health and Science University|No|Recruiting|September 2009|October 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|200|||Both|15 Years|N/A|No|||October 2009|October 5, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00990236||132352|
NCT00990249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0209|Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation|Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2009|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|N/A|65 Years|No|||August 2015|August 4, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00990249||132351|
NCT00981123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NHR-SER-2009/1|Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia|Non-interventional Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia||AstraZeneca|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients or hospitalised patients|January 2011|January 7, 2011|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00981123||133049|
NCT00981994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CI000611|Evaluation of an Algorithm to Reduce Antibiotic Prescribing for Acute Bronchitis|Development, Implementation, and Evaluation of Novel Strategies to Reduce Inappropriate Antimicrobial Use in Community and Healthcare Settings||University of Pennsylvania|No|Active, not recruiting|October 2009|September 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3300|||Both|16 Years|N/A|No|||April 2011|April 29, 2011|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00981994||132982|
NCT00981422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARMABIOMARKERS001|Search for Biomarkers in Human Glaucoma: Lymphocytes Alterations and Rate of Progression|Search for Biomarkers in Human Glaucoma: Possible Correlations Between Alterations in Peripheral Lymphocytes and Disease Severity||University of Parma|No|Completed|June 2007|June 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|40|||Both|19 Years|85 Years|No|Non-Probability Sample|Primary care clinic in Parma (University hospital of Parma)|September 2009|September 21, 2009|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981422||133026|
NCT00981435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081142|Steroids After Laser Trabeculoplasty for Glaucoma|Steroids And Laser Trabeculoplasty (SALT) Trial: Effect of Anti-Inflammatory Treatment on the Efficacy of SLT|SALT|University of California, San Diego|No|Completed|September 2009|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981435||133025|
NCT00988754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP00001 FA 08 07-26|School Based Health Promotion Program in Secondary Schools|School Children and Adolescents as Health Experts - Step 3|JuvenTUM 3|Technische Universität München|No|Completed|July 2008|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|595|||Both|9 Years|14 Years|No|||December 2012|December 10, 2012|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988754||132466|
NCT00982033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008625|Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction|A Randomized, Blinded, Placebo-Controlled Six Month Treatment Trial of Aliskiren to Improve Exercise Tolerance in Older Patients With Heart Failure and Normal Ejection Fraction|Aliskiren|Wake Forest School of Medicine|Yes|Completed|July 2009|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|55 Years|N/A|No|||November 2015|November 19, 2015|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00982033||132979|
NCT00982046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-09-05|A Clinical Comparison of Three Contact Lens Care Systems and Their Effect on Contact Lenses|A Clinical Comparison of Three Contact Lens Care Systems and Their Effect on Contact Lenses||Alcon Research|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|75|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|September 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00982046||132978|
NCT00978536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/11-K|A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).|A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).|BioCogS|Nantes University Hospital||Terminated|February 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|29|||Both|17 Years|66 Years|No|||September 2013|September 27, 2013|September 16, 2009||No|Difficulties of recruitment in a randomization arm|No||https://clinicaltrials.gov/show/NCT00978536||133234|
NCT00978549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCA-COUGAR-02|Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer|Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma||National Cancer Institute (NCI)||Completed|April 2008|October 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|320|||Both|18 Years|N/A|No|||September 2009|August 6, 2013|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978549||133233|
NCT00980382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-04-107|A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma|A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma||National Cancer Center, Korea|No|Completed|September 2004|August 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||September 2009|September 18, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980382||133097|
NCT00980707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-005 versican|Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma|Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma||Associated Scientists to Help Minimize Allergies|Yes|Completed|August 2009|November 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980707||133075|
NCT00979121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|670|Statins for Acutely Injured Lungs From Sepsis|Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis|SAILS|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Terminated|January 2010|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|745|||Both|18 Years|N/A|No|||August 2014|October 2, 2014|September 16, 2009|Yes|Yes|stopped for futility|No|August 22, 2014|https://clinicaltrials.gov/show/NCT00979121||133190|
NCT00979407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113535|Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)|Immunological Equivalence Between GSK2340272A and GSK2340274A Influenza Vaccines in Adults Aged 18 to 60 Years||GlaxoSmithKline||Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|336|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|November 1, 2012|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979407||133168|
NCT00979108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009133|The Value of Traction in the Treatment of Cervical Radiculopathy|The Value of Mechanical Traction in the Treatment of Cervical Radiculopathy||Intermountain Health Care, Inc.|No|Completed|July 2009|January 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|86|||Both|18 Years|70 Years|No|||November 2014|November 14, 2014|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979108||133191|
NCT00979732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSE 2009-050|The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension|Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effect of Grape Seed Extract Delivered in a Beverage on Blood Pressure in Individuals With Pre-hypertension.|GSE|Institute for Food Safety and Health, United States|No|Active, not recruiting|November 2009|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|72|||Both|25 Years|65 Years|No|||October 2015|October 5, 2015|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979732||133143|
NCT00980018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AUS17|An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment|An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment|MACS0999|Novartis|No|Completed|December 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|September 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00980018||133121|
NCT00980525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02|Development of Inflammatory Disease Model Protein, Genetic and Microbial Biomarkers|Development of Inflammatory Disease Model Protein, Genetic and Microbial Biomarkers||University of Michigan|No|Completed|May 2009|April 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|Samples With DNA|plaque, saliva, and intraoral specimens|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will involve two groups: 15 subjects who are IL-1 genotype positive and 15        subjects who are IL-1 genotype negative. Potential participants will be recruited at the        University of Michigan. A screening process will be performed by the study personnel to        all potential participants to determine eligibility according to the inclusion and        exclusion criteria. The prevalence of IL-1 genotype positive patients has been shown to be        related to the patients' ethnic group. In Caucasians, the prevalence was found to be        approximately 34% in non smokers. On the other hand, only about 2.3% of Asians and 26% of        Hispanics were found to be IL-1 genotype positive. In order to limit ethnic variations,        subjects in our study will be limited only to Caucasians.|December 2015|December 1, 2015|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980525||133087|
NCT00981396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-SMO-92509|The Effect of Emotional Freedom Techniques (EFT) in Smokers Failing a Smoking Cessation Program|The Effect of EFT (Emotional Freedom Techniques) in Smokers Failing a Smoking Cessation Program||Soul Medicine Institute|No|Recruiting|September 2009|December 2017|Anticipated|September 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 24, 2015|September 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00981396||133028|
NCT00981409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106206|The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)||GlaxoSmithKline|No|Completed|July 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|N/A|No|||July 2011|July 7, 2011|September 3, 2009||||No|October 14, 2009|https://clinicaltrials.gov/show/NCT00981409||133027|
NCT00989105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650867|Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer|A Cancer Research UK Phase I Trial of 99mTc Demobesin-4 (a Diagnostic Radiopharmaceutical) Given Once Via Bolus Intravenous Injection for Imaging of Prostate Cancer||Cancer Research UK||Terminated|June 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Male|18 Years|N/A|No|||February 2012|February 27, 2012|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989105||132439|
NCT00989118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endometriomatreatment|Randomized Study on Endometrioma Treatment|||Hospital Clinic of Barcelona|No|Completed|May 2000|March 2004|Actual|March 2004|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment|2||||||Female|18 Years|40 Years|No|||October 2009|October 1, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989118||132438|
NCT00979056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifa1|Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin|Prospective, Randomised, Placebo Controlled, Double Blind Monocenter Trial for the Prophylactic Treatment of Diarrhoea With Rifaximin for Travellers to South- and Southeast-Asia||University Hospital Tuebingen|No|Completed|October 2009|October 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|258|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979056||133194|
NCT00979524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U48DP001919-01|Addressing Mental Health in African American Job Training Adolescents and Young Adults|Addressing Mental Health in African American Job Training Adolescents and Young Adults||Johns Hopkins University|Yes|Recruiting|November 2008|November 2012|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1150|||Both|16 Years|24 Years|Accepts Healthy Volunteers|||September 2009|September 17, 2009|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979524||133159|
NCT00979537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISO-0702|Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers|Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|March 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|83|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 17, 2009|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979537||133158|
NCT00984555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A07-105|Residence Time of Biomarkers of Semen Exposure|Assessment of the Vaginal Residence Time of Biomarkers of Semen Exposure||CONRAD|No|Completed|December 2008|July 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|64|Samples With DNA|Vaginal swabs, semen|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|July 2010|July 21, 2010|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984555||132785|
NCT00984828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMY3024|Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients|A Randomized Study of 4 vs. 8 Cycles of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients||Shanghai Jiao Tong University School of Medicine|Yes|Terminated|August 2009|December 2014|Anticipated|June 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||March 2014|March 18, 2014|September 23, 2009||No|Very slow recruitment|No||https://clinicaltrials.gov/show/NCT00984828||132764|
NCT00984815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-CA-401|Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment|Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment||Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|40 Years|80 Years|No|||June 2013|June 19, 2013|September 23, 2009|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT00984815||132765|
NCT00985075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003-14|A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube|A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinitis and Conjunctivitis Following Allergen Exposure in the Allergen BioCube||ORA, Inc.|No|Completed|December 2008|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Subjects will be 18 years of age or older with a positive history of ocular and nasal        allergy and a positive skin test reaction to one of the allergens tested within the past        24 months|September 2009|September 25, 2009|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985075||132745|
NCT00985374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21884|A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors|Multiple Ascending Dose (MAD) Phase Ib/II Study of the mTOR Inhibitor (RAD001) in Combination With the IGF-1R Antagonist (R1507) for the Treatment of Patients With Advanced Solid Tumors||Hoffmann-La Roche||Terminated|November 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985374||132722|
NCT00986427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD9927|Restasis for Treatment of Brittle Nails|Restasis® Ophthalmic Emulsion for the Treatment of Brittle Nails||Columbia University|No|Completed|July 2009|December 2012|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 17, 2013|September 29, 2009|No|Yes||No|May 10, 2013|https://clinicaltrials.gov/show/NCT00986427||132642|Small Sample Size
NCT00986440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-E201|Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy|A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy||Daiichi Sankyo Inc.|No|Completed|July 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|September 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00986440||132641|
NCT00983489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ddu001|Comparison of Breast Feeding Counseling and Video Demonstration on Exclusive Breast Feeding Rates at 6 Weeks|Comparison of Impact of Breast Feeding Counseling of Mothers and Use of Audio-video Aids on Breast Feeding Rates at Six Weeks Postnatal Age||Deen Dayal Upadhyay Hospital|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|1411|||Both|N/A|24 Hours|No|||April 2013|April 5, 2013|September 22, 2009||No||No|April 5, 2013|https://clinicaltrials.gov/show/NCT00983489||132867|
NCT00983788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2008-006704-27|Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects|Evaluation of the Effect of Bezafibrate on Muscle Metabolism During Exercise in Patients With CPTII and VLCAD Deficiency|Bezafibrate|Rigshospitalet, Denmark|Yes|Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|70 Years|No|||May 2012|May 29, 2012|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983788||132844|
NCT00987246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 1005 6002 - 0702|Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis|Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II||Almirall, S.A.|No|Completed|June 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|470|||Both|18 Years|85 Years|No|||July 2015|July 27, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987246||132582|
NCT00983216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1012|Drug-Drug Interaction Study Between Colchicine and Ketoconazole|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Ketoconazole on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 12, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00983216||132888|
NCT00981266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A101-0501-10|Spectra Breast Implant Study|Study of the Safety and Effectiveness of the Mentor Spectra/Becker 80 Adjustable Breast Implant in Subjects Who Are Undergoing Primary Augmentation or Augmentation Revision||Mentor Worldwide, LLC|No|Withdrawn|June 2013|October 2026|Anticipated|January 2024|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|22 Years|N/A|No|||February 2013|February 27, 2013|July 28, 2009|Yes|Yes|Business decision. Study never started|No||https://clinicaltrials.gov/show/NCT00981266||133038|
NCT00981279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129/2009|Profile of HIV Seropositive Patients|Profile of HIV Seropositive Patients on Antiretroviral Therapy at the Clinical Hospital of the Federal University of Goiás|PHSP|Universidade Federal de Goias|Yes|Completed|June 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|222|||Both|N/A|N/A|No|Non-Probability Sample|Community sample, with HIV, in drug therapy in the Clinical Hospital of UFG.|September 2009|October 28, 2009|September 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00981279||133037|
NCT00980629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M516102-EU03|Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis|A Randomized, Placebo-Controlled, Double-blind, Parallel Group, Multi-centre Phase II Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis||Maruho Co., Ltd.||Completed|August 2008|September 2010||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind|||||||Both|18 Years|65 Years||||November 2010|November 2, 2010|July 24, 2009||||No||https://clinicaltrials.gov/show/NCT00980629||133080|
NCT00982124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC-INFOI|An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta|An International, Multicenter, Open-label, Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta|INFOI|Shriners Hospitals for Children||Active, not recruiting|October 2007|February 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|N/A|12 Months|No|||December 2015|December 29, 2015|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00982124||132972|
NCT00982384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7120-OK-CTIL|Comprehensive Disease Management Program in Chronic Obstructive Pulmonary Disease (COPD) Patients in the Community|Comprehensive Disease Management Program in COPD Patients in the Community: Randomized Controlled Trial|COPD_CDM|Sheba Medical Center|No|Completed|October 2009|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1202|||Both|40 Years|N/A|No|||May 2015|May 19, 2015|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00982384||132952|
NCT00982644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3579|Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes|NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)|BEGIN™|Novo Nordisk A/S|No|Completed|September 2009|December 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1030|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|September 22, 2009|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT00982644||132932|
NCT00982865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28062|Trial of MSC1936369B in Subjects With Solid Tumors|A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours||Merck KGaA|No|Active, not recruiting|December 2007|April 2016|Anticipated|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|205|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982865||132915|
NCT00978614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/1006|Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects|Valuation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration) Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled, Ascending Repeated-Dose, Three-Arm Parallel Design ECG Study in Healthy Adult Subjects||Merz Pharmaceuticals GmbH||Completed|September 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|1||Anticipated|126|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 14, 2011|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00978614||133228|
NCT00978887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0906-CU|Retorna Facial Cream in the Treatment of Facial Wrinkles|Efficacy of Retorna Facial Cream Usage in the Treatment of Facial Wrinkles||Catalysis SL|Yes|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Female|20 Years|60 Years|No|||May 2010|May 17, 2010|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978887||133207|
NCT00979550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK Aldara|The Effects of Aldara as an Adjunct to Laser Treatment|The Effects of Aldara as an Adjunct to Laser Treatment of Port Wine Stains||University of Kentucky|No|Completed|October 2008|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|2 Years|60 Years|No|||December 2014|December 23, 2014|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979550||133157|
NCT00985400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0288|Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery|Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2010|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|154|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985400||132720|
NCT00985647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-ENCORE2|Pharmacokinetics of Lamivudine at Two Different Doses|Pharmacokinetics of Plasma Lamivudine (3TC), and Its Active Intracellular Anabolite 3TC−Triphosphate Over a 24 Hour Dosing Interval Following Administration of 3TC 300 mg and 150 mg Once Daily to HIV−Negative Healthy Volunteers|ENCORE2|Kirby Institute|Yes|Completed|December 2009|March 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985647||132701|
NCT00985101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-109|Study of Cellular Impairments Involved in Diabetic Complications|Study of the Significance of Mitochondrial Dysfunction for Development of Diabetic Complications|diabmito I|Naestved Hospital|No|Active, not recruiting|April 2010|||||N/A|Observational|Observational Model: Case Control||2|Anticipated|80|||Both|18 Years|90 Years|No|Non-Probability Sample|outpatient diabetes clinic Naestved Hospital, denmark|September 2009|July 26, 2010|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00985101||132743|
NCT00985387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPK-1|Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients|Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study||Astellas Pharma Inc|No|Completed|August 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1215|||Both|18 Years|80 Years|No|Non-Probability Sample|OAB patients who were treated with solifenacin|October 2011|October 11, 2011|September 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00985387||132721|
NCT00985634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeGoo EURO rev D|Clinical Evaluation of LeGoo™ Internal Vessel Occluder Versus Traditional Vessel Loops|Randomized Clinical Evaluation of LeGoo™ Internal Vessel Occluder Vs Traditional Vessel Loops|LeGoo|Pluromed, Inc.|Yes|Recruiting|September 2008|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|79 Years|No|||September 2009|September 25, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00985634||132702|
NCT00983229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/NIR03/44|Comparison of CTrach, Intubating Laryngeal Mask Airway (ILMA) and I-gel for Tracheal Intubation|Position of Supraglottic Airway as a Conduit for Tracheal Intubation - A Comparison of CTrach, Intubating LMA and I-gel Supraglottic Airway||Northern Health and Social Care Trust|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|89 Years|No|||October 2010|November 12, 2010|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983229||132887|
NCT00983502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25988|Pilot Study of Alternative Treatments of Unexplained Chronic Fatigue|Pilot Study of Alternative Treatments of Unexplained Chronic Fatigue||University of Utah|No|Terminated|August 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|154|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The primary analyses will compare outcomes for 240 patients in four main groups (60 in        each group) defined by the background of the treating clinicians. Study subjects will be        UCF patients new to the practice of one of four groups of participating clinicians.|December 2011|December 13, 2011|September 22, 2009||No|IRB ended and NIH study ended|No||https://clinicaltrials.gov/show/NCT00983502||132866|
NCT00983801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-200|Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer|A Phase II Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer Previously Treated With Fluoropyrimidine-based Chemotherapy||R-Pharm|No|Completed|November 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|September 23, 2009|Yes|Yes||No|June 20, 2012|https://clinicaltrials.gov/show/NCT00983801||132843|
NCT00984061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-07-1006|Drug-Drug Interaction Study of Colchicine and Clarithromycin|A Pharmacokinetic Study to Evaluate the Effect of Clarithromycin on the Pharmacokinetic Profile of Colchicine in Healthy Adults||Mutual Pharmaceutical Company, Inc.|No|Completed|November 2007|January 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 5, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00984061||132823|
NCT00984334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAL-OIC-01|Naloxone SR Capsules in Patients With Opioid Induced Constipation|A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability and Efficacy of Naloxone SR Capsules in Subjects With Constipation Due to Opioids, Taken for Persistent Non-Cancer Pain||S.L.A. Pharma AG|No|Completed|October 2009|April 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|September 24, 2009||No||No|November 7, 2013|https://clinicaltrials.gov/show/NCT00984334||132802|Small number of subjects per group.
NCT00984347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|280808-HMO-CTIL|Breast Stimulation Versus Pitocin for Induction of Labor|Breast Pump Nipple Stimulation Versus Pitocin for Induction of Labor: Efficacy, Safety and Satisfaction||Hadassah Medical Organization|No|Not yet recruiting|November 2009|December 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984347||132801|
NCT00981851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RvB08.066.51196/GE|Interaction in Chronic Obstructive Pulmonary Disease Experiment|A Hazardous Combination of Cigarette Smoking and Bronchodilation in Chronic Obstructive Pulmonary Disease|ICE|Radboud University|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|40 Years|80 Years|No|||October 2009|July 4, 2011|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981851||132993|
NCT00982657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1131001|A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma|A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma||Pfizer|No|Terminated|September 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|34|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|September 22, 2009|Yes|Yes|Refer to statement in Summary Section/Detailed Description|No|March 13, 2015|https://clinicaltrials.gov/show/NCT00982657||132931|On 25 Oct 2012, due to data safety signals in separate clinical trial with CVX-060, all CVX-060 studies were discontinued. Ongoing participants in B1131001 were permitted to remain on study at a reduced dose if determined to derive clinical benefit.
NCT00982878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008437-10|The Maraviroc Central Nervous System (CNS) Study|The Penetration of Maraviroc Into the Central Nervous System in HIV-1 Infected Subjects on Stable Antiretroviral Therapy; a Phase I Pharmacokinetic Study||Imperial College London|No|Completed|September 2009|February 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||September 2010|March 23, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982878||132914|
NCT00978640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.09.2009|Sirtuin Mediated Effects of 36 Hour Fast and 1 Hour Exercise|Sirtuin Mediated Effects of 36 h Fast and 1 h Exercise||University of Aarhus|No|Active, not recruiting|September 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978640||133226|
NCT00978653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200931386|The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure|Prospective Study of Allopurinol Treatment That Improves Endothelial Function by Decreasing Uric Acid Levels of Patients With Chronic Kidney Disease||Istanbul University|No|Completed|April 2008|May 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|18 Years|60 Years|No|||September 2009|September 21, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00978653||133225|
NCT00978913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA 0914|Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma|Evaluation of Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA as a Treatment for Patients With Metastatic Breast Cancer or Malignant Melanoma||Herlev Hospital|Yes|Completed|September 2009|May 2014|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978913||133205|
NCT00978627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3594|Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes|NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401-3645: An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST™: T1)|BOOST™|Novo Nordisk A/S|No|Completed|August 2009|December 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|548|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|September 16, 2009|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT00978627||133227|
NCT00979186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-08-0005|A Trial to Evaluate Natural Orifice Transgastric Endoscopic Cholecystectomy With Laparoscopic Assistance|A Trial to Evaluate Natural Orifice Transgastric Endoscopic Cholecystectomy With Laparoscopic Assistance||Ethicon Endo-Surgery|No|Withdrawn|September 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2010|November 28, 2011|September 16, 2009|No|Yes|Study Terminated - No enrollment, business decision.|No||https://clinicaltrials.gov/show/NCT00979186||133185|
NCT00979810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-060|Image-Guided Stereotactic Biopsy of High Grade Gliomas|Image-Guided Stereotactic Biopsy of High Grade Gliomas||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|89 Years|No|||August 2015|August 27, 2015|September 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979810||133137|
NCT00985959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014776|A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)|A Phase I/II Clinical Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)||Janssen Pharmaceutical K.K.|Yes|Completed|July 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|101|||Both|20 Years|N/A|No|||October 2013|October 31, 2013|September 18, 2009||No||No|May 30, 2013|https://clinicaltrials.gov/show/NCT00985959||132677|
NCT00986180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015643|NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain|A Randomized, Double-Blind, Parallel-Group Study of NUCYNTA (Tapentadol) Immediate Release vs. Oxycodone Immediate Release for the Treatment of Acute Low Back Pain||Ortho-McNeil Janssen Scientific Affairs, LLC|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|667|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|September 25, 2009|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT00986180||132660|There were 19 subjects either did not take medication or did not have verifiable drug exposure. 2 subjects were randomized in two different sites, only one site information were included. 1 subject were randomized in error.
NCT00985933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285M00015|The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers|A Single Center, Double-Blind, Randomized, Double Dummy, Placebo-Controlled, Three-Period Crossover Study to Assess the Effects of a mGluR2/3 Positive Allosteric Modulator [AZD8529] Upon Ketamine-Induced Cortical Stimulation and Impairment of Working-Memory Related Activation of the Prefrontal Cortex||AstraZeneca||Completed|February 2010|April 2011|Actual|April 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|20|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 3, 2011|September 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00985933||132679|
NCT00985946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0050 (CO08209)|Study of Panobinostat in Patients With Neuroendocrine Tumors|A Phase II Trial of Panobinostat in Patients With Neuroendocrine Tumors||University of Wisconsin, Madison|Yes|Completed|May 2010|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|September 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985946||132678|
NCT00986154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-D-U305|Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).|A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).||Daiichi Sankyo Inc.|Yes|Completed|October 2009|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8292|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|September 25, 2009|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT00986154||132662|
NCT00986167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00043|Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry|Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry||Bayside Health|Yes|Not yet recruiting|October 2009|October 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|65 Years|No|||September 2009|September 28, 2009|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00986167||132661|
NCT00983242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1014|Drug-Drug Interaction Between Colchicine and Verapamil ER|A One-Directional, Open Label Drug Interaction Study to Investigate the Effects of Multiple Dose Verapamil HCl ER on Single Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 12, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00983242||132886|
NCT00983840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124505-01A1|Family Eats:Cancer Prevention for Families|Family Eats:Cancer Prevention for Families|Family Eats|Baylor College of Medicine|Yes|Completed|September 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|151|||Both|8 Years|10 Years|Accepts Healthy Volunteers|||February 2012|March 18, 2015|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00983840||132840|
NCT00984087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21284|rTMS for Adolescents and Young Adults|rTMS for Adolescent and Young Adult Depression|JHU|Johns Hopkins University|No|Withdrawn|October 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|15 Years|24 Years|No|||April 2013|April 1, 2013|September 23, 2009|Yes|Yes|Difficulty with recruitment and therefore funding has been pulled.|No||https://clinicaltrials.gov/show/NCT00984087||132821|
NCT00983814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa ADD201|Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa|A Two-Period Trial (Open-Label and Randomized Placebo-Controlled Substitution) of Droxidopa Treatment in Adults With ADHD With Co-administration of Carbidopa|ADD201|Chelsea Therapeutics|No|Completed|October 2009|July 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|55 Years|No|||March 2013|March 27, 2013|September 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00983814||132842|
NCT00984074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654169|MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer|A Pilot Study of Functional Mapping and Brain Perfusion Imaging in Patients Receiving Base of Skull and Brain Radiotherapy: Developing Neurocognitive Functional Organs At Risk for Individualized Conformal Radiotherapy||National Cancer Institute (NCI)||Recruiting|October 2008|||September 2010|Anticipated|Phase 1|Observational|N/A|||Anticipated|6|||Both|18 Years|N/A|No|||September 2009|February 24, 2011|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984074||132822|
NCT00981526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000790|Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia|Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia||University of Massachusetts, Worcester|Yes|Completed|March 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|65 Years|No|||August 2013|August 12, 2013|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981526||133018|
NCT00981539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IULTD-4747|Will Cleaning the Bowel With an Enema Before Vaginal Prolapse Surgery Prevent Complications?|Do Preoperative Enemas Prevent Complications in Vaginal Pelvic Reconstructive Surgery?||Illinois Urogynecology, Ltd.|No|Recruiting|September 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|310|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 21, 2009|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981539||133017|
NCT00981552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMRTCC|Dosimetric Planning Study Comparing Intensity Modulated Radiotherapy (IMRT) and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix|Dosimetric Planning Study Comparing IMRT and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix||Sunnybrook Health Sciences Centre|No|Completed|December 2008|September 2009|Actual|July 2009|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|N/A|N/A|No|||September 2009|September 21, 2009|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981552||133016|
NCT00981864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 07-0594-C|Concurrent Boost Radiotherapy|A Feasibility Study to Evaluate Intensity Modulated Radiation Therapy (IMRT) for Concomitant Boost Breast Radiotherapy (CBRT)||University Health Network, Toronto|Yes|Completed|November 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|N/A|No|||December 2012|December 19, 2012|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981864||132992|
NCT00982670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-96-D-032|A Study of the Metabolic Syndrome in Patients With Systemic Lupus Erythematosus|Association of the Metabolic Syndrome and Systemic Lupus Erythematosus in Taiwan||Far Eastern Memorial Hospital|Yes|Completed|July 2008|June 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|Samples Without DNA|Stored serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons aged 18 and above.|September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982670||132930|
NCT00982683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moon-01|Association of Lunar Phases With Post-surgical Morbidity|Association of Lunar Phases With Post-surgical Hemorrhagic Rate||National Institute for Cancer Research, Italy|No|Completed|January 1998|June 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|26244|||Both|18 Years|N/A|No|Non-Probability Sample|Patients operated at the National Cancer Institute, Genoa, Italy, during the period        2001-2008|September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982683||132929|
NCT00982891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROS-003|Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)|Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease: Understanding Patients' and Caregivers' Experiences of Opioid Therapy|ROS-003|Nova Scotia Health Authority|No|Completed|March 2010|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|45|||Both|N/A|N/A|No|||January 2013|January 22, 2013|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00982891||132913|
NCT00978666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090008|Functional Magnetic Resonance Imaging (fMRI) Imaging Study in Adolescents With Anorexia Nervosa|Neural Dysfunction of Interoception in Adolescents Diagnosed With Anorexia Nervosa|ADOL_AN|University of California, San Diego|Yes|Recruiting|June 2009|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|22|||Female|14 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants with anorexia nervosa will be selected from the community as well as from        local medical clinics and eating disorder treatment centers. Healthy volunteers will be        selected from the community at large.|September 2009|September 16, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978666||133224|
NCT00978679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-RGVM|Peripheral Optics in Myopia and Orthokeratology|Peripheral Refraction and Aberration in Myopic Progression and Myopic Control||The Hong Kong Polytechnic University|No|Completed|March 2008|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978679||133223|
NCT00978926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC02/15/07|A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies|A Study of the Pharmacodynamic Effects of Anti-vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies||National University Hospital, Singapore||Completed|September 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|21 Years|N/A|No|Probability Sample|This study aims to assess the pharmacodynamic effects of anti-VEGF therapy. The following        groups of patients will be approached:        Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab,        sunitinib, and sorafenib) as part of routine clinical management or on clinical studies|April 2010|April 8, 2010|June 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00978926||133204|
NCT00978939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016092|Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter|Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions|ASAP|Duke University|Yes|Completed|August 2009|October 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|19 Years|N/A|No|||December 2013|December 27, 2013|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978939||133203|
NCT00978952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803|Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta|Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta||Atrium Medical Corporation|Yes|Active, not recruiting|September 2009|May 2017|Anticipated|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|N/A|N/A|No|||June 2015|June 16, 2015|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00978952||133202|
NCT00979199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVINCI|Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease|Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease|EVINCI|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy||Completed|February 2009|June 2012|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|697|||Both|30 Years|75 Years|No|||June 2014|June 19, 2014|September 16, 2009||No||No|April 23, 2014|https://clinicaltrials.gov/show/NCT00979199||133184|
NCT00980135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13932|Sinecort Pilot Efficacy Study|An Investigator-blind, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a New Topical Medical Device in Patients With Mild Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin.|Sinecort Pilot|Bayer|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|65 Years|No|||April 2014|March 31, 2014|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00980135||133113|
NCT00986713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYH-CMU AmB Neph|Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation|||Capital Medical University|Yes|Recruiting|June 2008|October 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|65 Years|No|||September 2009|September 29, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986713||132621|
NCT00986739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 08205|Individual and Environmental Risk Factors of Unplanned Admissions of Elderly|Individual and Environmental Risk Factors of Unplanned Admissions of Elderly : RIEHO Inception Cohort|RIEHO|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|July 2009|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|80 Years|N/A|No|Non-Probability Sample|Patient aged 80 and over presenting to the emergency department (ED) for medical concern        eventually associated with social concern and admitted in a medical or surgical ward|December 2014|May 27, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986739||132620|
NCT00987259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLT006964|Myocardial Oedema in Acute Myocardial Infarction (AMI)|Determination of the Time Course of Myocardial Oedema Post Myocardial Infarction Treated With Primary Angioplasty Using Cardiac Magnetic Resonance Imaging||Barts & The London NHS Trust|No|Completed|November 2009|October 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to The London Chest Hospital following an ST elevation myocardial        infarction who have been successfully treated with primary angioplasty.|September 2009|January 31, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987259||132581|
NCT00983515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1013|Drug-Drug Interaction Between Colchicine and Ritonavir|A One-Directional, Open-label Drug Interaction Study to Investigate the Effects of Multiple-Dose Ritonavir on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 12, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00983515||132865|
NCT00983827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28376|Aquatic Treadmill Therapy for Improving Gait, Balance, Fitness and Quality of Life in Stroke Patients|Safety and Efficacy of Aquatic Treadmill Therapy for Improving Economy of Gait, Gait Speed, Balance, Cardiovascular Fitness, and Quality of Life in Ambulatory Adult Stroke Patients: A Pilot Study|ATT|University of Utah|No|Completed|May 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|August 25, 2009||No||No|July 2, 2012|https://clinicaltrials.gov/show/NCT00983827||132841|
NCT00975455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBS-002|Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer|Phase 3 Study of Hematuria Evaluation||Predictive Biosciences|No|Completed|July 2009|January 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1400||urine sample|Both|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects will be selected from Urology and Oncology practices.|November 2009|June 7, 2011|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975455||133467|
NCT00984100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-086|Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy||Baystate Medical Center|No|Completed|January 2009|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984100||132820|
NCT00984386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1002-028|Investigation of the Efficacy of Zesteem in Accelerating Early Wound Healing|A Single Site, Placebo and Standard Care Controlled, Double Blind, Randomised Trial to Investigate the Efficacy of Four Doses of Zesteem in Accelerating Early Wound Healing of Punch Biopsy Skin Wounds.||Renovo|No|Completed|March 2005|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984386||132798|
NCT00975442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221/00|Effects of Eccentric Training for Patients With Lateral Epicondylalgia|Effects of Eccentric Training for Patients With Lateral Epicondylalgia - a Randomized Controlled Trial||Karolinska Institutet|No|Completed|February 2005|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A||||September 2009|September 10, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975442||133468|
NCT00982137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-040-006|Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)|Randomised, Double-blind, Phase II Evaluation of the Safety and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)||Sanofi|Yes|Completed|July 2004|March 2007|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|108|||Both|18 Years|55 Years|No|||September 2012|September 18, 2012|September 21, 2009||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT00982137||132971|
NCT00982397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PainFree SST|Study to Evaluate System Safety and Clinical Performance of the Protecta Implantable Cardioverter Defibrillator (ICD) Plus Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The PainFree SST Clinical Study. Clinical Study to Evaluate System Safety and Clinical Performance of the Protecta ICD + CRT-D (Phase I, Protecta Clinical Study) and to Assess the Capacity of the Protecta Features to Reduce Inappropriate Shocks (Phase II, PainFree SST).||Medtronic Cardiac Rhythm Disease Management|No|Completed|September 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2791|||Both|N/A|N/A|No|||November 2013|November 22, 2013|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982397||132951|
NCT00982696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU 23429|Treatment of Advanced Head and Neck Cancer|Treatment of Advanced Head and Neck Cancer With Opioid Growth Factors: Phase II||Milton S. Hershey Medical Center|Yes|Terminated|February 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|September 22, 2009|Yes|Yes|Deemed ineffective|No||https://clinicaltrials.gov/show/NCT00982696||132928|
NCT00982904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiFEX001|Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole|Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers||Drugs for Neglected Diseases|No|Completed|September 2009|October 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 9, 2011|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982904||132912|
NCT00978692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-ZG30|Toric Orthokeratology - Slowing Eye Elongation|Toric Orthokeratology for Slowing Eye Elongation in Astigmatic Children|TO-SEE|The Hong Kong Polytechnic University|No|Completed|May 2008|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978692||133222|
NCT00979563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OTE-101|Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies|A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer(Q1DX5/W for 3W)|Oratecan-101|Hanmi Pharmaceutical Company Limited|No|Completed|July 2008|November 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|19 Years|N/A|No|||September 2009|December 5, 2011|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979563||133156|
NCT00979212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0839|Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)|Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy +/- Cetuximab in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)||Radiation Therapy Oncology Group|Yes|Active, not recruiting|February 2011|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979212||133183|
NCT00979576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.28|BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Pemetrexed - a Phase I, Open-label, Dose-escalation Study & a Phase II, 2 Arm, Randomized, Double-blind, Placebo-controlled Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy||Boehringer Ingelheim||Completed|October 2009|November 2014|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|19|||Both|20 Years|74 Years|No|||December 2014|December 19, 2014|September 17, 2009||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00979576||133155|The result is based on a snapshot taken on 27 Jun 2014. The result will be updated with final report. Pharmacokinetic (PK) data is only available after data base lock, therefore secondary PK endpoints will be disclosed with final report.
NCT00978484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-1-0755|A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder|A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder||United States Naval Medical Center, San Diego|Yes|Active, not recruiting|September 2009|October 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|No|||June 2014|June 27, 2014|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978484||133238|
NCT00986687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-189-3|Oocyte Cryopreservation Comparing Fresh and Vitrified Sibling Oocytes|Oocyte Cryopreservation: A Pilot Study Comparing Fertilization and Embryo Development Between Fresh and Vitrified Sibling Oocytes||University of Connecticut Health Center|No|Completed|August 2009|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|17|Samples With DNA|Embryos|Female|21 Years|37 Years|Accepts Healthy Volunteers|Non-Probability Sample|The Center for Advanced Reproductive Services patient population|December 2015|December 2, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986687||132623|
NCT00986700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7156-JI-CTIL|The Effect of Late Night Meals on Fasting Glucose in Type 2 Diabetes Patients|The Effect of Late Night Meals on Fasting Glucose in Type 2 Diabetes Patients||Sheba Medical Center|No|Not yet recruiting|October 2009|||October 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|30 Years|N/A|No|||September 2009|September 29, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986700||132622|
NCT00986973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-007154|Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy|A Pilot Study of FDG PET Findings in Patients With Phenylketonuria Before and After BH4 Supplementation|PKU|Children's Hospital of Philadelphia|Yes|Completed|March 2010|September 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|50 Years|No|||May 2015|May 12, 2015|September 28, 2009|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT00986973||132603|Due to small sample size, the statistical power of this study is low. While it is useful in exploring potential trends, the results of this pilot study should be cautiously interpreted. Further studies with a larger sample of subjects are needed.
NCT00986986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO|Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels|Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels||University of Hawaii|Yes|Completed|November 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|November 19, 2012|September 29, 2009|Yes|Yes||No|August 14, 2011|https://clinicaltrials.gov/show/NCT00986986||132602|Small sample sizeUn-blinded pilot studyIncrease in HDL was less than predicted in a non-HIV infected population
NCT00987272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-044|Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects|A Phase III Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the CAC Model of Acute Allergic Conjunctivitis in Japanese Subjects||Alcon Research|No|Completed|October 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|267|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|September 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987272||132580|
NCT00987285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 R01 DK035524-21|Linking Self-Management and Primary Care for Diabetes 2|Linking Self-Management and Primary Care for Diabetes|LB2|Kaiser Permanente|No|Completed|January 2007|December 2014|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|463|||Both|25 Years|75 Years|No|||May 2015|May 21, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987285||132579|
NCT00975182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4626g|A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors||Genentech, Inc.||Completed|September 2009|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00975182||133487|
NCT00975195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352.2046|Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy||Boehringer Ingelheim||Completed|February 2009|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2488|||Both|40 Years|N/A|No|||February 2015|February 9, 2015|September 10, 2009||||No|December 23, 2014|https://clinicaltrials.gov/show/NCT00975195||133486|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information".
NCT00975741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASM/P/01/1|Efficacy and Safety of Two Dry Power Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma|An Open-label, Comparative, Randomized, Parallel, Multicenter Study to Determine the Efficacy and Safety of Two Dry Powder Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma||Mantecorp Industria Quimica e Farmaceutica Ltd.|No|Completed|October 2002|August 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00975741||133447|
NCT00982176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2007/31|Determinants of Cognitive Impairment After Acute Coronary Syndrome|Anatomo-functional Determinants of Cognitive Impairment After Acute Coronary Syndrome: A Brain MRI and Cerebral Perfusion Scintigraphy Study|COSCA|University Hospital, Bordeaux|No|Completed|September 2009|May 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Both|35 Years|65 Years|No|Probability Sample|a cohort of patients admitted for evaluation of their cardio-vascular risk factor 4 ±1        months after an acute coronary syndrome|April 2014|April 1, 2014|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00982176||132968|
NCT00982150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-TAL-201-OL|Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)|A Multinational, Multicenter, Open Label Phase to Assess Tolerability and Safety of Talampanel 50mg Tid in Subjects With Amyotrophic Lateral Sclerosis (ALS)|ALSTAR OL|Teva Pharmaceutical Industries|Yes|Terminated|September 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|446|||Both|18 Years|80 Years|No|||August 2013|August 16, 2013|September 22, 2009|Yes|Yes|Core study unsuccessful|No||https://clinicaltrials.gov/show/NCT00982150||132970|
NCT00982410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAC 09-047|Managing Chronic Pain in Veterans With Substance Use Disorders|Managing Chronic Pain in Veterans With Substance Use Disorders||VA Office of Research and Development|No|Completed|April 2010|March 2014|Actual|August 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|September 21, 2009||No||No|November 21, 2014|https://clinicaltrials.gov/show/NCT00982410||132950|
NCT00978705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCTT-KRH-06|Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood|Clinical Study for Evaluation of Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood|keratinocyte|Modern Cell and Tissue Technology|Yes|Enrolling by invitation|November 2007|January 2010|Anticipated|May 2008|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|1 Year|70 Years|No|||September 2009|September 15, 2009|April 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978705||133221|
NCT00978965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPASNPVienna|Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs|Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept®) or Mycophenolate-natrium (Myfortic®) Therapy||Medical University of Vienna|No|Recruiting|October 2009|June 2013|Anticipated|March 2013|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a de novo kidney transplantation|April 2012|April 23, 2012|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00978965||133201|
NCT00979251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS-TCAD-PO206|Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects|A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects|PO206|Adamas Pharmaceuticals, Inc.|Yes|Completed|September 2009|August 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|1 Year|65 Years|No|||March 2014|March 17, 2014|September 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979251||133180|
NCT00979264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004022|Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study|Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study|CERTs-HF|Duke University|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|147|||Both|N/A|N/A|No|||June 2012|June 22, 2012|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00979264||133179|
NCT00979589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008ZX09312-008|Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events|Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke|CHANCE|Ministry of Science and Technology of the People´s Republic of China|Yes|Completed|July 2008|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5100|||Both|40 Years|90 Years|No|||March 2012|March 11, 2012|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979589||133154|
NCT00979602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113480|Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older|A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older||GlaxoSmithKline||Completed|November 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4066|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|July 11, 2013|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979602||133153|
NCT00979823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X0710100 Resident SimCare|Simulated Diabetes Training for Resident Physicians|Simulated Diabetes Training for Resident Physicians|SDT|HealthPartners Institute|No|Completed|September 2010|July 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|341|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979823||133136|
NCT00979836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-002858-37|Calcium Dobesilate for Chronic Venous Wounds|Randomized, Double-blind Multicenter Clinical Trial Comparing the Efficacy of Calcium Dobesilate With Placebo in the Treatment of Ulcer Secondaries to Chronic Venous Disease||Fundacion Iberoamericana Itaca|No|Suspended|April 2008|||July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||February 2011|February 16, 2011|September 17, 2009||No|The financial support was withdrawn.|No||https://clinicaltrials.gov/show/NCT00979836||133135|
NCT00978237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPOKAL|Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients|CT to Assess the Effect on the Subcutaneous Fat of Change of EFV for LPV/r in HIV-infected Patients Who Developed Lipoatrophy and Remains Despite Treatment With Efavirenz and Fixed-dose Combination of no Thymidine Nucleoside Analogues.|LIPOKAL|Hospital Clinic of Barcelona|No|Completed|October 2009|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978237||133257|
NCT00978250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090214|A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)|A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)||National Institutes of Health Clinical Center (CC)||Recruiting|August 2009|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|185|||Both|18 Years|120 Years|No|||September 2015|October 2, 2015|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978250||133256|
NCT00987025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSA290200600024I, TO #2|Initial Evaluation of Telehealth Blood Pressure Stations in Nutrition Centers|Technologies for Enhancing Access and Health Management|TEAhM|American Association of Homes and Services for the Aging|No|Active, not recruiting|October 2009|January 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|144|||Both|55 Years|N/A|No|||May 2010|May 27, 2010|September 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00987025||132599|
NCT00987038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9391007|A Midazolam Drug Interaction Study With PF-04171327|A Phase 1, Open Label, Multiple Dose Study Of The Effect Of PF-04171327 On Midazolam Pharmacokinetics In Healthy Volunteers||Pfizer|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 7, 2009|September 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00987038||132598|
NCT00986999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H002|Effect of Rosuvastatin on Endothelial Function|Pilot Study of the Effect of Low-Dose Rosuvastatin on Endothelial Function, Oxidative Stress and Inflammatory Parameters in HIV-Infected Individuals With Low HDL Cholesterol Levels and Low to Normal LDL Cholesterol Levels||University of Hawaii|No|Terminated|September 2009|||January 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 20, 2015|September 29, 2009|Yes|Yes|poor enrollment|No|January 20, 2015|https://clinicaltrials.gov/show/NCT00986999||132601|
NCT00987012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0044-09-HYMC|The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients|The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients - A Prospective Randomized Trial||Hillel Yaffe Medical Center||Not yet recruiting|October 2009|||April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|N/A|No|||September 2009|September 29, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987012||132600|
NCT00983255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-107|Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)|A Double-Blind, Placebo-Controlled, Single & Multiple Ascending Dose, Safety, Tolerability, & PK Study of an IV Form of TR-701 Free Acid & an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults|IV/SAD/MAD|Trius Therapeutics LLC|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|July 18, 2014|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983255||132885|
NCT00974909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2-079|Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence|Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence: a Multi-center, Randomized, Placebo Controlled Study||Maastricht University Medical Center|Yes|Completed|October 2009|August 2015|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||September 2010|August 25, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00974909||133508|
NCT00976352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGTC PD-AAV004|Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease|Phase I/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV-GAA) Gene Vector in Patients With Pompe Disease||University of Florida|Yes|Completed|September 2010|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|2 Years|18 Years|No|||December 2015|December 8, 2015|July 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976352||133400|
NCT00975468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCV vs. VCV during OLV|Pressure-Controlled vs Volume-Controlled Ventilation During One Lung Ventilation|Prospective, Randomized Study of the Effects of Pressure-controlled vs. Volume-controlled Ventilation During One Lung Ventilation on Lung Injury After Thoracotomy||King Faisal University|Yes|Recruiting|March 2009|July 2012|Anticipated|April 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||June 2011|June 21, 2011|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00975468||133466|
NCT00982163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003-26|A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season|||ORA, Inc.|No|Completed|August 2008|September 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|A community sample of subjects with allergic conjunctivitis and at least 18 years of age        were enrolled into the study.|September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982163||132969|
NCT00982423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003210|The Effects of Decreasing the Lasix Dose on the Cardiorenal System|To Define the Effects of Decreasing the Furosemide Dose on Cardiorenal and Humoral Function in Humans With Compensated Chronic Heart Failure (CHF) With and Without Renal Dysfunction|Aim1|Mayo Clinic|Yes|Completed|July 2009|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|90 Years|No|||June 2015|June 22, 2015|September 18, 2009|Yes|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT00982423||132949|
NCT00982917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-12867|Stamp-in-Safety Playground Safety Project|Stamp-in-Safety Playground Safety Project||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|June 2006|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|71|||Both|3 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982917||132911|
NCT00978718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0506-01|Selenium in Preventing Prostate Cancer|Phase III Trial of Selenium for Prostate Cancer Prevention||University of Arizona||Completed|August 2001|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Prevention|3||Anticipated|700|||Male|N/A|79 Years|No|||August 2012|August 13, 2012|September 16, 2009||||No||https://clinicaltrials.gov/show/NCT00978718||133220|
NCT00978731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-039|Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study|Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Subjects Who Experienced Clinical Benefit on Protocol CA180-002||Bristol-Myers Squibb|No|Completed|December 2005|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|September 16, 2009|No|Yes||No|November 23, 2010|https://clinicaltrials.gov/show/NCT00978731||133219|
NCT00978978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR484909CTIL|Propofol Versus Midazolam and Fentanyl for Diagnostic and Screening Colonoscopy in Patients With Advanced Liver Disease|Propofol Versus Midazolam and Fentanyl for Diagnostic and Screening Colonoscopy in Patients With Advanced Liver Disease||Soroka University Medical Center|No|Not yet recruiting|October 2009|||August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|2||Anticipated|60|||Both|18 Years|75 Years|No|||September 2009|October 11, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978978||133200|
NCT00978991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005140|Duke Urology Database and Specimen Bank|Duke Longitudinal Urologic Surgery Patient Outcome Database||Duke University|Yes|Completed|January 1988|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|87820|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Urology|February 2013|February 6, 2013|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978991||133199|
NCT00979277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC03/17/07|Transcriptomal and Molecular Characterization of Tumor Associated Monocytes/Macrophages in Human Cancers|Transcriptomal and Molecular Characterization of Tumor Associated Monocytes / Macrophages in Human Cancers||National University Hospital, Singapore||Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|21 Years|N/A||Probability Sample|15 subjects from each tumor type. (NUH: NPC 15, CRC 15, RCC 7, HCC 8. AH: HCC 7,TTSH: RCC        8)|January 2014|January 8, 2014|September 15, 2009||||No||https://clinicaltrials.gov/show/NCT00979277||133178|
NCT00979225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002524|Clinical Decision Support for Medication Management and Adherence|Improving Quality Through Decision Support for Evidence-Based Pharmacotherapy||Duke University|No|Completed|September 2009|March 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|5000|||Both|N/A|N/A|No|||December 2012|December 10, 2012|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00979225||133182|
NCT00979238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGT4HB|Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B|An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B||St. Jude Children's Research Hospital|Yes|Recruiting|August 2009|July 2031|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Male|18 Years|N/A|No|||February 2016|February 23, 2016|September 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979238||133181|
NCT00979849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1883C00001|AZD8683 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD8683 After Single Ascending Doses in Healthy Male Subjects||AstraZeneca||Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|130|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|September 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979849||133134|
NCT00984646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1003-0027|Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10)|A Single-centre, Placebo- and Standard-care-controlled, Double-blind, Randomised Trial to Investigate the Efficacy of Eight Doses of RN1003 in the Reduction of Scarring From the Approximated Wound Margins of Incisional Wounds||Renovo|No|Completed|April 2005|November 2006|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984646||132778|
NCT00980161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200908039R|Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C|The Predictive Role of Serum Micro RNA-122 to the Clinical Course of Chronic Hepatitis C Patients||National Taiwan University Hospital|No|Recruiting|September 2009|December 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples Without DNA|Serum and hepatic micro RNA-122|Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic hepatitis C receving combination therapy with peginterferon alfa-2a        and ribavirin|March 2010|March 25, 2010|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00980161||133111|
NCT00980512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH060195|Community Implementation of KEEP: Fidelity and Generalization of Parenting|Community Implementation of KEEP: Fidelity and Generalization of Parenting|KEEP|San Diego State University|No|Completed|September 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|354|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980512||133088|
NCT00974662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN903 LCM201|Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer|Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy on Obstructing Endobronchial Non-Small Cell Lung Cancer||Steba Biotech S.A.|No|Terminated|September 2009|December 2011|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|September 9, 2009||No|Early end of enrolment with regards to difficulty met to enrol patients.|No||https://clinicaltrials.gov/show/NCT00974662||133527|
NCT00974675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-354-0602|A Study to Assess the Safety and Tolerability of Multiple Doses of Multi-Level of a Drug in Subjects With Moderate Asthma|A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma||MedImmune LLC|No|Completed|September 2006|October 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||September 2009|September 9, 2009|September 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00974675||133526|
NCT00974311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPC2|Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy|AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-COntrolled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|AFFIRM|Medivation, Inc.|Yes|Active, not recruiting|September 2009|March 2018|Anticipated|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1199|||Male|18 Years|N/A|No|||February 2014|February 22, 2014|September 9, 2009|Yes|Yes||No|September 28, 2012|https://clinicaltrials.gov/show/NCT00974311||133553|
NCT00974324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTCL0908|Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma|Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma|PTCL|Fudan University|Yes|Recruiting|August 2009|September 2011|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||September 2010|September 14, 2010|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974324||133552|
NCT00987298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-090320|Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool|Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool||GE Healthcare|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|124|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Age between 18 and 90 BMI between 18.5 and 40|December 2010|December 6, 2010|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987298||132578|
NCT00987311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU311|Effect of Probiotic Fermented Dairy Drinks on Intestinal Immune Response|Pilot Study on the Effects of Probiotic Fermented Dairy Drinks on the Intestinal Immune Response in Healthy Adults||Danone Research|No|Completed|September 2009|||July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 15, 2011|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00987311||132577|
NCT00974883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/64/01|Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)|The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (GCA).|TABUL|University of Oxford|Yes|Completed|June 2010|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|880|Samples With DNA|Temporal artery biopsy samples Serum Plasma White cells Video images of temporal and      axillary arteries|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study cohort: Patients with suspected new giant cell arteritis Training cohort; patients        or healthy volunteers willing to have temporal artery and axillary artery ultrasound        examination|July 2015|July 16, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974883||133510|
NCT00974896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060134|Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors|A Phase 1b Study of AMG 479 With Biologics or Chemotherapy in Adult Subjects With Advanced Solid Tumors||Amgen||Completed|December 2006|April 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|September 10, 2009||||No||https://clinicaltrials.gov/show/NCT00974896||133509|
NCT00974649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZL FWO|Psychosocial Determinants of Continuing or Discontinuing Infertility Treatment: A Psychological Analysis|Psychosocial Determinants of Continuing or Discontinuing Infertility Treatment: A Psychological Analysis||University Hospital, Gasthuisberg|No|Completed|November 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|315|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 28, 2013|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00974649||133528|
NCT00975780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609001783|A Trial to Reduce Pneumonia in Nursing Home Residents|A Randomized Controlled Trial to Reduce Pneumonia in Nursing Home Residents|PRIDE|Yale University|Yes|Completed|October 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|834|||Both|65 Years|N/A|No|||November 2014|November 7, 2014|September 10, 2009|Yes|Yes||No|December 6, 2013|https://clinicaltrials.gov/show/NCT00975780||133444|Participant flow and outcome information pertains to data collected through 10/25/2012- the official trial termination date.Serious and Other Adverse Event information pertains to requested surveillance of subjects through 12/10/2012 per the NIA.
NCT00976079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13360|The Effect of Transcutaneous Electrical Nerve Stimulation on Quadriceps Central Activation and Gait|The Effect of Transcutaneous Electrical Nerve Stimulation on Quadriceps Central Activation and Gait||University of Virginia|No|Completed|November 2007|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|80 Years|No|||September 2009|September 11, 2009|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976079||133421|
NCT00975793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC - RC/RB001|Australasian Resuscitation In Sepsis Evaluation Randomised Controlled Trial|A Multi-centre, Randomised Controlled Trial of Early Goal-directed Therapy in Patients Presenting to the Emergency Department With Severe Sepsis in Australasia|ARISE|Monash University|Yes|Active, not recruiting|October 2008|April 2015|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975793||133443|
NCT00975806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-RCC-001|Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma|A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma||Celgene|No|Terminated|September 2009|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|September 9, 2009|Yes|Yes|MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.|No|December 17, 2014|https://clinicaltrials.gov/show/NCT00975806||133442|
NCT00976638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHP-CT-2007-037941|Clinical Trial to Reduce Antibiotic Resistance in European Intensive Cares|Mastering Hospital Antibiotic Resistance, a Cluster Randomized Intervention Study in Intensive Care Units Throughout Europe (Work Package 3)|MOSAR-ICU|UMC Utrecht|No|Completed|June 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|14318|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976638||133378|
NCT00982436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 0905|Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer|A Pilot Study to Evaluate Response to Neoadjuvant Chemotherapy With Cisplatin and Docetaxel Followed by Chemoradiation Therapy With Carboplatin in Stage IV Non-metastatic Head and Neck Cancer||University of Vermont|Yes|Recruiting|September 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982436||132948|
NCT00982449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J09111|124I-FIAU Imaging in EBV and KSHV Associated Cancers|Study of Imaging of Viral Thymidine Kinase Activity in EBV-Associated and KSHV-Associated Malignancies||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|June 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|75 Years|No|||October 2015|October 30, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982449||132947|
NCT00982202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0168|Pioglitazone in Alzheimer Disease|Pioglitazone in Alzheimer Disease Progression||National Institute on Aging (NIA)|Yes|Completed|January 2002|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|50 Years|N/A|No|||September 2009|September 22, 2009|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00982202||132966|
NCT00982709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4402|The Effects of Treadmill Versus Agility Training in Parkinson's Disease|The Effects of Treadmill Versus Agility Training in Parkinson's Disease||Oregon Health and Science University|No|Completed|January 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|50 Years|80 Years|No|||October 2014|October 31, 2014|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982709||132927|
NCT00982930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2303E1|Open Label Extension to Bridging Study CTBM100C2303|A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.||Novartis||Completed|August 2009|||October 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|6 Years|21 Years|No|||May 2012|May 2, 2012|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00982930||132910|
NCT00982956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007023|Application of Computer-assisted Navigation in Total Knee Arthroplasty: A Randomized Pair-matched Double-blind Trial|||Chinese PLA General Hospital||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|N/A|N/A||Probability Sample|the subjects who had been scheduled for simultaneous bilateral TKA,|September 2009|September 22, 2009|September 22, 2009||||No||https://clinicaltrials.gov/show/NCT00982956||132908|
NCT00978744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-002256/1; BWH|Evaluation of a Regional Electronic Health Information Exchange's Clinical Health Record|Evaluation of a Regional Electronic Health Information Exchange's Clinical Health Record||Brigham and Women's Hospital|No|Active, not recruiting|December 2008|June 2014|Anticipated|January 2012|Actual|N/A|Observational|N/A||1|Actual|113|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients are not being enrolled as subjects; their deidentified data will be reviewed only        if their associated physicians and practices are participating as subjects in the study.        Physicians, staff, and patients within the study population are representative of the        practices we are going to study. Patients' data will be included in the intervention study        to the extent that they are part of Shared Health's CHR system, are receiving care at one        of the selected practices, and meet eligibility requirements.|January 2014|January 23, 2014|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978744||133218|
NCT00979004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICA-105665-04|A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients|A Phase 2, Multi-Center, Single-Blind, Placebo-Controlled Pharmacodynamic Evaluation of ICA-105665 in Epilepsy Patients With a Photo-Induced Paroxysmal EEG Response||Pfizer|No|Terminated|September 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|60 Years|No|||September 2012|September 27, 2012|September 16, 2009|Yes|Yes|The study was terminated on September 12, 2010 per protocol following a serious adverse event    that occurred with the first subject dosed at 600 mg.|No||https://clinicaltrials.gov/show/NCT00979004||133198|
NCT00979017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019065|Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme|Avastin in Combination With Temozolomide and Irinotecan for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas||Duke University|No|Completed|November 2009|January 2013|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|September 15, 2009|Yes|Yes||No|June 5, 2013|https://clinicaltrials.gov/show/NCT00979017||133197|
NCT00979030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0119-14|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2009|||||N/A|N/A|N/A||||||||||||||March 9, 2010|September 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979030||133196|
NCT00979641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-003527-24|Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer|Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer|AINO|Tampere University Hospital|Yes|Recruiting|January 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Female|18 Years|N/A|No|||March 2012|February 5, 2014|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT00979641||133150|
NCT00979862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02919|Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma|A Phase Ib Study of Cediranib in Combination With Cilengitide in Patients With Recurrent Glioblastoma||National Cancer Institute (NCI)||Completed|March 2010|February 2014|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||December 2013|April 14, 2015|September 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979862||133133|
NCT00979615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-03|Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis|||Alcon Research||Completed|September 2009|||November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|12 Years|N/A|No|||April 2011|April 14, 2011|September 17, 2009|No|Yes||No|April 14, 2011|https://clinicaltrials.gov/show/NCT00979615||133152|
NCT00984906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103003|Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers|Inspiratory Flow Parameters and Device Handling With Empty Device-metered Dry Powder Inhalers, Easyhaler and Turbuhaler; an Open, Randomised, Multi Centre Study in Patients With Asthma or COPD|PIFECO|Orion Corporation, Orion Pharma|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|200|||Both|6 Years|N/A|No|||June 2010|June 7, 2010|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984906||132758|
NCT00985504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13018|A Study of Patients With Major Depressive Disorder and Residual Apathy|A Phase 4, 8-week, Double-blind, Randomized Study Comparing Switching to Duloxetine or Escitalopram in Patients With Major Depressive Disorder and Residual Apathy in the Absence of Depressed Mood||Eli Lilly and Company|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|483|||Both|18 Years|N/A|No|||August 2011|December 7, 2011|September 25, 2009|Yes|Yes||No|August 29, 2011|https://clinicaltrials.gov/show/NCT00985504||132712|
NCT00985192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000655574|Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer|A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach||Translational Oncology Research International|Yes|Completed|September 2009|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2015|October 30, 2015|September 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985192||132736|
NCT00985478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S342.1.001|First in Man Study With SLV342|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV342 in Young Healthy Male Subjects||Abbott|No|Terminated|January 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 24, 2011|September 25, 2009||No|Terminated on 14 Sep 2010 due to strategic considerations|No||https://clinicaltrials.gov/show/NCT00985478||132714|
NCT00974363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112148|Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612|Persistence of Antibodies After Vaccination With GSK Biologicals' Meningococcal Vaccine GSK134612 in Adolescents and Young Adults||GlaxoSmithKline||Completed|September 2009|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|697|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00974363||133549|
NCT00978497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA598-504|Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients With Chronic Hepatitis C Infection||Hoffmann-La Roche|Yes|Completed|September 2009|August 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|97|||Both|18 Years|65 Years|No|||November 2012|November 12, 2012|September 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978497||133237|
NCT00974610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-12 ICORG|Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. ICORG 07-12|Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Active, not recruiting|August 2008|||December 2015|Actual|N/A|Observational|Time Perspective: Prospective||5|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|5 different tumour types|February 2016|February 15, 2016|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974610||133531|
NCT00974623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPROACH-001|Bone Graft Materials Observational Registry|A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice|APPROACH-001|Apatech, Inc.|No|Terminated|September 2009|November 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|329|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled in this study will be identified from the surgeon's medical practice and        will include patients who failed conservative care and have been identified as requiring        spinal fusion surgery.|November 2013|November 12, 2013|September 8, 2009||No|Parent sponsor company (Baxter Healthcare) company cut funding|No||https://clinicaltrials.gov/show/NCT00974623||133530|
NCT00975481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451037|A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users|A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users||Pfizer|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|36|||Both|18 Years|55 Years|No|||February 2013|February 20, 2013|September 10, 2009|No|Yes||No|December 3, 2012|https://clinicaltrials.gov/show/NCT00975481||133465|
NCT00975494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444-05|Chronic Sildenafil Treatment in Heart Failure|Chronic PDE5-Inhibition With Sildenafil Improves Diastolic Function, Cardiac Geometry and Clinical Status in Patients With Stable HF: A 1-Year Prospective Randomized, Placebo-Controlled Study||University of Milan|Yes|Completed|April 2005|December 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Male|38 Years|80 Years|No|||September 2009|September 10, 2009|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00975494||133464|
NCT00975507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-009|ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)|A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children||Merck Sharp & Dohme Corp.|No|Completed|March 1998|June 1999|Actual|January 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|480|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 10, 2009|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00975507||133463|
NCT00983346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI33979|Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients|Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients||University of Utah|Yes|Completed|October 2009|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|September 22, 2009|Yes|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT00983346||132878|
NCT00983567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-55215-17998|An Interactive Web-Based Program to Improve Food and Activity Choices of Teens|An Interactive Web-Based Program to Improve Food and Activity Choices of Teens|Teen Web|Baylor College of Medicine|Yes|Completed|September 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|400|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00983567||132861|
NCT00983580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2009-01192|Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer|Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 2009|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|104|||Both|40 Years|N/A|No|||October 2015|October 9, 2015|September 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00983580||132860|
NCT00976092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE I01209|Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction|Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI|BRAVE-4|Deutsches Herzzentrum Muenchen|Yes|Active, not recruiting|September 2009|February 2015|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|548|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976092||133420|
NCT00982462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSM #2009-1024|Effect of Long-Chain Polyunsaturated Fatty Acid Supplementation on Toddler Cognition|The Effects of Extended Duration of Long-Chain Polyunsaturated Fatty Acid (LCP)-Supplementation on Neurological and Immunological Development in Toddlers||Retina Foundation of the Southwest|No|Active, not recruiting|October 2010|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|114|||Both|351 Days|379 Days|Accepts Healthy Volunteers|||February 2015|February 6, 2015|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00982462||132946|
NCT00982722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT 2007-003691-19|Vitamin D Supplementation After Parathyroid Surgery|Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism||Karolinska University Hospital|Yes|Active, not recruiting|April 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|N/A|N/A|No|||March 2016|March 11, 2016|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982722||132926|
NCT00982943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-97-C-022|The Epidemiological Study on Psychiatric Disorders and Psychotropic Drugs|The Epidemiological Study on Psychiatric Disorders and Psychotropic Drugs||Far Eastern Memorial Hospital|Yes|Active, not recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000000|||Both|N/A|N/A|No|Probability Sample|the health insurance data from persons who had diagnoses of ICD: 290-319 or were        prescribed with antidepressant agents during the period from 1998 to 2006|September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982943||132909|
NCT00982969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QFTinROKmilitary|The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis|The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis Among Young Adults||Armed Forces Capital Hospital, Republic of Korea|No|Completed|June 2008|April 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Soldiers in South Korean Army|September 2009|July 19, 2010|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982969||132907|
NCT00982982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901004662|Effects of Delta-9-THC and Iomazenil in Healthy Humans|Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis||Yale University|Yes|Recruiting|February 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|August 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00982982||132906|
NCT00979290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J120114933|Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs|Comparison of Adverse Reactions and Efficiency of Fixed-dose Combination Chemotherapy and Separate Formulations for Pulmonary Tuberculosis||E-DA Hospital||Completed|October 2008|November 2011|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|161|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Newly diagnosed TB patients in E-DA hospital|April 2015|April 14, 2015|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00979290||133177|
NCT00979303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08110505|Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia|The Adjunct Use of Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia||Children's Hospital Boston|Yes|Recruiting|January 2009|||September 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|8 Years|21 Years|No|||September 2009|September 17, 2009|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979303||133176|
NCT00979654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP212|A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Subjects With Systemic Lupus Erythematosus or Myositis|A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis||MedImmune LLC|No|Completed|August 2010|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979654||133149|
NCT00984126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3568|Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015|Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A||Novo Nordisk A/S|No|Active, not recruiting|October 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|214|||Male|6 Months|70 Years|No|||December 2015|December 16, 2015|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00984126||132818|
NCT00984919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654093|Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers|Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis||Barbara Ann Karmanos Cancer Institute|Yes|Completed|November 2009|February 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Male|40 Years|120 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cancer clinic|February 2016|February 12, 2016|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984919||132757|
NCT00979628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00020328a|Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)|Basal Bolus Versus Basal Insulin Regimen for the Treatment of Hospitalized Patients With Type 2 Diabetes Mellitus: a Randomized, Open Labeled, Non-inferiority Controlled Study|Basal Plus|Emory University|Yes|Completed|January 2010|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|375|||Both|18 Years|80 Years|No|||March 2014|March 24, 2014|September 16, 2009|Yes|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT00979628||133151|
NCT00985751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113171|Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination|Safety, Reactogenicity & Immunogenicity of GSK Biologicals' Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination||GlaxoSmithKline||Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|257|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||May 2011|May 26, 2011|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985751||132693|
NCT00985764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0006|Venous Air Embolism in Cesarean Delivery, Especially Placental Previa|||Yonsei University||Completed|May 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Female|20 Years|40 Years|No|Non-Probability Sample|cesarean delivery with placental previa|October 2010|November 3, 2010|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985764||132692|
NCT00986011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-USC-HS-0700681|Study of a Smart Growth Community's Effect on Prevention of Obesity in Middle-, Moderately Low- and Low-Income Families|Effects of A Smart Growth Community on Prevention of Family Obesity Risks||National Cancer Institute (NCI)||Completed|April 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|N/A|||Anticipated|780|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2009|July 9, 2013|September 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00986011||132673|
NCT00975247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 08-310|Impact of a Novel Patient Educational Booklet on Colonoscopy Quality|Impact of a Novel Patient Educational Booklet on Colonoscopy Quality||VA Greater Los Angeles Healthcare System|No|Completed|April 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|500|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975247||133482|
NCT00975520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 08.09|Neurotropic Melanoma of the Head and Neck|A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck|RTN2|Australia and New Zealand Melanoma Trials Group|Yes|Recruiting|September 2009|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975520||133462|
NCT00974922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091661|Vitamin D Deficiency in Patients With Hypertension|Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension||University of Connecticut Health Center|No|Terminated|August 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|No|||July 2012|July 23, 2012|September 10, 2009|Yes|Yes|Administrative/Sponsor Business Decision|No||https://clinicaltrials.gov/show/NCT00974922||133507|
NCT00974337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-123/2008|Relative Adrenal Insufficiency in Preterm Very Low Birth Weight Infants With Shock|Basal and Stimulated Cortisol Levels in Preterm Very Low Birth Weight Infants With and Without Shock: A Cross-sectional Study||All India Institute of Medical Sciences, New Delhi|No|Completed|March 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|39|||Both|N/A|7 Days|No|Probability Sample|Preterm (28 to 34 week gestation) very low birth weight (birth weight 750-1500grams)        infants born at AIIMS|January 2015|January 13, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974337||133551|
NCT00974636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00016384|Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial|Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial|BIA|University of Michigan|No|Completed|May 2009|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|85 Years|No|||August 2015|August 4, 2015|September 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974636||133529|
NCT00975234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mio/Reg/Quirur/Aleatorizado|Treatment With Autologous Skeletal Myoblasts|Phase II, Randomised, Controlled Study of Treatment With Revascularisation Surgery With or Without Injection of Autologous Skeletal Myoblasts in Patients With Old Myocardial Infarction||Clinica Universidad de Navarra, Universidad de Navarra|No|Terminated|May 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|30 Years|80 Years|No|||June 2012|June 7, 2012|September 10, 2009||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT00975234||133483|
NCT00983060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIM811B2202|Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients|A Randomized, Adaptive-design, Dose-finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With the Standard of Care (SOC) in Relapsed Patients Infected With HCV Genotype-1||Novartis||Completed|September 2009|||April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|69 Years|No|||November 2011|November 3, 2011|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00983060||132900|
NCT00983333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU00005635|Initial Test of the Time to Talk CARDIO (Creating a Real Dialogue In the Office) Program|Beta Test of the Time to Talk CARDIO (Creating a Real Dialogue In the Office) Web-based Tool for Improving Communication Between Patients and Health Care Professionals||Oregon Health and Science University|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|105|||Both|55 Years|70 Years|No|||October 2015|October 14, 2015|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983333||132879|
NCT00984204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90030638|Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)|Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)||St. Jude Medical|Yes|Completed|October 2009|January 2012|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|188|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|September 22, 2009|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT00984204||132812|
NCT00983593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34135|A Randomized Clinical Study of a Mind-Body Approach to Domestic Violence Offender Treatment|A Randomized Clinical Study of a Mind-Body Approach to Domestic Violence Offender Treatment||University of Utah|Yes|Recruiting|September 2009|September 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|N/A|No|||August 2012|August 28, 2012|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00983593||132859|
NCT00983905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1010|Drug-Drug Interaction Study of Colchicine and Theophylline|A One-Directional, Open-Label, Drug Interaction Study to Investigate the Effects of Multiple-Dose Colchicine on Single-Dose Pharmacokinetics of Theophylline in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 23, 2010|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00983905||132835|
NCT00982748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08803|Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy|Effects of Pranayama on Fatigue Among Patients Undergoing Chemotherapy||University of California, San Francisco|Yes|Completed|October 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|25|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00982748||132924|
NCT00982475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1889|Alster Man and Machine: Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation|Ablation at St. George Hospital - Prospective Randomized Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation||Asklepios proresearch|No|Recruiting|September 2009|||September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|30 Years|75 Years|No|||June 2011|June 21, 2011|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982475||132945|
NCT00982735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.540|An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice|An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice.||Boehringer Ingelheim||Completed|September 2007|||August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|987|||Both|20 Years|80 Years|No|Non-Probability Sample|Essential hypertensive patients|March 2014|March 26, 2014|September 22, 2009||||No|February 9, 2010|https://clinicaltrials.gov/show/NCT00982735||132925|
NCT00978757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#556|The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion|Phase 4: Study of Ketamine Inhibition of Interleukin 6 in Hepatic Resections Requiring Temporary Porto-arterial Occlusion||Hospital Italiano de Buenos Aires|No|Completed|June 2001|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|21 Years|N/A|No|||October 2009|December 11, 2009|September 16, 2009||No||No|September 23, 2009|https://clinicaltrials.gov/show/NCT00978757||133217|
NCT00979043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60AG010484-07|The Arthritis, Diet, and Activity Promotion Trial|The Arthritis, Diet, and Activity Promotion Trial|ADAPT|Wake Forest Baptist Health|No|Completed|November 1997|December 2000|Actual|December 2000|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|318|||Both|60 Years|N/A|No|||September 2009|September 16, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979043||133195|
NCT00983866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-04CSomk-02-B|CHOICES: Understanding Clinical Trials as a Treatment Option|Increasing Participation in Cancer Clinical Trials|CHOICES|Kaiser Permanente|Yes|Active, not recruiting|September 2009|December 2016|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2110|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00983866||132838|
NCT00984113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-115 / CPRT128A2104|Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment|An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects||Portola Pharmaceuticals|No|Terminated|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|44|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|September 16, 2009|No|Yes|For administrative reasons. Enrollment was sufficient to have statistical power without    compromising the integrity of the study data|No||https://clinicaltrials.gov/show/NCT00984113||132819|
NCT00984659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112989|Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease|Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|366|||Both|40 Years|N/A|No|||March 2012|April 6, 2015|September 24, 2009|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00984659||132777|
NCT00984932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed116613963|Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension|The Effect of Rosuvastatin on Vascular Dysfunction and Inflammatory Markers in Systemic Sclerosis-related Pulmonary Hypertension: Randomized, Double-Blind Placebo-Controlled Trial||Faculty of Medicine, University of Alexandria|Yes|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984932||132756|
NCT00984399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-110|Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen|Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00984399||132797|
NCT00985517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERE-120-09|Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease|A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease||Ceregene|Yes|Active, not recruiting|September 2009|November 2014|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|35 Years|70 Years|No|||December 2012|December 10, 2012|September 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985517||132711|
NCT00985777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15630|Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia|A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2009|February 2016|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|September 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00985777||132691|
NCT00985790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113237|Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children|Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children||GlaxoSmithKline||Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|599|||Both|18 Months|47 Months|Accepts Healthy Volunteers|||July 2015|July 2, 2015|September 24, 2009|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT00985790||132690|
NCT00986817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071215|Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin|Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study|TERAS|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2009|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986817||132614|
NCT00986830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1630-001|RELIEF: Healthcase Utilization and Outcomes of FinESS Treatment in the Office|Healthcare Utilization and Outcomes of FinESS Treatment in the Office|RELIEF|Entellus Medical, Inc.|No|Completed|September 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986830||132613|
NCT00974688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012482|Optimizing Health Among Children With Congenital Heart Defects|Optimizing Health Among Children With Congenital Heart Defects Through Rehabilitation Focused on Physical Activity Determinants||The Hospital for Sick Children|No|Completed|July 2009|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|172|||Both|4 Years|11 Years|No|||August 2013|August 25, 2013|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974688||133525|
NCT00975208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW1234|Osteogenesis and Dental Eruption Through Electrical Stimuli|Osteogenesis and Dental Eruption Through Electrical Stimuli Following Periosteoplasty for Alveolar Clefts in Patients With Cleft Lip and Palate Deformities. A Preliminary Report.||University of Guadalajara|Yes|Active, not recruiting|January 2006|August 2010|Anticipated|November 2007|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|9|||Both|N/A|N/A|No|Probability Sample|patients of the Institute of Reconstructive Surgery of Jalisco, México|September 2009|September 10, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975208||133485|
NCT00975221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070277|Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy|A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy||Amgen|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|September 10, 2009|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT00975221||133484|
NCT00976105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111849|Effects of Repeat Dosing of GSK1521498|A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of 10 Days of Repeat Dosing of GSK1521498 in Overweight or Obese But Otherwise Healthy Subjects.||GlaxoSmithKline|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976105||133419|
NCT00976118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04024|Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease|A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.||AB Science|No|Completed|February 2006|February 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|50 Years|N/A|No|||September 2009|May 21, 2013|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976118||133418|
NCT00983918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24815|Pain After Laparoscopic Cholecystectomy|Postoperative Pain After Laparoscopic Cholecystectomy After Anesthesia With Isoflurane, Desflurane, Sevoflurane or Propofol||Baylor College of Medicine|Yes|Completed|September 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|64 Years|No|||January 2014|January 25, 2014|September 22, 2009||No||No|February 14, 2012|https://clinicaltrials.gov/show/NCT00983918||132834|
NCT00985569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOOL|Surveying The Outcomes Of Lubiprostone (The STOOL Study) in Nursing Home Residents|Surveying The Outcomes Of Lubiprostone (The STOOL Study): The Effect of Lubiprostone on Reducing the Number of Medications Prescribed to Nursing Home Residents and Its Impact on Selected Quality Indicators|STOOL|Synergy Health Solutions|Yes|Withdrawn|November 2009|November 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Both|18 Years|N/A|No|Non-Probability Sample|Nursing Home Residents (adult subjects living in Nursing Homes)|November 2010|November 22, 2010|September 24, 2009||No|Enrollment was never begun.|No||https://clinicaltrials.gov/show/NCT00985569||132707|
NCT00984464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 020|Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma|A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma||Oncolytics Biotech|No|Completed|September 2009|October 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00984464||132792|
NCT00984477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2650C00006|Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects|A Phase I, Exploratory Study to Assess the Pharmacokinetics of Single Oral Doses and a Single Intravenous Radiolabelled Microtracer Dose of AZD5122 in Healthy Male Subjects||AstraZeneca|No|Completed|September 2009|November 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|100|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 3, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984477||132791|
NCT00987324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE NO. S02908|Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis|Randomized Trial of Paclitaxel-Eluting Balloon, Paclitaxel-Eluting Stent and Plain Balloon Angioplasty for Restenosis in "-Limus"-Eluting Coronary Stents|ISAR-DESIRE-3|Deutsches Herzzentrum Muenchen|No|Active, not recruiting|July 2009|September 2014|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|402|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00987324||132576|
NCT00982995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.048|Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients|UMCC 2008.048 Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients|HUM21469|University of Michigan Cancer Center|Yes|Terminated|November 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 21, 2009|Yes|Yes|site terminated due to lack of enrollment|No|September 5, 2014|https://clinicaltrials.gov/show/NCT00982995||132905|Accrual for the study was low. Due to issues with funding, we were unable to add a second site in order to accrue additional patients and the study was closed.
NCT00983528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090331|Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia||University of California, San Diego|Yes|Active, not recruiting|September 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|16 Years|N/A|No|||May 2011|May 3, 2011|September 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983528||132864|
NCT00983853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-950-110|Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV|A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C||Vertex Pharmaceuticals Incorporated|Yes|Completed|October 2009|||March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|No|||August 2013|August 2, 2013|September 22, 2009|Yes|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT00983853||132839|
NCT00984672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008802|Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery|Prospective Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery||Mayo Clinic|No|Enrolling by invitation|March 2009|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients age 18-75 with lumbar degenerative conditions including degenerative disk        disease, spondylolisthesis with significant back and or leg complaints that have failed        greater than 6 weeks of conservative therapy that are felt to be candidates for posterior        lumbar instrumented fusion with transforaminal interbody fusion (TLIF).|February 2016|February 17, 2016|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984672||132776|
NCT00985530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08H9|Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia|A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia||Northwestern University||Terminated|October 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|September 25, 2009|No|Yes|Supporting agency withdrew funding for study.|No||https://clinicaltrials.gov/show/NCT00985530||132710|
NCT00985205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE-ENERGIZE|The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury|Effects of Enteral Glutamine Supplementation on Mortality and Infectious Morbidity in Severely Burned Patients: a Multi-center Pilot Trial|RE-ENERGIZE|Clinical Evaluation Research Unit at Kingston General Hospital|Yes|Recruiting|December 2010|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2700|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985205||132735|
NCT00986037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-378|Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma|||Abbott|No|Completed|October 2009|||July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|April 12, 2011|September 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00986037||132671|
NCT00986284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-LCC-001|Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)|Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients||Tianjin Medical University Cancer Institute and Hospital|Yes|Suspended|September 2009|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||August 2012|December 21, 2015|September 27, 2009||No|Lack of patients and some progressed disease soon after surgery|No||https://clinicaltrials.gov/show/NCT00986284||132652|
NCT00981786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A434|24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol|Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma||Aristotle University Of Thessaloniki|No|Completed|August 2009|December 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|29 Years|80 Years|No|||May 2014|May 9, 2014|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00981786||132998|
NCT00981799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2008-002|Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL|A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|June 2010|||November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|1 Year|21 Years|No|||November 2015|November 20, 2015|September 9, 2009|No|Yes|Slow accrual rate|No||https://clinicaltrials.gov/show/NCT00981799||132997|
NCT00984217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-112|Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies|Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies||University of Pittsburgh|Yes|Withdrawn|August 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 23, 2009|Yes|Yes|Decided not to pursue at UPCI|No||https://clinicaltrials.gov/show/NCT00984217||132811|
NCT00984230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.22.INF|A New Adaptive Feeding Plan for Newborns|A New Adaptive Feeding Plan for Newborns: Effects on Gut Maturity and Gut Microbiota||Nestlé|No|Completed|September 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|186|||Both|N/A|3 Days|Accepts Healthy Volunteers|||June 2013|June 4, 2013|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00984230||132810|
NCT00975533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.335|Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial|A Randomized Study to Evaluate the Efficacy and Acceptability of Laparoscopic Placement of Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients Sub-optimally Controlled With Oral Anti-diabetic Agents.||Chinese University of Hong Kong|No|Not yet recruiting|October 2009|October 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|60 Years|No|||September 2009|September 10, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975533||133461|
NCT00975819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIR-DA-0901|Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies|A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|October 2009|October 2019|Anticipated|March 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|31 Years|No|||January 2015|February 3, 2015|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975819||133441|
NCT00974935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0009|Phase I STEBVax in Healthy Adults|Phase I Study of the Safety and Immunogenicity of Recombinant Staphylococcal Enterotoxin B Vaccine (STEBVax) in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2011|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|June 18, 2015|September 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00974935||133506|
NCT00975832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSvendsen|Adipocytokines and Polycystic Ovary Syndrome (PCOS)|Adipose Expression of Leptin, Adiponectin and IL-6, and Plasma Levels of Adipocytokines in Lean and Obese Women With PCOS||Hvidovre University Hospital|Yes|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|36 women (17 lean and 19 obese)with PCOS and 24 (8 lean and 16 obese) control women|September 2009|September 10, 2009|September 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00975832||133440|
NCT00983606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-MA213|An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants|An Observational Prospective Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants (32 to 35 Week Gestational Age) - Outcomes and Risk Tracking Study (The Report Study)||MedImmune LLC|No|Completed|September 2009|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples Without DNA|Serum (frozen)|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Premature babies at birth - (32-35 WGA)|November 2012|November 13, 2012|September 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983606||132858|
NCT00983619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP204|A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies|A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies||MedImmune LLC|No|Active, not recruiting|April 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|18||Anticipated|146|||Both|18 Years|99 Years|No|||March 2016|March 1, 2016|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983619||132857|
NCT00985322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCADIA|Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis|A Prospective, Randomized, Open Label, Blinded End-point (Probe) Trial to Evaluate Whether, at Comparable Blood Pressure Control, ACE Inhibitor Therapy More Effectively Than Non RAS Inhibitor Therapy Reduces CArdiovascular Morbidity and Mortality in Chronic DIAlysis Patients With Left Ventricular Hypertrophy and/or Arterial Hypertension (ARCADIA Study)|ARCADIA|Mario Negri Institute for Pharmacological Research|No|Active, not recruiting|May 2009|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|80 Years|No|||March 2016|March 15, 2016|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985322||132726|
NCT00985335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCU-09-VINJ004|Effectiveness of TheraNeem Lip Therapy for Herpes Simplex Labialis|Effectiveness of TheraNeem Lip Therapy of Common Symptoms of Herpes Simplex Labialis A Prospective Experimental Case Series (n=5)|Neem|Southern California University of Health Sciences|No|Completed|August 2009|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||November 2011|November 16, 2011|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00985335||132725|
NCT00985842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4378-R|Study to Determine if Different Prosthetic Sockets Effect How Much Oxygen is in the Tissue of Lower Limb Amputees While They Are Walking|Socket System Effect on Tissue Oxygenation During Amputee Gait||VA Office of Research and Development|No|Active, not recruiting|November 2009|December 2016|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT00985842||132686|
NCT00983879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhGALC-01|The Natural History of Infantile Globoid Cell Leukodystrophy|A Longitudinal Observational Study That Will Evaluate Prospectively Clinical and Surrogate Parameters That Are Affected in Infant Patients With Globoid Cell Leukodystrophy||Zymenex A/S|No|Completed|September 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|6|||Both|N/A|2 Years|No|Non-Probability Sample|Patients will be enrolled regardless of gender, race or ethnicity. Patients will be        identified through clinical referrals from other physicians or medical centers and also        those patients receiving clinical care at the Program for Neurodevelopmental Function in        Rare Disorders.|July 2015|July 17, 2015|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983879||132837|
NCT00983268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0934|Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer|Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer.||Vanderbilt-Ingram Cancer Center|Yes|Completed|October 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|September 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983268||132884|
NCT00984685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRP0002|"Assessment of Risk Factors for Depression Treatment at a Safety Net Clinic"|"Assessment of Risk Factors for Depression Treatment at a Safety Net Clinic"||Scranton-Temple Residency Program|No|Recruiting|August 2009|October 2009|Anticipated|September 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with the diagnosis of depression in theprimary care clinic|September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984685||132775|
NCT00984945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medicago H5VLP-001|Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults|Phase 1 Single Centre, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of Plant-based H5 VLP (Virus-like Particles), (H5N1) Pandemic Influenza Vaccine Adjuvanted With Aluminium Hydroxide and Administered to Healthy Adults 18-60 Years of Age||Medicago|Yes|Completed|September 2009|July 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2010|November 2, 2010|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984945||132755|
NCT00984412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-07-HMO-CTIL|Allo-Allo Tandem Bone Marrow Transplant (BMT)|Allo-allo Tandem Matched Stem Cell Transplantation (AATT) for the Treatment of Patients With Refractory Acute Leukemia; a Feasibility Phase I/II Study|AATT|Hadassah Medical Organization|No|Recruiting|November 2009|November 2020|Anticipated|April 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|3 Years|50 Years|No|||February 2016|February 18, 2016|September 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00984412||132796|
NCT00985244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amphia-ABR29500|Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease|Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial|COLUMBUS|Amphia Hospital|Yes|Completed|May 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985244||132732|
NCT00980590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-012|Airway Scope and Macintosh Laryngoscope for Tracheal Intubation in Patients Lying on the Ground|Airway Scope and Macintosh Laryngoscope for Tracheal Intubation in Patients Lying on the Ground||Outcomes Research Consortium|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|91 Years|No|||September 2009|November 23, 2011|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980590||133083|
NCT00985218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS 001 20080202|In Vitro Human Embryo Culture System|In Vitro Human Embryo Culture System||Incept BioSystems, Inc.|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|21 Years|35 Years|No|||September 2010|September 8, 2010|September 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00985218||132734|
NCT00985231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630|Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers|Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers||Bausch & Lomb Incorporated|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|272|||Both|30 Years|40 Years|No|||March 2015|March 4, 2015|September 25, 2009|Yes|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT00985231||132733|
NCT00981461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151.0805|Treatment of Androgenetic Alopecia in Females, 9 Beam|A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 9 Beam Model: For the Treatment of Androgenetic Alopecia in Females||Lexington International, LLC|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|September 21, 2009|Yes|Yes||No|April 12, 2012|https://clinicaltrials.gov/show/NCT00981461||133023|
NCT00982059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 07-0708-CE|Colorectal Cancer Screening for Cancer Survivors|Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy||University Health Network, Toronto|Yes|Active, not recruiting|May 2008|December 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|140|||Both|35 Years|49 Years|No|Non-Probability Sample|Patients who have received radiation treatment to the abdomen,pelvis or spine.|June 2015|June 12, 2015|November 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00982059||132977|
NCT00983944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08178|Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma|A Randomized Phase II Study of Dose-Adjusted EPOCH-R and R-VACOP-B in Primary Mediastinal (Thymic) Large B-Cell Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn|September 2009|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|10 Years|N/A|No|||October 2015|October 14, 2015|September 23, 2009|Yes|Yes|Inadequate Accrual|No||https://clinicaltrials.gov/show/NCT00983944||132832|
NCT00983957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-020|Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects|The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen®) in Healthy Female Subjects||Bristol-Myers Squibb|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|47|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|September 23, 2009|No|Yes||No|August 18, 2015|https://clinicaltrials.gov/show/NCT00983957||132831|
NCT00987103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2-016|Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients|Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients||Maastricht University Medical Center|Yes|Recruiting|September 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|18|||Both|18 Years|65 Years|No|||October 2010|October 21, 2010|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987103||132593|
NCT00983073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|441172|Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Pain Due to Osteoarthritis of the Knee Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.||Grünenthal GmbH|No|Completed|September 2009|September 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|40 Years|N/A|No|||February 2013|February 4, 2013|September 21, 2009||No||No|December 6, 2011|https://clinicaltrials.gov/show/NCT00983073||132899|
NCT00983359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654129|Stereotactic Radiation Therapy in Treating Patients With Brain Metastases|A Phase II Trial of Focal Therapy in the Treatment of Patients With 1-3 Brain Metastases||National Cancer Institute (NCI)||Recruiting|April 2007|||April 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2009|February 2, 2010|September 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00983359||132877|
NCT00985010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGDrDFF-Mn2008|Manganese in Women With Encephalopathy|Manganese, Possible Factor of Higher Mortality in Women With Encephalopathy||Materno-Perinatal Hospital of the State of Mexico|No|Terminated|January 2003|January 2005|Actual|January 2005|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients aged > 18 years, with hepatic encephalopathy and informed consent        signed by their families.|August 2009|July 26, 2010|January 5, 2009||No|The authors finished their jobs in the hospitals where the study was begun.|No|January 5, 2009|https://clinicaltrials.gov/show/NCT00985010||132750|Small numbers of subjects analyzed
NCT00985309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08213|Clinical Parameters Predicting Unsatisfactory Cervicovaginal Cytology in Conventional Smears|||Taichung Veterans General Hospital|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Female|N/A|N/A|No|Non-Probability Sample|A cohort of consecutive patients who received conventional Pap smear between March 2006        and August 2006 in Taichung Veterans General Hospital|September 2009|September 25, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00985309||132727|
NCT00985023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lisfranc|A Comparison of Stainless Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|A Randomized, Prospective Comparison of Stainless Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|Lisfranc|Rothman Institute Orthopaedics|Yes|Recruiting|August 2008|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|September 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985023||132749|
NCT00985855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-03|Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer|Feasibility of Cetuximab (ERBITUX®) Associated With Concomitant Radio-chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer: a Phase II, Randomised Study||Institut de Cancérologie de la Loire|Yes|Recruiting|September 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|70 Years|No|||January 2011|January 14, 2011|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00985855||132685|
NCT00985868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000653387|AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors|A CCLG/Cancer Research UK Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) Given for 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents With Relapsed and Refractory Solid Tumors||Cancer Research UK||Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|2 Years|18 Years|No|||April 2013|April 17, 2013|September 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00985868||132684|
NCT00984178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-005149-36|Trial of Hematopoietic Stem Cells in Acute Myocardial Infarction|Randomized Trial Comparing Intracoronary Delivery of Bone Marrow-derived Stem Cells Versus Stem Cell Mobilisation With GCSF, a Combination of Both Therapies and Conventional Treatment in Patients With Reperfused Acute Myocardial Infarction|TECAM2|TECAM Group|Yes|Recruiting|November 2005|||November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|75 Years|No|||September 2009|February 1, 2010|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984178||132814|
NCT00984139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112682|Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination|Long-term Persistence of Hepatitis B Antibodies and Immune Response to a Hepatitis B Vaccine Challenge in 12-13 Year Old Adolescents, Vaccinated in Infancy With GlaxoSmithKline (GSK) Biologicals' HBV Vaccine (Engerix™-B)||GlaxoSmithKline||Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|306|||Both|12 Years|13 Years|Accepts Healthy Volunteers|||March 2012|July 3, 2014|September 24, 2009|Yes|Yes||No|February 3, 2011|https://clinicaltrials.gov/show/NCT00984139||132817|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following complete retesting and reanalysis.
NCT00984152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08102303-IRB01|Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women|Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, & Immune Parameters in Different Compartments, Including Gut & Genital Tract|ICE-002|Rush University Medical Center|No|Withdrawn|June 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|60 Years|No|||May 2015|May 4, 2015|May 7, 2009|Yes|Yes|Decision not to go forth with study.|No||https://clinicaltrials.gov/show/NCT00984152||132816|
NCT00979706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHI-INMUNOMEDIADO|Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).|Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection With the Objective to Induce a Strong Specific HIV Immune Response Able to Control Viral Replication Without Highly Active Anti-Retroviral Therapy (HAART)|PHI-IMD|Hospital Clinic of Barcelona|Yes|Completed|March 2005|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979706||133145|
NCT00984958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bulkamid ISD2009 04|Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure|Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure Because of Suspected ISD: A Prospective Randomized Study||Skaraborg Hospital|Yes|Recruiting|October 2009|December 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|50 Years|N/A|No|||November 2014|November 20, 2014|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00984958||132754|
NCT00980252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080978|Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention|Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention||University of Illinois at Chicago|No|Completed|November 2009|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|34|||Both|16 Years|45 Years|No|||June 2014|June 13, 2014|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980252||133105|
NCT00981175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-040-005|A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults|Randomised, Double-blind, Phase 2 Study of the Safety, Immunogenicity and Duration of Immunity of ChimeriVax™-JE, Live Attenuated Vaccine in Healthy Adults||Sanofi|Yes|Completed|April 2003|February 2008|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|202|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||July 2012|July 11, 2012|September 21, 2009|Yes|Yes||No|April 5, 2011|https://clinicaltrials.gov/show/NCT00981175||133045|
NCT00981188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTrsinar|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2009|||||N/A|N/A|N/A||||||||||||||September 23, 2009|September 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981188||133044|
NCT00981201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-230|Celecoxib as a Chemopreventive Agent in Current and Former Smokers|A Randomized, Double-Blind Study of the Biological Effects and Tolerability of Celecoxib as a Chemopreventive Agent in Current and Former Smokers||M.D. Anderson Cancer Center|No|Completed|November 2001|September 2009|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|219|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||September 2009|July 31, 2012|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00981201||133043|
NCT00985803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAbrahao|Physical Activity in Patients With Systemic Lupus Erythematosus|Comparison of Cardiovascular Training Versus Resistance Training In Patients With Systemic Lupus Erythematosus: Controlled Randomized Clinical Trial|LESPA|Federal University of São Paulo|Yes|Enrolling by invitation|November 2009|March 2010||November 2009||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|September 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00985803||132689|
NCT00981812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cincinnati-01|Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner and Stereo Navigator Biopsy Accessory for the Diagnosis of Breast Cancer|Clinical Utility and Initial Experience With PEM Flex Solo II PET Scanner and Stereo Navigator Biopsy Accessory for the Diagnosis of Breast Cancer||University of Cincinnati|No|Recruiting|September 2009|April 2012|Anticipated|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Female|25 Years|N/A|No|||March 2012|March 2, 2012|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00981812||132996|
NCT00983931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1016|Drug-Drug Interaction Study Between Colchicine and Cyclosporine|A One-Directional, Open-label Drug Interaction Study to Investigate the Effects of Single-Dose Cyclosporine on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00983931||132833|
NCT00984516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1004-319-1002|Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times|A Single-site, Placebo-controlled, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and the Scar-improvement Efficacy of Intradermal Applications of Three Doses of Juvidex (5.64mg/100μl, 2.82mg/100μl and 11.28mg/100μl) Given Once Only or Three Times Within and Between Male and Female Subjects Aged 18-45.||Renovo|No|Completed|August 2004|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984516||132788|
NCT00984490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0942|Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery|Pre-Surgical Trial of Metformin in Patients With Operable Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|September 2009|July 2011|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|September 24, 2009|Yes|Yes|slow accrual|No|March 12, 2012|https://clinicaltrials.gov/show/NCT00984490||132790|Because this study was closed prematurely, no assay level markers or pathways were performed consequently no data are available to provide results.
NCT00984737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA07/101|Hyperglycemia in a Coronary Intensive Care Unit|Newly Diagnosed Hyperglycemia and Stress Hyperglycemia in a Coronary Intensive Care Unit||Baskent University|Yes|Completed|May 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984737||132771|
NCT00984750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIABASI|Acetyl-L-Carnitine in Type 2 Diabetes|A Prospective, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effect of 6-month Acetylcarnitine Therapy on Arterial Blood Pressure, Lipid and Metabolic Profile, and Kidney Function in Hypertensive Patients With Type 2 Diabetes on Background Simvastatin Therapy|DIABASI|Mario Negri Institute for Pharmacological Research|No|Completed|April 2008|December 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|229|||Both|40 Years|85 Years|No|||February 2013|February 22, 2013|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984750||132770|
NCT00985361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-055|Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus|Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus||ProMedica Health System|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|37|||Both|21 Years|75 Years|No|||October 2009|May 5, 2010|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985361||132723|
NCT00985582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA032|Antiviral Therapy for Influenza A H1N1|Antiviral Treatment in Adults and Children With Novel Influenza A (H1N1) Respiratory Tract Infection - a Clinical, Virological and Pharmacokinetic Study.|SEA032|South East Asia Infectious Disease Clinical Research Network|Yes|Completed|September 2009|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|181|Samples With DNA|Nasal swabs, throat swabs, nasopharyngeal aspirates, rectal swabs, urine, blood, will be      obtained for virological analyses, according to the age group specific study schedules|Both|1 Year|N/A|No|Probability Sample|This is a single arm clinical and virological study assessing the use of oral oseltamivir        or other agents in the treatment of patients with novel influenza A(H1N1) infection.        Any patient over 1 year of age with confirmed novel influenza A(H1N1) in whom appropriate        informed consent to collect data and samples is obtained. The protocol will be reviewed        after 6 months from starting or after 100 patients with new influenza A(H1N1) are        recruited.|May 2011|May 25, 2011|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985582||132706|
NCT00985595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165|Learning Effective Approaches to Prevention|Quality Community Services for Adolescent Drug Abuse|CASALEAP|The National Center on Addiction and Substance Abuse at Columbia University|Yes|Completed|January 2006|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|200|||Both|13 Years|17 Years|No|Non-Probability Sample|Adolescents screened for symptoms of substance abuse/dependence, and their families, will        participate in the study. Participants will include 260 male and female adolescents who        complete the enrollment process, meet eligibility criteria, and consent to be randomized        into one of two study conditions. Youth will be referred primarily from two sources:        juvenile justice agencies and local schools/community programs. Based on the demographics        of adolescents currently participating in partner sites, youth are likely to be        predominantly male (69%), Hispanic (68%), and African American (32%). Families are        generally low income from disadvantaged neighborhoods, with high rates of family mental        health and substance use problems.|August 2015|August 3, 2015|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985595||132705|
NCT00985881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4376-R|Use of Subtle Vibration to Improve Walking Ability by Lower Limb Amputees|Mechanically-induced Stochastic Resonance to Improve Amputee Gait||VA Office of Research and Development|No|Recruiting|April 2007|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|March 25, 2008||No||No||https://clinicaltrials.gov/show/NCT00985881||132683|
NCT00978809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPPV-2|Effects of Physical Treatment on Postural Stability in Benign Paroxysmal Positional Vertigo (BPPV) Patients|Epley Maneuver vs. Semont Maneuver for Benign Paroxysmal Positional Vertigo (BPPV): Evaluating Treatment Effectiveness by Postural Stability - a Double Blinded Randomized Controlled Trial.||Assuta Hospital Systems|No|Withdrawn|September 2009|June 2010|Actual|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2011|April 16, 2015|September 16, 2009||No|major difficulties recruiting patients|No||https://clinicaltrials.gov/show/NCT00978809||133213|
NCT00979095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-126|Genetic Examination of Patients With Primary Multiple Hernia|Genetic Differences Between Patients With Multiple Hernia and a Healthy Control Group||Herlev Hospital|No|Recruiting|June 2009|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Danish citizens. Data have been retracted from The Danish Hernia Database.|October 2010|October 12, 2010|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00979095||133192|
NCT00984425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2008-005|The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors|Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors||Istituto Clinico Humanitas|No|Completed|September 2009|August 2013|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984425||132795|
NCT00980304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22515|R Retreatment in 1st Relapsed DLBCL|A Multicenter, Open Label, Phase II Trial of Rituximab in Combination With ICE as Salvage Therapy in the Relapsed DLBCL Patients After 1st Line Induction Treatment of 6-8 Cycles of RCHOP-LIKE Chemo||Shanghai Jiao Tong University School of Medicine||Not yet recruiting||||||Phase 2|Interventional|N/A|1||||||Both|18 Years|65 Years|No|||September 2009|September 18, 2009|September 18, 2009||||No||https://clinicaltrials.gov/show/NCT00980304||133103|
NCT00980603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-296|Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer|A Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-line Chemotherapy After Cisplatin Plus S-1 or Capecitabine in Metastatic Gastric Cancer||National Cancer Center, Korea|Yes|Recruiting|November 2008|May 2011|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|18 Years|N/A|No|||September 2009|September 18, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980603||133082|
NCT00979940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712-15|Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)|Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After PCI|ESTATE|Indiana University|Yes|Terminated|November 2008|August 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|21 Years|85 Years|No|||August 2015|August 24, 2015|September 17, 2009|Yes|Yes|Slower than anticipated enrollment for pilot study.|No|August 24, 2015|https://clinicaltrials.gov/show/NCT00979940||133127|
NCT00979953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44CL240|Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee|A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee||Cubist Pharmaceuticals LLC|No|Completed|October 2009|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|408|||Both|18 Years|75 Years|No|||April 2015|July 27, 2015|September 17, 2009|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT00979953||133126|
NCT00982072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01492-52|Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease|Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease|MinTAC|Imperial College Healthcare NHS Trust|No|Recruiting|December 2009|October 2018|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||September 2015|October 5, 2015|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00982072||132976|
NCT00981162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 150109|Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride|A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer||Roswell Park Cancer Institute|Yes|Completed|August 2009|December 2012|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2013|February 24, 2014|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981162||133046|
NCT00982592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01425|Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer|A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma||National Cancer Institute (NCI)|Yes|Completed|September 2009|October 2014|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||August 2015|December 16, 2015|September 22, 2009|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT00982592||132936|
NCT00982605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK01|EBUS-guided TBNA for Molecular Diagnostic of Mediastinal Lymph Nodes (LN)|EBUS-guided TBNA for Molecular Diagnostic of Mediastinal Lymph Nodes||Heidelberg University|No|Recruiting|October 2009|January 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|lymph nodes|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with operable non-small cell lung cancer|October 2009|October 5, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982605||132935|
NCT00983671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-080|Standardisation of Measurements in Exhaled Breath and Exhaled Breath Condensate.|Optimising and Standardising Measurements of Inflammatory Markers in Exhaled Breath (EB) and Exhaled Breath Condensate (EBC)||Maastricht University Medical Center|No|Recruiting|February 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|255|Samples Without DNA|Exhaled breath condensate. Exhaled breath.|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|For study I and II: community sample For study III: healthy children recruited at a        primary school, children with asthma, cystic fibrosis, chronic lung disease or pneumonia,        recruited from the outpatient clinic of pediatric pulmonology|July 2011|July 21, 2011|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00983671||132853|
NCT00984243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281-92|Photodynamic Therapy (PDT) in Lung Cancer|An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.|PDT|Mayo Clinic|No|Completed|February 1994|October 2006|Actual|October 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Both|50 Years|75 Years|No|||November 2012|November 13, 2012|December 24, 2007|No|Yes||No||https://clinicaltrials.gov/show/NCT00984243||132809|
NCT00984503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1007|Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites|A Single-site, Randomised, Double-blind, Phase II Trial to Investigate the Safety, Toleration, Systemic Exposure, Accelerated Healing and Anti-scarring Potential of Juvista in Split Skin Graft Donor Sites in Male Subjects Aged 18-85 Years||Renovo|No|Completed|October 2003|January 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|102|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984503||132789|
NCT00985036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-VEGF-1|Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients|Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?||Marquette General Health System|Yes|Withdrawn|September 2009|January 2012|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|serum|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to Marquette General Hospital with a probable or confirmed diagnosis        of meningioma or glioma|April 2012|April 20, 2012|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985036||132748|
NCT00985348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01339|Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)|Randomized, Monocenter, Open Label, Two-way Cross-over, Single Dose Bioequivalence Study of Two Oral Formulations of Levetiracetam in Healthy Male & Female Japanese Subjects||UCB Pharma|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|September 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00985348||132724|
NCT00985907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2408|Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma|DMV|University of California, San Francisco|Yes|Completed|June 2004|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985907||132681|
NCT00985608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253/09|Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study|Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study||Catholic University of the Sacred Heart|No|Recruiting|April 2009|September 2009|Anticipated|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2009|January 25, 2010|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985608||132704|
NCT00985894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917162-1|Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis|Comparison Between Asynchronous Online Care Model for the Management of Atopic Dermatitis With That of Face-to-Face, Office Visits||University of California, Davis|No|Completed|September 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|183|||Both|4 Years|N/A|No|||June 2012|June 18, 2012|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985894||132682|
NCT00979719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8011 - 106 - 31/31.91|Improvement of a Physically Active Lifestyle|Improvement of a Physically Active Lifestyle in Orthopedic and Cardiologic Rehabilitation Patients With an Expert System|FaBA|Freie Universität Berlin|Yes|Completed|October 2009|September 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1377|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|November 13, 2012|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979719||133144|
NCT00979966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-II-006 / 2009-010143-13|Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib|Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma||Central European Society for Anticancer Drug Research|Yes|Completed|July 2009|||July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00979966||133125|
NCT00979368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB124-001|Safety Study of BMS-816336 in Healthy Male Subjects|Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects||Bristol-Myers Squibb|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|February 22, 2011|September 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00979368||133171|
NCT00979979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906047D|Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test|Clinical Performance of Abbott RealTime HCV Genotype II Test||National Taiwan University Hospital|No|Completed|July 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|255|Samples Without DNA|Patient stored serum with detectable HCV RNA levels|Both|18 Years|N/A|No|Non-Probability Sample|255 HCV patients both positive for anti-HCV and HCV RNA and 18 patients without ant-HCV        and HCV RNA; all 255 patients were tested for Abbott RealTime genotype II test and direct        HCV sequencing at 5'UTR and NS5B for the sensitivity, specificity, and the overall        diagnostic accuracy.|October 2014|October 19, 2014|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979979||133124|
NCT00980954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0724|Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy|Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy||Radiation Therapy Oncology Group|Yes|Recruiting|September 2009|||August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||November 2015|November 11, 2015|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00980954||133062|
NCT00981214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUR-1009-M|Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency||Forest Laboratories|Yes|Completed|May 2006|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|7 Years|No|||February 2014|February 24, 2014|September 21, 2009|No|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT00981214||133042|Protocol amendment 4 extended screening period to 14 days, but this period not included in result as all participants started treatment prior to site Institutional Review Board approval of protocol amendment 4, this did not affect study procedures.
NCT00981227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-207|Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2093) as Therapy for Patients With Post-herpetic Neuralgia: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial||Bial - Portela C S.A.|No|Completed|November 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|567|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|September 18, 2009||No||No|February 7, 2013|https://clinicaltrials.gov/show/NCT00981227||133041|
NCT00981500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0175|Glucose Homeostasis Pre and Post Bariatric Surgery|Effect of Bariatric Surgery-induced Weight Loss on Glucose Homeostasis|RB|Washington University School of Medicine|Yes|Active, not recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|plasma, tongue tissue, muscle tissue, fat tissue,liver tissue, colon tissue, stool|Both|20 Years|70 Years|No|Non-Probability Sample|A total of 20 (per surgical group) morbidly obese (BMI ≥ 35 kg/m2) subjects scheduled for        bariatric surgical procedures will participate in this study.|November 2015|November 16, 2015|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00981500||133020|
NCT00980889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Steel vs nitinol|RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction|RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction||Stockholm South General Hospital|Yes|Completed|May 2009|May 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|20 Years|N/A|No|||April 2014|April 5, 2014|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980889||133065|
NCT00980915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003560|Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury|Identifying Patients at Risk of Developing Acute Lung Injury at the Time of Hospital Admission:Toward the Prevention of Acute Lung Injury (ALI)|LIPS|Mayo Clinic|Yes|Recruiting|December 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6600|Samples With DNA|We will collect time sensitive peripheral blood samples for collaborative genome-wide      association, gene expression, cytokines and proteonomic studies. Blood samples of the      enrolled patients will be collected as baseline, after 24, 48 hours and at the time of      development of ARDS.|Both|18 Years|N/A|No|Non-Probability Sample|Olmsted County residents more than 18 years of age who were admitted to the two Mayo        Clinic Rochester hospitals.|January 2016|January 13, 2016|April 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00980915||133064|
NCT00982085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asthma Prevalence in ROK|The Status of Asthma in the Korean Military Personnel|The Status of Asthma in the Korean Military Personnel||Armed Forces Capital Hospital, Republic of Korea|No|Recruiting|June 2009|March 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|4000|||Male|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Korean Military personnel who resign in South Korea.|September 2009|September 21, 2009|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00982085||132975|
NCT00982098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO08974|Prevention of Urinary Incontinence After Prostatectomy|||Azienda Ospedaliero Universitaria Maggiore della Carita||Active, not recruiting|February 2007|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Male|18 Years|N/A|No|||September 2009|September 21, 2009|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00982098||132974|
NCT00981474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|680|Cerebral Autoregulation Monitoring During Cardiac Surgery|Continuous Cerebral Autoregulation Monitoring to Reduce Brain Injury From Cardiac Surgery||Johns Hopkins University|Yes|Recruiting|September 2009|August 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|280|||Both|60 Years|N/A|No|||September 2009|March 7, 2013|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981474||133022|
NCT00981487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUR-1025|Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)|Single-Dose Crossover Comparative Bioavailability Study to Assess the Effect of Food on the Pharmacokinetics of Ondansetron Modified-Release Capsules (EUR-1025) in Healthy Male and Female Volunteers|ODO-P8-689|Forest Laboratories|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2009|September 21, 2009|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981487||133021|
NCT00982618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-06-023|Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine|Post Operative Functional Restoration in Patients Undergoing Major Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine||McGill University Health Center|Yes|Completed|July 2009|June 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|85 Years|No|||November 2011|November 24, 2011|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00982618||132934|
NCT00984256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1583|Weekly Dosing of Malarone ® for Prevention of Malaria|Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone ®) for Malaria Chemoprophylaxis|MALWEEK|U.S. Army Medical Research and Materiel Command|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 29, 2013|September 24, 2009|Yes|Yes||No|September 4, 2012|https://clinicaltrials.gov/show/NCT00984256||132808|
NCT00983970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-2-06-2106-GG|Effects of Interactive Video Game Cycling on Obese Adolescent Health|Effects of Interactive Video Game Cycling on Obese Adolescent Health||Children's Hospital of Eastern Ontario|No|Completed|May 2007|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|17 Years|No|||September 2009|September 23, 2009|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983970||132830|
NCT00983983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA136152|High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis|Phase II Safety and Tolerability Study of High Fat/High Calorie Versus High Calorie Versus Optimal Nutrition in Subjects With Amyotrophic Lateral Sclerosis||Massachusetts General Hospital|Yes|Completed|October 2009|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|September 23, 2009|Yes|Yes||No|September 16, 2014|https://clinicaltrials.gov/show/NCT00983983||132829|
NCT00984763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC035|A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria|A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria||University of Oxford|Yes|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984763||132769|
NCT00984776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-1-036|Detection of Coronary Vulnerable Plaque With Contrast-enhanced Magnetic Resonance Imaging|Detection of Vulnerable Plaque With Coronary Vessel Wall MRI: Contrast Enhanced MRI With Gadofosveset MS-325.|T9M|Maastricht University Medical Center||Completed|March 2007|||February 2009|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||Actual|20|||Both|18 Years|90 Years|No|||September 2009|September 24, 2009|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984776||132768|
NCT00985049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p002323|TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)|Whole Genome Expression of Left Ventricular Myocardium During Cardiac Surgery||Brigham and Women's Hospital|No|Recruiting|March 2009|December 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|DNA, EDTA , peripheral blood leucocytes, and left ventricle myocardium are all stored in      -80C frreezer at BWH.|Both|20 Years|N/A|No|Non-Probability Sample|Adult patients undergoing cardiac surgery|January 2016|January 11, 2016|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00985049||132747|
NCT00984789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13082|Birth Control Patch Study|Transdermal Contraception Patch: EU Cycle Control Study Versus EVRA||Bayer|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|393|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00984789||132767|
NCT00985062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPG.03.02|Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization|Food Lifestyle and Fertility Outcome|FOLFO|Erasmus Medical Center|Yes|Completed|October 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|54|||Both|N/A|37 Years|No|||September 2009|September 25, 2009|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985062||132746|
NCT00985621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091030|Tanezumab In Osteoarthritis Of The Hip Or Knee|A Phase 3 Randomized, Double-Blind, Placebo- And Oxycodone-Controlled, Multicenter Study Of The Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip||Pfizer|Yes|Terminated|October 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|600|||Both|18 Years|75 Years|No|||August 2012|August 23, 2012|September 25, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00985621||132703|
NCT00986141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-0315|Effects of Selective Laser Trabeculoplasty|Effect of Selective Laser Trabeculoplasty (SLT) on Diurnal Intraocular Pressure in Open-Angle Glaucoma Patients on Medical Treatment|SLT|University of Kentucky|No|Terminated|May 2009|December 2012|Actual|December 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|30|||Both|40 Years|80 Years|No|Non-Probability Sample|Thirty patients, between the ages of 40 and 80, of either gender, from all ethnic        backgrounds will be recruited in this study.|April 2013|April 23, 2013|September 25, 2009||No|PI left the University|No||https://clinicaltrials.gov/show/NCT00986141||132663|
NCT00986414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2208|Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease|13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease||Novartis||Completed|September 2009|||December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|260|||Both|30 Years|80 Years|No|||February 2011|February 28, 2011|September 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00986414||132643|
NCT00986128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002860|A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients|A Comparative Study of the Steady State Pharmacokinetics of Lithium Before and During Multiple Oral Daily Topiramate (RWJ-17021) Dosing in Patients With Bipolar Disorders||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2001|October 2002|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|60 Years|No|||April 2010|June 8, 2011|September 25, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00986128||132664|
NCT00986375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FU-10-4711-001|Online Program Assisting Lifestyle Changes (Asterix 1.0 & Obelix 2.0)|Online Program Assisting Lifestyle Changes: Adopting and Maintaining Physical Activity and Fruit & Vegetable Consumption (Asterix 1.0 & Obelix 2.0)|OPAL|Freie Universität Berlin|Yes|Completed|October 2009|June 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1000|||Both|9 Years|N/A|Accepts Healthy Volunteers|||February 2011|November 12, 2012|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986375||132645|
NCT00986401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-SXR-09-002|Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects|Safety and Tolerability of Trospium Chloride Metformin Hydrochloride in Healthy Subjects||Allergan||Completed|October 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 16, 2011|September 16, 2009|Yes|Yes||No|November 16, 2011|https://clinicaltrials.gov/show/NCT00986401||132644|
NCT00980317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW062090715KT|A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties|A Clinical Study of the Living-unrelated Renal Transplantation With Restored Kidneys (Interventional Trial)||Tokushukai Medical Group|Yes|Recruiting|July 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||October 2009|October 9, 2009|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00980317||133102|
NCT00980278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00014299|Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation|Cell Therapy Using Autologous Bone Marrow Cells Expanded Ex Vivo and Delivered Using Tricalcium Phosphate||University of Michigan|Yes|Completed|March 2010|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|70 Years|No|||November 2015|November 18, 2015|September 18, 2009|Yes|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT00980278||133104|
NCT00980967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 09/1-F|Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study|Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study|COLT|Nantes University Hospital|Yes|Active, not recruiting|September 2009|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|700|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00980967||133061|
NCT00981240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10416|Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes|A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.||Sanofi|No|Completed|September 2009|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2012|March 26, 2012|September 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00981240||133040|
NCT00981253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015896|Stress Management and Biomarkers of Risk in Cardiac Rehabilitation|Enhancing Standard Cardiac Rehabilitation With Stress Management Training in Patients With Heart Disease|ENHANCED|Duke University|Yes|Completed|September 2009|February 2016|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|35 Years|N/A|No|||March 2016|March 7, 2016|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981253||133039|
NCT00981825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER0-2007-SAL-01-GX|Efficacy of Salivary Bacteria and Post Brushing|Efficacy of Salivary Bacteria and Post Brushing||Colgate Palmolive|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 10, 2011|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT00981825||132995|
NCT00982319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0822|Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue|Evaluating the Effect of Broccoli Sprouts (Sulforaphane) on Cellular Proliferation, an Intermediate Marker of Breast Cancer Risk||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|April 2009|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|34|||Female|18 Years|N/A|No|||March 2014|March 14, 2014|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00982319||132957|
NCT00979160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA 180-287|Evaluation of Response of Dasatinib to Treat Mastocytosis|Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis||Federico II University|Yes|Not yet recruiting|November 2009|December 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00979160||133187|
NCT00984282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14295|Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer|A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer||Bayer|Yes|Active, not recruiting|October 2009|June 2016|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|417|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|September 24, 2009|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT00984282||132806|
NCT00984542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0920|Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).||Vanderbilt-Ingram Cancer Center|Yes|Completed|September 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2013|January 23, 2014|September 24, 2009|Yes|Yes||No|August 16, 2013|https://clinicaltrials.gov/show/NCT00984542||132786|
NCT00984269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-09-14B|Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection|Lymphedema Following Elective Hand and Wrist Surgery in Women Who Are Post Axillary Lymph Node Dissection: A Prospective, Randomized, Clinical Trial||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|September 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984269||132807|
NCT00984529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CHR-ATA-2008/1|Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia|Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia||AstraZeneca|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care|January 2011|January 6, 2011|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00984529||132787|
NCT00984802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX-2043-2a|Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy|A Prospective, Randomized, Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)|SUPPORT-1|Ischemix, LLC|No|Completed|February 2010|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|142|||Both|18 Years|70 Years|No|||June 2011|June 17, 2011|September 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00984802||132766|
NCT00985088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113440|Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older|A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older||GlaxoSmithKline||Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|1343|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|November 17, 2011|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985088||132744|
NCT00985920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070199A|Topical Tranexamic Acid for Total Knee Arthroplasty|Efficacy of Intraoperative Topical Application of Tranexamic Acid in Reducing Perioperative Bleeding in Total Knee Arthroplasty||University Health Network, Toronto|Yes|Completed|September 2007|November 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|125|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00985920||132680|
NCT00986661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-LC-01|A Study to Assess PV-10 Chemoablation of Cancer of the Liver|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant||Provectus Pharmaceuticals|No|Recruiting|October 2009|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00986661||132625|
NCT00986674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01976|Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer|Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination With Cetuximab, IMC-A12 or Both in Patients With Advanced Non-Small Cell Lung Cancer Who Will Not Receive Bevacizumab-Based Therapy||National Cancer Institute (NCI)|No|Completed|September 2009|December 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|140|||Both|18 Years|N/A|No|||March 2014|September 19, 2014|September 29, 2009|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT00986674||132624|
NCT00987233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIA-NASO-05RB02-CE|A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis|||Apotex Inc.||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||||||Both|18 Years|65 Years|No|||September 2009|September 29, 2009|September 29, 2009||||No||https://clinicaltrials.gov/show/NCT00987233||132583|
NCT00986648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 UO1 DK072146-01|A Multi-Center Group to Study Acute Liver Failure in Children|A Multi-Center Group to Study Acute Liver Failure in Children||University of Pittsburgh|Yes|Completed|January 2000|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|Samples With DNA|whole blood, serum, tissue|Both|N/A|18 Years|No|Probability Sample|Children between birth and age 18 years who present with acute liver failure.|January 2016|January 11, 2016|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986648||132626|
NCT00986960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDA 08-372|Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)|Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study|ACTH|University at Buffalo|Yes|Terminated|December 2009|December 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|65 Years|No|||December 2013|December 9, 2013|September 29, 2009|No|Yes|Difficult to recruit due to protocol requirements - participant burden.|No|December 9, 2013|https://clinicaltrials.gov/show/NCT00986960||132604|Patients did not want to be in the placebo group.Too difficult to mask placebo vs. drug. Testing regimen too intensive - patients did not want to participate.
NCT00980330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016063|A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including PegIFNa-2a and Ribavirin in HCV Genotype 1 Infected Subjects Who Failed Previous Standard Therapy|ASPIRE|Tibotec Pharmaceuticals, Ireland|Yes|Completed|October 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|463|||Both|18 Years|70 Years|No|||May 2014|May 30, 2014|September 10, 2009|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT00980330||133101|
NCT00980616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0056|Use of Local Analgesia With Epinephrine During Total Hip Arthroplasty (THA)|Effect of the Injection of Local Analgesia With Epinephrine During Total Hip Arthroplasty on the Blood Losses Per and Operatively.||University Hospital, Clermont-Ferrand||Completed|September 2009|March 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Both|50 Years|85 Years|No|||March 2012|March 26, 2012|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980616||133081|
NCT00980941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Starch study 1|Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake|The Effect of Different Types of Starch on Glycemic Response, Subjective Appetite and Short-term Food Intake in Young Men||University of Toronto|Yes|Completed|December 2007|June 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|17|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||September 2009|September 18, 2009|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980941||133063|
NCT00982111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13908|First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin|A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)|INSPIRE|Eli Lilly and Company|Yes|Active, not recruiting|November 2009|December 2015|Anticipated|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|633|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00982111||132973|
NCT00982371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 08-281|An Investigation Into Bone Micro-architecture in Women With Type 2 Diabetes|A Cross-sectional Comparison of Bone Micro-architecture in Postmenopausal Women With Type 2 Diabetes and Age-matched Controls||McMaster University|Yes|Completed|September 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Female|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs|June 2012|June 17, 2012|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00982371||132953|
NCT00982631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO200902|A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer|A Phase Ib Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/ Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer||Radboud University|Yes|Recruiting|June 2009|August 2012|Anticipated|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00982631||132933|
NCT00981513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJC004.6|Direct and Indirect Benefits of Influenza Vaccination in Schools and Households|Direct and Indirect Benefits of Influenza Vaccination in Schools and Households||The University of Hong Kong|Yes|Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6300|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2011|August 18, 2011|September 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00981513||133019|
NCT00981838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEMO|Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)|A Prospective, Sequential Study to Assess the Efficacy of Rituximab Therapy in Maintaining Remission of Nephrotic Syndrome After Steroid and Immunosuppressive Therapy Withdrawal in Patients With Steroid-dependant or Multirelapsing Minimal Change Disease or Focal Segmental Glomerulosclerosis (NEMO Study)|NEMO|Mario Negri Institute for Pharmacological Research|No|Completed|April 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|2 Years|80 Years|No|||February 2013|February 22, 2013|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981838||132994|
NCT00982852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H0112|Intravascular Ultrasound Derived Virtual Histology and Intracoronary Serum Markers of Inflammation|Intravascular Ultrasound Derived Virtual Histology and Intracoronary Serum Markers of Inflammation in Patients Referred for Percutaneous Coronary Intervention.||Ohio State University|No|Terminated|December 2008|December 2010|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|9|Samples With DNA|The blood that is collected will be analyzed for markers of inflammation or irritation in      the blood (c-reactive protein, myeloperoxidase, Monocyte chemotactic protein-1), as well and      a gene called Matrix Metallopeptidase 3, which is believe to influence the progression of      plaque on the walls of arteries and the progression of coronary artery disease.|Both|18 Years|N/A|No|Non-Probability Sample|Patients in need of angioplasty or left heart catheterization|July 2013|July 11, 2013|January 26, 2009||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT00982852||132916|
NCT00978601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MULTI-LM-100|Improved Recovery Using Multimodal Peri-operative Analgesia in Minimally Invasive Myomectomy|Improved Recovery Using Multimodal Peri-operative Analgesia in Minimally Invasive Myomectomy.A Randomized Study.||Iakentro Fertility Centre|Yes|Completed|January 2007|September 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Female|20 Years|42 Years|No|||September 2009|September 16, 2009|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978601||133229|
NCT00982332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLYMYALGIA1|Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica|Efficacy of Micro-pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica||Bnai Zion Medical Center|No|Recruiting|March 2010|March 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||July 2010|July 18, 2010|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00982332||132956|
NCT00982345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901-13|Brain Imaging of Quetiapine Response in Anxious Depression|Brain Imaging of Quetiapine Response in Anxious Depression||Indiana University|No|Completed|March 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||March 2013|March 5, 2013|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00982345||132955|
NCT00982358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A2423|Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus|A 16-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Anti-inflammatory Actions of 320 mg Diovan in Patients With Type 2 Diabetes With and Without Coronary Artery Disease||Charite University, Berlin, Germany||Completed|July 2004|March 2007|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||121|||Both|30 Years|80 Years||||September 2009|September 22, 2009|September 22, 2009||||No||https://clinicaltrials.gov/show/NCT00982358||132954|
NCT00978900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 69/04|Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion|Carbohydrates and Non Caloric Sweeteners: Differential Effects on Appetite and Secretion of Gastrointestinal Satiety Peptide||University Hospital, Basel, Switzerland|No|Completed|December 2008|July 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2009|September 16, 2009|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978900||133206|
NCT00978224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0907-CU|Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment|Efficacy of Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment||Catalysis SL|Yes|Suspended|October 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|75 Years|No|||July 2010|July 6, 2010|September 15, 2009||No|Decision of the investigator|No||https://clinicaltrials.gov/show/NCT00978224||133258|
NCT00977990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909219|Amplification of Merkel Cell Polyomavirus From Skin Swabs|Amplification of Merkel Cell Polyomavirus From Skin Swab Specimens||National Institutes of Health Clinical Center (CC)||Completed|August 2009|May 2010||||N/A|Observational|N/A|||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|September 26, 2015|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977990||133276|
NCT00958360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6958-R|Low Vision Intervention Trial II (LOVIT II)|VA Low Vision Intervention Trial (LOVIT) II|LOVIT II|VA Office of Research and Development|Yes|Active, not recruiting|August 2010|September 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958360||134759|
NCT00958724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A2-1118|Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors|A Phase 1 Study Of Neratinib (HKI-272) In Combination With Vinorelbine In Japanese Subjects With Advanced Or Metastatic Solid Tumors||Puma Biotechnology, Inc.|Yes|Completed|July 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||May 2012|May 10, 2012|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00958724||134732|
NCT00958698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0259|Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|NURSE-DELIVERED WRITE SYMPTOMS© vs. SELF-DIRECTED WRITE SYMPTOMS© vs. CARE AS USUAL FOR OPTIMAL SYMPTOM MANAGEMENT FOR WOMEN WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER||Gynecologic Oncology Group|Yes|Active, not recruiting|January 2010|||September 2013|Anticipated|N/A|Interventional|Allocation: Randomized|1||Anticipated|480|||Female|18 Years|N/A|No|||August 2013|August 19, 2013|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958698||134734|
NCT00958711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-0801|The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer|The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer||Synovis Surgical Innovations|No|Terminated|January 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||September 2011|May 15, 2012|August 11, 2009||No|Budgetary|No||https://clinicaltrials.gov/show/NCT00958711||134733|
NCT00959049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-USF-07-36|A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population|A Phase III, Randomized, Observer-blind, Multi-center, Noninferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Trivalent Inactivated Split-Virion Influenza Vaccine in a Pediatric Population Aged Greater Than or Equal to 6 Months to Less Than 18 Years.||CSL Limited|Yes|Completed|September 2009|May 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|1474|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|August 12, 2009|Yes|Yes||No|July 3, 2011|https://clinicaltrials.gov/show/NCT00959049||134707|
NCT00959881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3183A1-1106|Study Evaluating The Coadministration of Begacestat And Donepezil|Combined Administration Of Begacestat And Donepezil: A Multiple-Dose Study In Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 1, 2011|August 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959881||134644|
NCT00960180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3260A1-1000|Study Evaluating Single Ascending Doses of MR1817|A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Doses of Orally Administered MR1817 in Healthy Adult Subjects||Mochida Pharmaceutical Company, Ltd.|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|January 9, 2014|August 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960180||134621|
NCT00955708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSR of ACUITY Spiral|Longitudinal Surveillance Registry (LSR) of ACUITY Spiral|Condition of Approval Study: Longitudinal Surveillance Registry of the ACUITY Spiral Lead||Boston Scientific Corporation|No|Recruiting|August 2009|December 2022|Anticipated|December 2022|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1700|||Both|N/A|N/A|No|Non-Probability Sample|The population will be a broad base representative of those recieving the ACUITY Spiral        lead.|November 2015|November 10, 2015|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955708||134961|
NCT00955721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090256|A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer|A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer||University of Miami|Yes|Completed|August 2009|||July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|August 6, 2009|No|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT00955721||134960|Of the 9 participants enrolled, only 6 had results that were evaluable.
NCT00955955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P000604 (2)|Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder|TRD - 2: A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF Among SSRI-Resistant Outpatients With Major Depressive Disorder (MDD)|TRD-2|Massachusetts General Hospital|No|Completed|July 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|65 Years|No|||May 2013|May 7, 2013|July 30, 2009||No||No|October 31, 2012|https://clinicaltrials.gov/show/NCT00955955||134942|
NCT00955968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT 1077HS|IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women|IMPAACT 1077HS: HAART Standard Version of the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Active, not recruiting|January 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1653|||Female|18 Years|N/A|No|||August 2015|August 5, 2015|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955968||134941|
NCT00956254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-09-011|Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis|Evaluate Safety and Tolerability and Compare Absorption/Distribution Kinetics of a Single 100 Mcg Dose of Fentanyl Sublingual Spray (Fentanyl SL Spray) in Cancer Subjects With or Without Oral Mucositis||INSYS Therapeutics Inc||Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|August 8, 2009|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT00956254||134919|
NCT00958815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18FDG (completed)|Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT|Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|14|||Both|35 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited through the AIDS Clinical Trials Unit (ACTU), Washington        University Infectious Diseases Clinics, primary care physicians in the community who refer        patients to these clinics and Volunteers for Health (VFH).|June 2012|June 22, 2012|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958815||134725|
NCT00984373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NBG-SER-2009/1|Epidemiology of Schizophrenia in Bulgaria|Epidemiological Study to Describe Approaches in Diagnosis, Treatment and Social Functioning of Schizophrenic Patients in Bulgaria||AstraZeneca|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|440|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|February 2010|February 2, 2010|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984373||132799|
NCT00975728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermIng E0709|High Total Antioxidant Capacity Products Added to Diet|High Total Antioxidant Capacity (TAC) Products Added to Diet: Clinical and Instrumental Evaluation of Their Effect on Skin Surface Parameters and on Photo-induced Acute Damage of the Skin (Double Blind Clinical Study vs Placebo)||Derming SRL|Yes|Completed|February 2010|October 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975728||133448|
NCT00976599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921073|A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis|An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis||Pfizer|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|29|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|September 11, 2009|Yes|Yes||No|December 4, 2012|https://clinicaltrials.gov/show/NCT00976599||133381|
NCT00977145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14215|Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma|Evaluation of the Safety and Immunogenicity of Intratumoral Injection of Interferon Gamma During Vaccination in Patients With Subcutaneous or Cutaneous Metastases of Melanoma|Mel 51|University of Virginia|Yes|Terminated|November 2009|||October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|September 14, 2009|No|Yes|Closed short of the enrollment goal, due to slow enrollment and adequate data to address    endpoints|No||https://clinicaltrials.gov/show/NCT00977145||133339|
NCT00976612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0901|Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)|Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib||Asan Medical Center|No|Completed|January 2009|December 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|Samples Without DNA|blood about 4ml|Both|15 Years|N/A|No|Non-Probability Sample|Patients with metastatic or unresectable gastrointestinal stromal tumor who failed to        imatinib and sunitinib.|July 2013|July 3, 2013|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976612||133380|
NCT00985452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000254/3;MGH|The Impact of GlowCaps Connect™ and Its Services on Hypertension Medication Adherence|The Impact of GlowCaps Connect™ and Its Services on Hypertension Medication Adherence: A Randomized Controlled Trial||Massachusetts General Hospital|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|139|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 9, 2012|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00985452||132716|
NCT00985465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113166|Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali|Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Malian Children||GlaxoSmithKline||Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|210|||Both|15 Months|21 Months|Accepts Healthy Volunteers|||November 2012|November 16, 2012|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985465||132715|
NCT00977392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK-Westminster-Self-Sampling|Self-Sampling in Women Who Do Not Undergo Routine Cervical Screening|The Potential Role of Self-sampling in Women Who do Not Attend for Cervical Screening - a Randomised Controlled Trial||National Cancer Institute (NCI)||Completed|June 2009|March 2011|Actual|February 2010|Actual|N/A|Observational|N/A|||Anticipated|3000|||Female|25 Years|N/A|Accepts Healthy Volunteers|||September 2009|August 6, 2013|September 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00977392||133320|
NCT00977964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK70|Tolerance of Healthy Term Infants Fed Infant Formulas #3|Tolerance of Healthy Term Infants Fed Infant Formulas||Abbott Nutrition|Yes|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|270|||Both|N/A|8 Days|Accepts Healthy Volunteers|||November 2010|November 24, 2010|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977964||133278|
NCT00977977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090223|Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy|Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy||National Institutes of Health Clinical Center (CC)||Recruiting|August 2009|January 2020|Anticipated|January 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|December 11, 2015|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977977||133277|
NCT00974350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN803-006-0006|A Safety and Efficacy Study of SABER™-Bupivacaine for Pain Following Hernia Repair|A Double-Blind, Placebo-Controlled, Pharmacodynamic and Pharmacokinetic Dose Response Study of SABER™-Bupivacaine Instilled Into the Wound in Patients Undergoing Open Inguinal Hernia Repair||Durect|No|Completed|January 2007|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|65 Years|No|||December 2009|April 25, 2012|September 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974350||133550|
NCT00958737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000647466|Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer|A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer|IDEA|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Active, not recruiting|April 2009|September 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|120 Years|No|||December 2015|December 10, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958737||134731|
NCT00958750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-AGA01|Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia|Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume||Charite University, Berlin, Germany|Yes|Completed|June 2008|June 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|113|||Female|18 Years|N/A|No|||August 2009|November 17, 2011|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958750||134730|
NCT00959335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60110|Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions|Randomized, Open-Label, 1-Way Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex (Reference) Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions.||Sandoz||Completed|August 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|19 Years|63 Years|Accepts Healthy Volunteers|||August 2009|August 13, 2009|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959335||134685|
NCT00959608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804917|Think Health! A Personal Weight Management Program|Modeling Effective Obesity Treatment to Reduce Disparities Through Primary Care|Think Health!|University of Pennsylvania|No|Active, not recruiting|June 2006|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2009|August 13, 2009|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959608||134664|
NCT00959894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2070|Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection|Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection||University of North Carolina, Chapel Hill|Yes|Completed|September 2009|May 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|August 14, 2009|Yes|Yes||No|March 27, 2015|https://clinicaltrials.gov/show/NCT00959894||134643|Pharmacokinetic (PK) data for two of the secondary outcomes of this study are pending. The lab in which these assays are conducted was relocated during the study and lab operations were therefore delayed. The PK assessment is currently in progress.
NCT00960167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906051R|A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)|A Phase I Dose Escalation Trial of Conformal Hypofractionated Radiation Therapy for Patients With Hepatitis B Virus-Related Child A Cirrhosis and Hepatocellular Carcinoma||National Taiwan University Hospital|Yes|Recruiting|September 2009|||August 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|70 Years|No|||October 2009|October 13, 2009|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00960167||134622|
NCT00955734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0566|Early Motion After Volar Fixation for Distal Radius Fractures|Early Motion After Volar Fixation for Distal Radius Fractures: A Prospective Trial||Washington University School of Medicine|No|Completed|June 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||June 2015|June 26, 2015|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955734||134959|
NCT00955981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-202|Gout Dose Response Study|Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout||Ardea Biosciences, Inc.|No|Completed|July 2009|September 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|123|||Both|18 Years|75 Years|No|||February 2014|February 5, 2014|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955981||134940|
NCT00955994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2394-03|Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome|A Randomized, Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of On-demand Treatment With Asimadoline in Patients With Irritable Bowel Syndrome Over 4 Weeks||Mayo Clinic||Completed|January 2005|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||100|||Both|18 Years|65 Years|No|||March 2011|March 22, 2011|August 6, 2009||||||https://clinicaltrials.gov/show/NCT00955994||134939|
NCT00956007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0920|Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer|A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer||Radiation Therapy Oncology Group|Yes|Recruiting|November 2009|||August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|August 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956007||134938|
NCT00956280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OBR-DUM-2008/1|Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer|Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer||AstraZeneca|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with Advanced Non Small Cell Lung Cancer|May 2010|May 11, 2010|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956280||134917|
NCT00956293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE19|Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program|6-month, Open-label, Randomized, Multicenter, Prospective, Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program|Senator|Novartis||Terminated|July 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|65 Years|N/A|No|||May 2014|May 23, 2014|August 7, 2009||No|The study was terminated because the required sample size of 240-260 de novo senior renal    transplant patients was not achieved within a reasonable time.|No|March 26, 2014|https://clinicaltrials.gov/show/NCT00956293||134916|
NCT00987779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451168|Bioequivalence Study Of Gabapentin Between Tablet And Liquid Formulation And The Food Effect Study Of Liquid Formulation|An Open, Randomized, Crossover Study In Healthy Subjects To Assess The Bioequivalence Of Gabapentin Between Japanese Commercial Tablet And Japanese Commercial Image Liquid Formulation And The Effect Of Food On The Pharmacokinetics Of Japanese Commercial Image Liquid Formulation||Pfizer|No|Completed|October 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 15, 2010|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987779||132541|
NCT00958841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230D2203|Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin|An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin||Novartis||Completed|September 2009|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|118|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|July 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00958841||134723|
NCT00976586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812061R|Role of Pseudogene in Incontinentia Pigmenti, and Its Potential Treatment|In Vitro Observation of Chromosome Recombination and Treatment in Vitro||National Taiwan University Hospital|Yes|Completed|August 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|blood for DNA and plasma. Skin for cultured fibroblast|Both|N/A|N/A|No|Probability Sample|Patients with Incontinentia Pigmenti|December 2013|December 3, 2013|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00976586||133382|
NCT00976625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-32 16.9.1992 (Zürich)|Diastolic Dysfunction in Aortic Regurgitation|Persistent Diastolic Dysfunction Late After Valve Replacement in Severe Aortic Regurgitation||University of Bern|No|Completed|January 1996|December 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2009|September 11, 2009|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976625||133379|
NCT00976300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU 8444-3|Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study|Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study|CYCLOFA-LUNE|Institute of Rheumatology, Prague|Yes|Completed|January 2002|April 2009|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||September 2009|June 22, 2010|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976300||133404|
NCT00976313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171/09|Does Thoracic Epidural Analgesia Influence Urinary Micturition by Patients Undergoing Thoracic Surgery?|Does Thoracic Epidural Analgesia Influence Urinary Micturition by Patients Undergoing Thoracic Surgery? An Observational, Prospective Study||University Hospital Inselspital, Berne|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|male and female patients undergoing thoracotomy or sternotomy|June 2010|June 8, 2010|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976313||133403|
NCT00976326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1989|A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function|A Trial Investigating the Pharmacokinetic and Safety Profiles of NN1250 in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment and in Subjects With Normal Hepatic Function||Novo Nordisk A/S|No|Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|September 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00976326||133402|
NCT00976911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22224|AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer|AURELIA: A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Hoffmann-La Roche||Completed|October 2009|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|361|||Female|18 Years|N/A|No|||February 2015|February 24, 2015|September 14, 2009||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00976911||133357|
NCT00977171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa CFS201|Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome|An Open-Label Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome|CFS201|Chelsea Therapeutics|No|Terminated|July 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||May 2014|May 21, 2014|September 11, 2009|Yes|Yes|Enrollment issues.|No|April 24, 2014|https://clinicaltrials.gov/show/NCT00977171||133337|
NCT00977379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21873|XERAD: A Study of Xeloda (Capecitabine) Plus Radiotherapy in Patients With Breast Cancer With Newly Diagnosed Brain Metastases|XERAD: Open-label, Phase II, Randomized, Comparative, Multicentre Trial of Concurrent Whole Brain Radiation Therapy (WBRT) and Capecitabine (Xeloda® ) Followed by Maintenance Capecitabine Compared With Standard WBRT in Breast Cancer Patients With Newly Diagnosed Brain Metastasis||Hoffmann-La Roche||Completed|September 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977379||133321|
NCT00976924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonMedical1|Clinical Test of Blood Glucose Test Strips|Clinical Test of Blood Glucose Test Strips||Andon Medical Co.,Ltd|No|Completed|July 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Both|22 Years|78 Years|Accepts Healthy Volunteers|||September 2009|September 14, 2009|September 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976924||133356|
NCT00978263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChongqingMU|Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes|An Efficacy and Safety Comparison of Basal Insulin and OADs in Newly Diagnosed Type 2 Diabetes After Short-term Intensive Insulin Therapy||Chongqing Medical University|Yes|Completed|February 2009|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|30 Years|70 Years|No|||February 2013|February 4, 2013|September 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00978263||133255|
NCT00977639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03072008-1032|Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies|Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies||Stanford University||Completed|February 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|Samples With DNA|a tissue biopsy specimen|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of malignancy|March 2010|March 26, 2010|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977639||133302|
NCT00977652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/070/HP|Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence|Short Term Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence:Randomized Controlled Study|TENSIA|University Hospital, Rouen|Yes|Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||August 2011|August 22, 2011|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977652||133301|
NCT00974051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0392|Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia|The Effect of Using Terbutaline or a Reduction in Basal Insulin Infusion as a Therapeutic Agent to Prevent Delayed Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes||University of Colorado, Denver|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|10 Years|17 Years|No|||August 2013|August 2, 2013|September 9, 2009||No||No|September 17, 2012|https://clinicaltrials.gov/show/NCT00974051||133572|
NCT00959062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF09213|Adjunctive Clonidine in the Sedation of Mechanically Ventilated Children|New Approaches to Pediatric Sedation: Adjunctive Clonidine in the Sedation of Mechanically Ventilated Children (NAPS Pilot Trial)|NAPS Pilot|McMaster University|Yes|Completed|January 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|1 Month|18 Years|No|||August 2014|August 11, 2014|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959062||134706|
NCT00959075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA6617|A Trial of Thiamin Supplementation in Patients With Heart Failure|A Randomized Controlled Trial of the Effect of Thiamin Supplementation on Heart Function in Ambulatory Patients With Heart Failure||St. Michael's Hospital, Toronto|Yes|Completed|September 2009|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 1, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959075||134705|
NCT00959348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 07-291|Effect of Inhaled Steroids on Glucose Regulation in Asthma Patients|The Effect of Inhaled Corticosteroids on the Risk of Diabetes, Impaired Glucose Tolerance and Characteristics of Glucose Regulation in Adults With Asthma : a Population Based Matched Controlled Study||The University of Hong Kong|No|Completed|August 2007|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1394|Samples With DNA|Plasma, serum and DNA|Both|35 Years|74 Years|No|Non-Probability Sample|Asthma patients will be recruited from asthma clinic in Queen Mary Hospital, Queen        Elizabeth Hospital, Kowloon Hospital, Kwong Wah Hospital and select matched controls at        1:1 ratio from the general population database of Cardiovascular Risk Factor Prevalence        Study 2 (CRISPS2).|August 2009|August 12, 2009|August 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00959348||134684|
NCT00959621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HABENOX|Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion|Role of LMWH (Enoxaparine) With or Without Aspirin in the Prevention of Habitual Abortion; Special Attention to the Thrombophilic Status of the Mother|HABENOX|Helsinki University|No|Completed|January 2002|December 2008|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|220|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2009|August 13, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00959621||134663|
NCT00960193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1018|Drug-Food Interaction Study of Seville Orange Juice and Colchicine|A One-Directional, Open-Label Drug-Food Interaction Study to Investigate the Effects of Multiple-Daily Consumptions of Seville Orange Juice on the Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|August 13, 2009|No|Yes||No|February 22, 2010|https://clinicaltrials.gov/show/NCT00960193||134620|
NCT00991679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-2007-12-111|CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome|Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the Tear Film and Ocular Surface of Patients With Dry Eye Syndrome||Chonnam National University Hospital|Yes|Completed|February 2008|December 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|Samples Without DNA|tears, conjunctiva|Both|24 Years|77 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991679||132241|
NCT00991692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deluca-ms1|A Multisite Trial of ACQUIREc Therapy|A Multisite Trial of ACQUIREc Therapy||University of Alabama at Birmingham|No|Completed|June 2008|October 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|18|||Both|3 Years|8 Years|No|||October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991692||132240|
NCT00987545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2206|Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence|A Post-shave Keloid Recurrence Study in Two Parts: A Biomarker Assessment Followed by a Randomized, Double-blind, Placebo Controlled Evaluation of Safety, Tolerability, and Efficacy of QAX576||Novartis|No|Terminated|June 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|70 Years|No|||May 2012|May 2, 2012|September 30, 2009|Yes|Yes|Negative pharmacodynamics due to lack of Interleukin-13 signature in biomarker data from Part    I of the study.|No||https://clinicaltrials.gov/show/NCT00987545||132559|
NCT00987792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14522|CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients|CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients||Bayer|No|Completed|September 2009|October 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2595|||Both|18 Years|N/A|No|Non-Probability Sample|Female and male hospitalized adult patients scheduled to be treated with moxifloxacin for        their CAP and starting treatment with intravenous administration will be documented after        the attending physician made the therapeutic decision at his/her discretion.|August 2015|August 6, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987792||132540|
NCT00958438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-GA-0816|PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy||Regeneron Pharmaceuticals||Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|244|||Both|18 Years|80 Years|No|||December 2011|December 1, 2011|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00958438||134753|
NCT00959712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG028668|Computer Agents to Promote Walking in the Elderly|Computer Agents to Promote Walking in Older Adults With Low Health Literacy||Boston Medical Center|Yes|Completed|October 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|263|||Both|65 Years|N/A|No|||November 2011|November 7, 2011|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00959712||134657|
NCT00959725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 09-1195|Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema|Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema||Icahn School of Medicine at Mount Sinai|No|Recruiting|August 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2009|August 14, 2009|August 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959725||134656|
NCT00976976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0604|Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer|Phase 2 Study of Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer|Adjuvant DXP|Asan Medical Center|No|Completed|May 2007|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|70 Years|No|||January 2014|January 13, 2014|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00976976||133352|
NCT00976937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10780|24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years|A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin||Sanofi|Yes|Completed|August 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|49 Years|No|||March 2014|March 10, 2014|September 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976937||133355|
NCT00976950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182.147|A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.|A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.||Boehringer Ingelheim||Completed|September 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|patients|February 2014|February 24, 2014|September 14, 2009||||No|May 30, 2012|https://clinicaltrials.gov/show/NCT00976950||133354|
NCT00977184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090221|50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease|Controlled Study of 50 Hz Repetitive Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease||National Institutes of Health Clinical Center (CC)|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|40 Years|80 Years|No|||November 2012|November 22, 2012|September 12, 2009||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT00977184||133336|
NCT00977704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1900-01|Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles|An Open-label Study of the Safety of Restylane and Perlane in the Correction of Peri-oral Wrinkles.||Medicis Global Service Corporation|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||May 2013|May 7, 2013|September 14, 2009|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT00977704||133297|
NCT00977158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8851|Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life|Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life||Tufts Medical Center|No|Withdrawn|May 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|3 Months|No|Non-Probability Sample|Infants with cystic fibrosis|March 2015|March 17, 2015|September 14, 2009||No|No problems with planned study- insufficient funding for this study to proceed.|No||https://clinicaltrials.gov/show/NCT00977158||133338|
NCT00977665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA-RAS-202|Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)|A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)||Teva Pharmaceutical Industries|Yes|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|174|||Both|30 Years|N/A|No|||February 2015|February 10, 2015|September 15, 2009|Yes|Yes||No|February 10, 2015|https://clinicaltrials.gov/show/NCT00977665||133300|
NCT00974038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4819|Cognitive Behavior Therapy for Adolescents With Bulimia|Cognitive Behavior Therapy for Adolescents With Bulimia Nervosa||New York State Psychiatric Institute|No|Completed|November 2006|February 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|12 Years|18 Years|No|||October 2012|October 25, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974038||133573|
NCT00978289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#080516|Microenvironment of Adipose Tissue in Endocannabinoid System|Microenvironment of Adipose Tissue in Endocannabinoid System Before and After Roux-en-y Gastric Bypass Surgery||Vanderbilt University|No|Completed|July 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Whole blood, adipose tissue, adipose tissue microdialysate|Both|20 Years|60 Years|No|Non-Probability Sample|Subjects approved and scheduled for gastric bypass surgery|June 2013|June 17, 2013|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978289||133253|
NCT00974948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND05.083|Trial of Endoscopic Ultrasound (EUS) - Guided Celiac Plexus Neurolysis|A Randomized, Double Blind, Sham-Controlled Trial of EUS-Guided Celiac Plexus Neurolysis (EUS-CPN) for Pain Due to Newly Diagnosed, Inoperable Pancreatic Cancer||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2006|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2009|September 10, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00974948||133505|
NCT00959088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5255|Faster Identification of TB and Evaluation of Drug Resistance in HIV-infected People|Faster AFB Identification, Speciation of TB, and Evaluation of Drug Resistance in HIV-Infected Persons Initiating TB Treatment|FASTER|AIDS Clinical Trials Group|Yes|Completed|August 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|641|Samples With DNA|samples of sputum and blood may be retained|Both|13 Years|N/A|No|Non-Probability Sample|HIV-infected individuals with suspected TB co-infection|April 2013|April 9, 2013|August 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959088||134704|
NCT00959634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-988|Pharmacokinetic Study of ABT-126 in Healthy Volunteers|||Abbott|No|Completed|August 2009|||September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|November 2, 2010|August 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959634||134662|
NCT00959647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4437g|A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study|An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study||Genentech, Inc.||Completed|September 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|August 10, 2009|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT00959647||134661|
NCT00959907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-CBED06|Comparison of Two Commercial Preparations of Botulinum Toxin Type A|A Phase iv Controlled Randomized Blinded Study on the Anhydrotic Action Halos and Muscle Activity of Two Commercial Preparations Type a Botulinum Toxin (Dysport® and Botox® ) Administered to the Upper Third of the Face||Brazilan Center for Studies in Dermatology|No|Completed|May 2005|December 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||November 2009|December 9, 2009|April 23, 2009||No||No|April 23, 2009|https://clinicaltrials.gov/show/NCT00959907||134642|The field of muscular effects of the studied toxins was objectively measured by EMG and it is not very precise. However, there is no more precise objective measurement to currently evaluate the field effects in muscles than EMG.
NCT00959920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201539|Study of Obstetric Foley Techniques|Study of Obstetric Foley Therapy (SOFT Trial)|SOFT|Loyola University|Yes|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Female|18 Years|N/A|No|||April 2012|April 24, 2012|August 14, 2009||No||No|April 24, 2012|https://clinicaltrials.gov/show/NCT00959920||134641|No limitations
NCT00991354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 080|Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX™-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in Healthy, HIV-1-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|November 2009|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 10, 2014|October 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00991354||132266|
NCT00991367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0909-CU|CICATRIX in the Treatment of Recent Post-surgical Scars|Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Recent Post-surgical Scars||Catalysis SL|Yes|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|55 Years|No|||December 2010|December 7, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991367||132265|
NCT00957281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 08-306|The Effect of Asthma on Systemic Inflammation, Oxidative Stress and Cardiovascular Morbidity|The Association of Asthma With Systemic Inflammation and Oxidative Stress, and Its Effect on the Risk of Cardiovascular Morbidity in Adult With Stable Asthma||The University of Hong Kong|No|Completed|September 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|748|Samples With DNA|Plasma, serum, DNA and exhaled breath condensate|Both|35 Years|74 Years|No|Probability Sample|Asthma patients will be recruited from asthma clinics of 4 centres in Hong Kong, including        Queen Mary Hospital, Queen Elizabeth Hospital, Kowloon Hospital and Kwong Wah Hospital.|August 2009|August 11, 2009|August 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00957281||134841|
NCT00957606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCa & Osteoporosis 09|Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer|Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer: Symptoms, Risc Factors, and Prevention|Osteoporosis|Odense University Hospital|Yes|Recruiting|August 2009|September 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Male|N/A|N/A|No|||April 2011|April 12, 2011|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957606||134817|
NCT00957853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0342|Preoperative Treatment With Cetuximab and/or IMC-A12|An Exploratory Study to Assess the Modulation of Biomarkers in Patients With Squamous Cell Carcinomas of the Head and Neck Randomized to Receive Preoperative Treatment With Cetuximab and/or IMC-A12, an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2011|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|August 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957853||134798|
NCT00958165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-2738|Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial Fibrillation|Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial Fibrillation||CardioFocus|No|Completed|August 2009|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|70 Years|No|||June 2012|June 19, 2012|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958165||134774|
NCT00958451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK0023|Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients|Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial||Salem Veterans Affairs Medical Center|No|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2009|March 23, 2011|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958451||134752|
NCT00958464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-00930|The Effect of Perthes' Disease on Hip Cartilage|The Effect of Perthes' Disease on Hip Cartilage||University of British Columbia|No|Suspended|January 2008|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|17 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers with healed unilateral Perthes' disease between the ages of 7-18 years|November 2015|November 30, 2015|August 11, 2009||No|The engineers are working on a new scanning protocol that would allow us to image both hips    simultaneously instead of having the subject come in on two days|No||https://clinicaltrials.gov/show/NCT00958464||134751|
NCT00955552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-093|Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee|A Multi-center, Randomized, Double Blind, Comparative of Efficacy and Safety From Association of Capsules Glucosamine and Chondroitin Sulfate (Eurofarma) Versus Condroflex (Zodiac) to Patients Treatment With Osteoarthrosis of the Knee Study|Artico|Eurofarma Laboratorios S.A.|No|Not yet recruiting|April 2010|November 2010|Anticipated|October 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|N/A|No|||August 2009|March 3, 2010|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00955552||134973|
NCT00976027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM07|Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older|Multi-Year Efficacy Study of Fluzone High-Dose Trivalent Vaccine Compared With Fluzone® Vaccine In Adults ≥ 65 Years of Age||Sanofi|Yes|Terminated|September 2009|April 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|9172|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 24, 2012|September 11, 2009|Yes|Yes|No safety concerns, study terminated due to lack of primary endpoint cases in 2009-2010 Flu    season (coincided with H1N1 Pandemic) Subjects followed per-protocol|No|June 19, 2012|https://clinicaltrials.gov/show/NCT00976027||133425|The study was terminated due to lack of primary endpoint cases in 2009-2010 influenza season (coincided with the H1N1 Pandemic). There were no safety concerns; enrolled subjects were followed per-protocol.
NCT00976040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THE BOTSHELO STUDY|Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis|A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis|Crypto|Botswana-UPenn Partnership|Yes|Completed|September 2009|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|21 Years|80 Years|No|||February 2012|February 3, 2012|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976040||133424|
NCT00984984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000590-37|Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses|Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses|COPOUSEP|Rennes University Hospital|Yes|Recruiting|March 2008|June 2014|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|55 Years|No|||December 2012|December 4, 2012|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984984||132752|
NCT00977717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-05-052|Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin|Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy||Samsung Medical Center|No|Completed|September 2008|April 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|DNA will be extracted from peripheral blood samples using DNA isolation kit.|Both|18 Years|N/A|No|Non-Probability Sample|Curatively resected stage III colon cancer|April 2010|April 15, 2010|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00977717||133296|
NCT00977769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009carb|Carbetocin Versus Oxytocin and Hemodynamic Effects|Hemodynamic Effects of Carbetocin 100 µg, Oxytocin 5 U or Placebo After Cesarean Delivery Under Spinal Anesthesia in Healthy Pregnant Women.||Oslo University Hospital|No|Completed|November 2009|October 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|76|||Female|18 Years|50 Years|No|||April 2014|April 4, 2014|September 15, 2009||No||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00977769||133293|
NCT00977678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STHF-1|Drop in Gastroscopy - Experience After 9 Months|Drop in Gastroscopy - Experience After 9 Months||Norwegian Department of Health and Social Affairs|Yes|Completed|November 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|213|||Both|18 Years|N/A|No|Non-Probability Sample|Current patients referred to our outpatient gastroscopy clinic|December 2009|December 29, 2009|May 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977678||133299|
NCT00977691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090225|Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia|Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia||National Institutes of Health Clinical Center (CC)||Suspended|September 2009|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|2 Years|N/A|No|||March 2016|March 16, 2016|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977691||133298|
NCT00978003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090217|Vasti Control of Patellofemoral Kinematics in Asymptomatic Volunteer|Vasti Control of Patellofemoral Kinematics in Asymptomatic Volunteers||National Institutes of Health Clinical Center (CC)||Completed|August 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|28|||Both|18 Years|55 Years|No|||October 2015|November 3, 2015|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978003||133275|
NCT00978276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-IHC|Immunohistochemical (IHC) Scoring for Receptors Expression in Breast Tissues|Concordance Study for Over Expression Level of Antibodies Within Breast Tissues||Applied Spectral Imaging Ltd.|No|Withdrawn|May 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|Samples Without DNA|Paraffin embedded tissue sections of the breast|Female|20 Years|N/A|No|Probability Sample|The breast samples were taken from female patients after tru cut biopsies, lumpectomies or        mastectomies. Paraffin embedded blocks were prepared from the specimens out of which        sections were stained immunohistochemically with the Vision Bio Systems mouse monoclonal        antibodies for Estrogen Receptor (NCL-ER-6F11) and Progesterone Receptor (NCL-PGR-312).        All stages were performed under the routine procedure of the hospital laboratory.|January 2016|January 4, 2016|September 15, 2009||No|Personal changes in the company|No||https://clinicaltrials.gov/show/NCT00978276||133254|
NCT00974701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-79|A Pilot and Feasibility Study to Evaluate Capsule Endoscopy|A Pilot and Feasibility Study to Evaluate Capsule Endoscopy in Subjects Presenting With Acute, Overt Upper Gastrointestinal Hemorrhage|MA-79|Given Imaging Ltd.|No|Completed|August 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||May 2010|June 9, 2011|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974701||133524|
NCT00974714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Facchinetti|L-arginine Effects on Chronic Hypertension in Pregnancy|Effects of Oral L-arginine on Chronic Hypertension in Pregnancy||University of Modena and Reggio Emilia|Yes|Completed|September 2007|December 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|40 Years|No|||September 2009|January 19, 2010|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974714||133523|
NCT00986531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285M00016|The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics|A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia||AstraZeneca||Completed|November 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|59|||Both|18 Years|45 Years|No|||October 2011|October 31, 2011|September 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00986531||132634|
NCT00986544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pic63|Drain After Elective Laparoscopic Cholecystectomy|Drain After Elective Laparoscopic Cholecystectomy. A Randomized Controlled Trial||University of Roma La Sapienza|No|Completed|December 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|80 Years|No|||February 2012|February 18, 2012|September 29, 2009||No||No|January 16, 2012|https://clinicaltrials.gov/show/NCT00986544||132633|
NCT00990496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31717|A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)|A Phase I-II Study of Allogeneic CMV Specific Cytotoxic T Lymphocytes (CTL) for Patients With Refractory Glioblastoma Multiforme (GBM)||Penn State University|Yes|Terminated|September 2009|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|5 Years|65 Years|No|||August 2010|August 18, 2011|October 5, 2009|Yes|Yes|Accrual goals not met|No||https://clinicaltrials.gov/show/NCT00990496||132332|
NCT00990769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015531|The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children|The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children||Duke University|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|40|||Both|2 Years|8 Years|No|||May 2013|May 30, 2013|October 5, 2009|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT00990769||132311|
NCT00990782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-634|Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment|CEPELA I Trial: Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment|CEPELA|The Cleveland Clinic|No|Completed|September 2009|September 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|18 Years|N/A|No|||March 2012|March 27, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00990782||132310|
NCT00991055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-96-61|Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes|To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes||National Cheng-Kung University Hospital|No|Recruiting|May 2008|October 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|80 Years|No|||October 2009|October 6, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00991055||132289|
NCT00991718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4683g|A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential|A Phase I, Open-Label Absorption, Distribution, Metabolism, and Excretion (ADME) Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential||Genentech, Inc.||Completed|October 2009|||July 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 22, 2010|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991718||132238|
NCT00987571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-US Med N JAOA|Carpal Tunnel Syndrome: Case Reports and Analysis - Ultrasound Imaging and Pathomechanics of Median Nerve Compression|Carpal Tunnel Syndrome: Case Reports and Analysis - Ultrasound Imaging and Pathomechanics of Median Nerve Compression||EMG Labs of Arizona Arthritis & Rheumatology Associates|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|4|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with upper extremity symptoms of pain, numbness, and tingling; Adult        subjects with no upper extremity pain, numbness, or tingling|September 2009|September 30, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987571||132557|
NCT00957866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:164|Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity|Prospective Anti-HCV Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity: PRAIRIE Study|Praire|University of Manitoba|Yes|Completed|May 2009|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|160|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 15, 2014|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00957866||134797|
NCT00958178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/S071038|A Novel Method of Preoxygenation Using a Bain Circuit|A Novel Method of Preoxygenation Using Partial Rebreathing Via a Coaxial Mapleson D Breathing System (Bain Circuit)||National Health Service, United Kingdom|Yes|Recruiting|August 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2009|August 12, 2009|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958178||134773|
NCT00958477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62242_002|A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer|Phase I, Open-label Study to Investigate Safety, Tolerability, PK, and PD of EMD 525797 After Single and Repeated Dosing at Different Dose Levels in Subjects With Hormone-resistant Prostate Cancer With Bone Mets and Progressive Disease Following Prior CTX||Merck KGaA|No|Completed|October 2008|March 2011|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|N/A|No|||July 2014|July 30, 2014|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958477||134750|
NCT00975754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5252M00001|Lung Deposition Via Different Inhalation Devices|A Phase I, Randomized, Open-label, 5-way Crossover, Single Centre Study in Healthy Subjects to Assess the Lung Deposition of Inhaled Budesonide Delivered Via Different Inhalation Devices||AstraZeneca|No|Completed|September 2009|November 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 10, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975754||133446|
NCT00975767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|265-103|A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer|A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)||Mirati Therapeutics Inc.|No|Terminated|August 2009|August 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|September 10, 2009|Yes|Yes|The study was terminated due to a need for a reformulation of the study drug. Phase 1    completed, no patients enrolled in Phase 2.|No||https://clinicaltrials.gov/show/NCT00975767||133445|
NCT00976053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-307|Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging|Clinical Effectiveness of Pharmacologic Stress Radionuclide Myocardial Perfusion Imaging as a Guide to Management of Patients With Known CAD: Comparison of Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)||Aspire Foundation|Yes|Completed|June 2009|October 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|330|||Both|30 Years|90 Years|No|||October 2014|October 30, 2014|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976053||133423|
NCT00976066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111848|[11C]Carfentanil PET Study of GSK1521498|An Open-label, Non-randomized [11C]Carfentanil PET Study in Healthy Male Subjects to Investigate Brain Mu-opioid Receptor Occupancy, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1521498 and Naltrexone.||GlaxoSmithKline|No|Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||February 2011|August 23, 2012|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976066||133422|
NCT00976339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC3089|Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer|Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer||Columbia University|Yes|Active, not recruiting|September 2007|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Female|21 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 11, 2013|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976339||133401|
NCT00985296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003-24|Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)|A Pilot Study Evaluating the Effect of Conjunctival Allergen Challenge (CAC) on Nasal and Ocular Allergic Symptoms Following Allergen Exposure in the Allergen BioCube (ABC) in Subjects With Seasonal Allergic Rhinoconjunctivitis|ABC CAC|ORA, Inc.|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Subjects will be 18 years of age or older with a positive history of ocular and nasal        allergy and a positive skin test reaction to ragweed within the past 24 months.|September 2010|September 20, 2010|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985296||132728|
NCT00977405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Collatamp G|Collagen-Gentamicin Implant in the Treatment of Contaminated Surgical Abdominal Wounds|Collagen-Gentamicin Implant in the Treatment of Contaminated Surgical Abdominal Wounds - A Randomized Controlled Trial||Singapore General Hospital|Yes|Recruiting|September 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 14, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977405||133319|
NCT00977418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-19|Brain and Cognitive Changes After Reasoning or Physical Training in Cognitively Normal Seniors|Brain & Cognitive Changes After Reasoning or Physical Training in Cognitively Normal Seniors||The University of Texas at Dallas|Yes|Not yet recruiting|October 2009|September 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||September 2009|September 14, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977418||133318|
NCT00978016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-B-078|A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)|A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)||Indivior Inc.|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|460|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978016||133274|
NCT00974064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905010391|The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease|The Natural History of Gene Expression in Lung Cells of Non-Smokers, Smokers, and Ex-Smokers in Health and Disease||Weill Medical College of Cornell University|No|Active, not recruiting|December 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|210|Samples With DNA|Subjects will not have more than 550 mL of blood drawn over a period of 8 weeks. Airway      epithelium from airway brushing samples and alveolar macrophages from bronchoalveolar lavage      is processed to yield high quality RNA. Complimentary DNA (cDNA) is transcribed from the RNA      in vitro and the product is hybridized onto gene microarray chips.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|New York Metropolitan area residents|July 2015|December 9, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974064||133571|
NCT00974376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA026758|Gabapentin Treatment of Cannabis Dependence|Gabapentin Treatment of Cannabis Dependence||The Scripps Research Institute|No|Recruiting|August 2009|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||October 2015|October 15, 2015|September 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00974376||133548|
NCT00986297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654621|Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status|Phase 1 Study of Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-IV Non-Small Cell Lung Cancer and Poor Performance Status||University of Texas Southwestern Medical Center|Yes|Completed|October 2009|||October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|September 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00986297||132651|
NCT00983645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53271|A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity|A Prospective, Open-label, Randomized Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity||Loma Linda University|No|Terminated|October 2004|March 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||September 2015|September 17, 2015|September 23, 2009|Yes|Yes|Insufficient funding|No|September 17, 2015|https://clinicaltrials.gov/show/NCT00983645||132855|
NCT00983658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXF4696g|A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma||Genentech, Inc.||Completed|September 2009|January 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||August 2013|August 16, 2013|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00983658||132854|
NCT00991068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-201|Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome|An Open-Label Pilot Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome||ZARS Pharma Inc.|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991068||132288|
NCT00991380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ach0rd-1001-09|Healthy Eating & Active Living for Diabetes in Primary Care Networks|Healthy Eating & Active Living for Diabetes in Primary Care Networks|HEALD-PCN|The Alliance for Canadian Health Outcomes Research in Diabetes|No|Completed|October 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|200|||Both|19 Years|75 Years|No|||July 2013|July 9, 2013|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991380||132264|
NCT00991393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-05|Sinus Augmentation With Dental Implant|An Open Label, Non Randomized, Single Arm, Multi Center Study to Assess Sinus Augmentation (Sinus Lift) Utilizing INFUSE® Bone Graft Concurrent With Dental Implant Placement|SinusDI|Medtronic Spinal and Biologics|No|Terminated|October 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Non-Probability Sample|Patients needing sinus augmentation (sinus lift) concurrent with placement of dental        implants|October 2011|February 15, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991393||132263|
NCT00991705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-109|A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|An Open-label, Two-treatment, Two-period, Two-sequence, Crossover Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991705||132239|
NCT00987558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-124|Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects|Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects||Bial - Portela C S.A.|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|September 30, 2009||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00987558||132558|
NCT00957294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lene Nyboe Jacobsen|Metabolic Syndrome in Patients With First-episode Schizophrenia|The Metabolic Syndrome in Patients With First-episode Schizophrenia - Prognosis and Prediction.||University of Aarhus|No|Completed|August 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|203|||Both|18 Years|50 Years|No|Probability Sample|Patients admitted to The OPUS project, Region of Midtjylland, Denamrk In comparison        in-patients with major depression, Aarhus University Hospital, Risskov and healthy        controls matched on gender, age and level of education.|March 2012|December 2, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00957294||134840|
NCT00957619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 7-2006|Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre)|Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre)||University of Zurich|No|Completed|March 2006|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|90 Years|No|||February 2015|February 9, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957619||134816|
NCT00958854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000644123|Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma|Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma||National Cancer Institute (NCI)||Recruiting|January 2006|||March 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||August 2009|August 23, 2013|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958854||134722|
NCT00959153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080108|Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney|Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney (Renal Pelvis)||Advance Shockwave Technology GmbH|No|Active, not recruiting|June 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 31, 2011|August 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959153||134699|
NCT00959413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5254|Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load|Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load||AIDS Clinical Trials Group|No|Completed|September 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Actual|328|Samples With DNA|Samples of saliva and blood will be kept|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected individuals|March 2015|March 17, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00959413||134679|
NCT00959426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0961002|A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Multiple Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Adult Subjects||Pfizer|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 3, 2010|August 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959426||134678|
NCT00976963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34776-B|Single Dose Monurol for Treatment of Acute Cystitis|Single Dose Monurol for Treatment of Acute Cystitis||University of Washington|Yes|Recruiting|September 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976963||133353|
NCT00977197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004404|A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome|A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome||Mayo Clinic|No|Active, not recruiting|March 2010|August 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|70 Years|No|||September 2015|September 29, 2015|September 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00977197||133335|
NCT00977210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH1/098|Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors|A Phase I Trial of OXi4503 (a Vascular Disrupting Agent) Given by 3 Weekly Intravenous Infusions to Patients With Advanced Solid Tumors.||OXiGENE|No|Completed|July 2005|||September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977210||133334|
NCT00976651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBLD2|Low Dose Human Chorionic Gonadotropin: Influence on the Endometrium|Influence of Ovarian Stimulation With 200 IU of hCG, (Administered in the Late Follicular Phase Among ICSI Patients Undergoing a GnRH-antagonist Protocol), on the Endometrium on the Day of Oocyte Pick-up||Universitair Ziekenhuis Brussel|No|Completed|January 2009|December 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|36 Years|No|||September 2009|March 24, 2010|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976651||133377|
NCT00977431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.38|Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform|Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM||Boehringer Ingelheim||Active, not recruiting|September 2009|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|69 Years|No|||February 2016|February 22, 2016|September 14, 2009||||No||https://clinicaltrials.gov/show/NCT00977431||133317|
NCT00977730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0848|The Effect of Protandim on Non-alcoholic Steatohepatitis|The Effect of the Dietary Supplement Protandim on Non-Alcoholic Steatohepatitis: A Randomized, Double Blind, Placebo-Controlled Study|NASH|University of Colorado, Denver|Yes|Completed|July 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||September 2009|February 1, 2013|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977730||133295|
NCT00977756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1058A|IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults|IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|No|Completed|August 2002|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||11|Actual|168|Samples With DNA|Blood samples|Both|6 Years|21 Years|No|Non-Probability Sample|HIV infected children, adolescents and young adults who are receiving a regimen of        antiretroviral drugs prescribed by their physician that includes one of the target        combinations.|August 2015|August 5, 2015|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977756||133294|
NCT00985543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-ENCORE3|Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.|Pharmacokinetics of Plasma Lopinavir/Ritonavir Over a 12 Hour Dosing Interval Following Administration of 400/100, 200/150, and 200/50 mg Twice Daily to HIV-negative Healthy Volunteers|ENCORE3|Kirby Institute|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 2, 2011|September 25, 2009|Yes|Yes||No|February 4, 2011|https://clinicaltrials.gov/show/NCT00985543||132709|
NCT00985816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-LR2009|The Effects of Lactobacillus Reuteri DSM 17938 on Immunomodulation and Gastric Motility in Preterm Newborns|The Effects of Lactobacillus Reuteri DSM 17938 on Immunomodulation and Gastric Motility in Preterm Newborns||University of Bari|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|N/A|1 Month|No|||September 2009|November 7, 2011|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985816||132688|
NCT00986050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATHREINE-DEBATER 2006|Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction|A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study|DEBATER|Catharina Ziekenhuis Eindhoven|Yes|Completed|January 2006|July 2009|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|907|||Both|N/A|N/A|No|||September 2009|July 25, 2011|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00986050||132670|
NCT00983372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1015|Drug-Drug Interaction Study Between Colchicine and Diltiazem ER|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Diltiazem ER on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|August 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 12, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00983372||132876|
NCT00983632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VNS|Selective Vagus Nerve Stimulation in Human|Selective Vagus Nerve Stimulation in Human|VNS|University Medical Centre Ljubljana|Yes|Completed|September 2009|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|90 Years|No|||January 2016|January 6, 2016|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983632||132856|
NCT00956969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU0000001|Stress Management for Chronic Headaches|Emotional Awareness and Expression Training and Relaxation Training for People With Chronic Headaches||Wayne State University|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|147|||Both|18 Years|60 Years|No|||June 2013|June 13, 2013|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956969||134864|
NCT00956982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KULDS2009|PEG-IFN Plus Ribavirin Combination Therapy for Older Patients|Pegylated Interferon Alpha-2b Plus Ribavirin Combination Treatment for Older Patients With Chronic Hepatitis C||Kyushu University|Yes|Recruiting|December 2004|December 2012|Anticipated|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1251|||Both|18 Years|N/A|No|||August 2009|August 10, 2009|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00956982||134863|
NCT00956657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/S0710/65|Improving Cardiac Rehabilitation Session Attendance: A Randomised Controlled Trial|Improving Cardiac Rehabilitation Session Attendance Using the Self-Regulatory Model and Motivational Interviewing: A Randomised Controlled Trial||NHS Greater Glasgow and Clyde|No|Completed|November 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|||Actual|31|||Both|18 Years|N/A||||August 2009|April 22, 2010|August 10, 2009||No||No|March 11, 2010|https://clinicaltrials.gov/show/NCT00956657||134888|The small sample size of this study does not allow definitive conclusions to be drawn about the success or failure or this intervention approach.
NCT00956670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0244|Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer|The LymphEdema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients|LEG|Gynecologic Oncology Group||Active, not recruiting|June 2012|||April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|1037|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|August 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956670||134887|
NCT00956943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809716|Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine|Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine|HDP|University of Pennsylvania|No|Completed|August 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|July 23, 2009|Yes|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00956943||134866|This was a proof of concept trial and, as such, was inadequately powered to detect statistically significant treatment arm effects and did not include a long-term follow-up assessment.
NCT00956956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1071002|A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects|A Phase I, Randomized, Placebo Controlled, Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects||Pfizer|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 5, 2010|August 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956956||134865|
NCT00958191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57|Trident® X3 Polyethylene Insert Study|An Open-label, Prospective, Post-market, Historically Controlled, Multi-center Clinical Evaluation of the Trident® X3 Polyethylene Acetabular Inserts.||Stryker Orthopaedics|No|Active, not recruiting|May 2005|December 2017|Anticipated|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|21 Years|75 Years|No|||November 2015|November 12, 2015|August 11, 2009|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT00958191||134772|
NCT00958490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2006:040|Effects of a Walking Program on Functional Status of Post-Surgical Lumbar Spinal Stenosis Patients|Effects of a Physical Activity Intervention Walking Program on Quality of Life, Physical Activity Monitoring, and Functional Status of Post-Surgical Lumbar Spinal Stenosis Patients||University of Manitoba||Enrolling by invitation|June 2009|||June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||August 2011|August 13, 2011|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958490||134749|
NCT00958503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAAT2 Biomarker|Effect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue|A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 14-Day Repeated-Dose Administration of Thiamphenicol (RUX 122) in Healthy Subjects||Psyadon Pharma|Yes|Completed|July 2007|April 2008|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958503||134748|
NCT00958516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 29102-C02|Assessment of the Phototoxic Potential of LEO 29102 Cream|A Phase 1 Study Evaluating the Phototoxic Potential of LEO 29102 Cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g) and the Cream Vehicle, Applied on Intact Skin of Healthy Male Subjects||LEO Pharma|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|32|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 24, 2013|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958516||134747|
NCT00959439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11704|Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)|A Comparative Bioavailability Study of Naproxen Delayed-Release Tablets, 375mg.||Sandoz||Completed|March 2002|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||August 2009|August 13, 2009|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959439||134677|
NCT00959452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17242|Follow up of Patients Treated With Cognitive Behavioural Therapy for Hypochondria From 1997 to 2007|Follow up of Patients Treated With Cognitive Behavioural Therapy at Clinic for Hypochondriacs, Haraldsplass Deaconal Hospital, From 1997 to 2007||University of Bergen|Yes|Recruiting|January 1997|December 2016|Anticipated|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959452||134676|
NCT00959738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061/08|Diverting Loop Ileostomy: With or Without Rod|A Prospective Multicenter Randomized Controlled Clinical Trial to Compare the Method of Protective Diverting Loop Ileostomy With or Without the Support of a Plastic Rod|ROLLI|University Hospital Inselspital, Berne|No|Terminated|August 2008|November 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|August 14, 2009||No|Difference found in interim analysis, not ethical to continue|No||https://clinicaltrials.gov/show/NCT00959738||134655|
NCT00959985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-308|Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer|Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer: A Randomized Trial||Massachusetts General Hospital|Yes|Terminated|August 2009|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|23|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|August 14, 2009||No|low accrual|No||https://clinicaltrials.gov/show/NCT00959985||134636|
NCT00976365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL-P|Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer|Phase IIa Study of Metastatic Breast Cancer||Taiwan THL Co.LTd.|Yes|Completed|October 2009|June 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|20 Years|80 Years|No|||June 2011|June 8, 2011|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976365||133399|
NCT00976378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXA12C001|NOX-A12 First-in-human (FIH) Study|NOX-A12 to Mobilize Stem Cells in Healthy Volunteers - A Single-center, Single Dose, Open Label, Dose Escalation Study of Intravenous NOX-A12 in up to 48 Healthy Subjects||NOXXON Pharma AG|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|June 25, 2014|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00976378||133398|
NCT00984698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0121|A Trial of Group Psychotherapy for Veterans and Military Personnel With Post Traumatic Stress Disorder (PTSD)|A Trial of Group Psychotherapy for Veterans and Military Personnel With Post Traumatic Stress Disorder (PTSD)||University of Arizona|Yes|Completed|May 2009|August 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Male|18 Years|65 Years|No|||February 2014|February 14, 2014|September 24, 2009||No||No|January 6, 2014|https://clinicaltrials.gov/show/NCT00984698||132774|
NCT00984971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIDS ID 10769|Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet|A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults|RMP02-MTN006|CONRAD|Yes|Completed|September 2009|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 27, 2015|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00984971||132753|
NCT00986310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917358|Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy|Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy||University of California, Davis|No|Completed|August 2009|June 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2012|November 2, 2012|September 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00986310||132650|
NCT00985257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2009-35|Performance of a New Glucose Meter System in Children and Young Adults|Performance of the DIDGET Blood Glucose Monitoring System in Children and Young Adults||Ascensia Diabetes Care|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|123|||Both|4 Years|24 Years|No|||January 2016|January 29, 2016|September 24, 2009|Yes|Yes||No|April 6, 2010|https://clinicaltrials.gov/show/NCT00985257||132731|
NCT00985270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifampisiini01|Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis|PXR-agonisti Rifampisiinin Vaikutukset Glukoosi-, Lipidi- ja Hormonihomeostaasiin||University of Oulu|No|Completed|September 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985270||132730|
NCT00985829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pdt bcc1|Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma|Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2008|March 2009|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||November 2009|November 18, 2009|September 26, 2009|Yes|Yes||No|September 30, 2009|https://clinicaltrials.gov/show/NCT00985829||132687|
NCT00986063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENPART|Genotype Based Personalized Prescription of Nevirapine|A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine|GENPART|Mahidol University|Yes|Completed|July 2009|December 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1200|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|September 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00986063||132669|
NCT00986843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OTE-102|Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)|A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer((Q1DX5/W)X2 for 3W)||Hanmi Pharmaceutical Company Limited|No|Completed|June 2008|September 2012|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|19 Years|N/A|No|||April 2013|April 4, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986843||132612|
NCT00983086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0059|Effects of Consumption of Orange Juice on Vascular Protection and Immune Function: Clinical Study on the Specific Contribution of Citrus Flavanones|Effects of Consumption of Orange Juice on Vascular Protection and Immune Function: Clinical Study on the Specific Contribution of Citrus Flavanones|FLORIDE|University Hospital, Clermont-Ferrand||Completed|August 2007|April 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|24|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983086||132898|
NCT00983099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/NA/1006|Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects|Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects||Merz Pharmaceuticals GmbH||Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|56|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|September 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983099||132897|
NCT00983112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-010802-12|Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery|Impact of a Biological Glue (Evicel®) on the Peri Operative Bleeding in Total Knee Prothesis Surgery||Clinique Mutualiste Chirurgicale de la Loire|No|Recruiting|September 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|116|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00983112||132896|
NCT00983385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|787579|Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.||Grünenthal GmbH|No|Completed|September 2009|July 2010|Actual|May 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|208|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 23, 2009||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT00983385||132875|
NCT00957658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59|Accolade® TMZF® Hip Stem Outcomes Study|Accolade® TMZF® Study A Prospective, Post-market, Non-randomized, Multi-center Evaluation of the Accolade® TMZF® Hip Stem||Stryker Orthopaedics|No|Completed|March 2006|May 2014|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|18 Years|90 Years|No|||November 2015|November 19, 2015|August 10, 2009|Yes|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT00957658||134813|
NCT00957307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014006|Breast Computed Tomography (CT) as a Diagnostic Tool|Breast CT as a Diagnostic Tool||Emory University|No|Completed|May 2009|January 2015|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Female|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women having breast biopsy for either masses or calcifications|July 2015|July 21, 2015|August 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00957307||134839|
NCT00957632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008089|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2009|||||N/A|N/A|N/A||||||||||||||December 29, 2009|April 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957632||134815|
NCT00957645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060116|Central Post-Stroke Pain - a Prospective Study|Central Post-Stroke Pain - a Prospective Study of Consecutively Admitted Patients With Recent Stroke||Danish Pain Research Center|No|Completed|February 2008|July 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|275|||Both|18 Years|N/A|No|Probability Sample|Consecutive stroke patients admitted to the Stroke Unit of the Department of Neurology at        Aarhus University Hospital between February 2008 to October 2009|August 2011|August 29, 2011|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957645||134814|
NCT00957879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000567|Different Vitamin D Preparations & FGF23 in Humans|Effect of Different Vitamin D Preparations on Circulating FGF23 Levels in Vitamin D Deficient Caucasian and African-American Men and Women||Massachusetts General Hospital|No|Completed|May 2009|March 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957879||134796|
NCT00958867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00365|EXCEL: Exercise for Cognition and Everyday Living for Seniors With Memory Complaints|Enhancing Cognition and Functional Independence in Senior Women With Mild Cognitive Impairment: A Randomized Trial of Aerobic vs. Resistance Training||University of British Columbia|Yes|Completed|August 2009|March 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|86|||Female|70 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 17, 2014|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958867||134721|
NCT00958880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS09-088|Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety|Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia||Southern Methodist University|No|Completed|March 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 6, 2013|August 12, 2009||No||No|May 30, 2013|https://clinicaltrials.gov/show/NCT00958880||134720|
NCT00959166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0712/17|Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection - A Positron Emission Tomography (PET) Study|A Prospective Case-control Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-infection - a PET Study||Imperial College London|No|Completed|June 2009|September 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|24|||Male|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive men with acute HCV infection|May 2010|February 19, 2016|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959166||134698|
NCT00959465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820902|A/H1N1 Immunogenicity and Safety in Adults|An Open Label Phase 1/2 Study to Assess Immunogenicity and Safety of Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Adults Aged 18 Years and Older||Nanotherapeutics, Inc.|Yes|Completed|August 2009|April 2010|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|408|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|October 7, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959465||134675|
NCT00959751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NXN-188-204|Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura|Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura||NeurAxon Inc.|No|Completed|July 2009|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|65 Years|No|||July 2014|July 12, 2014|August 14, 2009|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00959751||134654|
NCT00959764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGL-OR0801|A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women|A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48-Week, Study of Oral Recombinant Salmon Calcitonin (rsCT) Compared to Salmon Calcitonin (sCT) Nasal Spray in Postmenopausal Osteoporotic Women|ORACAL|Tarsa Therapeutics, Inc.|Yes|Completed|June 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|565|||Female|45 Years|N/A|No|||September 2013|September 16, 2013|August 14, 2009|Yes|Yes||No|October 26, 2012|https://clinicaltrials.gov/show/NCT00959764||134653|
NCT00959998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10915|Acupressure for Post-Treatment Cancer Fatigue|||University of Michigan|No|Completed|September 2007|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00959998||134635|
NCT00960011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERN-PROGRIP-01|Comparative Study on Self-adhesive Mesh for Open Inguinal Hernia Repair|Comparison of Self Gripping Semi-resorbable Mesh (PROGRIP) With Polypropylene Mesh in Open Inguinal Hernia Repair - a Randomized Study||The University of Hong Kong|No|Recruiting|June 2009|January 2011|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||August 2009|August 17, 2009|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00960011||134634|
NCT00955565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sacroliac screw-08|Accuracy of Navigation in Placement of Sacroiliac Screw|Accuracy of Navigation in Placement of Sacroiliac Screw. Multicenter Randomized Controlled Trial||AO Clinical Investigation and Documentation|No|Completed|June 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00955565||134972|
NCT00984191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NapadonChula_01|Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid|99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study||Chulalongkorn University|No|Active, not recruiting|March 2010|November 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|15|||Both|18 Years|N/A|No|||June 2011|June 23, 2011|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984191||132813|
NCT00984438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08081101|Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme|Phase I/II Trial for Patients With Recurrent Resectable Glioblastoma Multiforme Using Surgery With Implantable BCNU Polymer Followed by Post-operative Irinotecan and Bevacizumab||University of Cincinnati|No|Withdrawn|June 2009|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|September 24, 2009|Yes|Yes|No accrual|No||https://clinicaltrials.gov/show/NCT00984438||132794|
NCT00984451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-I-0226|A Pilot Study for Collection of Anti-Influenza A Immune Plasma|A Pilot Study for Collection of Anti-Influenza A Immune Plasma||National Institute of Allergy and Infectious Diseases (NIAID)|No|Active, not recruiting|September 2009|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male subjects with a history consistent with influenza infection and/or vaccination        against influenza.|December 2015|December 14, 2015|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00984451||132793|
NCT00984997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID92-038|Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors|Phase II Study of Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors||M.D. Anderson Cancer Center|No|Completed|October 1993|||June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|70 Years|No|||October 2015|October 14, 2015|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00984997||132751|
NCT00985283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21-AG29502-2|Feasibility and Effects of Preventive Home Visits for Older Adults|Feasibility and Effects of Preventive Home Visits for Older Adults||University of North Carolina, Chapel Hill|No|Completed|January 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|75 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 15, 2011|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985283||132729|
NCT00986570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XEO-001/07|Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face|Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face|XEO-001/07|Biolab Sanus Farmaceutica|No|Completed|September 2009|November 2010|Actual|June 2010|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|September 29, 2009||No||No|November 17, 2010|https://clinicaltrials.gov/show/NCT00986570||132631|
NCT00985556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650368|Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer|Randomized Phase II Study of S-1 (SOX) or Capecitabine (XELOX) in Combination With Oxaliplatin in Patients With Recurrent or Metastatic Gastric Cancer||National Cancer Institute (NCI)||Recruiting|January 2009|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||September 2009|October 19, 2011|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985556||132708|
NCT00983125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0058|Systematic Clonidine for Epidural Analgesia in Labour|Effects of a Systematic Addition of Clonidine in the Local Anaesthetic and Opiate Solution for Epidural Patient Controlled Analgesia in Labour (Levobupivacaine 0.568 mg.mLl-1 + Sufentanil 0.45 µg.mL-1)||University Hospital, Clermont-Ferrand||Completed|August 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|124|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 2, 2013|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983125||132895|
NCT00983684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN 34086741|Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer|TARGIT: A Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy With Conventional Post-operative Radiotherapy After Conservative Breast Surgery for Women With Early Stage Breast Cancer|TARGIT|University College, London|Yes|Completed|March 2000|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3451|||Female|45 Years|N/A|No|||December 2014|December 4, 2014|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983684||132852|
NCT00983697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654703|FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer|A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients|ACRIN 6685|American College of Radiology Imaging Network|Yes|Recruiting|April 2010|||September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|292|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983697||132851|
NCT00957905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01405|Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors|A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors||National Cancer Institute (NCI)||Completed|June 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||April 2015|May 11, 2015|August 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957905||134794|
NCT00957892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809649|Effects of Infant Formula Composition on Infant Feeding Behaviors|Effects of Infant Formula Composition on Infant Feeding Behaviors||Monell Chemical Senses Center|No|Completed|May 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|55|Samples With DNA|DNA collected for analysis of taste receptor and obesity-related genes|Both|1 Month|4 Months|Accepts Healthy Volunteers|Non-Probability Sample|Mothers with healthy infants who are between the ages of 1 to 4 months and are exclusively        feeding cows milk-based formulas will be recruited from the Philadelphia area for this        within-subject experimental research study.|October 2012|October 3, 2012|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00957892||134795|
NCT00958204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01015|Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression|Light and Ion Treatment to Enhance Medication Efficacy in Depression||University of British Columbia|Yes|Completed|October 2009|May 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|134|||Both|19 Years|60 Years|No|||June 2014|June 5, 2014|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958204||134771|
NCT00958529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0805M32121|Gastrointestinal Toleration of Inulin Products|Effect of Two Doses of Inulin Products on Gastrointestinal Tolerance||University of Minnesota - Clinical and Translational Science Institute|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|August 12, 2009|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958529||134746|
NCT00958893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-003 Extension 2|An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext|An Open-Label Extension Study Evaluating Safety and Efficacy of Proellex® In Women With Leiomyomata Who Have Previously Completed ZPU 003 Ext||Repros Therapeutics Inc.|Yes|Terminated|June 2008|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|50 Years|No|||August 2014|August 8, 2014|August 11, 2009|Yes|Yes|Repros stopped the study for safety and FDA put the study on hold for safety.|No|June 25, 2014|https://clinicaltrials.gov/show/NCT00958893||134719|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT00958906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 09-0611|Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema|Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema||Icahn School of Medicine at Mount Sinai|No|Withdrawn|August 2009|October 2009|Actual|||Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|August 11, 2009|Yes|Yes|PI left institution (there are no data results for this study)|No||https://clinicaltrials.gov/show/NCT00958906||134718|
NCT00959179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REFORM|The Registry Evaluating Functional Outcomes of Resynchronization Management|The Registry Evaluating Functional Outcomes of Resynchronization Management|REFORM|Saint Luke's Health System|No|Active, not recruiting|May 2007|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Population from In-patient and out patient setting|August 2009|August 13, 2009|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959179||134697|
NCT00960024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ulrika|Supported Employment in a Swedish Context|Supported Employment for People With Severe Mental Illness in a Swedish Context- A Randomised Controlled Trial||Vardalinstitutet The Swedish Institute for Health Sciences|Yes|Active, not recruiting|April 2008|December 2015|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|120|||Both|20 Years|65 Years|No|||August 2009|August 14, 2009|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960024||134633|
NCT00955578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDN-001|Genetic Identification (ID) of Segmental Dysplastic Nevi|Identification of the Genetic Mutation Responsible for Segmental Dysplastic Nevi||Nova Scotia Health Authority|No|Not yet recruiting|August 2009|March 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1|Samples With DNA|The participant will be involved in the study for the length of time required to obtain 5 to      6 skin biopsiesThe laboratory testing that will be performed includes a genetic analysis of      the tissue obtained from biopsy. The genetic analysis will take place in the genetics lab of      Dr. Hensin Tsao, Massachusetts General Hospital, Bartlett 622, 48 Blossom Street, Boston MA,      02114.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|One patient who is already known to the principal investigator|September 2009|September 1, 2009|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955578||134971|
NCT00955617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-052|DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases|Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases||Guerbet|Yes|Completed|July 2009|October 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|August 6, 2009||No||No|August 8, 2012|https://clinicaltrials.gov/show/NCT00955617||134968|Limitation of the study: descriptive study
NCT00955630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF 4147S|Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome|Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome|IVL for OHS|Retina Associates of Kentucky|Yes|Recruiting|August 2009|||August 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 7, 2009|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955630||134967|
NCT00984711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21427|Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice|A Phase IV, Post-marketing, Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice||PerCuro Clinical Research Ltd|No|Recruiting|May 2007|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|19 Years|N/A|No|Non-Probability Sample|Subjects with active rheumatoid arthritis|September 2010|September 23, 2010|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984711||132773|
NCT00984724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0372|Reducing Tobacco Related Health Disparities|Reducing Tobacco Related Health Disparities||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2011|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984724||132772|
NCT00986323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Air 3-03|Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma|Airsonett Airshower in Allergic Asthma a Double-blind Randomized Multi-centre Trial|4A|Airsonett AB|Yes|Completed|April 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|312|||Both|7 Years|70 Years|No|||November 2010|November 8, 2010|September 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00986323||132649|
NCT00986583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-683|Effect of Succinylcholine on Patients Using Statins|Effect of Succinylcholine on Patients Using Statins||Outcomes Research Consortium|Yes|Completed|September 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|70|||Both|40 Years|80 Years|No|Non-Probability Sample|Patients scheduled for elective surgery with a planned endotracheal intubation while may        or may not be taking statin medications.|September 2010|September 3, 2010|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00986583||132630|
NCT00986869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128-09|The Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension|Study of the Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension||Meir Medical Center|No|Recruiting|September 2009|September 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|All patients that will undergo a bronchoscopy according to the regular indications during        the study period (12 months) will be eligible for the study.|March 2012|March 15, 2012|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00986869||132610|
NCT00986557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650654|T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant|A Randomised Controlled Phase II Trial of the Adoptive Transfer of Selected Cytomegalovirus-Specific Cytotoxic T Lymphocytes (CMV-CTL) After Allogeneic Stem Cell Transplantation (SCT) in Patients at Risk of CMV Disease||National Cancer Institute (NCI)||Recruiting|September 2009|||August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|78|||Both|16 Years|N/A|No|||April 2010|August 23, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986557||132632|
NCT00986856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUC 0301 INT|Fucidin® Cream in the Treatment of Impetigo|A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients||LEO Pharma|No|Terminated|May 2004|March 2005|Actual|March 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|2 Years|11 Years|No|||March 2015|March 25, 2015|September 29, 2009||No|Enrollment failed|No|March 19, 2010|https://clinicaltrials.gov/show/NCT00986856||132611|It was planned to Incl. 360 Pts(Proport.3:1 Fucidin® cream:Fucidin® cream vehicle), but due to very slow recruitment in SE and N and inability to Incl. UK, only 59 Pts were enrolled. 58 Pts were randomised: 42Fucidin® cream:16 Fucidin® cream vehicle.
NCT00983138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-ASP.6/INF|Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)|Efficacy and Safety of Recombinant Asparaginase in Infants (<1 Year) With Previously Untreated Acute Lymphoblastic Leukaemia - Phase II Clinical Trial||medac GmbH|No|Completed|July 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|364 Days|No|||February 2011|February 28, 2011|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983138||132894|
NCT00983151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVF-324-301|Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation||Valeant Pharmaceuticals International, Inc.|No|Terminated|August 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|1050|||Male|18 Years|65 Years|No|||October 2010|August 24, 2012|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983151||132893|
NCT00987116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051055|Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis|Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study|MYACOR|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|June 2009|July 2016|Anticipated|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|80 Years|No|||July 2015|February 10, 2016|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987116||132592|
NCT00983710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSGT-06-083-01-CPPB|Prostate Cancer Symptom Management for Low Literacy Men|Prostate Cancer Symptom Management for Low Literacy Men||Baylor College of Medicine|Yes|Active, not recruiting|May 2009|December 2015|Anticipated|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|108|||Male|18 Years|N/A|No|||July 2015|July 21, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983710||132850|
NCT00983996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALEN-0243|Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)|Single-Dose Fasting In Vivo Bioequivalence Study of Alendronate Sodium Tablets (10 mg; Mylan) and Fosamax Tablets (10 mg; Merck) in Healthy Volunteers||Mylan Pharmaceuticals|No|Completed|June 2002|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 22, 2009|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00983996||132828|
NCT00958568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12115|A Study in Relapse Prevention of Treatment-Resistant Depression|A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients With Treatment-Resistant Depression||Eli Lilly and Company|No|Completed|August 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|892|||Both|18 Years|65 Years|No|||February 2014|February 17, 2014|August 12, 2009|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT00958568||134743|
NCT00958217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-016-09S|Intervention for Veterans With Depression, Substance Disorder, and Trauma|Intervention for Veterans With Depression, Substance Disorder, and Trauma||VA Office of Research and Development|Yes|Completed|December 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 11, 2009||No||No|June 26, 2015|https://clinicaltrials.gov/show/NCT00958217||134770|
NCT00958542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-00897|Prospective Study of Cerebral Palsy Scoliosis|Prospective Study of Scoliosis in Children With Cerebral Palsy||University of British Columbia|No|Suspended|March 2009|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Both|8 Years|18 Years|No|||June 2014|June 20, 2014|August 11, 2009||No|This study is coordinated by the Harms Study Group. It is already registered on this website|No||https://clinicaltrials.gov/show/NCT00958542||134745|
NCT00958555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS02/04/09|A Study of Predictive and Prognostic Markers in Patients With Non-small Cell Lung Cancer|A Study of Predictive and Prognostic Markers in Patients With Non-small Cell Lung Cancer||National University Hospital, Singapore||Active, not recruiting|April 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|||||Both|21 Years|N/A|No|Probability Sample|The investigators for this protocol are clinicians and scientists in the departments of        Cardiac/Thoracic and Vascular Surgery, Haematology and Oncology, Pathology, Radiation        Oncology, Respiratory Medicine, and the Cancer Sciences Institute of Singapore (CSIS) from        NUH, and NUS with major roles in their departments in the clinical management and/or        research of lung cancer. Each will be providing access to clinical information and        assisting in the collection and processing of samples, according to their resources and        expertise.|January 2014|January 13, 2014|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958555||134744|
NCT00959478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD057155|Emergency Department Brief Intervention to Increase Carbon Monoxide Detector Use|Emergency Department Brief Intervention to Increase Carbon Monoxide Detector Use|ProjectCODE|Nationwide Children's Hospital|Yes|Completed|June 2009|March 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 29, 2014|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959478||134674|
NCT00959777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3031_NP_I|Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating DA-3031 (PEG-G-CSF) to Filgrastim (Dong-A) in Healthy Volunteers|||Dong-A ST Co., Ltd.|No|Completed||||||Phase 1|Interventional|N/A|2||||||Male|20 Years|40 Years||||September 2014|September 29, 2014|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959777||134652|
NCT00959790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P8374|Vegetable Consumption in Relation to Health|Beneficial Effects of Vegetable Consumption and a Diet Intervention on Health in Lean and Obese Men.|8374|TNO|No|Completed|January 2009|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00959790||134651|
NCT00960037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08002|Trial to Assess Response to Oral Vitamin D3 Supplementation in Obese Individuals|The Vitamin D Dose Response Curve in Obesity||Winthrop University Hospital|No|Completed|January 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|57|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00960037||134632|
NCT00955591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643881|Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men|Comparison of Flocked vs. Dacron Swab for Anal Cytology, Correspondence With High Resolution Anoscopy||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|March 2009|January 2017|Anticipated|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|48|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955591||134970|
NCT00955604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/PM102 CR|Azilect + Antidepressant Chart Review|Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review|STACCATO|Teva Pharmaceutical Industries|No|Completed|July 2009|June 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|1500|||Both|N/A|N/A|No|Probability Sample|Male or female patients with a diagnosis of PD:          -  who received rasagiline at any dose, as mono- or adjunct therapy for PD, with             concomitant antidepressant medication, OR          -  who received rasagiline at any dose, as mono- or adjunct therapy for PD, without             concomitant antidepressant medication, OR          -  who received antidepressant medication and any other dopaminergic anti-PD therapy             besides rasagiline or selegiline including dopaminergic agents, anticholinergics,             amantadine, deep brain stimulation (DBS), pallidotomy, etc.|November 2010|November 30, 2010|August 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955604||134969|
NCT00955643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBOT900208-06|Periodontal Treatment Associated With Hyperbaric Oxygen Therapy|Periodontal Therapy in Severe Cases of Periodontitis: Preliminary Findings of Non-surgical Instrumentation With or Without Hyperbaric Oxygen Therapy (HBOT)||Escola Bahiana de Medicina e Saude Publica|No|Completed|March 2002|April 2003|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 7, 2009|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955643||134966|
NCT00986076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-010|Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery|Randomized Clinical Trial Evaluating Anti-inflammatory Effect of Low Molecular-Weight Heparin in Pediatric Cataract and Intraocular Lens Surgery||Iladevi Cataract and IOL Research Center|Yes|Completed|March 2008|September 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|23|||Both|N/A|15 Years|No|||September 2009|September 28, 2009|September 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00986076||132668|
NCT00986089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0938-F6A|Intrauterine Device (IUD) Placement at the Time of Cesarean Section|Pilot Study of Copper IUD Placement at the Time of Cesarean Section||University of Kentucky|No|Withdrawn|August 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnant women ages 18-40 who are undergoing a scheduled cesarean section, or women who        are attempting to VBAC and want an IUD post partum will be eligible.|August 2013|August 12, 2013|September 25, 2009||No|Principal Investigator left the University of Kentucky before enrollment could begin.|No||https://clinicaltrials.gov/show/NCT00986089||132667|
NCT00986336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002857|A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders|A Comparative Study of the Steady-state Pharmacokinetics of Risperidone and Topiramate on Monotherapy and During Combination Therapy in Patients With Bipolar or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2001|November 2002|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|55 Years|No|||April 2010|June 8, 2011|September 25, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00986336||132648|
NCT00986349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2|Study of EndoBarrier Liner for Treatment of Type 2 Diabetes Study|A Phase II Single-Center, Prospective, Open Label Efficacy Study, of the GI EndoBarrier™ Liner for the Treatment of Type 2 Diabetes||GI Dynamics|No|Completed|June 2010|November 2012|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|55 Years|No|||May 2013|May 10, 2013|September 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00986349||132647|
NCT00986596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2450|A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women|A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women||Tufts University|No|Completed|October 2006|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|65 Years|N/A|No|||January 2012|January 6, 2012|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986596||132629|
NCT00986908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F4452R|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2009|||||N/A|N/A|N/A||||||||||||||March 17, 2016|September 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00986908||132607|
NCT00986921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMi|Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks|Mifepristone vs. Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks|SAMi|Boston University|No|Completed|October 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|45 Years|No|||December 2013|December 28, 2013|September 23, 2009|Yes|Yes||No|September 7, 2012|https://clinicaltrials.gov/show/NCT00986921||132606|This study was completed as planned.
NCT00986882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAF312A2103|To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients|A Double-blind, Randomized, Single Dose, Placebo Controlled, Three Part Study to Evaluate the Safety and Tolerability, Efficacy and Dose Response of SAF312 in Postoperative Dental Pain Patients||Novartis||Completed|September 2009|||March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|214|||Both|18 Years|45 Years|No|||October 2011|October 16, 2013|September 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00986882||132609|
NCT00986895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 1204-002|A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group|||Horizon Pharma Ireland, Ltd., Dublin Ireland||Completed|September 2006|June 2007|Actual|||Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|N/A|No|||September 2009|June 8, 2015|September 15, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00986895||132608|
NCT00987129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 79278|Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).|Effect of Omega-6:Omega-3 Fatty Acid Ratio on Delaying Progression of Age-related Macular Degeneration (AMD) in Moderate to High Risk Individuals.||University of Alberta|Yes|Terminated|March 2012|December 2014|Actual|March 2014|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Whole blood for genotyping and measuring omega-3 FA status. Serum for Cytokine level      analysis.|Both|50 Years|N/A|No|Non-Probability Sample|Men and women with Neovascular (wet) AMD in one eye and early or intermediate dry AMD in        the fellow eye, taking AREDS vitamins (or equivalent).|August 2012|January 4, 2015|September 29, 2009||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT00987129||132591|
NCT00983424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08B7|Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer|A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer||Northwestern University|Yes|Completed|February 2010|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983424||132872|
NCT00983437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3069/ES/MN|Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury|A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/Day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury||Teva Pharmaceutical Industries||Terminated|August 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|65 Years|No|||August 2013|August 14, 2013|September 9, 2009|Yes|Yes|Study has been stopped by sponsor decision|No|May 9, 2013|https://clinicaltrials.gov/show/NCT00983437||132871|The sponsor’s decision to terminate the study early resulted in the small number of study participants, and related limitations to the interpretation of the study results.
NCT00983398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-5056|Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors|Phase I/II Study of Intra-arterial Melphalan Given With Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors||OHSU Knight Cancer Institute|Yes|Recruiting|September 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|1 Year|30 Years|No|||February 2016|February 11, 2016|September 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00983398||132874|
NCT00984009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-08-1017|A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice|A One-Directional, Open-Label Drug-Food Interaction Study to Investigate the Effects of Multiple-Daily Consumptions of Grapefruit Juice on the Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 11, 2011|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00984009||132827|
NCT00958581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA, Amicar, Placebo|Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery|A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery||New York University|Yes|Recruiting|December 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|390|||Both|10 Years|80 Years|No|||August 2009|August 12, 2009|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958581||134742|
NCT00958919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21721|Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)|The Role of Endorphins in the Perception of Dyspnea With Resistive Loading in Patients With COPD||Dartmouth-Hitchcock Medical Center|No|Completed|August 2009|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|50 Years|90 Years|No|||March 2013|March 1, 2013|August 13, 2009||No||No|November 5, 2012|https://clinicaltrials.gov/show/NCT00958919||134717|
NCT00958932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL084067-01A1|Telecommunication Enhanced Asthma Management|Telecommunication Enhanced Asthma Management|TEAM|National Jewish Health|Yes|Active, not recruiting|September 2009|May 2012|Anticipated|May 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|3 Years|12 Years|No|||July 2011|July 19, 2011|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00958932||134716|
NCT00959192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134K1-2206|Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease|Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.||Pfizer|Yes|Completed|August 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|50 Years|85 Years|No|||November 2015|November 30, 2015|August 13, 2009|No|Yes||No|May 9, 2014|https://clinicaltrials.gov/show/NCT00959192||134696|
NCT00959205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_KU_CARTO|The Efficacy and Safety of CARTO 3D Mapping System Versus Conventional Method in AF and VT|Phase Ⅳ Study of CARTO 3D Mapping System vs Conventional Method in AF & VT|CARTOAF&VT|Korea University|Yes|Enrolling by invitation|July 2009|February 2011|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|85 Years|No|||August 2009|May 19, 2010|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959205||134695|
NCT00959491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-9|A Prospective Study of a New Immunological Fecal Occult Blood Test|A Prospective Study of a New Immunological Fecal Occult Blood Test in Patients Referred for Colonoscopy|RLHV|National Institute of Gastroenterology, Cuba|Yes|Active, not recruiting|October 2009|November 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|160|Samples Without DNA|One fecal sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Residents of Havana City admitted at the investigation center.|October 2009|October 19, 2010|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959491||134673|
NCT00959504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILMN001|Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA|VeraCode Genotyping Test for Factor V and Factor II on the BeadXpress System||Illumina, Inc.|Yes|Completed|August 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|275|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient samples will be leftover EDTA-anticoagulated whole blood from patients referred        for Factor V and/or Factor II testing.|June 2011|June 7, 2011|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959504||134672|
NCT00959803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401004|Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.|An Investigator- And Subject-Blind Phase 1 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04447943 After Administration Of Single Oral Doses To Healthy Young Adult Japanese Subjects And Multiple Oral Doses To Healthy Elderly Japanese Subjects||Pfizer|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2009|December 3, 2009|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959803||134650|
NCT00959816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-954|A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans|||Abbott|No|Completed|August 2009|||August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2010|November 1, 2010|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959816||134649|
NCT00959829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 03/10035-4|Use of Music and Voice Stimulus on Coma Patients|Use of Music and Vocal Stimulus in Patients in Coma State - Relations Between Auditory Stimulus, Vital Signs, Face Expression and Glasgow Coma Scale or Ramsay Scale||University of Sao Paulo|Yes|Completed|February 2004|September 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|30|||Both|16 Years|89 Years|No|||August 2009|June 10, 2010|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959829||134648|
NCT00959530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-014|Comparison of Lingualized and Full Bilaterally Balanced Articulation|A Randomized Clinical Trial Comparing Lingualized and Full Bilaterally Balanced Articulation for Complete Dentures|denture|Nihon University|No|Completed|November 2007|December 2011|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2012|October 7, 2012|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959530||134670|
NCT00960050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000651820|Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone|Dapsone Induced Methemoglobinemia Study (DIMS)||National Cancer Institute (NCI)||Active, not recruiting|June 2009|||May 2015|Anticipated|Phase 1|Observational|N/A|||Anticipated|173|||Both|N/A|22 Years|No|||May 2010|May 28, 2010|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960050||134631|
NCT00955656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110132|Delta Primary Care Provider (PCP) Survey on Asthma Management|Delta Primary Care Provider (PCP) Survey on Asthma Management||Arkansas Children's Hospital Research Institute|Yes|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|21 Years|N/A|No|Probability Sample|Individuals who receive the survey will be the primary care provider identified by study        participants enrolled in our ongoing study entitled, "Asthma in the Delta Region of        Arkansas: Characterization of Disease and Impact of Environmental Factors" (ARIA#53054).|January 2012|January 18, 2012|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955656||134965|
NCT00986102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016321|PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region|A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region||Johnson & Johnson Pte Ltd||Completed|July 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|September 25, 2009||No||No|January 4, 2013|https://clinicaltrials.gov/show/NCT00986102||132666|
NCT00986362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-009|Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy|The MIC (Microplasmin In Children) Trial: A Randomized, Placebo-controlled, Double-masked, Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy|MIC|ThromboGenics|Yes|Completed|February 2010|April 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|N/A|16 Years|No|||April 2014|December 2, 2014|September 28, 2009|Yes|Yes||No|July 4, 2013|https://clinicaltrials.gov/show/NCT00986362||132646|
NCT00987181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-FS-0109-11005|Non-Contact Measurement of Aortic Compliance|Non Contact Measurement of Aortic Pulse Wave Velocity||Barts & The London NHS Trust|No|Completed|September 2010|March 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Non-interventional cardiology clinic. Patients undergoing elective angiography.|February 2015|February 20, 2015|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00987181||132587|
NCT00987155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2007.2271|Spinal Cord Injury: Endurance, Strength and Cardiac Function Induced by Efficient Training Protocols|Spinal Cord Injury: Endurance, Strength and Cardiac Function Induced by Efficient Training Protocols||Norwegian University of Science and Technology|No|Completed|January 2007|May 2012|Actual|February 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00987155||132589|
NCT00987142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002329-30|Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa|A Comparative Open-Label Multicentre Clinical Trial To Assess The Efficacy And Safety Of A New Therapy With Cultured Chimeric Skin For The Treatment Of Skin Lesions In Patients With Epidermolysis Bullosa|TCEB|Cellerix|No|Completed|December 2006|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|N/A|N/A|No|||June 2011|June 13, 2011|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987142||132590|
NCT00983736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVF-324-302|Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation||Valeant Pharmaceuticals International, Inc.|No|Terminated|October 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|1050|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|August 24, 2012|September 22, 2009||No|This study was terminated because of recruitment difficulties.|No||https://clinicaltrials.gov/show/NCT00983736||132848|
NCT00983749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOTRIAS Project 1|Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke|A Randomized, Controlled Phase 1 Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke|CUFFS|University of California, San Diego|No|Completed|December 2009|July 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|85 Years|No|||December 2014|December 4, 2014|September 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00983749||132847|
NCT00983411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGIR-02|Impact of Non-intentional Leaks on Noninvasive Ventilation|Impact of Non-intentional Leaks on Breathing Pattern and Work of Breathing During Non-invasive Ventilation: Study in Awakened Healthy Subjects and Awakened Obesity Hypoventilation Syndrome(OHS)Patients and During the Sleep in OHS Patients.|NIV-Leaks|AGIR à Dom|No|Completed|September 2009|April 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|10 healthy subjects recruited in professionnal area 10 patients with Obesity        hypoventilation syndrome addressed to the sleep laboratory for clinical assessment|September 2009|May 19, 2011|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983411||132873|
NCT00984295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-013|Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines|An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Frozen MMRV Given Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines in Healthy Children 12 to 15 Months of Age||Merck Sharp & Dohme Corp.|No|Completed|June 2000|December 2001|Actual|October 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1913|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||July 2015|July 16, 2015|September 23, 2009|Yes|Yes||No|February 3, 2010|https://clinicaltrials.gov/show/NCT00984295||132805|Two participants were incorrectly vaccinated and are not included in the efficacy/safety analyses. One received M-M-R™II+TRIPEDIA™+COMVAX™ and 1 received VARIVAX™+TRIPEDIA™+COMVAX™ instead of ProQuad™+TRIPEDIA™+COMVAX™
NCT00958282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812M54801|Treatment of Cocaine Dependence With Lisdexamfetamine|Lisdexamfetamine Treatment for Cocaine Dependence||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2009|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|No|||August 2015|August 13, 2015|August 12, 2009|Yes|Yes||No|June 11, 2015|https://clinicaltrials.gov/show/NCT00958282||134765|
NCT00958009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29651|The Multicenter, Open-label, Single-use Autoinjector Convenience Study|A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of a Ready-to-use, Single-use Autoinjector (SA) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc), Three Times a Week (Tiw)||EMD Serono|No|Completed|October 2009|June 2010|Actual|April 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|109|||Both|18 Years|65 Years|No|||August 2013|August 2, 2013|August 12, 2009|No|Yes||No|December 1, 2010|https://clinicaltrials.gov/show/NCT00958009||134786|
NCT00958945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FloSeal|Retrospective Chart Analysis in the Effective Use of FloSeal in Post-Operative Joint Replacements|Retrospective & Prospective Evaluation/Analysis of Hb/Hct in Patients Having Received FloSeal (5ml &10ml) When Undergoing Total Knee or Total Hip Arthroplasty||Desert Orthopedic Center Medical Research Foundation|No|Not yet recruiting|September 2009|||||N/A|Observational|Time Perspective: Retrospective||5|Anticipated|500|||Both|18 Years|95 Years|No|Non-Probability Sample|All Dr. Velyvis's patients that have had a Total Knee or Total Hip after January 1, 2007|August 2009|August 13, 2009|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958945||134715|
NCT00959218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cnp-MS-0601 / MC-2006-01|Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis|Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain||Bionorica Research GmbH|Yes|Completed|June 2007|April 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|70 Years|No|||February 2012|February 2, 2012|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959218||134694|
NCT00959231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643641|Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease|Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Haematological Diseases Using a Reduced Intensity Conditioning Regimen||National Cancer Institute (NCI)||Recruiting|January 2009|||August 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|60 Years|No|||April 2010|August 23, 2013|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959231||134693|
NCT00959244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502-08|Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105|1) Effects of Therapeutic Agents on Estrogens in the Breast 2) Utilizing the Resources of the Breast Cancer Collaborative Registry (BCCR)||University of Nebraska|No|Completed|February 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Urine|Female|19 Years|N/A|No|Non-Probability Sample|Women with breast cancer.|June 2010|June 10, 2010|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959244||134692|
NCT00959517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T26/181/33 A00017|Trial of Artesunate Combination Therapy in Pakistan|Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan||London School of Hygiene and Tropical Medicine|Yes|Completed|July 2001|August 2006|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|6||Actual|588|||Both|2 Years|N/A|No|||August 2009|August 13, 2009|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959517||134671|
NCT00959543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG09/068|MRI Findings in Throwing Shoulders of Waterpolo Players|MRI Findings in Throwing Shoulders of Waterpolo Players Abnormalities in Professional Waterpolo Players||Cantonal Hospital of St. Gallen|No|Completed|July 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|45|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2011|July 6, 2011|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959543||134669|
NCT00960063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05883|A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)|A Phase 1/1B Dose-Escalation Study to Determine the Safety and Tolerability of SCH 717454 Administered in Combination With Chemotherapy in Pediatric Subjects With Advanced Solid Tumors (Protocol No. 05883)||Merck Sharp & Dohme Corp.|No|Terminated|November 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4|||Both|N/A|21 Years|No|||January 2016|January 7, 2016|August 14, 2009|No|Yes|Study was terminated for business reasons.|No|November 19, 2015|https://clinicaltrials.gov/show/NCT00960063||134630|
NCT00955669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ldb2008101|Comparison of Autologous Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer|Comparison of Autologous Transplantation of Bone Marrow Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer||Third Military Medical University|Yes|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|40 Years|70 Years|No|||November 2010|November 30, 2010|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00955669||134964|
NCT00986115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816572|Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy|Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy|Forest|University of California, Davis|Yes|Withdrawn|July 2010|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|65 Years|No|||October 2012|October 17, 2012|September 25, 2009|Yes|Yes|our site was unable to enroll any qualified subjects|No||https://clinicaltrials.gov/show/NCT00986115||132665|
NCT00986947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00027111|Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates|Phase 2 Study of IVIg and Rituximab for Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates||Johns Hopkins University|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|75 Years|No|||August 2011|August 17, 2011|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986947||132605|
NCT00987168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 07024|Sandostatine® LP and Hyperinsulinism|Replace Sandostatine® in Three Daily Subcutaneous Injections by a Single Intramuscular Injection of Sandostatine® LP Per Month in Patients With a Diffuse Form of Hyperinsulinism||Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2009|June 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Months|16 Years|No|||October 2010|December 18, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987168||132588|
NCT00983463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #090657|Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)|Relative Abundance and Spatial Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)||Vanderbilt University|No|Enrolling by invitation|October 2009|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|Samples With DNA|liver biopsy, blood, plasma|Female|18 Years|65 Years|No|Non-Probability Sample|Subjects having bariatric surgery or elective abdominal surgery at Vanderbilt University        Medical Center|June 2015|June 1, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983463||132869|
NCT00983762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001220|Comparison of Functional Outcomes of Three Surgical Approaches in Knee Arthroplasty|Comparison of Functional Outcomes of Three Surgical Approaches in Knee Arthroplasty: The Minimally Invasive Surgery Mini-Incision (MIS) TKA, Standard Para-Patellar Surgery TKA and the Unicompartmental Knee Arthroplasty||Massachusetts General Hospital|No|Terminated|June 2009|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|12|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|TKA subjects:        Subjects will be selected and recruited from the MGH Arthroplasty Clinic. The surgical        decision for TKA approach will be made prior to recruitment for the study.        Healthy persons:        Healthy subjects will be recruited through orthopedic departmental advertisement flyers        and by word of mouth.|November 2009|November 4, 2009|September 23, 2009||No|No continued funding.|No||https://clinicaltrials.gov/show/NCT00983762||132846|
NCT00983177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colchicine1|Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis|Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis: Double Blind Placebo-controlled Study||Bnai Zion Medical Center|No|Recruiting|March 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2010|July 18, 2010|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983177||132891|
NCT00983164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120/07 CEP|Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial|Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial|HepCAntSup|Universidade do Sul de Santa Catarina|No|Completed|January 2007|April 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|32|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2009|September 22, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983164||132892|
NCT00984581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1006|Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects|A Single-site, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and Anti-scarring Potential of Intradermal Juvista in Female Subjects Aged 18-45 Years||Renovo|No|Completed|April 2003|August 2004|Actual|August 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|35|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00984581||132783|
NCT00983723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-001521|Clinical Proteomic Research for the Brain|Clinical Proteomic Research on the Brain|"CPR Brain"|Massachusetts General Hospital|Yes|Recruiting|July 2005|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult with acute ischemic brain injury, adults with neurological or vascular conditions        other than acute stroke and healthy adults.|May 2013|May 22, 2013|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983723||132849|
NCT00985114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1|Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity|An Open Label, Randomized, Controlled Study of a Second Generation EndoBarrier™ Liner vs. Diet Control for the Treatment of Type 2 Diabetes||GI Dynamics|Yes|Completed|October 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||August 2010|March 9, 2015|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985114||132742|
NCT00958022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-035|Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer|Phase I/ II Trial of Carboplatin and Etoposide Plus LBH589 for Previously Untreated Extensive Stage Small Cell Lung Cancer||University of Pittsburgh|Yes|Terminated|September 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2015|January 4, 2016|August 10, 2009|No|Yes|Based on the tolerabilty challenges of the combination|No||https://clinicaltrials.gov/show/NCT00958022||134785|
NCT00958607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212054-487481|Optimizing Stroke Family Caregiver Support Across the Care Continuum by Improving the Timing of Intervention Delivery|Optimizing Stroke Family Caregiver Support Across the Care Continuum by Improving the Timing of Intervention Delivery||University of Toronto|No|Completed|September 2009|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|310|||Both|N/A|N/A|No|||January 2014|January 20, 2014|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958607||134741|
NCT00958620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-07-001-RAS|Shockwave Therapy of Chronic Achilles Tendinopathy|Shockwave Therapy of Chronic Achilles Tendinopathy. A Double-blind, Randomized Clinical Trial of Efficacy||Northern Orthopaedic Division, Denmark|Yes|Completed|October 2004|June 2005|Actual|January 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958620||134740|
NCT00958958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEP012009|Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes|Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes|BRIDGE|Hospital do Coracao|Yes|Completed|January 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|1150|||Both|18 Years|N/A|No|||February 2012|February 25, 2012|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00958958||134714|
NCT00958971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2202|Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer|A Multi-center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative Breast Cancer||Novartis||Completed|July 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Female|18 Years|N/A|No|||February 2013|February 9, 2013|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00958971||134713|
NCT00958984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|294-09-FB|Continuous Hemoglobin Monitoring in Pediatric Transplant|Continuous Hemoglobin and Plethysmograph Variability Index Monitoring May Provide Superior Assessment During Visceral Solid Organ Transplantation in Children: a Prospective Cohort Study||University of Nebraska|No|Completed|August 2009|November 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|N/A|18 Years|No|Non-Probability Sample|Patients under age 19 years of age undergoing visceral solid organ transplant at The        Nebraska Medical Center|December 2014|December 16, 2014|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00958984||134712|
NCT00958997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-003-09|Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients|Quantitative PET Imaging of Pancreatic Beta-cell Mass in Healthy and Type 1 Diabetic Patients With 18F-FP-DTBZ (AV-133)||Yale University|No|Completed|August 2009|May 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|16|Samples Without DNA|Blood plasma|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|July 2012|July 20, 2012|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958997||134711|
NCT00959257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 08-407|The Effect of Long Term Inhaled Corticosteroids on the Risk of Cardiovascular Morbidities|The Effect of Long Term Inhaled Corticosteroids on the Risk of Cardiovascular Morbidities in Adults With Asthma :a Population Based Matched Controlled Study||The University of Hong Kong|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1394|Samples With DNA|Whole blood, plasma, serum and DNA|Both|35 Years|74 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asthma patients will be recruited from asthma clinics of 4 centres in Hong Kong, including        Queen Mary Hospital, Queen Elizabeth Hospital, Kowloon Hospital and Kwong Wah Hospital.        Matched controls at 1:1 ratio from the general population database of Cardiovascular Risk        Factor Prevalence Study II (CRISPSII) will be selected. Matching critera: age +/-5 years;        same gender and BMI+/-10%.|August 2009|August 12, 2009|August 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00959257||134691|
NCT00960089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chesson Labs CT001-01|Efficacy Study of LIQUICURE™ to Treat Toe Nail Fungus|Evaluation of the Efficacy of Chesson Labs LIQUICURE™ for Treatment of Onychomycosis|CT001|Chesson Laboratory Associates, Inc|Yes|Completed|July 2008|October 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|August 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00960089||134628|
NCT00960115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR063325_009|Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy|Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy||Merck KGaA|Yes|Completed|December 2008|June 2015|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|178|||Both|20 Years|N/A|No|||September 2015|September 21, 2015|August 5, 2009|No|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT00960115||134626|
NCT00960128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-3676|Observational Prospective Study on Patients Treated With Norditropin®|NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®||Novo Nordisk A/S|No|Enrolling by invitation|April 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|17000|||Both|N/A|N/A|No|Non-Probability Sample|The study population consists of children and adults who are on treatment with        Norditropin® in accordance with normal clinical practice|October 2015|November 3, 2015|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00960128||134625|
NCT00960141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-192|A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Fall Study||Merck Sharp & Dohme Corp.|No|Completed|August 2000|November 2000|Actual|October 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|829|||Both|15 Years|85 Years|No|||February 2015|February 24, 2015|August 14, 2009|Yes|Yes||No|August 31, 2009|https://clinicaltrials.gov/show/NCT00960141||134624|
NCT00955682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112036|Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612|Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers||GlaxoSmithKline||Completed|August 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|342|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||November 2012|November 16, 2012|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955682||134963|
NCT00986609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE16107|MUC1 Vaccine for Triple-negative Breast Cancer|Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer||Case Comprehensive Cancer Center|Yes|Active, not recruiting|August 2009|||August 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Female|18 Years|N/A|No|||June 2015|June 19, 2015|September 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00986609||132628|
NCT00986635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV139/09|Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study|||Johann Wolfgang Goethe University Hospitals|No|Completed|September 2009|April 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|Samples Without DNA|Plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|patients after hip or knee replacement surgery|September 2009|April 7, 2011|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986635||132627|
NCT00983190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeneMACS LVAD Study Rev 6Jan09|BeneMACS Study:HeartMate 2 (HM2)Left Ventricular Assist Device (LVAD) Survival in Non Transplant Patients is Equal/Better Than Results in Medical Literature|HeartMate II BeneMACS Long Term LVAD Study|BeneMACs|Thoratec Europe Ltd|No|Completed|July 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983190||132890|
NCT00983203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-014|Acute Comfort and Haze Profile of FID 114657|||Alcon Research|No|Completed|July 2009|||August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00983203||132889|
NCT00984048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-CROC-01|Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer|Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Standard First-line Therapy in Patients With Metastatic Colorectal Cancer||Jewish General Hospital|No|Recruiting|August 2009|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|Tumor tissue from a hepatic metastasis will be removed by needle core biopsy (NCB) obtained      under radiologic guidance and will be flash-frozen. To obtain sufficient material for tissue      banking, three needle core biopsies (NCB) will be removed from the same metastasis.      Additionally, monthly whole blood samples will be collected, as well as plasma.|Both|18 Years|N/A|No|Probability Sample|This study will be conducted in patients with a confirmed diagnosis of colorectal cancer        with the presence of liver metastasis, who will be receiving first-line treatment        (FOLFOX/bevacizumab or FOLFIRI/bevacizumab) for metastatic disease.|October 2015|October 28, 2015|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984048||132824|
NCT00984035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-135-B|Investigation of Cisplatin-Related Kidney Toxicity|Investigation of Germline Genetic Determinants and Early Biomarkers of Cisplatin-Related Nephrotoxicity||University of Chicago|No|Active, not recruiting|September 2009|July 2017|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|341|Samples With DNA|Urine Blood Serum/Plasma Whole Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving anti-cancer treatment with cisplatin (or previously treated with        cisplatin) at a participating academic medical center.|June 2015|June 22, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00984035||132825|
NCT00983450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0303-09-HMO|The Influences of Watching a Movie Clip of Normal Walking on Measurable Walking Parameters Among Post-Brain-Stroke Patients as Opposed to the Influences of a Control Movie Clip Showing Backwards Walking|The Influences of Watching a Movie Clip of Normal Walking on Measurable Walking Parameters Among Post-brain-stroke Patients as Opposed to the Influences of a Control Movie Clip Showing Backwards Walking||Hadassah Medical Organization|No|Not yet recruiting|October 2009|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||September 2009|June 2, 2010|September 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00983450||132870|
NCT00984854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1004-319-1001|Investigation Into the Safety of Intradermal Juvidex (M6P) Administered to Wounds of Healthy Subjects|A Trial to Investigate the Clinical Safety, Local Toleration, and Systemic Pharmacokinetics of Repeated, Escalating Concentrations of Intradermal RN1004 to Wounds of Healthy Subjects.||Renovo|No|Completed|January 2004|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984854||132762|
NCT00985127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4208-201|Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout|A Phase 2, Randomized, Double-Blind, Dose-Ranging, Two-Part, Multi-Center Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout||BioCryst Pharmaceuticals|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|99|||Both|18 Years|69 Years|No|||January 2012|January 18, 2012|September 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985127||132741|
NCT00984022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-003|Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage|Aquacel vs. Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage: A Randomized Control Study||Maricopa Integrated Health System|Yes|Completed|March 2008|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|65 Years|No|||October 2010|October 27, 2010|September 22, 2009||No||No|August 11, 2010|https://clinicaltrials.gov/show/NCT00984022||132826|
NCT00985426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-17|Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients|An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)||Dynavax Technologies Corporation|Yes|Completed|September 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|521|||Both|18 Years|75 Years|No|||August 2015|August 19, 2015|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985426||132718|
NCT00985660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NISO-0752|Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg|Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets (30 mg; Mylan) and Sular® Extended Release Tablets (30 mg; First Horizon) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 25, 2009|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00985660||132700|
NCT00985673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113536|Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults|A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age.||GlaxoSmithKline||Completed|October 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|611|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||December 2011|June 14, 2012|September 24, 2009|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00985673||132699|
NCT00958659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL08B1|Study of Specimens From Young Patients With Neuroblastoma|Prognostic Multigene Expression Classification of Neuroblastoma Patients||Children's Oncology Group|Yes|Recruiting|December 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|350|||Both|N/A|18 Years|No|Non-Probability Sample|Patients With Neuroblastoma|November 2015|November 16, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958659||134737|
NCT00958672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/074/HP|Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy|Evaluation Des Anomalies Muqueuses Intestinales Par vidéocapsule Endoscopique au Cours de la sclérodermie systémique : Etude Prospective, Multicentrique et Inter-régionale|sclero-video|University Hospital, Rouen|Yes|Completed|August 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|81 Years|No|Non-Probability Sample|40 consecutive patients with systemic sclerosis will be included in this prospective        study, without prior selection on digestive clinical manifestations|June 2014|June 18, 2014|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00958672||134736|
NCT00958295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/119/HP|Epidemiology of Acute Bacterial Uncomplicated Cystitis in General Practice|Epidemiology of Acute Bacterial Uncomplicated Cystitis in General Practice: Description and Prediction by Urine Dipstick Test|BaCyst|University Hospital, Rouen|No|Completed|March 2009|June 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|362|Samples Without DNA|Bacterial strains isolated in urine cultures|Female|18 Years|N/A|No|Non-Probability Sample|Adult female, no comorbidities.|December 2012|October 21, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958295||134764|
NCT00958308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-SC-9-BIK-01|Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection|A Double-blind, Randomized, Placebo-controlled, Single-center Study of the Efficacy and Safety of BIO-K+ CL-1285® in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection||Bio-K Plus International Inc.|Yes|Completed|December 2008|April 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|255|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|August 12, 2009||No||No|February 1, 2012|https://clinicaltrials.gov/show/NCT00958308||134763|
NCT00958633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01017|Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.|Mood Stabilizer Plus Antidepressant Versus Mood Stabilizer Plus Placebo in the Maintenance Treatment of Bipolar Disorder||University of British Columbia|Yes|Recruiting|November 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|70 Years|No|||June 2015|June 2, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958633||134739|
NCT00958646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB081209|Biomarkers of the Response to Osteopathic Manipulation|Identification of Biomarkers for Investigating Osteopathic Manipulative Treatment||West Virginia School of Osteopathic Medicine|No|Completed|August 2009|December 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|40|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||July 2011|July 12, 2011|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958646||134738|
NCT00959556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000633531|Study of Blood Samples in Patients With Breast Cancer|Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting||National Cancer Institute (NCI)||Recruiting|November 2007|||December 2011|Anticipated|N/A|Observational|N/A|||Anticipated|900|||Female|18 Years|N/A|No|||August 2009|January 7, 2011|August 13, 2009||||No||https://clinicaltrials.gov/show/NCT00959556||134668|
NCT00959569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO/URC/ER/mm 459/DG|Esmolol in Cardiac Surgery|Esmolol in Cardiac Surgery. A Randomized Controlled Trial With Clinical|BREVI|Università Vita-Salute San Raffaele||Recruiting|August 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959569||134667|
NCT00959296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSP0010-10000|Implantable Systems Performance Registry|Implantable Systems Performance Registry|ISPR|MedtronicNeuro|No|Recruiting|August 2003|||April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|11500|||Both|N/A|N/A|No|Probability Sample|Primary Care Clinic|September 2015|September 24, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959296||134688|
NCT00959309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000009542|Media Use in Preschooler Study (MUPS)|Media Use in Preschooler Study (MUPS) An Office Based Intervention to Improve Media Use in Preschool Children: a Randomized Controlled Trial||The Hospital for Sick Children|No|Completed|October 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|160|||Both|3 Years|3 Years|Accepts Healthy Volunteers|||December 2013|December 6, 2013|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00959309||134687|
NCT00959842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVZ 112860|Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia|Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia|ELLF|Sanford Research|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|79 Years|No|||November 2014|November 17, 2014|August 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959842||134647|
NCT00960076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680L00005|An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes|18-Week, Multicenter, Randomized, Double-Blind 3b Trial to Evaluate Efficacy/Safety of Saxagliptin in Combo With Metformin XR 1500mg vs Metformin Uptitrated to 2000mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control After Diet/Exercise and a Stable Dose of Metformin XR 1500mg|SCORE|AstraZeneca|No|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|78 Years|No|||August 2011|August 22, 2011|August 14, 2009|Yes|Yes||No|June 30, 2011|https://clinicaltrials.gov/show/NCT00960076||134629|
NCT00956228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390-02|Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer|Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer||Mayo Clinic|Yes|Completed|October 2006|December 2007|Actual|December 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Male|18 Years|N/A|No|||February 2011|February 23, 2011|August 7, 2009||||No||https://clinicaltrials.gov/show/NCT00956228||134921|
NCT00956241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS 01-62|J-pouch Versus Side-to-end Coloanal Anastomosis After Preoperative Radiotherapy and Total Mesorectal Excision for Rectal Cancer|J-pouch Versus Side-to-end Coloanal Anastomosis After Preoperative Radiotherapy and Total Mesorectal Excision for Rectal Cancer: a Multicenter Randomized Trial||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|April 2002|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|127|||Both|N/A|N/A|No|||August 2009|August 10, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956241||134920|
NCT00987194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-012|HIV Testing in the Emergency Department at Baystate Medical Center: A Pilot Program|HIV Testing in the Emergency Department at Baystate Medical Center: A Pilot Program Version 1.5, May 2009||Baystate Medical Center|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1087|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency department patients aged 18 years or older|July 2010|July 13, 2010|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00987194||132586|
NCT00987207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.490|Pharmacological Postconditioning During the Aortic Valvular Surgery|Pharmacological Postconditioning During the Aortic Valvular Surgery|PC Pharma CVA|Hospices Civils de Lyon|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||November 2011|November 8, 2011|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987207||132585|
NCT00987220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001428|Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid|A Methodology Study To Evaluate Cerebrospinal Fluid Acetylcholine Following A Single Dose Administration Of Donepezil In Healthy Subjects||Pfizer|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|12|Samples With DNA|DNA, plasma, CSF|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young (18-55) male and female healthy volunteers.|February 2011|February 10, 2011|September 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987220||132584|
NCT00983775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKPD_SQ_1|Pharmacology of Insulin Injected With Jet-Injection|Pharmacokinetic and Pharmacodynamic Profile of Rapid Acting Insulin Injected by Needle-free Jet-injection||Radboud University||Completed|November 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2009|August 10, 2011|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00983775||132845|
NCT00985166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-014|A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)|Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age||Merck Sharp & Dohme Corp.|No|Completed|August 2000|May 2003|Actual|May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|801|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|September 24, 2009|Yes|Yes||No|December 23, 2009|https://clinicaltrials.gov/show/NCT00985166||132738|GMTs (adjusted for prevaccination titer, study center, and primary vaccination history status) have been reported in the literature. One subject received diluent only at visit 1 and was excluded from all immunogenicity/safety summaries.
NCT00985439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIC2-08-03|Study of Diclofenac Capsules to Treat Dental Pain|A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars||Iroko Pharmaceuticals, LLC|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|202|||Both|18 Years|50 Years|No|||March 2012|May 15, 2012|September 25, 2009|Yes|Yes||No|November 22, 2011|https://clinicaltrials.gov/show/NCT00985439||132717|
NCT00984321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-116|A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer|A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|170|||Both|70 Years|N/A|No|||November 2015|November 17, 2015|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984321||132803|
NCT00984308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 06-233|Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease|Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease|Go To Sleep|VA Office of Research and Development|Yes|Completed|December 2008|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|40 Years|N/A|No|||August 2015|August 10, 2015|September 24, 2009||No||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00984308||132804|
NCT00984568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05553|Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)|Conventional Step-Up Versus Infliximab Monotherapy in Patients With Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study|MUNIX|Merck Sharp & Dohme Corp.|No|Terminated|November 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|September 24, 2009|Yes|Yes|Due to slow recruitment the study was stopped prematurely.|No|February 19, 2013|https://clinicaltrials.gov/show/NCT00984568||132784|Due to slow recruitment the study was stopped prematurely; participants on study at that time continued to receive treatment per protocol.
NCT00986193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Skejby 2008-1|Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis|Randomized Comparison of Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis||Aarhus University Hospital Skejby|Yes|Terminated|December 2008|April 2016|Anticipated|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|75 Years|N/A|No|||December 2013|December 4, 2013|September 25, 2009||No|By recommendation from the Data and safety monitoring board|No||https://clinicaltrials.gov/show/NCT00986193||132659|
NCT00984841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRP001|Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?|Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?"||Scranton-Temple Residency Program|No|Completed|January 2009|July 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|467|||Both|18 Years|75 Years|No|||September 2009|September 24, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984841||132763|
NCT00985140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0072|Phase II Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides|A Phase II Study of Total Skin Electron Beam Therapy (TSEBT) to Dose of 12 Gy in Stage IB-IIIA Mycosis Fungoides||Stanford University||Terminated|June 2009|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|17|||Both|18 Years|N/A|No|||May 2012|May 24, 2012|September 24, 2009||No|Competing studies|No||https://clinicaltrials.gov/show/NCT00985140||132740|
NCT00958061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|579|Long Term Health Outcomes of Women Veterans' Service During the Vietnam Era|CSP #579 - Long Term Health Outcomes of Women's Service During the Vietnam Era|Health ViEWS|VA Office of Research and Development|Yes|Completed|March 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|4219|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|For this study we will use a cohort of women who are on a roster of Vietnam Era women        veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and        characterized by a review of their military personnel records and link it to a list of        8,061 women who presumably served in Southeast Asia. This final cohort could potentially        contain approximately 14,000 women. After deceased individuals are removed from the active        cohort and contact information is updated, we estimate that there could be approximately        10,000 women to whom the informed consent and mailed survey will be initially mailed.|October 2015|October 2, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958061||134782|
NCT00959010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU01/PNE/MUCO1|Omega 3 Supplementation in Cystic Fibrosis Patients|Biochemical Effects of a Long-term Supplementation With Omega-3 Polyunsaturated Fatty Acids in Cystic Fibrosis||Queen Fabiola Children's University Hospital||Completed|October 2008|||June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|6 Years|60 Years|No|||October 2015|October 20, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959010||134710|
NCT00959270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 28027|Pennington Center Longitudinal Study (PCLS)|Pennington Center Longitudinal (PCLS)|PCLS|Pennington Biomedical Research Center|No|Recruiting|May 2009|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30000|Samples With DNA|Serum, plasma, buffy coat, whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community Sample|February 2016|February 4, 2016|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959270||134690|
NCT00959283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML08B1|Study of Blood Samples From Newborns With Down Syndrome|Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)||Children's Oncology Group|No|Recruiting|February 2009|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|blood|Both|N/A|1 Year|No|Non-Probability Sample|See Eligibility criteria.|November 2015|November 4, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959283||134689|
NCT00959023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000636371|Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer|UK Genetic Prostate Cancer Study||National Cancer Institute (NCI)||Recruiting|June 1993|||||N/A|Observational|N/A|||Anticipated|21000|||Male|N/A|N/A|No|||August 2009|August 23, 2013|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959023||134709|
NCT00959036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3242K1-2000|Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis|A Seamless, Phase 1/2, Multiple Ascending Dose, Proof Of Concept Study Of ATN-103 Administered To Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate||Ablynx|Yes|Completed|September 2009|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|252|||Both|18 Years|80 Years|No|||January 2013|January 28, 2013|August 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959036||134708|
NCT00959595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001834-29|Improvement of Sensibility in the Foot in Diabetic Patients Induced by EMLA-application to the Lower Leg|Improvement of Sensibility in the Sole of the Foot in Diabetic Patients, Induced by EMLA-application to the Lower Leg - a Double Blind Study||Lund University Hospital|Yes|Completed|November 2008|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||December 2013|December 13, 2013|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00959595||134665|
NCT00959582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-143|Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)|A Multicenter Trial to Measure Early Patterns of Change in [18F]-Fluorodeoxyglucose Uptake by PET/CT in Relapsed Ovarian Cancer Patients||Merck Sharp & Dohme Corp.|No|Completed|September 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Female|35 Years|N/A|No|||January 2015|January 21, 2015|August 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959582||134666|
NCT00960102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5551819|Children's Bilateral Cochlear Implantation in Finland|Children's Bilateral Cochlear Implantation in Finland: a Prospective, Controlled, Multicenter Study|FinBiCI|Kuopio University Hospital|No|Recruiting|August 2009|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|N/A|24 Months|No|||August 2015|August 5, 2015|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00960102||134627|
NCT00959855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITS-1-MCT|Long-term Impact of Pulmonary Rehabilitation|Long-term Evaluation of Activity and Health Status Pre and Post Pulmonary Rehabilitation - A Multi-Centred Trial.||Beaumont Hospital|No|Suspended|September 2009|September 2014|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|N/A|N/A|No|||September 2009|May 25, 2010|August 14, 2009||No|Pending modifications|No||https://clinicaltrials.gov/show/NCT00959855||134646|
NCT00959868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-01|A Study for Treatment of Superficial Bladder Cancer Using OGX-427|A Phase I Clinical Trial Assessing Intravesical Antisense Oligonucleotide Targeting Heat Shock Protein 27 for the Treatment of Superficial Bladder Cancer||Vancouver Coastal Health|Yes|Recruiting|July 2009|||December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959868||134645|
NCT00956267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU- 094|Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.|Letrozole Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome||Mansoura University|Yes|Completed|August 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Female|20 Years|36 Years|No|||August 2009|August 10, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956267||134918|
NCT00956592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003272|Clinical Evaluation of the Storz CMAC Laryngoscope|A Randomized Control Trial to Determine First Attempt Intubation Success With the CMAC Laryngoscope vs. Macintosh Blade in Airways Predicted to be Difficult||Oregon Health and Science University|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||July 2010|February 14, 2011|August 10, 2009||No||No|January 25, 2011|https://clinicaltrials.gov/show/NCT00956592||134893|
NCT00983476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-083|Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness (SMI)|Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness|Web-MOVE!|VA Office of Research and Development|No|Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|276|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00983476||132868|
NCT00984867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00010|Dapagliflozin DPPIV Inhibitor add-on Study|A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin||AstraZeneca||Completed|October 2009|September 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|833|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|September 23, 2009|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT00984867||132761|For participants who did not complete 8 and/or 24 weeks, respectively, LOCF was used. All endpoints were evaluated by excluding data after rescue with the exception of systolic blood pressure which was evaluated regardless of rescue medication.
NCT00984880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0510C00002|Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043|Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After a Single Ascending Bolus Dose, and a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Volunteers||AstraZeneca|No|Completed|September 2009|December 2009|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 17, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984880||132760|
NCT00984893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HCA10|Intra-venous Zoledronic Acid Once Yearly|A Real-world Study Cohort of Postmenopausal Women With Osteoporosis Taking Zoledronic Acid or Oral Bisphosphonates|IVORY|Novartis||Completed|November 2008|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1551|||Female|45 Years|N/A|No|Non-Probability Sample|Ambulatory Female patients, at least 45 years of age, diagnosed with osteoporosis and        taking either Zelodronic acid or any other oral bisphosphonates (OBP) as per the current        Canadian monograph|March 2016|March 3, 2016|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00984893||132759|
NCT00985686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22549|E-Mental Health Adolescent Depression Program (LEAP)|Evaluation of a Spirituality Informed E-mental Health Intervention (LEAP Project) for Major Depressive Disorder in Adolescents and Young Adults - A Randomized Controlled Pilot Trial|LEAP|Canadian Institute of Natural and Integrative Medicine|No|Completed|January 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|13 Years|24 Years|No|||July 2015|July 7, 2015|September 24, 2009||No||No|January 14, 2015|https://clinicaltrials.gov/show/NCT00985686||132698|Limitations Inconsistent followup by all study participants Overall generalizability is limited due to a predominantly female sample Self-selection of participants with an open attitude to spirituality No comparison to placebo or active treatment
NCT00984594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR2008|Evaluation of a Composite Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Knee Osteochondral Defects|Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Osteochondral Defects in High-Load-Bearing Region and Low-Load-Bearing Region of the Femoral Condyle||RTI Surgical|No|Terminated|January 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|September 24, 2009||No|Slow enrolment & potential regulatory changes for allograft in cartilage repair|No|July 10, 2013|https://clinicaltrials.gov/show/NCT00984594||132782|Enrollment was closed early due to slow enrollment & a potential change in the regulatory pathway for the allograft used in cartilage repair.
NCT00985699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000643248|S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma|Pharmacogenomics of Oxidative Stress-Related Genes in Lymphoma||Southwest Oncology Group|No|Completed|April 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|337|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled on S8516 S8736 S9125 S9240 consenting to banking|July 2014|July 23, 2014|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00985699||132697|
NCT00985712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12704|A Study on the Effect of 2 Pen Devices on HbA1c|A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults With Type 1 Diabetes: Novel Pen With Memory Function (HumaPen Memoir) vs. Conventional Pen Without Memory Function (HumaPen Luxura)||Eli Lilly and Company|No|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|263|||Both|8 Years|N/A|No|||May 2012|May 2, 2012|September 23, 2009|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT00985712||132696|
NCT00985153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-012|Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)|Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children||Merck Sharp & Dohme Corp.|No|Completed|March 2000|May 2001|Actual|May 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|3927|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||November 2015|November 20, 2015|September 25, 2009|Yes|Yes||No|January 13, 2010|https://clinicaltrials.gov/show/NCT00985153||132739|One additional subject received M-M-R™ II and ProQuad™ vaccines at the same visit in error; this child was excluded from all immunogenicity and safety summaries.
NCT00985413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP1003-01|Observational Study to Assess Natural History in Cockayne Syndrome Patients|An Observational Study to Assess the Natural History Including Growth and Hearing in Patients With Cockayne Syndrome||DNage B.V.|Yes|Terminated|September 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|40|Samples With DNA|whole blood, plasma, serum, white blood cells, urine, tissue|Both|1 Year|11 Years|No|Probability Sample|Pediatric patients up to 10 years of age for females and up to 11 years of age for males        who have received a diagnosis of Cockayne Syndrome|June 2011|June 22, 2011|September 25, 2009||No|The company DNage is in receivership and no longer functional|No||https://clinicaltrials.gov/show/NCT00985413||132719|
NCT00985985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-Nicotine Mint Lozenge-002|Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation|A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Evaluate Efficacy and Safety of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation||GlaxoSmithKline|No|Completed|May 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|723|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|September 2, 2009|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT00985985||132675|
NCT00986453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK VP-00065|PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction|A Prospective, Randomized, Controlled Study to Evaluate Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction|PRECISE|Medtronic Surgical Technologies|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|September 28, 2009|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT00986453||132640|
NCT00958347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/04|Omnifit Hydroxylapatite (HA) Hip Outcomes Study|Omnifit Hydroxylapatite (HA) Hip Outcomes Study||Stryker Orthopaedics|No|Terminated|October 1987|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|226|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|August 11, 2009|Yes|Yes|Terminated due to lagging follow-up|No|July 30, 2014|https://clinicaltrials.gov/show/NCT00958347||134760|
NCT00958334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-003 Ext|Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003|A Multicenter, Open-Label, Safety And Efficacy, Two Year Extension Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Pre-Menopausal Women With Symptomatic Leiomyomata Who Have Previously Completed Study ZPU 003||Repros Therapeutics Inc.|Yes|Completed|September 2006|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|65|||Female|18 Years|50 Years|No|||August 2014|August 5, 2014|August 11, 2009|Yes|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT00958334||134761|
NCT00958685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFI-112|Safety Study of Feeding With Ginger Extract in Acute Respiratory Distress Syndrome|Effect of Enteral Feeding With Ginger Extract in Acute Respiratory Distress Syndrome||Shahid Beheshti University|Yes|Completed|January 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 12, 2009|August 3, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00958685||134735|
NCT00959322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP-001|A Prospective Single Center Clinical Study for Capsulotomy Using the LenSx 550 Laser|A Prospective Single Center Clinical Study for Capsulotomy Using the LenSx 550 Laser||LenSx Lasers Inc.|No|Completed|August 2008|March 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|24 Years|N/A|No|||October 2009|October 12, 2009|August 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959322||134686|
NCT00960154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK VP-00078|PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy|A Prospective, Randomized, Controlled Study to Evaluate Use of the PEAK PlasmaBladeTM 4.0 in Breast Lumpectomy|PRECISE|Medtronic Surgical Technologies|No|Terminated|July 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|90 Years|No|||January 2013|January 3, 2013|August 13, 2009|Yes|Yes|Termination due to acquisition of PEAK Surgical by Medtronic|No|November 29, 2012|https://clinicaltrials.gov/show/NCT00960154||134623|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.
NCT00955695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KROG-4-2008-0276|Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib||National Cancer Institute (NCI)||Not yet recruiting|May 2009|||||Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Prevention|1||Anticipated|242|||Both|18 Years|N/A|No|||January 2010|August 1, 2013|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955695||134962|
NCT00955942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000644401|Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy|A Phase I Blinded, Randomized Feasibility Trial of Dietary Flaxseed Administration in Non-Small Cell Lung Cancer Patients Receiving Definitive Thoracic Chemoradiotherapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|December 2007|||July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|120 Years|No|||February 2016|February 9, 2016|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955942||134943|
NCT00956605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7703|A Trial of Computer-based Attention-training Systems in Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Randomized Trial of Computer-based Attention-training Systems With and Without Neurofeedback in Children With ADHD|CATS|Tufts Medical Center|No|Completed|May 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|3||Actual|35|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2009|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00956605||134892|
NCT00988013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0251|Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies|A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies|IM-TMI|University of Illinois at Chicago|Yes|Active, not recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|60 Years|No|||June 2015|June 17, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988013||132523|
NCT00984607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR-Gastric Band|Measurement of Gastric Band Stoma Diameter|Accurate Fluoroscopic Measurement of Adjustable Laparoscopic Gastric Band Stoma Diameter||Saint Raphael Healthcare System|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2009|July 26, 2010|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984607||132781|
NCT00984360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA027161-01|Study of Naltrexone for Methamphetamine Addiction|A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP||California Pacific Medical Center Research Institute|Yes|Completed|September 2009|September 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|No|||May 2013|May 29, 2013|September 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00984360||132800|
NCT00984620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.40|Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)|Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II)||Boehringer Ingelheim||Completed|September 2009|||April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|70 Years|No|||August 2015|August 7, 2015|September 24, 2009||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT00984620||132780|
NCT00984633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05976|Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED)|Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 Following a Single Intubating Dose in Adult Subjects Undergoing Operation Under Sevoflurane or Propofol Anesthesia||Merck Sharp & Dohme Corp.|Yes|Completed|June 2003|December 2003|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|20 Years|64 Years|No|||May 2015|May 11, 2015|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00984633||132779|
NCT00976898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-131|Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma|Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma||Massachusetts General Hospital|Yes|Active, not recruiting|August 2009|January 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976898||133358|
NCT00985179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FU-19-4711-008|Increasing Vitamin Intake and Physical Activity|Promoting the Adoption and Maintenance of a Physically Active Lifestyle and a Nutrition Rich in Vitamins With the Help of Two Theory-based Computerized Interventions "BI Vit" (Boehringer Ingelheim for a Nutrition Rich in Vitamines) and "BI Active" (Boehringer Ingelheim for Physical Activity) for Employees|BIV-BIA|Freie Universität Berlin|Yes|Completed|October 2009|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2011|November 12, 2012|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00985179||132737|
NCT00985972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANE0575-08|Physical Activity and Nutritional Education as School-based Interventions to Control Obesity in Children and Adolescents|Physical Activity and Nutritional Education as School-based Interventions to Control Overweight in Children and Adolescents: a Systematic Review (Project PANE)|PANE|University of Sao Paulo General Hospital|Yes|Completed|June 2009|September 2013|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|41634|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children and adolescents aged 6 to 18 years of age included in the school environment,        regardless of their ethnicity, social condition and weight range.|March 2014|March 14, 2014|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00985972||132676|
NCT00977626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2600C00002|Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Multiple Ascending Doses in Young and Elderly Healthy Volunteers||AstraZeneca|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|74|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2010|January 20, 2012|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977626||133303|
NCT00986206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIHRI-09-0030|Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer|Development of an Assay for the Early Detection of Ovarian Cancer.||National Cancer Institute (NCI)||Recruiting|June 2009|||April 2014|Anticipated|N/A|Interventional|Primary Purpose: Screening|1||Anticipated|640|||Female|21 Years|N/A|No|||September 2009|September 19, 2013|September 26, 2009||No||No||https://clinicaltrials.gov/show/NCT00986206||132658|
NCT00986466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09090|Vitamin D and Exercise in Falls Prevention|Effects of Vitamin D and Exercise in Preventing Falls of Elderly Women|DEX|UKK Institute|No|Completed|September 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|409|||Female|70 Years|80 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00986466||132639|
NCT00938132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-108|A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers|A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd||Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938132||136304|
NCT00938444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/190|Evaluation of the BRADA and ABILHAND Questionnaires|Prospective, Multicenter, Non-interventional Study in RA Patients Treated With Tocilizumab - Evaluation of the BRADA and ABILHAND Questionnaires||University Hospital, Ghent|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with moderate to severe RA.|July 2011|July 13, 2011|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938444||136280|
NCT00938769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009040|Enhanced Self-Efficacy Training|Enhanced Self-Efficacy Training For Informal Cancer Caregivers||Duke University|No|Completed|August 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|358|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 6, 2014|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938769||136255|
NCT00938782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11062007-818|Using the SEDLine for the Titration of Sevoflurane in Elderly Patients Recovery Using the SEDLine TM for the Titration of Sevoflurane in Elderly Patients Undergoing Non-Cardiac Surgery After Beta-Adrenergic Blockade|A Prospective, Randomized, Double-Blinded Study of the Effect on Improved Recovery Using the SEDLine TM for the Titration of Sevoflurane in Elderly Patients Undergoing Non-Cardiac Surgery After Beta-Adrenergic Blockade||Stanford University|No|Completed|July 2006|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|65 Years|N/A|No|||February 2015|February 9, 2015|July 10, 2009||No||No|January 23, 2015|https://clinicaltrials.gov/show/NCT00938782||136254|
NCT00983034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20061976|The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy|Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy||Istanbul University|No|Completed|March 2006|July 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|70|||Both|18 Years|70 Years|No|||September 2009|September 22, 2009|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00983034||132902|
NCT00980876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STPh 09/08|A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension|Multicentric, Double Blind, Randomized, Parallel Comparative Study Between Ciprofloxacin HCl 2 mg/mL + Hydrocortisone 10 mg/mL Ear Suspension and Cipro HC®, for the Assessment of Efficacy and Safety in Patients With Otitis Externa.||Farmoquimica S.A.|No|Completed|April 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|224|||Both|1 Year|70 Years|No|||March 2012|April 16, 2015|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980876||133066|
NCT00991406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4668-R|Neural Prostheses and Gait Performance: Model-Based Strategies|Neural Prostheses and Gait Performance: Model-Based Strategies||VA Office of Research and Development|Yes|Recruiting|June 2009|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00991406||132262|
NCT00991419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2750N00006|To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden|A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients With AD & HV||AstraZeneca|No|Completed|February 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|October 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00991419||132261|
NCT00989638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13073B|A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer|A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer||University of Chicago|Yes|Active, not recruiting|June 2004|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Women at high risk for breast cancer.|October 2015|October 13, 2015|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989638||132398|
NCT00990756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9291003|A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers|A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Inhaled Doses Of PF-03526299 In Healthy Male Subjects||Pfizer|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990756||132312|
NCT00991666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-200401|Association Between Laser Interferometric Measurement of Fundus Pulsation and Pneumotonometric Measurement of Pulsatile Ocular Blood Flow in Patients With Age-related Macular Degeneration|Association Between Laser Interferometric Measurement of Fundus Pulsation and Pneumotonometric Measurement of Pulsatile Ocular Blood Flow in Patients With Age-related Macular Degeneration||Medical University of Vienna|Yes|Completed|July 2001|March 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991666||132242|
NCT00988234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJHMZK01001|Comparison of Two Position for Ultrasound Guided Lumbar Plexus and Sciatic Nerve Block|Comparison of Lateral Decubitus Position Versus Prone Position for Ultrasound Guided Posterior Lumbar Plexus Block and Sciatic Nerve Block||Huazhong University of Science and Technology|Yes|Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||February 2011|February 16, 2011|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988234||132506|
NCT00988247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-303|Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)||Teva Pharmaceutical Industries|No|Completed|October 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|529|||Both|12 Years|N/A|No|||April 2012|April 23, 2012|September 30, 2009|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT00988247||132505|
NCT00940862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6009|Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis|Pilot Study on the Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis||Innovaderm Research Inc.|No|Completed|July 2009|August 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|80 Years|No|||October 2011|October 27, 2011|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00940862||136095|
NCT00941200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG01/02/09|Pharmacogenetic DNA Bank|Pharmacogenetic DNA Bank||National University Hospital, Singapore|No|Recruiting|April 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1||5000|Samples With DNA|Blood sample|Both|18 Years|N/A|No|Non-Probability Sample|Any individual who has been diagnosed with cancer is eligible.|January 2014|January 13, 2014|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941200||136069|
NCT00941408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR03/17/08|Biomarker Study of Breast Tumors|Biomarker Study of Breast Tumors||National University Hospital, Singapore|No|Recruiting|March 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1||400|Samples With DNA|During the diagnostic tumor core biopsy, 3-4 additional tumor samples will be obtained      through the same needle track for the purpose of this study. The tumor cores will be stored      in liquid nitrogen for subsequent histopathological analysis; DNA, RNA and protein will be      extracted from tumor cores for genetic, gene expression and proteomics studies.|Female|18 Years|N/A|No|Non-Probability Sample|Patients with breast lesions for whom a diagnostic core biopsy is planned|January 2014|January 13, 2014|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941408||136053|
NCT00941759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-056|Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer|A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2009|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Blood and tissue collection|Female|18 Years|N/A|No|Non-Probability Sample|Potential research subjects will be identified by a member of the patient's treatment        team, either at the time of consultation with the breast surgeon or breast medical        oncologist. Patients will be accrued from each of the 15 participating sites.|May 2015|May 27, 2015|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941759||136026|
NCT00941421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 09/5-G|Value of Oesophagal Videocapsul and Oeso-gastro-duodenal Fiber Endoscopy for the Screening of Oesophagal Varix for Cirrhotic Patients|"Comparision of Diagnostic Value of Oesophagal Videocapsul (VCO) and Oeso-gastro-duodenal Fiber Endoscopy (OGDFE) for the Screening of Oesophagal Varix (OV) for Cirrhotic Patients|VCO-VO|Nantes University Hospital|No|Terminated|September 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|310|||Both|18 Years|80 Years|No|||June 2013|June 11, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941421||136052|
NCT00941772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008017|Confirmation of Nasogastric Tube Placement Via Ultrasonography|Confirmation of Nasogastric Tube Placement Via Ultrasonography||Oklahoma State University Center for Health Sciences|No|Completed|July 2009|April 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 1, 2010|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00941772||136025|
NCT00937638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE BOLD-X|Beef in an Optimal Lean Diet (BOLD) Effects on Metabolic Syndrome|BOLD (Beef in an Optimal Lean Diet) Effects on Established and Emerging Cardiovascular Disease (CVD) Risk Factors: Effects on Metabolic Syndrome (BOLD-X)|BOLD-X|Penn State University|No|Completed|February 2009|March 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|30 Years|60 Years|No|||May 2014|May 20, 2014|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00937638||136342|
NCT00941785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC5550|Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso|Randomized Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of Dihydroartemisinin-piperaquine for Seasonal IPT to Prevent Malaria in Children Under 5 Years||London School of Hygiene and Tropical Medicine|Yes|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1500|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||March 2011|March 18, 2011|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00941785||136024|
NCT00938171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S538|Comparing Local Anesthesia With General Anesthesia for Breast Cancer Surgery|A Comparison of Local Anesthesia and General Anesthesia for Breast Cancer Surgery, a Prospective Randomized Trial||Mackay Memorial Hospital|Yes|Recruiting|June 2008|July 2013|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|21 Years|75 Years|No|||July 2009|July 10, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938171||136301|
NCT00938158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108370|A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.|An Adaptive Design Study for the Assessment of the Pharmacokinetics of Albiglutide in Subjects With Normal Renal Function and Subjects With Moderate-to-severe Renal Impairment and Hemodialysis.||GlaxoSmithKline|Yes|Completed|August 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|75|||Both|30 Years|75 Years|No|||January 2012|January 26, 2012|July 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938158||136302|
NCT00938457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0941|Stereotactic Radiation Therapy in Treating Patients With Liver Metastases|A Phase I/II Dose-Finding Study of Single-Fraction Stereotactic Body Radiotherapy (SF-SBRT) for the Treatment of Liver Metastases||Mayo Clinic|Yes|Terminated|July 2009|||April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|120 Years|No|||October 2015|January 7, 2016|July 9, 2009|Yes|Yes|poor accrual|No|June 4, 2012|https://clinicaltrials.gov/show/NCT00938457||136279|
NCT00938795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007468|Uncertainty Management Intervention|Uncertainty Management Intervention for Patients Awaiting Liver Transplant||Duke University|No|Completed|February 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|288|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 6, 2014|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938795||136253|
NCT00939458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1087/06|Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions|A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects,Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|55 Years||||July 2009|July 15, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00939458||136203|
NCT00939471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR01918|Safety and Efficacy of Balloon Sinuplasty in Pediatric Sinusitis|Clinical Evaluation of Confirm the Safety and Efficacy of Balloon Sinuplasty Devices in the Treatment of Pediatric Sinusitis|INTACT|Acclarent|Yes|Completed|April 2007|May 2010|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|2 Years|17 Years|No|||July 2012|July 10, 2012|July 14, 2009||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00939471||136202|
NCT00939809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0170N|A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Completed|July 2009|||July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||February 2015|February 27, 2015|July 14, 2009|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT00939809||136176|Note: due to the limited activity of this agent, it was decided not to expend resources assaying the PBMCs.
NCT00979342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP 200902|Comparative Sedation Study of the MyoSure Hysteroscopic Tissue Removal System|Interlace Medical Comparative Sedation Study||Hologic, Inc.|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Female|18 Years|65 Years|No|||July 2010|July 22, 2010|September 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00979342||133173|
NCT00979355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP- DSpect_001|Study to Compare a Fast Gama Camera for Nuclear Imaging to Conventional Camera|Evaluation of Multi Purpose D-spect Camera for General Nuclear Scans|GP_D-Spect|Spectrum Dynamics||Withdrawn|November 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|80 Years|No|||June 2010|June 24, 2010|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979355||133172|
NCT00981136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 07 133|Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Appendectomy|Single Incision Versus Standard Laparoscopic Appendectomy for Non-Perforated Appendicitis||Children's Mercy Hospital Kansas City|No|Completed|August 2009|December 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|1 Month|18 Years|No|||February 2013|February 13, 2013|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00981136||133048|
NCT00981149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040504|Duloxetine for Treatment of Painful Temporomandibular Joint Disorder|Duloxetine for Treatment of Painful Temporomandibular Joint Disorder||University of Maryland|Yes|Completed|May 2009|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981149||133047|
NCT00987376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-03|Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration|Comparison of Novel PET/CT Imaging Agents and MRS/MRI in Metastatic and High Risk Prostate Cancer: An Inter-SPORE Collaboration||Mayo Clinic|Yes|Completed|November 2003|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Male|18 Years|N/A|No|||January 2016|January 12, 2016|December 20, 2007||No||No||https://clinicaltrials.gov/show/NCT00987376||132572|
NCT00990470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-Endo-1009|Endoscopic Evaluation in Transplantation Candidates|Endoscopic Evaluation in Transplantation Candidates - Frequency and Prognostic Relevance of Upper and Lower Gastrointestinal Tract Findings||Hannover Medical School|No|Completed|February 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|80 Years|No|Non-Probability Sample|Patients evaluated for Tranplantation at Hannover Medical School|October 2011|October 7, 2011|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990470||132334|
NCT00990483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2009|||||N/A|N/A|N/A||||||||||||||October 5, 2009|October 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990483||132333|
NCT00990743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008204-41|Tolerance and Effect on Intraocular Pressure After Administration of SYL040012|Phase I Study With SYL040012. Tolerance and Effect on Intraocular Pressure||Sylentis, S.A.|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 21, 2010|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990743||132313|
NCT00987805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B090029|Efficacy of Banhasasim-tang on Functional Dyspepsia|Efficacy of Banhasasim-tang on Functional Dyspepsia : a Randomized, Double Blind, Placebo Controlled, Two-center Trial||Korea Health Industry Development Institute|Yes|Completed|September 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|75 Years|No|||June 2012|June 20, 2012|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987805||132539|
NCT00988026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MXMIN-001|Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne|Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks|MXMIN-001|Darier|Yes|Recruiting|June 2009|April 2010|Anticipated|February 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|14 Years|30 Years|No|||September 2009|September 30, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988026||132522|
NCT00988273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090821300|Confocal Endomicroscopy During Endoscopy|Confocal Endomicroscopy in Patients Undergoing Endoscopy||University of Alberta|No|Recruiting|October 2009|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|Biopsy samples|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing endoscopy: study group are patients evaluated for IBD symptoms and        control patients for other indications such as colon cancer screening, positive fecal        occult testing, constipation or diarrhea.|April 2012|April 27, 2012|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988273||132503|
NCT00941447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3R01DK074721|Development of Self-Regulation in Individuals With Type 2 Diabetes|||University of Tennessee|No|Completed|April 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|21 Years|65 Years|No|||May 2011|May 4, 2011|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941447||136050|
NCT00941460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIRECTOR|Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma|Dose-intensified Rechallenge With Temozolomide, One Week On One Week Off Versus Three Weeks On One Week Off in Patients With Progressive or Recurrent Glioblastoma|DIRECTOR|Heidelberg University|No|Completed|September 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|80 Years|No|||August 2014|August 13, 2014|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941460||136049|
NCT00942071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flu001|A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults|A Phase I Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults||University of Oxford|Yes|Completed|August 2008|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 28, 2012|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00942071||136002|
NCT00940849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-042|Gastric Emptying and Gallbladder Motility Study|Gastric Emptying of Plant Sterol-containing Mini Drinks in Different Meal Intake Scenarios and Their Effect on Gallbladder Emptying||Maastricht University Medical Center|No|Completed|October 2009|October 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940849||136096|
NCT00941161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMGlime-04|Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus|Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy||Laboratorios Silanes S.A. de C.V.|Yes|Completed|February 2009|||May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|28|||Both|40 Years|65 Years|No|||May 2010|May 17, 2010|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941161||136072|
NCT00941798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149A2210|Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma|A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma||Novartis||Completed|July 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2283|||Both|12 Years|70 Years|No|||August 2012|August 21, 2012|July 14, 2009|Yes|Yes||No|May 3, 2012|https://clinicaltrials.gov/show/NCT00941798||136023|
NCT00942019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-88/08|Study of Bronchial Inflammation in Adolescent Smokers With and Without Obesity|Bronchial Inflammation in Adolescent Smokers With and Without Obesity||Johann Wolfgang Goethe University Hospitals|No|Completed|October 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|110|Samples With DNA|serum: total IgE, RAST urin: cotinine, leukotrienes sputum: leukotrienes, white cells whole      blood|Both|14 Years|22 Years|Accepts Healthy Volunteers|Non-Probability Sample|Youth|July 2010|July 2, 2010|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942019||136006|
NCT00938808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2009-029|Long-term Intervention With Weight Loss in Patients With Concomitant Obesity and Knee Osteoarthritis. The LIGHT Study|Long-term Intervention With Weight Loss in Patients With Concomitant Obesity and Knee Osteoarthritis. The LIGHT Study|LIGH T|Frederiksberg University Hospital|No|Completed|June 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|50 Years|N/A|No|||January 2016|January 15, 2016|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938808||136252|
NCT00938470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0849|Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|January 2010|||March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938470||136278|
NCT00938483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0010|Tolerability and Safety of An Infant Formula|A Multicenter, Single-blind, Randomized, Phase II Study of the Tolerability and Safety of NPS-202 in Infants With Clinically Diagnosed Cow's Milk Allergy||Perrigo Nutritionals|No|Completed|August 2007|January 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|108|||Both|N/A|12 Weeks|No|||July 2009|July 14, 2009|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00938483||136277|
NCT00939094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00016|AZD2066 Neuropathic Pain - Mechanical Hypersensitivity|A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity|NP-MH|AstraZeneca||Terminated|August 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|80 Years|No|||August 2012|August 28, 2012|July 13, 2009|Yes|Yes||No|August 28, 2012|https://clinicaltrials.gov/show/NCT00939094||136230|Early termination of study for safety reasons leading to fewer subjects analyzed than originally planned.
NCT00940342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0102|Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia|Rituximab In Combination With Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2004|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|130|||Both|15 Years|N/A|No|||February 2016|February 1, 2016|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940342||136135|
NCT00980213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09045|Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland|Evaluation of the Cost and Effectiveness in the First-line Treatment of Advanced Renal Cell Cancer With Sunitinib Compared to Interferon-alfa in Finland.||Tampere University Hospital|No|Completed|September 2009|December 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|85 Years|No|Non-Probability Sample|advanced renal cell cancer patients|February 2014|February 5, 2014|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980213||133107|
NCT00980239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0410|HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver|A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver||M.D. Anderson Cancer Center|No|Completed|September 2009|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|115|||Both|N/A|N/A|No|||November 2015|November 9, 2015|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00980239||133106|
NCT00991081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09152009-3940|Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.|Exploratory/Developmental Study of Pharmacogenetic Smoking Cessation Therapy.||Stanford University|Yes|Completed|July 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|October 6, 2009||No||No|June 25, 2012|https://clinicaltrials.gov/show/NCT00991081||132287|Possible selection bias as 32 of 36 participants had taken part in previous research
NCT00987389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEXIVAS|Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis|Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial|PEXIVAS|University of Pennsylvania|Yes|Recruiting|May 2010|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|15 Years|N/A|No|||September 2015|September 4, 2015|September 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987389||132571|
NCT00987363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMo/ICPD/2008|Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization|Phase II Clinical Trial of Therapeutic Angiogenesis With Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Ischemia Diabetics Critical Limb (CLI) no Revascularization.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Completed|July 2009|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|80 Years|No|||November 2014|March 15, 2016|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987363||132573|
NCT00987584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMDS0023|Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk|A Biologic Correlates Study for "A Phase 2 Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-2 or High Ris||Stanford University|Yes|Completed|June 2009|February 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|Samples Without DNA|marrow and peripheral blood|Both|18 Years|N/A|No|Non-Probability Sample|Diagnosis of IPSS Intermediate or High risk MDS|February 2012|February 2, 2012|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00987584||132556|
NCT00987818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-190809|Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU|Reduction of Antibiotic Use in the ICU: Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU||Rijnstate Hospital|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|August 31, 2015|September 16, 2009||No|No MEC approval|No||https://clinicaltrials.gov/show/NCT00987818||132538|
NCT00988260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05969|Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)|A Phase II Bridging Trial of Org 37462||Merck Sharp & Dohme Corp.|No|Completed|February 2003|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|266|||Female|20 Years|39 Years|No|||July 2015|July 22, 2015|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988260||132504|
NCT00937703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00270-55|Multicentric Evaluation of Two Telematics Systems in Type 2 Diabetic Patients in Failure of Oral Treatment and Having to Start Treatment by Basal Insulin|Multicentric Evaluation of Two Telematics Systems (PDA Phone and IVS)in Type 2 Diabetics Patients in Failure of Oral Treatment and Having to Start a Treatment by Basal Insulin, Compared to a Conventional Care. National, Multicentric, Comparative Randomized Study|TELEDIAB-2|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|December 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|180|||Both|18 Years|N/A|No|||March 2010|December 12, 2013|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937703||136337|
NCT00941174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008487-2b|Folate Absorption Across the Large Intestine|Folate Absorption Across the Large Intestine, Study #2: Capsule Study||The Hospital for Sick Children|No|Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00941174||136071|
NCT00941434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1227-Ped/ERC-09|Community Based Management of Malnutrition|Community Based Management of Malnutrition. A Proposal for Pakistan Initiative for Mothers and Newborns||Aga Khan University||Completed|July 2009|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|800|||Both|6 Months|3 Years|No|||July 2009|July 7, 2011|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941434||136051|
NCT00937677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNAC/Tysabri/01|Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study|Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.||University at Buffalo|No|Completed|November 2007|November 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|MS patients that are followed at the Jacobs Neurological Institute, University at Buffalo,        Buffalo NY.|September 2011|September 6, 2011|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937677||136339|
NCT00938184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112811|Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects|An Open Label, Randomized, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Doses of the Controlled-release Paroxetine Tablets at the Dose Levels of 12.5, 25 and 50mg in Healthy Japanese Male Subjects||GlaxoSmithKline|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|18|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||February 2011|April 5, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00938184||136300|
NCT00942045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.OC.0802|Osteocel® Plus in Anterior Cervical Discectomy and Fusion (ACDF)|Osteocel® Plus in Anterior Cervical Discectomy and Fusion (ACDF): Evaluation of Radiographic and Patient Outcomes||NuVasive|No|Completed|February 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|182|||Both|18 Years|70 Years|No|Non-Probability Sample|Existing clinic patients|January 2014|January 7, 2014|July 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00942045||136004|
NCT00937664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1040C00008|Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine|A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies||AstraZeneca|Yes|Terminated|July 2009|February 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|74 Years|No|||February 2011|February 4, 2011|July 9, 2009|No|Yes|Termination of the study was made after a full review of program data and assessment of the    current risk-benefit profile.|No||https://clinicaltrials.gov/show/NCT00937664||136340|
NCT00939510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3805|Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer|Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer||Case Comprehensive Cancer Center|Yes|Completed|July 2005|December 2012|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Male|18 Years|N/A|No|||January 2013|January 24, 2013|July 14, 2009|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT00939510||136199|
NCT00939107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-01-057/03|The McKenzie Method Versus Manipulation for Patients With Chronic Low Back Pain|The Effect of the McKenzie Method as Compared With That of Manipulation When Applied Adjunctive to Information and Advice for Patients With Clinical Signs of Disc-related Chronic Low Back Pain: Randomized Controlled Trial.||Back and Rehabilitation Center, Copenhagen|No|Completed|September 2003|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|60 Years|No|||November 2009|November 9, 2009|July 13, 2009||No||No|August 13, 2009|https://clinicaltrials.gov/show/NCT00939107||136229|
NCT00939484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03020|Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma|A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma||National Cancer Institute (NCI)||Completed|June 2009|August 2015|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|22 Years|N/A|No|||March 2015|January 28, 2016|July 14, 2009|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT00939484||136201|
NCT00939497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1119/07|Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions|Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|55 Years||||July 2009|July 15, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00939497||136200|
NCT00939835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/05/002|Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|45 Years||||July 2009|July 15, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00939835||136174|
NCT00940069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYN-LC-001|TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer|A Multicenter, Open Clinical Trial of Using TS Gene Polymorphism to Predict Effect in Patients of Advanced Lung Adenocarcinoma to Pemetrexed Combining With Cisplatin Regiment as First-line Treatment|TPEIAL|Hunan Province Tumor Hospital|Yes|Completed|March 2009|January 2015|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940069||136156|
NCT00990808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-026|The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)|A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients||Merck Sharp & Dohme Corp.|No|Completed|November 2009|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|70 Years|No|||June 2015|June 3, 2015|October 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990808||132308|
NCT00991094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR05-0207|Data Collection of Normal Tissue Toxicity for Proton Therapy|Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults||M.D. Anderson Cancer Center|No|Recruiting|May 2005|||September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients, over 18 years of age, scheduled for radiation treatment with protons at        Univesity of Texas MDACC.|October 2015|October 13, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991094||132286|
NCT00991432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-04|Localized Alveolar Ridge Augmentation With Space Maintenance Devices|An Open Label, Non-randomized, Single-arm, Multi-center Study to Assess Localized Alveolar Ridge Augmentation Utilizing INFUSE® Bone Graft Concurrent With Space Maintenance Devices for Soft Tissue Management|Ridge Mesh|Medtronic Spinal and Biologics|No|Terminated|October 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients needing bone augmentation of the alveolar ridge|September 2011|February 15, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991432||132260|
NCT00987636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108128|Study in Localized and Disseminated Ewing Sarcoma|Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma|EWING 2008|University Hospital Muenster|Yes|Recruiting|October 2009|March 2018|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1383|||Both|48 Months|50 Years|No|||September 2009|November 17, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987636||132552|
NCT00987597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRB0801|Smoking Cessation for Patients With Acute Coronary Syndrome (ACS)|Effectiveness of a Managed Care Smoking Cessation Program in Patients With Acute Coronary Syndrome Based on Nicotine Replacement as a Treatment and a Cognitive-behavioral Approach|PATPAC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2008|April 2010|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|144|||Both|18 Years|70 Years|No|||September 2009|September 30, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987597||132555|
NCT00987831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRF 09-02|Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)|Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity|BOLD|Oklahoma Medical Research Foundation|Yes|Completed|May 2009|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|158|||Both|14 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|September 30, 2009|Yes|Yes||No|August 28, 2013|https://clinicaltrials.gov/show/NCT00987831||132537|
NCT00988065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06042|Sugammadex Hypersensitivity Study (Study P06042)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administrations of Sugammadex (SCH 900616) in Healthy Subjects||Merck Sharp & Dohme Corp.|Yes|Completed|September 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|448|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|September 30, 2009|No|Yes||No|April 13, 2011|https://clinicaltrials.gov/show/NCT00988065||132519|Results from this study in healthy/conscious subjects may not be fully applicable to anesthetized patient settings.
NCT00988039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U.1228.03.004.00021.01|Europe-Africa Research Network for Evaluation of Second-line Therapy|A Randomised Controlled Trial to Evaluate Options for Second-line Therapy in Patients Failing a First-line 2NRTI + NNRTI Regimen in Africa|EARNEST|Medical Research Council|Yes|Completed|March 2010|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1277|||Both|12 Years|N/A|No|||April 2014|April 3, 2014|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988039||132521|
NCT00988052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LAQ-301E|A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course|A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis||Teva Pharmaceutical Industries|Yes|Active, not recruiting|November 2009|October 2023|Anticipated|September 2023|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|844|||Both|18 Years|55 Years|No|||March 2016|March 16, 2016|September 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988052||132520|
NCT00937716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080807011|Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies|Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies||University of Alabama at Birmingham|Yes|Active, not recruiting|October 2008|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|75|Samples With DNA|Specimens will be tested for dopamine, serotonin, norepinephrine, and glutamine-related      genes. In previous studies, all of these neurotransmitters have been associated with      schizophrenia and/or schizoaffective disorder.|Both|19 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit fifty patients with a diagnosis of schizophrenia presenting at UAB clinics        who have stopped taking APD medication for at least 10 days and agree to antipsychotic        treatment, and twenty-five matched healthy volunteers.|April 2015|April 8, 2015|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937716||136336|
NCT00937729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/122/HP|Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules|Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment Containing Enfuvirtide (Fuzeon) Associated With Two Active Molecules|AMPHORE|University Hospital, Rouen|Yes|Terminated|June 2009|December 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|All patients HIV1 infected in virological failure (viral load > 50 copies/ml) by lack of        compliance,old of more than 18 years, who never received enfuvirted and without        opportunistic infection, yet treated by almost one molecule of each group.|February 2012|February 14, 2012|July 10, 2009||No|difficult to include patients|No||https://clinicaltrials.gov/show/NCT00937729||136335|
NCT00941811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|_1.0|Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment|An Explorative, Single Center and Controlled Study to Analyze the Immune Escape Mechanisms of HPV-associated Lesions and to Evaluate the Efficiency and Mechanisms of Imiquimod Treatment of Vulvar Intraepithelial Neoplasias 2/3 (VIN) and Anogenital Warts||Medical University of Vienna|Yes|Completed|December 2008|May 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 14, 2015|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941811||136022|
NCT00942058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808071|Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer|Serum Carbonic Anhydrase 9 (CA9) Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer : a Pilot Study|CA9CRM|Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|June 2009|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples Without DNA|Blood, urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a metastatic conventional renal cell cancer. All patients must sign a        consent form to be included in this study.|January 2014|January 28, 2014|June 17, 2009||No|Difficult for recruiting|No||https://clinicaltrials.gov/show/NCT00942058||136003|
NCT00938197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-107|A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers|An Open-label, Multiple-dosing, and Crossover Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|34|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938197||136299|
NCT00938522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-06-031|Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention|PREtreatment of Cilostazol Loading in Elective Percutaneous Coronary Intervention to Decrease Adverse Events|PRECEDE|Samsung Medical Center|Yes|Not yet recruiting|July 2009|October 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|No|||July 2009|July 20, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938522||136274|
NCT00937937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01935|Dinaciclib in Treating Patients With Stage IV Melanoma|A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma||National Cancer Institute (NCI)||Active, not recruiting|July 2009|||October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|July 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937937||136319|
NCT00938496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OCN-ZOL-2009/1|Non-Interventional Study of Zoladex in Endometriosis|A Non-interventional Study of Postoperative Treatment With Goserelin Acetate (Zoladex) in Moderate to Severe Endometriosis Patient||AstraZeneca|No|Completed|July 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|408|||Female|18 Years|N/A|No|Non-Probability Sample|Study Population Description: Patient with advanced endometriosis confirmed histological        (r-AFS score III-IV) with conservative laparoscopy or laparotomy has the indication of        Zoladex and has already been prescribed Zoladex according to physician's judgment,        irrespective of the inclusion in the study|February 2014|February 19, 2014|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00938496||136276|
NCT00938821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15028|Very Low Dose Caudal Morphine for Postoperative Pain Management|The Use of Very Low Dose Caudal Morphine for Postoperative Pain Management in Out Patients||University of Oklahoma|Yes|Active, not recruiting|January 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|1 Month|10 Years|No|Non-Probability Sample|This is a chart review from October 2008 to October 2009 of children from 1 month of age        to 10 years old that went to elective Urological procedures such us circumcision,        orchidopexy and inguinal hernia repair, orthopedic and general surgery procedures for        which caudal block are usually administered for pain management|February 2012|February 1, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00938821||136251|
NCT00939822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2015-0038|Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease|Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: "Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP)" Study|SHARP|University of Wisconsin, Madison|Yes|Active, not recruiting|March 2009|September 2017|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|88|||Both|40 Years|72 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00939822||136175|
NCT00940056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHOrebro|Totally Endoscopic Ablation of Atrial Fibrillation|Totally Endoscopic Ablation of Atrial Fibrillation|TEA|University Hospital Orebro|Yes|Completed|November 2009|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|50 Years|85 Years|No|||December 2015|December 1, 2015|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940056||136157|
NCT00949754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API092|Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation|A Multi-Center, Randomized, Double Blind, Active-Controlled, Parallel Group Clinical Study to Evaluate the Dose Effect of Intradermal Injections of Apitox vs. Histamine in Subjects With Osteoarthritis Symptoms of the Knee|HBV|Apimeds, Inc.|No|Completed|October 2009|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|85 Years|No|||May 2010|May 4, 2010|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00949754||135413|
NCT00949767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN166-001|Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-866949 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|July 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|7||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|January 24, 2011|July 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00949767||135412|
NCT00991107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE3286-0103|A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production|A Phase I, Open Label Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production When Administered Orally to Obese Insulin-Resistant Adult Subjects for 28 Days||Harbor Therapeutics|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 8, 2011|October 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991107||132285|
NCT00991445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAK-Incision|Minimal Versus Conventional Exposure in Unicompartmental Knee Arthroplasty|Minimal vs. Conventional Exposure in Unicompartmental Knee Arthroplasty||University Hospital Orebro|Yes|Recruiting|May 2009|September 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991445||132259|
NCT00991458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192371-018|Study of Cyclosporine in Post-LASIK Patients|Study of Cyclosporine in Post-LASIK Patients||Allergan|No|Completed|October 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|621|||Both|21 Years|50 Years|No|||July 2013|July 9, 2013|October 7, 2009|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT00991458||132258|
NCT00987649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-15|Ovarian Cancer Risk Estimation in Patients With Pelvic Mass|Evaluation of CA125 and HE4 Assays to Estimate the Risk of Ovarian Cancer in Patients Presenting to a General Surgeon or Obstetrician/Gynecologist With an Adnexal Mass||Fujirebio Diagnostics, Inc.|No|Completed|October 2009|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|512|Samples Without DNA|Serum, Plasma, Urine|Female|18 Years|N/A|No|Probability Sample|It is anticipated that approximately 10 general or specialty centers geographically        dispersed throughout the United States will be utilized.|February 2011|February 7, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987649||132551|
NCT00987610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-FORCE|Guidewire for Chronic Total Occlusion|Multicenter Prospective Randomized Study of First-choice Guidewires in Percutaneous Coronary Intervention for Chronic Total Occlusion|G-FORCE|Tokai University|Yes|Completed|October 2009|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Both|20 Years|N/A|No|||May 2015|May 1, 2015|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00987610||132554|
NCT00987623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-337-C-031|Clinical Evaluation of Two Daily Disposable Lenses in Neophytes|Clinical Evaluation of Two Daily Disposable Lenses in Neophytes||Alcon Research|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|326|||Both|N/A|45 Years|No|||January 2012|June 26, 2012|September 29, 2009|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT00987623||132553|
NCT00987844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-22|Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation|A Study to Evaluate the Long-Term Tolerability, Safety, Patient Satisfaction, Pharmacokinetics, and Use Patterns of Oral Prucalopride Tablets in Patients With Chronic Constipation||Movetis|No|Completed|July 1998|||November 2000|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1775|||Both|18 Years|N/A|No|||September 2009|September 30, 2009|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00987844||132536|
NCT00988325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP22849|A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection|An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to <12 Months of Age With Confirmed Influenza Infection||Hoffmann-La Roche||Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|58|||Both|N/A|12 Months|No|||October 2015|October 19, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988325||132499|
NCT00941824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808100|Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus Post Kidney Transplant: The Myfortic Study|Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus During the First 3 Months Post Kidney Transplant (the myFORTic Study)||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2010|March 24, 2010|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00941824||136021|
NCT00946894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN/501/ZKL/68/L|Outcomes of Different Thyroid Resections for Multinodular Non-toxic Goiter|Five-year Follow up of a Randomized Clinical Trial of Total Thyroidectomy Versus Dunhill Operation Versus Bilateral Subtotal Thyroidectomy for Multinodular Non-toxic Goiter.||Jagiellonian University|Yes|Completed|January 2000|December 2008|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|600|||Both|18 Years|65 Years|No|||July 2009|July 24, 2009|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT00946894||135633|
NCT00937690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13564|Pilot Study of Infrared Imaging of Cutaneous Melanoma|Pilot Study of Infrared Imaging of Cutaneous Melanoma|MEL49|University of Virginia|Yes|Completed|March 2008|||September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients and volunteers over the age of 18 with palpable cutaneous skin lesions. Patients        of all races and ethnic backgrounds are eligible. Efforts will be made to include        pigmented and non-pigmented lesions in participants with a range of skin colors, including        skin-colored papules in African-American and Hispanic patients when available.|December 2014|December 19, 2014|June 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00937690||136338|
NCT00937950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112024|Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects|Gynaecological Follow-up of a Subset of 580299/008 Study Subjects||GlaxoSmithKline||Completed|August 2009|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2022|||Female|18 Years|N/A|No|||September 2015|October 29, 2015|July 2, 2009|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT00937950||136318|
NCT00939120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110983|Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)|A Randomized, Double-blind, Placebo-controlled, Study of Safety and Efficacy of Dutasteride in Combination With Tolterodine ER or Placebo in Men With Lower Urinary Tract Symptoms (LUTS) Including Urgency and Frequency|LUTS|Siami, Paul F., M.D.|Yes|Completed|July 2009|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Male|50 Years|N/A|No|||April 2015|April 15, 2015|June 12, 2009|No|Yes||No|March 16, 2015|https://clinicaltrials.gov/show/NCT00939120||136228|
NCT00938509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor477208ctil|Ibuprofen Suppositories Administration in Infants and Children|Ibuprofen Suppositories Administration for Fever Treatment in Infants and Children||Soroka University Medical Center|Yes|Not yet recruiting|July 2009|December 2009|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|6 Months|12 Years|No|||July 2009|July 21, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938509||136275|
NCT00939133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2009-01|Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin|Double Blinded Vehicle Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Non-inflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients Post Oral Isotretinoin Use||Dermatrials Research|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|45 Years|No|||February 2015|February 9, 2015|July 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00939133||136227|
NCT00938834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2010-094|Qigong For Treatment Of Fibromyalgia|A Randomized Controlled Trial Of Qigong For Treatment Of Fibromyalgia||Nova Scotia Health Authority||Completed|August 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938834||136250|
NCT00938847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|996|Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration|Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration in Early Left Ventricular Dysfunction After Acute Myocardial Infarction And Successful Percutaneous Coronary Intervention||Asklepios proresearch|No|Completed|February 2006|October 2008|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|80 Years|No|||July 2009|July 13, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00938847||136249|
NCT00939146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011193|Outlook: An Intervention to Improve Quality of Life in Serious Illness|Outlook: An Intervention to Improve Quality of Life in Serious Illness||Duke University|No|Completed|February 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|154|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00939146||136226|
NCT00939159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0713|Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Phase II Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Terminated|August 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|July 10, 2009|Yes|Yes|Low Accrual|No|June 3, 2015|https://clinicaltrials.gov/show/NCT00939159||136225|Early termination leading to small numbers of subjects analyzed.
NCT00939172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0219|TTP607 in Refractory Solid Malignancies|An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies||M.D. Anderson Cancer Center|No|Withdrawn|March 2010|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|July 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00939172||136224|
NCT00939523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18129|Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy|Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy||Cedars-Sinai Medical Center|No|Recruiting|July 2009|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00939523||136198|
NCT00939536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/05/003|Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fasted Conditions|Studies in Fasted Healthy, Normal Subjects to Compare the Single Dose Bio-availability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets||Torrent Pharmaceuticals Limited|No|Completed|June 2005|July 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years||||August 2013|August 15, 2013|July 13, 2009||No||No|July 22, 2009|https://clinicaltrials.gov/show/NCT00939536||136197|
NCT00950001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0381|Resection Bed Post-Surgical Stereotactic Radiosurgery (SRS)|Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2009|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|3 Years|N/A|No|||February 2016|February 17, 2016|July 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00950001||135394|
NCT00950014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16783|Testing Numeric Formats for Presenting Data About Treatment Benefits and Harms|Testing Numeric Formats for Presenting Data About Treatment Benefits and Harms||White River Junction VAMC|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|5||Actual|2944|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|April 8, 2010|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950014||135393|
NCT00991471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226-2009|The Effect of an Physician-Nurse Supplementary Triage Assistance Team on Emergency Department Patient Wait Times|A Cluster Randomized Trial of the Effect of an Physician-Nurse Supplementary Triage Assistance Team (MDRN STAT) on Emergency Department Patient Wait Times|MDRNSTAT|Sunnybrook Health Sciences Centre|Yes|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|6300|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2012|October 25, 2012|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00991471||132257|
NCT00987402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH-PSW-ABHR|Study of the Efficacy of Plain Soap and Water Versus Alcohol-based Rubs for Surgical Hand Preparation|Surgical Site Infections: a Cluster-randomized, Cross-over Study of the Efficacy of Plain Soap and Water Versus Alcohol-based Rubs for Surgical Hand Preparation||University Hospital, Geneva|Yes|Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3317|||Both|N/A|N/A|No|||November 2009|August 20, 2012|September 30, 2009||No||No|October 7, 2009|https://clinicaltrials.gov/show/NCT00987402||132570|Most cases, post-discharge monitoring was not conducted by outpatient clinic visits following a standard protocol, some data was not collected, and routine microbiologic cultures were not obtained.
NCT00988624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451023|A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)|A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)||Pfizer|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 11, 2010|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00988624||132476|
NCT00987857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHS-GRH-HTA-05/12/01|Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus|Barrett's Oesophagus Two Yearly Surveillance Versus Endoscopy at Need: a Randomised Controlled Trial to Estimate Effectiveness and Cost-effectiveness Study (BOSS)||National Cancer Institute (NCI)||Recruiting|March 2009|||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2500|||Both|18 Years|N/A|No|||September 2009|August 9, 2013|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987857||132535|
NCT00987870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBFH772A2201|Safety and Efficacy of BFH772 in Psoriasis Patients|A Proof of Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Topical Administrations of BFH772 in Patients With Psoriasis.||Novartis||Completed|September 2009|||February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|15|||Both|18 Years|75 Years|No|||March 2011|March 25, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987870||132534|
NCT00988078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 2102/08|Effects of Metformin and Oral Hormonal Contraceptive in Adolescents With Polycystic Ovary Syndrome|Effect of Metformin Therapy on Insulin Resistance and Melatonin in Adolescents With Polycystic Ovary Syndrome.||Federal University of São Paulo|Yes|Recruiting|July 2011|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|11 Years|19 Years|Accepts Healthy Volunteers|||October 2009|June 24, 2012|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988078||132518|
NCT00988611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART Predictors Study|Assisted Reproductive Technology (ART) Predictors Study|Novel Predictors of ART Outcomes|ART|University of Oklahoma|No|Enrolling by invitation|September 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Telomere length assay|Female|18 Years|44 Years|No|Non-Probability Sample|Patients undergoing an ART treatment cycle at the OU Physicians Reproductive Health clinic        in Oklahoma City, Oklahoma will be approached regarding enrollment.        NOTE: Must be willing to travel to Oklahoma City to participate. Need to have the        transvaginal ultrasound and skin autofluorescence measurement at the OU Physicians        Reproductive Health Clinic in Oklahoma City, Oklahoma|May 2014|May 5, 2014|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988611||132477|
NCT00941837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMU R043/2008|Effect of Dietary Fat Type in Combination With High Protein on Plasma Homocysteine Levels|Effect of Dietary Fat Type in Combination With High Protein on Plasma Homocysteine Levels and Selected Markers of Cardiovascular Heart Disease Risk in Human Volunteers||Malaysia Palm Oil Board|No|Completed|February 2009|October 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|45|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 5, 2011|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941837||136020|
NCT00947453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009RESP01|Sputum Matrix Metalloproteinases (MMP) mRNA and Montelukast|The Effect of Montelukast Therapy on mRNA Profile of Matrix Metalloproteinases and Their Inhibitors in the Sputum of Patients With Asthma||University of East Anglia|No|Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|No|||August 2012|August 22, 2012|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947453||135590|
NCT00937963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE 103|Healthy Fatty Acids in Transition|Healthy FAT (Fatty Acids in Transition) Study|FAT|Penn State University|Yes|Completed|February 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||July 2009|May 6, 2010|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00937963||136317|
NCT00938210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBJ-1|Rehabilitation Following Laparoscopic Colonic Surgery|Changes in Fatigue and Physical Function Following Laparoscopic Colonic Surgery||Aarhus University Hospital|No|Completed|May 2009|August 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||August 2012|August 7, 2012|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938210||136298|
NCT00938223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8878|Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma|This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).|MEL39|University of Virginia|No|Active, not recruiting|August 2000|||November 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|85 Years|No|||December 2015|December 14, 2015|June 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938223||136297|
NCT00938535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2628|Community Based Obesity Prevention Among Black Women|Community Based Obesity Prevention Among Black Women||Duke University|No|Completed|November 2009|June 2014|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|194|||Female|25 Years|44 Years|No|||July 2014|July 28, 2014|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938535||136273|
NCT00948363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1335|The Effect of Kiwi on Blood Pressure, Endothelial Function, Antioxidant Capacity and Gene Expression|The Effect of Kiwi on Blood Pressure, Endothelial Function, Antioxidant Capacity and Gene Expression in Mildly Hypertensive Subjects||Oslo University Hospital|No|Completed|August 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|35 Years|69 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00948363||135520|
NCT00948649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805394|Effects of Chantix on Relapse Prevention for Smoking Cessation|Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence||University of Pennsylvania|No|Completed|September 2006|September 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Actual|62|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|August 16, 2010|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948649||135498|
NCT00948662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3276A1-1000|Study Evaluating The Safety And Tolerability Of Administration Of Single Oral Doses Of SAM-760 To Healthy Subjects|Ascending Single Dose Study Of The Safety, Tolerability And Pharmacokinetics Of SAM-760 Administered Orally To Healthy Young And Healthy Elderly Subjects||Pfizer|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 21, 2013|July 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00948662||135497|
NCT00948922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15697|Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma|Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|June 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948922||135477|
NCT00949208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-30|Development of Applications of the Given® Diagnostic System and Evaluation of Their Performance|Development of Applications of the Given® Diagnostic System and Evaluation of Their Performance||Medtronic - MITG|No|Recruiting|July 2008|March 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of healthy volunteers who fulfill all the inclusion        criteria and do not meet any of the exclusion criteria.|March 2016|March 2, 2016|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949208||135455|
NCT00949507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-209|Comparison of Two Regimens of Anesthesia for Children Undergoing Magnetic Resonance Imaging (MRI) in General Anesthesia|Comparison of Two Regimens of Anesthesia for Children Undergoing MRI in General Anesthesia. Advantages, Disadvantages and Time Consumption Regarding the Two Regimens.||Glostrup University Hospital, Copenhagen|Yes|Completed|October 2008|May 2011|Actual|May 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|1 Year|10 Years|No|Non-Probability Sample|120 children ASA 1-2 aged 1 to 10 yrs. scheduled for MRI in general anesthesia|May 2013|May 24, 2013|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949507||135432|
NCT00990821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-012|A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)|A Randomized, 5-Part, Intravenous Study of the Safety, Tolerability, Bioequivalence, and Drug Interaction Potential of Final Market Image Formulation of MK0517 in Young Healthy Subjects||Merck Sharp & Dohme Corp.||Completed|January 2005|January 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|14||Actual|188|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|October 6, 2009|No|Yes||No|April 9, 2010|https://clinicaltrials.gov/show/NCT00990821||132307|
NCT00991497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q2005/128|A Trial to Compare the Outcome of Localised Varicosity Compression for 24 Hours and 5 Days After Foam Sclerotherapy to Truncal Varices|A Randomised Controlled Trial to Compare the Outcome of Localised Varicosity Compression for 24 Hours and 5 Days After Foam Sclerotherapy to Truncal Varices||Gloucestershire Hospitals NHS Foundation Trust|Yes|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991497||132255|
NCT00987415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020011|Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels|Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients|EXACT-HF|Duke University|Yes|Completed|May 2010|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|September 30, 2009|Yes|Yes||No|October 14, 2014|https://clinicaltrials.gov/show/NCT00987415||132569|
NCT00988637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10144|Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis|An Open-label, Multi-center, Randomized, Evaluator-Blinded Study to Evaluate the Safety and Efficacy of Two Treatment Regimens Involving Vectical™ (Calcitriol) Ointment 3 µg/g and Clobex® (Clobetasol Propionate) Spray, 0.05% in the Treatment of Moderate Plaque Psoriasis||Galderma Laboratories, L.P.|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|80 Years|No|||September 2012|September 21, 2012|October 1, 2009||No||No|March 30, 2011|https://clinicaltrials.gov/show/NCT00988637||132475|
NCT00987883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-DPEN-09001|The Impact of Perioperational Malnutrition on the Cost on Gastroenterological Cancer Patients|Malnutrition and Its Impact on the Perioperational Hospitalization Cost: A Prospective, Cohort Study on Gastroenterological Cancer Patients||Peking Union Medical College Hospital|Yes|Recruiting|April 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Hospitalization patient in a teaching hospital|September 2009|September 30, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987883||132533|
NCT00988091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-03|Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee|A 26 Week, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Single Intra-Articular Injection 1.2% Sodium Hyaluronate for Treatment of Painful Osteoarthritis of the Knee, With Optional 26-Week Open-Label Safety Extension||Ferring Pharmaceuticals|No|Completed|September 2009|April 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|596|||Both|40 Years|N/A|No|||June 2012|June 13, 2012|September 29, 2009|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT00988091||132517|
NCT00988338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TY01AF|Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion|A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells (Trinity Evolution Matrix) in Subjects Undergoing Foot and Ankle Fusion|TAF|Orthofix Inc.|No|Completed|September 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00988338||132498|
NCT00989521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-1V2|Effect of PUR003 on Asthma|Double-blind, Placebo-controlled Crossover Evaluation of the Effect of PUR003 on Subjects With Asthma||Pulmatrix Inc.|No|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|60 Years|No|||November 2011|November 21, 2011|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989521||132407|
NCT00939198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-06-01|Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil|Determination of Prevalence and Intensity of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Northeastern Minas Gerais, Brazil||Albert B. Sabin Vaccine Institute|No|Completed|August 2009|December 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|87|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|July 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00939198||136222|
NCT00937976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPU082008|Treatment for Periodontal Disease in Dialysis Patients|Impact of Periodontal Therapy on Metabolic and Inflammatory Markers in Chronic Kidney Disease Patients|KPU|University of North Carolina, Chapel Hill|No|Completed|August 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||May 2012|May 4, 2012|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937976||136316|
NCT00938236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIS002|CIS001 Extension Study of Cyclosporine Inhalation Solution|CIS002: An Open-Label, Multi-Center, Extension Study of Cyclosporine Inhalation Solution in Subjects Previously Enrolled in the APT Study CIS001|CIS002|APT Pharmaceuticals, Inc.|Yes|Terminated|December 2009|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|July 9, 2009|No|Yes|Parent study CIS001 was completed|No||https://clinicaltrials.gov/show/NCT00938236||136296|
NCT00938249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-146|Effects of Monascus Garlic Fermented Extract on Serum Triglyceride Level|Effects of Monascus Garlic Fermented Extract on Serum Triglyceride Level: a Double-Blind, Randomized Controlled Trial||Hiroshima University||Completed|July 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2010|April 23, 2010|July 10, 2009||||No||https://clinicaltrials.gov/show/NCT00938249||136295|
NCT00947739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST CZ48-01|Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma|Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma||New Mexico Cancer Care Alliance|Yes|Completed|September 2008|March 2014|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|15||Actual|43|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947739||135568|
NCT00947752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM033|Safety of New Formulation of Glatiramer Acetate|An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection|Song|Teva Pharmaceutical Industries|No|Completed|July 2009|November 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|N/A|No|||May 2011|May 10, 2011|July 25, 2009|Yes|Yes||No|September 28, 2010|https://clinicaltrials.gov/show/NCT00947752||135567|Blinding in this study was not possible due to the subjects' ability to detect difference in the volume of each formulation. The lack of blinding was a known limitation.
NCT00948064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0685|Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)|A Phase 2 Trial of Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Who Are Ineligible for Other Leukemia Protocols||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2009|||April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|July 28, 2009||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT00948064||135543|
NCT00948935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 06208|Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma|Phase II Combination of Gemcitabine (Fixed Dose-rate Infusion, FDR), Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma||University of Pennsylvania|Yes|Active, not recruiting|April 2009|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||December 2011|February 6, 2013|May 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948935||135476|
NCT00948948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0005033|Mentor Adjunct Study for Silicone Gel-Filled Mammary Prosthesis|Mentor Adjunct Study for Silicone Gel-Filled Mammary Prosthesis|Adjunct|Mentor Worldwide, LLC||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Female|18 Years|N/A||||April 2013|April 3, 2013|July 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948948||135475|
NCT00949221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070152|Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!)|Evaluation of Long-term Efficacy of 2 Strategies of Real Time Continuous Glucose Monitoring, Compared to Self BG-monitoring in Children and Adolescent With Type 1 Diabetes: a Randomized, Multicenter, Open Trial|START-IN|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2009|July 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|2 Years|18 Years|No|||July 2012|July 26, 2012|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949221||135454|
NCT00949520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/12|Stress Multidetector Computed Tomography (MDCT) an New Diagnostic Tool for Myocardial Disease|Dual Source Computed Tomography (DSCT) During Injection of Dipyridamole : a New Technique for Myocardial Ischemia Assessment||Assistance Publique Hopitaux De Marseille|No|Completed|July 2009|||November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00949520||135431|
NCT00949780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCSP-HC|Chloral Hydrate to Perform Auditory Brainstem Response (ABR)|Use of Chloral Hydrate to Perform Auditory Brainstem Response (ABR)||Pontificia Universidade Catolica de Sao Paulo|No|Completed|October 2007|October 2008|Actual|March 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|41|||Both|1 Year|11 Years|No|||July 2009|July 30, 2009|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00949780||135411|
NCT00941304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP-201|Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain|A Double-Blind, Double-Dummy, Placebo- and Active Controlled Evaluation of the Efficacy, Safety and Tolerability of Buprenorphine HCl Buccal Film in the Treatment of Pain Associated With Third Molar Extraction||Endo Pharmaceuticals|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|153|||Both|18 Years|45 Years|No|||January 2016|January 4, 2016|July 15, 2009|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT00941304||136061|
NCT00990834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCAST|Muscle Characteristics Associated With Statin Therapy|Muscle Characteristics Associated With Statin Therapy||Scripps Health|Yes|Withdrawn|November 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|October 5, 2009||No|Unable to recruit subjects.|No||https://clinicaltrials.gov/show/NCT00990834||132306|
NCT00988104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A070045|Preventing Long Term Psychiatric Disability Among Those With Major Burn Injuries|Safety, Meaning, Activation and Resilience Trial (SMART)||Johns Hopkins University|No|Active, not recruiting|October 2007|November 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|18 Years|70 Years|No|||September 2015|September 1, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988104||132516|
NCT00988351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFIRB#384-09|Continuous Positive Airway Pressure (PAP) Titration and Treatment Versus Auto-adjusting PAP Treatment for Sleep Apnea|Portable Monitoring and APAP Treatment for Diagnosis and Treatment of OSA||North Florida Foundation for Research and Education|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|21 Years|89 Years|No|||October 2014|October 30, 2014|October 1, 2009||No||No|March 23, 2014|https://clinicaltrials.gov/show/NCT00988351||132497|Carefully selected group with male predominance
NCT00988923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1198/07|Hyperthermia As A Conservative Treatment For Carpal Tunnel Syndrome. A Randomized "Sham" Controlled Trial|Hyperthermia As A Conservative Treatment For Carpal Tunnel Syndrome. A Randomized "Sham" Controlled Trial||Catholic University of the Sacred Heart|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|45 Years|75 Years|No|||October 2009|October 1, 2009|June 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00988923||132453|
NCT00989248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPESq 0532/08|Comparative Study of Cardiopulmonary Exercise Test Land Versus Water|Comparative Study of Cardiopulmonary Exercise Test on Land and Underwater in Patients With Congestive Heart Failure|CHF|University of Sao Paulo General Hospital|Yes|Recruiting|April 2011|July 2012|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|90|||Both|55 Years|75 Years|No|||April 2011|April 27, 2011|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989248||132428|
NCT00989261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC220-002|Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)|Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations|ACE|Daiichi Sankyo Inc.|Yes|Completed|November 2009|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|85 Years|No|||November 2015|November 11, 2015|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00989261||132427|
NCT00989807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA-US-205-0122|Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis|Expanded Access for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression|EAP|Gilead Sciences||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|6 Years|N/A||||October 2012|December 12, 2012|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989807||132385|
NCT00942084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028772|A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)|An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants||Duke University|Yes|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|N/A|45 Days|No|||November 2013|November 19, 2013|July 17, 2009|No|Yes||No|August 27, 2013|https://clinicaltrials.gov/show/NCT00942084||136001|
NCT00942097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAM-01082009|Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder|Homeopathic Treatment in Pregnant Women With Overweight and Mental Disorder: a Double Blinded Controlled Clinical Trial||University of Sao Paulo|No|Completed|August 2009|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 8, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00942097||136000|
NCT00947193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-011-HEM|Study of Ataluren (PTC124®) in Hemophilia A and B|A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B||PTC Therapeutics|No|Suspended|August 2009|May 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||October 2011|October 31, 2011|July 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947193||135610|
NCT00947440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-056|Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation|An Open-Label, Randomized, Crossover Study to Evaluate the Bioavailability of Two Candidate Tablet Formulations of ABT-072 With Reference to the Capsule Formulation||Abbott|No|Completed|July 2009|||August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|October 19, 2010|July 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947440||135591|
NCT00947726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK7676 (completed)|Ceramide Containing Multivesicular Emulsion Application . . .|Ceramide Containing Multivesicular Emulsion Application as a Skin Hydration Treatment for Feet of Subjects With Non-insulin Dependent Diabetes Mellitus.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|July 2009|||October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|July 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00947726||135569|
NCT00948376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060223|Natural History of Asphyxiating Thoracic Dystrophy (DTJ)|Clinical and Molecular Study, Natural History of Asphyxiating Thoracic Dystrophy (DTJ)|DTJ|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|Samples With DNA|phenotype-genotype|Both|N/A|N/A|No|Non-Probability Sample|Patients with:          -  Short ribs with narrow thorax          -  Trident acetabular roof          -  Short hands|June 2011|December 12, 2011|July 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00948376||135519|
NCT00948675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13258|Study of Participants With Advanced Non-Small Cell Lung Cancer|A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquamous Histology||Eli Lilly and Company|No|Active, not recruiting|September 2009|June 2016|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|361|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 28, 2009|Yes|Yes||No|January 14, 2014|https://clinicaltrials.gov/show/NCT00948675||135496|
NCT00940693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.008|Pilot Study of Duloxetine in Adult Attention Deficit Hyperactivity Disorder(ADHD)|Pilot Study of the Efficacy of Duloxetine in Treating Adults With Attention Deficit Hyperactivity Disorder: a Randomized, Controlled Trial.||Université de Montréal|No|Completed|August 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||December 2010|December 13, 2010|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940693||136108|
NCT00940706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481987103/09|Promotion of a Physically Active Lifestyle in Cerebral Palsy|"Promotion of a Physically Active Lifestyle in Large Populations of Children and Teenagers With Cerebral Palsy in the Middle East"||Assaf-Harofeh Medical Center|Yes|Enrolling by invitation|March 2010|September 2013|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|120|||Both|14 Years|20 Years|No|||July 2009|September 27, 2011|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940706||136107|
NCT00940979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC 625-230609|Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities|Prospective Randomised Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities|ITT|Rijnstate Hospital||Terminated|January 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|July 16, 2009|||Interim analyses showed insufficient result. Termination for reasons of futility|No||https://clinicaltrials.gov/show/NCT00940979||136086|
NCT00940992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGT DER 45 EV 09|A Study of DER 45-EV Gel to Treat Rosacea|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Range Study of DER 45 EV Gel, 1% and 5%, and Vehicle Gel in the Treatment of Rosacea|SGTDER45EV|Sol-Gel Technologies, Ltd.|Yes|Completed|January 2012|January 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|July 14, 2009|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT00940992||136085|
NCT00941291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Macular hole 1|Outcome of Idiopathic Macular Hole|Long-term Outcome of Idiopathic Macular Hole Surgery||Centre Hospitalier Universitaire Dijon|No|Completed|January 2002|January 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|135|||Both|18 Years|90 Years|No|Non-Probability Sample|One hundred and thirty patients (135 eyes) with stage 2, 3, or 4 IMH were included after        successful IMH repair|July 2009|July 16, 2009|March 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00941291||136062|
NCT00941577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR645-CS2|Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma|A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Bronchial Allergen Challenge Study to Assess the Safety, Tolerability, and Efficacy of Inhaled AIR645 in Subjects With Mild Allergic Asthma||Altair Therapeutics, Inc.|No|Completed|October 2009|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||July 2010|July 21, 2010|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00941577||136040|
NCT00941590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POST-KME|Postencephalitic Symptoms After Tick Borne Encephalitis|Postencephalitic Symptoms After Tick Borne Encephalitis||University Medical Centre Ljubljana|No|Not yet recruiting|July 2009|||October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients with tick borne encephalitis|July 2009|July 16, 2009|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941590||136039|
NCT00991133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO08808|A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)|A Phase 1, Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) in First Relapse||Sanofi|Yes|Completed|October 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|1 Year|30 Years|No|||April 2015|April 29, 2015|October 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00991133||132283|
NCT00991159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481001|A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating, Intravenous Doses Of RN316 (PF-04950615) In Healthy Adult Subjects||Pfizer|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|October 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00991159||132281|
NCT00988117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA7 13D US45T|The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems|The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)||University of California, San Francisco|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|55 Years|N/A|No|||January 2014|January 24, 2014|September 29, 2009|Yes|Yes||No|July 28, 2013|https://clinicaltrials.gov/show/NCT00988117||132515|
NCT00988364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-123|Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.|Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome||Baylor College of Medicine|Yes|Not yet recruiting|October 2009|July 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00988364||132496|
NCT00989274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI:863, No. 777|Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1|Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Pandemic Influenza A/H1N1 Produced by Sanofi||Instituto Nacional de Salud Publica, Mexico|Yes|Withdrawn|June 2010|July 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|60 Years|No|||March 2012|March 28, 2012|October 2, 2009||No|Late approval by the Secretariat of Health, and expiration of vaccine|No||https://clinicaltrials.gov/show/NCT00989274||132426|
NCT00989287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113866|Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years||GlaxoSmithKline||Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|131|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00989287||132425|
NCT00988936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5-101|Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug|A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug|K5-101|Siemens Molecular Imaging|No|Completed|September 2009|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|35|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00988936||132452|
NCT00989534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11403A|Extended Work Schedules, Sleep Loss and Health|Extended Work Schedules and Health: Role of Sleep Loss|EW and EWD|University of Chicago|No|Completed|January 2003|September 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|21 Years|39 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989534||132406|
NCT00990119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-2009-03|High Flow Therapy (HFT) to Treat Respiratory Insufficiency in Chronic Obstructive Pulmonary Disease (COPD)|Vapotherm High Flow Therapy Via Nasal Cannula to Treat Respiratory Insufficiency in Patients With Chronic Obstructive Pulmonary Disease||Vapotherm, Inc.|No|Suspended|September 2009|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|N/A|No|||February 2014|February 26, 2014|August 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990119||132361|
NCT00950794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112376|Study of Salmeterol (SN408D) for Adult Asthma|Study of Salmeterol (SN408D) for Adult Asthma - Clinical Study of Salmeterol Compared With Hokunalin (Tulobuterol) Tape -||GlaxoSmithKline||Completed|September 2003|February 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|367|||Both|15 Years|N/A|No|||August 2009|August 6, 2009|July 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00950794||135333|
NCT00951093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTROBESE-004|Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass|The Impact of Gastric Bypass on Gastroesophageal Reflux Disease in Patients With Morbid Obesity: a Prospective Study Based on Montreal Consensus||Clinica Gastrobese|No|Completed|March 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|70 Years|No|Non-Probability Sample|Primary care clinic patients|February 2014|February 25, 2014|August 2, 2009||No||No|December 4, 2013|https://clinicaltrials.gov/show/NCT00951093||135310|
NCT00939575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-173|Pre-eclampsia and Metabolomics|Feasibility Study to Develop Analysis of the Metabolomics Patterns of Women With Hypertensive Disorders During Pregnancy.|GEM-1|Université de Sherbrooke|No|Active, not recruiting|March 2009|March 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Whole blood and urine are collected|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|women who deliver at the CHUS|March 2015|March 3, 2015|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939575||136194|
NCT00939588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPV100A2225|Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients|An 8 Week, Double-blind, Randomized, Parallel-group Study to Compare the Effect of Aliskiren 300mg + Valsartan 320mg vs. Telmisartan 80mg + Ramipril 10mg on Biomarkers of the Renin-angiotensin-aldosterone System in Moderate Hypertension||Novartis||Completed|July 2009|||December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|88|||Both|18 Years|65 Years|No|||February 2010|February 15, 2010|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00939588||136193|
NCT00947765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lateralepicondylitis- ChetanMD|A Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis|Phase 2/Phase 3 of the Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis.||Dojode, Chetan M., MBBS, MS|Yes|Completed|January 2007|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||October 2009|July 27, 2010|July 27, 2009||No||No|May 27, 2010|https://clinicaltrials.gov/show/NCT00947765||135566|
NCT00948077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009WFCRC-08|Pharmacokinetic Study for Anti-tuberculosis Drugs|A Single-Center, Open-Label, Randomized, Crossover Design Study to Evaluate the Effect of Dietary Status on Pharmacokinetic Profile of Orally Administered First-Line Anti-TB Drugs in Subjects With Pulmonary Tuberculosis|TBPK|Taipei Medical University WanFang Hospital|No|Recruiting|July 2009|December 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Both|20 Years|N/A|No|||April 2011|April 11, 2011|June 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00948077||135542|
NCT00940381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0226|Sirolimus and Cetuximab in Advanced Malignancies|A Phase I Trial of Sirolimus and Cetuximab in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Completed|July 2009|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Both|18 Years|N/A|No|||May 2014|November 16, 2015|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940381||136132|
NCT00940394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216020|Effectiveness of Family Group Interventions for People With Schizophrenia|Evaluation of the Effects of Mutual Support and Psycho-educational Group Interventions for Family Caregivers of People With Schizophrenia|MSG|The Hong Kong Polytechnic University|Yes|Completed|January 2007|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|128|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940394||136131|
NCT00940719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUMC09T43|Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)|The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot Study||Maastricht University Medical Center|No|Completed|August 2009|July 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|N/A|No|||August 2010|August 10, 2010|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940719||136106|
NCT00940732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/373|The Elite Athlete Mental Health Strategy Trial|The Elite Athlete Mental Health Strategy: A Randomised Controlled Trial of an Online Intervention for the Mental Health Help-Seeking of Elite Athletes|TEAMS|Australian National University|Yes|Completed|November 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940732||136105|
NCT00941005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0100|The Effect of Electroacustimulation on Postoperative Nausea, Vomiting and Pain in Outpatient Plastic Surgery Patients|The Effect of Electroacustimulation on Postoperative Nausea, Vomiting and Pain in Outpatient Plastic Surgery Patients: A Prospective, Randomized, Blinded Clinical Trial||University of Wisconsin, Madison|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|122|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2009|July 16, 2009|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941005||136084|
NCT00941018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-10001-002|Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers|A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers||Resolvyx Pharmaceuticals, Inc|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 1, 2009|July 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00941018||136083|
NCT00941317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.CIP.18157|Single-blind Evaluation of Device to Nail Micro-drilling in Onychomycosis|A Single-blind Evaluation of Device Performance and Tolerability to Nail Micro-drilling in Subjects With Onychomycosis||Galderma|No|Completed|July 2009|September 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|July 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00941317||136060|
NCT00941616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-BIO-08-54|Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease|An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Biostate® in Subjects With Von Willebrand Disease.||CSL Behring|Yes|Completed|June 2009|February 2012|Actual|||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|22|||Both|12 Years|N/A|No|||April 2013|April 4, 2013|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941616||136037|
NCT00991484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2009-123|Collagen Analysis and Genetic Analysis of Families With Tendency to Hernias|Collagen-subtype Analysis in Subcutaneous Tissue and Genetic Analysis on Patients From Families With a Tendency to Hernias||Herlev Hospital|No|Recruiting|December 2009|June 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|blood samples and subcutaneous tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients in Denmark operated or diagnosed with hernias who are member of a family with        tendency to hernias.|October 2010|October 12, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991484||132256|
NCT00987896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|megachannel|Megachannel Device for Advanced Colonoscopy|A Novel Endoscopic Device (Megachannel™) For Repeated Right Colonic Access During Colonoscopy||Medical University of Vienna|No|Completed|November 2007|October 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|41|||Both|18 Years|N/A|No|||September 2009|September 30, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987896||132532|
NCT00988377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kraft_whey protein: study 1|The Effect of Whey Protein on Short-Term Food Intake and Post-Meal Blood Glucose Response in Young Men|The Effect of Whey Protein on Short-term Food Intake and Post-meal Blood Glucose Response in Young Men||University of Toronto|Yes|Completed|May 2007|November 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|16|||Male|20 Years|27 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988377||132495|
NCT00988949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1071004|Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release|Phase I, Randomized, Placebo Controlled Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release In Healthy Male Adult Subjects||Pfizer|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 5, 2010|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00988949||132451|
NCT00988988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|399-09-FB|The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections|The Effects of Ethyl-alpha-Guanido-methyl Ethanoate on Skin Reactions Form Glatiramer Acetate||University of Nebraska|No|Withdrawn|February 2010|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|19 Years|65 Years|No|||August 2011|August 2, 2011|September 30, 2009||No|Not approved by IRB|No||https://clinicaltrials.gov/show/NCT00988988||132448|
NCT00989001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6621-045|A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)|A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation|ACT V|Cardiome Pharma|Yes|Terminated|October 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|85 Years|No|||February 2014|February 6, 2014|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00989001||132447|
NCT00989547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|593|Cord Blood Infusion for Type 1 Diabetes Mellitus (T1DM)|Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study.||Technische Universität München|Yes|Active, not recruiting|September 2008|||September 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|1 Year|N/A||||July 2013|July 22, 2013|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989547||132405|
NCT00989820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL20963.091.08|Efficacy of Hyperbaric Oxygen Therapy in the Treatment of Osteoradionecrosis|Efficacy of Adding Hyperbaric Oxygen Therapy to the Treatment of Late Radiation Damage of the Lower Jaw (Osteoradionecrosis).||Radboud University|Yes|Recruiting|October 2009|October 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00989820||132384|
NCT00989560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC-A 077/09|Post-operative Crohn's Endoscopic Recurrence Study|Post-Operative Crohn's Disease Endoscopic Recurrence "POCER" Study: Endoscopic Guided Therapeutic Intervention & Determination of Cause|POCER|University of Melbourne|Yes|Completed|August 2009|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|175|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989560||132404|
NCT00989573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-08-001|A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease|A Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease||Otsuka Pharmaceutical Co., Ltd.|No|Completed|October 2009|August 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|191|||Both|18 Years|64 Years|No|||February 2013|February 19, 2013|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989573||132403|
NCT00947206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA138778-01A1|Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans|Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans||University of California, San Francisco|No|Completed|September 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|909|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00947206||135609|
NCT00939237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000202 BWH|Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease|Trial of Ateronon for Carotid Atherosclerosis and Biomarkers in Patients With Stable Coronary Heart Disease||Brigham and Women's Hospital|Yes|Completed|July 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|50 Years|N/A|No|||August 2014|August 15, 2014|July 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00939237||136219|
NCT00939861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13072009|Laparoscopy Versus Laparotomy for Colorectal Endometriosis|Study Comparing Laparoscopy Versus Laparotomy in the Treatment of Colorectal Endometriosis||Tenon Hospital, Paris|No|Active, not recruiting|January 2006|September 2009|Anticipated|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Female|18 Years|50 Years|No|||July 2009|July 14, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939861||136172|
NCT00940095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-054-302|Clazosentan in Aneurysmal Subarachnoid Hemorrhage|A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Endovascular Coiling.|CONSCIOUS-3|Actelion|Yes|Terminated|July 2009|January 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|577|||Both|18 Years|75 Years|No|||April 2015|April 28, 2015|July 13, 2009|Yes|Yes|Lack of efficacy data from the Phase 3 clinical study (AC-054-301; CONSCIOUS-2)|No||https://clinicaltrials.gov/show/NCT00940095||136154|
NCT00940108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-CAL-09-60|A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children|A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months to < 9 Years.||CSL Limited|Yes|Completed|August 2009|April 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|370|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|July 13, 2009||No||No|July 9, 2013|https://clinicaltrials.gov/show/NCT00940108||136153|
NCT00940407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPRPA 08001|Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration|A Pilot Study to Evaluate Clinical Outcomes of Photobiomodulation in Patients With Age Related Macular Degeneration of the Dry Type.|TORPA|Merry, Graham, M.D.|Yes|Completed|January 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|50 Years|N/A|No|||November 2011|November 16, 2011|July 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940407||136130|
NCT00940420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16837|A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C|Safety and Tolerability of Ribavirin (Ro 20-9963) in Combination With Peginterferon Alfa in Patients With Chronic Hepatitis C||Hoffmann-La Roche||Completed|October 2002|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2695|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00940420||136129|
NCT00940433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 90713|Hernia Repair Four Arm Comparative Study|Four Arm Randomised Trial Comparing Laparoscopic And Open Hernia Repairs||Faculty of Medicine, University of Alexandria|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|100|||Male|N/A|N/A|No|||January 2010|January 14, 2010|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940433||136128|
NCT00940745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009JX4A03|Modified Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage:a Multi-center Controlled Study|Modified Stereotactic Aspiration and Thrombolysis of Spontaneous Intracerebral Hemorrhage|MSATIH|Huazhong University of Science and Technology|Yes|Not yet recruiting|July 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2009|July 15, 2009|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940745||136104|
NCT00941031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2211|AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis|A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis||Novartis|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|404|||Both|18 Years|N/A|No|||March 2015|July 30, 2015|July 16, 2009|Yes|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT00941031||136082|
NCT00941044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK BE 062/09|Non-invasive Neurally Adjusted Ventilatory Assist in Healthy Volunteers|Unloading of the Respiratory Muscles Using Non-invasive Neurally Adjusted Ventilatory Assist in Healthy, Resistively Loaded Volunteers||University Hospital Inselspital, Berne|No|Completed|July 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941044||136081|
NCT00941330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012969|Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers|Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)||Emory University|No|Completed|July 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00941330||136059|
NCT00987909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-C-01|Exposure Chamber Trial With Cat Immunotherapy|A Phase II Trial Assessing the Tolerability and Pharmacodynamic Effect of US SLIT Cat Hair in Subject With Cat Allergy and Investigating Efficacy Variables in an Environmental Exposure Chamber Model||ALK-Abelló A/S|Yes|Completed|September 2009|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|65 Years|No|||August 2010|August 17, 2010|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00987909||132531|
NCT00988390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TALKLA-MH068194|Mothers Living With HIV and Their Adolescent Children|Mothers Living With HIV and Their Adolescent Children|TALK LA|University of California, Los Angeles|No|Completed|February 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|543|||Female|18 Years|N/A|No|||October 2009|October 14, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988390||132494|
NCT00989339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00019153|Effects of Intralipid Versus Olive Oil Infusions on Endothelial Function, Immune Function, Inflammatory Markers|Effects of Intralipid and Olive Oil Infusion on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function, Autonomic Nervous System, Insulin Sensitivity and Carbohydrate Metabolism||Emory University|Yes|Withdrawn|November 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|July 2, 2014|October 2, 2009|No|Yes|Sub-investigator left facility prior to study initiation|No||https://clinicaltrials.gov/show/NCT00989339||132421|
NCT00988650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2006-277|Mediterranean Diet and the Metabolic Syndrome|Mechanistic Investigation of the Mediterranean Diet and Its Impact on the Metabolic Syndrome in Men|MedDiet|Laval University|No|Completed|May 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|26|||Male|18 Years|65 Years|No|||March 2013|March 4, 2013|September 25, 2009||No||No||https://clinicaltrials.gov/show/NCT00988650||132474|
NCT00988663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Memantine ECT trial|The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?|Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression|ECTAug|University of Iowa|Yes|Not yet recruiting|November 2009|May 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988663||132473|
NCT00988962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p001732|Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy|Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy||Brigham and Women's Hospital|No|Completed|July 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988962||132450|
NCT00988975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-046|Trial to Determine Which of Two Surgical Techniques Works Better to Correct Vaginal Bulging|Does Pelvicol Graft in the Posterior Compartment Offer Any Benefit to Surgical Outcomes During Laparoscopic Sacral Colpoperineopexy?||Urogynecology Associates, Indiana|No|Recruiting|September 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 1, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988975||132449|
NCT00989300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016333|Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel|Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel. A Prospective, placebo-and Active Treatment-controlled, Open Label, Randomized 3-way Cross Over Study in Healthy Subjects|CLARA|Janssen Cilag S.A.S.|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 19, 2012|October 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989300||132424|
NCT00990431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK_05_2009|Ablative Fractional Lasers to Treat Peri-orbital Rhytides|Ablative Fractional Lasers (CO2 and Er:YAG): A Randomized Controlled Blinded Split-face Trial of the Treatment of Peri-orbital Rhytides||Laserklinik Karlsruhe|No|Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990431||132337|
NCT00938899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012610|TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing|Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.||Tibotec Pharmaceuticals, Ireland||Completed|January 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|N/A|||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|May 18, 2011|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938899||136245|
NCT00941057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13469|Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium|Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV), Dienogest (DNG) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 2 mg Estradiol Valerate and 3 mg Dienogest Without and With 0.451 mg Levomefolate Calcium and a Tablet Formulation Containing 0.451 mg Levomefolate Calcium in 42 Healthy Postmenopausal Women||Bayer|No|Completed|September 2009|January 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 9, 2013|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941057||136080|
NCT00941070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02896|Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer|A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer||National Cancer Institute (NCI)||Completed|July 2009|July 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||December 2012|April 21, 2014|July 16, 2009|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT00941070||136079|
NCT00939874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROP|Switch From Tenofovir to Raltegravir for Low Bone Mineral Density|Switch From Tenofovir to Raltegravir for Low Bone Mineral Density|TROP|St Vincent's Hospital, Sydney|Yes|Completed|October 2009|April 2014|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|July 14, 2009||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT00939874||136171|
NCT00940121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-076|Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron|A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Assess the Pharmacokinetics of Mirabegron OCAS Formulations With Different Release Rates Versus IV Infusion in Healthy Volunteers||Astellas Pharma Inc|No|Completed|April 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|91|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|July 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940121||136152|
NCT00940134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B262|Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.|INGEAR-1: Effects of INtravenous Infusions of PYY3-36 and GLP-1, as Monoinfusion and in Combination, on ad Libitum Energy Intake, Appetite Sensation, and Energy Expenditure in Healthy Obese Subjects.|INGEAR-1|University of Copenhagen|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940134||136151|
NCT00940147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_01|Early Endoscopic Indicators for OACs After Lung Transplantation: Development of a Novel Mucosal Healing Score|Early Indicators for Obstructive Airway Complications After Lung|OAC|Hannover Medical School|Yes|Completed|January 2007|August 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|180|||Both|18 Years|80 Years|No|Probability Sample|LTx 01.2007-05.2009|June 2013|June 5, 2013|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940147||136150|
NCT00940160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2107|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients|A Randomized, Double Blind, Placebo Controlled, Study To Compare The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of Intravenous Administration Of QAX576 In Controlled Or Partially Controlled Asthma Patients||Novartis||Completed|July 2009|||January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|65 Years|No|||January 2010|January 20, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940160||136149|
NCT00940173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCT/DIA-06|Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) in Patients With Type I Diabetes Mellitus|A Phase I/IIa Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type I Diabetes Mellitus||Living Cell Technologies|Yes|Completed|July 2009|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|35 Years|65 Years|No|||February 2014|February 20, 2014|July 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940173||136148|
NCT00941941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/HD11/6219U|Non-Mesh Versus Mesh Method for Inguinal Hernia Repair|Comparison of Non-mesh (Desarda) and Mesh (Lichtenstein) Methods for Inguinal Hernia Repair at Mulago Hospital: a Double-blind Randomised Controlled Trial|IHR|Makerere University|Yes|Active, not recruiting|May 2009|September 2009|Anticipated|August 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||July 2009|July 16, 2009|July 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00941941||136012|
NCT00941694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N011060|Asthma Self-Management in Older Adults|Asthma Self-Management in Older Adults||University of Michigan|No|Completed|July 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|65 Years|N/A|No|||January 2013|January 15, 2013|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00941694||136031|
NCT00937560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22225|A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer|A Single-arm Phase II Clinical Study Investigating the Addition of Bevacizumab to Carboplatin and Weekly Paclitaxel as First-line Treatment in Patients With Epithelial Ovarian Cancer||Hoffmann-La Roche||Completed|June 2009|July 2013|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Female|18 Years|N/A|No|||February 2015|February 9, 2015|July 6, 2009||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00937560||136348|
NCT00937573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACS-6814|Xience V at Wake Forest University Baptist Medical Center (WFUBMC)|Xience V at WFUBMC: Real World Outcomes Using Second Generation DES||Wake Forest School of Medicine|No|Completed|July 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|59|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with coronary artery disease seen at WFUBMC cardiac catheterization laboratory who        received percutaneous coronary intervention with placement of one or more stents|December 2014|December 8, 2014|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937573||136347|
NCT00937807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-8-09-A-401|Hemodynamic Stability During Carotid Endarterectomy.Comparison of LENOXe™ (Xenon 100% v/v) Versus Sevoflurane|Hemodynamic Stability During Carotid Endarterectomy Under General Anesthesia in Elderly Patients: Comparison LENOXe™ (xénon 100% v/v) Versus SEVOFLURANE||Air Liquide Santé International|No|Completed|July 2009|April 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|84|||Both|55 Years|N/A|No|||June 2010|June 29, 2010|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937807||136329|
NCT00937820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-104|Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism|YM150 Long Term Study - Long-term Study in Patients With a History of Venous Thromboembolism||Astellas Pharma Inc|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|87|||Both|20 Years|N/A|No|||January 2011|January 5, 2011|July 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00937820||136328|
NCT00937833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-015|Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling|Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling||Cook||Completed|November 2009|November 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|150|||Male|18 Years|N/A|No|||December 2014|December 23, 2014|July 10, 2009|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT00937833||136327|
NCT00988130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000652331|High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer|HIFU Lesion Control in Patients With Non-metastatic Progressive Prostate Cancer||National Cancer Institute (NCI)||Recruiting|July 2009|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Male|N/A|N/A|No|||May 2011|August 23, 2013|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988130||132514|
NCT00988676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1010135|The Effect of Bowel Preparation Status on the Polyp Missing Rate|The Effect of Bowel Preparation Status on the Polyp Missing Rate During Colonoscopy: Prospective Study Using Tandem Colonoscopic Evaluation||Konkuk University Hospital|Yes|Completed|May 2009|March 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The patients underwent colonoscopy and 2nd stage colonoscopic polypectomy at Konkuk        University Medical Center|October 2009|April 19, 2010|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988676||132472|
NCT00989352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00591|Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma|Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy|PRIMAIN|University Hospital Freiburg|No|Recruiting|September 2009|September 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|65 Years|N/A|No|||October 2009|October 2, 2009|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989352||132420|
NCT00989313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-032|A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study|A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Locations (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-028 (REGION Ib)||Peplin|No|Completed|September 2009|October 2010|Actual|October 2010|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|43|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who achieved complete clearance of AK lesions at the Day 57 visit in the        PEP005-028 study|March 2015|March 25, 2015|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989313||132423|
NCT00989326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS037|Evaluate the Benefits of Pacemaker Follow-Up With Home-Monitoring|Comparative Follow-up Schedule With Home Monitoring|COMPAS|Biotronik France|Yes|Completed|December 2005|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|543|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|June 23, 2010|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989326||132422|
NCT00989586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09024|Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined With Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody, in Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|September 2009|September 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|October 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00989586||132402|
NCT00989859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2009-7046.|Photo-Plethysmographic Camera to Monitor Heart Rate, Respiration Rate and Oxygen Saturation in Infants|A Pilot Study Using Photo-plethysmographic (PPG) Camera to Monitor Heart Rate, Respiration Rate and Oxygen Saturation in Infants.||University of California, Irvine|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|N/A|1 Week|Accepts Healthy Volunteers|Non-Probability Sample|infant|August 2015|August 5, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989859||132381|
NCT00990145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDP-322-07-002|Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers||Enanta Pharmaceuticals|No|Completed|November 2008|September 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|October 5, 2009||Yes||||https://clinicaltrials.gov/show/NCT00990145||132359|
NCT00990444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA2-2009-010660-42|A Two Part Study of Peroral Insulin in Type 2 Diabetes|A Double-Blind Two Part Placebo-Controlled Study Consisting of a Single Ascending and Multiple-Dose Tolerance Study of Peroral Insulin in Patients With Type 2 Diabetes|ORA2|Bows Pharmaceuticals AG|Yes|Suspended|September 2009|December 2010|Anticipated|September 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||October 2010|October 3, 2010|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990444||132336|
NCT00990704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-609|Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism|Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism||Abbott|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|20 Years|N/A|No|||June 2011|June 30, 2011|October 5, 2009||No||No|May 20, 2011|https://clinicaltrials.gov/show/NCT00990704||132316|
NCT00938925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2009|Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)|Effectiveness of Supplementation With Nail Debridement in Ungual Lacquer Treatment in Podiatry Care on Onychomycosis: Pilot Study of Randomized Control Trial|EPOCAON|University of Malaga|Yes|Suspended|October 2009|March 2017|Anticipated|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||March 2010|December 3, 2014|July 13, 2009||No|No funds|No||https://clinicaltrials.gov/show/NCT00938925||136243|
NCT00939601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL067209|Evaluating Behavioral Treatments to Improve Adherence to CPAP in People With Obstructive Sleep Apnea|Evaluating Behavioral Treatments to Improve Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in People With Obstructive Sleep Apnea|BREATHE|Brown University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|3||||||Both|25 Years|85 Years|No|||July 2009|July 14, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939601||136192|
NCT00939614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1086/06|Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited, India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.|A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited., India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|55 Years||||July 2009|July 21, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00939614||136191|
NCT00939887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1071003|A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)|A Phase 1, Healthy Volunteer Qualification Of Ligand [11C] PF-04767135 And Randomized Determination Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET||Pfizer|No|Terminated|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|July 13, 2009|No|Yes|This study was terminated on January 6, 2010, due to toxicology findings in animals exposed to    PF-04455242 for three months.|No||https://clinicaltrials.gov/show/NCT00939887||136170|
NCT00941707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016414|An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis|A Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy With Synovial Biopsy Substudy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|February 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|75 Years|No|||April 2013|April 22, 2013|July 16, 2009||No|Due to a single, unexpected serious event, the trial was stopped.|No||https://clinicaltrials.gov/show/NCT00941707||136030|
NCT00941135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN2008|Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab|Phase II Study of TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab "Boost Concomitant" With Cetuximab in Patients With Local Advanced Larynx/Hypolarynx Carcinoma||Fundacion Miguel Servet|No|Terminated|May 2009|May 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|70 Years|No|||September 2011|September 28, 2011|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941135||136074|
NCT00941954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNR CLRN 10343|Walking Away: Structured Education Versus Written Information for Individuals With High Risk of Developing Type 2 Diabetes|Walking Away From Type 2 Diabetes: a Cluster Randomized Controlled Trial to Investigate the Effect of Structured Education on Walking Activity in Those With a High Risk of Developing Type 2 Diabetes||University Hospitals, Leicester|Yes|Completed|September 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|833|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941954||136011|
NCT00937586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO#00-0327|Prostate Cancer Prospective Cohort|Prostate Cancer Prospective Cohort||Washington University School of Medicine|No|Recruiting|May 2000|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4100|Samples Without DNA|Whole blood, serum, white cells, prostate tissue.|Male|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with newly diagnosed prostate cancer are being recruited for this study from        Siteman Cancer Center radiation oncology, medical oncology and urology clinics.|October 2015|October 14, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937586||136346|
NCT00937599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biovasc - 01|Brazil Nut Consumed on the Metabolic Profile, Oxidative Stress and Nutritive Microcirculatory Patterns|The Effect of Brazil Nut Consumed on the Metabolic Profile, Oxidative Stress and Skin Microcirculatory Patterns in Obese Female Adolescents||Rio de Janeiro State University||Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|18|||Female|12 Years|18 Years|No|||July 2009|July 13, 2009|July 10, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00937599||136345|
NCT00941967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000638394|Sorafenib Tosylate With or Without Gemcitabine Hydrochloride and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer|Randomized Phase II Trial Assessing the Combination of Nexavar® (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic) Hepatocellular Carcinoma.||National Cancer Institute (NCI)||Recruiting|December 2008|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||July 2009|April 7, 2010|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00941967||136010|
NCT00988143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC43|A Study of Influenza Virus Vaccines in Children and Adults|Immunogenicity and Safety Among Children and Adults of the 2009-2010 Trivalent Influenza Vaccine, 2008-2009 Trivalent Influenza Vaccine, and Quadrivalent Influenza Vaccine (Intramuscular Route)||Sanofi|No|Completed|October 2009|March 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|600|||Both|6 Months|N/A|Accepts Healthy Volunteers|||November 2013|November 18, 2013|October 1, 2009|Yes|Yes||No|July 3, 2013|https://clinicaltrials.gov/show/NCT00988143||132513|
NCT00988403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fructan|Investigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Dose Response Study|Investigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Randomized, Double-Blind Dose Response Study||University of Iowa|No|Active, not recruiting|June 2009|December 2010|Anticipated|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 7, 2011|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00988403||132493|
NCT00989014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18144|Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea|Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea||Galderma|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|122|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|September 30, 2009|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT00989014||132446|
NCT00979914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPOA|Effect of an Education Programme for Patients With Osteoarthritis in Primary Care - a Randomized Controlled Trial|||Lund University|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||March 2015|March 30, 2015|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979914||133129|
NCT00979927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC3649-202|SPC3649 Multiple Dose Study in Healthy Volunteers|A Placebo-controlled Double-blind, Randomised, Multiple Dose, Dose Escalating Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649||Santaris Pharma A/S|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00979927||133128|
NCT00989599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPRecutita-01|Use of Chamomilla Recutita in Phlebitis|Therapeutic Topic Use of Chamomilla Recutita in Phlebitis Due to Peripheral Intravenous Therapy||University of Sao Paulo|Yes|Completed|September 2004|September 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||October 2009|October 2, 2009|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989599||132401|
NCT00989612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113519|Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)|Immunogenicity and Safety Study of GSK Biologicals' Influenza Candidate Vaccine GSK2340274A||GlaxoSmithKline||Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||March 2011|March 10, 2011|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00989612||132400|
NCT00989872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDP-322-007-001|Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers|A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers||Enanta Pharmaceuticals||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 5, 2009|October 5, 2009||Yes||||https://clinicaltrials.gov/show/NCT00989872||132380|
NCT00990158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 6695|Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?|A Multicentre Study of Low Dose Oral Vitamin K for INR Control in Patients Receiving Warfarin|OVWAC VII|St. Joseph's Healthcare Hamilton|No|Completed|July 2010|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|235|||Both|18 Years|N/A|No|||December 2013|May 19, 2015|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990158||132358|
NCT00990457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|682|Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study)|Two Diets With Exercise in Abdominal Obesity: Cardiovascular Effects|SHAPE5|Johns Hopkins University|Yes|Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 1, 2013|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990457||132335|
NCT00940758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIST-CRC-01|Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy|Phase I and Pharmacokinetic Study of Biweekly PEP02 (Liposome Irinotecan) in Patients With Metastatic Colorectal Cancer Refractory to First-line Oxaliplatin-based Chemotherapy||PharmaEngine|No|Active, not recruiting|June 2009|June 2012|Anticipated|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00940758||136103|
NCT00939900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HKR08T|Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head|Multicenter, Open-labeled, Randomized Clinical Trial to Determine the Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head|EZAPCOFH|Seoul National University Bundang Hospital|Yes|Completed|July 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|19 Years|65 Years|No|||June 2015|June 7, 2015|July 14, 2009|No|Yes||No|May 18, 2015|https://clinicaltrials.gov/show/NCT00939900||136169|
NCT00939913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2006.212.A|Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy|N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes|NAC|Ochsner Health System|Yes|Recruiting|January 2007|May 2010|Anticipated|May 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2009|September 17, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939913||136168|
NCT00939926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1120/07|Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions|Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|55 Years||||July 2009|July 15, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00939926||136167|
NCT00941343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFUS_L_01816|Benign Prostatic Hyperplasia in Taiwan|Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin||Sanofi|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|362|||Male|40 Years|N/A|No|||March 2010|March 29, 2010|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941343||136058|
NCT00940771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCH 09-004|Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens|Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels||Phoenix Children's Hospital|No|Active, not recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Years|18 Years|No|||October 2015|October 21, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940771||136102|
NCT00941629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSLC-IRB #H2013-0037|Comparison of Videoconference and Face-to-Face Delivery of Cognitive Processing Therapy for Posttraumatic Stress Disorder|Randomized Controlled Equivalence Trial Comparing Videoconference and Face-to-Face Delivery of Cognitive Processing Therapy for PTSD||University of Wisconsin, Madison|No|Completed|December 2009|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941629||136036|
NCT00941642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOVAZA - NAFLD|Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease|Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease||Huntington Medical Research Institutes|No|Recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|July 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00941642||136035|
NCT00941655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090189|Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial|Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial||National Institutes of Health Clinical Center (CC)|Yes|Completed|July 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|July 16, 2009|Yes|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT00941655||136034|
NCT00941668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-1005-INF-UNC-FP|Evaluate Inflammation Caused by Gingivitis in Adults|Evaluate Inflammation Caused by Gingivitis in Adults||Colgate Palmolive|No|Completed|January 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT00941668||136033|
NCT00941681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 1021|Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure|An Open Label Study to Investigate the Pharmacokinetics of CK-1827452 Administered Orally to Patients With Stable Heart Failure||Cytokinetics|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|July 15, 2009|Yes|Yes||No|October 29, 2010|https://clinicaltrials.gov/show/NCT00941681||136032|
NCT00941395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0351|College Students and Smoking Cessation|Enhanced Smoking Cessation for University Students||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2009|||June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00941395||136054|
NCT00941733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P998|Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia|Randomized Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA (Percutaneous Transluminal Angioplasty) for the Treatment of Below the Knee Critical Limb Ischemia|INPACT-DEEP|Medtronic Endovascular|Yes|Active, not recruiting|September 2009|August 2017|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|358|||Both|18 Years|85 Years|No|||January 2016|January 24, 2016|July 16, 2009||No||No|August 29, 2014|https://clinicaltrials.gov/show/NCT00941733||136028|
NCT00941720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1A07|Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients With Plasma Cell Myeloma||Case Comprehensive Cancer Center|Yes|Active, not recruiting|June 2009|||February 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|July 17, 2009|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT00941720||136029|
NCT00937872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113260|A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects|Evaluation of the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects||GlaxoSmithKline|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|July 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00937872||136324|
NCT00988689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Starch study 2|Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake|The Effect of Different Types of Starch on Glycemic Response, Subjective Appetite and Short-term Food Intake in Young Men||University of Toronto|Yes|Completed|June 2008|June 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|16|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||September 2009|September 30, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988689||132471|
NCT00988702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chanwuyi-0006|Shaolin Dan Tian Breathing Fosters Relaxed and Attentive Mind|Shaolin Dan Tian Breathing Fosters Relaxed and Attentive Mind: A Randomized Controlled Neuroelectrophysiological Study||The Hong Kong Polytechnic University|No|Active, not recruiting|October 2008|December 2010|Anticipated|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2009|October 1, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988702||132470|
NCT00989027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08|Impact of Uterotonic Agents on Isolated Human Myometrium|Impact of Uterotonic Agents on Isolated Human Myometrium||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|June 2007|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 19, 2014|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00989027||132445|
NCT00989040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0049|Impact of Neuropathic Post-Zosterian Pain on the Cognition|Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)||University Hospital, Clermont-Ferrand||Completed|March 2009|September 2009|Actual|June 2009|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|100|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who suffer of neuropathic post-zosteria pain|January 2012|January 26, 2012|March 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00989040||132444|
NCT00982267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTKD-7840-002|A Trial Of SU14813 In Patients With Advanced Solid Malignancies|A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy||Pfizer|No|Completed|December 2003|June 2011|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||August 2011|August 4, 2011|September 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00982267||132961|
NCT00982280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|847022|Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.||Grünenthal GmbH|No|Terminated|September 2009|August 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|40 Years|N/A|No|||November 2011|November 9, 2011|September 22, 2009||No|Slow Recruitment and supply of Investigational Medicinal Product Issues|No|August 2, 2011|https://clinicaltrials.gov/show/NCT00982280||132960|
NCT00989625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108504|A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.|An Open Label, Single Dose, Randomised, Parallel Group Pharmacokinetic Study to Evaluate a Combination Product Containing Naproxen Sodium and Sumatriptan in Adolescent Subjects With Migraine and Healthy Adult Subjects Administered at Three Doses.||GlaxoSmithKline|Yes|Completed|November 2008|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|50|||Both|12 Years|55 Years|Accepts Healthy Volunteers|||February 2011|March 31, 2011|March 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00989625||132399|
NCT00989885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR132544|ESS as a Diagnosis Resource Aid of the Syndrome of Obstructive Sleep Apnea|The Effectiveness of the Epworth´s Sleepiness Scale as a Resource Aid in the Diagnosis of the Syndrome of Obstructive Sleep Apnea||Fortaleza University|Yes|Completed|January 2007|July 2007|Actual|March 2007|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|475|||Both|40 Years|60 Years|No|Non-Probability Sample|Patients that sought the CESF to probable diagnosis of some sleep disorder|October 2009|October 5, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00989885||132379|
NCT00990171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906084R|The Effects Nutrition Status and Body Composition On Peritoneal Dialysis Outcome|The Effects Nutrition Status and Body Composition On Peritoneal Dialysis Outcome||National Taiwan University Hospital|Yes|Recruiting|December 2011|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|plasma dianeal|Both|20 Years|90 Years|No|Probability Sample|PD patients|April 2014|April 11, 2014|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00990171||132357|
NCT00991341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|676|Red Cell Storage Duration Study|Red Cell Storage Duration Study|RECESS|New England Research Institutes|Yes|Completed|January 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1481|||Both|12 Years|N/A|No|||May 2014|May 22, 2015|October 7, 2009|Yes|Yes||No|February 17, 2015|https://clinicaltrials.gov/show/NCT00991341||132267|Only 4 pediatric subjects were enrolled. One treatment arm had only one subject with available data for analyzing the change in ALT outcome. Therefore, to protect patient confidentiality, results were not entered for this outcome.
NCT00939718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081011PSY|Comparison of Vitamin B12 Supplementation to Selective Serotonin Reuptake Inhibitor (SSRI) Versus SSRI Antidepressant Treatment Alone|Comparison of Vitamin B12 Supplementation and SSRI to SSRI Monotherapy in Treating Depression With Low Normal B12: A Randomized Open Label trialComparison of Vitamin B12 Supplementation to SSRI Versus SSRI Antidepressant Treatment Alone||Aga Khan University|No|Active, not recruiting|April 2009|September 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|268|||Both|18 Years|65 Years|No|||May 2010|May 28, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939718||136183|
NCT00940199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU#06-20027|PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial|Prospective Randomized Trial of Standard Versus pH-adjusted Radiocolloid for Patients Undergoing Sentinel Lymph Node Mapping and Biopsy for Breast Cancer PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial|PassionP|Walter Reed Army Medical Center|Yes|Completed|August 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|140|||Female|18 Years|N/A|No|Probability Sample|The study population will consist of female military health care beneficiaries over the        age of 18 years presenting with the diagnosis of breast cancer who meet inclusion        criteria.|July 2009|July 14, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940199||136146|
NCT00940459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-09-11|Subjective and Conjunctival Response to Edge Design of Different Silicone Hydrogels|Subjective and Conjunctival Response to Edge Design of Different Silicone Hydrogels||Alcon Research|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|5||Actual|30|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|July 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940459||136126|
NCT00940784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-0548-00108|Clopidogrel and Aspirin for the Treatment of Polycythemia Vera|MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera|ISCLAP|Icahn School of Medicine at Mount Sinai|Yes|Withdrawn|June 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|81 Years|No|||November 2014|November 24, 2014|July 14, 2009|Yes|Yes|Could not get drug|No||https://clinicaltrials.gov/show/NCT00940784||136101|
NCT00940797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIL-1099/2008|Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients (CLAMP)|Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients by Glucose CLAMP Technique|DMMETclamp|Laboratorios Silanes S.A. de C.V.|No|Completed|July 2008|||February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|60 Years|No|||July 2009|July 15, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940797||136100|
NCT00941083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC0509|Simplification From Protease Inhibitors to Raltegravir|Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS)|ODIS|Hospital Carlos III, Madrid|Yes|Recruiting|January 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||September 2009|September 9, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00941083||136078|
NCT00941096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17062009-136|Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination|Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension.||Larissa University Hospital||Completed|July 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941096||136077|
NCT00937885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-41-4870|Consequences From Use of Reminiscence: a Randomised Intervention Study in Ten Danish Nursing Homes|||University of Southern Denmark|Yes|Completed|August 2005|June 2008|Actual|September 2007|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||||||Both|N/A|N/A||||July 2009|July 9, 2009|July 7, 2009||||No||https://clinicaltrials.gov/show/NCT00937885||136323|
NCT00937898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE101|Beef in an Optimal Lean Diet (BOLD) Effects on Cardiovascular Disease (CVD) Risk|BOLD (Beef in an Optimal Lean Diet) Effects on Established and Emerging Cardiovascular Disease (CVD) Risk Factors|BOLD|Penn State University|No|Completed|August 2007|March 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|June 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00937898||136322|
NCT00941356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1285-MRSA-M03|Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients|A Single Center, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients|MRSA|Bio-K Plus International Inc.|No|Suspended|January 2010|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|January 15, 2009||No|Unable to recruit patients to continue on with the study.|No||https://clinicaltrials.gov/show/NCT00941356||136057|
NCT00941369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04079|Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients|Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-naive Type 2 Diabetes Patients Uncontrolled on Oral Hypoglycemic Agent Treatment Initiating Basal Insulin Therapy With Either Insulin Glargine or NPH Insulin||Sanofi||Completed|June 2009|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|345|||Both|18 Years|75 Years|No|||November 2012|November 21, 2012|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941369||136056|
NCT00941382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB Sil-02|Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients|Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients||Laboratorios Silanes S.A. de C.V.|Yes|Active, not recruiting|November 2008|September 2009|Anticipated|August 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|50 Years|No|||July 2009|July 15, 2009|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00941382||136055|
NCT00937625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM0909|T-cell Based Immunotherapy for of Melanoma|T-cell Based Immunotherapy for Treatment of Patients With Disseminated Melanoma.||Herlev Hospital|Yes|Completed|June 2009|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|70 Years|No|||August 2015|August 17, 2015|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937625||136343|
NCT00937859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC-SER120-DB1-200901|Treatment of Patients With Nocturia|A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia||Serenity Pharmaceuticals, Inc.|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|301|||Both|50 Years|N/A|No|||April 2014|April 24, 2014|July 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937859||136325|
NCT00938418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B/09/108|Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer|Phase II Study on Dose Escalated, Accelerated Hypofractionated Intensity Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer With Concurrent Chemotherapy||National University Hospital, Singapore||Recruiting|July 2009|||July 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|21 Years|70 Years|No|||July 2009|July 10, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00938418||136282|
NCT00938730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-021|A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation|A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of YM150 in Subjects With Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability With Warfarin|OPAL-2|Astellas Pharma Inc|Yes|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|1280|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|July 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00938730||136258|
NCT00988715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2309.00|Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome|Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|April 2010|||January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00988715||132469|
NCT00988728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06079|Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)|A Multicenter, Randomized, Parallel-Group, Double-blind, Fixed-Dose, 28-Day Trial to Assess the Efficacy and Safety of SCH 900435 Compared With Placebo, Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia (GUEST - Glycine Uptake Inhibitor Efficacy and Safety Trial, Phase 2, Protocol No. P06079)|GUEST|Merck Sharp & Dohme Corp.|Yes|Withdrawn|February 2011|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00988728||132468|
NCT00978783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMV vs PEEP|Speech Effects of a Speaking Valve Versus External Positive End-expiratory Pressure (PEEP) in Tracheostomized Ventilator-Dependent Neuromuscular Patients|Speech Effects of a Speaking Valve Versus External PEEP in Tracheostomized Ventilator-Dependent Neuromuscular Patients||University of Versailles|Yes|Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|N/A|No|||September 2009|September 16, 2009|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00978783||133215|
NCT00978796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP-32888|Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes|Pilot Study Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes||University of Colorado Denver School of Medicine Barbara Davis Center|No|Completed|September 2009|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||March 2010|March 29, 2010|September 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978796||133214|
NCT00981448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040355|Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes|Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes||University of Maryland|Yes|Completed|September 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|57|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00981448||133024|
NCT00982007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT09031|Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)|A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)||Luitpold Pharmaceuticals|No|Completed|September 2009|August 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|997|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|September 21, 2009|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00982007||132981|
NCT00982020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12117|Study in Adolescents With Schizophrenia or Bipolar Disorder|A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia||Eli Lilly and Company|No|Completed|September 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|13 Years|17 Years|No|||December 2014|December 8, 2014|September 15, 2009|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT00982020||132980|
NCT00990184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2|Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)|A Single-Blind Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)||Seattle Institute for Biomedical and Clinical Research|Yes|Completed|September 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||October 2012|October 22, 2012|October 2, 2009|Yes|Yes||No|February 1, 2012|https://clinicaltrials.gov/show/NCT00990184||132356|
NCT00987519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VODP|Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age|Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age - the Clinical Relevance of Newly Discovered Viruses||University Medical Centre Ljubljana|No|Recruiting|October 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|1260|Samples With DNA|Whole blood, stool and nasopharyngeal swab samples.|Both|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children under 6 years of age admitted to Department of Infectious Diseases, University        Medical Centre Ljubljana with a diagnosis of acute bronchiolitis, acute gastroenteritis or        febrile convulsion.|October 2009|July 6, 2010|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987519||132561|
NCT00987532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPH_KITA2008|A Participatory Parental Intervention Promoting Physical Activity in Preschools|||Universitätsmedizin Mannheim|No|Active, not recruiting|September 2008|December 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1047|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||September 2009|September 30, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00987532||132560|
NCT00941148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANT_001|Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin|Impact of Insulin (I.)Glargine Compared to NPH I. and to I. Detemir in Combination With Metformin on Prandial ß-cell Function and Overall Metabolic Control in Type 2 Diabetic Patients With Insufficient Metabolic Control During OAD Treatment||ikfe-CRO GmbH|Yes|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|40 Years|75 Years|No|||July 2009|July 16, 2009|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941148||136073|
NCT00940212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2600C00001|Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Male and Female Volunteers Without Childbearing Potential|SAD|AstraZeneca|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|80|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940212||136145|
NCT00940225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-203|Study of Cabozantinib (XL184) in Adults With Advanced Malignancies|A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors||Exelixis|Yes|Completed|August 2009|June 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|730|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|July 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940225||136144|
NCT00940472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIL-0790/2009|Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients|Randomized, Double-Blind, Efficacy and Safety, Controlled Study, Between DMMET-01 and Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetics Patients.|DMMET2|Laboratorios Silanes S.A. de C.V.|No|Completed|March 2009|||December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|60 Years|No|||May 2010|May 17, 2010|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940472||136125|
NCT00940485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22265|A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B|A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir||Hoffmann-La Roche||Completed|April 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|June 16, 2009||No||No|January 24, 2016|https://clinicaltrials.gov/show/NCT00940485||136124|
NCT00940498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2151001|Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors|A Phase 1 Study Of PF-05212384 (Also Known as PKI-587) Administered As An Intravenous Infusion To Subjects With Solid Tumors|B2151001|Pfizer|No|Completed|January 2010|October 2012|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|July 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940498||136123|
NCT00940511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDRC-CO-02|Effects of Coordinated Care for Disabled Medicaid Recipients|Effects of Coordinated Care for Disabled Medicaid Recipients||MDRC|No|Completed|August 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2618|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00940511||136122|
NCT00941109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7373-A001-101|Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)|A Phase 1 Open-Label, Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)||Eisai Inc.|No|Completed|September 2009|September 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00941109||136076|
NCT00941122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSA.VRE.Detection|Comparison of Elution Swab (ESwab) and Amies Transport Swabs for Screening Patients for Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant Enterococci (VRE) Colonization|Comparison of Elution Swab (ESwab) and Amies Transport Swabs for Screening Patients for Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant Enterococci (VRE) Colonization|MRSA VRE|McMaster University|No|Completed|July 2009|March 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|Hospitalized patients known to be colonized with MRSA/VRE|July 2011|July 19, 2011|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00941122||136075|
NCT00942032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAN-09|Clinical Experience With the Hindfoot Arthrodesis Nail for the Surgical Treatment of Ankle and Hindfoot Pathologies|Clinical Experience With the Hindfoot Arthrodesis Nail (HAN) for the Surgical Treatment of Ankle and Hindfoot Pathologies. A Retrospective Case Series.||AO Clinical Investigation and Documentation|No|Completed|May 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|39|||Both|N/A|N/A|No|Non-Probability Sample|Eligible patients will be identified from the study sites' medical records, information        systems, and OR logs. The responsible local investigator or co-investigator at each study        site will approach patients by letter or phone, and inquire about their interest in        participating in this study.|April 2011|April 6, 2011|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942032||136005|
NCT00941746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG110-01|Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain|A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in Patients With Pain Attributed to Osteoarthritis of the Knee||Abbott|No|Completed|August 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|56|||Both|18 Years|75 Years|No|||May 2011|June 3, 2011|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00941746||136027|
NCT00941980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.OC-0809|Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF)|Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF): Evaluation of Radiographic and Patient Outcomes||NuVasive|No|Completed|June 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Female|18 Years|70 Years|No|Non-Probability Sample|Existing clinic patients|January 2014|January 7, 2014|July 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00941980||136009|
NCT00938145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08063|3 Tesla MRI in Patients With Bladder Cancer|Imaging of Bladder Cancer Using Clinical 3 Tesla MRI and EX-VIVO Ultra-High-Field MRI.||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|May 2009|||May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|65|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|July 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00938145||136303|
NCT00989053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-GAR-078-CTIL|The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF)|The Effect of SSRI Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing In Vitro Fertilization for Unexplained Infertility - a Prospective Placebo-Controlled Study.||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2010|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|45 Years|No|||October 2009|October 1, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989053||132443|
NCT00979693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCA1|Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma|Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.||Multidisciplinary Association for Psychedelic Studies|No|Withdrawn|January 2012|June 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 16, 2009|Yes|Yes|The study was suspended because the PI was unable to get permission from his department to    submit the protocol to the local IRB?"|No||https://clinicaltrials.gov/show/NCT00979693||133146|
NCT00980577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUTH7275|Stimulating Catheter With or Without Ultrasound Guidance|Phase 2 Study of Stimulating Catheter for Continuous Femoral Nerve Block in Total Knee Replacement||Peking University Third Hospital|Yes|Recruiting|January 2008|||November 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|30 Years|90 Years|No|||September 2009|November 9, 2010|September 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00980577||133084|
NCT00989365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asthmatraining|Effect of Aerobic Training on Asthmatic Patients|Effect of Aerobic Training on Psychosocial Morbidity, Symptoms, Airway Inflammation and Autonomic Modulation in Asthmatic Patients||University of Sao Paulo General Hospital|Yes|Completed|January 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|20 Years|50 Years|No|||October 2009|October 2, 2009|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989365||132419|
NCT00989378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16026A|Individual Differences in Diabetes Risk: Role of Slow WaveSleep|Ancillary Studies to Major Ongoing NIDDK Clinical Research Studies||University of Chicago||Completed|November 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|5|Samples Without DNA|serum|Both|18 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|normal healthy men and women|September 2013|September 4, 2013|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989378||132418|
NCT00981760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-068|Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation|Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation||Massachusetts General Hospital|Yes|Recruiting|July 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|74 Years|No|||May 2010|May 3, 2010|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981760||133000|
NCT00981773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0 18.6.2009|The St. Marys and The Mater Switch Study|A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy|SMASH|Imperial College London|No|Completed|September 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||May 2011|May 20, 2014|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00981773||132999|
NCT00989898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI/2008/0036|Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes|Open Randomised, Two Period Cross-over Study to Assess the Feasibility, Efficacy and Safety of Automated Closed-loop Glucose Control Initiated at the Time of Dinner or Before Sleep in Children and Adolescents With Type 1 Diabetes|APCam05|University of Cambridge||Completed|February 2009|December 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|6 Years|18 Years|No|||June 2012|June 22, 2012|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00989898||132378|
NCT00991042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cytokine|Study of Cytokines Serum Levels in Chronic Low Back Pain|Analytical Transversal Study of Cytokines Serum Levels in Chronic Low Back Pain Due to Herniated Disk|cytokine|Federal University of São Paulo|Yes|Completed|August 2003|March 2005|Actual|September 2004|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|23|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 6, 2009|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991042||132290|
NCT00980174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080098|Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab Versus Placebo in Males With Low Bone Mineral Density||Amgen|No|Completed|October 2009|July 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|242|||Male|30 Years|85 Years|No|||January 2013|January 22, 2013|September 17, 2009|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT00980174||133110|
NCT00980187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-SCL-IQ v 1.0/04.07|A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM|A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate Hypertension and Type 2 Diabetes Mellitus|AISHA|LaborMed Pharma S.A.|No|Completed|March 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|75 Years|No|||June 2011|June 14, 2011|September 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00980187||133109|
NCT00940537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0229|Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)|MRS Validation Study of Hepatic Triglyceride Content in Non-alcoholic Fatty Liver Disease (NAFLD)Subjects Pre- and Post-Prandial|NAFLD|Washington University School of Medicine|No|Completed|June 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|St. Louis community|July 2010|July 2, 2010|July 14, 2009||No||No|April 13, 2010|https://clinicaltrials.gov/show/NCT00940537||136120|
NCT00939965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCLG-PK-2008-03|Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma|Pilot Study to Investigate the Feasibility of 13-cis-retinoic Acid Pharmacokinetic Monitoring in High-risk Neuroblastoma Patients||National Cancer Institute (NCI)||Recruiting|February 2009|||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|N/A|18 Years|No|||July 2009|August 9, 2013|July 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00939965||136164|
NCT00940238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/05/001|Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|45 Years||||July 2009|July 15, 2009|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00940238||136143|
NCT00940251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MER1|Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs|Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs||Jyoti Clinical and Pathological Laboratory|Yes|Completed|September 2008|November 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|30 Years|60 Years|No|||July 2009|July 14, 2009|July 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940251||136142|
NCT00941993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005000|Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to External Auditory Apparatus|First in Man Evaluation of the Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to the External Auditory Apparatus (FIM Iontophoresis Study)|IONTO|Acclarent|No|Completed|April 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|109|||Both|12 Months|N/A|No|||July 2014|July 2, 2014|July 14, 2009|No|Yes||No|July 2, 2014|https://clinicaltrials.gov/show/NCT00941993||136008|
NCT00942006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNB-doxy-ceftriaxone|Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis|Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count.||University Medical Centre Ljubljana|No|Not yet recruiting|July 2009|November 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|N/A|No|||July 2009|July 17, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00942006||136007|
NCT00940810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDDCC-001|Plasma Disc Decompression Versus Conservative Care|A Prospective, Randomized, Controlled, Multi Center, Clinical Study With Plasma Disc Decompression Versus Conservative Care||ArthroCare Corporation|No|Completed|August 2007|November 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|July 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00940810||136099|
NCT00940823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVEC-AVB|The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma|The Ahmed Versus Baerveldt (AVB) Study: Prospective, Multicenter Trial Comparing the Ahmed-FP7 Valve With the Baerveldt-350 Implant in Treating Refractory Glaucoma||Credit Valley EyeCare|No|Completed|July 2005|April 2015|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00940823||136098|
NCT00937924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 2007-5810|Adjunct Sedatives in Procedures Involving Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP)|A Randomized, Double-Blinded, Placebo-Controlled Trial of Promethazine and Diphenhydramine as Adjunct Sedatives for Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP)||University of California, Irvine|Yes|Recruiting|February 2008|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|465|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|June 4, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00937924||136320|
NCT00937651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-201|Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)|Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Antihypertensive Efficacy, Safety, Tolerability, and Pharmacodynamic/Pharmacokinetic Profiles After 4 Weeks of Oral Administration of Fimasartan(BR-A-657) at 20-180mg in Patients With Essential Hypertension|Fimasartan|Boryung Pharmaceutical Co., Ltd|Yes|Completed|April 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|81|||Both|18 Years|65 Years|No|||July 2009|July 10, 2009|July 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00937651||136341|
NCT00938119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS-200801|Care China-Diabetes|The Care China-Diabetes Registry A 12-month, Multi-centre, Prospective, Observational Registry Study to Investigate the Efficacy and Safety of CYPHER Select TM+ Sirolimus-eluting Coronary Stent Among Chinese Diabetic Patients With Coronary Artery Disease in Routine Clinical Practice||Johnson & Johnson Medical, China|Yes|Terminated|August 2009|December 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1603|None Retained|Diabetes patient|Both|18 Years|80 Years|No|Probability Sample|The registry will be conducted at approximately 45 centers in China where the CYPHER        SelectTM+ Sirolimus-eluting Coronary Stent is commercially available. Data will be        collected on 2,500 diabetic patients treated only with the CYPHER Select™+        Sirolimus-eluting Coronary Stent during the index procedure. Enrolled diabetic patients        are confirmed and diagnosed with Diabetes before or during the index procedure        hospitalization, i.e., those receiving active treatment with an oral hypoglycemic agent or        insulin, patients with diagnosis of diabetes who were on dietary therapy alone or patients        with an abnormal blood glucose level after an overnight fast as defined by local        standards.|July 2011|June 27, 2013|June 24, 2009||No|the product was delisted.|No||https://clinicaltrials.gov/show/NCT00938119||136305|
NCT00937911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-041|Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities|YM150 Phase III Study - An Open-label, Multi-center Study in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities||Astellas Pharma Inc|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|101|||Both|20 Years|N/A|No|||June 2010|June 14, 2010|July 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00937911||136321|
NCT01000740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1839IL/0052 SubStudy|A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa|An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa||AstraZeneca|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|59|||Both|N/A|N/A|No|||May 2010|May 20, 2010|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01000740||131548|
NCT01000480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13099|A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer|Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin With Concurrent Thoracic Radiotherapy, in Patients With Unresectable, Locally Advanced, Stage III, Nonsquamous Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Completed|October 2009|July 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|October 21, 2009|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT01000480||131568|
NCT00996489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1005185|Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence|||Merz Pharmaceuticals, LLC||Active, not recruiting|November 2007|February 2016|Anticipated|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|459|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|October 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996489||131873|
NCT01000766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50KR10957|Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury|Identification of New Biomarkers of Drug Induced Liver Injury||University of North Carolina, Chapel Hill|No|Recruiting|September 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|blood|Both|18 Years|80 Years|No|Non-Probability Sample|Patients will be identified in emergency rooms or inpatients at the University of North        Carolina Memorial Hospital.|March 2012|March 3, 2012|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000766||131546|
NCT00996515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0710C|A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies|A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies||New Mexico Cancer Care Alliance|Yes|Completed|June 2008|September 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Both|19 Years|N/A|No|||April 2013|April 30, 2013|October 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996515||131871|
NCT01005316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-04|Allo-Antibodies in Pediatric Heart Transplantation|Allo-Antibodies in Pediatric Heart Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|370|Samples With DNA|Blood collection and biopsy tissue samples|Both|N/A|21 Years|No|Non-Probability Sample|Pediatric heart transplantation candidates|October 2015|October 5, 2015|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01005316||131200|
NCT00996788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-IOB-0701|Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis|Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis||PT Otsuka Indonesia|No|Completed|October 2007|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|80 Years|No|||May 2013|May 14, 2013|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996788||131850|
NCT00996801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5442-012|MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)|A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate||Merck Sharp & Dohme Corp.|Yes|Completed|November 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|526|||Female|45 Years|85 Years|No|||January 2016|January 21, 2016|October 15, 2009|Yes|Yes||No|August 31, 2012|https://clinicaltrials.gov/show/NCT00996801||131849|
NCT01001052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-09-1027|Relative Bioavailability of Colcrys™ 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions|Relative Bioavailability of Colcrys™ (Colchicine, USP) 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|October 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 24, 2010|October 22, 2009|No|Yes||No|August 11, 2010|https://clinicaltrials.gov/show/NCT01001052||131524|
NCT01001065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-03-2009-USZ|Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis|||University of Zurich||Recruiting|October 2009|October 2010||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|Patients after renal transplantation with stable renal function|June 2010|June 28, 2010|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01001065||131523|
NCT01001078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR-Anesth-Joly|Comparison Study of Two Supraglottic Airway Devices Used for Patients Under General Anesthesia|Prospective Randomized Trial Comparing the Performance of Two Supraglottic Airway Management Devices: I-Gel and Supreme LMA||Maisonneuve-Rosemont Hospital|No|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 13, 2015|October 21, 2009||No||No|January 26, 2014|https://clinicaltrials.gov/show/NCT01001078||131522|
NCT01001637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Longvida|Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease|Phase II Study of Curcumin Formulation (Longvida) or Placebo on Plasma Biomarkers and Mental State in Moderate to Severe Alzheimer's Disease or Normal Cognition||Jaslok Hospital and Research Centre|No|Recruiting|October 2009|November 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|50 Years|80 Years|No|||October 2009|October 23, 2009|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01001637||131480|
NCT00997685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22298|Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)|A Single Arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of Capecitabine Plus Oxaliplatin (XELOX) in the Peri-operative Treatment of Patients With Potentially Resectable Liver Metastasis From Colorectal Cancer||Guangdong General Hospital|No|Not yet recruiting|November 2009|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|65 Years|No|||October 2009|October 18, 2009|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997685||131781|
NCT01002183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP015|Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate|Evaluation of Fosmidomycin and Clindamycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria|JP015|Jomaa Pharma GmbH|No|Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|15 Years|55 Years|No|||August 2010|September 26, 2011|October 26, 2009||No|Drug combination is no longer pursued|No||https://clinicaltrials.gov/show/NCT01002183||131438|
NCT01002508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0344-09|Influenza Vaccination in Patients With Scleroderma|Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Both|16 Years|90 Years|Accepts Healthy Volunteers|||August 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002508||131413|
NCT01002521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDRC-WHy-1|Wound Healing In Diabetes (WHy) Study|Molecular and Genetic Analysis of Disturbed Wound Healing in Barbadians With Diabetic Foot Ulcers|WHy|The University of The West Indies|Yes|Not yet recruiting|December 2009|June 2012|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|605|Samples With DNA|Whole blood,Serum,DNA,Urine|Both|N/A|N/A|No|Non-Probability Sample|Black Barbadians who are clinically diagnosed as type II diabetes mellitus patients|October 2009|October 26, 2009|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002521||131412|
NCT01007097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_201|Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus||Takeda|No|Completed|December 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|426|||Both|18 Years|80 Years|No|||October 2010|October 7, 2010|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007097||131064|
NCT01007318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khnmc IRB 2009-026|Safety and Efficacy Study of Single Port Laparoscopic Appendectomy in Acute Appendicitis|Prospective, Randomized Study of Single Port and Conventional Laparoscopic Appendectomy in Acute Appendicitis||Kyunghee University Medical Center|Yes|Recruiting|December 2009|February 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|7 Years|75 Years|No|||November 2009|May 26, 2010|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007318||131047|
NCT01009346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0916|A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck|A Phase 1/2 Study of RAD001 in Combination w/ Cetuximab and Cisplatin as First-line Therapy in Recurrent & Metastatic Squamous Cell Cancer of the Head & Neck||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|October 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|October 21, 2009|No|Yes|Toxicity|No|March 23, 2014|https://clinicaltrials.gov/show/NCT01009346||130893|Early termination leading to small numbers of subjects analyzed
NCT01008215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-282|Simple Warfarin Dosing Algorithm Study|Cluster Randomized Trial to Assess the Effect of Using a Simple Warfarin Maintenance Dosing Algorithm on the Quality of INR Control Among Canadian Family Practices|KT-INR|Population Health Research Institute|No|Completed|October 2009|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|553|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01008215||130979|
NCT01008501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM Hydatidiform Mole H7345|Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles|Genetic Studies in Gestational Trophoblastic Disease||Baylor College of Medicine|No|Recruiting|December 1998|January 2018|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|lymphoblast DNA; tissue|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who have had sporadic or recurrent hydatidiform moles and their first degree        relatives. Sometimes additional family members are also enrolled.|December 2010|December 21, 2010|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008501||130957|
NCT01008787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0257|Motivational Interviewing for Physical Activity|Peer-support Motivational Interviewing Physical Activity Intervention for African American Women||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2009|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|80|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008787||130935|
NCT01008748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0442|Determinants of Smoking Cessation Among Latinos|Determinants of Smoking Cessation Among Latinos||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2009|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|October 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01008748||130938|
NCT01009541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081225|An Investigation of the Absorption and Pharmacokinetics of Multiple Doses of Three Controlled Release Pregabalin Tablets as Compared to Multiple Doses of the Immediate Release Pregabalin Capsule|An Open-Label, Multiple-Dose, Randomized, Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Three Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal As Compared To The Immediate Release Formulation||Pfizer|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 28, 2009|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009541||130879|
NCT01008982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-BEL-01-1.0|Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome|A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Primary Sjögren's Syndrome.||University of Udine|Yes|Completed|August 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|90 Years|No|||September 2012|September 3, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008982||130920|
NCT01000753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANHL04B1|Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma|Rare And Cutaneous Non-Hodgkin Lymphoma Registry||Children's Oncology Group|No|Recruiting|May 2005|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|tumor tissue, bone marrow, blood|Both|N/A|21 Years|No|Non-Probability Sample|Patients with non-Hodgkin lymphoma (NHL)|November 2015|November 16, 2015|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000753||131547|
NCT01000779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG001|Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)|Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial||Govind Ballabh Pant Hospital|Yes|Completed|January 2005|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|2 Years|75 Years|No|||October 2009|December 21, 2010|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000779||131545|
NCT01001091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-034|AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation|||Alcon Research|No|Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|312|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|October 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001091||131521|
NCT01001104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12840|A Study of LY2189265 in Japanese Patients With Type 2 Diabetes|Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes||Eli Lilly and Company|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|145|||Both|20 Years|75 Years|No|||August 2015|August 28, 2015|October 22, 2009|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01001104||131520|
NCT01001117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-00001-0000|Laser Treatment of the Crystalline Lens|A Prospective Single-Center Clinical Trial to Evaluate the Feasibility of Laser Treatment of the Crystalline Lens in Subjects Having Elected to Undergo Lens Extraction and Intraocular Lens Implantation||LensAR Incorporated|No|Active, not recruiting|October 2008|April 2011|Anticipated|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|N/A|N/A|No|||April 2011|April 14, 2011|October 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001117||131519|
NCT01001390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIT09|The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop|The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop||St. Jude Children's Research Hospital|No|Terminated|October 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2|||Both|6 Years|18 Years|No|||January 2014|February 27, 2014|October 22, 2009||No|The study closed due to poor accrual and difficulty with participant compliance.|No|January 15, 2014|https://clinicaltrials.gov/show/NCT01001390||131498|The study was terminated due to poor accrual and poor participant compliance.
NCT01001650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sanaria.2008.001|Clinical Trial of the PfSPZ Vaccine|A Phase 1/2a Trial of the PfSPZ Vaccine Administered Subcutaneously or Intradermally to Malaria-Naïve Adult Volunteers||Sanaria Inc.|Yes|Completed|April 2009|September 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|October 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01001650||131479|
NCT01001663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090101|Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography|Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography: the CLOSE-UP I Randomized Trial|CLOSE-UP I|Aarhus University Hospital Skejby|Yes|Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1005|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|October 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001663||131478|
NCT01001910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-04-097|Pemetrexed Disodium and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|July 2008|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||March 2015|December 10, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001910||131459|
NCT01001923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT11286|Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain|Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Chronic Pancreatitis||Regeneron Pharmaceuticals|Yes|Terminated|December 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|No|||May 2013|May 20, 2013|October 26, 2009|Yes|Yes|Business decision due to low subject recruitment and enrollment|No||https://clinicaltrials.gov/show/NCT01001923||131458|
NCT01002196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RegionsenterBUP|Randomised Controlled Treatment Study of Selective Mutism|How to Help When Silence is Not Golden A RCT Study of Selective Mutism||Regionsenter for barn og unges psykiske helse|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|3 Years|9 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002196||131437|
NCT01002833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP1|Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection|Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection|TIP1|Radboud University|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|15|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2010|November 8, 2010|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002833||131388|
NCT01002846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC/5H/IRB/2009/007|Effects of Acupuncture at ST36 and PC6 on Blood Pressure and Endothelial Dysfunction in Hypertensive Patients|Effects of Acupuncture at ST36 and PC6 on Blood Pressure and Endothelial||Kyunghee University Medical Center|Yes|Recruiting|September 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002846||131387|
NCT01007877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-037|Energy Drinks & Driving Ability|'Study to Investigate the Effects of an Energy Drink During a 15-minute Break Versus Continued Driving on Driving Performance in the STISIM Driving Simulator'||Utrecht Institute for Pharmaceutical Sciences|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|24|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||April 2011|April 8, 2011|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01007877||131005|
NCT01009580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3592|Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes|A 26-week, Randomised, Open-labelled, Two-arm, Parallel-group, Treat-to-target Trial Comparing Efficacy and Safety of Soluble Insulin Analogue Combination (SIAC) Twice Daily (BID) With Biphasic Insulin Aspart (BIAsp) 30 BID, With or Without Metformin, With or Without DPP-4 Inhibitor, With or Without Pioglitazone in Subjects With Type 2 Diabetes in Inadequate Glycaemic Control on Once or Twice Daily Premixed or Self-mixed Insulin Regimen With or Without OADs (BOOST™: Intensify Premix 1)|BOOST™|Novo Nordisk A/S|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|November 5, 2009|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01009580||130876|
NCT01009034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS 353380|Concentrations of Maraviroc in the Semen of HIV-Infected Men|Study to Determine the Concentrations of Maraviroc in Semen, the Seminal to Plasma Ratio of Maraviroc and the Variability in Seminal to Plasma Ratios Over the Maraviroc Dosing Period.|NCT01009034|Canadian Immunodeficiency Research Collaborative|No|Completed|October 2009|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|12 HIV-positive males|September 2014|September 8, 2014|November 5, 2009||No||No|June 16, 2014|https://clinicaltrials.gov/show/NCT01009034||130916|
NCT01005537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355.00|Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma|Single Patient Study to Evaluate Cellular Adoptive Immunotherapy Using Autologous Lymphocytes Following Cyclophosphamide Conditioning for a Single Patient With Metastatic Melanoma||Fred Hutchinson Cancer Research Center||No longer available|June 2009|||October 2010|Anticipated|N/A|Expanded Access|N/A|||||||Both|18 Years|75 Years|No|||August 2010|August 4, 2010|October 30, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT01005537||131183|
NCT01005550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.519|Ropivacaine Hypobaric Spinal Anaesthesia in Traumatic Hip Surgery|Determining the Minimum Effective Ropivacaine Dose for Unilateral Hypobaric Spinal Anaesthesia During Traumatic Femoral Neck Surgery in the Aged Person: Prospective Comparative Randomized Study||Hospices Civils de Lyon|Yes|Completed|April 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|70 Years|N/A|No|||December 2010|March 8, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01005550||131182|
NCT01005823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 29102-C03|A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis|A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis||LEO Pharma|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|55 Years|No|||December 2010|October 21, 2013|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01005823||131161|
NCT01009554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNKPLT0002|Oral Tissue Tolerance of a Mouthrinse|Assessment of the Oral Tissue Tolerance of a Potassium Oxalate Containing Mouthrinse||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|November 5, 2009|Yes|Yes||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01009554||130878|
NCT01009307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000437072|Study of Blood and Cheek Cell Samples From Patients With Glioma|San Francisco Bay Area Adult Glioma Prognosis Study Protocol||University of California, San Francisco||Completed|October 2001|||July 2006|Actual|N/A|Observational|N/A|||Actual|1709|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009307||130896|
NCT01005472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000634373|Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma|A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|December 2008|July 2016|Anticipated|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01005472||131188|
NCT01000493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113211|Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study Evaluating the Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Orvepitant (GW823296) in Post Traumatic Stress Disorder (PTSD)||GlaxoSmithKline|Yes|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|64 Years|No|||March 2011|February 23, 2012|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000493||131567|
NCT01005030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB_PD001|Spectroscopy in Parkinson Disease|Evaluation of Blood Biospectroscopy as a Novel Diagnostic Test for Idiopathic Parkinson Disease|SPIN-PD|Molecular Biometrics, Inc.|No|Enrolling by invitation|October 2009|March 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|Blood plasma, cell free|Both|46 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson's subjects: from pool of subjects currently enrolled in PostCEPT study Control        subjects: general population|November 2009|November 9, 2009|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005030||131221|
NCT01005043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HITHD-01|Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma|Phase I/II Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma||Heidelberg University|No|Not yet recruiting|December 2010|January 2020|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|N/A|Accepts Healthy Volunteers|||October 2009|June 24, 2010|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01005043||131220|
NCT01001130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113596|Regulatory AVAMYS Nasal Spray PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamys® Administered in Korean Patients According to the Prescribing Information||GlaxoSmithKline|No|Completed|May 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3244|||Both|2 Years|N/A|No|Probability Sample|Patients administrated AVAMYS nasal spray at the site|June 2014|June 26, 2014|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01001130||131518|
NCT01001429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090202|Dexmedetomidine Versus Propofol in Vitreoretinal Surgery|Comparison of Dexmedetomidine vs. Propofol in Vitreoretinal Surgery Under Sub-Tenon's Block||Rutgers, The State University of New Jersey|No|Completed|October 2009|November 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|70 Years|No|||August 2014|September 3, 2014|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01001429||131496|
NCT01001442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|975|Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma||Biotest Pharmaceuticals Corporation|Yes|Active, not recruiting|August 2010|March 2016|Anticipated|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|October 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01001442||131495|
NCT01001689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811363|Fit For Delivery: A Study of the Effect of Exercise Sessions and Nutritional Counselling on Pregnancy Outcome|Fit For Delivery: A Study of the Effect of Exercise Intervention and Nutritional Counselling on Pregnancy Outcome.|FFF|Sorlandet Hospital HF|Yes|Completed|September 2009|September 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|606|||Female|N/A|N/A|No|||August 2015|August 10, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001689||131476|
NCT01001364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-091|A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma|A Phase III, Randomized, Open-Label, Non-Inferiority Comparative Study Between Foraseq Inhalation Capsules 12/200 µg And Formoterol/ Budesonide Inhalation Capsules 12/200 µg Eurofarma In Patients With Asthma|CAINAS|Eurofarma Laboratorios S.A.|Yes|Completed|February 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|12 Years|N/A|No|||June 2010|June 27, 2011|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001364||131500|
NCT01001377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080763|ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer|A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer||Amgen|Yes|Active, not recruiting|February 2010|March 2016|Anticipated|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1010|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|October 22, 2009|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01001377||131499|
NCT01001949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML5282 junior|In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Juniors)|In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects: a Randomized, Placebo-controlled, Double-blind, Cross-over Study||Fugeia NV|Yes|Completed|March 2009|October 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|29|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001949||131456|
NCT01001936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A1-102|Study Evaluating SKI-606 in Subject With Solid Tumors|Phase 1 Does-escalation Study of Oral SKI-606 in Subjects With Advanced Malignant Solid Tumors||Wyeth is now a wholly owned subsidiary of Pfizer|Yes|Completed|February 2006|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|20 Years|74 Years|No|||October 2009|October 26, 2009|October 26, 2009||Yes||No||https://clinicaltrials.gov/show/NCT01001936||131457|
NCT01002209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HODIVA|Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery|Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery (HODiVA) - A Double Blind, Randomized Controlled Study|HODiVA|Karolinska Institutet|No|Recruiting|October 2009|October 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|N/A|N/A|No|||May 2015|May 6, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002209||131436|
NCT01002534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARD-99|Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?|Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind, Placebo-controlled Study.||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Suspended|October 2011|June 2012|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|10|||Both|14 Years|N/A|No|||June 2012|June 6, 2012|October 26, 2009||No|not yet started|No||https://clinicaltrials.gov/show/NCT01002534||131411|
NCT01003444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1501004|Muscle Malonyl Coa Biomarker Assay Development|Muscle Biopsy Study In Healthy Subjects For Malonyl Coa Biomarker Assay Development||Pfizer|No|Terminated|November 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|November 23, 2010|October 14, 2009|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01003444||131341|
NCT01003457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uninsubria1|Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity|Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity||Università degli Studi dell'Insubria||Completed|January 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|all women with urinary dysfunction|October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003457||131340|
NCT01007903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000065|Mind-Body Exercise for COPD: A Pilot Study|Tai Chi Exercise in Patients With Chronic Obstructive Pulmonary Disease||Beth Israel Deaconess Medical Center||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2|||10|||Both|45 Years|N/A|No|||November 2009|November 3, 2009|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007903||131003|
NCT01008800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40 MC 15594-01|A Randomized Clinical Trial for Toddlers With ASD|Parent-mediated vs Center-based Intervention for Toddlers With ASD: An RCT||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Completed|September 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|22 Months|33 Months|No|||January 2016|January 22, 2016|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008800||130934|
NCT01008514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08177|Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer|A Single Institution, Prospective, Non-randomized Study of Partial Breast Irradiation Using the MammoSite Radiation Therapy System (Breast Brachytherapy Applicator)||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|45 Years|N/A|No|||March 2015|March 25, 2015|November 4, 2009||No|funding issues and Principal Investigator leaving the institution|No||https://clinicaltrials.gov/show/NCT01008514||130956|
NCT01008527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15383|Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100|A Phase I Study of Poly IC:LC and NY-ESO-1/gp100 Peptides Either Emulsified With Montanide ISA 51 or in Aqueous Solution With Escalating Doses of CP 870,893 in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|October 2009|September 2015|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01008527||130955|
NCT01008813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016226-13|Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)|A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)||French National Agency for Research on AIDS and Viral Hepatitis|Yes|Completed|October 2009|December 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|306|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008813||130933|
NCT01005563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905008129|Effects of Dietary Protein Intake From Beef/Pork and Soy/Legumes on Appetite, Mood, and Weight Loss|Effects of Dietary Protein Intake From Beef/Pork and Soy/Legumes on Appetite, Mood, and Weight Loss||Purdue University||Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|37|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 19, 2014|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005563||131181|
NCT00997698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondMMU|Contrast-enhanced Magnetic Resonance Angiography Investigation of Intracranial Aneurysms and Prospective Study of Risk Factors|Imaging Epidemiological Investigation of Intracranial Aneurysms and the Prospective Study of Risk Factors：Assessment of MR Imaging Trail|EIIA|Second Military Medical University|Yes|Enrolling by invitation|January 2009|June 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|People coming to Changhai hospital to get health check or consult docter, undergoing        cerebral CE-MRA, and according with the criteria were recruited. Assuming an 8 percent        prevalence of intracranial aneurysm in the general population and using a two-sided alpha        value of 0.05, we estimated that 4000 persons would need to be enrolled for the study.|October 2009|October 26, 2009|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997698||131780|
NCT01009320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMRvzaphi|The Potential Interference of Magnets From a Surgical Magnetic Drape With Cardiac Pacemakers|The Potential Interference of Magnets From a Surgical Magnetic Drape With Cardiac Pacemakers||Maisonneuve-Rosemont Hospital|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Out-patient clinic|March 2013|March 5, 2013|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009320||130895|
NCT01009567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-004|Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program|Compare the Efficacy of Human Albumin With Cabergoline to Prevent of Ovarian Hyper Stimulation in ART Program||Royan Institute|Yes|Completed|June 2009|July 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10|||Female|25 Years|45 Years|No|||November 2009|May 5, 2015|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009567||130877|
NCT01005745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15781|Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma|Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|October 2009|June 2016|Anticipated|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|October 27, 2009|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01005745||131167|
NCT01004744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC0553|Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer|Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer||Columbia University|Yes|Completed|February 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|21 Years|N/A|No|||February 2013|February 11, 2013|October 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01004744||131243|
NCT01005329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01982|Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer|A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer||National Cancer Institute (NCI)||Completed|November 2009|September 2013|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Female|18 Years|N/A|No|||June 2014|October 9, 2014|October 29, 2009|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT01005329||131199|
NCT01001143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1661 / 201012801|Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)|A Phase I Dose Escalation Study of Intravenous Decitabine in Combination With Oral Bexarotene in Patients With Acute Myeloid Leukemia (AML)|AML|Washington University School of Medicine|No|Completed|May 2010|May 2014|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|October 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01001143||131517|
NCT01001403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWJung_futhan-liver TPL|Effect of Nafamostat on Postreperfusion Syndrome (PRS)|Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft||Seoul National University Hospital|Yes|Completed|March 2009|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|62|||Both|18 Years|70 Years|No|||May 2010|May 4, 2010|October 23, 2009||No||No|March 21, 2010|https://clinicaltrials.gov/show/NCT01001403||131497|
NCT01001975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18119|Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)|Determination of Sun Protection Factors (PFA and SPF) in Sunscreen Formulas Containing Combinations of Zinc Oxide and Avobenzone|PFA and SPF|Bayer|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|October 23, 2009|Yes|Yes||No|November 4, 2010|https://clinicaltrials.gov/show/NCT01001975||131454|
NCT01001676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ktt1|Restenosis Following Paclitaxel Eluting Balloon Angioplasty of Hemodialysis Access Stenosis|Local Delivery of Paclitaxel for Prevention of Restenosis in Hemodialysis Access||University Health Network, Toronto|No|Completed|February 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||January 2012|November 14, 2014|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001676||131477|
NCT01002222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-2-US-c|Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)|Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects|MCS-2-US-c|Health Ever Bio-Tech Co., Ltd.|No|Completed|January 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Male|40 Years|N/A|No|||March 2015|March 1, 2015|October 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002222||131435|
NCT01002235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMDN-001/D|Gene Therapy for Painful Diabetic Neuropathy|A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Patients With Painful Diabetic Peripheral Neuropathy||ViroMed Co., Ltd. dba VM BioPharma|Yes|Completed|February 2010|April 2012|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|75 Years|No|||January 2015|January 30, 2015|October 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002235||131434|
NCT01002547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-015-08F|Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment|NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment|VA NASH|VA Office of Research and Development|Yes|Active, not recruiting|June 2010|December 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|70 Years|No|||November 2015|November 5, 2015|October 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002547||131410|
NCT01002859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 08 04|Effect of Preliminary Administration of Cyclosporine (Sandimmun ®) on Different Markers of Cardiac Ischaemia Induced by Cardiopulmonary Bypass|Double-Blind Phase II Pilot Monocentric Randomized Clinical Trial Evaluating the Effect of a Preliminary Administration of Cyclosporine on Different Markers of Cardiac Ischemia Led by the Aortic Cross-clamp During Coronary Artery Bypass Surgery With Cardiopulmonary Bypass.|Ciclo et CEC|University Hospital, Grenoble|Yes|Terminated|April 2009|July 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|October 26, 2009||No|difficulties to include patients|No||https://clinicaltrials.gov/show/NCT01002859||131386|
NCT01003470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTRDP- 2006BAI12B02-2|Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study|Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study||Tianjin University of Traditional Chinese Medicine|Yes|Recruiting|October 2006|October 2010|Anticipated|October 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|288|||Both|40 Years|75 Years|No|||October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003470||131339|
NCT01009021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSAID-PRP|Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy|Analgesic Effectiveness of Potassium Diclofenac for Retinal Photocoagulation in Patients With High-risk Proliferative Diabetic Retinopathy||University of Sao Paulo|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||November 2009|November 5, 2009|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009021||130917|
NCT01009333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1650|InterStim Therapy Programming Study|InterStim Therapy Programming Study||MedtronicNeuro|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|13|||Female|18 Years|N/A|No|||May 2013|May 17, 2013|November 2, 2009||No||No|November 28, 2011|https://clinicaltrials.gov/show/NCT01009333||130894|
NCT01009372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPP 67|The Intermittent Pneumoperitoneum Scheme of Work Breaks in Complex Laparoscopic Surgery|Prospective Study on the Effects of the Intermittent Pneumoperitoneum (IPP) Work Break Scheme on Surgeons and Patients.|IPP|Hannover Medical School|Yes|Completed|January 2007|July 2009|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|56|||Both|N/A|14 Years|No|||November 2009|November 5, 2009|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009372||130891|
NCT01009606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071239|Cardiopulmonary Resuscitation Witnessing by a Relative|Interest for a Relative of Seeing Himself Proposing to Witness Resuscitation of a Family Member Victim of a Cardiac Arrest|PRESENCE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|570|||Both|18 Years|N/A|No|||December 2012|January 17, 2013|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009606||130874|
NCT00997724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG96016|Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung Cancer|Feasibility of Assisted-VATS(Video-Assisted Thoracoscopic Surgery) Sleeve Lobectomy for Non-small Cell Lung Cancer|VATS|The First Affiliated Hospital of Guangzhou Medical University|Yes|Active, not recruiting|February 1996|January 2011|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||October 2009|January 4, 2010|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997724||131778|
NCT00997412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ATW07T|Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis|Randomized, Double-blind, Double-dummy Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis|Myfortic|Qualitix Clinical Research Co., Ltd.|No|Active, not recruiting|May 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|70 Years|No|||October 2009|October 16, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997412||131802|
NCT01005771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-080623-01|Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions|GF-001001-00 Cream.A Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of 3 Different Doses of GF-001001-00 Cream Versus Placebo Cream Applied 2 Times Daily for 7 Days in the Treatment of Adult Patients With Secondarily-infected Traumatic Lesions||Ferrer Internacional S.A.|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|N/A|No|||June 2010|June 8, 2010|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01005771||131165|
NCT01005784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-3|Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation|Fixed Versus Flexible GnRH Antagonist Initiation||Aristotle University Of Thessaloniki|No|Completed|June 2005|March 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Female|18 Years|39 Years|No|||October 2009|October 30, 2009|November 13, 2007||No||No||https://clinicaltrials.gov/show/NCT01005784||131164|
NCT01006070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901Wolf|Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine|Prospective Observation Study of Health-related QOL, Physical Function & Respiratory Function in Patients w/ Myeloma Affecting Spine: The Impact of Disease,Fractures & Effect of Vertebral Augmentation w/ Kyphoplasty||University of California, San Francisco|No|Completed|February 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Multiple myeloma patients with spinal lesions|March 2012|March 19, 2012|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006070||131142|
NCT01005056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06083|Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)|Drug Use Investigation of MARVELON||Merck Sharp & Dohme Corp.|No|Completed|May 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|3838|||Female|N/A|N/A|No|Non-Probability Sample|Participants will be selected from clinical institutions where Marvelon® was adopted and        delivered.|April 2015|April 28, 2015|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01005056||131219|
NCT01005069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS-32-0309|Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus|Phase-II Clinical Study: A Randomized, Double Blind, Dose Ranging, and Controlled Study to Evaluate the Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus||Dexa Medica Group||Completed|October 2009|August 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|72|||Both|18 Years|60 Years|No|||September 2010|September 26, 2010|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01005069||131218|
NCT01000831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02749|Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine After One andTtwo Doses in Young Children||University of British Columbia|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|167|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||April 2015|April 14, 2015|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000831||131541|
NCT01001715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT11308|Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain|Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Vertebral Fracture Associated With Osteoporosis||Regeneron Pharmaceuticals|Yes|Terminated|November 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|40 Years|80 Years|No|||May 2013|May 20, 2013|October 26, 2009|Yes|Yes|Business decision due to low subject recruitment and enrollment|No||https://clinicaltrials.gov/show/NCT01001715||131474|
NCT01001988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC05|Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers|Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers in Thailand and the Philippines||Sanofi|No|Completed|August 2009|August 2014|Actual|October 2013|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|591|||Both|2 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Particpants received a single dose of the Japanese encephalitis chimeric virus vaccine        (JE-CV) in Study JEC02 (NCT00735644)|February 2015|February 28, 2015|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001988||131453|
NCT01002898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4/2551|Ritonavir-boosted Lopinavir Monotherapy|Treatment Outcomes and Plasma Level of Ritonavir-boosted Lopinavir Monotherapy Among HIV-infected Patients Who Had Non-nucleoside Reverse Transcriptase Inhibitor (NRTI) and NNRTI Failure: A Pilot Study||Bamrasnaradura Infectious Diseases Institute|Yes|Completed|April 2007|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2009|November 10, 2011|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01002898||131383|
NCT01001702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-05-243|Oral Aripiprazole Open-Label Rollover Study|An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|April 2006|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|13 Years|18 Years|No|||July 2013|July 29, 2013|October 22, 2009|No|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01001702||131475|
NCT01001962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREHYPERTENSION|Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics|Double Blind Comparison Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics With Metformin|PREHYPD|Aristotle University Of Thessaloniki|Yes|Not yet recruiting|January 2016|January 2020|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1054|||Both|45 Years|65 Years|No|||April 2015|April 6, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001962||131455|
NCT01002560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3078|The Identification of Novel Prognostic Markers in Melanoma|Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples||Royal Marsden NHS Foundation Trust|No|Recruiting|December 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Group of subjects with malignant melanoma, who have been treated at the Royal Marsden        Hospital|October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002560||131409|
NCT01002872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH 09-156|The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease|The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23 ) in Chronic Kidney Disease||NorthShore University HealthSystem Research Institute|No|Active, not recruiting|October 2009|December 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01002872||131385|
NCT01003158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00010|Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.|A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer||AstraZeneca|No|Completed|October 2009|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|20 Years|N/A|No|||July 2014|July 9, 2014|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01003158||131363|
NCT01003171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-2-US-pk|Pharmacokinetics of MCS in Healthy Volunteers|An Open-Label, Multiple-Dose Study of MCS-2 to Examine the Pharmacokinetics of MCS and Other Components After Once-daily Oral Dosing in Healthy Adult Volunteers|MCS-2-US-pk|Health Ever Bio-Tech Co., Ltd.|No|Not yet recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 28, 2011|October 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003171||131362|
NCT01007630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-SOAR|A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients|A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease|PD-SOAR|The Parkinson's Institute|No|Active, not recruiting|November 2009|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|N/A|90 Years|No|||November 2013|November 27, 2013|November 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007630||131023|
NCT01007890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-304|Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer|Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer|PT-304|Precision Therapeutics|Yes|Terminated|November 2009|October 2012|Actual|October 2012|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|134|Samples With DNA|Core needle biopsy specimens will be collected and stored in RNAlater® until the time of RNA      extraction, using standard procedures. Isolated total RNA will be assayed for gene      expression using methods such as TaqMan® RT-PCR technology or Affymetrix or Agilent gene      array platforms.|Female|18 Years|N/A|No|Non-Probability Sample|Women 18 years or older with Palpable Operable Breast Cancer Measurable Disease|October 2012|October 4, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007890||131004|
NCT01009047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016675|An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia|A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age||Janssen Research & Development, LLC|No|Completed|December 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|228|||Both|12 Years|17 Years|No|||June 2013|June 20, 2013|November 5, 2009|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT01009047||130915|
NCT01009073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-958|A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer||AbbVie|No|Completed|October 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|N/A|No|||June 2013|July 2, 2013|October 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009073||130913|
NCT01009385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|snu23802|Cervical Epidural Pressure Measurement|Cervical Epidural Pressure Measurement: Comparison in the Prone and Sitting Positions||Seoul National University Bundang Hospital|Yes|Enrolling by invitation|October 2009|November 2009|Anticipated|November 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2009|November 5, 2009|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01009385||130890|
NCT01009619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZI001|Azithromycin in Bronchiolitis Obliterans Syndrome|Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation.|AZI001|Katholieke Universiteit Leuven|No|Completed|September 2005|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|83|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|November 6, 2009||No||No|April 21, 2011|https://clinicaltrials.gov/show/NCT01009619||130873|
NCT00997126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMRF093030|Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation|Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation in the Emergency Department||Minneapolis Medical Research Foundation|Yes|Completed|October 2009|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00997126||131824|
NCT00997737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL2008/26|Diaphragm Activity During Incentive Spirometry and Diaphragmatic Breathing|Diaphragm Mobility During Respiratory Exercises With Incentive Spirometry in Healthy Individuals||Hospital Sirio-Libanes|Yes|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2009|May 27, 2010|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997737||131777|
NCT00997711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0119|Evaluation of Diabetic Effects on Clinical Outcomes After Sirolimus-Eluting Stents in the AsIAN Population|Evaluation of Diabetic Effects on Clinical Outcomes After Sirolimus-Eluting Stents in the AsIAN Population|DESSIAN|CardioVascular Research Foundation, Korea|Yes|Completed|April 2009|June 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|953|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997711||131779|
NCT01005797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101273|Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers|A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.||Medical University of South Carolina|Yes|Active, not recruiting|November 2009|November 2016|Anticipated|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|October 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01005797||131163|
NCT01005810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19152|A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana|A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent Adolescents||Medical University of South Carolina|Yes|Recruiting|September 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|13 Years|21 Years|No|||October 2009|October 30, 2009|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01005810||131162|
NCT01006083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-IM-0540-CTIL|Antiplatelet Therapy Continuation in Spine Surgery - Its Effect on Postoperative Morbidity and Mortality|Impact of Continued Use of Clopidogrel and / or Aspirin on Outcomes in Patients Undergoing Lumbar Spine Surgery. A Prospective Observational Study||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2010|February 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|Patients admitted for lumbar laminectomy, discectomy or foraminotomy.|October 2009|October 30, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006083||131141|
NCT01005082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIN2002062925|Low Salt Diet in Idiopathic Hypercalciuria|Calcium Nephrolithiasis: Clinical Characteristics and Nutritional Determinants|LOSALT01|University of Parma||Completed|January 2005|December 2008|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|65 Years||||October 2009|October 29, 2009|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005082||131217|
NCT01005095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNFVD0209|The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients|A One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple Sclerosis||Carmel Medical Center|No|Terminated|October 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||September 2012|September 2, 2012|October 29, 2009||No|Interim analysis showed that the odds for proving primary hypothesis are low.|No||https://clinicaltrials.gov/show/NCT01005095||131216|
NCT01000844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-0436|Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency|Continuation of Children Enrolled in Protocol #95-011, 'A Randomized Prospective Study for the Prevention of Joint Disease in Children With Severe Factor VIII Deficiency'|JOSC|University of Colorado, Denver|Yes|Enrolling by invitation|November 2009|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Whole Blood - EDTA, Citrate Plasma, and DNA|Male|8 Years|18 Years|No|Non-Probability Sample|Study population will be invited based on their enrollment in the original Joint Outcome        Study (JOS). This population|June 2015|June 9, 2015|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000844||131540|
NCT01001455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth3|Clinical Test for Armed-used Blood Pressure Monitor With Preformed Cuff|||Andon Health Co., Ltd|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|90|||Both|23 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|resident of a community.|October 2009|October 23, 2009|October 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001455||131494|
NCT01001728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3131|SuPr Study (Supine Versus Prone Treatment Position in Breast Radiotherapy)|A Randomised Trial Investigating the Prone Treatment Position as a Method of Sparing Healthy Tissues in Women Prescribed Breast Radiotherapy (SuPr Study)|SuPr|Royal Marsden NHS Foundation Trust|No|Recruiting|November 2008|November 2009|Anticipated|November 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|25|||Female|18 Years|N/A|No|||October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001728||131473|
NCT01002287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABD-08-001|An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery|An Evaluation of the SprayShield Adhesion Barrier System in Reducing Post-Operative Adhesion in Abdominal Surgery||Integra LifeSciences Corporation|No|Terminated|October 2009|May 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|11|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|October 26, 2009||No|Study was terminated for business purposes, not for safety or efficacy reasons.|No|June 21, 2012|https://clinicaltrials.gov/show/NCT01002287||131430|Early termination leading to small numbers of subjects analyzed
NCT01003210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37011-B|Homeopathic Ear Drops for Otitis Media Study|Homeopathic Ear Drops for Children With Otitis Media Study||University of Washington|No|Completed|October 2009|December 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|210|||Both|6 Months|11 Years|No|||July 2014|July 23, 2014|October 26, 2009||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01003210||131359|Initially planned sample size --150. Study size was increased after analysis of initial data found a non-significant trend between antibiotic fill rates in the homeopathic ear drop and standard therapy treatment groups.
NCT00999791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8818|Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema|||hahid Beheshti University of Medical Sciences|Yes|Recruiting|July 2009|||||Phase 1|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Both|N/A|N/A||||October 2009|May 3, 2010|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00999791||131621|
NCT01002248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 339|Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients|A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients||AEterna Zentaris|Yes|Terminated|December 2009|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||March 2013|February 14, 2014|October 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002248||131433|
NCT01002573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-012|Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients|A Multicenter, Randomized, Open-Label, Parallel, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Pediatric Patients||Cumberland Pharmaceuticals|No|Completed|July 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|N/A|16 Years|No|||July 2014|July 7, 2014|October 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002573||131408|
NCT01002586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361-09-EP|Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia|Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia||University of Nebraska|No|Recruiting|November 2009|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|60 Years|N/A|No|||June 2010|June 1, 2010|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002586||131407|
NCT01002885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090163|Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles.|The Use of FSH Receptor Polymorphisms To Improve Pregnancy Rates In In-Vitro Fertilization||University Reproductive Associates|No|Completed|July 2009|May 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|75|Samples With DNA|2 EDTA containing lavender topped tubes will be collected before, during or within 3 months      after an IVF cycle. Genomic DNA will be extracted and saved for genotyping.|Female|18 Years|35 Years|No|Non-Probability Sample|Patients undergoing in-vitro fertilization will be recruited. Inclusion criteria will        limit the patient population to those patients most likely to have normal ovarian function        since age or disease related ovarian dysfunction will confound interpretation of our        results.|December 2013|December 9, 2013|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002885||131384|
NCT01003184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-EW-GWDL|Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes|Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulphonylurea||AstraZeneca|No|Completed|October 2009|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|October 15, 2009|Yes|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT01003184||131361|
NCT01003197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 2009|Novel Preoperative Score Predicting Outcome Following Liver Resection|Novel Preoperative Score Predicting Outcome Following Liver Resection||University of Zurich|Yes|Completed|February 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|18 Years|90 Years|No|Probability Sample|HPB center Zurich, Switzerland|October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003197||131360|
NCT01008228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/2009/38|Comparison of Exsufflation Versus Drainage in Primary Spontaneous Pneumothorax|Comparison of Efficacity of Simple Aspiration Versus Standard Drainage in the Management of Large Size Primary Spontaneous Pneumothorax|EXPRED|Centre Hospitalier Universitaire de Besancon|Yes|Active, not recruiting|June 2009|March 2015|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|50 Years|No|||February 2015|February 23, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01008228||130978|
NCT01000805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13399|A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms|A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients With Major Depressive Disorder and Associated Painful Physical Symptoms||Eli Lilly and Company|No|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|528|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|October 22, 2009|Yes|Yes||No|October 5, 2011|https://clinicaltrials.gov/show/NCT01000805||131543|
NCT00996528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Federal Identifier # AA017104|Neighborhood Alcohol & HIV Prevention in South African Townships (Philani)|Neighborhood Alcohol & HIV Prevention in South African Townships (Philani)||University of California, Los Angeles|No|Active, not recruiting|September 2007|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1239|||Female|18 Years|N/A|No|||June 2015|June 8, 2015|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996528||131870|
NCT00996814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26.111EXP|Proactive Ethics Intervention to Improve Intensive Care Unit (ICU) Care|Proactive Ethics Intervention to Improve ICU Care|PEI|California Pacific Medical Center Research Institute|No|Completed|October 2007|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|386|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00996814||131848|
NCT00997113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMRF093051|Stress During Deep Sedation With Propofol With and Without Alfentanil|Physiologic Stress During Procedural Sedation With and Without Alfentanil||Minneapolis Medical Research Foundation|Yes|Completed|October 2009|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2014|September 21, 2014|October 12, 2009|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT00997113||131825|
NCT00997425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6275-R|Home Evaluation of Exit Barriers in Wandering|Home Evaluation of Visual Exit Barriers in Dementia-related Wandering|HEEBW|VA Office of Research and Development|No|Completed|October 2009|December 2012|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|19|||Both|60 Years|N/A|No|||November 2014|November 19, 2014|October 15, 2009||No||No|October 9, 2013|https://clinicaltrials.gov/show/NCT00997425||131801|Radio Frequency Identification Device measurement method cumbersome and obtrusive; small sample size (n=19). Further investigation is necessary in order to draw conclusions about visual barriers deterring wandering defined as exit door approaching.
NCT00997438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5659|Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis|Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis||Portland VA Medical Center|No|Recruiting|August 2010|December 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 24, 2012|October 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997438||131800|
NCT00998010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000657015|Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|June 2011|||October 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00998010||131756|
NCT00997971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROS-CL3-001|Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein|Phase 3 Safety Study of a Partially Hydrolyzed Rice Protein Formula in Healthy Infants|Rose|Sodilac|No|Completed|September 2007|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|86|||Both|N/A|1 Month|No|||October 2009|October 19, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00997971||131759|
NCT01005836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH057347|Community Clinic Test of Youth Anxiety Treatment|Community Clinic Test of Youth Anxiety and Depression Study|YADS|Harvard University|Yes|Completed|February 1998|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|105|||Both|8 Years|15 Years|No|||October 2009|October 30, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005836||131160|
NCT01005849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09-prot-2-lal-01|Probiotics and the Prevention of Traveler's Diarrhea|A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea|TD|Lallemand SAS|Yes|Terminated|October 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|January 18, 2012|October 30, 2009||No|because of low rate recruitment and the inability to reach the target expected|No||https://clinicaltrials.gov/show/NCT01005849||131159|
NCT01006096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL-041509|Erlotinib for Treatment of Psoriasis|Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis||Northwestern University|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|October 29, 2009|Yes|Yes|IND not obtained|No||https://clinicaltrials.gov/show/NCT01006096||131140|
NCT01005108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 16108|Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors|Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|January 2009|||February 2014|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|124|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01005108||131215|
NCT01001468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-201-006|Study to Assess VB-201 in Patients With Psoriasis|A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis||Vascular Biogenics Ltd. operating as VBL Therapeutics|Yes|Completed|December 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|185|||Both|18 Years|75 Years|No|||November 2011|November 15, 2011|October 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001468||131493|
NCT01002599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0160-B|Oxygenation and Pulmonary Function in Morbidly Obese Patients Undergoing Bariatric Surgery|Does BoussignacTM CPAP Compared to Venturi Mask Improve Oxygenation and Pulmonary Function in Morbidly Obese Patients Undergoing Bariatric Surgery?||University Health Network, Toronto|No|Recruiting|June 2009|January 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|75 Years|No|||January 2010|January 22, 2010|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002599||131406|
NCT00999531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-221-0107|A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Volunteers||Gilead Sciences|No|Completed|October 2009|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 8, 2010|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999531||131640|
NCT00999804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25846|Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy|TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer|HELEX|Baylor Breast Care Center|Yes|Active, not recruiting|October 2011|January 2018|Anticipated|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Female|18 Years|N/A|No|||November 2014|July 27, 2015|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00999804||131620|
NCT00999817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471039|A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers|An Open Label Phase 1, Randomized Cross Over Trial To Estimate The Effect Of PF- 00299804 On The Pharmacokinetics Of Dextromethorphan In Healthy Volunteers||Pfizer|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 5, 2010|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00999817||131619|
NCT01002261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gal-FDGal|Hepatic Metabolism of Galactose and the Galactose Analog FDGal in Patients With Liver Disease and Healthy Subjects|Determination of Hepatic Metabolism of Galactose and the Galactose Analog FDGal in Patients With Liver Disease and Healthy Subjects||Aarhus University Hospital|No|Completed|October 2009|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients are out-patients recruited from Department of Hepatology, Aarhus University        Hospital Healthy subjects are recruited via add in a local newspaper|October 2009|January 22, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002261||131432|
NCT01000064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBI 090563|Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits|Psychostimulant Treatment of TBI-Related Attention Deficits: fMRI Analysis of Neural Mechanisms of Response||Vanderbilt University|No|Completed|October 2009|May 2015|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|16 Years|45 Years|No|||June 2015|June 3, 2015|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01000064||131600|
NCT01000077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007586|Establishment of Cell Culture Systems From Discarded Operating Room Tissue|||Wake Forest School of Medicine||Recruiting|February 2009|||||N/A|Observational|N/A||2|Anticipated|1000|||Both|N/A|80 Years|No|Non-Probability Sample|There is no specific study population for the this study. The patients from whom discarded        tissue will be harvested will be any patients within the set age criteria in the operating        room that have viable tissue excised for discard. In other words, when any investigators        from the study have discard tissue as a result of a surgical procedure, this tissue will        be a possible specimen for use in the protocol. Only discard tissue will be used, however,        so if the tissue isn't used in the study, it would simply be thrown away.|October 2009|October 21, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000077||131599|
NCT01000337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Σ-74/07-07-2009|Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol|The Impact of Sevoflurane and Propofol Anesthesia on Hepatic Apoptosis Markers||University of Athens|No|Completed|October 2009|April 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|67|||Female|30 Years|65 Years|No|||August 2012|August 12, 2012|October 22, 2009||No||No|May 7, 2012|https://clinicaltrials.gov/show/NCT01000337||131579|
NCT01000597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113477|Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects|An Open-label, Randomised, Two-way Crossover Study, to Evaluate and Compare the Pharmacokinetics of Fluticasone Furoate, Administered From a Novel Dry Powder Device (Repeat Dose) and Intravenously (Single Dose), in Healthy Caucasian, Japanese, Korean and Chinese Subjects||GlaxoSmithKline|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|20 Years|64 Years|No|||January 2011|January 27, 2011|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000597||131559|
NCT01008254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#1007523|Interdisciplinary Mobility Approach To Reduction Of Facility-Acquired Pressure Ulcers|Interdisciplinary Mobility Approach To Reduction Of Facility-Acquired Pressure Ulcers|TEAM|University of Cincinnati|Yes|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|2000|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2011|October 18, 2011|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008254||130976|
NCT01008826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002015|Cross-Over Broccoli Sprouts Trial|Cross-Over Broccoli Sprouts Trial - Qidong||Johns Hopkins Bloomberg School of Public Health|No|Completed|October 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 15, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008826||130932|
NCT01008839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protein Synthesis|Protein Synthesis in Midthigh Muscles PET/CT|||University of California, San Francisco||Completed|March 2010|||||N/A|Observational|N/A||2|Anticipated|10|||Female|25 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|healthy women|May 2011|May 13, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008839||130931|
NCT00996827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0815|Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma|Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma||New Mexico Cancer Care Alliance|No|Terminated|January 2009|December 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|Samples With DNA|-  Serum samples will be collected to evaluate the immune status of these patients.        -  Serum cytokine profiles        -  Whole blood samples - lymphocyte sub-populations from fresh, refrigerated whole blood           samples. Whole blood samples will be used to extract DNA and RNA material. The           remaining DNA for future research related to cytokine gene and vitamin D receptor           single nucleotide polymorphisms studies of the Molecular Epidemiology Laboratory        -  H & E slides will be evaluated by our collaborating pathologist to validate diagnoses           and Breslow thickness        -  Formalin-fixed paraffin embedded blocks will be sectioned and stained for           immunohistochemistry        -  One slide will be prepared from the skin block to evaluate the presence of solar           elastosis in relation to UV exposure|Both|18 Years|95 Years|No|Non-Probability Sample|Patients who have recieved interferon or IL-2 therapy.|June 2015|June 17, 2015|October 14, 2009|No|Yes|Sufficient samples collected when 73% of target enrollment was reached.|No||https://clinicaltrials.gov/show/NCT00996827||131847|
NCT00997139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-9892|Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment|Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment||Northwestern University|Yes|Completed|September 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 11, 2014|October 15, 2009|Yes|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT00997139||131823|
NCT00997152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT654-U-09-004|Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients|A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of JTT-654 Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients||Akros Pharma Inc.|No|Terminated|September 2009|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|70 Years|No|||January 2013|January 31, 2013|October 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997152||131822|
NCT00997451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 5R01NR010229 - 03|Fatigue Self-Management in Primary Care|Fatigue Self- Management in Primary Care: Efficacy, Credibility, and Economics||Stony Brook University|No|Completed|February 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|107|||Both|18 Years|70 Years|No|||September 2012|September 28, 2012|March 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00997451||131799|
NCT00997464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3200|An Exploration of Genetic Testing for Prostate Cancer Susceptibility|An Exploration of Factors Affecting Interest and Uptake of Genetic Testing for Prostate Cancer Susceptibility: The Clinical Application of Genetic Testing for Lower Risk Cancer Predisposition Genes||Royal Marsden NHS Foundation Trust|No|Recruiting|August 2009|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Male|40 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men with strong family history of prostate cancer.|October 2009|October 16, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997464||131798|
NCT00998543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VVL05|A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)|A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)||Sanofi|No|Completed|October 2006|March 2012|Actual|September 2011|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|147|||Both|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04        (NCT 00258947)|August 2012|August 2, 2012|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998543||131716|
NCT00998868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-RM-TRHan-RCTHS-01|Rotator Cuff Tears in Hemiplegic Shoulder|Observational Study to Evaluate the Prevalence of Rotator Cuff Tears in Hemiplegic Shoulders||Seoul National University Hospital|No|Completed|January 2008|August 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|51|||Both|20 Years|90 Years|No|Probability Sample|university hospital, department of rehabilitation medicine admitted patients due to        hemiplegia|September 2011|September 23, 2011|October 20, 2009||No||No|August 15, 2010|https://clinicaltrials.gov/show/NCT00998868||131691|
NCT00997984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-314|Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)|A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder||Shire||Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|340|||Both|6 Years|12 Years|No|||January 2014|January 7, 2014|October 19, 2009|Yes|Yes||No|September 16, 2011|https://clinicaltrials.gov/show/NCT00997984||131758|
NCT00997945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4320C00041|10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies|A Phase I, Open-label, Single-arm Study to Determine the Single and Multiple Dose Pharmacokinetics of 10mg ZD4054 (Zibotentan) Administered Once Daily in Male, Elderly Chinese Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|October 2009|April 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|50 Years|N/A|No|||May 2011|May 18, 2011|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00997945||131761|
NCT00998205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1115797|Early Diagnosis of Diastolic Dysfunction and Reliability of Dobutamine Stress Echo (DSE) in Detecting Stress Diastolic Dysfunction|Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction||University of Missouri-Columbia|No|Completed|June 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 15, 2011|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998205||131741|
NCT01001156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0043-2008|Effects of the Breathing Muscular Training of Institutionalized Elderly|Effects of the Breathing Muscular Training to Volume and the Pressure in MIP and MEP of Institutionalized Elderly||Universidade Castelo Branco|Yes|Completed|October 2008|May 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|37|||Both|60 Years|82 Years|No|||October 2009|October 22, 2009|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001156||131516|
NCT01001169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113847|Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years||GlaxoSmithKline||Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||January 2011|January 22, 2011|October 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001169||131515|
NCT01001481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013822|Schizophrenia Treatment Adherence Investigation (STAI)|Clinical Audit and Feedback Program to Determine Risk for Medication Adherence in Outpatients Diagnosed With Schizophrenia in Australia||Janssen-Cilag Pty Ltd|No|Completed|July 2007|September 2009|Actual|September 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|550|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatient clinics|April 2014|April 8, 2014|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001481||131492|
NCT01001494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/34|Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients|Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Almirall, S.A.|No|Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|828|||Both|40 Years|N/A|No|||July 2015|July 2, 2015|October 22, 2009|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT01001494||131491|
NCT00999544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0446|Aprepitant Effects on Oxycodone Response|New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone||University of Kentucky|No|Completed|October 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 19, 2013|October 20, 2009|No|Yes||No|November 13, 2012|https://clinicaltrials.gov/show/NCT00999544||131639|No significant adverse effects occurred. No adverse events led to study drop-out.
NCT01000636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29061|Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)|Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT||Galderma|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000636||131556|
NCT00999778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P50HD055784|Optimizing Social and Communication Outcomes for Toddlers With Autism|Optimizing Social and Communication Outcomes for Toddlers With Autism||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|July 2008|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|86|||Both|18 Months|36 Months|No|||August 2012|August 14, 2012|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999778||131622|
NCT01000350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090942|Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)|Intravenous Saline on Exercise Tolerance in Orthostatic Intolerance||Vanderbilt University|No|Active, not recruiting|October 2009|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|October 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01000350||131578|
NCT01000610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20549|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate||Hoffmann-La Roche||Completed|March 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|October 21, 2009||No||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01000610||131558|
NCT01000623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC09C7|Venlafaxine and Hypnosis or Focused Attention In Treating Patients With Hot Flashes|Evaluation of a Biobehavioral Intervention for Hot Flashes||Mayo Clinic|Yes|Active, not recruiting|November 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|February 23, 2016|October 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01000623||131557|
NCT00997542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-044|Allopurinol in Chronic Heart Failure|A Double-blind, Placebo-controlled, Cross-over Study of the Effects of Allopurinol on Oxidative Metabolism, Peripheral Blood Flow and Immune Function in Patients With Advanced Chronic Heart Failure (CHF).||National Heart and Lung Institute||Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|21 Years|N/A|No|||October 2009|October 16, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997542||131792|
NCT00996372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.130|Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women|24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States||Sprout Pharmaceuticals, Inc|Yes|Completed|October 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|949|||Female|35 Years|N/A|No|||May 2014|May 14, 2014|October 15, 2009|Yes|Yes||No|February 26, 2014|https://clinicaltrials.gov/show/NCT00996372||131882|
NCT01008852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3227K1-2000|Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis|Randomized, Parallel, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate||Pfizer|Yes|Completed|December 2009|July 2013|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|210|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|November 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008852||130930|
NCT01009060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113147|Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia|A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia||GlaxoSmithKline|No|Completed|December 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|55 Years|No|||January 2012|March 15, 2012|November 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01009060||130914|
NCT00996840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111592|SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS|Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).||GlaxoSmithKline|Yes|Completed|October 2009|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|80 Years|No|||April 2015|April 27, 2015|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996840||131846|
NCT00996853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113585|Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom|Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)|H1N1 PASS UK|GlaxoSmithKline||Completed|October 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9206|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The population studied will include individuals in priority groups currently considered        for H1N1 pandemic vaccination. Subjects not pertaining to these priority groups can also        be enrolled.|March 2012|June 14, 2012|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996853||131845|
NCT00997165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-Promoteur 08-01|Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort|Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort|NUMEVOX|University Hospital, Angers|No|Recruiting|March 2008|March 2017|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples With DNA|serum and DNA|Both|18 Years|80 Years|No|Non-Probability Sample|Any patient suspected of metabolic syndrome with or without sleep apnea or liver        steatosis.        Informed consent with signature.|October 2009|October 16, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997165||131821|
NCT00997178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR:07-003|Diabetes and Periodontal Therapy Trial|A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis|DPTT|Stony Brook University|Yes|Completed|October 2009|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|514|||Both|35 Years|N/A|No|||January 2014|January 17, 2014|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997178||131820|
NCT01007539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC09MISI0166|Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence|||Seoul National University Hospital|Yes|Completed|November 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|19 Years|60 Years|No|||August 2012|August 29, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007539||131030|
NCT01007552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 150509|A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts|A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts.||Roswell Park Cancer Institute|Yes|Completed|December 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007552||131029|
NCT00998881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A5|Monotherapy Study of MP-513 in Patients With Type 2 Diabetes|A Phase III, Double-blind, Placebo Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus - Confirmative Study||Mitsubishi Tanabe Pharma Corporation|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|203|||Both|20 Years|75 Years|No|||January 2014|January 8, 2014|October 15, 2009||No||No|January 8, 2014|https://clinicaltrials.gov/show/NCT00998881||131690|
NCT00997958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA1127|Study of CellCept for Advanced Pancreatic Cancer|Phase I Study of CellCept for Advanced Pancreatic Cancer||Columbia University|Yes|Completed|June 2004|January 2009|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||April 2014|April 24, 2014|October 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00997958||131760|
NCT00998478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKC01|Cardiovascular Disease and the Effects of a Cross-curricular Physical Activity Intervention|Cardiovascular Disease Risk Factors and the Effects of a Cross-curricular Physical Activity Intervention in 11-14 Year Olds. Activity Knowledge Circuit||University of Glamorgan||Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|192|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||October 2009|October 19, 2009|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998478||131720|
NCT01001182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-102329|Health Outcomes in Rheumatoid Arthritis in Greece|Rheumatoid Arthritis in Greece: The Economic Burden of the Disease and the Impact on Quality of Life|HORA|Pfizer|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|210|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 years or older with confirmed RA diagnosis will be included in the study.        The investigating physician must confirm RA diagnosis during the patient's visit.|July 2014|July 25, 2014|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001182||131514|
NCT01001195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210669-010|Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution|||Allergan|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|165|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|October 22, 2009|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01001195||131513|
NCT01001208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070559|The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis||Amgen||Completed|November 2009|February 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|478|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|October 15, 2009||||No|December 21, 2011|https://clinicaltrials.gov/show/NCT01001208||131512|
NCT01002001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-0459|Sleep Disorders Pre and Post Liver Transplantation|Prospective Study to Evaluate Sleep Disturbance in Patients With Liver Disease Pre and Post Liver Transplantation||University Health Network, Toronto|No|Enrolling by invitation|October 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients attending the pre and post-transplantation liver clinics|October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002001||131452|
NCT01002274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-2-TWN-c|Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms|Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects|MCS-2-TWN-c|Health Ever Bio-Tech Co., Ltd.|No|Completed|August 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Male|40 Years|N/A|No|||March 2015|March 1, 2015|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002274||131431|
NCT01000363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00029165|Diabetes Group Visits|Diabetes Medical Group Visits Pilot Study||Emory University|No|Completed|November 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|92|||Both|18 Years|80 Years|No|Non-Probability Sample|We plan to study a total of 40 patients with a known history of type 1 or type 2 diabetes,        ages 18-80. Patients included within this study will be determined by the set of inclusion        and exclusion criteria.|July 2013|July 7, 2014|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000363||131577|
NCT00996398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULREC 09/11|Cold Water Immersion Does Not Reduce Knee Joint Position Sense in Healthy Participants: a Randomised Cross-over Trial|Cold Water Immersion Does Not Reduce Knee Joint Position Sense in Healthy Participants: a Randomised Cross-over Trial'||University of Limerick|No|Completed|May 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 15, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00996398||131880|
NCT00996411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00009081|Human Psychopharmacology of Salvinorin A|||Johns Hopkins University||Completed|November 2008|||November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|14|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 21, 2014|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996411||131879|
NCT01000090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kzr200809|Surgical Versus Medical Treatment of Acromegaly|Surgical Versus Medical Treatment of Acromegaly: Effects on Biochemical Markers||University of Aarhus|No|Completed|October 2009|June 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|63|Samples Without DNA|Serum|Both|N/A|N/A|No|Non-Probability Sample|Acromegalic patients followed in the outpatient clinic at Århus University Hospital,        Medical Department M|June 2011|December 2, 2015|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000090||131598|
NCT01000103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071238|Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke|Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke: A Double Blind Study|NEGLECT|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2010|February 2014|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|148|||Both|18 Years|75 Years|No|||May 2011|October 28, 2011|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000103||131597|
NCT00997256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC 152/04|Study to Investigate Effects of a Herbal Drug Compared to Placebo on Sleep|Phase I, Placebo-controlled, Double-blind, Randomised, Single-centre Study of Single Cross-over Design to Investigate the Effects of the Herbal Preparation Neurapas® Balance Compared With Placebo on Sleep EEG, Mental Performance and Well-being|sleep-EEG|Pascoe Pharmazeutische Praeparate GmbH|Yes|Completed|December 2004|February 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 14, 2010|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997256||131814|
NCT00997555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC0001|Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients|Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients||Hurley Medical Center|No|Completed|October 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||December 2012|December 22, 2012|October 15, 2009||No||No|September 4, 2012|https://clinicaltrials.gov/show/NCT00997555||131791|
NCT00997815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajH|The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis|The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis||Siriraj Hospital|No|Completed|December 2009|June 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997815||131771|
NCT01000506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112997|Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma|DREAM|GlaxoSmithKline|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|621|||Both|12 Years|65 Years|No|||January 2016|January 7, 2016|October 22, 2009|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT01000506||131566|
NCT01000792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRI-2009-09-001-IV|3-D Visualization of the Anti-Obstructive Effect of Levocetirizine|3-D Visualization of the Anti-Obstructive Effect of Levocetirizine - A Monocentric Clinical Trail With One Patient (Phase-IV-Study)|LevoNasalFlo|Clinical Research International Limited|No|Completed|November 2009|July 2010|Actual|January 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||June 2011|June 21, 2011|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000792||131544|
NCT01000038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|085-09-FB|Wii-fit for Activity, Balance and Gait in Assisted Living|Wii-fit for Activity, Balance and Gait in Assisted Living||University of Nebraska|No|Recruiting|March 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|22|||Both|60 Years|N/A|No|||October 2009|October 23, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01000038||131602|
NCT00996606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22413|A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs|Open Label, Multicenter Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) of the Hand of Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|October 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996606||131864|
NCT00996619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-7285-09-AO-CTIL|Measuring the Spectrum of Tissues During Endoscopy|Measuring the Spectrum of Tissues During Endoscopy||Sheba Medical Center|No|Not yet recruiting|October 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Independent Adults|October 2009|October 15, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00996619||131863|
NCT00997191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6826/2009|Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)|Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)|IBeTA|University of Sao Paulo|Yes|Completed|October 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997191||131819|
NCT00997204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE049-3101|EASSI - Evaluation of the Safety of Self-Administration With Icatibant|Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema|EASSI|Shire|No|Completed|September 2009|September 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|October 16, 2009|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT00997204||131818|
NCT01008423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCF3002|Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis||Valeant Pharmaceuticals International, Inc.|No|Completed|November 2009|||March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|281|||Both|18 Years|N/A|No|||November 2012|May 17, 2013|November 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008423||130963|
NCT01008436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-03|Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.|||Cardiochirurgia E.H.|Yes|Terminated|January 2010|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|N/A|N/A|No|||February 2012|February 19, 2012|November 3, 2009||No|Lack of product due to industrial changes in the manufacturing process altering the final    product.|No||https://clinicaltrials.gov/show/NCT01008436||130962|
NCT00998218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAN-Twave alt|Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction|The Effect of Ranolazine on Cardiac Arrhythmias and Microvolt T- Wave Alternans in Patients With Significant Left Ventricular Dysfunction||Aspirus Heart and Vascular Institute-Research and Education|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|October 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00998218||131740|
NCT00998504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-039|resVida and Fat Oxidation|Effect of resVida on Fat Oxidation and Mitochondrial Biogenesis in Healthy Obese Subjects||Maastricht University Medical Center|No|Completed|October 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998504||131719|
NCT01001507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFR08-02986|Integrating Family Planning Services Into HIV Care and Treatment in Nyanza Province, Kenya|Cluster Randomized Trial of Integration of Family Planning Services Into HIV Care and Treatment in Suba, Kisumu East, Rongo and Migori Districts of Nyanza Province||University of California, San Francisco|No|Completed|September 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|5040|||Both|18 Years|45 Years|No|||December 2013|December 6, 2013|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01001507||131490|
NCT01001741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805891|Pilot Study of Text Message Reminders to Improve HIV Medication Adherence in Botswana|A Pilot Study of Cellular Phone Text Message Reminders to Improve HIV Medication Adherence at Independence Surgery Clinic Gaborone, Botswana||University of Pennsylvania|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|128|||Both|21 Years|N/A|No|||June 2010|September 16, 2015|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001741||131472|
NCT00999206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S203.3.013|Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine|Randomized, Double-Blind Study to Assess Safety, Immunogenicity, and Lot Consistency of Solvay's Cell-Derived Influenza Vaccine and Its Non-Inferiority Compared to Influvac®.||Abbott|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3138|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 25, 2011|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999206||131665|
NCT00999219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6199-CL-0006|A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia|FK199B (Zolpidem MR Tablet) Phase III Clinical Study - A Double-Blind, Crossover, Comparative Polysomnographic Study Using Zolpidem (Myslee®) as a Positive Control in Patients With Insomnia, Excluding Patients With Schizophrenia or Manic-Depressive Psychosis||Astellas Pharma Inc|No|Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|20 Years|65 Years|No|||August 2014|August 19, 2014|October 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00999219||131664|
NCT01000662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S09-0030|Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor|Phase III Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor||New York University School of Medicine|Yes|Active, not recruiting|March 2009|March 2022|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Female|18 Years|N/A|No|||May 2015|May 13, 2015|October 9, 2009||No||No|May 12, 2015|https://clinicaltrials.gov/show/NCT01000662||131554|
NCT01000675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002933|Registry for Study of Coils in Intracranial Aneurysms|Gaining Efficacy Long Term: Hydrosoft, an Emerging, New, Embolic Coil (Gel-the-nec)|Gel-the-nec|Mayo Clinic|No|Active, not recruiting|August 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|114|||Both|21 Years|90 Years|No|Non-Probability Sample|All people with cerebral aneurysms between the ages of 21 and 90 that are treated with        coils.|March 2016|March 17, 2016|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000675||131553|
NCT00996385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD4868|Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma|A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma||Columbia University|Yes|Recruiting|September 2009|September 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|October 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996385||131881|
NCT00996957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A041-01|Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma|A Phase 1 Open-Label, Multiple Dose, Dose Escalation Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma||Acceleron Pharma, Inc.|Yes|Completed|October 2009|October 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|October 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996957||131837|
NCT00996970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-053|Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons|Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons||Uniformed Services University of the Health Sciences|No|Active, not recruiting|October 2009|December 2015|Anticipated|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|132|Samples Without DNA|Blood samples will be collected for immunologic studies including antibody titers and      cellular responses. Viral isolates will be obtained and characterized among ILI cases during      study participation. Blood for CD4/HIV RNA levels will also be obtained among HIV patients      to determine the impact of the vaccine on these counts.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males and females of all races and all military beneficiaries including active duty        enlisted and officers (from all branches of service), retirees, and their dependents        presenting for H1N1 vaccination as part of routine clinical care will be eligible for        participation. Both HIV-positive and negative persons can participate. Since most of our        HIV patients are 18-50 years of age, and seroresponse varies by age, we will enroll        persons between the ages of 18-50 years.|May 2015|May 4, 2015|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996970||131836|
NCT00997269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0436|Benefit of CoQ-10 in Patients on Statins|Benefit of CoQ-10 in Patients on Statins|CoQ-10|Stony Brook University|Yes|Recruiting|September 2009|July 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|21 Years|N/A|No|||August 2011|August 11, 2011|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997269||131813|
NCT00996554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK II-MA 0263.5|Randomized Study Comparing Two Established Gastrointestinal Suture Techniques - One-layer-continuous Versus Double-layer-continuous Suture|Randomized Trial to Compare Two Gastrointestinal Anastomosis Techniques - Single Layer Continuous Versus Double Layer Continuous|ANATECH|Universitätsmedizin Mannheim|Yes|Terminated|January 2004|May 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 14, 2009||No|Feasibility reasons; recruitment was too slow.|No||https://clinicaltrials.gov/show/NCT00996554||131868|
NCT00996320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 08-74B|Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit|Effect of Reducing ICU Interns' Work Hours on Sleep, Intern Well-Being, and Medical Errors||Providence Health & Services|No|Completed|June 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2009|October 15, 2009|August 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00996320||131886|
NCT00996333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8628|Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)|Phase II Study of a Biochemically Synergistic Regimen for Metastatic Pancreatic Cancer (Stage IVB) With Gemzar, Taxotere and Xeloda (GTX)||Columbia University|Yes|Completed|June 2003|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|70 Years|No|||February 2013|February 12, 2013|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00996333||131885|
NCT00997490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC 120/99|Study of the Antidepressant Efficacy of a Combination Herbal Drug Preparation (NEURAPAS Balance)|Phase III Placebo-controlled, Randomised, Single-centre, Double-blind Study of the Antidepressant Efficacy of a Combination Herbal Drug Preparation||Pascoe Pharmazeutische Praeparate GmbH|Yes|Terminated|January 2001|February 2003|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|70 Years|No|||May 2010|May 14, 2010|October 16, 2009||No|Clearly identifiable benefits 50% of patients included|No||https://clinicaltrials.gov/show/NCT00997490||131796|
NCT00997763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0220|Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus|Randomized Comparison of Everolimus- Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus|ESSENCE-DM|CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|July 2008|March 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||January 2015|January 11, 2015|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997763||131775|
NCT01008462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2241.00|Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia|Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia||Fred Hutchinson Cancer Research Center|Yes|Recruiting|March 2010|||January 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|75 Years|No|||January 2016|January 20, 2016|November 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01008462||130960|
NCT01008735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FertHD|Gonadal Toxicity in Women With Hodgkin Lymphoma|Observational Retrospective Study to Evaluate the Incidence of the Gonadal Toxicity in Women of Reproductive Age With Hodgkin Lymphoma|FertHD|Gruppo Italiano Studio Linfomi|No|Recruiting|July 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Female|18 Years|40 Years|No|Non-Probability Sample|Female patients with Hodgkin lymphoma diagnosed until 2007 in Italy will be considered        eligible for this study. Cases will be identified from the archives of GISL.|November 2009|November 11, 2009|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01008735||130939|
NCT00999167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-008|A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy|HALT-HE|Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|December 2009|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|October 8, 2009|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT00999167||131668|
NCT00999180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFBA-064|Botulinum Toxin Type A and Kinesitherapy of Post-stroke Patients|Botulinum Toxin Type A and Kinesitherapy Use in the Functional Performance of Post-stroke Patients||Federal University of Bahia|Yes|Active, not recruiting|June 2009|April 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||October 2009|December 14, 2011|October 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00999180||131667|
NCT00998231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/15|Major Depression and Messenger RNAs|Major Depression and Messenger RNAs||Assistance Publique Hopitaux De Marseille|No|Completed|July 2009|||September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 24, 2014|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00998231||131739|
NCT01000324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112267|Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix™ Adult|An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-028 (208127/021) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.||GlaxoSmithKline||Completed|November 2009|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|44|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|October 22, 2009|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT01000324||131580|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/ml). The table shows updated results following partial or complete retesting/reanalysis.
NCT00998920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-CT02|Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers|Randomized, Double-Blind, Rising Multiple Dose Study of S-Equol in Normal Volunteers||Ausio Pharmaceuticals, LLC|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 11, 2012|October 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00998920||131687|
NCT00998907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/2009|PDS*Plus and Wound Infections After Laparotomy|Pathway Driven Study to Evaluate the Incidence of Wound Infections and Incisional Hernias After Laparotomy and Fascial Closure With PDS*Plus Sutures|PDS*plus|University Hospital, Saarland|No|Completed|September 2009|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1042|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00998907||131688|
NCT00999232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bengmark_v1|Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube|||Canisius-Wilhelmina Hospital||Completed|October 2004|||July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|80 Years|No|||October 2009|January 21, 2010|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999232||131663|
NCT01000116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-138|Fibrin Glue Versus Tacked Fixation in Groin Hernia Repair (TAPP)|Fibrin Glue Versus Tacked Fixation in Laparoscopic Groin Hernia Repair. A Randomized Double-blind Placebo-controlled Trial.||University Hospital Koge|Yes|Completed|September 2009|February 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Male|18 Years|80 Years|No|||April 2012|April 12, 2012|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01000116||131596|
NCT01000129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3122|Adaptive Planning in Bladder Cancer|Adaptive - Predictive Planning for Hypofractionated Bladder Radiotherapy|APPLY|Royal Marsden NHS Foundation Trust|No|Recruiting|January 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2009|October 21, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01000129||131595|
NCT01000402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-641|Juvenile Bipolar Disorder Outpatient Program|Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder|ProCAB|Federal University of Rio Grande do Sul|Yes|Recruiting|February 2008|November 2014|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||October 2009|October 22, 2009|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000402||131574|
NCT01000688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VILD1|Vildagliptin and Endothelium-dependent Vasodilatation|The Effect of Vildagliptin on Endothelium-dependent Vasodilatation. A Double Blind Cross-over Study in Type 2 Diabetes Mellitus.||Radboud University|Yes|Completed|January 2010|October 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|16|||Both|35 Years|75 Years|No|||October 2009|November 4, 2010|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000688||131552|
NCT00996424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/464|The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function|The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function.||University Hospital, Ghent|No|Terminated|January 2010|December 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|6 Years|64 Years|No|||August 2011|August 12, 2011|October 15, 2009||No|Insufficient recruitment.|No||https://clinicaltrials.gov/show/NCT00996424||131878|
NCT00996437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-151|Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)|An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy|N|Diabetic Retinopathy Clinical Research Network|Yes|Completed|June 2010|January 2013|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|October 14, 2009|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT00996437||131877|
NCT00996450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2903|Educational Follow-up in a Cohort of Children at the Royal Marsden Hospital (RMH)|Educational Follow-up in a Cohort of Children at the Royal Marsden Hospital, Following the Treatment of a Brain Tumour||Royal Marsden NHS Foundation Trust|No|Recruiting|June 2008|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Anticipated|110|||Both|4 Years|18 Years|No|Non-Probability Sample|Cases will be identified by looking at RMH coding database. Medical information will be        sort from the electronic patient records (EPR) and from the patient notes.|October 2009|October 15, 2009|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996450||131876|
NCT00996684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSEI-TG-AMD-001|Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration|Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin|AMD|University of California, Los Angeles|Yes|Recruiting|October 2009|December 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||September 2011|September 26, 2011|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996684||131858|
NCT00996697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARD12|Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)|A Proof Of Concept Study To Evaluate Tiotropium as Add-on Therapy to Inhaled Budesonide/Formoterol Combination in COPD|FARD12|University of Dundee|No|Completed|October 2006|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|50 Years|N/A|No|||October 2009|October 16, 2009|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996697||131857|
NCT00996983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIDON|Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer|Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer|ZIDON|National Cancer Institute, Naples|No|Active, not recruiting|September 2009|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00996983||131835|
NCT00996996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104517|Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma|Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin's Lymphoma||GlaxoSmithKline|No|Completed|June 1996|October 2011|Actual|March 1999|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||August 2012|March 20, 2014|October 8, 2009|Yes|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT00996996||131834|
NCT00997282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-09-001|A Study of OPC-262 in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arms Parallel Group Comparative Study of OPC-262 in Patients With Type 2 Diabetes (Phase 2/3 Study)||Kyowa Hakko Kirin Company, Limited|No|Completed|September 2009|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|255|||Both|20 Years|74 Years|No|||January 2014|January 6, 2014|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997282||131812|
NCT00997295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-29|Heat and Moisture Exchanger and Low-flow Gas|The Effects of a Heat and Moisture Exchanger on Temperature and Humidity in Low -Flow Anesthesia Workstation||UPECLIN HC FM Botucatu Unesp|Yes|Completed|January 2007|September 2009|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|30|||Female|18 Years|69 Years|No|Probability Sample|Thirty adult patients scheduled to gynecologic surgeries were randomly assigned in two        groups to received fresh gas flow of 1 l.min-1 with or without in circle anesthesia        system. Relative humidity, absolute humidity, temperature of gases and esophageal        temperature were measured at 15 min (T0)after respiratory circuit installation and then        every 30 min up to 120 min afterwards.|October 2009|October 16, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997295||131811|
NCT00996567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/337|A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.|Phase II Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.|MesoMab|University Hospital, Ghent|No|Recruiting|October 2009|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996567||131867|
NCT00996879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-006|Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects|Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects||Bristol-Myers Squibb|No|Completed|May 2013|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|48|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|October 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996879||131843|
NCT00996892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEK4752g|A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Completed|November 2009|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|179|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996892||131842|
NCT01007006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07247003|Telepharmacy Robotic Medicine Delivery Unit "TRMDU" Assessment|Evaluation of a Telepharmacy Robotic Medicine Delivery Unit in Warrior Transition Unit Patients With Traumatic Brain Injury, Post-Traumatic Stress Disorder, or Polytrauma||University of Illinois at Chicago|No|Not yet recruiting|March 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|165|||Both|18 Years|N/A|No|||November 2009|November 3, 2009|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007006||131071|
NCT00998257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14785|Regulatory Post Marketing Surveillance Study on YAZ|Regulatory Post Marketing Surveillance Study on YAZ||Bayer|No|Completed|July 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|770|None Retained|n.a|Female|18 Years|50 Years|No|Non-Probability Sample|Korean female who need only contraception or contraception and management of PMDD or        contraception and treatment of acne.|January 2015|January 19, 2015|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00998257||131737|
NCT00998270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-0901|Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma|A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation Compare With Allogeneic Bone Marrow Transplantation in Multiple Myeloma||Tehran University of Medical Sciences|Yes|Recruiting|October 2009|October 2017|Anticipated|October 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|185|||Both|18 Years|55 Years|No|||May 2012|May 31, 2012|October 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00998270||131736|
NCT01009294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-008-DMD|Study of Ataluren (PTC124®) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)|A Phase 2a Study of Ataluren (PTC124) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy||PTC Therapeutics|Yes|Terminated|November 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|7 Years|N/A|No|||August 2013|August 28, 2013|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009294||130897|
NCT00999765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-MBCT|Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder|Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder||Douglas Mental Health University Institute|No|Active, not recruiting|June 2008|December 2012|Anticipated|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|N/A|No|Non-Probability Sample|Bipolar Disorder of third-line bipolar disorders program|January 2012|January 30, 2012|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999765||131623|
NCT00999479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endometrioma|Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation|Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation||University of Oklahoma|Yes|Withdrawn|October 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|October 20, 2009|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00999479||131644|
NCT00999492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMF-09-001|Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront|Selection of Aspheric Diffractive Multifocal IOLS Based on Corneal Wavefront||Drs. Fine, Hoffman and Packer, LLC|No|Completed|October 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00999492||131643|
NCT00998933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S176.1.009|Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure|An Open-label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62%||Solvay Pharmaceuticals|No|Completed|October 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2009|November 24, 2009|October 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00998933||131686|
NCT00998946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-015|Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma||Spectrum Pharmaceuticals, Inc||Completed|September 2009|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|October 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00998946||131685|
NCT00999245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|683|THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)|Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)|IMPROVE|New England Research Institutes|Yes|Terminated|January 2010|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|10 Years|N/A|No|||April 2013|April 16, 2013|October 20, 2009||No|Inability to meet target enrollment prior to ending of network in March 2011.|No||https://clinicaltrials.gov/show/NCT00999245||131662|
NCT00999830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2101-201|Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma|Randomised Phase II Study Evaluating the Anti-tumour Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy|REMYKIR|Innate Pharma|Yes|Completed|September 2009|June 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|75 Years|No|||April 2014|February 23, 2016|October 21, 2009||No||No|October 15, 2013|https://clinicaltrials.gov/show/NCT00999830||131618|
NCT01000376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-E044-109|Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors|An Open-Label, Phase I Study to Evaluate the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors||Eisai Inc.||Completed|February 2009|September 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|October 22, 2009||No||No|December 22, 2011|https://clinicaltrials.gov/show/NCT01000376||131576|
NCT01000389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMD-02|A Clinical Trial of the Optimal Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism|||Medotech A/S|No|Completed|October 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|October 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01000389||131575|
NCT01000649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE 202158 CS02|Effects of the V1a Agonist FE 202158 in Patients With Septic Shock|A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock||Ferring Pharmaceuticals|Yes|Completed|November 2009|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|September 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000649||131555|
NCT01000415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGOC-03|Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients|Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma|TGOCphaseIII|Thai Gynecologic Oncology Collaborative Group|Yes|Recruiting|June 2009|June 2018|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|824|||Female|18 Years|60 Years|No|||March 2010|June 23, 2010|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000415||131573|
NCT00997035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9332-33965-02_2|Mycotic Ulcer Treatment Trial II|Mycotic Ulcer Treatment Trial|MUTT II|University of California, San Francisco|Yes|Active, not recruiting|May 2010|August 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|16 Years|N/A|No|||December 2015|December 9, 2015|October 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997035||131831|
NCT00996463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFG 08/002|Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients|Phase II Open Randomized Clinical & Health Economic Trial Comparing Intralesional Antimony Therapy Versus Wound Care Management in Old World Cutaneous Leishmaniasis Patients in Northern Afghanistan|LEICO|Waisenmedizin e. V. Promoting Access to Essential Medicine|Yes|Completed|January 2010|March 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|63|||Both|12 Years|N/A|No|||October 2009|March 25, 2011|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996463||131875|
NCT00996710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-068|Genomic Structural Variation in Cancer Susceptibility|Genomic Structural Variation in Cancer Susceptibility||Memorial Sloan Kettering Cancer Center||Enrolling by invitation|October 2009|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|1250|Samples With DNA|blood or saliva sample|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The majority of eligible probands will be identified prospectively through the clinics of        the Clinical Genetics, Medical Oncology and Pediatric Oncology Services of MSKCC by the        patient's physician, the protocol investigator, or a research team member.|August 2015|August 13, 2015|October 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996710||131856|
NCT00997022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD3519|Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients|Phase I Open-Label, Dose-Finding Study of BAY 43-9006 (Sorafenib) in High-risk Hepatocellular Cancer Patients After Liver Transplantation||Columbia University|Yes|Completed|May 2009|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|October 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00997022||131832|
NCT00997308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00009|A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Elderly Male and Female Volunteers During 4 Weeks of Treatment||AstraZeneca|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|97|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00997308||131810|
NCT00997321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMRF062661|Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED)|Propofol Versus Ketamine for Procedural Sedation During Painful Procedures in the Emergency Department||Minneapolis Medical Research Foundation|Yes|Completed|July 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|October 12, 2009|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT00997321||131809|
NCT00998153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA018686|Risk Reduction for Drug Use and Sexual Revictimization|Risk Reduction for Drug Use and Sexual Revictimization|RRFT|Medical University of South Carolina|Yes|Recruiting|December 2007|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|17 Years|No|||March 2016|March 15, 2016|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998153||131745|
NCT00998842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OU IRB 14853|Comparison of a Novel 12-Lead Wireless Electrocardiogram (ECG) and a Standard Wired ECG|Comparison of a Novel 12-Lead Wireless ECG and a Standard Wired ECG||University of Oklahoma||Completed|October 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals Age 18-64|October 2009|November 3, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00998842||131693|
NCT00998855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sunehagexercise|Glucose and Lipid Metabolism in Adolescents|Glucose and Lipid Metabolism in Adolescents||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|February 2004|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Both|13 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sedentary, post pubertal, Hispanic lean and obese adolescents|October 2009|June 6, 2011|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00998855||131692|
NCT01006746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS050|Observational Study of Patient Comprehension, Perception, Fears and Appreciation Following Home-Monitoring Implementation|Evaluation and Description of Mutual Influences Between Patient Training, Perception and Adoption of Home-Monitoring Technology|Educ@t|Biotronik France|No|Completed|February 2009|August 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|571|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in 46 french investigational sites (hospitals and private clinics)|March 2014|March 3, 2014|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006746||131091|
NCT01007838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R& D Ref no: MACDONALD 07/53|Intradialytic Progressive Resistance Training for Maintenance Haemodialysis Patients|Effects of Progressive Resistance Training During Haemodialysis on Muscle Quantity and Function in Patients With Chronic Kidney Disease|PRT|Bangor University|No|Completed|January 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|No|||December 2011|January 3, 2012|October 15, 2009||No||No|November 24, 2011|https://clinicaltrials.gov/show/NCT01007838||131008|Small sample size in healthy control group. Variable gender mix in all groups.
NCT01007279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMA55|Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)|ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis|ROMA|University of Roma La Sapienza|Yes|Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2010|October 25, 2010|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007279||131050|
NCT01008137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PanFlu-4002|Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults|Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults||Sinovac Biotech Co., Ltd||Completed|October 2009|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Actual|150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01008137||130985|
NCT01009008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0001|Patient Activated Controlled Expansion (PACE) Trial|Patient Activated Controlled Expansion (PACE) for Breast Reconstruction Utilizing Controlled CO2 Inflation|PACE|AirXpanders, Inc.|Yes|Completed|June 2009|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|65 Years|No|||June 2013|June 13, 2013|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009008||130918|
NCT01007799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16601A|Vitamin D for Chronic Sinusitis|A Randomized, Clinical Trial of a Novel Immunotherapy for Chronic Sinusitis: Vitamin D||University of Chicago|No|Recruiting|November 2009|October 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007799||131010|
NCT01007812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-242-C-032|Clinical Comparison of Two Silicone Hydrogel Toric Lenses in the US|Clinical Comparison of Two Silicone Hydrogel Toric Lenses in the US||Alcon Research||Completed|October 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||January 2012|June 26, 2012|November 2, 2009|Yes|Yes||No|September 29, 2010|https://clinicaltrials.gov/show/NCT01007812||131009|
NCT01000051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0106|Eltrombopag for Post Transplant Thrombocytopenia|Eltrombopag for Post Transplant Thrombocytopenia||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2010|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|October 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000051||131601|
NCT01000311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_33|A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months|A Phase 3, Randomized, Open Label, Controlled Multicenter Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months||Novartis||Completed|November 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|529|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||April 2014|April 3, 2014|October 22, 2009|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01000311||131581|
NCT00999843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-004|Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer|Maintenance of Sorafenib Following Combined Therapy of Three-dimensional Conformal Radiation Therapy/Intensity-modulated Radiation Therapy and Transcatheter Arterial Chemoembolization in Patients With Locally Advanced Hepatocellular Carcinoma: a Phase I/II Study.||Fudan University|Yes|Recruiting|October 2009|October 2012|Anticipated|October 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||October 2009|October 21, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999843||131617|
NCT01000142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501-332|Preventative Osteopathic Manipulative Treatment (OMT) and the Nursing Home Patient|Preventative OMT and the Nursing Home Patient||A.T. Still University of Health Sciences|No|Completed|October 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|22|||Both|65 Years|N/A|No|||July 2011|July 22, 2011|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01000142||131594|
NCT01000155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-237|Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease|A Phase II Pharmacodynamic Investigation of the Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Not Benefitted From Prior Therapy||Dana-Farber Cancer Institute|Yes|Completed|October 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|October 20, 2009|Yes|Yes||No|September 9, 2015|https://clinicaltrials.gov/show/NCT01000155||131593|The trial did not meet it's accrual goal due to slow accrual.
NCT00996476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016402|A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients|A Phase II, Randomized, Open-label Study in Japan to Investigate the Efficacy, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment naïve, Genotype 1, Chronic Hepatitis C Subjects|DRAGON|Janssen Pharmaceutical K.K.|No|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|92|||Both|20 Years|70 Years|No|||March 2014|March 21, 2014|October 15, 2009|Yes|Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT00996476||131874|All outcome measures reported in this study are "Exploratory;" not "Primary" as indicated. "Primary" was chosen for each outcome measure because "Exploratory" is not available as an outcome measure type.
NCT00997061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112791|SCOT Registry: Small Cell Lung Cancer Treatment and Outcome|SCOT Registry: Small Cell Lung Cancer Treatment and Outcome|SCOT|GlaxoSmithKline|No|Completed|November 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Probability Sample|Newly Diagnosed SCLC patients|January 2014|January 30, 2014|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997061||131829|
NCT00997360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3266A1-1002|Study of PKI-179 Administered Orally to Subjects With Solid Tumors|A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|February 2010|February 2012|Anticipated|February 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||December 2009|December 1, 2009|October 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00997360||131806|
NCT00997048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2002/139|Comparison Between Laying Open and Sinus Excision of Pilonidal Sinus - a Randomized Study|Comparison Between Laying Open and Sinus Excision of Pilonidal Sinus - a Randomized Study||Uppsala University|No|Completed|October 2002|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997048||131830|
NCT00997334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-210|Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC|First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations||Dana-Farber Cancer Institute|Yes|Active, not recruiting|December 2009|September 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|October 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997334||131808|
NCT00996723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJBG09|Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)|Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma||St. Jude Children's Research Hospital|Yes|Completed|October 2009|June 2014|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Months|21 Years|No|||April 2015|April 3, 2015|October 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996723||131855|
NCT00997009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO CERV 2|Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer|Randomized Phase II Study of Carboplatin and Paclitaxel +/- Cetuximab, in Advanced and/or Recurrent Cervical Cancer|MITO CERV 2|National Cancer Institute, Naples|No|Active, not recruiting|October 2009|March 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Female|18 Years|N/A|No|||October 2015|October 28, 2015|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997009||131833|
NCT00997906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000657121|Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC|A Randomised Phase II/III Study of Concurrent Cisplatin-Radiotherapy With or Without Induction Chemotherapy Using Gemcitabine, Carboplatin and Paclitaxel in Locally Advanced Nasopharyngeal Cancer||National Cancer Centre, Singapore|Yes|Active, not recruiting|September 2009|July 2023|Anticipated|July 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|October 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00997906||131764|
NCT00998166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB9652|A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)|A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma||Columbia University|Yes|Terminated|June 2007|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|October 14, 2009|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT00998166||131744|
NCT00999752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR-2009-02 (BYS-MD-27)|Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension|A 25 Week, Open Label Study to Determine the Effects of Nebivolol When Added to Hydrochlorothiazide on Diastolic Function and Arterial Stiffness in African Americans With Hypertension|NASAA|InVasc Therapeutics, Inc.|No|Completed|October 2009|May 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00999752||131624|
NCT01000285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1758 / 201108212|EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma|Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma|ATLL|Washington University School of Medicine|Yes|Active, not recruiting|September 2010|April 2018|Anticipated|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|October 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000285||131583|
NCT01007565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0801/053-013|Postoperative Pain After Volar Plating for Distal Radius Fractures|Postoperative Pain After Volar Plating for Distal Radius Fractures||Seoul National University Hospital|No|Completed|March 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|44|||Both|16 Years|89 Years||||November 2009|November 3, 2009|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01007565||131028|
NCT01007851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-48/07|Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles|||V.K.V. American Hospital, Istanbul||Terminated|September 2006|December 2007|Actual|||Phase 3|Interventional|N/A|2||||||Female|18 Years|45 Years|No|||November 2009|November 3, 2009|November 3, 2009|||Lower than anticipated recruitment|No||https://clinicaltrials.gov/show/NCT01007851||131007|
NCT01008150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-7|Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer|A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel Plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2-Positive Breast Cancer||NSABP Foundation Inc|No|Active, not recruiting|October 2010|June 2017|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|141|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|November 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008150||130984|
NCT01005485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#09-5287|Molecular and Morphologic Characterization of Circulating Endothelial Cells|Comprehensive Molecular and Morphologic Characterization of Circulating Endothelial Cells|CEC|Scripps Translational Science Institute|No|Recruiting|January 2010|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|325|Samples With DNA|Blood for each patient will be collected from arterial access established as part of      standard of care or via venipuncture. Blood must be collected in the order listed below. By      drawing the PAX gene tube first, the likelihood of contamination of the sample with vessel      wall endothelial cells is decreased.      Enrollment:        1. x 8.5 ml PAX gene (blue top) tube        2. x 10 ml EDTA purple top tubes      Follow-up visits: (healthy controls only)        1. x 5 ml red top (discard)        2. x 10 ml EDTA purple top tube|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the general in-patient and out-patient populations for        myocardial infarction and/or vascular surgery. Healthy controls will be recruited from the        general medical population and community.|January 2016|January 27, 2016|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005485||131187|
NCT00996346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0909|Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas|Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas||New Mexico Cancer Care Alliance|No|Terminated|October 2009|November 2013|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|10 Years|N/A|No|||August 2015|August 2, 2015|October 14, 2009|Yes|Yes|Original PI left institution and sponsor decided to end support.|No|June 6, 2015|https://clinicaltrials.gov/show/NCT00996346||131884|
NCT00999583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071217|High Dose of Erythropoietin Analogue After Cardiac Arrest|High Dose of Erythropoietin Analogue After Cardiac Arrest: a Multicentre, Randomised, Controlled Trial (Epo-ACR-02 Trial)|Epo-ACR-02|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2009|May 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|80 Years|No|||June 2014|June 25, 2014|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999583||131636|
NCT00999856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-2.1-C-01|Investigation of a Sub-Conjunctival Insert|Investigation of a Sub-Conjunctival Insert||EyeSense GmbH|No|Terminated|August 2008|May 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|28|||Both|18 Years|N/A|No|||October 2011|February 24, 2015|September 28, 2009||No|Two cohorts successfully completed; further cohorts not needed; no safety issue!|No||https://clinicaltrials.gov/show/NCT00999856||131616|
NCT01000168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20624506 (SunHF)|Treadmill Therapy and Brain Injuries|The Effect of Treadmill Therapy With Body Weight Support on Walking and Transfer in Patients With Moderate to Severe Ambulatory Deficits After Stroke||Sunnaas Rehabilitation Hospital|No|Completed|November 2004|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||October 2009|October 22, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000168||131592|
NCT00997074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7253-DS-CTIL|Efficacy Study of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion|The Effect of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion: A Double-blind Randomized Placebo Controlled Study||Sheba Medical Center|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997074||131828|
NCT00997087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGS-001|A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder|Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.|OCD|Parkway Medical Center|No|Terminated|October 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|19 Years|60 Years|No|||April 2014|April 18, 2014|October 14, 2009|Yes|Yes|Study completed and data was inconclusive.|No||https://clinicaltrials.gov/show/NCT00997087||131827|
NCT00997373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917341|Letrozole as a Treatment of Endometrial Cancer|Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma||University of California, Davis|No|Completed|October 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Female|40 Years|N/A|No|||April 2015|April 3, 2015|October 15, 2009|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT00997373||131805|
NCT00997347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2.2|The Extended Gestational Age Medical Abortion Study|The Extended Gestational Age Medical Abortion Study: The Effectiveness of Medical Abortion With Mifepristone and Misoprostol at 57-63 Days Versus 64-70 Days Gestation||Gynuity Health Projects|Yes|Completed|July 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1400|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 28, 2012|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997347||131807|
NCT00997633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPECT IK1991:5|Single-photon Emission Computed Tomography (SPECT) to Predict Peritoneal Chemotherapy|Single-photon Emission Computed Tomography for Prediction of Treatment Results in Sequential Intraperitoneal Chemotherapy at Peritoneal Carcinomatosis||Uppsala University|No|Completed|May 1991|August 2004|Actual|August 2004|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|51|||Both|14 Years|74 Years|No|Non-Probability Sample|Patients who had undergone cytoreductive surgery and intraperitoneal chemotherapy (SPIC)        at the Dept of Surgical Sciences, Uppsala University Hospital in the time period between        May 1991 and August 2004.|October 2009|October 16, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997633||131785|
NCT00997646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910008R|Performance of a Hospitalist-run Ward: a Prospective Observational Study|||National Taiwan University Hospital|No|Recruiting|October 2009|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|The patients who was admitted to a hospitalist-run ward|October 2009|October 16, 2009|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997646||131784|
NCT00997919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABE4662g|A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers|A Phase I, Single-Dose, Randomized, Parallel-Group, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers||Genentech, Inc.||Completed|November 2009|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 11, 2010|October 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997919||131763|
NCT00998179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS9/10|Effect of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Expiratory Flow Volume in Healthy Subjects|Effect of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Expiratory Flow Volume in Healthy Subjects||The Hong Kong Polytechnic University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|11|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 19, 2009|October 18, 2009||||No||https://clinicaltrials.gov/show/NCT00998179||131743|
NCT00998439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPCAD DES|Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter|PEPCAD DES - Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA Catheter||Klinikum Coburg|No|Active, not recruiting|October 2009|December 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00998439||131723|
NCT01000298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJM-antibiotics|Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition|Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Oral Antibiotics in the Community-based Treatment of Severe Acute Malnutrition in Malawian Children||Washington University School of Medicine|Yes|Completed|December 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2700|||Both|6 Months|5 Years|No|||July 2011|July 1, 2011|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000298||131582|
NCT01006499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-akdag|Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'|Phase 4 Study of Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Active, not recruiting|August 2009|December 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|204|||Both|N/A|90 Days|No|||March 2011|March 10, 2011|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006499||131109|
NCT01007578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-4601-900|Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease|An Open-Labeled Multicenter Study to Investigate Plasma Levels and Catheter Tolerability Following Application of Paclitaxel Coated Balloon Catheter in Patients With Stenotic, or Occluded Femoro-Popliteal Arteries Due to Atherosclerosis||Bayer|Yes|Completed|September 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|November 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01007578||131027|
NCT01007591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 80190-O25|A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas|Calcipotriol Plus Hydrocortisone in Paediatric Patients (Aged 6 to 17 Years) With Psoriasis Vulgaris on the Face and on the Intertriginous Areas||LEO Pharma|Yes|Completed|October 2009|December 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|6 Years|17 Years|No|||December 2010|October 25, 2013|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007591||131026|
NCT01007864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIR-007/K|Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists|Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists|PIVICOG-PD|Desitin Arzneimittel GmbH|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|35 Years|80 Years|No|||April 2012|May 23, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007864||131006|
NCT01008163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YY351-1|A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes|A Phase Ⅱ, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Efficacy and Safety of YY-351 in Patients With Type 2 Diabetes Mellitus||Yuyu Pharma, Inc.|Yes|Completed|January 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|72|||Both|18 Years|N/A|No|||November 2009|November 3, 2009|October 20, 2008||No||No||https://clinicaltrials.gov/show/NCT01008163||130983|
NCT01008176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0535241N|Restoring Sleep Homeostasis to Lower Blood Pressure|Restoring Sleep Homeostasis to Lower Blood Pressure: A Behavioral Prevention and Treatment Approach||Beth Israel Deaconess Medical Center|No|Completed|September 2005|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|23|||Both|25 Years|65 Years|No|||October 2014|October 15, 2014|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01008176||130982|
NCT01005498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M216-08|Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.|Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.|VÄSTKOST|Vårdcentralen Lyckorna|No|Completed|March 2009|December 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|N/A|N/A|No|||December 2011|December 4, 2011|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005498||131186|
NCT01005511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMD-01|Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism|A Single Centre, Randomised, Clinical Placebo Controlled Study of the Optimal Treatment and Long-term Effect of FES on Sleep Bruxism||Medotech A/S|No|Terminated|October 2009|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||October 2009|June 7, 2011|October 30, 2009|No|Yes|The population described via ex- and inclusion criteria did not excisit|No||https://clinicaltrials.gov/show/NCT01005511||131185|
NCT01005524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANR-TecSan-2009|Brain Computer Interface for Communication in ICU: a Feasibility Study|A Feasibility Study for Daily Use of a Brain Computer Interface for Communication in an ICU|RoBIK-1|University of Versailles|No|Completed|January 2010|May 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Quadriplegia, also known as tetraplegia, is paralysis caused by illness or injury to a        human that results in the partial or total loss of use of all of their limbs and torso;        paraplegia is similar but does not affect the arms. The loss is usually sensory and motor,        which means both sensation and control are lost.|May 2012|May 21, 2012|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005524||131184|
NCT01008397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHIST IND|Study of AHIST in Seasonal Allergic Rhinitis Patients|Phase 1 Study of AHIST in Seasonal Allergic Rhinitis Patients||Magna Pharmaceuticals, Inc.|Yes|Withdrawn|April 2011|May 2011|Anticipated|April 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|March 4, 2014|October 27, 2009|Yes|Yes|Manufacturer unable to produce|No||https://clinicaltrials.gov/show/NCT01008397||130965|
NCT01008410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCF3001|Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis||Valeant Pharmaceuticals International, Inc.|No|Completed|November 2009|||April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||November 2012|May 17, 2013|November 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008410||130964|
NCT01008111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009521|Wound Healing of Incisional Wounds for Bilateral Hernia Repair|The Effect of a Sodium Bicarbonate and Hydrogen Peroxide Gel on Wound Healing of Incisional Wounds for Bilateral Hernia Repair||Wake Forest School of Medicine|No|Recruiting|October 2009|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|N/A|5 Years|No|||November 2009|November 4, 2009|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008111||130987|
NCT01008124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWU 1718|The Liberatory Maneuver for the Treatment of Benign Paroxysmal Positional Vertigo (BPPV)|The Liberatory Maneuver for the Treatment of Benign Paroxysmal Positional Vertigo: A Randomized Controlled Trial|LM_BPPV|Midwestern University|No|Active, not recruiting|November 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2009|November 4, 2009|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008124||130986|
NCT00999596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMSDR-2008-002 & 2010-002|Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM)|Clinical Image Evaluation Study for Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM)||Philips Healthcare|Yes|Completed|April 2010|September 2011|Actual|January 2011|Actual|Phase 3|Observational|Time Perspective: Prospective||1|Actual|107|||Female|40 Years|N/A|No|Non-Probability Sample|Screening and diagnostic mammography patients|November 2012|November 30, 2012|October 21, 2009||No||No|June 14, 2011|https://clinicaltrials.gov/show/NCT00999596||131635|Change in requirements from FDA modified the reading study per the Nov 5, 2010 FDA Guideline for FFDM.
NCT00999609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAV2-hRPE65v2-301|Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis|A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]||Spark Therapeutics|Yes|Active, not recruiting|October 2012|July 2029|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|3 Years|N/A|No|||February 2016|February 16, 2016|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00999609||131634|
NCT00999869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajH-2|The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata|The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata||Siriraj Hospital|Yes|Recruiting|November 2009|February 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999869||131615|
NCT01000701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPUM-ACS|Inflammation and Acute Coronary Syndromes|Inflammation and Acute Coronary Syndromes (ACS) - Novel Strategies for Prevention and Clinical Management|SPUM-ACS|University of Zurich|Yes|Recruiting|October 2009|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Blood, Thrombus, blood cells, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients presenting with Acute Coronary Syndromes        3 control groups:          -  patients with stable coronary artery disease          -  healthy controls (blood bank)          -  peripheral artery occlusive disease (CLI/ALI)|December 2014|December 18, 2014|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000701||131551|
NCT01000714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol No. 1 ver. 1 9-Jan-09|Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis|||Etwal Ltd.||Completed||||||Phase 2|Interventional|N/A|||||||Both|18 Years|75 Years||||October 2009|October 22, 2009|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000714||131550|
NCT00996736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9332-33965-02|Mycotic Ulcer Treatment Trial I|Mycotic Ulcer Treatment Trial|MUTT I|University of California, San Francisco|Yes|Completed|April 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|16 Years|N/A|No|||March 2015|March 24, 2015|October 14, 2009|Yes|Yes||No|July 26, 2013|https://clinicaltrials.gov/show/NCT00996736||131854|
NCT00996749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 85108|Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer|Pilot Study to Determine the Optimal Dosage of Omega-3 Polyunsaturated Fatty Acid (PUFA) in Men With Advanced Prostate Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Withdrawn|May 2011|||January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||January 2013|January 16, 2013|October 15, 2009||No|No Participants enrolled; slow accrual|No||https://clinicaltrials.gov/show/NCT00996749||131853|
NCT00997100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09575704|Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)|An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)||Active Biotech AB|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997100||131826|
NCT00997386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0679-04|Study of Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) to Treat Hematologic Malignancies and Hematopoietic Failure States|A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States|ALBUM|University of Arizona|Yes|Recruiting|September 2009|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|75 Years|No|||January 2013|January 31, 2013|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997386||131804|
NCT00997659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5689|Chromium's Effect on Insulin Resistance in Obesity|Efficacy and Safety of Chromium as a Therapeutic Intervention for Insulin Resistance Associated With Obesity||Stony Brook University|Yes|Completed|April 2007|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 11, 2011|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997659||131783|
NCT00997932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP3-14|A Pilot Study of Early Postpartum Intrauterine Contraception|A Pilot Study of Early Postpartum Intrauterine Contraception|ImmPPIUD|University of North Carolina, Chapel Hill|No|Completed|June 2009|November 2012|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Female|21 Years|45 Years|No|||December 2013|December 23, 2013|September 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00997932||131762|
NCT01002456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-136|Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison|Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison||VA Office of Research and Development|No|Completed|October 2009|October 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|220|||Both|N/A|N/A|No|||September 2014|April 6, 2015|October 23, 2009||No||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01002456||131417|
NCT01002469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD07|Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment|Pilot Feasibility Study in Healthy Subjects and Healthy Asymptomatic Subjects Genetically Disposed to Urea Cycle Disorders to Evaluate the Use of 13 C Isotope Ratio Measurement||Cytonet GmbH & Co. KG|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002469||131416|
NCT01007292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-031|A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment|A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant||Astellas Pharma Inc|No|Completed|November 2009|June 2015|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007292||131049|
NCT01007604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21975|Treatment of Claudication With a Peristaltic Pulse Pneumatic Device|Efficacy Study of a Peristaltic Pulse Pneumatic Device in the Treatment of Claudication||White River Junction VAMC|No|Not yet recruiting|November 2009|March 2011|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2009|November 3, 2009|November 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01007604||131025|
NCT01008774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_04449|START: Swiss Taxotere Alopecia Prevention Trial|A Comparison of Different Scalp Cooling Systems for the Prevention of Chemotherapy Induced Alopecia||Sanofi||Completed|July 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|239|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01008774||130936|
NCT01008189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH049155|6-Year Follow-up of a Prevention Program for Bereaved Families|6-Year Follow-up of a Prevention Program for Bereaved Families||Arizona State University|Yes|Completed|January 1996|July 2009|Actual|July 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|244|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||November 2009|November 3, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01008189||130981|
NCT01008202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C024|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2009|||||N/A|N/A|N/A||||||||||||||January 25, 2011|November 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008202||130980|
NCT01008449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X090531008|Staples Versus Suture for Cesarean Wound Closure|Surgical Staples vs. Absorbable Subcuticular Suture for Wound Closure of Cesarean Deliveries|SVS|University of Alabama at Birmingham|Yes|Terminated|August 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|398|||Female|16 Years|N/A|No|||September 2014|September 2, 2014|November 4, 2009||No|New studies were reporting that sutures are beneficial, hindering the possibility of    enrollment.|No|July 15, 2014|https://clinicaltrials.gov/show/NCT01008449||130961|
NCT01009359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13150|Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers|Open-label, Non-randomized, Multicenter Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq BAY85-8102 F-18, DPA-714 for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimers Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of 150 MBq BAY858102 F-18, DPA-714 in Healthy Volunteers.||Bayer|No|Completed|October 2009|October 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|22|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 30, 2013|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009359||130892|
NCT01009593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-963|Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)|An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)||Abbott||Terminated|January 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1035|||Both|18 Years|N/A|No|||June 2012|September 7, 2012|October 14, 2009|Yes|Yes|See termination reason in detailed description|No||https://clinicaltrials.gov/show/NCT01009593||130875|
NCT01008709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090917|Comparison Study of Two Different Surgical Clips During Laparoscopic Urologic Surgery|Minimally Invasive Urologic Surgery Clip Evaluation: Can We Improve Our Surgical Technique, Reduce Costs and Waste With the Aesculap U-clip Versus the Tele-Flex Hemolock Clip?||Vanderbilt University|No|Recruiting|October 2009|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2010|October 18, 2010|October 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008709||130941|
NCT01008722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|684|The Dynamics of Human Atrial Fibrillation|The Dynamics of Human Atrial Fibrillation||University of California, San Diego|No|Recruiting|June 2009|May 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|98|||Both|21 Years|80 Years|No|Probability Sample|Subjects will be men and women of all races aged 21 to 80 years undergoing clinically        indicated ablation of Atrial Fibrillation.|December 2013|December 10, 2013|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008722||130940|
NCT01008696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013831|An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis|Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study||Janssen Korea, Ltd., Korea|No|Completed|May 2007|August 2008|Actual|August 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|75 Years|No|||July 2013|July 11, 2013|November 5, 2009|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT01008696||130942|
NCT01000181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCLADS09/1|Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT|A Mechanistic, Non-randomised Study to Examine the Uptake of a Specific Radionuclide (61CuATSM) in Carotid Artery Plaque||King's College London|No|Suspended|October 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|55 Years|N/A|No|Non-Probability Sample|Patients undergoing carotid endarterectomy|April 2012|April 5, 2012|October 21, 2009||No|Difficulty producing tracer|No||https://clinicaltrials.gov/show/NCT01000181||131591|
NCT01000727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480848/033|The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial|A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).|SOLID-TIMI 52|GlaxoSmithKline|Yes|Completed|December 2009|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13026|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|October 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000727||131549|
NCT01000428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2008-0511|The Role of Positron Emission Tomography (PET) During Erlotinib Treatment for Non-small Cell Lung Cancer|The Role of PET During Erlotinib Treatment to See the Responsiveness of Tumor Early in Patients With Non-small Cell Lung Cancer||Asan Medical Center||Recruiting|June 2009|December 2011|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|34|||Both|18 Years|85 Years|No|Probability Sample|Histologically documented non-small cell lung cancer with metastasis (Stage IV) or locally        advanced (Stage IIIB) with malignant effusion.|October 2009|October 23, 2009|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000428||131572|
NCT00996502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8399|Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer|A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer||Columbia University|Yes|Terminated|July 2006|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|October 14, 2009||No|Poor enrollment; PI left the institution|No|March 23, 2016|https://clinicaltrials.gov/show/NCT00996502||131872|
NCT00996762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112930|A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib|An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet||GlaxoSmithKline|No|Completed|November 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|432|||Both|18 Years|N/A|No|||July 2013|August 1, 2013|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996762||131852|
NCT00996775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP 62-109|Implementing Evidence-Based Mental Health Practices in Primary Care|Implementing Evidence-Based Mental Health Practices in Primary Care||VA Office of Research and Development|No|Active, not recruiting|December 2009|August 2016|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|October 14, 2009||No||No|July 22, 2014|https://clinicaltrials.gov/show/NCT00996775||131851|
NCT00997399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589X2105|Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function|A Phase I, Open-label, Multi-center Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Varying Degrees of Renal Function||Novartis||Completed|March 2010|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|37|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|October 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00997399||131803|
NCT00997672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA_LITIO_13|Lithium in Multiple System Atrophy|A Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy.|LAMU|Federico II University|Yes|Terminated|October 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||December 2013|December 17, 2013|October 16, 2009||No|Data Monitoring Committee decision on 22nd August 2011 for safety issues|No|March 6, 2013|https://clinicaltrials.gov/show/NCT00997672||131782|Limitation of the study is small sample size of nine randomized patients. This may have determined uneven distribution of AEs due to random variation. Taking into account these limitations, we do not encourage future studies with lithium in MSA.
NCT01002170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB2NDCSTDMTW|Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament|The Impact Factor Analysis of the Therapeutic Drug Monitoring of Oral 2nd Line Antituberculosis Agent, Cycloserine|CSPK|Taipei Medical University WanFang Hospital|No|Completed|May 2009|May 2010|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Probability Sample|Asia, Taiwan multidrug-resistant tuberculosis (MDR-TB) patients undergo Cycloserine        treatment|November 2010|November 1, 2010|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01002170||131439|
NCT01002482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGAO-REA-01|Computerized Glucose Control in Critically Ill Patients|Impact of the Use of a Computerized Protocol for Glucose Control Named CGAOtm on the Outcome of Critically Ill Patients|CGAO-REA|Centre Hospitalier of Chartres|Yes|Completed|October 2009|April 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2684|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|October 26, 2009||No||No|April 24, 2013|https://clinicaltrials.gov/show/NCT01002482||131415|
NCT01002495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMCAD-001/B|Gene Therapy for the Treatment of Chronic Stable Angina|A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia||ViroMed Co., Ltd. dba VM BioPharma|Yes|Withdrawn|March 2015|January 2016|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|21 Years|75 Years|No|||February 2015|February 6, 2015|October 24, 2009|No|Yes|The study was never initiated at any sites.|No||https://clinicaltrials.gov/show/NCT01002495||131414|
NCT01007305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSO 01|Bilateral Oophorectomy Versus Ovarian Conservation|Elective Bilateral Salpingo-oophorectomy Versus Ovarian Conservation: A Pilot Randomized, Controlled Trial||University of California, San Francisco|Yes|Completed|May 2009|||April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Female|40 Years|55 Years|No|||November 2009|August 4, 2011|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007305||131048|
NCT01008475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62242-004|EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wildtype Metastatic Colorectal Cancer|An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line Treatment for Subjects With K-ras Wild Type Metastatic Colorectal Cancer.|POSEIDON|Merck KGaA|No|Terminated|October 2009|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|229|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|October 19, 2009||No|The study is terminated prematurely as the sponsor decided to discontinue program with EMD    525797 in oncology.|No||https://clinicaltrials.gov/show/NCT01008475||130959|
NCT01008488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVOD-D33|Antibiotic Therapy of Acute Uncomplicated Colonic Diverticulitis|Is Antibiotic Therapy Mandatory for Treatment of Uncomplicated Acute Colonic Diverticulitis: a Randomized Clinical Trial||Uppsala University|Yes|Completed|November 2002|December 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|90 Years|No|||December 2011|December 22, 2011|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008488||130958|
NCT01008761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAWhZy2010|Trial for the Treatment of Acute Asthma in Wheezy Pre-school Aged Children|A Double Blind Randomized Control Trail of Azithromycin for the Acute Management of Wheezy Pre-school Children||Alberta Children's Hospital|No|Recruiting|January 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|12 Months|60 Months|No|||July 2012|July 11, 2012|November 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008761||130937|
NCT01008995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016318|A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis||Centocor, Inc.|Yes|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|322|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|November 5, 2009|Yes|Yes||No|August 15, 2012|https://clinicaltrials.gov/show/NCT01008995||130919|
NCT00995150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M360-L102|A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception|A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception||Medicines360|Yes|Active, not recruiting|November 2009|December 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2080|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||October 2015|November 10, 2015|October 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995150||131975|
NCT00995488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.025|Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer|ABX209: Phase II Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer.||University of Michigan Cancer Center|Yes|Terminated|October 2009|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|October 14, 2009|Yes|Yes|Terminated prematurely due to low accrual.|No|September 10, 2014|https://clinicaltrials.gov/show/NCT00995488||131949|
NCT00995475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEN001|A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease|A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease||University of Dundee|No|Completed|October 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|N/A|N/A||||October 2009|October 14, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995475||131950|
NCT00995748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIREG_R_04434|The RECORD Asia-Pacific Atrial Fibrillation Registry|REgistry on Cardiac Rhythm disORDers in Asia-Pacific|RECORDAF-AP|Sanofi|No|Completed|April 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2674|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from office or hospital-based cardiologists from Asia-Pacific countries|February 2012|February 16, 2012|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995748||131929|
NCT00995969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 327 PV 01-09|CT 327 in the Treatment of Psoriasis Vulgaris|A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a Topical Cream Formulation of Pegylated K252a, When Administered Twice Daily for Eight Weeks to Patients With Mild to Moderate Psoriasis Vulgaris||Creabilis SA|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|70 Years|No|||February 2011|February 9, 2011|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00995969||131913|
NCT00991978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGF early imaging|VEGF Early Imaging for Breast Cancer|Vascular Endothelial Growth Factor (VEGF) Imaging for Early Breast Cancer Detection A Feasibility Study||University Medical Center Groningen|Yes|Completed|March 2010|January 2012|Actual|January 2012|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991978||132218|
NCT00992290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM12123|Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy|Probiotic LGG in Patients With Minimal Hepatic Encephalopathy||Virginia Commonwealth University|Yes|Completed|October 2009|March 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|No|||January 2014|January 6, 2014|October 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992290||132194|
NCT01003730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120080132|The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs|The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs||Rutgers, The State University of New Jersey|No|Terminated|March 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|65 Years|No|||April 2015|May 1, 2015|October 21, 2009||No|PI has left the UMDNJ but may resume the study in her new place of employment.|No||https://clinicaltrials.gov/show/NCT01003730||131319|
NCT00994123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-01-101 (ARD11585)|A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer|A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer||Merrimack Pharmaceuticals|No|Active, not recruiting|February 2010|December 2014|Anticipated|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|October 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994123||132053|
NCT00994136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM008|Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters|Locking of Totally Implanted Venous Access Devices and Tunneled Catheters With or Without Heparin: a Randomised Open-labeled Controlled Trial||Universitaire Ziekenhuizen Leuven|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1100|||Both|1 Year|N/A|No|||June 2011|June 8, 2011|October 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994136||132052|
NCT00993135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000652517|Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia|Renal Dysfunction With Low to Intermediate Dose Methotrexate in Acute Lymphoblastic Leukemia Treatment||National Cancer Institute (NCI)||Completed|December 2008|||December 2009|Actual|N/A|Observational|N/A|||||||Both|N/A|21 Years|No|||December 2009|December 23, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993135||132129|
NCT00993148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDAS|Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1|Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile|MIDAS|Northwestern University|Yes|Completed|May 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|October 8, 2009|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT00993148||132128|
NCT00993759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM&R-0108-09-TXC|Efficacy Study of A Lotion to Prevent Common Colds|Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects||The Dial Corporation|No|Active, not recruiting|August 2009|December 2009|Anticipated|November 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|212|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 9, 2009|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993759||132081|
NCT00993772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0136-01-A|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2009|||||N/A|N/A|N/A||||||||||||||May 10, 2011|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993772||132080|
NCT00993785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-04|CoStar Catheter System Evaluation||CONCISE|Conor Medsystems||Terminated|February 2007|April 2008|Actual|||Phase 3|Interventional|N/A|1||Actual|58|||Both|18 Years|N/A||||October 2009|October 27, 2009|October 9, 2009||No|CoStar Stent IDE failed to meet primary endpoint|No||https://clinicaltrials.gov/show/NCT00993785||132079|
NCT01003119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-2009-0484|Computer-Based Alcohol Use Disorder Recovery System|Developing and Testing a Computer-Based Alcohol Use Disorder Recovery System||University of Wisconsin, Madison|Yes|Completed|February 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|350|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01003119||131366|
NCT01003691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1181002|Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy|A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy||Pfizer|No|Completed|August 2010|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|60 Years|85 Years|No|||March 2013|March 27, 2013|October 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003691||131322|
NCT01004224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGJ398X2101|A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies|A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies||Novartis||Recruiting|December 2009|February 2017|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004224||131282|
NCT01004237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-200912|Additive Effects of Pravastatin and Valsartan|||Gachon University Gil Medical Center||Completed|November 2009|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|52|||Both|25 Years|75 Years|No|||October 2010|August 8, 2012|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004237||131281|
NCT01004497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC09MIMS0255|First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL|A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|ALL|The Catholic University of Korea|Yes|Completed|March 2010|April 2015|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|15 Years|65 Years|No|||May 2015|May 28, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004497||131261|
NCT01004198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-204|Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients|A Multi-center, Randomized, Double-blind, Controlled Dose-finding Study to Evaluate the Safety and Efficacy of MP4OX Treatment Plus Standard of Care in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock||Sangart|Yes|Completed|December 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|80 Years|No|||August 2013|August 15, 2013|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004198||131284|
NCT01004211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-NBI-2009|Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging|A Phase III Prospective Multicenter Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging.||National Institute for Cancer Research, Italy|No|Active, not recruiting|August 2009|October 2013|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||October 2010|October 18, 2010|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004211||131283|
NCT01005121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7369-AL-CTIL|Colchicine for Diabetic Nephropathy|Colchicine for Diabetic Nephropathy||Sheba Medical Center|No|Recruiting|December 2009|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|90 Years|No|||January 2013|January 3, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005121||131214|
NCT01004783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN10B1|Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors|Validation of Prognostic Markers for Very Low Risk Wilms Tumors||Children's Oncology Group|No|Completed|October 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|165|Samples With DNA|Tumor Tissue|Both|N/A|18 Years|No|Non-Probability Sample|Patients with very low risk Wilms tumor registered on clinical trial COG-AREN03B2 or        patients with stage I or II epithelial tubular differentiated Wilms tumor registered on        clinical trial COG-Q9401 (NWTS-5)|May 2015|May 6, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004783||131240|
NCT00996034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0804003655|Nicotine Vaccination and Nicotinic Receptor Occupancy|123I-5-IA SPECT Imaging of Nicotinic Receptors and Effects of Nicotine Vaccine||Yale University|Yes|Completed|September 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|October 14, 2009|No|Yes||No|September 12, 2012|https://clinicaltrials.gov/show/NCT00996034||131908|
NCT00991770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H27681|Massage Therapy and Port-a-Catheter Insertion|Effect of Massage Therapy on Preoperative Anxiety and Postoperative Pain in Cancer Patients Undergoing Port Implantation||Boston Medical Center|Yes|Completed|February 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991770||132234|
NCT00995761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNUHIRB-2009-30|Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)|Phase II Study of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer||Gyeongsang National University Hospital|Yes|Completed|October 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||February 2014|February 9, 2014|October 14, 2009||No||No|June 21, 2011|https://clinicaltrials.gov/show/NCT00995761||131928|completed without a major limitation
NCT00995995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113030|Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK|Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK||GlaxoSmithKline|No|Completed|October 2008|February 2009|Actual|January 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|7641|||Both|N/A|N/A|No|Probability Sample|Adults - obtainable from the literature|June 2011|June 16, 2011|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00995995||131911|
NCT00996008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 327 AD 02-09|CT 327 in the Treatment of Atopic Dermatitis|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of the Safety and Efficacy of CT 327, Pegylated K-252, Formulated as a Cream, When Administered Twice Daily for 14 Days to Subjects With Mild-to-Moderate Atopic Dermatitis||Creabilis SA|No|Terminated|November 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|October 15, 2009||No|Due to slow recruitment, study was stopped before target enrollment was achieved|No||https://clinicaltrials.gov/show/NCT00996008||131910|
NCT00996021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111856|Study to Assess Cardiac Conduction of GSK1349572|A Study to Evaluate the Effect of a Single 250 mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856).||GlaxoSmithKline||Completed|September 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996021||131909|
NCT00991757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|333369EPY3004|An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period||SK Life Science||Completed|February 2007|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|991|||Both|16 Years|N/A|No|||June 2013|June 10, 2013|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991757||132235|
NCT00992576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005312-18|Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain|A Confirmatory, Placebo-controlled, Randomised, Double-blind, Single-dummy, Parallel Group, Ratio-finding Study in Constipated Pain Patients to Establish an Optimal Hydromorphone - Naloxone Ratio With an Improved Bowel Function and a Comparable Analgesic Efficacy Compared to Hydromorphone Alone|HMX3501|Mundipharma Research GmbH & Co KG||Completed|January 2010|January 2012|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00992576||132172|
NCT00992862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B035302|A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Moexipril HCl 15mg Tablets Under Fasting Conditions||Paddock Laboratories, Inc.||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|September 24, 2013|October 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992862||132150|
NCT01004575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T111E4|Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease|Clinical Evaluation of Kaname Cobalt-Chromium Coronary Stent System in the Treatment of Patients With Coronary Artery Disease|KARE|Terumo Europe N.V.|Yes|Active, not recruiting|October 2009|August 2016|Anticipated|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|280|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004575||131255|
NCT01004029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17P-ES-003|Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery|A Phase 3B, Multi-Center, Randomized, Double-Blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery|PROLONG|Lumara Health, Inc.|Yes|Recruiting|October 2009|November 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1707|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004029||131297|
NCT00993473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11202|6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes|A 24-week, Randomized, Open-label, Parallel Group Multinational Comparison of Lantus® (Insulin Glargine) Given in the Morning as Once-a-day Basal Insulin Versus Neutral Protamine Hagedorn (NPH) Insulin, in Children With Type 1 Diabetes Mellitus Aged at Least 1 Year to Less Than 6 Years|PRESCHOOL|Sanofi|No|Completed|October 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|1 Year|6 Years|No|||June 2012|June 25, 2012|October 9, 2009|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT00993473||132103|There are numerous potential biases that could affect the timing and frequency of performance of sporadic FSBG, such as mealtime dosing and choice of bolus insulin dose, stability and familiarity with insulin regimens, and parental anxiety levels.
NCT00993746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si433/2009|2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula|Comparison of Onset of Action Between 2% Lidocaine Plus 0.5% Bupivacaine and 0.5% Bupivacaine in Brachial Plexus Anesthesia for Creation of Arteriovenous Fistula in ESRD Patient||Mahidol University|No|Recruiting|October 2009|September 2011|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2009|May 14, 2010|September 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00993746||132082|
NCT00994695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRI/WHO/IVB-1|Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine|A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians|ETH-TVT|Armauer Hansen Research Institute, Ethiopia|Yes|Completed|November 2005|November 2007|Actual|January 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|412|||Both|2 Years|29 Years|Accepts Healthy Volunteers|||October 2009|October 15, 2009|October 13, 2009||||No||https://clinicaltrials.gov/show/NCT00994695||132009|
NCT01003132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN09CP213|Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following Psychosis|A Pilot Randomised Controlled Trial of Acceptance and Commitment Therapy for Distress Following Psychosis|PACT|University of Glasgow|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||November 2010|November 8, 2010|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003132||131365|
NCT01003145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU09001|Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders|A Clinical Study to Assess the Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers||Adimmune Corporation|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Prevention|3||Actual|292|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 19, 2012|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003145||131364|
NCT01003678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 144208|Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients|A Phase I Study Evaluating the Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients||Roswell Park Cancer Institute|Yes|Completed|October 2009|October 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|October 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01003678||131323|
NCT01003405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUC1302|Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder|A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder||Kissei Pharmaceutical Co., Ltd.|No|Withdrawn||||||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||July 2010|July 25, 2010|October 27, 2009||||No||https://clinicaltrials.gov/show/NCT01003405||131344|
NCT01003418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113629|Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 8 to 12 Weeks||GlaxoSmithKline||Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|8|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2011|June 9, 2011|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003418||131343|
NCT01004250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13034|A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer|A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC||Eli Lilly and Company|No|Completed|October 2009|December 2013|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|October 28, 2009|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01004250||131280|
NCT01004263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-086|A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)|A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura||Merck Sharp & Dohme Corp.|No|Completed|December 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|674|||Both|12 Years|17 Years|No|||September 2015|September 24, 2015|October 28, 2009|Yes|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01004263||131279|
NCT01004796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000357299|Study of Biomarkers in Tissue Samples From Patients With Breast Cancer|Estrogen-Related Receptor Alpha As A Novel Biomarker For Breast Cancer||National Cancer Institute (NCI)||Not yet recruiting||||||N/A|Observational|N/A|||||||Both|N/A|120 Years|No|||February 2016|February 26, 2016|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004796||131239|
NCT01005147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14456|Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding|Effect of Tranexamic Acid on Blood Transfusion in Upper Gastrointestinal Bleeding||University of Oklahoma|Yes|Withdrawn|November 2009|October 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||April 2012|April 5, 2012|October 28, 2009|Yes|Yes|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01005147||131213|
NCT01000857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112812|Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects|A Steady-state, Two-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Repeated Daily Dosing of the Controlled-release Paroxetine Tablet (25 mg) With That of the Standard Immediate-release Paroxetine Tablet (20 mg) in Healthy Japanese Male Subjects||GlaxoSmithKline|No|Completed|November 2009|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|26|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||February 2011|April 5, 2012|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000857||131539|
NCT01000870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-513-01|Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513|An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate Efficacy & Safety of MNI-513 Positron Emission Tomography for Detection/Exclusion of Cerebral Amyloid Beta in Patients w/ Alzheimer Disease Compared to Healthy Volunteers||Institute for Neurodegenerative Disorders|No|Terminated|October 2009|September 2010|Actual|September 2010|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|55 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 5, 2010|October 22, 2009|Yes|Yes|Results did not show reason to continue with study|No||https://clinicaltrials.gov/show/NCT01000870||131538|
NCT00992017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1086|Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women|A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Monovalent Influenza A (H1N1) Vaccine in HIV-1 Infected Pregnant Women||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|130|||Female|18 Years|39 Years|No|||December 2014|December 8, 2014|October 7, 2009|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT00992017||132215|
NCT00992316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1351001|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects||Pfizer|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|Samples With DNA|Blood|Male|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|young, healthy male volunteers|December 2009|December 16, 2009|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00992316||132192|
NCT00992589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014836|Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Disease (GERD)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|November 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|344|||Both|1 Month|11 Months|No|||April 2013|April 16, 2013|September 4, 2009|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT00992589||132171|
NCT00992602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6954|Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer|Phase II Study of the Combination of High-Dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients With Leptomeningeal Metastases With or Without Parenchymal Brain Involvement||University of Washington|Yes|Completed|April 2011|October 2014|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||November 2014|November 7, 2014|October 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992602||132170|
NCT00991991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1609|Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma|Identification of Genomic Lesions Promoting Nodal Metastasis in Malignant Melanoma||Case Comprehensive Cancer Center|No|Recruiting|July 2009|||March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|tumor tissue samples from patients with stage I, stage II, or stage III malignant melanoma|Both|N/A|N/A|No|Probability Sample|Tumor tissue samples from patients with stage I, stage II, or stage III malignant        melanoma. Primary care clinic|February 2016|February 16, 2016|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991991||132217|
NCT00992303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000653406|Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy|Tissue Procurement and Outcome Collection for Radiotherapy Treated Patients||University of Texas Southwestern Medical Center|Yes|Recruiting|September 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients|August 2015|September 12, 2015|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992303||132193|
NCT00993486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-GVH-001|Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor|Phase I, Dose-ranging, Open-label, Study of a Single Administration of T-cells Add-back Depleted of Host Alloreactive Cells Using Theralux™ Therapy, Following Haploidentical Peripheral Blood Stem Cell Transplantation Submitted to CD34+ Cell Selection, in Patients With Severe Hematologic Malignancies||Kiadis Pharma|No|Completed|January 2005|April 2013|Actual|October 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|19|||Both|18 Years|50 Years|No|||June 2013|June 19, 2013|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993486||132102|
NCT01004341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD057299|Role of Parenting Skills and Parenting Style in Pediatric Weight Loss Programs|Role of Parenting Skills, Style and Family Functioning in Pediatric Weight Loss||University of California, San Diego|No|Completed|June 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|8 Years|12 Years|No|||June 2013|June 18, 2013|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01004341||131273|
NCT00994409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSB-PatZuFrie|Patient Satisfaction in Stroke Patients|Berliner Schlaganfallregister - Nachbefragung Von Patienten Mit Schlaganfall|PatZuFrie|Charite University, Berlin, Germany|No|Completed|July 2008|November 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Stroke and TIA patients treated at the Charite with acute stroke or TIA onset less than 7        days|November 2010|November 30, 2010|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994409||132031|
NCT00994422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP010|Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects|A Double-Blind Randomized Study to Compare the Safety, Local Tolerability and Efficacy of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation||Topaz Pharmaceuticals Inc|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|2 Years|N/A|No|||April 2012|April 4, 2012|October 9, 2009|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT00994422||132030|
NCT01004835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 08-5099|The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)|The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)|MAPS|Scripps Translational Science Institute|No|Completed|January 2009|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Family-Based||1|Actual|61|Samples With DNA|Approximately 20 milliliters of blood will be dispensed as follows: 2 X 8.5 ml PAX DNA Tubes      OR 2 mLs of Saliva may be collected from each patient in a provided container. Saliva will      only be collected on those individuals who do not wish to undergo phlebotomy for blood      collection.|Both|10 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the Migraine disease patient population at Scripps Clinic        and around Southern California.|October 2015|October 14, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004835||131236|
NCT01003704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-059|Incidence of Phantom Limb Pain and Method of Anesthesia After Lower Extremity Amputation|Incidence of Phantom Limb Pain and Method of Anesthesia After Lower Extremity Amputation||North Texas Veterans Healthcare System||Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|||||Both|18 Years|N/A||Non-Probability Sample|Patients who receive lower extremity amputation|October 2009|October 28, 2009|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003704||131321|
NCT01003431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-036|A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)|A Randomized, Open-Label Clinical Study to Assess the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine When Administered Concomitantly With RotaTeq™ or Rotarix™ in Healthy Infants in South Africa||Merck Sharp & Dohme Corp.||Withdrawn|December 2009|September 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|0|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||October 2015|October 8, 2015|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003431||131342|
NCT01004003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.37|Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.||Boehringer Ingelheim||Active, not recruiting|October 2009|January 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|October 12, 2009||||No|July 9, 2015|https://clinicaltrials.gov/show/NCT01004003||131299|
NCT01004016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1202|A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|N/A|No|||September 2010|September 27, 2010|October 27, 2009||||No||https://clinicaltrials.gov/show/NCT01004016||131298|
NCT01003964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-08-371|Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV|Randomized phase2 Study of IP vs. GP as the First-line Therapy Followed by Two Different Sequences as the 2nd or 3rd-line Therapy for Patients With Advanced NSCLC;||National Cancer Center, Korea|No|Active, not recruiting|February 2009|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|284|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003964||131302|
NCT01003977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REWARDS XV|Registry Experience at the Washington Hospital Center, DES - Xience V|REWARDS (Registry Experience at the Washington Hospital Center, DES - Xience V)|REWARDS XV|Medstar Research Institute|No|Active, not recruiting|August 2009|September 2013|Anticipated|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with a Xience V, everolimus-eluting, Stent at the Washington Hospital        Center.|March 2013|March 28, 2013|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01003977||131301|
NCT01004822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1561001|A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Cvx-241, A Selective Angiopoietin-2 And Vascular Endothelial Growth Factor Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors||Pfizer|No|Terminated|March 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|October 28, 2009|No|Yes|See termination reason in detailed description.|No|May 11, 2015|https://clinicaltrials.gov/show/NCT01004822||131237|The study was terminated early by the sponsor due to lack of significant pharmacological effects (safety/Pharmacodynamics/efficacy) through 25 mg/kg cohort. Hence, no participant could reach out to Stage 2.
NCT01004510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US CZOL446EUS143T|Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer|An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer|ZAP|Rochester General Hospital|No|Terminated|November 2009|April 2011|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||November 2012|November 5, 2012|October 29, 2009|Yes|Yes|failure to accrue projected number of patients|No|August 14, 2012|https://clinicaltrials.gov/show/NCT01004510||131260|
NCT01004809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113797|AVODART® Alopecia Post-marketing Surveillance (PMS)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and Effectiveness of AVODART® Administered in Korean Androgenetic Alopecia Patients According to the Prescribing Information|AVODART®PMS|GlaxoSmithKline|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|712|||Male|18 Years|41 Years|No|Probability Sample|Patients administrated dutasteride with male pattern hair loss (androgenetic alopecia)|July 2014|July 31, 2014|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004809||131238|
NCT01000909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-02-2009-USZ|Venous Pressure Measurement of the Great Saphenous Vein Using Controlled Compression Ultrasound in Healthy Persons and Patients With Chronic Venous Disease as a New Non Invasive Method for Investigation of the Pathophysiology in Primary Varicose Veins|||University of Zurich||Recruiting|July 2009|July 2010||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic venous disease with complete incompetence of the great saphenous        vein|June 2010|June 28, 2010|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000909||131535|
NCT01000883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 9819|Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior|Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|December 1998|November 2022|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Primary tumor and metastatic site tumor tissue; whole blood|Female|18 Years|N/A|No|Non-Probability Sample|Participants will be selected from those individuals receiving diagnostic and treatment        related biopsies at the University of North Carolina at Chapel Hill.|November 2015|November 23, 2015|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000883||131537|
NCT01000896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8180C00020|Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel|A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies||AstraZeneca|Yes|Withdrawn|January 2010|March 2011|Anticipated|September 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|20 Years|N/A|No|||February 2010|February 3, 2010|October 14, 2009|No|Yes|AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical    studies will be initiated..|No||https://clinicaltrials.gov/show/NCT01000896||131536|
NCT00992030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-HD09-01|R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma|Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) With ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in Limited Stage (Stage I-IIA With no Areas of Bulk) Hodgkin's Lymphoma||Fondazione Michelangelo|No|Active, not recruiting|September 2009|December 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992030||132214|
NCT00992329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043432|Impact of Formulation on Ciprofloxacin Oral Absorption|Impact of Formulation on Ciprofloxacin Oral Absorption||University of Maryland|Yes|Completed|January 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00992329||132191|
NCT00992888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heliac-01|Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis|Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis. A Pato-etiological Study With Focus on the Endotoxin Pathway.|Heliac|University of Aarhus|Yes|Completed|August 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|69 Years|No|||September 2011|September 14, 2011|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992888||132148|
NCT00992615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP20-12|Comparison of 20-core Versus 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer|Comparison of 20-core vs 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer||Poitiers University Hospital||Completed||||||N/A|Interventional|N/A|2||||||Male|18 Years|N/A||||November 2009|August 28, 2012|October 8, 2009||||No||https://clinicaltrials.gov/show/NCT00992615||132169|
NCT00993187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-202|Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)|A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet®) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|May 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|292|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|October 9, 2009|Yes|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT00993187||132125|
NCT01003483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|616|Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients|Orlistat Administration Facilitates the Obesity Treatment Among Obese PCOS Women||Yazd Research & Clinical Center for Infertility|Yes|Completed|November 2008|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|80|||Female|15 Years|39 Years|Accepts Healthy Volunteers|||October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003483||131338|
NCT01004614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531088|Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet|An Open, Randomized, Parallel-Cohort, 2-Periods, Crossover, Single Dose Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet In Healthy Male Subjects||Pfizer|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 29, 2011|October 29, 2009|No|Yes||No|December 3, 2010|https://clinicaltrials.gov/show/NCT01004614||131252|
NCT01004627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Access 1|A Study of Routine Versus Selective Use of Ultrasound Scanning Prior to Haemodialysis Fistula Surgery|A Prospective Randomized Controlled Trial of the Clinical Effectiveness of Obligatory Versus Elective Duplex Ultrasound Scanning Prior to Arteriovenous Fistula Formation for Haemodialysis Vascular Access in a University Teaching Hospital.||University of Hull|No|Completed|March 2010|January 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004627||131251|
NCT01004289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1328P|POSTconditioning During Coronary Angioplasty in Acute Myocardial Infarction Study|POSTconditioning During Coronary Angioplasty in Acute Myocardial Infarction Study (POST-AMI)|POST-AMI|University of Padua|No|Completed|April 2007|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004289||131277|
NCT01004302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 521/02|Radiosurgical Treatment for Obsessive-compulsive Disorder|Ventral Capsular/Ventral Striatal Gamma Capsulotomy for Obsessive-compulsive Disorder: a Randomized Controlled Trial||University of Sao Paulo General Hospital|No|Terminated|July 2003|January 2015|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|60 Years|No|||October 2012|October 11, 2012|October 28, 2009||No|Our Co sources were in a state of advanced decay. That prolonged our surgical procedures,    making them inconveniently and perhaps dangerously long (> 12 hours)|No||https://clinicaltrials.gov/show/NCT01004302||131276|
NCT01004315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUC1301|A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder|A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|750|||Both|20 Years|N/A|No|||July 2010|July 25, 2010|October 27, 2009||||No||https://clinicaltrials.gov/show/NCT01004315||131275|
NCT01004536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-092|An Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix)|A Randomized Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix) in the Prevention of Hypertrophic Scar in Subjects Undergoing Caesarean Section||Samsung Medical Center|No|Active, not recruiting|October 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|47|||Female|20 Years|45 Years|No|||December 2010|December 9, 2010|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004536||131258|
NCT01004848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 05-0463|Effectiveness Study of Community-Based, Peer-Led Education on Weight Loss and Diabetes|Collaborations for Health Improvement in East Harlem—Project HEED|HEED|Icahn School of Medicine at Mount Sinai|No|Completed|March 2009|September 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|402|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|October 29, 2009||No||No|September 4, 2013|https://clinicaltrials.gov/show/NCT01004848||131235|
NCT01003717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REWARDS EMI|Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction|REWARDS-EMI (Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction)|REWARDS-EMI|Medstar Research Institute|No|Active, not recruiting|October 2009|October 2013|Anticipated|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who receive at least one Endeavor, zotarolimus-eluting, Stent as the primary        treatment for acute coronary syndrome, at the Washington Hospital Center.|March 2013|March 28, 2013|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01003717||131320|
NCT01003990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-077|Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access|Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study||Bristol-Myers Squibb|No|Active, not recruiting|October 2002|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|306|||Both|16 Years|75 Years|No|||August 2015|February 10, 2016|October 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003990||131300|
NCT01004276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-341|Increasing Smoking Cessation Counselling in Primary Care Using a Chronic Disease Management System|A Cluster Randomized Controlled Pilot Trial of the Effect of a New, Improved Smoking Cessation Management Module, Compared With Use of the Standard Version of Such a Management Module, on Smoking Counselling Initiation and Continuation Rates in Primary Care Practices Currently Using P-PROMPT Chronic Disease Management System in Ontario||McMaster University|Yes|Enrolling by invitation|November 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2009|October 28, 2009|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004276||131278|
NCT00996918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133K1-3002|A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000||Pfizer|Yes|Terminated|December 2009|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|51 Years|N/A|No|||November 2013|November 12, 2013|October 14, 2009|Yes|Yes|The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical    benefit. This decision was not based on any new safety concerns.|No|November 12, 2013|https://clinicaltrials.gov/show/NCT00996918||131840|Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.
NCT01004523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-94-72-53|Study of Tissue and Blood Samples From Patients With Low-Grade Glioma|Diagnostic and Prognostic Markers in Low-Grade Gliomas||Alliance for Clinical Trials in Oncology||Withdrawn||||||N/A|Observational|N/A|||Actual|0|||Both|N/A|N/A|No|||July 2013|July 15, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004523||131259|
NCT00997789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBBS-BE-REBAMIPIDE-KYUNGDONG|Bioequivalence of Rebamipide in Korean|Bioequivalence Evaluation of Two Rebamipide Preparations After a Single Oral Dose to Healthy Korean Volunteers||Chonnam National University Hospital|Yes|Completed|March 2008|December 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||October 2009|October 18, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00997789||131773|
NCT01005160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKD-19HPS09H|Drug Interaction Between CKD-501 and Metformin|A Sequence-randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Metformin After Oral Administration in Healthy Male Volunteers|CKD-19HPS09H|Chong Kun Dang Pharmaceutical|No|Completed|October 2009|February 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2009|January 10, 2011|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01005160||131212|
NCT00998296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1239.14|Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.|Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.||Boehringer Ingelheim||Completed|October 2009|July 2014|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|October 19, 2009||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT00998296||131734|Statistics of PK parameters are only estimated when at least 2/3 of the data are evaluable.
NCT00998309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661202|Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)|Zithromax-SR 2g, Special Investigation For Skin And Soft Tissue Infection, Sexually-Transmitted Infection, And Infection Of The Oral (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|October 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|502|||Both|N/A|N/A|No|Probability Sample|The patients whom an involving A0661202 prescribes the Azithromycin SR.|April 2012|April 2, 2012|October 16, 2009|No|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT00998309||131733|
NCT01001221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11068|Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor|A Dose-Escalation, Single Arm, Combination Study of Cabazitaxel With Gemcitabine to Determine The Safety, And Pharmacokinetics In Subjects With Advanced Solid Malignancies||Sanofi|No|Terminated|November 2009|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|October 23, 2009|Yes|Yes|Maximum tolerated dose not able to be determined|No|May 20, 2013|https://clinicaltrials.gov/show/NCT01001221||131511|Pharmacokinetic results need to be confirmed due to the limited data available.
NCT01002911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADIT|Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)|Phase III Pilot Study - A Simple Randomized Trial of Conventional Versus Multimodal Prevention of Arrhythmia Device Infection|PADIT|Population Health Research Institute|Yes|Completed|December 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01002911||131382|
NCT01003223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEIRB PKM 09-207|Phosphate Kinetic Modeling|Phosphate Kinetic Modeling|PKM|Fresenius Medical Care North America|No|Completed|October 2009|April 2011|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|18 Years|N/A|No|||November 2010|August 14, 2014|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003223||131358|
NCT00993200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35279|Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy|PerMIT: Warfarin : A Prospective Randomized Controlled Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy|PerMIT|University of Utah|Yes|Completed|August 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|October 8, 2009||No||No|August 13, 2012|https://clinicaltrials.gov/show/NCT00993200||132124|Small sample size in this pilot trial
NCT00993499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.70|Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib|A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib||Boehringer Ingelheim||Completed|October 2009|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|October 8, 2009||||No|September 4, 2015|https://clinicaltrials.gov/show/NCT00993499||132101|
NCT00993512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI 101/06|Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer|Phase I, Dose-escalating Study to Evaluate Safety and Tolerance of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Local Recurrence or Advanced/Metastatic, Cutaneous or Sub-cutaneous Malignancies||PCI Biotech AS|Yes|Completed|August 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2009|June 17, 2011|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993512||132100|
NCT01004042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-CBED09-02|Evaluation of Quality of Life and Self-steem After Botox® in Depressed and Non-depressed Patients|Evaluation of Quality of Life and Self-steem After Botulinum Toxin type-a (Botox®) Injections in Depressed and Non-depressed Patients||Brazilan Center for Studies in Dermatology|No|Completed|October 2009|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004042||131296|
NCT01004640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-29801|Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial|Molecular and Cytogenetic Monitoring of CML - A Mandatory Companion to CALGB 19804||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|December 1998|||February 2001|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|PATIENTS ENTERED ONTO CALGB TREATMENT STUDIES FOR CML|July 2015|July 23, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004640||131250|
NCT01004653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PanFlu-4001-1|A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines|An Open-Label Clinical Trial With Split-virion Influenza A/H1N1 Vaccines in Healthy Elders||Sinovac Biotech Co., Ltd||Completed|September 2009|November 2009|Actual|October 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 13, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004653||131249|
NCT01004861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-01|Safety Study of PLX108-01 in Patients With Solid Tumors|A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology||Plexxikon|No|Active, not recruiting|September 2009|September 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|October 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004861||131234|
NCT01004874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019960|Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma|Avastin in Combination With Radiation and Temozolomide Followed by Avastin, Temozolomide, and Topotecan for Glioblastoma Multiformes and Gliosarcomas||Duke University|No|Active, not recruiting|December 2009|July 2016|Anticipated|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|October 28, 2009|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT01004874||131233|
NCT01004549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Accomodation study|An Open-Label Evaluation of Degree of Accommodation in Pseudophakic Patients Bilaterally Implanted With Monofocal Intraocular Lenses|||Innovative Medical||Completed|October 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|June 2011|June 24, 2011|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004549||131257|
NCT01004562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000378061|Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence|The Breast Cancer Specialized Program of Research Excellence (SPORE): Core A-Administrative/Biostatistics Core||University of Alabama at Birmingham|No|Completed|August 2007|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1025|||Female|N/A|N/A|No|Non-Probability Sample|Breast cancer patients of any age|November 2012|October 11, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004562||131256|
NCT00996359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020901|Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation|Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation||Rutgers, The State University of New Jersey|No|Terminated|October 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|13 Years|N/A|No|||September 2013|September 13, 2013|October 15, 2009|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT00996359||131883|
NCT00996658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.61|Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone|A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone||Boehringer Ingelheim||Completed|October 2009|||March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|79 Years|No|||February 2014|February 24, 2014|October 15, 2009||||No|February 13, 2013|https://clinicaltrials.gov/show/NCT00996658||131860|During the conduct of this trial, pioglitazone was removed from the market in France due to safety issues, and this resulted in premature termination of a number of French patients.
NCT00997230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ODE-DUM-2009/1|Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m|An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer (Stage IIIB/IV Non-small Cell Lung Cancer)|REASON|AstraZeneca|No|Completed|September 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4243|||Both|18 Years|N/A|No|Probability Sample|clinical setting|October 2013|October 25, 2013|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997230||131816|
NCT00997516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF SILS 01|Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis|A Randomized, Controlled Trial of Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis||University of California, San Francisco|No|Terminated|May 2010|January 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|October 15, 2009|Yes|Yes|Planned interim analysis showed worse outcomes in experimental group|No|August 6, 2014|https://clinicaltrials.gov/show/NCT00997516||131794|
NCT00997802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000002097|Japanese National Computed Tomographic (CT) Colonography Trial|Evaluation of Accuracy of Computed Tomographic Colonography (CTC) in the Diagnosis of Colorectal Tumors by Gastroenterologists and Radiologists With Computer-aided Detection (CAD): A Multicenter Study|JANCT|Japanese CT Colonography Society||Active, not recruiting|October 2009|||January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1500|||Both|20 Years|N/A|No|||June 2012|June 9, 2012|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997802||131772|
NCT00998049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0889|Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant|Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy||Mayo Clinic|Yes|Completed|December 2009|April 2015|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|October 19, 2009|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT00998049||131753|
NCT00998062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CES-DUM-2009/1|Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain|Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population|DARIOS|AstraZeneca|No|Completed|November 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|30181|None Retained|No samples will be obtained, but biomarkers will be analysed from frozen serum samples      retained by the pervious studies performed.|Both|35 Years|74 Years|No|Probability Sample|Data from epidemiological studies performed after the year 2000 with patients between 35        and 74 years old|October 2011|October 19, 2011|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998062||131752|
NCT00998322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 017|A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma|A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma||Oncolytics Biotech|No|Completed|October 2009|February 2015|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00998322||131732|
NCT00998569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSYC-092-09|Neurocognitive Enhancement in Major Depressive Disorder|Neurocognitive Enhancement in Major Depressive Disorder|MDDNET|Queen's University|No|Completed|October 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00998569||131714|
NCT00998582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC-004|Artery Elasticity After Switch From Epzicom to Truvada|Artery Elasticity After Switch From Epzicom to Truvada||Minneapolis Medical Research Foundation|No|Terminated|October 2009|December 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|October 19, 2009|Yes|Yes|Low enrollment|No|January 16, 2012|https://clinicaltrials.gov/show/NCT00998582||131713|Study stopped early due to low/inadequate enrollment and findings are subsequently limited by low power to detect differences.
NCT01003236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4774|Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy|Evaluating the Preventive Effect of Milk Thistle Extract (Silymarin) on Progression of Diabetic Nephropathy, a Randomized, Double-blind, Placebo-controlled Clinical Trial.||Shiraz University of Medical Sciences|Yes|Completed|October 2010|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|70 Years|No|||June 2012|June 21, 2012|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003236||131357|
NCT01003509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hernia|A New Approach in Inguinal Hernia Repair: Double Repair. A Prospective, Randomized, Controlled Clinical Trial|A New Approach in Inguinal Hernia Repair: Double Repair. A Prospective, Randomized, Controlled Clinical Trial|herni|SB Istanbul Education and Research Hospital|No|Recruiting|January 2001|January 2012|Anticipated|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|90 Years|Accepts Healthy Volunteers|||October 2009|May 3, 2011|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003509||131336|
NCT01003522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2987|Evaluation of Stents to Open Restricted Airways in Patients With Centrally Placed Non-small Cell Lung Cancer|Randomised Evaluation of Stents to Open Restricted Airways in Patients With Centrally Placed Non-small Cell Lung Cancer (RESTORE-AIR)|RESTORE-AIR|Royal Marsden NHS Foundation Trust|Yes|Recruiting|September 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003522||131335|
NCT01003496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA/NIH 1RC1DA028467-01|Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial|Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial||Wright State University|No|Active, not recruiting|November 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|80 Years|No|||October 2010|October 6, 2010|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003496||131337|
NCT01003743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP165|Endolumenal Gastric Pouch and Gastrojejunal Anastomosis Reduction|Endolumenal Gastric Pouch and Gastrojejunal Anastomosis Reduction||USGI Medical|No|Completed||||||N/A|Interventional|N/A|||||||Both|19 Years|64 Years||||October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003743||131318|
NCT01004055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSMP-011|Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation|Efficacy of the PROCELLERA Wound Dressing in the Healing of Wounds After Curettage and Electrodesiccation of Skin Lesions||Vomaris Innovations|Yes|Completed|July 2008|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|80 Years|No|||October 2009|October 28, 2009|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004055||131295|
NCT01004328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS017817|Using Health Information Technology (HIT) to Improve Transitions of Complex Elderly Patients From Skilled Nursing Facility (SNF) to Home|Using HIT to Improve Transitions of Complex Elderly Patients From SNF to Home|RAMPAGEII|University of Massachusetts, Worcester|Yes|Completed|April 2011|January 2013|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|626|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 23, 2014|July 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01004328||131274|
NCT01004588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-056|The Effects of Resistance Training and Protein Supplementation in Healthy Elderly Men and Women.|The Effects of Resistance Type Exercise Training and Protein Supplementation on Skeletal Muscle Mass, Strength, and Muscle Characteristics in Healthy Elderly Men and Women||Maastricht University Medical Center|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01004588||131254|
NCT01004601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-2587B|Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer|Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taipei, Taiwan||Chang Gung Memorial Hospital|Yes|Completed|March 2005|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||October 2009|October 28, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01004601||131253|
NCT01004900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R657/07/2009|Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma|Comparison of Selective Laser Trabeculoplasty With Prostaglandin Analogues for Lowering Intraocular Pressure in Eyes With Primary Angle Closure Glaucoma||Singapore Eye Research Institute|No|Recruiting|June 2009|March 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|21 Years|N/A|No|||May 2010|May 10, 2010|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004900||131231|
NCT01005212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007-0202|Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair|Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair|AAA CEUS|The Methodist Hospital System|No|Completed|January 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Sujbects that have undgone endovascular repair of abdominal aortic aneurysms (EVAR).|May 2012|May 21, 2012|October 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01005212||131208|
NCT00996671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113581|Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers|A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects|FTIH|GlaxoSmithKline||Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|June 10, 2010|October 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996671||131859|
NCT00996931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-ASD-CHEZ-0329|Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders|A Phase II Pilot Study to Determine Efficacy and Safety of Lenalidomide (Revlimid) for Treatment of Autistic Spectrum Disorders(ASD) With Regression and Markers of Cerebrospinal Fluid Cytokine Elevation and Elevated TNF-alpha Levels||Sutter Medical Foundation|Yes|Completed|February 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|6 Years|16 Years|No|||April 2013|April 24, 2013|October 15, 2009|Yes|Yes||No|August 30, 2011|https://clinicaltrials.gov/show/NCT00996931||131839|
NCT00996944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113079|Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)|Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)||GlaxoSmithKline|No|Terminated|November 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|79 Years|No|||October 2011|July 3, 2013|October 8, 2009||No|Because GSK concluded that it was impossible to recruit sufficient participants within a    reasonable timeframe.|No|February 10, 2011|https://clinicaltrials.gov/show/NCT00996944||131838|
NCT00997243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09034|Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes|Phase II Study of 5-azacytidine and Lintuzumab in Myelodysplastic Syndromes (MDS)||Ohio State University Comprehensive Cancer Center|Yes|Terminated|November 2009|May 2011|Actual|September 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2013|November 30, 2013|October 16, 2009|Yes|Yes|Drug no longer being supplied by sponsor|No|May 7, 2013|https://clinicaltrials.gov/show/NCT00997243||131815|The study was terminated early by the sponsor due to the removal of lintuzumab from the market.
NCT00997529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-00-0154-FB/2001-P-000092/8|Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors|Nonmyeloablative Allogeneic Stem Cell Transplantation for the Treatment of Solid|MiniSolid|Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|November 2000|November 2012|Anticipated|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|May 5, 2008||No||No||https://clinicaltrials.gov/show/NCT00997529||131793|
NCT00999258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468X1-4504|Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients|Prospective Trial of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients With Chronic Allograft Nephropathy||Temple University|No|Recruiting|September 2009|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2009|October 20, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999258||131661|
NCT00998075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00007|Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately|A Phase I, Open-Label, Randomized, Single-Centre, 3-Way Crossover Bioequivalence Study Comparing a Fixed Dose Combination Capsule of Esomeprazole 40 mg and Acetylsalicylic Acid 325 mg With Free Combinations of Esomeprazole Capsule 40 mg and Acetylsalicylic Acid Tablet 325 mg and Esomeprazole Tablet||AstraZeneca||Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|138|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998075||131751|
NCT00998595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-1107-09/09 (AAMC-CDC)|Gestational Diabetes Follow Up Study|Es Mejor Saber: A Proactive Approach to Gestational Diabetes Follow Up||University of Southern California|No|Active, not recruiting|June 2009|October 2011|Anticipated|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|216|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 12, 2011|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998595||131712|
NCT01002937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3076|Novel Prognostic Markers in Renal Cancer|Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples||Royal Marsden NHS Foundation Trust|No|Recruiting|December 2008|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Tumour tissue from subjects with renal cell carcinoma, who have been treated at the Royal        Marsden Hospital|October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01002937||131380|
NCT01002950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4429-201|Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy|Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)||Acucela Inc.|Yes|Completed|October 2009|October 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|N/A|N/A|No|||February 2014|February 7, 2014|October 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002950||131379|
NCT01003249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009516|Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen|Treatment of Patients With Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen: a Randomized Double-blind Placebo-controlled Cross-over Trial||Wake Forest School of Medicine||Terminated|September 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|64 Years|No|||December 2013|December 18, 2013|October 21, 2009||No|recruitment was going too slowly|No||https://clinicaltrials.gov/show/NCT01003249||131356|
NCT01003756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20090099|Preoperative Exercise in Patients Undergoing Total Hip or Knee Replacement|||University of Southern Denmark||Completed|November 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|165|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003756||131317|
NCT01003769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC128A|Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia|A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)||Mayo Clinic|Yes|Recruiting|September 2013|||March 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003769||131316|
NCT01004068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2009|Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS)|Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study||University Magna Graecia|Yes|Completed|February 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|96|||Female|18 Years|35 Years|No|||November 2009|November 2, 2010|July 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01004068||131294|
NCT01001598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-0131|Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita|Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita||Children's Hospital Boston|Yes|Terminated|November 2009|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|3 Years|N/A|No|||September 2014|September 12, 2014|October 22, 2009|Yes|Yes|Study was terminated due to under enrollment|No||https://clinicaltrials.gov/show/NCT01001598||131483|
NCT01004913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kehila106/109|Vestibular Evoked Myogenic Potentials in Benign Paroxysmal Positional Vertigo (VEMP in BPPV)|Evaluation of the Otolithic Organs Function in Patients Suffering From Benign Paroxysmal Positional Vertigo (BPPV) by Vestibular Evoked Myogenic Potentials (VEMP).||Meir Medical Center|No|Completed|November 2009|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients suffering fron Benign Paroxysmal Positional Vertigo|August 2011|February 11, 2013|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01004913||131230|
NCT01004926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7325-IS-CTIL|Evaluation of the Efficiency of the Echelon Foot in Traumatic Trans Tibial Amputees|Evaluation of the Efficiency of the Echelon Foot in Traumatic Trans Tibial||Sheba Medical Center|No|Not yet recruiting|October 2009|March 2010|Anticipated|January 2010|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|20 Years|70 Years|No|||October 2009|October 29, 2009|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01004926||131229|
NCT01004887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-72-52|Study of Tissue and Blood Samples From Patients With High-Grade Glioma|Diagnostic And Prognostic Markers In High-Grade Glioma||Alliance for Clinical Trials in Oncology||Withdrawn||||||N/A|Observational|N/A|||Actual|0|||Both|N/A|N/A|No|||December 2012|June 27, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004887||131232|
NCT00998088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN96327523|Blood Management in Orthopedic Surgery|Optimal Blood Management in Elective Orthopaedic Surgery: The Transfusion "Op Maat" (TOMaat) Study|TOMaat|Sanquin Research & Blood Bank Divisions|Yes|Completed|May 2004|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|2598|||Both|18 Years|N/A|No|||October 2009|October 19, 2009|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998088||131750|
NCT00998335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060167|Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes|Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes||The University of Texas Health Science Center at San Antonio|No|Completed|June 2007|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||April 2012|April 26, 2012|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998335||131731|
NCT00997828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0272|Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)|Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease (BEST)|BEST|CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|July 2009|May 2019|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|888|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997828||131770|
NCT00998608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPH-2007-17|Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia|A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder||Kaohsiung Kai-Suan Psychiatric Hospital|Yes|Terminated|August 2007|October 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 18, 2009|October 8, 2009||No|terminated|No||https://clinicaltrials.gov/show/NCT00998608||131711|
NCT00998959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008p001576|Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients|Feasibility and Efficacy of a Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients||Massachusetts General Hospital|No|Completed|August 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||April 2012|April 27, 2012|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00998959||131684|
NCT00998621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADH-HEPC-2009-01|ADHEPTA Study: Adherence Questionnaire in Hepatitis C|Development and Validation of a Questionnaire Measuring Treatment Adherence in Patients With Hepatitis C|ADHEPTA|Fundacion IMIM|No|Completed|October 2009|January 2013|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with HCV and with HCV + HIV|October 2009|October 14, 2015|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998621||131710|
NCT00998634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCA_LITIO_12|Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)|Randomized, Placebo-controlled Trial to Test Safety, Tolerability and Efficacy of Lithium Carbonate in Spinocerebellar Ataxia 2|LISCA2|Federico II University|No|Completed|October 2009|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||January 2013|January 7, 2013|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00998634||131709|
NCT00998972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-CHUN1|N-acetyl-cysteine (NAC) and Kidney Graft Function|Preventive Administration of N-acetyl-cysteine (NAC) in Organ Donor: Effects on Kidney Graft Function||Institut d'Anesthesiologie des Alpes Maritimes|No|Completed|September 2006|June 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|70 Years|No|||June 2009|July 9, 2011|October 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00998972||131683|
NCT00999557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000657044|Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants|Efficacy of Topical Bimatoprost in Promoting Hair Growth in the Region of the Eyebrow and Eyelashes for Post-chemotherapy Patients Versus Normal Patients||Jonsson Comprehensive Cancer Center|Yes|Not yet recruiting|January 2016|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|October 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00999557||131638|
NCT00999570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/626/D|High Volume Specialty Knee Replacement Surgeons Achieve Better Clinical and Quality-of-Life Scores|High Volume Specialty Knee Replacement Surgeons Achieve Better Clinical and Quality-of-Life Scores||Singapore General Hospital|Yes|Completed|January 2004|December 2007|Actual|May 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|3458|||Both|37 Years|90 Years|No|Probability Sample|patients seen at Singapore General Hospital who require total knee arthroplasty|October 2009|October 21, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999570||131637|
NCT00999271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-2009-0025|Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism|On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans||Hvidovre University Hospital|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control||1||30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|October 2009|October 20, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999271||131660|
NCT01002924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-010|Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)|Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145||Endocyte|No|Active, not recruiting|December 2009|April 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01002924||131381|
NCT01002963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0631001|A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers|A Double-Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Doses Of PF-04418948 In Healthy Male Subjects||Pfizer|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Anticipated|56|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01002963||131378|
NCT01003262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3163864|Evaluating an Emergency Department Observation Syncope Protocol for Older Adults|||University of California, Los Angeles|Yes|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|123|||Both|50 Years|N/A|No|||December 2011|December 23, 2011|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003262||131355|
NCT01003548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405/08|Embryo Development in Microfluidics System of Culture|Comparison of the in Vitro Development of Human Embryos in Static and and Microfluidics Systems of Culture||Federal University of São Paulo|No|Recruiting|October 2009|October 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|400|||Female|21 Years|35 Years|Accepts Healthy Volunteers|||October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003548||131333|
NCT01003561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-TURP|Hemodynamic Changes of Upper and Lower Extremities After Spinal Anesthesia|||Yonsei University||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|1||Anticipated|40|||Male|65 Years|N/A|No|||October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003561||131332|
NCT01003535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JoergSpiegel1|Quantification of Cerebral Cholinergic Function in Parkinson´s Disease by Means of Nuclear Medicine Methods|Quantification of Cerebral Cholinergic Function in Patients With Parkinson´s Disease by Means of Nuclear Medicine Methods||Saarland University|No|Completed|January 2010|April 2012|Actual|April 2012|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|50 Years|75 Years|No|Probability Sample|Patients with Parkinson´s disease|July 2012|July 3, 2012|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01003535||131334|
NCT01004081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120BC201|Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding|Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor||Biogen|No|Completed|November 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Female|18 Years|N/A|No|||December 2011|September 17, 2015|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004081||131293|
NCT01004354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Docket #13212|Vitamin D Supplementation in Psychiatric Illnesses|Effect of Vitamin D Supplementation on the Metabolic Abnormalities of Second Generation Antipsychotics in Children and Adolescents|VDSS|University of Massachusetts, Worcester|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|10 Years|18 Years|No|||January 2012|January 10, 2012|October 28, 2009||No||No|October 17, 2011|https://clinicaltrials.gov/show/NCT01004354||131272|
NCT01004939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112937|Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism|Retrospektive Studie zu Patientinnen, Die pränatal, Perinatal Oder Postnatal Prophylaktisch Oder Therapeutisch Mit Fondaparinux Behandelt Wurden|FondaPPP|GlaxoSmithKline|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|120|||Female|N/A|N/A|No|Probability Sample|Pregnant women who received a prophylaxis against venous thromboembolism because of an        elevated thromboembolic risk and who were therefore treated in a haemostaseological        centre.|July 2011|July 28, 2011|October 1, 2009||No||No|June 30, 2011|https://clinicaltrials.gov/show/NCT01004939||131228|
NCT01004952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-137|Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection|Measuring Real Time Decision-Making About UVR Protection||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2009|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients whose FDRs may be eligible for this study will be identified by a member of the        patient's treatment team, the protocol investigator, or research team at Memorial        Sloan-Kettering Cancer Center (MSKCC) will identify patients who are melanoma patients.|November 2015|November 2, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004952||131227|
NCT01005238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASL28|Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine|A Randomized Open Label Study Evaluating the Efficacy of Continuous Telbivudine Versus Lamivudine in Patients With HBeAg-negative Chronic Hepatitis B Who Had Previously Achieved an Undetectable Viral Load During 24 Weeks of Telbivudine Therapy|SASL28|University Hospital, Basel, Switzerland|Yes|Terminated|September 2009|||December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|October 29, 2009||No|unsufficient patient recruitment|No||https://clinicaltrials.gov/show/NCT01005238||131206|
NCT01005251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00019|Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI|||AstraZeneca||Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|661|||Both|18 Years|70 Years|No|||March 2011|March 29, 2011|October 27, 2009|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT01005251||131205|
NCT00997568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEE-001|Safety of the PET-511BTM Transesophageal Transducer|Safety of the PET-511BTM Transesophageal Transducer (TEE)|TEE|Toshiba America Medical Systems, Inc.|Yes|Completed|October 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have been scheduled for a TEE procedure by their physician.|August 2010|August 19, 2010|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997568||131790|
NCT00997581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-GOUT-PI-0038|Apremilast Therapy for Acute Gouty Arthritis|Apremilast Therapy for Acute Gouty Arthritis||Dartmouth-Hitchcock Medical Center|Yes|Withdrawn|April 2010|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||January 2016|January 20, 2016|October 9, 2009|Yes|Yes|Colaborator withdrew support.|No||https://clinicaltrials.gov/show/NCT00997581||131789|
NCT00997841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC-9509|Conventional Versus Point-of-care Based Coagulation Management|Conventional Versus Point-of-care Based Coagulation Management in Cardiac Surgery Patients Suffering From Increased Bleeding Tendency - a Prospective and Randomized Study||Goethe University|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2009|May 3, 2010|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997841||131769|
NCT00997854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5376|Preterm Neonatal Feeding Protocol Comparing Feed Administration Time|Preterm Neonatal Feeding Protocol Comparing Feed Administration Time||Oregon Health and Science University|Yes|Recruiting|October 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|136|||Both|N/A|32 Weeks|Accepts Healthy Volunteers|||July 2010|July 21, 2010|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997854||131768|
NCT00998101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0816|Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy|A Phase II Trial of Carboplatin, Ixabepilone and Cetuximab in Chemotherapy Naive Advanced Non-Small Cell Lung Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Withdrawn|July 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|October 17, 2009|Yes|Yes|Study was withdrawn due issuses related to the science|No||https://clinicaltrials.gov/show/NCT00998101||131749|
NCT00998348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0354|Study of Parenting Intervention to Prevent Child Obesity|Healthy Child Weight Through Improved Parent Practices and Environmental Change||University of North Carolina, Chapel Hill|Yes|Completed|July 2009|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|324|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 13, 2013|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00998348||131730|
NCT00998361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE_clin.42_2009_S_sper|Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas|Hematopoietic Stem Cell Transplantation From HLA Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas||St. Orsola Hospital|Yes|Active, not recruiting|June 2009|June 2011|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|1 Month|60 Years|No|||October 2009|October 19, 2009|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00998361||131729|
NCT00998647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|370/08 MUF|Modified Ultrafiltration in Cardiac Surgery|Assessment of the Influence of Modified Ultrafiltration on Primary and Secondary Hemostasis in Cardiac Surgery Patients||Goethe University|No|Completed|June 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Probability Sample|electice cardiac surgery patients undergoing complex procedures: CABG and valve        double-valve aortic surgery Re-Dos|October 2009|April 22, 2010|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998647||131708|
NCT00999310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080238|Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome|Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome||University of Aarhus|No|Completed|November 2009|June 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|146|Samples With DNA|Whole blood, serum, plasma|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Klinefelter syndrome are recruited from endocrine and fertility clinics.        The control groups are recruited by advertising for healthy volunteers at the University        of Aarhus and at the Blood Bank at the Aarhus University Hospital.|September 2012|May 31, 2015|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999310||131657|
NCT00998985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-004|A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Grazoprevir (MK-5172) in Hepatitis C Infected Male Patients||Merck Sharp & Dohme Corp.|No|Completed|February 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|14||Actual|91|||Male|18 Years|65 Years|No|||January 2016|February 3, 2016|October 20, 2009|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT00998985||131682|
NCT00999284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96048|Ophthalmologic Examinations After Infusion of ZK200775|Ophthalmologic Examinations After 4-hour Infusion of ZK200775 in Healthy Elder Male Volunteers||Charite University, Berlin, Germany|Yes|Completed|December 1996|April 1998|Actual|April 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Male|55 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 20, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999284||131659|
NCT01002651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML5282|In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Adults)|In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects: a Randomized, Placebo-controlled, Double-blind, Cross-over Study||Fugeia NV|Yes|Completed|March 2009|October 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|66|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002651||131402|
NCT01002664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-2-TWN-a|Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms|A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects|MCS_LUTS|Health Ever Bio-Tech Co., Ltd.|No|Completed|May 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|272|||Male|40 Years|N/A|No|||March 2015|March 1, 2015|October 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002664||131401|
NCT01003275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35501-D|Metabolic Effects of Paricalcitol|Effects of Oral Paricalcitol on Glucose Tolerance, Immune Cell Function, and Oxidative Stress in Stage 3-4 Chronic Kidney Disease||University of Washington|No|Completed|October 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|October 26, 2009|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01003275||131354|
NCT01003574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECHOS|Evaluation of Cardiovascular Health Outcomes Among Survivors|Evaluation of Cardiovascular Health Outcomes Among Survivors|ECHOS|St. Jude Children's Research Hospital|No|Completed|March 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|509|||Both|25 Years|N/A|No|||November 2013|November 25, 2013|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003574||131331|
NCT01003782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAERCP|Routine Bile Collection for Microbiological Analysis During Cholangiography|Routine Bile Collection for Microbiological Analysis During Cholangiography and Its Impact on Management of Cholangitis: Results of a Prospective Study|ERCP|Hannover Medical School|No|Completed|January 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||Samples Without DNA|Bile samples for microbiological analysis|Both|18 Years|N/A|No|Probability Sample|patients presenting to Endoscopic retrograde cholangiography|October 2009|October 28, 2009|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003782||131315|
NCT01003795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P REWARDS|Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES)|P-REWARDS (Promus - Registry Experience at the Washington Hospital Center, DES)|P-REWARDS|Medstar Research Institute|No|Active, not recruiting|October 2009|October 2013|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with at least one Promus, everolimus-eluting, Stent at the Washington        Hospital Center.|March 2013|March 28, 2013|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01003795||131314|
NCT01004094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thompson_Squires_Quest_II|Squire's Quest! II: Implementation Intentions and Children's Fruit, Juice, and Vegetable (FJV) Consumption|Squire's Quest! II: Implementation Intentions and Children's FJV Consumption|SQ!II|Baylor College of Medicine|Yes|Completed|October 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|800|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004094||131292|
NCT01004107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0508332|Evaluation of Radiesse® Dermal Filler for Hand Rejuvenation|||Merz Pharmaceuticals, LLC|No|Completed|September 2008|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 17, 2014|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004107||131291|
NCT01004367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/462|Health Promotion in Adolescents in Ecuador|ACTIVITAL: Health Promotion Intervention in Ecuadorian Adolescents to Promote Healthy Dietary and Physical Activity Patterns.|ACTIVITAL|University Ghent|No|Recruiting|October 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|1400|||Both|11 Years|13 Years|No|||June 2015|June 3, 2015|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004367||131271|
NCT01001325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT113936|Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?|A Randomized Controlled Trial of the Effect of Seasonal Influenza Vaccination on the Incidence of Infection Due to the 2009 H1N1 Influenza||Mount Sinai Hospital, Canada|Yes|Completed|October 2009|July 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|468|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|October 23, 2009|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT01001325||131503|A major limitation to this study was the date of enrolment for the subjects: only 249 (53%) of the subjects were enrolled by the end of second wave of the pandemic (and a third wave did not occur before the end of the study).
NCT01001338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-203|Allopurinol Combination Study|Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients With an Inadequate Hypouricemic Response With Standard Doses of Allopurinol|RDEA594-203|Ardea Biosciences, Inc.|No|Active, not recruiting|October 2009|April 2015|Anticipated|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|216|||Both|18 Years|80 Years|No|||October 2014|October 6, 2014|October 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001338||131502|
NCT01001871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013476|Treatment of Iron Deficiency Anemia in Malaria Endemic Ghana|Seasonal Impact of Iron Fortification on Malaria Incidence in Ghanaian Children||The Hospital for Sick Children|Yes|Not yet recruiting|November 2009|May 2011|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|3880|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||October 2009|October 26, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01001871||131462|
NCT01005264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2007cardiovascolare|Removable Walker for Neuropathic Ulcers|Effectiveness of Removable Walker Cast Versus Non-removable Fiberglass Off-bearing Cast in the Healing of Diabetic Plantar Foot Ulcer- a Randomized Controlled Trial||IRCCS Multimedica|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|80 Years|No|||October 2009|October 29, 2009|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01005264||131204|
NCT00997594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274|Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation|Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation||Mie University|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|N/A|No|||April 2015|April 6, 2015|October 16, 2009||No||No|October 27, 2010|https://clinicaltrials.gov/show/NCT00997594||131788|Small patient series is one of limitations of this study
NCT00997607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 247|Evaluating an Ebola and a Marburg Vaccine in Uganda|A Phase IB Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults in Kampala, Uganda||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|108|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|October 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00997607||131787|
NCT00997867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Catheter Insertion Distance|Perineural Catheter Insertion Distance for Continuous Peripheral Nerve Blocks|Perineural Catheter Insertion Distance for Continuous Peripheral Nerve Blocks||University of California, San Diego|No|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|October 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997867||131767|
NCT00997893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0052|Research Investigation of Soy and Estrogen|Effects of Estradiol and Soy on Menopausal Symptoms|RISE|University of Illinois at Chicago|Yes|Completed|December 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Female|40 Years|65 Years|No|||July 2015|July 23, 2015|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997893||131765|
NCT00998114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1115737|Early Detection of Diastolic Dysfunction and the Role of Lifestyle Measures in Its Treatment|Early Detection of Diastolic Dysfunction and the Role of Lifestyle Measures in Its Treatment||University of Missouri-Columbia|No|Completed|June 2008|May 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|40 Years|65 Years|No|||June 2011|June 15, 2011|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998114||131748|
NCT00998127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1196|Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients|Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)|PARIS|Icahn School of Medicine at Mount Sinai|Yes|Completed|June 2009|March 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5031|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects in any of the participating US or European sites who have undergone successful        stent implantation in a native coronary artery.|February 2016|February 10, 2016|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00998127||131747|
NCT00998374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS08018|Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge|Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge||Medtronic - MITG|No|Completed|September 2009|April 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|||Both|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients >18 years of age BMI greater than or equal to 35|March 2014|March 19, 2014|October 15, 2009||No||No|January 27, 2014|https://clinicaltrials.gov/show/NCT00998374||131728|
NCT00998387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0803-058-239|Validation of the Korean Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)|Translation and Validation of the Korean Version of Confusion Assessment Method for the Intensive Care Unit||Seoul National University Hospital|Yes|Completed|July 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to medical ICU at Seoul National University Hospital longer than 24        hours|October 2009|October 17, 2009|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00998387||131727|
NCT00999323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.061.07|Endothelial Function and Heart Rate Variability After Stenting|Endothelial Function and Heart Rate Variability After Stenting in Coronary Arteries|FUNKIS|Helse Stavanger HF|No|Completed|July 2007|October 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|serum, plasma and full blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients who have been revascularized by coronary intervention with stent implantation|October 2009|July 27, 2015|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999323||131656|
NCT00999908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BIT01|Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity|Multicenter, Randomized, Blinded, Placebo-controlled, Crossover, Single-dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients||Novartis||Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|40 Years|N/A|No|||February 2016|February 16, 2016|October 21, 2009||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT00999908||131612|
NCT00999622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NABTT-0305 CDR0000363636|Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma|CD4 Count And Risk Of Infection In Patients With Brain Tumors||Sidney Kimmel Comprehensive Cancer Center||Completed|July 2004|||August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|N/A|No|Non-Probability Sample|High grade and low grade|May 2012|May 24, 2012|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999622||131633|
NCT00999297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 28016|Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate|Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate: A Double-blind Randomized Parallel Arm Study|CAPSPAL|Pennington Biomedical Research Center|No|Completed|July 2008|December 2014|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|79|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999297||131658|
NCT01002677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-000981|Behavioral Trial Studying Programmed Training to Improve Advocacy Skills for Individuals With Traumatic Brain Injury|Midwest Advocacy Project: A Community-based Randomized Practical Behavioral Trial of Programmed Advocacy Training for Individuals With Traumatic Brain Injury and Their Significant Others|MAP|Mayo Clinic|No|Completed|August 2007|September 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|234|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01002677||131400|
NCT01004666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-EE-0192-CTIL|Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions|Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions.||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|October 2009|October 2015|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|500|||Female|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A wide COHORT from all over Israel , in which the referring physician and/or the        breast-imaging physician will look for additional imaging modality. Women with equivocal        findings on Mammography, US and/or MRI. Women with discrepancy between clinical        examination and conventional breast imaging. Women with dense breast. Women with genetic        and/or family history high risk for Breast Cancer|January 2013|January 3, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004666||131248|
NCT01004965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-9760|Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720|Multidrug Resistance Studies in Acute Myeloid Leukemia||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|March 1997|||January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2034|Samples With DNA|Bone marrow, blood|Both|18 Years|N/A|No|Non-Probability Sample|Pateitns with acute myeloid leukemia enrolled on CALGB 9621, CALGB 9720, CALGB 19808 or        CALGB 10201|July 2015|July 23, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004965||131226|
NCT01004978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01981|Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion||National Cancer Institute (NCI)|No|Active, not recruiting|October 2009|||February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|March 24, 2016|October 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004978||131225|
NCT01003808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMF001J|Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer|IMF-001 Phase 1 Study With Refractory Esophageal Tumor||ImmunoFrontier, Inc.|Yes|Completed|November 2009|December 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|N/A|No|||April 2013|April 16, 2013|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01003808||131313|
NCT01003834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIRTVCU|Computerized Screening, Brief Intervention, and Referral to Treatment in Primary Care|Computer vs Therapist-Delivered Brief Interventions for Substance Use in Primary Care|SBIRT|Virginia Commonwealth University|Yes|Completed|November 2011|July 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|713|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003834||131312|
NCT01001026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02769|Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Aboriginal Children and Adults||University of British Columbia|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|156|||Both|6 Months|59 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01001026||131526|
NCT01001624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0914-CU|Melanil in the Treatment of Melasma|Efficacy of Melanil in the Treatment of Melasma||Catalysis SL|Yes|Completed|October 2009|November 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||May 2012|May 2, 2012|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001624||131481|
NCT01001897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09004201|Use of Misoprostol for Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol vs. Placebo for Cervical Preparation in IUD Insertion for Nulliparous Women||University of Arizona|Yes|Completed|October 2009|April 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Actual|61|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001897||131460|
NCT01001611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKD-19DM09B|An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus|An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus: A 24-week, Multi Center, Randomized, Double-blind, Parallel-group, Placebo Control, Therapeutic Confirmatory Study||Chong Kun Dang Pharmaceutical|Yes|Completed|October 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|80 Years|No|||July 2013|July 17, 2013|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001611||131482|
NCT01002118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200801761|Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients|Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients||University of Iowa|No|Recruiting|October 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||October 2009|October 26, 2009|October 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002118||131443|
NCT00997620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-4|Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis|A Double Blind, Placebo Controlled Randomized Trial Evaluating the Effects of Fluticasone Nasal Spray in Subjects With Seasonal Allergic Rhinitis and a History of Sleep Disturbance on Cognitive Performance and Daytime Sleepiness||Western Sky Medical Research|No|Completed|March 2010|October 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|41|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|December 15, 2015|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997620||131786|
NCT00997880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0361|Statin and Atheroma Vulnerability Evaluation|Effect of High-Dose and Low-Dose Statin for Coronary Plaque Modification|STABLE|CardioVascular Research Foundation, Korea|Yes|Completed|April 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997880||131766|
NCT00998140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHPR 08/90/a|Optimizing Resuscitation After Cardiac Arrest in the Community|Optimizing Resuscitation After Cardiac Arrest in the Community: Increasing the Probability of Survival While Reducing Costs||Shaare Zedek Medical Center|No|Active, not recruiting|March 2009|March 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1600|||Both|18 Years|N/A|No|Probability Sample|All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the        absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem        district.|May 2015|May 30, 2015|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00998140||131746|
NCT00998660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1649|RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)|RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)|RECHARGE|MedtronicNeuro|No|Completed|July 2009|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|7 Years|N/A|No|||February 2015|February 19, 2015|October 12, 2009||No||No|February 19, 2015|https://clinicaltrials.gov/show/NCT00998660||131707|Potential limitations of the study include the limited sample size to fully characterize recharge use by indication. In addition, inferences to a broader population should also be limited given the relatively short duration of the study.
NCT00998673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGF271-01|Silica Gel Fiber Wound Dressing for Chronic Venous Leg Ulcers|Randomized Standard-of-Care-Controlled Trial of a Silica Gel Fiber (SGF) Wound Dressing in the Treatment of Chronic Venous Leg Ulcers||Bayer|No|Terminated|April 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00998673||131706|
NCT00998686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-PROT402|Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin|A Phase 3, Randomized, Double-Blind, Active-Controlled, Multi-Center Extension Study to Evaluate Safety and Efficacy of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin||Phenomix|No|Terminated|November 2009|November 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|85 Years|No|||August 2010|August 10, 2010|October 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00998686||131705|
NCT00998998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD014122|The Anemia Control Program: Early Intervention|Iron Deficiency Anemia and Infant Behavior: Early Intervention Study II||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|April 1992|July 1996|Actual|July 1996|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|277|||Both|6 Months|12 Months|No|||June 2010|July 19, 2010|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00998998||131681|
NCT01000194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL19273.081.07|Acute Fatty Acid Intervention Study (AFAST)|Acute Fatty Acid Intervention Study|AFAST|Wageningen University|No|Completed|January 2008|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|21|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000194||131590|
NCT00999882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1600C00014|Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients|A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Tor Kinase Inhibitor (AZD8055) in Asian Patients With Advanced Stage Hepatocellular Carcinoma (HCC) and With Mild or Moderate Hepatic Impairment||AstraZeneca|Yes|Completed|October 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00999882||131614|
NCT00999895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NGR-DUM-2009/1|A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients|A Non-interventional, Prospective, Open-label Study for the Evaluation of the Selection and Outcome of the Antipsychotic Treatment Switch in Outpatients With Schizophrenia - ETOS Study|ETOS|AstraZeneca|No|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|574|||Both|18 Years|65 Years|No|Probability Sample|Subjects who have undergone a switch in their antipsychotic treatment and fulfill the        following criteria will participate in the study.|January 2011|January 31, 2011|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999895||131613|
NCT01002976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-09-0065-CTIL|Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma|Correlation Between Level of Free IgE, Total IgE, Specific IgE and FceRI Expression on Effectors Cells and the Respond to Omalizumab in Subjects With Severe Asthma. Single Arm Open Label Study|OM-2009-XO|Carmel Medical Center|No|Withdrawn|December 2009|December 2012|Anticipated|December 2011|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Blood Sputum|Both|18 Years|75 Years|No|Non-Probability Sample|male and female subjects with allergic asthma, aged 18-75 years that, based on standard        practice, have been assigned to omalizumab treatment and fulfill all requirements for such        treatment will be included in this study|January 2012|January 23, 2012|October 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01002976||131377|
NCT01004393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 0911|Methylnaltrexone for Opioid-induced Constipation in Cancer Patients|Phase II Trial of Subcutaneous Methylnaltrexone in the Treatment of Severe Opioid-induced Constipation in Cancer Patients||University of Vermont|Yes|Completed|October 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|October 28, 2009||No||No|June 14, 2015|https://clinicaltrials.gov/show/NCT01004393||131269|
NCT01004406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-010-09S|Intensive Lipid-Lowering Therapy for Patients With Acute Coronary Syndrome|Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER)|PREMIER|VA Office of Research and Development|Yes|Completed|September 2011|March 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|31|||Both|31 Years|N/A|No|||January 2015|January 14, 2015|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01004406||131268|
NCT01004692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL23988.048.08|The Effect of Occlusal Splints on Respiratory Variables in Obstructive Sleep Apnea (OSA) Patients|The Effect of Occlusal Splints on Sleep and Respiratory Variables of OSA Patients||Academic Centre for Dentistry in Amsterdam|No|Enrolling by invitation|December 2008|June 2010|Anticipated|January 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2009|October 29, 2009|October 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004692||131247|
NCT01004705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-080647-01|A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol|Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Study of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin, and Ramipril in Subjects With Elevated LDL Cholesterol||Ferrer Internacional S.A.||Terminated|September 2009|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|October 23, 2009|Yes|Yes||No|June 1, 2012|https://clinicaltrials.gov/show/NCT01004705||131246|Early termination leading to small numbers of subjects analyzed.
NCT01005277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTR02B1|Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|Genetic Polymorphisms in ALL Samples Submitted to Gene Array Analysis||Children's Oncology Group|No|Active, not recruiting|April 2002|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|120 Years|No|Non-Probability Sample|Acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML)|May 2015|September 30, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005277||131203|
NCT01004991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907010513|Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma|Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma||Weill Medical College of Cornell University|No|Recruiting|January 2010|||January 2013|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|October 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004991||131224|
NCT01005290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-080646-01|A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure|Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and Ramipril (Cardiovascular Fixed Dose Combination Pill) on Blood Pressure||Ferrer Internacional S.A.|No|Terminated|October 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|October 22, 2009|Yes|Yes||No|March 30, 2012|https://clinicaltrials.gov/show/NCT01005290||131202|Early termination leading to small numbers of subjects analyzed
NCT01001039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37055-E/A|Validation of the Facial and Cephalic Pain Inventory|Validation of the FAcial and CEphalic PAin INventory (FACE PAIN)|FACE PAIN|University of Washington|No|Completed|October 2009|June 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|68|||Both|18 Years|N/A|No|Probability Sample|Patients presenting to the Rhinology Clinic with a complaint of facial pain and evidence        of chronic sinusitis. Control subjects will be patients presenting to the Otology Clinic        with no evidence of sinusitis.|June 2012|June 27, 2012|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01001039||131525|
NCT00996242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYSINE1|An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia|An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia||Göteborg University|No|Completed|September 2007|March 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|10|||Both|23 Years|56 Years|No|||October 2009|October 15, 2009|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996242||131892|
NCT00996255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDKC-887-001|Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors|A Phase I Dose-Escalation Study of PHA-793887 Administered as a 1-hour IV Infusion on Days 1, 8 and 15 in a 4-Week Cycle in Patients With Advanced/Metastatic Solid Tumors||Nerviano Medical Sciences|No|Terminated|November 2006|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|October 14, 2009||Yes||No||https://clinicaltrials.gov/show/NCT00996255||131891|
NCT01002157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC09-2-075|The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification|The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification|VitaK-CAC|Maastricht University Medical Center|Yes|Recruiting|October 2011|||September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||October 2011|October 19, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002157||131440|
NCT01001884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902029R|The Efficacy of the Caregiver Psychoeducational Consultation Program|The Efficacy of the Caregiver Psychoeducational Consultation Program in Spouse Caregivers of Resectable Colorectal Cancer||National Taiwan University Hospital|No|Recruiting|February 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|65 Years|No|||June 2010|August 12, 2010|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01001884||131461|
NCT00998426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-337|Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients|Evaluation of Blood Glucose Levels for Hepatitis B Immune Globulin (HepaGam B) Administration||Georgetown University|No|Completed|October 2009|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|5|||Both|18 Years|N/A|No|||April 2015|August 26, 2015|October 7, 2009||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT00998426||131724|
NCT00998699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052076|Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well-controlled Type 1 Diabetes||XOMA (US) LLC|Yes|Completed|February 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|No|||March 2014|March 3, 2014|October 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00998699||131704|
NCT00999011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR10781-01A1|Dose of Early Therapeutic Mobility: Does Type or Frequency Matter?|Dose of Early Therapeutic Mobility: Does Type or Frequency Matter?|ETM|Case Western Reserve University|Yes|Completed|May 2009|March 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|54|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999011||131680|
NCT00999336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-016|A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment|Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function.||Portola Pharmaceuticals|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999336||131655|
NCT00999349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187050|Therapeutic Effects of Silymarin in Patients With B-thalassemia Major|Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial||Isfahan University of Medical Sciences||Active, not recruiting|March 2009|||December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|12 Years|N/A|No|||October 2009|October 20, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999349||131654|
NCT00999635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q2103/150|A Comparison of Insoles Used to Prevent Neuropathic Diabetic Foot Ulceration|A Comparison of Functional and Prefabricated Insoles Used for the Preventative Management of Neuropathic Diabetic Foot Ulceration: a Single Blind Randomised Control Trial||University of Plymouth|No|Completed|March 2006|September 2008|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|119|||Both|N/A|N/A|No|||October 2009|October 23, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999635||131632|
NCT00999921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSVP-107/08|Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer|A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status.||Medical College and Hospital Kolkata|Yes|Completed|January 2008|January 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|256|||Female|16 Years|N/A|No|||April 2015|April 28, 2015|October 21, 2009|Yes|Yes||No|November 15, 2010|https://clinicaltrials.gov/show/NCT00999921||131611|
NCT01000441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4507|Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis|Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis|ROC|University Hospital, Strasbourg, France|No|Recruiting|December 2009|May 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2010|June 25, 2010|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000441||131571|
NCT01000454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WaveRx CA-0071|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2009|||||N/A|N/A|N/A||||||||||||||October 22, 2009|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000454||131570|
NCT01000467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-KOB-0801i|Pharmacokinetics Study for Probucol|A Randomized, Open-label, Single-center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Probucol by Multiple Administration in Healthy Male Subjects||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|February 2009|September 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|30|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01000467||131569|
NCT01004380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-003-005|Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer|A Phase I Safety Study of Farletuzumab (MORAb-003), Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Subjects With Platinum-sensitive Ovarian Cancer||Morphotek|No|Completed|November 2009|October 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Female|18 Years|N/A|No|||July 2014|July 15, 2014|October 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01004380||131270|
NCT01004133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC 07-4789|The Healthy Elderly Longevity Cohort|The Healthy Elderly Longevity Cohort|Wellderly|Scripps Translational Science Institute|No|Recruiting|August 2007|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|N/A||1|Anticipated|5000|Samples With DNA|A single blood specimen or saliva specimen is collected from each subject. If blood is      collected, approximately thirty eight milliliters of blood will be dispensed as follows:      3 x 8.5 mls DNA Tubes      1 x 2.5 mls RNA tube      1 x 10 mls EBV tube (EDTA) for immortalized cell lines|Both|80 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General outpatient and community population.|October 2015|October 14, 2015|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01004133||131289|
NCT01004718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 21408|Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)|A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|May 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01004718||131245|
NCT01004731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X010524006|Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer|Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer||University of Alabama at Birmingham|Yes|Completed|June 2001|January 2006|Actual|January 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2010|June 25, 2010|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004731||131244|
NCT01005017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911111|Percutaneous Lesioning Splanchnic Nerves in Patients With Chronic Pancreatitis|Percutaneous Radiofrequent Lesioning of the Splanchnic Nerves in Patients With Chronic Pancreatitis|PRFLSN|Maastricht University Medical Center|No|Recruiting|February 2011|December 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005017||131222|
NCT01005004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N01-PMD|Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects|Phase I Study of the Safety and Preliminary Efficacy of Intracerebral Transplantation of HuCNS-SC® Cells for Connatal Pelizaeus-Merzbacher Disease (PMD)||StemCells, Inc.|Yes|Completed|November 2009|December 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Male|6 Months|5 Years|No|||January 2015|January 13, 2015|October 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01005004||131223|
NCT01001351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-201-102|A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease|PRT-201-102|Proteon Therapeutics|Yes|Completed|September 2009|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|October 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001351||131501|
NCT00991731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REE1-09-063|A Program to Increase Physical Activity Among Blacks|A Faith-Based Intervention to Increase Physical Activity Among Blacks||Gramercy Research Group|No|Completed|July 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|496|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||August 2015|August 10, 2015|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991731||132237|
NCT00991939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|675|Initial Treatment of Patients With Immune Thrombocytopenic Purpura|Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study|ITP^2|New England Research Institutes|Yes|Terminated|January 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|15 Years|N/A|No|||January 2014|January 2, 2014|October 7, 2009|Yes|Yes|The study was closed due to accrual futility there were only a total of 8 subjects enrolled.|No|January 2, 2014|https://clinicaltrials.gov/show/NCT00991939||132221|
NCT00992485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTG-ASC-201|Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula|A Phase I Dose Escalation Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate Safety and Efficacy||Anterogen Co., Ltd.||Completed|November 2008|March 2010|Actual|September 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2010|May 7, 2010|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00992485||132179|
NCT00998738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08CC|Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer|The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study||Mayo Clinic|Yes|Terminated|November 2009|January 2013|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|N/A|No|||November 2015|January 7, 2016|October 19, 2009|Yes|Yes|lack of accrual|No|May 16, 2013|https://clinicaltrials.gov/show/NCT00998738||131701|
NCT00998400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.1263|Treatment of Depression in Acute Coronary Syndrome (ACS) Patients|Cognitive-behavioral Treatment of Depression in Patients With Acute Coronary Syndrome|TREATED-ACS|University of Bologna|No|Active, not recruiting|September 2010|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||December 2015|December 1, 2015|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998400||131726|
NCT00998413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-088|Weight-reduction Intervention in Asthmatic Children With Overweight/Obesity|Secondary Prevention of Asthma in Overweight/Obese Children by a Combined Dietary-behavioural-physical Activity Intervention||Maastricht University Medical Center|No|Completed|January 2010|September 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|87|||Both|6 Years|16 Years|No|||September 2013|September 30, 2013|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998413||131725|
NCT00999024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT - 090709|Reflectometric Measurement of Retinal Oxygen Saturation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Grade IV and Healthy Subjects|Reflectometric Measurement of Retinal Oxygen Saturation in Patients With COPD Grade IV and Healthy Subjects||Medical University of Vienna|Yes|Completed|November 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|20 healthy subjects, 20 patients with grade IV COPD|October 2009|February 1, 2013|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999024||131679|
NCT00999362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC|Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?|Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?||University of Aarhus|Yes|Completed|October 2007|October 2009|Actual|March 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Kidney transplant recipients from Department of Nephrology, Aarhus University Hospital,        Skejby, Denmark|October 2009|October 20, 2009|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999362||131653|
NCT00999648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 138306|Efficacy of Myofascial Trigger Point Pressure Release on Tinnitus Patients|Efficacy of Myofascial Trigger Point Pressure Release on Tinnitus Patients With Both Tinnitus and Myofascial Pain: a Double-blind Placebo Controlled Randomized Clinical Trial.|MTP|University of Sao Paulo General Hospital|Yes|Completed|March 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|N/A|N/A|No|||October 2009|October 21, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999648||131631|
NCT00999934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eyemovements01|Neural Mechanisms Engaged in Control of Eye Movements|||Meir Medical Center|No|Recruiting|July 2009|February 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population: A grand total of about 250 individuals (normal subjects and patients) will be        recruited for the study. Patients will be recruited from the in- and out-patients of the        Neurology and Neuro-ophthalmology services of Meir Medical Center. Healthy normal subjects        will be recruited from faculty and staff of Meir Medical Center.|June 2014|May 19, 2015|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999934||131610|
NCT00999947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051067|Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy|Genetic Study of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy|DVDA|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2006|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|351|Samples With DNA|blood sample|Both|10 Years|N/A|No|Non-Probability Sample|Unrelated patients with ARVD/C. A clinical diagnosis of ARVD/C is made according to the        established European Society of Cardiology / International Society and Federation of        Cardiology Task Force major and minor criteria (Task Force 1994)        + All available relatives will be proposed for enrollement in the study|October 2012|November 21, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00999947||131609|
NCT01000207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110_08|Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects|A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric Subjects||Novartis|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|123|||Both|6 Months|19 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000207||131589|
NCT01004146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0622|Pre-op Use of Incentive Spirometry in Obese Patients|A Study on the Preoperative Use of Incentive Spirometry in Morbidly Obese Patients Undergoing General Anesthesia|IS|The University of Texas Health Science Center, Houston|Yes|Completed|March 2009|September 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|March 30, 2009||No||No|June 17, 2013|https://clinicaltrials.gov/show/NCT01004146||131288|Our analysis was limited to measuring lung volumes up until postoperative day 1.Extending this study a few days postoperatively likely would allow us to achieve a better understanding of the course of respiratory function recovery.
NCT00995397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERP 976-08|Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Insect Bite Related Symptoms|Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Lotion) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Insect Bite Related-symptoms||Mantecorp Industria Quimica e Farmaceutica Ltd.|Yes|Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|2 Years|60 Years|No|||October 2009|October 20, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995397||131956|
NCT00995410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA32540-303|Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers|A 12-Month, Phase 3, Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers||POZEN|Yes|Completed|October 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|380|||Both|55 Years|N/A|No|||January 2016|January 20, 2016|October 13, 2009|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT00995410||131955|
NCT01005303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGHT000395|Micronutrient Supplementation in Patients With Heart Failure|A Trial of Micronutrient Supplementation in Patients With Heart Failure|MINT-HF|Belfast Health and Social Care Trust|Yes|Active, not recruiting|February 2009|July 2015|Anticipated|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|80 Years|No|||January 2015|January 27, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005303||131201|
NCT00995904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0020-CL-P201|Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma|A Randomized, Open-Label, 3-Dose, 3-Period, Crossover Phase 2 Study Investigating the Tolerability and Pharmacokinetics of MAP0010 in Children 4 Through 11 Years Old With a History of Mild-To-Moderate Stable Asthma||Allergan|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|25|||Both|4 Years|11 Years|No|||December 2013|December 9, 2013|October 6, 2009|Yes|Yes||No|April 17, 2013|https://clinicaltrials.gov/show/NCT00995904||131917|
NCT00991744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHOALL2008-DepoCyte|Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)|Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol||Nordic Society for Pediatric Hematology and Oncology|Yes|Suspended|January 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Year|18 Years|No|||October 2012|October 6, 2012|October 7, 2009||No|Sterility problems in DepoCyte production|No||https://clinicaltrials.gov/show/NCT00991744||132236|
NCT00991952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03825|Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery|A Multicenter Random Assignment Phase II Study of Irinotecan and Alvocidib (Flavopiridol) Versus Irinotecan Alone for Patients With p53 Wild Type Gastric Adenocarcinoma||National Cancer Institute (NCI)||Completed|September 2009|April 2014|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||December 2013|May 9, 2014|October 7, 2009|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT00991952||132220|
NCT00992199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP chemo-AGC|Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer|Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer|IPchemo-AGC|Fudan University|Yes|Recruiting|August 2009|December 2011|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|79|||Both|18 Years|70 Years|No|||September 2010|September 7, 2010|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992199||132201|
NCT00992212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_04|Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10|A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of an Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above||Novartis|No|Completed|August 2009|November 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|418|||Both|18 Months|N/A|Accepts Healthy Volunteers|||January 2012|January 4, 2012|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992212||132200|
NCT00992498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2008|Rehabilitation in Chronic Obstructive Pulmonary Disease Outpatients|Effectiveness of Rehabilitation in COPD Outpatients With Comorbidities||Villa Pineta Hospital|No|Completed|January 2008|December 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|316|||Both|45 Years|85 Years|No|Non-Probability Sample|COPD outpatients eligible for pulmonary rehabilitation|December 2012|December 20, 2012|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992498||132178|
NCT00992511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113809|Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes|Immunological Non-inferiority Between Two Process-manufactured Influenza Vaccines in Adults Aged 18 to 60 Years||GlaxoSmithKline||Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|300|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992511||132177|
NCT00992784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113094|Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People|Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects||GlaxoSmithKline||Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|370|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2012|July 19, 2012|October 1, 2009|Yes|Yes||No|March 8, 2012|https://clinicaltrials.gov/show/NCT00992784||132156|
NCT01002794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSDU2009|Surgical or Exercise Therapy on Patients With Degenerative Meniscus Tears|The Effect of Arthroscopic Partial Meniscectomy or Exercise Therapy as Treatment of Degenerative Meniscus Tears in Middle-aged Patients. A Randomized, Controlled Trial||Oslo University Hospital||Active, not recruiting|November 2009|December 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|35 Years|60 Years|No|||May 2014|May 30, 2014|October 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01002794||131391|
NCT00998712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001255|Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction|Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction||Brigham and Women's Hospital|No|Recruiting|August 2009|January 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|88|Samples With DNA|blood and urine samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Black and white women currently in the thrid trimester of a pregnancy complicated or        uncomplicated by gestational diabetes.|August 2013|August 28, 2013|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00998712||131703|
NCT00998725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1500|Combined Oral Contraceptive (COC) Antiretroviral (ARV) Pharmacokinetics (PK) and Pharmacodynamics (PD) in Malawi|A Pilot Study of Pharmacokinetic and Pharmacodynamic Activity of LoFemenal|COCARVPK|University of North Carolina, Chapel Hill|No|Completed|November 2009|January 2011|Actual|January 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|9|||Female|21 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|9 women with known HIV status who have regular monthly menses.|June 2011|June 28, 2011|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00998725||131702|
NCT01003340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-10-360|A Community Health Worker Home Intervention to Improve Pediatric Asthma Outcomes|A Randomized Controlled Trial of a Community Health Worker Home-Based Asthma Intervention||Montefiore Medical Center|No|Recruiting|July 2009|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Both|2 Years|9 Years|No|||December 2012|December 12, 2012|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003340||131349|
NCT00999375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909234|Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)|Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)||National Institutes of Health Clinical Center (CC)||Completed|September 2009|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|321|||Both|8 Years|17 Years|No|||October 2015|November 3, 2015|October 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00999375||131652|
NCT00999388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910001|Shanghai Parkinson's Study|Shanghai Parkinson's Study||National Institutes of Health Clinical Center (CC)||Completed|October 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1500|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999388||131651|
NCT01003899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.72|A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]|A Phase II Trial of BIBW 2992 as a Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type EGFR||Boehringer Ingelheim||Completed|October 2009|||November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|80 Years|No|||August 2013|December 5, 2013|October 28, 2009||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01003899||131307|
NCT01004172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-224|Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases|Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2009|February 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|October 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01004172||131286|
NCT01000220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8735|Evaluation of Omeprazole Effect on Glaucoma|Evaluation of Omeprazole Effect on Glaucoma||hahid Beheshti University of Medical Sciences|No|Recruiting||||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|18 Years|70 Years|No|||October 2009|May 3, 2010|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01000220||131588|
NCT01004419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0009|Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer|Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer||University of Wisconsin, Madison|Yes|Withdrawn|November 2009|May 2011|Anticipated|November 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|October 28, 2009|Yes|Yes|Support for investigational products has been withdrawn.|No||https://clinicaltrials.gov/show/NCT01004419||131267|
NCT00994851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENCA_L_04746|Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.|National Study, Phase III, Parallel, Double Blind, Placebo Comparative and Randomized to Evaluate the Therapeutic Efficacy and Tolerability of the Combination Naturetti® (Cassia Fistula + Senna Alexandrina Miller) in the Chronic Functional Constipation.||Sanofi||Completed|September 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|59 Years|No|||March 2013|March 28, 2013|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994851||131997|
NCT00995072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB-09-0011|Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function|Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function||East Coast Institute for Research|Yes|Recruiting|October 2009|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|40 Years|N/A|No|||August 2012|August 13, 2012|October 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995072||131980|
NCT00995423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0497|Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent|Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease|PIPA|CardioVascular Research Foundation, Korea|Yes|Completed|April 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||August 2010|August 17, 2010|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995423||131954|
NCT00995696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11062007|Treatment Follow-up Study|Pharmaceutical Safety Tracking (PhaST): Managing Medications for Patient Safety|PhaST|Nationwide Children's Hospital|No|Completed|September 2008|May 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|800|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995696||131933|
NCT00995709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457C2303|Phase III Study in Refractory Behcet's Disease|A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy|SHIELD|Novartis||Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|118|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|October 13, 2009|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT00995709||131932|
NCT00995670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARA-023-09S|Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins|Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins||VA Office of Research and Development|No|Completed|March 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|59|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|October 13, 2009|No|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT00995670||131935|Some substudies were not completed because we had difficulty creating ischemia/reperfusion (I/R) injury or a consistent FBF response, which was critical to the purpose of the study to investigate the role of glucose and statins in I/R injury.
NCT00995683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-Lac-TBI|Preventive Sodium Lactate and Traumatic Brain Injury|Effect of Preventive Sodium Lactate Infusion on Intracranial Hypertension in Severe Trauma Tic Brain Injury||Institut d'Anesthesiologie des Alpes Maritimes|Yes|Completed|June 2009|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|75 Years|No|||May 2011|July 9, 2011|October 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00995683||131934|
NCT00996268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113412|An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.|An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836||GlaxoSmithKline|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 22, 2011|October 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996268||131890|
NCT00992563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-023|WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination|A Dose-Escalation Study of AL-39324 Suspension Versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration||Alcon Research|No|Completed|June 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|35|||Both|50 Years|N/A|No|||July 2014|July 16, 2014|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992563||132173|
NCT00991965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-03|Localized Alveolar Ridge Augmentation With Dental Implant|An Open Label, Non-randomized, Single-arm, Multi-center Study to Assess Localized Alveolar Ridge Augmentation Utilizing INFUSE® Bone Graft Concurrent With Dental Implant Placement|RidgeDI|Medtronic Spinal and Biologics|No|Terminated|October 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Patients needing bone augmentation of the alveolar ridge prior to placement of dental        implants|October 2011|February 15, 2012|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991965||132219|
NCT00992225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12265|A Study of LY573636 in Patients With Metastatic Breast Cancer|Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer||Eli Lilly and Company|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||July 2011|August 9, 2011|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992225||132199|
NCT00992238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03155|A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions|A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions||Paddock Laboratories, Inc.||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2009|September 24, 2013|October 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992238||132198|
NCT00992537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1977|Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics|A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties Between NN5401 and NN1250 and Between NN5401 and Insulin Aspart in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992537||132175|
NCT00992550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05144|Comparison of Hookah and Cigarette Smoking|Comparison of Hookah and Cigarette Smoking|6114|University of California, San Francisco|No|Completed|October 2009|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00992550||132174|
NCT01002807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-065|Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State|Bioavailability Study of Two Prototype Fixed Dose Combination (FDC) Formulations of 10 mg Dapagliflozin and 1000 mg Metformin Extended Release (XR) Tablet Relative to Dapagliflozin 10 mg Tablet and Glucophage® XR 2 X 500 mg Tablets Coadministered to Healthy Subjects in a Fasted State||AstraZeneca|No|Completed|November 2009|January 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|October 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01002807||131390|
NCT00999037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DK080984-01A1|FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease|||University of California, Los Angeles|Yes|Completed|October 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20|||Both|6 Years|21 Years|No|||December 2014|February 2, 2016|October 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00999037||131678|
NCT00999050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906010450|Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus With Body Mass Index (BMI) < 35|Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus: a Pilot Prospective Study in Overweight and Mildly Obese Subjects||Weill Medical College of Cornell University|Yes|Recruiting|October 2009|November 2013|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||January 2011|January 3, 2011|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00999050||131677|
NCT01003353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1241|Strength Training for Chronic Stroke Patients|Maximal Strength Training for Chronic Phase Stroke Patients||Norwegian University of Science and Technology|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|67 Years|No|||June 2012|June 22, 2012|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003353||131348|
NCT01003366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_CVC bevel|Effect of the Bevel Direction of Puncture Needle on Success Rate and Complications During Central Venous Catheterization|||Seoul National University Hospital|No|Completed|March 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|338|||Both|19 Years|70 Years|No|||March 2011|March 18, 2011|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003366||131347|
NCT01003626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0120|Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients|A Pilot Study Assessing the Feasibility and Safety of Measuring Interstitial Fluid Pressure (IFP) in Patients With Advanced Malignant Melanoma Before Starting Systemic Treatment||M.D. Anderson Cancer Center|No|Withdrawn|March 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|October 28, 2009|No|Yes|Slow accrual.|No||https://clinicaltrials.gov/show/NCT01003626||131327|
NCT01003912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010188|Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases|Treatment of Early Infantile-Onset Lysosomal Storage Diseases With Fetal Umbilical Cord Blood (UCB) Transplantation|IUHST-001|Duke University|Yes|Active, not recruiting|October 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|October 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01003912||131306|
NCT01004185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008085|Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis|A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis|CAMPIII|Warner Chilcott|No|Terminated|October 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|5 Years|17 Years|No|||April 2012|April 24, 2012|October 27, 2009|Yes|Yes|Pediatric enrollment very slow.|No|March 27, 2012|https://clinicaltrials.gov/show/NCT01004185||131285|
NCT01004445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIK-04-02|A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)|A Double-Blind, Placebo-controlled Parallel Group, Phase II Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Ventilated Patients With Nosocomial Pneumonia Due to Gram Negative Organisms||Bayer|Yes|Completed|May 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01004445||131265|
NCT01004432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016663|Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)|A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)||Janssen Biotech, Inc.|Yes|Completed|December 2009|October 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|433|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|October 29, 2009|Yes|Yes||No|March 13, 2014|https://clinicaltrials.gov/show/NCT01004432||131266|Since participants assigned to the double blind groups were non-responders to at least 2 anti-Tumor Necrosis Factors (TNF), thus comprising a very difficult group to treat.
NCT00994864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPITA 001|Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer|Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial|PePiTA|Jules Bordet Institute|No|Recruiting|November 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|205|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|October 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994864||131996|
NCT00995085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0012-09-GEH|Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects|Efficacy Study of Metadoxine SR Formulation in ADHD Subjects||Alcobra Ltd.|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|45 Years|No|||June 2011|April 27, 2014|October 13, 2009||No||No|December 27, 2010|https://clinicaltrials.gov/show/NCT00995085||131979|
NCT00995098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAMS-080384|Early Enteral Nutrition for Severe Acute Pancreatitis|The Impact of Early Enteral Nutrition on the Clinical Outcomes of Severe Acute Pancreatitis Patients: A Randomized Control Trial||Sichuan Academy of Medical Sciences|Yes|Completed|October 2009|October 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|No|||November 2010|November 29, 2010|October 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00995098||131978|
NCT00995917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A112809|A Pilot Study of Acupoint Injection for Primary Dysmenorrhea|A Randomized, Crossover, Pilot Trial of the Feasibility and Safety of Acupoint Injection of Vitamin K for Treatment of Primary Dysmenorrhea|DAT|University of California, San Francisco|No|Completed|October 2009|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995917||131916|
NCT00995930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885I2206|Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients|A Multi-center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT||Novartis|Yes|Completed|December 2009|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|74 Years|No|||June 2015|June 1, 2015|October 15, 2009|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT00995930||131915|
NCT00995956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/716a|Albumin, Total and Free Fraction of Mycophenolic Acid, and Measurement of IMPDH Activity in Liver Transplants.|Quantitative Measurements of Albumin, Total and Free Fraction of Mycophenolic Acid, and Measurement of IMPDH Activity in Liver Transplants.|Albumix|Oslo University Hospital|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Blood for drug analyzes|Both|18 Years|N/A|No|Non-Probability Sample|Liver transplant pations from Rikshospitalet HF|September 2012|September 13, 2012|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00995956||131914|
NCT00992875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008A057212|Does Mindfulness Training Change the Processing of Social Threat?|Does Mindfulness Training Change the Processing of Social Threat?||Massachusetts General Hospital|Yes|Completed|January 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Both|22 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00992875||132149|
NCT00992849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0918C|Bevacizumab for the Treatment of Corneal Neovascularization|Topical/Subconjunctival Injection of Bevacizumab(Avastin) for the Treatment of Corneal Neovascularization||Chang Gung Memorial Hospital|Yes|Active, not recruiting|May 2009|April 2012|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|N/A|No|||October 2009|October 13, 2009|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992849||132151|
NCT00992251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEUPR_L_04620|Eligard Observational Registry for Patients With Prostate Cancer|A Prospective, Single Product, Observational Registry Involving Patients Presenting With Locally Advanced or Metastatic Prostate Cancer Receiving Eligard as Androgen Deprivation Treatment.||CMX Research|Yes|Active, not recruiting|September 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|330|||Male|18 Years|N/A|No|Non-Probability Sample|Patients > 18 years of age. Histologically confirmed diagnosis of locally Advanced or        Metastatic Prostate Cancer Patient starting an androgen deprivation therapy with Eligard        at 3 or 4 month treatment frequency per standard of care.|May 2011|May 30, 2011|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992251||132197|
NCT00992524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORALTIMI|Oral Titrated Misoprostol for Induction of Labour|Oral Misoprostol Titrated Solution Versus Vaginal Misoprostol for Induction of Labour: Randomized Controlled Trial|OTISMISO|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|November 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2009|June 22, 2011|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992524||132176|
NCT00992823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708/2006|Iron Supplementation to Reduce Preschoolers Anemia: Comparison Between Intermittent and Cyclic Procedure|Iron Supplementation to Reduce Preschoolers Anemia: Comparison Between Intermittent and Cyclic Procedure||Sao Jose do Rio Preto University|No|Completed|March 2006|July 2008|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|24 Months|59 Months|Accepts Healthy Volunteers|||October 2009|October 14, 2009|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992823||132153|
NCT01002820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0602|A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601|A Treatment Protocol for Ganaxolone as add-on Therapy in Adult Patients With Uncontrolled Partial-onset Seizures Deriving Benefit From Protocol 1042-0601|0602|Marinus Pharmaceuticals|No|Completed|October 2009|August 2013|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|55 Years|No|||October 2015|October 1, 2015|October 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002820||131389|
NCT01003067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364/07|Intraperitoneal Mesh-Implementation After Laparotomy|Intraperitoneal Mesh-Implementation After Laparotomy to Reduce Risk of Incisional Hernia: a Prospective Randomized Controlled Trial||Kantonsspital Liestal|No|Active, not recruiting|March 2008|December 2018|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003067||131370|
NCT01003080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-05-145|Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial|Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial||Montefiore Medical Center||Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|111|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 4, 2011|October 27, 2009||No||No|November 19, 2010|https://clinicaltrials.gov/show/NCT01003080||131369|Operator dependent modifications may affect the standardization of the procedure; Surgeon is not blinded to the treatment used on each patient.
NCT01003379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5619-238-CRD-001|TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia||Targacept Inc.|No|Completed|October 2009|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|September 3, 2013|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003379||131346|
NCT01003639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORDIC01|Idiopathic Intracranial Hypertension Treatment Trial|A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss|IIHTT|St. Luke's-Roosevelt Hospital Center|Yes|Completed|January 2010|January 2014|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|March 3, 2015|October 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003639||131326|
NCT01003925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7 U18 HS016093 Leveraged|Conjoint Analysis of Treatment Preferences for Osteoarthritis|Conjoint Analysis of Patient Preferences in Medical Management of Osteoarthritis of the Knee||Baylor College of Medicine|No|Completed|August 2007|December 2010|Actual|August 2010|Actual|Phase 2|Observational|N/A||2|Actual|182|||Both|65 Years|95 Years|No|Non-Probability Sample|People aged 65-95 with knee pain|August 2015|August 20, 2015|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003925||131305|
NCT01003938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 08-613|Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer|Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation||New York University School of Medicine|Yes|Terminated|August 2009|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||December 2013|December 2, 2013|October 27, 2009|Yes|Yes|due to administrative issue and financial sponsor decision to suspend ovarian cancer studies|No|September 6, 2013|https://clinicaltrials.gov/show/NCT01003938||131304|
NCT01004458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCC2000|Cognitive Behavioral Therapy Trial in Fibromyalgia|Randomized Clinical Trial of Cognitive Behavioral Therapy in Women With the Fibromyalgia Disorder|(FIBCOG)|Uppsala University|No|Completed|January 2001|December 2008|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|65 Years|No|||October 2009|October 29, 2009|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004458||131264|
NCT01004471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3570581|An Exploratory Study of a Nasal Dilator Strip|An Exploratory Study of a Nasal Dilator Strip||GlaxoSmithKline|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|48|||Both|18 Years|N/A|No|||November 2011|October 11, 2012|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01004471||131263|
NCT01004757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOGILoFaReha|Effects of Low Versus High Carbohydrate Diet During Rehabilitation on Cardiovascular Function and Metabolism in Type 2 Diabetes|Improvement of Myocardial Function and Metabolic Syndrome in Type 2 Diabetes Patients by a Low Glycemic and Insulinemic Diet (LOGI®) Compared to the Traditional Low Fat Diet - a Prospective Parallel Group/Cross Over Study||Munich Municipal Hospital|Yes|Active, not recruiting|February 2008|February 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|41|||Both|30 Years|70 Years|No|||October 2009|October 29, 2009|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01004757||131242|
NCT00995124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEY/NL/003|Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application|A Randomised, Assessor Blind, Parallel Group, Comparative Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application||Altman Biomedical Consulting Pty. Ltd.|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|N/A|12 Years|Accepts Healthy Volunteers|||July 2010|July 26, 2010|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00995124||131977|
NCT00995137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCD19|Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia|Pilot Study of Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia||St. Jude Children's Research Hospital|Yes|Completed|October 2009|May 2014|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|18 Years|No|||February 2015|February 5, 2015|October 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00995137||131976|
NCT00995462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-025|Prevention of Weight Gain in University Students|Prevention of Weight Gain in University Students|PGP2|Université de Sherbrooke|No|Completed|September 2006|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|319|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995462||131951|
NCT00995436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q2401/50|Chesterfield Micro-implant Study Involving Three Types of Anchorage Methods in Orthodontics|Efficiency and Effectiveness of Three Methods of Anchorage Reinforcement in Orthodontics|PJSPhD|Chesterfield and North Derbyshire Royal Hospital|Yes|Enrolling by invitation|July 2008|July 2012|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||October 2009|October 19, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995436||131953|
NCT00995449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB003-02|Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis|A Phase 2, Randomized, Placebo‑Controlled, Dose‑Ranging Study to Evaluate the Safety and Efficacy of the Anti-GM-CSF Monoclonal Antibody KB003 in Subjects With Active Rheumatoid Arthritis and Inadequate Prior Treatment Outcome From Biologic Therapy||KaloBios Pharmaceuticals|Yes|Terminated|January 2010|February 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|9|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|October 5, 2009|Yes|Yes|Program refocus|No|May 7, 2012|https://clinicaltrials.gov/show/NCT00995449||131952|The study was terminated upon completion of safety run-in due to program refocus.
NCT00995722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-R-03710-01|Efficacy of Prednisone In the Treatment of Ocular Myasthenia|Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study|EPITOME'|University of Miami|Yes|Terminated|December 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|October 14, 2009|Yes|Yes|Slow recruitment rate|No|September 28, 2015|https://clinicaltrials.gov/show/NCT00995722||131931|Early termination leading to small numbers of subjects analyzed
NCT00995735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0209.0.314.000-08|IMTN Study- International Prospective Multicenter Trial on Clinical NOTES|IMTN Study- International Prospective Multicenter Trial on Clinical NOTES|IMTN|IMTN NOTES Research Group|Yes|Recruiting|June 2007|December 2009|Anticipated|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients submitted to Natural Orifice Surgery with local IRB aproval for human trials.|October 2009|October 14, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995735||131930|
NCT00995982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100004|VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years|VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years||National Institutes of Health Clinical Center (CC)||Completed|October 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||September 2010|September 4, 2010|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00995982||131912|
NCT00993798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-002-IM|An International Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery|An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery||Durect|No|Completed|April 2009|November 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|107|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|October 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993798||132078|
NCT00993811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902010241|The Shang Ring: A Novel Male Circumcision Device for HIV Prevention|The Shang Ring: A Novel Male Circumcision Device for HIV Prevention|ShangRing|Weill Medical College of Cornell University|No|Completed|October 2009|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Male|18 Years|54 Years|Accepts Healthy Volunteers|||October 2009|December 3, 2010|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993811||132077|
NCT00993161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00600-57|Upper Limb Evaluation in Non Ambulatory Patients With Neuromuscular Disorder|Development and Evaluation of a Clinical Test in Order Quantify Muscular Function in Upper Limb of Non Ambulatory Patients With Neuromuscular Disorder|ULENAP|Institut de Myologie, France|No|Recruiting|January 2010|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|8 Years|30 Years|Accepts Healthy Volunteers|||November 2011|November 16, 2011|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993161||132127|
NCT00993174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SETTA|Surgery for Esotropia Under Topical Anesthesia|Amount of Surgery for Esotropia Under Topical Anesthesia|SETTA|Hospital Universitario Ramon y Cajal|No|Active, not recruiting|May 2004|June 2013|Anticipated|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|60 Years|No|||May 2010|June 24, 2011|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993174||132126|
NCT00992264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA138598|'Questions About Quitting' Smoking Cessation Trial|Optimizing an Online Motivational Tobacco Cessation Program|Q2|Group Health Cooperative|No|Completed|May 2010|November 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|1865|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|October 7, 2009||No||No|April 4, 2014|https://clinicaltrials.gov/show/NCT00992264||132196|The study was powered to detect differences between each factor level of 5% or more.
NCT00992277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC75061|In-vivo Analysis and Clinical Evaluation of the Performance of a Fractional CO2 Laser System (eMatrixCO2)|In-vivo Analysis and Clinical Evaluation of the Performance of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue|eMatrixCO2|Syneron Medical||Completed|October 2009|||April 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 30, 2014|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992277||132195|
NCT00993460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #091145|Study of Changes in Skeletal Muscle After Caloric Restriction|Diacylglycerols and Insulin Action in Skeletal Muscle Upon Caloric Restriction||Vanderbilt University|No|Active, not recruiting|March 2011|November 2015|Anticipated|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|24|Samples With DNA|Whole blood, plasma, muscle tissue|Female|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female subjects approved for Roux-en-Y gastric bypass surgery at Vanderbilt University        Medical Center.|June 2015|June 1, 2015|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00993460||132104|
NCT01003392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC2500/04/120|Influence of Coffee on the Health and on the Heart of Normal, Diabetics e Coronary Artery Disease Patients|Study of Coffee and Its Influence on the Heart in Normal People, Those With Coronary Artery Disease and Diabetics.|Coffee&Heart|University of Sao Paulo|Yes|Recruiting|March 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|Blood samples.|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group of normal patients, group of patients with diagnosed coronary artery disease and        group of diabetic patients.|January 2014|January 6, 2014|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01003392||131345|
NCT01003093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYB-01|A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine|A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered at 0 and 2 Months|THYB-01|Statens Serum Institut|Yes|Completed|November 2005|June 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003093||131368|
NCT01003106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00032394|Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions|RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach(RELATE)|RELATE|Johns Hopkins University|No|Completed|November 2009|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|81|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 26, 2009|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT01003106||131367|
NCT01003951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-136|Acupuncture for the Treatment of Chronic Lymphedema|Acupuncture for the Treatment of Chronic Lymphedema: A Feasibility Study||Memorial Sloan Kettering Cancer Center||Completed|October 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Female|18 Years|N/A|No|||August 2012|August 15, 2012|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003951||131303|
NCT01003652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|St Luc|Clinical Trial on Harmonic Focus Shears|Randomized Clinical Trial on Harmonic Focus Shears Versus Clamp-and-technique for Total Thyroidectomy||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|January 2008|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|68|||Both|18 Years|N/A|No|Probability Sample|68 patients candidate to total thyroidectomy for multinodular goiter in an academic        hospital|October 2009|October 28, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003652||131325|
NCT01003665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNAP-2009-1|Comparison of Continuous Non-invasive Arterial Pressure (CNAP) With Invasive Arterial Pressure Monitoring|Accuracy of the CNAP™ Monitor (Continuous Non-invasive Arterial Pressure) Versus Invasive Radial Arterial Monitoring in Surgical Patients||University of Schleswig-Holstein|No|Completed|February 2009|January 2012|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|195|||Both|18 Years|N/A|No|Probability Sample|patients undergoing major surgery or intensive care unit treatement with the need for an        invasive blood pressure measurement|April 2012|April 13, 2012|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003665||131324|
NCT01004484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0480|Physiological Effects of Yogurt With Bb12 in Subjects With GI Symptoms Strointestinal Symptoms|Physiological Effects of Yogurt Containing Bifidobacterium Lactis (Bb12) in Subjects With Non-Diarrhea Functional Gastrointestinal Symptoms|GM-WGTT|University of North Carolina, Chapel Hill|No|Completed|June 2009|April 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|40|||Both|18 Years|70 Years|No|||December 2010|December 17, 2010|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01004484||131262|
NCT01004770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-145-001|Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)|An Intravenous, Single Dose Safety, Tolerance and Pharmacokinetic Study of GE-145 in Healthy Volunteers Undergoing a Contrast-enhanced Abdominal Computed Tomography (CT) Scan||GE Healthcare|Yes|Completed|October 2009|May 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|October 23, 2009|Yes|Yes||No|September 14, 2011|https://clinicaltrials.gov/show/NCT01004770||131241|
NCT00994890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091043|A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections|A Multicenter, Randomized, Double-Blind, Long Term Study Of The Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip||Pfizer|Yes|Terminated|November 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|679|||Both|18 Years|N/A|No|||October 2012|October 1, 2012|October 12, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00994890||131994|
NCT01008384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP-0683|The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk|The Effect of Vitamin D Repletion on Small LDL Particle Number in Subjects at Elevated Cardiovascular Risk||Rockefeller University|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|150|||Both|18 Years|85 Years|No|||May 2012|May 31, 2012|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01008384||130966|
NCT01008618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015541|A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain|A Verification Study of JNS020QD in Patients With Osteoarthritis or Low Back Pain||Janssen Pharmaceutical K.K.|No|Completed|January 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|218|||Both|20 Years|N/A|No|||November 2013|November 29, 2013|November 5, 2009|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01008618||130948|
NCT01008631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uehlinger-002|The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers|The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy||University Hospital Inselspital, Berne|Yes|Completed|September 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008631||130947|
NCT01009450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clipless cholecystectomy|Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel in Cirrhotic Patients a Prospective Randomized Study|Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel in Cirrhotic Patients a Prospective Randomized Study|CLC|Mansoura University|Yes|Completed|August 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|15 Years|80 Years|No|||November 2009|November 5, 2009|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009450||130885|
NCT00976391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108486|A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine|A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|September 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|586|||Both|18 Years|75 Years|No|||June 2014|July 31, 2014|September 11, 2009|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT00976391||133397|
NCT00976404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EraMune02|Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir|Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression|EraMune02|Northwestern University|Yes|Completed|November 2009|June 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|70 Years|No|||September 2014|September 10, 2014|September 9, 2009|Yes|Yes||No|September 4, 2014|https://clinicaltrials.gov/show/NCT00976404||133396|
NCT01005628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012958|Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)|Velcade - Regulatory Post Marketing Surveillance (PMS)||Janssen Korea, Ltd., Korea|No|Completed|June 2006|March 2012|Actual|March 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1121|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are newly prescribed bortezomib injection for the treatment of multiple        myeloma in Korea|February 2013|February 18, 2013|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01005628||131176|
NCT01005641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELBA|ELBA: Exemestane and Lapatinib in Advanced Breast Cancer|Phase II Multicentered Study of Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer|ELBA|National Cancer Institute, Naples|No|Withdrawn|December 2009|March 2012|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|N/A|N/A|No|||July 2012|July 12, 2012|October 29, 2009||No|Study not started for administrative reasons|No||https://clinicaltrials.gov/show/NCT01005641||131175|
NCT00976989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO22280|A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer|||Hoffmann-La Roche||Active, not recruiting|December 2009|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|225|||Female|18 Years|N/A|No|||December 2015|December 31, 2015|September 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976989||133351|
NCT00976690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2001-1|Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease|A Multicentre Randomized Open Study Comparing Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease|IMURELPOST|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|October 2002|December 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976690||133374|
NCT00977223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/049/HP|Effects of Substance P Antagonists on Adrenal Secretion|Pilot Study of the Action of the Substance P Antagonist Aprepitant on Aldosterone and Cortisol Secretion in Healthy Volunteers.|APHOS|University Hospital, Rouen|No|Completed|June 2009|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977223||133333|
NCT00994110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-039|Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess|Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess||Memorial Sloan Kettering Cancer Center||Completed|October 2009|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 13, 2009|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT00994110||132054|
NCT00994383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORP-T30-PVFS-3|Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled Release|A Single Dose, Three-Period, Three-Treatment, Six-Sequence, Three-Way Crossover Comparative Bioavailability Study of Morphine Sulfate Immediate Release Tablets and Solution and Controlled Release Capsules Under Steady-State Conditions.||Roxane Laboratories|No|Completed|January 2007|January 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00994383||132033|
NCT00994396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1139897|Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents|Use of Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents on a Standard Weight Loss Program||University of Missouri-Columbia|No|Completed|November 2009|April 2013|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|9 Years|19 Years|No|||December 2014|December 1, 2014|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00994396||132032|
NCT00994669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-150B|Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients|Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients||The University of Texas Medical Branch, Galveston|No|Completed|October 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|17|||Male|30 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample of healthy males and male lung cancer patients|December 2015|December 3, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994669||132011|
NCT00993707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C100-005|Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)|A Phase 2a, Ascending Dose, Placebo-Controlled Study to Evaluate the Safety of CTX-100 (Formerly ETX-100) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease||Turino, Gerard, M.D.|Yes|Recruiting|November 2010|October 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|48|||Both|40 Years|75 Years|No|||June 2011|June 16, 2011|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993707||132085|
NCT00993720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-001930-80|Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes|Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes||Hvidovre University Hospital|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|50 Years|No|||October 2009|January 20, 2011|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993720||132084|
NCT00994058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09034|Pilot Study of Electronic Uterine Contraction Inhibitor|Pilot Study to Evaluate A Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions|PSEUCI|Winthrop University Hospital|No|Withdrawn|October 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Female|18 Years|50 Years|No|||December 2015|December 22, 2015|October 7, 2009|Yes|Yes|The Investigator has changed institutions.|No||https://clinicaltrials.gov/show/NCT00994058||132058|
NCT00994071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090243|A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors|A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors||National Institutes of Health Clinical Center (CC)||Completed|September 2009|March 2013|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|21 Years|No|||July 2014|July 18, 2014|October 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00994071||132057|
NCT00995163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBD-5D|Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease|Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D)|MBD-5D|Kyowa Hakko Kirin Company, Limited|No|Completed|January 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8020|||Both|N/A|N/A|No|Probability Sample|patients who are undergoing hemodialysis and who also have secondary        hyperparathyroidism(2HPT)|August 2012|August 22, 2012|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995163||131974|
NCT00995176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 064|The Women's HIV SeroIncidence Study (ISIS)|The Women's HIV SeroIncidence Study (ISIS)||HIV Prevention Trials Network|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2099|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Men and women residing in areas from defined geographic areas with high HIV prevalence and        poverty|September 2014|January 20, 2016|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995176||131973|
NCT00994617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007749-29|Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension|Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension|Pathway 1|University of Cambridge|No|Recruiting|January 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|79 Years|No|||June 2013|June 11, 2013|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994617||132015|
NCT00994630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAPS STUDY|Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study|Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study|CHAPS|University of Sao Paulo|Yes|Suspended|January 2010|||August 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Dna and Rna analysis|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Bipolar Disease type I manic phase|May 2011|August 15, 2011|October 13, 2009||No|fail to get funding|No||https://clinicaltrials.gov/show/NCT00994630||132014|
NCT00994903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StatCol|Simvastatin in Colorectal Surgery|Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery|StatCol|University of Auckland, New Zealand|No|Completed|October 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|90 Years|No|||November 2013|November 27, 2013|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994903||131993|
NCT00974727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSN106189|A Gardening Program to Assess Unhealthy Lifestyle Contributions to Summer Weight Gain in Children|Use of Biomarkers to Assess Unhealthy Lifestyle Contributions to Summer Weight Gain in Children||University of Wisconsin, Madison|No|Completed|May 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|10 Years|14 Years|No|||September 2009|October 1, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974727||133522|
NCT01008332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH001|Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis|An Escalating, Multiple-dose Study in House Dust Mite Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune HDM||Circassia Limited|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|65 Years|No|||November 2010|November 9, 2010|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008332||130970|
NCT01008345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pharmaline1|Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol|Effect of Ezetimibe on Oxidized LDL Cholesterol||Hotel Dieu de France Hospital|Yes|Completed|September 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|80 Years|No|||November 2009|November 5, 2009|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008345||130969|
NCT01009151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00024778|Heart Failure Patient Self-Management Web Portal Pilot Study|University of Michigan Heart Failure Patient Self-Management Web Portal Pilot Study||University of Michigan|No|Completed|November 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|43|||Both|19 Years|N/A|No|||May 2015|May 26, 2015|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009151||130907|
NCT01009177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-281|Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine||Actelion|Yes|Completed|September 2005|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||April 2015|April 28, 2015|October 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009177||130906|
NCT01009190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-338-1014|A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens|A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor||Clovis Oncology, Inc.|No|Completed|February 2010|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|November 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009190||130905|
NCT01009463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102871|A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|September 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1626|||Both|40 Years|N/A|No|||August 2013|July 10, 2014|November 5, 2009|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01009463||130884|
NCT00976131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD8521|Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer|Phase I Randomized, Placebo-Controlled, Cross-Over, Dose-Finding Pharmacokinetic Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer||Columbia University|Yes|Active, not recruiting|September 2009|September 2016|Anticipated|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|18|||Female|21 Years|N/A|No|||June 2015|June 29, 2015|September 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00976131||133417|
NCT00976417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0708/35|Mechanisms of Action of Adaptive Servoventilation|Mechanisms of Action of Adaptive Servoventilation: Ventilatory Control in Heart Failure Patients With Central Sleep Apnoea||ResMed|No|Completed|September 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Venous blood will be collected.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients already recruited to the SERVE-HF study.|November 2011|December 5, 2011|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976417||133395|
NCT00976664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS IRB H-0904|Orthotic Use for Chronic Low Back Pain|Orthotic Use for Chronic Low Back Pain||National University of Health Sciences|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|September 11, 2009||No||No|April 30, 2012|https://clinicaltrials.gov/show/NCT00976664||133376|Subjects and clinicians were not blind to group. Subjects came from 1 region of the US, majority were white and ~50 years old. One type of orthotic was used as the only form of care. Several subjects felt discomfort/stiffness rather than pain.
NCT00977015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1691002|Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers.||Pfizer|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 9, 2010|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00977015||133349|
NCT00977028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 TLA Peak|Tumescent Lidocaine Maximum Safe mg/kg Dosage|Tumescent Lidocaine Bioavailability and Absorption Kinetics:Maximum Safe mg/kg Lidocaine Dosage|TLA|Klein, Jeffrey A., M.D.|No|Enrolling by invitation|January 2005|August 2011|Anticipated|July 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|72 Years|Accepts Healthy Volunteers|||June 2011|June 14, 2011|September 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00977028||133348|
NCT00977002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-23|Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation|Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation: Randomized Controlled Trial||UPECLIN HC FM Botucatu Unesp|No|Recruiting|March 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|15 Years|No|||February 2011|February 1, 2011|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977002||133350|
NCT00977457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06072|Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery|Pre-Surgical EPS Biomarkers as Predictors of Biochemical Recurrence||City of Hope Medical Center|Yes|Recruiting|November 2007|||February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1200|||Male|18 Years|N/A|No|||October 2015|October 1, 2015|September 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00977457||133315|
NCT01005173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK081406-01A1|Acetaminophen Biomarkers|Identification of New Mechanistic Biomarkers of Adverse Response to Acetaminophen||Arkansas Children's Hospital Research Institute|No|Enrolling by invitation|August 2009|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|253|||Both|1 Year|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children Ages 1-18        Group A - Hospitalized receiving acetaminophen        Group B - Healthy volunteers - no acetaminophen within 14 days        Group C - Acetaminophen Overdose - Hospitalized|June 2015|June 22, 2015|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01005173||131211|
NCT01005186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003CV40|Changing Lifestyle in Children|Changing Lifestyle in Children: All Change: Can This Reduce Cardiovascular Risk?|ALLChange|University of Dundee|No|Completed|July 2006|July 2007|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Both|9 Years|11 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|October 29, 2009||||No||https://clinicaltrials.gov/show/NCT01005186||131210|
NCT00994370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220080303|Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT|Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)||Rutgers, The State University of New Jersey|No|Completed|April 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|Samples Without DNA|Whole blood will be obtained at intervals based on standard of care blood draws. Each sample      will be analysed for circulating indicators of angiogenesis.|Both|18 Years|85 Years|No|Probability Sample|Subjects that have undergone Selective Internal Radiation Therapy for the treatment of        liver cancer|March 2014|March 18, 2014|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994370||132034|
NCT00994643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08S.461|Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma|Phase II Study of IL-2 and Rituximab Maintenance in High Risk B Cell Non-Hodgkin's Lymphoma||Thomas Jefferson University|Yes|Active, not recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00994643||132013|
NCT00994656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007194|Is Pleth Variability Index (PVI) a Surrogate for Pulse Pressure Variations (PPV) in Pediatric Spine Fusion (SF) Surgery?|Is the Pleth Variability Index (PVI) a Useful Surrogate for Pulse Pressure Variations (PPV) in a Pediatric Population Undergoing Spine Fusion?||Children's Hospital of Philadelphia|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|8 Years|18 Years|No|Non-Probability Sample|Subjects will be selected from those having posterior spinal fusion surgery at The        Children's Hospital of Philadelphia.|February 2011|February 9, 2011|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00994656||132012|
NCT00994916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0410047|Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine|Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine||University of Pittsburgh||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2015|December 7, 2015|October 8, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00994916||131992|
NCT00995800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT2503|Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma|A Double-blind, Randomised, Incomplete Block, Crossover, Placebo-controlled, Dose-response Study to Assess Bronchial Hyperresponsiveness and Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adult Subjects With Mild to Moderate Asthma|FLT2503|Mundipharma Research Limited||Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|55 Years|No|||August 2012|August 8, 2012|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995800||131925|
NCT00995813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS_Rota_vaccine_if|Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure|Pilot Study of the Safety and Immunogenicity of the Rotavirus Vaccine in Infants With Intestinal Failure||Seattle Children's Hospital|No|Completed|December 2009|July 2013|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|6 Weeks|14 Weeks|No|||November 2015|November 17, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00995813||131924|
NCT00995501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-010|The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))|The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))||The Cleveland Clinic|Yes|Terminated|January 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|970|||Both|40 Years|90 Years|No|||August 2015|August 19, 2015|October 14, 2009||No|Per interim analysis, it has been determined to stop this trial for futility.|No||https://clinicaltrials.gov/show/NCT00995501||131948|
NCT00995774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4719-R|Extension of the MIME Robotic System for Stroke Rehabilitation|Extension of the MIME Robotic System for Stroke Rehabilitation||VA Office of Research and Development|No|Completed|June 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|90 Years|No|||February 2014|February 14, 2014|October 8, 2009||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT00995774||131927|The limited therapy hours could mask potential gains that would have been made with additional therapy. Due to the small sample size, these results need to be confirmed in a larger scale study using a parallel study design.
NCT01008644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-126-09|Do Changes in Plasma Osmolality Influence Ventilation?|Do Plasma Osmolality Changes Influence Ventilation, and Are There Gender Differences?|OSM|Kalmar County Hospital|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008644||130946|
NCT01008917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC# 09455|Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma|Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma||University of California, San Francisco|Yes|Active, not recruiting|November 2009|April 2015|Anticipated|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|October 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01008917||130925|
NCT01008930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0478|Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System|Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System||M.D. Anderson Cancer Center|No|Completed|December 2009|||August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|19|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008930||130924|
NCT00975845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCTib 2008|BioCleanse Tibialis Tendon Anterior Cruciate Ligament (ACL) Study|A Prospective, Double-Blind Evaluation of the Effects of BioCleanse Tibialis Tendon Allograft and Donor Age on Clinical Outcomes of ACL Reconstruction||RTI Surgical|No|Active, not recruiting|December 2009|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|60 Years|No|||July 2015|July 17, 2015|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975845||133439|
NCT00975858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOM protocol 98/009|Long-term Comparison of Stenting Versus Off-pump Coronary Bypass Surgery|A Randomized Comparison of Long-term Clinical , Neurocognitive, Angiographical and Health-costs, After Stenting Versus Off-pump Coronary Bypass Surgery in Patients With Symptomatic Coronary Artery Disease|OCTOSTENT|UMC Utrecht|No|Completed|January 1998|February 2001|Actual|January 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|80 Years|No|||September 2009|September 14, 2009|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975858||133438|
NCT00976443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000002|Effects of Gastric Antral Botulinum Toxin Injections in Obese Subjects|Physiologic Effects of High-Dose Gastric Antral Botulinum Toxin Injections||Mayo Clinic|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 2, 2013|September 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00976443||133393|
NCT00976430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHC525|Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease|To Study the Safety and Efficacy of Bone Marrow Derived Mesenchymal Stem Cells Transplant in Parkinson's Disease||Jaslok Hospital and Research Centre|No|Suspended|July 2009|||November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|35 Years|70 Years|No|||September 2013|September 17, 2013|September 11, 2009||No|Adequate no. of patients could not be recruited in the set time frame.|No||https://clinicaltrials.gov/show/NCT00976430||133394|
NCT00976677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01967|Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer|Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Terminated|January 2010|November 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2013|May 23, 2014|September 11, 2009|Yes|Yes||No|April 24, 2013|https://clinicaltrials.gov/show/NCT00976677||133375|
NCT00977847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P0011908|Integrating Patient Generated Family Health History From Varied Electronic Health Record (EHR) Entry Portals|Integrating Patient Generated Family Health History From Varied Electronic Health Record Entry Portals||Brigham and Women's Hospital|No|Completed|November 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|5000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 17, 2012|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977847||133287|
NCT00977262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL2800108109|Postprandial Inflammation and Fatty Acids|Effects of Fatty Acids on Postprandial Inflammatory Response of Healthy Obese and Type 2 Diabetic Obese Subjects|PIFA|Wageningen University|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|9||Actual|42|||Male|50 Years|70 Years|Accepts Healthy Volunteers|||April 2010|April 20, 2010|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00977262||133330|
NCT00977483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-20557-3011|Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)|Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups|NATHAN1|MEDA Pharma GmbH & Co. KG|Yes|Completed|May 1998|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|64 Years|No|||September 2009|September 14, 2009|September 14, 2009||Yes||||https://clinicaltrials.gov/show/NCT00977483||133313|
NCT00978107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG4023.01|Trial of TG4023 Combined With Flucytosine in Liver Tumors|A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.||Transgene|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978107||133267|
NCT00977249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCTnumber 2008-006426-24|Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users|Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial||University Hospital, Gentofte, Copenhagen|Yes|Recruiting|September 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 14, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977249||133331|
NCT00977834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08147|Assessment of Older Adults With Cancer: Feasibility of Computer Survey Methodology|Assessment of Older Adults With Cancer: Feasibility of Computer Survey Methodology||City of Hope Medical Center|Yes|Completed|July 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Brawerman Center-Outpatient Clinics (City of Hope)|September 2011|September 19, 2011|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977834||133288|
NCT01005199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 77/08 and SASL 29|Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer|Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|November 2009|June 2017|Anticipated|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005199||131209|
NCT00994929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08070154, Wyeth 3067K1-2214|Efficacy and Safety of IL-11 in DDAVP Unresponsive|Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP|IL-11DDAVP|University of Pittsburgh|No|Completed|January 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 12, 2009|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT00994929||131991|
NCT00994682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070654|University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)|Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).||University of Florida|No|Completed|December 2008|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|146|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|October 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994682||132010|
NCT00995189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-09-03 / DRYS 1302 / IBIS|Clinical Evaluation of the Causes of Contact Lens Related Dry Eye|A Clinical Evaluation of the Causes of Soft Contact Lens Related Dry Eye||Alcon Research|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|159|||Both|18 Years|N/A|No|||March 2012|October 19, 2012|October 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995189||131972|
NCT00995514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GeCCO1|Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study|Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study|GeCCO|Medco Health Solutions, Inc.|No|Terminated|October 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4471|Samples With DNA|Saliva|Both|18 Years|75 Years|No|Non-Probability Sample|Adults between the ages of 18 and 75 with newly initiated clopidogrel (Plavix) or        prasugrel (Effient) therapy.|May 2012|May 29, 2012|October 14, 2009||No|Administrative reasons|No||https://clinicaltrials.gov/show/NCT00995514||131947|
NCT00995787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00026|Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea|A Randomized, Single-blind, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 Compared to Placebo in T2DM Patients Treated With Metformin and Sulfonylurea||AstraZeneca|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|30 Years|75 Years|No|||February 2010|February 25, 2010|October 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00995787||131926|
NCT00996060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0712C|Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies|A Phase 1 Protocol of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies||New Mexico Cancer Care Alliance|Yes|Completed|July 2008|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|March 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00996060||131906|
NCT01002014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-09-15B|Nipple Sparing Mastectomy - Cosmetic Outcomes|Preservation of the Nipple Areolar Complex With Skin Sparing Mastectomy||Carolinas Healthcare System|Yes|Recruiting|January 2009|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002014||131451|
NCT00996047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9007|S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers|S9007, Cytogenetic Studies in Leukemia Patients||Southwest Oncology Group|No|Completed|July 1991|January 2012|Actual|January 2012|Actual|N/A|Observational|N/A||1|Actual|3341|None Retained|Blood and bone marrow|Both|N/A|N/A|No|Non-Probability Sample|Patients registered to SWOG leukemia treatment protocols|March 2015|March 5, 2015|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996047||131907|
NCT00991783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-110|A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers|A Clinical Trial to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|14|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2009|November 2, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991783||132233|
NCT00991796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1008-A-E202|CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)|Randomised, Double-Blinded, Placebo Controlled, Phase 2 Study of CS-1008 in Combination With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer||Daiichi Sankyo Inc.|No|Completed|June 2009|December 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991796||132232|
NCT00992004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARKOS|Evaluation of the Efficacy of a Turmeric Extract (Arantal®) in Patients With Osteoarthritis of the Knee (Gonarthrosis).|Comparative, Randomized, Double-blind, Placebo-controlled, Parallel Group Study, to Evaluate the Efficacy of a Turmeric Extract (Arantal®) Versus Placebo in Patients With Osteoarthritis of the Knee (Gonarthrosis).||Bioxtract SA|Yes|Completed|June 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|40 Years|80 Years|No|||May 2010|May 6, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992004||132216|
NCT00975273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL89761-2|Breathing Training for Asthma|Targeting CO2 Levels in Breathing Training for Asthma||Southern Methodist University|Yes|Active, not recruiting|July 2008|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975273||133481|
NCT00975286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10781|24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine|A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin|GetGoal Duo1|Sanofi|Yes|Completed|October 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975286||133480|
NCT01008657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071213|Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique|Multipolar Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma Using Classical Intranodular Technique Versus Extra Nodular Technique So-called "No Touch" Technique: A Prospective Randomized Trial|ARMCENVIN|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|February 2010|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008657||130945|
NCT01008670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-Venography|Identification of the Pericardiophrenic Vein During Cardiac Device Implant Procedures to Prevent Extracardiac Stimulation|Identification of the Pericardiophrenic Vein During Cardiac Device Implant Procedures to Prevent Extracardiac Stimulation|IDPV-003|Respicardia, Inc.|No|Completed|December 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients currently under the care of an electrophysiologist or cardiac device implanter        who are scheduled to receive a CRT device, or those patients receiving an ICD or pacemaker        device who are future candidates for CRT device implantation.|November 2010|November 22, 2010|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008670||130944|
NCT00975546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-IUI|HIV-discordant Couple Intrauterine Insemination|Intrauterine Insemination for HIV-discordant Couples||University of Missouri-Columbia||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|38 Years||||November 2015|November 30, 2015|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975546||133460|
NCT00976144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113208|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects|A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 and GW642444 as Monotherapies and Concurrently in Healthy Japanese Subjects|DB2113208|GlaxoSmithKline|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|September 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00976144||133416|
NCT00976456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65 plus|Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer|Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer|65plus|Martha-Maria Krankenhaus Halle-Dölau gGmbH|Yes|Completed|September 2009|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|271|||Both|65 Years|N/A|No|||February 2016|February 11, 2016|September 11, 2009||No||No|January 12, 2016|https://clinicaltrials.gov/show/NCT00976456||133392|
NCT00976703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00392|Foley Bulb Traction for Cervical Ripening|Weighted Bag Versus Inner Thigh Taping for Cervical Ripening With a Foley Catheter Prior to an Induction of Labor||MetroHealth Medical Center|No|Completed|December 2009|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 31, 2013|September 11, 2009||No||No|February 26, 2013|https://clinicaltrials.gov/show/NCT00976703||133373|Nine patients had minor protocol violations yet were included in the intention to treat analysis. Patients and providers were not be blinded. Our inner city, minority population at a single site may also limit the generalizability of the results.
NCT00976716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191357|An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain|An Open-Label, Multicenter Study To Evaluate The Efficacy, Safety And Tolerability Of Celecoxib (YM177) In Patients With Posttraumatic Pain||Pfizer|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|20 Years|N/A|No|||April 2011|April 25, 2011|September 11, 2009|Yes|Yes||No|October 25, 2010|https://clinicaltrials.gov/show/NCT00976716||133372|
NCT00977860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-031|Hypofractionated SBRT For Prostate Cancer|Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer||University of Pittsburgh|Yes|Recruiting|October 2010|December 2023|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|111|||Male|18 Years|N/A|No|||March 2016|March 5, 2016|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977860||133286|
NCT00978120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT-AAIB-flu-001|Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma|A Phase II Study in Patients With Asthma to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|390|||Both|12 Years|N/A|No|||August 2012|August 8, 2012|September 15, 2009|Yes|Yes||No|June 27, 2012|https://clinicaltrials.gov/show/NCT00978120||133266|
NCT00978354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHFMR-0920|Furosemide in Early Acute Kidney Injury|A Phase II Randomized Blinded Controlled Trial of the Effect of furoSemide in Critically Ill Patients With eARly Acute Kidney Injury (The SPARK Study)|SPARK|University of Alberta|Yes|Terminated|September 2009|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 14, 2009||No|Feasibility of target enrollment within the context of available funding resources.|No||https://clinicaltrials.gov/show/NCT00978354||133248|
NCT00978367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1003|Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)|A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised Study to Investigate the Clinical Safety and Toleration (Including Systemic Pharmacokinetics), Wound Healing and Anti-scarring Potential of Two Applications of Intradermal RN1001 in Healthy Male Subjects.||Renovo|No|Completed|February 2002|November 2002|Actual|November 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 15, 2009|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978367||133247|
NCT00994942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORP-T30-PLFS-1|Bioequivalency Study of Morphine Sulfate Injection, Solution and Tablet Under Fasted Conditions|A Single Dose, Three-Period, Three-Treatment, Six-Sequence, Three-Way Crossover Pharmacokinetic and Comparative Bioavailability Study of Morphine Sulfate Injection, Solution, and Tablet Formulations Under Fasting Conditions.||Roxane Laboratories|No|Completed|April 2006|April 2006|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00994942||131990|
NCT00994955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRT-1|Selective Retina Therapy (SRT) for Clinically Significant Diabetic Macular Edema|Selective Retina Therapy (SRT) for Clinically Significant Diabetic Macular||University of Schleswig-Holstein|No|Completed|January 2006|October 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994955||131989|
NCT00995202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654114|Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer|Follow-Up of Fully Resected Stage II or III Colorectal Cancer. Phase III Multicentric Prospective Randomised Study||National Cancer Institute (NCI)||Recruiting|September 2009|||April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1925|||Both|18 Years|N/A|No|||October 2009|October 16, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995202||131971|
NCT00995527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090245|Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine|Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine||National Institutes of Health Clinical Center (CC)||Completed|September 2009|June 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|26|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995527||131946|
NCT01002027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2005/01895|Three Model Care Pathways for Postnatal Depression|Models of Care: Evaluating a Best Practice Model of Treating Postnatal Depression (PND)||University of Melbourne|No|Completed|November 2004|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|68|||Female|18 Years|N/A|No|||October 2009|October 26, 2009|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002027||131450|
NCT00996073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-SF003|Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion|A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Lumbar Interbody Fusion With Instrumentation||Mesoblast, Ltd.|Yes|Active, not recruiting|September 2009|July 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|70 Years|No|||November 2014|November 6, 2014|October 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996073||131905|
NCT00991809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0813|Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil|A Pilot Study of Prolonged, Intermittent Exposure to Alfentanil on Opioid-Induced Hyperalgesia in Healthy Volunteers|0813|Johns Hopkins University|No|Completed|February 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|22|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|October 7, 2009||No||No|August 9, 2013|https://clinicaltrials.gov/show/NCT00991809||132231|The sample size was intentionally small as this was to be a preliminary proof-of-concept step in the development of a human OIH model. Descriptive stats only were provided in the published manuscript.
NCT00975013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-07-02-009|Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass|Losing More Than Just Weight: Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass||Gundersen Lutheran Medical Foundation||Completed|April 2007|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|Samples With DNA|whole blood|Female|30 Years|65 Years|No|Non-Probability Sample|Study population will consist of patients undergoing laparoscopic gastric bypass at a        community-based teaching institution|September 2015|September 4, 2015|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975013||133500|
NCT00975299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13991|Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers|Open-label, Multicenter PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 18F Labeled PET Tracer BAY86-4367 Following a Single Intravenous Administration of 300 MBq (Corresponding to </= 40 µg Mass Dose) in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers||Bayer|No|Terminated|September 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|16|||Male|45 Years|N/A|No|||June 2014|June 25, 2014|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975299||133479|
NCT00974961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903050M|Levobupivacaine on Heart Rate Variability (HRV) in Spinal Anesthesia|Comparison of the Effects of Levobupivacaine and Bupivacaine on Heart Rate Variability in Spinal Anesthesia|HRV|National Taiwan University Hospital|No|Recruiting|September 2009|July 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|60 Years|No|||March 2010|March 16, 2010|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00974961||133504|
NCT00974974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX066-B09-02|A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).|A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease||IMPAX Laboratories, Inc.|No|Completed|September 2009|March 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|471|||Both|30 Years|N/A|No|||September 2013|January 21, 2016|September 10, 2009|Yes|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT00974974||133503|
NCT00975871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0961172000|Correlation of Genetic Polymorphism and Livedo Vasculitis|Correlation of Genetic Polymorphism and Livedo Vasculitis||National Taiwan University Hospital|Yes|Completed|October 2007|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Buccal mucosa cotton tip swab|Both|20 Years|N/A|No|Non-Probability Sample|General population|October 2009|October 21, 2009|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00975871||133437|
NCT00975884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113630|Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above||GlaxoSmithKline||Completed|September 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|312|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|January 5, 2012|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975884||133436|
NCT00975897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000648235|Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer|FOCUS 3 - A Study to Determine the Feasibility of Molecular Selection of Therapy Using KRAS, BRAF and Topo-1 in Patients With Metastatic or Locally Advanced Colorectal Cancer||National Cancer Institute (NCI)||Completed|July 2009|December 2012|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|3240|||Both|18 Years|N/A|No|||August 2011|December 18, 2013|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00975897||133435|
NCT00976157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-201|Serial Changes in sTREM-1 During Ventilator-associated Pneumonia (VAP)|Serial Changes of Soluble TREM-1 Level in Bronchoalveolar Lavage Fluid During Ventilator-associated Pneumonia||Mackay Memorial Hospital|Yes|Completed|August 2006|September 2008|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|86 Years|No|Non-Probability Sample|Patients who were clinically suspected to have VAP were enrolled in the study. VAP was        clinically diagnosed with a new infiltrate on a chest radiograph in a patient receiving        mechanical ventilation for more than 48 hr with at least one of the following: purulent        tracheal secretions, a body temperature >38°C or <36°C, and leukocytosis (WBC >        10,000/mm³) or leukopenia (WBC < 4000/mm³)|September 2009|September 14, 2009|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976157||133415|
NCT00976170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-002US|Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)|A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).||Chugai Pharmaceutical||Completed|September 2009|September 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|September 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00976170||133414|
NCT00977275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-585|Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant|The Treatment of T1N0 Invasive Breast Carcinoma by Local Excision and Interstitial Implant||Massachusetts General Hospital|Yes|Active, not recruiting|June 1997|||May 2001|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00977275||133329|
NCT00976729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXE36C001|NOX-E36 First-in-Human (FIH) Study|NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects||NOXXON Pharma AG|No|Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976729||133371|
NCT00976742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG17474|Gene - Exercise Research Study|Impact of Common Genetic Polymorphisms on CV Disease Risk Factor Changes With Endurance Exercise Training|GERS|University of Maryland|No|Completed|June 1998|||December 2004|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Prevention|1||Actual|225|||Both|50 Years|75 Years|No|||September 2009|September 11, 2009|September 11, 2009||||No||https://clinicaltrials.gov/show/NCT00976742||133370|
NCT00978393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-3630|A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers|A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects||Novo Nordisk A/S|No|Completed|September 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|49|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|September 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00978393||133245|
NCT00978133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dermabond colectomy wounds|Study of DERMABOND ProPen in Closure of Colectomy Wounds|Prospective Randomized Study to Evaluate the Use of DERMABOND ProPen (2-octylcyanoacrylate) in the Closure of Abdominal Wounds Versus Closure With Skin Staples in Patients Undergoing Elective Colectomy.||Singapore General Hospital|Yes|Terminated|May 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 14, 2009|September 14, 2009||No|Difficulty in accrual of study subjects, small numbers of potential subjects|No||https://clinicaltrials.gov/show/NCT00978133||133265|
NCT01005225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 004835|Genetic Investigation of Solid Tumors Cohort|Genetic Investigation of Solid Tumors Cohort||Scripps Translational Science Institute|No|Completed|February 2008|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|25|Samples With DNA|Approximately 19.5 milliliters (mls) of blood will be collected in (2 x 8.5 ml) PAXgene DNA      tubes and (1 x 2.5 ml) PAXgene RNA tube.      Solid tumor and/or benign hyperplasia samples will be collected from the participants during      surgery scheduled for standard medical care.|Both|18 Years|N/A|No|Non-Probability Sample|Outpatient clinic, physician referral|June 2014|June 10, 2014|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01005225||131207|
NCT01000935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01|Impact of Autologous Platelet Rich Plasma on Healing of Rotator Cuff Repairs|Impact of Autologous Platelet Rich Plasma on Enhancing Repair of Rotator Cuff Tendons: A Multicentre Randomized Controlled Trial||Sunnybrook Health Sciences Centre|Yes|Completed|March 2011|May 2015|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|70 Years|No|||May 2015|May 4, 2015|September 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01000935||131533|
NCT01000948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSIS40540005|A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer|An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer|DAPROCA-1|Aarhus University Hospital|Yes|Terminated|October 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|90 Years|No|||July 2011|January 7, 2014|October 22, 2009|Yes|Yes|A consequence of the results of the ENTHUSE phase III study program|No||https://clinicaltrials.gov/show/NCT01000948||131532|
NCT01000922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAJECT™-010JM|A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro|A Single Center, Randomized, Open-Label, Crossover Study, Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro Either in Combination With a Basal Insulin Infusion or With Insulin Glargine Relative to a Standardized Meal in Patients With Type 1 Diabetes||Biodel|No|Completed|June 2006|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|19 Years|70 Years|No|||July 2015|July 28, 2015|October 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000922||131534|
NCT01001234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-082|A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)|A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents||Merck Sharp & Dohme Corp.|Yes|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1382|||Both|6 Years|17 Years|No|||September 2015|September 24, 2015|October 23, 2009|Yes|Yes||No|April 10, 2012|https://clinicaltrials.gov/show/NCT01001234||131510|
NCT01001520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809858|Neural Substrates in Nicotine Withdrawal|Neural Substrates of Cognitive Deficits in Nicotine Withdrawal||University of Pennsylvania|Yes|Completed|January 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|65 Years|No|||May 2014|May 29, 2014|October 22, 2009|Yes|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01001520||131489|Genetic studies, particularly imaging studies, have drawbacks such as small sample size and focus on single candidate genes; both can be said of this study.
NCT01001754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526H04|Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection|Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection|EMERGE|ZymoGenetics|Yes|Active, not recruiting|May 2010|May 2012|Anticipated|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|70 Years|No|||December 2011|December 2, 2011|October 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01001754||131471|
NCT01002040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02820|Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Adults With Human Immunodeficiency Virus Infection||University of British Columbia|No|Completed|February 2010|August 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|20 Years|59 Years|No|||April 2015|April 14, 2015|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002040||131449|
NCT01002300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-395|Oxytocin and Social Cognition in Frontotemporal Dementia|Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia||Lawson Health Research Institute|No|Completed|September 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|30 Years|80 Years|No|||March 2014|March 17, 2014|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002300||131429|
NCT01002612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACHIN003.1|Reassessment of the Nutritional Status in Thai Orphans Living With HIV in a Family Style Community|Reassessment of the Nutritional Status in Thai Orphans Living With HIV in a Family Style Community: 6 Months After Nutrition Care Support by the Thai-Australian Collaboration HIV-Nutrition (TACHIN) Project|TACHIN003-1|Thai Red Cross AIDS Research Centre|No|Completed|December 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|73|||Both|4 Years|15 Years|No|Non-Probability Sample|Thai HIV-infected children living in a family style community located in rural central        region of Thailand|October 2009|November 6, 2009|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002612||131405|
NCT01002638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4436|The Occlusive Dressing|The Occlusive Dressing: a Comparative Randomized Trial on 2 Procedures of Treatment of Fingertips Traumatic Amputations||University Hospital, Strasbourg, France|No|Recruiting|December 2009|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002638||131403|
NCT00976183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOA-TCOV|Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma|A Phase I/II, Open-Label, Non-Randomized, Pilot Study of Weekly Paclitaxel, Every Four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed With Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer||Gynecologic Oncology Associates|No|Terminated|October 2009|October 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||March 2015|March 9, 2015|September 10, 2009||No|toxicities|No||https://clinicaltrials.gov/show/NCT00976183||133413|
NCT00976469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820903|A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents|An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of Two Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years||Nanotherapeutics, Inc.|Yes|Completed|September 2009|March 2011|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||May 2011|October 7, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976469||133391|
NCT00975559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1881-03|The Relationship Between the Response to Mental Stress and Vascular Endothelial Function|The Relationship Between the Response to Mental Stress and Vascular Endothelial Function||Mayo Clinic|No|Completed|September 2003|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|190|Samples Without DNA|Catecholomines|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Normal volunteers          2. Apical Ballooning syndrome as proven during coronary angiogram          3. Coronary Endothelial Dysfunction as proven during coronary angiogram          4. Women who have had a Myocardial Infarction with subsequent Percutaneous Intervention|April 2012|April 25, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00975559||133459|
NCT00975572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT001|Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older|A Double-blind, Randomized, Stratified and Controlled Clinical Trial With Split-virion, Adjuvanted and Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders, Adolescents and Children||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|July 2009|February 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|2200|||Both|3 Years|90 Years|Accepts Healthy Volunteers|||September 2009|September 11, 2012|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00975572||133458|
NCT00975910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090801|Effect of Lidocaine in Antiarrhythmic Dosage on Postoperative Cognitive Dysfunction in Supratentorial Craniotomy Dysfunction in Supratentorial Craniotomy|||Capital Medical University|Yes|Completed|September 2009|December 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|60 Years|No|||May 2013|May 21, 2013|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975910||133434|
NCT00976755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/08|Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer|Everolimus First-line Therapy in Non-rapidly Progressive Castration Resistant Prostate Cancer (CRPC). A Multicenter Phase II Trial.||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|September 2009|December 2017|Anticipated|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Male|18 Years|N/A|No|||January 2015|January 13, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976755||133369|
NCT00977041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36292-D Phase 2|Neurofeedback Treatment of Pain in Persons With Spinal Cord Injury (SCI)|Neurofeedback Treatment of Pain in Persons With SCI: Phase 2||University of Washington|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|85 Years|No|||October 2011|June 4, 2013|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT00977041||133347|
NCT00977288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-029|A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)|A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia||Merck Sharp & Dohme Corp.|No|Completed|September 2009|April 2014|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|408|||Both|20 Years|75 Years|No|||May 2015|May 5, 2015|September 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977288||133328|
NCT00977301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 08.04|Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)|The Effect of FOsamprenavir/Ritonavir on the Pharmacokinetics of a Single-dose of the Antipsychotic Agent olanZApine (FORZA)|FORZA|Radboud University|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 7, 2011|August 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00977301||133327|
NCT00977496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8784|Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S. Aureus|Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S Aureus||Tufts Medical Center|No|Withdrawn|May 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the Boston Dialysis Center Inc outpatient hemodialysis clinic of Tufts        Medical Center.|March 2015|March 17, 2015|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977496||133312|
NCT00978159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC 2009-058|Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia|Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study||Ruttonjee Hospital|Yes|Recruiting|September 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978159||133263|
NCT00978172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-P 001-2007|Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria|A Phase IV Study on the Safety and Effectiveness of a Fixed-dose Combination of Artesunate and Mefloquine (Artequin[TM] Paediatric) Administered for 3 Days in Children With Uncomplicated Plasmodium Falciparum Malaria in Africa||Mepha Ltd.|No|Completed|December 2007|March 2009|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|220|||Both|N/A|N/A|No|||September 2009|September 15, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00978172||133262|
NCT00974220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSS16327|Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)|Effect of Inhaled Nebulized Fentanyl on Exertional Dyspnea and Exercise Tolerance in Patients With Moderate-to-severe COPD||Queen's University|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|40 Years|N/A|No|||November 2015|November 19, 2015|September 9, 2009||No||No|September 25, 2013|https://clinicaltrials.gov/show/NCT00974220||133560|
NCT01000987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907005525|Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders|Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders||Yale University|Yes|Active, not recruiting|October 2009|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||October 2015|October 8, 2015|October 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01000987||131529|
NCT01001000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-01-2009-USZ|Colour Coded Duplex Ultrasound of Native Arterio-venous Fistula for Haemodialysis With Venous Pressure Measurement Using Controlled Compression Ultrasound as a Predictor for Shunt Maturation in the Early Postoperative Phase|||University of Zurich|Yes|Recruiting|October 2009|October 2010||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients after creation of a native arterio-venous fistula at the cephalic vein for        hemodialysis access|June 2010|June 28, 2010|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01001000||131528|
NCT01000961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP103-03|Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis|A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis||Raptor Pharmaceuticals Inc.|No|Completed|June 2010|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|6 Years|N/A|No|||June 2015|June 10, 2015|October 22, 2009|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT01000961||131531|
NCT01000974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112957|Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants|Phase III, Partially Double-blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals' Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants||GlaxoSmithKline||Completed|June 2010|July 2013|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|4003|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||October 2014|October 30, 2014|October 22, 2009|Yes|Yes||No|April 11, 2013|https://clinicaltrials.gov/show/NCT01000974||131530|
NCT01001247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016267|TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers|A Phase I, Open Label, Randomized, 4-way Crossover Trial to Evaluate the Pharmacokinetics of TMC278 25mg and 50mg in the Presence of Omeprazole 20mg q.d., in Healthy Subjects||Tibotec Pharmaceuticals, Ireland||Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 8, 2010|October 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01001247||131509|
NCT01001533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-0130|Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation|A Pilot Study to Assess the Ability of Non-invasive Bio-impedance Cardiac Monitoring to Detect and Trend Hemodynamic Variables During Dexmedetomidine (DEX) Sedation in Children for Radiology Procedures|DEX-CO|Children's Hospital Boston|No|Active, not recruiting|September 2009|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|1 Month|18 Years|No|Non-Probability Sample|All pediatric patients (1 month to 18 years of age) eligible for Radiology Sedation        Service for CT scan and Nuclear Medicine Scan procedure who agrees to participate in the        study will have their vital signs and ICON measurements recorded continuously        pre-sedation, during sedation and through recovery until discharge.|June 2011|June 22, 2011|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001533||131488|
NCT01001767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDS 10-08-24|Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease|Prospective Randomized Placebo Controlled Trial of Omega-3 Fatty Acids in HIV Infected Subjects to Modulate Cardiovascular Risk||University Hospital Case Medical Center|No|Completed|April 2009|June 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|35|||Both|18 Years|70 Years|No|||December 2014|December 18, 2014|October 22, 2009||No||No|March 12, 2012|https://clinicaltrials.gov/show/NCT01001767||131470|Small sample size may have precluded our ability to detect a small effect. Pill counts were used to monitor adherence. All participants were male.
NCT01002053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN 09-0803-AE|Can Ultrasound Predict Nerve Injury Following Posterior Tibial Nerve Block in Patients With Peripheral Neuropathy?|Can Ultrasound Predict Nerve Injury Following Posterior Tibial Nerve Block in Patients With Peripheral Neuropathy?||University Health Network, Toronto|No|Recruiting|February 2012|February 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Diabetic and non-diabetic patients undergoing foot surgery involving regional        anesthesia/nerve blockade.|November 2011|April 25, 2012|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002053||131448|
NCT01002313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-254-A|Effect of Prednisone onTregs and TH17|Effect of Prednisone on Peripheral Blood T-cell Function (Tregs and Th17) in Patients With Chronic Rhinosinusitis (CRS)||University of Chicago|No|Completed|November 2009|December 2010|Actual|May 2010|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with seasonal allergies taking prednisone and normal controls form the community.|March 2014|March 26, 2014|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002313||131428|
NCT01002625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0541008|A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers|Double-Blind, Randomized, Multiple-Dose, Placebo-Controlled, 2-Way Crossover Study To Study Effects Of PF-04457845 On Polysomnographic Endpoints In Healthy Volunteers||Pfizer|No|Terminated|November 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 6, 2010|October 26, 2009|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01002625||131404|
NCT00974753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERM-JG-2009|Prophylactic Ketorolac Post Epiretinal Membrane Surgery|A Placebo-controlled, Randomized, Clinical Trial of Prophylactic Ketorolac 0.5% in Patients Undergoing Pars Plana Vitrectomy and Phacovitrectomy Epiretinal Membrane Peel Surgery: Assessing Macular Volume With Spectral-domain OCT||Queen's University|No|Completed|March 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|18|||Both|19 Years|N/A|No|||January 2016|January 12, 2016|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00974753||133520|
NCT00975000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20062007|Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism||Amgen|No|Completed|October 2009|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|September 10, 2009|Yes|Yes||No|December 23, 2015|https://clinicaltrials.gov/show/NCT00975000||133501|
NCT00975585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0907|Clinical Performance Comparison of Two Contact Lenses|Clinical Evaluation of Two Silicone Hydrogel Frequent Replacement Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|August 2009|||October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|379|||Both|18 Years|45 Years|No|||May 2015|May 5, 2015|September 10, 2009|Yes|Yes||No|February 18, 2011|https://clinicaltrials.gov/show/NCT00975585||133457|
NCT00976768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0402|Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin|A Phase II Study of Biweekly Oxaliplatin and 5-Fluorouracil/Leucovorin Combination Chemotherapy (FOLFIRI) in Patients With Advanced Gastric Cancer (AGC) With Failure of Prior Chemotherapy Including Taxane, Fluoropyrimidine and Cisplatinum||Asan Medical Center|No|Completed|October 2004|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976768||133368|
NCT00977054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904053D|Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load|Double Filtration Plasmapheresis (DFPP) in Combination With Pegylated Interferon Alfa-2a and Ribavirin for Patients With Chronic Hepatitis C With Genotype 1 and High Viral Load: a Randomized Controlled Trial||National Taiwan University Hospital|No|Terminated|September 2009|December 2012|Actual|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|September 13, 2009||No|Novel HCV DAA approved by FDA|No||https://clinicaltrials.gov/show/NCT00977054||133346|
NCT00977067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP4050g|A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies|A Phase Ia, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0152, an IAP Protein Antagonist, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies||Genentech, Inc.||Completed|June 2007|||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||May 2010|May 17, 2010|September 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977067||133345|
NCT00977873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-010084-16|Trial of Vitamin D Supplementation in Chronic Obstructive Pulmonary Disease|Randomised, Multi-Centre, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in Patients With Chronic Obstructive Pulmonary Disease|ViDiCO|Barts & The London NHS Trust|Yes|Completed|September 2009|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Both|40 Years|N/A|No|||February 2014|February 3, 2014|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977873||133285|
NCT00977886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT70-CD018|Safety and Pharmacokinetics of ELB353 in Healthy Men|A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Oral ELB353 in Healthy Male Volunteers - A Double-Blind, Randomized, Placebo-controlled, Sequential Group Study||Biotie Therapies Corp.|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 15, 2010|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977886||133284|
NCT00977509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812092R|Gene Mutations in Non-Small Cell Lung Cancer Cells|Detection of Gene Mutations in Non-small Cell Lung Cancer Cells in Blood Samples or Fine-needle Aspiration||National Taiwan University Hospital|No|Recruiting|November 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|blood, pleural fluid, and biopsy.|Both|20 Years|N/A|No|Non-Probability Sample|primary care clinic|November 2013|November 29, 2013|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00977509||133311|
NCT00978432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012947|Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Duke University|No|Active, not recruiting|February 2012|June 2018|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978432||133242|
NCT00974259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS061860|Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)|Phase 2, Randomized Clinical Trial of the Safety and Efficacy of Brain Tissue Oxygen Monitoring in the Management of Severe Traumatic Brain Injury.|BOOST 2|University of Texas Southwestern Medical Center|No|Completed|October 2009|December 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|70 Years|No|||December 2015|December 31, 2015|September 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974259||133557|
NCT00978406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909209|National Cancer Institute Food Study|National Cancer Institute (NCI) Food Study||National Institutes of Health Clinical Center (CC)||Completed|August 2009|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|20 Years|70 Years|No|||January 2016|January 29, 2016|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978406||133244|
NCT00978419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091060|Pilot Trial of Statin Use in Burn Patients|Randomized, Placebo Controlled, Pilot Trial of Statin Use in Burn Patients|BURNSTAT|Vanderbilt University|Yes|Completed|March 2010|May 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|September 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978419||133243|
NCT01001013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL003|Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction of LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects||LG Life Sciences|No|Completed|February 2009|December 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01001013||131527|
NCT01001312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-560|Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure|Treating to Euvolemia by Clinical Assessment and Measured Blood Volume in Heart Failure|TEAM-HF|New York University School of Medicine|Yes|Terminated|October 2010|June 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Both|21 Years|N/A|No|||October 2015|October 8, 2015|October 22, 2009||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01001312||131504|
NCT01001299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22676|A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma|A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma||Hoffmann-La Roche||Completed|November 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|October 21, 2009|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01001299||131505|The data for ‘Duration of Response’, ‘Time to Response’, and ‘PFS’ was not collected as the outcomes were removed as per changes in planned analysis (protocol amendment).
NCT01001260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804975|PGD2 Formation in Vascular Injury|Biosynthesis of PGD2 in Vascular Injury|PGD2|University of Pennsylvania|No|Terminated|August 2007|January 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|51|Samples With DNA|-  Specimens:           3 urine collections will be obtained (Prior to PTCA, During PTCA and Post PTCA)        -  Genetic Testing:      analysis of the association of SNPs in Cox genes with variability in selectively or in the      PGEs genes in quantitative biosynthesis of PGD2 and related compounds.|Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled to have PTCA|December 2011|January 31, 2013|October 14, 2009||No|Unable to find subjects that met inclusion/exclusion criteria.|No||https://clinicaltrials.gov/show/NCT01001260||131508|
NCT01001273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-09-061|Hyperinsulinemic Normoglycemic Clamp for Pancreas and Simultaneous Pancreas/Kidney Transplant Recipients|Hyperinsulinemic Normoglycemic Clamp for Pancreas and Simultaneous Pancreas/Kidney Transplant Recipients||McGill University Health Center|No|Recruiting|April 2010|June 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01001273||131507|
NCT01001546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 08-032|Internet-Based Smoking Cessation for Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans|Internet-Based Smoking Cessation for OEF/OIF Veterans||VA Office of Research and Development|No|Completed|May 2010|July 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|413|||Both|18 Years|N/A|No|||December 2014|April 6, 2015|October 23, 2009||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01001546||131487|
NCT01001559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pamlab D-005|Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis|Combination Deplin® and Antidepressant Therapy Compared to Antidepressant Therapy Alone for an Episode of Major Depression- a Retrospective Analysis||Pamlab, Inc.|No|Completed|August 2009|June 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|242|||Both|18 Years|70 Years|No|Probability Sample|Adults ages 18-70 experiencing an episode of major depression|November 2013|November 25, 2013|October 22, 2009|No|Yes||No|April 19, 2013|https://clinicaltrials.gov/show/NCT01001559||131486|
NCT01001780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25260|Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease|Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease||University of Rochester|Yes|Withdrawn|August 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|October 26, 2009|Yes|Yes|Study stopped early due to poor accrual.|No||https://clinicaltrials.gov/show/NCT01001780||131469|
NCT01001793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEV01|Levacor™ Ventricular Assist Device (VAD) Bridge to Transplant Study|Evaluation of the Levacor™ Ventricular Assist Device as a Bridge to Cardiac Transplantation||World Heart Corporation|Yes|Terminated|August 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2011|December 22, 2011|October 24, 2009|Yes|Yes|Commercial considerations relating to required device modifications.|No||https://clinicaltrials.gov/show/NCT01001793||131468|
NCT01002066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT2010|Effectiveness Of Rapid Diagnostic Tests in the New Context of Low Malaria Endemicity in Zanzibar|Rapid Malaria Diagnostic Tests in Fever Patients Attending Primary Health Care Facilities in Zanzibar - Effectiveness as Diagnostic and Surveillance Tool in the New Context of Low Malaria Endemicity|RDTACT|Karolinska University Hospital|Yes|Completed|May 2010|February 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|3890|Samples With DNA|Whole blood collected on Rapid diagnostic tests (RDT)s and Filter paper (FP)|Both|2 Months|N/A|No|Non-Probability Sample|Primary health care units (PHCUs) and Primary health care centres (PHCCs) in North A and        Micheweni Districts in Zanzibar|November 2011|November 14, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002066||131447|
NCT01002326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002270|Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder|An Open Trial of Cognitive-Behavioral Therapy (CBT) for Pediatric Body Dysmorphic Disorder (BDD)||Massachusetts General Hospital|No|Completed|June 2009|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|10 Years|17 Years|No|||March 2016|March 15, 2016|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002326||131427|
NCT00975611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R076477PD14002|Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation|Amantadine Addition to Paliperidone ER or Risperidone Consta Therapy for Prolactin Elevation||North Suffolk Mental Health Association|No|Terminated|October 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|65 Years|No|||January 2013|May 3, 2013|September 10, 2009||No|The sponsor withdrew support due to slow accrual of eligible subjects.|No|January 28, 2013|https://clinicaltrials.gov/show/NCT00975611||133456|Too few subjects met study's eligibility criteria to run statistical analyses on primary outcomes. The baseline demographic data are reported here. Future research is needed to understand the prevalence of elevated prolactin in schizophrenia.
NCT00975923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VU050413|Safe Critical Care: Testing Improvement Strategies|Safe Critical Care: Testing Improvement Strategies||Vanderbilt University|No|Completed|February 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|59|||Both|1 Year|N/A|No|||December 2015|December 8, 2015|September 10, 2009||No||No|June 16, 2013|https://clinicaltrials.gov/show/NCT00975923||133433|Each participant tailored their interventions; we were not able to test the components of CQI. Data were dependent on self-reports. Our collaborative was virtual and does not address benefits from face-to-face networking of large scale projects.
NCT00975936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113191|Phase 0 Microdose Study|A Human Phase 0, Microdose Drug-Drug Interaction Study With [14C]-GSK706769 and Ketoconazole in Healthy Male Volunteers||GlaxoSmithKline||Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 28, 2010|September 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00975936||133432|
NCT00976196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-104|Platelet Hyperreactivity Project|Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients|PHP|University Hospital, Geneva|No|Completed|January 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|Samples With DNA|Plasma Serum Platelets|Both|18 Years|99 Years|No|Non-Probability Sample|Symptomatic atherothrombotic patients treated with aspirin.|December 2015|December 1, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976196||133412|
NCT00976482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09|Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications|Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications|OPTI-MIND|Guidant Corporation|Yes|Completed|September 2009|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1740|||Both|18 Years|N/A|No|Non-Probability Sample|Patient implanted with permanent pacemaker accroding to guidelines.|March 2014|March 5, 2014|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976482||133390|
NCT00977080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-967|Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D|The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism|IMPACT SHPT|Abbott|No|Completed|November 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|272|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|September 14, 2009|Yes|Yes||No|May 18, 2012|https://clinicaltrials.gov/show/NCT00977080||133344|Using a fixed dosing algorithm based on biochemical criteria may affect interpretation of the results. In the future, the risk/benefit profile of these interventions should be assessed by longer-term clinical outcomes.
NCT00977314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN002|Bone Conduction Auditory Performance Via the Tooth for Single-Sided Deafness|Bone Conduction Auditory Performance Via the Tooth for Single-Sided Deafness||Sonitus Medical Inc|Yes|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|80 Years|No|||October 2014|October 10, 2014|September 14, 2009|Yes|Yes||No|June 4, 2013|https://clinicaltrials.gov/show/NCT00977314||133326|
NCT00977522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9131005|A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia|A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic||Pfizer|No|Terminated|November 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|55 Years|No|||February 2012|February 2, 2012|September 14, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00977522||133310|
NCT00977548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15961|Erlotinib Study for Myelodysplastic Syndrome (MDS)|Phase II Study Evaluating the Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||May 2013|September 13, 2013|September 14, 2009|Yes|Yes||No|June 26, 2013|https://clinicaltrials.gov/show/NCT00977548||133309|
NCT00978146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHP-914|Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors|Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors in Adults and Children||Children's Hospital of Philadelphia|Yes|Withdrawn|October 2009|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|21 Years|No|||June 2011|March 11, 2015|September 15, 2009||No|Study was administratively withdrawn by the IRB; no subjects were enrolled|No||https://clinicaltrials.gov/show/NCT00978146||133264|
NCT00978445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vMetrics-AMS-01|Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System|Use of a Novel Remote Home PT/INR-monitoring Device for Long-Term Anticoagulation Management|vMetrics-AMS|ZIN Technologies, Inc.|Yes|Completed|September 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||March 2013|March 20, 2013|September 15, 2009||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT00978445||133241|
NCT00974272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-015|Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation|Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation||Carl T. Hayden VA Medical Center|No|Completed|August 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|35 Years|70 Years|No|||September 2009|September 9, 2009|September 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974272||133556|
NCT01002417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-2-US-a|MCS in the Treatment of Lower Urinary Tract Symptoms|An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects|MCS_LUTS|Health Ever Bio-Tech Co., Ltd.|No|Completed|July 2010|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|274|||Male|40 Years|N/A|No|||March 2015|March 1, 2015|October 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002417||131420|
NCT01002430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5101035|EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease|Endocardial VEGF-D Gene Therapy for the Treatment of Severe Coronary Heart Disease - A Phase 1 Single-blinded Placebo-controlled Phase 1 Clinical Trial|KAT301|Kuopio University Hospital|No|Active, not recruiting|October 2009|December 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|80 Years|No|||May 2015|May 12, 2015|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002430||131419|
NCT01001858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7387|Domiciliary Diagnosis and Follow up in Obstructive Apnoea Syndrome|Domiciliary Diagnosis and Follow up in Obstructive Apnoea Syndrome||Hospital Universitario San Juan de Alicante|No|Completed|June 2003|December 2004|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|66|||Both|18 Years|80 Years|No|||October 2009|July 26, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01001858||131463|
NCT01002105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGRIN4CTIL|Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients|Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients and Its Effect on Quality of Life, Clinical and Psychosocial Features: A 12-Week Double-Blind Randomized Controlled Trial||Sha’ar Menashe Mental Health Center|Yes|Recruiting|January 2010|December 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|64 Years|No|||August 2010|August 5, 2010|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01002105||131444|
NCT01001286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QS-001|Questscope Non-Formal Education Impact Study||QSNFEIS|University of Oxford|Yes|Completed|October 2009|April 2011|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||August 2011|August 3, 2011|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01001286||131506|
NCT01001572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489A2317|Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension|A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy||Novartis||Completed|September 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|932|||Both|18 Years|85 Years|No|||May 2011|May 18, 2011|October 15, 2009||No||No|April 22, 2011|https://clinicaltrials.gov/show/NCT01001572||131485|
NCT01001806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0199|A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification|A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification||Bucci Laser Vision Institute|No|Completed|October 2009|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 26, 2011|October 23, 2009||No||No|May 25, 2011|https://clinicaltrials.gov/show/NCT01001806||131467|
NCT01001819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-01-005E|DNA Microarray Analysis of Gene Expression in Chronic Rhinosinusitis|DNA Microarray Analysis of Gene Expression in Chronic Rhinosinusitis||Montefiore Medical Center|No|Recruiting|March 2005|||June 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Chronic Rhinosinusitis w/o nasal polyps who meet eligibilty requirements and        are undergoing sinus surgery and patients w/o sinus disease who are undergoing intranasal        surgery and meet eligbility requirements|October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001819||131466|
NCT01002365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bickel10-2009|Perioperative Hyperoxygenation and Wound Site Infection Following Surgery for Acute Appendicitis|||Western Galilee Hospital-Nahariya|No|Completed||||||N/A|Interventional|N/A|2||||||Both|15 Years|N/A||||October 2009|October 26, 2009|October 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01002365||131424|
NCT01002378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14656|The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib|A Phase I, Randomized, Open Label, 3-Way Cross-Over Study to Determine the Effect of a High-Fat Breakfast, a Low-Fat Breakfast and Fasting State on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers||Bayer|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|October 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01002378||131423|
NCT01003847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-200911|Differential Metabolic Effects of Fenofibrate and Fatty Acid|||Gachon University Gil Medical Center|Yes|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|150|||Both|25 Years|75 Years|No|||October 2010|May 9, 2011|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003847||131311|
NCT01002339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FundacionRC|Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation|Optimum Immunosuppression in Renal Transplant Recipients at High Risk of Developing New Onset Diabetes After Transplantation: A Multicenter, Prospective, Controlled and Randomized Trial.|01-DMPT|Fundación Canaria Rafael Clavijo para la Investigación Biomédica|No|Terminated|February 2010|June 2015|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|145|||Both|18 Years|65 Years|No|||October 2014|March 19, 2015|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002339||131426|
NCT00976222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-PED 08|Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments|Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration||University Hospital, Bonn||Active, not recruiting|December 2008|||September 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|N/A|No|||January 2013|January 17, 2013|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976222||133410|
NCT00976508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021040|Figitumumab Combined With Pegvisomant For Advanced Solid Tumors|Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors||Pfizer|No|Terminated|November 2009|October 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|10 Years|N/A|No|||October 2013|October 23, 2013|September 10, 2009|No|Yes|See termination reason in detailed description.|No|October 23, 2013|https://clinicaltrials.gov/show/NCT00976508||133388|The study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.
NCT00976781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB no. 4775|Identifying the Gaps in the Diagnosis and Management of Hepatitis C|Identifying the Gaps in the Diagnosis and Management of Hepatitis C||Henry Ford Health System|No|Active, not recruiting|August 2008|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with hepatitis C|September 2009|September 11, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00976781||133367|
NCT00976209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18122|Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)|A Randomized, Two-Way Crossover, Multicenter, Consumer Preference Study of Two Oral Formulations of Phenylephrine Hydrochloride.||Bayer|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|September 11, 2009|Yes|Yes||No|October 29, 2010|https://clinicaltrials.gov/show/NCT00976209||133411|
NCT00976495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-035|Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes|An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic and Blood Pressure (BP) Control||AstraZeneca|No|Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|75|||Both|18 Years|70 Years|No|||March 2015|March 24, 2015|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976495||133389|
NCT00977093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOV 303 / SOV 304|A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging|A Multicenter, Phase III, Open-label Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging|MR-IMPACT-II|Amersham Buchler, GmbH & Co KG|No|Completed|July 2003|June 2004|Actual|June 2004|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|533|||Both|18 Years|N/A|No|||September 2009|September 14, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977093||133343|
NCT00977327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-AK-0351|Comparison of Neuro-navigational Systems for Resection-Control of Brain Tumors|Comparison of Two Neuro-navigational Systems for Resection-control of Intra-axial Brain Tumors. The PoleStarN-20 Intra-operative Magnet Resonance Imager and the Mison SonoWand Intra-operative Ultrasound System||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2009|||May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2009|September 14, 2009|August 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00977327||133325|
NCT00977925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-08-002|The Severe Soft Tissue Bleeding Study|A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Severe Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery||Ethicon, Inc.|Yes|Completed|August 2009|March 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977925||133281|
NCT00977899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090213|Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2009|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|49 Years|No|||March 2013|February 19, 2014|September 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00977899||133283|
NCT00977912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.09.INF|Necrotizing Enterocolitis (Nec) and B. Lactis in Premature Babies|Prevention of NEC in Preterm Infants With B. Lactis||Nestlé|No|Terminated|November 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|318|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||November 2013|November 22, 2013|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977912||133282|
NCT00974558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091619|The Use of a Handheld Fan to Manage Breathlessness - A Feasibility Study|The Use of a Handheld Fan to Improve Breathlessness - a Feasibility Study to Assess Relief From Breathlessness After Five Minutes Use of a Handheld Fan Directed at the Cheeks||Cambridge University Hospitals NHS Foundation Trust|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|30 Years|N/A|No|||January 2015|January 30, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974558||133535|
NCT00974571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-246|Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis||Merck Sharp & Dohme Corp.||Completed|November 2001|May 2002|Actual|May 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1365|||Both|15 Years|85 Years|No|||June 2015|June 23, 2015|September 9, 2009|Yes|Yes||No|September 17, 2009|https://clinicaltrials.gov/show/NCT00974571||133534|
NCT01002131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19236|Exact Localisation of Impacted and Supernumerary Teeth by Cone Beam Computer Tomography (CT)|Exact Three-dimensional Localisation of Impacted and Supernumerary Teeth by Cone Beam Computer Tomography (CBCT)||Norwegian University of Science and Technology|Yes|Completed|May 2007|September 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|27|||Both|N/A|N/A|No|Probability Sample|All patients at the St.Olavs University Hospital with impacted and supernummerary teeth in        the maxilla who are scheduled to have surgery|November 2011|November 4, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002131||131442|
NCT01002144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPAHR - CTIL|C-Reactive Protein as a Predictor for Airway Hyper-Responsiveness|C-Reactive Protein as a Predictor for Airway Hyper-responsiveness||Rambam Health Care Campus|No|Completed|March 2007|May 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|people with suspected asthma underwent metacholine chalange test.|October 2009|October 26, 2009|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01002144||131441|
NCT01002742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0802|Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)|A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute GVHD (BMT CTN #0802)||Medical College of Wisconsin|Yes|Completed|January 2010|June 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|236|||Both|N/A|N/A|No|||September 2015|September 4, 2015|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002742||131395|
NCT01002755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0283|Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)|Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2010|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|October 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01002755||131394|
NCT01001585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-644|Anesthetic Effects in Mitochondrial Disease|Anesthetic Effects in Mitochondrial Disease||The Cleveland Clinic|No|Terminated|September 2006|October 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care|1||Actual|55|||Both|12 Months|16 Years|No|||March 2015|March 5, 2015|October 21, 2009||No|However, no intervention reduced the risk of major morbidity or 1 yr mortality|No||https://clinicaltrials.gov/show/NCT01001585||131484|
NCT01001832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-250|Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients|A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate||Bristol-Myers Squibb|No|Completed|December 2009|October 2012|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|20 Years|N/A|No|||January 2014|January 2, 2014|October 26, 2009|Yes|Yes||No|October 22, 2012|https://clinicaltrials.gov/show/NCT01001832||131465|
NCT01001845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53001|Comparative Effects of Milk Thistle Extract With Vitamin-E in Hemodialysis Patients|Comparative Effects of Milk Thistle Extract With Vitamin-E on Oxidative Stress Biomarkers in Hemodialysis Patients||Shiraz University of Medical Sciences|Yes|Completed|June 2009|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|80|||Both|18 Years|60 Years|No|||September 2010|January 21, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01001845||131464|
NCT01002079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-028|Drug-Drug Interaction Study With Rifampin|A Study of the Effect of Concomitant Administration of Rifampin on the Pharmacokinetics of BMS-708163 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|January 24, 2011|October 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01002079||131446|
NCT01002092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-65|A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma|A Randomized, Controlled Multicenter Trial of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma||Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd|No|Active, not recruiting|February 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|12 Years|60 Years|No|||August 2014|August 31, 2014|October 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01002092||131445|
NCT01002352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOLD|Bariatric Outcomes Longitudinal Database (BOLD)|Bariatric Outcomes Longitudinal Database (BOLD)|BOLD|Surgical Review Corporation|No|Active, not recruiting|June 2007|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600000|||Both|N/A|N/A|No|Non-Probability Sample|All patients who qualify for bariatric surgery|November 2011|November 21, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002352||131425|
NCT01003860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOM2009-01|Postoperative Analgesia After Shoulder Replacement|Comparison Of 0.5% Vs. 0.75% Ropivacaine Interscalene Brachial Plexus Block (ISB) Prior To Elective Total Shoulder Replacement Surgery On Use of Analgesic Medication During Post-Discharge Week||Thomas Jefferson University|No|Completed|June 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patients undergoing shoulder replacement surgery at Methodist Hospital.        Ethnicities and ages of patients varied.|October 2009|October 28, 2009|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003860||131310|
NCT01002690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COX2EAR090531|COX-2 Inhibition in Allergic Asthma|Effect of COX-2 Inhibition on Allergen-induced Airway Obstruction in Subjects With Asthma||Karolinska University Hospital|Yes|Completed|October 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|55 Years|No|||April 2013|April 23, 2013|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002690||131399|
NCT01002703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBP-01/08|Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma|Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma After Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077||University of Leipzig|Yes|Recruiting|September 2009|October 2014|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2009|August 11, 2011|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002703||131398|
NCT01002716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-OE-0453-CTIL|Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis|Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis||Tel-Aviv Sourasky Medical Center|No|Recruiting|October 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|90|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2009|October 26, 2009|October 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01002716||131397|
NCT00976248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-214|Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia|Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Active, not recruiting|November 2009|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|September 11, 2009|Yes|Yes||No|June 13, 2013|https://clinicaltrials.gov/show/NCT00976248||133408|
NCT00976261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112534|A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes|A 2-Part Trial: a Randomized 6-day Repeat-dose, Parallel-group Study in Subjects With T2DM to Assess the Safety and Tolerability of GSK1614235 Compared to Placebo and Sitagliptin; and a Randomized Single-dose, Food Effect Study in Healthy Volunteers to Assess Safety and Tolerability of GSK1614235|SGA112534|GlaxoSmithKline|No|Completed|October 2009|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2011|September 11, 2014|September 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00976261||133407|
NCT00976521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901|The INFUSE - Anterior Myocardial Infarction (AMI) Study|A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction||Atrium Medical Corporation|Yes|Completed|September 2009|April 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|452|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|September 11, 2009|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT00976521||133387|
NCT00976534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5090C00018|Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain|A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)|AVANT|AstraZeneca|No|Terminated|September 2009|February 2010|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||December 2009|December 21, 2009|September 9, 2009|Yes|Yes|The study was terminated due to results in another study (NCT00878501).|No||https://clinicaltrials.gov/show/NCT00976534||133386|
NCT00976794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2898|Efficacy of Combined Treatment for Young Bipolar I Disorder|Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients|LICAVAL|University of Sao Paulo|No|Completed|January 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|35 Years|No|||July 2013|July 10, 2013|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976794||133366|
NCT00976807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ1 09/N153|Rehabilitation Following Critical Illness|A Randomised Controlled Trial of Rehabilitation Following Critical Illness: A Short Term Feasibility and Follow-Up Pilot Study||Guy's and St Thomas' NHS Foundation Trust|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976807||133365|
NCT00977340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StudieAlptraum1|Study on the Psychotherapeutic Treatment of Chronic Nightmares|Psychotherapeutic Treatment of Chronic Nightmares: Differential Efficacy of Imagery Rehearsal Therapy Compared to Confrontation and Psychotherapeutic Placebo||Goethe University|No|Not yet recruiting|October 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||September 2009|September 14, 2009|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977340||133324|
NCT00977561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021032|A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer|A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer||Pfizer|No|Terminated|April 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|September 10, 2009|Yes|Yes|See termination reason in detailed description.|No|January 18, 2013|https://clinicaltrials.gov/show/NCT00977561||133308|The study was terminated prematurely due to low participants enrollment and the halting of the figitumumab development program. The only endpoint analyzed was safety and tolerability of figitumumab ± cisplatin (or carboplatin) and etoposide.
NCT00977574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01969|Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC#704865), Paclitaxel/Carboplatin/Temsirolimus (NSC#683864) and Ixabepilone (NSC#710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2009|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|330|||Female|18 Years|N/A|No|||February 2016|March 18, 2016|September 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977574||133307|
NCT00977938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRIG080186|The Dual Antiplatelet Therapy Study (DAPT Study)|A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions||Harvard Clinical Research Institute|Yes|Completed|October 2009|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25682|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 14, 2009|Yes|Yes||No|September 18, 2015|https://clinicaltrials.gov/show/NCT00977938||133280|
NCT00978185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649812|Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy|The Effectiveness and Cost Effectiveness of Acupressure for the Control and Management of Chemotherapy-related Nausea.||National Cancer Institute (NCI)||Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|1||Anticipated|699|||Both|16 Years|N/A|No|||September 2009|August 23, 2013|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978185||133261|
NCT00974285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.07.16-3|Clinical Trials on the Effect of Immunity 1 (Fuzheng 1) on Immune Reconstitution of HIV Patients|Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trials on the Effect of Immunity 1 (Fuzheng 1) on Immune Reconstitution of HIV Patients||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Recruiting|September 2009|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||September 2009|October 28, 2009|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974285||133555|
NCT00974298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090342|Uncemented Total Elbow Arthroplasty Data Collection|Uncemented Total Elbow Arthroplasty Data Collection||Vanderbilt University|No|Terminated|March 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who require total elbow arthroplasty.|August 2014|August 5, 2014|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00974298||133554|
NCT00974584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4628g|A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer||Genentech, Inc.||Completed|October 2009|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|4||Actual|65|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00974584||133533|
NCT00974597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#AW-101008DS|Comparison of AWBAT™-D and MEPILEX® AG for Treatment of Donor Sites in Burn Surgery|A Randomized, Prospective Comparison of AWBAT™-D and MEPILEX® AG for Treatment of Donor Sites in Burn Surgery||Aubrey Inc.|No|Terminated|September 2009|||September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2009|June 21, 2010|September 8, 2009||No|Management Decision|No||https://clinicaltrials.gov/show/NCT00974597||133532|
NCT01002443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS03-063|Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer|Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Intestinal Metaplasia in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer||National Cancer Center, Korea|Yes|Completed|July 2003|March 2009|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|70 Years|No|||October 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002443||131418|
NCT01002391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dinter01|Dressing Wear Time After Reduction Mammaplasty|Twenty-four Hours or 6 Days? A Prospective Randomized Trial Comparing Dressing Wear Time After Reduction Mammaplasty||Federal University of São Paulo|No|Completed|February 2009|September 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|70|||Female|18 Years|60 Years|No|||March 2012|March 12, 2012|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01002391||131422|
NCT01002404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23/180/2009|The Use of Guide Wire in Biliary Cannulation: Angled or Straight Tipped Guide Wire?|The Use of Guide Wire in Biliary Cannulation: Angled or Straight Tipped Guide Wire?||Turku University Hospital|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|90 Years|No|||October 2011|October 10, 2011|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01002404||131421|
NCT01002729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC91|Oseltamivir Pharmacokinetics in Morbid Obesity|Oseltamivir Pharmacokinetics in Morbid Obesity|OPTIMO|IWK Health Centre|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|October 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01002729||131396|
NCT01002989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microlife ABI|Validation of WatchBP Office Ankle-brachial Index (ABI) Function|Assessment of the Oscillometric Measurement of the Ankle-brachial Index (ABI) With WatchBP Office ABI Device.|ABI|University of Athens|No|Completed|June 2009|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|98|||Both|25 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Subjects assessed for hypertension including those with other cardiovascular risk factors|January 2012|January 20, 2012|October 27, 2009||No||No|August 23, 2010|https://clinicaltrials.gov/show/NCT01002989||131376|
NCT01003288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1N1VAC-2009, Version 1|Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen|Safety and Immunogenicity Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen|H1N1VAC|University of Bergen|No|Recruiting|October 2009|December 2016|Anticipated|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|8000|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|October 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01003288||131353|
NCT01004120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMSE|Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults|Double-blind, Placebo Controlled, Randomised, Cross-over Study to Determine the Effect of a Prebiotic Galactooligosaccharide on Microbiota and Metabolic Syndrome Risk Factors in Overweight Adults||Clasado|Yes|Completed|October 2009|December 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01004120||131290|
NCT00976547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMV 2009 001|Correlation Analysis of Hearing Thresholds, Validated Questionnaires and Psychoacoustic Measurements in Tinnitus Patients|Correlation Analysis of Hearing Thresholds, Validated Questionnaires and Psychoacoustic Measurements in Tinnitus Patients||Faculdade de Medicina de Valenca|No|Completed|January 2009|June 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|48|||Both|18 Years|70 Years||Non-Probability Sample|48 tinnitus patients sensorineural hearing losses|September 2009|September 11, 2009|September 11, 2009||||No||https://clinicaltrials.gov/show/NCT00976547||133385|
NCT00976846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDA-01|Investigation of Performance and Compatibility of the Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration|Clinical Study Investigating the Performance and Compatibility Characteristics of the Baxter Hollow Fiber Dialyzer Xenium XPH 210 During On-line Hemodiafiltration||Praxisverbund Dialyse und Apherese|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||September 2009|September 14, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00976846||133362|
NCT00976820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113482|Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age|A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age||GlaxoSmithKline||Completed|October 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|323|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||January 2012|June 14, 2012|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976820||133364|
NCT00976833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007879|Standardized Rehabilitation for Intensive Care Unit (ICU) Patients With Acute Respiratory Failure|Standardized Rehabilitation for ICU Patients With Acute Respiratory Failure||Wake Forest School of Medicine|Yes|Completed|October 2009|June 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976833||133363|
NCT00977353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH95-TD-B-111-TM002|N-methylglycine (Sarcosine) Treatment for Depression|N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder||China Medical University Hospital|Yes|Completed|April 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||July 2011|July 10, 2011|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00977353||133323|
NCT00977587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09075|Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction|Effect of Saccharomyces Cerevisiae CNCM I-3856 on Faecal Proteases and Symptoms Associated With IBS-D and Postinfective Bowel Dysfunction||University of Nottingham|No|Withdrawn|January 2011|July 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|September 15, 2009||No|unable to get MHRA approval for formulation in present form|No||https://clinicaltrials.gov/show/NCT00977587||133306|
NCT00977600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 1204-001|A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)|A Randomized, Crossover, Open-label Phase 1 Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)||Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|March 2005|July 2005|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|September 15, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT00977600||133305|
NCT00978458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000654697|Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma|Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas||National Cancer Institute (NCI)||Recruiting|September 2009|||May 2026|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|September 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978458||133240|
NCT00978471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSII-TTP|Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma|Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma|OSII-TTP|Centre Leon Berard|Yes|Recruiting|July 2009|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|1 Year|50 Years|No|||February 2015|February 10, 2015|September 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00978471||133239|
NCT00978198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0201|Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers|ASP1517 Phase 1 Clinical Study - Single and Multiple Oral Dosing of ASP1517 in Healthy Non-elderly Male Volunteers||Astellas Pharma Inc|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|100|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||June 2010|June 16, 2010|September 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00978198||133260|
NCT01005576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCRN-NMD 0901|Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia|A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)|URTH|Washington University School of Medicine|Yes|Active, not recruiting|January 2010|||April 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|16 Years|No|||April 2014|April 15, 2014|October 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01005576||131180|
NCT01005862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951011|Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers|A Randomized, Investigator And Subject-Blind, Sponsor-Open, Placebo-Controlled Study To Examine The Effects Of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers||Pfizer|No|Completed|March 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 25, 2012|October 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01005862||131158|
NCT01005875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090910004|Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma|RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma|RAD 0901|University of Alabama at Birmingham|Yes|Terminated|November 2009|June 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|N/A|No|||May 2014|May 12, 2014|October 30, 2009|Yes|Yes|Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is    insufficient data and will not be any study results/outcomes.|No|April 9, 2014|https://clinicaltrials.gov/show/NCT01005875||131157|The study was closed due to slow accural and enrolled 5 of the 10 planned patients.
NCT00993018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016438|A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Diabetic Painful Neuropathy, Followed by a Double-Blind Safety Extension and an Open-Label Safety Extension||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|November 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|77|||Both|18 Years|80 Years|No|||May 2015|May 18, 2015|October 8, 2009|Yes|Yes|Logistic reasons associated with the FDA-imposed clinical hold.|No||https://clinicaltrials.gov/show/NCT00993018||132138|
NCT00993343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070101|Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation|A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study.||Karolinska Institutet|Yes|Completed|September 2007|April 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|215|||Both|6 Months|75 Years|No|||April 2015|April 13, 2015|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993343||132113|
NCT01003002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e4773|Natural History of Levodopa-Induced Dyskinesia (LID)|Determining the Natural History of Levodopa-Induced Dyskinesia (LID)||Oregon Health and Science University|No|Withdrawn|December 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|21 Years|N/A|No|Non-Probability Sample|Parkinson's disease|October 2009|September 11, 2012|October 27, 2009|No|Yes|Funding not secured.|No||https://clinicaltrials.gov/show/NCT01003002||131375|
NCT01003015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14596|Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma|An Uncontrolled Open Label Multicenter Phase II Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (HCC)||Bayer|No|Completed|September 2009|March 2013|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01003015||131374|
NCT01003301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00027984|The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge|The Effects of Omalizumab on the Late-phase Response to Nasal Allergen Challenge||Johns Hopkins University|Yes|Completed|October 2009|September 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|October 27, 2009|Yes|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01003301||131352|
NCT01003314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC037|A Study of the Safety and Effectiveness of Two New Malaria Vaccines|A Phase I/IIa Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 MSP1 Alone and With MVA MSP1||University of Oxford|Yes|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003314||131351|
NCT01003028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW Jung_TCI_Remi_Cpmax|Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion|||Seoul National University Hospital|Yes|Not yet recruiting|November 2015|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|70 Years|No|||May 2015|May 27, 2015|October 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01003028||131373|
NCT01003327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|354/2009|Comparison of the I-gel Laryngeal Mask and the Classic Laryngeal Mask in Patients With a BMI>25|Comparison of the I-gel Laryngeal Mask and the Classic Laryngeal Mask in Patients With a BMI>25 During Elective Surgery||Medical University of Vienna|No|Completed|October 2009|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||October 2009|July 22, 2010|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003327||131350|
NCT01003587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH 09-049|Promoting Evidence-Based Decision-Making in India: District Evaluation Study on Health|Improving Use of Evidence in Policy: District Evaluation Study on Health|DESH|St. Michael's Hospital, Toronto|No|Active, not recruiting|July 2009|July 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|594|||Both|N/A|N/A|No|||June 2015|June 3, 2015|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003587||131330|
NCT01003600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-133|Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information|Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information||Memorial Sloan Kettering Cancer Center||Completed|October 2009|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|177|||Both|18 Years|N/A|No|Non-Probability Sample|Adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens        Cancer Center (QCC) at Queens Hospital|November 2014|November 26, 2014|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01003600||131329|
NCT01003873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/19|Gastric Bypass and Peripheral Activity of the Endocannabinoid System|Effect of Weight Loss Induced Either by Gastric Bypass or Lifestyle Intervention on the Peripheral Activity of the Endocannabinoid System|CC ENDO|University Hospital, Bordeaux|No|Completed|October 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|44|Samples Without DNA|Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral      adipose tissue will be done 6 months after surgery|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|2 groups : from primary care clinic          -  obese patients with gastric bypass          -  obese patients with lifestyle intervention 1 group : volunteer|January 2015|January 13, 2015|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003873||131309|
NCT00976560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113009|Clinical Study to Test a New Drug to Treat Major Depression|A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder|PKI113009|GlaxoSmithKline|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|60 Years|No|||March 2012|March 15, 2012|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976560||133384|
NCT00976859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STUDIEBESCHMUTZTHEITI|Efficacy of Cognitive Restructuring and Imagery Modification to Reduce the Feeling of Being Contaminated After Childhood Sexual Abuse|Efficacy of a Two-session Treatment of Cognitive Restructuring and Imagery Modification (CRIM) to Reduce the Feeling of Being Contaminated (FBC) in Adult Survivors of Childhood Sexual Abuse||Goethe University|No|Completed|June 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|65 Years|No|||May 2012|May 15, 2012|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00976859||133361|
NCT00977106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22017|TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF|Comparative Double Blind Placebo Controlled Clinical Study on Tocilizumab Rapid Efficacy on Patients Relief in rheumatoïd Arthritis With an Inadequate Response to DMARDs or Anti TNF :TORPEDO||Hoffmann-La Roche||Completed|June 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|August 18, 2009||No||No|June 26, 2014|https://clinicaltrials.gov/show/NCT00977106||133342|
NCT00977951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1004|Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects|A Single Centre, Double-blind, Methodology Trial to Investigate the Genomic Changes Associated With Accelerated Healing and Reduced Scarring of Small Wounds Using RN1001 in Healthy Male Subjects||Renovo|No|Completed|September 2002|September 2003|Actual|September 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 15, 2009|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977951||133279|
NCT00978211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAW002|DOTA-TOC in Metastasized Neuroendocrine Tumors|Phase II Study of [90Y-DOTA]-TOC and [177Lu-DOTA]-TOC in Metastasized Neuroendocrine Tumors||University Hospital, Basel, Switzerland|No|Completed|September 1997|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1499|||Both|N/A|N/A|No|||August 2015|August 5, 2015|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978211||133259|
NCT01009398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|167/09|Thoracic Paravertebral Catheters|Radiological Evaluation of Thoracic Paravertebral Catheters: A Prospective Clinical Trial||University Hospital Inselspital, Berne|No|Completed|November 2009|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who are scheduled for a thoracoscopic intervention with planned placement of        paravertebral catheters as their standard postoperative pain treatment strategy are        eligible for this prospective observational clinical trial.|February 2011|February 2, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009398||130889|
NCT01009632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC005643|Role of Exercise for Wound Healing in the Larynx|Role of Exercise for Wound Healing in the Larynx||University of Pittsburgh|No|Completed|February 2004|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|9|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2009|November 6, 2009|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009632||130872|
NCT01009645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fact versus Myth Messages|The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination|The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination||Northwestern University|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|125|||Both|50 Years|N/A|No|||August 2012|August 20, 2012|November 6, 2009||No||No|April 25, 2012|https://clinicaltrials.gov/show/NCT01009645||130871|Low participation in the trial due to the emergence of H1N1; many individuals >50 years of age opted to receive seasonal flu vaccine as they were initially unable to receive the H1N1 vaccine. Hence, the available study population shrank markedly.
NCT01009658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-696|MSG and Gastrointestinal Motility|Effect of Monosodium Glutamate on Upper Gastrointestinal Tract Motility||Gunma University||Completed|December 2009|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009658||130870|
NCT01009671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEC/ARTGT/081000N|Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee|Randomised, Comparative, Double-blind, Parallel-group Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee||Laboratoires NEGMA|No|Active, not recruiting|November 2009|October 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|210|||Both|40 Years|80 Years|No|||November 2009|November 6, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009671||130869|
NCT01005589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5026|CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis|Measurement of Neutrophil Membrane CD64 as an Early Indication of Neonatal Infection and Necrotising Enterocolitis (NEC).||Newcastle-upon-Tyne Hospitals NHS Trust|No|Recruiting|October 2009|February 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|N/A|1 Month|No|Non-Probability Sample|Patients from the neonatal ward who have suspected infection/NEC will be recruited into        the study.|October 2009|October 30, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005589||131179|
NCT00992745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX-P103|A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer|A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer||Molecular Insight Pharmaceuticals, Inc.|No|Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|24|||Male|18 Years|N/A|No|||October 2011|October 7, 2011|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992745||132159|
NCT00992758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104512|Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement|Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement||GlaxoSmithKline||Completed|May 1999|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992758||132158|
NCT00992771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8|Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3|A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3||University of South Florida||Completed|October 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||June 2012|June 15, 2012|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992771||132157|
NCT00993031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5741-34342|Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women|Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women|PROMOTE-PIs|University of California, San Francisco|Yes|Completed|December 2009|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|391|||Female|16 Years|N/A|No|||October 2013|October 15, 2013|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993031||132137|
NCT00993044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-00214|A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin|A Phase I Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin|VIT-B|Children's Hospital Los Angeles|Yes|Completed|September 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|12 Months|20 Years|No|||July 2014|July 22, 2014|October 8, 2009|Yes|Yes||No|January 3, 2014|https://clinicaltrials.gov/show/NCT00993044||132136|
NCT00993057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00009023|Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia|Comparing Two Glucose Sampling Frequencies for an Intensive Insulin Protocol During Craniotomy in Non-Diabetic Patients—How Efficiently and Safely Can We Maintain Target Glucose Levels||Northwestern University|No|Completed|October 2009|August 2012|Actual|August 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993057||132135|
NCT01002768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3538|Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics|A Trial Investigating the Hypoglycaemic Response to NN1250 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|October 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01002768||131393|
NCT01002781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0452-09|Efficacy and Safety of Tocilizumab in Adult's Still Disease|Efficacy and Safety of Tocilizumab (a Monoclonal Antibody to Receptor of IL-6) in the Treatment of Adult's Still Disease||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|90 Years|No|||September 2009|October 26, 2009|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01002781||131392|
NCT01003041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010|The Influence of Hearing Discrete Phonemes in Mother's Voice in the Infant's Natural Environment and With Natural Melody on Developing Phonetic Categories Between 4-10 Months Old|||Maaynei Hayesha Medical Center||Not yet recruiting|October 2009|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|||Both|4 Months|10 Months|Accepts Healthy Volunteers|Probability Sample|normal newborn infants|October 2009|October 27, 2009|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01003041||131372|
NCT01003054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-672|Autologous Transplantation for Chronic Myelogenous Leukemia|Busulfan, Cyclophosphamide, Imatinib Mesylate and Autologous Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Completed|March 2005|October 2009|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|70 Years|No|||October 2011|October 31, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01003054||131371|
NCT00994279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU97309|Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy|Yoga or Wellness Education During Breast Cancer Treatment: Establishing Community-Based Partnerships||Wake Forest NCORP Research Base|Yes|Completed|October 2009|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|N/A|No|||April 2013|April 2, 2013|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994279||132041|
NCT00994292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-201|Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes|A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes|RUBY-1|Astellas Pharma Inc|Yes|Completed|September 2009|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|1276|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|October 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994292||132040|
NCT01003613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3049/2009|Evaluation of Tranilast to Treat Pterygium Before Excision|Evaluation of Tranilast as Adjunctive Therapy Before Primary Pterygium Excision Compared With Conjunctival Autograft|TPS|Sao Jose do Rio Preto University|Yes|Completed|February 2009|March 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|April 16, 2012|October 28, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01003613||131328|
NCT01003886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0351068|A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)|A Post Marketing Surveillance Study To Determine The Safety, Tolerability And Effectiveness Of Doxazosin Mesylate GITS Among Filipino Adult Males With Benign Prostatic Hyperplasia (BPH)||Pfizer|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|989|||Male|18 Years|90 Years|No|Non-Probability Sample|Filipino adult males diagnosed with Benign Prostatic Hyperplasia (BPH) and prescribed with        Doxazosin mesylate GITS|September 2011|September 19, 2011|October 28, 2009|No|Yes||No|September 19, 2011|https://clinicaltrials.gov/show/NCT01003886||131308|
NCT01004159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 152009|Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan|A Phase II Study of High Dose Cetuximab Plus Irinotecan in Colorectal Cancer Patients With KRS-Wild Type Tumors Who Progressed After Failure of Prior Standard Dose ofCetuximab Plus Irinotecan||Roswell Park Cancer Institute|Yes|Terminated|September 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|99 Years|No|||September 2015|September 29, 2015|October 28, 2009|Yes|Yes|former PI left institute|No|December 26, 2013|https://clinicaltrials.gov/show/NCT01004159||131287|Early termination leading to small numbers of subjects analyzed
NCT00977132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valena-Study|Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome|Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile|VALENA|Heinrich-Heine University, Duesseldorf|Yes|Terminated|October 2009|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 14, 2009||No|delayed recruitment|No||https://clinicaltrials.gov/show/NCT00977132||133340|
NCT00977366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1004/21|Neurophysiology of Cough Reflex Hypersensitivity|Pilot Study Investigating Central Sensitisation of the Cough Reflex in Subjects With Chronic Cough and Healthy Volunteers|NOTCH|University of Manchester|No|Completed|March 2010|February 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 17, 2013|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977366||133322|
NCT00977119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-056-B|Investigation of Genetic Determinants of Capecitabine Toxicity|Investigation of Genetic Determinants of Capecitabine Toxicity||University of Chicago|No|Active, not recruiting|November 2009|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|Samples With DNA|Blood (including DNA)|Female|18 Years|N/A|No|Non-Probability Sample|Patients receiving treatment with capecitabine for breast cancer at a participating        academic medical center.|August 2015|August 14, 2015|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977119||133341|
NCT01008566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03186|Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer|A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|August 2009|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|19 Years|N/A|No|||December 2015|February 11, 2016|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01008566||130952|
NCT01008865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-01-2|A Comparison of the Studer Pouch Versus the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients|A Randomized Comparison of the Studer Pouch vs. the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients||University of Southern California||Active, not recruiting|January 2002|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|529|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008865||130929|
NCT01009411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-1-IS-001|Labor Progress Indices and the Dynamics of the Individual Contraction During the Active Stage of Labor|Physiological Study of the Active Stage of Labor||Western Galilee Hospital-Nahariya|No|Completed|September 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nulliparous women over 18 years admitted to the labor in active labor|June 2014|June 19, 2014|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01009411||130888|
NCT01005602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCP 2006-07|Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care|Use of a Simplified Nomogram and Pharmacogenetics to Individualize Digoxin Dosing in Heart Failure Patients vs. Standard Care||University of Illinois at Chicago|No|Completed|December 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|22 Years|N/A|No|||May 2014|May 19, 2014|October 30, 2009||No||No|April 16, 2014|https://clinicaltrials.gov/show/NCT01005602||131178|
NCT01005901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2304|A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo|A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease|GLOW 1|Novartis||Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1324|||Both|40 Years|N/A|No|||December 2011|March 15, 2012|October 30, 2009|Yes|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT01005901||131155|
NCT01005914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000642363|Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia||OHSU Knight Cancer Institute|Yes|Terminated|June 2009|May 2014|Actual|March 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|60 Years|No|||February 2015|February 12, 2015|October 30, 2009|Yes|Yes|Increased rate of bacterial infections|No|October 28, 2014|https://clinicaltrials.gov/show/NCT01005914||131154|Early termination of the study due to adverse events.
NCT00992797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUS-KIB-001|Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity|A Randomized Controlled Trial of the Effect of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Subjects With Type 2 Diabetes of Nordic and Sub-Indian Ethnicity .|DIVINE|University Hospital, Aker|No|Recruiting|September 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2009|November 2, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00992797||132155|
NCT00993070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-I-1-45/52|Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy|A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy||Thammasat University|No|Completed|October 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|20 Years|N/A|No|||May 2012|May 8, 2012|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993070||132134|
NCT00993083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flu002|A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults|A Phase IIA Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults||University of Oxford|Yes|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|August 10, 2011|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00993083||132133|
NCT00993382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI10936|Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death|Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death|ALPHEE|Sanofi|Yes|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|486|||Both|21 Years|N/A|No|||October 2013|October 12, 2013|October 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993382||132110|
NCT00993395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00020931|A Comprehensive Peer Mentor-based Disease Management Program for Medically Complex Substance Users|A Comprehensive Peer Mentor-based Disease Management Program for Medically Complex Substance Users||Johns Hopkins University|No|Not yet recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|160|||Both|N/A|N/A|No|||October 2009|October 9, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993395||132109|
NCT00993616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-01663|Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin|A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|December 2009|||July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|October 9, 2009|Yes|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT00993616||132092|
NCT00993993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00640-57|Relational Development in Children With Cleft Lips and Palates: Influence of the Waiting Period Prior to the First Surgical Intervention and the Parents' Psychological Perception of the Abnormality|||University Hospital, Strasbourg, France|No|Completed|January 2010|April 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|150|||Both|4 Months|12 Months|No|Non-Probability Sample|Primary care centers (France) Two referent centers Two competent centers|September 2015|September 29, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00993993||132063|
NCT00994006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-7339-09-SMC|The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects|The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease||Sheba Medical Center|No|Completed|January 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2011|May 3, 2011|October 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00994006||132062|
NCT00994552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0802/3|Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure|A Pilot Study: Comparing Physiological Parameters and Outcome Variables Using Pressure Support Ventilation Versus Pressure Controlled Ventilation in Patients With Chronic Respiratory Failure||Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|August 2009|||April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2009|October 13, 2009|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994552||132020|
NCT00994825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO/URC/ER/mm 768/DG|Levosimendan in High Risk Patients Undergoing Cardiac Surgery|Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial|CHEETAH|Università Vita-Salute San Raffaele||Recruiting|November 2009|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00994825||131999|
NCT00994838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091030|Reduced Calorie Diet Intervention in Kidney Transplant Recipients|Reduced Calorie Diet Intervention in Kidney Transplant Recipients||Vanderbilt University|No|Completed|October 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||July 2015|July 16, 2015|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00994838||131998|
NCT01007695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI36488|Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot|Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot|VAST|University of Utah|Yes|Terminated|May 2010|May 2016|Anticipated|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||June 2015|June 11, 2015|November 2, 2009|No|Yes|Enrollment was going slowly and needed to be closed.|No||https://clinicaltrials.gov/show/NCT01007695||131018|
NCT01007981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1124400|A Novel Echocardiography Modality to Assess Left Ventricular Dyssynchrony|A Novel Echocardiography Modality to Assess Left Ventricular Dyssynchrony: Hemodynamic Assessment by 4D Segmental Ejection Fraction||University of Missouri-Columbia|No|Withdrawn|November 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients followed in cardiology clinic will be included.|January 2013|January 24, 2013|November 4, 2009||No|investigator left the institution|No||https://clinicaltrials.gov/show/NCT01007981||130997|
NCT00977613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-07|Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients|Prospective Evaluation of Adherence to Recommended Activity Regimen in Patients Following Treatment of Stages II and III Colorectal Cancer.||Beth Israel Medical Center|No|Completed|April 2007|May 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment|1||Actual|50|||Both|N/A|N/A|No|||March 2011|March 1, 2011|September 15, 2009||No||No|November 30, 2010|https://clinicaltrials.gov/show/NCT00977613||133304|Many participants were lost to follow-up. Some participants had not been followed for at least 6 months at study termination.
NCT01008306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-07245b|Cardiovascular Risk Factors After Renal Transplantation in Children and Adults|Outcome After Pediatric Renal Transplantation: Cardiorespiratory Fitness, Cardiovascular Risk Factors and Quality of Life|HENT|Oslo University Hospital|No|Active, not recruiting|June 2007|||June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|60|Samples Without DNA|Freezing of serum and plasma from study participants|Both|2 Years|38 Years|No|Non-Probability Sample|Renal transplanted children, adolescents and young adults transplanted in the period        1983-2006 in the same center (Oslo University Hospital, Rikshospitalet)|November 2009|November 4, 2009|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01008306||130972|
NCT01008878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-003|Treatment of the Metabolic Syndrome in an Interdisciplinary Obesity Clinic: a Randomized Controlled Study|Treatment of the Metabolic Syndrome in an Interdisciplinary Obesity Clinic: a Randomized Controlled Study||Université de Sherbrooke|No|Completed|March 2004|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||60|||Both|18 Years|N/A|No|||November 2009|November 5, 2009|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008878||130928|
NCT01009112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1NR011728-01|Treating Insomnia & Nightmares After Trauma: Impact on Symptoms & Quality of Life|Treating Insomnia & Nightmares After Trauma: Impact on Symptoms & Quality of Life||University of California, San Diego|No|Completed|January 2010|November 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009112||130910|
NCT01009125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMC-2009-40|Healthcare Access and Utilization Among Living Kidney Donors|Randomized Trial of Financial Incentives to Increase Response Rates to a Mailed Survey of Healthcare Access and Utilization Among Living Kidney Donors||St. Barnabas Medical Center|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|N/A|No|||June 2010|June 8, 2010|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009125||130909|
NCT01009086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016315|A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis||Janssen Research & Development, LLC|Yes|Completed|December 2009|May 2013|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|615|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|November 5, 2009|Yes|Yes||No|October 11, 2013|https://clinicaltrials.gov/show/NCT01009086||130912|
NCT01009099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F6955-R|Reducing Dynamic Hyperinflation Through Breathing Retraining|Reducing Dynamic Hyperinflation Through Breathing Retraining||VA Office of Research and Development|Yes|Completed|July 2009|January 2015|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|21 Years|85 Years|No|||February 2015|February 2, 2015|November 5, 2009||No||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01009099||130911|
NCT01005342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCROS07|Influence of Dietary Fiber-rich Meals on Gene Expression and Postprandial Glucose and Lipid Response|The Influence of Dietary Fibre-rich Meals on Gene Expression in Leukocytes and Postprandial Glucose and Lipid Response in Healthy Subjects||Lund University|No|Completed|May 2007|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|6||Actual|18|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 29, 2009|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005342||131198|
NCT01005615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00014481|Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury|Advanced Restoration Therapies in Spinal Cord Injury. AIM1: Patterned FES Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Recruiting|September 2009|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||February 2016|February 22, 2016|October 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01005615||131177|
NCT01005927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTC Study|Fructooligosaccharide and Calcium Absorption in Adolescent Girls|Fructooligosaccharide and Calcium Absorption in Adolescent Girls||Purdue University|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|26|||Female|10 Years|12 Years|Accepts Healthy Volunteers|||July 2010|July 27, 2010|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005927||131153|
NCT01006473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq402024/2005-2|Exercise Training in Chagas Cardiomyopathy|A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy||Federal University of Minas Gerais|Yes|Completed|March 2007|March 2009|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|30 Years|65 Years|No|||August 2015|August 10, 2015|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006473||131111|
NCT00992810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0451-B|Medial Versus Lateral Approach in Ultrasound (US)-Guided Supraclavicular Block|Medial vs. Lateral Approach to Ultrasound-Guided Supraclavicular Block: A Prospective Randomized Controlled Trial||University Health Network, Toronto|No|Recruiting|August 2009|September 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|80 Years|No|||January 2010|January 22, 2010|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992810||132154|
NCT00992836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1088|Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth|A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Perinatally Infected Children and Youth||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|155|||Both|4 Years|25 Years|No|||December 2014|December 2, 2014|October 8, 2009|Yes|Yes||No|August 23, 2011|https://clinicaltrials.gov/show/NCT00992836||132152|
NCT00993096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3539|Investigation of the Response Relationship of NN5401 in Type 1 Diabetics|A Trial Investigating the Pharmacodynamic Response of NN5401 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|33|||Both|18 Years|65 Years|No|||June 2014|June 25, 2014|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00993096||132132|
NCT00993109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14511|Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension|Randomized,Open-label,Parallel Design Comparator Study of Effect of Nifedipine GITS/OROS (Adalat) 30 mg in Combination With Valsartan (Diovan) 80 mg Compared to Valsartan (Diovan) 160 mg Monotherapy in Patients Whose Blood Pressure is Not Well Controlled by Valsartan 80 mg Alone||Bayer|No|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|75 Years|No|||June 2014|June 4, 2014|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993109||132131|
NCT00993356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUFAH200401A|Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas|A Prospective, Randomized Trial of Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2004|December 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|80 Years|No|||October 2009|October 9, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993356||132112|
NCT00993369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00018811|Heart Rate Variability in Children Conceived Via Assisted Reproductive Technologies|Heart Rate Variability in Children Conceived Via Assisted Reproductive Technologies|HRV ART|University of Utah|No|Recruiting|July 2006|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|1 Day|Accepts Healthy Volunteers|Non-Probability Sample|Fetus and newborns.|June 2012|June 4, 2012|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00993369||132111|
NCT00993629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7064-W|Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans|Adjunctive Pregnenolone in PTSD and Depression in OEF/OIF Veterans||VA Office of Research and Development|Yes|Withdrawn|January 2010|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|October 7, 2009|No|Yes|PI turned down funding.|No||https://clinicaltrials.gov/show/NCT00993629||132091|
NCT00994019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2422|Study of Oral Papillomavirus In Teens and Twenties|Short-term Natural History of Oral HPV Infection Among Young Adults|SPITT|Johns Hopkins Bloomberg School of Public Health|No|Completed|January 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|550|||Both|18 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|High risk young adults|January 2015|March 30, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994019||132061|
NCT00994331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-CLIN-011|Stereotaxis Computed Tomography (CT) Co-Registration Study|Randomized Feasibility Study Comparing the Clinical Utility of the Stereotaxis Navigant™ Computed Tomography Angiography Importation and Co- Registration Feature, the NaviView™ Assisted Navigation Feature, and Standard Angiography||Stereotaxis|No|Terminated|October 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|80 Years|No|||March 2011|March 8, 2011|October 9, 2009||No|Study terminated due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT00994331||132037|
NCT00994305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACTX|Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant|Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant|NACTX|University of Sao Paulo General Hospital|Yes|Active, not recruiting|April 2005|December 2009|Anticipated|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|74|||Both|18 Years|N/A|No|||October 2009|October 13, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00994305||132039|
NCT00994318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-CKD-01|Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)|An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High and Low Dosage Regimens) Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease|FIND-CKD|Vifor Inc.|Yes|Completed|December 2009|February 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|626|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|October 12, 2009||No||No|April 4, 2014|https://clinicaltrials.gov/show/NCT00994318||132038|Initially 1,016 subjects were planned, but due to slow enrollment only 626 were randomised which was sufficient to make the primary comparison between FCM targeting high ferritin level and oral iron.
NCT00994565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoAct1RCT|The Effectiveness of Physical Activity Monitoring and Distance Counseling in an Occupational Health Setting|The Effectiveness of Physical Activity Monitoring and Distance Counselling in an Occupational Health Setting - a Randomised Controlled Trial (CoAct)|CoAct|Helsinki University of Technology|No|Completed|August 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|544|||Both|18 Years|61 Years|No|||June 2011|June 21, 2011|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994565||132019|
NCT01007994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-054|Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients|Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients||Northwell Health|No|Recruiting|November 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|5 Years|21 Years|No|||November 2015|November 6, 2015|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01007994||130996|
NCT01008319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2078|Traditional Clomiphene Citrate Administration vs. Stair-step Approach|Traditional Clomiphene Citrate Administration Versus a Stair-Step Approach: A Randomized Controlled Trial|Clomid|University of Oklahoma|Yes|Recruiting|October 2009|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|45 Years|No|||December 2014|December 2, 2014|November 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008319||130971|
NCT01008579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01655|Assessing Patient Care Through Routine Use of Patient-Reported Outcomes|Routine Use of Patient Reported Outcomes Among Older Adults at High Risk of Falls: A 12-Month Cohort Study||University of British Columbia|No|Recruiting|December 2009|January 2015|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|340|||Both|60 Years|N/A|No|Non-Probability Sample|Falls Prevention Clinic|September 2014|September 8, 2014|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008579||130951|
NCT01008891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTI-2009-01|Augment™ Injectable Bone Graft Compared to Autologous Bone Graft in Foot and Ankle Fusions|Prospective, Randomized, Controlled, Multi-Center, Pivotal Clinical Trial to Evaluate the Safety and Effectiveness of Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions||BioMimetic Therapeutics|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008891||130927|
NCT01009138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKZ 01GI0809|Evaluation of a Diabetes-specific Cognitive Behavioural Treatment for Subthreshold Depression|Development and Evaluation of a Diabetes-specific Cognitive Behavioural Treatment (DS-CBT) for Diabetic Patients With Subthreshold Depression||Forschungsinstitut der Diabetes Akademie Mergentheim|Yes|Completed|November 2009|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|November 5, 2009||No||No|August 14, 2015|https://clinicaltrials.gov/show/NCT01009138||130908|
NCT01009424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22131|A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease|A Multi-center, Placebo-controlled, Double Blind Multiple-ascending Dose Study in a Leapfrog Design to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of RO5024118 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease||Hoffmann-La Roche||Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|12|||Both|40 Years|70 Years|No|||May 2013|May 7, 2013|November 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009424||130887|
NCT01005355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13898|Study of IMC-1121B in Patients With Advanced Solid Tumors|Phase 1 Study of IMC-1121B in Patients With Advanced Solid Tumors||Eli Lilly and Company|Yes|Completed|September 2009|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||May 2014|May 16, 2014|October 5, 2009|No|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01005355||131197|
NCT01006200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1411B|Factors to Obstructive Granulation Tissue Formation After Ultraflex Stenting in Benign Tracheal Narrowing|Factors to Obstructive Granulation Tissue Formation After Ultraflex Stenting in Benign Tracheal Narrowing||Chang Gung Memorial Hospital|Yes|Completed|August 2001|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with benign tracheal stenosis who underwent endoscopic tracheal stent placements        at the Chang Gung Memorial Hospital, a university-affiliated hospital in Northern Taiwan,        were evaluated.        Chest surgeon were routinely consulted to evaluate feasibility of silicon stent placement        in benign airway obstruction. All patients in our study were those unsuitable to receive        silicon stent placement.|October 2009|October 30, 2009|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01006200||131132|
NCT01006486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COEP376/09|Outcomes of an Anticoagulation Clinic in an University Hospital|Evaluation of Impact of the Implantation of an Anticoagulation Clinic in an University Hospital in Brazil||Federal University of Minas Gerais|No|Completed|November 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|280|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006486||131110|
NCT00993122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ribavirin Pre-treatment|Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients|Phase 2 Randomized Multicenter Controlled Study of Ribavirin Pre-treatment (8 Weeks) Followed by Standard Therapy With Ribavirin and Pegylated Interferon (48 Weeks) in Transplanted Patients With Recurrence of Chronic Hepatitis C|RBV|University of Roma La Sapienza|Yes|Completed|October 2009|February 2012|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|65 Years|No|||June 2015|June 19, 2015|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00993122||132130|
NCT00993434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2009-1162|The Impact of Educational Materials on Family Behavior|The Impact of Educational Materials on Family Behavior||University of Wisconsin, Madison|No|Completed|October 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|95|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||November 2012|September 30, 2015|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00993434||132106|
NCT00993447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD13|Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America|Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America||Sanofi|Yes|Completed|October 2009|March 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|600|||Both|9 Years|16 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|October 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993447||132105|
NCT00993642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BUS46T|ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer|Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer||Tulane University Health Sciences Center|No|Terminated|September 2009|December 2010|Actual|September 2010|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Female|18 Years|N/A|No|||September 2009|July 20, 2011|October 9, 2009|No|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT00993642||132090|
NCT00993655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OV21|Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy||Canadian Cancer Trials Group|Yes|Active, not recruiting|September 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|275|||Female|18 Years|N/A|No|||May 2015|March 22, 2016|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993655||132089|
NCT00994032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPB-VP|Quality of Life After Vertebroplasty Versus Conservative Treatment in Patients With Painful Osteoporotic Vertebral Fractures|Analysis of the Impact in the Quality of Life of Patients With Pain Secondary to Osteoporotic Vertebral Fractures Receiving Conservative Treatment Versus Percutaneous Vertebroplasty||Hospital Clinic of Barcelona|No|Active, not recruiting|March 2006|June 2010|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2009|October 13, 2009|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994032||132060|
NCT00993668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0017|Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines|A Phase 4, Randomized, Single-blind, Placebo-controlled, Multicenter Study to Evaluate the Immunogenicity of Pneumococcal and Influenza Vaccines in Adult Subjects With Rheumatoid Arthritis Receiving Certolizumab Pegol or Placebo||UCB Pharma|No|Completed|September 2009|February 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|October 9, 2009|Yes|Yes||No|May 23, 2011|https://clinicaltrials.gov/show/NCT00993668||132088|
NCT00994045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIB692|Fibrinogen as an Alternative to FFP in Aortic Surgery.|Coagulopathy During Surgery for the Repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - Feasibility Study of the Use of Fibrinogen Concentrate by Infusion in Place of Fresh Frozen Plasma.||University of Edinburgh|No|Recruiting|June 2010|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994045||132059|
NCT00994578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013032|Intervention Study of Communication in Oncologist-Patient Encounters|The COPE Trial: Communication in Oncologist-Patient Encounters|COPE|Duke University|No|Completed|November 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|659|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 11, 2014|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00994578||132018|
NCT00994877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34/09|Thromboelastography in in Patients With Sepsis|Thromboelastography in Patients Admitted to the ICU for Severe Sepsis||Assaf-Harofeh Medical Center|No|Recruiting|March 2009|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients With sepsis or septic shock admitted to ICU|October 2009|October 13, 2009|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00994877||131995|
NCT01007734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RFR-DUM-2009/1|Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients|Factors Determining Quality of Life Related to Respiratory Status According to Gender of COPD Patients Followed by a Pneumologist|VITALITE|AstraZeneca|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|449|||Both|18 Years|N/A|No|Probability Sample|First 3 consecutive adults with COPD with at least a three month follow up, seen by        pneumologist|July 2010|July 26, 2010|October 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01007734||131015|
NCT01007747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 21033|EPT 100: Geranium Oil for the Relief of Neuropathic Pain|EPT 100: Geranium Oil for the Relief of Neuropathic Pain|Geranium Oil|Pennington Biomedical Research Center|No|Completed|November 2008|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|166|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007747||131014|
NCT01008007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0911-CU|Viusid in Adults With Acute Fever of Viral Etiology|Effect of VIUSID Administration on Adults With Acute Fever of Viral Etiology||Catalysis SL|Yes|Completed|September 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||May 2010|May 17, 2010|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01008007||130995|
NCT01008020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2009002|Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection|A Randomized Controlled Study on the Effects of Tea Catechin Consumption on the Prevention of Influenza Infection in Healthy Adults||University of Shizuoka|No|Completed|November 2009|October 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||July 2013|July 14, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01008020||130994|
NCT01008592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTS# 33519|The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism|The Effect of Levocetirizine (Xyzal®) on the Skin Levels of Inflammatory Mediators Histamine, Serine Proteases, Prostaglandin E2, Leukotriene B4 and Cathepsins in Patients With Symptomatic Dermatographism and Chronic Idiopathic Urticaria||Wake Forest School of Medicine|No|Terminated|April 2009|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|11|||Both|18 Years|60 Years|No|Non-Probability Sample|Study subjects will be adult patients with dermatographism and chronic idiopathic        urticaria from the Wake Forest University Health Sciences Dermatology Clinic population        and patients recruited via appropriate IRB-approved advertising. Subjects will show        definitive clinical findings compatible with dermatographism and chronic idiopathic        urticaria as assessed by one of the investigators. Twenty subjects with dermatographism        and chronic idiopathic urticaria will be recruited. Eligible subjects will include adult        men and women 18 to 60 years of age with chronic disease.|November 2009|August 8, 2012|November 5, 2009||No|Mediators of interest were not consistently detectable with the analytical methods employed.|No||https://clinicaltrials.gov/show/NCT01008592||130950|
NCT01008605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6711035|Caverject User Study|Representative Users Study Of Operating Characteristics Of The Caverject Delivery System.||Pfizer|No|Completed|February 2011|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|48|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|November 5, 2009|No|Yes||No|February 28, 2012|https://clinicaltrials.gov/show/NCT01008605||130949|
NCT01008904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12062|Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer|A Pilot Phase II Trial of Magnesium Supplements to Reduce Menopausal Hot Flashes in Cancer Patients||Virginia Commonwealth University|Yes|Completed|July 2009|March 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|31|||Female|18 Years|N/A|No|||December 2013|December 17, 2013|November 5, 2009|Yes|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT01008904||130926|
NCT01005368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-20203|Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia|Molecular Markers Of Chronic Lymphocytic Leukemia||Alliance for Clinical Trials in Oncology|No|Suspended|October 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|600|Samples With DNA|blood and bone marrow samples|Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with chronic lymphocytic leukemia and were previously untreated. The        patients must have also previously enrolled on a Cancer and Leukemia Group B protocol.|July 2015|July 9, 2015|October 29, 2009||No|Trial suspension due to NCI NCTN transition.|No||https://clinicaltrials.gov/show/NCT01005368||131196|
NCT01009437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008NTLS083|Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer|A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|May 2010|December 2016|Anticipated|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|52|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|November 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01009437||130886|
NCT01005940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0131|Dental Device for Treatment of Sleep Apnea|Health Outcomes of Treatment of Obstructive Sleep Apnea With Dental Devices|OSA-MAD|Ohio State University|Yes|Active, not recruiting|January 2010|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005940||131152|
NCT00977236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-RP3M|Myopic Control for High Myopes Using Orthokeratology|High Myopia - Partial Reduction Orthokeratology Study|HM-PRO|The Hong Kong Polytechnic University|No|Completed|July 2008|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00977236||133332|
NCT00993733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008019|Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care|Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care||Centre Hospitalier Universitaire de Saint Etienne|No|Withdrawn|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|N/A|N/A|No|||March 2016|March 22, 2016|October 9, 2009||No|This study has never been started|No||https://clinicaltrials.gov/show/NCT00993733||132083|
NCT00994084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26490-1|Healthy Kids-Houston: A Community Childhood Obesity Intervention Program|Healthy Kids-Houston: An Integrated Community Program for the Prevention of Obesity Among Minority Children|HKH|Baylor College of Medicine|No|Completed|September 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1094|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994084||132056|
NCT00994097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR014|NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer|NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||MolMed S.p.A.|No|Active, not recruiting|July 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994097||132055|
NCT00993408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-304/-02|Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)|A Multi-centre, Multinational, Open-label, Single-dose Acute Hemodynamic Study Followed by Multi-centre, Multinational, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy (Proof-of-concept) of ACT-293987 (NS-304) in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over||Actelion|Yes|Completed|April 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|1||Actual|43|||Both|18 Years|N/A|No|||October 2009|October 9, 2009|October 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00993408||132108|
NCT00993421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11892|A Weight Loss Study in Overweight Men and Women|LY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women||Eli Lilly and Company|Yes|Terminated|October 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|343|||Both|21 Years|65 Years|No|||June 2011|June 2, 2011|October 9, 2009|Yes|Yes|Clinical trial terminated due to results from recent nonclinical studies|No|May 11, 2011|https://clinicaltrials.gov/show/NCT00993421||132107|
NCT00993681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELT301|Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study|A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System||Intercell USA, Inc.|Yes|Completed|October 2009|April 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2036|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00993681||132087|
NCT00993694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000652603|Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone|Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia||National Cancer Institute (NCI)||Completed|January 2009|||December 2009|Actual|N/A|Observational|N/A|||Anticipated|200|||Both|N/A|18 Years|No|||December 2009|November 4, 2010|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993694||132086|
NCT00994357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENSOR-01|The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes|The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes: a Randomised Controlled Study||University of Copenhagen|No|Completed|February 2009|May 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Female|18 Years|N/A|No|||May 2012|May 8, 2012|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994357||132035|
NCT00994344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOPIDAR|Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens|Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens||Germans Trias i Pujol Hospital|No|Completed|October 2009|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||February 2014|February 12, 2014|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994344||132036|
NCT00994591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03693|Cotinine Metabolism in Infants and Children|Cotinine Metabolism in Infants and Children|1058|University of California, San Francisco|No|Completed|January 2007|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|56|||Both|2 Months|72 Months|Accepts Healthy Volunteers|||May 2013|May 23, 2013|October 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00994591||132017|
NCT00994604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-001|The Effects of Broccoli Sprout Extract on Obstructive Lung Disease|||Johns Hopkins University||Completed|October 2009|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|October 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994604||132016|
NCT01008358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-2007-01|Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma|Phase II Trial of Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|December 2008|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01008358||130968|
NCT01008371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19449|Investigation of Neuro-hormonal Mechanisms of Hunger, Fullness and Obesity.|CCK-dysregulation: Mechanisms of Abnormal Food Regulation and Obesity||Medical University of South Carolina|No|Withdrawn|October 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample, patients of a weight management clinic and patients of Medical        University of South Carolina|July 2010|May 21, 2013|November 3, 2009||No|No recruitment|No||https://clinicaltrials.gov/show/NCT01008371||130967|
NCT00990795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYCLO1|Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery|A Randomized Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery|CYCLO1|The University of Texas Health Science Center, Houston|No|Terminated|April 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|No|||November 2010|November 1, 2010|October 5, 2009||No|PI left institution.|No||https://clinicaltrials.gov/show/NCT00990795||132309|
NCT00998816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE 153-09|The Effect of Perioperative Pregabalin on the Incidence of Chronic Post-thoracotomy Pain Syndrome|A Multicenter Prospective Randomized Double-blind Placebo Controlled Trial Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome||Queen's University|No|Withdrawn|May 2012|October 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|75 Years|No|||April 2012|April 10, 2012|October 20, 2009|No|Yes|No funding|No||https://clinicaltrials.gov/show/NCT00998816||131695|
NCT00998829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-4611|Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis|An Australian Cross-Sectional Epidemiological Study To Evaluate The Prevalence Of Undiagnosed Psoriatic Arthritis In Psoriasis Patients In Dermatology Practice Focusing On Disease Severity, Disease Burden And Quality Of Life||Pfizer|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|458|||Both|18 Years|N/A|No|Probability Sample|Specialist dermatology clinics|November 2012|November 28, 2012|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00998829||131694|
NCT00999115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC08/00153|Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA)|Clinical Trial in Phase I-IIa to Study the Feasibility and Security of the Allogenic Use of Adipose-derived Stem Cells for the Local Treatment of Recto-vaginal Fistula in Crohn´s Disease|ALOREVA|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|No|Completed|September 2009|December 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||January 2012|January 25, 2012|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999115||131672|
NCT00997776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANGIONE-LEG STRENGTH 2006|Effect of Leg Strengthening Exercise After Hip Fracture|Effect of Leg Strengthening Exercise After Hip Fracture||Arcadia University|No|Completed|August 2002|June 2006|Actual|January 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|65 Years|N/A|No|||October 2009|October 18, 2009|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00997776||131774|
NCT00999518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091035|A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome|A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS)||Pfizer|Yes|Terminated|January 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|222|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|October 20, 2009|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT00999518||131641|
NCT01000272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-YS-439-CTIL|Respiratory Tract Inflammation in Children With Inflammatory Bowel Disease (IBD)|Pulmonary Inflammation in Children With Inflammatory Bowel Disease as Expressed by the Fraction of Exhaled Nitric Oxide Levels and Spirometry||Tel-Aviv Sourasky Medical Center|No|Completed|December 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|45|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|pediatric patients with IBD addmited to the pediatric ward due to exacerbations and        children with IBD who come for routine visit to the pediatric gastroenterology clinic at        the "DANA" Hospital for Childrens, at the Sourasky Medical Center, Tel-Aviv|October 2009|June 25, 2014|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01000272||131584|
NCT01005667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBT1600|Study to Determine if Monitoring of Labor Shortens the Time to Delivery|Management of Labor Using the BirthTrack Computerized Labor Monitoring System|BirthTrack|Barnev, Inc.|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|N/A|No|||October 2009|June 22, 2011|October 30, 2009||No|Lack of funding for the company has resulted in termination of the study.|No||https://clinicaltrials.gov/show/NCT01005667||131173|
NCT01005680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12878|A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer|A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.||Eli Lilly and Company|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|October 29, 2009|Yes|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT01005680||131172|
NCT01005966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3508605|In Situ Caries Model of Fluoride Toothpastes|Clinical Efficacy of Fluoride Toothpastes Using an in Situ Caries Model||GlaxoSmithKline|No|Completed|November 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|65|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|June 20, 2013|October 15, 2009|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT01005966||131150|
NCT01006239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-5261|The Biorepository for Scripps Health|The Biorepository for Scripps Health|BIF|Scripps Translational Science Institute|No|Active, not recruiting|November 2009|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|We will be collecting solid tumor and adjacent non-diseased tissue from patients undergoing      surgical resection of a solid tumor.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects over the age of 18 undergoing surgical resection of solid tumor.|April 2015|April 1, 2015|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01006239||131129|
NCT01007019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCD142 (YH4808-101)|Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects|A Dose-block Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and PKs/PDs of YH4808 After Oral Administration in Healthy Male Subjects||Yuhan Corporation|Yes|Completed|November 2009|March 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|12||Actual|134|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007019||131070|
NCT01007032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13905|A Study of IMC-A12 in Advanced Solid Tumors|A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-A12 Administered Every 2 Weeks or Every 3 Weeks to Japanese Patients With Advanced Solid Tumors||Eli Lilly and Company|Yes|Completed|November 2009|April 2015|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|N/A|No|||May 2015|May 8, 2015|November 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01007032||131069|
NCT01007045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMED-123-09|Limited Compression Ultrasound by Emergency Physicians to Exclude Deep Vein Thrombosis|Can Emergency Physicians Safely Exclude Proximal Deep Vein Thrombosis Using Limited Compression Emergency Department Ultrasound?||Queen's University|No|Completed|November 2009|June 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|227|||Both|16 Years|N/A|No|Non-Probability Sample|emergency patients suspected of deep vein thrombosis|June 2011|June 8, 2011|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007045||131068|
NCT00988221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA19977|A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis|A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis||Hoffmann-La Roche||Completed|November 2009|January 2013|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|188|||Both|2 Years|17 Years|No|||July 2014|July 16, 2014|October 1, 2009|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT00988221||132507|
NCT00988468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L10-004|Manual Therapy Versus Exercise on Knee Osteoarthritis|Effects of Manual Therapy Versus Therapeutic Exercise on Knee Osteoarthritis: A Randomized Control Trial||Texas Tech University Health Sciences Center|No|Terminated|October 2009|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||November 2010|November 15, 2010|September 30, 2009||No|Study failed to recruit a sufficient number of subjects in the time anticipated.|No||https://clinicaltrials.gov/show/NCT00988468||132488|
NCT00988481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200909-046|Topiramate Augmentation in Bulimia Nervosa Partial Responders|Topiramate Augmentation in Bulimia Nervosa Partial Responders||Neuropsychiatric Research Institute, Fargo, North Dakota|No|Withdrawn|September 2009|September 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|60 Years|No|||July 2015|July 13, 2015|October 1, 2009|Yes|Yes|Difficulty with enrollment.|No||https://clinicaltrials.gov/show/NCT00988481||132487|
NCT00988767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSERM RBM99.026|Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B|Specific Vaccine Therapy in Chronic Hepatitis B Using a Naked DNA: Phase I Study Using a GMO|RBM99026|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|February 2001|October 2004|Actual|November 2003|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|60 Years|No|||October 2009|October 2, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988767||132465|
NCT00988780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The CADIRIS Study|Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients|CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients|CADIRIS|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Active, not recruiting|December 2009|April 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|276|||Both|18 Years|N/A|No|||November 2012|November 22, 2012|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988780||132464|
NCT00988793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908-05|Laparoscopic Versus Open Pancreatectomy|Randomized Trial of Laparoscopic Versus Open Distal Pancreatectomy in Patients With Pancreatic Disease||Indiana University|Yes|Terminated||October 2021|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|89 Years|No|||March 2012|March 27, 2012|October 1, 2009||No|Protocol needed major revisions; lack of money to institute changes|No||https://clinicaltrials.gov/show/NCT00988793||132463|
NCT00989066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRA01|Brazil Xience V Everolimus-Eluting Coronary Stent System "Real-World" Outcomes Registry|Brazil Xience V Everolimus-Eluting Coronary Stent System "Real-World" Outcomes Registry|BRAVO|Cardiovascular Research Center, Brazil|Yes|Completed|September 2008|November 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|535|||Both|18 Years|N/A|No|Non-Probability Sample|Patients all comers assigned for percutaneous coronary intervention who present with at        least one angiographically documented coronary artery lesion suitable for percutaneous        treatment with implantation of Xience V|November 2012|November 26, 2012|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00989066||132442|
NCT00989079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-036|A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)|A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of PF-04971729 After Administration of Single Escalating Oral Doses Under Fed and Fasted Conditions in Healthy Volunteers||Merck Sharp & Dohme Corp.|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989079||132441|
NCT00989417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA041|Benefits of Implantable Cardioverter Defibrillator Follow-up Using Remote Monitoring|Effectiveness and Cost Of ICD Follow-up Schedule With Telecardiology|ECOST|Biotronik SE & Co. KG|Yes|Completed|January 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|473|||Both|18 Years|N/A|No|||May 2011|May 24, 2011|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989417||132415|
NCT00989677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL2568201508|Rheumatoid Arthritis Disease Activity Monitor|Rheumatoid Arthritis Disease Activity Monitor|RADAM|Maxima Medical Center|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|75|||Both|18 Years|N/A|No|Non-Probability Sample|The subject population will be patients visiting the Regionaal Reuma Centrum Eindhoven for        rheumatoid arthritis. Patient visiting this center will represent a cross section of RA        patients that are taken care of in an outpatient setting.|October 2009|October 2, 2009|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00989677||132395|
NCT00989924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906039R|Research on the Correlation Among Magnetocardiography Patterns and Known Cardiovascular Risk Factors in Diabetic Patients|Research on the Correlation Among Magnetocardiography Patterns and Known Cardiovascular Risk Factors in Diabetic Patients||National Taiwan University Hospital|Yes|Recruiting|October 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1100|||Both|18 Years|N/A|No|Non-Probability Sample|The Diabetic patient who receives follow-up at NTUH diabetics caring network|July 2010|August 12, 2010|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00989924||132376|
NCT00989911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Actelion - 1|Endothelin Blockade in Patients With Single Ventricle Physiology|Endothelin Blockade in Patients With Single Ventricle Physiology||University of California, Los Angeles|No|Completed|May 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|12 Years|N/A|No|||February 2015|February 9, 2015|October 5, 2009||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT00989911||132377|
NCT00989937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytocin Anxiety|Oxytocin Add-on Study for Stable Anxiety Patients|Double-Blind, Randomized, Placebo-Controlled, Cross-Over Pilot Study of Intranasal Oxytocin in Patients With Anxiety Disorder||University of California, San Diego|No|Active, not recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||June 2014|June 11, 2014|October 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989937||132375|
NCT00956332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGVS-MGA 002|Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia|Phase I/IIa Safety, Two-dose Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia||MultiGene Vascular Systems Ltd.|Yes|Active, not recruiting|February 2010|May 2026|Anticipated|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|50 Years|90 Years|No|||March 2015|March 4, 2015|August 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956332||134913|
NCT00996632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGiuricin|The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery|Randomized Controlled Study of Benefits of Ultrasonic Knife in Breast Cancer Surgery|UKBC|University of Trieste|No|Completed|September 2000|November 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|94|||Both|36 Years|95 Years|Accepts Healthy Volunteers|||November 2009|November 4, 2009|April 24, 2009||No||No|April 24, 2009|https://clinicaltrials.gov/show/NCT00996632||131862|
NCT00996645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-2006|Optimizing Audit and Feedback for Primary Care|Cluster Randomized Trial of a Goal-Setting Intervention With Performance Feedback Reports Regarding Diabetes and Coronary Artery Disease for Family Physicians in Ontario||Sunnybrook Health Sciences Centre|No|Completed|July 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|55|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996645||131861|
NCT00998023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|479-2009|Patient Comfort With Vascular Closure|Patient Comfort Study With Vascular Closure: Mynx vs. Angio-Seal Evolution||University of Florida|No|Completed|October 2009|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||November 2011|December 5, 2011|October 19, 2009||No||No|September 21, 2011|https://clinicaltrials.gov/show/NCT00998023||131755|The Angio-Seal Evolution is only one of a variety of potential vascular closure devices available on the market that would be suitable for comparison with the Mynx; however, this study was limited to just one of such alternative devices.
NCT00998036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD8279|Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors|Phase I Study of Combined Temosirolimus, Erlotinib and Cisplatin in Advanced Solid Tumors||Columbia University|Yes|Completed|September 2009|October 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|October 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00998036||131754|
NCT01008956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113924|Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults|Immunogenicity and Safety Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine GSK2340274A in Adults 18 to 64 Years of Age||GlaxoSmithKline||Withdrawn|April 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|November 5, 2009|Yes|Yes|Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|No||https://clinicaltrials.gov/show/NCT01008956||130922|
NCT00998283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-HM10460A-102|Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects|A Randomized, Double-Blind, Placebo-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Korean Subjects||Hanmi Pharmaceutical Company Limited|Yes|Completed|October 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|40|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00998283||131735|
NCT00999128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4740g|A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers|An Open-Label, Two-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers||Genentech, Inc.||Completed|October 2009|||February 2010|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 25, 2010|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00999128||131671|
NCT00999141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550901|Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy|A Randomized, Controlled Phase 3 Study to Evaluate Safety and Efficacy of Fibrin Sealant (FS) VH S/D 4 S-apr (ARTISS) to Adhere Tissues and Improve Wound Healing in Subjects Undergoing Rhytidectomy (Facelift)||Baxter Healthcare Corporation|No|Completed|September 2009|February 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 4, 2012|October 20, 2009|Yes|Yes||No|October 6, 2011|https://clinicaltrials.gov/show/NCT00999141||131670|
NCT01005394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-NE-002|Navigated Transcranial Magnetic Stimulation in Monitoring Stroke Recovery|Acute Longitudinal Transcranial Magnetic Stimulation (TMS) After Stroke||Nexstim Ltd|Yes|Terminated|October 2009|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients aged 20-80 years who have suffered a unilateral ischemic stroke and who will        undergo motor rehabilitation at the study center will be asked to participate in the        study.|April 2015|April 15, 2015|October 30, 2009|No|Yes|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01005394||131194|
NCT01006265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058B201|ACT-128800 in Relapsing-remitting Multiple Sclerosis|Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis||Actelion|Yes|Completed|October 2009|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|464|||Both|18 Years|55 Years|No|||September 2012|September 27, 2012|October 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01006265||131127|
NCT01006018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015390|DPP-4 Inhibition and TZD for DM Prevention|DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)|DInT DM|Emory University|No|Terminated|July 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|October 27, 2009|Yes|Yes|Unanticipated delays due to sterilization/stabilization testing of GLP-1.|No|March 14, 2013|https://clinicaltrials.gov/show/NCT01006018||131146|
NCT01006278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cyt.002|Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee|Molecular Biomarkers Associated With Degenerative Joint Disease||Scuderi, Gaetano J., M.D.|Yes|Completed|January 2008|March 2009|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|synovial fluid ananysis|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The operative group consisted of patients 18 years of age or greater with a history of        knee pain for more than three but less than six months who failed conservative management        including NSAIDs, physical therapy, and activity modification.|October 2009|October 30, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006278||131126|
NCT01006525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017355|Safety and Efficacy of Chronic Hypnotic Use|Abuse Liability Associated With Chronic Hypnotic Use||Henry Ford Health System|Yes|Completed|December 2005|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|Samples Without DNA|urine and saliva|Both|21 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Primary insomniacs meeting DSM-IV criteria, ages 23-70 yrs. old, were recruited from        public advisement for a double-blind placebo controlled study. Participants were in good        general health as determined by a physical exam and laboratory tests. The Structured        Clinical Interview for DSM Disorders (SCID) and the Hamilton Depression Scale were used to        exclude those with psychiatric disorders, drug, and alcohol dependence. To confirm the        absence of illicit drugs, participants underwent a urine drug screen. Additionally,        participants had a screening sleep efficiency of <85% on an 8-hr nocturnal polysomnogram        (NPSG) and had no primary sleep disorders. Pregnant or lactating females were excluded        from study participation.|November 2011|November 4, 2011|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006525||131108|
NCT01006772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHILIPROWE1|Rehabilitation of Early Stroke Patients Using an AFO: an RCT|Rehabilitation of Early Stroke Patients Using a Custom-made Solid Ankle-foot Orthosis: a Randomised Controlled Trial||University of Strathclyde|No|Recruiting|January 2010|September 2011|Anticipated|April 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|90 Years|No|||November 2009|January 11, 2010|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006772||131089|
NCT01007058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAB05-0326|Markers of Response to Intravesical Bladder Cancer Therapy|Markers of Response to Intravesical Bladder Cancer Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2009|||August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|4 tablespoons of urine and a bladder wash sample during catheterization (for planned      treatment) or during routine cystoscopic exam, both samples at 4 different time points      before, during and after therapy courses.|Both|18 Years|N/A|No|Non-Probability Sample|Bladder cancer patients, 18 years or older, who will be receiving treatment with BCG or        BCG + Interferon at UT MD Anderson Cancer Center.|December 2015|December 2, 2015|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007058||131067|
NCT01007071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10022009-4140|Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults|Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults||Stanford University||Recruiting|November 2009|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|65 Years|No|||November 2009|November 2, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01007071||131066|
NCT01007084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1391|TRAUMA HELP: Healing and Analgesia With Propranolol|Phase IIB Study: TRAUMA HELP: Healing and Analgesia With Propranolol|TRAUMA_HELP|University of North Carolina, Chapel Hill|Yes|Withdrawn|October 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||December 2011|December 7, 2011|November 2, 2009|Yes|Yes|Lack of eligible patient recruits/feasibility considerations.|No||https://clinicaltrials.gov/show/NCT01007084||131065|
NCT00958828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-337-C-028|Clinical Evaluation of Two Daily Disposable Lenses in a Population of Daily Disposable (DD) Lens Wearers|Clinical Evaluation of Two Daily Disposable Lenses in a Population of Daily Disposable (DD) Lens Wearers||Alcon Research|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|178|||Both|N/A|N/A|No|||January 2012|June 26, 2012|August 11, 2009|Yes|Yes||No|September 23, 2010|https://clinicaltrials.gov/show/NCT00958828||134724|
NCT00959127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-162-111|A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer|||Array BioPharma|No|Completed|August 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|August 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959127||134701|
NCT00988494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01050807|Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect|Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect||Santen Pharmaceutical Co., Ltd.||Completed|September 2009|||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|12 Years|N/A|No|||November 2012|November 21, 2012|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT00988494||132486|
NCT00988507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI10382|Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|Parallel Group, Double-blind, Randomized Study Assessing the Efficacy, Safety and Pharmacokinetic Profiles of Ferroquine Associated With Artesunate and a Single-blind Dose Level of Ferroquine Alone in a 3-day Treatment of Uncomplicated Malaria Due to Plasmodium Falciparum in an Immune Symptomatic African Adult and Pediatric Population.|FARM|Sanofi|Yes|Terminated|October 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|440|||Both|N/A|N/A|No|||June 2011|June 27, 2011|October 1, 2009|Yes|Yes|Company decision to modify the ferroquine development strategy; discontinuation not due to    safety or activity unexpected findings|No||https://clinicaltrials.gov/show/NCT00988507||132485|
NCT00988520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05977|Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)|Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 Following a Single Intubating Dose in Adult Patients Undergoing Operation Under Sevoflurane or Propofol Anesthesia.||Merck Sharp & Dohme Corp.|Yes|Completed|May 2003|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|38|||Both|20 Years|64 Years|No|||May 2015|May 11, 2015|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00988520||132484|
NCT00988806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAICA Study 2009|Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure|Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure|LAICA|Hospital Universitario de Canarias|No|Enrolling by invitation|November 2009|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|213|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00988806||132462|
NCT00989092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20000219|Darbepoetin Alfa and Anemia of Cancer|A Randomized, Open-label, Comparative Study to Estimate the Effect of Darbepoetin Alfa on Hospital Days, Economic Outcomes, and Health-related Quality of Life in Subjects With Nonmyeloid Malignancies and Anemia of Cancer||Amgen||Terminated|May 2002|June 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|287|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|October 1, 2009||Yes|slow enrollment and change in product development strategy|No|September 3, 2010|https://clinicaltrials.gov/show/NCT00989092||132440|
NCT00960219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC-97-2314-B-039-006-MY3|D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia|D-amino Acid Oxidase Inhibition for NMDA Modulation in Schizophrenia||China Medical University Hospital|Yes|Completed|April 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|65 Years|No|||July 2011|July 7, 2011|August 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00960219||134618|
NCT00955773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112110|A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects|An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors|Cancer|GlaxoSmithKline|No|Completed|August 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|August 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955773||134956|
NCT00955786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C3-05-001|Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas|A Phase I, Multicenter, Open-label, Dose-Escalation, Safety and Tolerance, and Pharmacokinetic Study of Intravenously Administered CX-3543,on a Daily x 5, Repeated Every 3 Weeks Schedule, in Patients With Advanced Solid Tumors or Lymphomas||Cylene Pharmaceuticals|No|Completed|July 2005|December 2008|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||August 2009|August 7, 2009|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955786||134955|
NCT00990223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141115|Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity|A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo-Controlled Trial To Evaluate The Effects Of 100 MG Once Daily Of Eplerenone On Serum Aldesterone And Plasma Renin Activity During 10 Days Of Dosing In Healthy Volunteers||Pfizer|No|Completed|October 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 16, 2011|October 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00990223||132353|
NCT00956345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7999-3639|Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B|A Multi-Centre, Multi-National, Open-Label, Dose Escalation Trial Evaluating Safety and Pharmacokinetics of Ascending Intravenous Doses of 40K Pegylated Recombinant FIX in Non-Bleeding Patients With Haemophilia B.||Novo Nordisk A/S|No|Completed|August 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|65 Years|No|||June 2012|July 4, 2012|August 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956345||134912|
NCT00956683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-006|Dual Endpoint Nerve Stimulation Versus Ultrasound in Infraclavicular Block for Hand Surgery|A Randomized Controlled Study Comparing Dual Endpoint Nerve Stimulation With Ultrasound-guided Infraclavicular Block for Hand Surgery.||University Health Network, Toronto|No|Completed|January 2006|December 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|80 Years|No|||August 2009|August 10, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00956683||134886|
NCT00997503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H7T-MC-TADN|TAXUS Libertē Post Approval Study|TAXUS Libertē Post Approval Study: A U.S. Post-Approval Study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System||Boston Scientific Corporation|Yes|Completed|December 2009|July 2015|Actual|March 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4199|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers study with follow-up through 3 years.|March 2015|July 20, 2015|October 15, 2009|Yes|Yes||No|March 13, 2014|https://clinicaltrials.gov/show/NCT00997503||131795|
NCT01009203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST OSI4641s|Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma|A Phase II Study of Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck||New Mexico Cancer Care Alliance|Yes|Terminated|December 2009|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|November 5, 2009|Yes|Yes|High patient withdrawal rate|No|June 15, 2015|https://clinicaltrials.gov/show/NCT01009203||130904|
NCT00999154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090238|Diet-Induced-Obesity Resistant Phenotypes in Humans|Diet-Induced-Obesity Resistant Phenotypes in Humans||National Institutes of Health Clinical Center (CC)||Terminated|September 2009|October 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|9|||Both|25 Years|50 Years|No|||October 2012|February 19, 2014|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999154||131669|
NCT01009476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011689|Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine|Non-interventional Study on Long-term Application of Galantamine and Nootropics in Patients With Alzheimer's Disease||Janssen-Cilag G.m.b.H|No|Completed|March 2006|August 2008|Actual|August 2008|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|1134|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with mild or moderate Alzheimer dementia with or without cerebrovascular disease|June 2014|June 17, 2014|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009476||130883|
NCT01005992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCCQFQ-1|Fractional Photothermolysis for the Treatment of Burn Scars|Fractional Photothermolysis for the Treatment of Burn Scars||Clinica las Condes, Chile|No|Not yet recruiting|November 2009|||April 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|6 Years|16 Years|No|||October 2009|October 30, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005992||131148|
NCT01006005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-177-0106|Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens|Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens||University of California, San Francisco|No|Completed|July 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|HIV infected, marginally housed|November 2012|November 20, 2012|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006005||131147|
NCT01006798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXVX-H5-103-001|Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1|Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn||PaxVax, Inc.|Yes|Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|166|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01006798||131087|
NCT01007110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11625|Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes|The Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes||University of Kansas Medical Center|Yes|Completed|May 2009|July 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|67|||Female|16 Years|35 Years|No|||June 2014|June 2, 2014|November 2, 2009|Yes|Yes||No|February 27, 2014|https://clinicaltrials.gov/show/NCT01007110||131063|
NCT01006538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/HO206/20|Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)|A Randomised Controlled Trial of Epimacular Brachytherapy Versus Ranibizumab Monotherapy for the Treatment of Subfoveal Choroidal Neovascularisation Associated With Wet Age-related Macular Degeneration in Patients Who Have Commenced Anti-VEGF Therapy|MERLOT|King's College Hospital NHS Trust|Yes|Active, not recruiting|November 2009|December 2015|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|363|||Both|50 Years|N/A|No|||July 2015|August 14, 2015|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006538||131107|
NCT01006785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1425-0209|Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer|Phase II Clinical Study: A Randomized, Open, and Dose Ranging Study to Evaluate the Efficacy and Safety of DLBS1425 in Subjects With Metastatic / Advanced Breast Cancer||Dexa Medica Group||Terminated|August 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|65 Years|No|||October 2012|October 17, 2012|November 1, 2009||No|The study was terminated due to difficulty of find eligible subjects|No||https://clinicaltrials.gov/show/NCT01006785||131088|
NCT00959140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1410|Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors|Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants From Matched Related Donors||University of Alabama at Birmingham|Yes|Recruiting|October 2014|October 2018|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|19 Years|N/A|No|||December 2015|December 17, 2015|August 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00959140||134700|
NCT00959387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Barretos-01|Induction Chemotherapy for Advanced Head and Neck Cancer|Induction Chemotherapy (IC) With Paclitaxel and Cisplatin (PC) Followed by Concomitant Chemoradiotherapy (CCRT) in Patient With Advanced Squamous Carcinoma of the Head and Neck (SSCHN).||Barretos Cancer Hospital|Yes|Completed|August 2009|April 2013|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|76 Years|No|||March 2014|March 22, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00959387||134681|
NCT00959686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|"BENTLY"|Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma|Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study "BENTLY"|BENTLY|French Innovative Leukemia Organisation|Yes|Completed|September 2009|February 2013|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||June 2011|February 11, 2013|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00959686||134659|
NCT00959946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A6-2208|Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer|A Phase 1/2, Open-Label Study Of Bosutinib Administered In Combination With Capecitabine In Subjects With Solid Tumor And ErbB2 Negative Locally Advanced Or Metastatic Breast Cancer||Pfizer|No|Terminated|September 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|August 14, 2009|Yes|Yes||No|October 4, 2012|https://clinicaltrials.gov/show/NCT00959946||134639|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.
NCT00955526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-009|Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)|6002-009|Kyowa Hakko Kirin Company, Limited|No|Completed|July 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|373|||Both|20 Years|N/A|No|||August 2012|August 28, 2012|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955526||134975|
NCT00955799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579/TI/3003|Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus|A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus||Merz Pharmaceuticals GmbH|No|Completed|September 2009|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|455|||Both|18 Years|75 Years|No|||November 2012|November 27, 2012|August 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955799||134954|
NCT00955812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0206|STAT3 Inhibitor for Solid Tumors|A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors||M.D. Anderson Cancer Center|No|Completed|June 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955812||134953|
NCT00956046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF09|A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months|Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months||Sanofi|No|Completed|September 2009|June 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|401|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||January 2014|January 10, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00956046||134935|
NCT01009216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-505|A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid|A Study to Evaluate the Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-384 in Healthy Male Volunteers||Abbott||Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|December 13, 2010|October 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009216||130903|
NCT01009229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uehlinger-001|A Reduced 11-b-HSD Activity, a Novel Mechanism of Salt Sensitivity and Hypertension After Renal Allograft Donation?|A Reduced 11 Beta Hydroxysteroid Dehydrogenase 2 (11 Beta HSD2) Activity, a Novel Mechanism of Salt Sensitivity and Hypertension After Renal Allograft Donation?||University Hospital Inselspital, Berne|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|70 Years|No|||May 2011|May 24, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009229||130902|
NCT01008683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|engelhard-HMO-CTIL|Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation|Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation||Hadassah Medical Organization|No|Recruiting|November 2009|July 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|80 Years|No|Non-Probability Sample|Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza        vaccination according to the clinical guidelines.|November 2009|November 5, 2009|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008683||130943|
NCT01008943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-013|Autologous Cell Therapy for Female Stress Urinary Incontinence|A Canadian Prospective Nonrandomized Study of Autologous Cell Therapy for Female Stress Urinary Incontinence||Cook||Completed|July 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|N/A|No|||November 2015|November 2, 2015|November 5, 2009|Yes|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01008943||130923|
NCT01005407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-16|Safety, Immunogenicity, Lot-to-lot Consistency Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine|An Observer-Blinded, Randomized, Parallel-Group, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Healthy Subjects 40 to 70 Years of Age||Dynavax Technologies Corporation|Yes|Completed|February 2010|May 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2452|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|October 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01005407||131193|
NCT01005420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27030|The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study|The Effect of Anthocyanins in the Form of Blueberry Powder on Enhancing Insulin Sensitivity in Insulin Resistant and Obese Humans|BLUEBERRY|Pennington Biomedical Research Center|No|Completed|February 2007|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|37|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01005420||131192|
NCT01005693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZNA-2008-FOD-GER001|Screening Tools to Predict Treatment Outcome in Older Cancer Patients Who Are Undergoing Treatment|Impact of Frailty in Senior Cancer Patients: Feasibility and Value of Screening Tools and Geriatric Intervention and Predictive Value of a Screening Tool in Relation to Treatment Outcome||National Cancer Institute (NCI)||Recruiting|October 2009|||October 2011|Anticipated|N/A|Interventional|Primary Purpose: Supportive Care|||Anticipated|300|||Both|65 Years|N/A|No|||May 2010|May 14, 2013|October 30, 2009||||No||https://clinicaltrials.gov/show/NCT01005693||131171|
NCT01005433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/2009|Dexmedetomidine for Cesarean Delivery|A Dose - Dependent Study of Dexmedetomidine in Suppressing Cardiovascular and Hormonal Responses for Cesarean Delivery||King Faisal University|No|Completed|December 2009|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|68|||Female|18 Years|45 Years|No|||March 2012|March 22, 2012|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005433||131191|
NCT01005706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wyeth Study - HR 19042|Sirolimus Conversions in African-American Renal Transplant Recipients|A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients||Medical University of South Carolina|No|Completed|August 2009|July 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||February 2014|February 12, 2016|October 9, 2009||No||No|May 14, 2015|https://clinicaltrials.gov/show/NCT01005706||131170|
NCT01006811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADIS|Use of the Modified Atkins Diet in Infantile Spasms|Efficacy and Tolerability of the Modified Atkins Diet in Patients With Infantile Spasms: a Pilot Study.|ADIS|All India Institute of Medical Sciences, New Delhi|Yes|Completed|October 2009|November 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|6 Months|3 Years|No|||November 2010|November 19, 2010|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006811||131086|
NCT01007123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3309-002|Study of A3309 in Patients With Chronic Idiopathic Constipation|A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of A3309 in Patients With Chronic Idiopathic Constipation|ACCESS|Albireo|No|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|190|||Both|20 Years|80 Years|No|||October 2010|January 19, 2012|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007123||131062|
NCT01007331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF-D200 Probørn|Probiotic Bacteria to Infants With Atopic Dermatitis|Probiotic Bacteria to Infants With Atopic Dermatitis; an Investigation of the Effect on Eczema, Immunologic Status and the Intestinal Microflora, Inflammation and Permeability||University of Copenhagen|No|Completed|November 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|||Actual|62|||Both|6 Months|24 Months|No|||November 2009|February 16, 2010|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007331||131046|
NCT01007617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0060|Low-energy Laser Therapy for Prevention of Oral Mucositis in Children|Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1"||University Hospital, Clermont-Ferrand||Recruiting|June 2009|July 2010|Anticipated|July 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|40|||Both|N/A|18 Years|No|||January 2011|January 18, 2011|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007617||131024|
NCT00959972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPRC-6551|Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease|Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial||Ottawa Heart Institute Research Corporation|Yes|Completed|April 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|75 Years|No|||April 2011|April 27, 2011|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00959972||134637|
NCT00959400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT059|Efficacy and Safety Study of Fentanyl Transdermal (Fentanest®)|||Cristália Produtos Químicos Farmacêuticos Ltda.||Withdrawn|November 2009|||June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||July 2015|July 15, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00959400||134680|
NCT00959699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05411|A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)|A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (Protocol No. P05411)||Merck Sharp & Dohme Corp.|Yes|Completed|November 2009|October 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|65 Years|No|||September 2015|September 4, 2015|July 29, 2009|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT00959699||134658|
NCT00959959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOK-200-05|ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer|ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer|ARMOR1|Tokai Pharmaceuticals|Yes|Completed|October 2009|August 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|49|||Male|18 Years|N/A|No|||September 2012|January 8, 2014|August 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00959959||134638|
NCT00956358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 09-107|Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation|Study on Systemic and Airway Cytokines and Oxidative Stress in Patients Undergoing Haemopoietic Stem Cell Transplantation (HSCT)||The University of Hong Kong|No|Recruiting|March 2009|December 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|230|Samples Without DNA|Plasma, buffy coat, red blood cell and exhaled breath condensate samples.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Haematological conditions requiring HSCT and healthy HSCT donors will be identified from        Bone Marrow Transplatation (BMT) Unit and post-HSCT patients with BOS will be identified        from Respiratory Medicine clinics at Queen Mary Hospital.|December 2014|December 1, 2014|August 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00956358||134911|
NCT00956696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPM2009|Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study|Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study||Chinese University of Hong Kong|Yes|Recruiting|May 2009|June 2013|Anticipated|June 2012|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Epilepsy patients in Prince of Wales hospital.|August 2009|August 10, 2009|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956696||134885|
NCT00956059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSX-090630-SAHXJTU|Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis|Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis||Xi’an Jiaotong University College of Medicine|No|Not yet recruiting|September 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|70 Years|No|||August 2009|August 10, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956059||134934|
NCT01009502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08H4|Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome|SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome||Northwestern University|Yes|Terminated|July 2009|May 2013|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|November 5, 2009|No|Yes|Lack of funding, never moved into the phase II portion that was originally planned.|No||https://clinicaltrials.gov/show/NCT01009502||130882|
NCT01009515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0903|Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma|Phase II Trial of Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma||New Mexico Cancer Care Alliance|Yes|Terminated|August 2009|June 2015|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|October 14, 2009|Yes|Yes|Low accrual; target accrual not met|No|August 14, 2015|https://clinicaltrials.gov/show/NCT01009515||130881|
NCT01005446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS - 901|RSP® Prospective Multi-Center Study|PS-901: Prospective Multicenter Open Label Study of the Encore Reverse® Shoulder Prosthesis|RSP|Encore Medical, L.P.|No|Active, not recruiting|December 2009|January 2018|Anticipated|January 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|224|||Both|60 Years|N/A|No|Non-Probability Sample|Subjects who are 60 years of age or older at the time of consent and are suffering from a        grossly rotator cuff deficient shoulder joints with severe arthropathy or have a        previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.|January 2016|January 19, 2016|October 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01005446||131190|
NCT01006551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-0012|Ziprasidone in Early Onset Schizophrenia Spectrum Disorders|Ziprasidone in Early Onset Schizophrenia Spectrum Disorders|ZEOSS|University of North Carolina, Chapel Hill|Yes|Completed|December 2002|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|6 Years|19 Years|No|||November 2009|November 2, 2009|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01006551||131106|
NCT01007357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290-09|Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation|Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation||University of Nebraska|No|Terminated|December 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|October 28, 2009|Yes|Yes|Principal Investigator left institution; did not complete the study|No||https://clinicaltrials.gov/show/NCT01007357||131044|
NCT01007370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM 2010-001|Comparison of LMA-Fastrach and I-gel for Blind Tracheal Intubation.|Comparison of LMA-Fastrach and I-gel for Blind Tracheal Intubation.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007370||131043|
NCT01007643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:115|Use of Wii Fit (TM) to Increase Compliance With Home Exercises in Treating Patellofemoral Syndrome|The Use of Wii Fit ™ to Increase Compliance With Home Exercises for Treatment of Patellofemoral Syndrome in Adolescent Females||University of Manitoba|No|Terminated|October 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|22|||Female|11 Years|17 Years|No|||June 2010|August 27, 2012|November 3, 2009||No|Difficulty in recruitment of study participants in alloted time and funding|No|July 23, 2012|https://clinicaltrials.gov/show/NCT01007643||131022|Early termination of the study lead to less than the required number of study subjects enrolled. Thus secondary outcome measures could not be calculated with certainty.
NCT01007344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000008297|Flaxseed Compared With Placebo in Patients With Hypercholesterolemia|A 4-week Study in Children and Adolescents With Familial or Severe Hypercholesterolemia Comparing Flaxseed Therapy to Placebo||The Hospital for Sick Children|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|8 Years|18 Years|No|||August 2013|August 25, 2013|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007344||131045|
NCT00955851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010902|A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine|A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine||George Washington University|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who have been admitted to the Medicine Ward under the Pneumonia Core Measure        Protocol as stated by the Joint Commission, and who receive the polyvalent pneumococcal        vaccine as an inpatient as indicated by ACIP guidelines.|August 2009|July 29, 2010|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955851||134950|
NCT00955838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCIStroke|Brain Computer Interface (BCI) Based Robotic Rehabilitation for Stroke|Brain Computer Interface (BCI) Based Robotic Rehabilitation for Stroke||National Neuroscience Institute|Yes|Recruiting|April 2007|October 2009|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|65 Years|No|||August 2009|August 7, 2009|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955838||134951|
NCT00956085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6924R/5972|Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder|Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder||New York State Psychiatric Institute|No|Active, not recruiting|August 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956085||134932|
NCT00955539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2009-057|Viability and Cardiac Resynchronization Therapy|The Importance of Viability for Response to Cardiac Resynchronization Therapy||University Hospital, Gentofte, Copenhagen|Yes|Recruiting|August 2009|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2011|October 4, 2011|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955539||134974|
NCT00955825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO61.08 USA|Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis|A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis||Stallergenes|No|Completed|October 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|473|||Both|18 Years|65 Years|No|||December 2009|December 11, 2012|August 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955825||134952|
NCT00956072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62063|Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate|A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients With Metastatic Gastro-intestinal Stromal Tumor Responding to Imatinib Mesylate.||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|May 2009|||March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|August 8, 2009||No|low accrual|No||https://clinicaltrials.gov/show/NCT00956072||134933|
NCT00957684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-301|Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial.||Bial - Portela C S.A.|No|Completed|July 2004|February 2007|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|402|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|August 10, 2009||No||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00957684||134811|
NCT00957697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060083|Pain After Stroke, Part 2: Clinical Characteristics and Classification of Pain in Patients After Stroke|Pain After Stroke, Part 2: Clinical Characteristics and Classification of Pain in Patients After Stroke||Danish Pain Research Center|No|Completed|April 2008|July 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|52|||Both|N/A|N/A|No|Non-Probability Sample|Cohort of stroke patients diagnosed in 2004-2005 in the County of Aarhus identified        through the National Indicator Project Stroke Database of Denmark|August 2011|August 29, 2011|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957697||134810|
NCT00957008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSA5211|Lifestyle Education for Activity and Nutrition for a Leaner You|Use of Electronic Feedback on Diet and Physical Activity to Enhance Weight Management|LEAN|University of South Carolina|Yes|Completed|February 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|197|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|August 7, 2009||No||No|February 21, 2011|https://clinicaltrials.gov/show/NCT00957008||134862|Large attrition rate due to time commitment; mostly female and highly educated sample; short intervention; GWL did not perform well
NCT01008969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC085513, H46038-33934|Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients|Practice Procedure for 99mTc-Sulfur Nanocolloid Lymphatic Drainage Mapping in Prostate Cancer Using SPECT-CT (Single Photon Emission Computed Tomography / Computed Tomography)||University of California, San Francisco|Yes|Completed|November 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Male|18 Years|N/A|No|||December 2011|December 29, 2011|November 5, 2009|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT01008969||130921|
NCT01009242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0010|To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Dose Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis on a Stable Dose of Methotrexate||UCB Pharma|Yes|Completed|October 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|40|||Both|18 Years|75 Years|No|||October 2011|August 26, 2014|November 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01009242||130901|
NCT01009255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110651|Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease.||GlaxoSmithKline|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|50 Years|N/A|No|||March 2012|March 29, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009255||130900|
NCT01005459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 9824|Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE|Comparison of Spinal Tetracaine With Fentanyl and Epinephrine Versus Bupivacaine With Fentanyl and Epinephrine for Combined Spinal Epidural Labor Analgesia||Wake Forest School of Medicine|Yes|Active, not recruiting|August 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|12 Years|N/A|No|||August 2015|August 31, 2015|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005459||131189|
NCT01005719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18135|Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)|Randomized, Crossover, Pharmacodynamic Study Comparing the Effects of Two Proton Pump Inhibitors||Bayer|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|October 30, 2009|Yes|Yes||No|January 4, 2011|https://clinicaltrials.gov/show/NCT01005719||131169|
NCT01006291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3668|Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes|A 26 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Three-arm, Treat to Target Trial Comparing Efficacy and Safety of Three Different Dosing Regimens of Either Soluble Insulin Basal Analogue (SIBA) or Insulin Glargine With or Without Combination With OAD Treatment, in Subjects With Type 2 Diabetes Mellitus (BEGIN™ : FLEX)|BEGIN™|Novo Nordisk A/S|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|687|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 30, 2009|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01006291||131125|
NCT01006564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3121|Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer|Multifunctional MR for Radiotherapy Planning in Prostate Cancer||Royal Marsden NHS Foundation Trust|No|Recruiting|March 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|30|||Male|16 Years|N/A|No|||November 2009|November 2, 2009|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006564||131105|
NCT01007396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-09-019|Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay|Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay||Samsung Medical Center|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|322|||Both|N/A|N/A|No|||December 2011|December 6, 2011|November 2, 2009||No||No|May 17, 2010|https://clinicaltrials.gov/show/NCT01007396||131041|
NCT01007409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-111|A Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|Randomized, Open-labeled, Single Dosing Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers||Boryung Pharmaceutical Co., Ltd||Completed|October 2009|||November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 23, 2009|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007409||131040|
NCT01007656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC01080923|A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects|A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects||Golden Biotechnology Corporation|No|Completed|November 2009|March 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 1, 2013|October 30, 2009||No||No|May 26, 2013|https://clinicaltrials.gov/show/NCT01007656||131021|
NCT01007929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4260C00010|Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects|An Open-Label. Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of 60 mg of [14C] AZD1236 in Healthy Male Subjects||AstraZeneca|Yes|Terminated|October 2009|November 2009|Anticipated|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||November 2009|November 19, 2009|October 29, 2009||No|Future development of AZD1236 is currently under review by the project team and no new studies    will be started until this review is completed.|No||https://clinicaltrials.gov/show/NCT01007929||131001|
NCT01007916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-336-C-016|Subjective Evaluation of a Commercially Marketed Contact Lens Amongst a Subset of the Contact Lens Wearing Population|||Alcon Research|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||January 2012|June 26, 2012|November 2, 2009|Yes|Yes||No|January 31, 2011|https://clinicaltrials.gov/show/NCT01007916||131002|Participants were masked to lotrafilcon B lenses only.
NCT01007942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001W2301|Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer|A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.|BOLERO-3|Novartis||Completed|October 2009|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|570|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007942||131000|
NCT00956397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 07-187|Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia|Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia||New Mexico VA Healthcare System|Yes|Completed|August 2007|||March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 22, 2012|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956397||134908|
NCT00956371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-7746POU001|ONO-7746 Study in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, SIngle Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd||Completed|August 2009|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956371||134910|
NCT00956384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSEF-137034|One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure|Acellular Dermal Matrix in One-Stage Breast Reconstruction: A RCT|AllodermRCT|University Health Network, Toronto|No|Active, not recruiting|September 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|198|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00956384||134909|
NCT00956709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/5-D|Regional Anesthesia for Major Surgery of the Foot. Levobupivacaïne Ropivacaine 0.5% Versus 0.5% in the Sciatic Block Through médiofémorale||SCIALERO|Nantes University Hospital|No|Terminated|December 2008|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||July 2014|August 1, 2014|August 10, 2009||No||No|July 7, 2014|https://clinicaltrials.gov/show/NCT00956709||134884|
NCT00957021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55|Triathlon® Posteriorly Stabilized (PS) Total Knee System - Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Triathlon® Posteriorly Stabilized (PS) Total Knee System||Stryker Orthopaedics|No|Completed|December 2005|January 2014|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|409|||Both|21 Years|80 Years|No|||April 2015|April 30, 2015|August 10, 2009|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00957021||134861|
NCT00957710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-24|Language Treatment for Progressive Aphasia|Slowing Language Decline in Progressive Aphasia Through Language Rehabilitation: Treatment and Neuroimaging Study||Baycrest|No|Completed|August 2009|December 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957710||134809|
NCT00957320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015324|Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)|A Phase I Study of Sirolimus With PEG-Asparaginase in Multiple Recurrent or Refractory Childhood Acute Lymphoblastic Leukemia||Emory University|Yes|Withdrawn|June 2009|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|21 Years|No|||November 2012|November 30, 2013|August 11, 2009||No|no patients enrolled, decided not to pursue study|No||https://clinicaltrials.gov/show/NCT00957320||134838|
NCT00957333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH98-NNB-1049|Effects of Ketamine on Human Bladders and Its Possible Mechanisms|Effects of Ketamine on Human Bladders and Its Possible Mechanisms||Taipei Medical University WanFang Hospital|No|Completed|March 2009|December 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|44|Samples Without DNA|1.Urine 2.Blood 3.Biopsy|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|primary care clinic|November 2010|December 8, 2015|August 3, 2009||No||No|December 8, 2015|https://clinicaltrials.gov/show/NCT00957333||134837|
NCT00957671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-034|Anterior Pituitary Hormone Replacement in Traumatic Brain Injury|Anterior Pituitary Hormone Replacement in Traumatic Brain Injury||The University of Texas Medical Branch, Galveston|No|Active, not recruiting|November 2003|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|21 Years|N/A|No|||January 2015|January 15, 2015|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957671||134812|
NCT01009268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1361|The Effect of a Pre- and Postoperative Orthogeriatric Service|The Effect of a Pre- and Postoperative Orthogeriatric Service. A Randomised, Controlled Trial||Oslo University Hospital|No|Completed|September 2009|December 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|332|||Both|N/A|N/A|No|||May 2013|May 15, 2013|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009268||130899|
NCT01009281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2202E1|An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease|A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Crohn's Disease||Novartis||Terminated|October 2009|||August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|75 Years|No|||May 2012|May 31, 2012|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009281||130898|
NCT01009528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-41-2792|Electronic Feedback on Diabetic Care to General Practitioners|Development and Evaluation of Electronic Feedback, a Tool for Quality Assurance of the Diabetic Care in General Practice||University of Aarhus|Yes|Completed|March 2007|November 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2458|||Both|40 Years|70 Years|No|||November 2009|November 6, 2009|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009528||130880|
NCT01006304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016666|An Exploratory Study to Assess the Effects of JNJ-39439335 on the Relief of Pain Using a Thermal-Grill Experimental Model|A Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Effects of JNJ-39439335 (a TRPV1 Antagonist) in Healthy Male Adult Subjects on the Paradoxical Pain Induced by a Thermal Grill||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2009|June 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01006304||131124|
NCT01006317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015396|Intervention on Maternal Health Care in Rural China|Structural Hinders to and Promoters of Good Maternal Care in Rural China|CHIMACA|National Institute for Health and Welfare, Finland|Yes|Completed|March 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|108|||Female|N/A|N/A|No|||August 2015|August 20, 2015|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006317||131123|
NCT01007136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082008-053|Transcranial Direct Current Stimulation (tDCS)-Enhanced Stroke Recovery|TDCS-enhanced Stroke Recovery and Cortical Reorganization||University of Texas Southwestern Medical Center|Yes|Completed|March 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|May 29, 2015|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007136||131061|
NCT01007669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20090058|Effects of Specified Work Site Physical Activity Intervention Among Employees With Physical Heavy Work|Effects of Specified Work Site Physical Activity Intervention on Musculoskeletal Disorders Among Employees With Physical Heavy Work||University of Southern Denmark|Yes|Completed|August 2009|September 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|67|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 8, 2013|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007669||131020|
NCT01007955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-12082|Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery|Assessment of Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Predictors of Cardiovascular Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass: Development of a New Paradigm in Defining "Morbid Obesity" and in the Application of Bariatric Surgery||University of Massachusetts, Worcester|No|Completed|November 2006|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|Samples With DNA|Subcutaneous and visceral adipose tissue.|Both|18 Years|65 Years|No|Non-Probability Sample|Severely obese patients undergoing gastric bypass surgery|August 2012|August 23, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007955||130999|
NCT01008267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63/09|Shockwave Lithotripsy (SWL) Under Selective, General Anesthesia.|Shockwave Lithotripsy (SWL) Under Regular General Anesthesia and Under General Anesthesia Using Bronchial Blocker.||Assaf-Harofeh Medical Center||Not yet recruiting|November 2009|||October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who failed in SWL process taken under sedation (standard protocol)|March 2009|November 4, 2009|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008267||130975|
NCT01008241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project HOPE|South Florida Residents Knowledge and Opinions on End-of-Life Issues|Project HOPE: Survey of South Florida Residents Knowledge and Opinions on End-of-Life Issues|Project HOPE|Nova Southeastern University|No|Recruiting|October 2009|January 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Convenience sample of adult residents of South Florida|September 2009|November 3, 2009|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01008241||130977|
NCT01008280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-014-09S|Baclofen to Reduce Alcohol Use in Veterans With HCV|Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV|BRAC|VA Office of Research and Development|Yes|Completed|October 2010|September 2015|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|November 3, 2009|No|Yes||No|April 22, 2015|https://clinicaltrials.gov/show/NCT01008280||130974|
NCT00956098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ-OPZ-201 study|Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Multicenter Trial of Oltipraz for the Evaluation of Efficacy and Safety in the Patients With Liver Fibrosis and Cirrhosis Induced by Chronic Hepatitis Type B or C||CJ HealthCare Corporation||Completed|February 2006|February 2007||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||81|||Both|25 Years|65 Years|No|||August 2009|August 10, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956098||134931|
NCT00956111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PanFlu-4001|A Clinical Trial With Influenza A/H1N1 Vaccines|A Double-blind, Randomized, Stratified and Controlled Clinical Trial With Split-virion and Whole-virion, Adjuvanted and Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders, Adolescents and Children||Sinovac Biotech Co., Ltd|Yes|Completed|July 2009|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|1614|||Both|3 Years|N/A|Accepts Healthy Volunteers|||October 2009|October 28, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956111||134930|
NCT00956124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017-f-S|Autofluorescence in Uveitic and Diabetic Macular Edema|||St. Franziskus Hospital||Suspended|October 2010|||October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with uveitis or diabetes|May 2015|May 21, 2015|August 10, 2009||No|Technical issue|No||https://clinicaltrials.gov/show/NCT00956124||134929|
NCT00956410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAD106A2201E1|To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients|An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106||Novartis|Yes|Completed|September 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|40 Years|85 Years|No|||November 2011|November 16, 2011|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956410||134907|
NCT00956423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R36CD000695-01|Comparison of Physical Activity Regimens as Treatments for Obstructive Sleep Apnea|Exercise: A Novel Treatment for Obstructive Sleep Apnea||University of South Carolina|No|Completed|August 2009|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00956423||134906|
NCT00956722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immuron Travelan HCV|Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy|Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy||Hadassah Medical Organization|No|Withdrawn|January 2012|April 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2011|August 27, 2012|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956722||134883|
NCT00956735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29970|Effects of Pistachios on Cardiovascular Responses to Stress in Type 2 Diabetes|Effects of Pistachios on Cardiovascular Responses to Stress in Type 2 Diabetes: A Novel Intervention for a High Risk Population|Pistachio|Penn State University|No|Completed|August 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|30 Years|75 Years|No|||December 2013|December 13, 2013|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956735||134882|
NCT00957034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009015|Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure|A Placebo-controlled Study to Determine the Efficacy and Safety of 300 and 450 µg/Day Transdermal Testosterone in Female Patients With Low Ejection Fraction and Symptomatic Heart Failure|CORDELIA|Warner Chilcott|No|Terminated|July 2009|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|17|||Female|50 Years|N/A|No|||November 2011|December 6, 2011|August 10, 2009|Yes|Yes|Due to difficult patient enrollment.|No|August 3, 2011|https://clinicaltrials.gov/show/NCT00957034||134860|
NCT00957047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-302|Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy|Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial||Bial - Portela C S.A.|No|Completed|July 2004|January 2008|Actual|August 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|395|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|August 10, 2009||No||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00957047||134859|
NCT00957346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.3.2|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP)|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP): A Randomized-controlled Double-blinded Trial||Gynuity Health Projects|No|Terminated|February 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 5, 2011|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00957346||134836|
NCT00957359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-954|Psilocybin Cancer Anxiety Study|Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients||New York University|Yes|Active, not recruiting|February 2009|August 2016|Anticipated|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|76 Years|No|||June 2015|June 11, 2015|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957359||134835|
NCT00957398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090009,JLF|Comparing of the Gastrointestinal Motility in Irritable Bowel Syndrome (IBS) Patients With Healthy Volunteers|Comparing of the Gastrointestinal Motility in Irritable Bowel Syndrome (IBS) Patients With Healthy Volunteers Using Magnetic Tracking System (MTS)||University of Aarhus|Yes|Terminated|August 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|N/A||2|Actual|10|||Both|18 Years|70 Years|No|Non-Probability Sample|12 patients with IBS-D and 12 patients with IBS-C who all meet the inclusion criteria.|May 2012|May 9, 2012|August 11, 2009||No|Not possible to include patients.|No||https://clinicaltrials.gov/show/NCT00957398||134832|
NCT00957411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000651250|Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer|Phase II Randomized Assessing Pelvic Irradiation Combined With Cisplatin Alone or Cisplatin Plus Cetuximab in Patients With Carcinoma of the Cervix Stage IB2, II and III||National Cancer Institute (NCI)||Recruiting|March 2009|||||Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Female|18 Years|N/A|No|||June 2012|August 23, 2013|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957411||134831|
NCT00957918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP002-09-001|Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy|Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy||Neuraltus Pharmaceuticals, Inc.|No|Completed|October 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|30 Years|83 Years|No|||September 2011|September 26, 2011|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957918||134793|
NCT00957931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC01|Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs|Pilot Study MUD HCT:Pts High Risk Sickle Cell,Other Non-Malignant RBC Disorders- Reduced Intensity Preparative Regimen, HAPLO-Identical Mesenchymal Stromal Cells||Stanford University|Yes|Terminated|March 2009|||August 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|1 Year|25 Years|No|||December 2012|December 20, 2012|August 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957931||134792|
NCT00958230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRL P001-09|dCell Vascular Patch in Peripheral Vascular Surgery Study for CE Mark Submission|An Open Arm Pilot Study to Evaluate the Safety and Performance of the dCell Vascular Patch in Reconstructive Peripheral Vascular Surgery||Tissue Regenix Ltd|No|Completed|August 2009|November 2011|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|80 Years|No|||September 2010|November 13, 2014|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958230||134769|
NCT01005732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30336-B|Effectiveness of Pressure Garment Therapy After Burns|Effectiveness of Pressure Garment Therapy After Burns||University of Washington|No|Completed|November 1995|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|67|||Both|7 Years|65 Years|No|||April 2011|April 1, 2011|October 30, 2009|Yes|Yes||No|January 11, 2011|https://clinicaltrials.gov/show/NCT01005732||131168|
NCT01006057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1990|A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function|A Trial Investigating the Pharmacokinetic and Safety of NN1250 in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function||Novo Nordisk A/S|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|85 Years|No|||October 2015|October 16, 2015|October 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01006057||131143|
NCT01006031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPAVIR_IFN_2009|Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4|Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy.||Sociedad Andaluza de Enfermedades Infecciosas|Yes|Completed|October 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2011|December 28, 2011|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01006031||131145|
NCT01006044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEND/GM|Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection|Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|October 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|70 Years|No|||September 2014|September 2, 2014|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006044||131144|
NCT01006824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-02C010|Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding|Randomized Controlled Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding||University of Southern California|No|Completed|March 2003|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|136|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006824||131085|
NCT01006837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1263 (REK)|Hypothermia in the Trauma Patient - When do Trauma Patients Get Cold?|Hypothermia in the Trauma Patient - Temperature Changes During Transport and Initial Treatment in Hospital||Norwegian University of Science and Technology|No|Completed|October 2009|August 2014|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|12 Years|N/A|No|Non-Probability Sample|Patients transported to St. Olavs Hospital (Trondheim, Norway), followed by an        anesthesiologist from the norwegian air ambulance and taken care of by the trauma team in        the emergency room.|December 2014|December 30, 2014|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006837||131084|
NCT01007149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025AFR05|Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma|A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy|NATAIR|Novartis||Completed|September 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|79|||Both|18 Years|70 Years|No|||July 2012|July 18, 2012|October 30, 2009||No||No|February 20, 2012|https://clinicaltrials.gov/show/NCT01007149||131060|
NCT01007383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 27847-S01|LEO 27847 - A Study in Healthy Male Subjects|LEO 27847 - A Phase 1, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects||LEO Pharma|No|Completed|September 2009|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|November 4, 2013|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01007383||131042|
NCT01007968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589X2101|Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function|A Phase I, Open-label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function||Novartis||Completed|March 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|October 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007968||130998|
NCT01008293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHE-VSL3-YKJ_AIIMS_ver1|Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life|Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life|MHE|CD Pharma India Pvt. Ltd.|No|Completed|October 2009|October 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|15 Years|80 Years|No|||June 2013|June 3, 2013|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008293||130973|
NCT01008540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I06016|Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients|Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients in the Prophylaxis Era, a French Multicentric Cohort Study|PHRC CMV|University Hospital, Limoges|Yes|Completed|August 2006|June 2012|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Anticipated|800|||Both|N/A|N/A|No|||October 2012|October 22, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01008540||130954|
NCT00956150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC 07-155|Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex|Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex||New Mexico VA Healthcare System|Yes|Recruiting|April 2009|||March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 30, 2013|August 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956150||134927|
NCT00956436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212HC201|Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)|A Phase 1b, Open-Label Study of Sorafenib With BIIB022 in Subjects With Advanced Hepatocellular Carcinoma||Biogen|Yes|Completed|August 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2011|September 12, 2013|August 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956436||134905|
NCT00956748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00953|N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media|N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media||St. Paul's Hospital, Canada|No|Not yet recruiting|January 2016|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956748||134881|
NCT00956761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_09S|Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects||Novartis||Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|August 8, 2009||No||No|December 21, 2015|https://clinicaltrials.gov/show/NCT00956761||134880|
NCT00957060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIME_L_04140|Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients|A Multicenter, Open, Randomized, 24 Weeks Study to Evaluate the Superiority of Glimepiride Over Sitagliptin for the Treatment of naïve Patients With Type 2 Diabetes Mellitus|SUMER|Sanofi||Completed|July 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|70 Years|No|||November 2010|November 26, 2010|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957060||134858|
NCT00957372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-303|Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy|Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Clinical Trial||Bial - Portela C S.A.|No|Completed|December 2004|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|253|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|August 10, 2009||No||No|March 26, 2013|https://clinicaltrials.gov/show/NCT00957372||134834|
NCT00957385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-AML-PI-166|Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients|A Randomized Phase II Study of Lenalidomide Maintenance Therapy in AML Patients Aged > 60 Years in CR1 or Higher and < 60 Years in CR2 or Higher||University Health Network, Toronto|Yes|Completed|June 2008|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2009|June 17, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957385||134833|
NCT00957099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014357|Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)|A Comparison Study of Contrast Enhanced Breast CT With MRI On Known Malignancies For Detection of Multifocal/Multicentric Disease||Emory University|No|Completed|June 2009|January 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Female|35 Years|N/A|No|Non-Probability Sample|The target population for this study is women who have been diagnosed with breast cancer        and have undergone breast MR imaging for detection of multifocal and/or multicentric        tumors before undergoing treatment.|September 2013|September 11, 2013|August 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00957099||134855|
NCT00957944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0957|Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body|Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5 mg/10 cm^2) From 2 Different Manufacturing Sites.||UCB Pharma|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|October 17, 2014|August 11, 2009|No|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT00957944||134791|
NCT00957957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-134|Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)|Gut Hormone Profiling in Peripheral Blood After Bariatric Surgery in Obese Patients With Type 2 Diabetes||Merck Sharp & Dohme Corp.||Completed|February 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|22|||Both|20 Years|60 Years|No|Non-Probability Sample|Morbidly obese type 2 diabetic patients|January 2016|January 19, 2016|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957957||134790|
NCT00958243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-CAL-09-62|A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA|A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population||CSL Limited|Yes|Completed|August 2009|April 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|473|||Both|6 Months|9 Years|Accepts Healthy Volunteers|||August 2011|February 10, 2012|August 12, 2009|Yes|Yes||No|July 13, 2011|https://clinicaltrials.gov/show/NCT00958243||134768|
NCT00958256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0057|Study of Bortezomib in Combination With Cyclophosphamide and Rituximab|Phase II Study of Bortezomib in Combination With Cyclophosphamide and Rituximab for Relapsed/Refractory Mantle Cell Lymphoma||M.D. Anderson Cancer Center|No|Completed|August 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|85 Years|No|||March 2015|March 31, 2015|August 11, 2009||No||No|March 31, 2015|https://clinicaltrials.gov/show/NCT00958256||134767|
NCT00958269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-PROT306|Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment|A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment Including Subjects on Hemodialysis||Phenomix||Terminated|August 2009|November 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|360|||Both|18 Years|85 Years|No|||February 2010|February 1, 2010|August 12, 2009|Yes|Yes|Technical/operational issues|No||https://clinicaltrials.gov/show/NCT00958269||134766|
NCT01005758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000632144|Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|DFCI ALL Adult Consortium Protocol: Adult ALL Trial||National Cancer Institute (NCI)||Not yet recruiting|January 2009|||January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|50 Years|No|||October 2009|January 9, 2014|October 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01005758||131166|
NCT01006616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05575|Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)|A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD||Merck Sharp & Dohme Corp.|Yes|Terminated|October 2009|November 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|616|||Both|41 Years|75 Years|No|||April 2015|April 24, 2015|October 1, 2009|No|Yes||No|October 2, 2014|https://clinicaltrials.gov/show/NCT01006616||131101|
NCT01006330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVR29190623|Dysphagia in Elderly Medical Patients|Dysphagia in Elderly Medical Patients: Occupational Therapy Evaluation and Prevalence|DEM|Herlev Hospital|Yes|Completed|November 2009|June 2011|Actual|June 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|65 Years|N/A|No|Non-Probability Sample|102 internal medical patients admitted to Herlev Hospital are included consecutively.|October 2009|June 15, 2011|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006330||131122|
NCT01006850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC05-11-307|Fixed Dose of Intravenous Hydromorphone in the Treatment of Acute Pain|Safety and Speed of Onset of a Fixed Dose of Intravenous Hydromorphone in the Treatment of Adult Patients Presenting to the Emergency Department With Acute Severe Pain||Montefiore Medical Center||Completed|July 2005|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|October 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01006850||131083|
NCT01006863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28/2004|Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study|Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study||King Faisal University|No|Completed|March 2004|March 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|150|||Both|18 Years|55 Years|No|||May 2010|May 26, 2010|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006863||131082|
NCT01007422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0822|Opioids Titration in Hospice Patients|Opioid Titration In the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol Stage 2, Part B||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn|June 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|21 Years|N/A|No|Non-Probability Sample|Out-patient hospice patients.|March 2013|March 29, 2013|November 3, 2009|No|Yes|Issues with Hospice|No||https://clinicaltrials.gov/show/NCT01007422||131039|
NCT01007448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7273-G000-401|Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)|Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2009|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|November 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007448||131037|
NCT00999661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-09-0007|A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C|A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C at 2 Years in a US Patient Population of Morbidly Obese Patients||Ethicon Endo-Surgery|No|Completed|November 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|231|||Both|18 Years|N/A|No|Probability Sample|At each participating center (after the initial 10 cases), all consecutively implanted        patients, will be considered for the study.|January 2014|January 8, 2014|October 20, 2009|No|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00999661||131630|
NCT00999960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 07074-NI07008|Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator|A Prospective Randomized Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Online Simulator|PERLE|Assistance Publique - Hôpitaux de Paris|No|Suspended|February 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|N/A|N/A|No|||October 2015|October 6, 2015|October 21, 2009||No|Decision of sponsor|No||https://clinicaltrials.gov/show/NCT00999960||131608|
NCT01008553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015544|A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome|A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome||Janssen Pharmaceutical K.K.|No|Completed|December 2008|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|258|||Both|20 Years|N/A|No|||June 2013|June 19, 2013|November 5, 2009|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01008553||130953|
NCT00955864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090180|Non-Invasive Non-Ionizing Polarized Imaging System to Assess Structure of Cervix|Non-Invasive Non-Ionizing Polarized Imaging System to Assess Structure of Cervix||National Institutes of Health Clinical Center (CC)||Completed|July 2009|||||N/A|Observational|N/A|||Actual|12|||Female|18 Years|60 Years|No|||September 2015|October 10, 2015|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00955864||134949|
NCT00956137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0190-AE|Ultrasound-assisted Spinal Anaesthesia in Patients With Difficult Anatomical Landmarks|A Randomised Controlled Trial of Ultrasound-assisted Spinal Anaesthesia in Patients With Difficult Anatomical Landmarks.||University Health Network, Toronto|No|Recruiting|May 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|80 Years|No|||January 2010|January 22, 2010|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00956137||134928|
NCT00956449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V78_07S|Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects|A Phase II, Single Center, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine [Ph.Eur], Formulation 2009/2010, When Administered to Non-Elderly Adult and Elderly Subjects||Novartis||Completed|June 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2009|August 10, 2009|August 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00956449||134904|
NCT00956774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Comparison of 3 Cannulas - HSG|Comparison of Three Cannulas for Hysterosalpingography|Comparison of Three Cannulas for Hysterosalpingography: A Prospective, Randomized Study||Carolinas Healthcare System|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|114|||Female|18 Years|N/A|No|||February 2013|February 13, 2013|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956774||134879|
NCT00956787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARN-AR67-IIS201|Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)|Phase 2 Study of AR-67 (DB-67) in Myelodysplastic Syndrome(MDS)||Arno Therapeutics|No|Recruiting|June 2009|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||August 2009|June 23, 2014|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956787||134878|
NCT00957073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360017-001|Rheos HOPE4HF Trial|Health Outcomes Prospective Evaluation for Heart Failure With EF ≥ 40%||CVRx, Inc.|Yes|Active, not recruiting|August 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|21 Years|N/A|No|||February 2015|February 4, 2015|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957073||134857|
NCT00957086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHN01|Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer|Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer||National Cancer Centre, Singapore|Yes|Recruiting|August 2009|June 2021|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|710|||Both|21 Years|70 Years|No|||March 2016|March 21, 2016|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957086||134856|
NCT00957749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cPMP01-08|Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A|A Multicenter, Open-Label Study of the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered cPMP (Precursor Z) in Patients With Molybdenum Cofactor Deficiency Type A||Orphatech Pharmaceuticals, GmbH|No|Withdrawn|August 2009|||April 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|6 Weeks|No|||January 2011|January 29, 2011|July 10, 2009|No|Yes|IND application was withdrawn, and therefore study listing is being withdrawn.|No||https://clinicaltrials.gov/show/NCT00957749||134806|
NCT00957723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56|Triathlon® Cruciate Retaining (CR) Total Knee System Outcomes Study|A Post-market, Non-randomized, Historical Controlled, Multi-center Study of the Outcomes of the Triathlon® Cruciate Retaining (CR) Total Knee System||Stryker Orthopaedics|No|Active, not recruiting|February 2005|January 2018|Anticipated|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|419|||Both|21 Years|80 Years|No|||November 2015|November 12, 2015|August 10, 2009|Yes|Yes||No|June 13, 2013|https://clinicaltrials.gov/show/NCT00957723||134808|
NCT00957970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-7-17|Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components|Periprosthetic Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components||Ewha Womans University|Yes|Completed|July 2006|July 2009|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||August 2009|August 12, 2009|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00957970||134789|
NCT00957983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGC20-1531-04|EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model|EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model||Danish Headache Center|Yes|Completed|August 2009|February 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2009|January 10, 2011|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00957983||134788|
NCT00957996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-303|Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza|A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Infection||BioCryst Pharmaceuticals|Yes|Completed|October 2009|August 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|234|||Both|6 Years|N/A|No|||January 2015|January 28, 2015|August 12, 2009|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT00957996||134787|
NCT01006343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0504001915|Dietary Pork, Appetite and Weight Loss in Human|||Purdue University||Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Female|21 Years|N/A|Accepts Healthy Volunteers|||October 2009|September 23, 2013|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006343||131121|
NCT01006629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W10-664|Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children|A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation||Abbott||Completed|November 2009|July 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|N/A|2 Years|No|||June 2011|June 21, 2011|November 2, 2009||No||No|April 29, 2011|https://clinicaltrials.gov/show/NCT01006629||131100|This study had no control group; relative comparisons are only possible with current product information for palivizumab. No RSV hospitalizations occurred during the study; therefore, secondary outcome measures could not be evaluated.
NCT01007162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3181|Patient Satisfaction in the Critical Care Unit: A Qualitative Phenomenological Study|Patient Satisfaction in the Critical Care Unit: A Qualitative Phenomenological Study||Royal Marsden NHS Foundation Trust|No|Recruiting|February 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|8|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients who were admitted to the Critical Care Unit at the Royal Marsden Hospital|November 2009|November 2, 2009|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007162||131059|
NCT01007682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192/09|Intrusive Reexperiencing: The Role of Working Memory Capacity and Thought Suppression|Intrusive Reexperiencing: The Role of Working Memory Capacity and Thought Suppression||University Hospital, Basel, Switzerland||Completed|September 2009|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 7, 2012|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01007682||131019|
NCT00999986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sheng-Qi-An|Low Dose Cyclophosphamide Treats Genital Warts|Phase III Study of the Treatment of Genital Warts by Low Dose Cyclophosphamide||Huazhong University of Science and Technology|No|Completed|January 2007|August 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2009|November 24, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999986||131606|
NCT01000246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIFLUVAC|Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy|Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy|RIFLUVAC|St. Antonius Hospital|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|50|||Both|18 Years|N/A|No|||December 2009|December 17, 2009|October 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01000246||131586|
NCT01000519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/0728/2003|Effects of Different Mode of Exercise Training on Type 2 Diabetes|Differential Effects of Aerobic Versus Progressive Resistance Training on Metabolic Profile and Fitness in Older Adults With Diabetes Mellitus - a Randomized Controlled Trial||Singapore General Hospital|No|Completed|December 2002|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|80 Years|No|||October 2009|March 23, 2010|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01000519||131565|
NCT01000233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS_PI081931|Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications|Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications|CALCIFICA|Hospital Universitari Son Dureta|No|Recruiting|August 2009|October 2012|Anticipated|March 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000233||131587|
NCT00955890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBC0901 FUCH|Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer|Randomized Phase II Trial Of Interventional Therapy Investigate Cardiac Protection of Dexrazoxane In Women With Breast Cancer Having Experienced Grade 1 Cardiotoxicity During Prior Anthracycline-based Chemotherapy.|cardioprotec|Fudan University|Yes|Terminated|June 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Female|18 Years|70 Years|No|||February 2012|February 27, 2012|August 7, 2009|Yes|Yes|Enrolled too slow|No||https://clinicaltrials.gov/show/NCT00955890||134947|
NCT00955877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeporDur2009|Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children|Randomized, Double-Blinded Placebo Controlled Trial of Epidural, Sustained-relief Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children||Washington University School of Medicine|Yes|Completed|March 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|13|||Both|2 Years|12 Years|No|||August 2011|January 22, 2015|August 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00955877||134948|
NCT00956163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02972|Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer|F-18 NaF PET for Detection of Bone Metastases in Men With Prostate Cancer: Exploratory Study||National Cancer Institute (NCI)||Completed|March 2010|May 2014|Actual|January 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Male|18 Years|N/A|No|||December 2013|July 1, 2014|August 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00956163||134926|
NCT00956462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trope2009|Steroids Versus Non-steroidal Anti-inflammatory Drugs Following Glaucoma Surgery|Topical Steroids Versus Topical Non-steroidal Anti-inflammatory Drugs Following Ahmed Valve Glaucoma Drainage Device Surgery||University Health Network, Toronto|Yes|Recruiting|July 2007|June 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|30 Years|85 Years|No|||July 2009|August 7, 2009|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT00956462||134903|
NCT00956800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roche 360|Remote Management of Diabetic Patients Via Data Transmission by Accu-Chek 360 Software|Remote Management of Diabetic Patients Via Data Transmission by Accu-Chek 360 Software||Columbus Research Foundation|No|Completed|September 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00956800||134877|
NCT00957424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000648665|Acceptability of Less Harmful Alternatives to Cigarettes|International Study of the Acceptability of Less Harmful Alternatives to Cigarettes (ISALHAC) - A Pilot Study||Roswell Park Cancer Institute||Completed|June 2009|November 2011|Actual|August 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|67|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957424||134830|
NCT00957437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3190C00016|Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305|A Phase I, Randomised, Open, Single-centre Study to Evaluate the Pharmacokinetics of Different Extended-release Formulations of AZD1305 When Given as Single and Repeated Oral Doses to Healthy Male Volunteers||AstraZeneca|No|Completed|August 2009|November 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 25, 2009|August 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00957437||134829|
NCT00957736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 0867|Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant|Targeted Single Nucleotide Polymorphisms (SNPs) to Classify Subtypes of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Transplant.||Vanderbilt-Ingram Cancer Center|Yes|Terminated|November 2008|December 2008|Actual|December 2008|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|252|Samples With DNA|blood|Both|N/A|N/A|No|Non-Probability Sample|allogeneic stem cell transplant patients|May 2013|May 11, 2013|August 11, 2009||No|study closed prematurely upon PI's departure from VICC|No||https://clinicaltrials.gov/show/NCT00957736||134807|
NCT01006356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015694|An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer|Cancer Pain Management With Hydromorphone HCl ORal Osmotic System in Korean Cancer Patient: Evaluation of Its Clinical Usefulness in Reduction of Breakthrough Pain Medication Frequency||Janssen Korea, Ltd., Korea|No|Completed|October 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Both|20 Years|N/A|No|||July 2013|July 9, 2013|October 29, 2009|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT01006356||131120|
NCT00998452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0350|Dissemination of a Weight Management Program Among US Veterans|Dissemination of a Weight Management Program Among US Veterans||University of North Carolina, Chapel Hill|No|Completed|December 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|732|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 20, 2013|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998452||131722|
NCT01006577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/105/08|Side-to-end Anastomosis Versus Colon J Pouch for Reconstruction After Low Anterior Resection for Rectal Cancer (SAVE)|Side-to-end Anastomosis Versus Colon J Pouch for Reconstruction After Low Anterior Resection for Rectal Cancer (SAVE)|SAVE|Charite University, Berlin, Germany|Yes|Not yet recruiting|June 2010|October 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|80 Years|No|||November 2009|November 2, 2009|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01006577||131104|
NCT01006590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680L00003|Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes|A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Sub-Maximal Doses of Metformin|PROMPT|AstraZeneca|No|Completed|October 2009|December 2010|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|October 31, 2009|Yes|Yes||No|November 30, 2011|https://clinicaltrials.gov/show/NCT01006590||131103|
NCT01006603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680L00002|Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin|A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy|GENERATION|AstraZeneca|No|Completed|October 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|957|||Both|65 Years|N/A|No|||September 2013|September 27, 2013|October 31, 2009|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01006603||131102|
NCT01007175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3242K1-2001|Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ATN-103 Administered To Japanese Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate||Ablynx|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|60|||Both|20 Years|75 Years|No|||January 2013|September 3, 2013|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007175||131058|
NCT01007435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA19926|A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Completed|October 2009|January 2014|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1162|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|November 3, 2009|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01007435||131038|
NCT00999401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC682-07|A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors|A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors||Cyclacel Pharmaceuticals, Inc.|No|Recruiting|February 2009|September 2012|Anticipated|March 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|October 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00999401||131650|
NCT01000259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8005|Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer|Validation of Tumor-Infiltrating T-Cells as a Biomarker for Advanced Epithelial Ovarian Cancer||Gynecologic Oncology Group||Recruiting|September 2004|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|174|||Female|N/A|N/A|No|Non-Probability Sample|patients who have undergone surgery for ovarian cancer|February 2016|February 9, 2016|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000259||131585|
NCT01000532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47-1|SIELLO Pilot Study for Comparison of Steroid Versus Non-Steroid Pacing Leads|Pilot Study to Compare Steroid (SIELLO T/JT) Versus Non-Steroid Pacing Leads (BPPU T/JT)||Biotronik SE & Co. KG|No|Completed|October 2009|February 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard pacemaker indication who are refered to the hospital.|November 2011|November 15, 2011|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000532||131564|
NCT01000545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLD-CKD-001|The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease|The Efficacy and Safety of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease: A Randomized Controlled Trial|DEFINE|Corbridge Group Philippines, Inc.|Yes|Not yet recruiting|November 2009|December 2012|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1508|||Both|19 Years|N/A|No|||October 2009|October 29, 2009|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000545||131563|
NCT01000818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-054|A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)|An Open-Label, 3-Period, Fixed-Sequence Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 Pharmacokinetics in HIV-Infected Patients on a Stable MK0518-Containing Regimen||Merck Sharp & Dohme Corp.||Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|October 22, 2009|No|Yes||No|March 10, 2010|https://clinicaltrials.gov/show/NCT01000818||131542|
NCT00996541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH070322-05|Support To Reunite Involve and Value Each Other|Diverting Homeless Youth From Chronic Homelessness and Risk for HIV|STRIVE|University of California, Los Angeles|No|Completed|September 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|302|||Both|12 Years|17 Years|No|||October 2009|November 6, 2009|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996541||131869|
NCT00955903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090430012|Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults|Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults|CROSSROADS|University of Alabama at Birmingham|No|Completed|June 2010|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|167|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2013|December 11, 2014|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00955903||134946|
NCT00956176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0040|Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis|Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study||M.D. Anderson Cancer Center|No|Withdrawn|September 2012|||September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956176||134925|
NCT00956475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11Z08|Quality of Life in Younger Leukemia and Lymphoma Survivors|Quality of Life in Young Adult Survivors of Hematologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|October 2008|August 2011|Actual|September 2010|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|48|||Both|18 Years|35 Years|No|Probability Sample|Records from the practice of the study investigators will be reviewed to identify        patients.|August 2011|August 23, 2011|August 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00956475||134902|
NCT00956813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N08C7|Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy|Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes||Alliance for Clinical Trials in Oncology|No|Completed|October 2009|May 2013|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|210|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|August 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00956813||134876|
NCT00957450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0043-CE|Intra-Pelvic Organ Motion for Cervix Cancer Patient Using Imaging|Validation Study of Modeled Intra-pelvic Organ Motion During External Beam Radiotherapy for Cervix Cancer Using Frequent Magnetic Resonance Imaging||University Health Network, Toronto|Yes|Active, not recruiting|February 2008|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|N/A|No|Probability Sample|In this study, the organ motion of Patients with cervical cancer will be assessed. The        study population will be selected from clinic.|March 2016|March 24, 2016|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957450||134828|
NCT00957112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000649750|Acupuncture or Self-Acupuncture in Managing Cancer-Related Fatigue in Women Who Have Received Chemotherapy for Stage I, Stage II, or Stage IIIA Breast Cancer|The Efficacy of Acupuncture and Self-acupuncture in Managing Cancer-related Fatigue in Breast Cancer Patients: a Pragmatic Randomised Trial||National Cancer Institute (NCI)||Completed|October 2007|February 2013|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|5||Anticipated|320|||Female|N/A|N/A|No|||August 2009|August 23, 2013|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957112||134854|
NCT00957125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMIX|A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early|PROMIX - Preoperative Treatment of Breast Cancer With a Combination of Epirubicin, Docetaxel and Bevacizumab. A Translational Trial on Molecular Markers and Functional Imaging to Predict Response Early. A Phase 2 Study.|PROMIX|Karolinska University Hospital|No|Active, not recruiting|September 2008|November 2016|Anticipated|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Female|18 Years|N/A|No|||September 2015|September 20, 2015|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00957125||134853|
NCT00957138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-02-31|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2009|||||N/A|N/A|N/A||||||||||||||August 11, 2009|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957138||134852|
NCT00957151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04007|Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis|Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis||Hospital Avicenne||Completed|April 2004|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|12|||Both|18 Years|65 Years|No|||August 2009|August 11, 2009|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957151||134851|
NCT00958035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-039|Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis|||Allergan||Completed|November 2009|August 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||November 2011|November 30, 2011|August 11, 2009|Yes|Yes||No|November 30, 2011|https://clinicaltrials.gov/show/NCT00958035||134784|
NCT00958048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812112R|Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis|Effects of Early Intervention With Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Controlled Trial||National Taiwan University Hospital|Yes|Completed|January 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|February 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00958048||134783|
NCT00958321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-35 ICORG|Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35|Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy||ICORG- All Ireland Cooperative Oncology Research Group||Terminated|March 2007|||December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|December 30, 2014|August 12, 2009||No|Low levels of recruitment|No||https://clinicaltrials.gov/show/NCT00958321||134762|
NCT01006369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070806|Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)||Rutgers, The State University of New Jersey|No|Suspended|May 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|October 30, 2009|Yes|Yes|Interim analysis|No||https://clinicaltrials.gov/show/NCT01006369||131119|
NCT00998777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SwimmersShoulder|Shoulder Injury Prevention Program in Swimmers|The Effect of a 6-week Shoulder Strengthening Program on Scapular Kinematics and Shoulder Strength in Division I Collegiate Swimmers||University of North Carolina, Chapel Hill|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|48|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998777||131698|
NCT00998790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0602|A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence|A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence||American Medical Systems|No|Active, not recruiting|January 2007|May 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Male|40 Years|N/A|No|||March 2011|March 31, 2011|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00998790||131697|
NCT01006876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI-COMPARE|Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation|Role of Coumadin in Preventing Periprocedural Thrombo-Embolism as a Complication of Radio Frequency Catheter Ablation in High-risk Atrial Fibrillation Patients|COMPARE|Texas Cardiac Arrhythmia Research Foundation|No|Completed|January 2010|April 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1584|||Both|18 Years|75 Years|No|||May 2015|May 19, 2015|November 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01006876||131081|
NCT01006889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20060167-2|Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease|A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)||The University of Texas Health Science Center at San Antonio|No|Completed|January 2008|February 2010|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||April 2012|April 26, 2012|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006889||131080|
NCT00999063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GTH-NEX-2009/1|Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand|Prevalence of GERD in Patients With upperGITsymptoms in Thailand|GerdQ|AstraZeneca|No|Completed|December 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4108|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic|March 2011|March 30, 2011|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999063||131676|
NCT00999076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-004|Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens|Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens||Samsung Medical Center|No|Terminated|September 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Sputum with positive AFB smear|Both|N/A|N/A|No|Non-Probability Sample|Patients with AFB-smear positive sputum|December 2012|December 17, 2012|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999076||131675|
NCT00999687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG280191|Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails|Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails||Chang Gung Memorial Hospital|Yes|Completed|September 2009|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|October 20, 2009||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT00999687||131628|
NCT00999973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8804|Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia|Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia||hahid Beheshti University of Medical Sciences|Yes|Recruiting|September 2009|||||Phase 1|Interventional|N/A|2||||||Both|19 Years|60 Years||||October 2009|October 21, 2009|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00999973||131607|
NCT00999739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maria Penaranda|Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults|A Sequential Vaccination Strategy With Conjugated and Polysaccharide Pneumococcal Vaccines Compared With Polysaccharide Vaccine in HIV- Infected Adults.||Hospital Universitari Son Dureta|No|Recruiting|December 2007|April 2010|Anticipated|April 2008|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|No|||October 2009|November 6, 2009|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999739||131625|
NCT00996580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-103-301|A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy|A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women||Teva Pharmaceutical Industries|No|Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3597|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|October 15, 2009|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT00996580||131866|
NCT00996593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104507|Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab|Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma Patients Who Have Previously Received Rituximab||GlaxoSmithKline||Completed|July 1998|April 2010|Actual|August 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|October 8, 2009|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT00996593||131865|
NCT00996281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491CLD_308|Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension|A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension||Takeda|No|Completed|October 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|837|||Both|18 Years|N/A|No|||October 2012|October 15, 2012|October 12, 2009|Yes|Yes||No|October 15, 2012|https://clinicaltrials.gov/show/NCT00996281||131889|
NCT00955916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15787|CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|August 2009|May 2014|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|August 5, 2009|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT00955916||134945|
NCT00956189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812110M|Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome|Easy Identification, Treatment Response Prediction, and Molecular Mechanism Exploration of Antipsychotic-related Metabolic Syndrome||National Taiwan University Hospital|No|Completed|November 2009|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|20 Years|N/A|No|||November 2012|January 2, 2013|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956189||134924|
NCT00956488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-08-15E|Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis|Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis||Carolinas Healthcare System|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|9|||Both|25 Years|75 Years|No|||July 2013|July 31, 2013|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956488||134901|
NCT00956826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fetal monitoring vaccum|Continuous Fetal Monitoring During Vacuum Delivery|Continuous Fetal Monitoring During Vacuum Delivery an Addition of a New Device||Hadassah Medical Organization|No|Not yet recruiting|September 2009|December 2010|Anticipated|April 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|1 Day|No|||August 2009|August 10, 2009|July 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00956826||134875|
NCT00957164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRONGSTAR*PAIN*PTSD|Treatment of Post-Traumatic Stress Disorder (PTSD) and Chronic Pain After Traumatic Orthopedic Injury|Treatment of PTSD and Chronic Pain After Traumatic Orthopedic Injury: A Randomized Clinical Trial||The University of Texas at Arlington|Yes|Completed|August 2009|September 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|70 Years|No|||January 2014|January 29, 2014|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00957164||134850|
NCT00957177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PregabaNeph|Analgetic Effect of Preoperative Pregabalin in Patients Undergoing Nephrectomy|Effect of Preoperative Pregabalin Administration on the Postoperative Opioid Consumption in Patients Undergoing Nephrectomy|PregabaNeph|Medical University of Graz|Yes|Completed|April 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2011|May 26, 2011|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957177||134849|
NCT00957489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTT project|A Prospective Randomized Controlled Trial to Evaluate the Effectiveness of the Two Different Appliances in the Treatment of Class II Division 1 Malocclusion|||University of Manchester|Yes|Terminated|January 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||August 2009|August 11, 2009|August 11, 2009||No|Study stopped due to increased harm and slow progress in the intervention group.|No||https://clinicaltrials.gov/show/NCT00957489||134825|
NCT00957463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 08-023|Effects of Obstructive Sleep Apnea and/or Cigarette Smoking on Endothelial Function|Effects of Intermittent Hypoxia and/or Cigarette Smoking on Endothelial Injury in Vivo - Relevance to Obstructive Sleep Apnea||The University of Hong Kong||Completed|June 2008|||December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive subjects who undergo polysomnograms (PSG) in the Sleep Disorder Centre,        Department of Medicine, Queen Mary Hospital, and who fulfill the study criteria will be        recruited.|December 2014|December 29, 2014|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00957463||134827|
NCT00957476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD057236-01A1|Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy|Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy||MetroHealth Medical Center|Yes|Recruiting|September 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 16, 2010|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957476||134826|
NCT00957762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6232I|Body Composition Assessment in Spinal Cord Injury|Body Composition Assessment in Spinal Cord Injury||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Recruiting|August 2009|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|65 Years|No|Non-Probability Sample|Individuals with a spinal cord injury of C5-L2 motor complete (AIS A&B only).|August 2009|August 11, 2009|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00957762||134805|
NCT00957775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA025072|Computer-delivered Psychosocial Intervention for Adolescent Substance Use Disorders|Computer-delivered Psychosocial Intervention for Adolescent Substance Use Disorders||National Development and Research Institutes, Inc.|No|Not yet recruiting|August 2009|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|12 Years|18 Years|No|||August 2009|August 11, 2009|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957775||134804|
NCT00999102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901010162|Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life|Nebivolol Vs. Metoprolol: Comparative Effects on Fatigue and Quality of Life||Weill Medical College of Cornell University|No|Completed|October 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|37|||Both|21 Years|80 Years|No|||March 2012|March 16, 2012|October 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00999102||131673|
NCT01006902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oncology therapy in elderly|Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change|Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change||University of Vermont|Yes|Terminated|November 2009|May 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples Without DNA|Serum samples will be obtained and stored at -80 degrees celsius|Both|65 Years|90 Years|No|Non-Probability Sample|Individuals age 65 or older diagnosed with a malignancy and receiving chemotherapy or        androgen deprivation therapy as part of their oncology therapy.|November 2011|November 28, 2011|November 2, 2009||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01006902||131079|
NCT00999414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111527|UARK 2009-32 Compassionate Use Study of Carfilzomib|Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma|2009-32|University of Arkansas|No|No longer available|November 2009|April 2015|Anticipated|April 2015|Anticipated|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 20, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00999414||131649|
NCT00999674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4113|The Effect of an Exercise Program on the Health-quality of Life (HQL) in Older Adults|The Effect of an Exercise Program on the Health-quality of Life (HQL) in Older|HQL|Shahrekord University|No|Completed|March 2008|May 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Health Services Research|||Actual|60|||Both|55 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 21, 2009|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00999674||131629|
NCT00999999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tachousb-1|Efficacy of Tachosil as Dural Sealant Compared to Standard Treatment|Fleece Bound Tissue Sealing With TachoSil® to Assist in Closing of the Dura Mater After Elective Craniotomy to Reduce Postoperative Cerebrospinal Fluid (CSF) Leakage.||University Hospital, Basel, Switzerland|Yes|Completed|October 2009|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT00999999||131605|
NCT01000012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A101-0501-08cu|Compassionate Use of the Becker Expander/Breast Implant|Compassionate Use of the Becker Expander/Breast Implant||Mentor Worldwide, LLC||No longer available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|N/A||||October 2013|October 28, 2013|October 21, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT01000012||131604|
NCT01000025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR26|PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer|A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease||Canadian Cancer Trials Group|Yes|Completed|September 2009|November 2015|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|720|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|October 21, 2009||No||No|September 19, 2014|https://clinicaltrials.gov/show/NCT01000025||131603|Despite the eligibility requirement for tumor samples, samples were not available or inadequate for translational studies in 30 - 40% of patients. This does limits the power of the secondary analyses examining biomarker driven outcomes.
NCT00997477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFOR258FTR03|Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics|A Single Arm, 12 Week, Multicentre, Open Label, Phase IV Study to Evaluate Correct Use of and Patient Satisfaction From Sequential Use of Formoterol and Budesonide Inhaler Capsules Via Aerolizer™ Device in Patients With Asthma.||Novartis||Withdrawn|June 2010|||July 2010|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00997477||131797|
NCT00997997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12237|Avelox in Complicated Skin and Skin Structure Infections|ARTOS - Avelox® in Routine Treatment of Complicated Skin and Skin Structure Infections|ARTOS|Bayer|No|Completed|October 2005|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6127|||Both|10 Years|N/A|No|Non-Probability Sample|Patients being diagnosed with complicated skin and skin structure infections, mainly in        hospital settings|November 2012|November 14, 2012|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00997997||131757|
NCT00997750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-CCH-51|Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome|Prospective Randomized Double-center Study of Nonsteroidal Antinflammatory Drug Lornoxicam in Patients With Acute Coronary Syndrome Without Persistent ST- Segment Elevation|PLEA|Central Clinical Hospital with Outpatient Health Center of Business Administration for the President of Russian Federati|Yes|Completed|March 2007|June 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||October 2009|October 18, 2009|October 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00997750||131776|
NCT00998517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOYA2009|Effectiveness Comparison of Three Supplementary Foods in the Treatment of Moderate Acute Malnutrition|Comparison of a Novel Fortified Blended Flour to Ready-to-use Supplemental Foods for the Treatment of Moderate Acute Malnutrition in Rural Malawian Children: a Randomized, Investigator-blinded, Clinical Effectiveness Trial||Washington University School of Medicine||Completed|October 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|2712|||Both|6 Months|59 Months|No|||April 2014|April 14, 2014|October 19, 2009||No||No|August 15, 2012|https://clinicaltrials.gov/show/NCT00998517||131718|
NCT00955929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005|Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy|A Randomized Trial of Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Male|18 Years|N/A|No|||October 2015|October 28, 2015|August 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00955929||134944|
NCT00956202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF08|A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years|Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years||Sanofi|No|Completed|August 2009|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|303|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00956202||134923|
NCT00956501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 02-09-12B|Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)|Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)||Carolinas Healthcare System|No|Completed|February 2009|February 2011|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with Amyotrophic Lateral Sclerosis|July 2013|July 31, 2013|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00956501||134900|
NCT00956514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02-045|Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder|Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder||University of California, Los Angeles|No|Completed|July 2009|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|64 Years|No|||February 2013|February 4, 2013|August 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956514||134899|
NCT00956527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0681|Martial Arts as Early Intervention for Teen Drug Abuse|Martial Arts as Early Intervention for Teen Drug Abuse||University of Colorado, Denver|No|Completed|May 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|13 Years|17 Years|No|||June 2013|June 18, 2013|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956527||134898|
NCT00956839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGI/AA/EMP/IEC/46/25.7.09|Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis|Double-blind Randomized Study to Determine the Efficacy of Intramuscular Vitamin D3 Supplementation in Tropical Calcific Pancreatitis||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Completed|July 2009|December 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|50 Years|No|||February 2013|February 10, 2013|August 10, 2009||No||No|July 23, 2012|https://clinicaltrials.gov/show/NCT00956839||134874|
NCT00957190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|157-00|The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)|Change in Optic Nerve Head Blood Flow,Optic Nerve Topography and Diurnal Fluctuation of Intraocular Pressure and Pulsatile Ocular Blood Flow in Glaucoma:Cosopt and Xalatan vs Xalatan Alone|DIOXXACT|Maisonneuve-Rosemont Hospital|Yes|Enrolling by invitation|June 2009|September 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|30 Years|80 Years|No|||August 2009|August 11, 2009|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957190||134848|
NCT00957502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA2009-03|ENTact™ Septal Stapler Shelf Life Extension|A Prospective, Limited-Use Evaluation of the ENTact™ Septal Stapler for Tissue Approximation Utilizing Staples With Extended Shelf Life|SSLE|ENTrigue Surgical, Inc.|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||August 2012|August 21, 2012|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957502||134824|
NCT00957788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST-CP-02|Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus|Safety and Feasibility Study of NST - 001 in Inner Ear Using Neuroject Injection Set for the Treatment of Tinnitus||NeuroSystec Corporation|Yes|Terminated|January 2009|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|8|||Both|18 Years|70 Years|No|||June 2011|April 18, 2013|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00957788||134803|
NCT00958074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6914|Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma|A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin||University of Washington|No|Terminated|July 2009|November 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|August 10, 2009|No|Yes|Terminated due to slow accrual|No|December 4, 2013|https://clinicaltrials.gov/show/NCT00958074||134781|Early termination leading to small numbers of subjects analyzed
NCT00998192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 021|A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung|A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung||Oncolytics Biotech|No|Completed|October 2009|August 2015|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00998192||131742|
NCT01000571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOVAC|Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults|Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults||St. Jude Children's Research Hospital|No|Completed|October 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|104|Samples With DNA|Blood sample collection will be done according to the description provided in the      institutional policy manual. When possible, blood draws will be made through existing      implanted catheters. If the research participant does not have a catheter, a peripheral      venipuncture will be performed. Serum and whole blood for immune assays will be frozen at      -20ºC or in liquid nitrogen until processed in batched assays.|Both|6 Months|21 Years|No|Probability Sample|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater        in body weight who have an underlying diagnosis of cancer, HIV, sickle cell disease or        receipt of a stem cell transplant more than a year prior to study entry and who will        receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of        2009-2010 as part of their routine clinical care. Stem cell transplant recipients in the        first year following their transplant are excluded.|October 2011|October 5, 2011|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01000571||131561|
NCT00998751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04016|A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)|Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)||AB Science|No|Active, not recruiting|June 2005|June 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998751||131700|
NCT00998764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3133K1-3003|A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.||Pfizer|Yes|Terminated|December 2009|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|494|||Both|51 Years|90 Years|No|||November 2015|November 30, 2015|October 16, 2009|Yes|Yes|The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical    benefit. This decision was not based on any new safety concerns.|No|October 15, 2013|https://clinicaltrials.gov/show/NCT00998764||131699|
NCT00999713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01FD003410-01|CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients|A Phase 3 Trial of Calfactant for ALI in Pediatric Leukemia and HSCT Patients|CALIPSO|Penn State University|Yes|Completed|June 2010|October 2015|Actual|September 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Months|21 Years|No|||November 2015|November 20, 2015|October 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00999713||131626|
NCT00999193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS-428/13/03/02/08|Treatment of Comminuted Fractures of the Proximal Humerus. A Randomised, Controlled Study|Effectiveness and Cost-Effectiveness of Operative and Conservative Treatment of Comminuted Fractures of the Proximal Humerus. A Randomised, Controlled Study.||Helsinki University|No|Recruiting|November 2010|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|65 Years|N/A|No|||October 2015|October 26, 2015|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999193||131666|
NCT00999505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-303|Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia|A Double-blind, Randomized, Placebo-controlled Trial With Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia||Hospital de Clinicas de Porto Alegre|No|Recruiting|May 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||February 2011|February 15, 2011|October 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00999505||131642|
NCT00996294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA-CHIR|Surgical Treatment of Type 2 Diabetes Mellitus in <35 Body Mass Index (BMI)|Surgical Treatment of Type 2 Diabetes Mellitus in Patients With BMI <35 kg/m2 (Italian Title: "La Terapia Chirurgica Del Diabete Mellito di Tipo 2 Nel Paziente Con BMI Inferiore a 35 kg/m2")||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Active, not recruiting|November 2007|October 2013|Anticipated|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|35 Years|70 Years|No|||October 2009|January 11, 2010|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996294||131888|
NCT00996307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V112_06|Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months|Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1) 2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months||Novartis|Yes|Completed|October 2009|December 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|654|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||December 2011|December 7, 2011|October 15, 2009|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT00996307||131887|
NCT00998244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0623|Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease|A Randomized, Double-Blind Crossover Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease||University of North Carolina, Chapel Hill|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||January 2012|January 6, 2012|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT00998244||131738|
NCT00998530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0138|Trichomoniasis: Genotype and Phenotype Correlations in African American Women|Trichomoniasis: Genotype and Phenotype Correlations in African American Women||University of Mississippi Medical Center|No|Recruiting|September 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|320|Samples With DNA|Trichomonas vaginalis clinical isolates|Female|18 Years|65 Years|No|Non-Probability Sample|Patients presenting to clinic sites with symptoms of a sexually transmitted disease|April 2012|April 11, 2012|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00998530||131717|
NCT00999453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-02|The Effects of Lowering Low-density Lipoprotein Cholesterol Levels to New Targets on Cardiovascular Complications in Peritoneal Dialysis Patients|||Clinical Research Center for End Stage Renal Disease, Korea|Yes|Recruiting|October 2009|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1222|||Both|20 Years|70 Years|No|||October 2009|January 18, 2011|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT00999453||131646|
NCT00956566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-SMART|Comparison of Low Fat and Low Carbohydrate Diets With Respect to Weight Loss and Metabolic Effects|Randomized Parallel Group Comparison on the Influence of a Low Carbohydrate and a Low Fat Hypocaloric 6 Months Diet on Body Weight Reduction, Metabolic and Cardiovascular Variables in Obese Healthy Women and Men.|B-SMART|Hannover Medical School|No|Completed|April 2007|July 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|60 Years|No|||July 2012|July 27, 2012|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956566||134895|
NCT00956865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|433|Community Glaucoma Screening Follow-up|Community Glaucoma Screenings: Assessment of Interventions to Improve Follow-up||Wills Eye|No|Completed|September 2002|September 2002|Actual|September 2002|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|3||Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2009|August 10, 2009|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956865||134872|
NCT00956215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Emend|Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients|A Randomized and Placebo-Controlled Evaluation of Aprepitant for Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients|PONV|University of Pennsylvania|Yes|Completed|May 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|125|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00956215||134922|
NCT00956878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC2008-166|Cancer Pain Single Nucleotide Polymorphisms (SNPs)|Storage and Analysis of Patient Blood-samples for Cancer Pain Research||Erasmus Medical Center|No|Completed|September 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|243|Samples With DNA|Whole Blood|Both|18 Years|N/A|No|Non-Probability Sample|Cancer pain patients in a large university hospital|December 2014|December 23, 2014|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956878||134871|
NCT00956540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29/06/09-54|Does Deflating the Tracheal Cuff Shorten Weaning Time?|Effect of Deflating the Tracheal Cuff During Ventilatory Disconnections on Weaning Time||Hospital Virgen de la Salud|Yes|Completed|December 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|195|||Both|18 Years|80 Years|No|||August 2011|August 19, 2011|August 6, 2009||No||No|July 1, 2011|https://clinicaltrials.gov/show/NCT00956540||134897|
NCT00956553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV CSP01|Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls|A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines|HPV CSP01|Public Health England|No|Completed|September 2009|September 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|400|||Female|13 Years|15 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956553||134896|
NCT00956852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 08-249|Study on Systemic and Airway Cytokines and Oxidative Stress in Lung Cancer Patients Undergoing Surgery|Study on Systemic and Airway Cytokines and Oxidative Stress in Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Surgical Lung Resections||The University of Hong Kong|No|Recruiting|September 2008|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Plasma, buffy coat, red blood cell and exhaled breath condensate samples.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with early stage NSCLC who undergo curative lung resections in the Division of        Cardiothoracic Surgery, Department of Surgery, Queen Mary Hospital will be recruited.|December 2014|December 1, 2014|August 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00956852||134873|
NCT00958113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0931|Autoimmune Thyroid Disease Genetic Study|Autoimmune Thyroid Disease Genetic Study||University of Colorado, Denver|No|Completed|July 2009|May 2015|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|199|Samples With DNA|Saliva|Both|7 Years|N/A|No|Non-Probability Sample|Patients seen in Endocrinology Clinic|May 2015|May 26, 2015|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00958113||134778|
NCT00958373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02333|Risk Factors for Psychiatric Disorders Associated With Adolescent Idiopathic Scoliosis|Risk Factors for Psychiatric Disorders Associated With Adolescent Idiopathic Scoliosis||University of British Columbia|No|Withdrawn|October 2006|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|11 Years|16 Years|No|Probability Sample|Patients between the ages of eleven and sixteen who may have a prevalence of psychiatric        illness at various time points in the course of treatment of AIS.|June 2011|May 5, 2015|August 12, 2009||No|Didn't have the resources necessary to carry out the study|No||https://clinicaltrials.gov/show/NCT00958373||134758|
NCT00957801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-070|Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men|Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men||The University of Texas Medical Branch, Galveston|No|Recruiting|March 2009|December 2018|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|60 Years|85 Years|Accepts Healthy Volunteers|||September 2015|November 30, 2015|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957801||134802|
NCT00958087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-PET|Cardiac Sarcoidosis and FDG-PET|18F-fluorodeoxyglucose Positron Emission Tomography Imaging in Cardiac Sarcoidosis Reveals Characteristic Heterogeneity of Tracer Uptake and the Disease Activity in Myocardium||Kurume University|Yes|Completed|March 2004|July 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|20|||Both|35 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Fasting FDG-PET will be performed in patients with sarcoidosis and age-matched DCM        patients. Among them, systemic sarcoidosis will be diagnosed clinically and/or        histologically, and referred for cardiac sarcoidosis. Patients with sarcoidosis will        reveal cardiac involvement based on guidelines established in 2006 by the Japanese        Ministry of Health and Welfare. Healthy control subjects will undergo FDG-PET.|July 2010|September 26, 2012|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958087||134780|
NCT00998465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-99|Hemodynamics, Salt Sensitivity and Body Composition in Patients With Morbid Obesity|Hemodynamics, Salt Sensitivity and Body Composition in Patients With Morbid Obesity - Effect of Weight Loss Following Laparoscopic Gastric Bypass||Roskilde County Hospital||Completed|November 2009|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|36|Samples With DNA|Blood samples: p-glucose, p-insulin, MR-proANP, hemoglobine, sodium, potassium, creatinine,      albumine.      Urine collections: u-sodium, u-potassium, u-creatinine|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The cases are recruited from the Bariatric Clinics at Glostrup Hospital, Koege Hospital        and The Private Hospital Hamlet.        Controls are recruited through public advertisement|March 2013|March 19, 2013|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998465||131721|
NCT01000584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02811|Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Adults, Including Randomized Comparison of Concurrent or Delayed Seasonal Influenza Vaccination||University of British Columbia|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|309|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01000584||131560|
NCT00999089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3CAB-STUDY|Arrested Versus Beating Heart Techniques in Coronary Revascularisation|Arrested Versus Beating Heart Techniques in Coronary Revascularisation: Randomized Clinical Trial in Unselected Patients||Martin-Luther-Universität Halle-Wittenberg|No|Active, not recruiting|January 2003|September 2010|Anticipated|September 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|616|||Both|18 Years|N/A|No|||October 2009|October 20, 2009|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00999089||131674|
NCT00999427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00289|Prostate Biopsy Antisepsis|Antiseptic Preparation of the Rectum Prior to Transrectal Prostate Biopsy||University of British Columbia|Yes|Completed|October 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|865|||Male|21 Years|N/A|No|||May 2012|May 4, 2012|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00999427||131648|
NCT00998556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPCM|Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy|Effect of Bromocriptine on LV Function in Women With Peripartum Cardiomyopathy A Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Bromocriptine for Improvement of Left Ventricular Function of Women With PPCM|PPCM|Hannover Medical School|No|Recruiting|June 2010|April 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||September 2012|September 12, 2012|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998556||131715|
NCT01000558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000390329|SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma|Central Lymphoma Serum Repository Protocol||Southwest Oncology Group|No|Completed|March 2005|July 2011|Actual|July 2011|Actual|N/A|Observational|N/A||1|Actual|939|Samples With DNA|blood and serum for patients consenting to banking on lymphoma treatment studies|Both|18 Years|N/A|No|Non-Probability Sample|Patients consenting to 8947 banking of blood and serum|May 2013|May 17, 2013|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01000558||131562|
NCT00996866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08028|Vitamin D Supplementation Requirement in Obese Subjects|Vitamin D Supplementation Requirement in Obese Subjects||Winthrop University Hospital|No|Completed|December 2008|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||December 2014|December 12, 2014|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996866||131844|
NCT01005953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R41MH086153-01|Comprehensive Collection, Charting, and Communication System|Phase 1 Study of a Digital/Internet/Mobile System for Collecting, Charting and Communicating About the Behaviors of Children on the Autism Spectrum|CCCCSys|SymTrend Inc.|No|Active, not recruiting|October 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|70|||Both|22 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Qualitative Family Research: This research is open to families with children 3-10 with        autism who have broadband Internet access at home or at work, whose children receive        services from more than one caregiver (OT, special educator, speech pathologist,        behavioral analyst/therapist).        Qualitative Professional Research: This research is open to professionals working with        children 3-10 with autism who have broadband Internet access and who keep detailed records        about the work they do with their clients.        Quantitative Research: Only open to families and professionals who are part of two school        districts: Cambridge, MA and Newton, MA, who also meet the above criteria.|June 2011|June 6, 2011|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005953||131151|
NCT00999466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0540C00004|The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen|A Double-blind, Placebo-controlled, Randomised, Parallel Group, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.||AstraZeneca|No|Completed|October 2009|December 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|No|||January 2016|January 28, 2016|October 20, 2009||No||No|August 31, 2015|https://clinicaltrials.gov/show/NCT00999466||131645|
NCT00956579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P001768|Sensory and Connectivity Abnormalities in Autism and Language Disorders|Psychophysics and Neurodynamic MEG/EEG Imaging of Sensory and Connectivity Abnormalities in Neurodevelopmental Disorders.||Massachusetts General Hospital|No|Recruiting|September 2005|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|260|||Both|6 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Massachusetts General Hospital other institution: Cambridge Hospital Child Development        Center|May 2010|May 3, 2010|October 23, 2007||No||No||https://clinicaltrials.gov/show/NCT00956579||134894|
NCT00957203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-010|Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients|Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)|6002-010|Kyowa Hakko Kirin Company, Limited|No|Completed|October 2009|March 2012|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|308|||Both|20 Years|N/A|No|||August 2012|August 30, 2012|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00957203||134847|
NCT00957216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-129|Coenzyme Q10 in Adult-Onset Ataxia|Safety and Tolerability of Coenzyme Q10 in Adult-Onset Sporadic Spinocerebellar Ataxia|CoQATAX|The University of Texas Medical Branch, Galveston|No|Completed|April 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|80 Years|No|||April 2010|April 15, 2010|June 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957216||134846|
NCT00957528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-302|Cycled Testosterone Replacement Study|The Effects of Cyclic Testosterone Administration on Muscle Function in Older Individuals||The University of Texas Medical Branch, Galveston|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|26|||Male|60 Years|85 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|August 10, 2009|Yes|Yes||No|July 19, 2012|https://clinicaltrials.gov/show/NCT00957528||134823|
NCT00957541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITSY02|Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device|Clinical Evaluation of the Physiological Diagnosis Function in the Paradym CRT Device|CLEPSYDRA|ELA Medical, Inc.|Yes|Completed|September 2009|April 2013|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|520|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|August 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957541||134822|
NCT00957814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS and HCPA 14741|Nutritional Orientations and Adherence, Nutritional Status, Clinical and Life Quality Parameters of Heart Failure (HF) Patients|Impact of Nutritional Orientations on Adherence to Diet and Relation to Nutritional, Clinical and Life Quality Parameters of Heart Failure Outpatients||Federal University of Rio Grande do Sul|Yes|Enrolling by invitation|September 2009|November 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|46|||Both|18 Years|N/A|No|||August 2009|August 11, 2009|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957814||134801|
NCT00958100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009−014316−35|Raltegravir Switch for Toxicity or Adverse Events|Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Combined Antiretroviral Regimen|RaSTA|Catholic University of the Sacred Heart|No|Completed|August 2009|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958100||134779|
NCT00957827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809859|Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip|Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip||University of Pennsylvania|No|Terminated|August 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Months|N/A|No|||December 2015|December 9, 2015|August 11, 2009|Yes|Yes|Not enough subject enrolled|No||https://clinicaltrials.gov/show/NCT00957827||134800|
NCT00958126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-CAL-09-61|A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA|A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults Aged 18 Years and Older||CSL Limited|Yes|Completed|August 2009|April 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1313|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 31, 2012|August 12, 2009|Yes|Yes||No|July 5, 2012|https://clinicaltrials.gov/show/NCT00958126||134777|
NCT00958386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-08-06|Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)|Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With Irinotecan in Patients With Wild-Type KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy|SPECTRA|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|August 2009|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958386||134757|
NCT00958763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G051003101|Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)|Alcohol Use Reduction in Methadone Individuals With HCV|NIAAA|University of California, Los Angeles|Yes|Completed|March 2006|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|219|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2009|August 12, 2009|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958763||134729|
NCT00958776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-301|A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza|A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza||BioCryst Pharmaceuticals|Yes|Terminated|November 2009|October 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|405|||Both|12 Years|N/A|No|||January 2015|January 28, 2015|August 12, 2009|Yes|Yes|This study was terminated for futility|No|January 16, 2015|https://clinicaltrials.gov/show/NCT00958776||134728|Interim analysis of the primary efficacy endpoint (time to clinical resolution) performed after the end of the 2012 Southern Hemisphere influenza season lead to study termination for futility. Final enrollment was ~70% of the planned enrollment.
NCT00958789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65|Triathlon Total Stabilizer (TS) Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Triathlon® Total Stabilizer (TS) Total Knee System||Stryker Orthopaedics|No|Active, not recruiting|July 2009|April 2019|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|181|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|August 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00958789||134727|
NCT00998803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUSRV|Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults|Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults||St. Jude Children's Research Hospital|No|Completed|October 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples With DNA|-  Nasopharyngeal swab collection is as follows: after tilting the tip of the patient's           nose upward, a swab is inserted through the nostril along the floor of the nose into           the nasopharynx. Then, the swab is gently rotated, removed and placed in its receptacle           for delivery to the laboratory.        -  Respiratory specimens will be stored at 2-8ºC and processed within 24-48 hours of           collection. Serum and whole blood for immune assays will be frozen at -20ºC or in           liquid nitrogen until processed in batched assays.        -  All blood specimens will be sent to the laboratory for immunologic assays.|Both|N/A|21 Years|No|Probability Sample|This is a prospective surveillance study that evaluates research participants who are ≤ 21        years of age and diagnosed at SJCRH with acute respiratory illness due to influenza virus        confirmed by antigen detection, PCR or viral culture of clinical respiratory specimens.|October 2012|October 30, 2012|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998803||131696|
NCT00996905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02|Does Ultrasound Scanning of the Lumbar Spine Improve Patient Satisfaction and the Ease of Insertion Epidurals?|Does Ultrasound Scanning of the Lumbar Spine Improve Patient Satisfaction and the Ease of Insertion of Labour Epidural Catheters||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|128|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 22, 2011|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996905||131841|
NCT00999700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT NUMBER 2009-013402-14|Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin|Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin|INTERCEPTOR|Gruppo Oncologico del Nord-Ovest|No|Recruiting|September 2009|May 2021|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|278|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00999700||131627|
NCT00997217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPCmulticenter|The Effect of Remote Ischemic Preconditioning in the Cardiac Surgery|The Effect of Remote Ischemic Preconditioning on Mortality and Morbidity in Cardiac Surgery: a Randomized Controlled Trial|RIPC|Seoul National University Hospital|Yes|Completed|October 2009|November 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|1200|||Both|18 Years|80 Years|No|||February 2011|February 22, 2011|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00997217||131817|
NCT00998894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-453|Randomized Trial of Alerts in Patients Demonstrating a "Triple Low"|A Randomized Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a "Triple Low" of Mean-arterial Pressure, End-tidal Anesthetic Concentration, and Bispectral Index||The Cleveland Clinic|Yes|Recruiting|October 2009|March 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|9846|||Both|18 Years|N/A|No|Probability Sample|adults presenting for non-cardiac surgery under volatile general anesthesia|February 2016|February 27, 2016|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT00998894||131689|
NCT00999440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-SB-0104-09-CTIL|QTc and Perceived Sleep Follow up Among Chronic Pain Patients With Opiate Medication|QTc and Perceived Sleep Follow up Among Chronic Pain Patients With Opiate Medication||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2010|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|90 Years|No|||December 2009|January 20, 2010|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT00999440||131647|
NCT01005381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0609004386|Effect of Calcium Supplement Particle Size and Vitamin D Supplement on Calcium Retention in Adolescent Girls|The Effect of Particle Size of Calcium Carbonate and Vitamin D on Calcium and Bone Parameters in Adolescent Girls||Purdue University|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|55|||Female|12 Years|14 Years|Accepts Healthy Volunteers|||October 2009|October 30, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005381||131195|
NCT01005654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090242|Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms|Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms||National Institutes of Health Clinical Center (CC)||Recruiting|September 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1350|||Both|7 Years|100 Years|No|||December 2015|January 1, 2016|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01005654||131174|
NCT01005979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00024085|A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)|A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and SLL||Emory University|Yes|Terminated|July 2010|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|September 30, 2009|No|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01005979||131149|
NCT01006226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1640|64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab|A Pilot Study of 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer Patients Treated With Carboplatin, Paclitaxel, and Bevacizumab||Washington University School of Medicine|No|Withdrawn||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|October 29, 2009|Yes|Yes|Withdrawn due to funding issues|No||https://clinicaltrials.gov/show/NCT01006226||131130|
NCT01006252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13101|A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma|A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients With Metastatic Melanoma|SUMMIT-1|Eli Lilly and Company|Yes|Terminated|December 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||March 2011|August 9, 2011|October 30, 2009|Yes|Yes|More possibly-related deaths on tasisulam arm; failed to pass futility hurdle|No||https://clinicaltrials.gov/show/NCT01006252||131128|
NCT01006759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRPUSP|Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients|Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients||University of Sao Paulo|Yes|Completed|January 2007|August 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|55|||Both|18 Years|N/A|No|||November 2009|November 2, 2009|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006759||131090|
NCT01006213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI070087|Group Motivational Intervention in Overweight/Obese Patients|Group Motivational Intervention in Overweight/Obese Patients in Primary Prevention of Cardiovascular Disease in the Primary Healthcare Area (IMOAP)|IMOAP|Jordi Gol i Gurina Foundation|No|Recruiting|January 2008|December 2010|Anticipated|January 2008|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1200|||Both|30 Years|70 Years|No|||October 2009|October 30, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006213||131131|
NCT00956904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00027540|Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy|Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy||Johns Hopkins University|Yes|Terminated|August 2009|June 2013|Actual|June 2013|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|35 Years|75 Years|No|||June 2013|June 18, 2013|August 10, 2009||No|IRB approval expired.|No||https://clinicaltrials.gov/show/NCT00956904||134869|
NCT00956891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-senU 5010 hepatitisB|Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation|Therapeutic Effects Including Short-term Changes And Long-term Outcomes of Liver Failure Patients Caused by Chronic Hepatitis B After Single Transplantation With Autologous Bone Marrow Mesenchymal Stem Cells.||Sun Yat-sen University|Yes|Completed|May 2005|July 2010|Actual|June 2009|Actual|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|158|||Both|15 Years|70 Years|No|Probability Sample|Liver failure patients with HBV infection|August 2009|December 6, 2010|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00956891||134870|
NCT00957229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-026|To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)|A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)|GDC-0449|Children's Hospital & Research Center Oakland|Yes|Completed|August 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|35 Years|75 Years|No|||January 2016|January 13, 2016|August 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00957229||134845|
NCT00957242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017156|AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis|AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)|ACE-IPF|Duke University|Yes|Terminated|October 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|35 Years|80 Years|No|||April 2013|July 14, 2014|August 10, 2009|Yes|Yes|Excess of mortality in the treatment group created safety concerns.|No|March 4, 2013|https://clinicaltrials.gov/show/NCT00957242||134844|
NCT00957554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBAM_R_04219|Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy|Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy|I-ADD|Sanofi||Completed|July 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|435|||Both|18 Years|N/A|No|||October 2010|October 25, 2010|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00957554||134821|
NCT00957567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008667|Comparison Study of Breast Tomosynthesis Slice Thicknesses|A Comparison Study of Breast Tomosynthesis Images Reconstructed at 1 Millimeter and 5 Millimeter Slice Thicknesses||Emory University|No|Completed|April 2009|December 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|182|||Female|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The target population for this study is women who are recalled for an abnormal finding on        a screening mammogram.|November 2013|November 19, 2013|August 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00957567||134820|
NCT00989391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0711002|A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects||Pfizer|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 15, 2009|October 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989391||132417|
NCT00989404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113625|Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days|A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects|NAI113625|GlaxoSmithKline||Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 23, 2009|September 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989404||132416|
NCT00989651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03730|Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent/ CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Recruiting|October 2009|||September 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|474|||Female|18 Years|N/A|No|||November 2015|February 24, 2016|October 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00989651||132397|
NCT00989664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104504|Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma|Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies||GlaxoSmithKline||Completed|November 1996|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2011|March 15, 2012|October 1, 2009|Yes|Yes||Yes|March 15, 2012|https://clinicaltrials.gov/show/NCT00989664||132396|
NCT00958399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701M00264|Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers|Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2008|April 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|August 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00958399||134756|
NCT00990197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-023|The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome|The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome: The STADIA Pilot Study|STADIA|Sir Mortimer B. Davis - Jewish General Hospital|Yes|Suspended|June 2005|December 2009|Anticipated|July 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2009|October 5, 2009|October 5, 2009||No|Difficulties with enrollment.|No||https://clinicaltrials.gov/show/NCT00990197||132355|
NCT00990210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-2009-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2009|||||N/A|N/A|N/A||||||||||||||October 2, 2009|October 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00990210||132354|
NCT01016106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH 2010-14049|Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population|Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population||Northwestern University|No|Completed|June 2010|September 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|35|||Both|6 Months|N/A|Accepts Healthy Volunteers|||April 2015|April 10, 2015|November 17, 2009||No||No|April 30, 2013|https://clinicaltrials.gov/show/NCT01016106||130377|
NCT01015807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36707-K|Transversus Abdominis Plane (TAP) Block for Cesarean Section|Transversus Abdominis Plane (TAP) Block for Cesarean Section|CLOTAP|University of Washington|Yes|Terminated|November 2009|August 2012|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|2|||Female|18 Years|45 Years|No|||September 2013|September 20, 2013|November 16, 2009||No|Limited number of eligible patients.|No||https://clinicaltrials.gov/show/NCT01015807||130399|
NCT01016704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTP-1|Reinforcing Therapist Performance|Reinforcing Therapist Performance|RTP|Chestnut Health Systems|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 26, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016704||130332|
NCT01016717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7345-MS-CTIL|Clopidogrel Proton-Pump Inhibitors Study|Clopidogrel Proton-Pump Inhibitors Study||Sheba Medical Center|No|Suspended|December 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||June 2012|June 14, 2012|November 18, 2009||No|Since the current data in the literature resolved the issue and answered the aim of the    current study|No||https://clinicaltrials.gov/show/NCT01016717||130331|
NCT01016730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03170|Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma|Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV||National Cancer Institute (NCI)||Active, not recruiting|January 2010|||September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01016730||130330|
NCT01022346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25025|A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection|A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and the Response Rate as to Histologic Resolution of 3 sc Administered Doses of RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection||Hoffmann-La Roche||Completed|October 2009|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|209|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|November 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022346||129905|
NCT01022684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOSEF20546|Correlation Between Various Inflammatory Markers and Vascular Inflammation Measured by 18FDG-PET|Correlation of Inflammatory Markers Such as LpPLA2,MCP-1 and hsCRP for Predicting Vascular Inflammation; Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography||Korea University|Yes|Completed|December 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|150|Samples Without DNA|Whole blood, serum|Both|20 Years|88 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participatin who underwent a medical health check in the health promotion center        in Korea Guro University|November 2009|February 19, 2010|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022684||129880|
NCT01022398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-15532|Vitamin D Replacement: The Effect on Statin-Related Myalgias|Vitamin D Replacement: The Effect on Statin-Related Myalgias||Creighton University|No|Terminated|February 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|19 Years|89 Years|No|||September 2012|March 28, 2013|November 27, 2009||No|Recruitment slow, funding ended.|No|March 28, 2013|https://clinicaltrials.gov/show/NCT01022398||129901|
NCT01023022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-CareLinkEval|CareLink® Network Evaluation|Medtronic CareLink® Network Evaluation Protocol||Medtronic Bakken Research Center|No|Completed|January 2010|October 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|176|||Both|N/A|N/A|No|Non-Probability Sample|Patients under the care at a participating study location who have an implanted Medtronic        Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy        Defibrillator (CRT-D) device that is supported by the Medtronic CareLink® Network.|April 2015|April 21, 2015|November 26, 2009||No||No|August 22, 2014|https://clinicaltrials.gov/show/NCT01023022||129854|
NCT01023256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-1001|Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis||MorphoSys AG|Yes|Completed|December 2009|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|November 19, 2009||No||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01023256||129836|Key limitations of this trial include its small sample size, limited duration, and exclusion of patients with severe rheumatoid arthritis. Larger clinical trials are needed to confirm these data and define the optimal MOR103 dosage.
NCT01022996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001NUS65|Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine- Based Treatment.|An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma||Novartis||Completed|December 2009|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022996||129856|
NCT01023009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC0006|Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion||Vitrectomy|Asociación para Evitar la Ceguera en México|No|Recruiting|May 2009|May 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|All the patients in inmediate postoperative vitreorretinal surgery without any        complications|November 2009|November 30, 2009|November 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01023009||129855|
NCT01025674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R305A080253|Randomized Trial of the Positive Action Program in Chicago Schools and Extension to Grade 8|Positive Action for Social and Character Development||Oregon State University|No|Completed|September 2004|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4230|||Both|6 Years|N/A|Accepts Healthy Volunteers|||September 2014|April 20, 2015|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01025674||129650|
NCT01025687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KidsStudy_21595|Television Viewing (TVV) & Puberty on Lunchtime Food Intake|Effect of Television Viewing (TVV) & Puberty on Lunchtime Food Intake & Subjective Appetite in Girls||University of Toronto|No|Completed|February 2009|October 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|25|||Female|9 Years|14 Years|Accepts Healthy Volunteers|||December 2009|December 2, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025687||129649|
NCT01026246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0009|EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults|Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|March 28, 2013|December 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026246||129607|
NCT01026259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29991-A|Local Warming of Surgical Incisions|Local Warming: Effects on Wound Infection and Healing||University of Washington|Yes|Completed|October 2005|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|146|||Both|18 Years|N/A|No|||December 2009|December 3, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01026259||129606|
NCT01025635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14955|Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea|Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Study to Investigate Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily in Subjects With Papulopustular Rosacea||Bayer|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|November 26, 2009|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT01025635||129653|
NCT01025960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-786|A Comparison of Methods to Detect Polyps During Colonoscopy|Comparison of Detection of Polyps During Both Insertion and Withdrawal Phases of Colonoscopy Versus the Standard Practice of Detection of Polyps During the Withdrawal Phase of Colonoscopy: A Prospective Quality Improvement Study||The Cleveland Clinic|Yes|Completed|November 2009|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|768|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025960||129628|
NCT01025973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-110|Evaluation and Validation of New Biomarkers by Mass Spectrometry|A New Approach by Mass Spectrometry for Evaluation and Validation of New Biomarkers of Fetus and Mother|DG7|Université de Sherbrooke|No|Completed|October 2009|February 2013|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|99|Samples Without DNA|Urine, whole blood, cord blood, plasma|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with or without diabetes and their newborn.|January 2016|January 4, 2016|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025973||129627|
NCT01026194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A7|Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes|A Phase III Study of MP-513 in Combination With Thiazolidinedione in Japanese Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|204|||Both|20 Years|75 Years|No|||January 2014|January 14, 2014|December 2, 2009||No||No|August 21, 2013|https://clinicaltrials.gov/show/NCT01026194||129611|
NCT01026181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002425|Gastric Procedures for Obesity|Phase II Study of Comparing Outcomes of Laparoscopic Sleeve Gastrectomy, Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Gastric Banding to Treat Morbid Obesity||University of Alberta|No|Completed|September 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|Morbidly obese patients aged from 18 to 65.|September 2011|September 22, 2011|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026181||129612|
NCT01026480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28518|Ileal Pouch-Anal Anastomosis Registry|Ileal Pouch-Anal Anastomosis (IPAA) Registry|IPAA|Boston Medical Center|No|Recruiting|November 2009|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|Patients scheduled for, or who have undergone, ileal pouch-anal anastomosis (IPAA)        procedure and have been treated by a Center for Digestive Disorders physician at Boston        Medical Center|June 2011|June 22, 2011|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01026480||129589|
NCT01015547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211864, 318/E0/2002|Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis|Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial.|ACUTE-JIA|Helsinki University Central Hospital|No|Completed|May 2003|December 2013|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|4 Years|15 Years|No|||October 2015|October 13, 2015|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015547||130419|
NCT01016405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0167|Prospective Health Assessment of Cataract Patients' Ocular Surface|Cataract and Dry Eye The PHACO Study (Prospective Health Assessment of Cataract Patients' Ocular Surface)||Innovative Medical||Completed|June 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|55 Years|N/A|No|Probability Sample|Primary care clinic.|January 2011|January 31, 2011|July 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01016405||130355|
NCT01016418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH Colostrum - HMO - CTIL|Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease|||Hadassah Medical Organization|Yes|Completed|January 2010|August 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||September 2010|September 16, 2010|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016418||130354|
NCT01016431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRON-INC-09|Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence|Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence||Federico II University|No|Recruiting|November 2009|August 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||November 2009|June 24, 2011|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01016431||130353|
NCT01021241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENZ-101|Safety and Efficacy Study of Intravenous Uricase-PEG 20|A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20||EnzymeRx|No|Active, not recruiting|October 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||February 2010|February 22, 2010|November 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021241||129988|
NCT01022359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0710/24|Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters|Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters|VyTes|Imperial College Healthcare NHS Trust|No|Recruiting|October 2008|January 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||July 2010|July 6, 2010|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022359||129904|
NCT01022372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009035|Endometrial Biopsy as Diagnostic Method for Endometriosis and Endometrioma|The Evaluation of Endometrial Biopsy in the Diagnosis of Endometriosis and Endometrioma: a Double Blind Study||Selcuk University||Active, not recruiting|November 2009|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Female|17 Years|45 Years|No|Non-Probability Sample|women in the reproductive age group undergoing laparoscopy for pelvic pain and/or        infertility, and not currently receiving hormonal treatment for at least 3 months prior to        laparoscopy will be included in the study.|July 2010|May 9, 2011|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022372||129903|
NCT01023035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06086|Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)|Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia||Merck Sharp & Dohme Corp.|Yes|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|687|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 24, 2009|No|Yes||No|October 16, 2012|https://clinicaltrials.gov/show/NCT01023035||129853|
NCT01018914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVLTx-0901-TW|A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients|A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus)/ Myfortic® and Advagraf® (Extended Release Tacrolimus) / Myfortic® in de Novo Liver Transplant Recipients||Astellas Pharma Inc|No|Completed|April 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|November 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018914||130164|
NCT01022697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00585-48|Evaluation of the Benefits of Glucose Drinks During Childbirth|Randomized Control Study : Evaluation of the Benefits of Glucose Drinks During Childbirth|SOLISO|University Hospital, Caen||Completed|January 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|4142|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 31, 2012|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022697||129879|
NCT01018901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 23808|Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment|Goals for Sexual Functioning of Prostate Cancer Survivors and Their Partners Following Cancer Treatment||Abramson Cancer Center of the University of Pennsylvania|No|Active, not recruiting|January 2009|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01018901||130165|
NCT01018524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSS-AHS 02-09|Open Mesh Versus Suture Repair in Treatment of Abdominal Wall Hernias|Results of Open Mesh Versus Suture Repair in Treatment of Abdominal Wall (Multicentric, Prospective, Randomised, Internet-based, Clinical Trial)|HSS-AHS|Hungarian Surgical Society|Yes|Completed|March 2002|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|2|||Both|18 Years|70 Years|No|||March 2010|March 7, 2010|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01018524||130194|
NCT01014988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113678|Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital|An Open-label, Multi-center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects With Confirmed Influenza Infection||GlaxoSmithKline|Yes|Completed|November 2009|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|6 Months|N/A|No|||August 2015|September 3, 2015|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014988||130462|
NCT01014429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLKA-937-001|Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors|A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors||Nerviano Medical Sciences|No|Completed|November 2009|||October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014429||130505|
NCT01025661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/7900-31/3|Effects of Chiropractic Care in Patients With Hip Osteoarthritis|Effects of Chiropractic Care on Pain and Function in Patients With Hip Osteoarthritis Waiting for Arthroplasty - a Controlled Clinical Pilot Trial||Scandinavian College of Chiropractic|Yes|Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|1||Actual|14|||Both|55 Years|80 Years|No|||December 2009|December 7, 2009|December 2, 2009||||No||https://clinicaltrials.gov/show/NCT01025661||129651|
NCT01025986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYEE120309|Uveitis in Relation to Perceived Stress: A Prospective Study|Uveitis in Relation to Perceived Stress: A Prospective Study||The New York Eye & Ear Infirmary|No|Recruiting|July 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting at the New York Eye and Ear Infirmary diagnosed with uveitis|December 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025986||129626|
NCT01026220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD0831|Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma|A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma||Children's Oncology Group|Yes|Active, not recruiting|December 2009|||September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|N/A|21 Years|No|||March 2015|March 3, 2015|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026220||129609|
NCT01026233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-007|Cardiac Safety Study of Brentuximab Vedotin (SGN-35)|An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies||Seattle Genetics, Inc.|No|Completed|January 2010|August 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|December 2, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01026233||129608|
NCT01026207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1989/08|Portable Monitoring Device for the Diagnosis of Sleep Apnea in Patients With Chronic Obstructive Pulmonary Disease|Validation of a Portable Monitoring Device for the Diagnosis of Obstructive Sleep Apnea Syndrome in Patients With Chronic Obstructive Pulmonary Disease||Associação Fundo de Incentivo à Pesquisa|Yes|Terminated|August 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Both|40 Years|80 Years|No|Probability Sample|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and        III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months,        and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.|February 2011|October 22, 2013|December 3, 2009||No|the data was completed.|No||https://clinicaltrials.gov/show/NCT01026207||129610|
NCT01026506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H34-08|c9,t11-CLA in Children and Adolescents With Allergic Asthma|Pilot Study on the Effects of Oral Intervention With c9,t11-conjugated Linoleic Acid in Children and Adolescents With Allergic Asthma||University of Jena|Yes|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|29|||Both|6 Years|18 Years|No|||December 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026506||129587|
NCT01020643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-168-GEN|Closed-loop Sedation of Propofol for Patients Undergoing Spinal Anesthesia|Comparison of Closed-loop Control System of Propofol Versus Manual Control Using Bispectral Index for Controlled Sedation - a Pilot Study||McGill University Health Center|No|Completed|November 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|203|||Both|18 Years|90 Years|No|||October 2013|October 24, 2013|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020643||130034|
NCT01020656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARIE02|Anticoagulant and Antiplatelet Agents in Patients Undergoing Vitreoretinal Surgery|Maintenance of Anticoagulant and Antiplatelet Agents for Patients Undergoing Vitreoretinal Surgery||Centre Hospitalier Universitaire Dijon|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||7|Actual|206|||Both|18 Years|N/A|No|Non-Probability Sample|We analyzed the chart of 239 eyes (206 patients) which underwent posterior segment surgery        with peribulbar anesthesia.|November 2009|November 24, 2009|November 24, 2009||||No||https://clinicaltrials.gov/show/NCT01020656||130033|
NCT01015820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002596|Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer|Detectable Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer||Mayo Clinic|Yes|Completed|June 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|37|||Both|18 Years|N/A|No|||July 2014|July 3, 2014|November 12, 2009||No||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01015820||130398|Small sample size, unmatched cohorts
NCT01016119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0915-CU|Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke|Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke||Catalysis SL|Yes|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|90 Years|No|||March 2010|March 4, 2010|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01016119||130376|
NCT01016132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-019-C-055|Clinical Evaluation of a Silicone Hydrogel Lens|||Alcon Research||Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|152|||Both|N/A|N/A|No|||September 2011|June 26, 2012|November 17, 2009|Yes|Yes||No|December 17, 2010|https://clinicaltrials.gov/show/NCT01016132||130375|
NCT01020929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09222009-3980|Incidence of Simultaneous Epidural and Intravascular Injection|Incidence of Simultaneous Epidural and Intravascular Injection During Cervical and Lumbosacral Transforaminal Epidural Injections||Stanford University|No|Completed|July 2009|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|We plan to enroll a total of 500 subjects ( 250 subjects undergoing cervical and 250        subjects undergoing lumbosacral transforaminal epidural injection ) ;(iii) patients will        have radiculopathies, herniated discs, and spinal stenosis coming to Stanford for an        epidural steroid injection|June 2012|June 5, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01020929||130012|
NCT01022073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|468F|Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation|CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort|CSP#468F|VA Office of Research and Development|Yes|Completed|June 2010|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|156|||Both|21 Years|95 Years|No|Non-Probability Sample|Patients with Parkinson's Disease who were enrolled in CSP 468, and received DBS.|May 2015|May 13, 2015|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01022073||129926|
NCT01022411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSCX1-YW-02-BR|Brown Rice Intervention on Metabolic Syndrome (BRIMS)|A Randomized Prevention Trial Substituting Brown Rice for White Rice to Lower Markers for Diabetes Risk|BRIMS|Chinese Academy of Sciences|No|Completed|October 2009|October 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|35 Years|60 Years|No|||October 2010|October 20, 2010|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022411||129900|
NCT01022086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiac CMR|Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab|Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study||St. Michael's Hospital, Toronto|No|Recruiting|November 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||5|Anticipated|50|Samples Without DNA|Mandatory: Troponin I/T and BNP will be assessed at each CMR time-point (and measured as per      the institution's standard biochemistry laboratory commercial assay techniques.      Optional: For consenting patients only, peripheral venous blood samples will be drawn at      each CMR time-point. Each sample will be obtained with a tourniquet free technique, then      undergo centrifugation to prevent platelet degranulation and enable platelet free serum to      be obtained. Serum will then be separated and stored at -800C for subsequent analysis. TGF      β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the      carboxyterminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay      with commercially available kits. The intra-assay variations for determining PINP, PIINP,      and CITP are 7%, 5%, and 8% respectively. CITP will be measured by ELISA according to the      manufacturer's instructions.|Both|18 Years|N/A|No|Non-Probability Sample|This will be a double-blinded prospective observational pilot study of breast cancer        patients with overexpression of HER2 on breast pathology (using either        immunohistochemistry [IHC] and/or fluorescence in-situ hybridization [FISH]), who have        never received trastuzumab before, who will be treated with chemotherapy (as per standard        of care) and trastuzumab. Target recruitment number will be 50 patients over 18-24 months.        Systemic therapy will include chemotherapy as dictated by Cancer Care Ontario's systemic        therapy practice guidelines for stage I-IV (i.e. early stage, locally advanced and        metastatic) breast cancer patients with HER2 overexpression.|December 2015|December 7, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022086||129925|
NCT01018927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110104|Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects|Role of Cardiac MR (CMR) In Detecting Features of Early Myocardial Infiltration With Amyloid and Light Chain Deposition Disease in Subjects With Multiple Myeloma||University of Arkansas|No|Active, not recruiting|June 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Multiple Myeloma subjects|April 2015|April 30, 2015|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01018927||130163|
NCT01018940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14882|Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease|Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease||University of Oklahoma|Yes|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|30|Samples With DNA|Blood specimens for platelet activity and genotyping|Both|18 Years|75 Years|No|Probability Sample|Patients with Coronary or Peripheral Artery Disease|December 2014|December 2, 2014|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01018940||130162|
NCT01023295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC402-201|Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)|OXiGENE OXC402-201: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Biological Effects of Intravenous Fosbretabulin in Asian Subjects With Polypoidal Choroidal Vasculopathy (PCV)||OXiGENE|Yes|Completed|July 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|20|||Both|21 Years|N/A|No|||October 2011|October 28, 2011|November 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01023295||129833|
NCT01019538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|897|Pre-flight Titration of Supplemental Oxygen|COPD and Air Travel: Oxygen Equipment and Pre-flight Titration of Supplemental Oxygen||Oslo University Hospital|Yes|Completed|December 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Arterial blood gases|Both|18 Years|N/A|No|Probability Sample|COPD patients|November 2009|July 3, 2011|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019538||130118|
NCT01015001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06382|A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine|A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine||Hospital de Clinicas de Porto Alegre|No|Completed|May 2008|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||August 2010|August 11, 2010|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01015001||130461|
NCT01026558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014185|A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients|Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients||Basilea Pharmaceutica|No|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|25|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|December 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026558||129583|
NCT01026831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2452-001|Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)|A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma and Ocular Hypertension||Merck Sharp & Dohme Corp.|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|643|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 2, 2009|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT01026831||129562|
NCT01027351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P6E1|Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine|A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Novartis Vaccine as Infants in Study V72P6||Novartis||Completed|January 2010|May 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|163|||Both|40 Months|62 Months|Accepts Healthy Volunteers|||February 2015|February 6, 2015|December 4, 2009|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT01027351||129522|
NCT01026545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0581002|Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects|A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects||Pfizer|No|Completed|December 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 3, 2011|December 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026545||129584|
NCT01026519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6R88-RA-0803|A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis|A Single-dose, Double-Blind, Placebo-Controlled, Parallel Group Safety, Tolerability and Pharmacodynamic Study of Subcutaneous REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate||Regeneron Pharmaceuticals||Completed|September 2008|May 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|No|||June 2011|September 27, 2013|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01026519||129586|
NCT01026532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2014-1481|Functional Activity of Airway Eosinophils in Allergic Disease|Functional Activity of Airway Eosinophils in Allergic Disease||University of Wisconsin, Madison|No|Recruiting|November 2009|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|38|||Both|18 Years|50 Years|No|||October 2015|October 9, 2015|December 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026532||129585|
NCT01020955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH/IGF-I|Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)|Effects on Insulin Sensitivity and Body Composition of GH and IGF-I in Adult-GHD With Impaired Glucose Tolerance or Diabetes||Karolinska University Hospital|Yes|Completed|October 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|14|||Both|18 Years|70 Years|No|||April 2015|April 6, 2015|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01020955||130010|
NCT01020331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Memantine in ALS|Memantine Therapy in Amyotrophic Lateral Sclerosis|Phase IIA Open Label Trial of Memantine in Combination With Riluzole (Customary Care) for the Treatment of ALS|TAME|Phoenix Neurological Associates, LTD|Yes|Completed|June 2005|October 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|85 Years|No|||November 2009|November 23, 2009|November 20, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01020331||130058|
NCT01020630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02-SUN-Case|Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI|A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI|SUN-CASE|Johannes Gutenberg University Mainz|Yes|Completed|November 2009|July 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020630||130035|
NCT01021618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELL002965HI|Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging|The Ex-Lex Trial: A Randomized Trial Combining Regadenoson With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging||Hartford Hospital|No|Completed|January 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|140|||Both|30 Years|N/A|No|||March 2013|March 18, 2013|November 25, 2009|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT01021618||129961|
NCT01021865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008750|Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes|Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1|GLP-1|Mayo Clinic|Yes|Completed|February 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|33|||Both|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|25 subjects with type 2 diabetes and 25non-diabetic subjects matched for age, gender and        degree of obesity will be studied.        The diabetic subjects will be between 40 and 60 years of age and will have a body mass        index of < or =35 kg/m2. Diabetic subjects treated according to ADA guidelines will be        eligible for study including a blood pressure < 140/90, LDL cholesterol < 130 mg/dl, HDL        cholesterol >40 mg/dl and triglycerides <200 mg/dl.        All nondiabetic subjects will not have a history of diabetes in their first degree family        members. None of the subjects will have any overt evidence of cardiac, renal, pulmonary or        hepatic disorder nor will they be engaging in regular vigorous physical activities. All        subjects will undergo a resting ECG and a treadmill ECG test to ensure that they do not        have active or occult coronary artery disease unless such testing had been completed        within six months of enrollment and reported as normal.|July 2015|July 3, 2015|October 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021865||129942|
NCT01023048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF008|Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)|First Use of Parental Support Technology(R) for Single Gene Analysis Plus Aneuploidy Screening in Preimplantation Genetic Diagnosis|IVF008|Natera, Inc.|No|Completed|November 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|56|||Both|N/A|40 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023048||129852|
NCT01022710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7107-R|Early Detection of Noise-Induced Hearing Loss|Early Detection of Noise-Induced Hearing Loss||VA Office of Research and Development|No|Withdrawn|January 2010|December 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|None Retained|No biospecimens will be collected for this study|Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Veterans reporting to the VA Loma Linda Healthcare System identified with sensorineural        hearing loss|December 2015|December 22, 2015|November 25, 2009||No|We did not enroll any subjects because we realized we needed to establish the technique more    definitively before proceeding to human testing.|No||https://clinicaltrials.gov/show/NCT01022710||129878|
NCT01023347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPM-0801|A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer|||Samyang Biopharmaceuticals Corporation||Active, not recruiting|May 2008|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|286|||Both|18 Years|N/A|No|||January 2010|January 4, 2010|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023347||129829|
NCT01019252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH083063|Skills Training for Adolescents With ADHD|Compensatory Executive Functioning Skills Training in Adolescents With ADHD||Massachusetts General Hospital|Yes|Active, not recruiting|October 2009|November 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|14 Years|18 Years|No|||May 2012|May 24, 2012|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01019252||130139|
NCT01019551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORVACS 010|Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients|International, Multicenter, Randomized, Non-comparative Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression|ERAMUNE-01|Objectif Recherche Vaccins SIDA|Yes|Completed|September 2010|February 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|70 Years|No|||June 2013|June 12, 2013|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019551||130117|
NCT01019564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMP-319-9424|Complete Easy Rub Comparative Efficacy Study|||Abbott Medical Optics||Withdrawn|December 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 15, 2012|November 20, 2009||No|Business decision|No||https://clinicaltrials.gov/show/NCT01019564||130116|
NCT01018836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050808|Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase I Trial of Riluzole in Combination With Radiation Therapy in Patients Undergoing Whole Brain Radiation Therapy for Brain Metastasis||Rutgers, The State University of New Jersey|No|Terminated|November 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|November 24, 2009|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01018836||130170|
NCT01018849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-15149|Role of Vitamin D in Secondary Prevention of Cardiovascular Events|Role of Vitamin D in Secondary Prevention of Cardiovascular Events||Creighton University|No|Completed|July 2009|May 2015|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|19 Years|N/A|No|||January 2016|January 14, 2016|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018849||130169|
NCT01018862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP441|A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 (0.15% Solution) and MP03-33 (0.10% Solution) in Children Ages >6 to <12 With Perennial Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|489|||Both|6 Years|12 Years|No|||May 2012|May 10, 2012|November 24, 2009|Yes|Yes||No|March 22, 2012|https://clinicaltrials.gov/show/NCT01018862||130168|
NCT01014715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042098|Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer|Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer|GCC 0919|University of Maryland|Yes|Active, not recruiting|September 2009|September 2018|Anticipated|December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|November 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01014715||130483|
NCT01014949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDM58100|Microcirculation Assessment in Diabetes and Metabolic Syndrome|Invasive Coronary Microcirculation Assessment in Diabetes and Metabolic Syndrome|MADAME|S.M. Misericordia Hospital||Completed|July 2008|June 2010|Actual|November 2009|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|80 Years|No|||November 2009|July 21, 2010|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014949||130465|
NCT01014962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114555|A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus|A Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Tolerability And Pharmacokinetic Study Of Escalating Doses Of Albaconazole In Healthy Subjects||GlaxoSmithKline|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|November 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01014962||130464|
NCT01027611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jsp-001|Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections|Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections||Illinois Retina Associates|No|Completed|October 2009|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||December 2009|May 3, 2010|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027611||129502|
NCT01026818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13086|A Study of Tadalafil After Radical Prostatectomy|A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy|REACTT|Eli Lilly and Company|Yes|Completed|November 2009|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|583|||Male|18 Years|67 Years|No|||December 2013|December 12, 2013|December 3, 2009|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT01026818||129563|
NCT01020942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJMZK016|Cardioprotective Effects of Electroacupuncture Pretreatment Against Coronary Stenting|Cardioprotective of Electroacupuncture Pretreatment in Patients Underwent Coronary Stenting: A Prospective, Multicenter, Randomized Control Trial||Xijing Hospital|Yes|Enrolling by invitation|January 2010|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2011|December 15, 2011|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020942||130011|
NCT01021267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920136|Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions|Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia||Bioforce AG|No|Not yet recruiting|November 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|80 Years|No|||November 2009|November 25, 2009|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021267||129987|
NCT01021644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0172|Genes, Exercise, Memory and Neurodegeneration|Effects of Standardized Aerobic Exercise-Training on Neurocognitive and Neurodegeneration||Howard University|Yes|Completed|October 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|60 Years|N/A|No|||February 2014|February 13, 2014|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021644||129959|
NCT01021657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alain01|Lipid Profile of Tenon's Capsule|Lipid Profile of Tenon's Capsule in Glaucoma Patients||Centre Hospitalier Universitaire Dijon|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|Samples Without DNA|Eye Tenon's Capsule|Both|18 Years|90 Years|No|Non-Probability Sample|Patient suffering from Glaucoma|November 2009|November 27, 2009|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021657||129958|
NCT01021878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCPR 01|Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients|A Study to Evaluate the Effects of Icodextrin vs 2.5% Dianeal Used for the Long Dwell in Apd: a Randomized, Open-label Clinical Trial to Analyse the Insulin Resistance Using the Homa Index in Prevalent, Non-diabetic Patients|STARCH|Pontifícia Universidade Católica do Paraná|Yes|Completed|October 2009|February 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|90 Years|No|||September 2014|September 30, 2014|November 27, 2009||No||No|June 24, 2014|https://clinicaltrials.gov/show/NCT01021878||129941|
NCT01023061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7048|Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer|Phase II Trial of Radiation With Androgen Deprivation (RAD): Abiraterone Acetate, Prednisone and LHRH Agonist Prior to Radiation Therapy||University of Washington|Yes|Active, not recruiting|March 2010|||September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|N/A|No|||October 2015|October 6, 2015|November 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023061||129851|
NCT01023308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589D2308|Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma|A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma|PANORAMA-1|Novartis||Completed|December 2009|July 2015|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|768|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|November 30, 2009|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01023308||129832|
NCT01018992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00022717|Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder|Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women With Post-traumatic Stress Disorder||Emory University|Yes|Completed|December 2009|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|278|||Female|21 Years|65 Years|No|||August 2015|August 31, 2015|November 6, 2009|Yes|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT01018992||130158|Limitations of this trial include short duration of treatment (6 weeks) and generalizability due to study population composed of only females.
NCT01019265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP07-KR-001|A Study Comparing Norspan Patch and Oral Tramadol|A Randomised Open Label Parallel Group Study Comparing Norspan Patch and Oral Tramadol||Mundipharma Korea Ltd|No|Completed|March 2008|May 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|170|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019265||130138|
NCT01014468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJNJ - 8 - 2009|Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration|Comparative Study - Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration|AxL-2009|Instituto de Olhos de Goiania|Yes|Active, not recruiting|March 2009|February 2012|Anticipated|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|50 Years|N/A|No|||November 2011|November 19, 2011|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014468||130502|
NCT01014741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO#09-0906|Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation|Modified Stepwise Ablation Guided by Low Dose Ibutilide in Chronic Atrial Fibrillation|MAGIC-AF|Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2009|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014741||130481|
NCT01015014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN3365-PK-101|Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections|First-in-human, Two-stage, Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN3365 in Single and Multiple Doses in Young Healthy Subjects||Anacor Pharmaceuticals, Inc.|Yes|Completed|November 2009|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|February 21, 2011|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01015014||130460|
NCT01015326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1918-004|Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors|Development of a Functional Assessment of Side-effects to Therapy (FAST) Questionnaire to Assess Dermatology-Related Quality of Life in Patients Treated With EGFR Inhibitors: The FAST-EGFR Inhibitors: The FAST-EGFRI and Development of an Investigator Grading System: The Skin and Eye Reactions to Inhibitors of EGFR (SERIES) Score|FAST|Northwestern University|Yes|Completed|July 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with an EGFRI and referred to a specialized dermatology clinic for skin        rash management.|December 2014|December 11, 2014|November 6, 2009||No||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01015326||130436|
NCT01015339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC-C|Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|A Randomized Multicenter Phase III Study Comparing Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment or Cisplatin Plus Capecitabine in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction||Peking University|Yes|Recruiting|November 2009|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015339||130435|
NCT01014442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22608|A Study of CellCept (Mycophenolate Mofetil) in Lung Transplant Recipients|Pharmacokinetics of Mycophenolate Mofetil in de Novo Lung Allograft Recipients||Hoffmann-La Roche||Completed|January 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014442||130504|
NCT01014455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006998|Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation|Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation||Mayo Clinic|Yes|Completed|January 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|November 13, 2009||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT01014455||130503|Study subjects received the additional questionnaire on smoking behavior, which itself could heighten awareness of perioperative tobacco use issues and could be viewed as an additional intervention.
NCT01014728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-317A|Intraoperative Bleeding During Endoscopic Sinus Surgery|Comparison of Intraoperative Bleeding During Endoscopic Sinus Surgery Between Patients Receiving Total Intravenous Anesthesia With Propofol and Patients Receiving an Inhalational Anesthetic With Sevoflurane||University of Chicago|No|Completed|November 2009|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|November 13, 2009|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01014728||130482|
NCT01015898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pdt1|Short Term Effects of Photodynamic Therapy in Basal Cell Carcinoma|Short Term Effects of Photodynamic Therapy in Basal Cell Carcinoma||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2008|September 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||November 2009|November 17, 2009|November 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01015898||130393|
NCT01015300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0904|Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease|D0904 - A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von Hippel-Lindau Disease.||Dartmouth-Hitchcock Medical Center|Yes|Terminated|December 2009|April 2012|Actual|October 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|November 16, 2009|Yes|Yes|Study terminated due to low accrual.|No||https://clinicaltrials.gov/show/NCT01015300||130438|
NCT01015586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#19550|Treatment of Alcohol Dependence and Comorbid Bipolar Disorder|A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence||Medical University of South Carolina|Yes|Recruiting|February 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2010|July 8, 2010|November 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01015586||130416|
NCT01027884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-III-003|Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)|A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients With Duchenne Muscular Dystrophy|DELOS|Santhera Pharmaceuticals|Yes|Completed|July 2009|April 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Male|10 Years|18 Years|No|||September 2015|September 23, 2015|December 8, 2009||No||No|June 15, 2015|https://clinicaltrials.gov/show/NCT01027884||129481|
NCT01023789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-386|ABSORB EXTEND Clinical Investigation|ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions|ABSORB EXTEND|Abbott Vascular|Yes|Active, not recruiting|January 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|807|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023789||129795|
NCT01020669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910455|Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development|Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development: Supplementary Control Subjects Recruitment||National Institutes of Health Clinical Center (CC)||Completed|October 2009|July 2011||||N/A|Observational|N/A|||Anticipated|24|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||July 2011|July 14, 2011|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020669||130032|
NCT01020682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APATHIE|Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study|Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study||University Hospital, Grenoble|No|Recruiting|January 2005|June 2011|Anticipated|February 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|70 Years|No|Probability Sample|Parkinson's disease|November 2009|November 24, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020682||130031|
NCT01021280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor492809ctil|Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome|Case-control Study of the PTH Homeostasis in Adolescents and Young Adults With Bartter Syndrome||Soroka University Medical Center|No|Not yet recruiting|January 2013|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|15|Samples Without DNA|Serum and urine will be later analyzed for FGF-23 and other key molecules in PTH      homeostasis.|Both|14 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescent and young adult patients with Bartter syndrome and age- and sex- matched        controls.|June 2012|June 13, 2012|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021280||129986|
NCT01021293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112679|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine|Immunogenicity and Safety of GSK Biologicals' IPV (Poliorix™) in Infants||GlaxoSmithKline||Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1101|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||February 2011|March 28, 2013|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021293||129985|
NCT01021631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transfusion|TRACS STUDY: Transfusion Requirements After Cardiac Surgery|Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)|TRACS|Instituto do Coracao|Yes|Recruiting|February 2009|April 2010|Anticipated|February 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||November 2009|November 27, 2009|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021631||129960|
NCT01021891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-015|A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)|A Phase 1b, Single-Dose, Open-Label, Parallel, Controlled Pharmacology Trial of Inhaled Technosphere®/Insulin in Non-Diabetic Subjects With COPD Versus Matched Non-Diabetic Subjects Without COPD.||Mannkind Corporation|No|Completed|July 2006|November 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|70 Years|No|||December 2013|December 13, 2013|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021891||129940|
NCT01022099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KneeNavy|Prospective Randomized Trial of Navigated and Conventional TKA|Prospective Randomized Trial of Navigated and Conventional TKA With Radiographic and CT Evaluations||Technische Universität Dresden|No|Completed|January 2006|December 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|N/A|No|||December 2009|December 17, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022099||129924|
NCT01022112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-04|An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally-Administered SGLT2 Inhibitor TA-7284||Mitsubishi Tanabe Pharma Corporation|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|383|||Both|20 Years|80 Years|No|||May 2014|May 27, 2014|November 29, 2009||No||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01022112||129923|
NCT01022749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 070165|Efficacy Safety Study of Flu Vaccine in Immunodepression Patients|Prospective, Multicentre, Open-label Study Evaluating the Immunogenicity and Safety of Influenza Vaccine in Patients With Inflammatory Bowel Disease (IBD) Receiving or Not Immunosuppressive Therapy|MICIVAX|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2009|July 2013|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|228|||Both|18 Years|64 Years|No|||July 2013|August 2, 2013|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022749||129875|
NCT01023321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0555-CL-101|First-in-Human Single Ascending and Multiple Dose of GLPG0555|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0555 in Healthy Subjects.||Galapagos NV|No|Completed|December 2009|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|35|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 11, 2010|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023321||129831|
NCT01023334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10002|Combined Intracameral Lidocaine for Manual Small Incision Cataract Surgery Under Topical Anesthesia|Combined Intracameral Lidocaine for Manual Small Incision Cataract Surgery Under Topical Anesthesia||Wenzhou Medical University|Yes|Completed|December 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||December 2009|July 30, 2010|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01023334||129830|
NCT01019317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0781|Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|A Phase II Study of Twice Daily Cytarabine and Fludarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Completed|November 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|12 Years|N/A|No|||October 2013|February 17, 2016|November 23, 2009||No||No|October 4, 2013|https://clinicaltrials.gov/show/NCT01019317||130135|
NCT01018953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-55-52060-004|Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome|Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome|CAMPANULA|Ipsen|No|Terminated|February 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||August 2015|August 6, 2015|November 24, 2009||No|Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1|No|June 15, 2015|https://clinicaltrials.gov/show/NCT01018953||130161|Due to premature termination of the study, no data was collected/analyzed and no patient participated in Part B.
NCT01018966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-029|Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors|Phase I Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors||Bristol-Myers Squibb|Yes|Completed|April 2004|April 2005|Actual|March 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|75 Years|No|||December 2009|December 16, 2009|November 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018966||130160|
NCT01015040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-066|Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers|A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Address the Relative Bioavailability of Solifenacin Liquid Suspension 10mg (Fed and Fasting) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet (Fasting) in Healthy Volunteers||Astellas Pharma Inc|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|November 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01015040||130458|
NCT01015053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-08-0398|Postoperative Pain After Pediatric Umbilical Hernia Repair|Postoperative Pain After Pediatric Umbilical Hernia Repair: a Randomized Clinical Trial of Ultrasound-guided Bilateral Rectus Sheath Blocks Versus Local Anesthetic Infiltration||Children's Hospital Boston|Yes|Active, not recruiting|November 2009|November 2011|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|53|||Both|3 Years|12 Years|No|||June 2011|June 22, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01015053||130457|
NCT01015365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORIHA|Cementless One-stage Revision of the Chronic Infected Hip Arthroplasty|Cementless One-stage Revision in Fast-track Setting of the Chronic Infected Hip Arthroplasty|CORIHA|University of Aarhus|Yes|Active, not recruiting|November 2009|January 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01015365||130433|
NCT01015027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AS-0907|Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study of the Safety and Tolerability of Intravenously Administered REGN668 in Healthy Volunteers||Regeneron Pharmaceuticals|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01015027||130459|
NCT01015638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114546|Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications|Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac® Topical Gel (Clindamycin 1% and Benzoyl Peroxide 5%) to ACANYA™ Gel (Clindamycin Phosphate 1.2% and Benzoyl Peroxide 2.5%) Topical Acne Medications||GlaxoSmithKline|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|November 17, 2009|Yes|Yes||No|July 12, 2010|https://clinicaltrials.gov/show/NCT01015638||130412|
NCT01015911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN75-001|A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma|A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma||Seattle Genetics, Inc.|No|Completed|November 2009|March 2012|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|November 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01015911||130392|
NCT01015651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0823|Assessment of the Nociception During Lumbar Surgery|Assessment of the Nociception During Lumbar Surgery|CARDEAN-2|University Hospital, Grenoble|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|80 Years|No|||April 2010|April 6, 2010|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015651||130411|
NCT01014975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T05018-1001|A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients|A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke||Grifols Therapeutics Inc.|Yes|Completed|November 2009|February 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|85 Years|No|||September 2015|September 22, 2015|November 16, 2009|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01014975||130463|
NCT01015599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA no. 2005-35215-15418|Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project|Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project|HOP'N|Kansas State University|No|Active, not recruiting|August 2005|May 2008|Anticipated|May 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|273|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|April 29, 2010|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015599||130415|
NCT01015846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14046|Ultrasound Assessment During Exercise|Assessment of Transverse Abdominis Muscle Function Associated With Stabilization Exercises in Low Back Pain Patients|Redcord RUSI|University of Virginia|Yes|Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|50 Years|No|||November 2009|November 16, 2009|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01015846||130396|
NCT01020708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTH12-003|Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis|A Phase I Double-blind, Randomized, Comparator-controlled Study of the Safety and Tolerability of N-acetylcysteine Plus Mesalamine Enema in Subjects With Left-sided Ulcerative Colitis||Altheus Therapeutics, Inc.|Yes|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|9|||Both|18 Years|64 Years|No|||March 2011|March 28, 2011|November 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01020708||130029|
NCT01020981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-420|National Guard Outreach and Linkage to Treatment|National Guard Outreach and Linkage to Treatment||VA Office of Research and Development|No|Completed|January 2010|December 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|141|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MI, IN, and OH ARNG|September 2014|April 6, 2015|November 24, 2009||No||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01020981||130008|
NCT01020968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-55-0811-1|Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy|Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy||Vericel Corporation|Yes|Completed|December 2009|December 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|86 Years|No|||May 2014|May 29, 2014|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01020968||130009|
NCT01021306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCRC1-P2|Conservative Treatment of Patients With Temporomandibular Disorders|Conservative Treatment of Patients With Temporomandibular Disorders|D1P2-TMD|Palmer College of Chiropractic|Yes|Completed|January 2010|May 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|80|||Both|21 Years|N/A|No|||December 2014|December 9, 2014|November 24, 2009||No||No|October 31, 2014|https://clinicaltrials.gov/show/NCT01021306||129984|
NCT01021319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE-FLAIR|Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)|PREdictive Value of FLAIR and DWI for the Identification of Acute Ischemic Stroke Patients ≤ 3 and ≤ 4.5 h of Symptom Onset - a Multicenter Observational Study|PRE-FLAIR|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|September 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|643|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined and        well known symptom onset|January 2012|January 31, 2012|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01021319||129983|
NCT01022424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-003|A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]|A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]||Otsuka Pharmaceutical Co., Ltd.|No|Completed|November 2009|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|N/A|No|||October 2015|October 16, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022424||129899|
NCT01022437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 28041|Geranium Oil and Its Components for the Relief of Numbness-OB 100|Geranium Oil and Its Components for the Relief of Numbness-OB 100||Pennington Biomedical Research Center|No|Completed|December 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01022437||129898|
NCT01022723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC_ver2_081109|Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells|Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells|CTC|National Cancer Centre, Singapore|Yes|Recruiting|October 2009|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|366|Samples With DNA|Circulating Tumor Cells|Both|N/A|N/A|No|Non-Probability Sample|Patients with the following cancers:        Lung Cancer Nasopharyneal carcinoma Breast cancer Prostate cancer Colorectal cancer        Gastric cancer|November 2015|November 8, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022723||129877|
NCT01023087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLISTIN.RF.10|Renal Impairment Associated With Colistin Levels|The Incidence of Renal Impairment Associated With Polymyxin E Treatment and the Impact of Measuring Colistin Levels||Shaare Zedek Medical Center|No|Completed|December 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|70|Samples Without DNA|Separated blood samples for Colistin levels assesment are kept in the immunology department      refrigirator for analysis when the immunological method of the blood Colistin levels will be      ready for use.|Both|18 Years|N/A|No|Probability Sample|Patients hospitalized in the Department of Internal Medicine with sepsis of any origin.|July 2010|July 24, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023087||129849|
NCT01023074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4762-R|Effects of Training on Central Auditory Function in Multiple Sclerosis|Effects of Training on Central Auditory Function in Multiple Sclerosis||VA Office of Research and Development|No|Completed|October 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|52|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|November 30, 2009||No||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01023074||129850|
NCT01016353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT2009-50|Open Abdomen Study Comparing ABThera™ Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique|A Prospective Study Examining Clinical Outcomes Associated With the Management of the Open Abdomen With the ABThera™ Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique||KCI USA, Inc.|Yes|Completed|December 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|75 Years|No|Non-Probability Sample|Emergent Care|November 2009|May 17, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016353||130359|
NCT01019603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114565|A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris|A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris||GlaxoSmithKline|No|Completed|October 2009|January 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|12 Years|N/A|No|||February 2012|February 23, 2012|November 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019603||130113|
NCT01019616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D09050703570904|Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy|A Phase Ⅲ Study of Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy||Peking University|Yes|Recruiting|December 2010|June 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|65 Years|No|||June 2015|June 9, 2015|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019616||130112|
NCT01019915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT-AIL-SUS 2009|Effect of Cardiac Resynchronization Therapy (CRT) on Skeletal Muscle Histology, Neuroendocrine Activation and Inflammatory Response|Effect of Cardiac Resynchronization Therapy on Skeletal Muscle Histology, Neuroendocrine Activation and Inflammatory Response||Helse Stavanger HF|No|Completed|January 2004|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2011|July 27, 2015|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019915||130090|
NCT01015066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD04405009B|Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents|A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults||State University of New York at Buffalo|Yes|Withdrawn|November 2009|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|25 Years|No|||June 2014|June 6, 2014|October 15, 2009||No|Study personnel left institution, anticipated funding did not occur|No||https://clinicaltrials.gov/show/NCT01015066||130456|
NCT01015079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910043R|The Association Between Cervical Cancer Screening and Cancer Occurrence|The Association Between Cervical Cancer Screening Participation and Corresponding Results and Subsequent Cancer Occurrence and Death||National Taiwan University Hospital||Recruiting|November 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|6000000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The entire Taiwan women with their information obtained from several national registries.|November 2009|November 16, 2009|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015079||130455|
NCT01015378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODIGE|Natural History of Sigmoid Diverticulitis: The Geneva Cohort Study|||University Hospital, Geneva|No|Recruiting|January 2007|January 2017|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|80 Years|No|Non-Probability Sample|This cohort study is designed in order to detect recurrent episodes of diverticulitis in a        population of patients who were previously admitted in our institution for a first        episode.        4.1. Study population        The cohort will consist in the population of patients with CT-scan demonstrated,        endoscopy-proven sigmoid diverticulitis who will be admitted in the Department of Surgery        of the University Hospital Geneva from January 1st, 2010 to December 31st, 2019. At        baseline, participants are between the ages of 18 and 90, and medical information will be        updated every year until the end of follow-up, which is December 31st, 2020.|November 2009|June 24, 2010|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015378||130432|
NCT01015664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN0209|Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||University of Tennessee Cancer Institute|Yes|Terminated|February 2010|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|November 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01015664||130410|
NCT01015677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6913-004|A Study of MK6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)|A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Examine MK6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women||Merck Sharp & Dohme Corp.|No|Terminated|December 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|99|||Female|35 Years|60 Years|No|||August 2015|August 11, 2015|November 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01015677||130409|
NCT01015352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-Aza-Epo-2008-01|Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)|A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA||Groupe Francophone des Myelodysplasies|Yes|Completed|February 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||November 2009|March 18, 2014|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015352||130434|
NCT01015924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rek 1.2009.1196|Plate Osteosynthesis Versus ESIN of Displaced Midclavicular Fractures|Intramedullary Nailing Compared With Plate Fixation of Displaced Mid-clavicular Fractures. A Prospective Randomized Controlled Trial||University Hospital, Akershus|No|Completed|July 2009|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|16 Years|60 Years|No|||January 2014|January 30, 2014|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015924||130391|
NCT01016223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32508|A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis|||Penn State University|Yes|Completed|March 2010|October 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|65 Years|No|||November 2012|November 29, 2012|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016223||130369|
NCT01016236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMARO-0409|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2009|||||N/A|N/A|N/A||||||||||||||December 22, 2010|November 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01016236||130368|
NCT01015313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208-12 (formerly 173-09)|Effects of Intensified Sodium Management in Hemodialysis Patients|A Multi-center, Randomized, Controlled and Prospective Pilot Study on the Effects of Intensified Sodium Management on Hospitalization in Chronic Hemodialysis Patients.||Renal Research Institute|No|Withdrawn|November 2009|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015313||130437|
NCT01015612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-PAVR-R2007|CoreValve® System Australia/New Zealand Clinical Study|CoreValve® System Australia/New Zealand Clinical Study||Medtronic Cardiovascular|Yes|Active, not recruiting|August 2008|September 2016|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|635|||Both|65 Years|N/A|No|||October 2015|October 26, 2015|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015612||130414|
NCT01021683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016597|The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants|The Relationship of Defeverscence and Itraconazole Plasma Level Using Sporanox IV as an Empiric Therapy in Immunocompromised Patients Who Have Been Treated With Sporanox Oral Solution as Prophylaxis||Janssen Korea, Ltd., Korea|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|203|Samples Without DNA|Blood cultures|Both|20 Years|N/A|No|Non-Probability Sample|Immunocompromized participants with neutropenic fever who have been treated with        itraconazole oral solution as prophylaxis and eligible for intravenous (into the vein)        itraconazole in accordance with the local label.|July 2013|July 24, 2013|November 25, 2009|No|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT01021683||129956|
NCT01021332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-057|Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms|An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component|Neptune II|Astellas Pharma Inc|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1067|||Male|45 Years|N/A|No|||December 2015|December 16, 2015|November 24, 2009|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01021332||129982|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01021358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-957|A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).|A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-263 (Navitoclax)||Abbott|No|Completed|January 2010|||October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2010|December 16, 2010|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021358||129981|
NCT01021371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT Cancer rehab|The GP's Role in Cancer Rehabilitation: a Randomised, Controlled Study.|The GP's Role in Cancer Rehabilitation: a Randomised, Controlled Study.||University of Southern Denmark|No|Active, not recruiting|May 2008|September 2012|Anticipated|August 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|959|||Both|18 Years|N/A|No|||November 2009|November 27, 2009|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021371||129980|
NCT01021670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016477|An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride|A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY or Alternate Care||Janssen Research & Development, LLC|No|Completed|September 2009|September 2012|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10027|||Male|18 Years|64 Years|No|Non-Probability Sample|Men diagnosed with premature ejaculation will be enrolled in the study by participating        health care providers in clinical practice settings.|November 2013|November 25, 2013|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021670||129957|
NCT01022450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200911033R|Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients|Rhabdomyolysis - A Retrospective Study in Hospitalized Patients||National Taiwan University Hospital|Yes|Recruiting|November 2009|||November 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2500|||Both|N/A|N/A|No|Non-Probability Sample|Patients who admitted to The National Taiwan University Hospital during        2003/1/1~2008/12/31 with rhabdomyolysis or related muscle diseases dignosis and clinical        presentation.|November 2009|November 30, 2009|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01022450||129897|
NCT01022463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-2/IEC/MAMC/09/No.192|Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm|Effect of Ivabradine vs Atenolol on Heart Rate and Effort Tolerance in Patients With Mild to Moderate Mitral Stenosis and Normal Sinus Rhythm|IVA-MS|Govind Ballabh Pant Hospital|Yes|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||November 2010|July 6, 2011|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01022463||129896|
NCT01022736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-128-06|Plasma Gabapentin Concentration During and Following Cardiac Bypass|Preemptive Gabapentin Administration and Perioperative Plasma Concentrations With Cardiac Bypass||Queen's University|No|Completed|May 2007|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2009|December 7, 2009|November 27, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01022736||129876|
NCT01023113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nand2010|To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation|To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation||L.V. Prasad Eye Institute|No|Recruiting|September 2009|March 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023113||129847|
NCT01023360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804034R|Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay|Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping™ Assay||National Taiwan University Hospital|Yes|Recruiting|May 2008|October 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2008|December 1, 2009|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT01023360||129828|
NCT01018979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-0054-02|Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients|A Phase II, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease||TaiGen Biotechnology Co., Ltd.|Yes|Completed|February 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|70 Years|No|||January 2015|January 13, 2015|November 24, 2009|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01018979||130159|
NCT01016626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKD-123HPS08E|Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 (Mycophenolate Mofetil) Tablet|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 Tablet, in Healthy Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|July 2009|October 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 18, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016626||130338|
NCT01016639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version1|Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer|Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer|CORGI|Lund University Hospital|No|Completed|June 2003|July 2009|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|N/A|No|||October 2011|October 14, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016639||130337|
NCT01016613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30DK081943|Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center|Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center|C-PROBE|University of Michigan|Yes|Recruiting|January 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|Urine, blood and renal tissue, if available|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nephrology clinic patients and community members|April 2011|April 7, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016613||130339|
NCT01018654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|514002|Validating Interventions for Diverse Adolescents|Efficacy of Group Treatment for Hispanic Adolescents - RCT|VIDA|University of Utah|Yes|Completed|June 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|13 Years|18 Years|No|||April 2013|April 19, 2013|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01018654||130184|
NCT01014273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rad-Fem PCI Access Study|A Trial of Trans-radial Versus Trans-femoral Percutaneous Coronary Intervention (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy|An International Randomized Trial of Trans-radial Versus Trans-femoral PCI Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy. An Extension to the CURRENT (OASIS 7) Substudy (EFC5695): Effect of Type of Access for PCI (Radial or Femoral) on Bleeding Rate-Substudy.|RIVAL|Population Health Research Institute|Yes|Completed|June 2006|March 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7021|||Both|18 Years|N/A|No|||February 2011|April 6, 2011|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014273||130517|
NCT01014806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX755.202|Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults|A Phase 2a Randomized, Double-Blind, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Older Adults||Novavax|Yes|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|467|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|November 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014806||130476|
NCT01015131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-139|18F-FLT-PET in Breast Cancer (MK-0000-139)|A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer||Merck Sharp & Dohme Corp.|No|Completed|April 2010|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|46|||Female|35 Years|75 Years|No|||February 2015|February 9, 2015|November 17, 2009|No|Yes||No|November 6, 2012|https://clinicaltrials.gov/show/NCT01015131||130451|
NCT01015690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNEXPLAINED|Incidence of Early Pregnancy Loss in Patients With Unexplained Infertility|Incidence of Early Pregnancy Loss in Patients With Unexplained Infertility Measured by hCG Rise in Urine|UNEXPLAINED|UMC Utrecht|No|Completed|June 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|134|Samples Without DNA|urine|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Patients with unexplained infertility and healthy controls have collected urine samples in        the luteal phase of the menstrual cycle for detection of hCG rise and pregnancy|November 2009|November 17, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015690||130408|
NCT01015703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR002-CLN-pro010|Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers|A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of CoVaccine HT™ in Healthy Adult Volunteers||BTG International Inc.|Yes|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|November 17, 2009||No||No|June 4, 2014|https://clinicaltrials.gov/show/NCT01015703||130407|
NCT01015950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917501-1, 200917501-2|Management of Children With Moderate Acute Malnutrition in Mali|Randomized, Community-Based Effectiveness Trial of Selected Dietary Strategies for the Management of Young Malian Children With Moderate Acute Malnutrition (MAM) in the Context of the National Community Management of Acute Malnutrition|Mali-MMAM|Helen Keller International|No|Active, not recruiting|May 2010|June 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1260|||Both|6 Months|35 Months|No|||September 2011|September 9, 2011|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015950||130389|
NCT01016262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ME-CAPSITUP508-01|Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis|A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis||Axcan Pharma|No|Terminated|September 2009|September 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|549|||Both|18 Years|N/A|No|||July 2011|July 6, 2011|November 17, 2009|No|Yes|The decision was taken solely for business/administrative reasons, no safety considerations    entered into this. Ongoing randomized patients to complete.|No||https://clinicaltrials.gov/show/NCT01016262||130366|
NCT01015937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3997|Effect of Turmeric on Diabetic Nephropathy|||Shaheed Faghihi Hospital|Yes|Completed|March 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015937||130390|
NCT01016249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#7055|Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis|Nebulized 5% Hypertonic Saline for Infirmary Treatment of Acute Infant Bronchiolitis: A Randomized Trial||Hamad Medical Corporation|No|Completed|April 2007|April 2009|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|187|||Both|N/A|18 Months|No|||November 2009|November 18, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016249||130367|
NCT01016509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT 246813|Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis|Tight Glycemic Control During Angioplasty Revascularization for Acute Coronary Syndrome Reduces Circulating Inflammatory Cytokines and Coronary Stent Restenosis||Second University of Naples|Yes|Completed|December 2009|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|70 Years|No|||December 2011|December 20, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016509||130347|
NCT01016522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00008855|Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)|Safety and Tolerability of the Ketogenic Diet in ALS||Johns Hopkins University|Yes|Terminated|November 2009|January 2012|Actual|February 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016522||130346|
NCT01021696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007490-20|Pain in Patients With Dementia and Behavioural Disturbances|The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial||University of Bergen|Yes|Completed|November 2009|October 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|352|||Both|65 Years|N/A|No|||November 2010|August 9, 2011|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021696||129955|
NCT01021904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37207|Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China|||Chinese Academy of Medical Sciences|Yes|Not yet recruiting|June 2010|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|6200|||Female|13 Years|15 Years|Accepts Healthy Volunteers|||November 2009|November 27, 2009|November 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021904||129939|
NCT01022125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016744|TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435|A Phase I Study in Healthy Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of Potential Phase III Formulations Compared to the Phase IIb Capsule and to Assess the Effect of Food on the Bioavailability of TMC435 Following Intake of the Phase IIb Capsule||Tibotec Pharmaceuticals, Ireland||Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 13, 2010|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01022125||129922|
NCT01022177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuDiab1|Influence of Acupuncture to Ocular Microcirculation in Patients With Diabetes Mellitus|Influence of Acupuncture to Ocular Microcirculation in Patients With Diabetes Mellitus||Technische Universität Dresden|No|Recruiting|October 2009|May 2012|Anticipated|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 1, 2011|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022177||129918|
NCT01022476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-014616-36|Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients|A Pilot Study of Pharmacokinetics, Tolerance and Efficacy of Raltegravir Combined to Two Fully Active Molecules Among Nucleosi(ti)de Analogs and Enfuvirtide Before and After Liver Transplant in HIV Infected Patients With End Stage Liver Disease (ANRS 148 LIVERAL)|LIVERAL|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|May 2010|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022476||129895|
NCT01022489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01589-46|High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled Study|Evaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) at High Frequency With Neuronavigation in the Treatment of Auditory Hallucinations : A Randomized Multicentric Controlled Study|TMS-Hz|University Hospital, Caen|Yes|Completed|August 2009|March 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|16 Years|65 Years|No|||July 2015|July 28, 2015|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022489||129894|
NCT01015768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-10|Corneal Staining and Physiological Compromise After Eight Hours of Soft Contact Lens Wear|Corneal Staining and Physiological Compromise After Eight Hours of Soft Contact Lens Wear||Southern California College of Optometry|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 8, 2010|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015768||130402|
NCT01015781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7213-R|Multi-Site Evaluation of Progressive Tinnitus Management|Multi-Site Evaluation of Progressive Tinnitus Management||VA Office of Research and Development|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|November 16, 2009||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT01015781||130401|
NCT01019005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMC-1975-HJ|Pain Relief After Forefoot Surgery|Pain Relief After Forefoot Surgery: Tibial Perineural Catheter vs. Wound Catheter Infusion||Nottingham University Hospitals NHS Trust|Yes|Not yet recruiting|February 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2009|November 24, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019005||130157|
NCT01019018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 0928|Efficacy of Subtenon's Block With Olive Tipped Cannula|Efficacy of Subtenon Anesthesia With Olive Tipped Cannula: a Randomized Controlled Trial||King Khaled Eye Specialist Hospital|Yes|Recruiting|November 2009|October 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Anticipated|120|||Both|18 Years|90 Years|No|||November 2009|November 24, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01019018||130156|
NCT01017224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 24|DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC)|DAHANCA 24: Prognostic Value of 18F-FAZA Positron Emission Tomography After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck||University of Aarhus|No|Completed|November 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples With DNA|tissue|Both|18 Years|N/A|No|Non-Probability Sample|head and neck cancer patients|May 2012|May 11, 2012|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017224||130293|
NCT01016951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1882C00002|A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease|A Phase I, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD9164 Given Once Daily as Inhaled Formulation Via Turbuhaler for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca|No|Terminated|December 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 18, 2010|November 19, 2009||No|Study stopped since it was considered that one of the pre-defined stopping criterion was met.|No||https://clinicaltrials.gov/show/NCT01016951||130313|
NCT01016964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12 2009-F-02|Treatment of Androgenetic Alopecia in Females, 12 Beam|A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 12 Beam Model For The Treatment of Androgenetic Alopecia in Females||Lexington International, LLC|Yes|Completed|January 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|November 18, 2009|Yes|Yes||No|June 25, 2012|https://clinicaltrials.gov/show/NCT01016964||130312|
NCT01014585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-27|Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia|A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment||Forest Laboratories|No|Completed|November 2009|||May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|340|||Both|N/A|N/A|No|||September 2011|September 2, 2011|November 13, 2009|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT01014585||130493|
NCT01014793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mattapr1|Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients|Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly||Federal University of São Paulo|Yes|Completed|May 2005|December 2008|Actual|May 2007|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|Samples Without DNA|serum for IGI-I, GH and prolactin measures|Both|18 Years|80 Years|No|Non-Probability Sample|Nineteen acromegalic patients (Neuroendocrine Unit-UNIFESP)with active disease, resistant        to octreotide were enrolled|November 2009|November 16, 2009|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014793||130477|
NCT01015729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00008|Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately|An Open-Label, Randomized, Single-Center, 3-Way Crossover Study Comparing The Therapeutic Efficacy of a Fixed Dose Combination Capsule of Esomeprazole 20 mg And Acetylsalicylic Acid (ASA) 81 mg With Free Combinations of ASA Tablet 81 mg And Esomeprazole 20 mg as a Capsule or Tablet in Patients At Risk of Gastrointestinal Events Using Low Dose ASA for Cardiovascular Protection||AstraZeneca|No|Terminated|November 2009|March 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 13, 2012|November 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01015729||130405|
NCT01015989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH085577|Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya|Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya|CARE+ Kenya|New York University|Yes|Recruiting|January 2011|June 2013|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 20, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015989||130386|
NCT01016327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDCA-354-001|Study of NMS-1116354 in Solid Tumors|A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors||Nerviano Medical Sciences|No|Terminated|April 2009|September 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||September 2012|September 6, 2012|November 17, 2009|Yes|Yes|Discontinuation of clinical investigation with NMS-1116354|No||https://clinicaltrials.gov/show/NCT01016327||130361|
NCT01015963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-60805|Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871|A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3 in Caucasian and African-American Cancer Patients||Alliance for Clinical Trials in Oncology||Active, not recruiting|October 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|69|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled on CLB-9871|July 2015|July 23, 2015|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015963||130388|
NCT01016275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-007|Misago Iliac Study|Physician Initiated Multi-center Belgian-German Trial Investigating the Terumo Misago Stent in the Treatment of TASC A & B Iliac Lesions|MISAGO ILIAC|Flanders Medical Research Program|Yes|Completed|January 2010|October 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with peripheral arterial disease, Rutherford 2 to 5.|August 2014|August 5, 2014|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016275||130365|
NCT01016288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS-FNA-DK-PV-2009|Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles (FNA-22G-25G)|Multicenter Randomized Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles||University Hospital, Gentofte, Copenhagen|No|Completed|November 2009|December 2012|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|135|Samples With DNA|Pathology samples obtained through EUS-FNA biopsy processed by paraffin embedding.|Both|18 Years|85 Years|No|Non-Probability Sample|Patients referred to one of the participating departments for an EUS examination with        EUS-FNA (mediastinal tumours and lymph nodes, celiac, perigastric and peri-pancreatic        lymph nodes, pancreatic masses, liver masses, adrenal masses, etc.).|April 2014|April 7, 2014|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016288||130364|
NCT01016301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPS1|Effects of a Clinical Pharmacist Service on Health-related Quality of Life|Effects of a Clinical Pharmacist Service on Health-related Quality of Life||Sahlgrenska University Hospital, Sweden|No|Completed|September 2007|July 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|400|||Both|N/A|N/A|No|||November 2015|November 17, 2015|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016301||130363|
NCT01018069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEG35156-206|AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen|An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen||Aegera Therapeutics|No|Terminated|November 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|November 19, 2009|Yes|Yes|Failed to reach endpoints|No||https://clinicaltrials.gov/show/NCT01018069||130229|
NCT01016548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0780-C|Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy|Evaluation of Pandemic H1N1(2009) Influenza Vaccine in Adults With Lymphoid Malignancies on Active Systemic Treatment or Post Stem Cell Transplantation||University Health Network, Toronto|No|Completed|November 2009|June 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|42|||Both|20 Years|65 Years|No|||June 2010|June 3, 2010|November 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01016548||130344|
NCT01016535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASM1|Care of Child's Hygiene From Zero to Two Years Old|Care of Child's Hygiene From Zero to Two Years Old: Health Professionals' Perceptions of the Strategy and the Family Caregivers|CCH|Faculdade Santa Marcelina|Yes|Completed|January 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|19|||Both|1 Month|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children's caregivers from zero to two years old monitored in a health center health        professionals of a team of a health center|November 2009|November 18, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016535||130345|
NCT01021436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-IN-AK004|Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia|An Open-Label, Multicenter, Multinational Study to Assess the Safety,Tolerability and Pharmacokinetics of Aerosolized Amikacin Delivered Via the Pulmonary Drug Delivery System (NKTR-061) in Intubated and Mechanically- Ventilated Patients With Nosocomial Pneumonia||Bayer|No|Completed|March 2007|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021436||129975|
NCT01021917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED013|SUCCESS Tracking Study|Weight Loss & Maintenance of Weight Loss Tracking Study (SUCCESS Tracking Study)||Medifast, Inc.|No|Active, not recruiting|March 2008|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|332|||Both|18 Years|69 Years|No|Non-Probability Sample|Community-dwelling|May 2014|May 21, 2014|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021917||129938|
NCT01022138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000657998|Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer|A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells After Second Line Chemotherapy in Women With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|February 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Female|18 Years|120 Years|No|||March 2016|March 17, 2016|November 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022138||129921|
NCT01022151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23/2007|Aminophylline and Cognitive Function After Sevoflurane Anaesthesia|Aminophylline Improves Early Postoperative Cognitive Recovery After Sevoflurane Anaesthesia: A Dose-Dependent Study||King Faisal University|No|Completed|November 2007|August 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|180|||Both|18 Years|55 Years|No|||November 2010|November 18, 2010|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022151||129920|
NCT01022164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC0005|Use of Fibrin Glue in Vitreoretinalsurgery|Safety and Efficacy in the Use of Fibrin Glue in Vitreoretinal Surgery|fibringlue|Asociación para Evitar la Ceguera en México|No|Recruiting|May 2009|April 2010|Anticipated|November 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|90 Years|No|||November 2009|November 30, 2009|November 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01022164||129919|
NCT01022502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG280391|Comparison of Refined and Crude Indigo Naturalis Ointment in Treating Psoriasis|Efficacy and Safety Comparison Between Refined and Crude Indigo Naturalis Ointment in the Treatment of Psoriatic Vulgaris||Chang Gung Memorial Hospital|Yes|Completed|November 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|November 25, 2009||No||No|October 1, 2011|https://clinicaltrials.gov/show/NCT01022502||129893|
NCT01022515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/081/HP|Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma|Clinical Application of New Pheochromocytoma Markers: INSERM Pilot Study of the Specificity of Elevated Plasma EM66 Concentrations in Patients With Pheochromocytoma or Paraganglioma Compared to Patients With Essential Hypertension|PHEO|University Hospital, Rouen|No|Completed|November 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|Samples Without DNA|5 ml blood sample on EDTA to collect 2,5 ml plasma, kept at -80°C, once a year.|Both|18 Years|90 Years|No|Non-Probability Sample|two distint population will be involved :          -  patients with pheochromocytoma or paraganglioma          -  patients with essential hypertension|June 2014|June 18, 2014|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01022515||129892|
NCT01022762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3783|Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment|A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naïve Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|75 Years|No|||June 2014|June 25, 2014|November 26, 2009|Yes|Yes||No|November 24, 2011|https://clinicaltrials.gov/show/NCT01022762||129874|
NCT01022801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-047|A Phase II Dose Response Study in Japan in Chronic Hepatitis B|A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) vs Lamivudine in Adults With Chronic Hepatitis B Infection||Bristol-Myers Squibb|Yes|Completed|August 2003|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|20 Years|75 Years|No|||November 2009|January 29, 2010|November 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022801||129871|
NCT01016028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0439|Chemotherapy-Induced Peripheral Neuropathy Survey|Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib||M.D. Anderson Cancer Center|No|Withdrawn|November 2009|||January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, age 18 years or older, receiving chemotherapy with cisplatin or oxaliplatin        (platinum agents), taxanes, and/or bortezomib at UT MD Anderson Cancer Center.|February 2013|February 18, 2013|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01016028||130383|
NCT01016652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-4558|Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients|||Johnson & Johnson Vision Care, Inc.|No|Completed|October 2009|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|35 Years|47 Years|No|||May 2015|May 6, 2015|November 18, 2009|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01016652||130336|
NCT01016665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904/04|Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy|Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study||Federal University of São Paulo|No|Completed|April 2005|June 2008|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Basic Science|3||Actual|71|||Female|40 Years|90 Years|No|||November 2009|November 18, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01016665||130335|
NCT01016015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01408|Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma|A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas||National Cancer Institute (NCI)|Yes|Completed|November 2009|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|16 Years|N/A|No|||May 2014|July 2, 2015|November 17, 2009|Yes|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT01016015||130384|
NCT01016041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL15206.101.06|A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial|A Randomized Controlled Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial|COMPARE 1|Maasstad Hospital|Yes|Completed|February 2007|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1800|||Both|18 Years|85 Years|No|||December 2015|December 24, 2015|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01016041||130382|
NCT01017510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7322-BA-CTIL|Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata|Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata||Sheba Medical Center|No|Recruiting|November 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2010|July 18, 2010|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01017510||130271|
NCT01017497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017062|Optimal Planning Target Volume With Stereotactic Radiosurgery|Determination of the Optimal Planning Target Volume for Brain Metastases Treated With Stereotactic Radiosurgery||Duke University|No|Completed|December 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|November 19, 2009||No||No|September 30, 2014|https://clinicaltrials.gov/show/NCT01017497||130272|
NCT01015417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amiens ABCAL|Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis|Antibiotic Treatment Versus no Antibiotics in the Postoperative Acute Cholecystitis Low and Moderately Severe|ABCAL|Centre Hospitalier Universitaire, Amiens|Yes|Completed|May 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|414|||Both|18 Years|N/A|No|||February 2012|September 2, 2013|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015417||130429|
NCT01016587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009055|Symptom Clusters and Immune Markers in Patients With Chronic Obstructive Pulmonary Disease (COPD) - a Longitudinal Study|Symptom Clusters and Immune Markers in Patients With COPD|SGIS|Oslo University Hospital|Yes|Completed|November 2009|February 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|275|Samples With DNA|One foci is to perform a genome wide association study in patient with COPD to identify      novel genetic markers for the patient subgroups who report different experiences with the      symptom cluster of pain, fatigue, breathlessness, sleep disturbance, and depression. It is      likely that genetic and immunologic factors may be involved in symptom severity and      morbidity. Specifically, low levels of circulating immunoglobulins have been observed in a      subset of COPD patients. Although hypogammaglobulinemia (HGG) is known to lead to frequent      airway infections in other patients groups, the relationship between HGG and clinical      symptoms in COPD has not been studied. The resulting knowledge can help clinicians to better      identify COPD patients at particular risk for severe single and multiple symptoms.|Both|18 Years|N/A|No|Non-Probability Sample|308 COPD patients|February 2014|February 10, 2014|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016587||130341|
NCT01016899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTPR-0002|Electronic Brachytherapy for the Treatment of NMSC|Xoft Electronic Brachytherapy Clinical Protocol For The Primary Treatment Of Non-Melanoma Skin Cancer||Xoft, Inc.|Yes|Recruiting|July 2009|February 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|50 Years|N/A|No|Non-Probability Sample|Primary basal cell and primary squamous cell carcinomas|July 2015|July 17, 2015|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01016899||130317|
NCT01017159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2009-013930-25|Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)||University of Aarhus|Yes|Completed|April 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||November 2011|November 9, 2011|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01017159||130298|
NCT01018368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-770-009|Study of VX-770 and Rifampin in Healthy Male Subjects|An Open-Label Phase 1 Study to Examine the Effect of Multiple Doses of Rifampin on the Single-Dose Pharmacokinetics of VX 770 in Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|November 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018368||130206|
NCT01016561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01809|Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer|A Pilot Study of MR Imaging Based Intracavitary Brachytherapy for Cervical Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|July 2009|||July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01016561||130343|
NCT01016847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018748|Moderate to Persistent Asthma in the Obese Subject|A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study to Evaluate the Effect of the Leukotriene Antagonist (Singulair©) Plus Moderate Dose Beclomethasone Compared to High Dose Beclomethasone in Obese Subjects With Moderate Persistent Asthma||Duke University|Yes|Terminated|January 2010|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|38|||Both|18 Years|65 Years|No|||December 2012|November 7, 2014|October 19, 2009|Yes|Yes|Unable to enroll enough study subjects. Study has been terminated|No|November 7, 2014|https://clinicaltrials.gov/show/NCT01016847||130321|Early terminiation due to poor enrollment.
NCT01021722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sphincter2009|A Modified Surgical Approach to Women With Obstetric Anal Sphincter Tears|A Modified Surgical Approach to Women With Obstetric Anal Sphincter Tears||Karolinska University Hospital|No|Completed|November 2002|August 2005|Actual|August 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|239|||Female|18 Years|N/A|No|||November 2009|November 27, 2009|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021722||129953|
NCT01021709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09343|Trial of Transcranial Direct Current Stimulation (tDCS) Using Alternative Electrode Montages|||The University of New South Wales|Yes|Recruiting|November 2009|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||September 2015|September 15, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021709||129954|
NCT01021930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMUOCT-DM vs NDM-1|Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT|Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study)|DM-COVER|Harbin Medical University||Recruiting|November 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||December 2009|May 25, 2010|November 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021930||129937|
NCT01022775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P000203|Dynamic Humeral Centering in Impingement Syndrome|Assessment of Dynamic Humeral Centering in Impingement Syndrome: a Randomized Clinical Trial|ADHCIS|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2001|February 2007|Actual|February 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|31 Years|N/A|No|||November 2009|November 30, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022775||129873|
NCT01022788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5316|Improving Newborn Survival In Southern Tanzania|Improving Newborn Survival in Rural Southern Tanzania: a Study to Evaluate the Impact and Cost of a Scaleable Package of Interventions at Community Level With Health System Strengthening|INSIST|London School of Hygiene and Tropical Medicine|Yes|Completed|January 2010|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|47688|||Both|N/A|49 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022788||129872|
NCT01023139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|c.2009.025|"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"|"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"|AOS|Brooke Army Medical Center|No|Recruiting|April 2009|March 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023139||129845|
NCT01023100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921115|A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers|A Study In Trained Taste Panel Healthy Adult Volunteers To Investigate The Palatability Of Select Formulations Of CP-690,550 Oral Solution||Pfizer|No|Completed|March 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2010|June 14, 2010|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023100||129848|
NCT01015456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-001|The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis|The Clinical Efficacy and Economic Evaluation of EC-MPS (Myfortic) in the Treatment of Relapse or Resistant Proliferative Lupus Nephritis|CONTROL|Chulalongkorn University|No|Terminated|January 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|16 Years|60 Years|No|||October 2014|October 9, 2014|November 17, 2009||No|Data Safety Monitoring Board concerning of the participants' safety|No||https://clinicaltrials.gov/show/NCT01015456||130426|
NCT01015755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR011825-01|Palliation of Thirst in ICU Patients|Palliation of Thirst in ICU Patients||University of California, San Francisco|No|Completed|January 2010|July 2012|Actual|July 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|353|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015755||130403|
NCT01016990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000659192|Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia|Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL||National Cancer Institute (NCI)||Recruiting|August 2009|||September 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||November 2009|January 9, 2014|November 19, 2009||||No||https://clinicaltrials.gov/show/NCT01016990||130310|
NCT01016366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12631A|Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia|Randomised, Double Blind, Placebo Controlled Study of Lu AA24493 in Patients With Friedreich's Ataxia to Evaluate Safety and Tolerability and to Explore Efficacy||H. Lundbeck A/S|Yes|Completed|October 2009|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016366||130358|
NCT01018160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015436|Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea|Practice and Patient Compliance on the PPI(Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea: A Prospective Observational Study||Janssen Korea, Ltd., Korea|No|Completed|June 2008|February 2009|Actual|February 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1197|||Both|18 Years|N/A|No|Non-Probability Sample|Among the patients who visit the department of gastroenterology with gastroesophageal        reflux disease and who need rabeprazole treatment according to the doctor's discretion|April 2014|April 24, 2014|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018160||130222|
NCT01017874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13021|A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer|A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC||Eli Lilly and Company|No|Completed|November 2009|October 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|November 19, 2009|Yes|Yes||No|February 21, 2014|https://clinicaltrials.gov/show/NCT01017874||130244|
NCT01025232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4571s|A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)|A Phase I/II Open Label, Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Intravitreal Injections of (Super-dose Anti-VEgf SAVE Trial) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab|SAVE|Greater Houston Retina Research|No|Terminated|December 2009|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 11, 2013|December 2, 2009|Yes|Yes|The last remaining subject withdrew consent because the collaborator Genentech stopped    supplying study drug.|No||https://clinicaltrials.gov/show/NCT01025232||129684|
NCT01024686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WR 1584|Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine|Phase 1/2a Trial to Assess the Safety, Immunogenicity and Efficacy of Genetically-attenuated Plasmodium Falciparum Parasites p52-/p36- (GAP) Vaccine, Administered by Bite of Infected Anopheles Mosquito to Malaria-naïve Adults Living in the United States.||Seattle Biomedical Research Institute|Yes|Terminated|March 2010|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|December 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024686||129726|
NCT01024699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.X0901|XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.|A Prospective Multi-Center Randomized Evaluation of the Clinical and Radiographic Outcomes of XLIF® Compared With MAS® TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis||NuVasive|No|Completed|November 2009|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|55|||Both|18 Years|N/A|No|Probability Sample|Study population will consist of patients from participating site locations.|April 2015|April 29, 2015|December 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024699||129725|
NCT01017432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2008-252|Compliance Of Medication After Discharge From the Hospital in the Elderly|Compliance Of Medication After Discharge From the Hospital in the Elderly|COMADE|William Beaumont Hospitals|Yes|Completed|December 2008|January 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients over the age of 65 who are discharged home from the hospital who meet the        eligibilty criteria.|April 2011|April 2, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01017432||130277|
NCT01017796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KN19201|Contrast Agent-associated Nephrotoxicity in Intensive Care Unit Patients|The Effect of Acetylcysteine and Ascorbic Acid on the Prevention of Radiographic-contrast-agent Induced Reduction in Renal Function in ICU Patients.|ICU|University of Thessaly|No|Active, not recruiting|January 2009|June 2010|Anticipated|January 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|14 Years|N/A|No|||November 2009|November 20, 2009|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01017796||130250|
NCT01018043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011731|Thai Cancer Anemia Survey in Chulalongkorn Hospital|Thai Cancer Anemia Survey in Chulalongkorn Hospital||Janssen-Cilag Ltd.,Thailand|No|Completed|April 2006|December 2009|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|264|||Both|18 Years|N/A|No|Non-Probability Sample|Anemic patients with cancer receiving chemotherapy|May 2014|May 22, 2014|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018043||130231|
NCT01018056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH085844-01A109|Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission|Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission||Johns Hopkins University|Yes|Completed|November 2009|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|8 Years|17 Years|No|||May 2014|May 29, 2014|November 20, 2009|Yes|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01018056||130230|Study was limited by its small sample size as well as a small placebo group.
NCT01018667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xijing-1|Assessment of Efficacies of Cardiac Resynchronization Therapies (CRT-P/D) for Heart Failure Patients in China|The ADOPT Trial (Assessment of Efficacies of Cardiac Resynchronization Therapies (CRT-P/D) for Heart Failure Patients in China): Rationale, Design and End-points|ADOPT|Xijing Hospital|Yes|Recruiting|October 2008|||December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|About eight hundred patients will be enrolled in this study at more than 40 centers in the        China. To participate in the study, patients must meet the Guideline for cardiac        resynchronization therapy in patients with chronic heart failure in China.|June 2010|July 21, 2010|November 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01018667||130183|
NCT01014299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0061|Recruitment Maneuver After Intubation|Recruitment Maneuver Increases Oxygenation After Intubation in Hypoxemic ICU Patients: a Randomized Controlled Study||University Hospital, Clermont-Ferrand||Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2009|November 23, 2009|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014299||130515|
NCT01016860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0705.cc|OSI-906 and Irinotecan in Patients With Advanced Cancer|A Phase I/IB Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With Colorectal Cancer Stratified by the OSI-906 Integrated Classifier||University of Colorado, Denver|Yes|Terminated|December 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|November 18, 2009|No|Yes|This study was discontinued due to a shown lack of efficacy in the investigational agent|No||https://clinicaltrials.gov/show/NCT01016860||130320|
NCT01016873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLH002|INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD|A Double-masked, Sham Controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Patients With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|INTREPID|Oraya Therapeutics, Inc.|Yes|Completed|November 2009|April 2014|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|230|||Both|50 Years|N/A|No|||December 2014|December 1, 2014|November 19, 2009||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT01016873||130319|
NCT01021475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM-01|Does Visceral Manipulation Works in Treating Functional Dyspepsia?|Does Visceral Manipulation Works in Treating Functional Dyspepsia? A Randomized Study||International College of Osteopathic Medicine|No|Recruiting|November 2009|||November 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||November 2009|November 27, 2009|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021475||129972|
NCT01021735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011268-13|Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy|Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy|ORBIT|University of Glasgow|Yes|Completed|April 2010|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021735||129952|
NCT01021748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206-010|A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)|A Phase I Study of Oral MK-2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|November 2009|July 2014|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021748||129951|
NCT01021943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-26|Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients|The Role of Spironolactone in Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients||Instituto Nacional de Cardiologia Ignacio Chavez|Yes|Suspended|November 2009|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01021943||129936|
NCT01021956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN905 MLT202|Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD|A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)||Steba Biotech S.A.|No|Terminated|June 2010|January 2014|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|50 Years|N/A|No|||April 2015|April 27, 2015|November 29, 2009|Yes|Yes|As two cases of retinal vascular occlusion in patients who received anti-VEGF|No||https://clinicaltrials.gov/show/NCT01021956||129935|
NCT01022190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2009-36182|Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement|Effect of Etoricoxib (Arcoxia) in Preventing Heterotopic Ossification After Total Hip Arthroplasty|Arcoxia|Radboud University|No|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Both|18 Years|95 Years|No|||August 2013|August 31, 2013|November 27, 2009|Yes|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT01022190||129917|Small sample size. However, due to ethical considerations, a two phase model is necessary to indicate effectivity of Etoricoxib in prevention HO in this phase.
NCT01015469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT5448081|Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)|International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)|GABY|ClinTrio Ltd.|No|Recruiting|February 2009|March 2015|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Both|18 Years|60 Years|No|||February 2011|February 16, 2011|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015469||130425|
NCT01017887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-107|Intraperitoneal Carbon Dioxide Concentration Measurement During Standard Laparoscopy With a New Airseal Access Port|SurgiQuest AirSeal CO2 Gas Quality||Baystate Medical Center|No|Withdrawn|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing a laparoscopic operation.|September 2013|September 3, 2013|August 4, 2009||No|Unable to recruit any subjects|No||https://clinicaltrials.gov/show/NCT01017887||130243|
NCT01016977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114566|A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris|A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris|C0000-411|GlaxoSmithKline|No|Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|12 Years|45 Years|No|||February 2012|February 23, 2012|November 19, 2009|No|Yes||No|January 19, 2012|https://clinicaltrials.gov/show/NCT01016977||130311|
NCT01018173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC25113|A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease|A Randomized Double Blind, Placebo-controlled Clinical Trial to Assess the Effects of Taspoglutide (RO5073031) on Cardiovascular Outcomes in Subjects With Inadequately Controlled Type 2 Diabetes and Established Cardiovascular Disease||Hoffmann-La Roche||Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2118|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01018173||130221|
NCT01018186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106839|Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study|A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma||GlaxoSmithKline|No|Completed|October 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|503|||Both|12 Years|N/A|No|||August 2013|October 31, 2013|November 5, 2009|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01018186||130220|
NCT01018498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25005|Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome|Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome||Baylor College of Medicine|No|Completed|October 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|7 Years|17 Years|No|||May 2013|May 11, 2013|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01018498||130196|
NCT01018797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BQ-1-09-ARVO|Intrastromal Corneal Ring for High Astigmatism on Postkeratoplasty|Intrastromal Corneal Ring Segment Implantation for High Astigmatism on Postkeratoplasty Eyes|Anel|Instituto de Olhos de Goiania|Yes|Completed|January 2007|November 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|50 Years|No|||November 2009|November 23, 2009|November 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01018797||130173|
NCT01024426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITGBVG01|Impact of Enhanced Health Facility Care in Uganda|Evaluating the Impact of Enhanced Health Facility-based Care for Malaria and Febrile Illnesses in Children in Tororo, Uganda||Uganda Malaria Surveillance Project|Yes|Completed|December 2010|July 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|25000|||Both|N/A|15 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024426||129746|
NCT01024972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13441|Safety Study of Dantrolene in Subarachnoid Hemorrhage|Dantrolene in the Prevention and Treatment of Cerebral Vasospasm in Subarachnoid Hemorrhage||University of Massachusetts, Worcester|Yes|Completed|October 2009|October 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|December 1, 2009||No||No|January 2, 2015|https://clinicaltrials.gov/show/NCT01024972||129704|Placebo group consisted of free water with 5% mannitol to achieve the same equiosmolar solution as IV-D which requires reconstitution in free water. Unable to differentiate whether hyponatremia or brain oedema was due to IV-D or its solution.
NCT01018381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC and HBV|Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection|Randomized Clinical Study of Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection||The 108 Military Central Hospital|No|Completed|June 2006|November 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|30 Years|70 Years|No|||November 2009|November 20, 2009|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018381||130205|
NCT01025869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|902|The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries|The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries|VANTAGE-1|Atrium Medical Corporation|Yes|Terminated|December 2009|March 2012|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|December 3, 2009||No|Terminated following completion of 2 year time point: Sponsor decision|No||https://clinicaltrials.gov/show/NCT01025869||129635|
NCT01014598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 70005|Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis|Phase I Study of Targeted Lung Chemotherapy in the Treatment of Metastatic Tumors||Roswell Park Cancer Institute||Active, not recruiting|December 2007|||May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014598||130492|
NCT01014819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-36|A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions|A Phase I Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions|Dermacorder|Children's Hospital & Research Center Oakland|No|Completed|October 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Males and females with multiple basal cell carcinomas|August 2011|August 2, 2011|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014819||130475|
NCT01014832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hygieia study -2|Efficacy and Safety of Frequently Modified Intensive Insulin|An Efficacy and Safety Evaluation of Frequently Modified Intensive Insulin Therapy in Subjects With Uncontrolled Type-I or Type-2 Diabetes||Hygieia, Inc|No|Completed|December 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|25 Years|65 Years|No|||November 2009|November 16, 2009|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014832||130474|
NCT01015144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502-11-585|The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle|The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle in Patients With Dilated Cardiomyopathy||Medical Universtity of Lodz|Yes|Completed|February 2007|February 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||Samples Without DNA|blood68|Both|18 Years|N/A|No|Probability Sample|Patients with dilated cardiomyopathy (according ESC 2007) with EF≤40% as documented by        echocardiography were included.|November 2009|November 17, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015144||130450|
NCT01015157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEAM1|Prospective Trial Using Gastric Stapling Line Reinforcement With Seamguard in Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass Outcomes With Systematic Gastric Stapling Line Reinforcement With Seamguard Biomaterial||Clinique de l'Anjou|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|N/A|N/A|No|||January 2010|January 4, 2010|August 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01015157||130449|
NCT01022216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSMP-013|Efficacy Study of a Bioelectric Dressing Used With Negative Pressure Wound Therapy to Treat Diabetic and Pressure Ulcers|A Randomized, Controlled Trial of the Procellera™ Wound Dressing Used With Negative Pressure Wound Therapy (NPWT) in the Healing of Diabetic and Pressure Ulcers of the Foot||Vomaris Innovations|Yes|Completed|August 2009|November 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||February 2012|February 20, 2012|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022216||129915|
NCT01021969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32003B-119706|Effects of Dietary Fructose on Glucose and Lipid Metabolism in Healthy Human Subjects|Effects of Dietary Fructose on Glucose and Lipid Metabolism in Healthy Human Subjects||University of Zurich||Completed|June 2007|July 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|36|||Male|20 Years|50 Years|No|||July 2011|July 18, 2011|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021969||129934|
NCT01022203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6756-R|Comparison of Couple-Based PTSD Treatment and Couple-Based PTSD Education|Couples Treatment of PTSD in OEF/OIF Veterans||VA Office of Research and Development|No|Active, not recruiting|August 2010|May 2016|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|70 Years|No|||February 2016|February 10, 2016|November 25, 2009||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01022203||129916|The study's small sample size makes results preliminary and precludes formal hypothesis testing of mediating variables. Our report of decreased PTSD may reflect regression toward the mean.
NCT01014845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro-HE-003|Clinical Trial of Recombinant Hepatitis E Vaccine|A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine||Xiamen University|Yes|Active, not recruiting|August 2007|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|112604|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 3, 2016|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014845||130473|
NCT01014858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5137|Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease|Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease|MUSTARDD-PD|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Suspended|January 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|November 16, 2009||No|Due to low recruitment|No||https://clinicaltrials.gov/show/NCT01014858||130472|
NCT01015183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-0904|Prevention Chemotherapy Induced Mucositis by Zinc Sulfate|Prevention High Dose Chemotherapy Induced Mucositis by Using Zinc Sulfate||Tehran University of Medical Sciences|Yes|Completed|November 2009|June 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||July 2011|July 25, 2011|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015183||130447|
NCT01016379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL08B2|Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia|Genome-Wide Interrogations in Childhood Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|No|Active, not recruiting|November 2009|||November 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|Samples With DNA|Blood and Bone Marrow|Both|1 Year|30 Years|No|Non-Probability Sample|Young Patients With Acute Lymphoblastic Leukemia|May 2015|May 1, 2015|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016379||130357|
NCT01017237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2157|Dexmedetomidine Sedation With Third Molar Surgery|Comparison of the Effectiveness of Sedation With i.v. Dexmedetomidine in Combination With Midazolam Alone or Midazolam and Low Dose Ketamine for Extraction of Third Molars.||University of North Carolina, Chapel Hill|No|Terminated|July 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2012|May 7, 2013|August 14, 2009|No|Yes|Protocol proved to be ineffective for adequate sedation for third molar surgery.|No|January 31, 2013|https://clinicaltrials.gov/show/NCT01017237||130292|Early termination due to ineffective sedation. We had to abandon the protocol in 5 of 10 patients in the dexmedetomidine plus midazolam group and 2 of 8 patients in the dexmedetomidine plus midazolam and ketamine group because of combative behavior.
NCT01017263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019063|Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity|Vyvanse and Glucose Intolerance in Children With ADHD and Obesity||Duke University|No|Terminated|December 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||September 2013|February 18, 2014|November 19, 2009|Yes|Yes|Due very high screen fail rate, pre study feasibility not consistent with screened population.|No|September 13, 2013|https://clinicaltrials.gov/show/NCT01017263||130290|Study was terminated due to the high number of failures of lab criteria for glucose intolerance which is one of the entry criterion. No data were analyzed.
NCT01017536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-017-402|Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults|Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of AERAS-402 in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3||Aeras|Yes|Completed|December 2009|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26|||Both|21 Years|45 Years|No|||October 2014|October 29, 2014|November 18, 2009||No||No|October 8, 2014|https://clinicaltrials.gov/show/NCT01017536||130269|
NCT01017549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-04|Post Market Study Using the Xoft Axxent System|Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer||Xoft, Inc.|Yes|Completed|March 2007|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|50 Years|N/A|No|||July 2015|July 17, 2015|November 18, 2009||No||No|September 7, 2010|https://clinicaltrials.gov/show/NCT01017549||130268|
NCT01017562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCU21-106|Differentiation of Aseptic From Septic Loosening by 18F-fluoride PET|Differentiation of Aseptic From Septic Loosening in Patients With Total Hip Arthroplasty Using 18F-fluoride PET||Yokohama City University Medical Center|No|Completed|April 2007|November 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|61|||Both|N/A|N/A|No|Non-Probability Sample|Patients after total hip arthroplasty who agreed with the informed consent for this study.|November 2009|November 19, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017562||130267|
NCT01017900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51-041-11-4-2|Surgery Versus Manual Rupture for Dorsal Carpal Ganglion|Comparison Between Surgical Excision and Manual Rupture for Dorsal Carpal Ganglion||Prince of Songkla University|No|Completed|August 2008|July 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|15 Years|60 Years|No|||May 2012|May 12, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017900||130242|
NCT01018199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFMG-PCT|Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia|Use of Procalcitonin (PCT) and C-reactive Protein (CRP) to Guide Antibiotic Therapy in Community Acquired Pneumonia: a Randomized Controlled Trial|CAP-Marker|Federal University of Minas Gerais|Yes|Withdrawn|January 2016|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|February 1, 2016|November 20, 2009||No|Changes in the profile of patients assisted by the hospital|No||https://clinicaltrials.gov/show/NCT01018199||130219|
NCT01024439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC-2009-080|Transumbilical Single Incision Versus Conventional Three Incisions Laparoscopic Appendicectomy|Double Blinded Randomized Controlled Study of Conventional Laparoscopic Appendicectomy Versus Transumbilical Single Incision Laparoscopic Appendicectomy||Pamela Youde Nethersole Eastern Hospital|No|Completed|October 2009|March 2013|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024439||129745|
NCT01024985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0190/09|Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct|Evaluation of Macular and Retinal Nerve Fiber Layer Thickness Measurements for Detection of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Optical Coherence Tomography.||University of Sao Paulo|No|Recruiting|September 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40|||Both|15 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|patients of ophthalmology and/or neurology departments of hopital das clinicas of medical        school of university of sao paulo|June 2010|June 24, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024985||129703|
NCT01024998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sFLT01-AMD-00106|Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)|A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration||Sanofi|Yes|Active, not recruiting|February 2010|July 2018|Anticipated|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|19|||Both|50 Years|N/A|No|||October 2015|January 5, 2016|December 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024998||129702|
NCT01025531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08060224|Cell Bound Complement Activation Proteins as Markers of Liver Injury|Cell Bound Complement Activation Proteins as Markers of Liver Injury||University of Pittsburgh|Yes|Withdrawn|December 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|All biologic samples will be under the control of the principal investigator . To protect      confidentiality, all personal identifiers will be removed and replaced with a specific code      number. The information linking these code numbers to the corresponding subjects' identities      will be kept in a separate, secure location.|Both|18 Years|N/A|No|Probability Sample|patients who are newly diagnosed with Hepatitis C|December 2014|December 5, 2014|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025531||129661|
NCT01025544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M37P2E1|Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China|A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection||Novartis||Completed|September 2009|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|846|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||December 2011|December 7, 2011|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025544||129660|
NCT01025557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Milk Study - Experiment 1|Isovolumetric and Isocaloric Preloads of Various Types of Milk on Food Intake, Subjective Appetite and Glycemic Response|The Effects of Isovolumetric and Isocaloric Preloads of Various Types of Milk on Food Intake, Subjective Appetite and Glycemic Response in Healthy Young Men and Women||University of Toronto|No|Completed|September 2009|May 2012|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|5||Actual|52|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025557||129659|
NCT01025882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000657523|Stereotactic Body Radiation Therapy With or Without Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|Phase I Study of Margin-Intense Combination Therapy for Patients With Potentially Resectable Pancreatic Adenocarcinoma||National Cancer Institute (NCI)||Recruiting|October 2009|||October 2014|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025882||129634|
NCT01025245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0511|Effect of Intraoperative Magnesium on Remifentanil-induced Postoperative Hyperalgesia After Thyroidectomy|||Yonsei University|Yes|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|84|||Both|20 Years|65 Years|No|||June 2010|June 15, 2010|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01025245||129683|
NCT01026116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHBCC09007|A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old||PAY|Fudan University|No|Recruiting|December 2009|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1664|||Female|18 Years|40 Years|No|||December 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026116||129616|
NCT01016002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foscan 1/2005|Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma|A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma||University of Salzburg|No|Recruiting|January 2006|||December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|19 Years|N/A|No|||November 2009|November 16, 2009|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01016002||130385|
NCT01014871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29081|Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles|Intra-individual Comparison of the Efficacy of Two Botulinum Toxins Type A on Moderate to Severe Forehead Wrinkles After One Injection||Galderma|No|Completed|July 2009|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|65 Years|No|||April 2012|April 17, 2012|November 16, 2009||No||No|August 12, 2011|https://clinicaltrials.gov/show/NCT01014871||130471|
NCT01014325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLG-2009-006B|Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy|Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy||Roxall Medizin||Not yet recruiting|September 2016|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|60 Years|No|||November 2015|November 2, 2015|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01014325||130513|
NCT01022528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0005-B|Analgesic Effect of Preoperative Dexamethasone in Gynecological Laparotomies - a Dose-ranging Study|||Women's College Hospital||Completed|March 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Female|18 Years|65 Years|No|||October 2013|October 15, 2013|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022528||129891|
NCT01022814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Momteclife-HMO-CTIL|Development of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine|||Hadassah Medical Organization||Not yet recruiting|January 2010|||January 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|300|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|An unrecognized amniotic fluid that passed a genetic analysis and appointed to be        disposed.|November 2009|November 30, 2009|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022814||129870|
NCT01023126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|972833|Obesity and Psychotherapy as an Alternative to Treatment|Poor Patients Adherence to Exercise and Group Therapy as an Approach to Obesity Treatment||Feevale|Yes|Completed|May 2007|September 2009|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|25 Years|62 Years|Accepts Healthy Volunteers|||December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023126||129846|
NCT01016054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009001|A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer|A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer||Astellas Pharma Inc|No|Terminated|October 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||February 2013|February 26, 2013|November 16, 2009|No|Yes|Trial was terminated to allow sponsors to evaluate the future development of the drug program|No||https://clinicaltrials.gov/show/NCT01016054||130381|
NCT01016678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAM2009|Treximet Early Intervention Adolescent Migraine|Early Intervention, Randomized, Mulitcenter, Placebo-Controlled, 4-Period Crossover, Multi-Attack Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents|TEAM|Premiere Research Institute|Yes|Completed|March 2010|July 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|104|||Both|12 Years|17 Years|No|||October 2014|October 27, 2014|November 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01016678||130334|
NCT01016691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1649|Safety and Efficacy of a Drug Delivery System in Glaucoma|||Vistakon Pharmaceuticals|No|Completed|October 2009|||February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|47|||Both|21 Years|N/A|No|||February 2015|February 18, 2015|November 18, 2009|Yes|Yes||No|September 26, 2011|https://clinicaltrials.gov/show/NCT01016691||130333|
NCT01017003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-07-1004|Pharmacokinetic Study With Colchicine in Healthy Volunteers|An Open Label, Two Period, Sequential, Single Dose and Multiple Dose Pharmacokinetic Study With 0.6mg Colchicine Tablets in Healthy Volunteers||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2007|December 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 5, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT01017003||130309|14 subjects were sought, 13 enrolled due difficult recruitment. It was impossible to determine the kinetics of metabolites because none reached the level of detectability.
NCT01017276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0005|A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis|A Phase 3 Study in Patients With Chronic Kidney Disease (CKD) With Hyperphosphatemia on Peritoneal Dialysis||Astellas Pharma Inc|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|20 Years|N/A|No|||April 2015|April 30, 2015|November 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01017276||130289|
NCT01022320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0024.0.338.000-09|Effect of Lateral Pharyngoplasty on Blood Pressure in Obstructive Sleep Apnea (OSA) Patients|Effect of Lateral Pharyngoplasty on Blood Pressure in Obstructive Sleep Apnea Patients||Hospital do Servidor Publico Estadual|No|Recruiting|May 2009|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022320||129907|
NCT01022658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090303|INSUlin Regimens and VASCular Functions|Effects of Different Insulin Regimens on Artery Compliance, Endothelium Function and Autonomic Cardiac Function in Patients With Poorly Controlled Type 2 Diabetes: a Pilot Study|INSUVASC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|30 Years|72 Years|No|||February 2013|February 20, 2013|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022658||129882|
NCT01023230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV4-HBT-02|A Study to Assess DV-601 in Subjects With Chronic Hepatitis B|A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue||Dynavax Technologies Corporation|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||August 2015|February 26, 2016|November 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023230||129838|
NCT01024959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009PCA301|Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result|Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result|PCA3|Gen-Probe, Incorporated|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|507|||Male|40 Years|N/A|No|||November 2012|November 6, 2012|December 1, 2009||No||No|October 8, 2012|https://clinicaltrials.gov/show/NCT01024959||129705|
NCT01025258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7380-OE-CTIL|Improving Adherence and Clinical Outcome in Cystic Fibrosis (CF) Patients|Improving Adherence and Clinical Outcomes of Cystic Fibrosis Patients Through a Collaborative Active Intervention Program of a Multidisciplinary Team||Sheba Medical Center|No|Completed|December 2009|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|1 Year|60 Years|No|||September 2013|September 2, 2013|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025258||129682|
NCT01025570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09456|A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer|A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma||University of California, San Francisco|Yes|Terminated|May 2010|June 2013|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|December 1, 2009|No|Yes|Terminated due to slow accrual|No||https://clinicaltrials.gov/show/NCT01025570||129658|
NCT01025583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184/08|Oral Rehydration Solution With Zinc and Prebiotics in Acute Diarrhea|Efficacy of a New Hypotonic Oral Rehydration Solution Containing Zinc and Prebiotics in the Treatment of Children With Acute Diarrhea||Federico II University|Yes|Completed|November 2007|March 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|3 Months|36 Months|No|||December 2009|January 12, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025583||129657|
NCT01025895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/09|Anterior Cruciate Ligament (ACL) Reconstruction: Single Bundle Versus Double Bundle|||Assaf-Harofeh Medical Center||Not yet recruiting|January 2010|January 2013|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|40 Years|No|||July 2009|December 3, 2009|December 3, 2009||Yes||No||https://clinicaltrials.gov/show/NCT01025895||129633|
NCT01026454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37162-A|Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons|A Randomized, Open-label, Crossover Trial of the Effect of High-dose Daily HSV-2 Suppressive Therapy on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons|ACV-VAL|University of Washington|No|Completed|February 2010|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|December 2, 2009||No||No|November 15, 2013|https://clinicaltrials.gov/show/NCT01026454||129591|
NCT01015209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT- 141009|Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers|||Medical University of Vienna|Yes|Completed|September 2010|January 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015209||130445|
NCT01015222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0521|Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies|A Phase I Trial of Dasatinib (Src Inhibitor), Bevacizumab (Anti-VEGF Monoclonal Antibody) and Metronomic Paclitaxel in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2009|||November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|218|||Both|N/A|N/A|No|||October 2015|October 26, 2015|November 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01015222||130444|
NCT01015196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 99/10-L|Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation|AML 2001: a Phase III Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation (ASCT) as Consolidation Strategy for Adults Aged 15 to 60 With Acute Myeloid Leukemia (AML) in First Complete Remission (CR).rémission complète d'Une Leucémie Aiguë Myéloblastique|AML2001|Nantes University Hospital|No|Completed|January 2001|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|832|||Both|15 Years|60 Years|No|||November 2009|November 17, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015196||130446|
NCT01014637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV4104A 2008 548|Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis|A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement|ONICO|Pierre Fabre Dermo Cosmetique|No|Recruiting|August 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||November 2009|November 16, 2009|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014637||130489|
NCT01015794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|404/09|Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation|Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation||Bayside Health|No|Completed|December 2009|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|1||Actual|25|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2009|February 12, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01015794||130400|
NCT01016392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700773-001|Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency|Kuvan® Adult Maternal Pediatric European Registry|KAMPER|Merck KGaA|No|Recruiting|December 2009|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|625|||Both|4 Years|N/A|No|Non-Probability Sample|All subjects with HPA due to PKU or BH4 deficiency followed at participating centres.        And specific groups (elderly, pediatric, pregnant women and subjects with renal or hepatic        insufficiency).|July 2015|July 31, 2015|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016392||130356|
NCT01017523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5840|Diabetes Support Project: Couples Intervention|Improving Diabetes Outcome: The Diabetes Support Project|DSP|State University of New York - Upstate Medical University|No|Completed|January 2010|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|268|||Both|21 Years|N/A|No|||May 2015|May 21, 2015|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01017523||130270|
NCT01021852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096-011|Polysomnography Study of MK6096 in Patients With Primary Insomnia (6096-011)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period Adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK6096 in Patients With Primary Insomnia||Merck Sharp & Dohme Corp.|No|Completed|November 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|326|||Both|18 Years|64 Years|No|||November 2014|November 20, 2014|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021852||129943|
NCT01022060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0913-CU|Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis|Efficacy of Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis||Catalysis SL|Yes|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|65 Years|No|||February 2010|February 3, 2010|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022060||129927|
NCT01022333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015-B|The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers|The Potential for Oral DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers||Women's College Hospital|Yes|Recruiting|July 2009|December 2010|Anticipated|July 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|300|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022333||129906|
NCT01023243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-002255|Natural Language Processing and Quality Assessment in Primary Care|Novel Use of Natural Language Processing and Targeted Patient Education Information Regarding the Process for Completion of the Foot Examination in Primary Care||Mayo Clinic|No|Completed|January 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Actual|389|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 9, 2008||No||No||https://clinicaltrials.gov/show/NCT01023243||129837|
NCT01023503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CES-CRE-2009/1|Observational Study To Evaluate Statins Patterns Of Use In Spain|Statins Use Patterns in Spain||AstraZeneca|No|Withdrawn|March 2011|July 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|To be recruited by Primary Care Physicians|July 2013|July 23, 2013|October 31, 2009||No|Changes affecting Post Authorization Study Regulatory effective from Dec09, impacted the    requirements for Spanish studies at National and Regional level.|No||https://clinicaltrials.gov/show/NCT01023503||129817|
NCT01024712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-CAMS-CHL-020|Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer|Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase Ⅱa Trial||National Cancer Institute (NCI)||Recruiting|May 2009|||||Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||December 2009|August 9, 2013|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024712||129724|
NCT01024725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH1N1-483-09THL|Evaluation of Pandemic Vaccination Campaign|Evaluation of a Vaccination Campaign With A(H1N1)v Pandemic Vaccines: a Prospective Cohort Study||National Institute for Health and Welfare, Finland|No|Completed|November 2009|September 2014|Actual|April 2010|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|3518|Samples With DNA|nasal/oral swabs, serum samples and peripheral blood mononuclear cells|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects will be invited from the population assigned to use the services of Tampere        health centre, according to the target groups for pandemic vaccination. Invitations will        be distributed at the maternity clinics for pregnant women, at work places for health        professionals, and letters will be sent home to random sample of subjects at age groups of        18-24 years, 25-64 years and potetially later at 65-75 years of age.|September 2014|September 24, 2014|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024725||129723|
NCT01025297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-07|Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone|A Phase I/IIa Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Add-On Treatment in Genotype 1 or 4 Hcv Infected Patients Resistant to Pegylated Interferon-Alpha and Ribavirin|Eclipse 2|Cytheris SA|Yes|Active, not recruiting|July 2008|March 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025297||129679|
NCT01025310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107-09|Visual Stress of the Open Urban Environment|Visual Stress of the Open Urban Environment||Meir Medical Center|Yes|Withdrawn|April 2011|December 2012|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects aged 18-60 years old will be recruited for the study from students,        faculty and staff of Tel Aviv University and of Meir Medical Center|November 2012|October 12, 2015|December 2, 2009||No|Administartive and technical problems|No||https://clinicaltrials.gov/show/NCT01025310||129678|
NCT01025323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHRI 2007-02|Study of Hispanics to Assess Risk Prevention in Prehypertension|Lifestyle Intervention in Multinational Hispanics With Prehypertension|SHARPP|Florida Heart Research Institute|No|Terminated|December 2007|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|58|||Both|18 Years|75 Years|No|||March 2013|March 12, 2013|December 2, 2009||No|The study was terminated due to difficult recruitment and retention of subjects, these were    attributed by subjects to conflict with their job schedule.|No||https://clinicaltrials.gov/show/NCT01025323||129677|
NCT01025271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: PRO09070202|Cerebrospinal Fluid Pharmacokinetics of Daptomycin|Cerebrospinal Fluid Pharmacokinetics of Daptomycin||University of Pittsburgh|Yes|Terminated|May 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|December 2, 2009|Yes|Yes|unable to enroll subjects study stopped due to lack of enrollment|No|August 23, 2012|https://clinicaltrials.gov/show/NCT01025271||129681|unable to meet enrollment no data available.
NCT01025284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12253|A Study for Patients With Small-Cell Lung Cancer|A Phase 2 Study of LY2523355 in Patients With Extensive-Stage Small-Cell Lung Cancer||Eli Lilly and Company|No|Completed|December 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||October 2012|January 11, 2013|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025284||129680|
NCT01025596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-05|Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)|A PHASE I/IIa DOSE ESCALATION STUDY IN ASIA OF REPEATED ADMINISTRATION OF "CYT107" (Glyco-r-hIL-7) ADDED ON TREATMENT IN GENOTYPE 1 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED INTERFERON-ALPHA AND RIBAVIRIN|ECLIPSE 1|Cytheris SA|Yes|Completed|May 2007|March 2012|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01025596||129656|
NCT01025921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARKAR161109|Tracheobronchitis Prevention Trial|Study of Inhaled Antibiotics for Prevention of Tracheobronchitis and Ventilator Associated Pneumonia|TRAMA|University of Thessaly|Yes|Completed|November 2009|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|84|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025921||129631|
NCT01025934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVBDRNA|Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy|Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy||Second University of Naples|No|Completed||||||Phase 4|Interventional|Primary Purpose: Treatment|3||||||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025934||129630|
NCT01026155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Respob|Respiratory Muscle Endurance Training in Obese Patients|Respiratory Muscle Endurance Training in Obese Patients||Fondation Edith Seltzer|No|Completed||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|60 Years|No|||December 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026155||129613|
NCT01025908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LABPR|Cognitive Behavior Psychotherapy in Panic Disorder|Cognitive-behavioural Therapyin Panic Disorder: the Preparation of Patients With Panic Disorder for Interoceptive and in Vivo Agoraphobic Exposure||Universidade Federal do Rio de Janeiro|No|Completed|May 2006|April 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||December 2009|January 29, 2010|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025908||129632|
NCT01026129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG 2010-002|Efficacy of Remifentanil Compared to Lidocaine on the Incidence of Coughing During Emergence of Anesthesia|Efficacy of a Bolus Dose of Remifentanil Compared to a Bolus Dose of Intravenous lidocaïne on the Incidence of Coughing During Emergence of Anesthesia.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2010|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|93|||Both|18 Years|80 Years|No|||July 2010|July 13, 2010|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026129||129615|
NCT01015508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HumBio_Westerterp09|Adipogenic Capacity as a Mediator of Weight Gain|The Role of the Genetic Background Involved in Weight Regain Through Mechanisms Including Energy Expenditure, Physical Activity and Adipogenic Capacity||Maastricht University Medical Center|Yes|Active, not recruiting|February 2010|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|200|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015508||130422|
NCT01015521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-AFP-002|Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer|A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients||Tigris Pharmaceuticals|No|Withdrawn|April 2010|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2010|November 1, 2010|November 16, 2009|Yes|Yes|Study was not initiated as planned|No||https://clinicaltrials.gov/show/NCT01015521||130421|
NCT01015495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fvf 3763s|Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks|Ranibizumab Therapy for Choroidal Neovascularization Associated With Angioid Streaks||University of Illinois at Chicago|No|Withdrawn|December 2009|January 2011|Actual|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 28, 2012|November 17, 2009|Yes|Yes|Not enough patients within the time frame to allow for a meaningful study.|No||https://clinicaltrials.gov/show/NCT01015495||130423|
NCT01015482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HighDose RemiSun|The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)|The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)||Medical University of Vienna|No|Recruiting|November 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||November 2009|November 17, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015482||130424|
NCT01016067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medtronic P07-01|Tibial Delayed Healing Pivotal Clinical Trial|A Prospective, Randomized, Multicenter Pivotal Clinical Trial of the INFUSE/MASTERGRAFT™ Delayed Healing Device With Rigid Internal Fixation in the Treatment of Tibial Delayed Healing||Medtronic Spinal and Biologics|Yes|Terminated|November 2010|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|November 17, 2009|Yes|Yes|Difficulty in patient recruitment|No|October 29, 2014|https://clinicaltrials.gov/show/NCT01016067||130380|This trial was terminated due to difficulty in patient recruitment. Early termination led to a small number of subjects analyzed. Results should be interpreted with caution.
NCT01016080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COA840/2008|Role of Oral Glutathione in Skin Whitening|Glutathione as an Oral Whitening Agent: a Randomized, Double-blind, Placebo-controlled Study||Chulalongkorn University|No|Completed|February 2009|June 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|25 Years||||November 2009|November 17, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01016080||130379|
NCT01016093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-0601|Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients|Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients: A Prospective Pilot Study||Tehran University of Medical Sciences|Yes|Active, not recruiting|November 2009|December 2011|Anticipated|November 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01016093||130378|
NCT01017250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018943|Radiosurgery and Avastin for Recurrent Malignant Gliomas|Radiosurgery and Avastin for Recurrent Malignant Gliomas||Duke University|No|Completed|December 2009|February 2012|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||January 2014|January 28, 2014|November 19, 2009|No|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT01017250||130291|
NCT01021592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012961|Quality of Life in Multiple Myeloma Patients Treated With Bortezomib|Evaluation of Improvement of Quality of Life in Multiple Myeloma Patients Treated With Velcade (Bortezomib) IV: Prospective, Multicenter, Observational Study||Janssen Korea, Ltd., Korea|Yes|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|140|||Both|18 Years|N/A|No|Non-Probability Sample|Among patients who are newly prescribed bortezomib injection as a secondary agent for the        treatment of multiple myeloma, those of whom can understand and fill out questionnaire,        and agree to provide information will be included.|December 2014|December 22, 2014|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021592||129963|
NCT01021605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-CA-1000|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2009|||||N/A|N/A|N/A||||||||||||||August 2, 2012|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021605||129962|
NCT01022671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11NSCLC08K|Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy|Single-Arm, Open-label, Multicenter, Phase 2 Clinical Trial to Assess the Efficacy and Safety of Single-Agent Camtobell Inj.(Belotecan) Administered on A Weekly Schedule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Previously Treated With Chemotherapy||Chong Kun Dang Pharmaceutical|Yes|Completed|September 2009|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|19 Years|N/A|No|||January 2016|January 27, 2016|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022671||129881|
NCT01022983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPLE|Preoperative Levosimendan and Heart Failure|Preoperative Levosimendan in Patients With Heart Failure Undergoing Elective Noncardiac Surgery: A Randomized, Placebocontrolled Trial. SIMPLE Study|PELS|Sykehuset i Vestfold HF|Yes|Withdrawn|April 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|November 24, 2009||No|Not finding patients for including|No||https://clinicaltrials.gov/show/NCT01022983||129857|
NCT01022385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0064-08-HYMC|The Effect of a Very Low-residual Diet on the Preparation Before Capsule Endoscopy|||Hillel Yaffe Medical Center||Not yet recruiting|December 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|2||||||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2009|November 30, 2009|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022385||129902|
NCT01022944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080605|Prevalence of Mucosal Biofilm Formations in Adenoidectomy Specimens|Prevalence of Mucosal Biofilm Formations in Adenoidectomy Specimens. A Case Control Study|BOLERO|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2010|May 2012|Actual|May 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|113|||Both|18 Months|10 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022944||129860|
NCT01022957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050605|Nephronophthisis : Clinical and Genetic Study|Characterization and Analysis of Long-term Evolution of Renal and Extra-renal Damages in the Course of Nephronophthisis|NEPHAER|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|7 Years|N/A|No|||March 2011|March 30, 2011|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022957||129859|
NCT01022970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2205|Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis|A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE)||Novartis||Completed|November 2009|||February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|50 Years|No|||November 2013|November 21, 2013|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022970||129858|
NCT01018875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-822|Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease|A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease||AbbVie|Yes|Completed|December 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|242|||Both|55 Years|90 Years|No|||January 2013|January 22, 2013|November 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01018875||130167|
NCT01025024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUH81510-886|Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients|Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients Patients, A Single-nucleotide Polymorphism(SNP)Analysis for Primary Open Angle Glaucoma||Chungnam National University|Yes|Completed|January 2007|November 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1224|Samples With DNA|Peripheral blood sample|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with open angle glaucoma who visited glaocoma clinic of departemtn of        Ophtalmology, Chungnam National University Hospital, Daejeon, south Korea|December 2009|December 2, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025024||129700|
NCT01025037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tornier-LIFC LFC2008.03.02|Outcomes in Rotator Cuff Repair Using Graft Reinforcement|A Prospective, Multi-Center, Single-Arm Study to Assess Clinical Outcomes In Primary Open or Mini-Open Rotator Cuff Repair Using Conexa Graft Reinforcement||Tornier, Inc.|No|Completed|October 2009|April 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|40 Years|70 Years|No|||January 2015|January 21, 2015|December 1, 2009|No|Yes||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01025037||129699|
NCT01025336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-3018|Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated|A Study To Evaluate The Persistence Of The Antibody Response Elicited By 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Adults Who Have Previously Been Vaccinated With Either 2 Doses Of 13vPnC Or 13vPnC And 23-Valent Pneumococcal Polysaccharide Vaccine In Different Sequential Order In Study 6115A1-3010 Or 6115A1 3005|AB PERSISTENCE|Pfizer|No|Completed|December 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|962|||Both|60 Years|N/A|No|||May 2012|May 16, 2012|November 20, 2009|Yes|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT01025336||129676|
NCT01025648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-A|Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.|Phase 1/2 A Randomized, Double-blinded or Evaluator-blinded, Placebo and Active Controlled, Six-arm, Crossover, Single Dose, Dose-ranging Study, for Initial Evaluation of Safety and Efficacy of E004 in Asthma Patients||Amphastar Pharmaceuticals, Inc.|No|Terminated|December 2009|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|9|||Both|18 Years|55 Years|No|||July 2013|July 11, 2013|December 1, 2009|Yes|Yes|Optimization of protocol|No||https://clinicaltrials.gov/show/NCT01025648||129652|
NCT01025609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-09-17E|Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury|Dietary Patterns & There Relationship to Cardiovascular Disease Risk Factors In Individuals With Chronic Spinal Cord Injury|SCIDS|Carolinas Healthcare System|Yes|Completed|September 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|100|||Both|38 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 individuals with chronic spinal cord injuries|July 2015|July 27, 2015|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025609||129655|
NCT01025622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011783-10|Intrahepatic Reinfusion of CD133+ Stem Cells in Cirrhotic Patients|Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease|Cirrhosis133|University of Bologna|Yes|Recruiting|October 2009|June 2012|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2010|October 28, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025622||129654|
NCT01025947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCUV|"Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder (ILR)"|Observational Study on Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder|CRYPTONITE|University of Valencia|No|Recruiting|March 2009|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|45 Years|85 Years|No|Non-Probability Sample|Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop        recorder implanted for detection of atrial fibrillation|June 2010|June 25, 2010|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025947||129629|
NCT01013987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TERCETO|Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients|A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients.|TERCETO|The Huesped Foundation|No|Recruiting|February 2010|||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|No|||November 2009|February 9, 2010|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013987||130539|
NCT01010074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD001|Retinal Function in Parkinson's Disease|Intrinsically Photosensitive Retinal Ganglion Cells in Parkinson's Disease||Edward Hines Jr. VA Hospital|No|Recruiting|October 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|movement disorders/neurology clinic|November 2009|November 6, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010074||130838|
NCT01010087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133312|Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU|A Randomized, Double-Blinded Controlled Trial Comparing High vs Standard Dose Oseltamivir in Severe, Influenza Infection in ICU. "ROSII Study"|ROSII|University of Manitoba|Yes|Terminated|November 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|12 Years|N/A|No|||June 2011|June 9, 2011|November 5, 2009|Yes|Yes|Patient population no longer available.|No||https://clinicaltrials.gov/show/NCT01010087||130837|
NCT01010399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL112948|Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects|A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza® in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva® 1400mg Plus Norvir® 100mg Plus Optimized Background|BuLLET|Felizarta, Franco, M.D.|No|Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2012|March 26, 2012|November 9, 2009|No|Yes||No|March 26, 2012|https://clinicaltrials.gov/show/NCT01010399||130813|
NCT01010659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PN1010940|The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora|Prospective Clinical Evaluation of Dacryocystorhinostomy (DCR) With Lacrimal Intubation||Aurolab|Yes|Completed|November 2009|June 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|15 Years|60 Years|No|||July 2011|July 14, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01010659||130793|
NCT01010945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-108|Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer|A Phase IB Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer||Astellas Pharma Inc|No|Completed|December 2009|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|November 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01010945||130771|
NCT01019044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORVACS 009|Exploration of HIV Reservoirs|Virologic and Immunologic Evaluation of the Deep Viral Reservoirs in HIV-1 Infected Patients With Long Term Viral Suppression|MUCOVIR|Objectif Recherche Vaccins SIDA|No|Completed|May 2009|November 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|None Retained|Plasma and total blood samples A maximum of 15 rectal mucosa biopsy samples|Both|18 Years|N/A|No|Non-Probability Sample|HIV-1 infected patients followed in specialized infectious disease/HIV hospital department|February 2013|February 12, 2013|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019044||130155|
NCT01011491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED014|Comparison of Medifast's 5 & 1 Plan to a Food-based Plan of Equal Calories|Efficacy of Medifast's 5 & 1 Program Compared to a Food-based Diet After a Period of Weight Loss and Weight Maintenance||Medifast, Inc.|No|Completed|March 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|No|||November 2009|November 10, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011491||130729|
NCT01011751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-LEU-100|Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma|Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma||Takeda|No|Completed|April 2004|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|311|||Male|18 Years|N/A|No|||July 2015|July 29, 2015|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01011751||130709|
NCT01012050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VNI1972NEB|Radioaerosol Pulmonary Deposition During Asthma Exacerbation Through Noninvasive Ventilation|Analysing the Effects of Coupling Nebulization to Noninvasive Ventilation Through Pulmonary Scintigraphy on the Radioaerosol Deposition During Asthma Exacerbation|NV|Universidade Federal de Pernambuco|Yes|Completed|June 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|65 Years|No|||November 2009|November 10, 2009|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01012050||130687|
NCT01012362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS001|Study of Pazopanib and Ixabepilone in Patients With Solid Tumors|Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors||Masonic Cancer Center, University of Minnesota|Yes|Terminated|December 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|November 12, 2009|No|Yes|PI left institution.|No||https://clinicaltrials.gov/show/NCT01012362||130663|
NCT01023269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.02.7004|Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder|Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder|ACCEPTANCE|Medtronic International Trading Sarl|Yes|Terminated|December 2009|September 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|November 30, 2009||No|difficulty in the enrolment|No||https://clinicaltrials.gov/show/NCT01023269||129835|
NCT01023282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACR325C005|Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients|Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure||NeuroSearch A/S|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|30 Years|75 Years|No|||June 2011|November 1, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023282||129834|
NCT01019486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0426|Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)|Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)|RABIT1D|University of Colorado, Denver|No|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|26|||Both|25 Years|65 Years|No|||November 2015|November 9, 2015|November 23, 2009|No|Yes||No|January 2, 2013|https://clinicaltrials.gov/show/NCT01019486||130122|3 subject had visual perfusion defects, leading to a small % of individuals being referred for invasive CFR measurements. MBF values were less than reported, either from microvascular disease in T1D subjects or the order of rest first then stress.
NCT01019213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-4-B695-A1464-22378|Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block|Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block||Aarhus University Hospital Skejby|No|Completed|September 2007|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019213||130142|
NCT01019226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7000-EK-CTIL|Implementation of Work in Progress (WIP) Sequences in Magnetic Resonance Imaging (MRI)|Implementation of Work in Progress (WIP) Sequences in MRI||Sheba Medical Center|No|Recruiting|December 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients undergoing cardiac MRI|May 2010|May 9, 2010|November 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01019226||130141|
NCT01020721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-070|The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma|Study of Gene, Inheritance Pattern and Genotype - Phenotype Correlations in South Korean Patients With Primary Congenital Glaucoma||Samsung Medical Center|Yes|Recruiting|September 2008|September 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|peripheral blood      - Genomic DNA was extracted from the peripheral leukocyte of all subjects through peripheral      blood sampling|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with primary congenital glaucoma who visit the glaucoma clinic in south Korea|August 2008|November 23, 2009|November 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01020721||130028|
NCT01020084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|monegfg09|Salivary Flow Rate and Oral Function|Effect of Hyposalivation on Mastication and Speech|SOF|University of Campinas, Brazil|No|Completed|August 2006|November 2007|Actual|August 2006|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|40|||Both|16 Years|27 Years|Accepts Healthy Volunteers|Probability Sample|Forty subjects were selected (20 male and 20 female) among people seeking for dental        treatment, students and staff of Piracicaba Dental School.Saliva collection was performed        for all subjects, and indivuduals with normal salivary flow rate composed the control        group. Hyposalivation group group, otherwise, was composed by subjects taking 0.5-0.7        mg/kg/day for at least one month prescribed by a dermatologist.|November 2009|November 24, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020084||130077|
NCT01020994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 552 000 - 0911|Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema|Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema||Almirall, S.A.|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||July 2010|July 8, 2010|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020994||130007|
NCT01021020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-07-1001|Bioequivalence Study of Colchicine Tablets|Randomized, 3-Way Crossover Bioequivalence Study of Single Dose Colchicine Tablets and Effect of Food||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2007|December 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 1, 2009|August 12, 2009|No|Yes||No|August 12, 2009|https://clinicaltrials.gov/show/NCT01021020||130005|
NCT01021033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100012|Screening Protocol for Patients With Stroke|Screening Protocol for Patients With Stroke||National Institutes of Health Clinical Center (CC)||Recruiting|November 2009|||||N/A|Observational|N/A|||Anticipated|1200|||Both|18 Years|N/A|No|||May 2015|June 10, 2015|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021033||130004|
NCT01013636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3960|Human Anaplasmosis in Eastern France|Epidemiology and Clinical Presentation of Human Anaplasmosis in Eastern France||University Hospital, Strasbourg, France|No|Recruiting|November 2009|||April 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|whole blood|Both|10 Years|N/A|No|Non-Probability Sample|patients with Anaplasma phagocytophilia|August 2011|August 29, 2011|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01013636||130566|
NCT01009762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-002980-15|Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection|Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With|HIV-VAC|Hvidovre University Hospital|Yes|Completed|September 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|60 Years|No|||February 2014|February 27, 2014|November 6, 2009||No||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01009762||130862|
NCT01010100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10139|Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care|A Multi-centre, Parallel, Double-blind, Randomised and Placebo Controlled Spanish Study, to Prevent or Delay the Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care (PREDIAP)||Bayer|No|Completed|August 2000|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|204|||Both|40 Years|75 Years|No|||December 2010|December 23, 2010|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01010100||130836|
NCT01010113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.02 INF|Effects of a Synbiotics-containing Starter Formula on Infant Growth|Growth of Infants Consuming Starter Formula Containing Synbiotics||Nestlé|No|Completed|November 2009|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|N/A|17 Days|Accepts Healthy Volunteers|||April 2012|April 20, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01010113||130835|
NCT01010412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVVENS|Ultrasound Visualization Versus Electrical Nerve Stimulation|Ultrasound Visualization v. Electrical Nerve Stimulation for the Safety and Effectiveness of Interscalene/Axillary Nerve Block in Upper Extremity Surgery: A Randomized Trial||Allentown Anesthesia Associates|No|Completed|February 2009|October 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010412||130812|
NCT01010425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-001 (Prot. 3695)|Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)|Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)||Ascendis Pharma A/S|Yes|Completed|November 2009|May 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|44|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 7, 2010|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010425||130811|
NCT01010672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-030|Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)|A Phase II Study of MK-8669 When Administered as Maintenance Therapy to Japanese Patients With Metastatic Bone or Soft-tissue Sarcomas||Merck Sharp & Dohme Corp.|Yes|Completed|November 2009|January 2013|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|13 Years|N/A|No|||April 2015|April 29, 2015|November 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01010672||130792|
NCT01010685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0302/104|Safety Study of Keyhole Gallbladder Surgery With Removal of Gallbladder Via the Stomach Rather Than Through the Skin|Safety and Feasibility Trial of Laparoscopic Small Port Cholecystectomy With Transgastric Gallbladder Recovery||Colchester Hospital University NHS Foundation Trust|Yes|Withdrawn|December 2009|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|65 Years|No|||February 2014|February 4, 2014|November 7, 2009||No|Specialised equipment required withdrawn from market|No||https://clinicaltrials.gov/show/NCT01010685||130791|
NCT01010958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD4523|Adjuvant Valproate for High Grade Sarcomas|A Pilot Study of Adjuvant Valproate for Patients With High Grade Sarcomas||Columbia University|Yes|Terminated|October 2009|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|November 6, 2009|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01010958||130770|
NCT01019642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-6371|Vitamin D, C-reactive Protein and Insulin Resistance|Effect of Vitamin D Supplementation on C-reactive Protein and Insulin Resistance in Postmenopausal Women With Type 2 Diabetes Mellitus||Instituto Nacional de Salud Publica, Mexico|Yes|Completed|March 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Female|45 Years|65 Years|No|||November 2009|November 23, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019642||130110|
NCT01011504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-08-02|Utilisation of Angiox® in European Practice|A Registry Study to Determine Utilisation Patterns in Patients Receiving Angiox®, and Collect Descriptive Safety and Outcome Data to Inform the Risk Management Strategy for Europe.|EURO-vision|The Medicines Company|No|Completed|May 2009|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2019|||Both|N/A|N/A|No|Probability Sample|Approximately, 2,000 patients will be included at centres throughout Europe|January 2012|January 18, 2012|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011504||130728|
NCT01019330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-15552|Radial Versus Femoral Arterial Access for Cardiac Catheterization: Comparison of Complications at 30 Days|Radial Versus Femoral Arterial Access for Cardiac Catheterization: Comparison of Complications at 30 Days||Creighton University|No|Completed|June 2010|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|243|||Both|19 Years|N/A|No|Non-Probability Sample|Patients presenting at Creighton University Medical Center Cardiac Catheterization        laboratory for either radial or femoral cardiac catherization|November 2015|November 27, 2015|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01019330||130134|
NCT01019343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100009|Physiological Investigations of Movement Disorders|Physiological Investigations of Movement Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|October 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2200|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019343||130133|
NCT01012063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0905/076-005|Perioperative Iron With Erythropoietin in Bilateral Total Knee Replacement Arthroplasty (TKRA)|Perioperative Intravenous Iron With Erythropoietin for the Prevention of Postoperative Severe Anemia and Reduction of Transfusion in Bilateral Total Knee Replacement Arthroplasty|SNUBH|Seoul National University Bundang Hospital|Yes|Completed|August 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Female|50 Years|80 Years|No|||August 2013|August 16, 2013|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012063||130686|
NCT01012375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00007|Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.|A Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-Over Study to Assess the Efficacy, Safety ,Tolerability and Pharmacokinetics of Three Oral AZD1446 Dose Regimens and Placebo During 2 Weeks of Treatment in Adult Non-Users and Users of Nicotine Containing Products||AstraZeneca|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|135|||Both|18 Years|65 Years|No|||September 2010|August 31, 2011|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012375||130662|
NCT01020851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA0835195N|The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial|The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating TIA or Stroke Trial|PREVENTS|Narrows Institute for Biomedical Research|No|Completed|September 2008|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|202|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01020851||130018|
NCT01021137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6841-R|Vestibular Consequences of Blast-related Mild Traumatic Brain Injury (TBI)|Vestibular Consequences of Blast-related Mild Traumatic Brain Injury||VA Office of Research and Development|No|Recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|192|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|OEF/OIF veterans|October 2015|October 21, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01021137||129996|
NCT01019239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LapLAND|LapLAND Laparoscopic Lavage for Acute Non-Faeculant Diverticulitis|Laparoscopic Lavage for Acute Non-Faeculant Diverticulitis|LapLAND|St Vincent's University Hospital, Ireland|Yes|Enrolling by invitation|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|85 Years|No|||November 2009|November 30, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019239||130140|
NCT01018888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PN1010941|Safety and Efficacy Study of Artificial Cornea|Clinical Assessment of Auro KPro|AuroKPro|Aurolab|Yes|Recruiting|August 2010|July 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|80 Years|No|||July 2011|January 7, 2013|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01018888||130166|
NCT01020097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17308|Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx|Is 18F-EF5 PET Imaging Useful in Determining the Prognosis of Newly Diagnosed Head and Neck Squamous Cell Carcinoma?||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|March 2009|||December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01020097||130076|
NCT01020422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dinter 02|Sexuality After Reduction Mammaplasty|Sexuality and Depression Predictors Among Breast Hypertrophy Women Undergoing Reduction Mammaplasty||Federal University of São Paulo|No|Completed|July 2008|September 2011|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 5, 2014|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01020422||130051|
NCT01020435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHiP|Chiropractic for Hypertension in Patients|Upper Cervical Manipulation for Patients With Stage 1 Hypertension|CHiP|Palmer College of Chiropractic|Yes|Completed|October 2010|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|21 Years|75 Years|No|||September 2015|September 3, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020435||130050|
NCT01021007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-1007-GIN-02-RR|Clinical Research Study Efficacy of a Prototype Oral Rinse|Clinical Research Study Efficacy of a Prototype Oral Rinse|Quigley|Colgate Palmolive|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|November 27, 2009|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT01021007||130006|
NCT01020734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000659891|Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission|Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study||Asan Medical Center|No|Completed|May 2011|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|263|||Both|15 Years|75 Years|No|||December 2015|December 29, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020734||130027|
NCT01021449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG870951 and CMRPG870952|Epigenetic Regulation of BDNF in Schizophrenia|Epigenetic Regulation of BDNF and TrK B in Schizophrenic Patients||Chang Gung Memorial Hospital|No|Completed|December 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|129|Samples With DNA|Blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will be conducted in our clinical setting. By a semi-structured interview for        DSM-IV criteria, total 160 subjectes (80 subjects every year, including 40 healthy        controls and 40 schizophrenia patients with acute exacerbation) will be recurited during a        2-year period. The data of blood BDNF and Trk B DNA methylation and histone remodelling of        all subjects will be collected.|September 2013|September 11, 2013|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021449||129974|
NCT01014000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOPT01|Comparative Study to Examine Whether Echocardiography Performed During Cardiac Resynchronization Therapy Device Implantation Can Improve the Response Rate|OPTimization of Left-Ventricular Lead Implantation by Echocardiography- E-OPT Study|E-OPT|Princess Margaret Hospital, Hong Kong|No|Withdrawn|June 2015|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|November 13, 2009|No|Yes|On reviewing of new data|No||https://clinicaltrials.gov/show/NCT01014000||130538|
NCT01009775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-034|A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma|A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma||Astellas Pharma Inc|No|Completed|November 2009|August 2012|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|November 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01009775||130861|
NCT01010126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02086|Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer|A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2009|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|299|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01010126||130834|
NCT01010139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODE-T60-PLFS-1|Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions|A Single Dose, 3-Period, 3-Treatment, 6-Sequence Crossover Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Tablet Formulations Under Fasting Conditions||Roxane Laboratories|No|Completed|August 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 6, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010139||130833|
NCT01010438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D006567|Clinical Evaluation of an Apnea Index for Diagnosis and Screening of Obstructive Sleep Apnea (OSA)|Clinical Evaluation of an Apnea Index Provided by a Capnograph/Pulse Oximeter to Assist in the Diagnosis and Screening of Obstructive Sleep Apnea||Oridion|Yes|Completed|October 2009|December 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|59|||Both|1 Year|N/A|No|Non-Probability Sample|Population includes consented adult patients and pediatric patients from 3 sites that have        been referred for sleep studies by a medical professional. The study will include both        patients with suspected OSA and patients that have been invited to a sleep lab for reasons        not related to OSA such as insomnia, para-insomnia and similar.|March 2012|March 12, 2012|November 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01010438||130810|
NCT01019057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.IL.0901|An Evaluation of Interlaminar Lumbar Instrumented (ILIF™)|A Prospective, Non-randomized, Multi-Center Evaluation of Interlaminar Lumbar Instrumented (ILIF™)|ILIF|NuVasive|No|Completed|November 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|||Both|40 Years|N/A|No|Non-Probability Sample|Study populuation will be comprised of 50 patients across different cities in the United        States.|July 2014|July 14, 2014|November 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01019057||130154|
NCT01019980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVOL458AVE02|Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections|A Comparative Double Blind, Double Dummy, Randomized Study on the Effectiveness of Diclofenac Potassium vs. Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections||Novartis||Terminated|March 2010|||March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|2 Years|6 Years|No|||October 2012|October 18, 2012|November 20, 2009|Yes|Yes|Placebo - Active Drug Not Available. No patients received drug. There are no study results to    disclose.|No|March 15, 2012|https://clinicaltrials.gov/show/NCT01019980||130085|This study was cancelled. Two patients were enrolled, but neither received drug as it was not available in the region.
NCT01019967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100024|A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder|A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder||National Institutes of Health Clinical Center (CC)||Terminated|November 2009|September 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|17|||Both|7 Years|17 Years|No|||September 2012|October 4, 2014|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019967||130086|
NCT01020214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLTZ-0624|Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg|Single-Dose Fasting Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01020214||130067|
NCT01019629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-230|Fabry Screening Study|Expanded Screening for Fabry Trait||Baylor Research Institute|No|Suspended|August 2008|January 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|5000|Samples With DNA|Blood and Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with any type of cardiac diagnosis|January 2016|January 12, 2016|November 23, 2009||No|Analysing current study samples|No||https://clinicaltrials.gov/show/NCT01019629||130111|
NCT01019954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 18308|Photodynamic Therapy for Early Head and Neck Tumors|Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|January 2009|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|November 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019954||130087|
NCT01020864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.08|Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer|Phase II Trial of Cetuximab in Combination With Chemotherapy (Carboplatin and Navelbine) for Patients With Platinum-resistant Head and Neck Cancer|CECAVI|Odense University Hospital|Yes|Recruiting|January 2010|January 2018|Anticipated|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|80 Years|No|||January 2015|January 20, 2015|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01020864||130017|
NCT01020877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10136019|Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects|A Study to Evaluate the Relative Bioavailability of Two Metronidazole Vaginal Gel Formulations||Teva Pharmaceuticals USA|No|Completed|November 2001|January 2002|Actual|November 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|38|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 21, 2010|November 24, 2009|No|Yes||No|February 22, 2010|https://clinicaltrials.gov/show/NCT01020877||130016|
NCT01019824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-1029/01-08|Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain|A Phase III Study to Assess the Efficacy and Safety of Ralfinamide.||Newron|Yes|Active, not recruiting|January 2009|June 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|85 Years|No|||February 2010|February 25, 2010|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019824||130097|
NCT01020110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUVEC-Version1|Study in an Ex-vivo Thrombosis Model With Human Umbilical Vein Endothelial Cells (HUVEC)-Perfusion|Human Umbilical Vein Endothelial Cells (HUVEC)-Perfusion|HUVEC|Medical University of Vienna|No|Active, not recruiting|November 2009|April 2012|Anticipated|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|supernatant of plasmin degraded thrombus including fibrin monomers|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|30 healthy subjects|April 2012|April 22, 2012|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020110||130075|
NCT01020747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC-P001|Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)|A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold||Massachusetts General Hospital|No|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|No|||December 2012|December 18, 2012|November 13, 2009|No|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT01020747||130026|
NCT01020760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1|Protocol for RCT of Posturing in Phacovitrectomy for Full Thickness Macular Hole (FTMH)|Pilot Study of Prone Posturing Following Phacovitrectomy for Thickness Macular Hole||NHS Greater Glasgow and Clyde|No|Completed|September 2008|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|16 Years|N/A|No|||April 2012|April 25, 2012|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01020760||130025|
NCT01021072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-PT004|A First in Man Study of MABp1 in Patients With Advanced Cancers|A Phase 1 Study of MABp1 in Patients With Advanced Cancers||XBiotech, Inc.|No|Completed|March 2010|August 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||October 2013|October 15, 2013|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021072||130001|
NCT01020786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12628|A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients|Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer||Eli Lilly and Company|No|Completed|November 2009|June 2012|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|20 Years|N/A|No|||June 2013|June 19, 2013|November 24, 2009|Yes|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT01020786||130023|
NCT01021085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-IVF-FS-102|Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies|Evaluation Of A Fetal Sex Determination Test At 36-56 Days Gestation In Assisted Reproductive Technology (ART) Achieved Pregnancies|PREVIEW|Sequenom, Inc.|No|Completed|April 2009|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|Maternal whole blood and urine will be collected. Whole blood will be processed to plasma      and buffy coat.|Female|18 Years|45 Years|No|Probability Sample|Women who are pregnant via assisted reproductive technology between days 36 and 56        gestational age|September 2011|September 1, 2011|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01021085||130000|
NCT01021462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-078|A Study to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates (MK-0000-078)|An Open-Label, 2-Period, Pilot Study in Healthy Male Subjects to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates||Merck Sharp & Dohme Corp.|No|Completed|August 2007|September 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021462||129973|
NCT01014013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-055|Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)|A Prospective, Multicenter, Partially-Blinded, Randomized, Comparative Study to Evaluate the Safety, Tolerability and Efficacy of INVANZ Versus Ceftriaxone Sodium in the Treatment of Complicated Urinary Tract Infections in Adults||Merck Sharp & Dohme Corp.|No|Completed|April 2008|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|November 12, 2009|No|Yes||No|January 19, 2010|https://clinicaltrials.gov/show/NCT01014013||130537|
NCT01014026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA08-KH/APACHE-1|Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention|Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women?|APACHE-1|University Hospital, Tours|No|Completed|September 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|734|||Female|20 Years|65 Years|No|||May 2011|May 12, 2011|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014026||130536|
NCT01009788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-261|ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer|A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers||Massachusetts General Hospital|Yes|Active, not recruiting|November 2009|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|November 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01009788||130860|
NCT01010451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3222|Antimicrobial Pulpotomy of Primary Molars|Survival of Primary Molars Treated With Antimicrobial Pulpotomy or Calcium Hydroxide Pulpectomy||Universidade Federal de Goias|Yes|Completed|August 2000|August 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2009|November 9, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010451||130809|
NCT01010698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044278|Class 3 Biowaivers|Evaluation of Biopharmaceutics Classification System Class 3 Drugs for Possible Biowaivers||University of Maryland|Yes|Completed|June 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|November 21, 2013|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010698||130790|
NCT01010971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-634|Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older||Sunovion|No|Completed|December 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|671|||Both|12 Years|N/A|No|||June 2012|June 8, 2012|November 6, 2009|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01010971||130769|This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg
NCT01010984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G090097|LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma|Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma|DEBDOX|University of Louisville|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 20, 2013|November 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01010984||130768|
NCT01019369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD8306|Study of Self or Clinic Administration of DepoProvera|Randomized Clinical Trial of Self Versus Clinical Administration of Depot Medroxyprogesterone Acetate||Columbia University|No|Completed|March 2010|November 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|132|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|November 18, 2009|No|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01019369||130131|
NCT01023373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|388-2002|Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy|Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease|NITER|Azienda Unità Sanitaria Locale di Piacenza|Yes|Active, not recruiting|October 2003|May 2009|Anticipated|September 2008|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|45 Years|80 Years|No|||December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023373||129827|
NCT01023386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-005|A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer|A Clinical Pharmacological Study to Assess the Distribution, Metabolism, and Elimination of YM155 After i.v. Infusion in Patients With Advanced Cancer||Astellas Pharma Inc|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|No|||April 2010|April 12, 2010|November 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023386||129826|
NCT01020266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJMZK015|Neuroprotective Study of Electroacupuncture Pretreatment in Patients Undergoing Cardiac Surgery|Clinical Trial of Cerebral Protective Effects of Repeated Electroacupuncture Pretreatment in Heart Valve Replacement Surgery||Xijing Hospital|Yes|Completed|December 2009|June 2013|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|40 Years|65 Years|No|||November 2009|June 23, 2015|November 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01020266||130063|
NCT01020279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPM-023|Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise|Multiple-dose, Randomized, Subject and Observer Blinded, Placebo-controlled, Double-dummy Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise||X-pert Med GmbH||Completed|October 2009|January 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 24, 2010|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01020279||130062|
NCT01020240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unimarco|Physiotherapy in Postpartum After a Cesarean|Effectiveness of an Orientation Guide for Puerperal Women After Cesarean.||Sao Marcos University|Yes|Completed|March 2009|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|45|||Female|15 Years|35 Years|No|||November 2009|November 25, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020240||130065|
NCT01020253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCU07-122|The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)|A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty|ETOD|Yokohama City University Medical Center|No|Active, not recruiting|January 2006|||April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Both|44 Years|82 Years|No|||December 2009|December 2, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020253||130064|
NCT01020227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1732|Usefulness of Integrative Medicine Tools As Adjunctive Care for Women After Coronary Artery Bypass Grafting|A Randomized Controlled Trial to Assess the Usefulness of Integrative Medicine Tools As Adjunctive Care for Women After Coronary Artery Bypass Grafting||Columbia University|No|Completed|February 2004|December 2007|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Female|18 Years|N/A|No|||January 2014|January 27, 2014|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020227||130066|
NCT01020565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-053|A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection|A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection||Bristol-Myers Squibb|Yes|Completed|February 2003|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||June 2010|August 4, 2010|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01020565||130040|
NCT01021202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM-PV3278/UKE|Timing of Dilation Tracheostomy in Mechanically Ventilated Chronic Obstructive Pulmonary Disease (COPD) Patients|Early vs. Late Percutaneous Dilation Tracheostomy in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease||Universitätsklinikum Hamburg-Eppendorf|No|Suspended|October 2009|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|October 6, 2009||No|unexpectedly slow recruitment|No||https://clinicaltrials.gov/show/NCT01021202||129991|
NCT01019512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02109|Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer|A Pilot, Randomized, Single-Blind Study to Assess the Efficacy of the FlexitouchÂ® Lymphedema System in Reducing Lymphedema in Patients Treated for Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Terminated|July 2009|||January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|60|||Female|N/A|N/A|No|||March 2015|March 24, 2015|November 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01019512||130120|
NCT01019525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBPF|Posture and Pulmonary Function of Mouth-breathing Children|Posture and Pulmonary Function of Mouth-breathing Children||Universidade Federal do Rio de Janeiro|No|Completed|June 2004|June 2008|Actual|June 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|34|||Both|8 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mouth-breathing children were referred by Pediatrics Service (Federal University of Rio de        Janeiro) and by School of Dentistry (Federal University of Rio de Janeiro), after the        diagnosis of mouth breathing was confirmed.        Nasal breathing children were recruited from Tia Ciata Municipal School (Praça Onze-Rio de        Janeiro, Brazil).|November 2009|November 25, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019525||130119|
NCT01019837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-ID-553-CTIL|Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and Biologics|Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases Treated With Immunomodulators and Biologics||Tel-Aviv Sourasky Medical Center|Yes|Active, not recruiting|November 2009|April 2010|Anticipated|November 2009|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|November 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019837||130096|
NCT01020448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-52014-168|Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer|Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study|Triptocare|Ipsen|No|Completed|November 2009|June 2013|Actual|November 2011|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|339|||Male|18 Years|N/A|No|||August 2015|August 6, 2015|November 24, 2009||No||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01020448||130049|
NCT01020461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/43|Evaluation of Accuvein in Adult Patients|Evaluation of Accuvein for Blood Sampling and for Intravenous Catheter Placement in Adult Patients||Hopital Foch|No|Terminated|January 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|522|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|November 22, 2009||No|Arm "placement periph iv cath" COMPLETED - Arm "blood sampling" : study will not be performed    because of the results of the arm "placement periph. iv cath"|No||https://clinicaltrials.gov/show/NCT01020461||130048|
NCT01020773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing Shijitan Hospital|Extubation With or Without Spontaneous Breathing Trial||SBT|Beijing Shijitan Hospital|Yes|Completed|June 2006|October 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|95 Years|No|||October 2009|October 14, 2009|March 21, 2009||No||No|March 21, 2009|https://clinicaltrials.gov/show/NCT01020773||130024|
NCT01021046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10001|Deep Anterior Lamellar Keratoplasty (DALK) Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients|Deep Anterior Lamellar Keratoplasty Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients||Wenzhou Medical University|Yes|Completed|December 2006|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||November 2006|August 2, 2010|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021046||130003|
NCT01021059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100021|A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer|A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults With Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer||National Institutes of Health Clinical Center (CC)||Completed|November 2009|February 2014|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|85 Years|No|||November 2015|December 15, 2015|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021059||130002|
NCT01021761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009 0199|A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification|A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification||Bucci Laser Vision Institute|No|Completed|October 2009|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 26, 2011|November 25, 2009||No||No|May 25, 2011|https://clinicaltrials.gov/show/NCT01021761||129950|
NCT01021982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-6958-AS-CTIL|Evaluation of Objective Perimetry Using Pupillometer|Objective Perimetry in Normal Subjects,Glaucoma Patients and Retinitis Pigmentosa Patients .||Sheba Medical Center|No|Completed|November 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|November 2014|November 18, 2014|November 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01021982||129933|
NCT01014039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPS|Telemark Polyp Study, a Trial on Colonoscopy Screening|Telemark Polyp Study, a Randomized Trial on Colonoscopy Screening|TPS|Norwegian Department of Health and Social Affairs|No|Active, not recruiting|March 1983|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|55 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014039||130535|
NCT01010152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODE-T30-PVFS-1|Comparative Bioavailability Study of Codeine Sulfate|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Comparative Bioavailability Study fo Codeine 30 mg Tablets and Tylenol #3 Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|January 2008|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010152||130832|
NCT01010165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0916|Determination of New Biomarkers of Septic Arthritis by Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight (SELDI-TOF)|Caractérisation de Nouveaux Biomarqueurs de l'Arthrite Septique Par Technique SELDI-TOF|NOUBASST|University Hospital, Grenoble|No|Completed|October 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|89|Samples Without DNA|joint fluid proteom|Both|18 Years|N/A|No|Non-Probability Sample|patients from the Grenoble University Hospital|December 2011|October 25, 2012|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010165||130831|
NCT01010178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT-1388-2|Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?|Combination of Approved Drug in COPD||Baqiyatallah Medical Sciences University|Yes|Completed|February 2008|July 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|64|||Both|22 Years|86 Years|No|||November 2009|November 6, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010178||130830|
NCT01022827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905041R|Shoulder Muscle Massage Shoulder Stiffness|Effects and Predictors of Effectiveness of Shoulder Muscle Massage for Patients With Posterior Shoulder Stiffness||National Taiwan University Hospital|Yes|Completed|October 2009|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2011|January 3, 2012|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01022827||129869|
NCT01023152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0423|Effect of Remote Ischemic Preconditioning on Acute Kidney Injury in Patients Undergoing Heart Valve Replacement Surgery With Cardiopulmonary Bypass|||Yonsei University|No|Completed||||||N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|1||Actual|74|||Both|18 Years|65 Years|No|||December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023152||129844|
NCT01023399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAMF_L_04314|Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire|A Nested Open Labeled Study to Compare the Effectiveness and Safety of a Fixed-dose Combination of Artesunate Plus Amodiaquine (ASAQ Winthrop®) in the Unsupervised Treatment of Uncomplicated Plasmodium Falciparum Malaria Attacks in Two Patient Groups Enrolled at Two Year-intervals in a Pilot District of Côte d'Ivoire||Sanofi||Completed|November 2009|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|580|||Both|N/A|N/A|No|||February 2015|February 20, 2015|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023399||129825|
NCT01019668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-98-DR-27|Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy|Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy||Shin Kong Wu Ho-Su Memorial Hospital|No|Completed|November 2008|June 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||July 2011|July 22, 2011|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01019668||130108|
NCT01019356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-075|Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome|Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome||Université de Sherbrooke|No|Active, not recruiting|August 2006|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|78|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019356||130132|
NCT01020305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-17242|Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer|Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer||Stanford University|Yes|Terminated|October 2009|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||October 2014|October 3, 2014|October 30, 2009|Yes|Yes|Decision by funding sponsor due to poor accrual|No|October 3, 2014|https://clinicaltrials.gov/show/NCT01020305||130060|
NCT01020591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2010-227|The Effect of Osteopathic Manual Therapy on the Vascular Supply to the Lower Extremity, Function and Symptoms of Subjects With Knee Osteoarthritis|||Nova Scotia Health Authority||Recruiting|December 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|75 Years|No|||December 2009|December 15, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020591||130038|
NCT01020604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OHU-ZOL-2009/1|PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients|PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients Assessment of the Correlation Between Body Mass Index and Recurrence Among Zoladex Treated Prostate Cancer Patients|PROTECT-Z|AstraZeneca|No|Completed|November 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1376|||Male|18 Years|N/A|No|Probability Sample|Adult men treated by adjuvant goserelin therapy for at least 1 month after primary        (curative) therapy of histologically proven, prostate cancer|April 2013|April 29, 2013|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01020604||130037|
NCT01020578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPIDS-IGT|Low Density Lipoprotein (LDL) Cholesterol Metabolism in Impaired Glucose Tolerance|Plasma Kinetics Study the of Free Cholesterol and Cholesterol Ester in Subjects With Impaired Glucose Tolerance||University of Sao Paulo General Hospital|No|Completed|June 2008|October 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|29|Samples Without DNA|whole blood samples|Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with impaired glucose tolerance and controls were recruited from the Hospital of        Clinics, Some were patients and staff of the Heart Institute and patients treated in        outpatient clinics, offices and clinics outside the Hospital of Clinics of University of        São Paulo.|November 2009|November 24, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020578||130039|
NCT01019850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000659059|N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma|Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744||New Approaches to Neuroblastoma Therapy Consortium|Yes|Completed|March 2010|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|2 Years|30 Years|No|||December 2015|December 11, 2015|November 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01019850||130095|
NCT01019863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122752|Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.|Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.|LNH-RGDOX|Centre Hospitalier Universitaire de Sherbrooke|Yes|Recruiting|October 2008|October 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2009|January 11, 2011|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019863||130094|
NCT01020123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00009|Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients|A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients||AstraZeneca|No|Completed|October 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|530|||Both|18 Years|N/A|No|||November 2012|November 22, 2012|November 11, 2009|Yes|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT01020123||130074|
NCT01020474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081180|Adolescent Fibromyalgia Study|A 15 Week, Randomized, Double Blind, Parallel-group, Placebo-controlled, Flexible-dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia||Pfizer|Yes|Completed|May 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|12 Years|17 Years|No|||June 2015|June 22, 2015|November 23, 2009|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01020474||130047|
NCT01020487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-149|Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children 10-16 With Chronic Kidney Disease (CKD)|Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 Years With Moderate to Severe Chronic Kidney Disease||AbbVie|No|Completed|February 2010|December 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|10 Years|16 Years|No|||May 2015|May 22, 2015|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01020487||130046|
NCT01020513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD-2010-0250|Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design|Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design|Hylenex-ED|University of California, San Diego|No|Withdrawn|November 2010|February 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|non-emergent patients in Emergency Departments|December 2013|December 10, 2013|November 24, 2009||No|This study was closed before accrual due to FDA recall of Medication|No||https://clinicaltrials.gov/show/NCT01020513||130044|
NCT01018420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-07-1002|Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study|A Randomized, Double-Blind, Double-Dummy Pharmacokinetic and Exploratory Electrocardiogram (ECG) Safety Study of a Standard Acute Gout Regimen||Mutual Pharmaceutical Company, Inc.|No|Completed|November 2007|January 2008|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2009|November 24, 2009|August 12, 2009|No|Yes||No|August 12, 2009|https://clinicaltrials.gov/show/NCT01018420||130202|
NCT01018706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHOST|Goodness of Clinical History During Stemi PCI|Goodness of Clinical History During Stemi PCI (GHOST)|GHOST|Umberto I Hospital, Frosinone Italy|No|Completed|March 2010|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Four hundred patients with STEMI treated with primary PCI or rescue PCI.|December 2013|December 16, 2013|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01018706||130180|
NCT01009801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 77/09|Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer|A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolization (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma||Swiss Group for Clinical Cancer Research|No|Terminated|February 2010|June 2015|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|November 6, 2009||No|due to slow patient recruitement.|No||https://clinicaltrials.gov/show/NCT01009801||130859|
NCT01009814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-006|Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1|Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects||Bristol-Myers Squibb|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|N/A|No|||July 2010|December 5, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009814||130858|
NCT01022541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2676|Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer|Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer||Royal Marsden NHS Foundation Trust|Yes|Completed|June 2006|February 2015|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||May 2013|November 23, 2015|January 23, 2006||No||No||https://clinicaltrials.gov/show/NCT01022541||129890|
NCT01022554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMT001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2009|||||N/A|N/A|N/A||||||||||||||November 25, 2009|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022554||129889|
NCT01023412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-IRTD-01-05-CH|Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery|Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial|IPOD-3|Nestlé|No|Terminated|January 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|November 16, 2009||No|interim review of the data indicated that the hypothesis put forth on the efficacy of a 3 day    regimen was not met.|No||https://clinicaltrials.gov/show/NCT01023412||129824|
NCT01019070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-012|Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032|Multiple-Dose Pharmacokinetics of BMS-650032 in Subjects With Hepatic Impairment Compared to Healthy Subjects||Bristol-Myers Squibb|No|Completed|December 2009|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|28|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|November 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01019070||130153|
NCT01019083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-066|Studies of Immune Responses to Orally Administered Vaccines in Developing Country|Studies of Acute and Memory Immune Responses to Orally Administered Vaccines in Developing Country Children and Factors That May Augment Such Responses||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|February 2008|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|1016|||Both|1 Year|45 Years|Accepts Healthy Volunteers|||November 2009|July 11, 2011|November 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01019083||130152|
NCT01019681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVD.Cord.Blood.2008|Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia|Umbilical Cord Blood Stem Cell Injection for Critical Limb Ischemia||Northwestern University|No|Terminated|November 2009|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|72 Years|No|||January 2014|January 31, 2014|November 19, 2009|Yes|Yes|Only patient enrolled on study died -the cause of death not study related|No||https://clinicaltrials.gov/show/NCT01019681||130107|
NCT01019694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012.62|Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease|Patient Acceptability of Ipratropium Bromide/Albuteroll Delivered by the Respimat® Inhaler in Adults With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|November 2009|||April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|470|||Both|40 Years|N/A|No|||October 2014|October 14, 2014|November 16, 2009||||No|April 5, 2012|https://clinicaltrials.gov/show/NCT01019694||130106|
NCT01019655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tempfer2.0|Heparin for Pregnant Women With Thrombophilia|Low Molecular Weight Heparin for Pregnant Women With Thrombophilia: a Prospective, Randomized, Open Trial||Medical University of Vienna|No|Not yet recruiting|January 2010|December 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|50 Years|No|||November 2009|November 24, 2009|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019655||130109|
NCT01020318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100006|Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury|Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Completed|October 2009|May 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|9|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020318||130059|
NCT01011075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST CST1571BUS240|Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer|A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer|6137p|New Mexico Cancer Care Alliance|Yes|Completed|August 2009|July 2012|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|70 Years|N/A|No|||June 2015|June 6, 2015|October 14, 2009|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT01011075||130761|
NCT01020617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D206 ProTeen|The Effect of Probiotics on Low-grade Inflammation, Microbiota and Risk Factors for Metabolic Syndrome in Obese Children|Association Between the Diet, the Composition of Microbiota of the Intestinal Tract, Human Health and Well-being||University of Copenhagen|No|Completed|April 2009|January 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|51|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||November 2009|January 18, 2011|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01020617||130036|
NCT01011088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-200911-MZ018|Paternal Psychosis After Baby Born|Paternal Psychosis Evaluation After First Baby Born|PAPABAB|Nanjing Medical University|Yes|Completed|November 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|387|||Male|19 Years|49 Years|No|Probability Sample|Fathers with their first baby born|June 2010|June 3, 2010|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011088||130760|
NCT01020890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GBG-NEX-2009/1|Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms|A Cross-sectional Study on the Prevalence of GERD in Primary Care Patients With Upper GI Symptoms Using the GERD-Q. The Bulgarian GERD-Q Study||AstraZeneca|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|2210|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic|July 2010|July 9, 2010|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01020890||130015|
NCT01020903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-045|Aprepitant for Post-operative Nausea|Aprepitant vs. Placebo for the Prevention of Postoperative Nausea and Vomiting: a Randomized, Double-blind Study in Patients Undergoing Laparoscopic Cholecystectomy||Northwell Health|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|November 24, 2009|No|Yes||No|May 8, 2014|https://clinicaltrials.gov/show/NCT01020903||130014|
NCT01019278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 22808|Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes|A Feasibility and Phase II Study of Proton Beam Radiotherapy for Patients With Cervical Cancer and FDG-PET Positive Para-aortic Lymph Nodes||Abramson Cancer Center of the University of Pennsylvania|Yes|Withdrawn|July 2009|||August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||October 2014|July 29, 2015|November 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019278||130137|
NCT01019291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3965|Role of Indoor Pollutants on House Dust Mite Allergic Asthma|Aldehyde and Nitrogen Dioxide at Homes: Measurement of the Exposure and Their Role on Allergic Asthma||University Hospital, Strasbourg, France|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator)|4||Actual|0|||Both|18 Years|50 Years|No|||March 2015|March 26, 2015|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019291||130136|
NCT01019577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-107|Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant|Phase II Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant||Bristol-Myers Squibb|Yes|Completed|October 2005|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Female|20 Years|N/A|No|||November 2009|February 3, 2010|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019577||130115|
NCT01019876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB0170|Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases|Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases||Columbia University|Yes|Recruiting|June 2002|May 2013|Anticipated|May 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|N/A|30 Years|No|||October 2011|October 18, 2011|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019876||130093|
NCT01019889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B070029|Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection|Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection|ESYUI|Korea Health Industry Development Institute|No|Completed|September 2008|July 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|480|||Both|18 Years|60 Years|No|||April 2012|April 4, 2012|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019889||130092|
NCT01020136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061063|A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers|A Phase 1 Bioequivalence Study To Compare The Plasma Pharmacokinetics Of AG-013736 Polymorph Form IV Versus Market-Image Polymorph Form XLI Tablets In Healthy Volunteers Under Fed Conditions||Pfizer|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|21 Years|47 Years|Accepts Healthy Volunteers|||April 2010|April 21, 2010|November 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01020136||130073|
NCT01020149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Evaluation of Nerve Regeneration After Nerve Transsection Using (Diffusion-tensor Magnetic Resonance Imaging) DTI MR Imaging|||University of Zurich|No|Recruiting|January 2010|December 2012||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|June 2010|June 24, 2010|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020149||130072|
NCT01020162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|429-05|Treatment of Ilioinguinal Entrapment Syndrome - an Often Overlooked Cause of Chronic Pelvic Pain|Treatment of Ilioinguinal Entrapment Syndrome - a Randomised Controlled Trial||Göteborg University|No|Completed|September 1995|November 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Female|15 Years|70 Years|No|||November 2009|November 23, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020162||130071|
NCT01020500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-79-52120-138|To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following Stroke|An International, Prospective Cohort to Document the Effectiveness of One BoNT-A Injection Cycle Based on Attainment of Individual Person-centred Goals in Adult Subjects Suffering From Upper Limb Spasticity Following Stroke|ULIS2|Ipsen|No|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|469|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital Clinics|June 2011|June 20, 2011|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020500||130045|
NCT01021488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-I053|Rosuvastatin for Preventing Deep Vein Thrombosis|Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial|STOP-DVT|Hallym University Medical Center|Yes|Recruiting|October 2009|March 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|19 Years|N/A|No|||November 2009|October 4, 2011|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021488||129971|
NCT01014338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15099|Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)|ACE-inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease||Imperial College London|No|Completed|October 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2011|March 24, 2015|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014338||130512|
NCT01014351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MEL 19|Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma|A Phase II Study of Everolimus in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma||SCRI Development Innovations, LLC|No|Completed|February 2010|August 2013|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||January 2014|February 10, 2014|November 16, 2009|No|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01014351||130511|
NCT01014650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLYX13-C-101|Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers|A Randomized, Double-Blind, Placebo-Controlled Single Intravenous Dose, Ascending Dose Level Study of the Safety, Tolerability and Pharmacokinetics of GLYX-13 in Normal Healthy Volunteers||Naurex, Inc|No|Completed|November 2009|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|53|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|November 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01014650||130488|
NCT01021995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920'134|Echinacea Safety Study|Safety and Efficacy of Long-term Treatment With Echinaforce® Over 4 Months||Bioforce AG|No|Completed|October 2009|April 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|757|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|July 22, 2014|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01021995||129932|
NCT01023165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-001|Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes|Multicenter Trial to Evaluate the Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetics Who Despite Tight Control and Proper Diet Still Suffer From Metabolic Problems||Global Infusion and Aspiration Systems, LLC|Yes|Recruiting|November 2009|November 2015|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|95 Years|No|||June 2011|June 21, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023165||129843|
NCT01019096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-06-045|Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer|Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer||Cornell University|Yes|Completed|May 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|55|Samples With DNA|For non-pregnant subjects 15 mL of blood are collected. For pregnant subjects two 15 mL      blood samples are collected. The placenta and up to 30 mL of cord blood are also collected      at delivery.|Female|15 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women and adolescents from Rochester, NY and non-pregnant women from Ithaca, NY.|March 2012|March 21, 2012|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019096||130151|
NCT01019382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0408/51|A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer|Phase II Trial of the Effect of Gemcitabine With Intravenous Omega-3 Fish Oil Infusion in Patients With Unresectable Pancreatic Adenocarcinoma||University Hospitals, Leicester|No|Completed|October 2009|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01019382||130130|
NCT01019707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50-18185-PI-EDL-A|Safety Assessment of Atomoxetine With MA IV Administration|A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine||University of California, Los Angeles|Yes|Terminated|October 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|50 Years|No|||June 2013|June 25, 2013|November 24, 2009|No|Yes|End in funding|No|April 2, 2013|https://clinicaltrials.gov/show/NCT01019707||130105|Early termination leading to small number of subject analyzed
NCT01019993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39-01-2004|Non-dependent Lung High Frequency Positive Pressure Ventilation (HFPPV) and Right Ventricular Function|Prospective Study of the Effects of Non-dependent Lung High Frequency Positive Pressure Ventilation on the Right Ventricular Function for Thoracotomy||King Faisal University|No|Completed|February 2004|February 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|60 Years|No|||May 2010|May 26, 2010|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019993||130084|
NCT01011608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK52|Effect of a Medical Food Supplement in Hospitalized Patients Recovering From Surgery|Effect of a Medical Food Supplement in Hospitalized Patients Recovering From Hip Fracture Surgery||Abbott Nutrition|No|Completed|November 2009|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|45 Years|N/A|No|||November 2010|April 1, 2011|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011608||130720|
NCT01020916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTM-1|Target Temperature Management After Cardiac Arrest|Target Temperature Management 33°C Versus 36°C After Out-of-hospital Cardiac Arrest, a Randomised, Parallel Groups, Assessor Blinded Clinical Trial|TTM|Helsingborgs Hospital|Yes|Completed|November 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|950|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01020916||130013|
NCT01019928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9127C00002|Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)|A Phase IIa, Double-blind, Randomized, 2-way Cross-over Study to Evaluate the Effect of a Single Dose of AZD1386 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity in GERD Patients With a Partial Response to PPI Treatment||AstraZeneca|No|Completed|November 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|70 Years|No|||October 2012|October 10, 2012|November 20, 2009||No||No|January 27, 2012|https://clinicaltrials.gov/show/NCT01019928||130089|
NCT01019941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKD-810_PK_phase I|Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics of Docetaxel Between Two Docetaxel Products, CKD-810 and Taxotere Inj., in Patients With Advanced Solid Cancer|126ASC08Q|Chong Kun Dang Pharmaceutical|No|Completed|August 2009|December 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||December 2010|December 15, 2010|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019941||130088|
NCT01020526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081231|Pregabalin In Adolescent Patients With Fibromyalgia|A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia||Pfizer|Yes|Completed|September 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|12 Years|18 Years|No|||December 2015|December 1, 2015|November 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01020526||130043|
NCT01019590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLTZ-0625|Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg|Single-Dose Fed Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers||Mylan Pharmaceuticals||Completed|November 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 23, 2009|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019590||130114|
NCT01020539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6378|Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia|Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML)|AML/MDS/JMML|Columbia University|Yes|Active, not recruiting|January 2005|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|1 Month|30 Years|No|||January 2016|January 5, 2016|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020539||130042|
NCT01019902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00024804|Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn|Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn||Cornell University|Yes|Completed|October 2008|October 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|144|Samples With DNA|At delivery a 15 mL maternal blood sample, 20 ml cord blood sample and the placenta are      collected.|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant adolescents in Rochester, NY.|March 2014|March 19, 2014|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019902||130091|
NCT01020812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0024|Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma|Phase II Study of Combination Stereotactic Body Radiotherapy (SBRT) With Transarterial Chemo-Embolization (TACE) for Unresectable Hepatocellular Carcinoma||Stanford University|Yes|Terminated|September 2009|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|November 24, 2009||No|enrollment was too low|No|December 5, 2014|https://clinicaltrials.gov/show/NCT01020812||130021|The low enrollment of patients led to the study being terminated before the full sample size could be reached. This resulted in a smaller than anticipated pool of patients to be analyzed and conclusions that are more difficult to generalize.
NCT01021098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-045|Acute Respiratory Infection Consortium|A Multi-center Military Consortium for Clinical Research Into the Natural History, Host Response, and Potential Therapy of Acute Respiratory Infection in Military Members and Their Families|ARIC|Uniformed Services University of the Health Sciences|No|Recruiting|November 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|nasopharyngeal swabs with storage of multiple harvested (expanded) first generation viral      isolates (all must opt in); buccal swab storage (may opt out) rectal swab storage (may opt      out) serum storage (may opt out)|Both|N/A|65 Years|Accepts Healthy Volunteers|Probability Sample|Males and females of all ages and of military (including active duty enlisted and active        duty officers from all branches of service), healthy retirees, and their dependents        (spouses and children) presenting to inpatient/outpatient facilities with ILI will be        eligible for participation. At select sites, military members and their family members        (healthy spouses and children) may be eligible for participation in the study of household        transmission of influenza. All children, regardless of study site, will be excluded from        the direct collection of blood specimens for research purposes alone. Only discard blood        will be collected from children and no additional needle sticks will occur in children.        Blood will only be collected from children if indicated by the primary care physician.|June 2015|June 9, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01021098||129999|
NCT01018121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103254|Behavioral Rx & Nutrition in Pediatric Chronic Disease|LAUNCH II: Learning About Activity and Understanding Nutrition for Better Child Health|LAUNCH|Children's Hospital Medical Center, Cincinnati|Yes|Completed|November 2007|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||November 2009|November 20, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018121||130225|
NCT01018407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH084864-01A109|Interventions for Communication in Autism Network|Multisite Randomized Control Treatment of Early Intervention for Spoken Communication in Autism|ICAN|University of California, Los Angeles|Yes|Completed|December 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Both|33 Months|54 Months|Accepts Healthy Volunteers|||June 2015|June 4, 2015|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018407||130203|
NCT01014884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7714|Coventry Outcomes Study of Seniors (COSS): A Comparative Effectiveness Study to Evaluate the Effect of a Multidisciplinary Team's Intervention on the Incidence of Nonelective Hospitalizations in a Medicare Population|Coventry Outcomes Study of Seniors: A Dual-arm, Controlled, Randomized, Comparative Effectiveness Study to Evaluate the Effect of a Multidisciplinary Team's Intervention Versus Usual Care on the Incidence of Nonelective Hospitalizations in a Medicare Population|COSS|Medco Health Solutions, Inc.|No|Terminated|November 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|N/A|2||Anticipated|2150|||Both|65 Years|N/A|No|||January 2010|January 20, 2010|November 12, 2009||No|Terminated by Sponsor|No||https://clinicaltrials.gov/show/NCT01014884||130470|
NCT01022567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPAC|Appendicectomy Versus Antibiotics in the Treatment of Acute Uncomplicated Appendicitis|Study of Surgical Treatment (Open Appendicectomy) Versus Antibiotic Treatment (Ertapenem) in the Treatment of Acute Uncomplicated Appendicitis|APPAC|Turku University Hospital|No|Active, not recruiting|November 2009|December 2025|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|530|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022567||129888|
NCT01022840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180808|The Preemptive Analgetic Potency of Low Dose S-Ketamine|The Opioid Sparing Effect of Minimal Dose S-Ketamine Applied as a Coanalgesic During the Perioperative Period - An Active Placebo-Controlled, Double Blinded, Randomized Clinical Trial (МiniKet)|Miniket|Medical University of Graz|Yes|Completed|February 2009|September 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||October 2012|October 1, 2012|November 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01022840||129868|
NCT01022853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.7|Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors|An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBF 1120 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|December 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|November 26, 2009||||No||https://clinicaltrials.gov/show/NCT01022853||129867|
NCT01023178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10272009-4262|Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure|Comparison of Transdermal and Oral Estrogens in Adolescents With Ovarian Failure||Stanford University||Completed|February 2007|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Female|12 Years|18 Years|No|||December 2013|December 2, 2013|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023178||129842|
NCT01023425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-02-072|Clinical Trial of Donepezil Between the Naive Group and the Switching Group|Comparative Assessment of Clinical Efficacy of Donepezil Between the Naive Group and the Switching Group||Samsung Medical Center|Yes|Completed|February 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|N/A|N/A|No|||January 2016|January 4, 2016|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023425||129823|
NCT01019109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0305|Scoliosis Surgery Using the PASS® LP System|Idiopathic Scoliosis Treated by Posterior Spinal Instrumentation. Evaluation of the 3D Correction, Aesthetic Outcomes and Quality of Life.||Medicrea, USA Corp.|No|Active, not recruiting|May 2010|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|N/A|N/A|No|||April 2013|April 22, 2013|November 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019109||130150|
NCT01019395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAP-PEDS-09-01|Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics|An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics||Cubist Pharmaceuticals LLC|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|23|||Both|3 Months|24 Months|No|||May 2012|May 22, 2012|November 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019395||130129|
NCT01019408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-HNI01|Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan|Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan|ECQNWFP|London School of Hygiene and Tropical Medicine|Yes|Completed|November 1993|January 1995|Actual|January 1995|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Both|6 Months|60 Years|No|||November 2009|November 23, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019408||130128|
NCT01019421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12936A|Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil||H. Lundbeck A/S|No|Completed|December 2009|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|278|||Both|50 Years|N/A|No|||January 2012|January 5, 2012|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019421||130127|
NCT01011101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100016|Internal Monitoring of Eye Movement in Schizophrenia|Internal Monitoring of Eye Movement in Schizophrenia||National Institutes of Health Clinical Center (CC)||Recruiting|November 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 7, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011101||130759|
NCT01020006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1001|Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine|Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine||Pharmacyclics|Yes|Completed|November 2009|||August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|November 20, 2009|No|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01020006||130083|
NCT01020292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01309|A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma|Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|April 2009|||December 2016|Anticipated|Phase 1|Interventional|N/A|||Anticipated|31|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020292||130061|
NCT01011348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81WH-07-1-0667|Q10 for Gulf War Veterans|Q10 for Gulf War Veterans|GULF|University of California, San Diego|No|Active, not recruiting|July 2008|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|46|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011348||130740|
NCT01011621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE/P/08-1|Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis|Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis||Mantecorp Industria Quimica e Farmaceutica Ltd.|Yes|Not yet recruiting|February 2010|||February 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|12 Years|60 Years|No|||November 2009|November 10, 2009|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011621||130719|
NCT01011868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.33|Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes|A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, Detemir, or NPH Insulin Only) With or Without Concomitant Metformin and/or Sulfonylurea Therapy and Insufficient Glycemic Control||Boehringer Ingelheim||Completed|November 2009|||May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|494|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|November 10, 2009||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01011868||130700|
NCT01011881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT AMIENS|Procalcitonin in Pleural Pleuritis|Evaluation de la Mesure du Taux de la Procalcitonine Dans Les Liquides Pleuraux||Centre Hospitalier Universitaire, Amiens||Completed|October 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|patients with pleuritis|November 2009|February 28, 2011|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011881||130699|
NCT01016938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043875|Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)|Dynamic MRI for Lung Tumor Motion and Lung Function||University of Maryland|Yes|Completed|November 2009|October 2015|Actual|October 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must be undergoing radiation therapy with or without chemotherapy for thoracic        and/or abdominal cancers.|November 2015|November 30, 2015|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01016938||130314|
NCT01020799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1151C00005|AZD7268 Safety and Tolerability Study|A Phase II, Multi-center, Randomized, Double-bind, Double-dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of AZD7268 in Patients With Major Depressive Disorder||AstraZeneca|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|247|||Both|18 Years|65 Years|No|||April 2012|April 11, 2012|November 25, 2009|Yes|Yes||No|January 11, 2012|https://clinicaltrials.gov/show/NCT01020799||130022|
NCT01017471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-169-11-4-2|Carpal Tunnel Syndrome Release Using PSU Retractor|Comparison Results of Carpal Tunnel Release Between Standard Incision and Limited Incision Using PSU Retractor: A Randomized Controlled Trial||Prince of Songkla University|No|Enrolling by invitation|September 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|15 Years|80 Years|No|||May 2012|May 12, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017471||130274|
NCT01017822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0932|Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase I/II Study of Induction Conatumumab and Gemcitabine, Followed by Conatumumab, Capecitabine and 3-D Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer||Radiation Therapy Oncology Group|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|November 20, 2009|Yes|Yes|This study was withdrawn due to study agent availability.|No||https://clinicaltrials.gov/show/NCT01017822||130248|
NCT01017835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503-5139-2|Simvastatin in Patients With Isolated Arterial Hypertension|Simvastatin in the Treatment of Isolated Arterial hyPertension and Prevention of cARdiovascular Events|STIPPARE|Medical Universtity of Lodz|No|Recruiting|November 2009|January 2012|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|plasma|Both|18 Years|N/A|No|Probability Sample|Patients hospitalized in the Department of Nephrology, Hypertension and Family        Medicine,Clinical Hospital of Medical University of Lodz|November 2009|November 20, 2009|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01017835||130247|
NCT01018108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17108|Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors|Effect of Acupuncture on Brain Serotonin Among Breast Cancer Survivors||Abramson Cancer Center of the University of Pennsylvania|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|7|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|November 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018108||130226|
NCT01018719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cardiotoxicity66809|Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)|Evaluation of Radiation Induced Cardiotoxicity by Multi-detector Computed Tomography (MDCT)||Western Galilee Hospital-Nahariya|No|Not yet recruiting|January 2010|||December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Female|18 Years|60 Years|No|Non-Probability Sample|Patients with breast cancer followed in the oncology clinic.|November 2009|November 23, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01018719||130179|
NCT01015235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-1678-002|Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain|A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain||KAI Pharmaceuticals|Yes|Completed|December 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|75 Years|No|||August 2011|August 31, 2011|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015235||130443|
NCT01015248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MALT2008-01|Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma|Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Completed|May 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|84 Years|No|||June 2011|May 26, 2014|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015248||130442|
NCT01022580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10842-33541-01A|Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia|Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide|TOLSURF|University of California, San Francisco|Yes|Active, not recruiting|January 2010|July 2015|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|524|||Both|N/A|14 Days|No|||September 2013|September 20, 2013|November 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022580||129887|
NCT01022606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE 2009-16|Intra-arterial Measurement of pO2 in Walking Induced Transient Hack Profiles|Intra-arterial Measurement of pO2 in Walking Induced Transient Hack ("WITH") Profiles|Initial-VHS|University Hospital, Angers|Yes|Terminated|October 2009|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|10|||Both|N/A|N/A|No|||March 2013|March 15, 2013|November 24, 2009||No|Stopped for one complication event (arterial occlusion)|No||https://clinicaltrials.gov/show/NCT01022606||129886|
NCT01022866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02370|Falls Prevention Clinic|Vancouver Falls Prevention Clinic Database||University of British Columbia|No|Recruiting|January 2010|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|||Both|70 Years|N/A|No|Non-Probability Sample|Falls Prevention Clinic|April 2015|April 7, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022866||129866|
NCT01023438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART SC|Strategies to Improve Prescribing in Heart Failure Patients|Strategies To Improve Appropriate Prescribing In Heart Failure Patients. Assessment of the Effectiveness of an Integrated Clinical Pathway Between Cardiology and Primary Care Physicians to Implement Pharmacological Treatment||Niguarda Hospital|No|Suspended|January 2010|||April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|122|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|November 30, 2009||No|Up to sponsor decision|No||https://clinicaltrials.gov/show/NCT01023438||129822|
NCT01019122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bone Growth in CP Patients|Longitudinal Assessment of Bone Growth in Children With Cerebral Palsy|Longitudinal Assessment of Bone Growth and Development in a Facility-Based Population of Children With Cerebral Palsy||Akron Children's Hospital|No|Completed|October 2009|November 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|56|||Both|N/A|N/A|No|Non-Probability Sample|Residents of a long-term care facility for children with disabilities who have severe to        profound CP and are non-ambulatory.|March 2011|March 8, 2011|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01019122||130149|
NCT01019135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardiac Rehab for Women|Cardiac Rehabilitation for Heart Event Recovery (HER)|A Randomized Controlled Trial of Women's Adherence to Women-only, Home-based and Traditional Cardiac Rehabilitation (Cardiac Rehabilitation for Her Heart Event Recovery [CR4HER])|CR4HER|University Health Network, Toronto|No|Completed|November 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|169|||Female|N/A|N/A|No|||October 2015|October 28, 2015|November 20, 2009||No||No|June 23, 2015|https://clinicaltrials.gov/show/NCT01019135||130148|
NCT01019434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26082-22081|Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|Radiation Therapy and Concurrent Plus Adjuvant Temsirolimus (CCI-779) Versus Chemo-Irradiation With Temozolomide in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Gene Promoter - A Randomized Multicenter, Open-Label, Phase II Study.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Active, not recruiting|October 2009|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019434||130126|
NCT01019447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDV-0909001|The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection|"The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection" Prospective, Randomized, Controlled, Double Blind, Multi-centre Study.||Cairo University|Yes|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|701|||Both|N/A|N/A|No|||November 2009|June 21, 2011|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019447||130125|
NCT01011114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-203|Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant|Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant||Montefiore Medical Center|No|Recruiting|November 2009|||November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|November 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01011114||130758|
NCT01011127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-200914|Different Metabolic Effects of Statins|||Gachon University Gil Medical Center|Yes|Completed|December 2009|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|25 Years|75 Years||Probability Sample|Hypercholesterolemia|October 2010|October 4, 2010|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011127||130757|
NCT01020019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6015|Combined Pharmacotherapy for Cannabis Dependency|A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence|D-LUCS|New York State Psychiatric Institute|Yes|Completed|January 2010|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|60 Years|No|||December 2015|December 7, 2015|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01020019||130082|
NCT01011634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10873-28990-01|Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions|A Double Blinded, Placebo-controlled Randomized Control Trial Comparing Intravenous Moderate Sedation and Oral/Sublingual Analgesia/Anxiolysis for First Trimester Surgical Abortions||University of California, San Francisco|Yes|Terminated|May 2007|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Female|16 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 14, 2013|November 9, 2009||No|7% enrollment. Study terminated after a small number of recruited patients|No|February 24, 2013|https://clinicaltrials.gov/show/NCT01011634||130718|
NCT01012206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-088M|Overweighed Children´s Health - Studies of the Effect of Lifestyle and Food Habits|Overweighed Children´s Health - Studies of the Effect of Lifestyle and Food Habits|SELFH|Umeå University|No|Completed|August 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|105|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012206||130675|
NCT01011894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-045|Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age|A Phase II Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age||Memorial Sloan Kettering Cancer Center||Completed|November 2009|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|65 Years|N/A|No|||February 2016|February 25, 2016|November 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01011894||130698|
NCT01012193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNUHIRB-2009-24|Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism|CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention|ACCEL-2C19|Gyeongsang National University Hospital|Yes|Completed|January 2008|September 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||May 2011|May 15, 2011|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012193||130676|
NCT01017211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-654-09|Does Auricular Acupuncture Improve Tolerance to Electromyography (EMG) Testing?|Does Auricular Acupuncture Improve Tolerance to Electromyography (EMG) Testing?||Kessler Foundation|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 16, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01017211||130294|
NCT01017185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-10083|Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions|Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions||Takara Bio Inc.|No|Completed|August 2009|March 2015|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|November 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01017185||130296|
NCT01017198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120ST104|Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors|An Assessment of the Effect of Food and Antacid on BIIB021 Pharmacokinetics in Subjects With Advanced Solid Tumors.||Biogen|Yes|Completed|November 2009|January 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2011|September 12, 2013|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01017198||130295|
NCT01017848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-031|Urine pH as a Predictor of Diabetes|Urine pH as a Predictor of Diabetes||Northwell Health|Yes|Completed|November 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|92|||Both|18 Years|N/A|No|Probability Sample|adult inpatients, nondiabetic, no CKD, no urine infection, no UTO|June 2013|June 10, 2013|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017848||130246|
NCT01018134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS 0906.00|Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study|A Double-Blind, Vehicle-Controlled, Randomized, Dose Ranging, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone Topical Sprays (0.05%, 0.25%) in Patients With Moderate to Severe Plaque Psoriasis||Taro Pharmaceuticals USA|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|151|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|November 19, 2009|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01018134||130224|
NCT01018433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH082824|Treatment for Non-Suicidal Self-Injury in Young Adults|Development of an Intervention for Non-Suicidal Self-Injury in Young Adults|T-SIB|Fordham University|Yes|Completed|September 2008|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018433||130201|
NCT01014364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR09006|Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu|Phase III Study of Hydrocortisone in Patients With Severe H1N1 Related Pneumonia|CORTIFLU|University of Versailles|Yes|Terminated|March 2010|December 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|N/A|No|||December 2014|December 17, 2014|November 16, 2009||No|the H1N1 pandemic is now over, and fewer cases than expected were observed|No||https://clinicaltrials.gov/show/NCT01014364||130510|
NCT01015534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/004/TEI|Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment|Phase II Randomized Study: Whole Brain Radiotherapy and Concomitant Temozolomide, Compared With Whole Brain Radiotherapy for Brain Metastases Treatment||Instituto Nacional de Cancerologia de Mexico|Yes|Completed|January 2006|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|80 Years|No|||March 2013|March 25, 2013|November 17, 2009|Yes|Yes||No|August 23, 2012|https://clinicaltrials.gov/show/NCT01015534||130420|Our study had methodological limitations, such as the two temozolomide dose levels, which in future clinical trials may be adjusted to a single level.
NCT01022879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC0004|Topical Anesthesia in Small Gauge Vitrectomy|Pain Scale in the Use of Topical Anesthesia in Small Gauge Vitrectomy|Anesthesia|Asociación para Evitar la Ceguera en México|No|Active, not recruiting|May 2009|May 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|80 Years|No|||November 2009|November 30, 2009|November 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01022879||129865|
NCT01022892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007607-01H|Contrast Ultrasound in the Surveillance of Endovascular Abdominal Aortic Aneurysm Repair|Contrast Ultrasound in the Surveillance of Endovascular Abdominal Aortic Aneurysm Repair||Ottawa Hospital Research Institute|Yes|Completed|September 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|140|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All patients who underwent EVAR at The Ottawa Hospital and are currently undergoing        post-EVAR surveillance will be eligible for the study.|March 2012|March 5, 2012|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022892||129864|
NCT01023191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Access 3|Open Versus Percutaneous Insertion of CAPD Catheters|A Prospective Randomized Controlled Trial of Local Anaesthetic Percutaneous Insertion Versus General Anaesthetic Open Surgical Placement of Continuous Peritoneal Dialysis Catheters in a University Teaching Hospital||University of Hull|No|Not yet recruiting|December 2011|September 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||May 2010|July 14, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023191||129841|
NCT01023451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091007|Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients|Serum Brain Natriuretic Peptide Levels and Its Correlation With Echocardiographic Measurements Suggestive of Pulmonary Hypertension in Pediatric Patients With Sickle Cell Disease||Akron Children's Hospital|No|Completed|December 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|21|||Both|7 Years|21 Years|No|Probability Sample|Sickle cell clinic|June 2014|June 24, 2014|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023451||129821|
NCT01023464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-030|Tear Film Break-Up Time Evaluation of FID 114657|||Alcon Research|No|Completed|October 2009|||January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01023464||129820|
NCT01010529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-0804-66|Feasibility of a Trial Evaluating the Effectiveness of Occupational Therapy in Parkinson's Disease||OTiP pilot|Radboud University|No|Completed|October 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|N/A|N/A|No|||October 2010|March 17, 2011|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010529||130803|
NCT01010802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO-001-PD|Safety Study of Erythropoietin (EPO) in Parkinson's Disease|Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)||International Center for Neurological Restoration, Cuba|No|Completed|August 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|45 Years|75 Years|No|||November 2009|November 9, 2009|November 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01010802||130782|
NCT01011140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0606|Physician Perceptions About Parenteral Hydration in Latin America and Spain|Physician Perceptions About Parenteral Hydration in Latin America and Spain: A Survey of Physicians Affiliated With the Latin American Association for Palliative Care (ALCP) and the Spanish Society for Palliative Care (SECPAL)||M.D. Anderson Cancer Center|No|Recruiting|January 2010|||January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|516|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians affiliated with the Latin American Association for Palliative Care (ALCP) and        the Spanish Society for Palliative Care (SECPAL)|December 2015|December 29, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011140||130756|
NCT01011361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-16209|Red Cell Mass and Plasma Volume Measurements in Elderly Men and Women With Anemia|Red Cell Mass and Plasma Volume Measurements in Elderly Men and Women With Anemia||Stanford University|No|Completed|April 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|65 Years|N/A|No|Non-Probability Sample|Outpatient elderly men and women (aged 65 years or older) with anemia, also enrolled in        the "Anemia in the Elderly" NCT00640172 study.|March 2016|March 23, 2016|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011361||130739|
NCT01011374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4638s|Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion|Impact of Lucentis on Psychological Morbidity in Patients With Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion||Retina Associates of Cleveland, Inc|No|Active, not recruiting|November 2009|November 2013|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 16, 2011|November 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01011374||130738|
NCT01012479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLO K027|Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension|Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension||Takeda|No|Completed|October 2009|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||July 2010|July 12, 2010|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012479||130654|
NCT01012492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abatacept|Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute Graft Versus Host Disease (aGVHD) During Transplant|Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant||Emory University|Yes|Recruiting|November 2009|December 2013|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|N/A|No|||November 2009|November 12, 2009|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012492||130653|
NCT01017861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04|The Effect of Pregnancy on Temporal Summation and Venipuncture Pain Perception|The Effect of Pregnancy on Temporal Summation and Venipuncture Pain Perception||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant patients presenting at the venipuncture clinic for routine bloodwork throughout        their pregnancy.        Full term pregnant patients admitted to the hospital for and elective cesarean section.        Non pregnant volunteers.|September 2010|September 27, 2010|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017861||130245|
NCT01017484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001236|Mechanism of the Blood Pressure Lowering Effect of the DASH Dietary Pattern|Mechanism of the Blood Pressure Lowering Effect of the DASH Dietary Pattern||Duke University|No|Completed|July 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|20|||Both|22 Years|N/A|Accepts Healthy Volunteers|||November 2009|April 9, 2013|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017484||130273|
NCT01018446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-SCT-0802|Hematopoietic Stem Cell Transplantation Based on Pharmacokinetic and Pharmacodynamic Modeling|Determination of Optimal Busulfan Dose Using Pharmacokinetic Modeling in Hematopoietic Stem Cell Transplantation||Seoul National University Hospital|Yes|Completed|December 2008|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|19 Years|No|||November 2013|November 17, 2013|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018446||130200|
NCT01018459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0037|Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso|A Phase I Randomized, Controlled, Double-Blinded, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabè, Semi-Immune, Healthy Adults 18 to 45 Years of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|June 5, 2014|November 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018459||130199|
NCT01018732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P6E1|A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY|A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vaccinated as Adolescents With Either MenACWY Conjugate Vaccine or Menomune®.||Novartis|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|155|||Both|16 Years|23 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|November 18, 2009|Yes|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT01018732||130178|
NCT01018745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA205-001|Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan|Phase 1 Multiple Ascending Dose Study of BMS-907351 (XL184) Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|20 Years|N/A|No|||June 2010|January 6, 2011|November 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018745||130177|
NCT01015287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12918|A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction|A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI): The ACCOAST Study|ACCOAST|Eli Lilly and Company|Yes|Completed|December 2009|February 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4033|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|November 17, 2009|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01015287||130439|
NCT01022905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-09-234|Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients|Prospective Cohort Study of the Influence of Age, Underlying Disease and Immunosuppression on Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients.||University Hospital, Geneva|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1141|||Both|6 Months|N/A|Accepts Healthy Volunteers|||February 2009|February 26, 2010|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022905||129863|
NCT01022918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TemAvIr|Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma|Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide|TemAvIr|Centre Georges Francois Leclerc|Yes|Completed|January 2009|January 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|70 Years|No|||September 2012|September 24, 2012|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022918||129862|
NCT01022931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1N1epidemiology|Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva|Evaluation of a New Virus(Influenza A H1N1/09) in Children: Epidemiology, Clinical Presentation and Outcome, and Response to Treatment||University Hospital, Geneva|Yes|Completed|October 2009|July 2012|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Nasal swab; DNA for genetic polymorphisms (Response to oseltamivir)|Both|N/A|16 Years|No|Non-Probability Sample|Children seen at the emergency ward|December 2012|December 10, 2012|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022931||129861|
NCT01023204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-371|Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer|Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer||Bristol-Myers Squibb|Yes|Completed|October 2002|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Female|20 Years|74 Years|No|||December 2009|February 2, 2010|November 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01023204||129840|
NCT01023217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2009-0536|Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir|Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir|CAESAR|Asan Medical Center|Yes|Completed|November 2009|September 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|16 Years|75 Years|No|||January 2014|January 15, 2014|December 1, 2009||No||No|November 23, 2013|https://clinicaltrials.gov/show/NCT01023217||129839|
NCT01009944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p002290|Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study|Genetic Mechanisms in Human Hypertension RAAS Inhibition Study||Brigham and Women's Hospital|Yes|Active, not recruiting|January 2007|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009944||130848|
NCT01010282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9965-002|Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects|||Allergan||Completed|November 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|288|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|November 6, 2009||No||No|November 9, 2011|https://clinicaltrials.gov/show/NCT01010282||130822|
NCT01010542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3226K1-1002|Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects|A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis||Pfizer|No|Terminated|December 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||July 2011|July 5, 2011|November 6, 2009|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01010542||130802|
NCT01010555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-368-C-104|In-vivo Wettability Grading and Assessment Study||CIAN|Alcon Research|No|Completed|October 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|25|||Both|17 Years|N/A|No|||January 2012|June 26, 2012|November 9, 2009|Yes|Yes||No|May 3, 2011|https://clinicaltrials.gov/show/NCT01010555||130801|
NCT01010815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gut Microbiome in UC Patients|Metagenomic Analysis of Gut Microbiome in Korean Patients With Ulcerative Colitis|Metagenomic Analysis of Gut Microbiome in Korean Patients With Ulcerative Colitis||Seoul National University Hospital|No|Recruiting|November 2009|November 2011|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|15|Samples With DNA|Participants will need to give stool samples and colorectal biopsy specimens on 1 or 2      separate occasions|Both|19 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|gastroenterology clinic at SNUH(Seoul National University Hospital)|November 2009|November 9, 2009|November 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01010815||130781|
NCT01010828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP12|Review on Minimally Invasive Skin Incision in Vanguard PS Artificial Knee Joint System|||Biomet, Inc.|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|N/A|N/A|No|||October 2012|October 15, 2012|November 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01010828||130780|
NCT01011153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20063|Survey Study - Sensitivity Comparison Between MelaFind and Physician Group|Comparison of Diagnostic and Biopsy/Referral Sensitivity to Melanoma Between Three Groups of Physicians and MelaFind||MELA Sciences, Inc.|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|241|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of health care providers who commonly encounter the skin will participate in        the study. The population will comprise ninety physicians of which thirty are pigmented        skin lesions experts, thirty general dermatologists and thirty primary care physicians.|February 2012|February 10, 2012|November 10, 2009|Yes|Yes||No|May 26, 2010|https://clinicaltrials.gov/show/NCT01011153||130755|The only limitation to having complete data sets was the time a physician was willing to spend on completing the survey.
NCT01011166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355-004|Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)|A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin in Subjects With Genotype 1 Chronic Hepatitis C Infection||Merck Sharp & Dohme Corp.|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|81|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|October 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01011166||130754|
NCT01011647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2042500|Prevalence of Sleep Disordered Breathing|Prevalence of Sleep Disordered Breathing||GE Healthcare|No|Terminated|November 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|No|Non-Probability Sample|Subject selection will come from patients admitted to the hospital with an acute cornonary        condition.|January 2012|January 4, 2012|November 10, 2009||No|Inadequate recruitment|No||https://clinicaltrials.gov/show/NCT01011647||130717|
NCT01011387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPWT 01|Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a NPWT (Negative Pressure Wound Therapy) System to be Used in the Treatment of Diabetic Foot Ulcers (DFUs) Including Post Amputation Wounds Associated With Diabetes.||Molnlycke Health Care AB|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|November 4, 2009||No||No|December 22, 2010|https://clinicaltrials.gov/show/NCT01011387||130737|
NCT01011400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121-09|Ultrasonic Measurements of the Clitoris in Fetuses|Measurements of the Fetal Clitoris by 2D Ultrasound||Meir Medical Center|Yes|Withdrawn|November 2009|December 2011|Actual|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Female|14 Weeks|37 Weeks|Accepts Healthy Volunteers|Probability Sample|pregnant women with a female fetus in the second or 3 ed trimester|August 2013|August 27, 2013|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011400||130736|
NCT01011907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGCRC0109|A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence|Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence||University of California, San Francisco|No|Completed|January 2010|June 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|99|||Both|21 Years|75 Years|No|||February 2013|February 22, 2013|November 9, 2009||No||No|January 14, 2013|https://clinicaltrials.gov/show/NCT01011907||130697|
NCT01011920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG32|Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma|Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma||International Extranodal Lymphoma Study Group (IELSG)|Yes|Active, not recruiting|November 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|126|||Both|18 Years|65 Years|No|||December 2014|December 22, 2014|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011920||130696|
NCT01012219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-114|A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)|A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia||Merck Sharp & Dohme Corp.||Completed|November 2009|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|75 Years|No|||October 2015|October 30, 2015|November 10, 2009|No|Yes||No|March 24, 2011|https://clinicaltrials.gov/show/NCT01012219||130674|
NCT01012232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2009-016|Local Anesthetic in Total Knee Arthroplasty (TKA): Volume Versus Concentration|The Volume-concentration Relationship of Analgesic Efficacy With Intra-capsular Local Anesthetic in Total Knee Arthroplasty: a Randomized, Double-blind, Cross-over Trial.||Lundbeck Foundation|No|Completed|June 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|No|||November 2009|November 10, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012232||130673|
NCT01018472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917427|Probiotics in Infants With Cyanotic Congenital Heart Disease|Probiotics in Infants With Cyanotic Congenital Heart Disease||University of California, Davis|Yes|Completed|November 2009|December 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Both|N/A|4 Months|No|||December 2014|December 1, 2014|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018472||130198|
NCT01018485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 2008.022|The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor|Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis||Melbourne Health|No|Completed|October 2008|June 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||May 2015|May 8, 2015|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018485||130197|
NCT01018147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-10395|4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition|4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition||Virginia Commonwealth University|Yes|Completed|September 2006|October 2015|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018147||130223|
NCT01014377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAS-01|Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia|Assessment of the Safety of the VascuActive™ Device and Its Preliminary Efficacy on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With Peripheral Vascular Disease and Limb Ischemia||VascuActive LTD||Completed|November 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|40 Years|70 Years|No|||May 2010|May 20, 2010|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01014377||130509|
NCT01014390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM 00027550|WallFlex Biliary Fully Covered (FC) Benign Stricture Study|A Multi-Center, Prospective Study of the WallFlex Biliary RX Fully Covered Stent for the Treatment of Benign Biliary Strictures||Boston Scientific Corporation|No|Active, not recruiting|December 2009|November 2017|Anticipated|November 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|187|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014390||130508|
NCT01014910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMTT# 4151-09|Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis|Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis||Children's Mercy Hospital Kansas City|Yes|Completed|December 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|161|||Both|N/A|24 Months|No|||February 2016|February 22, 2016|November 16, 2009||No||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01014910||130468|Our study was not designed or powered to detect differences in ICU transfers.
NCT01014663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXB-01|Non-contact Boxing Training and Traditional Therapeutic Exercise for Persons With Parkinson's Disease|Comparison of Non-contact Boxing Training and Traditional Therapeutic Exercise on Functional Outcomes in Persons With Parkinson's Disease||University of Indianapolis|No|Completed|September 2009|March 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014663||130487|
NCT01014676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valio-69|Probiotics and Infections in Children Attending Day Care Centres|||Valio Ltd||Completed||||||Phase 3|Interventional|N/A|2||||||Both|2 Years|6 Years||||July 2011|July 6, 2011|November 16, 2009||||No||https://clinicaltrials.gov/show/NCT01014676||130486|
NCT01014897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032009-067|Transcranial Direct Current Stimulation (tDCS) in Chronic Stroke Recovery|tDCS in Chronic Stroke Recovery-pilot||University of Texas Southwestern Medical Center|No|Recruiting|April 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|80 Years|No|||February 2016|February 3, 2016|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01014897||130469|
NCT01020344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-CVD2|Mechanisms of Vascular Damage in Patients With Chronic Obstructive Pulmonary Disease|Randomized Controlled Trial on the Cardiovascular Effects of Lung Volume Reduction Surgery in Patients With Chronic Obstructive Pulmonary Disease||University of Zurich|No|Completed|November 2009|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|75 Years|No|||October 2014|October 15, 2014|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020344||130057|
NCT01013532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICASSO|PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage|A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events|PICASSO|Asan Medical Center|Yes|Active, not recruiting|June 2009|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1600|||Both|20 Years|N/A|No|||December 2015|December 23, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01013532||130574|
NCT01014156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.123|Epoprostenol in Pulmonary Embolism|Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism||Free University Medical Center|No|Completed|January 2004|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||November 2009|November 13, 2009|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014156||130526|
NCT01009931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020702|Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies|A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia||Rutgers, The State University of New Jersey|No|Terminated|March 2011|September 2014|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|November 6, 2009|Yes|Yes|Study was terminated early due to lack of experimental medication (supply issues)|No|June 16, 2015|https://clinicaltrials.gov/show/NCT01009931||130849|
NCT01010295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG27|A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae|A Clinico-pathological Phase II Study With Translational Elements to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae With Particular Reference to Chlamydia Species and the Effects of MALT Lymphoma Treatment With Tetracycline|IELSG27|International Extranodal Lymphoma Study Group (IELSG)|No|Completed|September 2006|May 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||May 2012|November 22, 2013|August 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01010295||130821|
NCT01010568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB2009-315|Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)|Ofatumumab and Bendamustine in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia||Georgetown University|Yes|Terminated|April 2010|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2015|November 10, 2015|October 19, 2009|Yes|Yes|Unable to accrue patients due to change in standard CLL therapy|No|July 22, 2015|https://clinicaltrials.gov/show/NCT01010568||130800|
NCT01010581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC12267-5-2009|SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis|COMPONENT|4SC AG||Completed|November 2009|July 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010581||130799|
NCT01010841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMS4-MUL-CT|Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome|Multi-center, Randomized Intervention to Compare the Effects of 2 Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome|HMS4|MetaProteomics LLC|No|Completed|August 2008|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Female|20 Years|75 Years|No|||January 2012|January 11, 2012|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010841||130779|
NCT01011179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010809|Internet Self-Management Program With Telephone Support for Adolescents With Arthritis|An Internet-based Self-management Program With Telephone Support for Adolescents With Arthritis: A Pilot Randomized Controlled Trial||The Hospital for Sick Children|No|Completed|November 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|12 Years|18 Years|No|||January 2014|January 22, 2014|September 28, 2009||No||No|December 4, 2013|https://clinicaltrials.gov/show/NCT01011179||130753|
NCT01011192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFS 02|Performance of Two Different ke0s in the Same Pharmacokinetic Propofol Model|Performance of Two Different Ke0s in the Same Pharmacokinetic Propofol Model. Study on Loss and Recovery of Consciousness||Centro Medico Campinas|Yes|Completed|September 2009|November 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Male|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Twenty healthy male adult volunteers participated in this study. The volunteers appeared        at the testing location, having refrained from eating and drinking for six hours. All the        volunteers were monitored with electrocardiogram (DII and V1 derivation), pulse oximetry        (SpO2), non-invasive average arterial pressure and bispectral index (BIS). Oxygen under        2.0 L.min-1 nasal catheter was used and the left antecubital vein was punctured and        connected to the venous catheter filled with propofol (Propovan® - Cristália Laboratório        Ltda).|November 2009|November 12, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011192||130752|
NCT01011413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-ENCORE1|Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals.|A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks|encore1|Kirby Institute|Yes|Completed|August 2011|August 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|630|||Both|16 Years|N/A|No|||November 2012|December 18, 2014|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011413||130735|
NCT01011933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01958|Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2009|||October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|November 10, 2009|Yes|Yes||No|August 21, 2013|https://clinicaltrials.gov/show/NCT01011933||130695|
NCT01011660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115|Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients|Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks|CHIEF|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|October 2007|December 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|13542|||Both|50 Years|79 Years|No|||August 2012|August 9, 2012|November 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01011660||130716|
NCT01011946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16893A|Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer|Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer||University of Chicago|Yes|Completed|November 2009|May 2012|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Female|18 Years|75 Years|No|||June 2015|June 16, 2015|November 10, 2009|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01011946||130694|
NCT01012245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|912-OPT-0091-131|Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom|Project "XCHANGE" Non-Interventional Study|XCHANGE|Pfizer|No|Completed|January 2000|December 2008|Actual|December 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28812|||Both|N/A|N/A|No|Non-Probability Sample|patients with glaucoma or ocular hypertension treated by office-based ophthalmologists|February 2010|February 18, 2010|November 11, 2009||No||No|December 11, 2009|https://clinicaltrials.gov/show/NCT01012245||130672|Except at baseline, number of subjects analyzed in treatment groups do not necessarily summarize to “All subjects” total; subjects drop out of treatment group when therapy changes. “All subjects” shows all subjects irrespective of any therapy change.
NCT01018810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11431|A Study for Adults With Plaque Psoriasis|LY2525623 (IL-23 Antibody) Multiple-Dose Study in Adults With Plaque Psoriasis||Eli Lilly and Company|Yes|Terminated|December 2009|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|8|||Both|18 Years|N/A|No|||July 2011|July 27, 2011|November 24, 2009|Yes|Yes|The trial was terminated for several reasons, including complexities in development of    LY2525623, but not because of safety concerns|No|June 1, 2011|https://clinicaltrials.gov/show/NCT01018810||130172|Study BDAD was terminated early due to non-safety related complexities in LY2525623 development. Numerical summaries and statistical comparisons for the 8 patients enrolled are not appropriate and may be scientifically/clinically misleading.
NCT01018212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0902-CU|Cicatrix Cream in Cutaneous Groves|Effect the Cicatrix Cream in Cutaneous Groves Treatment||Catalysis SL|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|10 Years|18 Years|No|||December 2010|December 7, 2010|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018212||130218|
NCT01018758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLPal|Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy|Phase II Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy|NHLPal|Gruppo Italiano Studio Linfomi|No|Completed|July 2006|July 2008|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|86|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01018758||130176|
NCT01018771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0803PLF|Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion|A Prospective, Randomised Study Comparing the Use of Actifuse (Trademark) Advanced Bone Matrix (ABX) Synthetic Bone Substitute With INFUSE (Trademark) on Fusion in Patients Requiring Posterolateral Instrumented Lumbar Fusion|APPRAISET2|Apatech, Inc.|Yes|Completed|July 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||November 2013|November 12, 2013|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01018771||130175|
NCT01018784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAB-009-J081-102|A Study of MORAb-009 in Patients With Solid Tumor|A Phase 1 Study of MORAb-009 in Patients With Solid Tumor||Eisai Inc.||Completed|November 2009|February 2013|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|79 Years|No|||January 2016|January 19, 2016|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01018784||130174|
NCT01014689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29080|Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris|Efficacy and Safety Comparison of Epiduo Gel Associated With Lymecycline 300 mg Capsules Versus Epiduo Vehicle Gel Associated With Lymecycline 300 mg Capsules in the Treatment of Moderate to Severe Acne Vulgaris|TEAM|Galderma|No|Completed|August 2009|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|378|||Both|12 Years|35 Years|No|||April 2012|April 17, 2012|November 16, 2009||No||No|August 12, 2011|https://clinicaltrials.gov/show/NCT01014689||130485|
NCT01014702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-00006-000|Prospective Clinical Trial of the LensAR Laser System|Prospective Clinical Trial of the LensAR Laser System in the Treatment of Cataracts of Different Grades of Maturity||LensAR Incorporated|No|Active, not recruiting|November 2009|June 2011|Anticipated|June 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|N/A|No|||April 2011|April 14, 2011|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014702||130484|
NCT01015261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-0903|Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients|Comparison of Efficacy of Allogenic Bone Marrow Transplantation With Cytoreduction and Chemotherapy in ALL Patients||Tehran University of Medical Sciences|Yes|Completed|October 2008|September 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|16 Years|50 Years|No|||November 2010|November 19, 2010|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015261||130441|
NCT01015274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-150|Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients|Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients||The University of Texas Medical Branch, Galveston|No|Completed|October 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Male|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample of healthy males|July 2011|July 13, 2011|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015274||130440|
NCT01020357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-R01HL098045|Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study|Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity|CAP-S|McMaster University|No|Completed|November 2009|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|5 Years|7 Years|No|||December 2014|December 3, 2014|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020357||130056|
NCT01014169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28356|Study of the Impact of Parental Note Taking on the Effectiveness of Anticipatory Guidance|A Randomized Controlled Trial of The Impact of Parental Note Taking on the Effectiveness of Anticipatory Guidance: the Suzuki Music Model Applied to Urban Pediatrics||Boston Medical Center|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|126|||Female|15 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 20, 2012|November 13, 2009||No||No|August 20, 2012|https://clinicaltrials.gov/show/NCT01014169||130525|Conducted as a pilot study and not powered to demonstrate a significant difference between the two groups; subjects and NPs were aware of the group assignment; outcomes were determined using maternal self report.
NCT01009957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolEver|Everolimus on CKD Progression in ADPKD Patients|Everolimus on CKD (Chronic Kidney Disease) Progression in ADPKD Patients||A. Manzoni Hospital|Yes|Terminated|June 2008|June 2015|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 6, 2009||No|After primary completition date, experimental drug was no longer available|No||https://clinicaltrials.gov/show/NCT01009957||130847|
NCT01009970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL-HEART01|Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma|Multicenter Study of Phase II With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet ®), Vincristine, Prednisone, (R-COMP) in Non-Hodgkin's Lymphoma Diffuse Large B Cell in Cardiopathic Patients||Fondazione Italiana Linfomi ONLUS|No|Recruiting|May 2010|May 2012|Anticipated|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Months|N/A|No|||October 2011|October 12, 2011|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009970||130846|
NCT01010308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014079|Nadolol for Proliferating Infantile Hemangiomas|Nadolol for Proliferating Infantile Hemangiomas: A Prospective Open Label Study With a Historical Control||The Hospital for Sick Children|Yes|Completed|November 2009|February 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|1 Month|1 Year|No|||August 2013|August 1, 2013|November 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01010308||130820|
NCT01010594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090183|Two Pieces of Fruit to Type 2 Diabetics?|Two Pieces of Fruit to Type 2 Diabetics?||Hospitalsenheden Vest|Yes|Terminated|November 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|November 9, 2009||No|PI changed job and project was not economically viable and therefor terminated|No||https://clinicaltrials.gov/show/NCT01010594||130798|
NCT01010854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC# 087515|Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer|A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer|VPA-FEC100|University of California, San Francisco|Yes|Terminated|December 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|November 6, 2009|Yes|Yes|Halted for low accrual|No||https://clinicaltrials.gov/show/NCT01010854||130778|
NCT01010906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-005|A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)|An Open-label, 3-Part, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-7009||Merck Sharp & Dohme Corp.|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|60|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 23, 2015|November 6, 2009|No|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01010906||130774|
NCT01011205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1106|Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation|A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive Regimen of Advagraf (Immediately or Delayed Post-transplant) and MMF With or Without a Monoclonal Anti-IL2R Antibody (Basiliximab)|DIAMOND|Astellas Pharma Inc|Yes|Completed|September 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|893|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011205||130751|
NCT01011673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED treatment of ETTH|Metoclopramide Versus Ketorolac for Tension-type Headache|An RCT of Metoclopramide/Diphenhydramine vs. Ketorolac Alone for Tension-type Headache||Montefiore Medical Center|No|Completed|November 2009|November 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|21 Years|64 Years|No|||December 2012|December 5, 2012|November 9, 2009|Yes|Yes||No|November 3, 2012|https://clinicaltrials.gov/show/NCT01011673||130715|
NCT01011959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6R88-RA-0802|A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate||Regeneron Pharmaceuticals|No|Completed|December 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|N/A|No|||June 2011|September 27, 2013|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011959||130693|
NCT01011972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MER-1107-001|A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors|A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors|XMT-1107|Mersana Therapeutics|No|Active, not recruiting|March 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011972||130692|
NCT01012284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR007501|A Study of TMC207 in Patients With Moderately Impaired Hepatic Function|Pharmacokinetics, Safety, and Tolerability of TMC207 in Subjects With Moderately Impaired Hepatic Function||Tibotec BVBA|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|November 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01012284||130669|
NCT01018511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-055|Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms|A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component|Neptune|Astellas Pharma Inc|No|Completed|January 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1334|||Male|45 Years|N/A|No|||December 2015|December 16, 2015|November 19, 2009|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01018511||130195|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01023477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFHCC 09-002|Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)|Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial||Inova Health Care Services|Yes|Recruiting|December 2009|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023477||129819|
NCT01014403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082009-026|Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)|The Delayed vs Early Enoxaparin Prophylaxis (DEEP) Study After Traumatic Brain Injury: A Randomized, Double-Blinded, Placebo Controlled Pilot Trial|DEEP|University of Texas Southwestern Medical Center|No|Recruiting|November 2009|November 2010|Anticipated|November 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2009|November 16, 2009|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014403||130507|
NCT01014416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-KOA-0801|Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male|A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Tolvaptan in Healthy Korean Male Subjects Bipolar Disorder||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|46|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 10, 2010|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01014416||130506|
NCT01019733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE09-014|Intrathecal Stem Cells in Brain Injury|Intrathecal Autologous Stem Cells for Children With Hipoxic/Ischemic Brain Injury|ISC|Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|July 2009|January 2011|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|1 Year|8 Years|No|||January 2011|January 25, 2011|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019733||130104|
NCT01014923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE000947|Parent-based Intervention to Increase Safe Teen Driving|Parent-based Intervention to Increase Safe Teen Driving||University of Iowa|Yes|Completed|July 2007|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|163|||Both|18 Years|65 Years|No|||February 2011|February 18, 2011|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014923||130467|
NCT01014936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200095_001|First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors|A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors||EMD Serono|No|Completed|November 2009|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|149|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014936||130466|
NCT01020409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N N403 1815 34|INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery|INFLACOR - (INFLA-mmation, A-fter, C-ardiac, O-pe-R-ation) - Evaluation of Selected Genetic Polymorphisms, Inflammatory Mediators, and Physiologic Parameters in the Prognosis of Postoperative Complications in Patients Undergoing Cardiopulmonary Bypass Cardiac Surgery|INFLACOR|Medical University of Gdansk|Yes|Completed|October 2009|November 2012|Actual|April 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|525|Samples With DNA|plasma, serum, and blood morphologic elements after centrifugation frozen to -75C.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults (at least age 18), who signed informed consent, scheduled for elective cardiac        surgery with use of cardiopulmonary bypass.|May 2015|May 15, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020409||130052|
NCT01020695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHC-4917|Quantitative Electroencephalography (QEEG) and Low-resolution Electromagnetic Tomography (LORETA) Analysis in Post Traumatic Stress Disorder (PTSD) Patients|QEEG and LORETA Analysis in PTSD Patients||Beersheva Mental Health Center|Yes|Completed|November 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Veterans with chronic PTSD of at least 2 years.|November 2012|November 6, 2012|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020695||130030|
NCT01009697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODE-T15/30/60-PVFS-1|Dose Linearity Study of Codeine Sulfate Under Fasted Conditions|A Single Dose, 3-Period, 3-Treatment, 6-Sequence, 3-Way Crossover Study of the Dose Linearity of Codeine Sulfate Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009697||130867|
NCT01009983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU74108|Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer|A Phase II Clinical Trial of Weekly Paclitaxel and Carboplatin in Combination With Panitumumab in Metastatic Breast Cancer Patients With Triple Negative Disease||Comprehensive Cancer Center of Wake Forest University|No|Terminated|March 2010|March 2016|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|N/A|No|||November 2014|November 25, 2014|November 6, 2009|Yes|Yes|Slow accrual|No|May 19, 2014|https://clinicaltrials.gov/show/NCT01009983||130845|the worst adverse event of each type was recorded for the course of treatment
NCT01009996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMG-003|Efficacy Study of Kissing Drug‐Eluting Balloons in Coronary Bifurcation Lesions|Kissing Drug‐Eluting Balloons After Bare Metal Stenting of Coronary Bifurcation Lesions.|KISSING DEBBIE|Ospedale Santa Maria Goretti||Recruiting|October 2009|April 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|All coming|November 2009|November 10, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009996||130844|
NCT01010009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22P2|The Cognitive and Cerebral Blood Flow Effects of Resveratrol|Effects of Resveratrol on Cerebral Blood Flow Parameters and Cognitive Performance in Humans: a Double-blind, Placebo-controlled, Crossover Investigation||Northumbria University|No|Completed|June 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|November 6, 2009||No||No|June 26, 2010|https://clinicaltrials.gov/show/NCT01010009||130843|
NCT01010321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7295-AB-CTIL|Confocal Microscopy of Benign and Malignant Skin Tumors|Confocal Microscopy of Benign and Malignant Skin Tumors||Sheba Medical Center|No|Suspended|November 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Men and women over the age of 18        - Skin lesion suspected to either BCC,SCC etc|June 2010|June 27, 2010|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01010321||130819|
NCT01010334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0813|Comparison of Standard of Care or Treatment on Protocol|Randomized Study of Patients (Patient Choice) Who Are Not Eligible for Variations of Standard of Care Protocols When Treated Either on Best Standard of Care Pathways or Per a Protocol Arm That They Failed to Enroll to||New Mexico Cancer Care Alliance|No|Terminated|March 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|13|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|July 24, 2009|Yes|Yes|PI deparature and very low (<2%) accrual rate.(No results required)|No||https://clinicaltrials.gov/show/NCT01010334||130818|
NCT01010347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1088|A Comparison of Casting and Splinting in Pediatric Radial Buckle Fractures|A Comparison of Casting and Splinting in Pediatric Radial Buckle Fractures||Washington University School of Medicine|Yes|Completed|December 2005|April 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||September 2011|September 22, 2011|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01010347||130817|
NCT01010607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0305-09-HMO-CTIL|Use of Tendon Vibration and Mirror for the Improvement of Upper Limb Function and Pain Reduction|Use of Tendon Vibration and Mirror for the Improvement of Upper Limb Function and Pain Reduction After Stroke|VibMirror|Hadassah Medical Organization||Not yet recruiting|November 2009|November 2011|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2009|June 2, 2010|November 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01010607||130797|
NCT01010867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0846|Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT) - A Pilot Study|A Limited Institution Pilot Trial Evaluating the Safety of Administering the Probiotic, Lactobacillus Plantarum, to Children and Adolescents Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT)||Columbia University|Yes|Completed|February 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|2 Years|17 Years|No|||December 2014|December 15, 2014|November 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01010867||130777|
NCT01010880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKTSC001|Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients|A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma||Biokine Therapeutics Ltd|Yes|Completed|October 2008|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|16 Years|65 Years|No|||June 2011|June 9, 2011|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010880||130776|
NCT01010893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUVAL P-H-06|Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine|Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|Yes|Completed|August 2009|February 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|355|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 18, 2012|November 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01010893||130775|
NCT01011231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09103|Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma|Phase II Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Spectroscopy for Target Definition in Patients With Recurrent Glioma|GKS|University of California, San Francisco|Yes|Terminated|December 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|November 4, 2009|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01011231||130749|
NCT01011426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-148|Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients|Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients||The Cooper Health System|No|Completed|April 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|285|||Female|12 Years|N/A|No|||January 2014|January 16, 2014|November 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01011426||130734|
NCT01011439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDKO-125a-006|Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma|Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy||Tiziana Life Sciences, PLC|No|Recruiting|March 2009|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|November 3, 2015|November 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01011439||130733|
NCT01011686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-SM-101|Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence|A Phase I Clinical Study of ANT-SM (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Fecal Incontinence to Evaluate Safety||Anterogen Co., Ltd.||Terminated||||||Phase 1|Interventional|N/A|1||||||Both|18 Years|N/A|No|||March 2011|March 8, 2011|November 10, 2009||No|Few subject enrolled|No||https://clinicaltrials.gov/show/NCT01011686||130714|
NCT01011985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-07-336E|A Study Evaluating the Association of Inflammation With Hemodialysis Access Type|A Study of the Effect of Hemodialysis Access Type on Markers of Inflammation||Montefiore Medical Center|No|Completed|August 2006|June 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|64|Samples Without DNA|serum|Both|18 Years|95 Years|No|Probability Sample|Incident stage 4 and 5 chronic kidney disease patients receiving their first dialysis        access.|December 2009|December 2, 2009|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011985||130691|
NCT01011998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0901|A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)|A Phase II Study of Imatinib and Valproic Acid in Patients With CML||New Mexico Cancer Care Alliance|No|Withdrawn|September 2009|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|0|||Both|18 Years|N/A|No|||July 2011|September 23, 2011|November 5, 2009|Yes|Yes|Withdrawn due to lack of accrual per Center DSMP, with PI concurrence|No||https://clinicaltrials.gov/show/NCT01011998||130690|
NCT01023490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-SB-0494-CTIL|Vitamin D Treatment to Patients Suffering From Chronic Pain and Vitamin D Hypovitaminosis|A Randomised, Double-blind, Placebo-controlled Study to Check Whether Vitamin D Will Lead to a Decrease in Pain Intensity in Patients Suffering From Chronic Pain and Hypovitaminosis D||Tel-Aviv Sourasky Medical Center||Completed|January 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|90 Years|No|||October 2012|October 14, 2012|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023490||129818|
NCT01023516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00020|Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol|A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol||AstraZeneca|Yes|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|615|||Both|40 Years|80 Years|No|||June 2012|June 19, 2012|December 1, 2009||No||No|January 24, 2012|https://clinicaltrials.gov/show/NCT01023516||129816|
NCT01018823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-037|A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)|A Phase 1, Randomized, Placebo-Controlled, Parallel Group, 14 Day Repeated Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729 In Otherwise Healthy Overweight And Obese Adult Subjects||Merck Sharp & Dohme Corp.|No|Completed|December 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|November 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018823||130171|
NCT01019148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11182009-4402|Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa|Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa||Stanford University||Recruiting|November 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Skin biopsies, serum|Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with RDEB by a local dermatologist who are medically stable enough to        travel to Stanford University Medical Center. Patients should also be at least 7 years of        age.|March 2016|March 17, 2016|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01019148||130147|
NCT01019460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20070072|A Comparative Study of Capsule Endoscopy, Magnetic Resonance Imaging and Computer Tomography Scanning of the Small Bowel in Crohn's Disease|A Comparative Study of Capsule Endoscopy, Magnetic Resonance Imaging and Computer Tomography Scanning of the Small Bowel in Crohn's Disease||University of Southern Denmark|Yes|Completed|October 2007|August 2011|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|1||Actual|150|||Both|15 Years|N/A|No|||September 2011|September 20, 2011|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019460||130124|
NCT01019759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 02-119.3|The Value of add-on Arrhythmia Surgery in Patients With Atrial Fibrillation Undergoing Cardiac Surgery|The Value of add-on Arrhythmia Surgery in Patients With Paroxysmal or Persistent Atrial Fibrillation Undergoing Valvular or Coronary Bypass Surgery. A Randomised Comparison on Quality of Life, Cost-effectiveness, Morbidity and Rhythm Outcome.||Maastricht University Medical Center|Yes|Completed|September 2002|December 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|N/A|N/A|No|||November 2009|November 23, 2009|July 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019759||130102|
NCT01019772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-VHCL002|Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age|A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberix™ Vaccine in Healthy Infants at Two, Four and Six Months of Age||LG Life Sciences|No|Completed|July 2007|August 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|217|||Both|49 Days|84 Days|Accepts Healthy Volunteers|||November 2009|November 23, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019772||130101|
NCT01020032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMARC 200801|Effect of Music Therapy on Pain|Effect of Music Therapy on Chronic Pain in Hospitalized Patients in a Pain Center||Association de Musicothérapie Applications et Recherches Cliniques|No|Completed|September 2006|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|N/A|No|||November 2009|November 24, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020032||130081|
NCT01021384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28799|Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders|Supporting the Well Being of Families of Young Children With Autism Spectrum||Boston Medical Center||Completed|September 2009|March 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|122|||Female|N/A|N/A|No|||April 2013|April 26, 2013|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021384||129979|
NCT01021397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 255|Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children|Phase I Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-Passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|12|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||December 2012|December 31, 2012|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021397||129978|
NCT01009710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07162009-3301|Measured Hypocretin Levels and Recovery After Hip Surgery|Preoperative Cerebrospinal Fluid (CSF) Levels of Hypocretin and Recovery After Hip Surgery With Combined Spinal and General Anesthesia||Stanford University||Active, not recruiting|July 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients scheduled for elective total hip arthroplasty through the Stanford Orthopedic        Clinic.|June 2013|June 24, 2013|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009710||130866|
NCT01013935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1MH088307|A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]|A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]|CARE+ Spanish|New York University|Yes|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|556|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 21, 2014|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013935||130543|
NCT01010022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-13-02-JP|Trial of 6% HES130/0.4|Examination of Safety and Efficacy of 6% Hydroxyethyl Starch 130/0.4 vs. 6% Hydroxyethyl Starch 70/0.5 in Patients Undergoing Orthopedic Surgery - a Double-blind, Parallel Group, Comparative, Multi-centre Phase III Study||Fresenius Kabi|No|Completed|November 2009|November 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|20 Years|N/A|No|||March 2011|March 9, 2011|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010022||130842|
NCT01010035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPIDSDM|Cholesterol Metabolism and Lipid Transfer in Diabetes|Plasma Kinetics Study of Free Cholesterol and Cholesteryl Ester in Type 2 Diabetes Mellitus Patients||University of Sao Paulo General Hospital|No|Completed|September 2006|May 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|26|Samples Without DNA|whole blood samples|Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|outpatient of the endocrinology clinics of Hospital das clinicas of University of São        Paulo Medical school|November 2009|November 6, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010035||130841|
NCT01010620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043664|Screening Protocol for Research Participants|Screening Protocol for the Evaluation of Research Participants|ScreenProt|University of Maryland|No|Recruiting|December 2009|March 2025|Anticipated|March 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Population will see an advertisement in the community and call the NIDA call center. If        they appear to meet the qualifications for one or more NIDA/MPRC studies, they will be        scheduled to be screened.|October 2015|October 26, 2015|July 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01010620||130796|
NCT01010386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMN-PhOx|The Effects of Physiologic Oxygen Tension on Clinical In Vitro Fertilization Outcomes|A Prospective, Randomized, Double-Blind, Controlled Clinical Trial of the Effects of Oxygen Tension on Clinical In Vitro Fertilization Outcomes|PhOx|Yale University|Yes|Completed|March 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|851|||Both|18 Years|42 Years|No|||May 2014|May 12, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010386||130814|
NCT01010633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|576|Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery|||Bausch & Lomb Incorporated|No|Completed|November 2009|August 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|406|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|November 6, 2009|Yes|Yes||No|August 30, 2011|https://clinicaltrials.gov/show/NCT01010633||130795|
NCT01011244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTG-ASC-202|Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula|A Phase II Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate Safety and Efficacy||Anterogen Co., Ltd.|Yes|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011244||130748|
NCT01011218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0008|Management of Insomnia in Breast Cancer Patients|Management of Insomnia in Breast Cancer Patients: A Preliminary Pilot Study||Stanford University|Yes|Active, not recruiting|January 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|64|||Female|21 Years|N/A|No|||November 2015|November 18, 2015|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011218||130750|
NCT01011452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LREC 2000-108|Acute Montelukast in Asthma|Assessment of the Effect of Oral Montelukast as Additional Treatment in the Management of Patients With Acute Severe Asthma.|AcMk|University of East Anglia|No|Completed|May 2001|October 2004|Actual|August 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|50 Years|No|||November 2009|November 10, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011452||130732|
NCT01011725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_687|Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Efficacy of MK0773 in Healthy Postmenopausal Women||Merck Sharp & Dohme Corp.|No|Completed|November 2005|March 2009|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2009|November 10, 2009|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011725||130711|
NCT01011699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amiens NICOREN|Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients|Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients|NICOREN|Centre Hospitalier Universitaire, Amiens|No|Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011699||130713|
NCT01011712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100014|The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise|The Natural History of Severe Viral Infections and Characterization of Immune Defects||National Institutes of Health Clinical Center (CC)||Recruiting|October 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|125|||Both|2 Years|N/A|No|||June 2015|June 17, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011712||130712|
NCT01019174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-DSMM-0279|Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma|An Open, Randomized Clinical Phase I/II Trial to Investigate Maximum Tolerated Dose, Efficacy, and Safety of Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma|MM_LEN_DEX_CY|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Yes|Completed|November 2009|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019174||130145|
NCT01019161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1531C00012|An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)|A Phase I Open, Non-randomised, Single-centre Study to Assess the Metabolism, Excretion and Pharmacokinetics of AZD1152 and AZD1152 hQPA Following Intravenous Administration of [14C]-AZD1152 in Patients With Acute Myeloid Leukaemia (AML)||AstraZeneca|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||October 2010|October 19, 2010|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019161||130146|
NCT01019473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2207|Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea||Novartis||Terminated|November 2009|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|30 Years|85 Years|No|||September 2011|September 22, 2011|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01019473||130123|
NCT01019746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-07-002|Controlled Propofol Administration|Comparison of Closed-oop of Propofol Versus Manual Control Using Bispectral Index (BIS)||McGill University Health Center||Completed|August 2007|||May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||November 2009|November 23, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019746||130103|
NCT01019785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Delivery2009|Vitamin D During In Vitro Fertilisation (IVF) - A Prospective Randomized Trial||Delivery|Karolinska University Hospital|Yes|Enrolling by invitation|November 2009|||November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|N/A|No|||November 2009|November 23, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019785||130100|
NCT01020058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004:M-360|Randomized Study of Open Mesh Repair in Local Anesthesia Versus Cost-optimized Laparoscopic Repair for Inguinal Hernia|Randomized Controlled Trial Comparing Open Mesh Repair in Local Anesthesia to Cost-Optimized Laparoscopic Repair for Primary Inguinal Hernia||Uppsala University Hospital|No|Completed|April 2006|December 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|384|||Male|20 Years|80 Years|No|||January 2016|January 5, 2016|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020058||130079|
NCT01020071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB A/09/93|Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot Study|Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot Study||National University Hospital, Singapore|No|Completed|April 2009|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|21 Years|80 Years|No|||April 2014|April 24, 2014|November 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01020071||130078|
NCT01020045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027210|Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis|Effect of HIV Infection and HAART on Bone Homeostasis|OPG-2|Emory University|No|Completed|October 2010|October 2015|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy (HIV sero-negative) volunteers and otherwise healthy antiretroviral treatment        naïve HIV-1 sero-positive patients, age >18 years.|October 2015|October 15, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020045||130080|
NCT01021410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 09-0510|Acetaminophen-Protein Adduct Resolution|Serum Acetaminophen-Cysteine (APAP-cys) Adduct Concentrations After 16 Days of Acetaminophen Dosing|AR|Denver Health and Hospital Authority|No|Completed|November 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All subjects who have met completion criteria for COMIRB 06-1265 and were assigned to the        acetaminophen treatment group for that study.|August 2012|August 7, 2012|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021410||129977|
NCT01021423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MCL-003|A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma|RENEW|Celgene|Yes|Terminated|April 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|November 25, 2009|Yes|Yes|Terminated by sponsor due to new unpublished data that rendered the current design of the    study no longer clinically relevant. There were no safety concerns.|No|October 31, 2011|https://clinicaltrials.gov/show/NCT01021423||129976|Study terminated early. Most analyses were not performed.
NCT01013948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111116|Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting|Prevalence of Chronic Airway Onstruction in a Subject Population With a History of Cigarette Smoking in a Primary Care Setting||GlaxoSmithKline|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1574|||Both|30 Years|87 Years|Accepts Healthy Volunteers|Probability Sample|Current or previous cigarette smokers of at least 30 years of age with a history of        cigarette smoking of ≥ 10 pack-years, recruited from primary care centers.|October 2012|October 17, 2012|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013948||130542|
NCT01009723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGPS0001|Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers|Early Prediction Of Preterm Delivery By Measurement Of Maternal Serum Markers||Esoterix Genetic Laboratories, LLC|No|Active, not recruiting|March 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|Serum and plasma samples from the study subjects|Female|18 Years|N/A|No|Non-Probability Sample|General population of the US|June 2012|June 7, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01009723||130865|
NCT01010373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#77REV00|Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients|Application of AS101 in Combination With Chemotherapy for Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)||BioMAS Ltd|No|Suspended|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|60 Years|85 Years|No|||February 2015|February 9, 2015|November 9, 2009||No|The sponsor is currently focusing on different indications|No||https://clinicaltrials.gov/show/NCT01010373||130815|
NCT01009749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 072|Motivational Enhancement System for Adherence|Computer-Delivered Motivational Intervention to Prevent Adherence Problems Among Youth Newly Recommended for HIV Medications: Project MESA (Motivational Enhancement System for Adherence)||Westat|Yes|Completed|August 2009|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|76|||Both|16 Years|24 Years|No|||February 2016|February 29, 2016|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009749||130863|
NCT01010061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21004 (Stage 1a)|CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)|An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.||Hoffmann-La Roche||Active, not recruiting|December 2009|July 2020|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|787|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|November 6, 2009|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT01010061||130839|
NCT01010646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015121-37|Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4|Multicentre, Randomised, Open-label Study Comparing the Tolerability and Viral Reduction of the Combination of IFN Alpha-2b XL + Ribavirin Versus Peg IFN Alpha-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4.|COAT IFN|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|March 2010|November 2013|Anticipated|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|65 Years|No|||September 2013|September 19, 2013|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010646||130794|
NCT01010919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMI-005-01|A Study of Chicory for Treatment of Osteoarthritis of the Hip or Knee|A Phase I Study of Chicory for Treatment of Osteoarthritis of the Hip or Knee||Phytomedics Inc.||Completed||||||Phase 1|Interventional|N/A|||||||Both|50 Years|N/A||||November 2009|November 9, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010919||130773|
NCT01010932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-048|Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)|Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease||Guerbet|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|222|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|November 9, 2009|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01010932||130772|
NCT01011257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001863|Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.|Methods to Augment the Efficacy of Aspirin and Clopidogrel in Healthy Subjects (ASA Only) and Patients With Stable Coronary Artery Disease (Taking Clopidogrel Only) or (Taking Clopidogrel & ASA) With an Elevated Platelet Turnover (Reticulated Platelets).|Dual-Dosing|The Methodist Hospital System|No|Withdrawn|September 2009|September 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|November 9, 2009||No|No funding secured.|No||https://clinicaltrials.gov/show/NCT01011257||130747|
NCT01011465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG030632-01A2|The Biology of Resilience|The Biology of Resilience: Oxytocin, Social Relationships and Health||Harvard School of Public Health|No|Completed|February 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|270|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|November 10, 2009|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT01011465||130731|Data collected earlier in the study is missing blood pressure data due to technical problems.
NCT01011478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP-P-5|Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery|Statin Polyp Prevention Trial in Patients With Resected Colon Cancer||NSABP Foundation Inc|Yes|Terminated|March 2010|February 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|406|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011478||130730|
NCT01011738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV22009|An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys|A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)||Hoffmann-La Roche||Completed|April 2009|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1847|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C receiving treatment with peginterferon alfa-2a 40KD        (Pegasys)|November 2015|November 2, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011738||130710|
NCT01012037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.62|Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes|12 Week Randomised Double-blind BI 1356 2.5 mg Bid vs 5 mg qd add-on to Metformin||Boehringer Ingelheim||Completed|November 2009|||September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|491|||Both|18 Years|80 Years|No|||December 2013|June 17, 2014|November 10, 2009||||No|September 21, 2011|https://clinicaltrials.gov/show/NCT01012037||130688|
NCT01019200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#100940|Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis|A Case Control Study to Evaluate Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis.||George Washington University|No|Recruiting|November 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be selected from the Dermatology Clinic at George Washington University        Medical Faculty Associates.|February 2016|February 9, 2016|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01019200||130143|
NCT01019187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 19108|Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy|Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy||Abramson Cancer Center of the University of Pennsylvania||Active, not recruiting|June 2009|||August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Anticipated|226|||Both|21 Years|75 Years|No|||December 2015|December 15, 2015|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019187||130144|
NCT01019798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-01-08-03|Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer|Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer||Taipei Medical University Hospital|Yes|Recruiting|January 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|59 Years|No|||November 2009|November 24, 2009|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01019798||130099|
NCT01019499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPHIKTL|The Effect of Berry Consumption on Indicators of Cardiovascular Disease Risk|The Effect of Berry Consumption on Indicators of Cardiovascular Disease Risk||National Institute for Health and Welfare, Finland|No|Completed|February 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|37|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2010|June 18, 2010|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01019499||130121|
NCT01019811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STS-5xb-86|Innervated Sensory Cross-Finger Flap|The Innervated Sensory Cross-finger Flap Based on the Dorsal Branch Artery for Reconstruction of Fingertip Degloving Injury|ISCF|The Second Hospital of Tangshan|Yes|Completed|May 2001|May 2008|Actual|May 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|12 Years|59 Years|No|||November 2009|November 23, 2009|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01019811||130098|
NCT01020370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMMS030081ST|Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies|An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies||Wayne State University||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with RRMS who are participating in the CARE MS I and CARE MS II studies and are        receiving either alemtuzumab or interferon beta-1a SC|November 2009|November 24, 2009|November 24, 2009||||No||https://clinicaltrials.gov/show/NCT01020370||130055|
NCT01020383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-0081-2.1/09|Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients|A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro®) Over a Period of 24 Hours||Ablynx|Yes|Completed|September 2009|March 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020383||130054|
NCT01020396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCR-03|Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis|A Multi-Center, Double-Blind, Parallel Group Study Comparing the Bioequivalence of Teva Pharmaceuticals, USA's Generic Formulation of Metronidazole Vaginal Gel, 0.75% and MetroGel-Vaginal® Metronidazole Vaginal Gel, 0.75% in the Treatment of Bacterial Vaginosis||Teva Pharmaceuticals USA||Completed|January 2002|March 2003|Actual|March 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|579|||Female|18 Years|N/A|No|||November 2009|November 24, 2009|November 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01020396||130053|
NCT01009736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07041|Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy|Biomarkers of Prostate and Cardiovascular Health of Men Undergoing Prostatectomy Consuming Different Amounts of Soy-Tomato Juice||Ohio State University Comprehensive Cancer Center|Yes|Completed|January 2008|||July 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|N/A|N/A|No|||October 2014|October 15, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009736||130864|
NCT01010048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMU|Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus|the Therapeutic Effect Treated With Tamsulosin After ESWL in Urinary Calculus||Chongqing Medical University|Yes|Recruiting|October 2009|December 2010|Anticipated|October 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||November 2009|November 12, 2009|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010048||130840|
NCT01010360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-71|Identification of Celiac Ganglia|Identification of Celiac Ganglia for Endoscopic Ultrasound||Indiana University|No|Completed|August 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|N/A||1|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|EUS patients|February 2016|February 29, 2016|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010360||130816|
NCT01027481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1|Ranibizumab in Patients With Branch Retinal Vein Occlusion|Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor (VEGF) Treatment in Patients With Branch Retinal Vein Occlusion (BRVO)||Medical University of Vienna|No|Completed|December 2007|December 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||November 2007|December 7, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027481||129512|
NCT01027754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-537|Smoking Cessation Treatment for Methadone Maintenance Patients|Smoking Cessation Treatment for Methadone Maintenance Patients||Albert Einstein College of Medicine of Yeshiva University|Yes|Active, not recruiting|August 2009|||August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027754||129491|
NCT01027468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 548/2009|Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration|Functional, Morphological And Safety Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration - 3 Years Of Follow-up||Medical University of Vienna|No|Completed|August 2009|December 2009|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|50 Years|N/A|No|||January 2014|January 7, 2014|December 7, 2009||No||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01027468||129513|
NCT00993525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3003/2009|Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)|INTRAVITREAL RANIBIZUMAB FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (INIPE STUDY)|INIPE|University of Sao Paulo|Yes|Active, not recruiting|September 2008|March 2010|Anticipated|March 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||October 2009|October 9, 2009|October 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993525||132099|
NCT00993837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMMU-2-2009-3|Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma|Comparison of Effectiveness and Safety of Thyroidectomy for Thyroid Carcinoma in Patients Undergo Endoscopic Surgery and Those Receive Conversion||Second Military Medical University|No|Not yet recruiting|January 2010|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|45 Years|No|||October 2009|October 13, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT00993837||132075|
NCT01023906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ross Aging Initiative|Taste Perception and Chronic Disease Risk|Relationship Between Variations in Taste Perception and Chronic Disease Risk Factors as a Function of Age||Tufts University|No|Completed|July 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|90|Samples With DNA|Blood, and DNA|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|May 2014|May 21, 2014|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023906||129786|
NCT01024153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-140670|Active Video Games and Sustainable Physical Activity|Active Video Games and Sustainable Physical Activity|Exergames|Baylor College of Medicine|Yes|Completed|November 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|84|||Both|9 Years|13 Years|Accepts Healthy Volunteers|||February 2012|February 1, 2012|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024153||129767|
NCT00994162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIME 012|Evaluation of the Use of EZCare◊ in the Management of Acute and Chronic Wounds|A Prospective, Open Labelled, Multicentre Evaluation of the Use of EZCare◊ in the Management of Acute and Chronic Wounds|EZCARE-CIME|Smith & Nephew Wound Management Inc|No|Completed|April 2008|July 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|October 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994162||132050|
NCT00994474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK_06_2009|Comparison of Outcome Parameters in Laser Rhytide Treatment|Comparison of Clinical Outcome Parameters, the Patient Benefit Index (PBI) and Patient Satisfaction After Ablative Fractional Laser Treatment of Peri-orbital Rhytides||Laserklinik Karlsruhe|No|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|28|||Both|40 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994474||132026|
NCT00995280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHTB-03241705|Single Lumen Needle Without Flushing or Double Lumen Needle With Follicle Flushing in Oocyte Retrieval|Single Lumen Needle Without Flushing or Double Lumen Needle With Follicle Flushing in Oocyte Retrieval||Baskent University|Yes|Completed|March 2008|November 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|400|||Female|20 Years|41 Years|Accepts Healthy Volunteers|||October 2009|October 14, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995280||131965|
NCT00995293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_02557|Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial|An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere®) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck||Sanofi|No|Active, not recruiting|August 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||November 2015|November 10, 2015|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT00995293||131964|
NCT00995306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-05-01|Evaluating the Safety and Efficacy Civamide in Osteoarthritis (OA) of the Knee(s)|A Double-Blind, Randomized, Controlled, Parallel-Group, Multicenter Study Evaluating the Safety and Efficacy of Civamide Cream 0.075% as a Treatment in Subjects With Osteoarthritis of the Knee||Winston Laboratories|No|Completed|June 2003|June 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|695|||Both|40 Years|76 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|February 25, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT00995306||131963|
NCT00995592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Philani - original study|Philani Home-based Nutrition Intervention Program|Philani Home-based Nutrition Intervention Program||University of California, Los Angeles|No|Completed|November 2002|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|684|||Female|N/A|N/A|No|||October 2009|October 14, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995592||131941|
NCT00995605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-240-01|AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects|AMAP102 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Subjects||AnaMar AB|No|Terminated|April 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 14, 2009|October 13, 2009||No|Reached sufficient pharmacokinetic exposures|No||https://clinicaltrials.gov/show/NCT00995605||131940|
NCT01020175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSF-940136|Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation|A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome||European Group for Blood and Marrow Transplantation|Yes|Completed|January 1995|December 2002|Actual|December 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|55 Years|No|||November 2009|November 23, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01020175||130070|
NCT01020188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH1125|Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria|A Pilot Study Investigating the Role of Thrombin Generation and Rotational Thromboelastometry in Assessing the Prothrombotic Phenotype of Paroxysmal Nocturnal Haemaglobinuria||King's College Hospital NHS Trust|Yes|Recruiting|August 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with paroxysmal nocturnal haemoglobinuria|May 2010|May 25, 2010|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01020188||130069|
NCT01020201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJHMZK01003|Risk Factors for Post Operative Nausea and Vomiting(PONV) in Patients Underwent Gynecological Operation Under General Anesthesia|A Observational Cohort Study to Identify Risk Factors for Post Operative Nausea and Vomiting Following General Anesthesia in Female Patient Underwent Gynecological Operation||Huazhong University of Science and Technology|Yes|Completed|February 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|774|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients underwent gynecological operation under general anesthesia between 2009.02        and 2009.05.|July 2012|July 30, 2012|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01020201||130068|
NCT01020552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10035|Integrating Family Planning Into Postabortion Care|ESD: Integrated Services for Women Seeking Postabortion Care in Kenya||FHI 360|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|300|||Female|15 Years|N/A|No|Non-Probability Sample|non healthy participants|April 2010|April 28, 2010|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01020552||130041|
NCT01020825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX401-0303|Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled Trial|A Prospective Study for the Assessment of the Long-term Safety and Efficacy of Cx401 in Patients Taking Part in the FATT-1 Trial|LTE|Cellerix|No|Completed|September 2008|May 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that received at least one treatment dose in study Cx401/FATT1|June 2011|June 13, 2011|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01020825||130020|
NCT01020838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14595|Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology|An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology||Piramal Imaging SA|No|Completed|November 2009|May 2014|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|218|||Both|21 Years|N/A|No|||March 2015|March 13, 2015|November 16, 2009|Yes|Yes||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01020838||130019|
NCT01022008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K071202|Assessment Study of Faciocraniosynostosis by Craniofacial Osteodistraction|Respiratory Improvement of Faciocraniosynostosis by Craniofacial Osteodistraction|CRANIORESP|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|September 2009|June 2015|Anticipated|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|N/A|18 Years|No|||April 2015|April 9, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022008||129931|
NCT01022645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00014472|Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes|Postpartum Glucose Tolerance in Women With Recent Gestational Diabetes Using the Levonorgestrel IUD and Non-Hormonal Contraception: A Prospective Cohort Study||Northwestern University|No|Completed|November 2009|August 2014|Actual|August 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|42|||Female|18 Years|45 Years|No|Probability Sample|Postpartum women with gestational diabetes in the last pregnancy|November 2014|November 19, 2014|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01022645||129883|
NCT01022229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCNM-0903|The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Phase 3 Study of a Compound Natural Health Product in Children With ADHD||The Canadian College of Naturopathic Medicine|Yes|Completed|November 2013|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|6 Years|12 Years|No|||January 2016|January 27, 2016|November 26, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022229||129914|
NCT01022242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHSU02|Study of PXL01 Versus Placebo to Inhibit Adhesion Formation After Flexor Tendon Surgery|A Prospective Double-blind, Randomised Concept Study of PXL01 Versus Placebo in Flexor Tendon Surgery|PHSU02|Pergamum AB|No|Completed|December 2009|February 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|138|||Both|15 Years|65 Years|No|||April 2014|April 30, 2014|November 25, 2009||No||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01022242||129913|High drop out rate leading to a low number of subjects analyzed.
NCT01022255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMP0025-01|Autologous Vaccine for Follicular Lymphoma|Phase I Study of an Autologous Recombinant Idiotypic Vaccine Manufactured by magnICON® Technology for the Treatment of Patients With Relapsed or Transformed Follicular Lymphoma||Icon Genetics GmbH|No|Completed|January 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|November 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01022255||129912|
NCT01026701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015067|Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.|Observational Study of Osteoblast Activity in Velcade�(Bortezomib) IV Treated Multiple Myeloma Patients.||Janssen Korea, Ltd., Korea|Yes|Completed|March 2008|November 2009|Actual|November 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|N/A|No|Non-Probability Sample|Among patients who are newly prescribed bortezomib injection as a secondary agent for the        treatment of multiple myeloma, those of whom agree to provide information will be included        in Korea.|April 2014|April 24, 2014|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026701||129572|
NCT00992654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001096|A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India|A Local, Multicentre, Open Label Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India||ViiV Healthcare|No|No longer available|November 2009|February 2010|Anticipated|February 2010|Anticipated|Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||November 2010|November 15, 2010|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992654||132166|
NCT01023633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxali04882|OPTIMOX1 in Chinese mCRC Patients|A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer||Nanjing Medical University|Yes|Recruiting|October 2009|July 2015|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023633||129807|
NCT00993538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4452|Leukemia Cell Cultures for Research of New Anti-Cancer Therapies|Leukemia Cell Cultures for Research of New Anti-cancer Therapies||University Hospital, Strasbourg, France|No|Recruiting|July 2009|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|180|||Both|N/A|N/A|No|||August 2011|August 29, 2011|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993538||132098|
NCT01023620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Takeda IISR - MSA-PIO-028|HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)|Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations|HAL|University of Texas Southwestern Medical Center|Yes|Recruiting|October 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Male|18 Years|N/A|No|||December 2009|December 1, 2009|November 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01023620||129808|
NCT00994175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090244|A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma|A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma||National Institutes of Health Clinical Center (CC)||Recruiting|September 2009|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|October 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994175||132049|
NCT00995020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|522/99|Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion|A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ.||Oswaldo Cruz Foundation|No|Completed|November 1999|December 2010|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Female|N/A|N/A|No|||June 2015|June 14, 2015|June 16, 2009||No||No|October 15, 2012|https://clinicaltrials.gov/show/NCT00995020||131984|
NCT00996177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003943|A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously|Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control|EuroTrans|Janssen-Cilag International NV|No|Completed|June 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|657|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00996177||131897|
NCT00991900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-030409|Short Term and Day to Day Reproducibility of Reflectometric Measurement of Retinal Oxygen Saturation in Healthy Subjects|Short Term and Day to Day Reproducibility of Reflectometric Measurement of Retinal Oxygen Saturation in Healthy Subjects||Medical University of Vienna|Yes|Withdrawn|August 2009|December 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|20 healthy volunteers will be included.|October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991900||132224|
NCT00991887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-04-09A|Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma|Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma|Elbow HO|Carolinas Healthcare System|Yes|Completed|September 2005|||August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991887||132225|
NCT01021150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11088|Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors|An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With Ombrabulin Administered as a 30-minute Intravenous Infusion in Combination With Cisplatin Administered as an Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors||Sanofi|No|Completed|March 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|75 Years|No|||June 2011|June 10, 2011|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01021150||129995|
NCT01021163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0236|Effects of N-acetylcysteine on Pulmonary Function in High-risk Patients Undergoing Off-pump Coronary Bypass Surgery|||Yonsei University|Yes|Completed||||||Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|1||Actual|48|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 25, 2009|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021163||129994|
NCT01021514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET(RAGE)|Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE|Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE||Korea University|No|Completed|January 2009|November 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|82|||Both|16 Years|80 Years|No|Non-Probability Sample|type 2 DM diagnoed according to critereia of American Diabetes Asociation.|April 2011|April 5, 2011|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021514||129969|
NCT01021527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-099|A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)|A Randomized, 4-Period Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose||Merck Sharp & Dohme Corp.|No|Completed|February 2008|April 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|November 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01021527||129968|
NCT01021800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS|Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma||SYSTHER|Blood Transfusion Centre of Slovenia|Yes|Recruiting|April 2009|December 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|30 Years|70 Years|No|||November 2009|January 12, 2010|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021800||129947|
NCT01022021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11908|Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine|Adequacy of Peripheral Blood Stem Cell Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine: A Pilot Project and a Proof of Concept Study||University of Kansas Medical Center|Yes|Active, not recruiting|January 2010|September 2015|Anticipated|April 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|70 Years|No|||December 2013|March 31, 2015|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01022021||129930|
NCT01013207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA051109|Nexus Compliance Study|Assessment of the Compliance and Usability of the Nexus (S9) CPAP System in Sleep Disordered Breathing||ResMed|No|Completed|November 2009|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||September 2010|September 1, 2010|November 11, 2009||No||No|July 12, 2010|https://clinicaltrials.gov/show/NCT01013207||130598|
NCT00992368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1788.08|Cost-effectiveness of Reduction Mammaplasty|Cost-effectiveness of Reduction Mammaplasty||Federal University of São Paulo|No|Completed|July 2008|June 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Female|18 Years|59 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992368||132188|
NCT01027247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R539/27/2007|OculusGen™ Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: a Case-Control Study|||Singapore National Eye Centre|Yes|Completed||||||Phase 3|Interventional|N/A|||||||Both|21 Years|85 Years||||December 2009|December 4, 2009|December 4, 2009||||No||https://clinicaltrials.gov/show/NCT01027247||129530|
NCT00993252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42521|Canadian Computed Tomography (CT) Head Rule Study|Evaluation of an Active Strategy to Implement the Canadian CT Head Rule: Phase III||Ottawa Hospital Research Institute|No|Completed|September 2003|March 2009|Actual|January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4531|||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 13, 2010|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT00993252||132120|
NCT00992901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK083554|Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery|Hormonal and Neural Control of Insulin Secretion Following Gastric Bypass Surgery||Cedars-Sinai Medical Center|No|Active, not recruiting|October 2009|July 2020|Anticipated|July 2020|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|October 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992901||132147|
NCT00993213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-499|Mechanisms Defending Fat Mass in Humans After Lipectomy|Mechanisms Defending Fat Mass in Humans After Lipectomy||University of Colorado, Denver|Yes|Completed|April 2004|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00993213||132123|
NCT00994188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW062090617KT|A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members|A Clinical Study of the Living-related Renal Transplantation With Restored Kidneys (Interventional Trial)||Tokushukai Medical Group|Yes|Recruiting|July 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|N/A|No|||October 2009|October 13, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00994188||132048|
NCT00994149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bio-REB #08-151|Diazoxide In the Management Of Hypoglycemic Neonates|Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation|DIMOHN|University of Saskatchewan|Yes|Not yet recruiting|October 2009|October 2011|Anticipated|October 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|12 Hours|No|||October 2009|October 10, 2009|September 30, 2009||||No||https://clinicaltrials.gov/show/NCT00994149||132051|
NCT00993850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH080958|Sleep Disturbance and Bipolar Disorder|A Psychological Intervention for Individuals Who Suffer From Sleep Disturbance and Bipolar Disorder||University of California, Berkeley|Yes|Completed|October 2009|July 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00993850||132074|
NCT00994747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803712|Sensitive Periods in Early Flavor Learning|Sensitive Periods in Early Flavor Learning||Monell Chemical Senses Center|No|Completed|November 2006|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|6||Actual|79|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||October 2012|October 2, 2012|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00994747||132005|
NCT00995319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17436|Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area|Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area||Norwegian University of Science and Technology|Yes|Completed|January 2008|July 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Both|18 Years|N/A|No|Probability Sample|All cancer patients with radiation therapy concerning the oral cavity who are in care of        the Detal Team at St.Olavs University Hospital|August 2014|August 12, 2014|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995319||131962|
NCT00995618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3006GT|Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia|A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Febuxostat Compared With Tranilast Alone and Febuxostat Alone in Healthy Subjects With Hyperuricemia||Nuon Therapeutics, Inc.|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|70 Years|No|||January 2011|January 5, 2011|October 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00995618||131939|
NCT00996203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22665|A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.|Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ)||Hoffmann-La Roche||Completed|October 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Both|18 Years|N/A|No|||June 2014|September 22, 2014|October 15, 2009||No||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00996203||131895|
NCT00996216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108392|Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390|An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)|ENABLE-ALL|GlaxoSmithKline|No|Completed|September 2009|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||August 2013|October 10, 2013|October 1, 2009|Yes|Yes||No|October 10, 2013|https://clinicaltrials.gov/show/NCT00996216||131894|
NCT00992160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111364|Vestipitant 28-day Tolerance Study|A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/Day) for the Treatment of Primary Insomnia in Adult Outpatients||GlaxoSmithKline||Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|64 Years|No|||March 2012|March 22, 2012|July 16, 2009||No||No||https://clinicaltrials.gov/show/NCT00992160||132204|
NCT00992173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-IB-N201|Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma|A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma||Molecular Insight Pharmaceuticals, Inc.|Yes|Withdrawn|January 2010|||October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Months|N/A|No|||November 2015|November 24, 2015|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992173||132203|
NCT01021176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 27016|Evaluate a Medication on How Hunger and Appetite Are Influenced by Smell|A Single Dose Pilot Study to Evaluate the Safety and Dose-Response of Smell to Intranasal Diltiazem||Pennington Biomedical Research Center|No|Terminated|October 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021176||129993|
NCT01021189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00003|Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Young and Elderly Japanese Volunteers After Oral Single and Multiple Ascending Doses||AstraZeneca|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|97|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2010|June 9, 2010|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01021189||129992|
NCT01021540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009003|Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes|Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes|ACTH|Arizona Kidney Disease and Hypertension Center|No|Completed|December 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||July 2011|July 13, 2011|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021540||129967|
NCT01021553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109059|A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation|A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men With Premature Ejaculation||GlaxoSmithKline|No|Completed|December 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|75|||Male|18 Years|50 Years|No|||June 2011|February 16, 2012|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021553||129966|
NCT01021813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-009|A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients With Primary Insomnia||Merck Sharp & Dohme Corp.|Yes|Completed|December 2009|August 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|781|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|November 25, 2009|Yes|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01021813||129946|
NCT01022281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3631|Early Diagnosis in Glaucoma With GDxVcc|Evaluation of Scanning Laser Polarimetry Findings in Individuals With Exfoliation Syndrome Compared With Normal Controls||Aristotle University Of Thessaloniki|No|Completed|September 2007|December 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|82|||Both|60 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Individuals with and without exfoliation|May 2014|May 9, 2014|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022281||129910|
NCT01013220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH076227|Depression Management at the Workplace|Influencing Employer Purchasing Behavior|DMW|Florida State University|No|Completed|January 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|293|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 15, 2014|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013220||130597|
NCT00992667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nowak-01|Inhaled Apocynin Decreases Reactive Oxygen Species Concentrations in Exhaled Breath Condensate in Mild Asthmatics|Inhaled Apocynin Decreases Reactive Oxygen Species Concentrations in Exhaled Breath Condensate in Mild Asthmatics||Medical Universtity of Lodz|No|Completed|June 2008|November 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|22 Years|56 Years|No|||October 2009|October 8, 2009|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00992667||132165|
NCT00992628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0262-B|Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope|Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope||University Health Network, Toronto|Yes|Completed|July 2010|April 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2011|April 14, 2011|May 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00992628||132168|
NCT00993265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906005337|N-Acetylcysteine for Pediatric Trichotillomania|Double-Blind, Placebo-Controlled Trial of N-acetylcysteine for the Treatment of Pediatric Trichotillomania||Yale University|No|Completed|October 2009|March 2014|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|8 Years|17 Years|No|||June 2014|June 26, 2014|October 9, 2009||No||No|March 7, 2014|https://clinicaltrials.gov/show/NCT00993265||132119|
NCT00992914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU6644|Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes|Pilot Study of Stellate Ganglion Injection With Anesthetic as a Method to Provide Relief From Hot Flushes||Northwestern University|No|Active, not recruiting|February 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992914||132146|
NCT00993226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-001-IM|An International Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy|An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Primary, Elective, Open, Abdominal Hysterectomy||Durect|No|Completed|May 2009|July 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|115|||Female|18 Years|N/A|No|||January 2013|January 30, 2013|October 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00993226||132122|
NCT00993239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL32711-FIH-007-PTL-F|Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma|A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma||TetraLogic Pharmaceuticals|No|Completed|November 2009|March 2013|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00993239||132121|
NCT00994201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00005554|Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response|Pilot Study of DCE-MRI, DW-MRI, and MRS in the Assessment of Head and Neck Cancer Response to Chemo-radiation||OHSU Knight Cancer Institute|Yes|Terminated|October 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential subjects will be recruited by the Oregon Health and Science University head and        neck oncology staff.|March 2016|March 24, 2016|October 13, 2009||No|Study never accrued sufficient subjects|No||https://clinicaltrials.gov/show/NCT00994201||132047|
NCT00993863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33CL230|Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction|A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled Study of ADL5859 for the Treatment of Pain After Surgical Removal of Impacted Third Molars||Cubist Pharmaceuticals LLC|No|Completed|June 2007|||September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|201|||Both|18 Years|50 Years|No|||October 2009|July 16, 2015|October 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00993863||132073|
NCT00993876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KO 2067|Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment|Cognitive Flexibility and Its Correlation to Sleep and Neuroplasticity In The Course Of Depression During Different Treatments|Decoflex|Zentrum für Integrative Psychiatrie|No|Completed|August 2005|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|45|||Both|20 Years|45 Years|No|||October 2009|October 13, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993876||132072|
NCT00995033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-5-066|Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)|A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm , Study to Assess Efficacy and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or Placebo Co-Administered With Varenicline (Champix®) as an Aid in Smoking Cessation||Maastricht University Medical Center|Yes|Completed|October 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|558|||Both|18 Years|65 Years|No|||February 2013|February 18, 2013|October 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995033||131983|
NCT00996190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03|Best Regimen for Phenylephrine Administration During Cesarean Section|Study to Determine the Best Regimen for Administration of Phenylephrine During Spinal Anesthesia for Cesarean Delivery, as Determined by Maternal Blood Pressure and Cardiac Output||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 22, 2011|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996190||131896|
NCT00992459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-006|Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders|A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|October 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|October 8, 2009|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT00992459||132181|
NCT00992472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1670110293|Bioavailability of Prochlorperazine Suppositories, 25 mg|Bioavailability of Prochlorperazine Suppositories, 25 mg||Paddock Laboratories, Inc.||Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||42|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2009|September 24, 2013|October 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992472||132180|
NCT00991913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJHMZK02001|Risk Factors of Recovery Room Delirium After Elective Non-cardiovascular Surgery|Risk Factors of Recovery Room Delirium After Elective Non-cardiovascular Surgery in Post-anaesthesia Care Unit||Huazhong University of Science and Technology|Yes|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|715|||Both|18 Years|N/A|No|Probability Sample|Patients over the age of 18yr, who were admitted to the PACU after elective surgery under        general anaesthesia during regular working hours (9:00Am to 5:00Pm)|May 2013|May 28, 2013|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991913||132223|
NCT01021566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075783161516|Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis|Advances in Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis: A Comparison Study With Conventional Methadone Treatment (HPDMT)|HPDMT|First People's Hospital of Foshan||Active, not recruiting|November 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|45 Years|No|||November 2009|November 27, 2009|November 27, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01021566||129965|
NCT01021826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HyTe-1|Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement|Determinants of Perioperative Hyperglycaemia in Primary Hip and Knee Replacement|HyTe-1|Coxa, Hospital for Joint Replacement|No|Completed|December 2009|September 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|193|Samples Without DNA|plasma sample (one per patient, collected before surgery)|Both|18 Years|N/A|No|Non-Probability Sample|tertiary care clinic|August 2015|August 9, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021826||129945|
NCT01022034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Berg.2007|Pexy Versus Non-pexy for Full Thickness Rectal Prolapse|Pexy vs. No Pexy in Abdominal Surgery for Full Thickness Rectal Prolapse in Adults: A Randomized Controlled Trial|Bergamaschi|Societa Italiana di Chirurgia ColoRettale||Completed|January 2003|October 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||December 2009|December 1, 2009|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01022034||129929|
NCT01022294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20070261|Analgetic Effect of Nitrousoxide-oxygen Inhalation for Dental Treatment of Children|Analgetic Effect of Nitrousoxide-oxygen Inhalation for Dental Treatment of Children||University of Aarhus|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||January 2012|January 30, 2012|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01022294||129909|
NCT01022307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6120-R|Quantitative Automated Lesion Detection of Traumatic Brain Injury|Quantitative Automated Lesion Detection of TBI|QALD|VA Office of Research and Development|No|Completed|May 2009|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|212|None Retained|No biospecimen, only digital data.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Our targeted population is veterans from OEF/OIF. Other subjects will be recruited as        needed to fulfill recruitment targets.|December 2015|December 8, 2015|May 8, 2009||No||No|December 8, 2015|https://clinicaltrials.gov/show/NCT01022307||129908|
NCT01022632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharmacol no.01 /2008 Research|Effect of Curcumin as Nutraceutical in Patients of Depression|A Randomized, Active Controlled, Open Label, Parallel Group Study to Compare the Efficacy of Extract of Curcuma Longa (Turmeric) With Fluoxetine and to Study Its Effect as an Add on Therapy to Fluoxetine in Patients of Depression||Government Medical College, Bhavnagar||Completed|March 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|No|||January 2010|January 27, 2010|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022632||129884|
NCT00992680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-01|A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease|A Prospective, Randomized, Multicenter, Open Label, Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease||ROX Medical, Inc.|Yes|Completed|September 2009|December 2013|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|80 Years|No|||April 2014|April 17, 2014|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992680||132164|
NCT00994214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-55-52060-003|Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly|Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients|TULIPIA|Ipsen|No|Terminated|October 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|109|||Both|18 Years|75 Years|No|||November 2015|January 7, 2016|October 13, 2009|No|Yes|Preliminary data from this study does not support expected inhibition of GH and IGF-1|No|October 14, 2015|https://clinicaltrials.gov/show/NCT00994214||132046|The study was terminated prematurely due to lack of efficacy.
NCT00992641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSDIET 070014|The Effect of Nordic Recommended Diet on the Features of Metabolic Syndrome - Multicentre Study|The Effect of Nordic Diet Rich in Whole Grain, Berries, Fruits, Vegetables and Fish on Features of Metabolic Syndrome - a Systems Biology Approach|SYSDIET|University of Eastern Finland|No|Completed|August 2009|December 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|167|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992641||132167|
NCT00994773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV 14934|Simvastatin for the Treatment of Chronic Hepatitis B|A Pilot Trial of Simvastatin Alone and Added to Tenofovir or Entecavir for the Treatment of Chronic Hepatitis B||Bader, Ted, M.D.|No|Completed|December 2009|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|70 Years|No|||August 2012|August 15, 2012|October 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994773||132003|
NCT00993551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-017-E|Timing of Primary Surgery for Cleft Palate|Timing of Primary Surgery for Cleft Palate|TOPS|University of Manchester|Yes|Recruiting|July 2010|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Both|N/A|6 Months|No|||May 2015|May 26, 2015|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993551||132097|
NCT00993889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36154-C|Virtual Reality Analgesia During Pediatric Physical Therapy|Virtual Reality Analgesia During Pediatric Physical Therapy|VRD/Peds|National Institute of General Medical Sciences (NIGMS)|No|Recruiting|May 2009|July 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|200|||Both|5 Years|20 Years|No|||April 2015|April 20, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00993889||132071|
NCT00995631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0339|Following Lipectomy to Understand Adipose Tissue Re-accumulation|Regional Fat Re-accumulation Following Lipectomy in Pre- and Post-menopausal Women|FLARE|University of Colorado, Denver|No|Completed|January 2008|December 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|53|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00995631||131938|
NCT00994487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7828B|Breastfeeding in Infancy and Food Intake in Preschool-Aged Children|Breastfeeding, Parental Feeding Style, and Self-regulation Capabilities in Female Preschool-age Children||University of Tennessee|Yes|Completed|June 2010|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|7|||Female|3 Years|5 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00994487||132025|
NCT00995644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRBS #08-199|Natural History of Attempts to Stop Smoking|Natural History of Attempts to Stop Smoking||University of Vermont|No|Completed|February 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|238|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|September 2013|September 17, 2013|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995644||131937|
NCT01023815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIT12|Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.|Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).|EVIDENCE|Novartis||Completed|April 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|184|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|December 1, 2009||No||No|July 4, 2013|https://clinicaltrials.gov/show/NCT01023815||129793|
NCT01023828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAN/CC/394/07|K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications|K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications|007/055/OMI|National Institute of Cancerología|No|Completed|April 2005|June 2012|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Retrospective||4|Actual|150|Samples With DNA|The tumor samples, both formalin-fixed or paraffin-embedded, used for the histological      diagnosis of patients will be obtained from the Pathology Departments of the National Cancer      Institute and the National Institute of Respiratory Diseases; these samples will be used to      gather DNA for the analysis of K-RAS mutations. The clinical data of the patients will be      obtained from their medical files.|Both|18 Years|N/A|No|Non-Probability Sample|For the purpose of this research, the presence of mutations at the K-RAS oncogene were        evaluated retrospectively in 50 patients with advanced NSCLC who have a background of wood        smoke exposure and 50 patients with NSCLC who have a background of tobacco smoking.        Additionally, 50 patients with NSCLC with or without a background of exposure to any of        these risk factors for lung cancer will be prospectively evaluated.|June 2012|June 27, 2012|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023828||129792|
NCT01021215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00730|Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers|Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers||National Cancer Institute (NCI)|No|Completed|May 2010|March 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|84|||Both|18 Years|N/A|No|||October 2013|April 1, 2015|November 24, 2009|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01021215||129990|
NCT01021228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 18-2008|Preconditioning Volatile Anesthesia in Liver Surgery|Preconditioning is Indeed Protective||University of Zurich|No|Completed|August 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|257|||Both|18 Years|90 Years|No|Probability Sample|Consecutive patients were included undergoing any type of liver resection with inflow        occlusion for benign as well as malign diseases between January first, 2005 and December        31, 2007 in a single tertiary care center|November 2009|November 25, 2009|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021228||129989|
NCT01021579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS 84-258|Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study|||Fasa University of Medical Sciences|Yes|Completed|January 2008|November 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Female|16 Years|45 Years|No|||November 2009|November 27, 2009|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01021579||129964|
NCT01021839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006p-000081|Comparison of Bovine Carotid Artery and Expanded Polytetrafluoroethylene (ePTFE) for Permanent Hemodialysis Access|Bovine Carotid Artery Graft Revisited: A Prospective, Randomized Comparison of Bovine Carotid Artery and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access||Massachusetts General Hospital|No|Completed|April 2006|June 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||November 2009|November 25, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01021839||129944|
NCT01022047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF096|Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis|A Phase III, Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis in a Test Group Treated With Noex 32 mcg and a Reference Group Treated With Budecort Aqua® 32 mcg|NOEX|Eurofarma Laboratorios S.A.|Yes|Completed|February 2010|December 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2010|July 24, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022047||129928|
NCT01013870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0132|Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol|The Mission Connect Mild TBI Translational Research Consortium's Integrated Clinical Protocol||Baylor College of Medicine|No|Active, not recruiting|February 2010|December 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|50 Years|No|||August 2015|August 4, 2015|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013870||130548|
NCT01013883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RajPh.D2066|The Darlington Retrospective Outpatient Study|Long Term Outcomes in Patients With Heart Failure|DROPSY|County Durham and Darlington NHS Foundation Trust|No|Completed|January 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|509|||Both|18 Years|N/A|No|Non-Probability Sample|Secondary care one stop diagnostic heart failure clinic|January 2014|January 28, 2014|November 13, 2009||No||No|August 23, 2013|https://clinicaltrials.gov/show/NCT01013883||130547|
NCT00994227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-10-10|Clinicopathologic Findings for Macular Disease|Clinicopathologic Findings for Macular Disease||Hallym University Medical Center|Yes|Completed|May 2009|June 2010|Actual|October 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|20 Years|N/A|No|||April 2011|April 20, 2011|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994227||132045|
NCT00992927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-RM-SGChung-IHD-01|Should the Joint Capsule of the Painful Stiff Shoulder be Ruptured During Intra-articular Hydraulic Distension?|Comparative Study for the Efficacy of Capsule-Preserving Versus Capsule-Rupturing Intra-articular Hydraulic Distension in Patients With Painful Stiff Shoulders||Seoul National University Hospital|No|Completed|March 2008|August 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|20 Years|90 Years|No|||July 2011|July 21, 2011|October 7, 2009||No||No|August 15, 2010|https://clinicaltrials.gov/show/NCT00992927||132145|
NCT00993954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/29x|Nurse Reduction of Pulled Elbow|Reduction of Radial Head Subluxation in Children Via a Nurse Initiated Pathway: A Randomized Control Trial||Children's Hospital of Eastern Ontario|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|N/A|6 Years|No|||December 2014|December 28, 2014|October 8, 2009||No||No|November 25, 2014|https://clinicaltrials.gov/show/NCT00993954||132066|
NCT00993967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-III-001-E|Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)|A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.||Santhera Pharmaceuticals|Yes|Completed|June 2007|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|204|||Both|9 Years|N/A|No|||August 2012|August 28, 2012|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00993967||132065|
NCT00993564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090575|Magnetic Resonance Imaging (MRI) Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy (HIE)|MRI Thermal Imaging of Infants Undergoing Cooling for HIE||Vanderbilt University|No|Withdrawn|September 2009|July 2013|Actual|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|0|||Both|N/A|5 Days|No|Non-Probability Sample|Newborn infants who are treated with cooling for the amelioration of hypoxic ischemic        encephalopathy|July 2013|July 5, 2013|October 5, 2009||No|this is an accidentical duplication of 090575Walsh NCT01128673 and I would like to remove|No||https://clinicaltrials.gov/show/NCT00993564||132096|
NCT00993902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU1|Double and Single Intrauterine Insemination In Controlled Ovarian Stimulation (COH) Cycles With Multifollicular Development|||Baskent University|No|Completed|May 2008|July 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Female|20 Years|37 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|July 22, 2009||||No||https://clinicaltrials.gov/show/NCT00993902||132070|
NCT00993915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581185|Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications|Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications|LIGHT|Pfizer|Yes|Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|687|||Both|18 Years|80 Years|No|Non-Probability Sample|Coronary atery disease, prevention of high risk cardiovascular complications with statins.|January 2013|January 7, 2013|October 13, 2009|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT00993915||132069|The end of study final status of 3 participants was not completed and therefore defaulted to ongoing.
NCT00994786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-273|A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder|A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder||McMaster University|No|Recruiting|January 2009|October 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||March 2013|March 4, 2013|October 5, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00994786||132002|
NCT00994799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AHU04T|Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema|Comparison of the Effect of Intravitreal Ranibizumab Injections Compared to Macular Grid-pattern Laser Therapy for the Symptomatic Treatment of Diabetic Macular Edema (a Randomized, Controlled, Phase III Trial)||Szeged University|No|Recruiting|July 2009|February 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Diabetes patients having clinically significant macular edema due to diabetic retinopathy.|October 2009|October 15, 2009|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994799||132001|
NCT00994500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01980|Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma|A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas||National Cancer Institute (NCI)||Completed|August 2009|||July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|1 Year|21 Years|No|||July 2013|July 1, 2013|October 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00994500||132024|
NCT00994760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-1301-401-DE|Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years|A Prospective Non-interventional/Observational Patient Cohort Study on the Efficacy of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients.|GENISIS|Takeda|No|Completed|September 2009|November 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients|August 2012|August 27, 2012|October 5, 2009||No||No|March 13, 2012|https://clinicaltrials.gov/show/NCT00994760||132004|
NCT00995878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005095|The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.|The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids||Mayo Clinic|Yes|Active, not recruiting|October 2009|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Female|25 Years|N/A|No|||September 2015|September 8, 2015|October 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995878||131919|
NCT00996229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ernaehrung-Neuromod 02|Effects of Dietary Interventions on the Aging Brain|Phase IV Interventional Study: Effects of Dietary Interventions on Brain Functions in Healthy Elderly People||University Hospital Muenster|Yes|Recruiting|November 2009|February 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Anticipated|300|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||April 2013|April 18, 2013|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00996229||131893|
NCT00991926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroendoUnit-12|Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat|Evaluation of Baseline and Stimulated GH/IGF-1 AXIS in Obese Subjects in Treatment With Orlistat||Federico II University|No|Completed|December 2006|February 2009|Actual|December 2006|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Female|45 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|nondiabetic obese post-menopausal women|October 2009|October 13, 2009|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00991926||132222|
NCT01023841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-040|Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children|||Allergan|No|Completed|June 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|5 Years|17 Years|No|||July 2013|July 9, 2013|November 30, 2009|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01023841||129791|
NCT01012180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910007|Parents With Bipolar Disorder: Relationship of Adaptation to Own Illness With Risk Perception and Coping With Perceived Risk to a Child|Parents With Bipolar Disorder: Relationship of Adaptation to Own Illness With Risk Perception and Coping With Perceived Risk to a Child||National Institutes of Health Clinical Center (CC)||Completed|October 2009|June 2013||||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|90 Years|No|||June 2013|October 23, 2014|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012180||130677|
NCT01012453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-126|A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema|Hand Eczema Trial: A Randomised Clinical Trial of the Effect of Classification and Individual Counselling Among Health Care Workers With Hand Eczema|HET|Roskilde County Hospital|No|Recruiting|October 2009|||October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|300|||Both|N/A|N/A|No|||November 2009|November 12, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012453||130656|
NCT01012700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-0682|Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers|A Randomized, Placebo-controlled, Phase I Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers||Rockefeller University|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012700||130637|
NCT01012960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS001|Opioids and Esophageal Function|Is the Opioid-induced Pharyngeal and Esophageal Dysfunction Peripherally or Central Mediated?||University Hospital Orebro|Yes|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012960||130617|
NCT01012947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AjouU|Cognitive Health Promotion Project in the Community|Cognitive Health Promotion Project in the Community||Ajou University School of Medicine|Yes|Completed|February 2008|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|1115|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 19, 2012|November 12, 2009||No||No|August 18, 2011|https://clinicaltrials.gov/show/NCT01012947||130618|
NCT01013233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTST09|Cognitive Training to Improve Cognitive Function Following Chemotherapy|Training of Cognitive Function of Patients After Chemotherapy|KT|Charite University, Berlin, Germany|No|Not yet recruiting|December 2009|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2009|November 12, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013233||130596|
NCT01013545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G09-04-013-01|Developmental and Augmented Intervention for Facilitating Expressive Language|Developmental and Augmented Intervention for Facilitating Expressive Language|CCNIA|Autism Speaks|No|Completed|July 2009|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|5 Years|8 Years|No|||July 2013|July 10, 2013|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013545||130573|
NCT01013558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04.014|New Options for Preoperative Anesthesia in Intrauterine Needling|NO PAIN: New Options for Preoperative Anesthesia in Intrauterine Needling|NO PAIN|Leiden University Medical Center|No|Completed|September 2004|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||November 2009|December 7, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01013558||130572|
NCT01013896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00025417|Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience|Building Adherence to Live With And Navigate my CF Experience|BALANCE|Johns Hopkins University|Yes|Completed|July 2009|May 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|128|||Both|16 Years|N/A|No|||March 2015|March 30, 2015|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013896||130546|
NCT01009684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2009_01|International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens|INAS-SCORE International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens|INAS-SCORE|Center for Epidemiology and Health Research, Germany|Yes|Active, not recruiting|August 2009|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50203|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants are recruited by their attending gynecologists. The sample should be        representative of users of oral contraceptives (OCs).|October 2015|October 20, 2015|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009684||130868|
NCT00992940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0492-A|Patient-controlled Versus Anesthesiologist-controlled Propofol-remifentanil in Awake Craniotomy|A Comparison of Patient-controlled Versus Anesthesiologist-controlled Propofol-remifentanil in Awake Craniotomy for Tumor Surgery||University Health Network, Toronto|Yes|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|October 8, 2009||No|Funds needed to carry on the project were not secured.|No||https://clinicaltrials.gov/show/NCT00992940||132144|
NCT00994253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-083|Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics|A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tekturna (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension||William Beaumont Hospitals|Yes|Terminated|October 2009|October 2012|Anticipated|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|85 Years|No|||July 2012|July 30, 2012|October 12, 2009|Yes|Yes|Safety concerns regarding the concomitant use of aliskiren with an ACEi or ARB.|No||https://clinicaltrials.gov/show/NCT00994253||132043|
NCT00994266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0912-CU|Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy|Efficacy of Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy||Catalysis SL|Yes|Completed|October 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|116|||Both|40 Years|65 Years|No|||April 2011|April 27, 2011|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994266||132042|
NCT00995046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.482|Individually Tailored Prophylaxis in Patients With Severe Hemophilia A|Optimizing Prophylaxis in Patients With Severe Haemophilia A by Tailoring the Infusions to Individual Patients' Needs Using the Calibrated Automated Thrombin Generation Test|OPTIPHASE|Hospices Civils de Lyon|Yes|Terminated|September 2009|||September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|5|||Male|6 Years|45 Years|No|||October 2009|May 13, 2013|October 12, 2009||No||No||https://clinicaltrials.gov/show/NCT00995046||131982|
NCT00995332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rek VEST 231-06|Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine|Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine||University of Bergen|No|Completed|September 2009|June 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995332||131961|
NCT00995345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104-005|Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Safety and Efficacy of Once-Daily KRP-104 in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Alone.|Synergy104|ActivX Biosciences, Inc.|No|Completed|October 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|403|||Both|18 Years|75 Years|No|||June 2014|June 23, 2014|October 12, 2009|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT00995345||131960|
NCT00995384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2009-148|Cardiac Computed Tomography (CT) Scan Compared to Transesophageal Echocardiogram (TEE) in Endocarditis|A Novel Modality of Cardiac CT in Characterization of Acute Infective Endocarditis||William Beaumont Hospitals|Yes|Terminated|October 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|October 14, 2009||No|Difficult recruitment|No||https://clinicaltrials.gov/show/NCT00995384||131957|
NCT00995657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAW003|Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma|Dose Response of FENO to Inhaled Steroids in Mild-to-moderate Asthma||University of Dundee|No|Completed|October 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995657||131936|
NCT00995059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC078F|Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase I/II Study of a Novel Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients With Multiple Myeloma||Mayo Clinic|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2011|January 7, 2016|October 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995059||131981|
NCT00995358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMU-02|A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer|Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma||University of Yamanashi|Yes|Recruiting|November 2008|October 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|80 Years|No|||October 2009|October 14, 2009|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00995358||131959|
NCT01027897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00016181a|Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients|Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients With Sepsis at Grady Health System||Emory University|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|90 Years|No|||December 2013|December 19, 2013|December 8, 2009||No||No|April 5, 2012|https://clinicaltrials.gov/show/NCT01027897||129480|
NCT01023854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV|Merits of Continuous Paravertebral Block in the Management of Renal/Adrenal Surgery by Laparotomy|Consideration of the Merits of Continuous Paravertebral Block in the Management of Renal and/or Adrenal Surgery by Laparotomy in Adults|BPV|University Hospital, Brest|No|Terminated|October 2009|September 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|41|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|December 1, 2009||No|No more potentiel patients for study|No||https://clinicaltrials.gov/show/NCT01023854||129790|
NCT01024101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-372|Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer|Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer||Bristol-Myers Squibb|Yes|Completed|January 2004|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|20 Years|74 Years|No|||April 2011|April 8, 2011|November 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01024101||129771|
NCT01012466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5203|The Physical Effects of Pain Catastrophizing in Labor|The Physical Effects of Pain Catastrophizing on Normal Labor||Oregon Health and Science University|No|Recruiting|June 2009|June 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nulliparous women attending the prenatal clinic at Oregon Health & Science University|November 2009|November 12, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012466||130655|
NCT01012713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perfect Storm|Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis|Pilot Open-Label Clinical Trial to Test Efficacy and Safety of Combination of Clobex® Spray With Excimer Laser Therapy [Photomedex XTRAC ® Velocity] in the Treatment of Generalized Plaque Psoriasis Followed by Maintenance With Topical Vectical® Ointment||University of California, San Francisco|No|Completed|June 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|November 10, 2009|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01012713||130636|
NCT01012726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIST-MC-09|Study About the Effect of Doxycycline and Acetylcystein in the Treatment of CD-associated Fistulae|FIST-MC-09 Study About the Effect of Doxycycline and Acetylcystein in the Treatment of CD-associated Fistulae||University of Zurich||Terminated|November 2009|July 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2014|December 3, 2014|November 11, 2009||No|not enough patients enrolled|No||https://clinicaltrials.gov/show/NCT01012726||130635|
NCT01012973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14130|Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)|A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)|GALILEO|Bayer|Yes|Completed|October 2009|February 2012|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|October 30, 2009|Yes|Yes||No|October 23, 2012|https://clinicaltrials.gov/show/NCT01012973||130616|
NCT01013246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B268|Effects of Playing Video Games on Energy Balance|Effects of Playing Video Games on Energy Balance: a Randomized, 2-condition, Crossover Study in Adolescents||University of Copenhagen|No|Completed|November 2009|December 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Male|15 Years|19 Years|Accepts Healthy Volunteers|||November 2009|August 9, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013246||130595|
NCT01013571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04695|Self Titration With Apidra to Reach Target Study (START)|A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insulin Glulisine at Breakfast Following Optimization of Insulin Glargine||Sanofi||Completed|October 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|493|||Both|30 Years|N/A|No|||March 2012|March 20, 2012|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013571||130571|
NCT01013909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13957|Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo|An Investigator-blind, Randomized, Multicenter, 5-arm, Placebo- and Active Controlled Parallel Group Pilot Trial to Explore the Efficacy and Tolerability of Topical Bifonazole Liquid Spray in Patients With Athlete's Foot.|Porsche|Bayer|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|220|||Both|18 Years|70 Years|No|||January 2015|January 26, 2015|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01013909||130545|
NCT01013922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RSE-DUM-2008/1|A Descriptive Study to Explore Certain Characteristics of Patients at Risk for Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care Setting|A Descriptive Study to Explore Certain Characteristics of Patients at Risk for COPD in a Primary Care Setting||AstraZeneca|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|N/A||1|Actual|309|||Both|45 Years|80 Years|No|Non-Probability Sample|Primary care clinic|November 2010|November 18, 2010|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013922||130544|
NCT00993278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27361|Effects of the Atkins Diet Versus a Low Fat Diet on Inflammation|Effects of the Atkins Diet Versus a Low Fat Diet on Endothelial Function, Lipid Profiles, and Systemic Markers of Inflammation||Boston Medical Center|No|Completed|August 2008|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993278||132118|
NCT00993291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090873|Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)|Effect of Frequency Change in Bilateral Subthalamic Nucleus (STN)-DBS on Gait Function in PD||Vanderbilt University|Yes|Completed|November 2009|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||December 2011|December 21, 2011|October 8, 2009||No||No|August 22, 2011|https://clinicaltrials.gov/show/NCT00993291||132117|
NCT00993304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3534|A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics|A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||June 2014|June 25, 2014|October 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00993304||132116|
NCT00993317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-KOA-0801i|A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis|A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|October 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|75 Years|No|||September 2012|September 25, 2012|October 9, 2009||No||No|May 22, 2012|https://clinicaltrials.gov/show/NCT00993317||132115|
NCT00994513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAC08-07-02|Effect of Alpha Lipoic Acid on Obesity Related Comorbidities|Effect of Alpha Lipoic Acid on Obesity Related Comorbidities||Georgia Regents University|Yes|Completed|July 2009|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994513||132023|
NCT01026571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001639|Identification of Genetic Mechanisms of Bicuspid Aortic Valve Disease|Identification of Genetic Mechanisms of Bicuspid Aortic Valve Disease|BAV Genetics|Brigham and Women's Hospital|No|Recruiting|December 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Collection of salivary DNA|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators wish to identify genetic variation that is associated with BAV in        Americans.        Patients with a diagnosis of bicuspid aortic valve will be enrolled. Patients who have had        their bicuspid aortic valve previously replaced will also be enrolled.|February 2015|February 2, 2015|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026571||129582|
NCT01026584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBIRB0909-97|Efficacy and Safety of Aripiprazole in First Episode Psychosis|Efficacy and Safety of Aripiprazole in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study||Chonbuk National University Hospital|No|Completed|October 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|59 Years|No|||February 2012|February 9, 2012|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026584||129581|
NCT00994240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0252|Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC|Cure Rates of Superficial Basal Cell Carcinoma Following 1 Versus 3 Cycles of Electrodessication & Curettage: A Randomized Prospective Study||University of Wisconsin, Madison|Yes|Terminated|May 2008|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|October 9, 2009||No|slow enrollment, lack of funding|No|December 5, 2014|https://clinicaltrials.gov/show/NCT00994240||132044|
NCT00994526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU794|Processed Meat and Colon Carcinogenesis|Effect of Processed Meat on Colorectal Carcinogenesis. Study of Mechanisms. Choice of Preventive Strategies|Hemcancer|Institut National de la Recherche Agronomique|No|Completed|October 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|18|||Male|40 Years|75 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00994526||132022|
NCT01027364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|998HB102|Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B|B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B||Biogen|Yes|Completed|December 2009|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|123|||Male|12 Years|N/A|No|||June 2015|June 4, 2015|December 4, 2009|Yes|Yes||No|April 14, 2014|https://clinicaltrials.gov/show/NCT01027364||129521|
NCT01027377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|998HA101|Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A|An Open-Label, Crossover, Dose-Escalation, and Multi-Center Study to Determine the Safety, Tolerability, and Pharmacokinetic of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients With Severe Hemophilia A||Biogen|Yes|Completed|December 2009|May 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|12 Years|N/A|No|||June 2011|September 12, 2013|December 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01027377||129520|
NCT01027910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-352|PCI-24781 in Combination With Doxorubicin to Treat Sarcoma|Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy||Massachusetts General Hospital|Yes|Completed|February 2009|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027910||129479|
NCT01024335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5962 DA027124|Dronabinol Naltrexone Treatment for Opioid Dependence|Dronabinol Naltrexone Treatment for Opioid Dependence|Domino|New York State Psychiatric Institute|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||September 2014|September 3, 2014|November 30, 2009|Yes|Yes||No|April 28, 2014|https://clinicaltrials.gov/show/NCT01024335||129753|
NCT01012739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2222|Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices|A Randomized, Partially-blinded, Single-dose, 4-way Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Indacaterol Maleate Administered Via the Concept1 Device or Via the Simoon Device||Novartis||Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|75 Years|No|||August 2011|August 25, 2011|November 12, 2009||No||No|July 22, 2011|https://clinicaltrials.gov/show/NCT01012739||130634|
NCT01012986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|reading subtitles in Brazil|"Reading Subtitles Skills in the Elementary School"|"Reading Subtitles Skills in the Elementary School"||University of Sao Paulo|Yes|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|60|||Both|7 Years|9 Years||Probability Sample|students in 2nd and 4th grade|November 2009|November 12, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012986||130615|
NCT01013259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ecorhino|Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis|Explorative Analysis of the Immunomodulatory Capacities of Apathogenic Escherichia Coli Nissle 1917 in Patients With Rhinoconjunctivitis Due to Grass Pollen Allergy|Ecorhino|Charite University, Berlin, Germany|No|Completed|February 2009|October 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|No|||November 2009|November 12, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01013259||130594|
NCT01013272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKUHEP-01|Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load|Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load||The University of Hong Kong|No|Completed|June 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|November 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013272||130593|
NCT01013285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000628787|Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|June 2006|January 2017|Anticipated|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013285||130592|
NCT01013298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-PS-0543-CTIL|Video-guided Percutaneous Tracheostomy (PCT): A Feasibility Study|Video-guided Percutaneous Tracheostomy (PCT): Evaluating the Safety, Efficacy and Simplicity of a Novel Technique||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2010|August 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|90 Years|No|||November 2009|November 12, 2009|November 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013298||130591|
NCT01013311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM12076|Implantable Cardiac Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis|Efficacy if Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis||Virginia Commonwealth University|No|Enrolling by invitation|November 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Multi-center retrospective study. Up to 20 Elctrophysiologists at Academic Centers across        North America|June 2015|June 5, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01013311||130590|
NCT01013584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton 8|The Effect of Weight on Vitamin D Dose Response|The Effect of Weight on Vitamin D Dose Response|Weight|Creighton University|No|Completed|November 2009|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|67|||Male|19 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013584||130570|
NCT01013974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113377|A Study of GSK573719 in Healthy Japanese Male Subjects|Phase I Study of GSK573719 -A Randomized, Double Blind, Placebo Controlled, Dose Ascending, Single and Repeat Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled Dose of GSK573719 From a Novel Dry Powder Device in Healthy Japanese Male Subjects -||GlaxoSmithKline||Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|48|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||March 2011|March 24, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013974||130540|
NCT00993603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Non-DM Lifestyle.|Lifestyle Intervention in Obese Non-diabetic Adults With a Family History of Diabetes.|The Effect of an 8-month Intensive Lifestyle Intervention on Hormonal Factors Regulating Food Intake in Obese, Non-diabetic Adults With a Family History of Diabetes.||The Royal Bournemouth Hospital|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 4, 2012|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993603||132093|
NCT00993590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2008-1234|Mobile CHESS Research on Emergency Medical Services for Children|Mobile CHESS Research on Emergency Medical Services for Children||University of Wisconsin, Madison|Yes|Completed|June 2008|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|219|||Both|12 Years|18 Years|No|||February 2016|February 3, 2016|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00993590||132094|
NCT01026298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1038|Asthma and Obstructive Sleep Apnea (OSA)|The Relationship Between Asthma and Obstructive Sleep Apnea (OSA) - A Pilot Study of the Effects of OSA and Its Treatment on Asthma||University of Wisconsin, Madison|Yes|Recruiting|March 2007|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|46|||Both|18 Years|73 Years|No|||October 2015|October 9, 2015|December 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026298||129603|
NCT01026311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-076|Coenzyme Q10 in Older Athletes Treated With Statin Medications|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Coenzyme Q10 in Improving Mitochondrial Function in Older Athletes Treated With Statin Medications||Ochsner Health System|Yes|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 1, 2012|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01026311||129602|
NCT00994539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORP-T30-PVFS-2|Dose Proportionality and Food Effect of Morphine Sulfate|A Single Dose, Three-Period, Three-Treatment, Six-Sequence, Three-Way Crossover Study of the Dose Proportionality of and Effect of Food on Morphine Sulfate Tablets.||Roxane Laboratories|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 13, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00994539||132021|
NCT00994812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T59108|The Effects of Metformin on Pregnancy and Miscarriage Rates in Polycystic Ovary Syndrome (PCOS)|Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study||University of Oulu|No|Completed|August 2002|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|326|||Female|18 Years|40 Years|No|||October 2009|February 22, 2010|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00994812||132000|
NCT00995371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMD001LB|Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis|Comparative Study of Epidural Steroid Injection Versus Mild® (Minimally Invasive Lumbar Decompression) Procedure in Patients Diagnosed With Symptomatic Moderate to Severe Lumbar Central Canal Stenosis||Coastal Orthopedics & Sports Medicine|No|Completed|August 2009|May 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|October 14, 2009||No||No|July 2, 2013|https://clinicaltrials.gov/show/NCT00995371||131958|
NCT01027052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-03-008-01|Spices Inhibit the Formation and Absorption of Malondialdehyde From Hamburger Meat|Absorption, Metabolism and Antioxidant Effects of Common Herbs||University of California, Los Angeles|No|Completed|June 2008|May 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|August 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01027052||129545|
NCT01027390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-103|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS, Danish Acronym)|VIMS|University of Southern Denmark|No|Completed|January 2010|February 2011|Actual|January 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|573|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 8, 2012|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027390||129519|
NCT00995891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090229|Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies|Collection of Blood, Bone Marrow, Skin Biopsies and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols Laboratory Research Studies||National Institutes of Health Clinical Center (CC)||Recruiting|September 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|99999999|||Both|8 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 5, 2015|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995891||131918|
NCT01027624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CZA-DUM-2009/1|Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia|Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia.|CEPHEUS|AstraZeneca|Yes|Completed|November 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|Multi-centre survey of patients who are currently on lipid-lowering pharmacological        treatment in South Africa.|April 2011|April 14, 2011|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027624||129501|
NCT01023529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1684(REK)|Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers|A Prospective Multicenter Study of Symptoms and QOL in Patients With Prostate and Rectal Cancers Receiving Palliative Pelvic Radiation|PallRad1|Sorlandet Hospital HF|No|Completed|November 2009|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|Symptomatic patients referred for palliative pelvic radiotherapy of prostate and        rectosigmoid cancers.|November 2015|November 17, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023529||129815|
NCT01023542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUILT_01|CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation|A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores≥25|BUILT_01|University of Regensburg|Yes|Recruiting|June 2011|December 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023542||129814|
NCT01024348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gozal123456|Safety and Effectiveness of Tramadex-OD After Knee Arthroscopy|Open-label Study of the Safety and Effectiveness of Short-term Therapy With Extended-release Tramadol (TRAMADEX-OD) in the Management of Pain After Knee Arthroscopy.||Shaare Zedek Medical Center|Yes|Not yet recruiting|December 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||February 2010|February 1, 2010|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01024348||129752|
NCT01024361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120789|Cpap at Delivery Room for Preterm Infants|CPAP Application at Delivery Room at Very Low Birth Weight Infants|CPAP-DR|University of Sao Paulo|Yes|Active, not recruiting|January 2009|December 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|15 Minutes|No|||December 2009|December 21, 2009|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01024361||129751|
NCT01012505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7392-AM-CTIL|The Effect of Exposure to Maternal Human Milk Odor on Physiological State of Preterms.|The Effect of Exposure to Maternal Human Milk Odor on Physiological State of Preterms.||Sheba Medical Center|No|Not yet recruiting|December 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|4 Weeks|No|Non-Probability Sample|preterm infants at least 1 weekk of age no active disease or treatment (like respiratory        support) place in incubator|November 2009|November 12, 2009|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012505||130652|
NCT01012258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62241-054|Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects|Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects|CHANCE|Merck KGaA|No|Completed|February 2009|May 2014|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|November 10, 2009||No||No|July 5, 2012|https://clinicaltrials.gov/show/NCT01012258||130671|
NCT01012752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBC-2009-003B|A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts|A Multicenter, Double-Blind, Placebo-Controlled Study With a Modified Allergen Extract for Specific Immunotherapy in Patients With Seasonal Allergic Rhinitis/Rhinoconjunctivitis||Roxall Medizin||Not yet recruiting|October 2016|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||November 2015|November 2, 2015|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012752||130633|
NCT01012765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BDE01|Effect of Indacaterol on Inspiratory Capacity (IC)|A Randomized, Double-blind, Placebo Controlled, Multicenter, 3-period Crossover Study to Compare the Effect of Indacaterol (150μg o.d.) on Inspiratory Capacity to Placebo in Patients With Moderate COPD, Using Open Label Tiotropium (18μg o.d.) as Active Control||Novartis||Completed|November 2009|||January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|173|||Both|40 Years|N/A|No|||February 2016|February 16, 2016|November 11, 2009||No||No|January 17, 2012|https://clinicaltrials.gov/show/NCT01012765||130632|
NCT01012999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32225|A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain|Pain Control and Patient Satisfaction: a Dosing Study to Determine a Safe and Effective Dose of Intra-nasal Sufentanil to Treat Emergency Department Patients With Moderate to Severe Pain Due to Extremity Trauma||University of Utah|No|Terminated|November 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|70 Years|No|||September 2011|September 28, 2011|November 11, 2009|Yes|Yes|Difficulty enrolling patients|No||https://clinicaltrials.gov/show/NCT01012999||130614|
NCT01013012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0388|Efficacy of Dexamethasone Added to Ramosetron for Preventing Postoperative Nausea and Vomiting in Highly Susceptible Patients Following Spine Surgery|||Yonsei University|Yes|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|94|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013012||130613|
NCT01013025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303|Vantas Implant Retrieval Study|Phave IV, Multicenter, Open-label Study to Collect VANTAS® Implant Retrieval Data From Patients With Advanced Prostate Cancer and Difficult to Remove Implants||Endo Pharmaceuticals|No|Completed|July 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|12|||Male|45 Years|N/A|No|Non-Probability Sample|The study was planned to include approximately 10 patients with locally advanced or        metastatic prostate cancer who satisfied the inclusion and exclusion criteria.|July 2011|July 13, 2011|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013025||130612|
NCT01013610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNK754-0902-1AB|An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease|A Double-Blind, Randomized, Placebo-Controlled, Multiple, Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease||Link Medicine Corporation|Yes|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|110|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 14, 2011|November 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013610||130568|
NCT01013623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORD-STG4SURG-0409|Stage IV Surgery Versus Best Medical Therapy|A Phase III, Randomized Trial of Surgical Resection With or Without BCG Versus Best Medical Therapy as Initial Treatment in Stage IV Melanoma|STG4SURG|John Wayne Cancer Institute|Yes|Terminated|November 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|November 12, 2009||No|Lack of accrual, lack of continued funding.|No||https://clinicaltrials.gov/show/NCT01013623||130567|
NCT01013961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1908|Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia|A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab||Eastern Cooperative Oncology Group|Yes|Terminated|October 2010|July 2018|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|65 Years|N/A|No|||February 2016|February 1, 2016|November 13, 2009|Yes|Yes|Slow accrual|No|December 22, 2015|https://clinicaltrials.gov/show/NCT01013961||130541|
NCT00993980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QEBA-09|Qigong and Exercise Therapy for Low Back Pain in Adults|Randomized Multicenter Trial on the Effectiveness of Qigong and a Stabilizing Exercise Therapy in Patients With Low Back Pain|QEBA|Charite University, Berlin, Germany|No|Completed|October 2009|January 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|20 Years|60 Years|No|||July 2012|July 9, 2012|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00993980||132064|
NCT01026324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00522|Dinaciclib in Treating Patients With Stage III-IV Melanoma|A Phase 1/2 Study of SCH727965 in Patients With Malignant Melanoma||National Cancer Institute (NCI)||Active, not recruiting|September 2009|||October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2014|November 3, 2014|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026324||129601|
NCT01026844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-037|Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced NSCLC||Massachusetts General Hospital|Yes|Terminated|July 2007|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|December 2, 2009|No|Yes|slow enrollment|No|November 25, 2012|https://clinicaltrials.gov/show/NCT01026844||129561|Early termination of study leading to small numbers of subjects analyzed
NCT01026857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST261 DM 01 004|Propionyl-L-Carnitine in Ulcerative Colitis|Phase II, Parallel-group, Placebo Controlled, Double-blind, Randomised, Multicenter Study to Investigate the Efficacy of Two Dosages of Propionyl-L-Carnitine Colon Release Tablets in Patients Affected by Ulcerative Colitis Under Oral Stable Treatment||sigma-tau i.f.r. S.p.A.|No|Completed|May 2006|December 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|75 Years|No|||December 2009|December 16, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01026857||129560|
NCT01027065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-10|Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients|A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients|CONVERT|Cytheris SA|Yes|Active, not recruiting|December 2009|March 2013|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027065||129544|
NCT01027403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234/07|Evaluation of Circulating Levels of Adult Stem Cells in the Peripheral Blood of Patients With Acute Decompensated Heart Failure and Following Stabilization, in Comparison With Healthy Volunteers|Evaluation of Circulating Levels of Adult Stem Cells in the Peripheral Blood of Patients With Acute Decompensated Heart Failure and Following Stabilization, in Comparison With Healthy Volunteers|CIRCSTEM-HF|Monash University|No|Completed|December 2009|December 2014|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|30|Samples Without DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Acute decompensated heart failure and healthy volunteers.|June 2015|June 2, 2015|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027403||129518|
NCT01027637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS-PS1209|Regenerative Tissue Matrix for Breast Reconstruction|In Situ Elasticity of Alloderm® in Breast Reconstruction||Henry Ford Health System|Yes|Completed|January 2010|June 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Female|18 Years|70 Years|No|||December 2009|September 5, 2013|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027637||129500|
NCT01027650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208397-001|Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)|||Allergan|No|Completed|March 2010|February 2013|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|121|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|December 4, 2009|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01027650||129499|
NCT01024114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002678|Study to Evaluate the Diagnostic Value of a Combined Molecular Breast Imaging/ Breast Tomosynthesis Modality|Pilot Study to Evaluate the Incremental Diagnostic Value of a Combined Molecular Breast Imaging / Breast Tomosynthesis Modality||Mayo Clinic|No|Withdrawn|July 2009|||December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Female|25 Years|N/A|No|Non-Probability Sample|All patients will have had a molecular breast imaging study as part of their participation        in one of the current research protocols evaluating this technology. A requirement for        inclusion in this study is that patients will have had a digital mammography examination        at Mayo Clinic within the past 30 days.|April 2012|April 16, 2012|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024114||129770|
NCT01025180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT-F-2005-10|Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection|Randomized Multicentre Prospective Study of Procalcitonin-guided Treatment on Antibiotic Use and Outcome in Severe Sepsis ICU Patients Without Obvious Infection|Pro-SEPS|Brahms France|Yes|Terminated|December 2007|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|62|||Both|18 Years|N/A|No|||December 2009|December 3, 2010|December 1, 2009||No|65 patients were included after 2 years instead of 140|No||https://clinicaltrials.gov/show/NCT01025180||129688|
NCT01012271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Diagnostic Accuracy of Direct MR Arthrography Of The Wrist At 1.5, 3.0 And 7.0T|||University of Zurich||Not yet recruiting|October 2010|December 2012||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|June 2010|June 24, 2010|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012271||130670|
NCT01012531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLU-2008-001|Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen|Efficacy and Safety of Subcutaneous Cluster Immunotherapy With Cluster-allergoid CLUSTOID Grasses/Rye (Glutaraldehyde-polymerized Allergen Extract of Mixtures of Grass and Rye Allergens) in Patients With Allergic Rhinoconjunctivitis Sensitized to Grass and With or Without Rye Pollen Sensitization||Roxall Medizin||Completed|October 2008|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|75 Years|No|||November 2009|July 13, 2011|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012531||130650|
NCT01012518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-PS-0544-CTIL|Video-guided Percutaneous Tracheostomy (PCT) Versus Conventional PCT: Comparing Safety and Efficacy|Video-guided Percutaneous Tracheostomy (PCT): Evaluating the Safety, Efficacy and Simplicity of a Novel Technique, Compared to Conventional PCT||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2010|February 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|90 Years|No|||November 2009|November 12, 2009|November 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01012518||130651|
NCT01012778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAJMDKV2007|Implementation of Climb Up Program for Children With Attention Deficit Hyperactivity Disorder (ADHD) and Dyslexia in a School in India|Implementation of a Multimodal Program Including Yoga and Meditation as Well as Play Therapy for ADHD and Dyslexia in a Public School in Najibabad, India|ClimbUp|Climb Up Kids||Completed|May 2007|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|6 Years|11 Years|No|||August 2015|August 3, 2015|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01012778||130631|
NCT01012791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000597|Does Zumba Improve Cognition in Healthy APOE e4 Carriers and Noncarriers|Does Zumba Improve Cognition in Healthy APOE e4 Carriers and Noncarriers||Mayo Clinic||Completed|November 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Female|55 Years|80 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012791||130630|
NCT01013324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD11436|Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer|A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Cancer||Sanofi|Yes|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|N/A|No|||March 2013|April 9, 2013|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013324||130589|
NCT01013597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0173|Trial of LBH589 in Metastatic Thyroid Cancer|A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer||University of Wisconsin, Madison|Yes|Completed|January 2010|February 2016|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013597||130569|
NCT01013350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700568-012|Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials|Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials|PREMIERE|EMD Serono|Yes|Recruiting|November 2009|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1190|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with Multiple Sclerosis and had already participated in Sponsor oral cladribine        clinical development trials|March 2016|March 23, 2016|November 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013350||130587|
NCT01013649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01987|Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery|A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma||National Cancer Institute (NCI)|Yes|Recruiting|November 2009|||August 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|950|||Both|18 Years|N/A|No|||October 2015|March 24, 2016|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013649||130565|
NCT01013337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07109|Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain|Acupuncture and Aromatase Inhibitor Related Arthralgia||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|May 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Female|18 Years|N/A|No|||October 2012|October 11, 2012|November 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013337||130588|
NCT01025999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36417-A|Mechanisms of Glycemic Improvement After Gastrointestinal Surgery|Mechanisms of Glycemic Improvement After Gastrointestinal Surgery||University of Washington|Yes|Completed|January 2010|June 2015|Actual|June 2015|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|Samples Without DNA|Plasma collected to measure markers of metabolic activity.|Both|18 Years|N/A|No|Non-Probability Sample|Patients planning to undergo RYGB at UWMC with planned placement of gastrostomy tube.|March 2016|March 22, 2016|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025999||129625|
NCT01026272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35083-B|Novel Immune Markers in Patients With Multiple Sclerosis|Quantification of Novel Immune Markers in Human Serum of Patients With MS|NIMMS|University of Washington|No|Recruiting|January 2010|May 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Multiple Sclerosis|July 2010|July 9, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01026272||129605|
NCT01026285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016630|InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics|Observational, Non-interventional Registry to Assess Medication Usage Patterns in Clinical Routine Practice, in Subjects Receiving Antipsychotic Treatment With Risperidone Long Acting Injectable (Gluteal or Deltoid) or Oral Antipsychotics||Janssen-Cilag International NV|No|Completed|June 2009|March 2012|Actual|March 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|1085|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with schizophrenia|June 2013|June 21, 2013|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026285||129604|
NCT01026883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-290909|Evaluation of a Novel Method for Hematocrit Level Determination|Evaluation of a Novel Method for Hematocrit Level Determination||Medical University of Vienna|Yes|Terminated|April 2010|November 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|51|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01026883||129558|
NCT01026597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-0902|Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers|A Randomized,Double-Blind,Placebo-Controlled,Ascending,Single-Dose Study of the Safety,Tolerability and Bioeffect of Intravenously Administered REGN727 in Healthy Volunteers||Regeneron Pharmaceuticals|No|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|January 24, 2015|November 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026597||129580|
NCT01026870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06115|Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)|A 12-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids||Merck Sharp & Dohme Corp.|No|Withdrawn|June 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|N/A|No|||May 2015|May 28, 2015|December 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026870||129559|
NCT01027078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0212|Mechanism of Endothelial Dysfunction in Obstructive Sleep Apnea (OSA)|Mechanism of Endothelial Dysfunction in Obstructive Sleep Apnea||Ohio State University|Yes|Recruiting|November 2009|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|72|Samples With DNA|skin biopsies|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants: will be 36 patients with newly diagnosed OSA and 36 age and BMI matched        controls.        Patients with OSA will be enrolled from the sleep disorders center at OSU among patients        who underwent a recent (past 4 weeks) polysomnography that is positive for OSA, and never        were treated with CPAP.        Inclusion criteria will be AHI > 15 events per hours.|October 2015|October 19, 2015|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027078||129543|
NCT01023555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZMC-bromi|Increasing the Yield of Blood Cultures in Neonates|Increasing the Yield of Blood Cultures in the Neonatal Intensive Care Unit- A Prospective Controlled Trial||Shaare Zedek Medical Center|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1500|||Both|N/A|N/A|No|||July 2011|July 24, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023555||129813|
NCT01023867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-03-039|Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia|Comparative Assessment of Clinical Efficacy of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia||Samsung Medical Center|Yes|Completed|March 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|N/A|N/A|No|||January 2016|January 4, 2016|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023867||129789|
NCT01027663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0559|Impact of Host Iron Status and Iron Supplement Use on Erythrocytic Stage of Plasmodium Falciparum|Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum||University of North Carolina, Chapel Hill|No|Recruiting|November 2009|January 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027663||129498|
NCT01023880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18770/2043|Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy|An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy||Teva Pharmaceutical Industries||Terminated|January 2010|January 2013|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01023880||129788|
NCT01024127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B11|Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia|Genetic Predictors of AML Treatment Response||Children's Oncology Group|No|Active, not recruiting|December 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2500|Samples With DNA|blood and bone marrow|Both|N/A|30 Years|No|Probability Sample|Diagnosis of AML in remission|May 2015|May 6, 2015|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024127||129769|
NCT01012297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-01738|Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma|A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus||National Cancer Institute (NCI)||Completed|November 2009|||September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Female|18 Years|N/A|No|||November 2015|November 11, 2015|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012297||130668|
NCT01012310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1351002|Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects|A Double Blind, 3rd Party Open, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects||Pfizer|No|Completed|November 2009|April 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 15, 2010|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012310||130667|
NCT01012804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000078662|Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer|Assessment of Variation of PKA and Other Molecular Markers in Patients Undergoing Resection of Colon Cancer Metastases||Georgetown University|No|Withdrawn|January 2000|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|patients with colorectal cancer|March 2011|March 23, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012804||130629|
NCT01013038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008B101|Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study|Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II)|TAPAS II|University Medical Center Groningen|No|Recruiting|December 2007|June 2012|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||November 2009|November 12, 2009|November 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013038||130611|
NCT01013051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0002122|Effect of Gastric Bypass on the Absorption of Metformin|Effect of Gastric Bypass on the Absorption of Metformin|ABSORB-Met|University of Alberta|No|Completed|September 2009|December 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|34|||Both|18 Years|60 Years|No|Probability Sample|Post gastric bypass and obese controls          1. Male and Female          2. 18 - 60 years old          3. ≥ 3 months post-RYGB surgery or wait listed for bariatric surgery          4. Able to provide written informed consent.|March 2011|March 2, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013051||130610|
NCT01013363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0439|The Use of Music for Pain and Anxiety Control During Abortion|Music as an Auxiliary Analgesic and Anxiolytic During First Trimester Abortion||Columbia University|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2012|November 16, 2012|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01013363||130586|
NCT01013662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|scap1501|Lipid Profile in Patients With Severe Sepsis or Septic Shock Under Strict or Liberal Glycemic Control|Tight Glycemic Control and Sepsis Related Dyslipidemia||University of Sao Paulo|No|Completed|January 2005|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|69|||Both|18 Years|80 Years|No|||November 2009|August 2, 2011|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013662||130564|
NCT01025739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004475|Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD|Phase II Study of Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD||University of Alberta|Yes|Withdrawn|January 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||April 2015|April 27, 2015|December 2, 2009|Yes|Yes|No funding source for device purchasing|No||https://clinicaltrials.gov/show/NCT01025739||129645|
NCT01026012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040189|Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing|Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing|Rega Stress|University of Maryland|Yes|Completed|December 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|90 Years|No|||December 2014|December 18, 2014|November 30, 2009|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01026012||129624|
NCT01026896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mental Practice in Stroke|Mental Practice Efficacy in Stroke-Induced Hemiparesis|Mental Practice in Chronic Stroke-Induced Hemiparesis||National Center for Complementary and Integrative Health (NCCIH)||Active, not recruiting|September 2009|September 2014|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|75 Years|No|||December 2009|December 4, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01026896||129557|
NCT01026610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVCL007|Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B|A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy and Safety at Week 24 of the Treatment for Selecting Optimal Dose||LG Life Sciences|No|Completed|August 2009|May 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|115|||Both|18 Years|65 Years|No|||October 2012|October 4, 2012|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026610||129579|
NCT01027416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPCI I 110907|Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients|Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients||Roswell Park Cancer Institute|Yes|Completed|December 2009|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Female|18 Years|N/A|No|||January 2016|January 8, 2016|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027416||129517|
NCT01027091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/06-11-09|The Study of a Safe and Cost-effective Method to Identify Patients at Low Risk of Significant Hypocalcemia After Total Thyroidectomy.|The Study of a Safe and Cost-effective Method to Identify Patients at Low Risk for the Development of Significant Hypocalcemia After Total Thyroidectomy.||G. Hatzikosta General Hospital||Recruiting|November 2008|January 2011|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|16 Years|80 Years|No|Probability Sample|patients with any thyroid pathology undergoing total thyroidectomy regardless of gender,        age and medication|November 2009|December 4, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027091||129542|
NCT01027104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-13313|Evaluation of a Resident Curriculum in Firearm Injury Prevention|Evaluation of a Firearm Injury Prevention Web-based Curriculum||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|December 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|92|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2009|December 4, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027104||129541|
NCT01023568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-902|Comparison of Direct Laryngoscopy, Truview EVO2 and Glidescope in Pediatric Patients|Comparison of Direct Laryngoscopy, Truview EVO2 and Glidescope in Pediatric Patients||Outcomes Research Consortium|No|Terminated|December 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|134|||Both|N/A|10 Years|No|||September 2011|September 13, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023568||129812|
NCT01023581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322MET_302|Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes|AM7D|Takeda|Yes|Completed|November 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|784|||Both|18 Years|80 Years|No|||February 2013|February 17, 2013|December 1, 2009|Yes|Yes||No|February 17, 2013|https://clinicaltrials.gov/show/NCT01023581||129811|
NCT01023893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-0062-201|Blood Viscosity, End-Stage Renal Disease, And Mortality (BEAM-1)|Clinical Diagnostic Evaluation Study of Blood Viscosity, End-Stage Renal Disease, And Mortality|BEAM-1|ProMetrics, Inc.|No|Enrolling by invitation|November 2009|||November 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Dialysis clinic|December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023893||129787|
NCT01024621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009SDU-QILU-G06|Confocal Laser Endomicroscopy for the Detection of Gastric Intestinal Metaplasia: a Randomized Controlled Trial|Comparison of Confocal Laser Endomicroscopy With Standard Endoscopy for the Detection and Evaluation of Gastric Intestinal Metaplasia in a High Risk Population: A Randomized Controlled Trial||Shandong University|Yes|Completed|November 2009|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|168|||Both|40 Years|80 Years|No|||July 2012|July 16, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024621||129731|
NCT01024907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08309|Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas|Proton Radiation for Low Grade Gliomas||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|July 2009|||February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024907||129709|
NCT01024920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.26|Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.|A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer||Boehringer Ingelheim||Active, not recruiting|December 2009|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|99|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 24, 2009||||No||https://clinicaltrials.gov/show/NCT01024920||129708|
NCT01012011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14792|Regulatory Post Marketing Surveillance Study on Nexavar®|Regulatory Post Marketing Surveillance Study on Nexavar®||Bayer|No|Completed|September 2009|August 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2845|None Retained|n.a|Both|20 Years|91 Years|No|Non-Probability Sample|Patients with diagnosis of advanced renal cell carcinoma or hepatocellular carcinoma and        decision taken by the physician to precribe Nexavar|September 2015|September 18, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012011||130689|
NCT01012323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGAM01|Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases|Clinical Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam)in Patients With Primary Immunodeficiency Diseases|Newgam|Octapharma|Yes|Completed|November 2009|August 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|2 Years|75 Years|No|||August 2012|August 24, 2012|November 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01012323||130666|
NCT01012544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPCAT01|Platelet Reactivity in Stent Thrombosis Patients|The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).|MAPCAT|St. Antonius Hospital|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|187|||Both|18 Years|90 Years|No|||August 2011|August 22, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012544||130649|
NCT01012817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-00312|Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer|A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy||National Cancer Institute (NCI)||Suspended|October 2009|||June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 11, 2009|Yes|Yes|Completion of dose escalation phase|No||https://clinicaltrials.gov/show/NCT01012817||130628|
NCT01013064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-HM10760A-102|A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects|A Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics and Pharmacokinetics of Single Intravenous Doses of HM10760A in Healthy Adult Korean Subjects||Hanmi Pharmaceutical Company Limited|Yes|Completed|November 2009|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|48|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01013064||130609|
NCT01013077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11|The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability|The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability.||Southern California College of Optometry|No|Completed|November 2009|August 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 29, 2012|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01013077||130608|
NCT01013389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0702PLF|Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion (PLIF) With Interbody Fusion|A Prospective, Randomised Study Comparing the Use of Actifuse (Trademark)ABX Synthetic Bone Substitute With INFUSE (Registrered Trademark) in Patients Requiring Posterolateral Instrumented Lumbar Fusion With Interbody Fusion|APPRAISET1|Apatech, Inc.|Yes|Completed|June 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||November 2013|March 10, 2016|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01013389||130584|
NCT01013402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-012009|Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia|Phase IV Study to Compare the Accuracy and Precission of Five Different Home Glucose Monitors;Optium Xceed, Contour Ts, Accu-chek Go, One Touch Select and Ez Smart||Gulhane School of Medicine|No|Completed|December 2008|August 2009|Actual|April 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|51|||Both|N/A|N/A|No|||November 2009|November 12, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013402||130583|
NCT01013675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S203.2.009|Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly|Randomized, Double-blind, Active -Controlled Trial to Assess Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine, Including Revaccination, in Elderly Subjects||Abbott|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|622|||Both|61 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 26, 2011|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013675||130563|
NCT01025752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-058|Interactive Voice Response (IVR)-Based Treatment for Chronic Low Back Pain|IVR-based Cognitive Behavior Therapy for Chronic Low Back||VA Office of Research and Development|No|Active, not recruiting|May 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025752||129644|
NCT01026025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS09003|Duet TRS Used in Pulmonary Resections|A Prospective, Multi-Center Evaluation of Endo GIA Staplers With Endo GIA Single Use Loading Units (SULUs) With Duet TRS TM in a Pulmonary Resection||Medtronic - MITG|No|Withdrawn|January 2011|June 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 5, 2013|December 3, 2009||No|Sponsor is no longer pursuing this study|No||https://clinicaltrials.gov/show/NCT01026025||129623|
NCT01026909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEF-24812|Intraarticular Corticosteroid Therapy in Perthes Disease.|Intraarticular Corticosteroid Therapy in Legg-Calve Perthes Disease: a Randomized Controlled Clinical Trial.||Seattle Children's Hospital|Yes|Terminated|March 2009|January 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|4 Years|13 Years|No|||December 2015|December 22, 2015|October 6, 2009|Yes|Yes|low recruitment|No|November 22, 2014|https://clinicaltrials.gov/show/NCT01026909||129556|
NCT01027117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481275|A Relative Bioavailability Study of Revatio for the Crushed Tablets, Extemporaneously Prepared Formulation, and the Intact Tablets at 20 mg Dose in Healthy Volunteers|A Randomised, Open-Label 3-Way Crossover Study To Investigate The Relative Bioavailability Of The Crushed Revatio 20 Mg Tablet Mixed With Apple Sauce, The Extemporaneously Prepared Suspension (EP), And The Intact Revatio 20 Mg Tablet In Healthy Volunteers Under Fasting Conditions||Pfizer|No|Completed|September 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 11, 2010|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01027117||129540|
NCT01027130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPPET|Haptoglobin and Preeclampsia|||Bnai Zion Medical Center|No|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Female|N/A|N/A||Non-Probability Sample|women coming to give birth at our medical center|December 2009|December 4, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027130||129539|
NCT01027429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC134GL50124|Simplified Antibiotic Therapy for Sepsis in Young Infants|Simplified Antibiotic Regimens for the Management of Sepsis in Young Infants in First-level Facilities: Randomized Controlled Trial|SATT|Aga Khan University|Yes|Completed|December 2009|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2543|||Both|N/A|59 Days|No|||June 2015|June 26, 2015|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027429||129516|
NCT01027676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-09-433|Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)|Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)||National Cancer Center, Korea|No|Active, not recruiting|June 2010|March 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01027676||129497|
NCT01027689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131018|Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation|Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet||Pfizer|No|Withdrawn|April 2011|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 29, 2012|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027689||129496|
NCT01024140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEY-608|Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder|Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder||Northern California Institute of Research and Education|No|Completed|February 2003|December 2004|Actual|December 2004|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|20 Years|60 Years|No|||December 2009|December 1, 2009|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01024140||129768|
NCT01024374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|All-E-M-13244-01/02-10-09|Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face|Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face.|13244/2009|Allergisa Pesquisa Dermato-Cosmetica LTDA|No|Not yet recruiting|April 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects with seborrheic dermatitis on both sides of the face, both sexes, aged 18        to 60 years, skin types I through IV.|December 2009|December 1, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024374||129750|
NCT01024400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-33|Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women|Etude de Phase II évaluant l'immunogénicité et la tolérance d'un Vaccin inactivé Non adjuvanté Contre la Grippe A(H1N1)v Chez la Femme Enceinte|PREFLUVAC|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|November 2009|July 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Female|18 Years|45 Years|No|||March 2011|December 29, 2011|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024400||129748|
NCT01024647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMZ-2010|Optimizing Cimzia in Crohn's Patients|Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy||Atlanta Gastroenterology Associates|No|Recruiting|December 2009|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|December 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01024647||129729|
NCT01024660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285M00010|The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil|A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer's Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 Weeks||AstraZeneca|No|Completed|December 2009|January 2011|Actual|January 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|155|||Both|55 Years|85 Years|No|||February 2011|February 6, 2011|December 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024660||129728|
NCT01012336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-119|Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin|Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin||Samsung Medical Center||Completed|May 2010|April 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Female|20 Years|80 Years|No|||October 2012|October 8, 2012|November 10, 2009||No||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01012336||130665|
NCT01012557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1N1v|H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women|H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza AH1N1v Vaccination in Pregnant Women||Copenhagen Studies on Asthma in Childhood|Yes|Completed|November 2009|December 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|296|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2015|February 4, 2015|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012557||130648|
NCT01012570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM-07-019|The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients|||University of Zurich||Terminated|August 2009|||August 2011|Actual|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|65 Years|No|Probability Sample|Patients cohort of the University Hospital Zurich|December 2014|December 3, 2014|November 11, 2009||No|not enough patients enrolled|No||https://clinicaltrials.gov/show/NCT01012570||130647|
NCT01012830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|636-631|Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia|Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia||VA Nebraska Western Iowa Health Care System|No|Not yet recruiting|December 2009|April 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|59 Years|No|||November 2009|November 12, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012830||130627|
NCT01013090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-200911-MZ020|Fluid Volume-hypotension Association in Cesarean Under Neuraxial Anesthesia|Fluid Volume-hypotension Association in Elective Cesarean Section Under Neuraxial Anesthesia|VOHOCUNA|Nanjing Medical University|Yes|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|1000|||Female|21 Years|40 Years|No|||December 2009|December 22, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013090||130607|
NCT01013701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00029405|Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease|A Randomized, Doubel-Blind, Placebo-Controlled, Parallel-Group, Single Center Study to Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease||Johns Hopkins University|Yes|Not yet recruiting|November 2009|November 2010|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2009|November 13, 2009|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013701||130561|
NCT01013714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA09-07-100-01|Cardiac Sympathetic Denervation Surgery for Prevention of Ventricular Tacharrhythmias|Prophylactic Bilateral Cervicothoracic Sympathectomy for Prevention of Ventricular Tachyarrhythmias|PREVENT VT|University of California, Los Angeles|Yes|Not yet recruiting|July 2016|July 2021|Anticipated|July 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|322|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013714||130560|
NCT01013688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wangxin|Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease|Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease||China National Center for Cardiovascular Diseases|Yes|Recruiting|March 2008|May 2010|Anticipated|May 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||November 2009|November 16, 2009|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013688||130562|
NCT01026038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-3021|Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.|A Phase 3, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Pneumococcal Conjugate Vaccine in Healthy Children Who Have Been Previously Immunized With a 4-Dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 6096A1-008-EU and the Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Administered at Least 24 Months After the Last Toddler Dose of Pneumococcal Conjugate Vaccine||Pfizer|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|263|||Both|3 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 5, 2012|December 2, 2009|Yes|Yes||No|October 25, 2011|https://clinicaltrials.gov/show/NCT01026038||129622|
NCT01026051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC1106-MT-002|Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma|A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma||Mannkind Corporation|No|Terminated|October 2010|July 2012|Anticipated|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|December 3, 2009|Yes|Yes|Financial/Business Reasons|No||https://clinicaltrials.gov/show/NCT01026051||129621|
NCT01026337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03809|Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer|An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic or Locally Advanced Renal Cell Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|April 2009|||April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026337||129600|
NCT01026623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01406|Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer|Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration-Resistant Prostate Cancer (CRPC)||National Cancer Institute (NCI)||Completed|October 2009|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|N/A|No|||January 2016|January 21, 2016|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026623||129578|
NCT01027143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCJELK23|Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids|Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids|NOOA|Nemours Children's Clinic|Yes|Recruiting|July 2010|March 2016|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|25 Years|No|||October 2010|May 5, 2015|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027143||129538|
NCT01027156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI Intervention|The Influence of a High Intensity Physical Activity Intervention on a Selection of Health Related Outcomes: An Ecological Approach|||University of the West of Scotland|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Primary Purpose: Prevention|1||||||Both|15 Years|18 Years|Accepts Healthy Volunteers|||December 2009|December 4, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027156||129537|
NCT01027442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stereolithographic guides|The Use of Bone-, Tooth- and Mucosa- Supported Stereolithographic Guides for Dental Implant Placement|Conventional Versus Computer Aided Implantology|stereolitho|Istanbul University|No|Completed|July 2008|December 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2007|November 26, 2013|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027442||129515|
NCT01027702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCH BMT 09-02|Donor Lymphocyte Infusion After Alternative Donor Transplantation|Phase I/II Study of Donor Lymphocyte Infusion With Methotrexate GVHD Prophylaxis to Hasten Immune Reconstitution After CD34+ Cell-Selected Transplant||Carolinas Healthcare System|Yes|Recruiting|August 2009|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|30 Years|No|||February 2016|February 5, 2016|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027702||129495|
NCT01024387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-240|AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors|A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors||Dana-Farber Cancer Institute|Yes|Active, not recruiting|March 2010|||November 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01024387||129749|
NCT01024634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC 09599|Vascular and Neuro-inflammatory Effects of Endurance Exercise Training in African Americans|Vascular and Neuro-inflammatory Effects of Endurance Exercise Training in African Americans|VINE|University of Illinois at Urbana-Champaign|Yes|Completed|September 2009|December 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024634||129730|
NCT00994968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650694|Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer|Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel and S-1 in Breast Cancer||National Cancer Institute (NCI)||Recruiting|July 2009|||||Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Female|18 Years|N/A|No|||October 2009|October 28, 2010|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994968||131988|
NCT00995215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB08-00269/IRB98-00091|Sub-study to Spinal Cord Stimulation to Restore Cough|Evaluation of Wire Electrodes to Activate the Expiratory Muscles to Restore Cough||Case Western Reserve University|Yes|Active, not recruiting|October 2009|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|70 Years|No|||April 2015|April 20, 2015|October 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995215||131970|
NCT00995228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-IM-0501-CTIL|Fluid Management in the Post-Anesthetic Care Unit (PACU) at Sourasky Medical Center|The Practice of Fluid Management in the Post-anesthetic Care Unit (PACU) in Patients Undergoing Elective Surgery: an Observational Study||Tel-Aviv Sourasky Medical Center|Yes|Active, not recruiting|March 2009|December 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|patients from both sexes >18 y/o, undergoing elective general or orthopedic surgery|October 2009|October 14, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995228||131969|
NCT01012349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AASGEO0809|Efficacy and Safety Clinical Trial of the Combination of Acetylsalicylic Acid, Sodium Bicarbonate and Citric Acid, Produced by Geolab Pharmaceutical Industries Ltd., Compared to Acetylsalicylic Acid (Aspirin ® - Bayer) in Patients With Episodic Tension-type Headache.|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Not yet recruiting|February 2011|August 2011|Anticipated|May 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||October 2010|January 27, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012349||130664|
NCT01012583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT-001|Optical Coherence TomOgraphy Assessment of the Drug-Eluting Stent|Optical Coherence TomOgraphy Assessment of the Excel Drug-Eluting Stent With BiodegradablE polymeR vs. the Cypher Drug-Eluting Stent With Permanent Polymer|OCTOBER|Chinese PLA General Hospital||Not yet recruiting|November 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1|||Both|18 Years|75 Years|No|Probability Sample|This study intends to enroll up to 100 patients from a single center in China. Patients        will be randomized in a 1:1 fashion, Excel DES:Cypher DES.|November 2009|November 12, 2009|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012583||130646|
NCT01012843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTF-001|Do Antibiotics Prevent Anal Fistulae Formation?|Does Adjuvant Antibiotic Treatment After Drainage of Anorectal Abscess Prevent the Development of Anal Fistulae? A Prospective Randomized, Placebo Controlled, Double Blind, Multi-Center Clinical Study||Ankara University|No|Completed|September 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|151|||Both|18 Years|N/A|No|||November 2009|November 13, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012843||130626|
NCT01013103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-1002009|Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients|Effects of Atorvastatin on Endothelial Function, Vascular and Myocardial Redox State in High Cardiovascular Risk Patients||Hippocration General Hospital|No|Completed|October 2007|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|72|||Both|30 Years|80 Years|No|||March 2012|March 16, 2012|November 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01013103||130606|
NCT01013376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1101-CBF-01|A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD|A Pilot, Single-Center, Open-Label Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Non-exudative Age-Related Macular Degeneration||MacuCLEAR, Inc.|No|Completed|August 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 12, 2009|November 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013376||130585|
NCT01021501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZSYIC002|The Pharmacokinetics of Nifedipine Controlled Release Tablets in Hypertensive Patients on Hemodialysis|the Effect of Nifedipine Controlled Release Tablets in Hypertensive Patients on Chronic Maintenance Hemodialysis and the Influence of Hemodialysis on the Plasma Concentration of Nifedipine|PICASSO|Guangzhou First Municipal People’s Hospital|Yes|Not yet recruiting|December 2009|April 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|75 Years|No|||November 2009|November 27, 2009|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021501||129970|
NCT01014052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET IRD 01|Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations|Phase 1b Study to Evaluate QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)||QLT Inc.|No|Completed|November 2009|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|5 Years|65 Years|No|||May 2013|May 13, 2013|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01014052||130534|
NCT01026350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4811344-HMO-CTIL|Safety and Efficacy of Oral Colostrum Derived Anti Influenza Antibodies in Healthy Volunteers|||Hadassah Medical Organization||Not yet recruiting|January 2010|||January 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||November 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026350||129599|
NCT01026636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012304|A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age|An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients =3 Months to 17<18 Years of Age, Undergoing Treatment With Systemic Antibiotics||Basilea Pharmaceutica|No|Completed|August 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|64|||Both|3 Months|18 Years|No|||July 2012|July 26, 2012|December 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026636||129577|
NCT01027715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0888|The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy|The Impact of Electroencephalographic (EEG) Seizure Treatment in Near Term ≥ 36 Weeks Gestation and Term Infants With Neonatal Encephalopathy||Washington University School of Medicine|Yes|Completed|January 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|N/A|72 Hours|No|||December 2015|December 8, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01027715||129494|
NCT01027728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL003_354|Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis|CARAT-1|ChemoCentryx|Yes|Completed|December 2009|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|No|||February 2012|February 8, 2012|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027728||129493|
NCT01027169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28696|A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics|An Open-label, Parallel-group, Single Centre, Single Oral Dose Study to Investigate the Pharmacokinetics of 50 mg Safinamide in Subjects With Mild and Moderate Hepatic Impairment as Compared to Matched Subjects With Normal Hepatic Function||Newron||Completed|April 2009|||October 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2011|March 27, 2013|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01027169||129536|
NCT01027182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAL|Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers|Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers.||Changi General Hospital|No|Completed|December 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 18, 2010|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027182||129535|
NCT01027741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000708|Integrating Cancer Control Referrals and Navigators Into United Way 211 Missouri|Integrating Cancer Control Referrals and Navigators Into United Way 211 Missouri||Washington University School of Medicine|Yes|Recruiting|December 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|9696|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 24, 2010|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027741||129492|
NCT01023594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0908-040-290|Comparison of Feasibility Between Internal and External Pancreatic Drainage in Pancreaticoduodenectomy|Comparison of Feasibility Between Internal and External Pancreatic Drainage in Pancreaticoduodenectomy: Prospective Randomized Study||Seoul National University Hospital|Yes|Active, not recruiting|January 2010|January 2016|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|328|||Both|20 Years|85 Years|No|||September 2015|September 14, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023594||129810|
NCT01023919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMUOCT-DM vs NDM-2|Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus|Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography||Harbin Medical University||Recruiting|November 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||December 2009|March 29, 2010|December 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023919||129785|
NCT01024166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0776|Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study|A Usability Study of Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: Integrating PROs and Decision Support Into an Electronic Record||M.D. Anderson Cancer Center|No|Completed|November 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|18|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Palliative care patients receiving care at University of Texas MD Anderson Cancer Center        and their caregivers, physicians and nurses, all over the age of 21.|June 2013|June 6, 2013|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024166||129766|
NCT00994721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3207|A Phase III Study of Pancreatic Cancer|A Randomized Phase III Study of Adjuvant Gemcitabine Versus Gemcitabine Plus Concurrent Chemoradiation in Pancreatic Cancer Underwent Curative Intent (R0 / R1) Resection||National Health Research Institutes, Taiwan|Yes|Enrolling by invitation|February 2009|January 2015|Anticipated|January 2012|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|265|||Both|20 Years|75 Years|No|Probability Sample|We anticipate the 2-year disease free survival will increase from 25% to 40% with the        incorporation of CCRT into the adjuvant treatment for post-operative pancreatic        andenocarcinoma. With a significant level of 0.05,107 patients will be required for each        treatment arm to reach 80% statistical power. Since the drop out rate is approximately        10%, 265 patients will be enrolled to ensure that we will have 214(107x2) eligible        patients in this study. We anticipate that we will recruit roughly 67 patients per year,        therefore, patient recruitment will be completed in 4 years.|October 2009|October 11, 2009|March 26, 2008||No||No||https://clinicaltrials.gov/show/NCT00994721||132007|
NCT00994981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg-study|Magnesium Administration in Liver Transplantation and Reperfusion Injury|Does Pretreated Magnesium Protect Against Reperfusion Injury in Liver Transplanted Patients?||The Catholic University of Korea|Yes|Completed|September 2007|October 2008|Actual|September 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|61|||Both|20 Years|65 Years|No|||November 2011|November 27, 2011|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994981||131987|
NCT01012609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-014|External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas|A Phase II Trial of External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas (POE08-01)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2009|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|51|||Both|3 Years|21 Years|No|||October 2015|October 1, 2015|November 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012609||130644|
NCT01012596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34487|Creighton Model Effectiveness, Intentions and Behaviors Assessment (CEIBA)|Effectiveness, Intention, and Behavior in Creighton Model NFP Use|CEIBA|University of Utah|No|Completed|October 2009|May 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|624|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will enroll couples who are new or return Creighton Model (CrM) users and who        are trying to avoid a pregnancy at the time they begin use of the CrM. The participants        will be recruited from several CrM FertilityCare Centers across the United States and        Canada. Participants who do not live near a center will be offered long distance teaching.|May 2013|May 13, 2013|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01012596||130645|
NCT01012856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP00P1_ 123377|Randomized Clinical Trial of an Exposure-based Cognitive Therapy for Depression|Explicit and Implicit Change of Depression in Exposure-based Cognitive Therapy||University of Zurich|No|Active, not recruiting|January 2010|March 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012856||130625|
NCT01013415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU #8829-99|CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients|A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients|CD4-ZETA|University of Pennsylvania|No|Active, not recruiting|September 2001|June 2016|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|N/A|N/A|No|||January 2013|January 31, 2013|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013415||130582|
NCT01013428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|FLEX-Trial: Prospective Sonographic Assessment Of Healing Process Following Suture of Profound Flexor Tendon Due to Traumatic Rupture of FDP-Tendon in Zone II.|||University of Zurich||Recruiting|November 2009|December 2011||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|June 2010|June 24, 2010|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01013428||130581|
NCT01022268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1330|Understanding Childhood Infection, Inflammation and Allergy|A Comprehensive, Long-term Integrated Programme to Study the Aetiology and Immunopathology of Childhood Infectious, Inflammatory and Allergic Disease, Using the Large Patient Base of Children Attending St Mary's Hospital, London||Imperial College London|No|Recruiting|July 2009|September 2014|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Serum Plasma DNA RNA|Both|N/A|16 Years|No|Non-Probability Sample|Unwell children coming to St Mary's Hospital through any route (Emergency Department,        wards, intensive care)|November 2011|November 4, 2011|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01022268||129911|
NCT01021774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08493(REK)|Anal Fistula Treatment Outcome - Collagen Plug Versus Advancement Flap Surgery|Comparison of Anal Fistula Treatment Outcome - Collagen Plug vs Advancement Flap Surgery. A Randomised Prospective Blinded Multi-centre Study||University Hospital, Akershus|No|Active, not recruiting|November 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||December 2015|December 29, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01021774||129949|
NCT01021787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN.750.06|Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream|Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF 40 Sunscreen Cream With Micronized TiO2 and Anthelios SX SPF 40 Cream (With Pigmentary TiO2) Into the Stratum Corneum of Compromised (Induced Sunburn) Human Skin||Loreal USA|No|Completed|December 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2009|June 13, 2011|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021787||129948|
NCT01026363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001050/1|hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease|hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease||Massachusetts General Hospital|No|Withdrawn|December 2009|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|December 2, 2009||No|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT01026363||129598|
NCT01026376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015037|An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)|An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)||Janssen-Cilag Farmaceutica Ltda.||No longer available|June 2008|November 2011|Actual|November 2011|Actual|Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||April 2013|April 17, 2013|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026376||129597|
NCT01026649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_CVC two stage|The 2-stage Approach for Reducing Posterior Wall Puncture During the Internal Jugular Vein Catheterization|||Seoul National University Hospital|No|Recruiting|November 2009|||December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|334|||Both|19 Years|80 Years|No|||November 2011|November 10, 2011|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01026649||129576|
NCT01026662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eMatrixCO2 Preab|In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue|In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue|eMatrixCO2|Syneron Medical||Active, not recruiting|November 2009|||April 2010|Actual|Phase 2/Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|Samples Without DNA|Abdominal Skin tissue|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Subjects scheduled for an abdominoplasty surgery|November 2014|November 28, 2014|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026662||129575|
NCT01026675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-027|Early Screening for Gestational Diabetes Mellitus|Early Screening for Gestational Diabetes Mellitus|DG2|Université de Sherbrooke|No|Completed|April 2009|May 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1442|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women|January 2016|January 4, 2016|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026675||129574|
NCT01027221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT2010|Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer|Randomised Phase I/II Trial in Order to Evaluate the Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Neoadjuvant Low-Dose-Radiation Therapy in Primarily Resectable Pancreatic Cancer|IMPACT2010|German Cancer Research Center|Yes|Recruiting|November 2009|December 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|50 Years|N/A|No|||April 2012|April 5, 2012|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027221||129532|
NCT01023607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMUOCT-STATIN|Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT) Combined With Intravascular Ultrasound (IVUS)|Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT)Combined With Intravascular Ultrasound (IVUS)||Harbin Medical University|No|Completed|December 2009|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|75 Years|No|||September 2013|September 10, 2013|December 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023607||129809|
NCT00993824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03901-09-C|Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes|Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes||HealthPartners Institute|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|No|||February 2014|November 25, 2015|October 12, 2009||No||No|September 5, 2013|https://clinicaltrials.gov/show/NCT00993824||132076|
NCT00994435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1082/08|The Incretin Secretion in the Gut System Related to the Physiological Stimulus|The Incretin Secretion in the Gut System Related to the Physiological Stimulus||Catholic University of the Sacred Heart|No|Completed|January 2009|January 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|30 Years|60 Years|No|Non-Probability Sample|Studies are carried out in 20 obese subjects of both gender sexes, 10 of whom with type 2        diabetics and 10 with normal glucose tolerance.|October 2009|March 23, 2011|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00994435||132029|
NCT00994708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04002M|The Effect of Esomeprazole and Fundoplication on Airways|The Effect of Esomeprazole and Nissen Fundoplication on Bronchial Responsiveness, Quality of Life, Exhaled Nitric Oxide and Pulmonary Function in Patients With Gastroesophageal Reflux Disease||Tampere University Hospital||Completed|December 2004|||||Phase 3|Interventional|N/A|||||||Both|18 Years|N/A|No|||October 2009|October 13, 2009|October 12, 2009||||No||https://clinicaltrials.gov/show/NCT00994708||132008|
NCT00994448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA026513|Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents|Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents||University of California, Los Angeles|Yes|Completed|October 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|14 Years|21 Years|No|||February 2013|February 25, 2013|October 13, 2009|Yes|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT00994448||132028|Study was not powered or designed to determine if bupropion is more effective than placebo for treating methamphetamine dependence. Only for pilot testing procedures for a clinical trial in methamphetamine abusing adolescents.
NCT00994461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191345|Study Of Celecoxib In Healthy Subjects|A Randomized, Placebo-Controlled, Double-Blind, Phase 4 Study To Compare The Effect Of Celecoxib 100 Mg BID, Loxoprofen 60 Mg TID And Placebo On The Gastroduodenal Mucosa In Healthy Subjects||Pfizer|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|190|||Both|40 Years|74 Years|Accepts Healthy Volunteers|||May 2011|May 19, 2011|October 13, 2009|Yes|Yes||No|April 22, 2011|https://clinicaltrials.gov/show/NCT00994461||132027|
NCT00994734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2.3|Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion|Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion||Gynuity Health Projects||Completed|May 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|615|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|October 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00994734||132006|
NCT00994994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped Txa Cya|Tranexamic Acid in Pediatric Cardiac Surgery|Tranexamic Acid Reduces Blood Loss in Pediatric Cardiac Surgery|TXA|Okayama University|Yes|Completed|January 2006|April 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|160|||Both|2 Months|18 Years|No|||October 2009|October 13, 2009|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00994994||131986|
NCT00995007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090222|A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas|A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2009|January 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|100 Years|No|||December 2014|October 8, 2015|October 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00995007||131985|
NCT00995267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBoo1-HMO-CTIL|Eating Habits and Obesity in First and Second Grade School Children|The Influence of the Family as Agents of Change on Eating Habits and Obesity in First and Second Grade School Children in Israel.||Hadassah Medical Organization|Yes|Enrolling by invitation|March 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|600|||Both|6 Years|9 Years|No|||October 2009|October 14, 2009|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995267||131966|
NCT00995579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200809081R|Assessment of Energy Expenditure by Indirect Calorimetry for a Daily 10,000 Steps Goal|Assessment of Energy Expenditure by Indirect Calorimetry for a Daily 10,000 Steps Goal||National Taiwan University Hospital|Yes|Completed|November 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|Healthy college volunteers|October 2009|October 14, 2009|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00995579||131942|
NCT01012869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-070|AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study|AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study|ACE-CTO|North Texas Veterans Healthcare System|Yes|Completed|November 2009|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2012|October 28, 2013|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01012869||130624|
NCT01013116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBC-2009-002B|Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites|A Double-blind Placebo-controlled Trial to Evaluate Efficacy and Safety of Specific Subcutaneous Immunotherapy in Patients With Perennial Allergic Rhinitis Due to House Dust Mites||Roxall Medizin||Not yet recruiting|April 2016|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||November 2015|November 2, 2015|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01013116||130605|
NCT01021111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09242009-4061|The Design and Evaluation of an Active Intervention for the Prevention of Non-contact ACL Injury|The Design and Evaluation of an Active Intervention for the Prevention of Non-contact ACL Injury||Stanford University||Active, not recruiting|November 2009|December 2013|Anticipated|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|November 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01021111||129998|
NCT01021124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0077|Latent Tuberculosis Infection in Bone Marrow Transplant Recipients|A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Hematopoietic Stem Cell Transplant Recipients||Asan Medical Center|Yes|Completed|January 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|409|Samples Without DNA|whole blood|Both|16 Years|N/A|No|Probability Sample|Bone marrow transplant recipients|July 2013|July 17, 2013|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01021124||129997|
NCT01022619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61/09|The Association Between High Risk Pregnancy and Sleep-disordered Breathing|The Association Between High Risk Pregnancy and Sleep-disordered Breathing||Assaf-Harofeh Medical Center|No|Not yet recruiting|January 2010|||January 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|150|Samples With DNA|Cord blood will be obtained in EDTA tubes and serum-seperating tubes|Female|19 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Women in third trimester admitted to the high-risk pregnancy unit and women with        uncomplicated pregnancy attending a pre-labor course|November 2009|November 30, 2009|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01022619||129885|
NCT01027455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WARMIST|Warm Humid Gas Insufflation for Appendix Removal by Minimally Invasive Surgery Warm Humid Insufflation for Appendix Removal by Minimally Invasive Surgery Trial (WARMIST)|Warm Humidified Insufflation for Laparoscopic Appendicectomy in Children: a Randomised Controlled Trial|WARMIST|University of Auckland, New Zealand|Yes|Recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||October 2009|June 24, 2010|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027455||129514|
NCT01026935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231268|The Outcome After Lichtenstein Operation vs. ProGrip Patch Repair of Inguinal Hernia|The Effect of Mesh Type on Pain After Surgery for Inguinal Hernia. Randomized Clinical Trial of Lichtenstein Operation With Sutured Polypropylene Patch or Self-adhesive ProGrip Patch.||Helsinki University Central Hospital|No|Completed|February 2008|January 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|398|||Both|18 Years|N/A|No|||December 2009|July 19, 2011|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01026935||129554|
NCT01026779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCH-001|Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island|Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island: Active Hospital-Based Surveillance, Serotype Surveillance and a Case-Control Study||Lifespan|No|Active, not recruiting|July 2009|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|560|Samples Without DNA|Stools|Both|2 Months|5 Years|No|Probability Sample|Residents of Rhode Island|March 2016|March 1, 2016|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01026779||129566|
NCT01027546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YODA-0001|Effect of Tranexamic Acid on Reducing Postoperative Blood Loss in Cervical Laminoplasty|||Yodakubo Hospital|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A||||May 2008|December 7, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027546||129507|
NCT01027559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081348|fMRI Study of Treatment Changes in Major Depression|fMRI Studies of Emotional Circuitry in Major Depression: Treatment Changes||Washington University School of Medicine|No|Completed|February 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|97|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027559||129506|
NCT01027286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-548|Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty|Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty||The Cleveland Clinic|No|Completed|July 2009|June 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|85 Years|No|||October 2012|October 30, 2012|December 3, 2009|Yes|Yes||No|August 30, 2012|https://clinicaltrials.gov/show/NCT01027286||129527|
NCT01023724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-06 1|A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)|A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% BID and Bromfenac 0.09% BID||Bucci Laser Vision Institute|No|Completed|December 2009|February 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 28, 2011|December 1, 2009||No||No|May 25, 2011|https://clinicaltrials.gov/show/NCT01023724||129800|
NCT01023737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDD 08-52|Hydroxychloroquine + Vorinostat in Advanced Solid Tumors|Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|November 2009|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|16 Years|N/A|No|||November 2015|November 4, 2015|July 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023737||129799|
NCT01027793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-CBED08-01|Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Stretch Marks|Randomized Clinical Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Recent Stretch Marks||Brazilan Center for Studies in Dermatology|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|11 Years|25 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01027793||129488|
NCT01023685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAD106A2202E1|To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients|An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.||Novartis||Completed|December 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|N/A|No|||June 2013|June 25, 2013|December 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023685||129803|
NCT01024244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12781|A Study of LY2599506 in Patients With Type 2 Diabetes|A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients With Type 2 Diabetes Mellitus Treated With Diet and Exercise, With or Without Metformin||Eli Lilly and Company|No|Terminated|December 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|78|||Both|18 Years|70 Years|No|||November 2011|November 29, 2011|December 1, 2009|Yes|Yes|Terminated due to nonclinical safety findings|No|September 15, 2011|https://clinicaltrials.gov/show/NCT01024244||129760|Since Study GMAH was terminated after enrolling only 78 participants with just 10 participants completing 12 weeks of treatment with LY2599506, only disposition, demographics, and safety data are reported.
NCT01024478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CapitalMedicalU|Contrast-Enhanced Whole-Heart Coronary Magnetic Resonance Angiography at 3.0-T: A Multicenter Trial|Contrast-Enhanced Whole-Heart Coronary Magnetic Resonance Angiography at 3.0-T: A Multicenter Trial||Capital Medical University|No|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|272|||Both|20 Years|80 Years|No|Probability Sample|Consecutive eligible patients scheduled to undergo conventional coronary angiography.|December 2009|July 6, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024478||129742|
NCT01024491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPEP-01|Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation|A Parallel Randomized Double Blind Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation||MorePharma Corporation|No|Completed|August 2008|April 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|174|||Male|20 Years|70 Years|No|||December 2009|December 1, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024491||129741|
NCT01024751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|636|A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution|A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution||Bausch & Lomb Incorporated|No|Completed|November 2009|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|312|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|August 11, 2011|November 30, 2009|Yes|Yes||No|June 16, 2011|https://clinicaltrials.gov/show/NCT01024751||129721|
NCT00977808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12998|Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004)|Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes(BPK004)||University of Virginia|No|Completed|May 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|N/A|No|||August 2014|August 25, 2014|September 15, 2009|Yes|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT00977808||133290|
NCT00978055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIOT-0592|Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)|Single-Dose Fasting Bioequivalence Study of Liothyronine Sodium Tablets (50 Mcg; Mylan) to Cytomel® Tablets (50 Mcg; King) in Healthy Euthyroid Adult Volunteers||Mylan Pharmaceuticals||Completed|October 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 15, 2009|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978055||133271|
NCT00977821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901-F-054-CS|Embryo Developmental Capacity After Egg Banking in an Ovum Donation Program|||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|September 2009|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|625|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00977821||133289|
NCT00978081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650536|Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors|Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors||Abramson Cancer Center of the University of Pennsylvania||Active, not recruiting|January 2009|||October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|120 Years|No|||February 2016|February 9, 2016|September 15, 2009|No|Yes||||https://clinicaltrials.gov/show/NCT00978081||133269|
NCT00975065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AKR03T|Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus|A 24-week, Open-label, Randomized, Multi-center, Parallel-group Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Prior Metformin Monotherapy in Comparison to up Titrating Metformin Dose.||Handok Pharmaceuticals Co., Ltd.|No|Completed|August 2009|April 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|80 Years|No|||August 2012|August 21, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00975065||133496|
NCT00974129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507000430|A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas|Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six||Yale University|Yes|Withdrawn|September 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Over the course of the study, one blood draw will be performed on each patient. This blood      will be used for genetic analysis.|Both|N/A|1 Year|Accepts Healthy Volunteers|Probability Sample|Patients to be recruited will include infants with hemangiomas on any part of their body.|June 2014|June 23, 2014|September 9, 2009||No|no subjects were enrolled, study was halted due to study staff departure|No||https://clinicaltrials.gov/show/NCT00974129||133566|
NCT00974142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09050330|Oral Cyclosporine in Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blinded, Placebo-Controlled Protocol of Oral Cyclosporine in Patients With Advanced Stage Chronic Obstructive Pulmonary Disease||University of Pittsburgh|Yes|Active, not recruiting|September 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|43|||Both|45 Years|80 Years|No|||January 2016|January 4, 2016|September 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974142||133565|
NCT00974415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU11387|Study of the Carbon Dioxide Treatment for Fat Reduction|A Pilot Study of the Carbon Dioxide Treatment for Fat Reduction||Northwestern University|No|Active, not recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|60 Years|No|||January 2016|January 11, 2016|September 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974415||133545|
NCT01026142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22324|A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)|A Multicenter Randomized Phase III Study to Compare the Combination Trastuzumab and Capecitabine, With or Without Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer That Have Progressed After One Line of Trastuzumab-Based Therapy in the Metastatic Setting (PHEREXA)||Hoffmann-La Roche||Active, not recruiting|January 2010|October 2018|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|452|||Female|18 Years|N/A|No|||January 2015|January 19, 2015|November 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01026142||129614|
NCT01026493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0929|Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma|A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma||Radiation Therapy Oncology Group||Active, not recruiting|July 2010|||May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026493||129588|
NCT01027299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/CAD/4628|Temporary Epicardial Cardiac Resynchronisation.|A Randomised Study of Temporary Epicardial Cardiac Resynchronisation Versus Conventional Right Ventricular Pacing in Cardiac Surgical Patients.||Cardiff and Vale University Health Board|No|Recruiting|December 2009|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027299||129526|
NCT01027312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#07-842|Assessment of Ability Related to Vision|Reproducibility and Clinical Usefulness of AARV (Assessment of Ability Related to Vision)|AARV|Wills Eye|No|Completed|February 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|One hundred patients with bilateral unstable glaucoma and twenty patients who appear to be        normal will be enrolled.|November 2011|November 21, 2011|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027312||129525|
NCT01027325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1DK086472-01|Resistant Starch Insulin Sensitivity Trial|Effects of Resistant Starch on Lipid and Glucose Metabolism in Insulin Resistance|RESIST|Children's Hospital & Research Center Oakland|Yes|Completed|June 2010|November 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|52|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 10, 2013|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027325||129524|
NCT01027806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008A|Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children|A Randomized Double Blind Controlled Trial on the Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome|32543|University of Chicago|No|Recruiting|July 2010|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|83|||Both|2 Years|10 Years|No|||May 2014|May 20, 2014|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027806||129487|
NCT01027819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHOSK09MBFB|Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty|Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty||Seoul National University Hospital|No|Active, not recruiting|November 2009|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|No|||December 2012|December 13, 2012|December 7, 2009||No||No|March 6, 2011|https://clinicaltrials.gov/show/NCT01027819||129486|First, our study population is composed of elderly patients with large female dominanceSecond concern was inherent errors in making the measurements in this kind of study
NCT01027832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102/09|Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT)|Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT): A Randomized, Controlled Trial||Assaf-Harofeh Medical Center|No|Recruiting|September 2009|September 2011|Anticipated|September 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2009|December 8, 2009|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01027832||129485|
NCT01023750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DK084560|Predictors of Response to Fenofibrate|Pretreatment Genotyping at APOA5 and GCKR Loci and Response to Fenofibrate Therapy|PreFar|University of Alabama at Birmingham|No|Completed|January 2010|July 2012|Actual|July 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|39|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who are seen in the UAB Diabetes and Endocrine Clinic or Cardiology Clinic|November 2013|October 11, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023750||129798|
NCT01024023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0081|Hull Early Walking Aids for Transtibial Amputees - Randomised Control Trial (HEART)|Hull - Early Walking Aids for Transtibial Amputees - Does an Articulated Knee Have Benefits? A Randomised Controlled Trial|HEART|University of Hull|Yes|Active, not recruiting|December 2004|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|No|||December 2009|December 1, 2009|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01024023||129777|
NCT01024257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Famema0010|Pterygium Treatment Using Single Beta-therapy as Adjuvant Treatment Compared to Conjunctival Autograft|||Marilia Medicine School|No|Completed||||||Phase 3|Interventional|N/A|2||||||Both|18 Years|N/A||||December 2009|December 1, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024257||129759|
NCT01024465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1|ReShape Intragastric Balloon for the Treatment of Obesity|ReShape Intragastric Balloon for the Treatment of Obesity|ITALYIII|ReShape Medical, Inc.|No|Completed|September 2009|March 2011|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 10, 2015|November 25, 2009||No||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01024465||129743|No limitations nor caveats apply.
NCT01025050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905|Intrastromal Presbyopia Correction by Means of a Femtosecond Laser|Intrastromal Presbyopia Correction by Means of a Femtosecond Laser||Technolas Perfect Vision GmbH|Yes|Completed|December 2009|December 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|58|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01025050||129698|
NCT01025063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952AUS18T|Use of Spectral OCT in Combination Therapy|Use of Spectral OCT in Combination Therapy|Spectral OCT|Barnes Retina Institute|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|15|||Both|N/A|N/A|No|Non-Probability Sample|Barnes Retina Institute clinic|December 2009|December 2, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025063||129697|
NCT01025349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMUH-01-09-09|Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer|Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer||Taipei Medical University Hospital|No|Completed|January 2005|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|65 Years|No|||December 2009|December 2, 2009|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025349||129675|
NCT01025362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-09277c2009/5783|Baby-Friendly Community Health Services Evaluation|Baby-Friendly Community Health Services Evaluation: A Cluster Randomised Controlled Study||Oslo University Hospital|Yes|Completed|August 2009|August 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|2032|||Both|5 Months|13 Months|No|||October 2014|October 30, 2014|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025362||129674|
NCT00977470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-097|Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations|Phase II Study of Erlotinib With or Without Hydroxychloroquine in Patients With Previously Untreated Advanced NSCLC and EGFR Mutations||Massachusetts General Hospital|Yes|Active, not recruiting|October 2009|December 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977470||133314|
NCT00978341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081141|Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design|A Methodology Study to Assess the Ability of a Randomised, Double Blind, Placebo Controlled, Crossover Trial Design in Spinal Cord Injury Patients With Pain of Neuropathic Origin to Detect Improvement in Pain Endpoints Using Pregabalin as a Benchmark Compound||Pfizer|Yes|Terminated|February 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|15|||Both|18 Years|70 Years|No|||January 2010|January 6, 2010|September 15, 2009|No|Yes|See Detailed Description|No|September 28, 2009|https://clinicaltrials.gov/show/NCT00978341||133249|This study was terminated prematurely.
NCT00974155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-016|The Early Medication Change (EMC) Trial|Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial|EMC|Johannes Gutenberg University Mainz|Yes|Completed|September 2009|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|889|||Both|18 Years|65 Years|No|||March 2015|March 31, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974155||133564|
NCT00974428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A077-ATR08H|Multi-Center Study Evaluating the Efficacy of Wobenzym(R)N in Treating Knee Osteoarthritis|A 6 Week, Double Blind, Placebo-controlled, Multi-center Pilot Study Evaluating the Efficacy of Wobenzym(R)N at Reducing Pain Severity as Measured by the WOMAC Pain Score in Subjects With Knee Osteoarthritis||Atrium Innovations|Yes|Not yet recruiting|October 2009|||March 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|45 Years|80 Years|No|||September 2009|September 9, 2009|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974428||133544|
NCT00975338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-ABI-LSMODEL-706|The LETS Study: A Longitudinal Evaluation of Transition Services|The LETS Study: A Longitudinal Evaluation of Transition Services|LETS|Holland Bloorview Kids Rehabilitation Hospital|No|Active, not recruiting|September 2009|April 2016|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|331|||Both|16 Years|23 Years|No|Non-Probability Sample|Youth and young adult clients or recent graduates of Bloorview Kids Rehab who have either        participated in LIFEspan transition services or have transitioned to adult healthcare        without LIFEspan participation|February 2015|February 2, 2015|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975338||133476|
NCT00975026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005517|Measuring the Feasibility and the Effects of Chair Massage on Pain and Discomfort in the Cardiac Sonographer|Measuring the Feasibility and the Effects of Chair Massage on Pain and Discomfort in the Cardiac Sonographer - A Pilot Study||Mayo Clinic|No|Completed|September 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975026||133499|
NCT00975039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN904 CCM201|Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma|Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy in Non-resectable or Inoperable Cholangiocarcinoma||Steba Biotech S.A.|No|Terminated|September 2009|September 2012|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|September 10, 2009||No|Early end of enrolment with regards to difficulty met to enrol patients .|No||https://clinicaltrials.gov/show/NCT00975039||133498|
NCT00975312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEN-TriC-001|Solar Lentigines Treatment With the Triple Combination Cream|Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial.||Pontificia Universidad Catolica de Chile|No|Completed|August 2008|February 2009|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|30 Years|80 Years|No|||September 2009|September 10, 2009|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975312||133478|
NCT01026792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2014-00268|Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery|A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix||National Cancer Institute (NCI)|Yes|Completed|December 2009|November 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||February 2014|August 10, 2015|December 3, 2009|Yes|Yes||No|July 6, 2015|https://clinicaltrials.gov/show/NCT01026792||129565|
NCT01027013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-RED-203|Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye|A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo for the Treatment of Keratoconjunctivitis Sicca (Dry Eye)||Acucela Inc.|No|Completed|December 2009|November 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|December 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027013||129548|
NCT01027026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK: 6.2008.1724|The Acute Coronary Syndrome Study|The Acute Coronary Syndrome Study. Organization and Treatment of Patients With Acute Coronary Syndrome, With a Focus on Costs, Organization and Security|ACS|Ullevaal University Hospital|No|Recruiting|February 2009|May 2013|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2009|December 4, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027026||129547|
NCT01027858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00529|PROMOTE: Promotion of the Mind Through Exercise|Role of Exercise on Cognition and Function in Seniors With Vascular Cognitive Impairment: A Randomized Controlled Trial||University of British Columbia|Yes|Completed|December 2009|May 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|71|||Both|45 Years|N/A|No|||June 2015|June 10, 2015|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027858||129483|
NCT01027871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12149|A Study for Patients With Type 2 Diabetes|A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|January 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|131|||Both|18 Years|N/A|No|||March 2011|April 5, 2011|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027871||129482|
NCT01027572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RILM|Thalamic Stimulation of Patients in Vegetative or Minimally Conscious State|Efficacy of Thalamic Stimulation in the Treatment of Patients in Vegetative State and Minimally Conscious State From at Least Six Months. A Pilot Study|CATS\|IRCCS Policlinico S. Matteo|Yes|Recruiting|July 2009|July 2012|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|10 Years|65 Years|No|||June 2011|June 24, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01027572||129505|
NCT01027585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353/2008a|The Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Impaired Glucose Tolerance|Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Type 2 Diabetes or Impaired Glucose Tolerance||Skane University Hospital|Yes|Completed|May 2009|September 2009|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|80 Years|No|Probability Sample|All subjects were recruited from the population in southern Sweden.|May 2009|December 7, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027585||129504|
NCT01024049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-15|Identification Of Blood Markers For Asymptomatic Ventricular Dysfunction|Identification Of Blood Markers For Asymptomatic Ventricular Dysfunction|IBLOMAVED|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|July 2007|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control||5|Anticipated|1000|Samples Without DNA|plasma sample blood RNA sample|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Healthy individuals          2. Patients with cardiovascular risk          3. Patients with cardiovascular risk and asymptomatic left ventricular dysfunction          4. Chronic heart failure patients          5. Acute heart failure patients|January 2012|January 27, 2012|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024049||129775|
NCT01024062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA139-373|Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)|Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)||Bristol-Myers Squibb|Yes|Completed|December 2002|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|74 Years|No|||April 2011|April 8, 2011|November 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01024062||129774|
NCT01024283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3113|Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor|Analysis of Pharmacodynamic Changes Associated With the Administration of the Heat Shock Protein 90 Inhibitor AUY922A in Patients With Advanced Solid Malignancies||Royal Marsden NHS Foundation Trust|No|Recruiting|December 2008|August 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|16 Years|N/A|No|Non-Probability Sample|All patients entering the open label phase I dose escalation and phase II expansion arms        of AUY922A at the Royal Marsden Hospital will be asked to participate in this study.|December 2009|December 1, 2009|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024283||129757|
NCT01024036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016705|A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease|A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease||Janssen Research & Development, LLC|Yes|Active, not recruiting|March 2010|February 2017|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|November 30, 2009|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01024036||129776|
NCT01024270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-06-035|Cervical Priming With Misoprostol Prior to Operative Hysteroscopy|Cervical Priming With Misoprostol Prior to Operative Hysteroscopy||Samsung Medical Center||Completed|July 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Caregiver)|1||Actual|141|||Female|20 Years|55 Years|No|||July 2009|November 30, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01024270||129758|
NCT01017913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0143/06|Transcutaneous Electrical Nerve Stimulation and Interferential Currents in Chronic Low Back Pain|Effects of Transcutaneous Electrical Nerve Stimulation (TENS) and Interferential Currents (IFC) in Patients With Non Specific Chronic Low Back Pain: Randomized Clinical Trial||Federal University of São Paulo|No|Completed|March 2006|December 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|65 Years|No|||November 2009|November 20, 2009|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01017913||130241|
NCT01017926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6781002|Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption|An Open, Two Period, Two Treatment, Two Sequence, Crossed, Randomized, Single-Dose Study Of Two Oral Preparations Containing 0.25 Mg Of Triazolam (Halcion, Pharmacia & Upjohn S.A. De C.V. Vs. Product Made By Pfizer Pharmaceuticals LLC) In Healthy Volunteers Under Fasting Conditions||Pfizer|No|Withdrawn|August 2010|September 2010|Anticipated|September 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2010|March 4, 2015|November 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01017926||130240|
NCT01018225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC090001|Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness|||Cognitive Research Corporation|No|Withdrawn|November 2009|July 2010|Anticipated|||Phase 4|Interventional|N/A|2||Anticipated|24|||Both|21 Years|70 Years|No|||July 2010|July 27, 2010|November 20, 2009||Yes|Study was cancelled due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT01018225||130217|
NCT01018238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8209-3608|An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)|A Multiple Dose, Randomised, Double-blind, Placebo-controlled, Multiple Site Study of Anti-C5a Receptor Antibody (NNC 0151-0000-0000) in Subjects With Systemic Lupus Erythematosus (SLE)||Novo Nordisk A/S|No|Withdrawn|November 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|65 Years|No|||July 2014|August 14, 2014|November 16, 2009|No|Yes|See detailed description|No||https://clinicaltrials.gov/show/NCT01018238||130216|
NCT00978094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072155|Validation of a Novel Sham Cervical Spinal Manipulation Procedure|Validation of a Novel Sham Cervical Spinal Manipulation Procedure.||Canadian Memorial Chiropractic College|Yes|Completed|February 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|N/A||1|Anticipated|80|||Both|21 Years|55 Years|No|Non-Probability Sample|Participants in this study will be consenting adults, 21-55 years of age, male or female        who have chronic mechanical neck pain (NP) rated as between 30 and 65 on an NRS-101 scale        [74]. For the purposes of this study NP is defined as;|November 2010|November 16, 2010|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978094||133268|
NCT00974454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.07.16-1|Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)|Research on Effect of TCM on Immune Reconstitution of HIV/AIDS Patients After HAART||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Recruiting|September 2009|December 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|70 Years|No|||September 2009|October 28, 2009|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974454||133542|
NCT00974779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM2H-2009-02|High-cutoff Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients|Application of the "High-cutoff (HCO1100)" Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients With Elevated CRP Levels|HCO1100|Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|November 2009|December 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|80 Years|No|||January 2012|January 13, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974779||133518|
NCT00975351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR4/2008|Estimation of Plasma Folate Apparent Volume of Distribution in Adults|Estimation of Plasma Folate Apparent Volume of Distribution in Adults|FOLCAN|Institute of Food Research|No|Completed|June 2009|December 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975351||133475|
NCT00975325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOH-BE-2009|Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine|Characterisation of Relative Bioavailability and Assessment of Bioequivalence of Two Generic Yohimbine Formulations in Comparison With a Marketed Reference Product - an Open, Randomised, Single Dose, 3-period Change-over Study||Walter Ritter GmbH & Co|No|Completed|October 2009|December 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00975325||133477|
NCT00975637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090062|Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis||Amgen||Completed|December 2009|September 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|198|||Both|18 Years|70 Years|No|||July 2015|July 27, 2015|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975637||133455|
NCT01026805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP 200901|Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator|Retrospective Case Review - Clinical Evaluation of the Interlace Medical 1st Generation Hysteroscopic Morcellator||Hologic, Inc.|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|11|||Female|18 Years|N/A|No|Non-Probability Sample|Eleven (11) premenopausal women who had been treated with the new hysteroscopic        morcellator to resect intrauterine pathology (polyps and submucous myomas).|November 2012|November 20, 2012|April 30, 2009||No||No|April 30, 2009|https://clinicaltrials.gov/show/NCT01026805||129564|Small number of cases; retrospective study design
NCT01027598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 200|Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer|A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)||SCRI Development Innovations, LLC|No|Completed|January 2010|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 4, 2009|Yes|Yes||No|October 8, 2015|https://clinicaltrials.gov/show/NCT01027598||129503|
NCT01027845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112640|Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children|Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A Following Primary and Booster Vaccination of Healthy Japanese Children||GlaxoSmithKline||Completed|December 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|360|||Both|90 Days|118 Days|Accepts Healthy Volunteers|||September 2011|July 24, 2012|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027845||129484|
NCT01015833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01989|Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer|Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2010|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|N/A|No|||September 2015|March 7, 2016|November 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01015833||130397|
NCT01023763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1584a|Intravenous Treatment in Nursing Homes|Can a Structured Training Program in Intravenous Treatment of Infections in Nursing Homes Lead to a Better Patient Trajectory and Reduced Hospital Admittance?|3IV|University of Oslo|No|Recruiting|November 2009|December 2012|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|N/A|N/A|No|||December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023763||129797|
NCT01023776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 09-006|Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine|Evaluation of the Infectivity, Replication, and Immunogenicity of Live, Attenuated A/California/07/09 (nH1N1) Influenza Vaccine in Serosusceptible Adults||University of Rochester|No|Completed|November 2009|July 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|32 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|December 1, 2009|Yes|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT01023776||129796|
NCT01016444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERM B2AR|Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms|β2AR Polymorphisms and Albuterol Responsiveness in Acute Asthma||MetroHealth Medical Center|No|Recruiting|December 2009|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1250|Samples With DNA|DNA for analysis of B2AR polymorphysims, DNA for genes for inflamation,steroid and      leukotriene responsiveness.|Both|16 Years|75 Years|No|Non-Probability Sample|Asthmatic who presented to an Emergency Room with acute symptomatic airway obstruction who        are treated with standard doses of albuterol and who either terminate their attacks        rapidly or who are admitted to hospital for extensive treatment.|November 2009|May 24, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016444||130352|
NCT01016457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4980-KMA-CTIL|Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus|Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus||Sheba Medical Center|No|Recruiting|December 2008|December 2009|Anticipated|August 2009|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|1 Year|6 Years|No|||November 2009|November 18, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016457||130351|
NCT01016743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7279-OC-CTIL|The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease|||Sheba Medical Center|No|Not yet recruiting|November 2009|||July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|80 Years|No|||November 2009|November 18, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016743||130329|
NCT01017029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIT16|Everolimus in de Novo Heart Transplant Recipients|Early vs. Delayed EVERolimus in de Novo HEART Transplant Recipients: Optimization of the Safety/Efficacy Profile (EVERHEART Study)|EVERHEART|Novartis||Completed|September 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|182|||Both|18 Years|65 Years|No|||December 2014|December 23, 2014|November 19, 2009|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01017029||130308|
NCT01024504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/06.12|Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer|A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer||Hellenic Oncology Research Group|No|Completed|March 2006|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|70 Years|N/A|No|||April 2010|April 8, 2010|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01024504||129740|
NCT01024517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0259-CL-103|GLPG0259 Solid Formulation Bioavailability and Food Effect|An Open Label Study to Compare the Oral Bioavailability of a Solid Dose Formulation of GLPG0259 Relative to an Oral Solution After Single-dose Intake in Healthy Subjects and to Evaluate the Effect of Food on the Solid Dose Formulation.||Galapagos NV|No|Completed|November 2009|February 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024517||129739|
NCT01024764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS OBS P-001|Observational Study of the Preventive Trial With HIV-1 Tat Protein|Observational Study of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in HIV-1 Uninfected Adult Volunteers|ISS OBS P-001|Istituto Superiore di Sanità|No|Completed|November 2007|December 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|5|Samples Without DNA|Whole blood, serum, PBMCs|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Subjects previously included in the Preventive Phase I Clinical Trial with Tat        protein|February 2010|February 28, 2011|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024764||129720|
NCT01024777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00023005|Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis|A Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple Sclerosis||Johns Hopkins University||Completed|March 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||February 2013|February 5, 2013|December 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024777||129719|
NCT01018251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01109|Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer|Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT||Abramson Cancer Center of the University of Pennsylvania|Yes|Withdrawn|March 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01018251||130215|
NCT01018264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URGE-PD|Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease|URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease|URGE-PD|University of South Florida|No|Completed|January 2010|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|40 Years|80 Years|No|||September 2015|September 23, 2015|November 19, 2009|No|Yes||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01018264||130214|
NCT01018537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081794|Global Demyelinating Disease Registry|NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis|NARCOMS|University of Alabama at Birmingham|Yes|Recruiting|January 1996|||December 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who have been diagnosed with multiple sclerosis|February 2016|February 5, 2016|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018537||130193|
NCT00974168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-11 ICORG|Radiation Therapy in Treating Patients With Malignant Spinal Cord Compression Who Were Previously Treated With Radiation Therapy. ICORG 07-11|A Phase II Trial Evaluating the Efficacy of a Radio-Biological Based Re-Irradiation Strategy for Patients With Malignant Spinal Cord Compression||ICORG- All Ireland Cooperative Oncology Research Group|No|Recruiting|October 2007|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|120 Years|No|||October 2015|October 23, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974168||133563|
NCT00974467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-4-5932|Evaluating a Website for Parents of Injured Children|Evaluating a Website for Parents of Injured Children||Children's Hospital of Philadelphia|No|Completed|May 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|6 Years|N/A|No|||January 2012|March 11, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974467||133541|
NCT00974480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRP09008|Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging|Single Blind Study to Evaluate the Tolerance and Effectiveness of Redermic Versus Rejuva-A™ (0.025% Tretinoin) and Redermic in Combination With Rejuva-A™ (0.025% Tretinoin) Under Normal Conditions in Subjects With Signs of Aging||Cosmetique Active International|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 18, 2011|July 24, 2009||No||No|November 16, 2010|https://clinicaltrials.gov/show/NCT00974480||133540|
NCT00974792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000644893|Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma|A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk)||National Cancer Institute (NCI)||Recruiting|January 2006|||May 2011|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|60 Years|No|||September 2009|August 23, 2013|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974792||133517|
NCT00975104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080733|AMG 745 in Subjects With Age-associated Muscle Loss|A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss||Amgen||Withdrawn|April 2010|August 2011|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|65 Years|N/A|No|||July 2010|July 22, 2010|September 10, 2009|||Amgen has chosen at this time not to continue with AMG 745 study 20080733|No||https://clinicaltrials.gov/show/NCT00975104||133493|
NCT00975364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR05/2008|Folate Gene Polymorphisms and Cellular Folate Speciation Pilot Study|Pilot Study to Investigate Relationship Between Common Folate Gene Polymorphisms, Folate Status and Cellular Folate Speciation|FolGene|Institute of Food Research|Yes|Completed|February 2009|December 2010|Actual|July 2010|Actual|N/A|Observational|N/A||1|Actual|100|Samples With DNA|One-off blood sample collected. DNA extracted for genotyping of folate metabolism-related      gene single nucleotide polymorphisms|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults (male and female) aged 18-65|February 2013|February 15, 2013|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975364||133474|
NCT00975689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090185|Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine|Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine||National Institutes of Health Clinical Center (CC)|Yes|Completed|August 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|35|||Both|12 Months|N/A|No|||April 2013|April 30, 2013|September 10, 2009|No|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT00975689||133451|
NCT00975650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasobol-01-2009|Efficacy and Tolerability of an Intra-Nasal Testosterone Product|Efficacy and Tolerability of Nasobol®, an Intra-Nasal Testosterone Product, for Testosterone Replacement in Hypogonadal Men||Trimel Biopharma SRL|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Male|18 Years|80 Years|No|||August 2010|August 5, 2010|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975650||133454|
NCT00975949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13697|Neurodevelopmental Outcomes and Fluconazole Prophylaxis|Neurodevelopmental Outcomes and Quality of Life and Fluconazole Prophylaxis|NDFP|University of Virginia|Yes|Completed|June 2008|June 2010|Actual|October 2008|Actual|Phase 3|Observational|Time Perspective: Prospective||2|Actual|39|||Both|7 Years|10 Years|No|Probability Sample|Subjects were born <1000 grams, treated in our NICU, and are now 7 to 10 years of age.|January 2013|January 14, 2013|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00975949||133431|
NCT01027039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-829E|Will Listening to Music Make it Easier to Take a Visual Field Test?|The Effect of Mozart Music on Visual Field Testing in Glaucoma Patients: Will Music Tame the Savage Perimeter?||Wills Eye|No|Completed|June 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|160|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|glaucoma service|June 2010|June 24, 2010|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027039||129546|
NCT01027338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24AT000589|Tai Chi Exercise in Patients With COPD|Tai Chi Exercise in Patients With Chronic Obstructive Pulmonary Disease||National Center for Complementary and Integrative Health (NCCIH)|No|Completed||||||Phase 1|Interventional|N/A|2||||||Both|45 Years|N/A|No|||December 2009|December 4, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027338||129523|
NCT01015560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0916|S0916, MLN1202 in Treating Patients With Bone Metastases|S0916, A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 in Patients With Bone Metastases||Southwest Oncology Group|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|November 17, 2009|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01015560||130418|
NCT01015573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-188|Database Creation and Evaluation of Motor Function of Finger Tapping Measured by Magnetic Sensor System in Healthy Subjects|||Hiroshima University|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|375|||Both|40 Years|79 Years|Accepts Healthy Volunteers|||April 2010|April 23, 2010|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015573||130417|
NCT01016470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0916-CU|Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease|Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease||Catalysis SL|Yes|Completed|October 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|90 Years|No|||May 2012|May 2, 2012|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01016470||130350|
NCT01016483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200066_003|Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer|||Merck KGaA|No|Completed|November 2009|February 2015|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|141|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016483||130349|
NCT01016210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leuveris1.CTIL|The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)|||The Baruch Padeh Medical Center, Poriya|No|Completed|February 2010|April 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01016210||130370|
NCT01016145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Projesq-IPAP|Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm|Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia||University of Sao Paulo|No|Recruiting|April 2009|July 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|45 Years|No|||November 2009|November 18, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016145||130374|
NCT01016158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-2009-11-135|Umbilical Cord Serum Eye Drops|||Chonnam National University Hospital|Yes|Completed|April 2006|October 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||November 2009|November 18, 2009|November 18, 2009||||No||https://clinicaltrials.gov/show/NCT01016158||130373|
NCT01017042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-07-1003|Pharmacokinetic Study of an Acute Gout Regimen|Open-Label Pharmacokinetic Study of a Low-Dose Acute Gout Regimen||Mutual Pharmaceutical Company, Inc.|No|Completed|September 2007|October 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2009|October 5, 2009|August 12, 2009|No|Yes||No|August 12, 2009|https://clinicaltrials.gov/show/NCT01017042||130307|
NCT01017302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22709|A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.|A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 in Patients With Type 2 Diabetes Mellitus on Stable Background Therapy||Hoffmann-La Roche||Completed|December 2009|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|November 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01017302||130287|
NCT01017315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-197-11-4-2|Efficacy of Baby Talcum in Prevention of Pruritus Assosiated With Cast|Efficacy of Baby Talcum in Prevention of Pruritus Assosiated With Cast; a Randomized Controlled Trial||Prince of Songkla University|No|Enrolling by invitation|July 2009|October 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|15 Years|80 Years|No|||May 2012|May 12, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017315||130286|
NCT01017289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N.M.B. P Q REV I 03.09|Intramedullary Fixation of Humerus Fractures|A Study Evaluating the Quantum - Composite Nailing System for Intramedullary Fixation of Humerus Fractures||N.M.B. Medical Applications Ltd|No|Not yet recruiting|December 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||November 2009|November 19, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017289||130288|
NCT01017575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-022|Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)|A Phase 2a Study of Daclatasvir in Combination With Peginterferon Alfa-2a(Pegasys®) and Ribavirin (Copegus®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||Bristol-Myers Squibb|No|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|55|||Both|20 Years|70 Years|No|||August 2015|August 13, 2015|November 19, 2009|Yes|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01017575||130266|
NCT01017588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC52-200-11-4-2|PSU Lumbar Support for Prevention of Low Back Pain in Rubber Tapper|Lumbar Support for Low Back Pain Prevention in Rubber Tapper||Prince of Songkla University|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|200|||Both|15 Years|60 Years|No|||May 2012|May 12, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017588||130265|
NCT01017601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0923|Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|January 2010|||January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|99|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|November 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01017601||130264|
NCT01014182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTTER220179|Early Percutaneous Coronary Intervention (PCI) After Fibrinolysis Versus Standard Therapy in ST Segment Elevation Myocardial Infarction (STEMI) Patients|Early Invasive Strategy After Fibrinolysis vs Standard Management in STEMI Patients: Results From an Individual Patient Data Meta-analysis (OTTER Meta-analysis) OTTER: Optimal Timing for Post-Thrombolysis Elective Revascularization||Royal Brompton & Harefield NHS Foundation Trust||Recruiting|November 2009|December 2009|Anticipated|December 2009|Anticipated|N/A|Observational|N/A||2|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|STEMI patients.|November 2009|November 13, 2009|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014182||130524|
NCT00978380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13CD-3720|Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725|A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency|mentor™2|Novo Nordisk A/S|No|Completed|September 2009|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|6 Years|N/A|No|||October 2015|October 26, 2015|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00978380||133246|
NCT00974181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS08|The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)|The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)||Cordis Corporation|Yes|Completed|January 2004|March 2010|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974181||133562|
NCT00974194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPoCOT_2009|Safety and Cost-effectiveness Study of Single Port Laparoscopic Cholecystectomies|Single Port vs Tree Trocars Laparoscopic Cholecystectomy: a Randomized Controlled Trial|SPoCOT|University of Lausanne Hospitals|Yes|Recruiting|September 2009|July 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|75 Years|No|||December 2014|December 3, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00974194||133561|
NCT00975078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXA|Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment|Dexamethasone-suppression-test Predicts Later Development of Adrenal Insufficiency After a 14 Days' Course of Prednisone in Healthy Volunteers||University Hospital, Basel, Switzerland|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 8, 2011|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00975078||133495|
NCT00975091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-050|Continue Entecavir Rollover From China|A Study of the Safety and Antiviral Activity of Open-Label Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Who Have Completed Dosing in a Previous Phase II/III Study in China||Bristol-Myers Squibb|No|Completed|May 2004|August 2007|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|16 Years|75 Years|No|||November 2009|January 29, 2010|September 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00975091||133494|
NCT00975117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0905-CU|Spermotrend in the Treatment of Male Infertility|Assessment of the Efficacy of Dietary Supplement Spermotrend in the Treatment of Male Infertility||Catalysis SL|Yes|Completed|September 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|86|||Male|19 Years|60 Years|No|||March 2011|March 6, 2011|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975117||133492|
NCT00975377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-09-05-001|Clipping Versus No Hair Removal and the Risk of Surgical Site Infections|Clipping vs. No Hair Removal and the Risk of Surgical Site Infection: A Randomized, Assessor Blinded Non-inferiority Clinical Trial Among Patients Undergoing General Surgical Procedures at a Community Hospital||Gundersen Lutheran Medical Foundation|No|Completed|October 2009|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1678|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975377||133473|
NCT00975702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120080212|Remote Ischemic Preconditioning In Abdominal Organ Transplantation|Phase III Study of Efficacy of Remote Ischemic Preconditioning in Improving Outcomes in Organ Transplantation|RIPCOT|Rutgers, The State University of New Jersey|No|Completed|April 2009|June 2014|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|5 Years|N/A|No|||January 2015|January 13, 2015|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975702||133450|
NCT00975663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07038|Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation|Evaluation of the Interest of Therapeutic Drug Monitoring of Immunosuppressants (Tacrolimus, Mycophenolate Mofetil) Based on Bayesian Estimation During the Three First Years Following Lung Transplantation, in Patients With or Without Cystic Fibrosis|BASALT|University Hospital, Limoges|Yes|Terminated|September 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||April 2011|April 23, 2011|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975663||133453|
NCT00975962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK 19752|New Acute Treatment for Stroke - The Effect of Remote PERconditioning|New Acute Treatment for Stroke - The Effect of Remote PERconditioning||Aarhus University Hospital|No|Completed|July 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2011|June 22, 2011|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00975962||133430|
NCT00976235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT-002-LTM|A Long-Term Monitoring Study of the IMT-002 Patients|Five Year Follow up of IMT-002 Patients; A Long-Term Monitoring Study of IMT-002 Patients||VisionCare Ophthalmic Technologies, Inc.|No|Completed|June 2006|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|129|||Both|55 Years|N/A|No|||November 2015|November 2, 2015|September 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976235||133409|
NCT01023802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005183|The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer|The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer - A Pilot Study||Mayo Clinic|No|Completed|February 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|N/A|No|Non-Probability Sample|20 patients who present to the Internal Medicine Breast Cancer Clinic with breast cancer        and who after discussion with the consulting surgeon and oncologist have agreed to undergo        neoadjuvant chemotherapy or neoadjuvant hormone therapy.|May 2013|May 8, 2013|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023802||129794|
NCT01016184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|odds3153|Influence of Vitamin D Treatment on Multi-systemic Functions in Young Men With Vitamin D Deficiency Due to Work Conditions|Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Multi- Systemic Effect of Vitamin D Supplementation on Young Men With Vitamin D Deficiency||Rambam Health Care Campus|No|Completed|September 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|358|||Male|25 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016184||130372|
NCT01016496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRROR_UDGEE_09|New Perspectives in the Rehabilitation of Children With Motor Disorders : the Role of the Mirror Neuron System|Rehabilitation Strategies in Children With Neuro-motor Disorders Due to the Impairment of the Central Nervous System or the Peripheral Nervous System||University of Modena and Reggio Emilia||Completed|September 2009|November 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|6 Years|12 Years|No|||June 2014|June 23, 2014|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016496||130348|
NCT01016769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-131|Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)|A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2009|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|November 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01016769||130327|
NCT01016756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHACE_GENETICS|Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)|Genetic Analysis of PHACE Syndrome.(PHACE Syndrome is Defined as a Hemangioma Plus One or More of the Following: Brain, Heart, Eye, Sternal or Cerebral Artery Anomalies).|PHACE|Medical College of Wisconsin|No|Recruiting|February 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Blood (4 ml) for lymphocyte cell lines and DNA and tissue collection from tissue that would      otherwise be discarded after surgery.|Both|N/A|N/A|No|Probability Sample|Individuals with a facial hemangioma, along with one or more of the following:        posterior fossa malformation, arterial anomalies, cardiac defects, eye anomalies and        sternal anomalies.|March 2016|March 16, 2016|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016756||130328|
NCT01017068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRLLSAW|Aqueous Mushroom Extract and Intraocular Pressure|Aqueous Mushroom Extract as a Glaucoma Agent|AME|University of Benin|No|Not yet recruiting|November 2009|February 2010|Anticipated|February 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2009|November 23, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017068||130305|
NCT01017328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0648|Effect of Head Rotation on Overlap and Relative Position of Internal Jugular Vein to Carotid Artery in Infants and Children: A Study of the Anatomy Using Ultrasonography|Effect of Head Rotation on Overlap and Relative Position of Internal Jugular Vein to Carotid Artery in Infants and Children: A Study of the Anatomy Using Ultrasonography||Yonsei University|No|Completed|March 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|1 Year|12 Years|No|Non-Probability Sample|infants and children undergoing surgery with general anesthesia|November 2009|November 20, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017328||130285|
NCT01017341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC52-169-11-4-2|Hip Protector for Prevention of Hip Fracture|PSU Hip Protector for Prevention of Hip Fracture From Falling||Prince of Songkla University|No|Active, not recruiting|June 2010|September 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|200|||Both|50 Years|80 Years|No|||May 2012|May 12, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017341||130284|
NCT01017640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01473|Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors|ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair||National Cancer Institute (NCI)|Yes|Active, not recruiting|October 2009|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|November 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01017640||130261|
NCT01017653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015447|Panitumumab and Irinotecan for Malignant Gliomas|Phase II Study of Panitumumab in Combination With Irinotecan for Malignant Gliomas||Duke University|No|Terminated|February 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|November 19, 2009|Yes|Yes|study did not reach benchmark efficacy rule at 16 subjects|No|April 30, 2013|https://clinicaltrials.gov/show/NCT01017653||130260|
NCT01017666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204HV103|BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers||Biogen|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 16, 2010|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01017666||130259|
NCT01017614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-IBD-01|Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia|A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Oligosaccharide (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia||Pharmacosmos A/S|No|Completed|October 2009|August 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||November 2012|November 22, 2012|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017614||130263|
NCT01017627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090068|Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)|A Case Controlled Study to Determine the Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in ESRD||Fresenius Medical Care North America|No|Enrolling by invitation|November 2009|December 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|N/A|No|||April 2010|April 1, 2010|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01017627||130262|
NCT01017939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017128|A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer|An Abiraterone Acetate Plus Prednisone Drug-Drug Interaction Study With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer||Janssen Research & Development, LLC|No|Completed|January 2010|April 2012|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|18 Years|N/A|No|||April 2013|April 11, 2013|November 19, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01017939||130239|
NCT01017952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102970|A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|September 2009|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1635|||Both|40 Years|N/A|No|||August 2015|November 19, 2015|November 19, 2009|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01017952||130238|
NCT01014481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0435.3/1551|Appropriate Timing of HAART in Co-infected HIV/TB Patients|Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study)|TIME|Bamrasnaradura Infectious Diseases Institute|No|Terminated|October 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|156|||Both|18 Years|65 Years|No|||November 2011|November 16, 2011|November 16, 2009||No|this study was ended prematurely by ethical committees with a reason of the final outcome was    achieved with no longer recruitment was needed.|No||https://clinicaltrials.gov/show/NCT01014481||130501|
NCT00974493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVIVA|Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)|Randomized Open Label Study of Oral Versus Intravenous Antibiotic Treatment for Bone and Joint Infections Requiring Prolonged Antibiotic Treatment: Multi-centre Study|OVIVA|Oxford University Hospitals NHS Trust|Yes|Enrolling by invitation|June 2010|November 2016|Anticipated|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1050|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|September 4, 2009||No||No||https://clinicaltrials.gov/show/NCT00974493||133539|
NCT00974805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCB-001|An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease|An Investigation Into the Mechanisms of Action of a Combined Long Acting Beta Agonist/Inhaled Corticosteroid (Seretide 500 Accuhaler) on the Bacterial Colonisation, Immunology and Inflammation of Patients With Chronic Obstructive Pulmonary Disease|IMAS|University of Southampton|Yes|Completed|February 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|48|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00974805||133516|
NCT00974818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-118|Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients|Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients: A Randomized Phase III Non-inferiority Trial||Memorial Sloan Kettering Cancer Center|Yes|Terminated|September 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|September 9, 2009|Yes|Yes|Lack of accrual|No|October 20, 2015|https://clinicaltrials.gov/show/NCT00974818||133515|
NCT00975390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-066|Muscle Glycogen Synthesis When Caffeine and Protein is Co-Ingested With Carbohydrates|The Effect of Caffeine or Protein Co-ingestion With Carbohydrate on Post-exercise Muscle Glycogen Synthesis Rate.||Maastricht University Medical Center|No|Completed|February 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|14|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|September 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00975390||133472|
NCT00975715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476B1301|Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures|A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy||Novartis|No|Completed|September 2009|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|4 Years|14 Years|No|||July 2014|July 9, 2014|September 10, 2009||No||No|October 8, 2013|https://clinicaltrials.gov/show/NCT00975715||133449|
NCT00976287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zssy|Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis|Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis||Sun Yat-sen University|Yes|Active, not recruiting|January 2008|June 2010|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||September 2009|September 14, 2009|August 31, 2009||No||No||https://clinicaltrials.gov/show/NCT00976287||133405|
NCT00975676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000650841|Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02|A Substudy of the IBCSG 24-02/ SOFT Trial to Investigate Estrogen Suppression for Patients Participating in Arms B and C of the IBCSG 24-02/ SOFT Trial|SOFT-EST|International Breast Cancer Study Group|Yes|Active, not recruiting|November 2008|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|N/A|120 Years|No|||February 2016|February 24, 2016|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975676||133452|
NCT00975975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908-04; IUCRO-0256|Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer|Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer||Indiana University|Yes|Completed|September 2009|November 2013|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|September 11, 2009||No||No|January 28, 2016|https://clinicaltrials.gov/show/NCT00975975||133429|
NCT01015859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol IGxD04|Spontaneous Atrioventricular Conduction Preservation|A Prospective Canadian Multi-center Randomized Study of the Benefits of Spontaneous Atrioventricular Conduction (Can Save R)|CAN-SAVER|Montreal Heart Institute|Yes|Completed|June 2006|October 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|370|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015859||130395|
NCT01015872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C368-kyoto|The Roles of Prostanoids in Patients With Sleep Apnea Syndrome|The Investigation of the Roles of Prostanoids in Patients With Sleep Apnea Syndrome||Kyoto University, Graduate School of Medicine|No|Completed|December 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|20 Years|N/A|No|||March 2013|March 25, 2013|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015872||130394|
NCT01016197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH1|Surgical Versus Conservative Treatment of Acute Mallet Fingers; a Randomised Controlled Trial|||Mid Cheshire Hospitals NHS Foundation Trust|Yes|Not yet recruiting|January 2010|June 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|16 Years|N/A|No|||November 2009|November 18, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016197||130371|
NCT01017354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK39/09|Zurich Disability Prevention Trial|Monthly Vitamin D to Improve Vitamin D Status and Maintain Function in Pre-frail Older Individuals Living at Home|ZDPT|University of Zurich|Yes|Completed|January 2010|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|200|||Both|70 Years|N/A|No|||August 2015|August 21, 2015|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017354||130283|
NCT01017679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-JC-003|Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg|Phase II Multi-centre Randomized Controlled Study of Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg||Sun Yat-sen University|No|Completed|May 2009|December 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||January 2012|December 8, 2013|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01017679||130258|
NCT01017692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5825-MRI Variability|Magnetic Resonance Imaging (MRI) Interpretations for Lumbar Spinal Stenosis (LSS)|Variability of Magnetic Resonancy Imaging Interpretation for Lumbar Spinal Stenosis||State University of New York - Upstate Medical University|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who are seen at SUNY Upstate Medical Univeristy, Department of Orthopedic Surgery        office|September 2013|May 22, 2015|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01017692||130257|
NCT01016782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0444|Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea|Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0444 Gel||Fougera Pharmaceuticals Inc.||Completed|January 2008|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|867|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|November 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01016782||130326|
NCT01016795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCF 980266|Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma|A Randomized Study of Peripheral Blood Progenitor Cell Priming Comparing a Combination of r-metHuSCF and Filgrastim or Chemotherapy and Filgrastim on Mobilization and Engraftment in Patients With Relapsed or Refractory Lymphomas|SCF980266|Aalborg Universitetshospital|No|Terminated|January 1999|November 2009|Actual|November 2000|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||November 2009|June 24, 2015|November 18, 2009||No|Study closed Nov 2000 by Amgen, who stopped drug delivery|No||https://clinicaltrials.gov/show/NCT01016795||130325|
NCT01017055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090409003|Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery|Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery||University of Alabama at Birmingham|No|Recruiting|October 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|19 Years|N/A|No|Non-Probability Sample|Patients undergoing revision anterior cervical spine surgery|March 2016|March 2, 2016|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01017055||130306|
NCT01018290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002325/2|Navigated Transcranial Magnetic Stimulation in Tumor Surgery|Preoperative Non-Invasive Motor Mapping in Tumor Surgery by Navigated Transcranial Magnetic Stimulation||Nexstim Ltd|No|Terminated|November 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|20 patients with brain tumor in the vicinity of the central motor region scheduled for        elective surgery.Patients aged 18 and over with no other brain abnormalities.|June 2011|June 7, 2011|November 20, 2009||No|Recruitment goals not met|No||https://clinicaltrials.gov/show/NCT01018290||130212|
NCT01018277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-115|Effect of Mobilization on Acute Postoperative Pain and Nociceptive Function|Effect of Mobilization on Acute Postoperative Pain and Nociceptive Function After Total Knee Arthroplasty: A Prospective, Consecutive, Trial||Hvidovre University Hospital|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Patients operated with TKA|April 2012|April 19, 2012|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018277||130213|
NCT01018550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080615|AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma|A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects With Inadequately Controlled Asthma||Amgen||Completed|October 2009|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|November 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01018550||130192|
NCT01018563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-003-002A|An Open Label Extension Study of the Efficacy of MORAb-003|An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse||Morphotek|No|Completed|November 2009|August 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|N/A|No|||November 2015|November 13, 2015|November 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01018563||130191|
NCT01014195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEULS|Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors|Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors||St. Jude Children's Research Hospital|No|Completed|January 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|237|||Both|8 Years|N/A|No|Non-Probability Sample|Children originally enrolled and treated on the SJCRH TOTXV protocol. The study has        reviewed TOTXV patient database and has identified 343 patients (189 males and 154        females) who will meet the inclusion criteria (assuming no additional deaths or relapse).|August 2015|August 17, 2015|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014195||130523|
NCT01014494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1008-0083|Adaprev in Digital Flexor Tendon Repair|A Randomized, Double Blind Clinical Investigation to Evaluate the Safety, Tolerability, and Preliminary Performance of Adaprev™ in Improving Recovery of Tendon Function in Subjects Undergoing Surgical Repair of Flexor Tendons in Zone II of the Hand||Renovo|No|Recruiting|September 2009|December 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Both|18 Years|N/A|No|||December 2010|December 7, 2010|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014494||130500|
NCT01014507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFE|Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma|Randomisierte Phase II Studie Zum Einsatz Von Goserelin Und Oralen Kontrazeptiva Zur Reduktion Ovarieller Toxizitäten während Zytostatischer Primärtherapie Bei Fertilen Patientinnen Mit Hodgkin Lymphom in Fortgeschrittenen Stadien|PROFE|University of Cologne||Completed|January 2004|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|40 Years|No|||October 2011|June 22, 2012|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014507||130499|
NCT00974233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO08405|Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL|Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL||University of Wisconsin, Madison|No|Active, not recruiting|October 2009|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|September 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974233||133559|
NCT00974246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISK-02|The Effect on Depressive Symptoms in ECF Residents With COPD|The Effect of Advair Diskus Treatment on Depression in Nursing Home Residents With COPD|DISK-02|Valley Medical Research|No|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|94 Years|No|||June 2015|June 30, 2015|September 8, 2009||No||No|June 15, 2015|https://clinicaltrials.gov/show/NCT00974246||133558|
NCT00974506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMGER09|Pilot Study: Complementary Therapies in Geriatric Patients|Pilot Study Complementary Therapies in Geriatric Patients||Charite University, Berlin, Germany|No|Completed|August 2009|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2009|July 10, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974506||133538|
NCT00974519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.07.16-2|The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV/AIDS Patients|Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trials on the Effect of Combination of TCM and HAART on Immune Reconstitution of HIV/AIDS Patients||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Recruiting|September 2009|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|70 Years|No|||September 2009|October 28, 2009|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974519||133537|
NCT00975130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06129|Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)|An Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Biologic-Naïve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2)|GO-MORE|Merck Sharp & Dohme Corp.|No|Completed|September 2009|February 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3366|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 20, 2009|Yes|Yes||No|July 18, 2012|https://clinicaltrials.gov/show/NCT00975130||133491|
NCT00975143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISOCT.08.01|Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne|A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne||Cipher Pharmaceuticals Inc.|Yes|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|925|||Both|12 Years|54 Years|No|||June 2014|June 5, 2014|September 9, 2009|Yes|Yes||No|July 4, 2012|https://clinicaltrials.gov/show/NCT00975143||133490|Generic isotretinoin control because Accutane® was discontinued in the US. 201 PPP exclusions (CIP-Isotretinoin 101, Isotretinoin 100) due to discontinuation < Week 20 (61+51), non-compliance with treatment (76+75) or other requirements (≥1 reason).
NCT00976014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30519-E/A|Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study|Effects of Long-term Therapy With LDL-lowering Plus HDL Raising on Carotid Intima-media Thickness (CIMT) - Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study|FATS|University of Washington|Yes|Enrolling by invitation|September 2006|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|55|||Male|N/A|N/A|No|Non-Probability Sample|Subjects known to have Atheroscloerosis.|September 2009|September 18, 2009|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976014||133426|
NCT01006915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPNPSI-1|Surgical Decompression for Diabetic Neuropathy in the Foot|Surgical Peripheral Nerve Decompression for the Treatment of Diabetic Neuropathy in the Foot||Timothy J. Best Medicine Professional Corporation|No|Recruiting|March 2010|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2011|December 19, 2011|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01006915||131078|
NCT00975988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112477|Regulatory TYKERB® Tablets PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of TYKERB® Tablets Administered in Korean Patients According to the Prescribing Information||GlaxoSmithKline|No|Completed|January 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|750|||Both|N/A|N/A|No|Probability Sample|Patients administrated TYKERB® tablets at the site|October 2014|October 23, 2014|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00975988||133428|
NCT00976001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGSKAS-2300|Follow-up Pilot Study After a First Stroke|Open, Randomized Follow-up Pilot Study After a First Stroke||Skaraborg Hospital|No|Completed|March 2003|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|163|||Both|N/A|84 Years|No|||September 2009|September 11, 2009|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00976001||133427|
NCT00976274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2009-0015|Korean Red Ginseng and Metabolic Syndrome|Effects of Korean Red Ginseng on Cardiovascular Risks in Subjects With Metabolic Syndrome||The Korean Society of Ginseng|Yes|Completed|August 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|N/A|No|||February 2012|February 23, 2012|September 11, 2009||No||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00976274||133406|First, we could not fully control participants’ lifestyle such as exercise and diet.Second, the relationship between Korean red ginseng dosage and its effect on cardiovascular disease risks was not evaluated.
NCT01015625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG 28 / POSYTIVE|Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer|Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer, a Multicenter Prospective Randomized Study to Evaluate the Use of Local Therapy|POSYTIVE|Austrian Breast & Colorectal Cancer Study Group|No|Active, not recruiting|October 2010|June 2021|Anticipated|June 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|254|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015625||130413|
NCT01016808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q8003-008|Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients|A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of Q8003 With Oxycodone and Morphine for the Management of Acute Moderate to Severe Postoperative Pain Following Bunionectomy Surgery||QRxPharma Inc.|No|Completed|December 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|522|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|November 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01016808||130324|
NCT01017081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISIOPUL|Chest Physiotherapy in Pediatrics Patients With Pneumonia|Chest Physiotherapy in Pediatric Patients Hospitalised With Community-acquired Pneumonia: a Randomized Clinical Trial||Santa Casa de Porto Alegre|No|Completed|September 2001|September 2002|Actual|September 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|72|||Both|1 Year|12 Years|No|||November 2009|November 19, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017081||130304|
NCT01017094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 50/369-006|Pin Site Infection Prevention for Open Tibial Fracture|Can Silversulfadiazine Prevent Pin-site Infection in Open Tibial Fracture?: A Randomized Controlled Trial||Prince of Songkla University|No|Completed|September 2007|November 2009|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|15 Years|60 Years|No|||November 2009|November 19, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017094||130303|
NCT01017367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX1100-04|Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)|Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)|MDX1100-04|Bristol-Myers Squibb|Yes|Completed|February 2008|May 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01017367||130282|
NCT01017718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Nerve Conduction Velocity in Diabetic Children|Prevalence of Pathological Nerve Conduction Velocity in Children and Adolescents Suffering From Diabetes Mellitus Type I||Landeskrankenhaus Feldkirch|Yes|Completed|May 2009|July 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|8 Years|18 Years|No|Non-Probability Sample|children and adolescents with diabetes mellitus type 1 (duration of disease > 1 year, age        8 to 18a, insulin requirement > 0.5 IU/kg/d)|September 2011|September 24, 2011|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01017718||130256|
NCT01017731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13915|Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes|A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|November 2009|May 2014|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|68|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|November 19, 2009|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01017731||130255|
NCT01017965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0917|Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients|Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients|DIAPASOM2|University Hospital, Grenoble|No|Terminated|November 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|79|Samples Without DNA|A sample of serum will be retained in order to compare indicators of inflammation with sleep      duration and diabetes complications|Both|18 Years|N/A|No|Non-Probability Sample|This study will enroll type 1 diabetes patients who come for a consultation in Grenoble        University Hospital.|October 2012|October 4, 2012|November 20, 2009||No|intermediary analysis was performed and significant results were found for the main objective|No||https://clinicaltrials.gov/show/NCT01017965||130237|
NCT01017978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00023415|Quantitative MR Biomarkers for Sarcoma Treatment|Quantitative MR Biomarkers for Sarcoma Treatment||University of Michigan|Yes|Completed|July 2009|April 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|3 Years|N/A|No|||December 2015|December 2, 2015|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01017978||130236|
NCT01018303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0355|Safety and Efficacy of an Antioxidant-rich Multivitamin Supplement in Cystic Fibrosis|Safety and Efficacy of a Novel Antioxidant-rich Multivitamin Supplement for Persons With Cystic Fibrosis||University of Colorado, Denver|No|Completed|August 2007|November 2009|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|10 Years|40 Years|No|||October 2012|October 11, 2012|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018303||130211|
NCT01018576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200916964|Delayed Cord Clamping in Premature Infants|Delayed Cord Clamping: Prevention of Anemia and Hypothermia in Premature Infants||University of California, Davis|Yes|Terminated|September 2009|March 2012|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6|||Both|N/A|1 Minute|No|||December 2014|December 1, 2014|November 5, 2009||No|Inadequate numbers of babies enrolled and departure of co-investigator|No||https://clinicaltrials.gov/show/NCT01018576||130190|
NCT01018589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0904-CU|Cicatrix Cream in Post Surgical Scars and Epidermic Burn|Effect the Cicatrix Cream in in Treatment of Post Surgical Scars and and Epidermic Burn.||Catalysis SL|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|18 Years|No|||December 2010|December 7, 2010|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018589||130189|
NCT01014208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110928|Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma|Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)|ORCHARRD|GlaxoSmithKline|Yes|Completed|March 2010|November 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||February 2015|July 9, 2015|November 4, 2009|Yes|Yes||No|October 9, 2014|https://clinicaltrials.gov/show/NCT01014208||130522|
NCT01014221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9612|Acupuncture in Patients With Carpal Tunnel Syndrome ~ A Randomized Controlled Trial|Acupuncture in Patients With Carpal Tunnel Syndrome ~ A Randomized Controlled Trial||Kuang Tien General Hospital|No|Completed|July 2007|September 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|20 Years|80 Years|No|||November 2009|November 16, 2009|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014221||130521|
NCT00974532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0959|Analysis of Calcium Balance in Chronic Kidney Disease|Analysis of Calcium Balance in Chronic Kidney Disease||University of Colorado, Denver|Yes|Completed|May 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|December 3, 2012|June 3, 2009||No||No||https://clinicaltrials.gov/show/NCT00974532||133536|
NCT00974831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK51|Glucose Tolerance in Healthy Overweight Adults|Glucose Tolerance in Healthy Overweight Adults||Abbott Nutrition|Yes|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 24, 2010|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974831||133514|
NCT00974844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUHS-SWJA|Posterior Assisted Levitation of Dropped Nucleus|Posterior Assisted Levitation by Pars-Plana Levitator|PAL|Dow University of Health Sciences|Yes|Completed|January 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|14|||Both|30 Years|90 Years|No|Non-Probability Sample|Patients who had dropped nucleus during phacoemulsification|September 2009|August 23, 2011|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT00974844||133513|
NCT00975403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSS15110|Pathophysiological Mechanisms of Dyspnea and Activity-limitation in Mild Chronic Obstructive Pulmonary Disease (COPD)|Pathophysiological Mechanisms of Dyspnea and Activity-Limitation in Mild COPD||Queen's University|No|Completed|October 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|20|||Both|40 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 14, 2012|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975403||133471|
NCT01006642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009SDU-QILU-G04|Mucosal Barrier Defects in Functional Dyspepsia by Confocal Laser Endomicroscopy|Minimal Changes of Gastric Mucosal Barrier in the Pathophysiologic Mechanisms of Functional Dyspepsia||Shandong University|Yes|Recruiting|July 2009|July 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|80|Samples With DNA|Biopsies during endoscopy|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with indications for upper-endoscopy in Qilu Hospital outpatient and inpatient        department are the study population of this study.|November 2009|November 2, 2009|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006642||131099|
NCT01007201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU09002|Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population|A Clinical Study to Assess the Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Subjects Aged Over 1 Year Old to 18 Years Old||Adimmune Corporation||Completed|October 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|183|||Both|1 Year|17 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01007201||131056|
NCT00976573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N0879|Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma|A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, With or Without Everolimus for Therapy of Metastatic Malignant Melanoma||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|April 2010|||December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00976573||133383|
NCT00976872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|keren1|Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins|Supplementation of Omega-3 Fatty Acid Complex to Routine Statin Treatment Decreases Patients' Day-time Blood Pressure, Improves Inflammatory Status and Prohibits Platelet Aggregation||Assaf-Harofeh Medical Center|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|30 Years|70 Years|No|||September 2009|June 7, 2010|September 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00976872||133360|
NCT00976885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20090209006|Oxygen Consumption Required by Stroke Patients During Completion of the Modified Rivermead Mobility Index (MRMI)|||The Hong Kong Polytechnic University||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Both|50 Years|N/A||Non-Probability Sample|stroke unit of local hospital and community groups|September 2009|September 14, 2009|September 14, 2009||||No||https://clinicaltrials.gov/show/NCT00976885||133359|
NCT01016821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070213|Oxycodone for Labor Pain - Pharmacokinetics (PK), Safety and Efficacy|The Efficacy and Safety of Intravenous Oxycodone and Plasma Oxycodone Concentrations in Labour Pain|Oksiobs|Kuopio University Hospital|Yes|Completed|November 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|18 Years|45 Years|No|||January 2011|January 10, 2011|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01016821||130323|
NCT01017107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS 210284|Activated Protein C in Severe Acute Pancreatitis|APCAP - Activated Protein C in Severe Acute Pancreatitis: A Double-blind Randomized Human Pilot Trial||Helsinki University Central Hospital|No|Completed|June 2003|September 2007|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||November 2009|October 13, 2010|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017107||130302|
NCT01017744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0062|Pressure Support Ventilation With the Anesthetic Conserving Device|Respiratory Mechanical Effects of Sevoflurane Administered With the Anesthetic Conserving Device in Pressure Support Ventilation||University Hospital, Clermont-Ferrand||Completed|November 2009|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||September 2013|September 2, 2013|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01017744||130254|
NCT01018004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000659310|Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma|Prospective Randomized Trial for the Evaluation of a Theoretical Follow-Up Schedule in Cutaneous Melanoma Patients, the MELFO-Study.||National Cancer Institute (NCI)||Recruiting|March 2006|||December 2011|Anticipated|N/A|Observational|N/A|||Anticipated|178|||Both|18 Years|85 Years|No|||July 2010|August 23, 2013|November 20, 2009||||No||https://clinicaltrials.gov/show/NCT01018004||130234|
NCT01018680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12909|A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis|A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients With Knee Pain Due to Osteoarthritis Who Have Had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment.||Eli Lilly and Company|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|524|||Both|40 Years|N/A|No|||September 2012|September 4, 2012|November 23, 2009|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01018680||130182|
NCT01017991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.03.INF|Feeding Intervention for Infants With Crying|Effects of an Infant Formula With Probiotics on Signs and Symptoms of "Colic".||Nestlé|No|Terminated|December 2009|March 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|65|||Both|N/A|4 Months|Accepts Healthy Volunteers|||December 2012|March 25, 2015|November 20, 2009||No|The study has been terminated as a result of low enrollment.|No||https://clinicaltrials.gov/show/NCT01017991||130235|
NCT01014234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070034809|Rapamycin and Regulatory T Cells in Kidney Transplantation|Rapamycin and Regulatory T Cells in Renal Transplant Patients: a Two-year Randomized Prospective Study||IRCCS Policlinico S. Matteo|Yes|Completed|July 2008|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|75 Years|No|||March 2015|March 24, 2015|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014234||130520|
NCT01018602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808040006|PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)|A Phase II, Randomized, Double-blind, 2-arm Controlled Study to Evaluate Efficacy of the DPPIV-inhibitor Vildagliptin for Prevention of Type 2 Diabetes in Women With a Recent History of Insulin-requiring Gestational Diabetes||Institut fur Diabetesforschung, Munich, Germany|Yes|Recruiting|January 2008|June 2015|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 24, 2011|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018602||130188|
NCT01018615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1631|Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C|Steady-State Pharmacokinetic Interactions of Green Tea Catechins and Silymarin Flavonolignans in Treatment Naïve Patients With Chronic Hepatitis C Infection||University of North Carolina, Chapel Hill|Yes|Completed|November 2009|July 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|November 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01018615||130187|
NCT01016314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP-09-001|Efficacy of the Aspen Spinous Process System in Anterior Lumbar Interbody Fusion (ALIF)|A Multi-Center Prospective Randomized Study to Evaluate the Efficacy of the Aspen Spinous Process System for Use in Anterior Lumbar Interbody Fusion (ALIF)||Biomet, Inc.|No|Active, not recruiting|November 2009|December 2016|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|75 Years|No|||February 2016|February 26, 2016|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016314||130362|
NCT01016574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7326-09-SMC|Evaluating the Adequacy of Giro-Couch to Support Prone Breast Boost Irradiation Using IMRT Technique With IGRT.|Evaluating the Adequacy of Giro-Couch to Support Prone Breast Boost Irradiation Using Intensity Modulated Radiation Therapy(IMRT)Technique With Image-guided Radiation Therapy(IGRT).|IN902|Azimuth Therapy Ltd.|No|Not yet recruiting|December 2011|December 2012|Anticipated|September 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Female|40 Years|N/A|No|||August 2011|August 2, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016574||130342|
NCT01014754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU1460|Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels|Nephrogenic Systemic Fibrosis and Gadolinium—A Medical Record Review With Analysis of Existing Skin and Other Tissue Specimens to Assess Potential Causative or Associated Factors|NSF|Northwestern University|Yes|Completed|August 2007|June 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control||6|Actual|24|Samples With DNA|Existing skin tissue from standard of care biopsies|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Those with NSF (25). 40 subjects selected through Northwestern University Department of        Dermatology's existing medical records and pathology specimens. Medical records will be        reviewed to identify 10 subjects who have had a standard of care skin biopsy in the        dermatology clinics at Northwestern University and who were exposed to Gadolinium in the 2        years prior to skin biopsy. Another 10 subjects who have had skin biopsy and who have        never been exposed to GBCA during a medical imaging procedure will also be identified.        Another 10 subjects on dialysis or with eGFR ≤30 exposed to GBCA in the 2 years prior to        skin biopsy will be identified. Another group of 10 subjects on dialysis or with eGFR ≤30        who have had skin biopsy and who have never been exposed to GBCA during a medical imaging        procedure will also be identified. Neonatal skin tissue of up to 10 subjects with existing        skin tissue sample will be sent for analysis.|December 2014|December 2, 2014|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014754||130480|
NCT00974857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-4/13|Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis Patients|Effects Of Volume Control Guided By Bioimpedance Spectroscopy On Blood Pressure And Cardiac Condition In Hemodialysis Patients||Ege University|Yes|Completed|June 2009|September 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|126|||Both|18 Years|75 Years|No|||September 2013|September 6, 2013|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974857||133512|
NCT00975156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MH-08-0206|Improving Ambulation Post Stroke With Robotic Training|Improving Ambulation Post Stroke With Robotic Training||The University of Texas Health Science Center, Houston|No|Completed|May 2008|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|90 Years|No|||February 2013|February 20, 2013|September 10, 2009||No||No|August 14, 2012|https://clinicaltrials.gov/show/NCT00975156||133489|Limitations include: small sample (n=21 enrolled, n=20 completed) and significant (p=0.025) difference between groups in time since stroke (Lokomat group, time since stroke mean=1353.60 days; Conventional group, time since stroke mean=525.00 days).
NCT00975429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN902 PCM203|Study Using WST11 in Patients With Localized Prostate Cancer|Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer||Steba Biotech S.A.|No|Completed|September 2009|August 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Male|18 Years|N/A|No|||September 2012|April 27, 2015|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975429||133469|
NCT01006928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY0015-09-IL|Association Between the Support of NICU Team and Subjective Health of Parents|Association Between the Support of Neonatal Intensive Care Unit (NICU) Team and Subjective Health of Parents to a Premature Infant||Hillel Yaffe Medical Center|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|150|||Both|N/A|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mothers of infants in NICU|June 2011|June 5, 2011|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006928||131077|
NCT01006941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rigshospitalet, DMSC|Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study|Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study|TRIMS A|Rigshospitalet, Denmark|Yes|Completed|May 2010|September 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|55 Years|No|||November 2011|November 9, 2011|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01006941||131076|
NCT01007188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-412|Energy Value of Macronutrients From Almonds and Mechanisms of Nutrient Action|Energy Value of Macronutrients From Almonds and Mechanisms of Nutrient Action||USDA Beltsville Human Nutrition Research Center|Yes|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|18|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007188||131057|
NCT01007461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-1001-AMI-201|IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction|A Phase 2, Randomized. Double-Blind, Dose-Escalation, Dose-Expansion, Placebo-Controlled, Multi-Center Study of IK-1001 to Evaluate Safety, Pharmacokinetics , and Proof-of-Concept Efficacy in Subjects With Acute ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention||Ikaria|Yes|Withdrawn|December 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||April 2015|April 3, 2015|October 26, 2009||No|Company decision. Non-safety related|No||https://clinicaltrials.gov/show/NCT01007461||131036|
NCT01016834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX001-0901|Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine|A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans||Zogenix, Inc.|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|246|||Both|18 Years|65 Years|No|||November 2011|November 28, 2011|November 18, 2009|Yes|Yes||No|November 28, 2011|https://clinicaltrials.gov/show/NCT01016834||130322|
NCT01017393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_epidural ketamine PTPS|Preemptive Low-dose Epidural Ketamine for Preventing Chronic Post-thoracotomy Pain|||Seoul National University Hospital||Completed|April 2004|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|209|||Both|19 Years|81 Years|No|||November 2009|November 19, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017393||130280|
NCT01016925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/065/HP|Bacterial Colonization After Tunneling in Femoral Perineural Catheters|Bacterial Colonization After Tunneling in Femoral Perineural Catheters|Tunnelized KT|University Hospital, Rouen||Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|338|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01016925||130315|
NCT01017172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWG11.2009|Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients|Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adults||Goethe University|No|Recruiting|November 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||November 2009|November 19, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017172||130297|
NCT01018693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAK694A2205|A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance|Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis||Novartis||Completed|November 2009|||October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|60 Years|No|||April 2012|April 23, 2012|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01018693||130181|
NCT01018316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR-MEM|UMOX - New Device for Oropharyngeal Preoxygenation|||Maisonneuve-Rosemont Hospital|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers|November 2009|November 20, 2009|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018316||130210|
NCT01018628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114011|A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers|A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers||GlaxoSmithKline|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|8||Actual|64|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 21, 2011|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018628||130186|
NCT01018641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6123K1-1007|An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults|A Phase 1 Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Ascending Dose Levels Of A 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults||Pfizer|Yes|Completed|January 2010|July 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|449|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2014|April 23, 2014|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018641||130185|
NCT01014520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|883|Efficacy of Gabapentin or Amitriptyline to Reduce Postoperative Pain After Lumbar Laminectomy and Diskectomy|Comparative Effects of Single Dose Preemptive Gabapentin or Amitriptyline on Postoperative Pain and Opioid Consumption in Single Level Lumbar Laminectomy and Diskectomy: A Double Blind RCT With Placebo Control||Tabriz University|Yes|Recruiting|May 2009|March 2010|Anticipated|February 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||November 2009|November 16, 2009|November 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01014520||130498|
NCT01014533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00010947|Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence|This is a Study Exploring the Reasons Why People With Alcohol Dependence Have Sleep Disturbances, and Whether or Not a Study Medication, Gabapentin, vs. Placebo, Affects Those Sleep Patterns.|MA|University of Michigan|Yes|Completed|May 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014533||130497|
NCT01017419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Orientation for Hearing Aid Users: Information Retention|Orientation for Hearing Aid Users: Information Retention||University of Sao Paulo|Yes|Completed|March 2004|January 2008|Actual|January 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|88 Years|No|Non-Probability Sample|30 adults (18 female and 12 male) with age varying from 18 to 88 years, with post lingual        uni or bilateral hearing loss of various degrees and types.|November 2009|November 19, 2009|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017419||130278|
NCT01017770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTEffectiveness|Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso|Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy|ACTE|Centre Muraz|No|Completed|September 2008|August 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|6 Months|59 Months|No|||July 2015|July 29, 2015|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01017770||130252|
NCT01017783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-Nestle-01|Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults|Randomized Controlled Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults||University of North Carolina, Chapel Hill|No|Completed|March 2008|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|318|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 1, 2011|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01017783||130251|
NCT00974870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU15904|A Pilot Study Testing the Efficacy of a Needling Device for the Treatment of Acne Scars|A Split-face Randomized Controlled Trial to Assess the Efficacy of a Needling Device for the Treatment of Acne Scars||Northwestern University|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|September 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00974870||133511|
NCT00975169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902005R|Association Study of Genetic Polymorphisms of Candidate Genes With Thiazolidinedione-Related Peripheral Edema and Drug Responsiveness|Association Study of Genetic Polymorphisms of Candidate Genes With Thiazolidinedione-Related Peripheral Edema and Drug Responsiveness||National Taiwan University Hospital|No|Recruiting|February 2009|||December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|TZDs User, no insulin; CHF, according to New York heart Association III-V, liver cirrhosis        or renal insufficiency (Cr ≥ 1.7 mg/dL) before initiation of treatment with TZDs will be        excluded.|March 2010|March 16, 2010|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00975169||133488|
NCT00975416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908432|Oxytocin and Cognitive Behavioral Therapy in Drug Dependence|Oxytocin and Cognitive Behavioral Therapy in Drug Dependence||National Institutes of Health Clinical Center (CC)||Terminated|November 2008|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 10, 2009|Yes|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT00975416||133470|1 participant committed suicide outside of that occurred outside of adverse event time frame.There were 12 occurrences of computer malfunction during the study. This did not effect data collection for primary outcome measures.
NCT01006655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qvar-adenosineCTIL|The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children|The Effect of HFA - Beclomethasone Dipropionate - Qvar - on Bronchial Hyperreactivity in Preschool Children||Rambam Health Care Campus|No|Completed|March 2009|March 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|3 Years|7 Years|No|||October 2015|October 28, 2015|November 2, 2009|Yes|Yes||No|July 10, 2010|https://clinicaltrials.gov/show/NCT01006655||131098|
NCT01006668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-13|Sevoflurane Versus Propofol for Intubation in Neonatal Intensive Care|Sevoflurane Versus Propofol for Intubation in Neonatal Intensive Care||Assistance Publique Hopitaux De Marseille|No|Recruiting|November 2009|||November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|N/A|28 Days|No|||August 2014|August 28, 2014|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01006668||131097|
NCT01007227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|743EndothelialMetsyd|Metabolic Syndrome and Fingertip Endothelial Dysfunction|Achievement of Dietetic and Exercise Therapy Evaluated by Self-assessment Score Significantly Improved Endothelial Dysfunction in Patients With Metabolic Syndrome||Kumamoto University|No|Completed|August 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|20 Years|90 Years|No|||September 2013|September 25, 2013|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007227||131054|
NCT01007240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|siliconnanoHMO-CTIL|Antibacterial Properties of Silicon Incorporated With Quaternary Ammonium Polyethylenimine Nanoparticles|Clinical Study of the Antibacterial Properties of the Nano Particles Which Incorporated With the Soft Liner Silicone - in Obturators||Hadassah Medical Organization|Yes|Not yet recruiting|January 2010|December 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|90 Years|No|||November 2009|November 3, 2009|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007240||131053|
NCT01007474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-ICSP|Italian ClinicalService Project|Italian ClinicalService Project on Patients Implanted With Medtronic Implantable Devices or Treated by Medtronic Therapies||Medtronic Italia|No|Recruiting|January 2004|January 2020|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|The study population consists of patients who received a Medtronic device or were treated        by Medtronic therapy (currently available or future market-released devices) at one of the        participating study locations in Italy.|March 2016|March 3, 2016|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007474||131035|
NCT01007708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-IDP-108-P3-02|The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis|||Dow Pharmaceutical Sciences|No|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|780|||Both|18 Years|70 Years|No|||June 2012|June 20, 2012|November 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01007708||131017|
NCT01007721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.41|Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season|Randomised, Double-blind, Triple Dummy, Partial Cross-over (Each Active Treatment With Placebo) Study Using an Environmental Challenge Chamber (ECC) to Assess the Safety and Efficacy of 2 Weeks of Oral BI 671800 ED 50, 200 or 400 mg Bid, Compared to Montelukast 10 mg qd, Fluticasone Propionate Nasal Spray 200 µg qd (2 Nasal Actuations Each Nostril of 50 µg) Versus Placebo in Seasonal Allergic Rhinitis Patients Out of Season, Sensitive to Dactylis Glomerata.||Boehringer Ingelheim||Completed|October 2009|||April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|146|||Both|18 Years|65 Years|No|||April 2014|April 30, 2014|November 3, 2009||||No||https://clinicaltrials.gov/show/NCT01007721||131016|
NCT01017120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114576|A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris||GlaxoSmithKline|No|Completed|October 2009|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|742|||Both|12 Years|45 Years|No|||May 2012|May 31, 2012|November 19, 2009|Yes|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01017120||130301|
NCT01017380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC50/369-007|Preemptive Analgesia in Cruciate Reconstruction|Comparing Etoricoxib and Celecoxib for Preemptive Analgesia for Acute Postoperative Pain in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial||Prince of Songkla University|No|Completed|January 2008|June 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|15 Years|50 Years|No|||November 2009|November 19, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017380||130281|
NCT01015742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-0902|Unrelated Double Umbilical Cord Blood Units Transplantation|Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies||Tehran University of Medical Sciences|Yes|Recruiting|November 2009|January 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|50 Years|No|||May 2012|May 31, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015742||130404|
NCT01015170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/2008|STOP Study: Effectiveness of Zyban in a Clinical Population|The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population||Centre for Addiction and Mental Health|No|Active, not recruiting|October 2009|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|750|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015170||130448|
NCT01014312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30MH085943-02|Treatment for Depressed Primary Care Patients|Community-Based Depression Care Management for Elderly Primary Care Patients||Weill Medical College of Cornell University|Yes|Active, not recruiting|September 2009|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|60 Years|N/A|No|||December 2014|December 18, 2014|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01014312||130514|
NCT01014611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-23|Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle|Evaluation of Calcium Homeostasis and Mitochondrial Function in Skeletal Muscle in Subjects With Heart Failure, Before and After Exercise Training|Calcicard|Institut National de la Santé Et de la Recherche Médicale, France|No|Terminated|April 2010|November 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3|||Male|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|24 heart failure patients: 12 class II NYHA with a fraction of ejection between 40% and        30% and 12 class III NYHA with a fraction of ejection lower than 30% 24 sedentary healthy        male volunteers matched to patients on age and physical activity|September 2012|September 26, 2012|November 16, 2009||No|Difficulties of recruitement|No||https://clinicaltrials.gov/show/NCT01014611||130491|
NCT01014624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS747S-B-U4001|Prasugrel/Clopidogrel Maintenance Dose Washout Study|Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease||Daiichi Sankyo Inc.|No|Completed|February 2010|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|74 Years|No|||February 2012|February 8, 2012|November 16, 2009|Yes|Yes||No|May 31, 2011|https://clinicaltrials.gov/show/NCT01014624||130490|
NCT01014767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT-SIOP-2009|Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors|CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors||Tufts Medical Center|Yes|Suspended|November 2009|November 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|190|||Both|N/A|N/A|No|||October 2013|October 30, 2013|November 13, 2009|Yes|Yes|PI departure from coordinating institution|No||https://clinicaltrials.gov/show/NCT01014767||130479|
NCT01014780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-10|Tear Film Thickness Measured Using a Novel Technique|Tear Film Thickness Measured Using a Novel Technique||Southern California College of Optometry|No|Completed|November 2009|October 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will inculde up to 20 normals (i.e., non-dry eye) individuals, over the age of        18 years, adn 20 dry eye individuals.|September 2010|October 8, 2010|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01014780||130478|
NCT01015092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0702/156|Cardiovascular Risk Evaluation and Antiretrovirals in HIV|Predicted 10-year Coronary Heart Disease Risk in HIV and Implications for Clinical Management: the CREATE Study|CREATE1|King's College London|No|Completed|June 2005|November 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1024|||Both|18 Years|N/A|No|Probability Sample|All HIV outpatients patients attending two London Hospitals|November 2009|November 16, 2009|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015092||130454|
NCT01015105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TnT in Hip Fracture|Troponin Elevation in Consecutive Patients With Hip Fracture|Troponin Elevation in Consecutive Patients With Hip Fracture||Turku University Hospital|No|Recruiting|February 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|200 patients with hip fracture|November 2009|November 17, 2009|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015105||130453|
NCT01015118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.15|LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer|Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer||Boehringer Ingelheim||Active, not recruiting|November 2009|July 2016|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1366|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|November 9, 2009||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01015118||130452|
NCT01015391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TW2-001|Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease|A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection|T2|Jinling Hospital, China|No|Recruiting|November 2009|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|June 1, 2013|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015391||130431|
NCT01018030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113203|Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 2-week Treatment Study to Evaluate the Safety and Efficacy of Fluticasone Furoate Nasal Spray 110 Mcg in the Treatment in the Treatment of Uncomplicated Acute Rhinosinusitis in Adults and Adolescents >= 12 Years of Age||GlaxoSmithKline|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|741|||Both|12 Years|N/A|No|||April 2011|June 20, 2013|November 19, 2009||No||No|March 17, 2011|https://clinicaltrials.gov/show/NCT01018030||130232|
NCT01018355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hillerod-294|The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI|The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI|CryptoCard|Hillerod Hospital, Denmark|Yes|Terminated|October 2009|June 2015|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|51 Years|N/A|No|||November 2009|May 5, 2010|November 20, 2009||No|Dissatisfactory enrollment rate|No||https://clinicaltrials.gov/show/NCT01018355||130207|
NCT01006109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100003|Recording and Modulation of Neuronal Mechanisms During Operant Conditioning: a MEG Study|Recording and Modulation of Neuronal Mechanisms During Operant Conditioning: A MEG Study||National Institutes of Health Clinical Center (CC)||Recruiting|October 2009|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006109||131139|
NCT01006122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8801015|A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy|A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy||Pfizer|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|55 Years|No|||April 2014|April 8, 2014|October 29, 2009|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01006122||131138|
NCT01006382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1102/100|Adherence to Self-care Regimens for Young People With Food Allergy|To What Extent do Social Cognition Models Explain Adherence to Self-care Regimens in Adolescents and Young Adults With Food Allergy||Brighton & Sussex Medical School|Yes|Completed|January 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|275|||Both|13 Years|21 Years|No|Non-Probability Sample|Hospital and community sample|October 2009|June 21, 2011|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006382||131118|
NCT01006395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG2009_01|Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)|Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)||Austin Health|Yes|Recruiting|January 2011|April 2018|Anticipated|April 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|75 Years|No|||December 2015|December 28, 2015|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006395||131117|
NCT01006408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLLT-001|Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy|Pilot, Single Center, Randomized, Double Blind, Placebo Controlled, Single Crossover Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy|LLL|Legacy Health System|No|Completed|October 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006408||131116|
NCT01006954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-003|Outcome of Two Protocols in Poor Responders in Assisted Reproductive Technology (ART) Cycle|Comparison of Micro Dose Gonadotropin-Releasing Hormone (GnRH) Agonist Flare up & Flare Protocol in Poor Responders in Assisted Reproductive Technology (ART) Cycle||Royan Institute|Yes|Completed|September 2008|February 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Female|30 Years|42 Years|No|||November 2009|May 7, 2014|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006954||131075|
NCT01007253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-287-B|Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms|Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution Alone and In Combination on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen.||University of Chicago|No|Completed|November 2009|August 2011|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|November 3, 2009|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT01007253||131052|
NCT01007214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 133608|Guided Biopsy for Mapping Prostate Cancer|Hybrid Imaging Technique (HIT) Guided Biopsy to Map Prostatic Adenocarcinoma in Patients Undergoing Prostatectomy|HIT|Roswell Park Cancer Institute|Yes|Terminated|May 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Male|18 Years|N/A|No|||February 2014|February 26, 2014|October 29, 2009||No|Not able to meet accrual|No||https://clinicaltrials.gov/show/NCT01007214||131055|
NCT01007487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMSVUH1|Plastic Wound Retractors and Bacterial Translocation in Abdominal Surgery|Wound Retractor or Protector? Efficacy of a Plastic Wound Retractor (Alexis®) in Impeding Translocation of Enteric Bacteria to the Surgical Incision Site in Abdominal Surgery.||St Vincent's University Hospital, Ireland|No|Completed|January 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|250|||Both|14 Years|N/A|No|Non-Probability Sample|Patients undergoing abdominal surgery in which a plastic wound retractor is used.|November 2009|July 19, 2011|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007487||131034|
NCT01017133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01509|Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|May 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|56|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01017133||130300|
NCT01016600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1816 / 201101749|Azacitidine and Lenalidomide for Acute Myeloid Leukemia|Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia||Washington University School of Medicine|Yes|Completed|April 2010|October 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|November 17, 2009|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT01016600||130340|
NCT01016912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-021|Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients|A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron®) and Ribavirin (Rebetol®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||Bristol-Myers Squibb|No|Completed|December 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|51|||Both|20 Years|70 Years|No|||September 2015|September 23, 2015|November 19, 2009|Yes|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01016912||130316|
NCT01018394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005172|Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction|A Pilot Study to Compare the Nicotine Lozenge and Tobacco-Free Snuff for Smokeless Tobacco Reduction||Mayo Clinic|No|Completed|January 2009|July 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 11, 2013|November 19, 2009|Yes|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01018394||130204|
NCT01018017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114010|A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus|A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|86|||Both|18 Years|65 Years|No|||March 2012|March 29, 2012|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018017||130233|
NCT01014247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13796|Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation|A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 Trial||Bayer|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 31, 2013|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014247||130519|
NCT01018329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12309|Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma|Multimodality Statistical Model of Early Response of High Grade Glioma to Radiation Therapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|July 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01018329||130209|
NCT01018342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NITF-0256|Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules (100 mg; Mylan) and Macrobid® Capsules (100 mg; Procter & Gamble) in Healthy Volunteers.||Mylan Pharmaceuticals||Completed|July 2002|||August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 19, 2009|November 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01018342||130208|
NCT01015404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCB-1D-04|A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)|A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)||Kaken Pharmaceutical|No|Completed|November 2009|||March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|N/A|No|||October 2013|October 17, 2013|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01015404||130430|
NCT01015716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINALE-Health|Physical Exercise, Dietary Counseling and Cognitive Behavioral Training as a Combined Intervention to Reduce Weight and Increase Workability in Health Care Workers|Physical Exercise, Dietary Counseling and Cognitive Behavioral Training as a Combined Life-style Intervention to Reduce Weight and Increase Workability in Health Care Workers|FINALE-Health|University of Aarhus|Yes|Completed|November 2009|May 2012|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|146|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01015716||130406|
NCT01015976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803-272|A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects|A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects||Neuropsychiatric Research Institute, Fargo, North Dakota|No|Completed|February 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|October 1, 2009|Yes|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT01015976||130387|small sample size absence of men in either group. short data collection period, characterization of the linear elimination phase of the AUC was not possible.
NCT01024673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: PRO09090326|Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)|Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)||University of Pittsburgh|Yes|Recruiting|October 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|All the biologic samples and data will be under the control of the principal investigator .      To protect confidentiality, all personal identifiers will be removed and replaced with a      specific code number. The information linking these code numbers to the corresponding      subjects' identities will be kept in a separate, secure location. The investigators will      keep the samples and data indefinitely. All samples will be stored in the principal      investigators laboratory in Scaife Hall, Room 835.|Both|18 Years|N/A|No|Probability Sample|patients diagnosed clinically with H1N1|December 2015|December 16, 2015|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024673||129727|
NCT01023958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.2|Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer|An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy||Boehringer Ingelheim||Completed|November 2009|||December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|November 24, 2009||||No||https://clinicaltrials.gov/show/NCT01023958||129782|
NCT01014286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0756|Lung Cancer Mutation Consortium Protocol|Lung Cancer Mutation Consortium Protocol||University of Colorado, Denver|No|Recruiting|September 2009|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|Samples With DNA|Biopsy remnant tissue|Both|18 Years|N/A|No|Probability Sample|Stage IV adenocarcinoma of the lung who have undergone biopsy with remnant tissue|January 2016|January 5, 2016|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01014286||130516|
NCT01014572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0529A|The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart|The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart|AGE|University of Texas Southwestern Medical Center|Yes|Completed|July 2008|December 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|62|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|November 13, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014572||130494|
NCT01005888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVP2005-1/Part B|C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks|LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks||Shire|Yes|Completed|September 2005|August 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|26|||Both|6 Years|N/A|No|||March 2014|March 19, 2014|October 29, 2009|Yes|Yes||No|March 17, 2010|https://clinicaltrials.gov/show/NCT01005888||131156|
NCT01006135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.450|Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region|Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region||Boehringer Ingelheim||Completed|October 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4852|||Both|40 Years|N/A|No|Non-Probability Sample|patients|March 2014|March 12, 2014|October 30, 2009||||No|June 2, 2012|https://clinicaltrials.gov/show/NCT01006135||131137|
NCT01006148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1146218|Comparison of Allogenix Plus Demineralized Bone Matrix and Autogenous Bone Dust Versus Autogenous Bone Dust Alone in Ossification of Small Calvarial Defects, a Pilot Study.|Comparison of Allogenix Plus Demineralized Bone Matrix and Autogenous Bone Dust Versus Autogenous Bone Dust Alone in Ossification of Small Calvarial Defects, a Pilot Study.|DBM|University of Missouri-Columbia|No|Withdrawn|October 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Months|36 Months|No|||April 2014|April 15, 2014|October 30, 2009||No|problems obtaining the investigational agent, Allogenix(TM) Plus|No||https://clinicaltrials.gov/show/NCT01006148||131136|
NCT01006681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0560-09|Vaccination Against Influenza H1N1 in Rheumatic Diseases|Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Immunomodulatory Drugs||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2009|November 2, 2009|October 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01006681||131096|
NCT01006694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090928.1|Paraprofessional Treatment of Depression in Vietnam|Paraprofessional Treatment of Depression in Vietnam||Vietnam Veterans of America Foundation|No|Completed|March 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|473|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006694||131095|
NCT01006980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO25026|A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)|BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Global Study on Progression-free and Overall Survival in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving RO5185426 or Dacarbazine||Hoffmann-La Roche||Completed|January 2010|April 2015|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|677|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|October 30, 2009|Yes|Yes||No|July 29, 2011|https://clinicaltrials.gov/show/NCT01006980||131073|
NCT00974103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/798|Persistent Low Back and Pelvic Pain 3-6 Months Post Partum|Persistent Low Back Pain and Pelvic Pain 3-6 Months Post Partum||Helse Stavanger HF|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Female|16 Years|50 Years|No|||August 2012|August 31, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974103||133568|
NCT01007513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-020|Study of Cervix and Inflammation in Preterm Birth Prediction|Cervical Assessment by Supracervical, Cervical and Vaginal Markers: Simultaneous Transvaginal Ultrasound and Inflammatory Proteins Detection|COLIBRI|Université de Sherbrooke|No|Completed|June 2008|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Vaginal secretion|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|At risk women referred by their physician to the MFM clinic for evaluation of preterm        birth risk.|March 2012|March 28, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007513||131032|
NCT01007500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0407|Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery|||Yonsei University|Yes|Completed|September 2009|September 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|130|||Both|20 Years|75 Years|No|||October 2010|October 6, 2010|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007500||131033|
NCT01007760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRDRP-18FT-0049|Dose-dependent Effects of Second-hand Smoke on Vascular Function|Dose-dependent Biological Mechanisms of Second-hand Smoke on Endothelial Function and Oxidative Stress||University of California, San Francisco|No|Completed|November 2009|July 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|33|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007760||131013|
NCT01008033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-IDP-108-P3-01|Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis|||Dow Pharmaceutical Sciences||Completed|November 2009|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|870|||Both|18 Years|70 Years|No|||June 2012|June 20, 2012|November 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01008033||130993|
NCT01008046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU- 183|N-acetyl Cysteine and Clomiphene Citrate or Metformin and Clomiphene Citrate for Women With CC Resistant Polycystic Ovary Syndrome (PCOS).|N-acetyl Cysteine Plus Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Treatment of Clomiphene-resistant Polycystic Ovary Syndrome||Mansoura University|Yes|Completed|April 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|192|||Female|20 Years|36 Years|No|||November 2009|November 4, 2009|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008046||130992|
NCT01015430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22578|A Study With RO4917523 in Patients With Fragile X Syndrome|A Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Safety and Tolerability, and Exploratory Efficacy and Pharmacodynamic Effects Study of RO4917523 in Adult Patients With Fragile X Syndrome.||Hoffmann-La Roche||Completed|November 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|50 Years|No|||March 2016|March 1, 2016|November 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01015430||130428|
NCT01015443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR63325-012|Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population|A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects With Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy|INSPIRE|Merck KGaA|Yes|Terminated|December 2009|July 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|285|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|October 1, 2009||No|The study is terminated prematurely as the sponsor decided to discontinue program with    Tecemotide in NSCLC.|No||https://clinicaltrials.gov/show/NCT01015443||130427|
NCT01017809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 08-851|Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer|Pilot Study Exploring the Efficacy of Prolonged Emend to Reduce Nausea and Vomiting During Treatment in a Phase II Study (NYU 03-67) of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer||New York University School of Medicine|Yes|Withdrawn|December 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Female|18 Years|N/A|No|||March 2015|March 16, 2015|November 19, 2009|Yes|Yes|NYU 03-67 reached accrual prior to this study opening.|No||https://clinicaltrials.gov/show/NCT01017809||130249|
NCT01017406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-118-11-1-2|Heel Cushion for Plantar Fasciitis|PSU Heel Cushion for Treatment of Plantar Fasciitis:A Randomized Controlled Trial||Prince of Songkla University|No|Enrolling by invitation|January 2010|April 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|160|||Both|15 Years|60 Years|No|||July 2011|July 26, 2011|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017406||130279|
NCT01017757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LungCtRenalTx|Interstitial Lung Abnormalities in Renal Transplant Recipients|Cross-sectional Analysis of Subclinical Interstitial Lung Abnormalities in Stable Renal Transplant Recipients by High-resolution CT Scan|LCRT|University of Parma|No|Active, not recruiting|June 2007|November 2009|Anticipated|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|82 Years|No|Non-Probability Sample|Kidney or kidney-pancreas recipients, on immunosuppressive therapy for at least 24 months|November 2009|November 20, 2009|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01017757||130253|
NCT01014260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00001755|Doxycycline Outcomes in Lupus Erythematosus|Doxycycline Outcomes in Lupus Erythematosus: (DOLE)||Johns Hopkins University|Yes|Withdrawn|September 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||May 2010|March 29, 2012|November 12, 2009|Yes|Yes|We could not get funding for study.|No||https://clinicaltrials.gov/show/NCT01014260||130518|
NCT01014546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 154609|Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis|A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis||Roswell Park Cancer Institute|Yes|Active, not recruiting|April 2010|||February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|N/A|No|||August 2015|August 13, 2015|November 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01014546||130496|
NCT01014559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3505|Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients|Study of Efficacy of OXN PR, Compared to Oxy PR, for Reduction of Intensity of Opioid-induced Constipation Symptoms in Pts Treated for Cancer or Non-cancer Pain: A Randomised, Double-blind, Controlled, Multicentre Study|OXN3505|Mundipharma SAS|No|Terminated|February 2010|February 2013|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|November 16, 2009||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01014559||130495|
NCT01024179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMUOCT-PLAQUE|Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns|Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography||Harbin Medical University|No|Recruiting|December 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||December 2009|December 4, 2009|December 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024179||129765|
NCT01016886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00027 / Ethics 25253|Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research|A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications|MANTICORE|AHS Cancer Control Alberta|Yes|Active, not recruiting|September 2010|September 2016|Anticipated|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|99|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01016886||130318|
NCT01017146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114575|A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris||GlaxoSmithKline|No|Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|744|||Both|12 Years|45 Years|No|||May 2012|May 31, 2012|November 19, 2009|Yes|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01017146||130299|
NCT01023971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trust R&D_3704|Macular Function During Anti-VEGF Treatment|Study of Macular Function During Anti-VEGF Treatment|MAFAT|Royal Liverpool University Hospital|No|Recruiting|January 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|50 Years|N/A|No|Non-Probability Sample|AMD clinic|December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023971||129781|
NCT01023984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAES-2|Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas||TEMENDO|European Association for Endoscopic Surgery|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023984||129780|
NCT01024946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-142|Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity|Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity||Memorial Sloan Kettering Cancer Center||Completed|December 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|December 2, 2009|Yes|Yes||No|April 7, 2015|https://clinicaltrials.gov/show/NCT01024946||129706|
NCT01006161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05109|Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)|Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects With Severe Asthma||Merck Sharp & Dohme Corp.|Yes|Withdrawn|January 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|70 Years|No|||October 2015|October 12, 2015|October 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01006161||131135|
NCT01006174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707005641|Dietary Lipids as Primary Modulators of Carotenoid Absorption in Vegetables|Dietary Lipids as Primary Modulators of Carotenoid Absorption in Vegetables||Purdue University||Completed|March 2009|May 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006174||131134|
NCT01006421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB-NBVUB|Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo|Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial|GB|King Saud University|No|Recruiting|January 2009|January 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|160|||Both|12 Years|65 Years|No|Probability Sample|DERMATOLOGY CLINIC|November 2009|November 4, 2009|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006421||131115|
NCT01006434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-ER-WAIST|Weight Approximation in Stroke Before Thrombolysis||WAIST|University of Erlangen-Nürnberg Medical School|No|Recruiting|April 2008|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|All patients receiving intravenous thrombolysis for acute ischemic stroke.|May 2013|May 13, 2013|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006434||131114|
NCT01006720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNDRO20|Sugammadex and Neostigmine at Residual Neuromuscular Blockade|Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.2)|SUNDRO20|Technische Universität München|Yes|Completed|March 2009|December 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||11|Actual|99|||Both|18 Years|N/A|No|Probability Sample|Patients receiving rocuronium for neuromuscular blockade under general anesthesia|December 2012|December 12, 2012|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01006720||131093|
NCT01006967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ R18 HS18459|ActiveStep Comparative Effectiveness Trial|Randomized ActiveStep Comparative Effectiveness Trial|RACE|Dartmouth-Hitchcock Medical Center|No|Active, not recruiting|November 2009|August 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|507|||Both|65 Years|N/A|No|||January 2016|January 20, 2016|October 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01006967||131074|
NCT00974116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08NT07|Trial of the MEND Childhood Obesity Treatment Program|MEND Childhood Obesity Treatment Programme: An RCT to Improve Body Composition and Cardiovascular Health in Overweight and Obese Children.|MEND|Institute of Child Health|No|Not yet recruiting|January 2010|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|7 Years|13 Years|No|||September 2009|September 9, 2009|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00974116||133567|
NCT01007526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-04-033|Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma|Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by VIDL Chemotherapy With Risk-based Application of Autologous Stem Cell Transplantation in Stage I/II Extranodal NK/T-cell Lymphoma|CCRT-VIDL|Samsung Medical Center|No|Recruiting|April 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007526||131031|
NCT01007773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042821|Safety of Dexmedetomidine in Severe Traumatic Brain Injury|Safety of Dexmedetomidine in Severe Traumatic Brain Injury||University of Maryland|Yes|Withdrawn|January 2010|January 2012|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|80 Years|No|||July 2010|May 26, 2015|November 2, 2009||No|Study will not be intiated|No||https://clinicaltrials.gov/show/NCT01007773||131012|
NCT01008059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0715|Alfentanil: Simultaneous Testing Pilot|Novel Noninvasive Assessment of Cytochrome P4450 Activity: Simultaneous Testing Pilot||Washington University School of Medicine|No|Active, not recruiting|October 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|November 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01008059||130991|
NCT01008072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173/09|Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation.|||Assaf-Harofeh Medical Center||Not yet recruiting|December 2009|||December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|All opioid addicted patients who wants to undergo rapid detoxification under general        anesthesia.|November 2009|November 4, 2009|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008072||130990|
NCT01016340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCS-5-TWN-a|Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia (MCS_MOS)|MCS_MOS|Health Ever Bio-Tech Co., Ltd.|No|Recruiting|December 2009|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Male|20 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 13, 2011|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01016340||130360|
NCT01018082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW09/140, GC 942|Longitudinal Study of Neurologic, Cognitive, and Radiologic Outcomes of PHACE Syndrome|Longitudinal Study of Neurologic, Cognitive, and Radiologic Outcomes in PHACE Syndrome|PHACE|Medical College of Wisconsin|No|Active, not recruiting|September 2009|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|4 Years|6 Years|No|Probability Sample|Children between the ages of 4-6 years who fulfill the diagnostic criteria for PHACE        syndrome will be contacted for enrollment.|March 2016|March 16, 2016|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01018082||130228|
NCT01018095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|543793|Trichomonas Vaginalis Recurrence Among HIV+ Women|Randomized Phase IV Trial of Metronidazole Single Dose Versus 7 Day Dose for Treatment of Trichomonas Vaginalis Among HIV-infected Women||Tulane University Health Sciences Center|No|Completed|May 2005|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|270|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|November 20, 2009||No||No|April 11, 2013|https://clinicaltrials.gov/show/NCT01018095||130227|Generalizability is always a concern in clinical trials, however our findings are likely generalizable to the majority of HIV-infected women in the U.S. though studies in Caucasian and Hispanic women are needed.
NCT01027260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-257|Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation|A Randomized, Placebo Controlled Study on the Efficacy of Itopride HCI on Irritable Bowel in Patients of Irritable Bowel Syndrome With Constipation (IBS-C)||Abbott|No|Completed|June 2008|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|268|||Both|18 Years|50 Years|No|||June 2013|June 17, 2013|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027260||129529|
NCT01023932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NADA2009|Auditory Neuropathy and Cochlear Implants|Cochlear Implants in Children With Auditory Neuropathy/ Auditory Dys-Synchrony||University of Sao Paulo||Completed|September 2006|September 2009||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|2 Years|N/A||Non-Probability Sample|Children with auditory neuropathy who had received a cochlear implant|December 2009|December 1, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023932||129784|
NCT01023945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0070|A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Double-blind, Placebo Controlled, Monotherapy Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus||Astellas Pharma Inc|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|20 Years|75 Years|No|||January 2016|January 18, 2016|November 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01023945||129783|
NCT01027767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000455|Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging|Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging||Mayo Clinic|No|Completed|May 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|23|||Female|18 Years|90 Years|No|Non-Probability Sample|Women who are seen in the Mayo Clinic Breast Clinic|February 2012|February 13, 2013|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01027767||129490|
NCT01024413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG0901|Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations|A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations||Chinese Society of Lung Cancer|No|Completed|July 2009|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|256|||Both|N/A|N/A|No|||October 2015|October 7, 2015|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01024413||129747|
NCT01023997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3502|Central Corneal Thickness in Glaucoma|Central Corneal Thickness in Patients With Exfoliation Syndrome, Exfoliative Glaucoma, Exfoliative Glaucoma, Primary Open-angle Glaucoma and Ocular Hypertension||Aristotle University Of Thessaloniki|No|Completed|January 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|700|||Both|25 Years|89 Years|Accepts Healthy Volunteers|Probability Sample|individuals with and without exfoliation|May 2014|May 9, 2014|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01023997||129779|
NCT01024010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0983|Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)||Mayo Clinic|Yes|Active, not recruiting|August 2010|||May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01024010||129778|
NCT01024192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOLPI_L_04134|Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA|Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) Administered on as Needed Basis in Patients With Chronic insomNIA||Sanofi||Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|18 Years|65 Years|No|||October 2010|October 4, 2010|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024192||129764|
NCT01006187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014280|Comparison of Different Methods for Reducing Pain From Influenza Vaccine Injections|Comparison of Different Analgesic Methods for Reducing Pain From Adult Intramuscular Influenza Virus Vaccine Injection||The Hospital for Sick Children|No|Completed|October 2009|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|352|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01006187||131133|
NCT01006447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYC-023|Tai Chi/Qigong Exercise Persistence Among Residents of Senior Housing|Tai Chi/Qigong Exercise Persistence Among Residents of Senior Housing: a Randomized Field Trial||D'Youville College|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|77|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 1, 2009|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006447||131113|
NCT01006460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHR5/DK|A Study With Arctic Root Compared With the Extract When Combined With Schizandra and Russian Root (Adapt 232), Standardized Ginseng Extract and Placebo Regarding Impact on the Level of Energy, Ability to Work Under Stress, Quality of Life and Wellbeing, in Middleaged Women Who Are Still Employed|A Randomized, Placebo Controlled, Parallel, Double Blinded Trial With Rhodiola Rosea Extract SHR-5 (Arctic Root) Compared With the Extract When Combined With Schizandra and Russian Root (Adapt 232), Standardized Ginseng Extract and Placebo Regarding Impact on the Level of Energy, Ability to Work Under Stress, Quality of Life and Wellbeing, in Middleaged Women Who Are Still Employed||Frederiksberg University Hospital|No|Completed|November 2009|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Female|40 Years|N/A|No|||November 2009|August 26, 2010|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01006460||131112|
NCT01006707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10212009-4200|Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers|fMRI Imaging of Opioid Withdrawal in Healthy Human Volunteers||Stanford University||Enrolling by invitation|November 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01006707||131094|
NCT01007266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100002|Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study|Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study||National Institutes of Health Clinical Center (CC)||Completed|October 2009|January 2013|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|12 Years|20 Years|No|||April 2015|April 24, 2015|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01007266||131051|
NCT00978328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015670|Oxycodone User Registry (OUR)|A Prospective, Multi-center, Observational Registry of Patients Using Prescription Medications Containing Oxycodone Immediate Release for the Treatment of Pain||Ortho-McNeil Janssen Scientific Affairs, LLC||Completed|June 2009|January 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|827|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients presenting for treatment of a painful condition with a Schedule II opioid at an        outpatient setting will be potential candidates for enrollment for this registry.|April 2010|April 1, 2010|September 15, 2009||||No||https://clinicaltrials.gov/show/NCT00978328||133250|
NCT00974441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-0441|Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Extended Release Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2009|September 9, 2009|September 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00974441||133543|
NCT01007786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32371|The Ventricular Catheter Placement Study: Assessment of Efficacy and Safety of an Ultrasound Guided Shunt Insertion Technique|The Ventricular Catheter Placement Study: Assessment of Efficacy and Safety of an Ultrasound Guided Shunt Insertion Technique||University of Utah|No|Completed|December 2008|March 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric hydrocephalus patients undergoing first time shunt placement for hydrocephalus.|June 2012|June 12, 2012|November 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01007786||131011|
NCT01008085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST2009-02|STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)|Randomized Comparison Between the STENTYS Self-expanding Coronary Stent and a Balloon-expandable Stent in Acute Myocardial Infarction - APPOSITION II|APPOSITION ll|Stentys|Yes|Completed|November 2009|December 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01008085||130989|
NCT01008098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KR_12661A|Neuroprotective/Neurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder|Neuroprotective/Neurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder||Seoul National University Hospital|Yes|Recruiting|November 2008|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|65 Years|No|||June 2012|June 6, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01008098||130988|
NCT01017445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 50/369-011|Stick Versus Quadricep Exercise for Knee Osteoarthritis|Boonme Stick Exercise vs. Quadriceps Strengthening Exercise in Knee Osteoarthritis : A Randomized Controlled Trial||Prince of Songkla University|No|Enrolling by invitation|October 2007|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|50 Years|80 Years|No|||May 2012|May 12, 2012|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01017445||130276|
NCT01017458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0773-004|Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)|A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Endpoints of MK0773 in Healthy Older Men||Merck Sharp & Dohme Corp.|Yes|Completed|October 2007|October 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|November 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01017458||130275|
NCT01026753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009:312|Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba|Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba||University of Manitoba|Yes|Completed|August 2010|December 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|2395|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||June 2013|June 7, 2013|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01026753||129568|
NCT01026766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-32|Effects of Heat and Moisture Exchanger in Combination With Air Forced Warming Blankets or Warming Intravenous Solutions on Intraoperative Hypothermia Prevention in Obese and Non Obese Patients During Intravenous Anesthesia|||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|40|||Female|18 Years|65 Years|No|Probability Sample|Forty female obese and non obese patients scheduled to gynecologic surgeries were warmed        with warming blankets and warming intravenous fluids in association with heat and moisture        exchanger.|December 2009|December 3, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026766||129567|
NCT01026948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LWH0764|Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM)|Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM)|PRAM|Liverpool Women's NHS Foundation Trust|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|In Liverpool Women's Hospital, women who have completed 37 weeks of Pregnancy and require        induction of labour (as per inclusion/exclusion criteria above) while attending Antenatal        clinic, delivery suite or the Obstetric Assessment Unit are offered management options.        Women who have normal cardiotocogram(CTG), normal amniotic fluid volume and cephalic        presentation confirmed by ultrasound, and who decide to have induction of labour were        recruited.|November 2011|January 4, 2012|December 3, 2009||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT01026948||129553|
NCT01026961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381-A-101|Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers|A Randomized, Crossover, Double-Blind Study To Evaluate The Safety Of An Association Of Phenylephrine Hydrochloride 10mg + Acetaminophen 500mg + Dimethindene Maleate 1 Mg Compared To Phenylephrine Hydrochloride 10mg In Healthy Volunteers||Novartis|No|Withdrawn|September 2010|||November 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|0|||Both|18 Years|50 Years|No|||March 2016|March 2, 2016|December 4, 2009||No|Study is no longer required by Brazil health authority.|No||https://clinicaltrials.gov/show/NCT01026961||129552|
NCT01027273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 02-0515 Project 1|Prevent Return of Stroke Study|Preventing Recurrence of All Inner-city Strokes Through Education||Icahn School of Medicine at Mount Sinai|No|Completed|June 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|600|||Both|40 Years|N/A|No|||July 2014|July 24, 2014|December 4, 2009||No||No|June 19, 2014|https://clinicaltrials.gov/show/NCT01027273||129528|
NCT01027494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-017|Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora|Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora Distal to the Site of Infection||Alcon Research|No|Completed|December 2009|November 2012|Actual|November 2012|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|318|||Both|6 Months|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants were selected from medical practices serving pediatric patients.|March 2013|March 14, 2013|December 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027494||129511|
NCT01027507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353/2008b|Postprandial Hemodynamics|Relationship Between Postprandial Alterations in Hemodynamics, Blood Pressure, Blood Glucose, Insulin Concentrations, Gastric Emptying, and Satiety||Skane University Hospital|Yes|Completed|January 2009|November 2009|Actual|||N/A|Observational|Observational Model: Case-Only||1|Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects without symptoms or a history of gastrointestinal disease, abdominal        surgery or diabetes mellitus, were included in this crossover study.|December 2009|December 7, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027507||129510|
NCT01027780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG025474|Mindfulness to Improve Elders' Immune and Health Status|Mindfulness to Improve Elders' Immune and Health Status||University of Rochester|Yes|Completed|March 2006|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2014|August 12, 2014|December 6, 2009||No||No|June 14, 2012|https://clinicaltrials.gov/show/NCT01027780||129489|
NCT01023698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC0003|Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters|Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters|PFC|Asociación para Evitar la Ceguera en México|No|Enrolling by invitation|April 2009|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||December 2009|December 1, 2009|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01023698||129802|
NCT01023646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1DK073321|Glycemic Index - Variability Among Individuals|Evaluation of Glycemic Index to Assess Diet Associated Chronic Disease Risk||Tufts University|No|Recruiting|December 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|124|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01023646||129806|
NCT01023659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068/2009|Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts|An Innovative Approach to Maximizing the Impact of Efficacious Pharmacotherapies on Smoking Cessation Attempts.||Centre for Addiction and Mental Health|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|923|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 14, 2013|November 30, 2009||No||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01023659||129805|Baseline data for 11 participants were missing. Therefore the sum of all categories for these variables do not equal the total number of participants. Also, due to the unique nature of the protocol, adverse event data was not collected.
NCT01024452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-283|Randomized Comparison of Warfarin Dosing Quality Between the Hamilton Nomogram and a Commercial Computer System|Randomized Comparison of Warfarin Dosing Quality Between the Hamilton Nomogram and a Commercial Computer System||Population Health Research Institute|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1298|||Both|18 Years|N/A|No|||December 2009|July 19, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024452||129744|
NCT01024205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTG-SuMR|Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer|Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients With Metastatic Renal Cancer: A Pilot Phase II Study [SuMR]||National Cancer Institute (NCI)||Completed|August 2007|May 2012|Actual|August 2010|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||July 2011|August 9, 2013|December 1, 2009||||No||https://clinicaltrials.gov/show/NCT01024205||129763|
NCT01024218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTOCOVER|Preference Study Between NovoFine® Autocover™ and a NovoFine® 8 mm Needle|An Open-label, Multicenter, Handling Test and Prospective Cross-over Study on Nurse/Health Assistants Preference Between NovoFine® Autocover™ and 8 mm NovoFine® Needle||Novo Nordisk A/S|No|Completed|December 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|78|||Both|N/A|N/A|No|||January 2012|January 25, 2012|November 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024218||129762|
NCT01006733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL097036-01|Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT|Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis (DVT)|GIFT|Washington University School of Medicine|Yes|Recruiting|March 2011|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|1600|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|October 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01006733||131092|
NCT01006993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-0258|Feasibility and Safety of NeuroFlo in Stroke Patients Receiving Tissue Plasminogen Activator|Feasibility and Safety of NeuroFlo in Stroke Patients Receiving tPA|FASTFlo tPA|CoAxia|Yes|Completed|May 2007|January 2010|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|85 Years|No|||March 2010|March 10, 2010|November 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01006993||131072|
NCT00977782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPKC412A2104E1|Open-label Multicenter Study of PKC412 in Pts With AML and MDS With Either Wild-type or Mutated FLT3|An Open-label Phase I/II (Proof of Concept) Trial of PKC412 in Patients With Acute Myeloid Leukemia (AML) and Patients With High Risk Myelodysplastic Syndrome (MDS) With Either Wild Type or Mutated FLT3||Novartis||Completed|March 2003|October 2008|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|95|||Both|14 Years|N/A|No|||May 2012|May 1, 2012|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00977782||133292|
NCT00978029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06081|Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)|A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)||Merck Sharp & Dohme Corp.|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|203|||Both|50 Years|N/A|No|||February 2016|February 19, 2016|September 11, 2009|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT00978029||133273|
NCT00978042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLUMA-002|Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation|||Allergan||Completed|August 2009|April 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|345|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|September 15, 2009|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT00978042||133272|
NCT00974766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS/723/Res/276|Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis|Randomized Controlled Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis||Postgraduate Institute of Medical Education and Research|Yes|Completed|April 2009|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|N/A|N/A|No|||February 2015|February 22, 2015|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974766||133519|
NCT00978302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1001-319-1001|Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)|A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised, Parallel Group Study to Investigate the Clinical Safety, Toleration, Systemic Pharmacokinetics and Local Pharmacodynamics of Repeated, Escalating Concentrations of Intradermal RN1001 in Healthy Male Subjects.||Renovo|No|Completed|May 2001|August 2001|Actual|August 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|September 15, 2009|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00978302||133252|
NCT00974077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA1399/16-1|Psychophysiological Correlates of Mindfulness Based Cognitive Therapy (MBCT) in Recurrent Depression|Psychophysiological Correlates of Mindfulness and Attention in Recurrent Depression and Healthy Volunteers|MBCT & EEG|University Hospital Tuebingen|Yes|Completed|September 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974077||133570|
NCT00974090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A6|Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes|A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|September 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|194|||Both|20 Years|75 Years|No|||April 2014|April 7, 2014|September 8, 2009||No||No|April 7, 2014|https://clinicaltrials.gov/show/NCT00974090||133569|
NCT00974389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAKA-TRICC0901|S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery|Phase II Study of Combination Chemotherapy With S-1 Plus Avastin in Unresectable or Recurrent Colorectal Cancer After Failure of Prior Chemotherapy, Including Irinotecan and Oxaliplatin Regimens.||National Cancer Institute (NCI)||Recruiting|July 2009|||June 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|80 Years|No|||September 2009|August 9, 2013|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974389||133547|
NCT01026740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011416|Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers|An Exploratory Study to Evaluate the Penetration of Ceftobiprole Into Soft Tissue Determined by In Vivo Microdialysis in Healthy Volunteers||Basilea Pharmaceutica|No|Completed|June 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|55 Years|No|||July 2012|July 27, 2012|December 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026740||129569|
NCT01026987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1824 / 201011859|Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant|A Pilot Study of G-CSF +/- Plerixafor (AMD3100) Mobilized Donor CD34+ Enriched Peripheral Blood Mononuclear Cells for the Treatment of Allogeneic Stem Cell Transplant Recipients With Limited Donor Engraftment||Washington University School of Medicine|No|Active, not recruiting|April 2010|December 2016|Anticipated|April 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026987||129550|
NCT01027000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB 100701|Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|February 2010|||February 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|69 Years|No|||July 2015|July 31, 2015|December 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027000||129549|
NCT01026974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P9E1|Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine|A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9||Novartis||Completed|February 2010|May 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|120|||Both|40 Months|62 Months|Accepts Healthy Volunteers|||September 2014|September 18, 2014|December 4, 2009|Yes|Yes||No|May 13, 2013|https://clinicaltrials.gov/show/NCT01026974||129551|
NCT01027533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRS.1703|Visual Performance of New Apodized Diffractive Multifocal IOL With Addition of Plus Three|||University of Sao Paulo|No|Completed|December 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|32|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The sutdy population will be patients implanted bilaterally with the selected multifocal        IOL|March 2009|July 1, 2010|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027533||129508|
NCT01027520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cobandressing|Range of Motion Following Intraoperative Coban Dressing Application in Hand Burns|Day One Post Operative Range of Motion Following Skin Graft to Hand With Intraoperative Coban Dressing||University of Missouri-Columbia|Yes|Not yet recruiting|January 2010|January 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 7, 2009|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01027520||129509|
NCT01023711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 09-005|Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus|Assessment of the Effect of Age and Priming on the Immunological Response to an Inactivated Vaccine for Novel H1N1 Virus.||University of Rochester|No|Completed|November 2009|July 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|107|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 24, 2015|December 1, 2009|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01023711||129801|
NCT01024231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-004|Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma|A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma||Bristol-Myers Squibb|Yes|Active, not recruiting|December 2009|October 2017|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|136|||Both|18 Years|N/A|No|||November 2015|January 6, 2016|December 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024231||129761|
NCT01023672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003438|"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"|An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies||Mayo Clinic|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|90 Years|No|||June 2013|June 24, 2013|December 1, 2009|No|Yes||No|June 24, 2013|https://clinicaltrials.gov/show/NCT01023672||129804|
NCT01024738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2008-PLA-05-RR|Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse|Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse||Colgate Palmolive|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|November 27, 2009|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT01024738||129722|
NCT01025011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D20028132|Non-invasive Measurement of Hemoglobin in Retinal Arteries|Non- Invasive Measurement of the Absolute Hemoglobin Value in the Retinal Arteries of Anemic and Healthy Subjects Using a New Approach||Triemli Hospital|No|Recruiting|March 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|N/A||1|Anticipated|100|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects from the eye clinic of Triemli Hospital anemic and pregnant patients from        the gynecology department, Triemli Hospital|November 2009|December 2, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025011||129701|
NCT00977444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEE-002-2007|Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment|Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment|EFO|Nucitec|Yes|Active, not recruiting|November 2007|October 2009|Anticipated|February 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|114|||Both|40 Years|N/A|No|||January 2010|January 19, 2010|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00977444||133316|
NCT00977795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH09-377|A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors|A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain||NorthShore University HealthSystem Research Institute|Yes|Withdrawn|September 2009|January 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|September 15, 2009|Yes|Yes|PI moving to Southern Illinois University to start new protocol|No||https://clinicaltrials.gov/show/NCT00977795||133291|
NCT00978068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5747-34097|HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children|A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children|PROMOTE-PEDS|University of California, San Francisco|Yes|Completed|September 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|186|||Both|2 Months|10 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2013|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00978068||133270|
NCT00978315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-010083-42|Trial of Vitamin D Supplementation in Asthma|Randomised, Multi-centre, Double-blind, Placebo-controlled Trial of Vitamin D Supplementation in Adult and Adolescent Patients With Asthma|ViDiAs|Barts & The London NHS Trust|Yes|Completed|September 2009|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|250|||Both|16 Years|80 Years|No|||February 2014|February 3, 2014|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00978315||133251|
NCT00975052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-050|A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)|A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Four-Period Crossover Study to Assess the Effects of Concomitant Administration of MK0431 and Metformin Alone and in Combination on Post-Meal Incretin Hormone Concentrations in Healthy Adult Subjects||Merck Sharp & Dohme Corp.||Completed|January 2006|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|September 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00975052||133497|
NCT00974402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090194H|Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings|Psychotherapy Treatment of Deployment-related PTSD in Primary Care Settings||The University of Texas Health Science Center at San Antonio|Yes|Completed|March 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00974402||133546|
NCT00974740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/0136-Diator|DIATOR-Diabetes Intervention With Atorvastatin|DIATOR - Diabetes Intervention With Atorvastatin. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of Atorvastatin on Residual Beta-cell Function and Glycemic Control in Patients With Newly Diagnosed Type 1 Diabetes Mellitus||Profil Institut für Stoffwechselforschung GmbH|No|Terminated|March 2004|March 2009|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|39 Years|No|||September 2009|September 10, 2009|September 9, 2009||No|for lack of recruitment|No||https://clinicaltrials.gov/show/NCT00974740||133521|
NCT00974987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAKA-TRIBRAIN0902|Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II, Multicenter, Study for Newly Diagnosed Glioblastomas Using Boron Neutron Capture Therapy, Additional X-ray Treatment and Chemotherapy||Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Active, not recruiting|September 2009|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|15 Years|75 Years|No|||November 2014|November 27, 2014|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT00974987||133502|
NCT01026467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98709|Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|January 2010|||May 2014|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Stage IV Non-Small Cell Lung Cancer|July 2015|July 27, 2015|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01026467||129590|
NCT01040572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2009078|Laparoscopic Revision Gastric Bypass for Weight Recidivism|Laparoscopic Revision Gastric Bypass Surgery for Weight Recidivism: Our Experience in 170 Patients|WR|University of California, San Francisco|Yes|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|132|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with previously failed Roux-en-Y gastric bypass "RYGB" surgery with a weight        recidivism pattern.|October 2009|December 26, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01040572||128562|
NCT01041183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nasea-LC|The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy|||Seoul National University Bundang Hospital||Recruiting|November 2009|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|25 Years|65 Years|No|||November 2009|December 30, 2009|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041183||128517|
NCT01041742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0910-047-297|Pulse Pressure Variation (PPV) to Predict Fluid Responsiveness During Cardiac Displacement in Patients Undergoing Off-pump Coronary Artery Bypass Surgery (OPCAB)|Pulse Pressure Variation to Predict Fluid Responsiveness During Cardiac Displacement in Patients Undergoing Off-pump Coronary Artery Bypass Surgery||Seoul National University Hospital|No|Completed|December 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35|||Both|18 Years|80 Years|No|||July 2010|July 25, 2010|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041742||128475|
NCT01038115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005841|Study Comparing Pulmonary Vein Isolation With the Cryoballoon, Radiofrequency Energy, or Both in the Treatment of Atrial Fibrillation (AF)|A Randomised Study Comparing Pulmonary Vein Isolation Using the Occluding Cryoballoon, Conventional Radiofrequency Energy, or Both in the Treatment of Atrial Fibrillation (AF).|Cryo Vs RFA|Barts & The London NHS Trust||Completed|September 2008|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|237|||Both|18 Years|N/A|No|||March 2011|February 17, 2014|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01038115||128750|
NCT01038375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSN0912-000106|Tailored Interventions to Improve Hypertension Management After Stroke or Transient Ischemic Attack (TIA)|Tailored Interventions to Improve Hypertension Management After Stroke or TIA|TIMSII|McMaster University|Yes|Completed|March 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|56|||Both|19 Years|N/A|No|Non-Probability Sample|clients recruited from Stroke Prevention Clinics in Ontario with diagnosis of Stroke or        TIA, Hypertension, and cognitive deficits as indicated by MoCA score < 26, self-efficacy        rating < 100%, and self-report of missed pills; English speaking; able to give informed        consent; older than 18 years of age|April 2012|April 30, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038375||128730|
NCT01038661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_04827|Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy|Randomized, Controlled Study Comparing the Efficacy and Safety of Docetaxel （60mg/m2）Maintenance Treatment vs. Best Supportive Care Following First Line Chemotherapy With Different Doses of Docetaxel（75/60mg/m2）in Combination With Cisplatin in Patients With Local Advanced or Metastatic （Stage IIIB/IV）Non-Small Cell Lung Cancer|TFINE|Sanofi|No|Completed|November 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|375|||Both|18 Years|75 Years|No|||February 2014|February 27, 2014|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038661||128708|
NCT01038934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/FOA-Unesp-04|DNA of Oral Cytobrush in Three Means Conservation|Evaluation of Genomic DNA of Oral Cytobrush in Three Means Conservation||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2006|December 2009|Actual|December 2009|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|20 Years|33 Years|Accepts Healthy Volunteers|||December 2009|December 23, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038934||128687|
NCT01038947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENZ-102|Safety and Efficacy Study of Intramuscular Uricase-PEG 20|A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20||EnzymeRx|No|Recruiting|December 2009|May 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||December 2009|December 22, 2009|December 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01038947||128686|
NCT01039207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0170P|Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Gynecologic Oncology Group|Yes|Completed|October 2010|July 2014|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039207||128667|
NCT01039233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50013|Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting Conditions|Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions||Kremers Urban Development Company|Yes|Completed|May 2005|July 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|73 Years|Accepts Healthy Volunteers|||December 2009|December 23, 2009|December 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01039233||128665|
NCT01039519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-05|A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)|A Non-randomized, Open Label, Multi-center Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Patients With Metastatic and/or Unresectable GIST Resistant or Refractory to Prior Systemic Treatments Including Imatinib and Sunitinib||Synta Pharmaceuticals Corp.|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 23, 2009|Yes|Yes||No|February 11, 2016|https://clinicaltrials.gov/show/NCT01039519||128643|
NCT01039792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Autism Speaks 3031|Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism|Double Blind Placebo Controlled Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism|B12|University of California, San Francisco|No|Completed|January 2010|November 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|3 Years|7 Years|No|||November 2013|November 15, 2013|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039792||128622|
NCT01032668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYİEAH2|The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance||EFFICIENT|Bursa Postgraduate Hospital|No|Completed|September 2008|December 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|18 Years|80 Years|No|||August 2008|December 14, 2009|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032668||129117|
NCT01032681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62235_001|EMD 521873 in Advanced Solid Tumors, MTD Finding|A Phase 1, Open-Label, Two-Group, Dose- Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of EMD 521873 Alone and in Combination With Fixed Low Doses of Cyclophosphamide in Patients With Metastatic or Locally Advanced Solid Tumors or B-Cell Non-Hodgkin Lymphoma||Merck KGaA|No|Completed|December 2006|January 2012|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|N/A|No|||October 2012|July 30, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032681||129116|
NCT01032694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661200|Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia|Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia|PROSTO|Pfizer|No|Terminated|April 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Community-Acquired Pneumonia.|November 2011|November 21, 2011|December 14, 2009|Yes|Yes|This study was terminated January 11, 2011 due to low enrollment. This study is not being    terminated because of safety or efficacy concerns.|No|November 21, 2011|https://clinicaltrials.gov/show/NCT01032694||129115|
NCT01033292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11504|A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer|A Phase 2, Multi-Center, Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer||Sanofi|No|Completed|December 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|December 14, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01033292||129070|
NCT01033305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC-201|Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)|A Phase II, Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapsule Formulation of Ciclosporin (CyCol™) in the Treatment of Mild to Moderate Ulcerative Colitis||Sigmoid Pharma|Yes|Completed|March 2010|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033305||129069|
NCT01033331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290/06|Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy(SMA) Treated With Valproic Acid|Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy Type II and III Treated With Valproic Acid||University of Sao Paulo General Hospital|Yes|Completed|July 2006|December 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|2 Years|18 Years|No|Non-Probability Sample|22 children with spinal muscular atrophy disease|August 2008|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033331||129067|
NCT01033591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFICAR PS09/01498 -RD06/0018|Exercise for Patients With Heart Failure in Primary Care: the EFICAR|Rationale and Design of a Randomised Controlled Trial Evaluating the Effectiveness of an Exercise Program to Improve the Quality of Life of Patients With Heart Failure in Primary Care: The EFICAR Study Protocol|EFICAR|Basque Health Service|No|Active, not recruiting|January 2011|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|85 Years|No|||December 2014|December 19, 2014|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033591||129047|
NCT01033838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51801-B32220097328|Randomized Trial Comparing Laparoscopic-assisted Rectosigmoid Resection Versus Laparoscopic Rectosigmoid Resection With Transrectal Specimen Retrieval|Conventional Laparoscopic-assisted Rectosigmoid Resection Versus Laparoscopic Rectosigmoid Resection With Intracorporeal Anastomosis and Transrectal Specimen Retrieval|LATA|Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2009|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1|||Both|18 Years|90 Years|No|||December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033838||129028|
NCT01033851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000275|Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects|Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects||Massachusetts General Hospital|Yes|Completed|March 2008|February 2013|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|December 9, 2009||No||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01033851||129027|
NCT01040884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASNG-LFNA-101-IL-H|Safety And Accuracy Study Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Procedures|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Preliminary Safety and Accuracy of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Aspiration, Biopsy and RF Ablations||ActiViews Ltd.|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01040884||128538|
NCT01040897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD059794-01|Addressing Health Literacy and Numeracy to Prevent Childhood Obesity|Addressing Health Literacy and Numeracy to Prevent Childhood Obesity|GreenLight|Vanderbilt University|Yes|Active, not recruiting|December 2009|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|865|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2015|June 19, 2015|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040897||128537|
NCT01041209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE-186|Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia|Efficacy of BPS (Bacterial Pneumonia Score) Guided Antibiotic Use in Children With Community Acquired Pneumonia on Reducing Antibiotic Use as Compared to Standard Care Practice (Current Guidelines for CAP)||Hospital General de Niños Pedro de Elizalde|Yes|Completed|March 2010|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|120|||Both|3 Months|60 Months|No|||June 2013|June 10, 2013|December 30, 2009||No||No|June 29, 2012|https://clinicaltrials.gov/show/NCT01041209||128515|
NCT01041222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 333611- CS1|Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations|A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients With Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations|SOD-1|Ionis Pharmaceuticals, Inc.|Yes|Completed|January 2010|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|33|||Both|18 Years|N/A|No|||April 2012|April 12, 2012|December 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01041222||128514|
NCT01041196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2008091|Perforated Marginal Ulcer After Gastric Bypass|Laparoscopic Revision Gastric Bypass Surgery for Perforated Marginal Ulcer: A 10 Year Experience|PerforatedMU|University of California, San Francisco|Yes|Completed|January 2009|December 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who underwent laparoscopic repair of perforated marginal ulcer after Roux-en-Y        gastric bypass (RYGB) for weight loss.|December 2009|December 31, 2009|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01041196||128516|
NCT01041469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJL-IMM-EP10|Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome|Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome|IMMUTRI|Institut Jerome Lejeune|No|Completed|November 2009|December 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|72|Samples With DNA|whole blood and white cells|Both|8 Years|36 Years|No|Non-Probability Sample|Down syndrome patients followed in a specialized clinic devoted to healthcare of mentally        retarded children and adults|December 2009|March 21, 2012|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041469||128495|
NCT01041755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI09-002|Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.|The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy.||Centro Regional para el Estudio de las Enfermedades Digestivas|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||September 2014|September 22, 2014|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01041755||128474|
NCT01038128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001901|An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder|Antiglutamatergic Treatment of Bulimia Nervosa and Body Dysmorphic Disorder: An Open-Label Trial of Memantine||Mclean Hospital|No|Completed|December 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|December 21, 2009|Yes|Yes||No|March 19, 2012|https://clinicaltrials.gov/show/NCT01038128||128749|
NCT01038388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00017528|A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma|A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza ®) + RVD (Lenalidomide {Revlimid ®} + Bortezomib {Velcade ®} + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma||Emory University|Yes|Active, not recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|July 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01038388||128729|
NCT01038674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8226-3704|Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis|A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Dose-escalation, Phase 1 Trial of Anti-IL-20 in Subjects With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|December 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01038674||128707|
NCT01038687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006618|Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation|Effects of A3309, an Ileal Bile Acid Transport Inhibitor, on Gastrointestinal and Colonic Motor Functions in Female Patients With Functional Constipation||Mayo Clinic|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Female|18 Years|65 Years|No|||July 2012|July 31, 2012|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038687||128706|
NCT01038960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETHIC-SUS-AIL-09|Exercise Training in ICD Recipients; Effect on Therapy Delivered, Depression and Anxiety|Exercise Training to Reduce Ventricular Arrhythmia in Heart Failure Patients With ICD - The Ethic Study|ETHIC|Helse Stavanger HF|Yes|Recruiting|April 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||August 2012|August 29, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038960||128685|
NCT01039220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-AO1115-52|Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients|Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients|ANRS 2H|French National Agency for Research on AIDS and Viral Hepatitis|No|Completed|December 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1266|||Both|18 Years|N/A|No|||February 2011|February 10, 2011|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039220||128666|
NCT01039246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 09-168|Electrohydraulic Versus Laser Lithotripsy|Electrohydraulic Versus Laser Lithotripsy for Difficult to Remove Biliary Stones: A Randomized Study||The Cleveland Clinic|No|Active, not recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039246||128664|
NCT01039259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN3223 265/4.7|The Impact of Material on Microbiota in Association With Tongue and Lip Piercing|||Medical University Innsbruck||Completed|August 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2||170|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|85 subjects with lip piercing 85 subjects with tongue piercing|January 2009|December 23, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039259||128663|
NCT01039532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHI3|Comparison of Thrice Daily Biphasic Human Insulin With Basal Bolus Regimen in Type 2 Diabetes Mellitus Patients|Comparison of Thrice Daily Biphasic Human Insulin Versus Basal Detemir and Bolus Aspart in Patients With Poorly Controlled Type 2 Diabetes Mellitus||Postgraduate Institute of Medical Education and Research|Yes|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|50 type 2 diabetes mellitus patients inadequately controlled patients treated with human        premixed insulin twice daily for at least 3months along with metformin 2g/d and        pioglitazone 30mg/d.|October 2015|October 23, 2015|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039532||128642|
NCT01039805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112571|Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance|A Double-blind, Randomized, Placebo Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Critically Ill Male and Female Patients With Enteral Feed Intolerance||GlaxoSmithKline|No|Completed|December 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|85 Years|No|||April 2013|May 2, 2013|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039805||128621|
NCT01039818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-055|Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism|Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control||Hospital de Clinicas de Porto Alegre|No|Completed|February 1997|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||September 2012|September 4, 2012|December 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039818||128620|
NCT01032343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AICR 08-0131|An Immunonutritional Approach to the Prevention of Skin Cancer|The Effect of Omega-3 Polyunsaturated Fatty Acids on UV-induced Immunosuppression||University of Manchester|No|Completed|July 2008|November 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 21, 2013|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032343||129142|
NCT01033344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP005|Cat-PAD Exposure Chamber Study|A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber||Circassia Limited|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|65 Years|No|||September 2010|September 30, 2010|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033344||129066|
NCT01032993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AR055664|Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms|Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms||Beth Israel Deaconess Medical Center|No|Active, not recruiting|December 2009|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032993||129093|
NCT01033318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1809-001|A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)|A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers||Merck Sharp & Dohme Corp.|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|15||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|December 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01033318||129068|
NCT01033877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTdaP-01|Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults|Immunogenicity and Safety of a Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to a Tetanus and Diphtheria (Td) Vaccine When Given as a Booster Vaccination to Adults||Statens Serum Institut|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|802|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 18, 2013|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033877||129025|
NCT01033864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22641|A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients|Comparison of Pharmocokinetics of Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium in Calcineurininhibitor-free Treated Patients After Renal Transplantation||Hoffmann-La Roche||Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|December 16, 2009||No||No|May 8, 2014|https://clinicaltrials.gov/show/NCT01033864||129026|
NCT01034111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-178|A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)|An Open-label Study to Assess the Safety and Tolerability of JANUVIA (Sitagliptin) in 30 Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|79 Years|No|||August 2015|August 7, 2015|December 16, 2009|Yes|Yes||No|October 3, 2011|https://clinicaltrials.gov/show/NCT01034111||129007|
NCT01041248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 25245|Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab|Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis||Children's Hospital of Eastern Ontario|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|N/A|N/A|No|||July 2012|July 9, 2012|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041248||128512|
NCT01041495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|amrixfm001|Cyclobenzaprine Extended Release (ER) for Fibromyalgia|An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain||State University of New York - Upstate Medical University|No|Recruiting|June 2009|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2012|September 6, 2012|June 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041495||128493|
NCT01041235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI1123-101|Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies|A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered ATI-1123, a Liposomal Docetaxel Formulation, on an Every 3 Week Schedule, in Patients With Advanced Solid Tumors||Azaya Therapeutics, Inc.|No|Completed|December 2009|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|December 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01041235||128513|
NCT01041482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bay 43-9006|A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma|A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Locally Advanced Renal-Cell Carcinoma After Radical Nephrectomy|AGuo|Chinese Academy of Medical Sciences|Yes|Recruiting|November 2008|November 2013|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|70 Years|No|||August 2008|January 5, 2010|December 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041482||128494|
NCT01037777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-37|RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7|Prospective Study of Individuals at Risk for Spinocerebellar Ataxia Type 1, Type 2, Type 3, Type 6 and Type 7 (SCA1, SCA2, SCA3, SCA6, SCA7)|RISCA|Institut National de la Santé Et de la Recherche Médicale, France||Active, not recruiting|May 2009|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|French population|January 2012|January 27, 2012|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037777||128776|
NCT01037790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03909|PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER|Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2009|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|205|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037790||128775|
NCT01038141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|583-07315a 1.2007.2484(REK)|Recto Anal Repair or Milligan Morgans Operation of Grade 3 and 4 Symptomatic Haemorrhoidal Disease|Recto Anal Repair or Milligan Morgans Operation of Grade 3 and 4 Symptomatic Haemorrhoidal Disease. A Prospective Randomized Controlled Study||University Hospital, Akershus|No|Terminated|November 2009|||September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||June 2014|July 29, 2014|December 22, 2009||No|Due to lack of time.|No||https://clinicaltrials.gov/show/NCT01038141||128748|
NCT01038401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00239-46|Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study|Characterization of the Residual Replication of HIV-1 in the Gut-associated Lymphoid Tissue in Patients Receiving Effective Highly Active Antiretroviral Therapy: the ANRS EP 44 Study|EP 44|French National Agency for Research on AIDS and Viral Hepatitis|No|Completed|September 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 13, 2010|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038401||128728|
NCT01038700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070801|Circulating Endothelial Compartment During Normal and Pathological Aging|Impact du Vieillissement (VI) Sur le Compartiment Circulant et Sur la Mobilisation (MO) Des progéniteurs endothéliaux (PE) Par ischémie Locale (IL) : étude Pilote|VIMOPEIL|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2008|September 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|Samples Without DNA|whole blood|Male|10 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|September 2015|September 30, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038700||128705|
NCT01038986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC101-IL-01|A Post-marketing Observational Study of Cell Therapy for Chronic Wounds|A Post-marketing Multi-center Observational Study to Provide Data Describing the Safety and Effectiveness of CUREXCELL™ as it is Applied in a Real-life Setting for Treatment in Patients With Chronic and/or Refractory Wounds||Macrocure Ltd.|No|Completed|December 2009|October 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|70|||Both|N/A|N/A|No|Probability Sample|Patients with chronic and/or refractory wounds that have been referred by their physician        for CureXcell treatment|January 2013|January 30, 2013|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038986||128684|
NCT01033123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11503|A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer|A Phase 2, Multi-Center, Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer||Sanofi|No|Completed|December 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|December 14, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01033123||129083|
NCT01039272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/FOA-Unesp-03|Epstein-Barr Detection in Oral Cancer|Epstein-Barr Detection in Squamous Cell Carcinoma and Healthy Oral Mucosa||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2008|June 2015|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|Samples With DNA|paraffin-embedded tissue samples|Both|40 Years|N/A|No|Probability Sample|oral care clinic, community sample|June 2015|June 24, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039272||128662|
NCT01033448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21778|A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response|An Open-Label, Multi-Center Study Evaluating the Effect on Viral Activity and the Safety and Tolerability of Extended Treatment of Pegasys® (Peginterferon Alfa 2a ) in Combination With Copegus® (Ribavirin) in Genotype 1, 2 and 3 Chronic Hepatitis C Patients Defined as Slow Responders/Non-RVR||Hoffmann-La Roche||Completed|December 2009|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033448||129058|
NCT01039545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254/09|Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.|Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting. A Randomized, Double Blind Trial||University Hospital Inselspital, Berne|No|Terminated|February 2012|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|253|||Female|18 Years|70 Years|No|||July 2015|July 8, 2015|December 24, 2009||No|New power calculation (reduction of necessary patient number)|No||https://clinicaltrials.gov/show/NCT01039545||128641|
NCT01039831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0595-09-TLV|White Matter Pathology in Parkinson's Disease (PD)|The Role of White Matter Pathology in the Development of the Postural Instability and Gait Disturbance (PIGD) Type of Parkinson's Disease (PD)||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2010|January 2012|Anticipated|||N/A|Observational|Observational Model: Case Control||1|Anticipated|120|||Both|50 Years|80 Years|No|Non-Probability Sample|A total of 120 patients with idiopathic Parkinson's disease (PD) will be studied. Subjects        will be divided into two groups: Patients with PIGD and patients with tremor dominant.|December 2009|December 24, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039831||128619|
NCT01039844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0432|Study of Weekly LOC-paclitaxel Injection for Melanoma|Phase I Study of Weekly LOC-paclitaxel Injection||M.D. Anderson Cancer Center|No|Completed|December 2009|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039844||128618|
NCT01033006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-04115|Axillary Plexus Block in a High Resolution MRI|Axillary Plexus Block in a High Resolution MRI||Diakonhjemmet Hospital|Yes|Completed|January 2009|August 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|45|||Both|18 Years|75 Years|No|||February 2014|February 12, 2014|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033006||129092|
NCT01033890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC-026|Local Anesthesia With Sedation for Cochlear Implant Surgery|Local Anesthesia With Sedation for Cochlear Implant Surgery: 3 Case Report|IC|Instituto Paranaense de Otorrinolaringologia|Yes|Completed|December 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|3 adult patients with total deafness|December 2009|December 16, 2009|December 16, 2009||Yes||No||https://clinicaltrials.gov/show/NCT01033890||129024|
NCT01033903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-007661-20|Optimal Treatment of Miscarriage|Which is the Optimal Treatment for Miscarriage With a Gestational ac in the Uterus and Which Factors Can Predict if the Treatment Will be Successful?||Region Skane|No|Active, not recruiting|October 2008|February 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033903||129023|
NCT01033604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/033|Glyaderm + Split Thickness Skin Graft Versus Split Thickness Skin Graft Alone in Full Thickness Skin Defects|Clinical Application of a Novel Dermal Substitute Based on Glycerol Preserved Allograft: GLYADERM||University Hospital, Ghent|No|Completed|September 2007|December 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|N/A|80 Years|No|||December 2014|December 4, 2014|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033604||129046|
NCT01034410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1411-C-203|A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia|An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia||Antisoma Research|No|Terminated|January 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||February 2011|February 1, 2011|December 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01034410||128984|
NCT01034423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2008.2215|Omega-3 Fatty Acids and Health Effects|Omega-3 Fatty Acids and Health Effects||Oslo and Akershus University College of Applied Sciences|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|69|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034423||128983|
NCT01034436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2008.1368|Fatty Acid Quality and Overweight (FO-study)|Fatty Acid Quality and Overweight||Oslo and Akershus University College of Applied Sciences|No|Completed|February 2009|||June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|41|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034436||128982|
NCT01034124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-CH 05-2951|Mechanisms Underlying Drug-Diet Interactions|Mechanisms Underlying Drug-Diet Interactions||University of North Carolina, Chapel Hill|No|Completed|January 2007|June 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01034124||129006|
NCT01041547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091023002|Vascular Function, Insulin Sensitivity, and Vitamin D|Vitamin D, Vascular Function, and Insulin Sensitivity in Adults [The VIVID Study|VIVID|University of Alabama at Birmingham|Yes|Completed|December 2009|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|63|Samples Without DNA|Seum|Both|19 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Healthy adults with BMI below 32          -  Both males and females          -  Ages 19-60 years          -  Race: African Americans, White Hispanics, European Americans|January 2014|January 13, 2014|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01041547||128489|
NCT01041560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSKS2|Muscle Tone Changes in Acute Stroke According to Brain Injury|Muscle Tone Changes in Acute Stroke According to Brain Injury in Relation to Changes in Functioning||Jyväskylä Central Hospital|No|Recruiting|September 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Probability Sample|Stroke patients in Middle-Finland Central hospital|December 2009|December 30, 2009|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041560||128488|
NCT01041508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2008-005|Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.|Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematologic Malignancies||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Completed|February 2010|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|1 Year|21 Years|No|||May 2015|May 14, 2015|December 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01041508||128492|
NCT01041521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVZ112667|The Impact of Omega Three Fatty Acids on Vascular Function in HIV|The Impact of Omega Three Fatty Acids on Vascular Function in HIV|HOST|Tufts University|Yes|Active, not recruiting|January 2010|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|December 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041521||128491|
NCT01042028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE|A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer|A Randomised Fase I/II Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer||Odense University Hospital|Yes|Terminated|January 2010|January 2014|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|January 4, 2010||No|Emergence of FOLFIRINOX and slow recruitment|No||https://clinicaltrials.gov/show/NCT01042028||128453|
NCT01037803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USILAN-1|Perioperative Observation of the Sublingual Microcirculation With SDF|Visualisation of Changes in the Sublingual Microcirculation During Major Surgery Using Sidestream Darkfield Imaging (SDF).||Region Skane|No|Completed|October 2008|December 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|88 Years|No|Non-Probability Sample|Adults undergoing major surgery at one university hospital|January 2011|January 17, 2011|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037803||128774|
NCT01037816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS-67-HP01-E02|FS-67 in the Treatment of Pediatric Patients With Ankle Sprain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of FS-67 Patches in Adolescent Subjects With Ankle Sprain||Hisamitsu Pharmaceutical Co., Inc.|No|Completed|December 2009|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|252|||Both|13 Years|17 Years|No|||May 2015|May 12, 2015|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037816||128773|
NCT01037829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_12|Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study|A Post-Marketing, Observational, Comparative Safety Study of the Novartis Pandemic Influenza A (H1N1) Vaccine(s) in Pregnant Women Versus Non-Vaccinated Pregnant Women||Novartis||Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4529|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|September 2011|September 28, 2011|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037829||128772|
NCT01037556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-2004|PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia|Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection||Proacta, Incorporated|No|Active, not recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|December 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037556||128793|
NCT01032499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E01-GOU-INH-01-09|Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir|Multicenter Clinical Study,Phase III, Prospective, Randomized, Open and Comparative to Measure Tolerability and Efficacy of Taro Elixir on the Evolution Treatment of Acne Vulgaris II and III Degree or of Furunculosis Compared With Oxytetracycline|E01GOU-INH0109|Laboratorios Goulart S.A.|Yes|Not yet recruiting|May 2010|October 2010|Anticipated|July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|14 Years|N/A|No|||December 2009|March 18, 2010|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032499||129130|
NCT01032512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FALP001|Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology|Preoperative Nutrition Support in Major Oncologic Surgery||University of Chile|No|Terminated|December 2009|December 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|149|||Both|N/A|80 Years|No|||June 2015|June 5, 2015|December 14, 2009|No|Yes|impossibility to include patients in the study|No||https://clinicaltrials.gov/show/NCT01032512||129129|
NCT01032837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV22155|A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain|A Randomized, Multicenter Trial of Oseltamivir [Tamiflu] Doses of 75 mg for 5 or 10 Days Versus 150 mg for 5 or 10 Days to Evaluate the Effect on the Duration of Viral Shedding in Influenza Patients With Pandemic (H1N1) 2009||Hoffmann-La Roche||Terminated|November 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|102|||Both|1 Year|N/A|No|||September 2012|September 18, 2012|December 10, 2009|Yes|Yes|Study closed prematurely due to the end of the influenza (H1N1) 2009 pandemic|No|July 12, 2012|https://clinicaltrials.gov/show/NCT01032837||129105|
NCT01033435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gron09|The Influence of Cessation of Pomegranate Juice Intake on Inflammation and Oxidative Stress Markers and Glucose Control in Diabetic and Non Diabetic Chronic Hemodialysis Patients|||Western Galilee Hospital-Nahariya|No|Completed|December 2009|August 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|49|||Both|18 Years|N/A|No|Probability Sample|chronic Hemodialysis patients, treated in our unit.|August 2011|August 16, 2011|December 15, 2009||||No||https://clinicaltrials.gov/show/NCT01033435||129059|
NCT01033695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2009|Interobserver Agreement of Endoscopic Ultrasonography and Endoscopic Sonoelastography in the Evaluation of Lymph Nodes|Interobserver Agreement of Endoscopic Ultrasonography and Endoscopic Sonoelastography in the Evaluation of Lymph Nodes||Odense University Hospital|No|Completed|January 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Prospective||1||74|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients referred for EUS examination on the basis of a malignant indication.|August 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033695||129039|
NCT01033994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28980|A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery|A Randomized, Double Blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Primary Osteoarthritis of the Knee Who Are Not Expected to Require Knee Surgery Within One Year||Merck KGaA||Completed|October 2008|December 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|40 Years|N/A|No|||June 2014|June 24, 2014|December 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01033994||129016|
NCT01033981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181189|Cost Effectiveness Of Sunitinib In Central America And Caribbean|Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean||Pfizer|No|Terminated|May 2010|February 2011|Actual|February 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Adult men and women with mRCC will be evaluated for entering the study. The decision to        use Sunitinib, IFN-α or Bevacizumab + IFN must be a joint decision made by the subject and        the investigator. The investigator must discuss product information with the subject as        per usual practice.|April 2012|April 17, 2012|December 14, 2009|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01033981||129017|
NCT01034228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-018|Isoleucine Added ORS in Children With Diarrhoea|Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|July 2007|July 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Male|6 Months|36 Months|No|||April 2006|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034228||128998|
NCT01033357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014-VWAV07|Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access|A Long Term Safety Study of the Vascular Wrap(TM) Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® Graft in the Upper Extremity for Hemodialysis Vascular Access||Angiotech Pharmaceuticals|No|Terminated|March 2008|October 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|December 15, 2009|Yes|Yes|Imbalance in the # graft infections between the tx's (graft vs. graft + wrap)|No||https://clinicaltrials.gov/show/NCT01033357||129065|
NCT01033617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD08.147|IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG|The IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG With Left Ventricular Dysfunction: the IMPACT-CABG Study|IMPACT-CABG|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|December 2009|September 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||March 2014|March 25, 2014|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01033617||129045|
NCT01034150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1309-06|Effects of Home-based Neurostimulation Associated With Motor Training in Chronic Stroke Patients|Effects of Home-based Neurostimulation Associated With Motor Training in Chronic Stroke Patients||University of Sao Paulo General Hospital|No|Completed|December 2007|November 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||November 2009|December 16, 2009|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01034150||129004|
NCT01034137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22497|A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis|U-ACT-EARLY: A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Evaluate Remission in DMARD and Biological naïve Early Reumatoid Arthritis (RA) Subjects Treated With Tocilizumab (TCZ) Plus Tight Control Methotrexate (MTX) , TCZ Monotherapy or Tight Control MTX Monotherapy||Hoffmann-La Roche||Completed|January 2010|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|318|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034137||129005|
NCT01034722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-NV-593-CTIL|Fat Globules in Breast Milk|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||3|Anticipated|45|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Study population will include 45 volunteer mothers, that will divide to 3 groups: 15        vegetarians, 15 western diet and 15 Bedouins.        Each participant will be nursing a 2-5 months baby.|November 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034722||128960|
NCT01034735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28798|r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial|Phase I, Open Label, Randomised Three-way Cross Over, Single-centre Trial to Assess the Bioequivalence for Two Concentrations of the New r-hGH Liquid Multidose Formulation Versus the r-hGH Freeze-dried Multidose Formulation Administered in Healthy Volunteers||EMD Serono|No|Completed|July 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 22, 2013|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034735||128959|
NCT01034709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-CMV-001|Evaluation of the Artus® CMV PCR Test|Clinical Evaluation of the Artus® CMV RG PCR Test|CMV|QIAGEN Gaithersburg, Inc|No|Completed|December 2009|June 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|111|Samples With DNA|Extracted DNA|Both|18 Years|N/A|No|Non-Probability Sample|The study population includes subjects that have received a kidney transplant, and that        are hospitalized or that present to a hospital, clinic or physicians office for        post-transplantation care and will be treated with ganciclovir and/or valganciclovir for        symptomatic CMV infection.|August 2014|August 1, 2014|December 15, 2009||No||No|July 8, 2014|https://clinicaltrials.gov/show/NCT01034709||128961|
NCT01041573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-323|Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population|Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study||Valneva Austria GmbH|Yes|Completed|March 2010|July 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1869|||Both|2 Months|18 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|December 30, 2009|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT01041573||128487|
NCT01042041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08208|Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer|A Phase 1 Study of Sorafenib Integrated With Chemoembolization for Patients With Unresectable Hepatocellular Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01042041||128452|
NCT01042054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/S1102/17|Comparison of Analgesic Methods, and Their Effects on Patient Recovery, Following Liver Surgery|The Effects of Local Infiltration Versus Epidural on Recovery|LIVER|University of Edinburgh|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042054||128451|
NCT01037842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMEDIATE|Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus|Phase 3 Study of Combination of Mitiglinide and Metformin in Patients With Type 2 Diabetes Mellitus||Seoul National University Hospital|Yes|Completed|August 2006|May 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|145|||Both|30 Years|70 Years|No|||December 2009|December 19, 2009|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01037842||128771|
NCT01037855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110_07OB|Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine|A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine Celtura||Novartis||Completed|December 2009|January 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|4028|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|population of children, adolescents, adults and elderly|October 2011|October 4, 2011|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01037855||128770|
NCT01032850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0820|Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma|Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma||New Mexico Cancer Care Alliance|Yes|Terminated|September 2009|September 2015|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 14, 2009|Yes|Yes|Low accrual rate|No|June 6, 2015|https://clinicaltrials.gov/show/NCT01032850||129104|
NCT01033136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA2-012-09F|Exposure Therapy For Veterans With PTSD And Panic Attacks|Exposure Therapy for Veterans With PTSD and Panic Attacks||VA Office of Research and Development|Yes|Recruiting|January 2013|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01033136||129082|
NCT01033149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19223, 09-09-18-01|N-acetylcysteine in the Treatment of Bulimia Nervosa|||Lindner Center of HOPE|No|Terminated|December 2009|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||March 2014|March 4, 2014|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033149||129081|
NCT01033461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H33-08|Combination of Probiotic and Calcium in Healthy Adults|The Effect of the Probiotic L. Paracasei LPC 37 Alone or in Combination With a Calcium Supplement in Healthy Subjects||University of Jena|Yes|Completed|March 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033461||129057|
NCT01033474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|555-2009|Results Following the Vitrification of Human Oocytes Using 2 Methodologies|Embryonic Developmental Rates and Pregnancies Following the Vitrification of Human Oocytes Using Two Methodologies.||Northwest Center for Reproductive Sciences|Yes|Withdrawn|December 2009|July 2011|Actual|September 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Female|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will use infertile patients that need donor oocytes|July 2011|July 21, 2011|December 14, 2009||No|NW Center for Reproductive Sciences was sold and is no longer open|No||https://clinicaltrials.gov/show/NCT01033474||129056|
NCT01033708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET|A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder|A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder|NET|Zentrum für Integrative Psychiatrie|No|Recruiting|October 2009|October 2013|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|45 Years|No|||October 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033708||129038|
NCT01034241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-3-072|Effect of Different Protein Diets on Glucose and Insulin Metabolism and Substrate Partitioning|Effect of Different Protein Diets on Glucose and Insulin Metabolism and Substrate Partitioning||Maastricht University Medical Center|No|Completed|April 2009|March 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2010|July 22, 2010|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034241||128997|
NCT01034852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.018|Efficacy Study for Surgery After Previous Failed Catheter Ablation|Surgery After Previous Failed Catheter Ablation|SAVED|Cardiopulmonary Research Science and Technology Institute|No|Completed|May 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|45|None Retained|no biospecimens will be obtained.|Both|18 Years|N/A|No|Non-Probability Sample|Patients that have undergone surgical ablation after failing catheter based ablation at        investigator sites|February 2012|February 17, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01034852||128950|
NCT01034514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0034|4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy|4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy||Stanford University|Yes|Suspended|December 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must be greater than or equal to 18 years of age. There are no gender or ethnic        restrictions.AJCC Stage I, II, III or IV lung cancer of any histology to be treated using        radiotherapy will be eligible for this study.|September 2015|September 25, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034514||128976|
NCT01034527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0602|Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes|Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female||Children's Hospital Medical Center, Cincinnati|Yes|Completed|June 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|593|||Female|10 Years|19 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034527||128975|
NCT01035112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0004|Magnetic Resonance Imaging of Breast Cancer|Magnetic Resonance Imaging of Breast Cancer||Stanford University||Recruiting|April 1995|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|445|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women referred for MRI or mammography by their physicians to the Stanford department of        Radiology or from referrals from the Stanford Oncology Divison, the Stanford Radiation        Oncology Department, and the Stanford Surgery Department.|August 2015|August 5, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035112||128930|
NCT01033019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225B2204|To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)|Double-blind, Randomized, Vehicle-controlled Proof of Concept Study on the Efficacy, Safety, Local Tolerability, PK and Pharmacodynamics of Multiple Topical Administrations of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas||Novartis|No|Terminated|December 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||October 2015|October 1, 2015|December 15, 2009||No|The data from participants with sBCCs showed insufficient efficacy with current formulation    and treatment conditions.|No|August 18, 2015|https://clinicaltrials.gov/show/NCT01033019||129091|
NCT01033032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 161|Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer|Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer||SCRI Development Innovations, LLC|No|Completed|December 2009|October 2014|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Female|18 Years|N/A|No|||December 2014|December 22, 2014|December 15, 2009|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT01033032||129090|
NCT01033916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLIP - 09.111|Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery|Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery|SLIP|Inova Health Care Services|No|Active, not recruiting|December 2009|January 2016|Anticipated|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033916||129022|
NCT01033929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESEC-02|A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis|A Safety and Dose Finding Trial of the Diagnostic Test C-Tb, When Given Intradermally by the Mantoux Technique to Adult Patients Recently Diagnosed With Active TB|TESEC-02|Statens Serum Institut|Yes|Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|38|||Both|18 Years|65 Years|No|||January 2013|January 18, 2013|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033929||129021|
NCT01034787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBCC 905001|Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma|Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma||AHS Cancer Control Alberta|Yes|Active, not recruiting|January 2010|||January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||September 2011|January 18, 2012|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01034787||128955|
NCT01034800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906300|The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215|The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215||National Institutes of Health Clinical Center (CC)||Completed|September 2006|||||N/A|Observational|N/A|||||||Both|N/A|N/A|No|||January 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034800||128954|
NCT01034449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/12|Transplantation of Ex-vivo Expanded Cord Blood Stems Cells|Transplantation of Ex-vivo Expanded Human Cord Blood Hematopoietic Stem Cells Expanded: Evaluation of Hematopoietic and Immunologic Reconstitution After a Reduced-intensity Conditioning Regimen|GRAPA|University Hospital, Bordeaux|Yes|Completed|February 2010|September 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||January 2015|January 12, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034449||128981|
NCT01037218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-01309|Treatment of Erectile Dysfunction II|Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction||Warner Chilcott|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|601|||Male|19 Years|N/A|No|||May 2015|May 20, 2015|October 19, 2009|Yes|Yes||No|July 12, 2011|https://clinicaltrials.gov/show/NCT01037218||128818|
NCT01037231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC3-DB-02|Phase 2/3 Oxabact Study|A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria.||OxThera|Yes|Completed|December 2009|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|2 Years|N/A|No|||May 2012|May 7, 2013|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037231||128817|
NCT01035008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006345|Confocal Endomicroscopy of Pancreatic InVivo|Detection of Neoplastic Pancreatic Cysts Using Probe Based Confocal Laser Endomicroscopy: A Prospective in Vivo Study||Mayo Clinic|Yes|Completed|December 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 19, 2012|December 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01035008||128938|
NCT01036802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1596|Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease|An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease||University of North Carolina, Chapel Hill|Yes|Terminated|December 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|16 Years|65 Years|No|||January 2014|January 6, 2014|December 18, 2009|Yes|Yes|Difficulty in accruing subjects|No|July 3, 2013|https://clinicaltrials.gov/show/NCT01036802||128840|This study was terminated early due to difficulty in accruing subjects.
NCT01041768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA-CHIR-MULT-BMI 30-35|Multicentric Prospective Randomized Trial on Surgery Versus Standard Medical Care in Type 2 Diabetic Patients BMI 30-35|Multicentric Prospective Randomized Controlled Trial on the Effect of Gastric Bypass and Bilopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI Between 30 and 35|DIA-CHIR-MULT|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Yes|Recruiting|March 2009|December 2015|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|35 Years|70 Years|No|||December 2009|March 29, 2010|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01041768||128473|
NCT01041781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-30801|Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|February 2010|||January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|792|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|December 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041781||128472|
NCT01041794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091006004|Tissue Partitioning in Early Childhood|Tissue Partitioning in Early Childhood: A Critical Period for Obesity Risk?||University of Alabama at Birmingham|Yes|Completed|December 2009|June 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|24|Samples With DNA|Samples will be labeled with the study protocol number, a unique identifier, and the date of      collection.      Blood specimens will be obtained by the nursing staff at the PCIR. The PCIR processing lab      will process the samples, which will then be stored in a locked freezer at -80oC in the      restricted access CNRU Metabolism Core lab (WEBB 337).|Both|3 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children aged three to seven years|April 2012|April 18, 2012|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041794||128471|
NCT01042067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001895-18|Safer Warfarin Treatment|Safer Warfarin Treatment - the Influence of CYP2C9 Genotyping, Genotyping of Vitamine K Dependent Proteins and Dietary Vitamine K Status on Dosing, Clinical Effect and Adverse Events With Emphasis on the Initial Phase of Treatment|CYKOWAR|Oslo University Hospital|No|Suspended|January 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood, serum, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients in need of warfarin treatment (standard indications) are included in the study at        the onset of warfarin treatment. About 200 patients will be included.|April 2011|April 26, 2011|January 4, 2010||No|Enrolling participants has halted due to lack of investigator.|No||https://clinicaltrials.gov/show/NCT01042067||128450|
NCT01038154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGIM-1|Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer|Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer|AGIM-1|Hospital Donostia|Yes|Recruiting|November 2009|November 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|N/A|No|||December 2009|June 24, 2011|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01038154||128747|
NCT01033721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paloma P529 Ocular|Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration|A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients With Advanced Neovascular Age-Related Macular Degeneration (AMD)|P52901|Paloma Pharmaceuticals, Inc.|Yes|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|50 Years|N/A|No|||September 2012|September 20, 2012|December 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01033721||129037|
NCT01034007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHIRB12-00357|A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery|A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery||Nationwide Children's Hospital|Yes|Enrolling by invitation|December 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|1 Year|N/A|No|||May 2015|May 6, 2015|January 29, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01034007||129015|
NCT01034254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mothers'Gift 241 Field Trial|Field Trial of Maternal Influenza Immunization in Asia|Field Trial of Maternal Influenza Immunization in Asia|Mothers'Gift|Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|November 2010|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|3000|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034254||128996|
NCT01034540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-09009|Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia|A Double-blind, Randomized, Placebo-controlled, Crossover Trial to Assess the Effects of 4 g/d Prescription Omega-3 Acid Ethyl Esters on Indices of Glucose Homeostasis and Lipoprotein Lipids in Subjects With Hypertriglyceridemia||Provident Clinical Research|No|Completed|March 2010|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|79 Years|No|||August 2013|August 14, 2013|December 16, 2009|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01034540||128974|Potential limitations: 1) relatively small sample size, and 2) relatively short length of wash-out period between treatments.
NCT01035099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCMC-0075|RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF|A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients||Weill Medical College of Cornell University|Yes|Recruiting|November 2009|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|19 Years|45 Years|No|||June 2015|June 10, 2015|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035099||128931|
NCT01035398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000450143|Genetic and Environmental Risk Factors Related to Esophageal Cancer|Molecular Epidemiology of Esophageal Cancer: Pilot Project||Massachusetts General Hospital|No|Recruiting|April 2000|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1200|Samples With DNA|Blood and/or buccal cells may be collected|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with esophageal cancer and healthy controls aged 45 and over|September 2015|September 30, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035398||128908|
NCT01033630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE2005123T|Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen|A Novel Randomized Double-Blind Placebo-Control Clinical Trial in High-Risk Hypertensive Subjects||Chinese University of Hong Kong|No|Completed|January 2006|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|35 Years|70 Years|No|||January 2006|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033630||129044|
NCT01033656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NordicAOSD05|Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study|An Open, Randomized Study Treating Refractory Adult-onset Still's Disease With Interleukin-1 Receptor Antagonist Anakinra (Kineret), Compared to an Established, Single Anti-rheumatic Drug Treatment|NordicAOSD05|Helsinki University|No|Active, not recruiting|December 2005|April 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033656||129042|
NCT01035320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2004-004416-22 DMK001|Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment|Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment|PLAUDIT|Karolinska University Hospital|No|Completed|January 2006|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|80 Years|No|||December 2010|February 25, 2011|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035320||128914|
NCT01035632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906411|Study of Smoking Abstinence|Study of Smoking Abstinence||National Institutes of Health Clinical Center (CC)||Completed|April 2006|January 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|210|||Both|18 Years|N/A|No|||January 2011|September 26, 2015|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01035632||128890|
NCT01035645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110040|First Time in Human Study of Intravenous Interleukin-18 Antibody|A Single-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Intravenously Infused GSK1070806 in Healthy and Obese Subjects.|A18110040|GlaxoSmithKline|No|Completed|January 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|78|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035645||128889|
NCT01032473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC-9978|Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)|Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)||Children's Research Institute|No|Recruiting|August 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|Salivary cortisol|Both|7 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|May 2011|May 11, 2011|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032473||129132|
NCT01032486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNC-RAS-PD/01|Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease|An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects|PD|Teva Pharmaceutical Industries|No|Completed|December 2009|July 2011|Actual|June 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|N/A|N/A|No|Non-Probability Sample|This is a sample of participants with Parkinson's disease who will be prescribed Azilect®        treatment as per Canadian product monograph in order to observe changes in sleep        behaviour.|August 2013|August 27, 2013|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032486||129131|
NCT01032824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1MH074380|Self-Managing HIV and Chronic Disease|Community-based Self-management of HIV and Chronic Disease|PRIME|Group Health Cooperative|No|Completed|October 2007|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|452|||Both|50 Years|N/A|No|||March 2012|August 16, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032824||129106|
NCT01032551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-09-340|Vascular Access Decision Aid|Vascular Access Options in Coronary Angiogram Procedures: A Patient Decision Aid Randomized Controlled Trial|VADAS|McMaster University|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2009|January 17, 2011|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01032551||129126|
NCT01041807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-349|Cozaar XQ Re-examination Study (MK-0954-349)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of COZAAR XQ in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|February 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|669|||Both|18 Years|N/A|No|Probability Sample|Participants with essential hypertension not adequately controlled with amlodipine or        losartan monotherapy; initial therapy for participants with stage 2 hypertension|April 2015|April 9, 2015|December 31, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01041807||128470|
NCT01041820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090904001|Critical Periods of Exercise|Critical Periods of Exercise||University of Alabama at Birmingham|Yes|Completed|December 2009|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|3 Years|7 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041820||128469|
NCT01037868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDublinTC|Usefulness of Supportive Text Messages in the Treatment of Depressed Alcoholics|A Randomised Trial on the Usefulness of Supportive Text Messages in the Treatment of Depressed Patients With Co-morbid Alcohol Dependency Syndrome||University of Dublin, Trinity College|Yes|Completed|September 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|64 Years|No|||March 2013|March 26, 2013|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037868||128769|
NCT01032538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKN-002|Time-dependent Improvement of Functional Outcome Following Oxford Medial Unicondylar Knee Replacement|Time-dependent Improvement of Functional Outcome Following Oxford Medial Unicondylar Knee Replacement - A Prospective Longitudinal Study With Repetitive Measures of KOOS in 100 Patients||Martina Hansen's Hospital|No|Active, not recruiting|November 2003|February 2017|Anticipated|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|||Both|50 Years|80 Years|No|Probability Sample|Consecutive patients operated with total knee arthroplasty at Martina Hansens Hospital,        Akershus University Hospital and Baerum hospital|October 2013|January 3, 2015|December 14, 2009||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01032538||129127|
NCT01033487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0431010|A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease|A Phase 2A, Double Blind, Placebo-Controlled, Single Dose, 5-Way Crossover Study Assessing The Pharmacodynamic, Pharmacokinetic And Safety Profiles Of Oral Inhaled PF-03635659 In Patients With Moderate Chronic Obstructive Pulmonary Disease.||Pfizer|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|22|||Both|40 Years|80 Years|No|||January 2016|January 22, 2016|December 15, 2009||No||No|August 9, 2012|https://clinicaltrials.gov/show/NCT01033487||129055|
NCT01039610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107895|A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.|A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.||GlaxoSmithKline|No|Withdrawn|November 2009|August 2010|Anticipated|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|9||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|December 23, 2009|Yes|Yes|Internal decision to progress alternate molecule with more preferable profile|No||https://clinicaltrials.gov/show/NCT01039610||128636|
NCT01039623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vaccine-HMO-CTIL|Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference|Randomized Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference||Hadassah Medical Organization||Not yet recruiting|January 2010|April 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2009|December 24, 2009|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039623||128635|
NCT01039909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113682|A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers||GlaxoSmithKline|No|Withdrawn|January 2011|February 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|December 23, 2009||No|Subjects were never screened/enrolled|No||https://clinicaltrials.gov/show/NCT01039909||128613|
NCT01040195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-08:PGI/DM/IEC/45/7.2.2009|Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain|A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs (DMARDs) vs Monotherapy (Sulfasalazine) in Patients With Inflammatory Low Backache in Early Seronegative Spondylarthropathy||Sanjay Gandhi Postgraduate Institute of Medical Sciences|Yes|Completed|June 2009|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|60 Years|No|||March 2013|March 21, 2013|December 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01040195||128591|
NCT01040208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.114|12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress|Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire||Sprout Pharmaceuticals, Inc||Terminated|January 2010|||January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|111|||Female|18 Years|50 Years|No|||March 2012|March 2, 2012|December 28, 2009|Yes|Yes|Study terminated by Sponsor for administrative reasons prior to completion of all study visits|No||https://clinicaltrials.gov/show/NCT01040208||128590|
NCT01040468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809984|Surgery Or Lifestyle Intervention for Type 2 Diabetes (SOLID)|Lifestyle Intervention Versus Bariatric Surgery for Type 2 Diabetes|SOLID|University of Pennsylvania|Yes|Active, not recruiting|September 2009|||September 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Both|18 Years|65 Years|No|||February 2013|February 1, 2013|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01040468||128570|
NCT01040481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2009066|Adding Malabsorption for Failed Gastric Bypass|Laparoscopic Revisional Surgery: Adding Malabsorption for Failed Gastric Bypass||University of California, San Francisco|Yes|Completed|August 2009|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|19|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who had either clinically severe obesity (morbid obesity, MO, or super obesity,        SO) underwent a primary Roux-en-Y gastric bypass. The ones that were subsequently revised        ending up with an optimized malabsorptive distal gastric bypass were identified from our        prospectively maintained bariatric database and included in this study. Specific metabolic        and nutritional complications after RYGB surgery were defined according to standard        definitions based on signs, symptoms, and laboratory measurements.|December 2009|December 26, 2009|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01040481||128569|
NCT01040741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_09OB|Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine|A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine Focetria||Novartis||Completed|December 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|7284|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population of children, adolescents, adults and elderly|October 2011|October 4, 2011|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01040741||128549|
NCT01040728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.40|A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease|Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour FEV1-time Profiles of BI 1744 CL 5μg and 10μg (Oral Inhalation, Delivered by the Respimat® Inhaler) and Tiotropium Bromide 18μg (Oral Inhalation, Delivered by the HandiHaler®) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|January 2010|||January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|122|||Both|40 Years|N/A|No|||May 2014|May 28, 2014|December 29, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01040728||128550|
NCT01041014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55879RWJF|Cost Effectiveness of Language Services in Hospital Emergency Departments (EDs)|Cost Effectiveness of Language Services in Hospital Emergency Departments||Mathematica Policy Research, Inc.|No|Completed|October 2008|January 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|447|||Both|N/A|N/A|No|||December 2009|September 29, 2015|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01041014||128528|
NCT01041339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0075-09-WOMC|ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?|ST Elevation (Acute Coronary Syndrome Versus Pericarditis;Could Measurement of Lp-associated PLA2 -a Vascular Specific Marker of Inflammation- be Helpful to the Clinician?||Wolfson Medical Center|No|Completed|January 2010|January 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|plasma kept in -80 celsius refrigerator|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|acute chest pain patients admitted to ICCU with acute ST elevation and elevated troponin|June 2011|December 13, 2015|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041339||128505|
NCT01032811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SADHD1|Pilot Study Of Primary And Secondary Attention-Deficit/Hyperactivity Disorder Among Survivors Of Childhood Cancer|Pilot Study Of Primary And Secondary Attention-Deficit/Hyperactivity Disorder Among Survivors Of Childhood Cancer||St. Jude Children's Research Hospital|No|Completed|October 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|12 Years|17 Years|No|Probability Sample|Participants will be recruited through consecutive enrollment in the SJCRH Leukemia,        Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.        Participants will be accrued using a broad stratification process for gender (female,        male) and age (12-14 years, 15-17 years) for each diagnosis group (brain tumor, ALL).|September 2013|September 5, 2013|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032811||129107|
NCT01034475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 29109|Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies|An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|March 2010|August 2014|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||September 2014|October 3, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034475||128979|
NCT01036126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903384|Automatic Versus Evaluative Components of Cue Reactivity|Automatic Versus Evaluative Components of Cue Reactivity||National Institutes of Health Clinical Center (CC)||Completed|August 2003|August 2010||||N/A|Observational|N/A|||Anticipated|320|||Both|18 Years|50 Years|No|||August 2010|August 20, 2010|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036126||128866|
NCT01036659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE Induced Angioedema|Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema|Evaluation of Ecallantide for Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema|ACE|Bernstein, Jonathan A., M.D.|Yes|Recruiting|May 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 8, 2012|December 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01036659||128845|
NCT01036685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903379|Cognitive Task Development and Implementation for Functional MRI Studies|Cognitive Task Development and Implementation for Functional MRI Studies||National Institutes of Health Clinical Center (CC)||Recruiting|May 2003|||||N/A|Observational|N/A|||Anticipated|750|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|August 11, 2015|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036685||128844|
NCT01036711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902372|Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI|Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI||National Institutes of Health Clinical Center (CC)||Completed|September 2002|November 2012||||N/A|Observational|N/A|||Anticipated|400|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|February 19, 2014|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036711||128843|
NCT01033669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011071|Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction|A Randomized Cross-Over Study Investigating The Inhalation Profiles Of Four Dry Powder Inhalation Devices In Subjects With Asthma And Chronic Obstructive Pulmonary Disease.||Pfizer|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Both|18 Years|80 Years|No|Probability Sample|Asthma and COPD patients|March 2010|March 15, 2010|September 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01033669||129041|
NCT01033682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3175|Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging|Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging|FILL|Royal Marsden NHS Foundation Trust|No|Recruiting|May 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving radiotherapy to the rectum|December 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033682||129040|
NCT01037582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-3691|A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects|Investigation on Safety, Tolerability and Bioavailability of Oral NN9924 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|155|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|December 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01037582||128791|
NCT01037595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3441|Effect of Turmeric on Pruritus in Hemodialysis Patients|||Shiraz University of Medical Sciences|No|Completed|September 2010|December 2010|Actual|October 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 12, 2013|December 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01037595||128790|
NCT01037608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907423|Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation|Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation||National Institutes of Health Clinical Center (CC)||Completed|May 2007|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|1||Anticipated|108|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 31, 2011|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01037608||128789|
NCT01033500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0042|Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients|Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients||University of Wisconsin, Madison|Yes|Withdrawn|July 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||May 2013|May 6, 2013|December 15, 2009|Yes|Yes|Insufficient funding|No||https://clinicaltrials.gov/show/NCT01033500||129054|
NCT01033734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25139|A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza|An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection||Hoffmann-La Roche||Completed|December 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|1 Year|12 Years|No|||November 2015|November 9, 2015|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033734||129036|
NCT01041833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA/141/CB/563/09|Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker|Randomized Phase III Trial: Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarkers||National Institute of Cancerología|Yes|Not yet recruiting|January 2010|September 2013|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|80 Years|No|||September 2009|December 31, 2009|September 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01041833||128468|
NCT01042080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01099-48|Neurally Adjusted Ventilatory Assist and Synchrony in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Mechanical Ventilation With NAVA and PSV on Inspiratory Muscle Workload and Synchrony in Patients With Chronic Obstructive Pulmonary Disease|NAVASYNC|Hôpital Européen Marseille|No|Active, not recruiting|December 2009|November 2016|Anticipated|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042080||128449|
NCT01037569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907431|Optimizing Toxicological Screening in Drug Endangered Children|Optimizing Toxicological Screening in Drug Endangered Children||National Institutes of Health Clinical Center (CC)||Completed|July 2007|March 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|1 Year|18 Years|No|||March 2011|March 23, 2011|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01037569||128792|
NCT01032525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15094|Monroe County Inflammatory Bowel Disease (IBD) Registry|Epidemiologic Study of Inflammatory Bowel Disease in Monroe County, New York||University of Rochester|No|Completed|January 1981|March 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|720|||Both|N/A|N/A|No|Non-Probability Sample|Residents of monroe County who had been diagnosed with Crohn's Disease or Ulcerative        Colitis|October 2015|October 12, 2015|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032525||129128|
NCT01039324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010738|Care Transitions for Complex Patient - Cycle 1 and Cycle 2|Improving Care Transitions for Complex Patients Through Decision Support||Duke University|No|Completed|December 2009|September 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|8422|||Both|N/A|N/A|No|||February 2014|May 14, 2014|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039324||128658|
NCT01039922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAG 035.0002-20/19|SwissNET - a Registry for Neuroendocrine Tumours in Switzerland|SwissNET - a Prospective Registry of Patients With Neuroendocrine Tumours in Switzerland|SwissNET|University Hospital Inselspital, Berne|No|Recruiting|January 2008|January 2028|Anticipated|January 2028|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be selected either through the report of a pathological institute or of any        medical doctor within Switzerland treating patients with neuroendocrine tumours.|July 2015|July 16, 2015|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039922||128612|
NCT01040221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-11-384|Trichuris Suis Ova in Autism Spectrum Disorders|Trichuris Suis Ova in Autism Spectrum Disorders|TSO|Montefiore Medical Center|Yes|Active, not recruiting|November 2012|July 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|35 Years|No|||June 2014|June 12, 2014|December 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01040221||128589|
NCT01040494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200911004M|Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure|Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project)||National Taiwan University Hospital|No|Not yet recruiting|January 2010|January 2011|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2009|January 18, 2010|December 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01040494||128568|
NCT01040754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000096|fMRI Study of Expectancy on Acupuncture Treatment Outcomes in Knee OA|An fMRI Study of Expectancy on Acupuncture Treatment Outcomes in Knee OA|KOA|Massachusetts General Hospital|Yes|Completed|June 2009|February 2016|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|144|||Both|40 Years|70 Years|No|||March 2016|March 10, 2016|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040754||128548|
NCT01041378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0558|Efficacy of Intravenous Dexamethasone on Postoperative Caudal Analgesia in Pediatric Orchiopexy|||Yonsei University|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|||Actual|80|||Both|6 Months|5 Years|No|||May 2010|June 15, 2010|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041378||128502|
NCT01041638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01997|Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma|A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2009|||December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|N/A|N/A|No|||November 2014|February 25, 2015|December 31, 2009|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01041638||128482|
NCT01041027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-03-060|Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer|A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|September 2008|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||January 2016|January 11, 2016|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01041027||128527|
NCT01041040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETHEMA-LAM07|LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)|PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)||PETHEMA Foundation|Yes|Completed|October 2007|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|N/A|N/A|No|||July 2013|July 30, 2013|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01041040||128526|
NCT01041352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laryngeal mask or endotracheal|Laryngeal Mask or Endotracheal Tube for Back Surgery in the Prone Position|Laryngeal Mask or Endotracheal Tube for Back Surgery in the Prone Position. Advantages, Adverse Effects and Time Consumation for the Two Methods.||Glostrup University Hospital, Copenhagen|No|Completed|October 2009|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|70 Years|No|||January 2012|January 17, 2012|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041352||128504|
NCT01033409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-RASV-Sp-01|Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA|Comparative Phase I Safety and Immunogenicity in Adult Volunteers of Three Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae Surface Protein Antigen PspA||Arizona State University|Yes|Completed|August 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 1, 2011|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033409||129061|
NCT01034189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803088M|Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer|A Phase II Study of Combining Cetuximab Plus Twice Weekly Paclitaxel/Cisplatin Concurrent Chemoradiotherapy (TP-CCRT) Followed With or Without Esophagectomy for Loco-regional Esophageal Squamous Cell Carcinoma (ESCC)||National Taiwan University Hospital|No|Recruiting|October 2008|June 2012|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034189||129001|
NCT01035034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091217|Comparison of One-stop Hybrid Revascularization Versus Percutaneous Coronary Intervention for the Treatment of Multi-vessel Disease|Comparison of "One-stop" Hybrid Coronary Revascularization Versus Percutaneous Coronary Intervention for the Treatment of Multi-vessel Coronary Artery Disease||China National Center for Cardiovascular Diseases|Yes|Recruiting|December 2009|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|80 Years|No|||December 2009|December 18, 2009|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035034||128936|
NCT01044628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-99512|The International Nocturnal Oxygen (INOX) Trial|Multi-Center Randomized Placebo-controlled Trial of Nocturnal Oxygen Therapy in Chronic Obstructive Pulmonary Disease. The International Nocturnal Oxygen (INOX) Trial|INOX|Laval University|Yes|Active, not recruiting|October 2010|December 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|243|||Both|40 Years|N/A|No|||September 2015|September 24, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044628||128256|
NCT01044940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093137|Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma in Healthy and Sick Children|Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma in Healthy and Sick Children||Haukeland University Hospital|No|Completed|January 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|17|Samples Without DNA|Plasma and interstitial fluid|Both|N/A|2 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asphyxiated babyes Children with heart defects who need surgery Newborn who need blood        transfusion|September 2015|September 9, 2015|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044940||128232|
NCT01037543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-HM10460A-101|Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects|A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and PK of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Japanese and Caucasian Subjects.||Hanmi Pharmaceutical Company Limited|No|Completed|November 2009|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|84|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|December 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01037543||128794|
NCT01045174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH IRB # 09-08-06|Breath-Actuated Nebulizer Versus Conventional Continuous-Output Nebulizer in Pediatric Asthma Patients|A Randomized Controlled Trial Comparing the Effectiveness of a Breath-Actuated Nebulizer Device Versus a Conventional Continuous-Output Nebulizer in Treating Pediatric Asthma Patients in the Emergency Department||University Hospital Case Medical Center|No|Terminated|December 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|1 Year|17 Years|No|||June 2012|June 13, 2012|January 7, 2010||No|change in availability of study investigators|No||https://clinicaltrials.gov/show/NCT01045174||128214|
NCT01045187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR-0209|Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer|Feasibility Study Using the Xoft Axxent Electronic Brachytherapy System for the Treatment of Endometrial Cancer||Xoft, Inc.|No|Completed|October 2008|April 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||July 2012|July 24, 2012|November 19, 2009||No||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01045187||128213|Small sample size.
NCT01032876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-090/K|Cerebral Perfusion During Neonatal Cardiac Surgery|Randomized Controlled Trial on Deep Hypothermic Circulatory Arrest Versus Antegrade Cerebral Perfusion During Neonatal Cardiac Surgery||UMC Utrecht|No|Completed|January 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|37|||Both|N/A|4 Months|No|||June 2012|June 28, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032876||129102|
NCT01032889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-09-15|Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study|Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (SMF) Using Magnetic Resonance Imaging (MRI) and a Battery of Clinician- and Subject-reported Measurements.||Kythera Biopharmaceuticals|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|129|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|December 10, 2009|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01032889||129101|
NCT01038765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFN-2005-2010|Mindfulness Based Cognitive Therapy for Recurrent Depression|Mindfulness Based Cognitive Therapy for Patients With Recurrent Depression: a Clinical Trial||Radboud University|No|Active, not recruiting|January 2005|January 2011|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|338|||Both|18 Years|N/A|No|||December 2009|December 23, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038765||128700|
NCT01038778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02900|Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer|Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma||National Cancer Institute (NCI)|Yes|Recruiting|October 2009|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038778||128699|
NCT01037270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0124|Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity||ECLIPSE-01|Biosite|No|Completed|August 2009|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|271|Samples Without DNA|Plasma specimens for reference testing.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 210 subjects on OAT and 20 normal healthy subjects not on anticoagulation        therapy will be enrolled.|February 2013|February 8, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01037270||128815|
NCT01037283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003781|Interpersonal and Social Rhythm Therapy Enter the Brief Title for Protocol IRB 09-003781>|Feasibility of Interpersonal and Social Rhythm Therapy for Outpatients With Bipolar Disorder|IPSRT|Mayo Clinic|No|Completed|October 2009|August 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||September 2011|September 14, 2011|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01037283||128814|
NCT01033162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0222|Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care|Using Technology to Enhance Cancer Communication and Improve Clinical Outcome: Effectiveness of the CHESS Ehealth Cancer Support Intervention in Population-Based Care Study||University of Wisconsin, Madison|Yes|Completed|November 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|368|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01033162||129080|
NCT01033175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8/22.1.08|The Impact of Anemia of Chronic Disease on Chronic Obstructive Pulmonary Disease Patients|The Clinical Impact of Anemia of Chronic Disease on Chronic Obstructive Pulmonary Disease Patients||Aristotle University Of Thessaloniki|No|Completed|December 2009|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|60|||Both|40 Years|85 Years|No|||December 2009|July 6, 2010|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033175||129079|
NCT01039636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBS0701-CTP-03|Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload|A PHASE 1b OPEN LABEL, MULTI-CENTER, ESCALATING MULTIPLE DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF FBS0701 IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD||FerroKin BioSciences, Inc.|No|Completed|November 2009|||December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2011|February 8, 2012|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039636||128634|
NCT01040507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2009023|Very Long Term Results After Laparoscopic Retrocolic Antegastric Gastric Bypass|Very Long Term Results After Laparoscopic Retrocolic Antegastric Gastric Bypass|>10yrsRYGB|University of California, San Francisco|Yes|Completed|June 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|242|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who had clinically severe obesity and underwent a primary laparoscopic Roux-en-Y        Gastric Bypass more than years ago were identified form a prospectively maintained        database at UCSF Fresno / ALSA med group, Inc Minimally Invasive Surgery Program.|August 2009|December 28, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01040507||128567|
NCT01040767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002019/1|Comparison of Web- Versus Classroom-based Basic Ultrasound and Extended Focused Assessment With Sonography for Trauma (EFAST) Training in Two European Hospitals|Comparison of Web- Versus Classroom-based Basic Ultrasound and EFAST Training in Two European Hospitals||Brigham and Women's Hospital|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 29, 2009|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01040767||128547|
NCT01041066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nicardipine-labetalol|Nicardipine Versus Labetalol During Intubation|||Seoul National University Bundang Hospital||Recruiting|September 2009|||December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|20 Years|65 Years|No|||September 2009|December 30, 2009|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041066||128525|
NCT01041079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2008078|Chronic Marginal Ulcers After Gastric Bypass|Laparoscopic Revision Gastric Bypass Surgery for Chronic Marginal Ulcers: a 10 Year Experience|ChronicMU|University of California, San Francisco|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients after Roux-en-Y gastric bypass for clinically severe obesity complicated with        intractable or chronic marginal ulcer disease|December 2009|December 31, 2009|December 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01041079||128524|
NCT01041365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090824002|Vitamin D, Insulin Sensitivity, and Vascular Associations in Adolescents|Serum 25-hydroxyvitamin D, Vascular Functioning, and Insulin Sensitivity in Adolescent Girls [The DIVA Study (Vitamin D, Insulin, and Vascular Associations)] (Pediatric Physician Training in Translational Research)|DIVA|University of Alabama at Birmingham|Yes|Completed|December 2009|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|62|Samples Without DNA|Serum|Female|14 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adolescent African American and European American teenagers, ages 14-18, will be        recruited form the Birmingham, AL community|January 2014|January 13, 2014|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01041365||128503|
NCT01041664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091006003|Bad Genes or Genes Behaving Badly|Bad Genes or Genes Behaving Badly||University of Alabama at Birmingham|Yes|Completed|December 2009|June 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|Samples With DNA|Samples will be labeled with the study protocol number, a unique identifier, and the date of      collection.      Specimens will be obtained by the nursing staff at the PCIR. The PCIR processing lab will      process the samples, which will then be stored in a locked freezer at -80oC in the      restricted access CNRU Metabolism Core lab (WEBB 337).|Both|3 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be healthy children self-identifed as Hispanic American aged 3 to seven        years|April 2012|April 18, 2012|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041664||128481|
NCT01041391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5812-LSS|Lumbar Disc Herniation Outcome Measures|Lumbar Disc Herniation Outcome Measures-Surgical Versus Non-Operative Treatment||State University of New York - Upstate Medical University|No|Terminated|May 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|35|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients in the SUNY Upstate Orthopedic Surgery department|September 2013|September 6, 2013|November 18, 2009||No|Slow/low enrollment|No||https://clinicaltrials.gov/show/NCT01041391||128501|
NCT01041924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS/04/079|Dynamic Carbon Dioxide (CO2) Administration for Sleep Apnoea|Dynamic Carbon Dioxide Administration for Central Sleep Apnoea in Heart Failure||Imperial College London|Yes|Not yet recruiting|February 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|80 Years|No|||January 2010|January 4, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01041924||128461|
NCT01037660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23660|Effects of Lipemia and Metformin on Endothelial Function|Effects of Lipemia and Metformin on Endothelial Function||Boston University|No|Recruiting|September 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01037660||128785|
NCT01044069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-114|Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19|A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01044069||128299|
NCT01044316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V37_07|Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China|A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Using a Local Dosing Regimen in Infants||Novartis||Completed|April 2010|December 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|670|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||December 2011|December 27, 2011|January 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01044316||128280|
NCT01044329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8900|Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion|Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion|BRVO|hahid Beheshti University of Medical Sciences|Yes|Recruiting|January 2010|December 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|N/A|No|||January 2010|January 6, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044329||128279|
NCT01044342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285M00021|A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition|A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-period Cross-over Study to Evaluate the Scopolamine Cognition Model in Healthy Male Subjects Using AZD1446 and Donepezil Versus Placebo||AstraZeneca|No|Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044342||128278|
NCT01044641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065816|Measurement of Colloid Osmotic Pressure in Plasma and Interstitial Fluid in Children|Measurement of Colloid Osmotic Pressure in Plasma and Interstitial Fluid in Children||Haukeland University Hospital|No|Completed|December 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|Samples Without DNA|Interstitial fluid and serum|Both|2 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Secondary care clinic (ENT)|July 2014|July 3, 2014|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044641||128255|
NCT01044979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071223|Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma|Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma, a Methodological Study||Haukeland University Hospital|No|Completed|December 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Serum and interstitial fluid|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers over 18 years.|July 2014|July 3, 2014|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01044979||128229|
NCT01045200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR 01-498|Nurse-or Surgeon-led Follow-up After Rectal Cancer|Nurse-or Surgeon-led Follow-up After Rectal Cancer: a Randomised Trial.||Centrallasarettet Västerås|Yes|Completed|January 2002|September 2009|Actual|October 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|19 Years|N/A|No|Probability Sample|Operated for rectal cancer at the colorectal unit of the Central Hospital in Västerås,        Sweden.|January 2002|January 7, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01045200||128212|
NCT01044953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sportmed-saarland-01/2009|Injury Incidence in Professional Soccer|Repercussions of a Shortened Winter Break on Injury Incidence Within the German Professional Soccer Leagues||Saarland University|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Male|16 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|German professional male soccer players|January 2011|January 4, 2011|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044953||128231|
NCT01045213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0588|Integrated Care Program for Chronic Obstructive Pulmonary Disease|Phase 3 Study of the Efficacy of Proactive Integrated Care in Advanced COPD Patients Located in Areas With High COPD-related Mortality||University of Colorado, Denver|No|Completed|October 2008|June 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|40 Years|N/A|No|||October 2012|October 3, 2012|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045213||128211|
NCT01045499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1759|Laparoscopic Adjustable Gastric Banding (LAGB) as a Treatment for Morbid Obesity in Adolescents|LAGB Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents||Columbia University|No|Active, not recruiting|September 2005|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|14 Years|19 Years|No|||October 2015|October 27, 2015|January 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045499||128189|
NCT01038479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/S0501/49|Maternal Consumption of Xylitol to Reduce Early Childhood Decay (MaXED Study)|Maternal Consumption of Xylitol to Reduce Early Childhood Decay (MaXED Study)|MaXED|NHS Fife|Yes|Active, not recruiting|December 2009|May 2016|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|1064|||Both|N/A|5 Years|Accepts Healthy Volunteers|||December 2009|June 14, 2011|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038479||128722|
NCT01039350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEE200401|Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.|Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.||Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon|No|Terminated|February 2006|July 2009|Anticipated|July 2008|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|December 23, 2009||No|It was stopped due to a lack of recruitment after 48 patients included|No||https://clinicaltrials.gov/show/NCT01039350||128656|
NCT01039363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-029|Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia|Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older||Samsung Medical Center||Not yet recruiting||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|50 Years|N/A|No|||October 2009|December 24, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039363||128655|
NCT01039376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112517|Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy|A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy|PROLONG|GlaxoSmithKline|Yes|Active, not recruiting|May 2010|May 2017|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Both|N/A|N/A|No|||June 2015|July 2, 2015|December 23, 2009|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01039376||128654|
NCT01032863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-PAE-09-258|Association Between Hypermobility and Chronic Musculoskeletal Pain|A Study of Association Between Hypermobility And Chronic MusculoSkeletal Pain:a Pilot Study|HAMS|Amrita Institute of Medical Sciences & Research Center|Yes|Completed|December 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|112|||Both|25 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young Indian adults aged between 25 years and 40 years|December 2009|March 23, 2010|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032863||129103|
NCT01039038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURIEBOOST|Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer|A Phase II Study Evaluating the Feasibility of a Dose Increase by a Boost of Curietherapy in PDR Associated With the Extern Radiotherapy in Intermediate Risk in the Prostate Cancer|CURIEBOOST|Centre Francois Baclesse|Yes|Terminated|September 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|50 Years|75 Years|No|||November 2011|November 24, 2011|December 11, 2009||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01039038||128680|
NCT01040234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH_Z-Regional-001|Bilateral Dual TAP Block: Description of a Novel Four-point Approach|Ultrasound-guided Bilateral Dual Transversus Abdominis Plane (BD-TAP) Block: Description of a Novel Four-point Ultrasound-guided TAP Block Approach||Bispebjerg Hospital|Yes|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with postoperative pain following abdominal surgery that do not respond to        moderate doses of opioid analgesics or patients with failed epidurals|October 2015|October 21, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01040234||128588|
NCT01040247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0027-09-EMC|Optimal Timing For Embryo Transfer For Low Responder Patients|||HaEmek Medical Center, Israel||Terminated|November 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||June 2015|June 21, 2015|December 28, 2009||No|Difficulty in recruiting patients|No||https://clinicaltrials.gov/show/NCT01040247||128587|
NCT01040520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE KIM 2010.1|Value of CT-based Autopsy Compared With Conventional Autopsy in ICU Patients|Computertomography-based Autopsy (Virtopsy) Versus Conventional Autopsy in Patients Dying in Intensive Care Units||Universitätsklinikum Hamburg-Eppendorf|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|284|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who die while receiving treatment in the Department of Intensive Care        Medicine|May 2015|May 28, 2015|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040520||128566|
NCT01040533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2008085|Laparoscopic Revision of Jejunoileal Bypass to Gastric Bypass|One-stage Laparoscopic Revision of Failed and/or Complicated Jejunoileal Bypass to Roux-en-Y Gastric Bypass|JIB-to-RYGB|University of California, San Francisco|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who underwent laparoscopic revision of JIB to Roux-en-Y gastric bypass (RYGB) for        poor weight loss or JIB-related late complications were analyzed. Failed or JIB-related        late complications, mostly metabolic, were considered for surgical intervention after        optimized medical multidisciplinary management|December 2009|December 28, 2009|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01040533||128565|
NCT01040780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPI-2009|Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients|A Randomized,Double-blind,Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated With Chemotherapy|ICOGEN|Betta Pharmaceuticals Co.,Ltd.|Yes|Completed|February 2009|December 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|399|||Both|18 Years|75 Years|No|||January 2014|January 21, 2014|December 27, 2009||No||No|February 21, 2012|https://clinicaltrials.gov/show/NCT01040780||128546|
NCT01040793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.38|Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II|Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease.||Boehringer Ingelheim||Completed|January 2010|||April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|157|||Both|40 Years|75 Years|No|||July 2014|July 4, 2014|December 29, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01040793||128545|
NCT01041092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04T-504|Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women|Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women||Fundació Sant Joan de Déu|Yes|Completed|June 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|40 Years|N/A|No|||December 2009|December 30, 2009|December 30, 2009||Yes||No||https://clinicaltrials.gov/show/NCT01041092||128523|
NCT01041404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO18255|ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer|A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer||Hoffmann-La Roche||Completed|September 2005|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|584|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|December 29, 2009|No|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01041404||128500|
NCT01041677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013735|A Study of the Safety of R256918 in Obese Patients|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|February 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|65 Years|No|||January 2013|January 15, 2013|December 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041677||128480|
NCT01041937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clohisy TKA trial|Total Knee Arthroplasty (TKA) Cemented Versus Cementless Tibial Prosthesis Study|Total Knee Arthroplasty Randomized Clinical Trial- Cemented vs. Cementless Tibial Prosthesis Study|TKA|Washington University School of Medicine|Yes|Active, not recruiting|December 2009|December 2014|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|70 Years|No|||January 2010|January 5, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01041937||128460|
NCT01044355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-038-SDR (SARHT 1001)|Effect of Continuous Positive Airway Pressure (CPAP) Versus Auto-titrating Continuous Positive Airway Pressure (APAP) on Resistant Hypertension (HTN) and Arterial Stiffness|Effect of Fixed Versus Auto-titrating Continuous Positive Airway Pressure on Blood Pressure and Arterial Stiffness in Patients With Resistant Hypertension and Obstructive Sleep Apnea||McGill University Health Center|Yes|Recruiting|December 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044355||128277|
NCT01044654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-728-0902|Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients|A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy||Sangamo Biosciences|No|Completed|December 2009|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|19|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044654||128254|
NCT01044966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3542|A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma|Phase I/II Intraventricular DepoCyt (OD # 06-2348) in Glioblastoma (76,730, 11/06)||Medical University of South Carolina|Yes|Terminated|September 2009|September 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|85 Years|No|||September 2013|October 1, 2015|January 6, 2010|Yes|Yes|The study was terminated due to lack of adequate patient enrollment into trial.|No||https://clinicaltrials.gov/show/NCT01044966||128230|
NCT01045226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08809|Proton Radiation Therapy in Treating Patients With Prostate Cancer|A Phase II Trial of Proton Radiation Therapy of Using Standard Fractionation for Low-and Low-Intermediate Risk Adenocarcinoma of the Prostate||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|August 2009|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|262|||Male|18 Years|N/A|No|||January 2016|January 22, 2016|January 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01045226||128210|
NCT01045512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKSH-38|The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing|The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing|AntiCardAgeing|Martin-Luther-Universität Halle-Wittenberg|Yes|Terminated|October 2009|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|96|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|January 8, 2010||No|unsufficient recruitment|No||https://clinicaltrials.gov/show/NCT01045512||128188|
NCT01045525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2009-A00831-56|Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liversiderosis|Prospective Randomized Study Comparing the Effect of Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only on Glycemia in Patients With Dysmetabolic Liversiderosis|SAIGNEES|Rennes University Hospital|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045525||128187|
NCT01045759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1143800|Point of Care Ultrasound (US) Versus Detailed Radiology US for Deep Vein Thrombosis (DVT)|Intensivist Performed Limited B Mode Compression Ultrasound for Diagnosis of Deep Vein Thrombosis in the Intensive Care Unit||University of Missouri-Columbia|No|Withdrawn|November 2009|May 2015|Actual|May 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|The study population will consist of adult patients admitted to the intensive care units        at University hospital who have a duplex ultrasound of the lower extremities for detection        of deep vein thrombosis ordered by the primary team.|May 2015|May 27, 2015|January 7, 2010||No|Investigator left the institution|No||https://clinicaltrials.gov/show/NCT01045759||128169|
NCT01046006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-CAN-2021|Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network||University of Athens|No|Active, not recruiting|March 2007|||February 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046006||128150|
NCT01039077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR IRB#08-148|Single Incision Laparoscopic Gastric Banding Versus Conventional Five Port Laparoscopic Gastric Banding|Single Incision Laparoscopic Gastric Banding Versus Conventional Five Port Laparoscopic Gastric Banding||St. Luke's-Roosevelt Hospital Center||Completed|December 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039077||128677|
NCT01039090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-006045-10|Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease|Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study|APO-TEP|Rennes University Hospital|Yes|Recruiting|February 2009|August 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039090||128676|
NCT01039389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237/2008|Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease|Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease||University Hospital Inselspital, Berne|Yes|Completed|October 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|90 Years|No|||July 2013|July 11, 2013|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039389||128653|
NCT01039402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2009/3|Connection Between General Practitioner's (GP's) Estimation of Cardiovascular Risk and Theoretical Calculation in France|Connection Between GP's Estimation of Cardiovascular Risk and Theoretical Calculation in France||AstraZeneca|No|Completed|December 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|13502|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care|September 2010|September 14, 2010|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039402||128652|
NCT01033747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0105E2|Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study|A 5-year Open Label, Non-comparative Extension to a Randomized, Open-label, Phase IIa Study to Evaluate Safety, Tolerability and the Effects on Liver Iron Concentration of Repeated Doses of 10 and 20 mg/kg/Day of Deferasirox in Comparison With 40 mg/kg/Day Deferoxamine in Patients With Transfusion-dependent Iron Overload||Novartis||Completed|February 2003|January 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|October 16, 2009|Yes|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT01033747||129035|
NCT01039337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COHART|Conservative Treatment for Hip Osteoarthritis|Conservative Treatment for Hip Osteoarthritis: Effect of Manual Treatment and Hip School on Pain, Disability and Quality of Life - a Single-blinded Randomized Controlled Trial|COHART|Nordic Institute of Chiropractic and Clinical Biomechanics|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|118|||Both|40 Years|80 Years|No|||November 2012|November 6, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039337||128657|
NCT01040260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17RT-0081|Low-Cost Contingency Management for Smoking Cessation|Low-Cost Contingency Management for Smoking Cessation||University of California, San Francisco|No|Completed|June 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 23, 2013|December 27, 2009||No||No|June 23, 2013|https://clinicaltrials.gov/show/NCT01040260||128586|
NCT01040819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24253|Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?|Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?||Baylor College of Medicine|No|Completed|February 2010|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|21 Years|N/A|No|||March 2012|March 9, 2012|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01040819||128543|
NCT01040832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200068-006|EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)||EMD Serono|Yes|Completed|December 2009|||January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|December 29, 2009|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT01040832||128542|Few of the secondary outcome measures were planned and later removed due to Sponsor's decision to discontinue development of EMD 1201081. Overall survival data was analyzed only for participants who received EMD 1201081 plus cetuximab.
NCT01041105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2008086|Gastric Bypass After Previous Anti-reflux Surgery|Laparoscopic Revision Roux-en-Y Gastric Bypass Surgery After Previous Anti-rflux Surgery: Intermediate Results|RYGBafterARS|University of California, San Francisco|Yes|Completed|December 2008|December 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|22|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients who underwent laparoscopic Roux-en-Y gastric bypass (RYGB) after a previous        functional or failed anti-reflux procedure and met National Institutes of Health criteria        for bariatric surgery.|December 2009|December 31, 2009|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01041105||128522|
NCT01041430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T102010087a|Day-case or Inpatient Care Following Inguinal Hernia Repair in Elderly Patients|Randomized Clinical Trial Comparing Day-case and Inpatient Care Following Inguinal Hernia Repair in Elderly Patients||Helsinki University Central Hospital|No|Completed|February 2006|||February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|89|||Both|65 Years|N/A|No|||April 2015|April 17, 2015|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041430||128498|
NCT01041417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00030362|Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease|Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study|GPAD-2|Emory University|Yes|Completed|September 2009|||March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|159|||Both|21 Years|80 Years|No|||December 2014|December 12, 2014|December 29, 2009|Yes|Yes||No|May 15, 2014|https://clinicaltrials.gov/show/NCT01041417||128499|Study population were subjects with claudication who underwent angiography. Study design could not show therapeutic benefit of GM-CSF therapy with dose and duration changes. And study design encouraged all subjects to walk to claudication daily.
NCT01041690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beva-Cairo-A1|Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease|Bevacizumab (Avastin) as an Adjunct to Vitrectomy in the Management of Severe Proliferative Diabetic Retinopathy: a Prospective Case Series||Cairo University|Yes|Completed|June 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|9 Years|40 Years|No|||January 2007|December 31, 2009|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01041690||128479|
NCT01041950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUCAS-IVH|A Randomised Controlled Trial of Lumbar Drainage to Treat Communicating Hydrocephalus After Severe Intraventricular Hemorrhage|Lumbar Drainage for Communicating Hydrocephalus After Intraventricular Hemorrhage: a Randomised, Controlled Trial(LUCAS-IVH: LUmbar CAtheter for Severe IntraVentricular Hemorrhage)|LUCAS-IVH|University of Erlangen-Nürnberg Medical School|No|Completed|June 2010|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|85 Years|No|||February 2016|February 22, 2016|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01041950||128459|
NCT01038011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acto_2003|Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study|||University of Zurich||Completed|June 2004|August 2006||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||February 2010|February 2, 2010|December 15, 2009||||No||https://clinicaltrials.gov/show/NCT01038011||128758|
NCT01037686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3972-SH-CTIL|The Effect of Electrode Implantation for Deep Brain Stimulation (DBS) on Brain Function Using Single Photon Emission Computed Tomography (SPECT) With Technetium-99m-ethyl Cysteinatedimer (Tc-ECD)|Exploring the Effect of Electrode Implantation for DBS on Brain Function During Rest and During Semantic Verbal Fluency Task Using SPECT With Tc-ECD||Sheba Medical Center|No|Recruiting|February 2006|October 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||December 2009|December 22, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01037686||128783|
NCT01044667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myfortic 091423|A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic|Reduced Gastrointestinal Complaints and Improved Quality of Life in Lung Transplant Recipients Converted From Mycophenolate Mofetil (MMF) to Myfortic (Enteric-coated Mycophenolate Sodium, Ec-mps)||Vanderbilt University|No|Recruiting|January 2010|December 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2010|December 16, 2010|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044667||128253|
NCT01044992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 036 08|Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study|Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge|MSAJOY|University Hospital, Toulouse|No|Completed|May 2002|May 2006|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|38|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||February 2010|February 25, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044992||128228|
NCT01046019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35-07122b 1.2007.896|Measurement of Early Bone Loss Around a Total Hip Arthroplasty|Measurement of Early Bone Loss Around a Total Hip Arthroplasty. A Prospective Trial With Dual Energy X-ray Absorptiometry.|DXACorail|Oslo University Hospital|Yes|Completed|September 2007|August 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|N/A|N/A|No|Probability Sample|Patients with degenerative hip osteoarthritis decided for operation with total hip        arthroplasty.|January 2010|July 3, 2011|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046019||128149|
NCT01046305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0728|Symptom Burden in Chronic Myeloid Leukemia (CML)|Symptom Burden of Patients With Chronic Myeloid Leukemia (CML)||M.D. Anderson Cancer Center|No|Completed|November 2009|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|210|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Chronic myeloid leukemia (CML) patients and their caregivers, 18 years of age or older,        physicians and nurses.|February 2016|February 19, 2016|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046305||128127|
NCT01042405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0074-09-WOMC|Development of New Computerized Predictive Method for Morbidity and Mortality Risk in Hemodialysis (HD) Patients Based on Nutritional Evaluation and Scoring|Development of a Risk Computerized Predictive Method in HD Patients by Nutritional Scoring|HD- dialysis|Wolfson Medical Center|No|Enrolling by invitation|February 2010|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|patients on hemodialysis, Wolfson Hospital|December 2009|March 3, 2010|January 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01042405||128424|
NCT01039103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0303-CL-204|Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)|A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)||Galapagos NV|No|Suspended|December 2009|September 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|90|||Both|18 Years|65 Years|No|||October 2011|October 24, 2011|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01039103||128675|
NCT01039675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113120|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD||GlaxoSmithKline|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|40 Years|N/A|No|||March 2012|December 19, 2013|December 23, 2009|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01039675||128631|
NCT01039051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008BA158B07|Diet and Lifestyle Intervention Study in Postpartum Women in China|Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health||Huazhong University of Science and Technology|Yes|Recruiting|June 2009|June 2010|Anticipated|December 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|1600|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2009|December 23, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039051||128679|
NCT01039064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRG-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||December 23, 2009|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039064||128678|
NCT01039935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVO-0684|Genetic Basis of Odor Discrimination|Genetic Basis of Odor Discrimination||Rockefeller University|No|Completed|November 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|512|Samples With DNA|Blood sample taken|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|September 2012|September 5, 2012|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039935||128611|
NCT01039948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06162|A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer|A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162)||AVEO Pharmaceuticals, Inc.|No|Completed|December 2009|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039948||128610|
NCT01039974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112648|GSK962040 Drug-drug Interaction Study With Ketoconazole|An Open-label, Randomized, Single Sequence, Two Period Study to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of GSK962040 in Healthy Volunteers||GlaxoSmithKline|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 21, 2011|December 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01039974||128608|
NCT01040546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH97-TD-F-113-96002|The Effect of a Diet- and Exercise- Related Weight Control Intervention Program on Obesity in Adult Aged 40 and Over|The Association of Obesity With Food Intake and Metabolic Syndrome in Adult Aged 40 and Over and the Effect of a Diet- and Exercise- Related Weight Control Intervention Program on Obesity||China Medical University Hospital|Yes|Completed|March 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|240|||Both|40 Years|75 Years|No|||December 2009|December 28, 2009|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01040546||128564|
NCT01040806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H40013-34104-01|Peer Coaching for Low-Income Patients With Diabetes in Primary Care|Peer Coaching for Low-Income Patients With Diabetes in Primary Care||University of California, San Francisco|No|Completed|August 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|300|||Both|18 Years|N/A|No|||December 2011|December 9, 2011|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040806||128544|
NCT01041131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2009073|Laparoscopic Revision of Vertical Banded Gastroplasty to Gastric Bypass|Laparoscopic Revisional Gastric Bypass Surgery for Failed and/or Complicated Open Vertical Banded Gastroplasty: Our Experience With 70 Patients|VBG|University of California, San Francisco|Yes|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|70|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients status post failed and/or complicated Vertical Banded Gastroplasty (VBG)        undergoing conversion to laparoscopic Roux-en-Y gastric bypass (RYGB)|December 2009|December 31, 2009|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01041131||128521|
NCT01041703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000659585|Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)||Eastern Cooperative Oncology Group||Recruiting|January 2011|||February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|747|||Both|60 Years|N/A|No|||July 2014|July 24, 2014|December 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041703||128478|
NCT01041963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203/52|The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients|The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients||Chulalongkorn University|Yes|Recruiting|June 2009|September 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|20 Years|60 Years|No|||May 2010|May 9, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01041963||128458|
NCT01037699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502-C-M05-EB|Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles|||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|January 2005|March 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|720|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||December 2009|December 22, 2009|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037699||128782|
NCT01037712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070115|In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir|In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo|CYMEVAL|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|September 2009|June 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Female|18 Years|N/A|No|||February 2011|October 12, 2012|December 21, 2009||No|not enough inclusion|No||https://clinicaltrials.gov/show/NCT01037712||128781|
NCT01038024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 155409|Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage|A Pilot Study for the LC-MS/MS Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage||Roswell Park Cancer Institute|Yes|Completed|January 2010|July 2012|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 7, 2013|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01038024||128757|
NCT01038050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 98-10-02|Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease|||Taipei Veterans General Hospital, Taiwan|No|Enrolling by invitation|October 2009|December 2010|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||December 2009|December 22, 2009|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01038050||128755|
NCT01038297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXC 001-201|Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty|A Phase 2, Randomized, Double-Blind, Within-subject Controlled, Dose- Ranging Study to Evaluate Efficacy and Safety of EXC 001 for the Amelioration of Incision Scars in the Abdominal Pannus of Subjects Undergoing an Elective Abdominoplasty||Pfizer|Yes|Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|December 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038297||128736|
NCT01038310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JoergSpiegel2|Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease|Prognostic Value of FP-CIT-SPECT in Patients With Parkinson´s Disease||Saarland University|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Parkinson´s disease who underwent FP-CIT-SPECT in the years between 2003 and        2006.|July 2010|July 22, 2010|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038310||128735|
NCT01045239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMERC001|Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema|A Randomized, Controlled Trial Comparing Micropulse 577 nm Laser Photocoagulation And Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema|UMDMO|University of Malaya|Yes|Recruiting|October 2009|January 2012|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2010|January 7, 2010|January 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01045239||128209|
NCT01045538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0903|Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer|A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer|Zolinza+XP|Asan Medical Center|Yes|Active, not recruiting|February 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2015|January 11, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01045538||128186|
NCT01045772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCILTRA1|Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)|A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)|ACCILTRA1|Charite University, Berlin, Germany|Yes|Completed|January 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045772||128168|
NCT01033513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AoA90AM2665|SOS Nutrition Project|SOS Nutrition Project||University of North Carolina, Charlotte|No|Completed|May 2003|August 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|320|||Both|60 Years|N/A|No|Probability Sample|See inclusion and exclusion criteria below.|December 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033513||129053|
NCT01033526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11756|Symptomatic Treatment of Common Cold Symptoms|A Two-arm, Multicenter, Randomized, Double-blind, Single Dose Placebo-controlled Parallel Groups Study Evaluating Efficacy and Tolerability of 800 mg Acetylsalicylic Acid (Aspirina® C) in Adult Patients With a Common Cold During a Two Hour in Patient Phase; and a Follow-up Period of Five Days of Home Treatment as Required||Bayer|No|Completed|October 2005|June 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|388|||Both|18 Years|65 Years|No|||December 2009|December 15, 2009|December 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01033526||129052|
NCT01033773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-268|Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)|STEP-DC: Stop Emergency Room Visits for Uncontrolled Hyperglycemia Project in the District of Columbia|STEP-DC|Medstar Research Institute|No|Completed|September 2007|January 2009|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||December 2009|December 14, 2009|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01033773||129033|
NCT01033786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29966|Robotic Urogynecological Surgery: Hospital Stay and Perioperative Complications|Recovery After Robotic Urogynecological Surgery: Hospital Stay and Perioperative Complications of Patients Who Did Not Complete Questionnaires||University of Rochester|No|Completed|October 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|21|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who underwent DaVinci-assisted laparscopic surgery.|April 2011|April 8, 2011|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033786||129032|
NCT01039415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRBS #09-005|Attempts to Stop/Reduce Marijuana Among Dependent Users|Attempts to Stop/Reduce Marijuana Among Dependent Users||University of Vermont|No|Completed|June 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|234|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|adults 18 and older|September 2013|September 17, 2013|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039415||128651|
NCT01039441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-071|The Effect of Local Anesthesia and Simple Maneuver on Shoulder Pain After Gynecologic Laparoscopy|The Effect of Local Anesthesia and Simple Maneuver on Shoulder Pain After Gynecologic Laparoscopy||Samsung Medical Center|No|Completed|December 2008|July 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|291|||Female|15 Years|65 Years|No|||October 2008|December 23, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039441||128649|
NCT01039701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00006|4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease|Safety, Tolerability and Pharmacokinetics of 3 Dose Regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo Controlled, Parallel Group Phase IIa Study in Patients With Mild to Moderate Alzheimer's Disease During 4 Weeks of Treatment|ROBIN|AstraZeneca|No|Completed|December 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|99|||Both|60 Years|85 Years|No|||August 2010|August 10, 2010|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01039701||128629|
NCT01039649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905703|A Study to Test Lung Function After Radiation Therapy|Quantifying Radiation Induced Changes in Pulmonary Function in Irradiated and Non-irradiated Lung Tissue|PFS|University of Iowa|Yes|Completed|June 2009|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients with lung disease requiring radiation therapy. Lung tumor may be lung        cancer or metastasis to the lung. Radiation simulation method must be four-dimensional        computer tomography (4D-CT)|January 2015|January 16, 2015|December 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01039649||128633|
NCT01040273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA|Management of Postoperative Pain After Total Hip Arthroplasty|||Chang Gung Memorial Hospital||Not yet recruiting|December 2009|||December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2009|December 27, 2009|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01040273||128585|
NCT01040286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI/012F|The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis|The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis||Dexcel Pharma Technologies Ltd.|No|Completed|August 2009|June 2010|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|21 Years|N/A|No|||July 2010|July 5, 2010|December 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01040286||128584|
NCT01040845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-07-1005|A Pharmacokinetic Study of Colchicine With an Oral Contraceptive|A Pharmacokinetic Study to Evaluate the Effect of Colchicine on the Pharmacokinetic Profile of an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone in Healthy Women||Mutual Pharmaceutical Company, Inc.|No|Completed|August 2007|February 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 30, 2009|August 13, 2009|No|Yes||No|August 13, 2009|https://clinicaltrials.gov/show/NCT01040845||128541|
NCT01041443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09045|5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|A Phase I Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) in Myeloid Leukemia and MDS||City of Hope Medical Center|Yes|Completed|December 2009|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|December 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01041443||128497|
NCT01041716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/11VA03|Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria|Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria||Maimonides Medical Center|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Adult in-patients (age≥18 years) having an infection due to CRGNB (Klebsiella pneumoniae,        Acinitobacter baumanii and Pseudomonas aeruginosa only). CRGNB Infection will be defined        as isolation of CRGNB from any source requiring treatment with anti-infective agents with        or without manifestations of systemic inflammatory response syndrome.|August 2011|August 18, 2011|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041716||128477|
NCT01041976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7306-R|Supported Employment: Motivational Enhancement for Entry and Outcome|Supported Employment: Motivational Enhancement for Entry and Outcome||VA Office of Research and Development|No|Completed|January 2011|September 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|December 31, 2009||No||No|August 24, 2015|https://clinicaltrials.gov/show/NCT01041976||128457|
NCT01037725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3430C00001|Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers|A Phase-1, Single Center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics (Including Food Effect) of Ascending Oral Doses of AZD5847 in Healthy Male Subjects and Female Subjects of Non-childbearing Potential||AstraZeneca|No|Completed|December 2009|April 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 13, 2010|December 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01037725||128780|
NCT01038037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015068-32|First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer|A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status|Lung-TRIO|Vejle Hospital|Yes|Terminated|January 2010|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|December 22, 2009||No|1. Very low enrollment rate.      2. Recent studies question the effect of adding panitumumab in this category of patients.      3. Too high toxicity rate|No||https://clinicaltrials.gov/show/NCT01038037||128756|
NCT01038323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU 0904-08|Drug and Talk Therapy for Fibromyalgia|A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran||Indiana University|Yes|Completed|December 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|48|||Both|18 Years|65 Years|No|||March 2011|October 11, 2012|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038323||128734|
NCT01038583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR#09-3029|Aspirin in Reducing Events in the Elderly|Aspirin in Reducing Events in the Elderly|ASPREE|Minneapolis Medical Research Foundation|Yes|Active, not recruiting|January 2010|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|19000|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|December 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038583||128714|
NCT01032902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-HIV01|Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test|Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma||Chembio Diagnostic Systems, Inc.|Yes|Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2808|Samples Without DNA|serum and plasma|Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Point-of-care test sites including clinics and physician office settings|April 2012|April 27, 2012|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01032902||129100|
NCT01032915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457C2301|Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis|A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.|ENDURE|Novartis|Yes|Terminated|February 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|125|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|December 14, 2009|Yes|Yes|Results of a planned interim analysis did not show significant effects for any of the 3 AIN    dose regimens versus placebo on any primary or secondary endpoint|No|February 12, 2015|https://clinicaltrials.gov/show/NCT01032915||129099|
NCT01032928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7135-R|Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer|Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer|RSPT|VA Office of Research and Development|No|Completed|June 2011|September 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|N/A|No|||December 2014|December 9, 2014|December 14, 2009||No||No|November 25, 2014|https://clinicaltrials.gov/show/NCT01032928||129098|
NCT01033188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2009.234|Double Bundle Anterior Cruciate Ligament Reconstruction|Single Bundle or Double Bundle Anterior Cruciate Ligament Reconstruction. A Randomized, Controlled Trial.||Oslo University Hospital|No|Active, not recruiting|January 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|40 Years|No|||August 2015|August 4, 2015|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033188||129078|
NCT01033201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-000800|Alveoscopy, Endoscopic Confocal Microscopy and Lung Rejection, Parenchymal Lung Diseases in Vivo|The Role Of Endoscopic Alveoscopy by Confocal Endomicroscopy in Diagnosing Acute and Chronic Rejection in Lung Transplant Recipients, Diagnosis of End Stage Lung Disease, and Other Pulmonary Pathologies in Vivo||Mayo Clinic|No|Completed|April 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|71|||Both|18 Years|80 Years|No|Probability Sample|Patients scheduled to undergo bronchoscopy either before or after lung transplantation.|January 2012|January 25, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033201||129077|
NCT01033539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP U-08-008 BSS|To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans|To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans||Good Food Practice, Sweden|No|Completed|November 2009|August 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033539||129051|
NCT01033227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SN-SC-02-01|Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease|A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease||Children's Hospital Los Angeles|Yes|Terminated|December 2009|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|8 Years|23 Years|No|||July 2015|July 27, 2015|December 15, 2009|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT01033227||129075|
NCT01033799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU207|Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers|Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers||Danone Research|No|Completed|October 2006|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033799||129031|
NCT01039688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921069|Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX|Phase 3 Randomized, Double-Blind Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Compared To Methotrexate In Methotrexate-Naive Patients With Rheumatoid Arthritis|ORAL1069|Pfizer|Yes|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|968|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039688||128630|
NCT01040585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951154|Cost Effectiveness Of Linezolid In Central America|Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America||Pfizer|No|Withdrawn|July 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Adult men and women with VAP.|March 2012|March 1, 2012|December 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01040585||128561|
NCT01039662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-199|Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin|Effects of the Combination of L-Arabinose and Indigestible Dextrin on Glycemic Index: a Double-Blind, Crossover Trial||Hiroshima University|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039662||128632|
NCT01039961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113022|PK Study of IV Formulation of GW856553|Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Dose(s) and a Single Oral Dose of GW856553 in Healthy Volunteers||GlaxoSmithKline|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|October 1, 2015|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039961||128609|
NCT01040559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDASPHERE|Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas|Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas Combining DC Bead Microspheres Loaded With Idarubicin (Zavedos®): Phase I Trial||Centre Hospitalier Universitaire Dijon|Yes|Completed|December 2009|June 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040559||128563|
NCT01041144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seoul R&D Project|Effects of Health Care Provider-mediated, Remote Coaching System Through the PDA-type Glucometer and the Internet on Diabetes Management|||The Catholic University of Korea|Yes|Completed||||||N/A|Interventional|Primary Purpose: Supportive Care|1|||115|||Both|40 Years|85 Years||||June 2005|December 30, 2009|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041144||128520|
NCT01041157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSKS|Botulinum Toxin Injection Efficiency|Effectiveness of Botulinum Toxin Injection After Exercising Splenius Capitis Muscle in Patients With Cervical Dystonia||Jyväskylä Central Hospital|No|Active, not recruiting|September 2008|December 2011|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|80 Years|No|||December 2009|December 30, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01041157||128519|
NCT01041170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906410|Antagonist-Elicited Cannabis Withdrawal|Antagonist-Elicited Cannabis Withdrawal||National Institutes of Health Clinical Center (CC)||Completed|April 2006|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|1||||||Both|18 Years|45 Years|No|||January 2010|September 7, 2011|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041170||128518|
NCT01041989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL/TUET 122/2009|Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability|Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability|FINGER|National Institute for Health and Welfare, Finland|Yes|Active, not recruiting|September 2009|December 2018|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1200|||Both|60 Years|77 Years|No|||November 2014|November 20, 2014|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01041989||128456|
NCT01037738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC LCA 2B|Study of Autologous Conditioned Serum After Anterior Cruciate Ligament Reconstructive Surgery|Intraarticular Application of Autologous Conditioned Serum (ACS/Orthokine) Reduces Bone Tunnel Widening After ACL Reconstructive Surgery A Prospective, Randomized, Saline-controlled, Patient- and Observer-blinded, Parallel-design Trial||University of Zagreb|Yes|Completed|May 2006|January 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||January 2009|December 22, 2009|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01037738||128779|
NCT01038063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.07|Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period|Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period||Liverpool School of Tropical Medicine|Yes|Recruiting|October 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|4 Months|48 Months|No|||December 2010|December 8, 2010|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01038063||128754|
NCT01038336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7214-R|Hearing Loss Prevention for Veterans|Hearing Loss Prevention for Veterans|HLPP|VA Office of Research and Development|No|Completed|May 2011|October 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|129|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|December 21, 2009||No||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01038336||128733|
NCT01038596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HipMSC-Osteoarthritis|Mesenchymal Stromal Cells and Osteoarthritis|Proliferation and Osteogenic Differentiation of Bone Marrow-derived Mesenchymal Stromal Cells From Osteoarthritic Versus Healthy Donors||Technische Universität Dresden|No|Recruiting|January 2009|June 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|bone marrow aspirates|Both|50 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4, mean 67±6 years)        osteoarthritic and age-matched healthy donors|December 2009|December 23, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038596||128713|
NCT01038882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLaFe 324/08|Randomized Study With Midazolam for Sedation in Flexible Bronchoscopy|MIDAZOLAM EFFECTIVENESS TO THE SEDATION IN FLEXIBLE BRONCHOSCOPY. A RANDOMIZED STUDY||Hospital Universitario La Fe|Yes|Completed|October 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|238|||Both|18 Years|80 Years|No|||March 2009|December 23, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038882||128691|
NCT01039168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS 2003-0765|Return to Work After a Workplace-oriented Intervention for Patients on Sick Leave Due to Burnout|Reduction of Person-job Mismatch to Increase Work Capacity, by Education of, and Dialogue Between Involved Parties - Evaluation of an Intervention Program|ADA model|Region Skane|No|Completed|November 2003|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|76|||Both|N/A|N/A|No|||December 2009|December 22, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039168||128670|
NCT01032590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130902|Internet-Based Weight-Loss Program for Colorectal Cancer Survivors|Internet Weight Loss Intervention for Individuals Diagnosed With Colorectal Cancer||Rutgers, The State University of New Jersey|Yes|Active, not recruiting|July 2009|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|21 Years|N/A|No|||May 2015|May 20, 2015|December 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01032590||129123|
NCT01032603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-145|Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia|A Randomized Trial of Bilateral Lateral Rectus Recession Versus Unilateral Lateral Rectus Recession With Medial Rectus Resection for Intermittent Exotropia|IXT1|Jaeb Center for Health Research|Yes|Active, not recruiting|June 2010|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|336|||Both|3 Years|10 Years|No|||February 2016|February 22, 2016|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032603||129122|
NCT01032616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019880597 (Part b)|Uptake and Utilization of Amino Acids by Splanchnic Bed|Determination of the Difference in Uptake and Utilization of Two Amino Acids by the Splanchnic Bed||The Hospital for Sick Children|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|6|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032616||129121|
NCT01033214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMV-TAA-P1-001|ENTRUST - TAArget® Thoracic Stent Graft Clinical Trial|A Phase I Feasibility Study of the TAArget Thoracic Stent Graft for the Treatment of Aneurysms in the Descending Thoracic Aorta||Duke Vascular, Inc.|No|Active, not recruiting|January 2010|December 2015|Anticipated|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033214||129076|
NCT01033240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1008-A-U204|CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer|Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma||Daiichi Sankyo Inc.|No|Completed|March 2010|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|172|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033240||129074|
NCT01033253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44HL074482-02|Multi-media Obesity Prevention Program for Adolescents|Multi-media Obesity Prevention Program for Adolescents||Pro-Change Behavior Systems|Yes|Completed|July 2005|July 2008|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1800|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||December 2009|December 15, 2009|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01033253||129073|
NCT01033266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14587|Effect of Continuous Positive Airway Pressure (CPAP) and Cardiopulmonary Exercise Testing(CPET) in Patient With Obstructive Sleep Apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD)|Effect of Nasal CPAP on Cardiopulmonary Exercise Testing in Patients With Overlap Syndrome||University of Oklahoma|No|Completed|June 2009|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033266||129072|
NCT01033552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2009-09|Stem Cell Transplant for Epidermolysis Bullosa|Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|January 2010|October 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|N/A|25 Years|No|||January 2016|January 21, 2016|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033552||129050|
NCT01040598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE001|Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model|Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model||O & O Alpan LLC||Completed|June 2009|||December 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|19|||Both|12 Years|76 Years|No|||March 2012|March 13, 2012|December 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01040598||128560|
NCT01040299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-1-tDCS|Mechanized Gait Trainer Combine Transcranial Galvanic Stimulation (tDCS) in Chronic Stroke|Combine Mechanized Gait Trainer and Transcranial Direct Current Stimulation in Chronic Stroke Patients: Randomized Control Trial|GT-1-tDCS|Universita di Verona|Yes|Completed|July 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|20 Years|80 Years|No|||March 2012|March 23, 2012|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040299||128583|
NCT01040312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP009-062|An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors|A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors||Daiichi Sankyo Co., Ltd.|Yes|Active, not recruiting|October 2009|March 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|white cells|Both|N/A|N/A|No|Probability Sample|Patients with small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian        cancer and gastric cancer treated with CPT-11 plus platinum analogues (cisplatin,        carboplatin and nedaplatin) in clinical practice in Japan|March 2013|March 28, 2013|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01040312||128582|
NCT01040325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELT209|Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study|A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia||Intercell USA, Inc.|Yes|Completed|December 2009|December 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|723|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2012|March 13, 2012|December 25, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01040325||128581|
NCT01039987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK056961|Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease|Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) II|CRISP II|University of Pittsburgh|No|Enrolling by invitation|September 1999|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|211|Samples With DNA|blood, urine|Both|15 Years|45 Years|No|Non-Probability Sample|Participants who are diagnosed with ADPKD between the ages of 15 and 45 with risk factors        (2/3 of the study population) or without risk factors (1/3 of the study population)for        progression to ESRD with relatively normal renal function were be eligible for recruitment        into the CRISP I study. The objective of the recruitment process was to identify ADPKD        participants with the appropriate level of renal function who are either at high or low        risk for progression to ESRD, who will be available for the entire follow-up period and        who are likely to be compliant with the study protocols and visit schedules.|January 2016|January 26, 2016|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039987||128607|
NCT01040858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7217-R|Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder|Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder|CROVCD|VA Office of Research and Development|No|Completed|May 2011|September 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|December 28, 2009||No||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01040858||128540|
NCT01041729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STA-2009 NO-CRP|Long-term Pleiotropic Effect of Statins in Patients With Peripheral Arterial Disease|Phase IV Study of Statins for Assess the Long-term Pleiotropic Effect Upon Nitric Oxide and C-Reactive Protein Levels in Patients With Peripheral Arterial Disease||Hospital Universitario Getafe|No|Completed|January 2008|June 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|N/A|No|||December 2009|January 4, 2010|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01041729||128476|
NCT01042002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIT and gastric bypass|Effect of Exercise Before Gastric Bypass|Effect of Exercise Before Gastric bypass-a Pilot Study||Norwegian University of Science and Technology|Yes|Completed|August 2006|October 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Both|20 Years|80 Years|No|||November 2013|November 26, 2013|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042002||128455|
NCT01037751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0506|M. D. Anderson Symptom Inventory - Ovarian Cancer|M. D. Anderson Symptom Inventory - Ovarian Cancer: Development and Validation in Patients With Ovarian Cancer||M.D. Anderson Cancer Center|No|Completed|December 2009|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|158|||Female|18 Years|N/A|No|Non-Probability Sample|UT MD Anderson Cancer Center ovarian cancer patients, females over the age of 18 years.|January 2016|January 5, 2016|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01037751||128778|
NCT01038076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedCHEC|Medications for Chronic HIV: Education and Collaboration|Implementing Computerized Clinical Assessment of HIV Patient Adherence|MedCHEC|Boston University|Yes|Recruiting|December 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|348|||Both|18 Years|N/A|No|||February 2012|February 28, 2012|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01038076||128753|
NCT01038349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP-D-001|Applications for Methotrexate Optimization in Rheumatoid Arthritis|Applications for Methotrexate Optimization in Rheumatoid Arthritis|AMORA|Cypress Bioscience, Inc.|No|Completed|June 2009|February 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|256|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care and Rheumatology Clinics|June 2011|June 1, 2011|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01038349||128732|
NCT01038609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-058|Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy|A Randomized, Multicenter, Single-Blind Study Comparing Hydrocodone/Acetaminophen Extended Release 10/650, Morphine Extended Release, and Acetaminophen to Placebo in Subjects With Acute Pain Following Bunionectomy||AbbVie|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|250|||Both|18 Years|75 Years|No|||March 2014|March 10, 2014|December 22, 2009|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01038609||128712|
NCT01038895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPV002DIM2009|Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria|||University of Pavia|No|Recruiting|November 2009|June 2011|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||September 2009|December 23, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038895||128690|
NCT01039181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-09-00171|Calcitriol in Advanced Intrahepatic Cholangiocarcinoma|A Clinical Trial Phase II of Calcitriol in Combination With 5-fluorouracil, Mitomycin C and Leucovorin in an Open Label-non-randomized Study to Evaluate the Tumor Response in Patients With Advanced Intrahepatic Cholangiocarcinoma||National Science and Technology Development Agency, Thailand|Yes|Not yet recruiting|January 2010|October 2012|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|30 Years|65 Years|No|||December 2009|December 23, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039181||128669|
NCT01032278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000660615|Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)|A Multicenter Study in Patients Undergoing AnthRacycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2011|||December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|830|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01032278||129147|
NCT01032629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016627|CANVAS - CANagliflozin cardioVascular Assessment Study|A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus|CANVAS|Janssen Research & Development, LLC|Yes|Active, not recruiting|December 2009|June 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|4330|||Both|30 Years|N/A|No|||March 2016|March 18, 2016|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01032629||129120|
NCT01032941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSL3PHTNUoA|The Effect of Probiotics (VSL) on Portal Hypertension|A Randomized Controlled Trial on the Beneficial Effects of Probiotics on Portal Hemodynamics in Decompensated Cirrhotic Patients||University of Alberta|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01032941||129097|
NCT01033279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1158|Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy|Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts|ESCAPE|Montreal Heart Institute|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|120|||Both|18 Years|75 Years|No|||May 2012|May 29, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033279||129071|
NCT01033565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401-09|Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders|Controlled-Release Melatonin (Melatonin CR)for the Treatment of Impaired Sleep Maintenance (ISM) in 4-8 Year Old Children With Autism Spectrum Disorders (ASD).||University of Nebraska|Yes|Terminated|December 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|4 Years|8 Years|No|||September 2013|September 4, 2013|December 14, 2009||No|Unsuccessful in recruiting appropriate subjects.|No|June 24, 2013|https://clinicaltrials.gov/show/NCT01033565||129049|Unable to recruit a sufficient number of subjects to complete the study as designed.
NCT01040871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-LYM-2034|Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma|A Randomized, Open-Label, Multicenter Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma||Millennium Pharmaceuticals, Inc.|No|Completed|January 2010|August 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|December 29, 2009|Yes|Yes||No|July 5, 2013|https://clinicaltrials.gov/show/NCT01040871||128539|
NCT01040000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neogenix 0901|Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer|A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy||Precision Biologics, Inc|No|Active, not recruiting|January 2012|April 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|116|||Both|18 Years|99 Years|No|||November 2015|November 25, 2015|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01040000||128606|
NCT01041456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2009016|Laparoscopic Revision From Biliopancreatic Diversion to Gastric Bypass|Another Revisional Strategy to Address Severe Late Complications After Previous Biliopancreatic Diversion for Obesity: Major Revision From Standard Biliopancreatic Diversion to Proximal Roux-en-Y Gastric Bypass|BPD-to-RYGB|University of California, San Francisco|Yes|Completed|March 2009|October 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients referred with severe, persistent and/or recurrent metabolic/nutritional        complications after open biliopancreatic diversion for clinically severe obesity underwent        either laparoscopic or open conversion to Roux-en-Y gastric bypass. Intractability after        interdisciplinary optimized medical therapy for metabolic and/or nutritional complications        warranted surgical management.|December 2009|December 31, 2009|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01041456||128496|
NCT01042015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-07-1-0682|Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest From Trauma|Emergency Preservation and Resuscitation for Cardiac Arrest From Trauma|EPR-CAT|University of Pittsburgh|Yes|Active, not recruiting|January 2012|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|January 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042015||128454|
NCT01037764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ALLO-036|Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)|Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia in Remission Using HLA-matched Sibling Donors, HLA-matched Unrelated Donors, or HLA-mismatched Familial Donors-A Phase 2 Study|AHCTALL|Asan Medical Center|No|Active, not recruiting|January 2010|December 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|15 Years|75 Years|No|||July 2015|July 1, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037764||128777|
NCT01038089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28258|Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus|Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus||Boston University|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|21 Years|80 Years|No|||August 2010|December 17, 2010|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01038089||128752|
NCT01038102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS-2008-1364|Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance|Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance: a Randomized Controlled Study|HEPFAT|Uppsala University|No|Completed|February 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2009|July 12, 2010|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01038102||128751|
NCT01038362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27411|Effects of Almonds On Endothelial Function In Patients With Coronary Artery Disease|Effects Of Almonds On Vascular Reactivity And Biomarkers Of Inflammation, Oxidative Stress And Endothelial Function In Patients With Coronary Artery Disease||Boston University|No|Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Both|21 Years|80 Years|No|||December 2009|December 21, 2009|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01038362||128731|
NCT01038622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090203|Directed Immuno Nutrition by L-arginine for Critically Ill Patients|Randomized Directed Immuno Nutrition by L-arginine for Critically Ill Patients|Immunolarg|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2009|January 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2009|September 17, 2013|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038622||128711|
NCT01038635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0467|5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)|Phase I/II Study of the Combination of 5-azacitidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)||M.D. Anderson Cancer Center|No|Completed|December 2009|||November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|N/A|N/A|No|||December 2015|December 14, 2015|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038635||128710|
NCT01038648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITAGLIPTIN-003 IDRF|Sitagliptin in Prevention of Type 2 Diabetes Mellitus|Does the DPP4 Inhibitor Sitagliptin Have a Role in Preventing Type 2 Diabetes- A Randomised Controlled Study.|SITAGLIPTIN|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals|Yes|Withdrawn|December 2011|December 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038648||128709|
NCT01038908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00926|Breast Lymph Node Mapping|Axillary Reverse Mapping in Breast Cancer||University of British Columbia|No|Not yet recruiting|June 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|100|||Both|19 Years|N/A|No|||February 2013|February 12, 2013|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038908||128689|
NCT01038921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014784|Melatonin and the Metabolic Syndrome|Melatonin Supplementation and the Metabolic Syndrome: A Phase II Crossover Design Clinical Trial|MetSyn|Emory University|Yes|Completed|July 2009|July 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|30 Years|79 Years|No|||February 2015|February 11, 2015|December 22, 2009|No|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01038921||128688|Study was designed as a pilot Phase II cross-over design to study the safety of melatonin and to estimate the effect sizes associated with average changes while subjects were on melatonin versus average changes while subjects were on placebo.
NCT01039194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-009|Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)|A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects||Bristol-Myers Squibb|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|55 Years|No|||February 2010|January 24, 2011|December 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01039194||128668|
NCT01039506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP009-061|An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in mCRC|A Prospective Observational Study of the Efficacy and Safety of CPT-11 Based Regimens for UGT1A1 Genotype Guided Patients With Metastatic Colorectal Cancer||Daiichi Sankyo Co., Ltd.|Yes|Active, not recruiting|October 2009|March 2016|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|white cells|Both|N/A|N/A|No|Probability Sample|Patients with metastatic colorectal cancer treated with CPT-11 based regimens (FOLFIRI,        CPT-11+S-1, CPT-11) in clinical practice in Japan|March 2013|March 28, 2013|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039506||128644|
NCT01032291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-COLO-001|A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer|A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer||Celgene|No|Terminated|December 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|December 14, 2009||No|A business decision not to continue with Phase 2b based on non-safety observations during    proof of concept phase.|No|April 1, 2013|https://clinicaltrials.gov/show/NCT01032291||129146|Enrollment stopped prematurely due to lack of efficacy and failure to achieve the planned response objective.
NCT01032304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERD-01-08/EP|The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)|The Efficacy and Safety of Erdosteine in the Long-term Therapy of Chronic Obstructive Pulmonary Disease (COPD). A 12-month, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study|RESTORE|Edmond Pharma|Yes|Active, not recruiting|August 2009|September 2015|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|492|||Both|40 Years|80 Years|No|||June 2014|June 12, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032304||129145|
NCT01032980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF11|Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults|Post Authorization Safety Study of the Intramuscular Inactivated, Split Virion Pandemic A/H1N1 Influenza Vaccines in Children Aged Over 2 Months and in Adult Populations||Sanofi|No|Completed|December 2009|July 2011|Actual|January 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3934|||Both|2 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be vaccinated with HUMENZA or PANENZA according to the recommendations        provided in the product leaflet and local recommendations.        The HUMENZA Group will be divided in 6 defined age groups; the PANENZA Group will be        divided into 2 defined age groups.|September 2015|September 25, 2015|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032980||129094|
NCT01032954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-CBED09-02|Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)|Phase Iv Study On The Safety And Efficacy Of The Full Face Applications Of Variable Doses Of 125 To 250 Units Of A Commercial Botulinum Toxin Type A (Dysport®)||Brazilan Center for Studies in Dermatology||Active, not recruiting|November 2009|November 2010|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2009|July 6, 2010|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032954||129096|
NCT01032967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgery or CRT Ca Esophagus|Surgery or Chemoradiation for Esophageal Cancer|Multicenter Prospective Randomized Trial Comparing Standard Esophagectomy With Chemoradiotherapy for Treatment of Squamous Esophageal Cancer: Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)||Chinese University of Hong Kong|Yes|Completed|July 2000|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032967||129095|
NCT01033578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan-LCI-PVTT-1|Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Efficacy of Postoperative Adjuvant Treatments After Hepatectomy and Thrombectomy for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis||Fudan University|Yes|Recruiting|October 1999|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|75 Years|No|||October 2009|December 15, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033578||129048|
NCT01031680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00018|Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension|A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care||AstraZeneca||Completed|February 2010|December 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|922|||Both|45 Years|N/A|No|||September 2013|September 24, 2013|December 10, 2009|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT01031680||129193|For participants who did not complete 8 and/or 24 weeks, respectively, LOCF was used. For HbA1c: excluding data after glycemic rescue, Weight: including data after rescue, SBP: excluding data after anti-hypertensive rescue.
NCT01031693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909440|Pilot Study of Transcranial Magnetic Stimulation (TMS) in Nicotine Addiction|Pilot Study of Transcranial Magnetic Stimulation (TMS) in Nicotine Addiction||National Institutes of Health Clinical Center (CC)||Completed|July 2009|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|December 6, 2013|December 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01031693||129192|
NCT01038453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090097|Effects of Vitamin D Supplement Before and During Pregnancy on Birth Weight|Effects of Vitamin D Supplement Before and During Pregnancy on Complications, Birth Weight and Bone Mineral Density During Lactation|Gravita|University of Aarhus|No|Recruiting|December 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|400|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||November 2011|November 3, 2011|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01038453||128724|
NCT01038726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH AG035775-01|Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults|Neural Effects of Exercise, Cognitive, or Combined Training in AD At-Risk Elders||The Cleveland Clinic|No|Completed|December 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|108|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01038726||128703|
NCT01038739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-51/DIV|Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis|Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis||Dr. Falk Pharma GmbH|Yes|Terminated|January 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|330|||Both|30 Years|80 Years|No|||May 2014|May 15, 2014|December 22, 2009|Yes|Yes|Stopped due to futility.|No||https://clinicaltrials.gov/show/NCT01038739||128702|
NCT01029496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hainanmc|Immediate VS Delayed Cord Clamping on Newborns|Effect of Umbilical Cord Clamping Time on Newborns||Hainan Medical College|Yes|Recruiting|September 2009|June 2011|Anticipated|September 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|120|||Both|N/A|6 Months|No|||September 2009|March 1, 2010|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029496||129359|
NCT01029509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0488|Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes|An Open-label, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Leukemias or Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Terminated|July 2008|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|December 8, 2009|No|Yes|Colloborator-Sponsor decision to terminate.|No||https://clinicaltrials.gov/show/NCT01029509||129358|
NCT01029834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD053773-01|Treating Pre-School Children at Risk for Overweight in the Primary Care Setting|Treating Overweight Youth: A Family Based Approach in Primary Care||University at Buffalo|Yes|Completed|April 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|105|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029834||129333|
NCT01030068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003669|Yoga for Smoking Cessation Feasibility Study|Yoga for Women Attempting Smoking Cessation: An Initial Investigation||The Miriam Hospital|No|Completed|July 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 6, 2011|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030068||129315|
NCT01030042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-006254-26|Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients|Randomized, Phase III, Multicenter Trial Comparing Two Different Sequences of therapyFOLFOX-4 vs FOLFOX-4 Followed by Irinotecan/Cetuximab in Metastatic Colorectal Patients Treated With FOLFIRI /Bevacizumab as First Line Chemotherapy|COMETS|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|No|Completed|September 2009|June 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|No|||December 2009|July 14, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030042||129317|
NCT01030055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2112|Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors|A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors||Novartis||Completed|February 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|December 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030055||129316|
NCT01030354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA OPRS 03-06-120|Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial|||University of California, Los Angeles|No|Completed|July 2004|December 2005|Actual|July 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|N/A|Accepts Healthy Volunteers|||November 2009|December 10, 2009|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030354||129294|
NCT01030367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Pilot Study of Organic Nitrates on Endothelial Function in CAD Patients|Pilot Study of Organic Nitrates on Endothelial Progenitor Cells and Endothelial Function in Patients With Coronary Artery Disease|ONEEF|Julius-Maximilians University|No|Active, not recruiting|January 2007|January 2010|Anticipated|November 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|50|||Both|18 Years|90 Years|No|||January 2007|December 10, 2009|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030367||129293|
NCT01032018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE1932|Comparison of Depression Interventions After Acute Coronary Syndrome|Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS)|CODIACS|Columbia University|Yes|Completed|January 2010|July 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|150|||Both|35 Years|N/A|No|||July 2014|July 21, 2014|December 11, 2009||No||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01032018||129167|
NCT01040078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090601|Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month|||Centers for Disease Control and Prevention, China|Yes|Recruiting|December 2009|June 2010|Anticipated|February 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|900|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||December 2009|December 29, 2009|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01040078||128600|
NCT01040091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 Anderson|Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status|Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|December 2009|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|December 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01040091||128599|
NCT01040390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acne-001|Efficacy of Lappa Arctium (Homoeopathic Medicine) in Treatment of Acne Vulgaris|Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Lappa Arctium||Miglani, Anjali|Yes|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|12 Years|25 Years|No|||February 2012|February 15, 2012|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01040390||128576|
NCT01035073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1J-US-X018|Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome|Functional Change and Efficacy of Duloxetine in Patients With Major Depression and Co-Morbid Soft Tissue Discomfort Symptoms||University of Pennsylvania|Yes|Completed|April 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035073||128933|
NCT01040663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNE-0673|Isocaloric Dietary Interventions for Insulin Resistance and the Metabolic Syndrome|Isocaloric Dietary Interventions for Insulin Resistance and the Metabolic Syndrome||Rockefeller University|No|Completed|July 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01040663||128555|
NCT01040962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11481|Fall Risk Assessment in People With Diabetic Neuropathy|Fall Risk Assessment in People With Diabetic Neuropathy||University of Kansas Medical Center|Yes|Completed|August 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|37|||Both|40 Years|65 Years|No|Non-Probability Sample|Persons that have diabetic peripheral neuropathy|June 2012|June 15, 2012|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040962||128532|
NCT01036217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906412|Screening Protocol for the Evaluation of Research Participants|Evaluation of Potential Research Subjects - Screening Protocol for Clinical Studies||National Institutes of Health Clinical Center (CC)||Completed|May 2006|June 2010||||N/A|Observational|Time Perspective: Prospective|||Anticipated|55000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|September 26, 2015|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036217||128863|
NCT01030562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0012|Immunogenicity of Off-Schedule Dosing of HPV Vaccine|Immunogenicity of the HPV-6, 11, 16, 18 Vaccine Among Adolescent Girls Who Receive Vaccine Doses at Non-recommended Intervals and Factors Related to Non-adherence||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|June 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort||5|Anticipated|1400|Samples With DNA|Serum samples.|Female|9 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Girls 9-17 years old receiving third dose of HPV vaccine from primary care clinician.        Parent/legal guardian will participate by answering a questionnaire to determine factors        related to non-adherence to recommended vaccine schedule.|July 2013|December 26, 2013|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030562||129278|
NCT01037881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 29102-C21|LEO 29102 Cream in the Treatment of Atopic Dermatitis|A Phase 2, Proof of Concept and Dose Finding Study, Investigating Treatment Efficacy of LEO 29102 Cream, LEO 29102 Cream Vehicle, and Elidel® Cream 10 mg/g, After Cutaneous Administration Twice Daily for 4 Weeks||LEO Pharma|Yes|Completed|December 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|183|||Both|18 Years|65 Years|No|||April 2012|October 21, 2013|December 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01037881||128768|
NCT01038167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-950-021|A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults|An Open-Label Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus||Vertex Pharmaceuticals Incorporated|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2010|April 6, 2010|December 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01038167||128746|
NCT01038180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS-REK-1|Complications Following Pacemaker Implantation|Complications Following Pacemaker or ICD Implantation: Results From The Danish Pacemaker and ICD Register||University of Aarhus|No|Completed|January 1997|December 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28000|||Both|N/A|N/A|No|Probability Sample|All Danish patients receiving a permanent cardiac pacemaker during the years 1997 to 2008|December 2009|December 22, 2009|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01038180||128745|
NCT01038752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optimum-Suramin-1|Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer|Combination of Non-Cytotoxic Suramin With Docetaxel and Carboplatin in Chemo-Naive Non-small Cell Lung Cancer (NSCLC): A Randomized Single-Blind Placebo-Controlled Phase II Study||Optimum Therapeutics, LLC|Yes|Terminated|August 2010|May 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|December 22, 2009|Yes|Yes||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01038752||128701|The study was terminated prematurely due to the loss of follow-up of 6 of 14 participants before progression and slow accrual. Due to the resulting small numbers, no analysis was attempted.
NCT01029236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED010|Evaluation of Metabolism-Boosting Beverages|The Effect of Metabolism-Boosting Beverages on 24 Hr Energy Expenditure||Medifast, Inc.|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 8, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029236||129378|
NCT01029522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224CHL08F|Dyslipidemia in Cardiovascular Disease|A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea|KoLipilou|Chong Kun Dang Pharmaceutical|No|Completed|August 2008|November 2009|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|244|||Both|20 Years|85 Years|No|||August 2012|August 8, 2012|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01029522||129357|
NCT01039012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003503|Tai Chi for Osteopenic Women|Tai Chi for Osteopenic Women: A Pilot Randomized Controlled Trial||Harvard University Faculty of Medicine|No|Active, not recruiting|January 2008|June 2010|Anticipated|February 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Female|45 Years|70 Years|No|||December 2009|December 23, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039012||128682|
NCT01039025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM01-331|TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma|Phase II Study of High-Dose Topotecan, Cyclophosphamide and Melphalan for the Treatment of Multiple Myeloma||M.D. Anderson Cancer Center|No|Completed|February 2002|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|70 Years|No|||July 2012|July 31, 2012|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039025||128681|
NCT01029223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141/07|The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals|The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals||Bayside Health|No|Withdrawn|October 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|42|||Male|18 Years|70 Years|No|||November 2011|November 7, 2011|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029223||129379|
NCT01029821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pugh-2|Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis|Low-Molecular-Weight Heparin for DVT Prophylaxis After Open Reduction and Internal Fixation of Ankle Fractures: A Randomized, Prospective Trial||University of Tennessee|Yes|Recruiting|February 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2011|June 15, 2011|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029821||129334|
NCT01029548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS OBS T-003|Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects|Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects|ISS OBS T-003|Istituto Superiore di Sanità|No|Completed|April 2008|May 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|Samples With DNA|Whole Blood, serum, PBMCs|Both|18 Years|N/A|No|Non-Probability Sample|Asymptomatic HIV infected individuals|March 2016|March 3, 2016|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029548||129355|
NCT01031173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-REP-059|Treatment Protocol of Replagal for Patients With Fabry Disease|An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients With Fabry Disease.||Shire||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||February 2014|February 19, 2014|December 8, 2009|Yes|Yes||||https://clinicaltrials.gov/show/NCT01031173||129231|
NCT01030081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMORS|Amlodipine Prevents Morning Blood Pressure Surge Study|A Randomized Controlled Phase Ⅳ Trial With Two Equally Sized Treatment Groups: Amlodipine And Nifedipine GITS|ARMORS|Shanghai Jiao Tong University School of Medicine|Yes|Completed|October 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|510|||Both|40 Years|70 Years|No|||May 2014|May 21, 2014|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030081||129314|
NCT01031459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14261|Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.|An Observational 20-year, Cross-sectional, Long-term Follow up of the Patient Cohort Enrolled in the Pivotal Study of Betaseron® (Interferon Beta-1b) in Relapsing-remitting Multiple Sclerosis||Bayer|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|176|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Patients with MS that participated in the 16Y-LTF and Pivitol studies|January 2012|January 3, 2012|December 8, 2009||Yes||No||https://clinicaltrials.gov/show/NCT01031459||129210|
NCT01030380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-09-2009|Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging|Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging|Face|Bio-Medical Research, Ltd.|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 10, 2009|December 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030380||129292|
NCT01030640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091046|Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected|A Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density Of Intraepidermal Nerve Fibers After A Single Subcutaneous Administration Of Tanezumab In Healthy Volunteers||Pfizer|No|Completed|December 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 22, 2011|December 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030640||129272|
NCT01031823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32300|Adolescent Social Skills Training Program|The Multi-media Social Skills Project: Validation of an Intervention for Adolescents With Autism Spectrum Disorders|ASST|Penn State University||Active, not recruiting|November 2009|April 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||December 2010|January 25, 2011|December 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01031823||129182|
NCT01040104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7-202047.WP.2.1-2.2-2.4|Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals|Pilot Study of Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals|RESOLVE|Medical University of Vienna|Yes|Completed|July 2009|||July 2011|Actual|N/A|Observational|Time Perspective: Prospective||8|Actual|51|Samples With DNA|Skin biopsy Blood samples|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|WP 2.1 Individuals due for planned elective plastic surgery with regular wound healing        WP 2.2 Individuals, who suffered from burns, trauma or having undergone any type of        previous surgery with and without hypertrophic scar formation        WP 2.4 Individuals, who require split-thickness skin grafting for skin defects with or        without diabetes mellitus|November 2013|November 10, 2013|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040104||128598|
NCT01035385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VORP019|Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)|Phase III Study to Compared Preoperative and Postoperative With FOFLOX4 Chemotherapy and Postoperative With FOFLOX4 Chemotherapy in Patients With Resectable Liver Metastasis From Colorectal Cancer||Guangdong General Hospital|No|Recruiting|September 2009|December 2015|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|340|||Both|18 Years|80 Years|No|||September 2009|December 17, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035385||128909|
NCT01040676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121609ATNSUCSF|Automated Telephone Nutrition Support|The Use Of Automated Telephone Nutrition Support In Spanish-Speaking Latino Patients With Diabetes|ATNS|University of California, San Francisco|No|Completed|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|85 Years|No|||June 2012|June 22, 2012|December 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01040676||128554|
NCT01035697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0022|Inflammatory Cytokines Associated With Perinatal Brain Injury|A Study to Determine If Inflammatory Cytokines Are Associated With Perinatal Brain Injury and Long Term Neurodevelopmental Handicap or Death|Cytokines|NICHD Neonatal Research Network|No|Completed|July 1999|May 2004|Actual|July 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1067|Samples With DNA|Whole blood spots collected on filter paper.|Both|N/A|72 Hours|Accepts Healthy Volunteers|Probability Sample|Infants 401-1,000 grams at birth of both genders and all racial/ethnic groups.|June 2015|June 3, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035697||128886|
NCT01037296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005815|Catheter Ablation of Atrial Fibrillation Using Hansen Medical Robotic Navigation|Catheter Ablation of Atrial Fibrillation Using Hansen Medical Robotic Navigation - A Randomised Controlled Trial|Hansen|Barts & The London NHS Trust|No|Terminated|April 2008|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||March 2014|July 9, 2014|December 21, 2009||No|Based on interim analysis study felt unlikely to reach the primary aim|No||https://clinicaltrials.gov/show/NCT01037296||128813|
NCT01037309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO044-CLIN-01|Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)|A Phase I/IIa, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous and Intravenous Doses of PRO044 in Patients With Duchenne Muscular Dystrophy||BioMarin Pharmaceutical|Yes|Completed|December 2009|October 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|18|||Male|5 Years|16 Years|No|||March 2015|March 26, 2015|December 21, 2009|Yes|Yes||No|September 1, 2014|https://clinicaltrials.gov/show/NCT01037309||128812|
NCT01031121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909451|Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers|Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers||National Institutes of Health Clinical Center (CC)||Completed|June 2009|October 2010||||N/A|Observational|N/A|||Anticipated|240|||Both|18 Years|64 Years|No|||October 2010|October 26, 2010|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031121||129235|
NCT01038193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW004|Cognitive Dysfunction After Aneurysmal Subarachnoid Haemorrhage|Cognitive Dysfunction After Aneurysmal Subarachnoid Haemorrhage||Chinese University of Hong Kong|Yes|Recruiting|March 2009|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|240|||Both|21 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Aneurysmal subarachnoid hemorrhage patients|February 2015|February 2, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038193||128744|
NCT01028391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-064-10|30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)|A 30-Week Extension to: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.||Completed|September 2007|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|December 8, 2009|Yes|Yes||No|January 11, 2010|https://clinicaltrials.gov/show/NCT01028391||129443|
NCT01038466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB.0901|Observation Only Study Involving Participants Enrolled in the CHAT Trial|Follow-Up Observational Study In CHAT Trial Participants With Advanced And/Or Metastatic Breast Cancers That Overexpress HER2, Who Were Randomised To Receive Trastuzumab And Docetaxel With Or Without Capecitabine||Contact Asia Pacific|Yes|Enrolling by invitation|March 2009|November 2009|Anticipated|October 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|222|||Female|N/A|N/A|No|Non-Probability Sample|All 222 CHAT trial participants whose data was used in the final data analysis for the        CHAT study will be included in the Beyond CHAT follow-up observational study|September 2009|December 22, 2009|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01038466||128723|
NCT01028963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL004_140|A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus||ChemoCentryx|Yes|Completed|January 2010|November 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|159|||Both|18 Years|70 Years|No|||February 2012|February 8, 2012|December 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028963||129399|
NCT01028976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK062378-05|Obesity, Inflammation and Oxidative Stress|Obesity, Inflammation and Oxidative Stress||University of California, Berkeley|Yes|Completed|January 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|512|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028976||129398|
NCT01029535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOL-AP01|Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency|||Allergan||Completed|January 2009|October 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|30 Years|60 Years|No|||February 2016|February 8, 2016|December 8, 2009||No||No|May 1, 2012|https://clinicaltrials.gov/show/NCT01029535||129356|
NCT01029808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGAO002|Bleeding Symptoms of Carriers of Hemophilia A and B|Bleeding Symptoms of Carriers of Hemophilia A and B||Sahlgrenska University Hospital, Sweden|No|Completed|December 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|126|||Female|18 Years|N/A|No|Non-Probability Sample|Carriers of severe and moderate hemophilia A and B|September 2014|September 19, 2014|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029808||129335|
NCT01030926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1995|A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|39|||Both|6 Years|65 Years|No|||September 2015|September 24, 2015|December 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030926||129250|
NCT01030939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112861|Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers|A Single-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate Safety, Tolerability, Pharmacokinetics and the Effects on Cardiac Function of Repeat Oral Doses of SB-649868 in Adult and Elderly Healthy Volunteers||GlaxoSmithKline|Yes|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 19, 2011|November 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030939||129249|
NCT01030692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24716|Rivastigmine and Huperzine A as Treatments for Cocaine Dependence|Rivastigmine and Huperzine A as Treatments for Cocaine Dependence||Baylor College of Medicine|Yes|Completed|January 2009|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|72|||Both|18 Years|55 Years|No|||January 2015|January 26, 2015|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030692||129268|
NCT01030965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113589|28-day Repeat Dose Study of GSK573719|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD||GlaxoSmithKline|No|Completed|December 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|287|||Both|40 Years|80 Years|No|||February 2014|June 12, 2014|December 10, 2009|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01030965||129247|
NCT01031186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113324|First Time in Human Study|A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers|FTIM|GlaxoSmithKline|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|10||Actual|20|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 1, 2010|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01031186||129230|
NCT01031472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113391|A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761|A Single-center, Randomized, Two Part, Open-label, Crossover Study to Assess the Relative Bioavailability and Food Effect of New Formulations of GSK2248761 in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|December 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 2, 2010|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01031472||129209|
NCT01031797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-1256|QT Dispersion in Patients With Systemic Lupus Erythematosus (SLE)|QT Dispersion in Patients With Systemic Lupus Erythematosus: the Impact of Disease Activity||Shiraz University of Medical Sciences|Yes|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|124|||Both|18 Years|N/A|No|Probability Sample|One hundred twenty-four patients with SLE were enrolled in the study. Complete history and        physical exam, ECG, echocardiography, exercise test and SLE disease activity index        (SLEDAI) were recorded. Twenty patients were excluded on the basis of our exclusion        criteria. The patients were divided to two groups based on SLEDAI: 54 in the high-score        group (SLEDAI >10) and 50 in the low-score group (SLEDAI <10).|July 2007|December 12, 2009|December 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01031797||129184|
NCT01032044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-2009-BE-01|Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia||CLEAN-MARGIN|Mauna Kea Technologies|No|Completed|February 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|166|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032044||129165|
NCT01032057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000660755|Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery|A Multi-Center Randomized Phase II Study of Induction Chemotherapy Followed by Gemcitabine or Capecitabine Based Chemoradiotherapy for Locally Advanced Non-Metastatic Pancreatic Cancer|SCALOP|Cardiff University|Yes|Completed|July 2009|June 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|December 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01032057||129164|
NCT01040117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISM-2009|Sensori-motor Integration Training in Multiple Sclerosis|Effects of Sensori-motor Integration Balance Training on Balance Disturbances in Patients With Multiple Sclerosis||Universita di Verona|Yes|Completed|December 2009|January 2012|Actual|October 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||March 2012|March 14, 2012|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040117||128597|
NCT01040130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.37|Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I|Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease||Boehringer Ingelheim||Completed|January 2010|||April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|151|||Both|40 Years|75 Years|No|||July 2014|July 4, 2014|December 28, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01040130||128596|
NCT01036854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODO-P8-690|Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)|Parallel, Group, Laboratory-Blinded, Single and Multiple-dose Pharmacokinetic Study of Ondansetron Administered as the Immediate-Release (Zofran) and Modified-Release (EUR1025) Formulations||Forest Laboratories|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|128|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 17, 2009|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01036854||128838|
NCT01035359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRF intra|Intraarticular Distal Radius Fractures, X-fix or Volar Fixation|Dorsally Displaced Intraarticular Distal Radius Fractures - Volar Plate or External Fixation. A Prospective Randomized Trial.||Karolinska Institutet|No|Completed|August 2009|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|50 Years|74 Years|No|||March 2014|March 12, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035359||128911|
NCT01035372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H592-34987-01|Pilot Study on the Tolerability of Dietary Dried Plum|Pilot Study on the Tolerability of Dietary Dried Plum||University of California, San Francisco|No|Completed|December 2009|||September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2011|April 12, 2011|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035372||128910|
NCT01036230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904397|The Effects of Expectation on Natural and Drug -Induced Rewards|The Effects of Expectation on Natural and Drug -Induced Rewards||National Institutes of Health Clinical Center (CC)||Recruiting|September 2004|||||N/A|Observational|N/A|||Anticipated|128|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|December 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01036230||128862|
NCT01036841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/653|Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation|Influence of Food-intake on Pharmacokinetic and Pharmacodynamic Parameters of Desmopressin Oral Tablet Formulation, in Comparison With Desmopressin MELT Formulation|TM|University Hospital, Ghent|No|Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|6 Years|16 Years|No|||May 2011|May 25, 2011|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036841||128839|
NCT01041846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015895|A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome|A Prospective Multicenter Observational Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome||Janssen Korea, Ltd., Korea|Yes|Completed|December 2008|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|The patients who signed the subject informed consent form among the patients with        myelodysplastic syndrome who were treated with decitabine|July 2013|July 26, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01041846||128467|
NCT01028404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1952-3646|A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0148-0000-0106 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes||Novo Nordisk A/S|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 24, 2012|December 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028404||129442|
NCT01028677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0879|Oxytocin Treatment of Schizophrenia|Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia|OTS|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|November 2009|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|55 Years|No|||September 2012|September 7, 2012|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01028677||129421|
NCT01028690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lactobacilos vs helicobacter|Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri|Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri||Centro Regional para el Estudio de las Enfermedades Digestivas|No|Active, not recruiting|December 2009|January 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028690||129420|
NCT01030393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hCG 100|Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer|Intra-uterine Injection of Human Chorionic Gonadotrophin Before Embryo Transfer in ICSI||The Egyptian IVF-ET Center|Yes|Completed|January 2010|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|472|||Female|20 Years|39 Years|No|||August 2012|August 18, 2012|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030393||129291|
NCT01029249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5272|Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults|Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy||AIDS Clinical Trials Group|Yes|Completed|January 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples With DNA|Saliva and blood will be collected from participants.|Both|18 Years|N/A|No|Non-Probability Sample|Participants in this study will also be enrolled in ACTG A5257.|December 2013|December 5, 2013|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029249||129377|
NCT01030705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGNATE|Common Sensing and Right Ventricular Automatic Capture (COGNATE)|Common Sensing and Right Ventricular Automatic Capture|COGNATE|Boston Scientific Corporation|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic patients|September 2011|September 28, 2011|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030705||129267|
NCT01030952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDJN608ACN07|Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion|A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus||Novartis||Completed|December 2009|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|75 Years|No|||September 2012|September 18, 2012|December 11, 2009||No||No|February 20, 2012|https://clinicaltrials.gov/show/NCT01030952||129248|
NCT01031212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-09997|ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors|A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors||University of California, San Francisco|Yes|Withdrawn|January 2010|June 2013|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 9, 2013|December 8, 2009|Yes|Yes|The investigator has left the institution (UCSF) prior to study start-up|No||https://clinicaltrials.gov/show/NCT01031212||129228|
NCT01031199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13101|Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers|Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers||Bayer|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|16|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031199||129229|
NCT01031485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valio-70|Bioactive Milk Peptides and Blood Pressure|||Valio Ltd||Completed|January 2010|August 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||||||Both|30 Years|60 Years||||December 2009|December 19, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031485||129208|
NCT01031498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0389|Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting|Phase II, Open, Randomized Comparative Trial of Two Different Schedules of Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting in Patients With Hematologic Malignancies Receiving Regimens Containing High-dose Cytarabine||M.D. Anderson Cancer Center|No|Completed|September 2005|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|150|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|December 10, 2009||No||No|January 14, 2011|https://clinicaltrials.gov/show/NCT01031498||129207|
NCT01031810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6025|PET Biomarkers in Treatment Resistant Depression|Developing a Biomarker to Predict Response in Treatment Resistant Depression||New York State Psychiatric Institute|No|Terminated|November 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|September 15, 2014|December 12, 2009||No|Needed PET facility closed|No|October 8, 2013|https://clinicaltrials.gov/show/NCT01031810||129183|Early termination leading to small numbers of subjects analyzed
NCT01028235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20060112H|Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia|Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia||San Antonio Uniformed Services Health Education Consortium|Yes|Recruiting|January 2006|January 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|4 endoscopic biopsies from 5 locations: duodenum, stomach, distal esophagus, mid esophagus      and proximal esophagus|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients over age 18, presenting to the Gastroenterology Clinic with the complaint        of dysphagia|November 2009|December 8, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028235||129455|
NCT01028521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CellMed CM3.1-AC100/01|First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100|Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers||CellMed AG, a subsidiary of BTG plc.|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|56|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|July 14, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01028521||129433|
NCT01034501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP2112008|Adjunctive Photodynamic Therapy in Treatment of Chronic Periodontitis|Efficacy of Adjunctive Photodynamic Therapy in Non-surgical Treatment of Chronic Periodontitis: a Randomized , Controlled Clinical Trial||University of Sao Paulo|No|Completed|February 2010|September 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|30 Years|75 Years|No|||October 2013|October 9, 2013|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034501||128977|
NCT01042132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02066|Intramedullary Femoral Reaming, Human Study|Pathophysiological Effects of- and Inflammatory Response to Intramedullary Femoral Nailing in Patients With Femoral Shaft Fracture||Oslo University Hospital|No|Active, not recruiting|May 2003|May 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||April 2002|August 8, 2011|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042132||128445|
NCT01037920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HL089623|An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension|An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension||Denver Health and Hospital Authority|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|179|||Both|21 Years|N/A|No|||July 2012|July 11, 2012|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01037920||128765|
NCT01035723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905406|Effect of Functional Genetic Polymorphisms on Brain Morphology and Function|Effect of Functional Genetic Polymorphisms on Brain Morphology||National Institutes of Health Clinical Center (CC)||Completed|September 2005|February 2013||||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|50 Years|No|||February 2013|October 23, 2014|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01035723||128885|
NCT01037621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL R 152|Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C|The Interaction of HSV-2 Co-infection in Veterans With Chronic Hepatitis C: the Effect of Valacyclovir on HCV Viral Load||G.V. (Sonny) Montgomery VA Medical Center|No|Active, not recruiting|April 2010|February 2012|Anticipated|February 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 4, 2011|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037621||128788|
NCT01032564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00814-53|Interest of HI-RTE Elasticity in Obstetric|||Assistance Publique Hopitaux De Marseille|No|Completed|December 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|73|||Female|18 Years|65 Years|No|||August 2014|August 28, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032564||129125|
NCT01042093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1113723|Efficacy of Multimodal Perioperative Analgesia With Periarticular Drug Injection in Total Knee Arthroplasty(TKA)|Efficacy of Multimodal Perioperative Analgesia Protocol With Periarticular Drug Injection in Total Knee Arthroplasty: A Randomized, Double Blind Study||Towson Orthopaedic Associates|No|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|30 Years|85 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|January 4, 2010|Yes|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01042093||128448|
NCT01042106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6950153|Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Oral Dose Study to Evaulate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Type 2 Diabetic and Healthy Subjects||Sunovion|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|December 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01042106||128447|
NCT01037894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW003|Can Acupuncture Benefit Surgical Patients With Haemorrhagic Stroke?|Can Acupuncture Benefit Surgical Patients With Haemorrhagic Stroke?||Chinese University of Hong Kong|Yes|Completed|January 2009|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|70 Years|No|||January 2013|January 10, 2013|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037894||128767|
NCT01037907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGC20-0134-02|A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS||BTG International Inc.|Yes|Terminated|November 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|65 Years|No|||July 2013|July 25, 2013|December 21, 2009||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01037907||128766|
NCT01028157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-2002|S.T.A.R.S.: Sistas Talking About Real Solutions|STARS: Sistas Talking About Real Solutions|STARS|Emory University|No|Completed|October 2002|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|855|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01028157||129461|
NCT01028417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02265|Study to See if Microcoil Insertion Reduces the Rate of Open Thoracotomy for Removal of Lung Nodules|A Randomized Controlled Trial To Determine If Thoracoscopic Resection Of Subcentimetre Lung Nodules After Localization Using Percutaneously Inserted Platinum Microcoils Under CT Guidance Reduces Rate Of Conversion To Open Thoracotomy From 50% To 10%||University of British Columbia|No|Completed|January 2010|October 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|N/A|No|||July 2012|February 28, 2014|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01028417||129441|
NCT01030094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015856|A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy|A Cross-sectional, Comparative, Multi-center Study to Investigate the Effect of Topiramate Monotherapy on Markers of Bone Mineral Metabolism and Bone Mineral Density in Premenopausal Women With Epilepsy||Janssen Korea, Ltd., Korea|No|Completed|February 2007|April 2009|Actual|April 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|140|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Female participants with epilepsy who are receiving topiramate, carbamazepine or valproic        acid monotherapy for more than one year.|June 2013|June 25, 2013|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030094||129313|
NCT01030107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-08-JF-17|Effects of Sleep Duration on Eating and Activity Behaviors|Sleep Duration and Pediatric Overweight: the Role of Eating Behaviors||The Miriam Hospital|No|Completed|February 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|37|Samples Without DNA|2 ml of whole blood drawn at each of 3 assessments|Both|8 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children ages 8-11 years old recruited from Southeastern New England.|April 2011|October 4, 2012|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030107||129312|
NCT01030120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36414|Etanercept for the Treatment of Chronic Urticaria|A 6 Week Randomized, Double Blind, Placebo-controlled Study With a 6 Week Open Label Extension to Assess the Efficacy of Etanercept in the Treatment of Chronic Idiopathic Urticaria|EtanerceptCIU|University of Utah|Yes|Withdrawn|December 2010|October 2012|Anticipated|July 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|December 9, 2009|No|Yes|Unable to complete agreement with sponsor|No||https://clinicaltrials.gov/show/NCT01030120||129311|
NCT01030653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09010|Pharmacokinetics of Voriconazole in Obese Subjects|Pharmacokinetics of Voriconazole in Obese Subjects||Albany College of Pharmacy and Health Sciences|No|Completed|November 2009|May 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 12, 2010|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030653||129271|
NCT01030666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DoxP-01/2006|Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy|Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy. A Randomized Placebo-controlled Clinical Trial|GTRDOXY|Goethe University|No|Terminated|April 2007|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|December 10, 2009||No|shelf life of investigational drug ran out before 90 patients could be included|No|September 22, 2012|https://clinicaltrials.gov/show/NCT01030666||129270|The study had to be terminated due to shelf life of test drug running out prior to including 90 patients resulting in the low test power of 50%.
NCT01030978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908005608|Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program|Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program||Yale University|No|Completed|September 2009|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Both|11 Years|16 Years|No|||June 2014|June 16, 2014|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030978||129246|
NCT01031524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/04|Trial to Assess the Efficacy of Malaria Vaccine PfCS 102|Randomized Double-blind Controlled Phase I/IIa Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 (282-383) to Protect Against Artificial Challenge With P. Falciparum|DG002|Swiss Tropical & Public Health Institute|No|Completed|March 2004|November 2004|Actual|July 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2009|December 11, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01031524||129205|
NCT01031511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Ref Code: A/05/091|Effect of Cognitive Behavioural Therapy (CBT) for Children With Autistic Spectrum Disorders|A Randomised Controlled Trial on the Effect of Cognitive-behavioural Therapy for High-functioning Children With Autistic Spectrum Disorder||National Healthcare Group, Singapore|Yes|Active, not recruiting|June 2005|February 2011|Anticipated|January 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|9 Years|16 Years|No|||February 2009|December 11, 2009|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031511||129206|
NCT01031836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2800C00001|A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.|A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE)||AstraZeneca|Yes|Active, not recruiting|November 2009|July 2016|Anticipated|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|42|||Both|20 Years|130 Years|No|||January 2016|January 12, 2016|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031836||129181|
NCT01032070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-205|Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma|A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma|PETEY|Astellas Pharma Inc|Yes|Terminated|September 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|1 Year|21 Years|No|||June 2015|June 12, 2015|December 10, 2009|Yes|Yes|In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety    concerns. As a result, it has been stopped.|No|November 20, 2013|https://clinicaltrials.gov/show/NCT01032070||129163|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01034839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mcazevedo01|High-dose Cytarabine and Survival in AML|Role of Consolidation With High-dose Cytarabine in Overall Survival of Adults With Acute Myeloid Leukemia||University of Sao Paulo General Hospital|Yes|Completed|January 2006|December 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|499|||Both|18 Years|92 Years|No|Non-Probability Sample|Acute myeloid leukemia in adults treated in the University of Sao Paulo between 1978 and        2007|December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034839||128951|
NCT01035086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H36-08|Intervention With Lupin Kernel Fibre in Hypercholesterolemic Subjects|The Preventive Effects of Lupin Kernel Fibre-enriched Food on Colon Cancer and Cardiovascular Diseases in Moderate Hypercholesterolemic Subjects||University of Jena|Yes|Completed|June 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|54|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035086||128932|
NCT01042145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0542|Community Care for Croup (RCT)|Community Care for Croup (RCT)||Washington University School of Medicine|Yes|Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|1 Year|8 Years|No|||September 2014|September 11, 2014|January 4, 2010||No||No|December 24, 2012|https://clinicaltrials.gov/show/NCT01042145||128444|Our failure to demonstrate any difference bewteen the two study groups may be due to the small sample size. We were unable to recruit the targeted sample size of 200.
NCT01037322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|canabidiol1|Cannabidiol for Inflammatory Bowel Disease|Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease||Meir Medical Center|No|Completed|January 2010|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|80 Years|No|||April 2013|April 13, 2013|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01037322||128811|
NCT01038206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA025192-01A1|Familias Unidas: Preventing Substance Abuse in Hispanic Youth|Familias Unidas Stage III Study: Preventing Substance Abuse in Hispanic Youth||University of Miami|Yes|Completed|August 2010|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|746|||Both|12 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038206||128743|
NCT01032252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAU061209TUM|Prevention of Falls in General Practitioner for Community-dwelling Older Adults [PreFalls]|Prevention of Falls in Community-dwelling Older Adults by a Standardized Assessment of Fall Risks in the General Practitioner Setting and Through Implementation of a Network for Effective Individual Reduction on Fall Risks.||University of Erlangen-Nürnberg Medical School|No|Completed|April 2009|March 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|378|||Both|65 Years|N/A|No|||June 2012|June 15, 2012|December 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01032252||129149|
NCT01028131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA021668-01|Computer-Assisted Intervention for Smoking During Pregnancy|A Computer-Assisted Brief Motivational Intervention for Smoking During Pregnancy: The Healthy Pregnancy Project (HPP)|HPP|Wayne State University|No|Completed|June 2007|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|110|||Female|18 Years|N/A|No|||June 2013|June 6, 2013|December 8, 2009||No||No|October 12, 2011|https://clinicaltrials.gov/show/NCT01028131||129463|Although all effects favored brief computer session, the small sample size limited our ability to detect small effects. The sample was almost exclusively low-income African-American women. Follow-up period was also, of necessity, relatively brief.
NCT01028144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project ACT|The Active by Choice Today (ACT) Trial to Increase Physical Activity|Self-Determination for Increasing Physical Activity|ACT|University of South Carolina|Yes|Completed|July 2004|May 2009|Actual|May 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1422|||Both|10 Years|13 Years|Accepts Healthy Volunteers|||December 2009|December 9, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01028144||129462|
NCT01029275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/089/HP|Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone|Multicenter, Randomised Open Trial Comparing the Efficacy of a Medical Treatment With Sandostatin LP 30 mg Performed Before Surgery to a Prime Line transsphenoïdal Surgery in Previously Untreated Acromegalic Patients With Either a Micro or a Macro Pituitary Adenoma|SAPORO|University Hospital, Rouen|Yes|Completed|January 2005|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|89|||Both|18 Years|80 Years|No|||July 2014|July 30, 2014|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029275||129375|
NCT01029561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08/0800|Impact of Obstructive Sleep Apnea Syndrome on Metabolic Syndrome in Severe Obesity|Impact of Obstructive Sleep Apnea Syndrome on Metabolic Syndrome in Severe Obesity|SYBILA|Hospital Universitari de Bellvitge|No|Active, not recruiting|January 2009|January 2012|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|65 Years|No|||October 2009|December 9, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029561||129354|
NCT01029847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASIM|Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis|Adalimumab in Axial Spondyloarthritis. An Investigation of Whole-body MRI, MRI of Sacroiliac Joints and Spine and Soluble Biomarkers of Joint Inflammation and Damage.|ASIM|Glostrup University Hospital, Copenhagen|Yes|Completed|December 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||August 2015|August 18, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029847||129332|
NCT01029860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3244|The Impact of Hospitalization on Ambulatory Blood Pressure and Intraocular Pressure|A Study Investigating the Impact of Hospitalization on Ambulatory Blood Pressure and Intraocular Pressure in Subjects With Mild to Moderate Arterial Hypertension and Untreated Ocular Hypertension||Aristotle University Of Thessaloniki|No|Completed|March 2007|March 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|40|||Both|30 Years|65 Years|No|Probability Sample|Subjects with untreated ocular hypertension and stage 1 arterial hypertension with or        without treatment with anti-hypertensive agents.|March 2007|December 16, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029860||129331|
NCT01029873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-801-02-09|Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma|Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma||Altor Bioscience Corporation|Yes|Completed|February 2010|September 2013|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01029873||129330|
NCT01030133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Borckardt_19079|Effects of Transcranial Magnetic Stimulation (TMS) and Stimulus Controllability on Pain Perception|Effects of TMS and Stimulus Controllability on Pain Perception||Medical University of South Carolina|No|Active, not recruiting|October 2009|February 2010|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2010|December 22, 2010|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030133||129310|
NCT01030419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC_IRB_09765|Activity, Gait, and Efficacy (AGE II): Functional Limitations and Quality of Life|Activity, Gait, and Efficacy (AGE II): Functional Limitations and Quality of Life|AGE II|University of Illinois at Urbana-Champaign|Yes|Completed|February 2010|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030419||129289|
NCT01030406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-ADF-114|Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users|A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users||Acura Pharmaceuticals Inc.|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 8, 2010|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030406||129290|
NCT01030679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19DM05L|Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus|To Investigate the Glycemic Control and Lipid Profile of CKD-501 Monotherapy in Patients With Type 2 Diabetes Mellitus:a Eight-week, Multicenter, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-ranging Study.||Chong Kun Dang Pharmaceutical|Yes|Completed|July 2007|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|214|||Both|19 Years|N/A|No|||December 2009|December 14, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030679||129269|
NCT01031225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-06|A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)|A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer||Synta Pharmaceuticals Corp.|No|Completed|November 2009|February 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|November 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031225||129227|
NCT01031862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810035|BMS Reverse Cholesterol Transport (RCT) Study|A Pilot Study to Evaluate the Use of 3H Particulate Cholesterol as a Method to Study Reverse Cholesterol Transport in Humans||University of Pennsylvania|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2009|June 24, 2010|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031862||129179|
NCT01032083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO 1250|Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia|Individually Randomised, Placebo-controlled, Parallel Arm RCT With 12-month Follow-up to Establish the Clinical and Cost Effectiveness of the Antidepressant Citalopram in the Management of Negative Symptoms of Schizophrenia|ACTIONS|Imperial College London|Yes|Completed|July 2011|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|No|||November 2012|March 25, 2015|August 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01032083||129162|
NCT01031849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCSKAL-2009-01|Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir|Análisis de Los Cambios en el Tejido Adiposo de Pacientes Con infección VIH y Lipoatrofia en Tratamiento Con análogos de nucleósidos timidínicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir|BIOKAL|Hospital San Carlos, Madrid|No|Terminated|February 2010|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|December 4, 2009||No|patient sample not reached|No||https://clinicaltrials.gov/show/NCT01031849||129180|
NCT01027975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RKubiak|Comparison of Laparoscopic Nissen Versus Thal Fundoplication in Children|Long-term Outcome of Laparoscopic Nissen Fundoplication Compared With Laparoscopic Thal Fundoplication in Children||Oxford University Hospitals NHS Trust||Completed|July 1998|||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|1 Month|21 Years|No|||February 2007|December 10, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027975||129474|
NCT01028248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4714s|Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion|Phase I, Open-Label, Single-Center, Randomized, Study of the Safety and Efficacy of 0.5 mg and 2.0 mg Ranibizumab in Patients With Macular Edema Secondary to Perfused Central Retinal Vein Occlusion||California Retina Consultants|Yes|Completed|January 2010|June 2013|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028248||129454|
NCT01035749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113883|Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Children Aged 10 to Less Than 18 Years||GlaxoSmithKline||Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|310|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||May 2011|July 23, 2012|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035749||128884|
NCT01035775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909-22|Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?|Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?||Indiana University|No|Completed|December 2009|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|340|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2009|June 22, 2011|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035775||128883|
NCT01036243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.06 INF|Digestive Tolerance of Slightly Hydrolyzed Starter Infant Formula With Probiotics|Tolerance of a Slightly Hydrolyzed Starter Formula Containing Probiotics||Nestlé|No|Completed|December 2009|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|480|||Both|N/A|30 Days|Accepts Healthy Volunteers|||June 2012|June 21, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036243||128861|
NCT01037933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA2007020|Comedy in Chemotherapy (COMIC) Study|Comedy in Chemotherapy (COMIC) Study|COMIC|Queen's Medical Centre|No|Completed|February 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|N/A|No|||December 2009|December 22, 2009|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037933||128764|
NCT01038505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090531|Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus|Head to Head Comparison of Tacrolimus and Myfortic vs Tacrolimus and Sirolimus Used in Combination in Non-HLA Identical Living Donor Kidney Transplants||University of Miami|No|Withdrawn|January 2010|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||December 2009|March 9, 2012|December 23, 2009|Yes|Yes|Lost funding source|Yes||https://clinicaltrials.gov/show/NCT01038505||128720|
NCT01038791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|593|Patients-ventilator Interaction During Sleep: Effect of Humidification System|Patients-ventilator Interaction During Sleep: the Role of Humidification. A Pilot Short Term Study||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Completed|December 2009|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|15|||Both|18 Years|90 Years|No|||January 2013|October 8, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01038791||128698|
NCT01031979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-013-09F|Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine|Psychophysiology of Prolonged Exposure for PTSD With/Without Yohimbine||VA Office of Research and Development|No|Completed|December 2010|May 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|45 Years|No|||September 2015|September 24, 2015|December 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01031979||129170|
NCT01031992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAHHT|Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia|TAHHT|University Hospital, Saarland|Yes|Completed|March 2002|October 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||December 2009|December 12, 2009|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031992||129169|
NCT01032265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS dnr 2008-0952|Web-based Management of Female Stress Urinary Incontinence|Web-based Management of Female Stress Urinary Incontinence. Evaluation of a Treatment Programme With Pelvic Floor Muscle Training and Elements of Cognitive Behavioural Therapy||Umeå University|No|Completed|December 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|18 Years|70 Years|No|||February 2013|February 8, 2013|December 12, 2009||No||No|December 17, 2012|https://clinicaltrials.gov/show/NCT01032265||129148|
NCT01029288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK084009|Impact of Decision Aids to Enhance Shared Decision Making for Diabetes|Impact of Decision Aids to Enhance Shared Decision Making for Diabetes|DAD|Mayo Clinic|Yes|Completed|April 2010|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|110|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01029288||129374|
NCT01029574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0292/08|Platelet Rich Plasma on Rotator Cuff Repair|Platelet Rich Plasma on Arthroscopic Repair of the Complete Rotator Cuff Lesions: a Prospective and Randomized Study|PRP|University of Sao Paulo|No|Completed|September 2008|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|30 Years|80 Years|No|||December 2014|December 2, 2014|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01029574||129353|
NCT01029886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-MC-GWDE|Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes|Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications||AstraZeneca|No|Completed|January 2010|April 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|912|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|December 8, 2009|Yes|Yes||No|February 14, 2012|https://clinicaltrials.gov/show/NCT01029886||129329|
NCT01029899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFM-05|Characterize Differences in Force Patterns Used by Different Endoscopists and Trainee Endoscopists|Phase II Study of Evaluation of Handheld Colonoscopy Force Monitor by Expert and Trainee Endoscopists in the Performance of Colonoscopy||Artann Laboratories|Yes|Completed|December 2009|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|95|||Both|30 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adult male and female patients between the ages of 30 and 75 presenting for screening        or diagnostic colonoscopy to be performed by any of the investigators.|January 2016|January 20, 2016|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029899||129328|
NCT01030731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012448|Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease|An Open-Label Pharmacokinetic Study of Ceftobiprole in Healthy Volunteers and Patients With End Stage Renal Disease Receiving Hemodialysis||Basilea Pharmaceutica|No|Completed|May 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030731||129265|
NCT01030432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-016|Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin|A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection||Bristol-Myers Squibb|No|Completed|February 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|285|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030432||129288|
NCT01030718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-036|Rollover Study of BMS-354825 in Patients With CML and Ph+ALL|A Study to Document the Long-Term Safety and Efficacy of BMS-354825 in Subjects With Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Previous Treatment and Have Completed the Previous Phase I/II Protocol (CA180-031/NCT00337454)||Bristol-Myers Squibb|Yes|Completed|January 2006|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Both|20 Years|75 Years|No|||November 2010|November 15, 2010|December 10, 2009|Yes|Yes||No|July 26, 2010|https://clinicaltrials.gov/show/NCT01030718||129266|
NCT01031875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITA-MIL-IRCCS-INT-70/09|Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment|Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer||National Cancer Institute (NCI)||Completed|December 2009|August 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||September 2012|August 9, 2013|December 13, 2009||||No||https://clinicaltrials.gov/show/NCT01031875||129178|
NCT01032096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3168|The Physiological Response to Routine Head and Neck Cancer Surgery|The Neuroendocrine, Metabolic, Inflammatory and Immune Responses to Routine Head and Neck Surgery. An Observational Pilot Study||Royal Marsden NHS Foundation Trust|No|Recruiting|May 2009|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with a diagnosis of cancer involving the head and neck region of the body.|December 2009|December 14, 2009|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032096||129161|
NCT01027988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM 08-1050|Retina Microvascularisation and Cardiovascular Heart Disease Prediction|Retina Microvascularisation and Cardiovascular Heart Disease Prediction||Montreal Heart Institute|Yes|Completed|September 2009|October 2013|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|50 Years|70 Years|No|Probability Sample|(50 to 70 years old) with history of coronary heart disease (CHD) or one or more risk        factors.|October 2013|October 29, 2013|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027988||129473|
NCT01028261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-001|Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers|A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZGN-433 in Obese Volunteers||Zafgen, Inc.|No|Completed|December 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|December 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028261||129453|
NCT01028274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN-91109|Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.|Clinical Trial to Assess the Safety and Efficacy of a Combination Red Yeast Rice and Omega-3 (EPA+DHA) to Reduce LDL Cholesterol and Triglyceride Levels in Hypercholesterolemic and Hypertriglyceridemic Subjects.||Nordic Pharma, USA||Completed|September 2009|August 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|148|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028274||129452|
NCT01041612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RaMM-BO 2.0|Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi|Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study||Taewoong Medical Co., Ltd.|No|Recruiting|January 2010|July 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01041612||128484|
NCT01041885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|309-019|INSTRUCT for Repair of Knee Cartilage Defects|Prospective Feasibility, Non-randomized, Single Arm Multicentre, Multinational Interventional Clinical Investigation Using INSTRUCT Therapy for the Repair of Knee Cartilage Defects||CellCoTec B.V.|No|Completed|January 2010|June 2014|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|55 Years|No|||February 2015|February 2, 2015|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01041885||128464|
NCT01041898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091118001|The Bone-Fat-Pancreas Axis in Children|The Bone-Fat-Pancreas Axis in Children: Establishing a Role for Undercarboxylated Osteocalcin in Energy Homeostasis||University of Alabama at Birmingham|Yes|Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|28|Samples With DNA|Samples will be labeled with the study protocol number, a unique identifier, and the date of      collection.      Specimens will be obtained by the nursing staff at the PCIR. The PCIR processing lab will      process the samples, which will then be stored in a locked freezer at -80oC in the      restricted access CNRU Metabolism Core lab (WEBB 337).|Female|5 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy European American (Caucasian) girls aged five to ten years|February 2012|February 24, 2012|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041898||128463|
NCT01042119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHKUSZ15-2009|Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females|Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study||University of Zurich|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|patients who received at our clinic treatment with intravesical injection of Botox for        idiopathic overactive bladder syndrome|June 2010|June 23, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042119||128446|
NCT01041911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBL/CR/0102008/CT|To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids|Double-blind, Randomized, Placebo-controlled, Dose Response Study to Evaluate the Safety and Efficacy of Three Doses of Euphorbia Prostrata Dry Extract Tablets in Patients of Hemorrhoids||Panacea Biotec Ltd|No|Completed|March 2010|November 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|102|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|December 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041911||128462|
NCT01038219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC129-09CTIL|Reliability of Subjective Assessment of Fever by Parents and Health Care Providers in Children and Adolescents|Reliability of Subjective Assessment of Fever by Parents and Health Care Providers in Children and Adolescents||Meir Medical Center|No|Completed|May 2010|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|520|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children ages 0-18 years        Boys and girls|May 2014|April 13, 2015|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01038219||128742|
NCT01038232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910453|Measuring Distress Tolerance With Functional MRI|Measuring Distress Tolerance With Functional MRI||National Institutes of Health Clinical Center (CC)||Completed|December 2009|March 2015||||N/A|Observational|N/A|||Anticipated|200|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01038232||128741|
NCT01038245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903383|Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers|Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers||National Institutes of Health Clinical Center (CC)||Completed|July 2003|November 2011||||N/A|Observational|N/A|||Anticipated|72|||Both|18 Years|50 Years|No|||November 2011|November 19, 2011|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01038245||128740|
NCT01038258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAM 07|Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy|Monitoring Response After The First Chemotherapy Cycle In Newly Diagnosed Breast Cancer As A Guide For Neoadjuvant Therapy|PETBreast|Auxilio Mutuo Cancer Center|Yes|Active, not recruiting|July 2007|April 2013|Anticipated|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038258||128739|
NCT01037946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR009922|Family to Family: Psychoeducation to Improve Children's Outcomes in HIV+ Families|Family to Family: Psychoeducation to Improve Children's Outcomes in HIV+ Families||University of California, Los Angeles|No|Completed|September 2005|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1033|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|February 22, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037946||128763|
NCT01038492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012350|p16 Methylation for Smoking Cessation|Testing the Feasibility of Using an Epigenetic Marker, p16, to Promote Smoking Cessation||Duke University|No|Completed|April 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|35|||Both|N/A|N/A|No|||March 2012|June 26, 2013|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038492||128721|
NCT01038804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-CL-036|A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer|A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer||Astellas Pharma Inc|No|Completed|December 2009|June 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038804||128697|
NCT01028443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8546|Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes|||hahid Beheshti University of Medical Sciences||Completed||||||Phase 4|Interventional|N/A|2||||||Both|18 Years|65 Years||||April 2006|December 8, 2009|December 8, 2009||||No||https://clinicaltrials.gov/show/NCT01028443||129439|
NCT01028703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RKK3922|Effects of a Reduction in Kidney Function on Cardiovascular Structure and Function: A Prospective Study of Kidney Donors|Does a Reduction in Renal Function Increase Arterial Stiffness and Left Ventricular Mass? - A Prospective Study of Kidney Donors||University Hospital Birmingham NHS Foundation Trust|Yes|Completed|September 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|124|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Renal outpatient clinic|December 2015|December 2, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028703||129419|
NCT01028989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090407003|A Reduced Carbohydrate Diet Intervention for Polycystic Ovary Syndrome (PCOS)|A Reduced Carbohydrate Diet Intervention for PCOS||University of Alabama at Birmingham|No|Completed|December 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|23|||Female|19 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028989||129397|
NCT01029262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-005|A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Compare The Efficacy And Safety of Lenalidomide (Revlimid®) Versus Placebo In Subjects With Transufsion-Dependent Anemia Due to IPSS Low Or Imtermidate-1 Risk Myelodysplastic Syndromes Without Deletion 5Q(31) And Unresponsive Or Refractory To Erthropoiesis-Stimulating Agents|MDS-005|Celgene|Yes|Active, not recruiting|January 2010|June 2018|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 8, 2009|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01029262||129376|
NCT01029301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED-IOP- 01|Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System for Skin Wrinkle Treatment on Body Areas|Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System||Endymion Medical Ltd|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|30 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 8, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029301||129373|
NCT01029600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/870|Surgery or Capsular Distention With Steroid in the Treatment of Primary Frozen Shoulder?|Arthroscopic Capsulotomy vs Arthrographic Distention With Steroid in the Treatment of Primary Frozen Shoulder. A Randomized Study||Bergen Surgical Hospital|No|Recruiting|December 2009|April 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2009|December 15, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029600||129351|
NCT01029587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00032637|Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome|Phase 2 Study of the Use of Eculizumab to Prevent Thrombosis After Renal Transplantation in Patients With a History of Catastrophic Antiphospholipid Antibody Syndrome (CAPS)||Johns Hopkins University|No|Active, not recruiting|November 2009|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01029587||129352|
NCT01030445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11-0597|Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children|A Pilot Study: Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children From Acute Illness (Disease) to Recovery (Health).||Children's Hospital Boston|No|Active, not recruiting|December 2009|||June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|186|||Both|N/A|N/A|No|Non-Probability Sample|Hospitalized children|June 2011|June 22, 2011|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030445||129287|
NCT01031238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0479|Comparison of PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast|Pilot Study to Compare the PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast||M.D. Anderson Cancer Center|No|Completed|December 2009|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known or suspected tumors of the breast, 18 years or older scheduled for        routine clinical imaging at the PET/CT facility.|November 2015|November 19, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031238||129226|
NCT01030991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA 0835488N|Classification of Heart Failure With Preserved Ejection Fraction|Etiologic, Pathophysiologic, and Genetic Classification of Heart Failure With Preserved Ejection Fraction||Northwestern University|No|Recruiting|July 2008|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Whole blood, saliva|Both|21 Years|N/A|No|Non-Probability Sample|All patients with signs or symptoms of heart failure with left ventricular ejection        fraction > 50% are eligible for the study|June 2012|June 28, 2012|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030991||129245|
NCT01031004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1655|Vistakon Investigational Lens Worn as a Single Use Daily Wear|||Johnson & Johnson Vision Care, Inc.|No|Completed|October 2009|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|November 18, 2009|Yes|Yes||No|February 22, 2011|https://clinicaltrials.gov/show/NCT01031004||129244|
NCT01032109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCBK610|Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration|Verteporfin Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration||Kumamoto University|No|Completed|October 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|50 Years|N/A|No|||February 2016|February 25, 2016|December 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01032109||129160|
NCT01032122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIMM1|Rituximab in Metastatic Melanoma|Efficacy and Safety of Rituximab, an Anti-CD20 (Cluster of Differentiation Antigen 20) Therapeutic Agent, in Metastatic Melanoma: a Pilot Study||Medical University of Vienna|Yes|Terminated|October 2007|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|September 19, 2009|Yes|Yes|the only reason is that recruitment was not sufficient to meet the planned patient numbers,    because complete remissions are still infrequent.|No||https://clinicaltrials.gov/show/NCT01032122||129159|
NCT01028027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|617|Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis|A Clinical Safety and Efficacy Evaluation of Zylet® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis||Bausch & Lomb Incorporated|No|Completed|October 2009|March 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|December 8, 2009|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT01028027||129471|
NCT01028014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VESI-9E03-UAB|Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters|Medication Effects on Periurethral Sensation, Urethral Sphincter Activity and Pressure Flow Parameters||University of Alabama at Birmingham|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|56|||Female|19 Years|51 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|December 7, 2009|Yes|Yes||No|June 29, 2011|https://clinicaltrials.gov/show/NCT01028014||129472|
NCT01028586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27938|MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)|A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|MOTION|Newron|Yes|Terminated|October 2009|||May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|507|||Both|30 Years|80 Years|No|||August 2012|March 27, 2013|December 7, 2009|Yes|Yes|Trial is terminated due to a company decision to return all rights for Safinamide back to    Newron Pharmaceuticals|No||https://clinicaltrials.gov/show/NCT01028586||129428|
NCT01041625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCR 001|Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus|An Open-Label Pilot Study to Evaluate the Safety and Efficacy of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus||Virginia Clinical Research, Inc.|Yes|Not yet recruiting|February 2010|February 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|December 31, 2009|December 30, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041625||128483|
NCT01038271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-030|Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC||Massachusetts General Hospital|No|Active, not recruiting|May 2006|August 2016|Anticipated|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01038271||128738|
NCT01038531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28944|Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation|Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation||Boston Medical Center|Yes|Suspended|July 2010|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|December 22, 2009||No|pending further funding|No||https://clinicaltrials.gov/show/NCT01038531||128718|
NCT01038518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009124|Health2010-14: Monitoring Biomarkers of Chronic Diseases in the General Population|Health2010-14: Monitoring Biomarkers of Chronic Diseases in the General Population|Health2010-4|Glostrup University Hospital, Copenhagen|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1522|Samples With DNA|Urine, serum, whole blood, extracted DNA|Both|18 Years|72 Years|No|Non-Probability Sample|Random samples of persons living in 10 municipalities in the Western part of the Capital        Region of Denmark (Copenhagen).|January 2015|January 21, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038518||128719|
NCT01038817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070606|Impact of Fluoride Vanish Application in Dental Prevention for Elderly|Evaluation of the Impact of Fluoride Vanish Application in Dental Prevention Among Institutionalised Elderly People|VERNIS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2009|June 2015|Anticipated|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2009|October 13, 2014|December 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01038817||128696|
NCT01039116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA 2004-35215-14250|Taking Action Together- A Diabetes Prevention Program|Taking Action Together: Development, Implementation and Evaluation of Community-Based Programs That Aims to Reduce Risk of Type 2 Diabetes in High BMI African American Children.|TAT|University of California, Berkeley|No|Completed|March 2005|December 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|240|||Both|9 Years|11 Years|No|||March 2007|May 3, 2011|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039116||128674|
NCT01028716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2372.00|Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source||Fred Hutchinson Cancer Research Center|Yes|Recruiting|February 2010|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||December 2015|December 14, 2015|December 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028716||129418|
NCT01029002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-266|The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease|The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease||Albert Einstein College of Medicine of Yeshiva University|No|Completed|October 2009|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01029002||129396|
NCT01029912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD061593|Electrical Stimulation for Recovery of Ankle Dorsiflexion in Chronic Stroke Survivors|Contralaterally Controlled NMES in Chronic Ankle Dorsiflexor Paresis After Stroke||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|November 2009|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|80 Years|No|||December 2011|December 13, 2011|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01029912||129327|
NCT01031017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|418/04|Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies|Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies: A Randomized, Double-Blind, Placebo-Controlled Trial||University of Sao Paulo|No|Completed|June 2007|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|390|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031017||129243|
NCT01031264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0706002821|Chronic Alcohol and Brain Stress Circuit Response|Chronic Alcohol and Brain Stress Circuit Response||Yale University|No|Completed|January 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|social drinkers|July 2015|July 28, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031264||129225|
NCT01031277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GU-CRE-2009/1|Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States|Centralized Gulf States Survey on the Undertreatment of Hypercholesterolemia|CEPHEUS|AstraZeneca|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|None Retained|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Inhabitants of Gulf States visiting their cardiologist for regular follow-up of their        hypercholesterolaemia treatment|May 2011|May 24, 2011|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031277||129224|
NCT01031290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909443|Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving|Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2009|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||February 2012|March 20, 2012|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031290||129223|
NCT01031537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090246|A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory|A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory||National Institutes of Health Clinical Center (CC)||Recruiting|September 2009|November 2020|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|160|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 16, 2016|December 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031537||129204|
NCT01032135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807092|Adaptive Treatment for Cocaine Dependence|Adaptive Treatment for Cocaine Dependence||University of Pennsylvania|No|Completed|October 2008|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|300|||Female|18 Years|75 Years|No|||January 2016|January 4, 2016|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01032135||129158|
NCT01028287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTH-NRDN|Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)|"Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study"|ACTH-NRDN|Southeast Renal Research Institute|No|Completed|May 2009|July 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|No|||May 2013|May 30, 2013|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028287||129451|
NCT01028300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Military ProDisc-L Study|Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel|Clinical Outcomes of Lumbar Degenerative Disc Disease Treated Operatively in Active-Duty U.S. Service Personnel With Lumbar Total Disc Replacement||Synthes USA HQ, Inc.|Yes|Terminated|April 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|50 Years|No|||February 2016|February 2, 2016|December 8, 2009|No|Yes|Terminated due to enrollment failure|No|December 22, 2015|https://clinicaltrials.gov/show/NCT01028300||129450|Study was terminated early due to slow enrollment. Only Two subjects were seen for follow-up visits, and only at 3 months post surgery.
NCT01037959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071220|Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure|Randomized, Double-Blind, Placebo-Controlled Trial Assessing Norfloxacin in the Prevention of Complications in Patients With Cirrhosis and Severe Liver Failure|NORFLOCIR|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|April 2010|November 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|291|||Both|18 Years|N/A|No|||November 2015|December 8, 2015|December 21, 2009||No|lack of recruitement|No||https://clinicaltrials.gov/show/NCT01037959||128762|
NCT01037972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Galileo|Influence of Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Gonarthrosis|Influence of Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Gonarthrosis||University of Cologne|No|Completed|March 2010|October 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|30 Years|80 Years|No|Probability Sample|Patients with osteoarthritis of the knee.|October 2011|October 7, 2011|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037972||128761|
NCT01038284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 09 12|Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)|Evaluation of Multidisciplinary Collaboration Care Program in Pulmonary Arterial Hypertension|ETHAP|University Hospital, Grenoble|Yes|Completed|March 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|101|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038284||128737|
NCT01038544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 09.146|Endobronchial Ultrasound (EBUS) for Nodal Staging in Esophageal Cancer|Endobronchial Ultrasound (EBUS) for Nodal Staging in Esophageal Cancer|CT0003|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|December 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||November 2011|June 20, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038544||128717|
NCT01038557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-01|Frozen Red Blood Cell Transfusions in Trauma Patients|Efficacy and Safety of Frozen Red Blood Cells for Transfusion in Trauma Patients||Oregon Health and Science University|Yes|Not yet recruiting|January 2010|February 2011|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|350|||Both|15 Years|N/A|No|||December 2009|March 11, 2010|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038557||128716|
NCT01038830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QFTchange|QuantiFERON Change During Anti-tuberculosis Medication|The Change in Level of Interferon-gamma Assay in Active Tuberculosis Patients During Treatment||Armed Forces Capital Hospital, Republic of Korea|No|Completed|May 2008|May 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Young healthy subjects in Korean military|December 2009|June 11, 2010|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038830||128695|
NCT01038843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-005|Efficacy Study of VA106483 in Males With Nocturia.|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-titration Study to Determine the Efficacy and Safety of VA106483 in Male Subjects With Nocturia||Vantia Ltd|No|Completed|December 2009|August 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|152|||Male|18 Years|N/A|No|||June 2014|June 18, 2014|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038843||128694|
NCT01039129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR IRB#09-136|Hybrid Transvaginal-Transabdominal Endoscopic Surgery|Hybrid Transvaginal-Transabdominal Endoscopic Surgery||St. Luke's-Roosevelt Hospital Center|No|Withdrawn|December 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|60 Years|No|||August 2015|August 19, 2015|December 22, 2009||No|unable to recruit participants|No||https://clinicaltrials.gov/show/NCT01039129||128673|
NCT01039428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS219CCR-001|A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia|||KDL Inc.|Yes|Completed|December 2009|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|20 Years|N/A|No|||May 2012|August 31, 2015|December 24, 2009||No||No|February 29, 2012|https://clinicaltrials.gov/show/NCT01039428||128650|
NCT01028729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM090801|A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)|A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)|NSCLC|Simcere Pharmaceutical Co., Ltd|No|Recruiting|September 2009|August 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|No|||December 2009|December 8, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028729||129417|
NCT01028742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-122|Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity|Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity||Rigshospitalet, Denmark|No|Completed|October 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|463|Samples Without DNA|Serum and plasma|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients hospitalised with a traumatic brain injury at any danish hospital between        01.01.2008 - 31.12.2008|December 2014|December 2, 2014|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028742||129416|
NCT01029015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-009|Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects|A Pilot, Phase 4, Sleep Laboratory Study Comparing the Physiology of Nocturnal Bladder Function in Subjects With Overactive Bladder - Associated Nocturia to Subjects With Primary Insomnia and Healthy Normal Subjects|Nocturia Plt 1|Astellas Pharma Inc|No|Completed|November 2006|July 2007|Actual|July 2007|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|26|||Both|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects identified through urology physicians, sleep laboratory physicians and        advertising|November 2009|March 3, 2011|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01029015||129395|
NCT01029028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2009|||||N/A|N/A|N/A||||||||||||||December 9, 2009|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01029028||129394|
NCT01030146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sinus Rinse|Management of Allergic Rhinitis Patients With Nasal Steroids and NeilMed® Sinus Rinse™ System With Isotonic Saline|Management of Allergic Rhinitis Patients With Nasal Steroids and NeilMed® Sinus Rinse™ System With Isotonic Saline: A Prospective Pilot Study||Medical University of South Carolina|No|Completed|December 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||August 2014|August 14, 2014|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030146||129309|
NCT01030159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012703|National Cancer Institute Thai Cancer Anemia Survey|Anemia Survey in Cancer Patients Study||Janssen-Cilag Ltd.,Thailand|No|Completed|June 2006|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Anemic patients with cancer receiving chemotherapy|April 2014|April 8, 2014|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030159||129308|
NCT01030458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAAH version 5.0.2|Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial|Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial|NOAAH|Katholieke Universiteit Leuven|Yes|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Both|30 Years|69 Years|No|||November 2013|November 14, 2013|December 9, 2009||No||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01030458||129286|
NCT01030744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM Elasy|Evaluation of the Gestational Diabetes Self-Management Education Program and Quality Improvement Plan|Evaluation of the Gestational Diabetes Self-Management Education Program and Quality Improvement Plan|GDM Elasy|Vanderbilt University|Yes|Terminated|December 2015|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Female|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind        Diabetes Clinic and are participants in the gestational diabetes educational program.|July 2011|July 20, 2011|November 30, 2009||No|This is quality improvement review and should not have been registered.|No||https://clinicaltrials.gov/show/NCT01030744||129264|
NCT01031030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRST-IBIS-03|Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)|Adjuvant Treatment of Biologically Aggressive Breast Cancer (N-,N+1,3): Controlled Clinical Study||National Cancer Institute (NCI)||Active, not recruiting|November 1997|||December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Female|18 Years|70 Years|No|||December 2009|August 1, 2013|December 11, 2009||||No||https://clinicaltrials.gov/show/NCT01031030||129242|
NCT01031303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I57|Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age|Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34||Sanofi|No|Completed|December 2009|January 2011|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|123|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031303||129222|
NCT01031550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090226|Isoflurane Preconditioning for Liver Resections|Isoflurane Induced Anesthetic Preconditioning in Elective Liver Resection||Rutgers, The State University of New Jersey|No|Terminated|January 2010|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|December 10, 2009||No|We no longer had an appropriate patient population.Study closed|No|September 16, 2013|https://clinicaltrials.gov/show/NCT01031550||129203|Due to termination of the study no data analysis was performed.
NCT01031563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909447|Risk Perception in Drug-Dependent Adults With and Without Schizophrenia|Risk Perception in Drug-Dependent Adults With and Without Schizophrenia||National Institutes of Health Clinical Center (CC)||Completed|August 2009|May 2012||||N/A|Observational|N/A|||Anticipated|120|||Both|18 Years|64 Years|No|||May 2012|May 4, 2012|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031563||129202|
NCT01031888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803017M|Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries|Phase 1 Study of Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries||National Taiwan University Hospital|No|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|18|||Both|N/A|N/A|No|||December 2009|December 14, 2009|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01031888||129177|
NCT01032148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPCI I 147408|Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma|Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma||Roswell Park Cancer Institute|Yes|Recruiting|December 2009|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01032148||129157|
NCT01028053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-067-005|Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease|A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease||GE Healthcare|Yes|Completed|December 2009|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|365|||Both|60 Years|N/A|No|||September 2014|September 3, 2014|December 7, 2009|Yes|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT01028053||129469|
NCT01028040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0510C00004|AZD Single Ascending Dose Study In Healthy Japanese Subjects|Phase I, Single Centre, Open Label Study to Access The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After A) a Single Ascending Bolus Dose and B) a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Japanese Volunteers (Age Range 20-45 Years)|JSAD|AstraZeneca|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|72|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028040||129470|
NCT01028612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 62109|Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size|A Pilot Study of Interventional Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size|NSCLC|Comprehensive Cancer Center of Wake Forest University|Yes|Terminated|February 2010|November 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|December 8, 2009||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT01028612||129426|
NCT01037673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88201401|Subacromial Impingement - The Need of Arthroscopic Subacromial Decompression After Eccentric Physical Therapy Exercises|Does the Need of Arthroscopic Subacromial Decompression Change After Eccentric Physical Therapy Exercises in Patients With Subacromial Pain? - A Randomized Clinical Trial||Linkoeping University|No|Completed|January 2008|June 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|30 Years|N/A|No|||December 2009|June 16, 2011|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037673||128784|
NCT01037985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXC 001-202|Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty|A Phase 2, Randomized, Double-Blind, Within-subject Controlled Study to Evaluate Efficacy and Safety of EXC 001 for the Amelioration of Scarring of the Surgical Incision in Subjects Undergoing an Elective Abdominoplasty||Pfizer|Yes|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|December 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037985||128760|
NCT01038856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-TAR-766|Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera|Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera||University of Oklahoma|Yes|Terminated|December 2009|February 2014|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|December 22, 2009|Yes|Yes|The study was terminated by the sponsor|No||https://clinicaltrials.gov/show/NCT01038856||128693|
NCT01039142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis|EFFICACY AND SAFETY OF ACITRETIN IN DOSES OF 25mg,35mg or50mg IN PATIENTS WITH SEVERE PLAQUE TYPE PSORIASIS: A RANDOMISED,DOUBLE BLIND , PARALLEL GROUP DOSE- RANGING STUDY||Postgraduate Institute of Medical Education and Research||Completed|March 2008|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|65 Years|No|||February 2008|December 23, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039142||128672|
NCT01039454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109710|Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement|A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects||GlaxoSmithKline|No|Completed|December 2008|April 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 22, 2011|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01039454||128648|
NCT01039714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GXKVITD1|Vitamin D Levels and Postoperative Hypocalcemia After Total Thyroidectomy|Preoperative Vitamin D Levels as a Prognostic Factor for Postoperative Hypocalcemia and Hypoparathyroidism After Total Thyroidectomy||Aristotle University Of Thessaloniki|No|Recruiting|December 2009|May 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients subjected to total thyroidectomy in Third Surgical Clinic of AHEPA University        Hospital|December 2009|December 24, 2009|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01039714||128628|
NCT01040013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oxylap-2009|Gut Oxygenation and Laparoscopy|GUT OXYGENATION DURING AND AFTER LAPAROSCOPIC AND OPEN COLON RESECTION. A RANDOMIZAD CLINICAL TRIAL||University of Milano Bicocca|No|Completed|March 2008|September 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||November 2009|December 24, 2009|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01040013||128605|
NCT01029041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cappesq 0337/07|Stretching and Strengthening Exercise in Fibromyalgia Patients|Stretching and Strengthening Exercise in Treatment of Fibromyalgia Patients: a Randomized Clinical Trial||University of Sao Paulo General Hospital|No|Completed|August 2007|November 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Female|30 Years|55 Years|No|||December 2009|December 8, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029041||129393|
NCT01029314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353.29|Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass|Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass||Tyco Healthcare Group|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Adults greater than/equal to 18 years of age scheduled for a cardiac surgical procedure        requiring cardiopulmonary bypass.|December 2009|December 7, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029314||129372|
NCT01030185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-AAR-002|Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance|A Prospective, Multi-center, Open Label, Non-randomized Study to Investigate the Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance|PIONEER|NovaShunt AG|Yes|Completed|February 2010|June 2013|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030185||129307|
NCT01030198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C68-08-S|Laser Treatment for Fresh Surgical Scars and Mature Scars|Post-Market, Two-Arm, Single Blind, Controlled Study of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminum Garnet (EO QS Nd:YAG) Laser System for the Treatment of Scars||Cynosure, Inc.|No|Terminated|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|December 10, 2009||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01030198||129306|
NCT01030757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0819|Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver|Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver||New Mexico Cancer Care Alliance|Yes|Terminated|June 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||June 2015|June 13, 2015|December 9, 2009|Yes|Yes|Low accrual rate|No|June 13, 2015|https://clinicaltrials.gov/show/NCT01030757||129263|
NCT01031043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-244|Topical Bethanechol for Improvement of Esophageal Dysmotility|Topical Bethanechol for Improvement of Esophageal Dysmotility: A Pilot Study||Georgia Regents University|Yes|Completed|November 2009|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|December 10, 2009|No|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01031043||129241|
NCT01031589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016747|TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278|Study in Healthy Volunteers to Examine the Safety, Tolerability and Plasma Pharmacokinetics of One Intramuscular (IM) Injection of a Novel TMC278 LA Formulation at 2 Different Doses (Open Label), Followed by a Placebo-controlled Part of Multiple IM Injections at a Selected Dose (Double Blind)||Tibotec Pharmaceuticals, Ireland||Completed|January 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|||Actual|19|||Both|18 Years|58 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031589||129200|
NCT01031576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Postural Analysis in Patients With Knee Osteoarthritis|Postural Analysis and Eletromiographic Activity in Patients With Knee Osteoarthritis||University of Sao Paulo|Yes|Completed|February 2006|June 2009|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Female|60 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|15 with diagnosis of OA of knees unilaterally and 15 healthful citizens, both the groups        will be of the feminine sex with age between 65 to 75 years|April 2008|December 11, 2009|April 2, 2008||No||No||https://clinicaltrials.gov/show/NCT01031576||129201|
NCT01032161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIHMZK02002|Perioperative Risk Factors for Postoperative Delirium in Children|Perioperative Risk Factors for Postoperative Delirium in Children Following General Anesthesia||Huazhong University of Science and Technology|Yes|Completed|December 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|3 Years|12 Years|No|Probability Sample|Patients between 3 to 12 years old, who were admitted to the PACU after elective        non-cardiac surgery under general anaesthesia during regular working hours (9:00Am to        5:00Pm)|February 2013|February 24, 2013|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032161||129156|
NCT01028326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC 1635|PCV10 Reactogenicity and Immunogenicity Study - Malindi|Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months|PRISM|KEMRI-Wellcome Trust Collaborative Research Program|No|Active, not recruiting|January 2010|December 2016|Anticipated|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|600|||Both|12 Months|59 Months|Accepts Healthy Volunteers|||December 2015|December 4, 2015|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028326||129448|
NCT01028313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BMT 02|A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease|A Phase II Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease||SCRI Development Innovations, LLC|No|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|December 7, 2009|No|Yes|A decision was made to not move forward with the study. No participants were enrolled or    treated.|No||https://clinicaltrials.gov/show/NCT01028313||129449|
NCT01028885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 10809|MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate|A Prospective Study Implementing MRI Based Treatment Planning for Clinical Target Volume Definition and Immobilization in Post-Prostatectomy Radiation Treatment||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|June 2009|||February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||May 2012|January 25, 2016|December 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028885||129405|
NCT01037998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-09-03|UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer|Phase II Trial of Adding UFUR to Non-small-cell Lung Cancer Patients Treated With Iressa||Taipei Veterans General Hospital, Taiwan|Yes|Completed|November 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||December 2009|December 22, 2009|May 27, 2008||No||No||https://clinicaltrials.gov/show/NCT01037998||128759|
NCT01039155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02909|Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy|A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy||National Cancer Institute (NCI)|Yes|Completed|December 2009|July 2015|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2015|October 5, 2015|December 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01039155||128671|
NCT01039467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPARE Study|An Comparison of the Pacemaker Automatic Features in Reduction of Ventricular Pacing|Study of an Comparison of the Pacemaker Automatic Features in Reduction of Ventricular Pacing|COMPARE|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|June 2009|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|385|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039467||128647|
NCT01040026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK_MM_01|Expanded Natural Killer (NK) Cells for Multiple Myeloma Study|A Phase I/II Single Center Study to Assess Tolerability and Feasibility of Infusions of Allogeneic Expanded Haploidentical Natural Killer (NK) Cells in Patients Treated With High Dose Melphalan Chemotherapy and Autologous Stem Cell Transplantation for a Multiple Myeloma||University Hospital, Basel, Switzerland|No|Recruiting|December 2010|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||March 2016|March 14, 2016|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01040026||128604|
NCT01040338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809187|Effects of Nicotine on Brain Opioid Receptors|Functional Characterization of OPRM1 A118G in Nicotine Dependence: IV Nicotine Study||University of Pennsylvania|Yes|Terminated|February 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|15|Samples With DNA|The samples that shall be collected for this study are as follows:        1. A 2ml saliva sample will be collected for DNA extraction using the Oragene™ kit at the           Medical screening session for genetic analyses.        2. An additional saliva sample (~ 5ml) will be also be collected at Medical screening and           will be used to analyze baseline nicotine metabolites (i.e., cotinine and           3-hydroxycotinine).        3. All participants will provide two tubes of blood (10 ml each) to measure plasma           estradiol & cortisol levels before each PET scanning session. They will also provide           two tubes of blood (10 ml each) at the end of the scan to measure plasma nicotine and           cortisol levels.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|24 adult, non-treatment seeking smokers of European ancestry, reporting consumption of ≥10        cigarettes per day for at least the past 6 months.|July 2013|July 18, 2013|December 24, 2009|No|Yes|Issues & unreliability with [11C]Carfentanil production|No||https://clinicaltrials.gov/show/NCT01040338||128580|
NCT01029925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCA Breast NSCLC|Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)|A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer||Jonsson Comprehensive Cancer Center|Yes|Terminated|December 2009|November 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2013|January 14, 2016|December 9, 2009|Yes|Yes|DSMB determined, due to higher than expected risk/safety concerns, study should be closed.|No|April 2, 2013|https://clinicaltrials.gov/show/NCT01029925||129326|The greatest limitation in our study was early termination due to perceived lack of drug efficacy leading to small number of subjects analyzed.
NCT01030211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTSH ADEPT|Adult Dengue Platelet Study|Adult Dengue Platelet Study|ADEPT|Tan Tock Seng Hospital|Yes|Completed|January 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|372|||Both|21 Years|N/A|No|||August 2015|August 23, 2015|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01030211||129305|
NCT01030471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK81711|Supporting Treatment Adherence Needs in Diabetes|Supporting Treatment Adherence Needs in Diabetes: The STAND Study|STAND|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|13 Years|17 Years|No|||June 2011|June 21, 2011|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030471||129285|
NCT01030783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-09-301|A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma|A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)|TIVO-1|AVEO Pharmaceuticals, Inc.|Yes|Completed|December 2009|June 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|517|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030783||129261|
NCT01031056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09092009-3840|Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers|Collection of Biospecimen and Clinical Information in Patients With Gastrointestinal Cancers||Stanford University||Withdrawn|January 2010|January 2099|Anticipated|January 2099|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|Samples Without DNA|This study requires that we obtain archived tumor and normal tissue and blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with gastrointestinal cancer.|May 2012|May 24, 2012|December 10, 2009||No|Change in research focus|No||https://clinicaltrials.gov/show/NCT01031056||129240|
NCT01031316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810241|Patent Ductus Arteriosus (PDA) Screening Trial|The Role of Serial Echocardiography to Detect an Asymptomatic Patent Ductus Arteriosus (PDA) in Very Low Birth Weight (VLBW) Infants: A Pilot Randomized Controlled Trial||University of Pennsylvania|No|Completed|October 2009|August 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|88|||Both|N/A|72 Hours|No|||December 2013|December 31, 2013|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01031316||129221|
NCT01031329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111339|Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Turkey||GlaxoSmithKline||Withdrawn|November 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Middle ear fluid and urine.|Both|3 Months|5 Years|No|Non-Probability Sample|Subjects aged >= 3 months and < 5 years, diagnosed as having complicated acute otitis        media on routine clinical care in the study hospitals.|April 2015|April 9, 2015|December 10, 2009||No|Key aspects linked to sample management and analysis were not met during feasibility    assessment limiting the ability of the study to reach its objectives.|No||https://clinicaltrials.gov/show/NCT01031329||129220|
NCT01031602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0436|Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients|Assessment of the Prevalence of Sexual Dysfunction, Depression, and Anxiety in Underserved and Minority Patients With Gynecologic Cancers||M.D. Anderson Cancer Center|No|Completed|October 2007|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|160|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women seen at the Gynecologic Oncology Clinic at the Lyndon Baines Johnson (LBJ) General        Hospital and able to read and write either English or Spanish.|May 2013|May 24, 2013|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031602||129199|
NCT01031615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0504027679|Evaluation of the Child and Family Traumatic Stress Intervention|Evaluation of the Child and Family Traumatic Stress Intervention|CFTSI|Yale University|No|Completed|October 2005|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|112|||Both|7 Years|17 Years|No|||June 2011|June 14, 2011|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031615||129198|
NCT01031901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0259|Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)|Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1||The University of Texas Health Science Center, Houston|No|Completed|December 2009|June 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|52|||Both|13 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 24, 2012|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031901||129176|
NCT01028066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0443/07|Feeding Education in Patients Submitted to Coronary Angioplasty|Feeding Education in Patients Submitted to Percutaneous Transluminal Coronary Angioplasty: Randomized Clinical Trial|PTCA-Nutri|University of Sao Paulo General Hospital|No|Active, not recruiting|April 2008|January 2012|Anticipated|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|N/A|N/A|No|||December 2009|December 10, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028066||129468|
NCT01028079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11818|Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain|Placebo and Active Controlled, Double Dummy Phase III Study to Prove Efficacy of Aspirin (1000 mg Solid Dose) in Treatment of Acute Low Back Pain.||Bayer|No|Completed|November 2005|December 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|338|||Both|18 Years|70 Years|No|||December 2009|December 8, 2009|December 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028079||129467|
NCT01028898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS and metabolism|Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome|Screening and Identification of Abnormal Expression Proteins and miRNA From Colonic Mucosa of Patients With Irritable Bowel Syndrome.|IBS|Chinese PLA General Hospital|Yes|Active, not recruiting|January 2006|December 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|The investigators enrolled IBS-D and IBS-C patients on the Rome III criteria and healthy      volunteers as normal control group. Biopsies were taken from the cecum and sigmoid colon      under direct vision. Five pieces were taken separately at each site. Four pieces were      processed by cold saline water and frozen in liquid nitrogen immediately while the other one      was fixed in formalin and then embedded in paraffin three days later.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|IBS patients (IBS-D and IBS-C)and healthy control|December 2006|February 10, 2011|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028898||129404|
NCT01028911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8801016|A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease|A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy||Pfizer|No|Terminated|December 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|55 Years|85 Years|No|||May 2014|May 16, 2014|December 7, 2009|No|Yes|This study terminated 27Apr2010 due to slow recruitment and the need to use the existing    information to determine dosing for another study.|No|April 9, 2014|https://clinicaltrials.gov/show/NCT01028911||129403|The study was terminated early due to slow recruitment and the need to use the existing information to determine dosing for another study.
NCT01028625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201013037|Depression and Self-care in Heart Failure|Treatment of Functional Impairment in Patients With Heart Failure and Comorbid Depression|DASH|Washington University School of Medicine|Yes|Completed|January 2010|April 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|158|||Both|30 Years|N/A|No|||May 2014|May 27, 2014|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01028625||129425|
NCT01029470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700642-606|To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation|A Multicentre, Prospective, Open Study to Describe the Effects of rhLH Supplement in Women With Hyporesponse to rFSH After Pituitary Downregulation.||Peking University Third Hospital|No|Not yet recruiting|December 2009|March 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|20 Years|40 Years|No|||December 2009|December 9, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029470||129361|
NCT01040143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PneuCaSt|A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci|A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci|Pneucast|Public Health England|No|Completed|January 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|450|||Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community samples taken within the home of eligible subjects.|September 2010|September 2, 2010|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040143||128595|
NCT01038570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 071 03|Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo|Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study||University Hospital, Toulouse|Yes|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2010|January 6, 2010|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01038570||128715|
NCT01039753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912015R|Analysis of Clinical Outcomes in Patients Undergoing Acute Dialysis Therapy at Intensive Care Units|Analysis of Clinical Outcomes in Patients Undergoing Acute Dialysis Therapy at Intensive Care Units||National Taiwan University Hospital|No|Recruiting|January 2010|July 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Collect serum and urine sample for biomarkers at the following timing: start date of renal      replacement therapy, discontinuation date of renal replacement therapy, 7 days after      discontinuation date of renal replacement therapy. 10ml blood and 10ml urine will be      collected at each sampling|Both|18 Years|N/A|No|Probability Sample|Patients older than 18 years-old and admitted to intensive care units of National Taiwan        University Hospital|January 2010|January 28, 2010|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039753||128625|
NCT01040052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD532|A Study to Assess the Safety of Adacel® Vaccine|A Bridging Study to Assess the Safety of the Vaccine Adacel® in a Clinical Trial||Sanofi|No|Completed|December 2009|April 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|December 21, 2009|No|Yes||No|March 1, 2011|https://clinicaltrials.gov/show/NCT01040052||128602|
NCT01040039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECH-0675|Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV|Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV||Rockefeller University|No|Terminated|November 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|whole blood, mucosal samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|May 2013|May 16, 2013|November 19, 2009||No|Investigator left Rockefeller University|No||https://clinicaltrials.gov/show/NCT01040039||128603|
NCT01040351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hydrosalpinx1|Ultrasound Guided Aspiration of Hydrosalpingeal Fluid and IVF-ET Outcomes|Effect of Ultrasound Guided Aspiration of Hydrosalpingeal Fluid at the Time of Oocyte Retrieval on the Outcomes of IVF-ET, a Randomized Controlled Trial||Cairo University|Yes|Completed|October 2006|May 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|37 Years|No|||October 2010|July 29, 2011|December 28, 2009||No||No|May 10, 2010|https://clinicaltrials.gov/show/NCT01040351||128579|Several patients refused to participate in the study
NCT01029938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASC2|Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization|Comparative Study of Covered Stent With Coil Embolization in the Treatment of Cranial Internal Carotid Artery Aneurysm: A Nonrandomized Prospective Trial||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|April 2005|June 2010|Anticipated|September 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|10 Years|85 Years|No|||December 2009|July 22, 2010|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029938||129325|
NCT01030224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2690C00001|This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects|A Phase-1, Single Center, Double Blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 After Single Ascending Doses in Healthy Male and Female Subjects||AstraZeneca||Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|23 Years|45 Years|Accepts Healthy Volunteers|||March 2010|July 26, 2012|December 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030224||129304|
NCT01030237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-07-34|An Evaluation of the Safety and Efficacy of FID 114657|||Alcon Research|No|Completed|November 2009|||January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030237||129303|
NCT01030484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD Adult Database 2 (IND)|Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2|Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|October 2009|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|Samples With DNA|plasma, serum, liver tissue|Both|18 Years|N/A|No|Non-Probability Sample|adult patients with suspected or known non-alcoholic fatty liver disease (NAFLD) or        nonalcoholic steatohepatitis (NASH)-related cirrhosis of the liver|April 2015|April 15, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030484||129284|
NCT01030770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015559-25|Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:|Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: A Randomized, Double-masked, Controlled Study||King's College Hospital NHS Trust|No|Active, not recruiting|July 2010|May 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||January 2015|August 14, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030770||129262|
NCT01031069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109823|Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females|Safety and Immunogenicity of Cervarix™ in Human Immunodeficiency Virus Infected Females||GlaxoSmithKline||Active, not recruiting|October 2010|May 2017|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|649|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||February 2016|February 25, 2016|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031069||129239|
NCT01031082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112135|Study to Identify and Characterize Bacteria Causing Acute Otitis Media in South African Children|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in HIV-positive and HIV-negative Children in South Africa||GlaxoSmithKline||Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|265|Samples Without DNA|Middle ear fluid, nasopharyngeal aspirate and urine.|Both|3 Months|5 Years|No|Non-Probability Sample|Children aged >= 3 months and < 5 years seeking healthcare for the treatment of acute        otitis media.|May 2010|May 20, 2010|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031082||129238|
NCT01031342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-025014|Early Colonoscopy for Lower Gastrointestinal (GI) Bleeding|Early Versus Elective Colonoscopy in the Management of Lower Gastrointestinal Bleeding||University of Southern California|No|Terminated|August 2002|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|72|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|November 2, 2009||No|Change in ER rules (no longer allowed endoscopies in ER) prevented ability to perform study    according to protocol|No||https://clinicaltrials.gov/show/NCT01031342||129219|
NCT01031914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-0931-PBSW-SS|Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure (CPAP)|Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure Users Using Paced Breathing|PBSW|Philips Respironics|No|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Both|21 Years|70 Years|No|||April 2013|April 1, 2013|December 11, 2009||No||No|December 3, 2012|https://clinicaltrials.gov/show/NCT01031914||129175|
NCT01032174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661199|Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis|Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis|EASY|Pfizer|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|123|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Acute Maxillary Sinusitis|April 2012|April 10, 2012|December 14, 2009|Yes|Yes||No|February 21, 2012|https://clinicaltrials.gov/show/NCT01032174||129155|
NCT01028638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL28799.042.09|Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma|89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Everolimus; a Pilot Study|Everolimage|University Medical Center Groningen|No|Completed|December 2009|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|Samples With DNA|whole blood, white blood cells, plasma, serum, urine|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with metastatic renal cell carcinoma who will start treatment with        everolimus.|January 2015|January 27, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028638||129424|
NCT01039558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECURRENT GERD|The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease|Randomized Controlled Trial to Evaluate the Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease||Seoul National University Hospital|Yes|Completed|December 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 27, 2011|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039558||128640|
NCT01039571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-12-005|Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears|Prospective Randomized Case-controlled Blinded Study of Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears||Samsung Medical Center|No|Completed|January 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|71|||Both|N/A|N/A|No|Non-Probability Sample|Rotator cuff tear patients|April 2011|April 21, 2011|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039571||128639|
NCT01029171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H04-70171|Action Seniors! Exercise to Prevent Falls|"Action Seniors!: A 12 Month Randomized Controlled Trial of a Home Based Strength and Balance Retraining Program in Reducing Falls.||University of British Columbia|Yes|Recruiting|November 2009|July 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|344|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 8, 2014|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029171||129383|
NCT01040156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHT-1209|Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation|Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study||University Children’s Hospital Tuebingen|Yes|Completed|August 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|N/A|18 Years||Non-Probability Sample|Pediatric patients undergoing allogeneic stem cell transplantation|December 2009|December 28, 2009|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040156||128594|
NCT01040169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0308-SF-PROC-SEN-ED|Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction|Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction|Yeaple|Colgate Palmolive|No|Completed|May 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 15, 2013|September 27, 2008|Yes|Yes||No|September 27, 2008|https://clinicaltrials.gov/show/NCT01040169||128593|
NCT01040702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-40107|The Effect of Methylphenidate on Decision-making Ability of Attention Deficit Hyperactivity Disorder (ADHD) Adults|The Effect of Methylphenidate on Decision-making Ability of ADHD Adults||Shalvata Mental Health Center|Yes|Completed|January 2008|December 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|58|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2009|December 29, 2009|December 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01040702||128552|
NCT01038869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN0901|Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)|Efficacy and Safety of Finacea in the Treatment of Post-Inflammatory Hyperpigmentation and Acne Vulgaris||Derm Research, PLLC|No|Completed|December 2009|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|N/A|No|||August 2012|August 24, 2012|December 23, 2009|Yes|Yes||No|March 26, 2012|https://clinicaltrials.gov/show/NCT01038869||128692|This is an open-label study with a small number of subjects.
NCT01040065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-002|Distal Clavicle Resection With Rotator Cuff Repair|Distal Clavicle Resection of Symptomatic Acromioclavicular Joint Arthritis Combined With Rotator Cuff Tear. Prospective Randomized Trial||Samsung Medical Center|No|Recruiting|June 2008|March 2012|Anticipated|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|medium sized rotator cuff tears|June 2011|June 28, 2011|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01040065||128601|
NCT01039727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.U.N. B14320096694|Prerecorded Autosuggestion in Long-standing Pain Intervention|Prerecorded Autosuggestion in Long-standing Pain Intervention|PALPI|Free University Medical Center|No|Not yet recruiting|September 2011|December 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|July 15, 2011|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039727||128627|
NCT01039740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-08-092|Pharmacogenetic Study of Mirtazapine Response in Depressed Patients|Pharmacogenetic Study of Mirtazapine Response in Depressed Patients||Samsung Medical Center|Yes|Recruiting|February 2003|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|89 Years|No|||December 2015|December 30, 2015|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039740||128626|
NCT01040611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVA98-13|Effectiveness of Music Therapy|Effectiveness of Music Therapy on Anxiety, Depression and Physiological Responses for Inpatients of Tuberculosis|TMT|Taipei Medical University WanFang Hospital|No|Active, not recruiting|October 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|66|||Both|18 Years|65 Years|No|||November 2010|November 18, 2010|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01040611||128559|
NCT01040910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cannabis1|Cannabis for Inflammatory Bowel Disease|A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease||Meir Medical Center|No|Recruiting|January 2010|July 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|70 Years|No|||December 2011|December 15, 2011|December 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01040910||128536|
NCT01029951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A.06-2|Relative Effectiveness and Adverse Effects of Cervical Manipulation, Mobilisation and the Activator Instrument in Patients With Sub-acute Non-specific Neck Pain: a Pragmatic Randomised Trial|Neck Pain Comparative Study||Anglo-European College of Chiropractic|No|Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|64 Years|No|||July 2006|December 9, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029951||129324|
NCT01030497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0477|Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System|Feasibility Study for Detection of Cervical Lymph Node Metastases With a High-Resolution PET Imaging System in Patients With Known or Suspected Cancers of the Upper Aerodigestive Tract||M.D. Anderson Cancer Center|No|Completed|December 2009|||May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known or suspected primary cancer of the upper aerodigestive tract or        metastatic disease to cervical lymph nodes, over 18 years of age, and scheduled for        routine clinical imaging at the PET/CT facility.|May 2014|May 13, 2014|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030497||129283|
NCT01030796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011009 (completed)|Quitting Caffeine for Better Glucose Metabolism|Quitting Caffeine for Better Glucose Metabolism||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2011|February 3, 2011|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030796||129260|
NCT01031355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13468|Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium|Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 3 mg EV Without and With 0.451 mg Levomefolate Calcium and a Tablet Formulation Containing 0.451 mg Levomefolate Calcium in 42 Healthy Postmenopausal Women||Bayer|No|Completed|December 2009|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 18, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031355||129218|
NCT01031628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARC019|Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients|A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL||Sarcoma Alliance for Research through Collaboration|Yes|Terminated|January 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|5|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|December 11, 2009|No|Yes|Lack of feasibility secondary to slow accrual|No|June 12, 2013|https://clinicaltrials.gov/show/NCT01031628||129197|A decision was made to discontinue the SARC019 trial effective March 3, 2011, due to lack of feasibility secondary to slow accrual. Due to early termination of the study, no patients were analyzed.
NCT01032187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVTO-I|Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children|Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children|LVTO|University of Brasilia|No|Completed|October 2007|July 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|6 Months|12 Years|No|||March 2011|March 7, 2011|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032187||129154|
NCT01028092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVEROLD|mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation|mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation|EVEROLD|University Hospital, Brest|Yes|Completed|March 2009|July 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|327|||Both|60 Years|N/A|No|||July 2014|July 7, 2014|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028092||129466|
NCT01028339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSH versus mannitol|Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values|Mannitol Versus Hypertonic Saline to Treat Intracranial Hypertension After Severe Traumatic Brain Injury : a Comparative Study on the Effects on PtiO2 and Microdialysis Values||Direction Centrale du Service de Santé des Armées|No|Terminated|July 2008|December 2012|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|December 3, 2009||No|No patients enrolled during 2 years|No||https://clinicaltrials.gov/show/NCT01028339||129447|
NCT01039285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRU-09-02|Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia|Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia|CURDYS|Maternite Regionale Universitaire|Yes|Active, not recruiting|December 2009|December 2019|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|16 Days|No|||April 2015|April 7, 2015|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039285||128661|
NCT01039298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03090|Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL|Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS||University of British Columbia|Yes|Recruiting|January 2013|June 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|19 Years|N/A|No|||September 2014|September 8, 2014|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01039298||128660|
NCT01040182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 97-2321-B-038-002|Polymorphism of Estrogen Genes in Stroke|Polymorphism of Estrogen Genes in Stroke||Taipei Medical University WanFang Hospital|No|Recruiting|December 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|300|Samples With DNA|Buffy coat and plasma will be retained.|Both|N/A|N/A|No|Non-Probability Sample|A total of 300 incident ischemic stroke patients will be recruited in the program project.|December 2010|December 1, 2010|December 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01040182||128592|
NCT01039857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012/08|Does an Integrative Neuro-psychotherapy Program Foster the Adjustment in Depressed Stroke Patients? A Randomized Controlled Study.|Does an Integrative Neuro-psychotherapy Program Foster the Adjustment in Depressed Stroke Patients? A Randomized Controlled Study.||University of Bern|No|Terminated|January 2010|December 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|66 Years|No|||July 2015|July 8, 2015|December 24, 2009||No|Project end after 3 years; prolongation was rejected|No||https://clinicaltrials.gov/show/NCT01039857||128617|
NCT01039870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YTKim_PVB_Postthor Pain|The Effect of Paravertebral Block Using a Multi-orifice Catheter on Preventing Acute and Chronic Post-thoracotomy Pain|||Seoul National University Hospital|No|Completed|July 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|19 Years|80 Years|No|||February 2012|February 16, 2012|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039870||128616|
NCT01040715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNF-K-003|Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists|A Phase II, Randomized, Double-blind, Controlled Study to Evaluate the Immune Responses, Safety and Clinical Efficacy of Three Doses of Neovacs' TNF-Kinoid in Adult Patients With Rheumatoid Arthritis Who Have Relapsed Despite Anti-TNFα Biological Therapy||Neovacs|Yes|Completed|December 2009|September 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|70 Years|No|||September 2014|September 17, 2014|December 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01040715||128551|
NCT01030874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7278-R|Orthostatic Hypotension Treatment on Rehab Unit|Effect of Treatment of Orthostatic Hypotension on a Rehabilitation Unit||VA Office of Research and Development|Yes|Active, not recruiting|October 2011|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|99 Years|No|||February 2016|February 18, 2016|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030874||129254|
NCT01039480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRG_003_PW|Aspirin and Clopidogrel Resistance Study|Aspirin- and Clopidogrel-Resistance: Non-compliance and Other Contributing Factors||University Hospital, Basel, Switzerland|No|Completed|May 2010|October 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|82|Samples With DNA|blood samples for routine laboratory testing and platelet aggregometry blood samples for      pharmacogenetic analysis|Both|45 Years|N/A|No|Probability Sample|Patients with a prescription for aspirin and/or clopidogrel seeing their general        practitioner (GP) for any purpose|February 2012|February 8, 2012|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039480||128646|
NCT01040650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAM-0672|Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment|Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment||Rockefeller University|No|Terminated|August 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|23|Samples With DNA|Blood and urine|Both|40 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with statin associated myopathy and normal controls|August 2013|August 29, 2013|December 24, 2009||No|Principal Investigator left institution|No||https://clinicaltrials.gov/show/NCT01040650||128556|
NCT01040364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2009024|Internal Hernias After Laparoscopic Gastric Bypass|Incidence of Internal Hernias After Laparoscopic Roux-en-Y Gastric Bypass Over the Last Decade: 1997 to 2008|IHafterLRYGB|University of California, San Francisco|Yes|Completed|May 2009|July 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|220|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients presenting with internal hernia after different modifications of the mesenteric        closure technique after Primary Laparoscopic RYGB surgery from 1997-2009.|September 2013|September 23, 2013|December 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01040364||128578|
NCT01040624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0703 - PR05|Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer|A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma|PR05|University of Florida|Yes|Active, not recruiting|December 2009|January 2035|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Male|18 Years|N/A|No|||September 2015|September 29, 2015|December 24, 2009|Yes|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01040624||128558|
NCT01040637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067|A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation|A Phase 1/Phase 2, Randomized, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Effect on Opioid Analgesia of TD-1211 Administered Orally to Healthy Volunteers and to Assess the Safety, Pharmacokinetics, and Effect on Bowel Movements in Subjects With Opioid-Induced Constipation||Theravance Biopharma Antibiotics, Inc.|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|102|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01040637||128557|
NCT01041534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36720-E/A|Adjustable Gastric Band Survey Study|Data Investigation of Bariatric Surgery and Economic Savings: Adjustable Gastric Band (AGB) Survey Study|AGB|University of Washington|Yes|Active, not recruiting|July 2009|September 2012|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone adjustable gastric band (AGB) surgery between April 1, 2007        and July 1, 2008 at University of Washington Medical Center (UWMC) or other sites that        have been approved by our IRB (all within the Washington State area).|July 2012|July 3, 2012|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01041534||128490|
NCT01030250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08242|Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life|Adjuvant Therapy in Older Versus Younger Women With Breast Cancer: Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life||City of Hope Medical Center|Yes|Recruiting|July 2009|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Blood and Urine to be collected prior to commencement of chemotherapy|Both|18 Years|N/A|No|Non-Probability Sample|Patients with breast cancer receiving adjuvant chemotherapy at City of Hope Medical Center|October 2015|October 19, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030250||129302|
NCT01030263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001090|A Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies|A Prospective Randomized Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies With Random Biopsies in the Detection of Specialized Columnar Epithelium in Barrett's Esophagus||Mayo Clinic|No|Terminated|June 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|18|||Both|18 Years|N/A|No|||March 2010|March 24, 2010|December 7, 2009|No|Yes|The investigators left the institution.|No||https://clinicaltrials.gov/show/NCT01030263||129301|
NCT01030510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIVA_rocu|Study of Rocuronium Onset Time According to Remifentanil Infusion|The Effect of Remifentanil on the Onset Time of Rocuronium in Total Intravenous Anesthesia||Seoul National University Bundang Hospital|Yes|Completed|December 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|126|||Both|20 Years|65 Years|No|||December 2011|December 14, 2011|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030510||129282|
NCT01030523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-SHO-0002|Study on ASTRA TECH Implant System, Short Implants (OsseoSpeed™) Compared to Standard Length Implants (OsseoSpeed™) With Bone Substitution|Short Implants - An Alternative to Bone Grafting?||Dentsply Implants|No|Active, not recruiting|November 2009|February 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|75 Years|No|||January 2016|January 12, 2016|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030523||129281|
NCT01030809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP0901|Trial of a Treatment Algorithm for the Management of Crohn's Disease|A Cluster Randomized Controlled Trial of a Treatment Algorithm for the Management of Crohn's Disease|REACT|University of Western Ontario, Canada|No|Completed|January 2010|December 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1999|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030809||129259|
NCT01031641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910026|Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing|Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing||National Institutes of Health Clinical Center (CC)||Completed|November 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1499|||Both|18 Years|N/A|No|||July 2015|August 8, 2015|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031641||129196|
NCT01031654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04222009-2379|Marital Functioning Among Combat Veterans|Marital Functioning Among Combat Veterans||Stanford University||Recruiting|April 2008|April 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|A total of 10 couples (N=20) will be enrolled in the study. At least one of the marital        dyad will be an Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) veteran.|December 2009|December 10, 2009|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031654||129195|
NCT01031927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR96-IRB-75|N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)|Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study||China Medical University Hospital|Yes|Completed|June 2007|||February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||December 2009|December 24, 2009|December 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01031927||129174|
NCT01038414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA12165-8|Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence|Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence|EDC|Harvard University Faculty of Medicine|No|Recruiting|February 2008|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01038414||128727|
NCT01038713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01|Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction|A Prospective Randomized Trial of Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction||Dartmouth-Hitchcock Medical Center|Yes|Completed|December 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|94|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038713||128704|
NCT01038999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00905-50|Accelerated Aging, HIV Infection, Antiretroviral Therapies|Accelerated Aging, HIV Infection, Antiretroviral Therapies|EP 45|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|April 2009|March 2012|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 HIV1-infected naive patients (A group), apparied to 50 age- and sex-matched        seronegative control (C group) subjects and 100 HIV1-infected patients in first line of        antiretroviral therapy for at least 12 months (B group)|December 2012|December 26, 2012|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01038999||128683|
NCT01039883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114563|A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule|A Phase 1, Randomized, Open-Label, Crossover Safety and Pharmacokinetic Study of 400 mg Albaconazole as a Tablet Formulation Versus a Capsule Formulation in Healthy Subjects||GlaxoSmithKline|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039883||128615|
NCT01039896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_VCM_101|A Drug Interaction Study of SLM0807 and HKB0701 in Healthy Subjects|An Open-label, Randomized, Crossover Study to Evaluate the Safety and Pharmacokinetics After Multiple Administration of SLM0807 Alone and Multiple Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects||CJ HealthCare Corporation|No|Completed|June 2009|August 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 11, 2013|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039896||128614|
NCT01030341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK-GpCRC-3 GLUMIT-DG|Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis|Pilot Study of the Safety, Feasibility, and Potential Efficacy of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG)|GLUMIT-DG|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|May 2011|January 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|70 Years|No|||March 2016|March 18, 2016|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030341||129295|
NCT01040455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907053M|Lansoprazole for Subgroups of Functional Dyspepsia|Therapeutic Response to Lansoprazole Among Different Subgroups of Functional Dyspepsia: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial||National Taiwan University Hospital|Yes|Terminated|December 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|N/A|No|||April 2014|April 13, 2014|December 25, 2009||No|failure to recruit enough patients|No||https://clinicaltrials.gov/show/NCT01040455||128571|
NCT01030627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2.2|Treatment Approaches to Preeclampsia|Treatment Approaches to Preeclampsia||Gynuity Health Projects|No|Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Female|18 Years|N/A|No|||August 2011|August 10, 2011|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030627||129273|
NCT01039493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2009-1240|Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications|Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications||University of Wisconsin, Madison|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|40|||Both|18 Years|61 Years|No|Probability Sample|Patient Population: Patients ≥18 and <61 years old who were diagnosed with early cervical        cancer (stages I and II) at least 3 years prior to the interview. We cannot limit our        population to stage IB2 patients and meet our accrual goals due to the rarity of the        disease. Patients with stages I and II cervical cancer are included because they have the        potential to be exposed to the same treatment complications as patients with stage IB2        disease. Patients of all health statuses will be accepted.        Provider Population: Providers who care for patients with cervical cancer at the        University of Wisconsin, including: gynecologic oncologists, radiation oncologists,        physician's assistants and nurses. Providers must be ≥18 and <61 years old in any health        status.|September 2015|September 30, 2015|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039493||128645|
NCT01040403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.18|Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, 8 Treatments, 4 Periods, Incomplete Crossover Study to Determine the Optimal Free Dose Combination of BI 1744 CL and Tiotropium Bromide (Both Delivered by the Respimat® Inhaler) After 4 Weeks Once Daily Treatment in Patients With COPD||Boehringer Ingelheim||Completed|January 2010|||February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|233|||Both|40 Years|N/A|No|||June 2015|June 19, 2015|December 28, 2009||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01040403||128575|
NCT01040377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2009077|Laparoscopic Revision Gastric Bypass for Inadequate Initial Weight Loss|Laparoscopic Revision Gastric Bypass for Inadequate Initial Weight Loss After Gastric Bypass: Intermediate Results|IIWL|University of California, San Francisco|Yes|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|42|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients that underwent laparoscopic revision gastric bypass after previously failed        Roux-en-Y gastric bypass "RYGB" with an Inadequate initial weight loss "IIWL" pattern.|October 2009|December 28, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01040377||128577|
NCT01041261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAR1-BMC-CT|Effects of a Novel Dietary Intervention on Body Composition After Laparoscopic Gastric Bypass Surgery|Randomized, Pilot Study to Compare the Effects of a Novel Dietary Intervention With the Post-operative Standard of Care on Body Composition After Laparoscopic Gastric Bypass Surgery||MetaProteomics LLC|No|Terminated|September 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|7|||Female|25 Years|N/A|No|||January 2012|January 11, 2012|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01041261||128511|
NCT01041274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001342|DECIFER: Depression and Citalopram In First Episode Recovery|Citalopram in First Episode Schizophrenia|DECIFER|New York University School of Medicine|Yes|Active, not recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|16 Years|40 Years|No|||October 2015|October 6, 2015|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041274||128510|
NCT01030276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI (FWA00000190) 11/2008|Bright Light Therapy in Seasonal Affective Disorder (SAD)|Placebo-controlled, Double Blind RCT on the Efficacy of Bright Light Therapy in SAD|VAHAVA|University of Oulu|No|Recruiting|October 2009|April 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2009|December 10, 2009|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030276||129300|
NCT01030822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112909|Booster and Catch-up Vaccination With Vaccine GSK1024850A|Booster Vaccination With Pneumococcal Vaccine GSK1024850A in Primed Children and Catch-up Vaccination in Unprimed Children||GlaxoSmithKline||Completed|April 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|282|||Both|9 Months|18 Months|Accepts Healthy Volunteers|||July 2012|April 11, 2013|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030822||129258|
NCT01031108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114089|A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus|A Phase I, Randomized, Placebo-Controlled, Crossover Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2011|January 5, 2012|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031108||129236|
NCT01031095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYİEAH1|(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)|A RandomisED StUdy Comparing Standard Systemic Anticoagulation ThErapy to Low Dose Intracoronary Anticoagulation Therapy for Elective Percutaneous Coronary Intervention|REDUCED|Bursa Postgraduate Hospital|No|Completed|June 2009|June 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|80 Years|No|||December 2013|December 24, 2013|December 11, 2009||No||No|January 21, 2012|https://clinicaltrials.gov/show/NCT01031095||129237|The intraprocedural use of a heparinised flush was not controlled; however, given the maximum amount that was allowed to be used, this is not likely to have significantly affected the activated clotting times. .
NCT01031940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMAC-1|CMAC® Versus Airtraq® and Macintosh Laryngoscope in Difficult Tracheal Intubation.|Comparison of the CMAC® Device to the Airtraq® and the Macintosh Laryngoscope in Patients With Anatomical Characteristics Predictive of Difficult Tracheal Intubation.||University College Hospital Galway|No|Terminated|January 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||June 2012|June 17, 2012|December 14, 2009||No|Insufficient Recruitment. Findings of concurrent study in low risk population not supportive    of hypotheses in this study.|No||https://clinicaltrials.gov/show/NCT01031940||129173|
NCT01038427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70947201|A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Lek Pharmaceuticals) With NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis||Sandoz Inc.||Completed|December 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1103|||Both|12 Years|N/A|No|||December 2012|December 14, 2012|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038427||128726|
NCT01038440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-09005|Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells|Evaluation of the Relationships of Time and Dose of Eicosapentaenoic Acid and Stearidonic Acid to the Changes in Eicosapentaenoic Acid Levels in Red Blood Cells|NK|Solae, LLC|Yes|Completed|August 2009|August 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|137|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 15, 2012|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01038440||128725|
NCT01039311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14370|Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer|Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer|OCT|University of Oklahoma|Yes|Terminated|February 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Probability Sample|Patients ages 18-99 with the presence of of an endobronchial mass.|January 2013|January 31, 2013|December 11, 2009|Yes|Yes|Unable to enroll subjects|No||https://clinicaltrials.gov/show/NCT01039311||128659|
NCT01039584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-710|A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations|A Randomized Study Evaluating the Therapeutic Equivalence and Safety of Butoconazole Nitrate Vaginal Cream, 2% and Gynazole 1 (Butoconazole Nitrate) Vaginal Cream, 2%, Against a Vehicle Control in the Treatment of Vulvovaginal Candidiasis||Perrigo Company|No|Completed|February 2008|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|611|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 12, 2012|December 23, 2009|Yes|Yes||No|September 10, 2012|https://clinicaltrials.gov/show/NCT01039584||128638|
NCT01039597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORX102|Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Therapeutic Activity of ORE1001 in Subjects With Ulcerative Colitis||Ore Pharmaceuticals, Inc.|No|Recruiting|December 2009|June 2011|Anticipated|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||June 2011|June 7, 2011|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01039597||128637|
NCT01029782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGHQEII-0001|Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis|Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial||Kelowna General Hospital|No|Completed|May 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|19 Years|N/A|No|||January 2015|January 13, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029782||129337|
NCT01029795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13272|A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus|A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Terminated|February 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|70 Years|No|||November 2011|November 29, 2011|December 9, 2009|Yes|Yes|Terminated due to nonclinical safety findings|No|September 15, 2011|https://clinicaltrials.gov/show/NCT01029795||129336|Since Study GMAJ was terminated after enrolling only 38 participants with just 1 participant completing 12 weeks of treatment, only disposition, demographics, and safety data are reported.
NCT01030614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dxt-2009-01|Dexamethasone Improves Postoperative Symptoms After Laparoscopic Cholecystectomy|Dexamethasone Improves Postoperative Symptoms in Patients Undergoing Elective Laparoscopic Cholecystectomy: A Randomised Clinical Trial.|dxt|Instituto Mexicano del Seguro Social|No|Completed|January 2007|December 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|210|||Both|18 Years|79 Years|No|||January 2009|December 10, 2009|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030614||129274|
NCT01030913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-057|B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression|B-CLL Subgroups: Maturation Stage and Gene Expression||Northwell Health|No|Recruiting|December 1999|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|1248|Samples With DNA|Blood Cells, Bone Marrow|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Chronic Lymphocytic Leukemia Community Sample|October 2015|October 5, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01030913||129251|
NCT01039766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7128-AJW-CTIL|The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)|The Efficacy of the Proximate Administration of Oxytocin After a Traumatic Event in Preventing the Development of Post Traumatic Stress Disorder||Sheba Medical Center|No|Recruiting|February 2010|June 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|67 Years|No|||February 2010|February 7, 2010|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01039766||128624|
NCT01039779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRI-EX102-9805PI|Tai Chi Exercise in Older People|A Randomized Trial of Tai Chi Exercise on Reducing Falls in Older Taiwanese People||Taipei Medical University|Yes|Completed|January 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|456|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01039779||128623|
NCT01040416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC IRB No. 2008081|Endoscopic Therapy for Bleeding Marginal Ulcers After Gastric Bypass|Endoscopic Therapy for Actively Bleeding Marginal Ulcers: Our Experience After 7,020 Roux-en-Y Gastric Bypass Surgeries|BleedingMU|University of California, San Francisco|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|45|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with actively bleeding marginal ulcers after Roux-en-Y gastric bypass (RYGB)        surgery.|December 2009|December 28, 2009|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01040416||128574|
NCT01034826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNDP IGT study|Progression to Impaired Glucose Tolerance and Type 2 Diabetes in the Korean People-based KNDP Study|||Korea University Guro Hospital|Yes|Completed|February 2007|May 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|80 Years|No|Probability Sample|patients who vist the endocrinology department due to impaired fasting glucose or impaired        glucose tolerance, or both.|December 2009|June 8, 2010|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01034826||128952|
NCT01040923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-C102|Comparison of Digital Electronic Stethoscope to Computed Tomography (CT) Angiography in Detection of Coronary Artery Disease|Validation of the Cardiosond Sonospectrographic Digital Electronic Stethoscope in Diagnosing Coronary Artery Disease Versus CT Angiography||SonoMedica, Inc.|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|200|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be sourced from patients presenting themselves for cardiac CT        angiography who meet appropriate inclusion / exclusoin criteria.|June 2011|June 14, 2011|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01040923||128535|
NCT01040936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH-091228|Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients|Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention|ILLEPE-ACS|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|May 2010|November 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||February 2011|June 14, 2011|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01040936||128534|
NCT01040949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008540|En Pareja: A Latino Couples Intervention to Help Expectant Fathers Quit Smoking|En Pareja: A Latino Couples Intervention to Help Expectant Fathers Quit Smoking|Parejas|Duke University|No|Completed|September 2008|April 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|705|||Both|16 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 14, 2013|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01040949||128533|
NCT01041287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00013262|Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells|Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells in Subjects With Hypertension||Emory University|No|Completed|December 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|21 Years|80 Years|No|||December 2014|December 12, 2014|December 29, 2009|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01041287||128509|
NCT01030289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Borckardt_19429|The Effectiveness of Transcranial Direct Current Stimulation (tDCS) in Decreasing Food Cravings|The Effectiveness of tDCS in Decreasing Food Cravings||Medical University of South Carolina|No|Completed|October 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||December 2010|December 22, 2010|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030289||129299|
NCT01030536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP218|Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)|A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia||MedImmune LLC|No|Completed|March 2010|April 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|87|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030536||129280|
NCT01030549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRLAC-01|Latin American Multicenter Cardiovascular Magnetic Resonance Reference Study|Latin American Multicenter Cardiovascular Magnetic Resonance Reference Study||University of Campinas, Brazil|No|Completed|December 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|300|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy individuals|January 2015|January 2, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030549||129279|
NCT01031381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-01-RAD001BEV|Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer|Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital|RADBEV|University of Pittsburgh|Yes|Completed|September 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||April 2015|April 14, 2015|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031381||129216|
NCT01031394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F050820002|Frequency of Aerobic/Resistance Training in Older Women|Frequency of Aerobic/Resistance Training in Older Women|SWEET|University of Alabama at Birmingham|No|Completed|January 2004|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|105|||Female|60 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01031394||129215|
NCT01031667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0489|Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)|||Yonsei University|Yes|Completed|November 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|118|||Both|20 Years|N/A|No|||June 2011|June 16, 2011|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031667||129194|
NCT01031368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2335.00|Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia|Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients With AML||Fred Hutchinson Cancer Research Center|No|Completed|December 2009|||September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|70 Years|No|||August 2014|August 13, 2014|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01031368||129217|
NCT01042249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2009-069|Pelvic Floor Muscle Training(PFMT) on Lower Urinary Tract Symptoms (LUTS) in Men With Stroke|The Effect of Pelvic Floor Muscle Training on Lower Urinary Tract Symptoms (LUTS) in Men With Stroke||Glostrup University Hospital, Copenhagen|Yes|Active, not recruiting|February 2010|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 9, 2015|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042249||128436|
NCT01046487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALANGI-3 0804|Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate|Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)|PALANGI3|Centre Oscar Lambret|No|Completed|January 2009|February 2012|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046487||128114|
NCT01046448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-32/2009|The Cardiovascular Comorbidity in Children With Chronic Kidney Disease Study|The Cardiovascular Morbidity in Children With Chronic Renal Failure Study|4C|Heidelberg University|Yes|Recruiting|July 2009|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|650|Samples With DNA|serum, whole blood, urine, DNA, vessel biopsies,|Both|6 Years|17 Years|No|Probability Sample|650 children with CKD stage IIIb to V (GFR 10-45 ml/min/1.73m²). Children who reach        end-stage renal disease will be continuously followed while on renal replacement therapy.|January 2010|January 11, 2010|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01046448||128117|
NCT01046422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB117-003|Safety Study of BMS-770767 in Subjects With Type 2 Diabetes|A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin||Bristol-Myers Squibb|No|Completed|May 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|76|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01046422||128119|
NCT01046435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONDECYT 1061070|Effects of Periodontal Therapy on Systemic Inflammation|Effects of Periodontal Therapy on Markers of Systemic Inflammation in Subjects at Cardiovascular Disease Risk||University of Chile|Yes|Completed|March 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|35 Years|75 Years|No|||May 2006|March 24, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046435||128118|
NCT01042210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-JBV-PPM1|Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring|Genotype-phenotype Associations of Agouti-related Peptide (AgRP) in Postpartum Period in Preeclamptic and Non-preeclamptic Women and Their Offspring||Masaryk University|No|Completed|January 2005|December 2006|Actual|March 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|84|Samples With DNA|whole blood, umbilical blood|Female|18 Years|35 Years|No|Probability Sample|Patients of the Masaryk university afilliated hospital, Clinic of Obstetrics and        Gynecology,hospitalized due to preeclampsia or healthy women with uncomplicated        conception, pregnancy and delivery that came to give birth at the Clinic. Along with the        mothers, their offspring in included in the study. The study population originated from a        static region of the Czech Republic - South Moravia.|November 2009|January 4, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042210||128439|
NCT01043146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-1-01|Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide|A Single-Blind Placebo-Controlled Dose Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of Cor-1, An Anti-ß1 Receptor Antibody Cyclopeptide, in Five Different Strengths in Healthy Male Volunteers|COR-1-01|Corimmun GmbH|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|January 5, 2010|No|Yes||No|October 26, 2012|https://clinicaltrials.gov/show/NCT01043146||128368|
NCT01043094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.01US|Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers|A Study to Compare the Safety, Tolerability, and Pharmacokinetic Profile of a Single Oral Dose of Pitavastatin 4 mg in Adult Volunteers With Severe Renal Impairment Who Are Not Being Treated With Hemodialysis Versus Healthy Adult Volunteers||Kowa Research Institute, Inc.|No|Completed|December 2009|December 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 5, 2012|December 18, 2009|No|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT01043094||128372|
NCT01043393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS-0805|Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study|An Open Label, Safety/Efficacy Study to Assess the Potential for Adrenal Suppression Following Multiple Dosing With Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis||Taro Pharmaceuticals USA|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|January 4, 2010|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01043393||128350|
NCT01043705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-2009-2|TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD|Centurion and Citadel Studies of TYRX™ Anti-Bacterial Envelope and Custom Mesh for Prevention of Infection Following CIED Replacement With a CRT or ICD|Centurion|TYRX, Inc.|Yes|Completed|January 2010|May 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|1262|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone CIED replacement with an ICD or CRT, with or without (CRT        retrospective group only) an TYRX Anti-bacterial Envelope, at US medical centers.|October 2015|November 20, 2015|January 5, 2010|No|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT01043705||128326|This was a non-randomized study and did not have an active comparator.
NCT01043991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8042|Intracoronary Injection of Epo After Myocardial Infarct "Intra-CO-EpoMI"|Intracoronary Injection of Epo During Reperfusion in Patients Hospitalized for First Acute Myocardial Infarct STEMI||University Hospital, Montpellier|Yes|Completed|December 2008|October 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|80 Years|No|||October 2013|October 29, 2013|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01043991||128305|
NCT01044004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1896|Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue|A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue Undergoing Standard R-CHOP Chemotherapy or in Remission Following Chemo and/or Radiation||Washington University School of Medicine|Yes|Withdrawn|March 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044004||128304|
NCT01044264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC-501-601-727998|Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris||Perrigo Company|Yes|Completed|December 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|602|||Both|12 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 17, 2013|January 4, 2010|Yes|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT01044264||128284|
NCT01044277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 09-059|Oral Glutathione Supplementation on the Levels of Blood Glutathione|Effect of Oral Glutathione Supplementation on the Levels of Blood Glutathione and Markers of Oxidative Stress in Healthy Adults (Glutathione Supplementation and Health (GSH) Study)||Milton S. Hershey Medical Center|Yes|Active, not recruiting|February 2010|June 2015|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|61|||Both|30 Years|79 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044277||128283|
NCT01027962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC # 09-0637; Maine #3589|Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Psychosis (EOP)|Intensive Computerized Brain Training in Early Onset Psychosis-Pilot Phase||University of North Carolina, Chapel Hill|No|Completed|October 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|10 Years|19 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01027962||129475|
NCT01028222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107B2301|A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation|The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation|TEAM|Novartis||Completed|June 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 7, 2009|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01028222||129456|
NCT01028495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-0201-P2-A-07|A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer|A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer||Rexahn Pharmaceuticals, Inc.|Yes|Completed|May 2009|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028495||129435|
NCT01028508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0429|Prolonging Remission in Depressed Elderly (PRIDE)|Prolonging Remission in Depressed Elderly (PRIDE)|PRIDE|Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2010|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|247|||Both|60 Years|N/A|No|||September 2015|September 29, 2015|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028508||129434|
NCT01029327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353/2008c|Effects of Curcumin on Postprandial Blood Glucose, and Insulin in Healthy Subjects|||Skane University Hospital|Yes|Completed|June 2009|September 2009|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects recruited from the population in southern Sweden.|June 2009|December 8, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029327||129371|
NCT01029613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAP|Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers|Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers||Glostrup University Hospital, Copenhagen|Yes|Completed|December 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with rheumatoid arthritis according to the ACR criteria (1987) with high disease        activity starting TNF-alpha inhibitor|August 2015|August 18, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029613||129350|
NCT01029626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-091|Glasgow-Blatschford Score Validation in Digestive Hemorrhage|Glasgow-Blatschford Score Validation for Stratification of Patients With Digestive Hemorrhage||University Hospital, Geneva|No|Recruiting|October 2009|March 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|64|||Both|18 Years|N/A|No|||October 2009|December 9, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029626||129349|
NCT01045616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806070R|Evaluation of Refractive Status and Ophthalmological Problems of Prematurity|Evaluation of Refractive Status and Ophthalmological Problems of Prematurity||National Taiwan University Hospital|Yes|Completed|July 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|7 Years|9 Years|No|Non-Probability Sample|Children with premature birth history born between January 1, 1999 and December 30, 2001        in National Taiwan University Hospital|January 2010|January 8, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045616||128180|
NCT01045837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Celiac-Prednisolone|Effect of Addition of Short Course of Prednisolone to Gluten Free Diet in Naive Celiac Disease Patients|Effect of Addition of Short Course of Prednisolone to Gluten Free Diet and Gluten Free Diet Alone in the Recovery of Clinical, Histological and Immunological Features in Naive Adult Patients With Celiac Disease|CD|All India Institute of Medical Sciences, New Delhi|No|Completed|April 2009|August 2010|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|12 Years|N/A|No|||January 2012|January 18, 2012|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045837||128163|
NCT01045863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1651001|To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers|A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-03382792 After Administration Of Single Oral Doses To Healthy Adult Subjects||Pfizer|No|Terminated|February 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 3, 2010|January 8, 2010|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01045863||128161|
NCT01042262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120621|Maternal Oxygen Use During Delivery and Cord Blood Superoxide Dismutase|Maternal Oxygen Use During Delivery and Cord Blood Superoxide Dismutase: A Randomized Controlled Trial||George Washington University|No|Completed|February 2007|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2009|January 4, 2010|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01042262||128435|
NCT01042574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cleviprex Use In ICB Patients|The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy|The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Investigator Initiated Trial||Methodist Healthcare|No|Recruiting|May 2010|July 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042574||128411|
NCT01042223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boushahri Clinic|Laryngomalacia Exposed|Laryngomalacia Exposed||Boushahri Clinic Medical Center|Yes|Completed|January 2006|September 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1500|||Both|N/A|2 Years|Accepts Healthy Volunteers|Probability Sample|Primary care clinics|December 2008|July 16, 2010|December 1, 2008||No||No||https://clinicaltrials.gov/show/NCT01042223||128438|
NCT01042236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221064|Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients|A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Crossover Study Of The Efficacy Of Fesoterodine In Increasing Urethral Pressure In Stress Urinary Incontinence Patients.||Pfizer|No|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|65 Years|No|||July 2011|July 20, 2011|January 4, 2010|No|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01042236||128437|
NCT01042561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281-09|Vitamin D Status and Dose Response in Infants|Vitamin D Status and Dose Response in Infants||University of Nebraska|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|64|||Both|N/A|3 Months|Accepts Healthy Volunteers|||November 2011|November 7, 2011|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01042561||128412|
NCT01042860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061052|The Influence of Lutein Supplements on Age-related Macular Degeneration|The Influence of Lutein Supplements on Age-related Macular Degeneration||Maastricht University Medical Center||Completed|August 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|50 Years|80 Years|No|||January 2010|January 7, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042860||128390|
NCT01043744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CCID-5597|Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission|Treatment Outcomes for Non-malarial Febrile Illness in Children Aged 6-59 Months in Areas of Perennial Malaria Transmission||Centers for Disease Control and Prevention|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1000|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||March 2013|March 8, 2013|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043744||128323|
NCT01044043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREV_DERM_INTMED|Prevalence and Subjective Impairment of Quality of Life (QoL) Due to Dermatologic Diseases in Internal Medicine Patients|||University of Zurich|Yes|Completed|November 2009|December 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Prevalance and subjective inpairment of quality of life due to dermatologic deseases in        internal medicine patients|January 2011|January 10, 2011|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044043||128301|
NCT01043692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-AOO534-47|Acceptability of an Acupuncture Intervention in Painful Elderly|Acceptability of a Strategy Including Acupuncture in the Treatment of MusculoSkeletal Pain in Hospitalised Elderly|ACUPUNCTURE|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2007|December 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|60 Years|N/A|No|||June 2009|October 7, 2013|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01043692||128327|
NCT01043718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC32877|Delivering an Evidence-Based Lifestyle Intervention Via the Internet: A Randomized Controlled Study|Delivering an Evidence-Based Lifestyle Intervention Via the Internet: A Randomized Controlled Study||University of Pittsburgh|Yes|Completed|March 2010|December 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043718||128325|
NCT01043731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG09/151/2B|Laparoscopic Transvaginal Hybrid Anterior Resection: a Prospective Data Collection|||Cantonal Hospital of St. Gallen|No|Completed|September 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Female|18 Years|N/A|No|Non-Probability Sample|Given indication for laparoscopic anterior resection|July 2010|December 9, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043731||128324|
NCT01044017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22764|A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes|A Single-center, Double-blind, Randomized, Cross-over, Placebo-controlled, Single-dose Study to Investigate Glycemic Parameters of Efficacy During 24 Hours, Safety/ Tolerability and Pharmacokinetics of Two Dose Levels of RO4998452 in Patients With Type 2 Diabetes Mellitus||Hoffmann-La Roche||Completed|December 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|22|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01044017||128303|
NCT01044030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-09-0455|Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children|Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children||Children's Hospital Boston|Yes|Completed|February 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|326|||Both|6 Months|5 Years|No|||April 2015|April 8, 2015|January 6, 2010|Yes|Yes||No|March 10, 2015|https://clinicaltrials.gov/show/NCT01044030||128302|
NCT01013441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15408|CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia|Trial of Immune Reconstitution With CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia||University of Pennsylvania|No|Active, not recruiting|March 2009|March 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013441||130580|
NCT01028781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65681|Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis|Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis||University of North Carolina, Chapel Hill|Yes|Terminated|October 2006|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||December 2011|December 19, 2011|December 7, 2009|No|Yes|Difficulty finding eligible participants and lack of funding.|No||https://clinicaltrials.gov/show/NCT01028781||129413|
NCT01029054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2009.056|Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma|Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy||University of Michigan Cancer Center|Yes|Active, not recruiting|September 2009|June 2016|Anticipated|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|53|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|December 8, 2009|Yes|Yes||No|November 13, 2014|https://clinicaltrials.gov/show/NCT01029054||129392|
NCT01029340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12954|Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A|A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy|Leopold I|Bayer|Yes|Completed|December 2009|March 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|74|||Male|12 Years|65 Years|No|||July 2015|July 14, 2015|December 8, 2009|Yes|Yes||No|May 27, 2013|https://clinicaltrials.gov/show/NCT01029340||129370|
NCT01029639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-248|Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness|Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness||Florida Atlantic University|Yes|Terminated|January 2007|June 2012|Anticipated|January 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|400|||Both|20 Years|90 Years|No|||August 2009|December 9, 2009|August 6, 2009||No|Administrative|No||https://clinicaltrials.gov/show/NCT01029639||129348|
NCT01029665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006486|Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors|Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors|CDH|Duke University|No|Completed|September 2008|December 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|4 Years|6 Years|No|Non-Probability Sample|All infants with Congenital Diaphragmatic Hernia (CDH) born between 2001 and 2005 who were        managed at Duke University Medical Center will be eligible for inclusion in the study.|March 2013|March 7, 2013|November 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01029665||129346|
NCT01045629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09080|Competence Ability Study in People With Schizophrenia|Competence Ability Study in People With Schizophrenia|CompSchizo|Taichung Veterans General Hospital|Yes|Recruiting|October 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|90|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Schizophrenic patients and control; PANSS score; Macarthur comprehension evaluation        tool-clinical research Ed.|January 2010|January 13, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01045629||128179|
NCT01045850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTCIC-09-29|Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery|Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.|RECO|University Hospital, Grenoble|No|Completed|February 2006|January 2010|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1312|||Both|18 Years|N/A|No|Non-Probability Sample|patients with coronary stents undergoing non cardiac surgery or invasive procedures|January 2010|January 12, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045850||128162|
NCT01045642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMP/CR/070/0607|Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions|Open Label Balanced Randomized,Two-treatment,Two-period,Two-sequence,Single Dose,Crossover Oral Bioequivalence Study of Omeprazole Mg 20mg DR Capsules With Prilosec OTCTM 20mg in 38 Healthy,Adult,Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|December 2006|March 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045642||128178|
NCT01045876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH-1515-DA|The Effect of Dexamethasone on Cortisol Levels in Patients Undergoing Thyroid Surgery|The Effect of Dexamethasone on Plasma Cortisol Levels, Pain and PONV in Female Patients Undergoing Thyroid Surgery||St. Paul's Hospital, Canada|No|Recruiting|May 2010|February 2016|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Female|18 Years|N/A|No|||June 2012|June 5, 2012|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045876||128160|
NCT01046500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOMEN-2010|Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome|||University of Messina|No|Recruiting|January 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|50 Years|60 Years|No|||May 2014|May 19, 2014|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046500||128113|
NCT01046513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906364|PET Imaging of Nicotinic Acetylcholine Receptors|PET Imaging of Nicotinic Acetylcholine Receptors With 2-[18F]F-A-85380-Injection, Initial Evaluation of Radiotracer in Human Volunteers||National Institutes of Health Clinical Center (CC)||Completed|August 2007|September 2011||||N/A|Observational|N/A|||Anticipated|14|||Both|21 Years|45 Years|No|||September 2011|September 29, 2011|January 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01046513||128112|
NCT01046526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905398|fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia|fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia||National Institutes of Health Clinical Center (CC)||Completed|February 2005|May 2012||||N/A|Observational|N/A|||Anticipated|100|||Both|18 Years|50 Years|No|||May 2012|May 4, 2012|January 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01046526||128111|
NCT01042288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 183|Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC|A Phase II Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type Non-Small-Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|June 2010|July 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|December 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042288||128433|
NCT01042275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHKUZH10-2008|Patient-reported Outcome After Sling Insertion Using the Incontinence Outcome Questionnaire (IOQ)|Patient-reported Mid- and Long-term Outcome After Insertion of Retropubic and Transobturator Tapes Using the Incontinence Outcome Questionnaire (IOQ)||University of Zurich|No|Completed|March 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||5|Actual|628|||Female|18 Years|N/A|No|Non-Probability Sample|patients who were treated at 2 Swiss public teaching hospitals|April 2010|April 6, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042275||128434|
NCT01042886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24MD001660-03|PILI 'Ohana Project: Partnerships to Overcome Obesity Disparities in Hawaii (3-Year Pilot)|Partnerships to Overcome Obesity Disparities in Hawaii|PILI|University of Hawaii|Yes|Completed|February 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|277|||Both|18 Years|N/A|No|||January 2010|January 4, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042886||128388|
NCT01043107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CancerRe-008|Relationship Between Computer and Cancer|Study on the Relationship Between The Computer Radiation and The Recrudesce Rate of Thyroid Cancer||Guangdong General Hospital||Not yet recruiting|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|2000|||Both|10 Years|60 Years|No|Non-Probability Sample|The population of city of Guangdong province|January 2010|February 4, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043107||128371|
NCT01043120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200440 CS11|Effect of Oxytocin Antagonist on Reduction of Uterine Contractions|A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Trial in Oocyte Donors Assessing the Effects of Barusiban, a Selective Oxytocin Antagonist, on Uterine Contractions on the Day of Embryo Transfer|EFFORT|Ferring Pharmaceuticals|No|Completed|February 2010|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Female|18 Years|37 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043120||128370|
NCT01043432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7210-R|Executive Dysfunction and Suicide in Psychiatric Outpatients and Inpatients|Executive Dysfunction and Suicide in Psychiatric Outpatients and Inpatients||VA Office of Research and Development|No|Completed|June 2010|July 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|133|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants in this observational study will be all individuals willing and eligible        from the following populations: 1) those admitted to the locked inpatient psychiatric unit        at the Eastern Colorado Health Care System (ECHCS) Denver VA Medical Center (VAMC); 2)        those seeking outpatient mental health, rehabilitative, or psychological or other services        at the Denver VAMC or Colorado Springs Community Based Outpatient Clinic (CBOC) or other        CBOC's; 3) those in an ECHCS domiciliary (e.g., Valor Point); 4) those on existing        clinical and research databases; and 5) veterans in the community not seeking care within        the Veterans Health Administration (VHA).|April 2015|April 21, 2015|January 4, 2010||No||No|February 11, 2015|https://clinicaltrials.gov/show/NCT01043432||128347|Majority of control group had lifetime history of psychiatric disorders Significant challenges with recruiting
NCT01044303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080A-US78T|Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)|An Exploratory, Open-Label, Single Center Study to Assess the Efficacy and Dose Titration of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients||East Carolina University|No|Completed|January 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|No|||October 2014|October 16, 2014|January 6, 2010||No||No|August 27, 2014|https://clinicaltrials.gov/show/NCT01044303||128281|Lost to follow-up was a limitation in this study.
NCT01012388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1206248|Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color|Post-Marketing Study of Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color||Merz Pharmaceuticals, LLC|No|Completed|March 2007|February 2008|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 19, 2013|November 11, 2009|Yes|Yes||No|November 19, 2009|https://clinicaltrials.gov/show/NCT01012388||130661|
NCT01044615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mTBI|Advanced Imaging Tools in the Study of Mild Traumatic Brain Injury|Advanced Imaging Tools in the Study of Mild Traumatic Brain Injury|mTBI|Kettering Health Network|No|Completed|December 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients at Veteran's Administration Medical Center in Dayton, OH who have history of Mild        Traumatic Brain Injury within 24 months prior to enrollment.|January 2013|January 10, 2013|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044615||128257|
NCT01013168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-005|Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities|Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities|BP-005|BioPheresis GmbH|Yes|Terminated|August 2009|February 2011|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|November 4, 2009||No|Achievement of feasibility and safety without achievement of clinical response.|No||https://clinicaltrials.gov/show/NCT01013168||130601|
NCT01013454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051119|A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Patch Applied To The Skin|A Phase 1, Open-Label, Single Dose Study To Characterize The Pharmacokinetics Of A Varenicline (CP-526,555) Transdermal Delivery System Applied To The Skin Of Adult Smokers||Pfizer|No|Completed|December 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2009|December 18, 2009|November 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013454||130579|
NCT01028794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000001133|Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients|Phase 1/2A Study of Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Patients After Cerebral Embolism||National Cerebral and Cardiovascular Center|Yes|Completed|May 2008|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|75 Years|No|||July 2013|July 4, 2013|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028794||129412|
NCT01029067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT|Metacognitive Training in Schizophrenia|Metacognitive Training (MCT) Compared With Cognitive Remediation (CR) in Schizophrenia: a Randomized Controlled Study Over 4 Weeks|MCT|Universitätsklinikum Hamburg-Eppendorf|No|Completed|September 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||March 2015|March 2, 2015|December 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01029067||129391|
NCT01029353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0039|Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis|A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age|NEST|NICHD Neonatal Research Network|Yes|Recruiting|January 2010|July 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|8 Weeks|No|||November 2015|November 10, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029353||129369|
NCT01029366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04409|Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy|Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|July 2009|||July 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|December 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01029366||129368|
NCT01029964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BORIS|A Three-year Behavioral Treatment of Obese Children|A Three-year Behavioral Treatment of Obese Children: the Effect of Age on Change in BMI SDS and Dropout Rate||Karolinska University Hospital|No|Completed|January 1997|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1000|||Both|6 Years|16 Years|No|||January 1997|December 9, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029964||129323|
NCT01045655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH084897|MOMCare: Culturally Relevant Treatment Services for Perinatal Depression|For Moms: Culturally Relevant Treatment Services for Perinatal Depression|MOMCare|University of Washington|Yes|Completed|January 2010|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045655||128177|
NCT01046461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD1.0|Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer|A Phase II Study to Evaluate the Efficacy and Tolerability of Ramosetron, Aprepitant and Dexamethasone (RAD) in Preventing Cisplatin-induced Nausea and Vomiting in Chemotherapy-naïve Patients With Solid Cancer|RAD|Hallym University Medical Center|No|Active, not recruiting|January 2010|June 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|41|||Both|18 Years|75 Years|No|||February 2012|February 16, 2012|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046461||128116|
NCT01042613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACVEIN|A Comparison of the Success Rate Of Cannulation Between The Accuvein Apparatus And Standard Technique|A Comparison of the Success Rate Of Cannulation Between The Accuvein Apparatus And Standard Technique||St. Jude Children's Research Hospital|No|Completed|January 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|146|||Both|N/A|18 Years|No|||November 2011|November 2, 2011|January 4, 2010|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT01042613||128408|
NCT01042301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD07/5-A|Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes|Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes|Lymphoscreen|Nantes University Hospital|Yes|Completed|September 2007|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|120|||Both|7 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 7, 2015|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042301||128432|
NCT01042587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32704|Effect of Bright Light Treatment On Elders In a Long Term Care Environment|Effect of Bright Light Treatment On Elders In A Long Term Care Environment|BrightLights|Milton S. Hershey Medical Center|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2010|August 10, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042587||128410|
NCT01042899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B090010--01|Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions--Teen Online Problem Solving Study|Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions|RRTC--TOPS|Children's Hospital Medical Center, Cincinnati|Yes|Completed|March 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Both|11 Years|18 Years|No|||March 2016|March 7, 2016|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042899||128387|
NCT01042912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901M57884|Frequency Analysis of Carotid Artery Disease|A Single-centered Investigation Into the Frequency Domain Patterns in the Carotid Vessel in Patients With Suspected Stenosis||University of Minnesota - Clinical and Translational Science Institute|Yes|Withdrawn|May 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|40 Years|80 Years|No|Non-Probability Sample|Any inpatient or outpatient with inclusion criteria met and exclusion criteria not met        presenting for aniography to the University of Minnesota Fairview Hospital or Clinic in        Minneapolis or Redwing, Minnesota|September 2014|September 18, 2014|January 4, 2010||No|PI left inistitution|No||https://clinicaltrials.gov/show/NCT01042912||128386|
NCT01011764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G09-04-021-01A|Study of Peer Relationships at School|Autism Intervention Research Network on Behavior Health (AIR-B): Study of Peer Relationships at School|HRSAII|Health Resources and Services Administration (HRSA)|No|Completed|September 2009|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|7 Years|12 Years|No|||August 2012|August 14, 2012|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011764||130708|
NCT01011777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00026757|Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence|A Phase I Clinical Protocol to Study the Safety and Tolerability of Endoscopic Injection of Autologous Muscle Derived Cells (MDC) in Children With Exstrophy-epispadias Complex Related Urinary Incontinence|MDC|Johns Hopkins University|Yes|Not yet recruiting|July 2013|June 2017|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|N/A|No|||July 2013|July 1, 2013|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011777||130707|
NCT01011790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-002094|Evaluation of a Biofeedback-assisted Meditation Program as a Stress Management Tool for Hospital Nurses|Evaluation of a Biofeedback-assisted Meditation Program as a Stress Management Tool for Hospital Nurses: A Pilot Study||Mayo Clinic|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011790||130706|
NCT01043445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPR119|-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.|G Protein-coupled Receptor in the Intestine (GPR 119) Stimulated GLP-1 Secretion||Glostrup University Hospital, Copenhagen|No|Completed|September 2009|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|8|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01043445||128346|
NCT01043458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-108|Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia|A Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ABT-126 in Stable Subjects With Schizophrenia||Abbott|No|Completed|November 2009|||January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|55 Years|No|||September 2010|November 1, 2010|October 21, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01043458||128345|
NCT01012882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLG-2009-005B|Efficacy and Safety of Sublingual Immunotherapy (SLIT)|A Multicenter Randomized DBPC Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy (SLIT) With Allergen Extracts From Pollen in Patients With Seasonal Allergic Rhinitis||Roxall Medizin||Not yet recruiting|November 2016|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||November 2015|November 2, 2015|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012882||130623|
NCT01013129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000648179|Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives|Genetic Susceptibility, Environment & Prostate Cancer Risk||Portland VA Medical Center|No|Active, not recruiting|July 2008|||December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2250|Samples With DNA|10ml blood specimen drawn from probands consented in person at the Portland VA; saliva      samples from all consented probands; saliva samples from first degree relatives|Male|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Recontacting previously recruited Diet and Prostate Cancer Risk study participants;             cases and biopsy negative controls          2. Prospective recruitment of men referred for a prostate biopsy to the Portland VA             urology clinic          3. Men from the public sector who learn about our study and would like to participate|February 2013|February 21, 2013|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01013129||130604|
NCT01013142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-221-CL-010|Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase I Randomized, Double-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously to Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||MediciNova|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|40 Years|65 Years|No|||May 2015|May 12, 2015|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013142||130603|
NCT01009866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011617|Study of Immunotoxin, MR1-1|Phase I Study of Immunotoxin, MR1-1|MR1-1|Duke University|No|Terminated|November 2006|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|November 6, 2009|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01009866||130854|
NCT01009879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMGEN 2006_1112|Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants|Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants||University of Pittsburgh|No|Withdrawn|November 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 30, 2013|November 5, 2009|Yes|Yes|No subjects were enrolled|No||https://clinicaltrials.gov/show/NCT01009879||130853|
NCT01028807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|robdape2|Early Feeding vs 5-day Fasting After Distal Elective Bowel Anastomoses in Children. A Randomized Controlled Trial|Early Feeding vs 5-day Fasting After Distal Elective Bowel Anastomoses in Children. A Randomized Controlled Trial||Hospital Infantil de Mexico Federico Gomez|Yes|Completed|June 2003|November 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|1 Month|18 Years|No|||December 2009|December 9, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028807||129411|
NCT01029080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.435.08|Cerebrovascular Autoregulation During Sepsis|Dynamic Cerebrovascular Autoregulation During Sepsis and Sepsis-associated Delirium||Johannes Gutenberg University Mainz|No|Completed|December 2009|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|All patients at intensive care unit were screened to symptoms that definate sepsis|April 2013|April 12, 2013|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029080||129390|
NCT01029093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ref-Nr: StV 13-2009|Effects of Sensory and Motor Deprivation on Brain Plasticity|Effects of Sensory and Motor Deprivation on Brain Plasticity After Injury and Immobilisation of Right Upper Extremity||University of Zurich|Yes|Not yet recruiting|December 2009|December 2010|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with injury of right upper extremity|December 2009|December 7, 2009|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01029093||129389|
NCT01029379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progen1|Pharmacogenetics of Propofol and Depth of Anesthesia|The Effect of Pharamocogenetices on Anesthesia Induction With Propofol||University Hospital, Linkoeping|Yes|Completed|January 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|50 Years|No|Probability Sample|200 patients, ASA classification 1 planned for elective surgery of at least 30 minutes        duration|March 2013|March 1, 2013|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029379||129367|
NCT01029652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2356|Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study|A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week Double-blind Extension Study and an Open-label 48 Week Extension Study|β-RELIEVED|Novartis||Completed|December 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|85 Years|No|||September 2012|December 24, 2013|December 9, 2009|Yes|Yes||No|July 26, 2011|https://clinicaltrials.gov/show/NCT01029652||129347|Bioanalytical results: With analytical method used, anti-canakinumab antibodies were detected in 10 patients. However, no patients showed any unexpected PK/ PD profile nor had adverse events suggestive of immunogenicity.
NCT01029977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960-PRL-002|Imaging Modality Effects on the Multi-dimensional InfraRed Analysis (MIRA) Technology|||Real Imaging Ltd.|No|Withdrawn||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Female|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects arriving for a mammography or breast ultrasound|May 2015|May 4, 2015|December 9, 2009||No|Re-definition of MIRA technology goals.|No||https://clinicaltrials.gov/show/NCT01029977||129322|
NCT01045304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11418|Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer|Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibitor, SAR240550 (BSI-201), Administered Twice Weekly or Weekly, in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (mTNBC)||Sanofi|No|Completed|February 2010|November 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Female|18 Years|N/A|No|||January 2014|January 13, 2014|January 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045304||128204|
NCT01045317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1711001|A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body|An Exploratory, Open Label, Randomized, Parallel Group Study To Investigate The Pharmacokinetics Of Single Intravenous And Oral Micro Doses Of [14-C]-PF-04776548 In Healthy Male Subjects||Pfizer|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 1, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045317||128203|
NCT01046162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131021|A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions|An Open Label, Crossover, Randomized Study of Two Periods, Two Treatments, Two Sequences, and a Single Dose of Two Oral Drug Products of Alprazolam 2mg (Tafil ® 2 mg, Product of Pharmacia & Upjohn SA de CV vs Xanax ® 2 mg, Product of Pfizer Pharmaceuticals LLC) in Healthy Volunteers in Fasting Conditions||Pfizer|No|Withdrawn|July 2010|July 2010|Anticipated|July 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2010|August 5, 2010|January 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01046162||128138|
NCT01046175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-09326b|Effect of Air-stacking on Peak Cough Flow in Patients With Acute Cervical or High Thoracic Spinal Cord Injury|Effect of Two Different Air-stacking Techniques, Combined With Manually Assisted Cough, on Peak Cough Flow (PCF) in Patients With Acute Cervical or High Thoracic Spinal Cord Injury||Ullevaal University Hospital|No|Withdrawn|February 2010|June 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||December 2009|November 11, 2010|December 22, 2009||No|Lack of patients. Investigator changed job.|No||https://clinicaltrials.gov/show/NCT01046175||128137|
NCT01046188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFC01|Development of an Interactive Web-based Teaching Tool for in Vitro Fertilization (IVF) Patients|Development of an Interactive Web-based Teaching Tool for IVF Patients|WebIVF|Ottawa Fertility Centre|No|Recruiting|January 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Female|18 Years|N/A|No|||January 2010|January 14, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01046188||128136|
NCT01046474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS-PAPAS-project|Reducing Beverages and Sugar and Increasing Physical Activity in Public School Adolescents From Brazil|Preventing Excessive Weight Gain by Reducing Carbonated Beverage and Sugar Consumption and Increasing Physical Activity Among Public School Adolescents From the Metropolitan Area of Rio de Janeiro|PAPAS|Rio de Janeiro State University|No|Completed|February 2010|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|9 Years|15 Years|No|||July 2011|July 19, 2011|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046474||128115|
NCT01046565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10145|Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin||Galderma Laboratories, L.P.|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 15, 2011|January 8, 2010|Yes|Yes||No|February 28, 2011|https://clinicaltrials.gov/show/NCT01046565||128108|
NCT01042938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC1106|Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients|Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients||University of Rochester|Yes|Completed|January 2008|April 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Female|21 Years|N/A|No|||June 2012|June 19, 2012|January 4, 2010|No|Yes||No|January 26, 2012|https://clinicaltrials.gov/show/NCT01042938||128384|The primary limitation of this clinical study is the small sample size. This study was a pilot trial to generate an effect and sample size for a larger confirmatory trial. We accrued patients to this study until we had 30 fully evaluable patients.
NCT01042600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2599|Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation|Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation||Albany Medical College|Yes|Completed|December 2009|November 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|N/A|48 Hours|No|||June 2014|June 16, 2014|January 4, 2010|Yes|Yes||No|June 16, 2014|https://clinicaltrials.gov/show/NCT01042600||128409|
NCT01042925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD11439|Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen|A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen||Sanofi|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|No|||January 2013|January 14, 2013|January 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01042925||128385|
NCT01043471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2007-0342|The Effects of Gum Chewing on Energy Intake and Expenditure|The Effects of Gum Chewing on Energy Intake and Expenditure||University of Wisconsin, Madison|No|Completed|September 2008|January 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01043471||128344|
NCT01012401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2009-1223|Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer|Interactive Cancer Communication System (ICCS) in Lung Cancer: Evaluating Survival Benefits. Center of Excellence in Cancer Communication Research: Using Technology to Enhance Cancer Communication and Improve Clinical Outcomes||University of Wisconsin, Madison|Yes|Completed|November 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|284|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012401||130660|
NCT01044056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06650|A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)|An Open-label, Randomized, Parallel Group Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30)||Merck Sharp & Dohme Corp.|No|Completed|March 2004|June 2004|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Female|18 Years|40 Years|No|||June 2015|June 4, 2015|January 5, 2010|Yes|Yes||No|February 11, 2010|https://clinicaltrials.gov/show/NCT01044056||128300|
NCT01044290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-050|Outlook Quality of Life Intervention Study|Outlook: An Intervention to Improve Quality of Life in Serious Illness Study||VA Office of Research and Development|No|Completed|January 2011|April 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|221|||Both|18 Years|95 Years|No|||October 2015|October 19, 2015|January 5, 2010||No||No|February 23, 2015|https://clinicaltrials.gov/show/NCT01044290||128282|
NCT01012895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-011|Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care|Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected With Chronic Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|December 2009|February 2014|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|215|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012895||130622|
NCT01013155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERI-T8-PVFD-1|Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fed Conditions||Roxane Laboratories|No|Completed|May 2007|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 12, 2009|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01013155||130602|
NCT01028534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C359kyoto|Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA)|Comparison of the Effects of Different Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea||Kyoto University, Graduate School of Medicine|Yes|Completed|July 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|75 Years|No|||April 2015|April 1, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028534||129432|
NCT01028547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PONVDEX|Antiemetic Efficacy and Safety of Dexamethasone in Obstetric Surgical Patients|Antiemetic Efficacy and Safety of Dexamethasone in Patients Undergoing Caesarean Sections at Mulago Hospital||Makerere University|Yes|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|250|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028547||129431|
NCT01029106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVTSecur|Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)|Prospective, Non-Randomized, Observational, Multicentre, Study of the TVT Secur in the Surgical Management of Women With Stress Urinary Incontinence||Sunnybrook Health Sciences Centre|No|Terminated|September 2009|||September 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|125|||Female|18 Years|85 Years|No|Non-Probability Sample|Approximately 125 women with SUI from 5 centres across Canada will participate in this        study.|July 2011|July 27, 2011|October 19, 2009||No|Study design required a change in device|No||https://clinicaltrials.gov/show/NCT01029106||129388|
NCT01029119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Citizen - CH101|Clinical Test for Blood Pressure Meter of CH-101|Clinical Test of Blood Pressure Meter of CH-101||Citizen Systems Japan Co., Ltd.|No|Completed|August 2006|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|85|||Both|22 Years|84 Years|Accepts Healthy Volunteers|Probability Sample|Community sample|December 2009|December 8, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029119||129387|
NCT01029392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-189|Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D|Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D-A Pilot Study||William Beaumont Hospitals|No|Completed|November 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|75|||Both|1 Year|18 Years|No|||December 2014|December 9, 2014|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029392||129366|
NCT01029678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08011|Concomitant Radio-chemotherapy in the Elderly|Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC|RACCOSA|University Hospital, Limoges|Yes|Active, not recruiting|January 2010|June 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|70 Years|N/A|No|||March 2015|March 8, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029678||129345|
NCT01029691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F022873|Study of Positive Airway Pressure in Preeclampsia to Reduce Blood Pressure|Use of PAP in Women With Pre-eclampsia||University of Michigan|Yes|Completed|May 2009|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Female|14 Years|N/A|No|||August 2015|August 17, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029691||129344|
NCT01029990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCGbgSw0101|Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program|Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program||Göteborg University|No|Completed|September 2009|January 2011|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Screening|3||Actual|8800|||Female|29 Years|63 Years|No|||August 2012|August 29, 2012|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029990||129321|
NCT01030003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R000038|Snoring in Pregnancy and Adverse Maternal and Fetal Outcomes|The Impact of Sleep-Disordered Breathing on Adverse Pregnancy Outcomes||University of Michigan|No|Completed|January 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1685|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Eligible pregnant women are those receiving prenatal care and planning on delivering at        the University of Michigan.|March 2012|March 6, 2012|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01030003||129320|
NCT01045330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200803077R|a Modified NTU-HELP Program|Effect of the National Taiwan University Hospital Elder Life Program||National Taiwan University Hospital|Yes|Completed|August 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|304|||Both|65 Years|N/A|No|||May 2013|June 10, 2013|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045330||128202|
NCT01045902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10381|BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia|Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia||Bayer||Completed|February 2001|January 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||January 2010|January 8, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045902||128158|
NCT01045915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA2009/15/01|Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma|Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial|AMEP|Onxeo|Yes|Terminated|July 2010|January 2013|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|75 Years|No|||May 2012|September 10, 2015|January 8, 2010||No|The study has been halted due to the low enrolment rate.|No||https://clinicaltrials.gov/show/NCT01045915||128157|
NCT01046201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-034|Pediatric Obesity Research Registry|Pediatric Obesity Research Registry|PORR|Phoenix Children's Hospital|No|Withdrawn|January 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Whole Blood|Both|1 Year|18 Years|No|Non-Probability Sample|Obese patients up to age 18 years treated at Phoenix Children's Hospital|March 2011|October 19, 2015|January 7, 2010||No|To revise protocol for a more concise inclusion/exclusion criteria|No||https://clinicaltrials.gov/show/NCT01046201||128135|
NCT01011283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7373-A001-401|To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.|A Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of DACOGEN (Decitabine) for Injection and VIDAZA (Azacitidine) for Injection In Subjects With Intermediate or High Risk Myelodysplastic Syndromes (MDS)||Eisai Inc.||Terminated|November 2009|||January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|November 5, 2009|Yes|Yes|The study was stopped due to insufficient enrollment.|No|July 14, 2013|https://clinicaltrials.gov/show/NCT01011283||130745|
NCT01011543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B07620096009|Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis|Comparison of Induced Sputum and Bronchoscopic Approach (BAL, Fluoroscopy-guided Transbronchial Biopsies) in Patients Suspected of Pulmonary Tuberculosis With Negative Direct Exam on Three Consecutive Non-induced Sputum Samples||Centre Hospitalier Universitaire Saint Pierre|No|Recruiting|August 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|154|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01011543||130725|
NCT01011270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDM - 0012009|Rehabilitation of Dynamic Muscle, Back Pain and Postural Balance|Rehabilitation of Dynamic Muscle, Back Pain and Postural Balance of Industrial Operators|RDM|Universidade Castelo Branco|No|Enrolling by invitation|July 2009|November 2009|Anticipated|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|82|||Male|40 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|The sample consisted of industrial operators, individuals with low back pain, referred to        the industry of Physical Therapy. After the screening criteria of inclusion and exclusion,        82 individuals|November 2009|November 10, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011270||130746|
NCT01043172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATCO-1|A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection|A Phase II Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection||National Cancer Center, Korea|No|Active, not recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043172||128367|
NCT01043185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9120C00032|A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience|A Double-blind, Placebo Controlled, Randomised, Phase IIA Pharmacodynamic 4-way Cross-over Study to Estimate the Dose Response Relationship of AZD3355 on the Number of Reflux Episodes Assessed by Impedance/pH in Patients With GERD and a Partial Response to PPI Treatment||AstraZeneca|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|27|||Both|18 Years|70 Years|No|||May 2011|May 13, 2011|December 22, 2009|Yes|Yes||No|April 8, 2011|https://clinicaltrials.gov/show/NCT01043185||128366|
NCT01043484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-08-05|Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer|Phase II Randomized Study to Compare Capecitabine + Bevacizumab Concomitantly With Radiotherapy Versus Capecitabine Concomitantly With Radiotherapy, as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer|AVAXEL|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Active, not recruiting|December 2009|March 2016|Anticipated|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2015|March 23, 2015|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01043484||128343|
NCT01043497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCT-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2010|||||N/A|N/A|N/A||||||||||||||January 12, 2016|January 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01043497||128342|
NCT01012908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANBER0609|Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Active, not recruiting|March 2010|June 2011|Anticipated|April 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||November 2009|October 26, 2010|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012908||130621|
NCT01012076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G07-02-055-03|Promoting Development in Toddlers With Communication Delays|Promoting Development in Toddlers With Communication Delays||Autism Speaks|No|Completed|April 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|15 Months|30 Months|No|||June 2012|June 13, 2012|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01012076||130685|
NCT01012622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015481|An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children With ADHD (FOSCO)||Janssen Korea, Ltd., Korea|No|Completed|September 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|142|||Both|6 Years|12 Years|No|||February 2014|February 17, 2014|November 5, 2009|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT01012622||130643|
NCT01012635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36127-B|Chronic Pain and Brain Activity in Spinal Cord Injury|Cortical Modulation of Chronic Pain||University of Washington|Yes|Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|85 Years|No|Probability Sample|Subjects may be referred by their personal physician or enrolled after seeing recruitment        flyers or brochures. Subjects will be recruited from a previous survey study conducted by        the principal investigator, as well as a data registry maintained by the principal        investigator. Individuals recruited from these studies were recruited primarily from        rehabilitation clinics.|January 2013|January 14, 2013|October 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01012635||130642|
NCT01013805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 09.01|Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer|A Phase II Trial of Integrated Preoperative Radiotherapy and Chemotherapy With Oxaliplatin 5-FU and Folinic Acid in Patients With Locally Advanced Rectal Cancer|PROArCT|Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|November 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01013805||130553|
NCT01014104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-005|Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome|Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome in In-vitro Fertilization Cycles: A Randomized Controlled Trial||Royan Institute|Yes|Completed|October 2009|December 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|218|||Female|18 Years|35 Years|No|||November 2009|July 14, 2011|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01014104||130530|
NCT01014117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114009|Effect of SRT2104 on Endotoxin-induced Inflammation|A Phase I Study to Evaluate Single and Multiple (Seven) Oral Doses of SRT2104 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects||GlaxoSmithKline|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|41|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01014117||130529|
NCT01028560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI# 2007-280|Allergy Immunotherapy for the Reduction of Asthma|Efficacy of Allergy Immunotherapy in Preventing Asthma Morbidity in Atopic, Wheezing Children (Age 18 Months - 3 Years)|AIR|Albert Einstein College of Medicine of Yeshiva University|Yes|Suspended|October 2008|||April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Months|3 Years|No|||June 2015|June 29, 2015|December 7, 2009|Yes|Yes|No evidence of clinically meaningful benefits for asthma (reduction of asthma medication    scores and symptoms) in preliminary analysis|No||https://clinicaltrials.gov/show/NCT01028560||129430|
NCT01028573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|976|A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy|A Randomized, Controlled, Single-Blind Study Comparing the Efficacy, Tolerability and Safety of PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy||Southern California Institute for Research and Education|No|Recruiting|November 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Anticipated|400|||Both|18 Years|80 Years|No|||March 2012|March 12, 2012|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028573||129429|
NCT01029132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-04-021|Characteristics of Treatment Responders to Galantamine|Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease||Samsung Medical Center|Yes|Completed|April 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|N/A|N/A|No|||January 2016|January 4, 2016|December 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01029132||129386|
NCT01029405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-PSR-203|Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis|A Double-Blind,Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment B, 2% and 0.5%, Versus Ointment B Vehicle in the Treatment of Patients With Plaque Type Psoriasis|AN2728PSR203|Anacor Pharmaceuticals, Inc.|No|Completed|November 2009|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|145|||Both|18 Years|N/A|No|||February 2011|February 9, 2011|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01029405||129365|
NCT01029418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-20-HEP|AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma|A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma||National Cancer Centre, Singapore|No|Terminated|November 2009|January 2015|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|N/A|No|||April 2015|April 14, 2015|December 9, 2009||No|The phase II portion was not conducted due to funding issue.|No||https://clinicaltrials.gov/show/NCT01029418||129364|
NCT01029431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02199|Evaluation of the Intubating Laryngeal Airway in Children|Evaluation of the Intubating Laryngeal Airway in Children - Phase 2||University of British Columbia|No|Completed|December 2009|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|N/A|16 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029431||129363|
NCT01029704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-1442-C-402|Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus|A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Type 2 Diabetic Subjects||Theracos|Yes|Completed|December 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|70 Years|No|||July 2013|July 27, 2013|December 9, 2009|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT01029704||129343|
NCT01030302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015814|A Retreatment Study With Bortezomib for Multiple Myeloma|An Observational, Prospective Analysis of Retreatment With Bortezomib for Multiple Myeloma||Janssen Korea, Ltd., Korea|Yes|Completed|November 2008|September 2010|Actual|September 2010|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|N/A|No|Non-Probability Sample|Among patients who are scheduled to be re-treated with bortezomib for the recurrence of        multiple myeloma and who have submitted a written informed consent to provide their        personal data in relation to their former, prescribed use of bortezomib for the treatment        of multiple myeloma in Korea.|March 2013|March 7, 2013|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01030302||129298|
NCT01045889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ema2_LNH e HIV|High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk|First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at "High Risk", Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation|HDT-HIV|Azienda Ospedaliera Spedali Civili di Brescia|Yes|Active, not recruiting|January 2007|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|60 Years|No|||January 2016|January 5, 2016|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045889||128159|
NCT01045928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2409|Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma|Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma||Case Comprehensive Cancer Center|Yes|Terminated|January 2010|March 2012|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|January 8, 2010|Yes|Yes|Extreme toxicity in Phase I, study did not proceed to Phase II|No||https://clinicaltrials.gov/show/NCT01045928||128156|
NCT01042314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-008|Drug-Drug Interaction Study With Aricept® (Donepezil)|A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects||Bristol-Myers Squibb|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|55 Years|No|||April 2010|January 24, 2011|December 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01042314||128431|
NCT01011569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP trial|Comparison of Cage Versus Plate in One Level Cervical Disc Disease|Randomized Controlled Trial of Cage Versus Plate in One Level Cervical Disc Disease||Seoul National University Hospital|Yes|Completed|April 2004|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|20 Years|70 Years|No|Probability Sample|patient who needs surgery due to cervical disc disease|May 2014|May 13, 2014|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011569||130723|
NCT01011556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12641|A Study for the Transdermal Application of Teriparatide|A Phase 2 Study for Transdermal Application of Teriparatide||Eli Lilly and Company|Yes|Completed|November 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|233|||Female|55 Years|80 Years|No|||September 2012|September 21, 2012|November 9, 2009|Yes|Yes||No|September 21, 2012|https://clinicaltrials.gov/show/NCT01011556||130724|
NCT01011517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nature's Pearl - 01|Muscadine Grape Seed Supplementation and Vascular Function|Effect of Muscadine Grape Seed Supplementation on Vascular Function in Subjects With or at Risk for Cardiovascular Disease: A Randomized Crossover Trial||Wake Forest Baptist Health|No|Completed|June 2007|September 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2009|November 10, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011517||130727|
NCT01011530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C15005|Dose Escalation Study of MLN4924 in Adults With Melanoma|A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma||Millennium Pharmaceuticals, Inc.|No|Completed|December 2009|January 2013|Actual|May 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|November 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011530||130726|
NCT01012089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2375|Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease|Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease||University of Oklahoma|Yes|Completed|November 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|12 Years|17 Years|No|||December 2014|December 2, 2014|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01012089||130684|
NCT01013818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1029-C1080|A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies|A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies||Human Genome Sciences Inc.|No|Terminated|October 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|November 3, 2009|No|Yes|Terminated due to slow accrual|No||https://clinicaltrials.gov/show/NCT01013818||130552|
NCT01013831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00750|Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung|A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung||National Cancer Institute (NCI)||Terminated|October 2009|June 2013|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|40 Years|79 Years|No|||April 2014|February 17, 2015|November 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013831||130551|
NCT01013181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATU Romiplostim registry|Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults||ATU-r|Henri Mondor University Hospital|Yes|Completed|January 2008|August 2009|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Patients with primary Immune Thrombopenia receiving romiplostim in a compasionnate program|November 2009|November 16, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013181||130600|
NCT01013480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22002|An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome|An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome||Seaside Therapeutics, Inc.|No|Terminated|November 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|6 Years|40 Years|No|||March 2011|December 19, 2012|November 12, 2009|Yes|Yes|all active subjects rolled into 209FX303/NCT01013480|No||https://clinicaltrials.gov/show/NCT01013480||130577|
NCT01013792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-011091|A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers|A Multi-centered, Prospective, Randomized, Double-blinded, Comparison of an Investigational Non-adherent Dressing to 3M Tegaderm Matrix Dressing With PHI Technology in the Management of Non-healing Diabetic Foot Ulcers||3M|No|Terminated|November 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|November 13, 2009||No|Expired study materials; low subject recruitment|No|March 2, 2015|https://clinicaltrials.gov/show/NCT01013792||130554|Early termination leading to small numbers of subjects analyzed
NCT01010256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111245|The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia|The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia||University of Arkansas|No|Recruiting|November 2009|||January 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|During routine clinic visits, staff will present the option of participating in this        clinical trial to eligible patients with a diagnosis of CMML. Also, healthy control        patients will be asked to participate. The healthy control patients can be the subject's        family members, friends, or volunteers.|February 2016|February 25, 2016|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010256||130824|
NCT01028820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090795|FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders|Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms|AripfMRI|University of North Carolina, Chapel Hill|No|Completed|August 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|10 Years|55 Years|No|||February 2014|February 7, 2014|December 4, 2009|No|Yes||No|November 7, 2012|https://clinicaltrials.gov/show/NCT01028820||129410|The present study had 13 subjects. Due to sample size, analysis reflected an exploratory approach. If a mechanism for predicting RRB improvement is found in a study with a larger N, we could better understand therapies targeting core symptoms of ASD.
NCT01028833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2480|Effects of Power Mobility on Young Children With Severe Motor Impairments|Effects of Power Mobility on the Development and Function of Young Children With Severe Motor Impairments||University of Oklahoma|No|Completed|November 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|14 Months|30 Months|No|||January 2016|January 13, 2016|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028833||129409|
NCT01029145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NRO-SER-2009/1|Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR|Non-interventional Study to obSERve currENt Management of Index Episode in Patients With Bipolar Disorder Treated bY Seroquel XR||AstraZeneca|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|537|||Both|18 Years|N/A|No|Probability Sample|The programme will include patients with bipolar disorder currently experiencing a manic,        mixed or depressed episode( named in the protocol the index episode) treated with Seroquel        XR for 1 week|September 2010|September 16, 2010|December 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01029145||129385|
NCT01029743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14793|Xarelto Regulatory Post-Marketing Surveillance|Xarelto® Regulatory Post-Marketing Surveillance||Bayer|No|Completed|December 2009|May 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3451|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Patients who will be treated with rivaroxaban or other pharmacologic agents (e.g.        LMWH/VKA/Fondaparinux) to prevent VTE after elective total hip replacement or total knee        replacement|May 2015|May 25, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029743||129340|
NCT01029717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08EB20|CATCH - Catheter Infections in Children|A Randomised Controlled Trial Comparing the Effectiveness of Heparin Bonded or Antibiotic Impregnated Central Venous Catheters (CVCs) With Standard CVCs for the Prevention of Hospital Acquired Blood Stream Infection in Children||Institute of Child Health|No|Not yet recruiting|January 2010|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1200|||Both|N/A|16 Years|No|||December 2009|December 9, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029717||129342|
NCT01045681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFM2009-01|Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma|A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy|BVD|Intergroupe Francophone du Myelome|Yes|Active, not recruiting|January 2010|June 2013|Anticipated|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|65 Years|N/A|No|||March 2012|March 28, 2012|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045681||128175|
NCT01046539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33-008|Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults|A Phase 1 Study to Evaluate the Pharmacodynamics of RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults||National Institute on Drug Abuse (NIDA)||Completed|January 2010|July 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|55 Years|No|||July 2010|July 29, 2010|January 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01046539||128110|
NCT01046552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERCP123|Comparison Between Pre and Intraoperative ERCP in Treatment of Common Bile Duct Stones|Preoperative Versus Intraoperative Endoscopic Sphincterotomy for Management of Choledocholithiasis and Cholecystolithiasis||Mansoura University|Yes|Completed|June 2006|September 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|210|||Both|12 Years|80 Years|No|||September 2009|January 11, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01046552||128109|
NCT01012427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-108|Percutaneous Renal Tumor Cryoablation Followed by Biopsy|Percutaneous Renal Tumor Cryoablation Followed by Biopsy||Memorial Sloan Kettering Cancer Center||Completed|November 2009|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|21 Years|N/A|No|||January 2016|January 4, 2016|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012427||130658|
NCT01011816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR-BX01-2007|Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System|A Multicenter, Randomized, Blinded, Saline-Controlled Trial of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System||Spinal Restoration, Inc.|Yes|Terminated|March 2010|May 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|November 9, 2009|Yes|Yes|Stopped prior to last subject's last extended follow-up visit (78 weeks) due to lack of    efficacy at the primary study endpoint (26 weeks)|No|April 2, 2014|https://clinicaltrials.gov/show/NCT01011816||130704|
NCT01012102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200032-001|EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors|An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors||Merck KGaA|No|Completed|April 2008|September 2011|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|N/A|No|||October 2011|February 19, 2014|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01012102||130683|
NCT01011803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004079-05|Correlation of Phonation With Deglutition and Aspiration Risk in the ICU Patients - an Exploratory Study|Correlation of Phonation With Deglutition and Aspiration Risk in the ICU Patients - an Exploratory Study||Mayo Clinic|No|Completed|November 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Screening|1||Actual|60|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011803||130705|
NCT01012648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BURN|Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury|||University of Zurich||Recruiting|November 2009|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|48|||Both|16 Years|N/A|No|||March 2011|March 15, 2011|October 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01012648||130641|
NCT01009918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0806|Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab|Phase II Placebo-controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin®)||University of South Florida|Yes|Active, not recruiting|March 2010|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|468|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 6, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01009918||130850|
NCT01014130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 09.02|Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)|A Randomised Phase III Trial of Highly Conformal Hypofractionated Image Guided ("Stereotactic") Radiotherapy (HypoRT) Versus Conventionally Fractionated Radiotherapy (ConRT) for Inoperable Early Stage I Non-small Cell Lung Cancer (CHISEL)|CHISEL|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Active, not recruiting|December 2009|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|January 18, 2016|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01014130||130528|
NCT01009892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODE-T60-PVFS/FD-1|Food Effect Study of Codeine Sulfate|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Codeine Sulfate Tablets Under Fasting and Fed Conditions||Roxane Laboratories|No|Completed|January 2008|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009892||130852|
NCT01009905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGH-2149|An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)|Registry of Patients Being Treated With Norditropin®, Recombinant Human Growth Hormone|ANSWER|Novo Nordisk A/S|No|Enrolling by invitation|June 2002|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|18000|||Both|N/A|N/A|No|Non-Probability Sample|Patients from both general and specialty practice settings, existing and new users of        growth hormones, who have been deemed appropriate to receive Norditropin® as part of        routine out-patient care by the prescribing physician.|December 2015|January 12, 2016|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01009905||130851|
NCT01010243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM03|Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial|Third-line Therapy of Multiple Myeloma With Lenalidomide in Combination With Pioglitazone, Dexamethasone and Metronomic Low-dose Chemotherapy With Treosulfan|MM03|University of Regensburg|Yes|Recruiting|October 2009|October 2016|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||May 2012|May 29, 2012|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010243||130825|
NCT01010776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013744|A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone|A Study to Evaluate Switching From Risperidone to Paliperidone ER (Extended Release) in the Treatment of Stable But Symptomatic Schizophrenia Outpatients: Patients Satisfaction and Quality of Life||Janssen-Cilag Farmaceutica Ltda.|No|Completed|February 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|223|||Both|18 Years|60 Years|No|||September 2013|September 17, 2013|November 5, 2009|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT01010776||130784|
NCT01010789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cephalon_001|Armodafinil in Binge Eating Disorder (BED)|||Lindner Center of HOPE||Completed|November 2009|May 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||May 2015|May 13, 2015|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010789||130783|
NCT01028599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2009-004|Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients|Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients||Rigshospitalet, Denmark|No|Completed|September 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|N/A|N/A|No|||October 2015|October 26, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028599||129427|
NCT01028846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-414|Central Mechanisms That Regulate Glucose Metabolism in Humans|Central Mechanisms That Regulate Glucose Metabolism in Humans||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|May 2011|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|60 Years|No|||July 2014|July 10, 2014|December 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028846||129408|
NCT01029444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-66 BUD|Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes|Effects of Pulsatile Intravenous Insulin on Brittle Diabetes and Glucose Control||Florida Atlantic University|Yes|Terminated|March 2007|March 2012|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|August 6, 2009||No|Administrative|No||https://clinicaltrials.gov/show/NCT01029444||129362|
NCT01029730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 66|Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma|Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma||SCRI Development Innovations, LLC|No|Active, not recruiting|March 2010|March 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|December 8, 2009|Yes|Yes||No|November 19, 2015|https://clinicaltrials.gov/show/NCT01029730||129341|
NCT01030575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0036-2|Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)|Phase II Randomized, Double-Masked, Placebo-Controlled, Safety, Pharmacokinetic, and Dose-Ranging Study of Multiple Doses of Inositol in Premature Infants|INS-2|NICHD Neonatal Research Network|Yes|Completed|January 2010|September 2013|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|125|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||July 2015|July 27, 2015|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030575||129277|
NCT01030588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PerMIT:Warfarin UofL|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2009|||||N/A|N/A|N/A||||||||||||||December 10, 2009|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030588||129276|
NCT01030016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP-06/06356-8|Study of Atenolol Influence on Blood Pressure During Resistance Exercise|Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers||University of Sao Paulo|Yes|Completed|May 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|10|||Both|30 Years|60 Years|No|||May 2009|December 14, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01030016||129319|
NCT01030835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909444|Screening Protocol for the Evaluation of Research Participants at the Maryland Psychiatric Research Center (MPRC)|Screening Protocol for the Evaluation of Research Participants at MPRC||National Institutes of Health Clinical Center (CC)||Completed|May 2009|April 2012||||N/A|Observational|N/A|||Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|September 26, 2015|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01030835||129257|
NCT01030848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKN-001|Time-dependent Improvement of Functional Outcome Following LCS Rotating Platform TKR|Time-dependent Improvement of Functional Outcome Following LCS Rotating Platform TKR - A Prospective Longitudinal Study With Repetitive Measures of KOOS||Martina Hansen's Hospital|No|Active, not recruiting|February 2003|September 2013|Anticipated|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|40 Years|85 Years|No|Probability Sample|Consecutive patients operated with total knee arthroplasty at Martina Hansens Hospital|December 2009|December 14, 2009|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01030848||129256|
NCT01045694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1146517|Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint|Botulinum Toxin Versus Steroid Injection for Basal Joint Arthritis of the Thumb: a Randomized, Double Blind, Placebo-controlled Clinical Trial||University of Missouri-Columbia|Yes|Completed|March 2011|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|January 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045694||128174|
NCT01045941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00031399|Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma|Phase II Study of Adjuvant Gemcitabine Started One Week After Laparoscopic||Sidney Kimmel Comprehensive Cancer Center|Yes|Not yet recruiting|January 2010|January 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|90 Years|No|||January 2010|January 7, 2010|December 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045941||128155|
NCT01010711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOM-DS-CH-1|Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents|Study for Documentation of the Influence of a Specific Dietary Supplement Treatment of Migraine in Children and Adolescents||Complen Health GmbH|Yes|Recruiting|November 2009|April 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||February 2010|February 1, 2010|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010711||130789|
NCT01010724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPIRED ALS-001-2005|Efficacy and Safety Study on bIAP|A Randomized, Double-Blind, Placebo Controlled Study of Biap, an Endotoxin Detoxificating Moiety, in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass|APPIRED|Catharina Ziekenhuis Eindhoven|Yes|Completed||||||Phase 3|Interventional|N/A|2||||||Both|18 Years|N/A|No|||November 2009|November 9, 2009|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010724||130788|
NCT01046227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912031R|Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients|Antibody Titer Analysis Afer Monovalent Vaccination in Pediatric Haemato-oncology Patients||National Taiwan University Hospital|Yes|Recruiting|December 2009|June 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum for serology of H1N1 antibody Nasopharyngeal or oropharyngeal swab for Novel H1N1 PCR|Both|6 Months|18 Years|Accepts Healthy Volunteers|Probability Sample|This study is designed to investigate the antibodies titers before and after the novel        H1N1 influenza vaccination in pediatric haemato-oncology patients.|December 2009|January 8, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046227||128133|
NCT01045785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912018R|Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient|Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient||National Taiwan University Hospital|No|Active, not recruiting|December 2009|July 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Dialysis patients which follow-up at least monthly at National Taiwan University Hospital|December 2009|January 8, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045785||128167|
NCT01045798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-067|Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)|MSG-04 (Also Known as Merck Caspofungin Protocol 067): A Pilot, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Empirical Therapy for Invasive Candidiasis in High-Risk Patients in the Critical Care Setting||Merck Sharp & Dohme Corp.|Yes|Terminated|December 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|January 7, 2010|Yes|Yes|Low participant enrollment: 15 enrolled of 114 planned|No|March 26, 2013|https://clinicaltrials.gov/show/NCT01045798||128166|This study was terminated early due to low participant enrollment.
NCT01012661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0408329|Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler|Evaluation of Pain With the Use of Lidocaine-Mixed Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds||Merz Pharmaceuticals, LLC|No|Completed|September 2008|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 19, 2013|November 10, 2009|Yes|Yes||No|December 3, 2009|https://clinicaltrials.gov/show/NCT01012661||130640|
NCT01012115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14849|Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis|Temporal Behavior of Coagulation Factors,Cytokines and Tissue Injury Markers in Sepsis: Validation of Extracellular Histones|Histone|University of Oklahoma|No|Completed|October 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the ICU with suspected or proven sepsis.|April 2012|April 5, 2012|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01012115||130682|
NCT01012414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09C.110|Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease|The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D|VINCA-CKD|Thomas Jefferson University|No|Terminated|January 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|November 11, 2009|Yes|Yes|Futility in enrollment as of May 31, 2011|No|May 30, 2013|https://clinicaltrials.gov/show/NCT01012414||130659|Early termination secondary to enrollment futility.
NCT01013194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRRB/01/06|Human Fetal Liver Cell Transplantation in Chronic Liver Failure|Human Fetal Liver Cell Transplantation for Treatment of Chronic Liver Failure|hFLCTx|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|Yes|Completed|February 2007|July 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|70 Years|No|||October 2015|October 2, 2015|November 11, 2009||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01013194||130599|Using a single gynecology unit we had only a 22% rate of fetal donation, necessarily limiting the availability of hFLCs. Our strict inclusion criteria limited the pool of potential patients to enroll.
NCT01010269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.RROW1|Vanguard Complete Knee Versus Vanguard High Flex Rotating Platform (RP) Knee Study|A Prospective Controlled Multi-center Study on Vanguard Complete Knee and Vanguard High Flex RP Knee||Biomet, Inc.|No|Active, not recruiting|October 2009|October 2021|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||July 2015|July 20, 2015|October 26, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01010269||130823|
NCT01010516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia|Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia||University of Ioannina|No|Recruiting|October 2009|||December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|No|||November 2009|August 9, 2011|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010516||130804|
NCT01043302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-09-060|Multicenter Cross Sectional Study of Primary Intestine Lymphoma|Multicenter Cross Sectional Study of Primary Intestine Lymphoma: Treatment Outcome and Quality of Life||Samsung Medical Center|Yes|Completed|September 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|545|||Both|15 Years|85 Years|No|Probability Sample|University hosptial, general hospital, Cancer institute|July 2010|July 27, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01043302||128357|
NCT01043601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT0051002|Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control|A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled, Multi-dose, Four-period, Cross-over Study of Two Doses of Formoterol Fumarate MDI (PT005; 7.2 and 9.6 µg Ex-actuator), Administered Twice Daily for 1 Week in Patients With Moderate to Very Severe COPD, Compared to Open Label Marketed Formoterol Fumarate Inhalation Powder (Foradil® Aerolizer®, 12 µg) as an Active Control||Pearl Therapeutics, Inc.|No|Withdrawn|July 2010|April 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|40 Years|80 Years|No|||July 2014|July 9, 2014|January 5, 2010|Yes|Yes|Similar data obtained in another study [see NCT01085045], therefore study not implemented.|No||https://clinicaltrials.gov/show/NCT01043601||128334|
NCT01028859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127ASC09E|Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers|Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-516 in Patients With Advanced Solid Cancers Failed to Standard Therapy||Chong Kun Dang Pharmaceutical|Yes|Completed|December 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|75 Years|No|||December 2009|December 20, 2011|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01028859||129407|
NCT01028872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8547|Spherical Aberration and Contrast Sensitivity Function in Eyes Implanted With Spherical and Aspheric Intraocular Lenses: A Clinical Trial|||hahid Beheshti University of Medical Sciences||Completed||||||Phase 4|Interventional|N/A|3||||||Both|55 Years|75 Years||||September 2006|December 8, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028872||129406|
NCT01030315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-HM10760A-101|A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects|A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics and Pharmacokinetics of Single Intravenous Doses of HM10760A in Healthy Adult Caucasian and Japanese Subjects|EPO|Hanmi Pharmaceutical Company Limited|Yes|Completed|October 2009|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|65|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01030315||129297|
NCT01040975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016206|Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight|Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight|TeenCHAT|Duke University|No|Completed|September 2009|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|684|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01040975||128531|
NCT01041300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015-09-SHA|The Effects of Trancranial Magnetic Stimulation Multichannel Stimulator on Motor Excitation|The Effects of Trancranial Magnetic Stimulation Multichannel Stimulator on Motor Excitation||Shalvata Mental Health Center|Yes|Completed|January 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01041300||128508|
NCT01041586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAPOR-US|Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction|US Pilot Safety and Feasibility Study of Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction in Patients With Heterogeneous Emphysema With Upper Lobe Predominance|BTVA|Uptake Medical Corp|Yes|Completed|December 2009|August 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|40 Years|75 Years|No|||February 2012|February 21, 2012|December 22, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01041586||128486|
NCT01046214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1668|Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions|A Multiple-Dose, Double Blind, Double Dummy, Comparative Bioavailability Study of Two Formulations of Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Terminated|January 2010|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|8|||Both|25 Years|N/A|No|||November 2015|November 19, 2015|January 8, 2010|Yes|Yes|Recruitment issues|No||https://clinicaltrials.gov/show/NCT01046214||128134|
NCT01045954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCC 02-09|A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections|A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections||Diabetes Care Center|No|Recruiting|January 2010|October 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2010|January 8, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045954||128154|
NCT01011010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0902|Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC)||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|July 2009|November 2016|Anticipated|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011010||130766|
NCT01010997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORESEE HOME- 02|Foresee Home for Monitoring Age Related Macular Degeneration (AMD)|Foresee Home for Monitoring Age Related Macular Degeneration (AMD)|Foresee Home|Notal Vision Ltd|Yes|Completed|December 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10|||Both|50 Years|N/A|No|Probability Sample|AMD subjects|July 2012|July 30, 2012|November 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01010997||130767|
NCT01045564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112576|Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure|Safety and Immunogenicity of GSK 15574484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure||GlaxoSmithKline||Withdrawn|January 2011|February 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 19, 2015|January 7, 2010|Yes|Yes|Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|No||https://clinicaltrials.gov/show/NCT01045564||128184|
NCT01045577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04029|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis||AB Science|No|Completed|September 2005|February 2008|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||January 2010|January 8, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045577||128183|
NCT01013493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292|Association Between Breastfeeding and Likelihood of Myopia in 6-7 Years Old Children|Association Between Breastfeeding and Likelihood of Myopia in 6-7 Years Old Children||National Nutrition and Food Technology Institute|Yes|Completed|September 2008|June 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|245|||Both|6 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study is a retrospective case-control trial, in which subjects for case and control        groups will be chosen based on inclusion and exclusion criteria, from 6-7 years old school        children living in north Tehran.|December 2009|December 1, 2009|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013493||130576|
NCT01012921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 07/07|Comparison of a PEG Membrane and a Collagen Membrane for the Treatment of Bone Dehiscence Defects at Bone Level Implants|Straumann® MembraGel Comparison of a PEG Membrane and a Collagen Membrane for the Treatment of Bone Dehiscence Defects at Bone Level Implants||Institut Straumann AG|No|Completed|September 2009|December 2015|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012921||130620|
NCT01014143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2007-PLA-15-RR|Evaluating Commercial Anti-Plaque Products and Oral Rinse|Evaluating Commercial Anti-Plaque Products and Oral Rinse||Colgate Palmolive|No|Completed|August 2007|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|26|||Both|23 Years|81 Years|Accepts Healthy Volunteers|||June 2011|June 10, 2011|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT01014143||130527|
NCT01046643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AG031951-01A1|Early Menopause Hormone Treatment and Cognition|Hormones and Cognitive Processing in Early Postmenopausal Women|R21|University of Michigan|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|30|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|January 11, 2010|Yes|Yes||No|February 2, 2013|https://clinicaltrials.gov/show/NCT01046643||128102|
NCT01046656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152/2009|L Reuteri for the Prevention of Nosocomial Diarrhea|Efficacy of Lactobacillus Reuteri DSM 17938 in the Prevention of Nosocomial Diarrhea in Children. Randomized Double-blind Placebo Controlled Trial|PND|Medical University of Warsaw|Yes|Completed|December 2009|July 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|106|||Both|1 Month|48 Months|No|||December 2009|January 27, 2012|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01046656||128101|
NCT01042418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPM537|Appetite Profile After Intake of Rye Breakfast Meal|Appetite Profile After Intake of Rye Breakfast Meal||Swedish University of Agricultural Sciences|No|Completed|October 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|50|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2010|January 4, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042418||128423|
NCT01042431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0057-09-HYMC|Nutrition Day in Hospitals, Nursing Homes and Community. Israel January 2010|||Hillel Yaffe Medical Center||Not yet recruiting|January 2010|January 2010|Anticipated|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized in Orthopedic B' Ward|January 2010|January 4, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042431||128422|
NCT01042691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-135|Isolated Liver Perfusion With Oxaliplatin|A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases||University of Pittsburgh|Yes|Completed|May 2003|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|January 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01042691||128402|
NCT01042704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-089|Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma|Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma||University of Pittsburgh|Yes|Completed|February 2008|March 2015|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01042704||128401|
NCT01042717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 09-0824|Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection|Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection||Shi, Patricia, M.D.|No|Recruiting|February 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||September 2011|September 26, 2011|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042717||128400|
NCT01043913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mairapaschoin|Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue|Guaraná ("Paullinia Cupana") for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study||Faculdade de Medicina do ABC|No|Completed|February 2008|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||November 2009|January 6, 2010|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01043913||128311|
NCT01029158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1006-0100|A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo|A Double-blind, Placebo Controlled, Randomised Trial to Compare the Efficacy of 250ng and 500ng RN1006 (a New Formulation of Avotermin) and 250ng and 500ng Juvista (Standard Avotermin Formulation), in the Improvement of Scar Appearance in Healthy Volunteer Subjects|RN1006|Renovo|No|Completed|August 2009|November 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Anticipated|84|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01029158||129384|
NCT01029756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI PentaxAWS 10|Randomised Controlled Trial of Intubation, Comparing Pentax AWS Against Macintosh Laryngoscope.|A Randomised Controlled Trial of Intubation by Inexperienced Anaesthetists, Comparing the The Pentax Airway Scope AWS-S100 Rigid Video Laryngoscope(Pentax AWS) and the Macintosh Laryngoscope.|PAWS|NHS Grampian|No|Not yet recruiting|January 2012|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 15, 2011|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029756||129339|
NCT01040689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.39|Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease|Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced, Expiratory Volume After 1 Second (FEV1) Time Profiles of BI 1744 CL 5µg and 10µg (Oral Inhalation, Delivered by the Respimat® Inhaler) and Tiotropium Bromide 18µg (Oral Inhalation, Delivered by the HandiHaler®) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|January 2010|||January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|108|||Both|40 Years|N/A|No|||May 2014|May 28, 2014|December 29, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01040689||128553|
NCT01041599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4154|Correlation of Albuminuria With Arterial Stiffness|Assessment of the Association Between Albuminuria and Arterial Stiffness in Diabetic Patients, Hypertensive Patients and Healthy Controls||Istanbul University|No|Recruiting|October 2009|February 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|456|Samples Without DNA|Serum and urine samples.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with diabetes, patients with hypertension and healthy subjects|June 2011|June 22, 2011|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041599||128485|
NCT01041859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016051|A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy|A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating the Efficacy, Safety, and Tolerability of Tapentadol Extended-Release (ER) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|December 30, 2009|Yes|Yes||No|March 8, 2012|https://clinicaltrials.gov/show/NCT01041859||128466|
NCT01041872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/22|Comparison of Different Propofol Formulations|Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Lidocaine|Propofols|Hopital Foch|No|Completed|December 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|210|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01041872||128465|
NCT01010477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA024640-01A1|Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia|Double-Blind, Placebo-Controlled Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia||Rutgers, The State University of New Jersey|Yes|Completed|August 2009|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|November 6, 2009||No||No|March 6, 2014|https://clinicaltrials.gov/show/NCT01010477||130807|small sample size
NCT01045967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B046530|Lansoprazole 30 mg DR Capsule Fasting Study|A Relative Bioavailability Study of Lansoprazole 30 mg DR Capsules Under Fasting Conditions.||Teva Pharmaceuticals USA||Completed|May 2004|July 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 22, 2010|January 8, 2010||Yes||No|February 22, 2010|https://clinicaltrials.gov/show/NCT01045967||128153|
NCT01010464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043289|An Adhesion Reduction Plan in the Management of the Surgical Open Abdomen|Effect of an Adhesion Reduction Plan on Enteric Adhesions, Obstruction, and Fistulae in the Management of the Surgical Open Abdomen: A Prospective, Randomized Clinical Trial in Trauma and Emergency General Surgery||University of Maryland|Yes|Not yet recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2010|October 2, 2010|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010464||130808|
NCT01011829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-18185-PII-3|Varenicline vs Placebo for the Treatment of Methamphetamine Dependence|A Randomized, Double-blind Trial of Varenicline Versus Placebo, in Conjunction With Cognitive Behavioral Therapy, for Methamphetamine Dependence|RAVEN|University of California, Los Angeles|Yes|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|November 9, 2009|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT01011829||130703|Limitations in funding resulted in a small number of subjects enrolled.
NCT01011842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0028|Real-Time kV Imaging vs. Real-Time 3D Patient Surface Tracking for Head & Neck Cancer|Comparison of Intrafraction Motion in Patients With Head and Neck Cancer Using Real-Time kV Imaging vs. Real-Time 3D Patient Surface Tracking||Stanford University|Yes|Terminated|October 2009|November 2011|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011842||130702|
NCT01011296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0141001|First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers|A Randomized, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group, First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers||Pfizer|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 14, 2010|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01011296||130744|
NCT01012128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600687|Comparison of Three Methods of Taking Temperatures in the Newborn Intensive Care Unit|Comparison of Temporal Artery, Axillary, and Rectal Temperatures in Preterm Infants in the NICU||Christiana Care Health Services|No|Withdrawn|January 2010|December 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|N/A|6 Months|Accepts Healthy Volunteers|Probability Sample|Preterm infants corrected to 30-35 weeks gestation|April 2015|April 3, 2015|November 9, 2009||No|Closed: logistical problems that could not be resolved.|No||https://clinicaltrials.gov/show/NCT01012128||130681|
NCT01046058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016783|TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435|A Phase I, Open-label, Sequential Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of TMC435 in Subjects With Moderately or Severely Impaired Hepatic Function||Tibotec Pharmaceuticals, Ireland|Yes|Completed|January 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|January 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01046058||128146|
NCT01046071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-plp-09|The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy|The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy: A Randomized Controlled Trial||Glostrup University Hospital, Copenhagen|Yes|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||November 2011|November 17, 2011|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046071||128145|
NCT01013506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0977|Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer|A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn|August 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|November 12, 2009|Yes|Yes|Study was abandoned before opening to accrual. Replaced by another study.|No||https://clinicaltrials.gov/show/NCT01013506||130575|
NCT01013844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-01|Partner Assistance in Learning and Performing Skin Self-Examination|Partner Assistance in Learning and Performing Skin Self-Examination||Northwestern University|No|Completed|December 2003|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|70 Years|No|||September 2014|September 24, 2014|November 11, 2009||No||No|December 3, 2010|https://clinicaltrials.gov/show/NCT01013844||130550|
NCT01013857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H40013-33128-02|Treating to Target for Patients With Hypertension|Treating to Target for Patients With Hypertension||University of California, San Francisco|No|Completed|January 2009|December 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|30 Years|N/A|No|||November 2012|November 9, 2012|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013857||130549|
NCT01046318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-09-004|A Study of OPC-262 in Patients With Type 2 Diabetes|A Long-term Study of OPC-262 in Patients With Type 2 Diabetes||Kyowa Hakko Kirin Company, Limited|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|20 Years|74 Years|No|||January 2014|January 6, 2014|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01046318||128126|
NCT01046357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2710C00001|A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687|A Randomized, Blind, Placebo-controlled, Single-centre Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD7687 After Single Ascending Oral Doses||AstraZeneca|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|64|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|December 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01046357||128124|
NCT01046370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003509|A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia|A Pilot Study of Amygdala Retraining Program (ARP) Versus Control (C) in Patients With Chronic Fatigue Syndrome (CFS), Chronic Fatigue (CF) and Fibromyalgia (FM)||Mayo Clinic|No|Completed|October 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|59 Years|No|||May 2012|May 2, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046370||128123|
NCT01046669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDI-PMX-NA001|Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock|Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock|EUPHRATES|Spectral Diagnostics (US) Inc.|Yes|Recruiting|June 2010|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|478|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01046669||128100|
NCT01042444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gardia Medical Ltd.|Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft|Phase I Study to Demonstrate the Safety and Performance of the GARDEX™ Embolic Protection Device When Used During Percutaneous Coronary Intervention (PCI) of Saphenous Vein Graft||Gardia Medical|Yes|Terminated|December 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|90 Years|No|||November 2012|November 14, 2012|December 30, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01042444||128421|
NCT01042457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-002|Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis|||Chulalongkorn University|No|Completed|May 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|16 Years|60 Years|No|||September 2013|September 27, 2013|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042457||128420|
NCT01042470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHKUSZ11-2009|Pelvic Floor Study: Biomechanical Properties of the Female Pelvic Floor|Pelvic Floor Study: Biomechanical Properties of the Female Pelvic Floor - Evaluation of Clinical, Mechanical, Sonographic and Histological Parameters||University of Zurich|No|Recruiting|January 2010|December 2015|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|tissue (vaginal wall, urogenital diaphragm), whole blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|female patients who are referred to our university hospital|July 2015|July 25, 2015|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042470||128419|
NCT01042730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-LD-09|Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)|Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)||Juntendo University Hospital|Yes|Recruiting|January 2010|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|12600|||Both|20 Years|79 Years|No|||October 2011|October 17, 2011|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042730||128399|
NCT01042743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUHCRC001|Laparoscopic Surgery Versus Robot Surgery for Right-side Colon Cancer: Short-term Outcome of a Randomised Clinical Trial|||Kyungpook National University|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|80 Years|No|||December 2011|December 18, 2011|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042743||128398|
NCT01043042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091507|Identification of Inpatients at Risk for Poor Glycemic Control|Identification of Inpatients at Risk for Poor Glycemic Control||Vanderbilt University|No|Enrolling by invitation|January 2010|||June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|Candidates for inclusion will include all adult (age ≥ 18 years) patients admitted to        Vanderbilt University Medical Center from 04/01/2008 to 10/31/2009. Patients will be        excluded if they were pregnant at the time of admission or had length of stay < 24 hours.|January 2010|January 5, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01043042||128376|
NCT01040429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NorCAPITAL.02|The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial|The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial|NorCAPITAL|Oslo University Hospital|Yes|Completed|February 2010|November 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040429||128573|
NCT01040442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fabio wanderley|The Effect of Plantar Vibration Stimuli on the Balance of Older Women|The Effect of Plantar Vibration Stimuli on the Balance of Older Women||Universidade Federal de Sao Carlos|No|Completed|March 2008|August 2009|Actual|August 2008|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|30|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||August 2009|December 28, 2009|December 28, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01040442||128572|
NCT01041313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35063-A|Memantine for Post-Operative Pain Control|Memantine for Post-Operative Pain Control||University of Washington|No|Recruiting|January 2010|September 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||June 2010|June 25, 2010|December 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01041313||128507|
NCT01041326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006510|Preoperative Radiation Therapy for High Risk Prostate Cancer|A Phase I Dose-Escalation Study of Preoperative Radiation Therapy Followed by Radical Prostatectomy in Patients With High Risk, Localized Carcinoma of the Prostate||Duke University|Yes|Completed|April 2005|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|15|||Male|18 Years|70 Years|No|||July 2013|July 16, 2013|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01041326||128506|
NCT01031732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-2177c|Evaluation of Four Surgical Techniques in Primary Total Hip Arthroplasty|A Prospective Randomized Controlled 4-arm Study for the Evaluation of 4 Surgical Techniques in Primary Total Hip Arthroplasty||Chang Gung Memorial Hospital|Yes|Recruiting|November 2009|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|N/A|N/A|No|||May 2010|May 27, 2010|December 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01031732||129189|
NCT01031966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST1472-DM-09-005|A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine|A Pilot, Randomized, Open-label Study in Patients on Chronic Dialysis With End Stage Renal Disease (Esrd), to Evaluate the Enhancing Effect of Two Doses of Thymosin Alpha 1 on the Immunogenicity of h1n1sw Monovalent Vaccine||sigma-tau i.f.r. S.p.A.|Yes|Completed|November 2009|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|120|||Both|18 Years|80 Years|No|||March 2012|March 28, 2012|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031966||129171|
NCT01011036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|152/09|Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers|Effects of Gaba-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers||University Hospital Inselspital, Berne|Yes|Completed|December 2009|June 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|17|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 10, 2010|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01011036||130764|
NCT01011309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LCVTC-202|A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis|A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in the Treatment of Patients With Cutaneous Leishmaniasis||IDRI|Yes|Completed|October 2009|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|No|||November 2013|November 15, 2013|November 9, 2009|Yes|Yes||No|September 16, 2013|https://clinicaltrials.gov/show/NCT01011309||130743|A total of 150 patients was planned, including age de-escalation to adolescents after the first 60 adults enrolled. Owing to slow recruitment and insufficient evidence of efficacy in the immunotherapy group, enrollment was closed early.
NCT01010737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVX-003|A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers|A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose, Safety and Priming Potential Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers||BiondVax Pharmaceuticals ltd.|Yes|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|60|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01010737||130787|
NCT01012440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16895A|Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer|Role of PEM Flex Solo II PET Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer||University of Chicago|Yes|Terminated|November 2009|May 2012|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|75 Years|No|||June 2015|June 29, 2015|June 25, 2009|Yes|Yes|Poor accrual|No|May 27, 2015|https://clinicaltrials.gov/show/NCT01012440||130657|
NCT01012674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-049|Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)|Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease||Guerbet|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|211|||Both|18 Years|N/A|No|||April 2013|August 25, 2015|November 12, 2009|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01012674||130639|
NCT01012141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU 793|Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer|Pilot Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First Line Treatment of Hormone Independent Metastatic Prostate Cancer|PROTAXY|Centre Jean Perrin|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||November 2009|April 9, 2013|November 10, 2009||||No||https://clinicaltrials.gov/show/NCT01012141||130680|
NCT01012687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERI-T8-PVFS-1|Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fasting Conditions||Roxane Laboratories|No|Completed|April 2007|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|November 12, 2009|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01012687||130638|
NCT01012934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALEN-0244|Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)|Single-Dose Fasting In Vivo Bioequivalence Study of Alendronate Sodium Tablets (70 mg; Mylan) and Fosamax Tablets (70 mg; Merck) in Healthy Volunteers||Mylan Pharmaceuticals|No|Completed|July 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|November 12, 2009|September 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012934||130619|
NCT01046032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q1605/87|Metformin Treatment Before in Vitro Fertilization (IVF) in Women With Ultrasound Evidence of Polycystic Ovaries|Metformin Treatment Before IVF in Women With Ultrasound Evidence of Polycystic Ovaries; a Prospective, Randomised, Double Blind, Placebo Study||University of Oxford|Yes|Completed|December 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|134|||Female|N/A|38 Years|Accepts Healthy Volunteers|||January 2010|January 8, 2010|January 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01046032||128148|
NCT01046331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|688|Novel Influenza A (H1N1) Surveillance Registry|Novel Influenza A (H1N1) Surveillance Registry||National Heart, Lung, and Blood Institute (NHLBI)|No|Completed|October 2009|October 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|894|||Both|N/A|N/A|No|Non-Probability Sample|Subjects admitted to adult or pediatric ICUs with suspected or confirmed Novel H1N1        Influenza infection.|November 2010|November 9, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046331||128125|
NCT01042769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC22140|A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus|A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)||Hoffmann-La Roche||Completed|February 2010|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7226|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042769||128397|
NCT01042782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C24126|Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction|Phase I Study of Daily RAD001 Administered Orally in Combination With Mitomycin C, Administered Every Three Weeks to Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction|S387|Krankenhaus Nordwest|Yes|Completed|January 2008|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042782||128396|
NCT01043315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-09-25|Cognitive Function in Adults With Cardiac Disease|Cognitive Function in Adults With Cardiac Disease|TimePoints|University Hospital Case Medical Center||Recruiting|July 2009|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients hospitalized in the University Hospitals' (Cleveland, OH) coronary        intensive unit (CICU) being treated for acute cardiovascular conditions|January 2010|January 5, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043315||128356|
NCT01043627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004590|Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)|Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)|SITAR|Mayo Clinic|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|WHO Group I PAH patients being transitioned from sildenafil to tadalafil therapy.|November 2012|November 2, 2012|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043627||128332|
NCT01043328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/FOA-Unesp-05|Human Papillomavirus on Oral Tissue, Saliva and Serum|Comparison of Detection of Human Papillomavirus on Tissue, Saliva and Serum|CDHPOTSS|UPECLIN HC FM Botucatu Unesp|No|Completed|May 2009|December 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|80|Samples With DNA|This biospecimens will be retained: whole blood, exfoliated cells, saliva and formalin-fixed      paraffin-embedded tissues.|Both|30 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|university dental care clinic patients with or without a condition|March 2013|March 23, 2013|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043328||128355|
NCT01043900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cgmansur01|Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant OCD|Right Prefrontal High Frequency rTMS in Treatment of Resistant OCD: a Double Blind, Randomized Controlled Trial||University of Sao Paulo General Hospital|No|Completed|August 2003|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||September 2009|January 6, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043900||128312|
NCT01044160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSD2|Stress, Adjustment And Growth In Children With Cancer And Their Parents|Stress, Adjustment And Growth In Children With Cancer And Their Parents||St. Jude Children's Research Hospital|No|Recruiting|June 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|716|||Both|3 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Recruitment from the oncology group will be from outpatient clinics with procedures        designed to obtain a representative sample of research participants, in terms of diagnosis        and time since diagnosis. Control group participants will be accessed through schools in        the greater Memphis area.|September 2015|September 22, 2015|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01044160||128292|
NCT01040988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X09-04-0195|The Implantable Cardioverter-defibrillators (ICD)/Device Expectations, Adaptations, and Successes Study|The ICD/Device Expectations, Adaptations, and Successes (IDEAS) Study: the Relationship Between Implantable Cardioverter-defibrillators, Pacemakers and Psychiatric Symptoms in a Pediatric Population|IDEAS|Children's Hospital Boston|No|Enrolling by invitation|August 2009|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|254|||Both|6 Years|20 Years|No|Non-Probability Sample|Patients at participating center with pacemakers and ICDs who fit inclusion/exclusion        criteria.|December 2009|December 29, 2009|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01040988||128530|
NCT01041001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CRP-005|Study to Compare the Efficacy and Safety of Cartistem® and Microfracture in Patients With Knee Articular Cartilage Injury or Defect|Randomized, Open-Label, Multi-Center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of Cartistem® and Microfracture in Patients With Knee Articular Cartilage Injury or Defect||Medipost Co Ltd.|Yes|Completed|February 2009|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01041001||128529|
NCT01031433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909449|Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality|Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality||National Institutes of Health Clinical Center (CC)||Completed|July 2009|July 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|February 19, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031433||129212|
NCT01031771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105/09|Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy|Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy|CP|Fortaleza University|Yes|Completed|February 2009|November 2009|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|50|||Both|1 Year|5 Years|No|Non-Probability Sample|Children with Cerebral Palsy diagnoses|December 2009|December 14, 2009|December 12, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01031771||129186|
NCT01031745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-DA018577-S3|Contingency Management in the Delivery of HAART to Drug Users in Chennai, India|||Johns Hopkins University|No|Completed|May 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||February 2012|April 14, 2015|December 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01031745||129188|
NCT01031758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810103|Reverse Cholesterol Transport (RCT) Study|A Pilot Study To Evaluate The Use Of 3H Particulate Cholesterol As A Method To Study Reverse Cholesterol Transport In Humans Followed By A Study On The Effect Of HDL-C On RCT Measured By This Method|MeMo|University of Pennsylvania|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2009|June 25, 2010|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031758||129187|
NCT01011855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiant Warmer Trial|Radiant Warmer Trial|A Comparison of Thermal Responses Among Newborns to Proportional Versus Adaptive Heating Algorithms in Radiant Warmer Devices||GE Healthcare|No|Withdrawn|December 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Actual|0|||Both|32 Weeks|N/A|No|||September 2015|September 10, 2015|November 10, 2009|Yes|Yes|Study never developed due to a change in business priority.|No||https://clinicaltrials.gov/show/NCT01011855||130701|
NCT01011322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-02-UC-01|A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis|||Lipid Therapeutics GmbH|No|Active, not recruiting|December 2009|February 2012|Anticipated|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|156|||Both|18 Years|N/A|No|||August 2010|November 15, 2011|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011322||130742|
NCT01011582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB HM12562|Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza|Human Subjects Registry of Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza||Virginia Commonwealth University|No|Completed|November 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4|Samples Without DNA|Blood specimens and sputum specimens will be collected.|Both|12 Years|N/A|No|Non-Probability Sample|Patients admitted to the medical intensive care unit at Virginia Commonwealth University        Medical Center, Richmond, Virginia.|January 2013|January 7, 2013|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011582||130722|
NCT01045031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant Project number 12979|Cognitive Function in Elderly Marathon Runners|Austrian Prospective Cohort Study in Cognitive Function of Elderly Marathon-runners|APSOEM|Medical University of Vienna|No|Active, not recruiting|December 2008|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|136|Samples With DNA|Apolipoprotein E4 genotype, Insulin-like growth factor-1, Brain-derived neurotrophic factor,      rs6265-Genotype|Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Marathon runners, bicyclists and controls from the greater Vienna area|January 2014|January 3, 2014|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045031||128225|
NCT01045252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGGHHSR1132|Study of Hemodynamics of Neonates by Echocardiography and USCOM|Study of Hemodynamics of Healthy Neonates and Those With Congenital Heart Diseases and Sepsis by Echocardiography and USCOM|HNEU|Guangdong General Hospital|No|Active, not recruiting|October 2008|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|N/A|30 Days|No|Probability Sample|patients enrolled in the NICU of Guangdong General Hospital|January 2010|January 11, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045252||128208|
NCT01045551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE1745|Open Label Pilot Study of Apremilast in Treatment of Rosacea|An Open Label, Pilot Study to Determine the Efficacy of Apremilast in the Treatment of Rosacea in Patients With Both Erythematotelangiectatic Rosacea and Papulopustular Rosacea||Columbia University|No|Completed|June 2010|||January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|January 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01045551||128185|
NCT01046383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMN1207-07|Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients|Effect of IMN1207 Versus Casein on, Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients During or Following Chemotherapy, Radiation or Surgery: A Multi-center Randomized, Double-blind Study - Phase III Trial||Immunotec Inc.|No|Terminated|June 2010|June 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||June 2011|January 16, 2015|January 8, 2010||No|Slower than anticipated recruitment|No||https://clinicaltrials.gov/show/NCT01046383||128122|
NCT01046396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10149|Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin||Galderma Laboratories, L.P.|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 21, 2012|January 8, 2010|Yes|Yes||No|February 28, 2011|https://clinicaltrials.gov/show/NCT01046396||128121|
NCT01045811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC98-2629-B-038-002-MY3-WFH|Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms-3|||National Science Council, Taiwan|Yes|Withdrawn|May 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|45 Years|64 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|January 7, 2010||No|No participants were recruited at this study site. Study has been conducted and monitored with    ClinicalTrials.gov ID: NCT01044563.|No||https://clinicaltrials.gov/show/NCT01045811||128165|
NCT01046045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.004-T|Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients|Impact and Efficacy of Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients||Chinese University of Hong Kong|No|Completed|April 2008|June 2013|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||June 2015|June 19, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01046045||128147|
NCT01043354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA 7-08-CR-68|TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)|TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)|TACTICS|Narrows Institute for Biomedical Research|No|Completed|September 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|247|||Both|21 Years|N/A|No|||April 2014|April 1, 2014|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043354||128353|
NCT01043341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV vaccines|Knowledge and Attitude About HPV Vaccines|Knowledge and Attitude About HPV Vaccines Among Women||Universidade Cidade de Sao Paulo|No|Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|200|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||January 2010|January 8, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043341||128354|
NCT01043926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-017|Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)|A Single Dose Study to Investigate the Pharmacokinetics of MK-4305 in Patients With Hepatic Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|January 5, 2010|No|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01043926||128310|
NCT01043640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS088|Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders|Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|December 2009|June 2017|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|N/A|21 Years|No|||January 2016|January 21, 2016|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01043640||128331|
NCT01043666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-090|A Study of YM178 in Subjects With Symptoms of Overactive Bladder|Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder||Astellas Pharma Inc|No|Completed|December 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1126|||Both|18 Years|N/A|No|||October 2011|September 16, 2013|January 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01043666||128329|
NCT01030887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTPF/2008/12|PEACH Trial: Prescribed Exercise After Chemotherapy|Individually Prescribed Exercise Versus Usual Care in a Heterogeneous Cancer Survivor Population: A Pragmatic Randomized Controlled Trial|PEACH|University of Dublin, Trinity College|Yes|Completed|January 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|21 Years|70 Years|No|||November 2009|August 12, 2011|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01030887||129253|
NCT01030900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100011|Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas|Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2009|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|100 Years|No|||December 2015|December 30, 2015|December 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030900||129252|
NCT01031134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH084872-01A1|Shared Decision-Making for Elderly Depressed Primary Care Patients|Shared Decision-Making for Elderly Depressed Primary Care Patients||Weill Medical College of Cornell University|Yes|Recruiting|January 2011|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|210|||Both|65 Years|95 Years|No|||December 2014|December 18, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031134||129234|
NCT01031420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-GU-026|Dose Dense MVAC for Muscle Invasive Bladder Cancer|Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract||Fox Chase Cancer Center|Yes|Completed|December 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|December 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01031420||129213|
NCT01031784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-450|Radioactive Holmium Microspheres for the Treatment of Liver Metastases|Radioactive Holmium Microspheres for the Treatment of Patients With Non-resectable Liver Metastases of Mixed Origin; a Single Center, Interventional, Non-randomized, Open Label, Safety Study.|HEPAR|UMC Utrecht|Yes|Completed|December 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01031784||129185|
NCT01032005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFS efficacy trial|Efficacy of Double Fortified Salt (DFS) to Improve Work Productivity in Women in India|Double Fortified Salt Intervention and Work Performance (Productivity) of Women Plantation Workers in West Bengal, India|DFS|Micronutrient Initiative|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|248|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 29, 2011|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032005||129168|
NCT01027923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1825 / 201101703|IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)|A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia|AML|Washington University School of Medicine|No|Terminated|May 2010|September 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|70 Years|No|||January 2015|January 21, 2015|December 7, 2009|No|Yes|Withdrawal of support from sponsor|No||https://clinicaltrials.gov/show/NCT01027923||129478|
NCT01028430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-046|B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging|B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging||Northwell Health|No|Recruiting|July 1998|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|1000||Blood cells, tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Chronic Lymphocytic Leukemia Community Sample|October 2015|October 5, 2015|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028430||129440|
NCT01044407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10678|Developing a New, Dynamic, Therapeutic Pacemaker Algorithm for Stabilising Periodic Breathing in Chronic Heart Failure.|Developing a New, Dynamic, Therapeutic Pacemaker Algorithm for Stabilising Periodic Breathing in Chronic Heart Failure.||Imperial College London|No|Recruiting|January 2010|October 2010|Anticipated|February 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|14|||Both|18 Years|80 Years|No|||January 2010|January 22, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044407||128273|
NCT01012154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002874|In Vivo Confocal Microscopy Tumor Atlas Study|In Vivo Confocal Microscopy Tumor Atlas Study||Carl Zeiss Surgical GmbH|No|Recruiting|November 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2009|November 10, 2009|November 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01012154||130679|
NCT01012167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044324|Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia|Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia|CIDAR-3|University of Maryland|Yes|Completed|February 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|86|||Both|18 Years|64 Years|No|||December 2014|December 10, 2014|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01012167||130678|
NCT01045044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNIC-P09-004|Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy|Magnetic Resonance Imaging of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Anthracycline-based Systemic Chemotherapy||Kettering Health Network|No|Withdrawn|December 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer cohort will be patients of Medical Oncology Hematology Associates Inc.,        Dayton, OH        Normal controls will be recruited from Kettering College of Medical Arts and the Kettering        Health Network.|April 2012|April 4, 2012|January 6, 2010||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01045044||128224|
NCT01045265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP35369|Concentrations of Raltegravir in the Semen of HIV-Infected Men|Study to Determine the Concentrations of Raltegravir in Semen, the Seminal to Plasma Ratio of Raltegravir and the Variability in Seminal to Plasma Ratios Over the Raltegravir Dosing Period.||Canadian Immunodeficiency Research Collaborative|No|Completed|December 2009|July 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|12 HIV-positive males|August 2014|August 12, 2014|January 8, 2010||No||No|June 16, 2014|https://clinicaltrials.gov/show/NCT01045265||128207|
NCT01042522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0264|Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors|A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary||Gynecologic Oncology Group||Recruiting|February 2010|||January 2024|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|January 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042522||128415|
NCT01042158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAD-PH-001|A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis|A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis|ATPAHSS|United Therapeutics|Yes|Active, not recruiting|January 2010|February 2015|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|63|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|January 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042158||128443|
NCT01042171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009SDU-QILU-G07|Evaluation of Image Quality Over Time After Injection of the ﬂuorescein Sodium for Confocal Laser Endomicroscopy|Evaluation of Image Quality Over Time After Injection of the ﬂuorescein Sodium for Confocal Laser Endomicroscopy||Shandong University|Yes|Completed|December 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|patients without any disease of heart,liver or kidney;patients without serious gastritis        and other serious stomach lesions.|July 2012|July 17, 2012|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042171||128442|
NCT01042483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP003/2009|Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based+Continuous Vacuum Mode|Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based, Multiple Parameters+Continuous Vacuum Mode||Trig Medical Inc|No|Not yet recruiting|January 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|450|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 4, 2010|January 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01042483||128418|
NCT01042496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004163|Bipolar Depression Before and After Lamotrigine Treatment|1H-MR Spectroscopy of Bipolar Depression Before and After Lamotrigine Treatment|1HMRS-BP|Mayo Clinic|Yes|Completed|December 2009|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 4, 2010|Yes|Yes||No|September 24, 2015|https://clinicaltrials.gov/show/NCT01042496||128417|
NCT01042535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-8461|Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer|A Phase 1/2 Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|December 2009|April 2016|Anticipated|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|January 4, 2010|Yes|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01042535||128414|
NCT01042548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-028|Proteomics Research of Breast Cancer Markers in Interstitial Fluid and Serum|Proteomics Research of Breast Cancer Markers in Interstitial Fluid and Serum||University of Pittsburgh|Yes|Recruiting|September 2009|||January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Subjects will be asked to allow us to collect an extra 2 tablespoons of blood at the time of      pre-operative blood work. For those subjects with cancer who undergo surgery, a follow-up      blood sample will be collected prior to chemotherapy, radiation, or hormonal therapy, and      every six months afterwards at the time of their standard clinic/office visit for two years,      then once a year for year 3-5. This will allow researchers to examine the samples to      determine if blood changes over time after surgery, and what type of result may indicate a      risk for recurrence.      Any remaining blood samples not used for the study will remain in the laboratory for future      research.|Both|18 Years|N/A|No|Non-Probability Sample|All patients who are receiving or seeking medical care at the UPMC St. Margaret for breast        cancer will be invited to participate in the research study. Patients undergoing surgery        for breast nodules suspected of being cancer or high risk lesions will also be asked to        participate.|March 2016|March 15, 2016|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042548||128413|
NCT01043055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044809-HMO-CTIL|Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40|Evaluation the Diagnostic Ability of the CDT to Detect Breast Cancer Among Women Population Over Age 40||Hadassah Medical Organization|No|Not yet recruiting|January 2010|January 2011|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|140|Samples Without DNA|Blood|Female|40 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Breast cancer patients over age 40 before treatment. Healthy women recruited in Check Up        institute from asymptomatic women over age 40, referred to screening mammography and        received the negative result of mammography.|October 2009|January 5, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043055||128375|
NCT01043081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0143|Sexually Transmitted Infections Among African American Women Who Have Sex With Women|Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women|WSW|University of Mississippi Medical Center|No|Suspended|February 2009|June 2012|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples With DNA|Endocervical and vaginal secretion specimens are being retained for future research studies      in this field of sexually transmitted diseases.|Female|18 Years|N/A|No|Non-Probability Sample|The study population is African American women, aged 18 or above, who present to the        Crossroads Clinic (STD Clinic) in the Jackson, MS metropolitan area for STI        screening/evaluation who have engaged in sexual contact with another woman within the past        6 months.|July 2010|April 2, 2012|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01043081||128373|
NCT01043367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0908-CU|Deprexil in Subjects With Signs and Symptoms of Depression|Efficacy of Deprexil Administration in Subjects With Signs and Symptoms of Depression.||Catalysis SL|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|59 Years|No|||March 2011|March 6, 2011|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043367||128352|
NCT01043380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000002959|Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound|Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound|PRECISE-IVUS|Kumamoto University|Yes|Completed|January 2010|September 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|30 Years|85 Years|No|||March 2015|March 30, 2015|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043380||128351|
NCT01043952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20090035|Use of Bispectral Index (BIS) for Monitoring of Total Intravenous Anaesthesia in Pediatric Patients|Use of Bispectral Index (BIS) Monitoring of Anaesthesia With Propofol and Remifentanyl in Pediatric Patients in Ear Nose and Throat Surgery: Are There Clinical Advantages?||Aalborg Universitetshospital|No|Terminated|January 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|157|||Both|1 Year|65 Years|No|||June 2015|June 23, 2015|January 4, 2010||No|Poor enrollment.|No||https://clinicaltrials.gov/show/NCT01043952||128308|
NCT01044199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEZID-5506|Study of Intradermal Administration of PCEC Rabies Vaccine|A Single Center, Open-Label, Study of Intradermal Administration of an Inactivated PCEC Rabies Vaccine in Adult Subjects|Rabies-ID|Centers for Disease Control and Prevention|No|Completed|February 2009|August 2013|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 28, 2014|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044199||128289|
NCT01031160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909231|Health Behavior in School-Age Children: NEXT Longitudinal Study 2009-2013|Health Behavior in School-Age Children: NEXT Longitudinal Study 2009-2013||National Institutes of Health Clinical Center (CC)||Recruiting|September 2009|||||N/A|Observational|N/A|||Anticipated|9400|||Both|13 Years|22 Years|Accepts Healthy Volunteers|||March 2015|April 2, 2015|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031160||129232|
NCT01031147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASC3|Contrast-free Magnetic Resonance Angiography (MRA) at 3.0 T for Intracranial Aneurysm Detection|Detection of Intracranial Aneurysm With Non-enhanced, Three-dimensional Time-of-flight Magnetic Resonance Angiography(3D−TOF−MRA): a Prospective Comparison With Three-dimensional Reconstructed Digital Subtraction Angiography (3D RDSA)||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|June 2007|December 2010|Anticipated|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|15 Years|80 Years|No|Non-Probability Sample|We estimated that a sample of 350 patients including 12% dropout rate would be enrolled to        determine an accuracy of VR 3D-TOF-MRA versus VR RDSA as reference standard with a 95%        confidence interval of 5% (i.e., a standard error of approximately 2.5 %) above and below        the expected VR 3D-TOF-MRA accuracy of 95%. A P value of 0.05 was considered to indicate        statistical significance.|December 2009|February 25, 2010|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031147||129233|
NCT01028456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 H0716 68|Clinical Trial of Light Therapy for Epilepsy|A Randomised Placebo Controlled Clinical Trial of Light Therapy for Medically Intractable Epilepsy.||University College, London|No|Enrolling by invitation|September 2010|September 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||December 2009|December 8, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028456||129438|
NCT01044134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X09-11-0587|Think AHEAD (A Healthy Eating And Drinking) Study|A 6-Month Study on Diet and Weight Loss in Overweight Adolescents||Children's Hospital Boston|No|Terminated|February 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|January 5, 2010||No|We achieved n=38, due to slow recruitment (=2/3 of target).|No||https://clinicaltrials.gov/show/NCT01044134||128294|
NCT01044706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50014|Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions|Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fed Conditions||Kremers Urban Development Company|Yes|Completed|May 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Male|19 Years|70 Years|Accepts Healthy Volunteers|||February 2010|February 28, 2010|January 7, 2010|No|Yes||No|February 8, 2010|https://clinicaltrials.gov/show/NCT01044706||128250|
NCT01044719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBHADS001|Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis|What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa||Imperial College London|No|Not yet recruiting|January 2010|April 2011|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Both|16 Years|N/A|No|||April 2010|April 12, 2010|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01044719||128249|
NCT01044420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOLFIRI-AEC2|mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial|||Peking University||Recruiting|May 2009|June 2012|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||May 2009|January 6, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044420||128272|
NCT01045590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100684|Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus|Phase IV, Multicenter, Single-blind, Positive-controlled, Parallel Group Study of Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Adm||GlaxoSmithKline|No|Completed|December 2003|February 2006|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|75 Years|No|||February 2011|June 14, 2012|December 10, 2009||||No||https://clinicaltrials.gov/show/NCT01045590||128182|
NCT01045603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-1301-034-SP|Instanyl® Non-Interventional Study|A 3 Month Observational Prospective Patient Cohort Study of the Treatment of Breakthrough Pain in Cancer Patients With Instanyl®|INIS|Takeda|No|Completed|December 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|309|||Both|18 Years|N/A|No|Non-Probability Sample|Adult cancer patients (in- or out-patients) that are suffering from BTP who have not been        treated with Instanyl for one month prior to Baseline.|October 2012|October 26, 2012|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045603||128181|
NCT01046084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036522|Lansoprazole 30 mg DR Capsule Replicate Food Study|A Relative Bioavailability Replicated Crossover Study of Lansoprazole 30 mg Delayed-Release Capsules Under Non-Fasting Conditions.||Teva Pharmaceuticals USA||Completed|August 2003|September 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 22, 2010|January 8, 2010||Yes||No|February 22, 2010|https://clinicaltrials.gov/show/NCT01046084||128144|
NCT01045824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08202|Family-based Genetic Long-term Study of Brain Function in Schizophrenia|The Genetic Study of Longitudinal Brain Function Among Schizophrenic Patients With Family History|FamilySchizo|Taichung Veterans General Hospital|Yes|Recruiting|January 2008|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|600|Samples With DNA|10-20cc of blood will be drawn for DNA analysis|Both|N/A|N/A|No|Probability Sample|Schizophrenia family|January 2010|January 14, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01045824||128164|
NCT01042184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200909054M|Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori|Phase IV Study Comparing the Duration of Sequential Therapy||National Taiwan University Hospital|Yes|Completed|December 2009|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|900|||Both|20 Years|N/A|Accepts Healthy Volunteers|||June 2012|November 15, 2012|January 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01042184||128441|
NCT01042509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE09-013|Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease|Combination of Alemtuzumab (Anti-CD52) and Rituximab (Anti-CD20) at Low-doses in Chronic Graft Versus Host Disease Treatment After First-line Therapy Failure.|LowAR|Hospital Universitario Dr. Jose E. Gonzalez|Yes|Recruiting|October 2009|January 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||January 2010|January 5, 2010|January 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042509||128416|
NCT01042795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00030127|Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy|Phase II Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy||University of Michigan|Yes|Terminated|September 2009|January 2013|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|January 5, 2010||No|STudy closed due to poor accrual|No||https://clinicaltrials.gov/show/NCT01042795||128395|
NCT01042808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-115|Isentress Re-examination Study (MK-0518-115)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy of ISENTRESS in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|May 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|996|||Both|N/A|N/A|No|Probability Sample|HIV-1 Infected adults|July 2015|July 20, 2015|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042808||128394|
NCT01042873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0355-09-HMO-CTIL|The Hemodynamic Response to Prolonged Dobutamine Infusion|||Hadassah Medical Organization|Yes|Recruiting|January 2010|December 2019|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2011|July 3, 2011|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042873||128389|
NCT01043419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-8-09-A-101|Sympathetic Neural Outflow During Xenon Anesthesia in Humans|Sympathetic Neural Outflow During Xenon Anesthesia in Humans||Air Liquide Santé International|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|65 Years|No|||June 2010|June 29, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043419||128348|
NCT01043653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7156-R|Assessing Recovery|Assessing Recovery in Veterans With Serious Mental Illness|MARS|VA Office of Research and Development|No|Completed|January 2010|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|None Retained|no specimens collected|Both|25 Years|65 Years|No|Non-Probability Sample|We have elected to focus on individuals meeting accepted criteria for serious mental        illness, including a diagnosis of schizophrenia or schizoaffective disorder, bipolar I        disorder (with mania), and major depression with psychosis. Veterans meeting these        criteria represent a large population with significant costs and health concerns for VA.        Further, they are the primary target of efforts to transform mental health care in VA to a        recovery model, making this an arena in particular need of a sound recovery instrument.        We have elected to limit our sample to people in treatment for several reasons. One can        surmise that most people not in treatment are new cases, very ill (e.g., homeless), or        doing very well.|March 2014|March 26, 2014|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043653||128330|
NCT01043406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVC1001|Seizure Advisory System Feasibility Study|Safety and Effectiveness of a Seizure Advisory System in Epilepsy: A Feasibility Study (Victoria)||NeuroVista Corporation|No|Terminated|March 2010|October 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|January 4, 2010||No|Sponsor restructuring.|No||https://clinicaltrials.gov/show/NCT01043406||128349|
NCT01043679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01122009/S09070|Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania|A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania|UtapMani|Taichung Veterans General Hospital|Yes|Recruiting|July 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043679||128328|
NCT01044563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC98-2629-B-038-002-MY3-TMU|Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms|||National Science Council, Taiwan|Yes|Completed|May 2010|May 2012|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Female|45 Years|64 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01044563||128261|
NCT01027936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDB-001|An Age-Stratified Data Collection Study in Adult Males and Females, Ages 18 and Above to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II|An Age-Stratified Data Collection Study in Adult Males and Females, Ages 18 and Above to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II||Topcon Corporation|No|Active, not recruiting|April 2009|November 2010|Anticipated|March 2010|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|180 male and female volunteers from 6 centers with normal, healthy eyes form six age        groups, aged 18 years or older.|November 2010|November 8, 2010|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027936||129477|
NCT01031446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0949|Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer|A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|October 2009|June 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||February 2013|February 5, 2013|December 11, 2009|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01031446||129211|All patients began at the same dose level of the study drugs with no de-escalation of dose, thus results were combined for outcomes measures 3, 4, 5, and 6 for Phase II.
NCT01028170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REaCH-23.07.09|Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure|Assessing the Renal Consequences and Functional Efficacy of Low Dose Hypertonic Saline Solution and Furosemide for the Treatment of Congestive Heart Failure in a Randomized, Double Blind, Prospective Study|REaCH|Aspirus Heart and Vascular Institute-Research and Education|No|Completed|November 2009|January 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|November 27, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028170||129460|
NCT01028183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB pending|Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability|Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability||Duke University|Yes|Withdrawn|August 2010|July 2013|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|0|||Both|N/A|5 Days|No|Non-Probability Sample|We will enroll 10,000 infants at 40 centers. Infants will be enrolled into one of four        strata: extremely premature (<30 weeks, n=5,000), premature (30-36 weeks inclusive        n=2,000), hospitalized term (≥37 weeks gestation, n=2,000), and healthy term (≥37 weeks        gestation, n=1,000).|January 2013|January 15, 2013|December 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01028183||129459|
NCT01028469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP026|Artelon Metatarsophalangeal (MTP) Spacer|Artelon MTP Spacer - Surgical Treatment of Mild to Moderate Hallux Rigidus||Artimplant AB|No|Recruiting|December 2009|||December 2011|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|N/A|No|||December 2009|December 14, 2009|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028469||129437|
NCT01028482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-MB-301-CTIL|Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline|Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline||Tel-Aviv Sourasky Medical Center|Yes|Completed|March 2008|January 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|45 Years|No|||May 2011|May 9, 2011|June 3, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028482||129436|
NCT01044433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15309|Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck|A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|October 2009|||February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044433||128271|
NCT01045057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD743_FRITZ_MULTI|Clinical Feasibility of New Tracheoesophageal Puncture Set|Clinical Feasibility of a New Surgical Tool for Primary or Secondary Tracheoesophageal Puncture and Voice Prosthesis Insertion for Prosthetic Voice Rehabilitation After Total Laryngectomy||Atos Medical AB|No|Completed|December 2009|April 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|January 6, 2010|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01045057||128223|
NCT01046097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113381|Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines|Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines||GlaxoSmithKline||Terminated|May 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Both|6 Weeks|N/A|Accepts Healthy Volunteers|||September 2014|September 4, 2014|January 7, 2010|Yes|Yes|Local authorities no longer require routine PMS studies;GSK does not believe the study would    add meaningfully to the safety data already available for Synflorix|No||https://clinicaltrials.gov/show/NCT01046097||128143|
NCT01046110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3580|Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin|A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN™ : EARLY)|BEGIN™|Novo Nordisk A/S|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|458|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|January 8, 2010|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01046110||128142|
NCT01042197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2007-100|The Relation Between Vitamin D Production and UVB Exposed Body Surface Area|Interdependence Between Body Surface Area and UVB Dose in Vitamin D Production: A Randomized Controlled Trial||Bispebjerg Hospital|Yes|Completed|January 2008|December 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|9||Actual|92|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2007|January 11, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042197||128440|
NCT01046123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHAM!|Volumetric Modulated Arc Therapy (VMAT) for Brain Metastases|A Phase II Study of Whole Brain Radiotherapy With Simultaneous Integrated Boost Using Volumetric Modulated Arc Therapy for One to Ten Brain Metastases||British Columbia Cancer Agency|Yes|Active, not recruiting|January 2010|December 2019|Anticipated|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01046123||128141|
NCT01046136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-MUC-03|Mucinex Exploratory Cold Study|Double Blind, Randomized, Placebo Controlled Study of Mucinex® for the Treatment of Symptoms of an Acute Respiratory Tract Infection When Two 600 mg Tablets Are Given Every 12 Hours for 7 Days||Reckitt Benckiser LLC|No|Completed|December 2009|||March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|378|||Both|12 Years|N/A|No|||August 2012|August 24, 2012|January 7, 2010|Yes|Yes||No|March 3, 2011|https://clinicaltrials.gov/show/NCT01046136||128140|
NCT01042821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anal fistula|Treatment of Anal Fistulas Advancement Flap|Treatment of Anal Fistulas by Partial Rectal Wall Advancement Flap or Mucosal Advancement Flap: a Prospective Randomized Study|flap|Mansoura University|Yes|Completed|May 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2005|January 5, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042821||128393|
NCT01042834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0508078|Impact of Air Pollution on the Autonomic Nervous System Activity and the Presence of Sleep Apnea in Older Subjects|Impact of Air Pollution on the Autonomic Nervous System Activity and the Presence of Sleep Apnea in Older Subjects: Longitudinal Multicentric Study|POLLAIR|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects will have to live in districts where important atmospheric pollution is        established|January 2011|January 12, 2011|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042834||128392|
NCT01043068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPAM-1|The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients: A Pilot Study|A Pilot Study: The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients||National Cancer Center, Korea|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043068||128374|
NCT01043133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B02930|Study of Medical Student Use of Templates to Document Outpatient Asthma Care in Electronic Medical Record|Social Marketing in Medical Education: Influencing Medical Student Use of Evidence-based Templates in Outpatient Documentation of Asthma Care Using an Electronic Medical Record||Uniformed Services University of the Health Sciences|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|155|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|July 14, 2011|January 5, 2010||No||No|December 3, 2010|https://clinicaltrials.gov/show/NCT01043133||128369|
NCT01042847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09316|How Our Immune System Can Help Fight Cancer|The Effect of Genetic Polymorphisms in Indoleamine 2, 3-Dioxygenase in Epithelial Ovarian Cancer||Winthrop University Hospital|No|Not yet recruiting|January 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|surgical tissue ascites fluid|Female|20 Years|90 Years|No|Non-Probability Sample|Patients with histologically confirmed epithelial ovarian cancer (EOC) who have had        surgical resection as primary therapy for their disease will be included in this study.|January 2010|January 5, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042847||128391|
NCT01043965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0925|Myocardial Perfusion in Type 2 Diabetes|Evaluation of Myocardial Perfusion and Microvascular Reserve in Real-time Utilizing Myocardial Contrast Echocardiography in Type 2 Diabetes.||University of Sao Paulo General Hospital|Yes|Completed|August 2005|August 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|61|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2005|January 6, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043965||128307|
NCT01043978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715679|Prevention of Overfeeding During Infancy|Prevention of Overfeeding During Infancy||University of California, Davis|No|Completed|April 2010|August 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|231|||Both|N/A|3 Months|Accepts Healthy Volunteers|||August 2012|August 23, 2012|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043978||128306|
NCT01044225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-012324-83|Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma|CeCil: A Randomized, Non-comparative Clinical Trial of the Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma||Universitair Ziekenhuis Brussel|Yes|Terminated|September 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|January 6, 2010||No|Results of the phase III RTOG0525 trial made the manufacturer of cilengitide decide to end    their support to the trial|No||https://clinicaltrials.gov/show/NCT01044225||128287|
NCT01044238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA025084|Methylphenidate to Treat Methamphetamine Dependence|Sustained-Release Methylphenidate for Management of Methamphetamine Dependence|MPH|University of California, Los Angeles|Yes|Active, not recruiting|October 2010|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|55 Years|No|||May 2014|May 19, 2014|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044238||128286|
NCT01044251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22522|Frovatriptan as a Transitional Therapy in Medication Overuse Headache|Frovatriptan as a Transitional Therapy in Medication Overuse Headache||University of Calgary|No|Recruiting|January 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044251||128285|
NCT01044576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1387|Patient Research Cohort: Rapidly Evolving Multiple Sclerosis|Patient Research Cohort: Rapidly Evolving Multiple Sclerosis Opening the Window of Therapeutic Opportunity|PRC-REMS|Imperial College London|No|Completed|January 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|whole blood, serum, white cells|Both|18 Years|65 Years|No|Non-Probability Sample|Eligible patients with relapsing-remitting or secondary progressive multiple sclerosis.|March 2013|August 4, 2015|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044576||128260|
NCT01032031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB/G005575/1|The Effect of Green Tea and Vitamin C on Skin Health|The Effect of Dietary Bioactive Compounds on Skin Health in Humans in Vivo||University of Manchester|No|Completed|March 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|95|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032031||129166|
NCT01027949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-304|An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension|An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension|FREEDOM-EXT|United Therapeutics||Active, not recruiting|May 2006|||December 2020|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|900|||Both|12 Years|N/A|No|||October 2015|October 1, 2015|December 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027949||129476|
NCT01028196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NRU-DUM-2009/1|Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression|Epidemiological Observational Non-interventional Study to Research the Prevalence of Bipolar Criteria of Hospital In-patients With Schizophrenia and Patients With Recurrent Depression||AstraZeneca|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|750|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients having current diagnosis of schizophrenia/ schizoaffective disorder (in-patients)        and patients having current diagnosis of recurrent depression (both in-patients and        out-patients) will be included into this study.|October 2011|October 31, 2011|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028196||129458|
NCT01028209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBR06 001|Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions||PBR06|Institute for Neurodegenerative Disorders||Terminated|November 2009|September 2010|Actual|April 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 8, 2010|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028209||129457|
NCT01028755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12671|To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors|An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors||Bayer|No|Completed|November 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|November 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028755||129415|
NCT01028768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TE-1777-101-EC|Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function|Open Label Pharmacokinetic (PK) Study, Conducted at One Investigational Site in Germany, to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Teduglutide Following Subcutaneous Administration of 10 mg Teduglutide and to Evaluate Safety and Tolerability of 10 mg Teduglutide||Nycomed|No|Completed|October 2009|March 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|75 Years|No|||April 2010|May 4, 2012|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01028768||129414|
NCT01044732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avantis TER-08-06|Third Eye Retroscope Randomized Clinical Evaluation|Third Eye Retroscope Randomized Clinical Evaluation (The "TERRACE" Study)|TERRACE|Avantis Medical Systems|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|448|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|January 6, 2010|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01044732||128248|With mean subject age of 57.8 years, population was younger than in some studies, so polyp prevalence might be below average.
NCT01044745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|083-09|Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)||University of Nebraska|Yes|Active, not recruiting|December 2009|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|19 Years|75 Years|No|||May 2014|May 28, 2014|January 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01044745||128247|
NCT01045278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-nr 2007-001130-13|Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy|Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy||Region Skane|No|Completed|April 2008|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|277|||Both|N/A|N/A|No|||October 2013|October 1, 2013|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01045278||128206|
NCT01046409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0910-003-062|Comparison Between Main Branch and Side Branch Vessels|Comparison of Clinical, Electrical and Physiologic Significance Between Main Branch and Side Branch Vessels||Seoul National University Hospital|No|Active, not recruiting|January 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|51|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with significant coronary artery disease, involving the bifurcation lesions|August 2011|August 18, 2011|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046409||128120|
NCT01046149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC98-2629-B-038-002-MY3-TMUH|Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms-2|||National Science Council, Taiwan|Yes|Withdrawn|February 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|45 Years|64 Years|Accepts Healthy Volunteers|||September 2014|September 25, 2014|January 7, 2010||No|No participants were recruited at this study site. Study has been conducted and monitored at    ClinicalTrials.gov ID: NCT01044563.|No||https://clinicaltrials.gov/show/NCT01046149||128139|
NCT01034332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707051M|Paclitaxel/Cisplatin/Fluorouracil Followed by Paclitaxel/Cisplatin/Radiotherapy and Esophagectomy for Esophageal Cancer|A Phase II Study With One-cycle Weekly TP-HDFL Followed by Twice Weekly TP-CCRT and Esophagectomy for Locally Advanced Esophageal Cancer||National Taiwan University Hospital|Yes|Recruiting|December 2007|December 2009|Anticipated|December 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||December 2009|December 17, 2009|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT01034332||128990|
NCT01034345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sirolimus_Liver_Tolerance|Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients|Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients||Hospital Clinic of Barcelona|Yes|Recruiting|November 2009|November 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|75 Years|No|||November 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034345||128989|
NCT01034605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HumBio_Westerterp08|The Effect of PinnoThin on Satiety and Food Intake|The Effect of PinnoThin on Satiety and Food Intake|PinnoThin|Maastricht University Medical Center|Yes|Completed|December 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01034605||128969|
NCT01034618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-3-081|Protein Hydrolyzation and Glycemic Control|The Additional Effects of Protein Hydrolysate Supplementation on Glucose Homeostasis in Type 2 Diabetes||Maastricht University Medical Center|No|Completed|December 2007|April 2009|Actual|October 2008|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||||||Male|40 Years|70 Years|No|||December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034618||128968|
NCT01034917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETRA-SWITCH|Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression|Pilot Study to Assess the Efficacy and Safety of Switching Protease Inhibitor to Etravirine in HIV-1-infected Subjects With Viremia Suppression||Germans Trias i Pujol Hospital|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||July 2012|October 24, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01034917||128945|
NCT01035203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176-25/kmo|Exercise Versus Cognitive Behavioural Therapy on Cancer-related Fatigue|Effects of a Brief Endurance Exercise Program and of a Cognitive Behavioural Therapy on Patients With Cancer-related Fatigue||Charite University, Berlin, Germany|No|Recruiting|December 2009|September 2010|Anticipated|July 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||March 2010|March 29, 2010|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035203||128923|
NCT01035216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G07-10075|A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)||SBI Biotech Co., Ltd.|No|Terminated|September 2009|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2011|December 22, 2014|December 17, 2009|No|Yes|This study has been terminated.|No||https://clinicaltrials.gov/show/NCT01035216||128922|
NCT01035463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|446-08|Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy|Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma||University of Nebraska|Yes|Recruiting|November 2009|||December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|19 Years|N/A|No|||December 2014|December 2, 2014|December 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01035463||128903|
NCT01035905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-337-C-030|Comparative Clinical Evaluation of Daily Disposable Lenses in Symptomatic Daily Disposable Lens Wearers|Comparative Clinical Evaluation of Daily Disposable Lenses in Symptomatic Daily Disposable Lens Wearers||Alcon Research|No|Completed|September 2009|December 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|N/A|N/A|No|||January 2012|June 26, 2012|December 18, 2009|Yes|Yes||No|September 27, 2010|https://clinicaltrials.gov/show/NCT01035905||128878|
NCT01036360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0063|Acute Exercise and Energy Balance Regulation: Effect of Intensity|Regulation of the Energy Balance Following an Acute Exercise in Metabolic Chambers: Effect of the Exercise Intensity, Age and Weight Status||University Hospital, Clermont-Ferrand||Recruiting|December 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40||Defined population|Male|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean|January 2011|January 18, 2011|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036360||128857|
NCT01037374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0144|Anticipation of the Difficult Airway: the Preoperative Airway Assessment Form|Anticipation of the Difficult Airway: the Preoperative Airway Assessment Form as an Educational and Quality Improvement Tool||The University of Texas Health Science Center, Houston|Yes|Completed|August 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|89|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037374||128807|
NCT01032330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEI-146|Observation Versus Occlusion Therapy for Intermittent Exotropia|A Randomized Clinical Trial of Observation Versus Occlusion Therapy for Intermittent Exotropia|IXT2|Jaeb Center for Health Research|Yes|Completed|January 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|611|||Both|12 Months|10 Years|No|||February 2016|February 22, 2016|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032330||129143|
NCT00995865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-100-001|Trial of Yellow Fever Inactivated Vaccine|Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability,and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults.||GE Healthcare|Yes|Completed|January 2010|October 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00995865||131920|
NCT00992693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2009.140|Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities|Treatment of Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) With Intravenous Ribavirin in Department of Defense (DOD) Associated Medical Treatment Facilities: A Phase 2 Study||U.S. Army Medical Research and Materiel Command|No|Enrolling by invitation|September 2009|January 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|17 Years|65 Years|No|||December 2015|December 28, 2015|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992693||132163|
NCT00991861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 569 000 - 0908|Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis|Double-blind, Randomized, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41007 Once Daily and LAS41007 Twice Daily Versus LAS106521 Gel Twice Daily in the Treatment of Actinic Keratosis Grade I to II||Almirall, S.A.|No|Completed|August 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991861||132227|
NCT00991874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/S0801/53|A Longitudinal Study of Exhaled Nitric Oxide in Children|A Longitudinal Study of Exhaled Nitric Oxide in Children|LENOS|University of Aberdeen|No|Completed|August 2009|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|6 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with and without asthma|February 2016|February 26, 2016|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991874||132226|
NCT00993577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155/04|Stretching Exercises and Temporomandibular Disorders|Global Postural Reeducation and Static Stretching Exercises in the Treatment of Myogenic Temporomandibular Disorders. A Randomized Study|Stretching|University of Sao Paulo General Hospital|No|Completed|February 2004|March 2007|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|24|||Female|19 Years|40 Years|Accepts Healthy Volunteers|||October 2009|October 29, 2009|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993577||132095|
NCT00993928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N07C4|Home-Based Programs for Improving Sleep in Cancer Survivors|A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|April 2010|||September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|168|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00993928||132068|
NCT00993330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-310109|Macular Pigment Optical Density in Healthy Subjects|Macular Pigment Optical Density in Healthy Subjects||Medical University of Vienna|Yes|Terminated|May 2009|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||6|Actual|96|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects|November 2014|November 13, 2014|October 9, 2009||No||No||https://clinicaltrials.gov/show/NCT00993330||132114|
NCT01033812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 084|ID & Testing in Male Partners|A Pilot Study to Identify and Describe the Male Sexual Partners of Adolescent and Young Adult Women Enrolled in ATN 067||Westat|Yes|Completed|May 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|177|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will include index recruiters and their male sexual partners. The index        recruiters will be comprised of young women who served as index recruiters in ATN 067 and        members of their female friendship network members who tested HIV positive based on HIV        screening and a confirmatory test result that was conducted in ATN 067. All study        participants will be 18 years of age or older.|March 2016|March 1, 2016|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033812||129030|
NCT01034072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-116|Iron Overload in Pediatric Oncology Patients|Evaluation of Iron Overload in Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients||Feinstein Institute for Medical Research|No|Recruiting|October 2009|April 2011|Anticipated|November 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|160|||Both|78 Months|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients one to ten years post chemotherapy for Ewing sarcoma, osteosarcoma,        rhabdomyosarcoma, AML, or neuroblastoma and patients post-transplant for any malignancy.|December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034072||129010|
NCT01034358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000485|Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease|Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease||Mayo Clinic|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Female|9 Years|26 Years|No|||September 2012|September 21, 2012|December 10, 2009|Yes|Yes||No|September 21, 2012|https://clinicaltrials.gov/show/NCT01034358||128988|
NCT01034631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG GU09-145|BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma|Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors||Hoosier Cancer Research Network|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|December 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034631||128967|
NCT01034930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|316/03-207-507|Clinical Study on the Efficiency of Three Different Attachment Systems for Implant-supported Mandibular Overdenture|A 5-year Prospective Randomised Clinical Study on the Efficiency of Three Different Attachment Systems as Retention for Implant-supported Mandibular Overdenture.||Concordia Dent Srl|Yes|Completed|August 2004|December 2012|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01034930||128944|
NCT01034943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRF Extra|Extraarticular Distal Radius Fractures, X-fix or Volar Fixation|Dorsally Displaced Extraarticular Distal Radius Fractures - Volar Plate or External Fixation. A Prospective Randomized Trial||Karolinska Institutet|No|Completed|August 2009|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|50 Years|74 Years|No|||March 2014|March 12, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034943||128943|
NCT01035502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-205|A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia|A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia||Clavis Pharma|No|Completed|December 2009|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035502||128900|
NCT01035515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204HV102|BIIB014 Cardiovascular Monitoring Study|A Single-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Cardiovascular Effects of Single Doses of Oral BIIB014 in Healthy Volunteers||Biogen|No|Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 17, 2010|December 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01035515||128899|
NCT01035476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSA-P-2008-09|Optimizing NIPPV Use for Patients With ALS|Effectiveness Trial of Detailed NIPPV Feedback to Patients||University of Pittsburgh|Yes|Completed|December 2009|December 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|31|||Both|18 Years|90 Years|No|||January 2016|January 5, 2016|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035476||128902|
NCT01035489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1991|Trial in Cardiac Resynchronization Therapy (CRT): Right Ventricular Apex Versus High Posterior Septum|Echocardiographic Dyssynchrony in Heart Failure in CRT; Right Ventricular Apex v.s. High Posterior Septum||Haukeland University Hospital|No|Active, not recruiting|January 2009|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|90 Years|No|||May 2011|May 23, 2011|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035489||128901|
NCT01035944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-NU-2009-01|Chitosan Dressings to Facilitate Safe Effective Debridement of Chronic Wounds & Minimize Wound Bacterial Re-colonization|Evaluation of Use of Chitosan-Based Dressings to Facilitate Safe, Effective Debridement of Chronic Wounds in Operating Room and Inpatient Ward and Minimize Bacterial Re-Colonization of Wounds.||HemCon Medical Technologies, Inc|No|Terminated|February 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|N/A|No|||May 2014|June 20, 2014|December 17, 2009|Yes|Yes|Unable to meet enrollment milestones|No|May 12, 2014|https://clinicaltrials.gov/show/NCT01035944||128877|Early termination of the study; unable to reach enrollment milestones. No outcome measure data was analyzed; zero participants were analyzed.
NCT01036399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-PTCL-PI-277|Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients|||University of Bologna|Yes|Terminated|November 2008|August 2011|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|July 7, 2009||No|The EC withdrawn the approval becuase of possible conflicts of interests between our Institute    and Supporter (Celgene)|No||https://clinicaltrials.gov/show/NCT01036399||128856|
NCT01037075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906400|Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence|Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence||National Institutes of Health Clinical Center (CC)||Completed|May 2006|January 2013||||Phase 1|Observational|N/A|||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|October 9, 2014|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01037075||128829|
NCT01037088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614658|Effects of Vaporized Marijuana on Neuropathic Pain|CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain||University of California, Davis|No|Completed|December 2009|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|70 Years|No|||April 2013|April 5, 2013|December 17, 2009|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01037088||128828|Inclusion of patients with complex regional pain syndrome type I. In the past, there was no doubt that this disorder should be classified as classical neuropathic pain condition; Unmasking of blinding secondary to the psychoactive effects of cannabis
NCT01032356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WED1|Dynasplint for Distal Radius Fracture|Contracture Reduction Following Distal Radius Fracture Surgical Management||Dynasplint Systems, Inc.|Yes|Not yet recruiting|January 2016|||June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|December 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01032356||129141|
NCT01032642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inany-1|A Thin Catheter For Hystrosalpingography|A Simple Technique to Reduce the Pain in Hysterosalpingography Using A Thin Catheter|HSG|Kasr El Aini Hospital|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Female|18 Years|40 Years|No|||September 2008|December 15, 2009|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032642||129119|
NCT01032655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901042M|The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection|The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection||National Taiwan University Hospital|Yes|Completed|April 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|134|||Both|20 Years|N/A|No|||June 2012|June 23, 2012|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032655||129118|
NCT00992134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VI-1903|Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma|Immunochemotherapy With Rituximab-Bendamustine-Cytarabine for Patients With Mantle Cell Lymphoma Not Eligible for Intensive Regimens or Autologous Transplantation.||St. Bortolo Hospital|Yes|Completed|June 2009|June 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||September 2010|September 25, 2012|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992134||132206|
NCT00992147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTG-adip-301|Safety and Efficacy of Autologous Cultured Adipocytes in Patient With Depressed Scar|A Phase II/III Clinical Study of ANTG-adip for the Treatment of Depressed Scar to Evaluate Safety and Efficacy||Anterogen Co., Ltd.||Completed|May 2004|March 2007|Actual|||Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|19 Years|N/A|No|||October 2009|October 8, 2009|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT00992147||132205|
NCT00992953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05-005|Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)|The Efficacy of Virtual Reality (VR) as an Adjunct Therapy for Acute Combat-related Post-Traumatic Stress Disorder (PTSD) in Non-Combatants||United States Naval Medical Center, San Diego|Yes|Completed|January 2005|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|65 Years|No|||October 2009|October 8, 2009|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992953||132143|
NCT00992966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB048|Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms|Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms.||Deep Breeze|Yes|Suspended||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|3 Years|18 Years|No|Probability Sample|A total number of 80 patients in the age range of 3-18 and consisting of both boys and        girls, preferably in an equal distribution|August 2010|August 19, 2010|October 8, 2009||No|Study initiation has been delayed due to Sponsor decision|No||https://clinicaltrials.gov/show/NCT00992966||132142|
NCT01025401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905|Characterization of Epileptic Motor Patterns by Tridimensional Analysis of Movement 2|Caractérisation et détection Des Mouvements Durant Les Crises d'épilepsie à Des Fins d'Alarme, Pour un Usage en Institution et en Famille.|CAPAMETRIM2|University Hospital, Grenoble|No|Terminated|May 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|6 Years|N/A|No|||November 2010|November 22, 2010|June 29, 2009||No|departure of a collaborator in charge of the data collection|No||https://clinicaltrials.gov/show/NCT01025401||129671|
NCT01033825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-610|Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis|A 6-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of the Potential Inhibitory Effects on the Hypothalamic-Pituitary-Adrenal Axis of Ciclesonide HFA Nasal Aerosol and Ciclesonide Aqueous Nasal Spray in Subjects 12 Years and Older With Perennial Allergic Rhinitis||Sunovion|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|310|||Both|12 Years|N/A|No|||July 2012|July 17, 2012|December 16, 2009|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01033825||129029|Dose levels investigated were higher than the US FDA approved dose (74 mcg once daily) for allergic rhinitis subjects. Publication references to 148 and 282mcg are equivalent to 160 and 320mcg.
NCT01034371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091216|Comparison of One-stop Hybrid Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Disease|Comparison of "One-stop" Hybrid Coronary Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Coronary Artery Disease||China National Center for Cardiovascular Diseases|Yes|Recruiting|December 2009|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||December 2009|December 18, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034371||128987|
NCT01034644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200136_022|Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)|A Multinational, Multicenter, Single Visit, Exploratory Pharmacogenetic Trial and Long-term Follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Trial|PRISMS-15|Merck KGaA|No|Completed|March 2010|January 2011|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|290|Samples With DNA|Whole blood sampling for:      Genetic markers BAbs/NAbs|Both|18 Years|N/A|No|Non-Probability Sample|Group of patients coming from the PRISMS 6789 study|September 2011|July 30, 2014|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01034644||128966|
NCT01034657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BDE04|LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk MDS|A One Year, Open Label, Multicenter Trial of LBH589 Alone or in Combination With ESA in Red Blood Cell Transfusion-dependent LOW and INT-1 MDS Patients Being Either Refractory to ESA or With a Low Probability of Response - the GErman PAnobinostat Low Risk MDS Trial - GEPARD Study|GEPARD|Novartis||Completed|November 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034657||128965|
NCT01034956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.27|Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections|Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections||The New York Eye & Ear Infirmary|No|Completed|November 2009|May 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated by Principal Investigator with facial soft tissue filler within the past        2 years|April 2012|April 29, 2012|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01034956||128942|
NCT01035229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001O2301|Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.|A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study|EVOLVE-1|Novartis|Yes|Completed|April 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|546|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|December 17, 2009|Yes|Yes||No|September 24, 2014|https://clinicaltrials.gov/show/NCT01035229||128921|Three patients (1 in the everolimus arm and 2 in the placebo arm were excluded from the Safety Set. These three patients were randomized but never received any study treatment.
NCT01036009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC# 09082|A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies|A Phase II Study of Preemptive Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions for Achieving Complete Donor Chimerism Following Allogeneic Transplant for Pediatric Hematologic Malignancies||University of California, San Francisco|Yes|Active, not recruiting|October 2009|July 2015|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|6 Months|25 Years|No|||October 2014|October 26, 2014|December 17, 2009|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01036009||128874|
NCT01035983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VML 251-3MAM03|Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches|An Open Label Study to Assess the Safety, Tolerability and Efficacy of Frovatriptan in the Prevention of Menstrually Associated Migraine (MAM) Headaches.|MAM|Endo Pharmaceuticals|Yes|Completed|December 2003|June 2005|Actual|June 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|550|||Female|15 Years|N/A|No|||February 2010|February 12, 2010|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035983||128876|
NCT01035996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905401|Dopamine Function and Reward Processing In Schizophrenia|Dopamine Function and Reward Processing In Schizophrenia||National Institutes of Health Clinical Center (CC)||Recruiting|March 2005|||||N/A|Observational|N/A|||Anticipated|260|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|May 8, 2015|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01035996||128875|
NCT01036412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0456|Chlorhexidine Gel Therapy for Cariogenic Oral Microflora|Chlorhexidine Gel Therapy for Cariogenic Oral Microflora in Irradiated Head and Neck Cancer Patients||M.D. Anderson Cancer Center|No|Completed|December 2009|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|N/A|No|||August 2012|February 17, 2016|December 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01036412||128855|
NCT01036438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA 416|Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers|A Double-blind, Comparative, Superiority, Multi-centre Investigation Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers||Molnlycke Health Care AB|No|Completed|December 2009|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||December 2013|September 11, 2014|December 18, 2009||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01036438||128854|
NCT01037426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH190609-V1|Falls and Cardiovascular Events in Pacemaker Patients|Falls and Cardiovascular Events in Elderly Patients With Sinus Node Disease Treated With a MVPTM Pacemaker According to the ESC 2007 Guidelines||Medtronic Bakken Research Center|No|Completed|August 2009|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|86|||Both|50 Years|N/A|No|||April 2014|April 3, 2014|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01037426||128803|
NCT01037439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAEssenASV|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2008|||||N/A|N/A|N/A||||||||||||||December 21, 2009|December 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037439||128802|
NCT01037452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145-G-201|Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn|A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Proof-of-Concept Trial to Assess Relief of Meal Induced Heartburn by a Combination of Lansoprazole 15 mg and Antacid Versus Lansoprazole 15 mg and Antacid (Calcium Carbonate and Magnesium Hydroxide) Alone||Novartis||Completed|December 2009|||January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|N/A|No|||March 2011|March 1, 2011|December 22, 2009|Yes|Yes||No|December 14, 2010|https://clinicaltrials.gov/show/NCT01037452||128801|
NCT01032369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-NV-587-CTIL|The Additive Effect of Cognitive Behavioral Treatment (CBT) to Conventional Weight Loss Intervention Program for Young Adults With Intellectual Disabilities|The Additive Effect of Cognitive Behavioral Treatment - CBT to Conventional Weight Loss Intervention Program for Young Adults With Intellectual Disabilities||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2009|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|35 Years|No|||December 2009|December 14, 2009|December 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01032369||129140|
NCT01032382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-PERU-08-03, A-15809|Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)|Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Peru||U.S. Army Medical Research and Materiel Command|No|Completed|January 2010|July 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|5 Years|N/A|No|||August 2014|June 23, 2015|December 14, 2009|No|Yes||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01032382||129139|All randomized subjects were included in the mITT analysis. All subjects also met the criteria for the evaluable subset; therefore, no separate analysis of an evaluable subset of subjects was performed.
NCT01037400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKR Study|Biochemical Approach to Measuring Surgical Trauma|Further Development of a Biochemical Approach to Measuring Surgical Trauma to Musculoskeletal Tissues||McMaster University|No|Withdrawn|February 2010|||February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Plasma and Serum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee        replacement surgery with no musculoskeletal injury requiring medical attention in the past        3 months or producing pain in the previous 2 weeks and no inflammatory disease other than        osteoarthritis.|September 2014|September 16, 2014|December 22, 2009||No|No patients recruited|No||https://clinicaltrials.gov/show/NCT01037400||128805|
NCT01037413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXC 001-203|Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery|A Phase 2, Randomized, Double-Blind, Within-subject Controlled Study to Evaluate Efficacy and Safety of EXC 001 for the Amelioration of Scarring Following Revision of Scars Resulting From Prior Breast Surgery in Adult Female Subjects||Pfizer|Yes|Completed|November 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|December 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037413||128804|
NCT00992186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015907|A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer|An Open-Label, Multicenter, Phase 2 Study of Single-Agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects With Metastatic Castrate-Resistant Prostate Cancer||Centocor Research & Development, Inc.|Yes|Completed|September 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Male|18 Years|N/A|No|||June 2013|June 18, 2013|September 29, 2009|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT00992186||132202|
NCT00992407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015841|An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder|A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder||Janssen Korea, Ltd., Korea|No|Completed|December 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|55 Years|No|||February 2014|February 6, 2014|October 8, 2009|Yes|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT00992407||132185|
NCT00992420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P95082S|Genotype Information and Functional Testing Study|GIFT: Genotype Information and Functional Testing Study|GIFT|Scripps Health|No|Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients meeting inclusion criteria for GRAVITAS who undergo VerifyNow blood sampling for        VerifyNow P2Y12 platelet function testing and IVRS entry for GRAVITAS        randomization/selection determination.|August 2010|January 13, 2011|October 5, 2009||No||No||https://clinicaltrials.gov/show/NCT00992420||132184|
NCT00992433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0073|H1N1 Vaccine at Two Dose Levels in HIV Positive Adults|A Phase II Study in HIV-seropositive Adults to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|192|||Both|18 Years|64 Years|No|||February 2011|May 10, 2012|October 8, 2009|Yes|Yes||No|October 13, 2011|https://clinicaltrials.gov/show/NCT00992433||132183|
NCT00992706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 92/08|F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer|Local Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (PPE) in Patients Treated With Pegylated Liposomal Doxorubicin: A Randomized, Multicenter, Double Blinded, Phase III Trial||Swiss Group for Clinical Cancer Research|No|Completed|September 2009|June 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|1||Actual|91|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992706||132162|
NCT00992992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|393229/005|Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma|Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma||GlaxoSmithKline||Completed|June 2001|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2013|February 27, 2014|October 8, 2009|Yes|Yes||No|February 27, 2014|https://clinicaltrials.gov/show/NCT00992992||132140|
NCT01025726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProjectPATH|Positive Action for Today's Health|Improving Safety and Access for Physical Activity|PATH|University of South Carolina|Yes|Completed|July 2007|June 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|439|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 21, 2012|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01025726||129646|
NCT01025414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fistula-1|Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study|The Use of Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective, Randomized Clinical Trial|FIS-1|Jagiellonian University|No|Completed|July 2006|November 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2009|December 2, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025414||129670|
NCT01034085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909445|Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia|Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia||National Institutes of Health Clinical Center (CC)||Completed|June 2009|June 2013||||N/A|Observational|N/A|||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|October 9, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034085||129009|
NCT01034384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999901357|Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence|Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence||National Institutes of Health Clinical Center (CC)||Completed|December 2000|November 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|125|||Both|18 Years|50 Years|No|||November 2012|October 23, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034384||128986|
NCT01034670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06302009-2800|Advanced Gastrointestinal Endoscopic Imaging|Advanced Gastrointestinal Endoscopic Imaging||Stanford University|Yes|Suspended|June 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||February 2011|February 17, 2011|November 13, 2009|No|Yes|Device not ready|No||https://clinicaltrials.gov/show/NCT01034670||128964|
NCT01034683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACH2009001|Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma|Phase 3 Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Recurrent or Metastatic Esophageal Carcinoma||Taian Cancer Hospital|No|Active, not recruiting|December 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||December 2009|January 4, 2010|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034683||128963|
NCT01034969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE049-5134|Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS)|Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS)||Shire|No|Recruiting|May 2009|December 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|790|||Both|N/A|N/A|No|Non-Probability Sample|1. Patients receiving at least one dose of subcutaneous Firazyr®.          2. Written informed consent from the patient or, for patients below 18, consent from             parents and or patient's legal representative.|January 2015|January 29, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01034969||128941|
NCT01035242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE 540/3-1|"Association Splitting" in Obsessive-Compulsive Disorder (OCD)|"Association Splitting" Compared With Cognitive Remediation (CR) in Obsessive-compulsive Disorder (OCD): a Randomized Controlled Trial||Universitätsklinikum Hamburg-Eppendorf|No|Completed|March 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|65 Years|No|||March 2015|March 24, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035242||128920|
NCT01035528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HealthyHeart|Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)|Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data||Munich Municipal Hospital|Yes|Active, not recruiting|April 2005|August 2010|Anticipated|February 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|40 Years|80 Years|No|||August 2004|December 17, 2009|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035528||128898|
NCT01036516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999998391|PET Assays of Striatal Dopamine Marker in Cocaine Craving|PET Assays of Striatal Dopamine Markers in Cocaine Craving||National Institutes of Health Clinical Center (CC)||Completed|June 1998|March 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|14|||Both|21 Years|50 Years|No|||March 2012|March 28, 2012|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036516||128852|
NCT01036529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2005|Spinal Cord Stimulation With Precision® System Versus Reoperation for Failed Back Surgery Syndrome|Spinal Cord Stimulation With Precision® Spinal Cord Stimulation System Versus Reoperation for Failed Back Surgery Syndrome|Evidence|Boston Scientific Corporation|No|Terminated|February 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 30, 2013|December 17, 2009|Yes|Yes|Closed due to continued slow enrollment.|No|June 4, 2013|https://clinicaltrials.gov/show/NCT01036529||128851|This study was terminated early due to slow enrollment. Only 28 of the 200 planned subjects were enrolled. Based on the small numbers and early termination, the primary outcome measures were not analyzed.
NCT01036568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906405|Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia|Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia||National Institutes of Health Clinical Center (CC)||Completed|February 2006|March 2013||||N/A|Observational|N/A|||Anticipated|225|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||March 2013|October 23, 2014|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036568||128850|
NCT01036490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7264-R|Exercise in Obese Diabetic Patients With Chronic Kidney Disease|Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease|EX-ODCKD|VA Office of Research and Development|No|Active, not recruiting|July 2010|June 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036490||128853|
NCT01037101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-01-1896|D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights|D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults||CAMC Health System|No|Recruiting|July 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01037101||128827|
NCT01037114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112266|Long-term Persistence Study in Healthy Adults Previously Vaccinated With TwinrixTM Adult|An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-032 (208127/022) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.||GlaxoSmithKline||Completed|January 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|November 19, 2015|December 17, 2009|Yes|Yes||No|April 1, 2011|https://clinicaltrials.gov/show/NCT01037114||128826|A decrease in specificity of the anti-HB ELISA had been observed in some studies for low levels of antibody(10-100 mIU/mL).The tables show updated results following complete retesting/reanalysis for Y16-18.Y19 & 20 results were only analyzed by CLIA.
NCT01037478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4SC-201-2-2009|Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma|A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma|SAPHIRE|4SC AG||Completed|December 2009|March 2013|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037478||128799|
NCT01032395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_16TP|Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus|A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus||Chiltern Pesquisa Clinica Ltda||Completed|March 2010|August 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|342|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032395||129138|
NCT01032408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_14TP|Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection|A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Infection||Chiltern Pesquisa Clinica Ltda||Completed|April 2010|July 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|154|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032408||129137|
NCT01032759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019279|Memantine and Postoperative Pain|Memantine for Postoperative Analgesia||Duke University|No|Terminated|December 2009|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Male|18 Years|75 Years|No|||January 2016|February 15, 2016|December 14, 2009|Yes|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT01032759||129111|
NCT01032720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01334|Ultrasound (US)-Guided Versus Sham Ultrasound Corticosteroid (CS) Knee Injections|Ultrasound-guided Versus Sham Ultrasound Corticosteroid Knee Injections||VA Connecticut Healthcare System|No|Terminated|January 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|40 Years|89 Years|Accepts Healthy Volunteers|||February 2012|July 5, 2015|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032720||129114|
NCT01032733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3992006|Biological Effects of Weight Loss In Older, Obese Women|Biological Effects of Weight Loss Plus Exercise in Obese Older African-American Women: An Investigation of Aging-related Changes in Black and White Women|WL+E|University of Florida|No|Completed|September 2006|October 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|55 Years|79 Years|Accepts Healthy Volunteers|||May 2012|May 11, 2012|December 14, 2009||No||No|February 14, 2012|https://clinicaltrials.gov/show/NCT01032733||129113|Limitations include the following: (1) the sample size was relatively small,(2)the study was not adequately powered to detect differences between African American and Caucasian women in response to the intervention, (3) inclusion of only women.
NCT01032746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000661288|Personal Electronic Health Records in Improving Screening Rates for Colorectal Cancer|Use of a Personal Health Record to Improve Colorectal Cancer Screening||National Cancer Institute (NCI)||Recruiting|March 2005|||September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Screening|1||Anticipated|1000|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||June 2011|December 17, 2013|December 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01032746||129112|
NCT00993005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0910-CU|CICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars|Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Hypertrophic Scars and Keloids Scars.||Catalysis SL|Yes|Completed|October 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|55 Years|No|||December 2010|December 7, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00993005||132139|
NCT01024790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13269|Exercise Study to Help Patients Who Have Type 2 Diabetes and Depression.|Behavioral Activation Enhanced Exercise Intervention:Pre-Pilot||University of Massachusetts, Worcester|Yes|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Female|21 Years|65 Years|No|||October 2013|October 7, 2013|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024790||129718|
NCT01024803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-MC-CT-2009|Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients|Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Patients With Degenerative Retinal Diseases||Retina Implant AG|Yes|Active, not recruiting|December 2009|April 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|78 Years|No|||October 2015|October 26, 2015|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01024803||129717|
NCT00992446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2292.00|Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|December 2009|||December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|March 4, 2016|October 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992446||132182|
NCT00992719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0072|Novartis H1N1 Vaccine in Pregnant Women|A Phase II Study In Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|84|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||July 2010|August 1, 2013|October 8, 2009|Yes|Yes||No|January 19, 2012|https://clinicaltrials.gov/show/NCT00992719||132161|Although 200 pregnant and 100 non-pregnant subjects were targeted for enrollment, enrollment closed in May 2010 prior to reaching the target due to slow accrual.
NCT00992979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL09-01|Therapeutic Massage to Manage Withdrawal Related Anxiety|Use of Massage Therapy to Reduce Anxiety and Improve Sleep in Patients Participating in an Inpatient Withdrawal Management (Detox) Program: A Randomized Controlled Pilot Study||Dalhousie University|Yes|Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2009|October 8, 2009|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT00992979||132141|
NCT01025089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-038|Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma|A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|December 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025089||129695|
NCT01025765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905056M|The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin|An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin||National Taiwan University Hospital|No|Active, not recruiting|November 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|80 Years|No|||November 2012|November 23, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025765||129643|
NCT01034098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701144|Ventilatory Constraint, Breathing Pattern and Ventilatory Responses in Obese Postmenopausal Women|Ventilatory Constraint, Breathing Pattern and Ventilatory Responses in Obese Postmenopausal Women||National Taiwan University Hospital|Yes|Completed|December 2005|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|||Female|50 Years|69 Years|Accepts Healthy Volunteers|Probability Sample|Postmenopausal women (for at least 1 year) who aged below 69 y/o without hormone        replacement therapy|December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034098||129008|
NCT01034982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00017|AZD9668 Relative Bioavailability|A Phase I Open-label, Single-centre, Two Cohort Crossover Study to Assess the Relative Bioavailability After Oral Administration of AZD9668 Free Base Dosed as a Suspension Compared to AZD9669 Tosylate Salt Dosed as a Tablet||AstraZeneca|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01034982||128940|
NCT01035255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2314|This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction|PARADIGM-HF|Novartis||Completed|December 2009|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8442|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|December 16, 2009|Yes|Yes||No|August 6, 2015|https://clinicaltrials.gov/show/NCT01035255||128919|
NCT01035541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IROM|Goal Directed Hemodynamic Management and Renal Outcome After Major Non-cardiac Surgery|Can Goal Directed Hemodynamic Management Improve Renal Outcome After Major Non-cardiac Surgery?|IROM|Technische Universität München|Yes|Completed|December 2009|||December 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|180|||Both|18 Years|N/A|No|Probability Sample|Patients udndergoing Major non-cardiac surgery|January 2013|January 16, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035541||128897|
NCT01036022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111407|Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis|A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis||GlaxoSmithKline|No|Completed|September 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|65 Years|No|||August 2013|September 24, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036022||128873|
NCT01036594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC # 09553|Ketoconazole and Dexamethasone in Prostate Cancer|An Endocrinologically and Pharmacologically Directed Trial of Ketoconazole and Corticosteroids in Castration Resistant Prostate Cancer|Keto/Dex|University of California, San Francisco|Yes|Active, not recruiting|December 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01036594||128848|
NCT01037166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-052|Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy|A Phase II Study in Japan of the Safety And Antiviral Activity of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B With Incomplete Response to Current Lamivudine Therapy||Bristol-Myers Squibb|Yes|Completed|December 2002|February 2005|Actual|February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|20 Years|75 Years|No|||June 2010|January 24, 2011|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037166||128822|
NCT01037179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-050|An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis|An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis||Alcon Research|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|12 Years|N/A|No|||July 2014|July 31, 2014|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037179||128821|
NCT01037127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113583|Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor|An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated With or Without a BRAF Inhibitor||GlaxoSmithKline||Completed|November 2009|January 2013|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||January 2014|February 13, 2014|November 25, 2009|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01037127||128825|
NCT01037465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26547|ROS Signaling in Endothelial Function|ROS Signaling in Endothelial Function||Boston University|No|Active, not recruiting|September 2008|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|43|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01037465||128800|
NCT01032772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U84DD000438|ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy|ChoicesPlus: Preconception Approach to Reducing Alcohol- and Tobacco-Exposed Pregnancy|ChoicesPlus|University of Texas at Austin|Yes|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|261|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||November 2015|November 23, 2015|December 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01032772||129110|
NCT01035021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA_M_relax|Neuromuscular Block in Laryngeal Mask Airway(LMA) Insertion|Effect of Neuromuscular Blockade on the Insertion of ProSeal™ Laryngeal Mask Airway and Postoperative Pharyngolaryngeal Discomfort||Seoul National University Bundang Hospital|Yes|Completed|June 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Female|18 Years|70 Years|No|||November 2013|November 14, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035021||128937|
NCT01033045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGORA|Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure|Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure||Fundacion IMIM|Yes|Completed|September 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2178|||Both|18 Years|N/A|No|Probability Sample|Patients of both sexes older than 18 years old with hepatitis C who had previously failed        to the standard therapy.|February 2016|February 11, 2016|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033045||129089|
NCT01033370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003478|A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)|A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)|PROMPT|The Methodist Hospital System|No|Terminated|November 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 15, 2009|No|Yes|Project lacked funding.|No||https://clinicaltrials.gov/show/NCT01033370||129064|
NCT00992732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQP-1004-EB-03|Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders|A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders||HemaQuest Pharmaceuticals Inc.|Yes|Terminated|May 2010|||November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|3 Years|N/A|No|||July 2011|July 28, 2011|October 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00992732||132160|
NCT01024296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11062009-4361|Efficacy Study to Evaluate Laparoscopic Fascial Closure Device|Pivotal Study to Evaluate the Efficacy of a Laparoscopic Port Closure Device||Stanford University||Recruiting|May 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 11, 2009|November 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01024296||129756|
NCT01025076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008913|Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma|Phase II Study of Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma||University of Alberta|No|Completed|February 2009|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||February 2014|February 12, 2014|December 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025076||129696|
NCT01025375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HumBio_Westerterp08_2|Effects of Inulin on Satiety and Food Intake|Effects of Inulin on Satiety and Food Intake|Inulin|Maastricht University Medical Center|Yes|Completed|January 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025375||129673|
NCT01025388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-SA-CRE-2009/1|Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|CEPHEUS|AstraZeneca|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|4053|None Retained|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Subject who visits the primary care clinics, cardiology clinics and internal medicine        clinics, and who fulfil the inclusion criteria.|May 2011|February 7, 2013|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025388||129672|
NCT01025700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01999|Nabilone & Marijuana Addiction|A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal||University of British Columbia|No|Completed|June 2009|October 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Both|19 Years|65 Years|No|||February 2011|February 16, 2011|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025700||129648|
NCT01025713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-221-0106|A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)||Gilead Sciences|No|Withdrawn|December 2009|April 2010|Anticipated|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||July 2015|July 7, 2015|December 1, 2009||No|Development program terminated.|No||https://clinicaltrials.gov/show/NCT01025713||129647|
NCT01025102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gymoese007|The Addition of Sufentanil Interscalene Block in Shoulder Surgery|Phase III Study of the Addition of Sufentanil to Interscalene Block in Shoulder Surgery||Frederiksberg University Hospital|Yes|Completed|January 2010|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|26|||Both|18 Years|80 Years|No|||March 2013|March 30, 2013|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025102||129694|
NCT01025115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0918-CU|Diamel in the Treatment of Metabolic Syndrome|Efficacy of Diamel in the Treatment of Metabolic Syndrome||Catalysis SL|Yes|Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|70 Years|No|||March 2010|March 30, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025115||129693|
NCT01026064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112593|Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides|Utility of the Cantharidin-induced Skin Blister Assay for Evaluation of Anti-inflammatory Effects of Macrolides in Healthy Volunteers||GlaxoSmithKline||Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|44|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|January 4, 2013|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026064||129620|
NCT01034397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22648|A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs|A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs||Hoffmann-La Roche||Completed|March 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 16, 2009||No||No|July 9, 2014|https://clinicaltrials.gov/show/NCT01034397||128985|
NCT01034696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3224|Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting|Pain Prevalence and Risk Factors Amongst Sarcoma/Melanoma Oncology Outpatients. A Baseline, Cross Sectional Study Towards a Pain Free Hospital||Royal Marsden NHS Foundation Trust|No|Recruiting|May 2009|January 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Participants attending sarcoma and melanoma out patients clinics at the Royal Marsden        Hospital.|December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034696||128962|
NCT01035268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 SEIN 08|Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella|Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella. Adipocyte Transplant for Esthetical Relapse Treatment of Breast Conservative Treatment|GRATSEC|Institut Claudius Regaud|No|Active, not recruiting|January 2010|August 2026|Anticipated|August 2026|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Female|18 Years|N/A|No|||March 2015|March 26, 2015|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01035268||128918|
NCT01035281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U Calgary # UCNABDPN01|Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain|A Randomized, Double-Blind, Placebo Controlled, Parallel Assignment, Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain||University of Calgary|Yes|Recruiting|January 2008|April 2011|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2009|December 17, 2009|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035281||128917|
NCT01035554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|687|Behavioral Study to Control Blood Pressure|Effect of a Novel Behavioral Intervention on Blood Pressure Control in Hypertension Patients||Milton S. Hershey Medical Center|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|203|||Both|21 Years|80 Years|No|||November 2013|November 7, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035554||128896|
NCT01035567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N R13 008406/2009|Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease|Prospective Randomised Pilot Study Evaluating the Safety and Efficacy of Hybrid Revascularization in Multivessel Coronary Artery Disease|POL-MIDES|Silesian Centre for Heart Diseases|Yes|Completed|November 2009|October 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||December 2013|December 1, 2013|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035567||128895|
NCT01036035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THVD-201-001|Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects|Effects of THVD-201 on Pharmacokinetics and Pharmacodynamics of Tolterodine in Healthy Subjects||TheraVida, Inc.|Yes|Completed|September 2009|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01036035||128872|
NCT01036048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N28LBCF80-07|A Meta-analysis of Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease|Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease: Insights From a Meta-analysis||Catholic University of the Sacred Heart|No|Completed|May 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|5806|||Both|N/A|N/A|No|Non-Probability Sample|patients with CABG disease|December 2009|December 18, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01036048||128871|
NCT01036581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903380|Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging|Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging||National Institutes of Health Clinical Center (CC)||Recruiting|July 2003|||||N/A|Observational|N/A|||Anticipated|600|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|February 3, 2016|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036581||128849|
NCT01037140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005581-31|Effects of Vitamin D Supplementation in Obesity|Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Subject.||University of Aarhus|Yes|Completed|January 2010|July 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01037140||128824|
NCT01037153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999902371|Effects of Nicotine on Brain Activity as Measured by fMRI|Effects of Nicotine on Brain Activity as Measured by fMRI||National Institutes of Health Clinical Center (CC)||Completed|August 2002|July 2011||||N/A|Observational|N/A|||Anticipated|128|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 26, 2011|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01037153||128823|
NCT01036724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWICO1|Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation|Comparative Study of Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation|CO1|Biosense Webster, Inc.|No|Terminated|November 2009|||August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|107|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects referred for Radiofrequency ablation treatment for paroxysmal atrial        fibrillation.|July 2014|July 17, 2014|December 17, 2009||No|Enrollment challenges|No|June 18, 2014|https://clinicaltrials.gov/show/NCT01036724||128842|The study was terminated early, with 107 enrolled and 93 evaluable subjects, due to difficulty enrolling despite prolonged extension of the enrollment period. The original design called for 176 enrolled and 122 evaluable patients.
NCT01037192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOD|Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections|Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections|VOD|Fraser Health|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|19 Years|70 Years|No|||August 2015|August 18, 2015|December 18, 2009||No||No|May 10, 2011|https://clinicaltrials.gov/show/NCT01037192||128820|The main limitation was low enrollment, primarily caused by stringent inclusion criteria. The age limitation was required to ensure safe vancomycin administration. The weight limitation was required for medication preparation.
NCT01037491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH97-10-04|Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets|Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer||Taipei Veterans General Hospital, Taiwan||Recruiting|October 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||June 2010|June 6, 2010|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037491||128798|
NCT01032421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-284|Gonadal Steroid Manipulation and Personality Characteristics: Association With Mood Fluctuations and in Vitro Fertilization (IVF) Outcomes|Gonadal Steroid Manipulation and Personality Characteristics: Association With Mood Fluctuations & IVF Outcomes|IVF|Tel-Aviv Sourasky Medical Center|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women admitted for their first or second IVF cycle, under the age of 42. Please see the        detailed inclusion and exclusion criteria.|December 2009|December 13, 2009|November 25, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01032421||129136|
NCT01032434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS 458774|An 8-week, Open-label Study to Evaluate the Effect of Sertraline on Polysomnogram in Depressive Patients With Insomnia|An 8-week, Open-label Study to Evaluate the Effect of Sertraline on Polysomnogram in Depressive Patients With Insomnia||Guang Dong Provincial Mental Health Institute|No|Completed|December 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032434||129135|
NCT01035307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML09B2|Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421|Genomic and Proteomic Profiling of Childhood AML||Children's Oncology Group|No|Active, not recruiting|October 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|90|Samples Without DNA|Collected for laboratory studies, including phospho-protein signaling and gene expression      profiling studies.|Both|N/A|20 Years|No|Non-Probability Sample|Previously enrolled on POG 9421|May 2015|May 4, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035307||128915|
NCT01036087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0372|Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer|Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2010|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01036087||128868|
NCT01036646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0125|User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity||ECLIPSE-02|Biosite|No|Completed|August 2009|September 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|183|Samples Without DNA|Plasma specimens retained for reference method comparison.|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from their primary care clinic.|February 2013|February 8, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036646||128846|
NCT01024075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22476|Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes|The Adjunctive Use of a Dexamethasone-Sinufoam Mixture on Endoscopic Sinus Surgery Outcomes: A Randomized, Double-Blind, Placebo-controlled Trial||University of Calgary|No|Recruiting|November 2009|May 2011|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2009|December 1, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024075||129773|
NCT01024309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09072|A Trial Comparing Mini-posterior Approach and Direct Anterior Approach|A Prospective, Randomized, Clinical Trial Comparing the Clinical Outcomes Following Total Hip Arthroplasty by a Single Surgeon Using Either a Mini-posterior Approach or a Direct Anterior Approach||OrthoCarolina Research Institute, Inc.|Yes|Completed|November 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|25 Years|80 Years|No|||October 2014|October 28, 2014|November 30, 2009||No||No|December 31, 2013|https://clinicaltrials.gov/show/NCT01024309||129755|
NCT01024530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVY02|Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy|||Shin Kong Wu Ho-Su Memorial Hospital||Recruiting|May 2009|||May 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|20 Years|79 Years|No|||December 2009|December 11, 2009|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024530||129738|
NCT01024816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT004569-01A2|Practicing Restorative Yoga or Stretching for the Metabolic Syndrome|Practicing Restorative Yoga or Stretching for the Metabolic Syndrome|PRYSMS|University of California, San Francisco|Yes|Completed|December 2009|May 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|21 Years|65 Years|No|||June 2014|June 24, 2014|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024816||129716|
NCT01025427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H52889-35080|HIV Persistence and Viral Reservoirs|Treating HIV-infected Elite Controllers as a Model of HIV Remission||University of California, San Francisco|Yes|Active, not recruiting|December 2009|June 2013|Anticipated|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||April 2012|April 2, 2012|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01025427||129669|
NCT01025440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPHC LP-CPAP09-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2009|||||N/A|N/A|N/A||||||||||||||October 26, 2010|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025440||129668|
NCT01025453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-148|Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer|Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|N/A|No|||May 2015|May 14, 2015|December 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025453||129667|
NCT01026077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-30|The Savella Pregnancy Registry|The Savella Pregnancy Registry|SPR|INC Research|Yes|Recruiting|November 2009|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Women who are exposed to Savella during pregnancy.|December 2015|December 15, 2015|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01026077|1 Year|129619|
NCT01034995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI5687|A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder|An Eight-week, Multinational, Multicenter, Double-blind, Active- and Placebo-controlled Clinical Trial Evaluating the Efficacy and Tolerability of Three Fixed Doses of SSR125543 (20 mg Daily, 50 mg Daily and 100 mg Daily) in Outpatients With Major Depressive Disorder|AGATE|Sanofi|Yes|Completed|February 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|580|||Both|18 Years|64 Years|No|||April 2011|April 13, 2011|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01034995||128939|
NCT01033422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-231GL|Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure|A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure||Can-Fite BioPharma|No|Recruiting|October 2010|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033422||129060|
NCT01034202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8630-1822|Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®|A Randomised, Double Blind, Placebo-controlled, Single Dose, Dose-escalating Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin® SimpleXx® in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|August 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|56|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|December 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034202||129000|
NCT01034215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMR-117597|Multi-Media Imagery Program for Breast Cancer Patients (Phase II)|Multi-Media Imagery Program for Breast Cancer Patients (Phase II)||Mind Matters Research LLC|No|Recruiting|August 2008|October 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|135|||Both|18 Years|N/A|No|||December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034215||128999|
NCT01035658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GYN 26|Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma|A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma||SCRI Development Innovations, LLC|No|Terminated|January 2010|March 2014|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|22|||Female|18 Years|N/A|No|||May 2015|May 18, 2015|December 17, 2009|No|Yes|Based on analyses in Phase I, the study did not advance to Phase II.|No|December 16, 2014|https://clinicaltrials.gov/show/NCT01035658||128888|Per protocol, study did not proceed to phase II based on analyses from phase I. Therefore, Phase II outcomes (all outcomes other than determination of the MTD) were not evaluated and will not be posted.
NCT01035671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRD02|Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia|A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia||Penwest Pharmaceuticals Co.|No|Completed|December 2009|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|60 Years|No|||April 2011|April 21, 2011|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035671||128887|
NCT01036763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.455|Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example|Assessment of COPD Therapy From the Physicians Perspective Using Tiotropium as an Example||Boehringer Ingelheim||Completed|January 2010|||August 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients|February 2014|February 27, 2014|December 18, 2009||||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01036763||128841|
NCT01032785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0049-09-WOMC|Timing of Closure of Patent Foramen Ovale Following Birth|Timing of Closure of Patent Foramen Ovale and Patent Ductus Arteriosus Following Birth||Wolfson Medical Center|Yes|Recruiting|December 2009|March 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|4 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Population consits of newborn babies born in term and under normal delivery in Wolfson        M.C.|September 2010|September 12, 2010|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032785||129109|
NCT01032798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/00121-9|Local Anesthetics New Formulations: From Development to Clinical Tests|Efficacy and Pharmacokinetics of Liposomal Mepivacaine Formulations in Dentistry||University of Campinas, Brazil|Yes|Completed|May 2007|May 2008|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|1||Actual|30|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2007|January 19, 2010|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01032798||129108|
NCT01033058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN2009CV005|Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI|Effect of Intensive Statin Treatment on 90-day Prognosis of STEMI Patients Undergoing Emergency Primary PCI Compared With Usual Care||Beijing Chao Yang Hospital|No|Not yet recruiting|December 2009|June 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|75 Years|No|||November 2009|December 23, 2009|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033058||129088|
NCT01033942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 082|Pre-Exposure Prophylaxis in YMSM|Acceptability and Feasibility of a Pre-Exposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men (YMSM)||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|August 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|79|||Male|18 Years|22 Years|Accepts Healthy Volunteers|||August 2013|January 21, 2014|December 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033942||129020|
NCT01034163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589E2301|A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma|A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant|PATH|Novartis|Yes|Completed|June 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01034163||129003|
NCT01034748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471020|A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-00299804 in Healthy Male Volunteers||Pfizer|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|December 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034748||128958|
NCT01036113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2208-03|A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer|A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)|PEG-SN38|Enzon Pharmaceuticals, Inc.|Yes|Active, not recruiting|November 2009|June 2013|Anticipated|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Female|18 Years|N/A|No|||October 2012|October 1, 2012|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01036113||128867|
NCT01032460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMAC-3|Comparison of Two Novel Indirect Laryngoscopes to the Macintosh Laryngoscope in Patients With Cervical Spine Immobilization.|||University College Hospital Galway|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|85 Years|No|||July 2010|November 8, 2010|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032460||129133|
NCT01024088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P061016 -CRC 06040|Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.|Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.|DGVSB|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patient admitted in ICU with GBS and respiratory risk|February 2011|September 15, 2014|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024088||129772|
NCT01024569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B050003|Randomized Controlled Trial of Wellness Recovery Action Planning|Mental Illness Self-Management Through Wellness Recovery Action Planning In Ohio|WRAP RCT|University of Illinois at Chicago|Yes|Completed|December 2007|October 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|550|||Both|18 Years|N/A|No|||December 2009|December 2, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024569||129735|
NCT01024543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 06-2-074|Role of Angiotensin II in Insulin-induced Microvascular Activity|Role of Angiotensin II in Insulin-induced Microvascular Activity||Maastricht University Medical Center|No|Completed|October 2006|November 2009||November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2009|December 1, 2009|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01024543||129737|
NCT01024556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS OBS T-002|Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects|Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects|ISS OBS T-002|Istituto Superiore di Sanità|No|Completed|March 2008|February 2012|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|142|Samples With DNA|whole blood, serum, PBMCs|Both|18 Years|N/A|No|Non-Probability Sample|Hiv-1-infected haart-treated adult subjects|March 2016|March 3, 2016|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024556||129736|
NCT01024829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET Boost|Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC|Dose Escalation by Boosting Radiation Dose Within the Primary Tumor on the Basis of a Pre-treatment FDG-PET-CT Scan in Stage IB, II and III NSCLC: a Randomized Phase II Trial|PET Boost|The Netherlands Cancer Institute|Yes|Suspended|May 2010|August 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|December 1, 2009||No|safety issue|No||https://clinicaltrials.gov/show/NCT01024829||129715|
NCT01025791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8266-001|A Single Dose Study of MK8266 (8266-001)|A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266||Merck Sharp & Dohme Corp.|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|December 3, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01025791||129641|
NCT01025804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interfant-06, NOPHO|Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06|Post-marketing Surveillance Study of the Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06||Aarhus University Hospital|No|Completed|December 2009|December 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|Samples Without DNA|Serum is retained for measurement of enzyme activities and antibodies|Both|N/A|1 Year|No|Non-Probability Sample|Infants (children < 1 year) with ALL treated according to Interfant-06 at one of the        Pediatric Oncology Centers in the Nordic Countries|March 2016|March 3, 2016|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025804||129640|
NCT01027195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-615|Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty|Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty|Hip|The Cleveland Clinic|Yes|Completed|August 2006|June 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|85 Years|No|||October 2012|October 30, 2012|December 3, 2009|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01027195||129534|
NCT01027208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA163-130|A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline|A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline And Who Are Taxane Resistant Who Have Completed Study CA163107 And Who Are Benefiting From Continuation On Therapy With Ixabepilone||Bristol-Myers Squibb|Yes|Completed|December 2006|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|20 Years|N/A|No|||January 2010|February 3, 2010|December 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01027208||129533|
NCT01035294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13078|A Mindfulness-based Intervention for Treatment of Anxiety in ICD (Implantable Cardioverter Defibrillator) Patients|A Mindfulness-based Intervention for Treatment of Anxiety in ICD Patients||University of Massachusetts, Worcester|Yes|Completed|July 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|21 Years|N/A|No|||January 2012|January 25, 2012|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01035294||128916|
NCT01037244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-01209|Treatment of Erectile Dysfunction I|Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction||Warner Chilcott|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|618|||Male|19 Years|N/A|No|||December 2011|December 21, 2011|October 19, 2009|Yes|Yes||No|July 12, 2011|https://clinicaltrials.gov/show/NCT01037244||128816|
NCT01035333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-016|A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.|A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.||Albany College of Pharmacy and Health Sciences|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|December 15, 2009|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT01035333||128913|High drop out rate. Patients did not return to clinic and were lost to follow up.
NCT01036139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-10 / BF 2.649|Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease|A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase|HARPS1|Bioprojet|No|Completed|December 2009|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|268|||Both|30 Years|80 Years|No|||April 2013|April 11, 2013|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01036139||128865|
NCT01036165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29652|A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study|A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of an Electronic Autoinjector (RebiSmart™) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc) Three Times a Week (Tiw)|Performs|EMD Serono|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|103|||Both|18 Years|65 Years|No|||August 2013|August 2, 2013|December 18, 2009|Yes|Yes||No|November 30, 2010|https://clinicaltrials.gov/show/NCT01036165||128864|
NCT01036633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110227|Oral Mucositis in Patients Undergoing Antineoplastic Chemotherapy|Use of an Infrared Thermometer to Grade the Severity of Oral Mucositis in Patients Undergoing Antineoplastic Chemotherapy|Mucositis|University of Arkansas|No|Completed|August 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|4|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patients receiving Chemotherapy for Multiple Myeloma and suffering with mucositis|March 2012|March 21, 2012|October 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01036633||128847|
NCT01033383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908005581|Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents|Pilot Study: Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents||Yale University|No|Completed|December 2009|December 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|80|||Female|65 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 12, 2013|December 15, 2009||No||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01033383||129063|Of 320 urine specimens that should have been collected by nursing staff, 302 (94%) urine cultures and 294 (92%) urinalyses were obtained.
NCT01033396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0711005|The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis|A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.||Pfizer|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|60 Years|No|||August 2010|August 16, 2010|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01033396||129062|
NCT01033643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3614-002|A Multiple Dose Study of MK3614 (3614-002)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3614||Merck Sharp & Dohme Corp.|No|Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|December 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01033643||129043|
NCT01034761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132454|Using Clinical Alerts to Decrease Inappropriate Medication Prescribing|Using Clinical Alerts in a Computerized Provider Order Entry System to Decrease Inappropriate Medication Prescribing Among Hospitalized Elders||Baystate Medical Center|No|Completed|April 2013|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|719|||Both|65 Years|N/A|No|||March 2015|March 7, 2015|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01034761||128957|
NCT01034774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-490-003|Phase 1 Study to Determine Safety, Blood PK and Lung Penetration|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) ACHN-490 in Healthy Subjects||Achaogen, Inc.|No|Completed|January 2010|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 24, 2012|December 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034774||128956|
NCT01037205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAS181 - 2 - 03 (DMID 09-0090)|Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza|||Ansun Biopharma, Inc.|Yes|Completed|December 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|264|||Both|18 Years|70 Years|No|||July 2013|April 5, 2014|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037205||128819|
NCT01037530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05102009|Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants|A Double Blind, Randomised, Placebo Controlled Trial to Study the Clinical and Cost Effectiveness of the Angiotensin Converting Enzyme Inhibitor, Ramipril, in Intermittent Claudicants||University of Hull|Yes|Completed|December 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|80 Years|No|||December 2014|December 18, 2014|December 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037530||128795|
NCT01033071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491CLD_303|Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.|A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension||Takeda|No|Completed|January 2010|November 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1071|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|December 14, 2009|Yes|Yes||No|January 4, 2012|https://clinicaltrials.gov/show/NCT01033071||129087|
NCT01033084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-HU-001|Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder|A Factorial, Double-blinded, Randomized Clinical Trial on Major Depressive Disorder Using Transcranial Direct Current Stimulation|SELECT-TDCS|University of Sao Paulo|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|65 Years|No|||December 2011|December 2, 2011|December 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01033084||129086|
NCT01024322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas||Cxlusa||Recruiting|October 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1500|||Both|8 Years|N/A|No|Probability Sample|Primary care clinic.|August 2015|August 17, 2015|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01024322||129754|
NCT01024881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_CVC shoulder position|Influence of the Shoulder Position on the Catheter Tip Location During Infraclavicular Subclavian Approach|||Seoul National University Hospital|No|Completed|December 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|344|||Both|19 Years|80 Years|No|||December 2009|December 2, 2009|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024881||129711|
NCT01024842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-CORE 001|Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART|HIV-CORE 001 - A Randomised Placebo-controlled Study to Evaluate the Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVconsv, Delivered by Intramuscular Needle Injection to HIV-1 Seropositive Adult Subjects Receiving Antiretroviral Therapy (ART).||University of Oxford|Yes|Active, not recruiting|December 2009|June 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|60 Years|No|||February 2014|February 10, 2014|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024842||129714|
NCT01024855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBR-106-9608|Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions|||Abbott Medical Optics||Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||March 2012|September 30, 2015|December 2, 2009||No||No|April 13, 2011|https://clinicaltrials.gov/show/NCT01024855||129713|
NCT01025128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K129/09|Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density|||Clalit Health Services|No|Completed|January 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|210|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 18, 2014|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025128||129692|
NCT01026922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHSmartPill-01|Use of an Ambulatory Capsule to Characterize Gastrointestinal Pressure Patterns in Children|||Nationwide Children's Hospital|No|Recruiting|December 2009|||January 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|10 Years|18 Years|No|Non-Probability Sample|Patients coming to clinic for concerns of gastric or small bowel dysmotility|June 2009|June 17, 2010|December 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01026922||129555|
NCT01026402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2270C00001|Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014|A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTor Kinase Inhibitor AZD2014 Administered Orally to Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|December 2009|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|150 Years|No|||January 2016|January 13, 2016|December 3, 2009||No||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01026402||129595|
NCT01026415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-008|Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)|An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations||Seattle Genetics, Inc.|No|Completed|December 2009|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|73|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|December 2, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01026415||129594|
NCT01033097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDNK333B2103|Safety and Efficacy of DNK333 in Atopic Dermatitis Patients|A Multicenter, Randomized, Double-blinded, Placebo and Positive Controlled Study to Evaluate the Anti-pruritic Effect, Safety and Tolerability, Systemic and Skin Exposure, After 2 Weeks of Treatment With a Microemulsion Formulation of DNK333 in Atopic Dermatitis Patients||Novartis||Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|80|||Both|18 Years|60 Years|No|||July 2012|July 25, 2012|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033097||129085|
NCT01033110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-bischoff|Fit Over 45 - a Health Promotion Project for Inactive Female Hospital Staff Age 45+ From the University Hospital of Zürich|||University of Zurich||Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|108|||Female|45 Years|65 Years|No|||November 2014|November 6, 2014|November 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01033110||129084|
NCT01033955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001 CHAT 2009|Collaborative H1N1 Adjuvant Treatment Pilot Trial|Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial|CHAT|Canadian Critical Care Trials Group|Yes|Terminated|January 2010|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|16 Years|N/A|No|||February 2013|February 20, 2013|December 16, 2009||No|H1N1 pandemic concluded in early 2010|No||https://clinicaltrials.gov/show/NCT01033955||129019|
NCT01033968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lira-001|Pain Perception at Laser Treatment|Pain Perception at Laser Treatment of Peripheral Retinal Degenerations With Green and Infrared Wavelengths||University of Campinas, Brazil|Yes|Completed|January 2009|May 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 19, 2010|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01033968||129018|
NCT01035346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-09-12|Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection|Evaluation Of The Antipyretic Efficacy Of Ibuprofen Sodium Tablets In Subjects With An Uncomplicated Acute Infection||Pfizer|No|Terminated|January 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|12 Years|65 Years|No|||July 2012|July 13, 2012|December 8, 2009|Yes|Yes||No|July 13, 2012|https://clinicaltrials.gov/show/NCT01035346||128912|Definitive conclusion could not be made due to early termination of study, due to low enrollment rate, and small number of enrolled participants.
NCT01035580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00020139|Trial on Safety and Pharmacokinetics of Intravaginal Curcumin|Phase I Trial on Safety and Pharmacokinetics of Intravaginal Curcumin in Normal Female Subjects||Emory University|Yes|Completed|January 2010|January 2012|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035580||128894|
NCT01036061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108414|GSK618334 Repeat Dose Study|A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers.||GlaxoSmithKline|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|August 23, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036061||128870|
NCT01036074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999905399|Reward Processing in Cocaine Addiction|Reward Processing in Cocaine Addiction||National Institutes of Health Clinical Center (CC)||Completed|March 2005|April 2013||||N/A|Observational|N/A|||Anticipated|100|||Both|18 Years|50 Years|No|||April 2013|October 23, 2014|December 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01036074||128869|
NCT01032447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10262009-4240|Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program|Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program||Stanford University|Yes|Active, not recruiting|January 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Female|18 Years|N/A|No|Non-Probability Sample|diagnosis of any gynecologic or breast cancer and be pursuing treatment here at Stanford        within the last 2 years|June 2011|June 24, 2011|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032447||129134|
NCT01042626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO012010|Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects|Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects||University of Eastern Piedmont||Completed|July 2004|January 2005|Actual|January 2005|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||January 2010|January 4, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042626||128407|
NCT01034176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p000020|BK Treatment Study|Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study||Brigham and Women's Hospital|No|Completed|February 2009|October 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|December 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01034176||129002|
NCT01034462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-03|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|442|||Both|18 Years|80 Years|No|||August 2013|August 22, 2013|December 16, 2009|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01034462||128980|
NCT01035606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4605-I|Training in Goal-directed Attention Regulation for Individuals With Brain Injury|Plasticity in Brain Network to Enhance Cognitive Rehabilitation||VA Office of Research and Development|No|Recruiting|September 2009|January 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|75 Years|No|||September 2015|September 9, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035606||128892|
NCT01035619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1751005|Pediatric Pharmacokinetics And Safety Study Of Moxidectin|A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection||Pfizer|Yes|Withdrawn|April 2011|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|4 Years|11 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035619||128891|
NCT01043510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3762|The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin|A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 at Steady State Conditions in Subjects With Type 2 Diabetes of Different Race and/or Ethnicity||Novo Nordisk A/S|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|63|||Both|18 Years|70 Years|No|||November 2013|November 26, 2013|January 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01043510||128341|
NCT01043757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS-MN01|Financial Incentives for Increasing Exercise|A Randomized Controlled Trial of Financial Incentives for Increasing Exercise||Harvard University|Yes|Withdrawn|January 2010|October 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|June 23, 2015|January 6, 2010||No|The study was stopped prior to recruitment due to logistical issues with the company in which    it was going to be run.|No||https://clinicaltrials.gov/show/NCT01043757||128322|
NCT01024582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M08PBI|Radiation Therapy Followed by Surgery in Treating Patients With Early-Stage Breast Cancer|Image Guided Preoperative Accelerated Partial Breast Irradiation (PAPBI): Defining Radiotherapy Sensitivity|PAPBI|The Netherlands Cancer Institute|No|Recruiting|October 2009|December 2026|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|60 Years|120 Years|No|||December 2015|February 4, 2016|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024582||129734|
NCT01024868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDTSG-1|Assessment of Spread of Transversus Abdominis Plane Block|Assessment of Spread of Transversus Abdominis Plane Block After Administration of 20 ml Ropivacaine 0,5% Bilaterally||Herlev Hospital|No|Completed|December 2009|||March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing abdominal surgery|December 2009|May 3, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024868||129712|
NCT01024894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-09|Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy|A Phase I/IIa Dose Escalation Study in Asia of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Treatment in Genotype 1 HCV Infected Patients Resistant to Pegylated Interferon-alpha and Ribavirin|ECLIPSE 3|Cytheris SA|Yes|Active, not recruiting|January 2009|December 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024894||129710|
NCT01025141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070610|Efficacy of Skeletal Anchorage (MINISCREW)|Study of the Efficacy of Skeletal Anchorage (MINISCREW) Compared to Dental Anchorage During Orthodontic Treatment|Minivis|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2009|June 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|12 Years|50 Years|No|||January 2016|January 29, 2016|September 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01025141||129691|
NCT01025154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0431|Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction|Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML)||M.D. Anderson Cancer Center|No|Completed|January 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|60 Years|No|||August 2013|August 19, 2013|December 1, 2009||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01025154||129690|
NCT01025466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPECT|Exelon Patch and Combination With Memantine Comparative Trial|A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease|EXPECT|Inha University Hospital|Yes|Completed|December 2008|April 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|50 Years|90 Years|No|||May 2010|May 18, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025466||129666|
NCT01025479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OKR-CAS-2009/1|Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent|Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent||AstraZeneca|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|829|||Male|N/A|N/A|No|Probability Sample|Korean prostate cancer patients who are taking LHRH antagonist or anti- androgen or both        of them within 6 months since starting.|June 2010|June 28, 2010|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01025479||129665|
NCT01025778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUS2009/1|Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia|Clofarabine Based Remission Induction Followed by Haploidentical Stem Cell Transplantation in Children With Refractory Hematological Malignancies||Lund University Hospital|No|Completed|December 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|1 Year|21 Years|No|||March 2015|March 30, 2015|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01025778||129642|
NCT01026727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-4326-003.01|A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy|A Phase 2b Multicenter, Randomized, Open Label, Comparative Trial of MPC-4326 in Combination With a Two to Three Drug Optimized Background Regimen Versus an Optimized, Three to Four Drug Antiretroviral Regimen for the Treatment of Triple Class Antiretroviral Experienced, HIV-1 Infected Subjects Failing Current Therapy||Myrexis Inc.|Yes|Terminated|November 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||June 2010|June 10, 2010|December 2, 2009|Yes|Yes|For strategic buisness reasons.|No||https://clinicaltrials.gov/show/NCT01026727||129570|
NCT01027234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2590C00001|This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses|A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single-ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and Pharmacokinetics (Part A) and an Open-label Assessment of the Effect of Food on the Pharmacokinetics (Part B) of Orally Administered AZD8418||AstraZeneca|No|Terminated|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 25, 2010|December 4, 2009|No|Yes|Pre-Clinical Safety Tox Findings|No||https://clinicaltrials.gov/show/NCT01027234||129531|
NCT01034488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPEUR1009|Pharmacodynamics Aspects Of Porcine Heparin Sodium, Produced by Eurofarma, Compared Heparin Sodium, Produced by APP Pharmaceuticasls, in Patients With Chronic Renal Failure|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Not yet recruiting|August 2010|February 2012|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034488||128978|
NCT01045486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|schprobiotics|the Effectiveness of Probiotics on Atopic Dermatitis With Cow Milk Allergy|A Double Blind, Randomized, Placebo-Controlled, Crossover Study to Compare the Effectiveness of Probiotics on Atopic Dermatitis With Cow Milk Allergy in Korean Infants||Soonchunhyang University Hospital|Yes|Withdrawn|January 2010|September 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|6 Months|2 Years|No|||July 2011|July 20, 2011|January 8, 2010||No|failed to enroll patients|No||https://clinicaltrials.gov/show/NCT01045486||128190|
NCT01034813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-09-039|Joint Range of Motion in Burn Scars|Assessment of Joint Range of Motion and Cutaneous Functional Unit Recruitment: Association With Burn Scar Characteristics||United States Army Institute of Surgical Research|No|Terminated|March 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|43|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Military and civilian burn patients.Control population will be individuals without upper        extremity injury.|February 2015|February 2, 2015|December 16, 2009||No|New PI discovered that some of previously collected data may not be accurate|No||https://clinicaltrials.gov/show/NCT01034813||128953|
NCT01035593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 2201|Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation|Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation||Pharming Technologies B.V.|Yes|Withdrawn|December 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|December 16, 2009|Yes|Yes|Recent improvements in clinical practice have reduced the apparent incidence of AMR in renal    transplantation.|No||https://clinicaltrials.gov/show/NCT01035593||128893|
NCT01046240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL/SC-IV-2008|Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy|Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous (SC) Versus Intravenous Palonosetron in Cancer Patients Treated With Platinum Based Chemotherapy||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|October 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|N/A|No|||November 2012|January 26, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01046240||128132|
NCT01037504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2340C00002|AZD5423 Multiple Ascending Dose Study|Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects||AstraZeneca|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|December 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01037504||128797|
NCT01037517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCM-002|Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization|Open Label Phase II Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization||CancerCare Manitoba|No|Completed|January 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01037517||128796|
NCT01042327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0724/11|Study to Assess Clearances and Bio-compatibility of ELISIO Dialyzer|Study to Assess Clearances and Bio-compatibility of ELISIO Dialyzer||Royal Free Hampstead NHS Trust|No|Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||February 2009|September 14, 2015|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042327||128430|
NCT01042639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-09|The Effect of Physical Activity on Bone Mineralization and Immune System in Very Low Birth Weight Infants|The Effect of Physical Activity on Bone Strength and Immune System in Very Low Birth Weight Infants: is More Really Better??||Meir Medical Center|Yes|Recruiting|January 2010|September 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|45|||Both|N/A|14 Days|No|||March 2012|March 15, 2012|December 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01042639||128406|
NCT01042951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09047|To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh|Randomized, Double-blind, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of Orally Administered, Killed, Bivalent Whole-cell, Cholera Vaccine, ShanChol in Bangladeshi Adults and Children||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|January 2010|November 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|330|||Both|12 Months|45 Years|Accepts Healthy Volunteers|||January 2010|October 29, 2014|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042951||128383|
NCT01042964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-15/01|Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion|An Open-Label, Dose-Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of PR-15, an Inhibitor of Platelet Adhesion, in Six Different Strengths in Healthy Male Volunteers|PR-15/01|AdvanceCor GmbH|Yes|Completed|March 2006|October 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|January 5, 2010||Yes||No||https://clinicaltrials.gov/show/NCT01042964||128382|
NCT01043198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/26|Microarray Analysis in Syndromic Obesity|Phenotypic Characterization and Array CGH Analysis in Patients With Syndromic Obesity of Unknown Etiology|REMOB|University Hospital, Bordeaux|Yes|Completed|February 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|90|||Both|N/A|18 Years|No|||June 2012|June 13, 2012|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01043198||128365|
NCT01043211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091105002|Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery|Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery: A Randomized Controlled Trial||University of Alabama at Birmingham|Yes|Withdrawn|January 2012|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|0|||Both|19 Years|80 Years|No|||January 2015|March 6, 2015|December 28, 2009|Yes|Yes|Did not have the research staff necessary to follow through with this study.|No||https://clinicaltrials.gov/show/NCT01043211||128364|
NCT01043224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLQ-004|A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris|A Psoriasis Plaque Study Comparing Clobetasol Propionate Plus Calcipotriol Ointment With Clobetasol Propionate Ointment Alone, Calcipotriol Ointment Alone and a Vehicle Control for the Treatment of Psoriasis Vulgaris||LEO Pharma|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043224||128363|
NCT01043770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoL-08-H0402-142|The Reversal Intervention for Metabolic Syndrome Study|A Randomised Controlled Trial to Investigate the Effects of a Structured Self-management Education Programme for People With Metabolic Syndrome|TRIMS|University of Leicester|No|Completed|August 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|82|||Both|40 Years|74 Years|No|||December 2011|June 3, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043770||128321|
NCT01044082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081206|Prevention of Post-partum Haemorrhage|Impact of Controlled Cord Traction During the Third Stage of Labour on the Incidence of Post Partum Haemorrhage|TRACOR|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2010|March 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4382|||Female|18 Years|N/A|No|||March 2012|July 25, 2012|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044082||128298|
NCT01024595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS OBS T-001|Observational Study of the Therapeutic Study of Recombinant HIV-1 TAT|Observational Study of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in Hiv-1 Infected Adult Volunteers|ISS OBS T-001|Istituto Superiore di Sanità|No|Completed|September 2007|December 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|24|Samples Without DNA|Whole blood, serum, PBMCs|Both|18 Years|50 Years|No|Non-Probability Sample|HIV-1 Infected subject previously included in the Phase I Clinical Trial with Tat protein|February 2010|February 28, 2011|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01024595||129733|
NCT01024608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-301|Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR||Teva Pharmaceutical Industries|No|Completed|December 2009|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|340|||Both|12 Years|N/A|No|||April 2012|April 23, 2012|December 2, 2009|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT01024608||129732|
NCT01025817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AUS92|Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients|A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients||Novartis|Yes|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|613|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|November 19, 2009|Yes|Yes||No|March 3, 2014|https://clinicaltrials.gov/show/NCT01025817||129639|HLA mismatches ≥3, everolimus group 261 vs MMF group 240
NCT01025167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-SUP-09-DE|The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients|||Fresenius Kabi||Completed|September 2006|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|111|||Both|18 Years|N/A|No|||August 2010|August 19, 2010|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025167||129689|
NCT01025492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00030151|Study of Trilipix Effects on Lipids and Arteries|Mechanisms of Atheroprotection by Fenofibric Acid (ABT 335) Added to a Statin in Subjects With Insulin Resistance (Hypertriglyceridemia and Low HDL-C)||University of Utah|No|Terminated|November 2009|November 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 27, 2011|December 1, 2009|Yes|Yes|Corporate sponsor withdrew funding and permission to continue.|No||https://clinicaltrials.gov/show/NCT01025492||129664|
NCT01026090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRONE_L_04742|Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)|A Phase IV, Double-blind, Placebo-controlled, Canadian Multicentre Study Comparing Two Treatment Strategies of Dronedarone Administration Following ELECTive caRdioversion for Prevention of Symptomatic Atrial Fibrillation (AF) Recurrence||Sanofi|Yes|Terminated|November 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|292|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|December 2, 2009||No|'Sponsor decision following recruitment issues, not related to any safety concerns in the    study|No||https://clinicaltrials.gov/show/NCT01026090||129618|
NCT00992342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0281003|A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers|A Double Blind (3rd Party Open), Randomised, Placebo-Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03893787 In Healthy Subjects||Pfizer|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 17, 2010|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992342||132190|
NCT00992355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH-EYE01|Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery|Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial||Veroia General Hospital|Yes|Completed|January 2009|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|55 Years|95 Years|No|||October 2009|October 8, 2009|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992355||132189|
NCT01045733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-09-045|A Comparison of Corneal Aberrations in Subjects With Contralateral AcrySof IQ Toric Intraocular Lens (IOL) and AcrySof IQ IOL With Limbal Relaxing Incision (LRI)|A Prospective Contralateral Comparison of Corneal Aberrations in Subjects Undergoing Aspheric Lens Implantation With Concomitant LRI and Aspheric Toric IOL Implantation||Alcon Research|No|Completed|December 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|21 Years|N/A|No|||November 2012|November 27, 2012|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045733||128171|
NCT01035047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00010410|Randomized Investigation of Chest Pain Diagnostic Strategies|Randomized Investigation of Chest Pain Diagnostic Strategies||Wake Forest Baptist Health|Yes|Completed|January 2010|August 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|105|||Both|21 Years|N/A|No|||October 2012|October 31, 2012|December 17, 2009||No||No|October 31, 2012|https://clinicaltrials.gov/show/NCT01035047||128935|
NCT01035060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37268|Blood Flow, Muscle Regeneration and Sarcopenia|Role of Skeletal Muscle Blood in Muscle Regeneration and Sarcopenia||University of Florida|Yes|Completed|June 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|68|Samples Without DNA|Serum/Plasma; Skeletal Muscle; Adipose Tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|October 2012|December 4, 2012|December 17, 2009||No||No|December 4, 2012|https://clinicaltrials.gov/show/NCT01035060||128934|
NCT01046253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B036579|Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study|A Relative Bioavailability Replicate Sprinkle Study of Lansoprazole 30 mg Delayed-Release Capsules Under Fasting Conditions||Teva Pharmaceuticals USA||Completed|January 2004|January 2004|Actual|January 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 22, 2010|January 8, 2010||Yes||No|February 22, 2010|https://clinicaltrials.gov/show/NCT01046253||128131|
NCT01046578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHIRL-08-1200|Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women|Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women||University of Saskatchewan|No|Completed|January 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Actual|41|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046578||128107|
NCT01046591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R000041|Sleep and Behavior in Children With Cleft Palate|Sleep and Neurobehavioral Performance After Cleft Palate Repair||University of Michigan|Yes|Completed|December 2006|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|82|||Both|6 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children will be recruited from cleft palate clinics|March 2012|March 6, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046591||128106|
NCT01042340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Karolinska University Hospital|Energy Dense Oleic Acid Formula to Geriatric Patients|Energy Dense Oleic Acid Rich Formula to Newly Admitted Geriatric Patients - Feasibility and Effects on Energy Intake||Karolinska University Hospital|No|Completed|December 2005|July 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|65 Years|N/A|No|||December 2009|March 31, 2015|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01042340||128429|
NCT01042353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU BDX réa med|Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia|Rapid Bacterial Antibiograms Determined by Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia: a Prospective Comparison With Standard Culture Methods||Université Victor Segalen Bordeaux 2|No|Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2010|January 4, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042353||128428|
NCT01042366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 01-171|Dendritic Cells (DC) Vaccine for Metastatic Melanoma|Randomized Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Metastatic Melanoma Using Autologous Mature Dendritic Cells||University of Pittsburgh|Yes|Completed|October 2002|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|January 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01042366||128427|
NCT01042990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040264|Testing Adaptive Physical Activity in Stroke|Testing Adaptive Physical Activity in Stroke|TAPAS|Baltimore VA Medical Center|Yes|Recruiting|September 2008|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Both|40 Years|N/A|No|||December 2009|January 5, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01042990||128380|
NCT01042977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1690C00019|Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease|A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care||AstraZeneca||Completed|March 2010|December 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|964|||Both|45 Years|N/A|No|||December 2013|December 18, 2013|January 5, 2010|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT01042977||128381|For participants who did not complete 8 and/or 24 weeks, respectively, LOCF was used. For HbA1c: excluding data after glycemic rescue, Weight: including data after rescue, SBP: excluding data after anti-hypertensive rescue.
NCT01043237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901M57884|Frequency Analysis of Coronary Artery Disease|A Single-centered Investigation Into the Frequency Domain Patterns in Vessels of Patients With Coronary Artery Disease||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|330|||Both|18 Years|89 Years|No|Non-Probability Sample|Patients presenting to the University of Minnesota Medical Center (UMMC) Fairview Clinics,        Physicians (UMP) or the Redwing, Minnesota clinic|September 2014|September 3, 2014|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01043237||128362|
NCT01043523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13729|Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.|An Observational Study of the Administration of Eovist/Primovist in Pediatric Subjects (> 2 Months and Less Than 18 Years) Who Are Referred for a Routine Contrast Enhanced Liver MRI Because of Suspected or Known Focal Liver Lesions||Bayer|No|Completed|December 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|52|None Retained|Pediatric subjects who have had a Eovist/Primovist enhanced MRI for known or suspected focal      liver disease|Both|2 Months|18 Years|No|Non-Probability Sample|Pediatric subjects who have had a Primovist/Eovist enhanced MRI for known or suspected        focal liver disease|May 2014|May 6, 2014|January 4, 2010|No|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01043523||128340|
NCT01043796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCZVED-5794|Evaluation of Insecticide Treated Nets and Wall Liners for the Prevention of Malaria|Malaria Transmission Consortium: The Added Effects of Insecticide Treated Materials, Artemisinin-containing Combination Treatments, and Larviciding on Malaria Transmission and Illness|MTC-ITWL|Centers for Disease Control and Prevention|No|Completed|May 2010|December 2014|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1730|||Both|6 Months|11 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043796||128319|
NCT01044095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR1525|Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus|Evaluation of In Vitro Cross-Reactivity With Avian Influenza H5N1 Virus in Healthy Volunteers Vaccinated With a Prime Boost Regimen of Seasonal Influenza Vaccine||Armed Forces Research Institute of Medical Sciences, Thailand|No|Completed|November 2009|June 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|26|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044095||128297|
NCT01044368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2D Monotherapy-Internet BGM|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM) on Monotherapy|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus on Monotherapy||Endocrine Research Society|No|Suspended|January 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|25 Years|79 Years|No|||January 2010|September 14, 2011|January 6, 2010||No|To focus on a similar study NCT01175408 prior to recruiting participants.|No||https://clinicaltrials.gov/show/NCT01044368||128276|
NCT01044381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-0901-S|Open-Label Pharmacokinetics (PK)/Safety Study of Luliconazole Solution, 10% in Distal Subungual Onychomycosis|A Phase 1/2a, Open-Label Study Evaluating the Pharmacokinetics, Safety and Tolerability of Luliconazole Solution, 10% in Subjects With Moderate to Severe Distal Subungual Onychomycosis||Topica Pharmaceuticals|No|Completed|December 2010|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||November 2014|November 13, 2014|January 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044381||128275|
NCT01025505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1408|Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study|Front-line Treatment of Ph Positive (Ph+)/Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) With Two Tyrosine Kinase Inhibitors (TKI) (Imatinib and Nilotinib). A Phase II Exploratory Multicentric Study in Elderly Patients and in Patients Unfit for Program of Intensive Therapy and Allogeneic Stem Cell Transplantation. GIMEMA Protocol LAL1408. EudraCT 2009-01327122|LAL1408|Gruppo Italiano Malattie EMatologiche dell'Adulto|Yes|Active, not recruiting|June 2012|January 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01025505||129663|
NCT01025518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 25|DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients|A Randomized Trial Evaluationg Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients|DAHANCA 25A|Danish Head and Neck Cancer Group|Yes|Completed|September 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025518||129662|
NCT01025206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI-505-01|A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma|A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI 505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, in Patients With Relapsed/Refractory Multiple Myeloma||BioInvent International AB|Yes|Completed|December 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||October 2012|March 14, 2013|December 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01025206||129686|
NCT01026389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD 44-045|Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease|Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases|DALIA|Guerbet|No|Completed|October 2009|January 2012|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|189|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|December 3, 2009||No||No|November 14, 2012|https://clinicaltrials.gov/show/NCT01026389||129596|
NCT01026688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shah-1|Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Type 2 Diabetes|Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Type 2 Diabetes||Sunnybrook Health Sciences Centre|No|Completed|June 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1592|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01026688||129573|
NCT01026428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28780|A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics|A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease||Newron|No|Completed|September 2009|||July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Both|30 Years|N/A|No|||January 2012|March 27, 2013|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01026428||129593|
NCT01026441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vela100|Clinical Study to Evaluate the Safety and Efficacy of the Vela100|Clinical Study to Evaluate the Safety and Efficacy of the Vela100/eShape Uno Device for Cellulite and Circumference Reduction||Syneron Medical||Terminated|October 2008|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|December 3, 2009|Yes|Yes|Product was not developed and study was cancelled|No||https://clinicaltrials.gov/show/NCT01026441||129592|
NCT01026714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO CYP2C9|CYP2C9 Activity Evaluated With a Simple Finger Prick|Evaluation of the CYP2C9 Activity With Dried Blood Spots on Filter Paper Obtained With a Simple Finger Prick||University Hospital, Geneva||Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2009|January 10, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01026714||129571|
NCT00992082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAK-Spinal|Local Infiltration Analgesia or Intrathecal Morphine in Total Knee Arthroplasty|Local Infiltration Analgesia or Intrathecal Morphine in Total Knee Arthroplasty||University Hospital Orebro|Yes|Recruiting|August 2009|August 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|40 Years|85 Years|No|||October 2009|October 8, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992082||132210|
NCT01045993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-09-20|A Study To Evaluate Methods To Evaluate Back Pain|A Pilot Study To Evaluate Various Methodologies For Assessing The Treatment Of Low Back Pain||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|61|||Both|18 Years|55 Years|No|||February 2013|February 21, 2013|January 8, 2010|No|Yes||No|December 5, 2011|https://clinicaltrials.gov/show/NCT01045993||128151|No primary endpoint was prespecified in this Pilot study; 1 key efficacy endpoint was selected for reporting purposes only.
NCT01046266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22350|A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma|An Exploratory, Open Label Multicenter Study to Investigate Pharmacodynamic of RO5083945, a Human Monoclonal Antibody Antagonist of Epidermal Growth Factor Receptor (EGFR), Compared to Cetuximab in Patients With Operable Head and Neck Squamous Cell Carcinoma||Hoffmann-La Roche||Completed|December 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01046266||128130|
NCT01045980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJH-Renal-RCT-003|Effect of Bio-impedance Analysis and Vitamin D vs Usual Care on Left Ventricular Mass in Peritoneal Dialysis Patients: A Randomized Controlled Trial (FLUID Study)|The Effect of Bio-impedance Analysis and Vitamin D Versus Usual Care on Left Ventricular Mass in Peritoneal Dialysis Patients: a Randomized Controlled Trial|FLUID|St. Joseph's Healthcare Hamilton|Yes|Recruiting|August 2010|August 2015|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|70|||Both|18 Years|N/A|No|||June 2012|December 10, 2013|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045980||128152|
NCT01046604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECUomega3-01|Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery|Mitigating Cardiac Inflammation and Oxidative Stress in Atrial Myocardium Via Short-term Lovaza Treatment Prior to Surgery||East Carolina University|Yes|Active, not recruiting|January 2010|December 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|70 Years|No|||August 2013|September 6, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046604||128105|
NCT01042379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|097517|I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer|I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)|I-SPY 2|QuantumLeap Healthcare Collaborative|Yes|Recruiting|March 2010|||September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Anticipated|1200|||Female|18 Years|N/A|No|||December 2015|December 10, 2015|December 31, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042379||128426|
NCT01042652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X091221164|A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance|A Pilot Study With Randomized Controlled Open-label Design to Compare Drug-drug Interaction, Antiretroviral Efficacy and Tolerability of Raltegravir Versus Nevirapine as Anchor Drug in Combination Therapy for Treatment-naive HIV+ Chinese Injection Drug Users on Methadone Maintenance||Centers for Disease Control and Prevention, China|No|Recruiting|February 2011|June 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||June 2011|June 14, 2011|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01042652||128405|
NCT01043822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8481|Pain and Emotional Expression in Children With Autism or Mental Retardation|Pain and Emotional Expression in Children With Autism or Mental Retardation||University Hospital, Montpellier|Yes|Recruiting|December 2009|July 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|138|||Both|18 Months|6 Years|No|Probability Sample|46 children with autism spectrum disorders, 46 children with mental retardation, 46        children without developmental disorder|October 2010|October 28, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043822||128317|
NCT01043250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-04-005|Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients|Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain||Samsung Medical Center|Yes|Completed|May 2009|December 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|81|||Both|19 Years|59 Years|No|Non-Probability Sample|outpatients clinic for schizophrenia|July 2011|July 22, 2011|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01043250||128361|
NCT01043536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0244-1blni08 / 009.020|Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults|Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost in Association With a Temozolomide in the Treatment of Glioblastoma|SIB-IMRT|Centre Georges Francois Leclerc|Yes|Completed|September 2009|||January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||September 2012|September 24, 2012|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043536||128339|
NCT01043783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2009-1107|Preliminary Data for Breath Biofeedback of Dietary Compliance|Preliminary Data for Breath Biofeedback of Dietary Compliance||University of Wisconsin, Madison|No|Completed|July 2009|April 2011|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01043783||128320|
NCT01044680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-10- CN-Roquette-01|Effects of NUTRIOSE®FB Dietary Fiber Supplementation on Satiety, Body Fat, and Metabolic Syndrome in Overweight Adult Men|The Effects of NUTRIOSE®FB Dietary Fiber Supplementation on the Satiety, Body Fat Distribution, and Metabolic Syndrome Biomarkers of Overweight Adult Chinese Men 20-35 Years of Age.||Roquette Freres|No|Completed|October 2006|February 2007|Actual|February 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|120|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||January 2010|January 7, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044680||128252|
NCT01044693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091252|Nebivolol in the Supine Hypertension of Autonomic Failure|Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity||Vanderbilt University|No|Completed|January 2010|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|20|||Both|18 Years|80 Years|No|||April 2015|April 14, 2015|January 6, 2010|Yes|Yes||No|April 14, 2015|https://clinicaltrials.gov/show/NCT01044693||128251|
NCT01045005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05060CL−A|Doppler Ultrasound Investigation of Microcirculations|Doppler Ultrasound Investigation of Ocular and Skeletal Microcirculations in Health and Disease||Queen's University, Belfast|Yes|Recruiting|January 2006|May 2011|Anticipated|May 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2008|January 7, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01045005||128227|
NCT01045018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMET 001|A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis|BE Study With Clinical Endpoints Comparing Mesalamine Delayed Release Tablets 400 mg to the Reference Listed Drug ASACOL® Delayed Release Tablets 400 mg in Patients With Mild to Moderately Active Ulcerative Colitis||EMET Pharmaceuticals, LLC|No|Completed|January 2008|August 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|3||||||Both|18 Years|N/A|No|||December 2009|January 7, 2010|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045018||128226|
NCT01025193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 106342|Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant|One Year Exploratory Study to Evaluate the Efficacy and Safety of Belimumab for Normalization of Alloantibody Levels in Sensitized Patients Awaiting Kidney Transplantation||University of Pennsylvania|Yes|Terminated|February 2010|January 2012|Anticipated|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||January 2012|January 10, 2012|December 1, 2009|Yes|Yes|has not demonstrated efficacy in primary goal|No||https://clinicaltrials.gov/show/NCT01025193||129687|
NCT01025219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/B/01|A Contribution to the Analysis of the Phenotypic Heterogeneity in Crack/Cocaine Addiction : a Case Control Study|A Case Control Study on Contribution to the Analysis of the Phenotypic Heterogeneity in Crack/Cocaine Addiction|CRACK-ANT|Centre Hospitalier Universitaire de Fort-de-France|Yes|Recruiting|December 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 21, 2011|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01025219||129685|
NCT01025830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BETr|Triomune Bioequivalence With Innovators|Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults||Makerere University|No|Completed|February 2006|March 2008|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2009|December 31, 2009|April 21, 2009||No||No|April 21, 2009|https://clinicaltrials.gov/show/NCT01025830||129638|Stavudine (40mg) was used whereas currently it is Stavudine(30mg) that is recommended for usage. So our results may not be applicable to patients on Stavudine 30mg.
NCT01026103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS09004|Tri Staple Technology Stapler Used in Gastric Bypass|A Prospective, Single-center Investigation of the Safety and Performance of the Endo GIA™ Stapler With Endo GIA™ Sulu With Tri-Staple™ Technology in a Gastric Bypass Procedure||Medtronic - MITG|No|Completed|January 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|December 3, 2009||No||No|January 29, 2014|https://clinicaltrials.gov/show/NCT01026103||129617|
NCT00992043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eefeusp2|Creatine Supplementation and Diabetes|Efficacy and Safety of Creatine Supplementation Combined With Exercise Training in Type 2 Diabetic Patients||University of Sao Paulo|No|Completed|October 2009|January 2010|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|45 Years|N/A|No|||October 2009|March 22, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00992043||132213|
NCT00992056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYS-MD-33|Nebivolol Versus Metoprolol: Sodium Sensitivity|Comparative Effects of Nebivolol Versus Metoprolol on Sodium Sensitivity and Renal Sodium Handling in Hypertensive Hispanic Postmenopausal Women||University of Miami|No|Completed|December 2010|May 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Female|46 Years|N/A|No|||May 2014|May 20, 2014|October 7, 2009|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT00992056||132212|
NCT01045746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD pilot study I|Effects of Whole-Body Vibration on Balance in the Elderly Population|Effects of Stochastic Resonance Therapy on Postural Control in the Elderly Population (Pilot Study)||Bern University of Applied Sciences|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|65 Years|95 Years|No|||December 2014|December 19, 2014|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045746||128170|
NCT01046617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|153/2009|Lactobacillus Reuteri for the Treatment of Infantile Colic:|Lactobacillus Reuteri (DSM 17938) for the Treatment of Infantile Colic: a Randomized Double-blind Placebo Controlled Trial|LRTIC|Medical University of Warsaw|Yes|Completed|December 2009|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|1 Month|5 Months|No|||June 2012|June 4, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046617||128104|
NCT01046630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285C00001|Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects|A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Subjects Fulfilling the Criteria for Major Depressive Disorder||AstraZeneca|No|Completed|December 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|128|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01046630||128103|
NCT01046279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1700|Hypertension Monitoring in Glioma Patients Treated With Bevacizumab|Hypertension Monitoring in Glioma Patients Treated With Bevacizumab||University of Zurich|Yes|Terminated|January 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|Samples Without DNA|Plasma and Urine Samples|Both|18 Years|N/A|No|Non-Probability Sample|Glioma patients receiving bevacizumab|June 2013|June 12, 2013|January 8, 2010||No|Problems with enrollement of patients, less patients than expected|No||https://clinicaltrials.gov/show/NCT01046279||128129|
NCT01042665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20057259|Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo|Relationship Between Intraocular Pressure Fluctuation and Retinal Ganglion Cell Function in Eyes Receiving Latanoprost 0.005% Versus Placebo||University of Miami|Yes|Completed|February 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|82|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with primary open angle glaucoma or ocular hypertension from the Glaucoma Clinic        at Bascom Palmer Eye Institute- Palm Beach Office.|March 2014|March 27, 2014|January 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01042665||128404|
NCT01042678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP0112-CP02|Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema|A Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (DME)||Allergan|Yes|Terminated|February 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|January 1, 2010|Yes|Yes|The study was terminated due to a company decision.|No|April 14, 2014|https://clinicaltrials.gov/show/NCT01042678||128403|
NCT01043263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3324-201|Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain|A Phase IIB, Randomized, Double-blind, Two-arm, Multi-center, Placebo-controlled, Study to Assess the Efficacy and Safety of EN3324 (Axomadol) in Subjects With Moderate to Severe Chronic Low Back Pain|CLBP|Grünenthal GmbH|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|236|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01043263||128360|
NCT01043276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0751001|A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355|A Single Dose, Open, Randomized, 5-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of PF-00258210 Administered Alone Or PF-00258210 Administered Together With PF-00610355 Either As A Free Or A Fixed Dose Combination||Pfizer|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01043276||128359|
NCT01043549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-46|Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome|Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome|rTMSPPCGT|Institut National de la Santé Et de la Recherche Médicale, France|No|Terminated|February 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|70 Years|No|||February 2016|February 24, 2016|January 4, 2010||No|lake of efficacy|No||https://clinicaltrials.gov/show/NCT01043549||128338|
NCT01043809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEZID-5281|Evaluation of a Handwashing Promotion Program in Three Countries|Evaluation of a School-based Handwashing Promotion Program in Three Countries||Centers for Disease Control and Prevention|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|15000|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2013|February 5, 2013|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043809||128318|
NCT01035411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00007|AZD9668 Relative Bioavailability|An Open-label, Single-centre, 3-way Single Dose Crossover Study to Assess the Relative Bioavailability After Oral Administration of a Tablet Variant of AZD9668 Compared to AZD9668 Tablets and to Further Investigate the Safety and Tolerability of AZD9668 in Healthy Subjects||AstraZeneca|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|January 28, 2013|December 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01035411||128907|
NCT01044108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9161-3749|A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Two Part Trial (Sequential Single Subcutaneous Dose Rising Trial and Semi-Sequential Multiple Subcutaneous Dose Response Trial) to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0453 in Overweight/Obese Male and Female Subjects||Novo Nordisk A/S|No|Terminated|January 2010|September 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|January 6, 2010|No|Yes|See detailed description|No||https://clinicaltrials.gov/show/NCT01044108||128296|
NCT01044394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28808|Same-day, Reduced Volume Bowel Preparation|Evaluating the Effectiveness of a Same-day, Reduced Volume Polyethylene Glycol + Electrolyte Solution (PEG-ELS) Bowel Preparation for Afternoon Colonoscopies||Boston Medical Center|Yes|Withdrawn|January 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|January 5, 2010||No|A phase III RCT was published showing this approach is effective|No||https://clinicaltrials.gov/show/NCT01044394||128274|
NCT01036893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0001-C101|M0001 Effects on Oral Contraceptive Plasma Levels|The Effect of Prucalopride on the Plasma Levels of Oral Contraceptives (Ethinylestradiol and Norethisterone) in Healthy Subjects||Movetis|No|Completed|December 2009|May 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|May 16, 2011|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036893||128837|
NCT01036932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC MAMC 179|Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF|To Study the Safety and Efficacy of G-CSF Therapy on the CD 34 Cell Mobilization and Outcome of Patients With ACLF||Govind Ballabh Pant Hospital|Yes|Recruiting|December 2008|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Years|75 Years|No|||December 2009|December 18, 2009|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036932||128836|
NCT01037335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATA 1 123|Effect of Local Administration of Morphine for Analgesia After Iliac Bone Graft Harvest|Local Administration of Morphine for Analgesia After Iliac Bone Graft Harvest||Outcomes Research Consortium|Yes|Recruiting|April 2009|March 2010|Anticipated|March 2010||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|70 Years|No|||April 2009|December 22, 2009|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037335||128810|
NCT01032577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01-005-E|A Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations|Prospective Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations|PropR|Saint Francis Care|No|Completed|December 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population will include approximately 30-50 volunteers age >18, male and        female, both ischemic and nonischemic cardiomyopathy, with primary and secondary implant        indications.|February 2012|February 27, 2012|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01032577||129124|
NCT01024933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triumph|Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH)|Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH)|Triumph|Weill Medical College of Cornell University|Yes|Completed|January 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01024933||129707|
NCT00995826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0002|Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958|CS-8958 - A Phase I, Double-blind, Placebo-controlled, Ascending, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects.||Biota Scientific Management Pty Ltd|Yes|Completed|April 2009|November 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|October 11, 2009||No||No||https://clinicaltrials.gov/show/NCT00995826||131923|
NCT01025843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5478-001|Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)|A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension||Merck Sharp & Dohme Corp.|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|December 2, 2009|No|Yes||No|January 28, 2016|https://clinicaltrials.gov/show/NCT01025843||129637|
NCT01025856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46/09|Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes|Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes||Federico II University|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|45|||Both|35 Years|65 Years|No|||December 2012|December 3, 2012|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01025856||129636|
NCT00991822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-200198|A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma|A Double-masked Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma||Medical University of Vienna|Yes|Completed|May 1999|December 2003|Actual|December 2001|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|160|||Both|19 Years|N/A|No|||October 2009|October 7, 2009|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991822||132230|
NCT00991835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICT2009|Plaque Registration and Event Detection In Computed Tomography|Prospective Multicenter Study to Investigate the Relationship Between the Characteristics of Coronary Artery Plaques and Cardiovascular Events Using Multidetector Computed Tomography Coronary Angiography|PREDICT|Hiroshima University|No|Active, not recruiting|October 2009|December 2014|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3015|||Both|20 Years|N/A|No|Probability Sample|patients reffered to cardiovascular hospital|March 2013|March 18, 2013|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00991835||132229|
NCT00992069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5267|Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers|A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 1, 2013|October 1, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992069||132211|
NCT01046292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBE LI 1370|Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI|Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI: a Randomized, Double-blind, Placebo-controlled Exploratory Study||University Hospital, Basel, Switzerland|Yes|Completed|January 2010|October 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|85 Years|No|||October 2015|October 12, 2015|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046292||128128|
NCT01034020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906409|Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers|Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers||National Institutes of Health Clinical Center (CC)||Completed|February 2006|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|50 Years|No|||September 2010|September 23, 2010|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034020||129014|
NCT01034267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-04|Safety Study of F2695 SR in Major Depressive Disorder|A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder|LVM-MD-04|Forest Laboratories|No|Completed|December 2009|||June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|828|||Both|18 Years|80 Years|No|||August 2012|August 15, 2012|December 16, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034267||128995|
NCT01042392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AFR01|Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients|Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients|ALIAS|Novartis||Completed|November 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|506|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|January 1, 2010||No||No|January 12, 2012|https://clinicaltrials.gov/show/NCT01042392||128425|
NCT01034280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJL-PG-EP03|Correlations Phenotype / Genotype in Down Syndrome|Epidemiological Study of Trisomy 21 With Research of Correlations Between Phenotype (Physical, Psychometrical) and Genotype (Genome, Transcriptome, Proteome)|INTREPID|Institut Jerome Lejeune||Completed|March 2004|May 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|524|||Both|8 Years|N/A|No|Probability Sample|Down syndrome patients|December 2009|March 21, 2012|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034280||128994|
NCT01034553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC088A|Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase I/II Study of Combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|February 2010|||August 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|December 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01034553||128973|
NCT01034865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11022007-788|Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease &Hepatocellular CA|Risk Factors and Molecular Genomics for Hepatolcellular Carcinoma in U.S. Patients With Chronic Liver Disease: A Case Control Study||Stanford University||Completed|May 2001|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|750|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|For Experimental Subjects Only:        Patients with HCC        For Controls Only:        Patients with chronic liver disease without evidence of HCC|December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034865||128949|
NCT01035125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 39-07138b 1.2007.1416|Effect of One Week Self-management Program in Patients With Fibromyalgia|A Study of Effect of One Week Self-management Program in Patients With Fibromyalgia||Revmatismesykehuset AS|Yes|Completed|December 2008|July 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|153|||Both|20 Years|70 Years|No|||July 2011|July 27, 2011|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035125||128929|
NCT01036308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H32-07|Intervention With Legume Kernel Fibre in Healthy Subjects|Comparison of the Effects of Three Native Legume Kernel Fibres on Cholesterol Metabolism in Healthy Subjects||University of Jena|Yes|Completed|July 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|76|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2009|November 5, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01036308||128859|
NCT01036958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100019|Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease|Development and Validation of a Symptom Scale for Children With Chronic Graft-Versus-Host Disease||National Institutes of Health Clinical Center (CC)||Suspended|November 2009|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|3|||Both|5 Years|18 Years|No|||January 2016|February 9, 2016|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036958||128835|
NCT01035788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7331-R|Effects of Mindfulness-Based Cognitive-Behavioral Conjoint Therapy on PTSD and Relationship Function|Effects of Mindfulness-Based Cognitive-Behavioral Conjoint Therapy on PTSD and Relationship Function||VA Office of Research and Development|No|Active, not recruiting|July 2010|January 2017|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|December 17, 2009||No||No|September 23, 2015|https://clinicaltrials.gov/show/NCT01035788||128882|Detecting significant differences between groups may be limited by loss to follow-up of 3x more CBCT-S subjects than MB-CBCT. Differences between CAPS and PCL ratings may suggest issues with CAPS assessors although inter-rater reliability was strong.
NCT01035801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN105-CT1-005-09|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients|An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus||Biocon Limited|No|Recruiting|August 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|45 Years|No|||August 2010|August 19, 2010|December 18, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01035801||128881|
NCT01036282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03I/C14|Cognitive Skills Training Using Computer for Patients With Severe Mental Illness|Computerized Cognitive Skills Training in Severe Mental Illness||Nathan Kline Institute for Psychiatric Research|Yes|Recruiting|February 2003|December 2012|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2011|June 2, 2011|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036282||128860|
NCT01037023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113946|Regulatory Hycamtin(Oral) PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of HYCAMTIN Administered in Korean Patients According to the Prescribing Information|Hycamtin PMS|GlaxoSmithKline|No|Completed|October 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|N/A||1|Actual|92|||Both|N/A|N/A|No|Probability Sample|Patients administrated Topotecan at the site|April 2015|April 14, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01037023||128833|
NCT01037036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 08|A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG|An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Adjunctive Xalatan® Eye Drops in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|December 2009|July 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037036||128832|
NCT00995540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-201|Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults|A Multiple-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Tolerability, Safety, and Efficacy of INGAP Peptide Given Subcutaneously as Injections t.i.d. for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus||Exsulin Corporation|Yes|Terminated|November 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|19 Years|60 Years|No|||February 2014|February 11, 2014|October 13, 2009|Yes|Yes|Preserve clinical supplies|No||https://clinicaltrials.gov/show/NCT00995540||131945|
NCT00995553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6981-R|Remediation of Working Memory in Schizophrenia|Remediation of Working Memory in Schizophrenia||VA Office of Research and Development|No|Completed|January 2010|December 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|60 Years|No|||January 2016|January 22, 2016|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995553||131944|
NCT00996086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 480|Risk Stratification and Benefits With Cardiac Resynchronization Therapy (CRT)|Risk Stratification and Benefits With Cardiac Resynchronization Therapy|BENEFIT|St. Jude Medical|Yes|Completed|February 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|154|Samples With DNA|There is a genetic substudy that will evaluate the presence of certain protein markers.|Both|18 Years|N/A|No|Non-Probability Sample|All patients who undergo implantation of a market-approved St. Jude Medical CRT        defibrillator (CRT-D) and a compatible lead system may be included in the study.|July 2013|July 17, 2013|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00996086||131904|
NCT00996099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM-eMPC|Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients|Feasibility Study of the Use of Continuous Glucose Monitoring Combined With Computer-based eMPC Algorithm for Tight Glucose Control in Cardiosurgical ICU||Charles University, Czech Republic|No|Completed|September 2008|||August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||October 2009|October 15, 2009|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996099||131903|
NCT00996112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0265|Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections|Management by Primary Care Clinicians of Patients Suspected of Having Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections||University of Colorado, Denver|No|Completed|October 2009|August 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4518|||Both|N/A|89 Years|No|Non-Probability Sample|The study population comprises primary care patients in ambulatory clinics from two health        care systems.|November 2010|January 23, 2013|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996112||131902|
NCT00996125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112022|Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects|Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects||GlaxoSmithKline||Completed|October 2009|December 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|750|||Female|9 Years|17 Years|Accepts Healthy Volunteers|||May 2012|November 8, 2012|October 15, 2009|Yes|Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT00996125||131901|
NCT00992381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00035|Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone|A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500 mg of Naproxen Plus 20 mg of Esomeprazole Versus Naprosyn® Containing Naproxen 500 mg)||AstraZeneca|No|Completed|September 2009|October 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 15, 2010|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992381||132187|
NCT01033760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-014742-28|Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)|Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|April 2010|December 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01033760||129034|
NCT01034306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-204RA|Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis|A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors||Can-Fite BioPharma|No|Completed|October 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|75 Years|No|||March 2014|February 24, 2015|December 16, 2009|Yes|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01034306||128992|
NCT01034293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-032|Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning|Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning||Maastricht University Medical Center|No|Completed|October 2009|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|14|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2010|July 22, 2010|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034293||128993|
NCT01034878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2008-004|Sunitinib in Metastatic Renal Cancer|Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology||Istituto Clinico Humanitas|No|Completed|December 2009|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01034878||128948|
NCT01034891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA4649|Women At Risk: The High Risk Breast Cancer Program|Women At Risk: The High Risk Breast Cancer Program|WAR|New York Presbyterian Hospital|No|Recruiting|January 1991|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Female|18 Years|N/A|No|Non-Probability Sample|patients of the breast center at New York Presbyterian Hosptial/ Columbia University        Medical Center|October 2009|December 17, 2009|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01034891||128947|
NCT01035138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5930|A Study of Semagacestat for Alzheimer's Patients|Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC)|Identity XT|Eli Lilly and Company|No|Completed|December 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|55 Years|N/A|No|||September 2014|September 22, 2014|December 17, 2009|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT01035138||128928|Very few participants from LFBC rolled over into LFBF (N = 9). Due to insufficient sample size, the data for LFBC participants who rolled into LFBF were not analyzed.
NCT01035853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colistin nasal cf pilot|Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization|Sino-nasal Inhalation of Colistin Via the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Colonization of the Upper Airways With Pseudomonas Aeruginosa||University of Jena|No|Completed|December 2009|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Years|N/A|No|||March 2013|March 20, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035853||128880|
NCT01036971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906415|Screening Protocol for the Evaluation of Potential Research Subjects|Screening Protocol for the Evaluation of Potential Research Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|May 2006|||||N/A|Observational|N/A|||Anticipated|7500|||Both|13 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01036971||128834|
NCT01037348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AGB10|Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen|A Phase II, Open-label, Multicentre, 12 Month Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5mg) in Patients With Choroidal Neovascularisation Secondary to Pathological Myopia (PM)|REPAIR|Novartis||Completed|January 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|December 21, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037348||128809|
NCT01037049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3227|Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks|Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks?||Royal Marsden NHS Foundation Trust|Yes|Active, not recruiting|October 2009|July 2019|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|237|||Both|18 Years|N/A|No|||November 2013|June 22, 2015|December 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01037049||128831|
NCT01037062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-060|An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection|An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Who Have Completed Previous Phase II Studies in Japan But Who Require Further Treatment||Bristol-Myers Squibb|Yes|Completed|December 2003|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|282|||Both|20 Years|N/A|No|||December 2009|January 24, 2011|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037062||128830|
NCT01037634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 022|Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age|Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study||National Institute of Allergy and Infectious Diseases (NIAID)|No|Withdrawn|March 2010|||March 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Month|12 Months|No|||August 2014|August 5, 2014|December 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01037634||128787|
NCT01037647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070028|VLDL-triglyceride Kinetics in Type 2 Diabetes|VLDL-triglyceride Kinetics and -Metabolism in the Post Absorptive State and During Hyperinsulinemia in Type 2 Diabetes||University of Aarhus|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|Samples With DNA|Blood samples Subcutaneous adipose tissue biopsies Muscle biopsies|Male|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|11 men with type diabetes and 11 healthy men, matched for age and BMI.|November 2011|November 4, 2011|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01037647||128786|
NCT00995241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAL-IC|Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV|Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV||Germans Trias i Pujol Hospital|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||September 2010|September 9, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT00995241||131968|
NCT00995254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072223_CIA|Secondhand Smoke Exposure Reduction Among Young Children in China|Reducing Secondhand Smoke Exposure Among Young Children|China SHARE|Boston University|No|Completed|September 2008|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|85 Years|No|||June 2011|June 23, 2011|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995254||131967|
NCT00995852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 2009|Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study|Unilateral vs. Bilateral IBV Placement||Heidelberg University|Yes|Recruiting|September 2009|May 2011|Anticipated|May 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|80 Years|No|||October 2009|April 26, 2011|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995852||131921|
NCT00996138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110_05|Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects|A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Adult Subjects||Novartis||Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|200|||Both|29 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT00996138||131900|
NCT00995839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1065|Terlipressin in Septic Shock: Effects on Microcirculation|Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation||University of Roma La Sapienza|No|Completed|November 2008|February 2010|Actual|February 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||October 2009|February 3, 2010|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT00995839||131922|
NCT00992095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUPR-T8-PVFS-1|Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Buprenorphine HCl (Sublingual) 8 mg Tablets With a Naltrexone Block Under Fasting Conditions||Roxane Laboratories|No|Completed|August 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|October 9, 2009|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992095||132209|
NCT00992108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8295968|Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques|Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques||University of California, Los Angeles|Yes|Not yet recruiting|October 2009|October 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2009|October 8, 2009|October 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT00992108||132208|
NCT00992394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4535|Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept|Randomized Open-label Study Comparing 2 Different Strategies For Management Of Subjects With Plaque Psoriasis Who Have Responded To Etanercept Treatment|ReSPONSE|Pfizer|No|Completed|January 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|October 8, 2009|Yes|Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT00992394||132186|Enrollment in this study was slower than expected. Thus, recruitment was terminated early and only 58 percent of planned participants were randomized. As a result, no hypothesis testing was conducted and only descriptive statistics are reported.
NCT01034033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSNSTU0020|Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples|Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples||Stanford University||Recruiting|August 2001|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|blood|Female|18 Years|N/A|No|Non-Probability Sample|Women who have a high risk of developing breast or ovarian cancer due to a known germline        mutation in the BRCA1/2, PTEN, CDH1, or TP53 cancer susceptibility genes, or due to strong        family history of either breast or ovarian cancer, in the absence of known cancer        susceptibility gene mutation.|February 2015|February 3, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034033||129013|
NCT01034319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DK084527|Genetic Counseling and Lifestyle Change for Diabetes Prevention|Genetic Counseling and Lifestyle Change for Diabetes Prevention|GC/LC|Massachusetts General Hospital|Yes|Active, not recruiting|December 2009|December 2012|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|90|||Both|21 Years|N/A|No|||July 2011|July 19, 2011|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034319||128991|
NCT01034566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04509|Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma|Proton Radiotherapy for Retroperitoneal Sarcoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|November 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|December 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034566||128972|
NCT01034904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1250_5002_CA|Health Related Quality of Life of Youth and Young Adults With Hemophilia A|A Prospective Non-Interventional Study to Describe Health Related Quality of Life of Youth and Young Adults With Moderate or Severe Hemophilia A Using Recombinant Factor VIII (Helixate FS).||CSL Behring|Yes|Completed|October 2009|November 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|||Male|14 Years|30 Years|No|Non-Probability Sample|The study is focused on youth (14.0 to 18.0 years of age) and young adults (18.01 to 29.99        years of age), living in Canada, who have moderate and severe Hemophilia A, and who are        using Helixate FS either on-demand or as prophylaxis treatment.|December 2013|December 8, 2013|December 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034904||128946|
NCT01035151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS08022834|Smoking Cessation Intervention in Public Housing|Social Ecological Based Smoking Cessation Intervention in Public Housing Neighborhoods||Medical University of South Carolina|Yes|Enrolling by invitation|July 2009|December 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Female|18 Years|N/A|No|||December 2009|December 17, 2009|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035151||128927|
NCT01035164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91683|Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers|Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq (6.75 mCi) ZK 6032924 (18F-FEDAA1106) for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimer's Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of 185 MBq (5 mCi) ZK 6032924 in Healthy Volunteers.||Bayer|No|Completed|June 2007|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|25|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035164||128926|
NCT01035177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040404|In Vivo Hip Fracture Discrimination With Quantitative Computed Tomography (QCT)|In Vivo Discrimination of Hip Fracture With Quantitative Computed Tomography|FEMFRACT|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|February 2005|March 2009|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|107|||Female|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with a history of osteoporotic hip fracture (cases) will be recruited while        hospitalized in one of the study centres for immediate care of their fracture. Women        without osteoporotic fractures (controls) matched on age to the cases will be recruited        while receiving outpatient or inpatient care at one of the study centres. Inclusion and        exclusion criteria are detailed below|March 2008|December 17, 2009|December 17, 2009||No|Difficulties of recruitment, lack of elligible patients|No||https://clinicaltrials.gov/show/NCT01035177||128925|
NCT01035190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAH-F5_2009-223060|Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia|Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia|NEuroSIS|University Children’s Hospital Tuebingen|Yes|Active, not recruiting|April 2010|May 2016|Anticipated|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|850|||Both|N/A|12 Hours|No|||December 2015|December 2, 2015|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01035190||128924|
NCT01035424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901010186|Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis|Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis||Weill Medical College of Cornell University|Yes|Recruiting|March 2010|April 2025|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|32|Samples With DNA|whole blood, serum|Both|2 Years|18 Years|No|Probability Sample|The study will be carried out in children diagnosed with LINCL in all stages.|October 2015|December 9, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035424||128906|
NCT01035437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPCI I 148809|Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer|A Pilot Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer||Roswell Park Cancer Institute|Yes|Withdrawn|December 2009|February 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|December 17, 2009|Yes|Yes|no accrual|No||https://clinicaltrials.gov/show/NCT01035437||128905|
NCT01035450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C338|Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial|Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial|RESET|Kyoto University, Graduate School of Medicine|Yes|Completed|February 2010|May 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3206|||Both|N/A|N/A|No|||December 2015|December 9, 2015|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01035450||128904|
NCT01035879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2982-20920|Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes|Phase 2, Randomized, Double-Blind, Placebo and Active-Comparator Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes||CymaBay Therapeutics, Inc.|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|100|||Both|18 Years|70 Years|No|||March 2015|March 30, 2015|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01035879||128879|
NCT01036321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15835|Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness|Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness and Mechanism of Action Between African American and Caucasian Men||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|December 2009|August 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|71|||Male|30 Years|80 Years|No|||January 2016|January 12, 2016|December 17, 2009|Yes|Yes||No|June 18, 2015|https://clinicaltrials.gov/show/NCT01036321||128858|Since the accrual of African American Men (AAM) was far lower than expected, this study was ultimately underpowered to detect small changes in specific biomarkers of disease progression proposed in men with localized prostate cancer (PCa).
NCT01037387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP PI-825|Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients|Effect of the Noninvasive Mechanical Ventilation on the Daily Physical Activity and the Inflammatory Biomarkers in Stable Patients With COPD||Hospital Universitario La Paz|No|Recruiting|December 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|75 Years|No|||September 2015|September 21, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01037387||128806|
NCT01032317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZCF-125|Study of a New Catheter Using Force Sensing Capabilities for the Treatment of Atrial Fibrillation and Ventricular Tachycardia|EZ Steer™ THERMOCOOL® With CF Sensing Capability (THERMOCOOL SMARTTOUCH™) for the Treatment of Atrial Fibrillation and Ventricular Tachycardia|EZCF-125|Biosense Webster, Inc.|No|Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01032317||129144|
NCT01037361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100015|Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study.|Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study||National Institutes of Health Clinical Center (CC)||Completed|December 2009|June 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|17|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||June 2012|January 14, 2014|December 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01037361||128808|
NCT00995566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321045|A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin|Thelin (Sitaxentan Sodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin|PROSE|Pfizer|No|Terminated|April 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|N/A|No|Non-Probability Sample|-  All patients enrolled must meet the usual prescribing criteria for Thelin as per the             Summary of Product Characteristics (SmPC) and are enrolled in the registry at the             clinician's discretion.          -  All prescribers are offered the opportunity to participate in the registry, assuming             they have received appropriate educational materials|May 2011|February 6, 2012|September 17, 2009||No|The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new    emerging evidence of hepatic injury."|No|December 27, 2011|https://clinicaltrials.gov/show/NCT00995566||131943|The protocol did not identify the priority of endpoints. Therefore, all endpoints arbitrarily assigned as primary.
NCT00996164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.147|Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder|A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin (100 Milligrams) Administered Orally Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in the United States||Sprout Pharmaceuticals, Inc|Yes|Completed|October 2009|February 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1090|||Female|18 Years|55 Years|No|||April 2014|April 16, 2014|October 15, 2009|Yes|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT00996164||131898|
NCT00996151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTE11|Testosterone MD-Lotion Residual Washing Study|A Healthy Volunteer, Single Dose Phase I Trial to Determine the Amount of Testerone MD-Lotion 2% Remaining on the Axilla After Washing.|MTE11|Acrux DDS Pty Ltd|No|Completed|December 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||February 2010|February 28, 2010|October 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT00996151||131899|
NCT00991848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF09|Lidocaine on Manifestations of Fibromyalgia|Effect of Intravenous Lidocaine on Manifestations of Fibromyalgia|LIMAFIBRO|Federal University of São Paulo|Yes|Completed|January 2005|September 2008|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||October 2009|October 8, 2009|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT00991848||132228|
NCT00992121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111687|An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma|An Open-Label Study to Investigate the Pharmacodynamics of a Repeat Dose Regimen of Bevacizumab (10 mg/kg q2w) and Escalating Repeat Doses of Pazopanib in Renal Cell Carcinoma||GlaxoSmithKline|No|Completed|November 2009|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT00992121||132207|
NCT00993941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Bingliang|Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein|Evaluation the Efficacy and Safety of Autologous Bone Marrow Mesenchymal Stem Cells (MSCs) Transplantation in Patients With Early and Middle Stage of Liver Cirrhosis||Sun Yat-sen University|Yes|Active, not recruiting|October 2009|April 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||October 2009|December 3, 2010|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT00993941||132067|
NCT01034046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B08/09-031|Weight Loss and Abdominal Fat Responses to Different Diet Compositions|Weight Loss and Visceral Fat Responses to Different Diet Compositions||University of Nevada, Las Vegas|Yes|Active, not recruiting|April 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|65 Years|No|||December 2009|April 29, 2010|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034046||129012|
NCT01034059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806051R|Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever|Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever||National Taiwan University Hospital|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples With DNA|whole blood|Both|18 Years|84 Years|No|Non-Probability Sample|Patients with hematological malignancy developing neutropenic fever after chemotherapy|December 2009|December 16, 2009|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01034059||129011|
NCT01034579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200136_023|The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial|A Multinational, Multicenter, Single Blood Sampling Exploratory Pharmacogenetic Study of the REGARD (the REbif® vs Glatiramer Acetate in Relapsing MS Disease) Trial|REGARD-PGx|EMD Serono|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|324|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|December 16, 2009||No||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01034579||128971|
NCT01034592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12082009-4523|Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia|A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia||Stanford University|Yes|Recruiting|November 2009|November 2013|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|N/A|No|||March 2011|March 21, 2011|December 15, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01034592||128970|
NCT01056289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-4437|Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)|A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation||Pfizer|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|480|||Both|18 Years|N/A|No|||October 2011|February 25, 2012|January 22, 2010|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT01056289||127367|
NCT01056302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7124-R|Advanced Visuohaptic Surgical Planning for Trauma Surgery|Advanced Visuohaptic Surgical Planning for Trauma Surgery||VA Office of Research and Development|No|Active, not recruiting|November 2011|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will veterans who present to the Oral/Maxillofacial Surgery Clinic at the        San Francisco VA Medical Center. The study will use pre-existing data from patients        undergoing reconstructive facial surgery at the San Francisco VA with clinic indications        that require preoperative CT scans and preoperative radiographs as well as model casts.|December 2014|December 12, 2014|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056302||127366|
NCT01056523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ribavirin-002|Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia|A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression||Jewish General Hospital|No|Completed|January 2010|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056523||127349|
NCT01057121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02923|Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma|A Phase I/II Study of Lenalidomide in Patients With AIDS-Associated Kaposi's Sarcoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2010|||August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057121||127303|
NCT01057134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-UP01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2010|||||N/A|N/A|N/A||||||||||||||June 21, 2013|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057134||127302|
NCT01057056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-YL-0488-CTIL|The Role of Mind Body Therapy in Geriatric Rehabilitation|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2010|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Supportive Care|1||||||Both|18 Years|N/A||||January 2010|February 4, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057056||127308|
NCT01057407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0003|A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis|A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis||Astellas Pharma Inc|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|20 Years|N/A|No|||April 2015|April 30, 2015|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01057407||127281|
NCT01057069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09TNM|Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer|Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors|neo-TN|The Netherlands Cancer Institute|No|Recruiting|January 2010|||December 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|270|||Both|18 Years|59 Years|No|||January 2016|January 20, 2016|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057069||127307|
NCT01057082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100107001|Dietary Supplements and Aging Muscle|Dietary Supplements and Aging Muscle: Specific Amino Acids to Combat Sarcopenia||University of Alabama at Birmingham|Yes|Completed|February 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|65 Years|89 Years|Accepts Healthy Volunteers|||March 2012|March 16, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057082||127306|
NCT01057433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.02US|Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin|Drug-Drug Interaction Study to Assess the Effects of Steady-State Lopinavir/Ritonavir on Pitavastatin in Healthy Adult Volunteers||Kowa Research Institute, Inc.|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|January 25, 2010|Yes|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT01057433||127279|
NCT01057992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030|A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter|A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter||Torax Medical Incorporated|No|Completed|March 2007|January 2013|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|85 Years|No|||November 2013|November 22, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057992||127236|
NCT01057979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-043|Motivational Interventions for Lifestyle and Exercise in College Students|Motivational Interventions for Exercise in Hazardous Drinking College Students|MILE|University of Connecticut|Yes|Completed|January 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||May 2012|May 8, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057979||127237|
NCT01058785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND 8868|Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer|Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer||NovaRx Corporation|No|Completed|March 2003|December 2005|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||January 2010|July 28, 2010|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058785||127175|
NCT01054989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRE-01|Fat, Inflammation and Insulin Resistance|Fat, Inflammation and Insulin Resistance (FIRE-Study)|FIRE|German Diabetes Center|Yes|Active, not recruiting|March 2009|October 2012|Anticipated|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01054989||127465|
NCT01055002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QP09C08|A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers|A Pilot Phase II Study of the Efficacy of Antimalarial Drugs Against Plasmodium Falciparum by Experimental Challenge With a Low Dose of Blood Stage Parasites in Healthy Male Volunteers||Medicines for Malaria Venture|No|Completed|January 2010|August 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01055002||127464|
NCT01054976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015850|The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease|The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease||Janssen Korea, Ltd., Korea||Completed|October 2006|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|50 Years|85 Years|No|||November 2012|November 23, 2012|January 21, 2010||No||No|May 4, 2012|https://clinicaltrials.gov/show/NCT01054976||127466|A relatively low number of patients finished the study, which may have had an impact on the statistical power of data analysis. Difficulties in performing computer-based tests for elderly patients may have hampered detection of changes in attention.
NCT01051141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA 018122 01|Project U Connect - Optimizing Brief Alcohol Intervention for Underage Drinkers in the ER|Optimizing Brief Alcohol Intervention for Underage Drinkers in the ER||University of Michigan|No|Completed|September 2010|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Actual|870|||Both|14 Years|20 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051141||127757|
NCT01055366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-09-06|ELAZOP Switching Study in Korea|||Alcon Research|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|80 Years|No|||May 2012|December 13, 2012|January 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055366||127437|
NCT01055379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12962A|Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn|A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study|ACCORDO|Lundbeck Italia S.p.A.|No|Completed|March 2010|||July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|40 Years|80 Years|No|||July 2012|July 2, 2012|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055379||127436|
NCT01059591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105011|First Study in Humans With GSK424887|A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK424887 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin- Receptor Occupancy||GlaxoSmithKline||Completed|May 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 29, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059591||127114|
NCT01055392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVForlenza-Lithium|Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease|Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease: a Double-blind, Placebo-controlled Prevention Study in Elderly Patients With Mild Cognitive Impairment||University of Sao Paulo|No|Active, not recruiting|March 2007|||March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|60 Years|80 Years|No|||December 2009|January 22, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055392||127435|
NCT01055665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003969|Cognitive Behavioral Therapy, Self-Efficacy, and Depression in Persons With Chronic Pain|Cognitive Behavioral Therapy, Self-Efficacy, and Depression in Persons With Chronic Pain||Mayo Clinic|No|Completed|October 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|138|||Both|18 Years|N/A|No|Non-Probability Sample|Persons with chronic pain and depressive symptoms in a pain rehabilitation program.|May 2012|May 1, 2012|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01055665||127414|
NCT01055951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTR-045, VTR-075|Feasibility Study of the Solo™ Insulin Pump|Feasibility Study of the Solo™ Insulin Pump||Medingo Ltd|No|Completed|May 2009|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|16 Years|60 Years|No|||June 2011|June 1, 2011|January 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055951||127392|
NCT01055964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tacrobell-01|a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients|a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients||Seoul National University Hospital|Yes|Completed|September 2008|||December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|80|||Both|19 Years|65 Years||||May 2015|May 24, 2015|January 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01055964||127391|
NCT01055977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CCZ-CRE-2009/1|Statin Therapy Results in the Real World Practice in the Czech Republic|Statin Therapy Results in the Real World Practice in the Czech Republic|STEP|AstraZeneca|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|3253|||Both|18 Years|N/A|No|Probability Sample|specialist care clinics|August 2011|August 29, 2011|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055977||127390|
NCT01056315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131885|A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Analgesic Efficacy and Safety of a New Analgesic Compared to Placebo in Subjects With Painful Diabetic Peripheral Neuropathy||Grünenthal GmbH|No|Terminated|November 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|553|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|December 21, 2009|Yes|Yes|Trial was stopped due to difficult enrolment|No|April 5, 2012|https://clinicaltrials.gov/show/NCT01056315||127365|No participants were analyzed as the study was terminated
NCT01057147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-RED-204|Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea|A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo in Clearing of Fluorescein Staining of the Central Cornea in Subjects With Keratoconjunctivitis Sicca (Dry Eye)||Acucela Inc.||Completed|February 2010|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057147||127301|
NCT01057160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK 462|Rizatriptan 10 MG RPD in the Treatment of Acute Migraine|A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment|Rinotama|Universität Duisburg-Essen|No|Completed|May 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|65 Years|No|||January 2013|January 25, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057160||127300|
NCT01056783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/013/09|Proof of Concept Study of OC000459 in Eosinophilic Esophagitis|A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis||Oxagen Ltd|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|75 Years|No|||January 2012|January 4, 2012|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056783||127329|
NCT01057108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 002|Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia|A Double Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of FOSTRAP Chewing Gum in Patients With Chronic Kidney Disease and Hyperphosphatemia.||Denver Nephrologists, P.C.|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|121|||Both|18 Years|N/A|No|||January 2011|January 5, 2011|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01057108||127304|
NCT01057446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mütf|Comparison of Oral Sodium Phosphate and Sennoside A+B Calcium Lavage for Colonoscopy Preparation|Prospective Randomized Comparison of Oral Sodium Phosphate and Sennoside A+B Calcium Lavage for Colonoscopy Preparation||Maltepe University|No|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|18 Years|N/A||Probability Sample|Ninety-nine patients requiring diagnostic outpatient colonoscopy were prospectively        recruited for the study and randomized by internet based Easy sample random numbers        software program to two arms of sodium phosphate versus Sennosid A+B calcium preparation.|November 2009|February 4, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057446||127278|
NCT01057719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012.06|Climate Influence on Physiotherapy in Multiple Sclerosis|Climate Influence on Physiotherapy in Multiple Sclerosis|CIOPIMS|Haukeland University Hospital|No|Completed|June 2006|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||January 2010|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057719||127257|
NCT01058304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-056|Group Physical Therapy for Knee Osteoarthritis|Group Physical Therapy for Veterans With Knee Osteoarthritis||VA Office of Research and Development|No|Completed|February 2011|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|320|||Both|N/A|N/A|No|||March 2015|March 23, 2015|January 26, 2010||No||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01058304||127212|Because the target recruitment goal could not be met, a new sample size target was calculated, with a goal of being able to detect an effect size of 0.35. This translated into a target of n=226, which we exceeded by enrolling n=320.
NCT01058278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-002-1213|Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma|Impact of the Post-operative Treatment on the Intraocular Pressure Post Selective Laser Trabeculoplasty (SLT) on Patients With Primary Open-angle Glaucoma|SLT|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|March 2008|December 2015|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 26, 2016|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058278||127214|
NCT01055704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002996|Effect of Methylnaltrexone on GI Transit in Healthy Volunteers|Effect of Methylnaltrexone on Gastrointestinal and Colonic Transit in Health||Mayo Clinic|No|Completed|November 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|January 22, 2010|Yes|Yes||No|July 8, 2011|https://clinicaltrials.gov/show/NCT01055704||127411|We did not evaluate dose-response. A higher dosage of MNTX may be needed to produce a detectable effect on GI and colonic transit as well as bowel pattern in healthy subjects who are naive to opioid agonists during MNTX initiation.
NCT01055015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q8003-009|Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty|A Randomized, Double-Blind, Study of the Analgesic Efficacy and Safety of Flexible Dose Q8003 Versus Low Dose Q8003 in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty||QRxPharma Inc.|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055015||127463|
NCT01055028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARCOMA0006|Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma|Paclitaxel in Combination With Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma||Stanford University|Yes|Active, not recruiting|February 2010|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|13 Years|N/A|No|||June 2014|June 24, 2014|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055028||127462|
NCT01050868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000811|Comparison of the Management of Post-prandial Hyperglycemia by Multiple Bolus Calculators|||Hoffmann-La Roche||Completed|June 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|N/A||||January 2011|March 1, 2016|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050868||127778|
NCT01051115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D'Accord study|Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease|Dasatinib Combination for Chronic Lymphocytic Leukemia Patients With Chemo Refractory Disease|D'ACCORD|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|October 2008|January 2016|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|80 Years|No|||August 2011|August 29, 2011|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051115||127759|
NCT01051440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00517|Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression|A Magnetic Resonance Spectroscopy and fMRI Study of the Effects of Lisdexamfetamine on Bipolar Depression||Steward St. Elizabeth's Medical Center of Boston, Inc.||Terminated|February 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|21 Years|50 Years|No|||December 2012|December 19, 2012|January 14, 2010|Yes|Yes|Slow enrollment|No|July 30, 2012|https://clinicaltrials.gov/show/NCT01051440||127734|The study was terminated before completion due to low enrollment. One subject was randomized to lisdexamfetamine and one was randomized to placebo. Therefore, it was not possible to obtain complete data.
NCT01051466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12875|A Study of the Neurobiology of Depression|Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects With Major Depressive Disorder||Eli Lilly and Company|No|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|January 15, 2010|Yes|Yes||No|February 17, 2014|https://clinicaltrials.gov/show/NCT01051466||127733|Three healthy participants were identified as not meeting inclusion/exclusion criteria after enrollment. They were discontinued and excluded from secondary outcome analyses, but included in participant flow, primary outcome analyses, and safety.
NCT01056562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB # 09-0526-C|An Alternative to A Fixed Schedule In Management Of Prostate Cancer|Testosterone-Guided Schedule of Androgen Deprivation Therapy (ADT) as an Alternative to A Fixed Schedule In Management Of Prostate Cancer|TADS|University Health Network, Toronto|No|Completed|November 2009|June 2014|Actual|June 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|82|||Male|N/A|N/A|No|Probability Sample|Men with prostate cancer attending ambulatory clinics at Princess Margaret Hospital|April 2015|April 24, 2015|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056562||127346|
NCT01056575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/014/09|Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4|An Open Label Balanced Study in Healthy Subjects to Evaluate the Potential for Cytochrome P 450 3A4 Induction by Oral OC000459 Using Oral Midazolam as a Probe||Oxagen Ltd|No|Completed|February 2010|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 1, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056575||127345|
NCT01059253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7170-HW-CTIL|Pilot Study of AdvanStep in Improving Balance in at Risk Elderly|Feasibility and Pilot Study of AdvanStep in Improving Balance in Elderly at Risk for Falls|AdvanStep|Sheba Medical Center|No|Withdrawn|September 2010|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|January 28, 2010||No|equipment not functional|No||https://clinicaltrials.gov/show/NCT01059253||127140|
NCT01059266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/0035|PURETHAL Grasses Rush Study|A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis||HAL Allergy|No|Completed|February 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059266||127139|
NCT01055678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020382|To Evaluate the Characteristics of a Breast Cancer|Pilot Study to Characterize the HRHV Axis in the Microenvironment of Breast Cancers||Duke University|No|Withdrawn|January 2010|December 2011|Actual|December 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|No|||December 2012|December 14, 2012|January 24, 2010|No|Yes|PI left Duke|No||https://clinicaltrials.gov/show/NCT01055678||127413|
NCT01056016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH082714|Disseminating a Model Intervention to Promote Improved Attention-deficit Hyperactivity Disorder (ADHD) Care in the Community|Disseminating a Model Intervention to Promote Improved ADHD Care in the Community||Children's Hospital Medical Center, Cincinnati|No|Completed|July 2009|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|8|||Both|N/A|N/A|No|||February 2012|February 9, 2012|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056016||127387|
NCT01056029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-202-001|Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors|An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors||GenSpera, Inc.|No|Completed|January 2010|August 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056029||127386|
NCT01056328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90030928|Irrigated Ablation System Evaluation for Atrial Fibrillation (AF)|Irrigated Ablation System Evaluation for AF|IRASE-AF|St. Jude Medical|Yes|Completed|February 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|January 22, 2010|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01056328||127364|
NCT01055990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-0015|Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients|Phase1 An Observational Clinical Trial With an Influenza A (H1N1) 2009 Monovalent,Split-virion Vaccine in Healthy Adults, Aged 18-60 Years Phase2 Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients||Shanghai Public Health Clinical Center|Yes|Active, not recruiting|October 2009|May 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|7|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2009|January 25, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01055990||127389|
NCT01056003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gips in Kids|Prevalence of Gastric Inlet Patches of the Cervical Esophagus.|Gastric Inlet Patches of the Cervical Esophagus. Incidental Finding or Underrated Cause of Globus Sensations.||Technische Universität München|Yes|Not yet recruiting|June 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|90 Years|No|Non-Probability Sample|all patients admitting one of the above mentioned endoscopic departments for a scheduled        EGD|January 2010|January 24, 2010|January 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01056003||127388|
NCT01056809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGC-8|Treatment Strategies for Primarily Generalized Colorectal Cancer|Treatment Strategies for Primarily Generalized Colorectal Cancer Prospective Randomized Comparison Between Two Treatment Strategies|PGC|Vrinnevi Hospital|No|Terminated|January 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|N/A|N/A|No|||May 2012|May 30, 2012|January 25, 2010||No|Too slow recruitment|No||https://clinicaltrials.gov/show/NCT01056809||127327|
NCT01056822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AES08|Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.|Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.|MAXIMIZA|Novartis|Yes|Completed|May 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|January 25, 2010|No|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01056822||127326|
NCT01058317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-10-104|Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis|Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis||Massachusetts Eye and Ear Infirmary|No|Withdrawn|January 2010|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|10 Years|No|||April 2012|November 19, 2013|January 27, 2010||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01058317||127211|
NCT01056796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version: January 6, 2010|Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27|Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27||Niti Medical Technologies Ltd.|No|Recruiting|January 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2010|June 29, 2011|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056796||127328|
NCT01057095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B12|Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia|Mechanisms of PLAGL2-Induced Leukaemogenesis||Children's Oncology Group|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|Samples With DNA|tissue|Both|N/A|120 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia|May 2015|September 30, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057095||127305|
NCT01057732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3630405|Effects of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism|The Effect of Parathyroidectomy on Cardiovascular Risk Factors in Patients With Primary Hyperparathyroidism||HaEmek Medical Center, Israel|No|Completed|January 2005|December 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|76|Samples Without DNA|serum, urine|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Primary hyperparathyroidism referred to Endocrine clinic. Controls recruited        in community-based health centers.|January 2010|January 25, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01057732||127256|
NCT01058005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS325|Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis|A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis|SURPASS|Biogen||Terminated|March 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|84|||Both|18 Years|60 Years|No|||August 2014|August 18, 2014|January 26, 2010|Yes|Yes|Due to significantly slower than expected enrollment, the Sponsor decided to terminate the    study.|No|July 23, 2014|https://clinicaltrials.gov/show/NCT01058005||127235|Due to early termination of the study and the small size of the study population, there was insufficient power for efficacy and safety analyses. Only serious adverse events were to be captured and reported under the protocol.
NCT01058291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6500-004|Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500|Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)|6500-004|Kyowa Hakko Kirin Company, Limited||Completed|January 2010|||October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|N/A|No|||August 2012|August 30, 2012|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058291||127213|
NCT01059643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12848|A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck||Eli Lilly and Company|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||February 2013|April 30, 2013|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059643||127110|
NCT01058551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reveal XT-SA|Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study|Incidence of New Onset Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study||Queen's University|No|Recruiting|June 2011|July 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058551||127193|
NCT01055444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-202|Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome|An Open-Label Pilot Study Evaluating Synera® in the Treatment of Patients With Shoulder Impingement Syndrome||ZARS Pharma Inc.|No|Completed|March 2010|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055444||127431|
NCT01055457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1650|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2009|||||N/A|N/A|N/A||||||||||||||January 22, 2010|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055457||127430|
NCT01055470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharmacol no.02 /2008 Research|Comparative Clinical Trial of Lornoxicam to Diclofenac in Patients of Osteoarthritis of Knee Joint.|Open, Randomized, Controlled Clinical Trial of Lornoxicam as Compared to Diclofenac in Osteoarthritis of Knee Joint in Patients of Tertiary Care Hospital of Gujarat.||Government Medical College, Bhavnagar||Completed|December 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|25 Years|65 Years|No|||January 2010|January 22, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055470||127429|
NCT01050907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-MILT-201|Miltefosine to Treat Mucocutaneous Leishmaniasis|Treatment of Mucocutaneous Leishmaniasis With Miltefosine||Knight Therapeutics (USA) Inc|No|Completed|May 2010|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2011|March 24, 2015|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01050907||127775|
NCT01050881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/DNS|Notification of Donors With Positive Microbiology Markers|Assessment of the Impact of Notification of Blood Donors Testing Positive for Microbiology Markers: What is the Psychological Impact of Notification and Does the Method of Notification Influence the Outcome?||NHS Blood and Transplant|Yes|Not yet recruiting|February 2010|October 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|600|||Both|18 Years|65 Years|No|Non-Probability Sample|All donors testing positive for microbiology markers in 2008 and 2009, and those        identified as at risk of vCJD in 2008.|January 2010|February 12, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050881||127777|
NCT01050894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APS-001|Feasibility Study of Anti-inflammatory Cytokines in Whole Blood in Osteoarthritis Patients|A Feasibility Study to Determine the Up-regulation of Anti-inflammatory Cytokines in Whole Blood From Patients With Osteoarthritis||Biomet, Inc.|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with evidence of osteoarthritis.|December 2012|December 18, 2012|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050894||127776|
NCT01051167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT1-2007|Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer|Bi-weekly Cetuximab Combined With FOLFOX-6 as First-line Treatment in Metastatic Colorectal Cancer Patients With Wild-type K-ras Status|CEBIFOX|Universität Duisburg-Essen|No|Active, not recruiting|February 2009|December 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051167||127755|
NCT01056588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00399|Contingency Management for Smoking Abstinence With Adolescent Smokers|Predictors of Smoking Outcomes During Treatment Programs|CM|Nationwide Children's Hospital|Yes|Recruiting|February 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|126|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||January 2010|June 21, 2011|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056588||127344|
NCT01059617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113483|Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults|A Study to Evaluate Immune Responses Following A/California/7/2009 (H1N1)V-like Virus Vaccination Given 4 Months Following Seasonal Influenza Vaccination in Adults 19 to 40 Years of Age||GlaxoSmithKline||Completed|February 2010|May 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|133|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||May 2012|July 12, 2012|January 28, 2010|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT01059617||127112|
NCT01055405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JA Barbera|Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension|Phase IV Study on the Effects of Sildenafil in Combination With Pulmonary Rehabilitation Program on Exercise Tolerance in Patients With COPD and Pulmonary Hypertension|SIL-COPD-02|Hospital Clinic of Barcelona|Yes|Completed|August 2008|January 2012|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|40 Years|80 Years|No|||April 2012|April 3, 2012|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055405||127434|
NCT01056835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beraprost-01|Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy|Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy||Seoul National University Hospital|Yes|Completed|June 2009|June 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|20 Years|50 Years|No|||May 2015|May 24, 2015|January 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01056835||127325|
NCT01057173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA2009046|The Nordic Aortic Valve Intervention Trial|Transcatheter Versus Surgical Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis|NOTION|Rigshospitalet, Denmark|No|Active, not recruiting|December 2009|April 2018|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|70 Years|N/A|No|||November 2014|November 6, 2014|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057173||127299|
NCT01057186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21922|Hypophosphatemic Rickets in Norway|Hypophosphatemic Rickets in Norway||Haukeland University Hospital|No|Active, not recruiting|December 2009|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|80|Samples With DNA|EDTA plasma, serum, urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The cohorts will be selected from Norwegian patients with hypophosphatemia and        hyperphosphatemia.|September 2015|September 23, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057186||127298|
NCT01057485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFAPAFv1.3|Node and Atrial Fibrillation Ablation for Persistent Atrial Fibrillation|Node and Atrial Fibrillation Ablation for Persistent Atrial Fibrillation|NAFAPAF|Eastbourne General Hospital|No|Recruiting|February 2010|January 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2010|May 25, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057485||127275|
NCT01057498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.1.1.H1|Safety Study of Nebulized RNS60 to Treat Asthma.|A Phase I Study of Nebulized RNS60 in Adult Healthy Subjects and Patients With Mild to Moderate Asthma.||Revalesio Corporation|No|Completed|May 2010|January 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 11, 2012|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01057498||127274|
NCT01056536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST|Efficacy of a Brief Intervention and/or Distribution of Free Condoms During Pre-travel Consultation on Sexual Behaviour Abroad|Efficacy of a Brief Intervention and/or Distribution of Free Condoms During Pre-travel Consultation on Sexual Behaviour Abroad: a Randomized Controlled Trial||University of Lausanne Hospitals|No|Completed|January 2006|November 2011|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1000|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056536||127348|
NCT01056549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-0428-B|Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans|Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans.||University Health Network, Toronto|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01056549||127347|
NCT01058018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX222-CS-005|Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease|Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease|ASSERT|Resverlogix Corp|Yes|Completed|December 2009|||June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|299|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058018||127234|
NCT01058031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bremner Merit 007|Neural Correlates of PTSD Prevention With Mindfulness Based Stress Reduction (MBSR) in Iraqi Veterans|Neural Correlates of PTSD Prevention With MBSR in Iraqi Veterans||VA Office of Research and Development|Yes|Completed|January 2007|November 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|65 Years|No|||November 2013|November 4, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058031||127233|
NCT01058330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLC00038711|Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1|Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With Neurofibromatosis Type 1||Shriners Hospitals for Children|No|Completed|February 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|4 Years|19 Years|No|||November 2014|November 17, 2014|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058330||127210|
NCT01057459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150905|DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701|Natural Killer Cell KIR and HLA Genotypes May Predict Response to Antibody Therapy in Follicular Lymphoma||Alliance for Clinical Trials in Oncology|No|Recruiting|February 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|106|Samples With DNA|Blood|Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with follicular lymphoma treated on CALGB 50402 or 50701 protocols|July 2015|July 23, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057459||127277|
NCT01057472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK Vest 2009/1771|Repeatability and Feasibility of Infant Spirometry|Repeatability and Feasibility of Infant Spirometry||Haukeland University Hospital|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|Term born and preterm born babies|January 2012|January 24, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057472||127276|
NCT01058811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912012R|Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue|Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue: Find Lung Cancer Stem Cells and Test Its Chemotherapy Drug Resistance; Compare Stroma Cell Between Tumor Part and Surrounding Part||National Taiwan University Hospital|No|Recruiting|December 2009|December 2010|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Routine Surgical resection of lung tumor|Both|18 Years|N/A|No|Probability Sample|lung cancer patient|January 2010|January 27, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058811||127173|
NCT01058824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1601001|Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule|Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule 500 Mg Formulations, In Healthy Volunteers Using Formulations (Frademicina®) Manufactured By Pfizer Laboratories Ltd||Pfizer|No|Completed|April 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 25, 2011|January 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058824||127172|
NCT01059357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 60209|Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Lesions Using Da Vinci Robotic Surgical System|A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System|TORS|Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|June 2010|January 2016|Anticipated|January 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01059357||127132|
NCT01059370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0112|Autonomic Dysreflexia in Spinal Cord Injury|Autonom Dysrefleksi Ved Rygmarvsskade||University of Aarhus|Yes|Completed|December 2009|March 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|N/A|No|||October 2012|October 15, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01059370||127131|
NCT01055431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1013/69|A Functional Food for the Prevention of Iron-deficiency Anemia|Teff (Eragrostis Tef) as a Functional Food for the Prevention of Pregnancy Iron-deficiency Anemia||Manchester Metropolitan University|Yes|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|55|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2010|July 29, 2014|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055431||127432|
NCT01056380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM01-2027|Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza||Romark Laboratories L.C.|No|Terminated|January 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|65 Years|No|||May 2012|May 30, 2012|January 23, 2010|Yes|Yes|Insufficient enrollment during 2009-2010 flu season, new study initiated.|No||https://clinicaltrials.gov/show/NCT01056380||127360|
NCT01055080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINDIA2002|Insulin-free Cow Milk Formula in Prevention of Type 1 Diabetes Associated Autoimmunity - FINDIA Pilot Study|Pilot Study of Dietary Prevention of Type 1 Diabetes Associated Beta-cell Autoimmunity in Children at Genetic Risk|FINDIA|National Institute for Health and Welfare, Finland|No|Completed|May 2002|December 2009|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|987|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2010|January 22, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055080||127458|
NCT01055093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC-Study-01|Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients|Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients|GDC|German Diabetes Center||Recruiting|September 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole blood, PBMC, serum, plasma, urine, stool|Both|18 Years|69 Years|No|Non-Probability Sample|Patients are recruited from the general populations by screening|July 2012|July 12, 2012|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055093||127457|
NCT01051154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-785-107|Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia|The Effect of Enteral Administration of Polyunsaturated Omega-3 Fatty Acids on Nutritional Status; the Treatment Toxicity and Early Mortality in Children With Acute Lymphoblastic Leukemia - a Controlled Study|DHA-ALL|Coordinación de Investigación en Salud, Mexico|Yes|Enrolling by invitation|September 2010|July 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|268|||Both|4 Years|15 Years|No|||February 2016|February 8, 2016|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051154||127756|
NCT01051505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00007|A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Administration of Multiple Ascending Doses for 8 Days in Healthy Male or Female Subjects||AstraZeneca|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01051505||127730|
NCT01057225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0982|Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma|A Phase I/II Trial of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients With Newly Diagnosed Active Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|March 2010|||March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057225||127295|
NCT01056341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00400 SB 201 Study|Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy|A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind).||Pierre Fabre Dermatology|Yes|Completed|January 2010|November 2013|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|512|||Both|35 Days|150 Days|No|||November 2015|November 12, 2015|January 24, 2010|Yes|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT01056341||127363|
NCT01057199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B13|Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia|Critical Role of MicroRNA-34a and MicroRNA-194 in Acute Myeloid Leukemia With CEBPA Mutations||Children's Oncology Group|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|6|Samples With DNA|cell samples|Both|N/A|N/A|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia with CEBPA mutations|May 2015|May 5, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057199||127297|
NCT01057511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200113-600|Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration|Investigation of the Differences of Progesterone Concentration in Serum and Endometrium After Administration With Vaginal and Intramuscular Progesterone||Peking Union Medical College Hospital|Yes|Completed|December 2009|February 2012|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Female|N/A|55 Years|No|||April 2012|April 1, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057511||127273|
NCT01057771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0075|Meditation and Exercise for Prevention of Acute Respiratory Infection|Meditation and Exercise for Prevention of Acute Respiratory Infection|MEPARI|University of Wisconsin, Madison|Yes|Completed|June 2009|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|154|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01057771||127253|
NCT01057745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806062|Ovarian Freezing Before Cancer Treatment|Ovarian Tissue Freezing Prior to Chemotherapy or Radiation Therapy: a Study by the Oncofertility Consortium||University of Pennsylvania|No|Enrolling by invitation|February 2007|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|ovarian tissue|Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|cancer patients|March 2015|March 17, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057745||127255|
NCT01058044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU792|Adherence to Oral Anticancer Treatment Using Electronic Monitoring System|A Pilot Study of Adherence to Oral Anticancer Treatment Using Electronic Monitoring System||Centre Jean Perrin|No|Completed|July 2009|||January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058044||127232|
NCT01058343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN-K-001|Safety of IFNa Kinoid in Systemic Lupus Erythematosus|A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.||Neovacs|Yes|Active, not recruiting|March 2010|December 2014|Anticipated|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|28|||Both|18 Years|50 Years|No|||September 2014|September 17, 2014|January 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058343||127209|
NCT01058850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSBRN0008|Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas|A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas||Stanford University|Yes|Terminated|June 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|3 Years|18 Years|No|||October 2013|October 22, 2013|January 27, 2010|No|Yes|Resources can be better spent on higher enrolling studies|No||https://clinicaltrials.gov/show/NCT01058850||127170|
NCT01059123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071207|Short Course of Amoxicillin for Erysipelas|Randomized Non Inferiority Study Comparing Short Course of Oral Amoxicillin to One of the Usual Treatments of Lower Leg Erysipelas|SHARE|Assistance Publique - Hôpitaux de Paris|No|Terminated|September 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|January 28, 2010||No|Insufficient number of inclusion|No||https://clinicaltrials.gov/show/NCT01059123||127150|
NCT01058564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1709|A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter|A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter||Torax Medical Incorporated|No|Completed|May 2008|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|85 Years|No|||November 2013|November 22, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058564||127192|
NCT01058798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903079R|The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma|The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma||National Taiwan University Hospital|No|Completed|January 2008|April 2009|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|N/A|18 Years|No|Non-Probability Sample|From year 1990 to 2008, pediatric neuroblastoma patients treated at National University        Hospital, Taiwan|January 2010|January 27, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058798||127174|
NCT01058837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1HL100625|SCD-HeFT 10 Year Follow-up|Sudden Cardiac Death in Heart Failure Trial 10 Year Follow-up (SCD-HeFT 10 Year)|SCD-HeFT10 Yr|Seattle Institute for Cardiac Research|No|Active, not recruiting|September 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|1855|||Both|18 Years|90 Years|No|Probability Sample|At the close of follow-up of the original SCD-HeFT study on October 31, 2003 there were a        total of 666 deaths out of the enrollment population of 2521 patients. The American        Recovery and Reinvestment Act (ARRA) of 2009 offers a perfect opportunity to do a one-time        survey of the remaining 1855 patients from our last follow-up of October 31, 2003. Data on        this population would allow us to obtain 10 year ICD follow-up data on the most detailed        and largest ICD study ever done.|February 2010|February 9, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058837||127171|
NCT01055483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589B2116|A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia|A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia||Novartis||Completed|September 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|January 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055483||127428|
NCT01055743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009PHC001|The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma|A Randomized, Controlled Trial of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma||Simcere Pharmaceutical Co., Ltd|Yes|Recruiting|August 2009|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|75 Years|No|||January 2010|January 24, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055743||127408|
NCT01059084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37304-B|An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons|An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons||University of Washington|Yes|Withdrawn|January 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|January 27, 2010|No|Yes|We were unable to enroll any participants into this study.|No||https://clinicaltrials.gov/show/NCT01059084||127153|
NCT01059097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANCREAS2010|Effect of Surgeon Volume on Outcome of Pancreaticoduodenectomy|Effect of Surgeon Volume on Outcome of Pancreaticoduodenectomy in a High Volume Hospital.||Università Vita-Salute San Raffaele|No|Completed|August 2001|January 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|610|||Both|18 Years|90 Years|No|||January 2010|January 28, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01059097||127152|
NCT01059110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070701|Comparison of Five Treatments in Patients With Plantar Warts|Comparison of Occlusive Dressings, Salicylate Ointment, Cryotherapy, Topical 5-fluoro-uracil and Imiquimod in Immunocompetent Patients Presenting Plantar Warts in Office-based Settings: a Randomized Clinical Trial|VRAIE|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|February 2010|October 2016|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|358|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 30, 2009||No|Difficulty to enrollment patients|No||https://clinicaltrials.gov/show/NCT01059110||127151|
NCT01059383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCT007|Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms|Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms||Vecta Ltd.||Completed|December 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|January 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059383||127130|
NCT01059656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090402|Phase II Pazopanib Study in Advanced Dermatofibrosarcomas|A Phase IIa Open Multicenter, Trial, of Treatment With Pazopanib (Multi Tyrosine Kinase Inhibitor) in Dermatofibrosarcomas (DFSP), Unresectable Locally Advanced (Potentially Mutilating Surgery), Primary or Relapsing , Transformed or Not.|DFSP-PAZO|Assistance Publique - Hôpitaux de Paris|No|Terminated|July 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|20 Years|N/A|No|||June 2014|February 2, 2015|January 28, 2010||No|Decision of Study Principal Investigator|No||https://clinicaltrials.gov/show/NCT01059656||127109|
NCT01054768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-003|Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease|Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease||Children's Hospital & Research Center Oakland|Yes|Completed|August 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|10 Years|N/A|No|||July 2013|July 29, 2013|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054768||127482|
NCT01050933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POICO-A|Safety Study of Inhaling Carbon Monoxide in Healthy Volunteers|Safety and Tolerability of Inhaled Carbon Monoxide in Healthy Volunteers||Queen's University|No|Terminated|September 2010|October 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 15, 2015|January 13, 2010||No|resident left and no one to take over|No||https://clinicaltrials.gov/show/NCT01050933||127773|
NCT01050920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK03/32/09|Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population|||National University Hospital, Singapore||Recruiting|September 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Both|21 Years|N/A|No|Probability Sample|Germline DNA will be genotyped for variants in genes in the anti-coagulation pathway,        including CYP4F2, GGCX and EPHX1. The germline DNA was previously collected from a        warfarin study (C/00/510, NUH, C/00/535, TTSH, PI-Dr Goh Boon Cher). Samples were        anonymized, and data analysis will be done without patient identifiers. Germline DNA        previously collected from 279 patients who were on maintenance warfarin dose will be        genotyped.        The clinical data that has been collected and will be used for the study include: gender,        race, age, body weight, maintenance warfarin dose, serum albumin, two consecutive stable        INR values, and indications for warfarin use.|January 2014|January 21, 2014|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01050920||127774|
NCT01051778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aps/UFH/enox40|Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome|Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial||Cairo University|Yes|Completed|June 2006|December 2009|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|19 Years|37 Years|No|||January 2010|July 29, 2011|January 19, 2010||No||No|May 10, 2010|https://clinicaltrials.gov/show/NCT01051778||127709|
NCT01052064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS-09.01-ADHD|Transcranial Magnetic Stimulation in Children With Attention Deficit Hyperactivity Disorder (ADHD). A Safety Study|Therapy With rTMS in Children With Attention Deficit and Hyperactivity Disorder. Phase 1 Study.||International Center for Neurological Restoration, Cuba|Yes|Recruiting|April 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|7 Years|12 Years|No|||January 2010|January 19, 2010|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052064||127688|
NCT01056900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05CON|Observation of the Result After Chondron (Autologous Chondrocytes) Treatment|An Investigator-sponsored Trial for Observation of the Result After Chondron (Autologous Chondrocytes) Treatment||Sewon Cellontech Co., Ltd.|No|Completed|December 2008|November 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|127|||Both|15 Years|65 Years|No|Non-Probability Sample|In this exploratory clinical trial Chondron (autologous chondrocytes) is transplanted in        the cartilaginous defects and the effectiveness is observed through follow-up. Target        subjects are about 5% of about 2,000 patients with Chondron implants.|January 2010|January 24, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01056900||127320|
NCT01056848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-LX3431|International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430|International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430||CardioKine Inc.||Completed|January 2010|||June 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|135|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a        randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia        (CK-LX3401, CK-LX3405, or CK-LX3430)|June 2011|June 20, 2011|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056848||127324|
NCT01057524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0708/10|High Frequency Chest Wall Oscillation and Cystic Fibrosis|The Use of High Frequency Chest Wall Oscillation During an Acute Infective Pulmonary Exacerbation of Cystic Fibrosis||Imperial College London|Yes|Completed|February 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|16 Years|N/A|No|||February 2012|February 15, 2016|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057524||127272|
NCT01057784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11-095|Bariatric Surgery Outcomes|Bariatric Surgery Outcomes: Quality of Life / Reproductive-Age Women||University of California, Los Angeles|No|Withdrawn|March 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples With DNA|The subgroup of 10 reproductive-age women will have coded bloods samples retained for DNA      and RNA analysis.|Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing bariatric surgery.|January 2010|December 5, 2014|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057784||127252|
NCT01058083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB117-004|Safety Study of BMS-770767 in Subjects With Hypercholesterolemia|A Double-blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Primary Hypercholesterolemia||Bristol-Myers Squibb|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|81|||Both|18 Years|75 Years|No|||April 2012|April 18, 2012|January 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058083||127229|
NCT01057758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002019-42|STATIN-VAP STATIN-VAP - STATINs and Ventilator-Associated Pneumonia|Effect of the Association of a Statin to Antibiotics on the Prognosis of Patients Presenting With a Suspicion of Ventilator-associated Pneumonia||Assistance Publique Hopitaux De Marseille|Yes|Terminated|September 2009|June 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||April 2013|October 29, 2013|January 26, 2010||No|stopped for futility|No||https://clinicaltrials.gov/show/NCT01057758||127254|
NCT01058863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-201|A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma|A Double-blind, Randomized, Placebo-controlled, 5-way Crossover, Multicenter, Single-dose, Dose-ranging Study to Compare the Efficacy and Safety of Albuterol Spiromax® and ProAir® HFA in Adult and Adolescent Subjects Ages 12 and Older With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|72|||Both|12 Years|N/A|No|||May 2015|May 19, 2015|January 27, 2010|Yes|Yes||No|May 19, 2015|https://clinicaltrials.gov/show/NCT01058863||127169|
NCT01058577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1-2001-01|Changes in Serum Electrolytes at Different Glucose Concentrations + Impact on a Non-invasive Glucose Monitoring Method|A Single Center, Open Study to Evaluate Changes in Serum Electrolytes at Different Glucose Concentrations and Their Impact on a Non-invasive Glucose Monitoring Method||Profil Institut für Stoffwechselforschung GmbH|No|Completed|December 2001|August 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|January 27, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058577||127191|
NCT01059669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK nr 241.08|The Diagnosis of Chronic Pancreatitis|A Multimodal Approach to Diagnose Patients With Chronic Pancreatitis||Haukeland University Hospital|No|Recruiting|August 2009|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Pankreatic juice Duodenal tissue Blood|Both|16 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patient with suspected chronic pancreatitis age 18-67 years|December 2015|December 18, 2015|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01059669||127108|
NCT01059409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070309 / IC0705|Study of Meniscal Allografts|The Clinical and Medico-economical Evaluation of Meniscal Allografts in the Sequelae of Total or Sub-total Meniscectomy.|ERAM|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|September 2010|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059409||127128|
NCT01055756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOREMS0909|Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Withdrawn|January 2010|June 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|60 Years|No|||February 2010|October 26, 2010|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01055756||127407|
NCT01056094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-06094|Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers|Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers||Peking University|Yes|Recruiting|April 2010|August 2012|Anticipated|July 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||April 2009|June 21, 2012|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01056094||127382|
NCT01056107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005871|Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients|Effect of ROSE-010 on Gastrointestinal Motor Functions in Female Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)||Mayo Clinic|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|52|||Female|18 Years|65 Years|No|||April 2013|April 24, 2013|January 22, 2010||No||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01056107||127381|
NCT01055496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3129K2-1105|Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma|An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma||Pfizer|No|Completed|March 2010|March 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|January 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055496||127427|
NCT01055106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW05-0904|Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis|A Multicenter, Randomized, Investigator-Blinded, Phase 2, Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis||Graceway Pharmaceuticals, LLC|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|255|||Female|18 Years|N/A|No|||June 2011|June 28, 2011|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055106||127456|
NCT01051193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI476B1301E1|Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures|A Multicentre, Open-label, Extension Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy||Novartis||Active, not recruiting|January 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|4 Years|15 Years|No|||March 2016|March 21, 2016|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051193||127753|
NCT01051206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0057|The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery|The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery||Yonsei University|Yes|Completed|May 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Primary Purpose: Prevention|||Anticipated|106|||Both|20 Years|N/A|No|||June 2010|July 9, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051206||127752|
NCT01051180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0501/61|Is Doppler Necessary in Haemorrhoidal Artery Ligation Operation?|Haemorrhoidal Artery Ligation Operation; is Doppler Necessary?||Poole Hospital NHS Foundation Trust|No|Recruiting|January 2010|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|90 Years|No|Probability Sample|For consenting adults (18-90 years) with grade one and two piles listed for HALO at Poole        hospital by three consultants trained in the HALO technique, the patients will be offered        to be involved in the study.|January 2010|January 15, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051180||127754|
NCT01051518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2006-02|Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)|Clinical Evaluation of Percutaneous Implantation of the CoreValve Aortic Valve Prosthesis. Safety and Performance Study on Patients at High Risk for Surgical Valve Replacement (18Fr Safety and Efficacy Study)||Medtronic Cardiovascular|Yes|Completed|May 2006|June 2013|Actual|February 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|75 Years|N/A|No|||October 2015|October 29, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051518||127729|
NCT01052077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-09-222|Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPDC-34712 (1 to 3 mg/Day) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder.|STEP-D222|Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|March 2010|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|773|||Both|18 Years|65 Years|No|||September 2015|September 30, 2015|January 15, 2010|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01052077||127687|
NCT01048190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|imbcams-01|The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|The Phase I Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|IPV|Chinese Academy of Medical Sciences|Yes|Completed|August 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|130|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||August 2008|January 13, 2010|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048190||127984|
NCT01057212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-97B|Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Phase II Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Progressive After First-line Therapy||Providence Health & Services|No|Terminated|February 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|January 12, 2010|Yes|Yes|Lack of support from pharmaceutical collaborator.|No||https://clinicaltrials.gov/show/NCT01057212||127296|
NCT01057797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR08037|Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD)|Nurse Managed Upper Body Strength Training in COPD||University of Illinois at Chicago|No|Completed|September 2003|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|208|||Both|45 Years|N/A|No|||January 2010|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057797||127251|
NCT01058096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-32|Safety and Efficacy of Cariprazine for Mania|A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder||Forest Laboratories|No|Completed|January 2010|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|65 Years|No|||September 2011|September 30, 2011|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058096||127228|
NCT01058109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-11179|Study of the Effect of a Calcium-rich Diet on Bone Health in Girls|Effect of Calcium Foods on Bone Quality in Pubertal Females|Calkids|Creighton University|No|Completed|September 1997|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Female|9 Years|9 Years|Accepts Healthy Volunteers|||January 2010|January 27, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058109||127227|
NCT01058057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC EK-150/08|Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention (PCI) Study 2|Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study 2|TIPS-2|University Hospital, Motol|No|Recruiting|February 2008|||June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||January 2008|February 2, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058057||127231|
NCT01058070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306|An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter|An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter||Torax Medical Incorporated|No|Completed|February 2007|August 2013|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|85 Years|No|||May 2014|May 7, 2014|January 26, 2010|Yes|Yes||No|March 3, 2014|https://clinicaltrials.gov/show/NCT01058070||127230|
NCT01058603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07F/END01|Efficacy of Endocell® vs Conventional Medium in the Treatment of Infertility|Multicentre, Randomised, Controlled Clinical Study on the Efficacy in Terms of Clinical Pregnancy Rate of 1 Embryo Transfer at Day 5 After Co-culture on Autologous Endometrial Cells(ENDOCELL®) Versus 1 Embryo Transfer at Day 3 After Culture on Conventional Medium.||Laboratoires Genévrier|No|Recruiting|February 2008|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|720|||Female|18 Years|36 Years|No|||February 2010|February 3, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058603||127189|
NCT01058590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR494810ctil|Inflammatory Markers in Infants With Obstructive Sleep Apnea|Inflammatory Markers in Infants With Obstructive Sleep Apnea||Soroka University Medical Center||Not yet recruiting|February 2010|February 2012|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum and urine will be obtained before therapy (T%A) snd 3 months afterwards. The serum      will be stored at -70 throughout the study in the PI's Lab (DR.Goldbart) At the end of the      study the sampled will be assessed for the presence of inflammatory markers (cytokines).|Both|1 Month|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 0-3 years diagnosed with obstructive sleep apnea syndrome, refferred to        removal of tonsills and adenoids|January 2010|January 27, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058590||127190|
NCT01058889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352/2006|Tele-Diab: Electronic Diary for Patients With Type 2 Diabetes Mellitus|Tele-Diab: Electronic Diary for Patients With Type 2 Diabetes Mellitus|Tele-Diab|Medical University of Vienna|Yes|Recruiting|November 2009|August 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||August 2011|August 4, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01058889||127167|
NCT01059396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDESCI|Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal|Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension|PREDESCI|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|September 2009|December 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|210|||Both|18 Years|80 Years|No|||June 2011|June 21, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059396||127129|
NCT01059136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071216|Aldosterone Blockade Early After Acute Myocardial Infarction|Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL|ALBATROSS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2010|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1603|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059136||127149|
NCT01059708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004920|Outcome Following Carbon Monoxide Poisoning in Children|Outcome Following Carbon Monoxide Poisoning in Children|CO PED|Intermountain Health Care, Inc.|No|Terminated|November 2007|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|DNA will be obtained by mouthwash, spit collection, or buccal swab,|Both|6 Years|16 Years|No|Non-Probability Sample|Children, ages 6-16, following CO poisoning|March 2011|March 15, 2011|January 28, 2010||No|Low enrollment.|No||https://clinicaltrials.gov/show/NCT01059708||127105|
NCT01059682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC22703|A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease|A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography||Hoffmann-La Roche||Terminated|January 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|936|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059682||127107|
NCT01059695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-24-09/12|Analysis of the Results of Treatment for Cervical Carcinoma in Limburg|Retrospective Analysis of Treatment and Quality of Life of Women Treated for Cervical Carcinoma FIGO Stage IB-1 to IVb From 2000-2008 in Limburg, a Province in the South of the Netherlands.|CervixLimburg|Maastricht Radiation Oncology|No|Completed|February 2010|July 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|220|||Female|N/A|N/A|No|Non-Probability Sample|All women diagnosed with cervical cancer FIGO stage IB-1 to IV between 2000 and 2008 in        Limburg, a province in the south of the Netherlands.|January 2015|January 13, 2015|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01059695||127106|
NCT01055808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13614|Observational Study in Japanese Type 2 Diabetes Patients|A Prospective, Non-safety Observational Study in Japanese Type 2 Diabetes Patients(INSIGHTS)|INSIGHTS|Eli Lilly and Company|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|677|||Both|20 Years|N/A|No|Probability Sample|Japanese patients with type 2 diabetes who are treated with insulin and about to have        significant treatment change.|December 2010|December 9, 2010|January 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055808||127403|
NCT01055821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG4040.02|Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients|A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naïve Patients With Chronic Genotype 1 Hepatitis C.|HCVac|Transgene|Yes|Completed|May 2010|August 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|140|||Both|18 Years|70 Years|No|||August 2013|August 9, 2013|January 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055821||127402|
NCT01050946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCW 11491|Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit|Phase II Study: HSCT Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit|Haplo/Cord|Medical College of Wisconsin|Yes|Terminated|July 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||October 2015|October 21, 2015|January 14, 2010|No|Yes|Only one patient was enrolled. Due to low accrual study was terminated|No|August 26, 2015|https://clinicaltrials.gov/show/NCT01050946||127772|
NCT01050959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4005|Bion Occipital Nerve Stimulation (ONS) Compassionate Use Study|Compassionate Use Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches||Boston Scientific Corporation|No|Completed|January 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who were enrolled and implanted with the Bion® system during a prior feasibility        clinical investigation of the device for occipital nerve stimulation (ONS) in the United        States.|November 2013|November 6, 2013|January 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01050959||127771|
NCT01051544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06201|Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive|Randomised Study of First TIME Immunotolerance Induction in Patients With Severe Type A Haemophilia With Inhibitor at High Risk of Failure: Comparison of Induction of Immune Tolerance With FVIII Concentrates With or Without Von Willebrand Factor Acronym: RES.I.S.T.- Naive|RESIST NAIVE|City of Hope Medical Center|Yes|Active, not recruiting|June 2009|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|148|||Male|N/A|N/A|No|||March 2015|March 20, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051544||127727|
NCT01051531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016522|A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia|Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics||Johnson & Johnson Pte Ltd|No|Completed|April 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|546|||Both|18 Years|50 Years|No|||March 2014|March 27, 2014|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01051531||127728|
NCT01051765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-AEC1|Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial|Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial||Peking University|Yes|Recruiting|August 2009|August 2012|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||May 2009|January 19, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01051765||127710|
NCT01051791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-032|Phase II Study of RAD001 Head and Neck Cancer|Phase II Study of RAD001 for Treatment of Refractory, Recurrent, Locally Advanced Squamous Cell Carcinoma of the Head and Neck||University of Pittsburgh|Yes|Active, not recruiting|January 2010|December 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|January 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051791||127708|
NCT01052389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GiSAS 001|Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia|GiSAS Trial: Aripiprazole, Olanzapine, and Haloperidol in the Long Term Treatment of Schizophrenia.|GiSAS|Mario Negri Institute for Pharmacological Research|Yes|Completed|July 2007|June 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052389||127663|
NCT01057537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241849|UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events|A Randomised Controlled Trial of a Fixed-dose Combination Polypill Medication (the Red Heart Pill) and Usual Care in Those at High Risk of Cardiovascular Disease.|UMPIRE|Imperial College London|Yes|Completed|June 2010|September 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2004|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057537||127271|
NCT01057563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/582/CE/2009|Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent|IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent|IN-PACT CORO|Catholic University of the Sacred Heart|Yes|Recruiting|November 2009|||November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057563||127269|
NCT01057810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-095|Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer|Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer||Bristol-Myers Squibb|Yes|Completed|May 2010|July 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|602|||Male|18 Years|N/A|No|||September 2015|September 2, 2015|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057810||127250|
NCT01058122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kein Sponsor|Collection, Evaluation and Assessment of Adverse Drug Reactions on the Oncology Ward|Collection, Evaluation and Assessment of Adverse Drug Reactions on the Oncology Ward||University of Zurich|Yes|Completed|August 2007|October 2009||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|All patients hospitalized at the oncology ward G and H of the university hospital zurich        during the 5-month observation period|January 2010|January 27, 2010|December 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01058122||127226|
NCT01058356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KASID_lacidofil_1|Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea|Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea: Prospective, Randomized Double-blind, Multicenter Study||Pharmbio Korea Co., Ltd.|Yes|Completed|January 2009|February 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|214|||Both|18 Years|N/A|No|Probability Sample|Patients with respiratory tract infection who begin receiving antibiotic therapy (both        hospitalized patients and out-patients)|April 2010|April 15, 2010|January 26, 2010||No||No|March 8, 2010|https://clinicaltrials.gov/show/NCT01058356||127208|
NCT01049997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINE75+|Frailty as an INstrument for Evaluation of Elderly Patients With Non ST Elevation Myocardial Infarction (NSTEMI)|Frailty as an INstrument for Evaluation of Elderly Patients With Non ST Elevation Myocardial Infarction (NSTEMI)|FINE75+|Linkoeping University|Yes|Completed|October 2009|March 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|307|||Both|75 Years|N/A|No|Probability Sample|Consecutive evaluable patients, 75 years old or older, with diagnosed NSTEMI, and cared        for at one of the following hospital care units in the University Hospital of Linköping        and the County Hospitals in Trollhättan (NÄL-Uddevalla) and Jönköping (Ryhov): cardiology,        acute medicine, geriatrics, other internal medicine unit.|March 2015|March 30, 2015|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01049997||127845|
NCT01058902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018360-16|The Effect Of Aspirin On Survival in Lung Cancer|The Effect Of Aspirin On Survival Following Potentially Curative Resection Of Non Small Cell Carcinoma Of The Lung The Big A Trial||Liverpool Heart and Chest Hospital NHS Foundation Trust|Yes|Withdrawn|August 2010|August 2020|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|85 Years|No|||March 2016|March 4, 2016|January 26, 2010||No|failed to achive funding|No||https://clinicaltrials.gov/show/NCT01058902||127166|
NCT01058876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00158|Comparison of Low Yield Cigarettes in African Americans vs. Whites|Nicotine Regulation/Response to Low Yield Cigarettes in African-Americans vs. Whites|6162-AAPK2|University of California, San Francisco|No|Completed|December 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|January 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058876||127168|
NCT01059422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAL/ABC/3TC - HIV/TB|Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients|Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy||Central Institute of Epidemiology, Moscow, Russia|No|Recruiting|October 2010|||October 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2011|May 5, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059422||127127|
NCT01050790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000663409|Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma|Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy||Virginia Commonwealth University|Yes|Active, not recruiting|January 2010|August 2017|Anticipated|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||September 2015|September 1, 2015|January 14, 2010|No|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT01050790||127784|
NCT01046890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQUIDAR|Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir|Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir||Germans Trias i Pujol Hospital|No|Completed|January 2010|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2010|May 4, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046890||128083|
NCT01055509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNR-2008037-1|Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia|Effectiveness of Cognitive Adaptation Training Applied to Cognitive Impairment in Schizophrenia - A Randomised Trial|CAT-Denmark|University of Southern Denmark|Yes|Completed|January 2009|August 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|70 Years|No|||June 2013|June 27, 2013|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055509||127426|
NCT01047436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART003|Efficacy of ArTiMist™ in Children|An Open Label Randomised Comparative Trial to Establish the Efficacy of 3 mg/kg ArTiMist™ When Compared to Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications||Proto Pharma Ltd|Yes|Completed|December 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|N/A|N/A|No|||January 2011|January 26, 2011|January 8, 2010||No||No|September 29, 2010|https://clinicaltrials.gov/show/NCT01047436||128042|
NCT01051219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EME-08/43/15|Anti-Fibrotic Effects of Losartan In Nash Evaluation Study|A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis|FELINE|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|May 2011|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051219||127751|
NCT01051232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121035|A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers|A Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 (Filibuvir) Following Single Oral Administrations Of PF-00868554 (Filibuvir) Under Fasting Conditions In Japanese Healthy Adult Volunteers||Pfizer|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 22, 2010|January 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051232||127750|
NCT01051817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457B2201|POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler|A Randomized, Multi-center, Double-blind, Proof-of-concept Study to Assess the Effect of Multiple Infusion of AIN457 (10 mg/kg) Versus Placebo on Disease Activity as Measured by MRI Scans Over a 24 Week Period in Patients With Relapsing-remitting Multiple Sclerosis||Novartis|No|Completed|December 2009|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|55 Years|No|||February 2015|February 12, 2015|January 19, 2010||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01051817||127706|
NCT01051830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0327B-P04I99N|A Care Model for Hip-fractured Elderly Persons With Diabetes Mellitus|A Care Model for Hip-fractured Elderly Persons With Diabetes Mellitus||Chang Gung Memorial Hospital|Yes|Recruiting|January 2010|December 2014|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|264|||Both|60 Years|N/A|No|||February 2012|February 10, 2012|January 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01051830||127705|
NCT01051843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAC|Orofacial Difficulties in Rooming-in|Orofacial Difficulties During the Maternal Breastfeeding in Rooming-in|AMAC|Fortaleza University|Yes|Completed|August 2009|December 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|29|||Both|N/A|1 Month|Accepts Healthy Volunteers|Probability Sample|Cross-sectional study of 29 dyads in rooming-in. The data collection consisted in the        detection of the main orofacial difficulties during the maternal breastfeeding in        rooming-in.|August 2009|January 19, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01051843||127704|
NCT01051804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-33|Evaluation of the Repeated Usage of Systane Ultra Eyedrop|||Alcon Research|No|Completed|November 2009|||July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01051804||127707|
NCT01053676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13287|Bioequivalence Study of BAY77-1931 Granule|Bioequivalence Study of BAY77-1931 Granule - Randomized, Non-blind, Two-way, Crossover Study to Establish the Bioequivalence Between BAY77-1931 Granule 500 mg and Fosrenol Chewable Tablet 500 mg in Japanese Healthy Male Adult Subjects||Bayer|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053676||127565|
NCT01048684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FG2010-003|Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy|Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2011|May 4, 2011|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048684||127946|
NCT01048697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTUHSC 030032|Effect of Weight and/or Obesity on Ethambutol Drug Concentrations|Population Pharmacokinetics Analysis of Ethambutol in Overweight and Obese Volunteers||Texas Tech University Health Sciences Center|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|January 12, 2010||No||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01048697||127945|
NCT01057238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1NR8941|Intensive Communication for Chronically Critically Ill|Intensive Communication for Chronically Critically Ill||Case Western Reserve University|Yes|Completed|November 2005|May 2008|Actual|April 2008|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|571|||Both|18 Years|N/A|No|||January 2010|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057238||127294|
NCT01057550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000.117|Randomised Controlled Trial Comparing Tension-Free Vaginal Tape (TVT), Pelvicol & Autologous Slings for Stress Urinary Incontinence(SUI)|A Randomised Controlled Trial Comparing TVT, Pelvicol and Autologous Fascial Slings for the Treatment of Stress Urinary Incontinence in Women||Abertawe Bro Morgannwg University NHS Trust|Yes|Completed|October 2001|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|201|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2004|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057550||127270|
NCT01048931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 98-10-03|Single-port Access Laparoscopic-assisted Vaginal Hysterectomy|To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|October 2009|October 2010|Anticipated|October 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|30 Years|70 Years|No|||January 2010|January 13, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048931||127927|
NCT01049165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV202-001|Single Ascending Dose (BMS-813160) Study|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-813160 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|9||Actual|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01049165||127909|
NCT01049178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 090053|Randomized Controlled Trial of Silymarin in Asthma|Antioxidant Enzyme Induction as a New Approach to Therapy in Patients With Asthma||Vanderbilt University|Yes|Withdrawn|September 2010|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||February 2014|February 20, 2014|May 4, 2009|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01049178||127908|
NCT01049438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20020519|A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections|A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections||Natividad Medical Center|Yes|Completed|August 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049438||127888|
NCT01058369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ADE06T|Exjade-Early-Trial|Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study -||University of Erlangen-Nürnberg Medical School||Terminated|April 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|January 27, 2010||No|Insufficient patient recruitment (only 2 patients)|No||https://clinicaltrials.gov/show/NCT01058369||127207|
NCT01058382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008006|Progesterone Support of FET|Progesterone Support for Frozen Embryo Transfer: Intramuscular Versus Vaginal Suppository - A Prospective, Randomized, Controlled Trial|FETProg|Mayo Clinic|No|Completed|February 2010|October 2012|Actual|October 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|57|||Female|20 Years|50 Years|No|Probability Sample|Women having a frozen embryo transfer.|May 2013|May 8, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058382||127206|
NCT01059721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PatellaGraz|Outcome After Soft Tissue Realignment of the Tibial Insertion of the Patella Tendon|Treatment of Patella Dislocation in Childhood and Adolescence. Soft Tissue Realignment of the Tibial Insertion of the Patella Tendon. Long-term Outcome.||Medical University of Graz|No|Completed|January 2010|July 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|10 Years|18 Years|No|||February 2012|February 7, 2012|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01059721||127104|
NCT01050244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN 09-117|The Effect of Soy Protein on Neuropathic Pain|The Effect of Soy Protein on Neuropathic Pain: Randomized N-of-1 Trials||McGill University Health Center|No|Terminated|February 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|January 14, 2010||No|Funding ran out_difficulties with study product (delays in authorization).|No||https://clinicaltrials.gov/show/NCT01050244||127826|
NCT01059149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080604|Safety and Long-term Effectiveness of High Frequency Repetitive Transcranial Magnetic Stimulation of Stroke (RAICup)|Safety and Long-term Effectiveness of High Frequency Repetitive Transcranial Magnetic Stimulation at the Subacute Phase of Ischaemic Stroke|RAICup|Assistance Publique - Hôpitaux de Paris|No|Terminated|November 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|80 Years|No|||November 2012|January 15, 2015|January 28, 2010||No|sponsor decision|No||https://clinicaltrials.gov/show/NCT01059149||127148|
NCT01056419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08067|The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy|||Ankara University||Recruiting|January 2009|August 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||June 2009|January 25, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056419||127357|
NCT01047124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09044|Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder|Randomised Control Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder||University of Nottingham|Yes|Recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|219|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047124||128065|
NCT01056926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004092|Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction|Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction|NNN|Duke University|No|Completed|March 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|4||Actual|147|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|January 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01056926||127318|
NCT01051557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01409|Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma|Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas||National Cancer Institute (NCI)||Active, not recruiting|January 2010|||October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051557||127726|
NCT01052116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAACRC-10|The Study of Soy Isoflavones in Asthma|The Study of Soy Isoflavones in Asthma|SOYA|American Lung Association Asthma Clinical Research Centers|Yes|Completed|March 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|386|||Both|12 Years|N/A|No|||December 2015|December 10, 2015|December 4, 2009|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT01052116||127684|
NCT01052129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-137-NAPR-2005|Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting Condition|Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|May 2006|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052129||127683|
NCT01052090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP015|Safety and Efficacy Study in Hepatitis C Patients With PHN121|Safety and Efficacy Study in Non-Responder Hepatitis C Genotype 1 Patients With PHN121|ENCHAMP|PhytoHealth Corporation|Yes|Terminated|September 2009|December 2013|Anticipated|November 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||January 2010|November 24, 2013|January 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01052090||127686|
NCT01058655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-276|RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer|A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2010|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058655||127185|
NCT01058408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-342|RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer|A Phase I Trial Using RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer||Dana-Farber Cancer Institute|Yes|Terminated|February 2010|||February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|January 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058408||127204|
NCT01048463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPACT|Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor|Phase 3 Study of Enteral Nutrition Rich in Eicosapentaenoic Acid in Patients Receiving Chemotherapy for Gastric Cancer or Colorectal Cancer||Sun Yat-sen University|Yes|Recruiting|December 2009|January 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|90|||Both|N/A|N/A|No|||October 2011|October 4, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048463||127963|
NCT01049191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0177|Bone Microarchitecture in Women With and Without Fracture|Bone Microarchitecture in Women With and Without Fracture|mMRI|University of Wisconsin, Madison|No|Completed|October 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|78|Samples Without DNA|Blood samples are being collected to obtain chemistry panel and test related to skeletal      status. These samples will not be retained or stored after these analyses are completed.|Female|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Seventy-two postmenopausal volunteers age ≥ 50 years will be recruited from existing        databases of ~3500 women with expressed interested in research. All will have normal BMD        or osteopenia (T-score > -2.5 at the L1-4 spine, proximal femur and 1/3rd radius) by DXA.        Thirty-six will have sustained a "fragility" fracture of the spine, hip or wrist, defined        as a fracture occurring with everyday activities including a fall from standing height or        less. Historical radiographic documentation of fracture will be obtained. Thirty-six women        without fracture will serve as age- race- and BMD-matched controls. Age will be matched to        within 6 months; BMD in grams/cm2 at the non-dominant ultra-distal radius will be matched        to within 5%.|July 2010|October 1, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049191||127907|
NCT01049464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si628/2009|Magnesium Sulphate for Treatment of New Onset Atrial Fibrillation in Medical Intensive Care Unit Patient|Efficacy of Magnesium Sulphate for Rate and Rhythm Control of New-onset Atrial Fibrillation in the Medical Critically Ill Patients: A Randomized, Controlled Trial|EMSAF|Mahidol University|No|Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049464||127886|
NCT01049451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pulse ACTH vs. MP for MS|Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)|Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)||University of Southern California|Yes|Active, not recruiting|November 2009|July 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||April 2013|April 2, 2013|January 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01049451||127887|
NCT01049698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00009098|Improving Muscle for Functional Independence Trial|Improving Muscle for Functional Independence Trial|I'MFIT|Wake Forest School of Medicine|Yes|Completed|February 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01049698||127868|
NCT01059162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL-34-003 (03)|Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery|Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery||IOPtima Ltd.|No|Active, not recruiting|April 2010|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059162||127147|
NCT01059734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9031-S9126-S9333-S9500-B|S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia|Topoisomerase 2 Expression and Acute Myeloid Leukemia (AML)||Southwest Oncology Group|No|Completed|June 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|357|||Both|18 Years|N/A|No|Non-Probability Sample|patients enrolled on S0931, S9126, S9333 or S9500 consenting to use of specimens for        future research|March 2015|March 5, 2015|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01059734||127103|
NCT01055522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19IL2DTIC-03/07|Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma|Dose Definition and Activity Evaluation Study of the Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Combination With Dacarbazine in Patients With Metastatic Melanoma||Philogen S.p.A.|No|Terminated|June 2008|February 2014|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|N/A|No|||October 2012|February 24, 2014|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055522||127425|
NCT01055535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-008|Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion|An Open Label, Single Centre Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion|MIVI-8|ThromboGenics||Completed|January 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055535||127424|
NCT01055834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190-102|A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)|A Bioequivalence Study of Different Formulations of SEP-190 and Food Effect Study in Japanese Healthy Adult Males||Eisai Inc.||Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Male|20 Years|54 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|January 25, 2010||No||No|January 10, 2013|https://clinicaltrials.gov/show/NCT01055834||127401|
NCT01055847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-AI-003|Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection|A Blinded, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam for Inhalation (AI) in Cystic Fibrosis Patient With Lung Disease Due to P. Aeruginosa Infection||Gilead Sciences|Yes|Completed|June 2003|September 2004|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|13 Years|N/A|No|||January 2010|January 25, 2010|January 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055847||127400|
NCT01050504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6932|Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer|Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy||University of Washington|No|Recruiting|August 2009|||March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood and tissue|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with prostate or bladder/urothelial cancer treated in genitourinary oncology        practices at University of Washington Medical Center, Seattle Cancer care Alliance and        Harborview Medical Center and healthy controls|March 2016|March 1, 2016|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01050504||127806|
NCT01056432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUSS-02|Bone UltraSonic Scanner (BUSS) Clinical Optimization Study|Phase I Study of Portable Bone Ultrasonometer for Osteoporosis Assessment|BUSS|Artann Laboratories|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Both|21 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will consist of groups with no history of osteoporosis, established        osteoporosis and may include documented history of fracture.|March 2014|March 28, 2014|January 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01056432||127356|
NCT01056679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD-Rev|Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients|Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients|AVD-Rev|University of Cologne|Yes|Active, not recruiting|April 2010|April 2016|Anticipated|April 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|60 Years|75 Years|No|||October 2015|October 30, 2015|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01056679||127337|
NCT01056653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-21846|Fathers and Late Preterm Babies Study|Fathers and Late Preterm Babies Study: Effects of an Educational Intervention on Fathers' Interactions With Infants Born Between 34 and 36 Weeks Gestation|FLPTB|University of Calgary|No|Completed|March 2009|January 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|113|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056653||127339|
NCT01056666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR002CC|Conveen Optima Urisheaths With Collecting Bags Versus Absorbents|Evaluation de l'Impact Sur la qualité de Vie de l'Utilisation d'un système Collecteur Conveen( étuis pénien Conveen Optima Avec Poches de Recueil Conveen) Chez Des Hommes Souffrant d'Une Incontinence Urinaire modérée ou sévère, Comparativement à Leur Protection Absorbante Habituelle||Coloplast A/S|No|Completed|June 2007|March 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Male|18 Years|N/A|No|||April 2007|September 16, 2011|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056666||127338|
NCT01056939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK:118/2008|Neurally Adjusted Ventilatory Assist (NAVA) in Pediatric Patients|Neurally Adjusted Ventilatory Assist (NAVA) in Pediatric Patients||University of Oulu|No|Completed|September 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|N/A|16 Years|No|||May 2012|May 24, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01056939||127317|
NCT01057303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B15|Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia|EVI-1 Expression in Pediatric AML With 11q23 Abnormalities||Children's Oncology Group|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|Samples With DNA|Tissue|Both|N/A|18 Years|No|Non-Probability Sample|Diagnosis of pediatric acute myeloid leukemia with 11q23 abnormalities|May 2015|May 5, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057303||127289|
NCT01051011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZC22565|A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy|A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naive Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy.||Hoffmann-La Roche||Terminated|January 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|370|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|January 15, 2010||No|high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation    plan to address hypersensitivity reactions|No||https://clinicaltrials.gov/show/NCT01051011||127767|
NCT01052662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13261|Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults|Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults||University of Massachusetts, Worcester|Yes|Completed|October 2009|October 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|87|||Both|18 Years|25 Years|No|||March 2015|March 11, 2015|January 18, 2010|Yes|Yes||No|January 14, 2015|https://clinicaltrials.gov/show/NCT01052662||127642|Rapid discontinuation of buprenorphine was associated with dropout that may have limited the statistical power to evaluate some variables. Memantine for 7 weeks may have been too short, and a longer exposure may have yielded better results.
NCT01052961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK 7010015, MV22926|A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza|Initiating Oseltamivir in Adults Hospitalized With Influenza -- a Study on the Impact of Virological Clearance and Clinical Recovery for Higher-dose Treatment Started Within 96 Hours||Chinese University of Hong Kong||Completed|January 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052961||127619|
NCT01058967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0085|Prospective Evaluation of Aeromedical EMS Ultrasound in Major Trauma Victims|UTHSC-H Proposal for Prospective Evaluation of Aeromedical EMS Ultrasound in Major Trauma Victims.||The University of Texas Health Science Center, Houston|No|Active, not recruiting|January 2010|November 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have experienced a major traumatic injury highest acuity trauma activation        (Code III status) transported from scene to hospital via Life Flight (hospital        aeroambulance service)|July 2010|July 22, 2010|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058967||127162|
NCT01058941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG033613-01A1|Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease|Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease||Oregon Health and Science University|Yes|Active, not recruiting|September 2010|January 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|55 Years|N/A|No|||May 2014|May 7, 2014|January 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058941||127163|
NCT01048944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NIDA-2R01DA012289|Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers|NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial||Southern Illinois University Carbondale|Yes|Completed|June 2005|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|197|||Both|18 Years|55 Years|No|||November 2014|November 18, 2014|January 13, 2010|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01048944||127926|The modest sample size limited the ability to detect more subtle treatment effects. The exclusionary criteria limits generalization to excluded groups.
NCT01058928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-0912-090-012|Effects of Tracheal Tube Size on Pulmonary Aspiration|Effects of Tracheal Tube Size on Pulmonary Aspiration Different Endotracheal Tube Size Influences Pulmonary Aspiration||Seoul National University Bundang Hospital|Yes|Not yet recruiting|February 2010|October 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|36|||Male|20 Years|65 Years|No|Non-Probability Sample|Patients,scheduled for elective cardiac surgery under general anesthesia|December 2009|January 28, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01058928||127164|
NCT01059175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medtronic|Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial|Dual-Site LV Pacing in CRT Non Responders Multicenter Randomized V3 Trial|V3|Medtronic Bakken Research Center|Yes|Active, not recruiting|September 2010|April 2015|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01059175||127146|
NCT01059435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060220|A First-in-human Study Evaluating AMG 785 in Healthy Men and Postmenopausal Women|A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women||Amgen||Completed|December 2006|August 2008|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|45 Years|59 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|January 28, 2010||||No||https://clinicaltrials.gov/show/NCT01059435||127126|
NCT01059448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090402|Safety and Efficacy of AMG 827 in Subjects With RA|A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis||Amgen||Terminated|May 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|211|||Both|N/A|N/A|No|||July 2015|August 14, 2015|January 28, 2010|Yes|Yes|Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)|No||https://clinicaltrials.gov/show/NCT01059448||127125|
NCT01059461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00006379|Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy|Phase 2 Nerve Growth Factor (Cerebrolysin®) for Treatment of Neonatal Hypoxic Ischemic Encephalopathy|CerebroHIE|Ain Shams University|Yes|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|3 Months|6 Months|No|||September 2013|September 12, 2013|January 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059461||127124|
NCT01056185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603M83587 FLU 003|Respiratory Virus Hospitalization Study (FLU 003 Plus)|An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|August 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1000|Samples With DNA|Serum, plasma, respiratory for all participants. For participants with a confirmed targeted      non-influenza respiratory virus, attempts will be made to obtain a sample of the local      specimen used to confirm diagnosis.      Whole blood for human genomics (only for FLU 003 Plus sites opting to also participate in      INSIGHT Genomics and participant has signed an additional consent)|Both|18 Years|N/A|No|Probability Sample|Adult patients who are hospitalized with a diagnosis (confirmed or suspected) of influenza        or a targeted non-influenza viral respiratory infection, as soon as possible after the        suspected diagnosis is made. Participants may have already been admitted to the hospital        at the study site or may have been previously seen at another hospital where the diagnosis        of influenza or infection with a targeted respiratory virus was made.|November 2015|November 30, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056185||127375|
NCT01056198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-028|Santyl vs. Sharp Debridement of Diabetic Foot Wounds|Comparison of Sharp Surgical Debridement Versus Collagenase Santyl Ointment in the Care of Diabetic Foot Wounds||Healthpoint|No|Completed|February 2010|November 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|January 25, 2010|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT01056198||127374|
NCT01055548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2009-0138888-19|PPrime: Parents Views on Diagnosis and Information-giving in Neonatal Care (Pilot Study)|Parents Views on Diagnosis and Information-giving in Neonatal Care (Pilot Study)|PPrime|Imperial College London|Yes|Completed|October 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|N/A|33 Weeks|No|Non-Probability Sample|Parents of babies born before 33 week's gestation|January 2010|June 2, 2015|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055548||127423|
NCT01055860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09-02-007|One Year Outcome After Robotic Assisted Laparoscopic Sacral Colpopexy, a Case Series Review|One Year Outcome After Robotic Assisted Laparoscopic Sacral Colpopexy, a Case Series Review||Atlantic Health System|No|Completed|February 2009|July 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|75|||Female|21 Years|N/A|No|Non-Probability Sample|Our study population will be women who underwent Robotic assisted laparoscopic sacral        colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse        using a synthetic polypropylene mesh.|March 2011|March 21, 2011|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01055860||127399|
NCT01055873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-AO142-49|Immunology of the Infection Perinatal|Immunology of the Infection Perinatal|EP38|French National Agency for Research on AIDS and Viral Hepatitis|No|Completed|February 2007|February 2009|Actual|February 2009|Actual|N/A|Observational|N/A||1|Actual|93|||Both|15 Years|N/A|No|Non-Probability Sample|Patients are included in the French perinatal cohort (ANRS CO-10), or have been followed        since before 1996 in the same clinical sites as patients who belong to ANRS CO-10. In the        ANRS CO-10 cohort, all patients are prospectively followed from birth|November 2010|November 17, 2010|December 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01055873||127398|
NCT01056146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G060167|Interacting Together Everyday: Recovery After Childhood Traumatic Brain Injury (TBI) "I-InTERACT|An Online Intervention for Families of Young Children With TBI: I-InTERACT|I-InTERACT|Children's Hospital Medical Center, Cincinnati|No|Completed|June 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|3 Years|9 Years|No|||September 2014|October 27, 2014|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01056146||127378|
NCT01057628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0105|A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients|A Phase 3, Double-Blind, Placebo-Controlled, Monotherapy Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus||Astellas Pharma Inc|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01057628||127264|
NCT01056692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/004/05|OC000459 Bronchial Allergen Challenge|A Phase II Study of oc000459 in Subjects With Allergic Asthma; a Randomised, Double Blind, Two Way Balanced Crossover Comparing oc000459 With Placebo||Oxagen Ltd|No|Completed|February 2006|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|No|||January 2010|January 25, 2010|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01056692||127336|
NCT01058187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6000|Assessment of Fatty Acids in Infants' Blood Cells When Consuming Infant Formula Containing Long-Chain Polyunsaturated Fatty Acids|Assessment of Fatty Acids in Infants' Blood Cells When Consuming Infant Formula Containing Long-Chain Polyunsaturated Fatty Acids||Mead Johnson Nutrition||Completed|February 2010|July 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|86|||Both|N/A|25 Days|Accepts Healthy Volunteers|Probability Sample|Infants 12-25 days of age|March 2014|March 10, 2014|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058187||127221|
NCT01058200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 07 23|a Randomized Multicenter Trial Comparing Vacuum Assisted Delivery With the New Device "iCUP" Versus the Reference Cup.|Assess the Risk-benefit Balance of the New Vacuum Assisted-delivery Device "iCUP" Versus the Reference Vacuum. Multicenter Prospective Randomized Controlled Study|ICUP|University Hospital, Grenoble|Yes|Completed|October 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|668|||Female|18 Years|45 Years|No|||July 2013|July 19, 2013|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058200||127220|
NCT01051583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVG AV1|Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma|Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma||Cairo University|Yes|Completed|January 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|14 Years|72 Years|No|||December 2007|January 15, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01051583||127724|
NCT01051869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ulnar Nerve 06-Jan-10|Simple Decompression Versus Anterior Transposition of the Ulnar Nerve|A Multicentre, Randomized Trial of Simple Decompression Versus Anterior Transposition of the Ulnar Nerve for Acute, Displaced Fractures of the Distal Humerus Treated With Plate Fixation||St. Michael's Hospital, Toronto|No|Recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|16 Years|60 Years|No|||November 2015|November 16, 2015|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01051869||127702|
NCT01053182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH-RCT-001|Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches|A Phase Ⅲ Study of Respiratory Complications Associated With Esophagectomy Through Either Ivor-Lewis or Sweet Approach for the Treatment of Middle or Lower Third Intrathoracic Esophageal Carcinoma||Sichuan University|Yes|Recruiting|January 2010|January 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|70 Years|No|||December 2009|January 20, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053182||127602|
NCT01053455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911-106|Observational Crossover Study Comparing Oxygenation and Ventilation Using SiPAP Versus CPAP in LBW Infants|Observational Crossover Study Comparing Oxygenation and Ventilation Using Biphasic CPAP (SiPAP) Versus CPAP to Treat Respiratory Distress in Low Birth Weight Infants||Children's Hospitals and Clinics of Minnesota|Yes|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|20|||Both|N/A|N/A|No|Probability Sample|low birth weight infants|June 2012|June 21, 2012|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053455||127582|
NCT01054612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 28177|Tissue Sectioning by Electro-Dissociation|Tissue Sectioning by Electro-Dissociation||University of Arkansas||Withdrawn|March 2002|January 2010|Actual|January 2010|Actual|N/A|Observational|N/A||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Discarded human tissue obtained immediately following surgical resection|March 2015|March 3, 2015|December 21, 2007||No|The study was closed due to the departure of several of the co-investigators.|No||https://clinicaltrials.gov/show/NCT01054612||127493|
NCT01059513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-10-081|Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer|Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer||Jonsson Comprehensive Cancer Center|Yes|Recruiting|January 2010|||January 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|60|||Male|18 Years|N/A|No|Non-Probability Sample|Eligible patients will have clinical stage T1c, T2a, or T2b, a pre-biopsy PSA level <10        ng/mL and a biopsy Gleason score of 3+3 (or 3+4 if fewer than 30% of biopsy cores are        involved).|February 2016|February 16, 2016|January 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059513||127120|
NCT01059201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100022|Exome Sequencing in Autistic Spectrum Disorder|Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis||National Institutes of Health Clinical Center (CC)||Completed|January 2010|||||N/A|Observational|N/A|||Actual|322|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|June 6, 2015|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059201||127144|
NCT01058629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI 09-01|Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses|A 180 Day, Multicenter Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses for Daily Wear Use in the Correction of Refractive Error With or Without Astigmatism in Non-diseased Eyes||SynergEyes, Inc.|No|Active, not recruiting|August 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 24, 2010|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058629||127187|
NCT01058642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40CL234|Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia|A Phase 2A, Randomized, Blinded, Placebo- and Active-controlled, 2-Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of ADL5747 in Subjects With Postherpetic Neuralgia||Cubist Pharmaceuticals LLC|No|Terminated|January 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|75 Years|No|||July 2015|July 8, 2015|January 27, 2010|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01058642||127186|On the basis of the interim analysis, the results indicated that ADL5747 did not show sufficient efficacy to continue the study; therefore, formal and final efficacy analyses were not generated for this study.
NCT01059487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-003 CEG|Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine|Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine: A Pragmatic Clinical Trial Using Quality of Life Measures in a Community Health Care Setting||Chicago College of Oriental Medicine|No|Not yet recruiting|September 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|February 1, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01059487||127122|
NCT01055249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPM-024|UVB Model Validation Study|Single Centre, Subject and Observer Blinded, Placebo Controlled, Cross-over Study of the Effect of Oral Ibuprofen and Topical Hydrocortisone-21-acetate on Ultraviolet Radiation (UVR) Induced Pain and Inflammation in Healthy Volunteers||X-pert Med GmbH|No|Completed|January 2010|||June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 12, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055249||127445|
NCT01059474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMPS 09-125|Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion|Transdermal Absorption of DMPS and Its Effect on Urinary Mercury Excretion||Banner Health|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|June 21, 2011|January 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059474||127123|
NCT01055561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008SZ0135|A Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia|An Open-label Multi-center Safety and Tolerability Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia & Healthy Volunteers||Chengdu University of Traditional Chinese Medicine|Yes|Completed|January 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||April 2011|April 24, 2011|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055561||127422|
NCT01056445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-1239|Hemodynamic Instability Following Carotid Artery Stenting|Hemodynamic Instability Following Carotid Artery Stenting||Shiraz University of Medical Sciences|Yes|Completed|May 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|27|||Both|49 Years|80 Years|No|||March 2008|January 25, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01056445||127355|
NCT01056952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/15|Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure (OPTIFLOW)|Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure||University Hospital, Bordeaux|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01056952||127316|
NCT01056159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-101|A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)|Cumulative Dose Comparison of the Efficacy and Safety of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler) in Adult Patients With Asthma||Teva Pharmaceutical Industries|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|45 Years|No|||May 2012|May 11, 2012|January 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01056159||127377|
NCT01056172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUYH-CHC001|PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)|A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response||Pusan National University Yangsan Hospital|Yes|Recruiting|January 2010|December 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056172||127376|
NCT01057641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-DLSS|Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant|A Clinical Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant in Comparison With the Best Non-operative Treatment of Lumbar Spine Stenosis||University of Cologne|Yes|Terminated|March 2011|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|50 Years|99 Years|No|||December 2015|December 3, 2015|January 26, 2010||No|low enrollment|No||https://clinicaltrials.gov/show/NCT01057641||127263|
NCT01057862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901004667|Investigation of Naltrexone for Pathological Gambling|Double-Blind Placebo-Controlled Investigation of Naltrexone for Pathological Gambling||Yale University|Yes|Active, not recruiting|February 2009|February 2015|Anticipated|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057862||127246|
NCT01057875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO REB 09-186|Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.|The Effects of Caffeine on Exhaled Nitric Oxide Levels and Methacholine PC20||University of Saskatchewan|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|No|||October 2010|October 5, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057875||127245|
NCT01058213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR010249|Nurse Managed Sequential Strength Training and Bicycle Training in Chronic Obstructive Pulmonary Disease (COPD)|Nurse Managed Sequential Resistance Then Aerobic Training in COPD||University of Illinois at Chicago|No|Completed|November 2008|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|354|||Both|46 Years|N/A|No|||December 2013|December 17, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058213||127219|
NCT01052415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH081778|POL and Access Intervention to Reduce HIV Stigma Among Service Providers in China|POL and Access Intervention to Reduce HIV Stigma Among Service Providers in China||University of California, Los Angeles|Yes|Completed|September 2007|August 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|5400|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052415||127661|
NCT01054911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090910001|Evaluation of Patients With Bulky GIST Using Sunitinib|Pilot Trial of Neoadjuvant Sunitinib in Patients With Bulky GIST||University of Alabama at Birmingham|Yes|Active, not recruiting|October 2009|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|N/A|No|||August 2013|September 24, 2013|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054911||127471|
NCT01054352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016798|A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies|A Double-blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics and Pharmacodynamics of JNJ-38224342 in Healthy Patients and in Healthy Patients With Seasonal Allergic Rhinitis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2010|March 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|182|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054352||127513|
NCT01054872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 082|Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins|A Phase 1B Clinical Trial to Examine the Role of Host Genetics in Determining the Immune Response to HIV Vaccination (With VRC-HIVDNA016-00-VP and VRC-HIVADV014-00-VP) in Twin Pairs||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|January 2010|||November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|January 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054872||127474|
NCT01054885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112207|Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|October 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|1226|||Both|40 Years|N/A|No|||June 2013|July 10, 2014|January 14, 2010|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01054885||127473|
NCT01059006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091460|Peripheral PresbyLASIK Using the Allegretto Wavelight System For The Treatment of Presbyopia|Peripheral PresbyLASIK Using the Allegretto Wavelight System For The Treatment of Presbyopia||University of California, San Diego|No|Withdrawn|January 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|35 Years|80 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|January 28, 2010||No|Lead researcher completed fellowship and never got study off ground|No||https://clinicaltrials.gov/show/NCT01059006||127159|
NCT01055301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0833|S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma|S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years||Southwest Oncology Group|Yes|Withdrawn|July 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|January 22, 2010||No|lack of accrual|No||https://clinicaltrials.gov/show/NCT01055301||127442|
NCT01055314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02005|Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma|A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma||National Cancer Institute (NCI)|No|Completed|January 2010|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|N/A|49 Years|No|||September 2014|May 22, 2015|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055314||127441|
NCT01059188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 16/08|Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)|Preoperative Chemotherapy and Radiotherapy Concomitant to Cetuximab in Non-Small Cell Lung Cancer (NSCLC) Patients With IIIB Disease - A Multicenter Phase II Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|January 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|75 Years|No|||January 2016|January 31, 2016|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059188||127145|
NCT01055262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-09-06|Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back|An Open Label Study To Evaluate The Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back||Pfizer|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|169|||Both|35 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 7, 2012|January 21, 2010|Yes|Yes||No|May 7, 2012|https://clinicaltrials.gov/show/NCT01055262||127444|
NCT01055275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-016|Cook Iliac Branch Graft Post-market Registry|Cook Iliac Branch Graft Post-market Registry||Cook||Terminated|September 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with a Cook Iliac Branch Graft.|June 2013|June 19, 2013|January 22, 2010||No|Terminated due to low enrollment.|No||https://clinicaltrials.gov/show/NCT01055275||127443|
NCT01055899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6R88-RA-0801|Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate||Regeneron Pharmaceuticals|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||June 2011|September 27, 2013|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055899||127396|
NCT01055886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013158|Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)|Supplemental Nicotine Administration for Smoking Cessation in PTSD||Duke University|Yes|Completed|November 2009|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2013|December 16, 2014|January 24, 2010|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01055886||127397|
NCT01056211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/626|1540nm Non Ablative Fractional Laser Treatment of Scars|1540nm Non Ablative Fractional Laser Treatment of Scars : a Prospective Single Blinded Within Patient Controlled Randomized Trial.||University Hospital, Ghent|No|Completed|January 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|90|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056211||127373|
NCT01056224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0684-B|Effect of Remifentanil Boluses on Hemodynamics in Skull Pin Insertion|The Dose Effects of Remifentanil Boluses on the Hemodynamic Response to Skull Pin Insertion.||University Health Network, Toronto|No|Completed|May 2005|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|72|||Both|20 Years|75 Years|No|||January 2010|January 25, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056224||127372|
NCT01056965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-108 NAP Pilot|Davunetide (AL-108) in Predicted Tauopathies - Pilot Study|A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies||University of California, San Francisco|Yes|Active, not recruiting|January 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|40 Years|85 Years|No|||January 2016|January 26, 2016|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056965||127315|
NCT01056978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908039|Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliative Care Unit|Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliativecare Unit - Etude RHESO - Etude Monocentrique|RHESO|Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|April 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1230|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|August 2013|August 6, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01056978||127314|
NCT01057342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 15/08|Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Carboplatin and Paclitaxel Plus ASA404 as First Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial||Swiss Group for Clinical Cancer Research|No|Completed|January 2010|July 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057342||127286|
NCT01057368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBP01-AT004952|The Effects of Well-being Interventions on Affect, Attention, Sleep, Social Stress and Pain Regulation|The Effects of Well-being Interventions on Affect, Attention, Sleep, Social Stress and Pain Regulation||University of Wisconsin, Madison|Yes|Completed|November 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Actual|161|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01057368||127284|
NCT01057888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00026761|Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients|Randomized Controlled Trial of an Automated, Managed Care-based Reminder/Recall System on Improving Rates of Immunization and Preventive Care Visits for Publically Insured Adolescents||University of California, Los Angeles|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Actual|10599|||Both|11 Years|18 Years|No|||December 2015|December 16, 2015|January 25, 2010||No||No|October 18, 2012|https://clinicaltrials.gov/show/NCT01057888||127244|
NCT01058226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-001|Reproducibility of Malaria Challenge in Healthy Volunteers|Reproducibility of Malaria Challenge in Healthy Volunteers||Seattle Biomedical Research Institute|Yes|Completed|February 2010|September 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label|1||Anticipated|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 29, 2011|January 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058226||127218|
NCT01054625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN211|Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)|An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN||Genmab|No|Completed|March 2010|October 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|January 15, 2010|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01054625||127492|
NCT01054365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rev 09-20-09|Same Day Discharge After Coronary Stenting Trial|Same Day Discharge After Coronary Stenting Trial||University of Southern California|Yes|Recruiting|December 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|30 Years|80 Years|No|Probability Sample|This study will include four-hundred consented patients undergoing percutaneous coronary        stenting at the University of Southern California Hospital or LA County Hospital, patients        in the study group will be discharged the day of the procedure whereas patients in the        control group will be discharged at the discretion of the attending cardiologist not        earlier than 24 hours after their procedure. Patients will be stratified on the basis of        their initial clinical presentation, as determined by the medical history, physical        examination, ECG and laboratory studies. Patients must be hemodynamically stable, and able        to understand and sign an informed consent.|January 2010|January 21, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01054365||127512|
NCT01054924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV2009-01|Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening|Clinical Study to Assess the Performance of the Invendo C20 Colonoscope System in Persons Undergoing Colorectal Cancer Screening at Average Risk for CRC||Invendo Medical GmbH||Completed|November 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asymptomatic persons fulfilling U.S. screening criteria for colorectal cancer of age of        50-75 years|January 2010|January 21, 2010|January 21, 2010||||No||https://clinicaltrials.gov/show/NCT01054924||127470|
NCT01059578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101909|First Study in Humans With GSK206136|A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK206136 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin-1 Receptor Occupancy|NSB101909|GlaxoSmithKline|No|Completed|May 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|33|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059578||127115|
NCT01059500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS018519-01|Assessment of Acute Disease to Reduce Imaging Costs|Quantitative Pretest Probability to Reduce Cardiopulmonary Imaging in the ED|QUAADRICs|Carolinas Healthcare System|Yes|Completed|January 2010|February 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|850|||Both|18 Years|99 Years|No|||February 2016|February 15, 2016|January 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059500||127121|
NCT01059526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-88/24|Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema|A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity With Exposure to KALBITOR (Ecallantide) for the Treatment of Acute Attacks of HAE||Dyax Corp.|Yes|Completed|February 2010|June 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|81|Samples Without DNA|serum|Both|16 Years|N/A|No|Non-Probability Sample|patients with hereditary angioedema, either naive or non-naive to KALBITOR (ecallantide)        prior to enrollment in the study|October 2014|October 2, 2014|January 28, 2010|Yes|Yes||No|September 10, 2014|https://clinicaltrials.gov/show/NCT01059526||127119|44 patients (out of 200 planned) received treatment in this study. Additionally, the collection of evaluable efficacy data for the secondary endpoint was limited by a lack of response data collected for HAE attacks treated at alternate sites.
NCT01055912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK-LX2401|Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure|Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Efficacy and Safety Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure||CardioKine Inc.|Yes|Completed|January 2010|||September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||November 2010|June 20, 2011|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055912||127395|
NCT01055925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPV-AQUACEL|Clinical Comparative Trial of a Modified Polyurethane Dressing and Aquacel|||Klinik Bogenhausen|No|Completed||||||N/A|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||January 2010|January 25, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01055925||127394|
NCT01056458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98DMR291|Auricular Acupressure for Perimenopausal Women With Anxiety|Effect of Auricular Acupressure on Perimenopausal and Early Postmenopausal Women With Anxiety: a Double Blinded, Randomized and Controlled Study|AAA|Chang-Hua Hospital|Yes|Recruiting|January 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|40 Years|60 Years|No|||January 2010|May 28, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056458||127354|
NCT01056237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1002|Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis|Research Institute of Nephrology, Jinling Hospital,||Nanjing University School of Medicine|Yes|Completed|February 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|65 Years|No|||July 2015|July 30, 2015|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01056237||127371|
NCT01056250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT3|SILS Cholecystectomy: Cholangiography of the Biliary Tract|Performing Cholangiography During SILS Cholecystectomy: is it Feasible?||St John of God Hospital, Vienna|No|Completed|September 2009|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||July 2010|May 8, 2011|January 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01056250||127370|
NCT01056705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|imbcams-02|The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)|The Phase Ⅱ Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|Sabin IPV|Chinese Academy of Medical Sciences|Yes|Completed|July 2009|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|500|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||January 2012|January 17, 2012|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056705||127335|
NCT01056718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYS-MD-32|Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function|Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function||St. John's Health System, Missouri|No|Completed|November 2009|May 2014|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|90 Years|No|||February 2016|February 19, 2016|January 25, 2010|No|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01056718||127334|There was no placebo control. All patients received nebivolol and served as their own control before and after treatment. This study had a small study population and short duration.
NCT01056731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AVE01|A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.|A 16-week, Prospective, Open Label, Multicenter Study to Evaluate the Effectiveness and Safety of Rasilez® (Aliskiren) Monotherapy or in Addition With Hydrochlorothiazide 12.5 mg or 25 mg in Patients With Hypertension Stage I and II|ANDROMEDA|Novartis|Yes|Completed|February 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|253|||Both|18 Years|85 Years|No|||December 2012|December 11, 2012|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01056731||127333|
NCT01056991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/183/HAR|Prevention of IPH: Electric Warming Mattress vs Forced Air Warming Blanket|A Study to Determine if Modern Under-patient Warming Mattresses Are as Effective as Forced-air Warming Blankets in Preventing Peri-operative Hypothermia||Brighton and Sussex University Hospitals NHS Trust|No|Completed|February 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056991||127313|
NCT01057355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-004705|Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms|Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms||Mayo Clinic|Yes|Withdrawn|January 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|January 26, 2010|No|Yes|slow accural|No||https://clinicaltrials.gov/show/NCT01057355||127285|
NCT01057004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVITA-HF|EVIdence Based TreAtment - Heart Failure (EVITA-HF)|EVIdence Based TreAtment - Heart Failure (EVITA-HF)|EVITA-HF|Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|February 2009|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|June 2011|June 9, 2011|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057004||127312|
NCT01057381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17558|Dexmedetomidine in Pediatric Tonsillectomy|Dose Response Relationship of Dexmedetomidine in Decreasing Post Operative Analgesic Requirements in the Pediatric Tonsillectomy Patient||Baylor College of Medicine|Yes|Completed|August 2005|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|109|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057381||127283|
NCT01057394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-2758|Post-Market Randomized Controlled Trial: Endoscopically- Guided Ablation vs. Radiofrequency Ablation GuideD by Electroanatomical Mapping to Achieve Permanent Pulmonary Vein Isolation (En-GARDE)|Post-Market Randomized Controlled Trial: Endoscopically- Guided Ablation vs. Radiofrequency Ablation GuideD by Electroanatomical Mapping to Achieve Permanent Pulmonary Vein Isolation (En-GARDE)|En-GARDE|CardioFocus|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|No|||June 2012|June 19, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057394||127282|
NCT01057654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIF293/95apoB|A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin|A Stable-isotope Study in Healthy Normolipidemic Volunteers Comparing the Mechanisms of Action of Lifibrol and Pravastatin||University Hospital, Bonn|Yes|Completed|January 1996|June 1998|Actual|April 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057654||127262|
NCT01057901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.156|Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America|24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America||Sprout Pharmaceuticals, Inc|Yes|Terminated|January 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|748|||Female|35 Years|N/A|No|||June 2014|June 16, 2014|January 25, 2010|Yes|Yes|Study terminated for administrative reasons.|No|April 14, 2014|https://clinicaltrials.gov/show/NCT01057901||127243|
NCT01057914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTV-69151|Effects of Nutritional Supplementation and Dietary Advice in Elderly Patients After Hospital Discharge.|Effects of Six Months Treatment With Nutritional Supplements or Dietary Advice, Alone or in Combination on Mortality, Health-related Quality of Life and Health-care Consumption for Elderly Patients at Risk of Malnutrition.||Uppsala University|No|Active, not recruiting|February 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|800|||Both|65 Years|N/A|No|||January 2015|January 15, 2015|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01057914||127242|
NCT01057927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/006/06|Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects|Parallel Group, Randomised, Placebo Controlled, Double Blind Oral Assessment of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects||Oxagen Ltd|Yes|Completed|January 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|55 Years|No|||January 2010|January 27, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01057927||127241|
NCT01054040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03467 (UBC Ethics Board)|The Impact of Portion Plates for Weight Loss on Cardiac Rehabilitation Patients|The Impact of Portion Plates for Weight Loss on Cardiac Rehabilitation Patients||Richmond Health Services|No|Not yet recruiting|February 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|90|||Both|19 Years|N/A|No|||January 2010|January 20, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054040||127537|
NCT01054638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112872|HIV Treatment and CVD Events|HIV Treatment and CVD Events - Ingenix. Retrospective Database Analysis of Patients With Human Immunodeficiency Virus (HIV) Treatment and Cardiovascular Disease (CVD) Events||ViiV Healthcare|No|Completed|March 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Source population is from the proprietary Ingenix NHI Database, a large, geographically        diverse population of U.S. health insurance plan enrollees. Records are organized into a        medical file containing claims from providers and facilities, a pharmacy file with        outpatient pharmacy dispensing records, and an enrollment file that provides demographic        data and dates of insurance eligibility for persons in the database. Laboratory test        results are also available for a fraction of the population. In addition, i3 Drug Safety        will complement the data from the NHI Database with data from the Ingenix National Managed        Care (Impact) Database, a fully de-identified, HIPAA compliant database from health        insurance claims and enrollment data of more than 30 health plans separate from the plan        affiliated with the NHI Database. Patients in each data source have a common unique        identifier; therefore, it is possible to construct a combined population without concern        that some patients may be duplicated.|July 2011|July 26, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054638||127491|
NCT01054950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 33980|Quality of Life in Food Allergic Families|Quality of Life in Food Allergic Families||University of Michigan|No|Recruiting|January 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Anticipated|60|||Both|N/A|17 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054950||127468|
NCT01050842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0851|Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer|Pilot Trial to Evaluate the Safety and Efficacy of the Administration of Bicalutamide (Casodex TM) Per Day in Combination With Raloxifene (Evista TM) Per Day in Patients With Hormone Refractory Prostate Cancer||Mayo Clinic|Yes|Active, not recruiting|February 2010|||May 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||January 2015|January 13, 2015|January 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050842||127780|
NCT01059032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15017044793|Enhancement and Restoring of Low Dose Abdominal CT Images|Enhancement and Restoring of Low Dose Abdominal CT Images by a Novel Adaptive Nonlinear 3D Post Processing Filter - a Prospective Blinded Interventional Study||University of Oslo|No|Completed|December 2009|December 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|12|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||November 2009|June 1, 2015|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01059032||127157|
NCT01059045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CryoHaem|Prospective Controlled Study Evaluating Cryocontact Therapy of Infantile Hemangiomas of Preterm Infants|Prospective Controlled Study Evaluating Cryocontact Therapy of Infantile Hemangiomas of Preterm Infants||University Hospital Tuebingen|Yes|Terminated|August 2004|December 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|N/A|11 Weeks|No|||August 2004|June 25, 2010|January 28, 2010||No|Recruitement was much slower than anticipated.|No||https://clinicaltrials.gov/show/NCT01059045||127156|
NCT01059214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100034|Cardiac MRI for Patients Enrolled in INFUSE-AMI|Cardiac MRI for Patients Enrolled in INFUSE-AMI||National Institutes of Health Clinical Center (CC)||Completed|December 2009|October 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|3|||Both|18 Years|N/A|No|||October 2012|October 9, 2014|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059214||127143|
NCT01059227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100049|Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers|Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers||National Institutes of Health Clinical Center (CC)||Completed|January 2010|August 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|39|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 15, 2015|January 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059227||127142|
NCT01059539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-36|Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder|A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder||Forest Laboratories|No|Completed|January 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|403|||Both|18 Years|65 Years|No|||December 2012|December 6, 2012|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059539||127118|
NCT01055340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-159|A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)|A Randomized Clinical Trial to Study Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|April 2010|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|January 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055340||127439|
NCT01055353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2009/2|Evaluation of Target Organs Damage in Hypertensive Patients|Evaluation of Target Organs Damage in Hypertensive Patients Followed in General Practice With no Known Cardiovascular (CV) or Renal Disease, Stratified According to Blood Pressure Control|PreVENT-A GP|AstraZeneca|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1857|||Both|18 Years|N/A|No|Probability Sample|First 2 consecutive adults with hypertension, with no known cardiovascular (CV) or renal        disease, seen by general practitioner|May 2011|May 11, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01055353||127438|
NCT01055574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-09-05-002|Physical Capability Outcomes After Single-Level PD-L vs Single-Level ALIF: a Multi-Center Clinical Trial|Physical Capability Outcomes After Single-Level ProDisc-L Total Disc Replacement or Single-Level Anterior Lumbar Interbody Fusion: a Multi-Center Clinical Trial||Gundersen Lutheran Medical Foundation|Yes|Terminated|October 2009|January 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|45|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The target study population are those meeting all the FDA criteria for ProDisc-L. Patients        with third-party coverage for ProDisc-L that received surgical implantation of this device        will be in one group. Patients without third-party coverage for ProDisc-L that underwent        stand-alone ALIF with a device that incorporates fixation of the superior vertebral body        to the inferior vertebral body, and where an osteoinductive biologic agent is placed        within the device will be in the other group.|September 2011|September 8, 2011|January 22, 2010||No|Unanticipated study design flaw; PCO evaluator interrater reliability was not performed.|No||https://clinicaltrials.gov/show/NCT01055574||127421|
NCT01055587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-BR-29/09-1|Diagnostic of Infections Following Major Abdominal Surgery and Burn Injury|Impact of Biomarkers for Early Diagnostic of Infections Following Major Abdominal Surgery and Severe Burn Injuries|Earlygnost|Klinikum St. Georg gGmbH|No|Completed|September 2009|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|Samples Without DNA|plasma samples|Both|18 Years|N/A|No|Probability Sample|Group 1: patients who undergo major abdominal surgery Group 2: patients following severe        burn injury|December 2015|December 27, 2015|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055587||127420|
NCT01055327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113038|Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT)|Monitoring of Specific Birth Defects Associated With Exposure to Lamotrigine in Pregnancy Through the EUROCAT Network||GlaxoSmithKline|No|Completed|May 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Probability Sample|All infants/fetuses with congenital malformations registered on EUROCAT anti-epileptic        drug database between 1995 and 2012 (start date depends on date of lamotrigine        registration in country of participating register).        EUROCAT is a European network of population-based congenital anomaly registers for        surveillance. EUROCAT surveys 1.5 million births per year covering 29% of births in EU        Member States.        In 2007, 19 population-based congenital malformation registers within EUROCAT participated        in an initial study of the association of lamotrigine exposure in pregnancy and the risk        of isolated oral clefts. These registries covered at least part of the population of        Austria, Belgium, Croatia, Denmark, Finland, France, Germany, Ireland, Italy, Malta,        Norway, Poland, Spain, Switzerland and Wales.        It is anticipated, that if these registers participate in the current study, the study        will cover 8 million births and 200,000 congenital malformation registrations between 1995        and 2012.|September 2014|September 29, 2014|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01055327||127440|
NCT01055600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113101|Milk-only Lactation Study for Patients on Eltrombopag|A Phase IV Study Evaluating Eltrombopag Concentrations in Breast Milk of Nursing Mothers Taking Eltrombopag||GlaxoSmithKline|No|Withdrawn|March 2013|July 2014|Anticipated|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|N/A|26 Weeks|No|||May 2015|May 11, 2015|January 7, 2010|Yes|Yes|Protocol opened to recruitment in Nov 2009. No potential subjects identified in 5 years;    therefore, study was terminated in Jul 2014 due to lack of feasibility|No||https://clinicaltrials.gov/show/NCT01055600||127419|
NCT01055613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1624|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2009|||||N/A|N/A|N/A||||||||||||||January 22, 2010|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055613||127418|
NCT01055938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-636/06|Bioequivalence Study of Dr. Reddy's Divalproex Sodium Capsules (Sprinkle), 125 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|December 2006|March 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 25, 2010|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055938||127393|
NCT01056757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ribavirin-003|Treatment With Ribavirin for Patients With Metastatic Breast Cancer|A Phase I/II Exploratory Study of Ribavirin in Metastatic Breast Cancer Expressing Elevated eIF4E||Jewish General Hospital|No|Terminated|December 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|January 25, 2010||No|Study closed because of new overlapping study with ribavirin.|No||https://clinicaltrials.gov/show/NCT01056757||127331|
NCT01056770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_SPX_302|Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers|An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers||Seoul National University Hospital|Yes|Completed|October 2009|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|88|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|January 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01056770||127330|
NCT01056471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMM/EM/2008|Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis|Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|January 2010|June 2015|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||February 2015|August 4, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056471||127353|
NCT01056744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKJ-TCP-1|Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents|Endothelial Stent Coverage and Neointimal Proliferation at 6 Months After Implantation of a Coronary Everolimus-Eluting Stent Compared With a Bare Metal Stent Postdilated With a Paclitaxel-Eluting Balloon: A Randomised Study Using Optical Coherence Tomography|OCTOPUS|University of Jena|Yes|Completed|June 2009|June 2012|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056744||127332|
NCT01057030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-038|Multiple Dose Japanese Bridging Study|Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 125 mg in Healthy Japanese and Non-Japanese Subjects||Bristol-Myers Squibb|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|22|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2010|January 24, 2011|January 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01057030||127310|
NCT01057017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-CR-218|Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras|Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras||Brown University|Yes|Terminated|January 2010|December 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|January 20, 2010|Yes|Yes|possible lack of efficacy|No|May 9, 2013|https://clinicaltrials.gov/show/NCT01057017||127311|
NCT01057043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAI /230/09|Cupping in Osteoarthritis of the Knee|Randomised Controlled Clinical Trial on Pulsatile Cupping in Patients With Osteoarthritis of the Knee.||Charite University, Berlin, Germany|No|Completed|January 2010|January 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|80 Years|No|||October 2012|October 22, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057043||127309|
NCT01057940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008410|Pilot to Assess DBE as a Rescue Technique for Failed PEJ|A Pilot Study to Assess the Feasibility of Double Balloon Enteroscopy as a Rescue Technique for Failed Direct Percutaneous Endoscopic Jejunostomy Tube Placement||Mayo Clinic|No|Completed|April 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have failed conventional DPEJ placement|June 2013|June 26, 2013|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01057940||127240|
NCT01057953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/082/HP|Oligogenic Determinism of Colorectal Cancer|Oligogenic Determinism of Colorectal Cancer|DOCC|University Hospital, Rouen|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1550|||Both|18 Years|61 Years|Accepts Healthy Volunteers|||October 2013|October 15, 2013|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01057953||127239|
NCT01057667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV22621|A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4|A Randomized, Double-blinded, Multicenter Study to Evaluate the Antiviral Efficacy and Safety of Adding the HCV Polymerase Inhibitor Prodrug (RO5024048) for 24 Weeks to the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 or 4||Hoffmann-La Roche||Completed|February 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01057667||127261|
NCT01058746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-185|Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection|A Prospective Randomized Controlled Clinical Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058746||127178|
NCT01054651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEMRI SSC 1582|A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni|Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children||Kenya Medical Research Institute|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||January 2010|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054651||127490|
NCT01054937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4SC-203-2-2009|Single Dose Study With 4SC-203 in Healthy Volunteers|First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers||4SC AG||Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 12, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054937||127469|
NCT01050855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1-5658|Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders|Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders|RIC|Children's Hospital of Philadelphia|No|Recruiting|January 2008|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|6 Months|25 Years|No|||December 2015|December 17, 2015|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050855||127779|
NCT01059604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112914|Sumatriptan and Naratriptan Pregnancy Registry|The Sumatriptan and Naratriptan Pregnancy Registry||GlaxoSmithKline|No|Completed|December 2001|April 2013|Actual|April 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|868|||Female|N/A|N/A|No|Non-Probability Sample|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination during        pregnancy anywhere in the world.|October 2014|October 30, 2014|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059604|12 Years|127113|
NCT01059552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-TH-031|Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|NSCLC|Fox Chase Cancer Center|Yes|Completed|December 2009|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059552||127117|
NCT01055639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F6891-R|Telehealth Therapy for Chronic Pain|Telehealth Therapy for Chronic Pain|TTCP|VA Office of Research and Development|Yes|Completed|February 2010|September 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01055639||127416|
NCT01055652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692C00002|Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients|An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2 mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10 mg) in Japanese Patients With Type 2 Diabetes||AstraZeneca|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|20 Years|N/A|No|||October 2010|October 14, 2011|January 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055652||127415|
NCT01055626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBECUN-BF-01|New Body Mass Index (BMI) Cut-offs for the Diagnosis of Obesity and Comorbidities|Usefulness of the Determination of Body Composition for Establishing New Cut-offs for the Diagnosis and Follow-up of Obesity and Comorbidities||Clinica Universidad de Navarra, Universidad de Navarra|No|Recruiting|January 2005|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|6000|Samples Without DNA|Serum and plasma|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Caucasian subjects able to come to Clinica Universidad de Navarra, Pamplona, Spain.        Patients visiting the Departments of Endocrinology and Surgery of the University Clinic of        Navarra for weight loss treatment as well as hospital and University staff undergoing an        annual routine health check-up .|August 2012|August 27, 2012|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055626||127417|
NCT01056263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061065|Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012|Retrospective Observational Study Of Subjects With Cytokine-Refractory Metastatic Renal Cancer Treated With Axitinib (AG-013736) To Estimate 5-Yr Survival||Pfizer|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects participating in this observational study originally participated in study        A4061012 [NCT00076011], and may have also have participated in study A4061008        [NCT00828919].|April 2012|April 18, 2012|January 25, 2010|No|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT01056263||127369|
NCT01056276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MM 23|Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy|Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy||SCRI Development Innovations, LLC|No|Active, not recruiting|May 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056276||127368|
NCT01056497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090818B|The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion|The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion||University Health Network, Toronto|No|Completed|February 2010|June 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|15|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01056497||127351|
NCT01056510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22468|A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)|A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia||Hoffmann-La Roche||Completed|March 2010|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|January 25, 2010|No|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT01056510||127350|
NCT01056484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0118|Mindfulness Meditation for Health|Mindfulness Meditation For Alcohol Relapse Prevention||University of Wisconsin, Madison|Yes|Completed|September 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|January 22, 2010||No||No|April 30, 2014|https://clinicaltrials.gov/show/NCT01056484||127352|Lack of blinding of study staff to group status (except the statistician who was blinded during initial primary analyses); conducting most study related activities by the same core group of research staff may have introduced bias and placebo effect.
NCT01057420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O2Tc-2009|Effect of Hyperoxemia on Platelet Function in Healthy Volunteers|Effect of Hyperoxemia on Platelet Function in Healthy Volunteers||University of Zurich|No|Completed|April 2009|May 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 23, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01057420||127280|
NCT01057680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-169|Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone|Potential of Resistance-Exercise and Creatine Supplementation on Aging Musculoskeletal Health||University of Saskatchewan|Yes|Completed|January 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 26, 2012|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057680||127260|
NCT01057693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081242|Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy|A Phase 3b Multicenter, Double-Blind, Efficacy And Safety Study Of Pregabalin In The Treatment Of Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy||Pfizer|No|Completed|March 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|665|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|January 26, 2010|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT01057693||127259|
NCT01057706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP15127|Chiropractic and Exercise Management of Spinal Dysfunction in Seniors|Chiropractic and Exercise Management of Spinal Dysfunction in Seniors||Northwestern Health Sciences University|Yes|Completed|January 2010|December 2014|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057706||127258|
NCT01058499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008478|Mindfulness Based Stress Reduction in COPD|Mindfulness Based Stress Reduction in COPD||Mayo Clinic|No|Completed|February 2010|December 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|99 Years|No|||March 2016|March 17, 2016|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058499||127197|
NCT01058512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV205-C201|A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy|A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin|NOV-205|Cellectar Biosciences, Inc.|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||January 2011|July 9, 2013|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058512||127196|
NCT01057966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-32|Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets|||Alcon Research|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 31, 2012|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01057966||127238|
NCT01058538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19IL2-01/05|A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours|A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours||Philogen S.p.A.|No|Completed|November 2005|November 2009|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058538||127194|
NCT01054664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nephrop003|The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances|||Meir Medical Center||Not yet recruiting|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|hemodialysis patients with impaired liver enzymes|January 2010|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054664||127489|
NCT01054677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dnr 03-070|Swedish Antibiotic Nursing Home Trial||SANT|Karolinska Institutet||Completed||||||N/A|Interventional|Primary Purpose: Health Services Research|2||||||Both|N/A|N/A||||May 2003|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054677||127488|
NCT01054963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|419-2009|Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis - Peer Mentor Training|Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis - Peer Mentor Training||Sunnybrook Health Sciences Centre|No|Completed|January 2010|December 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2011|December 23, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054963||127467|
NCT01050829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13297|Gadobutrol Magnevist-controlled Body Study|A Multi-center/Multi-national, Randomized, Controlled, Single-blind, Group Comparison Phase 3 Study to Determine the Efficacy and Safety of Gadobutrol 1.0 Molar in Comparison to Magnevist Following Single Injection in Patients Referred for Contrast-enhanced MRI of the Body/Extremities Regions (Breast, Heart, Abdomen, Kidney, Pelvis, or Extremities)||Bayer|No|Completed|January 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|370|||Both|20 Years|N/A|No|||December 2014|December 26, 2014|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050829||127781|
NCT01051128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G090276|Continuous Intrathecal Baclofen Infusion for Chronic Spasticity|Continuous Intrathecal Baclofen Infusion for the Management of Chronic Spasticity|CIBI|Flowonix Medical|No|Withdrawn|January 2010|December 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|22 Years|N/A|No|||March 2015|March 5, 2015|January 15, 2010|Yes|Yes|Study was never started. Full IDE-approval not obtained. new IDE will be submitted|No||https://clinicaltrials.gov/show/NCT01051128||127758|
NCT01051414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-017|An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject|A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection||Bristol-Myers Squibb|No|Completed|April 2010|May 2012|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|20 Years|75 Years|No|||September 2015|September 23, 2015|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051414||127736|
NCT01056042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 50/370-029|Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain|Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial.||Prince of Songkla University|No|Completed|June 2007|October 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Female|18 Years|45 Years|No|||October 2014|October 28, 2014|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056042||127385|
NCT01077830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-043-10|An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)|A Multinational, Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS Trial||Merck Sharp & Dohme Corp.|No|Completed|March 2010|April 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1392|||Both|45 Years|85 Years|No|Non-Probability Sample|The cohort will include all patients from the five participating countries (Sweden,        Denmark, Norway, Finland, and United Kingdom) who were randomized into the SEAS base study        and who were known to be alive at the end of the base study.|October 2015|October 30, 2015|February 26, 2010||No||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01077830||125721|
NCT01050036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-H-54|Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia|Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission||Asan Medical Center|No|Recruiting|January 2010|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|15 Years|65 Years|No|||December 2015|December 28, 2015|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050036||127842|
NCT01046695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000141|Evaluating Transcutaneous Electrical Nerve Stimulation for Postoperative Pain After Video-Assisted Thoracotomy Surgery|Evaluating Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Postoperative Pain After Video-Assisted Thoracotomy Surgery (VATS)||Mayo Clinic|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|January 11, 2010||No||No|November 14, 2012|https://clinicaltrials.gov/show/NCT01046695||128098|
NCT01046734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09061|Virus Shedding and Environmental Deposition of a Novel Influenza Virus|Virus Shedding and Environmental Deposition of Novel A(H1N1) Pandemic Influenza Virus||University of Nottingham|No|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|105|||Both|1 Month|N/A|No|Non-Probability Sample|Adults and children with swine flu whi have had symptoms for less than 3 days|September 2012|September 26, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046734||128095|
NCT01046968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNNB232|Lepticore in Metabolic Syndrome and Weight Loss|The Use of LeptiCore® in Reducing Fat Gain and Managing Weight Loss in Patients With Metabolic Syndrome||University of Yaounde 1|Yes|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|1||Actual|92|||Both|19 Years|52 Years|Accepts Healthy Volunteers|||July 2009|January 11, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046968||128077|
NCT01047189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00007137|Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris|Adherence to ZIANA (Clindamycin Phosphate 1.2% With Tretinoin 0.025%)Gel Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris||Wake Forest School of Medicine|No|Completed|March 2009|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|12 Years|N/A|No|||November 2011|November 9, 2011|January 11, 2010|Yes|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT01047189||128060|
NCT01047202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-PanFlu-4003|Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants|A Blinded, Randomized and Controlled Clinical Trial With Influenza A/H1N1 Split-virion Vaccine in 6 to 35 Months Infants||Sinovac Biotech Co., Ltd||Completed|December 2009|May 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|310|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||March 2013|March 13, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047202||128059|
NCT01047800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGISP-RCT|Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial|Effectiveness of Counseling for Functional Gastrointestinal Disorder Patients: A Double-blind Randomized Controlled Trial|FGISP-RCT|Chinese University of Hong Kong|No|Active, not recruiting|January 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|60 Years|No|||August 2015|August 11, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047800||128014|
NCT01047774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A02-M102-07A|The Effect of Soy Protein on Post- Breast Cancer Surgery Pain|Soy-rich Diet for Preventing Chronic Pain After Breast Cancer Surgery||McGill University Health Center|Yes|Terminated|March 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6|||Female|21 Years|99 Years|No|||October 2015|October 5, 2015|January 12, 2010|Yes|Yes|Difficulty with recruitment - few eligible for enrolment.|No||https://clinicaltrials.gov/show/NCT01047774||128016|
NCT01047787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|823/01|Breathing Disorders in Patients With Congestive Heart Failure|Breathing Disorders in Patients With Congestive Heart Failure: Gender and Mortality Impact||University of Sao Paulo|Yes|Completed|November 2001|March 2004|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|89|||Both|18 Years|75 Years|No|Non-Probability Sample|Consecutive patients with CHF recruited from the outpatient Heart Failure Unit of the        Heart Institute (Instituto do Coraçao do Hospital das Clinicas da Faculdade de Medicina da        Universidade de Sao Paulo)|May 2007|January 12, 2010|May 15, 2007||No||No||https://clinicaltrials.gov/show/NCT01047787||128015|
NCT01047527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA025078|An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence|An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence||University of Pennsylvania|No|Completed|June 2009|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|525|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 10, 2015|January 11, 2010|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01047527||128035|Lack of placebo; low adherence to nicotine patches; nicotine patches are not the most effective treatment for nicotine dependence; participant attrition was high.
NCT01059071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC 002|Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide|A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide||Spectrum Health Hospitals|Yes|Active, not recruiting|February 2010|June 2016|Anticipated|October 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|N/A|No|||November 2014|November 17, 2014|January 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059071||127154|
NCT01059305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0723|Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin|Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin||M.D. Anderson Cancer Center|No|Completed|February 2011|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059305||127136|
NCT01059318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001X2201|A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis|An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis||Novartis||Completed|December 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|22|||Female|18 Years|N/A|No|||October 2012|October 22, 2012|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059318||127135|
NCT01056354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0603M83587 FLU 002|Respiratory Virus Outpatient Study (FLU 002 Plus)|An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|August 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|5000|Samples With DNA|Upper respiratory tract specimen      Serum and plasma      For participants with a confirmed targeted non-influenza respiratory virus, attempts will be      made to obtain a sample of the local specimen used to confirm diagnosis.      Whole blood for human genomics (only at FLU 002 Plus sites opting to also participate in      INSIGHT Genomics and participant has signed an additional consent)|Both|18 Years|N/A|No|Probability Sample|Persons who seek medical care and are suspected of having influenza or a targeted novel        respiratory virus* of major public health concern will be enrolled at numerous        participating clinical sites on several continents.        *The current list of other targeted novel respiratory viruses includes MERS-CoV and        SARS-CoV.|November 2015|November 30, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056354||127362|
NCT01056367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESIST|Resistant Hypertension in Patients With Type-II-Diabetes Mellitus|Resistant Hypertension in Patients With Type-II-Diabetes Mellitus: Prevalence, Characterization and Treatment|RESIST|Svendborg Hospital|No|Completed|June 2009|October 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|180|Samples Without DNA|Only serum and plasma samples are used and saved for later analysis.|Both|18 Years|80 Years|No|Probability Sample|Patients from diabetic outpatient clinic|October 2011|October 9, 2011|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056367||127361|
NCT01077349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071223|High Volume Veno-venous Hemofiltration Versus Standard Care for Post-cardiac Surgery Shock|Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery|HEROICS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2009|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|90 Years|No|||October 2012|November 13, 2013|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077349||125758|
NCT01050205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10010131|The Healthy Lifestyle Project|Diabetes Prevention Translation Project: the Healthy Lifestyle Project||University of Pittsburgh|No|Completed|September 2010|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|322|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050205||127829|
NCT01050465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN276200800445P|MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use|||University of Missouri-Columbia|No|Completed|May 2009|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|728|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 1, 2011|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050465||127809|
NCT01050738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUS09002|Local Analgesia in Knee- and Hipatroplastic Surgery in Patients With Rheumatic Disease: Extra- vs. Intracapsulare Position of Catheter|Local Analgesia in Knee- and Hipatroplastic Surgery in Patients With Rheumatic Disease: Extra- vs. Intracapsulare Position of Catheter||Spenshult Hospital|No|Recruiting|January 2010|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|N/A|N/A|No|||August 2010|August 17, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050738||127788|
NCT01046864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-046|Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)|A Phase Ib Multiple Ascending Dose Study to Evaluate the Safety of Brivanib in Combination With 5-Fluorouracil/Leucovorin (5FU/LV) and Brivanib in Combination With 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) in Subjects With Advanced or Metastatic Gastrointestinal Malignancies||Bristol-Myers Squibb|No|Completed|February 2010|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|49|||Both|20 Years|75 Years|No|||September 2014|September 15, 2014|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01046864||128085|
NCT01049711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUAEPO|Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients|Cost-Utility Analysis of Erythropoietin for Anemia Treatmentin Thai End-Stage Renal Disease Patients With Hemodialysis|CUAEPO|Mahidol University|No|Completed|November 2009|September 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|152|||Both|18 Years|85 Years|No|Non-Probability Sample|HD patients use EPO at least 6 months with titration of EPO therapy is permitted|September 2015|September 28, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01049711||127867|
NCT01050296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAST|Molecular Analysis Of Solid Tumors|Molecular Analysis Of Solid Tumors|MAST|St. Jude Children's Research Hospital|No|Recruiting|January 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|Samples With DNA|Tumor tissue - Tumor tissue will be obtained from patients with a diagnosis of      neuroblastoma, retinoblastoma, osteosarcoma, Ewing sarcoma or soft tissue sarcoma at some or      all of the following time points: initial biopsy, primary tumor resection, time of disease      recurrence. Whole blood - 5 ml of whole blood will be collected from each patient and be      used as a matched control. Bone marrow aspiration - 5ml of bone marrow will be taken at the      time a patient is having a bone marrow aspirate performed and processed to remove only tumor      cells.|Both|N/A|25 Years|No|Probability Sample|Patients identified at St. Jude Children's Research Hospital and collaborating        institutions with a suspected or known diagnosis of neuroblastoma, osteosarcoma,        retinoblastoma, Ewing sarcoma or soft tissue sarcoma based initial diagnostic workup and        evidence of gross disease amenable to excision.|February 2016|February 16, 2016|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050296||127822|
NCT01050569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01050569|Innovative Interventions for Smoking Cessation|Innovative Interventions for Smoking Cessation: Comparison of Very Low Nicotine Content Cigarettes Plus Nicotine Patch; Very Low Nicotine Content Cigarettes Alone or Nicotine Patch Alone||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|October 2008|June 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|235|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 14, 2010||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01050569||127801|Small sample size.
NCT01050348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004 / WPCI 2009-08|To Investigate the Role of Upstream High Dose Statin in STEMI|A Double Blinded Randomized Placebo Controlled Study: To Investigate the Role of Upstream High Dose Statin Treatment in Patients With ST Segment Elevation Myocardial Infarction|IMPRES|The Western Pennsylvania Hospital|Yes|Recruiting|June 2009|October 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|25 Years|90 Years|No|||May 2014|May 29, 2014|January 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050348||127818|
NCT01050608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20655-ICU extension|Evaluation of Body-worn Multimodal Hand Hygiene System. Impact on Health-Care Associated Infections|Real Time Deployment of Multimodal Personal Dispenser Hand Hygiene System in a Multidisciplinary Intensive Care Unit.|Sprixx-ICU|Dartmouth-Hitchcock Medical Center|Yes|Completed|December 2007|January 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2954|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Intensive Care Unit Patients Multidisciplinary Intensive Care Unit|June 2011|June 22, 2011|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050608||127798|
NCT01050621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITC-003|Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective|Phase I - II Clinical Trial of Combination Conventional Cytotoxic Chemotherapy and Intravenous Vitamin C in Patients With Advanced Cancer or Hematologic Malignancy for Whom Cytotoxic Chemotherapy Alone is Only Marginally Effective||Jewish General Hospital|No|Completed|January 2010|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01050621||127797|
NCT01046747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 12415 Pin Study|Pre-drilling or Self Drilling External Fixation Pins|Pre-drilling Pilot Holes for Self-drilling Schanz Pins: Does it Reduce the Incidence of Pin Tract Infection and Pin Loosening?||Temple University|Yes|Recruiting|July 2009|||August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|89 Years|No|||August 2009|January 11, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046747||128094|
NCT01048372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-0023471|Observational Study of Blood Treated With Cytolin|An Observational Study to Determine the In-vitro Immunologic and Virology Activity of Cytolin||CytoDyn, Inc.|No|Completed|January 2010|December 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult human subjects willing and able to have blood drawn at Massachusetts General        Hospital in Boston, MA at baseline, three months and six months. All healthy volunteers        have been enrolled and enrollment is now open only to subjects with earlyh HIV infection.|May 2013|May 17, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048372||127970|
NCT01048073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 019|Non-influenza Etiologies of Acute Respiratory Illness in Southeast Asia|Non-influenza Etiologies of Acute Respiratory Illness in Southeast Asia||South East Asia Infectious Disease Clinical Research Network|Yes|Completed|May 2010|December 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1200|Samples With DNA|-  nose swab        -  throat swab        -  nasopharyngeal aspirate        -  nasal wash        -  tracheal aspirate        -  bronchoalveolar lavage|Both|N/A|N/A|No|Non-Probability Sample|Hospitalized patients with lower respiratory tract infection and were tested for        influenza. These patients are admitted to South East Asia Influenza Clinical Research        Network hospitals.|May 2011|May 25, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048073||127993|
NCT01048034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMDSG08A|Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)|Clinical and Biological Evaluation of Azacitidine in Transfusion-dependent Patients With Low and Intermediate-1 Risk MDS, and Low-risk CMML, Who Are Either Refractory to or Not Eligible for Treatment With Erythropoietin +/- G-CSF||Nordic MDS Group|Yes|Completed|January 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048034||127996|
NCT01048047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPV001DIM2009|Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients|||University of Pavia|No|Active, not recruiting|November 2009|March 2010|Anticipated|December 2009|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|65 Years|No|||November 2009|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048047||127995|
NCT01048060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BANKPEDSBMS0001|Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure|Consent for Obtaining Additional Bone Marrow Specimens at the Time of a Diagnostic Bone Marrow Procedure||Stanford University||Recruiting|February 2002|February 2060|Anticipated|February 2060|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|bone marow|Both|N/A|21 Years|No|Non-Probability Sample|Subjects who are having a bone marrow procedure done as part of their standard oncology        work-up will be eligible to be consent on this study.|February 2015|February 3, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048060||127994|
NCT01056055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|titanick25|Outcomes of the Modified-Brostrom Procedure Using Suture Anchor for Chronic Lateral Ankle Instability|Outcomes of the Modified-Brostrom Procedure Using Suture Anchor for Chronic Lateral Ankle Instability - A Prospective, Randomized Comparison With the Bone Tunnel Technique||Chonbuk National University Hospital|Yes|Completed|February 2007|December 2009|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|40|||Both|15 Years|44 Years|No|Probability Sample|Of patients who underwent the modified Brostrom procedure under the diagnosis of chronic        lateral ankle instability, 40 patients (40 ankles) who could be followed during a minimum        period of 2 years were enrolled in the current study. The current study included patients        who complained of unilateral ankle joint instability.|March 2007|January 25, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056055||127384|
NCT01056081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEPAR 1768|Inspiratory Muscle Training in Chronic Obstructive Pulmonary Disease|Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disease Undergoing a Pulmonary Rehabilitation Program||Faculdade Evangelica do Parana|Yes|Completed|April 2006|December 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|19|||Both|40 Years|75 Years|No|||March 2006|January 25, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056081||127383|
NCT01056861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5307|Effects of Botulinum Toxin in Cervical Dystonia|Effects of Botulinum on the Afferent Input Modulation of Neuronal Circuits Involved in Cervical Dystonia||Henry Ford Health System|No|Completed|January 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|7|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects meeting the criteria for cervical dystonia (torticollis) who are receiving        botulinum toxin injections in the Neurology Clinic|April 2015|April 16, 2015|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056861||127323|
NCT01048489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI070937|Evaluation of a Program to Reduce Smoking in High School Students|Effectiveness of a Community Integrated Program to Reduce Smoking Incidence in High School Students|TAB_es|Jordi Gol i Gurina Foundation|No|Active, not recruiting|January 2008|July 2010|Anticipated|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2256|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||December 2009|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048489||127961|
NCT01050478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015427|IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation|Open-label, Single Arm, Interventional Study to Explore the Efficacy and Safety of Paliperidone ER in the Management of Patients With Acute Agitation and/or Aggression||Janssen Cilag N.V./S.A.|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050478||127808|
NCT01050764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT204|Haploidentical Allogeneic Transplant w/Post Transplant Infusion of Regulatory T-cells (BMT Protocol 204)|A Feasibility Trial of Post Transplant Infusion of Allogeneic Regulatory T Cells Simultaneously With Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical Related Donors||Stanford University||Active, not recruiting|June 2009|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|60 Years|No|||September 2012|September 13, 2012|January 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01050764||127786|
NCT01046877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005004|Singapore Tympanostomy Tube Delivery System Study|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System For The Treatment of Patients Requiring Tympanostomy Tube Insertion For Otitis Media||Acclarent|No|Completed|December 2008|June 2011|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|1 Year|N/A|No|||January 2015|January 4, 2015|January 11, 2010|Yes|Yes||No|November 12, 2014|https://clinicaltrials.gov/show/NCT01046877||128084|The protocol called for outcome measure assessing patency (openness/lack of obstruction) of unextruded tubes at 12 mos post procedure. Since all tubes had already been extruded by 12 mos, no ears with tubes remained for assessment and it was omitted.
NCT01047410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc 2014/190|ACtive Care After Transplantation|ACtive Care After Transplantation|ACT|University Medical Center Groningen|No|Recruiting|October 2010|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|219|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047410||128044|
NCT01047423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009‐011638‐90|Targeting Microvascular Dysfunction in Young Hypertensive Patients|Targeting Microvascular Dysfunction in Young Hypertensive Patients||Queen's University, Belfast|Yes|Recruiting|August 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|60 Years|No|||October 2009|January 11, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047423||128043|
NCT01049724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|351515|Lacritin and Heparanase Levels in Human Tears After Laser Refractive Surgery|Lacritin and Heparanase Levels in Human Tears After Laser Refractive Surgery||Fort Belvoir Community Hospital|Yes|Recruiting|January 2010|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|196|||Both|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Active duty military aged 21 to 55 with myopia up to -10.00 diopters eligible for care at        Walter Reed Army Medical Center.|February 2016|February 2, 2016|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049724||127866|
NCT01049737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIPP|Cardiovascular Risk Factors in Patients With Diabetes -a Prospective Study in Primary Care|Cardiovascular Risk Factors in Patients With Diabetes -a Prospective Study in Primary Care|CARDIPP|Linkoeping University|No|Active, not recruiting|May 2005|December 2020|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|761|Samples With DNA|Blood samples were drawn in the fasting state and analysed for levels of HbA1c, hs-CRP,      cytokines, lipid and lipoprotein status etc. RNA is extracted from whole blood and the      PPAR-gamma isoform was determined after RT-PCR and analysis of DNA sequence. Several small      vials of plasma and serum are stored for later analysis of different hormones, cytokines and      antibodies (when the economy of the project allows this, high priority is antibodies against      GAD and islet beta-cells and levels of hormones such as resistin, adiponectin, leptin and      markers of inflammation in terms of cytokines as IL-1, IL-6, IL-10). Other genetic      polymorphisms of importance for risk assessment will also be analysed when the economy      allows this.|Both|55 Years|65 Years|No|Non-Probability Sample|The patients in CARDIPP were consecutively recruited from primary health care centres in        the counties of Östergötland and Jönköping, Sweden from November 2005 through December        2008. The study enrolled 761 patients with type 2 diabetes, aged 55-65 years and the        participation in the study was performed as an extended annual follow up.|December 2009|January 13, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049737||127865|
NCT01050309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC CO102/09|An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers|An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers||Photocure||Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|8|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 14, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050309||127821|
NCT01050582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016687|A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children|Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|8 Years|16 Years|No|||October 2012|October 26, 2012|January 14, 2010||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01050582||127800|A total of 350 subjects in a 1:1 ratio between the two arms was planned. Recruitment difficulties led to an imbalance in the number of subjects per arm and to early termination of the study. The results should be interpreted within this context.
NCT01050595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107199|Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit|Methylnaltrexone for the Reversal of Opiate-Induced Constipation in the Intensive Care Unit|MOVE-IT|St. John Health System, Michigan|Yes|Recruiting|December 2009|December 2010|Anticipated|October 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050595||127799|
NCT01046994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA-BPD|Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion|Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion|DIA-BPD 25-30|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Yes|Recruiting|July 2009|December 2016|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|35 Years|70 Years|No|||January 2010|January 11, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046994||128075|
NCT01047254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005352-17|Bupropion for the Treatment of Apathy in Alzheimer's Dementia|A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)|APA-AD|University Hospital, Bonn|Yes|Completed|January 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|55 Years|90 Years|No|||October 2015|October 7, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047254||128056|
NCT01047540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIC316-01-II-01|Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2|A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection||AiCuris Anti-infective Cures GmbH|No|Completed|March 2010|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|156|||Both|18 Years|N/A|No|||October 2010|July 20, 2012|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047540||128034|
NCT01047553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5122C00002|Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients|An Open Phase III, Multi-centre 52-week, Parallel-group Study Evaluating the Safety and Efficacy of Formoterol 18 μg Daily Dose Compared With Standard COPD Treatment, in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca|Yes|Completed|December 2009|July 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|251|||Both|40 Years|N/A|No|||December 2012|December 4, 2012|January 12, 2010||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT01047553||128033|
NCT01048593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-01|Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery|A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Cataract Surgery Patients||ICON Bioscience Inc|No|Terminated|January 2010|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Both|40 Years|N/A|No|||August 2012|August 16, 2012|January 11, 2010|Yes|Yes|Study was terminated in order to examine study data.|No|May 24, 2012|https://clinicaltrials.gov/show/NCT01048593||127953|Early termination leading to small numbers of subjects analyzed.
NCT01048606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDionne_phyto_2008-2011|Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women|Exercise and Phytoestrogens: a Synergistic Effect on Factors Predisposing to CVD in Postmenopausal Women||Université de Sherbrooke|No|Completed|January 2009|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|45|||Female|50 Years|70 Years|No|||December 2013|December 18, 2013|January 12, 2010||No||No|December 18, 2013|https://clinicaltrials.gov/show/NCT01048606||127952|
NCT01048359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA026088|Multidisciplinary Approach to Reduce Injury and Substance Abuse|Multidisciplinary Approach to Reduce Injury and Substance Abuse||University of Texas at Austin|Yes|Completed|January 2010|June 2015|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|417|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048359||127971|
NCT01055717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB9306|Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults|Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults||Tufts University|Yes|Completed|March 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01055717||127410|
NCT01055730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-ILD|The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease|The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study|PR-ILD|University of California, San Francisco|No|Completed|February 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|19 Years|N/A|No|Non-Probability Sample|Any patient with interstitial lung disease who is referred to a participating pulmonary        rehabilitation program. These patients typically have exercise limitation and dyspnea, but        still possess the ability to perform some exercise.|November 2013|November 19, 2013|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01055730||127409|
NCT01056393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5460|Investigator-Sponsored Protocol - Continued Use of Ibalizumab|Investigator-Sponsored Protocol - Continued Use of Ibalizumab||Kaiser Permanente|No|Active, not recruiting|November 2009|November 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056393||127359|
NCT01056874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001097|Effect Of Maraviroc On The Pharmacokinetics Of Digoxin|Open-Label, Fixed Sequence, Crossover Study To Estimate The Effect Of Multiple Dose Maraviroc On Single Dose Digoxin Pharmacokinetics In Healthy Subjects||ViiV Healthcare|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|January 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056874||127322|
NCT01056887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17121979|Copeptin in Differentiation of Polyuria and Polydipsia|||University of Wuerzburg|Yes|Completed|March 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy probands Patients with diabetes insipdus centralis totalis/ partials Patients with        diabetes insipidus renalis Patients with primary polydipsia|November 2010|April 22, 2011|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056887||127321|
NCT01050777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86783|Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis|Pilot Study of Efficacy of Topical Nano-liposomal Meglumine Antimoniate (Glucantime) or Paromomycin in Combination With Systemic Glucantime for the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Caused by Leishmania Tropica||Tehran University of Medical Sciences|Yes|Completed|March 2011|March 2012|Actual|January 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|30|||Both|12 Years|60 Years|No|||February 2011|June 19, 2012|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050777||127785|
NCT01047111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001ECFD|Esophagectomy: Sweet Versus Ivor-Lewis|A Phase Ⅲ Study of Left Side Thoracotomy Approach (Sweet Procedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower Third Intrathoracic Esophageal Cancer|ESVIL|Fudan University|No|Active, not recruiting|May 2010|July 2016|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|70 Years|No|||July 2012|February 26, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047111||128066|
NCT01077336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G098881|Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility|Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility||University of Houston|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|450|||Both|18 Years|N/A|No|Non-Probability Sample|This will be a retrospective cohort study of 400 hospitalized patients with bloodstream        infections from January 2006 to January 2009 due to Candida species|July 2014|July 15, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077336||125759|
NCT01077596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111982|Carcinogenicity Study of Bupropion|Post-marketing Carcinogenicity Study of Bupropion||GlaxoSmithKline|No|Completed|June 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|50430|||Both|18 Years|N/A|No|Non-Probability Sample|New users of antidepressants January 1, 1996 through December 31, 2006, regardless of        indication for use (depression, smoking cessation, other) in Henry Ford Health System and        Kaiser Permanente Health Plan of Northern California. The study population is limited to        individuals 18 years of age or older with medical and pharmacy benefits and at least 6        months of health plan enrollment before the first antidepressant prescription. Patients        with a history of any cancer (cancer diagnosis recorded in the tumor registries anytime        before the first antidepressant prescription recorded during the study period) are        excluded. Cases and controls will be selected from this cohort of antidepressant-exposed        study subjects.|June 2011|June 2, 2011|February 25, 2010||No||No|January 21, 2011|https://clinicaltrials.gov/show/NCT01077596||125739|
NCT01050049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11959|The Effect of Implementing Hyper-acute Stroke Guidelines on Decision-Making for or Against Thrombolytic Therapy for Stroke in the Emergency Department|The Effect of Implementing Hyper-acute Stroke Guidelines on Decision-Making for or Against Thrombolytic Therapy for Stroke in the Emergency Department||Temple University|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|19 Years|N/A||Probability Sample|Patients presenting to the Emergency Department with acute stroke|October 2008|January 14, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050049||127841|
NCT01050062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.542|Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use|Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension||Boehringer Ingelheim||Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1452|||Both|N/A|N/A|No|Non-Probability Sample|1000|April 2014|April 4, 2014|December 24, 2009||||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01050062||127840|
NCT01050322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLICO-0801|Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.|A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment|GLICO-0801|Latin American Cooperative Oncology Group|Yes|Completed|November 2009|September 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|142|||Both|18 Years|N/A|No|||November 2010|June 4, 2013|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050322||127820|
NCT01050335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-07-0044|Collaborative Surgical Proficiency Initiative|Collaborative Surgical Proficiency Initiative||Phoenix Integrated Surgical Residency|No|Enrolling by invitation|June 2007|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|23 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Surgical residents and attendings from Banner Good Samaritan Medical Center|June 2009|January 14, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050335||127819|
NCT01050101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS 2009-052|The Effects of Fiber on Appetite and Digestion Hormones|The Effect of Meal Viscosity on Postprandial Metabolic, Gut Hormone and Satiety Responses to Low and High Glycemic Index Preload Meals in Overweight Pre- and Post-menopausal Women.|FS|Institute for Food Safety and Health, United States|No|Active, not recruiting|August 2008|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050101||127837|
NCT01050634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991079|Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)|Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) a Non-interventional Trial With Aromasin®|FAST|Pfizer|No|Completed|November 2005|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|980|||Female|N/A|N/A|No|Non-Probability Sample|Early Breast Cancer, post-menopausal, 2-3 yrs adjuvant tamoxifen therapy|June 2010|June 23, 2010|January 13, 2010|No|Yes||No|April 26, 2010|https://clinicaltrials.gov/show/NCT01050634||127796|
NCT01047007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1775-005|A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005)|A Phase I Dose Escalation Study of MK1775 in Monotherapy, in Combination With 5-Fluorouracil, and in Combination With 5-Fluorouracil and Cisplatin in Patients With Advanced Solid Tumor||Merck Sharp & Dohme Corp.|No|Terminated|January 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|20 Years|N/A|No|||February 2015|February 3, 2015|January 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01047007||128074|
NCT01047267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANIDULA-133|Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)|Pharmacokinetics of Anidulafungin in Critically Ill Patients With Invasive Candidiasis||University Medical Center Groningen|No|Completed|June 2010|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with invasive candidiasis admitted to an intensive care unit.|April 2012|April 5, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047267||128055|
NCT01047566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRONE_L_05066|Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)|The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Persistent Atrial Fibrillation|AFRODITE|Sanofi|No|Completed|April 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Both|46 Years|N/A|No|||November 2011|November 9, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047566||128032|
NCT01047813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1305/15|The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes|The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes||University of Leeds|Yes|Recruiting|September 2009|September 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the general population using emails and posters. These        will be distributed throughout the University of Leeds, Leeds Metropolitan University, and        NHS sites in Leeds. GP's and diabetes specialist doctors and nurses will be asked to        inform potential participants of the nature of the study. Ideally spouses, siblings or        other close friends/relatives of the experimental group will be recruited for the control        group in an attempt to control for education, social class and general lifestyle.|July 2009|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047813||128013|
NCT01048099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 166|Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer|Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing||SCRI Development Innovations, LLC|No|Completed|January 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|283|||Female|18 Years|N/A|No|||December 2015|December 22, 2015|January 12, 2010|No|Yes||No|October 8, 2015|https://clinicaltrials.gov/show/NCT01048099||127991|
NCT01048112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 10-086|Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection|Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection||University of Vermont|Yes|Recruiting|January 2010|September 2011|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 12, 2010|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01048112||127990|
NCT01048814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-103|Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases|Retrospective Study to Develop a Training Set for a Cross Validated Chemoresponse Marker Algorithm in Cases With Ovarian, Peritoneal or Fallopian Tube Cancer||Precision Therapeutics|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|512|||Female|18 Years|N/A|No|Non-Probability Sample|Approximately 512 cases of ovarian, peritoneal or fallopian tube, recurrent, persistent,        or refractory cancer that have had ChemoFx drug response marker results for NCCN        recommended second line therapy from August 2006 to January 31, 2009 will be included in        the compilation of the training set. Cases will be selected sequentially from each        participating clinical site.|June 2011|June 2, 2011|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048814||127936|
NCT01056601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LSUC012|Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy|Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination||Masonic Cancer Center, University of Minnesota|Yes|Terminated|September 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|January 25, 2010|Yes|Yes|Funding not available|No|July 28, 2011|https://clinicaltrials.gov/show/NCT01056601||127343|Study was terminated early leading to small numbers of subjects analyzed; no solid conclusion can be derived.
NCT01056120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0903|Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice|Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice Multinational, Prospective, Non-randomized, Multi-centre, Non-interventional Trial|ENERGY|Biotronik AG|No|Completed|March 2010|December 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1026|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample|January 2016|January 29, 2016|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01056120||127380|
NCT01056627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|637/06|Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|December 2006|March 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 25, 2010|January 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01056627||127341|
NCT01056614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1913.00|Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies|Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|September 2004|||August 2005|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|60 Years|No|||November 2015|November 3, 2015|January 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01056614||127342|
NCT01048710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tomofix_small|Treatment of Medial Compartmental Osteoarthritis Grade 1-4 With TomoFix™ Small or Conservatively|Treatment of Medial Compartmental Osteoarthritis Grade 1-4 (Kellgren-Lawrence) or Osteonecrosis With TomoFix™ Small or Conservatively||Synthes GmbH|No|Active, not recruiting|July 2009|July 2018|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|151|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with Indication for open wedge HTO with the TomoFix™ Small presenting in the        orthopaedic department of the participating hospitals|February 2016|February 11, 2016|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048710||127944|
NCT01048723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15962|Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas|A Single-arm, Open Label Phase II Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|January 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||July 2012|November 21, 2013|January 13, 2010|Yes|Yes|Novartis terminated funding|No|July 13, 2012|https://clinicaltrials.gov/show/NCT01048723||127943|This study was terminated early due to sponsor budget cuts. We could not meet our accrual goal to perform planned analysis of 40 participants.
NCT01081379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schlesinger - CMV|The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection|The Relation Between the Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection||Shaare Zedek Medical Center|No|Not yet recruiting|February 2012|August 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples Without DNA|serum|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with primary CMV|February 2012|February 20, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081379||125454|
NCT01077843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-163|Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)|A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in a Cohort of Patients With Ankylosing Spondylitis (AS) in the UK, France and Germany||Merck Sharp & Dohme Corp.|No|Active, not recruiting|August 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|11169|||Both|N/A|N/A|No|Non-Probability Sample|This study will use the combination of the General Practice Research Database (GPRD) in        the UK, The Health Improvement Network (THIN) database in the UK, and the IMS Disease        Analyzer Database (Disease Analyzer) in the UK, France and Germany.|February 2016|February 19, 2016|February 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077843||125720|
NCT01078077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005|The Impact of a Topical Vasodilating Cream on Female Sexual Experience|The Impact of a Topical Vasodilating Cream (When Applied to the Clitoris) on the Female Sexual Experience Using a Standard 7 Part Female Sexual Dysfunction Questionnaire|TVConFSD|East Suburban Ob Gyn|No|Recruiting|March 2010|July 2012|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Female|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sexually active females from ages 25 to sixty not on SSRI's without neurologic disease        able sign and understand informed consent|March 2012|March 1, 2012|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078077||125702|
NCT01078090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 03-1|Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice|Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice||AbbVie|No|Completed|April 2003|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5745|||Both|18 Years|N/A|No|Non-Probability Sample|General population: patients with rheumatoid arthritis who resided in Germany. German        regulations state that all patients are eligible for non-interventional studies; there are        no exclusions. Adult patients (≥ 18 years of age) with RA who were preparing to initiate        adalimumab therapy according to the product label were eligible for study enrollment. The        eligibility criteria below reflect the approved label as stated in the German Summary of        Product Characteristics (SPC) for Humira.|April 2014|April 23, 2014|February 26, 2010||No||No|March 19, 2014|https://clinicaltrials.gov/show/NCT01078090||125701|
NCT01078376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491_109|A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults|A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults||Takeda|Yes|Terminated|May 2010|September 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|29|||Both|1 Year|45 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|February 26, 2010|No|Yes|Business Decision (see below)|No|June 26, 2014|https://clinicaltrials.gov/show/NCT01078376||125680|The study was discontinued without complete enrollment of Cohort 3. Therefore, PK modeling will be used to determine the appropriate doses in children 1 to <6 years of age, in lieu of completing Cohort 3.
NCT01050075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09109|Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel|A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy||City of Hope Medical Center|Yes|Terminated|January 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|7|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|January 14, 2010||No|Unable to recruit patients in the 6 month extension allowed.|No||https://clinicaltrials.gov/show/NCT01050075||127839|
NCT01049802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR-001|Repetitive Transcranial Magnetic Stimulation (rTMS) to Contralesional Hemisphere in Patients With Stroke for Upper Limb Recovery|Evaluation of Therapeutic Effects of Navigation-guided 1 Hz rTMS Administered to the Contralesional Hemisphere in Patients With Stroke|ContraStim|Rehabilitation Institute of Chicago|No|Completed|January 2010|June 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||September 2014|September 11, 2014|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049802||127860|
NCT01046760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21 CFR 50.3.|Scholar Performance and Praxis Assessment in Children With Rolandic Epilepsy|Scholar Performance and Praxis Assessment in Children With Rolandic Epilepsy||University of Campinas, Brazil|Yes|Active, not recruiting|September 2009|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|7 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Amongst patients with rolandic epilepsy assisted at the Clinic of        Neurological-Psychological-Language in childhood of Hospital de Clínicas of Universidade        Estadual de Campinas (Unicamp).|October 2010|October 19, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046760||128093|
NCT01047280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2005:183|Use of Conjugated Linoleic Acid as a Nutraceutical for Weight Loss in Humans|Use of Conjugated Linoleic Acid as a Nutraceutical for Weight Loss in Humans|CLA|University of Manitoba|Yes|Completed|November 2006|May 2009|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|36|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2009|January 11, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01047280||128054|
NCT01047293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI38815|RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma|A Phase I/II Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma||University of Utah|Yes|Completed|May 2010|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|N/A|N/A|No|||November 2015|November 11, 2015|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047293||128053|
NCT01047579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DIL01|A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease|A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease|BETTER|Novartis||Completed|April 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|50 Years|N/A|No|||May 2012|May 15, 2012|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047579||128031|
NCT01048086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200904707|90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)|90Y-DOTA-tyr3-Octreotide With or Without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults. A Randomized, Placebo Controlled Phase II Trial With Dosimetry Guided Dosing||University of Iowa|Yes|Active, not recruiting|June 2009|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|6 Months|30 Years|No|||June 2012|June 13, 2012|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048086||127992|
NCT01048125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1141858|Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy|Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy||University of Missouri-Columbia|No|Withdrawn|August 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|January 11, 2010||No|no enrollment|No||https://clinicaltrials.gov/show/NCT01048125||127989|
NCT01048398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMI-001|Remifentanil Versus Paracetamol for Pain Treatment External Cephalic Versions.|Remifentanil Versus Placebo for Pain Treatment External Cephalic Versions. Randomized, Controlled and Masked||Basque Health Service|No|Completed|June 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|April 13, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048398||127968|
NCT01048411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|naja-comp-1-trial|Trial to Investigate the Influence of the Homeopathic Remedy Naja-comp on Stroke Therapy in Geriatric Rehabilitation|Multicenter Randomized Controlled Trial to Investigate the Influence of the Homeopathic Remedy 'Naja-comp' on Stroke Therapy in Geriatric Rehabilitation|naja-comp|University of Erlangen-Nürnberg Medical School|Yes|Completed|January 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|344|||Both|65 Years|N/A|No|||October 2009|January 12, 2010|October 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01048411||127967|
NCT01055769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951152|Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects|An Open Label, Single Dose, 2-Way, Randomized Cross-Over Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects||Pfizer|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 30, 2012|January 22, 2010|No|Yes||No|March 4, 2011|https://clinicaltrials.gov/show/NCT01055769||127406|
NCT01055782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-80|Colonoscopy Endoguide in Specialist Practice|Kan Anvendelse af Endoskopisk Positioneringsudstyr Ved coloskopiundersøgelsen (kikkertundersøgelse af Tarmen) i en højt Specialiseret Praksis Forbedre Patientens Subjektive Kvalitetsoplevelse (Smerteperception)?||The Specialist Doctors at Rolighedsvej|No|Completed|November 2009|June 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1004|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|January 24, 2010||No||No|March 23, 2012|https://clinicaltrials.gov/show/NCT01055782||127405|Early termination due to higher than expected eligible patients
NCT01055795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020190|Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors|Phase I Study of the Combination of Bevacizumab, Everolimus and LBH589 (BEL) for the Treatment of Advanced Solid Tumors|BEL|Duke University|Yes|Completed|March 2010|May 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|90 Years|No|||December 2012|December 21, 2012|January 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055795||127404|
NCT01056406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002171/1; MGH|Nutrition Intervention for the Promotion of Healthy Weight Gain During Pregnancy|Nutrition Intervention for the Promotion of Healthy Weight Gain During Pregnancy: The Revere Pregnancy Weight Management Study||Massachusetts General Hospital|No|Completed|December 2009|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Female|18 Years|49 Years|No|||March 2016|March 18, 2016|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056406||127358|
NCT01048476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC30872113|Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration|Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration||Peking University|Yes|Recruiting|September 2009|October 2012|Anticipated|April 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048476||127962|
NCT01047917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006601|Meditation to Reduce Stress and Improve Quality of Life|Meditation to Reduce Stress and Improve Quality of Life: A Feasibility Study||Mayo Clinic|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047917||128005|
NCT01077609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111983|Flixonase Safety in Patients With Allergic Rhinitis (AR)|Fluticasone Propionate Nasal Spray (Flixonase) Safety in Patients With Allergic Rhinitis Registered in the UK General Practice Research Database||GlaxoSmithKline|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1|||Both|4 Years|85 Years|No|Probability Sample|The General Practice Research Database (GPRD). Patient records dated between January 1990        - January 2002 were used to develop the overall study cohort.|July 2013|July 30, 2013|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077609||125738|
NCT01049204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 030|Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens|Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study on Maraviroc, an Oral ART CCR5 Inhibitor, on the Intensification of Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens||St Stephens Aids Trust|No|Terminated|July 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|N/A|No|||October 2011|October 31, 2011|January 12, 2010||No|The data from the first 48 patients recruited has now been analysed, and it has been    determined that it is sufficient to meet the study objectives.|No||https://clinicaltrials.gov/show/NCT01049204||127906|
NCT01049477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMC 2007-0906|The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery|The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery||Wake Forest School of Medicine|No|Completed|September 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049477||127885|
NCT01049750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090001127|Prevalence and Risk Factors of Erectile Dysfunction in Type 2 Diabetic Patients|||University of Pavia|Yes|Completed|June 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|220|||Male|18 Years|80 Years|No|Probability Sample|males with type 2 diabetes mellitus|March 2015|March 15, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01049750||127864|
NCT01050088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005411|Sucrose Analgesia in Infants Undergoing Casting for Club Foot|Effectiveness of Sucrose Analgesia in Infants Undergoing Casting for Club Foot|SCF|Rabin Medical Center|No|Not yet recruiting|March 2010|March 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|N/A|12 Months|No|||January 2010|January 14, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050088||127838|
NCT01050361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|321-09-FB|Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery|Echocardiography-Guided Hemodynamic Management Strategy for Patients Requiring Perioperative Care for Non-Cardiac Surgery|EGHEM|University of Nebraska|Yes|Recruiting|June 2010|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 18, 2011|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050361||127817|
NCT01050374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO.UGA.PZQ|Safety and Efficacy of Drug Combinations Against Schistosomiasis|Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Praziquantel Study||DBL -Institute for Health Research and Development|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|650|||Both|1 Year|15 Years|No|||January 2010|January 14, 2010|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT01050374||127816|
NCT01046773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD-0285|Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease|Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease||University of California, Los Angeles|Yes|Recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|18 Years|No|||November 2015|November 30, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046773||128092|
NCT01047306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-SAN-053|A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)|A Longitudinal, Prospective, Natural History Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)||Shire|No|Completed|April 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples With DNA|CSF, urine and serum|Both|1 Year|N/A|No|Non-Probability Sample|Initial patient eligibility will be based on patient age and on a confirmed diagnosis of        MPS IIIA by biochemical enzyme assay.|March 2014|March 6, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047306||128052|
NCT01047592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IR-014|Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia|N-methyl-D-aspartate (NMDA) Enhancers' Benefit to Schizophrenia Treatment||Chang-Hua Hospital|Yes|Completed|March 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|60 Years|No|||July 2014|July 6, 2014|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047592||128030|
NCT01047826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC09/128|M.I.P.O. vs Intramedullary Nailing in Tibia Fractures|Intramedullary Nailing vs. M.I.P.O. in Fractures of the Tibia a Randomized Controlled Trial|MINT|King Abdullah International Medical Research Center|Yes|Recruiting|December 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|60 Years|No|||October 2010|June 22, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047826||128012|
NCT01048424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRIT001|Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)|Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)|SPIRIT|University of California, San Francisco|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 29, 2013|January 11, 2010||No||No|May 22, 2013|https://clinicaltrials.gov/show/NCT01048424||127966|
NCT01048645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICC/302/07|Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer|Randomized Phase II Trial: Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer||National Institute of Cancerología|Yes|Completed|September 2007|November 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|80 Years|No|||January 2010|January 12, 2010|December 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01048645||127949|
NCT01056133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0874-A|Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)|A Pilot Study to Determine the Effect of Omega-3 Polyunsaturated Fatty Acids From Fish Oil on Patients With Non-Alcoholic Steatohepatitis (NASH)||University Health Network, Toronto|No|Recruiting|October 2009|March 2016|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||November 2014|November 25, 2014|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01056133||127379|
NCT01048216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2772|Partial Liver Radiotherapy for Unresectable Liver Metastases|Partial Liver Radiotherapy for Patients With Unresectable Colorectal Liver Metastases||Royal Marsden NHS Foundation Trust||Recruiting|November 2006|June 2008|Anticipated|June 2008|Anticipated|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|18|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048216||127982|
NCT01057836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neck HRQoL|Effect of Neck Strength Training on Health-related Quality of Life in Females With Neck Pain|Effect of Neck Strength Training on Health-related Quality of Life in Females With Chronic Neck Pain: A Randomized Controlled 1-year Follow-up Study||Jyväskylä Central Hospital|No|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Female|25 Years|53 Years|No|||January 2010|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057836||127248|
NCT01058161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01040-57|High-Field MRI Characterization of Wrist and Hand Cartilage Abnormalities in Inflammatory and Chronic Rheumatisms|High-Field MRI Characterization of Wrist and Hand Cartilage Abnormalities in Inflammatory and Chronic Rheumatisms||Assistance Publique Hopitaux De Marseille|No|Completed|December 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 27, 2014|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058161||127223|
NCT01048970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAN/CC/330/09|Effect on the Nutritional and Inflammatory Status of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement in Patients With Advanced Lung Cancer|A Prospective Randomized Trial: Effect of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement on the Nutritional and Inflammatory Status, Quality of Life, Toxicity and Response Rate to First-line Chemotherapy in Patients With Advanced Lung Cancer||National Institute of Cancerología|No|Recruiting|October 2009|December 2010|Anticipated|May 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|20 Years|75 Years|No|||January 2010|January 12, 2010|January 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01048970||127924|
NCT01048983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0345|Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)|A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|16||Actual|0|||Both|18 Years|65 Years|No|||March 2015|March 4, 2015|January 12, 2010|Yes|Yes|No accrual.|No||https://clinicaltrials.gov/show/NCT01048983||127923|
NCT01048957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999907418|The Neural Basis of Cue-Elicited Cigarette Craving and Its Control|The Neural Basis of Cue-Elicited Cigarette Craving and Its Control||National Institutes of Health Clinical Center (CC)||Completed|January 2007|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|1||Anticipated|130|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|October 23, 2014|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048957||127925|
NCT01049490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-2009-128|Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device|Safety and Efficacy of Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination With the Novel Microneedle Delivery Device||The University of Hong Kong|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|262|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 13, 2013|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049490||127884|
NCT01049503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP0162009|Effect of pH and Fluoride Concentration of Dentifrices on Caries Control|Effect of pH and Fluoride Concentration of Liquid Dentifrices on Caries Control in a Fluoridated Area: a Randomized Clinical Trial|EPHFCDCC|University of Sao Paulo|Yes|Completed|November 2009|February 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|315|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||August 2012|August 20, 2012|January 12, 2010||No||No|May 7, 2012|https://clinicaltrials.gov/show/NCT01049503||127883|
NCT01049763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 131|Open-Label Pharmacokinetic of Oseltamivir in Healthy Obese Thai Adult Subjects|Phase I, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Oseltamivir in Healthy Obese Thai Adult Subjects||South East Asia Infectious Disease Clinical Research Network|Yes|Completed|January 2010|October 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2010|October 7, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049763||127863|
NCT01049542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV.Protocol1|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers||University of Edinburgh|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 15, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049542||127880|
NCT01050387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909005699|Effects of Vitamin D Dose and Genotype of the Binding Protein in Infants and Children|A Randomized, Controlled Trial of Vitamin D Supplementation in Infants and Children: Effects of Vitamin D Dose and Genotype of the Binding Protein|VitaD|Yale University|No|Completed|January 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|193|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||July 2013|August 2, 2014|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050387||127815|
NCT01046786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN102B|Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord|Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Tiral||China Spinal Cord Injury Network|Yes|Completed|January 2010|December 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|8|||Both|18 Years|60 Years|No|||January 2014|January 27, 2014|January 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01046786||128091|
NCT01046799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005976-28|Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir|Prevention of HBV Reinfection After Liver Transplantation Using Entecavir Monotherapy After Short-term HBIg Administration: A Pilot Study||HepNet Study House, German Liverfoundation|No|Completed|March 2008|October 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|January 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01046799||128090|
NCT01047319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LAQ-302E|A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis|A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis||Teva Pharmaceutical Industries|Yes|Active, not recruiting|April 2010|October 2023|Anticipated|October 2023|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1047|||Both|N/A|N/A|No|||March 2016|March 1, 2016|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047319||128051|
NCT01047605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|173 S 09 PSY|Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers|Evaluation of the Pharmacological Effects of NEURAPAS® Balance and PASCOFLAIR® 425 mg by Quantitative Measurement of Brain Activity in 16 Healthy Volunteers. A Single-blinded, Randomised, Placebo-controlled, 3-armed Phase-I-study With Cross-over Design|NCAG 5209|Pascoe Pharmazeutische Praeparate GmbH|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|16|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||May 2010|May 14, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047605||128029|
NCT01048138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP0560/05|Use of Biperiden for the Prevention of Post-traumatic Epilepsy|Use of Biperiden as a Disease Modifying Agent After Traumatic Brain Injury: a Placebo Controlled, Randomized, Double Blind Study||Federal University of São Paulo|Yes|Recruiting|March 2014|September 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|75 Years|No|||April 2014|April 15, 2014|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048138||127988|
NCT01048151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-001.012|TNFerade Biologic to Treat Locally Advanced Prostate Cancer|A PHASE I SAFETY AND TOLERABILITY TRIAL OF RADIOTHERAPY, ANDROGEN DEPRIVATION, AND INTRATUMORAL INJECTIONS OF AdGVEGR.TNF.11D (TNFeradeTM) FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER||GenVec|No|Recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|N/A|N/A|No|||March 2012|March 8, 2012|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01048151||127987|
NCT01048905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01FD003531-01|Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension|Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension||Children's Hospital & Research Center Oakland|Yes|Completed|March 2009|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|4 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 17, 2014|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048905||127929|
NCT01049126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-106|Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients|Retrospective Case Study to Determine the Correlation of Patient Outcome to the ChemoFx Assay in Cases With Late Stage Endometrial Cancer||Precision Therapeutics|No|Completed|July 2009|February 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|76|||Female|18 Years|N/A|No|Non-Probability Sample|Approximately 70 cases of late stage endometrial cancer that have had ChemoFx drug        response marker results from August 2007 to January 31, 2009 will be included.|March 2011|March 14, 2011|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049126||127912|
NCT01047683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR-01-01-0016|Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL|Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL|MARINE|Amarin Pharma Inc.|No|Completed|December 2009|July 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|229|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047683||128023|
NCT01048203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08TASQ09|A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects|An Open Label, Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects||Active Biotech AB|No|Completed|January 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01048203||127983|
NCT01057602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP2008-004|Further Validation of the Memory Orientation Screening Test (MOST):A 5-minute Screening Test for Dementia in Primary Care Practice|Further Validation of the Memory Orientation Screening Test (MOST): A 5-minute Screening Test for Dementia in Primary Care Practice||Clionsky, Mitchell, Ph.D., ABPP(CN)|Yes|Recruiting|May 2008|September 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample and primary care clinic|January 2010|February 7, 2010|January 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01057602||127266|
NCT01057849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007BAI17B04|Standard Comprehensive Intervention to Treat First-episode Schizophrenia|Sequenced Atypical Antipsychotics Therapy With Intensive or Basic Psychosocial Intervention for First-episode Schizophrenia: An Effectiveness Study||Peking University|Yes|Recruiting|September 2008|||March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|600|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||September 2008|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057849||127247|
NCT01058174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-EC-0001|Liver Transplant European Study Into the Prevention of Fungal Infection|Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients|TENPIN|Astellas Pharma Inc|Yes|Completed|December 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|350|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|January 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058174||127222|
NCT01048996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|663|Genetic Variability and Biomarkers in Children With Acute Lung Injury|Genetic Variability and Biomarkers in Children With Acute Lung Injury|BALI|Medical College of Wisconsin|No|Withdrawn|October 2009|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|3 samples will be collected from each patient, one whole blood and three plasma samples will      be retained.|Both|N/A|18 Years|No|Non-Probability Sample|Subjects will be recruited concurrently with subjects recruited for the "RESTORE" sedation        study. All patients who have been admited to a Pediatric Intensive/Critical Care Unit and        on mechanical ventilation will be screened for eligibility at the participating        institutions.|August 2015|August 21, 2015|January 13, 2010||No|PI has left institution|No||https://clinicaltrials.gov/show/NCT01048996||127922|
NCT01049217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081244|Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial Of Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081244)||Pfizer|Yes|Terminated|April 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|377|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|January 13, 2010|Yes|Yes|See termination reason in detailed description.|No|May 6, 2013|https://clinicaltrials.gov/show/NCT01049217||127905|Based on Data Monitoring Committee (DMC) interim efficacy analysis results indicating a low probability for success, the study was terminated on April 2, 2012; the termination was unrelated to any safety findings that could impact participant health.
NCT01049516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074199P13|Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) Among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Personnel|Prolonged Exposure for PTSD Among OIF/OEF Personnel: Massed vs. Spaced Trials|STRONG STAR|University of Pennsylvania|Yes|Active, not recruiting|November 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|218|||Both|18 Years|65 Years|No|||January 2016|January 29, 2016|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049516||127882|
NCT01049776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILCC #2 IllinoisCancerCare #2|GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line|A Phase II Study of GW786034 in Patients With Non Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens. An Institutional Pilot Study||Illinois CancerCare, P.C.|No|Terminated|January 2010|||March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|January 12, 2010|Yes|Yes|Study was terminated due to positive results seen in statistical analysis. Adequate patient    enrollment was achieved.|No|August 11, 2014|https://clinicaltrials.gov/show/NCT01049776||127862|Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.
NCT01049789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 080|Treatment for Depression Among HIV-Infected Youth|Treatment for Depression Among HIV-Infected Youth||Westat|Yes|Completed|June 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|16 Years|24 Years|No|||March 2016|March 1, 2016|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049789||127861|
NCT01050114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-10-04 (BCM H-26296)|OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER|A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04)||Baylor College of Medicine|Yes|Recruiting|August 2013|September 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01050114||127836|
NCT01050127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-731|A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults|||Abbott||Completed|December 2009|||February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|November 2, 2010|December 4, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01050127||127835|
NCT01047020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTRPAL|Motor Proficiency And Physical Activity in Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)|Motor Proficiency And Physical Activity in Adult Survivors of Childhood ALL||St. Jude Children's Research Hospital|No|Completed|June 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|807|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study sample for this research will be recruited from participants in an        institutionally funded cohort study, St. Jude Life, as well as from active ACT patients        that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated        group who were followed in the After Completion of Therapy Clinic until age 18 years and a        minimum of 10 years after their treatment ended if they were older than age 11 at the end        of therapy. Potentially eligible comparison group participants will be recruited from the        parent, older sibling, relative or friend population who accompany the ACT patient for        follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older)        of children in remission, both from the active follow-up cohort (within five years of last        treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete        the same assessments that the ALL survivor participants will complete.|August 2013|August 26, 2015|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01047020||128073|
NCT01047618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0904|Venous Thromboembolism in Advanced Gastric Cancer Patients|The Incidence and Risk Factors of Venous Thromboembolism in Advanced Gastric Cancer Patients : Prospective Observational Study||Asan Medical Center|No|Completed|December 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|259|||Both|18 Years|N/A|No|Probability Sample|All patients of advanced gastric cancer with palliative chemotherapy|June 2015|June 24, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047618||128028|
NCT01047631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997-585|Role of Exercise in Diastolic Heart Failure|Relationship of Cardiovascular and Muscular Capacity to Daily Functioning in Frail Older Adults||University of Michigan|No|Completed|December 2008|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|N/A|No|||January 2010|May 27, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047631||128027|
NCT01047839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-322|Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries|Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries. Uncontrolled, Open-label Phase 3 Study||Valneva Austria GmbH|Yes|Completed|January 2010|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|100|||Both|2 Months|17 Years|Accepts Healthy Volunteers|||September 2014|December 10, 2014|January 12, 2010|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01047839||128011|
NCT01048658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB - 5146|Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures|Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures: Does it Increase Blood Loss and Interventions for Blood Loss and Why Do Anesthesiologists Choose to Use It?||Oregon Health and Science University|Yes|Completed|September 2009|August 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|164|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048658||127948|
NCT01048918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08128|Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer|Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer||City of Hope Medical Center|Yes|Recruiting|September 2008|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|280|Samples With DNA|Whole Blood|Female|18 Years|N/A|No|Non-Probability Sample|Brawerman Center-Outpatient clinics (City of Hope), Pasadena Satellite Office|November 2015|November 4, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048918||127928|
NCT01049139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 076|Preventative Misconception Intervention|Evaluation of an Intervention to Reduce Preventive Misconception in HIV Vaccine Clinical Trials||Westat|Yes|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|120|||Both|16 Years|19 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049139||127911|
NCT01049152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090003173|Continuous Glucose Monitoring and Inflammation in Nondiabetic and Diabetic Patients Undergone Hemodialysis|||University of Pavia|No|Recruiting|July 2009|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|36|||Both|50 Years|80 Years|No|Non-Probability Sample|outpatients will undergo CGM at two different hemodialysis methods in a croos-over design.        At the end of the study, it will evaluate inflammation markers intra-and inter-groups        during the different hemodialysis methods.|August 2013|August 18, 2013|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049152||127910|
NCT01057290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B16|Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia|Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML||Children's Oncology Group|No|Active, not recruiting|September 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|75|Samples With DNA|cell samples|Both|N/A|18 Years|No|Non-Probability Sample|Diagnosis of pediatric acute myeloid leukemia|May 2015|May 5, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057290||127290|
NCT01057316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-008|Formula PTX Renal Stent Clinical Study|Evaluation of Safety and Effectiveness of the Formula PTX Balloon-Expandable Stent for Renal Artery Stenosis||Cook||Active, not recruiting|February 2010|December 2018|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01057316||127288|
NCT01057615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910000751|Effect of Fish Oil and Vitamin C on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Comparative and Additive Effects of Fish Oil and Ascorbic Acid Supplementation on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma||Indiana University|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|40 Years|No|||January 2011|January 28, 2011|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057615||127265|
NCT01058668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-33|Safety and Efficacy of Cariprazine for Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder||Forest Laboratories|No|Completed|January 2010|||December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|507|||Both|18 Years|65 Years|No|||December 2011|December 30, 2011|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058668||127184|
NCT01058681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swiss national science fund|Impacts of Metabolic Variation on Neuroendocrine Control of Reproduction|Impacts of Metabolic Variation on the Activity of Neuroendocrine Reproductive Axis in Healthy Volunteers||Centre Hospitalier Universitaire Vaudois|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|9|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||October 2010|August 2, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01058681||127183|
NCT01048528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-6940|Health SMART (Stress Management and Relaxation Training)|Phase II Study of Stress Management and Vaccine Response Among Women at Risk for Breast Cancer||Fred Hutchinson Cancer Research Center|Yes|Completed|July 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|33|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01048528||127958|
NCT01049230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-263|Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors|Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors: Evaluation of Acute and Late Side Effects||Massachusetts General Hospital|Yes|Recruiting|June 2010|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|3 Years|25 Years|No|||March 2016|March 4, 2016|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049230||127904|
NCT01049529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/3603/72|Effect of Docosahexaenoic Acid on the Inflammatory Response and Clinical Outcomes From Surgical Patients|Efecto Modulador de la Administracion Del Acido Docosahexaenoico Sobre la Respuesta Inflamatoria, la evolución Clinica y el Estado Nutricional de Neonatos Sometidos a cirugía|DHA-IRCO|Coordinación de Investigación en Salud, Mexico|Yes|Completed|March 2007|September 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|N/A|45 Days|No|||January 2015|January 15, 2015|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049529||127881|
NCT01049256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0712/129|The Cyclocapnic Method for Measurement of Chemosensitivity|Developing an Improved Measure of Chemosensitivity for the Study of Periodic Breathing in Heart Failure: the Cyclocapnic Method||Imperial College London|No|Recruiting|January 2008|October 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||January 2010|January 13, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049256||127902|
NCT01050140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/10/2009|The Metabolic Effects of a High Fructose Versus a High Glucose Diet in Overweight Men|The Metabolic Effects of a High Fructose Versus a High Glucose Diet in Overweight Men||University of Nottingham|No|Completed|January 2010|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050140||127834|
NCT01050647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01082010-4683|Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.|Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.||Stanford University|No|Active, not recruiting|February 2010|September 2016|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|N/A|N/A|No|||March 2015|March 30, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050647||127795|
NCT01050660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 0902004803|Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates|Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates||Yale University|Yes|Completed|June 2009|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|136|||Both|N/A|48 Hours|No|||October 2014|October 27, 2014|December 23, 2009||No||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01050660||127794|
NCT01050673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE/030/VJT|Trial of Versajet Compared With Conventional Treatment in Acute and Chronic Wounds|A Study to Investigate the Time to Closure of Delayed Healing Dehisced Incisions, Delayed Healing Traumatic Wounds or Chronic Cutaneous Defects Surgically Excised With VERSAJET Compared Conventional Operating Room Techniques||Smith & Nephew Wound Management Inc|No|Completed|November 2007|September 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||September 2012|September 7, 2012|January 13, 2010|Yes|Yes||No|June 12, 2012|https://clinicaltrials.gov/show/NCT01050673||127793|
NCT01047033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA-2007-PE|Evaluation of Impacts of Health Education for Children of Microcredit Clients in Peru|||Innovations for Poverty Action|No|Completed|January 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|2453|||Both|18 Years|N/A||||January 2010|January 11, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01047033||128072|
NCT01048164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-000190|Measuring the Effect of Therapeutic Massage on Pain and Discomfort in Cardiac Cath Lab Staff|Measuring the Effect of Therapeutic Massage on Pain and Discomfort in Cardiac Cath Lab Staff - A Pilot Study||Mayo Clinic|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 3, 2012|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048164||127986|
NCT01048437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080726|Educating Missouri Patients About Preemptive Living Donor Transplantation|Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial||Washington University School of Medicine|No|Completed|September 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|370|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 13, 2011|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01048437||127965|
NCT01048671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-138|Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)|Collection of Data on the Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including the HIV Integrase Inhibitor Raltegravir|RACING|Merck Sharp & Dohme Corp.|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|482|||Both|18 Years|N/A|No|Non-Probability Sample|Participant Infected With HIV-1|October 2015|October 29, 2015|January 12, 2010|No|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT01048671||127947|
NCT01079481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-10-034|Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer|A Phase I Study of Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer||Samsung Medical Center||Completed|December 2009|April 2013|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01079481||125599|
NCT01079741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 13-1391|Safety Study of Adjuvant Vaccine to Treat Melanoma Patients|Phase I/Phase II Open Label Study of the TLR3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ® ISA-51 VG in Patients With High Risk Melanoma in Complete Clinical Remission||Icahn School of Medicine at Mount Sinai|Yes|Completed|September 2010|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||December 2014|January 6, 2015|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01079741||125579|
NCT01080014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200077_502|Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina|The Multiple Sclerosis Functional Composite (MSFC) in the Follow-up of MS Patients: Correlation With the Expanded Disability Status Scale (EDSS) Among Different Clinical Forms in Argentina||Merck KGaA||Completed|August 2008|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|252|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with MS in 20 sites across Argentina|October 2013|October 13, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01080014||125558|
NCT01057329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223/2008/TDM|Therapeutic Drug Monitoring in Child and Adolescent Psychiatry|Therapeutic Drug Monitoring (TDM) in Child & Adolescent Psychiatry|TDMKJP|Medical University of Vienna|No|Recruiting|January 2010|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|200|||Both|10 Years|19 Years|No|Probability Sample|university clinic population|January 2010|January 26, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057329||127287|
NCT01058447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00006|Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers|An Open, Single-Dose, Single-Centre, Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers|ADME|AstraZeneca|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058447||127201|
NCT01058980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM 08-1067|ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial|ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial|ADVICE|Montreal Heart Institute|Yes|Completed|December 2009|December 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|550|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01058980||127161|
NCT01048554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL0107|Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System|A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System|MEL0107|Mt. Sinai Medical Center, Miami|No|Completed|November 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|90 Years|No|||April 2012|April 18, 2012|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01048554||127956|
NCT01048775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLB-09|Bilateral Bispectral Index (BIS)-Monitoring in Cardiac Surgery Patients|Investigation on the Diagnostic and Predictive Value of Bilateral Bispectral Index (BIS)-Monitoring in Cardiac Surgery||University Hospital, Bonn|No|Completed|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|60 Years|N/A|No|Probability Sample|patients treated at a University Hospital|April 2012|April 15, 2012|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048775||127939|
NCT01048749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L08-144|Interventional Study of Effects on Spine Height With Two Unloading Positions|Immediate Changes in Spinal Height and Pain Following Aquatic Vertical Suspension in Patients With Low Back Pain and Signs of Nerve Root Compression||Texas Tech University Health Sciences Center|Yes|Completed|August 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|80 Years|No|||January 2010|January 13, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048749||127941|
NCT01049243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006468|A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis|An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis|Vanos|Wake Forest School of Medicine|No|Completed|March 2009|October 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|N/A|No|||January 2013|January 28, 2013|January 12, 2010||No||No|December 21, 2012|https://clinicaltrials.gov/show/NCT01049243||127903|
NCT01049022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11826|Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients|Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients||Bayer|No|Completed|May 2010|August 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|31|||Both|3 Months|14 Years|No|||July 2015|July 21, 2015|January 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01049022||127920|
NCT01049815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-285|Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease|A Randomized-controlled Trial Comparing the Efficacy of Two Phosphorous Binders, Renagel and Caltrate in Reducing the Rate of Progression of Femoral and Carotid IMT Thickening as Measured by B-mode Ultrasound in Dialysis Patients.|SUMMER|Tel-Aviv Sourasky Medical Center|No|Completed|February 2005|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|40 Years|75 Years|No|||January 2010|January 13, 2010|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049815||127859|
NCT01050699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 09-0232-01|Sleep Intervention During Acute Lung Injury|Sleep Intervention During Acute Lung Injury||University of Arizona|Yes|Recruiting|August 2009|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|85 Years|No|||December 2014|December 3, 2014|January 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050699||127791|
NCT01046812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR 09-141|Halitosis Devised Questionnaire Evaluating a New Treatment|Halitosis Devised Questionnaire Evaluating a New Treatment||New York Head & Neck Institute|Yes|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2009|October 5, 2015|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01046812||128089|
NCT01046825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJBC3|Mature B-Cell Lymphoma And Leukemia Study III|Mature B-Cell Lymphoma And Leukemia Study III||St. Jude Children's Research Hospital|No|Recruiting|January 2009|October 2022|Anticipated|October 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|122|||Both|N/A|21 Years|No|||February 2016|February 11, 2016|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01046825||128088|
NCT01047046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6162|Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder|Use of Combined Anticholinergic Medication and Sacral Neuromodulation in the Treatment of Refractory Overactive Bladder||University of California, Irvine|Yes|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|88|||Female|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone a placement of a SNM device to treat refractory OAB. A        retrospective chart review will be performed on all patients who underwent a one or        two-stage placement of an SNM device, which includes an implantable pulse generator (IPG),        for refractory urge incontinence and urgency frequency symptoms. The patients will be        those of Dr. Karen Noblett, having their device placed after 2001.|July 2010|July 13, 2010|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01047046||128071|
NCT01047332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-816|A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures|A Randomized Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures|Wallstent|Brigham and Women's Hospital|Yes|Active, not recruiting|August 2002|December 2010|Anticipated|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|276|||Both|18 Years|N/A|No|||January 2010|January 11, 2010|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047332||128050|
NCT01048177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-09-5381|A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia|A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia|VV/IC|Scripps Health|No|Withdrawn|December 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|80 Years|No|||May 2014|May 12, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048177||127985|
NCT01048450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709-1|Surgical Treatment for Hallux Rigidus|A Multi-Center Retrospective Review of Resectional Arthroplasty, Arthrodesis and, Hemi-Metallic Joint Implants in the Surgical Treatment of End Stage Hallux Rigidus||American College of Foot and Ankle Surgeons|No|Completed|July 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|158|||Both|21 Years|N/A|No|||January 2010|August 17, 2011|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048450||127964|
NCT01079754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 073/2010|0.05 Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy|The Comparison of 0.05 vs. 0.1 Milligram Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy With/Without Anterior and Posterior Vaginoplasty||Mahidol University|No|Recruiting|March 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||September 2011|September 10, 2011|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079754||125578|
NCT01080274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/10|Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test|Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test||Assaf-Harofeh Medical Center|No|Active, not recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|200|Samples Without DNA|blood will be collected for vit d and zinc , stored until all samples are collected and only      than the laboratoty will analyze it.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Over 18 years old          -  CCT > 60 ml/min          -  No IHD          -  No hyper/hypoparathyroidism          -  No active malignancy          -  Not taking calcium, phosphate|February 2010|April 6, 2010|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080274||125538|
NCT01080495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|787/2009|Evaluation of Radial Strain for Assessment of Left Ventricular Function in Transesophageal Echocardiography|Evaluation of Radial Strain Versus Fractional Shortening and Fractional Area Change for Assessment of Left Ventricular Function in Transesophageal Echocardiography|Strain|Medical University of Vienna|No|Recruiting|February 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|33|||Both|18 Years|N/A|No|||February 2010|March 3, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01080495||125521|
NCT01080508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lazarus 001|Spirometry in Esophageal Intubation|Analysis of the Spirometry Pattern in Esophageal Intubation||University Medical Center Groningen|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|ASA I & II patients|October 2009|October 25, 2010|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080508||125520|
NCT01058460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW09-377|HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN|A Randomized Controlled Trial Comparing Concomitant HPV-cytology Testing With Conventional Cytology Testing for the Detection of High Grade Cervical Intraepithelial Neoplasia in Primary Cervical Cancer Screening in Hong Kong|COCY|The University of Hong Kong||Recruiting|June 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|12000|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058460||127200|
NCT01058421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0214|Treatment of Critical Illness Polyneuromyopathy|Randomized Trial of Intensive Physical Therapy for Patients With Acute Respiratory Failure|Do-It-Now|University of Colorado, Denver|Yes|Active, not recruiting|September 2009|June 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058421||127203|
NCT01058434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2204|Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation|A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation||Novartis||Completed|May 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058434||127202|
NCT01058993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35419-D|AMD 3100 for Treatment of Myelokathexis|A Phase I Study of the CXCR-4 Inhibitor AMD3100 for the Treatment of Neutropenia Due to Mutations of CXCR-4, the Myelokathexis Syndrome||University of Washington|No|Completed|October 2010|April 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|January 27, 2010|No|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT01058993||127160|
NCT01048788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08-002|A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg|A Multicenter, Uncontrolled, Open-label Phase 3 Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg||Otsuka Pharmaceutical Co., Ltd.|No|Completed|December 2009|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|80 Years|No|||January 2014|January 30, 2014|January 7, 2010||No||No|December 15, 2013|https://clinicaltrials.gov/show/NCT01048788||127938|
NCT01049061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAB-003-J081-102|A Study of MORAb-003 in Patients With Solid Tumor|A Phase 1 Study of MORAb-003 in Patients With Solid Tumor||Eisai Inc.||Completed|January 2010|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|79 Years|No|||February 2014|February 20, 2014|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049061||127917|
NCT01048762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tp.afd-001|Multidisciplinary Rehabilitation After Cancer Pulmonis Operation|Multidisciplinary Rehabilitation After Cancer Pulmonis Operation - a Randomized Controlled Trial||Aalborg Universitetshospital|Yes|Completed|February 2006|September 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048762||127940|
NCT01049009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00017946|The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension|The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension||Emory University|No|Completed|December 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|21 Years|80 Years|No|||December 2014|December 12, 2014|January 12, 2010|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01049009||127921|
NCT01049555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-06|Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research|Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research|09-PP-06|Centre Hospitalier Universitaire de Nice|No|Completed|September 2011|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049555||127879|
NCT01049841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-124|Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors|Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|21 Years|No|||December 2015|December 7, 2015|January 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01049841||127857|
NCT01050400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-442|CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk|CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk||Lawson Health Research Institute|Yes|Recruiting|October 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|660|Samples With DNA|Saliva and breast milk samples.|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women undergoing elective caesarian section surgery and planning to breastfeed while        concurrently taking codeine for post-partum pain relief within St. Joseph's Hospital in        London and St. Michael's Hospital in Toronto.|January 2010|January 13, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01050400||127814|
NCT01050712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POICO-B|Study of Inhaling Carbon Monoxide to Treat Patients With Intestinal Paralysis After Colon Surgery.|Inhaled Carbon Monoxide in Patients With Post-Operative Ileus Following Colon Resection.||Queen's University|No|Terminated|April 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|70 Years|No|||November 2015|November 15, 2015|January 14, 2010||No|According to retired PI, resident graduated and next resident never carried it to fruition.|No||https://clinicaltrials.gov/show/NCT01050712||127790|
NCT01047059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIMEB|Molecular Imaging With Erlotinib and Bevacizumab|Clinical Pilot to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients With Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) Treated With Erlotinib and Bevacizumab and to Associate Imaging Findings With Molecular Markers|MIMEB|Lung Cancer Group Cologne|Yes|Recruiting|January 2010|June 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2011|July 1, 2011|January 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01047059||128070|
NCT01047072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2363.00|Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis|Phase II Clinical Trial of Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis||Fred Hutchinson Cancer Research Center|Yes|Withdrawn||||September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||October 2012|October 29, 2012|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047072||128069|
NCT01047345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-006|A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)|A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™||Merck Sharp & Dohme Corp.|Yes|Completed|February 2010|November 2015|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|924|||Female|12 Years|26 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|January 11, 2010|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01047345||128049|
NCT01047852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/10|Noninvasive Ventilation After Extubation in Hypercapnic Patients|Sequential and Early Used of Noninvasive Ventilation After Extubation in Hypercapnic Patients or in Patients With Chronic Respiratory Disorders|VHYPER|University Hospital, Bordeaux|No|Completed|January 2010|August 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01047852||128010|
NCT01078870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907058M|Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype|A Double-blind, Randomized, Placebo Controlled Clinical Trial on Comparing Escitalopram and Duloxetine add-on for Negative Symptoms in Schizophrenic Subjects With Neuregulin-1 (NRG1) Risk Genotype|TANESN|National Taiwan University Hospital|No|Active, not recruiting|February 2010|January 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Anticipated|75|||Both|18 Years|65 Years|No|||February 2010|March 9, 2010|February 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01078870||125642|
NCT01079182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-147|Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)|Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice||AbbVie|No|Completed|January 2006|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4681|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with AS in routine clinical practice.|June 2015|June 10, 2015|March 1, 2010||No||No|May 13, 2015|https://clinicaltrials.gov/show/NCT01079182||125621|
NCT01079195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-299|Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus|Effectiveness and Tolerability of Tarka in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus, Not Controlled on Single-drug Therapy: A Multicountry, Multicenter, Post-marketing Observational Study in the Routine Clinical Use|TARDIA|Abbott|No|Completed|October 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|N/A||1|Actual|15436|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a high risk of developing diabetes mellitus treated by secondary care        specialists (such as internal medicine specialists, nephrologists, endocrinologists,        etc.), whose hypertension is not controlled on single-drug therapy will be included.|April 2011|April 15, 2011|March 1, 2010||No||No|March 4, 2011|https://clinicaltrials.gov/show/NCT01079195||125620|
NCT01047137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0013|Response of Urticaria to Stress Intervention|Effect of Psychological Stress Intervention on Chronic Urticaria Activity and Immune Dysregulation||University of Mississippi Medical Center|No|Withdrawn|July 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|64 Years|No|||August 2011|August 2, 2011|January 11, 2010||No|No patients enrolled. A pilot study variation of this study was done instead.|No||https://clinicaltrials.gov/show/NCT01047137||128064|
NCT01047449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANNeCTIN09-11|Improving the Results of Heart Bypass Surgery Using New Approaches to Surgery and Medication|Surgical and Pharmacological Novel Interventions to Improve Overall Results of Saphenous Vein Graft Patency in Coronary Artery Bypass Grafting Surgery: An International Multi-Center Randomized Controlled Clinical Trial|SUPERIORSVG|Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|July 2011|December 2015|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1550|||Both|18 Years|N/A|No|||November 2011|November 17, 2015|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047449||128041|
NCT01047696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-8-165|Randomised Exposure Study of Pollution Indoors and Respiratory Effects|Particulate Air Pollution Exposure and Childhood Acute Respiratory Infections in Guatemala: A Randomized Intervention|RESPIRE|University of California, Berkeley|Yes|Completed|October 2002|March 2005|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|537|||Both|N/A|18 Months|Accepts Healthy Volunteers|||August 2009|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047696||128022|
NCT01047709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U024133|Positional Therapy After Stroke|Positional Therapy After Stroke||University of Michigan|No|Completed|December 2008|May 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|January 12, 2010||No||No|January 18, 2013|https://clinicaltrials.gov/show/NCT01047709||128021|
NCT01058473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMC IRB Number 09-115|Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain|Psychometric Evaluation of the Inpatient Pediatric Physical Activity Questionnaire (IPPAQ) in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain||Connecticut Children's Medical Center|No|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|159|||Both|7 Years|21 Years|No|Non-Probability Sample|Children, adolescents, and young adults with sickle cell disease.|July 2013|July 29, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058473||127199|
NCT01058694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005|The Impact of Short Message Services (SMS) on ARV Adherence in Western Kenya|Adherence to ARV Treatment and Its Effects on Medium Run Socio-Economic Outcomes: Evidence From Western Kenya|CAPS|Georgetown University|No|Completed|June 2007|July 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Actual|720|||Both|18 Years|N/A|No|||January 2010|January 28, 2010|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058694||127182|
NCT01058707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INK128-001|Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies|A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies Followed by an Expansion in Subjects With Measurable Disease||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|January 2010|January 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|January 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01058707||127181|
NCT01058733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARS-Project|Semi-automatic Response System(SARS)in Type 2 Diabetes|Seoul St. Mary's Hospital College of Medicine The Catholic University of Korea, Seoul, Korea|SARS|The Catholic University of Korea|Yes|Completed|October 2006|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2007|January 28, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01058733||127179|
NCT01049334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH 0901|A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis|A Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study to Determine the Efficacy, Onset, and Duration of Action of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis||Reckitt Benckiser LLC|Yes|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049334||127896|
NCT01049347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmiPar|Amitriptyline and Paroxetine Treatment of Major Depression|Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients||Central Institute of Mental Health, Mannheim|Yes|Completed|October 1997|May 2000|Actual|May 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|No|||December 2009|January 13, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049347||127895|
NCT01049048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0190|The Effect of Vitamin D Statues on Endothelial Function|The Effect of Vitamin D Statues on Endothelial Function|CVD Cookie|University of Wisconsin, Madison|No|Completed|March 2009|October 2010|Actual|October 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Female|55 Years|65 Years|Accepts Healthy Volunteers|||March 2011|October 1, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049048||127918|
NCT01049035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET39|A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine (TetraMen-T) in Infants and Toddlers|Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) Administered in Infants and Toddlers||Sanofi|No|Completed|December 2009|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|580|||Both|42 Days|365 Days|Accepts Healthy Volunteers|||April 2013|April 24, 2013|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049035||127919|
NCT01049269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK081206|Validation and Evaluation of a Portable Body Scanner for Determination of Obesity|Validation and Evaluation of a Portable Body Scanner for Determination of Obesity||University of Texas at Austin|Yes|Completed|January 2007|July 2013|Actual|July 2013|Actual|N/A|Observational|N/A||1|Actual|180|||Both|18 Years|60 Years|No|Non-Probability Sample|Subject will be 18-60 years old, BMI 18.50 to 39.99 kg/m3, and free of known diseases, who        are Hispanic and Not Hispanic or Latino Whites.|January 2007|June 23, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049269||127901|
NCT01049568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 078|Cell Phone Reminders Intervention|A Pilot Study Using Cell Phone Interactions to Improve Medication Adherence in Adolescents Who Have Previously Failed Antiretroviral Therapy Due to Non-Adherence||Westat|Yes|Completed|October 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|15 Years|24 Years|No|||March 2016|March 1, 2016|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049568||127878|
NCT01049828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU01201982|Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother|Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother||Washington University School of Medicine|No|Active, not recruiting|August 2010|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|19|||Both|45 Years|60 Years|No|Non-Probability Sample|20 adults between the ages of 45 and 60 years, age and hearing level-matched to the        bothered tinnitus cohort from the on-going research at Washington University. Subjects        will be recruited from an institutional tinnitus database, from Washington University        Otolaryngology Clinics, as well as the general public through poster advertisement on the        Washington University grounds.|July 2011|July 29, 2011|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01049828||127858|
NCT01050413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044108-HMO-CTL|Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors|Evaluation of Serum Thymidine Kinase Activity in Diagnosis,Prognosis and Monitoring of Treatment in Patients With Solid Tumors||Hadassah Medical Organization|No|Recruiting|February 2010|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Non-Probability Sample|patients from oncology department and patients visiting outpatient, daycare oncology        clinic|December 2009|June 2, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01050413||127813|
NCT01050686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/120/09|Need for Subcutaneous Wound Drains in Ileostomy Reversal|Need for Subcutaneous Wound Drains in Ileostomy Reversal|DRASTAR|Charite University, Berlin, Germany|No|Completed|March 2010|February 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050686||127792|
NCT01046838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011006-42|SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI)|SIDAMI - Sildenafil and Diastolic Dysfunction After AMI|SIDAMI|Rigshospitalet, Denmark|Yes|Completed|December 2009|May 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|50 Years|N/A|No|||May 2012|May 23, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046838||128087|
NCT01047371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Why in Hospital - Factors Determining Time to Discharge Readiness After Arthroplasty Surgery|Why in Hospital - Factors Determining Time to Discharge Readiness After Arthroplasty Surgery: An Prospective Observational Study||Hvidovre University Hospital|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients scheduled for total hip or knee arthroplasty|September 2011|September 28, 2011|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047371||128047|
NCT01047644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.0036|Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer.|Extended Interval Port Flushes: A Phase II Clinical Trial||James Graham Brown Cancer Center|Yes|Recruiting|March 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|90|||Both|18 Years|85 Years|No|||January 2016|February 29, 2016|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047644||128026|
NCT01047865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20053039|Type 1 Diabetes Recurrence in Pancreas Transplants|Recurrence of T1D in Pancreas Transplantation||University of Miami|No|Recruiting|May 2005|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Observational|Observational Model: Cohort||1|Anticipated|295|Samples Without DNA|peripheral blood|Both|18 Years|75 Years|No|Non-Probability Sample|Type 1 diabetes who received a simultaneous pancreas-kidney (SPK) transplant|November 2015|November 9, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047865||128009|
NCT01047878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSSARC0001|Genomic Analysis of Pediatric Bone Tumors|Genomic Analysis of Pediatric Bone Tumors (Other Title: Pediatric Bone Tumor Biology Study)||Stanford University||Recruiting|August 2007|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|tumor samples and blood|Both|N/A|18 Years|No|Non-Probability Sample|All patients with bone x-rays suggestive of a malignant bone tumor|September 2015|September 30, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047878||128008|
NCT01079208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.04.INF|Growth of Infants Fed New Starter Formula|Assessment of Growth of Infants Fed Starter Formulas With Modified Protein and Synbiotics||Nestlé|No|Completed|March 2010|October 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|297|||Both|N/A|6 Months|Accepts Healthy Volunteers|||October 2013|December 2, 2014|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079208||125619|
NCT01079494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JU8071383|Clinical Pharmacists Role in the Management of Hypertension in Jordan|Clinical Pharmacists Role in the Management of Hypertension in Jordan||University of Jordan|Yes|Completed|March 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|266|||Both|21 Years|88 Years|No|||March 2009|April 6, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079494||125598|
NCT01047150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB1|The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetro and Tc-99m Mibi|The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetrofosmin and Tc-99m Sestamibi||Cardiac Imaging of Augusta|Yes|Not yet recruiting|January 2010|February 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Patients referred for MPI|December 2009|January 11, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047150||128063|
NCT01047462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/177 (REK)|Scandinavian Diverticulitis Trial|Scandinavian Diverticulitis Trial. Laparoscopic Lavage vs Primary Resection as Treatment for Perforated Diverticulitis. A Randomized Prospective Multicenter Trial|SCANDIV|University Hospital, Akershus|No|Active, not recruiting|January 2010|July 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047462||128040|
NCT01047475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB104CLCT01|A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)|A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer||Microbio Co Ltd|Yes|Completed|October 2009|December 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|20 Years|N/A|No|||April 2015|April 28, 2015|December 22, 2009|No|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01047475||128039|
NCT01047722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3 BVT-ASA|In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction|Bleeding Volume Test: A Double-Blind Crossover Randomized Clinical Trial of an In-Vivo On-Line Test for Aspirin Effect and Resistance|Aspirin-BVT|Klein, Jeffrey A., M.D.|No|Active, not recruiting|January 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||July 2015|July 18, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047722||128020|
NCT01058239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-346|Bortezomib Plus Rituximab for EBV+ PTLD|Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)||Massachusetts General Hospital|Yes|Active, not recruiting|November 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058239||127217|
NCT01058720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004969|Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents|A Pilot Study to Evaluate the Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents||Mayo Clinic|No|Completed|December 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058720||127180|
NCT01049360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-MD-27|Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo|Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|LAC-MD-27|Forest Laboratories|No|Completed|December 2009|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|128|||Both|40 Years|80 Years|No|||September 2011|September 30, 2011|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049360||127894|
NCT01049295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-04-27-9683|Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer|The Effects of Omega-3 Fatty Acids on Chemotherapy-induced Neuropathy and Inflammation in Patients With Breast Cancer||Tehran University of Medical Sciences|Yes|Recruiting|April 2010|February 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|52|||Female|30 Years|65 Years|No|||April 2011|October 29, 2011|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049295||127899|
NCT01049282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYB-03|A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)|A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered in Different Antigen/Adjuvant Formulations in TST Negative and TST Positive Volunteers at 0 and 2 Months|THYB-03|Statens Serum Institut|Yes|Completed|December 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|39|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049282||127900|
NCT01050153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB # 09-0753|The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma|An Evaluation of the Clinical Utility of Thrombelastography (TEG) in Guiding Low Molecular Weight Heparin (LMWH) and Antiplatelet Prophylaxis of Venous Thromboembolism (VTE) Following Trauma|VTEPX|Denver Health and Hospital Authority|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|January 13, 2010|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT01050153||127833|lower than expected incidence of VTE eventsControl group patients were followed for 5 days, while TEG-guided group was followed as long as in SICUadherence to VTE prophylaxis with Daltaparin was significantly low in the TEG-guided group
NCT01050426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3065|A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)|A Multicentre Randomised Phase II Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)|PERU|Royal Marsden NHS Foundation Trust|Yes|Recruiting|March 2009|September 2015|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2010|January 14, 2010|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01050426||127812|
NCT01047384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acupuncture|Management of Postoperative Pain Following Total Knee Arthroplasty by Using Acupuncture-moxibustion Therapy|||Chang Gung Memorial Hospital||Completed|January 2010|||June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2010|May 19, 2014|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01047384||128046|
NCT01047397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112844|Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia|A Phase IIa, Randomized, Single-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 28-day Repeat Oral Doses of GSK1278863A in Anemic Pre-dialysis and Hemodialysis-dependent Patients||GlaxoSmithKline|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|85 Years|No|||July 2013|November 7, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047397||128045|
NCT01047657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBSTRUÇÃOHC-01|Effects of Weight Loss in Obese Difficult-to-treat Asthmatics|Effects of Weight Loss in Obese Difficult-to-treat Asthmatics: a Pilot Study||University of Sao Paulo General Hospital|No|Completed|November 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||December 2009|February 21, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047657||128025|
NCT01078350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BANKPEDSTS0001|Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy|Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy||Stanford University||Recruiting|May 2004|May 2099|Anticipated|May 2099|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|tissues sample|Both|N/A|21 Years|No|Non-Probability Sample|Subjects who are having a tissue procedure done as part of their standard oncology work-up        will be eligible to be consented on this study.|February 2015|February 2, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01078350||125682|
NCT01078584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-665|Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients|A Prospective, Non-interventional, Observational Study To Describe the Effectiveness of Trandolapril (Mavik®) in the Management of Patients Requiring Angiotensin Converting Enzyme Inhibitor Treatment (In-MAU-tion)|in-MAU-tion|Abbott||Completed|December 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7993|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinics|October 2012|October 19, 2012|March 1, 2010||No||No|September 7, 2012|https://clinicaltrials.gov/show/NCT01078584||125664|
NCT01050803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDSME|Effectiveness of the Farsi Diabetes Self-management Education (FDSME) Program for People With Type 2 Diabetes|Effectiveness of the Farsi Diabetes Self-management Education Program for People With Type 2 Diabetes: Randomized Controlled Trial|FDSME|Tehran University of Medical Sciences|No|Enrolling by invitation|August 2009|April 2011|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|280|||Both|18 Years|N/A|No|||March 2011|March 13, 2011|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050803||127783|
NCT01046903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6301085|An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®|An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® (Dalteparin Sodium) In Patients Undergoing Major Orthopedic Surgery||Pfizer|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|503|||Both|18 Years|N/A|No|Non-Probability Sample|The adult population (women and men) after major orthopedic surgery.|February 2012|February 24, 2012|January 4, 2010|No|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01046903||128082|
NCT01046916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21001|Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen|A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA)||Millennium Pharmaceuticals, Inc.|No|Completed|May 2010|March 2013|Actual|January 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||November 2013|November 15, 2013|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01046916||128081|
NCT01047488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tcapgbcomb1|Imipramine and Pregabalin Combination in Painful Polyneuropathy|Randomised, Double-blind, Placebo-controlled Trial of the Effect of the Combination of Imipramine and Pregabalin for the Treatment of Painful Polyneuropathy||Odense University Hospital|Yes|Not yet recruiting|February 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|75|||Both|20 Years|85 Years|No|||January 2010|January 12, 2010|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047488||128038|
NCT01047956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09075|Compare Methadone Combined With N-Acetyl-Cysteine (NAC) and Methadone Alone for Opioids Astaining|Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study|MNAC|Taichung Veterans General Hospital|Yes|Recruiting|June 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||January 2010|January 13, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01047956||128002|
NCT01047969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2759|Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy|Non-Operative Treatment for Rectal Cancer Following Complete Response to Neo-Adjuvant Therapy||Royal Marsden NHS Foundation Trust|No|Recruiting|September 2006|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2010|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047969||128001|
NCT01048294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc2005/160|Blue Enriched Versus Standard Light Treatment for Seasonal Affective Disorder(SAD)|Gerandomiseerde en Gecontroleerde Studie Naar de Effecten Van Lichttoediening Met Een Hogere Kleurtemperatuur in Vergelijking Met de Standaard Lichttherapie in de Behandeling Van Winterdepressie||University Medical Center Groningen|No|Completed|October 2005|March 2006|Actual|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|65 Years|No|||October 2005|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048294||127976|
NCT01059019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091487|Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery|Epithelial Healing and Visual Outcomes of Patients Using Omega-3 Supplements as an Adjunct Therapy Before and After Photorefractive Keratectomy (PRK) Surgery|Omega-3|University of California, San Diego|No|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|17|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059019||127158|
NCT01058486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004341|Multicomponent Intervention to Decrease Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations|Multicomponent Intervention to Decrease COPD-related Hospitalizations||Mayo Clinic|Yes|Recruiting|September 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|N/A|No|||March 2016|March 17, 2016|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01058486||127198|
NCT01059240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910033|SMN Copy Number Distribution in Mali, West Africa|SMN Copy Number Distribution in Mali, West Africa||National Institutes of Health Clinical Center (CC)||Completed|January 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1400|||Both|18 Years|N/A|No|||June 2015|July 2, 2015|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059240||127141|
NCT01059565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-205-0127|Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection|Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects With Cystic Fibrosis (CF) and Chronic Burkholderia Species Infection||Gilead Sciences|Yes|Completed|February 2010|January 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|6 Years|N/A|No|||February 2014|February 7, 2014|January 28, 2010|Yes|Yes||No|March 8, 2013|https://clinicaltrials.gov/show/NCT01059565||127116|
NCT01049945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMRC-020-021|Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma|A Phase I/II, Multicenter, Open-label, Dose-escalation Study of Bendamustine in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|February 2010|||November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|January 14, 2010|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01049945||127849|
NCT01049854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L 10,321|CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant|CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease||New York Medical College|No|Recruiting|September 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|35|||Both|N/A|70 Years|No|||March 2016|March 23, 2016|May 5, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01049854||127856|
NCT01050166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD MRI IKEM 1|MRI Imaging of Labeled Human Islets Transplanted Into the Liver|Phase 1 Study to Test Safety and Efficacy of Magnetic Resonance Imaging of Human Labeled Islets Transplanted Into the Liver in Type 1 Diabetic Recipients||Institute for Clinical and Experimental Medicine|No|Recruiting|August 2008|December 2015|Anticipated|December 2012|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|65 Years|No|Non-Probability Sample|Cohort will be selected from residents of Czech republic|January 2010|January 14, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050166||127832|
NCT01050725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09016|Pilot Study of Biomarkers for Radiation Therapy|Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study||Benaroya Research Institute|Yes|Suspended|November 2009|||June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100||whole blood samples.|Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing radiation for selected malignancies, including head and neck, lung,        esophageal, rectal, cervical and prostate cancers.|June 2011|June 29, 2011|January 13, 2010||No|On hold: pending grant funding for further enrollment|No||https://clinicaltrials.gov/show/NCT01050725||127789|
NCT01047891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAS 2009|Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer|A Randomized, Double-blind, Placebo Controlled, Multicenter Phase II Study to Assess the Efficacy and Safety of Sorafenib Added to Standard Treatment With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer|TRIAS 2009|Charite University, Berlin, Germany|Yes|Completed|January 2010|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|174|||Female|18 Years|N/A|No|||February 2015|February 17, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047891||128007|
NCT01047904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005006|Anesthetizing the Tympanic Membrane in Healthy Volunteers|Performance and Reliability of the Acclarent Iontophoresis System for Anesthetizing the Tympanic Membrane in Healthy Volunteers||Acclarent|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 6, 2014|January 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01047904||128006|
NCT01078363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12162009-4562|Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy|ACE Inhibition and Cardiac Allograft Vasculopathy||Stanford University|Yes|Active, not recruiting|June 2009|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|12 Years|N/A|No|||November 2014|November 21, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01078363||125681|
NCT01078883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090805R|Respiratory Muscle Performance and Functional Capacity in Primary Stage IIIb and IV Lung Cancer|Association Between Respiratory Muscle Performance and Functional Capacity in Patients With Primary Stage IIIb & IV Lung Cancer||National Taiwan University Hospital|Yes|Recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary stage IIIb and IV lung cancer|December 2010|January 6, 2011|February 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01078883||125641|
NCT01050517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO.UGA.TRIPLE|Safety and Efficacy of Drug Combinations Against Triple Infections|Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections||DBL -Institute for Health Research and Development|No|Completed|October 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|5 Years|18 Years|No|||January 2010|January 14, 2010|January 23, 2008||No||No||https://clinicaltrials.gov/show/NCT01050517||127805|
NCT01046682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-08-02|Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults|Assessment of the Use of Salsalate to Decrease Endothelial Cell Activation and Inflammation in HIV-infected Adults|Salsalate|University Hospital Case Medical Center|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|January 11, 2010|Yes|Yes||No|March 12, 2012|https://clinicaltrials.gov/show/NCT01046682||128099|Lack of placebo in the control group precluded blinding of the study investigators. Adherence was measured utilizing pill counts which assumes that pills not returned were taken by the participant. Sample size too small to detect a small effect.
NCT01046929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAz 09-0447-04|Limonene Study in Women With Breast Cancer|Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery||University of Arizona|Yes|Completed|August 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|59|||Female|18 Years|N/A|No|||June 2012|June 12, 2012|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01046929||128080|
NCT01047501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR-01-01-0017|Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)|Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy|ANCHOR|Amarin Pharma Inc.|No|Completed|December 2009|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|702|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047501||128037|
NCT01047761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myasthenia and Exercise|Exercise for Stable Myasthenia Gravis|Multi-modal Exercise Program for Chronic Stable Myasthenia Gravis||Baltimore VA Medical Center|Yes|Recruiting|January 2010|December 2020|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||August 2013|August 19, 2013|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047761||128017|
NCT01058525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/27|Influence of Ultrasonographic Hydro-dissection With Glucose 5% on Nerve Block Efficiency|Influence of Ultrasonographic Hydro-dissection With Glucose 5% Solution on Median Nerve Block Efficiency: a Prospective and Randomized Study|Hydro-Echo|Hopital Foch|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2011|January 22, 2011|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058525||127195|
NCT01058759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXA-NSCLC|Taxotere-Enoxaparin-(ENOXA)-Study|Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as Single Therapy or in Combination With Enoxaparin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, a Phase III Study||Hannover Medical School|No|Terminated|November 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||November 2011|November 10, 2011|January 28, 2010||No|The external funding (pharmaceutical company) was stopped and could not be substituded by    internal funding.|No||https://clinicaltrials.gov/show/NCT01058759||127177|
NCT01050218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A5-325|Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy|A 9-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Pain Associated With Diabetic Peripheral Neuropathy||Wyeth is now a wholly owned subsidiary of Pfizer|No|Terminated|July 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|237|||Both|18 Years|N/A|No|||July 2010|July 15, 2010|January 13, 2010|Yes|Yes|Business reasons|No|January 29, 2010|https://clinicaltrials.gov/show/NCT01050218||127828|
NCT01049581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|981947B|Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy|Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy||Chang Gung Memorial Hospital|Yes|Completed|October 2009|November 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|4 Years|12 Years|No|||February 2010|February 10, 2015|January 4, 2010||No||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01049581||127877|no pain or falling down or other adverse effect were report
NCT01049594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2009-011602-42|ePrime: Evaluation of Magnetic Resonance (MR) Imaging to Predict Neurodevelopmental Impairment in Preterm Infants|Evaluation of MR Imaging to Predict Neurodevelopmental Impairment in Preterm Infants|ePrime|Imperial College London|Yes|Active, not recruiting|April 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|625|Samples With DNA|Saliva samples containing DNA.|Both|N/A|33 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Preterm infants delivered at less than 33 weeks of gestation. The North and South west        London Perinatal Networks will provide a representative sample of the preterm infants        cared for by the NHS.|April 2010|June 2, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049594||127876|
NCT01049867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASOR01CMN093300CT051044-1895|CD133+ Cell Therapy for Refractory Coronary Heart Disease|Phase 1-2 Study of Intracoronary Infusion of CD133+ Endothelial Precursor Cells for Patients With Coronary Heart Disease in Selected Obstructed Artery||Hospital y Clinica OCA, S.A. de C.V.|No|Recruiting|December 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||January 2010|January 13, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049867||127855|
NCT01049880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804753|A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer|A Phase I Trial of Ascorbic Acid and Gemcitabine for the Treatment of Metastatic Pancreatic Cancer||University of Iowa|Yes|Completed|December 2009|March 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|January 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01049880||127854|
NCT01050179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0712/9|Chemoreflex Gain on Exercise|Chemoreflex Gain on Exercise||Imperial College London|No|Recruiting|February 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||April 2010|April 16, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050179||127831|
NCT01047085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Impedance|Does Cholecystectomy Increase the Esophageal Alkaline Reflux? Evaluation by Impedance-pH Technique|Does Cholecystectomy Increase the Esophageal Alkaline Reflux? Evaluation by Impedance-pH Technique||Istanbul University|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|24|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||March 2008|January 11, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047085||128068|
NCT01047358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991089|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer||Pfizer|No|Completed|June 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|206|||Female|18 Years|N/A|No|Non-Probability Sample|- Postmenopausal women diagnosed as estrogen-receptor positive early breast cancer, who        have received two to three years of tamoxifen and are switched to AROMASIN for completion        of a total of five consecutive years of adjuvant hormonal therapy OR postmenopausal women        with breast cancer that has progressed following anti-estrogen therapy.|October 2015|October 6, 2015|December 24, 2009||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01047358||128048|
NCT01078051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0647|Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)|Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients||CardioVascular Research Foundation, Korea|Yes|Recruiting|March 2010|December 2030|Anticipated|December 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1284|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078051||125704|
NCT01078064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-2010|Gastric Accommodation and Gastroesophageal Reflux|Gastric Accommodation as a Factor Influencing the Number of Reflux Episodes in Children and Adolescents||Nationwide Children's Hospital|No|Not yet recruiting|March 2010|November 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|33|||Both|1 Year|30 Years|No|Non-Probability Sample|children and adolescents older than 1-year old who were referred for combined esophageal        impedance pH monitoring for GERD symptoms, such as epigastric pain, respiratory symptoms,        heartburn, feeding difficulties, chest pain, nausea or vomiting.|February 2010|March 1, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01078064||125703|
NCT01050257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25118|A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza|A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years||Hoffmann-La Roche||Completed|January 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|118|||Both|13 Years|N/A|No|||August 2013|August 28, 2013|January 14, 2010|Yes|Yes||No|August 28, 2013|https://clinicaltrials.gov/show/NCT01050257||127825|
NCT01050270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZB/4/722|Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning Study (SNAP)|A Randomised Trial to Assess the Effectiveness of Pre-treatment With Ondansetron at Reducing Nausea and Vomiting in Patients Treated With Either the Conventional Regimen or a Modified Regimen of Acetylcysteine for Paracetamol Poisoning|SNAP|University of Edinburgh|Yes|Completed|September 2010|March 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|222|||Both|16 Years|N/A|No|||July 2013|July 30, 2013|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050270||127824|
NCT01050530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08-001|A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema||Otsuka Pharmaceutical Co., Ltd.|No|Completed|December 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|20 Years|80 Years|No|||January 2014|January 30, 2014|January 7, 2010||No||No|December 15, 2013|https://clinicaltrials.gov/show/NCT01050530||127804|
NCT01050543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06101|Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)|A Randomized Safety-Assessor Blinded Trial Comparing Sugammadex With Neostigmine in Korean Subjects Scheduled for Surgeries Requiring Moderate Neuromuscular Blockade|DANCHEONG|Merck Sharp & Dohme Corp.|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|January 14, 2010|Yes|Yes||No|February 13, 2012|https://clinicaltrials.gov/show/NCT01050543||127803|
NCT01046942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2007-0057|ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery|ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG Surgery|TEG-CABG|Rigshospitalet, Denmark|No|Recruiting|November 2008|September 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046942||128079|
NCT01047163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB03DR|Maintenance of Muscle Mass in Older People: the Negative Impact of Statin Therapy|Maintenance of Muscle Mass in Older People: the Negative Impact of Statin Therapy||University of Nottingham|No|Completed|June 2009|December 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|18|Samples With DNA|Plasma, Muscle biopsy, Serum & Whole blood|Male|65 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|September 2014|September 2, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047163||128062|
NCT01047514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01052010-4604|Healthier Living Canada|Chronic Disease Self-Management Online Workshop for Canada||Stanford University|No|Completed|January 2010|August 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|297|||Both|18 Years|N/A|No|||April 2013|September 15, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047514||128036|
NCT01047241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010|Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children|Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children||Danish University of Pharmaceutical Sciences|No|Completed|April 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|1 Year|19 Years|No|||September 2014|September 12, 2014|January 8, 2010||No||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01047241||128057|
NCT01047735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1DK086037|The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes|Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes (Triabetes) - Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes ARMMST2D)|TRIABETES|University of Pittsburgh|Yes|Active, not recruiting|September 2009|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|25 Years|55 Years|No|||September 2015|September 3, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047735||128019|
NCT01047748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20082058|A Trial of Digoxin Before Second-Trimester Abortion|A Randomized Clinical Trial of Intra-fetal Versus Intra-amniotic Digoxin Prior to Second-Trimester Pregnancy Termination||White, Katharine O'Connell, M.D., M.P.H.|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|272|||Female|18 Years|55 Years|No|||April 2013|April 29, 2013|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01047748||128018|
NCT01058252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIVF-1001|Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF|A Scientific & Clinical Review of Minimal Stimulation Protocol Using AROMEK (Letrozole) and Follitrope (Recombinant FSH)Combined With INVOCell(Intravaginal Culturing) - Effectiveness as Low Cost IVF|MSP-IVC|Galaxy Pharma (Pvt) Limited|No|Recruiting|February 2011|February 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|37 Years|Accepts Healthy Volunteers|Non-Probability Sample|IVF Network Centers across the country, selecting patients meeting inclusion criteria.|February 2011|February 6, 2011|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058252||127216|
NCT01058265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008497|Integrative Medicine Consultation for Patients With Pain or Fatigue|Effect of an Integrative Medicine Consultation on Outcome for Patients With Pain or Fatigue||Mayo Clinic|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||January 2012|January 23, 2012|January 27, 2010||No||No|December 15, 2011|https://clinicaltrials.gov/show/NCT01058265||127215|
NCT01059058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37062-E/B|Study of Treatments Used for White Spot Lesions After Orthodontic Treatment.|Treatment of White Spot Lesions After Orthodontic Treatment: A Practice-based Randomized Controlled Trial||University of Washington|Yes|Completed|March 2010|July 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059058||127155|
NCT01059279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7575-AL-CTIL|Heat Intolerance in the Group of FMF Patients|Heat Intolerance in the Group of FMF Patients||Sheba Medical Center|No|Enrolling by invitation|December 2009|April 2010|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|15|||Male|18 Years|30 Years|No|Probability Sample|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated        with colchicine, without attacks not less than 2 months|January 2010|January 28, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059279||127138|
NCT01059292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jia123456|TIPE2 Associated With Kidney Transplant|Department of Renal Transplantation, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|TIPE2|Xi’an Jiaotong University College of Medicine||Suspended|October 2009|||||N/A|Observational|N/A||4|Anticipated|93|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|kidney transplant patients and healty Volunteers|October 2009|January 28, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059292||127137|
NCT01050231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2005-4506|Robotics For Rehabilitation Therapy|Robotics For Rehabilitation Therapy||University of California, Irvine|No|Completed|October 2006|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|73 Years|No|||June 2013|June 27, 2013|February 21, 2008||No||No||https://clinicaltrials.gov/show/NCT01050231||127827|
NCT01050491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-25|Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma|Effect of a Receptor Antagonist of Endothelin 1 (Sitaxsentan, Thelin) on Bronchial Remodeling in Severe Asthma With Fixed Bronchial Obstruction|Sitax|Institut National de la Santé Et de la Recherche Médicale, France|No|Terminated|November 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|75 Years|No|||May 2012|May 9, 2012|January 14, 2010||No|sitaxentan is not commercialized anymore|No||https://clinicaltrials.gov/show/NCT01050491||127807|
NCT01049607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-03|Stapler Hepatectomy for Elective Liver Resection|Clamp-Crushing vs. Stapler Hepatectomy for Transection of the Parenchyma in Elective Hepatic Resection: CRUNSH - A Randomized Controlled Trial|CRUNSH|Heidelberg University|No|Completed|January 2010|March 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049607||127875|
NCT01049893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC220-004|Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors|A Phase 1 Open-Label, Dose Finding, Safety and Tolerability Study of AC220 Administered Daily to Patients With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049893||127853|
NCT01049906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-008192|Popliteal Sciatic Nerve Block Catheter Placement for Foot Surgery|A Study to Determine the Quality of Sensory and Motor Blockade of Popliteal Sciatic Nerve Block Catheters Placed Under Ultrasound Guidance With and Without Nerve Stimulation||Mayo Clinic|No|Completed|October 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|21|||Both|18 Years|80 Years|No|||June 2012|June 20, 2012|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049906||127852|
NCT01049919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IDE 13996|Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)|MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects With Severe Peripheral Arterial Disease (PAD)|MOBILE|Biomet, Inc.|Yes|Active, not recruiting|June 2010|May 2020|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|21 Years|N/A|No|||June 2015|June 24, 2015|January 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049919||127851|
NCT01050439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB3095|Unrelated Donor Transplant for Malignant and Non-Malignant Disorders|Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders||Columbia University|Yes|Terminated|November 2002|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|55 Years|No|||April 2015|April 14, 2015|June 3, 2008||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT01050439||127811|
NCT01050452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO.UGA.TRI|Safety and Efficacy of Drug Combinations Against Trichuris Trichiura|Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Study on Trichuris Trichiura.||DBL -Institute for Health Research and Development|No|Completed|October 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|750|||Both|5 Years|15 Years|No|||January 2010|January 14, 2010|January 22, 2008||No||No||https://clinicaltrials.gov/show/NCT01050452||127810|
NCT01047098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816261|Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation|Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation||University of California, Davis|No|Completed|October 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|114|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 16, 2014|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01047098||128067|
NCT01050010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-CIR-01|The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission. Preliminary Study|The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission.Preliminary Study||Centre Hospitalier Universitaire de Nice|No|Recruiting|April 2010|April 2012|Anticipated|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|80 Years|No|||December 2011|December 8, 2011|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01050010||127844|
NCT01050023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#965|Provant Therapy of Venous Stasis Ulcer Trial|Provant Therapy of Venous Stasis Ulcer Trial||Southern California Institute for Research and Education|No|Active, not recruiting|November 2009|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050023||127843|
NCT01050283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-144|A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)|A Multicenter Trial to Evaluate 18F-FDG Uptake by PET in Patients With Advanced Pancreatic Adenocarcinoma as an Early Indicator of Drug Activity||Merck Sharp & Dohme Corp.|No|Terminated|July 2010|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|35 Years|N/A|No|||July 2015|July 24, 2015|January 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01050283||127823|
NCT01050556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC8618|Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic|Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic|FACTA|Columbia University|Yes|Completed|September 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|600|||Both|20 Years|65 Years|No|||July 2012|July 31, 2012|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01050556||127802|
NCT01046708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFER|Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate|Ovulation Induction With Clomiphene Citrate: to Support or Not to Support the Luteal Phase||Universitair Ziekenhuis Brussel|No|Completed|September 2008|July 2012|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046708||128097|
NCT01046721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/6/2009-exenatide-CVS|Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms|Investigation of the Cardiovascular Effects of Exenatide in Healthy Male Subjects||University of Nottingham|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046721||128096|
NCT01046955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20010704|Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation|Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-term Nephrotoxic Calcineurin Inhibitor Therapy||University of Miami|No|Completed|November 2005|December 2008|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|38|||Both|14 Years|N/A|No|||May 2008|January 11, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046955||128078|
NCT01047176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-CRE-2009/1|Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take Statins|Observational Prospective Study to esTIMAte the Rates of Outcomes in Patients Undergoing PCI With Drug Eluting Stent (DES) Implantation Who Take Statins|OPTIMA|AstraZeneca|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|602|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital patient|February 2012|February 29, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01047176||128061|
NCT01046981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 TAD|Tumescent Antibiotic Delivery Pharmacokinetics|Tumescent Antibiotic Delivery: Pharmacokinetic Evidence for Improved Surgical Site Infection Prevention||Klein, Jeffrey A., M.D.|No|Completed|March 2009|August 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||September 2011|September 27, 2011|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01046981||128076|
NCT01047215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09032|Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine|Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine|HeartAriQue|Taichung Veterans General Hospital|Yes|Recruiting|August 2009|June 2010|Anticipated|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2010|January 11, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01047215||128058|
NCT01048008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTI-021|Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer|A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer|DM-CHOC-PEN|DEKK-TEC, Inc.|Yes|Completed|September 2010|November 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048008||127998|
NCT01058772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 22/09|Gestational Diabetes: Induction Versus Expectant Management of Labour|GINEXMAL RCT: Induction of Labour Versus Expectant Management in Gestational Diabetes Pregnancies|GINEXMAL|IRCCS Burlo Garofolo|Yes|Completed|March 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|425|||Female|18 Years|N/A|No|||April 2015|April 29, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058772||127176|
NCT01059331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1286-1|Postoperative Analgesia After Laparoscopic Living Donor Nephrectomy|Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study||Oslo University Hospital|Yes|Completed|February 2010|December 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||March 2014|March 20, 2014|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059331||127134|
NCT01059344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0203|Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis|A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis||Tillotts Pharma AG|No|Completed|November 2009|August 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|281|||Both|18 Years|N/A|No|||April 2013|September 16, 2013|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059344||127133|
NCT01059630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAO4753g|A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)|An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma||Genentech, Inc.||Active, not recruiting|April 2010|||September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|414|||Both|18 Years|N/A|No|||November 2015|November 8, 2015|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059630||127111|
NCT01055418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24AD1|Cognitive and Cerebral Blood Flow Effects of Vitamin C|Cognitive and Cerebral Blood Flow Effects of Vitamin C||Northumbria University|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055418||127433|
NCT01055691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1691C00002|A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets|A Two Part, Open Label, Randomized, Phase I Bioequivalence Study Comparing the Fixed Dose Combination Dapagliflozin/Metformin IR Tablet (2.5 mg/850 mg or 5 mg/1000 mg) vs. the Free Combination of Dapagliflozin and Metformin IR Tablets, in Healthy Volunteers, in the Fed State||AstraZeneca|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01055691||127412|
NCT01081028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Connect ® MM|Connect® MM- The Multiple Myeloma Disease Registry|Connect® MM- The Multiple Myeloma Disease Registry||Celgene|No|Recruiting|September 2009|December 2024|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with multiple myoloma and being treated in community or academic settings.|January 2016|January 21, 2016|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081028||125480|
NCT01081041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13611|A Study in Head and Neck Cancer|A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck||Eli Lilly and Company|No|Completed|June 2010|September 2015|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|187|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|March 3, 2010|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT01081041||125479|Unless specified otherwise, the entire record reports results using a September 27, 2013 data cut-off. This is the date the last data was collected for analysis of primary measure.
NCT01049620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-0905|RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer|A Phase I Dose Finding Study of RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer||Asan Medical Center|No|Completed|February 2010|September 2013|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||January 2015|January 11, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049620||127874|
NCT01049633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-0501|B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure|B-Lymphocyte Immunotherapy in Islet Transplantation: Single Subject Modification to Calcineurin-Inhibitor Based Immunosuppression for Initial Islet Graft (CIT-0501)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||June 2014|June 9, 2014|January 12, 2010|No|Yes||||https://clinicaltrials.gov/show/NCT01049633||127873|
NCT01049932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 037|Pre-Exposure Prophylaxis Using TMC278LA|PrEP TMC278LA: Safety, Tolerability and Pharmacokinetics of TMC278LA in HIV Negative Volunteers||St Stephens Aids Trust|Yes|Terminated|March 2010|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|January 11, 2010||No|Trial closed due to additional safety information.|No||https://clinicaltrials.gov/show/NCT01049932||127850|
NCT01050192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro0001271|Nutritional Content of Breast Milk From Mothers of Premies|The Nutritional Content of Breast Milk From Mothers of Premature Neonates During the First 28 Days of Life||Mednax Center for Research, Education and Quality|No|Terminated|December 2009|September 2010|Actual|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|64|||Both|23 Weeks|30 Weeks|Accepts Healthy Volunteers|Probability Sample|Neonatal Intensive Care Unit|October 2010|October 5, 2010|January 13, 2010||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01050192||127830|
NCT01050751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271039|Bioavailability Of Lersivirine Single 750 Mg Tablet Versus 3 X 250 Mg Tablets|Open-Label, Randomized, 2-Way Crossover Study To Estimate The Pharmacokinetics And Bioavailability Of Lersivirine (UK 453,061) Administered As A Single 750 Mg Tablet And 3 X 250 Mg Tablets In Healthy Subjects||Pfizer|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 8, 2010|January 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01050751||127787|
NCT01046851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISAN-001-09|A Study of Nopan Treatment of Acute Suicidality|Phase 3 Study of the Effects of Nopan as add-on Treatment to Antidepressants in Treating Depression and Suicidality||University of Haifa|Yes|Recruiting|September 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2011|December 31, 2011|January 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01046851||128086|
NCT01047670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esteroides725|Septic Shock em Steroids|Reposição de Esteróides em Crianças Com Choque Séptico||Unidade de Terapia Intensiva|Yes|Recruiting|May 2008|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|1 Month|20 Years|No|||March 2008|January 12, 2010|January 12, 2010||||No||https://clinicaltrials.gov/show/NCT01047670||128024|
NCT01061866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNN 36/06|Thalidomide Low Threshold in Epilepsy|Treatment of Refractory Epilepsy With Thalidomide: an Open Trial||National Institute of Neurology and Neurosurgery, Mexico|No|Completed|June 2006|January 2008|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|17 Years|40 Years|No|||December 2009|February 5, 2010|February 17, 2009||No||No|February 17, 2009|https://clinicaltrials.gov/show/NCT01061866||126940|
NCT01061632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTU_marklyft|High(Deadlift) Versus Low Intensity Motor Control Exercises on Low Back Pain|Effects of High(Deadlift) Versus Low Intensity Motor Control Exercises on Patients With Peripherally Mediated Low Back Pain||Luleå Tekniska Universitet|No|Completed|January 2010|January 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|70|||Both|25 Years|60 Years|No|||March 2013|March 7, 2013|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01061632||126958|
NCT01062152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.1104|Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)||Telik|No|Completed|November 2009|March 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|February 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01062152||126919|
NCT01062477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C5A06|A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants|Safety and Immunogenicity of the Sanofi Pasteur's DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Hib Conjugate (Act-HIB) Monovalent Vaccine as a Three-dose Primary and Booster Vaccination in Healthy Infants in China||Sanofi|No|Completed|January 2010|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1056|||Both|60 Days|89 Days|Accepts Healthy Volunteers|||December 2011|December 12, 2011|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062477||126894|
NCT01062490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-FludT.8/MDS|Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)|Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS)||medac GmbH|No|Completed|November 2004|October 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|60 Years|No|||February 2010|February 3, 2010|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062490||126893|
NCT01062711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMI 1484|Dose Response of Whey and Soy Protein Ingestion With and Without Resistance Exercise in Elderly Men|Responses of Muscle and Whole-body Protein Turnover to Ingestion of Differing Doses of Whey and Soy Protein With and Without Resistance Exercise in Elderly Men|NDC|McMaster University|No|Completed|July 2008|May 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|7||Anticipated|81|||Male|60 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062711||126876|
NCT01062958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-001|A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy|A Retrospective Analysis of Neevo® and Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy (N-001)||Pamlab, Inc.|No|Completed|December 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|100|||Female|21 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant Women Who Received Neevo®/Neevo® DHA or Another Standard Prenatal Vitamin|April 2013|April 12, 2013|February 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01062958||126857|
NCT01063491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001|Cardiac CAtheterization for Bypass Graft Patency Rate Optimization: the CABG-PRO Randomized-controlled Pilot Study|Cardiac CAtheterization for Bypass Graft Patency Rate Optimization: the CABG-PRO Randomized-controlled Pilot Study|CABG-PRO|North Texas Veterans Healthcare System|Yes|Active, not recruiting|February 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063491||126816|
NCT01063790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24390|The Effect of an Individualized Education Intervention on Pain Following Inguinal Hernia Repair Surgery|The Effect of an Individualized Education Intervention Versus Usual Care on Pain Following Ambulatory Inguinal Hernia Repair|HREI|University of Toronto|No|Completed|October 2009|July 2012|Actual|January 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|82|||Male|18 Years|90 Years|No|||July 2012|July 13, 2012|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063790||126793|
NCT01063777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03c-2009-NAR|Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis. Long-term Follow-up.|Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis. Long-term Follow-up of a Prospective, Randomized Controlled Intervention Study.||Oslo University Hospital|No|Active, not recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|40 Years|80 Years|No|||August 2012|August 17, 2012|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063777||126794|
NCT01061112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812M56082|Effects of Genotype on CYP2C9 Drug Interactions|Effects of Genotype on CYP2C9 Drug Interactions||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|December 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are selected from a pharmacogenetics registry in which their drug metabolism        genotype has been determined.|November 2013|November 12, 2013|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01061112||126998|
NCT01048346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999999|Efficacy of the Individual Placement and Support (IPS) Model|Efficacy of the Individual Placement and Support (IPS) Model for Consumers With Disability and Substance Use Disorders||Wright State University|Yes|Active, not recruiting|December 2004|May 2009|Anticipated|May 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|192|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2005|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048346||127972|
NCT01048333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5127C00001|Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®|A Randomised, Placebo-controlled, Double-blind (Double-dummy Technique),Crossover, Multi-centre Study, to Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler® 9 μg, Compared With Serevent® Diskus® 50 μg.||AstraZeneca|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|109|||Both|40 Years|N/A|No|||September 2012|September 25, 2012|January 12, 2010|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT01048333||127973|
NCT01060280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-DO 30|Effectiveness of Group GDS and Individual GDS for Treatment of Low Back Pain in Primary Care|The Effectiveness of the Physiotherapy Techniques Group GDS and Individual GDS for the Treatment of Nonspecific Low Back Pain in Primary Care. A Cluster, Randomized, Controlled Trial.||Kovacs Foundation|Yes|Completed|May 2010|September 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|461|||Both|18 Years|65 Years|No|||August 2014|August 15, 2014|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060280||127062|
NCT01060488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP24689|Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency|A Phase III, Multicentric, Open-label, Randomised, Comparative, Parallel Group Study of (GHRH + Arginine) Combination Test vs. Insulin Tolerance Test (ITT) in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)||Merck KGaA|No|Completed|January 2004|||November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|69|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2011|August 4, 2014|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060488||127046|
NCT01060761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMS-SDU- 2009-1|Involvement of Patients and Relatives in the Course of Cancer Disease|Involvement of Patients and Relatives in the Course of Cancer Disease With a Particular View to Rehabilitation and the Life With Cancer|KRIPP|University of Southern Denmark|No|Completed|March 2010|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|42|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060761||127025|
NCT01061060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BER-CL-AKR-2009-01|The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients|The Effect of Prostaglandin I2 (Beraprost Na), Administered Orally for Eight Weeks, on the Endothelial Cell Functional Disorder in Type II Diabetes Mellitus Patients With Symptoms of a Minute Peripheral Blood Flow Disorder||Yonsei University|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|45 Years|N/A|No|||February 2016|February 11, 2016|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061060||127002|
NCT01061333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-176|Early Airway Response to Allergen in Asthmatics (MK-0000-176)|A Two-Part, Randomized, Placebo-Controlled, Crossover Trial to Evaluate the Differential Effects of Inhaled Nedocromil, Oral Montelukast, and Inhaled Mometasone on Markers of the Early Airway Response to Allergen in Asthmatics||Merck Sharp & Dohme Corp.|No|Completed|June 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|55 Years|No|||September 2015|September 3, 2015|February 1, 2010|No|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT01061333||126981|
NCT01061593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRTBD-2259|Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV|Phase III, Double-blind, Placebo-controlled, Randomized, 1-month Clinical Trial of Immunoxel Combined With Anti-TB Therapy Versus Anti-TB Therapy With Placebo||Lisichansk Regional Tuberculosis Dispensary|No|Completed|January 2010|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061593||126961|
NCT01061346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 29025|Effect of Dietary Fat When Eaten With Fructose Versus Glucose|Effect of Dietary Fat When Eaten With Fructose vs. Glucose on Insulin Resistance and Liver Fat|Fructose|Pennington Biomedical Research Center|No|Completed|October 2009|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|19|||Both|28 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061346||126980|
NCT01061619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO 12|Pathway to Diagnosis of Ovarian Cancer|Pathway to Diagnosis of Ovarian Cancer: Observational Retrospective Multicenter Study|MITO-12|National Cancer Institute, Naples|No|Active, not recruiting|January 2010|September 2016|Anticipated|April 2016|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|400|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with confirmed diagnosis of ovarian cancer, presenting for first-line        chemotherapy|January 2016|January 22, 2016|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061619||126959|
NCT01061879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11973|Expansion of Umbilical Cord Blood Using a Unique Bio-system|Ex Vivo Expansion of Umbilical Cord Blood Using a Unique Bio-system||University of Kansas Medical Center|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|N/A||1|Actual|8|Samples With DNA|umbilical cord|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|umbilical cord collection from full-term caesarian section/normal vaginal delivery        patients|December 2012|December 28, 2012|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061879||126939|
NCT01062165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTHSC-A09-3566|Effect of Weight and/or Obesity on Caspofungin Drug Concentrations|Population Pharmacokinetic Analysis of Caspofungin in Overweight and Obese Volunteers||Texas Tech University Health Sciences Center|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|February 2, 2010||No||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01062165||126918|
NCT01062178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0512-CE|Efficacy of Ultrasound Contrast Agent to Assess Renal Masses|The Comparison of Accuracy of Contrast Enhanced Ultrasound on Diagnosis of Small Renal Masses and Distinguishing Renal Cell Carcinomas From Other Renal Masses, With Biopsy||University Health Network, Toronto|Yes|Completed|October 2009|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|167|||Both|N/A|N/A|No|||March 2016|March 7, 2016|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01062178||126917|
NCT01063296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM2010-02|Effects of Chemotherapy on Circulating Tumor Cells and Recurrences in Cervical Cancer Patients|Effects of Chemotherapy on Circulating Tumor Cells and Recurrences in IB-IIA Cervical Cancer Patients With Intermediate Risk Factors After Radical Surgery||Huazhong University of Science and Technology|Yes|Not yet recruiting|March 2010|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|sampling of peripheral blood|Female|18 Years|70 Years|No|Probability Sample|Patients with histologically confirmed Ib~IIa cervical carcinoma without previous        treatments|January 2010|February 8, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063296||126831|
NCT01062724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-785-080|Total Parenteral Nutrition Associated Cholestasis (TPNAC) and Plasma Amino Acid Levels in Neonates|Effect of Two Amino Acid Solutions on Blood Amino Acid Levels and Frequency of Cholestasis in Neonates|TPNAC|Coordinación de Investigación en Salud, Mexico|Yes|Active, not recruiting|February 2011|May 2016|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|N/A|28 Days|No|||February 2016|February 8, 2016|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062724||126875|
NCT01062971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOPHIA-PRO-122|Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide|Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination of Timolol-Brimonidine-Dorzolamide In Patients With Open Angle Glaucoma Or Ocular Hypertension||Laboratorios Sophia S.A de C.V.|Yes|Completed|February 2006|June 2008|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|90 Years|No|||February 2010|February 3, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062971||126856|
NCT01063283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-014-B|Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC|A Randomized, Open-Label, Dose Escalation Study of Bevacizumab With Ambulatory Blood Pressure Monitoring in Previously Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer|AVF4759|University of Chicago|Yes|Active, not recruiting|March 2010|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|89 Years|No|||June 2015|June 22, 2015|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063283||126832|
NCT01060098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2104091|T Cells and TNF: The Impact of TNF Blockade|T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents||Imperial College London|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|52|||Both|18 Years|80 Years|No|Non-Probability Sample|Primary care clinic|September 2011|March 23, 2015|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060098||127076|
NCT01060332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|grb03484888|The Body Constitution and Quality of Life of Diabetic|The Body Constitution and Quality of Life of Diabetic||Taichung Veterans General Hospital|Yes|Recruiting|January 2010|July 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Health Center for Diabetic Patient|March 2010|March 25, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060332||127058|
NCT01059812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3597|A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes|A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL)|BOOST™|Novo Nordisk A/S|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|424|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 29, 2010|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01059812||127097|
NCT01061671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|689|Simvastatin Therapy for Moderate and Severe COPD|Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)|STATCOPE|University of Minnesota - Clinical and Translational Science Institute|Yes|Terminated|March 2010|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|885|||Both|40 Years|80 Years|No|||March 2015|March 12, 2015|February 2, 2010|Yes|Yes|Futility|No|January 29, 2015|https://clinicaltrials.gov/show/NCT01061671||126955|Early termination by the Data and Safety Monitoring Board due to futility in respect to a treatment effect. The original study population goal was 1200 and the study was terminated at 885 participants.
NCT01048580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perifosine 141|Study of Perifosine + Capecitabine for Colon Cancer Patients|A Phase I Study of Perifosine + Capecitabine for Patients With Advanced Colon Cancer||AEterna Zentaris|No|Completed|October 2009|October 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2011|February 14, 2014|January 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048580||127954|
NCT01048567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIHA2009-82|Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly|Use of Lactobacillus Acidophilus/Rhamnosus Complex for the Prevention of Antibiotic-associated Diarrhea in Elderly Hospitalized Patients||Vancouver Island Health Authority|No|Terminated|September 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|7|||Both|60 Years|N/A|No|||December 2013|December 17, 2013|January 12, 2010||No|Insufficient resources to meet enrollment target|No||https://clinicaltrials.gov/show/NCT01048567||127955|
NCT01060293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3975|Dopamine in Acute Decompensated Heart Failure II|Comparison of High-dose Furosemide, Low-dose Furosemide, and the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure|DAD-HF II|Larissa University Hospital|No|Terminated|July 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|161|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|February 1, 2010||No|Safety issues in the LDFD-group (higher heart rate with dopamine)|No||https://clinicaltrials.gov/show/NCT01060293||127061|
NCT01060501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOGT1|Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer|Phase 3 Study of Adjuvant Chemoradiotherapy of Advanced Resectable Rectal Cancer Comparing Modulation of 5-FU With Folinic Acid or With Interferon-alpha|FOGT1|University of Ulm|Yes|Completed|July 1992|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|796|||Both|18 Years|N/A|No|||July 1991|February 1, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060501||127045|
NCT01060774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043039|Bupivacaine Versus Lidocaine on Inflammatory Regulation Following Endodontic Surgery|Comparison of Bupivacaine vs Lidocaine on Inflammatory Regulation Following Endodontic Surgery: A Double-Blind, Randomized, Controlled Clinical Trial||University of Maryland|No|Completed|July 2008|July 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|11|||Both|18 Years|65 Years|No|||July 2013|July 9, 2013|January 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01060774||127024|
NCT01061073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJ Alpha 2009|Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial|Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial||Poitiers University Hospital|No|Recruiting|February 2010|||March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||March 2010|March 2, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01061073||127001|
NCT01061086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CGR-DUM-2009/1|An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study|An Epidemiological Study of Acute Coronary Syndromes in The Greek Population|TARGET|AstraZeneca|No|Completed|January 2010|February 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|418|||Both|18 Years|N/A|No|Probability Sample|Emergency Room|December 2011|December 20, 2011|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061086||127000|
NCT01061905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WhartonAramark-BehavEcon-2|Behavioral Economics and Food Choice|Behavioral Economics Concepts Influencing Healthy Food Choice - Pilot 2||University of Pennsylvania|No|Completed|February 2010|June 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|4|||Both|N/A|N/A|No|||November 2011|November 11, 2011|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01061905||126938|
NCT01061918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tecnis MF/Restor|Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses|Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses||Innovative Medical|No|Completed|August 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2011|February 16, 2011|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061918||126937|
NCT01062191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-C-6U1101|Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl|Flexible Hydrogel Nanoparticle Wound Dressing Allows Greater Joint Range of Motion Compared to Typical Sodium Carboxymethylcellulose Dressing|ROM|ULURU|Yes|Terminated|May 2007|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3|||Both|2 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 7, 2011|February 2, 2010||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01062191||126916|
NCT01062737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR 2898|Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis|Evaluation of the Structure-modifying Effect and Safety of Avocado-Soybean Unsaponifiable (Piascledine 300) in Hip Osteoarthritis (OA) a 3 Years Multicenter Randomized, Double Blind, Placebo Controlled Trial|ERADIAS|Laboratoires Expanscience S.A.|No|Completed|December 1999|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|N/A|1||||||Both|45 Years|75 Years|No|||February 2010|February 3, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062737||126874|
NCT01062984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 15947A|Continuous Venovenous Hemofiltration Versus Continuous Venovenuous Hemodialysis|A Comparison of the Efficacy of Continuous Venovenous Hemofiltration Versus Continuous Venovenous Hemodialysis for Renal Replacement Therapy in Acute Kidney Injury||University of Chicago|No|Active, not recruiting|January 2009|September 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062984||126855|
NCT01060111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR011944|An Efficacy and Tolerability Study of Topiramate in Participants With Migraine|Adequate Therapy of Topiramate in Migraine||Janssen Korea, Ltd., Korea|No|Completed|July 2006|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|65 Years|No|||August 2013|August 14, 2013|January 29, 2010|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT01060111||127075|
NCT01063504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTHKnee|Teriparatide for Improved Knee Prosthesis Fixation|||University Hospital, Linkoeping|Yes|Completed|February 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|60 Years|80 Years|No|||June 2013|June 17, 2013|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063504||126815|
NCT01063517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00039|Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients|A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy||AstraZeneca|No|Active, not recruiting|February 2010|December 2016|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|267|||Both|18 Years|150 Years|No|||January 2016|January 19, 2016|February 4, 2010|Yes|Yes||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01063517||126814|
NCT01063803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3242K1-2003|Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis|An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis||Ablynx|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|80 Years|No|||January 2013|January 30, 2013|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063803||126792|
NCT01059825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-016|Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)|A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Merck Sharp & Dohme Corp.|No|Completed|March 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|328|||Both|18 Years|70 Years|No|||May 2015|May 6, 2015|January 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059825||127096|
NCT01060826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-003338-41|Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Randomized, Double-blind Study to Evaluate the Efficacy of Administration With Intravenous Bolus Followed by a Continuous Infusion of Somatostatin in the Prevention of Post-ERCP Pancreatitis|crepsmt1|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|May 2009|May 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|510|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060826||127020|
NCT01061125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPAF-A|Implantable Loop Recorders in Post-atrial Fibrillation (AF) Ablation: RPAF-A|Implantable Loop Recorders in Post-AF Ablation: RPAF-A|RPAF-A|The Cleveland Clinic|Yes|Completed|January 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|68|||Both|18 Years|100 Years|No|Probability Sample|Patients presenting for atrial fibrillation ablation|January 2016|January 29, 2016|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061125||126997|
NCT01060527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xi'an JTU091202|Altered Faecal Protease Activity in Irritable Bowel Syndrome Patients in China|||Xi’an Jiaotong University College of Medicine||Enrolling by invitation|January 2010|||||N/A|Observational|Observational Model: Case Control||3|Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Outpatients in the second affiliated hospital of xi'an jiaotong university|January 2010|February 1, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060527||127043|
NCT01060813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-AMI-2009-17|Study of the Benefit of Exercise and Aminoacid Supplements in Cirrhotic Patients|Study of the Benefit of Exercise and Aminoacid Supplements in Cirrhotic Patients||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|January 2010|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|80 Years|No|||September 2011|August 20, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060813||127021|
NCT01061684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD Pediatric Database 2|NAFLD Pediatric Database 2|Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Database 2|NAFLD Peds DB2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|December 2009|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|850|Samples With DNA|plasma, serum, liver tissue|Both|2 Years|17 Years|No|Non-Probability Sample|Participants at least 2 years of age and less than 18 years of age with known or suspected        NAFLD or NASH-related cirrhosis|April 2015|April 15, 2015|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061684||126954|
NCT01049074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKH 081|A Random Controlled Test (RCT): Acupuncture Treatment on Nonspecific Low Back Pain (NLBP)|A Random Controlled Test (RCT): Acupuncture Treatment on Nonspecific Low Back Pain (NLBP) (ANLBP)|ANLBP|Beijing Hospital of Traditional Chinese Medicine|Yes|Recruiting|November 2008|November 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|534|||Both|18 Years|79 Years|No|||November 2008|March 18, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049074||127916|
NCT01048801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTUGA2|Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria|Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria: Comparative Trials in Two Areas of High and Low Transmission in Uganda|ACTUGA2|DBL -Institute for Health Research and Development|Yes|Completed|March 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2000|||Both|5 Months|59 Months|No|||October 2012|October 11, 2012|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048801||127937|
NCT01060787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440|Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant|An Observational Bilateral Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant for at Least One Year||Bausch & Lomb Incorporated|No|Recruiting|August 2006|July 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|6 Years|N/A|No|Probability Sample|Subjects having the fluocinolone acetonide intravitreal implant (0.59 or 2.1 mg) in only        one eye for at least one (1) year.|February 2015|February 13, 2015|January 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060787||127023|
NCT01060800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011231|The Genetics of Chiari Type I Malformation|The Genetics of Chiari Type I Malformation (CMI) With or Without Syringomyelia||Duke University|No|Active, not recruiting|June 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|2000|Samples With DNA|Whole blood, serum, DNA|Both|N/A|N/A|No|Non-Probability Sample|Families who have TWO OR MORE family members with Chiari Type I Malformation, with or        without syringomyelia. These family members must be related to each other by blood, and        BOTH must be willing to participate.|August 2015|August 26, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060800||127022|
NCT01061099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-4-5947|Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta|A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta|STOD3|Nationwide Children's Hospital|No|Completed|February 2010|February 2014|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|N/A|19 Years|No|||April 2015|April 23, 2015|February 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061099||126999|
NCT01061359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|378-ONC-0030-0144|Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer|Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))||Pfizer|No|Completed|January 1999|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1981|||Female|N/A|N/A|No|Non-Probability Sample|Female patients with primary breast cancer|December 2010|December 16, 2010|February 1, 2010||No||No|October 14, 2010|https://clinicaltrials.gov/show/NCT01061359||126979|
NCT01061372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081184|12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects|Randomized Double-Blind, 12-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome||Pfizer|No|Withdrawn|May 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||June 2010|June 28, 2010|February 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061372||126978|
NCT01061645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOC31-PE|Study of MOC31-PE in Antigen Positive Carcinomas|Phase I Study of MOC31-PE in Antigen Positive Carcinomas||Oslo University Hospital|No|Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||May 2012|May 3, 2012|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061645||126957|
NCT01063530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000054110|Effects of DIammine SIlver Fluoride on Tooth Sensitivity|Effects of DIammine SIlver Fluoride Placed Over Cervical Lesions of Permanent Teeth to Reduce Tooth Sensitivity||Universidad Peruana Cayetano Heredia|Yes|Not yet recruiting|February 2010|April 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|50 Years|No|||February 2010|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063530||126813|
NCT01063816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-758|A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors|A Phase 1 Study of Veliparib in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors||AbbVie|No|Active, not recruiting|January 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|99 Years|No|||February 2016|February 17, 2016|February 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01063816||126791|
NCT01063829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIC246-01-II-02|Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients|A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug||AiCuris Anti-infective Cures GmbH|Yes|Completed|February 2010|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|133|||Both|18 Years|N/A|No|||December 2010|January 28, 2013|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063829||126790|
NCT01059838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005368|Speech Perception for Children With Cochlear Implants|Speech Perception in Noise for Children With Cochlear Implants||Mayo Clinic|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|4 Years|17 Years|No|||July 2011|July 15, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059838||127095|
NCT01060124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012256|An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics|Use of Durogesic D-TRANS in Cancer Pain Patients With Inadequately Controlled Pain Relief From Weak Opioids||Janssen Korea, Ltd., Korea|No|Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|20 Years|N/A|No|||April 2014|April 10, 2014|January 29, 2010|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT01060124||127074|
NCT01060345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-151-B|A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ|A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS)||University of Chicago|No|Terminated|May 2010|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|32|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|January 29, 2010|No|Yes|Drug no longer available|No||https://clinicaltrials.gov/show/NCT01060345||127057|
NCT01060540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD 09-039|Genetic Testing for Type 2 Diabetes|The Impact of Genetic Testing for Type 2 Diabetes on Health Behaviors||VA Office of Research and Development|No|Completed|August 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|601|||Both|21 Years|65 Years|No|||April 2014|April 6, 2015|January 29, 2010||No||No|April 16, 2014|https://clinicaltrials.gov/show/NCT01060540||127042|
NCT01060839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-001|Evaluation of Counseling for Partner Notification|Evaluation of Partner Notification for Sexually Transmitted Infections in Bangladesh|PN|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|April 2006|December 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1339|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060839||127019|
NCT01060852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44DA016044|Evaluation of the Media Detective Program for Elementary School-Aged Children to Prevention Substance Use|Randomized Controlled Trial Efficacy Study of a Media Literacy Education Substance Use Prevention Program for Elementary School-Aged Children|MD|Innovation Research & Training|Yes|Completed|March 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|679|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060852||127018|
NCT01061138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#03|Xpress Digital Mammography System Images for Computer Aided Detection Development|A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development||Konica Minolta Medical Imaging, USA|No|Completed|February 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|597|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|To achieve the goal of 107 cases with biopsy-proven cancer, it is expected that        approximatley 720 patients undergoing breast biopsy will need to be enrolled in the study.        In addition, we will enroll up to 330 patients from a screening population.|December 2012|December 3, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061138||126996|
NCT01061398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU#08-12032|CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification|CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification|CT-FIRST|Walter Reed Army Medical Center|Yes|Active, not recruiting|November 2007|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|240|||Both|18 Years|70 Years|No|||June 2012|June 27, 2012|February 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061398||126976|
NCT01061996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSX-002|Basiliximab Maintenance in Ulcerative Colitis|An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis||Cerimon Pharmaceuticals|No|Terminated|July 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|75 Years|No|||February 2010|February 2, 2010|February 2, 2010||No|lack of efficacy|No||https://clinicaltrials.gov/show/NCT01061996||126931|
NCT01062256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GG-09-06|Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections|A Methodology Study to Assess Cough Counts in Subjects With Acute Upper Respiratory Tract Infections||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|265|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|February 1, 2010|Yes|Yes||No|February 9, 2011|https://clinicaltrials.gov/show/NCT01062256||126911|
NCT01048840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-PediGERD|Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age|The Natural History of Children With Gastroesophageal Reflux Disease (Ages 15 Months to 11 Years)||Massachusetts General Hospital|No|Active, not recruiting|September 2004|December 2014|Anticipated|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|100|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects will be selected from a database of patients seen at Children's Hospital,        Boston or Massachusetts General Hospital between 1977 and 1990 who had biopsies or pH        probe for symptoms of GERD.|October 2013|October 23, 2013|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01048840||127934|
NCT01049308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-166|Cognitive Problems in Veterans With Heart Failure|Cognitive Impairment as a Risk for the Admission-Readmission Cycle Seen in Veterans With Heart Failure: Closing the Adherence Gap||VA Office of Research and Development|No|Completed|February 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|veteran patients enrolled in outpatient heart failure clinic|August 2014|April 6, 2015|January 12, 2010||No||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01049308||127898|
NCT01062997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-09101a 2009/2172|Volar Locked Plating Versus Bridging External Fixation|Volar Locked Plating Versus Bridging External Fixation||University Hospital, Akershus||Active, not recruiting|September 2009|April 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|70 Years|No|Probability Sample|All patients between the age of 18 and 70 diagnosed with a C2- or C3-type fracture|January 2016|January 8, 2016|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01062997||126854|
NCT01063010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-000036|Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock|Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock||Beth Israel Deaconess Medical Center|Yes|Withdrawn|February 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|February 3, 2010|Yes|Yes|no participants enrolled|No||https://clinicaltrials.gov/show/NCT01063010||126853|
NCT01063309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100029|Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System|Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System||National Institutes of Health Clinical Center (CC)||Recruiting|December 2009|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|September 24, 2015|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063309||126830|
NCT01063543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601069|Pharmacokinetics of Fondaparinux in Patients With Major Orthopedic Surgery|Population Pharmacokinetics of Fondaparinux Administered at Prophylactic Doses After Major Orthopedic Surgery in Everyday Practice|POP-A-RIX|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2004|February 2007|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|997|Samples Without DNA|blood sample for anti-Xaactivity measure|Both|18 Years|90 Years|No|Non-Probability Sample|patients with major orthopedic surgery who need prophylactic doses of fondaprinux|February 2010|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063543||126812|
NCT01063556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-107|Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.|Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.||Eisai Inc.||Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|20 Years|79 Years|No|||November 2010|May 13, 2013|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01063556||126811|
NCT01063842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR004990|A Study of the Tolerability of Titrated Dose Tramadol/Acetaminophen Combination Tablet in Korean Patients With Osteoarthritis|Tolerability Improvement of Tramadol/Acetaminophen (Ultracet) by Titration in Korean OA Patients:Multicenter, Randomized, Double-blind Study||Janssen Korea, Ltd., Korea||Completed|August 2005|May 2006|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|250|||Both|35 Years|75 Years|No|||February 2010|February 4, 2010|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01063842||126789|
NCT01059851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-023|Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4305 in Patients With Impaired Renal Function||Merck Sharp & Dohme Corp.|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|January 28, 2010|No|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01059851||127094|
NCT01059864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921109|Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550|Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis||Pfizer|Yes|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||November 2012|November 14, 2012|January 28, 2010|Yes|Yes||No|November 14, 2012|https://clinicaltrials.gov/show/NCT01059864||127093|
NCT01059877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMF-MID12610|Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia|Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.||Quietmind Foundation|Yes|Completed|January 2010|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|11|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059877||127092|
NCT01059890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-BRAIN|Cerebral Antibiotics Distribution After Acute Brain Injury|||Poitiers University Hospital|No|Recruiting||||||Phase 1|Interventional|N/A|4||||||Both|18 Years|N/A|No|||January 2010|January 29, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01059890||127091|
NCT01060358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0063|Assessment of Spinal Stability|Neuromuscular Neutral Zones in Humans: A New Method to Assess Spinal Stability||University of Colorado, Denver|Yes|Completed|August 2009|November 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|21 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Healty men and women between 21 and 45 years old with no history of low back pain of low        back injury.|January 2010|February 5, 2013|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060358||127056|
NCT01060553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 09-258|Pilot of Acupuncture to Improve Quality of Life in Veterans With TBI and PTSD|Pilot of Acupuncture to Improve Quality of Life in Veterans With TBI and PTSD||VA Office of Research and Development|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|69 Years|No|||August 2014|April 6, 2015|January 29, 2010||No||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01060553||127041|very small numbers of subjects due to dropout and loss to followup. data from the wait list subjects who completed the intervention were combined with those initially assigned to treatment for a pre/post single group analysis
NCT01060865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AIL02T|Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements|Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation|REALITY|Meir Medical Center|Yes|Terminated|March 2010|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||May 2011|May 5, 2013|February 1, 2010|Yes|Yes|The participants signed by mistake an old version of the informed consent. Their participation    was annulated, and the study was stopped|No||https://clinicaltrials.gov/show/NCT01060865||127017|
NCT01061151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1077BF (PROMISE)|Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries|Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)|PROMISE|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|March 2011|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|3485|||Both|N/A|N/A|No|||November 2015|November 2, 2015|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061151||126995|
NCT01061424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HL087769-01A1|The Community United to Challenge Asthma|A Community-Academic Partnership to Improve Asthma Management in Latino Children|Project CURA|Rush University Medical Center|No|Completed|October 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|5 Years|N/A|No|||August 2012|August 13, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061424||126974|
NCT01061437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0701|S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)|A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori||Southwest Oncology Group|Yes|Completed|June 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1859|||Both|21 Years|65 Years|No|||September 2012|September 24, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061437||126973|
NCT01061411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 145508|Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery|Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma||Roswell Park Cancer Institute|Yes|Active, not recruiting|February 2010|||November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061411||126975|
NCT01048385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoQ10-IVF|The Effect of Co Enzyme Q10 Together With Fertility Drugs on Pregnancy Outcome of in Vitro Fertilization|The Effect of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome of IVF|CoQ10-IVF|University of Toronto|No|Terminated|December 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|34|||Female|35 Years|43 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|January 11, 2010||No|A new study had shown that polar body biopsies might negatively effect the implantation    potential of the embryo.|No||https://clinicaltrials.gov/show/NCT01048385||127969|
NCT01048619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-01|Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome|Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome||Onconova Therapeutics, Inc.|No|Completed|December 2009|December 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01048619||127951|
NCT01048827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82516|Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen|A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation|Busulfan|University of California, San Francisco|Yes|Active, not recruiting|November 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|69 Years|No|||January 2015|January 26, 2015|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01048827||127935|
NCT01048866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH 0913|A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis|A Repeat-Dose, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Study to Determine the Safety and Efficacy of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis||Reckitt Benckiser LLC|Yes|Completed|November 2009|||March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048866||127932|
NCT01049113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-013105-01|Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia|Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia||Onconova Therapeutics, Inc.|No|Terminated|November 2009|December 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 11, 2010|No|Yes|Lack of available clinical drug supply|No||https://clinicaltrials.gov/show/NCT01049113||127913|
NCT01049087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-112|Plasma Volume Determination by 99mTc-labeled Albumin and 125I-labeled Albumin|Comparison of Plasma Volume Determination by 99mTc-labeled Albumin and 125I-labeled Albumin||Roskilde County Hospital|Yes|Completed|January 2012|December 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2010|March 19, 2013|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049087||127915|
NCT01049321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DASH and cardiovascular risks|The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients|||Isfahan University of Medical Sciences|Yes|Completed|December 2008|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|44 Years|70 Years|No|||March 2008|January 13, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049321||127897|
NCT01062204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-6U1102|Altrazeal™ Versus Aquacel® Ag for Partial Thickness Skin Donor Sites|A Randomized Comparison Study of a Flexible HydrogelNanoparticle Wound Dressing (Altrazeal) Versus a Sodium Carboxymethylcellulose Dressing (Aquacel Ag) as Dressings for Partial Thickness Skin Graft Donor Sites||ULURU|Yes|Completed|May 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|3 Years|85 Years|No|||February 2010|February 3, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062204||126915|
NCT01062217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-8U1207|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2008|||||N/A|N/A|N/A||||||||||||||February 3, 2010|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062217||126914|
NCT01062503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-0688-C|Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC|Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer|SubDueP|University Health Network, Toronto|No|Completed|January 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|||Male|18 Years|N/A|No|Probability Sample|This is a non-randomized observational study|April 2015|April 24, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062503||126892|
NCT01062750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1132|Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells|Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells||Kanazawa University|No|Completed|October 2012|May 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|20 Years|80 Years|No|||September 2015|September 4, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062750||126873|
NCT01062763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2009-017033-22|The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension|South Danish Hypertension and Diabetes Study|SDHDS|Odense University Hospital|No|Completed|March 2010|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|75 Years|No|||April 2014|April 8, 2014|February 3, 2010||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01062763||126872|
NCT01063023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-019|Drug Interaction Oral Contraceptive Pill (OCP)|Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects||Bristol-Myers Squibb|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2010|January 24, 2011|February 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01063023||126852|
NCT01063036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-203|Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment|A Study of the Safety and Efficacy of Entecavir Plus Tenofovir in Adults With Chronic Hepatitis B Virus Infection With Previous Nucleoside/Nucleotide Treatment Failure||Bristol-Myers Squibb|No|Completed|May 2010|February 2014|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|February 3, 2010|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT01063036||126851|
NCT01063582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMendezV001|Noise, a Risk for Heart in Airplane Pilots|Noise of Airplanes a Factor of Risk for the Health of the Heart in Pilots and Crew in Operations of the F16 Airplane||Universidad Politecnica de Madrid|Yes|Enrolling by invitation|February 2005|December 2010|Anticipated|September 2005|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|16|||Male|26 Years|37 Years|No|Non-Probability Sample|Group of subjects directly exposed to noise from military aircraft F-16 during its        operation and maintenance at the airbase Vicente Landaeta Gil de Barquisimeto. Lara.        Venezuela|January 2007|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063582||126809|
NCT01063855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016486|Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor|COUPLE|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2010|September 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|495|||Male|18 Years|N/A|No|||January 2013|January 16, 2013|February 4, 2010||No||No|October 4, 2012|https://clinicaltrials.gov/show/NCT01063855||126788|
NCT01060137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012259|Fentanyl Matrix in Lung Cancer Pain|Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients||Janssen Korea, Ltd., Korea||Completed|May 2006|May 2007|Actual|May 2007|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|268|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060137||127073|
NCT01060566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-770-010|Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770|An Open-Label Phase 1 Study to Examine the Effect of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 in Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|February 2010|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 15, 2010|January 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01060566||127040|
NCT01060579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-12286-CS202|Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure|A Phase 2, Double-masked, Randomized, Active-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure||Aerie Pharmaceuticals|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|217|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|January 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060579||127039|
NCT01061450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Statin_DD|Simvastatin and Diastolic Dysfunction|Effect of the Addition of Simvastatin to Enalapril in Hypertensive Individuals With Average Cholesterol Levels and Diastolic Dysfunction||Brasilia Heart Study Group|Yes|Completed|November 2006|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|40 Years|65 Years|No|||February 2010|February 2, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061450||126972|
NCT01061710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051117|Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)|Champix Tablets Special Investigation -Retrospective Survey For Subjects Who Have Been Retreated With Champix.-(Regulatory Post Marketing Commitment Plan).||Pfizer|No|Completed|July 2010|February 2014|Actual|February 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|||Both|N/A|N/A|No|Probability Sample|The subjects who have been retreated with varenicline in A3051109 (NCT# NCT00772941)        within 52 weeks of initial treatment.|January 2015|January 27, 2015|February 1, 2010|No|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01061710||126952|
NCT01061723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI11073|Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis|A Randomized Double Blind-placebo Controlled Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 in Patients With Ankylosing Spondylitis (AS)|ALIGN|Sanofi|Yes|Completed|February 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|301|||Both|18 Years|75 Years|No|||August 2012|August 2, 2012|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061723||126951|
NCT01061697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2006/072/A|Pregabalin and Radicular Pain Study (PARPS)|Open Labelled Study of Pregabalin in the Treatment of Neuropathic Pain in Cervical Myeloradiculopathy (Pregabalin and Radicular Pain Study (PARPS))|PARPS|Singapore General Hospital|No|Completed|January 2008|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|80 Years|No|||July 2011|July 4, 2011|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061697||126953|
NCT01061983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000204|Electrical Stimulation of the Internal Capsule for Intractable Obsessive-compulsive Disorder (OCD)|Electrical Stimulation of the Internal Capsule for Intractable OCD||Butler Hospital|Yes|Completed|January 2001|October 2012|Actual|April 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|55 Years|No|||February 2013|February 21, 2013|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061983||126932|
NCT01048632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 41510|Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants|A Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants After Cardiac Surgery||University of Utah|Yes|Recruiting|July 2010|May 2018|Anticipated|May 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|1 Month|No|||December 2015|December 3, 2015|January 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01048632||127950|
NCT01048853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0118|Conservative Surgery for Women With Cervical Cancer|Conservative Surgery for Women With Low-risk, Early Stage Cervical Cancer||M.D. Anderson Cancer Center|No|Recruiting|August 2009|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|195|||Female|N/A|N/A|No|||March 2016|March 23, 2016|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048853||127933|
NCT01049373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC144/03|Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain|Efficacy and Safety of Lymphdiaral Basistropfen (a Fixed Homoeopathic Remedy [HDC]) in the Treatment of Chronic Low-back Pain Considering Constitution and Diathesism: a Double Blind, Randomised, Placebo Controlled, Single-centre Study|144|Pascoe Pharmazeutische Praeparate GmbH|No|Completed|December 2003|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|75 Years|No|||June 2012|August 3, 2012|January 12, 2010||No||No|May 10, 2012|https://clinicaltrials.gov/show/NCT01049373||127893|
NCT01049100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108771|Surgical Staging in Cervical Cancer Prior to Chemoradiation|Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation|uterus11|Charite University, Berlin, Germany|Yes|Recruiting|April 2009|April 2017|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|70 Years|No|||August 2009|January 14, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049100||127914|
NCT01062230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI35813|Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma||University of Arkansas|Yes|Terminated|January 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|February 2, 2010||No|Slow accrual; PI left primary institution|No|September 24, 2014|https://clinicaltrials.gov/show/NCT01062230||126913|Complete data was not received from the primary institution for all six patients enrolled. Data available is represented.
NCT01062529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2008005|Peripheral Metabolic Effects of Somatostatin|Peripheral Metabolic Effects of Intra Arterial Somatostatin Infusion in Healthy Controls||University of Aarhus|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01062529||126890|
NCT01062516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC 2007-176 VerifyNow|Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin|Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin||Ruttonjee Hospital|Yes|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2010|October 2, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062516||126891|
NCT01063049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220100180|Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation|Gatorade/Miralax With or Without Bisacodyl vs NuLytely for Colonoscopy Preparation||Gastroenterology Services, Ltd.|Yes|Completed|February 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 15, 2013|February 3, 2010|Yes|Yes||No|August 20, 2013|https://clinicaltrials.gov/show/NCT01063049||126850|Both the BBPS and OPS suffer from poorly designed scoring systems that are not easily converted into the poor/fair/good/excellent subjective rating scale, which is often used by gastroenterologists in their colonoscopy reports.
NCT01063868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016978|A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)|A One-Year, Randomized, Open-Label, Parallel-Group, Multiple-Dose Long-Term Safety Study With Controlled Adjustment of Dose of Tapentadol Extended-Release (ER) and Oxycodone Controlled-Release (CR) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|January 2010|June 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||January 2013|January 30, 2014|February 4, 2010|Yes|Yes|Business decision|No|April 14, 2011|https://clinicaltrials.gov/show/NCT01063868||126787|Early termination, due to sponsor's discretion, lead to only 47 patients out of the 800 planned (5.9%) being available for analysis. The data should be interpreted with caution.
NCT01063322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100039|New Techniques to Evaluate Mitral Regurgitation|New Techniques to Evaluate Mitral Regurgitation||National Institutes of Health Clinical Center (CC)||Recruiting|January 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|21 Years|N/A|No|||May 2015|June 5, 2015|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063322||126829|
NCT01063569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.2007.2343|Glucocorticoid Treatment in Addison's Disease|Glucocorticoid Treatment in Addison's Disease||Haukeland University Hospital|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|No|||March 2013|March 19, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01063569||126810|
NCT01060150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015496|An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)|Efficacy and Learning Skill After OROS Methylphenidate Treatment in Adolescents With Attention-Deficit/Hyperactivity Disorder: A 12-week, Multi-center, Open-label Study||Janssen Korea, Ltd., Korea|No|Completed|July 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|12 Years|18 Years|No|||August 2013|August 14, 2013|January 21, 2010|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01060150||127072|
NCT01060163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|the TRACED trial|Tranexamic Acid in Clopidogrel Exposure to Decrease Hemorrhage and Transfusion|Effects of Antifibrinolytics on Bleeding and Transfusion Outcomes in Patients Receiving Coronary Artery Bypass Surgery With Preoperative Clopidogrel Exposure|TRACED|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Completed|January 2010|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|552|||Both|18 Years|85 Years|No|||November 2011|November 21, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01060163||127071|
NCT01060904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-009|A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma|A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma||Seattle Genetics, Inc.|No|Completed|January 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|60 Years|No|||December 2014|December 17, 2014|January 29, 2010|No|Yes||Yes||https://clinicaltrials.gov/show/NCT01060904||127014|
NCT01060917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/0097-Study 4|Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device|A Single Center, Open Study in Order to Prove Hypo- and Hyperglycaemic Episodes Using a Non-invasive Glucose Measuring Method in Healthy Volunteers and in Type 1 Diabetic Patients||Profil Institut für Stoffwechselforschung GmbH|No|Completed|January 2003|May 2003|Actual|March 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|21|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2010|February 1, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060917||127013|
NCT01060371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1NS068897|Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias|Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias||University of Florida|Yes|Recruiting|April 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|800|Samples With DNA|Blood samples collection for DNA analysis and genetic modifier study|Both|6 Years|N/A|No|Non-Probability Sample|The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) is seeking subjects        to participate in a clinical research study of patients with SCA 1, 2 3 and 6.        Potential participants should have symptoms of ataxia with a diagnosis of SCA 1,2,3 or 6        established by DNA tests either on the patient himself or herself or another affected        family member and be between 6 and 80 years of age. In addition, patients who have ataxia        with a dominant inheritance pattern but who do not yet know what type of SCA they have can        also be screened for this project.|December 2015|December 2, 2015|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060371||127055|
NCT01060384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|514-09-FB|Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma||University of Nebraska|Yes|Active, not recruiting|March 2010|January 2020|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||August 2015|August 11, 2015|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01060384||127054|
NCT01060592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02|LapBand Adjustment to Improve Early Weight Loss|Effect on Early Weight Loss by Adjusting Gastric Band During Surgery||Crospon|No|Completed|October 2009|March 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|January 30, 2010|No|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT01060592||127038|
NCT01060878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P58/07CL/ST/09/02|Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)|Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks|CONFIDENT-PD|Phytopharm|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|425|||Both|35 Years|75 Years|No|||March 2013|March 1, 2013|February 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060878||127016|
NCT01060891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLI-POP|Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria|||Poitiers University Hospital|No|Recruiting||||||Phase 1|Interventional|N/A|||||||Both|18 Years|N/A|No|||January 2010|February 1, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060891||127015|
NCT01061164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1074|IMPAACT P1074: Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents|A Prospective Surveillance Study of Long-Term Outcomes in HIV-Infected Infants, Children and Adolescents||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Completed|March 2009|June 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1207|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include participants in PACTG 219C or select IMPAACT treatment        studies.|October 2014|March 23, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061164||126994|
NCT01062022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G188NI|FOCUS-CI: A Preventive Intervention With Children and Families of the Combat Injured|FOCUS-CI: A Preventive Intervention With Children and Families of the Combat Injured|FOCUS-CI|Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Recruiting|January 2011|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|5 Years|N/A|No|||March 2015|March 18, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01062022||126929|
NCT01062295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|conductores|Efficacy and Safety of the Device Siesta-SystemTM for Inducing Objective Sleep and re Rest|Efficacy and Safety of the Device Siesta-SystemTM for Inducing Objective Sleep and re Rest.||Basque Health Service|No|Completed|November 2008|February 2010|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Primary Purpose: Supportive Care|2||Actual|40|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||October 2009|February 3, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062295||126908|
NCT01062009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPID 0876|Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children|A Safety and Dose-escalation Study of Zinc Supplementation in Pediatric Critical Illness||Children's Hospital & Research Center Oakland|Yes|Completed|November 2008|November 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|24|||Both|N/A|10 Years|No|||January 2015|January 26, 2015|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062009||126930|
NCT01062282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14184|Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)|VENIS - Prospective Observational Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension||Bayer|No|Completed|July 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|41|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Patients with pulmonary hypertension in Korea|April 2011|April 1, 2011|August 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01062282||126909|
NCT01048879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00033929|Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)|Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO||University of Michigan|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|N/A|N/A|No|||July 2012|July 17, 2012|January 13, 2010||No||No|June 13, 2012|https://clinicaltrials.gov/show/NCT01048879||127931|
NCT01048892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0911|Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features|A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features||Children's Oncology Group||Completed|September 2009|||June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|3 Years|21 Years|No|||January 2014|January 29, 2014|January 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01048892||127930|
NCT01049659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-04|Iodine Supplementation During Pregnancy and Neuropsychological Development|Effect of Iodine Supplementation and During Pregnancy on Neuropsychological Development of Children Assessed at 2 Years Old||Centre Hospitalier Universitaire de Nice|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|85|||Both|23 Months|25 Months|Accepts Healthy Volunteers|||December 2011|December 8, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049659||127871|
NCT01049646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS/09/019/26905 - 2|Interaction of Apelin and Angiotensin in the Systemic Circulation|||University of Edinburgh|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||August 2010|August 9, 2010|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049646||127872|
NCT01063062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22725|A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)|A Single-arm, Open-label, Multicenter Study of Tocilizumab Monotherapy or in Combination With Methotrexate to Assess Safety and the Efficacy in Reducing Disease Activity in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs (PICTURE)||Hoffmann-La Roche||Completed|February 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|February 3, 2010|No|Yes||No|July 8, 2014|https://clinicaltrials.gov/show/NCT01063062||126849|
NCT01063075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13420|A Study in Advanced Solid Tumors|Phase 2 Study to Evaluate the Pharmacokinetics and Drug-Drug Interaction of Cetuximab and Carboplatin in Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Completed|June 2010|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|34|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063075||126848|
NCT01062776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M114-09|Kinetic Method to Detect Dehydration|New Method to Detect Dehydration||Sodertalje Hospital|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|10|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||November 2009|August 18, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062776||126871|
NCT01063595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-203|A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD|A Comparative, Open-label, Randomized, Cross-over Phase I Trial in Healthy Volunteers to Investigate the Relative Efficacy, Safety and Tolerability of Octaplas LG™ vs. Octaplas®||Octapharma||Completed|December 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|February 4, 2010|No|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01063595||126808|
NCT01059929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16865B|Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)|A Double-blinded Randomized Controlled Trial of Dexmedetomidine Versus Propofol for Sedation in Mechanically Ventilated Medical Intensive Care Unit Patients.||University of Chicago|Yes|Active, not recruiting|September 2009|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059929||127089|
NCT01059903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0987|Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body|Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) Comparing Two Different Formulations||UCB Pharma|No|Completed|January 2010|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|January 28, 2010|No|Yes||No|February 4, 2011|https://clinicaltrials.gov/show/NCT01059903||127090|
NCT01060605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emendament 2001 to C99B901251|Pre Transplant Rapamycin Treatment in Islet Transplantation Alone|Effects of Pre-transplant Rapamycin Treatment and Tacrolimus Levels on the Outcome of Islet Transplantation Alone in Patients Receiving Edmonton Protocol.|ITA-Rp|IRCCS San Raffaele|Yes|Completed|October 2001|September 2009|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||January 2010|February 1, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060605||127037|
NCT01060618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROPISMVC|Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term|Estudio Comparativo de Dos métodos Para Predecir el Uso de Co-receptores Por el Virus de la Inmunodeficiencia 1 (HIV-1): el Ensayo fenotípico (Trofile ESTA®) y la Respuesta virológica a Corto Plazo a un Antagonista de CCR5|TROPISMVC|Asociacion para el Estudio de las Enfermedades Infecciosas|No|Completed|May 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|58|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|January 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01060618||127036|
NCT01060631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIS001|Influence of Intracranial Lesions on Bispectral Index|"Assessment of the Influence of Intracranial Space Occupying Lesions on the Reliability Off Monitoring of the Bispectral Index for Detection of Return of Consciousness."||University Medical Center Groningen|No|Completed|November 2009|June 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|plasma blood|Both|18 Years|N/A|No|Probability Sample|Bilateral BIS values at return of consciousness in patients with and without        supratentorial brain tumor.|November 2009|June 29, 2011|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060631||127035|
NCT01061177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107EIC01|Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase|A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase|`MACS1252|Novartis||Completed|May 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1088|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061177||126993|
NCT01061463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRSN-09079|Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study|Study of the Occupational Risk of Radiation-induced Cataracts Among Cardiologists||Institut de Radioprotection et de Surete Nucleaire|Yes|Completed|October 2009|March 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|250|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Interventional and non-interventional cardiologists from public and private French        hospitals/facilities, both groups of cardiologists being matched for age and gender.|April 2015|April 3, 2015|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061463||126971|
NCT01061736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11072|Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy|RA-MOBILITY|Sanofi|Yes|Completed|March 2010|October 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|1675|||Both|18 Years|75 Years|No|||November 2014|November 19, 2014|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061736||126950|
NCT01061749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02912|Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies|A Phase I, Single-Institution Open Label, Dose-Escalation Trial With an Expansion Trial Cohort Evaluating the Safety and Tolerability of AZD6244 and IMC-A12 in Subjects With Advanced Solid Malignancies||National Cancer Institute (NCI)||Completed|November 2009|September 2014|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2014|January 22, 2016|February 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061749||126949|
NCT01061762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-266|Adherence Intervention for People With Low-literacy|HIV Treatment Adherence Intervention for People With Poor Literacy Skills||University of Connecticut|No|Completed|February 2008|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|450|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061762||126948|
NCT01062035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000131|Study of a Screening Blood Test to Determine Patients' Potential Risk of Adenomatous or Advanced Colon Polyps (ACPs)|Peripheral Blood Telomere Length as a Biomarker of Advanced Colorectal Adenomas||Mayo Clinic|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|72|Samples With DNA|The only specimens obtained will be blood for PBL DNA. For all subjects two 10 cc EDTA tubes      will be obtained and processed into DNA.|Both|50 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Most subjects will be recruited at the time of a clinic visit in primary care, community        internal medicine, executive international physicals, and/or during a pre-colonoscopy        visit in the GI Department or GI Laboratory. The ACP subjects will be identified primarily        from those referred for ACP removal (EMR) and secondarily from those having screening        colonoscopy.|June 2014|June 24, 2014|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062035||126928|
NCT01062568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091676|The Adrenal Contribution to Androgen Production in Girls During Puberty|The Adrenal Contribution to Androgen Production in Girls During Puberty||University of California, San Diego|Yes|Completed|February 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|24|||Female|7 Years|18 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062568||126887|
NCT01049386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8738|Intestinal Permeability|Methods to Examine Intestinal Permeability Under Different Conditions||TNO|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|July 26, 2010|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049386||127892|
NCT01049672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/Q0104/47|Diamorphine or Alfentanil for Subcutaneous Use in Hospice In-patients?|An Open-label Pilot Comparison Between Alfentanil and Diamorphine for Palliative Care Patients Who Require Subcutaneous Opioids|DASH|Gloucestershire Hospitals NHS Foundation Trust|Yes|Completed|September 2010|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||March 2015|March 15, 2015|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049672||127870|
NCT01049685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-38|Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy|Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study||UPECLIN HC FM Botucatu Unesp|Yes|Active, not recruiting|August 2006|March 2010|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|No|||January 2010|February 12, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01049685||127869|
NCT01049958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robinson-2009-01|Study to Measure the Prevalence of Asynchrony In Mechanically Ventilated Patients|Prevalence of Patient Ventilator Asynchrony in Trauma and Surgical Patients|Asynchrony|University of Cincinnati|No|Completed|July 2009|April 2011|Actual|May 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Surgical and Neurosurgical Intensive Care Units at University        Hospital, Cincinnati, OH, who require mechanical ventilation and are aged 18 years or        older.|January 2013|January 13, 2013|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01049958||127848|
NCT01063088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|720903|Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine|An Open Label, Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population||Nanotherapeutics, Inc.|No|Completed|February 2010|July 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|211|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||July 2010|October 7, 2015|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063088||126847|
NCT01063101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950901|Phase 1 Dosing Study of BAX 513 in Healthy Volunteers|A Phase 1 Study to Evaluate the Effects of BAX 513 on Hemostatic Parameters in Healthy Volunteers||Baxalta US Inc.|No|Completed|January 2010|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2010|June 26, 2015|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063101||126846|
NCT01063335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100058|Imaging Cannabinoid CB1 Receptors in Schizophrenia|Imaging Cannabinoid CB1 Receptors in Schizophrenia||National Institutes of Health Clinical Center (CC)||Terminated|February 2010|September 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|1|||Both|18 Years|55 Years|No|||September 2012|February 19, 2014|February 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01063335||126828|
NCT01063881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016561|The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy|The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy||Johnson & Johnson Pte Ltd||Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|285|||Male|18 Years|N/A|No|||January 2013|January 31, 2013|February 4, 2010|Yes|Yes||No|August 1, 2012|https://clinicaltrials.gov/show/NCT01063881||126786|“Subgroup by dosage” was categorized based on dose-titration patterns observed during the course of the treatment period. Patients were not randomized to treatment by dosage group, disease type, or Intravaginal Ejaculation Latency Time.
NCT01059942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-258-A|Development and Validation of a Tool to Measure Hand-off Quality|Development and Validation of a Tool to Evaluate Hand-off Quality||University of Chicago|No|Completed|January 2010|December 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|27|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Academic Hosptialists and Internal Medicine Residents of the University of Chicago Medical        Center.|September 2013|September 4, 2013|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01059942||127088|
NCT01059955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-IST-001|Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study|Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study||University of Pennsylvania|No|Completed|January 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|January 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01059955||127087|
NCT01060176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA Trial China|Tranexamic Acid on Blood Loss and Transfusion in Cardiac Surgery|A Multicenter Clinical Trial of Tranexamic Acid on Blood Loss and Allogeneic Transfusions in Cardiopulmonary Bypass Cardiac Surgery||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|February 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|1200|||Both|18 Years|70 Years|No|||April 2015|April 9, 2015|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01060176||127070|
NCT01060397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0408-15077|A Controlled Trial of Extended Brief Interventions in Alcohol Dependent Patients|A Randomized Controlled Trial of Extended Brief Interventions for Alcohol-dependent Patients in an Acute Care Setting|ADPAC|Southport and Ormskirk Hospital NHS Trust|Yes|Completed|November 2009|November 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|267|||Both|16 Years|N/A|No|||January 2010|November 25, 2014|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060397||127053|
NCT01060410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30873124-CTX2008|Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment|Exploration of Genetic Polymorphisms Related to Individual Variations of Side Effects of Cyclophosphamide in Systemic Lupus Erythematosus Treatment||Sun Yat-sen University|No|Completed|May 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|222|Samples With DNA|Whole blood for DNA extraction as well as for pharmacokinetic studies|Both|12 Years|80 Years|No|Non-Probability Sample|SLE patients receiving treatment with cyclophosphamide|June 2012|June 18, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060410||127052|
NCT01061489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIN-Kol-09|Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment|Computer-based Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease (AD)||University of Konstanz|No|Completed|August 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|55 Years|N/A|No|||November 2013|November 26, 2013|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061489||126969|
NCT01060956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI1|The Clinical Impact of Isolation of Two Different Bacteria in Urinary Cultures|The Clinical Impact of Isolation of Two Different Bacteria in Urinary Cultures||Shaare Zedek Medical Center|Yes|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|81|||Both|18 Years|N/A|No|||February 2010|July 26, 2011|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060956||127010|
NCT01060930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISCO|Diesel Exhaust Inhalation, Systemic Nitric Oxide Inhibition and Cardiac Output|Diesel Exhaust Inhalation, Systemic Nitric Oxide Inhibition and Cardiac Output|DISCO|University of Edinburgh|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|December 15, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01060930||127012|
NCT01061190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIAS1.0|Beta Blockers In Acute Ischemic Stroke|Beta-Blocker in Acute Ischemic Stroke - a Prospective, Randomized, Double-blinded, Placebo-controlled Safety and Efficacy Trial of Early Treatment|BIAS|Charite University, Berlin, Germany|Yes|Completed|January 2010|April 2013|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061190||126992|
NCT01061476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00031257|Sleep Apnea Treatment With Expiratory Resistance(Provent™)|Sleep Apnea Treatment With Expiratory Resistance(Provent™)|SATER|Johns Hopkins University|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|21 Years|N/A|No|||July 2013|July 9, 2013|February 2, 2010|No|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01061476||126970|Small sample size and limited power for analysis.Oral breathing during expiratory nasal resistance (ENR) confounds the mechanism of action.
NCT01062841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG032298-01A1|Targeted Infection Control in Long-term Care|Targeted Infection Control Program (TIP) to Reduce Resistant Pathogens and Infections||University of Michigan|No|Completed|May 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1830|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062841||126866|
NCT01063140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB 1|Rabies Immune Plasma Booster Study|Rabies Immune Plasma Booster Program - A Clinical Study Conducted as an Investigational New Drug Study||CSL Behring||Completed|January 2009|May 2010|Actual|May 2010|Actual|Phase 4|Observational|Time Perspective: Prospective||2|Actual|491|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Source Plasma Donors. Donors must meet FDA and CSL Plasma requirements to be Source Plasma        Donors. Donors had previously participated in CSL's rabies vaccine immunization program.|September 2015|September 3, 2015|February 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01063140||126843|
NCT01062308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jeyaraj Pandian|STRIPS: Shoulder Taping Reduces Injury and Pain in Stroke|The Effectiveness of Taping Technique Versus Conventional Techniques in Prevention of Shoulder Injuries in Patients With Acute Stroke-A Prospective, Randomized, Interventional, Outcome Blinded (PROBE Design), Parallel Design Trial|STRIPS|Christian Medical College and Hospital, Ludhiana, India|Yes|Completed|August 2009|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|162|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|February 3, 2010||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT01062308||126907|Follow up period was short. Secondly, X rays of the shoulder were not done to document other shoulder injuries.
NCT01062581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0704M05324|University of Minnesota Transplant Registry|University of Minnesota Transplant Registry||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|March 1997|January 2050|Anticipated|January 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|University of Minnesota Transplant Center University of Minnesota Medical Center, Fairview|December 2015|December 16, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062581||126886|
NCT01049399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP031112-08B02|Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy|Tauros|Noscira SA|Yes|Completed|December 2009|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|146|||Both|40 Years|85 Years|No|||January 2012|January 2, 2012|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049399||127891|
NCT01049412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12151|A Study for Patients With Type 1 Diabetes|A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|January 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|65 Years|No|||February 2011|April 5, 2011|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01049412||127890|
NCT01049425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG AM04|Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer|Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer|planB|West German Study Group|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2448|||Female|18 Years|75 Years|No|||June 2015|June 18, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01049425||127889|
NCT01080482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/07/054|Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fasting Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 5 mg in Normal Healthy Male Subjects Under Fasting Condition||Panacea Biotec Ltd|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080482||125522|
NCT01049971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/089/07|REDWIL: Reduction of Wound Infections in Laparoscopic Colon Resections by Wound Protectors|Reduction of Wound Infections in Laparoscopic Colon Resections by Wound Protectors|REDWIL|Charite University, Berlin, Germany|No|Completed|December 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||December 2007|July 6, 2011|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01049971||127847|
NCT01049984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP-1012/PM103|Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease|A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease|ANDANTE|Teva Pharmaceutical Industries|No|Completed|December 2009|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|328|||Both|30 Years|N/A|No|||October 2014|October 9, 2014|January 13, 2010|Yes|Yes||No|October 9, 2014|https://clinicaltrials.gov/show/NCT01049984||127846|
NCT01063608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-HOP|Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.|Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Clinical Staff (FLU-HOP)|FLU-HOP|Institut National de la Santé Et de la Recherche Médicale, France|No|Active, not recruiting|October 2009|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|147|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 15, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063608||126807|
NCT01063621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6500-005|Extended Long-Term Safety Study of KW-6500|Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease)|6500-005|Kyowa Hakko Kirin Company, Limited||Completed|January 2010|March 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|N/A|No|||August 2012|August 30, 2012|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063621||126806|
NCT01063894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-09013|Effects of Breakfast on Cognitive Processes in Children|A Randomized, Controlled, Parallel Trial to Evaluate the Effects of Breakfast on Cognitive Processes in Children||Kellogg Company|No|Recruiting|December 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|280|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063894||126785|
NCT01060644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-08-0015-CTIL|Maxillary Sinus Floor Elevation Following Simultaneous Implant Installation Without Graft Material|Maxillary Sinus Floor Elevation Following Simultaneous Implant Installation Without Graft Material||Carmel Medical Center|No|Completed|March 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients (women, men) with a range of a age 18-65 years will be consecutively included.        The patients will be referred to the Department of Oral and Maxillofacial Surgery, Carmel        Medical Center, Haifa, for dental implant treatment in the posterior maxilla from every        Dental Clinic in Israel|November 2013|November 20, 2013|January 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01060644||127034|
NCT01060657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wgs1996|Clinical Values of Dose Reduction Techniques in Computed Tomography (CT) Coronary Artery Imaging With 64-row Multi-Slice Helical CT|||General Hospital of Chinese Armed Police Forces|Yes|Active, not recruiting|December 2009|December 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Five hundred patients will be recruited over one and half years from our institution and        other hospitals for suspected coronary artery disease. All patients will give informed        consent and our Institutional Review Board approved the study.|January 2010|February 1, 2010|January 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01060657||127033|
NCT01060189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI Trial China|Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery|Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|February 2010|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|350|||Both|18 Years|70 Years|No|||April 2015|April 9, 2015|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01060189||127069|
NCT01061203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-21|Grazax Asthma Prevention|Grazax Asthma Prevention|GAP|ALK-Abelló A/S|No|Active, not recruiting|January 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|5 Years|12 Years|No|||June 2015|June 23, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061203||126991|
NCT01061216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDT-09-ADC003|Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously|A Mono-center, Open Label, Randomised 2-period Crossover Study to Compare the Pharmacokinetics and Pharmacodynamics of Continuous Insulin Infusion Administered Either Intradermally or Subcutaneously in Subjects With Type 1 Diabetes Mellitus||Becton, Dickinson and Company|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|55 Years|No|||March 2010|March 9, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01061216||126990|
NCT01060969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-3977-ES-CTIL|Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention|Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention||Sheba Medical Center|No|Completed|January 2006|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 7, 2012|November 3, 2008||No||No||https://clinicaltrials.gov/show/NCT01060969||127009|
NCT01060982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/F/12.02|Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure|Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU)Treatment Procedure: A Monocentre, Open, Uncontrolled Study||Theraclion|No|Completed|February 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060982||127008|
NCT01061775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903-028|Effects of Exenatide on Hypothalamic Obesity|Effects of Exenatide on Hypothalamic Obesity||Children's Hospitals and Clinics of Minnesota|Yes|Active, not recruiting|January 2010|December 2016|Anticipated|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|10 Years|21 Years|No|||February 2016|February 22, 2016|February 2, 2010|Yes|Yes||No|February 25, 2015|https://clinicaltrials.gov/show/NCT01061775||126947|
NCT01062048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-181|Januvia Re-examination Study (MK-0431-181)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of Januvia in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|October 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3483|||Both|N/A|N/A|No|Probability Sample|Korean participants with Type 2 Diabetes Mellitus being treated with Januvia|February 2016|February 3, 2016|February 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01062048||126927|
NCT01062061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V210-059|Re-examination Study For Varivax (V210-059 AM2)|Re-examination Study for General Vaccine Use to Assess the Safety Profile of Varivax in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|June 2007|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|754|||Both|12 Months|N/A|Accepts Healthy Volunteers|Probability Sample|Korean participants being vaccinated with VARIVAX in usual practice|September 2015|September 3, 2015|February 2, 2010|No|Yes||No|April 16, 2013|https://clinicaltrials.gov/show/NCT01062061||126926|
NCT01062594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0858|Effect of Pre-operative Exercise in Abdominal Aortic Aneurysms (AAA) Patients.|A Randomised Controlled Trial to Assess the Effect of a Pre-operative Supervised Exercise Programme on Outcome Following Intervention for Abdominal Aortic Aneurysms.||University of Hull|Yes|Completed|December 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|124|||Both|20 Years|N/A|No|||December 2014|December 3, 2014|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062594||126885|
NCT01029483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT002753|The Energy Balance Study|Energy and Appetite Regulation by Low CHO Diets|EBS|Oregon Health and Science University|Yes|Completed|September 2005|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2009|December 9, 2009|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029483||129360|
NCT01063387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM2010-022|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and Supraclavicular Lymph Nodes in Locally Advanced Uterine Cervical Cancer|Molecular Markers in Lymph Node Metastasis of Cervical Cancer and Prophylactic Irradiation of the Para-Aortic Lymph Nodes and Supraclavicular Lymph Nodes in Locally Advanced Uterine Cervical Cancer||Huazhong University of Science and Technology|Yes|Active, not recruiting|January 2010|February 2015|Anticipated|February 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Female|18 Years|80 Years|No|||February 2010|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063387||126824|
NCT01080248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0434 / 201103201|Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer|A Phase II Study of Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer||Washington University School of Medicine|No|Terminated|August 2010|October 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|March 2, 2010|Yes|Yes|Closed due to delay by GSK|No|May 4, 2015|https://clinicaltrials.gov/show/NCT01080248||125540|
NCT01080261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2069|PROMUS Element Japan Small Vessel Trial|A Prospective Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of a Small Vessel De Novo Coronary Artery Lesion in Japan||Boston Scientific Corporation|Yes|Active, not recruiting|February 2010|November 2015|Anticipated|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|20 Years|N/A|No|||August 2012|August 17, 2012|March 2, 2010||No||No|March 19, 2012|https://clinicaltrials.gov/show/NCT01080261||125539|
NCT01080755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 24428|Metabolic Endocrinology and Growth Hormone in Adults|Study on the Prescription of the Growth Hormone Saizen® for Adults in France and Follow-up of Treated Patients|MEGHA FRANCE|Merck KGaA|No|Completed|December 2003|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|Samples Without DNA|Plasma|Both|N/A|N/A|No|Probability Sample|Adult subjects treated with Saizen, irrespective of whether it concerns a first time        prescription or a renewal were enrolled in the study.|March 2014|March 10, 2014|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080755||125501|
NCT01081054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01DIVER|Hospitalization or Ambulatory Treatment of Acute Diverticulitis|Randomized Trial Comparing Two Treatment Strategies for Acute Diverticulitis. Hospitalization or Ambulatory Antibiotic Treatment|01DIVER|Hospital Universitari de Bellvitge|No|Completed|September 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||June 2012|June 10, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081054||125478|
NCT01081067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3377-1 (6008)|Assessment of Efficiency and Safety of an Infant Formula Containing a Probiotic in Children|Assessment of Efficiency and Safety of an Infant Formula Containing a Probiotic in Children||Mead Johnson Nutrition|No|Completed|October 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|134|||Both|1 Month|18 Months|No|Probability Sample|CPPHO [Centro Pediátrico Professor Hosannah de Oliveira (Professor Hosannah de Oliveira        Pediatirc Center] C-HUPES [Complexo Hospitalar Professor Edgar Santos (Professor Edgar        Santos Hospital Complex)]|January 2011|January 3, 2011|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081067||125477|
NCT01080742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200006-510|An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients|A Prospective Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients|Lodoz OS|Merck KGaA|No|Completed|January 2010|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1007|||Both|18 Years|N/A|No|Non-Probability Sample|Residents of Thailand diagnosed with mild to moderate essential hypertension.|June 2012|August 4, 2014|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080742||125502|
NCT01063348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010PSPNAC|N-Acetyl Cysteine in Pathologic Skin Picking|A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking||University of Chicago|Yes|Completed|September 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|64 Years|No|||August 2015|August 14, 2015|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063348||126827|
NCT01063361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-192|Low Glycemic Index Diets (With Pulses) in Type 2 Diabetes|Effect of Low Glycemic Index Diets (With Pulses) on Glucose Control in Non-Insulin Dependent Diabetics||University of Toronto|Yes|Completed|February 2010|August 2015|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|21 Years|N/A|No|||December 2015|December 7, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063361||126826|
NCT01063634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIADUCT|Comparison of a Plastic Stent Without Central Lumen With Self Expandable Metal Stents in Patients With Malignant Distal Biliary Obstruction|Comparison of a Plastic Stent Without Central Lumen With Self Expandable Metal Stents in Patients With Malignant Distal Biliary Obstruction. A Randomized, Controlled Trial|VIADUCT|Kliniken Ludwigsburg-Bietigheim gGmbH|No|Recruiting|January 2010|January 2012|Anticipated|January 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|76|||Both|18 Years|N/A|No|Probability Sample|patients with malignant obstruction of the common bile duct|February 2010|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063634||126805|
NCT01063647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-FludT.6/L|Dose-range Finding Treosulfan-based Conditioning|Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Advanced Hematological Malignancies After Treosulfan-based Conditioning Therapy - A Clinical Phase II Study||medac GmbH|Yes|Completed|November 2001|June 2006|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|56|||Both|18 Years|N/A|No|||February 2010|February 4, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063647||126804|
NCT01063660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-FludT.7/AML|Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)|Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukaemia||medac GmbH|No|Completed|March 2004|July 2007|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|75|||Both|18 Years|60 Years|No|||February 2010|February 4, 2010|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063660||126803|
NCT01060423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2009-014728-44|TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer|A Randomized Phase II Trial of Irinotecan Drug-eluting Beads Administered by Hepatic Chemoembolization With Intravenous Cetuximab (DEBIRITUX) Versus Systemic Treatment With Intravenous Cetuximab and Irinotecan in Patients With Refractory Metastatic Colorectal Cancer and K-ras Wild-type Tumours|DEBIRITUX|Martin-Luther-Universität Halle-Wittenberg|No|Terminated|February 2010|September 2013|Anticipated|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|January 27, 2010||No|Terminated due to poor subject enrolment|No||https://clinicaltrials.gov/show/NCT01060423||127051|
NCT01060215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52008B000100044|The Effects of Joint Effusion on Proprioception|Clinical Trial for the Effects of Joint Effusion on Proprioception||The Catholic University of Korea|Yes|Completed|May 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|40|||Female|50 Years|N/A|No|||January 2010|February 1, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01060215||127067|
NCT01060943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01TRF|An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds|A Randomized, Multicenter, Prospective, Paired Comparison of the Efficacy and Safety of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds||Sewon Cellontech Co., Ltd.|Yes|Completed|May 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|73|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 1, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01060943||127011|
NCT01060670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRT/DFU US - 2009-3|A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers|A Multi-Center, Randomized, Controlled Clinical Trial to Evaluate The Safety and Effectiveness of Integra® Dermal Regeneration Template for the Treatment of Neuropathic Diabetic Foot Ulcers||Integra LifeSciences Corporation|No|Completed|April 2010|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|January 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060670||127032|
NCT01060683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpHb-001|Non-invasive Measurement of Hemoglobin Concentration With Pulse Co-oximetry|Liver Resection and Non-invasive Measurement of Hemoglobin Concentration With Pulse Co-oximetry||University Medical Center Groningen|No|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|laboratory hemoglobin, Coagulation variables,blood chemistry,Blood gas analysis|Both|18 Years|N/A|No|Non-Probability Sample|ASA class I and II patients for elective hepatic resection|August 2009|February 28, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060683||127031|
NCT01028352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.062|Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain|UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients||University of Michigan Cancer Center|Yes|Completed|October 2008|October 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|21 Years|N/A|No|||July 2013|July 26, 2013|December 8, 2009|Yes|Yes||No|January 30, 2012|https://clinicaltrials.gov/show/NCT01028352||129446|
NCT01061229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS EK 15 - 287/09|Homeopathic Drug Proving Trial|Homeopathic Drug Proving Trial|HAMSV|Charite University, Berlin, Germany|Yes|Completed|March 2010|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 9, 2012|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061229||126989|
NCT01061502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSMP-014|Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds|Efficacy of the PROCELLERA Wound Dressing in the Healing of Skin Graft Donor Sites||Vomaris Innovations|Yes|Completed|September 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|80 Years|No|||December 2010|December 9, 2010|February 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061502||126968|
NCT01061788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021317|A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer|A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial)|RAP|Duke University|Yes|Recruiting|April 2010|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|90 Years|No|||August 2015|October 13, 2015|February 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061788||126946|
NCT01061801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076.00|Spouses/Partners Expressing Their Thoughts After Transplant|Emotional Expression and Cancer Caregivers||Fred Hutchinson Cancer Research Center|No|Completed|August 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|122|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 4, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061801||126945|
NCT01062074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-059|GARDASIL Reexamination Study (V501-059)|Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|September 2007|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3605|||Both|9 Years|26 Years|Accepts Healthy Volunteers|Probability Sample|Females and males 9-26 Years Of Age who are vaccinated with GARDASIL in usual practice|February 2015|February 4, 2015|February 2, 2010|No|Yes||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01062074||126925|
NCT01062087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010002|Pain Perception After Tubal Ligation|Retrospective Investigation of Postoperative Pain Perception After Laparoscopic Tubal Sterilization||Oklahoma State University Center for Health Sciences|No|Completed|January 2010|December 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|62|||Female|21 Years|52 Years|Accepts Healthy Volunteers|Probability Sample|Urban clinic population, mix of ethnicities, most are Medicaid patients|May 2012|May 1, 2012|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062087||126924|
NCT01061515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0136 / 201107017|Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer|A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer||Washington University School of Medicine|No|Recruiting|May 2011|January 2021|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|48|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061515||126967|
NCT01062321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/7/239/07/RHN|Role of Cytokines in Hepatitis E Virus Infection During Pregnancy|Role of Cytokines in Hepatitis E Virus Infection During Pregnancy||Maulana Azad Medical College|No|Completed|August 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|491|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women of 18-40 years with jaundice and Healthy pregnant women as controls|July 2011|April 10, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062321||126906|
NCT01062334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20090147|Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer|Intraperitoneal Microdialysis Monitoring of Patients During the Early Postoperative Period After LAR With Reference to Early Diagnosis of Anastomotic Leakage Ore Other Complications||Odense University Hospital||Recruiting|March 2010|||March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01062334||126905|
NCT01062347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-004|A Novel Bio-marker of Zinc Status|Exploring the Possibility of Using Intestinal mRNA Levels of Zinc Transporter Genes, and Changes in Their Expression Levels in Response to Zinc Supplementation as a Bio-marker for Zinc Status||International Centre for Diarrhoeal Disease Research, Bangladesh||Completed||||||Phase 1|Interventional|N/A|1||||||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2010|February 3, 2010|February 3, 2010||||No||https://clinicaltrials.gov/show/NCT01062347||126904|
NCT01062607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NEU-DUM-2009/1|Study of the Clinical Management of Bipolar Disease|Multinational Ambispective Study of the Clinical Management and Burden of Bipolar Disorder (WAVE bd Study)|WAVE bd|AstraZeneca|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|2965|||Both|18 Years|N/A|No|Probability Sample|Bipolar patients seen in mental health centers, clinics, private settings, hospitals or        specialized units|May 2012|May 22, 2012|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01062607||126884|
NCT01062620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXL-001|A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer|A Dose Escalating Phase Ia-b Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer: A Prospective, Single Armed, Open Label, Dose-finding Phase Ia-b Study||Axelar AB|Yes|Completed|April 2008|||May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|February 3, 2010||||No||https://clinicaltrials.gov/show/NCT01062620||126883|
NCT01062633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N012/95|Effect of Erythritol and Xylitol on Dental Caries Prevention in Children|Effect of Erythritol and Xylitol on Dental Caries Prevention in Children||University of Tartu|Yes|Recruiting|January 2008|November 2011|Anticipated|February 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|450|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||December 2007|February 3, 2010|January 29, 2008||No||No||https://clinicaltrials.gov/show/NCT01062633||126882|
NCT01080768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A2201|Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension|A Double Blind, Randomized, Parallel Study to Assess the Effects of Aliskiren/Amlodipine and Amlodipine Monotherapy on Ankle Foot Volume (AFV) in Patients naïve to Trial Drugs With Mild to Moderate Hypertension||Novartis||Terminated|February 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||November 2011|November 22, 2011|March 3, 2010|Yes|Yes|Publication of data from a similar study made the current study redundant.|No|November 22, 2011|https://clinicaltrials.gov/show/NCT01080768||125500|
NCT01081392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-01.2|Inflammatory Markers in Sputum After LPS Inhalation|The Role of Inhaled Particle Size on the Inflammatory Response Induced by Endotoxin Inhalation||Centre Hospitalier Universitaire Brugmann|No|Active, not recruiting|January 2010|May 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 4, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01081392||125453|
NCT01063907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2478-INT-001|A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma|An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|March 2010|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|95|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|February 4, 2010|No|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01063907||126784|
NCT01059968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816305-1|Low Energy Availability, Menstrual Irregularity, and Low Bone Mass|The Role of Low Energy Availability and the H-P-A Axis, Menstrual Irregularity, and Low Bone Mass||USDA, Western Human Nutrition Research Center|No|Completed|September 2008|December 2009|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|45|||Female|15 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|adolescent female cross country runners|June 2011|June 22, 2011|December 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01059968||127086|
NCT01059981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-08-0656|Analysis of Emergency Department (ED) Volumes During Natural Disasters|Analysis of Emergency Department Volumes During Natural Disasters||The University of Texas Health Science Center, Houston|No|Completed|August 2009|June 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Three populations: Dialsysis patients, trauma patients, and patients experiencing carbon        monoxide poisonings during natural disasters.|July 2010|July 6, 2010|February 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01059981||127085|
NCT01052168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06-20E|Do Motion Metrics Lead to Improved Skill Acquisition on Simulators?|Do Motion Metrics Lead to Improved Skill Acquisition on Simulators?||Carolinas Healthcare System|Yes|Completed|November 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|42|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2013|March 22, 2013|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052168||127680|
NCT01032213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEG/Mg|Effect of Magnesium Sulphate on Coagulation|Effect of Magnesium Sulphate on Postoperative Coagulation as Measured by Thromboelastography||Seoul National University Bundang Hospital|Yes|Completed|January 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Female|20 Years|60 Years|No|||August 2013|August 22, 2013|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01032213||129152|
NCT01060436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00028854|Face of Sleepiness|The Face of Sleepiness|Face|University of Michigan|No|Completed|February 2010|August 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|No|Non-Probability Sample|University of Michigan Sleep Disorders Clinic|December 2014|December 31, 2014|February 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060436||127050|
NCT01028105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.003|Incidence and Relationship of Positive Preoperative Methicillin Resistant Staphylococcus Aureus (MRSA) Screens and Post-operative Infections|Evaluation of the Prevalence of Methicillin Resistant Staphylococcus Aureus Colonization in Pre-Surgical Patients and Post-Operative Infection|MRSA|Inova Health Care Services|No|Recruiting|February 2008|May 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|975|||Both|N/A|N/A|No|||December 2009|December 8, 2009|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028105||129465|
NCT01028664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/05|Use of an Ocular Telemetry Sensor in Diamox Treated Patients|Detection of IOP Fluctuation With SENSIMED Triggerfish in Patients With Glaucoma or Ocular Hypertension Treated With Diamox||Sensimed AG|No|Completed|December 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2010|December 2, 2010|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028664||129422|
NCT01028950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-044|YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness|A Multi-center, Open Label Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness||Astellas Pharma Inc|No|Completed|May 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Both|40 Years|N/A|No|||June 2010|June 14, 2010|December 7, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01028950||129400|
NCT01028651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIV-PH-414|A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension|Phase 4 Open-Label Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension||United Therapeutics|No|Completed|November 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|N/A|N/A|No|Probability Sample|Subjects will be recruited from four Pulmonary Hypertension Centers in the US, referred        for portopulmonary hypertension.|June 2014|June 25, 2014|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028651||129423|
NCT01028924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TE-1777-102-EC|Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers|A Randomised, 4-period, Placebo and Active-controlled, Single-dose, Change-over Trial to Evaluate the Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers||Nycomed|No|Completed|November 2009|April 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|45 Years|No|||April 2010|May 4, 2012|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01028924||129402|
NCT01028937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTK-1|Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System|Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System||NTK Enterprises, Inc.|Yes|Recruiting|December 2009|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|December 8, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028937||129401|
NCT01029184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.47.INF|Tolerance of Cereals for Atopic Children|Assessment of Tolerance of Cereals in Infants With Atopic Symptoms||Nestlé|No|Terminated|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|4 Months|4 Years|No|||June 2012|June 26, 2012|December 8, 2009||No|difficult to enrol and as a pilot study sample size was not powered anyway|No||https://clinicaltrials.gov/show/NCT01029184||129382|
NCT01029769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01KG0910|Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia|The Switch Study - Efficacy of Early Antipsychotic Switch Versus Maintenance in Patients With Schizophrenia Poorly Responding to Two Weeks of Antipsychotic Treatment||Technische Universität München|Yes|Completed|December 2009|March 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|351|||Both|18 Years|65 Years|No|||May 2015|May 22, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01029769||129338|
NCT01062360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11764|Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine|A Pivotal, Placebo Controlled, Phase III Study to Compare Efficacy and Tolerability of a Fixed Combination, Containing 500 mg ASA and 30 mg Pseudoephedrine, in Comparison to Its Single Components in Patients With Sore Throat and Nasal Congestion||Bayer|No|Completed|December 2005|May 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1016|||Both|18 Years|65 Years|No|||January 2015|January 22, 2015|December 9, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01062360||126903|
NCT01047943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KochiDermaTrial|STA-21 Topical Efficacy on Psoriasis|Intrapatient Comparison Study of Efficacy of STA-21 Ointment on Psoriatic Skin Lesions||Kochi University|No|Completed|June 2007|April 2008|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|8|||Both|20 Years|80 Years|No|||June 2007|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047943||128003|
NCT01047930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09060305|The Effect of Exercise on Acute Nicotine Withdrawal|The Effect of Exercise on Acute Nicotine Withdrawal: Human Study|NicEx|University of Pittsburgh|Yes|Completed|January 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|88|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047930||128004|
NCT01048229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTOR protocol|Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease|Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease|ACTOR|Qualissima|No|Terminated|October 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|70 Years|No|||May 2012|May 25, 2012|January 12, 2010||No|recruitment|No||https://clinicaltrials.gov/show/NCT01048229||127981|
NCT01048242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804640|Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)|Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)||University of Pennsylvania|Yes|Completed|July 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|60 Years|N/A|No|||January 2010|January 11, 2010|April 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048242||127980|
NCT01048255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-765-401|Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy|A Phase 2, Randomized, Double-blind,Placebo-controlled Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy||Vertex Pharmaceuticals Incorporated|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|64 Years|No|||December 2013|December 19, 2013|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048255||127979|
NCT01059994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-213|Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability|Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability||The University of Texas Medical Branch, Galveston|No|Completed|January 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|12|||Male|20 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|January 28, 2010|Yes|Yes||No|September 25, 2015|https://clinicaltrials.gov/show/NCT01059994||127084|
NCT01063933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0064|Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza|A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Investigational Intravenous Peramivir in Children With Influenza Disease (CASG 117)||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||December 2012|Anticipated|August 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|0|||Both|N/A|17 Years|No|||January 2010|November 10, 2011|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063933||126782|
NCT01063946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEX6587|A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor|A Phase I, Open Label Study Investigating the Disposition of 25 mg/m² [14C]-AVE8062 (1.85 MBq, 50 µCi) Administered at Cycle 1 as a 30-minute Intravenous Infusion to Patients With Advanced Solid Tumors||Sanofi|No|Completed|January 2010|September 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063946||126781|
NCT01060202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016750|Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib|A Prospective, Open-label, Multicenter Observational Study to Evaluate the QoL of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib||Janssen Korea, Ltd., Korea|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|20 Years|N/A|No|Non-Probability Sample|Non-transplant candidate patients who are newly prescribed bortezomib injection as a        secondary agent for the treatment of multiple myeloma, those of whom can understand and        fill out questionnaire, and agree to provide information will be included.|July 2013|July 16, 2013|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060202||127068|
NCT01060007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0696 / 201106272|Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer|A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer||Washington University School of Medicine|No|Completed|November 2009|September 2014|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||December 2014|January 23, 2015|January 28, 2010|Yes|Yes||No|January 23, 2015|https://clinicaltrials.gov/show/NCT01060007||127083|
NCT01032226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/03|Evaluation of CNAP During Anesthesia|Evaluation of CNAP During Induction and Maintenance of General Anesthesia|CnapEval|Hopital Foch|No|Terminated|December 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing major surgery with the need for an invasive blood pressure measurement|March 2011|March 19, 2011|December 12, 2009||No|Difficulty to include more patients|No||https://clinicaltrials.gov/show/NCT01032226||129151|
NCT01032239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.02.7001|SISTERS: Spasticity In Stroke Study - Randomized Study|A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment|SISTERS|Medtronic International Trading Sarl|Yes|Active, not recruiting|November 2009|March 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01032239||129150|
NCT01060228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015802|A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men|An Open-Label, Drug-Drug Interaction Study Between Steady-State Valproic Acid and Single-Dose Paliperidone Extended-Release in Healthy Men||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2009|February 2009|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|January 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01060228||127066|
NCT01032200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU97509|Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors|A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue||Wake Forest NCORP Research Base|Yes|Completed|August 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|54|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|December 13, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01032200||129153|
NCT01028365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD060229-01A1|Time to Conceive: A Study of Fertility|Time to Conceive: A Study of Fertility: Biomarkers of Fertility||University of North Carolina, Chapel Hill|No|Active, not recruiting|April 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|850|Samples With DNA|Serum, Urine|Female|30 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women living in Chapel Hill, Raleigh, Durham, and the surrounding communities of        the Triangle Area in North Carolina.|October 2015|October 1, 2015|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028365||129445|
NCT01028378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-CAT-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2009|||||N/A|N/A|N/A||||||||||||||December 3, 2012|December 7, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01028378||129444|
NCT01060709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TcCo2-001|Transcutaneous Measurement of Carbon Dioxide Versus Current Sedation Practices in Sedated Patients|Does Transcutaneous Carbon Dioxide Partial Pressure (TcCO2) Monitoring Detect Hypoventilation Prior to Current Sedation Monitoring Practices?||University Medical Center Groningen|No|Completed|December 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing elective colonoscopy and requiring sedation|November 2009|October 25, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060709||127029|
NCT01061021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-113|HIV Prevention Intervention for People Living With HIV/AIDS|HIV Treatment Adherence/Risk Reduction Integrated||University of Connecticut|No|Completed|March 2005|August 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|490|||Both|18 Years|N/A|No|||November 2010|November 15, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061021||127005|
NCT01061294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iLASIK|Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure|Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure (Wavescan Wavefront® System, Star S4 IR™ Excimer Laser System and Intralse™ FS System)||Innovative Medical|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||January 2011|January 12, 2011|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061294||126984|
NCT01029197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K01MH079343|Multicomponent Cognitive Behavioral Therapy(CBT) for Posttraumatic Stress Disorder (PTSD) and Substance Abuse|Multicomponent Cognitive Behavioral Therapy for Posttraumatic Stress Disorder and Substance Abuse: A Pilot Study|PTSD/SUD|University of North Carolina, Chapel Hill|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|No|||July 2010|July 6, 2010|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01029197||129381|
NCT01029210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0175/08|Temporomandibular Disorders and Osteoporosis|Temporomandibular Disorders in Climacteric Women: Pain Sensibility, Risk Posed by Systemic Bone Mass and Diagnostic Made by RDC/TMD Compared to MRI (3.0 Tesla)|TMDOST|University of Sao Paulo|No|Completed|May 2008|November 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|100|||Female|48 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients attended by the discipline of gynecology - outpatient clinic of climatério|November 2011|December 19, 2011|December 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01029210||129380|
NCT01060995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-DB-07-0593|SmartConsent: A Computerized Informed Consent for Patients|SmartConsent: A Computerized Informed Consent for Patients|SmartConsent|The University of Texas Health Science Center, Houston|Yes|Completed|January 2009|||July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Urgent Care Clinic at UT Dental Branch at Houston|January 2010|February 1, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060995||127007|
NCT01061242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00033951|Intensive Care Unit (ICU) Sleep Quality and Neurocognitive Performance|Post-ICU Neurocognitive Performance and Sleep Quality Ratings Following Exposure to a Medical ICU Sleep Quality Improvement Project||Johns Hopkins University|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|88|||Both|18 Years|N/A|No|||December 2009|June 22, 2011|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061242||126988|
NCT01061814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPO3200309|A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Relative Bioavailability, Pharmacokinetics, Safety, and Tolerability of Daily, Thrice Weekly, and Weekly Dosing Regimens of Mipomersen Administered Subcutaneously to Healthy Volunteers||Sanofi|Yes|Completed|January 2010|June 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|January 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01061814||126944|
NCT01062100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2009-THORN|Study To Investigate the Feasibility and Safety of A Dedicated High Resolution Nuclear Breast Imaging Camera|The Hamilton Prospective Pilot Study To Investigate the Feasibility and Safety of A Dedicated High Resolution Nuclear Breast Imaging Camera|THORN|Ontario Clinical Oncology Group (OCOG)|No|Completed|February 2010|February 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Female|18 Years|N/A|No|||February 2013|February 15, 2013|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062100||126923|
NCT01062373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-20|Effect of Docosahexaenoic Acid (DHA)-Enriched Human Milk in Premature Newborns|Improvement of Polyunsaturated Fatty Acids Status in Premature Newborns Following Docosahexaenoic Acid Enrichment of Human Milk|DHARMA|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Terminated|February 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2|||Both|N/A|40 Years|Accepts Healthy Volunteers|||January 2012|September 26, 2012|February 3, 2010||No|difficulties of recruitement|No||https://clinicaltrials.gov/show/NCT01062373||126902|
NCT01062386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/Mba/2010/MalPrev|Malaria Survey in Mbarara District, Uganda 2010|The Epidemiology of Malaria Among Children Under Five in Mbarara District, Uganda - A Cross-sectional Population-based Survey 2010||Epicentre|No|Completed|January 2010|July 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2320|Samples With DNA|Blood sample for:      Malaria rapid diagnostic test, Malaria Blood smear, Malaria PCR, Anopheles mosquitoes      anti-saliva antibodies|Both|1 Month|59 Months|Accepts Healthy Volunteers|Probability Sample|Children living in Great Mbarara district|August 2011|August 11, 2011|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062386||126901|
NCT01048515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBJ-1|The Effect of Caffeine in Elderly Citizen Following Eight Hour Abstinence From Caffeine Containing Drinks & Foods|The Effect of Caffeine as Endurance Enhancing Drug in the Elderly Following Eight Hour Abstinence From Caffeine Containing Drinks and Foods||Herning Hospital|Yes|Completed|February 2005|||November 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|70 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 12, 2010|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01048515||127959|
NCT01048268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIP HYPO (MC)|Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?|Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?||University Hospital, Gentofte, Copenhagen|No|Completed|December 2009|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 10, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048268||127978|
NCT01048281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIUPR0001|Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma|Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma||Stanford University||Recruiting|August 2002|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood, tumor|Both|18 Years|N/A|No|Non-Probability Sample|Adults with gastric or esophageal cancer|February 2015|February 3, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048281||127977|
NCT01048502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810598|Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia|Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia: The FFAME Study|FFAME|University of Pennsylvania|Yes|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 11, 2010|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01048502||127960|
NCT01063699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBAR 9260|Survival With Own Liver of Conventional Versus Laparoscopic Kasai for Biliary Atresia|Prospective Trial on Survival With Own Liver After Conventional Versus Laparoscopic Kasai for Biliary Atresia||Hannover Medical School|Yes|Completed|August 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|1 Month|4 Months|No|||December 2009|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063699||126800|
NCT01031719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_15TP|Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors|A Phase III, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Vaccine Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Invasive Solid Tumors||Chiltern Pesquisa Clinica Ltda||Completed|August 2010|July 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|59|||Both|2 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 12, 2012|December 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01031719||129190|
NCT01063959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 294EX|Sleeve Gastrectomy Versus Gastric Bypass for Private Pay Patients Seeking Obesity Surgery|Advantages of Sleeve Gastrectomy Over Gastric Bypass for Private Pay Patients Seeking Obesity Surgery||Pennington Biomedical Research Center|No|Withdrawn|February 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 4, 2010||No|No Enrollment|No||https://clinicaltrials.gov/show/NCT01063959||126780|
NCT01031953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000612580|Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy|Pilot Study of Fosaprepitant (MK-0517) for Breakthrough Chemotherapy Induced Nausea and Vomiting||OHSU Knight Cancer Institute|Yes|Terminated|August 2008|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|34|||Both|18 Years|120 Years|No|||October 2015|October 20, 2015|December 13, 2009|Yes|Yes|Drug contract timelines and inadequate enrollment|No|October 10, 2013|https://clinicaltrials.gov/show/NCT01031953||129172|Missing data did affect results for the 24 hour markLack of control group to measure possible neurokinin-1 antagonist (NK1a) inhibition
NCT01060241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2D Combination-Internet BGM|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM) on Combination Oral Therapy|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus on Combination Oral Therapy||Endocrine Research Society|No|Suspended|February 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|25 Years|79 Years|No|||January 2010|June 28, 2011|February 1, 2010||No|Other projects warranted more attention|No||https://clinicaltrials.gov/show/NCT01060241||127065|
NCT01028118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180/09|Violence Against Women and Consequences During Climacteric´s Phase|Domestic and Sexual Violence Against Women: Consequences for Climacteric´s Phase|DV|University of Sao Paulo General Hospital|Yes|Completed|April 2009|October 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|300|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||March 2009|April 7, 2010|December 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01028118||129464|
NCT01060722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-4-001|MOD-4023 Study in Healthy Male Volunteers|A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of a Long Acting Human Growth Hormone (hGH) Product (MOD-4023), in Healthy Volunteers||Opko Biologics|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|January 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060722||127028|
NCT01061008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC No : 07/WNo01/4|Handgrip Exercise for Arteriovenous Fistula Maturation|The Effects of Progressive Handgrip Exercise Training on Arteriovenous Fistula Maturation in Chronic Kidney Disease||Bangor University|No|Completed|January 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|31|||Both|18 Years|N/A|No|||June 2014|June 11, 2014|January 22, 2010||No||No|February 15, 2013|https://clinicaltrials.gov/show/NCT01061008||127006|
NCT01061554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AYANDA-CC-01|Bioavailability Study of Long Chain Omega-3 Fatty Acids From a Gastric Stable Emulsion|Correlation Between Level of Polyunsaturated Fatty Acid EPA and DHA in Blood After Digestion of ProBios Omega-3 Concordix™ Compared With Omega-3 Soft Capsules - a Pilot||Ayanda AS|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|27|||Both|19 Years|29 Years|Accepts Healthy Volunteers|||April 2009|February 2, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061554||126964|
NCT01061255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/8-M|Stress and Clinical Reasoning in Medical Students|Physiological and Psychological Responses to Stress in Year 6 Medical Students Faced to Ambulatory Symptomatic Patients||Nantes University Hospital|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|62|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2010|July 22, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061255||126987|
NCT01061528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHI0906-002|Coping Skills Treatment for Smoking Cessation|Distress Tolerance Treatment for Smoking Cessation|Project WIN|Butler Hospital|Yes|Active, not recruiting|September 2009|October 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061528||126966|
NCT01061541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208108/091|Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™|A Phase II, Double-blind, Randomized Study to Compare the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB/Hib2.5 to GSK Biologicals' Tritanrix™-HepB/Hiberix™ When Administered as a Three-dose Primary Vaccination Course to Healthy Infants at 6, 10 and 14 Weeks of Age. A Dose of Unconjugated Hib Vaccine (Plain PRP Booster) Will be Administered at the Age of 10 Months to 50% of the Subjects||GlaxoSmithKline||Completed|August 2003|August 2004|Actual|January 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|192|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||June 2014|June 26, 2014|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061541||126965|
NCT01062672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H--22516|Functional Neuroimaging of Cortical Plasticity in the Human Visual System|Functional Neuroimaging of Cortical Plasticity in the Human Visual System||Baylor College of Medicine|No|Recruiting|January 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with lesions of the visual pathway (cortical or retinal)|January 2016|January 26, 2016|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062672||126879|
NCT01062685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000323|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) to Measure Tissue Oxygen Saturation (St02)|St02|Beth Israel Deaconess Medical Center|No|Active, not recruiting|September 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|Samples With DNA|whole blood, serum|Both|18 Years|N/A|No|Probability Sample|Emergency Department|September 2015|September 8, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062685||126878|
NCT01062919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-08-070|Local Anesthetic Wound Infusion and Functional Recovery After Colon Surgery|Postoperative Determinants of Functional Recovery Following Colon Surgery: The Effect of Wound Infiltration With Local Anesthetics||McGill University Health Center|Yes|Terminated|July 2009|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|10|||Both|18 Years|85 Years|No|||August 2015|August 3, 2015|September 22, 2009||No|Low recruitment rate - >70% of colorectal procedures are done laparoscopically|No||https://clinicaltrials.gov/show/NCT01062919||126860|
NCT01062113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3191200|Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain|A Randomized, Double-Blind, Multicenter, Comparative Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In The Treatment Of Acute Pain After Oral Surgery Lateral Mandibular Impacted Third Molar Tooth Extraction||Pfizer|No|Completed|April 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|255|||Both|20 Years|64 Years|No|||October 2012|October 17, 2012|February 2, 2010|Yes|Yes||No|August 1, 2011|https://clinicaltrials.gov/show/NCT01062113||126922|
NCT01063439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BuEAM-DLBCL|BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)|Busulfan, Etoposide, Cytarabine and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With Diffuse Large B Cell Lymphoma (DLCBL) Previously Treated With Rituximab Based Regimen||Inje University|No|Recruiting|January 2010|February 2015|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|N/A|65 Years|No|||August 2010|December 1, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063439||126820|
NCT01047982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOGDM-2010|Myo-inositol in Obese Pregnant Women|Myo-inositol May Prevent Gestational Diabetes in Obese Women||University of Messina||Completed|March 2010|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|220|||Female|18 Years|45 Years|No|||February 2014|February 27, 2014|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047982||128000|
NCT01047995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 031|Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects|Plasma and Intracellular Pharmacokinetics of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects||St Stephens Aids Trust|No|Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||January 2010|January 12, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01047995||127999|
NCT01048736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008292|Investigating Fitness Interventions in the Elderly (INFINITE)|Investigating Fitness Interventions in the Elderly (INFINITE)|INFINITE|Wake Forest School of Medicine|Yes|Completed|October 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048736||127942|
NCT01063413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090986|Physical Activity, Weight and Fitness Outcomes in Children in After-Care|Impact Analysis of Metro Parks' After-School Programming on Physical Activity, Weight and Fitness Outcomes||Vanderbilt University|Yes|Completed|February 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|5 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|public school students|April 2012|April 18, 2012|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063413||126822|
NCT01031407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100027|Cognitive Neuroscience of Autism Spectrum Disorders|Cognitive Neuroscience of Autism Spectrum Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|November 2009|||||N/A|Observational|N/A|||Anticipated|1600|||Both|5 Years|89 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01031407||129214|
NCT01031706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1258|Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis|Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis||University of North Carolina, Chapel Hill|Yes|Completed|September 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|5 Years|12 Years|No|||March 2014|May 29, 2014|December 11, 2009|Yes|Yes||No|March 5, 2014|https://clinicaltrials.gov/show/NCT01031706||129191|
NCT01063738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB_PG_1208_18030|Rehabilitating Muscle After Intensive Care|Rehabilitating Muscle After Intensive Care|REMAIC|St Helens & Knowsley Teaching Hospitals NHS Trust|No|Completed|August 2010|November 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|93|||Both|45 Years|N/A|No|||January 2015|January 2, 2015|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01063738||126797|
NCT01063972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA101963-07|Smoking Cessation in Rural Hospitals|Centralized Disease Management for Rural Hospitalized Smokers||University of Kansas Medical Center|No|Completed|March 2010|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|606|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 18, 2015|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063972||126779|
NCT01060020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1780|Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis|Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis||Washington University School of Medicine|Yes|Completed|January 2010|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060020||127082|
NCT01060254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017017|A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|April 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|January 29, 2010|Yes|Yes|Logistic reasons associated with the FDA-imposed clinical hold.|No||https://clinicaltrials.gov/show/NCT01060254||127064|
NCT01060449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00016194|Stimulus Intensity in Left Ventricular Leads|Stimulus Intensity in Left Ventricular Leads and Response to Cardiac Resynchronization Therapy|SILVeR-CRT|Emory University|Yes|Completed|August 2008|February 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2013|December 15, 2013|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060449||127049|
NCT01060696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|615/2551|Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile Women|Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile Women. A Double Blind Randomized Controlled Trial||Mahidol University|No|Active, not recruiting|January 2009|May 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|138|||Female|20 Years|40 Years|No|||January 2010|February 1, 2010|January 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01060696||127030|
NCT01061034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180/07|Pharmacological Study That Measures Omeprazole Effect on Aspirins Absorption in Healthy Volunteers|The Effect of Proton Pump Inhibitor (Omeprazole) on Acetosalisylic Acid Absorption.||Assaf-Harofeh Medical Center|No|Completed|March 2007|June 2007|Actual|June 2007|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|60 Years|No|||November 2009|January 2, 2010|May 3, 2009||No||No|May 3, 2009|https://clinicaltrials.gov/show/NCT01061034||127004|
NCT01061268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMF-001|A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens|A Randomized Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens||Innovative Medical|No|Completed|January 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|21 Years|N/A|No|||February 2012|February 15, 2012|February 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061268||126986|
NCT01061281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tecnis MF/Crystalens|Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses|Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses||Innovative Medical|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01061281||126985|
NCT01061827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOHP/04/VC-GMS|Validation of the French Version of the Geriatric Mental State (GMS)|Validation of the French Version of the Geriatric Mental State: a Structured and Standardized Interview for Diagnosis of Psychiatric Disorders in the Elderly|GMS-Package|University Hospital, Tours|Yes|Completed|June 2008|November 2013|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|96|||Both|65 Years|N/A|No|Non-Probability Sample|Patients 65 years or more, Nearest available to assist with the interview of informal        caregivers For the subjects in the "dementia", meets the ICD-10 criteria for dementia, and        CDR score at 1 to 2, with or without treatment For the subjects in the "depression",        ICD-10 criteria for major depression, score on the depression scale MADRS of 18 or more,        with or without treatment For control subjects, level of education based on the number of        years of schooling (compulsory education until 16 years, extended school)        Non-inclusion criteria Subjects with symptoms involving mixed dementia and depression such        as not allowing complete ICD-10 criteria for dementia or depression.|August 2013|December 18, 2013|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061827||126943|
NCT01062126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD525|BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes|Advanced Bradycardia Device Feature Utilization and Clinical Outcomes|BRADYCARE|St. Jude Medical|No|Completed|February 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3389|||Both|19 Years|N/A|No|Non-Probability Sample|Patients indicated for standard Pacemaker indications|December 2012|December 12, 2012|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062126||126921|
NCT01062399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0913|Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma|RTOG 0913|Radiation Therapy Oncology Group|Yes|Active, not recruiting|December 2010|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|120 Years|No|||January 2016|January 20, 2016|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062399||126900|
NCT01062412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-00013-000 Rev C|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2009|||||N/A|N/A|N/A||||||||||||||February 3, 2010|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062412||126899|
NCT01062425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02012|Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma|Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2010|||October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||June 2015|November 20, 2015|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062425||126898|
NCT01062698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00753-54|Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke|The Contribution of Intra-arterial Thrombectomy in Acute Ischemic Stroke in Patients Treated With Intravenous Thrombolysis|THRACE|Central Hospital, Nancy, France||Terminated|June 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|412|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|February 3, 2010||No|Efficacy|No||https://clinicaltrials.gov/show/NCT01062698||126877|
NCT01062932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23305|Investigation of Cycloserine as a Smoking Cessation Treatment|Cycloserine Enhancement of Extinction Learning||Baylor College of Medicine|Yes|Completed|May 2009|September 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|34|||Both|18 Years|55 Years|No|||July 2012|July 25, 2012|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062932||126859|
NCT01062945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25442|The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine|The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine||Baylor College of Medicine|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|13|||Both|18 Years|55 Years|No|||July 2012|July 25, 2012|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062945||126858|
NCT01063218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR.09.001|Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application|Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application||Galderma Brasil Ltda.|No|Completed|December 2009|October 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|74|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063218||126837|
NCT01063231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-201|Evaluation of PillCam™ Colon 2 in Visualization of the Colon|Evaluation of PillCam™ Colon 2 in Visualization of the Colon||Given Imaging Ltd.|No|Completed|September 2009|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|119|||Both|18 Years|80 Years|No|||November 2010|November 25, 2010|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01063231||126836|
NCT01063452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Truvalve|Impact of Atkinson Product Design Urinary Slide Valve Versus Standard Catheter Drainage System on Social Functioning|Impact of Atkinson Product Design Urinary Slide Valve Versus Standard Catheter Drainage System on Social Functioning||The Cleveland Clinic|No|Completed|February 2010|December 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Male|18 Years|N/A|No|||February 2010|August 12, 2013|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063452||126819|
NCT01048320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR2731|Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer|A Phase I Study of Gemcitabine Plus Oxaliplatin in Combination With Imatinib Mesylate (Glivec) in Patients With Gemcitabine-refractory Advanced Adenocarcinoma of the Pancreas|RPGOG1|Royal Marsden NHS Foundation Trust|Yes|Completed|July 2006|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01048320||127974|
NCT01048307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-I-H-0902|Effect of Prontosan Wound Irrigation Solution on Venous Ulcers|Randomised, Controlled, Clinical Trial on the Safety and Efficacy of Prontosan Wound Irrigation Solution Compared to Standard Therapy in the Treatment of Hard-to-Heal Venous Leg Ulcers||Calvary Hospital, Bronx, NY|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|95 Years|No|||August 2010|August 16, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01048307||127975|
NCT01063205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24927|NAC as a Potential Treatment for Methamphetamine Dependence|N-AcetylCysteine as a Potential Treatment of Methamphetamine Dependence||Baylor College of Medicine|Yes|Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|10|||Both|18 Years|55 Years|No|||July 2012|July 25, 2012|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063205||126838|
NCT01063712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFM-P034|Safety and Effectiveness of the Device "Nit-Occlud® PDA-R"|Safety and Effectiveness of the Device "Nit-Occlud® PDA-R" for Percutaneous Closure of Patent Arterial Duct Between 2 and 8 mm in Patients Treated Interventionally in Specialized Centers||pfm S.R.L.|Yes|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|N/A|No|||May 2012|May 22, 2012|February 4, 2010||No||No|February 23, 2011|https://clinicaltrials.gov/show/NCT01063712||126799|The number of participants is small, because the participants were recruited in high altitude cities over 2700m above the sea level. At this altitude bigger defects are more frequent to find than little ones, so is pulmonary hypertension.
NCT01063985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091213|A Comparison of Skin Prick Tests, Clinical Symptoms, and Nasal Challenge Using a New Mouse Extract|A Comparison of Skin Prick Tests, Clinical Symptoms and Nasal Challenge Using a New Mouse Extract||Vanderbilt University|Yes|Completed|May 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|39|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Healthy individuals between the ages of 18-60 who are exposed to mice through occupation        or animal care.|July 2011|July 25, 2011|February 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01063985||126778|
NCT01060033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0033 / 201109278|MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer|A Study of Novel Magnetic Resonance Imaging Sequences for Target Delineation and Prognostication in Cervical Cancer|MRI|Washington University School of Medicine|No|Completed|November 2010|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01060033||127081|
NCT01061047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERTAMUSCLE|Comparison of Ertapenem Distribution in the Muscle of Six Healthy Volunteers and Six Critically Ill Patients by Microdialysis|||Poitiers University Hospital|No|Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2010|August 28, 2012|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01061047||127003|
NCT01061307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH2010/1|An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand|An Efficacy Trial of Fe, Zn and Vitamin A Fortified Rice in Children in Satun, Thailand||Swiss Federal Institute of Technology|No|Completed|September 2009|June 2010|Actual|March 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|203|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||April 2012|January 5, 2016|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061307||126983|
NCT01060735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005437ctil|Vitamin D Supplementation During Pregnancy and Bone Status in Children at Birth and at One Year of Age|The Effect of Different Doses of Vitamin D Supplementation During Pregnancy on Bone and Vitamin D Status in Children at Birth and at One Year Age||Rabin Medical Center|No|Recruiting|November 2010|December 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|January 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01060735||127027|
NCT01061580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1|BMAC Enhanced Coronary Artery Bypass Grafting (CABG)|Dose Response Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting (CABG) Surgery||Harvest Technologies|No|Terminated|May 2010|December 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01061580||126962|
NCT01061840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL 101|Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer|Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer||Gradalis, Inc.|Yes|Active, not recruiting|December 2009|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|12 Years|N/A|No|||January 2016|January 7, 2016|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061840||126942|
NCT01062451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23235|An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence|An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence||Baylor College of Medicine|Yes|Recruiting|May 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|80|||Both|18 Years|55 Years|No|||January 2016|January 11, 2016|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062451||126896|
NCT01062464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-00014-000|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2009|||||N/A|N/A|N/A||||||||||||||June 13, 2012|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01062464||126895|
NCT01062139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_COS_M01|Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy|A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis||CJ HealthCare Corporation|No|Enrolling by invitation|October 2009|||April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|66 Years|No|||February 2010|February 3, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062139||126920|
NCT01062438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST10B3|Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma|Genomic Study of Metastatic Osteosarcoma Using Next-Generation Sequencing Technology||Children's Oncology Group|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|99|Samples With DNA|Tumor Tissue|Both|N/A|N/A|No|Non-Probability Sample|Diagnosis of localized or metastatic osteosarcoma|May 2015|May 5, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062438||126897|
NCT01063270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB5974|Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa|Randomized Control Trial Comparing Efficacy of Antibiotic Therapy Alone Versus Antibiotic Therapy in Conjunction With Quadruple Pulse Therapy Using NdYag Laser in Treatment of Hidradenitis Suppurativa||Henry Ford Health System|Yes|Active, not recruiting|February 2010|December 2013|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|16 Years|N/A|No|||March 2013|March 27, 2013|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01063270||126833|
NCT01063465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Measurement of Mechanical Properties of the Healing Achilles Tendon With or Without Early Weightbearing|Measurement of Mechanical Properties of the Healing Achilles Tendon With or Without Early Weightbearing in a Clinical Randomized Trial||Linkoeping University|No|Recruiting|February 2009|||December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|60 Years|No|||January 2009|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063465||126818|
NCT01063478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-384-B|Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC|A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC|RAD001|University of Chicago|Yes|Terminated|February 2010|January 2012|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|89 Years|No|||January 2014|January 16, 2014|February 3, 2010|Yes|Yes|Poor accrual|No||https://clinicaltrials.gov/show/NCT01063478||126817|
NCT01063244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN-08-21|Comparison of Foley Balloon With or Without Traction for the Cervical Ripening|Comparison of Foley Balloon With or Without Traction for the Cervical Ripening||St. Luke's Hospital, Pennsylvania|Yes|Recruiting|January 2009|December 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|45 Years|No|||May 2014|May 1, 2014|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063244||126835|
NCT01063257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-CLO-08|Clofarabine in High Risk Myelodysplastic Syndrome (MDS)|A Phase I/II Multicenter Study of IV Clofarabine in Patients With High-Risk Myelodysplastic Syndrome Who Have Failed Therapy With Azacitidine: the NIDEVOL Study||Groupe Francophone des Myelodysplasies|Yes|Completed|April 2010|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||March 2013|March 18, 2014|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063257||126834|
NCT01060085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0842|Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging|A Comparison of the Diagnostic Accuracy of Adjunctive Digital Breast Tomosynthesis Versus Adjunctive Contrast Enhanced Breast Magnetic Resonance Imaging in the Preoperative Assessment of Breast Cancer||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|February 2009|August 2015|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|30 Years|N/A|No|Non-Probability Sample|Women who have histologically proven, non-inflammatory, breast cancer.|May 2015|May 12, 2015|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060085||127077|
NCT01048021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:061|Pulmonary Function Changes and Diaphragmatic Paralysis Following Ultrasound Guided Supraclavicular Brachial Plexus Blockade: The Effects of Decreased Local Anesthetic Volume|Pulmonary Function Changes and Diaphragmatic Paralysis Following Ultrasound Guided Supraclavicular Brachial Plexus Blockade: The Effects of Decreased Local Anesthetic Volume||University of Manitoba||Enrolling by invitation|October 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pateints at the HSC Pain Management Centre|November 2009|January 12, 2010|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01048021||127997|
NCT01048541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP061CC|Bladder Scan of Residual Urine With New Catheter|A Non-Inferiority Bladder Scan Study to Investigate Residual Urine After Use of Intermittent Catheters in Male Subjects||Coloplast A/S|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Male|18 Years|N/A|No|||August 2012|August 2, 2012|January 11, 2010||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT01048541||127957|
NCT01060267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC06/019|Intravenous Erythromycin Before Endoscopy in Patients With Variceal Bleeding: A Randomized, Double-Blind Trial|Effect of Intravenous Bolus Infusion of Erythromycin Prior to Endoscopy in Patients Presenting With Variceal Bleeding: A Prospective, Randomized, Double- Blind ,Placebo Controlled, Trial||King Abdulaziz Medical City|Yes|Completed|January 2007|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||February 2010|February 1, 2010|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01060267||127063|
NCT01063426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-I055|Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users|Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial|Re-STOP DVT|Hallym University Medical Center|No|Recruiting|November 2009|March 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|19 Years|N/A|No|||February 2010|February 4, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063426||126821|
NCT01063725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS1|A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms|A Multi-center, Randomized, Placebo-controlled Double Blind Clinical Study Assessing the Efficacy and Safety of Femarelle® in Menopausal Women With Vasomotor Syndrome||Se-cure Pharmaceuticals Ltd.|No|Recruiting|August 2011|October 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|40 Years|65 Years|No|||February 2010|October 9, 2011|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063725||126798|
NCT01060462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015691|Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients|Efficacy According to Treatment Timing in Immunocompromised Patients Treated With Itraconazole Injection as an Empiric Antifungal Therapy||Janssen Korea, Ltd., Korea|Yes|Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|438|||Both|18 Years|N/A|No|Probability Sample|Study population consists of the patients who visit a study center during the study period        and are judged to have neutropenic fever associated with hematologic malignancy such as        acute leukemia, hodgkin's lymphoma, non-hodgkin's lymphoma, myelodysplastic syndrome, and        multiple myeloma|May 2014|May 14, 2014|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060462||127048|
NCT01060475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIM-0705-CL-002|Safety and Tolerability of LIM-0705 in Healthy Male Subjects|A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 Given With or Without Tacrolimus in Healthy Male Subjects|LIM|Limerick BioPharma|Yes|Completed|February 2010|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 4, 2010|January 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01060475||127047|
NCT01060748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE527-102|Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea|Development of a Polyvalent Vaccine Against Enterotoxigenic Escherichia Coli (ETEC)Protective Efficacy of the Deletion-Attenuated, Multi-valent ACE527 Against Challenge With a Prototype Strain of Enterotoxigenic E.Coli Expressing LT and ST Enterotoxins and CFA/I (Strain H10407) in Human Challenge Model.||TD Vaccines A/S|Yes|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 4, 2011|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01060748||127026|
NCT01061606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02989|Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus|Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus||National Cancer Institute (NCI)||Terminated|January 2010|October 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||December 2012|September 5, 2014|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01061606||126960|
NCT01061853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN06-LV/RALIB|Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen|Efficacy of Topical Rapamycin in Treatment of Chronic Erosive Oral Lichen Planus. Double Blind Randomised Controlled Trial Rapamycin vs Topical Steroids|RALIB|University Hospital, Tours|Yes|Terminated|February 2008|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|85 Years|No|||October 2013|October 15, 2013|February 2, 2010||No|Per protocol intermediate analyses of 76 patients and enrollment difficulties.|No||https://clinicaltrials.gov/show/NCT01061853||126941|
NCT01061320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-I-1-53/52|Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients|Efficacy of Alpha Tocopherol and New Biomarker (Urine NGAL) for Prevention and Early Diagnosis of Contrast-induced Nephropathy in CKD Patients Undergoing Elective Coronary Procedures||Thammasat University|Yes|Enrolling by invitation|January 2010|December 2010|Anticipated|October 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2010|February 2, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061320||126982|
NCT01061567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.675|Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice|Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice||Boehringer Ingelheim||Completed|November 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1814|||Both|18 Years|N/A|No|Probability Sample|Patients|June 2014|June 6, 2014|December 24, 2009||||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01061567||126963|There was no PI assigned for the overall study.
NCT01051609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-09-058|Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients|Prospective Study of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|May 2010|||May 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|Women 18 years and older with non-metastatic hormone receptor (ER and/or PR) positive        breast cancer who are eligible for and planning on starting treatment with an AI within        one month of signing consent|September 2015|September 3, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051609||127722|
NCT01052480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-I-0043|Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza|A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)|IRC002|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2010|November 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|N/A|No|||December 2015|December 14, 2015|January 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052480||127656|
NCT01052493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICIM1420/09/01|A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects|A First Time in Human, Double Blind, Randomised, Placebo Controlled Dose Escalation Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects.||Imperial College London|Yes|Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 31, 2011|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052493||127655|
NCT01052506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215HV101|BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects|A Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Adult Volunteers||Biogen|No|Completed|January 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||May 2012|September 12, 2013|January 15, 2010||Yes||||https://clinicaltrials.gov/show/NCT01052506||127654|
NCT01052467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treatment with Xamiol® Gel|Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)|Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)||LEO Pharma|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|724|||Both|18 Years|N/A|No|Non-Probability Sample|Patients visiting their attending dermatologist in the primary care clinic|September 2010|February 18, 2014|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052467||127657|
NCT01052727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-DOLCE-01-2010-BO|Day-care Versus Overnight-stay Laparoscopic Cholecystectomy Randomized Controlled Trial.|DOLCE Study: Day-care Versus Overnight-stay Laparoscopic Cholecystectomy Randomized, Controlled Trial|DOLCE|St. Orsola Hospital|No|Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2009|January 19, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052727||127637|
NCT01053026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903006R|Evaluation of Effects of Exercise Training and ARB in DM Patients|Evaluation of Vascular Function, Effects of Exercise Training and Angiotensin Receptor II Antagonist in Patients With Type II Diabetes and Hypertension by Using Near-infrared Spectroscopy, Rapid Laser Doppler Blood Flow Imaging and Circulating Biomarkers||National Taiwan University Hospital|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|15|Samples Without DNA|serum|Both|30 Years|70 Years|No|Non-Probability Sample|patients with diabetes melitus and hypertension|July 2012|November 15, 2012|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01053026||127614|
NCT01053260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-067|Contingency Management for Promoting Weight Loss in University Students|Contingency Management for Promoting Weight Loss in University Students|WeLCoMe|University of Connecticut Health Center|Yes|Completed|February 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|17 Years|29 Years|No|||June 2012|June 14, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053260||127596|
NCT01053520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-957|Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects|||Abbott|No|Completed|October 2009|January 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|12|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|November 8, 2010|November 23, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01053520||127577|
NCT01053507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114126|Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction|Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction||Cady, Roger, M.D.|No|Terminated|May 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|23|||Both|18 Years|65 Years|No|||January 2014|January 28, 2014|January 19, 2010|Yes|Yes|Enrollment rate was slower than anticipated.|No|January 28, 2014|https://clinicaltrials.gov/show/NCT01053507||127578|
NCT01053741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00014051|Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission|The Effect of Seminal Fluid on Distal Colon Mucosal Permeability and Susceptibility to HIV Infection||Johns Hopkins University|Yes|Completed|March 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|14|||Male|21 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 2, 2014|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01053741||127560|
NCT01054092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0121|A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients|A Phase 3, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus||Astellas Pharma Inc|No|Completed|December 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054092||127533|
NCT01054105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJC-IIT-1001|Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension|The Prevalence of BMPR-2 Gene Mutations in Korean Patients With Pulmonary Arterial Hypertension (PAH) and the Effects of Gene Mutations on Hemodynamic Response by Drug Therapy|PILGRIM|Gachon University Gil Medical Center|No|Recruiting|October 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|80 Years|No|||February 2016|February 10, 2016|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054105||127532|
NCT01054417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPEL01|APPEndicitis and Laparoscopic Criteria; APPEL Study|A Prospective Evaluation to Determine Laparoscopic Criteria for the Diagnosis Appendicitis During a Diagnostic Laparoscopy|APPEL|University Medical Center Groningen|No|Completed|December 2009|July 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|142|Samples Without DNA|Slices of the appendix fixed for pathologic examnination will be retained (standard      procedure).|Both|N/A|N/A|No|Non-Probability Sample|All patients who will undergo a diagnostic laparoscopy for the clinical diagnosis        appendicitis.|November 2011|November 16, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054417||127508|
NCT01054430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-012|To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.|A PHASE I, OPEN LABEL, NON-RANDOMIZED, SINGLE-DOSE, PARALLEL-COHORT, MATCHED-CONTROL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF AVANAFIL (TA-1790) IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY CONTROL MALE SUBJECTS|avanafil|VIVUS, Inc.||Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Male|21 Years|75 Years|Accepts Healthy Volunteers|||January 2011|January 5, 2011|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054430||127507|
NCT01044589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008|Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone|||Cook||Completed|May 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|N/A|No|||February 2015|February 5, 2015|January 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044589||128259|
NCT01045161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-MD-38|Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose|LAS-MD-38|Forest Laboratories|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|544|||Both|40 Years|N/A|No|||November 2015|November 4, 2015|January 7, 2010|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT01045161||128215|
NCT01045135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pelvic floor ultrasound|The Effect of Pregnancy and Labour on the Pelvic Floor Diagnosed With 3D and 4D Ultrasound|The Effect of Pregnancy and Labour on the Pelvic Floor Diagnosed With 3D and 4D Ultrasound||University Hospital, Akershus|No|Recruiting|December 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women giving birth to their first child at Akershus University Hospital, Norway|December 2009|January 7, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045135||128217|
NCT01010191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M16986|Harnessing Placebo Effects: Non-Deceptive Use of Placebo in Irritable Bowel Syndrome (IBS)|Pilot Randomized Controlled Trial||Harvard University Faculty of Medicine|No|Completed|July 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||June 2011|June 21, 2011|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01010191||130829|
NCT01010204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH087928|Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder|Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder|BEST|University of Pittsburgh|Yes|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|November 5, 2009|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01010204||130828|
NCT01055223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113332|Fracture Risk With Thiazolidinediones|The Association Between Exposure to Spironolactone or Amiloride and Fracture Risk Among Subjects Treated With Thiazolidinediones||GlaxoSmithKline|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|98483|||Both|18 Years|65 Years|No|Non-Probability Sample|The study population will consist of type 2 diabetes patients aged 18 -65 years old        exposed to TZD for at least 6 months or at least 12 months. The study will use data from        the US health claims database, the Ingenix Impact National Managed Care Database (Impact        Database). The Impact Database system is a comprehensive, de-identified U.S. healthcare        claims database that is representative of the non-elderly, insurance-carrying population.        It includes 89.3 million lives from 1997 to 2008. Approximately 74 percent of all patients        in the database have pharmacy benefits and, on average, 25 months of enrollment/claims        information. The data are collected from over 46 different healthcare plans serving        members across nine census regions.|June 2011|June 2, 2011|January 21, 2010||No||No|December 16, 2010|https://clinicaltrials.gov/show/NCT01055223||127447|
NCT01051037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-08-026|Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways|Phase II Study Evaluating Safety and Efficacy of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable and Recurrent Lung Tumors Near Central Airways||Jonsson Comprehensive Cancer Center|Yes|Recruiting|February 2010|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051037||127765|
NCT01051323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22714|An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia|Non-interventional Study to Investigate Hemoglobin Levels and Dose Over Time in the Daily Use of Mircera for Renal Anemia in Larger Centers, and to Detect Differences Between Standard of Care in the Centers||Hoffmann-La Roche||Completed|March 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1580|||Both|18 Years|N/A|No|Probability Sample|CKD patients treated with Mirecera at different medical centers|November 2015|November 17, 2015|January 15, 2010||No||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01051323||127743|
NCT01051336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-100-101|Safety and Tolerability Study of the Taris Placebo System|Phase I Safety and Tolerability Study of the Taris Placebo System (A Novel Bladder Drug Delivery Platform)||TARIS Biomedical, Inc.|No|Completed|October 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2010|January 15, 2010|January 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01051336||127742|
NCT01051921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-1027-04|Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders|An Open-Label Trial of Pegylated Interferon Plus Ribavirin in Combination With CTS-1027 in HCV Null-Responders|CTS-1027-04|Conatus Pharmaceuticals Inc.|Yes|Completed|January 2010|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|January 18, 2010|No|Yes||No|March 13, 2012|https://clinicaltrials.gov/show/NCT01051921||127699|Although this study was completed, the entire CTS-1027 program was discontinued prior to database lock. Hence, only a safety analysis was carried out for this study. Analysis of the primary and secondary efficacy measures was not completed.
NCT01051934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100032|A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma|A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma||National Institutes of Health Clinical Center (CC)||Completed|December 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|January 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01051934||127698|
NCT01052519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708/2009, local IRB|Obesity and Goal-directed Intraoperative Fluid Therapy|Intraoperative Goal-directed Fluid Management in Non-Obese and Obese Patients Undergoing Laparoscopic Surgery||Medical University of Vienna|No|Completed|January 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|65 Years|No|||November 2014|November 18, 2014|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052519||127653|
NCT01052740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100042|X-Ray Mammography Standard of Care Protocol|X-Ray Mammography Standard of Care Protocol||National Institutes of Health Clinical Center (CC)||Completed|December 2009|September 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|108|||Female|18 Years|N/A|No|||September 2011|September 23, 2011|January 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01052740||127636|
NCT01053039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22518|The Use of Intrathecal Morphine in the Management of Acute Pain Following Decompressive Lumbar Spinal Surgery|The Use of Intrathecal Morphine in the Management of Acute Pain Following Decompressive Lumbar Spinal Surgery: A Randomized Controlled Trial|ITMP|University of Calgary|Yes|Completed|January 2010|February 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|N/A|N/A|No|||December 2015|December 15, 2015|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053039||127613|
NCT01053273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 27|A Randomized, Equivalence Trial of Percutaneous Lumbar Adhesiolysis and Caudal Epidural Steroid Injections|Comparative Effectiveness of Percutaneous Adhesiolysis and Caudal Epidural Steroid Injections in Low Back and/or Lower Extremity Pain: A Randomized, Equivalence Trial||Pain Management Center of Paducah|Yes|Active, not recruiting|February 2010|January 2014|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053273||127595|
NCT01053533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100118|A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza||200907001-2A|Beijing Ditan Hospital|Yes|Recruiting|January 2010|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|6 Years|N/A|No|||January 2010|June 7, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053533||127576|
NCT01053754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/23|Optimization of the Evaluation of the Adrenal Function After Discontinuation of a Prolonged Therapy With Corticosteroids|Optimization of the Evaluation of the Adrenal Function After Discontinuation of a Prolonged Therapy With Corticosteroids||Assistance Publique Hopitaux De Marseille||Terminated|January 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01053754||127559|
NCT01053767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98P2E1|A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine|A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotypes Ib and III Antibodies in Women Previously Immunized With a GBS Ib and III Crm-Glycoconjugate Vaccine||Novartis||Completed|January 2010|December 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|95|||Female|20 Years|42 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053767||127558|
NCT01053780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNESC|Effects of Remote Intercessory Prayer|Effects of Remote Intercessory Prayer in Outcomes of Pregnants Women: a Randomized Controlled Trial||Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude|No|Completed|August 2008|January 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|565|||Female|15 Years|45 Years|No|||October 2009|January 20, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053780||127557|
NCT01054443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0913M0621|A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy||Shionogi Inc.|No|Terminated|January 2010|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||July 2011|September 13, 2011|January 20, 2010|Yes|Yes|The study objectives became unachievable as a result of the termination of 0913M0621|No||https://clinicaltrials.gov/show/NCT01054443||127506|
NCT01054456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-08-13|A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)|A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)||Eisai Inc.|No|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2011|January 5, 2011|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054456||127505|
NCT01054690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H15 315/2007|Silver Alloyed Urinary Catheters and Incidence of Catheter Acquired Urinary Tract Infections (UTI)|A Comparative Study to Investigate if Silver Alloyed Urinary Catheters Can Reduce the Incidence of Catheter Acquired Urinary Tract Infections in Patients Undergoing Elective Surgery||Region Skane|No|Completed|October 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|511|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01054690||127487|
NCT01054703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR02082|Clinical Evaluation of the Ethmoid Sinus Spacer|Clinical Evaluation of the Safety and Feasibility of the Ethmoid Sinus Spacer and Access System With Drug (SPACER)|SPACER|Acclarent|No|Completed|April 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|N/A|No|||June 2011|June 10, 2011|January 20, 2010|No|Yes||No|February 8, 2010|https://clinicaltrials.gov/show/NCT01054703||127486|
NCT01044602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0282|Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes|Metabolic Surgery vs. Medical Management for Resolution of Type II Diabetes: A Prospective Group Match Study||Ohio State University|No|Completed|January 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|120|||Both|25 Years|70 Years|No|||April 2015|April 20, 2015|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044602||128258|
NCT01014065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00028 / 24942|A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)|A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients|SUPER|AHS Cancer Control Alberta|No|Completed|July 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|Samples With DNA|Blood and urine banked|Both|18 Years|N/A|No|Probability Sample|Patients with renal cell carcinoma scheduled to receive sunitinub.|March 2012|February 24, 2016|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01014065||130533|
NCT01045434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-175-0MEP-2006|Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions|Open Label, Balanced, Randomized, Two-treatment,Two-period,Single-dose, Cross-over Oral Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule With Prilosec® OTCTM 20 mg Tablets in Healthy Human Adult Subjects, Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|December 2006|March 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045434||128194|
NCT01045447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3593|Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes (BOOST™ : INTENSIFY BASAL)|BOOST™|Novo Nordisk A/S|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|465|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 8, 2010|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01045447||128193|
NCT01009840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273-08-205|IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients|A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||September 2014|September 23, 2014|November 6, 2009|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01009840||130856|
NCT01009853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODE-T15-PVFS-1|Steady State Study of Codeine Sulfate|A Single Dose, 1-Period, 1-Treatment Study of Codeine Sulfate 15 mg Tablets Under Steady State Conditions||Roxane Laboratories|No|Completed|January 2008|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009853||130855|
NCT01010217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0266|Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide|Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2009|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|337|||Both|N/A|75 Years|No|||July 2015|July 22, 2015|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01010217||130827|
NCT01051050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0573|Use of Wikis and Evidence-Based Medicine in Surgical Practice|Using Wikis to Improve the Dissemination, Evaluation, and Application of Evidence-Based Medicine in Surgical Practice||The University of Texas Health Science Center, Houston|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 14, 2011|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01051050||127764|
NCT01051349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205-MS-203|Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis|A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)|SELECTED|Biogen|Yes|Active, not recruiting|March 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|410|||Both|18 Years|60 Years|No|||August 2015|August 28, 2015|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051349||127741|
NCT01051362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20060216|Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer|Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|February 2006|November 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|85 Years|No|||January 2006|January 15, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051362||127740|
NCT01051622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113265|PBMC (Peripheral Blood Mononuclear Cells) /Lymphocyte SPECT (Single Photon Emission Computerized Tomography) Imaging in Crohn's Disease|An Exploratory SPECT Imaging Study to Assess the Utility of High-specific Activity 99mTc-HMPAO Labeling as a Tool to Detect PBMC and Lymphocyte Trafficking in the Small Bowel or Ileo-caecal Region of Crohn's Disease Patients||GlaxoSmithKline|No|Completed|January 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|December 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01051622||127721|
NCT01051947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-15168|Impact of Nebivolol on Central Aortic Pressure|Impact of Nebivolol on Central Aortic Pressure||Creighton University|No|Withdrawn|December 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|45 Years|75 Years|No|||July 2011|July 29, 2011|January 19, 2010||No|Similar study already published|No||https://clinicaltrials.gov/show/NCT01051947||127697|
NCT01051960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-05-003|Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan|Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study||University of California, Los Angeles|No|Recruiting|March 2009|December 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||February 2009|January 19, 2010|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051960||127696|
NCT01053065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPS|The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study|The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study|MAPS|University of Padua|No|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|60|||Both|50 Years|85 Years|No|||January 2005|January 25, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053065||127611|
NCT01052753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912118R|The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD)|The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention-deficit Hyperactivity Disorder||National Taiwan University Hospital|Yes|Not yet recruiting|August 2010|July 2013|Anticipated|||N/A|Observational|N/A||2|Anticipated|300|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|7 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The proband sample will consist of at least 150 drug-naïve children and adolescents with        ADHD, aged 7-18 (who are able to perform the CANTAB and time tasks) from Department of        Psychiatry, National Taiwan University Hospital (NTUH). Their biological parents (n = 300)        and siblings (estimated number = 150) born to the same biological parents will be        recruited as the parent controls and sibling controls, respectively, for the family-based        case control study. We will recruit 150 school controls without lifetime diagnosis of ADHD        in the same school districts and with similar age and gender distributions of the probands        with ADHD.|January 2010|January 19, 2010|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052753||127635|
NCT01053052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Femasys 300-001|Study of FemVue(TM) Sono Tubal Evaluation System for Sonography Evaluation of Fallopian Tubes and Uterus: Method Comparison to HSG|A Comparative Study of Methods for Tubal Patency Determination and Uterine Cavity Evaluation: Sonography With the FemVue(TM) Catheter System vs. Hysterosalpingography (HSG)||Femasys Inc.|No|Suspended|January 2010|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Female|18 Years|45 Years||||October 2010|October 18, 2010|January 18, 2010|Yes|Yes|Enrollment for this post-market study is on hold while protocol enhancements are considered by    the sponsor.|No||https://clinicaltrials.gov/show/NCT01053052||127612|
NCT01053793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11-004|Glycemic Index and Polyphenol Bioavailability of Potatoes|A Trial to Measure the Glycemic Index and Polyphenol Bioavailability of Four Different Varieties of Potato.|GI|Guelph Food Research Centre|Yes|Completed|January 2010|March 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 14, 2011|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053793||127556|
NCT01053806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-MM-0437-09-CTIL|Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome|A PHASE 2, SINGLE ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF AZACITIDINE, AND LENALIDOMIDE IN HIGHER RISK MYELODYSPLASTIC SYNDROME|ViLen 001|Tel-Aviv Sourasky Medical Center||Recruiting|August 2011|||March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||September 2012|September 23, 2012|January 19, 2010||||No||https://clinicaltrials.gov/show/NCT01053806||127555|
NCT01054118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016348|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin|Sitagliptin Combo Study||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2009|February 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|18|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|January 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054118||127531|
NCT01054469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003563|Transversus Abdominus Plane Block|Ultrasound Guided Transversus Abdominus Plane Block for Patients Undergoing Laparoscopic Hand-assisted Nephrectomy.||Mayo Clinic|No|Completed|March 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|21|||Both|18 Years|80 Years|No|||June 2012|June 20, 2012|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054469||127504|
NCT01054716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-RHD-105|Evaluation of a Noninvasive Fetal RHD Genotyping Test|Evaluation of a Noninvasive Fetal RHD Genotyping Test|IRIS|Sequenom, Inc.|No|Completed|May 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood collected, processed to plasma and buffy coat for DNA extraction.|Female|18 Years|64 Years|No|Non-Probability Sample|Pregnant subjects who are RhD negative and between 10 and 28 weeks gestation.|September 2011|September 1, 2011|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054716||127485|
NCT01054729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7977-0221|Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients|A Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Standard of Care (Pegylated Interferon and Ribavirin) in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1||Gilead Sciences|No|Completed|January 2010|August 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|65 Years|No|||March 2014|March 31, 2014|January 21, 2010|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01054729||127484|
NCT01013766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111823|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics|A Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||March 2011|March 31, 2011|October 29, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01013766||130556|
NCT01013779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 09.03|Merkel Positron Emission Tomography (PET) Protocol|A Phase II Efficacy Study of Chemo-Radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin|MP3|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Recruiting|December 2009|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|November 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01013779||130555|
NCT01045460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0997|Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma|Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma|aMILs|Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|December 2009|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|No|||April 2015|April 8, 2015|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045460||128192|
NCT01045473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMISS-001|Prospective Study of Minimally Invasive Spine Surgery|Prospective Study of Minimally Invasive Spinal Fusion Surgery for the Treatment of Spondylolisthesis, Degenerative Disk Disease, Spinal Stenosis and Degenerative Scoliosis||Society for Minimally Invasive Spine Surgery|No|Not yet recruiting|January 2010|June 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|450|||Both|21 Years|90 Years|No|Non-Probability Sample|Orthropedic surgeon's clinic. Neurosurgeon's clinic.|January 2010|January 8, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045473||128191|
NCT01055236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168/2550(EC1)|Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients|Hydroxyzine for the Prevention of Pruritus and Nausea Vomiting From Spinal Morphine in Patients Having Transabdominal Hysterectomy Under Combined Spinal-general Anesthesia: A Randomized Control Trial|TAH|Mahidol University|No|Completed|August 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|60 Years|No|||December 2008|March 26, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01055236||127446|
NCT01051063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111727|Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy|Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy||GlaxoSmithKline||Active, not recruiting|December 2009|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|December 8, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01051063||127763|
NCT01051375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/27E|Examining the Effectiveness of a Wait List Intervention for the Management of Adolescent Eating Disorders|Examining the Effectiveness of a Wait List Intervention for the Management of Adolescent Eating Disorders||University of Ottawa|No|Recruiting|December 2009|July 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|10 Years|17 Years|No|||January 2010|January 15, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051375||127739|
NCT01051635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100056|A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas|A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Recruiting|January 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|120 Years|No|||July 2015|February 5, 2016|January 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01051635||127720|
NCT01051648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triam1|Triamcinolone Assisted Anterior Vitrectomy|Triamcinolone Assisted Anterior Vitrectomy in Complicated Cataract Surgery and Anterior Segment Reconstruction||Cairo University|Yes|Completed|December 2007|June 2008|Actual|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|47 Years|79 Years|No|||February 2008|January 15, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051648||127719|
NCT01052246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK_08_2009|Pulsed Dye Laser Treatment of Acne Vulgaris|The Pulsed Dye Laser as an Adjuvant Treatment Modality in Acne Vulgaris - a Randomized Controlled Single Blinded Trial||Laserklinik Karlsruhe|No|Completed|October 2008|September 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|N/A|No|||January 2010|January 19, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052246||127674|
NCT01053078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 10087|Naltrexone and Hypoglycemia in Type 1 Diabetes|Study of the Effect of Naltrexone on Cerebral Blood Flow and Hypoglycemia in Type 1 Diabetes Mellitus|Naltrexone|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|October 2009|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 19, 2010|Yes|Yes||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01053078||127610|
NCT01052766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-134|Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis|The Use of Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung and Liver Lesions and Assessment of Tumor Glycolysis||Memorial Sloan Kettering Cancer Center||Terminated|January 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|January 18, 2010|No|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01052766||127634|
NCT01053572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 23|Role of Steroids and 10% Hypertonic Sodium Chloride in Adhesiolysis in Post Lumbar Surgery Syndrome Patients|Evaluation of the Role of Steroids and 10% Hypertonic Sodium Chloride in Adhesiolysis in Post Lumbar Surgery Syndrome Patients: A Prospective, Randomized, Double-Blind, Equivalence, Controlled Trial of Percutaneous Lumbar Adhesiolysis||Pain Management Center of Paducah|Yes|Active, not recruiting|February 2010|January 2014|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053572||127573|
NCT01053546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98109|Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer|Effects of Early vs Late Onset of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Terminated|November 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|156|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|January 20, 2010|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT01053546||127575|
NCT01053559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exempt IND|Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy|Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients With Small Bowel Crohn's Disease Treated With Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy||Shafran Gastroenterology Center|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|70 Years|No|||April 2014|April 23, 2014|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053559||127574|
NCT01053819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F070629011|Can We Miss Pigmented Lesions in Psoriasis Patients?|Can We Miss Pigmented Lesions in Psoriasis Patients?||University of Alabama at Birmingham|No|Completed|September 2007|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|19 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 21, 2012|February 6, 2009|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT01053819||127554|
NCT01053832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45|Ventricular Pace Suppression Study|Ventricular Pace Suppression Study With the EVIA/ENTOVIS DR-T/DR Pacemaker|VpS|Biotronik SE & Co. KG||Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|84|||Both|N/A|N/A|No|||October 2011|October 24, 2011|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053832||127553|
NCT01053845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0066|Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain|Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain|PhyDoNe|University Hospital, Clermont-Ferrand||Completed|April 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 4, 2014|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053845||127552|
NCT01054131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|420-2009|Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program|Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program||Sunnybrook Health Sciences Centre|No|Completed|January 2010|December 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2011|December 23, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054131||127530|
NCT01054742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04793 Part 2|Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)|PREDICT (Part 2)- Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With HCV Genotype 1 Low Viral Load (HCV LVL 1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24||Merck Sharp & Dohme Corp.|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|None Retained|Blood sample for polymerase chain reaction (PCR) Assay|Both|18 Years|N/A|No|Non-Probability Sample|Only participants who were originally treated in study P04793 and relapsed during the 24        week follow up phase were offered the chance to receive retreatment with PegIntron and        ribavirin for up to an additional 48 weeks.|January 2015|January 7, 2015|January 21, 2010|No|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT01054742||127483|
NCT01055041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharmacol no.03 /2008 Research|Controller Medications in the Management of Bronchial Asthma|A Randomized, Open Labeled Comparative Study to Assess the Efficacy and Safety of Controller Medications as Add on to Inhaled Steroid and Long Acting β2 Agonist in Treatment of Moderate to Severe Persistent Bronchial Asthma||Government Medical College, Bhavnagar|No|Completed|December 2008|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|15 Years|65 Years|No|||January 2010|January 22, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055041||127461|
NCT01055054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU-IRB-1587|Bariatric Surgery Registry|Analysis Bariatric Surgery Data||Virginia Commonwealth University|No|Enrolling by invitation|July 1980|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4803|||Both|12 Years|75 Years|No|Non-Probability Sample|Patients who have undergone bariatric surgical procedures at the Virginia Commonwealth        University Medical Center.|July 2015|July 9, 2015|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01055054||127460|
NCT01055067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-A-U251|ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors|Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors||Daiichi Sankyo Inc.|No|Completed|January 2010|July 2012|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Male|16 Years|N/A|No|||September 2013|September 30, 2013|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055067||127459|
NCT01044901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16653A|Cardiovascular Complications of Sickle Cell Disease|Cardiovascular Complications of Sickle Cell Disease||University of Chicago|No|Recruiting|March 2009|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|Samples With DNA|We will study blood samples for chemicals related to sickle cell and heart and lung disease,      and will be evaluating DNA for purposes of the study.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from clinics at the University of Chicago as well as from the        community via flyers posted at the University of Chicago and a web site posted on the        University of Chicago Medical Center web site.|December 2015|December 1, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044901||128235|
NCT01044914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-013028-21|Genes, Intermediate Phenotypes and Response to Quetiapine RX|Use of Clinical and Intermediate Phenotypes to Assess Response to Quetiapine: the Role of Putative Causative Genes||University of Bari|Yes|Suspended|December 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|The study will be carried out in a hospital unit of the psychiatric assistance system.We        will recruit 100 patients with schizophrenia with recent exacerbation of psychotic        symptomatology.|June 2010|March 3, 2011|January 7, 2010||No|Study stopped due to the relatively limited mean reduction in PANSS scores (symptomatology).|No||https://clinicaltrials.gov/show/NCT01044914||128234|
NCT01044927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0587|Advanced eHealth for Chronic Obstructive Pulmonary Disease (COPD) in Colorado|Phase 3 Clinical Trial Studying the Efficacy of a Proactive Integrated Approach to Care in Patients With Advanced COPD||University of Colorado, Denver|No|Completed|September 2006|June 2008|Actual|August 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|511|||Both|40 Years|N/A|No|||October 2012|October 3, 2012|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044927||128233|
NCT01010490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-009|Outcomes of Phacoemulsification With Torsional Ultrasound|A Randomised Trial of Torsional Ultrasound Versus Longitudinal Ultrasound During Phacoemulsification of Age-related Cataracts: Comparison of Intra-operative Performance and Impact on Post-operative Endothelium Integrity||Iladevi Cataract and IOL Research Center|Yes|Completed|May 2007|March 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||November 2009|November 11, 2009|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01010490||130806|
NCT01009827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 086|Managerial Database II|Network-Wide Assessment of Current Health Status and Behavioral Risk Factors||Westat|Yes|Completed|October 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1712|||Both|12 Years|24 Years|No|Non-Probability Sample|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their        affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV        status and understand written and/or verbal English will be included in the master list        from which the study sample will be derived.|March 2016|March 1, 2016|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01009827||130857|
NCT01050816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02CON|Effects of CHONDRON (Autologous Chondrocytes) With Ankle Cartilage Defect|An Investigator Clinical Trial to Observe Effects of CHONDRON (Autologous Chondrocytes) for 12 Months in Patients With Ankle Cartilage Defect||Sewon Cellontech Co., Ltd.|Yes|Completed|January 2006|February 2009|Actual|January 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|15 Years|65 Years|No|||May 2010|May 6, 2010|January 13, 2010||No||No|January 21, 2010|https://clinicaltrials.gov/show/NCT01050816||127782|
NCT01051388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGID0801|Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation|Prophylactic Efficacy of Proton Pump Inhibitor on Recurrence of Peptic Ulcer in Patients Continuously Treated With Low-dose Aspirin－Randomized, Multi-center, Single-blinded, Parallel-group, Comparative Study|CARE|Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Completed|August 2008|December 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|280|||Both|20 Years|N/A|No|||April 2011|April 1, 2011|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051388||127738|
NCT01051661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114000|Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age|A Study to Evaluate the Safety and Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children Aged 6 Months to Less Than 10 Years of Age||GlaxoSmithKline||Completed|February 2010|September 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|6154|||Both|6 Months|9 Years|Accepts Healthy Volunteers|||August 2013|August 29, 2013|January 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051661||127718|
NCT01051674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59217|A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss|A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss in Obese Individuals With or Without Type 2 Diabetes||Loma Linda University|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01051674||127717|
NCT01051973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-X|Cognitive Behavior Therapy (CBT) Compared to Stress Management for Irritable Bowel Syndrome|Internet-delivered Cognitive Behavior Therapy Compared to Stress Management in the Treatment of Irritable Bowel Syndrome - A Randomized Controlled Study.||Karolinska Institutet|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01051973||127695|
NCT01052233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9037/403/2006|Development of Knee Osteoarthritis After Arthroscopic Partial Resection of Degenerative Meniscus Tear|Effect of Arthroscopic Partial Resection of Degenerative Meniscus Tear on Development of Knee Osteoarthritis: Which is the Chicken and the Egg?||University of Tampere|Yes|Enrolling by invitation|January 2010|January 2024|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|35 Years|65 Years|No|||January 2015|January 20, 2015|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052233||127675|
NCT01052779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-CKD-201|Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease|Ferumoxytol Compared to Iron Sucrose Trial (FIRST): A Randomized, Multicenter, Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease|FIRST|AMAG Pharmaceuticals, Inc.|No|Completed|March 2010|April 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052779||127633|
NCT01052792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-BE-138-NAPR-2005|Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions|Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|May 2006|June 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 19, 2010|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052792||127632|
NCT01052831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810624|Naltrexone for Impulse Control Disorders in Parkinson's Disease|Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease||University of Pennsylvania|No|Completed|November 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||July 2015|July 13, 2015|January 15, 2010|Yes|Yes||No|March 10, 2015|https://clinicaltrials.gov/show/NCT01052831||127629|
NCT01053286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917225-1|Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin|Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin||University of California, Davis|No|Completed|October 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Otolaryngology clinic|April 2013|April 22, 2013|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01053286||127594|
NCT01053338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-07|Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fed Condition|Open Label,Balanced,Randomized,Two-treatment,Two-sequence,Two Period,Single-dose,Crossover Oral Bioequivalence Study of Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets of Dr.Reddy's and Advil®PM of Wyeth in Normal,Healthy,Adult,Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|April 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 20, 2010|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053338||127590|
NCT01053364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL-PROW-01|Feasibility Study of NL-Prow Interspinous Spacer to Treat Lumbar Spinal Stenosis|Feasibility Study of NL-Prow Interspinous Spacer Device and Procedure||Non-Linear Technologies||Active, not recruiting|January 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|50 Years|N/A|No|||January 2011|January 4, 2011|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053364||127589|
NCT01053858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_10_12|Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision|||Hallym University Medical Center|Yes|Completed|January 2008|January 2010|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|20 Years|N/A|No|||January 2010|January 20, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01053858||127551|
NCT01053871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009SDU-QILU-G08|Propofol Versus Midazolam With Fentanyl for EGD Endomicroscopy|||Shandong University|Yes|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|104|||Both|18 Years|80 Years|No|||December 2009|June 13, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01053871||127550|
NCT01054144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16018|Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma|Phase II Study of Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults With Newly Diagnosed, Standard Risk Multiple Myeloma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|January 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|65 Years|N/A|No|||November 2015|November 6, 2015|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054144||127529|
NCT01054157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROST-1|Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues|Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues||Meir Medical Center|No|Not yet recruiting|February 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|human lower lid skin and lashes will be derived from lateral tarsal strip (LTS) dissected        routinely in ectropion repair surgery, the skin strip is dissected routinely in this        surgery|January 2010|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054157||127528|
NCT01054482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20070218|Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer|A Randomized Phase II Study Preoperative Chemotherapy Versus Preoperative Concurrent Chemoradiotherapy for Patients With Locally Advanced Non-Small Cell Lung Cancer||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|February 2007|December 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||January 2007|February 1, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054482||127503|
NCT01054495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1-7|Placebo in Acupuncture|Evaluating Placebo Interventions in Acupuncture Research||National Research Centre of Complementary and Alternative Medicine, Norway|Yes|Not yet recruiting|February 2010|June 2010|Anticipated|June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 28, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054495||127502|
NCT01054781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-12-005|Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)|Open-labelled, Multicenter Phase II Study of Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)||Samsung Medical Center|No|Completed|January 2009|||November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054781||127481|
NCT01010503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22508|A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.|Evaluation of Adherence and Persistence to Tocilizumab in Combination With Methotrexate or Tocilizumab Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis in Local Environment.||Hoffmann-La Roche||Completed|June 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|November 9, 2009||No||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01010503||130805|
NCT01010763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.RROW2|A Study on M2a Magnum Total Hip Arthroplasty|A Prospective Controlled Multi-Center Study on M2a Magnum Total Hip Arthroplasty||Biomet, Inc.|No|Active, not recruiting|November 2009|April 2022|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|20 Years|N/A|No|||September 2015|September 21, 2015|November 5, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01010763||130785|
NCT01013727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4551|Functional Neuroimaging of Postural Reconstruction|Functional Neuroimaging of Postural Reconstruction: Preliminary Study on a Dorsiflexion Motion of the Ankle and Comparison Between an Arm Following Postural Reconstruction Program and a Comparator Arm Following a Muscular Stretching Program||University Hospital, Strasbourg, France|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2010|April 28, 2010|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01013727||130559|
NCT01013740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112620|Lapatinib in Combination With Vinorelbine|A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination With Vinorelbine or Capecitabine in Women With ErbB2 Overexpressing Metastatic Breast Cancer|VITAL|GlaxoSmithKline|No|Active, not recruiting|November 2009|June 2016|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Female|18 Years|N/A|No|||November 2015|November 5, 2015|October 29, 2009|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT01013740||130558|
NCT01011335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-035/Nabi-6801|Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial|A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers||Uniformed Services University of the Health Sciences|Yes|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|176|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 15, 2012|November 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01011335||130741|
NCT01014078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-116|A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease|||Merck Sharp & Dohme Corp.||Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014078||130532|
NCT01014091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113810|Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 9 Years||GlaxoSmithKline||Terminated|December 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|3 Years|9 Years|Accepts Healthy Volunteers|||May 2011|November 1, 2012|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01014091||130531|
NCT01051076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06200|Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)|Immune Tolerance Induction Study in Patients With Severe Type A Haemophilia With Inhibitor After Failure of a Previous Induction of Immune Tolerance With FVII Concentrates Without Von Willebrand Factor Rescue|RESIST EXP|City of Hope Medical Center|Yes|Active, not recruiting|June 2009|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|N/A|N/A|No|||March 2015|March 31, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051076||127762|
NCT01051401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98509|Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer|Statin Therapy as a Protective Technique for Potential Cardiovascular Event Occurrences Among Breast Cancer Patients Undergoing Chemotherapy Treatment||Comprehensive Cancer Center of Wake Forest University|Yes|Terminated|January 2010|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|70|||Female|N/A|N/A|No|||February 2014|February 17, 2014|January 15, 2010|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT01051401||127737|
NCT01051687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-101|Botulinum Toxin Treatment for Localized Vitiligo|Botulinum Toxin Treatment for Localized Vitiligo||King Saud University|Yes|Completed|April 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|50 Years|No|||January 2010|January 15, 2010|January 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01051687||127716|
NCT01052259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPCR2009|Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection|Pilot Study of Cycling Treatment of Deoxyspergualin in Biopsy-proven Chronic Rejection of Kidney Transplantation||Nippon Kayaku Co.,Ltd.|No|Terminated|June 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|11 Years|70 Years|No|||January 2014|January 7, 2014|January 14, 2010||No|Insufficient patient enrollment|No||https://clinicaltrials.gov/show/NCT01052259||127673|
NCT01051986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0803-024-237|A Prospective Randomized Study for Comparison of Y-Composite Grafts|A Randomized Comparison of the SAphenous VEin Versus Right Internal Thoracic Artery as a Y-Composite Graft (SAVE-RITA Trial)|SAVERITA|Seoul National University Hospital|No|Completed|September 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|40 Years|75 Years|No|||November 2013|November 21, 2013|January 17, 2010||No||No|May 29, 2013|https://clinicaltrials.gov/show/NCT01051986||127694|the current study is not a multicenter “all-comers” study, although it is a prospective, randomized, controlled trial.The 1-year graft patency rates and clinical outcomes of 34 months do not provide sufficient data to reach a definite conclusion
NCT01052818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAN/OfCA204/SO151/CB451/09|Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer|||National Institute of Cancerología|No|Recruiting|July 2007|||August 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Peripheral blood samples are collected were the cell pellet are collected from      centrifugation, lysed by TRIzol method to get RNA. The RNA is retrotranscribed to cDNA in      order to quantify cytokeratin (CK) 19, 18 and carcinoembrionic antigen which are markers of      epithelial cells presumambly coming form the tumor.|Both|18 Years|N/A|No|Non-Probability Sample|Advanced non small-cell lung cancer|January 2010|January 18, 2010|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052818||127630|
NCT01052558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-006|GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma|A Prospective, Randomized, Controlled, Parallel Groupos, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 in Conjunction With Cataract Surgery||Glaukos Corporation|Yes|Completed|January 2010|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|90 Years|No|||May 2015|May 18, 2015|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052558||127650|
NCT01052844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-2009|Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy|Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study||Faculdade de Medicina do ABC|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2014|January 18, 2014|December 17, 2009||No||No|September 24, 2010|https://clinicaltrials.gov/show/NCT01052844||127628|
NCT01052857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acupuncture|Efficacy of Acupuncture on Induction of Labor|Efficacy of Acupuncture on Induction of Labor||University of Modena and Reggio Emilia|Yes|Completed|November 2007|January 2009|Actual|May 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|40 Years|No|||December 2007|January 19, 2010|December 11, 2007||No||No||https://clinicaltrials.gov/show/NCT01052857||127627|
NCT01053299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VestreVikenKS 21517|Universal Ultrasound-screening for Developmental Dysplasia of the Hip in Newborn|Universal Ultrasound-screening for Developmental Dysplasia of the Hip. 5-12 Years Followup of 4 200 Newborns||Vestre VikenHF Kongsberg Sykehus|Yes|Enrolling by invitation|March 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|4200|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||January 2010|January 27, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053299||127593|
NCT01053312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE 067-008|PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus|A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied||GE Healthcare|Yes|Completed|December 2009|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|50 Years|N/A|No|||June 2012|June 7, 2012|January 19, 2010|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT01053312||127592|
NCT01053377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL27938.041.09|A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes|A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes|PEPpIE|National Institute for Public Health and the Environment (RIVM)|Yes|Enrolling by invitation|December 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|900|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2009|January 20, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053377||127588|
NCT01053585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1361|Structure and Function of the Gastro-esophageal Junction|Combined Magnetic Resonance Imaging and High Resolution Manometry Studies||University of Zurich|No|Completed|February 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|24|||Both|18 Years|50 Years|No|||May 2011|June 1, 2011|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01053585||127572|
NCT01053884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anidulafungin - MG-ECALTA1|Anidulafungin in Patients With Hematologic Malignancies|Anidulafungin in Patients With Hematologic Malignancies - An Open-label, Prospective Study to Evaluate the Safety Profile at Prophylactic and Therapeutic Dosages|ECALTA|Elisabethinen Hospital|No|Terminated|October 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|No|||July 2009|March 1, 2012|January 15, 2010||No|reduced recruitment rate due to non infectious, but competitive trials at our institution|No||https://clinicaltrials.gov/show/NCT01053884||127549|
NCT01053897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBT-09-001|Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery|A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery||Garnet BioTherapeutics, Inc.|No|Completed|January 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|70 Years|No|||August 2013|August 19, 2013|January 20, 2010|Yes|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT01053897||127548|Study was discontinued early due to difficulty in identifying and enrolling eligible subjects.
NCT01054170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00014|Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 12-week, Phase II, Double-blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60mg AZD9668 Administered Orally Twice Daily on Structural Changes in the Airways by Multi-Slice Computed Tomography in Patients With Chronic Obstructive Pulmonary Disease.||AstraZeneca|Yes|Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|50 Years|80 Years|No|||August 2012|August 14, 2012|January 20, 2010||No||No|January 24, 2012|https://clinicaltrials.gov/show/NCT01054170||127527|
NCT01054183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090903|The Use of the GlideScope Ranger in Pediatric Critical Care Transport|The Use of the GlideScope Ranger in Pediatric Critical Care Transport||Akron Children's Hospital|Yes|Completed|July 2010|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|N/A|17 Years|No|||February 2015|February 4, 2015|January 21, 2010||No||No|November 28, 2012|https://clinicaltrials.gov/show/NCT01054183||127526|The biggest limitation was slow patient enrollment, prompting the study to be closed prior to reaching the full study power. All data were reliably reported.
NCT01055119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD PUFA 2009|Effect of Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder|Effect of Supplementation With Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder|EFA|University of Ulm|No|Completed|April 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|95|||Both|6 Years|12 Years|No|||May 2013|May 2, 2013|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055119||127455|
NCT01055132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1476AG|Dispensing Evaluation of New Daily Disposable Toric Soft Contact Lens.|Dispensing Evaluation of New Daily Disposable Toric Soft Contact Lens.||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|40 Years|No|||May 2015|May 5, 2015|January 22, 2010|Yes|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT01055132||127454|
NCT01055145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0911-068-301|Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients|Comparison of the Effect Between Levofloxacin and Moxifloxacin on the Culture Conversion After 3 Months Treatment Among MDR-TB Patients; Prospective Multicenter Randomized Open Label Phase III Trial||Seoul National University Hospital|Yes|Terminated|March 2010|October 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|20 Years|75 Years|No|||November 2012|November 22, 2012|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01055145||127453|
NCT01011062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS01|Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes|Effect of Acute Angiotensin Receptor Blockade on Insulin Resistance and Selected Cytokines in Adipose Tissue in Type 2 Diabetes||Institute for Clinical and Experimental Medicine|Yes|Completed|January 2004|August 2009|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|23|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||November 2009|October 17, 2013|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011062||130762|
NCT01013467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1738|CoCo: Colour Coded Blood Pressure Control|Does a Colour-coded Blood Pressure Diary Improve Blood Pressure Control for Patients in General Practice? A Randomised Controlled Study|CoCo|University of Zurich||Completed|October 2009|October 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|85 Years|No|||December 2013|December 10, 2013|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01013467||130578|
NCT01013753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.27|A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.|A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation Solution Delivered by the Respimat® in Patients With Asthma||Boehringer Ingelheim||Completed|February 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|198|||Both|18 Years|70 Years|No|||May 2014|June 17, 2014|November 13, 2009||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01013753||130557|
NCT01043835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197691197392|Comparison of Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer:A Prospective Randomized Trial|Prospective Randomized Trial of Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer||Southwest Hospital, China|Yes|Active, not recruiting|February 2010|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|80 Years|No|||June 2012|June 4, 2012|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043835||128316|
NCT01010750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-115|Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase I, Randomized, Double Blind, Three-Period Crossover, Estimation Study Using Lisdexamfetamine Dimesylate, Immediate Release Mixed Amphetamine Salts and Placebo to Evaluate the Utility of a Standardized Computer Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)||Shire||Completed|January 2010|April 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|18|||Both|18 Years|55 Years|No|||February 2014|February 6, 2014|November 9, 2009|No|Yes||No|January 7, 2011|https://clinicaltrials.gov/show/NCT01010750||130786|
NCT01011023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|robdape1|Unnecessary Gastric Decompression in Distal Elective Bowel Anastomoses in Children. A Randomized Study|Unnecessary Gastric Decompression in Distal Elective Bowel Anastomoses in Children. A Randomized Study||Hospital Infantil de Mexico Federico Gomez|Yes|Completed|September 2000|November 2001|Actual|April 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|1 Month|18 Years|No|||November 2009|November 10, 2009|November 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01011023||130765|
NCT01051089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-459|Effects of Lifestyle Modification on Metabolic Parameters in Type 2 Diabetic Patients|Effects of Lifestyle Modification Focusing on Exercise Intervention on Risk of Atherosclerosis and Metabolic Parameters in Type 2 Diabetic Patients||Inha University Hospital||Recruiting|June 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|80 Years|No|||January 2010|January 15, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051089||127761|
NCT01051102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1983|Effect of NN5401 in Japanese Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN5401 in Japanese Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|20 Years|65 Years|No|||July 2014|August 14, 2014|January 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01051102||127760|
NCT01051999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00025564|Glutamine Supplementation in Cystic Fibrosis|Glutamine Supplementation and Immunity in Adults With Cystic Fibrosis|CFG|Emory University|No|Completed|February 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051999||127693|
NCT01052272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040105007|Impact of Diabetes on Left Ventricular Remodeling|Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.|P3|University of Alabama at Birmingham|Yes|Completed|July 2005|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|72|||Both|21 Years|N/A|No|||November 2012|November 16, 2012|January 15, 2010|Yes|Yes||No|March 20, 2012|https://clinicaltrials.gov/show/NCT01052272||127672|
NCT01052532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F0400105007|Molecular Mechanisms of Mitral Regurgitation—Aim 2|The Study to Define the Unique Molecular Mechanisms of Mitral Regurgitation in Order to Find New Targeted Therapy to Attenuate the Remodeling and Delay the Need for Surgery and Improve Surgical Outcomes.|P1A2|University of Alabama at Birmingham|No|Completed|June 2005|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|65|Samples With DNA|Plasma, myocyte tissue|Both|21 Years|N/A|No|Probability Sample|Ptaients scheduled for Mitral valve repair from c ardiology clinic / Hospital|December 2010|December 1, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01052532||127652|
NCT01052571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 24|Evaluation of the Effectiveness of Transforaminal Epidural Injections in Lumbar Disc Herniation or Radiculitis|A Randomized, Prospective, Double-Blind, Equivalence, Controlled Evaluation of the Effectiveness of Transforaminal Epidural Injections in Lumbar Disc Herniation or Radiculitis With or Without Steroids||Pain Management Center of Paducah|Yes|Completed|February 2010|August 2014|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052571||127649|
NCT01053390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xh2009-35|New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma|A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma||Shanghai Jiao Tong University School of Medicine|Yes|Completed|October 2009|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|75 Years|No|||December 2013|December 18, 2013|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053390||127587|
NCT01053091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-1374B|Effect of Exercise-based Rehabilitation on Circulatory Functions in Patients With Diastolic Heart Failure|Effect of Exercise-based Rehabilitation on Circulatory Functions in Patients With Diastolic Heart Failure||Chang Gung Memorial Hospital|Yes|Completed|October 2009|December 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 25, 2015|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053091||127609|
NCT01053325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMP0409|Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy|A Clinical Trial to Establish The Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy||Institute of Tropical Medicine, Belgium|Yes|Completed|September 2010|February 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|848|||Female|N/A|N/A|No|||October 2013|October 23, 2013|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01053325||127591|
NCT01053923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0695-CE|MRI for Tumor During Chemoradiation for Anal Canal and Perianal Cancer|A Feasibility Study of MRI in Assessment of Primary Tumor During Chemoradiation for Anal Canal and Perianal Cancer||University Health Network, Toronto|No|Withdrawn|December 2009|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with anal canal or perianal cancer|June 2013|June 11, 2013|January 21, 2010||No|Patient eligibility has limited accrual and patient sample has changed with the change in    referral patients.|No||https://clinicaltrials.gov/show/NCT01053923||127546|
NCT01053598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|821183|Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting|EVALUATION OF THE PERFORMANCE OF THE NITRATE REDUCTASE AND RESAZURIN TITRE ASSAY FOR THE DETECTION OF MYCOBACTERIUM TUBERCULOSIS COMPLEX FROM SPUTUM IN A HIGH TB AND HIV SETTING|NRA RETA|Epicentre|No|Completed|September 2011|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|14 Years|N/A|No|Probability Sample|All patients presenting at the outpatient department of the MRRH will be eligible if they        meet the inclusion criteria|February 2013|February 16, 2013|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053598||127571|
NCT01053910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE498_4099|Ramipril 10 mg/Day Prevention|A Multicentre Open, Non Comparative Study of the Safety of Ramipril (Tritace) 10 mg/Day in Prevention of Cardiovascular Events in High-risk Patients||Sanofi||Completed|October 2003|||July 2005|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1012|||Both|45 Years|N/A|No|||February 2009|January 20, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01053910||127547|
NCT01054196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909010623|Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study|Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study||Weill Medical College of Cornell University|No|Recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054196||127525|
NCT01054508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRED012010|Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers|Effect of Tredaptive on Serum Lipoproteins, Lipoproteins Metabolism, Oxidative Stress and HDL Antioxidant Function||Central Manchester University Hospitals NHS Foundation Trust|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|38|||Both|20 Years|75 Years|No|||January 2011|October 10, 2012|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054508||127501|
NCT01050972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Large Population|Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Population of an Extensive Territory||University of Turin, Italy|No|Recruiting|June 2009|November 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15000|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||July 2010|July 8, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01050972||127770|
NCT01051245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1494|Effectiveness of a High-risk Diabetic Patients Program|Effectiveness of a High-risk Diabetic Patients Program||Hospital Italiano de Buenos Aires|No|Completed|March 2010|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|80 Years|No|||April 2013|April 26, 2013|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051245||127749|
NCT01010230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIBE|Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors|Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors||St. Jude Children's Research Hospital|No|Completed|May 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|7 Years|17 Years|No|||April 2014|May 27, 2014|November 6, 2009||No||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01010230||130826|Dropout was higher than expected leading to small numbers for analysis. It was estimated that 30 persons were needed in each arm to detect a 5.5% difference in change in bone outcomes between the active device and placebo device arms of the study.
NCT01043575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBTC Study 29PK|High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis|Pharmacokinetic and Pharmacodynamic Studies of Efficacy, Tolerability and Safety of Higher Dosage Rifapentine for Treatment of Tuberculosis|TBTC-29PK|Centers for Disease Control and Prevention|Yes|Completed|April 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||August 2012|August 15, 2012|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01043575||128336|
NCT01043588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K060401|TRP Versus Photo Selective Vaporization for Obstructive Benign Prostatic Hyperplasia Management|Transurethral Resection of the Prostate With Photo Selective Vaporization of the Prostate Using the High Powered 532nm Laser Obstructive Benign Prostatic Hyperplasia Management: Focus on Efficiency and Cost-effectiveness|REVAPRO|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2007|February 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Male|50 Years|N/A|No|||December 2012|April 30, 2013|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01043588||128335|
NCT01011595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 09.107|Minimally Invasive, Diagnosis and Staging of Lung Cancer|Minimally Invasive, Trans-Luminal Diagnosis and Staging of Lung Cancer: A Prospective Head-to-Head Comparison With Traditional Gold Standard Diagnostic Techniques||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|October 2009|June 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|166|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01011595||130721|
NCT01051700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113555|A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans|A Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses of Pazopanib in Healthy Adult Subjects||GlaxoSmithKline||Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 10, 2010|January 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01051700||127715|
NCT01052012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C803-025|Bupivacaine Effectiveness and Safety in SABER™ Trial|Bupivacaine Effectiveness and Safety in SABER™ Trial (BESST)|BESST|Durect|No|Completed|December 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|305|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|January 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052012||127692|
NCT01052025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWUEC9/2552|Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance|Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance||Srinakharinwirot University|No|Recruiting|August 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|35 Years|N/A|Accepts Healthy Volunteers|||March 2009|January 19, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052025||127691|
NCT01052545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-104|Asymptomatic Bacteriuria Guideline Implementation Study|Guideline Implementation to Decrease Inappropriate Bacteriuria Treatment|ABU|VA Office of Research and Development|No|Completed|July 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1598|||Both|N/A|N/A|No|||April 2015|April 17, 2015|January 15, 2010||No||No|October 20, 2014|https://clinicaltrials.gov/show/NCT01052545||127651|Modification may be necessary for private sector facilities. We do not know what aspect of our intervention had the biggest impact, and whether the entire bundle is necessary.
NCT01052805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912006R|Anatomy Study in Control Nerve From Normal Human|Anatomy Study in Control Nerve From Normal Human||National Taiwan University Hospital|No|Recruiting|August 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20||nerve from cadaveric donor nerve from nerve graft operation patient|Both|10 Years|90 Years|No|Non-Probability Sample|cadaveric donor patients receiving nerve graft operation|October 2011|October 20, 2011|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052805||127631|
NCT01053117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:101|Reducing Hemodialysis Catheter Use in Prevalent Hemodialysis Patients|Reducing Hemodialysis Catheter Use in in a Prevalent Hemodialysis Population; A Pilot Randomized Control Trial||University of Manitoba|No|Terminated|February 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|January 19, 2010||No|Unable to enrol patients|No||https://clinicaltrials.gov/show/NCT01053117||127607|
NCT01053403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 2009.099-1 (JMen)|Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.|The Effects of MDMA on Sleep Architecture, Water Homeostasis and Cognitive Function|2C|California Pacific Medical Center Research Institute|No|Completed|April 2010|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053403||127586|
NCT01053104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mobile Datacap|Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring|Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients With Metastatic Colorectal or Metastatic Breast Cancer|DATACAP|University of Oxford|No|Completed|November 2009|April 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|July 2012|July 24, 2012|January 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01053104||127608|
NCT01053936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-C-0902|Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease|A Multi-Center, Open-Label, Randomized, Parallel Group, Dose-Ranging, Pharmacodynamic Phase II Trial to Determine the Effects of Bardoxolone Methyl (RTA 402, Amorphous Dispersion) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease (eGFR 15-45 mL/Min/1.73m2)||Reata Pharmaceuticals, Inc.|No|Completed|January 2010|February 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|129|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053936||127545|
NCT01053949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_28/0924|IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma|A Multicenter Randomized Open Label Phase II Study of Pomalidomide and Dexamethasone in Relapse and Refractory Multiple Myeloma Patients Who Are Progressive and Did Not Achieve at Least a Partial Response to Bortezomib and Lenalidomide|IFM2009-02|University Hospital, Lille|Yes|Completed|October 2009|April 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|19 Years|N/A|No|||November 2015|November 3, 2015|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01053949||127544|
NCT01054222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221090|Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder|A Local, Multicentre, Open-Label, Extension Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder||Pfizer|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|65 Years|N/A|No|||February 2013|April 2, 2013|January 20, 2010|Yes|Yes||No|December 17, 2012|https://clinicaltrials.gov/show/NCT01054222||127523|Due to the small sample size and that this is a single country study (Portugal) the results should be interpreted with caution.
NCT01054209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/165/HAR|A Study to Determine the Effectiveness of a Warming Mattress in Preventing Inadvertent Peri-operative Hypothermia and Shivering in Patients Undergoing Elective Cesarean Section|A Study to Determine the Effectiveness of a Warming Mattress in Preventing Inadvertent Peri-operative Hypothermia and Shivering in Patients Undergoing Elective Cesarean Section|ObsIPH|Brighton and Sussex University Hospitals NHS Trust|Yes|Completed|February 2010|August 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|116|||Female|16 Years|N/A|No|||December 2012|December 6, 2012|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054209||127524|
NCT01054521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wbanhiran|A Randomized Study of Temperature-controlled and Bipolar Radiofrequency for Inferior Turbinate Reduction|A Randomized Comparison Study of Temperature-controlled and Bipolar Radiofrequency for Inferior Turbinate Reduction in Patients With Chronic Rhinitis|CompareRFIT|Mahidol University|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054521||127500|
NCT01054534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000293|Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads|Real-time Ultrasound Guided Placement of Sacral Quadripolar Leads With Ultrasound Image Fusion of Acquired Magnetic Resonance Scan (MRI)||Mayo Clinic|No|Terminated|July 2010|December 2012|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Female|30 Years|90 Years|No|||April 2015|April 10, 2015|January 20, 2010||No|Sponsor withdrew funding|No||https://clinicaltrials.gov/show/NCT01054534||127499|
NCT01054560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWIFT|SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study|SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study|SWIFT|ev3|Yes|Active, not recruiting|January 2010|December 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|22 Years|85 Years|No|||June 2011|June 6, 2011|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054560||127497|
NCT01054794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS01|Temporary Gastric Electrical Stimulation for Gastroparesis|Temporary Gastric Neurostimulation for Gastroparesis||University of Calgary|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054794||127480|
NCT01054807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0915|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2009|||||N/A|N/A|N/A||||||||||||||December 2, 2014|January 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01054807||127479|
NCT01051258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C08-003PLVGP4-5|AeriSeal System for Lung Volume Reduction|A Study of the AeriSeal System for Lung Volume Reduction in Patients With Advanced Emphysema||Aeris Therapeutics|Yes|Completed|November 2009|April 2013|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|40 Years|N/A|No|||June 2013|June 25, 2013|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01051258||127748|
NCT01043003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06136|Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers|Support for Hispanic Breast Cancer Patients and Caregivers||City of Hope Medical Center|Yes|Completed|August 2006|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|49|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01043003||128379|
NCT01043016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008L03278|Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors|Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors||Fujian Longhua Pharmaceutical Co. Ltd|Yes|Recruiting|March 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|70 Years|No|||January 2010|January 5, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01043016||128378|
NCT01043029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC22419|A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment|Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®||Hoffmann-La Roche||Completed|May 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01043029||128377|
NCT01011049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FID33|Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM|Safety and Immunogenicity of Revaccination With Influenza Vaccine in Healthy Adult Subjects Aged 18 to 64 Years Who Were Previously Vaccinated With Fluzone ID or Fluzone IM||Sanofi|No|Completed|September 2009|October 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1250|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|November 9, 2009|Yes|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT01011049||130763|
NCT01043562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04-0209|Precise Measurement of Pediatric Defibrillation Thresholds|Defibrillation Thresholds in a Pediatric Cohort Using Binary Search Protocol||Children's Hospital Boston|No|Recruiting|June 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|All patients seen by the electrophysiology service at Children's Hospital Boston who are        identified to be at very high risk of sudden cardiac death and in need of an ICD|January 2010|January 6, 2010|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01043562||128337|
NCT01044446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2009.481|Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis|Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients||Chinese University of Hong Kong|No|Completed|January 2010|April 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|January 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044446||128270|
NCT01044121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Duke-Pain-1113291|Effects of Mattress Firmness on Pain in Patients With Chronic Low-Back Pain|A Latin-Square Crossover Study of the Effects of Mattress Firmness on Pain in Patients With Chronic Low-Back Pain||Sleep To Live Institute||Terminated|January 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|40|||Both|21 Years|64 Years|No|||January 2013|January 8, 2013|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01044121||128295|
NCT01051427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORLEPI1|Control of Epistaxis With Surgiflo|Control of Epistaxis With Surgiflo||Hospital Universitario Ramon y Cajal|Yes|Terminated|March 2010|August 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|January 14, 2010||No|Now we use better procedures for the patient instead of nasal catheter for epistaxis. So it    would be unethical to use the nasal catheter to complete the trial.|No||https://clinicaltrials.gov/show/NCT01051427||127735|
NCT01052038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00018901|Post Operative Sore Throat and Dexamethasone|The Effect of Systemic Prophylactic Dexamethasone on the Incidence of Postoperative Sore Throat in Patients Undergoing Ambulatory Laparoscopic Gynecologic Surgery: A Prospective, Randomized, Double Blinded, Placebo Controlled Trial||Northwestern University|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Female|18 Years|64 Years|No|||April 2012|April 5, 2012|January 19, 2010||No||No|October 31, 2011|https://clinicaltrials.gov/show/NCT01052038||127690|Study was limited to 2 doses of dexamethasone and was underpowered to assess side effects such as hyperglycemia or delayed wound healing. Study was limited to a single type of surgery and results may differ in different types of surgery.
NCT01052324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0609|The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation|The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation||Yonsei University|Yes|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Primary Purpose: Prevention|||Actual|19|||Both|20 Years|65 Years|No|||May 2011|May 12, 2011|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01052324||127668|
NCT01052285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-plp-10|The Efficacy of Transversus Abdominis Plane Block After Groin Hernia Repair|The Efficacy of Transversus Abdominis Plane Block Versus Placebo Versus Local Infiltration in Patients Undergoing Groin Hernia Repair in Day Case Surgery.||Glostrup University Hospital, Copenhagen|Yes|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|75 Years|No|||November 2011|November 17, 2011|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052285||127671|
NCT01052298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13013|Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)|Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (GOLD I - II), Following Inhalation of Ciprofloxacin PulmoSphere Inhalation Powder.||Bayer|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|25|||Both|35 Years|N/A|No|||May 2013|May 29, 2013|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01052298||127670|
NCT01053130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCH1639|Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial|The Effect of Weight Loss Surgery on Preservation of Kidney Function and Cardiovascular Disease Risk Factors in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial||King's College Hospital NHS Trust|No|Recruiting|January 2010|January 2014|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053130||127606|
NCT01053637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22684|Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair|Randomized Control Trial of Oral Narcotic Medication for Pain and Anxiety Management During Laceration Repair in the Pediatric Emergency Department||Texas Children's Hospital|No|Completed|February 2009|May 2015|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|2 Years|17 Years|No|||May 2015|May 11, 2015|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053637||127568|
NCT01053611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.083|Composite Variability Index Versus Bispectral Index (BIS)|Changes in a Composite Variability Index (CVI) and Bispectral Index (BIS) in Response to Standardized Pain Stimuli During Propofol Remifentanil Infusion||University Medical Center Groningen|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|12||Actual|140|||Both|18 Years|N/A|No|||September 2009|March 24, 2011|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053611||127570|
NCT01054573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016678|VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo|An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX- 950-TiDP24-C216 Trial Who Failed Therapy for Virologic Reasons||Janssen Infectious Diseases BVBA|No|Completed|April 2010|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|70 Years|No|||May 2013|May 6, 2013|January 21, 2010|No|Yes||No|March 8, 2013|https://clinicaltrials.gov/show/NCT01054573||127496|
NCT01054235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199901118|Prenatal Care Program in Dingyuan County|Evaluation of Prenatal Care Program in Rural China|EPCP|National Institute for Health and Welfare, Finland|Yes|Completed|August 2000|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5000|||Female|20 Years|N/A|No|||January 2010|January 20, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054235||127522|
NCT01054547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093/2006|Topical Formulations of Liposomal Local Anesthetics|Local Anesthetic Activity of Liposomal Formulations in Dentistry||University of Campinas, Brazil|Yes|Completed|September 2006|April 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|80|||Both|18 Years|43 Years|Accepts Healthy Volunteers|||May 2006|January 21, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054547||127498|
NCT01054820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K353-09-4001|Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain|Multicenter, Open-Label Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain||Pfizer|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|January 20, 2010|No|Yes||No|July 10, 2012|https://clinicaltrials.gov/show/NCT01054820||127478|
NCT01055158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH080630|Telephone Based Cognitive Behavioral Therapy for HIV Related Depression|Connect: A Pilot Study of Telephone Based Cognitive Behavioral Therapy for HIV Related Depression||University of Maryland|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||January 2010|April 9, 2015|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055158||127452|
NCT01054586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111949|Fosamprenavir in Pts With Hepatic Impairment|HI FPV Study: Using Observational Cohorts to Monitor Safety of Fosamprenavir in Patients With Mild/Moderate Hepatic Impairment||GlaxoSmithKline|No|Completed|January 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|167|||Both|18 Years|N/A|No|Non-Probability Sample|The source population is from three HIV patient cohorts; ICONA, HEPAVIH and MASTER cohort        in Europe. Data from these cohorts are comprised of the clinical records (or a defined        subset thereof) of HIV infected patients. The ICONA Foundation study collects data on HIV        infected individuals from 67 infectious disease centres across Italy and has been        established since 1997. The ICONA cohort only includes patients who are treatment naïve at        initial presentation. HEPAVIH is a cohort of HIV-hepatitis co-infected patients,        identified from three other ongoing French HIV cohorts: RIBAVIC, SEROCO and AQUITAINE and        an additional 12 clinical departments. The MASTER cohort collects data on HIV infected        individuals from centres across Italy and includes treatment-experienced and naive        patients.|April 2013|May 2, 2013|January 21, 2010||No||No|January 14, 2011|https://clinicaltrials.gov/show/NCT01054586||127495|
NCT01043614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-04574|Peer Education, Exercising and Eating Right - Obesity Prevention in Freshmen Women|Project PEER: Peer Education, Exercising and Eating Right|ProjectPEER|University of Illinois at Urbana-Champaign|No|Active, not recruiting|August 2008|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|300|||Female|17 Years|19 Years|Accepts Healthy Volunteers|||January 2010|January 6, 2010|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01043614||128333|
NCT01043289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPK-2004|Light Therapy for Depression During Pregnancy|A Randomised, Double-blind, Placebo-controlled Study of Light Therapy for Antepartum Depression||Psychiatric Hospital of the University of Basel|No|Completed|October 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Female|18 Years|45 Years|No|||January 2010|January 5, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01043289||128358|
NCT01045070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/34/08|Periodontitis and Coronary Heart Disease|Periodontitis and Its Microbiological Agents as Prognostic Factors in Patients With Coronary Heart Disease||Martin-Luther-Universität Halle-Wittenberg|No|Completed|October 2009|May 2012|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|960|Samples With DNA|Blood-samples and samples from gingival pockets|Both|18 Years|N/A|No|Probability Sample|Patients with coronary heart disease, admitted to the Martin Luther-University        Halle-Wittenberg|May 2012|May 1, 2012|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045070||128222|
NCT01043848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSCI-NU-2/09|Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients|Therapeutic Effects of Early and Late Onset Peripheral Pudendal Neurostimulation on Bladder Function and Autonomic Neuroplasticity in SCI - a Controlled European Multicenter Study||University of Zurich||Suspended|December 2009|||October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|85 Years|No|||March 2016|March 18, 2016|January 6, 2010||No|Poor patient recruitment, necessary number of patients could not be included within the    required time frame|No||https://clinicaltrials.gov/show/NCT01043848||128315|
NCT01043874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107FJP01|Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response|A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib|MACS0911|Novartis|No|Completed|December 2009|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 5, 2010|Yes|Yes||No|January 14, 2015|https://clinicaltrials.gov/show/NCT01043874||128314|
NCT01051479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 60109|A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer|A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|March 2010|December 2017|Anticipated|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051479||127732|
NCT01051492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR07/30/09|Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer|||National University Hospital, Singapore||Recruiting|January 2010|||December 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any individual who has been diagnosed with breast cancer|January 2014|January 13, 2014|January 15, 2010||||No||https://clinicaltrials.gov/show/NCT01051492||127731|
NCT01051713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1DK087126-01|ENGAGED: E-Networks Guiding Adherence to Goals for Exercise and Diet|ENGAGED: E-Networks Guiding Adherence to Goals for Exercise and Diet|ENGAGED|Northwestern University|Yes|Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051713||127714|
NCT01051726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10018|Effects of Aromatherapy on Childbirth|Effects of Aromatherapy on Childbirth||University of Nottingham|No|Recruiting|January 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|3||Anticipated|90|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051726||127713|
NCT01052337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blade-runner|Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy|Anesthesia Induction With Propofol or Sevoflurane in Patients Undergoing Fiberoptic Intubation for Cervical Myelopathy: Effects on Heamodynamics|Blade runner|University of Roma La Sapienza|Yes|Recruiting|April 2009|||March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|75 Years|No|||December 2009|January 19, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01052337||127667|
NCT01052311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7418-MS-CTIL|The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients|The Impact of Tredaptive (ER Niacin/Laropiprant) Compared to Placebo on Brachial Artery Endothelial Function in Patients With Stable Coronary Artery Disease on Statin Therapy||Sheba Medical Center|No|Terminated|July 2010|July 2014|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|80 Years|No|||April 2013|April 21, 2013|January 16, 2010||No|In January, 2013 Merck had decided to take steps to suspend the availability of TREDAPTIVE    globally|No||https://clinicaltrials.gov/show/NCT01052311||127669|
NCT01053416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARMAPIGMO|Pigment Dispersion Syndrome: Natural History and Possible Protective Effect of a YAG Laser Iridotomy|10-year Follow up of Patients With Pigment Dispersion Syndrome: Risk Factors for Conversion to Pigmentary Glaucoma and Potential Protective Effect of a Yag-laser Iridotomy in High Risk Eye||University of Parma|No|Completed|January 1993|December 2003|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|72|||Both|N/A|N/A|No|||January 2003|January 21, 2010|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053416||127585|
NCT01053650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0065|Placebo Effect of Paracetamol in Healthy Volunteers|Placebo Effect of Paracetamol in Healthy Volunteers|HOP|University Hospital, Clermont-Ferrand||Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053650||127567|
NCT01053624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0064|Concomitant Tracheostomy and Lung Resection|Concomitant Tracheostomy and Lung Resection in Patient With Low Postoperative Pulmonary Function||University Hospital, Clermont-Ferrand||Recruiting|October 2001|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|79 Years|No|||January 2011|January 18, 2011|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01053624||127569|
NCT01051271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAU-200/1563|Prophylaxis Against Metoclopramide-Induced Akathisia|||Pamukkale University||Completed|July 2009|November 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|225|||Both|18 Years|65 Years|No|||July 2009|January 15, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051271||127747|
NCT01054833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-019|Clinical Evaluation of the Needleless® Sling|A Clinical Evaluation of the Needleless® Sling for the Treatment of Female Stress Urinary Incontinence||Samsung Medical Center|No|Completed|January 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||May 2013|May 29, 2013|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054833||127477|
NCT01055171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19489|Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence|Treatment Implications of Trauma Memory Modulation for PTSD & Alcohol Dependence||Medical University of South Carolina|Yes|Completed|January 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||September 2012|February 8, 2016|January 21, 2010|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT01055171||127451|Lack of a “no retrieval” control group. Lack of determination of plasma propranolol levels following the medicated retrieval session. The sample size was insufficient to assess the more distal effects at 1-week follow-up.
NCT01050985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-479|A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer|A Phase I Study of the mTOR Inhibitor Temsirolimus Plus Capecitabine in Patients With Advanced Malignancies||Georgetown University|Yes|Completed|July 2010|June 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|January 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01050985||127769|
NCT01054599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000107|Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?|Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial||American Academy of Neurology|No|Recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|65 Years|No|||January 2013|January 4, 2013|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01054599||127494|
NCT01043887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-046|Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)|A Single Dose Study to Investigate the Pharmacokinetics of Ridaforolimus in Patients With Hepatic Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|January 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01043887||128313|
NCT01045291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT0095101|Pacing for Heart Failure With Preserved Ejection Fraction|Pacing for Heart Failure With Preserved Ejection Fraction|HFpEF|Medtronic Cardiac Rhythm Disease Management|No|Completed|June 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045291||128205|
NCT01045083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22651|A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers|Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor (Escitalopram [Lexapro&#61650;]), a Dopamine||Hoffmann-La Roche||Completed|January 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 6, 2014|January 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01045083||128221|
NCT01051752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL29420.091.09|PK and PD of Drugs for Nontuberculous Mycobacterial Diseases in Dutch Patients|Pharmacokinetics and Pharmacodynamics of Drugs for Nontuberculous Mycobacterial Diseases in Dutch Patients|NTM|Radboud University|No|Completed|January 2010|May 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|Blood samples for pharmacokinetic analysis will be retained. Sputum samples for      pharmacodynamic analysis will be retained.|Both|18 Years|N/A|No|Probability Sample|Patients with NTM infection are generally middle aged or higher aged, white males with        COPD or bronchiectasis. They will be recruited from the outpatient clinics of University        Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other        outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients        with NTM disease will be recruited.|May 2012|May 21, 2012|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01051752||127711|
NCT01051739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7098-R|Variability in Perimetry Study|Improved Assessment of Visual Field Change|VIP II|VA Office of Research and Development|No|Completed|July 2010|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|157|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Probability Sample|glaucoma patient with 0 to -25 dB mean deviation and normal subjects|February 2016|February 4, 2016|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051739||127712|
NCT01052870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HairDx2009|Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia|Study Evaluating the Association of CAG Repeat Polymorphisms and Finasteride Response in Women With Androgenetic Alopecia||HairDx, LLC|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|12|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2010|January 19, 2010|January 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052870||127626|
NCT01058395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#H133A080044 -01|Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)|Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans|TBI|Wayne State University|Yes|Recruiting|February 2010|January 2016|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Male|18 Years|75 Years|No|||May 2014|May 11, 2014|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058395||127205|
NCT01053962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-SP304201-09|SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation|A Phase IIa Randomized, Double-Blind, Placebo-Controlled, 14-Day Repeat, Oral, Dose Ranging Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of SP-304 in Patients With Chronic Idiopathic Constipation|CIC|Synergy Pharmaceuticals Inc.|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|80|||Both|18 Years|75 Years|No|||November 2010|November 16, 2010|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053962||127543|
NCT01051856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000362|TissueLink Versus SEAMGUARD After Distal Pancreatectomy|A Multicenter Mayo-initiated Randomized Controlled Trial Comparing Pancreatic Leaks After TissueLink vs SEAMGUARD After Distal Pancreatectomy (PLATS)|PLATS|Mayo Clinic|Yes|Terminated|December 2009|March 2015|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|68|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|January 15, 2010|Yes|Yes|The trial closed early due to poor accrual.|No|May 29, 2015|https://clinicaltrials.gov/show/NCT01051856||127703|The trial closed early due to poor accrual of subjects.
NCT01052103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13261|A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms|A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia||Eli Lilly and Company|Yes|Completed|January 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|65 Years|No|||July 2012|September 18, 2012|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052103||127685|
NCT01052402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810706|Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents|A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years||Nanotherapeutics, Inc.|Yes|Completed|December 2009|November 2012|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|684|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||November 2012|October 7, 2015|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052402||127662|
NCT01053169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE1116_5001|Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)|Non-interventional Observational Study of Beriplex® P/N in Prophylaxis and Treatment of Acute Bleeding Perioperatively (Diagnostic Intervention or Surgery)||CSL Behring|No|Completed|May 2010|January 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|445|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with coagulopathy due to liver disease or other conditions requiring correction        of coagulopathy who require surgical or diagnostic intervention and patients experiencing        acute bleeding perioperatively|June 2012|June 13, 2012|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01053169||127603|
NCT01054001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS486539|Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy|Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy|SILRALP|Seoul National University Bundang Hospital|Yes|Recruiting|June 2010|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Male|N/A|N/A|No|||August 2011|August 18, 2011|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054001||127540|
NCT01055197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0937|Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer|Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)||Radiation Therapy Oncology Group|Yes|Active, not recruiting|March 2010|||March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055197||127449|
NCT01055210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELD002|Optimisation of Cardiac Resynchronisation Therapy by Non-invasive Cardiac Output - The CHOICE2 Study|Optimisation of Cardiac Resynchronisation Therapy by Non-invasive Cardiac Output - The CHOICE2 Study|CHOICE2|University of Dundee|No|Not yet recruiting|February 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2010|January 22, 2010|January 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01055210||127448|
NCT01044147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS018155|Online Counseling to Enable Lifestyle-focused Obesity Treatment in Primary Care|Online Counseling to Enable Lifestyle-focused Obesity Treatment in Primary Care|OCELOT-PC|University of Pittsburgh|Yes|Completed|April 2010|September 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|21 Years|75 Years|No|||January 2016|January 13, 2016|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01044147||128293|
NCT01044472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-09-048-EU-HF|Multi-site Left Ventricular (MSLV) Pacing With Quartet 1458Q Lead|Multi-site Left Ventricular (MSLV) Pacing With Quartet 1458Q Lead|MSLV|St. Jude Medical|No|Active, not recruiting|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard CRT-D indications|May 2010|May 22, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044472||128268|
NCT01044459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-MD-35|Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)|A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide At Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease|LAS-MD-35|Forest Laboratories|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|605|||Both|40 Years|N/A|No|||August 2012|August 14, 2012|January 5, 2010|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT01044459||128269|Site 1420 randomized 31 patients who were discontinued by 21 Jan 2011 due to significant deviations documented in a letter to the FDA on 07 Jan 2011.No changes to the analyses were prospectively specified in the amended statistical analysis plan.
NCT01044758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC2AG036419|Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)|Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI||Johns Hopkins University|Yes|Completed|December 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|144|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|January 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044758||128246|
NCT01044771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALPIR|Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria|A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads|RALPIR|Metropolis Medical|Yes|Completed|January 2010|June 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|January 6, 2010|Yes|Yes||No|January 20, 2014|https://clinicaltrials.gov/show/NCT01044771||128245|
NCT01044823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08040135|Use of Thermal and 3D Imaging to Quantify Arthritis|Use of Thermal and 3D Imaging to Quantify Arthritis||University of Pittsburgh|No|Recruiting|January 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|||Both|4 Years|N/A|No|Non-Probability Sample|children with JRA adults with RA|February 2011|February 16, 2011|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044823||128241|
NCT01044836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE-I-09|Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers|A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers|SPH|Hanwha Chemical|No|Completed|January 2010|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|42|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 13, 2014|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01044836||128240|
NCT01045109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRF #P-06-068|Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.|Vitamin D and Prostate Cancer|D3/PCa|Medical University of South Carolina|Yes|Completed|October 2007|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Male|18 Years|90 Years|No|||August 2010|August 4, 2011|January 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045109||128219|
NCT01052350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0706|PET Imaging in Parkinson Disease Dementia|Investigations of Dementia in Parkinson Disease||Washington University School of Medicine|No|Recruiting|August 2006|July 2030|Anticipated|July 2030|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|320|Samples With DNA|whole blood|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants with and without Parkinson disease will be recruited from the Movement        Disorders Center at Washington University, the St. Louis metro area, and throughout the        midwest region.|January 2016|January 12, 2016|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01052350||127666|
NCT01052363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU1309|OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas|OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas||West Virginia University|Yes|Not yet recruiting|January 2010|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||January 2010|January 19, 2010|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052363||127665|
NCT01052051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPS08-15024|Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women|Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women|CAPS|Creighton University|Yes|Completed|June 2009|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2303|||Female|55 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052051||127689|
NCT01052584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCZVED-5628|Ethiopia Malaria Therapeutic Efficacy Study|Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection||Centers for Disease Control and Prevention|Yes|Completed|October 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|354|||Both|6 Months|N/A|No|||November 2010|November 17, 2010|January 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01052584||127648|
NCT01052597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWUEC30/2550|Curcumin for Type 2 Diabetic Patients|Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients||Srinakharinwirot University|No|Recruiting|July 2009|March 2010|Anticipated|February 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|35 Years|N/A|No|||August 2007|January 19, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052597||127647|
NCT01052883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016903|TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions|A Phase I, Open Label, Randomized, Single Dose, Crossover Study in Healthy Subjects to Compare the Oral Bioavailability of a Prototype Tablet Formulation of Darunavir 800mg(G002) to That of the Commercial 400mg(F030) Tablet Formulation Under Fed & Fasted Conditions, in Presence of Low-dose Ritonavir||Tibotec Pharmaceuticals, Ireland||Completed|March 2010|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01052883||127625|
NCT01053429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281140|A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule|Post-Marketing Surveillance (PMS) Study to Evaluate Safety and Efficacy of Zeldox Capsule||Pfizer|No|Completed|June 2005|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3391|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with schizophrenia or acute manic or mixed episodes associated with        bipolar disorder, with or without psychotic features will be included in the study.|December 2010|December 21, 2010|January 19, 2010|No|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT01053429||127584|Per the Statistical Analysis Plan Amendment CGI-S and CGI-I endpoints analyzed as frequency counts (categorical) rather than the planned CGI-S mean change from baseline and CGI-I mean scores (continuous); any additional analyses would be exploratory.
NCT01054248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU0905|Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy|A Randomised Open Label Trial Comparing Standard Dose of Dihydroartemisinin-piperaquine, Standard Fixed Artesunate-mefloquine Regimen and a Longer Regimen of Artemether-lumefantrine in the Treatment of Uncomplicated Malaria in Pregnancy|DMA|University of Oxford|Yes|Recruiting|February 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|1005|||Both|18 Years|45 Years|No|||August 2013|August 27, 2013|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054248||127521|
NCT01054846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parkview - 001|Impact of Helmet Use in Preschool Children|The Impact of Helmet Use in Preschool Children From Low-income Families in Northeastern Indiana||Parkview Hospital, Indiana|No|Completed|May 2008|January 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|609|||Both|3 Years|5 Years|No|||January 2010|January 22, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054846||127476|
NCT01050998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP219|A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis|A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects With Rheumatoid Arthritis||MedImmune LLC|No|Completed|January 2010|July 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|291|||Both|18 Years|80 Years|No|||January 2014|January 13, 2014|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01050998||127768|
NCT01052649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNC -1-4|Gene Expression Monitoring of Mononuclear Cells (MNC) Subpopulations and Immunological Status and Metabolome Defining of Healthy Population|Gene Expression Monitoring of Peripheral Blood Mononuclear Cells Subpopulations (CD4+ Cells, CD56+ Cells and CD4+CD25+ Cells) and Immunological Status and Metabolome Defining of Healthy Population||Blood Transfusion Centre of Slovenia|No|Completed|August 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|healthy population|July 2009|January 19, 2010|July 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01052649||127643|
NCT01052935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98P1E1|A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine|A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotype Ia Antibodies in Women Previously Immunized With a GBS Ia Crm-Glycoconjugate Vaccine||Novartis||Completed|January 2010|October 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Female|20 Years|42 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052935||127621|
NCT01052948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7231031|The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events|The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events||Pfizer|Yes|Completed|January 2007|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|86939|||Both|N/A|N/A|No|Non-Probability Sample|General research practice databases or record linkage systems in Europe that provide        access to original medical information. These are: The Health Information Network (THIN),        Health Search Database (HSD)-THALES, the Integrated Primary Care Information (IPCI) and        PHARMO-Record Linkage System (RLS) and meeting criteria for entry into any of the 4        cohorts between 1995 - 2007|March 2011|March 17, 2011|January 19, 2010||No||No|December 28, 2010|https://clinicaltrials.gov/show/NCT01052948||127620|
NCT01053663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25138|A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza|An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection||Hoffmann-La Roche||Active, not recruiting|January 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|365 Days|No|||May 2013|May 13, 2013|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01053663||127566|
NCT01054859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-015|A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.|A PHASE I, A SINGLE-CENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, THREE-PERIOD, THREE-WAY CROSSOVER STUDY OF THE HEMODYNAMIC INTERACTIONS OF AVANAFIL AND ALCOHOL IN HEALTHY MALE SUBJECTS||VIVUS, Inc.||Completed|January 2010|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|15|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 5, 2011|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054859||127475|
NCT01051284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-169|A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer|A Pilot Study of Full Dose Gemcitabine and Hypofractionated Stereotactic Radiosurgery in the Treatment of Unresectable Pancreatic Cancer||Georgetown University|Yes|Completed|November 2009|March 2012|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|January 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051284||127746|
NCT01044485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0205-1isni 07 / 001.112|Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer|A Multicenter Open-label, Phase I/II Dose Escalation Study of Oral Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer|LapDoc|Centre Georges Francois Leclerc|Yes|Completed|November 2008|||November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|N/A|No|||September 2012|September 24, 2012|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01044485||128267|
NCT01044498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22775|A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis|An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)||Hoffmann-La Roche||Completed|December 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||March 2013|March 22, 2013|January 7, 2010|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01044498||128266|
NCT01044784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60028011|Acute Evaluation of the Safety of Left Ventricular-left Ventricular (LV-LV) Delays and Its Effects on Mechanical Dyssynchrony|Acute Evaluation of the Safety of LV-LV Delays and Its Effects on Mechanical Dyssynchrony||St. Jude Medical|No|Completed|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated for standard CRT-D indications.|March 2012|March 24, 2012|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044784||128244|
NCT01044797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Given Imaging DHMC|Remote Manipulation of a Capsule Endoscope|Remote Manipulation of a Capsule Endoscope in the Esophagus and Stomach of a Human Volunteer Using an External Hand-held Magnet|Remote capsule|Dartmouth-Hitchcock Medical Center|No|Completed|April 2008|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|One Human Volunteer, Healthy|January 2010|January 7, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044797||128243|
NCT01045096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-P107-174|Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease|A Phase 1, Randomized, Open-Label, Parallel Design, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Delayed Release Capsules in Pediatric Subjects Ages 1 to 11 Years Old With Symptomatic Gastroesophageal Reflux Disease||Takeda|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|36|||Both|1 Year|11 Years|No|||March 2012|March 8, 2012|January 7, 2010|No|Yes||No|January 30, 2012|https://clinicaltrials.gov/show/NCT01045096||128220|
NCT01044524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S334.1.004|Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion|An Open Label Study to Determine ADME of 14C Labeled SLV334 and Its Metabolites After Single Intravenous Dose Infusion||Solvay Pharmaceuticals|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 16, 2010|December 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01044524||128264|
NCT01045668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI-VISTA|Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation|Comparison of the Effect of Ablation of the Clinically Presenting Ventricular Tachycardia (VT) Only Versus the Addition of Substrate Ablation Based on Scar Mapping; on the Long Term Success Rate of VT Ablation|VISTA|Texas Cardiac Arrhythmia Research Foundation|No|Completed|January 2010|July 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||August 2014|August 21, 2014|January 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01045668||128176|
NCT01045382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJB0909|MSC and HSC Coinfusion in Mismatched Minitransplants|Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study||University Hospital of Liege|No|Recruiting|July 2010|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|75 Years|No|||May 2015|May 29, 2015|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045382||128198|
NCT01052376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD08/6-A|Endomicrocancer: Confocal Endomicroscopy in Patients With High Risk of Colorectal Cancer|Confocal Endomicroscopy in Patients With High Risk of Colorectal Cancer: Potential for Diagnosis of Early Neoplasia||Nantes University Hospital|Yes|Terminated|December 2008|January 2011|Actual|||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|73|||Both|18 Years|75 Years|No|||January 2010|May 22, 2012|January 19, 2010||||No||https://clinicaltrials.gov/show/NCT01052376||127664|
NCT01052610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502-12-760, 503-2056-1|Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites|Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites||Medical Universtity of Lodz|No|Recruiting|June 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Years|18 Years|No|||February 2013|February 6, 2013|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01052610||127646|
NCT01052623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA.GHAT.2009|Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)|Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia|GHAT|Johann Wolfgang Goethe University Hospitals|No|Recruiting|January 2010|September 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|3 Years|18 Years|No|||July 2010|July 2, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052623||127645|
NCT01052896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20090188H|Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition|Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition||Wilford Hall Medical Center|No|Not yet recruiting|March 2010|May 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2010|January 20, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01052896||127624|
NCT01052909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30286|Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition|Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fasting Condition||Dr. Reddy's Laboratories Limited|No|Completed|December 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 19, 2010|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052909||127623|
NCT01053143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF14|Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India|Bridging Study on Safety and Immunogenicity of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India||Sanofi|No|Completed|January 2010|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053143||127605|
NCT01052428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F040601008|Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)|Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)|P1A1|University of Alabama at Birmingham|Yes|Completed|August 2004|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|January 15, 2010|Yes|Yes||No|July 29, 2011|https://clinicaltrials.gov/show/NCT01052428||127660|
NCT01052675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD07/10-C|Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation|Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation||Nantes University Hospital|No|Recruiting|January 2008|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Probability Sample|Pharmacodependent patients|January 2010|January 31, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052675||127641|
NCT01054261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-013|To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.|A Phase I, Open-Label, Parallel-Group, Single Dose, Non-Randomized Study to Compare the Pharmacokinetics of Avanafil in Male Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function||VIVUS, Inc.|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|21 Years|78 Years|Accepts Healthy Volunteers|||January 2011|January 5, 2011|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054261||127520|
NCT01055184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 09-009|Effects of Age on Response to the 2009 H1N1 Virus Vaccine|Assessment of the Effect of Age on the Immunological and Virological Response to a Live Attenuated Influenza Vaccine for the 2009 H1N1 Virus||University of Rochester|No|Completed|March 2010|||April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2010|August 2, 2011|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01055184||127450|
NCT01051570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000663630|Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel|Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.||Barbara Ann Karmanos Cancer Institute|Yes|Completed|February 2010|November 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|N/A|No|||August 2014|August 9, 2014|January 15, 2010||No||No|August 9, 2014|https://clinicaltrials.gov/show/NCT01051570||127725|Small sample size; Correlates were conducted in <50% of the patients.
NCT01053195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WDF07-308|Qingdao Diabetes Prevention Project|A Community-based Lifestyle Intervention to Reduce the Risk of Diabetes in Qingdao, China----Qingdao Diabetes Prevention Project (2005-2012)|QDDPP|Helsinki University|Yes|Enrolling by invitation|December 2005|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20000|||Both|35 Years|N/A|No|||January 2010|January 20, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01053195||127601|
NCT01053442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETHZ-SIA2|Absorption, Stable Isotope Appearance and Non-transferrin-bound Iron (NTBI) Profile From NaFeEDTA and Ferrous Sulphate|Absorption, Stable Isotope Appearance and NTBI Profile From NaFeEDTA and Ferrous Sulphate|SIA|Swiss Federal Institute of Technology|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|17|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053442||127583|
NCT01054274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320924197612177170|a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent|Self-Expandable Esophageal Radiation Stent:a Multicentric Randomized Controlled Trial in Patients With Advanced Esophageal Cancer||Southeast University, China|Yes|Recruiting|December 2009|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Both|20 Years|80 Years|No|||December 2009|March 30, 2012|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054274||127519|
NCT01054287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQO150|Falls Prevention in Acute Care Hospital|Falls Prevention Program in Acute Care Hospital|PRECEPT|Centre Hospitalier Universitaire Vaudois|No|Not yet recruiting||||||N/A|Interventional|N/A|2||||||Both|N/A|N/A||||January 2010|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054287||127518|
NCT01054300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-040|Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|52|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054300||127517|
NCT01054027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-109|Study on Effective Mydriasis in Premature Infants|A Randomized Controlled Trial to Determine the Lowest Effective Dose for Adequate Mydriasis in Premature Infants||Georgetown University|No|Completed|March 2007|March 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|15|||Both|N/A|N/A|No|||January 2010|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054027||127538|
NCT01054339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGTC-AAT-002|Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency|A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency||Applied Genetic Technologies Corp|Yes|Active, not recruiting|March 2010|December 2015|Anticipated|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|75 Years|No|||June 2015|June 25, 2015|January 21, 2010|Yes|Yes||No|August 14, 2012|https://clinicaltrials.gov/show/NCT01054339||127514|Study results based on small number of subjects.
NCT01044511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUEST- AFD A|Quality of Life With Esophageal Stent Trial|Prospective, Randomized Trial of the Effects on HRQoL, Cost-Utility and Reintervention Rate, of Nurse Home Visits, in Patients With SEMS Treated Malignant Disease in the Esophagus and Cardia.|QUEST|Odense University Hospital|No|Recruiting|January 2010|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01044511||128265|
NCT01044173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20090033|Plain Magnetic Resonance (MR) in the Assessment of Patients With Acute Abdomen|Assessment of Patients With Nontraumatic Acute Abdominal Pain With Plain MR of the Abdomen - a Comparison With CT||Koege Sygehus|No|Withdrawn|October 2011|October 2012|Actual|September 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01044173||128291|
NCT01044186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0117|A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity|A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity||Novartis||Completed|June 2003|||December 2007|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|2 Years|N/A|No|||November 2012|November 26, 2012|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044186||128290|
NCT01044537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621001|A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Escalating Oral Doses Of PF-04937319 In Adult Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|50|||Both|18 Years|65 Years|No|||June 2010|June 7, 2010|January 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01044537||128263|
NCT01044810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDI-EFV|Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity|Comparison of Virological and Immunological Results of Efavirenz-based Regimen in HIV-infected Patients With or Without Allergic Reactions to Nevirapine||Bamrasnaradura Infectious Diseases Institute|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|559|||Both|18 Years|70 Years|No|Non-Probability Sample|HIV-infected patients who started EFV-based regimens between January 2002 and December        2008 at Bamrasnaradura Infectious Diseases Institute|March 2011|March 14, 2011|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044810||128242|
NCT01045395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2008:139|Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis|Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis|PCA|University of Manitoba|Yes|Completed|September 2009|November 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2010|March 15, 2011|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01045395||128197|
NCT01045408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-TMU-98-02|The Effect of Berry Extract on Helicobacter Pylori Eradication|The Adjuvant Effect of Berry Extract on Triple Therapy for Helicobacter Pylori Eradication||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|January 2009|June 2010|Anticipated|December 2009|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2010|January 13, 2010|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01045408||128196|
NCT01052636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRI-EX90-9023PL|Intervention Program for Elderly Patients With Hip Fracture|Intervention Program for Elderly Patients With Hip Fracture||Chang Gung Memorial Hospital|Yes|Completed|January 2001|December 2003|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|162|||Both|60 Years|N/A|No|||February 2012|February 10, 2012|January 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01052636||127644|
NCT01054326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR 02-37|Effects of Supervised Physical Therapy With Early Activation of the Rotator Cuff Versus Home Exercises in Patients After Arthroscopic Subacromial Decompression|Effects of Supervised Physical Therapy With Early Activation of the Rotator Cuff Versus Home Exercises in Patients After Arthroscopic Subacromial Decompression||Linkoeping University|No|Completed|January 2003|January 2007|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|25 Years|65 Years|No|||January 2006|January 21, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054326||127515|
NCT01051596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-170|A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer|A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer||Georgetown University|Yes|Completed|September 2009|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01051596||127723|
NCT01052142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipovaxin-MM-001|Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma|A Phase I Open-label Study of the Safety and Immunogenicity of Escalating Doses of Lipovaxin-MM, a Novel Melanoma Immunotherapeutic, in Patients With Metastatic Melanoma||Lipotek Pty Ltd|Yes|Completed|September 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052142||127682|
NCT01057823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16685B|Understanding Sleep in Hospitalized Older Patients|Environment and Perceived Control: Improving Sleep in Hospitalized Older Patients||University of Chicago|No|Recruiting|January 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|800|||Both|50 Years|N/A|No|Probability Sample|Community-dwelling ambulatory patients age 50 or above hospitalized on the University of        Chicago general medicine service.|December 2015|December 1, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01057823||127249|
NCT01058135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Effects of Hi-maize Resistant Starch on Insulin Sensitivity|A Randomized, Controlled, Double-blind Crossover Study to Assess the Effects of a Dietary Fiber Ingredient, at Two Doses, on Insulin Sensitivity||National Starch LLC|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|32|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||September 2010|September 15, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01058135||127225|
NCT01052207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00034236|Pilot Study Assessing Oxidative Stress in Children|Prevalence of Oxidative Stress in Critically Ill Children and Its Relationship to Adrenal Insufficiency; a Pilot Study|OxStress|Emory University|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|102|Samples Without DNA|Serum from critically ill patients|Both|N/A|18 Years|No|Non-Probability Sample|Population 1 consists of critically ill patients being care for in quaternary PICU.        Population 2 consists of relatively healthy children undergoing MRI for sedation|May 2015|May 11, 2015|January 15, 2010||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT01052207||127677|
NCT01052688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM T21-305|Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies|Noninvasive Screening for Fetal Chromosomal Aneuploidy and Abnormality: Assay Development & Optimization in Affected Pregnancies|CHARMM-AP|Sequenom, Inc.|No|Recruiting|November 2009|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples With DNA|Plasma, white blood cells|Female|N/A|N/A|No|Probability Sample|Pregnant women who have been definitively diagnosed by amniocentesis, CVS or QF/PCR as        carrying a fetus with aneuploidy|September 2015|September 15, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01052688||127640|
NCT01052974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI2008-07|Perioperative Analgesia by Femoral Perineural Catheter for Femoral Neck Fracture - Study KTcol|Perioperative Analgesia by Femoral Perineural Catheter for Femoral Neck Fracture - Study KTcol -|KTcol|University Hospital, Angers|No|Recruiting|March 2009|September 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2010|February 3, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052974||127618|
NCT01052987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3008GT|Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia|A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Allopurinol Compared With Tranilast Alone and Allopurinol Alone in Healthy Subjects With Hyperuricemia||Nuon Therapeutics, Inc.|No|Completed|January 2010|November 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|24|||Both|21 Years|70 Years|No|||January 2011|January 5, 2011|January 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01052987||127617|
NCT01052441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEH-CRLLC-1.2009|Iodine Content for Diagnostic AccuRacy and Patient Comfort For Individuals Undergoing Cardiac Computed Tomography (CT) Scanning|Iodine Content for Diagnostic AccuRacy and Patient Comfort For Individuals Undergoing Cardiac CT Scanning: The Multicenter ICARUS Trial|ICARUS|MDDX LLC|No|Completed|January 2010|September 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|80 Years|No|Probability Sample|Subjects are over 18 years or older. They have been referred to a cardiologist for        suspected CAD and then scheduled for an elective invasive coronary angiography.|December 2012|December 8, 2012|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01052441||127659|
NCT01052454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT002910|Mindfulness-Based Stress Reduction for Hot Flashes|Pilot Study to Assess the Feasibility of MBSR for Hot Flashes||University of Massachusetts, Worcester|No|Completed|September 2005|||May 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2010|January 19, 2010|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052454||127658|
NCT01053468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROACTIVE|Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy|Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy|PROACTIVE|Athabasca University|No|Recruiting|August 2010|April 2013|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Female|18 Years|75 Years|No|||January 2010|June 30, 2011|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053468||127581|
NCT01053689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30287|Bioequivalence Study of Dr.Reddys Laboratories Limited, Glimepiride 1 mg Tablets in Healthy Subjects Under Fed Condition|Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fed Condition||Dr. Reddy's Laboratories Limited|Yes|Completed|December 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 19, 2010|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053689||127564|
NCT01053702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-0909|Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury|||Regeneron Pharmaceuticals|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|50 Years|No|||April 2011|April 17, 2011|January 19, 2010|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01053702||127563|
NCT01053481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-04-07-Ca41|Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health|Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health||Swiss Federal Institute of Technology|Yes|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|25|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053481||127580|
NCT01053715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1250_5002_EU|Quality of Life Study of Helixate NexGen|A European, Prospective, Non-Interventional Study to Assess Health Related Quality of Life and to Identify Key Transitional Life Events in Patients With Moderate or Severe Haemophilia A Using Helixate NexGen||CSL Behring|No|Completed|January 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Male|14 Years|35 Years|No|Non-Probability Sample|Patients with a diagnosis of moderate or severe Hemophilia A using Helixate NexGen        identified by selected European hemophilia treatment centers.|March 2015|March 18, 2015|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01053715||127562|
NCT01054378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0614|Diaphragmatic Movement Before and After Stellate Ganglion Block : A Ultrasonographic Study|||Yonsei University||Completed|January 2010|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Primary Purpose: Treatment|||Actual|43|||Both|20 Years|65 Years|No|||December 2010|December 6, 2010|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054378||127511|
NCT01043939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS074|Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors|A Pilot Study to Evaluate the Effects of Purple Grape Juice on the Vascular Health of Childhood Cancer Survivors|JAVA|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2009|December 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|10 Years|30 Years|No|||December 2014|December 9, 2014|January 5, 2010|No|Yes||No|December 4, 2011|https://clinicaltrials.gov/show/NCT01043939||128309|
NCT01044550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mlhgid004|Laparoscopy Versus Clinical Follow up to Detect Diaphragm Injury|Laparoscopy (to Detect Occult Diaphragm Injury) Versus Clinical and Radiological Follow up to Detect Diaphragm Injury and Herniation, in Patients With Asymptomatic Left Thoracoabdominal Stab Wounds: A Prospective Randomized Controlled Study||University of Cape Town|Yes|Completed|September 2009|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|66|||Both|18 Years|60 Years|No|||January 2015|January 21, 2015|January 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01044550||128262|
NCT01044849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-609|Clinical Test Report for Blood Pressure Meter CH-609|||Citizen Systems Japan Co., Ltd.|No|Completed|November 2007|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|85|||Both|22 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Community Sample|January 2010|January 7, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044849||128239|
NCT01045343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDICATE HF|Feasibility Study of an Integrated Diagnostic System to Manage Heart Failure|Integrated Diagnostics Can Alter Heart Failure|INDICATE HF|Medtronic Cardiac Rhythm Disease Management|No|Completed|March 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|136|||Both|18 Years|N/A|No|||April 2012|April 13, 2012|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045343||128201|
NCT01045356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|x10-01-0006|Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass|Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass||Children's Hospital Boston|Yes|Completed|January 2010|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|55|||Both|N/A|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with congenital heart defects having cardiac surgery requiring cardiopulmonary        bypass|June 2011|July 29, 2015|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01045356||128200|
NCT01045421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14007|MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies|A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies||Millennium Pharmaceuticals, Inc.|No|Completed|February 2010|January 2014|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|273|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045421||128195|
NCT01054014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016795|A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers|A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-40346527 in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2010|January 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054014||127539|
NCT01054313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0558|Docetaxel and Sirolimus in Patients With Advanced Malignancies|A Phase I Trial of Docetaxel and Sirolimus in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Completed|January 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|N/A|N/A|No|||October 2015|October 5, 2015|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054313||127516|
NCT01051297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1132357|Obstructive Sleep Apnea and Venous Thromboembolism|Patients With Obstructive Sleep Apnea (OSA), Independent of Obesity, Are at Increased Risk of Venous Thromboembolic Events (VTE)|OSAVTE|University of Missouri-Columbia|No|Withdrawn|March 2009|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Adult patients (>=18 years) with sleep study , OSA or VTE|May 2015|May 27, 2015|January 15, 2010||No|Investigator left the institution|No||https://clinicaltrials.gov/show/NCT01051297||127745|
NCT01051310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-2007-03|Medtronic CoreValve REDO Study|Feasibility Study of Percutaneous Aortic Valve Implantation With the Medtronic CoreValve System for Percutaneous Aortic Valve Replacement (PAVR) in Patients With a Failing Previously Surgically Implanted Aortic Bioprosthesis and Presenting a High Risk for Repeat Surgical Valve Replacement|REDO|Medtronic Cardiovascular|Yes|Completed|June 2008|January 2011|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|75 Years|N/A|No|||October 2015|October 29, 2015|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051310||127744|
NCT01058616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-315-01|Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour|Phase 1 Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour||Lytix Biopharma AS|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058616||127188|
NCT01058915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003111-43|Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI)|Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition Assessed by Virtual Histology in Patients With ST-Segment Elevation Acute Myocardial Infarction (VIRHISTAMI)|VIRHISTAMI|Odense University Hospital|No|Completed|November 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|81 Years|No|||January 2010|January 28, 2010|January 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01058915||127165|
NCT01058148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910036|A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening|A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening||National Institutes of Health Clinical Center (CC)||Completed|December 2009|April 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|400|||Female|26 Years|65 Years|No|||April 2011|April 14, 2011|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01058148||127224|
NCT01052220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904007039|Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention|Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention||Wayne State University|Yes|Recruiting|June 2009|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2010|January 19, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052220||127676|
NCT01052181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBISR/2010/01|A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity|A Double Blind Randomized Control Trial to Study the Effect of Long Term Vitamin D Supplementation on Peripheral Insulin Sensitivity in Apparently Healthy Middle Aged Centrally Obese Adults|LongtermVitD|Sitaram Bhartia Institute of Science and Research|Yes|Active, not recruiting|January 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|January 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01052181||127679|
NCT01052194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-509-101|A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis|A 12-week, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis||Vertex Pharmaceuticals Incorporated|Yes|Completed|February 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|206|||Both|18 Years|75 Years|No|||December 2012|December 12, 2012|January 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052194||127678|
NCT01053221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2005-0357|Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation|Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation||University of Wisconsin, Madison|Yes|Completed|March 2006|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||October 2015|October 9, 2015|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053221||127599|
NCT01052701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00023807|Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment|Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment||Johns Hopkins University|No|Recruiting|December 2009|June 2012|Anticipated|March 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|28|||Male|18 Years|55 Years|No|||January 2010|June 22, 2011|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01052701||127639|
NCT01052714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7358-R|Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2|Management of Antipsychotic Medication Associated Obesity - 2|MAMAO2|VA Office of Research and Development|Yes|Active, not recruiting|September 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||March 2016|March 8, 2016|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01052714||127638|
NCT01053000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-0901|Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses|Photodynamic Therapy With Levulan® Topical Solution And Blue Light +/- Topical Retinoid Pre-Treatment In The Treatment Of Dorsal Hand/Forearm Actinic Keratoses||Stewart, Roger H., M.D., P.A.|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|January 19, 2010||No||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01053000||127616|
NCT01053208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149-07|Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fasting Condition|Open Label,Balanced,Randomized,Two-treatment,Two-sequence,Two Period,Single-dose,Crossover Oral Bioequivalence Study of Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets of Dr.Reddy's and Advil®PM of Wyeth in Normal,Healthy,Adult,Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|April 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|January 20, 2010|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053208||127600|
NCT01054053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/042/HP|Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®|Phase 3, Vaccinal Activity Assessment of MenBVac Against Nesseiria Menigitidis B:14,P1.7,16 Strain in Child.|EFFIVAC|University Hospital, Rouen|Yes|Completed|April 2009|January 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|Samples Without DNA|blood samples|Both|1 Year|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|children born between 06/04/2004 and 17/04/2008, living Neufchatel en bray.|March 2012|March 22, 2012|November 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01054053||127536|
NCT01054066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-317|Managing Chronic Kidney Disease in Eastern North Carolina|Management of Chronic Kidney Disease in Eastern North Carolina (MARKER)||East Carolina University|No|Completed|August 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1257|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01054066||127535|
NCT01054391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEC001|Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae|NEC Trial - Nfocus - Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae - A Non-Randomized Pilot Study||Nfocus Neuromedical||Recruiting|October 2008|||December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|80 Years|No|||January 2010|January 20, 2010|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01054391||127510|
NCT01044212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29359|Bowel Function After Minimally Invasive Urogynecologic Surgery|Bowel Function After Minimally Invasive Urogynecologic Surgery: A Prospective Randomized Controlled Trial||University of Rochester|No|Completed|November 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Female|18 Years|89 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|January 5, 2010|No|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT01044212||128288|
NCT01044875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMERC002|Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy|A Randomised Control Trial Comparing the Effectiveness of Yellow 577 nm Laser to Conventional Green 532 nm Laser for Proliferative Diabetic Retinopathy|UMPDR|University of Malaya|Yes|Recruiting|September 2009|October 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2010|January 7, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044875||128237|
NCT01044888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0142|Heparin Resistance: Predictors and Outcomes|Heparin Resistance During Off-pump Coronary Artery Bypass Graft Surgery: Predictors and Clinical Implication||Yonsei University|Yes|Completed|April 2007|September 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|199|||Both|18 Years|85 Years|No|||January 2012|January 31, 2012|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01044888||128236|
NCT01045707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3590|Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes|NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1)|BOOST™|Novo Nordisk A/S|No|Completed|January 2010|May 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|530|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|January 8, 2010|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01045707||128173|
NCT01054898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 06-105 T/1130|Effectiveness of a Telephone Intervention to Improve the Mental Health of Abused Women|A RCT to Test the Effectiveness of a Telephone Intervention to Improve the Mental Health of Community Dwelling Women Abused by Their Intimate Partners||The University of Hong Kong|No|Completed|February 2007|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01054898||127472|
NCT01051024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-0917-CU|Diamel in the Treatment of Polycystic Ovary Syndrome|Efficacy of Diamel in the Treatment of Polycystic Ovary Syndrome||Catalysis SL|Yes|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|40 Years|No|||May 2012|May 2, 2012|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01051024||127766|
NCT01056640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005259|Telemonitoring Versus Usual Care|A Randomized Controlled Trial of Telemonitoring Versus Usual Care in a High Risk Elderly Population.||Mayo Clinic|No|Completed|November 2009|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|205|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 7, 2013|January 25, 2010||No||No|November 6, 2012|https://clinicaltrials.gov/show/NCT01056640||127340|Patients in the usual care group had access to a tertiary care hospital and to some case management for treatment of heart failure and diabetes. These services may have biased the results to show no difference between the groups.
NCT01057277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-H&N-229|RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer|BrUOG-H&N-229-RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer: A PHASE I STUDY- Novartis CRAD001CUS134T||Brown University|Yes|Terminated|December 2009|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|December 9, 2009|Yes|Yes|Pharmaceutical co- re aligned their specialties- no longer will fund H&N ca|No|July 8, 2015|https://clinicaltrials.gov/show/NCT01057277||127291|
NCT01057576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC26006|Safety and Efficacy Study of Tarragon on Insulin Action in Humans|The Effect of Artemisia Dracunculus L. on Insulin Sensitivity in Obese, Insulin-Resistant Human Subjects|5011|Pennington Biomedical Research Center|No|Completed|March 2006|October 2008|Actual|March 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|30 Years|N/A|No|||December 2012|December 7, 2012|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01057576||127268|
NCT01057589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12170|A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer|Phase 2 Study of Pemetrexed in Combination With Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||Eli Lilly and Company|No|Completed|February 2010|October 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|January 20, 2010|Yes|Yes||No|February 6, 2013|https://clinicaltrials.gov/show/NCT01057589||127267|
NCT01053156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917522-1|Trial of Minocycline to Treat Children With Fragile X Syndrome|Randomized Double-Blind Controlled Cross Over Trial of Minocycline in Children With Fragile X Syndrome||University of California, Davis|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|42 Months|16 Years|No|||June 2014|June 30, 2014|January 19, 2010|Yes|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT01053156||127604|Results may be potentially biased by study design weaknesses, including unblinding of subjects when they completed the study, drug-related side effects unblinding and preliminary efficacy analysis results known to investigators.
NCT01051882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-NTF-001-HMO-CTIL|Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.|A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.||Hadassah Medical Organization||Completed|June 2011|March 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|75 Years|No|||August 2012|November 6, 2013|January 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01051882||127701|
NCT01051895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020428|Colposcopy Versus HPV Testing to Identify Persistent Cervical Precancers|Randomized Controlled Trial Comparing Routine Colposcopy to HPV Testing to Identify Persistent or Recurrent High Grade Cervical Cancer Precursors|CoHIPP|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|2253|||Female|18 Years|N/A|No|||February 2015|August 21, 2015|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01051895||127700|
NCT01053013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911010739|Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer|An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma|Macrobead|The Rogosin Institute|Yes|Recruiting|February 2010|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01053013||127615|
NCT01053234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRS 2006-1032|Different Insulin Regimens and Postprandial Coagulation Activation|Effects of Standardised Meals on Postprandial Coagulation Activation in Patients With Type 2 Diabetes Treated With Two Different Insulin Regimens||Hospital of South West Denmark|No|Completed|February 2007|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|30 Years|75 Years|No|||January 2010|January 20, 2010|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053234||127598|
NCT01053247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0416|Study of 0416 Ointment in the Treatment of Atopic Dermatitis|Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0416 Ointment.||Fougera Pharmaceuticals Inc.|No|Completed|January 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|793|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|December 9, 2009|Yes|Yes||No|September 30, 2014|https://clinicaltrials.gov/show/NCT01053247||127597|
NCT01053494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97709|Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer|The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|April 2010|||February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|80|||Both|3 Years|17 Years|No|||July 2015|July 22, 2015|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01053494||127579|
NCT01053728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU10987|Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)|Randomized, Double-blind, Euglycemic Glucose Clamp Study of Four Formulations of SAR161271, in Single Doses in Healthy Subjects and Single Ascending Doses in Patients With Type 1 Diabetes Mellitus||Sanofi|No|Completed|February 2010|November 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|46|||Male|18 Years|60 Years|No|||July 2011|July 25, 2011|January 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01053728||127561|
NCT01054079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98309|Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer|A Phase II Trial to Assess the Effect of Cinacalcet Hydrochloride on PSA Levels in Patients With Biochemically Recurrent Prostate Cancer After Failed Definitive Local Therapy||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|September 2011|||August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||September 2015|September 29, 2015|January 21, 2010|Yes|Yes||No|August 14, 2015|https://clinicaltrials.gov/show/NCT01054079||127534|
NCT01054404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00016126|Furosemide vs Placebo for Brain Relaxation|The Effect of Furosemide Versus Placebo on Brain Relaxation and Incidence of Significant Intravascular Volume Depletion in Human Subjects Receiving Mannitol||Northwestern University|No|Terminated|February 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|January 20, 2010||No|Concern for volume depletion and electrolyte abnormalities in furosemide arm.|No|May 8, 2013|https://clinicaltrials.gov/show/NCT01054404||127509|Recruitment was stopped at 23 subjects because of concern that the administration of furosemide was producing such a large diuresis that clinically significant and potentially unsafe hypovolemia and electrolyte abnormalities were developing.
NCT01044862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMN-AMIGOS|Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation|Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation|AMIGOS|Yale University|Yes|Completed|June 2010|March 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|900|||Female|18 Years|40 Years|No|||January 2015|January 22, 2015|January 7, 2010|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01044862||128238|
NCT01045148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Virtual HDR CK Radiosurgery|CyberKnife Radiosurgery for Localized Prostatic Carcinoma|Virtual HDR CyberKnife Radiosurgery for Localized Prostatic Carcinoma: A Phase II Study||CyberKnife Centers of San Diego|No|Recruiting|March 2006|||December 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|258|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 13, 2014|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01045148||128216|
NCT01045122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleep Study CReFF award|Sedation in Patients at Risk for Upper Airway Collapse|Sedation in Patients at Risk for Sleep-induced Upper Airway Collapse||University of Rochester|Yes|Completed|December 2006|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|15|||Both|18 Years|75 Years|No|||April 2015|April 24, 2015|December 11, 2009||No||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01045122||128218|
NCT01045369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-001|A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects|A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects|KALYINTE|Therapeutic Concepts|Yes|Recruiting|January 2010|June 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2010|February 12, 2010|January 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01045369||128199|
NCT01045720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08200|The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia|The Treatment Effect of 2 Traditional Chinese Medicines[Suo Quan Wan]and [Wu Lin San] in Clozapine-induced Hypersalivation in Schizophrenia Patient.||Taichung Veterans General Hospital|Yes|Recruiting|January 2010|March 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|45|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2010|January 13, 2010|January 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01045720||128172|
NCT01052155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 26|Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients|Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective Analysis of Immunoassay and Liquid Chromatography Tandem Mass Spectometry (LC/MS/MS)||Pain Management Center of Paducah|Yes|Completed|February 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic pain management with or without controlled substance therapy.|March 2011|March 11, 2011|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01052155||127681|
NCT01056913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2|NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery|Compression Anastomosis: Initial Clinical Experience With the ColonRingTM||St John of God Hospital, Vienna|No|Completed|October 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|90 Years|No|||December 2013|December 11, 2013|January 24, 2010||No||No|December 11, 2013|https://clinicaltrials.gov/show/NCT01056913||127319|
NCT01057251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-20|Nebivolol in Patients With Systolic Stage 2 Hypertension|Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of 5 mg or 20 mg Nebivolol Once Daily on Blood Pressure in Patients With Systolic Stage 2 Hypertension|NEB-MD-20|Forest Laboratories|No|Completed|March 2010|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|433|||Both|18 Years|64 Years|No|||December 2011|December 6, 2011|January 26, 2010|Yes|Yes||No|December 6, 2011|https://clinicaltrials.gov/show/NCT01057251||127293|
NCT01057264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0741|HAI Abraxane With Gemcitabine and Bevacizumab|A Phase I Study of Hepatic Arterial Infusion (HAI) of Abraxane in Combination With Gemcitabine and Bevacizumab for Patients With Advanced Cancers Metastatic to the Liver||M.D. Anderson Cancer Center|No|Completed|January 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01057264||127292|
NCT01052922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3R01CA121125-03S1|Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement|Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement||Group Health Cooperative|No|Completed|August 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|2260|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||August 2012|August 15, 2012|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01052922||127622|
NCT01053975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-102-005|SPIROCOR Coronary Outcome by Respiratory Stress Examination|SPIROCOR Coronary Outcome by Respiratory Stress Examination - SCORE Study|SCORE|Spirocor|Yes|Terminated|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|30 Years|N/A|No|Probability Sample|Subjects referred to cardology clinics for evaluation of severe coronary artery disease        (S-CAD)|November 2010|November 5, 2010|January 20, 2010||No|Based on analyses of studies separately of the SCORE study, sponsor has decided to discontinue    the Study. Data collected during the study will not be analyzed|No||https://clinicaltrials.gov/show/NCT01053975||127542|
NCT01053988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112206|A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|October 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1031|||Both|40 Years|N/A|No|||June 2013|September 12, 2013|January 14, 2010|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01053988||127541|
NCT01063998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-125|A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma|A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma||William Beaumont Hospitals|No|Terminated|September 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|23|Samples With DNA|Renal tumor.|Both|18 Years|N/A|No|Probability Sample|Patients having nephrectomy.|November 2013|November 6, 2013|September 2, 2009||No|Preliminary data did not show expected outcomes.|No||https://clinicaltrials.gov/show/NCT01063998||126777|
NCT01064297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112913|Lamotrigine Pregnancy Registry (LAM05)|Lamotrigine Pregnancy Registry (LAM05)||GlaxoSmithKline|No|Completed|November 2001|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3416|||Female|N/A|N/A|No|Non-Probability Sample|Women exposed to lamotrigine during pregnancy anywhere in the world.|February 2013|February 21, 2013|January 28, 2010||No||No|June 14, 2010|https://clinicaltrials.gov/show/NCT01064297||126754|
NCT01073748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-RS-422-CTIL|The Effect of Single Dose Paracetamol on the Lower Airways of Asthmatic and Healthy Children|The Effect of Paracetamol on Lower Airway Obstruction in Asthmatic Versus Non Asthmatic Children||Tel-Aviv Sourasky Medical Center|No|Recruiting|March 2010|||March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|7 Years|16 Years|Accepts Healthy Volunteers|||January 2011|January 23, 2011|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073748||126035|
NCT01074294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-08-213|Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/ Hyperactivity Disorder|STEP-A|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|March 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|740|||Both|18 Years|55 Years|No|||October 2012|October 23, 2012|February 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074294||125993|
NCT01074528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCV2010|Mindfulness Based Stress Reduction: Supportive Treatment for Adult Patients With Cancer and Their Partners|Mindfulness Based Stress Reduction: Supportive Treatment for Adult Patients With Cancer and Their Partners||Belgian Federal Public Service, Food Chain Safety and Environment|No|Suspended|April 2010|May 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|February 18, 2010||No|Financial support ( grant) stopped|No||https://clinicaltrials.gov/show/NCT01074528||125975|
NCT01074268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3585|Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes|NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN™: BB T1)|BEGIN™|Novo Nordisk A/S|No|Completed|February 2010|June 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|456|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|February 22, 2010|Yes|Yes||No|October 15, 2015|https://clinicaltrials.gov/show/NCT01074268||125995|
NCT01074281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084000-501|An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)|Examination of Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With ENEAS®.||Merck KGaA||Completed|June 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2065|||Both|50 Years|N/A|No|Probability Sample|Subjects with ISH ≥ 140 / < 90 mmHg were enrolled in the study.|February 2014|February 16, 2014|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074281||125994|
NCT01074801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN01|Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes|An Open-label, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of 36-hour Closed-loop Glucose Control in Comparison With Conventional Subcutaneous Insulin Pump Treatment in Adolescents With Type 1 Diabetes||University of Cambridge|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|12 Years|18 Years|No|||February 2010|April 5, 2011|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074801||125954|
NCT01074814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SO-BCA-001|Pilot Study Using Molecular Profiling to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.|A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray, and Reverse Phase Protein Microarray (RPMA) of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.|Side-Out|Translational Drug Development|No|Completed|February 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||July 2012|August 27, 2013|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074814||125953|
NCT01076673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLSMC-001|Effect of Autologous Peripheral Blood Stem Cell Treatment on Articular Cartilage Regeneration|Articular Cartilage Regeneration With Autologous Peripheral Blood Stem Cells Versus Hyaluronic Acid: A Randomized, Controlled Trial||Kuala Lumpur Sports Medicine Centre|No|Completed|October 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||March 2015|March 12, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076673||125810|
NCT01070017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH083550-01A2|Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru|Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru|CASA|Brigham and Women's Hospital|Yes|Active, not recruiting|February 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1244|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 31, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070017||126319|
NCT01070030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100ATH01|Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension|Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT|ACADEMY|Novartis||Completed|January 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|230|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|February 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070030||126318|
NCT01075542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082099|Astigmatism Management in Cataract Surgery With the AcrySof Toric Intraocular Lens|Efficacy and Cost-effectiveness of Toric Intraocular Lenses in Correcting Astigmatism in Cataract Surgery: a Randomised Clinical Trial||Maastricht University Medical Center|No|Completed|February 2010|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|21 Years|N/A|No|||January 2014|January 13, 2014|February 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075542||125897|
NCT01067495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSFO-SRA5977|Adapted Cardiac Rehabilitation After Stroke|Feasibility and Effects of Cardiac Rehabilitation for Individuals After Stroke||Toronto Rehabilitation Institute|No|Completed|January 2006|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|N/A|N/A|No|||February 2010|February 10, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01067495||126509|
NCT01067508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-12-097-03|Effects of Naturally Silicon-Rich Water on Bone Metabolism in Women|Effects of Naturally Occurring Silicon in Drinking Water on Bone Metabolism||University of California, Los Angeles||Completed|June 2007|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 8, 2013|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01067508||126508|
NCT01076868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU0909|Incidence of Vivax Along the Thai Burma Border|Determining the Incidence of New Plasmodium Vivax Infections After Radical Treatment Following Vivax Malaria Along the Thai Burma Border|VHC|University of Oxford|No|Recruiting|February 2010|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|6 Months|N/A|No|||August 2013|August 28, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076868||125795|
NCT01072916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1149|Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)|The Role of Serine-Proteases in Gastrointestinal Function and Irritable Bowel Syndrome||University of North Carolina, Chapel Hill|No|Completed|February 2009|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Urine and Stool.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women of any race or ethnicity at least 18 years or older who have Diarrhea        predominant Irritable Bowel Syndrome (D-IBS, n = 30) and healthy controls (n = 30).|April 2014|March 10, 2016|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072916||126098|
NCT01068041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP016|Effects of PH3 in Diabetic Nephropathy|Effects of PH3 in Diabetic Nephropathy|PH3|PhytoHealth Corporation|No|Completed|August 2010|September 2015|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|100|||Both|18 Years|70 Years|No|||November 2015|November 3, 2015|February 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01068041||126469|
NCT01072903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1106|The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)|The Role of Intestinal Inflammation in the Pathophysiology of IBS|K23|University of North Carolina, Chapel Hill|No|Completed|January 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|78|Samples Without DNA|8 rectosigmoidal intestinal biopsies, stool, and blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This research plans to study 33 diarrhea predominant Irritable Bowel Syndrome and        IBS-mixed/alternators patients with current symptom activity (abdominal pain at least once        a week in the past month) and 33 healthy controls. The subjects will be of any gender,        race or ethnicity and at least 18 years of age. Recruitment for the proposed study takes        advantage of an ongoing NIH-supported research study on the heterogeneity of IBS (NIDDK        Grant DK 31369, WE Whitehead - PI, IRB#01-1397, GCRC# 1846) currently conducted at UNC.|December 2013|December 11, 2013|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072903||126099|
NCT01072890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917514|Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors|Phase I Study of the Combination of Temsirolimus (CCI-779) and Pazopanib (GW786034) in Patients With Advanced Solid Tumors||University of California, Davis|Yes|Completed|February 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2012|March 26, 2012|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072890||126100|
NCT01064557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDA0493|"AIDA" Protocol (LAP 0493)|Guideline for the Treatment of Newly Diagnosed Patients Eith Acutypromyelocytic Leukemia, Aged > 12 Months (1 Year) and <75 Years, Using All-trans Retinoic Acid in Combination With Idarubicin||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|October 1993|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1068|||Both|1 Year|75 Years|No|||March 2014|March 21, 2014|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064557||126734|
NCT01065064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOB-01/09|Visual Performance After RESTOR Implantation|Visual Performance After Implantation of an Aspheric Multifocal Diffractive Intraocular Lens||Hospital Oftalmologico de Brasilia|Yes|Completed|January 2009|December 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||February 2010|February 8, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065064||126695|
NCT01073436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.083|Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha|Discontinuation of Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myeloid Leukemia, Previously Treated With Interferon-Alpha||University of Michigan Cancer Center|Yes|Terminated|May 2009|October 2016|Anticipated|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Diagnosed with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia in chronic        phase.|March 2016|March 10, 2016|February 19, 2010||No|Closed prematurely due to low accrual.|No||https://clinicaltrials.gov/show/NCT01073436||126059|
NCT01074008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-602|A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072|A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Champion2|AbbVie|No|Completed|March 2010|January 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|74|||Both|18 Years|65 Years|No|||December 2014|December 29, 2014|February 22, 2010|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01074008||126015|
NCT01074840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112009-006|Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy|Dendritic Cell Responses to Viral Stimulation in Peanut Allergic Subjects Undergoing Peanut Oral Immunotherapy|DCOIT|University of Texas Southwestern Medical Center|Yes|Completed|February 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|3 Years|16 Years|No|||December 2014|December 1, 2014|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074840||125951|
NCT01075126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abbottdepakote1|Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder|Depakote Vs. Lithium in African Americans With Bipolar Disorder||Lawson, William B., M.D., PhD, DFAPA||Withdrawn|December 2006|December 2006|Anticipated|December 2006|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||February 2010|February 23, 2010|February 23, 2010|Yes|Yes|key investigator relocated.|No||https://clinicaltrials.gov/show/NCT01075126||125929|
NCT01074827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/225|Improving Gait in Multiple Sclerosis (MS) - Strength Training or Treadmill Walking?|Strength Training or Treadmill Walking? A Randomized Control Study on the Effect on Gait in Multiple Sclerosis||St. Olavs Hospital|No|Completed|March 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074827||125952|
NCT01075113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12122|Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer|A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma||Virginia Commonwealth University|Yes|Recruiting|August 2010|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|February 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01075113||125930|
NCT01075347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200701021R|Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries|Clinical Study: Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries||National Taiwan University Hospital|No|Completed|March 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|165|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2010|September 7, 2010|December 4, 2008||No||No|July 14, 2010|https://clinicaltrials.gov/show/NCT01075347||125912|
NCT01075360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806005R|The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression|The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression||National Taiwan University Hospital|No|Completed|August 2008|April 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|N/A|18 Years|No|Non-Probability Sample|From year 1990 to 2009, pediatric neuroblastoma patients treated at National University        Hospital, Taiwan|February 2010|February 24, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075360||125911|
NCT01075854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700623_507|An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)|A Prospective, Multi-center, Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to IVF/ICSI||Merck KGaA||Completed|April 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1539|Samples Without DNA|Serum samples|Female|N/A|N/A|No|Non-Probability Sample|Female subjects who are prescribed Gonal-F FbM by their treating physician for their        IVF/ICSI treatment cycle will be eligible for the study.|September 2010|July 30, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075854||125873|
NCT01076426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-98-083|Probiotics Use in the Chronic Peritoneal Dialysis Patients|The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis||National Cheng-Kung University Hospital|Yes|Recruiting|February 2010|March 2011|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|75 Years|No|||February 2010|February 25, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076426||125829|
NCT01075269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreanAES001|Postoperative Distress and Cosmetic Outcomes After Open Versus Robotic Thyroidectomy|Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report.|Robot1|Korean Association of Endocrine Surgeons|Yes|Active, not recruiting|April 2009|May 2010|Anticipated|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|84|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with differentiated thyroid carcinoma who were scheduled to underwent        thyroidectomy in Ajou University Medical center (Tertial oncologic center).|February 2010|February 24, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075269||125918|
NCT01072877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV015|Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence|A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Polidocanol Injectable Foam 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence|VANISH-1|BTG International Inc.|Yes|Completed|December 2010|November 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|279|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|February 19, 2010|Yes|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT01072877||126101|
NCT01075841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62241-510|A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck|A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck||Merck KGaA|No|Withdrawn|March 2009|||March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with recurrent and/or metastatic SCCHN undergoing treatment with Erbitux in        Korea.|December 2010|July 1, 2014|February 24, 2010||No|After loss of orphan drug status in Korea, study was withdrawn due to Regulatory Authority    request. Patients will be enrolled into NCT01075828 instead.|No||https://clinicaltrials.gov/show/NCT01075841||125874|
NCT01076881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCPelotas01|Combined Resistance and Aerobic Exercise is Better Than Resistance Training Alone to Improve Functional Performance of Hemodialysis Patients - Results of a Randomized Trial|Combined Resistance and Aerobic Exercise is Better Than Resistance Training Alone to Improve Functional Performance of Hemodialysis Patients - Results of a Randomized Trial||Universidade Católica de Pelotas|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||February 2010|February 25, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01076881||125794|
NCT01068054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fk506vscyclosporine_vkc|Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC)|A Double-blind Comparison of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drops in the Treatment of Vernal Keratoconjunctivits (VKC)||Siriraj Hospital|Yes|Completed|June 2003|May 2005|Actual|May 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|N/A|N/A|No|||June 2003|February 11, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068054||126468|
NCT01064024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-PHN-001|Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo|A Double Blind, Randomized, Parallel Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo as a Urinary Analgesic for Short Term Treatment in Female Subjects Suffering From Pain or Burning When Passing Urine Associated With Uncomplicated Urinary Tract Infections (uUTI)||Amneal Pharmaceuticals, LLC|Yes|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|233|||Female|18 Years|N/A|No|||January 2013|January 24, 2013|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064024||126775|
NCT01073462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-680|Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years|Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.||AbbVie|No|Completed|December 2008|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|Investigational sites were clinic centers with experience in the treatment of chronic        kidney disease stage 5 patients and hemodialysis.|June 2014|June 9, 2014|February 20, 2010||No||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01073462||126057|
NCT01073150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nahin Geha|Tea Tree Oil in the Treatment of Chronic Blepharitis|Tea Tree Oil in the Treatment of Chronic Blepharitis||Federal University of São Paulo|Yes|Completed|April 2009|November 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||February 2010|February 19, 2010|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01073150||126080|
NCT01073137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK079283-01A1|Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions|Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions||Portland VA Medical Center|Yes|Recruiting|June 2006|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|44|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetese subjects with no hearing impairement.|September 2009|February 22, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073137||126081|
NCT01073423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&R Pilot|Improving Sleep and Quality of Life in Adults With HIV Disease|Improving Sleep and Quality of Life in Adults With HIV Disease: A Pilot Study|R&R|University of California, San Francisco|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01073423||126060|
NCT01073774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|He61491994|Side by Side - Prediction of Couples' Adjustment to Breast or Gynecological Cancer|Side by Side - Prediction of Couples' Adjustment to Breast or Gynecological Cancer|Side by Side|Technical University of Braunschweig|No|Completed|February 2006|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||||||Both|18 Years|80 Years||||February 2010|February 22, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073774||126033|
NCT01074307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 084000-608|A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea|Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM)|PRISM|Merck KGaA|No|Completed|October 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|80 Years|No|||January 2014|January 13, 2014|February 22, 2010||No||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01074307||125992|
NCT01074554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091103|Trial of Antimycobacterial Therapy in Sarcoidosis|Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis|CLEAR|Vanderbilt University|Yes|Active, not recruiting|February 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|32|||Both|18 Years|N/A|No|||December 2010|December 16, 2010|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074554||125973|
NCT01074567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174/09|DMSO Efficacy in IC/PBS Patients During and After Treatment|Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment||Assaf-Harofeh Medical Center|No|Recruiting|December 2009|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||March 2010|April 4, 2011|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074567||125972|
NCT01074853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAW004|Beta Blockers for the Treatment of Asthma|Evaluation of Beta Blockers for the Treatment of Asthma. A Randomised Controlled Trial of Propranolol||University of Dundee|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||February 2013|February 6, 2013|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074853||125950|
NCT01075139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N/A (unfunded trial)|Brief Motivational Intervention to Increase Physical Activity and Fruit/Vegetable Intake|Pilot Trial of a Brief Motivational Intervention to Increase Physical Activity and Fruit/Vegetable Intake Among College Students||University of Missouri-Columbia|No|Completed|October 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 20, 2011|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075139||125928|
NCT01075373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807021R|A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations|A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations|SONPOS|National Taiwan University Hospital|No|Enrolling by invitation|March 2009|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|360|Samples With DNA|Whole blood|Both|16 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|16-45 y/o early stage schizophrenia|February 2010|March 4, 2010|February 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075373||125910|
NCT01075659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP2011|Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge|Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge: A Study in Healthy Smokers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|200|||Both|19 Years|55 Years|No|||July 2012|July 6, 2012|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075659||125888|
NCT01075880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701068-519|Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®|Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif|SKORE|Merck KGaA|No|Completed|May 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with RRMS prescribed with Rebif across 14 centres in Czech Republic.|September 2013|September 5, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075880||125871|
NCT01075646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANESTHESIA SERVICE HUB|Local Anesthesia Versus Saline Serum in Surgical Incision of Colorectal or Hepatic Surgery|Randomised and Double-blind Clinical Trial on Post-operative Analgesic Efficacy in Colorectal Surgery and Hepatic Surgery With Continuous Infusion of Local Anesthesia vs Saline Serum in the Surgical Incision.|CATROP-2007|Hospital Universitari de Bellvitge|No|Completed|March 2009|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|80 Years|No|||March 2015|March 17, 2015|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01075646||125889|
NCT01073241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SouthwestH|Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate|Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate||Southwest Hospital, China|No|Active, not recruiting|March 2010|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Male|45 Years|90 Years|No|||February 2010|March 12, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073241||126073|
NCT01073267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0444|Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides|A Phase II Study of Total Skin Electron Beam Therapy (TSEBT) to Dose of 12 Gy in Stage IB-IIIA Mycosis Fungoides||M.D. Anderson Cancer Center|No|Completed|February 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|February 19, 2010||No||No|November 25, 2015|https://clinicaltrials.gov/show/NCT01073267||126072|
NCT01076296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU_Vscan_02|A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System|A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System||GE Healthcare|No|Completed|February 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|In-patient and outpatient population of OHSU Division of Cardiovascular Medicine|February 2016|February 8, 2016|February 24, 2010|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01076296||125839|
NCT01076309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH4|Corneal Endothelium Cell Loss After Cataract Extraction in Patients Taking Tamsulosin|Corneal Endothelium Cell Loss After Cataract Extraction in Patients Taking Systemic Sympathetic Alfa-1-a-antagonist Medication (Tamsulosin)||Frederiksberg University Hospital|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Male|N/A|N/A|No|Non-Probability Sample|Patients referred for catarct surgery.|January 2010|July 19, 2011|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076309||125838|
NCT01076647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3718|Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes|A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)|BEGIN™|Novo Nordisk A/S|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|467|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|February 25, 2010|Yes|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT01076647||125812|
NCT01076387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-016|Randomized Trial Comparing Robotic and Open Radical Cystectomy|A Prospective, Randomized Trial Comparing Robotic and Open Radical Cystectomy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2010|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|19 Years|N/A|No|||March 2016|March 1, 2016|February 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01076387||125832|
NCT01076660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reynolds03073103|Left Ventricular Structural Predictors of Sudden Cardiac Death|Left Ventricular Structural Predictors of Sudden Cardiac Death [Substudy of: Functional Energetics and Imaging for Phenotypic Characterization of Patients at Risk for Sudden Cardiac Death, See Also NCT000181233]||Johns Hopkins University|No|Recruiting|October 2003|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|21 Years|80 Years|No|Non-Probability Sample|Patients with LV ejection fraction (LVEF) ≤35% of ischemic or nonischemic etiology (as        measured by a clinical echocardiogram, ventriculogram, or radionuclide study) referred        clinically for ICD insertion for primary prevention purposes (i.e. no prior history of        sustained ventricular arrhythmias)|February 2016|February 22, 2016|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076660||125811|
NCT01073501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111.CT.IL|Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus|Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus||Shaare Zedek Medical Center||Not yet recruiting|April 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2010|February 22, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01073501||126054|
NCT01076621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD-3795|Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months|A 12 Month Non-interventional (Observational), International, Multi-centre, Prospective Study to Evaluate the Bleeding Pattern of Ultra-low Dose Continuous Combined Hormone Replacement Therapy Containing 0.5 mg Estradiol and 0.1 mg Norethisterone Acetate (Eviana®)||Novo Nordisk A/S|No|Completed|May 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|176|||Female|N/A|N/A|No|Non-Probability Sample|The postmenopausal women (who are ammenorrheic) are to be offered participation in the        study at the discretion of the treating physician following the decision to prescribe 0.5        mg estradiol and 0.1 mg norethisterone acetate for the treatment of their menopausal        symptoms.|October 2014|October 24, 2014|February 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01076621||125814|
NCT01076634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3678|Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1250 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||June 2014|June 12, 2014|February 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01076634||125813|
NCT01072929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3071|A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder||Teva Pharmaceutical Industries|Yes|Completed|January 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|433|||Both|18 Years|65 Years|No|||January 2015|January 15, 2015|February 19, 2010|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01072929||126097|
NCT01073176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH085898|Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies|Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies|TEAMS|Queens College, The City University of New York|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|5 Years|No|||September 2011|September 13, 2011|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073176||126078|
NCT01073189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR-FTA|Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury|Effect of Combination Intra-Renal Infusion of Fenoldopam Mesylate and High Dose Diuretics on Peak Serum Creatinine and Incidence of Renal Replacement Therapy in Patients With Early Acute Kidney Injury|IR-FTA|Southeast Renal Research Institute|No|Withdrawn|April 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2009|July 20, 2011|February 22, 2010|Yes|Yes|withdrew due to funding|No||https://clinicaltrials.gov/show/NCT01073189||126077|
NCT01073787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008034|Intravenous Fluid for Pediatric Migraine in the Emergency Department|Single-blind, Placebo-challenge Study of Intravenous Fluid Hydration in the Management of Pediatric Migraine in the Emergency Department|EDMigraine3|University of Alberta|No|Completed|July 2010|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|5 Years|17 Years|No|||August 2013|August 28, 2013|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073787||126032|
NCT01073449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAVBS1|Actions Elicited by In-hospital Follow-up of Cardiac Devices|Action Elicited By Scheduled In-Hospital Follow-Up of Cardiac Devices|ATHENS|Cliniche Humanitas Gavazzeni|No|Completed|February 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3362|||Both|N/A|N/A|No|Probability Sample|All patients who will undergo an in-hospital follow-up of a cardiac device|January 2011|February 2, 2011|February 22, 2010||No||No|January 10, 2011|https://clinicaltrials.gov/show/NCT01073449||126058|
NCT01073761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 034|Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study|Pharmacokinetics of Darunavir/Ritonavir Once Daily and Atazanavir/Ritonavir Once Daily Over 72 Hours Following Drug Intake Cessation||St Stephens Aids Trust|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073761||126034|
NCT01074541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-08-0461|The Vitamin D Dose-Response Relationship|Vitamin D Production Depends on Ultraviolet-B Dose But Not on UV-intensity. A Randomized Controlled Trial||Bispebjerg Hospital|No|Completed|January 2008|February 2010|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074541||125974|
NCT01074580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22209|Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease|High Frequency Ultrasound and Contrast Enhanced Ultrasound of Patients Treated for Deterioration of Crohn's Disease||Haukeland University Hospital|No|Terminated|November 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Mucosal biopsies from the colon and terminal ileum.|Both|18 Years|N/A|No|Probability Sample|Patients treated for deterioration of Crohn's disease either in the out patient clinic or        the medical ward of Haukeland University Hospital.|January 2016|January 25, 2016|February 23, 2010||No|Did not get enough patients|No||https://clinicaltrials.gov/show/NCT01074580||125971|
NCT01074866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVA_NIV|Neurally Adjusted Ventilatory Assist for Non Invasive Ventilation and Patient-ventilator Interaction|The Effects of Neurally Adjusted Ventilatory Assist (NAVA) on Improving Patient-ventilator Interaction in Patients Undergoing Ventilation for Acute Respiratory Failure||University Hospital, Geneva|No|Completed|July 2010|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Both|18 Years|90 Years|No|||January 2010|September 20, 2012|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074866||125949|
NCT01075152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIDS-ES ID 10795|Cryptococcal Optimal ART Timing Trial|Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis|COAT|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2010|March 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|14 Years|N/A|No|||August 2015|August 13, 2015|February 23, 2010||No||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01075152||125927|The differences in mortality in the two arms were of sufficient magnitude that trial enrollment was stopped early by the Data and Safety Monitoring Board. Historically, trials stopped early routinely over-estimate the magnitude of benefit or harm.
NCT01075386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo01|The Effects of the Endocrine System on Endometrial Cancer|Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer|Ghrelin|Queensland Centre for Gynaecological Cancer|No|Active, not recruiting|October 2009|December 2014|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|80|Samples Without DNA|Endometrial tissue|Female|18 Years|N/A|No|Non-Probability Sample|Patients with endometrial cancer and patients who are having a hysterectomy for        non-cancerous conditions such as fibroids, chronic pelvis pain or abnormal uterine        bleeding are eligible for the study|September 2014|September 7, 2014|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075386||125909|
NCT01075399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX4-200|Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors|A Pilot, Phase II , Open Label, Nonrandomized, Multi- Center Study of [F 18]HX4 Positron Emission Tomography (PET) to Detect Hypoxia in Tumors|HX4-200|Siemens Molecular Imaging|No|Completed|February 2010|February 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|February 23, 2010|No|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01075399||125908|
NCT01075672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002479|Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals|Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting||Massachusetts General Hospital|No|Recruiting|January 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01075672||125887|
NCT01075685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evalcoometre|Evaluation of an Internet-based Intervention for Hazardous Drinkers|||Institut national de prevention et d'education pour la sante|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|1157|||Both|18 Years|N/A|No|||January 2010|October 15, 2010|January 6, 2010||No||No|August 19, 2010|https://clinicaltrials.gov/show/NCT01075685||125886|High rate of loss to follow-up lead to small number of subjects analyzed. Some participants were lost to follow-up even before completing baseline measures.
NCT01075893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McCallum-001|Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer|Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer||Newcastle University|No|Active, not recruiting|February 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|Samples Without DNA|Rectal pinch biopsies - x 9 (10 cm from anal verge)|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients referred for lower gastrointestinal (GI) endoscopy at a participating centre        will be considered for inclusion. Patients with a previous adenomatous polyp resection        under surveillance will be considered for inclusion to the polyp group. Patients with        ulcerative colitis under surveillance will be considered for inclusion to the ulcerative        colitis group.|October 2011|October 25, 2011|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075893||125870|
NCT01076153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08-331|Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR|A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR||Abbott|No|Completed|December 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|760|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients in Thailand|June 2011|July 1, 2011|February 24, 2010||No||No|April 22, 2011|https://clinicaltrials.gov/show/NCT01076153||125850|
NCT01076413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09080228|Comparison of Two Exercise Interventions to Improve Gait in Older Persons|Comparison of Two Exercise Interventions to Improve Gait in Older Persons: The PRIME (Program to Improve Mobility in The Elderly) Study|PRIME|University of Pittsburgh|Yes|Completed|March 2010|March 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076413||125830|
NCT01076829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-11-023|Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes|Inhibition of Absorption of Cytoxic Lipid Peroxidation Products and Abnormalities of Postprandial Endothelial Function by Spice Polyphenols Fed Together With High Fat Meat Patty in Men With Type 2 Diabetes Mellitus or Impaired Glucose Tolerance||University of California, Los Angeles|No|Completed|July 2009|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|35 Years|70 Years|Accepts Healthy Volunteers|||December 2013|June 9, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076829||125798|
NCT01076400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1775-008|A Study of MK1775 in Combination With Topotecan/Cisplatin in Patients With Cervical Cancer (1775-008)|A Two Part, Phase I-IIa Study Evaluating MK1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer||Merck Sharp & Dohme Corp.|No|Terminated|May 2010|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|7|||Female|18 Years|N/A|No|||February 2015|February 3, 2015|February 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01076400||125831|
NCT01072955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV1109BOV_EUR|Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Recruiting|April 2010|October 2011|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|104|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072955||126095|
NCT01073215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-005084|Primary Care Research Network for the Treatment of Adolescent Obesity|Primary Care Research Network for the Treatment of Adolescent Obesity|TEENS|Children's Hospital of Philadelphia|No|Completed|July 2006|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|12 Years|16 Years|No|||February 2012|February 17, 2012|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01073215||126075|
NCT01073228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-010|Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease||FORUM Pharmaceuticals Inc|No|Completed|April 2010|February 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|409|||Both|50 Years|85 Years|No|||February 2013|March 28, 2014|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01073228||126074|
NCT01073163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/3070|Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)|A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)||Teva Pharmaceutical Industries||Completed|February 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|February 19, 2010|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01073163||126079|
NCT01073475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP MNH|Maternal Newborn Health Registry|Global Network for Women's and Children's Health Research Maternal Newborn Health Registry|MNH|NICHD Global Network for Women's and Children's Health|Yes|Recruiting|May 2008|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women meeting participant-level criteria and the infant(s) from their        pregnancy.|October 2015|October 28, 2015|February 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01073475||126056|
NCT01073488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN EmONC|Emergency Obstetric and Neonatal Care: The EmONC Trial|Evaluation of an Emergency Obstetric and Neonatal Care (EmONC) Intervention Package to Reduce Adverse Pregnancy Outcomes in Low Resource Settings (The EmONC Trial)|EmONC|NICHD Global Network for Women's and Children's Health|Yes|Completed|December 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|267181|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 15, 2013|February 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01073488||126055|
NCT01074021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CT-001|Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer|A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer||Biotech Pharmaceutical Co., Ltd.|Yes|Active, not recruiting|October 2009|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|70 Years|No|||August 2015|October 28, 2015|February 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01074021||126014|
NCT01074320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03918-09|Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors|Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors|AIMS|HealthPartners Institute|No|Completed|February 2010|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Post-menopausal breast cancer patients receiving aromatase inhibitors|August 2015|December 15, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074320||125991|
NCT01074879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071323007|Protein Ingestion and Resistance Exercise in Elderly|Effects of Protein Quantity and Quality in Combination With Resistance Exercise on Muscle Mass and -Strength in Icelandic Elderly.|IceProQualita|University of Iceland|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|220|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074879||125948|
NCT01075698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H21-1|A Trial of Telmisartan Prevention of Cardiovascular Disease|A Trial of Telmisartan Prevention of Cardiovascular Disease|ATTEMPT-CVD|Kumamoto University|Yes|Active, not recruiting|July 2009|March 2017|Anticipated|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|40 Years|79 Years|No|||March 2015|March 30, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075698||125885|
NCT01076179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-021|Kaletra in Combination With Antiretroviral Agents|KALETRA in Combination With New Substances|PROTEKT|AbbVie|No|Completed|September 2008|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|531|||Both|18 Years|99 Years|No|Non-Probability Sample|Community sample: Human Immunodeficiency Virus-positive patients|February 2016|February 4, 2016|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076179||125848|
NCT01076439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-270-0006|An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo|A Pilot Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo Nasal Spray in Reducing Nasal Allergic Symptoms Following Ragweed Exposure in the Allergen BioCube (ABC)||ORA, Inc.||Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076439||125828|
NCT01076712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCKESOP0016a|Effectiveness of Physiotherapy Interventions for Patients With Parkinson's Disease|The Effectiveness of Physiotherapy Interventions in Patients With Parkinson's Disease, a Randomized Controlled Trial||Queen Elizabeth Hospital, Hong Kong|No|Recruiting|March 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|35 Years|75 Years|No|||March 2010|March 9, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076712||125807|
NCT01076166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-813|Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid® Granules for Oral Suspension.|A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid Granules for Oral Suspension.||Abbott|No|Completed|April 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|337|||Both|6 Months|12 Years|No|Non-Probability Sample|Out-patients in Thailand|April 2011|April 7, 2011|February 24, 2010||No||No|January 7, 2011|https://clinicaltrials.gov/show/NCT01076166||125849|
NCT01076595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15098|Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period|Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program|SEPLUS|Bayer|No|Completed|May 2010|July 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Outpatients|July 2015|July 2, 2015|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076595||125816|
NCT01073735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSURE|Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience|Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience||St. Jude Children's Research Hospital|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1178|||Both|25 Years|N/A|No|Probability Sample|The study sample will be recruited from long-term childhood cancer survivors who are        currently participating in the CCSS and whose pediatric malignancy was not treated at St.        Jude Children's Research Hospital|February 2012|February 8, 2012|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073735||126036|
NCT01074242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-037|ROTATEQ Reexamination Study (V260-037)|Re-examination Study for General Vaccine Use to Assess the Safety Profile of ROTATEQ in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|September 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3798|||Both|6 Weeks|32 Weeks|Accepts Healthy Volunteers|Probability Sample|6-32 week old Korean Infants who are vaccinated with Rotateq in usual practice|April 2015|April 1, 2015|February 22, 2010|No|Yes||No|February 11, 2014|https://clinicaltrials.gov/show/NCT01074242||125997|
NCT01073202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPH05B41|Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation|||Shanghai Jiao Tong University School of Medicine||Completed|May 2005|January 2009|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||December 2009|December 29, 2010|February 22, 2010||||No||https://clinicaltrials.gov/show/NCT01073202||126076|
NCT01072968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-09 / BF2.649|BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.|Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy|HAROSA2|Bioprojet|Yes|Completed|October 2011|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|268|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072968||126094|
NCT01072981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG0405|Immunotherapy Study for Surgically Resected Pancreatic Cancer|A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer||NewLink Genetics Corporation|Yes|Active, not recruiting|April 2010|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|722|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|February 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072981||126093|
NCT01074359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL01|Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation|A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 Day, Two-arm, Parallel Group Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitochondrial Function||Penwest Pharmaceuticals Co.|No|Terminated|February 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||April 2011|April 21, 2011|February 22, 2010||No|Terminated for Commercial Reasons. There were no safety issues involved in the decision to    terminate the study.|No||https://clinicaltrials.gov/show/NCT01074359||125988|
NCT01074645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hitendra garg|Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure|Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial|ACLF|Govind Ballabh Pant Hospital|Yes|Completed|November 2007|October 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|27|||Both|2 Years|75 Years|No|||October 2009|February 23, 2010|February 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074645||125966|
NCT01072942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14019|To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)|Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD; GOLD II-III), Following Multiple Inhalation of Ciprofloxacin PulmoSphere Inhalation Powder||Bayer|No|Completed|January 2010|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|80 Years|No|||April 2014|April 1, 2014|January 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072942||126096|
NCT01073800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASTVALUS|Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill|Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill|VASTVALUS|University of Alberta|Yes|Completed|April 2009|September 2011|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|70 Years|No|||December 2011|December 15, 2011|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01073800||126031|
NCT01073813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minocycline in Optic Neuritis|Neuroprotection and Repair in Optic Neuritis|Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON)|Mino in ON|University of Calgary|No|Terminated|February 2010|January 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|60 Years|No|||January 2013|January 21, 2013|February 22, 2010||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01073813||126030|
NCT01073826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donath-1|Role of Interleukin-6 in Exercise|A Lifestyle Intervention Study Investigating the Role of Interleukin-6 in the Beneficial Effect of Exercise on Beta-cell Function in Obese People and Patients With Type 2 Diabetes|Exil-6|University of Zurich|Yes|Recruiting|February 2010|March 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|56|||Both|18 Years|75 Years|No|||December 2014|December 16, 2014|October 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01073826||126029|
NCT01074060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08186|Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma|A Phase I/Pilot Study of Intravenous PLERIXAFOR Following Cyclophosphamide Mobilization in Patients With Multiple Myeloma||City of Hope Medical Center|Yes|Completed|April 2010|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|70 Years|No|||February 2013|February 13, 2013|February 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01074060||126011|
NCT01074034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G040067|REASSURE AV Registry|Clinical Research Evaluation of the ASSURE Device Atrial and Ventricular Tachyarrhythmia Therapies Registry|REASSURE Reg|Boston Scientific Corporation|No|Completed|April 2006|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Both|18 Years|N/A|No|||September 2011|September 28, 2011|February 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074034||126013|
NCT01074047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-AML-001|Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)|A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia||Celgene|Yes|Active, not recruiting|June 2010|February 2016|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|488|||Both|65 Years|N/A|No|||November 2015|November 4, 2015|February 16, 2010|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01074047||126012|
NCT01074593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTBER0609|Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects|Clinical Study of Pharmacokinetics and Pharmacodynamics of the Drug Interferon Beta-1a Produced By Laboratorio Quimico Farmaceutico Bergamo Compared To Interferon Beta-1a (Rebif - Merck Serono) In Healthy Subjects||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|January 2011|July 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|November 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01074593||125970|
NCT01075412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906786|FLT PET Imaging for Cervical Cancer|`F-18 Fluorothymidine ([18F]FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Cervical Cancer||University of Iowa|Yes|Active, not recruiting|September 2009|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|February 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075412||125907|
NCT01076192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-067|Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)|Post-authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA®) on Moderate-severe Psoriasis Under Conditions of Routine Clinical Practice in Spain.|PROMISE|AbbVie||Completed|February 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|547|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with moderate-to-severe chronic plaque psoriasis|December 2015|December 1, 2015|February 24, 2010||No||No|September 25, 2015|https://clinicaltrials.gov/show/NCT01076192||125847|
NCT01076452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|468 Phase II|Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial|CSP #468 Phase II - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease, Phase II||VA Office of Research and Development|Yes|Completed|April 2002|April 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|299|||Both|22 Years|N/A|No|||June 2014|June 27, 2014|February 24, 2010|Yes|Yes||No|September 11, 2013|https://clinicaltrials.gov/show/NCT01076452||125827|We observed differences between STN and GPi DBS groups on several secondary measures but these findings should be interpreted cautiously. We did not adjust for repeated significance tests and the differences may have limited clinical significance.
NCT01076725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUBH|Rotation Technique for the Insertion of the ProSeal Laryngeal Mask Airway in Pediatric Patients|Insertion of the ProSeal Laryngeal Mask Airway is More Successful With the 90 Degree Rotation Technique in Pediatric Patients: a Randomized Controlled Trial|PLMA|Seoul National University Bundang Hospital|Yes|Completed|May 2009|December 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|63|||Both|3 Years|9 Years|No|||April 2009|February 25, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076725||125806|
NCT01076933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 153 02|Transcranial Magnetic Stimulation for Borderline Personality Disorder|Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Borderline Personality Disorder (BPD)|SiMaT-B|University Hospital, Toulouse|No|Completed|January 2010|April 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|20 Years|45 Years|No|||June 2012|June 25, 2012|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01076933||125790|
NCT01076946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pathophysiology TLVBS|Insights in the Pathophysiology of Transient Left Ventricular Ballooning Syndrome (TLVBS)|Insights in the Pathophysiology of Transient Left Ventricular Ballooning Syndrome (TLVBS)||University Hospital, Gasthuisberg|No|Not yet recruiting|March 2010|December 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|plasma|Both|N/A|N/A|No|Probability Sample|patients that were or will be admitted with TLVBS|December 2009|February 25, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076946||125789|
NCT01076920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505008|Mesenchymal Stem Cells and Myocardial Ischemia|Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy|MESAMI|University Hospital, Toulouse|Yes|Completed|October 2009|September 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01076920||125791|
NCT01072071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDL2009/003|The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Critically Ill Patients|The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Mechanically Ventilated Critically Ill Patients With Secondary Intra-abdominal Hypertension||Ziekenhuis Netwerk Antwerpen (ZNA)|No|Recruiting|February 2010|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2010|February 19, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072071||126163|
NCT01072357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-062|Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival|Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival||Massachusetts Eye and Ear Infirmary|Yes|Completed|December 2009|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2015|October 1, 2015|February 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072357||126141|
NCT01076907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL0055|Techniques to Enhance Patient Comfort in Sedation-risk Free Colonoscopy|Can Simple and Inexpensive Techniques Enhance Patient Comfort in Sedation-risk Free Screening and Surveillance Colonoscopy?||VA Greater Los Angeles Healthcare System|No|Terminated|December 2007|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|85|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|February 25, 2010||No|Necessary equipment to perform the study arms was removed by the medical center    administration.|No||https://clinicaltrials.gov/show/NCT01076907||125792|
NCT01074086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD 001|Phase I Study in RAD 001 Patients With Relapse AML|Multicentric Study of GOELAMS Phase I Evaluation of RAD001 in Association With Aracytine and Daunorubicine in AML Treatment in Patients Less Than 65 Years in Relapse More Than One Year After First Complete Remission||French Innovative Leukemia Organisation|Yes|Completed|February 2008|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||December 2012|December 21, 2012|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074086||126009|
NCT01074099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Harvest 2009-1|Feasibility Study of BMAC Enhanced CABG|Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery||Harvest Technologies|No|Terminated|February 2011|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||August 2014|December 14, 2015|February 1, 2010|Yes|Yes|Pilot results in change to protocol, new study needed.|No|August 18, 2014|https://clinicaltrials.gov/show/NCT01074099||126008|The study was terminated early. Only 5 subjects were enrolled and they were followed for a year for safety data only. One efficacy data was collected.
NCT01074112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFR-US-01|Keller Prehospital Ultrasound Study|Keller Fire Rescue Study of Prehospital Ultrasound Use||Keller Fire Rescue|No|Not yet recruiting|March 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||10|Anticipated|30|||Both|N/A|N/A|No|Probability Sample|Residents and visitors of Keller,TX and the cities that Keller Fire Rescue provides mutual        aide services to|February 2010|February 23, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074112||126007|
NCT01073514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-IR-001|Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction|Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction|MBO—IR|Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|December 2009|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|bile,blood and urine specimen|Both|18 Years|70 Years|No|Probability Sample|Malignant obstructive jaundice (MBO)|February 2010|December 21, 2015|February 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01073514||126053|
NCT01073839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONK USZ 001-2008|Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.|Adjuvant Treatment of Resectable Cholangiocellular Carcinoma (CCC) With Cisplatin Plus Gemcitabine. A Prospective Single Center Phase Ib-II Study.||University of Zurich|Yes|Completed|August 2008|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|June 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01073839||126028|
NCT01074073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050247|Lithium Drug-Drug Interaction Study With Lurasidone HCl|A Phase 1, Open-Label, 2-Period, Sequential, Drug-Drug Interaction Study To Determine The Effect Of Lithium 600 Mg BID On The Safety And Pharmacokinetics Of Lurasidone 120 Mg QD In Patients With Schizophrenia Or Schizoaffective Disorder||Sunovion|Yes|Completed|August 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|65 Years|No|||September 2011|September 6, 2011|February 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074073||126010|
NCT01074346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701068-511|Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis|A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif®) Therapy for Korean Patients With Multiple Sclerosis||Merck KGaA|No|Completed|August 2008|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|N/A|N/A|No|Probability Sample|Subjects with MS undergoing treatment with Rebif in Korea.|February 2014|February 16, 2014|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074346||125989|
NCT01074333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-507|An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment|Prospective, Multicenter, Observational Study on Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer||Merck KGaA|No|Terminated|September 2008|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|146|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with EGFR-expressing, KRAS wild-type mCRC undergoing treatment with Erbitux in        Korea.|June 2014|June 16, 2014|February 22, 2010||No|This study was terminated due to low recruitment|No||https://clinicaltrials.gov/show/NCT01074333||125990|
NCT01074606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-0902|Visual Function After Implantation of AcrySof® Toric Lens|||Alcon Research|No|Terminated|January 2010|||March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|20 Years|N/A|No|||August 2011|September 18, 2012|February 23, 2010|No|Yes|The study was terminated based on a business decision.|No||https://clinicaltrials.gov/show/NCT01074606||125969|
NCT01074892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK nr 25/2004|A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia|A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia|Mirena|University Hospital of North Norway|No|Active, not recruiting|May 2005|December 2014|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|170|||Female|30 Years|70 Years|No|||May 2012|May 11, 2012|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074892||125947|
NCT01075165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-09-041|Efficacy of Spray Silicone in Alteration of Burn Scar|The Efficacy of Spray Silicone in the Alteration of Physical Burn Scar Characteristics: A Double Blinded Randomized Controlled Trial||United States Army Institute of Surgical Research|No|Withdrawn|March 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||February 2015|February 2, 2015|February 23, 2010||No|IRB closed study due to no enrollment over 4 yrs|No||https://clinicaltrials.gov/show/NCT01075165||125926|
NCT01076205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-973|Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis|Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice (AGIL)|AGIL|AbbVie|No|Recruiting|September 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4500|||Both|18 Years|99 Years|No|Non-Probability Sample|Community sample: Patients with rheumatoid arthritis|January 2016|January 27, 2016|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076205||125846|
NCT01076465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI081280|Efficacy of a Disease Management Program in Very Old Patients With Heart Failure|Efficacy of a Disease Management Program in Very Old Patients With Heart Failure and Significant Comorbidity: a Multicenter Randomized Trial||Hospital de Meixoeiro|No|Recruiting|October 2009|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|700|||Both|75 Years|N/A|No|||June 2011|June 15, 2011|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076465||125826|
NCT01076738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIREG_L_04222|Screening DIVA - Diffuse Vascular Disease|The Value of Routine Screening for Diffuse Vascular Disease in the Canadian Post-Acute Coronary Syndrome/Ischemic Stroke/Transient Ischemic Attack General Practice Population With Previously Undocumented Peripheral Arterial Disease||Sanofi||Completed|April 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2233|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with documented ACS or/and IS / TIA|September 2010|September 10, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076738||125805|
NCT01076959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-559|Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis|Humira 40 mg/0.8 mL for Subcutaneous Injection - Drug Use Investigation (All Patient Investigation) for Rheumatoid Arthritis||Abbott||Completed|June 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7972|||Both|16 Years|N/A|No|Non-Probability Sample|All patients prescribed and treated with Humira included in this survey.|August 2012|August 27, 2012|February 25, 2010||No||No|June 29, 2012|https://clinicaltrials.gov/show/NCT01076959||125788|
NCT01073007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARS07|Stroke Treatment With Acute Reperfusion and Simvastatin|Multicentric, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy of Simvastatin in the Acute Phase of Ischemic Stroke||Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|April 2009|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||June 2014|June 18, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01073007||126091|
NCT01071200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP25289|Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle|A Phase III, Multicentric, Randomized, Open, Comparative Study to Evaluate if the Addition of Recombinant Human Luteinising Hormone [r-hLH (Luveris®)] to Follicle Stimulating Hormone (FSH) From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing Assisted Reproduction Technology (ART), Who Required High FSH Dose in a Previous Cycle|Luveris in ART|Merck KGaA||Terminated|March 2005|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Female|18 Years|40 Years|No|||December 2013|December 2, 2013|February 18, 2010|No|Yes||No|May 14, 2012|https://clinicaltrials.gov/show/NCT01071200||126228|
NCT01071226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOP 07/216|Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device|CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With The CliniMACS Device for T and B Cell Depletion||Medical College of Wisconsin|Yes|Recruiting|May 2008|May 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|22 Years|No|||February 2016|February 11, 2016|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01071226||126227|
NCT01071473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARHAB|Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy|Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy||St. Jude Children's Research Hospital|No|Completed|February 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01071473||126209|
NCT01073852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pending|Hydroxychloroquine Efficacy in Chronic Urticaria|Hydroxychloroquine Efficacy in Chronic Urticaria||Vanderbilt University|Yes|Withdrawn|June 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||January 2013|January 21, 2013|February 22, 2010|Yes|Yes|withdrawn, not funded|No||https://clinicaltrials.gov/show/NCT01073852||126027|
NCT01073865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8666C00001|Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer|An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer.||AstraZeneca|No|Active, not recruiting|February 2010|December 2016|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Female|20 Years|130 Years|No|||February 2016|February 3, 2016|February 22, 2010|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01073865||126026|
NCT01074385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 09CC3|Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making|Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making||Northwestern University|No|Completed|April 2010|October 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|24|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074385||125986|
NCT01074905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU0908|Study on the Treatment of Vivax Malaria|A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border|VHX|University of Oxford|Yes|Completed|May 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|655|||Both|6 Months|N/A|No|||August 2013|August 27, 2013|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074905||125946|
NCT01075178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-681|Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease|Palivizumab (Synagis®) Post-marketing Surveillance Cohort Study in Children < 24 Months of Age With Hemodynamically Significant Congenital Heart Disease||Abbott|No|Completed|July 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2036|||Both|N/A|24 Months|No|Non-Probability Sample|Children less than 24 months of age with hemodynamically significant congenital heart        disease|March 2011|March 18, 2011|February 23, 2010||No||No|January 28, 2011|https://clinicaltrials.gov/show/NCT01075178||125925|Only serious adverse events of infection and arrhythmia as well as deaths were collected in this study. The criterion for non-inferiority was not met for death, most likely because the reported mortality rates were lower than expected in both groups.
NCT01075425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12517|Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome|Phase I Study of Belinostat (PXD-101) and Velcade (Bortezomib) in Relapsed or Refractory Acute Leukemia/ Myelodysplastic Syndrome||Virginia Commonwealth University|Yes|Active, not recruiting|May 2010|June 2016|Anticipated|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|February 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01075425||125906|
NCT01075438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7444-GB-CTIL|Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients|Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar®, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax® Aventis Pasteur MSD) in Ataxia-telangiectasia Patients||Sheba Medical Center|No|Not yet recruiting|March 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Serum for specific anti-pneumococcal antibody levels and Immunoglobulin levels.|Both|2 Years|25 Years|No|Non-Probability Sample|Ataxia Telangiectasia patients, not cuurntly on replacement Immunoglobulin G therapy|March 2010|March 15, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075438||125905|
NCT01074619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-087|Study on Cognitive Disorders of Multiple Sclerosis|Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis||University Hospital, Caen||Completed|September 2005|November 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|60 Years|No|||August 2012|August 31, 2012|September 12, 2005||No||No||https://clinicaltrials.gov/show/NCT01074619||125968|
NCT01074632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050267|Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl|A Phase 1, Open-Label Study to Determine the Effect of Calories and Fat Content on the Pharmacokinetics of Repeated Dose Lurasidone 120 mg in Subjects With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.||Sunovion||Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|N/A|||Actual|26|||Both|18 Years|65 Years|No|||September 2011|September 6, 2011|February 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074632||125967|
NCT01075724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDBH3|Comparison of a New Patient Warming System Using a Polymer Conductive Warming Under-body and Upper-body Blanket With Forced Air Warming|Comparison of a New Patient Warming System Using a Polymer Conductive Warming Under-body and Upper-body Blanket With Forced Air Warming During Surgery||Medical University of Vienna|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||January 2015|January 14, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01075724||125883|
NCT01075971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04451|Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)|Evaluation of Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy||Indivior Inc.|No|Completed|September 2005|November 2005|Actual|November 2005|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||April 2010|April 14, 2011|February 24, 2010|Yes|Yes||No|March 26, 2010|https://clinicaltrials.gov/show/NCT01075971||125864|
NCT01075906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-006-09-1001|Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients|An Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMF||Mutual Pharmaceutical Company, Inc.|Yes|Completed|August 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|75|||Both|2 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|February 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01075906||125869|
NCT01075919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16N1|Cognitive and Mood Effects of Docosahexaenoic Acid (DHA)-Rich and Eicosapentaenoic Acid (EPA)-Rich Fish Oil in Healthy Young Adults|Cognitive and Mood Effects of DHA-rich and EPA-rich Fish Oil in Healthy Young Adults||Northumbria University|No|Completed|December 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|159|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2010|February 24, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075919||125868|
NCT01076751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIREG_C_05073|Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients|Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen|PORTREAT|Sanofi||Terminated|February 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Male|N/A|N/A|No|Non-Probability Sample|Patients with metastatic castrate-resistant prostate cancer|February 2011|February 11, 2011|February 25, 2010||No|delay in recruitment|No||https://clinicaltrials.gov/show/NCT01076751||125804|
NCT01076972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMOS-JAP-00-001|Drug Use Investigation of Kaletra|Drug Use Investigation of Kaletra||Abbott||Completed|December 2000|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1184|||Both|N/A|N/A|No|Non-Probability Sample|Hospital|January 2012|January 31, 2012|February 25, 2010||No||No|December 9, 2011|https://clinicaltrials.gov/show/NCT01076972||125787|
NCT01076985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMOS-JAP-00-002|Special Investigation of Kaletra in Pregnant Women|Special Investigation of Kaletra in Pregnant Women||Abbott||Completed|December 2000|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Female|N/A|N/A|No|Non-Probability Sample|Hospital|December 2011|December 9, 2011|February 25, 2010||No||No|December 9, 2011|https://clinicaltrials.gov/show/NCT01076985||125786|
NCT01076998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-059|Acute Comfort and Blur Profile of a Lubricant Eye Drop Versus a Marketed Eye Ointment|||Alcon Research|No|Completed|January 2010|||January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01076998||125785|
NCT01073020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-001610|Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes|Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D)|SLIMM-T2D|Joslin Diabetes Center|Yes|Active, not recruiting|January 2010|April 2017|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|21 Years|65 Years|No|||March 2015|March 30, 2015|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01073020||126090|
NCT01073033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.10 INF|Oral Supplement for Pregnant and Lactating Mothers|Oral Supplement for Pregnant and Lactating Mothers to Promote Infant Immune Maturation and Protection Against Early Life Infections||Nestlé|No|Completed|April 2010|August 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|234|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 25, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01073033||126089|
NCT01073332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA_IRB_03-08-087-01|The Effects of a Dietary Supplement on Exercise Performance in Healthy Older Adults"|Arginine and Antioxidant Supplement on Performance in Elderly Male Cyclists: A Randomized Controlled Trial||University of California, Los Angeles|No|Completed|October 2004|February 2005|Actual|February 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2010|May 6, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073332||126067|
NCT01073592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORESEE HOME-POST-03|Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)|Comparison Between Home Macular Perimeter (FORESEE HOME) and OCT Visual Field Defects in Patients With CNV||Notal Vision Ltd|No|Completed|August 2009|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|50 Years|N/A|No|Non-Probability Sample|Subjects suspected to have CNV secondary to AMD in at least one eye|May 2013|May 16, 2013|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073592||126047|
NCT01073605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93-8122-001|Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation|A Two Years Multicentre Study of Genotropin Treatment of Short Prepubertal Children With Intra-Uterine Growth Retardation||Pfizer|No|Completed|July 1993|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|208|||Both|3 Years|12 Years|No|||February 2010|November 8, 2010|February 22, 2010|Yes|Yes||No|May 6, 2010|https://clinicaltrials.gov/show/NCT01073605||126046|
NCT01071239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA 08/89|Hematopoietic Stem Cell Transplant for Fanconi Anemia|A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|FA|Medical College of Wisconsin|Yes|Active, not recruiting|April 2009|May 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||September 2015|September 29, 2015|May 20, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01071239||126226|
NCT01071252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2220|A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis||Novartis||Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|125|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|February 18, 2010|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01071252||126225|
NCT01071499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03286|Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population Presenting for Elective Surgery|Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population (2 - 6 Years of Age) Presenting for Elective Surgery||University of British Columbia|No|Completed|March 2010|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|43|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01071499||126207|
NCT01072149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110946|A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo|A Three-way Incomplete Block Crossover Study to Investigate the 24-hour Pulmonary Function of Three Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|January 2010|December 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|54|||Both|40 Years|N/A|No|||September 2013|November 7, 2013|February 12, 2010|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01072149||126157|
NCT01073553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14784|Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules|Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef (Cephalexin 500 mg Capsules) From Bayer and Keflex (Cephalexin 250 mg Capsules) From Eli Lilly po in Healthy Subjects Using Equivalent Concentrations||Bayer|No|Completed|October 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073553||126050|
NCT01073878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMT-4-001|Athena Pelvic Muscle Trainer - DUETS Trial|Athena PMT - Device to Treat Urinary Incontinence - Effectiveness, Tolerability and Satisfaction "Athena D.U.E.T.S. Trial"|DUETS|Athena Feminine Technologies, Inc.|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|462|||Female|30 Years|70 Years|No|||July 2011|July 13, 2011|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01073878||126025|
NCT01074125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-305|A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease|A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period||Keryx Biopharmaceuticals|Yes|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|February 17, 2010|Yes|Yes||No|October 4, 2014|https://clinicaltrials.gov/show/NCT01074125||126006|
NCT01074138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KXO1-002-09|A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy|A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy||Kinex Pharmaceuticals Inc|No|Completed|February 2010|October 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Male|18 Years|85 Years|No|||April 2013|April 29, 2013|February 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074138||126005|
NCT01074372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-0904|Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers|A Randomized, Double-Blind,Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneously Administered REGN727 in Healthy Volunteers||Regeneron Pharmaceuticals|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|January 24, 2015|February 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01074372||125987|
NCT01074658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advance|CoreValve Advance International Post Market Study|CoreValve Advance International Post Market Study: Evaluation of the Medtronic CoreValve System in a "Real-World" Patient Population.||Medtronic Cardiovascular|No|Active, not recruiting|March 2010|December 2016|Anticipated|November 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1015|||Both|18 Years|N/A|No|Non-Probability Sample|patients with severe aortic valve stenosis requiring treatment, who are selected to be        treated electively with the Medtronic CoreValve System|October 2015|October 19, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074658||125965|
NCT01074918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012007-080|Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients|Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients; Role of Natriuresis||University of Texas Southwestern Medical Center|Yes|Completed|September 2009|December 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|35|||Both|21 Years|95 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074918||125945|
NCT01075191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05-103|Kaletra: Therapy With Double Protease Inhibitors|PMOS: Kaletra Double Protease Inhibitors||AbbVie|No|Completed|January 2004|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample; Human Immunodeficiency Virus-infected participants|January 2013|January 14, 2013|February 23, 2010||No||No|September 28, 2012|https://clinicaltrials.gov/show/NCT01075191||125924|
NCT01075711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062215-500|Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)|Non-interventional Study for Determining the Improvement in the Activity Status / Life Quality of Patients With Rheumatoid Arthritis Being Treated With the Tempus Tablet|LODOTRA|Merck KGaA||Completed|April 2009|November 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2728|Samples With DNA|Blood sample|Both|18 Years|N/A|No|Probability Sample|Subjects with RA who are treated with Tempus tablet and subjects with re-diagnosed RA are        also included in the study, if the RA is treated with glucocorticoides.|February 2014|February 16, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075711||125884|
NCT01076218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC08-075|Navigator 1.5 Accuracy Study|In Clinic Evaluation of the FreeStyle Navigator® Continuous Glucose Monitoring System Version 1.5|FSNQS|Abbott Diabetes Care|No|Completed|April 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with type 1 diabetes requiring multiple daily insulin injections or using an        insulin pump|February 2010|February 24, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076218||125845|
NCT01076504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 199|A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer|A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer||SCRI Development Innovations, LLC|No|Completed|December 2009|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|December 8, 2009|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01076504||125823|
NCT01075932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16N2|Effects of Docosahexaenoic Acid (DHA)-Rich Fish Oil on Cerebral Haemodynamics|The Cognitive And Cerebral Hemodynamic Effects Of DHA-Rich Fish Oil: A Dose-Ranging Study||Northumbria University|No|Completed|April 2009|August 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|65|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2010|February 24, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075932||125867|
NCT01075945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP v AL01|Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan|||University of Khartoum|Yes|Recruiting|February 2010|April 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|5 Years|95 Years|No|||February 2010|February 24, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01075945||125866|
NCT01077024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0046|Smoking-Cessation and Stimulant Treatment (S-CAST)|Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes|S-CAST|University of Cincinnati|Yes|Completed|February 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|538|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|February 25, 2010||No||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01077024||125783|Stimulant use was relatively low throughout the study; this may have limited our ability to make inferences about the treatment.
NCT01073046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1053222|Gastric Decompression After Sub-total Gastrectomy|Naso-gastric/Jejunal Tube Placement After Sub-total Gastrectomy. A Multicenter Prospective Randomized Trial||Catholic University, Italy|No|Completed|January 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|276|||Both|N/A|N/A|No|Probability Sample|Patients will be included, using a randomization list provided to each center, in one of        two groups:          1. placement of a polyurethane nasogastric/jejunal tube, preferentially 12-14 Fr;          2. no feeding tube placement.|January 2010|August 1, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01073046||126088|
NCT01073345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-4|Portal Venous Hemodynamic Changes After Hepatectomy|Portal Venous Hemodynamic Changes After Hepatectomy and the Incidence of Postoperative Ascites||Heidelberg University|No|Enrolling by invitation|February 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|110|Samples Without DNA|Blood samples for liver function tests and cytokine levels|Both|18 Years|N/A|No|Probability Sample|Patients treated at a University Hospital|February 2010|February 22, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073345||126066|
NCT01073618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501067|Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV|Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV||Pfizer|No|Completed|March 2006|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|692|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are indicated for VFEND according to drug package insert.|May 2012|May 31, 2012|February 22, 2010|No|Yes||No|August 20, 2010|https://clinicaltrials.gov/show/NCT01073618||126045|
NCT01073631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501068|Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea|Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet||Pfizer|No|Completed|March 2006|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|543|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are indicated for voriconazole tablet according to the drug package insert.|May 2012|May 31, 2012|February 22, 2010|No|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT01073631||126044|
NCT01073644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181118|Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients|Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients||Pfizer|No|Terminated|February 2010|April 2010|Actual|April 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|75 Years|No|Probability Sample|Study population will be selected by primary care clinic.|July 2013|July 3, 2013|February 22, 2010||No|The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were    no safety concerns that led to the decision to terminate.|No||https://clinicaltrials.gov/show/NCT01073644||126043|
NCT01073943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02|Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep|A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety and Tolerability of "Day Before" PicoPrep™ for Oral Administration Versus HalfLytely® for Colon Cleansing in Preparation for Colonoscopy||Ferring Pharmaceuticals|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|603|||Both|18 Years|80 Years|No|||October 2012|October 23, 2012|February 22, 2010|Yes|Yes||No|August 10, 2012|https://clinicaltrials.gov/show/NCT01073943||126020|
NCT01073917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK375122009|Effects of Spontaneous Breathing Activity on Atelectasis Formation During General Anaesthesia|Effects of Spontaneous Breathing Activity on Atelectasis Formation During General Anaesthesia: A Randomized Clinical Trial|SBAFGA|Technische Universität Dresden|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|30|||Both|18 Years|65 Years|No|||October 2010|October 28, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073917||126022|
NCT01073930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01|Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep|A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety and Tolerability of "Split-Dose" PicoPrep™ for Oral Administration Versus HalfLytely® for Colon Cleansing in Preparation for Colonoscopy||Ferring Pharmaceuticals|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|608|||Both|18 Years|80 Years|No|||February 2013|February 11, 2013|February 22, 2010|Yes|Yes||No|August 10, 2012|https://clinicaltrials.gov/show/NCT01073930||126021|
NCT01074164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 20535|Acupressure in Pruritus for Atopic Dermatitis|Evaluating the Effectiveness of Acupressure in Relieving Pruritus Related to Atopic Dermatitis||Northwestern University|Yes|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|February 22, 2010||No||No|July 30, 2012|https://clinicaltrials.gov/show/NCT01074164||126003|
NCT01071486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-AdultPK/PGx1|Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation|Busulfan Pharmacokinetic Analysis and Glutathione S-transferase (GST)Genetic Polymorphism (A1,T1,M1,P1)in Adults Undergoing Hematological Bone Marrow Transplantation (HSCT).||Rambam Health Care Campus|No|Withdrawn|August 2009|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||November 2015|November 8, 2015|February 18, 2010||No|lack of participants|No||https://clinicaltrials.gov/show/NCT01071486||126208|
NCT01071824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303/08|Comparison of Limb Size of Transverse Coloplasty Pouch|Prospective Randomised Study for Comparison of the Size of Limb of Transverse Coloplasty Pouch After Low Rectal Resection With Total Mesorectal Excision||Kantonsspital Liestal|Yes|Recruiting|June 2009|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071824||126182|
NCT01072409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM5255|Clinical Evaluation of the Nucleus 5 Cochlear Implant (CI) System|Clinical Evaluation of the Nucleus 5 Cochlear Implant System||Cochlear|No|Completed|March 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 18, 2014|February 18, 2010|Yes|Yes||No|September 18, 2014|https://clinicaltrials.gov/show/NCT01072409||126137|
NCT01073891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14413|Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults|Single-dose, Open-label, Randomized, Non-blinded, Three-fold Crossover Study in Healthy Subjects to Compare the Bioavailability of Moxifloxacin (BAY12-8039) 400 mg Tablet and 400 mg Oral Suspension Under Fasting Conditions, and to Investigate the Effect of Food on the Bioavailability of 400 mg Suspension.||Bayer|No|Completed|May 2010|January 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|February 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01073891||126024|
NCT01075243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4000685|Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy|A Study to Compare the Analgesic Efficacy of Two Different Paracetamol Doses as Measured by Post-operative Pain Relief||GlaxoSmithKline|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|401|||Both|18 Years|45 Years|No|||April 2015|April 27, 2015|February 23, 2010||No||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01075243||125920|
NCT01074931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-398|Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China|Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China: A Multicenter Post-Marketing Observational Study||Abbott|No|Completed|April 2008|June 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital|July 2011|July 7, 2011|February 22, 2010||No||No|May 20, 2011|https://clinicaltrials.gov/show/NCT01074931||125944|The location of lipodystrophy was not summarized as there was not a place to record the information on the case report form. Too few participants withdrew from treatment to conduct planned analyses of duration to adverse event(s)/discontinuation.
NCT01074944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD03109|A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)|A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638||Sanofi|Yes|Completed|June 2010|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|February 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074944||125943|
NCT01075217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP 119|Isovue in Peripheral Digital Subtraction Angiography (DSA)|A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)||Bracco Diagnostics, Inc|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|174|||Both|18 Years|N/A|No|||April 2012|May 23, 2013|February 23, 2010|Yes|Yes||No|February 25, 2013|https://clinicaltrials.gov/show/NCT01075217||125922|
NCT01074671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-CS-2009-06|CG Future® Annuloplasty Ring/Band Clinical Trial|Colvin-Galloway Future® Annuloplasty Ring/Band Clinical Trial: Interventional Multi-center Prospective Clinical Outcome Study||Medtronic Cardiovascular|No|Completed|June 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|85 Years|No|||October 2015|October 28, 2015|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01074671||125964|
NCT01074684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIR-2009-01|Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer|Defining Predictive Factors of Clinical, Laboratory and Imaging Criteria Routinely Used in the Diagnosis of Thyroid Cancer: Observational, Prospective Multicentered Study|TIR-2009-01|National Cancer Institute, Naples|No|Active, not recruiting|January 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|959|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with palpable thyroid nodules with indication for surgery (positive        cytology, 2 consecutive inconclusive cytologies, or negative cytology with at least 2 of        the following: previous exposure to neck radiation, calcitonin greater than twice normal        values, positive pentagastrin test, or irregular margins or hypoechogenicity on        ultrasound.|November 2015|November 27, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074684||125963|
NCT01075204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-989|Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)|Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)|CLOSER|Abbott|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|335|||Both|18 Years|N/A|No|Non-Probability Sample|Assignment to clarithromycin therapy falls within current clinical practice and was not        decided in advance by this protocol. Study participants were selected from patients seen        at the primary care clinic, with a preliminary clinical diagnosis of an upper or lower        respiratory tract infection who were considered for antibiotic treatment and prescribed        clarithromycin.|February 2013|February 6, 2013|February 23, 2010||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT01075204||125923|
NCT01075477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22609|An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)|Naturalistic Prospective Non-interventional Study on Rheumatoid Arthritis (RA) Patients Treated With Rituximab According to Local Treatment Guidelines||Hoffmann-La Roche||Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|151|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis on or commencing treatment with rituximab [MabThera]|March 2016|March 1, 2016|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075477||125902|
NCT01075490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF7874|Neonatal Spinal Anesthesia: Effects of the Addition of Clonidine|Neonatal Spinal Anesthesia: Effects of the Addition of Clonidine||University Hospital, Montpellier|Yes|Recruiting|November 2006|December 2009|Anticipated|November 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|N/A|60 Weeks|No|||June 2009|February 24, 2010|May 12, 2009||No||No||https://clinicaltrials.gov/show/NCT01075490||125901|
NCT01075451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT104711|Antimicrobial Drug Use and Resistant Staphylococcus Aureus|Antimicrobial Drug Use and Resistant Staphylococcus Aureus in a Network of Academic Medical Center Hospitals.||Virginia Commonwealth University|Yes|Completed|January 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|Aggregate antibacterial drug use from adult inpatients at 60 UHC hospitals for 2006 - 2009|May 2013|May 17, 2013|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075451||125904|
NCT01075464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEF4797g|A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, a Human IgG1 Antibody, in Combination With Bevacizumab and Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Completed|February 2010|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075464||125903|
NCT01076517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHEP0016-NOT-RESEARCH|A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma|A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma||Stanford University||Available|December 2008|December 2099|Anticipated|December 2099|Anticipated|N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||November 2015|November 16, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076517||125822|
NCT01076478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLT-004-01|Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines||ASCEND|Otsuka Pharmaceutical, Inc., Philippines|No|Completed|March 2004|November 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|70 Years|No|||February 2010|February 25, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076478||125825|
NCT01076491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM-DEV-102b|High Dose Inhaled Mannitol Study|A Pilot Study to Investigate the Feasibility and Tolerability of Inhaling a High Dose of Dry Powder Mannitol (IDPM) Per Breath Administered Via a Dry Powder Inhaler Loaded With a Single Capsule in Subjects With Bronchiectasis||Pharmaxis|No|Completed|January 2009|April 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2010|February 24, 2010|November 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01076491||125824|
NCT01073358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-5|Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy||RELY|Heidelberg University|Yes|Enrolling by invitation|February 2010|October 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|N/A|No|||February 2010|February 22, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073358||126065|
NCT01073657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 09-254|Supported Education Pilot|Supporting Education Goals of OIF/OEF Veterans With PTSD: Pilot Process & Outcome|SEd|VA Office of Research and Development|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|33|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2014|April 6, 2015|February 18, 2010||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01073657||126042|
NCT01073670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-062-00|Indomethacin and Cardiac Bypass Surgery|Quantification of Postoperative Coagulation Following Administration of Indomethacin to Expedite Fast-tracking of Cardiac Surgical Patients||Queen's University|No|Completed|August 2000|April 2002|Actual|April 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|82|||Both|N/A|N/A|No|||February 2010|February 22, 2010|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01073670||126041|
NCT01074177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-092|Understanding Mechanisms of Acquired Resistance to BIBW2992|Understanding Mechanisms of Acquired Resistance to BIBW2992||Massachusetts General Hospital|Yes|Active, not recruiting|February 2011|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01074177||126002|
NCT01074424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000665346|Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer|Development of a Serum Proteomic Profile for Cervical Cancer With Potential Prognostic Value||National Cancer Institute (NCI)||Not yet recruiting|February 2010|||March 2010|Anticipated|N/A|Observational|N/A|||Anticipated|84|||Female|N/A|N/A|No|||February 2010|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074424||125983|
NCT01074723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL-2008-02591-C02-02|B-cryptoxanthin and Phytosterols on Bone Remodeling and Cardiovascular Risk Factors|Bioavailability of Added B-cryptoxanthin and Phytosterols; In Vitro and in Vivo Interactions and Effect on Bone Remodelling and Cardiovascular Risk Markers||Puerta de Hierro University Hospital|No|Completed|February 2010|December 2012|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|36|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074723||125960|
NCT01074983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA8650-05-2-6518-661150|Pre-hospital Hypoxemia in Trauma Patients|Prevalence of Pre-hospital Hypoxemia in Trauma Patients: Do Trauma Patients Need Oxygen?||University of Cincinnati|No|Completed|February 2010|February 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|224|||Both|18 Years|N/A|No|Probability Sample|Trauma patients arriving at a Level 1 Trauma Center by designated EMS units|December 2015|December 8, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074983||125940|
NCT01072136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0082|Empiric Therapy of Mucopurulent Cervicitis (MPC)|A Randomized Trial to Evaluate the Need for Empiric Therapy for Mucopurulent Cervicitis of Unknown Etiology||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|March 2010|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Female|18 Years|N/A|No|||January 2012|December 4, 2014|February 18, 2010|Yes|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01072136||126158|The study closed early due to slow accrual with 11% of the targeted sample size enrolled. Therefore, precision and power were low.
NCT01072422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2008/1929-31/5|Smoking Cessation in Primary Health Care Patients With Obstructive Pulmonary Disease|Smoking Cessation in Primary Health Care Patients With Obstructive Pulmonary Disease||Karolinska Institutet|No|Not yet recruiting|March 2010|May 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|No|||February 2010|February 19, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072422||126136|
NCT01074697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAND-emesis|Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin|A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin.|GAND-emesis|Odense University Hospital|Yes|Completed|April 2010|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|246|||Female|18 Years|N/A|No|||April 2015|April 23, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074697||125962|
NCT01076023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMR-301-CCDC|Cohort Study in Type 2 Diabetes in China|Comprehensive Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Disease in China|CCDC|China Cardiometabolic Registries|No|Active, not recruiting|February 2010|March 2013|Anticipated|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|40 Years|N/A|No|Non-Probability Sample|Out patients of Tier 3 hospitals|February 2010|February 13, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076023||125860|
NCT01075516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 09 021 IT RC|Health Economic Evaluation of Remote Follow up for Implantable Cardioverter Defibrillator (ICD) Patients|TARIFF Health Economics Evaluation Registry for Remote Follow up|TARIFF|St. Jude Medical|No|Completed|December 2009|April 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|N/A|No|Probability Sample|Patients implanted with ICD according to current guidelines and with the possibility to        use Merlin@home transmitters|January 2014|January 30, 2014|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01075516||125899|
NCT01075776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007143|The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels|The Effects of C-type Natriuretic Peptide on Endothelial Function Following Ischaemia-Reperfusion in the Human Forearm||Queen Mary University of London|Yes|Not yet recruiting|January 2017|April 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075776||125879|
NCT01075230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR08-004|Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)|A Prospective, Randomized, Single-blind, Multi-center Clinical Study to Evaluate the Effect of Platelet Rich Plasma (PRP) on Short-term Patient Outcomes Following Total Knee Replacement.||Exactech|No|Terminated|February 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||November 2013|November 20, 2013|February 23, 2010|Yes|Yes|Intended as multi-center. 1 of 2 sites could not participate. Enrollment discontinued after    50/100. Subjects followed per protocol.|No||https://clinicaltrials.gov/show/NCT01075230||125921|
NCT01076010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-09-902|An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)|An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)||AVEO Pharmaceuticals, Inc.|No|Completed|March 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|February 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01076010||125861|
NCT01075503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSTMZ.1|Clinical Research of Retrograde Infraclavicular Brachial Plexus Blockade|New Approach for Brachial Plexus Block: Clinical Research of Retrograde Infraclavicular Brachial Plexus Blockade|RIBPA|Beijing Jishuitan Hospital|Yes|Completed|March 2008|January 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|3||Actual|90|||Both|18 Years|60 Years|No|||February 2010|February 24, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01075503||125900|
NCT01075750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUViennaAnemev|Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants|Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants - Effects of Normal Saline Versus Balanced Infusates on the Incidence of Electrolyte and Acid-base Disturbances||Medical University of Vienna|Yes|Completed|June 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Both|18 Years|N/A|No|Probability Sample|All patients receiving a cadaveric renal transplant in the General Hospital of Vienna|February 2013|February 10, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075750||125881|
NCT01075763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24386|A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease|Pilot Trial of Interferon Beta-1a in Alzheimer's Disease|REAL|Merck KGaA||Completed|November 2004|May 2008|Actual|May 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|50 Years|75 Years|No|||January 2014|January 20, 2014|February 24, 2010|No|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT01075763||125880|
NCT01075737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200077-501|An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers|Observational Study to Assess the Quality of Life of the Caregivers of Patients With Multiple Sclerosis||Merck KGaA|No|Completed|August 2008|March 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|141|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects with diagnosed MS and their caregivers in Argentinean population.|February 2014|February 14, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075737||125882|
NCT01075958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16N3|Polyunsaturated Fatty Acids (PUFA) Status and Cognitive Function in Healthy Young Adults|The Relationship Between Serum PUFAs and Cognitive Function in Healthy Young Adults||Northumbria University|No|Completed|July 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|283|Samples Without DNA|Serum|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The sample will be drawn from a student and professional population in the Newcastle upon        Tyne area in the UK|August 2011|August 2, 2011|February 24, 2010||No||No|February 23, 2011|https://clinicaltrials.gov/show/NCT01075958||125865|
NCT01076777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.2007.499 (REK)|Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial|Effects of Physical Exercise on Anxiety and Co-morbid Emotional Disturbances: A Clinical Trail in a Day Care Unit||University of Bergen|No|Completed|May 2007|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|50 Years|No|||February 2010|February 25, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076777||125802|
NCT01077037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006263|Impact of a Decision Aid on Patient Decision Making in Emergency Department Chest Pain Patients|Impact of a Decision Aid on Patient Participation in Decision Making and Resource Use in Low Risk Chest Pain Patients: A Randomized Trial||Mayo Clinic|No|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|204|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01077037||125782|
NCT01076764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6204|Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy|Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban With Unfractionated Heparin + Eptifibatide, in Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy|TAO|Sanofi|Yes|Completed|April 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|13220|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01076764||125803|
NCT01077011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-060|Acute Comfort and Blur Profile of a Lubricant Eye Drop Versus a Marketed Lubricant Eye Gel|||Alcon Research|No|Completed|January 2010|||January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01077011||125784|
NCT01064518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL024LCL|Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults||Revance Therapeutics, Inc.|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064518||126737|
NCT01073956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FES-2009-01|Efficacy of Electrotherapy in Subacromial Impingement Syndrome|Efficacy of Electrotherapy in Subacromial Impingement Syndrome: Randomised Placebo-controlled Clinical Trial||Fundacio Espai Salut||Active, not recruiting|February 2010|December 2011|Anticipated|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|N/A|No|||July 2011|July 6, 2011|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073956||126019|
NCT01065272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#9105/09|Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma|Dexamethasone Versus Placebo in the Treatment of Viral Bronchiolitis in Patients With Either Eczema and or Parental or Sibling History of Asthma.A Randomized Controlled Trial.|#9105|Hamad Medical Corporation|Yes|Completed|February 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|N/A|18 Months|No|||September 2012|September 11, 2012|January 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065272||126679|
NCT01065519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2009-010923-14|STACCATO: Stent sTrut Apposition and Coverage in Coronary ArTeries: an Optical Coherence Tomography (OCT) Study|Assessment of Vessel Healing After DES Implantation With STEMI, NSTEMI and Stable/Unstable Angina Patients: a Randomized Study Between Everolimus and Biolimus A9-eluting Stents: an Optical Coherence Tomography (OCT) and Intravascular Ultrasound Tissue Characterisation (IVUS-TC) Study|STACCATO|University Hospital, Gasthuisberg|No|Recruiting|June 2009|June 2015|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2009|February 8, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065519||126660|
NCT01065805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-24513/DX-FLT-002|A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma|A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-L-fluorothymidine (18F-FLT)in Patients With Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and With Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma||AHS Cancer Control Alberta|No|Recruiting|February 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|170|||Both|16 Years|N/A|No|||June 2014|June 10, 2014|December 19, 2008||No||No||https://clinicaltrials.gov/show/NCT01065805||126638|
NCT01072162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111718|Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect|A Randomized-open-label-five-period-balanced-crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag PfOS Formulation Relative to the 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in HV||GlaxoSmithKline|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|40|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|February 12, 2010||||No||https://clinicaltrials.gov/show/NCT01072162||126156|
NCT01068392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISL-MZL-10-3|Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)|A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma||Dong-A University Hospital|Yes|Completed|October 2009|September 2014|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|N/A|No|||November 2014|November 2, 2014|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068392||126442|
NCT01068678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3724|Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)|BEGIN™|Novo Nordisk A/S|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|February 12, 2010|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01068678||126420|
NCT01074957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNISUAM|Effects of Physical Therapy on Cardiac Surgery|Effects of Physical Therapy on Pulmonary Volumes||Centro Universitário Augusto Motta|No|Completed|November 2007|November 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074957||125942|
NCT01074970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRE09-146|PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations|PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146||Hoosier Cancer Research Network|Yes|Active, not recruiting|February 2010|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|February 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01074970||125941|
NCT01067222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-03 / BF2.649|Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy|Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy|Harmony1|Bioprojet|No|Completed|May 2009|December 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067222||126530|
NCT01076244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#D1|Vertos Mild - Post Market Patient Outcomes|Single - Center, Prospective, Patient Outcomes Assessment of Minimally Invasive Lumbar Decompression With the Mild Devices in Patients With Symptomatic Central Canal Stenosis.||The Center for Pain Relief, Inc.|Yes|Completed|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 22, 2013|February 24, 2010|No|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT01076244||125843|
NCT01076543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01456|Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma|Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas||National Cancer Institute (NCI)|No|Active, not recruiting|April 2010|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01076543||125820|
NCT01067196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 0903-CN01|Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck|A Study of Late Effects After Proton Radiotherapy for Pediatric Tumors of the Brain, Head, and Neck|CN01|University of Florida|No|Completed|February 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|442|||Both|N/A|20 Years|No|Non-Probability Sample|Patients treated at a radiation oncology clinic|December 2015|December 16, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067196||126532|
NCT01067209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1295|Reversal of Diabetic Cardiomyopathy After Gastric By-pass Surgery|Reversal of Diabetic Cardiomyopathy in Patient Who Have Undergone Gastric by Pass Surgery.|DRTC|Washington University School of Medicine|Yes|Active, not recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|Samples With DNA|Blood samples|Both|35 Years|70 Years|No|Probability Sample|Patients with known diabetes or those with a high likelihood of diabetes who will undergo        gastric bypass surgery.|December 2015|December 22, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067209||126531|
NCT01076790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kotoe_01|Dexmedetomidine-propofol-remifentanil Anaesthesia and Reactivity to Noxious Stimuli|The Effect of Dexmedetomidine on Reactivity to Noxious Stimuli During Propofol-remifentanil Anaesthesia and Surgery||Tampere University Hospital|No|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|44|||Both|18 Years|70 Years|No|||October 2013|October 8, 2013|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076790||125801|
NCT01075984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05520|Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)|Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05520)||Merck Sharp & Dohme Corp.|Yes|Completed|February 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|279|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|February 24, 2010|No|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT01075984||125863|
NCT01075997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU#07-13025|The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus|The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus||Walter Reed Army Medical Center|No|Active, not recruiting|November 2007|October 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|170|||Both|18 Years|89 Years|No|||June 2009|February 24, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075997||125862|
NCT01073371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131843/2008-7|Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia|Local Anesthetics New Formulations: From Development to Clinical Tests||University of Campinas, Brazil|Yes|Completed|July 2008|November 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|32|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2008|February 22, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01073371||126064|
NCT01073683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC5476|Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer|Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF)||Rabin Medical Center|No|Not yet recruiting|April 2010|December 2014|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2010|March 3, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01073683||126040|
NCT01073059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH_2009_VPA|Pharmacokinetic Interactions in Combination Treatment of Valproic Acid and Ertapenem in Normal Subjects|Open-label, Two-period, One Sequence, Multiple Dose, Crossover Study, A Study to Investigate Pharmacokinetic Interactions in Combination Treatment of Valproic Acid and Ertapenem in Normal Healthy Male Subjects||Chonbuk National University|Yes|Completed|August 2009|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|10|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||February 2010|December 7, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01073059||126087|
NCT01073696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/43/C|Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects|A Phase I Study to Evaluate the Effect of External Heat on the Pharmacokinetics of a Transdermal Granisetron Patch in Healthy Subjects||Prostrakan Pharmaceuticals|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|September 24, 2010|February 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01073696||126039|
NCT01065012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-01409|Treatment of Erectile Dysfunction - Long Term Safety and Efficacy|Open-Label Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction||Warner Chilcott|No|Completed|January 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1027|||Male|19 Years|N/A|No|||March 2015|March 30, 2015|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065012||126699|
NCT01065025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4SC-205-1-2009|Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies|Open Label, Dose Escalation Trial of Oral 4SC-205 in Patients With Advanced Malignancies: First-In-Man Study of a Newly Developed, Oral Inhibitor of Kinesin-spindle Protein, Eg5|AEGIS|4SC AG|Yes|Completed|January 2010|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01065025||126698|
NCT01074190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00007275|The Effect of Neuraxial Analgesia on Maternal Breastfeeding|The Effect of Neuraxial Analgesia on Maternal Breastfeeding||Northwestern University|No|Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|345|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 9, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074190||126001|
NCT01064999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDRT-002|A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer|An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer||Fudan University|Yes|Recruiting|March 2010|December 2014|Anticipated|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|75 Years|No|||March 2012|March 12, 2012|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064999||126700|
NCT01065285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 090901|Vaccination Against Influenza in Autoimmune Diseases|Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX)|MAIVAX|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2009|February 2012|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|234|||Both|18 Years|N/A|No|||July 2012|January 5, 2016|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01065285||126678|
NCT01066039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200006-509|Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control|A Prospective, Multi-center, Open-label, Single Arm Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II DIAbetic patieNTs With Suboptimal Blood Pressure Control (GIANT Study)|GIANT|Merck KGaA||Completed|April 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|20 Years|80 Years|No|||June 2014|June 4, 2014|February 8, 2010||No||No|June 4, 2014|https://clinicaltrials.gov/show/NCT01066039||126621|
NCT01066052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GF 5834|Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years|Collaborative Study to Assess the Effects of Treatment With Recombinant Growth Hormone Saizen® in the Prevention of Short Stature in Young Girls Suffering From Turner Syndrome Before the Age of 4 Years. Original French Title: " Etude Collaborative Pour apprécier Les Effets du Traitement Par l'Hormone de Croissance Recombinante SAIZEN® Dans le Retard de Croissance de la Fillette Atteinte de Syndrome de Turner Avant l'âge de 4 Ans "||Merck KGaA|No|Completed|February 1992|August 2010|Actual|March 1999|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Female|N/A|4 Years|No|||August 2011|July 30, 2014|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01066052||126620|
NCT01072721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081207|Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis|Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of FIBROSCANN.|PEDISCAN|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|January 2010|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|264|||Both|6 Months|18 Years|No|||January 2016|January 29, 2016|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072721||126113|
NCT01069289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589DC00007|Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler® 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis® Turbuhaler® 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease|SUMIRE|AstraZeneca|No|Completed|January 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1293|||Both|40 Years|N/A|No|||September 2012|September 25, 2012|February 11, 2010|Yes|Yes||No|March 21, 2012|https://clinicaltrials.gov/show/NCT01069289||126373|
NCT01069562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|closed loop isoflurane|Closed Loop Isoflurane Administration With Bispectral Index in Open Heart Surgery|Comparison of Isoflurane Anaesthesia by Closed Loop Controlled Administration Versus Manually Controlled Administration Using Bispectral Index in Open Heart Surgery||Postgraduate Institute of Medical Education and Research|No|Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Both|18 Years|65 Years|No|||July 2010|January 24, 2011|February 1, 2010||No||No|August 2, 2010|https://clinicaltrials.gov/show/NCT01069562||126352|
NCT01075789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGTIPPS|Using Lignocaine Spray and Gel to Reduce the Pain Associated With Nasogastric Tube Insertion in Children|The Combined Use of Intranasal Lignocaine Spray and Oral Lignocaine Gel to Reduce the Pain and Trauma Associated With Nasogastric Tube Insertion in Hospitalised Children.|NGTIPPS|Queensland Children's Medical Research Institute|No|Recruiting|May 2010|December 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|130|||Both|6 Years|N/A|No|||February 2011|February 23, 2011|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075789||125878|
NCT01066910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0611M96906|Parents As The Agent Of Change For Childhood Obesity (PAAC)|Parents As The Agent Of Change For Childhood Obesity (PAAC)|PAAC|University of Minnesota - Clinical and Translational Science Institute|No|Completed|December 2006|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|8 Years|12 Years|No|||July 2012|July 9, 2012|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066910||126554|
NCT01067755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 35|Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System|Clinical Product Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System||Broncus Technologies|No|Recruiting|July 2009|March 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted in patients who are indicated for procedures that fall within        the intended use of the device. Examples of those patient populations are:          -  Patients who have been recommended for bronchoscopy for the purpose of obtaining a             biopsy sample of a central or peripheral pulmonary lesion.          -  Patients who have been recommended for bronchoscopy for the purpose of diagnosing             mediastinal or hilar lymphadenopathy.          -  Patients who have been recommended for bronchoscopy for the purpose of lung fiducial             placement.|February 2010|February 10, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01067755||126490|
NCT01067430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP 35166|Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)|Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis.||Northumbria Healthcare NHS Foundation Trust|No|Not yet recruiting|April 2010|April 2011|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2010|February 10, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067430||126514|
NCT01076231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 25508|Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery|Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|January 2010|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|February 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01076231||125844|
NCT01076530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02011|Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors|A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors||National Cancer Institute (NCI)||Completed|February 2010|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|1 Year|21 Years|No|||May 2013|May 1, 2013|February 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01076530||125821|
NCT01068275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHAnes1|Lumbar Plexus Catheter Versus Femoral Nerve Catheter for Postoperative Pain After Anterior Cruciate Ligament (ACL) Repair|Lumbar Plexus Catheter Versus Femoral Nerve Catheter Versus Single-shot Femoral Block for Postoperative Pain Control After Anterior Cruciate Ligament Reconstruction||Seattle Children's Hospital|No|Recruiting|April 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|114|||Both|11 Years|21 Years|No|||August 2010|August 24, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068275||126451|
NCT01064258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/30MARS/67|Trial of Auto Continuous Positive Airway Pressure (CPAP)|Reliability of Automatic CPAP Devices. A Double Blind Dummy Controlled Phase 1 Study||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 15, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01064258||126757|
NCT01064271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10640602|Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition|A Relative Bioavailability Study of Two Risperidone 1 mg Tablet Formulations Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064271||126756|
NCT01065038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOP03007|Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia|A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia|ANAHYDRET|AOP Orphan Pharmaceuticals AG|Yes|Completed|September 2002|||||Phase 3|Interventional|N/A|2||||||Both|18 Years|N/A||||September 2005|October 5, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065038||126697|
NCT01065051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14549|Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)|HEARTWORK|Bayer|No|Terminated|November 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|February 8, 2010|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01065051||126696|The study was terminated prematurely due to low recruitment (one subject enrolled only). No statistical analyses of efficacy parameters were performed. Therefore, no clinically meaningful conclusions can be drawn from the data generated.
NCT01064778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-003|Glycemic Index and Brain Function|The Effects of Dietary Glycemic Index on Brain Function||Beth Israel Deaconess Medical Center|No|Completed|February 2010|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 1, 2012|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064778||126717|
NCT01064791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2214|Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients|A Partially Blinded, Prospective, Randomized Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral Sotrastaurin Plus Standard or Reduced Exposure Tacrolimus vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients||Novartis||Completed|December 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|298|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064791||126716|
NCT01065558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ecopipam and Lesch-Nyhan|Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease|A Safety and Pilot Activity Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease||Psyadon Pharma|No|Completed|February 2010|June 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|6 Years|65 Years|No|||April 2013|April 17, 2013|February 6, 2010|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01065558||126657|This was an open label trial of oral ecopipam in pediatric, adolescent and adult patients with Lesch-Nyhan Disease.In this population, ecopipam's safety and PK was similar to non-LND subjects.
NCT01065831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAITH 09-0558|Faith-based Approaches in the Treatment of Hypertension (FAITH)|Faith-based Approaches in the Treatment of Hypertension (FAITH)|FAITH|New York University School of Medicine|Yes|Completed|November 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|373|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065831||126636|
NCT01066351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-E-1-57/52|Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery|Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery||Thammasat University|Yes|Enrolling by invitation|January 2010|June 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2010|February 9, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066351||126597|
NCT01068977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAM4224g|A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Completed|August 2007|||January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|N/A|No|||November 2010|November 11, 2010|February 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01068977||126397|
NCT01069276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.041.08|Prehospital Transcranial Duplex in Patients With Acute Stroke|Prehospital Transcranial Duplex in Patients With Acute Stroke||Johannes Gutenberg University Mainz|No|Terminated|September 2008|December 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Patients with clinical signs of acute stroke in the teritorial of the middle cerebral        artery|June 2012|June 12, 2012|February 16, 2010||No|Changes in preclinical treatment of stroke patients, no more emergency physician will met this    patients|No||https://clinicaltrials.gov/show/NCT01069276||126374|
NCT01069575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS-21-72|Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer|Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy||Shiga University|Yes|Recruiting|February 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|20 Years|85 Years|No|||September 2013|September 16, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069575||126351|
NCT01066572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-PG-0606-1241|Paramedic Initiated Lisinopril For Acute Stroke Treatment|Paramedic Initiated Lisinopril For Acute Stroke Treatment: a Pilot Randomised Controlled Trial|PIL-FAST|Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|40 Years|N/A|No|||October 2015|October 7, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066572||126580|
NCT01066585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP011|A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation|A Double-Blind Randomized Study to Compare the Efficacy, Safety and Local Tolerability of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation|LICE OUT|Topaz Pharmaceuticals Inc|No|Completed|March 2010|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|410|||Both|6 Months|N/A|No|||April 2012|April 4, 2012|February 8, 2010|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT01066585||126579|
NCT01066598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-009 (GVHD-R01)|A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)|A Phase II Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease||University Health Network, Toronto|No|Terminated|May 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2011|September 6, 2011|February 8, 2010||No|Poor Accrual|No||https://clinicaltrials.gov/show/NCT01066598||126578|
NCT01066897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02042010-4902|Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole|Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole||Stanford University|No|Completed|February 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066897||126555|
NCT01067781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELT208|Gender-Stratified Safety and Immunogenicity Study|A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Two Vaccination Regimen With the Travelers' Diarrhea Vaccine System in Healthy Adults||Intercell USA, Inc.|No|Completed|February 2010|March 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|600|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|February 9, 2010|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT01067781||126488|
NCT01066858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1084s (PROMISE)|Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding|Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2011|November 2015|Actual|November 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1765|||Both|N/A|N/A|No|Non-Probability Sample|For antepartum (AP) exposure part of P1084s: Mother/infant pairs enrolled in the        antepartum components of 1077BF or 1077FF (1077BA and 1077FA respectively) at African        clinical sites approved as P1084s DXA sites.        For postpartum (PP) exposure part of P1084s: Mothers and their infants enrolled in the        postpartum component of 1077BF (107BP) at African clinical sites approved as P1084s DXA        sites.|January 2016|January 13, 2016|February 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01066858||126558|
NCT01066871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700692_003|Sprifermin (AS902330) in Cartilage Injury Repair (CIR)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Trial to Investigate the Efficacy and Safety of Weekly Intra-articular (i.a.) Injections of 10, 30, and 100 µg of AS902330 for Three Consecutive Weeks in Patients With Acute Cartilage Injury of the Knee||Merck KGaA|No|Terminated|March 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|45 Years|No|||February 2016|February 22, 2016|February 9, 2010||No|The study was discontinued due to low recruitment.|No|February 22, 2016|https://clinicaltrials.gov/show/NCT01066871||126557|The study was discontinued due to low recruitment.
NCT01067443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAP 0208|Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa|A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Primary Visceral Leishmaniasis in Eastern Africa||Drugs for Neglected Diseases|Yes|Completed|March 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|183|||Both|7 Years|60 Years|No|||September 2014|September 26, 2014|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067443||126513|
NCT01067482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 52-336-02-1-2|The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes|The Performances of Spectral Domain Optical Coherence Tomography for Distinguishing Between Normal Eyes, Glaucoma Suspect and Glaucomatous Eyes|cirrusOCT|Prince of Songkla University|Yes|Completed|September 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|glaucoma patient from glaucoma clinic that is POAG Glaucoma suspect cases normal        population case|October 2009|March 22, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067482||126510|
NCT01067768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100-66592|Reduction of Catheter-associated Urinary Tract Infection With a Daily Nursing Review of the Indication|Reduction of Catheter-associated Urinary Tract Infection With a Daily Nursing Review of the Indication. Randomized Controlled Trial||Hospital Pablo Tobón Uribe|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1209|||Both|18 Years|N/A|No|||March 2014|March 2, 2014|February 10, 2010||No||No|July 11, 2011|https://clinicaltrials.gov/show/NCT01067768||126489|
NCT01068015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intervention20100105|(Men Who Have Sex With Men) MSM Community Intervention Trial|A COMMUNITY-BASED, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF COMPREHENSIVE HIV/STIs INTERVENTION AMONG MEN WHO HAVE SEX WITH MEN IN 8 CITIES IN CHINA||National Center for AIDS/STD Control and Prevention, China CDC|Yes|Active, not recruiting|June 2009|December 2010|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3214|||Male|18 Years|N/A|No|||April 2010|April 7, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068015||126471|
NCT01077050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPS|SciBase International Melanoma Pivotal Study|SciBase International Melanoma Pivotal Study||SciBase AB||Completed|April 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|1951|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 8, 2013|February 25, 2010|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01077050||125781|
NCT01073072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00875-50|Study Comparing Tutomesh® Repair to Conventional Surgical Techniques in Potentially Contaminated Hernia Repair and Abdominal Wall Reconstruction|Multicentric Prospective Randomized Study Comparing Technique of Tension-free Repair With Placement of a Bovine Pericardium Bioprosthesis (Tutopatch® and Tutomesh®) to Current Conventional Surgical Techniques in Potentially Contaminated Hernia Repair and Abdominal Wall Reconstruction|Tutomesh|Centre Hospitalier Régional Universitaire Montpellier|No|Completed|January 2009|October 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01073072||126086|
NCT01064531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-CR-130|Mini Stem Radiostereometric Analysis Study|A Randomized Controlled Trial to Compare Implant Migration of the MIS Stem Versus The Synergy Total Hip Systems by Radiostereometric Analysis|MISRSA|Smith & Nephew, Inc.|No|Active, not recruiting|June 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|75 Years|No|Probability Sample|The purpose of the current investigation is to compare migration of the device after        implantation with a modular, short hip stem called the "MIS Stem" or a standard THA using        the Synergy Hip System using Radiostereometric Analysis (RSA). The intended use of this        product is for patients with inflammatory and non-inflammatory degenerative joint disease        who require a primary total hip replacement.|May 2015|May 1, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064531||126736|
NCT01064804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0041005|To Test The Relative Bioavailability Of PF-04191834 When Dosed As An Immediate Release Tablet Compared With Solution Following Single And Multiple Dosing|An Open Randomised 4-Way Crossover Single Dose And A Parallel Group Multiple Dose Comparative Pharmacokinetic Study Of The PF-04191834 Phase 2 Tablet And The Phase 1 Dispersion Formulations.||Pfizer|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|whole blood, plasma, urine, saliva|Male|21 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|young, healthy male volunteers|February 2010|February 5, 2010|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01064804||126715|
NCT01065844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905704|Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck|A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck||University of Iowa|Yes|Active, not recruiting|October 2009|December 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065844||126635|
NCT01065298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABMSCT2|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus||Postgraduate Institute of Medical Education and Research|Yes|Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|30 Years|75 Years|No|Probability Sample|Patients with type 2 Diabetes mellitus with triple Oral hypoglycemic failure and on        Insulin for glycemic control|October 2015|October 19, 2015|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065298||126677|
NCT01066364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091491|Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis|Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis||University of California, San Diego|No|Enrolling by invitation|February 2010|February 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066364||126596|
NCT01065532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2009-011440-20|SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study|Healing Responses After Treatment of Bare Metal Stent Restenosis With Implantation of an Everolimus-eluting Xience V Stent Versus Use of a Paclitaxel-eluting Balloon: Optical Coherence Tomography Study|SEDUCE|University Hospital, Gasthuisberg|No|Recruiting|May 2009|December 2015|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2009|February 9, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065532||126659|
NCT01065545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08H6|The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia|A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia||Northwestern University|Yes|Withdrawn|June 2011|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|55 Years|N/A|No|||April 2015|April 9, 2015|February 8, 2010|No|Yes|Due to funding issues.|No||https://clinicaltrials.gov/show/NCT01065545||126658|
NCT01066936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-CR-131|Mini Stem DEXA (Dual Energy X-ray Absorptiometry)|Bone Density by Dual Energy X-ray Absorptiometry (DEXA) Following Total Hip Arthroplasty With the "Short Mini Stem"|MISDexa|Smith & Nephew, Inc.|No|Active, not recruiting|August 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|The purpose of this investigation is to assess the bone growth after implantation with a        modular, short hip stem using Dual Energy X-ray Absorptiometry (DEXA). The intended use of        this product is for patients with non-inflammatory and inflammatory degenerative joint        disease who require a total hip replacement.|March 2016|March 24, 2016|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066936||126552|
NCT01069302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C369|Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan|Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan|CHOICE|Kyoto University, Graduate School of Medicine|Yes|Completed|February 2010|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|106|||Both|N/A|N/A|No|||January 2016|January 7, 2016|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069302||126372|
NCT01069588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090805|Anterior Cruciate Ligament (ACL) Reconstruction- Bioabsorbable Screw|ACL Reconstruction - Bioabsorbable Screws- 2 Year Follow-up||Vanderbilt University|Yes|Completed|December 2009|April 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|67|||Both|12 Years|35 Years|No|Non-Probability Sample|Patients 2-4 years post ACL reconstruction performed by Dr. Kurt Spindler, under age 35,        injured in sport, unilateral primary ACL.|June 2014|June 6, 2014|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069588||126350|
NCT01069952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G010351|Electrical Stimulation of the Internal Capsule for Intractable Depression|Electrical Stimulation of the Internal Capsule for Intractable Depression||Butler Hospital|Yes|Completed|December 2002|||May 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||July 2012|July 23, 2012|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069952||126323|
NCT01066624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090454H|Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation|A Prospective, Randomized, Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.||The University of Texas Health Science Center at San Antonio|No|Completed|August 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|117|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|February 8, 2010||No||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01066624||126576|
NCT01067794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13095|Chemotherapy in Treating Patients With Lung Cancer|First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study on Overall Survival|FRAME|Eli Lilly and Company|No|Completed|April 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|1610|||Both|18 Years|N/A|No|Non-Probability Sample|Patients (> 18 yrs.) initiating first-line treatment for advanced or metastatic (stage        IIIB-IV) NSCLC with any platinum-based doublet chemotherapy, with or without additional        targeted agents treated in public hospitals, private hospitals or by office based        physicians|August 2012|August 23, 2012|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01067794||126487|
NCT01067807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-001|Proellex Pharmacokinetics Bridging Study|Proellex Pharmacokinetics Bridging Study||Repros Therapeutics Inc.|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067807||126486|
NCT01067456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000389|Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain|Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain|CAPTURE|Massachusetts General Hospital|No|Completed|May 2008|January 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|59|||Both|30 Years|N/A|No|||October 2014|October 14, 2014|February 10, 2010||No||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01067456||126512|
NCT01067469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0597|Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)|Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2010|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067469||126511|
NCT01064011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Prospective Randomized, Controlled Trial for Treatment of Intraventricular Hemorrhage|A Prospective Randomized, Controlled Trial for Treatment of Intraventricular Hemorrhage: External Ventricular Drainage and Intraventricular Thrombolysis vs. External Ventricular Drainage and Endoscopic Evacuation|IVH|Albany Medical College|No|Recruiting|January 2010|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|75 Years|No|||January 2010|June 24, 2011|February 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01064011||126776|
NCT01068028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098008|Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741|Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of ORM-12741||Orion Corporation, Orion Pharma|Yes|Completed|February 2010|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 13, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01068028||126470|
NCT01067742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-295|The Natural History of Mucolipidosis Type IV|The Natural History of Mucolipidosis Type IV||Baylor Research Institute|No|Recruiting|September 2010|January 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|Samples With DNA|blood, urine and skin|Both|1 Year|64 Years|No|Non-Probability Sample|Subjects previously identified with Mucolipidosis Type IV|January 2016|January 12, 2016|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067742||126491|
NCT01067989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0078-09-EMC|Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer|Antiangiogenic Treatment Strategy With Metronomic Chemotherapy Regimen Combined With a Cox-2 Inhibitor and a Bisphosphonate for Patients With Metastatic Breast Cancer||HaEmek Medical Center, Israel|No|Terminated|March 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|80 Years|No|||July 2015|July 6, 2015|February 11, 2010||No|No satisfactory acrual|No||https://clinicaltrials.gov/show/NCT01067989||126473|
NCT01068002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071-09-EMC|Cardiovascular an Echocardiographic Assessment in Hypertension During Pregnancy|Hypertension During Pregnancy: Cardiovascular & Echocardiographic Assessment: CREATION - P (01)|CREATION-P|HaEmek Medical Center, Israel|No|Recruiting|June 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80|||Female|18 Years|60 Years|No|Probability Sample|Pregnant Women|February 2010|February 11, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068002||126472|
NCT01068262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-059|Safety and Tolerability of Odanacatib (0822-059)|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Odanacatib (MK0822) in Healthy Male and Postmenopausal Female Subjects||Merck Sharp & Dohme Corp.|No|Completed|December 2009|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|44|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|February 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068262||126452|
NCT01064544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09.37 M / SHINE|Study on Hemodialysis: Illumination Effects|Effects of Light Therapy on Sleep, Melatonin Rhythm and Mood in Hemodialysis Patients|SHINE|Meander Medical Center|No|Completed|March 2010|September 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|85 Years|No|||July 2011|July 19, 2011|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01064544||126735|
NCT01064817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRM151B-21GL|PRM-151 in the Prevention of Scarring Following Trabeculectomy|A Randomized, Double-Masked, Placebo-Controlled Study of PRM-151 in the Prevention of Postoperative Scarring in Glaucoma Patients Following Primary Trabeculectomy||Promedior, Inc.|Yes|Completed|June 2010|November 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|124|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|February 5, 2010||No||No|April 14, 2014|https://clinicaltrials.gov/show/NCT01064817||126714|
NCT01065311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG Mi 700/4|Mindfulness-based Cognitive Therapy for Chronic Depression|Mindfulness-based Cognitive Therapy for Chronic Depression||Ruhr University of Bochum|No|Completed|October 2010|May 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|70 Years|No|||May 2014|May 14, 2014|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065311||126676|
NCT01066104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001325|Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis|Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis|Xolair CRS|Massachusetts General Hospital|Yes|Completed|December 2009|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066104||126616|
NCT01074502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELG0001|Apremilast in the Treatment of Moderate to Severe Acne|An Open-label, Single-arm Pilot Study of the Safety and Efficacy of an Oral PDE4-inhibitor Agent, Apremilast, in the Treatment of Moderate to Severe Acne||University of North Carolina, Chapel Hill|Yes|Terminated|February 2010|October 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|February 22, 2010|No|Yes|lack of funding due to Celgene administrative decision|No|October 6, 2011|https://clinicaltrials.gov/show/NCT01074502||125977|
NCT01074515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37332-B|Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)|Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation|CASCADE|University of Washington|No|Active, not recruiting|February 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Whole blood|Both|40 Years|N/A|No|Non-Probability Sample|Pulmonary and primary care clinics and community sample|December 2015|December 1, 2015|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01074515||125976|
NCT01066091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU800|Postprandial Inflammatory Response in Healthy Men: Effect of Dietary Fat Source, Obesity and Age|Postprandial Inflammatory Response in Healthy Men: Effect of Dietary Fat Source, Obesity and Age||Institut National de la Recherche Agronomique|No|Completed|March 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|32|||Male|20 Years|90 Years|Accepts Healthy Volunteers|||January 2011|March 24, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066091||126617|
NCT01075100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08007|Ixabepilone + Carboplatin Metastatic Breast Cancer|Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study||US Oncology Research|Yes|Completed|January 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|January 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075100||125931|
NCT01069315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-299|Fluid Lavage of Open Wounds (FLOW): Pilot Trial|Fluid Lavage of Open Wounds (FLOW): A Multi-Center, Blinded, Factorial Pilot Trial Comparing Alternative Irrigating Solutions and Pressures in Patients With Open Fractures|FLOW|McMaster University|No|Completed|July 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|111|||Both|N/A|N/A|No|||February 2010|February 16, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069315||126371|
NCT01069328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11956|Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)|Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)||Bayer|No|Completed|July 2006|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|33|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|February 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01069328||126370|
NCT01070225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHO001|Reversal of Acute β-Blocker Induced Bronchoconstriction|Reversal of Acute β-Blocker Induced Bronchoconstriction||University of Dundee|Yes|Completed|March 2010|October 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||October 2010|June 8, 2012|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070225||126303|
NCT01067248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09-1971|Chronic Obstructive Pulmonary Disease (COPD) and Osteoporosis|Patho-physiology of Osteoporosis in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Catharina Ziekenhuis Eindhoven|No|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|120|Samples With DNA|Markers of ageing, such as telomere length and sirtuin 1.|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In total 120 patients will be included. All subjects will be included from the outdoor        clinic of the department of Pulmonology of the Catharina Hospital Eindhoven or Diagnostic        Centre Eindhoven (DCE). The subjects are divided into 6 groups of 20 subjects each, I:        COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD        patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients        with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients        without osteoporosis based on T-score and without vertebral fractures, V: healthy controls        with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls        without osteoporosis based on T-score and without vertebral fractures.|July 2015|July 28, 2015|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067248||126528|
NCT01076348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4965|Model 4965 Post-Approval Study|Medtronic Model 4965 Capsure Epi® Steroid-eluting Unipolar Epicardial Pacing Lead Post Approval Study||Medtronic Cardiac Rhythm Disease Management|No|Completed|September 1996|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|73|||Both|19 Years|N/A|No|Non-Probability Sample|Subjects 19 years or older implanted with Model 4965 Capsure Epi Lead.|September 2012|September 12, 2012|February 24, 2010|No|Yes||No|May 16, 2012|https://clinicaltrials.gov/show/NCT01076348||125835|The study cohort was limited to subjects >19 years of age at the time of implant, limiting the survival analysis of the Model 4965 lead in a pediatric population.
NCT01076361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4968|Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study|Medtronic Model 4968 CapSure Epi® Steroid-Eluting Bipolar Epicardial Pacing Lead Post-approval Study|4968|Medtronic|No|Completed|September 1999|September 2010|Actual|September 2010|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|370|||Both|N/A|N/A|No|Non-Probability Sample|Subjects implanted with a 4968 lead.|October 2014|October 24, 2014|February 24, 2010|No|Yes||No|June 28, 2013|https://clinicaltrials.gov/show/NCT01076361|5 Years|125834|
NCT01067235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07-07 / BF2.649|Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy|Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy|Harmony2|Bioprojet|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||June 2012|February 8, 2013|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067235||126529|
NCT01064037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14836|A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) Within 12 Hours After Hospital Admission (Pulmonary Artery Catheter eg, Swan-Ganz Not Required)|COMPOSE EARLY|Bayer|Yes|Terminated|April 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|N/A|No|||October 2014|September 23, 2015|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064037||126774|
NCT01064310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113046|Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer|A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma.|PISCES|GlaxoSmithKline|No|Active, not recruiting|May 2010|June 2016|Anticipated|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|N/A|No|||November 2015|February 4, 2016|February 4, 2010|Yes|Yes||No|June 7, 2012|https://clinicaltrials.gov/show/NCT01064310||126753|
NCT01068288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013658|Perforated Appendicitis With Delayed Presentation|Perforated Appendicitis With Delayed Presentation: Laparoscopic Appendectomy vs Expectant Management. A Randomized Clinical Trial (The PADLE Trial)||The Hospital for Sick Children|Yes|Recruiting|July 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|18 Years|No|||May 2015|May 29, 2015|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068288||126450|
NCT01064284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABB - 09 - 001|Survey of Inhibitors in Plasma-Product Exposed Toddlers|Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial|SIPPET|Fondazione Angelo Bianchi Bonomi|Yes|Completed|January 2010|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|303|||Male|N/A|6 Years|No|||November 2015|November 16, 2015|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064284||126755|
NCT01065324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812154R|Balloon-assisted Enteroscopy and Bacteria|Intestinal Barrier Permeability Defects, Recovery, and Risk of Bacterial Translocation Induced After Deep Intestinal Manipulation by Balloon-assisted Enteroscopy: From Basic to Clinical Research||National Taiwan University Hospital|Yes|Recruiting|February 2010|December 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Bacterial DNA, host DNA|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|tertiary medical center,patients with clinical presentation necessitating deep enteroscopy        examinations.|February 2010|February 8, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065324||126675|
NCT01065571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0073|Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity|Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity||University of Illinois at Chicago|Yes|Recruiting|January 2010|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065571||126656|
NCT01073995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1376|The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery|The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery in Patients With Lumbar Disc Herniations||Horizon Health Network|Yes|Completed|March 2010|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073995||126016|
NCT01066117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5481|Effectiveness of PeeRelease - a Gel Absorbent Pad in Moderate to Severe Urinary Incontinence|Effectiveness of PeeRelease - a Gel Absorbent Pad in Moderate to Severe Urinary Incontinence Over Existing Solutions||Tisteron Ltd.|No|Not yet recruiting|February 2010|May 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|90|||Both|18 Years|80 Years|No|||February 2010|February 9, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01066117||126615|
NCT01075633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLONFAM|Colorectal Cancer Screening in Familiar-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy|Colorectal Cancer Screening in Familiar-Risk Population: a Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy|COLONFAM|Fundación Canaria Rafael Clavijo para la Investigación Biomédica|No|Completed|January 2006|June 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1501|||Both|40 Years|75 Years|No|||January 2014|January 7, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075633||125890|
NCT01066650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWENTE I|The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente|The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario|TWENTE|Cardio Research Enschede BV|Yes|Completed|June 2008|September 2012|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1391|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066650||126574|
NCT01075867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPUM-ACS-SP1|Multi-dimensional Prevention Program After Acute Coronary Syndrome (ELIPS) (SPUM-ACS- SP1)|||University Hospital, Geneva||Recruiting|April 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3500|||Both|18 Years|N/A|No|Probability Sample|Patients Admitted for an Acute Coronary Syndrome|January 2014|March 17, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075867||125872|
NCT01070004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/14|Effect of Countermeasures on Nocturnal Driving Performance|Countermeasures for Sleepiness at the Wheel and Prediction of Inter- Individual Differences to Their Responses (KillSleep)|KILLSLEEP|University Hospital, Bordeaux|No|Completed|January 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|72|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01070004||126320|
NCT01070238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA.4240.UKGiessen.021219.B|Metabolic Response of Slow Released Carbohydrates in Diabetes Mellitus|Explorative, Pilot Study With Cross-over Design on the Metabolic Response of Orally Applied Slow Released Carbohydrates in Diabetes Type 2 Patients||University of Giessen|No|Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|||||||Both|18 Years|75 Years|No|||November 2002|February 16, 2010|February 16, 2010||||No||https://clinicaltrials.gov/show/NCT01070238||126302|
NCT01065714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGV0901|A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis|Transepidermal Water Loss (TEWL) and Corneometry With Hydrogel Vehicle in the Treatment of Atopic Dermatitis - A Randomized, Investigator-Blind Pilot Study||Derm Research, PLLC|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|N/A|No|||April 2013|April 22, 2013|February 8, 2010||No||No|March 30, 2012|https://clinicaltrials.gov/show/NCT01065714||126645|Small number of participants, pilot study, short term
NCT01065961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-01|Randomized Controlled Trials of the Effects of Decadron on Swallowing, Airway, and Arthrodesis|Prospective Randomized Controlled Trail of the Effects of Steroids on Swallowing, Airway and Arthrodesis Related to Myulti-Level Anterior Cervical Reconstruction||Albany Medical College|No|Recruiting|November 2008|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2008|February 9, 2010|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065961||126627|
NCT01066832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eur-001|The Valentines Trial|The Valentines Trial||Eurocor GmbH||Completed|February 2010|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|276|||Both|18 Years|N/A|No|||February 2010|June 16, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066832||126560|
NCT01066494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS1413-C-101|A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)|A Phase IIa Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Adult Patients With Acute Myeloid Leukemia (AML)||Antisoma Research|No|Active, not recruiting|January 2010|January 2011|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2011|January 14, 2011|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066494||126586|
NCT01066507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-Her2F|Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections|Concordance Study for Amplification Detection of Her2 FISH in Breast Tissue Sections|Her2F test|Applied Spectral Imaging Ltd.|No|Completed|July 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|126|Samples Without DNA|Paraffin embedded tissue sections|Female|21 Years|N/A|No|Probability Sample|The breast samples were taken from female patients after cut biopsies. Paraffin embedded        blocks were prepared and the secssion slides were stained with the PathVysion prove for        Her2 FISH applification detection|February 2010|February 9, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066507||126585|
NCT01066819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV21542|PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naïve HCV-infected Patients Treated With Pegylated Interferons||Hoffmann-La Roche||Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1611|||Both|18 Years|N/A|No|Probability Sample|Patients receiving peginterferon alfa treatment at a medical centre|November 2015|November 2, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066819||126561|
NCT01067378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH09172|Peer Debriefing Versus Instructor Debriefing for Interprofessional Simulation Based Education|Peer Debriefing Versus Instructor Debriefing for Interprofessional Simulation Based Education (PICS|PICS|St. Michael's Hospital, Toronto|No|Completed|June 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|120|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01067378||126518|
NCT01067352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP23681|A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)|An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)|SAIZEN in SGA|Merck KGaA||Terminated|February 2004|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|4 Years|6 Years|No|||December 2013|December 2, 2013|February 10, 2010||No|This study was discontinued prematurely due to difficulty in participant recruitment.|No|October 5, 2011|https://clinicaltrials.gov/show/NCT01067352||126520|The primary and secondary efficacy objectives were not met because of poor participant enrollment and no quality RNA samples obtained to evaluate (RNA degradation in nearly all of the blood samples).
NCT01067677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Cladis|Rescue Emetic Therapy for Children Having Elective Surgery|Rescue Emetic Therapy for Children Having Elective Therapy|RETCHES|Children's Hospital of Pittsburgh|No|Recruiting|February 2010|February 2014|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1600|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||September 2009|June 21, 2011|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067677||126496|
NCT01067950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 09/5-J|Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study|International, Multicenter, Prospective, Randomized, Parallel Group, Open Label Protocol to Evaluate Safety and Efficacy of Isolated Pancreas Transplantation Compared to Intensive Insulin Therapy in Type 1 Diabetic Patients With Overt Diabetic Nephropathy and Mildly Reduced Renal Function|PANCREAS|Nantes University Hospital|Yes|Recruiting|March 2010|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|25 Years|55 Years|No|||March 2010|June 1, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01067950||126476|
NCT01064505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK.007|Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients|A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)||Quark Pharmaceuticals|No|Completed|February 2010|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|48|||Both|50 Years|N/A|No|||May 2013|May 9, 2013|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064505||126738|
NCT01064765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16233A|ACT-HF: Attention, Cognition and Self-Management in Heart Failure|ACT-HF: Attention, Cognition and Self-Management in Heart Failure|ACT-HF|University of Chicago|No|Completed|September 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|72|||Both|18 Years|75 Years|No|Non-Probability Sample|All patients with history of heart failure 6 months or more meeting inclusion criteria        recruited from outpatient clinic who receiving routine care for their heart failure|September 2013|September 4, 2013|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01064765||126718|
NCT01076101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-263|Autoimmunity in Sisters of Lupus Patients|Mapping Autoimmune Phenotypes in Multiplex Families (MADGC 2)|SisSLE|Northwell Health|No|Active, not recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|800|Samples With DNA|We will use your DNA blood sample to study the function of genes and biomarkers and gain      understanding of their role in protection against disease or the role they play in      increasing the risk factors of developing lupus. No, you will not get test results since the      information we gather is only useful for research and is not diagnostic. Participation in      this study is not a substitute for regular medical care.      The information and blood sample that is collected for research will be analyzed for many      years and it is not possible to know how long this analysis and follow-up will take.      Therefore, participation allows the information and banking of your blood sample to be      indefinite.|Female|10 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Sisters: One sister must be diagnosed with Systemic Lupus Erythematous ( SLE ) by and        including age 40 who has a sister(s) or half sister(s) not affected with SLE currently        between the ages of 10 and 45 are being recruited nation wide through community and        physician referrals.|September 2015|September 9, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076101|7 Years|125854|
NCT01067573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF 6175-A675E9|The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment|The Role of Leptin Levels in Multiple Sclerosis|Leptin|University of South Florida|Yes|Completed|December 2009|July 2011|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|USF Medical Clinic Tampa, Flrida|February 2010|June 14, 2012|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067573||126503|
NCT01067846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111989|Cognitive Enhancement and Relapse Prevention in Cocaine Addiction|The Clinical and Neural Response of Cocaine Addicts to Combination Treatment With a Cognitive Enhancer and Extinction-Based Psychotherapy||University of Arkansas|Yes|Completed|June 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|65 Years|No|||October 2013|October 31, 2013|February 10, 2010||No||No|June 11, 2013|https://clinicaltrials.gov/show/NCT01067846||126483|
NCT01068119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GREECE|Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)|Feasibility and Safety of Same-Day Discharge of Troponin Negative Patients After Coronary PTCA Via the Transfemoral Approach|GREECE|Piedmont Healthcare|No|Terminated|February 2010|March 2012|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|February 11, 2010||No|Slow enrollment and high number of screen failures|No||https://clinicaltrials.gov/show/NCT01068119||126463|
NCT01064648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02015|Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma|A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Active, not recruiting|March 2010|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||February 2016|March 22, 2016|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064648||126727|
NCT01064414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017008|An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment||Janssen Research & Development, LLC|Yes|Completed|June 2010|August 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|272|||Both|25 Years|N/A|No|||August 2013|August 2, 2013|February 4, 2010|Yes|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01064414||126745|
NCT01066247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMed-Ow-001|Premedication and Haemodynamics After Spinal Anesthesia|The Influence of HRV-changing Premedication on Hemodynamic Parameters After Spinal Anesthesia||Medical University of Gdansk|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2010|July 25, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066247||126605|
NCT01066000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21736|A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia|A Single Arm Open Label Interventional Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous Methoxy-polyethylene Glycol-epoetin Beta for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066000||126624|
NCT01066520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRS-ESP|TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain|A Randomized, Controlled, Multi-center Study on the Effectiveness of Traumeel S (Both Ointment and Gel) in Terms of Pain and Function Compared With a Topical NSAID in Athletes With Acute Ankle Sprain|TAASS|Biologische Heilmittel Heel GmbH|No|Completed|August 2009|March 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|449|||Both|18 Years|40 Years|No|||December 2013|December 9, 2013|February 9, 2010||No||No|February 18, 2013|https://clinicaltrials.gov/show/NCT01066520||126584|
NCT01066533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|583|Immunohistochemical Study of Human Teeth Pulp Capped With Mineral Trioxide Aggregate (MTA) and Novel Endodontic Cement (NEC)|Histologic and Immunohistochemical Study of Fibronectin and Tenascin in Human Teeth Pulp Capped With MTA and NEC||Mashhad University of Medical Sciences|Yes|Terminated|October 2009|February 2010|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|16 Years|30 Years|Accepts Healthy Volunteers|||July 2009|February 9, 2010|February 9, 2010||No|immunohistochemistry markers are not recieved yet|No||https://clinicaltrials.gov/show/NCT01066533||126583|
NCT01066546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451030|An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease|An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease||Pfizer|Yes|Terminated|April 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|50 Years|N/A|No|||August 2012|August 30, 2012|February 9, 2010|Yes|Yes|See termination reason in detailed description.|No|July 30, 2012|https://clinicaltrials.gov/show/NCT01066546||126582|Results are not summarized because of early termination of the study due to modification in the development plan of the study treatment following lack of demonstration of efficacy in the completed DIM14 CONNECTION (B1451002/NCT00675623) study.
NCT01067144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0054|Stanford Accelerated Recovery Trial (START)|Stanford Accelerated Recovery Trial (START)||Stanford University|Yes|Active, not recruiting|May 2010|May 2024|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|560|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|February 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01067144||126536|
NCT01067157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOGIC|Long-term Effects of Lifestyle Intervention in Obesity and Genetic Influence|Long-term Effects of Lifestyle Intervention in Obesity and Genetic Influence in Children - LOGIC-Study|LOGIC|Technische Universität München|No|Recruiting|January 2006|July 2022|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Both|6 Years|19 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067157||126535|
NCT01067170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-21937|Pneumatic Compression Stockings During Hemodialysis|The Effect of Pneumatic Compression Stockings on Hemodynamic Parameters in Hemodialysis Patients: A Randomized Crossover Trial||University of Calgary|No|Completed|November 2008|August 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067170||126534|
NCT01067690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKS/IND-CX/05|Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma|Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy||Istituto Superiore di Sanità||Active, not recruiting|June 2008|June 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067690||126495|
NCT01067937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/6-L|Study for a Rational Management of Appendicitis in Children|Multicenter Prospective Study for a Rational Management of Appendicitis in Children|ALGAP|Nantes University Hospital||Completed|February 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Masking: Open Label|||Actual|891|||Both|4 Years|15 Years|No|||February 2013|February 6, 2013|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01067937||126477|
NCT01064245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-01|Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests|Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests||Queen's University|No|Active, not recruiting|February 2010|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|65 Years|No|||September 2015|September 14, 2015|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01064245||126758|
NCT01095432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-066-B|Partial Wave Spectroscopic Detection of Colon Cancer Risk|Partial Wave Spectroscopic Detection of Colon Cancer Risk|Brushings|University of Chicago|No|Recruiting|March 2010|||January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|A sample of rectal mucosa will be collected during the subject's standard of care      colonoscopy or flexible sigmoidoscopy.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are scheduled to undergo a standard of care flexible sigmoidoscopy or a        colonoscopy and have a history of UC.|January 2013|September 4, 2013|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01095432||124377|
NCT01095445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXACT-R(3)|EXtended Therapy in Hepatitis C Genotype 3 Infected Patients|EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR)|EXACT-R(3)|University Health Network, Toronto|Yes|Terminated|February 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||March 2010|September 27, 2011|March 26, 2010||No|Unlikely to recruit the adequate number of patients within a reasonable timeline|No||https://clinicaltrials.gov/show/NCT01095445||124376|
NCT01076114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-320|Comparison of Critical Flicker Fusion Versus Automated Visual Fields in the Detection of Early Glaucoma|Comparison of Critical Flicker Fusion vs. Automated Visual Fields in the Detection of Early Glaucoma||Northwell Health|Yes|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects will be selected from routine clinic patients seen at the Eye Center at Nassau        University Medical Center, in East Meadow, NY.|March 2011|March 14, 2011|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076114||125853|
NCT01076127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIMS02|Effect of Kettlebell Training on Musculoskeletal and Cardiovascular Health|Effect of Kettlebell Training on Musculoskeletal and Cardiovascular Health||National Research Centre for the Working Environment, Denmark|No|Completed|March 2010|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 12, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076127||125852|
NCT01067274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFA-0703 Study - P060205|ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)|A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Therapy in Older Patients With Acute Myeloblastic Leukemia (AML)|ALFA-0703|Acute Leukemia French Association||Withdrawn|April 2010|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|0|||Both|65 Years|79 Years|No|||February 2010|December 29, 2015|February 10, 2010||No|Study abandoned|No||https://clinicaltrials.gov/show/NCT01067274||126526|
NCT01067586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTUC053|Novel Determinants and Measures of Smokeless Tobacco Use: Study 1|Toxicant Exposure Across Brands of Smokeless Tobacco||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|359|Samples Without DNA|Urine, buccal cells and blood will be collected from subjects in this study.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Smokeless tobacco users of 6 brands of tobacco|December 2015|December 11, 2015|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067586||126502|
NCT01067859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14663|A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY58-2667 (25 µg/h, 10 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|COMPOSE 2|Bayer|Yes|Terminated|March 2010|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|N/A|No|||November 2014|September 23, 2015|February 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067859||126482|
NCT01068132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007524-25|Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.|Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. An Italian Trial||Regione Lombardia|Yes|Completed|April 2009|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|80 Years|No|||May 2014|May 9, 2014|May 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01068132||126462|
NCT01068145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05567|Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)|Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled, Incomplete Crossover, Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and COPD Patients||Merck Sharp & Dohme Corp.|No|Terminated|February 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|9||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068145||126461|
NCT01065155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|428/A/09|Relationship of Central Blood Pressure and Pulse Wave Velocity With Target Organ Damage|Central Blood Pressure and Pulse Wave Velocity: Relationship to Target Organ Damage and Cardiovascular Morbidity-mortality in Diabetic Patients. An Observational Prospective Study. LOD-DIABETES: Study Protocol|LOD-DIABETES|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|Yes|Active, not recruiting|February 2010|March 2014|Anticipated|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|110|Samples Without DNA|blood and urine).|Both|20 Years|80 Years|No|Non-Probability Sample|Consecutive inclusion will be made of the patients referred to the research unit and who        meet the corresponding inclusion criteria, i.e., patients diagnosed with DM2 and aged        20-80 years A total of 52 patients are required in each group, estimating a loss to        follow-up of 10%. A final total of 110 patients therefore will be included.|March 2011|March 4, 2014|February 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01065155||126688|
NCT01065168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si637/2008|Serial Measurement of Serum Antimullerian Hormone in Women Undergoing Laparoscopic Cystectomy of Endometrioma|Serial Measurement of Serum Antimullerian Hormone in Women Undergoing Laparoscopic Cystectomy of Endometrioma||Mahidol University|Yes|Active, not recruiting|January 2009|March 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|43|||Female|20 Years|40 Years|No|Non-Probability Sample|ovarian endometrioma performed laparoscopic cystectomy|January 2009|February 16, 2010|February 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01065168||126687|
NCT01065428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437129519|Extubation Readiness and Neuroventilatory Efficiency After Acute Respiratory Failure|Department of Critical Care Medicine, Nanjing Zhong-Da Hospital, Southeast University School of Medicine, China; Department of Critical Care Medicine St. Michaels's Hospital, University of Toronto, Canada||Southeast University, China|Yes|Completed|December 2008|July 2010|Actual|July 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|52|Samples Without DNA|Parameters of arterial blood gases, haemodynamic and mechanics of breathing|Both|18 Years|85 Years|No|Non-Probability Sample|Patients who required mechanical ventilation for more than 24 h.|August 2011|August 29, 2011|February 8, 2010||No||No|October 18, 2010|https://clinicaltrials.gov/show/NCT01065428||126667|Early termination leading to small numbers of subjects analyzed
NCT01066273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-12-056|Somatosensory Based Treatments for Tinnitus|Somatosensory Based Treatments for Tinnitus||Massachusetts Eye and Ear Infirmary|No|Withdrawn|December 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2008|February 9, 2010|February 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01066273||126603|
NCT01066286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-10-069|Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia|Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia||Samsung Medical Center|Yes|Recruiting|February 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|Samples With DNA|Stored bone marrow specimens of patient with core binding factor positive acute myeloid      leukemia treated with chemotherapy between 1995 and 2008 at Samsung Medical Center and      Hwasun Chonnam National University Hospital|Both|18 Years|N/A|No|Non-Probability Sample|core binding factor positive acute myeloid leukemia|February 2010|February 9, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01066286||126602|
NCT01066260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-24 MET|Efficacy of a Probiotic Formulation on Energy Balance in Overweight Subjects|Efficacy of a Probiotic Formulation on Energy Balance in Overweight Subjects||Nestlé|Yes|Completed|October 2009|September 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 3, 2013|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066260||126604|
NCT01067183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-22185|Does a Portable Biofeedback Tool Reduce Physician Stress?|Does a Portable Biofeedback Tool Reduce Physician Stress?||University of Calgary|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2010|February 17, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067183||126533|
NCT01066845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13693|Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension|Safety and Effectiveness of Adcirca (Tadalafil) in Japanese Patients With Pulmonary Arterial Hypertension: Open-label, Non-interventional Observational Study in Japan||Eli Lilly and Company|No|Completed|January 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1809|||Both|15 Years|N/A|No|Non-Probability Sample|Japanese patients prescribed Adcirca from clinical practices|October 2015|October 23, 2015|February 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01066845||126559|
NCT01067404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 200903CVC-203708/99971|TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B|TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B|TITRE II|British Columbia Centre for Disease Control|No|Enrolling by invitation|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Months|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants of earlier clinical trial (TITRE I); enrolled in winter 2008/09 as previously        unimmunized infants and toddlers (6-23 months of age)|February 2010|February 10, 2010|February 10, 2010||||No||https://clinicaltrials.gov/show/NCT01067404||126516|
NCT01067729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#AW-101508MC|A Postmarket Randomized Study of the Treatment of Superficial Partial-Thickness Burns Using Two Dressings|A Multi-Center, Randomized, Prospective Study of the Treatment of Superficial Partial-Thickness Burns: AWBAT™ vs. Biobrane®||Aubrey Inc.|No|Terminated|November 2009|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|1 Year|70 Years|Accepts Healthy Volunteers|||February 2010|January 23, 2015|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067729||126492|
NCT01067391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cialis 2009|Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males|A Randomized, Double-blind, Placebo-controlled Cross-over Trial Assessing the Effect of Tadalafil (Cialis) on the Cardiovascular System in Men With Complete Spinal Cord Injury (SCI) at or Above the Sixth Thoracic Level||University of Manitoba|No|Completed|October 2009|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|70 Years|No|||July 2015|July 16, 2015|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067391||126517|
NCT01067703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME 3559/1-1|Remote Ischaemic Preconditioning for Heart Surgery (RIPHeart-Study)|Remote Ischaemic Preconditioning for Heart Surgery||University of Schleswig-Holstein|Yes|Terminated|December 2010|May 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1400|||Both|18 Years|90 Years|No|||September 2014|December 1, 2015|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067703||126494|
NCT01067716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-107-AVSS|Performance and Acceptability of VSS-R|A Prospective Study to Evaluate the Performance and Acceptability of Advanced Variable Spot Scanning (AVSS) Ablations With the STAR S4 IR® Excimer Laser System||Abbott Medical Optics|No|Completed|February 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|21 Years|N/A|No|||October 2013|October 7, 2013|February 10, 2010|No|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT01067716||126493|
NCT01095133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0289|Do Acid Sensing Ion Channels Contribute to Heartburn?|Do Acid Sensing Ion Channels (ASICs) Contribute to Heartburn in Proton Pump Inhibitor (PPI)-Complete Responders or PPI-Partial Responders With Nonerosive Reflux Disease (NERD)?||University of North Carolina, Chapel Hill|No|Completed|March 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|59 Years|No|||September 2012|September 18, 2012|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095133||124400|
NCT01095458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL16529|Phone Versus Clinical Approach to Weight Loss|Equivalent Weight Loss for Phone and Clinic Weight Management Programs||University of Kansas Medical Center|Yes|Completed|July 2007|June 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|395|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01095458||124375|
NCT01095484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0953|Named Patient Program With Rotigotine Transdermal System|Named Patient Program With Rotigotine Transdermal System||UCB Pharma|No|Completed|November 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|520|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a documented medical necessity to receive treatment with rotigotine        treatment in accordance with standard medical practice.|December 2012|October 17, 2014|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095484||124373|
NCT01076140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0222|Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab|Comparative Blood Pressure Effects of Nebivolol Versus Lisinopril in Patients With New Onset or Exacerbated Hypertension Induced by Bevacizumab: a Crossover Study||University of Mississippi Medical Center|No|Withdrawn|February 2010|August 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 5, 2012|February 24, 2010||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01076140||125851|
NCT01067287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-061|Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation|Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Active, not recruiting|March 2010|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 29, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067287||126525|
NCT01064154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02117|Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions|Randomized,2-way Crossover, Bioequivalence Study of Carvedilol 25 mg Film-coated Tablets and COREG® 25 mg Film-coated Tablets Administered as 1 x 25 mg Film-coated Tablet in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|May 2002|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 4, 2010|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064154||126765|
NCT01064427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-FATQV|Factors Correlated With Fatigue in Breast Cancer|Factors Correlated With Fatigue in Breast Cancer Patients Before, During and After Adjuvant Chemotherapy|FATSEIN|Central Hospital, Nancy, France|No|Recruiting|July 2008|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|557|||Female|18 Years|80 Years|No|Probability Sample|Recruitment began in September 2008 and is planned over a 24-month period. Participants        with breast cancer are recruited from three French cancer centers, the Alexis Vautrin        anti-cancer center of Vandoeuvre-les-Nancy, the Georges-François Leclerc anti-cancer        center of Dijon and the Paul Strauss anti-cancer center of Strasbourg, France.        Participation to study is proposed to all women with newly diagnosed breast cancer the day        preceeding surgery.Included patients are asked to complete the questionnaires several        times.|February 2010|February 5, 2010|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064427||126744|
NCT01067885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARIS-01|A Post-market Registry of the MARIS-stent (Invatec) Implanted in the Superficial Femoral Artery|MARIS - Prospective, Multicenter Registry|MARIS|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|No|Completed|April 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1051|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01067885||126481|
NCT01065454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14308|A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction|Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction|LEPHT|Bayer|Yes|Active, not recruiting|April 2010|April 2020|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|201|||Both|18 Years|80 Years|No|||January 2016|January 22, 2016|February 8, 2010|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT01065454||126665|Subjects had advanced disease and were heavily pretreated. Baseline values were not comparable between treatment groups.
NCT01065727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC/09-06|Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis|Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis|IQUALYSEP|Rennes University Hospital|Yes|Recruiting|February 2010|February 2019|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|250|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065727||126644|
NCT01065441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITL-002-HMC|Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer|A Phase I/II Study of an Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancers||Immunovative Therapies, Ltd.|No|Withdrawn|December 2009|July 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2011|November 29, 2012|February 7, 2010|Yes|Yes|Protocol withdrawn for lack of financial support|No||https://clinicaltrials.gov/show/NCT01065441||126666|
NCT01097837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|137557|Epilepsy Birth Control Registry|Epilepsy Birth Control Registry|EBCR|Neuroendocrine Associates P.C.|No|Recruiting|March 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Female|18 Years|47 Years|No|Non-Probability Sample|Participants are women with epilepsy between the ages of 18 and 47.|October 2015|October 14, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097837||124194|
NCT01097850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 09D1|Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome|Prospective Randomized Controlled Open-label Trial of a Topical Henna Preparation for the Treatment of Hand-Foot Skin Syndrome and Its Associated Symptoms||Northwestern University|Yes|Withdrawn|March 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|March 31, 2010|Yes|Yes|No subject accrual.|No||https://clinicaltrials.gov/show/NCT01097850||124193|
NCT01066559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/11|Improvement of Humoral Immune Response With Hemodialysis on BK-F Membrane: Correlation to Soluble CD40 Clearing|Multicentric Randomized Trial of the Impact of Hemodialysis With Polymethylmetacrylate Membrane on the Improvement of Humoral Immune Response in the Hemodialyzed Patients: Application to Hepatitis B Vaccination and Correlation to sCD40 Clearing|HEPADIAL|University Hospital, Bordeaux|No|Completed|April 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|85 Years|No|||June 2015|June 24, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066559||126581|
NCT01067417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCQ-01|Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients|Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients|HCQ-01|Medical Research Council|Yes|Active, not recruiting|June 2008|February 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|65 Years|No|||February 2010|July 29, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067417||126515|
NCT01098695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3R01DA016110|Early Family-Centered Prevention of Drug Use Risk (Aka Early Steps)|Early Family-Centered Prevention of Drug Use Risk|Early Steps|University of Oregon|No|Active, not recruiting|March 2003|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|731|||Both|2 Years|3 Years|No|||April 2010|April 2, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098695||124129|
NCT01067963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0939|Self-Management and Resourceful Transition of Type 2 Diabetes With Stage 3 Kidney Disease|Self-management of Type 2 Diabetes and Chronic Kidney Disease|SMaRT|University of Colorado, Denver|No|Terminated|December 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||January 2013|June 5, 2015|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067963||126475|
NCT01067976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91743|Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI|An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI||Bayer|No|Completed|February 2010|January 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|446|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|February 11, 2010|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT01067976||126474|
NCT01068236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD050931-04|Primary Care Treatment for Overweight Adolescent Females (SHINE)|Primary Care Treatment for Overweight Adolescent Females|SHINE|Kaiser Permanente|Yes|Completed|August 2005|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Female|13 Years|15 Years|Accepts Healthy Volunteers|||March 2010|March 23, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068236||126454|
NCT01068249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0059|Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer|A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2010|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|February 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01068249||126453|
NCT01095146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-PAE-10-284|New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome|Comparison of Predictive Ability of New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome|MAS-D|Amrita Institute of Medical Sciences & Research Center|No|Enrolling by invitation|March 2010|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients admitted in the Pediatrics, Internal Medicine, Rheumatology/Clinical Immunology        departments of hospitals|March 2010|March 29, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095146||124399|
NCT01095705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090802|Hypnosis for Transesophageal Echocardiography|Utility of Hypnosis for Transesophageal Echocardiography|I-SLEPT|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2010|February 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||March 2010|December 18, 2013|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095705||124356|
NCT01076894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDA-ICB 198/06|Thoracotomy: Intercostal Nerve Block Versus Epidural Anesthesia|Analgesia and Pulmonary Function After Thoracic Surgery: is an Intercostal Nerve Block Plus Intravenous Morphine as Effective as Epidural Anesthesia? A Prospective Randomized Clinical Study.||University of Ulm|No|Completed|February 2007|October 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||February 2010|February 25, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076894||125793|
NCT01067300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-17|A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission|A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|February 2010|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|N/A|35 Years|No|||September 2015|September 29, 2015|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067300||126524|
NCT01064440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMCLI-II-09-002/E|Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subject With Critical Limb Ischemia||ViroMed Co., Ltd. dba VM BioPharma|Yes|Completed|March 2010|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|90 Years|No|||October 2015|October 14, 2015|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064440||126743|
NCT01064700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSA-3469|Bright Light: A Novel Treatment for Anxiety|Bright Light: A Novel Treatment for Anxiety||University of South Carolina|No|Completed|October 2006|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2010|February 5, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01064700||126723|
NCT01064713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0624|Phase II Study of Tesetaxel in Metastatic Melanoma|A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH||M.D. Anderson Cancer Center|No|Completed|February 2010|||October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064713||126722|
NCT01065207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0222|Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection|ANRS HIV CONTROLLERS NATIONAL OBSERVATORY|ANRS CO18|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|March 2009|March 2012|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|250|||Both|18 Years|65 Years|No|||December 2012|December 26, 2012|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065207||126684|
NCT01065220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP13214ONB|Sex Steroids and the Serotonin Transporter|The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography||Medical University of Vienna|Yes|Completed|February 2010|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|55 Years|No|||January 2014|January 2, 2014|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065220||126683|
NCT01064934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELAILa-01|Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a)|Randomized Controlled Trial of Efficacy and Safety of Lipid Apheresis for the Prevention of Cardiovasc. Events in Patients With Progr. Cardiovasc. Disease, Lp(a)≥ 60 mg/dl and LDL-C <130 mg/dl on Maximally Tolerated Lipid-lowering Therapy|ELAILa|Charite University, Berlin, Germany|Yes|Withdrawn|September 2010|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2010|June 3, 2015|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01064934||126705|
NCT01065181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Safethrow01|Youth Throwers Respond to Stretching|Shoulder Posterior Capsular Contracture in Youth Baseball Players: It Can be Improved by Stretching|Safethrow|Metzger, Charles, M.D.|No|Active, not recruiting|January 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1261|||Male|8 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|1261 male baseball players ages 8 to 15|February 2010|February 8, 2010|February 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01065181||126686|
NCT01065974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK80909-2|A Test of Nutritional Interventions to Enhance Weight Loss Maintenance|A Test of Nutritional Interventions to Enhance Weight Loss Maintenance||Drexel University|Yes|Active, not recruiting|October 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|295|||Both|18 Years|65 Years|No|||February 2016|February 6, 2016|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065974||126626|
NCT01065987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01221|Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Tizanidine Hydrochloride 4mg Tablets and Zanaflex® 4mg Tablets Administered As 1 x 4mg Tablet in Healthy Adult Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|September 2001|November 2001|Actual|September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 8, 2010|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065987||126625|
NCT01097551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080608|Endothelial Dysfunction and Diabetes|Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes|DENDI|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|38|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with type 1 diabetes: Diabetes duration >= 5 years, age >= 18 and <= 60 years        old, patients with no visible diabetic retinopathy, and no arterial hypertension        Healthy subjects: Sex and age-matched control healthy subjects|July 2012|July 2, 2012|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097551||124216|
NCT01097863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-346-C-010|Clinical Validation of the New Print on Focus DAILIES Toric|||Alcon Research|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|280|||Both|N/A|N/A|No|||January 2012|June 26, 2012|March 31, 2010|Yes|Yes||No|May 27, 2011|https://clinicaltrials.gov/show/NCT01097863||124192|
NCT01098149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THIRD-01|Tolerance to Hemodialysis in Insulin-Requiring Diabetic Patients: BD vs AFB With Blood Volume Biofeedback|Tolerance to Hemodialysis in Insulin-Requiring Diabetic Patients: a Prospective Randomized,Cross-over Multicenter Study Between Bicarbonate Dialysis (BD) and Blood Volume Controlled Acetate-Free Biofiltration (BVC-AFB)|THIRD|Università degli Studi di Brescia|Yes|Completed|March 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|85 Years|No|||March 2010|April 1, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01098149||124170|
NCT01098162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0973|Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug|A Non-interventional Post-marketing Study, Evaluating Seizure Control and Tolerability of Vimpat® as Adjunctive Therapy to One Baseline Antiepileptic Drug in Epilepsy Patients With Partial-onset Seizures With or Without Secondary Generalization in Daily Clinical Practice in Germany|VITOBA|UCB Pharma|No|Completed|March 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|576|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with Partial-Onset Seizures not sufficiently controlled with one Baseline        Antiepileptic Drug (AED), treated by Epilepsy centers, clinics or office-based        neurologists with adjunctive Vimpat® in routine daily practice.|August 2014|August 22, 2014|April 1, 2010|No|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT01098162||124169|
NCT01098435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33-101|ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Pilot Study of the Safety and Efficacy of RDC-0313 in Adults With Binge Eating Disorder||Alkermes, Inc.|No|Completed|May 2010|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||August 2011|August 18, 2011|April 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098435||124149|
NCT01098708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0067|This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy|Clinical Outcomes Validation in Non Ambulatory and Young Boys/Men With Duchenne Muscular Dystrophy (DMD)|DMD|Washington University School of Medicine|No|Recruiting|March 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|105|||Male|7 Years|22 Years|No|Non-Probability Sample|Non ambulatory boys and men with Duchenne muscular dystrophy|April 2010|April 1, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098708||124128|
NCT01098968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDUFIT|Education and Fitness: EDUFIT Study|Effects of a Physical Education Program Focused on Improving Physical Fitness in Adolescents Aged 12-14 Years|EDUFIT|Universidad de Granada|No|Completed|January 2007|September 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|70|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||September 2010|September 7, 2011|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01098968||124108|
NCT01099241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20076777|Central Venous Pressure (CVP) Assessment by Ultrasound and Physical Examination|Use of Ultrasound to Determine Central Venous Pressure in Critically Ill Patients||University of Iowa|No|Completed|August 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Intensive care unit.|March 2010|April 5, 2010|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01099241||124087|
NCT01099254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20076778|Internal Jugular Vein Cross Sectional Area|Effect of Position on Cross Sectional Area of IJV||University of Iowa|No|Completed|August 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Intensive care unit.|April 2010|April 5, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01099254||124086|
NCT01099280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gungorduk-08|Induction of Labor in Term Premature Rupture of Membranes: A Comparison Between Oxytocin and Dinoprostone Followed Six Hours Later by Oxytocin|||Erzincan Military Hospital||Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|225|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|April 8, 2011|April 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01099280||124084|
NCT01095159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP-TVTOxTVTS|TVTO™ X TVTS ™ for Treatment of Stress Urinary Incontinence|Comparative Study of TVTO™ X TVTS ™ for Treatment of Stress Urinary Incontinence|TVTOxTVTS|Federal University of São Paulo|Yes|Active, not recruiting|February 2009|December 2016|Anticipated|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Female|18 Years|90 Years|No|||March 2012|March 9, 2012|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095159||124398|
NCT01095471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/04|13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study|A follow-on, Multi-centre, Open-label, Clinical, Phase 4 Trial to Investigate the Persistence of Serotype-specific Antibodies at 40 Months of Age in Children Who Have Received Either the 7-valent or the 13-valent Pneumococcal Conjugate Vaccine at 2, 4 and 12 Months of Age and Assessing the Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Booster Dose Given at 40 Months of Age||University of Oxford|Yes|Completed|April 2010|March 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|39 Months|46 Months|Accepts Healthy Volunteers|||March 2011|March 21, 2011|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01095471||124374|
NCT01072994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|691|Fish Oil In Heart Transplantation|Fish Oil Effect on Heart Muscle Cells in Heart Transplant Patients (FOHMC)|FOHMC|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Not yet recruiting|April 2010|||April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||February 2010|February 19, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072994||126092|
NCT01073280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT150210|Cerebral, Meningeal Biopsy by Flexible Endoscopy in Patients Without Neurological Diagnosis|Cerebral, Meningeal Biopsy by Flexible Endoscopy in Patients Without Neurological Diagnosis||Universidad Autonoma de San Luis Potosí|No|Recruiting|November 2009|October 2010|Anticipated|January 2010|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|N/A|85 Years|No|Probability Sample|Patients between 0 and 85years old with neurological diseases that there are not a        diagnosis|February 2010|February 22, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073280||126071|
NCT01076686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402-C-318|Observational Study to Assess Long-Term Follow-Up of Breast Augmentation Subjects|An Observational Study to Assess the Long-Term Follow-Up of Subjects Who Had Participated in SKY0402 Breast Augmentation Studies||Pacira Pharmaceuticals, Inc|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|94|||Female|18 Years|N/A|No|Non-Probability Sample|All patients who had been exposed to study drug and had undergone breast augmentation.|December 2011|April 15, 2012|February 25, 2010|Yes|Yes||No|November 6, 2011|https://clinicaltrials.gov/show/NCT01076686||125809|
NCT01076699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVG-09-005|A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)|A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Four-Arm Trial to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo for the Treatment of Abdominal Pain in Patients With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)||Revogenex, Inc.|No|Suspended|March 2010|March 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|192|||Both|18 Years|75 Years|No|||July 2010|July 16, 2010|December 1, 2009|Yes|Yes|recruiting/enrolling participants has halted prematurely but potentially will resume Oct|No||https://clinicaltrials.gov/show/NCT01076699||125808|
NCT01067313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-RE-01-F|Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane|Evaluation of Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane in Intensive Care||Fresenius Medical Care France|No|Completed|July 2008|January 2011|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||February 2010|March 28, 2011|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067313||126523|
NCT01064947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT113706|Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis|Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study||Derm Research, PLLC|No|Completed|February 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|2 Years|N/A|No|||April 2013|April 24, 2013|February 8, 2010|No|Yes||No|April 24, 2013|https://clinicaltrials.gov/show/NCT01064947||126704|small number of subjects/short duration of study treatment
NCT01064726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011065|A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.|A Double Blind (3rd Party Open), 3-Way Crossover Study To Explore The Reproducibility Of Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis (Out Of Season) And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.||Pfizer|No|Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|19 Years|55 Years|No|||June 2010|June 1, 2010|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01064726||126721|
NCT01065493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44DA026682|QuitAdvisorMD: A Point-of-care Tool for Brief Smoking Cessation Interventions|QuitAdvisorMD: A Point-of-care Tool for Brief Smoking Cessation Interventions||Silverchair Science & Communications, LLC|No|Active, not recruiting|January 2011|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 18, 2014|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065493||126662|
NCT01065506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA027533|Smoking Termination Enhancement Project (STEP)|Smoking Termination Enhancement Project (STEP)|STEP|Southern Methodist University|Yes|Completed|September 2009|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 8, 2010||No||No|November 20, 2015|https://clinicaltrials.gov/show/NCT01065506||126661|
NCT01096680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-207|Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss|A Phase 2, Randomized, Double-Blind, Single Center, Parallel Group, Placebo and Active Comparator, Controlled Study to Evaluate the Pharmacodynamic Profile of Single Doses of SPD489 in Healthy Adult Male Subjects Undergoing a Nocturnal Period of Acute Sleep Loss||Shire|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|135|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2012|March 30, 2010|Yes|Yes||No|May 25, 2011|https://clinicaltrials.gov/show/NCT01096680||124281|
NCT01065740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phrq/09-01|Optimized Supervised Education Program for Peripheral Arterial Disease|Optimized Supervised Education Program for Peripheral Arterial Disease: Ambulatory Management With Patient Education|POPART|Rennes University Hospital|Yes|Recruiting|February 2010|February 2014|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||December 2012|December 4, 2012|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065740||126643|
NCT01065753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07220|Multi-faceted Evaluations Following Weight Reduction in Subjects With Metabolic Syndrome|Study of Wight Reduction by Life-style Modification||Taichung Veterans General Hospital|No|Completed|April 2008|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2009|February 8, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065753||126642|
NCT01065766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-182|Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of JANUMET in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|March 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4065|||Both|N/A|N/A|No|Probability Sample|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin in        usual practice|February 2015|February 18, 2015|February 8, 2010|No|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT01065766||126641|
NCT01097564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081214|COL4A1 Gene Related Cerebra-retinal Angiopathy|COL4A1 Gene Related Cerebra-retinal Angiopathy : Clinical Spectrum From Children to Adult, Mutational Spectrum and Application to Routine Management of Affected Patients : a Prospective Cohort Study|COL4A1|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|132|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  patients children          -  patients young adult          -  family adult symptomatic          -  family adult asymptomatic|January 2016|January 14, 2016|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01097564||124215|
NCT01097876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0401012|A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects|A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Healthy Volunteers When Combined With Donepezil||Pfizer|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 3, 2010|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01097876||124191|
NCT01098214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09310|The Role of Cytokines in Apparently Normal Pregnancies|The Role of Cytokines (and Other Biomarkers) in Apparently Normal Pregnancies||Winthrop University Hospital|No|Withdrawn|April 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Amniotic fluid samples from patients undergoing amniocentesis with an apparently normal      pregnancy will have a small aliquot of fluid stored for future analysis, including the      cytokine profile, proteomics, metabolomics, etc.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing amniocentesis with an apparently normal pregnancy|December 2014|December 9, 2014|April 1, 2010||No|Decided not to pursue study at this time. Resources not available|No||https://clinicaltrials.gov/show/NCT01098214||124165|
NCT01098175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52233|Peritoneal Cavity Conditioning During Open Surgery.|Peritoneal Cavity Conditioning During Open Surgery Decreases Postoperative Pain and Inflammation and Decreases Time to Restore Transit||Katholieke Universiteit Leuven|No|Not yet recruiting|April 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|60 Years|No|Non-Probability Sample|Standard open surgery such as hysterectomy, cancer surgery, bowel resections, cardiac        surgery|March 2010|April 1, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098175||124168|
NCT01098188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD20-0703|LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia|Open, Non-controlled, Multicentre, First-in-man Study Using Escalating Doses of LFB-R603 in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia||Laboratoire français de Fractionnement et de Biotechnologies||Completed|November 2008|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|80 Years|No|||April 2012|April 27, 2012|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01098188||124167|
NCT01098448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR-012861|Control of Periodontal Infections|Control of Periodontal Infections||The Forsyth Institute|No|Completed|September 1999|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Actual|187|||Both|20 Years|N/A|No|||April 2010|April 1, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098448||124148|
NCT01098721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBI-1001-102|A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks|A Double-blinded, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Topically Applied 1.0% WBI-1001 Cream for 12 Weeks, in the Treatment of Mild to Moderate Plaque Psoriasis.|134993|Welichem Biotech Inc.|Yes|Completed|January 2010|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098721||124127|
NCT01099007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL085405|Healthy Bodies, Healthy Hearts: A Physical Activity Intervention Trial|Phase II: Healthy Bodies, Hearts After Menopause|HBHH|University of Pittsburgh|No|Completed|June 2009|February 2011|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01099007||124105|
NCT01098981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEREVAST THERAPEUTICS CP-01|Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke|A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke|CLOTBUST-ER|Cerevast Therapeutics, Inc.|Yes|Terminated|May 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|675|||Both|18 Years|80 Years|No|||April 2015|April 3, 2015|April 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098981||124107|
NCT01099267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MDS-009|Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003|Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003||Celgene|Yes|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|54|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects Previously Enrolled in Celgene Protocol NCT00065156 (CC-5013-MDS-003)|November 2011|November 30, 2011|April 5, 2010||No||No|October 5, 2011|https://clinicaltrials.gov/show/NCT01099267||124085|
NCT01094912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08014/TALViSoP|Procedures of Locoregional Analgesia and Quality of Life in Palliative Care Units|Procedures of Locoregional Analgesia and Quality of Life in Palliative Care|TALViSoP|University Hospital, Limoges|No|Suspended|April 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|||Anticipated|38|||Both|18 Years|N/A|No|||March 2015|August 31, 2015|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094912||124417|
NCT01095497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-200|A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration|An Open-Label Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Versus Intravenous (IV) Administration of CINRYZE in Adolescents and Adults With Hereditary Angioedema (HAE)||Shire|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|12 Years|N/A|No|||April 2014|April 24, 2014|February 22, 2010|Yes|Yes||No|December 23, 2011|https://clinicaltrials.gov/show/NCT01095497||124372|
NCT01073306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 254|Safety and Immune Response to an Investigational Dengue Type 2 Vaccine|A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|February 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01073306||126069|
NCT01073319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23064|Rivastigmine as a Treatment for Methamphetamine Dependence|Rivastigmine as a Treatment for Methamphetamine Dependence||Baylor College of Medicine|Yes|Completed|July 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|17|||Both|18 Years|55 Years|No|||July 2012|July 25, 2012|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01073319||126068|
NCT01073527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1038|Hypertonic Saline as Add on Therapy in Preschool Children With Acute Wheezing Attack.|Interventional Study: Hypertonic Saline as Add on Treatment to the Usual Therapy for Preschool Children With Acute "Asthmatic" Attack Presenting to the ER: A Double Blind Control Study||Wolfson Medical Center|No|Completed|January 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|1 Year|6 Years|No|||August 2011|August 7, 2011|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01073527||126052|
NCT01073293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-007|A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)|A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds)||Merck Sharp & Dohme Corp.|Yes|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1054|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|February 19, 2010|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01073293||126070|
NCT01067898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS-S-D-II|A Study on Oral Vitamin D Megadoses|A Randomized, Double-blind, Placebo-controlled Study on Oral Vitamin D Megadoses - 100 000 or 200 000 IU Vitamin D3 Every Three Months||Helsinki University Central Hospital|No|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Female|70 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 26, 2012|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01067898||126480|
NCT01068158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP012|A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects|A Double-Blind Randomized Study to Compare the Efficacy, Safety, and Local Tolerability of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation|LICE OUT|Topaz Pharmaceuticals Inc|No|Completed|March 2010|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|371|||Both|5 Months|N/A|No|||April 2012|April 4, 2012|February 11, 2010|Yes|Yes||No|March 7, 2012|https://clinicaltrials.gov/show/NCT01068158||126460|
NCT01064141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD08|A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines|Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines||Sanofi|Yes|Completed|January 2010|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|210|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||February 2013|February 5, 2013|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064141||126766|
NCT01065194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007407-86|Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure|Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure - A Multicenter, Double-blind, Placebo Controlled Prospective Trial With Two Arms|LevoRep|Medical University Innsbruck|Yes|Recruiting|August 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||August 2009|August 27, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065194||126685|
NCT01096888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-FM|Fit Moms- an Internet-based Postpartum Weight Loss Program|FFit Moms- an Internet-based Postpartum Weight Loss Program|FM|California Polytechnic State University-San Luis Obispo|No|Completed|June 2010|November 2010|Actual|September 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|25|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096888||124265|
NCT01065467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-427|Panobinostat (LBH589) in Patients With Metastatic Melanoma|A Pilot/Phase I Study of Panobinostat (LBH589) in Patients With Metastatic Melanoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2010|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|February 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01065467||126664|
NCT01066013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB 2009-093|Antimicrobial De-escalation Strategy in Medical Patients|Antimicrobial De-escalation Strategy in Medical Patients||Fraser Health|No|Active, not recruiting|February 2010|June 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|N/A|No|||January 2010|August 17, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01066013||126623|
NCT01097889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013545|Evaluating the Relative Effectiveness of Two Feeding Interventions for the Treatment of Moderate Acute Malnutrition|Evaluating the Relative Effectiveness of Two Feeding Interventions for the Treatment of Moderate Acute Malnutrition in Children 6-60 Months of Age in Southern Ethiopia||The Hospital for Sick Children|No|Active, not recruiting|April 2009|July 2010|Anticipated|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2600|||Both|6 Months|60 Months|No|||March 2010|March 31, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097889||124190|
NCT01098227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147914|Exhaled Nitric Oxide Levels in Infants and Young Children Infected With RSV or Other Viral Infections|A Prospective Study Measuring Exhaled Nitric Oxide Levels in Infants and Young Children Admitted to the Hospital for Respiratory Syncytial Virus (RSV) or Other Viral Lower Respiratory Tract Infections||Winthrop University Hospital|Yes|Withdrawn|January 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|0|None Retained|Exhaled air for Nitric Oxide measurement|Both|N/A|4 Years|Accepts Healthy Volunteers|Probability Sample|Children admitted to Winthrop University Hospital with lower respiratory tract viral        illness, bronchiolitis or pneumonia.        The control group will include children in the same age range without respiratory        conditions and who are well enough to perform the test from the out patient setting|December 2015|December 23, 2015|March 18, 2010||No|The equipment to be used for the study was inoperable and not repairable.|No||https://clinicaltrials.gov/show/NCT01098227||124164|
NCT01098201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB - 27553|Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)|The Effect of Certolizumab on Lower Extremity Lymph Flow in Rheumatoid Arthritis||University of Rochester|No|Completed|October 2010|July 2014|Actual|July 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female RA sufferers not less than 18 yrs of age who are currently experiencing        knee synovitis. Racial and ethnic origin of subjects will be monitored to reflect the        diversity of our community.|September 2015|September 17, 2015|March 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01098201||124166|
NCT01098461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110932|Dose Ranging Study of Albiglutide in Japanese Subjects|A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|April 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|215|||Both|20 Years|75 Years|No|||April 2014|May 29, 2014|February 12, 2010|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01098461||124147|
NCT01098474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112899|Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants|Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants||GlaxoSmithKline||Completed|July 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|302|||Both|2 Months|7 Months|Accepts Healthy Volunteers|||July 2012|August 16, 2012|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098474||124146|
NCT01099020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULAB10008|Temporal Pattern of Circulating DNA for Patients Receiving Irradiation|Temporal Pattern of Circulating DNA for Patients Receiving Total Body Irradiation||University of Rochester|No|Terminated|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving large volume of radiation for the treatment of their cancer|May 2015|May 29, 2015|April 2, 2010||No|Funding for project was withdrawn|No||https://clinicaltrials.gov/show/NCT01099020||124104|
NCT01094951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30MH085943-03|Engaging Depressed Low-Income Seniors in Mental Health Services|Engaging Depressed Low-Income Seniors in Mental Health Services|ENGAGE|Weill Medical College of Cornell University|No|Active, not recruiting|March 2010|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|141|||Both|60 Years|N/A|No|||December 2014|December 18, 2014|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094951||124414|
NCT01098994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-CT-12|Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes|Pilot and Feasibility Study for a Pharmacogenomic Trial in Type 1 Diabetes|HAP-E|University of Pittsburgh|No|Completed|February 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|87|||Both|30 Years|N/A|No|||June 2014|June 2, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01098994||124106|
NCT01095172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RituxiRT|RituxiMab INDuction in Renal Transplantation|A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation|ReMIND|Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|November 2010|October 2023|Anticipated|October 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|612|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01095172||124397|
NCT01066949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK72325|Behavioral Intervention and Adherence in Dialysis|Behavioral Intervention and Adherence in Dialysis||University of Iowa|No|Completed|June 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|119|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066949||126551|
NCT01073904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14782|Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg|Open-label, Randomized, Crossover Study to Prove the Bioequivalence Between Opxion® (Levonorgestrel 1.5 mg Coated Tablet From Bayer de Mexico) and Postinor 2® (Levonorgestrel 1.5 mg Tablet From Biofarma Natural CMD) in Healthy Volunteers|LEVEQ-3|Bayer|No|Completed|September 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073904||126023|
NCT01074151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12938|The Cymbalta Pregnancy Registry|The Cymbalta Pregnancy Registry||Eli Lilly and Company|Yes|Recruiting|July 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|484|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning        on or after the first day of the last menstrual period|October 2015|October 23, 2015|February 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01074151||126004|
NCT01073540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14783|Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension|Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef Suspension From Bayer (Cephalexin Suspension 250 mg/5 mL) and Equivalent Concentration of Keflex Pediatrico From Eli Lilly (Cephalexin Suspension 125 mg/5mL) in Healthy Subjects||Bayer|No|Completed|September 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073540||126051|
NCT01073566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-00007|Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections|The Effects of Finesse on Glycemic Control in Adults With Diabetes Using MDI: Finesse vs. Pen or Syringe and Vial as Bolus Prandial Insulin Device||Calibra Medical, Inc.|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|75 Years|No|||March 2012|March 13, 2012|February 22, 2010||No||No|February 9, 2012|https://clinicaltrials.gov/show/NCT01073566||126049|The short duration of the study precludes comments on longer-term outcomes.
NCT01064167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWMZ013|Tranexamic Acid in Off-pump Coronary Surgery|Tranexamic Acid Reduces Blood Loss After Off-pump Coronary Artery Bypass Grafting|TAOPCAB|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Completed|February 2009|December 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|N/A|No|||February 2010|January 11, 2011|February 4, 2010||No||No|August 30, 2010|https://clinicaltrials.gov/show/NCT01064167||126764|
NCT01064180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02118|Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed Conditions|Randomized,2-way Crossover, Bioequivalence Study of Carvedilol 25 mg Film-coated Tablets and COREG® 25 mg Film-coated Tablets Administered as 1 x 25 mg Film-coated Tablet in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|May 2002|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 4, 2010|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064180||126763|
NCT01064739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN 1767|Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration|Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration||Vanderbilt University|No|Completed|January 2007|December 2012|Actual|September 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|February 5, 2010|Yes|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT01064739||126720|
NCT01064973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22007|An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders|An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders||Seaside Therapeutics, Inc.|No|Terminated|February 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|6 Years|17 Years|No|||December 2012|December 19, 2012|February 5, 2010|Yes|Yes|all active subjects were rolled into study 209AS209/NCT01706523|No||https://clinicaltrials.gov/show/NCT01064973||126702|
NCT01064960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|997677|Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner|Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner||Philips Healthcare|Yes|Completed|January 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|59 Years|No|||December 2012|December 3, 2012|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064960||126703|
NCT01096693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV.Procotol 2|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 2)|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers||University of Edinburgh|No|Suspended|August 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|March 30, 2010||No|Awaiting supply of peptide from a different company|No||https://clinicaltrials.gov/show/NCT01096693||124280|
NCT01065779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-267|FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of FOSAMAX PLUS and FOSAMAX PLUS D in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|March 2006|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|880|||Both|18 Years|N/A|No|Probability Sample|Patients with Osteoporosis treated with FOSAMAX PLUS or FOSAMAX PLUS D|July 2015|July 17, 2015|February 8, 2010|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT01065779||126640|
NCT01065792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0831-028|Stocrin Re-examination Study (0831-028)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of STOCRIN in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|March 2009|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|728|||Both|3 Years|N/A|No|Probability Sample|Patients with HIV-1 infection treated with STOCRIN|July 2015|July 20, 2015|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065792||126639|
NCT01097538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hicks -MS exercise|Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS)|Total Body Recumbent Stepper Training in Progressive MS: An Alternative Training Therapy for Patients With Impaired Mobility||Hicks, Audrey, Ph.D.|No|Completed|April 2010|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|60 Years|No|||August 2011|August 11, 2011|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097538||124217|
NCT01097824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0508|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2008|||||N/A|N/A|N/A||||||||||||||March 31, 2010|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097824||124195|
NCT01098240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3331017|A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression|A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression||Pfizer|Yes|Terminated|June 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|297|||Both|18 Years|65 Years|No|||July 2013|July 18, 2013|April 1, 2010|Yes|Yes|See termination reason in detailed description.|No|September 18, 2012|https://clinicaltrials.gov/show/NCT01098240||124163|
NCT01098500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113153|Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs|Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs Using the LabRx Database||GlaxoSmithKline|No|Completed|February 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3800|||Both|18 Years|N/A|No|Probability Sample|Retrospective cohort study using the LabRx medical claims EMR database. This database        contains medical claims information including diagnoses, treatments, medications, and        laboratory results for 23.3 million US residents. The study cohort included adult patients        (age ≥18 years) with any cancer diagnosed between October 1, 2004-June 1, 2009 who were        treated with 1 one or more of the TKI agents—erlotinib, gefitinib, dasatinib, imatinib,        nilotinib, or lapatinib. The index date for this cohort was the date of first        administration or prescription of the TKI agent on or following the date of the first        cancer diagnosis.|June 2011|September 1, 2011|April 1, 2010||No||No|May 2, 2011|https://clinicaltrials.gov/show/NCT01098500||124144|
NCT01098487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112940|A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)||GlaxoSmithKline|No|Completed|May 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|March 25, 2010|Yes|Yes||No|January 5, 2015|https://clinicaltrials.gov/show/NCT01098487||124145|
NCT01098734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBI-1001-202 : # 133148|Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream|A 12-week Efficacy Evaluation of WBI-1001 Cream in Patients With Atopic Dermatitis: A Multi-centered, Double-blinded Study (6-week Placebo-controlled Phase Followed by a 6-week Non-placebo Controlled Phase).||Welichem Biotech Inc.|Yes|Completed|November 2009|November 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098734||124126|
NCT01095185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLEPS|Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding|A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding||Hospital Clinic of Barcelona|No|Completed|November 2010|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||March 2015|March 18, 2015|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095185||124396|
NCT01094925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01|The Effectiveness of Gabapentin for Post-operative Pain Following Cesarean Section|The Effectiveness of a Pre-operative Single Dose Administration of Gabapentin for Management of Post-operative Pain Following Cesarean Section: a Randomised, Double-blind, Placebo-controlled, Dose-finding Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|April 2010|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|126|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 22, 2011|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094925||124416|
NCT01095731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA8597|The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage|Phase II Study of the Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage||Columbia University|Yes|Completed|April 2010|July 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|21 Years|N/A|No|||June 2015|June 9, 2015|March 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095731||124354|
NCT01066676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV/48.4|Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee|Prospective, Clinical Trial to Investigate Safety, Tolerability and Efficacy of Dexibuprofen Gebro 400 mg Powder for Oral Suspension (Test) Compared to Ibuprofen 400 mg Powder for Oral Suspension (Reference) in Patients Suffering From Osteoarthritis of the Hip or Knee||Gebro Pharma GmbH|No|Completed|October 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|482|||Both|18 Years|75 Years|No|||July 2012|July 9, 2012|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066676||126572|
NCT01066689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN07-YL RITUX-ERAH|Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation|Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation.|RITUX-ERAH|University Hospital, Tours|No|Recruiting|October 2008|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01066689||126571|
NCT01074411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02014|Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Active, not recruiting|April 2010|||April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||January 2016|March 4, 2016|February 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01074411||125984|
NCT01073579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13101A|Sabril Patient Registry|Sabril Patient Registry||Lundbeck LLC|Yes|Enrolling by invitation|August 2009|||August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15000|||Both|N/A|N/A|No|Non-Probability Sample|All patients in the U.S. who are prescribed Sabril must participate in this patient        registry in order to receive Sabril. There are no other eligibility criteria for this        study.|August 2015|August 17, 2015|February 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01073579||126048|
NCT01074398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000663840|Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182|ERCC1 Expression as a Predictor of Progression Free and Overall Survival in Patients With Epithelial Ovarian Cancer Treated on GOG Protocols 0172 and 0182||National Cancer Institute (NCI)||Not yet recruiting|February 2010|||March 2010|Anticipated|N/A|Observational|N/A|||Anticipated|513|||Female|18 Years|N/A|No|||February 2010|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074398||125985|
NCT01064453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14841|Angeliq Regulatory Post Marketing Surveillance|Angeliq Regulatory Post Marketing Surveillance|Angeliq rPMS|Bayer|No|Completed|June 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4078|||Female|N/A|N/A|No|Non-Probability Sample|Korean women who take Angeliq for postmenopausal symptoms or/and prevention of        osteoporosis|November 2013|November 18, 2013|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064453||126742|
NCT01065233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/8-M|Pangenomic Study During Alcoholic Cirrhosis|Genetical Predisposition in Hepatocellular Carcinoma : Pangenomic Link Study During Alcoholic Cirrhosis|CDCHC|Nantes University Hospital||Recruiting|May 2008|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|2 blood samples of 5ml for DNA extraction|Both|35 Years|70 Years|No|Probability Sample|2 groups with 2 subgroups:          -  patient with HCC          -  HCC with Child A          -  HCC with Child B/C          -  patient without HCC          -  Child A without HCC          -  Child B/C without HCC|April 2010|August 12, 2011|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065233||126682|
NCT01065246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-CAT-AC-04|Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites|Phase II Open Label Study to Evaluate the Safety of a Second I.P. Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Due to Carcinoma, Requiring Their First Therapeutic Puncture After Treatment in the CASIMAS Study|SECIMAS|Neovii Biotech|Yes|Completed|November 2009|October 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2012|October 2, 2012|January 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01065246||126681|
NCT01065480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6052/7087R|Training Clinicians in Motivational Interviewing|Training Motivational Interviewing Using Live Supervision|MITraining|New York State Psychiatric Institute|No|Recruiting|March 2010|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Substance Abuse Clinicians, Therapist and Counselors|April 2015|April 21, 2015|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065480||126663|
NCT01096706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV.Protocol 3|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 3)|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers||University of Edinburgh|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096706||124279|
NCT01097213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AA017900 SA2|Neural Mechanisms Underlying Alcohol Induced Disinhibition|Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 2: To Examine the Effect of Acute Alcohol Administration on Forebrain Disinhibition Using Functional Magnetic Resonance Imaging (fMRI)||Technische Universität Dresden|No|Completed|December 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|19 Years|Accepts Healthy Volunteers|Probability Sample|Residents living within 15 km (9.5 miles) from downtown Dresden|March 2013|March 11, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01097213||124241|
NCT01097226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR06-2009|Bioavailability and Vascular Effects of Apple Polyphenols|Bioavailability and Vascular Effects of Apple Polyphenols|POLYMALUS|Institute of Food Research|No|Completed|April 2010|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|12|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097226||124240|
NCT01097239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0808/43|Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer|A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer||Imperial College London|Yes|Recruiting|November 2009|||November 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|February 16, 2016|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097239||124239|
NCT01065077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14560|BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|COMPOSE 1|Bayer|Yes|Terminated|March 2010|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||November 2014|September 23, 2015|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065077||126694|
NCT01098747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-09-10|Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain|Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain: Study I||Pfizer|No|Completed|April 2010|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|335|||Both|16 Years|40 Years|No|||July 2012|July 12, 2012|April 1, 2010|Yes|Yes||No|July 12, 2012|https://clinicaltrials.gov/show/NCT01098747||124125|
NCT01098760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14898|Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients|A Phase IV, Single-arm, Open-label Study of Sorafenib (Nexavar®) in Advanced Hepatocellular Carcinoma (HCC)|HATT|Bayer|No|Completed|August 2010|October 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098760||124124|
NCT01099033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0066|The Biologic Basis of Hernia Formation|The Biologic Basis of Hernia Formation||Washington University School of Medicine|No|Enrolling by invitation|August 2007|||August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|small tissue biopsies of gastrohepatic, gastrophrenic, and phrenoesophageal ligaments|Both|18 Years|N/A|No|Non-Probability Sample|Patients to be enrolled in the study will be standard referrals to our group from primary        care physicians or other specialists who feel that surgical correction of a diaphragmatic        hernia or achalasia is necessary. Additionally, patients referred to our practice for        weight reduction surgery will also be considered eligible for enrollment.|April 2010|April 5, 2010|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01099033||124103|
NCT01094938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDICOAAS|Cardiac Output Monitoring in Aortic Aneurysm Surgery|||NHS Lothian|No|Completed|July 2007|July 2008|Actual|July 2007|Actual|N/A|Observational|N/A||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Edinburgh based trial in aortic aneurysm repair|March 2010|March 26, 2010|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094938||124415|
NCT01066130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI DNR 00-065|Psychosocial Treatment Intervention in Persons Newly Diagnosed With Rheumatoid Arthritis or Diabetes|Psychosocial Treatment Intervention in Persons Newly Diagnosed With Rheumatoid Arthritis or Diabetes||Karolinska Institutet|No|Completed|January 2001|December 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|65 Years|No|||February 2010|February 9, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066130||126614|
NCT01095510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-203|CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12|Open-Label, Single-Dose Study to Evaluate the Response and Pharmacokinetics/Pharmacodynamics of Different Doses of CINRYZE® [C1 Inhibitor (Human)] For Treatment of Acute Angioedema Attacks in Children Less Than 12 Years of Age With Hereditary Angioedema||Shire|No|Completed|March 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|9|||Both|2 Years|11 Years|No|||June 2014|July 14, 2015|March 24, 2010|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01095510||124371|Change in C1 INH antigen and functional C1 INH concentrations endpoint was not analyzed as no participants agreed to additional and optional blood sampling. As a result, no PK parameters were calculated for this study.
NCT01095523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100037|Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases|Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases||National Institutes of Health Clinical Center (CC)||Withdrawn|January 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||February 2012|March 20, 2012|March 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095523||124370|
NCT01066663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-421|Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Dana-Farber Cancer Institute|Yes|Recruiting|March 2010|February 2019|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||August 2015|September 2, 2015|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066663||126573|
NCT01066702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-01|Confirmatory Study of NeoCart in Knee Cartilage Repair|A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee||Histogenics Corporation|Yes|Recruiting|May 2010|June 2020|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|245|||Both|18 Years|59 Years|No|||March 2016|March 14, 2016|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066702||126570|
NCT01066715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052078|Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy||XOMA (US) LLC|Yes|Completed|January 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|421|||Both|18 Years|75 Years|No|||September 2011|September 30, 2011|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066715||126569|
NCT01074996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC-307PLAH-XJM|Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers|A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers|APC-S1|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Active, not recruiting|February 2010|July 2014|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|75 Years|No|||January 2014|January 15, 2014|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074996||125939|
NCT01075256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z3690607|Dose Response of a Tubule Occlusion Agent|An Exploratory Clinical Study to Evaluate the Efficacy of Two Currently Marketed Toothpastes Containing Different Concentrations of a Tubule Occlusion Agent||GlaxoSmithKline|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|195|||Both|18 Years|50 Years|No|||April 2013|April 25, 2013|February 23, 2010|Yes|Yes||No|September 23, 2011|https://clinicaltrials.gov/show/NCT01075256||125919|An issue with study product packaging was discovered post-study completion. The nature indicated that subject response was likely to have been liable to a positive bias. Efficacy cannot be considered as valid and no reliable conclusions possible.
NCT01074710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URA-09-001|Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers|A Phase I, Double-Blind, Placebo-Controlled, Randomized, 3-Period, Safety and Pharmacokinetic Study of 13C-uracil in a Semi-solid Meal at Single Oral Doses of 50, 100, and 200 mg in Healthy Volunteers||Otsuka Pharmaceutical Co., Ltd.|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|July 16, 2010|February 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01074710||125961|
NCT01064752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9133-26156-04|A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection|A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection||University of California, San Francisco|Yes|Completed|April 2005|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|Samples With DNA|Samples of both cerebrospinal fluid and blood will also be frozen and stored.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected subjects >18 years old not on antiretroviral therapy who are willing to        volunteer to take minocycline and undergo the four study LPs and other evaluations        recruited from the San Francisco Bay area.|April 2009|February 5, 2010|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064752||126719|
NCT01096121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071222|Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children|Interest of Angiotensin-converting Enzyme Inhibitors on Early Sickle Cell Renal Disease in Children. A Randomized, Double-blind Trial Enalapril vs Placebo.|MADREPIEC|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|June 2010|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|2 Years|18 Years|No|||June 2012|July 25, 2012|March 29, 2010||No|Not enough inclusions|No||https://clinicaltrials.gov/show/NCT01096121||124324|
NCT01096407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0928|Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel|The Role of COX-2 Mediated Prostaglandin Production on Paclitaxel-Induced Myalgias and Arthralgias.||Vanderbilt-Ingram Cancer Center|No|Terminated|November 2009|November 2010|Actual|November 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Probability Sample|Cancer patients that will be treated with paclitaxel.|March 2013|April 1, 2013|March 30, 2010||No|slow accrual|No||https://clinicaltrials.gov/show/NCT01096407||124302|
NCT01096927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 09079|Non Operative Treatment for Acute Appendicitis|Non Operative Treatment for Acute Appendicitis: Study on Efficacy and Safety of Antibiotic Treatment (Amoxicillin and Clavulanic Acid) in Patients With Right Sided Lower Abdominal Pain|NOTA|Maggiore Bellaria Hospital, Bologna|No|Completed|January 2010|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|14 Years|N/A|No|||January 2011|July 26, 2011|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096927||124262|
NCT01096940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00029|Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin|A Randomized, Open-label, 3-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Simvastatin During Coadministration With AZD1656 and to Evaluate the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin||AstraZeneca|No|Completed|March 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|44|||Both|18 Years|N/A|No|||November 2010|November 5, 2010|March 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01096940||124261|
NCT01096953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21MH079984-01|Telepsychiatry in Rural Youth|A Randomized Exploratory Study of Telepsychiatry Outcomes in Rural Youth||Oregon Health and Science University|Yes|Not yet recruiting|April 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Both|6 Years|17 Years|No|||March 2010|March 30, 2010|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096953||124260|
NCT01096901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-CTL|Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors|Weight Loss to Reduce Breast Cancer Risk Factors|CTL|California Polytechnic State University-San Luis Obispo|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|19|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096901||124264|
NCT01097252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCCH GY 1005|Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer|Randomized Trial of Concurrent Chemoradiation With Weekly Versus Three-week Cisplatin in Patients With Advanced Cervical Cancer||Korea Cancer Center Hospital|No|Completed|January 2002|December 2009|Actual|December 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Female|30 Years|75 Years|No|||May 2014|May 7, 2014|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01097252||124238|
NCT01097265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBZ-EnRoute+|Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery|The Influence of Micrometastases on Prognosis and Survival in Stage I-II Colon Cancer Patients: The EnRoute+ Study||National Cancer Institute (NCI)||Recruiting|July 2010|||January 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1500|||Both|18 Years|N/A|No|||September 2011|August 9, 2013|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097265||124237|
NCT01064830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1141|Topical Cyclosporine Suspension for the Treatment of Brittle Nails|A Single Center, Investigator-blinded Study of the Efficacy of Topical Cyclosporine 0.05% Ophthalmic Suspension (RESTASIS®) Under Occlusion Versus Vehicle in the Treatment of Brittle Nail Syndrome||University of North Carolina, Chapel Hill|No|Completed|February 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|February 5, 2010|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT01064830||126713|
NCT01064843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3M ESPE CR-09-020|Clinical Evaluation of the Mandibular Mini-Implant Overdenture|Clinical Evaluation of the Mandibular Mini-Implant Overdenture||3M|No|Completed|February 2010|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Both|N/A|N/A|No|Non-Probability Sample|Dental implant|May 2014|May 29, 2014|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064843||126712|
NCT01065090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIMS|A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis|A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis|ACTIMS|Biogen|Yes|Completed|June 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|38|||Both|18 Years|64 Years|No|Non-Probability Sample|Patients on AVONEX 3-6 months after treatment initiation|April 2015|April 9, 2015|February 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01065090||126693|
NCT01065337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDZ-SBE-2004|Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia|Study on Induced Wound Healing Through Application of Expanded Autologous Bone Marrow Stem Cells in Diabetic Patients With Ischemia-induced Chronic Tissue Ulcers Affecting the Lower Limbs||Ruhr University of Bochum|No|Completed|August 2005|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|80 Years|No|||May 2012|May 24, 2012|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065337||126674|
NCT01065584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSCITT10|An Observational Study to Assess the Effect of Calcineurin Inhibitors on Markers of Transplant Tolerance|An Observational Study to Assess the Effect of Calcineurin Inhibitors on Markers of Transplant Tolerance|OSCITT|University Medical Center Goettingen|Yes|Recruiting|February 2010|April 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|58|Samples Without DNA|Blood cells for fluorescence activated cell sorting and leukocytes for ImmuKnow/Cylex assay|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing liver transplantation|September 2011|September 14, 2011|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065584||126655|
NCT01065597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040324|Nonconvulsive Electrotherapy: a Proof-of-concept Trial|Nonconvulsive Electrotherapy: a Proof-of-concept Trial||University of Maryland|No|Completed|May 2010|April 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|February 8, 2010||No||No|June 12, 2015|https://clinicaltrials.gov/show/NCT01065597||126654|
NCT01065610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurolab_RD_001|Oxytocin Buffers Stress Response in Individuals With Impaired Coping Abilities|Oxytocin Buffers Cortisol Responses to Stress in Individuals With Impaired Coping Abilities||University of Osnabrueck||Completed|January 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|N/A|2||||||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2010|February 8, 2010|February 8, 2010||||No||https://clinicaltrials.gov/show/NCT01065610||126653|
NCT01066377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB/H00470X/1|PRIMAGE (Probiotics, Immunity and Ageing)|A Randomised, Controlled, Parallel Study to Determine the Immunomodulatory Effects of Pre- and Probiotics Upon the Immune Response to Influenza Vaccination in Young and Older Volunteers|PRIMAGE|University of Reading|No|Active, not recruiting|April 2010|January 2013|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2011|July 12, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066377||126595|
NCT01066390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015748-40|A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma|||Universitair Ziekenhuis Brussel|No|Completed|December 2009|May 2014|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||August 2012|May 5, 2014|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01066390||126594|
NCT01066403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03T-342-DRE|Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia|Dopaminergic Modulation of Prefrontal Functions in Schizophrenic Patients: Adjuvant Therapy With Pergolide||Heidelberg University|No|Completed|October 2003|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|65 Years|No|||December 2008|February 9, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066403||126593|
NCT01066728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E98:242|CO2 Inhalation as a New Treatment Modality for Apnea of Prematurity|||University of Manitoba|Yes|Completed|August 2001|March 2007|Actual|September 2005|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|27 Weeks|32 Weeks|No|||January 2010|March 1, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066728||126568|
NCT01067014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1318|The iO-Flex® Study: Evaluation of the Baxano iO-Flex® System for Decompressive Lumbar Surgery|The iO-Flex® Study: Evaluation of the Baxano iO-Flex® System for Decompressive Lumbar Surgery||Baxano Surgical, Inc.|No|Active, not recruiting|February 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at least 18 years of age presenting with failed conservative treatment for one or        two level lumbar spinal stenosis|September 2013|September 19, 2013|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067014||126546|
NCT01066026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-CBED08-02|Comparison of Safety and Efficacy of a Metallic Cannula Versus a Standard Needle to Inject Hyaluronic Acid for Nasolabial Fold|Double-blind, Randomized and Controlled Clinical Trial to Compare Safety and Efficacy of a Metallic Cannula vs a Standard Needle for the Injection of Hyaluronic Acid Gel Dermal Filler (Restylane®) to Treat Nasolabial Folds||Brazilan Center for Studies in Dermatology|No|Completed|July 2009|March 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2010|November 22, 2010|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01066026||126622|
NCT01075529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPH-2007-16|Early Prediction of Fluoxetine Response|Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine||Kaohsiung Kai-Suan Psychiatric Hospital|Yes|Completed|March 2007|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|18 Years|70 Years|No|||February 2010|February 24, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075529||125898|
NCT01066299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXT_PSY1|Influence of Oxytocin on the Startle Reflex and on Its Modulation|A Randomized, Double-blind, Placebo-controlled Single-center Study on the Influence of Oxytocin on the Startle Reflex and on Its Modulation in Healthy Male Subjects||University of Zurich|Yes|Recruiting|May 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01066299||126601|
NCT01065259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CON-I-07-CN-029-B|Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children|Randomized Control Study of Concerta and Strattera on the Improvement of Executive Function in Attention Deficit Hyperactivity Disorder Children||Peking University|Yes|Completed|April 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|262|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||July 2011|July 20, 2011|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065259||126680|
NCT01095900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TheodorBRI|Comparison of Botulinum Toxin and Sphincterotomy in the Treatment of Chronic Anal Fissure|||Theodor Bilharz Research Institute|Yes|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|55 Years|No|Probability Sample|This trial included consecutive adult patients presenting with symptomatic chronic anal        fissure in which conservative treatment had failed.|March 2010|March 29, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095900||124341|
NCT01096134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36448|Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention|Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention|MDI|Jhpiego|No|Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8000|||Female|9 Years|13 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01096134||124323|
NCT01096420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9713|Acupuncture in Chronic Migraine: A Randomized Controlled Trial|Acupuncture in Chronic Migraine: A Randomized Controlled Trial||Kuang Tien General Hospital|No|Completed|August 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|75 Years|No|||August 2013|August 12, 2013|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096420||124301|
NCT01097317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669234|First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer|NMES for Patients With NSCLC Receiving Palliative Chemotherapy. Is Neuromuscular Electrical Stimulation an Acceptable and Feasible Supportive Therapy for Patients With Non-Small Cell Lung Cancer Receiving Palliative Chemotherapy?||National Cancer Institute (NCI)||Recruiting|September 2009|||September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|52|||Both|16 Years|N/A|No|||September 2010|August 5, 2011|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097317||124234|
NCT01096914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|epatologia1|Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma|Radiofrequency Ablation Versus Laser Ablation for the Treatment of Small Hepatocellular Carcinoma: a Randomized Controlled Trial||Cardarelli Hospital|No|Completed|January 2009|November 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|85 Years|No|||January 2014|January 28, 2014|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096914||124263|
NCT01097278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0812|S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer|Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|November 2011|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|50 Years|No|||January 2015|January 7, 2015|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097278||124236|
NCT01097577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20100004H|A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery|A Comparison of Pregabalin (Lyrica®) to Placebo in Postoperative Pain Relief of Patients Status-post Photorefractive Keratectomy: A Double-masked Randomized Prospective Study||Wilford Hall Medical Center|Yes|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|N/A|No|||June 2010|June 21, 2010|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097577||124214|
NCT01064856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-883|Study of Adalimumab in Subjects With Peripheral Spondyloarthritis|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis||AbbVie|No|Completed|February 2010|May 2014|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064856||126711|
NCT01065103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03435|Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI)|Fractional Flow Reserve Stability Study of Non-culprit Vessels in Patients With ST Elevation Myocardial Infarction||Cardiology Research UBC|Yes|Completed|March 2010|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|19 Years|N/A|No|||September 2014|September 8, 2014|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065103||126692|
NCT01065350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22063|A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters|A Comparison of Ketofol (Ketamine and Propofol Admixture) vs. Propofol as Induction Agents on Hemodynamic Parameters||Mayo Clinic|Yes|Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|60 Years|No|||March 2013|March 21, 2013|February 7, 2010||No||No|February 15, 2013|https://clinicaltrials.gov/show/NCT01065350||126673|The dose ratio implemented was not ideal. Enrollment was limited to ASA I and II patients only.
NCT01065623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12672|Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors|An Open Label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY79-4620 Administered as an Intravenous Infusion Once Every 2 Weeks in Patients With Advanced Solid Tumors||Bayer|No|Terminated|April 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|February 8, 2010||No|The study was terminated due to safety reasons|No||https://clinicaltrials.gov/show/NCT01065623||126652|
NCT01065636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG031176|Lifestyle Intervention Trial in Obese Elderly|Exercise Interventions During Voluntary Weight Loss in Obese Older Adults|LITOE|Biomedical Research Institute of New Mexico|Yes|Active, not recruiting|February 2010|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|65 Years|85 Years|No|||January 2014|February 24, 2015|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065636||126651|
NCT01065857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-PICOS2006|Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.|Phase III, Multicenter, Randomized, Assessor-blind Study to Evaluate the Safety and Efficacy of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.||Laboratorios Casen-Fleet S.L.U.|No|Completed|January 2010|February 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|547|||Both|18 Years|80 Years|No|||April 2011|April 14, 2011|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065857||126634|
NCT01065870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD6491|Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)|Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma||Columbia University|Yes|Recruiting|December 2009|||December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065870||126633|
NCT01066143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001662|Generalized Anxiety and Seroquel|Pharmacotherapy of Generalized Anxiety Disorder With Seroquel: Normalization of Brain Stress and Reward Function|GAD|Mclean Hospital|Yes|Terminated|February 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 24, 2013|February 8, 2010||No|The underwriter stopped the funding|No||https://clinicaltrials.gov/show/NCT01066143||126613|
NCT01066416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Effects of Endoscopic Sinus Surgery for Chronic Sinusitis on Asthma Control|Effects of Endoscopic Sinus Surgery for Chronic Sinusitis on Asthma Control||NorthShore University HealthSystem Research Institute|Yes|Recruiting|July 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066416||126592|
NCT01066741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOMEODENT|Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer|Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer||Centre Leon Berard|No|Terminated|May 2009|August 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|78|||Both|18 Years|85 Years|No|||October 2012|October 31, 2012|February 5, 2010||No|insufficient recruitment, the planed sample size appears not achievable|No||https://clinicaltrials.gov/show/NCT01066741||126567|
NCT01066325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sit-n-Reach Study|Improving Flexibility With a Mindbody Approach|Improving Flexibility With a Mindbody Approach||Parker Research Institute|Yes|Completed|March 2010|August 2010|Actual|August 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|October 23, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066325||126599|
NCT01066312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMT Study|The Accuracy of Manual Muscle Testing|Investigating the Accuracy of Manual Muscle Testing for Distinguishing Congruent From Incongruent Statements Under Varying Levels of Blinding||Parker Research Institute|Yes|Completed|March 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|N/A||2|Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Practitioenrs - Healthcare providers - healthy adults          2. Testees - Healthy adults with no prior experience with MMT|November 2014|November 29, 2014|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066312||126600|
NCT01095913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0564|Fluorescent Dyes for Lymph Node Mapping|Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping||M.D. Anderson Cancer Center|Yes|Completed|March 2010|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||January 2015|January 7, 2015|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095913||124340|
NCT01096147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Octad study|Efficacy Study of the Octapolar Lead in Patients With Failed Back Surgery Syndrome (FBSS) With Chronic Pain|Octad Study: Evaluation of the Effectiveness of the Octopolar Lead in Patients With Failed Back Surgery Syndrome With Low Back and/or Leg Pain During a One Year Follow-up Period||Medtronic Neuromodulation Europe|Yes|Completed|February 2010|November 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096147||124322|
NCT01096433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-411|Circadian Variations of Prostaglandin in Sleep Apnea|Association of Circadian Variations,Sleep Architecture, Hypertension, and Prostaglandin in Sleep Apnea||Kyoto University|Yes|Completed|May 2010|January 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|20 Years|N/A|No|||January 2012|January 24, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096433||124300|
NCT01097330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEASE-VT|Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia|Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia: A Multi-center Randomized Trial|CEASE-VT|Population Health Research Institute|No|Terminated|August 2010|December 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|19 Years|84 Years|No|||August 2011|August 4, 2011|March 31, 2010||No|Anticipated non-feasibility of recruitment objectives|No||https://clinicaltrials.gov/show/NCT01097330||124233|
NCT01097603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTMED01-0310|Larsen & Toubro (L&T) Noninvasive Blood Pressure Module Performance Validation|L&T Noninvasive Blood Pressure Module Performance Validation||Larsen & Toubro Limited|No|Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|||||Both|1 Year|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Total 92 numbers of subjects or patients were studied during this study.|March 2010|March 31, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097603||124212|
NCT01097304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00450|Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia|Clinical Study of Ursodeoxycholic Acid in Barrett's Patients||National Cancer Institute (NCI)||Completed|April 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Both|18 Years|N/A|No|||October 2014|April 29, 2015|March 31, 2010|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01097304||124235|
NCT01097902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03012010-5102|Study of Experimental Models of Pain and Inflammation.|Experimental Inflammatory and Micro-incisional Pain Model Analysis by Gene Expression and Interstitial Fluid Proteomics of Skin Tissue||Stanford University||Completed|February 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|March 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01097902||124189|
NCT01064869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/NIR/03/32|A Nurse Led Programme to Improve Adherence in Difficult Asthma|Evaluation of the Benefits of an Individualised Menu Driven Nurse Led Programme to Improve Adherence in Difficult Asthma||Belfast Health and Social Care Trust|No|Completed|January 2005|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01064869||126710|
NCT01065116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMDIS -Blisterpack|Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs|Effectiveness and Treatment Adherence to Artemether/Lumefantrine Pre-packs Versus Blister Packs in the Treatment of Uncomplicated Malaria in Uganda||Malaria Consortium, Uganda|Yes|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|920|||Both|4 Months|7 Years|No|||May 2010|July 20, 2011|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065116||126691|
NCT01065363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906036R|Health Promotion and Management for Hepatitis B Carriers|Project of Health Promotion and Management for Hepatitis B Carriers in NTU Campus||National Taiwan University Hospital|Yes|Active, not recruiting|August 2009|December 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|160|||Both|18 Years|N/A|No|||February 2010|February 8, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065363||126672|
NCT01065649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102.0.398.000-09|Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients|Effect of Nortriptyline in the Cortical Representation of Heartburn in Patients With Nonerosive Reflux Disease|NORGERD|Universidade de Passo Fundo|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 14, 2012|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065649||126650|
NCT01065883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HL093346-01A1|The Community United to Challenge Asthma|A Family Intervention for Pediatric Asthma Self-Management in Puerto Ricans|Project CURA|Rush University Medical Center|No|Completed|October 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|18 Years|No|||August 2012|August 13, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01065883||126632|
NCT01066156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001664|Post-Traumatic Stress Disorder (PTSD) and Seroquel|Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes||Cambridge Health Alliance|Yes|Completed|February 2010|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|65 Years|No|||June 2015|June 13, 2015|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01066156||126612|
NCT01066429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-EDOCH14-R/07|DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma|Treatment With Infusional Dose-adjusted Etoposide/Vincristine/Doxorubicin/Bolus Cyclophosphamide/Dexamethasone and Rituximab (DA-EDOCH14-R) in Patients With Poor-prognosis Diffuse Large B-cell Lymphoma||Hospital Universitario Principe de Asturias|No|Recruiting|December 2009|December 2012|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||December 2009|February 11, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01066429||126591|
NCT01067092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK061289|MATCH: The Mexican-American Trial of Community Health Workers|MATCH: The Mexican-American Trial of Community Health Workers|MATCH|Rush University Medical Center|Yes|Completed|May 2005|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|21 Years|N/A|No|||November 2011|November 30, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067092||126540|
NCT01067326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007617|The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis|The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis||Mayo Clinic|No|Terminated|February 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|February 8, 2010|Yes|Yes|Novartis ended all studies regarding Aliskiren.|No|January 9, 2013|https://clinicaltrials.gov/show/NCT01067326||126522|The study was terminated early due to safety concerns from the ALTITUDE trial; there was an unexpected increase in adverse events (non-fatal stroke, renal complications, hyperkalemia and hypotension). Novartis ended all studies regarding Aliskiren.
NCT01066611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263-02|Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-263 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge||Gilead Sciences|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|55 Years|No|||May 2011|May 4, 2011|January 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01066611||126577|
NCT01066884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20569|A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer|||Hoffmann-La Roche||Completed|April 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|February 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01066884||126556|
NCT01096160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8266-002|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 (8266-002)(COMPLETED)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266||Merck Sharp & Dohme Corp.|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|40|||Male|15 Years|58 Years|No|||March 2015|March 17, 2015|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01096160||124321|
NCT01096173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUL_VABUF_01|Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum|Determination of the in Vitro Effects of CALM on COPD Sputum||Pulmatrix Inc.|No|Completed|April 2010|October 2010|Actual|June 2010|Actual|N/A|Observational|N/A||1|Anticipated|10|None Retained|Sputum samples|Both|35 Years|90 Years|No|Non-Probability Sample|Outpatient clinic setting|April 2011|April 7, 2011|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01096173||124320|
NCT01096472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 552 000-0919|Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis|Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis||Almirall, S.A.|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||November 2010|July 5, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096472||124297|
NCT01096446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSF-118|Intravenous Fat Emulsions and Premature Infants|Tolerance of Higher Infusion Rates of Intravenous Fat Emulsions in Extremely Low Birthweight Infants During the First Week of Life||OSF Healthcare System|Yes|Terminated|April 2008|July 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|2 Days|No|||November 2014|November 19, 2014|March 30, 2010||No|To many infants in the experimental group developed hypertriglyceridemia|No|November 25, 2013|https://clinicaltrials.gov/show/NCT01096446||124299|This study was terminated early because 100% of the infants in the experimental grouped developed hypertriglyceridemia (>200 gm/dl), which did not support our primary hypothesis.
NCT01096459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-029|Nerve Rerouting Treatment for Neurogenic Bladder in Spina Bifida|Safety and Efficacy of Nerve Rerouting for Treating Neurogenic Bladder in Spina Bifida||William Beaumont Hospitals|Yes|Withdrawn|January 2013|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|5 Years|N/A|No|||July 2013|July 31, 2013|March 23, 2010|No|Yes|Protocol as presented by investigator was not approved by the NIDDK.|No||https://clinicaltrials.gov/show/NCT01096459||124298|
NCT01096719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 8107 B|The Healthy Eating Choices for Life Program|The Effect of Diets Targeting Energy Density and Energy Restriction on Weight Loss and Feelings of Deprivation, Satisfaction, and Hunger During Behavioral Weight Loss Treatment.|HEC4L|University of Tennessee|No|Completed|January 2010|August 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|21 Years|65 Years|No|||November 2012|November 14, 2012|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01096719||124278|
NCT01097590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLA001|A Study to Evaluate a Leukapheresis Treatment in Patients With Ulcerative Colitis|A Randomized Placebo Controlled, Single Centre Study to Evaluate a Novel Leukapheresis Treatment in Patients With Ulcerative Colitis.||IBD Column Therapies International AB|No|Completed|March 2010|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|75 Years|No|||March 2010|August 20, 2013|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01097590||124213|
NCT01064583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flavanols-PAD|Cocoa Flavanols and Painfree Walking Distance|Long-term Effect of Dietary Intervention With Flavanol-containing Cocoa on Vascular Function of Diabetic Patients||Heinrich-Heine University, Duesseldorf|No|Completed|October 2009|December 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|62|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064583||126732|
NCT01064596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908104|Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery|Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2010|May 2014|Actual|April 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|4 blood samples to measure anti-Xa activity|Both|18 Years|N/A|No|Non-Probability Sample|obesity patients who need a bariatric surgery|September 2014|September 25, 2014|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01064596||126731|
NCT01064882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-051|Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence|||Allergan||Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Female|30 Years|55 Years|No|||November 2011|November 7, 2011|February 5, 2010|Yes|Yes||No|August 18, 2011|https://clinicaltrials.gov/show/NCT01064882||126709|
NCT01064895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-CL0015 Revision C|Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)|Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)|PROVIDE|Angiodynamics, Inc.|No|Active, not recruiting|February 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|For use in patients undergoing medical, interventional, or surgical procedures, where the        procedure carries an elevated risk of iatrogenic acute kidney injury for the patient. Also        indicated in patients who have demonstrated symptoms of acute kidney injury, and in whom        arterial catheterization with the Benephit infusion systems is feasible.|September 2011|September 26, 2011|February 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01064895||126708|
NCT01065129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0150 / 201101810|Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)|A Phase I Trial Evaluating the Effects of Plerixafor (AMD3100) and G-CSF in Combination With Azacitidine (Vidaza) for the Treatment of MDS|MDS|Washington University School of Medicine|No|Active, not recruiting|September 2010|March 2016|Anticipated|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|February 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01065129||126690|
NCT01065142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0067|ETIC (Therapeutic Education in Heart Failure)|Does Therapeutic Education Improve Heart Failure Patient Quality of Life?|ETIC|University Hospital, Clermont-Ferrand||Active, not recruiting|April 2011|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|200|||Both|50 Years|N/A|No|||March 2014|March 27, 2014|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065142||126689|
NCT01065376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-99-DR-28|The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation|The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation in Women Undergoing Assisted Reproduction||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Completed|January 2010|July 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||April 2011|July 20, 2011|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065376||126671|
NCT01065662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-397|AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies|A Phase I/IB Study fo AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2010|||September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||August 2015|August 6, 2015|February 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01065662||126649|
NCT01065675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-068|Medication Histories Conducted by Nurses (RNs), Pharmacy Techs (CPhTs) & Pharmacists (RPhs)|Electronic Patient Triage Development and Implementation Involving Nurse (RN), Pharmacy Technician (CPhT), and Pharmacist (RPh) Obtained Medication Histories in the Emergency Department (ED)and Impact on Medication Reconciliation||Wesley Medical Center|No|Terminated|February 2010|May 2011|Actual|April 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|1||Actual|153|||Both|N/A|N/A|No|||December 2012|December 26, 2012|February 3, 2010||No|Statistical analysis of 153 enrolled Phase 1 patients showed that specific patients could not    be targeted for medication histories by discipline.|No||https://clinicaltrials.gov/show/NCT01065675||126648|
NCT01065896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4162C-12|Coronary Computed Tomography (CT) to Measure Coronary Calcification in Spinal Cord Injury (SCI)|The Use of Non-invasive Multidetector Coronary Computed Tomography Imaging for the Assessment of Coronary Calcification in Persons With Spinal Cord Injury||VA Office of Research and Development|No|Completed|February 2010|February 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|70 Years|No|Non-Probability Sample|SCI subjects will be included in the study if they have moderate or high risk for coronary        heart disease, who have participated in a previous screening study.|October 2012|October 2, 2012|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065896||126631|
NCT01066169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09.187|Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza|Immune Response After Vaccination Against Pandemic A/H1N1 Influenza in the Immunocompromised Host. Vaccination Response in ImmunoCompromised Host|RICH-3|Leiden University Medical Center|Yes|Completed|November 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|104|Samples Without DNA|Serum, Plasma, Peripheral blood mononuclear cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|HIV patients at the department 'Infectious Diseases' of the Leiden University Medical        Centre and healthy volunteers (hospital employees of the Leiden University Medical Centre)|February 2010|January 27, 2012|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066169||126611|
NCT01066442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-11 / BF2.649|Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease|A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase|HARPS2|Bioprojet|No|Completed|March 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|273|||Both|30 Years|80 Years|No|||April 2013|April 11, 2013|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066442||126590|
NCT01066767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02041|Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|April 2002|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 9, 2010|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066767||126565|
NCT01067911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00188|Optimizing Dietary Fatty Acids to Lower Metabolic Risk Factors Among Canadians|Optimizing Dietary Fatty Acids to Lower Metabolic Risk Factors Among Canadians||University of British Columbia|No|Suspended|July 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Anticipated|56|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 24, 2011|February 10, 2010||No|The protocol needs to be revised to enable accurate results|No||https://clinicaltrials.gov/show/NCT01067911||126479|
NCT01065818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD5444|Early Prediction of Pathologic Complete Response (pathCR) With Fluoro-L-Thymidine (FLT) Positron Emission Tomography (PET)|Early Prediction of Pathology Response of Chemoradiotherapy With Fluoro-L-Thymidine (FLT) Positron Emission Tomography (PET)||Columbia University|Yes|Recruiting|August 2009|August 2014|Anticipated|August 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2011|October 27, 2011|February 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01065818||126637|
NCT01066065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCIII0110|Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients|Metabolic Profile and Cardiovascular Biomarker Pattern Compared in naíve Patients Initiating HAART With TDF-FTC and Raltegravir 400mg BID Vs Darunavir 800 mg Plus Ritonavir 100 mg QD; a One Year Follow-up Observational Study||Hospital Carlos III, Madrid|No|Recruiting|February 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Consecutive naïve patients regularly attended at a referral outclinic. 1:1 Randomization        in two arms by a local electronic process.|February 2010|June 24, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066065||126619|
NCT01066078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGEA01 - CAP PEA|Echocardiography and Peak Endocardial Acceleration (PEA) Measurements in Cardiac Resynchronization Therapy (CRT)|Echocardiography and PEA Measurements in CRT Therapy||LivaNova|No|Completed|October 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|216|||Both|18 Years|N/A|No|Probability Sample|CRT recipients|March 2010|March 4, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066078||126618|
NCT01066338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-10-070|Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype|Genome-wide Pharmacogenetic Candidate Gene SNP Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype||Samsung Medical Center|Yes|Recruiting|February 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|Samples With DNA|The stored bone marrow specimens of patients with normal karyotype AML who were treated with      chemotherapy|Both|18 Years|N/A|No|Non-Probability Sample|The patients who were diagnosed as acute myeloid leukemia with normal karyotype will be        enrolled.|February 2010|February 17, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01066338||126598|
NCT01096485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13956|Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel|Open-label, Randomized, Crossover Study to Compare the Bioavailability of One Coated Tablet of Opxion® (Levonorgestrel 1.5 mg From Bayer de Mexico) vs. Two Tablets of Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers|LEVEQ-1|Bayer|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 9, 2013|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096485||124296|
NCT01096511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14537|Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)|Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)||Bayer|No|Completed|December 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1001|None Retained|n.a.|Both|18 Years|N/A|No|Non-Probability Sample|Adult female and male patients with cIAI, who are at least 18 years of age and are        scheduled to be treated with Moxifloxacin infusion, can be documented after the therapy        decision has been made.|June 2013|June 20, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01096511||124294|
NCT01096732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRD 201014|Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)|Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period|HIPPoS|Cambridge University Hospitals NHS Foundation Trust|No|Terminated|February 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|March 30, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01096732||124277|
NCT01096966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K843-09-2001|Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Bupivacaine TTS (Bupivacaine Patch) in Patients With Chronic Low Back Pain||Pfizer|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|70 Years|No|||August 2011|May 24, 2012|March 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096966||124259|
NCT01096979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-102-CL-04|An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity|A Double-Masked, Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity||Neothetics, Inc|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|October 16, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096979||124258|
NCT01064323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00011747|Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study|Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study||Johns Hopkins University|No|Recruiting|January 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||May 2010|May 27, 2010|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064323||126752|
NCT01064063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU29|Randomized Controlled Clinical Evaluation to Compare Vanguard Cruciate Retaining and AGC Total Condylar Knee Implants|Randomized Controlled Clinical Evaluation to Compare Vanguard Cruciate Retaining and AGC Total Condylar Knee Implants|Vanguard|Biomet, Inc.|No|Active, not recruiting|May 2011|June 2023|Anticipated|February 2022|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||September 2014|June 25, 2015|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064063||126772|
NCT01064570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDA2000|AIDA 2000 Guidelines|Guidelines for Treatment of Acute Promyelocytic Leukemia||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|May 2000|||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|1 Year|60 Years|No|||November 2010|November 24, 2010|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064570||126733|
NCT01064609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-003232-38|"Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps.|"Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps:a Randomized Clinical Trial"||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|June 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|75|||Both|18 Years|80 Years|No|||June 2011|January 21, 2013|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064609||126730|
NCT01064908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/181/HAR|A New Oxygen Mask for Carotid Endarterectomy Under Local Anaesthesia|A Study To Determine The Effectiveness Of A New Oxygen Mask At Increasing Arterial Oxygen Content During Carotid Endarterectomy Under Local Anaesthesia||Brighton and Sussex University Hospitals NHS Trust|No|Completed|January 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|16 Years|N/A|No|Non-Probability Sample|Vascular Surgical Outpatients, booked for CEA under local anaesthetic|August 2013|August 7, 2013|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01064908||126707|
NCT01065402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPB-R-203-01|A Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With Diabetes|A Randomized, Two-Regimen, Crossover, Comparative Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With Diabetes||Pharma Power Biotec Co., Ltd.||Recruiting|February 2010|April 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|20|||Both|20 Years|65 Years|No|||February 2010|February 8, 2010|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01065402||126669|
NCT01065415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07-019|Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC)|The Efficacy of Coregistered Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer||Samsung Medical Center|No|Completed|February 2010|October 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|272|||Both|20 Years|N/A|No|Probability Sample|Patient under the suspicion of lung cancer or Patients with NSCLC proved at pathologic        examination|December 2011|December 25, 2011|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065415||126668|
NCT01065389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRI/2010/091/000014|Resistance Training in Intradialysis Patients|Phase 1 RCT of Progressive Resistance Training on Small Solute Clearance, Functional Capacity and Quality of Life in Intradialysis Patients|DIAPRE|Sikkim Manipal University|Yes|Active, not recruiting|October 2010|August 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|30 Years|60 Years|No|||September 2013|September 8, 2013|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01065389||126670|
NCT01065935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-RSV01-109|Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)|A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)||Alnylam Pharmaceuticals|Yes|Completed|February 2010|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065935||126629|
NCT01066793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV21020|PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naïve HCV-infected Patients Treated With Pegylated Interferons.||Hoffmann-La Roche||Completed|October 2007|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2272|||Both|18 Years|N/A|No|Probability Sample|Patients receiving peginterferon alfa treatment at a medical centre|November 2015|November 2, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066793||126563|
NCT01065909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIREG_L_04182|Observatory on Elderly Patients "Les S.AGES"|National Observatory on the Therapeutic Management in Ambulatory Care Patients Aged 65 and Over, With Diabetes Type 2, Chronic Pain or Atrial Fibrillation||Sanofi||Completed|May 2009|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3491|||Both|65 Years|N/A|No|Non-Probability Sample|Ambulatory primary care patient over 65 years|October 2014|October 2, 2014|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065909||126630|
NCT01066182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0603/49|The DHA (Docosahexaenoic Acid) Oxford Learning and Behaviour (DOLAB) Study|A Randomised Controlled Trial of DHA (Docosahexaenoic Acid)for Learning and Behaviour in Children Aged 7 - 9 Years|DOLAB|University of Oxford|Yes|Completed|January 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|7 Years|10 Years|No|||February 2010|October 27, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066182||126610|
NCT01066780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0309|ClearVoice Sound-processing Strategy for AB HiRes 120 Cochlear Implant Users|Evaluation of the ClearVoice™ Strategy in Adults Using HiResolution® Fidelity 120® Sound Processing||Advanced Bionics|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|February 9, 2010|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT01066780||126564|
NCT01067664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHR-7|Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome|The Effect of Serum Progesterone Levels on the Day of hCG Administration on the Probability of Pregnancy in Patients Treated by IVF Using GnRH Antagonists and Recombinant Gonadotrophins|PROG2|Aristotle University Of Thessaloniki|No|Completed|May 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|Samples Without DNA|6ml of serum will be frozen and stored for later analysis|Female|18 Years|39 Years|No|Probability Sample|Women undergoing ovarian stimulation with the use of rFSH and GnRH antagonists for        in-vitro fertilization.|June 2013|October 17, 2013|November 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01067664||126497|
NCT01068184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2580C00001|A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase I, Randomised, Double-Blind, Placebo-Controlled, 3-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD6553 in Healthy Volunteers (Parts A and B) and Patients (Part C) With Chronic Obstructive Pulmonary Disease||AstraZeneca|No|Terminated|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|109|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 22, 2010|February 11, 2010||No|temporary hold in May 2010 due to an emerging PK profile that could not be aligned to the    known pharmaceutical properties of the IMP (AZD6553).|No||https://clinicaltrials.gov/show/NCT01068184||126458|
NCT01066637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0986|iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.|Imaging iNOS Activity Using [18F] (+/-) NOS With Positron Emission Tomography (PET) in Cellular Inflammation.|F-NOS|Washington University School of Medicine|Yes|Active, not recruiting|September 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066637||126575|
NCT01066923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMW-2008-FP-01638|Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation|Enhanced Firefighter Rehab Trial|EFFoRT|University of Pittsburgh|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|124|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01066923||126553|
NCT01068067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC+WUZHI|Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Recipients|Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Chinese Renal Transplant Recipients: A Prospective Randomized Controlled Study||Sun Yat-sen University|No|Recruiting|March 2010|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||January 2010|July 26, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068067||126467|
NCT01068080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Toujinkai Clincal Study-2|Involvement of FFA Metabolism and Insulin Resistance in Cardiac Death|Prediction of Impaired Myocardial Fatty Acid Metabolism and Insulin Resistance for Cardiac Death of Hemodialysis Patients With Normal Coronary Arteries|CD_HD_FAIR|Toujinkai Hospital|No|Completed|January 2001|December 2004|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|||Both|40 Years|90 Years|No|Non-Probability Sample|Hemodialysis patients who had normal coronary arteries identified by coronary angiography        and underwent the examination of BMIPP SPECT and measurement of HOMA-IR as a parameter of        insulin resistance.|October 2000|February 11, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068080||126466|
NCT01096745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNUHIRB-2010-5|Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer|Randomized Phase II Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer Patients||Gyeongsang National University Hospital|No|Terminated|July 2010|September 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|20 Years|N/A|No|||June 2011|June 21, 2011|March 30, 2010||No|Planning for randomized phase III trial for this issue.|No||https://clinicaltrials.gov/show/NCT01096745||124276|
NCT01096992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0546|Fludarabine, Bendamustine, and Rituximab (FBR) in Chronic Lymphocytic Leukemia (CLL)|A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2010|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|16 Years|N/A|No|||August 2015|August 10, 2015|March 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096992||124257|
NCT01097005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-765|Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections|Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections||Abbott||Completed|January 2009|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|203|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with Pulmonary non-tuberculous mycoplasma infection and who are indicated for        treatment with Klaricid|May 2014|May 22, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01097005||124256|
NCT01064076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-03909|S-ICD® System IDE Clinical Study|S-ICD® System Clinical Investigation||Boston Scientific Corporation|Yes|Active, not recruiting|January 2010|October 2013|Anticipated|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|330|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064076||126771|
NCT01064336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113327|Promacta Pregnancy Registry|Promacta Pregnancy Registry||GlaxoSmithKline|No|Recruiting|March 2010|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|Women exposed to eltrombopag during pregnancy, as well as infants whose mothers were        exposed to eltrombopag during pregnancy.|May 2015|May 8, 2015|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01064336|6 Years|126751|
NCT01064622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01454|Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer|A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)||National Cancer Institute (NCI)||Completed|September 2009|January 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|21 Years|N/A|No|||March 2014|July 20, 2015|February 5, 2010|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01064622||126729|
NCT01064635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000665188|Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)|Letrozole Adjuvant Therapy Duration (LEAD) Study: Standard Versus Long Treatment. A Phase III Trial in Post-Menopausal Women With Early Breast Cancer.|GIM4|National Institute for Cancer Research, Italy||Active, not recruiting|August 2005|||August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2056|||Female|18 Years|N/A|No|||May 2015|May 22, 2015|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064635||126728|
NCT01064921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09120|Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma|A Phase I Trial Of Vorinostat In The Treatment Of Advanced Laryngeal, Hypopharyngeal, Nasopharyngeal And Oropharyngeal Squamous Cell Carcinoma Of The Head And Neck.||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|February 2010|||August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064921||126706|
NCT01066221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-001|Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile|Comparative Study of Enzyme Immunoassays:Techlab Toxins A&B, C Diff Quick Check for Glutamate Dehydrogenase (GDH);3 PCRs,and Cytotoxin Assay (CTA) for the Detection of Clostridium Difficile Toxin in Adult Stool Specimens||McMaster University|No|Completed|September 2009|May 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|470|||Both|12 Years|N/A|No|Probability Sample|Hamilton Regional Laboratory Medicine Program - patients with clostridium difficile|February 2010|July 19, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066221||126607|
NCT01065688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMU-GC03|A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer|A Prospective Randomized Controlled Trial Comparing Billroth-I Reconstruction With Roux-en Y Reconstruction After Distal Gastrectomy for Gastric Cancer||Wakayama Medical University|Yes|Recruiting|January 2009|December 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|80 Years|No|||September 2010|September 8, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01065688||126647|
NCT01066806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-14739|Adequate Dairy Intake on Weight Change in Girls|Efficacy of Optimal Levels of Dietary Dairy on Modulation of Adolescent Weight|DQ|Creighton University|Yes|Completed|July 2008|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|274|||Female|13 Years|14 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01066806||126562|
NCT01067118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01292010-4823|A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.|Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Glycemia||Stanford University|Yes|Suspended|April 2010|June 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|20|||Both|18 Years|50 Years|No|||January 2011|January 31, 2011|February 9, 2010|Yes|Yes|The study was suspended due to lack of study drug|No||https://clinicaltrials.gov/show/NCT01067118||126538|
NCT01066195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-04-030|Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy|A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy||Samsung Medical Center||Enrolling by invitation|May 2008|||October 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|129|||Both|18 Years|N/A|No|||February 2010|February 9, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01066195||126609|
NCT01066208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACREULAR001|American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis|ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis|DCVAS|University of Oxford|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||14|Anticipated|3588|Samples With DNA|Patients may be given the option of having blood, urine or other tissue obtained as part of      their routine care retained for use in future ethically approved studies. They may also be      asked to provide additional blood to be stored for this purpose. This component is an      optional extra, and does not form part of the main study.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with primary systemic vasculitis or a mimic of these diseases seen in        participating secondary or tertiary care centres in Europe, USA, Mexico, Japan, Asia,        Australasia.|June 2014|June 3, 2014|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066208||126608|
NCT01066455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITT1109|Cardiac Outcome Measures in Children With Muscular Dystrophy|PITT1109: Cardiac Outcome Measures in Children With Muscular Dystrophy||Cooperative International Neuromuscular Research Group|Yes|Completed|January 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|48|None Retained|Prospective collection of blood sample for BNP measurements.|Both|8 Years|18 Years|No|Non-Probability Sample|8 to 18 years old Confirmed diagnosis of Duchenne, Becker, or autosomal recessive        limb-girdle muscular dystrophy (LGMD: 2C-2F and 2I)|January 2013|January 10, 2013|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066455||126589|
NCT01066754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02040|Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|April 2002|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 9, 2010|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066754||126566|
NCT01067924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22490|Motivational Interviewing to Promote Maintenance of Physical Activity in People With Type 2 Diabetes|Motivational Interviewing to Promote Maintenance of Physical Activity in People With Type 2 Diabetes||University of Calgary|Yes|Completed|September 2009|August 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|80 Years|No|||July 2014|July 17, 2014|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067924||126478|
NCT01064206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_03/0814|ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease|Study of Psychological and Addictive Profile of Patients With Buerger's Disease|ADDICTAO|University Hospital, Lille|No|Recruiting|September 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|urine|Both|18 Years|N/A|No|Non-Probability Sample|We include 200 Buerger's disease patients and 200 atheromatous arteritis patients, smoking        tobacco or cannabis|December 2015|December 1, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064206||126761|
NCT01064219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hCG and Treg cells|Intrauterine Human Chorionic Gonadotrophins (hCG) and Endometrial Treg Cells|The Effect of Intrauterine Injection of Human Chorionic Gonadotrophins (hCG) on the Endometrial T-regulatory Cells and the Electronmicroscopic Endometrial Characteristics||The Egyptian IVF-ET Center|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|20|||Female|20 Years|38 Years|No|||December 2010|November 2, 2013|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064219||126760|
NCT01067261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-2008-127|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Preservation and Restoration of Urinary Continence and Erectile Function and in the Treatment of Erectile Dysfunction and Urinary Incontinence in Conjunction With Nerve Sparing Radical Prostatectomy|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Preservation and Restoration of Urinary Continence and Erectile Function and in the Treatment of Erectile Dysfunction and Urinary Incontinence in Conjunction With Nerve Sparing Radical Prostatectomy||Copenhagen University Hospital at Herlev|No|Completed|February 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Male|18 Years|N/A|No|||December 2012|May 23, 2013|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067261||126527|
NCT01075620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-2-16|Comparison of Nonposterior- and Posterior-Stabilized Mobile-Bearing Total Knee Arthroplasty|Comparison of Nonposterior- and Posterior-Stabilized Mobile-Bearing Total Knee Arthroplasty A Prospective, Randomized Study||Ewha Womans University|Yes|Completed|May 2002|January 2010|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|30 Years|90 Years|No|||January 2010|February 24, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01075620||125891|
NCT01067547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA 2009 TL|A Trial of Iron Replacement in Patients With Iron Deficiency.|A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency.||University of Alberta|No|Completed|March 2010|May 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|75 Years|No|||April 2015|April 28, 2015|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067547||126505|
NCT01064050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708042|Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers|Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence After Therapeutic Bronchoscopy in Lung Cancers (SPOC Study)|SPOC|Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|November 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 2, 2010||No|Difficulty to include patient|No||https://clinicaltrials.gov/show/NCT01064050||126773|
NCT01068093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-ACS-E|The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome|Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome||Yokohama City University Medical Center|No|Recruiting|October 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|N/A|No|||October 2010|October 21, 2010|February 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01068093||126465|
NCT01064089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSP990A1101|Dose Escalation of HSP990 in Japan/Korea|A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally Once Weekly in Adult Japanese and Korea Patients With Advanced Solid Malignancies||Novartis||Terminated|February 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01064089||126770|
NCT01064102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007-06|Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition|Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|January 2006|February 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 5, 2010|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064102||126769|
NCT01064349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113349|Breast Cancer With Over-expression of erbB2-BRAINSTORM|Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)||GlaxoSmithKline|No|Completed|May 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|144|||Female|N/A|N/A|No|Probability Sample|This study aims to enrol approximately 300 Erb2+ breast cancer cases with brain metastases        in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).|April 2015|April 14, 2015|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01064349||126750|
NCT01064362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113962|Hemorrhage Risk Prescribed Arixtra|Risk of Hemorrhage in Patients Prescribed Arixtra Compared to LMWH||GlaxoSmithKline|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13442|||Both|18 Years|N/A|No|Non-Probability Sample|Patients age 18 years and older with a primary discharge diagnosis of hip fracture surgery        or hospitalization for hip replacement surgery or knee replacement surgery treated with        either fondaparinux sodium or LMWH for thrombopropylaxis between January 2003 and        September 2008|June 2011|April 23, 2015|February 4, 2010||No||No|January 25, 2011|https://clinicaltrials.gov/show/NCT01064362||126749|Differences among hospitals in the registration of events (not all events were captured), the presence of policlinical pharmacy, and different drug usage patterns in each hospital did not enable a valid comparison of the risk of haemorrhage.
NCT01064661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0337|Pilot Study Studying Physiological Effects of Probiotic Pills in Patients With Abdominal Pain/Discomfort and Bloating|Physiological Effects of Probiotic Bacteria Lactobacillus Acidophilus NCFM Alone Versus a Combination With Bifidobacterium Lactids - LBi07 in Patients With Mild to Moderate Abdominal Pain/Discomfort and Bloating||University of North Carolina, Chapel Hill|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|22|||Female|18 Years|70 Years|No|||December 2013|December 11, 2013|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064661||126726|
NCT01064674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVDiagnostikpratransplantation|Cardiovascular Evaluation Before Renal Transplantation|Cardiovascular Diagnostic Before Renal Transplantation: a Prospective Study to Assess Cardiovascular Morbidity Before Renal Transplantation and to Improve Standard Diagnostic Procedures.||University Hospital Muenster|No|Recruiting|December 2009|September 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with endstage renal disease which are awaiting their ergsitration to our        transplantation programm since July 2009 until July 2010.|January 2010|February 5, 2010|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064674||126725|
NCT01065948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS-2009-05|A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours|A Feasibility Study to Assess Critical Aspects of FAS Performance and Safety Over Several Hours|FAS|BioTex, Inc.|Yes|Completed|November 2009|August 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|80 Years|No|||February 2016|February 3, 2016|February 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01065948||126628|
NCT01066234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-04-004|Adjuvant CCRT vs CT in Minimal N2 NSCLC|A Randomized Phase II Study of Adjuvant Concurrent Chemoradiotherapy vs Chemotherapy Alone in Completely Resected Microscopic N2 Non-small Cell Lung Cancer||Samsung Medical Center||Recruiting|April 2009|March 2017|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2013|June 3, 2015|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01066234||126606|
NCT01066468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A2110|Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.|A Non-randomized, Open-label Study to Characterize the Pharmacokinetics (PK) of Glivec/Gleevec® (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) or Other Glivec/ Gleevec® Indicated Hematological Disorders (HES, CEL, MDS/ MPN)||Novartis|No|Terminated|October 2010|||May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|1 Year|3 Years|No|||March 2012|March 12, 2012|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01066468||126588|
NCT01066481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1451010|A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease|A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled Safety And Efficacy Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Withdrawn|April 2010|April 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|50 Years|N/A|No|||June 2010|June 28, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066481||126587|
NCT01067131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCAN001|Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection|A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers||Pevion Biotech Ltd|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|48|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067131||126537|
NCT01067365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-003 Extension Study|Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism|An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003|ZA-003Ext|Repros Therapeutics Inc.|No|Completed|March 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Male|18 Years|68 Years|No|||June 2014|June 26, 2014|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067365||126519|
NCT01067105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-635|A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older|A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older||Sunovion|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|824|||Both|12 Years|N/A|No|||June 2012|June 8, 2012|February 9, 2010|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01067105||126539|Open label study investigating a dose higher than the US FDA approved dose (74 mcg once daily) for allergic rhinitis subjects. Publication references to 148 mcg is equivalent to 160 mcg.
NCT01067339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000044|Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III|Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III||Mayo Clinic|Yes|Completed|February 2010|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|85 Years|No|||September 2015|January 7, 2016|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067339||126521|
NCT01067651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-20062|Comparison of Casting Materials for the Treatment of Clubfoot Using the Ponseti Method|Comparison of Two Different Cast Materials for the Treatment of Congenital Idiopathic Clubfoot Using the Ponseti Method: A Prospective Randomized Controlled Trial||Alberta Children's Hospital|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|12 Weeks||||April 2007|February 10, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067651||126498|
NCT01068197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23RR022227; IRB # 3195|Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes|Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes|COOL Kids|Children's Research Institute|Yes|Completed|October 2003|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|7 Years|14 Years|No|||September 2014|September 8, 2014|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068197||126457|
NCT01068210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-215|Lung Cancer Exercise Training Study|Lung Cancer Exercise Training Study: A Randomized Trial of Aerobic Training, Resistance Training, or Both in Postsurgical Lung Cancer Patients||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|October 2015|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|82|||Both|21 Years|N/A|No|||October 2015|October 6, 2015|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068210||126456|
NCT01068223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016609|A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers|A Single-Center, Single-Dose, Double-Blind, Modified-Double-Dummy, Placebo and Active-Controlled, Randomized, Three-Way, Six-Sequence Cross-Over Study to Investigate the Effect of JNJ-39758979 on Histamine Induced Pruritus in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2010|May 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068223||126455|
NCT01064232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10640601|Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition|A Relative Bioavailability Study of Two Risperidone 1 mg Tablet Formulations Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064232||126759|
NCT01075321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0981|Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma|A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy||Mayo Clinic|Yes|Active, not recruiting|January 2011|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|February 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075321||125914|
NCT01075334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|porimore.CTIL|Is a Carnitine Based Food Supplement (PorimoreTM) for Infertile Men Superior to Folate and Zinc With Regard to Pregnancy Rates in Intrauterine Insemination Cycles?|||Shaare Zedek Medical Center|No|Recruiting|February 2010|December 2012|Anticipated|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|50 Years|No|||February 2010|February 24, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075334||125913|
NCT01076374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nEw3 PAS|nEw3 Post-approval Study|Medtronic Adapta/Versa/Sensia Long Term Reliability Study||Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|July 2008|March 2016|Anticipated|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|336|||Both|N/A|N/A|No|Non-Probability Sample|Subjects implanted with a Medtronic Adapta®, Sensia™, or Versa™ IPG.|July 2014|July 25, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076374||125833|
NCT01067560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02574|Measuring Cerebrospinal Fluid (CSF) Glucose Levels in Patients Under Going an Elective Cesarean Section With Spinal Anesthesia|Measurement of CSF Glucose Levels Using Three Different Glucose Meters in Parturients Undergoing Spinal Anesthesia for Elective Cesarean Section||University of British Columbia|No|Completed|January 2010|June 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|Samples With DNA|Whole blood, CSF|Female|19 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Parturients undergoing Cesarean delivery under spinal anesthesia at BC Women's Hospital|November 2010|November 8, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01067560||126504|
NCT01067833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJO-201|Phase 2 Study of Oral K201 for Prevention of AF Recurrence|A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary EffiCacy Study of K201 Oral for the Prevention of ATrial FIbrillation (AF) Recurrence in Subjects Post-Conversion From AF|ARCTIC-AF|Sequel Pharmaceuticals, Inc|Yes|Terminated|April 2010|December 2011|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|300|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067833||126484|
NCT01068106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S03010|Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents|Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings|ISAR-TEST6|Deutsches Herzzentrum Muenchen|Yes|Active, not recruiting|February 2010|September 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2010|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068106||126464|
NCT01064115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-06|Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition|A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|January 2006|February 2006|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 4, 2010|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064115||126768|
NCT01064128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-093|Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy|Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy||Samsung Medical Center|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|30 Years|60 Years|No|||July 2011|July 18, 2011|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064128||126767|
NCT01064375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|El-porCEA|Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer|Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer|El-porCEA|Karolinska University Hospital|Yes|Active, not recruiting|December 2009|October 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064375||126748|
NCT01064388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2690C00002|A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days|A Phase I, Single Center, Double-blind Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects||AstraZeneca|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|23 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|February 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01064388||126747|
NCT01064401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205MS301|Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis|Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis|(DECIDE)|Biogen|Yes|Completed|May 2010|July 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1841|||Both|18 Years|55 Years|No|||August 2015|August 21, 2015|January 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064401||126746|
NCT01064687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11373|A Study in Participants With Type 2 Diabetes Mellitus|A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)|AWARD-1|Eli Lilly and Company|No|Completed|February 2010|May 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|978|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|February 5, 2010|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01064687||126724|
NCT01065701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InDex3|Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children|Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children - a Double-blinded Randomized Controlled Trial||The University of Hong Kong|No|Recruiting|July 2009|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|1 Year|8 Years|No|||February 2010|February 8, 2010|February 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01065701||126646|
NCT01068509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-003|Ovarian Cancer Vaccine for Patients in Remission|A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (Cvac) for Epithelial Ovarian Cancer Patients in First or Second Remission||Prima BioMed Ltd|Yes|Completed|June 2010|April 2015|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Female|18 Years|N/A|No|||July 2014|May 26, 2015|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01068509||126433|
NCT01068808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|640/2552(EC4)|The Development of Allergic Rhinitis in Children Previously Diagnosed as Nonallergic Rhinitis|The Development of Allergic Rhinitis in Children Previously Diagnosed as Nonallergic Rhinitis||Mahidol University|Yes|Completed|January 2010|August 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|175|||Both|1 Year|15 Years|No|Non-Probability Sample|The patient from pediatric allergy clinic will be selected.|February 2013|February 18, 2013|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01068808||126410|
NCT01077583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0148|Performance Evaluation Study for Clearblue Pregnancy Test|Performance Evaluation Study for Clearblue Pregnancy Test||SPD Development Company Limited|No|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|Samples Without DNA|Daily early morning urine samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Eligibility:        Ages Eligible for study: 18 - 45 years. Gender Eligible for study Female. Healthy        Volunteers Yes.|January 2011|September 27, 2011|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077583||125740|
NCT01081366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0905 DELUX|Drug Eluting Pantera Lux Catheter Registry|Evaluation of the Safety Profile of the Pantera Lux Paclitaxel Releasing Balloon for Coronary Arteries in Daily Clinical Practice||Biotronik AG|Yes|Completed|April 2010|May 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1064|||Both|18 Years|N/A|No|Non-Probability Sample|All comers registry. Patients treated with the Pantera Lux Paclitaxel releasing balloon        catheter are enrolled consecutively to represent a typical set of patients at each site.|January 2016|January 21, 2016|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081366||125455|
NCT01077323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA406|A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents|A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Byetta (Exenatide) and Other Antidiabetic Agents||AstraZeneca|No|Completed|September 2004|March 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|363766|||Both|N/A|N/A|No|Non-Probability Sample|This retrospective study utilized medical claims data from a large US health plan        affiliated with i3 Drug Safety. The individuals covered by this health plan are        geographically diverse across the United States. The health plan provides fully insured        coverage for physician, hospital and prescription drug services. The providers of these        services submit their claims for payment directly to the health plan. i3 Drug Safety uses        de-identified data derived from these claims daily for a wide range of safety,        utilization, and economic analyses.|March 2015|March 25, 2015|February 25, 2010|No|Yes||No|August 12, 2010|https://clinicaltrials.gov/show/NCT01077323||125760|
NCT01069653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS-21-74|Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer|Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*24 (CDCA1,KIF20A) in Patients With Small Cell Lung Cancer Refractory to Standard Therapy||Shiga University|Yes|Recruiting|February 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|20 Years|85 Years|No|||September 2013|September 16, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069653||126345|
NCT01070056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL087301-01|Practice-based Trial of Blood Pressure Control in African Americans|Practice-based Trial of Blood Pressure Control in African Americans|TLC-Clinic|New York University School of Medicine|Yes|Completed|February 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070056||126316|
NCT01070277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5059-ES-CTIL|Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea|||Sheba Medical Center|No|Recruiting|March 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01070277||126299|
NCT01070290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-206|A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen|A Randomized Phase 2 Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen||ArQule|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01070290||126298|
NCT01070602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRIFIS-001|The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients|||Meir Medical Center||Recruiting|July 2010|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|55 Years|N/A|No|||March 2013|June 27, 2013|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070602||126274|
NCT01070615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-INT-10|Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic Constipation|A Study to Evaluate the Long-Term Tolerability and Safety of Oral Prucalopride Administered to Patients With Chronic Constipation||Movetis|No|Completed|June 1998|||November 2000|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|693|||Both|18 Years|N/A|No|||February 2010|March 1, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070615||126273|
NCT01070862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020879|Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.|Multiple Myeloma Treatment With Thalidomide. Three Randomized Studies on Thalidomide as Induction Treatment Before Autotransplant (MY-TAG) or With a Conventional Chemotherapy (MY-DECT) and as Consolidation/Maintenance at Plateau Phase (MY-PLAT).|MAG 2002|University Hospital, Caen|No|Completed|May 2003|December 2009|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||||||Both|18 Years|80 Years|No|||February 2010|February 17, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070862||126254|
NCT01071148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200061-502|A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth|A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth.||Merck KGaA|No|Completed|June 2009|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|166|||Female|18 Years|42 Years|No|Probability Sample|A total of 176 subjects justifying IVF therapy at a single IVF centre in Norway will be        recruited into this trial. Subjects must have been treated with three or more previous        IVF-cycles without live birth.|May 2014|May 2, 2014|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071148||126232|
NCT01064479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0395|Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck|A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel And Cisplatin With Or Without Erlotinib In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of the Head And Neck||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2010|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|February 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064479||126740|
NCT01064492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0961004|A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects|A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects||Pfizer|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 16, 2010|February 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01064492||126739|
NCT01078805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8492|Study of FORTEO Use in Subjects in the Community Setting|Direct Assessment of Non-Vertebral Fractures in Community Experience (DANCE)|DANCE|Eli Lilly and Company|No|Completed|August 2003|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4167|||Both|N/A|N/A|No|Probability Sample|Community sample|May 2012|May 16, 2012|March 1, 2010|No|Yes||No|January 30, 2012|https://clinicaltrials.gov/show/NCT01078805||125647|
NCT01079091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS001|Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units|Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units|HEPATICUS-1|Hepa Wash GmbH|Yes|Terminated|September 2010|October 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|March 1, 2010||No|The foundations of our pilotstudy planning has changed.|No||https://clinicaltrials.gov/show/NCT01079091||125627|
NCT01080222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-222-103|A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection|A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C||Vertex Pharmaceuticals Incorporated|No|Terminated|August 2010|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|152|||Both|18 Years|65 Years|No|||February 2014|February 28, 2014|March 1, 2010|Yes|Yes|Study discontinued|No||https://clinicaltrials.gov/show/NCT01080222||125542|
NCT01079988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25180|Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence|A Phase IV Open Label, Multicentre, Investigational Study of the Therapeutic Options for Subjects Discontinuing Efalizumab Therapy and Experiencing Inflammatory Disease Recurrence||Merck KGaA|No|Completed|February 2004|April 2005|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|41|||Both|N/A|N/A|No|||January 2014|January 26, 2014|March 2, 2010||No||No|April 12, 2010|https://clinicaltrials.gov/show/NCT01079988||125560|
NCT01080209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-033D|Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System|||Allergan|No|Completed|February 2010|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|7||Actual|215|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|February 26, 2010|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01080209||125543|
NCT01079689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BANS10|Brain Activity Changes Measured by EEG and fMRI on Healthy Volunteers After Complex Somatosensory Stimulation|Brain Activity Changes Measured by EEG and fMRI on Healthy Volunteers After Complex Somatosensory Stimulation With Acupuncture Needles|BANS|Charite University, Berlin, Germany|No|Completed|February 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079689||125583|
NCT01080729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700623-508|An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen|A Prospective, Observational and Multicentric Study to Compare the Dose of GONAL-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of GONAL-fTM FbM Pen||Merck KGaA|No|Terminated|February 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|Blood Serum|Female|18 Years|35 Years|No|Non-Probability Sample|Female subjects, who are being considered for an IVF/ICSI treatment and a Gonal-f        treatment based on the PFS and inclusion and exclusion criteria will be eligible for the        study.|October 2011|July 1, 2014|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080729||125503|
NCT01068821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000685-01|Trendelenburg's Slide Prevention Study|Randomized Controlled Trial Comparing Commonly Used Techniques to Prevent Slippage During Steep Trendelenburg's Position|SPS|Mayo Clinic|No|Completed|March 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 16, 2012|February 12, 2010||No||No|August 15, 2011|https://clinicaltrials.gov/show/NCT01068821||126409|Evaluation of postoperative outcomes was non-systematic using chart review for all participants except for one participant whose identity was not listed on data abstraction sheet.
NCT01069081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2010-01|Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer|Phase II Study of Docetaxel and Cisplatin Chemotherapy Versus Docetaxel and Cisplatin Chemotherapy Combined With High Dose Proton Pump Inhibitor in Metastatic Breast Cancer||Fudan University|Yes|Completed|August 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|94|||Female|18 Years|N/A|No|||March 2015|March 4, 2015|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01069081||126389|
NCT01069094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZN-001|A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata|A Single Dose lead-in PK Followed by a Randomized, Double-blinded, Controlled, Multiple Dose Study of the Selective Progesterone Receptor Modulator Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata||Repros Therapeutics Inc.|No|Completed|July 2004|January 2005|Actual|January 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|29|||Female|18 Years|50 Years|No|||June 2014|June 27, 2014|February 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069094||126388|
NCT01069393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15581|Alternative Delivery of Dose Adjustment For Normal Eating (DAFNE) Trial in Patients With Type 1 Diabetes|Improving Management of Type 1 Diabetes in the UK: The DAFNE Programme as a Research Test-bed - 5 x 1 Day RCT||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|June 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|80 Years|No|||November 2014|November 18, 2014|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01069393||126365|
NCT01069666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|366/2550(EC3)|Knowledge Base in the Treatment of Atopic Dermatitis Among Thai Pediatricians|||Siriraj Hospital|No|Completed|July 2008|December 2008||||N/A|Observational|Time Perspective: Prospective||1|||||Both|N/A|N/A||Probability Sample|900 self-administered questionnaires were randomly mailed to pediatricians throughout        Thailand|May 2010|May 3, 2010|February 16, 2010||||No||https://clinicaltrials.gov/show/NCT01069666||126344|
NCT01069692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBR759A2304|Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients|A Double-blind, Randomized, Placebo-controlled Multi-center Trial to Compare the Phosphate Lowering Efficacy of Different Doses of SBR759 to Placebo|SBR759|Novartis||Completed|February 2010|||October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|115|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|February 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069692||126343|
NCT01070069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0001|Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial|Prospective, Multicenter, Randomized Controlled Trial of Endovascular Aneurysm Repair Using a Bilateral Percutaneous Approach (PEVAR) vs. Standard Approach (SEVAR) Using the IntuiTrak Endovascular AAA Delivery System and the Prostar XL or Perclose ProGlide Suture-Mediated Closure System|PEVAR|Endologix|Yes|Completed|April 2010|January 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01070069||126315|
NCT01070303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M02-433 Open Label|Remission in Subjects With Crohn's Disease, Open Label Extension|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease, Open Label Extension|CLASSICII|Abbott|No|Completed|August 2002|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|177|||Both|18 Years|75 Years|No|||April 2011|April 7, 2011|February 16, 2010|Yes|Yes||No|March 11, 2010|https://clinicaltrials.gov/show/NCT01070303||126297|
NCT01070316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0998|Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)|Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|March 2015|March 2020|Anticipated|March 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|N/A|No|||April 2015|April 28, 2015|February 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070316||126296|
NCT01070875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM 2010-002|Partial Thromboplastin Time During the First 24 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin (UFH)|Partial Thromboplastin Time During the First 24 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin: Comparison of a 2 Times Per Day Versus Per 3 Times a Day Dosage||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070875||126253|
NCT01080287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-778|The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras|The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras||The Cleveland Clinic|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult Migraineurs with and without auras, half having orthostatic intolerance.|February 2012|February 20, 2012|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080287||125537|
NCT01080521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0256|Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy|A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer||Gynecologic Oncology Group||Active, not recruiting|April 2010|||January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|242|||Female|18 Years|N/A|No|Non-Probability Sample|patients with ovarian, primary peritoneal or fallopian tube cancer receiving chemotherapy|February 2016|February 9, 2016|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080521||125519|
NCT01064986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220070126|The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers|The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers||Rutgers, The State University of New Jersey|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|February 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01064986||126701|
NCT01078818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tratamiento con hierro/2007|Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation|A Phase IV, Unicenter, Randomized, Double-Blind, Parallel-Group, Comparaty Study of Intravenous and Oral Iron vs Placebo in Patient Under Extracorporeal Circulation in Cardiovascular Surgery||Fundación Canaria Rafael Clavijo para la Investigación Biomédica|No|Completed|May 2007|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|78 Years|No|||May 2007|March 2, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078818||125646|
NCT01079104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS002|Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units|Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units|HEPATICUS-2|Hepa Wash GmbH|Yes|Terminated|September 2010|October 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|March 1, 2010||No|The foundations of our pilotstudy planning has changed.|No||https://clinicaltrials.gov/show/NCT01079104||125626|
NCT01079117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUB9001|Morphine Slow-release Capsules in Substitution Therapy|Randomised, Controlled Clinical Study Regarding the Feasibility of Converting Opiate Dependents From Methadone Substitutes to Slow Release Morphine Sulphate (Sevre-Long™)||Mundipharma Medical Company|No|Completed|October 2006|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079117||125625|
NCT01080456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/07/052|Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 1 mg in Normal Healthy Male Subjects Under Fasting Condition||Panacea Biotec Ltd|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080456||125524|
NCT01080716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15647|Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate|Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults||U.S. Army Medical Research and Materiel Command|Yes|Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|December 23, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080716||125504|
NCT01080443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328-07|Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fasting Condition|Open Label Balanced Randomized Two-treatment Two-period Two-sequence Single Dose Two-way Crossover Oral Bioequivalence Study of Mycophenolate Mofetil Capsules 250 mg in Normal Healthy Adult Human Subjects Under Fasting Conditions||Panacea Biotec Ltd|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080443||125525|
NCT01072851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910001-E|Tools for Improving Colorectal Cancer Screening Rates: Multimedia Versus Print|Tools for Improving Colorectal Cancer Screening Rates: Multimedia vs Print||Saint Francis Care|No|Completed|July 2008|September 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|920|||Both|50 Years|80 Years|No|||September 2012|September 6, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072851||126103|
NCT01078597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-983|A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA|A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA||AbbVie|No|Completed|September 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|None Retained|There are no biospecimens specifically retained for the purposes of the study. Routine blood      samples may be retained as per routine practice of the participating centre.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Rheumatoid Arthritis attending specialist rheumatology clinics.|August 2013|August 16, 2013|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078597||125663|
NCT01069107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1300 REK|Acute Admission to Hallingdal Sjukestugu|Acute Admission to Hallingdal Sjukestugu. Can Acute Admissions to a Community Hospital be a Realistic Alternative to General Hospital Admissions?||Helse Sor-Ost|No|Completed|April 2010|September 2015|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|140|||Both|N/A|N/A|No|||February 2016|February 17, 2016|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01069107||126387|
NCT01069406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor493710CTIL|The Association Between Uterine Artery Notch and First Trimester Bleeding|The Association Between Uterine Artery Notch and First Trimester Bleeding||Soroka University Medical Center|No|Completed|March 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with abnormal uterine artery Doppler at second trimester. pregnant women with        eather: elevated HCG and/or aFP at triple test, patients with history of pre eclampsia,        IUGR, APD, and patients with thrombophilia.|May 2015|May 18, 2015|February 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069406||126364|
NCT01069705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2303E2|Second Open Label Extension to Bridging Study CTBM100C2303|A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Completed Participation in Study CTBM100C2303E1.||Novartis||Completed|February 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|6 Years|21 Years|No|||May 2012|May 2, 2012|February 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069705||126342|
NCT01069718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WakeMEd Study 751|Evaluating Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance|Evaluating the Effect of Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance in Infants With Feeding Dysfunction||KC BioMediX, Inc|No|Completed|March 2008|November 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|24|||Both|34 Weeks|18 Months|No|Probability Sample|Infants born prematurely may suffer multiple adverse events in the Intensive Care Nursery,        and these experiences may negatively impact normal developmental processes of immature        cardiorespiratory, gastrointestinal and central nervous systems. As a result, many infants        have at least transient difficulties learning to successfully manage oral feedings. Oral        feeding difficulties in the ICN may prolong the time to discharge, cause significant        parental anxiety, and persist throughout infancy. Indeed, as many as 40% of patients        followed in feeding disorder clinics are former preterm infants.|February 2010|February 16, 2010|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069718||126341|
NCT01079767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000666229|Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis|Advanced Hepatocellular Carcinoma on Child B Cirrhosis: Tolerance and Efficacy of Torisel® (Temsirolimus)||Federation Francophone de Cancerologie Digestive|Yes|Terminated|January 2010|||December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2010|March 3, 2014|March 2, 2010||No|The study treminated early according to DSMB recommendantions|No||https://clinicaltrials.gov/show/NCT01079767||125577|
NCT01080053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200077-511|Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)|Observational Study to Determine the Relationship Between the Degree of Disability and the Presence of Sexual Dysfunction and Between Sexual Dysfunction and the Quality of Life in Patients With Multiple Sclerosis (RRMS)||Merck KGaA||Completed|November 2008|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|306|||Both|22 Years|N/A|No|Non-Probability Sample|Subjects with established diagnosis of RRSM for more than one year.|October 2013|October 13, 2013|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080053||125555|
NCT01080027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701068_506|Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)|An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings|STAR|Merck KGaA||Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|254|||Both|18 Years|60 Years|No|Non-Probability Sample|Subjects diagnsoed with RRMS from approximately 80 sites across seven countries.|July 2014|July 30, 2014|March 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01080027||125557|
NCT01080040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200077-507|To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients|Observational Study to Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Patients With Multiple Sclerosis in Argentina||Merck KGaA||Completed|August 2008|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|21 Years|60 Years|No|Non-Probability Sample|Subjects with established diagnosis of RRSM for more than one year.|October 2013|October 13, 2013|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080040||125556|
NCT01080313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13440|Head and Neck Cancer Registry (LORHAN)|Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Cancer|LORHAN|Eli Lilly and Company|No|Completed|August 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|26000|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|February 2012|February 10, 2012|March 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01080313||125535|
NCT01080833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBIRE-GI-004|Effect of ERCP Mechanical Simulator (EMS) Practice on Endoscopic Retrograde Cholangiopancreatography (ERCP) Training|Effect of Simulator Practice on Trainees' ERCP (Endoscopic Retrograde Cholangiopancreatography) Performance in the Early Learning Period: a Multi-center Randomized Controlled Observational Study|ERCP|East Bay Institute for Research and Education|Yes|Completed|July 2008|December 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|30 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 18, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01080833||125495|
NCT01080534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/07/055|Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 5 mg in Normal Healthy Male Subjects Under Fed Condition||Panacea Biotec Ltd|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080534||125518|
NCT01080794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000002|Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial|Repetitive Transcranial MAgnetic STimulation (rTMS) for MotoR and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial|MASTER-PD|Beth Israel Deaconess Medical Center|Yes|Completed|May 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|85|||Both|21 Years|85 Years|No|||February 2015|February 13, 2015|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080794||125498|
NCT01095679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090207|Baclofen and Hypoxia-induced Periodic Ventilation|Assessment of the Effect of the GABA-B Receptor Agonist, Baclofen, on Hypoxia-induced Periodic Ventilation, in Healthy Subjects|PERIODIBAC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2009|October 30, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095679||124358|
NCT01079728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICT|Prediction of Stroke-associated Pneumonia|Prediction of Stroke-associated Pneumonia|PREDICT|Charite University, Berlin, Germany|No|Completed|February 2010|April 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|486|Samples Without DNA|Blood sample (serum, plasma)|Both|18 Years|N/A|No|Probability Sample|ischemic stroke in the anterior (ACA, MCA) and posterior cerebral circulation (PCA, BA) of        any severity in the last 36h|June 2013|July 27, 2015|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079728||125580|
NCT01080001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200077-506|A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina|Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina||Merck KGaA|Yes|Completed|August 2008|November 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|21 Years|60 Years|No|Non-Probability Sample|Subjects diagnosed with MS in Argentina.|March 2014|March 6, 2014|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080001||125559|
NCT01080235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPS 485|Improving Quality of Care for Elderly Patients in the Educational Setting|Improving Quality of Care for Elderly Patients in the Educational Setting: A Multicenter Exploratory Study of Quality Improvement|MacyCoVE|American Board of Internal Medicine|Yes|Completed|October 2006|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|42|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 2, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01080235||125541|
NCT01080989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980096|The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands|The Sero-prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|March 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1477|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2011|September 4, 2013|August 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01080989||125483|
NCT01068522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33888-B|Study to Improve Outcomes for Survivors of Traumatic Brain Injury in Latin America|Traumatic Brain Injury in Latin America: Lifespan Analysis||University of Washington|Yes|Active, not recruiting|July 2007|March 2013|Anticipated|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|324|||Both|13 Years|N/A|No|||October 2012|October 31, 2012|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068522||126432|
NCT01078610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-023|Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine|Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Psoriatic Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice|ELAN|Abbott|No|Withdrawn||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample: patients with psoriatic arthritis.|June 2012|August 8, 2012|February 26, 2010||No|Study stopped prior to enrollment.|No||https://clinicaltrials.gov/show/NCT01078610||125662|
NCT01078909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE LPS|Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation|Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation||Penn State University|Yes|Completed|October 2011|April 2014|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Actual|116|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01078909||125640|
NCT01079221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42009297|Effects of Knee-extensor Exercise Training in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of Knee-extensor Exercise Training in Chronic Obstructive Pulmonary Disease (COPD) Patients||Norwegian University of Science and Technology|Yes|Completed|February 2009|December 2012|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|50 Years|80 Years|No|||April 2013|April 8, 2013|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079221||125618|
NCT01079234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3770|Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes|A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)|BEGIN™|Novo Nordisk A/S|No|Completed|March 2010|May 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|493|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|March 2, 2010|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01079234||125617|
NCT01079507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-06-060|Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia|Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia||Samsung Medical Center|Yes|Recruiting|February 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Stored bone marrow specimens of patients with acute lymphoblastic leukemia|Both|18 Years|N/A|No|Non-Probability Sample|Patients were diagnosed as adult acute lymphoblastic leukemia at Samsung Medical        Center(Sungkyunkwan University School of Medicine, Seoul, South Korea) between 1994 and        2008.|March 2010|March 2, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079507||125597|
NCT01079780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000666736|Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy|A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy||Eastern Cooperative Oncology Group|No|Recruiting|November 2010|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|147|||Both|18 Years|N/A|No|||June 2012|September 19, 2014|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01079780||125576|
NCT01080326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008389|Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus|Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus||Mayo Clinic|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 2, 2010|No|Yes||No|April 1, 2015|https://clinicaltrials.gov/show/NCT01080326||125534|
NCT01080300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0064|Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER_ Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women|Breeze3|Depomed|No|Completed|August 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|600|||Female|18 Years|70 Years|No|||November 2011|February 7, 2014|March 2, 2010|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01080300||125536|
NCT01081132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-312|Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl|A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)||Shire|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|314|||Both|13 Years|17 Years|No|||April 2014|June 6, 2014|March 3, 2010|Yes|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01081132||125472|For the secondary outcomes, the p-values are not controlled for multiplicity, therefore they should be considered as descriptive not inferential.
NCT01081145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-315|Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)|A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised Withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention Deficit/Hyperactivity Disorder||Shire||Completed|May 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|528|||Both|6 Years|17 Years|No|||May 2014|November 25, 2014|March 3, 2010|Yes|Yes||No|May 9, 2014|https://clinicaltrials.gov/show/NCT01081145||125471|
NCT01081158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04695|Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)|Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)||Merck Sharp & Dohme Corp.|No|Completed|July 2007|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|65 Years|No|||February 2015|February 6, 2015|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081158||125470|
NCT01077115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHMNE001|Extent of Surgical Trauma in Open and Laparoscopic Cholecystectomy|Extent of Surgical Trauma in Open and Laparoscopic Cholecystectomy|ESTOLC|Ministry of Health, Montenegro|Yes|Completed|June 2003|September 2006|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||February 2010|February 25, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077115||125776|
NCT01095692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090304|Evaluating the Necessity of TOT Implantation in Women With Pelvic Organ Prolapse and Occult Stress Urinary Incontinence|Evaluating the Necessity of TOT Implantation in Women With Pelvic Organ Prolapse and Occult Stress Urinary Incontinence|ATHENA|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Female|18 Years|N/A|No|||June 2014|June 5, 2014|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095692||124357|
NCT01079702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCmedonc08/010|Everolimus and Capecitabine in Patients With Advanced Malignancy|A Phase I/II, Non-randomized, Multi-center, Dose-escalating, Two-stage Efficacy and Feasibility Study of the Combination of Everolimus and Capecitabine in Patients With Advanced Malignancies|m-TOR|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|April 2008|January 2011|Anticipated|April 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2008|March 2, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01079702||125582|
NCT01079715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Number 2010-018737-21|Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity|Safety and Efficacy of Treatment With Propranolol in Newborns With Retinopathy of Prematurity: a Pilot Study|PROP-ROP|Azienda Ospedaliero, Universitaria Meyer|Yes|Completed|January 2010|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|22 Weeks|32 Weeks|No|||November 2012|November 24, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079715||125581|
NCT01072019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0018|A Randomized Prospective Trial of Total Knee Arthroplasty Options Comparing Standard Knee Cutting Guides and MRI Generated Patient Specific Custom Cutting Guides|Comparative Clinical Study of the Vanguard® Knee System Using Signature™ Custom Guides & Conventional Techniques|Cutting Block|Washington University School of Medicine|Yes|Completed|March 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||September 2014|September 2, 2014|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072019||126167|
NCT01080469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/07/053|Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 1 mg in Normal Healthy Male Subjects Under Fed Condition||Panacea Biotec Ltd|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080469||125523|
NCT01072305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAIIPC01|Pneumatic Compression of the Legs to Reduce Fluid Demand in Minor Surgery|Einfluss Der Intermittierenden Pneumatischen Kompression Der Unteren Extremitäten Auf Den Intraoperativen Flüssigkeitsbedarf||University Hospital, Bonn|No|Completed|February 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||January 2010|February 19, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072305||126145|
NCT01078103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J.nr.2005-41-4933|Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes Mellitus Type II|Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes||Frederiksberg University Hospital|No|Completed|July 2005|April 2008|Actual|April 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|60 Years|N/A|No|Probability Sample|30 typoe II diabetic and 30 non diabetic undergoing catarct surgery|August 2009|March 1, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078103||125700|
NCT01078623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/40464/26|Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate|Efficacy, Safety and Tolerability of Two Fixed-Dose Combinations of Aclidinium Bromide With Two Doses of Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo All Administered Twice Daily in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease Patients.|ALIGHT-COPD|Almirall, S.A.|No|Completed|February 2010|||September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|120|||Both|40 Years|80 Years|No|||November 2010|November 5, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078623||125661|
NCT01078636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA0175|Alzheimer's Disease Neuroimaging Initiative Grand Opportunity|Alzheimer's Disease Neuroimaging Initiative Grand Opportunity|ADNI-GO|Alzheimer's Disease Cooperative Study (ADCS)|Yes|Completed|April 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|342|Samples With DNA|blood, urine, cerebrospinal fluid|Both|55 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|community sample|September 2014|September 15, 2014|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078636||125660|
NCT01078922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFT113588 (0908)|Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas|A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas||Oncology Specialists, S.C.|No|Terminated|February 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|February 23, 2010|Yes|Yes|Study terminated due to slow acrual|No|April 1, 2014|https://clinicaltrials.gov/show/NCT01078922||125639|
NCT01078935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prob-bl.CTIL|The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation|The Effect of Probiotics on Bowel Disease||The Baruch Padeh Medical Center, Poriya|No|Not yet recruiting|December 2012|||April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|80 Years|No|||March 2010|August 10, 2011|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01078935||125638|
NCT01079247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABA-MCTG-0001|A Trial of Restrictive Versus Traditional Blood Transfusion Practices in Burn Patients|A Randomized Clinical Trial of Restrictive vs. Traditional Blood Transfusion Practices in Burn Patients||American Burn Association|Yes|Enrolling by invitation|February 2010|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||July 2013|January 14, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01079247||125616|
NCT01079520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-053|Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)|A Prospective Trial of Endobronchial Ultrasound- Transbronchial Needle Aspiration Compared to Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer||Samsung Medical Center||Completed|March 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|138|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01079520||125596|
NCT01080066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62202-512|A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)|A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)||Merck KGaA|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|215|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with SCCHN and are eligible to receive cetuximab and radiotherapy according to        the local label|July 2014|July 7, 2014|February 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01080066||125554|
NCT01080079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-9|Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis|A Subject Blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail||Nitric BioTherapeutics, Inc|No|Completed|May 2010|June 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|168|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080079||125553|
NCT01080560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/AHD/07/013|Bioequivalence Study of Cyclosporine 100mg Capsule Under Fasting Condition|A Randomized Single Dose Open Label Bioequivalence Study of Cyclosporine Capsules USP (Modified)100mg in Normal Healthy Male Subjects Under Fasting Condition||Panacea Biotec Ltd|No|Completed|August 2007|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080560||125516|
NCT01080547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009C13017|Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer|Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer||Zhejiang University|Yes|Recruiting|March 2010|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|220|||Both|18 Years|N/A|No|||April 2010|April 12, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01080547||125517|
NCT01081184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08010|Neurotrophins Implications in Primary Sjögren Syndrome|Neurotrophins Implications in Primary Sjögren Syndrome|Neuro-SGSp|University Hospital, Limoges|No|Completed|March 2010|August 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People with primary Sjögren syndrome        People free of disease : healthy volunteers|March 2010|April 16, 2013|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081184||125469|
NCT01095718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB 2009-A01303-54|Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease|Comparison of 3 Learning Methods and Their Underlying Mechanisms to Improve Independent Living in the Activities of Daily Living in Alzheimer's Dementia: a Randomized Controlled Trial|C3LM-ILAD|Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2010|||March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|300|||Both|60 Years|N/A|No|||December 2011|March 23, 2012|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01095718||124355|
NCT01095926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOC-MS-001|Pharmacokinetic Study of Doxorubicin in Children With Cancer|Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia|Doxo|University Hospital Muenster|Yes|Completed|May 2010|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|N/A|17 Years|No|||March 2010|June 27, 2013|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01095926||124339|
NCT01071421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEBULOSA PROJECT|Sleep Apnea Syndrome and Community Acquired Pneumonia|Prevalence of Sleep Apnea-hypopnea Syndrome in Patients With Community Acquired Pneumonia, Prospective and Comparative Case-control Study|NEBULOSA|Hospital Universitario San Juan de Alicante|Yes|Completed|April 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|123|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients admitted to hospital with the diagnosis of community acquired pneumonia,        excluding nosocomial pneumonia compared to patients with other infections excluding        respiratory infections, admitted to hospital, paired by age, sex and body mass index|February 2006|February 18, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071421||126213|
NCT01072032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7251-W|Cortical and Biomechanical Dynamics of Ankle Robotics Training in Stroke|Cortical and Biomechanical Dynamics of Ankle Robotics Training in Stroke|AbotMot|VA Office of Research and Development|Yes|Completed|May 2010|September 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|85 Years|No|||December 2014|December 22, 2014|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01072032||126166|
NCT01072045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq0931/09|Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma|A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma||University of Sao Paulo|No|Completed|January 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|2 Years|No|||December 2014|December 1, 2014|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072045||126165|
NCT01071668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-041|Onset of Labor and Metabolomics (GEM-2)|Feasibility Study to Develop the Analysis of the Metabolome During the Onset of Labor During Pregnancy|GEM-2|Université de Sherbrooke|No|Active, not recruiting|April 2009|June 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Vaginal secretions, whole blood and urine are collected|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women between 20-30 weeks of gestation who have a low risk pregnancy.|May 2015|May 11, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071668||126194|
NCT01071681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14675|Survey to Assess Why People Are Not Responding to Treatment in Hypertension|Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.||Bayer|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1589|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Uncontrolled hypertensive patients under a combination therapy, either fixed or not, of a        renin-angiotensin system blocker and hydrochlorothiazide|November 2011|November 1, 2011|October 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01071681||126193|
NCT01071694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15110|QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea|QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea||Bayer|No|Withdrawn|January 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|None Retained|n.a|Both|18 Years|N/A|No|Non-Probability Sample|Tertiary hospital|April 2012|April 12, 2012|February 18, 2010||No|Study Manager could not embark on it during the timeline.|No||https://clinicaltrials.gov/show/NCT01071694||126192|
NCT01072565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03914-09-C|Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring|Optimization of SMBG Employing Modal Day Analysis: Examining Clinical Decision-making Processes Using Blinded FreeStyle Navigator Continuous Glucose Monitoring System (CGM)||HealthPartners Institute|No|Completed|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|No|||April 2013|November 25, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072565||126125|
NCT01072578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1691C00004|A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose|An Open-label, Randomised, Two-period Crossover Study to Assess the Effect of Dapagliflozin on Percent Inhibition of Glucose Re-absorption When Administered Once a Day (10 mg OD) Versus Twice a Day (5 mg BID) in Healthy Male and Female Volunteers||AstraZeneca|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|February 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072578||126124|
NCT01072552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCREW-001|Effect of Palivizumab on Later Recurrent Wheezing in Preterm Infants|Effect of Palivizumab Treatment on Subsequent Recurrent Wheezing in Preterm Infants: Case-control Study by Scientific Committee of Recurrent Wheezing (SCREW)||Tokyo Women's Medical University|Yes|Completed|March 2008|August 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|444|Samples Without DNA|serum|Both|3 Months|1 Year|No|Non-Probability Sample|Infants with the gestational age between 33 and 35 weeks|April 2012|April 1, 2012|December 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01072552||126126|
NCT01072864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917508-1|Effects of California Walnuts on Vascular Function in Postmenopausal Women|Effects of California Walnuts on Vascular Function in Postmenopausal Women||University of California, Davis|No|Completed|June 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|5|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||October 2010|October 28, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072864||126102|
NCT01078389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67_204|Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout|A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout||Takeda|Yes|Completed|March 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|314|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|February 26, 2010|Yes|Yes||No|September 3, 2014|https://clinicaltrials.gov/show/NCT01078389||125679|
NCT01078649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 1143-101 (AT-406-CS-001)|Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas|A Phase I, Open Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Properties of Orally Administered AT-406 in Patients With Advanced Solid Tumors and Lymphomas||Debiopharm International SA|No|Completed|February 2010|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|March 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01078649||125659|
NCT01078948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|157/2007|Transcranial Direct Current Stimulation (tDCS) in the Treatment of Major Depressive Disorder (MDD)|A Double-blind Sham Controlled Trial of Transcranial Direct Current Stimulation (tDCS) in Treating Refractory Major Depressive Disorder (MDD)||Centre for Addiction and Mental Health|No|Completed|February 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||February 2012|February 9, 2012|February 25, 2008||No||No||https://clinicaltrials.gov/show/NCT01078948||125637|
NCT01079260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC300|An Investigation of the Efficacy of Oral Nutritional Supplements in Participants at Risk of Malnutrition|An Investigation of the Efficacy of High Energy, Low Volume Oral Nutritional Supplements in Participants at Risk of Malnutrition||Nutricia UK Ltd|No|Completed|February 2010|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01079260||125615|
NCT01079533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA112223-01A2|Initiation of Colon Cancer Screening in Veterans or "Start Screening Now"|Initiation of Colon Cancer Screening in Veterans|SSN|The University of Texas Health Science Center, Houston|Yes|Active, not recruiting|July 2008|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|1504|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01079533||125595|
NCT01079793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000666842|Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery|A Phase I/II Study of Adjuvant Prostate Irradiation and Ixabepilone For High Risk Prostate Cancer Post-Prostatectomy||National Cancer Institute (NCI)||Recruiting|May 2010|||March 2012|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Male|18 Years|N/A|No|||May 2010|June 11, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079793||125575|
NCT01080339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-12-0611|Substudy of Change in Cardiometabolic Disease (CMD) Risk Factors During an Interactive Fitness Program|Change in Cardiometabolic Risk Factors During an Interactive Fitness Program: An Exploratory Sub-study|EXCEL|Children's Hospital Boston|No|Terminated|February 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|3|||Both|8 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children attending 3rd-5th grades at select Boston Public Schools will be eligible for        participation.|June 2011|June 22, 2011|March 3, 2010||No|Unable to recruit participants.|No||https://clinicaltrials.gov/show/NCT01080339||125533|
NCT01080859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-004|Vessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Assessed By Optical Coherence Tomography|Early Coverage and Vessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Implanted in Acute Coronary Syndrome Assessed By Optical Coherence Tomography (BASE-OCT)|BASE-OCT|The Hospital District of Satakunta|Yes|Completed|December 2009|May 2011|Actual|May 2011|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients presenting with acute coronary syndrome and who were treated either BAS or EES        during the index PCI.|May 2011|May 4, 2011|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080859||125493|
NCT01080846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.6|Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage|Assessment of Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage||Gynuity Health Projects|Yes|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|14 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 9, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080846||125494|
NCT01077167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090618|Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients|An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart Failure||Amgen||Withdrawn|July 2010|May 2011|Anticipated|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||May 2011|May 26, 2011|February 25, 2010|||Study cancelled due to sponsor's decision to redesign the study|No||https://clinicaltrials.gov/show/NCT01077167||125772|
NCT01077180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360005-001|Rheos Feasibility Trial|Rheos Feasibility Trial- A Study of Baroreflex Hypertension TherapyTM in Refractory Hypertension||CVRx, Inc.|Yes|Completed|January 2005|October 2010|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|21 Years|N/A|No|||October 2011|October 28, 2011|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077180||125771|
NCT01077427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115-09|Hyperthermia European Adjuvant Trial|A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Alone (Arm G) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)|HEAT|Klinikum der Universitaet Muenchen, Grosshadern|Yes|Recruiting|March 2012|March 2017|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|336|||Both|18 Years|75 Years|No|||July 2012|July 18, 2012|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077427||125752|
NCT01096186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX066-B09-03|An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease|An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease||IMPAX Laboratories, Inc.|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|617|||Both|30 Years|N/A|No|||September 2013|February 4, 2016|March 25, 2010|Yes|Yes||No|December 9, 2015|https://clinicaltrials.gov/show/NCT01096186||124319|
NCT01096199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK02/12/09|A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)|A Phase I Study of TS-1, Cisplatin & RAD001 (Everolimus)||National University Hospital, Singapore|No|Terminated||||September 2012|Actual|Phase 1|Interventional|N/A||||35|||Both|21 Years|80 Years|No|||January 2014|January 21, 2014|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096199||124318|
NCT01071707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMET|Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)|COMET: Correlating Outcomes With Biochemical Markers to Estimate Time-progression in IPF. A Prospective, Multi-Center, Longitudinal Follow up Study of Subjects With Idiopathic Pulmonary Fibrosis|COMET|University of Michigan|No|Completed|December 2009|August 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|108|Samples With DNA|whole blood, tissue|Both|35 Years|80 Years|No|Non-Probability Sample|Individuals with suspected or confirmed diagnosis of Idiopathic Pulmonary Fibrosis|November 2009|October 16, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071707||126191|
NCT01072331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A12|Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus|Pharmacokinetic/Pharmacodynamic Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|20 Years|75 Years|No|||April 2013|April 2, 2013|February 18, 2010||No||No|November 20, 2012|https://clinicaltrials.gov/show/NCT01072331||126143|
NCT01072344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT005074|Long Term Chamomile Therapy for Anxiety|Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)||University of Pennsylvania|Yes|Completed|February 2010|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|February 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072344||126142|
NCT01072318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG007|Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene|Evaluate Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Have Completed 5 Years of Toremifene|LEXTOP|Korean Breast Cancer Study Group|Yes|Enrolling by invitation|January 2010|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|495|||Female|N/A|N/A|No|||February 2010|February 18, 2010|February 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01072318||126144|
NCT01068301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZBMT|A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation|A Phase I Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation||St. Jude Children's Research Hospital|No|Completed|May 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|21 Years|No|||December 2013|December 31, 2013|February 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068301||126449|
NCT01077856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-033|GARDASIL™ Vaccine Impact in Population Study (V501-033)|GARDASIL™ Vaccine Impact in Population Study|VIP|Merck Sharp & Dohme Corp.|Yes|Completed|May 2007|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community||2|Actual|54516|Samples With DNA|Tissue, cervical cells|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Registry data from the Population, Cervical Cancer Screening, Pathology, Cancer, and Death        registries; Survey: Questionnaire sent to random sampling of women from the Central        Population Registry Database; HPV Data: liquid-based cytology and histology samples from        hospitals in participating countries|November 2015|November 5, 2015|February 26, 2010|No|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT01077856||125719|
NCT01078402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-919|EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries|Evaluation of Clinical Outcome, Treatment Compliance and Tolerability of humIRA (Adalimumab) in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries; EviraEAST - a Multi-country, Multi-Center Post Marketing Observational Study in Routine Clinical Use|EviraEAST|AbbVie|No|Completed|April 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|809|||Both|18 Years|N/A|No|Non-Probability Sample|Study population consists of adult patients in Eastern European countries with rheumatoid        arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) who can be        administered Humira as per locally approved label.|February 2013|February 8, 2013|February 27, 2010||No||No|November 19, 2012|https://clinicaltrials.gov/show/NCT01078402||125678|
NCT01078415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-205|Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)|A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)||Angiodynamics, Inc.|No|Active, not recruiting|February 2010|October 2013|Anticipated|October 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2011|September 26, 2011|February 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01078415||125677|
NCT01079273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_06TP_OPERA|Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects|An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 to 60 Years||Opera Srl|No|Completed|December 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079273||125614|
NCT01079546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC ZG09 156 CTIL|Human Papillomavirus (HPV) in Squamous Cell Carcinoma of the Head and Neck|Retrospective Trial to Assess HPV Epidemiology in Squamous Cell Carcinoma of Head and Neck|HPV|Tel-Aviv Sourasky Medical Center|Yes|Enrolling by invitation|January 2010|January 2011|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||7|Anticipated|100|Samples With DNA|Parafin blocks from squamous cell carcinoma of head and neck|Both|18 Years|N/A|No|Probability Sample|The group will include patients treated with primary surgery or biopsy, with or without        adjuvant radiotherapy between 1998 and 2010 for SCC of the oral cavity, oropharynx,        hypopharynx, larynx and paranasal sinuses.        The anatomic site and extent of the primary tumor will be documented. The TNM        classification of will be based on the staging system revised by the American Joint        Committee on Cancer (AJCC). Patients will be recruited from seven national cancer referral        hospitals, including Soroka Medical Center in the Negev (Beer Sheva), Sourasky Medical        Center (Tel Aviv), Rabin Medical Center (Petach Tikva), Hadassa Medical (Jerusalem),        Rambam Medical Center (Haifa), Sheba medical center (Ramat- Gan) and French Hospital        Nazareth (Nazareth). These centers cover almost the entire population in Israel, including        Israeli Jews, Bedouins, Druze and Israeli Arab population.|March 2010|March 2, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079546||125594|
NCT01079806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-189 ST|A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection|A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) Versus Placebo in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive||Bristol-Myers Squibb|Yes|Active, not recruiting|June 2010|March 2018|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|2 Years|17 Years|No|||August 2015|August 11, 2015|March 2, 2010|Yes|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT01079806||125574|
NCT01079819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-029|Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163|Randomized, Placebo-controlled, Double-blind, Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163 in Healthy Young Male and Elderly Male and Female Chinese Subjects||Bristol-Myers Squibb|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|N/A|No|||February 2011|February 4, 2011|March 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01079819||125573|
NCT01080092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/020|Effect of Stress-management and Biofeedback on Craving in Smoking Abstinence: A Pilot Study|Effect of Stress-management and Biofeedback on Craving in Smoking Abstinence: A Pilot Study||University Hospital, Ghent|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 1, 2011|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080092||125552|
NCT01080573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMFM 100|Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis|A Questionnaire Based Survey to Identify Issues With Patient Compliance and to Develop Solutions to Improve Rebif Compliance and Improve Patient Outcomes|AIMS|Merck KGaA|No|Completed|January 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1257|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who have been prescribed Rebif and referred to Bupa Home Healthcare service by        one of the participating referring centres.|April 2011|July 30, 2014|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080573||125515|
NCT01080586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US/AHD/07/014|Bioequivalence Study of Cyclosporine 100mg Capsule Under Fed Condition|A Randomized Single Dose Open Label Bioequivalence Study of Cyclosporine Capsules USP (Modified)100mg in Normal Healthy Male Subjects Under Fed Condition||Panacea Biotec Ltd|No|Completed|September 2007|October 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080586||125514|
NCT01080599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0137|Comparison of the Success Rate of Two Approaches for Obturator Nerve Block in TURB (Conventional Pubic Approach [Labat Technique] and Inguinal Approach)|Comparison of the Success Rate of Two Approaches for Obturator Nerve Block in TURB (Conventional Pubic Approach [Labat Technique] and Inguinal Approach)||Yonsei University||Completed|June 2009|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment|2||Actual|100|||Both|20 Years|N/A|No|||March 2010|March 3, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080599||125513|
NCT01081197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE_ARP_Somatic_AlcoholAddicts|Somatic Disease Among Alcohol Abusers in an Out-day Patients' Clinic|Somatic Disease Among Alcohol Abusers in an Out-day Patients' Clinic. A Neglected Area||Levanger Hospital|No|Completed|March 2010|May 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|150|Samples Without DNA|Conventional blood samples including i.e. glycosylated haemoglobin, serum ferritin, serum      gamma-GT, B-type natriuretic peptide.|Both|18 Years|N/A|No|Non-Probability Sample|Alcohol abusers referred to the out-day patients' clinic at Dep. of Psychiatry, Levanger        Hospital, Norway|May 2013|May 2, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081197||125468|
NCT01077154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060359|Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)||Amgen|Yes|Active, not recruiting|May 2010|August 2022|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4509|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077154||125773|
NCT01081210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH-2010-1|Screening of Patients Admitted to a Local Hospital With Pocket-sized Ultrasound|Screening With Pocket-sized Ultrasound of Patients Admitted to Department of Medicine at a Local Hospital||Levanger Hospital|Yes|Completed|March 2010|October 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Serum blood samples including; hematology, electrolytes, creatinine, liver enzymes and      cholestasis parametres, brain natriuretic peptides etc.|Both|16 Years|N/A|No|Probability Sample|Patients admitted to Dep. of Medicine at Levanger Hospital Randomized study. Both sexes.        Age above 16 years|February 2010|March 29, 2011|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01081210||125467|
NCT01077193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-09-0006|Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication|Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication||Ethicon Endo-Surgery|No|Terminated|November 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|65 Years|No|||January 2014|January 8, 2014|February 25, 2010||No|Study was terminated due to commercial considerations and potential patient attrition at 3    years. There were no patient safety or procedure efficacy reasons.|No|July 9, 2013|https://clinicaltrials.gov/show/NCT01077193||125770|
NCT01095939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-136|Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Benazepril (ATC N° C09AA07) in the Treatment of Persistent Renal Dysfunction in Pre-eclamptic Women|RPPEC|University Hospital, Geneva|No|Recruiting|April 2010|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||January 2013|January 24, 2013|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095939||124338|
NCT01095952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVNS|AV-node Stimulation Clinical Download Study to Reduce Ventricular Rate During AF|Reduction of Ventricular Rate During Atrial Fibrillation by AV Node Stimulation" AVNS Download Study|AVNS|Medtronic BRC|No|Completed|November 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01095952||124337|
NCT01096212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asan Medical Center_sevofran_1|Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia|A Multi-center, Open-Label, Randomized, Active-controlled, Parallel, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia||Asan Medical Center|No|Completed|September 2008|March 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Both|19 Years|N/A|No|||March 2010|March 30, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096212||124317|
NCT01096498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14355|Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel|Open-label, Randomized, Crossover Study to Prove Bioequivalence Between Opxion® (Levonorgestrel 0.75 mg From Bayer de Mexico) and Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers|LEVEQ-2|Bayer|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 8, 2013|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096498||124295|
NCT01071733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FREEUS|Fracture Evaluated in Emergency Room by Ultra Sound|Fracture Evaluated in Emergency Room by Ultra Sound|FREEUS|University of Aarhus|No|Recruiting|December 2009|December 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|patients in emergency room|September 2012|September 12, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071733||126189|
NCT01072058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CapPesq1252/07|Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker|Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker||University of Sao Paulo|No|Active, not recruiting|February 2008|||February 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|100|||Both|18 Years|70 Years|No|||June 2013|June 5, 2013|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072058||126164|
NCT01077089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dorlac-2010-01|Effects of Transport on Patients With Traumatic Brain Injury|Effects of Transport on Patients With Traumatic Brain Injury||University of Cincinnati|No|Completed|February 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with traumatic brain injury|February 2013|February 22, 2013|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077089||125778|
NCT01072591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2460C00001|Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee|A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee||AstraZeneca|Yes|Terminated|February 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|40 Years|80 Years|No|||January 2013|January 28, 2013|February 19, 2010||No|Amended clinical development plan.|No||https://clinicaltrials.gov/show/NCT01072591||126123|
NCT01072604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14558|Pharmacokinetic Study Comparing Aspirin and Aspirin Granules|An Open Label Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Aspirin Tablets and Aspirin Dry Granules in Healthy Adult Subjects||Bayer|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 18, 2014|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072604||126122|
NCT01077622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112758|A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia|A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia||GlaxoSmithKline||Completed|September 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||February 2012|October 31, 2013|February 25, 2010||No||No|December 21, 2011|https://clinicaltrials.gov/show/NCT01077622||125737|
NCT01078662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00042|Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats|A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation||AstraZeneca|No|Active, not recruiting|February 2010|December 2016|Anticipated|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|318|||Both|18 Years|130 Years|No|||November 2015|December 4, 2015|March 1, 2010|Yes|Yes||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01078662||125658|
NCT01078961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-443|An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma|A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2010|||February 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|March 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01078961||125636|
NCT01079286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCmedonc09/039|Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers|Phase I Study of Nelfinavir in Combination With Temsirolimus in the Treatment of Patients With Advanced Cancers, Including Second Line Renal Cell Cancer|I-NET|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|June 2009|August 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01079286||125613|
NCT01079559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-2010-222495|The Effectiveness of Antibiotic Cement (ABC) Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Trial|The Effectiveness of Antibiotic Cement Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Feasibility Study|ABC|University of Western Ontario, Canada|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079559||125593|
NCT01079832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE13808|Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies|A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|May 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||September 2013|September 27, 2013|March 2, 2010|Yes|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01079832||125572|
NCT01080105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU IRB STU00020637|Internet Intervention for the Prevention of Depression - Approaches to Improving Mood|Technology Assisted Behavioral Intervention for the Prevention of Depression|AIM|Northwestern University|No|Withdrawn|June 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 29, 2012|March 2, 2010||No|This is withdrawn because we started working on studies that are funded.|No||https://clinicaltrials.gov/show/NCT01080105||125551|
NCT01077206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW005|High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage|High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage: Is it Better?|HDS-SAH|Chinese University of Hong Kong|Yes|Completed|September 2010|September 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|255|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077206||125769|
NCT01080872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-005|Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome|Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome|BASE-CFR|The Hospital District of Satakunta|Yes|Completed|December 2009|May 2011|Actual|May 2011|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|30 Years|90 Years|No|Non-Probability Sample|Patients with acute coronary syndrome who were treated with BAS or EES during index PCI.|May 2011|May 4, 2011|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080872||125492|
NCT01077726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22203|A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression|A Single Arm, Open-label Trial Assessing the Effect of Capecitabine (Xeloda® ) on Progression-free Survival Rate at Four Months in Breast Cancer Patients With CNS Progression After Whole Brain Radiotherapy||Hoffmann-La Roche||Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01077726||125729|
NCT01067521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-GA-301|A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo|A Multinational, Multicenter, Randomized, Parallel-group Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess Efficacy, Safety and Tolerability of Glatiramer Acetate Injection 40mg Compared to Placebo in a Double-blind Design|GALA|Teva Pharmaceutical Industries|Yes|Active, not recruiting|May 2010|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1404|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067521||126507|
NCT01067534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOT_PATR_2010|Bronchodilator Responsiveness in Healthy Young Adults Using Forced Oscillations Technique (FOT)|Assessment of Bronchodilator Responsiveness in Healthy Young Adults Using Forced Oscillations||University of Patras|No|Completed|February 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||April 2010|January 18, 2011|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067534||126506|
NCT01067820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX222-CS-007|ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation|Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound|ASSURE I|Resverlogix Corp|Yes|Completed|September 2011|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067820||126485|
NCT01081080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITT0110|Cardiac Magnetic Resonance in Children With Muscular Dystrophy|PITT0110 - Cardiac Magnetic Resonance: A Parallel Protocol to Cardiac Outcome Measures in Children With Muscular Dystrophy||Cooperative International Neuromuscular Research Group|Yes|Completed|April 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|8 Years|18 Years|No|Non-Probability Sample|Participants will be recruited from the parallel protocol: PITT1109 Cardiac Outcome        Measures in Children with Muscular Dystrophy|January 2013|January 10, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081080||125476|
NCT01081093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bivent001AR-AHK|Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement|Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement|BIVENT|Johann Wolfgang Goethe University Hospitals|No|Completed|April 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081093||125475|
NCT01077375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-28|Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia||Forest Laboratories|No|Completed|February 2010|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|70 Years|No|||December 2011|December 21, 2011|February 25, 2010|Yes|Yes||No|December 21, 2011|https://clinicaltrials.gov/show/NCT01077375||125756|
NCT01077362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016483|A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s)||Janssen Research & Development, LLC|Yes|Completed|March 2010|November 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|312|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|February 25, 2010|Yes|Yes||No|October 11, 2013|https://clinicaltrials.gov/show/NCT01077362||125757|
NCT01077869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/621|A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis|A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis||University Hospital, Ghent|No|Terminated|January 2010|May 2011|Actual|May 2011|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Squamous cell carcinoma of the oral cavity, oropharynx and lymph node metastases from        unknown primary tumor.|May 2011|May 25, 2011|February 25, 2010||No|poor recruitment rate|No||https://clinicaltrials.gov/show/NCT01077869||125718|
NCT01077882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/691|Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis|Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis|OnderHUIDs|University Hospital, Ghent|No|Completed|January 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|75 Years|No|||July 2012|July 4, 2012|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077882||125717|
NCT01078675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3561C00002|An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia|An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (Aged From 6 to Less Than 18 Years) With Familial Hypercholesterolaemia||AstraZeneca|No|Completed|February 2010|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|315|||Both|6 Years|17 Years|No|||March 2015|March 19, 2015|February 25, 2010|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01078675||125657|
NCT01078688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RFR-DUM-2009/2|Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma|Evaluation of the Frequency of Limitation of Activity, Depending on Gender and Age-group, in Patients With Persistent Asthma Consulting a General Practitioner|ASMAVIE|AstraZeneca|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1942|||Both|18 Years|N/A|No|Probability Sample|First 3 consecutive patients with persistent asthma seen by general practitioner receiving        long-term maintenance treatment with inhaled steroids|January 2013|January 28, 2013|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01078688||125656|
NCT01078974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007|Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia|Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Relapsed or Refractory Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2010|December 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|March 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01078974||125635|
NCT01078987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51018|Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)|Use of Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) and Understanding Its Etiology|NFD|Loma Linda University|No|Terminated|February 2002|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|February 5, 2010||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01078987||125634|
NCT01079572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI-2010-01|Cost-Effectiveness of Web-Based Follow Ups|Cost-Effectiveness of Web-Based Follow Up Following Total Joint Arthroplasty||University of Western Ontario, Canada|No|Completed|February 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|260|||Both|N/A|N/A|No|||February 2013|February 6, 2013|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079572||125592|
NCT01079845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02-0069|A Cooking and Eating Study|Low-glycemic Load vs. Low-fat Diet for Treating PCOS in Obese Adolescents and Young Adults|ACES|Children's Hospital Boston|No|Terminated|July 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Female|13 Years|21 Years|No|||February 2015|February 4, 2015|March 2, 2010||No|For this pilot, we constructed conditional power curves and noted that we would not    substantially enhance power by enrolling additional participants.|No||https://clinicaltrials.gov/show/NCT01079845||125571|
NCT01079858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-61|Evaluation of FID 114657 in Dry Eye Subjects|||Alcon Research|No|Completed|February 2010|||April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079858||125570|
NCT01079871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-65|Evaluation of FID 114657 in Sjogren's Syndrome Subjects|||Alcon Research|No|Completed|February 2010|||June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079871||125569|
NCT01080118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00007644|Effectiveness of Video System in Improving Learning of Tracheal Intubation Using Standard Laryngoscopy Among Novices|A Clinical Trial on the Effectiveness of Video System in Improving Learning of Tracheal Intubation Using Standard Laryngoscopy Among Novices||Northwestern University|No|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|90|||Both|18 Years|75 Years|No|||October 2013|October 29, 2013|February 26, 2010||No||No|March 2, 2012|https://clinicaltrials.gov/show/NCT01080118||125550|The intubating laryngeal mask airway the optical laryngoscope device used in this study does not allow for ventilation of the patient if intubation fails. We did not study retention of airway management skills between the groups.
NCT01080885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-149|Healthy Homes/Healthy Kids Preschool|Linking Home Environments and Primary Care: Obesity Prevention for 2-5 Year Olds|HHHK|HealthPartners Institute|Yes|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|2 Years|4 Years|No|||April 2012|April 20, 2012|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080885||125491|
NCT01080352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008692-33|Vitamin C as an Anti-cancer Drug|Evaluation of Cytotoxicity and Genetic Changes of High Dose Vitamin C Infusions in Castration Resistant Metastatic Human Prostate Cancer||Copenhagen University Hospital at Herlev|Yes|Completed|November 2010|March 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Male|18 Years|N/A|No|||March 2015|March 25, 2015|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080352||125532|
NCT01080365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3160A4-1120|Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions|A Single Dose Bioequivalence Study Comparing The Commercial Tablet Formulation To The Clinical Tablet Of Bosutinib In Healthy Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 3, 2010|March 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01080365||125531|
NCT01077232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-446|Documentation of Humira in Psoriasis Patients in Routine Clinical Practice|Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of HUMIRA (Adalimumab sc) for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice|LOTOS|AbbVie|No|Active, not recruiting|January 2008|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5500|||Both|18 Years|99 Years|No|Non-Probability Sample|Community Sample: Patients with Plaque Psoriasis|January 2016|January 25, 2016|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077232||125767|
NCT01077479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGWH009|Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome|Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome|MVENT|Western Sydney Local Health District|Yes|Completed|February 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Male|18 Years|N/A|No|||May 2014|May 13, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077479||125748|
NCT01077466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAPMS version 3.4|Natalizumab Treatment of Progressive Multiple Sclerosis|Natalizumab Treatment of Progressive Multiple Sclerosis|NAPMS|Rigshospitalet, Denmark|Yes|Completed|March 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|19 Years|55 Years|No|||February 2012|February 15, 2012|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077466||125749|
NCT01077739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22519|A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin|A Single-arm Open-label Phase II Study: Treatment Beyond Progression by Adding Bevacizumab to XELOX or FOLFOX Chemotherapy in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI + Bevacizumab Combination||Hoffmann-La Roche||Completed|July 2009|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|February 26, 2010||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01077739||125728|
NCT01066962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015113-44|Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects|An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001)|ANRS 143|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|August 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|800|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066962||126550|
NCT01066975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7645-NS-CTIL|Mechanical Load on the Shoulders While Carrying a Backpack- Towards a Knowledge-Based Backpack Design|Mechanical Load on the Shoulders While Carrying a Backpack- Towards a Knowledge-Based Backpack Design||Sheba Medical Center|No|Not yet recruiting|February 2010|April 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Male|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Five young (18-30 yrs), healthy, and fit males will participate in this study. Prior to        signing a consent form, the PI will explain to the subjects about the MRI that they are        about to participate in if they will decide to sign including all the discomforts involved        in this study. For subjects that don't have contraindications for MRI there are no        reported risks.        The subjects will be informed that each one of them is free to decide, and is free to stop        his participation any time he wishes to.|February 2010|February 9, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01066975||126549|
NCT01066988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-046|Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness|||Alcon Research|No|Completed|January 2010|||February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01066988||126548|
NCT01081106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 09CC2|Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer|Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer||Northwestern University|Yes|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Female|18 Years|N/A|No|||July 2012|July 30, 2012|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01081106||125474|
NCT01081119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA016577|Brief Voluntary Alcohol and Drug Intervention for Middle School Youth|Brief Voluntary Alcohol and Drug Intervention for Middle School Youth|CHOICE|RAND|No|Completed|September 2008|June 2014|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6455|||Both|11 Years|15 Years|No|||July 2014|July 9, 2014|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081119||125473|
NCT01077102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUHC Pilot Project 2007|Eccentric Exercise Training as Novel Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD)|Eccentric Training as Novel Rehabilitation for COPD||McGill University Health Center|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|40 Years|80 Years|No|||December 2015|December 4, 2015|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077102||125777|
NCT01077895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/721|The Influence of Fluid Removal Using Continuous Venovenous Hemofiltration (CVVH) on Intra-abdominal Pressure and Kidney Function|The Influence of Fluid Removal Using Continuous Venovenous Hemofiltration (CVVH) on Intra-abdominal Pressure and Kidney Function in Critically Ill Adults With Intra-abdominal Hypertension and Acute Kidney Injury||University Hospital, Ghent|No|Recruiting|February 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077895||125716|
NCT01077635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112880|PENTA Fosamprenavir Study|An Observational Multi-cohort Study on the Use of Fosamprenavir-Ritonavir Among HIV-infected Children and Adolescents in Europe||ViiV Healthcare|No|Completed|October 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|6 Years|18 Years|No|Probability Sample|Seven paediatric HIV cohorts participating in the European Pregnancy and Paediatric HIV        Cohort Collaboration (EPPICC) as follows: French Perinatal Cohort Study / Enquête        Périnatale Français; Hospital St.Pierre Cohort, Brussels; Italian Register for        HIV-infection in Children; Madrid Cohort of HIV-infected Children; Spanish Perinatal        Cohort Study [NENEXP], Catalonia, Spain; UK National Study of HIV in Pregnancy and        Childhood [NSHPC] & Collaborative HIV Paediatric Study [CHIPS]; and the "Victor Babes"        Hospital Cohort, Romania.|January 2012|February 2, 2012|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077635||125736|
NCT01079013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7425-AN-CTIL|Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies|Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies||Sheba Medical Center|No|Active, not recruiting|March 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|68 Years|No|||December 2015|December 1, 2015|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079013||125632|
NCT01079299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-VU-0308|Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema|Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency||Calvary Hospital, Bronx, NY|No|Completed|December 2007|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|21 Years|95 Years|No|||August 2010|January 9, 2012|March 2, 2010||No||No|August 18, 2011|https://clinicaltrials.gov/show/NCT01079299||125612|
NCT01080131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2357|Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.|A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective Including a 12 Weeks Extension Study and a 1 Year Open-label Extension Study|β-RELIEVED-II|Novartis||Completed|March 2010|October 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|85 Years|No|||April 2013|December 24, 2013|March 2, 2010|Yes|Yes||No|August 30, 2011|https://clinicaltrials.gov/show/NCT01080131||125549|
NCT01080144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 156 02|Feasibility of Critical Flicker Frequency Procedure for the Diagnosis of Minimal Encephalopathy|A Pilot Study Aiming to Assess the Feasibility of Critical Flicker Frequency for the Diagnosis of Minimal Encephalopathy in Patients With Cirrhosis||University Hospital, Toulouse|No|Completed|October 2009|December 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080144||125548|
NCT01080378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB C/09/604|Metabolic Effects of Birth Weight on Overweight and Obese Chinese Adults and Their Responses to Weight Loss|Developmental Pathways to Metabolic Diseases: To Investigate the Metabolic Effects of Birth Weight on Overweight and Obese Chinese Adults and Their Responses to Weight Loss Over 16 Weeks|SAMS-2|National University Hospital, Singapore|No|Not yet recruiting|April 2010|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|180|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|February 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01080378||125530|
NCT01080612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081239|A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Pregabalin Controlled Release Formulation Administered Following Various Caloric Intakes As Compared To The Immediate Release Formulation||Pfizer|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|March 4, 2015|February 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01080612||125512|
NCT01080625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWJung_phen_epi_liver TPL|Effect of Epinephrine/ Phenylephrine for Preventing the Postreperfusion Syndrome During Reperfusion in Liver Transplantation|Effect of Preventive Medicine on the Postreperfusion Syndrome||Seoul National University Hospital|No|Completed|April 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|96|||Both|18 Years|75 Years|No|||May 2012|May 1, 2012|March 2, 2010||No||No|February 13, 2012|https://clinicaltrials.gov/show/NCT01080625||125511|
NCT01080898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K080904|Evaluation of Optical Coherence Tomography.|Evaluation of the Sensitivity and Specificity of Optical Coherence Tomography Combined With Fundus Color Photos for Diagnosis of Choroidal Neovessels in Age-related Macular Degeneration|ESSO|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|151|||Both|50 Years|N/A|No|Probability Sample|patients > 50 years with suspicion of choroidal neo-vessels complicating age relatid        macular degeneration (DMLA)|April 2011|July 20, 2012|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01080898||125490|
NCT01080911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si073/2010|0.05 mg Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy|0.05 vs. 0.1 Milligram Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy With/Without Anterior and Posterior Vaginoplasty||Mahidol University|No|Recruiting|March 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|N/A|No|||September 2011|September 5, 2011|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080911||125489|
NCT01081223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVI-AST-002|Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma|Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma||TVAX Biomedical|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|March 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081223||125466|
NCT01077245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-001|Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections|A Phase 2 Study to Evaluate the Safety and Potential Efficacy of Clostridium Butyricum MIYAIRI 588 Strain (MIYA-BM Fine Granules) for the Prevention of Recurrent Clostridium Difficile Infections||Osel, Inc.|Yes|Withdrawn|February 2010|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||November 2013|November 8, 2013|February 25, 2010|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01077245||125766|
NCT01077492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/327|Virtual Bronchoscopy Transbronchial Needle Aspiration(TBNA): a Proof of Concept Study|CT-PET Virtual Bronchoscopy Guided Transbronchial Needle Aspiration for Mediastinal Lymph Node Staging in Suspected Lung Cancer||VU University Medical Center|No|Terminated|April 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected lung cancer requiring mediastinal lymph node staging after CT-PET        scan during routine work-up according to local guidelines.|February 2010|November 1, 2012|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077492||125747|
NCT01077752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 08028|Local Anesthetic Continuous Preperitoneal Infiltration and Wound Hyperalgesia|Effect of Local Anesthetic Continuous Preperitoneal Wound Infiltration on Incisional Hyperalgesia Following Colorectal Laparoscopic Surgery|CATCH|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2010|February 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|95|||Both|18 Years|80 Years|No|||January 2014|January 20, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077752||125727|
NCT01067001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amneal-10-01|Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study|Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover, Bioequivalence Study in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.|Minocycline|Amneal Pharmaceuticals Co. India Private Limited|No|Completed|September 2009|November 2009|Actual|October 2009|Actual|N/A|Observational|N/A||2|Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.|February 2010|February 9, 2010|February 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01067001||126547|
NCT01077388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01HL075263-05|e-Care for Heart Wellness|Collaborative Behavioral e-Care to Decrease Cardiovascular Risk (e-Compare)|e-Compare|Group Health Cooperative|Yes|Completed|May 2010|August 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|30 Years|69 Years|No|||July 2013|July 16, 2013|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077388||125755|
NCT01077648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112951|Brain Metastasis in Breast Cancer Patients|Occurrence of Brain Metastasis in Breast Cancer Patients Diagnosed at Advanced Stages of the Disease||GlaxoSmithKline|No|Completed|February 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Female|30 Years|N/A|No|Probability Sample|This study aims to retrospectively collect data on nearly 4,000 advanced breast cancer        cases treated within the Henry Ford Health System|May 2014|May 22, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077648||125735|
NCT01077908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-2008-01|Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study|A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant|CMV-IMPACT|Cell Medica Ltd|Yes|Completed|July 2008|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|91|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077908||125715|
NCT01078129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-094B|Cognitive Remediation Therapy and Schizophrenia|Efficacy of Hierarchized Computer-assisted Cognitive Remediation Therapy in Schizophrenia||Hôpital le Vinatier|No|Completed|January 2006|December 2010|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|77|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01078129||125698|
NCT01078454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02010|Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis|A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation||National Cancer Institute (NCI)|Yes|Completed|November 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||April 2014|November 20, 2014|February 27, 2010|Yes|Yes||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01078454||125674|
NCT01078467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100020|The Molecular Anatomy of Oral Wound Healing|The Molecular Anatomy of Oral Wound Healing||National Institutes of Health Clinical Center (CC)||Completed|February 2010|||||N/A|Observational|Time Perspective: Prospective|||Actual|53|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 11, 2016|February 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01078467||125673|
NCT01078116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-159|Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)|Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis|HEOR|Abbott|No|Completed|November 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with rheumatoid arthritis, from hospital centres and private physicians, who were        prescribed adalimimab according to the approved SmPC in the European Union, prior to the        study enrollment|August 2011|August 9, 2011|February 26, 2010||No||No|June 24, 2011|https://clinicaltrials.gov/show/NCT01078116||125699|Study NCT 01078116 (P10-159) is a substudy of NCT 01086033(GREC-2004-06). Adverse events were not recorded in this study but will be reported in the main study upon completion. Only adverse events leading to withdrawal are reported in this substudy.
NCT01078428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 193/2009|Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars|Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars||Mahidol University|Yes|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|February 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01078428||125676|
NCT01079312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a001c|Patient-controlled Sedation With Propofol and Remifentanyl for Endoscopic Retrograde Cholangiopancreatography (ERCP)|Patient-controlled Sedation vs Propofol Infusion for ERCP:a Randomized Controlled Study||Helsinki University Central Hospital|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||July 2012|July 4, 2012|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079312||125611|
NCT01079325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-509-0901|Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy|A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderately Severe Diabetic Neuropathy||Sangamo Biosciences|No|Active, not recruiting|November 2009|December 2015|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||November 2015|November 16, 2015|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01079325||125610|
NCT01079585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-NV-014-CTIL|The Effect of 40gr Okara on Gastric Emptying|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|March 2010|December 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind|1||Anticipated|10|||Both|20 Years|65 Years||||February 2010|March 2, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01079585||125591|
NCT01079598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFS-09-01|RFS - Radiofrequency Perforator Vein Treatment Study|A Prospective Multicenter Study on the Treatment of Incompetent Perforators With the VNUS® Closure Radiofrequency Stylet|TRIPLE|VNUS Medical Technologies, A Covidien Company|No|Terminated|March 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||April 2012|April 18, 2012|February 24, 2010|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT01079598||125590|
NCT01080157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2712|Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes|An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes|ENGINE|VeraLight, Inc.|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|509|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Volunteers age 18 and above, of either sex and of any ethnic background, will be recruited        at up to 12 clinical sites. All subjects will be at risk for diabetes based on the        American Diabetes Association Standard of Care Guidelines. Those in the 18-44 age group        will have an additional risk factor, and the addition of the waist circumference and        hypertension thresholds from the National Cholesterol Education Program Adult Treatment        Panel III Guidelines for metablolic syndrome|December 2012|December 3, 2012|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080157||125547|
NCT01080391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-009|Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma|A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma||Onyx Pharmaceuticals|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|792|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|March 2, 2010|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT01080391||125529|
NCT01080638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0906-046-283|Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.|||Seoul National University Hospital|Yes|Recruiting|October 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||March 2010|March 2, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01080638||125510|
NCT01080924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/10 Pabes|Demonstration of Broncholytic Effects in Subjects With Obstructive Airway Diseases by Low Frequency Ultrasound||Pabes|Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080924||125488|
NCT01081236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-125|Intestinal Barrier Function and Liver Cirrhosis|The Role of the Intestinal Barrier Function in Liver Cirrhosis||Maastricht University Medical Center|No|Recruiting|May 2010|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|62|||Both|18 Years|65 Years|No|Non-Probability Sample|The study population will be selected from a hospital providing both secondary and        tertiary care|December 2010|December 15, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081236||125465|
NCT01077219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905044R|Study on Energy Cost Prediction of Cycle Ergometer|||National Taiwan University Hospital|Yes|Completed|June 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|40|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy female|February 2010|February 26, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077219||125768|
NCT01077765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040601|Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy|Open Label, Multicenter, Single Arm Trial of the Safety and Efficacy of Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus-Related Facial Lipoatrophy : THE LIPOPHILL TRIAL|LIPOPHILL|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2005|September 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||January 2010|February 26, 2010|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077765||125726|
NCT01077505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107032|An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .|An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With Albiglutide in Healthy Adult Female Subjects||GlaxoSmithKline|Yes|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077505||125746|
NCT01077518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110918|Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen|A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment|COMPLEMENT A+B|Novartis|Yes|Recruiting|August 2010|July 2023|Anticipated|July 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|346|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077518||125745|
NCT01078272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-25|The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)|The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)|SaFR|St. Francis Hospital, New York|No|Not yet recruiting|March 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|40 Years|80 Years|No|||February 2010|March 1, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078272||125688|
NCT01078532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS018167|Self Management and Reminders With Technology: SMART Appraisal of an Integrated Personal Health Record (PHR)|Self Management & Reminders With Technology: SMART Appraisal of an Integrated Personal Health Record (SMART PHR)|SMART PHR|University of Pittsburgh|No|Completed|April 2010|September 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1815|||Both|18 Years|75 Years|No|||May 2014|May 20, 2014|February 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01078532||125668|
NCT01067027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colic001|Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri|Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri||Children's Investigational Research Program, LLC|Yes|Recruiting|June 2009|June 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|60 Days|Accepts Healthy Volunteers|||June 2011|June 28, 2011|February 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01067027||126545|
NCT01067040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2009-01-SEN-IARG2-ED|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2009|||||N/A|N/A|N/A||||||||||||||February 9, 2010|August 19, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067040||126544|
NCT01067053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-0901|Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.|A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment|BECOX|Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Active, not recruiting|November 2009|March 2014|Anticipated|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|70 Years|N/A|No|||January 2014|January 8, 2014|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01067053||126543|
NCT01077401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00034586|Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study|Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study|READ 3|Johns Hopkins University|Yes|Recruiting|February 2010|March 2013|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||February 2010|March 29, 2010|February 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077401||125754|
NCT01077414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090227|Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness|Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness||National Institutes of Health Clinical Center (CC)||Completed|September 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|37|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077414||125753|
NCT01077661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113554|Regulatory Nebilet PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Nebilet Administered in Korean Patients According to the Prescribing Information|Nebilet PMS|GlaxoSmithKline|No|Completed|October 2009|January 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|743|||Both|N/A|N/A|No|Probability Sample|Patients administrated Nebivolol at the site|March 2011|March 10, 2011|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077661||125734|
NCT01077674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kotoe_03|Comparison of Two Electroencephalogram (EEG)-Derived Indices With Electroencephalogram Signals|Comparison of Bispectral Index and Entropy With Electroencephalogram During Sevoflurane Anaesthesia||Tampere University Hospital|No|Completed|December 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|65|||Both|50 Years|N/A|No|Non-Probability Sample|Middle aged and elderly surgical patients|October 2013|October 8, 2013|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01077674||125733|
NCT01078142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341|Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma|A Phase I/II Trial to Evaluate the Safety, Feasibility and Efficacy of the Addition of Temsirolimus to a Regimen of Bendamustine and Rituximab for the Treatment of Patients With Follicular Lymphoma or Mantle Cell Lymphoma in First to Third Relapse|BERT|Johannes Gutenberg University Mainz|Yes|Active, not recruiting|January 2010|March 2018|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01078142||125697|
NCT01078155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-733|Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis|Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis||AbbVie|No|Completed|March 2009|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|131|Samples With DNA|osteocalcin (OC), C-terminal type I procollagen peptide (CICP), C-telopeptide of type I      collagen (CTX-I), whole blood (serum)|Both|18 Years|N/A|No|Non-Probability Sample|Patients with active rheumatoid arthritis|May 2015|May 29, 2015|February 26, 2010||No||No|May 12, 2015|https://clinicaltrials.gov/show/NCT01078155||125696|
NCT01078701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHB-CS07|Dose Finding Study of Single Dose GHB11L1 in Healthy Adults|Randomised, Double-blind, Placebo-controlled, Phase IIa Dose Finding Study of Single Dose GHB11L1 in Healthy Adults|GHB-CS07|AVIR Green Hills Biotechnology AG|No|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 4, 2011|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078701||125655|
NCT01078441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02002|Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant|A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant||National Cancer Institute (NCI)|No|Terminated|September 2010|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||July 2014|January 5, 2015|February 27, 2010|Yes|Yes|The study was closed early due to weak accrual on June 26, 2012.|No|January 5, 2015|https://clinicaltrials.gov/show/NCT01078441||125675|
NCT01079624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIP/GLP-gastric empt-APP-hor|GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose|Effects of GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose Homeostasis|GIP-GLP-gas|Uppsala University|No|Completed|August 2006|November 2009|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2009|March 2, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079624||125588|
NCT01079923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007602|Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation|Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation||Mayo Clinic|Yes|Completed|February 2010|June 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079923||125565|
NCT01079936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0661|Lenalidomide and High-Dose Melphalan|Phase I/II Study Of The Combination Of Lenalidomide With High-Dose Melphalan For Autologous Transplant in Patients With Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Completed|March 2010|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|80 Years|No|||March 2015|March 30, 2015|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079936||125564|
NCT01079949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27262|A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age|Lutropin Alfa (Luveris®) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age: Phase II Clinical Trial||Merck KGaA|No|Terminated|November 2007|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Female|35 Years|42 Years|No|||January 2014|January 26, 2014|March 2, 2010||No|Trial was terminated due to low recruitment rate|No|November 12, 2012|https://clinicaltrials.gov/show/NCT01079949||125563|
NCT01079884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSESOM0438|Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance|Gastroesophageal Reflux Disease, Sleep, and the Relationship to Driving Simulator Performance||Digestive & Liver Disease Specialists|No|Completed|July 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|18|||Both|18 Years|60 Years|No|||February 2012|February 21, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079884||125568|
NCT01079897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133-002|Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis|A Randomized, Comparator-controlled, Double-blind, Multicenter Intra-individual Clinical Trial to Evaluate the Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis||Bitop AG|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||October 2011|October 17, 2011|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079897||125567|
NCT01080404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5551821|A Study of Surgical Weight Loss to Treat Obstructive Sleep Apnea|Obesity, Metabolism and Obstructive Sleep Apnea: Prevalence and the Effect of Bariatric Surgery||Kuopio University Hospital|No|Recruiting|May 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080404||125528|
NCT01080651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT09_Vori2C19_B|Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole|Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part B)||Seoul National University Hospital|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||August 2011|August 17, 2011|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080651||125509|
NCT01077258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-448|Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice|Effectiveness and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice||AbbVie|No|Completed|April 2004|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4208|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample: patients with rheumatoid arthritis who resided in Germany. German        regulations state that all patients are eligible for non-interventional studies; there are        no exclusions. Adult patients (≥ 18 years of age) with RA who were preparing to initiate        adalimumab therapy according to the product label were eligible for study enrollment. The        eligibility criteria below reflect the approved label as stated in the German Summary of        Product Characteristics (SPC) for Humira.|April 2014|April 9, 2014|February 25, 2010||No||No|February 28, 2014|https://clinicaltrials.gov/show/NCT01077258||125765|
NCT01081249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB 080953|Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting|Physiologic Correlates of Perceived [Therapist] Empathy and Social-Emotional Process During Psychotherapy: Testing Oxytocin in a Cross-Over Design Pilot Study|OT-PT|MacDonald, Kai, M.D.|No|Completed|December 2008|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|65 Years|No|||October 2014|October 13, 2014|March 3, 2010|Yes|Yes||No|September 16, 2014|https://clinicaltrials.gov/show/NCT01081249||125464|
NCT01081262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02516|Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer|A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)||National Cancer Institute (NCI)|Yes|Active, not recruiting|October 2010|||July 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|332|||Female|18 Years|N/A|No|||November 2015|March 4, 2016|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081262||125463|
NCT01077544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2120|A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)|A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL||Novartis|Yes|Completed|April 2011|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|1 Year|18 Years|No|||December 2015|December 18, 2015|February 26, 2010|No|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01077544||125743|
NCT01077986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCmedonc08/345|Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer|A Phase I/ II, Non-randomized, Feasibility/ Safety and Efficacy Study of the Combination of Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|August 2009|August 2011|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||September 2010|May 19, 2014|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077986||125709|
NCT01077999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCmedon08/381|Chemoradiation and Panitumumab for Esophageal Cancer|Chemoradiation Combined With Panitumumab Followed by Surgery for Patients With Operable Esophageal Cancer||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|January 2010|April 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|75 Years|No|||August 2014|August 26, 2014|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077999||125708|
NCT01067066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0357|A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma|A Phase I/II Open-Label Study TPI 287 in Combination With Temozolomide in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2010|||February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|15 Years|N/A|No|||December 2015|December 28, 2015|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067066||126542|
NCT01067079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M49P8E1|Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen|A Phase III, Single Center, Open Label, Follow-up Immunogenicity Study in Subjects Who Previously Received Post-exposure Rabies Vaccine According to the Essen or 2:1:1 (Zagreb) Schedule||Novartis||Terminated|January 2010|January 2010|Actual|January 2010|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who received complete vaccine series in accordance to the designated vaccination        schedule in the previous M49P8 study|December 2011|December 27, 2011|February 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01067079||126541|
NCT01077700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-503|Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-288 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)||AbbVie|Yes|Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|214|||Both|20 Years|55 Years|No|||January 2013|March 29, 2013|February 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077700||125731|
NCT01077921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018427|Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)|Phase II Study of Propranolol as Anti-Adhesive Therapy for Sickle Cell Disease||Duke University|No|Completed|June 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|February 26, 2010|Yes|Yes||No|December 30, 2014|https://clinicaltrials.gov/show/NCT01077921||125714|
NCT01078181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW ADIP STUDY 15|Banded Versus Non-banded Roux-en-Y Gastric Bypass|A Prospective Randomized Comparison on Weight Loss After Gastric Bypass and Banded Gastric Bypass Using the A.M.I B-Band (Soft Gastric Bypass Band)||Medical University of Vienna|No|Recruiting|November 2009|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|60 Years|No|||November 2009|June 23, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078181||125694|
NCT01078480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-001-CMJ|Conservative Treatment Compared to Osteosynthesis in Patients With a Fractured Collar Bone|Conservative Treatment Versus Plate Osteosynthesis Using Angular Stabile Screws and Precontoured Plates in Displaced Midshaft Clavicular Fractures. A Prospective Randomized Multicenter Study||Northern Orthopaedic Division, Denmark|No|Completed|April 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|60 Years|No|||January 2016|January 21, 2016|February 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01078480||125672|
NCT01078727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-950320|Safety Study of Thermal Stimulation on Upper Extremity Motor Recovery to Stroke|Thermal Stimulation on Upper Extremity Movement and Function in Patients With Stroke||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|August 2007|January 2010|Actual|July 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|No|||February 2008|March 1, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01078727||125653|
NCT01078714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB09-017|Efficiency of Bumetanide in Autistic Children|Study of the Efficiency of a Treatment by Bumetanide in a Population of Autistic Children|BUMEA|University Hospital, Brest|No|Completed|March 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|3 Years|10 Years|No|||December 2011|December 20, 2011|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078714||125654|
NCT01079000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR operating grant # 201109|Emergency Department (ED)-Directed Interventions to Improve Asthma Outcomes|Emergency Department (ED)-Directed Interventions to Improve Outcomes After Asthma Exacerbations||University of Alberta|No|Recruiting|June 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|366|||Both|17 Years|55 Years|No|||September 2015|September 3, 2015|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079000||125633|
NCT01079637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFB 2010|Midfoot Fusion Bolt (MFB) in the Early Stage of Diabetic-neuropathic Charcot Feet|Midfoot Fusion Bolt (MFB). A Randomized Controlled Multicenter Study to Assess the Effectiveness of Surgical Treatment With Midfoot Fusion Bolt in the Early Stage of Diabetic-neuropathic Charcot Feet|MFB|AO Clinical Investigation and Documentation||Terminated|May 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|March 1, 2010||No|The study was stopped because there were not enough eligible patients to complete the study.|No||https://clinicaltrials.gov/show/NCT01079637||125587|
NCT01079650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39/10|Diagnosis of Acute Appendicitis, Ovary Torsion and Inflammation, and Testicular Torsion and Inflammation by Infrared Thermography|||Assaf-Harofeh Medical Center||Not yet recruiting|May 2010|||May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|children (<18 years old) having abdominal or testicle pain.|March 2010|March 2, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079650||125586|
NCT01080417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|303-07|Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fed Condition|Open Label Balanced Randomized Two-treatment Two-period Two-sequence Single Dose Two-way Crossover Oral Bioequivalence Study of Mycophenolate Mofetil Capsules 250 mg in Normal Healthy Adult Human Subjects Under Fed Conditions||Panacea Biotec Ltd|No|Completed|June 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|84|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2010|March 3, 2010|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080417||125527|
NCT01079910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3450803|Clinical Efficacy of an Experimental Toothpaste|Clinical Efficacy of an Experimental Toothpaste||GlaxoSmithKline|No|Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|February 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01079910||125566|
NCT01080170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09060055|The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer||Silhouette|University of Pittsburgh|No|Completed|March 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|Samples With DNA|Frozen serum samples. No further testing planned at the moment.|Female|60 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer patients will be recruited via the Magee Breast Cancer Program of the Cancer        Center at the University of Pittsburgh Medical Center. Healthy controls will be recruited        via registries.|December 2014|December 3, 2014|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080170||125546|
NCT01080937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFC-OFICA|French Observatory of Acute Heart Failure|French Observatory of Acute Heart Failure|OFICA|French Cardiology Society|No|Completed|March 2009|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1818|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patient, whatever the mode of initial admission with acute heart failure (de        novo heart failure or decompensation of chronic heart failure)|June 2012|June 13, 2012|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01080937||125487|
NCT01081275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 4221-A-2|Improving Hand Use in Multiple Sclerosis|Rehabilitating Extremity Use After Multiple Sclerosis||National Multiple Sclerosis Society|Yes|Active, not recruiting|February 2010|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|21 Years|80 Years|No|||April 2015|April 14, 2015|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081275||125462|
NCT01081301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEH 08-186|Living With Hope Program for Rural Women Caregivers|Living With Hope: Developing a Psychosocial Supportive Program for Rural Older Women Caregivers of Spouses With Advanced Cancer|LWH|University of Saskatchewan|No|Completed|January 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|36|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 22, 2014|March 3, 2010||No||No|November 6, 2013|https://clinicaltrials.gov/show/NCT01081301||125460|
NCT01077531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111601|Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis|A Randomized, Placebo-controlled, Single-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Otelixizumab in Rheumatoid Arthritis Subjects||GlaxoSmithKline|No|Terminated|April 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|February 25, 2010||No|The risk-benefit ratio for patients has changed since we initiated the study, and that the    study in its current form cannot be justified|No||https://clinicaltrials.gov/show/NCT01077531||125744|
NCT01078298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051122|Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression|A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression||Pfizer|Yes|Completed|March 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|525|||Both|18 Years|75 Years|No|||March 2013|March 6, 2013|February 26, 2010|Yes|Yes||No|January 17, 2013|https://clinicaltrials.gov/show/NCT01078298||125686|
NCT01078311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWWH009|Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Phase 2 Study of Measurement of Trough Levels of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|DOSE-HEP|South West Sydney Local Health District|Yes|Recruiting|February 2010|February 2014|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced HCC who are to commence Sorafenib|February 2010|March 1, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078311||125685|
NCT01077778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051068|Magnetic Resonance Diagnosis of Pulmonary Embolism|Magnetic Resonance Diagnosis of Pulmonary Embolism: Prospective Evaluation in 280 Patients, With Comparison to Multi-slice CT Angiography|IRM-EP|Assistance Publique - Hôpitaux de Paris|No|Terminated|March 2007|February 2010|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|patients with acute pulmonary embolism suspicion who fulfil the inclusion criteria|March 2007|January 22, 2016|February 26, 2010||No|the number of patients will be included is reach|No||https://clinicaltrials.gov/show/NCT01077778||125725|
NCT01079130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2357|Efficacy and Safety of Different Doses of Indacaterol|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Adult Patients With Persistent Asthma, Using Salmeterol as an Active Control||Novartis||Completed|February 2010|||July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|511|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|March 1, 2010|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT01079130||125624|
NCT01067599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA141531-01|Novel Determinants and Measures of Smokeless Tobacco Use: Study 2|Novel Determinants and Measures of Smokeless Tobacco Use: Study 2 Effects of Switching Levels of Nicotine and TSNA in Products on Smokeless Tobacco Use||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|March 2012|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 17, 2013|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067599||126501|
NCT01067625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR-0009 Rev F|Endoscopic Bariatric Stapling Pilot Study||TOGA®|Satiety, Inc.||Enrolling by invitation|February 2006|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|60 Years|No|||February 2010|February 10, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01067625||126500|
NCT01067638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0488|The Effect of Tranexamic Acid on Postoperative Blood Loss and Coagulation in Patients With Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft; Double Blind Randomized Control Study|||Yonsei University|Yes|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|90|||Both|20 Years|N/A|No|||December 2010|December 3, 2010|January 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01067638||126499|
NCT01077713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21868|A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer|Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES||Hoffmann-La Roche||Completed|February 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|70 Years|N/A|No|||September 2015|September 9, 2015|February 9, 2010||No||No|September 9, 2015|https://clinicaltrials.gov/show/NCT01077713||125730|
NCT01078194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW ADIP STUDY 16|Secondary Bypass Banding for Weight Regain or Weight Loss Failure After Lap. Gastric Bypass|Observational Study on the Secondary Placement of the A.M.I. Soft Gastric Band in Weight Regain or Weight Loss Failure After Lap. Gastric Bypass||Medical University of Vienna|No|Recruiting|January 2010|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|20 Years|60 Years|No|Probability Sample|Weight regain of more than 10 kg from nadir or weight loss failure defined as excessive        weight loss of less than 50% 18 months after laparoscopic gastric bypass|January 2010|May 24, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078194||125693|
NCT01077934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-10-14b|Assessment of Near Infrared Spectroscopy as a Diagnostic Tool in Acute Compartment Syndrome|Assessment of Near Infrared Spectroscopy as a Diagnostic Tool in Acute Compartment Syndrome||J&M Shuler|Yes|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|||Both|13 Years|85 Years|No|Non-Probability Sample|All Patients admitted to Grady with Unilateral Lower leg injury at risk for compartment        syndrome|April 2015|April 24, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01077934||125713|
NCT01078168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAM|Alzheimer`s Disease Acitretin Medication|Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study|ADAM|Johannes Gutenberg University Mainz|No|Recruiting|March 2010|April 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||September 2010|September 14, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078168||125695|
NCT01078740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM001|Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects|Detection of Cystic Fibrosis Transmembrane Conductance Regulator CFTR) Activity in Rectal Tissues From Human Subjects||CF Therapeutics Development Network Coordinating Center|Yes|Completed|October 2009|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|57|Samples With DNA|Rectal biopsy|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Non-CF subjects: Adults undergoing endoscopic procedures (colonoscopies) who meet the        eligibility criteria.        CF subjects: Adults with a diagnosis of CF who meet the eligibility criteria. CF subjects        can include both patients who will be undergoing endoscopic (colonoscopies) and        nonendoscopic procedures requiring anesthesia or sedation as a part of clinical care        (e.g., sinus surgery, central line placement), or CF subjects not undergoing planned        surgical/anesthetic procedures.|March 2013|March 5, 2013|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01078740||125652|
NCT01079052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263_FAMOT_07|A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition|||Ranbaxy Inc.|No|Completed|November 2007|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01079052||125630|
NCT01079338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFSSAPS-2009-A00320-57|Salivary Proteome and Sensitivity to Bitterness||PROTAMER|Institut National de la Recherche Agronomique|No|Completed||||||N/A|Interventional|Primary Purpose: Basic Science|1||||||Male|25 Years|45 Years|Accepts Healthy Volunteers|||February 2010|March 2, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079338||125609|
NCT01079026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYt.003|Outcome After Lumbar Epidural Steroid Injection|Functional Outcome After Lumbar Epidural Steroid Injection||Scuderi, Gaetano J., M.D.|Yes|Completed|March 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|Samples With DNA|lavage fluid from epidural space|Both|18 Years|70 Years|No|Non-Probability Sample|Patients considered candidates for ESI were 18 years of age or greater with a history of        leg sensory complaints primarily dictated by pain with associated sensory symptoms and/or        low back pain for two weeks or more who had failed expectant management with NSAIDS,        activity modification, and/or physical therapy.|March 2010|March 1, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079026||125631|
NCT01080183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09080140|Functional Assessment Screening Tablets - Patient Reported Measures|Functional Assessment Screening Tablets - Patient Reported Measures Translating Research Into Practice Pilot||University of Pittsburgh|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|150|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|February 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01080183||125545|
NCT01080196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26292|Reducing Falls With RENEW in Older Adults Who Have Fallen|Reducing Falls With RENEW in Older Adults Who Have Fallen||University of Utah|Yes|Recruiting|April 2008|February 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|65 Years|95 Years|No|||June 2012|June 12, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080196||125544|
NCT01080664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27335|A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies|A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies||EMD Serono|No|Terminated|December 2006|August 2011|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|March 2, 2010|No|Yes|Please see Purpose Statement below|No||https://clinicaltrials.gov/show/NCT01080664||125508|
NCT01080677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02112010-4963|Caffeine/Propranolol Acute Migraine|Randomized Double-Blind Study to Evaluate the Dose-Related Efficacy and Safety of Caffeine/Propranolol in the Treatment of Acute Migraine||Stanford University||Completed|January 2007|December 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 2, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080677||125507|
NCT01080690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01102|Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)|Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)|EFRAIM|Technische Universität München|No|Recruiting|January 2010|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2010|March 3, 2010|January 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080690||125506|
NCT01080950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitamin d zinc and fever|Vitamin D Zinc Fever|Vitamin d and Zinc Levels in Patients With Fever||Assaf-Harofeh Medical Center|No|Not yet recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|blood drawn for vitamin d will be freezed and stored until all samples have been collected      and only than will it be analyzed.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients hospitalized with fever and or sepsis.|March 2010|March 4, 2010|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080950||125486|
NCT01080963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBC134ADAPRO|Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections|Prospective Randomised Study of Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections After Median Sternotomy|DaPro|Hannover Medical School||Completed|November 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|650|||Both|18 Years|80 Years|No|||April 2012|April 16, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01080963||125485|
NCT01081288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0710/9|Extending the National Health Service (NHS) Breast Screening Age Range|Nationwide Cluster-randomised Trial of Extending the NHS Breast Screening Age Range in England||University of Oxford|Yes|Enrolling by invitation|June 2009|December 2026|Anticipated|December 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000000|||Female|47 Years|73 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081288||125461|
NCT01077791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070112|A Study of a Remediation Program of Social Cognition in Schizophrenia|Cognitive Remediation of the Ability to Infer Intention of Others in Schizophrenic Patients - A Controlled, Randomized Trial (Phase IIb)|REMEDCOG|Assistance Publique - Hôpitaux de Paris|No|Terminated|July 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|57 Years|No|||October 2010|October 7, 2013|February 26, 2010||No|no reponse of the of the treatment|No||https://clinicaltrials.gov/show/NCT01077791||125724|
NCT01077271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-040|Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA|PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA Over 3 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria||Abbott|No|Completed|October 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|||Both|N/A|1 Year|No|Non-Probability Sample|Medical practices specialized in pediatrics.|August 2012|August 20, 2012|February 25, 2010||No||No|May 17, 2012|https://clinicaltrials.gov/show/NCT01077271||125764|
NCT01078831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-HO Ref 191-01055, 03052001|Intrabronchial Airway Pressures in Intubated Patients During Bronchoscopy|Intrabronchial Airway Pressures in Intubated Patients During Bronchoscopy Under Volume Controlled (VC) and Pressure Controlled (PC) Ventilation||Oslo University Hospital|No|Completed|March 2002|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Arterial blood gases|Both|18 Years|85 Years|No|Probability Sample|ARDS/ALI patients on mechanical ventilation where a therapeutic or diagnostic bronchoscopy        has been requested by the staff physician.|November 2010|November 10, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078831||125645|
NCT01079143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AFR10|Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients|Prospective, Multicenter, Randomized Open Study to Evaluate the Progression of Renal Graft Fibrosis According to the Epithelial-mesenchymal Transition (EMT) in de Novo Renal Transplant Recipients Treated Either by a CNI Free Immunosuppressive Regimen With Everolimus and Enteric-coated Mycophenolate Sodium or a CNI Based Regimen With Cyclosporine and Enteric-coated Mycophenolate Sodium|CERTITEM|Novartis||Completed|September 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|194|||Both|19 Years|75 Years|No|||January 2014|January 31, 2014|March 1, 2010||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01079143||125623|
NCT01079169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/280|Effect of Cranberry Capsules on Urinary Infection Rates in Spinal Cord Injured Patients During Post Acute Rehabilitation|Evaluation of the Effect of Cranberry Capsules on the Occurrence of Urinary Tract Infections During Post-acute Rehabilitation of Spinal Cord Injured Patients||Uppsala University|No|Terminated|March 2010|||March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|3|||Both|16 Years|N/A|No|||January 2010|February 8, 2012|February 19, 2010||No|Terminated early due to recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01079169||125622|
NCT01068171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-GEN-09-0418|Developing a Diabetic Foot Ulcer Protocol|Developing a Diabetic Foot Ulcer Protocol in a Multi-ethnic, Underserved Population||The University of Texas Health Science Center, Houston|No|Recruiting|May 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|180|||Both|18 Years|N/A|No|||December 2010|December 3, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068171||126459|
NCT01078207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV-MO-PO-A105|Oxygen Saturation Patterns in Post-Op Patients at Risk for Obstructive Sleep Apnea|A Prospective Non-Randomized Study of Pulse Oximetry Saturation Patterns in Postoperative Patients at High Risk of Obstructive Sleep Apnea||Medtronic - MITG|Yes|Completed|January 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients older than 18 years undergoing thoracic, vascular, head and neck, gynecological,        urological, general, orthopedic, and plastic surgery.|August 2014|August 5, 2014|February 26, 2010|Yes|Yes||No|May 14, 2012|https://clinicaltrials.gov/show/NCT01078207||125692|
NCT01078493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC1000031|Wrinkle Injection With Autologous Platelet Rich Plasma Study|Phase 1 Study of Intradermal Injection of Autologous Platelet Rich Plasma for Facial Wrinkles|WIPES|Novena Medical Center|No|Terminated|February 2010|May 2012|Anticipated|February 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 16, 2010|February 27, 2010||No|Protocol revision necessary.|No||https://clinicaltrials.gov/show/NCT01078493||125671|
NCT01078753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS35|Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis|A Double-blind, Placebo-controlled, Phase III Comparative Study With FE992026 in Children and Adolescents With Reduced Night-time Urinary Osmolarity-type Nocturnal Enuresis|PNE|Ferring Pharmaceuticals|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|6 Years|15 Years|No|||September 2011|September 27, 2011|March 1, 2010|No|Yes||No|September 27, 2011|https://clinicaltrials.gov/show/NCT01078753||125651|
NCT01079065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261_FAMOT_07|A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Famotidine 20 mg Tablets of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With PEPCID AC Tablets (Containing Famotidine 20 mg) of Johnson & Johnson Merck Consumer Pharmaceutical Co. in Healthy, Adult, Human, Male Subjects Under Fasting Condition.||Ranbaxy Inc.|No|Completed|November 2007|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01079065||125629|
NCT01079676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF-026|A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer|A Phase III, Non-inferiority Study Comparing Two Filgrastim Preparations in Preventing Chemotherapy Induced Neutropenia in Breast Cancer||Eurofarma Laboratorios S.A.|Yes|Completed|March 2011|October 2012|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Female|18 Years|N/A|No|||October 2012|October 15, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079676||125584|
NCT01079351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13103A|A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy|A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy||Lundbeck LLC|Yes|Completed|April 2007|April 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||April 2010|April 22, 2010|March 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01079351||125608|
NCT01079611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVP1|Non-invasive Assessments of Central Venous Pressure|Non-invasive Assessments of Central Venous Pressure by Ultrasound and Clinical Examination: a Prospective Comparative Study||University Hospital, Basel, Switzerland|No|Completed|May 2010|November 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|N/A|No|Probability Sample|This single center, prospective observational study will be performed at the surgical        intensive care unit (ICU) of the tertiary care teaching hospital of the University of        Basel. ICU, rather than Emergency Department patients will be consecutively enrolled        because of the higher prevalence of CVP catheters and the higher likelihood of clinical        stability (by means of hemodynamic parameters, therapeutic interventions etc.).|June 2012|June 19, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079611||125589|
NCT01079975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200077- 500|To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis|Predicting Factors for Depression in Patients With MS in Argentina||Merck KGaA|No|Completed|August 2008|July 2012|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with diagnosed MS in Argentinean population.|August 2012|July 30, 2014|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079975||125561|
NCT01080976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000356|Comparing Google With A Focused Diabetes Search Engine|Comparing Google With A Focused Diabetes Search Engine||Beth Israel Deaconess Medical Center||Recruiting|March 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Care Physicians, Informaticians, Diabetologists|March 2010|June 3, 2010|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080976||125484|
NCT01081314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36517-C|Treating PTSD in Patients With Borderline Personality Disorder|Treating PTSD in Patients With Borderline Personality Disorder||University of Washington|Yes|Completed|August 2009|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Female|18 Years|60 Years|No|||November 2015|November 20, 2015|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081314||125459|
NCT01080430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGH-VR02|Effects of a Vestibular Rehabilitation Maneuver|Short-term and Long-term Effects of the Rotational Maneuver in Patients With Chronic Vestibular Imbalance||Day General Hospital.|Yes|Completed|November 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|23|||Both|30 Years|60 Years|No|||September 2009|March 3, 2010|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01080430||125526|
NCT01081327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELD007|Warfarin - How Good Are we at Maintaining Target Range ?|Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.||University of Dundee|No|Active, not recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|All patients receiving Warfarin for lone atrial fibrillation|March 2010|June 24, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081327||125458|
NCT01077297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-051-206|Tezosentan in Pulmonary Arterial Hypertension|Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines||Actelion|No|Terminated|August 2010|September 2011|Actual|November 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|February 25, 2010|Yes|Yes|Due to slow recruitment, the study was prematurely discontinued|No||https://clinicaltrials.gov/show/NCT01077297||125762|
NCT01077804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V210-036|A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)|Fifteen Year Follow-up to Evaluate Long-term Effectiveness of VARIVAX Among Children and Adolescents||Merck Sharp & Dohme Corp.|No|Completed|June 1995|November 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7585|||Both|12 Months|23 Months|Accepts Healthy Volunteers|Probability Sample|15 years prospective follow-up of the original study cohort|October 2015|October 22, 2015|February 26, 2010|Yes|Yes||No|September 29, 2011|https://clinicaltrials.gov/show/NCT01077804||125723|
NCT01077557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111950|Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status|Fractures Over Time Stratified by HIV Infection and Antiretroviral Therapy (ART) Exposure||ViiV Healthcare|No|Completed|November 2006|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|1|||Both|18 Years|N/A|No|Probability Sample|The study population will consist of adults (>18 years of age) with and without HIV        infection continuously enrolled for at least 12 months in the Integrated Health Care        Information Services (IHCIS) National Managed Care Benchmarked Database, a health        insurance claims database, during the interval between January 1, 1997 and March 31, 2008,        and with continuous eligibility for pharmacy benefits. Health plan enrollees in this        database are located in the continental US|January 2012|February 2, 2012|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077557||125742|
NCT01078324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-11-115-12|Study of Ischemic Colitis Compared to Other Diagnoses in Patients With Lower Gastrointestinal Bleeding|Ischemic Colitis Is a Common Cause of Severe Hematochezia and Patient Outcomes Are Worse Than With Other Colonic Diagnoses||University of California, Los Angeles|No|Completed||December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|550|||Both|18 Years|N/A|No|Probability Sample|Patients who were admitted into the hospital|December 2009|March 1, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078324||125684|
NCT01078337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11022007-790|T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis|T-cell MRD Evaluation Using Flow Cytometric Analysis||Stanford University||Completed|November 2002|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|blood and bone marrow|Both|N/A|18 Years|No|Non-Probability Sample|children with newly diagnosed T-cell ALL|February 2010|March 1, 2010|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01078337||125683|
NCT01078012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMOH pilot|Short Intervention for Medication Overuse Headache (MOH) - Pilot|Pilot Study of Short Intervention for Medication Overuse Headache in General Practice|SIMOHpilot|University Hospital, Akershus|No|Completed|March 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|50 Years|No|||December 2015|December 29, 2015|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078012||125707|
NCT01078025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG09/150/1B|Evaluation of Microbial Colonisation and Contamination Caused by the Transvaginal and Transabdominal Access for Cholecystectomy||NOBACT|Cantonal Hospital of St. Gallen|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients with symptomatic cholecystolithiasis and given informed consent for        laparoscopic cholecystectomy or transvaginal hybrid cholecystectomy|July 2010|December 9, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078025||125706|
NCT01078571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-077|Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis|Safety and Effectiveness of Adalimumab (HUMIRA®) in Patients Diagnosed With Rheumatoid Arthritis (DALI Study)|DALI|Abbott|No|Completed|May 2006|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|705|||Both|18 Years|N/A|No|Non-Probability Sample|Rheumatologist consultant|October 2011|October 26, 2011|March 1, 2010||No||No|May 27, 2011|https://clinicaltrials.gov/show/NCT01078571||125665|
NCT01070563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAM 2010-1|Transcranial Doppler Ultrasonography and Brain Death|Evaluation of Transcranial Doppler Ultrasonography to Guide the Time of Cerebral Angiography for the Brain Death Diagnosis||Institut d'Anesthesiologie des Alpes Maritimes|No|Completed|February 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|44|||Both|18 Years|N/A|No|Probability Sample|ICU patients showing brain injury due to stroke or trauma and developping subsequently        brain death|June 2011|June 30, 2011|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01070563||126277|
NCT01078844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAM_MD_69|Memantine in Adult Autism Spectrum Disorder|Memantine in Adult Autism Spectrum Disorder||Johns Hopkins University|Yes|Enrolling by invitation|October 2009|April 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|85 Years|No|||March 2010|March 1, 2010|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01078844||125644|
NCT01078857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812088R|Small-fiber Neuropathy in Chronic Kidney Disease|Small-fiber Neuropathy in Chronic Kidney Disease||National Taiwan University Hospital|No|Recruiting|February 2009|||August 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||February 2010|March 1, 2010|February 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01078857||125643|
NCT01071109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTTM301|The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy|The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy|RTTM301|Floyd Memorial Hospital and Health Services|No|Not yet recruiting|November 2010|April 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|48|||Female|18 Years|N/A|No|||February 2010|February 17, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01071109||126235|
NCT01064193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/12|Impact of Local Biopsy to the Endometrium Prior to Controlled Ovarian Stimulation on Clinical Pregnancy|Influence of Local Biopsy of the Endometrium Prior to Controlled Ovarian Stimulation for IVF or ICSI Procedure on the Rates of Embryo Implantation, Clinical Pregnancy and Live Birth in ART|NIDABRECHE|University Hospital, Bordeaux|No|Completed|February 2010|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|190|||Female|18 Years|38 Years|No|||April 2015|April 7, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01064193||126762|
NCT01078220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-031|Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)|A Post-licensure Surveillance Program for the Safety of GARDASIL™ in a Managed Care Organization Setting||Merck Sharp & Dohme Corp.|Yes|Completed|February 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|189629|||Female|9 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Managed Care Organizations (MCO) databases|July 2015|July 21, 2015|February 26, 2010|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT01078220||125691|Details of syncope and cellulitis findings and null findings for hundreds of other general safety analyses will be described in future publications.
NCT01078233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-058|Observational Data Analysis in EuroSIDA (MK-0518-058)|Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period||Merck Sharp & Dohme Corp.|Yes|Completed|May 2008|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|6617|||Both|16 Years|N/A|No|Non-Probability Sample|Adults 16 years old and older in the EuroSIDA database|August 2015|August 17, 2015|February 26, 2010|No|Yes||No|June 15, 2015|https://clinicaltrials.gov/show/NCT01078233||125690|
NCT01078506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW006|Prevalence of Intracranial Aneurysm in Hong Kong Chinese|Prevalence of Intracranial Aneurysm in Hong Kong Chinese||Chinese University of Hong Kong|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|200|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hong Kong Chinese without a history of known intracranial pathologies|April 2013|April 22, 2013|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01078506||125670|
NCT01078766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090440|Constraint-induced Movement Therapy and Hand Arm Bimanual Training in Children With Hemiplegic Cerebral Palsy (CP)|Constraint-induced Movement Therapy and Hand Arm Bimanual Training in Children With Hemiplegic CP||Alyn Pediatric & Adolecent Rehabilitation Center|No|Enrolling by invitation|August 2009|||March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|6 Years|9 Years|No|||June 2015|June 22, 2015|February 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01078766||125650|
NCT01079078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144_ACETA_07|A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fed Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gelcaps (Containing Acetaminophen 650 mg) of OHM Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals Inc.) With TylenolÒ Arthritis Pain Extended Release Caplets (Containing Acetaminophen 650 mg) of McNeil-PPC Inc. in Healthy, Adult, Human, Male Subjects Under Fed Condition.||Ranbaxy Inc.|No|Completed|October 2007|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 1, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01079078||125628|
NCT01079663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI/013P|The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis|The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis||Dexcel Pharma Technologies Ltd.|No|Completed|March 2010|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Primary Purpose: Treatment|2||||||Both|21 Years|N/A|No|||November 2011|November 14, 2011|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079663||125585|
NCT01079429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2008-A01023-52|Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.|Large Scale Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From Monoclonal Gammopathy of Undetermined Significance (MGUS) and Indolent Myeloma (SMM).|GENOMGUS|Rennes University Hospital|Yes|Active, not recruiting|November 2010|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Whole blood Plasma Urine Bone marrow|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with Monoclonal gammopathy of undetermined significance or Smoldering myeloma|October 2015|October 27, 2015|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079429||125603|
NCT01079364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_04717|Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting|Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting|BASAAL PLUS|Sanofi||Terminated|January 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||May 2013|May 27, 2013|February 25, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01079364||125607|
NCT01080703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-076-B|To Determine if a Lower Extremity Strengthening Program Improve Quadriceps Muscle Strength|Does The Lower Extremity Resistance Program Improve Quadriceps Strength, Endurance, And Quality Life In Pre-Lung Transplant Patients?|Resistance|University of Chicago|No|Completed|March 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||December 2014|December 3, 2014|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080703||125505|
NCT01077310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908005572|Alcohol Pharmacotherapy for HIV+ Prisoners|Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking|INSPIRE|Yale University|No|Completed|August 2010|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077310||125761|
NCT01077570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3822|An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients|The Clinical Safety and Effectiveness of Repaglinide in Treatment-naive Type 2 Diabetes Subjects in China. A 16-week Multicentre, Prospective, Open Label, Non-interventional Study.|SAFE|Novo Nordisk A/S|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2033|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from both general and speciality practice settings who have been deemed        appropriate to receive Repaglinide as initial treatment and as part of routine out-patient        care by the prescribing physician.|June 2014|June 25, 2014|February 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01077570||125741|
NCT01077284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67_201|Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones|A Multicenter, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase 2 Study to Evaluate Febuxostat in the Medical Management of Subjects With Hyperuricosuria and Calcium Oxalate Stones||Takeda|Yes|Completed|February 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|February 25, 2010|Yes|Yes||No|October 15, 2012|https://clinicaltrials.gov/show/NCT01077284||125763|
NCT01077817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-352|Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)|The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women||Merck Sharp & Dohme Corp.|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||8|Actual|684815|||Female|55 Years|N/A|No|Probability Sample|Women who have at least two years of experience in the GPRD and are 55 or older between        1996 and 2008; all cases of esophageal cancer were identified and matched to all women in        the comparison sample (all women with same year of birth drawn from the random subsample        of 25,000).|April 2015|April 27, 2015|February 26, 2010|No|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT01077817||125722|
NCT01078038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0250|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III: Sirolimus vs. Everolimus-eluting Stent|LONG-DES-III|CardioVascular Research Foundation, Korea|Yes|Completed|June 2008|August 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|451|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01078038||125705|
NCT01070043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489ATW01|To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone|A Single Center, Randomized, Double-blind, Active Controlled, Parallel Group Study to Demonstrate Non-inferiority of a Fixed Dose Combination of 5 mg Amlodipine and 80 mg Valsartan to 160 mg Valsartan in the Treatment of Hypertension||Novartis|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|February 6, 2010||No||No|September 13, 2011|https://clinicaltrials.gov/show/NCT01070043||126317|
NCT01070251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTLasti_PA_kiga|Effects of a Multimodal Preference-based Parental Intervention on Preschoolers' Physical Activity Behaviour - a Cluster-randomized Trial|Effects of a Multimodal Preference-based Parental Intervention on Preschoolers' Physical Activity Behaviour - a Cluster-randomized Trial||Heidelberg University|No|Completed|September 2008|April 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|826|||Both|3 Years|6 Years|No|||July 2012|July 31, 2012|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070251||126301|
NCT01070264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050074|A Pilot Observational Clinical Survey: Impacts of Tahitian Noni Juice on the Quality of Life of Patients With Osteoarthritis|A Pilot Observational Clinical Survey: Impacts of Tahitian Noni Juice on the Quality of Life of Patients With Osteoarthritis||University of Illinois at Chicago|No|Completed|March 2006|February 2007|Actual|February 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment|1||||||Both|40 Years|75 Years|No|||February 2007|February 16, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070264||126300|
NCT01070550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV21012|PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a)|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naïve HCV-infected Patients Treated With Pegylated Interferons.||Hoffmann-La Roche||Completed|June 2007|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4598|||Both|18 Years|N/A|No|Probability Sample|Patients receiving peginterferon alfa-2a treatment at a medical centre|November 2015|November 2, 2015|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01070550||126278|
NCT01070576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-09-2-123|Arginine and Nitric Oxide (NO) Early Prognostic Markers for Non-union Development|Arginine and Nitric Oxide (NO) Metabolism During Bone Healing and Non-union Development- Early Prognostic Markers||Maastricht University Medical Center|No|Recruiting|March 2010|||March 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|bone debris and bloodsamples for amino acid determination|Both|18 Years|N/A|No|Non-Probability Sample|Patients with an acute fracture of the femur or tibia|April 2010|April 6, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070576||126276|
NCT01070589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC01922009CTIL|The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise|The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise||Meir Medical Center|Yes|Recruiting|February 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Healthy female Age 18-40 years|March 2012|March 16, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070589||126275|
NCT01070849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8011 - 106 - 31/31.87|A Bio-psycho-social Exercise Program (RÜCKGEWINN) for Chronic Low Back Pain in Rehabilitation Aftercare|Effect and Sustainability of a Bio-psycho-social Exercise Program (RÜCKGEWINN) for Chronic Low Back Pain in Rehabilitation Aftercare - a Randomised Controlled Trial|RÜCKGEWINN|University of Erlangen-Nürnberg|No|Completed|November 2009|October 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|299|||Both|18 Years|65 Years|No|||August 2012|August 17, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070849||126255|
NCT01071122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14696|FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)|A Prospective, Open-label, Active-controlled, Randomized Study Comparing Nifedipine GITS Versus Valsartan Versus a Combination of Both on Central Blood Pressure in Inadequately Controlled Essential Hypertension.||Bayer|No|Completed|January 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|365|||Both|20 Years|70 Years|No|||January 2014|January 24, 2014|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071122||126234|
NCT01071135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00018|Quetiapine XR in Schizophrenic Patients|Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study-||Hannover Medical School|No|Terminated|September 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|60 Years|No|||August 2011|November 10, 2011|February 18, 2010||No|Planned number of 30 subjects could not be recruited during recruitment phase.|No||https://clinicaltrials.gov/show/NCT01071135||126233|
NCT01064466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00015357|Retrospect Stage IND EXEMPT Clinical Study - Etoposide and Single Nucleotide Polymorphisms|Personalize Etoposide Chemotherapy Toward Small Cell Lung Cancer (SCLC) With Maximizing Effectiveness and Minimizing Risk Via Assay Single Nucleotide Polymorphisms (SNPs) of Relative Etoposide Targets, Topoisomerase II and CYP4503A4|Drugs-SNPs|Medicine Invention Design, Inc|Yes|Active, not recruiting|March 2016|August 2018|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|22 Years|75 Years|No|||March 2016|March 15, 2016|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01064466||126741|
NCT01078519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00992524|Combined Anesthesia for Labor and Maternal Temperature|Combined Spinal and Epidural Anesthesia and Maternal Intrapartum Temperature During Vaginal Delivery: a Randomized Clinical Trial|feveranalg|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2007|July 14, 2010|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01078519||125669|
NCT01078779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E/09/482|The Chloroquine for Influenza Prevention Trial|A Randomised, Double-blind, Placebo Controlled Trial of Chloroquine for the Prevention of Influenza|CHIP|National University Hospital, Singapore|Yes|Active, not recruiting|November 2009|August 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1516|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|February 28, 2010|February 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01078779||125649|
NCT01079442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-6|Coffee Trial - Does Coffee Intake Reduce Postoperative Ileus After Elective Colectomy?|Does Coffee Intake Reduce Postoperative Ileus After Elective Colectomy?||Heidelberg University|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079442||125602|
NCT01079377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6035/#7001R|Psychological Symptoms Among Adolescents Enrolled in a Bariatric Surgery Program|Psychological Symptoms Among Adolescents Enrolled in a Bariatric Surgery Program||New York State Psychiatric Institute|No|Active, not recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|186|||Both|12 Years|18 Years|No|Non-Probability Sample|Adolescent Surgical Candidates, Obese Comparison Subjects, Normal-Weight Comparison        Subjects|September 2015|December 3, 2015|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01079377||125606|
NCT01079390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000904|An Acupuncture Functional Magnetic Resonance Imaging (fMRI) Study on Chronic Pain: Response Reliability and Dose Effect|An Acupuncture fMRI Study on Chronic Pain: Response Reliability and Dose Effect||Massachusetts General Hospital|Yes|Active, not recruiting|January 2010|March 2014|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|36|||Both|40 Years|70 Years|No|||May 2013|May 15, 2013|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079390||125605|
NCT01079416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-11-047-12|Study of Capsule Endoscopy to Determine the Accuracy for Detection of Esophageal Varices|Is Capsule Endoscopy Accurate and Cost-effective Enough to Screen Cirrhotic Patients for Varices & Other Lesions?||University of California, Los Angeles|No|Completed|June 2006|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|65|||Both|18 Years|85 Years|No|Non-Probability Sample|Cirrhotic patients|January 2013|January 31, 2013|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079416||125604|
NCT01079962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD 084000-505|An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])|A Prospective, Multi-center, Randomized, Open-label, Clinical Trial to Compare the Aortic Pulse Pressure Effects of Bisoprolol and Atenolol in 12 Weeks Treatment of Hypertension||Merck KGaA|No|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|209|||Both|20 Years|75 Years|No|||January 2014|January 20, 2014|March 2, 2010||No||No|August 30, 2012|https://clinicaltrials.gov/show/NCT01079962||125562|
NCT01081340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091029|Building Social Networks to Enhance Postpartum Weight Loss and Appropriate Infant Feeding Practices|Building Social Networks to Enhance Postpartum Weight Loss and Appropriate Infant Feeding Practices||Vanderbilt University|Yes|Completed|May 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|41|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 18, 2012|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081340||125457|
NCT01081353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14961|Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin|An Open Label 4-Way Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Effervescent Aspirin in Healthy Adult Subjects||Bayer|Yes|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01081353||125456|
NCT01081002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 101/09|Propofol Sedation During Upper Endoscopy With and Without Topical Pharyngeal Anesthesia|Study of Propofol Sedation During Upper Endoscopy With and Without Topical Pharyngeal Anesthesia||University Hospital, Basel, Switzerland|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|294|||Both|18 Years|85 Years|No|||March 2010|December 2, 2014|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081002||125482|
NCT01081015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Connect™ CLL|Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry|Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry||Celgene|No|Active, not recruiting|September 2009|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1494|||Both|18 Years|N/A|No|Non-Probability Sample|An adult population (>=18 years old) of both men and women who have chronic lymphocytic        leukemia treated in either community or academic medical centers.|December 2015|December 11, 2015|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081015||125481|
NCT01071369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 16|Treatment of Chronic Thoracic and Neck and Upper Extremity Pain|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Cervical and Thoracic Interlaminar Epidural Injections in Thoracic and Cervical Disc Herniation, Discogenic Pain, and Post-Cervical Laminectomy Syndrome||Pain Management Center of Paducah|No|Completed|February 2008|June 2014|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|February 14, 2008||No||No||https://clinicaltrials.gov/show/NCT01071369||126217|
NCT01071382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Epidemiology of Aeromedical Evacuation|Epidemiology of Aeromedical Evacuation||Ruhr University of Bochum|No|Completed|February 2010|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|504|||Both|N/A|N/A|No|Non-Probability Sample|Patients who were repatriated from abroad because of a medical emergency|October 2012|October 15, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071382||126216|
NCT01071603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910060|Tuberculosis in China|A Natural History Study of Tuberculosis in China; Correlates of a Successful Response to Treatment||National Institutes of Health Clinical Center (CC)||Completed|February 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|210|||Both|18 Years|65 Years|No|||July 2015|July 30, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071603||126199|
NCT01072227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113932|Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Taiwan|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Taiwan||GlaxoSmithKline||Terminated|July 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Tissue|Both|3 Months|5 Years|No|Non-Probability Sample|Subjects aged >= 3 months and < 5 years of age, diagnosed as having AOM in hospital by        pediatricians or ear nose and throat (ENT) specialists.|May 2011|May 12, 2011|February 18, 2010||No|The study was terminated for logistic reasons|No||https://clinicaltrials.gov/show/NCT01072227||126151|
NCT01072474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2680/10|Capnography During ERCP|Capnography as an Adjunct to Standard Monitoring During Midazolam and Propofol Sedation for ERCP|EndoBreath|Technische Universität München|No|Completed|February 2010|March 2012|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|242|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072474||126132|
NCT01072773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0985|Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis|Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis||Mayo Clinic|Yes|Completed|March 2010|June 2012|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|February 17, 2010|Yes|Yes||No|November 7, 2012|https://clinicaltrials.gov/show/NCT01072773||126109|
NCT01068470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59210|Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy|Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy|LAK|Loma Linda University|No|Terminated|November 2009|March 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing Interleukin-2 therapy under the care of physicians at Loma Linda        University Cancer Center|May 2014|May 28, 2014|February 11, 2010||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT01068470||126436|
NCT01073397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT004234-01A2|Effect of Yoga on Objective and Subjective Menopausal Hot Flashes|Effectiveness of Integral Yoga on Objective and Subjective Menopausal Hot Flashes|GLAM|Wake Forest School of Medicine|Yes|Completed|January 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|54|||Female|45 Years|58 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073397||126062|
NCT01069042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-98-096|Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human|A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement||National Cheng-Kung University Hospital|No|Recruiting|February 2010|November 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|80 Years|No|||February 2010|February 23, 2010|February 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069042||126392|
NCT01069367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110_10|Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects|Open-label, Uncontrolled Postmarketing Study to Evaluate Immunogenicity, Safety and Tolerability of Cell-derived A/H1N1 Influenza HA Vaccine in Healthy Japanese Elderly Subjects||Novartis|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|61 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 4, 2012|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069367||126367|
NCT01069627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19309|A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma|An Open-label Study to Assess the Anti-tumor Activity of Avastin in Combination With Fotemustine as First-line Therapy in Patients With Metastatic Melanoma||Hoffmann-La Roche||Completed||April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|December 15, 2009|No|Yes||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01069627||126347|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT01061385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDUCE-IDE|The Safety and Efficacy of the ReShape Intragastric Balloon in Obese Subjects|IDE G090121 A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Intragastric Balloon (RIBTM) in Obese Subjects||ReShape Medical, Inc.|Yes|Completed|February 2010|July 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|February 1, 2010|Yes|Yes||No|August 7, 2015|https://clinicaltrials.gov/show/NCT01061385||126977|Given the small sample size of this feasibility cohort, it was not expected to show significant effectiveness.
NCT01061658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL/BRV-TV/Form1/PhI/2009/0100|Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine|Phase I/II, Randomized, Double-blind, Placebo-controlled, Dosage Selection (10e5.5 or 10e6.25 FFU of Each Constituent Serotype Per 0.5 mL) Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Infants||Shantha Biotechnics Limited|Yes|Recruiting|July 2010|December 2010|Anticipated|November 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|90|||Both|6 Weeks|8 Weeks|Accepts Healthy Volunteers|||October 2010|October 1, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061658||126956|
NCT01060072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|577|Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery|A Randomized, Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate, 0.5% Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|February 2010|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|407|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|January 29, 2010|Yes|Yes||No|September 20, 2011|https://clinicaltrials.gov/show/NCT01060072||127078|
NCT01072708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.523/24|Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients|Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients (Study DIAMUCO)|DIAMUCO|Hospices Civils de Lyon|Yes|Completed|April 2009|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|230|||Both|10 Years|65 Years|No|||February 2016|March 24, 2016|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072708||126114|
NCT01068379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cryo laser|Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation|Randomized Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery||University of Campinas, Brazil|Yes|Completed|July 2006|||January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|86|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2010|May 24, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068379||126443|
NCT01068639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3787|An Observational Study on Treatment Compliance by Children Treated With Growth Hormone|IMprove PAtient Compliance sTudy: An Observational, Cross-sectional Study on Children Treated With Growth Hormone in France|IMPACT|Novo Nordisk A/S|No|Withdrawn|February 2010|April 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|N/A|18 Years|No|Non-Probability Sample|Children treated for at least one year with growth hormone with any growth hormone product        whatever the reason for prescription|June 2014|June 25, 2014|February 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068639||126423|
NCT01068652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3782|Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs|Effect of 50-week Treatment With Stepwise Insulin Intensification of Basal-bolus Insulin Analogues (Insulin Detemir and Aspart) or Biphasic Insulin Aspart 30 (NovoMix 30) All in Combination With Fixed Dose of Metformin on Glycaemic Control (Measured as HbA1c) in Subjects With Type 2 Diabetes. Open Labelled, Randomized, Two-arm, Parallel Group, Multi-centre, Multi-national Trial||Novo Nordisk A/S|No|Completed|March 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|February 12, 2010|Yes|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01068652||126422|
NCT01068665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3672|Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: LOW VOLUME)|BEGIN™|Novo Nordisk A/S|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 12, 2010|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01068665||126421|
NCT01069549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1RGPT2DM|Association of AGTR1 and ACACB Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes|Study of the Association of AGTR1 and ACACB Gene Polymorphism and Susceptibility of Diabetic Nephropathy in North Indian Type 2 Diabetic Patients||Postgraduate Institute of Medical Education and Research|No|Completed|November 2009|May 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|476|Samples With DNA|4 ml of whole blood sample.|Both|30 Years|85 Years|No|Non-Probability Sample|Study Population for Group 1 and Group-2 (Subjects with diabetic nephropathy and without        nephropathy respectively)will be recruited from the diabetic Out Patient and in patient        services of Postgraduate Institute of Medical Education & Research and Nehru hospital,        Chandigarh. Only North Indian Ethnic subjects will be recruited.|October 2015|October 23, 2015|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069549||126353|
NCT01070784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589DC00008|A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan|An Open-label Phase III, Multi-centre 52-week , Parallel-group Study Evaluating the Safety and Efficacy of Symbicort Turbuhaler 320/9 Twice Daily Compared With Standard Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca|No|Completed|January 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|328|||Both|40 Years|N/A|No|||April 2014|April 14, 2014|February 11, 2010|Yes|Yes||No|October 8, 2012|https://clinicaltrials.gov/show/NCT01070784||126260|
NCT01070797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26374-VIRAGE|Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)|Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes for the Prophylaxis and Treatment of EBV, CMV, and Adenovirus Infection Post Allogeneic Stem Cell Transplant (VIRAGE)||Baylor College of Medicine|Yes|Completed|January 2011|April 2014|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|N/A|N/A|No|||September 2014|September 2, 2014|February 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070797||126259|
NCT01071044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCBM11|Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome|Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study||Rochester Center for Behavioral Medicine|No|Completed|November 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|February 17, 2010|Yes|Yes||No|October 29, 2012|https://clinicaltrials.gov/show/NCT01071044||126240|Relatively small sample size, imbalance of participants in active vs. placebo group due to pre-randomization, heterogenous sample (only one male participant in the study, who was in the control group and not the treatment group).
NCT01071356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA024714|Intensive Motivational Interviewing for Methamphetamine Dependence|Intensive Motivational Interviewing for Methamphetamine Dependence||Public Health Institute, California|No|Completed|February 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 25, 2013|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01071356||126218|
NCT01071629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOA-2010|Exercise Training Effects in Patients With Heart Failure|Aerobic Interval Training Versus Combined Aerobic Interval Training and Strength Training Effects in Patients With Heart Failure||University of Athens|No|Active, not recruiting|November 2004|September 2015|Anticipated|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2015|March 12, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071629||126197|
NCT01071642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor495209ctil|The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography|||Soroka University Medical Center||Completed|March 2010|November 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|18 Years|N/A|No|||October 2011|October 30, 2011|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071642||126196|
NCT01071616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910458|Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis|Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis||National Institutes of Health Clinical Center (CC)||Completed|January 2010|November 2013|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|45 Years|No|||November 2013|March 14, 2014|February 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01071616||126198|
NCT01071954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090340|A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura|An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)||Amgen|No|Active, not recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|66|||Both|1 Year|N/A|No|||January 2016|January 19, 2016|December 17, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01071954||126172|
NCT01072240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22754|An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia|An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.||Hoffmann-La Roche||Completed|September 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|N/A|No|Probability Sample|CLL patients receiving standard of care rituximab infusions at haematological or medical        clinics|December 2015|December 1, 2015|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01072240||126150|
NCT01072253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Velux270479|Quality of Life of Eye Amputated Patients in Denmark|Quality of Life of Eye Amputated Patients in Denmark||University of Copenhagen||Completed|February 2008|||May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|152|||Both|18 Years|N/A|No|Non-Probability Sample|eye clinic Rigshospitalet, Denmark. Rigshospitalet is a public, regionalized and national        specialized hospital with a recruitment area of Eastern Denmark (approximately 2 million        people). Nearly all cases of eye amputation and cancer in the eye region in Eastern        Denmark are performed at Rigshospitalet|February 2010|February 19, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072253||126149|
NCT01072799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX 754 H1N1-MEX|Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine|A Phase 2 Study to Assess the Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine||Novavax|Yes|Completed|October 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|4560|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072799||126107|
NCT01072812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QR 12001|Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment|An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment||QR Pharma Inc.|No|Terminated|February 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|55 Years|80 Years|No|||April 2015|April 20, 2015|February 19, 2010|Yes|Yes|Business decision based on funding|No||https://clinicaltrials.gov/show/NCT01072812||126106|
NCT01068483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120X2101|Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients|A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies||Novartis|No|Completed|November 2008|August 2012|Actual|September 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|February 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068483||126435|
NCT01073982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e5825|Efficacy of Tart Cherry Juice to Reduce Pain and Inflammation Among Patients With Inflammatory Osteoarthritis|Efficacy of Tart Cherry Juice to Reduce Pain and Inflammation Among Patients With Inflammatory Osteoarthritis||Oregon Health and Science University|No|Completed|February 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|70 Years|No|||January 2011|January 19, 2011|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01073982||126017|
NCT01074203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006000|A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation|A Pilot Study to Explore a Potential Role of Nitazoxanide (NTZ) in the Prevention of Recurrent Hepatitis C Virus (HCV) Infection After Orthotopic Liver Transplantation||Mayo Clinic|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|75 Years|No|||July 2012|July 27, 2012|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074203||126000|
NCT01074437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12901|Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)|A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)||Seattle Children's Hospital|Yes|Terminated|February 2010|February 2013|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|N/A|9 Months|No|||December 2013|December 11, 2013|February 22, 2010|Yes|Yes|Insufficient enrollment|No|July 22, 2013|https://clinicaltrials.gov/show/NCT01074437||125982|Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable.
NCT01075009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT104983|Predictors of Rates of Resistant Gram-Negative Bacteria|Predictors of Rates of Resistant Gram-Negative Bacteria in a Consortium of Academic Medical Center Hospitals.||Virginia Commonwealth University|Yes|Completed|February 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized adult patients|July 2014|July 8, 2014|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075009||125938|
NCT01075022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33598290|Effect of a Single Colecalciferol Dose on Insulin Resistance|Effect of a Single Colecalciferol Dose on Insulin Resistance: A Prospective Randomized Trial||Hospital de Clinicas de Porto Alegre|No|Enrolling by invitation|May 2009|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075022||125937|
NCT01061944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-369|Biopsies of Cancer Patients for Tumor Molecular Characterization|Biopsies of Cancer Patients for Tumor Molecular Characterization||Massachusetts General Hospital|Yes|Recruiting|February 2010|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Tumor biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be identified by their oncologist and the service performing the biopsy as a        good candidate for the repeat tumor biopsy procedure. Review of the medical record and        laboratory data is also performed to ensure the risks of complications are reasonable low        and within standard parameters.|September 2015|September 16, 2015|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061944||126935|
NCT01060514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 09L1|Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer|Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer||Northwestern University|Yes|Terminated|February 2010|September 2013|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|January 29, 2010|No|Yes|Lack of timely accrual.|No||https://clinicaltrials.gov/show/NCT01060514||127044|
NCT01068951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS2010-0180|Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells|Open Study to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells in Treatment of Recently Diagnosed Patients With Type 1 Diabetes Mellitus||Uppsala University Hospital||Completed|June 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|40 Years|No|||February 2014|February 4, 2014|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01068951||126399|
NCT01068964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-052|Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension|||Allergan||Completed|February 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|235|||Both|18 Years|70 Years|No|||September 2014|September 15, 2014|February 12, 2010|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT01068964||126398|
NCT01069263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/10|Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis|Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial||Assaf-Harofeh Medical Center|No|Recruiting|February 2010|July 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||February 2010|April 4, 2011|January 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01069263||126375|
NCT01070758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7165-DM-CTIL|Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy|Treatment With Lanreotide Autogel (Somatostatin Analogue) in Patients With Congenital Hyperinsulinism of Infancy Already Treated With Somatostatin Analog by Pump||Sheba Medical Center|No|Recruiting|February 2010|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|8 Years|No|||December 2012|December 12, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070758||126262|
NCT01071057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03001|Naloxone for the Treatment of Opioid-Induced Pruritus|Naloxone for the Treatment of Opioid-Induced Pruritus: A Double-Blind, Prospective, Randomized, Controlled Study||University of British Columbia|No|Completed|December 2010|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|92|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01071057||126239|
NCT01071993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15097|Efficacy of Statins In Prevention of CIN|Efficacy Of Statins In The Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Insufficiency (SCIN Trial): A Double-Blind, Placebo-Controlled Trial|SCIN|University of Oklahoma|Yes|Terminated|March 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 13, 2014|February 18, 2010|No|Yes|Sponsor can not supply drugs anymore|No||https://clinicaltrials.gov/show/NCT01071993||126169|
NCT01071967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-C-91360/3-01|Effect of a Community-based Nursing Intervention on Mortality in Chronically Ill Older Adults|Effect of a Longitudinal, Multifactorial Community-based Nursing Intervention on Mortality in Chronically Ill Older Adults||Health Quality Partners|No|Enrolling by invitation|April 2002|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|65 Years|N/A|No|||September 2013|September 6, 2013|December 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01071967||126171|
NCT01072526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNJ-1|Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease|Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease||University of Missouri-Columbia|No|Recruiting|December 2007|September 2008|Anticipated|September 2008|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|N/A|No|||February 2010|February 19, 2010|December 31, 2007||No||No||https://clinicaltrials.gov/show/NCT01072526||126128|
NCT01068795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0048-09-EMC ANTIXA-02|Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome|Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome||HaEmek Medical Center, Israel|Yes|Completed|July 2009|August 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|144|||Female|18 Years|45 Years|No|||February 2016|February 20, 2016|January 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01068795||126411|
NCT01069055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HerniaAnalgesia2010-001|Comparison of Lornoxicam and Paracetamol for Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair|Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair: Prospective Randomized Double-blinded Placebo Controlled Comparison of Lornoxicam and Paracetamol||Diskapi Teaching and Research Hospital|Yes|Not yet recruiting|February 2010|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069055||126391|
NCT01069068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD-2009-001|Assessment of the Impact of a Stepped Mouthpiece on the Upper Airways Measured Through Acoustic Pharyngometry|Assessment of the Impact of a Stepped Mouthpiece on the Upper Airways Measured Through Acoustic Pharyngometry||Doctor's Directive Strategies Inc.|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will be performed as an open investigation including 60 subjects. The 60        subjects will be stratified such that 30 subjects should have been diagnosed with OSA, and        30 subjects should not have been diagnosed with OSA.|December 2011|December 7, 2011|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069068||126390|
NCT01069380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-4|Resting Metabolic Rate in Chronic Bed-Ridden Patients|Resting Metabolic Rate in Chronic Bed-Ridden Patients|RMR|Reuth Medical Center|No|Recruiting|February 2010|December 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|chronically bed ridden patients for at least 1 year, hospitaqlized in REUTH MEDICAL CENTER|February 2010|February 16, 2010|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069380||126366|
NCT01070888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08080372|Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma|A Randomized, Double-blind, Double Dummy Crossover Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma in Patients With Persistent Asthma||Children's Hospital Boston|Yes|Terminated|February 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|12 Years|50 Years|No|||December 2014|December 17, 2014|February 17, 2010|Yes|Yes|Unable to reach target goal|No|November 19, 2014|https://clinicaltrials.gov/show/NCT01070888||126252|
NCT01073722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL30799,091,09|EZ Blocker Versus Left Sided Double-lumen Tube|Endobronchial EZ Blocker Compared to Left Sided Double-lumen Tube for One-lung Ventilation||Radboud University|No|Completed|February 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2010|April 29, 2011|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01073722||126037|
NCT01074476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00146|Effects of Glucosamine on Joint Fluid in Osteoarthritis Patients|Investigation of Oral Glucosamine Effects on Synovial Fluid Viscosity and Viscoelasticity in Osteoarthritis Patients||University of British Columbia|No|Recruiting|June 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|30 Years|85 Years|No|||July 2015|July 22, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074476||125979|
NCT01075048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ197-A-U252|ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer|A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy||Daiichi Sankyo Inc.|Yes|Completed|January 2010|September 2014|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075048||125935|
NCT01075295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/2009|Prevention of Weight Gain in Early Psychoses|Prevention of Weight Gain in Early Psychoses||Centre for Addiction and Mental Health|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|14 Years|45 Years|No|||December 2012|December 4, 2012|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075295||125916|
NCT01061957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37593|Raltegravir Treatment in Patients Failing Highly Active Antiretroviral Therapy (HAART) in Denmark|Clinical, Virological and Immunological Course in Danish Patients With Triple Class Failure Receiving Raltegravir as Part of a Salvage Regimen.||Rigshospitalet, Denmark|Yes|Completed|January 2006|December 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|96|||Both|16 Years|N/A|No|Non-Probability Sample|One cohort of HIV patients with virological failure initiating Raltegravir One control        cohort of HIV patients initiating HAART for the first time.|January 2010|February 3, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01061957||126934|
NCT01061970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-50605|Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy|Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study||QuatRx Pharmaceuticals Company||Completed|January 2007|October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|15|||Male|20 Years|N/A|No|||February 2010|February 2, 2010|February 2, 2010||||No||https://clinicaltrials.gov/show/NCT01061970||126933|
NCT01061931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACPAF|Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation|HD Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation - Efficiency and Safety of PV Ablation Systems|MACPAF|Charite University, Berlin, Germany|No|Terminated|March 2009|November 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|75 Years|No|||June 2014|June 23, 2014|February 2, 2010||No|reason|No||https://clinicaltrials.gov/show/NCT01061931||126936|
NCT01069913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV105|Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient|A Pharmacokinetics Profile Determination of BG00012 Standard Formulation and the BG00012 Active Pharmaceutical Ingredient (API) After a Single Oral Dose Administered to Healthy Male Volunteers||Biogen|No|Completed|October 2009|January 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2010|February 16, 2010|February 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01069913||126326|
NCT01070186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-068|Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma|Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma||Jonsson Comprehensive Cancer Center|Yes|Withdrawn|October 2010|||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|February 16, 2010|Yes|Yes|No participants were enrolled.|No||https://clinicaltrials.gov/show/NCT01070186||126306|
NCT01070472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:149|Efficacy and Safety of Titrated Oral Misoprostol Solution for Labor Induction at Term|Efficacy and Safety of Titrated Oral Misoprostol Solution for Labor Induction at Term||University of Manitoba|Yes|Completed|March 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Female|18 Years|44 Years|No|||December 2013|December 9, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070472||126284|
NCT01070485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15468|BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease|An Open-label Phase IIa, Non-randomized Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy||Bayer|No|Completed|January 2010|January 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|21 Years|N/A|No|||June 2014|June 24, 2014|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070485||126283|
NCT01070498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAI-TSO-1|Trichuris Suis Ova in Peanut and Tree Nut Allergy|Trichuris Suis Ova Therapy for Mild to Moderate Peanut and Tree Nut Allergy in Adults and Children||Beth Israel Deaconess Medical Center|Yes|Completed|February 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|64 Years|No|||May 2012|May 30, 2012|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070498||126282|
NCT01071395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valid Dyskin Rating Scales|Validation of Dyskinesia Rating Scales|Validation of Dyskinesia Rating Scales||Rush University Medical Center|Yes|Completed|January 2010|June 2013|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|68|||Both|30 Years|90 Years|No|||May 2015|May 7, 2015|February 17, 2010|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01071395||126215|Study limitations include the patient population universally derived from university centers and the short duration of the program.
NCT01071408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23NS058571|Trial of a Secondary Stroke Prevention Program|Development of a Stroke Prevention Program for an Underserved Minority Community||Sepulveda Research Corporation|No|Completed|March 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|N/A|N/A|No|||May 2012|May 14, 2012|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01071408||126214|
NCT01071070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M06-823|Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease|A Phase 3b, Randomized, Active-Controlled, Single-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Injection in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects Receiving Hemodialysis||Abbott||Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|216|||Both|20 Years|N/A|No|||December 2011|December 20, 2011|November 25, 2009|Yes|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT01071070||126238|
NCT01072539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074X1-4527|Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment|A Post-marketing Surveillance (Pms) Study Of Safety And Effectiveness In Patients With Tigecycline Treatment||Pfizer|No|Completed|May 2010|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|General Hospitals|August 2015|August 5, 2015|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072539||126127|
NCT01072825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/622|A European Network for the Investigation of Gender Incongruence|A European Network for the Investigation of Gender Incongruence|ENIGI|University Hospital, Ghent|No|Recruiting|February 2010|January 2020|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|transsexual persons older than 18 years, who are not yet treated with hormonal therapy|June 2015|June 2, 2015|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072825||126105|
NCT01072266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 28060-101|A Dose-escalation Study in Subjects With Advanced Malignancies|A Phase 1, Open-label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB028060 in Subjects With Advanced Malignancies||Incyte Corporation|No|Completed|January 2010|January 2013|Actual|July 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|February 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072266||126148|
NCT01072279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4001-IFPRI-00|Preventing Malnutrition in Children Under Two Years of Age Approach|Strengthening and Evaluating the "Preventing Malnutrition in Children Under Two Years of Age Approach" (PM2A) in Guatemala and Burundi||International Food Policy Research Institute|No|Completed|April 2010|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|10||Actual|16895|||Both|N/A|42 Months|Accepts Healthy Volunteers|||January 2013|February 23, 2016|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072279||126147|
NCT01068496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R707/57/2009|Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium|Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium||Singapore National Eye Centre|No|Terminated|March 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|Samples With DNA|Pterygium and conjunctival tissue samples|Both|21 Years|N/A|No|Non-Probability Sample|Pterygium patients from the investigator's clinic as well as other clinics at the        Singapore National Eye Center will be recruited for this study.|January 2013|May 18, 2015|February 12, 2010||No|Other and future studies on lipiview in pterygium will cover this current trial sufficiently.|No||https://clinicaltrials.gov/show/NCT01068496||126434|
NCT01068782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-205|Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse|A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse||Exelixis|Yes|Completed|April 2010|October 2013|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|February 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068782||126412|
NCT01075282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11374|A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)|A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride|AWARD-2|Eli Lilly and Company|No|Completed|February 2010|November 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|810|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|February 23, 2010|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01075282||125917|
NCT01075555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000666232|Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis|Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma||Federation Francophone de Cancerologie Digestive|Yes|Active, not recruiting|February 2010|June 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||February 2010|March 3, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075555||125896|
NCT01076270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2385.00|Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Pilot Study of Combined Plerixafor + Filgrastim for Mobilization of Peripheral Blood Stem Cells From Normal Donors||Fred Hutchinson Cancer Research Center|No|Terminated|June 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|February 24, 2010|No|Yes|Funding withdrawal|No||https://clinicaltrials.gov/show/NCT01076270||125841|
NCT01076283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906000002|A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking|A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking||Brown University|No|Completed|December 2009|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|65 Years|No|||October 2013|October 15, 2013|February 25, 2010||No||No|May 5, 2013|https://clinicaltrials.gov/show/NCT01076283||125840|Very small sample. This pilot trial was primarily aimed to determine a power analysis for future larger trials.
NCT01070342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSAP1|Ambulatory Blood Pressure Monitoring in Children|Methodological Improvement in Measuring Efficacy Outcome in Antihypertensive Trials in Children|ABPM|University Hospital Case Medical Center|No|Not yet recruiting|February 2010|May 2012|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Both|6 Years|18 Years|No|Non-Probability Sample|Children ages 6 to 18 years will be available for participation in this multicenter study.        Subjects will be enrolled from community based general pediatric clinics and other        well-child care areas within participating hospitals and clinics of the four participating        sites. Enrollment will continue until a total of 85 subjects from each age category (6-<12        years and ≥12- <18 years) successfully complete the study. In addition, enrollment will be        dependent upon mean qualifying blood pressure and arm circumference such that a wide range        of both are represented in each age group.|December 2009|February 17, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070342||126294|
NCT01074229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00023440|Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy|The Effect of Pre-operative Transversus Abdominis Plane (TAP) Block in the Quality of Recovery of Patients Undergoing Laparoscopic Hysterectomy: a Prospective, Randomized, Blinded Study|TAP HYS|Northwestern University|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|75|||Female|18 Years|64 Years|No|||April 2014|April 9, 2014|February 22, 2010||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01074229||125998|Ropivacaine blood levels were not obtained. Distribution of study drug unable to gauge due to general anesthesia. Study underpowered to detect a difference in opioid consumption or global QoR-40 between the ropivacaine 0.25% and 0.5% groups.
NCT01075061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-06|Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification PROJET " MOMIC "|Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification : MOMIC|MOMIC|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|February 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|40|||Both|11 Years|82 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01075061||125934|
NCT01076075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-229|A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)|A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With Metformin||Merck Sharp & Dohme Corp.|No|Completed|June 2010|January 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|427|||Both|18 Years|78 Years|No|||January 2016|January 21, 2016|February 24, 2010|Yes|Yes||No|June 28, 2012|https://clinicaltrials.gov/show/NCT01076075||125856|
NCT01062269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OO1|A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study|A Randomized Single Blind Placebo Controlled Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study in Generally Healthy Subjects||Louisville Metabolic and Atherosclerosis Research Center|No|Completed|January 2010|April 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2011|July 1, 2011|February 2, 2010|Yes|Yes||No|May 18, 2010|https://clinicaltrials.gov/show/NCT01062269||126910|(1)It was performed in generally healthy subjects, for whom lipid-altering medication may not be indicated.(2)The subjects’ preference or dislike of the 1st or 2nd powder mixture might have influenced their ratings of the 2nd or 3rd powder.
NCT01062243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133A070036|Brain Injury Inpatient Educational Intervention for Families and Caregivers|Brain Injury Inpatient Educational Intervention for Families and Caregivers (a Research Project Within the Traumatic Brain Injury Model System)|BIIG-FACS|Virginia Commonwealth University|No|Completed|July 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|110|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01062243||126912|
NCT01069926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00007|To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients|A Phase I, Multi-center, Open-label, Single Dose Study, to Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients With or Without Renal Impairment||AstraZeneca|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|21|||Both|18 Years|N/A|No|||December 2010|December 8, 2010|February 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01069926||126325|
NCT01069939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961PC00001|Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin|A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use||AstraZeneca|Yes|Completed|February 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|427|||Both|20 Years|N/A|No|||October 2012|October 24, 2012|February 16, 2010|Yes|Yes||No|October 24, 2012|https://clinicaltrials.gov/show/NCT01069939||126324|
NCT01070199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK079913|Effects of Food Form and Fitness on Appetite and Digestion.|Effects of Food Form and Fitness on Appetite and Digestion.||Purdue University|No|Completed|January 2009|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|81|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070199||126305|
NCT01070511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA 158944|Tadalafil in Becker Muscular Dystrophy|Functional Muscle Ischemia and PDE5A Inhibition in Becker Muscular Dystrophy||Cedars-Sinai Medical Center|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01070511||126281|
NCT01072006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7031-W|Top-Down Executive Control in Traumatic Brain Injury (TBI), PTSD and Combined|Top-Down Executive Control in TBI, PTSD and Combined TBI/PTSD||VA Office of Research and Development|No|Recruiting|June 2011|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|OEF/OIF veterans enrolled in the Northern California Health Care System|July 2015|July 29, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072006||126168|
NCT01071655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-09-01(ML25052)|Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer|Selecting Treatment in Colorectal Cancer: Capecitabine or 5-fluorouracil Selection According to Polymorphisms in TS-3'UTR and ERCC1-118 to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer|SETICC|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|February 2010|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|N/A|No|||March 2014|March 23, 2015|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01071655||126195|
NCT01071980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIMS00|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Industrial Workers|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Industrial Workers|VIMS|National Research Centre for the Working Environment, Denmark||Completed|January 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|522|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01071980||126170|
NCT01076803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/289|Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients|Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients||University Hospital, Ghent|No|Completed|October 2009|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01076803||125800|
NCT01072838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S09-001|Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB|Safety and Feasibility of Short-Course, Accelerated, Hypofractionated Partial Breast Radiotherapy in Women With Early Stage Breast Cancer Using the Contura MLB Breast Brachytherapy Catheter: A Phase II Trial||SenoRx, Inc.|Yes|Terminated|December 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|50 Years|N/A|No|||June 2013|June 14, 2013|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072838||126104|
NCT01073969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-08011|Study to Determine the Digestive and Physiological Effects of an Extract From Bran in Healthy Men and Women|A Double-blind, Randomized, Controlled Crossover Trial to Assess the Digestive and Physiological Effects of a Wheat Bran Extract in Healthy Men and Women||Kellogg Company|No|Completed|March 2009|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2010|February 22, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01073969||126018|
NCT01075035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075832-R01|Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder|Evidence Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder at the Saint Louis University Advanced Neurosurgical Innovation Center (SANIC)|SANIC|St. Louis University|Yes|Completed|August 2008|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|224|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|50-60 Normal Healthy Controls 50-60 Civilian TBI 50-60 Military TBI|April 2014|December 9, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01075035||125936|
NCT01076062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210013|Elective Induction of Nulliparous Labor|Elective Induction of Nulliparous Labor: A Randomized Clinical Trial||Madigan Army Medical Center|Yes|Recruiting|February 2010|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 22, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076062||125857|
NCT01076816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/518|Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure|||University Hospital, Ghent|Yes|Terminated|December 2009|May 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|1 Month|15 Years|No|||October 2011|October 3, 2011|February 25, 2010||No|Poor inclusion rate.|No||https://clinicaltrials.gov/show/NCT01076816||125799|
NCT01070355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA09/9094|Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases|The Effects of Eicosapentaenoic Acid (EPA) on Biomarkers of Growth and Vascularity in Human Colorectal Cancer Liver Metastases (The EPA for Metastasis Trial)|EMT|University of Leeds|Yes|Completed|April 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01070355||126293|
NCT01074762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCGP1989|Randomised Controlled Trial of Structured Personal Care of Type 2 Diabetes Mellitus|The Diabetes Care in General Practice Study: Randomised Controlled Trial of Structured Personal Care of Type 2 Diabetes Mellitus|DCGP|Research Unit Of General Practice, Copenhagen|No|Completed|March 1989|February 1996|Actual|February 1996|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1470|||Both|40 Years|N/A|Accepts Healthy Volunteers|||July 2003|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074762||125957|
NCT01075581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-RL-0035-CTIL|Intranasal Injection Versus Topical Administration of Epinephrin During Endoscopic Sinus Surgery|Hemostatic and Hemodynamic Effects of Intranasal Injection Compared to Topical Administration of Epinephrin in Endoscopic Sinus Surgery||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|April 2010|June 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||February 2010|February 24, 2010|February 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01075581||125894|
NCT01075594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CBG-CRE-2009/1|Study of Undertreatment of Patients With Dyslipidemia in Bulgaria|Centralized Pan-Bulgarian Survey on the Undertreatment of Hypercholesterolemia|CEPHEUS|AstraZeneca|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2500|None Retained|whole blood, serum|Both|18 Years|N/A|No|Probability Sample|Primary care clinic|September 2010|September 9, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01075594||125893|
NCT01062815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080651|Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants|Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants||University of Miami|No|Terminated|February 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Both|N/A|7 Days|No|||November 2015|November 20, 2015|February 3, 2010||No|Difficulty in recruiting patients|No||https://clinicaltrials.gov/show/NCT01062815||126868|
NCT01062789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004069|Optical Breath-hold Control System for Image-guided Procedures|Use of an Optical Breath-hold Control (OBC) System for Image-guided Interventional Radiology Procedures: A Feasibility Study|OBC|Mayo Clinic|No|Withdrawn|February 2010|May 2011|Actual|May 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||May 2011|May 16, 2011|January 28, 2010||No|Closed due to funding and never enrolled a subject|No||https://clinicaltrials.gov/show/NCT01062789||126870|
NCT01069965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGP-15-CLIN-IR04|Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus|Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety & Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin & Sulfonylurea or Metformin in T2 Diabetic Patients||N-Gene Research Laboratories, Inc.|No|Terminated|October 2010|October 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|196|||Both|30 Years|70 Years|No|||September 2014|September 26, 2014|February 16, 2010|Yes|Yes|Funding support withdrawn.|No||https://clinicaltrials.gov/show/NCT01069965||126322|
NCT01069991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2642|Asthma Self-Management For Adolescents|Educating Adolescents To Preventively Manage Their Asthma|ASMA|Columbia University|No|Completed|January 2002|February 2007|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|345|||Both|13 Years|18 Years|No|||February 2013|February 11, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069991||126321|
NCT01070212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK079913-2|Effects of Gum Chewing on Appetite and Digestion|Effects of Gum Chewing on Appetite and Digestion||Purdue University|No|Completed|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070212||126304|
NCT01070823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101JC401|JC-Virus (JCV) Antibody Program|JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri®: STRATIFY-1|STRATIFY-1|Biogen|No|Completed|March 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1096|Samples Without DNA|Serum, Urine and Plasma|Both|N/A|N/A|No|Probability Sample|Patients with relapsing Multiple Sclerosis (MS) receiving commercial Tysabri®        (natalizumab) and patients being considered for such treatment.|August 2014|August 18, 2014|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070823||126257|
NCT01071096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001AL|Calcitonin Gene-related Peptide Levels in Chronic Migraine|Calcitonin Gene-related Peptide (CGRP) Levels in the Pathogenesis of Chronic Migraine||Cady, Roger, M.D.|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||February 2013|February 6, 2013|February 17, 2010|Yes|Yes||No|January 16, 2012|https://clinicaltrials.gov/show/NCT01071096||126236|Due to identified lab errors related to processing of samples for CGRP and cytokine levels, samples are currently being re-processed. Results will be posted following re-analysis of all study data related to sample values.
NCT01072292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KO1 NR010749|Cognitive Behavioral Therapy for Insomnia in People With Chronic Obstructive Pulmonary Disease(COPD)|Nurse Managed Cognitive Behavioral Therapy for Insomnia in People With Chronic Obstructive Pulmonary Disease||University of Illinois at Chicago|Yes|Completed|June 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|45 Years|N/A|No|||June 2014|June 1, 2014|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072292||126146|
NCT01073709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143_ACETA_07|A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gelcaps of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc.), With Tylenol® Arthritis Pain Extended Release Caplets (Containing Acetaminophen 650 mg) of Mc Neil-PPC Inc., in Healthy, Adult, Human, Male Subjects Under Fasting Condition.||Ranbaxy Inc.|No|Completed|November 2007|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 22, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01073709||126038|
NCT01074463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-1203|Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 0.25 mg Pramipexole Dihydrochloride Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA||Completed|February 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|February 22, 2010||Yes||No|April 8, 2010|https://clinicaltrials.gov/show/NCT01074463||125980|
NCT01075568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-NV-016-CTIL|The Satiety Effect After Okara Compared to Porridge Eating|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2010|December 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind|1||Anticipated|10|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||February 2010|March 2, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01075568||125895|
NCT01075815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700642-500|A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age|Exploratory Study to Determine the Effect of Lutropin Alfa on Embryo Quality and Their Implantation in Women of Advanced Reproductive Age||Merck KGaA|No|Terminated|November 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Female|35 Years|N/A|No|||January 2014|January 20, 2014|February 24, 2010|No|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01075815||125876|
NCT01076569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B14|Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia|Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis||Children's Oncology Group|No|Recruiting|March 2010|January 2100|Anticipated|January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|250|Samples With DNA|bone marrow|Both|N/A|21 Years|No|Non-Probability Sample|Any patient with a diagnosis of acute myeloid leukemia meeting the other criteria.|November 2015|November 16, 2015|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076569||125818|
NCT01076582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14567|Comparative Trial in Hormone Withdrawal Associated Symptoms|A Multi-centre, Randomized, Double-blind, Active Control, Parallel-group, 2-arm Study to Investigate the Effect of Ethinylestradiol / Drospirenone (0.02 mg/3 mg) Oral Contraception in a 24/4 Regimen Compared to Ethinylestradiol / Desogestrel (0.02 mg/0.15 mg) Oral Contraception in a 21/7 Regimen on Hormone Withdrawal Associated Symptoms in Otherwise Healthy Women After 4 Cycles of Treatment||Bayer|No|Completed|April 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|592|||Female|18 Years|35 Years|No|||October 2014|October 27, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076582||125817|
NCT01073098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01187-50|Evaluation of Muscle StO2 as a Prognostic Factor After Out of Hospital Cardiac Arrest|Evaluation of Muscle StO2 as a Prognostic Factor After Out of Hospital Cardiac Arrest||Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2010|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|51|||Both|18 Years|80 Years|No|||December 2011|March 23, 2012|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073098||126084|
NCT01070628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939131|Levodopa Concentration Profile With Stalevo 75/125 mg|Levodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel Groups|NEWSTA|Orion Corporation, Orion Pharma|No|Completed|December 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2010|August 12, 2010|November 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01070628||126272|
NCT01070368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231/2552(EC4)|Accuracy Of Skin Prick Test Using In-house Wheat Extract For The Diagnosis Of IgE-mediated Wheat Allergy: A Pilot Study|Accuracy Of Skin Prick Test Using In-house Wheat Extract For The Diagnosis Of IgE-mediated Wheat Allergy: A Pilot Study||Mahidol University|No|Completed|June 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|1 Year|15 Years|No|||February 2013|February 27, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070368||126292|
NCT01070381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-346-C-008|Daily Disposable Toric Comparative Trial in Europe|||Alcon Research||Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|N/A|N/A|No|||January 2012|November 19, 2013|February 16, 2010|Yes|Yes||No|February 25, 2011|https://clinicaltrials.gov/show/NCT01070381||126291|
NCT01070394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00909|Effectiveness and Duration of Effect of Open Treatment in Adult Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate- LDX (Vyvanse)|Effectiveness and Duration of Effect of Open Treatment in Adult ADHD Patients Treated With Lisdexamfetamine Dimesylate- LDX (Vyvanse)||New York University School of Medicine|Yes|Completed|October 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|No|||March 2013|March 11, 2013|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01070394||126290|
NCT01071161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL19886.075.08|The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough|Phase III (c) The Effect of Azithromycin in Patients With COPD and Chronic Productive Cough|CACTUS|Isala|Yes|Completed|September 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|40 Years|N/A|No|||September 2015|September 17, 2015|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01071161||126231|
NCT01071746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/HO714/8|Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)|The Predictive Utility of the Dimethylarginines and Ischemia Modified Albumin as Prognostic Biomarkers in Patients With Acute-on-chronic Liver Failure|DASIMAR|University College London Hospitals|No|Recruiting|September 2008|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|RNA|Both|18 Years|N/A|No|Probability Sample|Inpatients with acute clinical deterioration of cirrhosis.|April 2008|February 18, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071746||126188|
NCT01062828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081180|Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants|Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants||University of Miami|No|Active, not recruiting|July 2009|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Probability Sample|Premature infants with gestational age between <32 weeks regardless of birth weight born        at University of Miami/Holtz Children's Hospital Neonatal Intensive Care Unit, or        transferred in within the first 72h of life.|January 2016|January 26, 2016|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062828||126867|
NCT01062542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0115-B|Assessment of Ovarian Reserve in Female Cancer Survivors|Fertility in Female Cancer Survivors - Novel Assessment of Ovarian Reserve||University Health Network, Toronto|No|Active, not recruiting|September 2008|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|210|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients are selected from their primary care clinic.|June 2015|June 16, 2015|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01062542||126889|
NCT01062555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604M85327|Calcineurin Inhibitor Sparing After Kidney Transplantation|Calcineurin-Sparing in a Steroid-free Maintenance Immunosuppression Protocol After Kidney Transplantation|CNI-Sparing|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|October 2006|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062555||126888|
NCT01062802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB/EL/R0135|Statin Use in Abdominal Aortic Aneurysm Repair|Randomised Controlled Trial of Effect of Pre-operative Statin Use on Matrix Metalloproteinases (MMP) & Tissue Inhibitors of Matrix Metalloproteinases (TIMP) in Abdominal Aortic Aneurysm (AAA).||University of Hull||Completed|January 2005|December 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|40|||Both|20 Years|N/A|No|||December 2007|February 3, 2010|February 3, 2010||||No||https://clinicaltrials.gov/show/NCT01062802||126869|
NCT01070524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0909-PR-0020|Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma|A Randomised, Double-blind, Active-controlled, 3 Way Cross-over Study to Evaluate the Effect on Trough FEV1 After 4 Weeks Treatment With CHF 5188 pMDI qd (Fixed Combination Budesonide / Carmoterol) in Adult Patients With Moderate or Severe Persistent Asthma||Chiesi Farmaceutici S.p.A.|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|113|||Both|18 Years|N/A|No|||February 2010|May 4, 2011|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070524||126280|
NCT01070810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-000053|Thiamine as a Metabolic Resuscitator in Septic Shock|Thiamine as a Metabolic Resuscitator in Septic Shock||Beth Israel Deaconess Medical Center||Completed|February 2010|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070810||126258|
NCT01071083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS205|Treatment Interruption of Natalizumab|Randomized Treatment Interruption of Natalizumab|RESTORE|Biogen||Completed|March 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|18 Years|60 Years|No|||November 2012|September 12, 2013|February 17, 2010|Yes|Yes||No|October 25, 2012|https://clinicaltrials.gov/show/NCT01071083||126237|
NCT01074775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBC-INNATE01|Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection|An Investigation Of In Vivo Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection|UBC-INNATE01|St George's, University of London|No|Completed|September 2006|September 2007|Actual|September 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074775||125956|
NCT01074788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tasmc-09-yl-0488|Mind Body Therapy During Geriatric Rehabilitation|||Tel-Aviv Sourasky Medical Center||Active, not recruiting|November 2009|||November 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2010|February 23, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074788||125955|
NCT01075828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62241-508 (EMR 62202-551)|Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea|A Korean Post Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (SCCHN)||Merck KGaA|No|Completed|March 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|221|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with locally advanced or recurrent and/or metastatic SCCHN eligible for Erbitux        treatment will be enrolled in the study.|August 2014|August 28, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075828||125875|
NCT01076088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-121|Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)|A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of Co-administration of Sitagliptin and Metformin in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|November 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|744|||Both|18 Years|78 Years|No|||April 2015|April 27, 2015|February 24, 2010|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01076088||125855|
NCT01076608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149092003|DETECT-Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment|Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment (DETECT)|DETECT|Technische Universität Dresden|Yes|Completed|September 2003|December 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|55518|Samples Without DNA|whole blood, serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Representative random sample of 3188 General Practitioners in Germany (general        practitioners and internists serving as GPs), who included patients:          -  Main study: 55,518 (unselected consecutive)          -  Longitudinal observation study in a random subset of 7519 patients|February 2010|February 25, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076608||125815|
NCT01074216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-143|Vitamin D Levels in Stage IV Colorectal Cancer Patients|Vitamin D Levels in Stage IV Colorectal Cancer Patients: A Phase II Study||Memorial Sloan Kettering Cancer Center||Completed|February 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|February 22, 2010|Yes|Yes||No|January 4, 2016|https://clinicaltrials.gov/show/NCT01074216||125999|
NCT01074450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-1202|Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 0.25 mg Pramipexole Dihydrochloride Tablets Under Fasting Conditions||Teva Pharmaceuticals USA||Completed|February 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|February 22, 2010||Yes||No|April 8, 2010|https://clinicaltrials.gov/show/NCT01074450||125981|
NCT01074736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 007|Host Genetic Susceptibility to Avian Influenza A/H5N1|Host Genetic Susceptibility to Avian Influenza A/H5N1 in Vietnam, Thailand, Indonesia and Singapore||South East Asia Infectious Disease Clinical Research Network|Yes|Completed|July 2008|October 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|500|Samples With DNA|-  whole blood in tubes containing EDTA        -  mouth wash.        -  buffy coat; cell pellet from centrifuged blood, nucleic acid extracted for diagnostic           purposes, serum, throat, nose or endotracheal swabs|Both|N/A|N/A|No|Non-Probability Sample|-  symptomatic cases with laboratory confirmed H5N1 infection will be eligible for             inclusion.          -  Priority for recruitment will be given to cases from multi-case families in order             tomaximize the probability of including cases with a genetic etiology.|November 2010|November 3, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01074736||125959|
NCT01069731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WakeMed Study 748|Comparison of Non-nutritive Suck (NNS) Measures to Clinical Estimates of Suck and Feeding Readiness in Preterm Infants|Comparison of NNS Performance Measures to Clinical Estimates of Suck and Feeding Readiness in Preterm Infants Using the NTrainer Device||KC BioMediX, Inc|No|Completed|January 2008|November 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|30 Weeks|36 Weeks|No|Non-Probability Sample|Infants born prematurely may suffer multiple adverse events in the NICU, and these        experiences may negatively impact normal developmental processes of immature        cardiorespiratory, gastrointestinal and central nervous systems. As a result, many infants        have at least transient difficulties learning to successfully manage oral feedings. Oral        feeding difficulties in the NICU may prolong the time to discharge, cause significant        parental anxiety, and persist throughout infancy.|February 2010|February 16, 2010|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069731||126340|
NCT01070082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-066|Europain®: A Study of Procedural Pain|Pain Associated With ICU Procedures: An International Study|Europain®|Saint-Louis Hospital, Paris, France|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5150|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients who are undergoing any of the study procedures and consent to participate.        Adults age 18 and over will be eligible for the study if they meet study inclusion        criteria and don't meet any exclusion criteria.|April 2010|August 17, 2011|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070082||126314|
NCT01070329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13630|A Study in Depression and Associated Painful Physical Symptoms|Duloxetine Versus Placebo in the Acute Treatment of Patients With Major Depressive Disorder and Associated Painful Physical Symptoms||Eli Lilly and Company|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|527|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|February 16, 2010|Yes|Yes||No|January 10, 2012|https://clinicaltrials.gov/show/NCT01070329||126295|
NCT01070095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-052|The Electronic Asthma Action Plan System for Implementation in Primary Care|The Electronic Asthma Action Plan System for Implementation in Primary Care|eAAPS|St. Michael's Hospital, Toronto|No|Completed|July 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|19|||Both|16 Years|N/A|No|||November 2014|November 25, 2014|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070095||126313|
NCT01070706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-08-369|Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib|Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib in Patients With HER2-negative Stage II/III Breast Cancer|PGS|National Cancer Center, Korea|No|Completed|March 2009|November 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||January 2012|January 1, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070706||126266|
NCT01070953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-175|EZETROL® Re-examination Study (MK0653-175)(COMPLETED)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of EZETROL® in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|January 2005|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4467|||Both|10 Years|N/A|No|Probability Sample|Participants with Hypercholesterolemia treated with EZETROL®|October 2015|October 12, 2015|February 17, 2010|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT01070953||126247|
NCT01070966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-174|Vytorin Reexamination Study (0653A-174)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of VYTORIN in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|July 2005|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|2089|||Both|10 Years|N/A|No|Probability Sample|Participants with Primary Hypercholesterolemia and Homozygous Familial        Hypercholesterolemia (HoFH) treated with Vytorin|October 2015|October 30, 2015|February 17, 2010|Yes|Yes||No|April 14, 2011|https://clinicaltrials.gov/show/NCT01070966||126246|
NCT01070641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT carvidalol vs EVBL|RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage|RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage||Aga Khan University|Yes|Recruiting|June 2002|July 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|148|||Both|18 Years|75 Years|No|||February 2010|February 17, 2010|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070641||126271|
NCT01070901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG-9F09|Immune Status in Solid Organ Transplantation|Evaluation of Predictors of Immune Status in Solid Organ Transplantation||Dartmouth-Hitchcock Medical Center|No|Completed|May 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|75 Years|No|Non-Probability Sample|Tranplant clinic population|February 2013|February 4, 2013|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070901||126251|
NCT01071174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 015|A Safety Study of Dapivirine Vaginal Ring in Africa|A Double-Blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety of an Intravaginal Matrix Ring With Dapivirine in Healthy, HIV-Negative Women.||International Partnership for Microbicides, Inc.|Yes|Completed|April 2010|July 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|280|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2011|August 1, 2011|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01071174||126230|
NCT01071187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-17|Varenicline for Alcohol Dependence|Investigation of the Efficacy and Safety of Varenicline in the Postacute Treatment of Alcohol Dependence - a Prospective, Double-blind, Placebo-controlled, Randomised Phase-II Study||Johannes Gutenberg University Mainz|Yes|Recruiting|March 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||September 2010|September 14, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071187||126229|
NCT01062854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00023548|Effects of Earplugs on Sleep and Sleep Apnea|Effects of Earplugs on Sleep and Sleep Apnea||University of Michigan|No|Completed|November 2008|August 2012|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|407|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062854||126865|
NCT01062867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 12.4.104|First Administration to Man Of Org 25435 a New Intravenous Anesthetic|First Administration to Man Of Org 25435 a New Intravenous Anesthetic||University of Plymouth|No|Completed|January 2000|March 2000|Actual|March 2000|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|February 3, 2010|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01062867||126864|
NCT01063114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-361|Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma|Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma: An Assessment of Acute Toxicity and Long Term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes||Massachusetts General Hospital|Yes|Recruiting|April 2010|April 2024|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|3 Years|25 Years|No|||February 2016|February 25, 2016|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063114||126845|
NCT01063374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-193|Low Glycemic Index Diet for Type 2 Diabetics|Low Glycemic Index Diets to Improve Glycemic Control and Cardiovascular Disease in Type 2 Diabetics||University of Toronto|Yes|Active, not recruiting|March 2010|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|169|||Both|21 Years|N/A|No|||December 2015|December 3, 2015|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01063374||126825|
NCT01070537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVIBO|Evaluation of the Bonfils Fiberscope for Predicted Difficult Intubation in Awake Patients With Ear, Nose, and Throat (ENT) Cancer (INVIBO)|INVIBO: Evaluation of the Feasibility and Tolerance of an Intubation Procedure Performed by Means of the Bonfils Fiberscope in Awake Patients With Predicted Difficult Intubation in the Context of ENT Cancer Surgery|INVIBO|Centre Leon Berard|No|Completed|February 2008|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment|1||Actual|41|||Both|18 Years|N/A|No|||February 2010|February 17, 2010|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01070537||126279|
NCT01070836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101JC402|JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab|JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2|STRATIFY-2|Biogen|No|Completed|March 2010|November 2015|Actual|November 2015|Actual|N/A|Observational|N/A||1|Actual|36065|Samples With DNA|Plasma, Serum, Urine, Whole Blood, Peripheral blood mononuclear cell (PBMC)|Both|N/A|N/A|No|Probability Sample|US participants with relapsing MS receiving commercial natalizumab.|January 2016|January 14, 2016|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01070836||126256|
NCT01076842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-13028|Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment|The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents||Walter Reed Army Medical Center|Yes|Completed|April 2008|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|90 Years|No|||June 2011|June 24, 2011|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01076842||125797|
NCT01076855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/008|Guidance for Elderly With Cognitive Disorders|Guidance Programme for Elderly With Cognitive Disorders|BOCS|University Hospital, Ghent|No|Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|70 Years|N/A|No|Non-Probability Sample|elderly (>70 years) with mild dementia in presence of a carer.|June 2015|June 2, 2015|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01076855||125796|
NCT01076322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-TWB-0801|A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients|||Taiwan Otsuka Pharm. Co., Ltd|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|17|||Both|16 Years|N/A|No|||February 2010|August 10, 2010|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076322||125837|
NCT01076335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0273|Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer|Phase II Study of Neoadjuvant Hormonal Therapy Plus Docetaxel Followed by Radical Prostatectomy for Men With Proven or Suspected Node-positive Prostate Cancer||M.D. Anderson Cancer Center|No|Completed|May 2005|||June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|N/A|N/A|No|||June 2015|June 5, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01076335||125836|
NCT01076556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01373|Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients With High Risk B-cell CLL/SLL||National Cancer Institute (NCI)||Terminated|April 2010|||July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|February 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01076556||125819|
NCT01069120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPU-307|Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids|A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304||Repros Therapeutics Inc.|Yes|Terminated|April 2009|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 5, 2014|February 10, 2010|Yes|Yes|Repros stopped study due to safety and FDA placed study on hold|No|June 25, 2014|https://clinicaltrials.gov/show/NCT01069120||126386|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.
NCT01069133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAJAJ010|Study of Rifaximin in Minimal Hepatic Encephalopathy|Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy,Diffusion Tensor Imaging Microbiome and Metabolome: a Prospective Trial||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Completed|February 2010|December 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||December 2012|December 10, 2012|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069133||126385|
NCT01074749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-09-058-ND-LV|Optimal Sensing in Atrial Tachyarrhythmia's Study|OSAT: Optimal Sensing in Atrial Tachyarrhythmia's Study|OSAT|St. Jude Medical|Yes|Terminated|July 2010|July 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|February 22, 2010||No|Interim analysis indicated that endpoints can not be analysed with current dataset.|No||https://clinicaltrials.gov/show/NCT01074749||125958|
NCT01069419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0027|Observation of Treatment With Certolizumab Pegol in Daily Practice|A Multicenter, Observational, Non-interventional Study to Evaluate the Safety and Efficacy of Anti-TNF (Anti-Tumor Necrosis Factor) Alpha Therapy With Certolizumab Pegol Observed in Daily Practice in Adult Rheumatoid Arthritis (RA) Patients|FasT|UCB Pharma|No|Completed|October 2009|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1117|||Both|18 Years|N/A|No|Non-Probability Sample|Male or female ≥ 18 years of age with RA and is eligible for treatment with Cimzia.        Recruited in Germany.|October 2015|October 6, 2015|February 15, 2010|No|Yes||No|August 27, 2015|https://clinicaltrials.gov/show/NCT01069419||126363|
NCT01069445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/08|Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene|Open Label, Randomized Study of the Impact of Diet on Gut Microbiota, Inflammageing and Oxidative Stress in Elderly People. Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene. French Part of a Multicentric European Study|RISTOMED|University Hospital, Bordeaux|No|Completed|March 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|48|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|February 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01069445||126361|
NCT01069744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oprmc1|Oral Entrainment on Suck Development of Preterm Infants Born 23 to 34 Weeks Gestational Age (GA)|Randomized Control Trial Evaluating The Effect Of Patterned Oral Somatosensory Entrainment Stimulation Program (NTrainer System) On Suck Development and Feeding Performance of Preterm Infants Born Between 23 And 34 Weeks Gestational Age||KC BioMediX, Inc|No|Completed|November 2007|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|71|||Both|23 Weeks|34 Weeks|No|Probability Sample|Preterm Infants Born Between 23 And 34 Weeks Gestational Age|February 2010|February 16, 2010|February 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01069744||126339|
NCT01070121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091007003|Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository|Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository|TETRAD|University of Alabama at Birmingham|No|Completed|February 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Whole blood, red blood cells, white blood cells, plasma, serum, DNA, RNA|Both|19 Years|N/A|No|Non-Probability Sample|Speciality/referral clinic, Community|October 2015|October 12, 2015|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070121||126311|
NCT01070654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM0910|Inflammatory Effects of a Lung Recruitment Manoeuvre|Prospective, Open, Uncontrolled, Non-randomized and Monocentric Trial on the Efficacy and the Inflammatory Effects of a Lung Recruitment Manoeuvre in Mechanical Ventilated Patients With Respiratory Failure||Azienda Ospedaliero, Universitaria Pisana|Yes|Recruiting|June 2010|December 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2010|July 6, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070654||126270|
NCT01070914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hackmon-2|Early Detection and Characterization of Primary Ciliary Dyskinesia|The Israeli National Consortium for Early Detection and Characterization of Primary Ciliary Dyskinesia||Ziv Hospital|No|Recruiting|June 2011|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|130|||Both|N/A|N/A|No|Non-Probability Sample|Residents of Israel|May 2012|May 7, 2012|February 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01070914||126250|
NCT01063127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|749/09|A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity|A Longitudinal, Open-label Study on the Short-term Effects of Roux-en-Y Gastric Bypass Surgery vs. Gastric Banding on Glucose Homeostasis in Obese Subjects||Catholic University of the Sacred Heart|No|Completed|February 2010|July 2012|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|23|None Retained|Blood sampling|Both|25 Years|55 Years|No|Non-Probability Sample|Twenty morbidly obese subjects scheduled for RYGB or LAGB for will be included in the        study.|February 2013|February 14, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01063127||126844|
NCT01063920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-NS001-003|Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®|A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Non-Inferiority Study of LT-NS001 Versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates||Logical Therapeutics|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|534|||Both|45 Years|80 Years|No|||January 2011|January 20, 2011|January 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063920||126783|
NCT01075802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TADE study|Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms|A Multi-Centre Study of Tamoxifen Dose Escalation Study in Breast Cancer Patients With CYP2D6 Polymorphisms|TADE|Western Sydney Local Health District|Yes|Completed|March 2010|December 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|121|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075802||125877|
NCT01076036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corindus-Corbic-2010|CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)|CorPath™ 200 System: Coronary Remote Catheterization Feasibility Study||Corindus Inc.|Yes|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|February 24, 2010||No||No|July 31, 2012|https://clinicaltrials.gov/show/NCT01076036||125859|
NCT01073410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02173|Chitinases and Transforming Growth Factor Beta (TGFB) in Human Asthma|Chitinases and TGFB in Human Asthma|AADCRC|University of California, San Francisco|No|Recruiting|February 2010|April 2018|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|Samples With DNA|sputum, blood, saliva, DNA, RNA, Plasma|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|March 2015|March 4, 2015|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01073410||126061|
NCT01076049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108527|Evaluation of IrriSept for Irrigation of Skin and Soft Tissue Infections in the Emergency Room Setting|Evaluation of a Novel Solution, IrriSept, Containing a Long-Acting Antimicrobial Agent for Irrigation of Skin and Soft Tissue Infections in the Emergency Setting|USF|Irrimax Corporation|Yes|Terminated|December 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|114|||Both|18 Years|80 Years|No|||June 2013|June 12, 2013|February 23, 2010|Yes|Yes|suboptimal recruitment|No||https://clinicaltrials.gov/show/NCT01076049||125858|
NCT01076257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1823B|Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage|Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage: Evidence of Kinematic Study||Chang Gung Memorial Hospital|Yes|Completed|June 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|4 Years|15 Years|No|||May 2010|July 30, 2012|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01076257||125842|
NCT01073384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-ENT-01|A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer|A Phase 1/2 Study to Evaluate Escalating Doses of SGX201 [Delayed Release Oral Beclomethasone Dipropionate (BDP)] for Prevention of Signs and Symptoms of Acute Enteritis in Patients With Rectal Cancer Treated With Combined Chemotherapy and Radiation Therapy||Soligenix|No|Completed|December 2009|November 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|16|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01073384||126063|
NCT01068860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885I2207|To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies|A Multi-center, Double-blind, Placebo-controlled, Randomized Study to Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes Treated With Differing Baseline Diabetes Therapies||Novartis|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|246|||Both|18 Years|74 Years|No|||August 2011|August 3, 2011|February 12, 2010|Yes|Yes||No|August 3, 2011|https://clinicaltrials.gov/show/NCT01068860||126406|
NCT01069432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1019|Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia|Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia||Dartmouth-Hitchcock Medical Center|Yes|Withdrawn|May 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples With DNA|10cc of peripheral blood.|Both|18 Years|N/A|No|Non-Probability Sample|Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center|January 2012|January 25, 2012|February 15, 2010||No|IRB delayed their review for an extensive period of time. Funding for this protocol is no    longer available.|No||https://clinicaltrials.gov/show/NCT01069432||126362|
NCT01069146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hymosh|Mild Therapeutic Hypothermia During Severe Sepsis|Mild Therapeutic Hypothermia During Severe Sepsis||University Hospital, Brest|Yes|Completed|January 2002|January 2005|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2010|February 16, 2010|February 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01069146||126384|
NCT01069458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1375|The Effect of High Protein Diet Versus a Low Fat Diet on Body Weight After Smoking Cessation|The Effect of High Protein Diet Versus a Low Fat Diet on Body Weight and Composition, Total Energy Expenditure, Metabolic Risk Factors and Eating Behavior After Smoking Cessation||Oslo University Hospital|No|Recruiting|January 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069458||126360|
NCT01069471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD 133|Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella|Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults||GlycoVaxyn AG|Yes|Completed|February 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 11, 2010|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069471||126359|
NCT01069757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-003|A Study of ARQ 197 in Combination With Erlotinib|A Phase I Study of ARQ 197 in Combination With Erlotinib in Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer||Kyowa Hakko Kirin Company, Limited||Completed|February 2010|||September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|N/A|No|||March 2013|March 22, 2013|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069757||126338|
NCT01070108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ketamine|Escalating Ketamine Doses and Pre-emption|EARLY PREOPERATIVE ESCALATING DOSES OF KETAMINE ATTENUATE POSTOPERATIVE PAIN AND REDUCE MORPHINE CONSUMPTION IN HUMANS||Tel-Aviv Sourasky Medical Center|No|Completed|January 2007|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|15 Years|75 Years|No|||February 2010|February 16, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070108||126312|
NCT01070134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mipsy trial|Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial|Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial|Mipsy|Psychiatry Roskilde|Yes|Recruiting|February 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|65 Years|No|||February 2010|June 6, 2011|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070134||126310|
NCT01071265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-536|Remote Ischemic Preconditioning in Cardiac Surgery Trial|Remote Ischemic Preconditioning in Cardiac Surgery: a Pilot Randomized Controlled Trial|Remote IMPACT|McMaster University|Yes|Completed|March 2011|January 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071265||126224|
NCT01071278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-115|Lipid Management in Clinical Practice (MK-0524A-115)|Lipid Management in Clinical Practice||Merck Sharp & Dohme Corp.|No|Completed|October 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|2390|||Both|18 Years|N/A|No|Probability Sample|Patients in routine medical care either statutorily health insured or privately insured|July 2015|July 21, 2015|February 17, 2010|Yes|Yes||No|February 1, 2012|https://clinicaltrials.gov/show/NCT01071278||126223|
NCT01071291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-069|Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effects of Niaspan™ on Reverse Cholesterol Transport in Healthy Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|February 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01071291||126222|
NCT01071304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-044|Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)|A Study to Evaluate the Effect of Multiple Doses of Ridaforolimus (AP23573; MK-8669) on the Single Dose Pharmacokinetics of Midazolam.||Merck Sharp & Dohme Corp.|No|Completed|March 2010|February 2012|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01071304||126221|
NCT01070667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DROPPAF V2.1|Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation|Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation|DROPPAF|Eastbourne General Hospital|No|Not yet recruiting|March 2010|March 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2010|February 19, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070667||126269|
NCT01070680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a004c|Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation|Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study||Helsinki University Central Hospital|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||July 2012|July 13, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070680||126268|
NCT01070927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22383|An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer|An Exploratory Study on Anti-tumour Activity of Orally Administered RO4929097, a Gamma-secretase Inhibitor, as a Single Agent in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer (NSCLC).||Hoffmann-La Roche||Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070927||126249|
NCT01070940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP.FHC.1.2009|L-NMMA Dose-response Study in Healthy Subjects|L-NMMA's Effect on Renal and Cardiovascular Variables in Healthy Subjects. A Randomized, Placebo-controlled Crossover Study.||Regional Hospital Holstebro|Yes|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2011|February 18, 2011|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070940||126248|
NCT01030029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/2009|Auricular Acupuncture in Postoperative Pain|Auricular Acupuncture in Postoperative Pain: a Randomized Controlled Trail||Medical University of Vienna|Yes|Completed|January 2006|February 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|60 Years|No|||January 2006|April 7, 2015|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030029||129318|
NCT01030328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH09001|AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis|Atorvastatin Plus Fenofibric Acid in the Reduction of Intermediate|AFRICA|Piedmont Healthcare|No|Terminated|November 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|18|||Both|18 Years|85 Years|No|||April 2014|April 14, 2014|November 4, 2009||No|Lack of patient population|No||https://clinicaltrials.gov/show/NCT01030328||129296|
NCT01063673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110114|The Relation Between Running Patterns and Overuse Injuries in Runners|The Relation Between Running Patterns and Overuse Injuries in Runners||Northern Orthopaedic Division, Denmark|Yes|Completed|June 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|940|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Beginners: n = 1000. By means of the Danish Personal Register adult citizens (age 18-65        years) from Aarhus Municipality are identified, contacted by phone, and invited to        participate in the study. A question on running experience in the past is used to assess        the novelty to running. 500 beginners with previous running experience and 500 beginners        without previous running experience (former runners) will be included in the study. It is        estimated that 11000 persons have to be contracted to include 1000 individuals. Healthy        persons who have not sustained an injury in the lower extremity in the last 3 months        before inclusion and who have not been running for the last 12 months, are eligible for        the study. Participants are excluded if there are absolute contraindications for vigorous        physical activities according to the ACSM, or in case of unwillingness to keep a training        log / wear a heart rate belt during training.|April 2015|April 9, 2015|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063673||126802|
NCT01063400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS09328|Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors|OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors||University of Wisconsin, Madison|Yes|Terminated|January 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Non-small cell lung cancer patients receiving chemotherapy.|February 2012|February 10, 2012|February 3, 2010||No|lack of funding|No||https://clinicaltrials.gov/show/NCT01063400||126823|
NCT01073111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSESS|Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents|Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems|ASSESS|Hyogo College of Medicine||Recruiting|April 2010|||October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|25 Years|80 Years|No|||March 2013|March 18, 2013|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073111||126083|
NCT01073124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2008.0006|Sensitivity Diagnosing Traumatic Knee Injuries With and Without Injection of Blue Dye Into the Knee Joint|Sensitivity of the Saline Load Test With and Without Methylene Blue Dye in the Diagnosis of Traumatic Knee Arthrotomies||United States Naval Medical Center, San Diego|Yes|Completed|May 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2010|February 22, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01073124||126082|
NCT01074489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM Gold 1|Challenging the Gold Standard: Pilot Study Comparing Continuous Glucose Monitoring System (CGMS), Capillary Glucose Monitors and 3 Hour Glucose Tolerance Test (GTT) to Diagnose Gestational Diabetes Mellitus (GDM)|Challenging the Gold Standard: A Pilot Study Comparing CGMS and Capillary Glucose Monitors Versus 3 Hour GTT to Diagnose Gestational Diabetes Mellitus||University of Cincinnati|No|Completed|February 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant women between 18 & 50 years old who are having a 3 hour GTT as directed by their        doctor|August 2015|August 21, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01074489||125978|
NCT01068314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UI200308021|Effect of Exercise on Endothelial Function and Vascular Compliance in Chronic Kidney Disease|Effect of Forearm Exercise on Flow Mediated Vasodilation Prior to Arteriovenous Fistula Placement for Hemodialysis||University of Iowa|No|Completed|January 2007|June 2010|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068314||126448|
NCT01077063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0940|An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites|An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|February 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|100 Years|No|||October 2015|October 6, 2015|February 25, 2010||No|Study was closed by PI because of low enrollment.|No|September 15, 2014|https://clinicaltrials.gov/show/NCT01077063||125780|The study was closed by investigator due to low enrollment. Subject JH006 S-B did have abdominal pain, post Pleurx placement, so it was removed and she was taken out of the study.
NCT01073085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stamp|Effectiveness of a French Automated Web-based Smoking Cessation Program|Effectiveness of a French Automated Web-based Smoking Cessation Program : a Randomized Controlled Trial|Stamp|Institut national de prevention et d'education pour la sante|No|Completed|March 2010|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|2478|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01073085||126085|
NCT01068834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKROBATS|Additional KIF6 Risk Offers Better Adherence to Statins|Additional KIF6 Risk Offers Better Adherence to Statins|AKROBATS|Medco Health Solutions, Inc.|No|Completed|March 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1282|Samples With DNA|DNA samples|Both|18 Years|N/A|No|Non-Probability Sample|Adults (> 18y/o) newly started on either a brand name or generic statin (atorvastatin,        fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin with or        without ezetimibe) being followed in Medco's RationalMed® program|January 2012|January 30, 2012|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01068834||126408|
NCT01068873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Temple IRB 12848|Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)|Kaletra and Maraviroc in Antiretroviral Therapy-Naïve Patients - KALMAR Study -Version 1.0 Amendment 2|KALMAR|Temple University|No|Terminated|April 2010|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|February 12, 2010|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01068873||126405|
NCT01069159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|505-2010|Propranolol Treatment of Traumatic Memories (PTTM)|Propranolol Treatment of Traumatic Memories (PTTM)|PTTM|Mela, Mansfield, M.D.|No|Recruiting|February 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|70 Years|No|||June 2011|June 19, 2011|February 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01069159||126383|
NCT01069484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2799004|Postpartum Pelvic Floor Muscle Training in Women With and Without Injured Pelvic Floor Muscles|The Effect of Postpartum Pelvic Floor Muscle Training in Women With Injured and Non-injured Pelvic Floor Muscles. A Single Blind Randomized Controlled Trial|PP-PFMT|Norwegian School of Sport Sciences|Yes|Completed|February 2010|January 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|175|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069484||126358|
NCT01069497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V15|Preventability of Infections in Residents of French Nursing Homes|Impact of a Multifaceted Intervention on the Preventability of Infections in Residents of French Nursing Homes: Cluster-randomised Controlled Trial (ENLIL Study)|ENLIL|Observatoire du Risque Infectieux en Gériatrie|Yes|Active, not recruiting|November 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3500|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2009|February 16, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069497||126357|
NCT01069770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sutent-IIR|Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)|Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma Patients: a Prospective Study||Korean Urological Oncology Society|Yes|Recruiting|July 2009|June 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01069770||126337|
NCT01069783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3309-005|Study of A3309 in Patients With Dyslipidemia|A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia||Albireo|No|Completed|February 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|80 Years|No|||October 2010|October 19, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069783||126336|
NCT01070420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0910-002-062|Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement|||Seoul National University Hospital|Yes|Completed|December 2009|May 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|66|||Both|N/A|N/A|No|||July 2011|July 15, 2011|January 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01070420||126288|
NCT01070693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH1333|Lichtenstein Patch or Prolene Hernia System (PHS) for Inguinal Hernia Repair|Randomized Clinical Trial of Lichtenstein Patch or Prolene Hernia System for Inguinal Hernia Repair||Helsinki University Central Hospital|No|Completed|September 2001|December 2009|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|February 17, 2010||No||No|December 2, 2013|https://clinicaltrials.gov/show/NCT01070693||126267|
NCT01071863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-FOF-ACT-2010|Association of Fear of Falling and Physical Activity in Rheumatoid Arthritis Comparison Before and After Biological Therapy|Association of Fear of Falling and Physical Activity in Rheumatoid Arthritis Comparison Before and After Biological Therapy||Newcastle-upon-Tyne Hospitals NHS Trust|No|Not yet recruiting|March 2010|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|20 patients with Rheumatoid arthritis refered for biological treatment 20 control subjects        matched for age and sex|February 2010|February 19, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071863||126179|
NCT01071876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-08 / BF2.649|BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS|BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS)|HAROSA1|Bioprojet|Yes|Completed|August 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071876||126178|
NCT01070979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-03602.1|Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.|A Multicenter, Double-Blind, Controlled, Randomized Study to Compare the Efficacy in Relief of Hot Flushes in Women Receiving Oral Estradiol Acetate Tablets, Oral Estradiol Tablets or Oral Conjugated Equine Estrogens||Warner Chilcott|No|Completed|February 2003|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|249|||Female|35 Years|N/A|No|||April 2013|April 15, 2013|February 17, 2010|Yes|Yes||No|February 14, 2011|https://clinicaltrials.gov/show/NCT01070979||126245|
NCT01070992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-00004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2010|||||N/A|N/A|N/A||||||||||||||February 17, 2010|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01070992||126244|
NCT01071512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-094A|Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis|Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis||University of Chicago|No|Recruiting|April 2010|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||December 2013|December 6, 2013|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01071512||126206|
NCT01071525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Niacin-OS|The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker|||Rambam Health Care Campus|No|Not yet recruiting|April 2010|October 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|February 25, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071525||126205|
NCT01071811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1975|The Effect After 12 Weeks of Having Received a Pedometer and a Pedometer Program on Physical Activity and Health|The Effect After 12 Weeks of Having Received a Pedometer and a Pedometer Program on Physical Activity, Health Measurements, Self-rated Health, Stress, and Sleep Quality: a Randomized Controlled Trial||University of Southern Denmark|No|Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|668|||Both|18 Years|N/A|No|||February 2010|February 19, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071811||126183|
NCT01062646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSICANXCHILD|Multimodal Music Therapy for Children With Anxiety Disorders|A Randomized Controlled Trial of Multimodal Music Therapy for Children With Anxiety Disorders||University of Ulm|No|Completed|May 2006|September 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|8 Years|12 Years|No|||May 2006|February 3, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062646||126881|
NCT01063686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc-0191|The Cervical Cap in the Diagnosis of Rupture of Membranes in the Second Trimester|Use of a Cervical Cap as an Aid in Uncertain Rupture of Membranes in the Second Trimester||Rabin Medical Center|Yes|Withdrawn||||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|50 Years|No|||October 2015|October 27, 2015|February 4, 2010||No|Insufficient Funding|No||https://clinicaltrials.gov/show/NCT01063686||126801|
NCT01030861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TrialNet - tep (IND)|Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"|AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|August 2010|January 2022|Anticipated|January 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|8 Years|45 Years|No|||February 2016|February 18, 2016|December 11, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01030861||129255|
NCT01074255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-184|Re-examination Study of EMEND (Aprepitant) (MK-0869-184)|Re-examination Study For General Drug Use to Assess the Safety and Efficacy Profile of EMEND in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|April 2007|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3546|||Both|18 Years|N/A|No|Probability Sample|Korean patients treated with EMEND in usual practice.|April 2015|April 2, 2015|February 22, 2010|No|Yes||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01074255||125996|
NCT01075074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00023475|Pre Operative Transversus Abdominis Plane Block Laparoscopic Gynecological Surgery|The Effect of Pre Operative Transversus Abdominis Plane (TAP) Block in the Quality of Recovery of Patients Undergoing Outpatient Laparoscopic Gynecological Surgery: A Prospective, Randomized Blinded Study||Northwestern University|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|75|||Female|18 Years|64 Years|No|||October 2013|October 29, 2013|February 23, 2010||No||No|March 6, 2012|https://clinicaltrials.gov/show/NCT01075074||125933|We did not obtain local anesthetic levels to compare safety profile. We were underpowered to detect a difference in the physical comfort dimension of the QOR questionnaire between the ropivacaine groups and the saline group.
NCT01075308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I195|SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer|A Phase II Study of SB939 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer||Canadian Cancer Trials Group|No|Completed|February 2010|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Male|18 Years|N/A|No|||February 2015|July 10, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01075308||125915|
NCT01072643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007076|Sedation With Dexmedetomidine During Cardiac Catheterization|The Pharmacodynamics, Safety, and Pharmacokinetics of Sedation With Dexmedetomidine in Children Undergoing Hemodynamic Cardiac Catheterization With Special Reference to the Pulmonary Vascular Bed||Children's Hospital of Philadelphia|Yes|Completed|March 2010|April 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|8 Years|21 Years|No|||September 2014|September 5, 2014|February 15, 2010|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT01072643||126119|
NCT01068327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|441-07|Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer||University of Nebraska||Active, not recruiting|November 2007|||August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|19 Years|N/A|No|||July 2014|July 1, 2014|January 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068327||126447|
NCT01068886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 04-04|External Pancreatic Duct Stent After Pancreaticoduodenectomy|External Pancreatic Duct Stent After Pancreaticoduodenectomy: a Prospective Randomized Multicenter Trial||University Hospital, Angers|Yes|Completed|January 2006|December 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2010|February 12, 2010|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT01068886||126404|
NCT01069172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-C-2.0|Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery|A Prospective, Randomized Study of Cataract Surgery With the Assistance of the OptiMedica Femtosecond Laser System Compared to Standard Surgical Procedure of Continuous Curvilinear Capsulorhexis and Ultrasonic Phacoemulsification||Abbott Medical Optics|No|Completed|February 2010|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|80 Years|No|||August 2014|August 25, 2014|February 13, 2010|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT01069172||126382|This evaluation was performed on a relatively small number of patients; assessment of CDE should be repeated in a larger number of subjects.
NCT01069809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-004-003|Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption|A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption||Argos Therapeutics|Yes|Active, not recruiting|July 2010|August 2015|Anticipated|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|60 Years|No|||December 2014|December 18, 2014|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069809||126334|
NCT01069822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6702C00008|A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels|A Phase I Open-label, Fixed Sequence Study to Determine the Effect of Multiple Intravenous Doses of AZD6765 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Substrate) in Healthy Subjects||AstraZeneca|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|February 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01069822||126333|
NCT01070147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100189|A Computerized Asthma Management System in the Pediatric Emergency Department|A Computerized Asthma Management System in the Pediatric Emergency Department||Vanderbilt University|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|2400|||Both|2 Years|28 Years|No|||March 2011|March 21, 2011|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01070147||126309|
NCT01070407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV001|A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV)|A Phase I Study to Assess the Safety and Immunogenicity of New Hepatitis C Virus Vaccine Candidates AdCh3NSmut and Ad6NSmut||ReiThera Srl|Yes|Completed|July 2007|February 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|9||Actual|41|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070407||126289|
NCT01071551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR471208CTIL|The Impact of the "Nutrition Enrichment and Healthy Living Model" ( NEHLM) on Diet Quality, Physical Activity and Dental Health Among Children From Socioeconomically Disadvantaged Families in Beer Sheva|The Impact of the "Nutrition Enrichment and Healthy Living Model" ( NEHLM) on Diet Quality.|NEHLM|Soroka University Medical Center|No|Active, not recruiting|September 2008|September 2011|Anticipated|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|258|||Both|48 Months|84 Months|Accepts Healthy Volunteers|||November 2009|February 18, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071551||126203|
NCT01071564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02064|RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery|A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC # 749225) Administered in Patients With Advanced Breast Cancer||National Cancer Institute (NCI)|Yes|Terminated|November 2009|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||April 2014|April 14, 2015|February 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01071564||126202|
NCT01072448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2354|12-week Efficacy of Indacaterol|A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease||Novartis||Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 19, 2010|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT01072448||126134|
NCT01068405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-API-07|Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo|Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo - Assessment of Structural and Clinical Action of Magnetic Resonance Imaging|ADEM|Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|40 Years|85 Years|No|||December 2011|December 8, 2011|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01068405||126441|
NCT01071538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUILD|Buprenorphine for Late-Life Treatment Resistant Depression|Buprenorphine for Late-Life Treatment Resistant Depression|BUILD|University of Pittsburgh|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|50 Years|N/A|No|||February 2016|February 18, 2016|February 17, 2010|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01071538||126204|
NCT01071837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APG101_CD_002|APG101 in Glioblastoma|A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma||Apogenix GmbH|Yes|Completed|December 2009|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071837||126181|
NCT01071850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0004|A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects With Type 2 Diabetes Mellitus||Astellas Pharma Inc|No|Completed|March 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|412|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|February 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01071850||126180|
NCT01062659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCell|Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients|Characterization of Cellular Immune Responses in the Liver in Patients With Chronic Hepatitis C Virus Infection||University of Ulm|No|Withdrawn|February 2010|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|65 Years|No|Non-Probability Sample|All patient with established chronic hepatitis C presented to the liver unit of the        outpatient clinic how are eligible to antiviral therapy.|March 2014|March 31, 2014|February 3, 2010||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01062659||126880|
NCT01063153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000174|Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials|Diagnostic Utility of ADHD by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials||Massachusetts General Hospital|Yes|Completed|September 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|71|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|February 3, 2010|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01063153||126842|
NCT01063166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 AA017900 SA1|Prospective Assessment of Adolescent Drinking Trajectories With Computer-Assisted Self-administration of Ethanol (CASE)|Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 1: Assess the Initial Slope of Adolescent Drinking Trajectories, Beginning at the Age of Eighteen||Technische Universität Dresden|No|Completed|June 2010|December 2015|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|96|||Both|18 Years|19 Years|Accepts Healthy Volunteers|Probability Sample|Residents living within 15 km (9.5 miles) from downtown Dresden|January 2016|January 20, 2016|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063166||126841|
NCT01063179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIMEMA-MM-03-05|Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients|A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS||Fondazione Neoplasie Sangue Onlus|Yes|Active, not recruiting|May 2006|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|511|||Both|18 Years|N/A|No|||March 2010|March 24, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01063179||126840|
NCT01063192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2209|A Study of Locally Advanced Pancreatic Cancer|A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer||National Health Research Institutes, Taiwan|Yes|Enrolling by invitation|November 2009|September 2016|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|73|||Both|20 Years|75 Years|No|||February 2010|February 4, 2010|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01063192||126839|
NCT01075087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00023482|The Effect of Pre-Operative Transversus Abdominis Plane (TAP) Block in the Post Operative Opioid Consumption in Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery: A Prospective,Randomized, Blinded Study|TAP) Block in Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery: A Prospective,Randomized, Blinded Study||Northwestern University|No|Completed|March 2010|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|19|||Both|18 Years|65 Years|No|||May 2014|May 23, 2014|February 23, 2010||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01075087||125932|
NCT01075607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911-04|Lymph Fluid and Blood Collection for Identification of Novel Biomarkers|The Comparison of Lymph Fluid and Blood From Metastatic and Non-metastatic Invasive Breast Cancer Patients for Identification of Novel Biomarkers||Indiana University|No|Terminated|April 2010|April 2022|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|80 Years|No|Non-Probability Sample|Women with adenocarcinoma of the breast - no prior chemotherapy treatment.|March 2012|March 27, 2012|February 24, 2010||No|Halted prematurely due to lack of funding.|No||https://clinicaltrials.gov/show/NCT01075607||125892|
NCT01072656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGM-001|Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome|Deep Brain Stimulation for Thalamic Pain Syndrome|DBS|The Cleveland Clinic|Yes|Active, not recruiting|May 2010|February 2016|Anticipated|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|21 Years|N/A|No|||April 2015|April 16, 2015|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072656||126118|
NCT01068340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPSBO_TRAUMA_2010|Early Small Bowel Obstruction Following Laparotomy For Trauma|Retrospective Review of the Incidence of Early Small Bowel Obstruction in Patients Undergoing an Exploratory Laparotomy Following Trauma||University of Southern California|No|Recruiting|January 2010|June 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|650|||Both|15 Years|N/A|No|Non-Probability Sample|Patients undergoing an exploratory laparotomy for trauma|February 2010|February 11, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068340||126446|
NCT01068535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35352-A|Early Vascular Wall Changes by Magnetic Resonance Imaging (MRI) in Metabolic Syndrome Versus Metabolically Normal Pre-Menopausal Women: A Pilot Study|Early Vascular Wall Changes by MRI in Metabolic Syndrome vs. Metabolically Normal Pre-Menopausal Women: A Pilot Study||University of Washington|No|Active, not recruiting|May 2009|July 2013|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|43|Samples Without DNA|Lipids, LDL-Buoyancy, Apo-B, Apo-A1 Inflammatory markers: hs-CRP, SAA, IL-6, & TNF-α      Vascular Adhesion Markers: VCAM, sICAM|Female|35 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pre-menopausal Women|September 2012|September 12, 2012|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068535||126431|
NCT01068548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 09-288|Reducing Length of Stay for Veterans Hospitalized With Pneumonia|Reducing Length of Stay for Veterans Hospitalized With Pneumonia||VA Office of Research and Development|No|Completed|February 2011|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|129|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|February 8, 2010||No||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01068548||126430|
NCT01068847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA010017-03|Drug Discrimination in Methadone-Maintained Humans Study 3|Drug Discrimination in Methadone-Maintained Humans Study 3|OMDD3|University of Arkansas|Yes|Completed|February 2010|November 2012|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|65 Years|No|||March 2013|March 6, 2013|February 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068847||126407|
NCT01069211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG006|Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women|Assessment of Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|LETTER|Korean Breast Cancer Study Group|Yes|Recruiting|January 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|876|Samples Without DNA|Breast Cancer Tissue|Female|N/A|N/A|No|Non-Probability Sample|Patients recruited into the study are postmenopausal women with estrogen receptor positive        breast cancer.|May 2011|May 10, 2011|February 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01069211||126379|
NCT01069185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100-66779|Differences in Morbidity Between a Necessity Endotracheal Suctioning Protocol Versus a Routine Endotracheal Suctioning Protocol in Pediatric Intensive Care Unit (PICU)|Differences in Morbidity Frequency Between a Necessity Endotracheal Suctioning Protocol Versus a Routine Endotracheal Suctioning Protocol in Hospital Pablo Tobon Uribe´s Pediatric Intensive Care Unit (PICU). A Randomized Controlled Trial||Hospital Pablo Tobón Uribe|Yes|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|1 Month|14 Years|No|||August 2010|August 15, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01069185||126381|
NCT01069198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09018|A Community Trial for Visceral Leishmaniasis (VL)|A Randomized, Double Blind, Community Trial to Assess the Efficacy of a Combination of Anti-helminth, and Vitamin A, Zinc and Iron Supplementation in Preventing Visceral Leishmaniasis (VL) Disease Among Asymptomatic Individuals With VL||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|October 2009|November 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|2 Years|60 Years|No|||January 2010|November 12, 2012|February 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01069198||126380|
NCT01070719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-001-TY|Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort|Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort||Rocky Mountain MS Research Group, LLC|Yes|Completed|February 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|270|Samples Without DNA|Serum will be collected, and spun for specific tests. The back-up specimens (plasma)will be      held in case of a laboratory error.|Both|18 Years|75 Years|No|Non-Probability Sample|Patients with relapsing forms of MS currently being treated with natalizumab.|February 2012|February 28, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070719||126265|
NCT01071005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEUBER0409|Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ® (Leuprorelin Acetate - Abbot)|Randomized Clinical Trial of the Pharmacodynamics of Lorelin Depot 3.75Mg (Leuprorelin Acetate) Produced by Laboratório Químico Farmacêutico Bergamo LTDA. Compared to Lupron Depot ® 3.75 Mg Produced by Abbott in Healthy Subjects||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|August 2010|January 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Male|40 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|June 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01071005||126243|
NCT01072201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-0107-PERIO-MUC-ITA-PC|To Access the Effects of Mucositis in Adults With Dental Implants|To Access the Effects of Mucositis in Adults With Dental Implants|implantitis|Colgate Palmolive|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||September 2010|September 29, 2010|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT01072201||126153|
NCT01072175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113220|Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212|An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma||GlaxoSmithKline|No|Active, not recruiting|March 2010|May 2016|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|430|||Both|18 Years|N/A|No|||July 2015|September 28, 2015|February 12, 2010|Yes|Yes||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01072175||126155|
NCT01072188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-2008-07-SEN-PROPREC-ED|Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste|Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste||Colgate Palmolive|No|Completed|July 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 10, 2011|September 26, 2008|Yes|Yes||No|September 26, 2008|https://clinicaltrials.gov/show/NCT01072188||126154|
NCT01072435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a005c|Target-controlled Infusion Versus Patient-controlled Sedation With Propofol in Endoscopic Retrograde Cholangiopancreatography (ERCP)|Target-controlled Infusion vs Patient-controlled Sedation With Propofol in ERCP. A Randomized Prospective Clinical Trial||Helsinki University Central Hospital|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|75 Years|No|||July 2012|July 13, 2012|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072435||126135|
NCT01063751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69|Tritanium® Primary Acetabular Shell Study|A Prospective, Post-market, Multi-center Study of the Tritanium® Acetabular Shell||Stryker Orthopaedics|No|Recruiting|July 2011|July 2027|Anticipated|July 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|February 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01063751||126796|
NCT01030601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDDMECS|Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS)|Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS)|IDDMECS|University Health Network, Toronto||Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|N/A|No|||January 2011|January 10, 2011|December 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01030601||129275|
NCT01072617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000395|Cerebellar rTMS for the Treatment of Schizophrenic Patients|Safety and Therapeutic Efficacy of Cerebellar Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia||Beth Israel Deaconess Medical Center|Yes|Completed|February 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072617||126121|
NCT01072630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3072|Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder||Teva Pharmaceutical Industries|Yes|Completed|March 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|492|||Both|18 Years|65 Years|No|||January 2015|January 15, 2015|February 19, 2010|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01072630||126120|
NCT01072370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACBSC09|Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children|A Placebo-Controlled, Observer-Blinded, Crossover Study to Evaluate the Safety and Effectiveness of a Single, Autologous, Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children||Georgia Regents University|Yes|Recruiting|January 2010|July 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Year|12 Years|No|||July 2015|July 20, 2015|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072370||126140|
NCT01072669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nbose2010|Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet|Evaluation of the Effect of Ambrisentan on Digital Microvascular Flow in Patients With Systemic Sclerosis Using Laser Doppler Perfusion Imaging|ambrisentan|The Cleveland Clinic|Yes|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||March 2013|March 22, 2013|February 19, 2010||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01072669||126117|Small sample size and short duration of study Some patients had hand contractures which made the LDPI images somewhat inaccurate Could not adjust for all variables in final analysis Placebo effect reflected in patient responses to questionnaires
NCT01072682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARF002|Safety Study of a Selective Cytopheric Device (SCD) in Patients With Acute Renal Failure|A Multi-Center Pilot Study to Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) Treatments In Patients With Acute Renal Failure (ARF)||CytoPherx, Inc|No|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|80 Years|No|||August 2011|August 31, 2011|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072682||126116|
NCT01068353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEADI-09|Safety and Tolerability of Etanercept in Alzheimer's Disease|A Phase 2, Double-blind, Placebo-controlled Study of the Safety and Tolerability of Etanercept in Patients With Alzheimer's Disease|STEADI-09|University of Southampton|Yes|Completed|January 2011|||December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|55 Years|N/A|No|||April 2014|April 22, 2014|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01068353||126445|
NCT01068600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2355|Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks|A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease||Novartis||Completed|January 2010|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|318|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|February 12, 2010|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT01068600||126426|
NCT01068613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX028A2201|Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-blind, Double-dummy, Three Period Incomplete Cross-over Study to Evaluate the Safety and Efficacy of Multiple Daily Doses of QAX028 as Compared to Tiotropium Bromide (Positive Control) and Placebo in COPD Patients||Novartis||Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|62|||Both|40 Years|N/A|No|||May 2012|May 2, 2012|February 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01068613||126425|
NCT01068561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPRS|Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa|Phase 1 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa||University of Sao Paulo|Yes|Completed|May 2009|February 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01068561||126429|
NCT01069835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORU-IRE-2009/1|Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN)|Epidemiological Study to Describe NSCLC Clinical Management Patterns in Central Eastern Europe and Russia. Lung-EPICLIN|EPICLIN|AstraZeneca|No|Completed|February 2010|March 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|840|Samples With DNA|Paraffin embedded tumour tissue samples|Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients from Oncological Dispensaries and Cancer Research Institutes|May 2015|May 18, 2015|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01069835||126332|
NCT01069848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Avedro T4|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2010|||||N/A|N/A|N/A||||||||||||||June 22, 2015|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069848||126331|
NCT01069510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB 5845|Spironolactone in Adult Congenital Heart Disease|Heart Failure in Congenital Heart Disease: the Role of Myocardial Fibrosis. Treatment Sub-Study: Spironolactone vs. Placebo||Oregon Health and Science University|No|Active, not recruiting|February 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|80 Years|No|||February 2015|October 15, 2015|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069510||126356|
NCT01069796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-Taxel (GINECO BR108)|Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer|A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer||ARCAGY/ GINECO GROUP|Yes|Terminated|April 2010|June 2014|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|February 16, 2010||No|The number of inclusion was reached normally|No||https://clinicaltrials.gov/show/NCT01069796||126335|
NCT01071018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206-007|A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)|A Phase I Study of MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|N/A|No|||September 2015|September 4, 2015|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01071018||126242|
NCT01071031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-v-001|HIV Vaccine Study in HIV Positive Patients|A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v||PepTcell Limited|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|54|||Male|18 Years|50 Years|No|||September 2012|September 25, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01071031||126241|
NCT01071317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED Migraine Intervention|Trial of Comprehensive Migraine Intervention|An RCT of a Comprehensive Migraine Intervention at the Time of Discharge From the ED After Treatment for Acute Migraine||Montefiore Medical Center|No|Completed|February 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|21 Years|70 Years|No|||April 2012|April 26, 2012|February 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01071317||126220|
NCT01071889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0076-10-RMB|Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults|Double-blind, Randomized, Placebo and Active Controlled Study to Assess the Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults(Zolpidem or Brotizolam)||Coeruleus Ltd.|Yes|Completed|May 2010|July 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01071889||126177|
NCT01068743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-121|Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 850 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 850 mg Metformin (Glucophage Marketed by Merck Serono) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed Conditions||AstraZeneca|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|April 21, 2015|February 12, 2010|No|Yes||No|January 9, 2012|https://clinicaltrials.gov/show/NCT01068743||126415|
NCT01068756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-074|Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects|Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects||AstraZeneca|No|Terminated|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|February 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068756||126414|
NCT01072734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090104|Auto-immunity in Lupus Patients After Influenza Vaccine|Role of CXCR4/CXCL12 Axis on the Control of Humoral Immunity and Auto-immunity in Lupus Patients After Influenza Vaccine Challenge|GRIPLUP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2009|February 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2010|October 11, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072734||126112|
NCT01072747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPSBCCV1109BOV_BER|Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass|Randomized, Blind and Comparative Clinical Trial of Efficacy and Security of Unfractioned Heparin Sodium of Bovine Origin in Patients Submitted to Cardiovascular Surgery With Cardiopulmonary Bypass||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Recruiting|April 2010|November 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072747||126111|
NCT01068418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p002062|Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity|Vitamin D Deficiency Augments Renin-Angiotensin System Activity in Obesity||Brigham and Women's Hospital|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|19|||Both|18 Years|64 Years|No|||July 2012|July 5, 2012|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068418||126440|
NCT01068704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-016|Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer|An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy||Bristol-Myers Squibb|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|February 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01068704||126418|
NCT01068691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706|Arterial Properties of Thoracic Aorta Disease|Blood Pressure Control and Arterial Properties After Surgical Treatment of Type A Thoracic Aortic Dissection or Haematoma|ao_diss|University Hospital, Grenoble|Yes|Recruiting|May 2008|June 2010|Anticipated|June 2010|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|180|Samples Without DNA|Plasma samples for inflammation, oxidative stress and collagen markers|Both|18 Years|N/A|No|Probability Sample|This is a pilot, descriptive and single-centre study.|February 2010|February 12, 2010|June 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01068691||126419|
NCT01063764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01223|An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures|An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 Anti-Epileptic Drugs||UCB Pharma|No|Completed|January 2010|October 2013|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|4 Years|16 Years|No|||February 2015|February 16, 2015|February 1, 2010|Yes|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT01063764||126795|
NCT01062880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|961-38 62 61 / 891|Neuropattern - Assessment of a Translational Diagnostic Tool for Depression, Adjustment- and Somatoform-disorders|Neuropattern - Clinical Trial of a Psychobiological Stress Diagnostic Tool (Neuropattern - Erprobung Einer Psychobiologischen Stressdiagnostik)|Neuropattern|University of Trier|Yes|Recruiting|February 2010|May 2012|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|18 Years|65 Years|No|||October 2009|February 3, 2010|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062880||126863|
NCT01062893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 9631|Combined Spinal/Epidural (CSE) Saline Duration/Spread|Effect of Epidural Saline on Duration and Spread of Subsequent Spinal Analgesia/Anesthesia Using a CSE Technique||Wake Forest School of Medicine|Yes|Completed|August 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|12 Years|N/A|No|||March 2013|March 5, 2013|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01062893||126862|
NCT01071460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prov 01-2009|Evaluation of Efficacy and Safety of the FlexStent Self-Expanding Stent System|The FlexStent-Registry, Evaluation of Efficacy and Safety of the FlexStent Femoropopliteal Self-Expanding Stent System||Provascular GmbH|Yes|Completed|November 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|35 Years|85 Years|No|||November 2012|November 8, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071460||126210|
NCT01071759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDAH-D-97(P)014A|Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes|Effects of Dietary Heme/Non-heme Iron and Hp Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes - a Perinatal Longitudinal Study||E-DA Hospital|Yes|Recruiting|February 2009|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|140|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Ladies|February 2010|February 18, 2010|February 18, 2010||||No||https://clinicaltrials.gov/show/NCT01071759||126187|
NCT01071772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M20080151|The Effect of Hyperglycemia on LV Function and Exercise Capacity in Diabetics With and Without Heart Failure.|Metabolic Substrate Modulation in Insulin Treated Diabetics With and Without Heart Failure: The Effect of Hyperglycemia on Left Ventricular Function and Exercise Capacity.|METAMOD|University of Aarhus|Yes|Completed|April 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|30 Years|80 Years|No|||June 2011|June 8, 2011|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01071772||126186|
NCT01072084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAEM|Endomicroscopy in Patients With Food Allergy: a New Diagnostic Option|Endomicroscopy in Patients With Food Allergy: a New Diagnostic Option||University of Erlangen-Nürnberg Medical School|No|Not yet recruiting|February 2010|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Both study groups will be acquired from the ambulant gastrointestinal consultation of the        Medical department 1 of the Universityhospital Erlangen.|February 2010|February 18, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072084||126162|
NCT01072383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|973|Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis|A Randomized, Placebo-controlled, Double-blind, Multicentre, Multiple Dose, Cohort Study With Escalating Doses to Evaluate the Safety and Efficacy of the Humanized Monoclonal Antibody BT061 Administered to Patients With Moderate to Severe Chronic Plaque Psoriasis||Biotest|Yes|Completed|February 2010|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|75 Years|No|||March 2012|March 12, 2012|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072383||126139|
NCT01068925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113096|Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers|An Open-Label, Single Sequence, Three-Period Drug Interaction Study of GSK1349572 and Tipranavir/Ritonavir in Healthy Adult Subjects (ING113096)|ING|GlaxoSmithKline|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 22, 2011|February 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068925||126401|
NCT01069224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MozesG|Analysis of Proinflammatory Factors in the Synovial Fluid In Patients With Rotator Cuff Disease|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|Synovial fluid lavages will be collected at the time of arthroscopic RC reconstruction or      other shoulder arthroscopy that will be performed for therapeutic goals (instability repair,      SLAP lesion).|Both|18 Years|65 Years|No|Probability Sample|This study will include a consecutive series of patients who met the study inclusion        criteria. Study group patients will be diagnosed RC tear on clinical examination and        imaging findings (US and MRI) that will be verified at arthroscopy in order to complete        the enrollment.        Control group will include patients suffering from shoulder instability that scheduled for        elective surgical repair.|February 2010|February 16, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01069224||126378|
NCT01069237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-45|Compliance and Contamination in Soft Contact Lens Wearers|Compliance and Contamination in Soft Contact Lens Wearers||Alcon Research|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Contact Lens Wearers|January 2012|January 30, 2012|February 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069237||126377|
NCT01068574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002546|Evaluation of the Basic Assessment of Severity of Illness in Children (BASIC) Scale|Evaluation of the BASIC Scale (Basic Assessment of Severity of Illness in Children): A Simple Triage Tool for Resource-limited Settings||Brigham and Women's Hospital|No|Recruiting|January 2010|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|2 Months|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged two months to five years presenting to a rural health center in Rwanda.|August 2010|August 2, 2010|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01068574||126428|
NCT01068587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I196|MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy|A Phase I/II Study of Foretinib in Patients With Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy||Canadian Cancer Trials Group|No|Completed|December 2009|February 2015|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01068587||126427|
NCT01068899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111597|Energy Expenditure|Energy Expenditure||Arkansas Children's Hospital Research Institute|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy women and children who do not have any respiratory or pulmonary disorders|May 2011|May 16, 2011|February 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01068899||126403|
NCT01070433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEBO-DFU-PII-001 v. 4.0|A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers|A Phase II, Randomized, Controlled, Multi-Center Study of the Safety and Efficacy of Topically Applied MEBO Wound Ointment Compared to Standard of Care in Subjects With Diabetic Foot Ulcers||Skingenix, Inc.|No|Completed|September 2012|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01070433||126287|
NCT01070732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOTEL01|Paracetamol as Antipyretic and Analgesic Medication|An Open-label Non-randomized Phase IV Trial of the Clinical Efficacy of Intravenously Administered 1000mg Paracetamol as Antipyretic and Analgesic Medication|APOTEL01|University of Athens|No|Completed|January 2010|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|No|||February 2010|February 17, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01070732||126264|
NCT01071577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100053|Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products|Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products||National Institutes of Health Clinical Center (CC)||Recruiting|January 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 12, 2015|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071577||126201|
NCT01071590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100057|The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait|The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait||National Institutes of Health Clinical Center (CC)||Completed|February 2010|January 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|45|||Both|40 Years|80 Years|No|||January 2014|February 19, 2014|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071590||126200|
NCT01071902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-033|Safety and Efficacy of Moxidex Otic|Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media With Otorrhea in Tympanostomy Tubes||Alcon Research|No|Terminated|February 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|400|||Both|6 Months|12 Years|No|||November 2012|November 29, 2012|February 18, 2010|Yes|Yes|Management decision|No||https://clinicaltrials.gov/show/NCT01071902||126176|
NCT01071915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS42|Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer|An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy||Ferring Pharmaceuticals|No|Completed|March 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Male|18 Years|N/A|No|||January 2013|January 8, 2013|February 18, 2010||No||No|October 29, 2012|https://clinicaltrials.gov/show/NCT01071915||126175|
NCT01068769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-400|Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor|A Multi-center Phase II Study Evaluating the Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST), Resistent or Intolerant to at Least Imatinib and Sunitinib||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2010|June 2016|Anticipated|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|February 12, 2010|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01068769||126413|
NCT01068431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2NL|Short Term Effectiveness Study of Juxta-Fit Versus Trico Bandages in the Treatment of Leg Lymphedema|Prospective, Randomized Controlled Trial Comparing the Effect of CircAid(R) Juxta-Fit(tm) Versus Trico Bandages in the Treatment of Leg Lymphedema||Nij Smellinghe Hosptial|No|Completed|February 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01068431||126439|
NCT01068717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-118|Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 500 mg Metformin (Glucophage Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States||AstraZeneca|No|Completed|March 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|February 12, 2010|No|Yes||No|August 10, 2011|https://clinicaltrials.gov/show/NCT01068717||126417|
NCT01068990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AICUP|Detection and Characterization of Lower Respiratory Infections in Critically Ill Patients|Detection and Characterization of Lower Respiratory Infections in Critically Ill Patients||Asan Medical Center|Yes|Recruiting|March 2010|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|16 Years|N/A|No|Non-Probability Sample|Patients admitting or admitted in medical ICU with pneumonia|December 2015|December 28, 2015|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01068990||126396|
NCT01069003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP114|EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events|EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen|EDUCATE|Medtronic Vascular|Yes|Completed|April 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|2272|||Both|19 Years|N/A|No|||December 2015|December 11, 2015|February 12, 2010|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01069003||126395|
NCT01062906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN#08-021|Intravenous Lidocaine for Laparoscopic Cholecystectomy|The Effect of Intravenous Lidocaine on Short-term Outcomes After Laparoscopic Cholecystectomy||McGill University Health Center|Yes|Completed|March 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||February 2010|January 12, 2011|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01062906||126861|
NCT01059747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98A1-PHPP41|Therapeutic Drug Monitoring and Pharmacogenomics Study of Methadone Therapy||M0108|National Health Research Institutes, Taiwan|No|Recruiting|December 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|heroin-addicted patients|January 2010|January 29, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01059747||127102|
NCT01071785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA-06370|Dietetic Intervention With Soluble Fiber in Type 2 Diabetes Mellitus (DM) Patients With Metabolic Syndrome (MS)|Dietetic Intervention With Soluble Fiber in Type 2 Diabetes Mellitus (DM) Patients With Metabolic Syndrome (MS)||Hospital de Clinicas de Porto Alegre|No|Completed|June 2007|December 2009|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|40 Years|80 Years|No|||February 2010|February 25, 2010|June 6, 2008||No||No||https://clinicaltrials.gov/show/NCT01071785||126185|
NCT01072097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85/2006|The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women|The Effect of Atorvastatin on Androgen Synthesis, Glucose Metabolism and Inflammation in Women With Polycystic Ovary Syndrome (PCOS). A Placebo Controlled Trial||University of Oulu|No|Completed|September 2006|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|30 Years|50 Years|No|||September 2011|September 6, 2011|February 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072097||126161|
NCT01072396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.440|Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva® HandiHaler®, 18 µg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|February 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|126|||Both|40 Years|N/A|Accepts Healthy Volunteers|||April 2013|November 27, 2013|February 19, 2010||||No|November 22, 2012|https://clinicaltrials.gov/show/NCT01072396||126138|
NCT01069536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAU-200/030-0515|Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide|||Pamukkale University||Completed|March 2007|May 2008|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|65 Years|No|||March 2007|February 16, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069536||126354|
NCT01069861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481276|Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)|A Single Arm Single Centre Study To Investigate Safety And Efficacy Of Sildenafil In Near Term And Term Newborns With Persistent Pulmonary Hypertension Of The Newborn (PPHN)||Pfizer|Yes|Terminated|December 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|N/A|72 Hours|No|||November 2012|November 1, 2012|February 15, 2010||No|See termination reason in detailed description.|No|November 1, 2012|https://clinicaltrials.gov/show/NCT01069861||126330|The study was prematurely discontinued, therefore not all data was analyzed.
NCT01069874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-010085-35|Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)|Cluster-randomised, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections in Sheltered Accommodation (ViDiFlu)|ViDiFlu|Barts & The London NHS Trust|Yes|Completed|March 2010|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 3, 2014|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069874||126329|
NCT01068912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T705aUS204|Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Favipiravir in Adult Patients With Uncomplicated Influenza||MDVI, LLC|Yes|Completed|February 2010|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|530|||Both|20 Years|80 Years|No|||October 2015|October 20, 2015|February 12, 2010|Yes|Yes||No|February 11, 2014|https://clinicaltrials.gov/show/NCT01068912||126402|
NCT01070160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HD052668-02|Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)|Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)||Yale University|No|Completed|June 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|14|Samples With DNA|blood, endometrium tissue biopsy|Female|18 Years|42 Years|No|Probability Sample|Women will be recruited from the multi-physician Yale Reproductive Endocrinology clinical        practice and Yale Fertility Center. Metformin is a routinely employed therapeutic strategy        utilized for managing PCOS by practitioners at YFC. Almost 1/3 of the patients with PCOS        are not interested in pursuing fertility in the immediate future and it is these patients        who will be offered participation in the trial.|June 2014|June 13, 2014|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01070160||126308|
NCT01070446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-7044|Choline Nutrition in Children With Cystic Fibrosis|Choline Nutrition in Children With Cystic Fibrosis||University of British Columbia|No|Completed|October 2007|February 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||February 2010|February 17, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01070446||126286|
NCT01071343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF-283379|Transcutaneous Electric Muscle Stimulation (TEMS) in Septic Patients|Effect of Transcutaneous Electric Muscle Stimulation on Muscle Volume in Patients With Septic Shock||Rigshospitalet, Denmark|No|Completed|January 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|||Actual|8|||Both|18 Years|80 Years|No|||January 2010|February 18, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071343||126219|
NCT01072214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113748|A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers|A Randomized, Placebo-controlled, Double-masked, Parallelgroup Study to Evaluate the Safety, Tolerability,and Pharmacokinetic Profile of Repeat Doses of Pazopanib Eye Drops in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|37|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|February 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072214||126152|
NCT01072487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2681/10|Capnography During Colonoscopy|Capnography as an Adjunct to Standard Monitoring During Midazolam and Propofol Sedation for Colonoscopy|ColoCap|Technische Universität München|No|Completed|February 2010|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|760|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 2, 2011|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01072487||126131|
NCT01072461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD058301-02|Optimizing Hand Rehabilitation Post-Stroke Using Interactive Virtual Environments|Optimizing Hand Rehabilitation Post-Stroke Using Interactive Virtual Environments||New Jersey Institute of Technology|No|Completed|March 2009|March 2015|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01072461||126133|
NCT01069640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMS-21-73|Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer|Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy||Shiga University|Yes|Recruiting|February 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|20 Years|85 Years|No|||September 2013|September 16, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069640||126346|
NCT01068444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-HB9608|The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis|A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|April 2009|July 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||October 2013|April 1, 2015|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01068444||126438|
NCT01068730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-120|Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects|Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets Manufactured by Bristol-Myers Squibb Relative to 500 mg and 1000 mg Diabex (Metformin) Tablets Marketed in Australia by Alphapharm Administered to Healthy Subjects in the Fed State||AstraZeneca|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|April 21, 2015|February 12, 2010|No|Yes||No|January 20, 2012|https://clinicaltrials.gov/show/NCT01068730||126416|
NCT01069016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS/PNS|Comparison of Sacral Nerve Modulation and Pudendal Nerve Stimulation in Treatment of Fecal Incontinence|Comparison of Sacral Nerve Modulation and Pudendal Nerve Stimulation in Treatment of Fecal Incontinence||Cantonal Hospital of St. Gallen|No|Active, not recruiting|February 2010|December 2016|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 29, 2015|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01069016||126394|
NCT01059760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154-002|Expression of Longevity Genes in Response to Extended Fasting|Expression of Longevity Genes in Response to Extended Fasting|FEELGOOD|Intermountain Health Care, Inc.|No|Completed|January 2010|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01059760||127101|
NCT01059773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016639|A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate|An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)|TRANSIT|Janssen-Cilag International NV|Yes|Completed|October 2009|August 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|490|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|January 28, 2010|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT01059773||127100|
NCT01059786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100025|Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia|Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia||National Institutes of Health Clinical Center (CC)||Recruiting|December 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|100 Years|No|||February 2016|February 12, 2016|January 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01059786||127099|
NCT01059799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3586|Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes|A Pan Asian Trial Comparing Efficacy and Safety of Insulin NN1250 and Insulin Glargine as Add on to OAD(s) in Subjects With Type 2 Diabetes (BEGIN™: ONCE ASIA)|BEGIN™|Novo Nordisk A/S|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|435|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|January 29, 2010|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01059799||127098|
NCT01060046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPO 06-1151|Analysis and Characterization of Biologic Implants|Analysis and Characterization of in Vivo Tissue Remodeling in Routine Biologic Mesh Explants From Patients Undergoing Reoperation for Recurrent Hernia or Revision of a Prior Surgical Site||Washington University School of Medicine|No|Enrolling by invitation|August 2007|||August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Biopsy samples of previously implanted biologic meshes, biopsy samples of native abdominal      wall fascia|Both|N/A|N/A|No|Non-Probability Sample|Patients will be selected from the practices of the surgeons listed on the investigational        team.|January 2010|January 28, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01060046||127080|
NCT01071798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22639|An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis|A Prospective, Multi-center, Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months (in Case of Re-therapy the First 12 Months) of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care||Hoffmann-La Roche||Completed|January 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1653|||Both|18 Years|N/A|No|Probability Sample|Participants starting treatment with rituximab|January 2016|January 25, 2016|February 18, 2010||No||No|November 12, 2015|https://clinicaltrials.gov/show/NCT01071798||126184|
NCT01072110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0001|Confocal Laser Endomicroscopy (CLE) in Patients With Diarrhea|Confocal Laser Endomicroscopy in Patients With Diarrhea||University of Erlangen-Nürnberg Medical School|No|Recruiting|February 2010|February 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients of a tertiary referral hospital.|January 2013|January 23, 2013|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01072110||126160|
NCT01072123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08313|Asthma Education Using Child Life Services and an Asthma-based Computer Game|Innovative Asthma Education Using a Unique Blend of Child Life Services and an Asthma-based Computer Game in the Pediatric Emergency Room||Winthrop University Hospital|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator)|1||Actual|27|||Both|6 Years|18 Years|No|||January 2016|January 13, 2016|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01072123||126159|
NCT01068626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990312|Rosuvastatin in Visceral Adiposity|A 26-week, Single Center, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Effect of Rosuvastatin on Visceral Adipose Tissue in Male Patients With Abdominal Obesity|RIVIERA|Göteborg University|No|Completed|May 2006|December 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Male|40 Years|65 Years|No|||August 2015|August 6, 2015|February 12, 2010||No||No|February 7, 2011|https://clinicaltrials.gov/show/NCT01068626||126424|
NCT01069887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|578/06|A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoietic Stem Cell Transplant|A Non-interventional Multicentre Prospective Registry to Monitor the Incidence of Invasive Fungal Infections and to Monitor the Diagnostic and Therapeutic Management of Suspected Fungal-related Febrile Episodes in Patients With Malignant Hemopathies or Subjected to Haematopoietic Cell Transplant for the Treatment of Onco-haematological Diseases (HEMA E-CHART REGISTRY)|HEMA E-CHART|Catholic University of the Sacred Heart|No|Completed|March 2007|March 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|3000|||Both|18 Years|N/A|No|Probability Sample|patients with newly diagnosed malignant haematological diseases (acute and chronic myeloid        and lymphoid leukaemia, multiple myeloma, non-Hodgkin's and Hodgkin's lymphoma, aplastic        anaemia, myelodysplastic syndromes), or patients who, as a result of onco-haematological        pathologies, have undergone allogenic or autologous haematopoietic cell transplants, and        have ongoing febrile episodes|April 2009|February 23, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069887||126328|
NCT01069900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11643|Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection|A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection|MOXIPEDIA|Bayer|Yes|Completed|July 2010|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|458|||Both|3 Months|17 Years|No|||January 2016|February 16, 2016|February 15, 2010|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01069900||126327|
NCT01070173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5H08|Ghrelin Levels in Children With Poor Growth|Ghrelin Levels in Children With Gastrointestinal Symptoms and/or Poor Growth||Tripler Army Medical Center|No|Completed|January 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|52|||Both|3 Months|21 Years|No|Non-Probability Sample|Twenty-five (25) patients seen for evaluation of short stature in the pediatric        endocrinology clinic will have serum ghrelin levels measured in addition to their usual        routine bloods tests.        Twenty-five (25) patients will be selected from patients who present with chronic        gastrointestinal symptoms (symptoms of gastrointestinal disease for greater than 6 weeks        or recurrent symptoms) and who have poor growth.        The remaining 25 will be selected from patients with chronic gastrointestinal symptoms        (symptoms of gastrointestinal disease for greater than 6 weeks or recurrent symptoms) who        have normal growth.|January 2013|January 15, 2013|February 12, 2010||No||No|December 8, 2012|https://clinicaltrials.gov/show/NCT01070173||126307|
NCT01069523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2009-499H|Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)|Electrophysiological Effects of Guanfacine Extended-Release (GXR) on Inhibitory Control in Children With Attention Deficit/Hyperactivity Disorder (ADHD)||The University of Texas Health Science Center at San Antonio|Yes|Completed|March 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|6 Years|12 Years|No|||August 2012|August 1, 2012|February 15, 2010|No|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT01069523||126355|The intent of the study was to examine ERP waveforms associated with impulse control. Unfortuanately, the Stop signal task and EEG proved very difficult for this young group of subjects. The ERP data could not be fully analyzed and is not reported.
NCT01070745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chammerman3|Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA)|Ibuprofen vs. Indomethacin as Second Course of Therapy for Resistant PDA in Low Birth Weight Neonates||Shaare Zedek Medical Center|Yes|Withdrawn|June 2010|||June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|2 Months|No|||February 2010|June 6, 2012|February 17, 2010||No|Changes in approach to PDA therapy|No||https://clinicaltrials.gov/show/NCT01070745||126263|
NCT01071928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU09-144|Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma|A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144||Hoosier Cancer Research Network|Yes|Withdrawn|June 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|February 18, 2010|No|Yes|Lack of efficacy of experimental treatment|No||https://clinicaltrials.gov/show/NCT01071928||126174|
NCT01071941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-042|rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors|rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors||Massachusetts General Hospital|Yes|Recruiting|October 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01071941||126173|
NCT01072500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AG022376|The LIFE Study - Lifestyle Interventions and Independence for Elders|The LIFE Study - Lifestyle Interventions and Independence for Elders|LIFE|University of Florida|Yes|Completed|February 2010|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1635|||Both|70 Years|89 Years|No|||July 2015|July 20, 2015|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01072500||126130|
NCT01072513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI-0908-PR08|Semen Analysis After Proton Therapy for Prostate Cancer|Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone|PR08|University of Florida|No|Completed|March 2010|July 2015|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Male|18 Years|N/A|No|||September 2015|September 29, 2015|February 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072513||126129|
NCT01072760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QHD201002|Kirschner Wire and Pull-out Wire Fixation for the Treatment of Bony Mallet Finger|Kirschner Wire and Pull-out Wire Fixation for the Treatment of Bony Mallet Finger||The Second Hospital of Qinhuangdao|Yes|Completed|May 2003|February 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|54|||Both|N/A|N/A|No|||February 2010|February 19, 2010|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01072760||126110|
NCT01072786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 268|Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|141|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|February 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01072786||126108|
NCT01068457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VATS-hb2008-059|Chronic Pain After Thoracotomy (Video Assisted Thoracic Surgery - VATS)|Chronic Pain After Thoracotomy (VATS)||Rigshospitalet, Denmark|No|Completed|December 2009|||April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|48|||Both|19 Years|N/A|No|Non-Probability Sample|Lung cancer patients|July 2010|July 13, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01068457||126437|
NCT01077076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18132|Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)|Randomized, Placebo-Controlled, Crossover Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole||Bayer|No|Completed|December 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|February 25, 2010|Yes|Yes||No|March 11, 2010|https://clinicaltrials.gov/show/NCT01077076||125779|
NCT01069029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aurore 1|Combined Versus Successive Macular Hole and Cataract Surgery|Macular Hole and Cataract Extraction: Combined Surgery Versus Two Times Surgery||Centre Hospitalier Universitaire Dijon|No|Completed|January 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|120|||Both|18 Years|75 Years|No|Non-Probability Sample|patients with symptomatic visual loss and needed vitrectomy for Macular Hole treatment.|January 2006|February 16, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069029||126393|
NCT01069341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF 4297s|Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery|Ranibizumab in Subjects With Dense Cataract and Rubeosis Due to Proliferative Diabetic Retinopathy (PDR)||Bhagat, Neelakshi, M.D., M.P.H.|No|Completed|July 2007|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|February 15, 2010|Yes|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT01069341||126369|Uncontrolled pilot study with a small sample size.
NCT01069354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P120677|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2012|||||N/A|N/A|N/A||||||||||||||June 27, 2014|February 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01069354||126368|
NCT01069601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017052-27|H1N1sw Vaccine in Adult Transplant Recipients|A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers||HepNet Study House, German Liverfoundation|Yes|Terminated|February 2010|April 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|February 15, 2010||No|End of H1N1 Swine Flu Pandemic|No||https://clinicaltrials.gov/show/NCT01069601||126349|
NCT01069614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-09|A Skin Stretching Wound Closure System|||Hillel Yaffe Medical Center||Not yet recruiting||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|N/A|No|||February 2010|February 16, 2010|February 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01069614||126348|
NCT01060306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMG-005|Optical Coherence Tomography Evaluation of a Biodegradable Polymer-based Drug-eluting Stent|Prospective Optical cohereNce Tomography Evaluation of neoINtimal Coverage of a biodegrAdable Polymer-based Drug-eluting Stent|PONTINA|Ospedale Santa Maria Goretti|No|Recruiting|January 2010|January 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|50 Years|85 Years|No|Non-Probability Sample|Patients with stable or unstable coronary artery disease undergoing percutaneous coronary        intervention on the left anterior descending artery with a Biomatrix stent placement or on        the left circumflex artery with a Gazelle stent placement|January 2010|February 1, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01060306||127060|
NCT01060319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLDR0011|A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies|A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies||Stanford University||Not yet recruiting|December 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Bladder cancer specimens|Both|18 Years|N/A|No|Non-Probability Sample|non-melanoma skin and bladder cancer patients that are recommended for surgical removal of        tumor tissues|October 2013|October 10, 2013|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01060319||127059|
NCT01060059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-IT-B014|Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes|EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients With Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment||AstraZeneca|No|Completed|April 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|888|||Both|18 Years|N/A|No|Probability Sample|The targeted population consists of adult patients with type 2 diabetes mellitus treated        in outpatient setting by specialists.|March 2015|March 20, 2015|January 26, 2010|No|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01060059||127079|
NCT01072695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-196-0112|Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection|A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112)||Gilead Sciences|No|Completed|February 2010|January 2012|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|70 Years|No|||May 2012|May 30, 2012|February 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01072695||126115|
NCT01068366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38813|Nickel Allergy With Septal Closure Devices|Nickel Allergy With Septal Occluder Using Amplatzer and Helex Devices (NASAH) Trial|NASAH|University of Utah|Yes|Terminated|February 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Probability Sample|Patients already scheduled for ASD or PFO closure with Amplatzer or Helex devices.|May 2013|May 14, 2013|February 11, 2010||No|PI re-located.|No||https://clinicaltrials.gov/show/NCT01068366||126444|
NCT01068938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-SCOPE|Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter|Detection of Visual Field Defects and Scotoma Progression in Glaucomatous Optic Neuropathy, Using Short-term Intervals With Automated Scotoma-oriented Perimetry (SCOPE) and the Fast Thresholding Strategy GATE (German Adaptive Threshold Estimation)|X-SCOPE|University Hospital Tuebingen|No|Active, not recruiting|November 2008|December 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|99 Years|No|Probability Sample|University Eye Hospital|January 2016|January 31, 2016|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01068938||126400|
NCT01069250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001 448/01|Dynamic and Static Autoregulation After Brain Injury|Serial Measurement of Static and Dynamic Cerebrovascular Autoregulation After Brain Injury||Johannes Gutenberg University Mainz|No|Completed|August 2001|February 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Patients after traumatic brain injury or intracranial bleeding wich had a        Glasgow-Coma-Scale (GCS) of less than 8 and were initially sedated, intubated and        mechanically ventilated.|August 2013|August 21, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01069250||126376|
NCT01070771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 3 dated 01/10/2009|Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?|Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?|RIPCORD|University Hospital Southampton NHS Foundation Trust.|Yes|Completed|June 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|203|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|February 17, 2010||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01070771||126261|
NCT01070459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B30020107752|The Effect of an Aerobic Exercise Programme in Stroke Patients|The Effect of an Aerobic Training Programme on the Aerobic Capacity, Functional Behavior and the Cardiovascular Risk Factors in Stroke Patients||University College of Antwerp|Yes|Enrolling by invitation|February 2010|December 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|50|||Both|N/A|80 Years|No|||April 2010|April 13, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01070459||126285|
NCT01085058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISP_CU01|Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy|Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy|CU01|WiSP Wissenschaftlicher Service Pharma GmbH|No|Completed|May 2003|December 2004|Actual|December 2004|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|169|||Both|18 Years|70 Years|No|||March 2010|March 10, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085058||125173|
NCT01082003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHS T-E01|Prevention of Capsular Contracture Using Trental and Vitamin E|A Single Center, Prospective Treatment Trial to Assess Prophylactic Use of Trental (Pentoxifylline) and Vitamin E to Prevent Capsular Contracture After Implant Reconstruction in Patients Requiring Adjuvant Radiation Therapy||Legacy Health System|Yes|Active, not recruiting|October 2009|June 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|N/A|No|||August 2013|August 27, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082003||125407|
NCT01082887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/5-R|A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)|A Phase I/II Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)||Nantes University Hospital|Yes|Terminated|January 2010|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|75 Years|No|||June 2013|June 11, 2013|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082887||125339|
NCT01082900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5720108|Prophylactic Continuous Positive Airway Pressure (CPAP) in Delivery Room, in the Prevention of Transient Tachypnea of Newborn (TTN): A Randomized Controlled Trial|Prophylactic CPAP/PEEP in Delivery Room (DR) Resuscitation, Effects on Natriuretic Peptide in the Prevention of Transient Tachypnea of Newborn (TTN): A Randomized Controlled Trial||New York Hospital Queens|Yes|Completed|November 2009|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|138|||Both|N/A|30 Minutes|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082900||125338|
NCT01082926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07082|Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2|Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2||City of Hope Medical Center|Yes|Completed|May 2010|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||June 2015|June 3, 2015|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01082926||125336|
NCT01083745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022-10|Assessment of Blood and Follicular Fluid Immune Cell Constitution in Patients Undergoing in Vitro Fertilization|||Hillel Yaffe Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Female|27 Years|43 Years|No|Non-Probability Sample|IVF clinic patients in tertiary care center|March 2010|March 16, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083745||125273|
NCT01083758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0801|Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis|Effect of Calcipotriol Plus Betamethasone Dipropionate Topical Suspension on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 17 Years) With Scalp Psoriasis||LEO Pharma|No|Completed|April 2010|October 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|12 Years|17 Years|No|||August 2015|September 7, 2015|March 8, 2010|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01083758||125272|
NCT01082211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1014|Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery|A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|June 2010|||November 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|120 Years|No|||October 2015|October 13, 2015|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082211||125391|
NCT01082224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000667125|Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy|A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation|ACRIN 6690|American College of Radiology Imaging Network|Yes|Recruiting|December 2010|||July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|440|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082224||125390|
NCT01083706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2240.00|Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant|Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine||Fred Hutchinson Cancer Research Center|Yes|Completed|April 2010|||December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|N/A|N/A|No|||December 2013|December 10, 2013|March 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01083706||125276|
NCT01083719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHD1234|A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.|Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.||Medanta Institute of Clinical Research|No|Not yet recruiting|April 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||March 2010|March 9, 2010|March 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01083719||125275|
NCT01084824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NID-001|A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin|A Randomized Clinical Trial Examining the Efficacy of Treatment of Cutaneous Verruca Vulgaris in Adult Patients With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin||North Idaho Dermatology||Completed|June 2007|September 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 10, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084824||125191|
NCT01085110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2009-126-A|Persistent Pain After Laparoscopic Inguinal Hernia Repair|Neurophysiological Characterization of Persistent Pain After Laparoscopic Inguinal Hernia Repair||Rigshospitalet, Denmark|No|Completed|January 2010|May 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|11|||Male|18 Years|80 Years|No|Non-Probability Sample|Patients with persistent pain after laparoscpic inguinal hernia repair|May 2012|May 29, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085110||125169|
NCT01084369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Testosterone version1|Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism|Phase IV: Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism||Tameside Hospital NHS Foundation Trust|No|Recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|50 Years|80 Years|No|||January 2014|January 3, 2014|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084369||125226|
NCT01085227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-16.1|Clinical, Molecular and by Neuroimaging of LRRK2 Mutations|Clinical, Molecular and by Neuroimaging Characterization of Monogenic Forms of Parkinsonism Syndromes: Mutations of the LRRK2 Gene.|LRRK2|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|April 2008|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|French population|January 2012|September 26, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085227||125160|
NCT01084837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENVEL|Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure|A National, Multicentric, Open-label Study of Induction Treatment With VELCADE and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure|RENVEL|PETHEMA Foundation|Yes|Completed|March 2010|December 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|March 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01084837||125190|
NCT01085162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS747158-501|A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)|An Open-Label Prospective, Non-Randomized, International, Multi-center, Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in Patients Suspected of Coronary Artery Disease (CAD)||Lantheus Medical Imaging|Yes|Withdrawn|March 2013|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from prior BMS747158 clinical studies. They will have known or        suspected CAD and have received at least 1 dose of BMS747158.|April 2013|April 2, 2013|March 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01085162||125165|
NCT01084850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH5|Corneal Endothelium Morphology and Central Thickness in Type II Diabetes Mellitus and Normal Subjects|Corneal Endothelium Morphology and Central Thickness in Type II Diabetes Mellitus and Normal Subjects||Frederiksberg University Hospital|No|Recruiting|June 2009|September 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients visiting Frederiksberg hospital for any reason|January 2010|March 10, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01084850||125189|
NCT01085448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRX18590|Clinical Prediction Rule for Clinical Lumbar Instability|Identifying the Subgroup of Patient With Mechanical Low Back Pain Who Have Clinical Lumbar Instability||Drexel University|No|Terminated|March 2010|October 2013|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|21 Years|65 Years|No|||November 2013|November 4, 2013|March 10, 2010||No|lack of timely recruitment of subjects|No||https://clinicaltrials.gov/show/NCT01085448||125143|
NCT01085461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESC-002|Assessment of Suicidality in Epilepsy - Rating Tools|Assessment of Suicidality in Epilepsy - Rating Tools|ASERT|The Epilepsy Study Consortium|No|Completed|January 2010|December 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with partial epilepsy for at least two years, who are treatment resistant,        experience at least 1 seizure/month, and are receiving 1-3 AEDs/month will be selected.|March 2012|March 1, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085461||125142|
NCT01091584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO: 2009/293|Nurse Intervention Project|A Randomized Trial to Assess the (Cost) Effectiveness of the Use of the Distress Thermometer by a Nurse in Addition to Usual Care for Patients Treated With Curative Intent for Breast Cancer.|VIP|Radboud University|No|Recruiting|March 2010|March 2015|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|193|||Female|18 Years|N/A|No|||August 2013|August 19, 2013|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01091584||124673|
NCT01081405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLI-001-2007|Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Hematologic Malignancies|TLI|Fondazione Neoplasie Sangue Onlus|Yes|Recruiting|November 2007|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|70 Years|No|||March 2010|March 4, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01081405||125452|
NCT01085942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288-05082 (REK)|Longitudinal Study of Asymptomatic Rotator Cuff Tears|Longitudinal Study of Asymptomatic Rotator Cuff Tears. A Eight Year Follow-up of Symptomatic Status and Tear Characteristics Like Tear Size, Muscle Atrophy and Fatty Degeneration||Martina Hansen's Hospital|No|Completed|October 2008|August 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects identified with an asymptomatic rotator cuff tear|December 2015|December 18, 2015|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085942||125105|
NCT01082016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABRC 9-022|Sleep Promotion in Critically Ill and Injured Patients Cared for in the Intensive Care Unit|||University of Arizona|Yes|Enrolling by invitation|April 2010|June 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|75|||Both|18 Years|55 Years|No|||March 2010|September 17, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082016||125406|
NCT01082367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2304|Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years|A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years|EARLY|Novartis||Active, not recruiting|April 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|3 Months|6 Years|No|||April 2015|April 14, 2015|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082367||125379|
NCT01082939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM02-593|Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Completed|December 2002|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|N/A|No|||February 2012|February 17, 2012|March 5, 2010||No||No|July 26, 2011|https://clinicaltrials.gov/show/NCT01082939||125335|
NCT01083186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-978|Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience|Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience|PROTECT|AbbVie|No|Completed|June 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from 24 hospital-based specialty, nephrology clinics in Greece|March 2013|March 11, 2013|February 20, 2010||No||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01083186||125316|
NCT01083160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-604|Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use|Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use|FALLA|Abbott||Terminated|April 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|75 Years|No|Non-Probability Sample|Community sample|January 2012|January 17, 2012|February 19, 2010||No|The study was terminated due to low enrollment because inclusion criteria are obsolete.|No|November 23, 2011|https://clinicaltrials.gov/show/NCT01083160||125318|
NCT01083173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-068|Surveillance of Kaletra in Korean Patients|Post-Marketing Surveillance of Safety and Efficacy of Kaletra® Tablet in Korean Patients Under the "New Drug Re-Examination"||AbbVie|No|Completed|October 2009|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|595|||Both|2 Years|99 Years|No|Non-Probability Sample|general hospitals|January 2016|January 25, 2016|February 19, 2010||No||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01083173||125317|
NCT01083394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. B00210|Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery|Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS)|ISAR-PEBIS|Deutsches Herzzentrum Muenchen|No|Recruiting|March 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2010|March 7, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01083394||125300|
NCT01084577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0142-09-U354|AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers|A Prospective, Multi-centre, Randomized, Open-label, Parallel, Comparative Study to Evaluate Effects of AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers||ConvaTec Inc.||Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|266|||Both|18 Years|N/A|No|||February 2011|February 17, 2011|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084577||125210|
NCT01084096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN ACT Study|Trial of the Use of Antenatal Corticosteroids in Developing Countries|Trial of the Use of Antenatal Corticosteroids in Developing Countries|ACT|NICHD Global Network for Women's and Children's Health|Yes|Completed|October 2011|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6214|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 29, 2014|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084096||125247|
NCT01085240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-B44-06A|Getting on With the Rest of Your Life After a Stroke|Getting on With the Rest of Your Life After Stroke: A Cross-Canada Program Aimed at Enhanced Life Participation, Prevention of Deterioration and Optimization of Health Care Utilization||McGill University|No|Active, not recruiting|September 2008|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|240|||Both|N/A|N/A|No|||April 2013|April 26, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085240||125159|
NCT01094704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0670|Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis|Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis||University of North Carolina, Chapel Hill|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|N/A|No|||August 2012|July 17, 2012|March 19, 2010|Yes|Yes||No|September 26, 2011|https://clinicaltrials.gov/show/NCT01094704||124433|
NCT01084863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P6/1.1|Evaluate Safety, Efficacy and Pharmacokinetics|Double-blind Randomised Phase I/IIb Study|Compare|Celltrion|Yes|Active, not recruiting|January 2010|December 2017|Anticipated|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|174|||Female|18 Years|N/A|No|||February 2015|February 11, 2015|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01084863||125188|
NCT01084876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P6/3.1|Demonstrate Efficacy and Safety of Metastatic Breast Cancer|Double-blind, Randomised, Parallel Group, Phase III Study|Compare|Celltrion|Yes|Active, not recruiting|June 2010|December 2017|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|383|||Female|18 Years|N/A|No|||February 2015|February 11, 2015|March 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01084876||125187|
NCT01085175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMI 1195-201|Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing|A Multicenter, Phase II, Open Label Trial to Determine Optimal Imaging Parameters and Assess the Safety of LMI 1195 in Low Risk Patients and Heart Failure Patients With a History of Firing of an Implantable Cardioverter-Defibrillator|LMI1195-201|Lantheus Medical Imaging|Yes|Withdrawn|May 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|No|||February 2011|October 12, 2015|February 12, 2010|Yes|Yes|Sponsor is re-evaluating the clinical development path|No||https://clinicaltrials.gov/show/NCT01085175||125164|
NCT01085188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1018-1201|Effectiveness of Assertive Continuing Care for Youth|||Chestnut Health Systems||Completed|January 2003|||January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Primary Purpose: Treatment|4||Actual|342|||Both|12 Years|18 Years|No|||March 2010|March 10, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085188||125163|
NCT01085474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RES-DUM-2009/1|Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient|Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient||AstraZeneca|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|384|||Both|18 Years|N/A|No|Probability Sample|60 community pharmacies 10 patients per pharmacy|January 2013|January 25, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085474||125141|
NCT01091922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading-2009-01|The Impact of Dietary Flavanols on the Gut Microflora|Prebiotic Evaluation of Cocoa-derived Flavanols in Healthy Humans Using a Randomized, Double Blind, Crossover, Placebo-controlled Intervention Study||University of Reading|Yes|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2008|March 23, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091922||124647|
NCT01081704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016207|A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects|A Study to Evaluate the Pharmacokinetics of Ustekinumab Following a Single Subcutaneous Administration of 45 mg or 90 mg to Healthy, Chinese, Male Subjects||Centocor, Inc.|No|Completed|October 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 26, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01081704||125430|
NCT01082640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67_203|Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment|A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment||Takeda|Yes|Completed|April 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|March 5, 2010|Yes|Yes||No|May 31, 2013|https://clinicaltrials.gov/show/NCT01082640||125358|
NCT01082653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-ALS-I|Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis|Phase I, Single Center, Prospective, Non-randomized, Open Label, Safety/Efficacy Study of the Infusion of Autologous Bone Marrow-derived Stem Cells, in Patients With Amyotrophic Lateral Sclerosis|ALS|TCA Cellular Therapy|Yes|Suspended|March 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|6|||Both|18 Years|80 Years|No|||September 2013|May 7, 2014|March 1, 2010|Yes|Yes|Suspended due to lack of funding.|No||https://clinicaltrials.gov/show/NCT01082653||125357|
NCT01082913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSE|The Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology|Study of the Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology|SSE|Shiga University|No|Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2010|March 8, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01082913||125337|
NCT01082679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTB-20080242|Treatment for Opioid Dependent Offenders|Treatment for Opioid Dependent Offenders||University of Wisconsin, Madison|No|Active, not recruiting|June 2009|February 2011|Anticipated|February 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||March 2010|March 5, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082679||125355|
NCT01082965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001437|Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease|A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease||Pfizer|No|Terminated|July 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Both|50 Years|N/A|No|||July 2013|July 3, 2013|February 26, 2010|No|Yes|The study was terminated because of slow enrollment. The decision to terminate the trial was    not based on any safety or efficacy concerns.|No|July 3, 2013|https://clinicaltrials.gov/show/NCT01082965||125333|The study was terminated because of the prohibitively low recruitment rate and the reassessment of the Neuroscience Research Unit portfolio. The decision to terminate the study was not based on any safety or efficacy concerns.
NCT01082952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|effect of eosinophil on ASM|Role of Eosinophils in the Proliferation of Airway Smooth Muscle (ASM) Cells|Role of Eosinophils in the Proliferation of ASM Cells in Asthma||King Saud University|Yes|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|12|||Both|14 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|12 patients per group|October 2011|October 11, 2011|March 8, 2010||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT01082952||125334|
NCT01083433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBCDM-01|Study to Find Out if Intensive Diabetes Clinic and Continuous Glucose Monitors Help Teenagers With Diabetes|Intensive Diabetes Clinic and Intermittent Continuous Glucose Monitoring in Adolescents With Type 1 Diabetes Mellitus in Poor Glycemic Control||University Hospital Case Medical Center|No|Completed|May 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|62|||Both|10 Years|18 Years|No|||June 2012|June 12, 2012|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01083433||125297|
NCT01084291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 253|Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine|A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2010|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|March 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01084291||125232|
NCT01083784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-038|The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia|The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia||Samsung Medical Center|No|Enrolling by invitation|March 2010|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||July 2011|July 21, 2011|March 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01083784||125270|
NCT01084330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2202|Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer|A Randomized, Open-label, Multi-center Phase II Study to Compare AUY922 With Docetaxel or Irinotecan in Adult Patients With Advanced Gastric Cancer, Who Have Progressed After One Line of Chemotherapy||Novartis||Terminated|April 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01084330||125229|
NCT01084343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYM-V101-CT08-101|Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects|A Dose Escalating Phase I Study, Double-blind, Randomized, Placebo-controlled for Examining the Safety and Tolerability to a Prophylactic HIV-1 Vaccine Called MYM-V101, Administered i.m. in Combination With i.n. Administrations to Healthy Female Subjects.||Mymetics Corporation|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2009|July 12, 2012|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084343||125228|
NCT01090505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-ChinaPLAGH-2010|Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer|Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced||Chinese PLA General Hospital|No|Recruiting|November 2009|December 2015|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|75 Years|No|||November 2009|March 19, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01090505||124756|
NCT01084590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A08-132|Healthy Homes/Healthy Kids_5-9|Healthy Homes/Healthy Kids: Pediatric Primary Care-based Obesity Prevention|HHHK_5-9|HealthPartners Institute|Yes|Completed|March 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|421|||Both|5 Years|9 Years|No|||March 2015|March 25, 2015|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084590||125209|
NCT01084603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1065/A6431116|Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product|Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product. A Study in Healthy Smokers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2009|June 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|45|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|March 9, 2010|Yes|Yes||No|April 16, 2010|https://clinicaltrials.gov/show/NCT01084603||125208|
NCT01084889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pfm 10k001 TiLOOP® Total 6|Anterior Pelvic Prolapse Reconstruction With TiLOOP® Total 6|National, Multicentre Post-marketing Surveillance Study on Anterior Pelvic Prolapse Reconstruction With Titanium-coated Polypropylene Mesh (TiLOOP® Total 6)||pfm medical ag|Yes|Active, not recruiting|April 2010|December 2017|Anticipated|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|290|||Female|18 Years|N/A|No|Non-Probability Sample|Women with a symptomatic genital descensus treated in the center|March 2016|March 17, 2016|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084889||125186|
NCT01085201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-308|Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease|Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease||Dana-Farber Cancer Institute|Yes|Completed|April 2010|March 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|39|||Both|10 Years|70 Years|No|||February 2014|February 5, 2014|March 10, 2010|No|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT01085201||125162|The highest dose we examined (dose level 2, 1.44 mcg/kg/hr) may not be the maximally tolerated dose. No toxicities definitely or probably attributable to the drug occurred, so it is possible that there is a higher dose that can be tolerated safely.
NCT01085214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02929|AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma|A Phase 2 Study of AZD6244 in Multiple Myeloma||National Cancer Institute (NCI)|No|Completed|March 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||May 2015|July 24, 2015|March 10, 2010|Yes|Yes||No|July 24, 2015|https://clinicaltrials.gov/show/NCT01085214||125161|
NCT01091324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-97-108|Dextromethorphan and Silymarin in Chronic Kidney Disease (CKD) Patients|The Reno-protective and Cardiovascular Effect of Dextromethorphan and Silymarin in Patients With Chronic Kidney Disease|CKD|National Cheng-Kung University Hospital|Yes|Active, not recruiting|January 2010|July 2010|Anticipated|June 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|75 Years|No|||March 2010|March 22, 2010|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01091324||124693|
NCT01091337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOIAA-MPT-2005-01|Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room|Comparative Study on the Efficacy and Safety of Procaterol vs Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room||Otsuka Pharmaceutical, Inc., Philippines|No|Completed|May 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 22, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01091337||124692|
NCT01092247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-NV-0056-CTIL|The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|March 2010|September 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|85 Years|No|||February 2010|March 23, 2010|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01092247||124622|
NCT01092260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/741|Renal Function Measurements in Children|Glomerular Filtration Rate in Children - a Methodological Study With Iohexol Clearance||Haukeland University Hospital||Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|96|Samples Without DNA|serum and urine|Both|N/A|17 Years|No|Non-Probability Sample|Children with clinical indication for measurement of renal function|January 2012|January 3, 2012|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092260||124621|
NCT01081977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|991-Ped/ERC-08|Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants|Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants at Birth and Three Months of Age||Aga Khan University|Yes|Completed|August 2008|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|340|||Both|N/A|3 Months|Accepts Healthy Volunteers|||August 2012|August 1, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081977||125409|
NCT01082302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 1022|Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage|An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage||MediGene|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 7, 2010|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01082302||125384|
NCT01082315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-509 (EMR 62202-551)|A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment|A Korean Post-Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer||Merck KGaA|No|Completed|April 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|730|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with EGFR-expressing, KRAS wild-type mCRC undergoing treatment with Erbitux in        Korea.|August 2014|August 28, 2014|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01082315||125383|
NCT01092208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100084|Studies of Autistic Patients: Gene Networks and Clinical Subtypes|Studies of Autistic Patients: Gene Networks and Clinical Subtypes||National Institutes of Health Clinical Center (CC)||Terminated|March 2010|September 2013||||N/A|Observational|Time Perspective: Retrospective|||Actual|11|||Male|4 Years|18 Years|Accepts Healthy Volunteers|||September 2013|February 19, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092208||124625|
NCT01092221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7724-MW-CTIL|Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode|Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode.||Sheba Medical Center|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|65 Years|No|||May 2012|May 6, 2012|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01092221||124624|
NCT01082666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_53/0919|Continuous Control of Tracheal Cuff Pressure and Microaspiration in Critically Ill Patients|Phase 4 Study of Continuous Control of Tracheal Cuff Pressure and Microaspiration in Critically Ill Patients||University Hospital, Lille|No|Completed|October 2009|December 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082666||125356|
NCT01083212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00030|To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656|A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656||AstraZeneca|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||June 2010|June 30, 2010|March 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01083212||125314|
NCT01083225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/2/0325|Effect of Patient Participation in Mental Health Care|Randomised Controlled Trial on the Effect of Individual User Involvement in a Mental Health Center||Norwegian University of Science and Technology|No|Completed|January 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01083225||125313|
NCT01083849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-681|Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice|Long-Term Therapy Outcomes When Treating CKD-patients With Paricalcitol in German Clinical Practice (TOP Study)|TOP|AbbVie|No|Completed|March 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|761|||Both|18 Years|N/A|No|Non-Probability Sample|Participating sites were facilities specialized in the treatment of chronic kidney disease        and offices of community-based specialists/nephrologists in Germany and Austria.|December 2014|December 11, 2014|February 25, 2010||No||No|December 11, 2014|https://clinicaltrials.gov/show/NCT01083849||125266|
NCT01083199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE0702|Global Performance Evaluation of the AMS CONTINUUM™ Device|Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy||American Medical Systems|No|Completed|October 2007|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|40 Years|N/A|No|||June 2011|June 6, 2011|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01083199||125315|
NCT01083420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7335-NY-CTIL|The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus|The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial||Sheba Medical Center|No|Not yet recruiting|March 2010|March 2012|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2010|March 8, 2010|March 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01083420||125298|
NCT01083771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-MED/PROS-219|Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer|Eight Week Plant-based Mediterranean Diet as Prevention of Metabolic Syndrome in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A BrUOG Pilot Study||Brown University|Yes|Completed|February 2009|August 2012|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Male|18 Years|N/A|No|||July 2015|July 21, 2015|March 9, 2010||No||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01083771||125271|
NCT01084109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN CF|First Bites: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial|Complementary Feeding - A Global Network Cluster Randomized Controlled Trial|First Bites|NICHD Global Network for Women's and Children's Health|Yes|Completed|July 2008|July 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1236|||Both|3 Months|4 Months|Accepts Healthy Volunteers|||November 2013|November 22, 2013|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084109||125246|
NCT01084122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEIV-DC-09|Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia|Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia||Hospital Clinic of Barcelona|No|Not yet recruiting|May 2010|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|360|||Both|65 Years|N/A|No|||January 2010|March 9, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084122||125245|
NCT01084356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-EES-0649-CTIL|Evaluation of a New CZT System|Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2010|||March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|consequtive patiants admitted for the above scans and consented to be further investigated        by the CZT system|March 2010|March 9, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084356||125227|
NCT01090817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC2009/123|An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease|A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn's Disease||Royal Perth Hospital|Yes|Completed|January 2010|June 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|55 Years|No|||June 2015|June 7, 2015|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01090817||124732|
NCT01091116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKOS-02|A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS|Intra-articular Treatment With MEN16132 in Patients With Symptomatic Primary Osteoarthritis of the Knee: A Randomized, Multi-centre, Double Blind, Placebo Controlled, Five Parallel Group, Dose Finding Study|ALBATROSS|Menarini Group|No|Completed|March 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|423|||Both|40 Years|N/A|No|||January 2013|January 16, 2013|March 18, 2010|Yes|Yes||No|November 8, 2012|https://clinicaltrials.gov/show/NCT01091116||124709|
NCT01084616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-804|Vaginal Microbiota Among Postmenopausal Women|The Role of Vaginal Microbiota in Symptoms of Vaginal Dryness in Postmenopausal Women||Lawson Health Research Institute|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|16|||Female|30 Years|80 Years|No|Probability Sample|Postmenopausal women|December 2010|December 16, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084616||125207|
NCT01084629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-006981|The Role of the Fujinon Intelligent Chromo Endoscopy (FICE™) in Barrett's Esophagus|The Role of the Fujinon Intelligent Chromo Endoscopy (FICE™) for the Detection of Dysplasia in Barrett's Esophagus and in Post Ablation Barrett's Esophagus||Mayo Clinic|No|Suspended|January 2010|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|85 Years|No|Non-Probability Sample|Barrett's esophagus|March 2016|March 18, 2016|March 9, 2010||No|This voluntary action is being taken by Fujinon in response to an inquiry by the US FDA    regarding the potential use of FICE|No||https://clinicaltrials.gov/show/NCT01084629||125206|
NCT01085773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2628-04|Effects of Nordic Walking and Exercise on Glucose Metabolism in Type 2 Diabetes Mellitus: A Randomized Controlled Trial|Effects of Nordic Walking and Exercise on Prescription on Glucose Metabolism in Type 2 Diabetes Mellitus: A Randomized Controlled Trial||Hospital of South West Denmark|No|Completed|February 2005|December 2007|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|68|||Both|20 Years|80 Years|No|||January 2005|March 11, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085773||125118|
NCT01081509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OHU-ARI-2010/1|Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence|Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex|ARIADNE|AstraZeneca|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1077|||Female|N/A|N/A|No|Probability Sample|Early breast cancer patients on adjuvant aromatase inhibitor|November 2011|November 15, 2011|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081509||125445|
NCT01081522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0510-09-U352|A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds|A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds||ConvaTec Inc.||Completed|October 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|Samples With DNA|tissue (3mm punch biopsy)|Both|18 Years|N/A|No|Non-Probability Sample|secondary care clinics|March 2010|March 4, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081522||125444|
NCT01091597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00008424|Pulmonary Vein (PV) Isolation Versus Box Isolation for the Treatment of Atrial Fibrillation|PV Isolation Versus Box Isolation for the Treatment of Atrial Fibrillation||Johns Hopkins University|No|Completed|June 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||March 2010|March 23, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091597||124672|
NCT01091935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-341|Safety of Intravenous Lidocaine Infusions|Safety of Intravenous Lidocaine Infusions for Chronic Neuropathic Pain||Lawson Health Research Institute|No|Completed|June 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult outpatients attending St Joseph's Chronic Pain Clinic in one of two time periods who        have been diagnosed with chronic neuropathic pain by clinical history and examination and        are scheduled to receive a lidocaine infusion for pain management|March 2010|March 23, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091935||124646|
NCT01081730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016723|Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database|A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Psoriasis Treated With Ustekinumab and Other Types of Biological and Systemic Non-biological Treatments||Janssen Biotech, Inc.|No|Active, not recruiting|February 2010|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1000|||Both|N/A|99 Years|No|Non-Probability Sample|This study will include cohorts of participants who have claims consistent with a        diagnosis of psoriasis and who initiate ustekinumab, anti-TNF biologics, non-anti-TNF        biologics, or systemic non-biological treatments|February 2016|February 26, 2016|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081730||125428|
NCT01081990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH10-073|Use of Cyclobenzaprine After Vaginal Surgery|The Short-term Use of Cyclobenzaprine in Patients Undergoing Vaginal Surgery||NorthShore University HealthSystem Research Institute|Yes|Recruiting|April 2010|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081990||125408|
NCT01092767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigational Plan #117|Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury|Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System for the Endovascular Treatment of Blunt Thoracic Aortic Injuries (RESCUE)|RESCUE|Medtronic Endovascular|Yes|Active, not recruiting|April 2010|May 2017|Anticipated|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|March 16, 2010|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT01092767||124582|
NCT01092780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7288-010|Pharmacodynamics and Efficacy of MK7288 (MK-7288-010)|An Active-Comparator Controlled Single Dose Study to Evaluate the Pharmacodynamics/Efficacy of MK7288 in Sleep Apnea Patients||Merck Sharp & Dohme Corp.|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|64 Years|No|||April 2015|April 1, 2015|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01092780||124581|
NCT01082354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP28018|A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)|Non Interventional Study on the Follow-up, by Specialists, of Short Children Born Small for Gestational Age and Treated With SAIZEN®- SEPAGE Study|SEPAGE|Merck KGaA|No|Completed|March 2009|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|N/A|N/A|No|Non-Probability Sample|48 hospital pediatric and endocrinology centers or in mixed private and hospital practice        will enroll 150 children|February 2016|February 11, 2016|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082354||125380|
NCT01092741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID01-292|Late Chronic Phase Chronic Myelogenous Leukemia|Therapy of Late Chronic Phase Chronic Myelogenous Leukemia (CML) With High-Dose Gleevec (STI571)||M.D. Anderson Cancer Center|No|Completed|July 2001|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|15 Years|N/A|No|||September 2013|January 7, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092741||124584|
NCT01093027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007889|Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor|Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor||Mayo Clinic|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|March 24, 2010||No||No|February 1, 2012|https://clinicaltrials.gov/show/NCT01093027||124562|
NCT01093040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP224|A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects|A Phase I, Single-Center, Single-blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CAT-354 Following Subcutaneous Administration in Healthy Male and Female Japanese Subjects||MedImmune LLC|No|Completed|April 2010|October 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|30|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|March 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01093040||124561|
NCT01084135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013682|Rivastigmine Study in Adolescents With Down Syndrome|A 20-Week Double-Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Rivastigmine in Children (Ages 10-18) With Down Syndrome|DS-Riv|Duke University|No|Completed|November 2009|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|10 Years|17 Years|No|||February 2015|March 17, 2015|March 8, 2010|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01084135||125244|
NCT01083797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 106/2009|Sedation to Electroencephalography With Dexmedetomidine or Chloral Hydrate|Sedation to Electroencephalography With Dexmedetomidine or Chloral Hydrate: a Comparative Study of the Qualitative and Quantitative Electroencephalogram Pattern||Federal University of Minas Gerais|Yes|Completed|December 2009|October 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|25|||Both|12 Years|38 Years|No|||October 2013|October 24, 2013|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083797||125269|
NCT01083810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAL 1 RO|Evaluation of Kaletra Therapy Over the Long-term|Evaluation of Kaletra Therapy Over the Long-term||Abbott|No|Completed|June 2001|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|284|||Both|18 Years|N/A|No|Non-Probability Sample|Human Immunodeficiency Virus-infected, protease inhibitor-naïve patients from a clinical        setting|August 2011|August 9, 2011|February 26, 2010||No||No|June 30, 2011|https://clinicaltrials.gov/show/NCT01083810||125268|
NCT01083823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364-2007|Calling for Care: Cell Phones for Mood Telemetry in Teens|Calling for Care: Cell Phones for Mood Telemetry||Sunnybrook Health Sciences Centre|No|Completed|March 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|33|||Both|14 Years|20 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083823||125267|
NCT01084642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-034|Female Cancer Patients' Preference For Sexual Health Interventions|A Pilot Study Surveying Female Cancer Patients' Preference For Sexual Health Interventions||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|21 Years|N/A|No|Non-Probability Sample|Clinics at MSKCC|April 2015|April 28, 2015|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084642||125205|
NCT01094379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aretaieion01|A Randomised Comparison Between Single Incision Laparoscopic Cholecystectomy and Standard Laparoscopic Cholecystectomy|A Randomised Comparison of Postoperative Pain and Recovery Between Single Incision Laparoscopic Cholecystectomy Using One Port and Standard Laparoscopic Cholecystectomy Using Four Ports||University of Athens|Yes|Recruiting|April 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|15 Years|N/A|No|||June 2010|June 24, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01094379||124458|
NCT01090440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112891|Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects|An Open Label, Randomised, Three-way Cross-over Study to Evaluate the Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Male and Female Subjects|MNK112891|GlaxoSmithKline||Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2010|May 20, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01090440||124761|
NCT01091129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0004|Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis|Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis||Miramar Labs|No|Completed|February 2010|January 2012|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|March 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01091129||124708|
NCT01091389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL30199.018.10|Atrial Fibrillation Ablation and Autonomic Modulation Via Thorascopic Surgery|A Randomized Single Center Study to Prospectively Investigate the Effect of Ablation of the Autonomic Ganglia in Addition to Minimally Invasive Surgical Isolation of Pulmonary Veins in Patients With Atrial Fibrillation|AFACT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|March 2010|March 2016|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||January 2015|January 12, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091389||124688|
NCT01085487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14536|MiCo - Mirena or Conventional Medical Treatment for Menorrhagia|MiCo - Mirena or Conventional Medical Treatment for Menorrhagia (MA0901)||Bayer|No|Completed|April 2009|June 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1211|None Retained|n.a.|Female|18 Years|45 Years|No|Non-Probability Sample|Primary care|April 2012|April 9, 2012|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01085487||125140|
NCT01090804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47660279|The Effectiveness of BreatheMAX Breathing Device on Secretion Clearance|The Effectiveness of BreatheMAX Breathing Device on Airway Secretion Clearance in Patients With Ventilatory Dependence|ESMOSC|Khon Kaen University|Yes|Recruiting|August 2009|||December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|14|||Both|15 Years|85 Years|No|||January 2010|March 22, 2010|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01090804||124733|
NCT01091064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20636|Impact Of A Health Care Protocol For Patients Suffering Symptoms Of Mild Acute Viral Bronchiolitis On Early Release In The Emergency Department|IMPACT OF A HEALTH CARE PROTOCOL FOR PATIENTS SUFFERING SYMPTOMS OF MILD ACUTE VIRAL BRONCHIOLITIS ON EARLY DISCHARGE IN THE EMERGENCY DEPARTMENT.||Laval University|Yes|Withdrawn|October 2011|April 2014|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|3 Months|12 Months|No|||September 2015|September 4, 2015|March 19, 2010||No|The study was stopped because it was not approved for funding|No||https://clinicaltrials.gov/show/NCT01091064||124713|
NCT01091350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orchestra vs Diprifusor|Influence of Equilibration Rate Constant (ke0) of Propofol on the Effect Site Concentration for Loss of Consciousness|Influence of Equilibration Rate Constant (ke0) of Propofol on the Effect-site Concentration for Loss of Consciousness||Seoul National University Hospital||Completed|May 2009|November 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|60|||Female|20 Years|60 Years|No|||May 2013|May 29, 2013|March 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01091350||124691|
NCT01091363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA021243-02|Tobacco Dependence Treatment for Asian Americans|A Randomized Controlled Clinical Trial of a Combination of Pharmacotherapy and Culturally Tailored Cognitive Behavior Therapy With Korean Americans||University of Massachusetts, Worcester|No|Completed|September 2009|January 2014|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|March 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01091363||124690|
NCT01091948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-079|GlideScope Video Laryngoscope Versus Fiberoptic Intubation|GlideScope Video Laryngoscope vs Fiberoptic Intubation||Outcomes Research Consortium|No|Completed|February 2008|January 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|75|||Both|18 Years|N/A|No|||March 2010|April 2, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01091948||124645|
NCT01093066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908038|Prospective Multicentric Evaluation of a Bladder Preservation Strategy|Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma|ReChiVe|Centre Hospitalier Universitaire de Saint Etienne|Yes|Recruiting|September 2010|December 2022|Anticipated|December 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|18 Years|69 Years|No|||March 2016|March 9, 2016|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093066||124559|
NCT01093079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5489|Laparoscopic Versus Open Partial Nephrectomy - Surgical and Oncological Outcomes||LapVsOpen prtn|Rabin Medical Center||Recruiting|September 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to partial nephrectomy due to renal lesion , suspected to be a tumor|July 2009|March 24, 2010|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01093079||124558|
NCT01081457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/163/HP|Effect of Deep Brain Stimulation on Gastrointestinal (GI) Motility|Effect of Deep Brain Stimulation on Voluntary and Involuntary Gastrointestinal Motility in Parkinson's Disease|SCP-Comodig|University Hospital, Rouen|Yes|Completed|January 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081457||125448|
NCT01081743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB : 2009-A00326-51|Effectiveness of Care Management in Alzheimer Patients|Evaluation de la Mise en Place d'un Auxiliaire d'évaluation Dans la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées en France|AIDALZ|Institut de Sante Publique, d'Epidemiologie et de Developpement|Yes|Recruiting|November 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|N/A|N/A|No|||July 2011|July 5, 2011|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081743||125427|
NCT01093430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM2009/1|Is the Anterior Superior Iliac Spine a Useful Landmark at Laparoscopy?|Anterior Superior Iliac Spine - A Useful Surface Anatomical Landmark for Safe and Symmetric Accessory Laparoscopic Port Entry||Royal Free Hampstead NHS Trust|No|Recruiting|September 2009|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|20 Years|55 Years|No|||March 2010|March 24, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01093430||124531|
NCT01093664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF004A|Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02|Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002||Affiris AG|Yes|Completed|October 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|85 Years|No|||October 2010|October 18, 2010|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01093664||124513|
NCT01093677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIM-0705-CL-003|Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance|A Single-Blind,Randomized,Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance|LIM|Limerick BioPharma|No|Withdrawn|March 2010|July 2010|Anticipated|June 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|70 Years|No|||June 2010|June 4, 2010|March 15, 2010||No|no subjects enrolled|No||https://clinicaltrials.gov/show/NCT01093677||124512|
NCT01082380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081009|Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-02341066 In Healthy Male Volunteers||Pfizer|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|March 5, 2010|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT01082380||125378|
NCT01082692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-001|Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants|A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants|HIV-001|Inovio Pharmaceuticals|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|50 Years|No|||November 2012|November 8, 2012|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01082692||125354|
NCT01093391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scitech 001|A Trial of Bare Metal Stent - Cobalt Chromium Versus Stent Coating With Sirolimus|A Randomized Trial of Bare Metal Stent (Cronus®) - Cobalt Chromium Versus Stent Coating With Sirolimus (DES)|INSPIRON|Scitech Produtos Medicos Ltda|Yes|Completed|November 2010|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|March 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01093391||124534|
NCT01093404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAAR-001|Thrombus Aspiration in Myocardial Infarction|Thrombus Aspiration in ST- Elevation Myocardial Infarction in Scandinavia|TASTE|University Hospital Orebro|Yes|Completed|July 2010|August 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7243|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01093404||124533|
NCT01094197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|695|Detailed Evaluation of Microchimerism|Evaluation to Determine Whether Transfusion-associated Microchimerism Involves Engraftment With Hematopoietic Progenitor Cells||Blood Systems Research Institute|No|Withdrawn|March 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|Leukapheresis filtrate and/or whole blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Previous study participants|April 2013|April 11, 2013|March 25, 2010||No|Investigators could not identify subjects who met all inclusion criteria.|No||https://clinicaltrials.gov/show/NCT01094197||124472|
NCT01090570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-02|Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate|||Plexxikon|No|Withdrawn|May 2010|||December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|March 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090570||124751|
NCT01093365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067/2009|Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia|Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia||Centre for Addiction and Mental Health|Yes|Active, not recruiting|March 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093365||124536|
NCT01093378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071224|Diet and Its Relationship With Couple Infertility|Impact of the Diet Fertility : A Case-control Multicentric Study|ALIFERT|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2009|June 2015|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|400|Samples With DNA|Impact of genetic polymorphism on clinical and biological phenotypes linked to food      behaviour in infertility context|Both|18 Years|45 Years|No|Non-Probability Sample|Defined population after a screening in out-hospitalized patients in selected        investigation sites|August 2015|August 28, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01093378||124535|
NCT01083446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-NV-236|A Nutritional Approach to Minimal Hepatic Encephalopathy|A Nutritional Approach to Minimal Hepatic Encephalopathy||Tel-Aviv Sourasky Medical Center|No|Recruiting|July 2008|August 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2008|March 8, 2010|June 17, 2008||No||No||https://clinicaltrials.gov/show/NCT01083446||125296|
NCT01083459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD004011-01|Impact of PCV on Disease and Colonization Among Native American Communities|Impact of PCV on Disease and Colonization Among Native American Communities||Johns Hopkins Bloomberg School of Public Health|No|Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Actual|6628|Samples With DNA|Nasopharyngeal swab Blood|Both|7 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The target population for the nasopharyngeal study is American Indian children 7-24 months        of age (index child) and their adult and child household members who reside in the        Whiteriver, Shiprock, Chinle, Fort Defiance and Gallup service units on the White Mountain        Apache and Navajo reservations. In addition those children and adults who have close        contact with the index child but may not live in the same household as the child are        eligible to participate. This may be relatives or close contacts of the index child who        reside in the same family compound (a compound is a group of homes in close proximity to        each other) but do not live in the same household as the index child.|January 2015|January 16, 2015|March 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01083459||125295|
NCT01084655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21003|Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer|An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer||Millennium Pharmaceuticals, Inc.|No|Completed|July 2010|February 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||January 2013|July 1, 2013|March 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01084655||125204|
NCT01094158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aramchol NAFLD Phase-II|Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis|A Phase II Placebo Controlled Randomised Study of Aramchol on Liver Triglyceride in Patients With Steatosis Due to NAFLD or NASH|Aramchol003|Galmed Medical Reserch|Yes|Completed|November 2010|January 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||January 2012|January 30, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01094158||124475|
NCT01090453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113615|Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants|Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age||GlaxoSmithKline||Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|480|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2014|July 24, 2014|March 18, 2010|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT01090453||124760|
NCT01090713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDX in BED|Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder|Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity||Lindner Center of HOPE|No|Completed|January 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01090713||124740|
NCT01090518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFT2009-02-1|Cortisol Augmentation of a Psychological Treatment in Warfighters With Post Traumatic Stress Disorder (PTSD)|Cortisol Augmentation of a Psychological Treatment in Warfighters With Post Traumatic Stress Disorder (PTSD)||Bronx VA Medical Center|No|Recruiting|February 2010|||November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|89 Years|No|||February 2013|February 4, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01090518||124755|
NCT01090791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A007419-48|FLOTRAC/VIGILEO in Acute Circulatory Failure|Assessment of the FLOTRAC/VIGILEO Third Generation Software to Predict Fluid Responsiveness in Critically Ill Patient With Acute Circulatory Failure|FLOVAC|Hôpital Européen Marseille|No|Suspended|May 2011|November 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients with acute circulatory failure, as defined by two or more of the        inclusion criteria.|February 2016|February 21, 2016|March 22, 2010||No|Major change in protocol anticipated|No||https://clinicaltrials.gov/show/NCT01090791||124734|
NCT01091376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH02|Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)|A Phase II Study of Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer|RT0901|Zhejiang Cancer Hospital|Yes|Recruiting|January 2010|March 2013|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|75 Years|No|||March 2010|May 13, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01091376||124689|
NCT01091610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK21-01-10|Work Related Injuries Among Prehospital Emergency Medical Staff, an Observational Study|Work Related Injuries Among Prehospital Emergency Medical Staff, a Retrospective, Observational Study||University Hospital Inselspital, Berne|No|Withdrawn|May 2010|||||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|all ambulance companies in Switzerland (including air, ground and water associated) will        be contacted to provide data of their personnel of the past 10 years. All accidents        leading to leave from work will be analyzed according to parameters concerning the        ambulance organisation, the person and the emergency mission. In addition, data of        additionally injured non-medical persons due to an emergency mission will be analyzed.|March 2011|July 9, 2015|March 21, 2010||No|no collaboration|No||https://clinicaltrials.gov/show/NCT01091610||124671|
NCT01091623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/2005|Effects of Strength Training in Combination With Endurance Training on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)|||Medical University of Vienna||Completed|June 2005|||January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|36|||Both|40 Years|75 Years||||May 2005|March 23, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091623||124670|
NCT01092819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 2988.B|A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial|Functional Outcome and Recovery After STROKE: The FIRST Trial|FIRST|Penumbra Inc.|No|Active, not recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Male|18 Years|85 Years|No|Probability Sample|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom        onset and with an imaging-defined large cerebral vessel occlusion and a known infarct        volume will be enrolled and followed for 90-days.|March 2016|March 14, 2016|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092819||124578|
NCT01093092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 163509|Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery|A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors||Roswell Park Cancer Institute|No|Terminated|September 2011|November 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|March 24, 2010|No|Yes|Study transferring to INOVA Health|No||https://clinicaltrials.gov/show/NCT01093092||124557|
NCT01093105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-GLD-056|An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)|A Multicenter, Prospective, Longitudinal, Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (Krabbe Disease)||Shire|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|21 Months|No|Non-Probability Sample|Subjects with a documented diagnosis of GLD and clinical signs and symptoms consistent        with that diagnosis|February 2014|February 19, 2014|March 24, 2010||No|Study halted prior to enrollment of first participant|No||https://clinicaltrials.gov/show/NCT01093105||124556|
NCT01081483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-310|A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults|A Blinded, Randomized, Placebo-controlled Phase 1 Study in Healthy Male Adults to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Doses of ABT-072||Abbott|No|Completed|March 2010|||June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2010|October 22, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081483||125447|
NCT01081496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OES-DUM-2009/1|Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)|Epidemiological Study to Evaluate the Prevalence of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)|Spanish REASON|AstraZeneca|No|Completed|March 2010|February 2011|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|To be recruited by Oncologist|March 2011|March 15, 2011|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01081496||125446|
NCT01081756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP-25346|A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)|An Open, Randomized, Comparative Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)||Merck KGaA||Completed|December 2003|September 2004|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|218|||Female|N/A|N/A|No|||March 2010|July 30, 2014|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081756||125426|
NCT01081769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015199|Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics|A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia|PROSIPAL|Janssen-Cilag International NV|No|Completed|February 2010|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|769|||Both|18 Years|65 Years|No|||February 2015|February 17, 2015|March 4, 2010|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01081769||125425|
NCT01094210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43DE020998-01|Evaluation of a Low-fluoride Anticaries Toothpaste|Evaluation of a Low-fluoride Anticaries Toothpaste Containing an Innovative Calcium Technology||Indiana Nanotech, LLC|Yes|Completed|September 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|This in situ study will recruit 30 adult subjects (between 18-50 years of age). No        potential subject will be excluded from this study, regardless of their gender or        racial/ethnic origins. However, it is expected that about 18 (60%) of the 30 subjects in        the trial will be women. This distribution will allow for meaningful comparisons between        gender groups. We will recruit patients attending the clinics of UTHSCSA dental school        clinics, which reflect the ethnic mix of the area the clinics serve. However, majority of        subjects will be Hispanic due to the high Hispanic prevalence (57.8%) in San Antonio.        Thus, minorities will be included at a similar rate to that in the general population        attending for dental care,|June 2011|March 23, 2015|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094210||124471|
NCT01094223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBRP1R21DA029255-01|Mindfulness Based Relapse Prevention for Stimulant Users|Mindfulness Based Relapse Prevention for Stimulant Users|MBRP|University of California, Los Angeles|Yes|Active, not recruiting|April 2010|December 2015|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|59 Years|No|||December 2015|December 17, 2015|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094223||124470|
NCT01092507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC07|A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers|A Controlled Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Comparison With SA14-14-2 Vaccine in Infants and Toddlers in Thailand||Sanofi|No|Completed|March 2010|October 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|9 Months|18 Months|Accepts Healthy Volunteers|||November 2013|November 30, 2013|March 23, 2010||No||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01092507||124602|
NCT01090583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09042|Can Non-invasive Sampling Determine the Inflammatory Status of the Intra-uterine Environment?|Can Non-invasive Sampling Determine the Inflammatory Status of the Intra-uterine Environment?||Winthrop University Hospital|No|Completed|March 2010|July 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20||observational study, no specimens required.|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The researchers seek to obtain fluid samples from nine maternal-fetal compartments and        determine the inflammatory mediator expression in each. These mediators include cytokines,        chemokines, and growth factors via the Bio-Plex™ Suspension Array system. In this study,        we plan to enroll 20 patients undergoing cesarean delivery at term.|December 2014|December 8, 2014|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090583||124750|
NCT01084382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLU-AGKrawi_Spiru|" Arthrospira Platensis" as Nutrition Supplementation for Female Adult Patients Infected by HIV in Yaoundé Cameroon|||University of Giessen|Yes|Enrolling by invitation|April 2010|September 2010||June 2010||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|70|||Female|18 Years|49 Years|No|||February 2010|March 9, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084382||125225|
NCT01094171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113586|Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia|A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation||GlaxoSmithKline||Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|400|||Both|3 Months|6 Months|Accepts Healthy Volunteers|||August 2014|January 28, 2016|March 4, 2010|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT01094171||124474|
NCT01094496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1307-03|A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)|A Phase II, Open-Label Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-β||Celldex Therapeutics|No|Terminated|April 2010|October 2017|Anticipated|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 25, 2010|Yes|Yes|Portfolio prioritization due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01094496||124449|
NCT01090531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-002|Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy|A Multicenter, Prospective, Observational, Long-Term Follow-Up Study of Subjects With Chronic Hepatitis B and Low Viremia Who Do Not Receive Antiviral Therapy||Johann Wolfgang Goethe University Hospitals|No|Recruiting|August 2009|||August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|whole blood, serum|Both|18 Years|79 Years|No|Probability Sample|Patients with chronic hepatitis B not receiving antiviral therapy|May 2012|May 21, 2012|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01090531||124754|
NCT01090544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Helios TNI 2010|Transnasal Insufflation (TNI) and Chronic Obstructive Pulmonary Disease|Transnasal Insufflation for Patients With COPD GOLD IV and Hypercapnia|TNICOPD|Helios Klinik Ambrock|No|Completed|December 2009|September 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|85 Years|No|||September 2010|September 29, 2010|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01090544||124753|
NCT01091636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-06-222|Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer|The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer||National Cancer Center, Korea|Yes|Enrolling by invitation|March 2010|December 2017|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|170|||Female|N/A|75 Years|No|||September 2014|September 24, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091636||124669|
NCT01091649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-797|Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450|An Open-label, Randomized, Crossover Study to Evaluate the Bioavailability of Two Candidate Tablet Formulations of ABT-450 With Reference to the Hard Gelatin Capsule Formulation||Abbott||Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|December 17, 2010|February 26, 2010||Yes||No||https://clinicaltrials.gov/show/NCT01091649||124668|
NCT01091077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFN-001|A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection|A Pilot Study of the Grapefruit Flavonoid Naringenin for the Treatment of HCV Infection||Massachusetts General Hospital|Yes|Completed|June 2009|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01091077||124712|
NCT01091090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006264|Cognitive Behavioral Smoking Cessation Intervention for Adults With Chronic Pain|Cognitive Behavioral Smoking Cessation Intervention for Adults With Chronic Pain||Mayo Clinic|No|Completed|November 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|80 Years|No|||May 2012|May 23, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01091090||124711|
NCT01092273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prostaglandins-Cairo-1A|Bimatoprost Versus Travoprost at Cairo University|Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.||Cairo University|Yes|Completed||||||N/A|Observational|Time Perspective: Prospective||1|||||Both|20 Years|72 Years||Non-Probability Sample|Hospital Based Study at Cairo University and Al Nour Eye Hospital|January 2008|March 23, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092273||124620|
NCT01092546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-067-009|Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus|A Principal, Prospective, Open-label Biopsy Study to Validate Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Normal Pressure Hydrocephalus (NPH) Subjects.||GE Healthcare|Yes|Terminated|March 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|50 Years|N/A|No|||November 2013|November 20, 2013|March 23, 2010|Yes|Yes|Changed focus of the program|No|September 5, 2013|https://clinicaltrials.gov/show/NCT01092546||124599|
NCT01092559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2010-001|Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide|An Open Label Pilot Study Evaluating Preliminary Safety and Performance of the GeNO Nitrosyl Delivery System|PILOT|Geno LLC|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|February 16, 2010|Yes|Yes||No|April 18, 2013|https://clinicaltrials.gov/show/NCT01092559||124598|
NCT01092806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVA-09|Insulin Secretion and Advagraf|Effects on Insulin Secretion and Sensitivity of Two Different Formulations Tacrolimus - Prograf® and Advagraf®|ADVA-09|University of Oslo School of Pharmacy|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092806||124579|
NCT01091896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBEViH|Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage|Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage Secondary to Diabetic Retinopathy||University of Sao Paulo|Yes|Recruiting|January 2010|March 2011|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1|||Both|18 Years|N/A|No|||March 2010|March 23, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091896||124649|
NCT01091909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR- 225568|Post-extraction Wound Healing in Patients With Type 2 Diabetes|Post-extraction Wound Healing in Patients With Type 2 Diabetes|PEWHPD|University of Sao Paulo|No|Completed|March 2010|June 2014|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 16, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091909||124648|
NCT01092520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013007|Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children|Open Label Pilot Study of Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children||The Hospital for Sick Children|No|Withdrawn|July 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Years|18 Years|No|||August 2013|August 19, 2013|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092520||124601|
NCT01092754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1177-01-597|Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients|An Open-Label, Multicenter, Phase 4 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark(R) in Pediatric Patients (2-11 & 12-18 Yrs) Referred for Contrast-Enhanced MRI||Mallinckrodt|No|Completed|May 2002|December 2003|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|2 Years|18 Years|No|||March 2010|March 24, 2010|March 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092754||124583|
NCT01094236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR40-2|Interactive Program for Effective Playground Supervision|Interactive Program for Effective Playground Supervision|Playground_2|Oregon Center for Applied Science, Inc.|No|Completed|August 2005|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|2316|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 25, 2010|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094236||124469|
NCT01094249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017029|A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder|An Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Paliperidone Extended-Release on the Steady-State Pharmacokinetics of Valproic Acid in Clinically Stable Subjects With Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|65 Years|No|||April 2014|April 7, 2014|February 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01094249||124468|
NCT01093053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08144040|Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations|A Randomized Controlled Study of Mind-Body Skills Groups for Treatment of War Zone Stress in Military and Veteran Populations||The Center for Mind-Body Medicine|No|Completed|September 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 27, 2014|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093053||124560|
NCT01093924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILI 'Ohana 5 year|Partnerships to Overcome Obesity Disparities in Hawaii: 18-month CBPR Study|Partnerships to Overcome Obesity Disparities in Hawaii||University of Hawaii|Yes|Completed|October 2009|February 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|240|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01093924||124493|
NCT01093937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|229/2009|Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolar Disorder|A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder||Centre for Addiction and Mental Health|Yes|Completed|November 2009|June 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||June 2011|June 22, 2011|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01093937||124492|
NCT01090856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 0209/09|Predilation of Side Branch During Percutaneous Treatment of Bifurcation Lesions With Provisional T Stenting|Predilation of Side Branch During Percutaneous Treatment of Bifurcation Lesions With Provisional T Stenting.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|No|Completed|February 2009|May 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|420|||Both|30 Years|85 Years|No|||May 2013|December 4, 2014|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01090856||124729|
NCT01093638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTILYAB004409LND10LaniadoH|Insulin Food Supplement for Preterm Infants|A Multi-center, Randomized, Double-blinded Clinical Study to Assess the Effect of Insulin Enriched Formula on Gastrointestinal Tract Maturation in Pre-term Infants.||Laniado Hospital|Yes|Recruiting|August 2010|June 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|26 Weeks|33 Weeks|Accepts Healthy Volunteers|||April 2012|April 17, 2013|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093638||124515|
NCT01093898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36824|The Neuroeconomics of Behavioral Therapies for Adolescent Substance Abuse|The Neuroeconomics of Behavioral Therapies for Adolescent Substance Abuse|Imaging|Dartmouth-Hitchcock Medical Center|No|Completed|April 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|51|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents recruited into the Marijuana Trial and the Alcohol Trial during the period of        the R21 project would participate in a single neuroimaging session as soon after the        intake session as possible.|August 2014|August 18, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01093898||124495|
NCT01093911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0013|Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity and to Explore the Pharmacodynamics of CDP7657 Administered in Healthy Subjects and in SLE Patients.||UCB Pharma|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|44|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01093911||124494|
NCT01090557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07029|Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study|A Prospective, Pilot Study Measuring Exhaled Nitric Oxide Levels in Infants and Young Children Admitted to the Hospital for Respiratory Syncytial Virus (RSV) or Other Viral Lower Respiratory Tract Infections||Winthrop University Hospital|Yes|Completed|October 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|N/A|4 Years|Accepts Healthy Volunteers|Probability Sample|The parents of children admitted to WUH with a diagnosis of lower respiratory tract viral        illness (LRTVI) will be offered the opportunity to participate|March 2010|March 19, 2010|October 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01090557||124752|
NCT01090830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCH003|Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer|Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.|HCH003|Holy Cross Hospital, Florida|No|Terminated|April 2010|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|March 22, 2010|Yes|Yes|Principal Investigator has left institution. IND withdrawn.|No||https://clinicaltrials.gov/show/NCT01090830||124731|
NCT01091103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPC-MDA-1|Determine the Effect of Enzalutamide (Formerly MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide to Identify Potential Predictors of Response or Resistance to Therapy|A Study of Continuous Oral Dosing of a Novel Antiandrogen MDV3100, in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Micro-Environment.||Medivation, Inc.|No|Completed|February 2010|August 2013|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|N/A|N/A|No|||November 2014|November 10, 2014|March 19, 2010|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01091103||124710|
NCT01092585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOM202|Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH|A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH||Genta Incorporated|No|Recruiting|February 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01092585||124596|
NCT01091402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Autologous Serum Skin Test and Serum IL-18 Levels in Chronic Idiopathic Urticaria and Respiratory Allergic Diseases|||Eskisehir Osmangazi University||Completed|January 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|||||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients from Outpatient clinic|January 2009|March 23, 2010|March 23, 2010||||No||https://clinicaltrials.gov/show/NCT01091402||124687|
NCT01091961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-487|Study of Preoperative Management of Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Medications|Pre-Operative Inhibition of the Angiotensin System Study: A Prospective Randomized Single-Blinded Trial of Pre-Operative Management of Medications That Inhibit the Renin-Angiotensin System|PASS|Lawson Health Research Institute|No|Recruiting|January 2010|December 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2010|March 23, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091961||124644|
NCT01092286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2006-12888|Effect of Neuromuscular Warm-up on Injuries in Female Athletes|Effect of Neuromuscular Warm-up on Injuries in Female Athletes in Urban Public High Schools: A Cluster-randomized Controlled Trial||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|July 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1653|||Both|14 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092286||124619|
NCT01092572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-Man-Statin-1|Statins To Treat Adult Cystic Fibrosis|The Effect of Simvastatin on Systemic Inflammation in Adult Cystic Fibrosis Subjects: A Pilot Study|CFStatin|University of British Columbia|No|Withdrawn|May 2010|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|March 23, 2010||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01092572||124597|
NCT01093469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-AF-ATD-Aquaphor|Comparing the Efficacy and Cost-Effectiveness of Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis|An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis||Wake Forest School of Medicine|No|Completed|September 2009|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|39|||Both|2 Years|17 Years|No|||December 2015|December 9, 2015|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093469||124528|
NCT01093482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISMV-2010|Third International Study on Mechanical Ventilation|Third Prospective, Observational, International, Multicenter Study on Mechanical Ventilation|ISMV|Hospital Universitario Getafe|No|Completed|April 2010|September 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8151|||Both|18 Years|N/A|No|Probability Sample|Mechanically ventilated patients|May 2012|June 15, 2013|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01093482||124527|
NCT01093976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909M72088|Marinol in Trichotillomania or Obsessive Compulsive Disorder|An Open-Label Study of Dronabinol, a Cannabinoid Agonist, for Obsessive Compulsive Disorder and the Obsessive-Compulsive Spectrum Disorders Trichotillomania and Pathological Skin Picking||University of Chicago|Yes|Completed|April 2010|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||August 2013|August 6, 2013|March 24, 2010|Yes|Yes||No|March 1, 2012|https://clinicaltrials.gov/show/NCT01093976||124489|
NCT01092234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/105-02|Effectiveness of a Observational Unit at St. Olavs Hospital|A Open Randomized Trial of the Effectiveness of a Observational Unit at St. Olavs Hospital||St. Olavs Hospital|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|105|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092234||124623|
NCT01092793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Krill-2010|Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease|Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease||Oslo University Hospital|No|Recruiting|February 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label|3|||60|||Both|18 Years|80 Years|No|||March 2010|March 23, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092793||124580|
NCT01093417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-30|Study of Vitamin D and Effect on Heart Disease and Insulin Resistance|The Effect of Vitamin D Supplementation on Endothelial Function, Inflammation and Insulin Resistance in HIV||University Hospital Case Medical Center|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|45|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|March 24, 2010||No||No|January 28, 2012|https://clinicaltrials.gov/show/NCT01093417||124532|
NCT01094522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03012010-5083|Measuring the Amount of Methadone or Morphine in the Blood of Neonates, Infants & Children After Cardiac Surgery.|A Randomized, Double-blind, Controlled, Multi-site Study of the Pharmacokinetics and Pharmacodynamics of Methadone vs. Morphine During Mechanical Ventilation Following Cardiac Surgery in Neonates, Infants and Children||Stanford University||Completed|March 2010|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|N/A|5 Years|No|||June 2012|June 5, 2012|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094522||124447|
NCT01093950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-09-FB-0235|White Light Scanning to Aid Body Contouring: A Pilot Project|White Light Scanning to Aid Body Contouring: A Pilot Project||Eastern Virginia Medical School|No|Recruiting|January 2005|October 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy, prospective, surgical candidates for body contouring surgery, including:        lipoplasty, abdominoplasty, breast reduction, breast augmentation, thigh lift,and        brachioplasty are being asked to participate in this research project.|October 2014|October 7, 2014|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01093950||124491|
NCT01091194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10920|Effect of Exercise After Heart Transplantation|Effect of High Intensity Interval-based Aerobic Exercise 1-8 Years After Heart Transplantation. 1 Year Follow Up.|TEX|Oslo University Hospital|No|Completed|October 2009|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091194||124703|
NCT01093651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEY03222010|Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV|A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women|DPPIVinHIV|Washington University School of Medicine|Yes|Completed|June 2010|June 2012|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Both|18 Years|65 Years|No|||January 2014|January 22, 2014|March 23, 2010||No||No|May 13, 2013|https://clinicaltrials.gov/show/NCT01093651||124514|Potential for type 2 error given small sample size. But, study was powered to detect significant decline in CD4 count. Measures of monocyte and lymphocyte activation should be conducted.
NCT01094184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22780|A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer|Open-label Study of Bevacizumab (Avastin) and Taxane Monotherapy for the First-line Treatment of Patients With Advanced Triple Negative Breast Cancer.||Hoffmann-La Roche||Completed|March 2010|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01094184||124473|
NCT01094483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00036|A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin|A Phase I Prospective, Randomized, Double-blind, Placebo-controlled Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN 400 and Low Dose Aspirin||AstraZeneca||Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|March 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01094483||124450|
NCT01091415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECT|Comparison of Volar Locking Plate Fixation Alone and Volar Locking Plate Fixation Plus Calcium Phosphate Bone Cement Augmentation for Distal Radius Fractures Patients Aged More Than 65|Comparison of Volar Locking Plate Fixation Alone and Volar Locking Plate Fixation Plus Calcium Phosphate Bone Cement Augmentation for Distal Radius Fractures Patients Aged More Than 65||Ewha Womans University|Yes|Completed|March 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|41|||Both|65 Years|N/A|No|||December 2009|March 23, 2010|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01091415||124686|
NCT01092299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00008|A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions|A Phase I Study to Investigate the Relative Bioavailability of Modified-release Formulations of AZD1446 Compared to an Immediate-release Capsule Under Fed and Fasting Conditions Following Single and Repeated Dose Administration to Young and Elderly Healthy Volunteers||AstraZeneca|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|62|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2010|August 26, 2010|March 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01092299||124618|
NCT01092598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H54355-35547-O1|Factors Association With Poor Physical Function in Older Adults With Schizophrenia|The Impact of Neurocognition and Symptomatology on Physical Function Among Older Adults With Schizophrenia||University of California, San Francisco|Yes|Completed|March 2010|May 2015|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|46|||Both|55 Years|N/A|No|Non-Probability Sample|English speaking adults older than or equal to 55 with a Diagnostic and Statistical Manual        of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia or schizoaffective        disorder that pass a capacity to consent test based on comprehension of the consent form.|May 2015|May 26, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092598||124595|
NCT01091974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCS07090|Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy|Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy||University of Rochester|Yes|Completed|February 2008|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|138|||Both|21 Years|75 Years|No|||August 2015|August 4, 2015|December 9, 2009||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01091974||124643|
NCT01093131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-11-097-DT / WPCI 2009-28|Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy|Oral Hydration and Alkalinization is Non-Inferior to Intravenous Therapy for Prevention of Contrast Induced Nephropathy in Patients With Chronic Kidney Disease.|HYDRATE|The Western Pennsylvania Hospital|Yes|Completed|February 2005|February 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|91|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01093131||124554|
NCT01093716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADSTMS2010|Anti-craving Efficacy of Right and Left Prefrontal High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Alcohol Dependence|Comparison of Anti-craving Efficacy of Right and Left Prefrontal High Frequency rTMS in Alcohol Dependence: a Randomized Double-blind Study||Central Institute of Psychiatry, Ranchi, India|Yes|Completed|August 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|60 Years|No|||March 2010|March 25, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01093716||124509|
NCT01093729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EXC-101|A Study of HM11260C in Healthy Male Subject|A Dose Block-randomized, Double-blind, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM11260C After Subcutaneous Administration in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|February 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|41|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2011|February 6, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01093729||124508|
NCT01093742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-GHA-101|A Study of HM10560A in Healthy Male Subject|A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM10560A After S.C. Administration in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|March 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|20 Years|54 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01093742||124507|
NCT01094015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HISTEROS-07|Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysteroscopy Practice|Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysteroscopy Practice: a Prospective Randomized Clinical Trial|HISTEROS-07|Consorci Sanitari de Terrassa|Yes|Completed|July 2007|April 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Female|18 Years|N/A|No|||March 2006|April 8, 2010|March 23, 2010||||No||https://clinicaltrials.gov/show/NCT01094015||124486|
NCT01094028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07|Intraumbilical Vein Injection of Oxytocin in Routine Practice for Active Management of the Third Stage of Labor|||Erzincan Military Hospital|Yes|Completed|December 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|412|||Female|15 Years|35 Years|Accepts Healthy Volunteers|||December 2009|March 25, 2010|March 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094028||124485|
NCT01093755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007252|Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?|Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial||Mayo Clinic|No|Completed|March 2010|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||February 2016|February 19, 2016|March 24, 2010|Yes|Yes||No|February 19, 2016|https://clinicaltrials.gov/show/NCT01093755||124506|
NCT01092533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-009998-10|Myfortic for the Treatment of Non-infectious Intermediate Uveitis|Myfortic (Enteric-coated Mycophenolate Sodium) for the Treatment of Non-infectious Intermediate Uveitis - a Prospective, Controlled, Randomized Multicenter Trial|MYCUV-IIT02|STZ eyetrial|Yes|Active, not recruiting|March 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|80 Years|No|||August 2015|August 20, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092533||124600|
NCT01093690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si094/2009|Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin|Randomized, Placebo-controlled Trial of Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis in Patients Receiving High Dose Cisplatin in Routine Medical Practice||Mahidol University|No|Completed|April 2009|October 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||November 2010|November 4, 2010|March 24, 2010||No||No|October 10, 2010|https://clinicaltrials.gov/show/NCT01093690||124511|
NCT01093963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDX BP|Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression|Adjunctive Lisdexamfetamine in Bipolar Depression||Lindner Center of HOPE|No|Terminated|January 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|March 25, 2010||No|Enrollment goals not met|No||https://clinicaltrials.gov/show/NCT01093963||124490|
NCT01094535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC0218|Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery|MRCP With Secretin Stimulation for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic Adenocarcinoma||Columbia University|Yes|Withdrawn|September 2007|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 3, 2015|March 25, 2010|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01094535||124446|
NCT01094548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR63325-008|Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy|A Randomized, Open-label, Phase II Study With Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Either Chemotherapy-naïve, Slowly Progressive, Asymptomatic Multiple Myeloma or With Stage II/III Multiple Myeloma in Stable Response/Plateau Phase Following Anti-tumor Therapy||Merck KGaA|No|Completed|January 2008|March 2012|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|March 24, 2010||No||No|October 15, 2015|https://clinicaltrials.gov/show/NCT01094548||124445|
NCT01094782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P 0001551|Evaluating the Effect of Acupuncture on Pain Relief Using Quantitative Sensory Testing (QST)|Evaluating the Effect of Acupuncture on Pain Relief Using QST||Massachusetts General Hospital|No|Recruiting|January 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01094782||124427|
NCT01094769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/10|Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease|Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy||Baker IDI Heart and Diabetes Institute|No|Recruiting|April 2011|April 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|No|||December 2013|December 16, 2013|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094769||124428|
NCT01094795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-125|Safety Study of Abatacept in Sweden|A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Sweden Using the ARTIS Register||Bristol-Myers Squibb|No|Active, not recruiting|March 2011|October 2019|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100000|||Both|N/A|N/A|No|Non-Probability Sample|Residents of Sweden|January 2016|January 26, 2016|March 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01094795||124426|
NCT01094756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75-01|Brain, Obesity, Dopamine and You Study|Central Dopamine Receptors In Obesity|BODY|Washington University School of Medicine|No|Active, not recruiting|July 2010|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01094756||124429|
NCT01091454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0937|Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|June 2010|||June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01091454||124683|
NCT01094509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02042010-4903|Activities for Cognitive Enhancement of Seniors|Tai Chi and Guided Autobiography for Remediation of Age-related Cognitive Decline|ACE-Seniors|Stanford University|No|Completed|March 2010|December 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|6||Actual|175|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 18, 2014|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094509||124448|
NCT01094730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1636AY|Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens|A Multi-site Dispensing Evaluation Comparing a New Galyfilcon A Prototype Lens With a Marketed Galyfilcon A Contact Lens||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2010|||April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|39 Years|No|||May 2015|May 6, 2015|March 24, 2010|No|Yes||No|November 4, 2011|https://clinicaltrials.gov/show/NCT01094730||124431|
NCT01094743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1636AZ|Dispensing Evaluation of a Prototype Contact Lens and a Marketed Contact Lens|||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2010|||March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|39 Years|No|||May 2015|May 6, 2015|March 24, 2010|No|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT01094743||124430|
NCT01091155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol COMPRES 23/11/2009|COMPRES - COMpression Anastomosis Ring (CAR™ 27/ColonRing™) Post maRketing Evaluation Study|COMPRES - COMpression Anastomosis Ring (CAR™ 27/ColonRing™) Post maRketing Evaluation Study|COMPRES|novoGI|Yes|Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|288|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|March 19, 2010|Yes|Yes||No|June 4, 2013|https://clinicaltrials.gov/show/NCT01091155||124706|The study had acceptable rate of AE, and technical problems.
NCT01091987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/031|Non-pharmacological Treatment of Insomnia in Nursing Homes.|Pilot Study on the Feasibility of Non-pharmacological Treatment of Insomnia in Nursing Homes.||University Ghent|No|Completed|April 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|55 Years|N/A|No|||June 2011|June 7, 2011|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01091987||124642|
NCT01092000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB: 8087B|The Nutrition Challenge: A Health Promotion Campaign|The Nutrition Challenge: A Health Promotion Campaign||University of Tennessee|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|56|||Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All participants in each group are associated with the Department of Nutrition at the        Unviersity of Tennessee.|November 2012|November 14, 2012|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01092000||124641|
NCT01092312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBMET.CR.G4|Signature Personalised Patient Care System With the Vanguard Knee System Study|Study on the Signature Personalised Patient Care System With the Vanguard Knee System||Biomet, Inc.|No|Recruiting|March 2010|May 2023|Anticipated|May 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|628|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|March 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092312||124617|
NCT01092325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-1020-01|Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure|A Phase I/IIa Dose-Escalation Study Evaluating the Safety and Tolerability of CXL-1020 and Specific Effects on Electrocardiographic and Non-Invasive Hemodynamic Parameters in Patients With Chronic Heart Failure||Cardioxyl Pharmaceuticals, Inc|Yes|Completed|June 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|28|||Both|18 Years|85 Years|No|||February 2013|February 11, 2013|March 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092325||124616|
NCT01092858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14853|NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)|Effect of Exercise Alone or in Combination With Testosterone Replacement on Muscle Strength and Quality of Life in Older Men With Low Testosterone Concentrations: a Randomized Double-blind, Placebo Controlled Study||Bayer|No|Terminated|September 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Male|60 Years|N/A|No|||November 2014|November 3, 2014|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01092858||124575|
NCT01092871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-09-1008|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2010|||||N/A|N/A|N/A||||||||||||||December 18, 2014|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092871||124574|
NCT01092832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501085|A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients|A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects||Pfizer|Yes|Terminated|October 2010|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|2 Years|17 Years|No|||August 2015|August 10, 2015|March 10, 2010|Yes|Yes|This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of    any safety issues or concerns.|No|June 2, 2014|https://clinicaltrials.gov/show/NCT01092832||124577|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.
NCT01093118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCP-TMI-7007|A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis|A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TMI-358 in the Treatment of Distal Subungual Onychomycosis of the Toenail||Talima Therapeutics, Inc.|No|Terminated|September 2009|||April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||January 2011|January 14, 2011|March 23, 2010|Yes|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT01093118||124555|
NCT01093157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006328-GN|A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy|A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN)||University Health Network, Toronto|Yes|Active, not recruiting|February 2010|February 2013|Anticipated|January 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|72 Years|No|||January 2013|January 14, 2013|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093157||124552|
NCT01093768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100068|Brain Imaging Study of Adults With Autism Spectrum Disorders|Effects of Prosocial Neuropeptides on Human Brain Function in Healthy Volunteers and Individuals With Autism Spectrum Disorders||National Institutes of Health Clinical Center (CC)||Completed|February 2010|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Diagnostic|1||Actual|38|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|February 19, 2014|March 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01093768||124505|
NCT01085071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRIP-COMPASS trial|Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients|GRIP-COMPASS Trial: Computer-driven Glucose and Potassium Regulation Program in Intensive Care Patients With COMparison of PotASSium Targets Within normokAlemic Range|GRIP-COMPASS|University Medical Center Groningen|No|Completed|June 2009|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1225|||Both|16 Years|N/A|No|||January 2013|January 18, 2013|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01085071||125172|
NCT01093443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/196|Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days|Administration of a GnRH Antagonist During 3 Days at Initiation of the Cycle: Impact on the Stimulation in IVF/ICSI||Universitair Ziekenhuis Brussel|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|39 Years|No|||November 2009|October 8, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093443||124530|
NCT01093703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005049|Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients|Randomized Trial to Explore the Effect of Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern and Improve Allograft Function in Kidney Transplant Recipients||Mayo Clinic|Yes|Completed|December 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|99|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093703||124510|
NCT01090622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPF-001-202|Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)|Phase 2a, Double-blind, Placebo-controlled, 2-period, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients With Inherited Erythromelalgia.||Xenon Pharmaceuticals Inc.|No|Completed|April 2010|September 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|75 Years|No|||March 2012|March 14, 2012|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090622||124747|
NCT01090609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scitech 002|Study to Evaluate the Safety of Cronus® - Cobalt Chromium Coronary Stent|Multicenter, Prospective, Non-randomized Study to Evaluate the Safety of Cronus® Cobalt Chromium Coronary Stent - Study After 9 Months|CRONUS|Scitech Produtos Medicos Ltda|Yes|Completed|May 2010|November 2014|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|263|||Both|18 Years|75 Years|No|||November 2014|November 13, 2014|March 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090609||124748|
NCT01090596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ResearchANY|Changes in mRNA Expression Following Exposure to Naproxen|Changes in mRNA Expression Following Exposure to Naproxen|Lesions3|Research Associates of New York, LLP|No|Completed|April 2007|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2010|March 18, 2010|March 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090596||124749|
NCT01091220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0001|Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers|A Randomized, Single-center, Double-blind, Placebo-controlled Study to Explore the Effect of a Single Dose of Certolizumab Pegol 400 mg on Semen Quality in Healthy Male Volunteers||UCB Pharma|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|September 2, 2011|March 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01091220||124701|
NCT01091701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM/CS/09-10/001|Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke|A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase -I/ II Study Assessing The Safety And Efficacy Of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells In Patients With Ischemic Cerebral Stroke||Stempeutics Research Pvt Ltd|Yes|Not yet recruiting|December 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|20 Years|80 Years|No|||June 2011|June 16, 2011|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091701||124664|
NCT01090843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 961/2009|Video Capsule Endoscopy (VCE) Comparison Study|Comparison Study of IntroMedic®'s MiroCam® and Olympus®' Enteropro EndoCapsule®||Medical University of Vienna|No|Completed|April 2010|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|85 Years|No|||October 2011|October 3, 2011|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01090843||124730|
NCT01091142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP001 Single Dose - ALS|Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)|Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)||Neuraltus Pharmaceuticals, Inc.|No|Completed|July 2010|||September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|21 Years|75 Years|No|||October 2010|October 4, 2010|March 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01091142||124707|
NCT01091428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14008|MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer|Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|May 2010|September 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|172|||Female|18 Years|N/A|No|||January 2015|January 29, 2015|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01091428||124685|
NCT01091662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093-046|Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic|Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs||Sunovion|No|Completed|June 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|16 Years|70 Years|No|||November 2015|November 16, 2015|March 17, 2010|Yes|Yes||No|October 2, 2015|https://clinicaltrials.gov/show/NCT01091662||124667|
NCT01092013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 12-2008|Comparative Evaluation of Simulator Based and Traditional In-surgery Laparoscopic Camera Training's Efficiency in Novices|||University of Zurich|Yes|Completed|September 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2010|August 3, 2010|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01092013||124640|
NCT01092026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-UCB2009|Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells|A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies||Universitair Ziekenhuis Brussel|No|Recruiting|November 2010|December 2017|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|15 Years|60 Years|No|||June 2015|June 22, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092026||124639|
NCT01092611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114083|Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine|Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462||GlaxoSmithKline||Completed|March 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|190|||Both|18 Years|55 Years|No|||November 2014|May 21, 2015|March 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092611||124594|
NCT01092884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092009-036|Polypodium Leucotomos Extract for the Treatment of Melasma|Polypodium Leucotomos Extract as an Adjunct to Sunscreen for the Treatment of Melasma||University of Texas Southwestern Medical Center||Completed|March 2010|July 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|July 23, 2012|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092884||124573|
NCT01092897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-782|Pulmonary Hypertension and Imatinib|Biomarkers in Pulmonary Arterial Hypertension Treated With Imatinib||The Cleveland Clinic|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with PAH that are enrolled in the Imatinib clinical trial.|February 2014|February 3, 2014|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01092897||124572|
NCT01092910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204|Esteem Totally Implantable Hearing System|Esteem Totally Implantable Hearing System Clinical Trial U.S. Pivotal Trial||Envoy Medical Corporation|Yes|Completed|January 2008|August 2010|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 19, 2010|Yes|Yes||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01092910||124571|
NCT01092845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0541010|Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers|Double-Blind, Randomized, Multiple-Dose, Placebo-Controlled, 2-Way Crossover Study To Study Effects of PF-04457845 On Polysomnographic Endpoints In Healthy Volunteers||Pfizer|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 14, 2010|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01092845||124576|
NCT01093144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 006/2010|Assessment of Pelvis Diameters as a Predictor for the Mode of Delivery ,Using Non-invasive, Ultrasound Based Measurements|Assessment of Pelvis Diameters as a Predictor for the Mode of Delivery ,Using Non-invasive, Ultrasound Based Measurements.||Trig Medical Inc|No|Not yet recruiting|April 2010|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 24, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093144||124553|
NCT01093170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144101a|A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy|A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy||University of Kentucky|No|Withdrawn|March 2011|October 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|N/A|No|||September 2012|September 17, 2012|March 22, 2010|No|Yes|Study was not conducted, no subjects recruited.|No||https://clinicaltrials.gov/show/NCT01093170||124551|
NCT01093495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081230|Weaning Preterm Neonates From Nasal Continuous Positive Airway Pressure|A Randomized Controlled Trial on Weaning Preterm Neonates From Nasal Continuous Positive Airway Pressure||Mansoura University|Yes|Completed|January 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|28 Weeks|36 Weeks|No|||March 2010|March 24, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093495||124526|
NCT01093781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007837|Aliskiren in Patients With Idiopathic Membranous Nephropathy|A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy||Mayo Clinic|Yes|Withdrawn|November 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||March 2013|March 12, 2013|March 24, 2010|No|Yes|Manufacturer asked to close study due to AEs experienced by subjects in other studies.|No||https://clinicaltrials.gov/show/NCT01093781||124504|
NCT01085409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82500-98-9207|The Q in the Quality Adjusted Life Years (QALY): Exploring New Methods|The Q in the QALY: Exploring New Methods|MOMENTUM|Maastricht University Medical Center|No|Completed|April 2010|December 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|139|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from the Maastricht University Medical Hospital or Adelante        centre of expertise in rehabilitation and audiology. Healthy controls will be recruited by        advertisement in local newspapers and flyers.|May 2013|May 6, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085409||125146|
NCT01093989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909M72852|Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition|Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|June 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|239|||Both|18 Months|5 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093989||124488|
NCT01094002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI02069-00|Effects of a Structured Occupational Therapy Intervention in an Acute Geriatric Unit|Effects of a Structured Occupational Therapy Intervention in an Acute Geriatric Unit. A Randomised Clinical Trial||Complejo Hospitalario Universitario de Albacete|No|Completed|November 2002|June 2003|Actual|June 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|65 Years|N/A|No|||February 2010|April 9, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01094002||124487|
NCT01093456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML6275|Diurnal Variation of Mineral Metabolism and Protein Fermentation Metabolites in Peritoneal Dialysis Patients and Healthy Volunteers|Diurnal Variation of Mineral Metabolism and Protein Fermentation Metabolites in Peritoneal Dialysis Patients and Healthy Volunteers||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|February 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|10|Samples Without DNA|whole blood, serum, urine and dialysate|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Peritoneal dialysis patients Healthy volunteers|December 2013|December 2, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01093456||124529|
NCT01094808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008469|Pregabalin and Colonic Function|Effect of Pregabalin on Colonic Sensorimotor Function in Healthy Adults.||Mayo Clinic|Yes|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|62|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|March 24, 2010|Yes|Yes||No|January 26, 2012|https://clinicaltrials.gov/show/NCT01094808||124425|
NCT01090661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPO2800209|A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects|A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial||Sanofi|Yes|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|March 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090661||124744|
NCT01090882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCW 1|Intraperitoneal Techniques of Local Anaesthesia During Laparoscopic Cholecystectomy|Efficacy of Intraperitoneal Local Anaesthetic Techniques During Laparoscopic Cholecystectomy: A Double Blind Randomized Controlled Trial||University Hospitals Coventry and Warwickshire NHS Trust|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 22, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090882||124727|
NCT01090635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1|Imaging the Uterine Cervix - UltraSightHD™|Imaging the Uterine Cervix - UltraSightHD™||STI-Medical Systems|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy non-pregnant females over 18 years old.|February 2011|February 3, 2011|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090635||124746|
NCT01090869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF-2006-6443|Physical Training Per se|Physical Activity is Healthy - Effect of Weight Loss or Physical Training Per se?|TPS|University of Copenhagen|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|60|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2007|March 22, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01090869||124728|
NCT01091168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00070 IN 308 B0|Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer|||Pierre Fabre Medicament|Yes|Active, not recruiting|September 2009|December 2013|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|594|||Female|18 Years|75 Years|No|||August 2013|August 19, 2013|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01091168||124705|
NCT01091181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-valentin|The Effect of Hysterotomy Technique on the Rate of Large Defects in the Hysterotomy Scar|The Effect of Hysterotomy Technique on the Rate of Large Defects in the Hysterotomy Scar||Region Skane|No|Recruiting|October 2009|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 25, 2013|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01091181||124704|
NCT01091675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRE-2009-01|Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs|Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to ≥2 Nonsteroidal Antiinflammatory Drug (NSAID)||Spanish Foundation of Rheumatology|Yes|Completed|September 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|March 22, 2010||No||No|May 6, 2015|https://clinicaltrials.gov/show/NCT01091675||124666|
NCT01092338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007332|Vitamin D Dose Finding Study|Safe and Effective Vitamin D Supplementation in HIV||Children's Hospital of Philadelphia|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|5 Years|24 Years|No|||August 2013|August 1, 2013|March 23, 2010||No||No|January 7, 2013|https://clinicaltrials.gov/show/NCT01092338||124615|
NCT01092351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIT 001-2006|Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults|Open Label Study on the Bacteriological and Clinical Efficacy and Safety of a Nitrofurantoin Formulation Given Twice Daily (Bid) for Seven Days in Uncomplicated Urinary Tract Infection in Adults||Mepha Ltd.|No|Completed|January 2007|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2010|March 22, 2010|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01092351||124614|
NCT01092624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TULI003042|Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse|A Randomized, Placebo-Controlled Parallel-Design Trial of the Effect of Solifenacin Treatment for Overactive Bladder in Women With Anterior Vaginal Wall Prolapse Managed With a Pessary (the "PESSARY" Study)|PESSARY|Hartford Hospital|No|Terminated|March 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|94|||Female|18 Years|N/A|No|||November 2011|November 3, 2011|March 4, 2010|Yes|Yes|sponsor closed study due to poor enrollment|No||https://clinicaltrials.gov/show/NCT01092624||124593|
NCT01083680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-278|Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine|Postmarketing Observational Study to Evaluate the Safety and Efficacy of HUMIRA (Adalimumab sc) for the Treatment of Moderate to Severe Crohn's Disease in Daily Clinical Practice||AbbVie|No|Completed|June 2007|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3969|||Both|18 Years|99 Years|No|Non-Probability Sample|Community sample: patients with Crohn's Disease|January 2016|January 25, 2016|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01083680||125278|
NCT01093183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|479-09|Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer|A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate Cancer||University of Nebraska|Yes|Active, not recruiting|March 2010|||February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Male|19 Years|N/A|No|||April 2014|April 3, 2014|March 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01093183||124550|
NCT01093508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APD916-001|Single-dose Safety Study of APD916 in Healthy Volunteers|Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects||Arena Pharmaceuticals|No|Completed|March 2010|July 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 1, 2010|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01093508||124525|
NCT01084525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-200901|OTO-104 for Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 1B Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease||Otonomy, Inc.|Yes|Completed|March 2010|April 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|75 Years|No|||June 2011|June 7, 2011|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01084525||125214|
NCT01085422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-070|A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer|A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies||AbbVie|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|N/A|No|||January 2013|January 4, 2013|March 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01085422||125145|
NCT01085682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCMC07OT255|Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program|Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program||The Catholic University of Korea|No|Completed|January 2008|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|59|||Both|30 Years|69 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|February 19, 2010||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01085682||125125|
NCT01094327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070206|Proteinuria in Pre and Post Transplant|Evaluation of Recipients With and Without Proteinuria, Pre and Post Kidney Transplantation||University of Miami|No|Recruiting|February 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|25 Years|No|Non-Probability Sample|Pediatric population up to the age of 25 years old, with biopsy diagnosed of FSGS (focal        segmental glomerulosclerosis).|January 2016|January 12, 2016|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094327||124462|
NCT01094340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG034155-01|Thalidomide for Patients With Mild to Moderate Alzheimer's Disease|"Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease||Banner Health|Yes|Recruiting|March 2010|January 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|90 Years|No|||August 2012|August 6, 2012|March 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094340||124461|
NCT01094262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017092|A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis|A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Terminated|April 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|196|||Both|40 Years|80 Years|No|||April 2015|April 13, 2015|March 25, 2010|Yes|Yes|Logistic reasons associated with the FDA-imposed clinical hold.|No||https://clinicaltrials.gov/show/NCT01094262||124467|
NCT01085396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 09-077|Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin|Optical Spectroscopy for Non-invasive Diagnosis of Melanoma and Assessment of Impact of UV Exposure on Skin||University of Pittsburgh|Yes|Terminated|March 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|16|Samples With DNA|A pigmented lesion is removed as part of the subjects routine care when it is felt to be      suspicious for severe atypica or early malignancy, and sometimes because the patient desires      removal of lesions for cosmetic reasons, or because the lesion is irritated or located in a      zone of traum.      For this research study, samples of the tumor tissue from these clinical care biopsies will      be studied.      Researchers will look at markers and search for additional characteristics that may help      them better understand Melanoma. This will be optional to subjects. If subjects do not agree      to have their tissue kept for future research purposes they can still participate in the      rest of this study.|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. normal volunteers          2. patients without personal and family history of melanoma          3. patients with personal or family history of melanoma who are followed in the UPCI             Melanoma Program with either atypical nevi or without atypical nevi.|May 2014|May 26, 2015|March 10, 2010|Yes|Yes|Ran out of funding|No||https://clinicaltrials.gov/show/NCT01085396||125147|
NCT01094561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1038|Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) as Screening in Familial Pancreatic Cancer (CA) Patients|Secretin-Stimulated MRCP as an Early Screening Modality for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot Study||Columbia University|Yes|Active, not recruiting|June 2007|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|October 22, 2013|March 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094561||124444|
NCT01094821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 276-05|Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Effect of ATI-7505 on Gastric Emptying and Small Bowel and Colonic Transit in Healthy Volunteers||Mayo Clinic|No|Completed|January 2005|December 2005|Actual|December 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 26, 2010|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094821||124424|
NCT01094834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWP05195-P002|A Multiple Dose Study of DWP05195 in Healthy Adult Subjects|A Multiple Dose Study To Determine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP05195 in Healthy Adult Subjects||Daewoong Pharmaceutical Co. LTD.|Yes|Completed|April 2010|||October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094834||124423|
NCT01090648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017038|TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients|A Study to Survey the Swallowability of Uncoated 200-mg Tablets of Etravirine in HIV-1 Infected Subjects||Tibotec Pharmaceuticals, Ireland||Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|49|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090648||124745|
NCT01091233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/722|The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study|The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study||University Hospital, Ghent|No|Suspended|March 2010|December 2015|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients with liver cirrhosis and ascites requiring Paracentesis according        to treating physician|June 2015|June 3, 2015|March 19, 2010||No|logistical problems|No||https://clinicaltrials.gov/show/NCT01091233||124700|
NCT01091207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-102|Sorafenib for Imatinib/Sunitinib-failed GIST|A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib||Samsung Medical Center|No|Completed|November 2009|August 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|November 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01091207||124702|
NCT01091467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08140|Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction|Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction: Prevalence, Characterisation and Prognostic Significance of Cardiac Desynchrony|KaRen|French Cardiology Society|Yes|Completed|October 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|362|||Both|18 Years|N/A|No|Probability Sample|Patients presenting to the hospital with congestive heart failure|September 2013|September 27, 2013|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01091467||124682|
NCT01091480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09273|French Hypertrophic Cardiomyopathy Observatory|French Hypertrophic Cardiomyopathy Observatory|REMY|French Cardiology Society|No|Recruiting|January 2010|December 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|600|||Both|15 Years|N/A|No|Probability Sample|Patients ≥ 15 years old with HCM (sarcomere of origin or not) defined by an ultrasound        thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic|February 2015|February 12, 2015|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01091480||124681|
NCT01091441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06302|Permanent Observatory of Heart Failure|Permanent Observatory of Heart Failure|ODIN|French Cardiology Society|Yes|Completed|February 2007|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3248|||Both|18 Years|N/A|No|Probability Sample|All patients with heart failure in France        The definition of heart failure selected for inclusion is that recommended by the European        Society of Cardiology (The Task Force for the Diagnosis and Treatment of Congestive Heart        Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115 -- 1140):        presence of at least two signs or symptoms of heart failure (dyspnea, edema of the ankles        crackles) at rest or during exercise associated with objective evidence (preferably by        echocardiography) of cardiac dysfunction ( systolic and / or diastolic) (resting) and in        case of doubt, a response to specific treatment of heart failure|July 2014|July 8, 2014|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091441||124684|
NCT01092039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XIGO-001|Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common Cold|XIGO Effectiveness Study: An Investigation of the Safety and Efficacy of Oral XIGO Tablets on Patients Diagnosed With the Common Cold||Xigo Health LLC|Yes|Completed|March 2010|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|July 23, 2012|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01092039||124638|
NCT01092364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018786|Cell Phone Intervention in Young Adults|Cell Phone Intervention in Young Adults|CITY|Duke University|Yes|Completed|November 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|365|||Both|18 Years|35 Years|No|||October 2015|November 2, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092364||124613|
NCT01083368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE7808|Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy|Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)||Case Comprehensive Cancer Center|Yes|Completed|January 2009|October 2014|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|N/A|No|||August 2015|August 12, 2015|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01083368||125302|
NCT01083693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-726|Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs|An Open Label Multicenter Post Marketing Observational Study for the Evaluation of Quality of Life Outcomes and Tolerability of HUMIRA in Routine Clinical Use in Patients With RA PsA AS After Unsustainable Response to Disease Modifying Antirheumatic Drugs and or Biologicals||Abbott|No|Completed|September 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic and medical practice specialized in rheumatology|August 2011|August 9, 2011|February 28, 2010||No||No|June 28, 2011|https://clinicaltrials.gov/show/NCT01083693||125277|
NCT01084005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.63|Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes|A Phase III Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin (5 mg) Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients (Age >= 70 Years) With Insufficient Glycaemic Control( HbA1c >= 7.0) Despite Metformin and/or Sulphonylurea and/or Insulin Therapy||Boehringer Ingelheim||Completed|March 2010|||June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|241|||Both|70 Years|N/A|No|||December 2013|December 11, 2013|March 9, 2010||||No|June 14, 2012|https://clinicaltrials.gov/show/NCT01084005||125254|
NCT01084018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 09.214|Development and Evaluation of a Nursing Virtual Intervention Tailored for Pain After Cardiac Surgery|Development and Evaluation of a Nursing Virtual Intervention Tailored for Pain After Cardiac Surgery-SOULAGETAVIE|SOULAGETAVIE|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Completed|February 2010|September 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|September 14, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01084018||125253|
NCT01084265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP25345|A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism|Clinical Trial on Application of Injectable Recombinant Human Luteinizing Hormone (Luveris®) in the Treatment of Chinese Female Patients With Hypogonadotropic Hypogonadism: A Multi-center, Open, Prospective Drug Clinical Trial for Registration||Merck KGaA||Completed|February 2004|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|N/A|N/A|No|||December 2013|December 2, 2013|March 4, 2010|No|Yes||No|February 6, 2012|https://clinicaltrials.gov/show/NCT01084265||125234|
NCT01084798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200077-503|A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years|A Retrospective Study On The Management of Multiple Sclerosis (MS) Over The Last 10 Years||Merck KGaA|No|Completed|August 2008|November 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|123|||Both|N/A|N/A|No|Non-Probability Sample|Subjects diagnosed with MS between 1997 and 2007 in Taiwan|March 2010|July 30, 2014|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084798||125193|
NCT01081431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MDS-PI-409|Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q|A Multicenter, Single-arm, Open-label Phase II Study of the Safety of Lenalidomide Monotherapy and Markers for Disease Progression in Patients With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Associated With an Isolated Deletion 5q Cytogenetic Abnormality (Del 5q)|MDS-LE-MON-5|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||March 2013|March 11, 2013|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01081431||125450|
NCT01081444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/122/HP|Repetitive Transcranial Stimulation (rTMS) in Post Stroke Dysphagia|Effect of Pharyngeal Inhibition Induced by Repetitive Transcranial Stimulation in Post Stroke Dysphagia|rTMS AVC|University Hospital, Rouen|No|Completed|March 2009|October 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||March 2012|March 22, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01081444||125449|
NCT01094275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003846|Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole|Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole||The Methodist Hospital System|No|Recruiting|January 2010|August 2017|Anticipated|June 2017|Anticipated|Phase 4|Observational [Patient Registry]|Observational Model: Case-Crossover, Time Perspective: Prospective||4|Anticipated|75|None Retained|Cheek swabs for DNA, blood samples for drug metabolite estimation and platelet function      study.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy subjects aged 18-65.|March 2016|March 15, 2016|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094275|6 Months|124466|
NCT01094288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14009|A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen|A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|September 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01094288||124465|
NCT01081691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015574|A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 5825 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects||Centocor, Inc.||Completed|February 2010|September 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 30, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01081691||125431|
NCT01090908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-3100-1001|Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa|A Multi-Center, Open Label Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Ciprofloxacin For Inhalation (CFI) Given Daily For 14 Days To Stable Cystic Fibrosis Patients Ages 6 To 17 With Pseudomonas Aeruginosa||Aradigm Corporation|No|Withdrawn|September 2010|June 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|0|||Both|6 Years|18 Years|No|Non-Probability Sample|Pediatrics|August 2012|August 27, 2012|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090908||124725|
NCT01085916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KingAbdulazizMC 001|Prevalence of Asthma and Rhinitis Symptoms Among Secondary School Students in Saudi Arabia|Prevalence of Asthma and Rhinitis Symptoms Among Secondary School Students in Saudi Arabia||King Abdulaziz Medical City|Yes|Enrolling by invitation|April 2010|May 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|4000|||Both|15 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|4000 students will be selected out of secondary schools for boys and girls , Their ages        range from 16 to 18 years.|February 2010|March 11, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085916||125107|
NCT01085929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMass12522|Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses|Ultrasound Guided Needle Drainage Versus Formal Incision and Drainage of Superficial Soft Tissue Abscesses in the Emergency Department Setting||University of Massachusetts, Worcester|No|Completed|August 2008|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||March 2010|March 11, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085929||125106|
NCT01090895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Violi012009|Treatment of Reperfusion Event by Vitamin C Infusion|Effect of Vitamin C Infusion on Coronary Reperfusion Indexes|TREVI|University of Roma La Sapienza|Yes|Recruiting|March 2010|December 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|No|||March 2016|March 8, 2016|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090895||124726|
NCT01081938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04572|Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition|National, Phase IV, Multicentric, Open Label, Comparative Study to Evaluate the Efficacy and Safety of Insulin Glargine Plus Glulisine and Sliding Scale Plus Glulisine in Hospitalized Patients With Diabetes Metabolism Type II Under Enteral Nutrition.||Sanofi|No|Terminated|February 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2012|March 26, 2012|March 4, 2010||No|Recruitment challenges|No||https://clinicaltrials.gov/show/NCT01081938||125412|
NCT01091688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25701|The Impact of Just-in-time Information on Neonatal Intensive Care Unit (NICU) Discharges|The Impact of "Just-in-time" Information on NICU Discharges||Baylor College of Medicine|No|Completed|March 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|229|||Both|N/A|N/A|No|||July 2015|July 24, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091688||124665|
NCT01092052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDCA-354-002|Study of NMS-1116354 in Advanced/Metastatic Solid Tumors|A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced/Metastatic Solid Tumors||Nerviano Medical Sciences|No|Terminated|January 2010|||July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||September 2012|September 6, 2012|March 22, 2010||No|Discontinuation of clinical investigation with NMS-1116354|No||https://clinicaltrials.gov/show/NCT01092052||124637|
NCT01083108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100064|Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus|Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus||National Institutes of Health Clinical Center (CC)||Completed|February 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|5|||Both|18 Years|60 Years|No|||April 2015|April 9, 2015|March 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01083108||125322|
NCT01082835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0081122|Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study|Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat), Randomized, Parallel-controlled, Multi-center Clinical Study|JZQG|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|March 2010|August 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|65 Years|No|Probability Sample|Combined metabolic syndrome in patients with essential hypertension|March 2010|March 15, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082835||125343|
NCT01083121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-053|Surveillance of Humira Injection in Korean Patients|Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"||AbbVie|No|Completed|April 2007|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1779|||Both|19 Years|N/A|No|Non-Probability Sample|Primary care clinics, general hospitals|August 2013|August 20, 2013|February 24, 2010||No||No|June 13, 2013|https://clinicaltrials.gov/show/NCT01083121||125321|
NCT01083381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09123272376|Is MS14 Helpful in Schizophrenia?|The Effect of MS14 in Association With Risperidone in Treatment of Schizophrenia: A Double Blind Randomized Control Trial||Farzan Institute|Yes|Recruiting|February 2010|April 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2010|March 8, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083381||125301|
NCT01084031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0470|Dose Titration of Propofol for Tracheal Intubation in Children With Sevoflurane Inhalation Induction|Dose Titration of Propofol for Tracheal Intubation in Children With Sevoflurane Inhalation Induction||Yonsei University|Yes|Completed|November 2009|March 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|50|||Both|6 Months|5 Years|No|||February 2014|February 17, 2014|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01084031||125252|
NCT01084044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0420|Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery|Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery||Yonsei University|Yes|Completed|January 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|20 Years|N/A|No|||January 2012|January 31, 2012|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01084044||125251|
NCT01084538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-231|Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis|A One-year, Multicountry, Multicenter Study of Zemplar Injections in Patients With End Stage Chronic Kidney Disease, Undergoing Hemodialysis, Not Adequately Controlled With Oral Vitamin D Receptor Activator (Calcitriol or Alfacalcidol)||Abbott|No|Completed|September 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|181|||Both|18 Years|N/A|No|Non-Probability Sample|Haemodialysis patients|September 2011|September 19, 2011|February 22, 2010||No||No|June 30, 2011|https://clinicaltrials.gov/show/NCT01084538||125213|
NCT01081717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016720|Golimumab Safety and Surveillance Program Using the Ingenix NHI Database|A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments||Janssen Biotech, Inc.|No|Active, not recruiting|April 2009|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|1000|||Both|N/A|99 Years|No|Non-Probability Sample|This study will include cohorts of patients who have claims consistent with a diagnosis of        rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who initiate        golimumab, anti-TNF biologics, non-anti-TNF biologics, or systemic non-biological        treatments, within the Ingenix Normative Health Informatics Database.|March 2016|March 24, 2016|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081717||125429|
NCT01085734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA001|Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion|A 6-Month, Single Site, Masked, Randomized,Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion||Maturi, Raj K., M.D., P.C.|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 10, 2010|Yes|Yes||No|April 24, 2013|https://clinicaltrials.gov/show/NCT01085734||125121|
NCT01085747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98/13/03/03/08|Endoscopic Treatment of Biliary Stricture Caused by Chronic Pancreatitis|Covered Self-expandable Metal Stents Versus Multiple Plastic Stents for Benign Biliary Stricture Caused by Chronic Pancreatitis: a Prospective Randomized Study||Helsinki University Central Hospital|No|Active, not recruiting|March 2008|May 2015|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|All consecutive patients admitted for ERCP and treated for benign biliary stricture caused        by chronic pancreatitis are prospectively enrolled in the study.|August 2013|August 14, 2013|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01085747||125120|
NCT01084772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISSTD01|Visionaire™ Versus Standard Instrumentation Safety and Efficacy in Total Knee Arthroplasty (TKA)|A Multicenter, Randomized, Clinical Outcome of VISIONAIRE™ Patient Matched Technology vs. Standard Surgical Instrumentation in Total Knee Arthroplasty||Smith & Nephew, Inc.|No|Recruiting|April 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|196|||Both|N/A|N/A|No|||March 2016|March 2, 2016|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01084772||125195|
NCT01084785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-06-23/01|Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer|Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic|Biobank|Maastricht Radiation Oncology|No|Recruiting|January 2003|January 2025|Anticipated|January 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|December 2012|December 27, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084785||125194|
NCT01094301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDI-0122-CSP-001|Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain|A Prospective Multi-Center Pilot Study of the SPR™ System for the Treatment of Post-Stroke Shoulder Pain||NDI Medical, LLC||Recruiting|April 2010|||June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|45|||Both|21 Years|N/A|No|||February 2016|February 17, 2016|March 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094301||124464|
NCT01094314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML4562|Impact of Culture Medium on Embryo Quality|||University Hospital, Gasthuisberg|No|Completed|January 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|790|||Both|N/A|3 Days|Accepts Healthy Volunteers|||March 2010|March 25, 2010|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094314||124463|
NCT01082276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050270|Rifampin Drug-Drug Interaction Study With Lurasidone HCl|||Sunovion|Yes|Completed|August 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082276||125386|
NCT01082289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050279|Digoxin Drug-Drug Interaction With Lurasidone HCl|A Phase 1, Open-Label, Drug-Drug Interaction Study to Determine the Effect of Repeated Dose Lurasidone 120 mg Administration on the Pharmacokinetics of Orally Administered Digoxin 0.25 mg in Patients With Schizophrenia or Schizoaffective Disorder.||Sunovion||Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment|||Actual|24|||Both|18 Years|65 Years|No|||September 2011|September 6, 2011|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082289||125385|
NCT01085656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF OXi4503 AML MDS|A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS|A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)||University of Florida|Yes|Terminated|February 2011|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01085656||125127|
NCT01082250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050263|The Bioequivalence Of Two Different Lurasidone Formulations In Patients|AN OPEN-LABEL, RANDOMIZED, THREE-PERIOD, TWO-SEQUENCE CROSSOVER, REPEATED-DOSE, REPLICATE DESIGN STUDY TO DETERMINE THE BIOEQUIVALENCE OF TWO DIFFERENT LURASIDONE FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE, OR SCHIZOPHRENIFORM DISORDER||Sunovion|Yes|Completed|July 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|52|||Both|18 Years|65 Years|No|||September 2011|September 6, 2011|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082250||125388|
NCT01082263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050269|Midazolam Drug-Drug Interaction Study With Lurasidone HCl|||Sunovion|Yes|Completed|October 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|65 Years|No|||September 2011|September 6, 2011|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082263||125387|
NCT01082627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nanjing Jinling Hospital|Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction|Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction||Nanjing PLA General Hospital|Yes|Completed|June 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||February 2010|August 2, 2011|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082627||125359|
NCT01081678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080394|Study To Assess Fracture Healing With Sclerostin Antibody|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults With a Fresh Unilateral Hip Fracture, Status Post Surgical Fixation||Amgen||Completed|June 2010|January 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|332|||Both|55 Years|95 Years|No|||January 2014|January 15, 2014|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081678||125432|
NCT01082861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIS144|Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination|A Phase 4, Randomized, Open Label Clinical Trial to Determine Efficacy and Immunomodulation of Simultaneous HPV/HBV Vaccination Tango-trial)|TANGO|National Institute for Public Health and the Environment (RIVM)|No|Terminated|September 2010|April 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|0|||Female|11 Years|12 Years|Accepts Healthy Volunteers|||March 2010|March 18, 2010|March 8, 2010||No|Due to recent strategic policy developments in the national vaccination program it is    uncertain preadolescent girls will receive the HBV vaccin.|No||https://clinicaltrials.gov/show/NCT01082861||125341|
NCT01083134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-4077B|The Correlation of Heart Hemodynamic Status Between 320 Multidetector Computed Tomography, Echocardiography and Cardiac Catheterization in Patients With Coronary Artery Disease|||Chang Gung Memorial Hospital|Yes|Recruiting|March 2010|March 2020|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|According to Diamond and Forrester colleague, there are risks including age, gender,        smoking, diabetes, and dyslipidemia for coronary artery disease.|June 2011|July 28, 2014|March 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01083134||125320|
NCT01083147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ForeseeHome-US3|Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment|Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment|AMD|Notal Vision Ltd|Yes|Completed|October 2009|September 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|50 Years|N/A|No|Probability Sample|intermediate AMD|September 2010|September 22, 2010|March 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01083147||125319|
NCT01091714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2010|Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?|Is Omega-3 Fatty Acid RBC Saturation Product Dependent?||Bucci Laser Vision Institute|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091714||124663|
NCT01082822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEFMMU|Periodontal Ligament Stem Cell Implantation in the Treatment of Periodontitis|Periodontal Ligament Stem Cell Implantation in the Treatment of Periodontitis||Fourth Military Medical University|Yes|Active, not recruiting|January 2010|January 2012|Anticipated|November 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|40 Years|50 Years|Accepts Healthy Volunteers|||October 2009|March 8, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082822||125344|
NCT01082848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIANE|ARIpiprazole in Anorexia NErvosa|Efficacy of Aripiprazole in the Treatment of Anorexia Nervosa in Teenagers: a Pilot, Randomised, Double Blind, Placebo-controlled Clinical Trial|ARIANE|Hospital Clinic of Barcelona|No|Recruiting|March 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|18 Years|No|||February 2013|February 21, 2013|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082848||125342|
NCT01085123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1220C00005|Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers|An Open Label, Positron Emission Tomography (PET) Study With [11C]AZ10419369 to Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers||AstraZeneca|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 2, 2010|March 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01085123||125168|
NCT01085136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.42|LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib|Phase III Randomized Trial of BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Previous Erlotinib or Gefitinib Treatment (LUX Lung 5)||Boehringer Ingelheim||Completed|February 2010|January 2016|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1155|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 10, 2010||||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01085136||125167|
NCT01084278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-09-1028|Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)|Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease||Takeda|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|March 8, 2010|Yes|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT01084278||125233|
NCT01084551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-09-001|Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)|A Phase 3 Multi-Center, Placebo-Controlled, Double Blind, 3-Armed Parallel Group, Comparative Study of SPM 962 4.5 and 6.75 mg/Day to Investigate Superiority to Placebo in Patients With Restless Legs Syndrome||Otsuka Pharmaceutical Co., Ltd.|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|284|||Both|20 Years|79 Years|No|||May 2014|May 28, 2014|March 4, 2010||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01084551||125212|
NCT01084564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CCO-ATA-2007/1|Economic Evaluation of Heart Failure Management in Colombian Clinics|Economic Evaluation of Heart Failure Management in Colombian Clinics|EconoHeart|AstraZeneca|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Both|18 Years|65 Years|No|Probability Sample|Moderate to severe uncontrolled asthma.|March 2010|March 9, 2010|March 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01084564||125211|
NCT01084811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1720(REK)|Chronic Rhinosinusitis: Biochemical Markers and Biofilm|||University Hospital, Akershus|No|Recruiting|April 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|230|Samples With DNA|Nasal mucosa and nasal polyps|Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to sinonasal surgery at Ahus, Norway|July 2010|July 6, 2011|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084811||125192|
NCT01085695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-033|Study of E3810 for Healthy Japanese Male (Under Fasting Condition)|A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Fasting Condition)||Eisai Inc.||Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||September 2010|May 9, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085695||125124|
NCT01085084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-LAQ-202|Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus Arthritis||Teva Pharmaceutical Industries|Yes|Completed|July 2010|October 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|75 Years|No|||September 2013|September 23, 2013|March 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085084||125171|
NCT01085097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LN-LAQ-201|Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids)||Teva Pharmaceutical Industries|No|Completed|July 2010|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|75 Years|No|||March 2014|March 17, 2014|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085097||125170|
NCT01085721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POE/P/09-1|Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections|Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in the Relief of Allergic Symptoms in Rhinitic Patients With Viral Upper Respiratory Tract Infections and Productive Cough||Mantecorp Industria Quimica e Farmaceutica Ltd.|Yes|Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|60 Years|No|||March 2010|March 10, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01085721||125122|
NCT01085760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008247|A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis|A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis|PSC|Mayo Clinic|No|Completed|February 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|75 Years|No|||July 2013|July 12, 2013|March 10, 2010|Yes|Yes||No|November 2, 2012|https://clinicaltrials.gov/show/NCT01085760||125119|
NCT01085669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 304/09|Infection Rate of Vertical Expandable Prosthetic Titanium Rib Implants (VEPTR)|Infection Rate of VEPTR-Implants in Children With Severe Spinal and Thoracic Deformities||Centre Hospitalier Universitaire Vaudois|No|Recruiting|September 2009|May 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|1 Year|30 Years|No|Non-Probability Sample|Children with severe spinal or throacic deformities treates with VEPTR-implants. In these        patients the implant has to be revised every half a year due to grow and achieved        correction.|March 2010|March 11, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085669||125126|
NCT01094847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_J1252001P|Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine|Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine||Daewoong Pharmaceutical Co. LTD.||Completed|April 2010|||May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|30|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 19, 2011|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094847||124422|
NCT01094860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0717|Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies|A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Recruiting|June 2010|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|N/A|N/A|No|||November 2015|November 17, 2015|March 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01094860||124421|
NCT01082328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700773-503|Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period|ENDURE: A Phase IV, Prospective, Open-label, Uncontrolled, Multi-centre Cohort Trial to Assess the Responsiveness of Subjects With Phenylketonuria (PKU) to Treatment With Kuvan® 20 mg/kg/Day for 28 Days|ENDURE|Merck KGaA|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|4 Years|N/A|No|||January 2014|January 26, 2014|March 5, 2010||No||No|May 31, 2013|https://clinicaltrials.gov/show/NCT01082328||125382|
NCT01082341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVDC-2008-005|Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites|Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites|SPZ-Irrad|Malaria Vaccine and Drug Development Center|Yes|Active, not recruiting|June 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082341||125381|
NCT01081951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0810C00041|Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer|A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer||AstraZeneca|No|Active, not recruiting|February 2010|December 2016|Anticipated|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Female|18 Years|125 Years|No|||November 2015|December 4, 2015|February 26, 2010|Yes|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT01081951||125411|
NCT01081964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-101-200|Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia|A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity||IASO Pharma Inc.|No|Terminated|March 2010|June 2012|Anticipated|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||May 2012|May 4, 2012|February 19, 2010|Yes|Yes|Financial considerations|No||https://clinicaltrials.gov/show/NCT01081964||125410|
NCT01082237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1MH088438|Biomarkers for Outcomes In Late-life Depression (BOLD)|Biomarkers for Outcomes In Late-life Depression|BOLD|University of California, Los Angeles|Yes|Completed|October 2009|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|62 Years|N/A|No|||April 2013|April 15, 2013|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082237||125389|
NCT01083407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral care and VAP in children.|Oral Care Interventions and Ventilator Associated Pneumonia in Critically Ill Children|Oral Care Interventions With 0.12% Chlorhexidine and Ventilator Associated Pneumonia in Critically Ill Children: Prospective, Randomic and Double Blind Study||Federal University of São Paulo|No|Completed|June 2005|June 2008|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|146|||Both|N/A|18 Years|No|||March 2009|March 8, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01083407||125299|
NCT01082874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POISE-2 01MAR2010|PeriOperative ISchemic Evaluation-2 Trial|A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event|POISE-2|McMaster University|Yes|Completed|July 2010|January 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|10010|||Both|45 Years|N/A|No|||April 2015|April 7, 2015|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082874||125340|
NCT01083732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.89|Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age|Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Successive Groups of Children Aged 2 Years to Less Than 12 Years Followed by 1 Year to Less Than 2 Years||Boehringer Ingelheim||Completed|March 2010|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|1 Year|11 Years|No|||February 2016|February 23, 2016|March 8, 2010||||No||https://clinicaltrials.gov/show/NCT01083732||125274|
NCT01084070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARGERICH1|Early Oral Feeding Versus Traditional Postoperative Care in Emergency Abdominal Surgery|Randomized Clinical Trial of Early Oral Feeding Versus Traditional Postoperative Care in Emergency Abdominal Surgery||Hospital General de Agudos “Dr. Cosme Argerich”|No|Completed|March 2010|September 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|336|||Both|14 Years|N/A|No|||June 2012|June 11, 2012|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084070||125249|
NCT01084083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000665170|Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer|A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx||Eastern Cooperative Oncology Group|No|Completed|March 2010|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|March 9, 2010|Yes|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01084083||125248|
NCT01091727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0922006|Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity|Prospective Randomized Double-blind Trial of Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Spinal Cord Injury or Multiple Sclerosis||Sunnybrook Health Sciences Centre|No|Completed|October 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|75 Years|No|||March 2010|March 22, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091727||124662|
NCT01082601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-137|Catheter Ablation for Atrial Fibrillation and Heart Failure|Pulmonary Vein Isolation for Rhythm Control in Patients With Atrial Fibrillation and Left Ventricular Dysfunction: A Pilot Study||St. Luke's-Roosevelt Hospital Center|Yes|Withdrawn|April 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients seen in either the out patient or in hospital environment at St.Luke's-Roosevelt        Hospital or The Valley Hospital, Ridgewood New Jersey, with systolic left ventricular        dysfunction and atrial fibrillation. Class I-III CHF based on symptoms(shortness of        breath,fatigue, peripheral edema and documented ejection fraction of less than 40%.|June 2011|October 15, 2012|March 5, 2010||No|no enrollment|No||https://clinicaltrials.gov/show/NCT01082601||125361|
NCT01082614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59162|Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Abdominal Surgery|Evaluation of the Use of Arterial Pulse Waveform Contour Analysis for Early Goal Directed Therapy in Patients Undergoing Major Abdominal Surgery||Loma Linda University|No|Completed|August 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|March 3, 2010|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01082614||125360|
NCT01084057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08166|Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer|Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer||City of Hope Medical Center|Yes|Active, not recruiting|May 2010|||June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|March 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01084057||125250|
NCT01084304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0172|Assessment of Stress Levels in Consumers Using Ovulation Tests in Order to Conceive|Assessment of Stress Levels in Consumers Using Ovulation Tests in Order to Conceive||SPD Development Company Limited|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|Urine samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Females aged 18 to 40 wishing to become pregnant|September 2011|August 14, 2012|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084304||125231|
NCT01084317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/603/09/KB|Evaluation of the Delay in Asthma Diagnosis in Children From the Lodz Region|Evaluation of the Delay in Asthma Diagnosis in Children From the Lodz Region After the Program for Prevention of Allergic Diseases||Medical Universtity of Lodz|Yes|Completed|March 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|907|||Both|6 Years|18 Years|No|Probability Sample|patients under 18 age, with newly diagnosed asthma,|February 2013|February 6, 2013|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084317||125230|
NCT01085435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-15627; DN 15677|Boston Scientific Post Market S-ICD Registry|Evaluation oF Factors ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD (The EFFORTLESS S-ICD Registry)|EFFORTLESS|Boston Scientific Corporation|Yes|Active, not recruiting|October 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Post CE mark ICD patients eligible for implantation of the S-ICD system|September 2014|December 1, 2014|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085435||125144|
NCT01085708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-034|A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)|A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)||Eisai Inc.||Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||September 2010|May 9, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085708||125123|
NCT01085149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|h123-HMO-CTIL|The Effect Of Simvastatin On Bone Remodeling In Socket Of Mandibular Teeth|||Hadassah Medical Organization|Yes|Not yet recruiting|May 2010|||October 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 10, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085149||125166|
NCT01081418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2005-001069-32|Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders|Assertive Community Treatment (ACT) as Part of Integrated Care Versus Standard Care: a 12-month Trial in Patients With First- and Negatively Selected Multiple-episode Schizophrenia-spectrum Disorders Treated With Quetiapine IR|ACCESS|Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2005|April 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|65 Years|No|||March 2010|March 4, 2010|March 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081418||125451|
NCT01112917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-104|VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial|VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial||B. Braun Interventional Systems, Inc|Yes|Completed|December 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|149|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01112917||123039|
NCT01113450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAN Cuiaba|Results of a Program of Newborn Hearing Screening (NHS) in Cuiaba-Brazil|Results of a Program of Newborn Hearing Screening in Cuiaba-Brazil||Centro de Diagnostico Auditivo de Cuiaba|Yes|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|3148|||Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|There were two groups:          1. high risk for hearing loss          2. low risk for hearing loss|December 2009|April 29, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01113450||122998|
NCT01113463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0759|TPI 287 in Patients With Recurrent Glioblastoma Multiforme|A Phase 2 Open-Label Study of the Efficacy of TPI 287 in Patients With Glioblastoma Multiforme That Has Recurred or Progressed Following Prior Therapy With Radiation Plus Temozolomide||M.D. Anderson Cancer Center|No|Terminated|April 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|April 27, 2010|Yes|Yes|Low Accrual|No||https://clinicaltrials.gov/show/NCT01113463||122997|
NCT01113723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019845|Intubation of Patients With an Unstable Cervical Spine Using the CMAC Device|A Randomized Prospective Study to Compare Tracheal Intubation With the CMAC Device to Fiberoptic Bronchoscopy in Patients With an Unstable Cervical Spine||Cedars-Sinai Medical Center|Yes|Completed|December 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|140|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|April 23, 2010||No||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01113723||122977|
NCT01113489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002565|Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone|Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone||Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|6 Years|14 Years|No|||May 2010|July 26, 2010|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01113489||122995|
NCT01083472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFC2009.01.01|Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair (StAR)|A Multicenter, Prospective, Single-Blind, Randomized, Controlled Study of the Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair|StAR|LifeCell|Yes|Terminated|March 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|March 8, 2010|Yes|Yes|Surgical practice evolution changed acceptable standard of care and lead to potential    enrollment bias.|No|September 18, 2013|https://clinicaltrials.gov/show/NCT01083472||125294|
NCT01083485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN4505|OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty|A Randomised, Double-blind, Parallel Group Multicentre Study to Demonstrate Non-inferiority of the Analgesic Efficacy of Oxycodone/Naloxone 10/5 or 20/10 mg Prolonged Release Tablets (OXN PR) BID Compared to Oxycodone 10 or 20 mg Prolonged Release Tablets (OXY PR) BID in Subjects With Postoperative Pain After Knee Arthroplasty|OXN4505|Mundipharma Oy|No|Completed|March 2010|November 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|75 Years|No|||February 2012|February 15, 2012|March 8, 2010||No||No|June 10, 2011|https://clinicaltrials.gov/show/NCT01083485||125293|
NCT01083862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIMDM-CS09052/GR090501|Impact of Health Literacy on Outcomes and Effectiveness of Shared Decision Making Programs in Patients With Chronic Diseases|||University of Cincinnati|No|Completed|October 2005|September 2009|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|187|||Both|18 Years|N/A|No|||March 2010|March 9, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01083862||125265|
NCT01114009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFHR9803|Effects of Recruitment Maneuvers in Early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) Patients|Effects of Recruitment Maneuvers in Early ALI and ARDS Patients||Chi Mei Medical Hospital|Yes|Completed|March 2009|July 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|19 Years|N/A|No|||August 2013|August 1, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01114009||122955|
NCT01084148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00034 CR 308 ORF|Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis|Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis||Orfagen|No|Completed|January 2007|March 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|March 9, 2010||No||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01084148||125243|
NCT01084668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-708|Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs|A Post-marketing Observational Study of the Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic DMARDs Over a Period of 1 Year (QUALITY)|QUALITY|Abbott|No|Completed|November 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital, Dermatology|June 2012|June 25, 2012|February 28, 2010||No||No|April 26, 2012|https://clinicaltrials.gov/show/NCT01084668||125203|
NCT01084681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Balt 2010-01|Efficacy Trial of Intracranial Aneurysm Treatment Using Two Different Endovascular Techniques|Multicenter Randomized Trial on Selective Endovascular Aneurysm Occlusion With Coils Versus Parent Vessel Reconstruction Using the SILK Flow Diverter (MARCO POLO Post-Market Clinical Investigation)||Balt International|No|Recruiting|March 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01084681||125202|
NCT01084941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00030742|Lifestyle Intervention to Limit Excessive Weight Gain During Pregnancy in Minority Women|Lifestyle Intervention to Limit Excessive Weight Gain During Pregnancy in Minority Women||Emory University|Yes|Completed|April 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|57|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|November 20, 2013|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084941||125182|
NCT01084954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040907|Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection|Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection||George Washington University|No|Active, not recruiting|March 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Infectious Disease clinic|August 2015|August 18, 2015|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084954||125181|
NCT01085279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fractional-3|Fractional Laser as Treatment Option for Various Pigment Disorders (Fractional-3)|Non-ablative 1,550 nm Fractional Laser Therapy Versus Triple Topical Therapy for the Treatment of Melasma: a Randomized Controlled Split-face Study||Netherlands Institute for Pigment Disorders|Yes|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||March 2010|March 10, 2010|March 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085279||125156|
NCT01085292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXE36C101|NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus|NOX-E36 - A Phase Ib, Multiple Intravenous Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties in Healthy Subjects and Then in Three Groups of Patients With Type 2 Diabetes Mellitus to Compare Three Ascending Dose Regimens in a Double-blind and Placebo-controlled Manner||NOXXON Pharma AG|Yes|Completed|July 2010|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085292||125155|
NCT01115101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KJ-2009-MD|Superiority Study for Pain Treatment After Cesarean|A Randomized Controlled Trial: Pain Management After Cesarean Section: Oxycodon vs. Intravenous Piritramide||University of Rostock|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|239|||Female|18 Years|N/A|No|||January 2013|January 15, 2013|April 27, 2010||No||No|February 21, 2012|https://clinicaltrials.gov/show/NCT01115101||122871|
NCT01115556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4836S|A Pilot Study to evaLuate the Role of High-dose rAnbizumab (2.0mg) in the Management of AMD in Patients With perSistent/recurrenT Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)|This is a Single-masked Study to Compare Intravitreally Administered 0.5 mg Ranibizumab to 2.0 mg Ranibizumab in Subjects Who Manifest Persistent or Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy.|LAST|Vitreous -Retina- Macula Consultants of New York||Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|9|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 30, 2015|April 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01115556||122836|
NCT01115348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALGOT|SALGOT; Stroke Arm Longitudinal Study at the University of GOThenburg|Stroke Arm Longitudinal Study at the University of Gothenburg;SALGOT|SALGOT|Göteborg University|No|Active, not recruiting|March 2009|December 2016|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|The group consists of consecutively included persons from stroke units (Sahlgrenska        University Hospital)|March 2016|March 15, 2016|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01115348||122852|
NCT01115582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAC-001-01|Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis|Open Label, Single Center, Nonrandomized Study Comparing Efficacy of To Be Marketed Cholic Acid With That of the Currently Used Formulation of Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis||Retrophin, Inc.|No|Completed|April 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|N/A|N/A|No|||April 2015|April 15, 2015|January 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01115582||122834|
NCT01115907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G100014|Freedom SOLO Stentless Heart Valve Study|Clinical Investigation of the Freedom SOLO Stentless Heart Valve in North America|SOLO|Sorin Group USA, Inc.|Yes|Completed|December 2010|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|251|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01115907||122811|
NCT01116206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017173|An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation|A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prucalopride (Resolor) Tablets in Participants With Chronic Constipation|Resolor|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|507|||Both|18 Years|65 Years|No|||March 2016|March 24, 2016|May 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01116206||122788|
NCT01116752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005792|Pediatric Intensive Care Units (ICUs) at Emory-Children's Center Glycemic Control: The PedETrol Trial|Pediatric ICUs at Emory-Children's Center Glycemic Control: The PedETrol Trial|PedETrol|Indiana University|Yes|Completed|August 2010|August 2015|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|1 Month|18 Years|No|||August 2015|August 28, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116752||122746|
NCT01116479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-109|Optimal Transfusion in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)|Randomised Feasibility Study of Optimal Transfusion Thresholds in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)|HaemOPtimal|Rigshospitalet, Denmark|No|Terminated|March 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|April 28, 2010||No|low accrual|No||https://clinicaltrials.gov/show/NCT01116479||122767|
NCT01116492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1948-05|Study of the Inflammatory Reaction in Standard vs Single Port Cholecystectomy for Uncomplicated Cholelithiasis|Study of the Inflammatory Reaction in Standard vs Single Port Cholecystectomy for Uncomplicated Cholelithiasis|Lap vs SILS|G. Hatzikosta General Hospital|Yes|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|N/A|N/A||||May 2010|May 20, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01116492||122766|
NCT01116726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0894|Promoting Behavioral Change for Oral Health in American Indian Mothers and Children|Promoting Behavioral Change for Oral Health in American Indian Mothers and Children||University of Colorado, Denver|Yes|Active, not recruiting|August 2011|August 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|15 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01116726||122748|
NCT01082978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHF-06-124-ML|Portable Health Files Improve Quality of Care and Health Outcomes: a Randomized Controlled Trial|A Randomized Controlled Trial of Portable Electronic(USB)and Paper Medical Records as an Adjunct to Usual Care (Portable Health File RCT): an Evaluation of Short Term Quality Measures and Long-term Clinical Outcomes|PHF-RCT|St George Hospital, Australia|Yes|Recruiting|March 2010|March 2021|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|750|||Both|60 Years|N/A|No|||May 2015|May 20, 2015|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082978||125332|
NCT01112930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02921|Essential Fatty Acid (EFA) Nutrition 5-Year-Olds X Section|n-3 Fatty Acids and Early Child Nutrition: 5-Year-Olds X-Section Study||University of British Columbia|No|Completed|February 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|187|Samples With DNA|Plasma and blood cells|Both|5 Years|6 Years|Accepts Healthy Volunteers|Probability Sample|This is a cross-sectional study of children 5-6 years-old.|April 2015|April 14, 2015|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112930||123038|
NCT01113229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 081104|Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage|Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage|CYTOCINON|Assistance Publique - Hôpitaux de Paris|No|Terminated|March 2010|December 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1721|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 28, 2010||No|reason of halt prematurely: futility of the trial|No||https://clinicaltrials.gov/show/NCT01113229||123015|
NCT01083888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1517-CL-0203|ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis|ASP1517 Clinical Pharmacology Study - PK/PD Study in Renal Anemia Patients on Hemodialysis||Astellas Pharma Inc|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|20 Years|74 Years|No|||June 2010|June 16, 2010|March 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01083888||125263|
NCT01084161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1539-04|Study to Evaluate the Efficacy, Safety and Tolerability of N1539|A Randomized Double-Blind, Placebo- and Active-Controlled, Dose-Ranging Study to Evaluate the Analgesic, Efficacy, Safety and Tolerability of Intravenous N1539 in Subjects After Open Abdominal Hysterectomy||Alkermes, Inc.|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|486|||Female|18 Years|65 Years|No|||November 2011|November 28, 2011|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01084161||125242|
NCT01083875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-C-9U01|Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region|A Double-blind, Randomized, Vehicle-controlled Phase II Study to Determine the Effects of Concomitant Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region||Access Pharmaceuticals, Inc.|No|Completed|February 2000|June 2001|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||March 2010|March 16, 2010|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01083875||125264|
NCT01084421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00020148|A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos|A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos||University of Michigan|No|Active, not recruiting|September 2007|June 2010|Anticipated|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|260|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2010|March 9, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084421||125222|
NCT01084967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD008|Genetics of Obesity in Chinese Youngs|Study of Clinical Characteristics and Genetic Susceptibility in Chinese Obese Youngs|GOCY|Shanghai Jiao Tong University School of Medicine|No|Recruiting|March 2009|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|2000|Samples With DNA|Whole blood,fasting serum and morning urine|Both|14 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|The population from which cohorts will be selected include students, residents, staff,        and/or faculty who are present on Shanghai Jiaotong University school of medicine, and        surrounding areas.|July 2013|July 21, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084967||125180|
NCT01085305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2006.789|The Effectiveness of Parent-Child Interaction Therapy (PCIT)|The Effectiveness of Parent-Child Interaction Therapy (PCIT) in Treating Behavior Problems in Young Children||Norwegian University of Science and Technology|No|Completed|September 2006|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|2 Years|7 Years|No|||August 2013|August 19, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085305||125154|
NCT01085318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29665|Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial|A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 Mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group||EMD Serono||Completed|June 2010|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 2, 2013|March 10, 2010|No|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT01085318||125153|
NCT01085526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BasoScit|Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis|Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Patients With Allergic Rhinitis Due to Grass Pollen Allergy - a Prospective Randomized Controlled Study||Aarhus University Hospital|Yes|Completed|February 2010|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|40 Years|No|||July 2014|February 16, 2015|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085526||125137|
NCT01085539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV-M0-PO-A108|Oxygen Saturation Alarms in the Neonatal Intensive Care Unit|Oxygen Saturation Monitoring in the Neonatal Intensive Care Unit (NICU): An Observational Study of Response to Alarms||Medtronic - MITG|No|Completed|January 2010|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|neonates in the intensive care unit|August 2014|August 5, 2014|March 10, 2010|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT01085539||125136|The study oximeter's detection could have been 60 seconds before or after the recorded clinical intervention because of sampling bias. There were many desaturations that led to alarms that had no interventions.
NCT01096771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipids for ARDS|The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)|The Effect of Intravenous Lipid Emulsions on Lung Function in ARDS: A Pilot Study||Methodist Research Institute, Indianapolis|Yes|Terminated|June 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|90 Years|No|||April 2014|April 25, 2014|March 24, 2010|Yes|Yes|Unable to secure product from international source, low recruitment rate.|No|March 26, 2014|https://clinicaltrials.gov/show/NCT01096771||124274|
NCT01115127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myo-Mela-2010|Myo-inositol and Melatonin in Pre-menopausal Women|Myo-inositol and Melatonin in Menopausal Transition. A Prospective, Randomized Trial||University of Messina|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Female|40 Years|55 Years|No|||March 2012|March 1, 2012|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01115127||122869|
NCT01115140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2010|Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women|Effect of Metformin With or Without Folate Addiction on Uterine Blood Flow and Trophoblastic Invasion in Pregnant Patients With Polycystic Ovary Syndrome||University Magna Graecia|Yes|Completed|March 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|50|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||May 2011|May 23, 2011|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01115140||122868|
NCT01115361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|890028|Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services|Improving Access to and Uptake of Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services|PPFP-IZ|FHI 360|No|Completed|February 2010|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 28, 2012|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01115361||122851|
NCT01115595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|336/2552|Efficacy of Allergen Immunotherapy for Allergic Rhinitis in Thais|Efficacy of Mite Allergen Vaccine Among Thai Patients With Allergic Rhinitis||Mahidol University|Yes|Recruiting|March 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|12 Years|N/A|No|||August 2011|August 2, 2011|May 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01115595||122833|
NCT01115608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHAN-001|Pharmaceutical Follow-up of Coronary Heart Disease (CHD) Patients|Development of a Standardized Clinical Pharmacist Service for Patients Discharged From Hospital. Measurement of Drug Prescribing Quality in Secondary Prevention of Coronary Heart Disease Utilizing a Medication Assessment Tool (MAT-CHDsp)||Hospital Pharmacy of North Norway Trust|No|Active, not recruiting|February 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|80 Years|No|||April 2011|May 3, 2011|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01115608||122832|
NCT01116245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lm-LLO-E7-07|An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+|A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3|ADXS11-001|Advaxis, Inc.|Yes|Terminated|April 2010|April 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|81|||Female|18 Years|45 Years|No|||December 2015|December 30, 2015|April 20, 2010|Yes|Yes|Study stopped due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT01116245||122785|
NCT01116258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3430C00002|A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5847 Following Oral Administration to Healthy Male Subjects and Female Subjects of Non-childbearing Potential||AstraZeneca|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 8, 2010|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01116258||122784|
NCT01116505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R07122|Treatment of Screen-detected Celiac Disease|Treatment of Screen-detected Celiac Disease in Adults||Tampere University Hospital|No|Completed|August 2008|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116505||122765|
NCT01116739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0892|Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs|Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs||University of Colorado, Denver|Yes|Active, not recruiting|April 2011|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1040|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116739||122747|
NCT01083251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-10|The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection|The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic HBV Viral Infection||Ziv Hospital|Yes|Recruiting|March 2010|December 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||March 2010|January 17, 2011|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01083251||125311|
NCT01083238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00010|This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose|A Phase I, Two-part Study to Investigate the Effects of Food on the PK, Safety and Tolerability of a Single Oral Dose of AZD5069 (120 mg) in Healthy Adult Volunteers (Part A) and to Compare the PK of AZD5069 in Adult and Elderly Healthy Volunteers (Part B)||AstraZeneca|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|February 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01083238||125312|
NCT01083901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0343|Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training|Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training||University of Colorado, Denver|No|Completed|May 2006|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|34|||Male|50 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 17, 2013|March 8, 2010||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT01083901||125262|This was a preliminary study that was limited by small sample size, exclusion of women, and the duration of intervention which was too brief to measure changes in bone mineral density.
NCT01084174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00032256|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy||Johns Hopkins University|Yes|Active, not recruiting|March 2010|January 2013|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|21 Years|No|||March 2010|June 22, 2011|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01084174||125241|
NCT01084694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 888|Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant|The Impact of Hematopoeitic Stem Cell Transplantation on Primary Caregiver Level of Burden and Distress||Northside Hospital, Inc.|No|Recruiting|March 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|The study population will be an autologous patient and their caregiver and an allogeneic        patient and their caregiver|February 2016|February 29, 2016|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084694||125201|
NCT01084980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCNS001|Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome|A Pilot Study for Comparative Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap®) in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome|MCNS|Seoul National University Hospital||Completed|June 2010|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||August 2011|August 12, 2011|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084980||125179|
NCT01085331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200066_004|MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)|A Double-blind, Randomized, Comparative, Multicenter, Exploratory, and Placebo-controlled Phase II Trial of FOLFIRI Plus MSC1936369B or Placebo With a Safety run-in Part as Second-line Treatment of Metastatic K Ras Mutated Colorectal Cancer Subjects||EMD Serono|No|Completed|March 2010|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085331||125152|
NCT01085552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EICE07060|Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects|A Phase I Single Centre Open Label Trial to Investigate the Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta (NeoRecormon®) in Healthy Japanese and Caucasian Male Subjects||InCROM Europe Clinical Research|No|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|23|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085552||125135|
NCT01085565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM011|Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System|Phase II Study to Evaluate the Safety and Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System||InSightec|No|Completed|March 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085565||125134|
NCT01085825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPNYC 001|Study of the Sensitivity of Manual vs Electric Aspiration to Detect Completed Early Abortion|The Sensitivity of Manual Versus Electric Vacuum Aspiration to Detect Completed Abortion at Less Than Six Weeks of Pregnancy||Planned Parenthood of New York City, Inc.||Completed|April 2010|||October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|March 10, 2010||No||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01085825||125114|
NCT01085838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-ERLOTINIB-08|Erlotinib in Higher Risk Myelodysplastic Syndrome|Phase I-II Trial of Erlotinib in Higher Risk Myelodysplastic Syndrome||Groupe Francophone des Myelodysplasies|Yes|Completed|July 2010|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||March 2013|March 18, 2014|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085838||125113|
NCT01097967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NC.10.01|Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy|Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm|SAS-CARE|Ospedale Civico, Lugano|No|Active, not recruiting|July 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|246|||Both|35 Years|75 Years|No|||October 2015|October 23, 2015|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01097967||124184|
NCT01115153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74186942|Prophylaxis With Single Versus Five Dose of Antibiotic Therapy as Treatment of Patients With Gangrenous Acute Appendicitis|Prophylaxis With Single Versus Five Dose of Antibiotic Therapy as Treatment of Patients With Gangrenous Acute Appendicitis (Randomized, Controlled Clinical Trial)||Universidad Industrial de Santander|No|Completed|December 2007|February 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|12 Years|65 Years|No|||August 2011|August 22, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01115153||122867|
NCT01115374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LES_OBSF_DLM|Lymphedema Therapy With Sound Wave Lymphatic Drainage|Efficacy of Low Frequency Sound Waves in the Treatment of Breast Cancer Related Lymphedema: a Cross-over Randomized Trial||Fundacion IMIM|No|Completed|May 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115374||122850|
NCT01115621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZI310/14-1|BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk|BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk||Institut fur Diabetesforschung, Munich, Germany|No|Active, not recruiting|February 2001|December 2016|Anticipated|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Both|N/A|3 Months|Accepts Healthy Volunteers|||April 2010|April 30, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01115621||122831|
NCT01115920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRI-101|Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults|A Phase I Study in Healthy Male and Healthy Female Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MTP-131 (Bendavia™) Using a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design||Stealth BioTherapeutics Inc.|Yes|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 17, 2010|April 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115920||122810|
NCT01115933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-385|A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population|SPIRIT PRIME JAPAN (SV JAPAN)|SV JAPAN|Abbott Vascular|No|Completed|April 2010|December 2013|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|20 Years|N/A|No|||June 2015|July 17, 2015|April 5, 2010||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT01115933||122809|
NCT01081808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWH 111-32|Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors|A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors||Roger Williams Medical Center|Yes|Terminated|October 2009|February 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|January 28, 2010|No|Yes|Funding ended|No||https://clinicaltrials.gov/show/NCT01081808||125422|
NCT01082055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELD006|Antiarrythmic Drugs - Long-term Follow-up in the Modern Era|Retrospective Record Linkage Study to Investigate the Incidence of Complications and Follow-up Associated With Anti-arrythmic Drug Therapy||University of Dundee|No|Active, not recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|All patients in Tayside receiving a prescription for an anti-arrythmic drug since 1994|March 2010|March 4, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082055||125403|
NCT01116518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/2007|Treatment of Atraumatic Rotator Cuff Rupture in Elderly Patients|Treatment of Atraumatic Rotator Cuff Rupture in Elderly Patients|toarcriep|Turku University Hospital|No|Completed|February 2009|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|55 Years|N/A|No|||May 2010|November 24, 2013|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01116518||122764|
NCT01116531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60/180/2009|Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin|Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain||Turku University Hospital|No|Withdrawn|April 2010|December 2012|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||May 2013|May 30, 2013|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01116531||122763|
NCT01117025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDAFA-029|Combined Treatment of Resistant Hypertension and Atrial Fibrillation|The Role of Renal Denervation in Improving Outcomes of Catheter Ablation in Patients With Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|April 2010|April 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|70 Years|No|||July 2013|July 8, 2013|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01117025||122725|
NCT01117038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-019|Drug Interaction Study of Avanafil and Enalapril or Amlodipine|A Phase I, Double-Blind, Randomized, Placebo-Controlled, Two-Period, Two-Cohort Crossover Study to Assess the Potential Interaction of Avanafil on the Pharmacokinetic and/or Hemodynamic Effects of Enalapril or Amlodipine in Male Subjects||VIVUS, Inc.|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 9, 2011|April 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01117038||122724|
NCT01112904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01633|Essential Fatty Acid (EFA) Nutrition 5-Year-Olds Follow-Up Study|n-3 Fatty Acids and Early Child Nutrition: 5-Year-Olds Follow-Up Study||University of British Columbia|No|Completed|February 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|Samples With DNA|Plasma and blood cells|Female|19 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Mothers who participated in study (REB # C03-0242 and C&W W03-0084) and who have already        provided written consent for re-contact to participate with their 5 year old child will        participate in this follow-up study|April 2015|April 14, 2015|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112904||123040|
NCT01113203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq471600/2008-3|Chronic and Acute Effects of Resistance Exercise on Older Subjects' Blood Pressure|Chronic and Acute Effects of Resistance Exercise on Older Subjects' Blood Pressure|RTBP|University of Sao Paulo|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||April 2010|April 28, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113203||123017|
NCT01083264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91608|Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites|Open-label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Transdermally Administered Ethinylestradiol (EE) and Gestodene (GSD) After Repeated Applications of a Fertility Control Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene to 3 Different Application Sites (Buttocks, Arm Versus Abdomen) in Healthy Young Female Subjects||Bayer|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Female|18 Years|45 Years|No|||June 2014|June 20, 2014|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083264||125310|
NCT01083277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27864|Variable Ventilation During Acute Respiratory Failure|Variable Ventilation During Acute Respiratory Failure||Boston Medical Center|Yes|Recruiting|September 2012|October 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|September 18, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01083277||125309|
NCT01083290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0300012|Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets|Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets in Healthy Subjects Under Fasting Conditions.||Orion Corporation, Orion Pharma|No|Completed|April 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 7, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083290||125308|
NCT01083498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fractional-2|Fractional Laser as Treatment Option for Various Pigment Disorders|Ablative Fractional Laser Therapy as Treatment for Becker's Nevus; a Pilot Study|fractional-2|Netherlands Institute for Pigment Disorders|No|Completed|March 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||March 2010|March 8, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083498||125292|
NCT01084447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-2010|Inspiratory Muscle Training After Gastroplasty|Effect of Inspiratory Muscle Training on Muscular and Pulmonary Function Following Gastroplasty in Obese Patients||University of Sao Paulo|Yes|Completed|January 2004|August 2005|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|58 Years|No|||March 2010|March 9, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01084447||125220|
NCT01084733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOTINE-HN|Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer|Correlative Study of Nicotine Levels With Response Rates to Therapy Using Radiation Alone or in Combination With Chemotherapy in Head and Neck Cancer||University of Kentucky|Yes|Recruiting|August 2007|||August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood will be obtained weekly during the treatment phase. Serum will be collected and      aliquoted into eppendorf tubes. Serum samples will be stored in -20C freezer until assayed      for cotinine levels using Immulite immunoassay for cotinine (Immulite 2000 Assay, DPC,      United States, Technical Services 800-372-1782).|Both|18 Years|N/A|No|Non-Probability Sample|Male or female aged 18 or older|October 2015|October 13, 2015|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084733||125198|
NCT01084707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1066-A6431117|Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product.|Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product. A Study in Healthy Smokers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2009|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|March 9, 2010|Yes|Yes||No|April 16, 2010|https://clinicaltrials.gov/show/NCT01084707||125200|
NCT01084720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00034 CR 302 (ORF)|Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis|Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients Undergoing Maintenance Renal Dialysis With Uremic Xerosis (MRD)||Orfagen|No|Completed|December 2002|December 2003|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|||Actual|100|||Both|10 Years|N/A|No|||March 2010|March 9, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084720||125199|
NCT01085591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4261-007|Study of CB-183,315 in Participants With Clostridium Difficile Infection|A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.||Cubist Pharmaceuticals LLC|Yes|Completed|April 2010|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 9, 2010|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01085591||125132|
NCT01085851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERE 976-08|Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Sunburn Related Symptoms|Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Lotion) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Sunburn Related Symptoms||Mantecorp Industria Quimica e Farmaceutica Ltd.|Yes|Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|2 Years|60 Years|No|||October 2009|March 11, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085851||125112|
NCT01081626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700623-501|Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction|A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II)||Merck KGaA|No|Completed|March 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|310|||Female|18 Years|37 Years|No|||January 2014|January 20, 2014|March 4, 2010||No||No|September 3, 2012|https://clinicaltrials.gov/show/NCT01081626||125436|
NCT01097421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.674|Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease|Influence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's Disease||Boehringer Ingelheim||Completed|March 2010|||September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|329|||Both|30 Years|N/A|No|Probability Sample|specialist care|March 2014|March 14, 2014|March 25, 2010||||No|September 14, 2012|https://clinicaltrials.gov/show/NCT01097421||124226|
NCT01115634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-skin-002|Autologous Fibroblast Transplantation in Facial Deformities|Autologous Transplantation of Cultured Fibroblast for Facial Contour Deformities||Royan Institute|Yes|Completed|September 2008|November 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|50 Years|No|||May 2010|July 14, 2011|May 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01115634||122830|
NCT01115946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0008|A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers|ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Enalapril -||Astellas Pharma Inc|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|May 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115946||122808|
NCT01115959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Seizures Post Intracerebral Hemorrhage|Are Post Intracerebal Hemorrhage Prevented By Anti-Epileptic Treatment?||Wolfson Medical Center|No|Completed|February 2003|December 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|72|||Both|N/A|N/A|No|||May 2010|June 11, 2014|May 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01115959||122807|
NCT01116219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 19/09|Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).|Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|June 2010|January 2017|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|149|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01116219||122787|
NCT01116232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000671822|Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation|A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|August 2010|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|18 Years|120 Years|No|||December 2015|December 9, 2015|May 3, 2010||No|Lack of funding.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT01116232||122786|Study terminated due to lack of funding. No analysis, patient data on this protocol due to the fact that only four patients was able to be accrued.
NCT01082068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD11437|Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer|A Phase 1/2 Dose-Escalation Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor||Sanofi|Yes|Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|N/A|No|||April 2013|April 9, 2013|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01082068||125402|
NCT01081782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4641POU006|A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis|A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis|DreaMS|Ono Pharmaceutical Co. Ltd|Yes|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|407|||Both|18 Years|55 Years|No|||November 2013|November 30, 2013|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081782||125424|
NCT01081795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013681|A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine|A Placebo-Controlled Dose-Finding Study of JNS019 (Topiramate) in Migraine Patients||Janssen Pharmaceutical K.K.|No|Completed|April 2007|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|387|||Both|20 Years|64 Years|No|||June 2013|June 20, 2013|March 4, 2010|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01081795||125423|
NCT01116765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01191-56|Impact of Early Oral Stimulation on Reducing Cardiorespiratory Events and Transition to Oral Feeding in Preterm Infants|Impact of Early Oral Stimulation on Reducing Cardiorespiratory Events and Transition to Oral Feeding in Preterm Infants||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|May 2010|April 2016|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|62|||Both|29 Weeks|33 Weeks|No|||April 2015|April 20, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116765||122745|
NCT01117051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0001-C301|Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation|A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride in Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation|OIC|Shire|No|Terminated|May 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|N/A|No|||April 2014|June 6, 2014|April 29, 2010||No|The study was stopped by the sponsor based on a non-safety related business priority decision|No|April 2, 2013|https://clinicaltrials.gov/show/NCT01117051||122723|Due to the early termination of the study, results should be interpreted with caution.
NCT01083927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMERC003|Rotational Narrow Strip Versus Full Conjunctival Graft in Pterygium Excision|Rotational Narrow Strip Versus Full Conjunctival Graft in Pterygium Excision||University of Malaya|Yes|Completed|July 2007|July 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|94|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 9, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083927||125260|
NCT01083940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66708|Impact of Computerized Decision Support on Racial/Ethnic Disparities in Hypertension Outcomes|Evaluating the Impact of Computerized Decision Support on Racial/Ethnic Disparities in Hypertension Outcomes||Brigham and Women's Hospital|No|Active, not recruiting|October 2010|October 2011|Anticipated|October 2011|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|3600|||Both|20 Years|N/A|No|||June 2011|June 22, 2011|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083940||125259|
NCT01083511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-INFLUENZA-002|Collection and Extraction of Respiratory Specimens|Collection & Extraction of Respiratory Specimens for the Validation of the Artus Influenza RG PCR Test||QIAGEN Gaithersburg, Inc|No|Completed|March 2010|June 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|600|Samples With DNA|Extracted nucleic acid, Residual Universal Transport Medium.|Both|N/A|N/A|No|Non-Probability Sample|The study population includes individuals having the signs and symptoms of a respiratory        tract infection caused by an Influenza virus.|May 2014|May 13, 2014|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083511||125291|
NCT01085006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|830|The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery|The Effect of Tranexamic Acid Administration on Postpartum Hemorrhage During and After Cesarean Delivery||Tehran University of Medical Sciences|Yes|Completed|September 2009|September 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2010|January 2, 2011|March 10, 2010||No||No|January 2, 2011|https://clinicaltrials.gov/show/NCT01085006||125177|
NCT01085019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2009-253|Impact of Spices and Herbs on Endothelial Function|Investigation of the Impact of Spices and Herbs on Endothelial Function and Other CVD Risk Factors in Men and Women.||Laval University|No|Completed|March 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|6||Actual|224|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01085019||125176|
NCT01084434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F3168407|Probiotic, Prebiotic and Synbiotic Effect on Immunity|Double-blind, Placebo Controlled Randomized Parallel Study to Determine the Effects of Pre-pro and Synbiotic Administration on the Immune Response to Influenza Vaccination and Faecal Microbiota in Healthy Adults||University of Reading|No|Not yet recruiting|May 2010|June 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||February 2010|March 9, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01084434||125221|
NCT01085344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019970022|Canadian Hemophilia Prophylaxis Study|Moderate Term Musculoskeletal Outcomes With Escalating Dose Prophylaxis: the Canadian Hemophilia Prophylaxis Study Follow-up Study|CHPS|The Hospital for Sick Children|Yes|Completed|July 1997|December 2014|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Male|12 Months|30 Months|No|||June 2015|June 4, 2015|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01085344||125151|
NCT01085578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG400549-1-01|CG400549 Single Ascending Dose Study|Evaluation of Safety,Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers||CrystalGenomics, Inc.|No|Completed|October 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085578||125133|
NCT01085864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1106|Biomarkers for Diagnosis of Lung Nodules|Biomarkers for Diagnosis of Lung Nodules|Nodule|University of Colorado, Denver|No|Recruiting|March 2010|April 2020|Anticipated|April 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood specimen, a sputum sample, a urine sample, and an exhaled breath sample.|Both|18 Years|85 Years|No|Probability Sample|Patients being evaluated by CT Scan with Lung Nocules|February 2016|February 29, 2016|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085864||125111|
NCT01081639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 24554|To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen|Phase III Study on the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Formulation Applied by a Pen Versus Follitropin Beta Liquid Formulation Applied by Pen||Merck KGaA||Completed|November 2003|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|39 Years|No|||November 2010|July 30, 2014|February 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01081639||125435|
NCT01082575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV-MO-PO-A109|Oxygen Monitoring of Patients After Surgery on the Hospital General Care Floor|Oxygen Saturation Monitoring in the General Care Floor (GCF): An Observational Study of Repetitive Reductions in Airflow||Medtronic - MITG|No|Completed|February 2010|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Hospital Patients|August 2014|August 5, 2014|March 5, 2010|Yes|Yes||No|February 8, 2012|https://clinicaltrials.gov/show/NCT01082575||125363|
NCT01081886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK VP-00082|PEAK PlasmaBlade 4.0 Versus Traditional Electrosurgery in Total Knee Replacement.|A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade 4.0 in Total Knee Replacement|PRECISE|Medtronic Surgical Technologies|No|Terminated|June 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|80 Years|No|||January 2013|January 3, 2013|March 4, 2010|Yes|Yes|Termination due to acquisition of PEAK Surgical by Medtronic|No|November 29, 2012|https://clinicaltrials.gov/show/NCT01081886||125416|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.
NCT01084902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU1H001|Efficacy Comparison of Xalatan and Azopt on POAG and OH|Comparison of the Effects of Latanoprost(0.005%) and Brinzolamide(1.0%) on Intraocular Pressure in Primary Open-angle Glaucoma and Ocular Hypertension||Peking University First Hospital||Active, not recruiting|February 2010|December 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||March 2010|March 10, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084902||125185|
NCT01084915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|680-070110-Aarts|The Results and Outcomes of the Modified Swedish Adjustable Gastric Band (SAGB-VC)|The Results and Outcomes of the SAGB-VC in a High Volume Bariatric Centre|ROS|Rijnstate Hospital|No|Completed|March 2010|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|840|||Both|18 Years|N/A|No|Probability Sample|Patients who received a SAGB-VC band from 2004-2008|March 2014|March 5, 2014|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01084915||125184|
NCT01115400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-07-31|Quality of Life Evaluations in Patients With Abdominal Wall Hernias|Quality of Life Evaluations in Patients With Abdominal Wall Hernias|QOL|University Hospital Case Medical Center|Yes|Completed|July 2007|August 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This protocol will involve patients presenting to University Hospitals Case Medical Center        for evaluation of abdominal hernias.        The study population will include all adult patients with the diagnosis of abdominal wall        hernias, without incarceration or strangulation of bowels. The investigators will need        about 90 subjects to participate in this study.        The survey will be entirely anonymous; no patient information will be given out in any        part of the survey.|March 2013|March 15, 2013|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01115400||122848|
NCT01115647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMH0110|Treating Moderate Malnutrition in 6-24 Months Old Children|Treating Moderate Malnutrition in 6-24 Months Old Children: Acceptability, Efficacy and Cost-effectiveness of a Local Soy-based RUTF vs. Enhanced Corn Soy Blend vs. Child-centered Counselling|LUCOMA|Institute of Tropical Medicine, Belgium|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2088|||Both|6 Months|24 Months|No|||November 2011|November 21, 2011|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01115647||122829|
NCT01115972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0009|A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers|ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Valsartan -||Astellas Pharma Inc|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|May 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115972||122806|
NCT01115985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0010|A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers|ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Atorvastatin -||Astellas Pharma Inc|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|May 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115985||122805|
NCT01082497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P REK NORD-134/2008|Mindfulness Training for Staff (MTS)|Mindfulness Training and Developing the Ability of Empathy at an Inpatient Ward for Dual Diagnoses|MTS|University Hospital of North Norway|No|Completed|May 2009|January 2011|Actual|January 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|53|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2012|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082497||125369|
NCT01082744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.558|Thoracic Paravertebral Block for Postoperative Analgesia After Video-assisted Thoracic Surgery.|Thoracic Paravertebral Block: a Comparative Study of Ropivacaine With Ropivacaine and Sufentanil for Treating Pain After Video-assisted Thoracic Surgery.|PARAVI|Hospices Civils de Lyon|Yes|Completed|March 2010|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082744||125350|
NCT01082393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/599|Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)|Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)|Koebner|University Hospital, Ghent|No|Recruiting|February 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|70 Years|No|||December 2014|December 4, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01082393||125377|
NCT01082406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1841-3788|Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects|A Single Centre, Randomised, Double-blind, Cross-over Trial in Healthy Male Subjects Investigating Bioequivalence and Pharmacokinetics of rFXIII (Avecia DS) to rFXIII (Novo Nordisk DS)||Novo Nordisk A/S|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01082406||125376|
NCT01082705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT TZ IV2010|Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children|Impact Tanzania in Vivo Efficacy 2010: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children Aged 6-59 Months||Centers for Disease Control and Prevention|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|6 Months|59 Months|No|||January 2012|January 27, 2012|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082705||125353|
NCT01083953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|supreme sevo vs des|Optimal End-Tidal (ET) Sevoflurane and Desflurane Concentration for Extubation of Supreme Laryngeal Mask Airway (LMA) in Adults|Optimal End-Tidal Concentration of Sevoflurane and Desflurane for Removal of Supreme Laryngeal Mask Airway in Anaesthetized Adults||University of Malaya|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|54|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083953||125258|
NCT01084187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDAH2010|Correlation Study of Vascular Parameters in Hypertensive Men With Erectile Dysfunction|Correlation of Flow Mediated Dilation of Brachial Artery and Carotid Intima Media Thickness With Erectile Dysfunction Severity and Clinical Response to PDE 5 Inhibitor in Hypertensive Men||Hospital Universitario Pedro Ernesto|No|Completed|January 2010|February 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|100|||Male|50 Years|70 Years|No|||April 2011|April 15, 2011|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084187||125240|
NCT01085617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000667211|Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Recruiting|January 2010|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|720|||Both|25 Years|65 Years|No|||June 2011|August 23, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085617||125130|
NCT01085877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG-3821|Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis|An Open Randomized Two-Way Cross-Over Comparative Bioavailability Study to Compare the Extent of Systemic Absorption of Estradiol After a Single Dose Treatment With Two 25 mcg Estradiol Vaginal Tablet Formulations Administered in Postmenopausal Women With Vaginal Atrophy||Novo Nordisk A/S|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|55 Years|75 Years|No|||June 2014|June 25, 2014|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01085877||125110|
NCT01085890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI 2006/1285-31|Hypertension in Primary Health Care: Lifestyle Change and Blood Pressure Goals|Hypertension in Primary Health Care: Can More Intensive Work With Lifestyle Change Help Patients Achieve Blood Pressure Goals?||Karolinska Institutet|No|Completed|March 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|30 Years|N/A|No|||March 2010|March 11, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085890||125109|
NCT01084993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASY-B2B|EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding|EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding: Bivalirudin to Reduce Bleeding EASY-B2B Study|EASY-B2B|Laval University|No|Recruiting|March 2010|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084993||125178|
NCT01085604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01HD053632T|Recurrent Low Back Pain:Linking Mechanisms to Outcomes|Recurrent Low Back Pain:Linking Mechanisms to Outcomes||Drexel University|No|Completed|August 2009|June 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|69|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic physical therapy clinic community|August 2015|August 3, 2015|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085604||125131|
NCT01082172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0001 TAA Trial|South American Thoracic Stent-Graft Study|A Pilot Trial to Evaluate the Performance of the TriVascular Thoracic Stent Graft System||TriVascular, Inc.|No|Completed|November 2009|May 2011|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082172||125394|
NCT01082185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0002|South American Abdominal Stent Graft Trial|A Clinical Study to Evaluate the Safety and Performance of the TriVascular Modular Abdominal Stent Graft System||TriVascular, Inc.|Yes|Active, not recruiting|November 2009|May 2016|Anticipated|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082185||125393|
NCT01082562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV198-002|Safety Study of BMS-844421 for Treatment of Hypercholesterolemia|Randomized, Double-blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study to Evaluate the Safety , Pharmacokinetics and Pharmacodynamics of BMS-844421 in Healthy Subjects and in Subjects With Elevated Cholesterol||Bristol-Myers Squibb|No|Terminated|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|16||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 25, 2011|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01082562||125364|
NCT01082809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02-025|Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma|Phase II Study of Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma: Multicenter, Multinational Study||Samsung Medical Center|No|Completed|March 2009|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01082809||125345|
NCT01114139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-IDA-301|A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia|A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia||AMAG Pharmaceuticals, Inc.|Yes|Completed|June 2010|October 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|812|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114139||122945|
NCT01082796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMM-DMPK-090903|Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects|Investigate the Relationship Between CYP2C19 Genetic Polymorphisms and Pharmacokinetics of Glipizide in Healthy Chinese Subjects||Chinese Academy of Sciences|Yes|Completed|November 2009|January 2010|Actual|||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2009|March 8, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082796||125346|
NCT01094457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|825004-5|Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation|||Shenyang Northern Hospital|Yes|Completed|March 2009|June 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|840|||Both|35 Years|75 Years|No|||June 2012|June 13, 2012|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094457||124452|
NCT01094470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWS-BARELA|Body Weight Support Training on Ground Level|Ground-level Partial Body Weight Support Gait Training for Individuals With Chronic Stroke|BWSGR|Universidade Federal de Sao Carlos|No|Completed|August 2007|April 2008|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||July 2006|March 26, 2010|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094470||124451|
NCT01085500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008118|Mastery Learning Inguinal Hernia Repair|Mastery Learning Totally Extraperitoneal Inguinal Hernia Repair: Linking Surgical Simulation to Patient Level Outcomes||Mayo Clinic|No|Completed|February 2010|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|March 10, 2010||No||No|May 16, 2011|https://clinicaltrials.gov/show/NCT01085500||125139|
NCT01085786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS97-CT6-08|Sequential and Hybrid Therapies for H Pylori Infection|Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection||Kaohsiung Veterans General Hospital.|Yes|Completed|August 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|80 Years|No|||September 2015|September 6, 2015|March 11, 2010||No||No|April 12, 2011|https://clinicaltrials.gov/show/NCT01085786||125117|The trial was performed in a single country.
NCT01081535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0107|The Effect of Intravenous (IV) Patient Controlled Analgesic (PCA) With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy|The Effect of IV PCA With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy||Yonsei University|Yes|Completed|May 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|6 Months|5 Years|No|||January 2010|March 4, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081535||125443|
NCT01081548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0288|A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia|A Multi-center, Randomized, Open-labeled Clinical Trial to Evaluate Efficacy and Safety of Lipinon® 20mg Versus Lipitor® 20mg in Korean Patients With Hypercholesterolemia||Yonsei University||Completed|August 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|17|||Both|N/A|N/A|No|||January 2010|March 4, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081548||125442|
NCT01081561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#20090780|Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs|Randomized Study of Corneal Collagen Cross-Linking With the UV-X System for the Treatment of Keratectasia in Eyes With Intacs Compared to Eyes Without Intacs||Cornea Genetic Eye Institute|Yes|Recruiting|June 2009|June 2015|Anticipated|June 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|21 Years|65 Years|No|||December 2012|December 17, 2012|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081561||125441|
NCT01082757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62202-513|Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients|Prevalence of the Mutational Status of KRAS in mCRC in Argentine Patients||Merck KGaA||Completed|June 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1524|||Both|22 Years|N/A|No|Non-Probability Sample|Subjects with histologicaly confirmed metastatic adenocarcinoma of the colon/rectum in        Argentina|July 2014|July 30, 2014|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082757||125349|
NCT01082029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-435|Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children|Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study||McMaster University|No|Completed|March 2010|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|1 Year|17 Years|No|||April 2015|April 12, 2015|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082029||125405|
NCT01082042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGS05/2008|Exercising With Computers in Later Life|Exercising With Computers in Later Life (EXCELL) - Pilot and Feasibility Study of the Nintendo® WiiFit in Community-dwelling Fallers|EXCELL|NHS Grampian|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|21|||Both|70 Years|N/A|No|Non-Probability Sample|Standard Care: The standard care group was recruited from the local falls group that is        run from the local Medicine for the Elderly Department.        Intevention Group: Participants were recruited following a publicity campaign.|June 2009|March 4, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082042||125404|
NCT01082419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/21|Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity|Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity - Norms in ARFI: Distribution and Reproducibility of ARFI Values in Disease-free Livers or Pathological Livers.|NARFI|University Hospital, Bordeaux|No|Completed|April 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|7||Actual|109|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 6, 2014|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082419||125375|
NCT01082432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SES 327|Electrical Stimulation to Recover Greater Range of Motion After Surgery|Superimposed Electrical Stimulation Real-time Effects on Repeated Muscle Contractions Enable to Increase Recovery From Thumb Joint Stiffness After Surgery of the Ulnar Collateral Ligament||Université Joseph Fourier|No|Completed|April 2008|August 2009|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Hand physical therapy center|February 2010|March 5, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01082432||125374|
NCT01082718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAACT PK|Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection|Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection||Centers for Disease Control and Prevention|Yes|Withdrawn|March 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||April 2012|April 12, 2012|March 8, 2010||No|Logistical difficulties|No||https://clinicaltrials.gov/show/NCT01082718||125352|
NCT01082991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15723A|Patient Acuity Rating: a Tool to Prevent In-Hospital Cardiac Arrest|Strategies to Predict and Prevent In-Hospital Cardiac Arrest|PAR|University of Chicago|No|Recruiting|October 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20768|||Both|18 Years|N/A|No|||March 2010|September 4, 2013|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082991||125331|
NCT01084226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/13/03/00/08|Rye Bread Trial; Antioxidative and Cholesterol Lowering Effects|Dietary Intervention Trial of Alkylresorcinols and Plant Sterols in High-Fibre Rye Bread and Their Effects on Serum Lipids in Normo- and Mildly Hypercholesterolemic Subjects|Rye-2008|Helsinki University||Completed|February 2008|February 2010||April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|68|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2010|March 9, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084226||125237|
NCT01084460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200812083R|Follow-up of the Natural Course of the Small EUS-suspected Gastric Gastointestinal Stromal Tumors|||National Taiwan University Hospital|No|Completed|January 1997|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|18 Years|90 Years|No|Probability Sample|This was a retrospective study. We reviewed 256 consecutive patients with the diagnosis of        suspected gastric GISTs by EUS, from January 1997 to December 2008 at the National Taiwan        University Hospital, Yuan's General Hospital and En Chu Kong Hospital.|March 2010|March 9, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01084460||125219|
NCT01084200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJHMZK01004|Comparison of Sevoflurane, Propofol, and Sevoflurane Plus Propofol for Maintenance of Anaesthesia|Comparison of Postoperative Pain of Sevoflurane, Propofol, and Sevoflurane Plus Propofol in Maintenance of Anaesthesia for Gynaecological Laparoscopic Surgery||Huazhong University of Science and Technology|Yes|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Female|18 Years|40 Years|No|||August 2012|August 9, 2012|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01084200||125239|
NCT01084473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GADEX|Effect of Dexmedetomidine on Gastric Emptying and Gastrointestinal Transit|Effect of Dexmedetomidine Infusion on Gastric Emptying and Gastrointestinal Transit in Healthy Volunteers|GADEX|University of Turku|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|June 3, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084473||125218|
NCT01081665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-120|Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism|A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism||Abbott||Completed|December 2006|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|237|||Both|18 Years|N/A|No|Non-Probability Sample|Hemodialysis patients with secondary hyperparathyoidism treated with IV Paricalcitol        according to the approved Summary of Product Characteristics|March 2012|March 26, 2012|February 27, 2010||No||No|February 7, 2012|https://clinicaltrials.gov/show/NCT01081665||125433|
NCT01085357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMI-09-01|Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery|A Prospective, Randomized, Comparative, MultiCenter Clinical Study to Assess the Safety and Effectiveness of the Transcend CyPass Glaucoma Implant in Patients With Open Angle Glaucoma Undergoing Cataract Surgery|COMPASS|Transcend Medical, Inc.|Yes|Completed|September 2009|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|897|||Both|45 Years|N/A|No|||February 2016|February 24, 2016|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085357||125150|
NCT01081899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFPS-2006-6-341619|The Effectiveness of the LCP in Improving End of Life Care for Dying Cancer Patients in Hospital.|The Effectiveness of the Liverpool Care Pathway in Improving End of Life Care for Dying Cancer Patients in Hospital. A Cluster Randomised Trial.||Regional Palliative Care Network|No|Completed|November 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|308|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081899||125415|
NCT01082588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002524|Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia|Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia||Massachusetts General Hospital|Yes|Completed|June 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|68 Years|No|||March 2014|March 26, 2014|March 5, 2010|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01082588||125362|
NCT01113879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7175-M|Exercise as an Adjuvant to Aphasia Therapy|Exercise as an Adjuvant to Aphasia Therapy||VA Office of Research and Development|No|Completed|July 2009|August 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|20 Years|95 Years|No|||August 2012|August 3, 2012|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113879||122965|
NCT01114477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19-50001-000|NeuroStar TMS Therapy System: Utilization and Outcomes|NeuroStar TMS Therapy System: Data Management, Analysis and Reporting Format for Clinical Treatment Utilization and Outcomes (Protocol no. 19-50001-000,Rev D||Neuronetics|No|Completed|March 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|307|||Both|N/A|N/A|No|Non-Probability Sample|Clinical practice locations providing clinical treatment with the NeuroStar TMS Therapy        System.|November 2015|November 11, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01114477||122919|
NCT01114152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2690C00003|AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects|A Phase I, Single Center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous AZD9742 in Healthy Male and Female Japanese Subjects||AstraZeneca|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|23 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 2, 2010|April 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114152||122944|
NCT01114490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-039|Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)|A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114490||122918|
NCT01094717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00031865|Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis|A Comparison of Treatment of Psoriasis With Acitretin or Tazarotene Gel 0.1% and Active or Sham Treatments With the 308 nm Excimer Laser||University of Utah|No|Terminated|January 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|March 25, 2010|Yes|Yes|lack of efficacy and lack of funding|No||https://clinicaltrials.gov/show/NCT01094717||124432|
NCT01085799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-09-214|Education Intervention to Reduce Helminth Infections and Absenteeism in Grade 5 School-children|Effectiveness of a Post-deworming Education Intervention to Reduce Soil-transmitted Helminth Infections and Absenteeism in Grade 5 School-children in a Community of Extreme Poverty, Peruvian Amazon||McGill University Health Center|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1101|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|March 15, 2011|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085799||125116|
NCT01081574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 3009/PED|Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)|A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria||Faes Farma, S.A.|No|Completed|January 2010|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|2 Years|11 Years|No|||September 2012|September 25, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081574||125440|
NCT01081587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.522/23|Preventing Malnutrition and Restoring Nutritional Status in Hospitalized Children|Developing an Organization to Improve the Screening and Care of Starved Children in Hospital|PREDIRE|Hospices Civils de Lyon|Yes|Completed|October 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1457|||Both|1 Month|18 Years|No|||May 2013|May 14, 2013|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01081587||125439|
NCT01081834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017011|The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise||Janssen Research & Development, LLC|Yes|Completed|March 2010|March 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|678|||Both|18 Years|80 Years|No|||June 2013|June 12, 2013|March 4, 2010|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT01081834||125420|
NCT01081821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016753|Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent|A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Investigate the Safety and Pharmacokinetics of JNJ-39758979 in Healthy Japanese and Caucasian Adult Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01081821||125421|
NCT01083069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cool-Trial Follow up|Follow up After Survived Therapy With Mild Induced Hypothermia (MIH) After Restoration of Spontaneous Circulation (ROSC)|Neurological Outcome After Mild Induced Hypothermia (MIH) After Restoration of Spontaneous Circulation||University of Leipzig|No|Recruiting|January 2010|June 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients after restoration of spontaneous circulation|January 2010|March 8, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01083069||125325|
NCT01083342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-12-087|High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study|Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study||Samsung Medical Center||Completed|January 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|20 Years|70 Years|No|||May 2012|May 22, 2012|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083342||125304|
NCT01082445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACPIEDE|Effects of N-acetylcysteine on Diabetic Foot Oxygenation|Effects of Prolonged N-acetylcysteine Administration on Foot Ulcer Oxygenation in Diabetic Patients||University of Turin, Italy|No|Completed|August 2009|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|45 Years|70 Years|No|||March 2012|March 7, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082445||125373|
NCT01082458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0519|Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia|Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia||Yonsei University|Yes|Completed|February 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Primary Purpose: Prevention|||Actual|67|||Female|20 Years|N/A|No|||November 2010|November 18, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01082458||125372|
NCT01082471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M6G022|An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours|A Randomised Double-blind Study to Compare the Analgesic Efficacy and Safety Profiles of M6G and Morphine, as a Loading Dose Followed by PCA, in Patients Suffering Moderate to Severe Post-operative Pain Requiring PCA for at Least 24 Hours||Paion UK Ltd.|No|Completed|November 2005|December 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|517|||Both|18 Years|N/A|No|||March 2010|March 5, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082471||125371|
NCT01082731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAACT-PF|Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil|A Multi-center, Open-label, Randomized, Phase 4, Trial of Artemether-Lumefantrine and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Falciparum Malaria Parasitemia in Pregnant Women in Brazil|PAACT-PF|Centers for Disease Control and Prevention|Yes|Terminated|November 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Female|15 Years|N/A|No|||April 2012|April 12, 2012|March 8, 2010||No|Extremely slow enrollment|No||https://clinicaltrials.gov/show/NCT01082731||125351|
NCT01083004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BlueIce001|Brilliant Blue Versus Indocyanine Green|A Randomized Study Comparing Brilliant Blue and Indocyanine Green as Intravitreal Dye in Macular Pucker and Macular Hole||University of Cologne||Recruiting|January 2008|||May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|N/A|No|||October 2007|April 15, 2011|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083004||125330|
NCT01083017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAHyCOstudy|Resistant Arterial Hypertension Cohort Study|Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.|RAHyCo|University Hospital, Geneva|No|Recruiting|April 2011|April 2018|Anticipated|June 2013|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|Samples With DNA|serum, DNA, urine|Both|18 Years|N/A|No|Non-Probability Sample|patients addressed to a speciality consultation at Geneva University Hospital|August 2011|August 26, 2011|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083017||125329|
NCT01085032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA024876|Nicotine Patch Trial in Syrian Primary Care Settings|Transdermal Nicotine Therapy as an Adjunct to Behavioral Smoking Cessation Counseling in Syrian Primary Care Settings||University of Memphis|Yes|Completed|August 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2010|March 10, 2010|March 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085032||125175|
NCT01084746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-01-084|Tailored Interactive Intervention to Increase CRCS|Tailored Interactive Intervention to Increase CRCS|PCCaSO|The University of Texas Health Science Center, Houston|Yes|Completed|January 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Actual|1224|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||March 2010|March 9, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084746||125197|
NCT01117233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0141002|Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429|A Randomised, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers||Pfizer|No|Completed|May 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 17, 2012|May 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01117233||122710|
NCT01117246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|998771A|Pilot Study for Palliation of Pain in Bone Metastases by MR-HIFU|Pilot Study for the Treatment of Bone Metastases by High Intensity Focused Ultrasound Guided by MRI to Perform Pain Palliation||Philips Healthcare|Yes|Completed|May 2010|October 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|2|||Both|18 Years|80 Years|No|||February 2012|February 17, 2012|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117246||122709|
NCT01081652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 25347|A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)|An Open, Randomized, Comparative, Phase III Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)||Merck KGaA||Completed|May 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|238|||Female|N/A|N/A|No|||March 2010|July 30, 2014|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01081652||125434|
NCT01082198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000666511|Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes|Adjuvant Vaccination With Melanoma Antigen Pulsed Dendritic Cells (DCs) in Stage III Melanoma Patients||National Cancer Institute (NCI)||Recruiting|October 2002|||April 2010|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||March 2010|August 23, 2013|March 5, 2010||||No||https://clinicaltrials.gov/show/NCT01082198||125392|
NCT01113619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G28-001|Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effectiveness, Safety and Tolerability of RP-G28 in Subjects With Symptoms Associated With Lactose Intolerance||Ritter Pharmaceuticals, Inc.|No|Completed|April 2011|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|64 Years|No|||December 2011|December 6, 2011|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113619||122985|
NCT01114503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112480|A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease|A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy||GlaxoSmithKline||Terminated|July 2010|August 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|75 Years|No|||September 2013|May 29, 2014|April 29, 2010||No|Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of    an efficacious dose with Otelixizumab from other clinical studies.|No||https://clinicaltrials.gov/show/NCT01114503||122917|
NCT01114516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00019610|Multifactorial Approach to Emergent Cerclage|Role in Emergent Cerclage of Indomethacin and Antibiotics|RECIA|Northwestern University|No|Completed|March 2010|March 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Female|18 Years|80 Years|No|||November 2014|November 5, 2014|April 29, 2010||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01114516||122916|Because this study was not adequately powered to detect differences in perinatal outcomes, whether this adjunctive therapy affects these outcomes remains uncertain.
NCT01085513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-68|Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy|Intestinal Motility Evaluation by Endoluminal Image Analysis Using Capsule Endoscopy (CE-EIA): a Multi-center Clinical Trial||Given Imaging Ltd.|No|Terminated|February 2009|June 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|143|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|March 11, 2010|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01085513||125138|
NCT01081600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27112008 version 1|89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition|Imaging the Effect of HSP90 Inhibitor AUY922 on HER2 Expression by Means of 89Zr-trastuzumab PET. Side Study to Phase I-II Study With AUY922 in Either HER2 or ER Positive Locally Advanced or Metastatic Breast Cancer: Protocol CAUY922A2101|AUY922|University Medical Center Groningen|Yes|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Probability Sample|Patients with HER2 positive breast cancer which has become trastuzumab resistent, who are        participating in the phase I-II trial with HSP90 inhibitor AUY922|May 2013|May 13, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081600||125438|
NCT01082081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4000684|Post-operative Dental Pain Study Comparing Analgesic Efficacy|A Study to Compare the Analgesic Efficacy of Two Different Paracetamol Doses as Measured by Post-operative Dental Pain Relief||GlaxoSmithKline|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|45 Years|No|||March 2015|April 27, 2015|February 18, 2010||No||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01082081||125401|
NCT01082107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU 031650|Solar Disinfection of Drinking Water|Solar Disinfection of Drinking Water for Use in Developing Countries or in Emergency Situations|SODISWATER|Council for Scientific and Industrial Research, South Africa||Completed|October 2006|August 2009|Actual|||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|800|||Both|N/A|5 Years|Accepts Healthy Volunteers|||June 2009|March 5, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082107||125399|
NCT01082094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTCS-001|Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure|An Open Label Dose Escalation Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure||Juventas Therapeutics, Inc.|Yes|Completed|February 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082094||125400|
NCT01082484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016301-42|Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers|Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers|INFLUX-IT-VS|University Hospital, Grenoble||Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 5, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01082484||125370|
NCT01083602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589DUS71|Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma|A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma|MACS1271|Novartis|No|Completed|June 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||February 2015|April 8, 2015|March 8, 2010|Yes|Yes||No|February 23, 2015|https://clinicaltrials.gov/show/NCT01083602||125284|
NCT01083615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGX-011-10|A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)|A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer||OncoGenex Technologies|Yes|Terminated|March 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|99 Years|No|||November 2015|January 11, 2016|February 26, 2010|Yes|Yes|Unable to enroll due to criteria for stable baseline pain|No||https://clinicaltrials.gov/show/NCT01083615||125283|
NCT01083628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68556-35551-01|Text Messaging and Cognitive Behavioral Therapy for Depression|Using Text Messaging to Enhance Cognitive Behavioral Therapy (CBT) for Depression|Txt4CBT|University of California, San Francisco|Yes|Enrolling by invitation|March 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01083628||125282|
NCT01083030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pac 12|Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis|Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis|PACIFIER|University Hospital, Saarland|Yes|Completed|March 2010|December 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|N/A|No|||July 2013|July 25, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01083030||125328|
NCT01083303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC08BI05089CTIL|Weaning Preterm Infants at 1500 Grams From Incubators|A Randomized Trial of Weaning Preterm Infants at 1500g From Incubators: Effect on Failure to Wean, Weight Gain and Energy Expenditure||Tel-Aviv Sourasky Medical Center|No|Completed|May 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|N/A|N/A|No|||August 2012|August 1, 2012|July 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01083303||125307|
NCT01083524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCA 20001|Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension|A Phase I, Open-Label, Two Centre Study to Evaluate Dichloroacetate(DCA) in Advanced Pulmonary Arterial Hypertension.||University of Alberta|Yes|Completed|March 2010|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083524||125290|
NCT01083914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-113|Comparing Blood Loss, RBC Transfusions and Inflammatory Marker Changes Among Methods of CPB|Investigation of the Ability of the MECC System to Provide Reduced Risk Over the Existing CECC System and Equivalent Risk to Off-Pump CABG Surgery: The IMPROVE TRIAL||Baylor Research Institute|No|Completed|March 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|102|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Hospital facility|August 2013|August 22, 2013|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083914||125261|
NCT01085630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-30901|Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy|Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy||Alliance for Clinical Trials in Oncology|No|Recruiting|April 2010|||December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|137|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085630||125129|
NCT01085643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17482|Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)|The Effect of Lubiprostone on Patterns of Contractions in the Small Bowel in Female Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)||Cedars-Sinai Medical Center|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|4|||Female|18 Years|N/A|No|||November 2011|November 8, 2011|March 11, 2010||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT01085643||125128|Limited time period resulting in recruitment of only 4 patients.
NCT01085370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICARTA-B|Psychological Interventions in Children After Road Traffic Accidents or Burns|Psychological Interventions in Children After Road Traffic Accidents or Burns: a Randomized Controlled Study|PICARTA-B|University Children's Hospital, Zurich|No|Completed|April 2010|August 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Both|2 Years|16 Years|No|||March 2014|March 17, 2014|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085370||125149|
NCT01113372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMIZE|Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial|Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial|OPTIMIZE|Cardiovascular Research Center, Brazil|Yes|Completed|April 2010|July 2015|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|3119|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01113372||123004|
NCT01081912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX002-0801|Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain|A Randomized Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Tolerability and Safety of Hydrocodone Bitartrate Controlled-Release Capsules in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain||Zogenix, Inc.|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|510|||Both|18 Years|75 Years|No|||March 2014|March 25, 2014|March 4, 2010|Yes|Yes||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01081912||125414|
NCT01081925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSM0021620817-HKJC|Congestive Heart Failure: Causes of Sudden Worsening|Congestive Heart Failure: Causes of Sudden Worsening||University Hospital Hradec Kralove|No|Recruiting|February 2010|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients suffering from sudden worsening of congestive heart failure, who are examined at        the Emergency department or admitted to University Hospital|February 2010|March 4, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081925||125413|
NCT01113346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/09-AVVA RUS|A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis|Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Filtrum-STI, 0,4g Tablets (Produced by AVVA RUS) in Children With Viral Gastroenteritis|F-GE-09|Avva Rus, JSC|Yes|Recruiting|June 2010|February 2011|Anticipated|December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|1 Month|4 Years|No|||July 2010|July 13, 2010|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113346||123006|
NCT01113359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCY-CV-2010001|The Link Between Human Cytomegalovirus (HCMV) and Hypertension|The Potential Link Between HCMV Infection and Essential Hypertension||Beijing Chao Yang Hospital|No|Recruiting|April 2010|May 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|300|Samples Without DNA|plasma|Both|30 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|essential hypertensive patients:|April 2010|April 28, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113359||123005|
NCT01114204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-IDA-302|A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia|A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia||AMAG Pharmaceuticals, Inc.|Yes|Completed|June 2010|June 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|605|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114204||122940|
NCT01114217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-IDA-303|Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia|A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia||AMAG Pharmaceuticals, Inc.|Yes|Completed|July 2010|May 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|634|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114217||122939|
NCT01114165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM-SF-042010|Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients|Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients||University Hospital Muenster||Completed|May 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|150|||Both|18 Years|N/A|No|||November 2012|December 4, 2012|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01114165||122943|
NCT01114178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL 2009/14|Walking Impairment Questionnaire in PAD|Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Des Patients adressés Pour un Test de Marche Sur Tapis Roulant|WELCH|University Hospital, Angers|Yes|Recruiting|November 2009|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|patients referred for treadmill testing|June 2010|June 24, 2010|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01114178||122942|
NCT01114191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-306|A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)|Ph I Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)||Abbott|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114191||122941|
NCT01114529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2429|Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients|A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion|ELEVATE|Novartis|Yes|Completed|August 2010|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|825|||Both|18 Years|75 Years|No|||October 2015|October 5, 2015|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114529||122915|
NCT01085812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-05|Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|348|||Both|18 Years|65 Years|No|||December 2011|December 29, 2011|March 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085812||125115|
NCT01081847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVDC 2003-002|Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants|Malaria Vaccine Phase IB Clinical Trial: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants|Fase1B|Malaria Vaccine and Drug Development Center|Yes|Completed|July 2005|April 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 5, 2010|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01081847||125419|
NCT01082120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00028|Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus|Open, Randomized, Phase I Study in Subjects With Type 2 Diabetes Mellitus Treated With Metformin to Evaluate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa||AstraZeneca|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|N/A|No|||July 2010|July 9, 2010|March 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01082120||125398|
NCT01082510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMBARK|Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)|Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study||Urological Oncology Council of Northern Tokyo|No|Recruiting|January 2010|December 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|288|||Both|20 Years|80 Years|No|||October 2010|March 22, 2011|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082510||125368|
NCT01084252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10893|Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies|A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies||Sanofi|No|Recruiting|May 2010|July 2018|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|278|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01084252||125235|
NCT01083043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06035|Continuous Glucose Monitoring in Type 2 Diabetes Mellitus|Glycemic Variability Predicts Endothelial Dysfunction||Winthrop University Hospital|No|Completed|December 2006|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|Samples Without DNA|Serum samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult subjects with Type 2 Diabetes Mellitus from an outpatient Endocrinology Practice|January 2013|January 15, 2013|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01083043||125327|
NCT01083316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28441|Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis|Phase II Trial of Induction Therapy With Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation in Patients With AL Amyloidosis||Boston Medical Center|Yes|Active, not recruiting|September 2009|December 2040|Anticipated|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01083316||125306|
NCT01083563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB-27325|Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy|The Morphologic and Functional Relationship Between the Draining PLN and Synovial Inflammation in the Knee Joints of RA Patients Before and After Anti-TNF or B Cell Depletion Therapy||University of Rochester|No|Terminated|July 2009|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female RA sufferers not less than 18 yrs of age who are currently experiencing        knee synovitis. Racial and ethnic origin of subjects will be monitored to reflect the        diversity of our community.|April 2015|April 7, 2015|March 8, 2010|No|Yes|Funding has ended prior to complete enrollment|No||https://clinicaltrials.gov/show/NCT01083563||125287|
NCT01083537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBO-CHEMO-BSC|Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction|Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction||University Health Network, Toronto|No|Terminated|February 2010|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|March 1, 2010|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01083537||125289|
NCT01083550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-0986-BE|Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer|Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial)||University Health Network, Toronto|No|Active, not recruiting|February 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|74|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01083550||125288|
NCT01116674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045186|Pediatric Critical Illness Hyperglycemia and Glycemic Control Registry|Pediatric Critical Illness Hyperglycemia and Glycemic Control Registry: A Project to Assist in the Improved Understanding of Hyperglycemia and Glycemic Control in Pediatric Critical Illness.||Indiana University|Yes|Completed|May 2010|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|206|||Both|N/A|21 Years|No|Non-Probability Sample|Childern upto 18 or 21 years old admitted to pedaitric intensive care units who are ar        risk for deleveloping critical illness hyperglycemia.|August 2015|August 28, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116674||122752|
NCT01085903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110644|Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia|Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia||University of Arkansas|Yes|Completed|March 2010|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|19 Years|85 Years|No|||August 2015|August 3, 2015|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01085903||125108|
NCT01113385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4657|Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome|Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study||Children's Research Institute|No|Completed|October 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|2 Years|21 Years|No|||September 2014|September 8, 2014|April 28, 2010|No|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT01113385||123003|
NCT01113073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN_IC_BL_01/2010|The Distribution of Pressure in the Thorax During Mechanical Ventilation and Its Effects on the Circulation|The Distribution of Pressure in the Thorax During Mechanical Ventilation and Its Effects on the Circulation||Radboud University|Yes|Recruiting|January 2010|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|N/A|N/A|No|||January 2010|August 30, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01113073||123027|
NCT01113086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001806|Use of Noninvasive Brain Stimulation in Parkinson's Disease|Selective Modulation of Cognitive, Affective, and Motor Function by Transcranial Direct Current Stimulation as Co-adjuvant Therapy in Parkinson's Disease.||Spaulding Rehabilitation Hospital|No|Completed|December 2009|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|12|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01113086||123026|
NCT01113892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCV00001506|Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.|Comparison of Safety and Primary Patency Between FUSION Vascular Graft With Bioline and EXXCEL Soft ePTFE (FINEST)|FINEST|Maquet Cardiovascular|Yes|Completed|April 2010|October 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|207|||Both|21 Years|N/A|No|||January 2014|January 15, 2014|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113892||122964|
NCT01114568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-039|Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)|A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04971729 in Lean To Obese, Otherwise Healthy Adult Subjects||Merck Sharp & Dohme Corp.|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|12|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|April 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114568||122912|
NCT01114581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-MUC-01|Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection||MCC/CC|Reckitt Benckiser LLC||Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||September 2012|September 7, 2012|April 28, 2010|Yes|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT01114581||122911|
NCT01114542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1993|A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes|A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|66|||Both|18 Years|65 Years|No|||September 2015|September 24, 2015|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114542||122914|
NCT01114555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-015|Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma|Combination of Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma: A Phase II Study||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|N/A|N/A|No|||November 2015|November 30, 2015|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114555||122913|
NCT01114880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-991|Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis|A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis||Abbott|No|Completed|January 2010|February 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|344|||Both|18 Years|65 Years|No|||November 2011|November 22, 2011|February 5, 2010||No||No|September 29, 2011|https://clinicaltrials.gov/show/NCT01114880||122888|
NCT01081613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2101|Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)|Imaging the Effect of HSP90 Inhibitor AUY922 on VEGF by Means of 89Zr-bevacizumab PET||University Medical Center Groningen|Yes|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Probability Sample|Patients with ER positive, hormone therapy refractory breast cancer, who are participating        in the phase I-II trial with HSP90 inhibitor AUY922|September 2012|September 5, 2012|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01081613||125437|
NCT01082133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicenter FA SCT|Multicenter Transplant Study for Fanconi Anemia|A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|October 2009|December 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||January 2016|January 26, 2016|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082133||125397|
NCT01082523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-AB_01|"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"|"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"||University of Texas Southwestern Medical Center|No|Recruiting|February 2010|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|40|||Both|12 Years|30 Years|No|||January 2010|March 5, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01082523||125367|
NCT01082770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEGOIRL|Randomised Controlled Trial of Needle Free Access Devices in Preventing Hemodialysis Blood Stream Infection|A Randomised Controlled Trial Comparing Bacteraemia Rates in Closed Luer Lock Access Devices(TEGO) With Standard Devices in the Outpatient Haemodialysis Population|TEGO|Beaumont Hospital|Yes|Enrolling by invitation|March 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|106|||Both|18 Years|N/A|No|||January 2010|March 8, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082770||125348|
NCT01083056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILM Peeling|Observational Study - ILM Peeling|Observational Study On Retinal Structure And Function Before And After Epimacular Membrane Peeling||University Hospital Tuebingen|No|Completed|March 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatients at the University Eye Hospital Tuebingen|July 2014|July 30, 2014|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083056||125326|
NCT01115517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pterygium Avastin study|Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery|A Pilot Study to Assess Safety and Efficacy of Intraoperative Topical Mitomycin C and Bevacizumab (Avastin) Applied to Bare Sclera in Pterygium Surgery||The University of Texas Health Science Center, Houston|No|Completed|October 2010|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01115517||122839|
NCT01083329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0816302|Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects|Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects|ANITA|University Hospital, Toulouse|No|Completed|January 2010|June 2012|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Male|25 Years|45 Years|No|||October 2012|October 22, 2012|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01083329||125305|
NCT01083576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-PANAMA-08-04; A-15810|Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama|Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama||U.S. Army Medical Research and Materiel Command|No|Completed|March 2010|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|5 Years|N/A|No|||May 2014|June 23, 2015|March 8, 2010|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01083576||125286|There are no PK tables for gentamicin due to low sample size; only 2 individuals with measureable gentamicin.
NCT01083589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0726|Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)|Phase II Study of Imatinib Mesylate and Docetaxel in Pretreated Patients With Metastatic NSCLC||M.D. Anderson Cancer Center|No|Completed|January 2005|July 2011|Actual|October 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083589||125285|
NCT01084239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002331|Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography|Rule Out Myocardial Ischemia/Infarction by Computer Assisted Tomography|ROMICAT-II|Massachusetts General Hospital|Yes|Completed|April 2010|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1000|||Both|40 Years|75 Years|No|||April 2014|April 8, 2014|January 7, 2010||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT01084239||125236|Enrollment occurred only during weekday hours.Lack of blinding to the intervention.Results may not be applicable to populations we did not study (i.e. patients younger than 40 years of age and those older than 74 years of age).
NCT01083966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912010765|Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma|Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma (Acoustic Neuroma)||Northwell Health|No|Suspended|August 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|March 8, 2010|No|Yes|In the process of transferring IRB to PI's current institution.|No||https://clinicaltrials.gov/show/NCT01083966||125257|
NCT01084213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiPcMA05|Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy|A Trial of Intermittent Preventive Treatment With Sulfadoxine-pyrimethamine Versus Intermittent Screening and Treatment of Malaria in Pregnancy|IPTp_IST|London School of Hygiene and Tropical Medicine|Yes|Completed|June 2010|October 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|5354|||Female|16 Years|45 Years|No|||April 2014|April 10, 2014|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01084213||125238|
NCT01084499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCD143|Bioequivalence Study of Letrozole 2.5 mg Tablets|Bioequivalence Study of YUHAN Letrozole 2.5 mg Tablets||Yuhan Corporation|No|Completed|January 2009|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084499||125216|
NCT01117272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-98009|The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women|Relationship of Metabolic Parameters, Endocrine and Prolactin Levels in Taiwan's Women With Polycystic Ovary Syndrome and Hyperprolactinemia.||Taipei Medical University WanFang Hospital|No|Completed|May 2009|April 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|474|||Female|15 Years|45 Years|No|Probability Sample|Polycystic Ovary syndrome(PCOS)|November 2013|November 13, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117272||122708|
NCT01113099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-1072|Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients|Assisted Detailing to Improve Guideline Adherence||Washington University School of Medicine|No|Completed|June 2006|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|247|||Both|18 Years|N/A|No|||April 2010|April 27, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01113099||123025|
NCT01116921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004M81177|Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates|Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|N/A|36 Hours|No|||July 2015|July 7, 2015|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116921||122733|
NCT01113398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022491|AMG 102 and Avastin for Recurrent Malignant Glioma|Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma||Duke University|No|Completed|August 2010|September 2015|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|April 28, 2010|Yes|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT01113398||123002|11/21/14 Amgen notified PI they stopped their own AMG102 studies due to increased risk found in the TX arm on a different study. Dr. Peters decided to stop TX on the 3 current subjects on her study at that time although no increased risks were found.
NCT01113684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091215017|Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)|Clinical and Neurophysiological Study of Subthalamic Brain Stimulation in PD||University of Alabama at Birmingham|Yes|Recruiting|April 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with Parkinson's disease who have undergone subthalamic deep brain stimulation|August 2015|September 15, 2015|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01113684||122980|
NCT01113632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CLL 11|Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||SCRI Development Innovations, LLC|No|Active, not recruiting|July 2010|November 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|April 28, 2010|Yes|Yes||No|May 18, 2015|https://clinicaltrials.gov/show/NCT01113632||122984|
NCT01113645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC0901|Impact of Cranioplasty On Cerebral Perfusion|The Impact of Cranioplasty on Local and Global Cerebral Blood Flow as Clinical Outcome Prognostic Factor in Patients Undergoing Decompressive Craniectomy for Severe Head Injury.|CCP|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2010|April 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Patient over 18 and up to 65 years who underwent decompressive craniectomy after severe        head injury, subarachnoid hemorrhage, intracerebral hemorrhage, venous sinus thrombosis        with hemorrhage / malignant edema and malignant middle cerebral artery stroke requiring of        course reconstructive cranioplasty.|December 2012|April 30, 2013|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113645||122983|
NCT01113905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-222|Role of Beta-Endorphin in Cancer Therapy Fatigue|Beta-Endorphin as a Mediator of Cancer Therapy-Induced Fatigue||Massachusetts General Hospital|Yes|Terminated|December 2009|August 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|18|Samples Without DNA|Blood samples to be measured for levels of beta-endorphin|Both|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients who plan to have radiation therapy only or radiation therapy and        chemotherapy after their mastectomy or lumpectomy.|August 2014|August 5, 2014|April 28, 2010||No|Insufficient recruitment was obtained|No||https://clinicaltrials.gov/show/NCT01113905||122963|
NCT01113918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-97070|Expression of CVD and HA Between Obesity and Non-obesity Polycystic Ovary Syndrome (PCOS) Women in Taiwan|A Study of Clinical Presentation and Cardiovascular Disease of Hyperandrogenism and Polycystic Ovary Syndrome in Obese and Non-obese Taiwanese Women||Taipei Medical University WanFang Hospital|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|627|||Female|15 Years|45 Years|No|Probability Sample|Polycystic Ovarian Syndrome(PCOS) women in wanfang hospital.|September 2013|September 29, 2013|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113918||122962|
NCT01114256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0053|FNA Tumor Sampling for CD137 Modulation: A Pilot Study|FNA Tumor Sampling for CD137 Modulation: A Pilot Study||Stanford University||Recruiting|March 2010|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|peripheral blood, fine needle aspiration biopsy|Both|21 Years|N/A|No|Non-Probability Sample|Patients at Stanford Cancer Center with lymphoma, squamous cell carcinoma of the head and        neck, HER2+ breast adenocarcinoma, colorectal adenocarcinoma, or other solid tumor.|August 2015|August 5, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01114256||122936|
NCT01114269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000840, 3041108|PRE-DETERMINE Cohort Study|PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study||Brigham and Women's Hospital|No|Active, not recruiting|June 2007|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5763|Samples With DNA|plasma, buffy coat, and red blood cells|Both|18 Years|N/A|No|Probability Sample|Participants will be recruited throughout multicenter sites participating in the        PRE-DETERMINE Cohort Study. We plan to enroll patients with a history of coronary artery        disease and documentation of either a prior myocardial infarction (MI) or mild to moderate        left ventricular dysfunction (LVEF 35-50%). The clinical study staff at each site, which        may be a research nurse, fellow, or physician will approach eligible patients to discuss        their potential participation.|September 2015|September 15, 2015|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114269||122935|
NCT01114893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-075|Travoprost Five Day Posology Study|||Alcon Research|No|Completed|April 2010|||May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|N/A|No|||May 2011|May 26, 2011|April 30, 2010|Yes|Yes||No|May 26, 2011|https://clinicaltrials.gov/show/NCT01114893||122887|
NCT01115114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090135H|Treatment of Metabolic Syndrome in a Community Mental Health Center|Treatment of Metabolic Syndrome in a Community Mental Health Center||The University of Texas Health Science Center at San Antonio|Yes|Completed|January 2009|January 2014|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|130|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01115114||122870|
NCT01081860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIF CTS|Stiffness of the Skin and Joints in Relation to Carpal Tunnel Syndrome|Correlation of Joint Stiffness and Stiffness of the Skin and the Prevelation of Carpal Tunnel Syndrome (CTS)|STIF-CTS|St. Antonius Hospital|No|Not yet recruiting|May 2010|December 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting with complaints of:          -  Carpal tunnel syndrome          -  Trigger finger          -  Dupuytren contracture          -  an acute trauma to the hand|April 2010|April 26, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01081860||125418|
NCT01081873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMOS-BELG-04-001|Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer|A Post-Marketing Observational Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatment of Advanced Prostate Cancer||Abbott||Completed|June 2004|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2717|||Male|18 Years|N/A|No|Non-Probability Sample|Urologists|October 2012|October 26, 2012|February 27, 2010||No||No|December 22, 2011|https://clinicaltrials.gov/show/NCT01081873||125417|
NCT01082536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRAC 120|Prospective Analysis of Cerebral Perfusion Using Head Ultrasound and Multi-source-detector Near Infrared Spectroscopy (NIRS) Imaging|Prospective Analysis of Regional Cerebral Perfusion Using Head Ultrasound and Multi-source-detector Near Infrared Spectroscopy (NIRS) Imaging||University of Texas Southwestern Medical Center|No|Active, not recruiting|May 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|70|Samples With DNA|Whole blood|Both|N/A|2 Months|No|Non-Probability Sample|Infants (up to 2 months) with congenital heart disease that undergo surgery at Children's        Medical Center Dallas (CMCD) will be eligible. All such patients will receive standard        pre-, intra-, and post-operative care.|December 2014|December 1, 2014|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082536||125366|
NCT01082549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11553|Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)|Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)|ECLIPSE|Sanofi|Yes|Completed|March 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|780|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 5, 2010|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01082549||125365|
NCT01082783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARIMIS|Autoimmune Phenomena After Acute Stroke|Autoimmune Phenomena After Acute Stroke - the Role of Stroke-induced Immunodepression|ARIMIS|Charite University, Berlin, Germany|No|Active, not recruiting|December 2009|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|65|Samples Without DNA|blood samples (serum and plasma)|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|acute media infarct or intracerebral bleeding|February 2013|February 26, 2013|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01082783||125347|
NCT01083641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO09711|Estrogen for Triple Negative Breast Cancer|A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer||University of Wisconsin, Madison|Yes|Terminated|January 2010|March 2015|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|N/A|No|||July 2015|July 22, 2015|March 8, 2010|Yes|Yes|did not meet efficacy goals after interim analysis|No||https://clinicaltrials.gov/show/NCT01083641||125281|
NCT01083082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/00233|Lifestyles and Endothelial Dysfunction|Physical Exercise, Fitness and Dietary Pattern and Theirs Relationship With Blood Pressure Circadian Pattern, Augmentation Index and Endothelial Dysfunction Biological Markers. (EVIDENT Study)|EVIDENT|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Recruiting|March 2010|March 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1500|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy people 20-80 aged that visit their family doctor and accept be involved in study        from six Spanish cities|March 2011|March 4, 2014|March 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01083082||125324|
NCT01116128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-210|Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients|A Multicenter, Open-label, Phase Ii Study of Dasatinib in Combination With Melphalan and Prednisone (D-MP) in Advanced, Relapsed / Refractory Multiple Myeloma Patients|D-MP|Fondazione Neoplasie Sangue Onlus|Yes|Terminated|February 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|75 Years|No|||June 2011|June 13, 2011|March 17, 2010||No|difficulty in enrolling patients|No||https://clinicaltrials.gov/show/NCT01116128||122794|
NCT01083979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021|Intravesical Liposomes for Ulcerative Cystitis|Intravesical Liposomes for Ulcerative Cystitis||William Beaumont Hospitals|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|20 Years|N/A|No|||July 2013|July 31, 2013|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01083979||125256|
NCT01084486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WolfsonMC-2007-9|Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease|||Wolfson Medical Center||Completed||||||Phase 1/Phase 2|Interventional|N/A|1||||||Both|40 Years|80 Years|No|||March 2010|March 9, 2010|March 9, 2010||||No||https://clinicaltrials.gov/show/NCT01084486||125217|
NCT01084759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J09121, NA_00033419|A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer|A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Terminated|March 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||November 2014|November 17, 2014|March 9, 2010||No|All study procedures are completed as planned.|No||https://clinicaltrials.gov/show/NCT01084759||125196|
NCT01085383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTUMI-03|Aripiprazole and Prolactin Study|Aripiprazole Treatment for Antipsychotic Induced Hyperprolactinaemia in Patients With Severe Mental Illness and Learning Disabilities|APS|University of Oxford|No|Completed|April 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|16 Years|60 Years|No|||May 2015|May 27, 2015|March 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085383||125148|
NCT01116973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1911|Reliability of Central Venous Pressure Measurements|Reliability of Central Venous Pressure Measurements From Peripherally Inserted Central Catheters vs. Centrally Inserted Central Catheters|CVP|University of Oklahoma|No|Recruiting|September 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|65|||Both|18 Years|90 Years|No|||December 2014|December 3, 2014|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116973||122729|
NCT01113112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0737 / 201104242|Biobehavioral Influences and the Ovarian Tumor Microenvironment|Biobehavioral Influences and the Ovarian Tumor Microenvironment||Washington University School of Medicine|No|Recruiting|July 2009|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|195|Samples With DNA|serum, saliva, tissue, ascites|Female|18 Years|N/A|No|Non-Probability Sample|Gyn/Onc patients at Washington University School of Medicine|December 2012|December 20, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113112||123024|
NCT01113125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015163-14|Scars After Central Venous Catheters|Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children||Aarhus University Hospital|Yes|Active, not recruiting|March 2010|July 2016|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|21 Years|No|||February 2014|February 11, 2014|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113125||123023|
NCT01113411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-525|Effectiveness of Intensive Rehabilitation on Shoulder Function After Proximal Humerus Fracture|Effectiveness of Intensive Rehabilitation on Shoulder Function After a Fracture of the Proximal Humerus Treated by Locked Plate. A Prospective Randomized Study||Hopital de l'Enfant-Jesus|No|Recruiting|December 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113411||123001|
NCT01113658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNaP-113009|Clinical Evaluation of the SNaP Wound Care System|Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System||Spiracur, Inc.|No|Recruiting|March 2010|March 2013|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2010|October 22, 2010|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113658||122982|
NCT01113671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDL005|Type 2 Diabetes Haptoglobin Phenotype and Vitamin E|Evaluating the Effect of Vitamin E Treatment on HDL Function of Type 2 Diabetic Patients and the Correlation to Hp Phenotype. A Prospective, Double Blind, Randomized, Placebo Controlled Trial (IDEAL2 Study)|IDEAL2|Technion, Israel Institute of Technology|No|Completed|January 2009|January 2011|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|90|||Both|55 Years|N/A|No|||January 2011|January 10, 2011|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113671||122981|
NCT01114243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03112010-5202|Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis|Pilot Study: Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis||Stanford University|No|Withdrawn|May 2010|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|21 Years|No|Probability Sample|We will enroll any gender and/or ethnic background child or young adult meeting the        inclusion/exclusion criteria as detailed above.|November 2011|November 10, 2011|March 30, 2010||No|The PI has left Stanford University.|No||https://clinicaltrials.gov/show/NCT01114243||122937|
NCT01114295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTE vs Capsule 2010|Computed Tomography Enterography (CTE) Versus Capsule Endoscopy for Overt, Obscure Gastrointestinal (GI) Bleeding|Comparative Effectiveness of Wireless Capsule Endoscopy and Dual Energy, Phase CT Enterography in the Evaluation of Overt Obscure GI Bleeding||Brigham and Women's Hospital|Yes|Withdrawn|March 2010|January 2012|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|April 29, 2010||No|The study was stopped before the first patient was enetered due to logistical issues and lack    of funding.|No||https://clinicaltrials.gov/show/NCT01114295||122933|
NCT01114308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-806|A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction|A Randomized, Placebo and Active-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence||Titan Pharmaceuticals|Yes|Completed|April 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|287|||Both|18 Years|65 Years|No|||October 2012|October 6, 2014|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114308||122932|
NCT01114594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003010924|Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease|Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease||The Rogosin Institute|No|Completed|April 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|42|Samples With DNA|Plasma, serum, monocytes, urine|Both|18 Years|N/A|No|Probability Sample|20 outpatients, 20 patients control|August 2012|August 9, 2012|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01114594||122910|
NCT01114906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RES-DUM-2010/1|Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia|Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia||AstraZeneca|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|292|||Both|15 Years|N/A|No|Probability Sample|Ambulatory patients followed-up in Primary or Specialized Care Services (hospital)|September 2011|September 16, 2011|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01114906||122886|
NCT01082146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050262|RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [Issthiazolyl-3-14C]-Lurasidone Following Postprandial Single Oral Dose Administration in Health Male Subjects||Sunovion|Yes|Completed|August 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|March 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01082146||125396|
NCT01082159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiDAS II|MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study||Vertos Medical, Inc.|Yes|Completed|February 2010|January 2013|Actual|October 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|March 4, 2010|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT01082159||125395|
NCT01083355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29278|Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury (ALI)|Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury||Boston Medical Center|No|Recruiting|March 2010|June 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to adult medical, surgical, and coronary critical care units at Boston        Medical Center.|July 2015|July 20, 2015|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01083355||125303|
NCT01083654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0194|Menominee Stop Tobacco Abuse Renew Tradition Study|Menominee Smoking Cessation Clinical Trial|START|University of Wisconsin, Madison|No|Completed|February 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|March 8, 2010||No||No|December 29, 2015|https://clinicaltrials.gov/show/NCT01083654||125280|
NCT01083667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903010259|SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)|Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS||Weill Medical College of Cornell University|Yes|Active, not recruiting|November 2009|April 2016|Anticipated|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 17, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01083667||125279|
NCT01083992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD+ Vitamin D|Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)||Ziv Hospital|Yes|Not yet recruiting|April 2012|June 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2010|April 27, 2011|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01083992||125255|
NCT01084512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701293|Chest Wall Kinematics and Respiratory Muscle Action During Supine Breathing in Individuals With and Without Spinal Cord Injury|Phase 0 Study of Chest Wall Kinematics and Respiratory Muscle Action During Supine Breathing in Individuals With and Without Spinal Cord Injury.|SCI|National Taiwan University Hospital|Yes|Completed|July 2005|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|50|||Male|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|February 2010|March 9, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01084512||125215|
NCT01115790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13129|A Phase 1 Study in Participants With Advanced Cancer|A Phase 1 Study of LY2606368 in Patients With Advanced Cancer||Eli Lilly and Company|No|Active, not recruiting|February 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|April 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115790||122818|
NCT01085045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT0031002|Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (7 Days), Four-Period, Eight-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Two Doses of PT003, Two Doses of PT005 and One Dose of PT001 in Patients With Moderate to Very Severe COPD, Compared With Foradil® Aerolizer® (12 μg, Open-Label) and Spiriva® Handihaler® (18 μg, Open-Label) as Active Controls||Pearl Therapeutics, Inc.|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|118|||Both|40 Years|80 Years|No|||September 2012|September 11, 2012|March 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01085045||125174|
NCT01116401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001557|Impact of Hot Flashes on Sleep and Mood Disturbance|Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance||Massachusetts General Hospital|Yes|Active, not recruiting|October 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116401||122773|
NCT01116934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLS-Cytokines|Cytokines in Papillon-Lefèvre Syndrome|Observational Study on Cytokine Production by Leukocytes of Papillon-Lefèvre Syndrome Patients and Healthy Probands in Whole Blood Cultures||Goethe University|No|Completed|July 2006|December 2009|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|17|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|5 patients with established diagnose of PLS are under periodontal treatment at the        Department of Periodontology, Center for Dental, Oral, and Maxillofacial Medicine        (Carolinum) of the JWG-University Frankfurt am Main. Antiinfective therapy with adjunctive        antibiotics has been rendered to all of them and they are under regular and frequent        supportive therapy. The Department of Periodontology has contact to additional 5 PLS        patients that are edentulous or under periodontal therapy elsewhere.|February 2016|February 23, 2016|May 3, 2010||No||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01116934||122732|
NCT01113138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9727b|Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers|Pharmacokinetic Study of Mablet as Oral Supplement and Magnesium Sulfate as Infusion||University of Aarhus|Yes|Completed|December 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|10|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113138||123022|
NCT01113151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9727c|Daily Magnesium-supplement for Severe Asthmatics|Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics||University of Aarhus|Yes|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|70 Years|No|||September 2013|September 3, 2013|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113151||123021|
NCT01113164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA016079-01A1|Matching Genotypes and Serotonergic Medications for Alcoholism|Matching Genotypes and Serotonergic Medications for Alcoholism||Brown University|Yes|Completed|September 2008|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|79|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 18, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113164||123020|
NCT01113424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1071|Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum|Bioequivalence Between Oral Nicotine Replacement Products and Nicorette® Gum - A Study in Healthy Smokers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|September 2008|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|88|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113424||123000|
NCT01113931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-04809|Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin|Safety and Efficacy of WC2031 Versus Vibramycin for the Treatment of Uncomplicated Urogenital Chlamydia Trachomatis Infection: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter Study||Warner Chilcott|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|495|||Both|19 Years|45 Years|No|||December 2011|December 21, 2011|April 28, 2010|Yes|Yes||No|November 9, 2011|https://clinicaltrials.gov/show/NCT01113931||122961|
NCT01113944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YEL1|Training in the Workplace|Training in the Workplace||Massachusetts General Hospital|No|Completed|April 2010|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113944||122960|
NCT01114230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009002|A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer|A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma||Astellas Pharma Inc|No|Completed|August 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|26|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114230||122938|
NCT01113957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-757|A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer|A Phase 2 Randomized Clinical Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects With Recurrent High Grade Serous Ovarian Cancer||AbbVie|No|Completed|March 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Female|18 Years|N/A|No|||June 2014|June 25, 2014|February 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113957||122959|
NCT01113970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBL2001|Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer|Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer||Ziopharm|No|Active, not recruiting|March 2010|May 2013|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2012|January 29, 2013|April 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113970||122958|
NCT01114932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011544|The Optimum Time for Preoxygenation Based on Body Mass Index|The Optimum Time for Preoxygenation Based on Body Mass Index||Cedars-Sinai Medical Center|Yes|Completed|July 2007|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|75|||Both|18 Years|50 Years|No|Non-Probability Sample|The study population will consist of 100 subjects between the ages of 18-50 classified as        ASA 1 or 2 with no limitations as to gender or race that are scheduled for elective        surgery at Cedars-Sinai Medical Center. There are changes to lung functioning as        functional residual capacity (FRC), closing capacity, and lung volume after age 50;        therefore, the age limitation is set to age 50. Changes in lung and chest wall compliance        necessitate the exclusion of anyone over the age of 50. Minors are also excluded as there        is difficulty fitting the face mask due to a smaller physiology.|February 2012|February 14, 2012|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01114932||122884|
NCT01114607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114203|A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects|A Single Dose, Randomized, Five-Period Crossover Study to Assess the Relative Bioavailability of Four New Formulations of the CCR9 Receptor Antagonist GSK1605786A (CCX282) in Healthy Male and Female Subjects||GlaxoSmithKline||Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 8, 2010|April 29, 2010||||No||https://clinicaltrials.gov/show/NCT01114607||122909|
NCT01114620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114270|Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older|Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine Arepanrix™ (GSK2340274A) in Adults 65 Years of Age or Older||GlaxoSmithKline||Completed|May 2010|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 21, 2013|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114620||122908|
NCT01114633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-98039|Obesity and Clinical Presentation of Hyperandrogenism|Obesity and Clinical Presentation of Hyperandrogenism||Taipei Medical University WanFang Hospital|No|Completed|June 2009|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Female|15 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Polycystic Ovary Syndrome(PCOS)|November 2013|November 4, 2013|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114633||122907|
NCT01114919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|282/2009|Helping Problem Drinkers on the Internet|Helping Problem Drinkers on the Internet||Centre for Addiction and Mental Health|No|Completed|May 2010|||November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|246|||Both|19 Years|N/A|No|||December 2010|December 1, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01114919||122885|
NCT01083095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVDC-2003-003|Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers|Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers|ChallengeII|Malaria Vaccine and Drug Development Center|Yes|Completed|January 2005|December 2006|Actual|March 2005|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2006|March 8, 2010|March 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01083095||125323|
NCT01114815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU IRB #09-0214|Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)|Natural History of CADASIL: Migraine, Diagnosis and Misdiagnosis||New York University School of Medicine|Yes|Completed|March 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Anyone with confirmed diagnosis of CADASIL|January 2013|January 18, 2013|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114815||122893|
NCT01114828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-004|A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema|A Multi-center, Double-blind, Parallel-arm Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema||Otsuka Pharmaceutical Co., Ltd.|No|Completed|February 2010|December 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|80 Years|No|||January 2014|January 30, 2014|April 29, 2010||No||No|December 15, 2013|https://clinicaltrials.gov/show/NCT01114828||122892|
NCT01115062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-10-2182|Comparison of Synera Patch Versus LMX-4 Cream Versus Placebo Patch for Pain Reduction During Venipuncture in Children|Comparison of Lidocaine/Tetracaine Patch (SyneraTM), 4% Liposomal Lidocaine Cream (LMX-4) and Placebo for Pain Reduction During Venipuncture in Children||CAMC Health System|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||January 2014|January 31, 2014|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01115062||122874|
NCT01115283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01EY001728|An Active Approach to Treat Amblyopia: Perceptual Learning and Video Games|Improving Spatial and Temporal Vision in Adult and Juvenile Amblyopia||University of California, Berkeley|No|Recruiting|July 2015|May 2020|Anticipated|May 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|5 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01115283||122857|
NCT01115296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-Progastria|Control of Helicobacter Pylori Infection by Probiotics|Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri||University of Bari|Yes|Recruiting|January 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||August 2012|August 16, 2012|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01115296||122856|
NCT01115842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10184-2009CTIL|Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI)|Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels||Meir Medical Center|Yes|Recruiting|June 2010|January 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2010|August 19, 2010|May 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01115842||122816|
NCT01115855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141114|Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure|The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure||Pfizer|Yes|Completed|July 2010|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|55 Years|N/A|No|||October 2015|October 6, 2015|April 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01115855||122815|
NCT01115803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12531|A Study of LY2584702 With Erlotinib or Everolimus in Patients With Solid Tumors|A Phase 1b Trial of LY2584702 in Combination With Erlotinib or Everolimus in Patients With Solid Tumors||Eli Lilly and Company|No|Terminated|March 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|No|||January 2012|January 6, 2012|April 22, 2010|No|Yes|Primary objective has been met; safety and pharmacokinetics have been characterized.|No||https://clinicaltrials.gov/show/NCT01115803||122817|
NCT01116414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|697|Molecular Phenotypes for Cystic Fibrosis Lung Disease|Molecular Phenotypes for Cystic Fibrosis Lung Disease||University of North Carolina, Chapel Hill|No|Enrolling by invitation|July 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|15 Years|N/A|No|Non-Probability Sample|CF patients who have the same CFTR genetic background, i.e., homozygous deltaF508, and who        are at the extremes of pulmonary phenotype, i.e., the most severe and mildest lung        disease.|June 2015|June 11, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116414||122772|
NCT01116115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InFat_005|The Effects of Dietary Palmitic Acid Triacylglyceride Position on Intestinal Parameters in Infants (InFat_005)|The Effects of Dietary Palmitic Acid Triacylglyceride Position on Intestinal Parameters, Anthropometric Parameters and Stool Characteristics in Term Infants||Enzymotec|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|30|||Both|N/A|7 Days|Accepts Healthy Volunteers|||May 2011|May 16, 2011|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01116115||122795|
NCT01116947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LABioMed 13892-01|Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study|Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study: An Investigator Initiated Study|FrEDI|Los Angeles Biomedical Research Institute|Yes|Completed|July 2010|February 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|108|||Both|18 Years|85 Years|No|||February 2012|February 27, 2012|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116947||122731|
NCT01116700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-AF-02-2010|Dexmedetomidine in Seizure Patients|The Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Patients With Seizure Disorders||University of California, San Francisco|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116700||122750|
NCT01112852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVL + PPI|EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding|A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding|EVL|National Science Council, Taiwan|Yes|Completed|December 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|80 Years|No|||April 2010|April 27, 2010|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01112852||123044|
NCT01112865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6281297|Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects|A Multicenter, Open-label, Randomized Two Arm Cross Over Study Assessing Dyad (Subject and Caregiver) and Adult Subject Perception of Convenience and Preference of the Newly Developed Genotropin Mark VII Pen.|CHOOSE|Pfizer|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|4 Years|N/A|No|||May 2012|May 15, 2012|April 20, 2010|Yes|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT01112865||123043|
NCT01113177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-2010|Effect of Functional Treatment on Mandibular Asymmetric Growth|Effect of Functional Treatment on Mandibular Asymmetry Caused by Unilateral Temporomandibular Joint Involvement in Children With Juvenile Idiopathic Arthritis||University of Aarhus|No|Completed|June 1994|October 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|22|||Both|5 Years|18 Years|No|Non-Probability Sample|Juvenile Idiopathic arthritis patients diagnosed with unilateral temporomandibular joint        arthritis and an asymmetric mandibular growth pattern|November 2010|November 8, 2010|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01113177||123019|
NCT01113996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081108|Monitoring Patients Who Are Obese Surgery for Gastric By-pass Protein Supplementation and Physical Training (PROMISE)|Optimization of Monitoring Patients Who Are Obese Surgery for Gastric By-pass Protein Supplementation and Physical Training: Interventional Randomized Trial|PROMISE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|78|||Female|18 Years|60 Years|No|||April 2015|April 27, 2015|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01113996||122956|
NCT01113697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02114|Genetics of the Early and Late Response to Allergen Challenge|Molecular Mechanisms Involved in the Early and Late Responses to Allergen Challenge, in Asthmatic and Allergic Rhinitis Cohorts||University of British Columbia|No|Recruiting|August 2009|September 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|520|Samples With DNA|Whole blood, plasma, white cells|Both|19 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Asthmatic and/or allergic rhinitis ('hay fever') individuals, 19 years or older|December 2015|December 17, 2015|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113697||122979|
NCT01113983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EW-P-001|Transfemoral & Transapical Placement of Aortic Balloon Expandable Transcatheter Valves Trial (JAPAN)|A Clinical Trial of a Transcatheter Bioprosthetic Valve for Patients With Aortic Stenosis|PREVAIL JAPAN|Edwards Lifesciences|Yes|Active, not recruiting|April 2010|April 2016|Anticipated|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|N/A|N/A|No|||February 2014|February 19, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01113983||122957|
NCT01114282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMYL0014|Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM|A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma||Stanford University||Completed|August 2010|||February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114282||122934|
NCT01114659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-98076|The Study of Polycystic Ovary Syndrome(PCOS) With Gene and Questionnaire|The Study of Metabolic and Cardiac Vascular Risk in Patients With Polycystic Ovary Syndrome||Taipei Medical University WanFang Hospital|Yes|Completed|November 2009|October 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|169|||Female|15 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Polycystic Ovary Syndrome(PCOS)|December 2013|December 30, 2013|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114659||122905|
NCT01115166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVECC|Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation|Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation||University Hospital, Linkoeping|No|Completed|May 2010|May 2012|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients subjected to open cardiac surgery, with the help of extracorporal circulation.|September 2012|September 6, 2012|May 3, 2010||No||No|May 11, 2012|https://clinicaltrials.gov/show/NCT01115166||122866|The number of patients was small and it was not possible to use a reference method. Standardization was difficult due to the fact that it was a clinical study.
NCT01115387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-11-008|GARM II: A Study on the Genetics of Age-related Maculopathy|Genetics of Age Related Maculopathy||University of California, Los Angeles|No|Recruiting|August 2009|August 2016|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|7000|Samples With DNA|Saliva or blood|Both|49 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nationwide study|March 2012|March 1, 2012|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01115387||122849|
NCT01114451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002576|Early Versus Delayed Skin Staple Removal Following Cesarean Delivery in the Obese Patient|A Randomized Controlled Trial of Early Versus Delayed Skin Staple Removal Following Cesarean Delivery in the Obese Patient||Greenville Health System|No|Terminated|October 2009|February 2012|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|292|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||March 2012|March 16, 2012|April 16, 2010||No|Funding limits exceeded prior to complete enrollment.|No||https://clinicaltrials.gov/show/NCT01114451||122921|
NCT01114464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD09/6-J|Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer|Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer|Resova|Nantes University Hospital|No|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|250|Samples Without DNA|Serum|Female|18 Years|39 Years|No|Non-Probability Sample|Young women with breast cancer|September 2013|September 27, 2013|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01114464||122920|
NCT01115075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 29017|Oscillations of Dietary Fat/Carbohydrate Intake Over Interval of 3 to 4 Days|Oscillations in Dietary Fat Intake and Leptin Changes Among People Who Record Dietary Intake Accurately: the Dietitian Study II|Dietitian II|Pennington Biomedical Research Center|No|Completed|March 2010|June 2014|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01115075||122873|
NCT01115309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1677-001|XprESS Registry Study|XprESS Registry Study||Entellus Medical, Inc.|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|175|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01115309||122855|
NCT01115322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114573|A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers||GlaxoSmithKline|No|Completed|April 2010|August 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|9||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|April 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115322||122854|
NCT01115530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7142-R|Exercise and Nutritional Intervention for Deconditioned Older Adults|An Exercise and Nutritional Intervention for Deconditioned Older Adults||VA Office of Research and Development|Yes|Withdrawn|May 2011|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Male|65 Years|90 Years|No|||April 2012|April 11, 2012|February 25, 2010||No|Insufficient subject recruitment.|No||https://clinicaltrials.gov/show/NCT01115530||122838|
NCT01116453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002022R|Randomized Controlled Trial of Acupuncture for Dysmenorrhea|Randomized Controlled Trial of Acupuncture on the Effect of Quality of Life and Clinical Efficacy for Dysmenorrhea Patients.||National Taiwan University Hospital|Yes|Completed|May 2010|November 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Female|13 Years|N/A|No|||February 2013|March 5, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116453||122769|
NCT01116466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-SA844-100|Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System|Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System||Otto Bock Healthcare Products GmbH|No|Completed|August 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|April 23, 2010||No||No|July 22, 2013|https://clinicaltrials.gov/show/NCT01116466||122768|
NCT01116427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN035AI|A Cooperative Clinical Study of Abatacept in Multiple Sclerosis|A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis|ACCLAIM|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2010|February 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116427||122771|
NCT01116141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-4051-RA202|A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)|A Phase II, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy|MOTION|Chelsea Therapeutics|Yes|Completed|September 2010|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|250|||Both|18 Years|80 Years|No|||April 2013|April 9, 2013|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116141||122793|
NCT01116687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02845|RO4929097 in Treating Patients With Metastatic Colorectal Cancer|A Phase 2 Open-Label Study of RO4929097 in Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|May 2010|March 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2012|May 2, 2014|April 28, 2010|Yes|Yes||No|April 13, 2012|https://clinicaltrials.gov/show/NCT01116687||122751|
NCT01116960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13878|How do Attitude About Pay for Performance Differ Among Different Anesthesia Care Provider and Over Time|How do Attitute About Pay for Performance Differ Among Different Anesthesia Care Provider and Over Time|P4P|University of Oklahoma|No|Completed|April 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|100|||Both|24 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|anesthesia care providers|May 2010|May 4, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116960||122730|
NCT01116999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19781007|Retrograde Light Target Tracheal Intubation Technique:Clinical Comparison With Direct Pharyngoscopic Tracheal Intubation|Clinical Comparison of Direct Pharyngoscopic Tracheal Intubation Technique With Light-guided Tracheal Intubation||Second Military Medical University|Yes|Completed|May 2010|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|200|||Both|18 Years|55 Years|No|||September 2011|September 25, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01116999||122727|
NCT01112878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019373|Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery|Randomized, Double-Blinded, Placebo-controlled Study to Evaluate the Analgesic Efficacy of Oral Clonidine and Gabapentin as Part of a Multi-modal Analgesic Regimen for Preventing Pain After Arthroscopic Shoulder or Knee Surgery||Cedars-Sinai Medical Center|Yes|Withdrawn|June 2015|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 10, 2015|April 23, 2010||No|Several studies going on at the same time.|No||https://clinicaltrials.gov/show/NCT01112878||123042|
NCT01113190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA026029|Healthier You: Optimizing Screening, Brief Interventions, and Referral to Treatment (SBIRT) in the Emergency Department|Optimizing SBIRT for Drug-Using Patients in an Inner-City Emergency Department||University of Michigan|No|Completed|February 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Actual|878|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01113190||123018|
NCT01113749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-3105|Improving Decision Making About Feeding Options for Dementia|Improving Decision Making About Feeding Options for Dementia||University of North Carolina, Chapel Hill|Yes|Completed|May 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|256|||Both|65 Years|N/A|No|||April 2012|July 3, 2012|April 15, 2010||No||No|April 17, 2012|https://clinicaltrials.gov/show/NCT01113749||122975|Cluster randomization required, preventing double-blinding.
NCT01113710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0948|Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise|Non-Interventional Study (NIS) in Patients With Restless Legs Syndrome (RLS) to Assess the Effectiveness and Safety of Neupro® in Daily Practise|RLS-Practise|UCB Pharma|No|Completed|May 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|687|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with a diagnosis of moderate to severe idiopathic RLS treated with Neupro®        in routine daily practice.|August 2012|August 28, 2012|April 28, 2010|No|Yes||No|July 6, 2012|https://clinicaltrials.gov/show/NCT01113710||122978|
NCT01114646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03001334HU|Functional Status, Morbidity and Mortality in Cemented Versus Press-Fit Hemiarthroplasty|Functional Status, Morbidity and Mortality in Cemented Versus Uncemented Hemiarthroplasty for Subcapital Hip Fractures: A Prospective Randomized Trial||Hartford Hospital|No|Completed|March 2005|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|55 Years|N/A|No|||January 2012|February 9, 2012|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114646||122906|
NCT01084395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H03-00001528-MI|Reducing HIV Risk Among Mexican Youth|Reducing HIV Risk Among Mexican Youth||University of Michigan|No|Completed|September 2002|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1620|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2010|March 17, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084395||125224|
NCT01084408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pac 14|Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™|Randomized Trial on the Treatment of Coronary De-novo Lesions With a Drug Eluting Stent or a Drug Coated Balloon|PEPCAD-DEBonly|University Hospital, Saarland|No|Recruiting|March 2010|March 2018|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|19 Years|N/A|No|||November 2011|November 29, 2011|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01084408||125223|
NCT01114945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019199|Comparative Effectiveness of Intubating Devices in the Morbidly Obese|A Prospective Study Comparing Video Laryngoscopy Devices to Direct Laryngoscopy for Tracheal Intubation of Patients Undergoing Bariatric Surgery||Cedars-Sinai Medical Center|Yes|Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|121|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|April 23, 2010||No||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01114945||122883|
NCT01115179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APSIC 04-014|Propofol and Perioperative Inflammation|Propofol and/or Its Solvent Modify the Course of Inflammatory Response After Surgical Stress: A Randomized, Controlled, Double-blind Study||University Hospital, Geneva|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|79|||Male|30 Years|70 Years|Accepts Healthy Volunteers|||April 2010|May 17, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01115179||122865|
NCT01114841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114572|A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers||GlaxoSmithKline|No|Completed|March 2010|September 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|254|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114841||122891|
NCT01114854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|538P108|A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)|A Conversion Study to Determine the Relative Bioavailability of TPM MR vs TPM IR in Subjects With Epilepsy||Supernus Pharmaceuticals, Inc.|No|Completed|June 2010|January 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||May 2013|May 22, 2013|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114854||122890|
NCT01115335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS123541-06|Feasibility, Acceptability, and Safety of Neonatal Male Circumcision in Lusaka, Zambia|Feasibility, Acceptability, and Safety of Neonatal Male Circumcision at the University Teaching Hospital in Lusaka, Zambia and in the Lusaka District in Zambia Using Gomco; Plastibell; and Mogen Methods||University of Alabama at Birmingham|Yes|Completed|October 2009|January 2012|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|661|||Male|N/A|28 Days|Accepts Healthy Volunteers|||April 2010|July 12, 2012|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115335||122853|
NCT01115543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|358/2551|Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism|A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients||Mahidol University|Yes|Completed|August 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||May 2010|May 1, 2010|May 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01115543||122837|
NCT01116167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|you070316|Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine|Letrozole and Berberine in Infertile PCOS Patients||Heilongjiang University of Chinese Medicine|No|Recruiting|October 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|660|||Female|20 Years|40 Years|No|||May 2013|May 17, 2013|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116167||122791|
NCT01116180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HypoRas|Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System|Influence of Blockade of the Renin-angiotensin System for Preservation of Cognitive Function, Hormonal Counter-regulatory Response, Symptomatology and Cardiac Repolarisation During Hypoglycaemia in Patients With Type 1 Diabetes||Hillerod Hospital, Denmark|No|Completed|April 2010|February 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01116180||122790|
NCT01116154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08144|Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma|A Phase I Study of the Combination of Lenalidomide With the Histone Deacetylase Inhibitor, Vorinostat in Hodgkin and Non Hodgkin's Lymphoma||City of Hope Medical Center|Yes|Terminated|May 2010|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2010|December 8, 2010|April 30, 2010|No|Yes|Sponsor withdrew support for the study|No||https://clinicaltrials.gov/show/NCT01116154||122792|
NCT01116440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGS649A2202|A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis|A Double Blind, Randomized, Controlled, Multicenter, Efficacy and Safety Study of Oral BGS649 vs. Placebo (Each Co-administered With a Combined Oral Contraceptive) Assessing Pain Response in Patients With Refractory Endometriosis||Novartis||Terminated|April 2010|||July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Female|18 Years|49 Years|No|||July 2011|July 20, 2011|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116440||122770|
NCT01117012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX08-770-105|Rollover Study of VX-770 in Cystic Fibrosis Subjects|An Open-Label, Rollover Study to Evaluate the Long Term Safety and Efficacy of VX-770 in Subjects With Cystic Fibrosis||Vertex Pharmaceuticals Incorporated|Yes|Completed|July 2010|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Both|6 Years|N/A|No|||June 2015|June 12, 2015|May 3, 2010|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01117012||122726|
NCT01112891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01261|Vitamin D in Pregnancy and Lactation|Vitamin D Dose-response Study Throughout Pregnancy and Lactation||University of British Columbia|No|Completed|March 2010|February 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|225|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112891||123041|
NCT01113736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-09-23|Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy|Pilot Study Evaluating the Efficacy of AlloMEM in Prevention of Intraperitoneal Adhesions & Peritoneal Regeneration After Loop Ileostomy|AlloMem|University Hospital Case Medical Center|Yes|Completed|January 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 12, 2014|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113736||122976|
NCT01113476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0855|Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies|Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|April 2010|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|N/A|N/A|No|||January 2016|January 14, 2016|April 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01113476||122996|
NCT01114321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0070|Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease|Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease||University Hospital, Clermont-Ferrand||Recruiting|May 2010|December 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|70 Years|No|||January 2011|January 18, 2011|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114321||122931|
NCT01114334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH082997|Motivational Interviews for Depression in Primary Care|Motivational Interviews Adapted to Improve Depression Treatment in Primary Care||Denver Health and Hospital Authority|Yes|Active, not recruiting|April 2010|May 2017|Anticipated|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|167|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114334||122930|
NCT01084928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035893|A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians|A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians|SHAPE|Emory University|Yes|Completed|April 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|16|||Both|25 Years|N/A|No|||September 2013|September 24, 2013|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01084928||125183|
NCT01085253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-15|Nucleipark:High Field MR Imaging (7T and 3T) of the Brainstem, the Deep Nuclei and Their Connections in the Parkinsonian Syndromes. Applications to Prognosis, Pathophysiology and Improvement of Therapeutic Strategies|High Field MR Imaging (7T and 3T) of the Brainstem, the Deep Nuclei and Their Connections in the Parkinsonian Syndromes. Applications to Prognosis, Pathophysiology and Improvement of Therapeutic Strategies|Nucleipark|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective||3|Anticipated|85|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|parkinson's disease (PD) supranuclear palsy (PSP) controls|January 2012|September 27, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085253||125158|
NCT01085266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM20EXT|An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease|HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease|HORIZON PLUS|Medivation, Inc.||Completed||||||Phase 3|Interventional|N/A|1||||||Both|30 Years|N/A|No|||March 2012|March 5, 2012|March 10, 2010||Yes||||https://clinicaltrials.gov/show/NCT01085266||125157|
NCT01114867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-YH-0128-CTIL|Fetal Penile Length and Corpus Cavernosum Length - Normal Measurement Via Ultrasound|Prospective Cross-sectional Study of Fetal Penis and Corpus Cavernosum Length||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Male|14 Weeks|34 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Fetuses of healthy pregnant women|April 2010|March 26, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114867||122889|
NCT01115088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 25030|Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults|Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults: A Pilot Study||Pennington Biomedical Research Center|No|Completed|January 2006|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01115088||122872|
NCT01115569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX002-0802|Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain|A Long-Term Open-Label Safety Study of Hydrocodone Bitartrate Controlled-Release Capsules With Flexible Dosing to Treat Subjects With Moderate to Severe Chronic Pain||Zogenix, Inc.|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|424|||Both|18 Years|75 Years|No|||March 2014|March 25, 2014|April 30, 2010|Yes|Yes||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01115569||122835|
NCT01115868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN1003-0110|Prevascar in African Continental Group Scarring|An Exploratory, Single Centre, Randomized, Placebo Controlled, Assessor Blind Clinical Trial to Assess the Effects of Intradermal Administrations of Prevascar on Scarring in Human Subjects of African Continental Ancestral Origin||Renovo|No|Active, not recruiting|April 2010|August 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|56|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115868||122814|
NCT01115881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT-1|Relationship Between Macular Thickness Measurement and Signal Strength in Optical Coherence Tomography|||Meir Medical Center|No|Not yet recruiting|May 2010|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy|January 2010|May 3, 2010|May 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01115881||122813|
NCT01115894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA015553-01A1S1|Medication and Counseling for Controlled Drinking|Naltrexone and CBT for Problem-Drinking MSM|ProjectSMART|Research Foundation for Mental Hygiene, Inc.|Yes|Active, not recruiting|February 2007|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Male|18 Years|65 Years|No|||December 2012|December 6, 2012|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115894||122812|
NCT01116193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01b|Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia|A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment|RV-405 LAL|Institut de Cancérologie de la Loire|Yes|Recruiting|January 2010|July 2013|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||January 2011|January 14, 2011|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01116193||122789|
NCT01116713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dxt-2010-breast cancer|Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer|Preoperative Dexamethasone Reduces Postoperative Pain, Nausea and Vomiting Following Mastectomy for Breast Cancer.|dxt2010brca|Instituto Mexicano del Seguro Social|Yes|Completed|June 2009|May 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Female|18 Years|79 Years|No|||May 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01116713||122749|
NCT01116986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0204|Identifying Optimal Smoking Cessation Intervention Components (Cessation)|Project 2: Identifying Optimal Smoking Cessation Intervention Components|Cessation|University of Wisconsin, Madison|Yes|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|32||Actual|637|||Both|18 Years|99 Years|No|||November 2015|November 12, 2015|April 27, 2010||No||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01116986||122728|
NCT01113216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFF-CFRD01|Genetic Modifiers of Cystic Fibrosis Related Diabetes|Genetic Modifiers of Cystic Fibrosis Related Diabetes||Johns Hopkins University|No|Recruiting|April 2008|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Blood will be drawn from study participants and their parents. Two tablespoons of blood (one      tablespoon in small children) will be drawn by standard techniques from a vein in the arm.      Whenever possible, blood samples for this study will be collected at the same time that it      is done for medically needed blood tests. This blood will be used to extract DNA and to      establish cell lines that we will store as a permanent source of DNA. We will compare your      clinical symptoms with your DNA to see if additional genes that affect CF symptoms can be      found. Some serum and plasma will be stored for later testing, as additional knowledge      becomes available. Any tests done in the future with your stored blood samples or your DNA      will only be to answer questions about genes for CF.|Both|3 Months|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals affected with Cystic Fibrosis and family members|December 2015|December 22, 2015|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113216||123016|
NCT01113437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0804/43|Omalizumab in Non-atopic Asthma|The Effect of a Humanised Monoclonal Anti-IgE Antibody,Omalizumab, on Disease Control and Bronchial Mucosal Inflammation in Non-atpic Asthma||King's College London|Yes|Recruiting|April 2010|||August 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||April 2010|January 20, 2011|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01113437||122999|
NCT01099072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8642|Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder|Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder Children and Adolescents in the Placebo Control Double -Blind Randomized Clinical Trail||Tehran University of Medical Sciences|Yes|Enrolling by invitation|April 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|17 Years|No|||December 2012|December 6, 2012|April 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01099072||124100|
NCT01096017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589LC00002|To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study|A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler® 0.4 mg and Salbutamol Pressurized Metered Dose Inhaler (pMDI) 200 μg - a Single Blind, Single Dose, Randomized, Crossover, Phase III Study in Japanese Adult Asthma Patients||AstraZeneca|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|16 Years|N/A|No|||July 2012|July 27, 2012|March 19, 2010|Yes|Yes||No|October 3, 2011|https://clinicaltrials.gov/show/NCT01096017||124332|
NCT01096030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14996|Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors|Uncontrolled, Open-label, Non-randomized, Phase 1 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors||Bayer|No|Completed|July 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096030||124331|
NCT01096290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-250|Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications|Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications||University of South Alabama|Yes|Completed|April 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|March 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01096290||124311|
NCT01096303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0362|Effects of Marijuana Used on Lung Function in Persons With Chronic Obstructive Pulmonary Disease (COPD)|Effects of Marijuana Smoking on Pulmonary Function in Patients With COPD||The University of Texas Health Science Center, Houston|No|Recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|25 Years|90 Years|No|Non-Probability Sample|COPD patients recruited in pulmonary clinic.|June 2015|June 13, 2015|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01096303||124310|
NCT01097447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL (2)|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas||Cxlusa|No|Recruiting|December 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|8 Years|N/A|No|Probability Sample|Primary care clinic|August 2015|August 17, 2015|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01097447||124224|
NCT01097460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-111-02-12-02|MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer|MM-111-02-12-02: A Phase 1 Study of MM-111 in Combination With Herceptin in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Breast Cancer||Merrimack Pharmaceuticals|No|Completed|April 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|March 30, 2010|Yes|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01097460||124223|
NCT01097733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000555|Dual-Source Computed Tomography to Improve Prediction of Response to Cardiac Resynchronization Therapy|Dual-Source Computed Tomography to Improve Prediction of Response to Cardiac Resynchronization Therapy|DIRECT|Massachusetts General Hospital|No|Active, not recruiting|February 2009|September 2016|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Outpatient or inpatient heart failure patients scheduled for CRT implantation|June 2014|June 22, 2014|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01097733||124202|
NCT01097746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0186|First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer|A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2010|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097746||124201|
NCT01098032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTCM01|RenalGuard System and Contrast Media|Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury|REMEDIALII|Clinica Mediterranea|Yes|Completed|January 2009|December 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|292|||Both|18 Years|N/A|No|||March 2015|March 7, 2015|April 1, 2010||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01098032||124179|
NCT01097434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S03110|Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence Tomography|Randomized Comparison of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coating Regarding Stent Coverage Assessed by Optical Coherence Tomography|TEST-6-OCT|Deutsches Herzzentrum Muenchen|No|Completed|April 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097434||124225|
NCT01107938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Livzon-IY-81149R-09|Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients|Efficacy and Safety of Ilaprazole for GERD: A Randomized,Double-Blind, Esomeprazole-Controlled,Phase2,Multicenter Trial in China||Livzon Pharmaceutical Group Inc.|Yes|Not yet recruiting|May 2010|||June 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|70 Years|No|||April 2010|April 20, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107938||123422|
NCT01088542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22805-G|The Community Youth Development Study: A Test of Communities That Care|The Community Youth Development Study: A Test of Communities That Care|CYDS II|University of Washington|Yes|Enrolling by invitation|October 2003|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|53000|||Both|10 Years|N/A|Accepts Healthy Volunteers|||March 2010|March 15, 2010|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01088542||124907|
NCT01088802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0988, NA_00026771|Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx|A Phase II Study on Treatment De-Intensification in Favorable Squamous Cell Carcinoma of the Oropharynx||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|January 2010|February 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|August 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01088802||124887|
NCT01097356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2414VV|The Effect of Probiotics on the Clearance of the Human Papillomavirus and on Cytological Lesions Caused by the Virus|||Universiteit Antwerpen|No|Recruiting|April 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||January 2010|April 22, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097356||124231|
NCT01097369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASBU_L_02990|Elitek (Rasburicase) Immuno-Monitoring Study|A Multicenter Registry Study of Anti-rasburicase Antibodies in Patients Retreated With Rasburicase (SR29142) in the Context of Relapsing Leukemia/Lymphoma Who Experienced Subsequent Hypersensitivity Reaction(s) or Loss of Uricolytic Activity: An Immuno-Monitoring Observational Study||Sanofi||Terminated|February 2010|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|2 Years|N/A|No|Non-Probability Sample|Patients are selected as the clinical manifestations for study inclusion (hypersensitivity        reaction or the loss of uricolytic activity) are recognized during clinically-indicated        re-challenge with rasburicase.|January 2013|January 30, 2013|March 31, 2010||No|business decision due to low subject recruitment|No||https://clinicaltrials.gov/show/NCT01097369||124230|
NCT01089959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS Astra Zeneca 7 day Nexium|Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD|The Effect of Esomeprazole 40 mg. Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With Gastroesophageal Reflux Disease (GERD).|ISS|Southern Arizona VA Health Care System|No|Recruiting|March 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||August 2010|August 18, 2010|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01089959||124798|
NCT01089972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1-2009-0033|Ultrasonographic Evaluation of the Radial and Ulnar Blood Flow After Radial Arterial Cannulation|||Severance Hospital||Completed|May 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|20 Years|N/A|No|Probability Sample|The patient(age >20) who are scheduled for elective surgery and need arterial|March 2010|March 31, 2011|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01089972||124797|
NCT01090232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00945-52|Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection|Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection||Assistance Publique Hopitaux De Marseille|No|Completed|February 2010|August 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|17|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090232||124777|
NCT01098266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR015|NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed|NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM)||MolMed S.p.A.|Yes|Active, not recruiting|March 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098266||124161|
NCT01098838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCL161A2101|Safety and Efficacy of LCL161 in Patients With Solid Tumors|A Phase I, Multi-center, Open-label, Dose-escalation Study of Oral LCL161 in Adult Patients With Advanced Solid Tumors||Novartis||Completed|November 2008|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|April 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098838||124118|
NCT01095575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|weinbroum pain|Pre- Versus Post-Incisional Epidural Morphine: Higher Postoperative Pain Perception and Extra Morphine Consumption|Pre- vs. Post-Incisional Epidural Morphine: Higher Postoperative Pain Perception and Extra Morphine Consumption||Tel-Aviv Sourasky Medical Center|No|Completed|January 2006|January 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||March 2010|April 9, 2010|March 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01095575||124366|
NCT01094990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX111|Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy|Efficacy of Dexamethasone for The Prevention of Nausea and Vomiting Associated With Intrathecal Chemotherapy and Ketamine Sedation in Children With Leukemia||Phramongkutklao College of Medicine and Hospital|Yes|Completed|April 2011|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|32|||Both|2 Years|15 Years|No|||January 2012|January 9, 2012|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094990||124411|
NCT01095250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457C2302|Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis|A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)|INSURE|Novartis||Terminated|April 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|March 25, 2010|Yes|Yes|Terminated: Study in Behcet's disease with mostly active uveitis did not meet its primary    endpoint.|No|February 12, 2015|https://clinicaltrials.gov/show/NCT01095250||124391|Study CAIN457C2302 was terminated to avoid continuing patients on a study with a low probability of success. Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.
NCT01095809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBEV|Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema|Open , Randomized Study About Efficacy, Safety and Tolerability od Repeated Dosis of Intravitreous Bevacizumab in Patients With Uveitic Macular Oedema|EBEV|Hospital Clinic of Barcelona|No|Terminated|April 2010|April 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||December 2010|March 22, 2012|March 29, 2010||No|New intraocular steroid in the market. Recruitment no longer ethical.|No||https://clinicaltrials.gov/show/NCT01095809||124348|
NCT01096602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-412|Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission|Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission||Dana-Farber Cancer Institute|Yes|Recruiting|May 2010|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096602||124287|
NCT01096823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AR057318-01|Iyengar Yoga for Young People With Rheumatoid Arthritis|Iyengar Yoga for Young People With Rheumatoid Arthritis||University of California, Los Angeles|Yes|Recruiting|June 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|35 Years|No|||March 2010|March 30, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01096823||124270|
NCT01097109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02171013Exp.|The Effect of Somatic Dysfunction of the Pelvis, Sacrum and Lower Lumbar Spine on Weight Bearing|The Effect of Somatic Dysfunction of the Pelvis, Sacrum and Lower Lumbar Spine on Weight Bearing||Nova Southeastern University|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|111|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Medical students of Nova Southeastern University College of Osteopathic Medicine (NSUCOM)        ages 18-40.|April 2012|April 21, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097109||124248|
NCT01097473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-001|Long Term Physical Training in Asthma|Effects of Long Term Physical Training Once a Week on Fitness and Quality of Life in Elderly Asthmatics||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 1996|March 1998|Actual|January 1998|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||March 2010|March 31, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097473||124222|
NCT01098045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-001836|HIV Fat Redistribution and the Evaluation of Brown Fat|FDG/PET Imaging for the Assessment of Brown Adipose Tissue in HIV Lipodystrophy||Massachusetts General Hospital|No|Completed|March 2010|August 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|27|Samples With DNA|Blood tests will include a complete blood count, creatinine, SGPT TSH and Free T4,      triglyceride, total, HDL and LDL cholesterol, HIV test, CD4 count (for HIV+ subjects only),      HIV viral load (for HIV+ subjects only), fasting glucose, 2 hour OGTT, as well as tissue      samples from fat biopsy.|Male|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV infected patients with fat redistribution and non HIV controls|March 2016|March 14, 2016|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01098045||124178|
NCT01098058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0721/49|Cognitive-Behavioural Therapy (CBT) for Adult Attention Deficit Hyperactivity Disorder (ADHD)|A Proof of Concept Randomised Controlled Trial to Examine the Potential Efficacy, Patient Acceptability and Feasibility of Cognitive-behavioural Therapy for Adults With Attention Deficit Hyperactivity Disorder (ADHD)||South London and Maudsley NHS Foundation Trust|Yes|Active, not recruiting|April 2010|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2013|June 18, 2013|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01098058||124177|
NCT01098071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04367 - Lebanon|Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)|Open Label Pilot Trial, Evaluating the Role of Nasonex in the Management of Nasal Obstruction Secondary to Adenoids Hypertrophy in Children|NAHCh|Merck Sharp & Dohme Corp.|No|Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|2 Years|11 Years|No|||October 2015|October 15, 2015|April 1, 2010|No|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT01098071||124176|
NCT01098344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669535|MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery|A Cancer Research UK Phase I Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage III and IV Pancreatic Cancer||Cancer Research UK||Completed|April 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098344||124155|
NCT01098357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC1-CT1|Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer|A Phase I/II, Multicentre, Randomised, Controlled, and Open-label Trial Comparing the Efficacy and Safety of Three Dose Regimens of BioChaperone PDGF-BB to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer||Virchow Group|No|Completed|June 2010|September 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|192|||Both|18 Years|75 Years|No|||August 2012|December 12, 2014|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098357||124154|
NCT01108211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT AIS 02|Improving Low Bone Mass With Vibration Therapy in Adolescent Idiopathic Scoliosis (AIS)|Improving Low Bone Mass With Vibration Therapy for Girls With Adolescent Idiopathic Scoliosis (AIS) - A Randomized Controlled Trial||Chinese University of Hong Kong|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|149|||Female|15 Years|25 Years|No|||July 2015|July 28, 2015|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01108211||123401|
NCT01089426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-08-00127|Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury|Research Study of an Intravenous Fat Emulsion Comprised of Fish Oils (Omegaven) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury||Children's Hospital Los Angeles|Yes|Recruiting|September 2008|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|21 Years|No|||February 2015|February 2, 2015|March 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01089426||124839|
NCT01089699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03302|A Trial Testing Professional and Peer-led Support Online Support Groups for Young Canadian Breast Cancer Survivors|A Randomized Control Trial Testing the Efficacy of Professional and Peer-Led Online Support Groups for Young Canadian Breast Cancer Survivors|CBCRA09|British Columbia Cancer Agency|Yes|Not yet recruiting|April 2010|March 2015|Anticipated|March 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|210|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2009|March 17, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089699||124818|
NCT01098552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1937-00|Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up|Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up||Mayo Clinic|No|Completed|February 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|4900|Samples With DNA|Blood, urine, prostate tissue|Male|18 Years|N/A|No|Non-Probability Sample|There are six patient cohorts which are being recruited to the Prostate Clinical Follow-up        Core in support of the Specialized Program of Research Excellence (SPORE). The six groups        are: 1. High-risk radical prostatectomy patients, 2. Primary external beam radiotherapy        patients, 3. Primary prostate brachytherapy patients, 4. Hormone refractory prostate        cancer patients, 5. Active Surveillance. 6. Prostate biopsy patients. The inclusion        criterion for group 6 is that the patient is scheduled to undergo a prostate biopsy for        the purposes of definitive prostate cancer diagnosis. There are no exclusion criteria for        group 6.|January 2013|January 9, 2013|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098552||124140|
NCT01097993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU324|A Single-centre, Randomised, Double-blind, Controlled, Parallel-group Study to Evaluate the Effect of a Fermented Dairy Product on Abdominal Distension, Digestive Symptoms and Rectal Sensitivity in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|||Danone Research|No|Completed|February 2010|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||||||Female|18 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01097993||124182|
NCT01097642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002243|Neo-Adjuvant Study in Triple Negative Breast Cancer Patients|Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients|ICE|The Methodist Hospital System|Yes|Active, not recruiting|October 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097642||124209|
NCT01097941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 09-007|Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children|Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated A/California/07/09 H1N1 Influenza Vaccines in Children|H1N1Children|University of Rochester|No|Withdrawn|March 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|4 Years|9 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|March 30, 2010|Yes|Yes|Live H1N1 vaccine expired and unable to get new supply|No||https://clinicaltrials.gov/show/NCT01097941||124186|
NCT01098539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114130|A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.|A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment||GlaxoSmithKline|Yes|Completed|May 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|507|||Both|18 Years|N/A|No|||May 2014|July 24, 2014|April 1, 2010|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01098539||124141|
NCT01095276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120030304|Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients|Inhaled Dnase (Pulmozyme®) as a Non-Invasive Treatment of Atelectasis in Mechanically Ventilated Patients||Rutgers, The State University of New Jersey|No|Completed|November 2005|January 2006|Actual|January 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2010|March 29, 2010|July 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095276||124389|
NCT01095302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11089|Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors|An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Docetaxel and Cisplatin Every 3 Weeks in Patients With Advanced Solid Tumors||Sanofi|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|20 Years|75 Years|No|||October 2013|October 12, 2013|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01095302||124387|
NCT01095315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|delayed positioning|Delayed Positioning in Cesarean Section|||Seoul National University Hospital||Completed|October 2007|September 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|86|||Female|28 Years|44 Years|No|||March 2010|April 9, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01095315||124386|
NCT01095783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0087/09|Treatment of Low Back Pain in Patients With End-stage Renal Disease on Hemodialysis|||Federal University of São Paulo||Withdrawn|March 2009|September 2014|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||August 2015|August 10, 2015|March 29, 2010||No|My main collaborator got sick and cannot continue the project. The study ended.|No||https://clinicaltrials.gov/show/NCT01095783||124350|
NCT01095796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0102|Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults||Gilead Sciences|Yes|Completed|March 2010|September 2014|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|707|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|March 17, 2010|Yes|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01095796||124349|There were no limitations affecting the analysis or results.
NCT01096316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37061-G|Depression Attention for Women Now (The DAWN Study)|Reducing Disparities and Improving Care for Depression in OB-GYN Clinics: Depression Attention for Women Now (The DAWN Study)|DAWN|University of Washington|Yes|Completed|November 2009|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|205|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|March 25, 2010||No||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01096316||124309|Patients were recruited from university-affiliated OB/GYN clinics, which potentially limits generalizability to other OB/GYN populations; non-English speaking women were not included; and antidepressant adherence was based on self-report data.
NCT01096836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGF-01-2010|Low Carbohydrate and Conventional Diets Associated to Resistance Training on Muscle Fitness and Health Markers|Combined Effects of Resistance Training and Low Carbohydrate or Conventional Diets on Strength, Muscle Mass, Body Composition, Blood Lipids and Endothelium Function|LCD-RT|Universidade Gama Filho|Yes|Completed|September 2006|August 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2007|March 30, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01096836||124269|
NCT01097772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0004|TriVascular European Union (EU) Abdominal Stent Graft Trial|A Clinical Study to Evaluate the Safety and Performance of the TriVascular Ovation™ Abdominal Stent Graft System||TriVascular, Inc.|Yes|Completed|March 2010|October 2015|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097772||124199|
NCT01097122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGEAH FTR-3|Effects Of Unilateral Vibration On Contralateral Forearm Muscle Activity|Effects Of Unilateral Forearm Vibration On Electrical Activity Of Untrained Contralateral Forearm Muscle|BMRR3|Vakif Gureba Training and Research Hospital|Yes|Completed|March 2010|July 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|90|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 24, 2012|March 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01097122||124247|
NCT01098409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK3719|Nitrite Mediated Cardioprotection During Coronary Artery Bypass Surgery|Mechanisms of Nitrite Mediated Cardioprotection in Coronary Artery Bypass Surgery||University Hospital Birmingham NHS Foundation Trust|No|Recruiting|February 2010|July 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|80 Years|No|||January 2010|April 1, 2010|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01098409||124151|
NCT01098383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7151-LG-CTIL|Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders|Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism||Sheba Medical Center|No|Recruiting|March 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|10 Years|18 Years|No|||January 2016|January 28, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01098383||124153|
NCT01098396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-TG-0349|Rasagiline for Gait Treatment|Rasagiline for the Treatment of Gait Disturbances in Patients With Parkinson´S Disease (PD): an Open Label Study||Tel-Aviv Sourasky Medical Center||Not yet recruiting|May 2010|||||N/A|Observational|Observational Model: Case-Only||1|Anticipated|10|||Both|50 Years|85 Years|No|Non-Probability Sample|Patients with PD|September 2009|April 1, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098396||124152|
NCT01098643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669012|Satisfaction With Placement of Implantable Venous Access Devices in Patients With Solid Tumors|Patient Satisfaction With Placement of Implantable Venous Access Devices||National Cancer Institute (NCI)||Recruiting|October 2009|||May 2015|Anticipated|Phase 1|Interventional|Primary Purpose: Health Services Research|1||Anticipated|396|||Both|18 Years|N/A|No|||March 2010|April 2, 2010|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01098643||124133|
NCT01098942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001445|Bariatric Surgery and Skeletal Health|Effects of Bariatric Surgery on Skeletal Health||Massachusetts General Hospital|No|Active, not recruiting|November 2009|November 2016|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Obese adults|September 2015|September 21, 2015|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01098942||124110|
NCT01098630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0247|Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer|Patient, Physician And Nurse Factors Associated With Entry Onto Clinical Trials And Completion Of Treatment For Women With Primary Or Recurrent Invasive Cancer Of The Uterine Corpus Or Uterine Cervix, All Stages||Gynecologic Oncology Group||Active, not recruiting|July 2010|||May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|778|||Female|N/A|N/A|No|Non-Probability Sample|Patient with uterine, endometrial or cervical cancer|February 2016|February 9, 2016|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01098630||124134|
NCT01104025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT-HLH|Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis|An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|April 2010|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|18 Years|No|||January 2016|January 26, 2016|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104025||123722|
NCT01097018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 343|Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer|A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer|X-PECT|AEterna Zentaris|Yes|Completed|April 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|468|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|March 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097018||124255|
NCT01097031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP4061|Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomized Clinical Trial|Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomized Clinical Trial|UP4061|Instituto de Cardiologia do Rio Grande do Sul|No|Completed|October 2007|April 2009|Actual|||N/A|Observational|Time Perspective: Prospective||3|Actual|140|||Both|N/A|93 Months|No|Probability Sample|patients with congenital heart disease|March 2010|March 31, 2010|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097031||124254|
NCT01098305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811047|Efficacy of Varenicline for Smokeless Tobacco Use in India|Efficacy of Varenicline for Smokeless Tobacco Use in India||University of Pennsylvania|No|Completed|April 2011|October 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 9, 2015|March 23, 2010||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01098305||124158|Sample size and reduced power; lack of long-term assessments; a priori inclusion of covariates in prediction models; adherence to medication was low.
NCT01097655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-131|Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet|PMOS: Kaletra Tolerability||AbbVie|No|Completed|August 2006|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3187|||Both|18 Years|99 Years|No|Non-Probability Sample|-  Community sample; Human Immunodeficiency Virus-infected patients          -  For Belgium: AIDS references centers (probability sample)|February 2016|February 4, 2016|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01097655||124208|
NCT01097954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146548|A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma|A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma||Winthrop University Hospital|Yes|Completed|April 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|8 Years|21 Years|No|Probability Sample|Subject with symptoms consistent with exercise induced asthma|June 2013|June 13, 2013|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097954||124185|
NCT01098279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810643|Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis|Multidisciplinary Approach to the Study of Chronic Pelvic Pain: Trans-MAPP Epidemiology and Phenotyping (EP) Study|MAPP-EP|University of Pennsylvania|Yes|Completed|December 2009|June 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|424|Samples With DNA|DNA Blood Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Trans-MAPP EP Study population will include adult participants, at least 18 years of        age, with urological chronic pelvic pain syndromes. Approximately half of the participants        will be male, and half will have recent onset (within two years) of pelvic pain symptoms        and/or limited treatment as determined by self-report.|May 2013|December 8, 2014|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098279||124160|
NCT01095003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00070 IN 305 B0|Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer|A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.||Pierre Fabre Medicament|Yes|Completed|May 2009|October 2015|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|770|||Female|21 Years|N/A|No|||April 2014|October 30, 2015|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01095003||124410|
NCT01095016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-TWB-0901|A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients|An Open-label, Randomized, Cross-over, Active-controlled Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients||Taiwan Otsuka Pharm. Co., Ltd|No|Completed|March 2010|October 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01095016||124409|
NCT01095289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emgca-01|Electromyographic Activity of Masseter Muscle During Deglutition in Total Laryngectomized Subjects|Electromyographic Activity of Masseter Muscle During Deglutition in Total Laryngectomized Subjects||Universidade Federal de Pernambuco|Yes|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|16|||Both|18 Years|80 Years|No|Non-Probability Sample|16 subjects underwent total laryngectomy|January 2010|March 29, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095289||124388|
NCT01095822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DT-NOV-09-37918|Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics|A Randomized Evaluation of the Effects of Valsartan and Aliskiren in Combination Versus Tekturna Alone on Hemostatic Biomarkers in Patients With Newly Diagnosed Mild to Moderate Hypertension and Type 2 Diabetes Mellitus||HeartDrug Research LLC|Yes|Active, not recruiting|March 2010|March 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|65 Years|No|||March 2010|March 29, 2010|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01095822||124347|
NCT01095588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-016|Study the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects|A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm Study of the Effects of Avanafil on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects||VIVUS, Inc.|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 5, 2011|January 6, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01095588||124365|
NCT01096615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13609|Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens|Evaluation of the Effect of Probiotic Lactobacillus Paracasei Lp-33 for the Management of Rhinitis in People Sensitized to Allergens. A Double Blind Randomized Parallel Placebo Controlled Study. (GA2LEN STUDY) BIONATLANTA Project|BionAtlanta|Merck Medication Familiale|No|Completed|April 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|500|||Both|18 Years|60 Years|No|||July 2012|July 25, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096615||124286|
NCT01097486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-CF002|Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy|Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation||Mesoblast, Ltd.|Yes|Active, not recruiting|June 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|No|||August 2012|November 6, 2014|March 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097486||124221|
NCT01098084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-DEC-LMMC-2007|Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)|A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia||Groupe Francophone des Myelodysplasies|Yes|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment|1||Actual|41|||Both|18 Years|N/A|No|||March 2011|March 19, 2014|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098084||124175|
NCT01098097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06011|Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)|Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin|POMOSCH|Merck Sharp & Dohme Corp.|No|Completed|June 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|963|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who failed prior treatment with interferon alpha (pegylated or non-pegylated)        with or without ribavirin|November 2014|November 14, 2014|April 1, 2010|No|Yes||No|October 17, 2012|https://clinicaltrials.gov/show/NCT01098097||124174|
NCT01098110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06124|6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)|A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)||Merck Sharp & Dohme Corp.|Yes|Completed|May 2010|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|532|||Both|20 Years|64 Years|No|||April 2015|April 2, 2015|April 1, 2010|No|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01098110||124173|
NCT01098123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-A01070-57|Metabolic Effects of Rowing Multi-races Events|Nutritional and Metabolic Context in Rowers||University of Paris 5 - Rene Descartes|Yes|Completed|April 2006|April 2006|Actual|April 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|45|Samples Without DNA|Serum samples|Male|18 Years|36 Years|Accepts Healthy Volunteers|Probability Sample|Competitive athletes|February 2006|April 1, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098123||124172|
NCT01098955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0362|Smoking Cessation Treatment for Head & Neck Cancer Patients|Smoking Cessation Treatment for Head & Neck Cancer Patients: Acceptance and Commitment Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2010|||March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|April 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01098955||124109|
NCT01098656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-21081|Lenalidomide Maintenance Post-debulking in Advanced CTCL|A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Terminated|July 2010|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|April 2, 2010||No|recruitment prematurely halted following company's decision to stop financial support to the    study|No||https://clinicaltrials.gov/show/NCT01098656||124132|
NCT01099202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID02-591|Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy|A Randomized Study of Procrit Versus No Procrit in Patients With Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy||M.D. Anderson Cancer Center|Yes|Completed|March 2003|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|N/A|N/A|No|||July 2012|July 24, 2012|April 5, 2010||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT01099202||124090|
NCT01098929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-07-105R|Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia|Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia||Massachusetts General Hospital|Yes|Recruiting|July 2002|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|whole blood, tissue, saliva, urine|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Children/infants with a congenital diaphragmatic hernia        Women who are currently pregnant with a fetus diagnosed with congenital diaphragmatic        hernia        Individuals with a family history of congenital diaphragmatic hernia|December 2015|December 16, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01098929||124111|
NCT01112540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT_AE_02|Morphine in Acute Abdominal Pain|||Akdeniz University||Completed||||||Phase 4|Interventional|N/A|2||||||Both|65 Years|N/A||||April 2010|April 27, 2010|April 26, 2010||||No||https://clinicaltrials.gov/show/NCT01112540||123068|
NCT01097044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV030|Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)|A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)||Clinuvel Pharmaceuticals Limited|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|March 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01097044||124253|
NCT01098318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT005230|Rhodiola Rosea Therapy of Major Depressive Disorder|Rhodiola Rosea Therapy of Major Depressive Disorder||University of Pennsylvania|Yes|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|58|||Both|18 Years|80 Years|No|||June 2014|June 3, 2014|April 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098318||124157|
NCT01098331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000668741|Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer|Surgery and Brachytherapy: A Randomized Evaluation. Randomized Controlled Trial of Brachytherapy Versus Radical Prostatectomy in Good Risk Prostate Cancer: A Feasibility Study||National Cancer Institute (NCI)||Recruiting|May 2009|||November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label|1||Anticipated|400|||Male|18 Years|N/A|No|||March 2010|February 18, 2011|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098331||124156|
NCT01098851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV-MO-PO-1000|Oxygen Saturation Monitoring During Surgery|Saturation Pattern Detection Prevalence Study Protocol||Medtronic - MITG|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|21|||Both|21 Years|N/A|No|Non-Probability Sample|Primary care hospital|August 2014|August 5, 2014|March 31, 2010|No|Yes||No|December 16, 2010|https://clinicaltrials.gov/show/NCT01098851||124117|Small numbers of subjects analyzed.
NCT01099111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 -116|Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders|Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic Gastrointestinal Disorders (IBS, IBD, CRC)||King Fahad Medical City|Yes|Completed|July 2010|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Actual|225|Samples With DNA|Colonic washing samples from 4 specific segments (cecum, transverse, proximal sigmoid and      rectum) of every subject will be retained for 16S rRNA analysis for the study purpose, and      more samples will be retained for further analysis later on.      Samples from the unified colonic segments (each collected as 15 cc in each of four 20 cc      tubes and stored in -70 Freezer) were completely recruited from 50 normal subjects, 50 IBS,      50 UC, 46 CD and only 29 CRC.      One to two tubes from each segment sample of all subjects have been utilized for DNA      extraction and accepted if identified sufficient according to lab. Hence submitted for 16S      rRNA analysis. Currently we are waiting for intra-cohort comparison of samples, then      inter-cohort comparisons among different study groups will be done.|Both|16 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|We propose to recruit our cohort of patients from the King Fahad Medical City in Riyadh        (largest tertiary care hospital of Saudi MOH with wide open referral system), over one        year between July 2010 and July of 2011. Fifty participants with each of the focus        conditions (IBS, UC, CD, CRC) will be compared to fifty participants with no GI complaints        and have a normal colonic mucosa (by endoscopic and histological examination).|April 2014|April 24, 2014|April 1, 2010||No||No|March 22, 2014|https://clinicaltrials.gov/show/NCT01099111||124097|After completing recruitment, the colonic mucosal washing sampling did not result in enough DNA extract and we had to drop some of the participants for analysis.
NCT01099124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-CTI-001|Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)|Single-center, Open Trail of Phase 1 of M2ES With TC Regimen in Advanced NSCLC||Tianjin Medical University Cancer Institute and Hospital|Yes|Completed|December 2009|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|No|||April 2010|January 28, 2013|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01099124||124096|
NCT01099137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_ENDO3|Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin|The Study About Glucose Lowering Effect of Vildagliptin in Type 2 Diabetes Patients Who Are Uncontrolled With Metformin and a Sulphonylurea||Seoul National University Bundang Hospital|Yes|Completed|January 2010|May 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|344|||Both|18 Years|90 Years|No|||May 2014|May 26, 2014|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01099137||124095|
NCT01095328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL30340.042.09|A Screening Strategy for Q Fever Among Pregnant Women|Cost-effectiveness of a Screening Strategy for Q Fever Among Pregnant Women in Risk Areas: a Clustered Randomized Controlled Trial||University Medical Center Groningen|No|Recruiting|March 2010|March 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|4000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|June 30, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095328||124385|
NCT01095341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR-2010|Postoperative Hyperthyroidism|Postoperative Hyperthyroidism After Parathyroidectomy||Heidelberg University|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|57|||Both|18 Years|90 Years|No|Probability Sample|patients with tertiary hyperparathyroidism undergoing surgery for this reason|March 2010|March 29, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095341||124384|
NCT01096069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/585|Complement Regulatory Proteins Expression and Clinical Response in Rheumatoid Arthritis (RA) Patients Treated With Rituximab|Expressão de Cregs e a Resposta clínica em Pacientes AR Tratada Com Rituximabe||Hospital de Clinicas de Porto Alegre|Yes|Not yet recruiting|June 2010|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|70 Years|No|Probability Sample|Patients diagnosed with RA and clinical indication for treatment with rituximab and who        have obtained access to medication (private purchase, delivery by a private health plan,        lawsuit or donation by the laboratory Roche) will be invited to participate in the study        during the physician appointment.|March 2010|March 29, 2010|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01096069||124328|
NCT01096043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-1020-02|A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure|A Phase IIa, 3 Strata Dose-Defining Study Evaluating the Hemodynamic Effects, Safety and Tolerability of CXL-1020 in Patients With Systolic Heart Failure||Cardioxyl Pharmaceuticals, Inc|Yes|Completed|April 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|69|||Both|18 Years|85 Years|No|||April 2012|April 13, 2012|March 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096043||124330|
NCT01096056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114182|Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children|Safety and Immunogenicity of GSK2186877A Candidate Seasonal Influenza Vaccine in Healthy Children 6 to 35 Months of Age.||GlaxoSmithKline||Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||April 2012|April 12, 2012|March 29, 2010|Yes|Yes||No|April 12, 2012|https://clinicaltrials.gov/show/NCT01096056||124329|
NCT01097759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58061302393|LigaSure Hemorrhoidectomy Versus Stapled Hemorrhoidopexy|LigaSure Hemorrhoidectomy vs Stapled Hemorrhoidopexy: a Prospective Randomized Clinical Trial||Kuwait Oil Company Ahmadi Hospital|Yes|Completed|January 2006|July 2008|Actual|July 2007|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|115|||Both|18 Years|N/A|No|Probability Sample|A total of 68 patients with symptomatic grade III or grade IV hemorrhoids entered the        study.|January 2006|April 1, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01097759||124200|
NCT01097161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA 0097/06|Stuttering and Apraxia of Speech: the Efficacy of an Intervention Program|The Speech Prosody of People With Stuttering and Developmental Apraxia: the Efficacy of an Intervention Program|SAS:EIP|Federal University of Minas Gerais|Yes|Completed|April 2007|June 2008|Actual|October 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2007|April 1, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097161||124244|
NCT01097499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH-Biolux2010|Low Level Laser (LED) Use to Increase Dental Implant Stability and Post Operative Analgesia|Role of Light Emitting Diode on Implant Stability, Bone Resorption and Analgesia Post Dental Implant Placement||Mount Sinai Hospital, Canada|Yes|Not yet recruiting|April 2010|October 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2010|March 31, 2010|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097499||124220|
NCT01097785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-1135098|Targeting Sympathetic Overactivity in Heart Failure Patients With Statins|Targeting Sympathetic Overactivity in Heart Failure Patients With Statins||University of Missouri-Columbia|Yes|Completed|March 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01097785||124198|
NCT01098136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/174-4|Pelvic Girdle Pain in a Pregnant Population in Western Norway.|A Study of Pelvic Girdle Pain in a Pregnant Population in Western Norway - Incidence, Cumulative Prevalence, Course and Intervention.||Helse Stavanger HF|No|Completed|March 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|650|||Female|N/A|N/A|No|||August 2012|August 30, 2012|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01098136||124171|
NCT01087359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-010|Antiinflammatoric and Antioxidative Effect of Melatonin in Human Endotoxaemia|Antiinflammatoric and Antioxidative Effect of Melatonin in Human Endotoxaemia||Herlev Hospital|Yes|Completed|June 2010|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Anticipated|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|June 17, 2011|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087359||124997|
NCT01087645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9925-3779|A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects|Investigation of Safety, Tolerability and Bioavailability of NN9925 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|March 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01087645||124976|
NCT01099215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVS 03-001|Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)|An Open-Label Dose Escalation Safety Study of PVS-10200 for the Treatment of Restenosis in Patients Undergoing Minimally Invasive Peripheral Revascularization (TRIUMPH)|TRIUMPH|Shire Regenerative Medicine, Inc.|Yes|Completed|April 2010|October 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|April 1, 2010|No|Yes||No|June 28, 2013|https://clinicaltrials.gov/show/NCT01099215||124089|Small patient number, no control arm
NCT01099228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200602763|Combination Targeted Radiotherapy in Neuroendocrine Tumors|Combination Targeted Radiotherapy in Neuroendocrine Tumors||University of Iowa|No|Enrolling by invitation|March 2007|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01099228||124088|
NCT01095107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCH-KW|Food Energy Density in Eating Disorders|Relationship of Energy Density of Foods Within a Nutritional Insufficiency Patient's Diet to Inpatient Hospital Stay Duration, Body Image, Mood and Gastrointestinal Symptoms||The Cleveland Clinic|No|Enrolling by invitation|January 2010|April 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|9 Years|24 Years|No|||March 2010|March 26, 2010|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01095107||124402|
NCT01095120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOG201|Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer|A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer||Genta Incorporated|No|Active, not recruiting|March 2010|October 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095120||124401|
NCT01095094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2307|Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma|Phase II Trial of Ritonavir/Lopinavir in Patients With Progressive of Recurrent High-Grade Gliomas||Case Comprehensive Cancer Center|Yes|Terminated|January 2009|November 2011|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|March 26, 2010|Yes|Yes|Study did not meet its primary objective|No|April 24, 2013|https://clinicaltrials.gov/show/NCT01095094||124403|
NCT01087320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100065|Whole Genome Medical Sequencing for Genome Discovery|Whole Genome Medical Sequencing for Gene Discovery||National Institutes of Health Clinical Center (CC)||Recruiting|February 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|N/A|N/A|No|||August 2015|January 6, 2016|March 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01087320||125000|
NCT01097694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000170|Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)|A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)|KIA|Brigham and Women's Hospital|Yes|Active, not recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|March 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097694||124205|
NCT01097707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10373|A Study in Men With Benign Prostatic Hyperplasia|A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)||Eli Lilly and Company|Yes|Terminated|April 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|414|||Male|45 Years|N/A|No|||January 2012|February 10, 2012|March 31, 2010|Yes|Yes|Terminated due to insufficient efficacy|No||https://clinicaltrials.gov/show/NCT01097707||124204|
NCT01098292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810668|Observational Study of Control Participants for the MAPP Research Network|Multidisciplinary Approach to the Study of Chronic Pelvic Pain: Trans-MAPP Control Study|MAPP-Control|University of Pennsylvania|Yes|Completed|December 2009|June 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|615|Samples With DNA|DNA Blood Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Trans-MAPP Control Study population will include adult participants, at least 18 years        of age, with no urological chronic pelvic pain syndromes. These participants will fall        into two categories: Healthy Controls and Positive Controls.|May 2013|December 8, 2014|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098292||124159|
NCT01099163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2387|Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E in Patients With Type 2 Diabetes Mellitus|Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E on Insulin Sensitivity, Beta Cell Function, Markers of Inflammation, Body Fat Mass and Other Biochemical Indicators in Patients With Type 2 Diabetes Mellitus||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2009|October 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|60|||Both|30 Years|70 Years|No|||April 2010|June 14, 2011|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01099163||124093|
NCT01098565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1654|Deep Brain Stimulation Effects Study|Deep Brain Stimulation Effects: Human Proof-of-Concept Study||MedtronicNeuro|Yes|Terminated|April 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|6|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|March 25, 2010||No|The goal of collecting proof-of-concept information was met through additional modeling    studies, new published evidence and information collected from the study|No||https://clinicaltrials.gov/show/NCT01098565||124139|
NCT01098578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baxter BS09-000313|Floseal Treatment for Posterior Epistaxis Study|Floseal Posterior Epistaxis Pilot Study (PEPIS)||Ottawa Hospital Research Institute|No|Completed|April 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|April 1, 2010||No||No|June 4, 2013|https://clinicaltrials.gov/show/NCT01098578||124138|
NCT01098864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109639|Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting.|Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting.||University of Arkansas|Yes|Withdrawn|May 2011|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|January 19, 2010|Yes|Yes|Study was withdrawn prior to the first subject being enrolled due to the Co-Investigator    leaving the university|No||https://clinicaltrials.gov/show/NCT01098864||124116|
NCT01095029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Cerebral Responses During Bilateral/Unilateral Sacral Nerve Stimulation for Idiopathic Faecal Incontinence|Cerebral Responses During Bilateral/Unilateral Sacral Nerve Stimulation for Idiopathic Faecal Incontinence - Assessed With Positron Emission Tomography Scan (PET-scan)||University of Aarhus|Yes|Completed|February 2010|July 2014|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|10|||Both|18 Years|N/A|No|||March 2012|July 3, 2014|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01095029||124408|
NCT01096849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-490-002|Study of Plazomicin (ACHN-490) Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis|A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis||Achaogen, Inc.|No|Completed|March 2010|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|145|||Both|18 Years|85 Years|No|||July 2013|July 9, 2013|March 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096849||124268|
NCT01096329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTS-102|A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®|A Phase 1, Open-label, Randomized, Three-cohort, Two-period Crossover Study to Determine the Relative Bioavailability of Testosterone Following Application of Two Testosterone Transdermal Spray (TTS) Formulations Once Daily and Intrinsa® Patch Twice Weekly in Healthy, Surgically and Naturally Post-menopausal Women Receiving Estrogen Replacement Therapy||VIVUS, Inc.|No|Terminated|February 2010|||April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|16|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|March 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01096329||124308|
NCT01096342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02795|Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma||National Cancer Institute (NCI)||Completed|July 2009|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2013|June 2, 2014|March 30, 2010|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT01096342||124307|
NCT01096355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01550|Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies|A Phase I Study of Various Administration Schedules of RO4929097 With Multi-parameter Assessment (Biomarkers, Pharmacokinetics, Pharmacodynamics) in Patients With Advanced Solid Cancers||National Cancer Institute (NCI)||Completed|February 2010|||July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|28|||Both|18 Years|N/A|No|||December 2013|April 1, 2014|March 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01096355||124306|
NCT01097174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMI-09-02|CyPass Clinical Experience Study|A Multicenter Registry Study to Capture Data With Respect to CyPass Clinical Experience|CyCLE|Transcend Medical, Inc.|No|Completed|December 2009|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|555|||Both|N/A|N/A|No|||November 2015|November 2, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097174||124243|
NCT01097798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBB-ALI-01/09|To Evaluate the Efficacy and Safety Aliviador Compared to Gelol in Patients With Contusions, Sprains, Trauma and Muscle Injury.|Multicenter, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety Aliviador Compared to Gelol in the Relief in Patients With Contusons, Sprains,Trauma and Muscle Injury.|LBB-ALI-01/09|Laboratorio Brasileiro de Biologia|Yes|Not yet recruiting|June 2010|August 2010|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Years|N/A|No|||February 2010|April 15, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01097798||124197|
NCT01097811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-41|Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy|Erythromycin Versus Neomycin Treatment for Overt Hepatic Encephalopathy: a Double-blind, Randomised, Controlled Trial.||UPECLIN HC FM Botucatu Unesp|Yes|Active, not recruiting|June 2008|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||April 2010|April 27, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097811||124196|
NCT01098422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071960|A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver|A Phase II Study of Yttrium-90 Radioactive Resin Microspheres in the Treatment of Colorectal Adenocarcinoma Metastatic to the Liver After Failure of First-Line Combination Chemotherapy||University of California, San Diego|Yes|Terminated|January 2010|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|April 1, 2010|Yes|Yes|Halted due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01098422||124150|
NCT01098669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669342|Impact of Secondary Lymphedema on Symptoms, Functional Status, and Quality of Life After Treatment in Patients With Head and Neck Cancer|The Impact of Secondary Lymphedema After Head and Neck Cancer Treatment on Symptoms, Functional Status, and Quality of Life||Vanderbilt University|No|Completed|December 2009|February 2012|Actual|February 2012|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|Adult head and neck cancer survivors|February 2012|February 20, 2012|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01098669||124131|
NCT01098682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1153478|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||April 1, 2010|April 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098682||124130|
NCT01087086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESMENA-S|Reduction of the Metabolic Syndrome in Navarra-Spain|Reduction of the Metabolic Syndrome in Navarra-Spain (RESMENA-S) Through an Innovative Multidisciplinary Strategy Based on the Crononutrition and Dietary Training Concepts, in Addition to Both Dietary and Psychological Control|RESMENA-S|Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|January 2010|November 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|35 Years|70 Years|No|||November 2011|February 27, 2015|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01087086||125018|
NCT01087372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Incretins2010|Stress Hyperglycemia. Potential Role of Incretin Analogs|Stress Hyperglycemia in Critically Ill Patients. Potential Role of Incretin Analogs. A Preliminary Study||Hospital Universitari Son Dureta|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Plasma and serum samples to analyze glucorregulatory hormones.|Both|18 Years|N/A|No|Non-Probability Sample|Medical-surgical ICU patients|June 2010|June 7, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01087372||124996|
NCT01087658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALI_L_03768|Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity|A Multicentre, Randomized, Open-label, Phase III Study Comparing the Efficacy of Oral Glutamine and Calcium-magnesium With Calcium-magnesium Alone in the Prevention of Oxaliplatin-induced Neurotoxicity in Patients With Colorectal Cancer Treated With Oxaliplatin in Adjuvant or 1st Line Metastatic Settings.|GLUTOX|Sanofi||Completed|February 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087658||124975|
NCT01087385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-Nr. 59/10|Troponin T as Risk Stratification Tool in Peripheral Arterial Occlusive Disease|Troponin T as Risk Stratification Tool in Patients With Peripheral Arterial Occlusive Disease||Heart Center Bad Krozingen|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|patients with peripheral arterial occlusive disease (Fontaine stages II-IV)|April 2015|April 14, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087385||124995|
NCT01088217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HL097163|A Linkage and Association Study in Pulmonary Fibrosis|GWAS in Fibrosing Interstitial Lung Disease|GWAS|National Jewish Health|No|Recruiting|July 2008|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|8000|Samples With DNA|whole blood, serum, plasma, lung tissue, DNA, RNA|Both|N/A|N/A|No|Non-Probability Sample|Families with two or more individuals diagnosed with Idiopathic Pulmonary Fibrosis (IPF)        or Idiopathic Interstitial Pneumonia (IIP)|April 2015|April 14, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01088217||124932|
NCT01087333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100066|Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment|Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment||National Institutes of Health Clinical Center (CC)||Recruiting|February 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 5, 2015|March 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01087333||124999|
NCT01098604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNU 08-01|The Comparison of 32mm and 28mm Head Components in Alumina-alumina Total Hip Arthroplasty|The Comparison of 32mm and 28mm Head Components in Alumina-alumina Total Hip Arthroplasty: A Randomized Clinical Trial|THA|Seoul National University Bundang Hospital|Yes|Completed|May 2006|December 2009|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|20 Years|85 Years|No|||March 2010|March 19, 2014|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098604||124136|
NCT01098617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMS207|Antihemostatic Therapy and Endoscopic Biliary Sphincterotomy Induced Bleeding|The Effect of Antiaggregant, Anticoagulant and Nonsteroidal Antiinflammatory Therapy on Endoscopic Biliary Sphincterotomy Induced Bleeding||Yuksek Ihtisas Hospital|Yes|Recruiting|April 2010|December 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|350|||Both|17 Years|N/A|No|Non-Probability Sample|The patients who had undergone endoscopic sphincterotomy|April 2010|April 2, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098617||124135|
NCT01097681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0073|A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment|An Open-Label Study to Assess the Effect of Different Grades of Renal Impairment in Japanese Patients With Type 2 Diabetes Mellitus on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP1941 Relative to Type 2 Diabetes Mellitus Patients With Normal Renal Function||Astellas Pharma Inc|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|25|||Both|20 Years|79 Years|No|||January 2016|January 18, 2016|March 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01097681||124206|
NCT01097980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT098-02|Trazodone for SSRI-sexual Dsyfunction|The Efficacy of Trazodone for Selective Serotonin Reuptake Inhibitor-induced Sexual Dysfunction|T-SSRI-SD|Beitou Armed Forces Hospital, Taipei, Taiwan|Yes|Completed|April 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|March 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01097980||124183|
NCT01095055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC036|A Study of AdCh63 AMA1 Alone and With MVA AMA1|A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 AMA1 Alone and With MVA AMA1||University of Oxford|Yes|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01095055||124406|
NCT01098591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW - Meta|Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE|Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE|ACCRUE|Medical University of Vienna|No|Recruiting|November 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|1000|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients treated with cell-based cardiac therapy at one of the participating centers|March 2015|March 1, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01098591||124137|
NCT01098877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1261002|First In Human Study Of Increasing Oral Doses Of PF-04634817|A Double Blind, Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Pharmacokinetics (In The Fed And Fasted State), Safety And Toleration Of Single Oral Doses Of PF-04634817 In Healthy Volunteers||Pfizer|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|11||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 12, 2010|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01098877||124115|
NCT01099150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600|Dark Chocolate and Platelet Function in Humans|Acute Effects of the Consumption of Dark Chocolate Enriched in Flavan-3-ols on Platelet Function and the Platelet Proteome||University of Aberdeen|Yes|Completed|March 2009|May 2011|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 15, 2012|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01099150||124094|
NCT01095861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-126|Comparison of Parker Flex-Tip Endotracheal Tube to Standard Endotracheal Tube|Comparison of Parker Flex-Tip Endotracheal Tube to Standard Endotracheal Tube: A Randomized Controlled Trial||Lawson Health Research Institute|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|85 Years|No|||August 2011|August 4, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01095861||124344|
NCT01095601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-020|Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects|A Phase I, Single-Centre, Open-Label, Randomized, Four-Period Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Avanafil, to Determine The Relative Bioavailability of Two Avanafil Tablet Formulations and to Investigate Dose Proportionality in Healthy Male Subjects||VIVUS, Inc.||Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 5, 2011|March 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095601||124364|
NCT01095835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18253|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)|A Randomized, Open-label Study of 2 Different Treatment Durations of PEGASYS With or Without Lamivudine on ALT and HBV DNA Levels/Correction in Patients With HBeAg-negative Chronic Hepatitis B Infection||Hoffmann-La Roche||Completed|February 2005|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01095835||124346|
NCT01095848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-DPX-0907-01|A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer|A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer||ImmunoVaccine Technologies, Inc.|Yes|Completed|March 2010|November 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095848||124345|
NCT01097135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIFJPAR-10-02|Evaluating the Effectiveness of 2 Surgical Skin Preparation Methods in Reducing Surgical Wound Drainage After Total Hip or Knee Replacement|Prospective, Randomized Clinical Study to Evaluate the Efficacy of 2 Surgical Skin Preparations in Reducing Wound Drainage Following Total Joint Arthroplasty||Rothman Institute Orthopaedics||Completed|March 2010|December 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||September 2013|September 16, 2013|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097135||124246|
NCT01097148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V.09.231/R-09|Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients|Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients|POP-II|St. Antonius Hospital||Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|65 Years|No|||November 2009|October 12, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097148||124245|
NCT01086410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106851|Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis|Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 Versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics||GlaxoSmithKline|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|185|||Both|12 Years|65 Years|No|||June 2013|September 12, 2013|March 11, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01086410||125069|
NCT01086423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112584|Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine|Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib™) in Infants||GlaxoSmithKline||Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|985|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||June 2011|June 23, 2011|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086423||125068|
NCT01086436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113552|Study to Evaluate the Safety of Rotarix™ in Chinese Children|Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Children||GlaxoSmithKline||Completed|March 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086436||125067|
NCT01086449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113819|Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults|Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults||GlaxoSmithKline||Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086449||125066|
NCT01086826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H&N07|Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study.|H&N07|Associazione Volontari Pazienti Oncologici|No|Completed|March 2008|December 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|320|||Both|18 Years|N/A|No|||June 2013|January 23, 2015|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086826||125038|
NCT01087073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16867B (TRACS ID: 40596)|Improving Diabetes Care and Outcomes on the South Side of Chicago|Improving Diabetes Care and Outcomes on the South Side of Chicago||University of Chicago|No|Recruiting|January 2009|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|5000|||Both|18 Years|N/A|No|||October 2014|October 31, 2014|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087073||125019|
NCT01087346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100076|Mothers' Thoughts About What Their Children Eat|Mothers' Thoughts About What Their Children Eat||National Institutes of Health Clinical Center (CC)||Completed|March 2010|||||N/A|Observational|N/A|||Actual|232|||Female|18 Years|N/A|No|||July 2015|August 5, 2015|March 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01087346||124998|
NCT01087398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-0905|Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis|Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis||Tehran University of Medical Sciences|Yes|Recruiting|September 2009|December 2012|Anticipated|November 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|5 Years|No|||May 2012|May 31, 2012|March 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01087398||124994|
NCT01087411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPP-8|Intervention Study to Prevent Obesity in Sedentary 8 Year Old Swedish Children|A Controlled Study Aiming to Increase Physical Activity and Decrease Risk Bio-markers in Sedentary 8 Year Old Swedish Children Via Physical Activity and Fish Liver Oil Supplementation|STOPP-8|Karolinska Institutet|No|Terminated|October 2008|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|240|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||March 2011|May 13, 2011|March 15, 2010||No|2010 represented complications recruiting. The team suffered from sick-leave.|No||https://clinicaltrials.gov/show/NCT01087411||124993|
NCT01087671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77553|Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops|Ocular Signs and Symptoms in Patients With Ocular Hypertension or Open-angle Glaucoma Switched From Preserved Latanoprost 0.005% Eye Drops to Preservative Free Tafluprost Eye Drops||Santen Oy|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|18 Years|N/A|No|||November 2010|May 30, 2013|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01087671||124974|
NCT01087684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459-2004|Response to SLT vs. ALT in Patients Under 60 Years of Age|A Prospective, Randomized, Clinically Based Study on the Response to Selective Laser Trabeculoplasty Versus Argon Laser Trabeculoplasty in Patients Who Are Under 60 Years of Age||Sunnybrook Health Sciences Centre|No|Completed|December 2004|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|60 Years|No|||October 2013|October 8, 2013|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087684||124973|
NCT01088243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-2360B|Targeting Oxidative Stress in Chronic Beryllium Disease|Targeting Oxidative Stress in Chronic Beryllium Disease||National Jewish Health|Yes|Completed|March 2010|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|80 Years|No|||March 2015|March 19, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01088243||124930|
NCT01088256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etoricox09-10|Efficacy of Etoricoxib on Peripheral Hyperalgesia|Efficacy of Etoricoxib in Patients With Neuropathic Pain With and Without Peripheral Hyperalgesia - A Prove of Concept Trial||Ruhr University of Bochum|No|Terminated|February 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|9|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088256||124929|
NCT01098903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGWH0008|Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients|Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib (Sutent, SU11248) in Patients With Cancer|CLEARSUN|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|January 2009|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Probability Sample|Patients with a malignancy treated with sunitinib|July 2012|July 11, 2012|March 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01098903||124113|
NCT01098916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0078572|The RAD-HOME Project: a Pilot Study of Domiciliary Teleradiology|The RAD-HOME Project: a Randomized Pilot Study of a Domiciliary Teleradiology Program for Frail Elderly Patients|RHP|Azienda Ospedaliera San Giovanni Battista|No|Completed|June 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|69|||Both|65 Years|N/A|No|||May 2008|April 2, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01098916||124112|
NCT01098006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113854|A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays|A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays||GlaxoSmithKline||Completed|April 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|99|||Both|18 Years|65 Years|No|||July 2012|July 19, 2012|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098006||124181|
NCT01098019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6014|Treatment of Notalgia Paresthetica With Xeomin|Efficacy and Safety of Xeomin for the Treatment of Notalgia Paresthetica||Innovaderm Research Inc.|No|Completed|April 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||April 2012|April 20, 2012|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098019||124180|
NCT01095393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0005|National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)|National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies||UCB Pharma|No|Enrolling by invitation|September 2009|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|12500|||Both|N/A|N/A|No|Non-Probability Sample|Rheumatologist referral or patient direct enrollment|November 2015|February 22, 2016|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095393||124380|
NCT01095406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSJ-3011|Safety and Feasibility Study of a Mechanical Ventilation Computerized Protocol: Intellivent|Safety, Feasibility and Efficacy of Ventilation Weaning in Children With a Computerized Protocol: a Pilot Study on S1 Ventilator With Intellivent(Hamilton Medical).|CloserPed|St. Justine's Hospital|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|18 Years|No|||September 2012|September 18, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095406||124379|
NCT01095627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/04 AEROB|Characterization of Aerosol Generation and Transport in the Human Lung|Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Mild Intermittent Allergic Asthma Before and After Methacholine Challenge||Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2011|February 8, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01095627||124362|
NCT01095042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0817|Cognition and Emotion in the SII and IBD|Etude de la réactivité émotionnelle Des Patients MICI ou SII|EMOTION|University Hospital, Grenoble|No|Completed|October 2008|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01095042||124407|
NCT01095354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013927|Investigation of Lung Ventilation Inhomogeneity in Pediatric Asthma|Investigation of Lung Ventilation Inhomogeneity in Pediatric Asthma: Multiple Breath Washout and Asthma||The Hospital for Sick Children|No|Recruiting|November 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|samples will be processed and divided into two categories: eosinophilic (% eosinophils      >2.5%) and non-eosinophilic (<2.5% eosinophils). The two categories of asthmatics will be      used to categorize asthmatics for comparison on parameters such as SnIII analysis of SF6,      LCI etc. In addition, % eosinophilia will be considered as a continuous measure in those      with % eosinophils > 2% and correlated with LCI.|Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asthma patients will be recruited from the Respiratory Medicine clinic at the Hospital for        Sick Children. A member of the medical team in the Asthma Clinic, known to the patient,        will introduce the study, and obtain permission for the patient/caregiver to meet with        study personnel. Subjects will then be approached by the Principal investigator or her        delegate. They will be informed that enrolment is voluntary and that they can withdraw        from the study at any time.|March 2015|March 6, 2015|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01095354||124383|
NCT01096381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 0983|Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor|A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension||Vanderbilt-Ingram Cancer Center|Yes|Terminated|March 2010|August 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|||Both|18 Years|N/A|No|Probability Sample|Patients with stage IV breast, colorectal, or non-small cell lung cancer (NSCLC) who will        get bevacizumab as a standard of care, as well as patients with breast, colorectal,        ovarian/fallopian tube/peritoneal, head and neck, or NSCLC cancer about to initiate        bevacizumab. Where possible, the study population will include a control group not        receiving bevacizumab.|February 2012|February 23, 2012|March 30, 2010||No|funding withdrawn due to fellow's departure from VICC|No||https://clinicaltrials.gov/show/NCT01096381||124304|
NCT01096082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-418|Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3|Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3||Hospital de Clinicas de Porto Alegre||Completed|May 2011|January 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|16 Years|80 Years|No|||January 2013|January 29, 2013|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096082||124327|
NCT01096368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS0831|Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma|Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years||Children's Oncology Group|Yes|Recruiting|March 2010|||March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|1 Year|21 Years|No|||February 2016|February 29, 2016|March 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096368||124305|
NCT01096628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HP15124|Chiropractic and Exercise for Low Back Pain in Adolescents|Chiropractic and Exercise for Low Back Pain in Adolescents||Northwestern Health Sciences University|Yes|Completed|March 2010|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|185|||Both|12 Years|18 Years|No|||January 2014|January 30, 2014|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096628||124285|
NCT01096641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FICS 20084002|An Explorative Study on Physiological and Neurophysiological Determinants of Fatigue in Cancer Survivors|An Explorative Study on Physiological and Neurophysiological Determinants of Fatigue in Cancer Survivors||Radboud University|No|Active, not recruiting|April 2010|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|57|||Both|19 Years|65 Years|No|||June 2012|June 21, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096641||124284|
NCT01096862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PS01|A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis|A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis||Astellas Pharma Inc|No|Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|124|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096862||124267|
NCT01086202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59247|Clinical Outcome Comparison Between Medial and Lateral Offset Reverse Shoulder Arthroplasty|Clinical Outcome Comparison Between Medial and Lateral Offset Reverse Shoulder Arthroplasty||Loma Linda University|Yes|Completed|May 2010|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|37|||Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Elderly/aged, Inpatient and outpatient, healthy patients, females, males physically        handicapped, Seventh-day Adventist cohort.|June 2011|September 3, 2015|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086202||125085|
NCT01086462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114041|Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633|A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects||GlaxoSmithKline||Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01086462||125065|
NCT01086475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-09|D-Cycloserine and Social Skills Training in Autism Spectrum Disorders|A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders||Indiana University|Yes|Completed|March 2010|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|5 Years|11 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|March 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086475||125064|
NCT01086839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaCl 6.0%-nasal-CF|Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial||University of Jena|No|Completed|March 2010|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|8 Years|N/A|No|||November 2014|November 28, 2014|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086839||125037|
NCT01087424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH03-7B|Mini-CHOP and Rituximab in Patients Aged Over 80 Years|Phase II Study of Mini-CHOP Plus Rituximab in Non Previously Treated Patients Aged Over 80 Years With CD 20+ Diffuse Large B-Cell Lymphoma||Lymphoma Study Association|No|Active, not recruiting|April 2006|April 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|80 Years|N/A|No|||March 2010|March 15, 2010|August 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01087424||124992|
NCT01087151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT4710n|A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)|A Phase II, Multicenter, Randomized, Controlled, Open-label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-intensive Rituximab, or Dose-intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)||Genentech, Inc.||Completed|August 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|118|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01087151||125013|
NCT01087697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNG-CL009|Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit|A Phase 1 Open Label Exploratory Study of an Autologous Neo-Urinary Conduit in Subjects Requiring Incontinent Urinary Diversion Following Radical Cystectomy||Tengion|Yes|Completed|March 2010|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||December 2014|December 9, 2014|March 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01087697||124972|
NCT01087710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK22|Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children|Effect of Novel Medical Food on Reducing the Frequency and Severity of Asthma Symptoms and Airway Hyper-responsiveness in Children With Mild to Moderate Persistent Asthma||Abbott Nutrition|No|Completed|July 2004|January 2006|Actual|December 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|6 Years|14 Years|No|||March 2010|March 15, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01087710||124971|
NCT01087931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100096|Pain Relief at Iliac Crest Bone Harvest Sites in Spine Surgery Using Bupivacaine|Local Anesthetic Use at Iliac Crest Bone Graft Site in Spinal Reconstructive Surgery||Vanderbilt University|No|Recruiting|April 2010|July 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2011|January 11, 2011|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01087931||124954|
NCT01088269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPM IN AF|Blood Pressure Assessment in Atrial Fibrillation|Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes||University of Athens|No|Recruiting|March 2010|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|25 Years|85 Years|No|Non-Probability Sample|SUBJECTS REFERRED TO HYPERTENSION CENTER|August 2014|August 15, 2014|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088269||124928|
NCT01099189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Access 4|Vein Histology in Arteriovenous Fistulas and Its Effect on Fistula Surgery Success|A Cohort Study of the Histopathological Changes Evident in Vein Wall at the Time of Arteriovenous Dialysis Access Fistulas and the Effects of Such Changes on Biomechanical Compliance and Patient's Clinical Outcomes in a University Teaching Hospital.||University of Hull|No|Not yet recruiting|July 2010|September 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|vein samples collected at time of fistula formation|Both|18 Years|N/A|No|Non-Probability Sample|All patient referred for access formation|March 2010|April 5, 2010|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01099189||124091|
NCT01098890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22461|Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage|Intraventricular Tissue Plasminogen Activator in the Management of Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Pilot Study||University of Calgary||Recruiting|October 2009|April 2012|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||April 2010|November 10, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098890||124114|
NCT01095887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003392|Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation|A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi LDKTx)|ABOi|Mayo Clinic|No|Terminated|May 2010|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|March 26, 2010|Yes|Yes|Poor enrollment|No|June 3, 2015|https://clinicaltrials.gov/show/NCT01095887||124342|The study was terminated early due to poor enrollment.
NCT01095367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03436|Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer|Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer||University of British Columbia|No|Terminated|April 2010|January 2014|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Female|N/A|N/A|No|||September 2014|September 25, 2014|March 22, 2010||No|due to company changes and lack of funding-unlikely to have sufficient numbers to analyze    meaningfully|No||https://clinicaltrials.gov/show/NCT01095367||124382|
NCT01095380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD041487|Comparison of Post-pinal Cord Injury (SCI) Locomotor Training Techniques|Comparison of Post-SCI Locomotor Training Techniques||University of Miami|No|Completed|November 2003|November 2008|Actual|November 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|74|||Both|16 Years|65 Years|No|||January 2009|March 29, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095380||124381|
NCT01095614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0068|Substrate Utilization and Hormonal Status in Women|Impact of Women Hormonal Status (Oral Contraception vs no Contraception) on Substrate Utilization During Exercise||University Hospital, Clermont-Ferrand||Completed|February 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|N/A||2|Anticipated|24|||Female|19 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|24 healthy young women (12 with OC and 12 without any contraception) will complete a        maximal test on an ergometer cycle to obtain their maximal oxygen consumption        (VO2max).Their body composition will be assessed by DXA. They will be asked to complete 3        experimental sessions|January 2011|January 18, 2011|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01095614||124363|
NCT01096654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|avs-ct1|SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan.|Towards Cost-effective Management of Patients With Hypertension Due to Primary Aldosteronism: Adrenal Vein Sampling or Ct-scan?|SPARTACUS|Radboud University|No|Completed|July 2010|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096654||124283|
NCT01096667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-042|Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)|A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control||Merck Sharp & Dohme Corp.|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|195|||Both|18 Years|65 Years|No|||May 2015|May 6, 2015|March 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096667||124282|
NCT01096875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT0043|Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery|Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial||Ankara University|Yes|Completed|February 2010|October 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|75 Years|No|||July 2014|July 4, 2014|March 16, 2010||No||No|February 10, 2013|https://clinicaltrials.gov/show/NCT01096875||124266|The major limitation of this study is lack of functional assessment of EPCs using in vitro analysis of colony forming units because of the financial constraints.
NCT01097200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bataller01|Sacrocolpopexy Versus Vaginal Mesh Procedure for Pelvic Prolapse|Anatomic and Functional Outcomes of Vaginal Mesh ( ELEVATE) Compared With Laparoscopic Sacrocolpopexy for Pelvic Organ Prolapse||Hospital Clinic of Barcelona|Yes|Active, not recruiting|May 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|21 Years|N/A|No|||May 2015|May 7, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097200||124242|
NCT01097512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27902|AS703569 and Gemcitabine Combination in Advanced Malignancies|A Phase I, Dose-escalation Study of a Combination AS703569 and Gemcitabine Given to Subjects With Advanced Malignancies||Merck KGaA|No|Completed|June 2007|February 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097512||124219|
NCT01097525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20481|Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery|Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery||Fort Belvoir Community Hospital|Yes|Completed|April 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|224|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097525||124218|
NCT01086488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 08-03|Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma|A Phase II, Randomized Controlled Trial of Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Recurrent or Persistent Nasopharyngeal Carcinoma|FOSCAN|Ministry of Health, Malaysia|No|Recruiting|January 2009|October 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|69 Years|No|||July 2011|July 7, 2011|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086488||125063|
NCT01086501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXC-044/K|ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients|Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters||Desitin Arzneimittel GmbH||Completed|February 2010|October 2012|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|225|||Both|6 Years|N/A|No|Non-Probability Sample|newly diagnosed epileptic patients or patients who will be switched from other        antiepileptic drugs to oxcarbazepine ER|March 2010|February 28, 2013|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086501||125062|
NCT01086852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ten03|Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery|A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL's High Purity FACTOR X in the Treatment of Factor X Deficient Subjects Undergoing Surgery|Ten03|Bio Products Laboratory|No|Terminated|March 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|12 Years|N/A|No|||July 2015|July 3, 2015|November 10, 2009|Yes|Yes|Closed early due to difficulties in enrolling the target number of 10 surgical procedures.|No|January 12, 2015|https://clinicaltrials.gov/show/NCT01086852||125036|none reported
NCT01086865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E02-CIF-APE-02-08|Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.|Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.|Apetiviton BC|Cifarma Cientifica Farmaceutica Ltda|Yes|Not yet recruiting|August 2010|January 2011|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|2 Years|80 Years|No|||March 2009|May 18, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086865||125035|
NCT01087099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/322|A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children|A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children|WORMCON|University Ghent|No|Completed|January 2009|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1750|||Both|6 Years|14 Years|No|||July 2011|July 30, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087099||125017|
NCT01087437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAM002-HMO-CTIL|Testing the Effect of Crustacean's Gastrolith Nutraceutical on Mineralization Rate During Distraction Osteogenesis|||Hadassah Medical Organization|Yes|Recruiting|January 2011|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Both|4 Years|30 Years|No|||March 2014|March 30, 2014|March 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01087437||124991|
NCT01087723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-BIV-08-03|European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial|Multi-centre, Multi-national, Prospective, Randomised, Open-label, Comparison of Bivalirudin to Other Guideline Based Current Therapies (Excluding Bivalirudin)|EUROMAX|The Medicines Company|Yes|Completed|March 2010|August 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2198|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 12, 2010||No||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01087723||124970|
NCT01087450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15474|The Effect of Erythropietin on Microcircualtory Alteration in Intensive Care Unit Patients With Severe Sepsis|The Effect of rHuEPO on Microcircualtory Alteration in ICU Patients With Severre Sepsis and Septic Shock||London Health Sciences Centre|Yes|Recruiting|August 2009|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|29|||Both|18 Years|N/A|No|Probability Sample|Recruitment Critical Care research coordinators and a Research Fellow will screen patients        for severe sepsis and septic shock in the London Health Sciences Center-Critical Care        Trauma Center (LHSC-CCTC). The patients who meet the inclusion criteria will be introduced        to this study. Informed consent will be obtained from the patient or a family member or a        substitute decision maker.|October 2015|October 22, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087450||124990|
NCT01087944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25154|A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C|Tolerability and User Handling Study of an Autoinjector to Administer 180 µg/0.5 mL Peginterferon Alfa-2a (Pegasys, PEG-IFN)||Hoffmann-La Roche||Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|March 9, 2010|Yes|Yes||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01087944||124953|
NCT01087957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSTRIDE|WalkAide Compared to Ankle-Foot Orthosis (AFO) in Stroke Patients|Randomized Trial of the Innovative Neurotronics WalkAide Compared to Conventional Ankle-Foot Orthosis (AFO) in Stroke Patients (INSTRIDE)||Innovative Neurotronics|Yes|Completed|March 2010|June 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|495|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|March 15, 2010|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01087957||124952|
NCT01087970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13491|A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer|Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||Eli Lilly and Company|No|Completed|August 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|March 15, 2010|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT01087970||124951|Efficacy populations excluded data from a noncompliant site (11 participants).
NCT01088282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECICOFPALIORES09|Visual and Economic Profits of ReSTOR® Multifocal Intraocular Lenses (IOL) on Public Health Patients in Spain|Visual Function, Non-dependence on Glasses and Global Economic Cost in Patients Undergoing Lens Surgery With ReSTOR® Multifocal Aspheric Iol Implants||University of Barcelona|No|Not yet recruiting|March 2010|March 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|50 Years|N/A|No|||February 2010|March 16, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088282||124927|
NCT01095419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-CABG|Effects of Massage Therapy on Sleep After Heart Surgery|Effects of Massage Therapy on Sleep Quality After Coronary Artery Bypass Graft Surgery|MT and CABG|University of Sao Paulo|Yes|Completed|May 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|80 Years|No|||March 2010|March 29, 2010|March 29, 2010||||No||https://clinicaltrials.gov/show/NCT01095419||124378|
NCT01099176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ministry of Science|Effects of Hypolipemic Treatment on Adipokines|The Effects of 90-day Monotherapies With Atorvastatin, Fenofibrate and Combined Therapy With Atorvastatin and Fenofibrate on Lipid Profile, Fasting Plasma Glucose, Proinflammatory Cytokines and Adipokines||Medical University of Silesia|Yes|Completed|May 2008|September 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|4||Actual|78|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||March 2006|April 8, 2010|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01099176||124092|
NCT01095068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3661|Effects of Physical Exercise in Type 2 Diabetics|Beneficial Effects of Exercise Training on Physical Capacity in Type 2 Diabetics: Improvement in Skeletal Muscle Energetic Capacity, Endothelial Dysfunction and Glycemic Control||University Hospital, Strasbourg, France|No|Recruiting|March 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|40 Years|70 Years|No|||November 2015|November 13, 2015|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01095068||124405|
NCT01088204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-09-448|Feasibility Study of Laparoscopy-assisted D2 Distal Gastrectomy to Treat Advanced Gastric Cancer|A Multicenter Randomized Phase II Clinical Trial of Laparoscopy Assisted Versus Open Distal Gastrectomy With D2 Lymph Node Dissection for Advanced Gastric Cancer|COACT_1001|National Cancer Center, Korea|Yes|Active, not recruiting|June 2010|December 2016|Anticipated|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|20 Years|80 Years|No|||October 2015|October 5, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01088204||124933|
NCT01095640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAP-0.3/2008|Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel|A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study Comparing 0.3% Adapalene Topical Gel (Actavis Mid Atlantic LLC) to Differin® (0.3 % Adapalene Topical Gel) (Galderma Laboratories, L.P.) and Both Active Treatments to a Vehicle Control (Actavis Mid Atlantic LLC) in the Treatment of Mild to Moderate Acne Vulgaris||Actavis Inc.|No|Completed|March 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1159|||Both|12 Years|N/A|No|||March 2010|March 29, 2010|March 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095640||124361|
NCT01095874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGRAAH 08-01|Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study|Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study Comparing Outcome of Patients Aged From 50 to 70 Years With or Without Donor|ONIalloMDS|Saint-Louis Hospital, Paris, France|No|Completed|January 2008|||January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|164|||Both|50 Years|70 Years|No|Non-Probability Sample|Patients from 50 to 70 years with high risk myelodysplasia and eligible for        transplantation|January 2014|January 17, 2014|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095874||124343|
NCT01096095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP CAAE 0527.0.001.000-07|Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3|Phenylbutyrate in SCA3: a Double-blind, Placebo-controlled Study to Determine Safety and Efficacy of Sodium Phenylbutyrate in Patients With SCA3||Hospital de Clinicas de Porto Alegre|No|Withdrawn|June 2010|July 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|80 Years|No|||May 2010|August 15, 2012|March 29, 2010|Yes|Yes|Regulatory authorities did not allow the entrance of the study drug in the country|No||https://clinicaltrials.gov/show/NCT01096095||124326|
NCT01089582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2501054|Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets|Quality Of Life Assessment In AD Patients Receiving Aricept Tablets (Donepezil Hydrochloride)|QUEST|Pfizer|No|Completed|November 2007|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|628|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with mild to moderate dementia of the Alzheimer's type|April 2011|April 25, 2011|March 17, 2010||No||No|June 29, 2010|https://clinicaltrials.gov/show/NCT01089582||124827|
NCT01090141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ-07-003|Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers|Pharmacokinetic Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers|Micafungin|University of Texas Southwestern Medical Center|Yes|Completed|November 2009|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2010|September 12, 2014|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090141||124784|
NCT01090375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KF-306126|Regulation of Intraarticular and Synovium-related Biomarkers of Osteoarthritis. Effect of Acute Mechanical Joint Loading|||Bispebjerg Hospital|No|Completed|August 2008|||March 2009|Actual|Phase 0|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Basic Science|2||||||Female|55 Years|75 Years||||March 2010|March 18, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090375||124766|
NCT01090388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDU07-BlCa-PRO|Bladder Cancer Patient-Reported Outcomes|A Cross-Sectional Study Of Patient-Reported Outcomes For Bladder Cancer Patients With Non-Invasive Disease||Baylor College of Medicine|No|Active, not recruiting|July 2007|December 2016|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Bladder cancer patients (all stages) recruited at hospitals affiliated with Baylor College        of Medicine and MD Anderson Cancer Center and via the websites of bladder cancer survivor        organizations|July 2015|July 23, 2015|July 16, 2008||No||No||https://clinicaltrials.gov/show/NCT01090388||124765|
NCT01086176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MaisonneuveRH-09092|The Impact of Post-tetanic Count on Subsequent Train-of-four During Recovery From Rocuronium|||Maisonneuve-Rosemont Hospital||Completed|March 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|22|||Both|18 Years|75 Years|No|Non-Probability Sample|Poeple having general anesthesia at HMR|March 2010|April 26, 2010|March 10, 2010||||No||https://clinicaltrials.gov/show/NCT01086176||125087|
NCT01086189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/66|Does Green Tea Affect Postprandial Glucose, Insulin and Satiety in Healthy Subjects|||Skane University Hospital||Completed|December 2009|February 2010|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||14|Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|14 healthy volunteers|December 2009|March 11, 2010|March 11, 2010||||No||https://clinicaltrials.gov/show/NCT01086189||125086|
NCT01086514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-024|Digital Mammography for the Detection and Preoperative Staging of Breast Cancer|Dual Energy Contrast Enhanced Digital Mammography for the Detection and Preoperative Staging of Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|March 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|82|||Female|21 Years|N/A|No|||September 2015|September 28, 2015|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086514||125061|
NCT01086878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHP031|Safety of Cotrimoxazole in HIV- and HAART-exposed Infants|Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana||Harvard School of Public Health|No|Completed|February 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|222|||Both|N/A|N/A|No|||February 2011|February 24, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086878||125034|
NCT01087112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPPS-02|Mother-Infant Psychoanalysis Project of Stockholm (MIPPS)- Follow-up at 4½ Years|A Follow-up Study of a Randomized Controlled Trial of Mother-Infant Psychoanalytic Treatment and Treatment As Usual at Child Health Centres|MIPPS-02|Karolinska Institutet|Yes|Recruiting|December 2009|June 2013|Anticipated|June 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|71|||Both|54 Months|54 Months|No|||December 2009|March 15, 2010|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01087112||125016|
NCT01088295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATH|HIV and Fat Accumulation|Metabolic Abnormalities, Telmisartan and HIV Infection|MATH|University of California, Los Angeles|Yes|Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|March 16, 2010|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT01088295||124926|
NCT01087736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5220-34690-01|Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy|Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy|TAP|University of California, San Francisco|Yes|Completed|April 2010|December 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||May 2014|May 1, 2014|March 15, 2010|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01087736||124969|
NCT01087983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0743|Lapatinib With Sirolimus or Metformin|A Phase 1 Trial of Lapatinib in Combination With 1) Sirolimus or 2) Metformin in Advanced Cancer||M.D. Anderson Cancer Center|No|Completed|March 2010|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|N/A|N/A|No|||November 2015|November 9, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087983||124950|
NCT01087996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090352|The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)|A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction||University of Miami|Yes|Completed|March 2010|October 2012|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|21 Years|90 Years|No|||May 2015|May 21, 2015|March 15, 2010|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01087996||124949|
NCT01088009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-02|Efficacy Optimizing Research of Lamivudine Therapy|A Prospective, Randomised, Open-label, Multi-centre Study to Compare Three Chronic Hepatitis B (CHB) Treatment Strategies Over a 2year Period in Chinese HBeAg Positive CHB Patients|EXPLORE|Nanfang Hospital of Southern Medical University|Yes|Completed|March 2010|May 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|366|||Both|18 Years|65 Years|No|||September 2013|October 28, 2013|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01088009||124948|
NCT01089127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2356|Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease, Using Salmeterol as an Active Control||Novartis||Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|552|||Both|40 Years|N/A|No|||July 2011|July 22, 2011|March 17, 2010|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT01089127||124862|
NCT01096524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-09-1007|Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty|Phase III Study Investigating the Effects of 6-weeks of Neuromuscular Electrical Stimulation (NMES) Peri-total Knee Arthroplasty (TKA).|KneehabTKA|Bio-Medical Research, Ltd.|No|Completed|March 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2013|July 18, 2014|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096524||124293|
NCT01087632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMP-09|Armolipid Plus and Metabolic Syndrome|Effects of Armolipid Plus on Indices of Insulin Resistance in Patients With Metabolic Syndrome||Rottapharm|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||September 2010|September 1, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087632||124977|
NCT01095081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14823|GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients|GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients|GARDIAN|Bayer|No|Completed|July 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23775|None Retained|n.a|Both|N/A|N/A|No|Non-Probability Sample|Evaluate the safety and tolerability of Gadovist in patients requiring contrast-enhanced        MRI.|January 2015|January 19, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01095081||124404|
NCT01095653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-054|A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise||AstraZeneca|Yes|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|393|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095653||124360|
NCT01096108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008NTLS155|Quit and Win Contests to Improve Smoking Cessation Among College Students|Enhancing Quit and Win Contests to Improve Smoking Cessation Among College Students||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2010|March 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|1318|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 21, 2014|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096108||124325|
NCT01096394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090075|Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer|Orthotopic Propagation of Primary Human Ovarian Tumors for Preclinical Investigation of Novel Anti-Tumor Agents.||Vanderbilt University|No|Completed|November 2009|October 2015|Actual|October 2015|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Metastatic and primary tumor tissue.|Female|18 Years|80 Years|No|Non-Probability Sample|Females age 18-80 with a diagnosis of Stage III-IV ovarian cancer, primary fallopian tube,        or primary peritoneal papillary serous carcinoma and scheduled treatment for epithelial        ovarian malignancies.|December 2015|December 9, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096394||124303|
NCT01089595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-SAR-023|Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)|Open Label Phase II Randomized Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or in Combination With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced GIST That Have Progressed on High Dose Imatinib||Fox Chase Cancer Center|Yes|Terminated|February 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|January 28, 2010|Yes|Yes|Novartis is ending their research program for Nilotinib in GIST.|No||https://clinicaltrials.gov/show/NCT01089595||124826|
NCT01090167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOAML10508|A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)|A Phase I, Open-label, Multi-center Study of Clofarabine (JC0707) in Japanese Patients With Acute Myeloid Leukemia (AML)||Sanofi|Yes|Completed|February 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|74 Years|No|||March 2014|March 17, 2014|March 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090167||124782|
NCT01089881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200706006M|The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer|The Effectiveness of 18F-fluorocholine PET in Detecting, Staging and Following-up Prostate Cancer||National Taiwan University Hospital|No|Recruiting|January 2008|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|150|||Male|35 Years|90 Years|No|Non-Probability Sample|1. Group 1: 50 patients with BPH          2. Group 2: 50 patients with newly diagnosed prostate cancer and          3. Group 3: 50 patients who have received curative treatment for prostate cancer and are             suspicious of recurrence/metastases because of a persistent increase in their serum             PSA.|March 2010|March 18, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089881||124804|
NCT01090414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-99|An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study|An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies||Gilead Sciences|No|Active, not recruiting|March 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090414||124763|
NCT01086215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEARLII|Registry of AngioJet Use in the Peripheral Vascular System|PEARL II: PEripheral Use of AngioJet® Rheolytic Thrombectomy With a Variety of Catheter Lengths|PEARLII|Boston Scientific Corporation|No|Completed|January 2010|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|500|||Both|N/A|N/A|No|Non-Probability Sample|Community population|November 2014|November 3, 2014|January 20, 2010||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01086215||125084|
NCT01086254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11420|SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer|Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer||Sanofi|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086254||125081|
NCT01086527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37885|Genotype Stratified Pharmacokinetic Study of Montelukast|Genotype Stratified Pharmacokinetic Study of Montelukast|GSPOM|Nemours Children's Clinic|No|Recruiting|March 2010|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Both|7 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086527||125060|
NCT01086891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/060/793|Efficacy of Two Liquid Oxygen Devices in Deambulation|Efficacy of Two Liquid Oxygen Devices in Deambulation||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|April 2008|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||May 2012|August 29, 2013|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01086891||125033|
NCT01087125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-121|Abatacept Pregnancy Exposure Registry|Abatacept Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project: An Extension Study||Bristol-Myers Squibb|No|Recruiting|September 2006|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women|August 2015|August 28, 2015|March 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01087125||125015|
NCT01087138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-11384|Study to Determine How Exercise and Calcium Affect Pubertal Bone|Effect of Exercise and Calcium Foods on Pubertal Bone Gain|Exkids|Creighton University|No|Completed||April 2007|Actual|April 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|134|||Female|9 Years|9 Years|Accepts Healthy Volunteers|||March 2010|March 15, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087138||125014|
NCT01095536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001019IC|Risk Factors for Shoulder Pain and Emesis After Laparoscopic Cholecystectomy|The Observational Cohort Study to Identify Risk Factors for Shoulder Pain and Emesis After Laparoscopic Cholecystectomy Under General Anesthesia||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|February 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients scheduled for elective laparoscopic cholecystectomy|March 2010|October 4, 2010|March 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01095536||124369|
NCT01088555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01098|Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers|Pilot Study : Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers||VA New York Harbor Healthcare System|No|Completed|November 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||December 2013|December 23, 2013|March 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01088555||124906|
NCT01088815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1013, NA_00036883|Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas|A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2010|October 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01088815||124886|
NCT01096758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-PKU2010|Follow-up of Adult Phenylketonuria (PKU) Patients|5-year Follow-up of the Comparison of Life and Physical Health in Adult Patients With PKU and Healthy Age Matched Controls||Ludwig-Maximilians - University of Munich|No|Completed|March 2010|September 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|Samples With DNA|blood cheek cells|Both|25 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult PKU patients who are or have been attending the Departements of Metabolic Diseases        of the Klinikum der Universität München will be recruited for this study, if they had been        participating already in the last study trial comparing adult PKU patients with healthy        controls.        It will be attempted to include the same control persons as in the last study trial.|September 2013|September 9, 2013|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096758||124275|
NCT01095666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-055|A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone||AstraZeneca|Yes|Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|445|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|March 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095666||124359|
NCT01087892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCRN7582|Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection|Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection|NU278|University of Sussex|Yes|Completed|October 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1126|||Both|55 Years|N/A|No|||July 2014|July 21, 2014|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087892||124957|
NCT01088737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trial Photoderm Graz 2010-1|Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna|An Open Monocentric Pilot Study to Investigate the Potential of Imiquimod 5% Cream to Detect Residual and to Prevent Recurrence of Lentigo Maligna After Surgical Excision||Medical University of Graz|No|Recruiting|January 2011|January 2020|Anticipated|January 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088737||124892|
NCT01088750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000667369|Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma|First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents||Martin-Luther-Universität Halle-Wittenberg|Yes|Recruiting|November 2009|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|17 Years|No|||November 2015|November 17, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088750||124891|
NCT01089023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22440|A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis|Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and the Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti- TNF Therapy.||Hoffmann-La Roche||Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|March 8, 2010||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT01089023||124870|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT01089036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200911043R|Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in Extracorporeal Membrane Oxygenation (ECMO) Patients|Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in ECMO Patients|ECMO|National Taiwan University Hospital|Yes|Recruiting|March 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|serum,plasma, and cells for study. Once the study is completed, biospecimen will be      discarded.|Both|18 Years|N/A|No|Non-Probability Sample|Inclusion criteria:          1. ≧ 18 yr.          2. cardiogenic shock, needing ECMO support        Exclusion criteria          1. pre-existing sepsis          2. pre-existing chronic renal failure (dialysis dependent), liver failure, multiple             organ failure|October 2013|October 18, 2013|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089036||124869|
NCT01089322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBSTRUÇÃOHC-02|Risk Factors Associated to Difficult-to-control Asthma|Risk Factors Associated to Difficult-to-control Asthma: Characterization of Clinical, Structural and Inflammatory Factors Related to Treatment Response||University of Sao Paulo General Hospital|No|Completed|October 2006|May 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|65 Years|No|||February 2010|March 16, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01089322||124847|
NCT01089608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PII-06/09|Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis|Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis (Pilot Phase II Clinical Study, Multicentre, Randomised, Double Masked, Comparative, 2 X 40 Patients)||Laboratoires Thea|No|Completed|March 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||October 2014|November 3, 2014|March 17, 2010||No||No|October 7, 2014|https://clinicaltrials.gov/show/NCT01089608||124825|
NCT01089621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12865|A Study for Adolescents With Fibromyalgia Syndrome|An Open-label Feasibility Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome: A Pilot Study||Eli Lilly and Company|No|Terminated|March 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|13 Years|17 Years|No|||August 2010|August 23, 2010|March 17, 2010|Yes|Yes|Terminated due to study design changes; zero patients randomized to treatment|No||https://clinicaltrials.gov/show/NCT01089621||124824|
NCT01090180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6902-R|Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD|Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD|VA CORT|VA Office of Research and Development|Yes|Active, not recruiting|April 2010|December 2014|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|102|||Male|18 Years|N/A|No|||June 2014|June 23, 2014|March 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090180||124781|
NCT01090154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37823-B|Study of Cimzia for the Treatment of Ulcerative Colitis|Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study|UC CIMZIA|University of Washington|Yes|Recruiting|October 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||June 2012|June 13, 2012|March 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090154||124783|
NCT01090401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48-1|Linox Smart S DX PME/Master Study|PME/Master Study of the Linoxsmart S DX ICD Leads||Biotronik SE & Co. KG|Yes|Completed|March 2010|October 2011|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090401||124764|
NCT01086228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-384|XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan|XIENCE V/PROMUS Everolimus-Eluting Stent System Japan Post-marketing Surveillance Protocol||Abbott Vascular|No|Active, not recruiting|March 2010|August 2016|Anticipated|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2032|||Both|N/A|N/A|No|Non-Probability Sample|Only patients in Japan, who are eligible to receive treatment for coronary arteries using        the XIENCE V / PROMUS Everolimus-Eluting Stent System are to be enrolled.|April 2015|April 17, 2015|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086228||125083|
NCT01086241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-TOM-001 25232|Tomosynthesis in Screening Mammography|A Study to Determine Patient Benefit of Tomosynthesis in Screening Mammography||AHS Cancer Control Alberta|No|Completed|May 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|500|||Female|40 Years|69 Years|No|||March 2016|March 10, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086241||125082|
NCT01087164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911-50|Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers|Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers in Adolescents||Indiana University|No|Active, not recruiting|September 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|February 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01087164||125012|
NCT01087463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N.M.B. P_HY Q REV I 09.09|Intramedullary Fixation of Humerus Fractures Without Intramedullary Reaming|Composite Nailing System for the Intramedullary Fixation of Humerus Fractures Without Intramedullary Reaming||N.M.B. Medical Applications Ltd|No|Not yet recruiting|April 2010|April 2012|Anticipated|April 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||February 2010|March 14, 2010|March 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01087463||124989|
NCT01088022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-APRE1|Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting|Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting: a Phase III, Double-blind, Randomized, Placebo-controlled Trial in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting|PG-APRE1|Azienda Ospedaliera di Perugia|Yes|Not yet recruiting|April 2010|April 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2010|March 16, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088022||124947|
NCT01088035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH 09C4|Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma|A Phase II Multi-Institutional Trial of Focal Radiotherapy With Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children With Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively||Ann & Robert H Lurie Children's Hospital of Chicago|No|Terminated|April 2010|April 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|12 Months|21 Years|No|||February 2015|February 27, 2015|March 16, 2010||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT01088035||124946|
NCT01096550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1DA028407-01|Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans|Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans||Friends Research Institute, Inc.|Yes|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|85 Years|No|||March 2015|March 25, 2015|March 30, 2010||No||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01096550||124291|OP condition participants received more counseling services at the clinics as part of their regular care than was initially expected and IOP condition participants received slightly less that 9 hours of counseling, on average.
NCT01095744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-30|Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease|Influence of Age on amyloïd Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease Like Posterior Cortical Atrophy (PCA) and Logopenic Progressive Aphasia (LPA)Using Positron Emitting Tomography (PET) Imaging|BIOMAGE|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|March 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|60|Samples With DNA|DNA sample immortalized blood cell cultures csf aliquots for patients who beneficiated from      a lumbar puncture.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients have to fulfil criteria for (1)AD with an amnesic syndrome of the media-temporal        type, EOAD have lower frequency and (2) and for atypical Ad respecting episodic memory,        inaugural language disorder or visual-spatial disorder|February 2012|October 8, 2012|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01095744||124353|
NCT01096225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immunity_S-OIV_A/H1N1_vaccine|Immunogenicity Study of S-OIV H1N1 Influenza Vaccine|Study of Humoral and Cellular Immunogenicity of Split-vaccine to Swine-origin H1N1 Influenza||Chinese Academy of Sciences|No|Active, not recruiting|March 2010|August 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Serum Peripheral Blood Mononuclear Cell (PBMC)|Both|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers of age 20 and older who have no history of novel influenza H1N1 2009        infection in latest 3 months or novel influenza H1N1 2009 vaccination.|March 2010|April 9, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096225||124316|
NCT01096537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00622-53|Early Incidence of Occupational Asthma Among Bakers, Pastry-makers and Hairdressers|Evolution of the Incidence of Occupational Asthma at the Beginning of the Activity of Young Bakers, Pastry-makers and Hairdressers, and Exploration of Its Risk Factors|ABCD|Central Hospital, Nancy, France|No|Recruiting|December 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1150|Samples Without DNA|whole blood, serum, plasma|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All bakers, pastry-makers and hairdressers who graduated between 2001 and 2006 from nine        vocational schools in Lorraine, North-Eastern France, and all subjects who graduated in        2001 in the sale or the food sectors (butcher, pork butcher, caterer, cook job,…) from the        same vocational schools.|March 2010|December 27, 2010|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01096537||124292|
NCT01088477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUG 2009-4529|Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer|Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer||University Medical Center Groningen|No|Completed|February 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients with acquired anti-hormonal resistance, treated with at least 2        lines of anti-hormonal therapy|May 2014|May 20, 2014|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088477||124912|
NCT01088490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2S_1|Hydrogen Sulfide as Prognostic Factor|Hydrogen Sulfide as Prognostic Factor|H2S-1|University Medical Centre Ljubljana|Yes|Completed|January 2010|January 2014|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|95 Years|No|Non-Probability Sample|Critically ill patients how are admitted in shock or hemodynamicaly unstable ino intensive        care|December 2014|December 3, 2014|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01088490||124911|
NCT01088230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-0904010371|The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke|The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke: A Double Blind, Placebo-Controlled Pilot Study||New York Presbyterian Hospital|No|Completed|June 2009|November 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|85 Years|No|||November 2010|April 22, 2011|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01088230||124931|
NCT01088503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12549|Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome|The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome|TRANSLATE-ACS|Eli Lilly and Company|Yes|Completed|March 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12227|||Both|18 Years|N/A|No|Non-Probability Sample|Participants admitted or already in hospital with acute myocardial infarction (MI) who are        treated with percutaneous coronary intervention (PCI) and an ADP receptor inhibitor.|December 2015|December 22, 2015|March 15, 2010|No|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01088503||124910|
NCT01089049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDI: 136987|Effect of a Natural Health Product on Urinary Estrogen Metabolites|A Clinical Trial to Assess the Efficacy of a Supplemental Formula Targeting Breast Health in Beneficially Altering Urinary Estrogen Metabolites Levels in Both Pre- and Post-menopausal Women||Nutrasource Diagnostics Inc.|No|Completed|August 2009|May 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|98|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01089049||124868|
NCT01089335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/71|Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia|Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential|SNTC|Region Skane|No|Recruiting|March 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|- Patients diagnosed and operated for papillary thyroid cancer > 10 mm at the Department        of Surgery, Skåne University Hospital, Lund, Sweden        _ Patients with diagnosed and operated for a thyroid tumour of unclear malignant potential        at the Department of Surgery, Skåne University Hospital, Lund, Sweden|May 2015|May 5, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089335||124846|
NCT01089894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712071R|Clinical Application of 18F-3'-Fluoro-3'-Deoxy-L-thymidine (18F-FLT) Positron Emission Tomography (PET) in Lung Tumors|Clinical Application of 18F-FLT PET in Lung Tumors||National Taiwan University Hospital|No|Recruiting|August 2008|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|90|||Both|18 Years|90 Years|No|Non-Probability Sample|18F-FLT 1: 18F-FLT in differentiating benign from malignant pulmonary nodules        18F-FLT 2: 18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The        chemotherapeutic drugs used in the study are all approved by the Department of Health        18F-FLT 3: 18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors        (The target therapeutic drugs used in the study are all approved by the Department of        Health, Taiwan.)|March 2010|March 18, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089894||124803|
NCT01089920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.06.MET|Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans|Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans||Nestlé|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|6||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 4, 2014|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01089920||124801|
NCT01085955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPAC|Investigation in Pregnancy Associate Cardiomyopathy|Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy|IPAC|University of Pittsburgh|Yes|Completed|October 2009|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|100|Samples With DNA|Specimens for cellular analysis, complete blood count, DNA banking and genotyping, RNA      analysis and banking, serum banking and for mediator analysis.|Female|16 Years|N/A|No|Probability Sample|100 women diagnosed with peripartum cardiomyopathy|January 2016|January 14, 2016|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085955||125104|
NCT01085981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006|Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow|The Quantitative Analysis of Clitoral Blood Before and After a Topically Applied Vasodilating Cream Using Sonographic Doppler Flow Plethysmography||East Suburban Ob Gyn|No|Not yet recruiting|April 2010|July 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||March 2010|March 11, 2010|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01085981||125102|
NCT01086553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUG-2/CDA|9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease|Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease||Dr. Falk Pharma GmbH|Yes|Completed|November 2009|December 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|471|||Both|18 Years|75 Years|No|||October 2014|October 29, 2014|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086553||125058|
NCT01099046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yk19700512|Stress Management Therapy for Meniere's Disease|Reduction of Plasma Vasopressin Level in Patients With Meniere's Disease|SMT|Osaka University|Yes|Recruiting|January 2009|January 2020|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|N/A|N/A|No|||April 2010|April 3, 2010|December 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01099046||124102|
NCT01094964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-TU-BL3010-HYMN|Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer|HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy||National Cancer Institute (NCI)||Recruiting|October 2009|||October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|242|||Both|18 Years|N/A|No|||March 2010|August 9, 2013|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094964||124413|
NCT01095198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTself|Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)|Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation||McMaster University|No|Enrolling by invitation|April 2010|January 2013|Anticipated|November 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1440|||Female|35 Years|69 Years|No|||July 2011|July 19, 2011|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095198||124395|
NCT01096238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002050R|Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months|Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months||National Taiwan University Hospital|No|Enrolling by invitation|March 2010|||||N/A|Observational|N/A||1|Anticipated|185|||Both|18 Years|N/A|No|Probability Sample|age>=18 who had AdimFlu-S(A/H1N1) injection|April 2010|April 11, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096238||124315|
NCT01096251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCAU-STRATOB-1|STRATOB: a Randomized Controlled Clinical Trial of Cognitive Behavioural Therapy and Brief Strategic Therapy With Telecare for Binge-eating Disorder|Systemic and STRATegic Psychotherapy for OBesity|STRATOB|Catholic University of the Sacred Heart|No|Active, not recruiting|January 2008|January 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|65 Years|No|||March 2010|March 30, 2010|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01096251||124314|
NCT01108159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM0013|Integrated Whole-Genome Analysis of Hematologic Disorders|Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies||Stanford University||Recruiting|September 2009|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood, bone marrow, skin biopsy|Both|18 Years|N/A|No|Non-Probability Sample|participants with hematologic disorders|February 2015|February 3, 2015|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01108159||123405|
NCT01108172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216852-PHE-CEAJ-25173|A Virtual Ward to Reduce Readmissions After Hospital Discharge|A Virtual Ward to Reduce Readmissions After Hospital Discharge||St. Michael's Hospital, Toronto|Yes|Active, not recruiting|June 2010|June 2014|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1928|||Both|18 Years|N/A|No|||December 2013|December 6, 2013|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01108172||123404|
NCT01089075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-014909-14|Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency|Phase IV Study to Evaluate the Neuropsychological Effects of Hydrocortisone Substitution in Patients With Partial Adrenal Insufficiency After Traumatic Brain Injury or Subarachnoidal Haemorrhage|CSMünchen01|Max-Planck-Institute of Psychiatry|No|Terminated|February 2010|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||April 2015|April 7, 2015|February 2, 2010||No|Insufficient recruitment of suitable patients.|No||https://clinicaltrials.gov/show/NCT01089075||124866|
NCT01089361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000259|Immunomodulatory Properties of Ketamine in Sepsis|Immunomodulatory Properties of Ketamine in Sepsis||Beth Israel Deaconess Medical Center|No|Active, not recruiting|December 2009|June 2011|Anticipated|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|21 Years|N/A|No|||October 2010|October 19, 2010|March 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01089361||124844|
NCT01089374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS0929|Phyllodes Tumor Partial Breast Radiation Study|A Prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|January 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||October 2015|October 15, 2015|March 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01089374||124843|
NCT01088763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02024|Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia|A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA||National Cancer Institute (NCI)||Terminated|March 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|1 Year|21 Years|No|||October 2011|November 4, 2014|March 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01088763||124890|
NCT01089062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0004-CL-P102|Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure|A Randomized, Double Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of Intravenous Dihydroergotamine (DHE) and Orally Inhaled DHE (MAP0004) on Pulmonary Arterial Pressure and Tolerability in Healthy Adults||Allergan|No|Completed|March 2010|December 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|March 17, 2010|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01089062||124867|
NCT01089348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/09-AVVA RUS|A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis|Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis|LF-BV-09|Avva Rus, JSC|Yes|Recruiting|July 2010|December 2010|Anticipated|October 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|45 Years|No|||July 2010|July 20, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089348||124845|
NCT01089907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906028R|Genomic Changes in Childhood Acute Lymphoblastic Leukemia|Genomics Evolution in Childhood Acute Lymphoblastic Leukemia||National Taiwan University Hospital|Yes|Not yet recruiting|April 2010|June 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|400|Samples With DNA|bone marrow, peripheral blood|Both|N/A|18 Years|No|Non-Probability Sample|Acute lymphoblastic leukemia patients under 18 years of age|March 2010|March 18, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089907||124802|
NCT01089647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adult OSA drug study|Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)|Montelukast and Nasa ICS for Treatment of Mild Obstructive Sleep Apnea in Adults||Romaker & Associates|Yes|Active, not recruiting|September 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01089647||124822|
NCT01085994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT-2010|Procalcitonin Monitoring May Decrease Antibiotic Use in the Intensive Care Unit|Procalcitonin-guided Algorithms of Antibiotic Stewardship in the Intensive Care Unit: Systematic Review and Meta-analysis||University of Athens|No|Enrolling by invitation|January 2010|March 2010|Anticipated|February 2010|Anticipated|N/A|Observational|N/A||2|||||Both|N/A|N/A|No|Probability Sample|We will systematically search PubMed, Scopus and the Cochrane Central Register of        Controlled Trials to identify relevant randomized controlled trials by using the following        search terms: procalcitonin AND ("critically ill" OR "intensive care" OR "critical care").        The reference lists of the initially retrieved articles will also be reviewed. Abstracts        of conference proceedings will not be sought because they commonly present data that        differ from the full publications. Finally, the corresponding authors of each one of the        included studies will be contacted by e-mail for additional information and clarifications        if needed.|January 2010|October 6, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01085994||125101|
NCT01085968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7185-R|Cognitive Rehabilitation in Parkinson's Disease|PC-based Rehabilitation of Motor Planning Deficits in Parkinson Disease||VA Office of Research and Development|No|Completed|July 2010|August 2015|Actual|August 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|58|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01085968||125103|
NCT01098786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V110_11|Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine|Observational Study to Evaluate Safety of Cell-derived A/H1N1 Influenza HA Vaccine in Healthy Japanese Subjects||Novartis||Completed|February 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|556|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|October 2011|October 24, 2011|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01098786||124122|
NCT01095211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elderly St.Ingbert|B-vitamins Treatment for Improvement of Cognitive Function|Effect of B-Vitamins on Cognitive Function in Elderly People||Saarland University|No|Completed|January 2003|December 2009|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|79|||Both|65 Years|N/A|No|||December 2003|March 29, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095211||124394|
NCT01095224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 083|Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Regimens Utilizing Recombinant Adenovirus Serotype 35 (rAd35) With HIV-1 Clade A Env Insert and Recombinant Adenovirus Serotype 5 (rAd5) With HIV-1 Clade A or B Env Inserts in Healthy, HIV-1-Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|September 2010|||October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|180|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095224||124393|
NCT01095237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mdt-09k006|Clinical Pilot-Study of ProEndoTecc Vascular Grafts as Superficial Femoral Artery Bypass / Interponate|Multicenter, Clinical Pilot-Study of ProEndoTecc Vascular Grafts (6, 7 or 8 mm Diameter) as Superficial Femoral Artery Bypass/Interponate||NonWoTecc Medical GmbH|Yes|Terminated|March 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|89 Years|No|||July 2014|July 8, 2014|March 23, 2010||No|Study has been halted due to safety reasons|No||https://clinicaltrials.gov/show/NCT01095237||124392|
NCT01095549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V99C1-010|Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients|Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|March 2010|||April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|90 Years|No|||March 2010|May 25, 2010|March 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01095549||124368|
NCT01095757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027735|Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection|Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization||Emory University|Yes|Completed|March 2010|February 2014|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|70 Years|No|||September 2014|September 16, 2014|March 26, 2010||No||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01095757||124352|
NCT01096784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROPP-2008-01|IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity|Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study||Shire|Yes|Active, not recruiting|June 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|1 Day|No|||January 2016|January 7, 2016|March 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01096784||124273|
NCT01096797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-HSG 02-2009|Correlation Between Pain and Emergence Delirium After Adenotonsillectomy in Preschool Children|Prospective Cohort Study Evaluating Incidence and Correlation Between Pain and Emergence Delirium After Adenotonsillectomy in Preschool Children|e-PONB ENT|San Gerardo Hospital|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|2 Years|6 Years|No|||November 2009|March 30, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01096797||124272|
NCT01095965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MuchiriUP|Nutrition Education Intervention in Adults With Type 2 Diabetes Mellitus in a Resource Poor Setting|Implementation and Evaluation of a Nutrition Education Programme for Adults With Type 2 Diabetes Mellitus in a Resource Poor Setting of the Moretele Sub-District, North West Province, South Africa||University of Pretoria|Yes|Completed|April 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|82|||Both|40 Years|70 Years|No|||January 2015|January 9, 2015|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095965||124336|
NCT01095978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-979|Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine|Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine|KLARAINE|Abbott|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2822|||Both|18 Years|N/A|No|Non-Probability Sample|Consulting rooms of general practitioners, pulmonologists, and allergologists and centers        with experience in the treatment of patients with acute upper respiratory tract diseases,        acute bronchitis or acute exacerbation of chronic bronchitis or mild community-acquired        pneumonia.|June 2011|June 29, 2011|February 28, 2010||No||No|May 17, 2011|https://clinicaltrials.gov/show/NCT01095978||124335|
NCT01097668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-MS-1467-002|ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis|SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).||Apitope Technology (Bristol) Ltd.|Yes|Completed|March 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|55 Years|No|||February 2015|February 3, 2015|March 31, 2010||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01097668||124207|
NCT01087905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009-0074|Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines|Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines||University of Wisconsin, Madison|No|Completed|April 2010|November 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Actual|987|||Both|18 Years|N/A|No|||April 2013|September 30, 2015|March 15, 2010||No||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01087905||124956|
NCT01087918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-21/2008|Lokomat Versus Strength Training in Chronic Incomplete Spinal Cord Injury|Effects of Automated Treadmill Training and Lower Extremity Strength Training on Walking-related and Other Outcomes in Subjects With Chronic Incomplete Spinal Cord Injury||University of Zurich|No|Completed|July 2009|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|9|||Both|16 Years|70 Years|No|||October 2012|October 22, 2012|March 15, 2010|Yes|Yes||No|May 10, 2012|https://clinicaltrials.gov/show/NCT01087918||124955|Issues to find participants led to small numbers of subjects analyzed. Ambulatory activity besides our interventions was not controlled for.
NCT01089114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100080|Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology|Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology||National Institutes of Health Clinical Center (CC)||Completed|March 2010|August 2015||||N/A|Observational|N/A|||Actual|168|||Both|18 Years|N/A|No|||August 2015|August 8, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089114||124863|
NCT01089634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEARN2007|Left Ventricular Capture Management Study|Left Ventricular Capture Management (LEARN) Study|LEARN|Medtronic|No|Completed|October 2007|December 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|151|||Both|N/A|N/A|No|Non-Probability Sample|-  Patients who will be implanted with their first CRT defibrillator system.          -  Patients who will be implanted with a Medtronic CRT defibrillator containing the LVCM             feature.          -  Patients who are willing and able to sign an IRB/MEC approved patient informed             consent.          -  Patients who are geographically stable and available for follow-up at the study             center for the required follow-up duration of the study|April 2015|April 7, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089634||124823|
NCT01089387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT06-07|Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction|Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction|INSTIN|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|April 2010|June 2012|Anticipated|May 2012|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Male|45 Years|70 Years|No|||April 2011|December 29, 2011|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089387||124842|
NCT01089660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPF18|A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults|Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects||Sanofi|No|Completed|March 2010|December 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|202|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089660||124821|
NCT01090219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002.0.379.174.08|Polypropylene Meshes in Hernia Repair|Morphofunctional Evaluations of Heavyweight and Ultralightweight Polypropylene Meshes in Men Inguinal Hernia Repair||Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude|Yes|Recruiting|February 2008|July 2010|Anticipated|February 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|32|||Male|20 Years|50 Years|No|||February 2008|March 18, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090219||124778|
NCT01098253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-09-CR-07|Integrating Depression Services Into DM Management|Integrating Depression Services Into Type 2 Diabetes Mellitus Management||University of Pennsylvania|Yes|Completed|January 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|30 Years|N/A|No|||February 2012|February 8, 2012|April 1, 2010||No||No|November 29, 2011|https://clinicaltrials.gov/show/NCT01098253||124162|Our primary care sites might not be representative of most primary care practices. Patients in the usual care group did not have the same number of in person contacts as those in the integrated care intervention to control for attention.
NCT01090193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BZYK01|Human Kidney Histopathology in Obstructive Jaundice|Phase 4 Study :Human Kidney Histopathology in Acute Obstructive Jaundice: a Prospective Study||Turkish Ministry of Health Izmir Teaching Hospital|No|Completed|January 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|26 Years|86 Years|No|||January 2009|March 18, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090193||124780|
NCT01090206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT 104212|Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia|Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia||Virginia Commonwealth University|No|Active, not recruiting|March 2010|March 2014|Anticipated|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|40|||Male|2 Years|21 Years|No|||January 2014|January 6, 2014|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01090206||124779|
NCT01094977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013836|Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid|Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid Undergoing Craniosynostosis Reconstruction: A Randomized Placebo-Controlled Double Blind Study of Low and High Dose Therapy||The Hospital for Sick Children|No|Recruiting|January 2010|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|2 Months|2 Years|No|||August 2013|August 27, 2013|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01094977||124412|
NCT01095562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-854|Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)||AbbVie|Yes|Completed|March 2010|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|207|||Both|20 Years|55 Years|No|||January 2013|January 2, 2013|March 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01095562||124367|
NCT01095770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAAPITUP|Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP|Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP|LAAPITUP|Eastbourne General Hospital|No|Not yet recruiting|April 2010|November 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|50|||Both|16 Years|80 Years|No|||March 2010|March 29, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01095770||124351|
NCT01095991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00032|Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus|A Randomised, Open, Phase I Study in Patients With Type 2 Diabetes Mellitus Treated With Metformin to Evaluate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin and Vice Versa||AstraZeneca|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|No|||June 2010|June 30, 2010|March 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01095991||124334|
NCT01096004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2060M00001|Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue|A Randomised, Single-blind, Placebo-controlled, Single-centre, Phase I Study in Abdominally Obese Healthy Volunteers to Evaluate Methods to Assess 11-βHSD1 Activity in Adipose Tissue and Related Downstream Biomarkers After Single and Repeated Oral Doses of AZD4017 for 10 Days||AstraZeneca|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|15|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 9, 2010|March 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01096004||124333|
NCT01096264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-03|Non-Invasive Quantitative Imaging of Human Local Arterial Wall Elasticity Using Supersonic Shear Imaging|Establishment of Local Arterial Stiffness Normal Values (Carotid and Femoral) on Healthy Volunteers Using Supersonic Shear Imaging|ULTRAFASTECHO|French Cardiology Society|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|145|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01096264||124313|
NCT01096810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBL 12|Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma|A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma||Jagannath, Sundar, M.D.|No|Terminated|September 2008|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|February 22, 2010|Yes|Yes|The research is permanently closed to enrollment. All subjects have completed all    research-related interventions.|No||https://clinicaltrials.gov/show/NCT01096810||124271|
NCT01097382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOLPI_L_04551|Sleep Satisfaction and Psychomotor Performance of Adults|National, Multicenter, Open Label, Phase IV, Before-after Design Study, in Adult Patients With Primary Insomnia to Evaluate Sleep Satisfaction and Psychomotor Performance After 1 Month of Treatment With Zolpidem CR (Ambien®CR) in 6 Sites in Argentina|MORFEO CR|Sanofi||Completed|March 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|N/A|No|||July 2012|July 16, 2012|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097382||124229|
NCT01097395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1198|Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection|Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection||University of Colorado, Denver|No|Completed|February 2010|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||August 2015|August 6, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097395||124228|
NCT01107613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011325|The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits|The Lung Attack Alert Study|TLAL|University of Alberta|No|Not yet recruiting|April 2010|October 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|40 Years|N/A|No|||April 2010|May 4, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01107613||123446|
NCT01107626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000666482|Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC||National Cancer Institute (NCI)||Recruiting|August 2010|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1282|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|April 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107626||123445|
NCT01088516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aluvia Breastfeeding Study|Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa|Use of an Aluvia Based Highly Active Antiretroviral Therapy (HAART) Regimen in the Prevention of Mother to Child HIV Transmission (PMTCT) Antepartum, Intrapartum and Postpartum in Africa||University of Zambia|Yes|Completed|December 2008|May 2012|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|280|||Female|15 Years|N/A|No|||June 2015|June 22, 2015|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01088516||124909|
NCT01089712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-00005|Management Practices and the Risk of Infection Following Cardiac Surgery|Management Practices and the Risk of Infection Following Cardiac Surgery||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2010|March 2013|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5158|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing cardiac surgical interventions at the 10 CT Surgery Network        institutions|April 2014|April 4, 2014|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089712||124817|
NCT01088776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012569|Omega-3 Fatty Acid Supplementation in Children|Omega-3 Fatty Acid Supplementation to Treat Hypertriglyceridemia in Children With Chronic Kidney Disease||The Hospital for Sick Children|No|Recruiting|March 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|2 Years|18 Years|No|||June 2010|June 21, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088776||124889|
NCT01088789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J09100, NA_00031401|A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine|A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2010|April 2023|Anticipated|April 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|March 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01088789||124888|
NCT01089088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000667764|Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium|A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium||Wales Cancer Trials Unit|Yes|Active, not recruiting|April 2009|February 2014|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|16 Years|N/A|No|||February 2013|February 28, 2013|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089088||124865|
NCT01089101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03173|Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma|A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma||National Cancer Institute (NCI)|No|Recruiting|April 2010|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|3 Years|21 Years|No|||March 2016|March 11, 2016|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01089101||124864|
NCT01089933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006711-01|Reducing Pain and Disability After Breast Cancer Surgery|Efficacy of Thoracic Paravertebral Block in Reducing Chronic Pain and Disability After Breast Cancer Surgery With Axillary Lymph Node Dissection|RELIeF|Ottawa Hospital Research Institute|No|Completed|September 2009|June 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|145|||Female|18 Years|N/A|No|||October 2014|October 14, 2014|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089933||124800|
NCT01089946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-4074|Cardiovascular Changes and Changes in Tissue Oxygenation During Early Postoperative Mobilization in Total Hip Arthroplasty (THA) Patients|Cardiovascular Changes and Changes in Tissue Oxygenation During Early Postoperative Mobilization After Primary Total Hip Arthroplasty||Rigshospitalet, Denmark|No|Completed|March 2010|||June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing primary THA.|October 2012|October 9, 2012|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089946||124799|
NCT01097928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03292010-5502|Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: PERFECT|Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: The PERFECT Registry||Stanford University||Recruiting|January 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Any adult patient who has developed a pulmonary embolism, and who will be undergoing        catheter directed debulking of the embolus.|May 2015|May 18, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097928||124187|
NCT01098812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIOL-103-TCNS|Clinical Evaluation of a 1-Piece Intraocular Lens|Clinical Evaluation of the TECNIS® Toric 1-Piece Intraocular Lens||Abbott Medical Optics|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|269|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 28, 2013|March 31, 2010|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT01098812||124120|
NCT01098825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 10-218X|Vaccine Hesitancy: A Survey of Pediatric Clinicians|Vaccine Hesitancy: A Survey of District VI Pediatric Clinicians||Children's Mercy Hospital Kansas City|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|District VI American Academy of Pediatrics clinicians|June 2011|June 22, 2011|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098825||124119|
NCT01099059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8630|Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)|Amantadine VS Ritalin in the Treatment of ADHD: a Double Blind Randomized Trial||Tehran University of Medical Sciences|Yes|Recruiting|April 2010|June 2010|Anticipated|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|April 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01099059||124101|
NCT01086267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA206-001|Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer|A Phase 1/2 Study of BMS-908662 (XL281) Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer||Bristol-Myers Squibb|No|Completed|July 2010|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|17|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086267||125080|
NCT01086540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ASC01|Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)|A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|August 2010|January 2019|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086540||125059|
NCT01095263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSG-10-4711DBS|Effects of Deep Brain Stimulation in Treatment Resistant Major Depression|Assessment of Efficacy, Safety and Effects on Quality of Life of Deep Brain Stimulation to the Medial Forebrain Bundle in Patients With Treatment Resistant Major Depression (FORESEE: FOREbrain Stimulation dEprEssion)|FORESEE|University Hospital, Bonn|No|Active, not recruiting|April 2011|June 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|20 Years|70 Years|No|||August 2014|August 21, 2014|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01095263||124390|
NCT01096277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH_NPH_SS_1/2010|Vascular Effects of Sitagliptin in Diabetes Mellitus|Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus||Hannover Medical School|No|Not yet recruiting|October 2010|December 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2010|March 30, 2010|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01096277||124312|
NCT01096563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1882C00004|A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD9164 After Administration of Single and Multiple Ascending Doses for 13 Days in Healthy Male and Female Japanese Subjects|JSMAD|AstraZeneca|No|Terminated|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|27|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 2, 2010|March 25, 2010|No|Yes|Sponsor has taken the decision to terminate further development of the compound|No||https://clinicaltrials.gov/show/NCT01096563||124290|
NCT01096576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP22799|A Study of Balapiravir in Patients With Dengue Virus Infection|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Dengue Virus Polymerase Inhibitor (Balapiravir) in Male Patients With Confirmed Dengue Virus Infection||Hoffmann-La Roche||Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Male|18 Years|65 Years|No|||March 2016|March 1, 2016|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01096576||124289|
NCT01096589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU Study-05-000012|Assessment of 3M Oedema Reduction System in the Treatment of Lymphoedema Compared to Commercial Short-stretch Bandage|Preliminary Study to Assess the Effectiveness of 3M Oedema Reduction System in the Treatment of Lymphoedema Treatment Compared to Comprilan Short-stretch Bandage Compression Therapy||3M|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|March 22, 2010||No||No|July 20, 2012|https://clinicaltrials.gov/show/NCT01096589||124288|
NCT01097720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P000379|Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine|Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine, Sodium Valproate, or Carbamazepine||Massachusetts General Hospital|No|Active, not recruiting|March 2005|September 2010|Anticipated|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|298|||Both|36 Months|83 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children 36-83 months of age, prenatally exposed to LTG, VPA, or CBZ monotherapies,        recruited through mothers enrolled in the North American Antiepileptic Drug Pregnancy        Registry.|March 2010|March 31, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01097720||124203|
NCT01097096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAD106A2203|Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients|A 90-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study in Patients With Mild Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Abeta-specific Antibody Response Following Repeated i.m. Injections of Adjuvanted CAD106||Novartis||Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|177|||Both|N/A|85 Years|No|||February 2013|February 7, 2013|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097096||124249|
NCT01097057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2310.00|Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells|Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|July 2010|||September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|March 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01097057||124252|
NCT01097070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bevirimat Study 206|A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days|A Phase II Multicenter, Open-label, Randomized, Parrallel Group Study to Assess the Pharmacokinetics of Bevirimat (BVM) 100 mg Tablets Administered to HIV-1 Positive Patients for 15 Days||Myrexis Inc.|No|Completed|November 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||March 2010|March 30, 2010|March 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01097070||124251|
NCT01097083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma|A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy||National University Hospital, Singapore|No|Terminated|April 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||20|||Both|21 Years|N/A|No|||January 2014|January 13, 2014|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097083||124250|
NCT01097408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV689-105|Pharmacokinetics of AZD7295 Capsules|A Randomised, Double-Blind, Placebo-Controlled Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD7295 Capsules in Healthy Volunteers||Arrow Therapeutics|Yes|Completed|March 2010|August 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 6, 2010|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01097408||124227|
NCT01107639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 75/08|Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery|Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|April 2010|June 2019|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|297|||Both|18 Years|75 Years|No|||November 2015|November 2, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01107639||123444|
NCT01088529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016945|Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer|A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone||Cougar Biotechnology, Inc.|Yes|Completed|December 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Male|18 Years|N/A|No|||May 2014|May 1, 2014|March 15, 2010|Yes|Yes||No|March 4, 2014|https://clinicaltrials.gov/show/NCT01088529||124908|
NCT01097343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2104|Clopidogrel Pharmacogenomics Project|Clopidogrel Pharmacogenomics Project||University of North Carolina, Chapel Hill||Completed|March 2010|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|March 30, 2010|Yes|Yes||No|July 9, 2012|https://clinicaltrials.gov/show/NCT01097343||124232|
NCT01089400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-39|Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage|Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage in Patients Requiring Mechanical Ventilation in Intensive Care Unit|FluBAL|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|October 2009|April 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|Samples Without DNA|Bronchoalveolar lavage fuid Nasal sample Peripheral mononuclear blood cells Plasma Serum|Both|13 Years|N/A|No|Non-Probability Sample|Patients with severe influenza A/H1N1v infection with pulmonary involvement in intensive        care unit|January 2012|January 27, 2012|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089400||124841|
NCT01089413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25117|Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)|A Multicenter, Non-interventional, Post-authorization Study to Observe in Daily Clinical Practice the Treatment Duration of Patients Treated With Avastin (Bevacizumab) in 1st Line mCRC in Belgium||Hoffmann-La Roche||Completed|January 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|||Both|18 Years|N/A|No|Probability Sample|Patients with 1st line treatment with bevacizumab in Belgium|November 2015|November 13, 2015|March 15, 2010||No||No|November 13, 2015|https://clinicaltrials.gov/show/NCT01089413||124840|
NCT01089673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-016|A Retrospective Study of the Effects of Molecular Diagnostics on Wound Care Outcomes|A Retrospective Study of the Effects of Molecular Diagnostics on Wound Care Outcomes||Southwest Regional Wound Care Center|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Patient records would be extracted from the electronic health record system of Southwest        Regional Wound Care Center.|September 2011|September 6, 2011|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089673||124820|
NCT01089686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS10-01|Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients|Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study (Liberation Study)||The Vascular Group, PLLC|No|Terminated|August 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|2|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|March 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01089686||124819|
NCT01097616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-028|Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study A||Merck Sharp & Dohme Corp.|No|Completed|May 2010|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1023|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|March 26, 2010|Yes|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01097616||124211|
NCT01097629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-029|Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study B||Merck Sharp & Dohme Corp.|No|Completed|May 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1020|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|March 26, 2010|Yes|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01097629||124210|
NCT01097915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICADBSITB-1|Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste|Sensitivity to 6-n-propylthiouracil (PROP) Association With Gustin (CA6) Gene Polymorphism, Salivary Zinc and BMI in Humans|gustinprop|University of Cagliari|No|Completed|October 2009|April 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples With DNA|DNA and zinc analyses in saliva|Both|20 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|Seventy-five non-smoking volunteers (28 men and 47 women) were recruited for the study.        Mean age was 25 y, ranging from 20 to 29 y. Thresholds for the 4 basic tastes were        evaluated in all subjects in order to rule out any gustatory impairment. The volunteers        showed no variation of body weight > 5 kg over the last 3 mo. They were not following a        prescribed diet or using medications that might interfere with taste perception; none had        food allergies. They were assessed for cognitive eating behaviours using the Three-Factor        Eating Questionnaire|March 2010|April 1, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01097915||124188|
NCT01098526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114005|GSK1349572 Drug Interaction Study With Efavirenz|A Phase 1, Open Label, Single Sequence, Three Period Study to Evaluate the Single Dose Pharmacokinetics of GSK1349572 100mg Versus 50mg and the Effect of Efavirenz 600mg Once Daily on the Pharmacokinetics, Safety and Tolerability of GSK1349572 50mg Once Daily in Healthy Adult Subjects (ING114005)||GlaxoSmithKline|No|Completed|March 2010|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01098526||124142|
NCT01098799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dahiliye-2-Urotensin|Urotensin II in Chronic Kidney Diseases and Kidney Transplants|Urotensin II in Chronic Kidney Diseases||Vakif Gureba Training and Research Hospital|Yes|Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|110|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy controls,CRF patients and kidney transplants aged more than 18|June 2013|June 12, 2013|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01098799||124121|
NCT01099085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-12-019|Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients|Placebo-controlled, Double-blinded Phase III Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients||Samsung Medical Center|No|Active, not recruiting|February 2009|January 2014|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|244|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|April 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01099085||124099|
NCT01099098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0909-054-295|Prevalence of Latent Tuberculosis (TB) Infection Diagnosed by Interferon-gamma Release Assay and Tuberculin Skin Tests in Patients With Old Healed TB|||Seoul National University Hospital|No|Completed|January 2010|March 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|480|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with TB sequelae in their CXR|May 2011|May 11, 2011|April 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01099098||124098|
NCT01098513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113674|GSK1349572 Relative Bioavailability Study|Relative Bioavailability Study of Three Different Tablet Formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in Healthy Male and Female Volunteers (ING113674)||GlaxoSmithKline|No|Completed|April 2010|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|March 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01098513||124143|
NCT01098773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0069|Pulmonary and Cardiac Ultrasound During Weaning From Mechanical Ventilation|Pulmonary and Cardiac Ultrasound During Weaning From Mechanical Ventilation|PULCO|University Hospital, Clermont-Ferrand||Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Prospective observational clinical multicentric study on ICU ventilated patients requiring        chest ultrasound analysis during weaning from mechanical ventilation with 48 hours of        follow-up. Studying variations of cardiac markers|July 2014|July 4, 2014|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01098773||124123|
NCT01087853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09063|The Effect of Crystalloids and Colloids on Visceral Blood Flow|The Effects of Balanced and Unbalanced Crystalloids and Colloids on Serum Biochemistry and Visceral Blood Flow: A Two Phase, Double Blind, Randomised Crossover Study||University of Nottingham|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|25|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087853||124960|
NCT01088191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-CAR001|Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction|Phase 2 Study to Assess Safety & Tolerability of a Single Injection Into the Knee Joint of Two Different Doses of MSB-CAR001 Combined With Hyaluronan Compared to Hyaluronan Alone in Patients Who Have Undergone an ACL Reconstruction||Mesoblast, Ltd.|Yes|Active, not recruiting|March 2009|September 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|40 Years|No|||January 2014|November 6, 2014|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01088191||124934|
NCT01088165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASTIP1|The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis|The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris|CASTIP|Medical University of Vienna|No|Recruiting|May 2010|May 2014|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|66|||Both|18 Years|80 Years|No|||January 2012|January 18, 2012|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088165||124936|
NCT01088425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH-HL-09-195|Vitrification Versus Spontaneous Conception and Slow- Rate Freezing|Maternal Pregnancy and Neonatal Outcome After Assisted Reproduction. Comparison of Vitrification vs. Spontaneous Conception||University of Luebeck|Yes|Active, not recruiting|March 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|850|||Both|N/A|N/A|No|Non-Probability Sample|tertiary university hospital|June 2014|June 5, 2014|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088425||124916|
NCT01088438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBME0708-12|Measuring Quality of Medical Student Performance at Contextualizing Care|Measuring Quality of Medical Student Performance at Contextualizing Care||University of Illinois at Chicago|No|Completed|July 2008|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|189|||Both|21 Years|N/A|No|||March 2011|April 11, 2011|March 12, 2010||No||No|March 14, 2011|https://clinicaltrials.gov/show/NCT01088438||124915|Small number of cases and variants. Alternating assignment of site to intervention/control. Substantial drop-out (sensitivity analysis finds results robust to conservative imputation for drop-outs).
NCT01088711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-004|Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|March 16, 2010|No|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01088711||124894|
NCT01089010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 4021|A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)||Cytokinetics|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||May 2011|May 11, 2011|March 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01089010||124871|
NCT01089309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WolfsonMC-2004-388|Effect of Aldosterone Blockade on Arterial Compliance|Effect of Aldosterone Blockade on Metabolic Parameters and Arterial Compliance|RAAS LAEI SAEI|Wolfson Medical Center|Yes|Completed|May 2004|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|51|||Both|45 Years|85 Years|No|||March 2010|March 26, 2010|March 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01089309||124848|
NCT01089556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13084|A Study in Painful Diabetic Neuropathy|Use of Duloxetine or Pregabalin in Monotherapy Versus Combination Therapy of Both Drugs in Patients With Painful Diabetic Neuropathy "The COMBO - DN (COmbination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study"|COMBO-DN|Eli Lilly and Company|No|Completed|March 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|811|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|March 15, 2010|Yes|Yes||No|October 30, 2012|https://clinicaltrials.gov/show/NCT01089556||124829|
NCT01089569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03951-10-C|Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine|Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis||HealthPartners Institute|No|Completed|April 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|75 Years|No|||October 2013|November 30, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089569||124828|
NCT01089855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTEG111ZMA01|Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain|Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of Tegretol® in Diabetes Neuropathy Pain.||Novartis||Completed|December 2009|||July 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|18 Years|65 Years|No|||February 2011|February 25, 2011|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089855||124806|
NCT01089868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGN-ZP9|Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients|Quantification of Therapy Effects After Microsurgery, Percutaneous Irradiation and Chemotherapy by FET-PET Analysis||Ludwig-Maximilians - University of Munich|No|Completed|January 2007|July 2012|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|79|Samples With DNA|DNA and RNA samples for MGMT methylation and LOH 1p and 19q status analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been referred to a neurosurgical department for diagnosis and therapy of        a brain tumor|August 2012|August 5, 2012|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089868||124805|
NCT01089842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08/90182|Health Coaching to Promote Physical Activity for Coronary Heart Disease Prevention|Randomized Clinical Trial to Assess the Efficacy and Cost-efficacy of Health Coaching to Promote Physical Activity in Secondary Prevention of Coronary Heart Disease||Corporacion Parc Tauli|No|Recruiting|June 2009|January 2012|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|262|||Both|18 Years|80 Years|No|||February 2010|March 18, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01089842||124807|
NCT01090102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164320|Mesalamine to Reduce T Cell Activation in HIV Infection|Mesalamine to Reduce T Cell Activation in HIV Infection||University of California, San Francisco||Completed|June 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|March 17, 2010||No||No|May 20, 2014|https://clinicaltrials.gov/show/NCT01090102||124787|
NCT01090115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-001|Study to Look at the Effects of ART-123 on Patients With Sepsis and Disseminated Intravascular Coagulation (DIC)|A Randomized, Double-Blind, Placebo-Controlled Phase 2B Study ot Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation||University of South Alabama||Withdrawn|March 2008|October 2008|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|N/A|No|||January 2013|January 23, 2013|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090115||124786|
NCT01080781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 159 02|Ephrin B1 Regulation in Human Right Appendage|Ephrin B1 Regulation in Human Right Appendage|REBORD|University Hospital, Toulouse|No|Completed|March 2010|December 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|30|Samples With DNA|right appendage|Both|18 Years|N/A|No|Non-Probability Sample|Cardiac diseases, right appendage|January 2013|January 22, 2013|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01080781||125499|
NCT01088334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trousseau studie|Mortality Due to Malignancy in Patients With Idiopathic Venous Thromboembolism|Trousseau Studie, Mortaliteit Door Maligniteit Bij patiënten Met Idiopatische Veneuze Tromboembolie|Trousseau|Slotervaart Hospital|Yes|Terminated|December 2002|December 2008|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|630|||Both|40 Years|N/A|No|Probability Sample|Consecutive patients with IVTE diagnosed in academical centres and teaching hospitals in        the Netherlands|March 2010|March 26, 2010|February 25, 2010||No|Terminated because of futility to continue, after planned interim analysis.|No||https://clinicaltrials.gov/show/NCT01088334||124923|
NCT01088347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-11-2009 (versions 2.0)|Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer|A Phase 1b/2 Study With the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination With Cisplatin and Radiotherapy as a First Line Therapy in Patients With Advanced Cervical Cancer.||University Medical Center Groningen|Yes|Completed|March 2010|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||April 2015|April 21, 2015|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01088347||124922|
NCT01094132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCR-H09-03303|Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection|Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.|MDC_Algo|British Columbia Cancer Agency|No|Recruiting|December 2012|December 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|618|||Female|18 Years|N/A|No|||August 2015|September 1, 2015|March 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01094132||124477|
NCT01094145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK-09157|Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease|Deep Brain Stimulation of the Nucleus Basalis Meynert to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease|MeynD-DBS|University of Cologne|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|6|||Both|60 Years|80 Years|No|||June 2013|June 6, 2013|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094145||124476|
NCT01090999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR04/04/2007|Long - Term Respiratory Rehabilitation Programs in Chronic Obstructive Pulmonary Disease (COPD) Patients: Study of Cost- Effectiveness|Long - Term Respiratory Rehabilitation Programs in Chronic Obstructive Pulmonary Disease (COPD) Patients: Study of Cost- Effectiveness.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|October 2006|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|N/A|77 Years|No|||February 2014|February 21, 2014|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01090999||124718|
NCT01089153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-015|Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research|Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research||Southwest Regional Wound Care Center|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|Samples With DNA|human blood, urine and fecal samples|Both|18 Years|N/A|No|Non-Probability Sample|Blood, feces and urine samples may be collected from subjects with known or suspected        spirochetal disease or from subjects not suspected to be infected with spirochetes|September 2011|September 6, 2011|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089153||124860|
NCT01089166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07- 016|Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition|To Compare the Bioavailability of Extended Release Metformin HCl Tablet(Test Formulation, Torrent Pharmaceuticals Ltd.,India) Versus Glucophage XR® Tablets ( Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers Under Fasting Condition||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|2||||||Male|18 Years|45 Years||||March 2010|June 18, 2010|March 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01089166||124859|
NCT01089452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01/09|Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study|ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy.|ACCESS|Monash University|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|March 17, 2010||No|Study not started due to administrative reasons.|No||https://clinicaltrials.gov/show/NCT01089452||124837|
NCT01086072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELD003|Survival Trends in Myocardial Infarction 1994 - 2010|Survival Trends in Myocardial Infarction 1994 - 2010||University of Dundee|No|Active, not recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|8000|||Both|N/A|N/A|No|Non-Probability Sample|All patients with Myocardial Infarction in Tayside 1994 - 2010|March 2010|March 11, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01086072||125095|
NCT01086319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-103|Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments|Comparison of Risk of Hospitalization for Severe Hypersensitivity (Including Severe Cutaneous Reactions) Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments||Bristol-Myers Squibb|No|Completed|August 2009|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|113505|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be carried out using databases containing administrative claims data        (HealthCore Integrated Research DatabaseSM (HIRD) and Medicare in the U.S.) and electronic        medical records (General Practice Research Database (GPRD) and The Health Improvement        Network (THIN) in the UK). The US population includes patients from health plans in the        northeast, southeastern, mid-Atlantic, central, mid-western, and western regions (HIRD) as        well as US citizens 65 years of age and older (Medicare). The UK population includes        patients seeking medical care from general practitioners (GPRD and THIN)|January 2016|January 19, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086319||125076|
NCT01087879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191/2006|The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism|The Impact of Different Administration Routes of Hormonal Contraceptives on Androgen Synthesis, Glucose Metabolism and Inflammation. A Prospective Randomized Trial.||University of Oulu|No|Completed|October 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087879||124958|
NCT01092065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2216|Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia|A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia||Novartis||Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|30 Years|80 Years|No|||March 2013|March 6, 2013|March 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092065||124636|
NCT01092377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FeFA study 2010|The Effects of Iron and Omega-3 Fatty Acid Supplementation on Cognition and Immune Function in Iron Deficient Children|The Effects of Iron and Omega-3 Fatty Acid Supplementation, Alone and in Combination, on Cognition, Immune System and Gut Microbiota: a Randomized, Double-blind, 2x2 Intervention Trial in Iron Deficient South African Children|FeFA|North-West University, South Africa|Yes|Completed|February 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|320|||Both|6 Years|10 Years|No|||December 2010|January 13, 2011|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092377||124612|
NCT01092091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-503C|Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)|Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC)|BCT-100-002|Bio-Cancer Treatment International Limited|Yes|Completed|March 2010|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||March 2012|March 13, 2012|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092091||124634|
NCT01088451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912S24|Joint Application of Human Insulin and Rapid Insulin Analogue in Control of Postprandial Glycemia|Joint Application of Human Insulin and Rapid Insulin Analogue in Control of Postprandial Glycemia|CPIT|University Hospital Hradec Kralove|No|Active, not recruiting|December 2009|September 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|25 Years|No|||February 2010|March 16, 2010|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01088451||124914|
NCT01088724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OORRPED 1|Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)|Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)|FCD-R|A.O. Ospedale Papa Giovanni XXIII|No|Completed|February 2002|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|4|||Both|6 Months|18 Years|No|||March 2010|March 16, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01088724||124893|
NCT01092923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03749|Physiological Effects of Nitrous Oxide on Anaesthesia|Nitrous Oxide and Inhalational Agent Pharmacokinetics During Anaesthetic Induction and Emergence||Austin Health|Yes|Completed|October 2009|October 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 11, 2012|March 10, 2010||No||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01092923||124570|
NCT01093196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMN01|Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients|A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects||Fondazione Neoplasie Sangue Onlus|Yes|Active, not recruiting|October 2009|November 2017|Anticipated|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|660|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093196||124549|
NCT01093209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ramón y Cajal Hospital|Efficacy of the Interferential Laser Therapy in Pain Reduction in Carpal Tunnel Syndrome|Efficacy of the Interferential Laser Therapy in Pain Reduction in Carpal Tunnel Syndrome||Hospital Universitario Ramon y Cajal|Yes|Completed|February 2010|April 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||March 2010|June 27, 2011|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093209||124548|
NCT01093521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35876-D|A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients|A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients||University of Washington|Yes|Active, not recruiting|April 2010|September 2018|Anticipated|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|55 Years|No|||December 2015|December 8, 2015|March 24, 2010|Yes|Yes||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01093521||124524|The primary limitation of our study was that it was uncontrolled without a blinded placebo. Thus, subjective endpoints could have been biased by either the subjects or the investigators.
NCT01093794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-122|Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)|A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet||Merck Sharp & Dohme Corp.|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|March 19, 2010|No|Yes||No|June 3, 2011|https://clinicaltrials.gov/show/NCT01093794||124503|
NCT01093807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 15/2375-IT-CL 0336|Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension|Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension|FELT|Recordati Industria Chimica e Farmaceutica S.p.A.|No|Completed|March 2010|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|1039|||Both|18 Years|75 Years|No|||April 2011|April 28, 2011|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093807||124502|
NCT01090128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI53989|Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer|Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer|NAC|University of Utah|No|Recruiting|September 2008|March 2020|Anticipated|March 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|March 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090128||124785|
NCT01090362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI08888|Global Anticoagulant Registry in the Field|Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.|GARFIELD-AF|Thrombosis Research Institute|Yes|Recruiting|December 2009|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|55000|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients newly diagnosed with permanent atrial fibrillation (AF) who are        with at least one additional risk of stroke from 18 countries globally.|December 2014|December 4, 2014|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090362||124767|
NCT01080807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/4030|Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder||Teva Pharmaceutical Industries||Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|385|||Both|18 Years|65 Years|No|||May 2012|May 17, 2012|March 3, 2010|Yes|Yes||No|October 21, 2011|https://clinicaltrials.gov/show/NCT01080807||125497|
NCT01080820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX157-101/A01|A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of CMX157 in Healthy Adult Volunteers.||Chimerix|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|March 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01080820||125496|
NCT01089179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07- 017|Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions|An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 500 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fed Conditions||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|2||||||Male|18 Years|45 Years||||March 2010|May 6, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089179||124858|
NCT01089192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-018|Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.|An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fasting Conditions.||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|2||||||Male|18 Years|45 Years||||March 2010|October 13, 2010|March 16, 2010||||No||https://clinicaltrials.gov/show/NCT01089192||124857|
NCT01089205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-019|Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.|An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fed Conditions.||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|2||||||Male|18 Years|45 Years||||March 2010|July 28, 2010|March 16, 2010||||No||https://clinicaltrials.gov/show/NCT01089205||124856|
NCT01089140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013524|Non-Idiopathic Scoliosis Treated With Tranexamic Acid|Blood Loss and Transfusion Requirement in Pediatric Patients With Non-Idiopathic Scoliosis Treated With Tranexamic Acid Undergoing Posterior Spinal Instrumentation and Fusion.||The Hospital for Sick Children|No|Suspended|November 2014|November 2014|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2|||Both|8 Years|17 Years|No|||August 2013|August 27, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01089140||124861|
NCT01088594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S337.1.004|A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers|A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers||Solvay Pharmaceuticals||Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 16, 2010|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01088594||124903|
NCT01089439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071003|Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children|Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children: Randomized, Double Blind Placebo-controlled Concept-proof Trial|INNOSTAPED|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2010|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|1 Year|18 Years|No|||August 2013|December 3, 2014|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01089439||124838|
NCT01090011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.71|Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer|A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)||Boehringer Ingelheim||Completed|March 2010|August 2014|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||August 2015|August 29, 2015|March 10, 2010||||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01090011||124794|
NCT01090271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSCar-214/2007|Effects of Eccentric Training for Shoulder Abductors in Subjects With Shoulder Impingement Syndrome|Eccentric Training for Shoulder Abductors Improves Pain, Function and Isokinetic Performance Steadiness in Subjects With Shoulder Impingement Syndrome||Universidade Federal de Sao Carlos|Yes|Completed|October 2007|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|60 Years|No|||September 2007|March 18, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090271||124774|
NCT01086059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M03-604|OTIS Autoimmune Diseases in Pregnancy Project|Humira (Adalimumab) Pregnancy Exposure Registry: OTIS Rheumatoid Arthritis in Pregnancy Project||University of California, San Diego|Yes|Active, not recruiting|November 2003|February 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|554|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who reside in the United States, Canada or Puerto Rico.|January 2016|January 26, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086059||125096|
NCT01086332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905705|Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer|A Phase I/II Trial of the HIV Protease Inhibitor Nelfinavir and Concurrent Radiation and Chemotherapy in Patients With Locally Advanced Pancreatic Cancer||University of Iowa|Yes|Active, not recruiting|May 2009|October 2014|Anticipated|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086332||125075|
NCT01092078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0151|Community-based Approaches to Treating Hypertension and Colon Cancer Prevention|Community-based Approaches to Treating Hypertension and Colon Cancer Prevention|MISTER-B|New York University School of Medicine|Yes|Completed|May 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|740|||Male|50 Years|N/A|No|||April 2015|April 20, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01092078||124635|
NCT01091766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 25/09|Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine|Sensitivity of Electrocardiogram on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine: a Study in Children of Different Age||University Children's Hospital, Zurich|No|Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Both|N/A|16 Years|Accepts Healthy Volunteers|||July 2012|July 23, 2012|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091766||124659|
NCT01092104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-2-201|A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients|A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients||Tobira Therapeutics, Inc.|Yes|Completed|February 2009|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|52|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|March 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092104||124633|
NCT01092117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0006|Clinical Study of the TriVascular Ovation™ Abdominal Stent Graft System|A Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the Ovation™ Abdominal Stent Graft System||TriVascular, Inc.|Yes|Active, not recruiting|March 2010|October 2017|Anticipated|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|March 15, 2016|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092117||124632|
NCT01092130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTR-ECG-4|Study to Investigate the Effects of Vitamin D Administration on Plasma Renin Activity in Patients With Stable Chronic Heart Failure|An Open-label, Blinded-endpoint, Randomized, Prospective Trial Investigating the Effects of Vitamin D Administration on Plasma Renin Activity in Patients With Stable Chronic Heart Failure|VitD-CHF|University Medical Center Groningen|Yes|Completed|March 2010|September 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01092130||124631|
NCT01088464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13904|Study of IMC-11F8 in Patients With Advanced Solid Tumors|A Phase 1 Study of IMC-11F8 in Patients With Advanced Solid Tumors||Eli Lilly and Company|Yes|Completed|January 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|20 Years|N/A|No|||October 2011|November 5, 2013|March 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01088464||124913|
NCT01092936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS|Italian Validation of the Revised MDS-Unified Parkinson's Disease Rating Scale|Italian Validation of the Revised MDS-Unified Parkinson's Disease Rating Scale|IRIS|Fondazione Neureca|Yes|Not yet recruiting|March 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Native Italian-speaking PD patients ranging from mild to severe|March 2010|March 24, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01092936||124569|
NCT01092949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 081111|Reference Ranges for Placental Perfusion Using Magnetic Resonance Imaging (MRI)PLACENTIMAGE|Reference Ranges for Placental Perfusion Using Magnetic Resonance Imaging (MRI)PLACENTIMAGE||Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2010|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|135|||Female|18 Years|N/A|No|Non-Probability Sample|All patients undergoing TOP at 16 to 32 weeks will be offered to participate in this        study.|August 2015|August 18, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01092949||124568|
NCT01093222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02027|Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma|Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma||National Cancer Institute (NCI)||Completed|April 2010|September 2014|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2015|June 3, 2015|March 24, 2010|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01093222||124547|The first stage of accrual was met with 40 registered patients. Insufficient number of patients were alive and free from progression at four months to warrant accruing to a second stage.
NCT01093235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000668530|Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer|ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer||National Cancer Institute (NCI)||Recruiting|April 2009|||April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|18 Years|N/A|No|||March 2010|March 24, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093235||124546|
NCT01093534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-007|Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.|A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.|SHRINK|Astellas Pharma Inc|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|547|||Female|18 Years|N/A|No|||April 2014|April 25, 2014|March 24, 2010|Yes|Yes||No|February 26, 2014|https://clinicaltrials.gov/show/NCT01093534||124523|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.
NCT01093547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOS|Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR|Multi-centre, Open-label, Randomized Trial to Determine the Effect of Icodextrin (Extraneal) Versus Dextrose (Dianeal 2.5%) Used in Long-dwell Exchange, Measuring the HOMA Index in Non-diabetic Prevalent CAPD Patients|ECOS|Baxter Healthcare Corporation|No|Active, not recruiting|February 2010|December 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|18 Years|75 Years|No|||March 2010|March 24, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093547||124522|
NCT01094041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007344|Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome|Gluten Intolerance in Irritable Bowel Syndrome With Diarrhea: The Role of HLA-DQ2||Mayo Clinic|No|Completed|February 2010|January 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||May 2013|May 8, 2013|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094041||124484|
NCT01094353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ophira|A Comparative Study Minisling Versus Transobturator (TOT)Sling|Randomised Trial of Ophira™ Minisling System and Unitape™ for the Treatment of Stress Urinary Incontinence in Women|sui|Federal University of São Paulo|Yes|Enrolling by invitation|June 2008|January 2012|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||March 2010|March 25, 2010|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094353||124460|
NCT01094054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008460|Adjustable Gastric Banding and Its Effects on Postprandial Glucose Metabolism Independent of Weight Loss|Adjustable Gastric Banding and Its Effects on Postprandial Glucose Metabolism Independent of Weight Loss||Mayo Clinic|No|Completed|October 2010|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|29|||Both|30 Years|65 Years|No|||May 2013|May 8, 2013|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01094054||124483|
NCT01088074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1108-0328|A Comparative Study of Incision Closure Methods for Total Knee Replacement|A Comparative Study of Incision Closure Methods for Total Knee Arthroplasty||Foundation for Southwest Orthopedic Research|Yes|Completed|January 2009|October 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|75|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 21, 2012|March 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01088074||124943|
NCT01089478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L05-099|Cytology Study of Cells From Patients With Low Back Pain|Cells in the Lumbar Epidural Space of Patients With Low Back Pain and/or Radiculopathy||Texas Tech University Health Sciences Center|No|Active, not recruiting|April 2005|October 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|605|Samples Without DNA|During epiduroscopy up to five (5) specimen samples will be collected from different sites      in the epidural space|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|consecutive patients receiving epidural neurolysis treatment for back pain|May 2015|May 11, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089478||124835|
NCT01088607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-003709|Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis|Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinstitution Trial||University of Tennessee|Yes|Recruiting|October 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|5 Years|21 Years|No|||August 2015|August 16, 2015|March 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01088607||124902|
NCT01088841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 69/04.01|Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY|The Functional Significance of Gut-expressed Taste Receptors in the Secretion of Glucagon-like Peptide-1 and Peptide YY||University Hospital, Basel, Switzerland|No|Completed|April 2009|March 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2011|February 22, 2011|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088841||124884|
NCT01090284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH001GENI|The Immunologic Reaction to Polypropylene Mesh in Inguinal Hernioplasty|The Immunologic Reaction to Polypropylene Mesh Implantation: a Comparison Between Heavyweight and Lightweight Mesh.||University Hospital, Catania|Yes|Recruiting|March 2010|December 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Serum|Both|18 Years|90 Years|No|Probability Sample|All patients affected by primary inguinal hernia|February 2010|March 22, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090284||124773|
NCT01086085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22266|A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive|A Study on Optimizing the Treatment in HBeAg Positive CHB Patients With Response Guide Treatment (RGT) Method.||Hoffmann-La Roche||Completed|April 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|265|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086085||125094|
NCT01086098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELD004|PACE30: 30 Years in Cardiac Pacing|Trends in Cardiac Pacing - 30 Years of Implants|PACE30|University of Dundee|No|Active, not recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|All patients with pacemakers|March 2010|March 11, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01086098||125093|
NCT01087242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008L00307|Clinical Trail of Tang-min-Ling Pills in Type 2 Diabetes Mellitus|Randomized，Double-blind，Dose Parallel Controlled, Multicentre Clinical Trail of Tang-min-Ling Pills and Placebo in Diabetes Mellitus(Liver-stomach Heat Retention Syndrome) (Phase Ⅲ)||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Active, not recruiting|May 2009|June 2010|Anticipated|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|30 Years|65 Years|No|||May 2009|March 15, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01087242||125006|
NCT01091779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0543|Changes of Upper and Lower Limb Blood Flow and Vascular Resistance in Hyperbaric Spinal Anesthesia for Transurethral Resection of the Prostate (TURP) Using Duplex Ultrasonography: Comparison of Normotensive and Hypertensive Patients|||Yonsei University|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Male|65 Years|N/A|No|Non-Probability Sample|Male patients scheduled elective transurethral surgery|January 2012|January 26, 2012|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091779||124658|
NCT01091792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0947|Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)|DMS 0947 Exploratory Study of the Modulation of the Immune System by Vascular Endothelial Growth Factor (VEGF) Blockade in Patients With Glioblastoma Multiforme (GBM)||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|March 2010|July 2016|Anticipated|August 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|11|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091792||124657|
NCT01092403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASM-024/II/STA-01|Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Inhalation Once Daily to Subjects With Mild Allergic Asthma||Asmacure Ltée|No|Completed|April 2010|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|No|||January 2012|January 25, 2012|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092403||124610|
NCT01092442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSG801.002-M|CryoValve SG Pulmonary Human Heart Valve Post Clearance Study|CryoValve SG Pulmonary Human Heart Valve Post Clearance Study|SGPV|CryoLife, Inc.|No|Completed|January 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|140|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients who have had a CryoValve SG Pulmonary Human Heart Valve implanted in        the pulmonary position for right ventricular outflow tract (RVOT) reconstruction or as        part of the Ross procedure at selected institutions.|December 2015|December 8, 2015|March 23, 2010||No||No|November 2, 2015|https://clinicaltrials.gov/show/NCT01092442||124607|
NCT01092637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN89547571|The TOBY Children Study|School Age Outcomes Following a Newborn Cooling Trial||Imperial College London|No|Completed|September 2009|July 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|280|||Both|72 Months|87 Months|No|Non-Probability Sample|All participants were recruited to the TOBY randomised controlled trial as newborns, with        confirmed moderate or severe hypoxic ischaemic encephalopathy.        They were allocated either standard intensive care or standard intensive care plus        moderate whole body hypothermia within 6 hours of birth.|November 2013|December 15, 2015|March 23, 2010||No||No|March 4, 2015|https://clinicaltrials.gov/show/NCT01092637||124592|
NCT01092650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0707M13481|Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine|Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2007|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 24, 2014|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01092650||124591|
NCT01092962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071221|Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children|Cyclophosphamide Versus Mycophenolate Mofetil for Children With Steroid-dependent Idiopathic Nephrotic Syndrome : a Multicenter Randomized Controlled Trial|NEPHROMYCY|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2010|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|2 Years|16 Years|No|||August 2013|March 25, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01092962||124567|
NCT01093248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99A1-PHPP39|Methadone Maintenance Treatment Outcome Study in Taiwan|Methadone Maintenance Treatment Outcome Study in Taiwan|M0508|National Health Research Institutes, Taiwan|No|Recruiting|July 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|heroin-addicted patients who seek help for methadone maintenance treatment|August 2012|August 14, 2012|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093248||124545|
NCT01093261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU de Nantes|Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury|Phase 3 Study of Hydrocortisone and Fludrocortisone in Glucocorticoid Insufficiency Related to Traumatic Brain Injury|Corti-TC|Nantes University Hospital|Yes|Completed|August 2010|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|336|||Both|15 Years|65 Years|No|||December 2012|December 12, 2012|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01093261||124544|
NCT01093560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36899-D|Fat Effects in Women With Metabolic Syndrome|Fat Effects in Women With Metabolic Syndrome|FEMMES II|University of Washington|No|Active, not recruiting|March 2010|September 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Anticipated|10|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2011|August 3, 2011|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01093560||124521|
NCT01093833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDT-08-CGM-02|A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces|A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces||Becton, Dickinson and Company|No|Completed|January 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|65 Years|No|||February 2015|February 19, 2015|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01093833||124500|
NCT01093820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 DR 2029|Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction|Documentation of Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEAT-STEMI Pilot)|BEATSTEMIPi|University Hospital, Basel, Switzerland|Yes|Completed|April 2010|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||February 2012|February 28, 2012|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01093820||124501|
NCT01093846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457C2303E1|38 Week Extension Study to CAIN457C2303|A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study)|SHIELD|Novartis||Terminated|March 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|100 Years|No|||January 2016|January 22, 2016|March 24, 2010|Yes|Yes|Core Study in Behcet's disease with mostly active uveitis did not meet its primary endpoint|No|February 12, 2015|https://clinicaltrials.gov/show/NCT01093846||124499|Due to early termination of the study AIN457C2303E1, the analysis of extension period was changed. No efficacy analyses were completed, the safety analyses were reduced to summary of AEs occurred during the extension and safety follow-up periods.
NCT01094067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-051-207|Tezosentan in Patients With Pulmonary Arterial Hypertension|Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.||Actelion|No|Terminated|September 2010|September 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|2|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|March 25, 2010|Yes|Yes|Due to slow recruitment, the study was prematurely discontinued.|No||https://clinicaltrials.gov/show/NCT01094067||124482|
NCT01094093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080767|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis||Amgen||Completed|April 2010|September 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|March 25, 2010||||No||https://clinicaltrials.gov/show/NCT01094093||124480|
NCT01088854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-30|Acute Effect of Continuous Positive Airway Pressure in Heart Failure|Acute Effect of Continuous Positive Airway Pressure on Left Ventricular Diastolic Function and Exercise Tolerance in Compensated Heart Failure||UPECLIN HC FM Botucatu Unesp|No|Completed|October 2009|November 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||April 2010|June 19, 2015|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01088854||124883|
NCT01088867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36255-A|Using Diffuse Noxious Inhibitory Control (DNIC) to Predict Acupuncture Therapy Outcome: A Pilot Study|Using DNIC to Predict Acupuncture Therapy Outcome: A Pilot Study||University of Washington|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01088867||124882|
NCT01090297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGIR-01|Continuous Positive Airway Pressure (CPAP) Mode Impact on Clinical Blood Arterial Pressure|CPAP Treatment : Fixed Versus Auto-adjusting Mode Impact on Clinical Blood Arterial Pressure. Randomised, Controlled and Double Blinded Trial in SAOS Patients|AgirSASadom|AGIR à Dom|No|Completed|September 2009|November 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|322|||Both|18 Years|80 Years|No|||April 2011|February 14, 2013|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090297||124772|
NCT01089465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-API-01|Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role|Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role||Centre Hospitalier Universitaire de Nice|No|Recruiting|March 2010|||March 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|135|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2010|December 7, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01089465||124836|
NCT01089777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP04|Monitoring and Characterization of Coronary Flow By Transthoracic Parametric Doppler (TPD) During Exercise Stress Test|||Echosense Ltd.|No|Terminated|April 2010|February 2014|Actual|January 2014|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Scheduled to exercise stress test|May 2011|August 2, 2014|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089777||124812|
NCT01089764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00300|Couplelinks.ca - An Online Intervention for Couples Affected by Breast Cancer|A Randomized Controlled Trials of Couplelinks.ca: The First Online Couples Intervention for Young Women Dealing With Breast Cancer and Their Male Partners|couplelinks|Canadian Breast Cancer Research Alliance|No|Recruiting|November 2010|June 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|260|||Both|18 Years|53 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089764||124813|
NCT01086722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAROBE/1|Pharmacokinetics in Morbid Obesity After Bariatric Surgery|Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques in Drugs Metabolism.|FAROBE/1|Fundacion IMIM|No|Completed|February 2010|March 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01086722||125046|
NCT01087008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZABACHE: 2009-017440-13|Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse|Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group|AZABACHE|PETHEMA Foundation|Yes|Active, not recruiting|April 2010|May 2016|Anticipated|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|103|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|March 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01087008||125024|
NCT01087580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 08U3|Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer|A Randomized Phase-II Pilot Trial of Docetaxel and Prednisone Versus Radiation Therapy Plus Docetaxel and Prednisone in Patients With Nonmetastatic and Oligometastatic Castrate Resistant Prostate Cancer||Northwestern University|Yes|Withdrawn|March 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||October 2012|October 15, 2012|March 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01087580||124980|
NCT01091805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006309|Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux|Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux|Pepsin|Wake Forest Baptist Health|No|Active, not recruiting|December 2008|||September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|170|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Wake Forest University Baptist Medical Center, Section of Gastroenterology Pediatric        Clinic|March 2013|March 28, 2013|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091805||124656|
NCT01092143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.17|BI 671800 ED in Steroid-naive Asthmatic Patients|A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma||Boehringer Ingelheim||Completed|March 2010|||April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|389|||Both|18 Years|65 Years|No|||April 2014|April 30, 2014|March 19, 2010||||No||https://clinicaltrials.gov/show/NCT01092143||124630|
NCT01092390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK080372|Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease|"Go Fish"Omega-3 Fatty Acid Supplementation in Diabetic Kidney Disease||Johns Hopkins University|Yes|Completed|March 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 27, 2012|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01092390||124611|
NCT01092663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-29|The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus|The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Patients With Type 2 Diabetes||KineMed|Yes|Completed|March 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|80 Years|No|||January 2013|January 15, 2013|March 23, 2010|No|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT01092663||124590|
NCT01092676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08-502|Regular vs Intermittent Dose Ibuprofen for the Treatment of Ankle Sprains in Children|Regular vs Intermittent Dose Ibuprofen for the Treatment of Ankle Sprains in Children||Lawson Health Research Institute|No|Recruiting|February 2010|||February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|7 Years|17 Years|No|||June 2010|June 2, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092676||124589|
NCT01093287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-075|Predictors for Responsiveness to Corticosteroid in Patients With Early Acute Respiratory Distress Syndrome|Predictors for Responsiveness to Corticosteroid in Patients With Early Acute Respiratory Distress Syndrome||Samsung Medical Center|No|Terminated|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|All patients meeting the American European Consensus definition of acute respiratory        distress syndrome will be included, regardless of etiology of respiratory failure.|June 2012|June 10, 2012|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093287||124542|
NCT01093573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1908|Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia|A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.||Case Comprehensive Cancer Center|Yes|Recruiting|July 2009|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||March 2016|March 4, 2016|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01093573||124520|
NCT01093859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-09-001|An Exploratory Phase 1 Microdose Study of PRX-105|An Exploratory Phase 1 Study to Assess the Safety and Pharmacokinetics of PRX-105, Administered as a Single, Microdose, Intravenous Slow Bolus Injection to Healthy Volunteers||Protalix|No|Completed|March 2010|August 2010|Actual|May 2010|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|March 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01093859||124498|
NCT01094080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502042|Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health|Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health|BEMIM|Ludwig-Maximilians - University of Munich|No|Completed|February 2010|December 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|505|||Both|N/A|4 Days|Accepts Healthy Volunteers|||December 2012|December 17, 2012|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01094080||124481|
NCT01077128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-984|Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab|[E S] A Greek, Post-marketing, Observational Study of the quAlity of Life in Patients With Psoriasis Treated With Adalimumab - GOAL Study||AbbVie|No|Completed|September 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with Adalimumab according to routine medical practice from hospital and        private physicians.|February 2014|February 19, 2014|February 25, 2010||No||No|September 13, 2013|https://clinicaltrials.gov/show/NCT01077128||125775|
NCT01077141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-054|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2010|||||N/A|N/A|N/A||||||||||||||December 22, 2010|February 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01077141||125774|
NCT01089231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWLUH-001|Effects of Omega-3 Fatty Acids on the Human Gene Expression|Effects of Omega-3 Fatty Acids From Fish Oil on the Gene Expression in Healthy Humans and Humans With Hypertriglyceridemia||Gottfried Wilhelm Leibniz Universität Hannover|No|Completed|March 2010|July 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|40|||Male|20 Years|51 Years|Accepts Healthy Volunteers|||December 2011|December 12, 2011|March 17, 2010||No||No|October 27, 2011|https://clinicaltrials.gov/show/NCT01089231||124854|A higher number of participants would be better to compensate drop outstwo pre-screening procedures of lipid levels are generally desirableCO is not an optimal placebo control
NCT01089491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L10-081|Study of Cells From Spinal Cavity of Patients With Low Back Pain|Localization and Characterization of Cells in the Lumbar Epidural Cavity of Patients With Low Back Pain With or Without Radiculopathy||Texas Tech University Health Sciences Center|No|Withdrawn|March 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Up to two (2) cell samples will be collected from different sites in the epidural space|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive patients receiving outpatient lysis of adhesions treatment at University        Medical Center in Lubbock TX.|May 2015|May 11, 2015|March 17, 2010||No|PI chose not to conduct the study; no data collected.|No||https://clinicaltrials.gov/show/NCT01089491||124834|
NCT01086137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCS-100.1|Biomarkers of Metabolic Syndrome and Prediabetes|Assessing Salivary Biomarkers for Risk Stratification in Metabolic Syndrome||West Virginia School of Osteopathic Medicine||Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|102|Samples With DNA|saliva|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|August 2013|August 5, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086137||125090|
NCT01089790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT-MD-403|Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone|A Phase III, Multicenter, Double-blind, Active-Controlled, 52 Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone|REDWOOD403|Forest Laboratories|No|Terminated|March 2010|||August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|86 Years|No|||September 2011|September 14, 2011|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01089790||124811|
NCT01086111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51169|The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient|Mechanisms of Type 2 Diabetes Improvement, Besides Weightloss After Gastric Bypass||University Hospital, Gasthuisberg|Yes|Completed|February 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples With DNA|blood samples|Both|18 Years|70 Years|No|Non-Probability Sample|type 2 diabetes patients with a BMI > 35kg/m²|December 2015|December 3, 2015|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01086111||125092|
NCT01090024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.53|Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids|A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI||Boehringer Ingelheim||Completed|March 2010|||February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|108|||Both|18 Years|65 Years|No|||April 2014|April 30, 2014|March 18, 2010||||No||https://clinicaltrials.gov/show/NCT01090024||124793|
NCT01087021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TES10884|Effect of Cabazitaxel on the QTc Interval in Cancer Patients|QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients|QT-Cab|Sanofi|No|Completed|March 2010|November 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|March 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01087021||125023|
NCT01087255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF000123|Caregivers and Electronic Medication Monitoring in Chronic Kidney Disease|Caregivers and Internet Based Monitoring to Improve Medication Use in HPHC Enrollees With Chronic Kidney Disease||Harvard Pilgrim Health Care|No|Recruiting|November 2009|December 2011|Anticipated|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2010|June 21, 2011|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087255||125005|
NCT01087593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151 662/01|Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia|Hormonal Replacement Therapy Does Not Affect Self-estimated Pain or Experimental Pain Responses in Postmenopausal Women Suffering From Fibromyalgia: A Double-blind, Randomized, Placebo-controlled Trial||Ostergotland County Council, Sweden|No|Terminated|August 2001|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|29|||Female|40 Years|60 Years|No|||September 2001|March 15, 2010|March 15, 2010||No|Due to ethical concerns regard to the results from the WHI study|No||https://clinicaltrials.gov/show/NCT01087593||124979|
NCT01092156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614137-5|Prenatal Breastfeeding Education to Reduce Nipple Pain|Prenatal Breastfeeding Education to Reduce Nipple Pain|BEST|University of California, Davis|Yes|Completed|January 2007|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|N/A||||June 2010|June 21, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01092156||124629|
NCT01093872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2008/061/A|Repetitive Transcranial Magnetic Stimulation for Tinnitus Treatment|Repetitive Transcranial Magnetic Stimulation for Tinnitus Treatment||Singapore General Hospital|No|Recruiting|August 2008|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|90 Years|No|||August 2012|December 6, 2012|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093872||124497|
NCT01094418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-2008-B0001-00099|Electrodiagnostic Parameters in Patients With Impaired Glucose Tolerance and Diabetes Mellitus|A Observational Cross Sectional Study to Evaluate the Sensory Nerve Conduction Parameters of the Distal Sensory Nerves in Patients With Impaired Glucose Tolerance and Diabetes Mellitus||The Catholic University of Korea|No|Completed|June 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|150|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|University affiliated medical center|March 2010|March 26, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01094418||124455|
NCT01092416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORBIT II|Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions|Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°® Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II)|ORBIT II|Cardiovascular Systems Inc|Yes|Active, not recruiting|May 2010|January 2016|Anticipated|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|443|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 23, 2010|Yes|Yes||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01092416||124609|
NCT01092429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-1504B|2D and Tissue Doppler Imaging Echocardiography Analysis of Left Ventricular Regional Wall Motion and Prognosis||TDI|Chang Gung Memorial Hospital|Yes|Recruiting|February 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Accoring to recommendation of ACC/AHA, patient had classI indication to perform coronary        angiography|June 2011|July 28, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092429||124608|
NCT01092975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO09901|Safety of Phenylephrine for Oral Mucositis Prevention|A Phase I Safety Study of Phenylephrine Applied Topically to the Oral Mucosa in Cancer Patients Receiving Radiation to Sub-mandibular Lymph Nodes||University of Wisconsin, Madison|Yes|Terminated|March 2010|April 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|8||Actual|1|||Both|18 Years|80 Years|No|||July 2015|July 22, 2015|March 23, 2010|No|Yes|formulation/dose changes; planned changes to safety monitoring/reporting|No||https://clinicaltrials.gov/show/NCT01092975||124566|
NCT01093274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gal001|Efficacy and Safety of Polyethylene Glycol Compared With Sodium Picosulphate for Bowel Preparation Before Colonoscopy|Efficacy and Safety of Polyethylene Glycol Compared With Sodium Picosulphate for Bowel Preparation Before Colonoscopy, a Prospective Randomized, Controlled Study||Rabin Medical Center|No|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2010|March 24, 2010|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01093274||124543|
NCT01092481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-008|Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy|A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer||Samsung Medical Center|No|Recruiting|January 2010|December 2016|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2660|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|November 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01092481||124604|
NCT01094431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fever 2010|Etiology of Uncomplicated Fever in Children <5 in Rural Zanzibar|Infectious Disease Etiologies of Uncomplicated Febrile Illness in Children <5 Years of Age in Rural Zanzibar|RDTNEG|Karolinska University Hospital|Yes|Completed|April 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|690|Samples Without DNA|Urine collected in deep ager Frozen Nasopharyngeal secretions|Both|2 Months|59 Months|No|Non-Probability Sample|Kivunge Primary Health Care Center (PHCC) in North A District in Zanzibar|December 2014|December 2, 2014|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094431||124454|
NCT01090765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100062|A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)|A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)||National Institutes of Health Clinical Center (CC)|No|Completed|February 2010|June 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|21|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|March 19, 2010|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01090765||124736|
NCT01094106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCHAne001|Infiltration Analgesia After Caesarean Section|Local Infiltration Analgesia for Postoperative Pain After Caesarean Section. A Prospective, Randomised, Controlled Trial||North Karelia Central Hospital|No|Completed|April 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|45 Years|No|||January 2012|January 1, 2012|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01094106||124479|
NCT01094405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC003|Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy|Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy||Chinese University of Hong Kong|No|Recruiting|March 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01094405||124456|
NCT01077440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000666593|Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant|Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants||Vanderbilt University|No|Terminated|February 2010|December 2014|Actual|December 2014|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|Samples With DNA|Your sample will only be used for research at Vanderbilt University and will not be sold.      Health insurance companies and group health plans may not request your genetic information      that comes from this research. As part of this study, we ask that the data from the semen      analysis can be put into a databank at Vanderbilt and kept with data from other people in      the study. Your data will be given a special code and will not identify you directly. We ask      you to select yes or no to allow/disallow us to:        -  Use your semen sample for gene research.        -  Store/share your semen sample for future gene research in hematopoietic stem cell           transplantation.        -  Store/share your semen sample for future gene research for other health problems (such           as cancer, heart disease, etc).|Male|18 Years|N/A|No|Non-Probability Sample|Males over the age of 18 who have a history of allogeneic stem cell transplant >365 days        ago with history of full donor engraftment, whose disease is in remission,|December 2014|December 8, 2014|February 26, 2010||No|PI leaving institution|No||https://clinicaltrials.gov/show/NCT01077440||125751|
NCT01077687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200810016R|Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan|Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan|S-TOGET|National Taiwan University Hospital|No|Recruiting|July 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|1050|Samples With DNA|Whole blood.|Both|16 Years|90 Years|No|Non-Probability Sample|schizophrenia Han Chinese Population one sibling with his/her parents|November 2008|February 26, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01077687||125732|
NCT01090037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100CRS02/533-CL-003|TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)|TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)||Toray Industries, Inc|Yes|Completed|March 2010|January 2015|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|892|||Both|18 Years|75 Years|No|||February 2015|February 3, 2015|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01090037||124792|
NCT01090310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457C2301E1|Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis|A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis|ENDURE|Novartis|Yes|Terminated|August 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|March 18, 2010|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01090310||124771|
NCT01090336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC01|Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)|Prevalence of Inadequate Platelet Inhibition After Oral Loading With Prasugrel/Clopidogrel in Patients With an Acute Coronary Syndrome Undergoing Early PCI||Heidelberg University|No|Recruiting|August 2009|December 2011|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|26|||Both|18 Years|75 Years|No|Probability Sample|The study population includes 80 subjects with moderate to high-risk ACS, ie patients with        unstable angina (UA) and non-ST-segment elevation MI (NSTEMI) and TIMI risk score of 3 or        higher, within 72 hours after onset of symptoms. In all patients early PCI is planned.        Patients with exclusion criteria for prasugrel will be excluded for clopidogrel as well.|March 2010|April 15, 2011|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01090336||124769|
NCT01086124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-010|Objective Systolic Function Recuperation Assessed by Echocardiography|Objective Systolic Function Recuperation Assessed by Echocardiography|ROSE|Université de Sherbrooke|No|Completed|March 2010|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to teaching hospital or sent from community hopitals to teaching        hospital for primary PCI|July 2013|July 3, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086124||125091|
NCT01086345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4309|Radiosurgery Plus Bevacizumab in Glioblastoma|Phase I/II Trial of Radiosurgery Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma||Case Comprehensive Cancer Center|Yes|Terminated|February 2010|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|March 11, 2010|Yes|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01086345||125074|
NCT01087034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-SInf|Bracing During Infantile Scoliosis: Airways Study|Bracing During Infantile Scoliosis: Airways Study by Acoustic Method, EOS™ Acquisition and Noninvasive Respiratory Muscles Assessment|MASI|Club d'Anesthésie-Réanimation Pédiatrique Armand Trousseau|No|Completed|February 2010|June 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Both|6 Years|18 Years|No|Non-Probability Sample|Children with evolutive juvenile thoracic scoliosis requiring either a Milwaukee or a        Cheneaux brace|June 2012|June 11, 2012|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087034||125022|
NCT01087268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000667367|Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer|Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II)||National Cancer Institute (NCI)||Recruiting|January 2009|||December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|1||Anticipated|75|||Both|18 Years|N/A|No|||March 2010|July 14, 2011|March 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01087268||125004|
NCT01087619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/51|Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up|Primary Hyperparathyroidism in Patients Older Than 65 Years: A Prospective Randomized Trial of Surgical Treatment Compared With Follow-up||Region Skane|No|Recruiting|August 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|66 Years|N/A|No|||May 2015|May 5, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087619||124978|
NCT01087866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070471|Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus|Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus: a Randomized Controlled Study||University of Oulu|No|Completed|June 2005|October 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Female|18 Years|50 Years||||March 2010|March 15, 2010|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087866||124959|
NCT01086293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-100|Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments|Comparison of Risk of Hospitalization With Acute Liver Failure Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments||Bristol-Myers Squibb|No|Completed|January 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|113505|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be carried out using databases containing administrative claims data        (HealthCore Integrated Research DatabaseSM (HIRD) and Medicare in the U.S.) and electronic        medical records (General Practice Research Database (GPRD) and The Health Improvement        Network (THIN) in the UK). The US population includes patients from health plans in the        northeast, southeastern, mid-Atlantic, central, mid-western, and western regions (HIRD) as        well as US citizens 65 years of age and older (Medicare). The UK population includes        patients seeking medical care from general practitioners (GPRD and THIN)|January 2016|January 19, 2016|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086293||125078|
NCT01092689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712M23122|The Role of Meat-borne Carcinogens in Pancreatic Cancer|Understanding the Role of Meat-Borne Carcinogen in Pancreatic Cancer Etiology||University of Minnesota - Clinical and Translational Science Institute|Yes|Withdrawn|January 2012|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|March 23, 2010|Yes|Yes|Needed New IND per FDA|No||https://clinicaltrials.gov/show/NCT01092689||124588|
NCT01091298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL/BRVTV/Form1/Adlts/PhI/2010|A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers|Phase I Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Tolerability of a Single Administration (10e6.25 FFU of Each Constituent Serotype Per 0.5 ml) of Live Attenuated Tetravalent (G1-G4) Bovine-human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Adult Males||Shantha Biotechnics Limited|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01091298||124695|
NCT01093313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USydney9274|Attention Training and Cognitive Therapy|Comparison of Attention Training and Cognitive Therapy in the Treatment of Social Phobia: a Randomized Controlled Trial||University of Sydney|Yes|Completed|August 2006|March 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2010|March 24, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093313||124540|
NCT01093326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058B202|Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis -Extension Study|Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis||Actelion|Yes|Active, not recruiting|May 2010|January 2022|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|353|||Both|18 Years|55 Years|No|||October 2015|October 9, 2015|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01093326||124539|
NCT01090479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2% Chlorhexidine Cloths|Pre-operative Preparation Using 2% Chlorhexidine Cloth For Shoulder Surgery|Efficacy of Home Pre-Operative Use of 2% Chlorhexidine Cloths Prior to Shoulder Surgery||Northwestern University|Yes|Completed|January 2010|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 30, 2013|March 18, 2010|Yes|Yes||No|July 9, 2012|https://clinicaltrials.gov/show/NCT01090479||124758|No specific limitations other than the study was underpowered to detect a difference in the clinical infection rate between the chlorhexidine and control groups.
NCT01091311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2420-PIV-CE-01/10|Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases|Phase IV Multicentric Study, 30 Patients Suffering of Meibomian Glands Dysfunction.|ESPOIR|Laboratoires Thea|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|4 Years|N/A|No|||June 2011|June 7, 2011|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01091311||124694|
NCT01091571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/347|The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia|The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia.||Radboud University|Yes|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2010|November 4, 2010|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01091571||124674|
NCT01077453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00757|Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer|Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer||National Cancer Institute (NCI)||Completed|March 2010|||June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|112|||Female|35 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 17, 2014|February 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01077453||125750|
NCT01090323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A0109E1|Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).|A One Year Open Label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration (LIC) of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to Deferoxamine (DFO) in Sickle Cell Disease (SCD) Patients With Transfusional Hemosideresis (THS) [Amendment 3: Extension Prolonged to 4-years]||Novartis|Yes|Completed|July 2004|||July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|2 Years|N/A|No|||May 2011|May 3, 2011|March 15, 2010|Yes|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT01090323||124770|
NCT01090076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABOUND|The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial|The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates-A Placebo Controlled Trial||Changi General Hospital|No|Completed|April 2010|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|26|||Both|21 Years|N/A|No|||June 2013|June 14, 2013|March 18, 2010||No||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01090076||124789|Limitations of trial include small sample size and it was difficult to standardise wound care regimen as the pressure ulcers were of different stages and locations.
NCT01086358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-602|Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?|A Single Center, Randomized, Open-Label, Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan. Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?|TRXvUsualTrptn|The Cleveland Clinic|No|Recruiting|September 2009|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086358||125073|
NCT01086735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P010506|Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation|Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation: a Phase I/II Clinical Study|ILD-TK01|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2010|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|70 Years|No|||January 2013|January 11, 2013|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086735||125045|
NCT01087047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAVAG|Upper Airways in Pregnancy: Evaluation by the Acoustic Reflection Method|Upper Airways in Pregnancy: Evaluation by the Acoustic Reflection Method|MAVAG|Club d'Anesthésie-Réanimation Pédiatrique Armand Trousseau|Yes|Completed|March 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Female|18 Years|N/A|No|Non-Probability Sample|Healthy pregnant women|June 2012|June 11, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01087047||125021|
NCT01087281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100047|Top-Down Attentional Control of Visual-Processing|Top-Down Attentional Control of Visual-Processing||National Institutes of Health Clinical Center (CC)||Recruiting|February 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|March 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01087281||125003|
NCT01087294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100054|Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation|Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T-cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Recruiting|February 2010|March 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|May 8, 2015|March 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01087294||125002|
NCT01091740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2009-0010|ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months|ComparisiOn of Neointimal coVerage betwEen zotaRolimus Eluting Stent and Everolimus Eluting Stent Using Optical Coherence Tomography at 3 Months|COVER OCT-II|Yonsei University|Yes|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|90 Years|No|||January 2012|January 26, 2012|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091740||124661|
NCT01091753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0440|Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers|Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers||Yonsei University|No|Completed|March 2008|September 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|70 Years|No|||October 2010|October 7, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01091753||124660|
NCT01090258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-2009|Pilot Evaluation of Closed Loop Ventilation and Oxygen Controller|Pilot Evaluation of Closed Loop Ventilation and Oxygen Controller|CLOSER1|Laval University|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|90 Years|No|||February 2014|February 24, 2014|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090258||124775|
NCT01094626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE5847|Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection|MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic Cancer||Columbia University|Yes|Withdrawn|April 2010|January 2013|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|75 Years|No|||January 2013|January 17, 2013|March 25, 2010|Yes|Yes|Pharmaceutical company did not decide to renew contract.|No||https://clinicaltrials.gov/show/NCT01094626||124439|
NCT01094639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-092-2|Periodontal Infection and Systemic Inflammation in Renal Patients|Periodontal Infection and Systemic Inflammation in Renal Patients|PeriRen|University of Connecticut Health Center|Yes|Recruiting|August 2009|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|21 Years|85 Years|No|||December 2014|December 1, 2014|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01094639||124438|
NCT01090739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC0807|Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence|An Investigation of the Treatment of Fecal Incontinence Using the TOPAS Sling System For Women (TRANSFORM)|TRANSFORM|ASTORA Women’s Health|Yes|Active, not recruiting|April 2010|December 2017|Anticipated|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|152|||Female|18 Years|N/A|No|||December 2015|December 11, 2015|March 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090739||124738|
NCT01090466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000667766|Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium|A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium||National Cancer Institute (NCI)||Completed|February 2008|||January 2010|Actual|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99|||Both|16 Years|N/A|No|||September 2012|August 23, 2013|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090466||124759|
NCT01092195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100083|A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression|A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|February 5, 2016|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01092195||124626|
NCT01092468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-063|Comparison of Harmonic Scalpel to Conventional Diathermy in Perforator Flap Elevation for Head and Neck Reconstruction|Prospective, Randomised, Single-blinded Study : Comparison of Harmonic Scalpel to Conventional Diathermy in Perforator Flap||Samsung Medical Center||Completed|January 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|N/A|No|||October 2011|October 2, 2011|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01092468||124605|
NCT01094652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480-2009|The Addition of Whole Grains to the Diets of Middle-school Children|The Addition of Whole Grains to the Diets of Middle-school Children: A Study of Digestive Health and Immune Defenses||University of Florida|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|83|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||July 2012|August 1, 2012|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01094652||124437|
NCT01091025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-1210|Comparing Two Different Approaches in the Screening of Cystic Fibrosis Related Diabetes|A Comparative Analysis of the Clinical Efficacy of Two Approaches in the Screening for Cystic Fibrosis Related Diabetes in Adult With Cystic Fibrosis: i) a Selective Approach; ii) an Unselected Annual Oral Glucose Tolerance Test|CFRD|Imperial College London|Yes|Completed|March 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Actual|100|||Both|16 Years|N/A|No|||March 2010|June 3, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091025||124716|
NCT01091870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIPCEVA|Sildenafil for Prevention of Cerebral Vasospasm|Sildenafil for Prevention of Cerebral Vasospasm Secondary to Subarachnoid Haemorrhage - Phase II Randomized Clinical Trial|SIPCEVA|Hospital de Clinicas de Porto Alegre|Yes|Withdrawn|March 2010|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|20 Years|80 Years|No|||March 2015|March 24, 2015|March 17, 2010||No|Absence of inclusion criteria|No||https://clinicaltrials.gov/show/NCT01091870||124651|
NCT01091883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM016|Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma|Phase IIIA Study Comparing the Safety and Effectiveness of MR Guided Focused Ultrasound and External Beam Radiation for Treatment of Metastatic Bone Tumors and Multiple Myeloma||InSightec|No|Recruiting|May 2010|March 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091883||124650|
NCT01092494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02-020|Postoperative Cyclic Oral Contraceptive Use for the Prevention of Endometrioma Recurrence|Efficacy of Postoperative Cyclic Oral Contraceptive Use After Gonadotropin-releasing Hormone Agonist for the Prevention of Endometrioma Recurrence||Samsung Medical Center|No|Not yet recruiting|March 2010|March 2010|Anticipated|March 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|232|||Female|15 Years|49 Years|No|Non-Probability Sample|Reproductive aged women who underwent conservative laparoscopic surgery for ovarian        endometrioma and followed up at Samsung Medical Center between January 2000 and December        2007.|March 2010|March 24, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092494||124603|
NCT01077947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00006921|Value of Functional Anesthetic and Provocative Discography in the Surgical Treatment of Discogenic Pain|Comparing the Value of Functional Anesthetic and Provocative Discography in the Surgical Treatment of Discogenic Pain||Northwestern University|No|Withdrawn|February 2010|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|224|||Both|21 Years|65 Years|No|||September 2010|September 15, 2010|February 26, 2010|Yes|Yes|Internal|No||https://clinicaltrials.gov/show/NCT01077947||125712|
NCT01090089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSMM XIII|Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma|The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma|DSM XIII|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|No|Recruiting|March 2010|January 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|376|||Both|60 Years|75 Years|No|||August 2015|August 19, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090089||124788|
NCT01090349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-09-064-WW-RC|Clinical Evaluation Of Remote Monitoring With Direct Alerts To Reduce Time From Event To Clinical Decision|CLINICAL EVALUATION OF REMOTE MONITORING WITH DIRECT ALERTS TO REDUCE TIME FROM EVENT TO CLINICAL DECISION. (REACT Study)|REACT|St. Jude Medical|No|Completed|March 2010|April 2014|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|220|||Both|18 Years|N/A|No|||April 2015|October 21, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090349||124768|
NCT01086163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-Oma-09/27D|Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia|Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD)|OMPA-CAD|HeartDrug Research LLC|Yes|Not yet recruiting|October 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Serial blood samples - at baseline, day 7, and day 14 after treatment assignment|Male|50 Years|60 Years|No|Probability Sample|Serial assessments of platelet characteristics from 10 patients in each of the 3 study        groups at 2 time points for the total of 60 platelet samples. First, patients with stable        coronary disease will be identified, telephone interviews will be conducted, and screening        visits scheduled to those who qualify. We expect to triage 50 patients who then will be        examined, and biochemistry markers tested. Patients will be allocated to one of three        treatment arms based on randomization. Enrollment will continue until all 3 cells will be        filled (n=10 each).|March 2010|March 11, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086163||125088|
NCT01086150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO|Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy|Use of Topical Lidocaine (Lidoderm 5% Patch) to Reduce Pain in Patients With Diabetic Neuropathy: Does the Density and Subtype of Sodium Channels Affect Response?||Albany Medical College|No|Recruiting|October 2009|October 2013|Anticipated|October 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2010|June 21, 2011|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086150||125089|
NCT01086748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11958|A Study in Schizophrenia Patients|A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia||Eli Lilly and Company|Yes|Completed|March 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|880|||Both|18 Years|65 Years|No|||May 2012|September 18, 2012|March 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086748||125044|
NCT01086761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP0112-CP01|Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration|A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)||Allergan|Yes|Terminated|March 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|32|||Both|50 Years|N/A|No|||April 2014|April 14, 2014|March 9, 2010|Yes|Yes|The study was terminated due to a company decision following completion of Part A.|No|April 14, 2014|https://clinicaltrials.gov/show/NCT01086761||125043|
NCT01086774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-39|Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects|||Alcon Research|No|Completed|July 2010|||November 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 31, 2012|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086774||125042|
NCT01087060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bosniak|Detection of Renal Malignancy of Complicated Renal Cysts|Does Hounsfield Unit (HU) Predict the Detection of Cystic Renal Malignancy of Complicated Renal Cysts?||Seoul National University Hospital|Yes|Completed|January 1997|May 2009|Actual|March 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|269|||Both|20 Years|80 Years||Probability Sample|All 2,992 patients who were diagnosed as renal cysts in this institute|March 2010|March 12, 2010|March 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01087060||125020|
NCT01087307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100063|Sample Collection Registry for Quality Control of Biological and Environmental Specimens and Assay Development and Testing|Sample Collection Registry for Quality Control of Biological and Environmental Specimens and Assay Development and Testing||National Institutes of Health Clinical Center (CC)||Recruiting|February 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|February 12, 2016|March 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01087307||125001|
NCT01091246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP208|A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children|A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children|LAIV|MedImmune LLC|Yes|Completed|March 2010|December 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2312|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||September 2011|September 22, 2011|March 19, 2010|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT01091246||124699|
NCT01091493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEPOC-ATB|Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy|Utility of Antibiotic Treatment in Acute Non-purulent Exacerbations of COPD: a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy|AEPOC-ATB|Fundacion Clinic per a la Recerca Biomédica|Yes|Recruiting|July 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|224|||Both|40 Years|90 Years|No|||February 2016|February 1, 2016|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01091493||124680|
NCT01090752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|Renal and Hormonal Effects of Pioglitazone|Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects||University Hospital, Geneva|No|Completed|October 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|70 Years|No|||January 2009|March 24, 2010|March 19, 2010|Yes|Yes||No|March 24, 2010|https://clinicaltrials.gov/show/NCT01090752||124737|The sample size may seem small but the cross over design of the study increased the statistical power. Each of 16 individuals was examined 4 times after the 4 different phases (pioglitazone-low salt, and high salt, placebo low salt and high salt).
NCT01091012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOM-SIL-2009|Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension|Study About Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension, at Last Moderate and Secondary at Valve Disease(Corrected With a Normally Functioning Prosthesis).||Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|September 2011|February 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01091012||124717|
NCT01091558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090943|Study of Effects of L-Arginine in Colitis and Colon Cancer|Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer||Vanderbilt University|Yes|Active, not recruiting|September 2009|December 2016|Anticipated|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|blood, urine and tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any patient scheduled to have a colonoscopy as part of medical care for either ulcerative        colitis or as a routine screening colonoscopy.|December 2015|December 17, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091558||124675|
NCT01093001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008690|Tricuspid Regurgitation Study|The Effect of Cardiac Pacing Leads on Tricuspid Regurgitation||Mayo Clinic|No|Active, not recruiting|May 2010|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|200|||Both|18 Years|90 Years|No|||January 2016|January 14, 2016|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093001||124564|
NCT01088061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pcos0509|Adipose Expression of Leptin, Adiponectin and IL-6 and Plasma Levels of Adipocytokines in Women With and Without Polycystic Ovary Syndrome (PCOS)|Adipocytokines in Lean and Obese Women With and Without PCOS||Copenhagen University Hospital, Hvidovre|Yes|Completed|January 2004|April 2006|Actual|April 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|65|Samples With DNA|Fat biopsies, plasma|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Lean and obese women with and without PCOS, age 18-40 years.|January 2008|October 27, 2011|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088061||124944|
NCT01088308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPS1010|Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion|Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion||Medtronic BRC|No|Recruiting|March 2010|December 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2011|April 19, 2011|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01088308||124925|
NCT01088321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-045A|Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)|Safety of Disease Modifying Antirheumatic Drug (DMARD) and Biologic Treatment of Rheumatoid Arthritis||Bristol-Myers Squibb|No|Active, not recruiting|March 2005|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|40000|||Both|N/A|N/A|No|Non-Probability Sample|United Healthcare|November 2015|November 19, 2015|March 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01088321||124924|
NCT01088568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091231|Randomized, Prospective Comparison of the Outcome of Toric Implantable Contact Lens (TICL) and Q-LASIK for the Correction of Myopia With Astigmatism|Randomized, Prospective Comparison of the Outcome of TICL and Q Value Customized LASIK for the Correction of Myopia With Astigmatism||Wenzhou Medical University|Yes|Active, not recruiting|November 2007|March 2010|Anticipated|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2009|March 16, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088568||124905|
NCT01093339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLEEP DEPRIVATION|To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure|To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure, and if This Effect is Mediated in Gastroesophageal Reflux Disease (GERD)Patients by Altering Appetite Regulation|IRUSESOM0428|Southern Arizona VA Health Care System|No|Completed|August 2006|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Serum samples collected and stored -80 freezer in GI lab.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|25 subjects w/ GERD 25 subjects w/o GERD|August 2010|August 18, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093339||124538|
NCT01093352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1207/108|Effect of Alveolar-decortication on Velocity of Tooth Movement|The Efficacy of Surgical Exposure With Alveolar-decortication vs. Conventional Surgical Exposure to Reduce Treatment Time for Orthodontic Alignment of Palatally Impacted Canines||University of Birmingham|No|Active, not recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|10 Years|N/A|No|||June 2015|June 16, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01093352||124537|
NCT01077960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25373 (NCT01077960)|Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome|Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS)||EMD Serono|No|Completed|February 2005|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||August 2013|August 4, 2013|February 26, 2010|Yes|Yes||No|May 25, 2010|https://clinicaltrials.gov/show/NCT01077960||125711|
NCT01094366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 6071|Paracervical Block for Pain Control in First Trimester Abortion|An Evaluation of the Paracervical Block for Pain Control in First Trimester Surgical Abortion||Oregon Health and Science University|No|Active, not recruiting|April 2010|June 2011|Anticipated|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|120|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094366||124459|
NCT01094574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10012009-4121|Evaluation of Propranolol's Effect on Pain and Inflammation.|Investigation of Analgesic and Anti-inflammatory Effects of Beta-adrenergic Antagonist Propranolol||Stanford University||Completed|January 2010|August 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 18, 2013|March 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01094574||124443|
NCT01086800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC2HL101417-01|Heart Biomarker Evaluation in Apnea Treatment|Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity|HeartBEAT|Brigham and Women's Hospital|Yes|Completed|February 2010|August 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|318|||Both|45 Years|75 Years|No|||February 2013|February 21, 2013|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086800||125040|
NCT01086813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0510C00005|Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043|Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly (=65 Years) Healthy Volunteers|AZD3043|AstraZeneca|No|Withdrawn|March 2010|April 2010|Anticipated|April 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|March 9, 2010||No|The compound is being re-evaluated|No||https://clinicaltrials.gov/show/NCT01086813||125039|
NCT01090921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05153|Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma|Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma||Boston VA Research Institute, Inc.|Yes|Completed|May 2007|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01090921||124724|
NCT01090934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00574-53|Localizing the Epileptogenic Zone With High Resolution Electroencephalography|Etude de la Performance Diagnostique de l'EEG-Haute Résolution Sur la Localisation de la Zone épileptogène Pour le Traitement Chirurgical Des épilepsies Partielles Pharmaco-résistantes|EEG-HR|Central Hospital, Nancy, France|Yes|Completed|October 2009|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|115|||Both|15 Years|N/A|No|||January 2016|January 26, 2016|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01090934||124723|
NCT01091259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 09-0029|Irinotecan and Bevacizumab for Recurrent Ovarian Cancer|Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.||New York University School of Medicine|Yes|Completed|March 2010|May 2015|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|March 19, 2010|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01091259||124698|
NCT01091506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-003|A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients|A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients||Pamlab, Inc.|No|Completed|March 2010|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|55|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||January 2015|January 30, 2015|March 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01091506||124679|
NCT01086618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000667364|Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery|A Randomized Trial of Initial Surgery in Advanced Asymptomatic Colorectal Cancer Patients Receiving Chemotherapy for Metastatic Disease||National Cancer Institute (NCI)||Completed|January 2010|July 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||March 2010|August 23, 2013|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086618||125053|
NCT01086631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100040|Rituximab for Autoimmune Retinopathy|Rituximab for Autoimmune Retinopathy||National Institutes of Health Clinical Center (CC)||Completed|January 2010|July 2014|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|March 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086631||125052|
NCT01086657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100069|An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...|VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine||National Institutes of Health Clinical Center (CC)||Completed|February 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|64|||Both|18 Years|60 Years|No|||December 2011|December 14, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086657||125051|
NCT01086670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100073|Physical, Functional and Neural Effects of Two Lower Extremity Exercise Protocols in Children With Cerebral Palsy|Physical, Functional and Neurological Effects of Two Lower Extremity Exercise Programs in Children With Cerebral Palsy||National Institutes of Health Clinical Center (CC)||Recruiting|March 2010|September 2020|Anticipated|June 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||May 2015|July 2, 2015|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086670||125050|
NCT01091857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0604.12|Mediators and Moderators of Exercise Behavior Change|Mediators and Moderators of Exercise Behavior Change|COSTRIDE|University of New Mexico|No|Completed|September 2004|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|2||Actual|238|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|March 22, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091857||124652|
NCT01087190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0009|Isoniazid (INH) Treatment Based on ELISPOT Assay|A Prospective, Randomized, Open Labeled Trial of Isoniazid Treatment Based on ELISPOT Assay to Prevent Tuberculosis in a Kidney Transplant Recipient||Asan Medical Center|Yes|Completed|June 2010|November 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|831|||Both|16 Years|N/A|No|||December 2013|December 11, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01087190||125010|
NCT01087749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUCSF2010|Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers|Pharmacokinetic Study of Propranolol, Losartan, and Eprosartan in Healthy Volunteers and Patients With Chronic Kidney Disease|CKD|University of California, San Francisco|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087749||124968|
NCT01087762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS001|Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis|Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis||UCB Pharma|No|Completed|March 2010|August 2015|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|325|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|March 15, 2010|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT01087762||124967|
NCT01087775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seal_BFP|Enhancing Cognitive Function and Reintegration in Iraq and Afghanistan Veterans With Post Traumatic Stress Disorder (PTSD) Using Computer-Based Cognitive Training|Enhancing Cognitive Function and Reintegration in Iraq and Afghanistan Veterans With PTSD Using Computer-Based Cognitive Training||San Francisco Veterans Administration Medical Center|Yes|Active, not recruiting|April 2010|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087775||124966|
NCT01087489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00825|Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye|Clinical Comparison of Two Anesthetic Preparations for Intravitreal Injection||Miami VA Healthcare System|No|Completed|April 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||November 2012|November 19, 2012|March 15, 2010|Yes|Yes||No|April 28, 2012|https://clinicaltrials.gov/show/NCT01087489||124987|discomfort One hour after injection was assessed the next day via telephone and might be affected by recall bias.
NCT01088581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2005-0203|Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma|Adjuvant Hepatic Arterial Infusional Chemotherapy With 5-fluorouracil and Cisplatin After Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Study||Yonsei University|Yes|Completed|January 2006|December 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|70 Years|No|||January 2012|January 31, 2012|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088581||124904|
NCT01077973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-09-11|Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache|Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Episodic Tension-Type Headache||Pfizer|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|200|||Both|18 Years|65 Years|No|||July 2012|July 13, 2012|February 26, 2010|Yes|Yes||No|July 12, 2012|https://clinicaltrials.gov/show/NCT01077973||125710|
NCT01078246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-268|Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network (MK-0518-268)|Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network||Merck Sharp & Dohme Corp.|Yes|Completed|August 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|7956|||Both|18 Years|N/A|No|Non-Probability Sample|Adults 18 years old and older|February 2016|February 3, 2016|February 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01078246||125689|
NCT01094392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hemostasis-NOPHO|Hemostasis During Asparaginase Treatment in Acute Lymphoblastic Leukemia(ALL)|Influence on Hemostasis During Prolonged Asparaginase Treatment in Childhood and Adolescent ALL||Aarhus University Hospital|No|Recruiting|March 2010|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|250|||Both|1 Year|18 Years|No|Non-Probability Sample|Children and young adults (age 1-17.9 years) newly diagnosed with ALL in the Nordic        Countries and treated according to the Nordic ALL-protocol NOPHO ALL-2008.        Written informed consent has been obtained|March 2016|March 3, 2016|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01094392||124457|
NCT01094613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol C2/13/DR-6MP-02|Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease|MultiCTR Randomized Double-Blind Double-Dummy Study to Evaluate Clinical Efficacy/Safety of DR 6MP for Targeted Ileal Delivery vs Purinethol in Patients w/Moderately Active Crohn's Disease||Teva GTC|No|Terminated|November 2010|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||March 2013|March 6, 2013|March 25, 2010|Yes|Yes|Sponsor withdrew support of study due to reorganization and project prioritization|No||https://clinicaltrials.gov/show/NCT01094613||124440|
NCT01094587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10142009-4180|Sutureless vs Sutured Gastroschisis Closure|Sutureless vs Sutured Gastroschisis Closure||Stanford University||Recruiting|November 2009|March 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|N/A|N/A|No|||June 2013|June 21, 2013|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094587||124442|
NCT01086371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAS Gait MS|Rhythmic Auditory Stimulation and Walking Performance in Multiple Sclerosis (MS) Patients|Rhythmic Auditory Stimulation and Walking Performance in MS Patients||The Cleveland Clinic|No|Withdrawn|January 2012|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|No|||January 2012|January 18, 2012|January 29, 2010||No|Study being redesigned in anticipation of new study protocol.|No||https://clinicaltrials.gov/show/NCT01086371||125072|
NCT01086787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTR-ECG-5|Paracrine Mechanisms of Bone Marrow Stem Cell Signalling in Chronic Heart Failure|Paracrine Mechanisms of Bone Marrow Stem Cell Signalling in Chronic Heart Failure|BM-CHF|University Medical Center Groningen|No|Not yet recruiting|August 2010|December 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|125|Samples With DNA|Whole blood, serum, white cells, urine, bone marrow|Both|18 Years|N/A|No|Non-Probability Sample|Man and woman, undergoing cardiothoracic surgery, older than 18 years of age, with and        without preserved left ventricular ejection fraction (LVEF <40% and >40%). Controls are        man and women, older than 18 years of age, scheduled for orthopaedic surgery without a        history of cardiac disease.|March 2010|June 10, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086787||125041|
NCT01090674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR01/01/2007|Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases|Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|June 2007|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with amyotrophic lateral sclerosis.|February 2014|February 21, 2014|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01090674||124743|
NCT01090947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP002IN|Data Aquisition for Optimization of Coronary Artery Disease Algorithm|Data Aquisition for Optimization of Coronary Artery Disease Algorithm||Coloplast A/S|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|729|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to CAG.|March 2015|March 16, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090947||124722|
NCT01090960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAM4743g|A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors|An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors||Genentech, Inc.||Completed|March 2010|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01090960||124721|
NCT01091519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221073|Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy|Facts Study (Fakten-studie): Non-interventional Study to Investigate Whether Information Provided to Patients Influences Satisfaction With Toviaz Therapy As Perceived by the Patient||Pfizer|No|Terminated|December 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|781|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with overactive bladder symptoms presenting during routine clinical practice        visits|January 2013|January 29, 2013|March 17, 2010|Yes|Yes|See termination reason in detailed description.|No|January 29, 2013|https://clinicaltrials.gov/show/NCT01091519||124678|This was an open label observational study in Germany, which was stopped early due to low participant recruitment rates. The results should therefore be interpreted with caution due to the lower than planned sample size.
NCT01091818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dexmedetmidazchildintsed|Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children|A Prospective, Double-blind Study of Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children||Oslo University Hospital||Recruiting|March 2010|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|2 Years|17 Years|No|||July 2011|July 20, 2011|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091818||124655|
NCT01091831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-EMN-441|Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects|A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects||Fondazione Neoplasie Sangue Onlus|Yes|Recruiting|July 2009|August 2013|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|65 Years|No|||March 2010|March 23, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091831||124654|
NCT01086995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH2007-588|Weaning And Variability Evaluation (WAVE)|Weaning And Variability Evaluation|WAVE|Ottawa Hospital Research Institute|No|Completed|November 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Mechanically ventilated patients weaning or near extubation (i.e. within 1-5 days) in the        intensive care unit.|April 2014|April 2, 2014|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086995||125025|
NCT01086904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-32|Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients|Etude de Phase II évaluant l'immunogénicité et la tolérance d'un Vaccin inactivé Non adjuvanté Contre la Grippe A (H1N1) après Transplantation rénale|Transfluvac|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|November 2009|May 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|120|||Both|18 Years|60 Years|No|||July 2010|December 29, 2011|November 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01086904||125032|
NCT01086917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP2|Experimental Human Malaria Infection by PfSPZ|Experimental Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites (PfSPZ Challenge)||Sanaria Inc.|Yes|Completed|August 2010|July 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|18|||Both|19 Years|34 Years|Accepts Healthy Volunteers|||April 2015|April 17, 2015|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086917||125031|
NCT01087177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-001734|Effectiveness of Pedialink CEASE Module|Evaluating Online Clinical Office-Systems Training to Address SHS Exposure of Children||Massachusetts General Hospital|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|647|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087177||125011|
NCT01086969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA51|A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India|Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects 2-55 Years of Age in India||Sanofi|No|Completed|June 2010|June 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|300|||Both|2 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|March 11, 2010|Yes|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01086969||125027|
NCT01087203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091031|A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy||Pfizer|Yes|Terminated|March 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|March 11, 2010|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01087203||125009|
NCT01088048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-07|Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia|A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia||Gilead Sciences|No|Completed|April 2010|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|241|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|March 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01088048||124945|
NCT01087502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.64|Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment|A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|March 2010|||May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|241|||Both|18 Years|N/A|No|||May 2014|June 17, 2014|March 15, 2010||||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01087502||124986|
NCT01087476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetropolitanAU|Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate|Phase 2 Double-blind, Randomized, Placebo Controlled Clinical Trial for the Prevention of Oral Mucositis Using Sub-microbial Doses of Doxycycline Hyclate in Patients With Acute Leukemia Receiving Induction Chemotherapy||Metropolitan Autonomous University|Yes|Not yet recruiting|May 2010|February 2013|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|164|||Both|18 Years|N/A|No|||March 2010|March 15, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087476||124988|
NCT01088087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GangnamSH|Effect of Colostrum on Gut Permeability and Endotoxin Level in Chronic Alcoholic Disease|Effect of Colostrum Administration on Improving Gut Permeability and Serum Endotoxin Level in Chronic Alcohol Drinkers With Hepatic Dysfunction||Gangnam Severance Hospital|Yes|Recruiting|March 2010|December 2010|Anticipated|September 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|34|||Male|20 Years|N/A|Accepts Healthy Volunteers|||November 2009|March 16, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088087||124942|
NCT01088360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-045B|Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)|An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies||Bristol-Myers Squibb|No|Active, not recruiting|March 2005|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|20000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients being treated for rheumatoid arthritis in the US|November 2015|November 19, 2015|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01088360||124921|
NCT01087788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsA001|Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis|Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)||UCB Pharma|No|Completed|March 2010|August 2015|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|409|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|March 15, 2010|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01087788||124965|
NCT01078545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-612|Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)|Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms. International, Multicenter Post-marketing Observational Study.|LEMON|Abbott|No|Completed|September 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|729|||Male|50 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2012|January 12, 2012|February 28, 2010||No||No|November 29, 2011|https://clinicaltrials.gov/show/NCT01078545||125667|
NCT01078792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001-10|Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence|||Hillel Yaffe Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Probability Sample|Patients admitted to hospital due to COPD exacerbation|March 2010|March 1, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078792||125648|
NCT01090726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1A-INF-STORZ-AIR|Intubation With Storz Videolaryngoscope® Versus Airtraq® - in an Infant Population|Intubation With Storz Videolaryngoscope® Versus Airtraq® - in an Infant Population||Rigshospitalet, Denmark|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|10|||Both|1 Month|2 Years|No|||March 2010|December 10, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01090726||124739|
NCT01094600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC7911|Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency|Comparison of Secretin Enhanced MRCP to Endoscopic Pancreatic Function Testing in Diagnosing Exocrine Insufficiency in Patients Who Have Undergone Pancreas Cancer Resection||Columbia University|Yes|Withdrawn|June 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|75 Years|No|||June 2012|June 29, 2012|March 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01094600||124441|
NCT01086384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106837|Asthma Exacerbation Study|A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma||GlaxoSmithKline|Yes|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2020|||Both|12 Years|N/A|No|||November 2014|June 17, 2015|March 11, 2010|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01086384||125071|
NCT01086397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6115A1-4007|Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia|Distribution Of PCV13 Serotype Streptococcus Pneumoniae In Adults 50 Years And Older Presenting To Select US Hospitals With Radiographically-Confirmed Community-Acquired Pneumonia (CAP)||Pfizer|No|Completed|February 2010|October 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|782|Samples Without DNA|urine serum and potentially blood isolates|Both|50 Years|N/A|No|Non-Probability Sample|Adults 50 years and older presenting to Selected US Hospitals With Chest X-ray Confirmed        Community-Acquired Pneumonia (CAP)|March 2012|March 14, 2012|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086397||125070|
NCT01090687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC-UMASS|Role of 3D Tomography in Breast Cancer|Role of 3D Tomography in Breast Cancer||University of Rochester|Yes|Completed|March 2010|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Female|40 Years|N/A|No|Non-Probability Sample|Women, age 40 or older, who are scheduled for biopsy after classification as BI-RADS 4/5        and have had a screening or diagnostic full-field digital mammography (FFDM) exam, and who        meet the inclusion criteria, are eligible to participate.|July 2013|July 31, 2013|February 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090687||124742|
NCT01090973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15971|Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)|Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|March 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2012|November 21, 2013|March 18, 2010|Yes|Yes|Pharmaceutical company request.|No|January 27, 2012|https://clinicaltrials.gov/show/NCT01090973||124720|The study was abandoned after only one patient due to low accrual and the sponsor losing interest in the single-agent.The one patient had disease progression requiring more aggressive treatment and did not complete the study.
NCT01091272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1661001|A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers|A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04995274 After Administration Of Single Oral Doses To Healthy Adult Subjects||Pfizer|No|Completed|April 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 17, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01091272||124697|
NCT01091844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1286|Efficacy of Retrograde Fill Vs Spontaneous Fill to Assess Voiding Function|Efficacy of Retrograde Fill Vs Spontaneous FIll to Assess Voiding Function||University of North Carolina, Chapel Hill|No|Completed|December 2009|August 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Female|18 Years|N/A|No|||October 2010|October 12, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091844||124653|
NCT01092988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF032|A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids|A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids||InSightec|No|Completed|March 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||February 2012|February 19, 2012|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01092988||124565|
NCT01086605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1031|Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer|Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|May 2010|||January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|March 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086605||125054|
NCT01086930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIPA Hands-On|SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury|SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury|SCIPA Hands-On|University of Melbourne|Yes|Recruiting|September 2009|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|16 Years|N/A|No|||March 2010|August 4, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086930||125030|
NCT01086943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2420-PI-CE-07/07|Clinical Safety Study on an Eyelid Warming Device to Evaluate the Eyelid and Cornea Temperature in Healthy Volunteers|Clinical Safety Study on an Eyelid Warming Device, Moist Heat Technology BLEPHASTEAM®, to Evaluate the Eyelid and Cornea Temperature in Healthy Volunteers||Laboratoires Thea|No|Completed||||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2012|January 27, 2012|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086943||125029|
NCT01086956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0319|Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy|Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy||Yonsei University|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Diagnostic|||Actual|60|||Both|65 Years|N/A|No|||November 2010|November 10, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086956||125028|
NCT01087541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEGUDIAB|SEGUDIAB Study: Evaluation of Safety in the Diabetic Patients|SEGUDIAB Study: Safety in Diabetic Patients. Evaluation of an Educational Program for the Professionals to Improve the Safety in Diabetic Patients|SEGUDIAB|Jordi Gol i Gurina Foundation|No|Completed|January 2008|June 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|6830|||Both|45 Years|75 Years|No|||March 2011|March 27, 2011|March 15, 2010||No||No|May 31, 2010|https://clinicaltrials.gov/show/NCT01087541||124983|
NCT01087554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0729|Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer|A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer||M.D. Anderson Cancer Center|No|Recruiting|March 2010|||March 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|249|||Both|N/A|N/A|No|||February 2016|February 11, 2016|March 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01087554||124982|
NCT01087515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/11 PILOCELL|Pilot Study for Cell Based Therapies in Patients With Asthma|Development and Validation of Magnetic Cell Separations Techniques Using a Good Manufacturing Practice (GMP) Grade Manufacturing Process for Clinical Applications and Generation of Pre-clinical Data||Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Completed|March 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|60 Years|No|||November 2011|November 8, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01087515||124985|
NCT01087528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-202|Evaluation of PillCam™ Colon 2 in Visualization of the Colon|Evaluation of PillCam™ Colon 2 in Visualization of the Colon||Given Imaging Ltd.|No|Completed|July 2009|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Both|18 Years|70 Years|No|||March 2012|June 10, 2012|March 15, 2010||No||No|April 3, 2012|https://clinicaltrials.gov/show/NCT01087528||124984|
NCT01087814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910M73917|Sustiva Levels With Use of a Gel Capsule|Effect of Encapsulation Upon Efavirenz Pharmacokinetics||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2010|September 2011|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 5, 2014|March 15, 2010||No||No|November 7, 2011|https://clinicaltrials.gov/show/NCT01087814||124963|
NCT01087801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-05|A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers|A Placebo Controlled, Double-Blind, Parallel, Multicenter Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers|CRC2006-05|ChiRhoClin, Inc.|No|Completed|October 2007|December 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|64|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|March 15, 2010|Yes|Yes||No|June 7, 2011|https://clinicaltrials.gov/show/NCT01087801||124964|
NCT01088646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-300|Evaluation of PillCam® Express Capsule Endoscopy Delivery System|Evaluation of PillCam® Express Capsule Endoscopy Delivery System|RD-300|Given Imaging Ltd.|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|25|||Both|2 Years|85 Years|No|||March 2012|May 6, 2012|March 15, 2010||No||No|March 27, 2012|https://clinicaltrials.gov/show/NCT01088646||124899|
NCT01088880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885DTR01|Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever|An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever||Novartis||Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|75 Years|No|||April 2012|April 27, 2012|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088880||124881|
NCT01088373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-REV-09|Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q|A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q|GFM-AZA-REV-09|Groupe Francophone des Myelodysplasies|Yes|Active, not recruiting|March 2010|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||October 2015|October 27, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088373||124920|
NCT01088620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISP_AG47|Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer|CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With Particular Regard to the KRAS Status||WiSP Wissenschaftlicher Service Pharma GmbH|Yes|Suspended|April 2010|January 2014|Anticipated|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|March 16, 2010||No|the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has    not yet been verified|No||https://clinicaltrials.gov/show/NCT01088620||124901|
NCT01088633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/05 AEROC|Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease||Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 8, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01088633||124900|
NCT01078285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581184|Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor|Impact Of An Integrated Intervention Program On Adherence To Atorvastatin||Pfizer|No|Completed|March 2010|November 2011|Actual|November 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|500|||Both|21 Years|N/A|No|Non-Probability Sample|-  Male and female aged >21 years          -  Have received a new or re-fil prescription for atorvastatin at first study visit to             Prairie Heart Institute          -  Signed informed consent|July 2015|July 30, 2015|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01078285||125687|
NCT01078558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM04-28|A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis Who Are Treated With HUMIRA (Adalimumab)|ProAct|AbbVie|No|Active, not recruiting|May 2004|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5914|||Both|18 Years|99 Years|No|Probability Sample|Rheumatologists|January 2016|January 25, 2016|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01078558||125666|
NCT01090427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017053|A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the of Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasis (CADMUS)||Janssen Research & Development, LLC|Yes|Completed|May 2010|January 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|110|||Both|12 Years|18 Years|No|||January 2015|January 16, 2015|March 18, 2010|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01090427||124762|
NCT01094873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV002TV|Study of a Novel Therapeutic Vaccine for Hepatitis C Virus|A Phase I Study to Assess the Safety and Immunogenicity of Ad6NSmut and AdCh3NSmut in Patients With Hepatitis C Virus Infection||ReiThera Srl|Yes|Completed|November 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|35|||Both|18 Years|65 Years|No|||August 2013|April 22, 2015|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094873||124420|
NCT01094886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016531|Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement|A Open-Label Study of the Transition to Rivaroxaban From Low-Molecular Weight Heparin for Venous Thromboembolism Prophylaxis After Total Joint Replacement: The Safe Simple Transitions Study||Ortho-McNeil Janssen Scientific Affairs, LLC|Yes|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|56|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|March 25, 2010|Yes|Yes||No|December 1, 2011|https://clinicaltrials.gov/show/NCT01094886||124419|There were 56 subjects enrolled in the study, but only 53 of them were treated with study medication.
NCT01090986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR02/02/2007|Home Mechanical Ventilation Effectiveness and Air Leaks|Prediction of Home Mechanical Ventilation Effectiveness by Means of Non-controlled Air Leaks Estimation.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|June 2006|||July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|-  Patients with a restrictive pulmonary disease (slow evolution neuromuscular or thorax             cage diseases, obesity or nocturnal hypoventilation) and hypercapnic chronic             respiratory failure with standard criteria for NIV.          -  Also COPD patients who need NIV because of another reason (obesity, nocturnal             hyperventilation or nocturnal hypercapnic response to oxygen).|February 2014|February 21, 2014|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01090986||124719|
NCT01094665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0689-C|MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer|Phase 1 Study of MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer|FLTT002|University Health Network, Toronto|No|Recruiting|November 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|45 Years|80 Years|No|||March 2016|March 7, 2016|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094665||124436|
NCT01090778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/0121|Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)|Pharmacokinetic Profiles of GH Using Two Different Administration Regimes; a Bolus and an Infusion Both With and Without Exercise, in Adults With Growth Hormone Deficiency||Aarhus University Hospital|Yes|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|8|||Both|18 Years|75 Years|No|||January 2014|January 8, 2014|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01090778||124735|
NCT01092702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-00672|Varenicline For Smokers In Recovery From Alcohol Dependence|A Pilot Study of Varenicline for Tobacco Dependence Treatment in Recovering Alcoholic Smokers: the Clinical Trial||Mayo Clinic|No|Completed|April 2008|September 2009|Actual|September 2008|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 15, 2011|March 19, 2010|Yes|Yes||No|October 28, 2010|https://clinicaltrials.gov/show/NCT01092702||124587|
NCT01093586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3Z07|Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|March 2009|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|12 Years|64 Years|No|||December 2015|December 18, 2015|March 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01093586||124519|
NCT01094119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-146|A Randomized Comparison of Intraoperative Warming With the LMA PerfecTemp and Forced-air|A Randomized Comparison of Intraoperative Warming With the LMA PerfecTemp and Forced-air||Outcomes Research Consortium|No|Completed|March 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|70|||Both|18 Years|75 Years|No|||January 2011|January 5, 2011|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094119||124478|
NCT01087567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16037|INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes|A Pilot Study of Intensive Insulin Regimen as a Primary Treatment of New Onset of Type 2 DM|INSPIRE|Ohio University|Yes|Completed|July 2010|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|March 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01087567||124981|
NCT01088139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE-08-0118/ER3|Nutritional Intervention for Geriatric Hip Fracture Patients|A Randomized Controlled Study of Nutritional Intervention for Geriatric Hip Fracture Patients and Its Effect on Rehabilitation Outcomes||Kowloon Hospital, Hong Kong|No|Completed|November 2008|April 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|126|||Both|60 Years|N/A|No|||April 2011|May 3, 2011|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088139||124938|
NCT01086046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cstc2009ab5033|Study of Blood Clotting After Transcatheter Atrial Septal Defect Closure|A Multicentre, Randomized Controlled Study of Blood Clotting After Transcatheter Atrial Septal Defect Closure||Third Military Medical University|Yes|Recruiting|January 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|3 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|March 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01086046||125097|
NCT01086306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-101|Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment|Comparison of Risk of Hospitalization for Infections Between Patients With Type 2 Diabetes Exposed to Saxagliptin and Those Exposed to Other Oral Anti-Diabetic Treatments||Bristol-Myers Squibb|No|Completed|January 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|113505|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be carried out using databases containing administrative claims data        [HealthCore Integrated Research Database (HIRD) and Medicare in the U.S.] and electronic        medical records [General Practice Research Database (GPRD) and The Health Improvement        Network (THIN) in the UK]. The US population includes patients from health plans in the        northeast, southeastern, mid-Atlantic, central, mid-western, and western regions (HIRD) as        well as US citizens 65 years of age and older (Medicare). The UK population includes        patients seeking medical care from general practitioners (GPRD and THIN)|January 2016|January 19, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086306||125077|
NCT01088126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN09239|Linear Ablation Versus Focal Ablation of Complex Fractionated Atrial Electrograms in Persistent Atrial Fibrillation|Comparison of Linear Ablation Versus Focal Ablation of Complex Fractionated Atrial Electrograms After Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation: A Prospective & Randomized Controlled Study||Korea University Anam Hospital||Recruiting|January 2010|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||January 2010|March 16, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01088126||124939|
NCT01088100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVH-01|Study of the Correlation Between Specific Genes and Cognitive Dysfunction After Surgery|The Correlation Between Certain Clock-gene Genotypes and POCD (Post-operative Cognitive Dysfunction)||Herlev Hospital|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|279|Samples With DNA|Whole blood on filter paper|Both|40 Years|N/A|No|Non-Probability Sample|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al.        Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery.        Anesthesiology 2004;101:855-61)100 patients with POCD whose blood samples are stored will        be included together with 100 controls (without POCD), who will be matched by type of        surgery, age and sex.|January 2011|January 7, 2011|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01088100||124941|
NCT01088399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6448|A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults|The Global Hypopituitary Control and Complications Study|HypoCCS|Eli Lilly and Company|No|Completed|September 2002|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10673|Samples With DNA|DNA Addendum - implemented in Germany only. Germany: DNA sample is kept, if participant      consented to German DNA Addendum|Both|18 Years|N/A|No|Non-Probability Sample|Clinics, private practices|March 2014|March 25, 2014|February 25, 2010|No|Yes||No|January 13, 2014|https://clinicaltrials.gov/show/NCT01088399||124918|
NCT01088113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20080828002|The Relationship Between Cranial Near-InfraRed Oxygenation(NIRO) and Heart Rate Variability During Mental Exercise|The Relationship Between Cranial Near-InfraRed Oxygenation(NIRO) and Heart Rate Variability During Mental Exercise||The Hong Kong Polytechnic University||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|August 2008|March 16, 2010|March 16, 2010||||No||https://clinicaltrials.gov/show/NCT01088113||124940|
NCT01088386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12991|Zyprexa® Relprevv™ Patient Care Program|Zyprexa® Relprevv™ Patient Care Program||Eli Lilly and Company|No|Enrolling by invitation|March 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical practices in the United States|January 2016|January 4, 2016|March 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01088386||124919|
NCT01088906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECP09-01Phalcis|Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC|Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial|Phalcis|Spanish Lung Cancer Group|Yes|Terminated|January 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|March 15, 2010||No|No safety reasons. Low recruitment.|No||https://clinicaltrials.gov/show/NCT01088906||124879|
NCT01088919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0060|A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects|A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride After Separate and Concomitant Administration to Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 15, 2010|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01088919||124878|
NCT01088932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN007|Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Multiple-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers|AVN007|Azevan Pharmaceuticals|No|Completed|March 2010|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 17, 2010|March 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01088932||124877|
NCT01088893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OOTR-N006|Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy|A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy||Organisation for Oncology and Translational Research||Recruiting|November 2009|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||May 2012|May 22, 2012|August 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01088893||124880|
NCT01089218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|postFB fever|The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines|The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines||Seoul National University Hospital|Yes|Completed|April 2008|February 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|241|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|March 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01089218||124855|
NCT01079455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-014274-17|Comparison of Hyaluronic Acid and Corticosteroid Intra-articular Injections for the Treatment of Osteoarthritis of the Hip|Comparison of Hyaluronic Acid and Corticosteroid Intra-articular Injections for the Treatment of Osteoarthritis of the Hip Controlled With Intra-articular Injections With Bupivacaine||University Hospital Pellenberg|No|Not yet recruiting|May 2010|December 2013|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|489|||Both|30 Years|70 Years|No|||February 2010|March 2, 2010|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01079455||125601|
NCT01092715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1423-02|Cervical Mobilization vs. Standard Physical Therapy for Chronic Neck Pain|A Comparison of Cervical Spine Mobilization and "Standard" Physical Therapy Intervention in the Treatment of Chronic Neck Pain, A Pilot Study||Mayo Clinic|No|Completed|June 2003|June 2004|Actual|June 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|80 Years|No|||March 2010|March 24, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092715||124586|
NCT01092728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0447|Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma|A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma||M.D. Anderson Cancer Center|Yes|Terminated|March 2011|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|March 23, 2010||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT01092728||124585|
NCT01093014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7097-R|Novel Intervention to Influence Muscle Plasticity in Veterans|Novel Intervention to Influence Muscle Plasticity in Veterans||VA Office of Research and Development|No|Completed|April 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|March 23, 2010||No||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01093014||124563|
NCT01094899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08-25|Abnormal Structure and Bone Density in Diabetes|Study of Abnormal Structure and Bone Density at the Feet of Diabetic Patients||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|March 2010|March 2013|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|80|||Male|30 Years|70 Years|No|||January 2012|January 27, 2012|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01094899||124418|
NCT01094678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-518|Zilver® PTX™ Global Registry|Evaluation of the Safety and Performance of the Zilver® PTX™ Drug-Eluting Stent for Treating De Novo or Restenotic Lesions of the Above-the-knee Femoropopliteal Artery||Cook||Completed|April 2006|April 2011|Actual|January 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|788|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094678||124435|
NCT01094691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1519|Haufen Diagnostic Biomarkers of BK Renal Disease|Polyomavirus Aggregates, Haufen, in Voided Urine Samples as Diagnostic Biomarkers of Intra Renal BK-virus Disease: a Prospective Proof-of-concept Study||University of North Carolina, Chapel Hill|No|Enrolling by invitation|November 2008|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01094691||124434|
NCT01091532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3941010|A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.|A Double Blind, Randomized 3rd Party Open, Placebo Controlled, Parallel Group Multiple Oral Escalating Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UK-396,082 In Healthy Subjects||Pfizer|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 27, 2010|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01091532||124677|
NCT01091545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2009/770|Malmö Breast Tomosynthesis Screening Trial|Malmö Breast Tomosynthesis Screening Trial|MBTST|Region Skane|No|Active, not recruiting|March 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15000|||Female|40 Years|74 Years|No|||May 2015|May 11, 2015|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01091545||124676|
NCT01093300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOST-ISR trial|Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -|||Seoul National University Hospital|Yes|Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|264|||Both|18 Years|80 Years|No|||March 2010|March 24, 2010|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093300||124541|
NCT01086566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0059|Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines|Evaluation of the Safety and Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines Representing Different Clades||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|95|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2012|December 31, 2015|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086566||125057|
NCT01086579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BELLO|Balloon Elution and Late Loss Optimization (BELLO) Study|Balloon Elution and Late Loss Optimization (BELLO) Study: A Multicentre Randomized Study of the IN.PACT Falcon™ Paclitaxel Drug-eluting Balloon to Reduce Restenosis in Small Coronary Vessels|BELLO|Fondazione Mediolanum per Attività e Ricerche Cardiovascolari Onlus|Yes|Active, not recruiting|March 2010|May 2014|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086579||125056|
NCT01086592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-UCH-87|Effects of a Program of Physical Exercise and Electrotherapy on Muscle Strength in Subjects of the Fourth Age|Effects of a Program of Physical Exercise and Electrotherapy on Muscle Strength in Subjects of the Fourth Age||Cardenal Herrera University|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|118|||Both|75 Years|N/A|Accepts Healthy Volunteers|||June 2010|July 2, 2010|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01086592||125055|
NCT01086982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTBER0409|Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A.|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Suspended|March 2010|||May 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2010|October 26, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086982||125026|
NCT01087216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-08|Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo|||Centre Hospitalier Universitaire de Nice|No|Completed|March 2010|March 2011|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|85 Years|No|||March 2010|March 23, 2012|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087216||125008|
NCT01089257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06PHR03|Cardiovascular Impairments and Obstructive Sleep Apnea Syndrome|Subclinical Cardiovascular Impairments in Patients With Obstructive Sleep Apnea Syndrome|INFRASAS|University Hospital, Grenoble|No|Recruiting|September 2007|January 2021|Anticipated|November 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|580|||Both|18 Years|78 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with obstructive sleep apnea syndrome (Apnea/Hypopnea index > 15)|March 2016|March 4, 2016|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089257||124852|
NCT01089504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28907|Prophylactic Phenobarbital After Neonatal Seizures|Prophylactic Phenobarbital After Resolution of Neonatal Seizures|PROPHENO|University of Rochester|Yes|Terminated|September 2010|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|N/A|2 Weeks|No|||January 2016|January 4, 2016|March 17, 2010|Yes|Yes|Inadequate rate of enrollment|No|January 4, 2016|https://clinicaltrials.gov/show/NCT01089504||124833|Due to low enrollment, there was limited data available for analysis and therefore insufficient power to provide meaningful results for our primary analysis.
NCT01088659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22364|A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.|A Multicenter Randomised Study Comparing the Antiviral Efficacy of Pegylated Interferon-alfa-2a Plus Placebo vs. Pegylated Interferon-alfa-2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis||Hoffmann-La Roche||Active, not recruiting|February 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088659||124898|
NCT01088672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DQR0036|Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)|Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)|TREVO|Stryker Neurovascular|No|Completed|February 2010|November 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|79 Years|No|||July 2015|July 13, 2015|March 15, 2010|No|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01088672||124897|
NCT01089803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008NTLS104|Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer|Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2009|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|279|||Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed squamous cell carcinoma of the larynx (cartilage invading-T3 and all T4)        or hypopharynx (T2 and T3) for which curative treatment is planned. The tumor must be        resectable with total laryngectomy alone as determined by the treating surgeon - this        requirement is regardless of whether the surgery of chemoradiation is planned for the        patient.|December 2015|December 3, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089803||124810|
NCT01089244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGN-CP4|FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma|Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas||Ludwig-Maximilians - University of Munich|No|Active, not recruiting|June 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|38|Samples With DNA|High molecular wight DNA and RNA speciments for MGMT promoter methylation, IDH1/IDH2 and p53      mutation, LOH 1p and 19q analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a suspected referred to a Neurosurgical Department in order to provide a        diagnosis and therapy|September 2015|September 18, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089244||124853|
NCT01079468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIUHOZ 10-01|Cognition in Postoperative Total Hip Arthroplasty and Total Hip Resurfacing Patients|Cognition in Postoperative Total Hip Arthroplasty and Total Hip Resurfacing Patients||Rothman Institute Orthopaedics|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing either Total Hip Arthroplasty or Total Hip Resurfacing Arhtroplasty at        our Institution|November 2011|November 7, 2011|March 1, 2010||||No||https://clinicaltrials.gov/show/NCT01079468||125600|
NCT01090700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017044|TMC435-TiDP16-C112 - Interaction Trial With Antidepressants|A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state||Tibotec Pharmaceuticals, Ireland||Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01090700||124741|
NCT01090492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7331010|PF-00489791 For The Treatment Of Raynaud's|A Phase 2a Randomized Double-Blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-Over Multi-Center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (PF-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomen||Pfizer|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|243|||Both|18 Years|65 Years|No|||July 2014|July 25, 2014|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01090492||124757|
NCT01091285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1728a (REK)|Induction of Labor With Single and Double Balloon Catheters, a Randomized Controlled Study|Induction of Labor With Single and Double Balloon Catheters, a Randomized Controlled Study||Haukeland University Hospital||Completed|March 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Female|N/A|N/A|No|||April 2010|August 16, 2011|March 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01091285||124696|
NCT01092455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|208-09|Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment|Citrasate® Effect On Heparin N Requirements During Hemodialysis Treatment: A Phase IV,Study to Investigate the Effects of Citrasate on Heparin N Requirements During Hemodialysis Treatment in Subjects Maintained on Thrice Weekly Hemodialysis||Fresenius Medical Care North America|No|Completed|December 2009|October 2010|Actual|June 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the hemodialysis population in the participating        facilities (study sites).|August 2011|August 31, 2011|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092455||124606|
NCT01086280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-099|Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments|Comparison of Risk of Major Cardiovascular Events Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments||Bristol-Myers Squibb|No|Completed|January 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|113505|||Both|18 Years|N/A|No|Non-Probability Sample|This study will be carried out using databases containing administrative claims data (HIRD        and Medicare in the U.S.) and electronic medical records (GPRD and THIN in the UK). The US        population includes patients from health plans in the northeast, southeastern,        mid-Atlantic, central, mid-western, and western regions (HIRD) as well as US citizens 65        years of age and older (Medicare). The UK population includes patients seeking medical        care from general practitioners (GPRD and THIN)|January 2016|January 19, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086280||125079|
NCT01086033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMOS GREC 2004 06|A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece|A 3-year Post-marketing Observational Study Following up Patients With Moderate to Severe RA Treated With Humira in Greece||AbbVie|No|Completed|May 2006|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|566|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Rheumatoid Arthritis on Humira (adalimimab) treatment|September 2013|September 24, 2013|February 26, 2010||No||No|July 17, 2013|https://clinicaltrials.gov/show/NCT01086033||125098|
NCT01087840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAL-NPEP version 1.|Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men|Safety, Tolerability, and Adherence to a Raltegravir-based Antiretroviral Regimen for HIV Non-occupational Postexposure Prophylaxis|RAL-NPEP|St Vincent's Hospital, Sydney|No|Completed|July 2010|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Male|18 Years|70 Years|No|||April 2014|April 15, 2014|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087840||124961|
NCT01088152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORSS-80731|Celiac Disease School for Women Living on a Gluten-free Diet|Structured Education of Swedish Celiac Women Living on a Gluten-free Diet for Years|CDST|Medical Research Council of Southeast Sweden|Yes|Recruiting|August 2008|March 2010|Anticipated|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Female|20 Years|N/A|No|||January 2001|March 16, 2010|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088152||124937|
NCT01087229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2008/AD-01|Effectiveness of an Oxygen-nitrous Oxide Mixture During Physical Therapy for Frozen Shoulder|Comparative Study of the Effectiveness of an Equimolar Oxygen-nitrous Oxide Mixture During Physical Therapy for Adhesive Shoulder Capsulitis|MEOPA|Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2010|September 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01087229||125007|
NCT01087827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC29150|Body Structures Determining Differences in Forearm and Upper Arm Blood Pressures|Anatomical Determinants of Forearm and Upper Arm Oscillometric Blood Pressure Differences||Christiana Care Health Services|No|Completed|March 2010|August 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing non-emergent cardiac catheterization|November 2012|November 6, 2012|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01087827||124962|
NCT01088698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-110 ex 09/10|Golimumab Plus UVB-311nm in Psoriasis|Prospective Study of the Combination of Golimumab and UVB-311nm Phototherapy in Patients With Psoriatic Arthritis and Psoriatic Skin Lesions||Medical University of Graz|No|Terminated|March 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|March 15, 2010||No|Difficulties in recruiting patients;|No||https://clinicaltrials.gov/show/NCT01088698||124895|
NCT01088971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CellBiotech|Effect of Duolac 7S Administration on Improving Symptom in Irritable Bowel Syndrome|||Cell Biotech Co., Ltd.||Completed|October 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||December 2011|December 22, 2011|March 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01088971||124874|
NCT01088984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/2046|Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia|An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia||Teva Pharmaceutical Industries||Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|1 Year|20 Years|No|||March 2013|September 24, 2014|March 16, 2010|Yes|Yes||No|September 24, 2014|https://clinicaltrials.gov/show/NCT01088984||124873|
NCT01089270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-EES-0519-CTIL|Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives|||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|March 2010|||March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|First degree relatives of diagnosed Parkinson patients that carry either LRRK2 or GBA gene        mutation.        Ages: 30-80|March 2010|March 17, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089270||124851|
NCT01089283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-EES-087-CTIL|Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics|I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|March 2010|||March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Diagnosed parkinson patients ages: 40-80|March 2010|March 17, 2010|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01089283||124850|
NCT01089816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA034|Rapid Diagnostic Test for Influenza|Clinical Validation of the Point-of-Care MSD Influenza Test in Asia||Meso Scale Diagnostics, LLC.|No|Completed|March 2010|October 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|569|Samples With DNA|Viral transport media containing nasal swab extract.|Both|N/A|N/A|No|Non-Probability Sample|Individuals visiting a health care facility.|April 2015|April 17, 2015|March 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01089816||124809|
NCT01090050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112839|Treximet in the Treatment of Chronic Migraine|Treximet in the Treatment of Chronic Migraine||Cady, Roger, M.D.|No|Completed|September 2010|July 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||May 2013|May 29, 2013|March 18, 2010|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT01090050||124791|
NCT01090063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Palmar Plantar Psoriasis|Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis|An Investigator-Initiated, Open-label Study Evaluating the Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis|PPP|Tufts Medical Center|No|Completed|February 2010|April 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|85 Years|No|||January 2013|January 31, 2013|March 15, 2010||No||No|August 13, 2012|https://clinicaltrials.gov/show/NCT01090063||124790|
NCT01071434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0042|Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors|Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors||Stanford University||Terminated|February 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible disease(s)/stage(s) &#61485;&#61472;AJCC Stage I, II, III or IV lung, liver or        pancreatic cancer of any histology to be treated using radiotherapy will be eligible for        this study.|December 2012|December 5, 2012|December 16, 2009||No|PI left|No||https://clinicaltrials.gov/show/NCT01071434||126212|
NCT01093885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ambrj55501.|Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis|An Open Label Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Treatment of Diffuse Systemic Sclerosis||University of Pennsylvania|Yes|Recruiting|February 2010|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|90 Years|No|||March 2015|March 30, 2015|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01093885||124496|
NCT01093599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0039|Trial on the Effectiveness of Mindfulness Training for Smokers|Phase 2 Randomized Trial on the Effectiveness of Mindfulness Training for Smokers, a Novel Intervention Designed to Help Smokers Quit Smoking|MTS|University of Wisconsin, Madison|Yes|Completed|March 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||January 2015|September 30, 2015|March 24, 2010||No||No|May 17, 2014|https://clinicaltrials.gov/show/NCT01093599||124518|A principal limitation of this study is that it is designed to compare MTS to a less intensive usual care therapy and as such lacks a time/intensity matched control.
NCT01093612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09101|Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer|64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer||City of Hope Medical Center|Yes|Completed|March 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Female|18 Years|N/A|No|||May 2015|May 29, 2015|March 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01093612||124517|
NCT01093625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0916|Assessment of Daily Disposable Silicone Hydrogel Lens Wear|||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|157|||Both|15 Years|39 Years|No|||May 2015|May 5, 2015|March 24, 2010|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01093625||124516|
NCT01091038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0008-44|Improving Safety by Basic Computerizing Outpatient Prescribing|Improving Safety by Basic Computerizing Outpatient Prescribing||Indiana University|No|Completed|August 2001|August 2007|Actual|August 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|228|||Both|N/A|N/A||||March 2010|April 1, 2010|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01091038||124715|
NCT01091051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6012|Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis|Safety and Efficacy of Ustekinumab in the Treatment of Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis||Innovaderm Research Inc.|No|Terminated|March 2010|November 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|March 18, 2010||No|Manufacturer ceased to produce vials used for this study.|No||https://clinicaltrials.gov/show/NCT01091051||124714|
NCT01092169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64/2009|Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia|||Hillel Yaffe Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Both|N/A|25 Years|No|Non-Probability Sample|Young people suffering from SCA as well as those who suffer from combined sickle        cell/beta-thalassemia, between 0-25 years old.|March 2010|March 23, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01092169||124628|
NCT01092182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100052|Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma|Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma||National Institutes of Health Clinical Center (CC)||Recruiting|February 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|194|||Both|18 Years|N/A|No|||April 2015|May 5, 2015|March 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01092182||124627|
NCT01086007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2009-126-B|Pain Related Sexual Dysfunction After Laparoscopic Inguinal Hernia Repair|Pain Related Sexual Dysfunction After Laparoscopic Inguinal Hernia Repair||Rigshospitalet, Denmark|No|Completed|February 2010|June 2010|Actual|May 2010|Actual|N/A|Observational|N/A||2|Actual|1172|||Male|18 Years|50 Years|No|Non-Probability Sample|Patients who have had a laparoscopic inguinal hernia repair|October 2015|October 29, 2015|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086007||125100|
NCT01086020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20100101|Atorvastatin Plus Ezetimibe on Coronary Plaque Progression|Same Lipid Lowering by Atorvastatin Versus Atorvastatin Plus Ezetimibe on Coronary Plaque Progression|AEPP|Shanghai Jiao Tong University School of Medicine||Recruiting|January 2010|December 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||December 2009|April 1, 2011|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01086020||125099|
NCT01090245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA025627-01A1|Using Incentives to Improve Parolee Participation and Attendance in Community Treatment|Using Incentives to Improve Parolee Participation and Attendance in Community Tx|PIP|University of California, Los Angeles|Yes|Completed|April 2010|August 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Male|18 Years|N/A|No|||December 2014|December 2, 2014|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01090245||124776|
NCT01089998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14641|PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations|Open-label, Multicenter Study of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596 Following a Single Intravenous Administration of 200 or 300 MBq (Corresponding to ≤ 18 µg Mass Dose) for Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers (200 MBq) as Well as Investigation of Safety, Tolerability and Diagnostic Performance in Patients (300 MBq) With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and in Patients With Inflammation.||Piramal Imaging SA|No|Completed|May 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|35|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01089998||124795|
NCT01088178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCP.2009.0062|Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period|Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period: A Prospective, Randomized Pilot Study of Three Time Intervals||United States Naval Medical Center, Portsmouth|Yes|Recruiting|November 2009|July 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|16 Years|45 Years|No|||September 2010|September 29, 2010|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01088178||124935|
NCT01088412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2712|Observational Study of Somatropin Treatment in Children|The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)|GeNeSIS|Eli Lilly and Company|No|Completed|April 1999|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|22929|Samples With DNA|If patient consented a DNA sample is kept until the end of the study|Both|N/A|N/A|No|Non-Probability Sample|Clinics and private practices|October 2015|October 23, 2015|February 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01088412||124917|
NCT01088685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNKEDI0001|Hydrogel Blister Patch Prototype Treatment for Foot Blisters on the Heel|Feasibility Study to Evaluate the Safety and Performance of a Hydrogel Blister Patch Prototype for the Treatment of Foot Blisters||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||October 2011|October 4, 2011|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088685||124896|
NCT01088945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26059|Safe Passages: Ensuring Quality Transitions From NICU (Neonatal Intensive Care Unit) to Ambulatory Care|Safe Passages: Ensuring Quality Transitions From NICU to Ambulatory Care||Baylor College of Medicine|No|Completed|March 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|229|||Both|N/A|N/A|No|||July 2015|July 24, 2015|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01088945||124876|
NCT01088958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEZID-5039|Effectiveness of Selling Micronutrient Sprinkles in Rural Kenya|Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project|NICHE|Centers for Disease Control and Prevention|No|Completed|January 2007|September 2014|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|7200|||Both|6 Months|3 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01088958||124875|
NCT01088997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007384|Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn|Milrinone Pharmacokinetics and Pharmacodynamics in Newborns With Persistent Pulmonary Hypertension of the Newborn - a Pilot Study to Enable a Randomized Trial of Intervention||Children's Hospital of Philadelphia|Yes|Terminated|June 2010|May 2015|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|N/A|10 Days|No|||May 2014|May 29, 2014|March 12, 2010|Yes|Yes|Inadequate enrollment|No||https://clinicaltrials.gov/show/NCT01088997||124872|
NCT01089296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/370-00/09-A|The Norwegian Physical Therapy Study in Preterm Infants|Parental Participation in Individually Customized Physiotherapy for Preterm Infants in the Neonatal Intensive Care Unit: Effects and Experiences. The Pragmatic Randomized Controlled Part.||University Hospital of North Norway|No|Active, not recruiting|March 2010|December 2020|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|10 Weeks|No|||December 2015|December 30, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089296||124849|
NCT01089530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03/07|Clinical Intervention Study in the Primary Care Setting of Patients With High Plasma Fibrinogen (EFAP)|Clinical Intervention Study in the Primary Care Setting of Patients With High Plasma Fibrinogen in Primary Prevention of Cardiovascular Disease|EFAP|Jordi Gol i Gurina Foundation|Yes|Completed|January 2003|December 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1|||436|||Both|35 Years|75 Years|No|||March 2010|March 17, 2010|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01089530||124831|
NCT01089543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-204|A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)|A Multi-Center, Randomized, Double-Blind Study of E3810 for Japanese Subjects With Functional Dyspepsia||Eisai Inc.||Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|338|||Both|20 Years|N/A|No|||November 2013|November 27, 2013|March 17, 2010||No||No|September 17, 2013|https://clinicaltrials.gov/show/NCT01089543||124830|
NCT01089517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPH1001|A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration|A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration||Ophthotech Corporation|No|Completed|March 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|449|||Both|50 Years|N/A|No|||November 2013|November 13, 2013|March 12, 2010|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01089517||124832|
NCT01089829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRiley&NJones|Risk Factors for Foot Ulceration in the Chronic Kidney Disease (CKD) Population|The Pathological Relationships Between Chronic Kidney Disease (CKD)and the Development of Lower Limb Threatening Complications||Cardiff University|Yes|Not yet recruiting|April 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|It is proposed to identify patients with CKD level 4 (renal function at between 15 and 30%        of normal)in the Nephrology clinics at University Hospital of Wales, Cardiff. It is this        group of patients that are most at risk of progression of renal disease towards end stage        and subsequent need for dialysis.        A proportion of the patients will be identified from the pre-dialysis clinics that are due        to commence dialysis imminently. It is this group of patients that will used to examine        the specific effects of dialysis modality on risk factors for foot ulceration The        directorate of Nephrology and Transplantation in Cardiff has 450 haemodialysis patients,        140 peritoneal dialysis (CAPD) patients, and around 400 CKD level 4 patients.        Approximately 100 new patients commence dialysis each year of which 35 will start CAPD and        the rest haemodialysis.|January 2010|March 18, 2010|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01089829||124808|
NCT01071447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoUS09001|Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment|Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment:a Randomized Controlled Trial Comparing Nurse-led Clinic Versus Rheumatologist Clinic||Spenshult Hospital|Yes|Recruiting|October 2009|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|N/A|N/A|No|||August 2010|August 17, 2010|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01071447||126211|
NCT01071720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKD-19HPS09L|The Effect of Food on the Pharmacokinetic Characteristics of CKD-501|Clinical Study to Assess the Effect of Food on the Pharmacokinetic Characteristics of CKD-501 in Healthy Subjects|CKD-501 FDI|Chong Kun Dang Pharmaceutical|No|Completed|March 2010|August 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2010|December 9, 2010|February 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01071720||126190|
NCT01088828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC/BM056|Exploring the Causes of Clubfoot Using Magnetic Resonance Imaging, MRI|The Pma Mouse and the Developmental Basis of Clubfoot: MRI Anatomical Modelling of Human ICTEV (Clubfoot)||University of Aberdeen|Yes|Completed|May 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Actual|35|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Group A: Pregnant women carrying a foetus with suspected clubfoot. Group B: Neonates        affected by clubfoot Group C: Unaffected neonates Group D: Young adults who have undergone        treatment for clubfoot Group E: Control group of young unaffected adults|November 2015|November 4, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01088828||124885|
NCT01094444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.15|Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis|Placebo-controlled Trial Investigating the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis||Odense University Hospital|Yes|Completed|May 2010|November 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||January 2015|January 20, 2015|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01094444||124453|
NCT01089725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091027|Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee||Pfizer|Yes|Terminated|March 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|385|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|March 11, 2010|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01089725||124816|
NCT01089985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R724/08/2010|Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye|Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye||Singapore National Eye Centre|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|21 Years|75 Years|No|||January 2012|January 15, 2012|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01089985||124796|
NCT01089738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1651003|A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals|An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-03382792 In Healthy Elderly Subjects||Pfizer|No|Withdrawn|November 2010|April 2011|Anticipated|April 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|40|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||July 2010|July 6, 2010|March 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01089738||124815|
NCT01089751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-SXR-09-004|Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily|||Allergan|No|Completed|March 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|322|||Female|18 Years|75 Years|No|||September 2013|September 24, 2013|March 17, 2010|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01089751||124814|
NCT01086683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225 06 001|Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course|Rehabilitation of Cancer Survivors in Denmark: A Randomized Controlled Trial on the Effect of a Multi-focused Psychosocial Rehabilitation Course||Danish Cancer Society|No|Completed|May 2004|December 2009|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|513|||Both|18 Years|N/A|No|||March 2010|March 12, 2010|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086683||125049|
NCT01086696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100078|A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers|A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers||National Institutes of Health Clinical Center (CC)||Completed|March 2010|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|3|||Both|18 Years|100 Years|No|||June 2015|November 18, 2015|March 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01086696||125048|
NCT01086709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910059|Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191|Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191(NCI)/IC-200403(INCIENSA)||National Institutes of Health Clinical Center (CC)||Completed|January 2010|March 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|7466|||Female|21 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01086709||125047|
NCT01103557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC_CND_LND|Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma|The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis||Pusan National University Hospital|Yes|Completed||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|62|||Both|20 Years|76 Years|Accepts Healthy Volunteers|||January 2010|April 13, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103557||123758|
NCT01103570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cholangiography|Cholecyst- Versus Cystic Duct Cholangiography During Laparoscopic Cholecystectomy|Cholecystocholangiography Versus Cystic Duct Cholangiography During Laparoscopic Cholecystectomy: A Prospective Controlled Randomized Trial||Theodor Bilharz Research Institute|Yes|Completed|March 2009|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|55 Years|No|||April 2010|April 13, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01103570||123757|
NCT01099371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAAA|Resistance Training in Knee Osteoarthritis|Progressive Resistance Training in Women With Knee Osteoarthritis||Federal University of São Paulo|Yes|Active, not recruiting|February 2009|February 2011|Anticipated|February 2009|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Female|40 Years|70 Years|No|||January 2009|May 6, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01099371||124077|
NCT01099384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003981|Tobacco Cessation Treatment for Alaska Native Youth|Tobacco Cessation Treatment for Alaska Native Youth||Mayo Clinic|Yes|Completed|September 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01099384||124076|
NCT01099657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31498-A|Virtual Reality Hypnosis for Chronic Pain Reduction|Virtual Reality Hypnosis for Chronic Pain Reduction|VRHChP|National Institute of General Medical Sciences (NIGMS)|Yes|Recruiting|June 2007|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|13 Years|75 Years|No|||March 2010|April 6, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01099657||124055|
NCT01099670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-01/2009 (SURD)|Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days|A Double-blind, Placebo-controlled, Randomised, Parallel-group, Dose-escalating, Repeat Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of the Once Daily Rectal Application of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days||Norgine|Yes|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 23, 2010|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01099670||124054|
NCT01099618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026272|Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment|Ketosis-Prone Diabetes in African Americans: Predictive Markers, Underlying Mechanisms, and Treatment Outcomes: The Effects of Metformin vs. Sitagliptin on Beta-Cell Preservation in Obese Subjects With Ketosis-Prone Type 2 Diabetes Mellitus||Emory University|Yes|Completed|March 2010|August 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|48|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2015|March 15, 2010|Yes|Yes||No|May 9, 2015|https://clinicaltrials.gov/show/NCT01099618||124058|
NCT01100281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-29|Prefrontal Cortex and Abstract Thinking|Neuropsychological and Anatomical Study of Concept Formation in Frontal Patients||Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|April 2010|April 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|69|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|3 groups including : PSP, FTD, AD|December 2011|December 8, 2011|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100281||124009|
NCT01100294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUVAL P-H-08|Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children|Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|Yes|Completed|September 2009|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||May 2012|May 18, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01100294||124008|
NCT01100541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPHCFMRPUSP-11099|Evaluation of a Polymeric Plate Derived From Castor Oil to Thermotherapy|Evaluation of a Polymeric Plate Derived From Castor Oil to Thermotherapy||University of Sao Paulo|No|Completed|February 2010|February 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01100541||123989|
NCT01100554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980717A3|Upper Airway Collapsibility Evaluation in Different Sedative Levels by Sleep Endoscopy|Upper Airway Collapsibility Evaluation in Different Sedative Levels by Sleep Endoscopy||Chang Gung Memorial Hospital|Yes|Recruiting|October 2009|||June 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2010|April 11, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100554||123988|
NCT01100853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811095|Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland|Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland||University of Pennsylvania|No|Completed|May 2010|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|April 7, 2010|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01100853||123965|
NCT01100866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML-01054|Study of POMELLA™ Extract to Treat Prostate Cancer|Randomized Controlled Trial of POMELLA™ Extract in Prostate Cancer Patients Scheduled for Surgery||Vancouver Coastal Health|No|Terminated|January 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Male|19 Years|N/A|No|||March 2014|March 10, 2014|April 2, 2010||No|due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01100866||123964|
NCT01101178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1008|To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets to OxyContin® 80-mg Tablets||Purdue Pharma LP|No|Completed|August 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|79|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|April 8, 2010|Yes|Yes||No|April 14, 2010|https://clinicaltrials.gov/show/NCT01101178||123940|
NCT01101542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112485|Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females|Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix® When Administered to Healthy Females According to the Prescribing Information in Korea||GlaxoSmithKline||Completed|July 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3091|||Female|10 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy female subjects aged between and including 10 to 25 years who receive Cervarix®        according to the current practice of Korean doctors.|December 2014|October 29, 2015|April 8, 2010|No|Yes||No|November 10, 2011|https://clinicaltrials.gov/show/NCT01101542||123913|
NCT01130922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/099|Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass|Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass.|DRUG10_MOXI|University Ghent|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2011|April 15, 2011|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01130922||121666|
NCT01130935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GAL-NEX-2010/1|Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium|A National, Multicentre, Open-label, Non-comparative, Non-interventional Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium||AstraZeneca|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|491|||Both|18 Years|N/A|No|Probability Sample|Male or female subjects, age > 18 years, having had upper GI symptoms requiring acid        suppression treatment.|February 2011|February 23, 2011|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01130935||121665|
NCT01102049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|535-ICL-673|Food-related Differences in Human Metabolite Profiles|Food-related Differences in Human Metabolite Profiles||Imperial College London|No|Completed||||||N/A|Interventional|N/A|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 9, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01102049||123874|
NCT01102036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-X-Ray U-09-017|Effects of Cultura Yoghurt in Relation to Transit Time and Digestive Discomfort in Healthy Women and Men|Effects of Cultura Yoghurt in Relation to Transit Time and Digestive Discomfort During 2 Weeks of Treatment in Comparison to Placebo in Healthy Women and Men||Good Food Practice, Sweden|No|Completed|February 2010|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2010|August 25, 2011|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102036||123875|
NCT01102296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200903063M|Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection|Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital||National Taiwan University Hospital|Yes|Completed|June 2009|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|582|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 25, 2012|January 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102296||123855|
NCT01102842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-192-A|Unattended In-home Sleep Recording: A Pilot Study|Unattended In-home Sleep Recording: A Pilot Study||University of Chicago||Completed|April 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult volunteers (18 years of age and older) who have had a polysomnography recording in        the laboratory at the University of Chicago.|September 2013|September 4, 2013|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102842||123813|
NCT01103076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HighCO Hemo study|Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease|Effects of High Cut-off Hemodialysis on Central Memory CD4+ T Cells and Regulatory T Cells in Patients With End-stage Kidney Disease||Centre Hospitalier du Centre du Valais|Yes|Recruiting|April 2011|February 2012|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||March 2010|July 6, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103076||123795|
NCT01109264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-79-001|Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia|Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|March 2010|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|75 Years|No|||August 2013|August 21, 2013|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01109264||123320|
NCT01109277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010ICTPAGR|Prediction of Neonatal Hyperbilirubinemia|An Evidence-based Strategy for Assessing the Risk of Significant Neonatal Hyperbilirubinemia|2010ICTPAGR|University of Patras|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|3500|||Both|N/A|15 Days|No|Non-Probability Sample|Healthy term and late-preterm neonates|April 2010|January 18, 2011|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109277||123319|
NCT01103323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14387|Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy|A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy||Bayer|Yes|Completed|April 2010|January 2014|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|760|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|April 8, 2010|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT01103323||123776|At 2nd IA, pre-specified O’Brien-Fleming-type efficacy boundary was crossed. DMC concluded OS result positive and after positive risk benefit assessment, recommended unblinding of study. OS from 2nd IA are the final formal and definitive results.
NCT01103583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008521-29|Hydroxyurea in Primary Progressive Multiple Sclerosis|||S. Andrea Hospital|Yes|Terminated|July 2011|||December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|60 Years|No|||December 2013|February 10, 2014|April 13, 2010||No|No efficacy (interim.analysis)|No||https://clinicaltrials.gov/show/NCT01103583||123756|
NCT01099397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFIRB2372009|Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study|Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study||University of Florida|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|Samples With DNA|Serum and plasma|Both|18 Years|65 Years|No|Non-Probability Sample|Primary care clinic, PEAR participants|August 2012|August 29, 2012|April 1, 2010|Yes|Yes||No|May 10, 2012|https://clinicaltrials.gov/show/NCT01099397||124075|This was a pilot study to evaluate two glucose phenotypes in a small sample from a larger trial. As such, our sample size was small. Further, if participants were withdrawn from the parent trial, they were also withdrawn from the sub-study.
NCT01100008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 042 02|Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion|Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion: Its Role in the Diagnosis of the Severity of Pulmonary Hypertension in Adults and in the Follow-up. Preliminary Study.||University Hospital, Toulouse|No|Completed|September 2007|June 2014|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|29|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01100008||124028|
NCT01100021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-017|Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin|A Phase 1, Single-centre, Double-blind, Randomized, Placebo-controlled, Two-cohort, Two-period Crossover Study of the Hemodynamic Interactions Between Avanafil and Two α-Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle-aged Healthy Male Subjects||VIVUS, Inc.||Completed|February 2010|April 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 5, 2011|January 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100021||124027|
NCT01099982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00030622|Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease|Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease, Effects of Mechanical Unloading on Myocardial Function and Structure in Humans||University of Utah|Yes|Recruiting|September 2008|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Serum and myocardial tissue.|Both|13 Years|N/A|No|Non-Probability Sample|Either gender, ≥ 13 years of age, any ethnicity, diagnosed with end stage heart failure        undergoing either VAD implantation or heart transplantation.        Control samples will be obtained from individuals undergoing other types of cardiac sugery        during which it is routine to discard some tissue intraoperatively.|March 2016|March 21, 2016|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099982||124030|
NCT01100307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751034|A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema|A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium, With Sham Injections, And Open Study (For 30 Weeks) To Confirm The Safety Of 0.3 MG Pegaptanib Sodium In Subjects With Diabetic Macular Edema (DME)||Pfizer|No|Completed|May 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|243|||Both|20 Years|N/A|No|||May 2013|August 16, 2013|April 7, 2010|Yes|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT01100307||124007|During the study, an issue was reported concerning proper maintenance of treatment masking. Due to this masking process issue, the study results cannot be interpreted as that arising from a well-controlled double-masked trial.
NCT01100320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1004|A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 40-mg Tablets to OxyContin® 40-mg Tablets||Purdue Pharma LP|No|Completed|January 2007|July 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|88|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|April 7, 2010|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT01100320||124006|
NCT01100567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-10-0461|Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia Nervosa|EFFECT OF BIOMECHANICAL STIMULATION ON SKELETAL HEALTH IN ADOLESCENT AND YOUNG WOMEN WITH ANOREXIA NERVOSA||Children's Hospital Boston|No|Completed|April 2009|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Female|11 Years|25 Years|No|||August 2015|August 5, 2015|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100567||123987|
NCT01100580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORST-1028|The Links Between Water and Salt Intake, Body Weight, Hypertension and Kidney Stones: a Difficult Puzzle|The Links Between Water and Salt Intake, Body Weight, Hypertension and Kidney Stones: a Difficult Puzzle||University of Parma|Yes|Not yet recruiting|May 2010|May 2012|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01100580||123986|
NCT01100879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-AOC-MM|Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy|Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy|AOC-MM|Vifor Inc.|No|Terminated|March 2010|October 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2011|October 11, 2011|March 29, 2010||No|Lack of Recruitment|No||https://clinicaltrials.gov/show/NCT01100879||123963|
NCT01111968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUTVAC - Influenza A (H1N1)|Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines|Evaluation of Safety, Tolerability and Immunogenicity of Adjuvanted Candidate Vaccines Against Pandemic Influenza A (H1N1)||Butantan Institute|Yes|Completed|January 2010|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|10||Actual|266|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01111968||123112|
NCT01112475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0140-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2010|||||N/A|N/A|N/A||||||||||||||May 13, 2010|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112475||123073|
NCT01112761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000191|Cortical Plasticity Assessment in Athletes With a History of Concussion|Cortical Plasticity Assessment in Athletes With a History of Concussion||Spaulding Rehabilitation Hospital|No|Terminated|April 2010|||April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|1|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|April 20, 2010||No|Lack of resources to run the trial|No||https://clinicaltrials.gov/show/NCT01112761||123051|
NCT01101555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113299|Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study|A Randomised, Single-blind, Placebo-controlled, Study Toevaluate the Safety, Tolerability, Pharmacodynamics Andpharmacokinetics of Repeat Subcutaneous Administration Ofotelixizumab in Subjects With Rheumatoid Arthritis||GlaxoSmithKline|No|Completed|May 2010|November 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|28|||Both|18 Years|75 Years|No|||May 2013|September 26, 2013|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101555||123912|
NCT01102309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN-TN-2007|Robot-assisted Rehabilitation of the Upper Limb in Acute and Subacute Post-stroke Patients|Clinical and Social-economic Impact Assessment of Robot-assisted Rehabilitation of the Upper Limb in Acute and Subacute Post-stroke Patients||Eremo Hospital, Arco|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|85 Years|No|||June 2011|June 23, 2011|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102309||123854|
NCT01102595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENOM-009|Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma|A Phase II Open Label Randomised Multicentric Study in Patients With Unresectable Glioblastoma Using Neo-adjuvant Treatment With Two Cycles of Temozolomide Previous Temozolomide Plus Radiation Therapy and Adjuvant Temozolomide vs. Neo-adjuvant Treatment With Two Cycles of Temozolomide Plus Bevacizumab Previous Temozolomide, Bevacizumab and Radiation Therapy and Adjuvant Temozolomide.||Grupo Español de Investigación en Neurooncología|No|Completed|December 2009|December 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01102595||123832|
NCT01109004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0702|Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)|A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients With Multiple Myeloma (BMT CTN 0702)||National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|May 2010|May 2020|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|750|||Both|N/A|70 Years|No|||March 2016|March 7, 2016|April 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01109004||123340|
NCT01109563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37852-G|Teen Marijuana Check-Up|Reaching and Motivating Change in Teen Marijuana Smokers||University of Washington|No|Active, not recruiting|March 2011|September 2015|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Both|14 Years|19 Years|No|||March 2015|March 4, 2015|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109563||123297|
NCT01103596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-124|Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)|Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to ARVs - EOLE|EOLE|Abbott|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|94|Samples Without DNA|Frozen plasma for determination of Lopinavir/ritonavir (LPV/r) Cmin|Both|18 Years|N/A|No|Non-Probability Sample|Virology laboratories|December 2011|December 13, 2011|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01103596||123755|
NCT01099410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curtis 0015|Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)|Apoptotic Cell Ingestion by Normal Human Alveolar Macrophages||VA Office of Research and Development|No|Completed|February 2010|December 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|None Retained|whole blood, white blood cells, serum, bronchoalveolar lavage fluid|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Volunteer subjects recruited from the community; may be current or ex-smokers or        never-smokers, but must be healthy enough to undergo research bronchoscopy safely.|January 2016|January 4, 2016|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01099410||124074|
NCT01099683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-02/2009 (SAGE)|Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects|A Double-blind, Randomised, Placebo-controlled Study in Elderly Subjects to Evaluate the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in a 2 g Suppository||Norgine|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 23, 2010|February 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01099683||124053|
NCT01110070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-08|ChonDux for Filling Full Thickness Cartilage Defects in the Femoral Condyle of the Knee|Pivotal Study in Europe for CE Mark||Biomet, Inc.|No|Terminated|July 2010|December 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|55 Years|No|||July 2013|July 17, 2013|April 22, 2010||No|Enrollment suspended; follow up continue|No||https://clinicaltrials.gov/show/NCT01110070||123258|
NCT01110356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDNA 2009-01|Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age|A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age|Prefer|Vifor Inc.|No|Completed|June 2010|October 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|294|||Female|18 Years|N/A|No|||November 2012|November 13, 2012|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110356||123236|
NCT01110369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1002-2|A Protein Supplementation and Exercise Strategy to Promote Muscle Protein Anabolism in Frail Elderly People|A Protein Supplementation and Exercise Strategy to Promote Muscle Protein Anabolism in Frail Elderly People|ProMuscle|Wageningen University|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|65 Years|N/A|No|||January 2012|January 30, 2012|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01110369||123235|
NCT01110382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016789|A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections||Janssen Research & Development, LLC|Yes|Terminated|December 2010|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|3 Months|18 Years|No|||July 2014|July 2, 2014|April 15, 2010|Yes|Yes|Trial terminated early per business decision|No|May 30, 2014|https://clinicaltrials.gov/show/NCT01110382||123234|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with meropenem.
NCT01099995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO89-2|Hyperbaric Oxygen Therapy for Comatose Patients With Acute Carbon Monoxide Poisoning|Phase 3 Study of Hyperbaric Oxygen Therapy for Comatose Patients With Acute Domestic Carbon Monoxide Poisoning||University of Versailles|No|Terminated|October 1989|February 2000|Actual|January 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|15 Years|N/A|No|||April 2010|April 7, 2010|April 5, 2010||No|the study was halted after the first interim analysis as there were significantly more    patients who recovered at one month in the control arm|No||https://clinicaltrials.gov/show/NCT01099995||124029|
NCT01100593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28195|Ultrasound IV Study|Optimal Catheter Length for Ultrasound-Guided Peripheral Vascular Access||Christiana Care Health Services|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100593||123985|
NCT01100892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-IDEA|Cystic Fibrosis - Insulin Deficiency, Early Action|Cystic Fibrosis - Insulin Deficiency, Early Action|CF-IDEA|Sydney Children's Hospital, Randwick|Yes|Recruiting|December 2010|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|5 Years|19 Years|No|||May 2015|May 22, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01100892||123962|
NCT01101230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE 104|Effects of Almonds on Cardiovascular Risk Factors|Effects of a Diet Rich in Almonds on LDL Cholesterol, LDL Particle Size, Abdominal Adiposity and Vascular Health|ALD|Penn State University|No|Completed|September 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01101230||123936|
NCT01102101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHPRG-HighDoseRemiPostHerpetic|Effect of Opioids in Neuropathic Pain in Postherpetic Patients|Effect of Opioids in Neuropathic Pain in Postherpetic Patients|VHPRG-HDRPH|Medical University of Vienna|No|Not yet recruiting|August 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2010|April 9, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01102101||123870|
NCT01102374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0899|Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents|Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents||University of Colorado, Denver|Yes|Active, not recruiting|May 2010|December 2015|Anticipated|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|60 Years|N/A|No|||May 2015|May 26, 2015|April 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102374||123849|
NCT01102387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 552 000 - 0920|Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections|Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at the Trunk||Almirall, S.A.|No|Completed|February 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|137|||Both|18 Years|N/A|No|||January 2011|July 3, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01102387||123848|
NCT01101776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701068-522|Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.|Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting|ReNew|Merck KGaA|No|Completed|January 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with MS who have experienced two or more relapses within last 2 years and to be        treated with Rebif New Formulation in Australia.|August 2014|August 12, 2014|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101776||123895|
NCT01101789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-surg-006|Triclosan Coated Suture Wound Closure for Peripheral Vascular Surgery: a Prospective Multicenter Study|Triclosan Coated Suture Wound Closure for Peripheral Vascular Surgery: a Prospective Multicenter Study||North Karelia Central Hospital|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|100 Years|No|||October 2015|October 11, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101789||123894|
NCT01102062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|557-ICL-649|Human Urinary Biomarker for Orange Juice Consumption|Human Urinary Biomarker for Orange Juice Consumption||Imperial College London|No|Completed||||||N/A|Interventional|N/A|||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 9, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01102062||123873|
NCT01102322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002021R|Factors Associated With the Use of Lung Protective Ventilation Strategy (LPV) in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients in Intensive Care Unit (ICU)|Factors Associated With the Use of Lung Protective Ventilation Strategy (LPV) in ALI/ARDS Patients in ICU||National Taiwan University Hospital|No|Completed|March 2010|February 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|111|||Both|18 Years|N/A|No|Non-Probability Sample|Acute respiratory distress syndrome patients|February 2011|February 18, 2011|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01102322||123853|
NCT01102335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-001|Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy|The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy|TACEHBV|Fudan University|Yes|Recruiting|April 2010|December 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||April 2010|April 12, 2010|April 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102335||123852|
NCT01110122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJA-PROT-IAB-001|Effect of Whey Protein on Soccer Performance|The Effect of Post-exercise Supplementation With Whey Protein Versus Carbohydrate on Soccer Performance.||VU University of Amsterdam|No|Recruiting|March 2010|July 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|50|||Male|15 Years|19 Years|Accepts Healthy Volunteers|||March 2010|April 22, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110122||123254|
NCT01108991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|679|Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD|Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD|COPD-SMART|The University of Texas Health Science Center at Tyler|Yes|Completed|April 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|325|||Both|45 Years|N/A|No|||December 2015|December 24, 2015|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108991||123341|
NCT01109290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED10|Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia|Validation of Non-invasive Technologies for the Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia, Their Heterozygous Family Members and Healthy Controls||University Hospital Erlangen||Completed|April 2010|June 2011|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|65|||Both|N/A|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with recessively inherited hypohidrotic ectodermal dysplasia (HED), their        heterozygous family members and healthy controls|September 2011|September 13, 2011|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109290||123318|
NCT01110785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000671002|Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer|Safety and Efficacy of the Addition of Simvastatin to Panitumumab in K-ras Mutant Advanced or Metastatic Colorectal Cancer Patients. A Single-Arm, Multicenter, Phase II Study Using a Simon Two Stage Design.||National Cancer Institute (NCI)||Recruiting|April 2010|||April 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||April 2011|September 16, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110785||123203|
NCT01110460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRISMA|Prospective Study on Asthma Control|Cross-sectional and Prospective Observational Study Aimed to Assess the Prevalence of Uncontrolled and Partially Controlled Asthmatics in Italy and the Prevalence of Uncontrolled/Partially Controlled Patients Achieved Asthma Control After 12 Months|PRISMA|Chiesi Farmaceutici S.p.A.|Yes|Completed|January 2009|November 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2875|||Both|18 Years|N/A|No|Probability Sample|Asthmatic patients|January 2011|January 31, 2011|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110460||123228|
NCT01109537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2010-12345|Altered Brain GABA and Glutamate in Restless Legs Syndrome|Thalamic and Anterior Cingulate Cortex GABA and Glutamate in Restless Legs Syndrome: A 1-HMRS Study|RLS|Brigham and Women's Hospital|No|Completed|April 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female subjects who have RLS or are normal controls will be recruited from the        greater Boston metropolitan area. We anticipate enrolling 70 subjects with RLS and 70        normal controls, under a plan to complete 15 subjects in each group.|January 2015|January 6, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109537||123299|
NCT01109550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILIARY-CANDIDIASIS_2010|Biliary Candidiasis - Optimization of Diagnostics and Therapy|Biliary Candidiasis - Evaluation of Risk Factors, Implementation of an Algorithm in Diagnostics and Therapy||University Hospital Muenster|No|Recruiting|April 2011|November 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|bile samples, buccal smears, stool samples, blood samples, transpapillary biopsies (bile      duct)|Both|18 Years|80 Years|No|Non-Probability Sample|Patients referred to a hospital of maximum care.|December 2012|December 7, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109550||123298|
NCT01109810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-10-02|Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)|Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)|IDEaL|Coram Clinical Trials|No|Recruiting|August 2010|August 2025|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The IDEaL Registry program will collect data representative of patients receiving Ig        therapy (IVIg and SCIg) in a homecare setting and/or through Coram's ambulatory infusion        suites.|February 2014|February 4, 2014|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109810||123278|
NCT01110083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200096-001|First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors|A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors||EMD Serono|No|Terminated|April 2010|||March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|April 19, 2010|No|Yes|Please see "Purpose" statement below.|No||https://clinicaltrials.gov/show/NCT01110083||123257|
NCT01110408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016792|A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections||Janssen Research & Development, LLC|Yes|Terminated|December 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|3 Months|18 Years|No|||July 2014|July 2, 2014|April 15, 2010|Yes|Yes|Trial terminated early per business decision|No|May 30, 2014|https://clinicaltrials.gov/show/NCT01110408||123232|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with cefepime.
NCT01110421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016975|A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia||Janssen Research & Development, LLC|Yes|Terminated|December 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|3 Months|18 Years|No|||July 2014|July 2, 2014|April 15, 2010|Yes|Yes|Trial terminated early per business decision|No|May 30, 2014|https://clinicaltrials.gov/show/NCT01110421||123231|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with cefepime.
NCT01110772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09003INI|Comparison of Iodine + Isopropyl Alcohol Versus Iodine + Antimicrobial Sealant for Skin Preparation|Comparative Study of a Iodine + Cyanoacrylate (Integuseal) vs. Iodine and Isopropyl Alcohol in Skin Preparation for Prevention of Surgical Site Infections in Oncologic Surgery||National Institute of Cancerología|No|Recruiting|May 2009|December 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|18 Years|N/A|No|||April 2010|April 26, 2010|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110772||123204|
NCT01100333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700623-500|GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)|Observational Study GONAL-f® Consort||Merck KGaA||Completed|April 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2552|Samples Without DNA|Whole Blood|Female|N/A|35 Years|No|Probability Sample|Subjects undergoing Assisted Reproductive Technologies (ART) receiving Gonal-f in Germany|January 2013|July 30, 2014|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01100333||124005|
NCT01111006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0620092310|The Effect of Electronic Cleansing Toilet System (Bidet) on Anal Resting Pressure|The Effect of Electronic Cleansing Toilet System (Bidet) on Anal Resting Pressure in Normal Healthy Volunteers||Seoul National University Hospital|Yes|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||April 2010|April 26, 2010|April 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01111006||123186|
NCT01111019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 26545 (EMR701048-506)|Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children|Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children With Hypochondroplasia||Merck KGaA|No|Active, not recruiting|June 2009|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|3 Years|N/A|No|||July 2015|July 20, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01111019||123185|
NCT01111383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMA-0631-PR-0010 Extension|A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®|A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa)|CT03Ext|Chiesi Farmaceutici S.p.A.|No|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|209|||Both|6 Years|N/A|No|||November 2011|November 18, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01111383||123157|
NCT01111370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL900360|Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System|Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System||DexCom, Inc.|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|80|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111370||123158|
NCT01111682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shutter-2010-01|Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure|Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure||University of Cincinnati|No|Terminated|April 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|70 Years|No|||March 2013|March 4, 2013|April 22, 2010||No|A significant reduction in head injuries coupled with more frequent use of crainectomy reduced    the number of potential subjects.|No||https://clinicaltrials.gov/show/NCT01111682||123134|
NCT01102660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631026|Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee|A Randomized, Double-Blind, Double-Dummy, Placebo And Active Controlled Two Period Four Treatment Cross-Over Clinical Trial To Examine The Pain Relief Of PH-797804 Alone Or With Naproxen In Subjects With Flare-Enriched Osteoarthritis Of The Knee||Pfizer|Yes|Completed|May 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|172|||Both|18 Years|75 Years|No|||August 2014|August 20, 2014|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102660||123827|
NCT01103414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSDC-C004|Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients|Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients||Metabolic Solutions Development Company|No|Completed|September 2010|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|356|||Both|18 Years|75 Years|No|||April 2013|April 6, 2015|April 7, 2010|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT01103414||123769|
NCT01102894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903M60781|Pilot Study Using a Wireless Motility Capsule|Measurement of Whole Gut Transit Time After a Dietary Fiber Treatment Using a Wireless Motility Capsule||University of Minnesota - Clinical and Translational Science Institute|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|March 24, 2010||No||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01102894||123809|The study interventions were not randomized, which doesn't allow for period effect calculations. The SmartPill can reside in the stomach for longer than a few hours, which can skew results.
NCT01112449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-012|Influence of Selenium on Prostate Cancer Related Biomarkers|Influence of Selenium on Prostate Cancer Related Biomarkers||Milton S. Hershey Medical Center|Yes|Completed|May 2008|May 2014|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|130|||Male|20 Years|79 Years|Accepts Healthy Volunteers|||October 2014|July 8, 2015|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112449||123075|
NCT01112735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550902|Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty|A Randomized, Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of ARTISS (FS VH S/D 4 S-apr) for Flap Adherence in Subjects Undergoing Abdominoplasty||Baxter Healthcare Corporation||Completed|May 2010|February 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112735||123053|
NCT01112748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIDO-2009|Topical Lidocaine: Predictors of Response in Peripheral Nerve Injury|Evaluation of Predictors of Response for the Efficacy of Topical Lidocaine Patch (Versatis) on Chronic Neuropathic Pain After Peripheral Nerve Injury||Danish Pain Research Center|Yes|Completed|April 2010|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112748||123052|
NCT01108393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL2-20098-072|Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder|Efficacy of Agomelatine 25mg/Day (With Possible Increase to 50mg/Day After 8 Weeks of Treatment) Given Orally During 16 Weeks in Patients With Obsessive-Compulsive Disorder. A Randomised, Double-blind, Placebo-controlled, Parallel Groups, International Study||Servier|No|Completed|May 2010|April 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|No|||February 2014|February 12, 2014|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01108393||123387|
NCT01108406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN005.00|Long Term Safety of the Sonitus SoundBite System|Long Term Safety of the Sonitus SoundBite System||Sonitus Medical Inc|Yes|Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|80 Years|No|||October 2014|October 10, 2014|April 15, 2010|Yes|Yes||No|June 1, 2013|https://clinicaltrials.gov/show/NCT01108406||123386|
NCT01108731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIMC #212-09|The Effect of Milnacipran in Patients With Fibromyalgia|The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced "Brain Fog."||Beth Israel Medical Center|No|Completed|March 2010|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|68 Years|No|||October 2014|October 13, 2014|March 30, 2010|Yes|Yes||No|July 7, 2014|https://clinicaltrials.gov/show/NCT01108731||123361|
NCT01110434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA026778|Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents|Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents||Brown University|Yes|Completed|December 2009|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|15 Years|20 Years|Accepts Healthy Volunteers|||July 2012|July 11, 2012|April 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110434||123230|
NCT01110447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHE2-VSL#3-Ver3_30032010|Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation|Secondary Prophylaxis of Hepatic Encephalopathy: A Double Blind, Randomized, Placebo Controlled Study With Supplementation With a Probiotic Preparation|VSL#3|CD Pharma India Pvt. Ltd.|No|Completed|April 2010|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|70 Years|No|||December 2013|December 26, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110447||123229|
NCT01110473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-943|ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies||AbbVie|No|Completed|April 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110473||123227|
NCT01109823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/167|Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration|Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration||University Ghent|No|Recruiting|May 2010|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109823||123277|
NCT01110096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FamilY|Family Based Intervention in Childhood obesitY|Randomised Controlled Clinical Trial Comparing Two Family Interventions to Treat Obesity in Children Between 7 and 12 Years.||Sykehuset i Vestfold HF|No|Active, not recruiting|April 2010|May 2016|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01110096||123256|
NCT01110109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV-MO-PO-A111|Removing Fluid Above Breathing Tubes in the Operating Room|EVAC Use in the OR: A Randomized Clinical Study to Evaluate the Content of Fluid Extracted From the Endotracheal Tube Cuff Using Intermittent and Continuous Suctioning During Surgery||Medtronic - MITG|No|Completed|April 2010|October 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|48|Samples Without DNA|Suction secretions|Both|18 Years|N/A|No|Probability Sample|Adults undergoing surgery requiring intubation using the TaperGuard EVAC Endotracehal Tube|October 2010|October 25, 2010|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110109||123255|
NCT01110395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0533|Phosphorous Magnetic Resonance Spectroscopy of Heart|31P Magnetic Resonance Spectroscopy of Heart||Washington University School of Medicine|Yes|Recruiting|June 2009|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|15|||Both|18 Years|N/A|No|Probability Sample|The study population will be individuals with left ventricular dysfunction including men        and women of all races.|February 2014|February 18, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110395||123233|
NCT01110759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019315|Medical Review: Hand Surgery After Local Block Versus Non-block|Retrospective Chart-review Study Involving Outpatients Who Underwent Hand Surgery With Local Anesthesia: Comparing Outcome With a Peripheral Nerve Block vs. Local Infiltration Alone||Cedars-Sinai Medical Center|No|Completed|August 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Outpatients undergoing hand surgery|October 2013|October 30, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110759||123205|
NCT01111994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDC2009Z|Efficacy & Safety of Clindamycin and Tretinoin in Acne|Efficacy & Safety of Clindamycin Phosphase 1.2% and Tretinoin 0.025% Gel vs. Vehicle for the Treatment of Acne and Acne-Induced Post Inflammatory Hyperpigmentation in Patients With Skin of Color||Callender Center for Clinical Research|No|Active, not recruiting|November 2009|April 2010|Anticipated|March 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|N/A|No|||May 2010|May 19, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111994||123110|
NCT01110733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPLETE Registry|Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry|Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma|COMPLETE|Spectrum Pharmaceuticals, Inc||Active, not recruiting|February 2010|February 2019|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be enrolled from academic and community cancer centers in the United States,        France, Germany, Italy and Japan.|June 2015|June 2, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110733||123207|
NCT01110746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject -032J|To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy|A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy||Biodel|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||July 2015|July 30, 2015|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110746||123206|
NCT01111695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 09-013|Evaluation of a Ionic Silver and Honey Preparation to Treat Chronic Wounds of the Lower Legs|Open Label Study (Phase 2) to Evaluate the Safety, Tolerance and Efficacy of a Ionic Silver and Honey Preparation to Treat Chronic Wounds of the Lower Legs||University Hospital, Geneva|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2011|September 29, 2011|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111695||123133|
NCT01111981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDC2009O|Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia|Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia||Callender Center for Clinical Research|No|Recruiting|October 2009|October 2010|Anticipated|February 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|80 Years|No|||April 2010|April 27, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111981||123111|
NCT01112202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dabi2010|Effect of Dabigatran on Coagulation parameters-an ex Vivo Study|Effect of Dabigatran on Coagulation Parameters in Patients Undergoing Elective Orthopaedic Surgery||Johann Wolfgang Goethe University Hospitals|No|Completed|April 2010|April 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|patients after hip or knee replacement surgery treated with Dabigatran 150-220 mg/d|April 2010|June 5, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112202||123094|
NCT01112462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC02009|To Test Bioequivalence Between Two Formulations of Paracetamol/Phenylephrine|A Single-dose, Randomized, Crossover Bioequivalence Study to Compare Two Formulations of Paracetamol/Phenylephrine||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112462||123074|
NCT01103427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFP-743-08|Usefulness of Supportive SMS in Addition to an Internet Based Quit Smoking Program (Www.Slutta.no)|Mobile Text Messaging as an Adjunct Function to an Internet-based Smoking Cessation Intervention Implemented in the General Population and in a Health Care Setting||University of Tromso|No|Completed|May 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|4300|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 16, 2013|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103427||123768|
NCT01109069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1103-CA|Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia|A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia.||Pharmacyclics|No|Active, not recruiting|June 2010|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01109069||123335|
NCT01109082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIS-2010|Gait and Postural Stability Assessment in Children With Idiopathic Scoliosis Undergoing Posterior Spine Instrumentation|Gait and Postural Stability Assessment in Children With Idiopathic Scoliosis Undergoing Posterior Spine Instrumentation||Shriners Hospitals for Children|Yes|Completed|December 2007|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|1 Year|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents with idiopathic scoliosis that have a Cobb angle greater than 50 degrees.|March 2013|March 18, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01109082||123334|
NCT01109017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3811|Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Long-term Safety and Efficacy of Norditropin® Formulation in Patients With AGHD||Novo Nordisk A/S|No|Completed|October 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|387|||Both|N/A|N/A|No|Probability Sample|Adult patients with growth hormone deficiency including newly-diagnosed patients, who are        considered to need treatment with Norditropin® (somatropin) or already on therapy with        Norditropin® (somatropin) are eligible for inclusion in the study|January 2015|January 7, 2015|April 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01109017||123339|
NCT01109030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94976|Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder|Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder||Tehran University of Medical Sciences|Yes|Completed|April 2010|October 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||May 2012|May 8, 2012|April 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01109030||123338|
NCT01109303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-446|Static Implant Versus Dynamic Implant in the Surgical Treatment on Ankle Syndesmosis Rupture|Prospective Randomized Multicentric Trial Comparing a Static Implant and a Dynamic Implant in the Surgical Treatment of Ankle Syndesmosis Rupture||Hopital de l'Enfant-Jesus|No|Completed|October 2008|January 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||December 2012|December 19, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109303||123317|
NCT01109316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12174|Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use|An Open-Label, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|132|||Both|13 Years|N/A|No|||September 2012|September 27, 2012|April 19, 2010|Yes|Yes||No|August 8, 2012|https://clinicaltrials.gov/show/NCT01109316||123316|Input to primary endpoint measurements (SMBG) contained approximately 40% missing data. Several analyses to account for missing data have been conducted and results from these additional analyses were consistent with results of original analysis.
NCT01109576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7460-P|Workshops for Veterans With Vision and Hearing Loss|Pilot Study: Self Management Groups for Veterans With Dual Sensory Loss|DSLW|VA Office of Research and Development|No|Completed|November 2011|August 2013|Actual|July 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|55 Years|N/A|No|||August 2015|August 28, 2015|April 19, 2010||No||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01109576||123296|The sample size was too small to draw any definitive conclusion from the data.
NCT01110148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917169-1|Use of Portable Technology in Patient Education of Shave/Punch Biopsies|Use of MP3 Portable Technology in Patient Education and Informed Consent of Shave and Punch Biopsies||University of California, Davis|No|Completed|July 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|84|||Both|18 Years|N/A|No|||April 2010|April 23, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01110148||123252|
NCT01109836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUK-2010-001|Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke|ASPIS-Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke|ASPIS|Danube University Krems|Yes|Completed|June 2010|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|202|||Both|40 Years|80 Years|No|||June 2010|January 12, 2015|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01109836||123276|
NCT01109849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH083692|Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth|Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth||Florida International University|Yes|Active, not recruiting|November 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|230|||Both|5 Years|12 Years|No|||July 2015|July 22, 2015|April 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01109849||123275|
NCT01110499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210961-002|Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|||Allergan|No|Completed|June 2010|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|163|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|April 23, 2010|Yes|Yes||No|May 31, 2013|https://clinicaltrials.gov/show/NCT01110499||123225|
NCT01110135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7176|Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma|A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)||University of Washington|No|Completed|August 2010|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110135||123253|
NCT01111097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-2010|Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors|Phase 1, Open-Label, Single-Arm, Clinical and Metabolomics Study of Dichloroacetate (DCA) in Adults With Recurrent Malignant Brain Tumors||University of Florida|Yes|Completed|April 2010|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|21 Years|90 Years|No|||September 2015|September 18, 2015|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111097||123179|
NCT01111071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER-09-03|Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study|Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study||University College, London|Yes|Active, not recruiting|April 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|300000|||Both|30 Years|N/A|No|Non-Probability Sample|Patients admitted with acute coronary syndrome to acute hospitals in England and Wales        participating in the Myocardial Ischaemia National Audit Project (MINAP)|December 2011|December 19, 2011|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01111071||123181|
NCT01111396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK153052009|Longitudinal Investigation of Hippocampal Function and Morphology in Acute Lymphatic Leukemia (ALL) Patients Treated With Chemotherapy|Longitudinal Investigation of Hippocampal Function and Morphology in ALL Patients Treated With Chemotherapy: A Monocentric, Interdisciplinary Pilot Study|HIF-ALL|Technische Universität Dresden|No|Recruiting|February 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|40 Years|No|Non-Probability Sample|Consecutive patients of the Department of Internal Medicine at the Dresden University of        Technology hospital, who are initially diagnosed of acute lymphatic leukemia (ALL) and        included into the GMALL 2003 chemotherapy study. All treatment procedures and outcome        measurements of the GMALL 2003 study (most importantly also the safety outcome measures)        are regularly performed in the sub population of the present sub study. Inclusion and        exclusion criteria are given below.|April 2010|April 26, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01111396||123156|
NCT01111708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Close Rectal - IPAA|Clinical Outcome After Close Rectal Ileo Pouch Anal Anastomosis for Colitis Ulcerosa(CU)|Clinical Outcome After Close Rectal Ileo Pouch Anal Anastomosis for Colitis Ulcerosa Compared to the Ileo Neo Rectal Anastomosis and the Ileo Pouch Anal Anastomosis|CR-IPAA|University Medical Center Nijmegen|Yes|Recruiting|April 2010|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2010|April 26, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111708||123132|
NCT01111721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1433|Project POWER, Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners|Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners|POWER|University of North Carolina, Chapel Hill|No|Completed|March 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|598|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 13, 2013|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01111721||123131|
NCT01111032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treadmill Comparison|Comparison of Two-treadmill Test Protocols to Evaluate Endurance in People With Cancer|Comparison of Two-treadmill Test Protocols to Evaluate Endurance in People With Cancer.||McMaster University|No|Completed|May 2011|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|16 Years|N/A|No|Non-Probability Sample|Adult well cancer survivors|September 2013|September 29, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111032||123184|
NCT01111045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-OA-002|Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee|A Phase 2, Double Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee||Stryker Biotech|Yes|Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|355|||Both|40 Years|N/A|No|||January 2012|January 30, 2012|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111045||123183|
NCT01111058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-266-B|Everolimus Versus Placebo in Head and Neck Cancer|Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)||University of Chicago|No|Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111058||123182|
NCT01112488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPS|Patient Engagement Program for Stroke - Pilot Study|Patient Engagement Program for Stroke - Pilot Study|PEPS|Kowloon Hospital, Hong Kong|Yes|Not yet recruiting|May 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|N/A|N/A|No|||March 2010|April 27, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01112488||123072|
NCT01112774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p000190|Application of Transcranial Direct Current Stimulation (tDCS) in Patients With Chronic Pain After Spinal Cord Injury|Investigation of the Mechanisms of Transcranial Direct Current Stimulation of Motor Cortex for the Treatment of Chronic Pain in Spinal Cord Injury||Spaulding Rehabilitation Hospital|No|Terminated|April 2010|||August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 20, 2010||No|Funding ended|No||https://clinicaltrials.gov/show/NCT01112774||123050|
NCT01108432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122286|DPBRN Hygienists Internet Quality Improvement in Tobacco Cessation (HiQuit)|Hygienists Internet Tobacco Cessation Study (HiQuit)|HiQuit|Dental Practice-Based Research Network|Yes|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 24, 2013|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108432||123384|
NCT01102686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013660|Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)|Proposed Investigator-Initiated Clinical Trial of Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)||The Hospital for Sick Children|Yes|Completed|August 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|17 Years|N/A|No|||February 2012|February 22, 2012|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01102686||123825|
NCT01103167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|korea_bcm_hd|Body Composition Monitor in Hemodialysis Patients|The Association Between Body Composition and Biomarkers in Hemodialysis Patients||Gachon University Gil Medical Center|No|Recruiting|April 2010|December 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|80 Years|No|||April 2010|April 13, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01103167||123788|
NCT01109888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12101967|Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)|Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian During Controlled Ovarian Stimulation(COH) for In Vitro Fertilisation(IVF)||Wolfson Medical Center|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|N/A|1||Actual|0|||Female|18 Years|35 Years||||April 2010|June 15, 2014|April 22, 2010||No|there was no percipitant enrolled|No||https://clinicaltrials.gov/show/NCT01109888||123272|
NCT01109901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213|Comparison of Effect of Anterior Subcutaneous and Submuscular Transposition on Cubital Tunnel Syndrome|Study of Surgical Methods for Cubital Tunnel Syndrome||Isfahan University of Medical Sciences|Yes|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|April 22, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01109901||123271|
NCT01109329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 270|Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults|Phase 1 Inpatient Study of rHMPV-SHs, a Human Metapneumovirus Challenge Strain, Administered to Healthy Adults in Isolation||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2012|December 31, 2012|April 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01109329||123315|
NCT01109589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP-UIO-2010|Respiratory Tract Infections and Prescription Drugs in Children and in Pregnancy|Respiratory Tract Infections and Prescription Drugs in Children and in Pregnancy - a Study From Norwegian General Practice||University of Oslo|No|Completed|December 2004|April 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60000|||Both|N/A|60 Years||Non-Probability Sample|Contacts with general practitioner in different parts of Norway. Women aged 15-60 yrs and        children 0-2 yrs are selected.|April 2010|April 22, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109589||123295|
NCT01110161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan-2009-04|Technical Validation of Lunar iDXA Visceral Fat Tool|Technical Validation of Lunar iDXA Visceral Fat Tool||GE Healthcare|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|148|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Ages 18 and up, BMI between 18.5 and 40|December 2010|December 6, 2010|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01110161||123251|
NCT01110486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-944|ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors||AbbVie|No|Completed|March 2010|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|102|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|March 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110486||123226|
NCT01110512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLANEO0210|Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Not yet recruiting|October 2010|March 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||April 2010|October 26, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01110512||123224|
NCT01111448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-TEMDS1-042|Temsirolimus in Myelodysplastic Syndrome (MDS)|Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study|TEMDS|Technische Universität Dresden|Yes|Terminated|April 2010|June 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|April 23, 2010||No|Unfavourable Risk-Benefit-Ratio|No||https://clinicaltrials.gov/show/NCT01111448||123152|
NCT01111461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-204|Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression|An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy||Eisai Inc.|No|Active, not recruiting|February 2010|||May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Female|18 Years|N/A|No|||January 2015|January 26, 2015|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111461||123151|
NCT01110811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2009-10|Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD)|A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD: the TIF vs. Sham Study||EndoGastric Solutions|No|Active, not recruiting|April 2010|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110811||123201|
NCT01110798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000671070|J-Pouch Colorectal Anastomosis or Straight Colorectal Anastomosis in Treating Patients With Rectal Cancer Who Have Undergone Surgery to Remove the Tumor|Colonic J-Pouch Reconstruction Versus Straight Colorectal Anastomosis After Low Anterior Resection for Rectal Cancer: Impact on Anastomotic Leak, Bowel Function and Quality of Life||National Cancer Institute (NCI)||Recruiting|October 2009|||October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|N/A|No|||February 2011|September 16, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110798||123202|
NCT01111084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP24846|A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α|Prospective Multi-centre Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α|P450|Merck KGaA||Completed|March 2004|June 2005|Actual|June 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|410|Samples With DNA|Serum|Female|N/A|N/A|No|Non-Probability Sample|Female subjects who were infertile due to anovulation undergoing OI treatment with        follitropin alpha prescribed in accordance with the standard practice and in accordance        with the technical specifications.|April 2010|July 15, 2014|April 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01111084||123180|
NCT01111409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-08-013|A Pilot Study to Evaluate the Clinical Effectiveness and Safety of the VFIX Device as Treatment for Apical Prolapse|A Prospective, Multi-Centre Pilot Study to Evaluate the Clinical Effectiveness and Safety of the VFIX Device as Treatment for Apical Prolapse||Ethicon, Inc.|No|Completed|March 2010|June 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||December 2011|October 10, 2014|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111409||123155|
NCT01111422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ewha 219-3-40|Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients|A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis||Ewha Womans University|No|Recruiting|March 2010|December 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|70 Years|No|||March 2010|April 26, 2010|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01111422||123154|
NCT01108471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04082010-5622|Non-Invasive Measurement of Hemoglobin (Using Pulse Co-Oximetry) in Patients Undergoing Elective Cesarean Delivery|Study Comparing Non-Invasive Measurement of Hemoglobin (Using Pulse Co-Oximetry) With Laboratory Measurement in Patients Undergoing Elective Cesarean Delivery||Stanford University|No|Completed|April 2010|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy pregnant patients undergoing elective cesarean delivery under neuraxial anesthesia|August 2011|August 25, 2011|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01108471||123381|
NCT01112215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008934-35|Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations|Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations||Hospital Universitari Vall d'Hebron Research Institute|Yes|Active, not recruiting|December 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||March 2015|March 31, 2015|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112215||123093|
NCT01112228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clinical Obesity Staging Tools|Clinical Obesity Staging Tools|Assessing Clinical Staging Tools for Tracking the Impacts of Obesity on Individuals|COST|Imperial College London||Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|16 Years|N/A|No|Non-Probability Sample|Individuals with BMI > 40 or >35 and a obesity-related medical condition|September 2010|September 17, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112228||123092|
NCT01112501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5031339|SPECT/CT in the Diagnosis of Dementia|SPECT/CT in the Diagnosis of Dementia|DEMSPET|Kuopio University Hospital||Completed|September 2006|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|82|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects with possible/suspected early dementia|April 2010|April 27, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112501||123071|
NCT01112787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114571|A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Cumulative Irritation Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers||GlaxoSmithKline|No|Completed|March 2010|July 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112787||123049|
NCT01108445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020714|Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma|A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)|ASPEN|Duke University|Yes|Completed|September 2010|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||August 2015|December 10, 2015|April 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01108445||123383|
NCT01108458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0010|A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma|A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma||Stanford University|Yes|Terminated|July 2010|March 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2011|November 6, 2012|April 20, 2010|Yes|Yes|Extreme toxicity of Pertuzumab and Erlotinib combination|No||https://clinicaltrials.gov/show/NCT01108458||123382|
NCT01134029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL089444|Planned CORR: Planned Care for Obesity and Risk Reduction|Planned CORR: Planned Care for Obesity and Risk Reduction|Planned CORR|University of California, San Diego|No|Completed|November 2009|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|262|||Both|25 Years|70 Years|No|||December 2014|December 3, 2014|February 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01134029||121429|
NCT01109628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1002-1|Protein Supplementation to Promote Muscle Protein Anabolism in Frail Elderly People|Protein Supplementation to Promote Muscle Protein Anabolism in Frail Elderly People|ProMuscle|Wageningen University|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|65 Years|N/A|No|||January 2012|January 30, 2012|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01109628||123292|
NCT01109641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-PINGEP|PhrenIc Nerve mappinG and Stimulation EP Catheter Study: PING-EP Study|PhrenIc Nerve mappinG and Stimulation EP Catheter Study: PING-EP Study|PING-EP|Medtronic Italia|No|Completed|February 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2010|October 6, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109641||123291|
NCT01109602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-195|Strength, Flexibility, And Balance Therapy After Stroke|Yoga as a Complex Intervention for Vets With Stroke|HEALTHY|VA Office of Research and Development|No|Completed|July 2010|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|April 2, 2010||No||No|October 5, 2015|https://clinicaltrials.gov/show/NCT01109602||123294|
NCT01109862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019-10-WOMC|Prospective Randomized Comparison of Bipolar Hemiarthroplasty and Total Hip Arthroplasty With Large Femoral Heads for the Treatment of Displaced Intracapsular Femoral Neck Fractures in the Elderly|Prospective Randomized Comparison of Bipolar Hemiarthroplasty and Total Hip Arthroplasty With Large Femoral Heads for the Treatment of Displaced Intracapsular Femoral Neck Fractures in the Elderly||Wolfson Medical Center||Recruiting|April 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|70 Years|90 Years|No|||April 2010|June 16, 2011|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109862||123274|
NCT01109875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Screening for Fabry Disease Among Young Stroke Patients in an Israeli Stroke Clinic|||Wolfson Medical Center||Active, not recruiting|May 2010|||December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|55 Years|No|||June 2014|June 11, 2014|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01109875||123273|
NCT01111110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 103-2008|Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm|Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm||University of Florida|No|Completed|May 2008|March 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|65 Years|No|||May 2012|May 14, 2012|April 23, 2010||No||No|January 10, 2012|https://clinicaltrials.gov/show/NCT01111110||123178|Nocturnal asthma model is a very sensitive model, but very labor intensive and to get more completed subjects, we might need to do multicenter trial
NCT01111123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1061 0001 01 DE|Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis|A Randomized, Double-blind Study to Evaluate the Efficacy of Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis.||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||40|||Both|18 Years|N/A|No|||April 2010|April 23, 2010|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111123||123177|
NCT01111474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|odf2008|Cyanoacrylate and Laser and Dentin Sensitivity|Effectiveness of Cyanoacrylate and of the Laser in the Treatment of Cervical Dentin Sensitivity|Cyano-laser|Federal University of São Paulo|Yes|Completed|August 2008|February 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|17|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2008|April 26, 2010|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01111474||123150|
NCT01101867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novo Nordisk xxxx|Prandial Insulin Dosing in Hospitalized Patients|Prandial Insulin Dosing Using the Carbohydrate Counting Technique in Hospitalized Patients With Diabetes|ICHO|Ohio State University|No|Completed|June 2010|March 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|80 Years|No|||July 2013|July 2, 2013|April 8, 2010|Yes|Yes||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01101867||123888|
NCT01111734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909M72855|Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents|N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2011|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111734||123130|
NCT01111747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0162/08|Patellar Tendon Regeneration With Platelet-rich Plasma|Regeneration of the Patellar Tendon After Harvesting Its Central Third With Platelet-rich Plasma. Prospective and Randomized Study.||University of Sao Paulo General Hospital|No|Completed|November 2008|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|N/A|45 Years|No|||April 2010|March 13, 2012|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111747||123129|
NCT01111435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spasticity2010|A Prospective Study of Spasticity in Individuals With Multiple Sclerosis|A Prospective Study of Spasticity in Individuals With Multiple Sclerosis in Transition From Interferon to Glatiramer Acetate (Copaxone®)||Fraser, Cira, Ph.D., RN, ACNS-BC|No|Active, not recruiting|April 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with Multiple Sclerosis living in the community|March 2012|March 2, 2012|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111435||123153|
NCT01112020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10-0088|Components of Chlorhexidine Gluconate Dressing|Components & Tolerability of Chlorhexidine Gluconate Dressing Patch Compared to BioPatch & Tegaderm Chlorhexidine Gluconate Securement Dressing After Application to Healthy Subjects Over a 7-day Period||CareFusion|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 21, 2013|April 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01112020||123108|
NCT01112241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOS-01|Bronchodilator Responsiveness in Obliterative Bronchiolitis|Acute Bronchodilator Responsiveness in Obliterative Bronchiolitis (OB) Following Hematopoietic Stem Cell Transplantation|BD-OB|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|N/A|N/A|No|||April 2010|February 28, 2011|April 27, 2010||No||No|November 30, 2010|https://clinicaltrials.gov/show/NCT01112241||123091|
NCT01112007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V99C1-153|Accomplices of Insulin Resistance in Prehypertension: Aldosterone?|Searching for Accomplices in the Transgression of Insulin Resistance in Prehypertension: Aldosterone?||Taipei Veterans General Hospital, Taiwan|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|43|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with prehypertension, that is, individuals with systolic blood pressure (BP) in        the range of 120-139 mmHg or diastolic BP between 80-89 mmHg.|December 2011|December 5, 2011|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112007||123109|
NCT01109095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24487 - HERT GBM|CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM|Administration of HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells Ins Patients With Glioblastoma Multiforme (HERT-GBM)|HERT-GBM|Baylor College of Medicine|Yes|Active, not recruiting|October 2010|November 2028|Anticipated|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||January 2016|January 28, 2016|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01109095||123333|
NCT01108484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIAFYS-2010-01|Program of Exercise, Diet and Control of Psychological Stress in Cancer Survivors|Evaluation of the Effects of Exercise, Diet and Control of Psychological Stress in Cancer Survivors|EDICOS|Grupo de Investigación en Actividad Física y Salud|Yes|Active, not recruiting|March 2010|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 10, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108484||123380|
NCT01108497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSHEM0001|Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia|Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia||Stanford University||Recruiting|July 2001|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|bone marrow|Both|N/A|18 Years|No|Non-Probability Sample|All children who present at Packard hospital with a new diagnosis or relapse of acute        leukemia will be eligible.|October 2013|October 28, 2013|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108497||123379|
NCT01108510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-216-0114|Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults||Gilead Sciences|Yes|Completed|April 2010|April 2015|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|698|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|April 20, 2010|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT01108510||123378|
NCT01109342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 283/WRAIR 1631|Extended Follow-Up of Participants in Preventive HIV Vaccine Studies in Uganda|Extended Follow-Up for Participants in VRC HIV-1 Recombinant Adenovirus-5 Vector Vaccine Studies in Uganda||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||Samples With DNA|Blood samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People who received either vaccine or placebo in two previous trials:          1. RV 156A/WRAIR 1078A "A Phase I Clinical Trial To Evaluate The Safety And             Immunogenicity Of A Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine,             VRC-HIVADV014-00-VP Administered Alone Or Administered As A Boost To A Multiclade             HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, In Uninfected Adult Volunteers In             Uganda," or          2. RV 172/WRAIR 1218 "A Phase I/II Clinical Trial To Evaluate The Safety And             Immunogenicity Of A Multiclade HIV-1 DNA Plasmid Vaccine, VRCHIVDNA016-00-VP, Boosted             By A Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP,             In HIV Uninfected Adult Volunteers In East Africa." (NCT00123968)|August 2013|August 28, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109342||123314|
NCT01134315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-053|Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice|A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice||AbbVie|No|Terminated|June 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|61|||Both|N/A|16 Years|No|Non-Probability Sample|This was a multicenter, United States only study of pediatric (0 to 16 years) males and        females receiving peritoneal dialysis, treated in a routine clinical setting. Patients        were recruited from private nephrology practices or hospitals.|May 2013|May 17, 2013|May 28, 2010|No|Yes|Terminated after FDA agreement.|No|May 17, 2013|https://clinicaltrials.gov/show/NCT01134315||121407|
NCT01100151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK37-003|ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)|A Phase 2 Study of the Effects of RDC-1036 Administered to Subjects With Opioid-induced Constipation During Treatment With Opioids for Chronic Pain||Alkermes, Inc.|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||August 2011|August 18, 2011|April 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100151||124018|
NCT01110174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917637|Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms|Assessing Response to Neoadjuvant Chemotherapy With Dedicated Breast High Definition PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms|ENIGMA|University of California, Davis|No|Recruiting|March 2010|April 2013|Anticipated|April 2013|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Female|18 Years|N/A|No|||September 2012|September 18, 2012|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110174||123250|
NCT01110525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00015|A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives|A Phase I, Double-blind, Randomised, Placebo-controlled, Two-cycle Crossover, Drug-drug Interaction Study to Investigate the Effects of AZD1981 Tablets 400 mg Twice Daily on the PK and PD of Oral Contraceptives in Healthy Female Volunteers||AstraZeneca|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|April 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110525||123223|
NCT01110538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000387|The Massachusetts General Hospital Optical Coherence Tomography Registry|The Massachusetts General Hospital Optical Coherence Tomography Registry||Massachusetts General Hospital|No|Active, not recruiting|August 2010|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2714|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have intracoronary OCT imaging performed during cardiac catheterization are        eligible for this registry. Subjects may be identified prior to or after cardiac        catheterization and OCT imaging.|April 2015|April 6, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110538||123222|
NCT01101308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1013|A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities|A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets Manufactured at the Totowa, NJ Facility to Oxycodone Tamper Resistant (OTR) 10-mg Tablets Manufactured at the Wilson, NC Facility||Purdue Pharma LP|No|Completed|July 2008|January 2009|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|55|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 17, 2010|April 8, 2010|Yes|Yes||No|April 14, 2010|https://clinicaltrials.gov/show/NCT01101308||123930|
NCT01101321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1015|To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities|A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets Manufactured at the Totowa, NJ Facility to Oxycodone Tamper Resistant (OTR) 80-mg Tablets Manufactured at the Wilson, NC Facility||Purdue Pharma LP|No|Completed|June 2008|November 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|58|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|April 8, 2010|Yes|Yes||No|April 14, 2010|https://clinicaltrials.gov/show/NCT01101321||123929|
NCT01101334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-U204|Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer|Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy||Daiichi Sankyo Inc.|No|Completed|March 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|April 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101334||123928|
NCT01101347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-03|A Feasibility Study of the Surpass Aneurysm-Embolization System in Intracranial Arteries|A Feasibility Study of the Surpass Aneurysm-Embolization System in Intracranial Arteries||Surpass Medical Ltd.|Yes|Withdrawn||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||November 2010|November 26, 2010|April 8, 2010||No|Product received Approval for Commercial Distribution|No||https://clinicaltrials.gov/show/NCT01101347||123927|
NCT01101633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-088|The Effect of Sodium Alginate on Appetite Sensation|The Effect of Sodium Alginate Containing Beverage on Appetite and Body Weight Regulation|B247Algobes|University of Copenhagen|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||August 2009|April 9, 2010|August 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01101633||123906|
NCT01101659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017161|Ketamine Challenge Study With JNJ-40411813|A Double-Blind, 2-Way Crossover Study to Investigate the Effects of JNJ-40411813 on Ketamine-Induced Alterations in Neuropsychiatric Performance||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2010|July 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|4||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101659||123904|
NCT01102153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COOL-NSE|Neuron Specific Enolase (NSE) as Outcome Parameter of Cooling Therapy After Survived Sudden Cardiac Death|NSE as an Outcome Predictor of Therapeutical Hypothermia After Survived Sudden Cardiac Death||University of Leipzig|No|Completed|April 2008|January 2010|Actual|January 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|108|||Both|18 Years|N/A|No|Probability Sample|Patients who survived sudden cardiac arrest and where treated with cooling-therapies|January 2010|April 12, 2010|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102153||123866|
NCT01112033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLVRA1|Biliverdin Reductase A in Chronic Hepatitis C Virus Infection|Biliverdin Reductase A in Chronic Hepatitis C Virus Infection||Charles University, Czech Republic|No|Completed|June 2010|June 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|113|Samples With DNA|peripheral blood, liver biopsy|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Estimated enrollment: BLVRA expression study: 50 - 100 HCV patients 50 healthy volunteers        Polymorphisms of BLVRA study: 300 HCV patients|August 2015|August 5, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01112033||123107|
NCT01112254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGR IRCIS 1503|Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer|Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer|IRCIS|Gustave Roussy, Cancer Campus, Grand Paris||Completed|February 2010|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Female|18 Years|80 Years|No|||January 2016|January 25, 2016|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112254||123090|
NCT01112267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016222|An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain|A Randomized, Placebo-Controlled, Parallel Group, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Tramadol HCl/Acetaminophen Extended Release Tablet in Subjects With Chronic Low Back Pain||Janssen Korea, Ltd., Korea|No|Completed|May 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|248|||Both|25 Years|75 Years|No|||June 2013|June 20, 2013|April 1, 2010|Yes|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT01112267||123089|
NCT01102712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vapor-OUS|Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction|Evaluation Study of Unilateral Bronchoscopic Thermal Vapor Ablation (BTVA) in Patients With Heterogeneous Emphysema and Upper Lobe Predominance|BTVA|Uptake Medical Corp|No|Completed|November 2009|August 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|40 Years|75 Years|No|||February 2012|February 21, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102712||123823|
NCT01112514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-398|Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract|A Pilot Study of Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract||Massachusetts General Hospital|Yes|Completed|February 2010|April 2013|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|April 27, 2010||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT01112514||123070|
NCT01112527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-468|PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma|An Open-Label, Phase 2 Trial of Orally Administered PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (GBM)||Massachusetts General Hospital|Yes|Active, not recruiting|April 2010|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112527||123069|
NCT01108796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.579|Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan|Additional Effect of a Life Style Program on Antihypertensive Treatment With Telmisartan||Boehringer Ingelheim||Completed|September 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1856|||Both|18 Years|N/A|No|Probability Sample|Patients with hypertension|February 2014|February 28, 2014|March 11, 2010||||No|September 1, 2011|https://clinicaltrials.gov/show/NCT01108796||123356|
NCT01108809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|502.592|Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients|Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg; 80/25 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients||Boehringer Ingelheim||Completed|April 2010|||January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|295|||Both|18 Years|N/A|No|Probability Sample|Patients with arterial hypertension|February 2014|February 28, 2014|April 19, 2010||||No|July 4, 2012|https://clinicaltrials.gov/show/NCT01108809||123355|
NCT01103726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241013|Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects|Evaluation Of Regional Glucose Metabolism In Striatum As Measured By [18f]-Fluorodeoxyglucose Positron Emission Tomography Following Single Oral Dose Administration Of PF-02545920 In Healthy Subjects||Pfizer|Yes|Completed|May 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 11, 2011|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01103726||123745|
NCT01103739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1351007|To Explore The Potential For PF-04531083 To Effect The Blood Concentrations Of Simvastatin And Its Main Acid Metabolite Following Co-Administration Of Both Medications|A Phase 1, Open Label, Fixed Sequence Study To Investigate The Effect Of Multiple Doses Of PF-04531083 On Simvastatin And Simvastatin Acid Pharmacokinetics Following Single Dose Of Simvastatin in Healthy Volunteers||Pfizer|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 3, 2010|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01103739||123744|
NCT01109355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Berg 01|Positive and Expiratory Pressure and Hemorrhagic Stroke|Effect of Positive End Expiratory Pressure on Cerebral Perfusion Pressure in Adult Patients With Hemorrhagic Stroke||Universidade Federal de Pernambuco|Yes|Completed|January 2008|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|25|||Both|42 Years|86 Years|No|||December 2009|April 22, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01109355||123313|
NCT01108822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-157|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2010|||||N/A|N/A|N/A||||||||||||||June 30, 2011|April 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01108822||123354|
NCT01134627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 26588|Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]|A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis|RECYCLINE|Merck KGaA|Yes|Terminated|February 2006|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|55 Years|No|||December 2013|December 2, 2013|May 28, 2010|No|Yes||No|August 2, 2012|https://clinicaltrials.gov/show/NCT01134627||121383|
NCT01134640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESST|A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment|A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment||Merck KGaA|No|Completed|January 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|286|||Both|N/A|N/A|No|Non-Probability Sample|EGFR expressing, KRAS wild-type subjects with metastatic colorectal cancer, who are        indicated for Erbitux treatment according to the nationally authorized label (in        combination with irinotecan, metastatic colorectal cancer after failure of        irinotecan-including cytotoxic therapy)|May 2014|May 8, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01134640||121382|
NCT01101048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080389|An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density||Amgen|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|45 Years|75 Years|No|||October 2012|October 15, 2012|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101048||123950|
NCT01100736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/W/CRC/01|Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)|Characterisation of the Role of ETA and ETB Receptors in Regulating Plasma ET-1 and the Vasodilator Response to ET-3 in Man||University of Edinburgh|Yes|Completed|January 2009|January 2010|Actual|September 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01100736||123974|
NCT01101009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSE- SEV-02-09|Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure|Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-||Daiichi Sankyo Inc.|No|Completed|April 2010|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|486|||Both|40 Years|80 Years|No|||January 2013|January 14, 2013|April 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101009||123953|
NCT01101022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-403|Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-controlled, Parallel Group Study Evaluating the Safety and Efficacy of SPD489 on Executive Function (Self-Regulation) Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Reporting Clinically Significant Impairment of Real-World Executive Function Behavior.||Shire|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|55 Years|No|||January 2014|January 7, 2014|April 7, 2010|Yes|Yes||No|September 6, 2011|https://clinicaltrials.gov/show/NCT01101022||123952|
NCT01101035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67_301|Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities|A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities|CARES|Takeda|Yes|Recruiting|April 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|7500|||Both|50 Years|N/A|No|||August 2015|August 11, 2015|April 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101035||123951|
NCT01101360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC75761|Port Wine Stains Treatment Matrix RF Study|Evaluation of Fractional Radiofrequency (Matrix RF) Stand Alone and Combined With PDL Treatment on Port Wine Stains||Syneron Medical|No|Completed|March 2010|||September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||November 2014|November 30, 2014|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01101360||123926|
NCT01101893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113392|A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects|A Phase I, Open Label, Single Sequence, Drug Interaction Study Evaluating Plasma GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects.||GlaxoSmithKline|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 22, 2011|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101893||123886|
NCT01101373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00851|Treatment of Severe Depressive Illness by Targeted Brain Surgery|Bilateral Anterior Capsulotomy For Intractable Depression||University of British Columbia|No|Completed|October 2000|April 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|18 Years|75 Years|No|Non-Probability Sample|All subjects who received BAC for treatment resistant depression between 2000 and 2009|April 2010|April 8, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101373||123925|
NCT01101646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014827|A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers|A Phase 1, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Rabeprazole Phase 3 Pediatric Bead Formulation Versus the Phase 1 Pediatric Bead Formulation and Effect of Food on the Pharmacokinetics of Rabeprazole Phase 3 Pediatric Bead Formulation in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 26, 2014|March 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101646||123905|
NCT01102725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-09-39|Assessing Infectious Risk and Visceral Closure in Natural Orifice Translumenal Endoscopic Surgery (NOTES)|The Challenge of Assessing Infectious Risk and Visceral Closure in NOTES: A Prospective Study Examining Routine Colorectal Surgery as a Model in Humans|NOTES|University Hospital Case Medical Center|Yes|Completed|April 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Our institution performed over 200 laparoscopic colon resections in the past year and        should have no trouble accruing the number of patients required for the study. Subjects        will be recruited until 90 patients have been enrolled. We will not specifically recruit        or specifically exclude potential patients on the basis of their race or on the basis of        our study demographics to date. No vulnerable subjects will be recruited into this study        as this study will prolong the surgery by approximately 15 minutes which can be        significant in the vulnerable population such as pregnant women and minors. Potential        subjects who meet inclusion criteria will be approached for possible participation during        a pre-operative clinic visit or on the day of surgery in the pre-operative area.|December 2014|December 12, 2014|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102725||123822|
NCT01101880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7144|Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm|Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm||University of Washington|No|Active, not recruiting|August 2010|||June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|64 Years|No|||December 2015|December 28, 2015|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101880||123887|
NCT01102452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPB-R-203-02|A Study to Evaluate the Blood Glucose Regulation and Safety of PPB-R-203-02 Based Noodle Versus Commercially Available Wet Noodle in Patients With Diabetes|A Randomized, Two-Regimen, Crossover, Comparative Study to Evaluate the Blood Glucose Regulation and Safety of PPB-R-203-02 Based Noodle Versus Commercially Available Wet Noodle in 24 Patients With Diabetes||Pharma Power Biotec Co., Ltd.||Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|24|||Both|20 Years|65 Years|No|||April 2010|December 24, 2012|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102452||123843|
NCT01102465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOHY-T100/25-PVFD-2|Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide Tablets 100 mg/25 mg Under Fed Conditions||Roxane Laboratories|No|Completed|February 2005|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 12, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102465||123842|
NCT01102699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSF-DM|Bone Marrow Progenitor Cell Mobilization in Diabetes|Bone Marrow Responsiveness to Pharmacologic Mobilization of Progenitor Cells in Diabetic Versus Non-diabetic Patients|GCSF-DM|University of Padova|No|Completed|June 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|48|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102699||123824|
NCT01099293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-100-09/10-1|Cerebrovascular Reactivity in Hepatic Encephalopathy|Correlation Between Cerebrovascular Reactivity and Hepatic Encephalopathy in Patients With Cirrhosis||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|March 2010|September 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|90|Samples Without DNA|1. Patients with cirrhosis without hepatic encephalopathy.        2. Patients with cirrhosis and minimal hepatic encephalopathy.        3. Patients with cirrhosis and hepatic encephalopathy stage 1.        4. Healthy subjects willing to participate.|Both|18 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population from which the cohorts will be selected are from a hospital care        population.        Control group will be selected from the health personal by invitation to volunteer.|May 2012|May 17, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01099293||124083|
NCT01103193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/493|Nitrous Oxide - Sevoflurane-Remifentanil Interaction|Nitrous Oxide - Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance.||University Hospital, Ghent|No|Terminated|February 2010|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|4|||Both|18 Years|60 Years|No|||May 2012|May 7, 2012|March 19, 2010||No|Need of change to the protocol. As the Principal Investigator has left the University Hospital    Ghent end 2010, the change of protocol was never submitted.|No||https://clinicaltrials.gov/show/NCT01103193||123786|
NCT01112800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARCI|Markers of Anthracycline-Related Cardiac Muscle Injury|Markers of Anthracycline-Related Cardiac Muscle Injury||St. Jude Children's Research Hospital|No|Withdrawn|May 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|A blood sample will be collected at baseline, prior to and at the end of each doxorubicin      infusion (48- or 72-hour) and following completion of chemotherapy for osteosarcoma, ESFT,      rhabdomyosarcoma or intermediate and high-risk non-rhabdomyosarcoma soft tissue      sarcomas.cTn-T and NT-BNP will be measured at baseline, prior to and at the end of each      doxorubicin infusion (48- or 72-hour) and following completion of chemotherapy for      osteosarcoma, ESFT, rhabdomyosarcoma or intermediate and high-risk non-rhabdomyosarcoma soft      tissue sarcomas.|Both|N/A|21 Years|No|Non-Probability Sample|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH)        between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT,        rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas        whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375        mg/m2.|June 2013|June 18, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112800||123048|
NCT01112813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Li-2010|The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study|The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study||Sunnybrook Health Sciences Centre|Yes|Recruiting|April 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|40 Years|N/A|No|||November 2015|November 26, 2015|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112813||123047|
NCT01099527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02-041|A Trial of RAD001/Capecitabine in Refractory Gastric Cancer|A Phase I/II Trial of RAD001/Capecitabine in Refractory Gastric Cancer||Samsung Medical Center|No|Completed|October 2009|December 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099527||124065|
NCT01099540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-090|Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor|Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor||Samsung Medical Center|No|Completed|April 2010|March 2013|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099540||124064|
NCT01108835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/Ko/2010/001|A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease|A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease||Chinese University of Hong Kong|No|Completed|April 2010|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|40 Years|90 Years|No|||February 2015|February 2, 2016|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01108835||123353|
NCT01134653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-00110|A Comparison of Early Mobilization Versus Traditional Treatment for Acute Ankle Sprains.|Efficacy of Stretch Band Ankle Traction Technique in the Treatment of Acute Ankle Sprains.||Nationwide Children's Hospital|No|Completed|January 2010|February 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|8 Years|21 Years|No|||February 2015|February 2, 2015|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134653||121381|
NCT01100437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-01-09-111|Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients|A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA¿||Pfizer|No|Terminated|April 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|14|||Both|21 Years|N/A|No|||November 2011|July 5, 2012|April 7, 2010|Yes|Yes|See termination reason in detailed description.|No|February 27, 2012|https://clinicaltrials.gov/show/NCT01100437||123997|Sponsor terminated study early on 10-Mar-2011.
NCT01100749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Geno3-Demographics Study|Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada|Demography, Clinical Characteristics, Metabolic Status, Viral Subtype and Genetics of Infection With Hepatitis C Genotype 3 in Canada||University Health Network, Toronto|No|Terminated|February 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|Samples With DNA|Saliva samples will be collected for DNA extraction. Also, blood specimens will be collected      for genotype subtype analysis and HOMA score calculation.|Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects across Canada with chronic hepatitis C, genotype 3 infection who are        treatment naïve.|May 2015|May 27, 2015|April 7, 2010||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT01100749||123973|
NCT01101906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-206|A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC|A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib||Astellas Pharma Inc|Yes|Terminated|October 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|April 8, 2010|Yes|Yes|Company decided not to pursue the development of this drug in this patient population at this    time|No||https://clinicaltrials.gov/show/NCT01101906||123885|
NCT01101919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921065|CP-690,550 Pharmacokinetics In Healthy Chinese Subjects|An Open Label, Single And Multiple Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Healthy Chinese Subjects||Pfizer|No|Completed|October 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 11, 2011|April 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101919||123884|
NCT01101685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1V-DEP-CT02-09|Neural Responses and Dysphoria: Modulation by a Pharmacological Probe|Blood Oxygen Level Dependent (BOLD) Responses During Emotional and Cognitive Processing in Dysphoric and Non-dysphoric Participants and Their Modulation by a Pharmacological Probe of Serotonin Function||University of Oxford|No|Completed|February 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|160|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01101685||123902|
NCT01102179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Domain E/09/643|Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease (CKD) Patients in Singapore|Prevalence of Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease Patients in Singapore||National University, Singapore|No|Completed|April 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|196|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with stage 2-5 chronic kidney disease who are not on dialysis|October 2014|November 6, 2014|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102179||123864|
NCT01101945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX1149-PROT202E|Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus|An Open Label, Multi-Center, Long-Term Follow-up Study to Evaluate the Safety of PHX1149T in Subjects With Type 2 Diabetes Mellitus - Extension to Protocol PHX1149-PROT202||Phenomix||Terminated|July 2007|March 2010|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|339|||Both|18 Years|75 Years|No|||August 2010|August 10, 2010|April 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101945||123882|
NCT01102192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thymus in myasthenia gravis|The Role of the Thymus in Myasthenia Gravis|||Charite University, Berlin, Germany|No|Active, not recruiting|August 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|80|Samples Without DNA|Blood sample (serum, plasma), Thymoma tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with and without Mystenia gravis (with and without thymona) and patients with an        indication for a heart or thyroid surgery|January 2016|January 20, 2016|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102192||123863|
NCT01102959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1182/07|The Effectiveness of Photographic Educational Material on Carbohydrate Counting for Adolescents With Diabetes|The Effectiveness of Photographic Educational Material on Carbohydrate Counting for Adolescents With Diabetes||University of Sao Paulo General Hospital|Yes|Recruiting|March 2010|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|11 Years|19 Years|Accepts Healthy Volunteers|||March 2010|April 12, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01102959||123804|
NCT01103219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRENU-1|Nutrition, Growth and Development Among Very Preterm Infants|Nutrition, Growth and Development Among Very Preterm Infants|PRENU|University of Oslo|Yes|Terminated|August 2010|December 2016|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|N/A|N/A|No|||May 2015|May 27, 2015|April 12, 2010||No|A planned interim-analysis revealed increased number of infections in the intervention arm.|No||https://clinicaltrials.gov/show/NCT01103219||123784|
NCT01102166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fabricio 01|Acapella With Nebulization in Normal Subjects|Effect of the Use the Acapella Device in Regional Lung Deposition of Radio-aerosol||Universidade Federal de Pernambuco|Yes|Completed|August 2005|April 2006|Actual|March 2006|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2009|April 12, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102166||123865|
NCT01102478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOHY-T100/25-PVFS-1|Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide Tablets 100 mg/25 mg Under Fasting Conditions||Roxane Laboratories|No|Completed|February 2005|March 2005|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 12, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102478||123841|
NCT01102491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1001/091-003|Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty|The Effect of Multimodal Anti-emetic Protocol on Postoperative Nausea and Vomiting After Total Knee Arthroplasty||Seoul National University Hospital|No|Completed|September 2009|March 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|153|||Both|18 Years|86 Years|No|||June 2012|June 3, 2012|April 8, 2010||No||No|April 26, 2010|https://clinicaltrials.gov/show/NCT01102491||123840|
NCT01103232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGEAH FTR|Cross-Education Of Contralateral Antagonists|Cross-Education Of Muscular Strength: Is Cross-Training Effects Confined To Untrained Contralateral Homologous Muscle||Vakif Gureba Training and Research Hospital|Yes|Completed|January 2008|June 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|April 12, 2010||No||No|August 13, 2011|https://clinicaltrials.gov/show/NCT01103232||123783|This study has small sample size.
NCT01102920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2008-70X-20838-01-3 PÅ|Life-style Changes in Obstructive Sleep Apnea|Health Behaviour Modifications in Obstructive Sleep Apnea. Tailored Behavioural Medicine Strategies to Promote Physical Activity and Weight Loss.||Uppsala University|No|Active, not recruiting|May 2010|July 2014|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||October 2012|October 11, 2012|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102920||123807|
NCT01103206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/172/HP|Evaluation of a Cincalcet Suppression Test|Evaluation of a Parathyroid Hormone Suppression Test With Cinacalcet. Comparison: 1- With the Results of the Intravenous Calcium Suppression Test in Healthy Controls; 2- Between Healthy Controls and Patients With Primary Hyperparathyroidism.||University Hospital, Rouen|Yes|Completed|April 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 15, 2013|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103206||123785|
NCT01103453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC090105CTIL|Change in Executive Function and IADL Using a Virtual Supermarket Environment Among People With MCI|Change in Executive Functions and in Instrumental Activities of Daily Living as a Result of Intervention by Virtual Supermarket Environment Among People With Mild Cognitive Impairment.|EF-VAPS|Carmel Medical Center|Yes|Recruiting|November 2010|May 2012|Anticipated|November 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|60 Years|90 Years|No|||July 2011|July 20, 2011|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01103453||123766|
NCT01099514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02-026|Study of Nilotinib in Metastatic Melanoma With KIT Aberrations|Phase II Study of Nilotinib in Metastatic Melanoma With KIT Aberrations||Samsung Medical Center|No|Completed|August 2009|June 2015|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099514||124066|
NCT01134679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20424|(EASY)-IMProving Adherence to Clopidogrel Trial (IMPACT))|Telephone Contacts to Improve Adherence to Dual Anti-Platelet Therapy Following Drug-Eluting Stent Implantation; A Randomized Controlled-Trial|EASY-IMPACT|Laval University|No|Completed|June 2009|June 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|300|||Both|N/A|N/A|No|||February 2012|February 13, 2012|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01134679||121379|
NCT01100762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040670|Transcranial Direct Current Stimulation (tDCS) and Parkinson's Disease|Can Transcranial Direct Current Stimulation (tDCS)Modulate Protective Stepping and Gait Performance of People With Parkinson's Disease||University of Maryland|Yes|Completed|January 2010|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|85 Years|No|||June 2012|June 13, 2012|March 19, 2010|No|Yes||No|December 19, 2011|https://clinicaltrials.gov/show/NCT01100762||123972|The absence of a placebo CESLimiting the stimulation to only one region of interest (Right M1)Non-random order of interventionCES for only one 20 minute session
NCT01101386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0136|Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis|Evaluation of Sulfobutylether-ß-cyclodextrin Sodium (SBECD) Accumulation and Voriconazole Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy||University of Colorado, Denver|No|Completed|May 2010|November 2012|Actual|November 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Whole blood, serum, urine, effluent fluid from dialysis machine|Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients|May 2014|May 20, 2014|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01101386||123924|
NCT01101061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090378|A Single-dose Study Evaluating AMG 785 in Healthy Postmenopausal Japanese Women|A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Postmenopausal Japanese Women||Amgen||Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||March 2011|March 31, 2011|April 8, 2010||||No||https://clinicaltrials.gov/show/NCT01101061||123949|
NCT01101672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW09-341|Trial for Single Port Versus Conventional Laparoscopic Colectomy|A Randomized Controlled Trial Comparing the Outcomes of Patients Who Undergo Single Port Laparoscopic Colectomy and Conventional Laparoscopic Colectomy for Colonic Neoplasia||The University of Hong Kong|Yes|Recruiting|November 2009|October 2011|Anticipated|July 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|89 Years|No|||April 2010|April 9, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101672||123903|
NCT01101932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0861002|Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers|A Phase 1, Placebo-Controlled, Multiple-Dose Escalation Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04308515 (Part 1), And A Single Dose Pharmacokinetic Assessment Of A PF-04308515 Tablet Formulation (Part 2), In Healthy Volunteers||Pfizer|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101932||123883|
NCT01102205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tastoshashi|Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease|Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease||Vakif Gureba Training and Research Hospital|Yes|Completed|April 2010|October 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|130|Samples Without DNA|after overnight fasting state,venous blood will be taken to obtain serum.speciemens stored      -70 cantigrade celcius untillanalysing.|Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|adult with Hashimoto disease in euthyroid or subclinical hypothyroid state and healthy        control.|June 2013|June 11, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102205||123862|
NCT01102530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p000042|Diabetes Prevention in Women With a Recent History of Gestational Diabetes (Focus Groups)|Diabetes Prevention in Women With a Recent History of Gestational Diabetes||Brigham and Women's Hospital|Yes|Completed|January 2009|March 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|29|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Healthy women with a diagnosis of gestational diabetes during a pregnancy within the past        5 years|June 2011|June 27, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102530||123837|
NCT01102244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-35|A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis|||Alcon Research|No|Completed|April 2010|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||January 2011|June 7, 2012|April 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102244||123859|
NCT01102751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Istanbul University|Serum FGF-23 and Vitamin D Deficiency|Effects Of Vitamin D Replacement Therapy on Serum FGF-23 Concentrations in Vitamin D Deficient Women In Short Term||Istanbul University|No|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|||||Both|9 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|Group 1: Eighteen premenopausal female patients with a diagnosis of vitamin D deficient        osteomalacia were included in this group. Vitamin D deficiency was diagnosed according to        the serum 25 hydroxy vitamin D3 (25OHD) concentrations (< 30 ng/mL). Reasons for vitamin D        deficiency were verified as insufficient exposure to sunlight, frequent parturition and        prolonged lactation. All of these patients received a standard treatment regimen; oral        Vitamin D3 150 000 IU once for all and subsequently 880 IU D3 and 1000 mg calcium        carbonate for six weeks. This group was also evaluated after replacement therapy at sixth        week.        Group 2: Nineteen healthy premenopausal women who had normal levels of serum 25OHD Vitamin        (>30 ng/mL) composed the control group.        Group 3: Thirteen hypophosphatemic rickets (3 autosomal dominant and 10 X-linked; 9 female        and 4 male) were included in this group.|August 2009|April 12, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102751||123820|
NCT01102764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAC 09-040|Prolonged Exposure (PE) for Post Traumatic Stress Disorder (PTSD): Telemedicine Versus In Person|Prolonged Exposure (PE) for PTSD: Telemedicine vs. In Person||VA Office of Research and Development|No|Completed|October 2010|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|226|||Both|21 Years|99 Years|No|||January 2016|January 5, 2016|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01102764||123819|
NCT01102985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0801003383|Women With Cancer: An Exercise Study to Promote Health|An Exercise Intervention to Improve Health in Postmenopausal Cancer Survivors||Yale University|No|Completed|January 2008|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|154|||Female|18 Years|75 Years|No|||June 2015|June 30, 2015|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01102985||123802|
NCT01103245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091072|Aldosterone and the Metabolic Syndrome|Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism||Vanderbilt University|Yes|Recruiting|March 2010|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|168|||Both|18 Years|70 Years|No|||August 2011|August 4, 2011|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103245||123782|
NCT01102933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-09-003|RElevance of Biomarkers for Future Risk of Thromboembolic Events in UnSelected Post-myocardial Infarction Patients|RElevance of Biomarkers for Future Risk of Thromboembolic Events in UnSelected Post-myocardial Infarction Patients - an Observational Study (REBUS)|REBUS|Uppsala University|No|Completed|April 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|425|Samples With DNA|Blood samples will be collected for analysis of biomarkers and platelets. At the first visit      after the hospital stay blood for DNA analysis will also be collected.|Both|N/A|N/A|No|Non-Probability Sample|All patients diagnosed wilth myocardial infarction and hospitalized at the Cardiology        Department, Uppsala University Hospital, the study population will be unselected.|March 2014|March 22, 2014|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102933||123806|
NCT01102946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRaHi|Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy|Panretinal Photocoagulation Versus Panretinal Photocoagulation Plus Intravitreous Ranibizumab for High Risk Proliferative Diabetic Retinopathy|IRaHi|University of Sao Paulo|Yes|Completed|February 2009|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||January 2011|August 3, 2011|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102946||123805|
NCT01099878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS07136|Cycling Exercise With Functional Electrical Stimulation Improves Postural Control in Stroke Patients|Institutional Review Board of Chung Shan Medical University Hospital||Chung Shan Medical University|Yes|Completed|January 2009|December 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|29 Years|70 Years|No|||April 2010|April 6, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099878||124038|
NCT01099566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPSP2Y12|The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation|The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation||Medical University of Vienna|No|Completed|November 2009|November 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|19 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 8, 2011|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099566||124062|
NCT01103752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2009-096|Postoperative Cognitive Dysfunction After Total Knee or Hip Replacement Surgery in Fast-track Set-up|Postoperative Cognitive Dysfunction After Total Knee or Hip Replacement Surgery in Fast-track Set-up||Rigshospitalet, Denmark|No|Completed|October 2009|December 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|225|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients undergoing fast-track knee or hip replacement surgery at one of the hospitals        participating (Hidovre, Holstebro, Hørsholm, Århus)|December 2011|December 13, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103752||123743|
NCT01099891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_EGF010P|The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients|||Daewoong Pharmaceutical Co. LTD.||Active, not recruiting|March 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099891||124037|
NCT01100164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF097|A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia|A Phase III, Non-inferiority, Double-blind, Unicenter Clinical Trial With Two Treatment Arms - Test Group With Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia|Eszo|Eurofarma Laboratorios S.A.|Yes|Completed|March 2011|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|263|||Both|20 Years|64 Years|No|||March 2010|July 24, 2015|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01100164||124017|
NCT01100177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENOM-008|Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients|An Open Label Non- Randomized Multicentric Phase II Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients||Grupo Español de Investigación en Neurooncología|No|Completed|June 2009|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||March 2013|March 8, 2013|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01100177||124016|
NCT01100190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-08-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2010|||||N/A|N/A|N/A||||||||||||||February 9, 2015|April 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100190||124015|
NCT01100463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OIC-1UO-C001|Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome|A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine||Cahaba Pharmaceuticals|No|Recruiting|December 2009|December 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|N/A|No|||April 2010|April 8, 2010|April 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100463||123995|
NCT01099839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0062|A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol|A Phase I Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol.||Astellas Pharma Inc|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|30|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||June 2010|June 8, 2010|March 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01099839||124041|
NCT01099852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/B/08|Cohort of Patients Infected by an Arbovirus|Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r|CARBO|Centre Hospitalier Universitaire de Fort-de-France|Yes|Recruiting|June 2010|July 2021|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|whole blood, serum, white cells, plasma, DNA, Urine|Both|N/A|N/A|No|Non-Probability Sample|Hospital cohort of children and adults with suspected of infectious by an arbovirus in        French.|February 2016|February 29, 2016|February 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01099852||124040|
NCT01134692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG002|Probiotics for Portal Hypertension|COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST||Govind Ballabh Pant Hospital|No|Recruiting||||||Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|3||||||Both|12 Years|75 Years|No|||May 2010|June 1, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01134692||121378|
NCT01134705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-302|Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older)||Teva Pharmaceutical Industries|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|474|||Both|12 Years|N/A|No|||April 2012|April 23, 2012|May 27, 2010|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT01134705||121377|
NCT01101412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0237|Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies|Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI)||M.D. Anderson Cancer Center|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|April 9, 2010||No|Study was not opened.|No||https://clinicaltrials.gov/show/NCT01101412||123922|
NCT01101074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V111_05|Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine|A Prospective Observational Study of Safety and Effectiveness Following Administration of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine||Novartis||Completed|October 2009|September 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|135469|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population of children, adolescents, adults and elderly|October 2011|October 7, 2011|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01101074||123948|
NCT01101399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-FID-CHEMO|Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy|Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Lymphoid Malignancies & Functional Iron Deficiency Receiving Chemotherapy|FID-CHEMO|Vifor Inc.|No|Completed|May 2010|November 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01101399||123923|
NCT01102218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-01|A Safety Study of Pentoxifylline for the Treatment of Anemia|A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis||Fresenius Medical Care North America|Yes|Terminated|August 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2012|March 26, 2012|April 9, 2010|Yes|Yes|Lack of statistical difference between both arms of the trial.|No|January 18, 2012|https://clinicaltrials.gov/show/NCT01102218||123861|Release of new FDA guidelines re target Hgb values impacted EPO dosing.
NCT01101984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08901|Study of DE-089 Ophthalmic Solution in Patients With Dry Eye|A Randomized, Parallel- Group Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Comparison With 0.1% Sodium Hyaluronate Ophthalmic Solution) － A Multinational Study －||Santen Pharmaceutical Co., Ltd.||Completed|February 2010|April 2012|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|400|||Both|21 Years|69 Years|No|||November 2012|November 11, 2012|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01101984||123879|
NCT01102257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1099|Dry Eye Assessment and Management: Feasibility Study|Clinical Trial of Essential Fatty Acids for Dry Eye Disease: Feasibility Study|DREAM|Asbell, Penny, M.D.|Yes|Completed|January 2010|March 2011|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|90 Years|No|||July 2012|July 20, 2012|April 9, 2010|No|Yes||No|April 29, 2011|https://clinicaltrials.gov/show/NCT01102257||123858|DREAM: Feasibility Study, is labeled “feasibility” because its primary end-point is to demonstrate an ability to execute the protocol rather than generate statistically relevant data on the safety and efficacy of omega-3 EFA in patients with DED.
NCT01102543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUR7101|Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)|Observational Study in Neonatal Intensive Care Units (NICU) on the Real Life Use of Curosurf in Prophylaxis of RDS in Premature Babies.||Chiesi Farmaceutici S.p.A.|Yes|Completed|March 2010|March 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|972|||Both|N/A|12 Hours|No|Probability Sample|900 premature babies in 2 groups/cohorts : group 1 - babies born before 28 weeks GA ;        groupe 2 - babies born at 28 - 32 weeks GA|April 2012|April 5, 2012|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102543||123836|
NCT01103284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiaPep277-1001|Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults|A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects|DIA-AID2|Andromeda Biotech Ltd.|Yes|Active, not recruiting|April 2010|December 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|450|||Both|20 Years|45 Years|No|||July 2013|July 10, 2013|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103284||123779|
NCT01103518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMI 1-16-08-09|Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation|Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin||Fundação Educacional Serra dos Órgãos|No|Active, not recruiting|December 2009|January 2011|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|65 Years|No|||April 2010|August 5, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103518||123761|
NCT01103531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-08-099|Exercise to Improve Outcomes of Treatment for Methamphetamine Users|Aerobic Exercise to Improve Outcomes of Treatment for Methamphetamine Dependence||University of California, Los Angeles|Yes|Completed|March 2010|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|55 Years|No|||November 2015|November 30, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01103531||123760|
NCT01102504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLANUM 2.0.0|Supplementation of Lycopene in Carotid Atheroma|Supplementation of Lycopene on Carotid Atheroma: Neovascularisation and Morphology (SOLANUM) Study|SOLANUM|Cambridge University Hospitals NHS Foundation Trust|Yes|Withdrawn|August 2015|April 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|40 Years|90 Years|No|||April 2015|April 2, 2015|April 12, 2010||No|lack of funding|No||https://clinicaltrials.gov/show/NCT01102504||123839|
NCT01102517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007039|A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung Cancer|||Sun Yat-sen University|Yes|Recruiting|January 2010|January 2018|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||May 2015|May 20, 2015|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01102517||123838|
NCT01102738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR01542|Defining the Intestinal Microbiota in Premature Neonates|The Microbiota of the Premature Neonatal Gastrointestinal Tract: Its Development and Relation to Necrotizing Enterocolitis and Bloodstream Infection||Imperial College London|Yes|Completed|January 2011|June 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|369|Samples Without DNA|Faecal samples, surplus gut tissue samples (if patient requires bowel resection due to      Necrotizing Enterocolitis).|Both|N/A|32 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Premature babies born at less than 32 completed weeks gestation|February 2011|March 25, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01102738||123821|
NCT01103466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP204OC|Investigation of the Performance of Ostomy Base Plate|A Randomised Controlled Cross-over Study Investigating the Performance and Safety of the Ostomy Base Plate SSH||Coloplast A/S|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 22, 2013|April 13, 2010||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT01103466||123765|
NCT01103479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA140177-01|Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening|Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening||Northwestern University|Yes|Completed|April 2010|September 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|569|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|April 12, 2010||No||No|August 28, 2014|https://clinicaltrials.gov/show/NCT01103479||123764|
NCT01103492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07-46|Treatment of Hemorrhagic Radiation Proctitis Using the Halo System|Treatment of Hemorrhagic Radiation Proctitis Using the Halo System||University Hospital Case Medical Center|No|Completed|July 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 12, 2014|April 13, 2010||No||No|March 29, 2011|https://clinicaltrials.gov/show/NCT01103492||123763|
NCT01103505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ForeseeHome AREDS2|HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device|The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)|AREDS|Notal Vision Ltd|Yes|Completed|May 2010|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1520|||Both|55 Years|N/A|No|||October 2014|October 2, 2014|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103505||123762|
NCT01099553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29152|Improving Bowel Preparation With an Educational Video|Improving Bowel Preparation With an Education Video||Boston Medical Center|No|Completed|March 2010|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 29, 2012|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01099553||124063|
NCT01099865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET(DM)|High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes|High-sensitivity C-reactive Protein and UKPDS Risk Score in Type 2 Diabetes: Nalysis With 18F-Fluorodeoxyglucose Positron Emission Tomography||Korea University|Yes|Completed|December 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|56|||Both|16 Years|80 Years|No|Probability Sample|type 2 diabetes|April 2010|April 7, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01099865||124039|
NCT01099579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-397|PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)|A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)|PRINCE1|Bristol-Myers Squibb|No|Active, not recruiting|November 2011|March 2017|Anticipated|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|82|||Both|3 Months|66 Months|No|||August 2015|October 5, 2015|April 6, 2010|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT01099579||124061|
NCT01099904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP21536|A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048|The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048||Hoffmann-La Roche||Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|3||Actual|30|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099904||124036|
NCT01100203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALBLOCK-2|Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function|Aldosterone Blockade in Chronic Kidney Disease. Influence on Arterial Stiffness and Kidney Function|ALBLOCK-2|Herlev Hospital|Yes|Terminated|April 2010|February 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|80 Years|No|||February 2012|February 7, 2012|April 6, 2010|No|Yes|It was not possible within the time frame to recruit the planned no. of patients.|No||https://clinicaltrials.gov/show/NCT01100203||124014|
NCT01100476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 - M5|Mynx M5 One Hour Ambulation Study|Single-center, Post Market, Prospective, Consecutive, Single-arm Study Compared to Historical Control (Diagnostic Arm of the Mynx 6/7F Study)|Mynx|Cardiovascular Associates of the Delaware Valley|Yes|Completed|March 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01100476||123994|
NCT01100489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1109|Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer|A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer||Case Comprehensive Cancer Center|Yes|Withdrawn|February 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|April 7, 2010|Yes|Yes|No accrual|No||https://clinicaltrials.gov/show/NCT01100489||123993|
NCT01130584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK01/02/10|Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer|||National University Hospital, Singapore||Completed|April 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|21 Years|N/A|No|Probability Sample|Any cancer patient|December 2013|December 10, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130584||121692|
NCT01130597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLY5016-204|Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease|A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for Patiromer in Heart Failure Patients With Chronic Kidney Disease||Relypsa, Inc.|No|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 24, 2010|Yes|Yes||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01130597||121691|
NCT01101698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACSK2|Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients|Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease|CACSK2|Medical Universtity of Lodz|Yes|Recruiting|June 2009|June 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|30 Years|70 Years|No|||April 2010|April 12, 2010|April 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101698||123901|
NCT01101958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-0011|A Study of the Use of Chartis Assessment System to Optimize Subject Selection for Endobronchial Lung Volume Reduction.|||Pulmonx, Inc.||Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 4, 2013|April 8, 2010||No||No|December 4, 2013|https://clinicaltrials.gov/show/NCT01101958||123881|
NCT01101971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBGY-199-10|Preparing Medical Students to Undertake a First Female Pelvic Exam.|Can a MEdTech E-learning Module Adequately Prepare Medical Students to Undertake a First Female Pelvic Exam?||Queen's University|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101971||123880|
NCT01101997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA10-001|Non-Invasive Reduction of Abdominal Fat|Non-Invasive Reduction of Abdominal Fat Utilizing the JUNO Applicator|JUNO|Zeltiq Aesthetics|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|June 16, 2011|April 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101997||123878|
NCT01102231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-0803|Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)|Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)||Intergroupe Francophone de Cancerologie Thoracique|No|Active, not recruiting|March 2010|December 2016|Anticipated|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|April 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01102231||123860|
NCT01102777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-366|Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)|Effectiveness of an Automated Walking Program Targeting Veterans With COPD||VA Office of Research and Development|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|307|||Both|40 Years|N/A|No|||December 2014|December 3, 2014|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102777||123818|
NCT01102790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243/09|Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure|Generation of HIT-antibodies Without Prior Heparin Exposure Following Orthopedic Surgery (Subgroup Study) (Change of Coagulation Parameters Under Exposition With New Anticoagulants [Title of the Main Study])||Johann Wolfgang Goethe University Hospitals|No|Recruiting|April 2010|October 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|serum citrated blood edta blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients in a primary care clinic undergoing orthopedic surgery without heparin exposure|April 2010|April 14, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01102790||123817|
NCT01103024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457C2302E1|Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis|A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study)|INSURE|Novartis||Terminated|December 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|April 9, 2010|Yes|Yes|Core study in non-infectious active uveitis was terminated. Patients came only for the planned    safety follow-up visit in this extension study.|No||https://clinicaltrials.gov/show/NCT01103024||123799|
NCT01103037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAV680A2201E1|Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma|A Randomized, Double-blind, Parallel Group Study to Compare the Pharmacodynamics/Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Moderate Persistent Asthma||Novartis||Terminated|March 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||May 2012|May 2, 2012|April 12, 2010|Yes|Yes|Terminated by sponsor|No||https://clinicaltrials.gov/show/NCT01103037||123798|
NCT01102998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTSLP|Assessment of Sleep Complaints in Brain Tumor Survivors|Assessment of Sleep Complaints in Brain Tumor Survivors||St. Jude Children's Research Hospital|No|Completed|April 2010|April 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|153|||Both|8 Years|18 Years|No|Non-Probability Sample|Children ages 8 to 18 years of age who are patients at St Jude Children's Research        Hospital and are at least 5 years from diagnosis and at least 2 years post treatment or        observation only for a brain tumor were targeted to assess the prevalence of sleep        complaints.|November 2013|November 15, 2013|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102998||123801|
NCT01103258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 05-2-014|FOAM-study, Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins|FOAM-study Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins: a Randomized Controlled Study||Maastricht University Medical Center|No|Completed|February 2006|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|N/A|No|||April 2010|April 12, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01103258||123781|
NCT01103271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p002469|Pilot Study of Open-label Placebo to Treat Major Depressive Disorder|Harnessing the Placebo Effect in Major Depressive Disorder||Massachusetts General Hospital|Yes|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||January 2013|January 8, 2013|April 9, 2010||No||No|May 2, 2012|https://clinicaltrials.gov/show/NCT01103271||123780|
NCT01102972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113734|A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)|A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects|ASSURE|ViiV Healthcare|No|Completed|April 2010|December 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|297|||Both|18 Years|N/A|No|||September 2013|October 24, 2013|April 8, 2010|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT01102972||123803|This study consists of a 35-day Screening Period, a 48-week Treatment Period, and a Follow-up Period (contact ~2-4 weeks after the Week 48/Withdrawal Visit). Data from Week 24 (primary endpoint) and Week 48 (final data) are presented in this summary.
NCT01099943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1022|Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians|Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians||University of Colorado, Denver|Yes|Completed|August 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|8|||Both|N/A|N/A|No|||October 2015|October 5, 2015|November 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01099943||124033|
NCT01099306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUaym8071383|Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome|Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome||University of Jordan|Yes|Completed|March 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|199|||Both|32 Years|88 Years|No|||March 2009|April 5, 2010|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01099306||124082|
NCT01099592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10.004|Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression|Predictors of Depression Treatment Response Following an Acute Coronary Syndrome|ARCADE|Centre hospitalier de l'Université de Montréal (CHUM)|No|Terminated|November 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 1, 2010|Yes|Yes|inability to recruit|No||https://clinicaltrials.gov/show/NCT01099592||124060|
NCT01099917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-094|Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?|Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? A Phase II Trial||Memorial Sloan Kettering Cancer Center||Completed|April 2010|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 3, 2014|April 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01099917||124035|
NCT01099930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200037401H|Autologous Stem Cell Transplant for Multiple Sclerosis|Targeting Multiple Sclerosis as an Autoimmune Disease With Intensive Immunoablative Therapy and Immunological Reconstitution: A Potential Curative Therapy for Patients With a Predicted Poor Prognosis|MS/BMT|Ottawa Hospital Research Institute|Yes|Active, not recruiting|August 2001|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|No|||May 2012|May 28, 2012|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01099930||124034|
NCT01100216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS097|Human Laboratory Study of Smokeless Tobacco Products|Human Laboratory Study of Smokeless Tobacco Products||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn|March 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|0|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|April 6, 2010|No|Yes|Funding expired prior to implementing subject recruitment.|No||https://clinicaltrials.gov/show/NCT01100216||124013|
NCT01100242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 0812|Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma|Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma||New Mexico Cancer Care Alliance|Yes|Terminated|April 2010|February 2015|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|April 6, 2010|Yes|Yes|Low accrual|No|June 15, 2015|https://clinicaltrials.gov/show/NCT01100242||124012|
NCT01100502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-005|A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant||Seattle Genetics, Inc.|Yes|Active, not recruiting|April 2010|April 2020|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|329|||Both|18 Years|N/A|No|||September 2015|October 7, 2015|April 6, 2010|Yes|Yes||Yes|July 31, 2015|https://clinicaltrials.gov/show/NCT01100502||123992|Patients are currently being followed for survival; final overall survival data are not available and will be reported upon study closure.
NCT01100827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS01/03/10|A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status|||National University Hospital, Singapore||Recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|1 Year|N/A||Probability Sample|In order to determine the EGFR mutation status, data analysis will be performed on        demographic data and medical records (i.e. case notes and pathology reports) from patient        with advanced stage adenocarcinoma NSCLC|December 2013|December 10, 2013|April 7, 2010||||No||https://clinicaltrials.gov/show/NCT01100827||123967|
NCT01100840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS03/20/08|A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer|A Retrospective Study of Biomarkers in Non-small Cell Lung Cancer||National University Hospital, Singapore|No|Recruiting|April 2009|||April 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|||||Both|N/A|N/A|No|Probability Sample|Archived paraffin-embedded and fresh frozen NSCLC tumor tissue will be obtained via the        Department of Pathology at Tan Tock Seng Hospital and National University Hospital and the        National University Tissue Repository respectively. Clinico-pathological characteristics        will be obtained from the case records, Pathology and Tissue Repository.|December 2013|December 10, 2013|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01100840||123966|
NCT01130857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0123-09-TLV|Diagnostic Study of Temporal Arteritis|Diagnostic Tools in Temporal Arteritis - Towards the Development of a Diagnostic Algorithm||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2010|July 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Inpatients suspected of temporal arteritis and referred to temporal artery biopsy|January 2010|May 25, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130857||121671|
NCT01130870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Dose Response Curve - Sacral Nerve Stimulation for Faecal Incontinence|Dose Response Curve - Sacral Nerve Stimulation for Faecal Incontinence||University of Aarhus|Yes|Completed|April 2010|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||November 2011|November 9, 2011|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01130870||121670|
NCT01100775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044959|Effects of Galantamine on Cognition|Effects of Galantamine on Cognition||University of Maryland|Yes|Recruiting|May 2010|August 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|64 Years|No|||March 2015|March 3, 2015|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01100775||123971|
NCT01100788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0806M37444|Satiety Response of Short Chain Fructooligosaccharide|Satiety Response of Short Chain Fructooligosaccharide||University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01100788||123970|
NCT01101737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|General Nursing Council 2007|Trial of a Nurse Led Hypertension Clinic in Inner City General Practices|Evaluation of a Nurse-led Hypertension Clinic in Two Inner City General Practices: Randomised Controlled Trial||St George's, University of London|No|Completed|February 2008|April 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|353|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 9, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01101737||123898|
NCT01101113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINA-Kor-01|Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level|Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients|CUPID|Seoul National University Hospital|No|Completed|September 2010|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|70 Years|No|||June 2012|June 6, 2012|April 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01101113||123945|
NCT01101126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7741-OK-CTIL|Disease Management in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Patients|Disease Management Program for Chronic Obstructive Pulmonary Diseases in Maccabi Health Services|ACDM-Maccabi|Sheba Medical Center|Yes|Terminated|March 2010|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|492|||Both|40 Years|N/A|No|||January 2015|January 20, 2015|April 8, 2010||No|An excess of all-cause acute health services utilization in the intervention arm|No||https://clinicaltrials.gov/show/NCT01101126||123944|
NCT01101711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65/2006|Endocrine Dysfunction and Quality of Life After Subarachnoid Hemorrhage|Endocrine Dysfunction and Quality of Life After Subarachnoid Hemorrhage||Lund University Hospital|No|Completed|November 2006|September 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|None Retained|Blood and urine samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients from the southern part of Sweden who have suffered subarachnoid hemorrhage and        admitted to the Department of Neurosurgery in Lund|September 2012|September 6, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101711||123900|
NCT01101724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5520163IRC|Effect of Early Rest on Recovery From Pediatric Concussion|Effect of Early Rest on Recovery From Pediatric Concussion||Medical College of Wisconsin|Yes|Completed|April 2010|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|11 Years|22 Years|No|||November 2013|November 1, 2013|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101724||123899|
NCT01102556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6154|PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease|PREDICT: Pancreatic Disease Cohort. A Registry and Biospecimen Bank To Better Understand Pancreatic Disease.||Columbia University|Yes|Recruiting|July 2004|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|-  Peripheral Blood Specimens: Three tubes of blood will be collected from each study           participant.        -  Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or           elsewhere, will be requested after obtaining consent for study participation.        -  Fresh Tissue Collection: At the time of surgery for any tumor resection, tumor tissue           and adjacent normal tissue will be requested from the Pathology Department. At the time           of endoscopy, aspirated fluid or biopsied tissue will be requested. No additional           tissue will be resected beyond that required for surgical or endoscopic management. In           no circumstance will tissue be obtained solely for the purpose of the study.|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who have been diagnosed with pancreatic cancer or suspicion of pancreatic        cancer, a pre-neoplastic lesion in the pancreas, or who have been identified to be at        high-risk for developing pancreatic cancer.|January 2016|January 28, 2016|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102556|1 Year|123835|
NCT01102803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS09-81|D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia|Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes||Southern Methodist University|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|January 18, 2013|April 9, 2010||No||No|December 12, 2012|https://clinicaltrials.gov/show/NCT01102803||123816|Sample may not have been severe enough to see an effect of DCS; there may have been a ceiling effect; there was no pre-session pill administration; assessors were blind but not independent; only one dose of DCS was examined
NCT01102816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI0908|Acupuncture for Pain Management of Hemodialysis Patients|Acupuncture for Pain Management of Hemodialysis Patients: a Randomized, Controlled Pilot Study||Korea Institute of Oriental Medicine|Yes|Terminated|May 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1|||Both|19 Years|N/A|No|||January 2011|January 25, 2011|April 9, 2010||No|We failed to recruit enough patients by regular recruitment methods (i.e., newspaper ads,    hospital postings, radios and television ads).|No||https://clinicaltrials.gov/show/NCT01102816||123815|
NCT01103050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAV680A2204|A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine|A Randomized, Double-blind, Double-dummy, Placebo Controlled Three-period Incomplete Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine on Total Nasal Symptom Score in Allergic Rhinitis Patients in an Environmental Exposure Chamber||Novartis||Completed|March 2010|||July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||January 2011|January 6, 2011|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103050||123797|
NCT01103063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661158|Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa|A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa||Pfizer|Yes|Terminated|October 2010|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2891|||Female|16 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 7, 2010||No|See termination reason in detailed description.|No|August 25, 2014|https://clinicaltrials.gov/show/NCT01103063||123796|This program was terminated by Pfizer based on the results of the pre-planned interim analysis for this pivotal study. The interim analysis showed no benefit of the study drug (AZCQ) compared to standard of care (SP).
NCT01103011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0611/001|Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611|A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611||NeuroDerm Ltd.||Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2010|October 3, 2010|April 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01103011||123800|
NCT01099332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CopperProof-2|Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease|CopperProof-2: Prospective, Randomized, Double-Blind Placebo-Controlled Clinical Trial Comparing the Effects of a Novel Once-Daily Oral Zinc Cysteine Preparation on Zinc and Copper Parameters in Mild Cognitive Impairment and Alzheimer's Disease||Adeona Pharmaceuticals|Yes|Active, not recruiting|November 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|55 Years|90 Years|No|||January 2011|January 27, 2011|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01099332||124080|
NCT01099605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP# 10.0042|Continuous Infusion of Local Anesthetic for Optimal Post Operative Pain Control Following Hemorrhoidectomy|Continuous Infusion of Local Anesthetic for Optimal Post Operative Pain Control Following Hemorrhoidectomy: A Randomized Double-blind Controlled Trial||United States Naval Medical Center, Portsmouth|Yes|Recruiting|April 2010|||April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 6, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099605||124059|
NCT01099345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-040|A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)|A Pilot, Overactive Bladder Syndrome Study Utilizing a Sleep Laboratory Setting to Compare Detrusor Positive Nocturia Female Subjects to Detrusor Negative Nocturia Female Subjects||Astellas Pharma Inc|No|Terminated|July 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|15|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects identified through urology physicians, family practice physicians and advertising|June 2014|June 2, 2014|March 30, 2010||No|Slow Enrollment|No||https://clinicaltrials.gov/show/NCT01099345||124079|
NCT01099358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13418|Study in Advanced Solid Tumors|Phase 2 Study to Evaluate the Pharmacokinetics and Drug-Drug Interaction of Cetuximab and Cisplatin in Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Active, not recruiting|April 2010|June 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Anticipated|8|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01099358||124078|
NCT01099319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-1001-CU|Renalof in the Treatment of Elderly Patients With Gallstones|Efficacy and Safety of Renalof Administration in the Treatment of Elderly Patients With Gallstones||Catalysis SL|Yes|Completed|January 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|N/A|No|||May 2012|May 6, 2012|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01099319||124081|
NCT01100515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO89|Hyperbaric Oxygen Therapy for Acute Domestic Carbon Monoxide (CO) Poisoning|Phase 3 Study of Hyperbaric Oxygen Therapy in Non-Comatose Patients With Acute Domestic Carbon Monoxide Poisoning||University of Versailles|No|Terminated|October 1989|February 2000|Actual|January 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|15 Years|N/A|No|||April 2010|April 8, 2010|April 5, 2010||No|this study was suspended for futility|No||https://clinicaltrials.gov/show/NCT01100515||123991|
NCT01100801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA01/01/10|A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients|A Phase II Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients|3G|National University Hospital, Singapore|No|Recruiting|July 2010|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|21 Years|N/A|No|||June 2015|June 17, 2015|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100801||123969|
NCT01101139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMAR|Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery|Small Dose of Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery (TOF 0.9)||Technische Universität München||Completed|April 2010|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|65 Years|No|||December 2012|December 14, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101139||123943|
NCT01101191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1009|A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets to OxyContin® 80-mg Tablets||Purdue Pharma LP|No|Completed|August 2007|January 2008|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 17, 2010|April 8, 2010|Yes|Yes||No|April 14, 2010|https://clinicaltrials.gov/show/NCT01101191||123939|
NCT01101490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0724|Changes of Right and Left Cerebral Oxygen Saturation and Blood Flow During Nephrectomy in Lateral Decubitus Position|||Yonsei University|Yes|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|20 Years|65 Years|No|Probability Sample|the patients who visit Severance hospital for nephrectomy|April 2011|April 21, 2011|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101490||123916|
NCT01131182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-263|Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)|An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting||Merck Sharp & Dohme Corp.|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1147|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|May 25, 2010|Yes|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT01131182||121646|
NCT01131195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 24/09|Bevacizumab and Paclitaxel or Bevacizumab, Cyclophosphamide, and Capecitabine as First-Line Therapy in Treating Women With Locally Advanced, Recurrent, or Metastatic Breast Cancer|Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|June 2010|February 2016|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Female|18 Years|N/A|No|||December 2015|December 29, 2015|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131195||121645|
NCT01101464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05937|A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)|A Single-center, Open-label, 2-way Crossover Relative Bioavailability and Safety Trial With Two Differing Strength Tablets (3 x 5 mg vs. 1 x 15 mg) of Sublingually Administered Org 5222 in Subjects With Schizophrenia or Schizoaffective Disorder.||Merck Sharp & Dohme Corp.|No|Completed|October 2002|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|8|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|March 3, 2010|Yes|Yes||No|June 3, 2010|https://clinicaltrials.gov/show/NCT01101464||123918|
NCT01101477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-3441A3|Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation|Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation: Determining the Optimal Titrating Regimen||Chang Gung Memorial Hospital|No|Terminated|February 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|144|||Both|18 Years|95 Years|No|||November 2011|November 5, 2011|April 7, 2010||No|Hypoxemia(SPaO2<80%) episodes occured significantly in the arm titration by 0.5ug/ml|No|November 5, 2011|https://clinicaltrials.gov/show/NCT01101477||123917|Early termination leading to small numbers of subjects analyzed.
NCT01102010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBTFEHF|Postoperative Blood Transfusion for Frail Elderly With Hip Fracture|Postoperative Blood Transfusion for Frail Elderly With Hip Fracture - a Clinical Randomized Controlled Trial||University of Aarhus|Yes|Completed|January 2010|October 2014|Actual|October 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|284|||Both|65 Years|N/A|No|||August 2013|July 16, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102010||123877|
NCT01102270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000818|The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome|A Double-Blind Randomized Physiological Study Examining the Effects of Eszopiclone on the Arousal Threshold and Obstructive Sleep Apnea Severity||Brigham and Women's Hospital|No|Completed|January 2009|May 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|64 Years|No|||November 2012|November 22, 2012|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01102270||123857|
NCT01102569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6344|Pancreatic Cancer Genetics|Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients||Columbia University|Yes|Recruiting|January 2008|August 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|-  Peripheral Blood Specimens: Three tubes of blood will be collected from each study           participant. A portion of the blood will be utilized to extract white blood cells that           will be immortalized by Epstein-Barr virus (EBV) infection.        -  Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or           elsewhere, will be requested after obtaining consent for study participation.        -  Fresh Tissue Collection: At the time of surgery for tumor resection, tumor and adjacent           normal tissue will be requested from the Pathology Department. At the time of           endoscopy, aspirated fluid or biopsied tissue will be requested. No additional tissue           will be resected beyond that required for surgical or endoscopic management.        -  Genetic Testing: Genetic testing will be performed in a New York State certified           research laboratory . Test results from research laboratories will not be disclosed to           patients.|Both|18 Years|85 Years|No|Non-Probability Sample|Study subjects will be pancreatic cancer patients at CUMC who are of Ashkenazi Jewish        descent.|July 2015|July 2, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102569||123834|
NCT01102829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCC|Early Migration in a High Congruent Rotating Platform Total Knee Prosthesis Design|Early Migration in a High Congruent Rotating Platform Total Knee Prosthesis Design. A Synchronised Motion Analysis Study With Fluoroscopy and RSA|ROCC|Leiden University Medical Center|No|Completed|September 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|April 2010|April 12, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102829||123814|
NCT01103336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0722|Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study)|Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study): A Investigator-initiated, Control- Randomized, Phase IV Multicenter Study||Yonsei University|Yes|Completed|March 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|173|||Both|20 Years|N/A|No|||February 2012|February 2, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01103336||123775|
NCT01103310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14207|Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation|Open-label, Multi Center Study for an Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 100 µg Total Quantity) in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability, Pharmacokinetics, and Diagnostic Performance of the Tracer in PET/CT in Cancer Patients or Patients With Inflammation.||Piramal Imaging SA|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|46|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01103310||123777|
NCT01103297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALCPDR|2.4 mm Variable Angle LCP Two-Column Volar Distal Radius|A Prospective Multicenter Case-series of Patients Treated With the 2.4 mm Variable Angle LCP Two-Column Volar Distal Radius Plate ®|VALCP2010|AO Clinical Investigation and Documentation|No|Completed|June 2010|May 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01103297||123778|
NCT01103544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JONAS-1|JAVLOR® Online Non-Interventional Trial|Usage of Vinflunine i.v. (JAVLOR®) for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in Adult Patients After Failure of a Cisplatinum-containing Therapy|JONAS-1|Pierre Fabre Pharma GmbH|No|Completed|April 2010|August 2013|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced or metastatic transitional cell carcinoma of the urothelium after        failure of a Cisplatinum-containing therapy|May 2015|May 12, 2015|April 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01103544||123759|
NCT01099631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS003|IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread|A Phase 1 Study of an IL-2 Expressing, Attenuated Salmonella Typhimurium in Patients With Unresectable Hepatic Spread From Any Non-Hematologic Primary||Masonic Cancer Center, University of Minnesota|Yes|Completed|April 2010|June 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01099631||124057|
NCT01099644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-090|Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum|Phase I Study of Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum||Memorial Sloan Kettering Cancer Center||Recruiting|April 2010|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|1 Year|N/A|No|||January 2016|January 26, 2016|April 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01099644||124056|
NCT01100255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6906R/5883|Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)|Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine||New York State Psychiatric Institute|Yes|Completed|April 2010|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Both|18 Years|55 Years|No|||August 2015|February 29, 2016|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01100255||124011|
NCT01099956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/28|Low Grade Inflammation in Type 1 Diabetes Children|Low Grade Inflammation in Type 1 Diabetes Children|Coccinelle|University Hospital, Bordeaux|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|2 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 children in type 1 diabetes group and 30 children in control group|October 2011|October 24, 2011|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01099956||124032|
NCT01099969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0456|Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy|Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy||The University of Texas Health Science Center, Houston|No|Active, not recruiting|March 2010|March 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01099969||124031|
NCT01100268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6133|Enhancing Attention in Adults With Compulsive Hoarding|Enhancing Attention in Adults With Compulsive Hoarding: A Pilot Study||New York State Psychiatric Institute|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|50 Years|No|||August 2014|September 10, 2014|April 5, 2010||No||No|June 4, 2013|https://clinicaltrials.gov/show/NCT01100268||124010|
NCT01100528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2609|Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance|Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance||Case Comprehensive Cancer Center|Yes|Active, not recruiting|November 2009|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|N/A|N/A|No|||March 2016|March 1, 2016|April 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100528||123990|
NCT01100814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA01/08/08|Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer|Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer||National University Hospital, Singapore|No|Active, not recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|||||Both|N/A|N/A|No|Probability Sample|200 gastric tumour and normal tissue samples, as well as up to 50 non-neoplastic gastric        tissues samples from individuals without gastric cancer (treated for other reasons, such        as gastric ulcers) will be obtained from the tissue archives of the NUH Department of        Pathology. These samples were selected because relevant clinical information of these        samples are available from gastric database and will allow us to perform association        studies.|January 2014|January 21, 2014|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01100814||123968|
NCT01101204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSF|The Effects of Hypolipemic and Antidiabetic Treatment on Cytokines|Effects of High and Low Doses of Metformin, Fenofibrate and Simvastatin, Administered Together and in Sequence With Lifestyle Intervention on Lipid Profile, Glucose Metabolism, Low-grade Inflammation and Hemostasis in Patient's Blood Plasma in Type 2 Diabetic Patients With Serious Mixed Dyslipidemia|MSF|Medical University of Silesia|No|Not yet recruiting|July 2012|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|9||Anticipated|200|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01101204||123938|
NCT01101217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4542|Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients|||Shiraz University of Medical Sciences|Yes|Completed|February 2009|September 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||January 2009|April 8, 2010|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101217||123937|
NCT01130896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-08-12-11|Clinically Indicated Magnetic Resonance Imaging in Patients With Cardiac Devices|Clinically Indicated Magnetic Resonance Imaging of Patients With Permanent Pacemakers (PPM) and Implantable Defibrillators (ICD)||Johns Hopkins University|Yes|Recruiting|May 2003|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|9 Years|N/A|No|Non-Probability Sample|Patients with Implanted Cardiac Rhythm Management Devices|May 2010|May 25, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01130896||121668|
NCT01130909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285M00008|A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765|A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo|AZD6765 EEG|AstraZeneca|No|Terminated|May 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|36|||Male|30 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|May 19, 2010||No|The benefit of halting the study to analyze the available data outweighs the benefit of    delaying the analysis to include data from remaining treatment periods|No||https://clinicaltrials.gov/show/NCT01130909||121667|
NCT01101763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-108|A Study of the Kinetics of a 13C-Cholesterol Infusate in Healthy Male Subjects (0000-108)(COMPLETED)|A Pilot Study to Evaluate the Plasma Enrichment Kinetics of a 13C-Cholesterol Infusate in Healthy Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|August 2008|December 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Plasma|Male|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited for the study|April 2015|April 21, 2015|April 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101763||123896|
NCT01101750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GardasilMerckGomez-Lobo|Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?|Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients.||Medstar Research Institute|No|Recruiting|May 2010|January 2014|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|9 Years|17 Years|No|||February 2011|February 9, 2011|April 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101750||123897|
NCT01102023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2009067(254)|Effect of Solar Salt Diet in Elderly Hypertensive Patients|||Chung-Ang University Hospital||Completed||||||Phase 3|Interventional|N/A|1||||||Both|50 Years|N/A||||March 2010|April 9, 2010|April 8, 2010||||No||https://clinicaltrials.gov/show/NCT01102023||123876|
NCT01102283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-022|Treatment of Colonic Obstruction With Cook Evolution® Colonic Stent System|Treatment of Colonic Obstruction With Cook Evolution® Colonic Stent System||Cook||Completed|April 2010|February 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Referral Centers|September 2013|September 16, 2013|March 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01102283||123856|
NCT01102582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Norva100408|An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia|A Six-month Observational Study to Investigate Prevalence of Neuropsychiatric Symptom in Korean Patients With Parkinson's Disease Dementia||The Catholic University of Korea|Yes|Completed|April 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|||Both|18 Years|N/A|No|Probability Sample|The tertiary clinic in university hospital|February 2015|February 2, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102582||123833|
NCT01100385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091763|TomVasc - Vascular Effects of Tomato Extract|Vascular Effects of Nutritional Supplementation With a Standardised Preparation of Tomato Extract (Ateronon) in Vivo in Man|TomVasc|Cambridge University Hospitals NHS Foundation Trust|No|Completed|February 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|72|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||July 2012|June 23, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01100385||124001|
NCT01100671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET_Coronary CT|Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation|Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation in Healthy Population||Korea University|Yes|Completed|April 2010|August 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|120|Samples Without DNA|plasam and serum|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants who underwent a medical health check in the health promotion center        in Korea Guro University|March 2010|October 12, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01100671||123979|
NCT01101282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(not yet specified)|Does Positive Expiratory Pressure Mask Therapy Improve Recovery From Acute Exacerbations of Chronic Obstructive Pulmonary Disease?|Does the Addition of Positive Expiratory Pressure (PEP) Mask Therapy to Usual Medical Care Improve Patients' Symptoms, Quality or Life and Risk of Future Exacerbations in Individuals With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)?||La Trobe University|No|Completed|July 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|N/A|N/A|No|||February 2013|February 13, 2013|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01101282||123932|
NCT01101295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECAI|The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.|The ITP-RITUX Cohort: An Observational Study on Rituximab Off-label Use for Immune ThrombocytoPenia.|ITP-RITUX|Henri Mondor University Hospital|Yes|Recruiting|April 2010|April 2017|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Immune ThrombocytoPenia (ITP) patients according to the American Society of Hematology        (ASH).|March 2012|March 20, 2012|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01101295||123931|
NCT01132651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 28933|Cooling Pillow for Atopic Dermatitis|Novel Use of a Cooling Pillow for Treatment of Severe Hand and Neck Atopic Dermatitis||Northwestern University|Yes|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|9|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|May 26, 2010||No||No|July 30, 2012|https://clinicaltrials.gov/show/NCT01132651||121535|
NCT01132664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120X2107|Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer|A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab||Novartis|No|Terminated|May 2010|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|May 7, 2010|Yes|Yes|Due to the rare patient population and challenges to enroll patients.|No|August 4, 2015|https://clinicaltrials.gov/show/NCT01132664||121534|
NCT01132950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE 07-42|Contraceptive Awareness and Reproductive Education|Empowering Women to Make Contraceptive Choices While Incarcerated|CARE|Memorial Hospital of Rhode Island|No|Recruiting|February 2009|June 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2010|September 8, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132950||121512|
NCT01133197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0829|The Impact of Thumb Carpometacarpal Osteoarthritis on General Health|The Impact of Thumb Carpometacarpal Osteoarthritis on General Health||Washington University School of Medicine|Yes|Completed|July 2009|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|188|||Both|18 Years|80 Years|No|Non-Probability Sample|patients presenting for treatment have thumb arthritis|June 2015|June 26, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01133197||121493|
NCT01102140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPROVEHF|The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study|The Impact of Pomegranate (Punica Granatum) Polyphenol Extract on Oxidative Stress, Ventricular Remodeling and Endothelial Function in Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study|ImPrOVE|University of Michigan|No|Recruiting|July 2010|||May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||December 2012|December 17, 2012|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102140||123867|
NCT01134042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106829|Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics|HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents||GlaxoSmithKline|No|Completed|June 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|587|||Both|12 Years|N/A|No|||July 2014|July 31, 2014|May 27, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01134042||121428|
NCT01134328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-100-0005|Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model|||Aciex Therapeutics, Inc.||Completed|May 2010|||July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|83|||Both|10 Years|N/A|No|||February 2012|February 27, 2012|May 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01134328||121406|
NCT01116076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRSQ20131|DECISION+, a Training Program to Improve Optimal Drug Prescription|DECISION+: Une Formation Pour Les médecins de Famille Sur la Prise de décision partagée Afin d'Optimiser Les décisions Cliniques Concernant l'Utilisation d'Antibiotiques Pour Les Infections aiguës Des Voies Respiratoires (IAVR)|Decision+|Centre Hospitalier Universitaire de Québec, CHU de Québec||Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|712|||Both|N/A|N/A|No|||January 2013|January 30, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116076||122798|
NCT01116349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-530|Conservative Treatment Versus the Surgical Treatment of Diaphyseal Fractures of Humerus|Diaphyseal Fractures of the Humerus: A Prospective Cohort Study Comparing the Conservative Treatment and the Surgical Treatment.||Hopital de l'Enfant-Jesus|No|Terminated|January 2010|July 2014|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|May 3, 2010||No|Difficulties to recruit participants A similar Canadian multicentric study started at about    the same.|No||https://clinicaltrials.gov/show/NCT01116349||122777|
NCT01116362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-2|Comparing Primary With Secondary Repair of Based on Electrodiagnostic Assessment and Clinical Examination|Study of Surgical Methods for Repair of Clean Transections in Peripheral Nerve Injuries||Isfahan University of Medical Sciences|Yes|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2008|May 19, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116362||122776|
NCT01101802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX18694|Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)|A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE.|MISSILE|Guy's and St Thomas' NHS Foundation Trust|Yes|Completed|March 2006|October 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Female|18 Years|60 Years|No|||May 2005|September 27, 2011|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01101802||123893|
NCT01102634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20100407006|Effects of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Blood Lactate and Excessive Post-exercise Oxygen Consumption (EPOC)|||The Hong Kong Polytechnic University||Recruiting|April 2010|||August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2010|April 12, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01102634||123829|
NCT01102361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioXbot|Ultrasound Based Transperineal Robotic Biopsy of the the Prostate|Study of Prostate Cancer Detection With in House Developed Robot|BxB|Singapore General Hospital|No|Recruiting|May 2006|June 2011|Anticipated|January 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Male|N/A|N/A|Accepts Healthy Volunteers|||May 2006|April 12, 2010|April 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01102361||123850|
NCT01103388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0239|Rituximab Maintenance After Autologous Transplantation|Maintenance Therapy With Rituximab After Autologous Transplantation for Non-Hodgkin's Lymphoma||M.D. Anderson Cancer Center|No|Terminated|August 2003|April 2010|Actual|April 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|N/A|N/A|No|||July 2012|July 27, 2012|April 12, 2010||No|Closed early due to slow patient accrual and sponsor's withdrawal of support.|No||https://clinicaltrials.gov/show/NCT01103388||123771|
NCT01102621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL1|Hearing Loss and Complaint in Patients With Head and Neck Cancer Treated With Radiotherapy|Hearing Loss and Complaint in Patients With Head and Neck Cancer Treated With Radiotherapy||Hospital A.C. Camargo|No|Completed|January 2005|July 2007|Actual|January 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|282|||Both|11 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study design: Prospective, case-control study. Setting: Tertiary care center hospital.|March 2010|April 12, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01102621||123830|
NCT01103115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIS_Ca_VitD_01|Calcium + Vitamin D Supplementation for Low Bone Mass in Adolescent Idiopathic Scoliosis (AIS)|Can Calcium and Vitamin D Supplementation Improve Bone Mineral Density and Curve Progression in Girls With Adolescent Idiopathic Scoliosis?||Chinese University of Hong Kong|No|Completed|April 2010|February 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|330|||Female|11 Years|14 Years|No|||February 2015|February 2, 2015|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01103115||123792|
NCT01100073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.657|Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life|Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life||Boehringer Ingelheim||Completed|February 2008|||August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1703|||Both|N/A|N/A|No|Non-Probability Sample|Neurologists|March 2014|March 14, 2014|March 18, 2010||||No|July 30, 2010|https://clinicaltrials.gov/show/NCT01100073||124023|
NCT01100086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1003|A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin® 10-mg Tablets||Purdue Pharma LP|No|Completed|January 2007|June 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 17, 2010|April 6, 2010|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT01100086||124022|
NCT01131949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-147|Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition|Single Dose Two-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets With Lamictal 25 mg Chewable Tablets in Healthy Volunteers Under Fasting Condition||Dr. Reddy's Laboratories Limited|No|Completed|January 2003|March 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|41 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131949||121589|
NCT01131962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|egsbl1|Comparing Two Methods to Stop Vomiting of Blood Using the Endoscope|Control of Acute Variceal Bleeding Using the Multi-shooter Band Ligator Compared to Injection Sclerotherapy.||Faculty of Medicine, University of Alexandria|No|Completed|May 2008|July 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01131962||121588|
NCT01131975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-148|Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition|Single Dose Two-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets With Lamictal 25 mg Chewable Tablets in Healthy Volunteers Under Fed Condition||Dr. Reddy's Laboratories Limited|No|Completed|January 2003|March 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|41 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131975||121587|
NCT01132352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA06209|Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Levetiracetam Tablets, 750 mg and Keppra® 750 mg Tablets of UCB Pharma in Healthy Adult Male Volunteers Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2003|November 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132352||121558|
NCT01132963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN09GE487|The Effects of Footwear on Balance and Confidence in Older Inpatients|A Prospective Randomised Crossover Study to Evaluate the Effect Different Footwear Type Has on Measures of Balance and Confidence in Older Hospital Inpatients||NHS Greater Glasgow and Clyde|No|Not yet recruiting|May 2010|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||March 2010|May 27, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132963||121511|
NCT01133210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0533|Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)|Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)||Washington University School of Medicine|Yes|Completed|January 2011|November 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|64 Years|No|||December 2013|December 9, 2013|May 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01133210||121492|
NCT01133223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG 09-587|Safety and Efficacy of the Penumbra™ System in Acute Middle Cerebral Artery (MCA) Stroke|Randomized Clinical Trial Comparing Intravenous Thrombolysis With Thrombectomy by the Penumbra™ System in Patients With Middle Cerebral Artery Stem Occlusion - Pilot Study||Hospital de Clinicas de Porto Alegre|No|Withdrawn|May 2010|September 2015|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||September 2015|September 2, 2015|May 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01133223||121491|
NCT01133470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-VIN-029|Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2007|April 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133470||121472|
NCT01133483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-VIN-057|Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|April 2007|May 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133483||121471|
NCT01133496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095-06|Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions|Open Label, Balanced, Randomized, Two-way, Single-dose, Crossover Bioequivalence Study of Alendronate Sodium 70 mg Tablets of Dr Reddy's, India and Fosamax® Tablets of Merck & Co., Inc., USA, in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|December 2006|April 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133496||121470|
NCT01133457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012744|Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia in Healthy Adult Males Under Fed Condition.||Dr. Reddy's Laboratories Limited|No|Completed|April 2002|May 2002|Actual|May 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2002|May 27, 2010|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133457||121473|
NCT01134341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-018|Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma|A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma||Spectrum Pharmaceuticals, Inc||Active, not recruiting|March 2010|December 2015|Anticipated|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134341||121405|
NCT01134614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02039|Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|August 2016|Anticipated|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|April 27, 2010|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01134614||121384|
NCT01117181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG033032-01|Apathy in Dementia Methylphenidate Trial (ADMET)|Apathy in Dementia Methylphenidate Trial (ADMET)|ADMET|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|June 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2011|April 1, 2013|May 4, 2010|Yes|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT01117181||122713|
NCT01117194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200804031D|Effect on Shoulder Training Using Rehabilitation Robot for Stroke Patients|Rehabilitation Robot for Upper Limbs, Component Project 5: Effect on Shoulder Training Using Rehabilitation Robot for Stroke Patients||National Taiwan University Hospital|No|Recruiting|January 2010|February 2013|Anticipated|February 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|12|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||November 2012|December 20, 2012|January 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01117194||122712|
NCT01102647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:133|Cholesterol Metabolism in Heterozygous Phytosterolemia|Assessment of Cholesterol Metabolism in Heterozygous Phytosterolemia||University of Manitoba|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|26|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||April 2011|April 28, 2011|April 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102647||123828|
NCT01103128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0097|Validation of a Mouse Model of Pancreatic Carcinogenesis|BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis||Columbia University|Yes|Terminated|March 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|450|Samples With DNA|-  Peripheral Blood Specimens: Three tubes of blood will be collected from each study           participant. Two tubes will be EDTA-whole blood and one tube will be serum. Each tube           will contain ~4-5 ml. A portion of the blood will be utilized to extract white blood           cells that will be immortalized by EBV infection.        -  Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or           elsewhere, will be requested after obtaining consent for study participation.        -  Fresh Tissue Collection: At the time of surgery for tumor resection, tumor and adjacent           normal tissue will be requested from the Pathology Department. At the time of           endoscopy, aspirated fluid or biopsied tissue will be requested. No additional tissue           will be resected beyond that required for surgical or endoscopic management.        -  Genetic Testing: All genetic testing will be performed in a research laboratory. Test           results from research laboratories will not be disclosed to patients.|Both|18 Years|80 Years|No|Non-Probability Sample|All subjects have a tissue-confirmed diagnosis of pancreatic adenocarcinoma, MCN or IPMN        and underwent surgical resection for pancreatic adenocarcinoma, MCN or IPMN at        Columbia-Presbyterian Medical Center.|July 2012|June 22, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103128||123791|
NCT01103141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-012|Femoral Micropuncture or Routine Introducer Study||FEMORIS|Cook||Terminated|June 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|144|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|April 12, 2010|No|Yes|This original design is no longer consistent with current clinical practice.|No||https://clinicaltrials.gov/show/NCT01103141||123790|
NCT01103648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSaoPaulo|Effect of Simvastatin and Ezetimibe on Lipid and Inflammation|Synergistic Effect of Simvastatin and Ezetimibe on Lipid and Pro-inflammatory Profiles in Pre-diabetic Subjects||Federal University of São Paulo|No|Completed|June 2005|November 2007|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|75 Years|No|||November 2007|April 14, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103648||123751|
NCT01103661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-1140|Safety and Efficacy Study of The Combined Ablation Procedure To Treat Longstanding Persistent Atrial Fibrillation|Feasibility Study For Safety and Efficacy Evaluation Of The Combined Ablation Procedure For The Treatment Of LongStanding Persistent Atrial Fibrillation|CAPstopsLSPAF|nContact Surgical Inc.|Yes|Terminated|April 2010|April 2013|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||April 2013|April 2, 2014|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103661||123750|
NCT01099436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOOG-2010-01|Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients|A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC)|NEO-ZOTAC|Borstkanker Onderzoek Groep|Yes|Completed|April 2010|September 2013|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|18 Years|N/A|No|||July 2014|July 15, 2014|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099436||124072|
NCT01099449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N08CB|Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy|A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity||Alliance for Clinical Trials in Oncology|Yes|Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|362|||Both|18 Years|N/A|No|||July 2015|July 4, 2015|April 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01099449||124071|
NCT01099748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271031|Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone|Open Label, Single-Sequence Study To Estimate The Effect Of Lersivirine (UK-453,061) On S- And R-Methadone In Subjects Receiving Chronic Methadone Treatment||Pfizer|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 26, 2010|April 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01099748||124048|
NCT01100970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0008-10HMO-CTIL|Cortisol Levels in Infants Born by C-section - Electric Unipolar Needle Versus Electric Bipolar Needle|Cortisol Levels in Infants Born by C-section - A Comparison of Using an Electric Unipolar Needle and Electric Bipolar Needle||Hadassah Medical Organization|No|Active, not recruiting|May 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|Samples Without DNA|Bouth umbilical Blood samples and saliva samples will be kept in a -20C freezer utill      assayed.|Female|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|pregnant women who needs c-section.|February 2010|January 30, 2011|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01100970||123956|
NCT01132365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-05-02|Knee Arthroplasty Registry|Knee Arthroplasty Registry a. Function and Survival Stratified by BMI b. Return of Quadriceps Strength After Primary TKA||Heekin Orthopedic Research Institute|No|Enrolling by invitation|April 2005|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3156|||Both|21 Years|N/A|No|Non-Probability Sample|All male and non-pregnant females undergoing knee arthroplasty.|March 2015|March 30, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132365||121557|
NCT01132677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA-CS-OA1|A Study Comparing Viscosupplementation and Corticosteroid Injections for Knee Osteoarthritis|A Randomized Clinical Trial Comparing Hyaluronic Acid (Hylan G-F 20) and Corticosteroid (Methylprednisolone Acetate) for Knee Osteoarthritis||LifeMark Health|No|Enrolling by invitation|May 2010|December 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|78|||Both|19 Years|75 Years|No|||February 2010|May 27, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132677||121533|
NCT01133236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS and HCPA 09117|Fluid and Salt Restriction in Decompensated Heart Failure Patients|Randomized Clinical Trial to Assess the Effect of Fluid and Salt Restriction on the Management of Patients Hospitalized Due to Decompensated Heart Failure||Hospital de Clinicas de Porto Alegre|Yes|Completed|August 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01133236||121490|
NCT01133509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33249|A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study|A Model for the Implementation of the Cervical Cancer Screening and HPV Vaccination in the Emergency Department: a Pilot Study.||Eastern Virginia Medical School|Yes|Recruiting|September 2009|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|November 4, 2008||No||No||https://clinicaltrials.gov/show/NCT01133509||121469|
NCT01133782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|luftvagsPCR-01|Clinical Application of PCR-based Diagnosis of Community-onset Viral Respiratory Infections.||luftvagsPCR|Göteborg University|No|Completed|October 2006|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|406|||Both|18 Years|N/A|No|||October 2006|May 28, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01133782||121448|
NCT01133769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAH 1198|Operative Versus Non-Operative Treatment of Clavicle Fracture in PolyTrauma|Operative Versus Non-Operative Treatment For Clavicle Fracture in the PolyTrauma Patient With Associated Chest Injury. A Prospective, Randomized Clinical Trial||University of Kentucky|Yes|Withdrawn|June 2010|June 2013|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|79 Years|No|Probability Sample|Patients who present with a unilateral clavicle fractures which are >2cm displaced, >2cm        shortened, significantly comminuted, or are tenting the skin or which are bilateral and        with associated chest injury and with or without additional injuries to the abdomen,        pelvis or extremities will be approached for the study.|May 2012|May 9, 2012|May 27, 2010||No|Institutional issues Institution issues|No||https://clinicaltrials.gov/show/NCT01133769||121449|
NCT01134354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEFTOM EURASIA|The Role of Patient Expectations in Traumatic Orthopedic Outcomes-TEFTOM EURASIA|The Role of Patient Expectations in Traumatic Orthopedic Outcomes TEFTOM: The Trauma Expectation Factor - Trauma Outcomes Measure TEFTOM EURASIA||AO Clinical Investigation and Documentation|No|Completed|June 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|199|||Both|18 Years|N/A|No|Non-Probability Sample|Patient 18 years of age or older with an isolated ankle or distal tibia fracture,        scheduled for and undergoing one of the following surgeries for their fracture (Open        fracture and internal fixation (ORIF, external fixation (EF) or EF followed by ORIF)|June 2014|June 18, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134354||121404|
NCT01116869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901|China CellSearch Study|A Multi-Center, Prospective Study to Evaluate the Ability of CTC Enumeration Using the CellSearch® Circulating Tumor Cell Kit to Predict Prognosis and to Assess the Agreement Between CTC and Imaging Determined Response in MBC Patients 一项评价CellSearch® 循环肿瘤细胞检测试剂盒对复发转移性乳腺癌患者进行循环肿瘤细胞检测 以预测病人预后的能力及循环肿瘤细胞检测和影像学疗效判断之间一致性的多中心、前瞻性的研究||Johnson & Johnson Medical, China|Yes|Active, not recruiting|March 2010|December 2013|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|500|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The hazard ratio of disease progression in patients with unfavorable versus favorable CTC        counts at baseline, 3-4 weeks and 6-8 weeks after the initiation of therapy will be        estimated using Cox regression.        Kaplan-Meier plots for PFS will be constructed using the favorable and unfavorable CTC        patient groups. The log-rank test will be used to determine if the curves for the two CTC        groups are statistically significantly different.        The hazard ratio of death in patients with unfavorable versus favorable CTC counts at each        blood draw time point will be estimated using Cox regression. Kaplan-Meier plots for OS        will be constructed using the favorable and unfavorable CTC patient groups.|September 2011|May 29, 2013|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01116869||122737|
NCT01116882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPH00|Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings|A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site|MASS COMM|Harvard Clinical Research Institute|Yes|Completed|June 2006|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3691|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|April 29, 2010||No||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01116882||122736|
NCT01113047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100ADE01|Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Single Pill (SPC) Combination of Aliskiren 300 mg / Amlodipine 10 mg in Hypertensive Patients Not Adequately Respond to an Uptitrated 4 Week Therapy With the SPC of Olmesartan 40 mg / Amlodipine 10 mg, With a Potential Extension if Patients Still Not Adequately Respond With a 4 Week Therapy With the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg|AWESOME|Novartis||Completed|May 2010|||October 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|347|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|April 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01113047||123029|
NCT01113060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFACTs2010-001|Aspirin Effectiveness Study|Aspirin Effectiveness in Coronary Artery Disease Patients in Ireland||Royal College of Surgeons, Ireland|No|Recruiting|April 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Representative sample of coronary artery disease patients in Ireland receiving aspririn        therapy for secondary prevention of cardiovascular events|May 2010|May 7, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113060||123028|
NCT01099475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2-067|Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery|Randomized Controlled Trial on the Effect of Intermittent Pedicle Clamping Using 15 or 30 Minutes Ischemic Intervals During Liver Surgery||Maastricht University Medical Center|No|Completed|October 2007|April 2011|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|No|||October 2014|October 13, 2014|April 1, 2010||No||No|January 18, 2014|https://clinicaltrials.gov/show/NCT01099475||124069|
NCT01099787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00022|Pediatric Alliance for International Neurogastrointestinal Functional Research|Pediatric Alliance for International Neurogastrointestinal Functional Research Registry||Nationwide Children's Hospital||Recruiting|April 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|4 Years|16 Years|No|Non-Probability Sample|Patients ages 4 through 16 years of age (up to the day of the 17th birthday) will be        recruited from the Nationwide Children's Hospital Gastrointestinal Department that are        presenting with chronic or intermittent abdominal pain of any severity lasting at least 2        months.|June 2011|June 21, 2011|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01099787||124045|
NCT01103687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ad26.ENVA.01 Mucosal/IPCAVD003|Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults|A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety, Mucosal Immunogenicity and Innate Immune Responses of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad26.ENVA.01 (rAd26) HIV-1 Mucosal/IPCAVD-003 Vaccine Study)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|July 2010|||September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01103687||123748|
NCT01103401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH-EYE02|Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery|Ketorolac Plus Tobramycin/Dexamethasone vs. Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery||Veroia General Hospital|Yes|Completed|October 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|145|||Both|55 Years|95 Years|No|||April 2010|April 14, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103401||123770|
NCT01100398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Williams-NASH1|Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy|Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Utilizing Ultrasound and Percutaneous Liver Biopsy: A Prospective Cohort Study||Brooke Army Medical Center|Yes|Completed|January 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples Without DNA|liver biopsies and serum blood samples may be obtained|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients 18 to 70 years of age who have access to care through the Primary Care Clinics or        the Gastroenterology Clinic at Brooke Army Medical Center|December 2010|December 23, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01100398||124000|
NCT01099462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/07*3|Ibuprofen Concentration in Cerebro Spinal Fluid (CSF) of Infants and Children|||Assaf-Harofeh Medical Center|No|Recruiting|June 2007|June 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Whole blood CSF|Both|3 Months|18 Years|No|Non-Probability Sample|children and Infants 3 month to 18 years of age with fever (rectal temperature >38.0OC or        oral temperature > 37.6 OC)|March 2010|April 6, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099462||124070|
NCT01099761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A031-03|Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy||Acceleron Pharma, Inc.|Yes|Terminated|April 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Male|4 Years|N/A|No|||January 2013|January 31, 2013|April 2, 2010|Yes|Yes|Based on preliminary safety data.|No||https://clinicaltrials.gov/show/NCT01099761||124047|
NCT01099774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-048|Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|||Allergan|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|597|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|April 6, 2010|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT01099774||124046|
NCT01100983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ssallon-HMO-CTC|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2010|||||N/A|N/A|N/A||||||||||||||April 19, 2015|March 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100983||123955|
NCT01100996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/168|Anti-inflammatory Effects of Enriched Enteral Nutrition During Human Experimental Endotoxemia|The Effect of Enriched Enteral Nutrition on Inflammation and Sub-clinical Organ Dysfunction During Human Endotoxemia|VIHE|Radboud University|Yes|Completed|February 2010|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2010|June 6, 2011|April 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100996||123954|
NCT01132690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-06-005|A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease|A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease||Protalix|Yes|Completed|August 2010|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|2 Years|17 Years|No|||November 2014|November 10, 2014|May 26, 2010|Yes|Yes||Yes|October 28, 2014|https://clinicaltrials.gov/show/NCT01132690||121532|
NCT01132976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-1207-15046|The Personal Concerns Inventory Study (PCI)|The Addition of a Goal-based Motivational Interview to Standardised Treatment as Usual to Reduce Dropouts From a Service for Patients With Personality Disorder: A Feasibility Study|PCI|Nottinghamshire Healthcare NHS Trust|No|Completed|December 2009|July 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132976||121510|
NCT01132989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RevMM2009|Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma|Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma|REvMM2009|Florida Academic Dermatology Centers|Yes|Recruiting|May 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132989||121509|
NCT01133249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-09-01|Total Hip Registry|Total Hip Registry||Heekin Orthopedic Research Institute|No|Enrolling by invitation|July 2005|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|942|||Both|21 Years|N/A|No|Non-Probability Sample|Population: All total hip replacements        Selection: Males and non-pregnant females over the age of 21|March 2015|March 30, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01133249||121489|
NCT01133522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080398|Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 145 in Subjects With Hyperlipidemia on Stable Doses of a Statin||Amgen|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|May 27, 2010|No|Yes||No|September 23, 2015|https://clinicaltrials.gov/show/NCT01133522||121468|
NCT01133795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAFRI|Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment|Effect of Administration of Intravenous Albumin and Oral Midodrine on Renal Function in Patients With Cirrhosis and Functional Renal Impairment|MAFRI|Hospital Clinic of Barcelona|Yes|Recruiting|February 2010|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||March 2015|March 18, 2015|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01133795||121447|
NCT01134055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110852|Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration|MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration||GlaxoSmithKline|Yes|Completed|June 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|510|||Both|50 Years|N/A|No|||July 2013|March 27, 2014|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01134055||121427|
NCT01134367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GRS-DUM-2010/1|An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease|An Epidemiological, Postmarketing Observational Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease (GERD) on Patients' Daily Life||AstraZeneca|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|primary care clinics|July 2011|July 13, 2011|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134367||121403|
NCT01134666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 062202-517|An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer|An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer||Merck KGaA||Terminated|November 2009|April 2017|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|165|Samples With DNA|Whole Blood and Tissue|Both|N/A|N/A|No|Non-Probability Sample|Subjects with KRAS wild-type CRC receiving FOLFOX/FOLFIRI and cetuximab in India.|November 2014|November 7, 2014|May 28, 2010||No|The study was discontinued due to slow recruitment and subjects not completing follow up    period.|No||https://clinicaltrials.gov/show/NCT01134666||121380|
NCT01116908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA270|Safe Drinking Water For Households With Infants Born to HIV-Positive Mothers Pilot Study|Safe Drinking Water For Households With Infants Born to HIV-Positive Mothers in Zambia: Piloting a Household Water Treatment Intervention|SWIM|London School of Hygiene and Tropical Medicine|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Female|N/A|N/A|No|||August 2011|August 12, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01116908||122734|
NCT01117220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281196|Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)|Four Week, Double Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)||Pfizer|Yes|Withdrawn|June 2010|April 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117220||122711|
NCT01105260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901040|Effects of an Early Wheelchair Reconditionong Program on Functional Independence in Spinal Cord-inured Individuals|Effects of an Early Wheelchair Reconditionong Program on Functional Independence in Spinal Cord-inured Individuals||Centre Hospitalier Universitaire de Saint Etienne|Yes|Terminated|March 2010|June 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with acute spinal cord injury (SCI) from trauma, medical or surgical pathology at        levels between C7 and L1|July 2015|July 27, 2015|March 23, 2010||No|Difficulty to include patients|No||https://clinicaltrials.gov/show/NCT01105260||123627|
NCT01103440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO-07-0200|Aspirin Resistance and Percutaneous Coronary Intervention (PCI)|A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention|RESIST|Icahn School of Medicine at Mount Sinai|Yes|Completed|April 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103440||123767|
NCT01103700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003030R|Evaluation of Multidisciplinary Palliative Care on Terminal Cancer Patients in Taiwan|Evaluation of Multidisciplinary Palliative Care on Terminal Cancer Patients in Taiwan||National Taiwan University Hospital|Yes|Not yet recruiting|May 2010|August 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|65 Years|No|Probability Sample|Main care givers of deceased patients|April 2010|April 14, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103700||123747|
NCT01103713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661201|Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa|An Open Label, Non-comparative Study To Evaluate Parasitological Clearance Rates And Pharmacokinetics Of Azithromycin And Chloroquine Following Administration Of A Fixed Dose Combination Of Azithromycin And Chloroquine (Azcq) In Asymptomatic Pregnant Women With Plasmodium Falciparum Parasitemia In Sub-saharan Africa||Pfizer|Yes|Terminated|March 2011|October 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Female|16 Years|35 Years|No|||January 2015|January 22, 2015|April 7, 2010||No|See termination reason in detailed description.|No|July 16, 2014|https://clinicaltrials.gov/show/NCT01103713||123746|
NCT01100099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007068|HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease|||Oslo University Hospital|No|Completed|September 2006|September 2012|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 18, 2012|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01100099||124021|
NCT01100112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-01-02/06|(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets|Multicenter, Open-Label Efficacy and Safety Study of Oral Budesonide-MMX 9mg Extended Release Tablets in Patients With Mild to Moderate, Active Ulcerative Colitis||Valeant Pharmaceuticals International, Inc.|No|Completed|February 2010|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|75 Years|No|||May 2014|May 30, 2014|April 6, 2010|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01100112||124020|This was an open label study. There was no reference therapy for statistical analysis.
NCT01099488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113737|A Study in Healthy Adults Having Received a Single Vaccine Administration to Support the Development of Immunological Assays|A Study in Healthy Adults Having Received a Single Vaccine Administration to Support the Development of Immunological Assays||GlaxoSmithKline||Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01099488||124068|
NCT01099800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005216-01|Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM|Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM||Arizona State University|Yes|Enrolling by invitation|July 2010|August 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|600|||Both|5 Years|12 Years|No|Non-Probability Sample|To ensure diverse representation of Latino families and healthcare settings, the sample        will be recruited from two school-based health clinics and one clinical practice site in        Phoenix, AZ, and two inner-city hospital asthma clinics in the Bronx, NY. Approximately        300 families will be recruited and enrolled from the asthma/allergy and general pediatric        clinics and ER at Jacobi Medical Center and North Central Bronx Hospital (N= 150), Phoenix        Children's Hospital Breathmobile (N= 75), and the two school-based health clinics in        Phoenix (N= 75).|June 2011|June 22, 2011|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099800||124044|
NCT01100684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMP3001|Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)|A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)||Tioga Pharmaceuticals|No|Completed|May 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|611|||Both|18 Years|79 Years|No|||December 2013|December 17, 2013|April 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100684||123978|
NCT01100697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH-HL-09-181|Outcome of Fetal Spina Bifida|Fetal Spina Bifida -Prenatal Course and Outcome in 103 Cases A Single Center Experience.||University of Luebeck|No|Recruiting|December 2009|||October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|110|||Both|12 Weeks|12 Years|No|Non-Probability Sample|Fetuses with spina bifida identified at prenatal ultrasound examination between 1993 and        2009|September 2014|September 10, 2014|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01100697||123977|
NCT01100424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-20|Assessment of Tear Film-Based Proteins Associated With Care Solution Induced Corneal Staining|Assessment of Tear Film-Based Proteins Associated With Care Solution Induced Corneal Staining||Alcon Research|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2012|October 19, 2012|April 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100424||123998|
NCT01100710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHD|Age Gender Left Ventricular Mass and Cardiac Troponin T|Relative Contribution of Age, Gender and Left Ventricular Mass as Quantified by Cardiac Magnetic Resonance Tomography to Detectable Levels of Cardiac Troponin T in a Healthy Reference Population Aged Below 70 Years||Heidelberg University|No|Completed|March 2007|December 2009|Actual|March 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|116|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|residents of Heidelberg and urban hinterland|February 2007|April 8, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01100710||123976|
NCT01100723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0623|Trial to Optimize Mineral Outcomes in Dialysis Patients|Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients||University of Colorado, Denver|No|Completed|March 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||October 2012|December 3, 2012|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100723||123975|
NCT01132391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAC|Perianal Versus Endoanal Application of Glyceryl Trinitrate 0.4% Ointment for Chronic Anal Fissure|Perianal vs Endoanal Application of Glyceryl Trinitrate 0.4% Ointment in the Treatment of Chronic Anal Fissure: Results of a Randomized Controlled Trial.||Hospital General Universitario Elche|No|Completed|January 2009|June 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||September 2009|May 27, 2010|September 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01132391||121555|
NCT01132703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPI 101|Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers|A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of RP-1127 (Glyburide for Injection) in Healthy Male and Female Volunteers||Remedy Pharmaceuticals, Inc.|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|June 3, 2014|April 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132703||121531|
NCT01132716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-T1000-PVFD-1|Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions||Roxane Laboratories|No|Completed|September 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01132716||121530|
NCT01132729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALA-T1000-PVFS-1|Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions||Roxane Laboratories|No|Completed|September 2006|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01132729||121529|
NCT01133262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WashU-Tai10|Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device|Effectiveness in Head and Neck Cancer Detection Using PET Insert Device||Washington University School of Medicine|Yes|Withdrawn|June 2010|December 2011|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with biopsy proven squamous cell carcinoma of the head and neck with suspected        lymph node metastasis|March 2015|March 9, 2015|May 26, 2010||No|Feasibility/pilot study of 5 subjects registration not required|No||https://clinicaltrials.gov/show/NCT01133262||121488|
NCT01133535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHC-001|Idiopathic Recurrent Acute Pancreatitis (IRAP)|The IRAP Registry is a Multi-center Prospective, Collaborative Database Designed to Create a National Registry That Collects Information Concerning Episodes of Idiopathic Recurrent Acute Pancreatitis From Major 'Pancreas' Centers. Intent is to do a Comparative Effectiveness Study of Interventions.|IRAP|Aurora Health Care|Yes|Completed|June 2010|April 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with recurrent pancreatitis presenting to major centers for pancreatic disorders|June 2014|June 24, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01133535||121467|
NCT01133808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0371|Effectiveness of Rotavirus Immunization in Nicaragua|Effectiveness of Rotavirus Immunization at the Community Level in Nicaragua||University of North Carolina, Chapel Hill|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|667|Samples Without DNA|Stool samples obtained from children who develop diarrhea during the course of the study. In      addition, stool samples will also be collected from normal children to serve as controls in      laboratory analysis.|Both|N/A|5 Years|No|Probability Sample|Children under age 5 in Leon, Nicaragua|September 2011|September 8, 2011|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133808||121446|
NCT01133821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08090019|Acute Psychotherapy for Bipolar II Depression|Acute Psychotherapy for Bipolar II Depression||University of Pittsburgh|Yes|Completed|August 2010|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|65 Years|No|||February 2016|February 10, 2016|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133821||121445|
NCT01134068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADJUST|Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism|Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism: a Prospective Outcome Study.|ADJUST|University Hospital, Geneva|No|Completed|October 2010|December 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3306|||Both|18 Years|N/A|No|||April 2013|May 27, 2015|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134068||121426|
NCT01134380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIANT200905-04|Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment|Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment|GIANT|Biotronik France|Yes|Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1500|Samples With DNA|DNA Samples from saliva to observe CYP2C19 genetic variants|Both|18 Years|N/A|No|Probability Sample|STEMI patients treated within the first 24 hours following the first chest pain by Primary        PCI (with stent implantation)|July 2011|October 7, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134380||121402|
NCT01104909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DryWeightESRDxBloodPressure|How to Get a Better Dry Weight in End-stage Renal Disease (ESRD) Population for Improving Blood Pressure Control|Randomized Clinical Trial Evaluating Different Protocols for Improving the Way of Getting the Best Dry Weight for Hemodialysis Patients, Looking for Blood Pressure Control, Measured by ABPM||Universidade de Passo Fundo|Yes|Completed|April 2008|January 2010|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||April 2008|April 14, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104909||123654|
NCT01103674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAL-1150|Safety and Efficacy Study of the Combined Ablation Procedure to Treat Paroxysmal Atrial Fibrillation|Feasibility Study For Safety and Efficacy Evaluation Of The Combined Ablation Procedure For The Treatment Of Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation|CAP STOPS AF|nContact Surgical Inc.|Yes|Terminated|March 2010|July 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||July 2012|April 2, 2014|April 13, 2010|Yes|Yes|enrollment challenges, only one patient enrolled|No||https://clinicaltrials.gov/show/NCT01103674||123749|
NCT01134549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-4169-001|Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Rising Single Intravenous Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers||KAI Pharmaceuticals|No|Completed|June 2010|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 20, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134549||121389|
NCT01134562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-4169-002|Safety, Tolerability and Pharmacokinetics of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism|A Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism||KAI Pharmaceuticals|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134562||121388|
NCT01134848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/10/2007|A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers|A Randomised, Double Blind Cross-over Study of Serial MRCP Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers||University of Nottingham|No|Completed|January 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2010|June 1, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134848||121366|
NCT01099501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHMD- OT- 01|Oxepa in Multiple Trauma|Oxepa in Multiple Trauma: Prospective, Randomized, Comparative, Double-blind, Controlled Clinical Study|OMT|Rabin Medical Center|Yes|Recruiting|April 2010|August 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|90 Years|No|||October 2013|November 21, 2013|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01099501||124067|
NCT01135108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-1678-004|Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Two-Period Crossover Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Spinal Cord Injury||KAI Pharmaceuticals|No|Completed|March 2009|May 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01135108||121346|
NCT01130753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-08-029|Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer|A Phase II Trial of Neoadjuvant Erlotinib (Tarceva®) Followed by Surgery for Selected Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer||Samsung Medical Center||Completed|January 2007|December 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01130753||121679|
NCT01131039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00023366|Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer|A Phase II Trial of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer||Emory University|Yes|Withdrawn|January 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|19 Years|N/A|No|||December 2013|December 19, 2013|May 21, 2010|Yes|Yes|PI left Emory|No||https://clinicaltrials.gov/show/NCT01131039||121657|
NCT01100125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_ENDO2|Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment|Comparison Between Sitagliptin Add-on Therapy and Insulin Dose Increase Therapy for Uncontrolled Type 2 Diabetes on Insulin Therapy||Seoul National University Bundang Hospital|Yes|Completed|April 2010|November 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|90 Years|No|||October 2013|October 24, 2013|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01100125||124019|
NCT01100411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-10-01|Changes in Invitro and ex Vivo Lens Metrology With Daily Wear Contact Lenses|Changes in Invitro and ex Vivo Lens Metrology With Experienced Daily Wear Contact Lens Wearers||Alcon Research|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|July 17, 2012|April 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100411||123999|
NCT01131624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-ASAP-2009-01|Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women|An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women|ASAP|Vifor Inc.|Yes|Completed|May 2010|April 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Female|18 Years|N/A|No|||December 2014|May 27, 2015|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131624||121614|
NCT01131637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-01-301|Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure||Zensun Sci. & Tech. Co., Ltd.|Yes|Terminated|April 2010|December 2012|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|80 Years|No|||July 2012|August 1, 2012|May 25, 2010||No|Sponsor has designed another study to replace the current study|No||https://clinicaltrials.gov/show/NCT01131637||121613|
NCT01131988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859002|Bioavailability Study of Tacrolimus Capsules, 5 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Two Way Crossover, Balanced, Single Dose, Comparative Evaluation of Relative Bioavailability of Tacrolimus Capsules 5 mg With That of 'Prograf' Capsules 5 mg in Healthy Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2008|March 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131988||121586|
NCT01132001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBP5|Ambulatory Versus Home Blood Pressure Measurement|EVALUATION OF BLOOD PRESSURE MEASUREMENTS OUTSIDE OFFICE: COMPARISON OF DIAGNOSIS BASED ON EITHER AMBULATORY OR HOME BLOOD PRESSURE MEASUREMENTS||University of Athens|No|Recruiting|October 2009|December 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|20 Years|90 Years|No|Non-Probability Sample|Subjects referred to an outpatient hyperetension clinic for arterial hypertension|October 2012|October 9, 2012|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132001||121585|
NCT01132378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-01-01|Midvastus Versus Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty|Mini-midvastus vs. Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty||Heekin Orthopedic Research Institute|No|Completed|January 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|80 Years|No|||February 2012|December 16, 2013|May 26, 2010||No||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01132378||121556|The strength of the study is the standardized surgical protocol performed by a single surgeon and a prospectively randomized consecutive and blinded subjects
NCT01132742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPEN|Malnutrition and Outcome in Hospitalized Children in Europe|Malnutrition and Outcome in Hospitalized Children in Europe (ESPEN Network Grant Project)||Ludwig-Maximilians - University of Munich||Completed|February 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2567|||Both|1 Month|18 Years|No|Non-Probability Sample|This study will be performed in hospitalized children attending general paediatric wards.        The network comprises at least 13 teams from at least 11 countries. A total of 2700        patients will be recruited.|January 2013|January 10, 2013|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132742||121528|
NCT01133002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOXA_L_02260|Canadian Outpatient VTE Management Registry|National, Prospective, Observational, Cohort Study of Venous Thromboembolism (VTE) Management With the Low Molecular Weight Heparin, Enoxaparin, in the Outpatient Setting in Canada|RECOVERY|Sanofi||Completed|August 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|915|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with objectively confirmed symptomatic VTE treated at approximately 15 outpatient        clinics across Canada which use enoxaparin for the treatment of acute VTE.|August 2010|August 30, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01133002||121508|
NCT01133275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16099|Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS|A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|April 2010|August 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||November 2015|December 14, 2015|May 25, 2010|No|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01133275||121487|The study was terminated at the end of step one, as no signal of higher response of the combination was observed compared to what was reported on the MDS-002 study.
NCT01133548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S176.1.010|Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males|A Multiple Dose Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of 5 g Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males||Abbott|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Male|18 Years|80 Years|No|||June 2011|June 30, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01133548||121466|
NCT01133561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHafez 2010|Pioglitazone in Psoriasis- A Clinical and Molecular Study.|The CLINICAL And MOLECULAR EFFECTS Of An INSULIN SENSITIZING DRUG: 'PIOGLITAZONE'On PSORIASIS TREATMENT||Cairo University|Yes|Completed|January 2010|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||February 2011|February 22, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01133561||121465|
NCT01133834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|meningococcemia|Correlation Between Cytokines and the Severity of Meningococcal Disease|Clinical and Laboratorial Factors Associated With the Severity of Meningococcal Disease||University of Sao Paulo General Hospital|Yes|Completed|March 2003|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|None Retained|blood sample cerebral spinal fluid|Both|6 Months|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients admitted at the Intensive Care Unit of the Instituto de Infectologia Emílio Ribas|February 2003|June 14, 2011|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133834||121444|
NCT01134081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-PER-002-CTX Bio Adjunct|Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts|Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts||University of Michigan|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|48|||Both|21 Years|N/A|No|||January 2008|May 28, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01134081||121425|
NCT01105845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100092|Genetics of Motor Learning|Genetics of Motor Learning||National Institutes of Health Clinical Center (CC)||Terminated|April 2010|December 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|5|||Both|18 Years|100 Years|No|||December 2015|December 22, 2015|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01105845||123582|
NCT01103180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH084904|Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder|SSRIs and Self-harm in Borderline Personality Disorder||University of Chicago|Yes|Completed|September 2010|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|40 Years|No|||April 2015|April 7, 2015|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103180||123787|
NCT01135134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06332|Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)|Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No.P06332)||Merck Sharp & Dohme Corp.|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|333|||Both|5 Years|15 Years|No|||March 2015|March 30, 2015|May 28, 2010||No||No|October 14, 2011|https://clinicaltrials.gov/show/NCT01135134||121344|
NCT01135147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40/09|Obesity and Obstructive Sleep Apnea (OSA) in Children|Dietary Therapy for Obesity-related Sleep-disordered Breathing in Children||Assaf-Harofeh Medical Center|No|Not yet recruiting|June 2010|||June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||May 2010|June 1, 2010|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01135147||121343|
NCT01130766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01-059|Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)|Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC)||Samsung Medical Center|Yes|Enrolling by invitation|June 2008|||May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||April 2010|May 25, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130766||121678|
NCT01135121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wean1|Role of Diaphragm Fatigue in Weaning From Mechanical Ventilation|Pilot Study on the Role of Diaphragm Fatigue in Weaning From Mechanical Ventilation||University Medical Center Nijmegen|Yes|Recruiting|May 2010|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients weaning from mechanical ventilation|June 2015|June 9, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135121||121345|
NCT01131325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AUS20|Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations|A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations|MACS1148|Novartis|No|Terminated|October 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01131325||121636|
NCT01131351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-08-210|Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis|A Phase 2, Multi-center, Non-controlled, Open-label Dose Escalation Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Orally Administered OPC-67683 Two Times Daily to Patients With Pulmonary Multidrug-Resistant Tuberculosis Refractory to Conventional Treatment||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|64 Years|No|||June 2012|June 26, 2012|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131351||121635|
NCT01131299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100088|Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol|Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol||National Institutes of Health Clinical Center (CC)||Completed|March 2010|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2014|February 21, 2015|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131299||121638|
NCT01131312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908076|Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)|Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)||National Institutes of Health Clinical Center (CC)||Completed|February 2008|||||Phase 3|Observational|N/A|||Anticipated|5060|||Female|18 Years|N/A|No|||July 2015|October 17, 2015|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131312||121637|
NCT01132014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 19809|Autologous OC-DC Vaccine in Ovarian Cancer|A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|May 2010|||July 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Primary Purpose: Treatment|||Actual|67|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132014||121584|
NCT01132027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859003|Bioavailability Study of Tacrolimus Capsules, 5 mg of Dr. Reddys's Laboratories Limited Under Non-Fasting Conditions|An Open Label, Two Way Crossover, Balanced, Single Dose, Comparative Evaluation of Relative Bioavailability of Tacrolimus Capsules 5 mg With That of 'Prograf' Capsules 5 mg in Healthy Subjects Under Non-fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2008|March 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132027||121583|
NCT01132040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-620/06|Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced. Randomized, Two-treatment, Two-period, Two-sequence, Single Dose,Crossover, Bioequivalence Study of Primidone 50 mg Tablets of Comparing With That of Mysoline® 50 mg Tablets Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|August 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132040||121582|
NCT01132053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-P-000089|Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)|Role of Inflammation in PML||Beth Israel Deaconess Medical Center|Yes|Enrolling by invitation|June 2004|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|180|Samples With DNA|Blood, Urine, CSF if needed for clinical management.|Both|18 Years|N/A|No|Non-Probability Sample|PML patients of 18 years of age or older in the Boston area will be included in this        study.        The control groups will include HIV+ and HIV- individuals who need to have a lumbar        puncture for their clinical management.|January 2016|January 19, 2016|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132053||121581|
NCT01132066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-000102|Transcranial Direct Current Stimulation (TDCS) for Facilitating Swallowing Improvement After an Acute Unilateral Hemispheric Stroke|Pilot Study of Transcranial Direct Current Stimulation for Facilitating Swallowing Improvement After an Acute Unilateral Hemispheric Infarction||Beth Israel Deaconess Medical Center|No|Completed|April 2007|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|21 Years|N/A|No|||February 2014|February 27, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01132066||121580|
NCT01132755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-011|Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage|Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|115|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132755||121527|
NCT01132768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSE-OLM-01-09|The Confirmatory Olmesartan Plaque Regression Study|Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study|CONFIRM|Daiichi Sankyo Inc.|No|Terminated|May 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|40 Years|N/A|No|||March 2012|March 30, 2012|May 26, 2010|No|Yes|Low recruitment|No||https://clinicaltrials.gov/show/NCT01132768||121526|
NCT01133015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001-009-305|Comparison of Fractional Flow Reserve and Intravascular Ultrasound|Comparison of Fractional Flow Reserve and Minimal Luminal Area by Intravascular Ultrasound in Evaluating Intermediate Coronary Artery Stenosis in Each Coronary Artery||Seoul National University Hospital|Yes|Recruiting|March 2009|November 2011|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|191|||Both|21 Years|85 Years|No|||July 2011|July 20, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01133015||121507|
NCT01133574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S354.1.001|This is a Single Ascending Dose Tolerance Study|A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects||Abbott|No|Terminated|February 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|14||Actual|47|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 25, 2011|May 21, 2010||No|Part A completed successfully 22 July 2010, Part B will be separate PET study|No||https://clinicaltrials.gov/show/NCT01133574||121464|
NCT01134120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13201|A Study in Myeloproliferative Disorders|A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders||Eli Lilly and Company|No|Active, not recruiting|April 2010|August 2015|Anticipated|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134120||121422|
NCT01134133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gurgle|Can Hospital Acquired Pneumonia be Prevented in Patients Who Gurgle?|Can Hospital Acquired Pneumonia be Prevented in Patients Who Gurgle?||Bridgeport Hospital|No|Withdrawn|February 2010|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2010|June 21, 2011|May 25, 2010||No|Slow recruitment (preemptive treatment of gurglers, after association was published)|No||https://clinicaltrials.gov/show/NCT01134133||121421|
NCT01134393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.33|TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch|A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension"..."||Boehringer Ingelheim||Completed|May 2010|||May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|502|||Both|18 Years|85 Years|No|||December 2013|December 13, 2013|May 28, 2010||||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01134393||121401|
NCT01134406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR 1.0|Hydros Joint Therapy and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis (OA)|A Prospective, Multi-center, Randomized, Double-blind Feasibility Study to Evaluate the Safety and Performance of Hydros Joint Therapy and Hydros-TA Joint Therapy for Management of Pain Associated With Osteoarthritis in the Knee||Carbylan Therapeutics, Inc.|No|Completed|April 2010|October 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|98|||Both|40 Years|85 Years|No|||November 2011|November 2, 2011|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01134406||121400|
NCT01134718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017155|TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration|Pilot BA Study With Phase III/Commercial Versus Phase IIB Formulation. A Phase I, Open Label, Randomized, Single Dose, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of Potential Phase III Formulations Compared to the Phase IIb Capsule||Tibotec Pharmaceuticals, Ireland|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134718||121376|
NCT01134094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROSSBAT|Combined Randomised and Observational Study of Type B Ankle Fracture Treatment|Combined Randomised and Observational Study of Type B Ankle Fracture Treatment|CROSSBAT|The University of New South Wales|Yes|Completed|August 2010|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134094||121424|
NCT01134107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12175|Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use|A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|133|||Both|13 Years|N/A|No|||April 2013|April 4, 2013|May 27, 2010|Yes|Yes||No|September 27, 2012|https://clinicaltrials.gov/show/NCT01134107||121423|Input to primary endpoint measurements (SMBG) contained approximately 40% missing data. Several analyses to account for missing data were conducted and results from these additional analyses were consistent with results from the original analysis.
NCT01134913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0101-1|Multi-Markers In the Diagnosis of Acute Coronary Syndrome|Multi-Markers In the Diagnosis of Acute Coronary Syndrome - Sample Procurement Cohort 3|Midas 3|Biosite|No|Completed|March 2010|December 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|621|Samples Without DNA|EDTA Plasma Specimens|Both|19 Years|N/A|No|Non-Probability Sample|Patients presenting to the ED within 6 hours with symptoms consistent with ACS.|August 2012|August 30, 2012|May 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01134913||121361|
NCT01134926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0014-10-EMC|Non Surgical Management for Uterine Residua After Pregnancy Termination, Abortion or Delivery|Phase Study Comparing Between Expectant Management and Misoprostol Treatment for Intra-uterine Residua After Pregnancy Termination, Abortion or Delivery||HaEmek Medical Center, Israel||Terminated|June 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Female|18 Years|N/A|No|||June 2015|June 21, 2015|May 29, 2010||No|The principal investigator left the organization|No||https://clinicaltrials.gov/show/NCT01134926||121360|
NCT01105858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910091|Molecular and Clinical Profile of Diabetes Mellitus and Its Complications|Molecular and Clinical Profile of Diabetes Mellitus and Its Complications||National Institutes of Health Clinical Center (CC)||Recruiting|March 2010|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 3, 2016|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01105858||123581|
NCT01106716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-1678-003|Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia|A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia||KAI Pharmaceuticals|No|Completed|March 2009|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106716||123515|
NCT01134302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013962|Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation|The Influence of Postoperative Systemic Oxygen Transport on Neurologic and Functional Outcomes in Infants Undergoing Single Ventricle Palliation With Norwood and Hybrid Management Strategies||The Hospital for Sick Children|Yes|Recruiting|March 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|3 Months|No|||May 2010|May 27, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01134302||121408|
NCT01134575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0872|CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)|Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2010|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|16 Years|N/A|No|||April 2015|April 10, 2015|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134575||121387|
NCT01130480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD000933|Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study|Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study||Hoffmann-La Roche||Completed|May 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1000|||Both|1 Year|70 Years||||June 2010|March 1, 2016|May 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130480||121700|
NCT01130493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX066-B09-06|A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066|A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease|CLE with OLE|IMPAX Laboratories, Inc.|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|30 Years|N/A|No|||September 2013|September 27, 2013|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130493||121699|
NCT01130506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01488|Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia||National Cancer Institute (NCI)||Completed|May 2010|November 2014|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|59 Years|No|||June 2014|December 19, 2014|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01130506||121698|
NCT01131052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00038789|Diabetes in the Elderly: Prospective Study|Diabetes Care in Nursing Home Residents: A Randomized Controlled Study|DMElderly|Emory University|Yes|Completed|March 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|60 Years|N/A|No|||December 2014|December 18, 2014|May 19, 2010|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01131052||121656|
NCT01131078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18524|A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum|A Randomized, Open-label Study Comparing the Effect of 3 Chemotherapy Regimens Containing Avastin on Time to Disease Progression in Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|June 2005|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|306|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 20, 2010||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01131078||121654|
NCT01131650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mc201106|Prevalence of Diabetic Retinopathy in São José do Rio Preto-SP-Brazil|Prevalence of Diabetic Retinopathy in São José do Rio Preto-SP-Brazil||Hospital do Olho Rio Preto|Yes|Completed|March 2009|May 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|710|||Both|N/A|N/A|No|Probability Sample|The study sample, of 710 patients was derived from the HIPERDIA (Diabetes and High-blood        pressure social health care program) of São José do Rio Preto|May 2010|May 26, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01131650||121612|
NCT01131663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0063-09-ZIV|Design and Development of an Infant's Oriented Face Mask|Design and Development of an Infant's Oriented Face Mask||Ziv Hospital|No|Recruiting|April 2010|April 2012|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|hospitals,primary care clinic, community sample|May 2010|May 25, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131663||121611|
NCT01131676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.25|BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).|A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk||Boehringer Ingelheim||Completed|July 2010|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|7064|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 26, 2010||||No||https://clinicaltrials.gov/show/NCT01131676||121610|
NCT01131689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-10-009|Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma|Phase 1 Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma||Samsung Medical Center|No|Completed|September 2009|September 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131689||121609|
NCT01132404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18002|Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448|A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin||Millennium Pharmaceuticals, Inc.|No|Terminated|November 2010|December 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Male|40 Years|72 Years|No|||January 2012|January 26, 2012|May 26, 2010|No|Yes|Developing new formulation of study drug. New study to open next year under a new protocol.|No||https://clinicaltrials.gov/show/NCT01132404||121554|
NCT01132417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074X1-4548|In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance|In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance||King Faisal University|No|Suspended|September 2009|July 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples Without DNA|Sputum, whole blood, urine, tissue|Both|N/A|N/A|No|Non-Probability Sample|Definition: For observational studies only, a description of the population from which the        groups or cohorts will be selected (e.g., primary care clinic, community sample, residents        of a certain town).|June 2011|June 21, 2011|September 19, 2009||No|researchers delay|No||https://clinicaltrials.gov/show/NCT01132417||121553|
NCT01133288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00024249|Yulex Glove Prospective Study in Spina Bifida|Yulex Glove Prospective Study||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Terminated|July 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|60 Years|No|||November 2011|November 21, 2011|May 26, 2010||No|The funder never paid for the study.|No|July 11, 2011|https://clinicaltrials.gov/show/NCT01133288||121486|The study was not completed because funding was never received. The two (2/7)enrolled participants who met screening eligibility criteria were terminated early without receiving the yulex glove intervention.
NCT01133847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0531|Interventions for Children With Attention and Reading Disorders|Reading ICARD: Interventions for Children With Attention and Reading Disorders|ICARD|The University of Texas Health Science Center, Houston|Yes|Completed|November 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|288|||Both|7 Years|12 Years|No|||December 2015|December 8, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01133847||121443|
NCT01133860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eltrombopag-MYH9-2008|Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease|An Exploratory Phase II Dose Escalation Study of Eltrombopag in MYH9 Related Disease||IRCCS Policlinico S. Matteo|Yes|Completed|January 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|16 Years|N/A|No|||July 2010|July 22, 2011|May 28, 2010||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT01133860||121442|
NCT01134146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0057|Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)|A Phase I Study of Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma After Radical Pleurectomy/Decortication (PD)||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2010|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134146||121420|
NCT01134159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REWARDS TLX|Registry Experience at the Washington Hospital Center, Des - Taxus Liberte Versus Xience V|Registry Experience at the WAshington Hospital CenteR, DeS - Taxus Liberte vs Xience V|REWARDS TLX|Medstar Research Institute|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients male or female, 18 years or older whom have undergone PCI with either Taxus        Liberte or Xience V|June 2011|June 1, 2011|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134159||121419|
NCT01134445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT07/02|An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement|Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy PROXIMA™ Hip in Subjects With Indications Suitable for a Primary Total Hip Arthroplasty||DePuy International|No|Active, not recruiting|February 2010|January 2026|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|70 Years|No|||September 2015|December 14, 2015|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01134445||121397|
NCT01134419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X09-01-0040|Implementing a Comprehensive Handoff Program to Improve Pediatric Patient Safety|Implementing a Comprehensive Handoff Program to Improve Pediatric Patient Safety||Children's Hospital Boston|No|Completed|July 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|84|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01134419||121399|
NCT01134939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1536|Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data|Non-interventional Observational Study With Viramune® Plus Antiretroviral Backbone Combination in HIV-infected Women and Male Patients. Gender Specific Evaluation of Data.||Boehringer Ingelheim||Completed|May 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|265|||Both|18 Years|N/A|No|Non-Probability Sample|patients|January 2015|January 9, 2015|June 1, 2010||||No|December 31, 2014|https://clinicaltrials.gov/show/NCT01134939||121359|
NCT01134952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO12961|Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)|A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection||London Health Sciences Centre|No|Completed|June 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|May 27, 2010||No||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01134952||121358|Greater than expected baseline variation; technical problems with laboratory measurement of HCV (two different platforms used); and poor recruitment over a long period make the results difficult to interpret.
NCT01134965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.158|to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers|An Open Two-way Cross-over Study to Evaluate the Effect of Multiple Doses of Flibanserin 100 mg Film-coated Tablets Given Once Daily on the Single Dose Pharmacokinetics of Digoxin 0.5 mg in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|June 2010|||July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|June 1, 2010||||No||https://clinicaltrials.gov/show/NCT01134965||121357|
NCT01130610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 089/2009|Pre-anesthetic Evaluation and Cost Reduction|Pre-anesthetic Evaluation and Cost Reduction Perioperative||Santa Casa de Misericórdia de Belo Horizonte|Yes|Completed|September 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|1 Year|90 Years|No|Probability Sample|patients admitted to the institution to undergo elective surgery or diagnostic procedures        with anesthesia.|May 2010|May 24, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130610||121690|
NCT01106989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-203|Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points|An Open-label Pilot Study Evaluating Synera® in the Treatment of Patients With Pain Associated With Myofascial Trigger Points||ZARS Pharma Inc.|No|Completed|June 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106989||123494|
NCT01134588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2009/VL-01|Assessment of Quality of Life in Disorders of the Pelvic Floor|Assessment of Quality of Life in Disorders of the Pelvic Floor|U-GYN-QOL|Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|129|||Female|18 Years|N/A|No|||March 2015|March 24, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01134588||121386|
NCT01134601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100132|A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum|A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum||National Institutes of Health Clinical Center (CC)||Terminated|May 2010|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2012|February 19, 2014|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134601||121385|
NCT01134861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-9410|Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|A Three-Arm Phase III Study of Concomitant Versus Sequential Chemotherapy and Thoracic Radiotherapy for Patients With Locally Advanced Inoperable Non-small Cell Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|July 1994|March 2012|Actual|October 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|610|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134861||121365|
NCT01134874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09040121|The Comparison of a Technology-Based System and an In-Person Behavioral Weight Loss Intervention|The Comparison of a Technology-Based System and an In-Person Behavioral Weight Loss Intervention||University of Pittsburgh|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|55 Years|No|||August 2015|August 4, 2015|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01134874||121364|
NCT01130792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCHPROBIO|Probiotics for Infectious Diarrhea in Children in South India|Probiotics for Infectious Diarrhea in Children in South India||Christian Medical College, Vellore, India|Yes|Completed|May 2010|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|124|||Both|6 Months|5 Years|No|||February 2015|February 2, 2015|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130792||121676|
NCT01130779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-07-078|The Continuation of Erlotinib|The Continuation of Erlotinib Treatment in Non-small Cell Lung Cancer Patients Whose Brain Lesion is the Only Site of Progression : Pilot Study||Samsung Medical Center||Enrolling by invitation|August 2009|||August 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130779||121677|
NCT01131065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG0907|Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients|Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients.||Grifols Biologicals Inc.|No|Completed|July 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|May 25, 2010|Yes|Yes||No|December 28, 2015|https://clinicaltrials.gov/show/NCT01131065||121655|
NCT01131390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bpthosp11001|Ventilator Settings and Comfort|What Ventilator Settings Are Most Comfortable for Patients With COPD or Obesity.||Bridgeport Hospital|No|Recruiting|March 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2010|June 21, 2011|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131390||121632|
NCT01131364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-F16IL2DOXO-04/07|Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients|A Dose-finding, Pharmacokinetic, Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours||Philogen S.p.A.|No|Terminated|June 2008|December 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131364||121634|
NCT01131377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCAZM-150|Acetazolamide Facilitates Ventilator Weaning|Acetazolamide Facilitates Ventilator Weaning Multicenter, Prospective, Double Blinded, Randomised Controlled Trial||Asan Medical Center|No|Recruiting|May 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||April 2010|May 26, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01131377||121633|
NCT01132079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. ELBE-2005|Pimecrolimus and Epidermal Barrier Function|Role for Pimecrolimus in Restoring Skin Barrier Function and Normalizing Epidermal Lipid Content and Differentiation in Atopic Epidermis: a Randomized, Intra-patient, Double-blind (Right/Left Arm) Study in Adults With Atopic Dermatitis Treated With 1 % Pimecrolimus Cream and 0.1 % Betamethasone Cream as Treatment Control Twice Daily for 3 Weeks||University of Kiel||Completed|March 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|N/A|No|||March 2005|May 26, 2010|May 26, 2010||||No||https://clinicaltrials.gov/show/NCT01132079||121579|
NCT01132092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCISAL-IS-001|The Normal Standard of Brainstem Auditory Evoked Potential in Adults Using a New Device|The Normal Standard of Brainstem Auditory Evoked Potential in Adults Using a New Device||Universidade Estadual de Ciências da Saúde de Alagoas||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|||||Both|25 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Adults Normal hearing subjects and hearing loss Subjects|May 2010|May 26, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132092||121578|
NCT01132430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBMC001|Motivational Interviewing for Medication Adherence in Asthma|Impact of a Motivational Interviewing Intervention on Medication Adherence in Patients With Asthma||Hopital du Sacre-Coeur de Montreal|No|Completed|June 2008|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132430||121552|
NCT01132443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115902|W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne|A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne Vulgaris||GlaxoSmithKline|No|Completed|May 2010|July 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|12 Years|45 Years|No|||May 2015|May 21, 2015|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01132443||121551|
NCT01133301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Naltrexone-BPD|Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder|Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder||Central Institute of Mental Health, Mannheim|Yes|Completed|August 1998|October 2001|Actual|August 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|50 Years|No|||May 2010|May 26, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01133301||121485|
NCT01133587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1704|Patient Guided Psychiatric Admissions|Patient Guided Psychiatric Admissions (Self-referral to Inpatient Beds)||St. Olavs Hospital|No|Completed|May 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01133587||121463|
NCT01134432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHA-KA04062-gms|Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia|Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial.||Copenhagen University Hospital at Herlev|No|Completed|March 2005|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134432||121398|
NCT01134744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-3|Evaluating Validity of Clinical Criteria for Requesting Chest X-Rays in Trauma Patients|Study of Accuracy of Clinical Examination for Chest Trauma||Isfahan University of Medical Sciences|Yes|Completed|October 2006|October 2007|Actual|October 2007|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|385|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Three hundred and eighty six|October 2006|June 18, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134744||121374|
NCT01134978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16758|Neural Mechanisms of the Contextual Interference Effect: A fNIRs and EEG Study|Neural Mechanisms of the Contextual Interference Effect: A fNIRs and EEG Study|GRID12007|Drexel University|No|Completed|November 2007|June 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|November 4, 2011|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134978||121356|
NCT01130883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-109|Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR|Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR in Patients With Upper Respiratory Infection, Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in the Czech Republic||Abbott|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3130|||Both|18 Years|N/A|No|Non-Probability Sample|patients with: acute tracheitis, acute tracheobronchitis or acute bronchitis, acute        exacerbation of chronic bronchitis, mild community-acquired pneumonia|September 2011|September 8, 2011|May 6, 2010||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT01130883||121669|
NCT01106404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1651|RestoreSensor Study|RestoreSensor Study||MedtronicNeuro|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||August 2012|August 17, 2012|April 2, 2010|Yes|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT01106404||123539|
NCT01134887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-190|Controlling Hypertension Outcomes by Improved Communication & Engagement|Controlling Hypertension Outcomes by Improved Communication & Engagement (CHOICE)|CHOICE|VA Office of Research and Development|No|Completed|August 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134887||121363|
NCT01130519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100114|A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer|A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|85|||Both|18 Years|N/A|No|||August 2015|September 17, 2015|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130519||121697|
NCT01130532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13461|A Study in Erectile Dysfunction|Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function||Eli Lilly and Company|No|Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|623|||Male|18 Years|N/A|No|||December 2012|December 3, 2012|May 24, 2010|Yes|Yes||No|December 3, 2012|https://clinicaltrials.gov/show/NCT01130532||121696|
NCT01130805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-03-068|A Study of Pazopanib With CAPEOX in AGC Patients|A Phase II Study of Pazopanib in Combination With Capecitabine and Oxaliplatin (CAPEOX) in Patients With Advanced Gastric Cancer||Samsung Medical Center|No|Recruiting|May 2010|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130805||121675|
NCT01130818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0492-CL-101|First-in-Human Single Ascending Dose of GLPG0492|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of GLPG0492 in Healthy Subjects and Open Relative Bioavailability Study of Oral Solution Versus Solid Formulation, Fasted and Fed, in Elderly Subjects||Galapagos NV|No|Completed|May 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|28|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 20, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01130818||121674|
NCT01131091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK-0403-1.02US|A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403|A Phase 1, Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403||Kowa Research Institute, Inc.|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Anticipated|30|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131091||121653|
NCT01131403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC/wet wipe|Clinical Analysis of the Influence of Using the Skin Care Products on the Diaper Area in Comparison With Using a Cotton Wool Cloth, Moistened With Clear Water on the Skin Physiology of the Newborns From the 1st Day to the 4th Week of Life|Standardized Skin Care Regimen in the Diaper Area: a Prospective, Randomized Clinical Study on Skin Barrier Function and Epidermal IL-1α||Charite University, Berlin, Germany|Yes|Completed|May 2007|October 2007||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2||44|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|group of 40 healthy full-term newborn babies|May 2007|June 21, 2011|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01131403||121631|
NCT01131702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02399|Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions|Randomized,2-way Crossover, Bioequivalence Study of Ranitidine 300 mg Tablets Zantac 300 mg Tablets Administered as 1 x 300 mg Tablet in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2003|March 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|June 8, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131702||121608|
NCT01131715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHAN-002|Pharmacist Follow-up, a Qualitative Study of Patient Experience|Pharmacist Follow-up of Patients With Coronary Heart Disease. A Qualitative Study of Patient Experience.||Hospital Pharmacy of North Norway Trust|No|Active, not recruiting|March 2010|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|N/A||1|Actual|4|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients included in the study "Pharmacist follow-up of patients with CHD".|May 2010|May 26, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01131715||121607|
NCT01132105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCISAL-PM-001|Vestibular Evoked Myogenic Potential: A New Device Propose|Vestibular Evoked Myogenic Potential: A New Device Propose||Universidade Estadual de Ciências da Saúde de Alagoas||Completed||||||N/A|Observational|Time Perspective: Prospective||1|||||Both|25 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults, Normal Hearing, Normal Vestibular fuction,|May 2010|May 26, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132105||121577|
NCT01132118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001926|Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis|Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis|RA PLUS|Brigham and Women's Hospital|Yes|Completed|June 2010|June 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|May 25, 2010||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01132118||121576|
NCT01133028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0066-00|Classroom-Level Intervention to Promote Peers' Acceptance of Children With Attention Deficit Hyperactivity Disorder (ADHD)|Classroom-Level Intervention to Promote Peers' Acceptance of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)||University of Virginia|No|Not yet recruiting|January 2011|June 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01133028||121506|
NCT01133899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-85E-S09|Guanidinoacetic Acid (GAA) Administration in Physically Active Men and Women|The Effects of Medium-term Oral Guanidinoacetic Acid (GAA) Administration on Human Performance, Body Composition, and Metabolic Outcomes in Physically Active Men and Women||Metropolitan University, Serbia|Yes|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|20 Years|25 Years|Accepts Healthy Volunteers|||December 2011|December 18, 2011|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01133899||121439|
NCT01133613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-OA-003|Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee|||Stryker Biotech||Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|51|||Both|40 Years|N/A|No|||January 2012|January 30, 2012|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133613||121461|
NCT01134172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-071|Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life|Breast Cancer and the Workforce: Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life (BCW)||Memorial Sloan Kettering Cancer Center||Recruiting|May 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|750|||Female|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit participants from Memorial Sloan-Kettering Cancer Center (MSKCC), four of        its community-based outpatient treatment centers, and four urban community hospitals and        clinics that serve large populations of ethnic minorities in New York City. The MSKCC        outpatient regional sites are located in New Jersey (Basking Ridge) and New York, with two        in Long Island (Commack and Rockville Centre) and another in Westchester County (Sleepy        Hollow).|October 2015|October 5, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134172||121418|
NCT01134185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0001-C103|Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment|Evaluation of Pharmacokinetics, Safety and Tolerability of a Single Dose of Prucalopride, in Subjects With Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects|HI|Movetis|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|70 Years|No|||October 2011|April 17, 2012|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01134185||121417|
NCT01134458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024341|Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes|Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes|FIMDM_CVD|Duke University|No|Completed|December 2010|February 2014|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|98|||Both|18 Years|90 Years|No|||July 2014|July 18, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134458||121396|
NCT01134731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100329001|Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation|Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation|AFSP|University of Alabama at Birmingham|No|Completed|May 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|19 Years|65 Years|No|||February 2016|February 3, 2016|May 20, 2010||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01134731||121375|The inherent risk of the condition and concerns about the safety of the study, the high risk of impulsive and aggressive behavior, and high levels of distress making placebo-controlled studies difficult. Placebo arm terminated early due to dropout.
NCT01135004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912060R|Pathogenesis of Primary Spontaneous Pneumothorax|Molecular Pathogenesis of Primary Spontaneous Pneumothorax||National Taiwan University Hospital|No|Recruiting|March 2010|February 2013|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Thoracoscopic bullectomy will be performed in spontaneous pneumothorax patients. Part of the      surgcal specimen (lung tissue) will be obtained for RNA and protein analyses.|Both|14 Years|40 Years|No|Non-Probability Sample|Primary spontaneous pneumothorax most commonly occurs in young, tall, lean males without        underlying pulmonary disease.|March 2010|June 1, 2010|May 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01135004||121354|
NCT01107015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041426|Mobile Diabetes Management|Mobile Diabetes Management||University of Maryland|Yes|Completed|June 2008|September 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|230|||Both|18 Years|64 Years|No|||December 2013|December 10, 2013|April 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01107015||123492|
NCT01107522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T09-10644|Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas|A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas||Tactical Therapeutics, Inc.||Recruiting|May 2010|||June 2015|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|3||||||Both|18 Years|N/A|No|||July 2014|July 10, 2014|April 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01107522||123453|
NCT01134900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081002|Achieving Medication Safety During Acute Kidney Injury|Achieving Medication Safety During Acute Kidney Injury: The Impact of Clinical Decision Support and Real-Time Pharmacy Surveillance||Vanderbilt University|Yes|Completed|June 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|540|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|May 27, 2010||No||No|January 25, 2012|https://clinicaltrials.gov/show/NCT01134900||121362|
NCT01130558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-0022131|Efficacy of Structured Insulin Order|Efficacy of Structured Insulin Orders in Improving Glycemic Control||Massachusetts General Hospital|No|Completed|March 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||May 2010|May 24, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130558||121694|
NCT01130545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100115|Imaging Techniques in MRI|Imaging Techniques in MRI||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 1, 2016|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130545||121695|
NCT01131130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655|Feasibility of a New Silicone Hydrogel Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Lens||Bausch & Lomb Incorporated|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|120|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|May 25, 2010|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01131130||121650|
NCT01131416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10FEB010938|The Effects of Gum Chewing on Bowel Function Recovery Following Cesarean Section|The Effects of Gum Chewing on Bowel Function Recovery Following Cesarean Section: Randomized Controlled Trial|GUM01|Chiang Mai University|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131416||121630|
NCT01131104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11638|A Study to Determine if There is a Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Phosphodiesterase Type 5 (PDE5) Inhibitors|A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)||Eli Lilly and Company|No|Completed|May 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|312|||Male|18 Years|N/A|No|Non-Probability Sample|Potential cases of acute NAION will be prospectively identified by approximately 20        neuro-ophthalmology centers in the US|February 2016|February 15, 2016|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01131104||121652|
NCT01131117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110889|Fetal Programming of Obesity|||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|April 2010|August 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|Samples With DNA|Blood, urine, stool, placenta, cord blood and umbilical cord may be collected from study      participants.|Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women|September 2015|September 9, 2015|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01131117||121651|
NCT01132131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/486|Management of Urinary Tract Infections in Primary Care Facilities.|Use of Standardized Delegation Form in Diagnosing and Treating Acute Cystitis in Primary Care Facilities.||University of Oslo|No|Completed|August 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|443|||Female|16 Years|55 Years|No|||February 2012|February 1, 2012|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132131||121575|
NCT01132144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP10340/09|Endometrial Injury for Assisted Reproduction|Endometrial Injury Prior Ovulation Induction for Assisted Reproductive Techniques: a Randomized Controlled Trial||University of Sao Paulo|No|Terminated|June 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Female|18 Years|38 Years|No|||January 2014|January 2, 2014|May 26, 2010||No|Stopped after safety analysis because of significant benefit of intervention.|No|June 18, 2013|https://clinicaltrials.gov/show/NCT01132144||121574|
NCT01131728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391/04|Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fasting Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Naproxen Sodium 220 mg + Pseudoephedrine HCL 120 mg ER Tablets and Aleve Cold and Sinus® Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|July 2004|September 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131728||121606|
NCT01131741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2009-141|Comparison of Perfusion Index, T Wave Amplitude, Systolic Blood Pressure and Heart Rate|Comparison of Perfusion Index, T Wave Amplitude, Systolic Blood Pressure and Heart Rate as an Indicator for Detecting Intravascular Injection of Epinephrine Containing Test Dose During Operation in Anesthetized Adults||Seoul National University Hospital|No|Recruiting|May 2010|April 2011|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|20 Years|80 Years|No|||February 2011|February 13, 2011|May 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01131741||121605|
NCT01132781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007ENT03|Theophylline in Rhinitis|The Effect of Theophylline in Patients With Allergic Rhinitis||University of East Anglia|No|Completed|May 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|16 Years|65 Years|No|||August 2012|August 22, 2012|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132781||121525|
NCT01132794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707176037|A Study to Assess the Analgesia and Sedation Using Intranasal Dexmedetomidine in Third Molar Surgery Under Local Anaesthesia|||The University of Hong Kong||Completed||||||Phase 3|Interventional|N/A|2||||||Both|18 Years|40 Years|No|||May 2010|June 15, 2010|May 24, 2010||||No||https://clinicaltrials.gov/show/NCT01132794||121524|
NCT01133041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHCH2010L2|Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps|Prospective Comparison of NBI and i-Scan in Real-time Histological Prediction of Diminutive Colonic Polyps||Soon Chun Hyang University|Yes|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|142|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|September 26, 2011|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133041||121505|
NCT01133054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-0908-010-060|Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis|Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis||Seoul National University Hospital|No|Completed|August 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|85 Years|No|||December 2013|December 1, 2013|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01133054||121504|
NCT01133626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-304|Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP HFA Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis When Administered in Adolescent and Adult Subjects (12 to 45 Years of Age) With Perennial Allergic Rhinitis (PAR)||Teva Pharmaceutical Industries|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|107|||Both|12 Years|45 Years|No|||May 2012|May 31, 2012|May 27, 2010|Yes|Yes||No|April 23, 2012|https://clinicaltrials.gov/show/NCT01133626||121460|
NCT01133639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000047|Ketorolac Effects on Post-operative Pain and Bone Healing|Does Ketorolac Delay Bone Healing and Improve Post-operative Pain?: A Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial||Beth Israel Deaconess Medical Center|No|Recruiting|May 2010|May 2013|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|65 Years|No|||May 2010|May 27, 2010|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133639||121459|
NCT01133912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-08-370|Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)|Phase Ib Study of Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) in Patients With HER2 Positive Operable Breast Cancer|PGT|National Cancer Center, Korea|No|Completed|March 2009|October 2011|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||January 2012|January 1, 2012|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01133912||121438|
NCT01134198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6013|Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients|Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients||New York State Psychiatric Institute|Yes|Active, not recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Male|18 Years|60 Years|No|||August 2015|August 31, 2015|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01134198||121416|
NCT01134211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-337-C-033|Clinical Comparison of Two Daily Disposable Lenses Among Daily Disposable Lens Wearers|||Alcon Research||Completed|May 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|316|||Both|N/A|N/A|No|||October 2011|June 26, 2012|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134211||121415|
NCT01100346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700623-509|Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen|A Prospective, Single Center, Observational Study on the Predictive Factors of Ovarian Response in Ovulation Induction (OI) With Intrauterine Insemination (IUI) of a Gonal-f Low-dose Step-up Regimen||Merck KGaA|No|Terminated|January 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Serum|Female|20 Years|35 Years|No|Non-Probability Sample|Female subjects with regular menstrual cycles aged between 20 and 35 years in Taiwan.|November 2012|March 17, 2014|March 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100346||124004|
NCT01134757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-17/10|Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.|A Retrospective and Prospective, Diagnostic, Open-label, Single-center Study of the Safety of the Bronchial Allergen Challenge With House Dust Mite, Grass Pollen and Alternaria and Predictors for Positive Reaction.||Johann Wolfgang Goethe University Hospitals|No|Completed|January 2011|October 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|425|||Both|5 Years|18 Years|No|||March 2015|March 16, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01134757||121373|
NCT01134991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0041-10LND /FX2010-02|Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients|Pilot, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Moderate to Severe Rosacea Patients||Foamix Ltd.|No|Terminated|June 2010|||March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|N/A|No|||August 2010|August 25, 2015|May 26, 2010||No|Difficulty in recruitment|No||https://clinicaltrials.gov/show/NCT01134991||121355|
NCT01100905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-11|An Iron-containing Food Product for the Prevention of Diminished Iron Status in Soldiers|Utility of an Iron-containing Food Product for the Prevention of Diminished Iron Status During Basic Combat Training||United States Army Research Institute of Environmental Medicine|No|Completed||||||N/A|Interventional|N/A|||||||Female|18 Years|42 Years|No|||April 2010|April 23, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100905||123961|
NCT01101243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-072|Maintenance of Vitamin D Level by UVB Radiation|How Much UVB Radiation is Necessary to Maintain Summer Vitamin D Level During Winter?||Bispebjerg Hospital|No|Completed|October 2008|April 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2010|April 8, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101243||123935|
NCT01130623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100120|A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors|A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors||National Institutes of Health Clinical Center (CC)||Withdrawn|May 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|25 Years|No|||November 2011|December 30, 2011|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01130623||121689|
NCT01130636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV22970|Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation|An Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation, Phase IV Trial||Pharmahungary Group|Yes|Completed|June 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Female|18 Years|N/A|No|||October 2012|October 4, 2012|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130636||121688|
NCT01130649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epitrack|Remote Tracking of Epilepsy Patients|Pilot Study of Real-time Automated Tracking System for Patients With Epilepsy||University of California, San Francisco|No|Withdrawn|July 2010|July 2013|Anticipated|July 2011|Anticipated|N/A|Observational|N/A||2|Actual|0|||Both|6 Months|65 Years|No|Probability Sample|Patients will be recruited from the UCSF and VAMC Outpatient Epilepsy Centers. All study        participants must have a confirmed diagnosis of epilepsy (defined by two or more        unprovoked seizures) for at least 6 months.|April 2012|April 2, 2012|May 24, 2010||No|not funded|No||https://clinicaltrials.gov/show/NCT01130649||121687|
NCT01107548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080250hb|Prevention of Stroke and Dementia in Primary Care|Intervention Project of Cerebrovascular Diseases and Dementia in the District of Ebersberg|INVADE|Technische Universität München|No|Terminated|January 2001|March 2010|Actual|December 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3908|||Both|55 Years|N/A|Accepts Healthy Volunteers|||April 2010|February 16, 2012|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107548||123451|
NCT01107561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011192|Different Techniques for Emergency Cricothyroidotomy|Incision-first Versus Classic Seldinger Technique for Emergency Cricothyroidotomy|CRIC|University of Alberta|No|Completed|April 2010|July 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2011|October 13, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01107561||123450|
NCT01130571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS03/05/09|Establishment and Characterization of Patient-Derived Non-Small Cell Lung Cancer Xenografts and Cell Cultures|||National University Hospital, Singapore||Recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|21 Years|N/A|No|Probability Sample|The investigators for this protocol are clinicians and scientists in the departments of        Cardiac/Thoracic and Vascular Surgery, Haematology and Oncology, Pathology, Radiation        Oncology, Respiratory Medicine and the Cancer Sciences Institute of Singapore (CSIS) from        NUH and NUS with major roles in their departments in the clinical management and/or        research of lung cancer. Each will be providing access to clinical information and        assisting in the collection and processing of samples, according to their resources and        expertise.|January 2014|January 21, 2014|May 24, 2010||||No||https://clinicaltrials.gov/show/NCT01130571||121693|
NCT01130831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-702|Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy|A Phase IV, Multi-Centre, Non-interventional Study Evaluating the Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium Based Phosphate Binder Therapy on Serum Phosphorous Control, Concomitant Vitamin D Therapy and Bone Related Biochemical Parameters in End Stage Renal Disease Patients on Hemodialysis||Shire||Completed|May 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|N/A|No|Non-Probability Sample|Haemodialysis patients with hyperphosphataemia|July 2013|July 9, 2013|May 20, 2010|No|Yes||No|April 19, 2013|https://clinicaltrials.gov/show/NCT01130831||121673|
NCT01131429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGH-TKIs|A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations|Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations||Chinese PLA General Hospital|Yes|Not yet recruiting|June 2010|June 2015|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2010|May 26, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131429||121629|
NCT01131754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA 2007|Heparin 100U/L for Prevention of PVC Complications|STUDIO CLINICO RANDOMIZZATO SULL'UTILIZZO DI EPARINA PER LA PROFILASSI DELLA TROMBOFLEBITE DA CATETERE VENOSO PERIFERICO||IRCCS Policlinico S. Matteo|No|Completed|June 2007|September 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|214|||Both|18 Years|N/A|No|||February 2007|June 13, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01131754||121604|
NCT01131767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|398/04|Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Naproxen Sodium 220 mg + Pseudoephedrine HCL 120 mg ER Tablets and Aleve Cold and Sinus® Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|July 2004|September 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131767||121603|
NCT01131780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|432/04|Bioequivalency Study of Ibuprofen 200 mg and Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's Under Fasting Conditions|A Randomized, Open Label, 2-treatment, Single Dose, Crossover, Bioequivalence Study of Ibuprofen 200 mg+Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2004|November 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131780||121602|
NCT01132157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0598|Comparison of the Protective Effect of Desflurane and Propofol in Patients With Renal Transplantation|The Comparison of Preconditioning Effect of Desflurane and Antiapoptotic Effect of Propofol in Patients With Kidney Transplantation||Yonsei University|No|Completed|March 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|99|||Both|20 Years|N/A|No|||March 2014|March 4, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01132157||121573|
NCT01132170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-623/06-00|Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, 2-treatment, 2-period, 2-sequence, Single Dose, Crossover, Bioequivalence Study of Divalproex Sodium DR 500 mg Tablets and Depakote® DR 500 mg Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2006|November 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132170||121572|
NCT01132456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP123|RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia|RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia|R-A|Medtronic Vascular|Yes|Active, not recruiting|June 2010|April 2016|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|May 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01132456||121550|
NCT01132469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA09-003|Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer|Long-term Follow-up After Endoscopic Submucosal Dissection for Early Gastric Cancer|ESD|National Evidence-Based Healthcare Collaborating Agency|No|Recruiting|May 2010|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1158|||Both|20 Years|N/A|No|||May 2010|May 26, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01132469||121549|
NCT01132807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50604|Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma|Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|May 2010|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|149|||Both|18 Years|60 Years|No|||July 2015|July 23, 2015|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132807||121523|
NCT01132820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02043|Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Cediranib (Recentin; AZD2171, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|June 2010|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132820||121522|
NCT01133600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0020-15|Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens|Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens||Clinical Alliance for Research & Education - Infectious Diseases, LLC.|Yes|Terminated|August 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|May 28, 2010|Yes|Yes|Lack of patient enrollment|No||https://clinicaltrials.gov/show/NCT01133600||121462|
NCT01133873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP20C-101|Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects|A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of Sequential Ascending Dose Levels to Assess the Safety, Tolerability and Electrocardiographic Effects of Propoxyphene Napsylate Capsules (and Its Metabolite Norpropoxyphene) When Administered Orally to Healthy Adult Subjects||Xanodyne Pharmaceuticals|No|Terminated|June 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||April 2011|April 12, 2011|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133873||121441|
NCT01133886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEC-MDS|Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure|Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure|DEC-MDS|King's College London|No|Recruiting|September 2010|September 2013|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2010|September 2, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01133886||121440|
NCT01099423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-30073|Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer|Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma|SURTIME|European Organisation for Research and Treatment of Cancer - EORTC||Recruiting|April 2010|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|458|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099423||124073|
NCT01133925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG-003-08|Optical Coherence Tomography in Long Lesions|Optical Coherence Tomography in Long Native Coronary Artery Lesions Treated With Multiple Novel Zotarolimus-eluting Stents: LONG OCT STUDY|LONG OCT|A.O. Ospedale Papa Giovanni XXIII|Yes|Active, not recruiting|May 2008|May 2011|Anticipated|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||May 2010|May 28, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01133925||121437|
NCT01100034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4654|Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis|A Long-term, Prospective, Observational Cohort Study Of The Safety And Effectiveness Of Etanercept In The Treatment Of Paediatric Psoriasis Patients In A Naturalistic Setting: A Post-authorization Safety Study (Pass)|PURPOSE|Pfizer|No|Active, not recruiting|November 2010|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|6 Years|17 Years|No|Non-Probability Sample|dermatology clinics|January 2016|January 25, 2016|April 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100034||124026|
NCT01100645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCPEMS0210|Efficacy and Safety of the Herbal Medicine Sominex ® (Passiflora Incarnata L., Valeriana Officinalis L. and Crataegus Oxyacantha L.), Manufactured by the Laboratory EMS S / A in Patients With Psychophysiological Insomnia|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|October 2010|February 2011|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||April 2010|October 26, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100645||123981|
NCT01134770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1092|Prenatal Exposure Effects Psychophysiology Study|Prenatal Cocaine and Neurobehavioral Factors Underlying Mother-Infant Interaction|PEEPS|University of North Carolina, Chapel Hill|No|Enrolling by invitation|July 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|150|Samples With DNA|Plasma from mothers and buccal cells from infants will be stored for possible DNA analysis      of target genes pending additional funding.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women or mothers with their newborn infants.|January 2016|January 4, 2016|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134770||121372|
NCT01101568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113506|A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects|A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects||GlaxoSmithKline|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101568||123911|
NCT01101581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hA20/90Y-hLL2-01|Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL|Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin's Lymphoma||Immunomedics, Inc.|No|Active, not recruiting|May 2010|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|March 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101581||123910|
NCT01130662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12010|Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia|Phase I Open-Label Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients With Acute Myeloid Leukemia||University of Kansas Medical Center|Yes|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130662||121686|
NCT01101256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|66/09|Determination of Residual Anticoagulatory Effects of Fondaparinux|Determination of Residual Anticoagulatory Effects of Prophylactic or Therapeutic Treatment With Fondaparinux||Johann Wolfgang Goethe University Hospitals|No|Recruiting|April 2010|October 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|110|Samples With DNA|Citrated blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with s.c. anticoagulant therapy (fondaparinux)|April 2010|April 12, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01101256||123934|
NCT01107847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH ROP/RCP|Regional Lung Opening and Closing Pressures in Patients With Acute Lung Injury|Measurement of Regional Lung Opening and Closing Pressures in Patients With Acute Lung Injury Using Electrical Impedance Tomography||University of Schleswig-Holstein|No|Recruiting||||||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2010|April 20, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107847||123429|
NCT01130844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-112|Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis|A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis||Shire|No|Completed|October 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|52|||Both|5 Years|17 Years|No|||June 2015|June 15, 2015|May 20, 2010|No|Yes||No|May 9, 2014|https://clinicaltrials.gov/show/NCT01130844||121672|
NCT01131143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902-70|Trial of Provider-to-Patient Interactive Voice Response (IVR) Calls to Improve Weight Management in Community Health Centers (CHCs)|An RCT of Provider-to-Patient IVR Calls to Improve Weight Management in CHCs|IVR|Indiana University|No|Completed|June 2009|January 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1228|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 29, 2013|September 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01131143||121649|
NCT01131442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG270371|Immunological Change and the Single Nucleotide Polymorphism (SNP) in Children With Irritable Bowel Syndrome (IBS)|||Chang Gung Memorial Hospital||Recruiting|November 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|out patient clinics in the hospital|May 2010|May 26, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131442||121628|
NCT01132183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-638/06|Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)|An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|February 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 26, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132183||121571|
NCT01132196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-624/06-00|Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, 2-treatment, 2-period, 2-sequence, Single Dose, Crossover, Bioequivalence Study of Divalproex Sodium DR 500 mg Tablets and Depakote® DR 500 mg Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2006|November 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132196||121570|
NCT01131793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-019|PowerAssert Radio-Frequency (RF) Guidewire Coronary In-Stent Chronic Total Occlusion (CTO)|Total Occlusion With Angioplasty After Using a Radiofrequency Guide Wire-Magnetic-Coronary|TOTAR|Stereotaxis|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01131793||121601|
NCT01132833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0802|Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy|Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.||UNC Lineberger Comprehensive Cancer Center|No|Active, not recruiting|December 2008|December 2018|Anticipated|December 2012|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Actual|18|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed multiple Multiple Myeloma|October 2015|October 21, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132833||121521|
NCT01132482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sildenafil CFTR|Effects of Sildenafil on CFTR-dependent Ion Transport Activity|Phase II Study of the Effects of Sildenafil on CFTR-dependent Ion Transport Activity||National Jewish Health|Yes|Recruiting|October 2015|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132482||121548|
NCT01133314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-eff 2010-2|Artemether-Lumefantrine Effectiveness in Guinea-Bissau 2|The Routine Use of Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Bissau - 2||Bandim Health Project|No|Active, not recruiting|May 2010|March 2014|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|App 50 - 100 microliters blood on filterpaper for identification of parasite. Furthermore,      whenever the health staff use a RDT this will be saved for the same analyses.|Both|N/A|15 Years|No|Non-Probability Sample|Children seeking a health centre and by the health staff given the diagnosis: malaria        and/or being treated with an antimalarial.|November 2012|March 16, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01133314||121484|
NCT01133093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENRICA|Cardiovascular Risk in Spain.|Study on Nutrition and Cardiovascular Risk in Spain.|ENRICA|Universidad Autonoma de Madrid||Enrolling by invitation|March 2008|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|13000|||Both|18 Years|N/A|No|Probability Sample|Community sample representative of the non-institutionalized Spanish population|May 2010|May 27, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133093||121501|
NCT01133327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTI|Adapt Monorail Carotid Stent System: A Postmarket Clinical Follow-up Study|Adapt™ Monorail™ Carotid Stent System: A Postmarket Clinical Follow-up Study|ASTI|Boston Scientific Corporation|No|Completed|June 2010|June 2012|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133327||121483|
NCT01099735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005565|Effect of Continuous Positive Airway Pressure (CPAP) on Lower Esophageal Sphincter Pressure in Morbidly Obese Patients|Effect of Continuous Positive Airway Pressure On Lower Esophageal Sphincter Pressure in Subjects Undergoing Bariatric Surgery||Oregon Health and Science University|Yes|Enrolling by invitation|January 2010|June 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|Adult Patients|January 2011|January 27, 2011|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01099735||124049|
NCT01099696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009120|Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and Bloating|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Benefit of a Probiotic (Bifidobacterium Infantis 35624) in Healthy Subjects With a History of Abdominal Discomfort and Bloating||Procter and Gamble|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099696||124052|
NCT01099709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1002|A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin® 10-mg Tablets||Purdue Pharma LP|No|Completed|January 2007|August 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|85|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2010|April 13, 2010|April 6, 2010|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT01099709||124051|
NCT01100359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUI-AGO-15|Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer|Phase II Multicenter Trial of the Austrian AGO With the Combination of Liposomal Doxorubicin (Myocet®) and Carboplatin in Primary Advanced or Metastatic and Recurrent Endometrial Cancer||National Cancer Institute (NCI)||Recruiting|November 2007|||October 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2011|August 6, 2013|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100359||124003|
NCT01100632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEREMS0310|Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals in Improvement of Stress and Fatigue|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Suspended|September 2010|December 2010|Anticipated|November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2010|October 26, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100632||123982|
NCT01100606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-011|A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age|A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF)||Forest Laboratories|Yes|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|1 Month|12 Months|No|||March 2014|March 5, 2014|March 31, 2010|Yes|Yes||No|March 5, 2014|https://clinicaltrials.gov/show/NCT01100606||123984|
NCT01100619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-008|A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors|A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors||Exelixis|No|Completed|April 2010|||August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|March 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100619||123983|
NCT01102400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2840C00001|A Study of MEDI-575 in Patients With Advanced Solid Malignancies|A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid Malignancies||AstraZeneca|Yes|Completed|March 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|20 Years|N/A|No|||February 2013|February 5, 2013|March 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01102400||123847|
NCT01102413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-CKD-02|Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia|A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia||Pharmacosmos A/S|Yes|Completed|April 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|March 26, 2010|Yes|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01102413||123846|
NCT01101815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA026336|Adherence to HIV Therapy in Heroin Addicts|Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone||University of Pennsylvania|No|Not yet recruiting|July 2010|June 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|64 Years|No|||January 2012|January 10, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101815||123892|
NCT01116271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9010C00009|Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec|A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination With Irinotecan, in 2nd Line Patients With K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer||AstraZeneca||Completed|April 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|April 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116271||122783|
NCT01131156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58108|Prevention of Postpartum Smoking Relapse in Mothers of Infants in the Neonatal Intensive Care Unit (NICU)|Prevention of Postpartum Smoking Relapse in Mothers of Infants in the Neonatal Intensive Care Unit||Loma Linda University|Yes|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|54|||Both|N/A|1 Week|No|||May 2014|May 12, 2014|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131156||121648|
NCT01131169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-051|Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions|A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Recruiting|May 2010|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|77|||Both|21 Years|72 Years|No|||January 2016|January 26, 2016|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131169||121647|
NCT01131455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTH-0071|ACP for Local Application in Ankle Arthrodesis|Autologous Concentrated Platelet-rich Plasma (Arthrex ACP®) for Local Application in Ankle Arthrodesis: A Prospective Outcome Analysis.||Columbia Orthopaedic Group, LLP|No|Terminated|October 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|70 Years|No|||November 2014|November 12, 2014|May 26, 2010||No|Study was terminated due to the untimely death of the investigator|No|July 29, 2014|https://clinicaltrials.gov/show/NCT01131455||121627|
NCT01131507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-018|PR-018: An Open-Label, Safety Extension of Study PR-011|A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF)||Forest Laboratories|Yes|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|12 Months|No|||January 2014|January 27, 2014|May 25, 2010|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01131507||121623|
NCT01132495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904|FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT|Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease||St. Jude Medical|Yes|Completed|May 2010|May 2015|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1170|||Both|21 Years|N/A|No|||October 2015|October 2, 2015|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01132495||121547|
NCT01132508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND-AUS-01|Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures|Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures||Synthes GmbH|No|Completed|September 2008|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|May 2015|May 26, 2015|February 16, 2010||No||No|November 11, 2014|https://clinicaltrials.gov/show/NCT01132508||121546|
NCT01132521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI/SAP-S|Ulinastatin in Severe Acute Pancreatitis|Multicenter, Double-bind, Randomised, Placebo Controlled Study of Ulinastatin in Severe Acute Pancreatitis||Techpool Bio-Pharma Co., Ltd.|Yes|Suspended|June 2010|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|70 Years|No|||July 2015|December 23, 2015|May 26, 2010||No|Revised project|No||https://clinicaltrials.gov/show/NCT01132521||121545|
NCT01133067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROJECT NO 754|Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients|A Prospective Study of Telephonic Contact and Subsequent Physical Follow up of Radically Treated Lung Cancer Patients|TELE001|Tata Memorial Hospital|Yes|Active, not recruiting|July 2010|August 2014|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|All curative lung cancer patients after there intial primary treatment who have already        been given scheduled appointment shall be called telephonically every 3 months. A set of        questions shall be asked to the patient in his /her vernacular during the telephonic        interview.After the telephonic interview, the patients shall then report to the cancer        care specialist at the Hospital for the due follow up visit.|July 2014|July 25, 2014|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133067||121503|
NCT01132846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024136|Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study|Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study|ROSE/RED ROSE|Duke University|Yes|Completed|August 2010|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|360|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|May 27, 2010|Yes|Yes||No|July 7, 2014|https://clinicaltrials.gov/show/NCT01132846||121520|
NCT01133106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37952-J|Living Well With Stroke|Psychosocial/Behavioral Intervention in Post-Stroke Depression (PSD)|PSD2|University of Washington|No|Active, not recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|21 Years|N/A|No|||May 2015|May 26, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01133106||121500|
NCT01133340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECTAL MRI SIM 25409|A Feasibility Study to Compare the Benefits of Endoscopic Tumor Clip Placement and 3T-MRI Simulation for Accurate Target Volume Definition for Rectal Cancer Patients Undergoing Pre-operative Chemoradiation|A Feasibility Study to Compare the Benefits of Endoscopic Tumor Clip Placement and 3T-MRI Simulation for Accurate Target Volume Definition for Rectal Cancer Patients Undergoing Pre-operative Chemoradiation||AHS Cancer Control Alberta|Yes|Completed|June 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133340||121482|
NCT01100658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS075|Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors|Effects of Methylphenidate on Neuropsychological Functioning in Children With Attention Deficits Secondary to Childhood Cancer||University of Minnesota - Clinical and Translational Science Institute|Yes|Terminated|May 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|8 Years|17 Years|No|||March 2015|March 16, 2015|April 7, 2010||No|Due to slow accrual|No|July 28, 2011|https://clinicaltrials.gov/show/NCT01100658||123980|Only 1 patient was enrolled in this study, no analysis/outcome data can be reported. This patient completed baseline assessment, but withdrew from the study before beginning the medication trial. No medications/placebo were administered.
NCT01100047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00005|Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 in Healthy Japanese Subjects After Single and Multiple Ascending Doses|JSMAD|AstraZeneca|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|63|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|March 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01100047||124025|
NCT01102426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-C-001-09|Aplidin - Dexamethasone in Relapsed/Refractory Myeloma|Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma|ADMYRE|PharmaMar|Yes|Active, not recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|March 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102426||123845|
NCT01101269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14815|Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease|Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease (KXK005).||University of Virginia|No|Recruiting|February 2010|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|April 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101269||123933|
NCT01101594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hLL1-DOX-01|A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma|A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma||Immunomedics, Inc.|No|Completed|July 2010|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|March 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101594||123909|
NCT01100918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004844BLT|Utility of Tissue Doppler Echocardiography for Selecting Patients for Cardiac Resynchronisation Therapy|Utility of Tissue Doppler Echocardiography for Selecting Patients for Cardiac Resynchronisation Therapy in Heart Failure|TIBI-HF|Barts & The London NHS Trust|No|Completed|February 2007|December 2010|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01100918||123960|
NCT01100931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100051|A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)|A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)||National Institutes of Health Clinical Center (CC)|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|April 8, 2010|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01100931||123959|
NCT01100944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100077|A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies|||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2010|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2015|July 22, 2015|March 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100944||123958|
NCT01103154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carvedilol vs. N+I|A Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding|A Controlled Trial of Nadolol Plus Isosorbide Mononitrate vs. Carvedilol for the Prevention of Variceal Rebleeding|Carvedilol|E-DA Hospital|Yes|Completed|March 2005|January 2010||January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Both|20 Years|75 Years|No|||October 2010|October 24, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01103154||123789|
NCT01116024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2005 Rev. 17-MAY-2007|ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000|ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000|Enable|Medtronic Cardiovascular|Yes|Active, not recruiting|May 2006|August 2014|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|173|||Both|21 Years|N/A|No|||February 2012|February 14, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01116024||122802|
NCT01116037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2008 Rev. D|ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study|ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study|PAS|Medtronic Cardiovascular|No|Terminated|September 2009|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|N/A|70 Years|No|||December 2015|December 15, 2015|April 8, 2010|Yes|Yes|Business decision to end study due to limited enrollment and study population|No||https://clinicaltrials.gov/show/NCT01116037||122801|
NCT01116284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-10-016|Laparoscopic Revision of an Enlarged Gastric Outlet After Gastric Bypass|Laparoscopic Suture Plication of an Enlarged Gastric Stoma in the Gastric Bypass Patient||Baystate Medical Center|No|Terminated|April 2010|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||February 2013|February 26, 2013|May 3, 2010|No|Yes|no patients to recruit|No||https://clinicaltrials.gov/show/NCT01116284||122782|
NCT01131468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTOTOXICITY RESEARCH IN PD|Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine|The Evaluation of the Protective Effect of N-Acetylcysteine Against Drug Induced Ototoxicity in Peritoneal Dialysis Patients||TC Erciyes University||Completed|February 2008|May 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|70 Years|No|||March 2010|May 26, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01131468||121626|
NCT01131481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Number 7248|Evaluation of Glistenings in Intraocular Lenses Implanted in Normal Patients Following Routine Cataract Extraction.|Evaluation of Glistenings in Intraocular Lenses AVS Model X-60 Vs AcrySof MA50-BM.|AVS Vs MA50BM|Fry Eye Associates and Fry Eye Surgery Center|Yes|Withdrawn|June 2010|July 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|0|||Both|18 Years|N/A|No|||June 2011|September 14, 2015|May 26, 2010|Yes|Yes|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01131481||121625|
NCT01131533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_134|Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human|Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human||Hallym University Medical Center|Yes|Recruiting|January 2009|December 2011|Anticipated|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|80 Years|No|||September 2010|September 14, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131533||121621|
NCT01131845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-120|The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil|An Evaluation of the Pharmacokinetics and Safety of a Single Dose of UT-15C SR (Treprostinil Diethanolamine) in Subjects With Renal Impairment.||United Therapeutics|No|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01131845||121597|
NCT01131806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB No. 98-10-16|Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients|Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients||Taipei Veterans General Hospital, Taiwan|No|Recruiting|December 2009|April 2011|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|40 Years|90 Years|No|||January 2010|July 7, 2010|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01131806||121600|
NCT01131819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00523|Use of an Interactive Video Game as Part of a New Amputee Rehabilitation Program|Use of an Interactive Video Game as Part of a New Amputee Rehabilitation Program||University of British Columbia|No|Completed|May 2010|September 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|19 Years|N/A|No|||September 2014|September 18, 2014|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01131819||121599|
NCT01132209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STITCH trial MEC 2009-026|Suture Techniques to Reduce the Incidence of The inCisional Hernia|Suture Techniques to Reduce the Incidence of The inCisional Hernia|STITCH|Erasmus Medical Center|Yes|Completed|October 2009|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|576|||Both|18 Years|N/A|No|||July 2014|July 31, 2014|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132209||121569|
NCT01132222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|431-04|Bioequivalence Study of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets Under Fed Conditions|A Randomized, Open Label, 2-treatment, Single Dose, Crossover, Bioequivalence Study of Ibuprofen 200 mg+Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132222||121568|
NCT01132235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENBRECAP2009|An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use|An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use|ENBRECAP2009|Florida Academic Dermatology Centers|No|Recruiting|April 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132235||121567|
NCT01132534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB D/07/163|A Randomized Study Comparing Autofluorescence Imaging(AFI) Followed by Narrow Band Imaging(NBI) With Videoendoscopy for the Detection of High Risk Lesions of Stomach|A Randomized Study Comparing Endoscopic Video-Autofluorescence Imaging Followed by Narrow Band Imaging With Standard Videoendoscopy for the Detection of High Risk Lesions of Stomach|CAFBI|National University Hospital, Singapore|Yes|Completed|June 2007|April 2008|Actual|December 2007|Actual|Phase 3|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|64|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The inclusion criteria of this study is based on our previous study "Dan YY, So JBY, Yeoh        KG. Endoscopic screening for gastric cancer: Clin Gastroenterol Hepatol 2006;4:709-716."        which showed that ethnic Chinese and aged 50 or above have increased risk of developing        gastric cancer.        In another study "Zhu F, Yeoh KG, So JBY, et al. Risk factors associated with intestinal        metaplasia, a gastric pre-malignant lesion, in a chinese cohort under surveillance for        gastric cancer: AACR; L.A. 2007 April" which is still ongoing, showed that the prevalence        of intestinal metaplasia, a precancerous gastric lesion, is about 35% in this high risk        population. Our sample size calculation is based on this finding and other relevant        literature.|May 2010|June 15, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132534||121544|
NCT01133080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-0008-10|Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study|||Shalvata Mental Health Center|Yes|Recruiting|June 2010|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|65 Years|No|||January 2012|January 4, 2012|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133080||121502|
NCT01103349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.16|BI671800 in Asthmatic Patients on Inhaled Corticosteroids|Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)||Boehringer Ingelheim||Completed|March 2010|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|243|||Both|18 Years|65 Years|No|||December 2011|April 30, 2014|March 19, 2010||||No||https://clinicaltrials.gov/show/NCT01103349||123774|
NCT01103362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.133|A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder|Open-label Extension Trial for Pre- and Postmenopausal Women With HSDD||Sprout Pharmaceuticals, Inc|Yes|Terminated|April 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|596|||Female|18 Years|N/A|No|||April 2014|April 11, 2014|April 13, 2010|Yes|Yes|administrative reasons|No|April 11, 2014|https://clinicaltrials.gov/show/NCT01103362||123773|
NCT01103609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00027|Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients|An Open-Label, Randomised, Placebo-Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Warfarin During Co-administration With AZD1656||AstraZeneca|No|Completed|April 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2010|November 5, 2010|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01103609||123754|
NCT01103622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00031|Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients|An Open-label, Randomised, Placebo Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics of Digoxin During Co-administration With AZD1656||AstraZeneca||Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01103622||123753|
NCT01101841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N30-004|24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms|A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause||Noven Therapeutics|No|Completed|March 2010|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|570|||Female|40 Years|N/A|No|||October 2015|October 14, 2015|April 8, 2010|Yes|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01101841||123890|
NCT01100957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aScope-1+2 a|Evaluation of the Single Use Flexible Optical Scope Versus Multiple Use Flexible Optical Scopes for Intubation|Evaluation and Comparison of the New Single Use Ambu aScope With Olympus BF 160 Multiple Use Scope for Securing the Airway of the Anaesthetised/Awake Patients' Normal or Difficult Airway||Rigshospitalet, Denmark||Completed|October 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2010|August 23, 2011|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01100957||123957|
NCT01102673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611001|Single Dose Study of PF-04991532 in Healthy Subjects|A Phase 1 Placebo-Controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Food Effect of Single Escalating Oral Doses of PF-04991532 in Healthy Adult Subjects||Pfizer|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 3, 2010|April 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01102673||123826|
NCT01101828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37822-A|Self-collected Swabs for HPV Testing in 18-24 Year Old Women|Self-collected Swabs for HPV Testing in 18-24 Year Old Women|DRY|University of Washington|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|Self-collected vaginal samples for HPV testing|Female|18 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|18 to 24 year old women who date online|February 2011|February 10, 2011|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01101828||123891|
NCT01102114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-4515|A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation|A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation||Nabi Biopharmaceuticals|Yes|Completed|March 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|65 Years|No|||May 2012|May 8, 2012|March 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102114||123869|
NCT01102439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-082|Clopidogrel/Aspirin Interaction Study|Randomized, Factorial Study to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent|INTERACTION|Population Health Research Institute|No|Completed|April 2010|February 2013|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|April 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102439||123844|
NCT01116830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22445|A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Patients With Schizophrenia and Schizoaffective Disorder|A Randomized, Double-blind, Placebo-controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder||Hoffmann-La Roche||Completed|November 2010|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116830||122740|
NCT01116843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS590266|Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment|A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804||University Health Network, Toronto|Yes|Completed|May 2010|February 2014|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116843||122739|
NCT01117103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200039-500|A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes|A Prospective, Observational Study on the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes||Merck KGaA|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3592|Samples Without DNA|Plasma|Both|N/A|N/A|No|Non-Probability Sample|Subjects diagnosed with type 2 diabetes in Asia Pacific region.|May 2010|July 15, 2014|May 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01117103||122719|
NCT01131208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000671515|Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab|Gene Expression Profiling Using Paraffin-embedded Tissues and the Nuclease Protection Assay in Diffuse Large B-cell Lymphoma (DLBCL) Treated With CHOP or R-CHOP: An ECOG and SWOG Correlative Study of E4494||National Cancer Institute (NCI)||Not yet recruiting|July 2010|||August 2010|Anticipated|N/A|Observational|N/A|||Anticipated|200|||Both|60 Years|N/A|No|||April 2010|May 25, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131208||121644|
NCT01131494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|249/2008|Swallowing Training in Parkinson`s Disease|Dysphagia Therapy for Parkinson`s Disease: the Role of the Oral Motor Exercises||Federal University of Bahia|Yes|Completed|March 2009|December 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|17|||Both|N/A|N/A|No|||October 2011|October 4, 2011|May 25, 2010||No||No|May 5, 2011|https://clinicaltrials.gov/show/NCT01131494||121624|There was a delay because of faulty equipment that performs videofluoroscopy of swallowing.Study limitations include small number of participants and no comparison group.
NCT01102075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOMC MIRB 2009-6|The Effect of Electroacupuncture on Obesity|The Effect of Low Frequency Electroacupuncture on Waist Circumference in Obesity-Three Arm Randomized Controlled Trial, Pilot Study||Kyunghee University Medical Center|Yes|Active, not recruiting|January 2010|May 2010|Anticipated|May 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|39|||Both|16 Years|65 Years|No|||September 2009|April 9, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01102075||123872|
NCT01102088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0847|Simultaneous Integrated Boost (SIB) in Esophageal Cancer|Phase I Study of Evaluating the Safety of Using a Simultaneous Integrated Boost for Dose Escalation in Patients With Esophageal Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2010|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|April 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01102088||123871|
NCT01131832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:073|Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols|Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols||University of Manitoba||Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|71|||Both|30 Years|75 Years|No|||January 2015|January 30, 2015|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131832||121598|
NCT01132248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDC-2010-1|Activity of Mefloquine Against Urinary Schistosomiasis|Activity of Mefloquine Against Urinary Schistosomiasis||Albert Schweitzer Hospital|No|Completed|May 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Female|N/A|N/A|No|||January 2013|January 23, 2013|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132248||121566|
NCT01102855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0002|Endomicroscopy and Crohn´s Disease|Confocal Laser Endomicroscopy in Patients With Crohn´s Disease||University of Erlangen-Nürnberg Medical School|Yes|Completed|October 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|85 Years|No|Probability Sample|Patients with Crohn´s disease.|August 2011|August 10, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102855||123812|
NCT01103089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ONL-IRE-2009/1|Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)|Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)||AstraZeneca|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|10|||Both|N/A|N/A|No|Probability Sample|Patients from the gefitinib Expanded Access Programme in the Netherlands.|October 2011|October 11, 2011|April 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01103089||123794|
NCT01132859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100109|VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older|VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|November 19, 2015|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01132859||121519|
NCT01103375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 91209|Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma|A Phase I Single Arm Open Label Study of Erlotinib and 13-cis-Retinoic Acid (CRA) in Patients With Recurrent Malignant Gliomas||Comprehensive Cancer Center of Wake Forest University|No|Terminated|May 2010|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|April 13, 2010|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01103375||123772|
NCT01103635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 05609|Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma|A Phase 1 Dose-Escalation Trial To Evaluate Safety, Tolerability And Immune Pharmacodynamics Of Combined Administration Of Tremelimumab (Blocking Anti-CTLA-4 Antibody) And CP-870,893 (Agonist Anti-CD40 Antibody) In Patients With Metastatic Melanoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|February 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||May 2014|January 13, 2015|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103635||123752|
NCT01099722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3507|Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma|||Mundipharma Research Limited|No|Completed|April 2010|||November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|261|||Both|12 Years|N/A|No|||August 2014|August 12, 2014|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099722||124050|
NCT01102127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNUS122009|Elastography in Thyroid Nodules|Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.||Castilla-León Health Service|No|Completed|February 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|128|Samples Without DNA|Thyroid cells|Both|18 Years|N/A|No|Non-Probability Sample|General population with nodular goiter.|April 2011|May 24, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102127||123868|
NCT01132638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PZ-9999-401-BR|Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease|Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, Prospective, Randomized, Double-blind, Parallel-group, Phase III|PAMES 0109|Takeda||Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|713|||Both|18 Years|65 Years|No|||June 2012|June 24, 2012|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01132638||121536|
NCT01101607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHIRB 2008-006|Closed Reduction of Distal Forearm Fractures by Pediatric Emergency Medicine Physicians: A Prospective Study|Closed Reduction and Cast Immobilization of Distal Radius Fractures by Pediatric Emergency Medicine||InMotion Orthopaedic Research Center|No|Completed|April 2008|April 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|104|||Both|6 Months|18 Years|No|||April 2010|April 8, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101607||123908|
NCT01101620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Levo1|Effect of Levosimendan on Respiratory Muscle Function in Healthy Subjects|Pilot Study on the Effects of Levosimendan on in Vivo Respiratory Muscle Function in Healthy Subjects|LSD1|University Medical Center Nijmegen|Yes|Completed|April 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|January 19, 2011|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01101620||123907|
NCT01101854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004H0278|Gene Expression Profiles in Healing and Non-Healing Wounds|Gene Expression Profiles in Healing and Non-Healing Wounds|WHGS1|Ohio State University|No|Recruiting|December 2004|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1300|Samples With DNA|Tissue|Both|18 Years|N/A|No|Probability Sample|Patients who have a chronic wound(s) (defined as a wound that has been present for at        least 4 weeks).|September 2015|September 28, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101854||123889|
NCT01102907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Food Form and Satiety|Effect of Food Form on Satiety and Gastric Emptying|Beverages and Obesity: Effect of Food Form on Satiety and Hunger||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|10|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Healthy women; age 18 - 35; body mass index in the healthy range between 18.5 and 25;        proficient English speakers; non-smoking; not taking medications; non-dieting (weight        stable over last 3 months); able to swallow a large capsule|March 2012|March 28, 2012|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102907||123808|
NCT01133756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-701|E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125.||Eisai Inc.|No|Terminated|March 2010|September 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Female|18 Years|N/A|No|||June 2015|June 11, 2015|May 21, 2010|Yes|Yes|No participants|No||https://clinicaltrials.gov/show/NCT01133756||121450|
NCT01116336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014010|Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck|Phase I Study of Chemoprevention With Green Tea Polyphenon E (PPE) and the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) in Patients With Premalignant Lesions of the Head and Neck||Emory University|Yes|Recruiting|March 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|34|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|April 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01116336||122778|
NCT01116596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0072|Paracetamol and Glutathion|Effect of Paracetamol on the Status in Glutathione for the Aged Person||University Hospital, Clermont-Ferrand||Completed|February 2007|May 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|18|||Both|70 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01116596||122758|
NCT01116609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epi-perfusion|Local Effects of Epinephrine on Lactate, Glucose, Lipid and Protein Metabolism in Bilaterally Perfused Human Legs|Local Effects of Epinephrine on Lactate, Glucose, Lipid and Protein Metabolism in Bilaterally Perfused Human Legs||University of Aarhus|No|Completed|October 2004|January 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 4, 2011|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01116609||122757|
NCT01131221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000671527|S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma|Vitamin D Insufficiency and Follicular Lymphoma Prognosis||Southwest Oncology Group|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|196|||Both|18 Years|N/A|No|Non-Probability Sample|patients enrolled in S8947-9800-9911-0016 consenting to banking|May 2014|May 8, 2014|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131221||121643|
NCT01131520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08-173|Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico|SBIRT in New Mexico||Friends Research Institute, Inc.|Yes|Completed|June 2010|July 2015|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01131520||121622|
NCT01102881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902M60241|Laxation and Satiety Response of Novel Dietary Fibers|Laxation and Satiety Response of Novel Dietary Fibers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 8, 2010|March 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01102881||123810|
NCT01131858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1678-31/4|Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency|A Placebo Controlled Double Blinded Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency|VITAPID|Karolinska University Hospital|Yes|Completed|March 2010|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|75 Years|No|||April 2012|April 4, 2012|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01131858||121596|
NCT01102348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-uP Pilot|Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients|Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients: A Single Center Feasibility Trial of The PEP uP Protocol|PEP-uP|Clinical Evaluation Research Unit at Kingston General Hospital|No|Completed|May 2008|||April 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||April 2010|April 13, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01102348||123851|
NCT01102608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS15|Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma|Phase II Study of Neoadyuvant High-dose Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma and Identification of Response Predictors||Grupo Espanol de Investigacion en Sarcomas|No|Completed|March 2008|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|No|||March 2012|March 19, 2012|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01102608||123831|
NCT01102868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMS1234|IMS-treatment and Canalis Carpi Syndrome|An Randomized Controlled Trial of IMS-treatment Versus Scam for Canalis Carpi Syndrome||Uni Research|No|Completed|April 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01102868||123811|
NCT01103102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20090462H|Dose-Response Study of Iocide Oral Rinse|Phase II Study: Evaluate Dose-Response of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects of Biological Markers Indicative of Systemic Disease||Biomedical Development Corporation|Yes|Completed|April 2010|April 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|97|||Both|18 Years|N/A|No|||January 2013|January 27, 2013|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103102||123793|
NCT01100060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661195|A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects|A Phase 1, Open-Label, Randomized, Single Dose, Parallel Design Study To Estimate The Relative Bioavailability Of Co Administered Formulations Of Azithromycin Microsphere (AZ) And Chloroquine Test Formulation (CQ) Compared With Co Administered Immediate Release Individual AZ And CQ Tablets In Healthy Adult Subjects|AZCQ|Pfizer|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 24, 2010|March 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01100060||124024|
NCT01100372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669716|Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|Randomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the Peritoneum||National Cancer Institute (NCI)||Recruiting|July 2009|||May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Primary Purpose: Treatment|1||Anticipated|154|||Female|18 Years|N/A|No|||April 2010|August 23, 2013|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01100372||124002|
NCT01107418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25163|A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma|A Phase I, Randomized, Open-label, Multi-center, Multiple Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO5185426 Administered as 240 mg Tablets to Previously Treated BRAF V600E Positive Metastatic Melanoma Patients||Hoffmann-La Roche||Completed|May 2010|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|April 12, 2010|No|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01107418||123461|
NCT01107704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AG032875|Family Support Intervention in Intensive Care Units (The Four Supports Study)|A Randomized Controlled Trial to Test the Effectiveness of a Multi-faceted Communication Intervention for Family Members of Critically Ill Patients.||University of Pittsburgh|No|Completed|April 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|159|||Both|50 Years|N/A|No|||January 2014|January 23, 2014|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107704||123440|
NCT01104350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-031|Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy|Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy||Memorial Sloan Kettering Cancer Center||Recruiting|April 2010|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|April 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104350||123697|
NCT01105884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS01|Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers|||M.V. Hospital for Diabetes|No|Recruiting|October 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|35 Years|75 Years|No|||April 2012|April 21, 2012|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01105884||123579|
NCT01104610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-2009|Target Volume Mode Controlled Ventilator in Obesity Hypoventilation Syndrome|Target Volume With a Pressure Controlled Ventilator in Obesity Hypoventilation Syndrome With Persistent Oxygen Desaturations With Continuous Positive Airway Pressure|OVO|Breas Medical S.A.R.L.|No|Suspended|May 2009|May 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|48|||Both|20 Years|75 Years|No|||February 2012|February 27, 2012|April 14, 2010||No|Change in sponsorship: Breas is no longer the sponsor since 17JAN2012|No||https://clinicaltrials.gov/show/NCT01104610||123677|
NCT01104922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 06-093|Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck|Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck||University of Pittsburgh|Yes|Active, not recruiting|July 2007|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01104922||123653|
NCT01104935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-SAS BC 07|Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients|Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled Trial|RESPECT|Comprehensive Support Project for Oncology Research|Yes|Active, not recruiting|October 2009|October 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|70 Years|80 Years|No|||June 2011|February 19, 2015|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01104935||123652|
NCT01105299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_ANS_B01|Bioequivalence Study of Anastrozole 1 mg Tablet|Bioequivalence Study of CJ Anastrozole 1mg Tablet and Arimidex® 1 mg Tablet||Asan Medical Center|Yes|Completed|June 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 15, 2010|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105299||123624|
NCT01105312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N093B|Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer|Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|September 2010|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105312||123623|
NCT01106170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31886 Melaluca-ProvexCV|Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure|A Double-Blind, Placebo-Controlled, Crossover Evaluation of a Grape Seed Extract and Quercetin Supplement (Provex CV) to Reduce Markers of Inflammatory Cytokines and Blood Pressure in Subjects With Metabolic Syndrome||University of Utah|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||January 2015|January 13, 2015|April 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01106170||123557|
NCT01128244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2RO1DKO72398-05|Vitamin B6 Effects for Women Taking Birth Control Pills|Vitamin B6 Effects on One-Carbon Metabolism||University of Florida|No|Completed|April 2010|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|May 20, 2010||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01128244||121868|
NCT01113034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAS181 - 1 - 04, 10 - I - 0085|A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis|A Phase 1 Randomized Double-Blind Placebo-Crossover Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis|DAS181|Ansun Biopharma, Inc.|Yes|Recruiting|July 2010|||December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|No|||July 2010|July 29, 2010|April 27, 2010|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01113034||123030|
NCT01105832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017320-29|Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?|Påskyndar PTH läkningen av Konservativt Behandlade Humerusfrakturer?||University Hospital, Linkoeping|Yes|Completed|April 2010|September 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|50 Years|N/A|No|||December 2014|December 9, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01105832||123583|
NCT01105819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROHYG 1B|Chlorhexidine vs Lactobacillus Plantarum for Oral Care in Intubated ICU Patients|A Study Comparing a Suspension of Lactobacillus Plantarum 299 With Chlorhexidine for Oral Care in Intubated Mechanically Ventilated Patients in Intensive Care||Region Skane|Yes|Active, not recruiting|April 2010|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01105819||123584|
NCT01113593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-089|A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease|A Randomized, Multiple-Dose, Crossover Study Characterizing the Pharmacodynamic Profiles of Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler in Subjects With Stable Chronic Obstructive Pulmonary Disease||Dey|No|Completed|May 2010|||May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|45|||Both|40 Years|N/A|No|||May 2013|May 17, 2013|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113593||122987|
NCT01113853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOV 1360|Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients|Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients Stopping Anti-inflammatory Treatment||Universita di Verona|No|Completed|January 2007|January 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|40|||Both|5 Years|N/A|No|Probability Sample|children with asthma visited in the outpatients clinic at University of Verona were        invited to participate to the study|January 2007|April 30, 2010|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113853||122967|
NCT01106937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG-1|Factor XIII and Pulmonary Embolism in Neurosurgical Patients|Risk Factors for Perioperative Pulmonary Embolism in Neurosurgical Patients in Respect of Factor XIII Activity||Ludwig-Maximilians - University of Munich|No|Recruiting|October 2007|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|N/A|N/A|No|Non-Probability Sample|Neurosurgical patients with a postoperative occurence of pulmonary embolism in with        laboratory-confirmed preoperatively low levels of Factor XIII|March 2010|April 19, 2010|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106937||123498|
NCT01106950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010LS010|Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)|Adoptive Transfer of Haploidentical Natural Killer Cells to Treat Refractory or Relapsed AML MT2010-02||Masonic Cancer Center, University of Minnesota|Yes|Terminated|July 2010|December 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|2 Years|N/A|No|||June 2013|June 25, 2013|April 19, 2010|Yes|Yes|study drug (Ontak) no longer available|No|May 6, 2013|https://clinicaltrials.gov/show/NCT01106950||123497|
NCT01103778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05320|Pilot Study of Velcade® in IgA Nephropathy|Velcade Therapy for Severe IgA Nephropathy||The Rogosin Institute|No|Recruiting|July 2010|December 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103778||123741|
NCT01114789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0071|Impact on the Proteolysis of Obesity in Dialysis|Impact on the Proteolysis of Obesity in Dialysis|IPOD|University Hospital, Clermont-Ferrand||Recruiting|January 2011|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||January 2011|January 25, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01114789||122895|
NCT01114802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00026896|E-health Intervention for Cancer Survivors|Project Onward: an Innovative E-health Intervention for Cancer Survivors|Onward|Northwestern University|No|Completed|April 2010|June 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|19 Years|N/A|No|||June 2013|March 18, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114802||122894|
NCT01107990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H64391-34645-01|Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques|Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques||University of California, San Francisco|Yes|Recruiting|November 2009|January 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects: Patients with univentricular hearts who have undergone a Fontan procedure        will be recruited for participation in the study.|October 2009|April 20, 2010|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01107990||123418|
NCT01108250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC387715/HTRA1|LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population|LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population|PCV|Kyungpook National University|Yes|Completed|April 2010|August 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|215|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 28, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01108250||123398|
NCT01104064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric Hemiplegia and rTMS|Pediatric Hemiplegia: Synergistic Treatment Using rTMS and CIT|Pediatric Hemiplegia: Synergistic Treatment Using rTMS and CIT||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Both|8 Years|16 Years|No|||August 2013|August 16, 2013|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104064||123719|
NCT01105598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETC-1002-002|A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia|A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ETC-1002 in Subjects With Mild Dyslipidemia||Esperion Therapeutics|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|53|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 16, 2010|April 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01105598||123601|
NCT01105611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-2010-01|Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users|An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone||St. James's Hospital, Ireland|Yes|Recruiting|August 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2010|July 20, 2011|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105611||123600|
NCT01105338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11046/A10052|Lycopene or Green Tea for Men at Risk of Prostate Cancer|Lycopene or Green Tea a Feasibility Study in Men at Risk of Prostate Cancer|ProDiet|University of Bristol|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|126|||Male|50 Years|69 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105338||123621|
NCT01104961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032010-081|Studying the Relationship Between Contact Lens Packaging Solutions and Bacterial Binding to Surface Eye Cells|A Masked, Randomized, Prospective, Single Center Crossover Clinical Trial on the Relationship Between Chemically Preserved Contact Lens Packaging Solutions and Bacterial Binding to Corneal Epithelial Cells||University of Texas Southwestern Medical Center||Completed|April 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|20|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||April 2010|October 13, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01104961||123650|
NCT01104974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 08-310|HIV Physician's Survey|Canadian Health Care Providers' Attitudes of Pregnancy, Fertility Care, and Assisted Reproductive Technologies for HIV-Positive Individuals||St. Michael's Hospital, Toronto|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|167|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|HIV Providers in Canada|January 2016|January 20, 2016|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104974||123649|
NCT01105897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETLQ62/81|Prospective Study of the Outcomes of the Surgical Treatment of Deeply Infiltrating Endometriosis|Incidence of Deeply Infiltrating Endometriosis in Surgically Treated Endometriosis Patients and Long-term Results of Surgical Treatment in Terms of Pain, Quality of Life and Sexual Functioning||PaijatHame Central Hospital|No|Active, not recruiting|January 2005|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|||Female|18 Years|65 Years|No|Non-Probability Sample|Women scheduled for operation on suspected endometriosis in two study hospitals between        January 2005 - December 2007 (Päijät-Häme Central Hospital) and January 2008 - December        2008 (Helsinki University Hospital).|August 2012|August 30, 2012|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105897||123578|
NCT01128595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113126|Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response|A Randomised, Double-blind, Placebo-controlled, Four-way Crossover, Repeat Dose Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination, GW642444M and Fluticasone Furoate on the Allergen-induced Asthmatic Response in Subjects With Mild Asthma||GlaxoSmithKline|No|Completed|May 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|65 Years|No|||June 2013|August 22, 2013|May 20, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01128595||121843|
NCT01128582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rozerem|Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.|Effect of Rozerem on the Perception of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Chronic Insomnia.|Rozerem|Southern Arizona VA Health Care System|No|Active, not recruiting|March 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|82 Years|No|||March 2011|May 11, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01128582||121844|
NCT01128881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050901|IMMUNINE Pre-Treatment Study|IMMUNINE - Purified Factor IX Concentrate Virus-Inactivated: A Phase 4, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B Who Are Planned to Enter BAX 326 Study 250901 to Investigate a New Recombinant FIX Concentrate||Baxalta US Inc.|Yes|Completed|May 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|N/A|64 Years|No|||January 2013|June 26, 2015|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01128881||121821|
NCT01105234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCO 0901 FR|An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects|An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects||LEO Pharma|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01105234||123629|
NCT01105247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1102-CA|Safety of PCI-32765 in Chronic Lymphocytic Leukemia|A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia||Pharmacyclics|No|Completed|May 2010|February 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|133|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|April 13, 2010|No|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01105247||123628|
NCT01106079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR07/8350|TIght COntrol of Psoriatic Arthritis|A Randomised Controlled Trial to Compare Intensive Management vs Standard Care in Early Psoriatic Arthritis|TICOPA|University of Leeds|Yes|Completed|May 2008|January 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106079||123564|
NCT01114126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-P11|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia|Randomized, Double-blind, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia||Neurim Pharmaceuticals Ltd.|Yes|Completed|April 2010|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|24|||Both|18 Years|65 Years|No|||April 2011|April 6, 2011|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01114126||122946|
NCT01107457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12060|A Study in Participants With Moderate to Severe Psoriasis|A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis||Eli Lilly and Company|No|Active, not recruiting|April 2010|June 2018|Anticipated|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|125|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|April 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107457||123458|
NCT01107470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chenzj|Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in ART|Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in Follicular Stimulation for Assisted Reproduction Purposes. A Randomised, Prospective, Multi-centre Clinical Trial||Shandong University|Yes|Recruiting|April 2010|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|2000|||Female|18 Years|42 Years|No|Probability Sample|Patients addressed to follicular stimulation for in vitro fertilisation purposes will        constitute the study population.|April 2010|March 22, 2012|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01107470||123457|
NCT01107171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008002P2A02|Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes|Multi-center Randomized Controled and Double Blind Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|210|||Both|30 Years|70 Years|No|||May 2008|April 20, 2010|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01107171||123480|
NCT01103765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK0801|Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis|A Prospective Randomized Multicenter Study of the Efficacy and Safety of Systematic Post -Dilatation With Noncompliant Balloon After Successful Drug-eluting Stent Implantation. IVUS Analysis.|PODIUM|Recherches et etudes en sciences sociales et sante, France|No|Recruiting|April 2010|November 2011|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|75 Years|No|||June 2011|June 14, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103765||123742|
NCT01105325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-CRE-2010/1|Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care|Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care (CIC) - Electronic Measurement of Compliance|SCAVANCE|AstraZeneca|No|Terminated|April 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|First 10 patients admitted to the CIC unit for a first episode of acute coronary syndrome,        in whom the CIC cardiologist considers that Crestor® - rosuvastatin is the most        appropriate statin for management in hospital, in combination with a platelet aggregation        inhibitor (Plavix® - clopidogrel).|October 2010|October 1, 2010|March 25, 2010||No|due to poor patient recruitment|No||https://clinicaltrials.gov/show/NCT01105325||123622|
NCT01106183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38766 4Life-Transfer Factor|Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults|A Double Blind Study on the Efficacy of a Colostrum and Egg Yolk Supplement vs. Placebo to Reduce Frequency and Duration of Upper Respiratory Tract Infections in Healthy Adults||University of Utah|No|Completed|January 2010|||March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|49|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 14, 2011|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106183||123556|
NCT01106144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-094|Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia|Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia||Samsung Medical Center|Yes|Recruiting|May 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|500|Samples With DNA|Preserved bone marrow sample from the adult patients with acute myeloid leukemia|Both|15 Years|N/A|No|Probability Sample|Adult patients with acute myeloid leukemia receiving induction/consolidation combination        chemotherapy at Samsung Medical Center from 1996 to 2005|May 2011|May 23, 2011|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106144||123559|
NCT01106157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF-ATG-GCSF001|Reversing Type 1 Diabetes After it is Established|Reversing Type 1 Diabetes After it is Established: A Pilot Safety and Feasibility Study of Anti-Thymocyte Globulin (Thymoglobulin®)and Pegylated GCSF (Neulasta®) in Established Type 1 Diabetes||University of Florida|Yes|Active, not recruiting|April 2010|January 2018|Anticipated|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|12 Years|45 Years|No|||January 2016|January 19, 2016|April 15, 2010|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01106157||123558|
NCT01106755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSCar-240781|Effects of Ground Level Gait Training With Body Weight Support (BWS) and Functional Electrical Stimulation (FES)|Ground-level Gait Training Combining Body Weight Support and Functional Electrical Stimulation in People Following Chronic Stroke||Universidade Federal de Sao Carlos|Yes|Completed|September 2008|December 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|40 Years|70 Years|No|||August 2008|April 19, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01106755||123512|
NCT01106729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB/H004963/1|Tracing the Path of an Ingested Plant Pigment Through the Human Body|Tracing the Path of the Plant Pigment Cyanidin-3-glucoside, Through the Human Body After Consumption||University of East Anglia|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 1, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01106729||123514|
NCT01106742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbM2009-IBD|Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)|Potential Anti-inflammatory Effect of Mushroom Extract From Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)||Oslo University Hospital|Yes|Completed|March 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||March 2009|July 18, 2011|March 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01106742||123513|
NCT01128608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Effect of PCO2 Solution|The Effect of High PCO2 Solution on Esophageal Acid Sensation|The Effect of High PCO2 Solution on Esophageal Acid Sensation in Healthy Patients Versus Those With Non-Erosive Reflux Disease.|PC02|Southern Arizona VA Health Care System|No|Recruiting|September 2009|November 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2010|July 20, 2010|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128608||121842|
NCT01128894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114179|A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.|A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|Yes|Completed|May 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|841|||Both|18 Years|N/A|No|||April 2014|May 22, 2014|April 29, 2010|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01128894||121820|
NCT01105546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENJOIH 01|rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors|An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors|ENJOIH|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Active, not recruiting|December 2010|April 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|N/A|8 Years|No|||April 2013|April 5, 2013|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105546||123605|
NCT01106365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS in MS|Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis|Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis - A Pilot Study to Evaluate Safety and Efficacy of Deep rTMS on Fatigue and Depressivity in Patients With Multiple Sclerosis|rTMS in MS|Charite University, Berlin, Germany|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 20, 2016|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106365||123542|
NCT01106963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKP|Anterior Knee Pain After Tibial Nailing|Nail Position Has an Influence on Anterior Knee Pain After Tibial Intramedullary Nailing||University of Zagreb|No|Completed|January 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The population consists of primary care hospital trauma patients with tibial shaft        fractures treated with intramedullary nailing.|April 2010|April 19, 2010|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01106963||123496|
NCT01106066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-06-013|Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT|A Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer||Samsung Medical Center|No|Terminated|March 2009|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|April 15, 2010||No|Difficulties in recruiting patients|No||https://clinicaltrials.gov/show/NCT01106066||123565|
NCT01106339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anae_Pain_Ulm_DSM-IV|Immune Patterns in Pain Patients DSM-IV|Phase 1 Study of Immune, Psychometric and Sociodemographic Patterns in Pain Patients Classified by DSM-IV|IPPPDIV|University of Ulm|No|Completed|August 2007|April 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|Samples With DNA|Whole blood, serum, and white cells will be retained.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|chronic pain patients with a somatoform disorder due to DSM-IV|April 2013|April 3, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106339||123544|
NCT01107743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841063|Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Caduet® Drug Use Investigation (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1291|||Both|N/A|N/A|No|Probability Sample|The subjects whom an investigator involving A3841063 prescribes the Amlodipine        /Atorvastatin (Caduet®) Combination Tablets.|June 2013|June 10, 2013|April 20, 2010|No|Yes||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01107743||123437|
NCT01108029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008210-38|Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease|Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial|FOGG-I|University Hospital, Lille|Yes|Completed|October 2009|October 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|30 Years|80 Years|No|||July 2009|March 23, 2012|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01108029||123415|
NCT01104077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD6106|Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)|Family and Personal History of Pancreatic and Other Malignancies in Patients With Intraductal Papillary Mucinous Neoplasms||Columbia University|Yes|Recruiting|November 2008|November 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|400|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients seen at Columbia University Medical Center's Pancreas Center who have been        diagnosed with intraductal papillary mucinous neoplasm, a cystic neoplasm of the        pancreatic duct that has malignant potential.|July 2015|July 2, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104077||123718|
NCT01104090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0161|Initial Experience With Storz C-MAC Video Intubation System|Initial Experience With Storz C-MAC Video Intubation System|C-MAC|The University of Texas Health Science Center, Houston|No|Completed|February 2010|February 2012|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104090||123717|
NCT01107444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11766|Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer|A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy||Eli Lilly and Company|No|Completed|May 2010|June 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107444||123459|
NCT01107717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTT20080456H|Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM|Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes||The University of Texas Health Science Center at San Antonio|Yes|Recruiting|January 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||January 2016|January 11, 2016|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107717||123439|
NCT01104636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051141|"VIBRATIONS" - A Study In Smokers Who Are Willing And Motivated To Stop Smoking With The Aid Of Varenicline Which Will Be Prescribed According To Usual Clinical Practice In Germany|"VIBRATIONS": Varenicline In Patients Ambitioned To Terminate Smoking - A Non-Interventional Study|VIBRATIONS|Pfizer|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1177|||Both|18 Years|N/A|No|Non-Probability Sample|Adult smokers who are willing and motivated to stop smoking|March 2012|March 1, 2012|April 14, 2010|No|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT01104636||123675|It is highly likely that Adverse Events were under reported for this study as it was a Non Interventional study.
NCT01104649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM7KAJM7|Efficacy of Riluzole in Hereditary Cerebellar Ataxia|Efficacy of Riluzole in Hereditary Cerebellar Ataxia: a Randomized Double-blind Placebo-controlled Trial.||S. Andrea Hospital|Yes|Completed|April 2010|March 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|14 Years|70 Years|No|||April 2015|April 20, 2015|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01104649||123674|
NCT01105650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS142|Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer|Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)||Masonic Cancer Center, University of Minnesota|Yes|Completed|July 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Female|18 Years|N/A|No|||February 2016|February 18, 2016|April 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105650||123597|
NCT01105910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-21|Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye|||Alcon Research|No|Completed|February 2010|||December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|70|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105910||123577|
NCT01104987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090618|Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)|Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS), an Open Label Prospective Trial||Göteborg University|Yes|Active, not recruiting|October 2009|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|80 Years|No|||October 2015|October 15, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104987||123648|
NCT01105000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 08-326|Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity|The Role of Socioeconomic Status and Ethnicity in Influencing HPV Vaccine Knowledge and Attitudes in Adult Women||St. Michael's Hospital, Toronto|No|Completed|September 2008|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|160|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women attending Gynecology clinic|April 2010|November 30, 2010|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105000||123647|
NCT01106196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 09-08|The Role of Influenza as a Trigger for Acute Myocardial Infarction: a CALIBER Study|The Role of Influenza as a Trigger for Acute Myocardial Infarction: a Self-controlled Case Series Analysis of Linked Data From the Myocardial Ischaemia National Audit Project (MINAP) and the General Practice Research Database (GPRD)||University College, London|Yes|Completed|April 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|11208|||Both|40 Years|N/A|No|Non-Probability Sample|Patients with an incident myocardial infarction who also have a record of a visit to        primary care with a respiratory tract infection occurring within the study period        (01/01/99 - 31/12/2008)|December 2014|December 1, 2014|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106196||123555|
NCT01105624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-117|A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)|||Merck Sharp & Dohme Corp.|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105624||123599|
NCT01105637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV02-11-15-05|A Trial of an Augmented Exercise Program in the Prevention of Deconditioning Among Survivors of Severe Burns|A Trial of an Augmented Exercise Program in the Prevention of Deconditioning Among Survivors of Severe Burns|AEP|Johns Hopkins University|Yes|Recruiting|July 2007|||January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|65 Years|No|||April 2010|April 15, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01105637||123598|
NCT01107041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MH090318 STU00021825|Mobile Phone Sensing and Outreach as Adjuncts to Internet-Based Behavioral Intervention for Depression|Technology Assisted Intervention for the Treatment and Prevention of Depression||Northwestern University|Yes|Enrolling by invitation|December 2014|July 2016|Anticipated|February 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|N/A|No|||October 2015|March 21, 2016|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107041||123490|
NCT01106781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OCN-DUM-2009/1|A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology|A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology|ICAN|AstraZeneca||Completed|August 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|591|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from Thoracic surgery department|March 2014|March 17, 2014|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01106781||123510|
NCT01107028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJ230|Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis|Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis||National Jewish Health|No|Completed|February 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|41|||Both|40 Years|N/A|No|Probability Sample|Idiopathic pulmonary fibrosis, as defined by the American Thoracic Society Consensus        Guidelines|April 2015|April 14, 2015|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01107028||123491|
NCT01128920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA026773-01|Reducing Health Problems Associated With Injection Drug Use|Reduction of Medical Complications Associated With Injection Drug Use||University of Northern Colorado|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 30, 2011|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01128920||121818|
NCT01128907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR03/03/2007|Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients|Galactomannan Antigen and Real Time - PCR for Aspergillus DNA Detection in Bronchoalveolar Lavage. Application in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|October 2006|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|1. hematological neutropenic patients at high risk of IA in which we usually perform a             BAL for microbiological study when they present persistent fever and an opportunist             infection suspicion.          2. patients without hematological illness and without IA suspicion, in which we perform             an BAL because of another reason.|February 2014|February 21, 2014|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01128907||121819|
NCT01129193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09102|AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma|Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|May 2010|December 2016|Anticipated|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129193||121797|
NCT01106677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017023|The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)|A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy||Janssen Research & Development, LLC|Yes|Completed|May 2010|May 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1284|||Both|18 Years|80 Years|No|||July 2013|July 25, 2013|April 1, 2010|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01106677||123518|
NCT01106690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017032|The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy||Janssen Research & Development, LLC|Yes|Completed|June 2010|July 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|344|||Both|18 Years|80 Years|No|||June 2013|June 26, 2013|April 1, 2010|Yes|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01106690||123517|
NCT01106651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017014|A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy||Janssen Research & Development, LLC|Yes|Completed|June 2010|May 2013|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|716|||Both|55 Years|80 Years|No|||October 2014|October 27, 2014|April 1, 2010|Yes|Yes||No|April 1, 2013|https://clinicaltrials.gov/show/NCT01106651||123520|
NCT01106664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-7746POU002|ONO-7746 Study in Healthy Adult Subject|A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd||Completed|April 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01106664||123519|
NCT01107210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3617|Evaluation of Physical Fitness After Stroke|Evaluation of Physical Fitness After Stroke: Evolution and Determinants||Katholieke Universiteit Leuven|Yes|Completed|May 2006|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|subjects with a first ever stroke|April 2010|June 22, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01107210||123477|
NCT01106625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017005|The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy||Janssen Research & Development, LLC|Yes|Completed|May 2010|April 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|469|||Both|18 Years|80 Years|No|||June 2013|June 12, 2013|April 1, 2010|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT01106625||123522|
NCT01106638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA023362|A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)|A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)||Montefiore Medical Center|No|Recruiting|November 2009|May 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||April 2010|April 29, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01106638||123521|
NCT01103817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014567|Influence of Vitamin D on Vascular Function in Adolescents and Young Adults With Type 1 Diabetes|Influence of Vitamin D on Vascular Function in Adolescents and Young Adults With Type 1 Diabetes||The Hospital for Sick Children|No|Recruiting|March 2010|January 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|12 Years|18 Years|No|||April 2010|April 14, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103817||123738|
NCT01103830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST3073-ST3074-DM-09-006|Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers|Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers||sigma-tau i.f.r. S.p.A.|No|Completed|February 2010|December 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|287|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103830||123737|
NCT01104103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAR UTH 001|Effectiveness Study of the BOA(R)-Constricting IV Band|The BOA(R)-Constricting IV Band: A Single Blind, Cohort Study of Effectiveness||The University of Texas Health Science Center, Houston|No|Terminated|March 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|467|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|April 9, 2010|Yes|Yes|Pre-determined stopping point met with signficant difference between intervention and control    groups.|No|July 16, 2012|https://clinicaltrials.gov/show/NCT01104103||123716|There was a significant disparity between subjective opinion and objective results. Nurses and paramedics who used the BOA were uniformly positive in their comments about the device.
NCT01104675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-CL-004|Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer|A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer||CASI Pharmaceuticals, Inc.|No|Completed|April 2010|December 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Female|18 Years|N/A|No|||August 2014|August 4, 2014|April 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104675||123672|
NCT01108003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 129408|Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery|Pilot Pre-cystectomy Trial of Broccoli Extract in Patients With Superficial or Locally Advanced Bladder Cancer||Roswell Park Cancer Institute|Yes|Terminated|April 2010|October 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|April 19, 2010|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01108003||123417|
NCT01108016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03012010-5082|Expanding Rural Access: Distance Delivery of Support Groups (Main Study)|Expanding Rural Access: Distance Delivery of Support Groups (Main Study)||Stanford University||Completed|May 2008|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|100|||Female|21 Years|N/A|No|||December 2010|December 2, 2010|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01108016||123416|
NCT01104662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-022|Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment|A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment|RENSE|Cubist Pharmaceuticals LLC|No|Terminated|April 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Actual|92|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 2, 2010|Yes|Yes|Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can    stop.|No|April 28, 2015|https://clinicaltrials.gov/show/NCT01104662||123673|
NCT01105351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Folate Forms MTHFR|Effect of Folic Acid on Primary Folate Forms in Relation to MTHFR|Effect of Mild Increase in Folic Acid Intake on the Distribution of Folate Forms in Relation to a Common Polymorphism in One Folate Catabolising Enzyme||Saarland University|No|Completed|June 2010|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|75|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|April 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01105351||123620|
NCT01105663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007453|Pharmacologic Impact on Sedation Assessments|Pharmacologic Impact on Sedation Assessment|PISA|Children's Hospital of Philadelphia|Yes|Completed|March 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|175|Samples With DNA|The primary evaluation will be the assessment of morphine/midazolam pharmacokinetics (PK)      and pharmacodynamics (PD). Data from all fully evaluable subjects will be included in the      analysis. Analyses will be model based.|Both|1 Year|17 Years|No|Probability Sample|Subjects must be enrolled in the parernt study RESTORE, be at least 10kg, and be receiving        either morphine and/or midazolam continuous infusions.|January 2014|January 17, 2014|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01105663||123596|
NCT01105923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001846|Study of an Intervention to Improve Problem List Accuracy and Use|Making Accurate Problem Lists in the EHR|MAPLE|Brigham and Women's Hospital|No|Active, not recruiting|May 2010|November 2017|Anticipated|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105923||123576|
NCT01106469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017065|Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants|Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2010|July 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|74|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106469||123534|
NCT01106417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-CF001|Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion|Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation||Mesoblast, Ltd.|Yes|Active, not recruiting|June 2010|June 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|70 Years|No|||August 2012|November 6, 2014|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106417||123538|
NCT01106430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-317|Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate|A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel Group Study to Assess the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy||Shire|No|Completed|June 2010|September 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|267|||Both|6 Years|17 Years|No|||February 2014|June 6, 2014|April 14, 2010|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT01106430||123537|
NCT01107054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7881014|A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers|A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects||Pfizer|No|Completed|June 2010|December 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 12, 2011|April 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01107054||123489|
NCT01115660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019690|Stroke Education Intervention Trial - Pilot|AVAIL interVention Trial (Adherence Evaluation After Ischemic Stroke - Longitudinal): Pilot Protocol|AVAIL II|Duke University|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|19 Years|N/A|No|||December 2012|October 11, 2015|May 2, 2010||No||No|August 10, 2012|https://clinicaltrials.gov/show/NCT01115660||122828|Adverse events not collected
NCT01107275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I49P1|Early Rabies Vaccine Immunization in Primary School Children|Compare Immunogenicity, Safety and Long-term Booster Response After Primary Vaccination With 2 Intradermal Doses Versus 3 Intradermal Doses of PCEC Rabies Vaccine (Rabipur) in Healthy School Children in Thailand (5-8 Years of Age)|I49P1|Provincial Public Health Office, Phetchabun|Yes|Completed|November 2002|November 2008|Actual|November 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|703|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||April 2010|April 19, 2010|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01107275||123472|
NCT01129206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10018|Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy|Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.||Ohio State University Comprehensive Cancer Center|Yes|Completed|July 2010|||September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|May 21, 2010|Yes|Yes||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01129206||121796|
NCT01129219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2007.347|Observation and Progressive Strength Training After Hip Fracture|Observation and Progressive Strength Training After Hip Fracture||Oslo University Hospital|Yes|Active, not recruiting|June 2007|December 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|150|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2007|May 21, 2010|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01129219||121795|
NCT01106092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113264|Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers|Immunogenicity and Reactogenicity of a Booster Dose of GlaxoSmithKline Biologicals' GSK2036874A Vaccine in Healthy Toddlers||GlaxoSmithKline||Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|312|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||December 2011|December 8, 2011|April 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106092||123563|
NCT01106105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCO|Impact of Obesity on Postural Control|||Université Joseph Fourier|No|Completed|April 2010|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ten healthy non-obese adults (control group, age = 42.4 ± 15.1, BMI = 22.4 ± 1.3, five        women and five men) and ten obese adults (obese group, age = 46.2 ± 19.6, BMI = 35.2 ±        2.8, five women and five men, F(1,18)=0.3, p>0.05, and F(1,18)=176.3, p<.001, for control        vs. obese age and BMI, respectively) voluntarily took part in this investigation.|April 2010|April 16, 2010|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106105||123562|
NCT01107496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812P201|A Phase I/IIa, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Safety, and Efficacy of SPN-812V in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Phase I/IIa Study of the Safety, and Efficacy of SPN-812V in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Supernus Pharmaceuticals, Inc.|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|52|||Both|18 Years|64 Years|No|||December 2012|December 21, 2012|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107496||123455|
NCT01106976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7285-R|Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease|Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease||VA Office of Research and Development|No|Completed|May 2010|March 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|None Retained|Saliva|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Recruited in previous study|December 2015|December 23, 2015|April 14, 2010||No||No|November 6, 2015|https://clinicaltrials.gov/show/NCT01106976||123495|Observational study.
NCT01108042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TISOC-1|TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer|Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer||University of Jena|Yes|Active, not recruiting|November 2009|December 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|80 Years|No|||October 2009|December 16, 2014|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01108042||123414|
NCT01108055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLDR0010|Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer|A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer||Stanford University||Recruiting|April 2010|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|April 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01108055||123413|
NCT01107197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|473/CE (Study n° CE 61/07)|Nutritional Support in Pressure Ulcer Patients|Nutritional Support in Malnourished Pressure Ulcer Patients: the Oligoelement Sore Trial (OEST)|OEST|Azienda Ospedaliero Universitaria Maggiore della Carita|Yes|Completed|February 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|90 Years|No|||January 2014|January 16, 2014|April 15, 2010||No||No|March 10, 2013|https://clinicaltrials.gov/show/NCT01107197||123478|Limited to specific settings: long-term care and home-care services Limited to malnourished patients
NCT01104688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100008|Non Invasive Imaging of Abdominal Aorta Aneurysm Hemodynamics and Wall Structure|Non Invasive in Vivo Evaluation of Abdominal Aorta Aneurysm Hemodynamics, Wall Stress, and Inflammation Using Magnetic Resonance Imaging||Aarhus University Hospital|No|Completed|March 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|20|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Twenty patients diagnosed with an infrarenal abdominal aorta aneurysm will be selected        from our clinical database.|January 2015|January 12, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104688||123671|
NCT01104701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB111|A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension|A Randomized, Multi-dose, Controlled Trial Investigating the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension.||AstraZeneca|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|121|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|April 13, 2010|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT01104701||123670|
NCT01104363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSPFBF-NB-01|Enhancing Prosthetic Results by Predictable Impression Technique and Reliable NobelProcera™ Systems|Heavy Vinyl PolySiloxane and Splinted Implants Impression Technique in Edentulous Patients Rehabilitated With the All-on-4 Concept and Procera® Implant Bridge||Hospital San Pietro Fatebenefratelli|Yes|Suspended|June 2010|May 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|12|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||March 2010|April 13, 2010|April 2, 2010||No|Pending approval of the Ethics Committee|No||https://clinicaltrials.gov/show/NCT01104363||123696|
NCT01105364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA-CIT07-FB-CREIN|Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer|Early Assessment of Anti-Angiogenic Treatment Efficacy in Advanced Renal Cancer by Using Contrast-Enhanced Sonography||National Cancer Institute (NCI)||Recruiting|December 2007|||March 2012|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|N/A|No|||September 2011|August 9, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105364||123619|
NCT01105676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/204, GC 821|Vascular Malformations and Abnormalities of Growth|Vascular Malformations and Abnormalities of Growth||Medical College of Wisconsin|No|Completed|November 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|12 Months|N/A|No|||January 2014|January 6, 2014|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105676||123595|
NCT01105936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3360529|Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)|A Randomised, Double-blind, Evaluation of the Effects of Paracetamol on the BOLD fMRI Response to Painful Stimuli in Subjects With Osteoarthritis||GlaxoSmithKline|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|31|||Both|45 Years|N/A|No|||March 2015|March 26, 2015|March 4, 2010||No||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01105936||123575|
NCT01106209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39621|Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Necrotizing Enterocolitis|Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Necrotizing Enterocolitis||University of Utah|No|Recruiting|April 2010|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|blood and intestinal tissue samples|Both|N/A|1 Year|Accepts Healthy Volunteers|Non-Probability Sample|Preterm and healthy term infants born at the University of Utah Hospital. Infants <1 year        who are undergoing elective surgery at Primary Children's Medical Center.|December 2015|December 2, 2015|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106209||123554|
NCT01106443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88888|Central Compartment Neck Dissection With Thyroidectomy|Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial||University of Alberta|No|Recruiting|February 2010|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01106443||123536|
NCT01106456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11862|Smoking Cessation for American Indians|Culturally-Tailored Smoking Cessation for American Indians||University of Kansas Medical Center|Yes|Completed|September 2010|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106456||123535|
NCT01115673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACEPAI2001|To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Safety and Efficacy Study of Acetaminophen 1000 mg and Acetaminophen 650 mg in Post Operative Dental Pain||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|540|||Both|16 Years|50 Years|No|||April 2012|April 26, 2012|April 30, 2010|Yes|Yes||No|January 4, 2012|https://clinicaltrials.gov/show/NCT01115673||122827|Analysis is based on the Intent-to-Treat (ITT) set, which included all subjects who were randomized, took study medication, did not vomit within 60 minutes after dosing, and had a baseline pain score and at least one post-randomization assessment.
NCT01107067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aa001|Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism|Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism||Gulhane School of Medicine|No|Completed|June 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|32|||Male|20 Years|25 Years|No|||May 2008|April 19, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107067||123488|
NCT01107288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-156|Effects of a Music-Based Multitask Exercises Program on Gait, Balance and Fall Risk in the Elderly|A Randomized Controlled Trial of Music-Based Multitask Exercises (Jaques-Dalcroze Eurhythmics) on Gait, Balance and Fall Risk in the Elderly||University Hospital, Geneva|No|Completed|February 2008|December 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|134|||Both|65 Years|N/A|No|||February 2014|February 21, 2014|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107288||123471|
NCT01106118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14872|Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice|Therapeutic Effectiveness of Vardenafil in ED Patients With the Metabolic Syndrome in Daily Clinical Practice|REVITALISE|Bayer|No|Completed|January 2010|August 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2289|None Retained|n.a|Male|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil        in routine treatment|February 2014|February 19, 2014|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106118||123561|
NCT01106131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19DM09F|Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin|Efficacy and Safety of CKD-501 or Pioglitazone Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: Multi Center, Randomized, Double Blind, Therapeutic Confirmatory Study||Chong Kun Dang Pharmaceutical|Yes|Completed|May 2010|November 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|80 Years|No|||February 2013|February 13, 2013|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106131||123560|
NCT01107249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002562|A Trial of Esophageal and Gastric Stenting for Leak or Perforation|A Phase II Trial of Esophageal and Gastric Stenting for Leak or Perforation|ESO-stent|The Methodist Hospital System|No|Completed|May 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|April 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107249||123474|
NCT01107756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_04775|A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen|A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen|Grano-Tax|Sanofi|No|Completed|March 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|403|||Both|21 Years|75 Years|No|||October 2012|October 4, 2012|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01107756||123436|
NCT01107769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISVAL01|VISIONAIRE™ Value Study|A Single-center, Randomized, Value Study of VISIONAIRE™ Patient Matched Technology vs. Standard Surgical Instrumentation||Smith & Nephew, Inc.|No|Completed|April 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|38|||Both|18 Years|N/A|No|Probability Sample|The patient population considered for this study includes patients with osteoarthritis        (degenerative joint disease)of the knee requiring unilateral TKA.|November 2011|November 18, 2011|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01107769||123435|
NCT01107483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endotoxaemiaobservation|Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic Hepatitis B Virus (HBV) Infection|Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic HBV Infection|OCEHBV|Sun Yat-sen University|No|Completed|December 2009|March 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|140|||Both|24 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with chronic HBV infection admitted to The Third Affliated Hospital of Sun        Yat-sen University|January 2010|May 6, 2010|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01107483||123456|
NCT01103791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOPNP101|A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies|A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies||Samyang Biopharmaceuticals Corporation||Recruiting|April 2010|||||Phase 1|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|N/A|No|||April 2010|April 25, 2010|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01103791||123740|
NCT01104402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL001|Early Intervention in Cystic Fibrosis Exacerbation|Early Intervention in Cystic Fibrosis Exacerbation|eICE|Johns Hopkins University|Yes|Completed|October 2011|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|267|||Both|14 Years|N/A|No|||September 2015|September 9, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104402||123693|
NCT01104415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol LX1606.1-203-CS|Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome|A Phase 2, Open-Label, Multi-Center, Serial Ascending Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome||Lexicon Pharmaceuticals|No|Completed|May 2010|||February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104415||123692|
NCT01104714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2008/BL-01|Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers|Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers|APPROCHE ORL|Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|Samples With DNA|Surplus blood, tumor tissue from biopsies, and DNA will be stocked in the Biothèque of the      Nîmes University Hospital|Both|30 Years|80 Years|No|Non-Probability Sample|The patients included in this study have been diagnosed with an advanced stage squamous        cell carcinoma in the buccal, oropharyngeal, laryngeal or hypopharyngeal areas.|March 2015|March 25, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104714||123669|
NCT01104376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808-16|Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers|Effect of Cytochrome P450 2B6 Genetic Polymorphism and Voriconazole on CYP2B6 Activity in Healthy Volunteers||Indiana University|Yes|Completed|March 2010|April 2013|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|61|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|April 12, 2010||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01104376||123695|
NCT01104389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISI-FHU-2010-01|Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging|A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors||Intuitive Surgical|No|Withdrawn|May 2010|||July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|80 Years|No|||August 2015|August 24, 2015|April 7, 2010||No|Study was never started|No||https://clinicaltrials.gov/show/NCT01104389||123694|
NCT01105377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-02024|Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of Azacitadine and Entinostat in Patients With Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Completed|April 2010|May 2014|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|April 15, 2010|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01105377||123618|
NCT01105962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBIRR-01|Hyperbaric Oxygen Therapy in Chronic Traumatic Brain Injury or Post-Traumatic Stress Disorder|Multicenter Observational Study of Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post-Concussion Syndrome (PCS) and/or TBI/Post-Traumatic Stress Disorder (PTSD)|NBIRR-1|International Hyperbaric Medical Foundation|Yes|Terminated|May 2010|December 2015|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|18 Years|65 Years|No|Non-Probability Sample|One thousand subjects will be recruited. Subjects will be 18-65 years old and have been        diagnosed with mild or moderate (but not severe) TBI or TBI/PTSD or PTSD by either the        military (any etiology) or civilian neurologists or neuropsychologists. This diagnosis        will especially include war veterans who have had a significant decrease in their        neuropsychological test scores.        There will be no gender restriction. However, it is anticipated that the cohort will        consist mostly of males, due to the nature of the injury. There will be no race or        ethnicity restriction.        All subjects will be legally capable of consenting. No subjects who need 3rd party consent        will be enrolled in the NBIRR study.        Military - Unless specifically approved by a military site IRB, active duty participants        will have to voluntarily contact NBIRR participating sites or respond to a recruitment        outreach outside of the command.|March 2015|March 31, 2015|April 15, 2010||No|regulatory requirements require funding for restart as a new study|No||https://clinicaltrials.gov/show/NCT01105962||123573|
NCT01105949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3560645|An Evaluation of Two Novel Nasal Strip Prototypes on Nasal Patency|An Evaluation of Two Novel Breathe Right Nasal Strip Prototypes on Nasal Patency||GlaxoSmithKline|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 25, 2012|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105949||123574|
NCT01106222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-151|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2010|||||N/A|N/A|N/A||||||||||||||April 16, 2010|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106222||123553|
NCT01106235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2390.00|Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma|Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous IL-21 Modulated CD8+ Antigen-Specific T Cells For Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center|Yes|Terminated|April 2010|||November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|75 Years|No|||December 2011|December 20, 2011|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01106235||123552|
NCT01106768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00616-49|Evaluation of Oral Needs of Children With Disorder Attention Deficit/Hyperactivity Disorder|Evaluation of Oral Needs of Children With Disorder Attention Deficit/Hyperactivity Disorder||University Hospital, Strasbourg, France|No|Recruiting|May 2009|December 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|140|||Both|5 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|children with attention deficit disorder with or without hyperactivity|June 2012|June 28, 2012|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01106768||123511|
NCT01115426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGAMsPGNPMsPGN|Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis|Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis||University Magna Graecia|Yes|Completed|January 1997|January 2008|Actual|January 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||January 1997|April 30, 2010|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01115426||122846|
NCT01115998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07956|Effect of Power Wheelchairs on the Development and Function of Young Children With Severe Physical Disabilities|Learning Early Travel Skills: Effects of Power Mobility on the Development of Young Children With Severe Motor Impairments||University of Oklahoma|No|Completed|June 2002|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|14 Months|30 Months|No|||May 2010|May 20, 2010|March 19, 2009||No||No|March 19, 2009|https://clinicaltrials.gov/show/NCT01115998||122804|Small sample limited power; matched pairs design limited sample size and analyses; not all children were independent using power wheelchair in 1 year; cognitive measure probably unresponsive to changes in children with physical limitations.
NCT01129466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0410|Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers|Effects of Sulforaphane Containing Supplements on Nasal Cell Phase 2 Gene Expression in Healthy Volunteers.|Broccosprout|University of North Carolina, Chapel Hill|No|Completed|May 2010|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|11|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129466||121776|
NCT01129479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-EMR-4008|Galantamine Treatment for Nonfluent Aphasia in Stroke Patients|Galantamine Treatment for Nonfluent Aphasia in Stroke Patients||University of North Carolina, Chapel Hill|No|Completed|October 2004|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||May 2010|May 21, 2010|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129479||121775|
NCT01107223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAAIR2|Long Term Effect of General Practitioner Education on Antibiotic Prescribing|Long Term Effect of General Practitioner Education on Antibiotic Prescribing: a Large Scale Randomized Study|PAAIR2|Henri Mondor University Hospital|Yes|Active, not recruiting|September 2004|April 2010|Anticipated|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|170|||Both|N/A|N/A|No|||February 2010|April 19, 2010|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01107223||123476|
NCT01107236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICP-109-201|Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction|A Phase 2, Single-center, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study of a Single Dose of IW-6118, in Patients Undergoing Third Molar Extraction||Ironwood Pharmaceuticals, Inc.||Completed|June 2010|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107236||123475|
NCT01108081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-063|Telemedicine Interventions for Obstructive Sleep Apnea (OSA)|An RCT of Telemedicine Interventions for OSA||VA Office of Research and Development|No|Active, not recruiting|October 2010|January 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|216|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108081||123411|
NCT01107509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIURCCEVERO|Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers|A Pilot Study of Neo-Adjuvant Everolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy - Analysis of Serum and Tissue Biomarkers||St. Joseph's Healthcare Hamilton|No|Active, not recruiting|October 2010|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01107509||123454|
NCT01104116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD9508|Use of PET Imaging to Distinguish Malignant From Benign IPMN|Utility of [18F]-FDG PET Imaging to Distinguish Malignant From Benign Intrapapillary Mucinous Neoplasms||Columbia University|Yes|Recruiting|August 2009|December 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients seen at the Pancreas Center at Columbia University Medical Center with a        diagnosis of IPMN that meets the inclusion criteria.|February 2014|February 20, 2014|April 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104116||123715|
NCT01103804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GRO-DUM-2009/1|Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment|A Prospective, Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Systematic Treatment With PPIs in GERD Patients in Primary Care Setting in Romania, Using the Validated GerdQ Questionnaire.||AstraZeneca|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|952|||Both|18 Years|N/A|No|Probability Sample|The study population are patients known/newly diagnosed with GERD or with symptoms        suggesting GERD( hearburn, regurgitations) who presented to their family physician(primary        care clinic)|January 2011|January 10, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103804||123739|
NCT01104428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhangjun555678|Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura|Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura||Liaoning University of Traditional Chinese Medicine|Yes|Recruiting|November 2009|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|256|||Both|5 Years|18 Years|No|||September 2010|September 7, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01104428||123691|
NCT01105065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03-019 (75643)|Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma|Effect of Brimonidine 0.15% on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Tension Glaucoma||Massachusetts Eye and Ear Infirmary||Active, not recruiting|March 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|35 Years|80 Years|No|||February 2014|February 21, 2014|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105065||123642|
NCT01105013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEU-TOL-03/09|Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections|Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body"|Tonaftato|Laboratório Teuto Brasileiro S/A|Yes|Not yet recruiting|April 2012|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|90|||Both|12 Years|N/A|No|||April 2012|April 11, 2012|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105013||123646|
NCT01105689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-171|Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers|Utility of the Urine Calcium Creatinine Ratio as a Screening Tool for Vitamin D Deficiency in Infants and Toddlers||Nemours Children's Clinic|No|Completed|March 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|Samples Without DNA|Whole Blood will be obtained from which we will collect serum and fresh urine which will be      used for study labs. Urine and serum may be stored for future studies.|Both|6 Months|3 Years|Accepts Healthy Volunteers|Probability Sample|Infants and Toddlers from 6 months to 3 years part of a group known to be in at least one        high-risk group for vitamin D deficiency:          1. child has been exclusively breast fedfor at least 1 month          2. darkly pigmented children          3. children born at a gestational age of 32 weeks or less          4. recent immigrant from developed country          5. child is underweight (wt/ht < 10%)          6. children with bowed legs or wrist enlargement|September 2011|September 8, 2011|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105689||123594|
NCT01114347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2009/VL-01|Prevention of Nosocomial E. Coli Infections After Placement of an Indwelling Catheter During Pelvic Surgery: an Evaluation of Cranberry Gel Capsules|Prevention of Nosocomial Escherichia Coli Infections After Placement of an Indwelling Catheter During Pelvic Surgery: a Randomized, Prospective, Double Blind Study for the Evaluation of Cranberry (Vaccinium Macrocarpon) Gel Capsules|NosoPink|Centre Hospitalier Universitaire de Nīmes|No|Completed|August 2010|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|270|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01114347||122929|
NCT01114672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10020|A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients|A Randomized Prospective, Double-Blind Placebo Controlled Study of Oral Ergocalciferol in the Treatment of Pruritis in Hemodialysis Patients|CRN11|Winthrop University Hospital|No|Completed|July 2010|February 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||February 2013|February 15, 2013|April 29, 2010|Yes|Yes||No|January 8, 2013|https://clinicaltrials.gov/show/NCT01114672||122904|
NCT01114958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 090772|Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases|A Phase I / Pilot Study of Intra-Arterial Supradose Cisplatin With Simultaneous Intravenous Thiosulfate Neutralization in Patients With Primary Lung Cancer or Lung Metastases||University of California, San Diego||Recruiting|April 2010|||October 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||April 2010|May 4, 2010|April 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01114958||122882|
NCT01115192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OptimaCologne|Blephacura Versus Baby Shampoo to Treat Blepharitis|Blephacura Versus Baby Shampoo to Treat Blepharitis||University of Cologne|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|N/A|N/A|No|||April 2013|April 23, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01115192||122864|
NCT01106482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M48P3E1|An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE|A Phase IV, Open-label, Multi-center Follow-up Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE||Novartis||Completed|May 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|126|||Both|4 Years|14 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01106482||123533|
NCT01106495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EECP-1|Effect of Enhanced External Counterpulsation (EECP) on Subclinical Atherosclerosis|Study of the Effect of EECP on Subclinical Atherosclerosis|SESA|Sun Yat-sen University|Yes|Recruiting|May 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106495||123532|
NCT01116583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-002769-11|The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy|The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy - A Randomized, Double-blind, Placebo-controlled Trial|GABATEA|University of Aarhus|Yes|Completed|May 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|80 Years|No|||September 2012|August 4, 2014|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01116583||122759|
NCT01115686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08024|Branched-chain Aminoacids in Sleep Apnea Syndromes (ARSAS)|Which Place for Branched-chain Aminoacids in the Treatment of Sleep Apnea Syndromes?|ARSAS|University Hospital, Limoges|Yes|Withdrawn|June 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2010|December 4, 2012|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115686||122826|
NCT01116011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1151C00004|Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers|A Phase I, Single-Centre, Randomised, Double-Blind, Placebo-controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7268 When Given in Multiple Ascending Oral Doses in Japanese Healthy Male Subjects|JMAD|AstraZeneca|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2010|December 14, 2010|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01116011||122803|
NCT01126541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19895|SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy|A Comparative Study to Assess the Effect of Retreatment With 2 Doses of MabThera on Disease Activity Score in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to antiTNF-alfa Therapy.(SMART)||Hoffmann-La Roche||Completed|September 2006|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|May 18, 2010||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01126541||121998|Nonserious adverse events (AEs) presented in this record include all AEs reported during the study, not just nonserious events.
NCT01126554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIM_MB 002|ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill Patients|ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill|Greenpep|University of Zurich|Yes|Completed|July 2010|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|N/A|N/A|No|Probability Sample|Critically ill patients of a 10 bed ICU unit|April 2014|April 28, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126554||121997|
NCT01107002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-006|Comparison of 5 Day Embryo Transfer With 2-3 Day Transfer in Patients With Previous In Vitro Fertilization Failure|Comparison of 5 Day Embryo Transfer With 2-3 Day Transfer in Patients Who Failed to Conceive in Two or More Day 2-3 Embryo Transfer Cycle in Royan Institute||Royan Institute|Yes|Completed|July 2008|August 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2010|July 14, 2011|April 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01107002||123493|
NCT01107535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMOS-PERU 07-01|Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection|Observational Study of the Effectiveness of Synagis Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus Infection|INSPIRA|Abbott||Completed|September 2007|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|N/A|6 Months|No|Non-Probability Sample|Pre term neonates who received Synagis (palivizumab) according to the clinical practice.        The study is implemented in 4 hospitals of Peru.|October 2012|October 26, 2012|February 20, 2010||No||No|February 7, 2012|https://clinicaltrials.gov/show/NCT01107535||123452|
NCT01103843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006|Plavix, Prasugrel and Drug Eluting Stents Pilot Trial|PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents|PPD|St. Francis Hospital, New York|Yes|Recruiting|April 2010|May 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|21 Years|75 Years|No|||April 2010|April 14, 2010|April 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103843||123736|
NCT01108094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0004-TX|Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas|Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas||Stanford University|Yes|Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01108094||123410|
NCT01103856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH085527-01A1|Test of an Intervention to Improve HIV Care|Test of an Intervention to Improve HIV Care||Baylor College of Medicine|No|Active, not recruiting|May 2010|May 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|434|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103856||123735|
NCT01108068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-40536|Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome|Trial of Lithium Carbonate for Treatment of Osteoporosis Pseudoglioma Syndrome||University of Maryland|Yes|Completed|July 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|4 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|April 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01108068||123412|
NCT01103869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC7449A|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||December 14, 2010|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01103869||123734|
NCT01104727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAES-3|Multi-Port Versus Single-port Cholecystectomy|Multi-Port vs. Single-port Cholecystectomy|MUSIC|European Association for Endoscopic Surgery|Yes|Completed|April 2011|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104727||123668|
NCT01113242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4682|Neuropsychological Assessment of Cognitive Decline in Patients With a Definite Parkinson's Disease|Characteristics of Cognitive Decline During Parkinson's Disease in the Elderly||University Hospital, Strasbourg, France|No|Recruiting|June 2010|September 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|65 Years|N/A|No|Non-Probability Sample|Patients with idiopathic PD are issued from an ambulatory following at the department of        Geriatrics|November 2010|November 30, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113242||123014|
NCT01105026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT-109-CT|A Clinical Investigation to Evaluate the Healing of Tooth Extraction Sites Filled With BioRestore™|Bone Regeneration by Means of a Bioactive Glass Scaffold.||University of Trieste|Yes|Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2009|April 15, 2010|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105026||123645|
NCT01105039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-125X|Detailed Pain Pattern After Laparoscopic Inguinal Hernia Repair|Early Pain Pattern and Its Components After Laparoscopic Inguinal Hernia Repair||University Hospital Koge|No|Completed|November 2009|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Male|18 Years|69 Years|No|Probability Sample|Patients are consecutively included in this study. They are all undergoing elective        laparoscopic groin hernia repair.|February 2011|April 15, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01105039||123644|
NCT01114022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OST08029|Prevention Inhalation of Bacterial by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane|Comparison of Prevention Bacterial Inhalation of Patients on Mechanical Ventilation by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane|Top-cuff|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2010|July 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|620|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114022||122954|
NCT01114360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021300|Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study|Melatonin and Nighttime Blood Pressure in African Americans- 8 mg Study||Emory University|Yes|Completed|March 2010|September 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 15, 2015|April 29, 2010|Yes|Yes||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01114360||122928|
NCT01114685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlgaeCal 1 & 2|A Comparison of Changes in Bone Density With the Same Bone-health Plan, But With Different Bone-health Supplements|Bone Mineral Density (BMD) Changes in a Bone Health Plan Using Two Versions of a Bone Health Supplement: A Comparative Effectiveness Research (CER) Study||Integrative Health Technologies, Inc.|Yes|Completed|June 2006|March 2010|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|354|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 30, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01114685||122903|
NCT01114698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016579|A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder|A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder||Janssen Research & Development, LLC|Yes|Terminated|March 2011|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|65 Years|No|||February 2013|February 11, 2013|April 22, 2010|Yes|Yes|Study was terminated due to sponsor portfolio decision.|No||https://clinicaltrials.gov/show/NCT01114698||122902|
NCT01114971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019328|Labetalol and Esmolol: Vital Signs and Post Operative Pain Management|Randomized, Double-Blinded, Active-Controlled Study to Evaluate the Intraoperative Use of Labetalol vs. Esmolol for Maintaining Hemodynamic Stability During Laparoscopic Surgery: Effect on Recovery and Postoperative Pain||Cedars-Sinai Medical Center|Yes|Recruiting|September 2009|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|80 Years|No|||September 2015|September 10, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01114971||122881|
NCT01115413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH-HL-10-064|The Effect of Teenage Maternity on Obstetrical and Perinatal Outcomes|Influence of Young Maternal Age on Pregnancy Outcome in Central Europe||University of Luebeck|No|Completed|April 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|150|||Female|11 Years|50 Years|No|Non-Probability Sample|retrospective cohort analysis of all deliveries at the Schleswig-Holstein University        Hospital Center in Lübeck from January 2000 through December 2009|June 2014|June 5, 2014|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115413||122847|
NCT01116063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPDVEN 2009|Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)|Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease|COPDVEN|Carmel Medical Center|No|Not yet recruiting|May 2010|June 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|25 Years|90 Years|No|||May 2010|May 3, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116063||122799|
NCT01116323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AE1.7.005.11.N.00|Emergency Department Crowding in Relation to In-hospital Adverse Medical Events|Emergency Department Crowding in Relation to In-hospital Adverse Medical Events||Katholieke Universiteit Leuven|No|Recruiting|June 2010|December 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|104000|None Retained|None Retained - no samples retained|Both|18 Years|N/A|No|Probability Sample|All adult (18 years or older) patients presenting to the ED|September 2011|September 20, 2011|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116323||122779|
NCT01123122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHEndo0510|A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation|A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation||Vancouver Coastal Health|No|Withdrawn|September 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||May 2011|March 31, 2015|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01123122||122259|
NCT01123135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6434|The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence|The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence||University of California, Irvine|Yes|Recruiting|July 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Female|N/A|N/A|No|||November 2010|November 16, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01123135||122258|
NCT01107782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-821|Sildenafil and Uteroplacental Perfusion|Phase 2 Study of Fetal Growth Retardation Treatment by Sildenafil||Tehran University of Medical Sciences|Yes|Recruiting|June 2008|January 2012|Anticipated|June 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2011|February 22, 2011|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107782||123434|
NCT01107795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F091104002|Prospective Study to Evaluate Outcomes From Trans-oral Base of Tongue Resection for Obstructive Sleep Apnea Hypopnea Syndrome|Prospective Study to Evaluate Outcomes From Trans-oral Base of Tongue Resection for Obstructive Sleep Apnea Hypopnea Syndrome||University of Alabama at Birmingham|Yes|Recruiting|March 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who choose to undergo transoral robotic assisted tongue base operations for        Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS).|March 2016|March 2, 2016|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01107795||123433|
NCT01108107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20100014|Neoadjuvant Treatment of Colon Cancer|Neoadjuvant Chemotherapy and Biological Treatment for Patients With Locally Advanced Colon Cancer||Vejle Hospital|Yes|Completed|April 2010|March 2015|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||March 2014|May 20, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01108107||123409|
NCT01107808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB MHRC SBW|Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females|Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females.||University of Alabama at Birmingham|No|Withdrawn|June 2009|March 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|14 Years|19 Years|Accepts Healthy Volunteers|||March 2011|March 9, 2015|April 1, 2010||No|Poor recruitment to the study|No||https://clinicaltrials.gov/show/NCT01107808||123432|
NCT01107821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/597|Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation|Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation||University Hospital, Ghent|No|Recruiting|February 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|80 Years|No|||June 2015|June 2, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01107821||123431|
NCT01104441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08022|Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia|Cardiovascular Events at One Year of Patients Hospitalized for Critical Limb Ischaemia and Aspirin Resistant Using the VerifyNow®. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia|Aspirine|University Hospital, Limoges|No|Recruiting|April 2010|April 2014|Anticipated|April 2013|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|153|||Both|18 Years|N/A|No|Probability Sample|patients hospitalized for critical limb ischaemia and aspirin resistant using the        VerifyNow®.|April 2010|December 4, 2012|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104441||123690|
NCT01112943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-2-Acu|Acupuncture Combined With Pulmonary Rehabilitation: Are There Additional Benefits?|The Impact of Acupuncture as an Adjunct to Pulmonary Rehabilitation||Beaumont Hospital|No|Completed|July 2007|January 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|44|||Both|35 Years|N/A|No|||August 2012|August 12, 2012|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112943||123037|
NCT01113801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10168|A Study in Participants With Diabetic Kidney Disease|A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes||Eli Lilly and Company|Yes|Terminated|July 2010|July 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|417|||Both|25 Years|N/A|No|||September 2015|September 4, 2015|April 28, 2010|Yes|Yes|Interim Assessment: Lack of Efficacy|No||https://clinicaltrials.gov/show/NCT01113801||122971|
NCT01105052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/23-31/4|Self-help Cognitive Behavioral Therapy (CBT) for Insomnia|Cognitive Behavioral Therapy as Guided Self-help for Insomnia - a Randomized Controlled Trial||Karolinska Institutet|No|Completed|February 2008|December 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|133|||Both|18 Years|N/A|No|||April 2010|April 14, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01105052||123643|
NCT01114035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 070163|Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or Tufting Enteropathy (TE)|Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or TE|DEI|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2010|July 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|41|||Both|N/A|15 Years|No|||August 2013|August 1, 2013|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114035||122953|
NCT01115218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeVeTra-2009|The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy|The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy||University of Cologne|No|Completed|October 2009|March 2012|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients from the University Eye Hospital of Cologne|April 2013|April 12, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01115218||122862|
NCT01115699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000401|Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as Adjuvant Treatment for Depression|Pilot Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as Adjuvant Treatment in Patients With Non-remitting Depression: Third Stage of Citalopram/Escitalopram Study|rTMS|Mayo Clinic|No|Terminated|April 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|85 Years|No|||October 2013|October 23, 2013|April 30, 2010||No|Stopped due to funding constraints and recruitment was slower than was expected|No|October 23, 2013|https://clinicaltrials.gov/show/NCT01115699||122825|This study was stopped early due to funding constraints and recruitment was slower than was expected.
NCT01116050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-104|Intrarectal Misoprostol in Postpartum Haemorrhage|Second-line Treatment of Post-partum Haemorrhage With Intrarectal Misoprostol: a Multicentre, Double Blind, Randomized Placebo-controlled Trial|HEMOSTOP|University Hospital, Caen|Yes|Completed|January 2004|||December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Female|18 Years|N/A|No|||May 2011|May 19, 2011|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116050||122800|
NCT01115205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 1264|Supervised Walking Groups as a Model to Increase Physical Activity in Type 2 Diabetes|Assessment of Feasibility and Efficacy of a Project Aimed to Improve Metabolic Control in Type 2 Diabetes Through Lifestyle Changes and Self-monitoring of Blood Glucose||Universita di Verona|No|Completed|March 2006|January 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|50 Years|75 Years|No|||May 2010|May 3, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01115205||122863|
NCT01115725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP25404|A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)|Phase IV Study to Evaluate the Ease of Use, Local Tolerance Safety and Effectiveness of Gonal-f® (Filled-by-Mass in a Prefilled Pen)||Merck KGaA||Completed|November 2005|July 2008|Actual|June 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Female|18 Years|39 Years|No|Non-Probability Sample|Primary care clinic|December 2012|July 16, 2014|April 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115725||122823|
NCT01123772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-09-2009|Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers|Phase I, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate Tolerability, Safety & PK of BID Topical Ocular Application of INO-8875 in Healthy Older-Adult Volunteers||Inotek Pharmaceuticals Corporation|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 27, 2012|April 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01123772||122210|
NCT01123785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-10-2009|A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|A Phase I/II Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics (Efficacy) of Chronic Twice-Daily Topical Monocular Application of INO-8875 Ophthalmic Formulation in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma||Inotek Pharmaceuticals Corporation|No|Completed|May 2010|January 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|77 Years|No|||October 2012|October 11, 2012|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01123785||122209|
NCT01127061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESET-HCM|Study of Exercise Training in Hypertrophic Cardiomyopathy|A Randomized Trial of Moderate Intensity Exercise Training in Hypertrophic Cardiomyopathy|RESET-HCM|University of Michigan|Yes|Active, not recruiting|April 2010|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|128|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01127061||121958|
NCT01127308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-038|A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)|An Open Label, Single-Period, Phase 1 Study To Evaluate The Pharmacokinetics, Excretion Balance And Metabolism Of [14C]-PF04971729 In Healthy Adult Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|May 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01127308||121939|
NCT01116791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPCUpp-trial|Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer|Cytoreductive Surgery Plus Hyperthermic Intraoperative Peritoneal Chemotherapy With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer; the HIPCUpp-trial||University Hospital, Gasthuisberg|No|Terminated|July 2010|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|May 3, 2010||No|Insufficient enrollment in Pancreatic & Biliary arm|No||https://clinicaltrials.gov/show/NCT01116791||122743|
NCT01103882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT.CR.LKR1.10|Short-Term Clinical Outcome of Total Hip Arthroplasty Using Larger Diameter of 4th Generation Ceramic Bearing|Short-Term Clinical Outcome Including Dislocation Rate and Ceramic Fracture of Total Hip Arthroplasty Using Larger Diameter of 4th Generation Ceramic Bearing||Biomet, Inc.|No|Active, not recruiting|May 2010|May 2017|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|277|||Both|20 Years|N/A|No|Probability Sample|Patients indicated for total hip arthroplasty|July 2015|July 20, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103882||123733|
NCT01104129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD8007|Stool Testing for Pancreatic Cancer|Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study||Columbia University|Yes|Active, not recruiting|July 2009|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|-  Tissue Collection: Fresh frozen resected tumor and IPMN tissue will be obtained           whenever possible. All resected specimens, cancer and IPMN, will have histologic review           to confirm the diagnosis. Ten slices of 10 microns each from each specimen will be           prepared and sent to Mayo Clinic on dry ice.        -  Stool Collection: Prior to any surgery, stool will be collected from both study and           control patients. Collection containers and mailing materials will be provided to           subjects at time of their recruitment. Stool specimens will be mailed directly to Mayo           Clinic within 48 hours of collection. Stool will be stored at 80 °C until assayed.        -  Stool DNA extraction: After stool is homogenized, crude stool DNA will be extracted and           purified.        -  Digital melt curve mutation analysis: Target gene copies in captured stool DNA and           tissue DNA will be quantified with real-time PCR. To target the mutations detected in           tumor specimens, we will utilize PCR primers that scan for specific gene abnormalities.|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with a diagnosis of pancreatic cancer/IPMN who are scheduled for surgical        resection at Columbia University Medical Center's Pancreas Center will be accrued to this        study.|March 2015|March 4, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104129||123714|
NCT01104142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-900222|Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy|Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy||DexCom, Inc.|No|Completed|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|This clinical study population will consist of a minimum of 100, and up to 120 subjects        with insulin-requiring diabetes mellitus on Multiple Daily Injections (MDI) or Continuous        Subcutaneous Insulin Infusion (CSII) therapy; equal number of subjects will be enrolled        among each therapy group. It is desirable to have a similar distribution of baseline A1C        in each study group.|April 2010|April 14, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104142||123713|
NCT01104155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-205|Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer|The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.||Eisai Inc.||Active, not recruiting|November 2009|November 2014|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104155||123712|
NCT01117064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006804|Neuromodulation Therapy Device for the Treatment of Sleep Apnea|Neuromodulation Therapy Device for the Treatment of Sleep Apnea||Mayo Clinic|No|Completed|February 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||May 2013|May 26, 2013|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01117064||122722|
NCT01113255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070146|Validation of a Simulated Clinical Evaluation of Ventilators|Validation of a Simulated Clinical Evaluation of Ventilators|SIMULVENTI|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2009|December 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|6 Years|N/A|No|||November 2014|November 5, 2014|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01113255||123013|
NCT01113814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-003|Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV|Performance of Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for the Non-invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C||Johann Wolfgang Goethe University Hospitals|No|Completed||||||N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|79 Years|No|||May 2012|May 21, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113814||122970|
NCT01113502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17409|Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)|A Phase I/II Study of Eltrombopag in Elderly Patients With AML||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|April 2010|November 2015|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Actual|44|||Both|60 Years|N/A|No|||December 2015|December 14, 2015|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113502||122994|
NCT01113515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novalead-Galnobax-0210|Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers|An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax®) for the Treatment of Diabetic Foot Ulcer (DFU)||Novalead Pharma Private Limited|No|Active, not recruiting|February 2014|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|95 Years|No|||April 2015|April 14, 2015|April 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01113515||122993|
NCT01105390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1B09|AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma|A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma||National Cancer Institute (NCI)||Withdrawn|April 2010|||May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|August 1, 2013|April 15, 2010|Yes|Yes|withdrawn|No||https://clinicaltrials.gov/show/NCT01105390||123617|
NCT01105403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POL-2|Exploratory Study on POL6326 in Stem Cell Mobilization|A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma||Polyphor Ltd.|Yes|Completed|April 2009|April 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|70 Years|No|||April 2014|April 22, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01105403||123616|
NCT01114711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001452|Frovatriptan and Menstrual Migraine|Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)|FROVA|Mclean Hospital||Terminated|April 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|24|||Female|18 Years|N/A|No|Non-Probability Sample|Females who suffer from menstrual migraine who are over the age of 18 and have not yet        experienced menopause are the study population.|May 2010|May 26, 2010|April 29, 2010|No|Yes|A sister study using Frova at a 10 mg dose had adverse effects.|No||https://clinicaltrials.gov/show/NCT01114711||122901|
NCT01114724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP # 118|Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections|Valiant® Thoracic Stent Graft With the Captivia Delivery System. Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections||Medtronic Endovascular|Yes|Active, not recruiting|May 2010|June 2017|Anticipated|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 26, 2010|Yes|Yes||No|May 30, 2014|https://clinicaltrials.gov/show/NCT01114724||122900|
NCT01115231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7428-R|Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration|Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration|CFH&AMD|VA Office of Research and Development|No|Active, not recruiting|October 2010|December 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Whole blood will be collected into dipotassium ethylenediaminetetraacetic acid (EDTA) tubes      resulting in a final EDTA concentration of 4.5 mM. Plasma will be separated from whole blood      by centrifugation (10 minutes at 3000 RPM) and frozen at -80 degrees C until further use.      Subjects will be genotyped for signal nucleotide polymorphisms for I62V and Y402H using      TaqMan single nucleotide polymorphisms (SNP) genotyping assays. Complement pathway protein      analysis will be performed by ELISAs.|Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The case and control subjects will be derived from a group of Veterans at the Charleston,        SC VA Medical Center.|January 2016|January 4, 2016|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01115231||122861|
NCT01115010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE-1|Effectiveness of Stiffening Wire in Colonoscopy With Pre-Owned Colonoscopes|Effectiveness of a Proprietary Intraluminal Stiffening Wire in Decreasing Procedure Time and Improving Cecal Intubation Rate With Pre-owned Colonoscopes; a Randomized, Controlled Trial||Cornwall Regional Hospital|No|Terminated|December 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|112|||Both|18 Years|N/A|No|||July 2011|August 2, 2011|April 29, 2010|No|Yes|Colonoscope being used in study not repairable at economic cost.|No||https://clinicaltrials.gov/show/NCT01115010||122878|
NCT01115023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L1IDA1|Effect of Consuming Food Cooked in Iron Utensils on Iron Status in Children With Iron Deficiency Anemia (IDA)|Randomized Controlled Trial to Study the Effect of Consuming Food Cooked in Iron Utensils on Iron Status in Children With Iron Deficiency Anemia (IDA)|IDA|Dhande, Leena Ajay, M.D.|No|Completed|October 2003|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|2 Years|12 Years|No|||April 2010|April 30, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115023||122877|
NCT01116297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P000384 BIDMC|Tissue Oxygenation Measurements With Modulated Light (S-FLARE)|Tissue Oxygenation Measurements During Plastic Surgery Using Spatially Modulated Light (S-FLARE)||Beth Israel Deaconess Medical Center|No|Completed|January 2010|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Female|21 Years|N/A|No|||February 2013|February 14, 2013|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116297||122781|
NCT01116310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCF-GIN-2008-EC02|Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause|Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Tolerability of the Combination of Soy Isoflavones and Red Clover Extract (FITOGYN) in the Treatment of the Hot Flushes in Menopausal Women.|TRYSEM|Laboratorios Casen-Fleet S.L.U.|No|Recruiting|April 2010|July 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Female|45 Years|60 Years|No|||September 2011|September 27, 2011|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116310||122780|
NCT01116661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10101|Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain|ALA|University of California, San Francisco|Yes|Recruiting|August 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|72 Years|No|||October 2014|October 27, 2014|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116661||122753|
NCT01116895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 22811-S22|A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris|An International, Multi-centre, Prospective, Randomised, Double-blind, 4-arm, Placebo Controlled, Parallel Group Study With 12 Weeks Once Daily Oral Treatment in Subjects With Psoriasis Vulgaris||LEO Pharma|Yes|Completed|May 2010|July 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|63|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01116895||122735|
NCT01127945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0014|Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients|A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients||Yonsei University|Yes|Completed|May 2010|November 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 4, 2014|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01127945||121890|
NCT01128452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR104589|Safety and Efficacy of EVT 101 in Treatment-Resistant Depression|A 4-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression||Janssen Research & Development, LLC|Yes|Terminated|June 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|55 Years|No|||January 2016|January 4, 2016|May 19, 2010|Yes|Yes|Evotec has indicated that this study was discontinued due to a clinical hold issued by the FDA|No||https://clinicaltrials.gov/show/NCT01128452||121852|
NCT01128465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC|Pharmacokinetic and -Dynamic of Propofol During Awake Craniotomy|Investigation on the Pharmacokinetic and -Dynamic of Propofol During Awake Craniotomy||University Hospital, Bonn|No|Completed|February 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients of a University Hospital requiring an awake craniotomy for resection of a brain        tumor or lesion|March 2011|March 16, 2011|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01128465||121851|
NCT01107262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVIFLU -XPD09-010|Avian Influenza Studies In Lebanon|Avian Influenza Studies In Lebanon||St. Jude Children's Research Hospital|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|250|Samples Without DNA|A trained phlebotomist will collect a tube of blood (7.5ml) in serum separator tubes. The      blood will be allowed to clot at room temperature then centrifuged on the same day. Serum      specimens will be aliqouted into multiple cryovials, labelled and preserved at -20°C until      ready for laboratory study.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This study will be conducted in the rural areas of Lebanon where poultry production is        located.Specifically, three main regions will be included in this study, the Beqaa, North        Lebanon, and South Lebanon regions.The Mount Lebanon and Beirut regions are heavily        urbanized and poultry production in these regions is minimal.Poultry-exposed individuals        will be enrolled according to the following scheme:100 from Beqaa, 50 from North Lebanon,        and 50 from South Lebanon. The 50 non-exposed individuals will be enrolled from Beirut.        Villages will be randomly selected from each of the 3 regions where enrollment will        occur.Each village will be assigned a number and then a random digit sheet will be        generated and used to randomly select villages.        Controls, adults who were never exposed to poultry, will be enrolled from urban areas such        as the capital Beirut. Controls will be invited to volunteer by word of mouth at        public/community sites.|October 2011|October 26, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107262||123473|
NCT01107834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0121|Heart Function in HIV-Negative Children Exposed to HIV and HAART|Left Ventricular Function in HIV-Negative Children Exposed to HIV and HAART In Utero||Washington University School of Medicine|Yes|Recruiting|May 2010|July 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV-negative children will be recruited through their HIV+ mothers who are seen at the        AIDS Clinical Trials Unit at Washington University and surrounding St. Louis community        clinics. HIV-negative children will be recruit through Washington University and        surrounding St. Louis pediatric clinics, and through Washington University Volunteers for        Health service.|March 2011|March 3, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107834||123430|
NCT01116804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/115|Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)|Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)||University Hospital, Ghent|No|Recruiting|May 2010|October 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116804||122742|
NCT01116817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-MONOKAL|Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy|Exploratory, Cross-sectional Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy||Germans Trias i Pujol Hospital|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||July 2011|July 13, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01116817||122741|
NCT01103895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-C-HCE101-4A-H|Measurement of Cardiac Output Before and After Cardiopulmonary Bypass.|Ultrasound Dilution Measurement of Cardiac Output Before and After Adult Cardiopulmonary Bypass||Transonic Systems Inc.|No|Enrolling by invitation|July 2007|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|21 Years|N/A|No|||June 2012|June 4, 2012|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103895||123732|
NCT01103908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-HCE101-5A-H|Cardiac Output Measurement at the Conclusion of Cardiopulmonary Bypass|Ultrasound Dilution Cardiac Output at the Conclusion of Cardiopulmonary Bypass in Pediatric Patients||Transonic Systems Inc.|No|Terminated|April 2010|August 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|N/A|21 Years|No|||June 2012|June 4, 2012|April 13, 2010||No|Site PI left current position and study was not continued due to lack of a suitable    replacement PI.|No||https://clinicaltrials.gov/show/NCT01103908||123731|
NCT01116544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT NS060192|Treatment of Chronic Stroke With AMES + EMG Biofeedback|Treatment of Chronic Stroke With AMES + EMG Biofeedback|AMES|AMES Technology|No|Active, not recruiting|April 2010|December 2014|Anticipated|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|80 Years|No|||December 2014|December 19, 2014|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116544||122762|
NCT01116778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA0809005101|the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis|A Phase III, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Efficacy and Safety of Probiotics eN-Lac® Capsules (Lactobacillus Paracasei GMNL-32) for the Treatment of Children With Perennial Allergic Rhinitis|PAR|GenMont Biotech Incorporation|Yes|Completed|May 2010|June 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|236|||Both|5 Years|16 Years|No|||August 2015|August 31, 2015|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01116778||122744|
NCT01113541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281190|One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome|A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar Disorder||Pfizer|No|Terminated|July 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||June 2012|June 5, 2012|April 28, 2010|No|Yes|See termination reason in detailed description.|No|October 12, 2011|https://clinicaltrials.gov/show/NCT01113541||122991|This study was terminated due to slow enrollment and changes in organizational strategy and resources; most of the planned analyses in the statistical analysis plan were not performed.
NCT01114386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFPS-2006-8-334056|Clinical Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure (CHF)|Clinical, Functional and Biological Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure(CHF) in Stable Conditions and During Exacerbation||University of Modena and Reggio Emilia|No|Completed|October 2006|December 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Blood sampling for routine (haemachrome and differential cells blood count, bilirubin,      cholesterol, high density lipoprotein, low density lipoprotein, glycemia, blood urea, blood      electrolytes (sodium, potassium, chloride), glutamic-oxaloacetic transaminase,      glutamic-pyruvic transaminase, γGT, triglycerides, creatinine, uric acid, creatine      phosphokinase, glycosylated haemoglobin).      Blood sampling for selected biomarkers: NTBNP, HS-PCR and IL-6, IL1-β, cellular receptor D6      and TIR8, IL-1 decoy receptor PTX3.      Measurement of arterial blood gases.|Both|50 Years|95 Years|Accepts Healthy Volunteers|Probability Sample|100 patients older than 50 years with diagnosis of COPD and/or CHF, male or female,        smokers or ex-smokers with more than 10 pack-years, in stable conditions.|June 2012|June 6, 2012|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01114386||122926|
NCT01113528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHDA-1962|Omega-3 and Aspirin in Periodontal Regeneration|The Effect of Host Response Modulation Therapy (Omega 3 Plus Low-dose Aspirin) as an Adjunctive Treatment of Chronic Periodontitis (Clinical and Biochemical Study)|PR|October 6 University|Yes|Completed|November 2009|May 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 13, 2010|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01113528||122992|
NCT01113762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF20050133|Metal-metal Articulations Versus Standard 28 mm Cementless Total Hip Arthroplasty|Metal-metal Articulations vs Standard 28 mm Cementless Total Hip Arthroplasty in Younger Patients. Randomized Studies||University of Southern Denmark|No|Active, not recruiting|February 2007|November 2019|Anticipated|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|71|||Both|40 Years|65 Years|No|||December 2014|December 4, 2014|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113762||122974|
NCT01114984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019341|Post-Breast Procedure Pain Syndrome Study|A Prospective Cohort Study to Evaluate the Incidence and Characteristics of Post-Operative Pain Among Patients Undergoing Various Breast Surgeries||Cedars-Sinai Medical Center|No|Withdrawn|July 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||8|Actual|0|||Female|18 Years|80 Years|No|Non-Probability Sample|Patients undergo breast surgery. (breast biopsy, lumpectomy, simple mastectomy,mastectomy        with reconstruction, radical mastectomy, radical mastectomy with reconstruction, cosmetic        augmentation and breast reduction)|February 2015|February 26, 2015|April 23, 2010||No|Bad design.|No||https://clinicaltrials.gov/show/NCT01114984||122880|
NCT01114763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHMetS-01-AP|Hämeenlinna Metabolic Syndrome Research Program: Oxidized LDL and Arterial Elasticity in Metabolic Syndrome and Controls (HMS-01)|Hämeenlinna Metabolic Syndrome Research Program (HMS): Comparison of Men With Metabolic Syndrome and Their Physically Active Controls - Circulating Oxidized LDL and Arterial Elasticity|HMS-01|Central Hospital of Kanta-Hame|No|Completed|June 2003|September 2007|Actual|November 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80|Samples Without DNA|serum, EDTA plasma, citrate plasma|Male|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic.|April 2010|May 3, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01114763||122897|
NCT01116089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0908-PR-0029|Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer|PHARMACOKINETIC STUDY OF BRAMITOB® ADMINISTERED FOR INHALATION BY PARI eFLOW® RAPID ELECTRONIC NEBULIZER VS PARI LC® PLUS NEBULIZER COUPLED WITH THE PARI TURBO BOY® N COMPRESSOR IN CYSTIC FIBROSIS PATIENTS INFECTED WITH PSEUDOMONAS AERUGINOSA||Chiesi Farmaceutici S.p.A.|No|Completed|July 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01116089||122797|
NCT01115439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1002|Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria|Efficacy and Safety of Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Centers in Nangarhar, Kunar, Thakhar and Faryab Provinces of Afghanistan|ASPF|University of Oxford|No|Completed|March 2010|July 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|6 Months|N/A|No|Non-Probability Sample|Febrile children (above six months of age) and non-pregnant adults with confirmed        uncomplicated P. falciparum infection|July 2012|July 11, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01115439||122845|
NCT01115452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z3770633|Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity|A Proof of Principle Study Investigating the Effects of a Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|65 Years|No|||January 2015|January 22, 2015|April 30, 2010|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01115452||122844|
NCT01115712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-170|Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)|A Randomized Clinical Trial to Measure the Effect of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males||Merck Sharp & Dohme Corp.||Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|April 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115712||122824|
NCT01104597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-272|Study to Evaluate Subclinical Atherosclerosis (an Early Sign of Heart Disease) in Healthy Adult Immigrant Asian Indians|Assessment of Subclinical Atherosclerosis in Healthy Adult Immigrant Asian Indians Using Flow Mediated Endothelial Dysfunction Method||Northwell Health|No|Withdrawn|April 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|April 9, 2010|Yes|Yes|No subjects were enrolled into the study|No||https://clinicaltrials.gov/show/NCT01104597||123678|
NCT01105286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLQ-005|A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis|||LEO Pharma|No|Completed|April 2010|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105286||123625|
NCT01127672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59295|Treatment of Plantar Fasciitis With Platelet Rich Plasma|Platelet Rich Plasma Injection Compared to Corticosteroid Injection for Treatment of Plantar Fasciitis. A Prospective, Randomized Control Trial||Loma Linda University|No|Withdrawn|May 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|89 Years|No|||April 2014|April 15, 2014|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127672||121911|
NCT01123993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R006h/53|The Effect of Thai Traditional Music on Cognitive Function, Psychological Health and Quality of Sleep Among Thai Older Individuals With Dementia|The Effect of Thai Traditional Music on Cognitive Function, Psychological Health and Quality of Sleep Among Thai Older Individuals With Dementia.||Phramongkutklao College of Medicine and Hospital|Yes|Completed|February 2010|September 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|60 Years|N/A|No|||January 2011|January 3, 2011|May 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01123993||122193|
NCT01123447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB14-2004|Study Comparing Surgical Treatment Versus Non-surgical Treatment of Ulnar Fractures|A Prospective Randomized Trial Comparing Open Reduction and Internal Fixation With Non-operative Treatment for Ulnar Shaft Fractures||University of Calgary|No|Recruiting|May 2010|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01123447||122234|
NCT01108120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|q9jhrvf3-2|The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers|The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers||Wuhan General Hospital of Guangzhou Military Command|Yes|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||April 2010|July 4, 2013|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01108120||123408|
NCT01117077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10ZR1423900|The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis|||Shanghai Jiao Tong University School of Medicine||Enrolling by invitation|May 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|65 Years|No|Probability Sample|liver transplantation patients with aspergillus infection or without aspergillus infection|May 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117077||122721|
NCT01112956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-1127|Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2|Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2: Development of Testing Strategies||Centers for Disease Control and Prevention|No|Completed|July 2009|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2500|Samples Without DNA|Serum specimens|Both|16 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will comprise of diverse ethnic and racial populations derived from 3        Health and Human Services Regions and recruited from different type of clinics: 1) STD        clinics 2) Prenatal clinic 3) Health clinic for gay men|March 2011|March 22, 2011|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01112956||123036|
NCT01114087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070131|Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility|Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility|GLIFERTI|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|18 Years|60 Years|No|||January 2011|March 28, 2011|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114087||122949|
NCT01113294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFCT001|Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation|Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial||Wuhan University|Yes|Recruiting|January 2009|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2040|||Both|18 Years|75 Years|No|||January 2009|April 27, 2010|April 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01113294||123010|
NCT01113567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-785-016|Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy|Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy. Double- Blind, Randomized, Controlled Clinical Trial||Coordinación de Investigación en Salud, Mexico|No|Suspended|July 2010|July 2015|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||May 2015|July 28, 2015|April 28, 2010||No|We didn't find differences among both groups|No||https://clinicaltrials.gov/show/NCT01113567||122989|
NCT01114048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMM-97|Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)|Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) Who Are Eligible for Autologous Stem Cell Transplantation: Multicenter Phase 2 Study|KMM-97|Chonnam National University Hospital|Yes|Recruiting|March 2010|||March 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|65 Years|No|||September 2011|September 21, 2011|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01114048||122952|
NCT01113775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRU Unipg 02-06|Pulmonary Embolism: Multifunctional Assessment of Prognosis|Right Ventricular Dysfunction in Acute Pulmonary Embolism as Assessed by Spiral CT Scan: Comparison With Transthoracic Echocardiography and Evaluation of Prognostic Value|PE-MAP|University Of Perugia||Recruiting|January 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients with spiral CT scan positive for acute pulmonary embolism and with        transthoracic echocardiography ± 6 hours from spiral CT scan and baseline troponin levels        evaluation.|October 2009|May 14, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01113775||122973|
NCT01113788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-414|Tricuspid Isthmus Imaged by CARTOsound, Patients With Typical Atrial Flutter|Tricuspid Isthmus Architecture as Imaged by CARTOsound, Determines Ablation Times in Patients With Typical Atrial Flutter||Lawson Health Research Institute|No|Recruiting|March 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|patients with typical atrial flutter|April 2010|April 29, 2010|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01113788||122972|
NCT01114997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020608|Effect of Lidocaine and Esmolol to Improve the Quality of Recovery|Effect of Lidocaine and Esmolol Alone or in Combination to Improve the Quality of Recovery, Maintaining Hemodynamic Stability During Abdominal Surgery||Cedars-Sinai Medical Center|No|Terminated|April 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|32|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|April 23, 2010||No|The early report didn't show any benefit.|No||https://clinicaltrials.gov/show/NCT01114997||122879|
NCT01115738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13533|Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients|TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET||Eli Lilly and Company|No|Completed|May 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|282|||Both|18 Years|74 Years|No|||November 2012|November 15, 2012|April 23, 2010|Yes|Yes||No|September 25, 2012|https://clinicaltrials.gov/show/NCT01115738||122822|
NCT01115751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13127|A Study in Patients With Advanced or Metastatic Cancer|A Phase I Trial of Single-Agent LY2780301 in Patients With Advanced or Metastatic Cancer||Eli Lilly and Company|No|Completed|March 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01115751||122821|
NCT01115764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10023/2010kCTIL|LV Diastolic Dysfunction Among the Patients With Systolic Heart Failure-clinical Significance and Prognostic Importance.|LV Diastolic Dysfunction Among the Patients With Systolic Heart Failure|dd|Meir Medical Center|Yes|Not yet recruiting|May 2010|June 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Study population        This study will be performed on the base of Natania Heart Institute (out of hospital        clinic).        Within community-based population study we'll select the patients with LV systolic        dysfunction.        The participants will be classified according to their LV systolic function, functional        class (NYHA) of HF.        Approximately 200 subjects will be enrolled.|May 2010|May 2, 2010|May 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01115764||122820|
NCT01115777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P001629|Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies|Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-CNS Malignancies||Massachusetts General Hospital||Recruiting|September 2005|March 2029|Anticipated|June 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|2 Years|25 Years|No|Non-Probability Sample|Patients coming to MGH for radiation therapy with curative intent.|February 2016|February 25, 2016|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115777||122819|
NCT01115244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100273|Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis|Dapsone Gel, 5% for Topical Treatment of Dermatitis Herpetiformis||Vanderbilt University|Yes|Not yet recruiting|July 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5|||Both|12 Years|N/A|No|||April 2010|April 29, 2010|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01115244||122860|
NCT01115465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPQ092006|Study of Macroplastique Safety and Effectiveness in the Treatment of Female Stress Urinary Incontinence|Real-time Observation of Safety and Effectiveness in the Treatment of Female Stress Urinary Incontinence|ROSE|Uroplasty, Inc|No|Active, not recruiting|January 2008|||December 2021|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|275|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|April 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01115465||122843|
NCT01116635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02833|Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)|Phase I/II Study Examining Pharmacokinetics, Adverse Events, and Surgically Resected Histopathological Response Utilizing a Dose Escalation Model of Doxorubicin Loaded Drug Eluting Superabsorbent Polymer Microspheres in Surgically Resectable Hepatocellular Carcinoma in Humans||University of British Columbia|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 14, 2014|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116635||122755|
NCT01105559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L26|Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine|Antibody Persistence in Healthy South African Children After Primary Series and Booster Vaccination With an Investigational (DTaP-IPV-Hep B-PRP-T) or Control Vaccines||Sanofi|No|Completed|April 2010|December 2011|Actual|November 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|455|||Both|41 Months|43 Months|Accepts Healthy Volunteers|Non-Probability Sample|Participants aged 3 years and a half on the day of inclusion and must have received the        primary series of vaccinations and a booster vaccination in Study A3L15 (NCT 00362336). No        vaccination will be provided or administered in this study.|December 2011|December 12, 2011|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105559||123604|
NCT01105572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomonitoring099|Aetna_Intel Medicare Home Biomonitoring Study|Study of Impact of Home Biomonitoring With Nurse Case Manager Support for a Congestive Heart Failure Cohort, Compared to Case Manager Support Without Biomonitoring||Aetna, Inc.|No|Completed|November 2008|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|316|||Both|50 Years|N/A|No|||April 2010|April 15, 2010|April 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01105572||123603|
NCT01123460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000670992|Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride|Measurement of Potential Biomarkers Predicting Erlotinib Response||National Cancer Institute (NCI)||Not yet recruiting|April 2010|||April 2011|Anticipated|N/A|Observational|N/A|||Anticipated|127|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01123460||122233|
NCT01116557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWI130|Efficacy, Safety and Efficiency Study of CARTO® 3 System Guided THERMOCOOL® Catheter Ablation Versus Fluoroscopy Guided Ablation With the Pulmonary Vein Ablation Catheter® (PVAC®)|CARTO® 3 System-guided RF Ablation Using the THERMOCOOL® Catheter Versus Fluoroscopy-guided RF Ablation Using the Pulmonary Vein Ablation Catheter® (PVAC®) in Subjects With Paroxysmal Atrial Fibrillation: A Prospective, Multi-center, Randomized (2:1), Controlled, Two-arm, Unblinded Clinical Study|CLARITY-AF|Biosense Webster, Inc.|Yes|Terminated|April 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|May 3, 2010||No|Biosense stopped Study enrollment following publications that reported PVAC ablation is linked    with a higher incidence of asymptomatic cerebral embolic lesions|No||https://clinicaltrials.gov/show/NCT01116557||122761|
NCT01113268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081116|PREdisposition Genetical in Cardiac Insufficiency = Genetic Predisposition to Heart Failure|Role of Candidate Genes/Signalling Pathways in the Progression Towards Heart Failure: Study in a Cohort of Patients With a First Myocardial Infarction (PREGICA Patient Collection : Genetic Predisposition to Heart Failure)|PREGICA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2010|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|750|||Both|18 Years|80 Years|No|||October 2015|October 6, 2015|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113268||123012|
NCT01113281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPM1002-ZA-1.10TB|Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa|Phase Ib Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Volunteers in South Africa||Vakzine Projekt Management GmbH|No|Completed|April 2010|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 18, 2011|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01113281||123011|
NCT01117142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100097|A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers|A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers.||National Institutes of Health Clinical Center (CC)||Recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|105|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 23, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117142||122716|
NCT01117090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1656|Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery|Feasibility of Measuring Cerebrospinal Fluid (CSF) Signatures in Subjects With Intrathecal Catheter-Related Problems||MedtronicNeuro|No|Completed|June 2010|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Both|12 Years|N/A|No|Non-Probability Sample|Subjects with implanted Medtronic drug infusion system for chronic intrathecal        administration, and who report decreased therepeutic benefit or who present with visible        signs and/or symptoms of decreased therapeutic benefit, suggesting possible        catheter-related problems.|September 2013|September 12, 2013|May 3, 2010||No||No|September 12, 2013|https://clinicaltrials.gov/show/NCT01117090||122720|"Normal" subjects who received intrathecal baclofen without experiencing catheter complications were not enrolled.Subjects who received intrathecal drug delivery for chronic pain were not enrolled.This was not a longitudinal study.
NCT01112969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSCAR|OSCAR - An Internet-based Supportive Coaching for Informal Caregivers of Adult Individuals With an Acquired Brain Injury|OSCAR - An Internet-based Supportive Coaching for Informal Caregivers of Adult Individuals With an Acquired Brain Injury.||University of Bern|No|Terminated|January 2010|March 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|April 5, 2010||No|Project end after 3 years; prolongation was rejected|No||https://clinicaltrials.gov/show/NCT01112969||123035|
NCT01113827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-01-OLIV|Effects of Water-soluble Olive Extract Supplementation|Effects of Water-soluble Olive Extract on Antioxidant Status, Exercise Performance, Muscle Metabolism, Muscle Damage and Inflammation||University of Texas at Austin|Yes|Completed|February 2010|February 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|61|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||February 2012|March 23, 2012|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113827||122969|
NCT01114061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT4813|Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the InsuPatch Device During Daily Life|Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the InsuPatch Device During Daily Life||Insuline Medical Ltd.|No|Suspended||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|65 Years|No|||June 2011|September 12, 2012|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114061||122951|
NCT01113307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-103|The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds|A Multi-Center Post- Marketing Study to Define Procedures for the Use of CureXcellTM in a Community Setting for the Treatment of Wounds||Macrocure Ltd.|No|Completed|May 2010|September 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|18 Years|90 Years|No|Non-Probability Sample|Adults with chronic ulcers; pressure ulcers, venous ulcers, diabetic foot ulcers or post        operative ulcers.|January 2013|January 30, 2013|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113307||123009|
NCT01114412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-4-045.8|Basic Sensations Coming From the Bladder|Description of Basic Visceral Sensations Coming From the Bladder||Maastricht University Medical Center|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers        Patients with overactive bladder|April 2010|April 30, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114412||122924|
NCT01114737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-016|Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients|A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Subjects With Phenylketonuria||BioMarin Pharmaceutical|Yes|Completed|August 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|8 Years|65 Years|No|||December 2015|December 24, 2015|April 27, 2010|Yes|Yes||No|August 19, 2015|https://clinicaltrials.gov/show/NCT01114737||122899|As specified in the SAP, no multiplicity adjustment was made in the analyses; therefore, the family-wise error rate was not controlled in this study
NCT01114750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA3-2010-019098-14|A Study to Determine the Absorption of Peroral Insulin in Dextran Matrix (ORA3)|A Placebo-controlled Study of Insulin Absorption in Healthy Volunteers After Single-dose Oral Administration of Insulin in Dextran Matrix|ORA3|Bows Pharmaceuticals AG|Yes|Suspended|April 2010|October 2010|Anticipated|August 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|8|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|October 3, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114750||122898|
NCT01114373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021300a|Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study|Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study||Emory University|Yes|Completed|June 2010|September 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|April 29, 2010|Yes|Yes||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01114373||122927|
NCT01114399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009IFR01|Diet and Vascular Health Study|Diet and Vascular Health Study|BROCCOLI|Institute of Food Research|No|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|48|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 28, 2014|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01114399||122925|
NCT01115504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THF|Thiamine Supplementation in Heart Failure Patients Receiving Full Medical Therapy|Thiamine Supplementation in Heart Failure Patients Receiving Full Medical Therapy||Mashhad University of Medical Sciences|Yes|Completed|May 2010|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||November 2010|December 22, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01115504||122840|
NCT01108237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08003|Alignment Comparison Between TruMatch™ Personalized Solutions and Conventional Total Knee Replacement Instrumentation|Comparison of In Vivo Alignment With TruMatch™ Personalized Solutions Compared to Conventional Instrumentation in Total Knee Replacement (TKR)||DePuy Orthopaedics|No|Completed|October 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|80 Years|No|||December 2013|December 18, 2013|April 1, 2010|Yes|Yes||No|March 27, 2012|https://clinicaltrials.gov/show/NCT01108237||123399|
NCT01116375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control?|Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control? A Multi-Centered Prospective Cohort Study|IMPACT Obesity|Katz, Sherri Lynne, M.D.|No|Recruiting|June 2010|September 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|54|||Both|8 Years|16 Years|No|Non-Probability Sample|Obese children (body mass index (BMI) ≥ 95th %ile for age and sex) 8-17 years old with        moderate-severe OSA will be recruited for this study from four pediatric tertiary care        centres across Canada. As per current standard of care, those children with        moderate-severe OSA, defined as ≥ 10 obstructive events per hour on polysomnography, will        be prescribed PAP treatment.|June 2011|June 15, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01116375||122775|
NCT01116648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02938|Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer|Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|March 2010|||January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Female|18 Years|N/A|No|||February 2016|February 17, 2016|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01116648||122754|
NCT01116388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-002385|A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders|A Study to Assess the Role of a Gluten Free-Casein Free Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders|GFCF|Massachusetts General Hospital|No|Completed|April 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|2 Years|17 Years|No|||April 2015|April 7, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01116388||122774|
NCT01105585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-09-003|A Comparative Pilot Study Of High-Order Aberrations With Aspheric IOL Models SN60WF and ZCB00|A Comparative Pilot Study Of High-Order Aberrations With Aspheric Intraocular Lens (IOL) Models SN60WF And ZCB00||Alcon Research|No|Completed|April 2010|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|N/A|No|||November 2012|November 27, 2012|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105585||123602|
NCT01127958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL3148701810|DARE-trial: A Trial Studying the Effect of the SeQuent Please Drug-eluting Balloon Compared to the Xience Prime Drug-eluting Stent for the Treatment of Stenosis of an Earlier Implanted Stent.|DARE-Trial: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomized Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the Xience Prime Drug-eluting Stent for the Treatment of In-stent Restenosis.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|May 2010|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01127958||121889|
NCT01127971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-04-147E|Patient Registry: Partial Breast Irradiation|Patient Registry: A Study of the Use of Accelerated Partial Breast Irradiation to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities|PBI Registry|Aurora Health Care|No|Terminated|February 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|145|None Retained|No biospecimens collected|Both|19 Years|N/A|No|Non-Probability Sample|Aurora Health Care system patients receiving accelerated partial breast irradiation|October 2014|October 22, 2014|May 20, 2010||No|administrative reasons (no impact/concern of subject rights, welfare, safety)|No||https://clinicaltrials.gov/show/NCT01127971||121888|
NCT01128257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22927|A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis|Controllability and Real Life Efficacy of Bonviva 3 mg iv Quarterly vs. Oral Alendronate Generics||Hoffmann-La Roche||Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|6054|||Female|55 Years|N/A|No|Probability Sample|Female post-menopausal patients over the age of 55 years|March 2016|March 1, 2016|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01128257||121867|
NCT01124019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17109|Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography|SNP Panels and Risk Assessment in Women Undergoing Mammography||Abramson Cancer Center of the University of Pennsylvania|No|Completed|February 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1600|||Female|40 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Adult women will be recruited for this study. Women undergoing screening mammography will        be chosen if they are between the ages of 40 and 65. Women will be excluded if they have a        personal history of breast or ovarian cancer, DCIS, or mantle radiation, or known BRCA 1/2        mutation in self or in family members.|October 2014|October 10, 2014|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124019||122191|
NCT01116570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001035|Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients|Exercise and Myopathies. Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients: Functional, Tissue and Quality of Life Benefits.|FSHD1|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01116570||122760|
NCT01117168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100111|Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group|Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group||National Institutes of Health Clinical Center (CC)||Recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|N/A|18 Years|No|||September 2015|March 1, 2016|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117168||122714|
NCT01113008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0327/2008|Remote Ischemic Postconditioning in Humans|Remote Ischemic Postconditioning. Can it Prevent Myocardial Injury During Percutaneous Coronary Intervention?||Hospital Universitario Virgen de la Victoria|Yes|Completed|February 2009|May 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|266|||Both|18 Years|N/A|No|||January 2015|January 11, 2015|April 26, 2010||No||No|January 11, 2015|https://clinicaltrials.gov/show/NCT01113008||123032|
NCT01113554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99309|Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors|A Pilot Study to Evaluate the Feasibility of a Breast Cancer Rehabilitation Program in Survivors of Breast Cancer||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|June 2010|October 2016|Anticipated|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01113554||122990|
NCT01114074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3-015|Thrombus Formation Under Different Flow-conditions|The Influence of the Proteins of the Contact Activation System on Thrombus Formation Under Different Flow-conditions in Blood||Maastricht University Medical Center|No|Recruiting|May 2011|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||5|Anticipated|46|Samples Without DNA|-  Whole blood        -  Platelet poor plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients:        Patients with a congenital factor XII-deficiency Patients with a congenital factor        XI-deficiency Patients with a congenital prekallikrein-deficiency Patients with a        congenital high molecular weight kininogen-deficiency        Controls:        Healthy individuals without any coagulation defects|March 2016|March 15, 2016|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01114074||122950|
NCT01114113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010IBS-G/D eval|Assessment of Gastric Emptying Speed in Patients Who Experience Diarrhea Following a Trigger Meal|Pilot Study: Assessment of Gastric and Intestinal Motility Following a Trigger Meal in Patients With Post Prandial Diarrhea||Money, Mary E., M.D.|No|Withdrawn|April 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|April 25, 2010||No|Lack of interest in participation by patients locally and lack of funding.|No||https://clinicaltrials.gov/show/NCT01114113||122947|
NCT01106911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09060334|Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment|Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment: a Prospective Study||University of Pittsburgh|No|Completed|May 2010|||September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1080|||Female|35 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|April 16, 2010||No||No|January 25, 2016|https://clinicaltrials.gov/show/NCT01106911||123500|
NCT01106924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08.22 NRC|Effects of a Probiotic on Body Weight|Effects of Consumption of a Probiotic Formulation on Weight Control in Obese Subjects||Laval University|No|Completed|January 2010|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|May 25, 2012|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01106924||123499|
NCT01113840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P.A.R.I.S. I and II|Prospective Aerobic Reconditioning Intervention Study|Exercise Conditioning in Elderly Patients With Heart Failure|PARIS|Wake Forest School of Medicine|Yes|Completed|July 1993|December 2009|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|60 Years|N/A|No|||January 2014|January 29, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01113840||122968|
NCT01114100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC99-128|The Effects of Treatment With Sertraline for Noncardiac Chest Pain|The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study||Maastricht University Medical Center|No|Completed|January 2000|December 2002|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|N/A|No|||May 2010|May 17, 2010|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01114100||122948|
NCT01115478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD57941-01A2|Malaria in Pregnancy: Nutrition and Immunologic Effects|Malaria in Pregnancy: Nutrition and Immunologic Effects|MAL2|Harvard School of Public Health|Yes|Completed|July 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115478||122842|
NCT01107977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K01AT005093|Iyengar Yoga for Young People With Irritable Bowel Syndrome|Iyengar Yoga for Young People With Irritable Bowel Syndrome||University of California, Los Angeles|Yes|Recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|14 Years|26 Years|No|||April 2010|April 20, 2010|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01107977||123419|
NCT01104337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INPAWA2-URT|Drug Interaction Between Paracetamol and Warfarin|Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial|INPAWA2|Hopital Lariboisière|No|Completed|March 2007|February 2010|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|3||Actual|45|||Both|18 Years|N/A|No|||February 2010|April 13, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104337||123698|
NCT01116102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1838-009|Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)|The INcreased Flow Utilizing Subcutaneously-Enabled Fluids Administration Technique 1A Study (INFUSE-AT 1A): A Randomized, Parallel Group Study to Evaluate the In-line Pressure, Flow Rate, Safety and Tolerability of Hylenex-facilitated Subcutaneous Fluid Administration In Healthy Volunteers Using Various Subcutaneous Infusion Techniques|INFUSE-AT1A|Baxter Healthcare Corporation|No|Terminated|May 2010|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|April 30, 2010|No|Yes|Strategic business decision (not related to safety or efficacy concerns)|No|September 12, 2011|https://clinicaltrials.gov/show/NCT01116102||122796|Due to small numbers of subjects in each treatment arm, no conclusions can be drawn on the influence of any of the individual potential pressure-affecting factors or the combinations of these factors on in-line fluid pressure.
NCT01104324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/20E|Osteonecrosis in Children With Acute Lymphoblastic Leukemia|Steroid Induced Osteoporosis in the Pediatric Population Ancillary Study- Osteonecrosis in Children With Acute Lymphoblastic Leukemia||Halton, Jacqueline, M.D.|No|Recruiting|July 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|Platlet free plasma|Both|5 Years|18 Years|No|Probability Sample|Patients with Acute lymphoblastic leukemia who have participated in the STOPP - CIS study        will be eligible for this ancillary study.|April 2010|April 14, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104324||123699|
NCT01104948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-8031|A Study to Characterize the Pharmacokinetics of DA-8031 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of DA-8031 After Oral Administration in Healthy Male Subjects||Dong-A ST Co., Ltd.||Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104948||123651|
NCT01128270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#107-10|Pharmacotoxicology of Trichloroethylene Metabolites|Pharmacotoxicology of Trichloroethylene Metabolites Aim 3||University of Florida|No|Completed|April 2010|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|27|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|May 20, 2010|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01128270||121866|Subjects were asked to wait 30 days in between doses of medication. Some of the participants could not wait the entire 4 months to finish the study and thus dropped out before they completed the 4 arms. Ten were enrolled, screened, but did not start
NCT01128283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09681|Indicators of Inflammation and Coagulation in Sepsis|Temporal Behavior of Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis||University of Oklahoma|No|Completed|January 2002|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|500|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|ICU patients|September 2014|September 11, 2014|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128283||121865|
NCT01128205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMR-302-3B|Nationwide Assessment of Cardiovascular Risk Factors: in Chinese Patients With Type 2 Diabetes|Nationwide Assessment of Cardiovascular Risk Factors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients With Type 2 Diabetes, A Study of China Cardiometabolic Registries (CCMR)|3B|China Cardiometabolic Registries|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|25000|||Both|18 Years|N/A|No|Non-Probability Sample|Chinese type 2 diabetic out-patients with diagnosis for 6 months or more|August 2010|June 14, 2011|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01128205||121870|
NCT01116856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRONAF|Nutrition and Physical Activity for Obesity|Nutrition and Physical Activity Programs for Obesity Treatment (PRONAF)|PRONAF|Universidad Politecnica de Madrid|No|Recruiting|January 2009|December 2011|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 29, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01116856||122738|
NCT01117116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK LABA|Sub-Sensitivity to Long-Acting Bronchodilators (LABA)|Sub-Sensitivity to Long-Acting Bronchodilators (LABA)||National Jewish Health|No|Completed|March 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117116||122718|
NCT01117129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21826|A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)|Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study)||Hoffmann-La Roche||Terminated|April 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||March 2014|March 27, 2014|May 4, 2010||No|This study was prematurely terminated as 2 patients were recruited and both of them withdrawn    from the study before reaching the primary end point.|No||https://clinicaltrials.gov/show/NCT01117129||122717|
NCT01113333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU10820|Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis|A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis||Sanofi|No|Completed|April 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||March 2011|March 22, 2011|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01113333||123007|
NCT01113021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0072.0.135.000-08|Study of Effects of Low Level Laser Therapy in the Physical Training and the Muscle Responses in Humans.|Phase 1. Muscle Genic Expression Under Strength Training and Photostimulated by Laser.||Universidade Federal de Sao Carlos||Completed||||||Phase 1|Interventional|N/A|1||||||Male|18 Years|28 Years|Accepts Healthy Volunteers|||August 2008|April 28, 2010|April 28, 2010||||No||https://clinicaltrials.gov/show/NCT01113021||123031|
NCT01113320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR701165_023|Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects|A Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesias|Safinamide-LID|Newron|No|Completed|April 2010|January 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|26|||Both|30 Years|N/A|No|||January 2012|March 28, 2013|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01113320||123008|
NCT01113580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-ASU-10-66|A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population|A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)||CSL Limited|No|Completed|May 2010|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|April 26, 2010|Yes|Yes||No|June 13, 2012|https://clinicaltrials.gov/show/NCT01113580||122988|
NCT01114425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382426005_1|Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection|Etude Observationnelle Multicentrique Relative à la tolérance de ISENTRESS® + TRUVADA® Prescrite en Prophylaxie Post-exposition de Personnes récemment Soumises au Risque de Transmission d'Une Infection Par le VIH||Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux|No|Not yet recruiting|September 2010|May 2012|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 30, 2010|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01114425||122923|
NCT01114438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1|Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner|Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner||GI Dynamics|No|Completed|October 2010|July 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|65 Years|No|||March 2014|March 28, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01114438||122922|
NCT01107184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 28041.018.09|Remote Ischemic Conditioning and Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)|A Clinical Study on the Effect of Remote Ischemic Conditioning on Atrial Fibrillation and Outcome After Coronary Artery Bypass Grafting|RICO|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Terminated|January 2010|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|191|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|April 19, 2010||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT01107184||123479|
NCT01107431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharmachem 40-47|Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin|A Combination of L-Arabinose and Chromium Lowers Circulating Glucose and Insulin Levels After Acute Oral Sucrose Challenge|L-Arabinose|Integrative Health Technologies, Inc.|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 11, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107431||123460|
NCT01115036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020612|A Panobinostat Presurgery|Phase II Study of Panobinostat (LBH589) for Recurrent Glioblastoma (GBM) Undergoing Planned Surgical Resection|CLBH589C|Duke University|No|Withdrawn|April 2010|April 2012|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2011|June 17, 2013|April 30, 2010|Yes|Yes|No subjects were enrolled on this study, so study was closed and IND withdrawn.|No||https://clinicaltrials.gov/show/NCT01115036||122876|
NCT01115257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0016258|Severe Proliferative Diabetic Retinopathy|Severe Proliferative Diabetic Retinopathy Treated With Vitrectomy or Panretinal Photocoagulation: a Prospective Comparative Study||Universita degli Studi di Catania|No|Completed|October 2001|||October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|180|||Both|21 Years|80 Years|No|||October 2006|May 3, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01115257||122859|
NCT01115270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NS054881-04|A Study Comparing Shunt Placement Versus Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus|A Study Comparing Shunt Placement Versus Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus||University of California, Los Angeles|Yes|Recruiting|February 2007|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|40 Years|N/A|No|Non-Probability Sample|Hospitalized NPH and non-NPH patients|April 2010|May 3, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01115270||122858|
NCT01115491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25152|A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme|A Single Arm Phase II Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme||Hoffmann-La Roche||Completed|June 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|April 30, 2010|No|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT01115491||122841|
NCT01104051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBSI001|Radiofrequency Nerve Ablation Versus Sham to Treat Chronic Low Back Pain Caused by Sacroiliac Joint Dysfunction|A Prospective, Single Center, Double Blind, Randomized, Sham Controlled, Crossover Study to Evaluate the Clinical Efficacy of Radiofrequency Nerve Ablation Using Simplicity III Versus Sham for the Treatment of Chronic Low Back Pain Associated With Sacroiliac Joint Dysfunction||Coastal Orthopedics & Sports Medicine|No|Completed|April 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|28|||Both|18 Years|N/A|No|Probability Sample|Patients presenting with low back pain associated with SIJD for longer than 6 months, and        who have not had positive responsive to the conservative treatments:          -  Pharmacologic Management          -  Therapies; physical, acupuncture, massage etc…          -  Other alternative treatments|July 2015|July 27, 2015|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104051||123720|
NCT01104623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AiF KF2247401-AK9-1|ADHD - Voice Analysis, Vocal Acoustic Biomarkers in Attention Deficit Hyperactivity Disorder|Phase 1 Study of Vocal Acoustic Biomarkers in Attention Deficit Hyperactivity Disorder (ADHD)|ADHD|Charite University, Berlin, Germany|Yes|Recruiting|April 2010|December 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|German speaking: Adults, age 18-50 years.|February 2012|February 7, 2012|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104623||123676|
NCT01105871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35974-D|Subjective Analgesic Effects of Naloxone and Virtual Reality|Subjective Analgesic Effects of Naloxone and Virtual Reality|Narcan|University of Washington|Yes|Active, not recruiting|August 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 17, 2012|March 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01105871||123580|
NCT01104038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMBCHB007|EXCEL: Change in Cardiometabolic Disease Risk Factors During an Interactive Fitness Program|EXCEL: Change in Cardiometabolic Disease Risk Factors During an Interactive Fitness Program|EXCEL|University of Massachusetts, Boston|Yes|Completed|April 2010|July 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|8 Years|12 Years|No|||May 2014|May 22, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104038||123721|
NCT01105273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCPHO-SCT0802|Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia|HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia After Conditioning of Fludarabine, Cyclophosphamide and Antithymocyte Globulin||Asan Medical Center||Completed|July 2009|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|21 Years|No|||December 2012|December 30, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01105273||123626|
NCT01106378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC09-02|Cynergy: the CYPHER-NEVO Registry|Cynergy - The CYPHER-NEVO Registry. An Observational Registry, to Evaluate the Safety and Performance of the NEVO™ Sirolimus-eluting Coronary Stent in Routine Clinical Practice, and to Compare Its Safety and Performance With the CYPHER Select® Plus Sirolimus-eluting Coronary Stent (SES)|CYNERGY|Cordis Corporation|No|Terminated|April 2010|December 2011|Anticipated|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|14000|||Both|N/A|N/A|No|Non-Probability Sample|Subjects treated in routine clinical practice with a NEVO™ Sirolimus-eluting Coronary        Stent,once commercially available, OR a CYPHER Select® Plus Sirolimus-eluting Coronary        Stent and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus        and/or multi vessel disease.|July 2011|July 11, 2011|April 16, 2010||No|Early termination of patient enrollment based on business decision|No||https://clinicaltrials.gov/show/NCT01106378||123541|
NCT01106391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EE09-01|A MULTICENTER, OPEN LABEL, PROSPECTIVE, NON-RANDOMIZED STUDY OF INCRAFT™ IN SUBJECTS WITH ABDOMINAL AORTIC ANEURYSMS (INNOVATION)|A Multicenter, Open Label, Prospective, Non-Randomized Study Of INCRAFT™ In Subjects With Abdominal Aortic Aneurysms|INNOVATION|Cordis Corporation|Yes|Active, not recruiting|March 2010|June 2016|Anticipated|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|April 16, 2010||No||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01106391||123540|
NCT01106703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A060655|The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels|The Effects of PG102 on Allergy-related Risk Factors: A Randomized, Double Blind, Placebo Controlled Study||Seoul National University Hospital|Yes|Completed|December 2006|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 23, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01106703||123516|
NCT01128296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 09-122|Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas|Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas||University of Pittsburgh|Yes|Active, not recruiting|October 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|19 Years|N/A|No|||January 2015|January 13, 2015|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128296||121864|
NCT01128218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COZ-SIU 10-002-1|A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors|A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain||Southern Illinois University|Yes|Recruiting|March 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|May 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128218||121869|
NCT01116622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0228|Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract|A Phase I Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract||Dartmouth-Hitchcock Medical Center|Yes|Completed|April 2003|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|April 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01116622||122756|
NCT01117155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100105|A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas|A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas||National Institutes of Health Clinical Center (CC)||Withdrawn|April 2010|October 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|1 Year|17 Years|No|||November 2012|November 20, 2012|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117155||122715|
NCT01105533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8051001|A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors|Phase I, Open-Label, Multi-Center, Accelerated Dose Escalation Study Of The Anti-Angiogenesis Agent PF-00337210 In Patients With Advanced Solid Tumors||Pfizer|No|Completed|May 2006|September 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|46|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|April 14, 2010|No|Yes||No|December 20, 2012|https://clinicaltrials.gov/show/NCT01105533||123606|Designation of outcomes as primary and secondary was based on study team input as study did not specify primary or secondary outcome measures.
NCT01113606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSEF001-06|A Trial of Skin Care Protocols for Facial Resurfacing|A Double-Blind, Randomized, Controlled Trial to Assess the Effects of the Obagi Nu-Derm System on Re-Epithelialization After Chemical Peel or Ablative Laser Resurfacing.|SPAR|Plastic Surgery Educational Foundation||Completed||||||Phase 4|Interventional|N/A|2||||||Female|18 Years|65 Years||||April 2010|April 29, 2010|April 28, 2010||||No||https://clinicaltrials.gov/show/NCT01113606||122986|
NCT01113866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-1997-2002_A0013-29943|Biomarkers for Prognosis of Ambulatory Chronic Heart Failure Patients|Circulating Biomarkers as Prognostic Indicators of Death in Ambulatory Heart Failure Patients||University of Parma|No|Completed|October 1998|January 2009|Actual|May 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|124|Samples Without DNA|serum|Both|N/A|N/A|No|Non-Probability Sample|heart failure patients with preserved or impaired systolic function|January 2009|May 3, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01113866||122966|
NCT01112982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000136|An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.|Shifting the Paradigm of Gout: An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.||University of South Florida|No|Completed|May 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|76|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112982||123034|
NCT01112995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0023|A Pilot Trial to Determine the Efficacy of Lactobacillus Rhamnosus for Reducing Colonization by Methicillin-resistant Staphylococcus Aureus (MRSA) (PROSE)|A Pilot Randomized Trial to Determine the Efficacy of a Probiotic, Lactobacillus Rhamnosus for Reducing Colonization by Methicillin-resistant Staphylococcus Aureus (MRSA)|PROSE|University of Wisconsin, Madison|Yes|Completed|January 2010|March 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|49|||Both|18 Years|N/A|No|||April 2011|October 1, 2015|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112995||123033|
NCT01106352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15469|A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)|A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer||Bayer|No|Completed|July 2010|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Male|18 Years|N/A|No|||July 2015|July 3, 2015|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106352||123543|
NCT01106599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP4834g|A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors|An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0623 Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Completed|April 2010|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01106599||123524|
NCT01106612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-07-07-197-a26|Study Comparing CT Scan and Stress Test in Patients With Known Coronary Artery Disease Hospitalized for Chest Pain|A Randomized Controlled Trial Comparing Coronary CT Angiography and Radionuclide Stress Myocardial Perfusion Imaging in Symptomatic Inpatients With Known Coronary Artery Disease|PROSPECT-CAD|Montefiore Medical Center|Yes|Terminated|April 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|7|||Both|21 Years|N/A|No|||April 2015|April 7, 2015|April 12, 2010||No|low recruitment|No||https://clinicaltrials.gov/show/NCT01106612||123523|
NCT01107730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268/27-07-09|Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures|Randomized Double Blind Study of Administration of Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures||Attikon Hospital|No|Completed|April 2010|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|33|||Both|15 Years|90 Years|No|||September 2015|September 28, 2015|April 20, 2010||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01107730||123438|
NCT01114776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-068|Multi-Center Study of Iron Overload: Pilot Study|Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias|MCSIO|Children's Hospital & Research Center Oakland|No|Active, not recruiting|November 2009|September 2013|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|20|Samples With DNA|whole blood, serum, plasma, and urine|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There is no gender predisposition for sickle cell disease, thalassemia major, or        Diamond-Blackfan anemia. Sickle cell anemia most frequently affects people of African        descent, thalassemia affects people of Mediterranian, northern African, Southeast Asia and        Indian descent. Diamond-Blackfan anemia occurs across all racial and ethnic groups.|July 2013|July 29, 2013|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01114776||122896|
NCT01115049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEDII_RS_1|Hexetidine and Chlorobutanol for Lesions Due to Prostheses|Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial||Federico II University|Yes|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|44|||Both|37 Years|79 Years|Accepts Healthy Volunteers|||April 2010|April 30, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01115049||122875|
NCT01109654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200088-500|An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)|A Prospective, Observational Study on the Use of Cetrotide (GnRH Antagonist) With GONAL-f in Assisted Reproductive Technologies (ART)||Merck KGaA|No|Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2175|Samples Without DNA|Plasma, Serum, Tissue, Urine|Female|N/A|N/A|No|Non-Probability Sample|Female subjects undergoing controlled ovarian stimulation.|January 2012|July 15, 2014|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01109654||123290|
NCT01109667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPK-235|Differences in Coagulation Test Kits|The Effects of Different Reagents on Coagulation Tests: Innovin Versus Thromborel-S.||Yuksek Ihtisas Hospital|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|350|||Both|N/A|N/A|No|Probability Sample|Patients receiving and not receiving oral anticoagulant therapy|January 2010|April 22, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109667||123289|
NCT01109953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-054|Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images|Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images||Memorial Sloan Kettering Cancer Center||Terminated|April 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for whole body FDG PET/CT examination as part of their routine clinical        care.|March 2012|March 15, 2012|April 20, 2010||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01109953||123267|
NCT01110226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040420|Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies|Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies|0805 GCC|University of Maryland|Yes|Recruiting|May 2010|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|December 14, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110226||123246|
NCT01110213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS - 14544|Goal Setting and Lifestyle|Goal Setting and Decisional Balance Applied to Physical Activity and Fruit & Vegetable Consumption|GSDB|University of Hawaii|Yes|Completed|August 2006|August 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||April 2010|April 22, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01110213||123247|
NCT01111188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903010300|Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma|Phase I Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma||Weill Medical College of Cornell University|Yes|Recruiting|June 2010|November 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111188||123172|
NCT01111201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-045|International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients|Pilot Survey to Assess International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients at Memorial Sloan-Kettering Cancer Center||Memorial Sloan Kettering Cancer Center||Completed|April 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|The goal accrual is 50 patients from each of the following oncology services:        Breast, Lymphoma, Autologous Stem Cell Transplant, and Allogeneic Stem Cell Transplant.|May 2012|May 30, 2012|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01111201||123171|
NCT01110850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-054|Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water|Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia Using Deuterated Water (GAC 0004)||Northwell Health|No|Active, not recruiting|June 2001|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood Cells, Bone MArrow|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Chronic Lymphocytic Leukemia|April 2015|April 13, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01110850||123198|
NCT01111539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-08-255|Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|ACES 255|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Terminated|July 2010|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|65 Years|No|||August 2012|August 24, 2012|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111539||123145|
NCT01111786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007486|Finger Hardness Measure in Scleroderma|Durometer Skin Assessment in Scleroderma: a Study to Validate This New Tool in the Digital Tufts||Mayo Clinic|No|Completed|April 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Scleroderma and controls without tight skin attending our rheumatology clinic for a        regularly schedualled visit|June 2014|June 24, 2014|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01111786||123126|
NCT01111799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004608K|Does Local Injury of the Endometrium Improve Controlled Ovarian Hyperstimulation (COH) + Intrauterine Insemination (IUI) Outcome?|Exploration of the Possibility That Local Injury of the Endometrium Has the Same Beneficial Effect on IUI Outcome as Demonstrated in IVF Treatment||Meir Medical Center|No|Recruiting|June 2010|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|600|||Female|18 Years|38 Years|No|||March 2012|March 15, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01111799||123125|
NCT01112098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X070502003|Improving Quality of Osteoporosis Care Through Patient Storytelling|Randomized Trial of a Mailed Intervention and Self-Scheduling to Improve Osteoporosis Screening in Postmenopausal Women||University of Alabama at Birmingham|No|Completed|July 2008|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|2997|||Female|65 Years|N/A|No|||May 2011|May 6, 2011|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112098||123102|
NCT01101529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr: 2009-010545-31|Treatment of Chemotherapy-induced Nausea and Vomiting|A Randomized Controlled Study to Compare (EMEND®)to Standard Treatment as Prevention for Delayed Chemotherapy-induced Nausea and Vomiting (CINV) After Myeloablative Therapy for Patients Undergoing Autologous Stem Cell Transplantation.||Uppsala University Hospital|No|Completed|May 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|April 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101529||123914|
NCT01107899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11983|Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes|Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary Syndromes||Eli Lilly and Company|No|Terminated|October 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|79 Years|No|||March 2012|March 7, 2012|April 19, 2010|No|Yes|Terminated due to Enrollment futility|No|December 1, 2011|https://clinicaltrials.gov/show/NCT01107899||123425|Trial was terminated early due to enrollment futility which resulted in limited data and the inability to analyze some outcome measures.
NCT01107912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12835|Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease|A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease|GENERATIONS|Eli Lilly and Company|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|155|||Both|45 Years|N/A|No|||September 2012|September 27, 2012|April 19, 2010|No|Yes||No|September 27, 2012|https://clinicaltrials.gov/show/NCT01107912||123424|
NCT01107925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12921|Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease|A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease|FEATHER|Eli Lilly and Company|No|Completed|March 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|74 Years|No|||July 2012|July 27, 2012|April 19, 2010|No|Yes||No|July 27, 2012|https://clinicaltrials.gov/show/NCT01107925||123423|
NCT01108185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-060|Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection|Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis or Mild Community-acquired Bronchopneumonia in Common Clinical Practice in the Slovak Republic||Abbott|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3181|||Both|18 Years|N/A|No|Non-Probability Sample|Patients included in this PMOS will be those with acute tracheitis, acute        tracheobronchitis, acute bronchitis, mild CAP and acute exacerbation of chronic bronchitis        with infectious etiology caused probably by an atypical agent.|September 2011|September 9, 2011|April 20, 2010||No||No|July 26, 2011|https://clinicaltrials.gov/show/NCT01108185||123403|
NCT01105195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00008875|Efficacy of Surgical Preparations in Lumbar Spine Surgery|Efficacy of Surgical Preparations in Lumbar Spine Surgery||Northwestern University|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2010|November 16, 2010|April 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01105195||123632|
NCT01105208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15188|Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension|Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef From Bayer (Cephalexin Suspension 250 mg/5 mL and Equivalent Concentration of Keflex Pediatrico From Eli Lilly (Cephalexin Suspension 125 mg/5mL) in Healthy Subjects Under Fasting Conditions||Bayer|No|Completed|March 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01105208||123631|
NCT01104545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_525|A Single Dose Study of MK3614|A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK3614||Merck Sharp & Dohme Corp.|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 13, 2010|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104545||123682|
NCT01104857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diam1|Respiratory Muscle Dysfunction in Critically Ill Patients|||University Medical Center Nijmegen|No|Active, not recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|90 Years|No|||June 2015|June 9, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104857||123658|
NCT01104870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-202|A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension|A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension||United Therapeutics|No|Completed|April 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|75 Years|No|||November 2015|November 24, 2015|January 4, 2010|Yes|Yes||No|November 24, 2015|https://clinicaltrials.gov/show/NCT01104870||123657|
NCT01105793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP1198-002|An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia|||FemmePharma Global Healthcare, Inc.|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 25, 2011|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105793||123586|
NCT01109914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICH P10.011|Mucosal Response in Immunocompromised Host|Immune Response After Inactivated Oral Cholera Vaccine (Dukoral) in Renal Transplant Recipients|MICH|Leiden University Medical Center|No|Completed|April 2010|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01109914||123270|
NCT01109927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LundUH-LADA101|Early Insulin Treatment in Patients With Latent Autoimmune Diabetes|Early Insulin Treatment in Patients With Latent Autoimmune Diabetes (LADA)||Lund University Hospital|No|Completed|February 1995|May 2005|Actual|April 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|90 Years|No|||February 1995|April 22, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01109927||123269|
NCT01106027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005627DD|Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant|A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Acute Humoral Rejection (AHR) in Positive Crossmatch Deceased Donor Kidney Transplantation (+XMatch DDKTx)||Mayo Clinic|No|Active, not recruiting|March 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106027||123568|
NCT01106040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO3-09|Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes|A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping||Navidea Biopharmaceuticals|No|Completed|June 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|163|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|April 14, 2010|Yes|Yes||No|April 13, 2013|https://clinicaltrials.gov/show/NCT01106040||123567|
NCT01106053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEDA-Pramipexole|Pramipexole for Binge Eating Disorder|An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder||Neuropsychiatric Research Institute, Fargo, North Dakota|No|Withdrawn|April 2010|||July 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|50 Years|No|||May 2013|May 3, 2013|April 15, 2010|Yes|Yes|No participants were recruited and study has been closed.|No||https://clinicaltrials.gov/show/NCT01106053||123566|
NCT01109680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 92579-1048-0|A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects|A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects||Merz Pharmaceuticals GmbH||Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|55 Years|65 Years|Accepts Healthy Volunteers|||April 2010|February 7, 2011|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109680||123288|
NCT01109693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sun-d|Strategic Use of New Generation Antidepressants for Depression|Strategic Use of New Generation Antidepressants for Depression|SUN(^_^)D|Kyoto University|Yes|Completed|December 2010|December 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2012|||Both|25 Years|75 Years|No|||February 2016|February 22, 2016|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109693||123287|
NCT01110603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_528|A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)|A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Terminated|July 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110603||123217|
NCT01110577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-171|Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)|Inter-Center Reproducibility Study of Magnetic Resonance Imaging (MRI) for Quantification of Hepatic Fat Fraction in Diabetic and Pre-Diabetic Patients||Merck Sharp & Dohme Corp.|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited for the study|April 2015|April 8, 2015|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110577||123219|
NCT01110590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14612|Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552|Randomized, Double-blind, Placebo-controlled, Group-comparison, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administration of Different Doses of Vardenafil (2 Dose Strengths) and BAY60-4552 (4 Dose Strengths) Given Once-daily (od) Over 14 Days in Patients With Erectile Dysfunction (ED).||Bayer|No|Completed|January 2010|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|37|||Male|18 Years|70 Years|No|||February 2013|February 21, 2013|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01110590||123218|
NCT01110902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178C2302|Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)|A 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD)||Novartis||Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|589|||Both|18 Years|70 Years|No|||September 2012|September 19, 2012|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110902||123194|
NCT01110915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AdvisaMRI|Advisa MRI Clinical Study|Advisa MRI™ System Clinical Investigation||Medtronic Cardiac Rhythm Disease Management|No|Completed|June 2010|March 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|269|||Both|N/A|N/A|No|||April 2013|April 23, 2013|April 23, 2010|Yes|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT01110915||123193|
NCT01111175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-133|Triple Negative Breast Cancer Biomarker Study|Triple Negative Breast Cancer Biomarker Study||US Oncology Research|No|Completed|May 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|Samples With DNA|Whole blood and tumor tissue|Female|18 Years|N/A|No|Non-Probability Sample|Evaluable patients with metastatic or locally advanced TNBC who are scheduled for surgical        tumor biopsy or resection|July 2013|July 19, 2013|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01111175||123173|
NCT01111812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC131-09CTIL|Prediction of Weight Gain by Children and Adolescents|Prediction of Weight Gain by Children and Adolescents That Participate in a Multi-disciplinary Intervention Program for Treatment of Overweight and Obese||Meir Medical Center|No|Recruiting|January 2011|December 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|overweight and obese children and adolescence, boys and girls, ages 5-18|October 2015|October 19, 2015|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111812||123124|
NCT01111825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005|Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer|A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer||Puma Biotechnology, Inc.||Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111825||123123|
NCT01111838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-029|Clinical and Translational Study of STA-9090|A Phase II Clinical and Translational Study of STA-9090 in Patients With Refractory Metastatic Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Completed|April 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|April 26, 2010|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01111838||123122|
NCT01112111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS|A Novel Stimulation Protocol and the Conventional Low Dose Step-up and Step Down Regimens|Conventional Step-up, Step Down and a Novel Stimulation Regime in Controlled Ovarian Stimulation of Older Than 30 Years PCOS Patients Undergoing IVF- A Prospective Randomized Study.||Genesis Center for Fertility & Human Pre-Implantation Genetics|Yes|Enrolling by invitation|May 2010|||September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|225|||Both|30 Years|36 Years|No|Probability Sample|PCOS is defined as the presence of polycystic ovaries, described as enlarged under US with        more than 10 cysts (2 and 8 mm) in mean diameter and symptoms of oligomenorhrea/        amenorhea, high LH/FSH ratio, obesity, hyperandrogenism hirsuitism and acnes), and        withdrawal bleeding after administration of progesterone. All women had either failed to        ovulate after receiving a maximum daily dosage of 100-150 mg of clomiphene citrate for 5        days or failed to conceive after at least three ovulatory cycles using CC or gonadotropin        treatment. Other inclusion criteria included: patients between 30 and 36 years old with        patent fallopian tubes, no previous IVF attempts, and nortmo-spermic partners.|April 2010|April 26, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112111||123101|
NCT01112124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14594B|Behaviors of Children Ages 15 Months to Five Years Around Microwave Ovens|Behaviors of Children Ages 15 Months to Five Years Around Microwave Ovens||University of Chicago|No|Completed|September 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|15 Months|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Typically developing children ages 15 months to 5 years born full term|September 2013|September 4, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112124||123100|
NCT01112189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG08-005|Use of Stem Cells in Lymphedema Post Mastectomy|Postoperative Lymphedema Treatment in Upper Extremities Following Axillary Lymphadenectomy by Transplanting Autologous Endothelial Progenitor Cells (EPC)|SCL|Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|September 2009|September 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|75 Years|No|||February 2010|March 23, 2011|April 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112189||123095|
NCT01108198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212|Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study|Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study in 98 Boys||University of Oulu||Recruiting|October 2006|||June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|6 Years|16 Years|No|||April 2010|April 20, 2010|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108198||123402|
NCT01103986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912-255X|Assessing the Effectiveness of a Health Literacy Intervention in the Workplace|Assessing the Effectiveness of a Health Literacy Intervention in the Workplace: A Quasi-experimental Pre-post Randomized Controlled Study||Children's Mercy Hospital Kansas City|No|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|184|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 22, 2011|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01103986||123725|
NCT01103999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2009/MCL-01|Prospective Evaluation of Spleen Injury Treatments in Languedoc Roussillon|Prospective Evaluation of Spleen Injury Treatments in Languedoc Roussilon, France||Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|93|||Both|16 Years|N/A|No|Non-Probability Sample|The population includes patients hospitalized for trauma to the spleen.|March 2015|March 25, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01103999||123724|
NCT01104298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS-20|Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS|Randomized, Open, Multicenter, Prospective, Phase II Clinical Trial of Doxorubicin vs. Trabectedin Plus Doxorubicin in the First Line Treatment of Patients With Advanced Non Operable and/or Metastatic Soft Tissue Sarcomas||Grupo Espanol de Investigacion en Sarcomas|Yes|Terminated|November 2009|May 2014|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|April 13, 2010||No|Interim analysis did not show good results for main objective|No||https://clinicaltrials.gov/show/NCT01104298||123701|
NCT01105494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21906|An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia|Prospective Study Evaluating the Quality of Life in Dialysis Patients With End Stage Renal Disease||Hoffmann-La Roche||Completed|December 2008|June 2012|Actual|June 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6000|||Both|18 Years|N/A|No|Non-Probability Sample|Dialysis patients with end-stage kidney disease on treatment with epoetin beta        [Neorecormon]|June 2011|September 12, 2012|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105494||123609|
NCT01105507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885DCA01|The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada|An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada||Novartis||Completed|August 2010|||May 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|4 Years|N/A|No|||September 2012|September 30, 2012|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01105507||123608|
NCT01105520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-XYZ-003|Neurologic and Neurophysiologic Assessment of Clinical Course in Patients With Intraspinal Processes|||University of Zurich||Recruiting|January 2010|December 2015||||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients treated surgically for intraspinal processes|April 2010|April 15, 2010|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105520||123607|
NCT01105806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-043|Cardiopulmonary Resuscitation (CPR) Video to Enhance Advance Care Planning in Advanced Upper Gastrointestinal Cancer Patients|The Use of a CPR Video to Enhance Advance Care Planning in Advanced Upper Gastrointestinal Cancer Patients: A Randomized Controlled Pilot Tria||Memorial Sloan Kettering Cancer Center||Completed|April 2010|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|57|||Both|18 Years|N/A|No|Probability Sample|Patients will be recruited from the MSKCC GI medical oncology group of listed study        investigators, and as above, 18 years of age or older with no advance directive completed,        and will be English speaking, due to the study tools being based in English.|July 2015|July 15, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105806||123585|
NCT01109368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912010770|The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository|The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository||The Rogosin Institute|No|Recruiting|June 2010|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Plasma, serum, monocytes|Both|N/A|N/A|No|Non-Probability Sample|Males and females of any age with severely elevated LDL cholesterol levels without        secondary causes and a family history consistent with an autosomal dominant disorder.|February 2016|February 8, 2016|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109368||123312|
NCT01110187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPS-001|A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide|A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide||University of Alabama at Birmingham|Yes|Terminated|May 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|11|||Both|18 Years|N/A|No|||February 2014|March 26, 2014|April 16, 2010|No|Yes|Lack of enrollement|No|June 19, 2013|https://clinicaltrials.gov/show/NCT01110187||123249|Early termination due to lack of enrollment. Statistical comparisons between groups are not possible and were not performed.
NCT01110239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080406|Preconditioning for Aneurismal Subarachnoid Hemorrhage|Remote Ischemic Preconditioning to Ameliorate Delayed Ischemic Neurological Deficit After Aneurismal Subarachnoid Hemorrhage||University of Miami|Yes|Completed|November 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|April 21, 2010||No||No|August 9, 2011|https://clinicaltrials.gov/show/NCT01110239||123245|
NCT01110252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/ASSIS Unesp - 001|Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease|Unicentric Study Protocol of Cell Therapy in Chronic Obstructive Pulmonary Disease|COPD-01|UPECLIN HC FM Botucatu Unesp|No|Completed|May 2009|November 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|40 Years|72 Years|No|||February 2012|February 22, 2012|April 20, 2010||No||No|November 3, 2011|https://clinicaltrials.gov/show/NCT01110252||123244|small number of subjects analyzed
NCT01110876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0651|Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)|Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme||M.D. Anderson Cancer Center|Yes|Terminated|June 2011|||July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|April 22, 2010||No|Unanticipated Toxicities|No||https://clinicaltrials.gov/show/NCT01110876||123196|
NCT01110889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178C2301|Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder|An 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD)||Novartis||Completed|May 2010|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|582|||Both|18 Years|70 Years|No|||February 2013|February 21, 2013|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110889||123195|
NCT01110642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-15|Novel Treatment for Syndromic Ichthyoses|Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses||Northwestern University|No|Withdrawn|July 2011|||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|N/A|No|||May 2015|May 15, 2015|April 22, 2010|Yes|Yes|Study was withdrawn due to lack of eligible population for study|No||https://clinicaltrials.gov/show/NCT01110642||123214|
NCT01110928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3812|Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate on Long-term Safety and Efficacy of Norditropin® Formulation in Patients With SGA Short Stature Without Closure of Epiphyseal Discs||Novo Nordisk A/S|No|Active, not recruiting|November 2009|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|||Both|N/A|N/A|No|Non-Probability Sample|Patients with SGA short stature that are still growing, who will either receive        Norditropin® (somatropin) treatment or completed the GHLIQUID-1517 trial.|December 2015|December 8, 2015|April 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110928||123192|
NCT01111552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-08-256|Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|ACES 256|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Terminated|July 2010|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|65 Years|No|||August 2012|August 24, 2012|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111552||123144|
NCT01111565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-08-263|Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|ACES 263|Otsuka Pharmaceutical Development & Commercialization, Inc.||Terminated|July 2010|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|No|||August 2012|August 24, 2012|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111565||123143|
NCT01111851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-183|Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)|MK0869 and MK0517 Time-on-Target PET Study||Merck Sharp & Dohme Corp.|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 6, 2015|April 26, 2010|No|Yes||No|September 29, 2011|https://clinicaltrials.gov/show/NCT01111851||123121|
NCT01112137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLN5031|Effects of Clopidogrel on Blood Pressure|Phase IV Study of the Effects of Clopidogrel on Soluble CD40 Ligand, Endothelial Function and Blood Pressure||University of Cologne|No|Completed|January 2005|April 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|46|||Both|45 Years|75 Years|No|||April 2010|April 27, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112137||123099|
NCT01108744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000313|Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).|Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).||Beth Israel Deaconess Medical Center|Yes|Withdrawn|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|April 16, 2010||No|Timeline to consent prior to intervention start was unfeasible.|No||https://clinicaltrials.gov/show/NCT01108744||123360|
NCT01104012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2009/NM-01|Validation of Proteomic Analyses for Allergic Asthma and Rhinitis|The VAPARA Study: Validation of Proteomic Analyses for Allergic Asthma and Rhinitis|VAPARA|Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|133|Samples Without DNA|Serum and plasma samples are taken on patient inclusion. For the purposes of this study,      only proteomic profiles via SELDI-TOF will be characterized. Excess serum and plasma will be      stored in the CHU de Nîmes Biothèque.|Both|18 Years|65 Years|No|Non-Probability Sample|The asthma and allergic rhinitis patients included in this study are recruted from the        Pneumology Departments of the University Hospitals of Nîmes, Marseilles, and Montpellier.|March 2015|March 26, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01104012||123723|
NCT01104285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/03/VA02|Chest Tube Drainage of Transudative Pleural Effusions Hastens Liberation From Mechanical Ventilation|Chest Tube Drainage of Transudative Pleural Effusions Hastens Liberation From Mechanical Ventilation||Maimonides Medical Center|No|Completed|March 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|198|||Both|18 Years|N/A|No|Non-Probability Sample|112 patients standard; 86 patients chest tube|April 2012|April 18, 2012|April 14, 2010||No||No|November 16, 2011|https://clinicaltrials.gov/show/NCT01104285||123702|
NCT01104883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-PJ-2009|The Efficacy of Adductor-Canal-Blockade on Morphine Consumption, Pain and Mobilisation After Total Knee Arthroplasty|The Efficacy of Adductor-Canal-Blockade on Morphine Consumption, Pain and Mobilisation After Total Knee Arthroplasty||Rigshospitalet, Denmark|Yes|Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|50 Years|85 Years|No|||April 2010|April 12, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104883||123656|
NCT01108523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|828-101-09-017|Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage|Open Label Evaluation of the Effects of HP828-101 in the Management of Moisture Associated Skin Damage in Adults||Healthpoint|No|Terminated|April 2010|February 2012|Actual|July 2010|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|April 20, 2010|Yes|Yes|Business decision|No|October 9, 2013|https://clinicaltrials.gov/show/NCT01108523||123377|
NCT01108536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPSHI/IRB 00002053|Dynamic Management of Excess Residual Limb Pressure With New Smart Socket Technology/Intelligent Prosthetic Socket With Variable Volume and Elevated Vacuum Systems|Dynamic Management of Excess Residual Limb Pressure With New Smart Socket Technology/Intelligent Amputee Sockets Employing Real Time Advanced Photonic Sensors for Optimum Fit and Pressure Relief Through Active Controls/Intelligent Prosthetic Socket With Variable Volume and Elevated Vacuum Systems|SMARTsocket-|University of Wisconsin, Milwaukee|Yes|Active, not recruiting|January 2011|August 2012|Anticipated|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|80 Years|No|||July 2012|July 30, 2012|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01108536||123376|
NCT01104558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMD084000-500|Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients.|Association Between Beta-1 and Beta-2 Adrenergic Receptor Polymorphism and Beta-blocker (Bisoprolol) Therapy in Heart Failure|ABBA|Merck KGaA|No|Completed|December 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|80 Years|No|||January 2014|January 20, 2014|February 24, 2010||No||No|March 13, 2012|https://clinicaltrials.gov/show/NCT01104558||123681|
NCT01104571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669882|Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer|Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B)|EPHOS-B|Institute of Cancer Research, United Kingdom|Yes|Recruiting|April 2010|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|250|||Female|18 Years|N/A|No|||May 2014|May 27, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104571||123680|
NCT01104584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91782|Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)|An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI|GEMMA 2|Bayer|No|Completed|May 2010|January 2012|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|460|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|April 14, 2010|Yes|Yes||No|July 10, 2014|https://clinicaltrials.gov/show/NCT01104584||123679|
NCT01104896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICOREA|Effect of Daily Nicotine Patch Application on Mechanical Ventilation Weaning in Smoking Patients|Multicentric Evaluation of a Daily Nicotine Patch Administration on Mechanical Ventilation Weaning in Smoking Patients Hospitalized in Intensive Care Unit|NICOREA|University of Paris 5 - Rene Descartes|Yes|Recruiting|January 2010|February 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|600|||Both|18 Years|80 Years|No|||April 2010|April 14, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104896||123655|
NCT01105221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI1001|Acupuncture for Dry Eye|Acupuncture for Dry Eye: a Multicenter Randomized Controlled Trial With Active Comparison Intervention (Artificial Tear Drop) Using a Mixed Method Approach||Korea Institute of Oriental Medicine|Yes|Completed|April 2010|January 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|65 Years|No|||April 2010|January 7, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01105221||123630|
NCT01109381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT08-01|Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori|A Single-centre, Open-label, Non-controlled, Exploratory Safety and Efficacy Clinical Trial of GT08 in Volunteers and Patients Who Are Infected With Helicobacter Pylori||Synergy Pharmaceuticals Pte. Ltd.|No|Terminated|May 2010|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|April 20, 2010||No|Poor efficacy (2 of 31 completing participants with H.pylori eradication)|No|May 23, 2013|https://clinicaltrials.gov/show/NCT01109381||123311|The trial has no control group. All participants had current H.pylori infection at study entry. Only two participants had this infection eradicated, making an efficacy control group unnecessary.
NCT01109147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017673-38|Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients|Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients During Emotional Tasks and With Reference to Controls||Qualissima|No|Completed|December 2010|May 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|67|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|April 21, 2010||No||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01109147||123329|
NCT01109394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100086|Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies|Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies||National Institutes of Health Clinical Center (CC)||Recruiting|April 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|6035|||Both|N/A|99 Years|Accepts Healthy Volunteers|||July 2015|March 19, 2016|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109394||123310|
NCT01109979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006p002137|Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function|Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study||Brigham and Women's Hospital|Yes|Completed|December 2009|||January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|24|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|April 22, 2010|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT01109979||123265|There may have been an order effect of E+DRSP on FMD. For this, however, we would expect %FMD to be lower in the 2nd treatment period, regardless of specific treatment. It is unclear whether this was true cross-over effect or due to the study size.
NCT01109992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH|Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET|Integrated Dual Exercise and Lexiscan PET: IDEAL PET|IDEALPET|Brigham and Women's Hospital|No|Recruiting|February 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01109992||123264|
NCT01110265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USydney11760|Attention Training and Its Effects on Body Image Disturbance|||University of Sydney|No|Completed|June 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|37 Years|No|||April 2010|April 22, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110265||123243|
NCT01110616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134-010|EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)|A Double Blind, Randomized, Crossover Study to Assess EEG Platform Standardization in Healthy Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|25|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110616||123216|
NCT01110954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK01|Fluorescence-guided Resection in Breast Cancer|Evaluation of the Suitability of PD L 506 for Intraoperative Visualisation of Palpable and Nonpalpable Breast Cancer Tissue||photonamic GmbH & Co. KG|No|Suspended|April 2010|||December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|16|||Female|18 Years|N/A|No|||December 2012|December 20, 2012|April 22, 2010||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01110954||123190|
NCT01111253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/233|Diverticulitis: Antibiotics or Close Observation?|DIABOLO Trial: A Multicenter Randomized Clinical Trial Investigating the Cost-effectiveness of Treatment Strategies With or Without Antibiotics for Uncomplicated Acute Diverticulitis.|DIABOLO|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Active, not recruiting|May 2010|October 2014|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|533|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 26, 2012|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111253||123167|
NCT01111266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-I-H-09-02|Determination of in Vivo Ultrafiltration Coefficient (KUF) in Patients With Chronic Kidney Disease (CKD)|Evaluation of Performance and Safety Profile of Xevonta High Flux Dialyzer With Special Focus on Determination of in Vivo Ultrafiltration Coefficient in Patients With CKD||B.Braun Avitum AG|No|Completed|March 2010|March 2012|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|No|||March 2012|March 13, 2012|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111266||123166|
NCT01111214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4434|Child Pneumococcal Serotype Epidemiology In Greece|Incidence And Serotypes Of Invasive Pneumococcal Disease, After The Introduction Of The Heptavalent Conjugated Vaccine In Greece||Pfizer|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|457|||Both|N/A|14 Years|No|Non-Probability Sample|Hospitalized children in participating centers|January 2013|January 9, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01111214||123170|
NCT01110941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOL feasibility study|Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China|A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer|SCI-101|Peking University||Completed|September 2009|October 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|80 Years|No|||May 2015|May 17, 2015|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01110941||123191|
NCT01111240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 05-3|Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice|A Long Term Documentation to Demonstrate Long Term Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis Under Conditions of Daily Practice||AbbVie|No|Completed|August 2005|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4635|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical routine patients with psoriatic arthritis|December 2014|December 29, 2014|February 26, 2010||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01111240||123168|
NCT01111578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17610|Evaluation of a New Enteral Feeding Tube for the Measurement of Esophageal and Gastric Pressure|Evaluation of a New Enteral Feeding Tube for the Measurement of Esophageal and Gastric Pressure||Policlinico Hospital|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|All patients admitted to a general and post-operative intensive care unit and who, for        clinical reasons, need the placement of an enteral feeding tube|April 2010|November 29, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01111578||123142|
NCT01111864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-cercamondi|Changes in Microbiota and Iron Status After Iron Fortification of Complementary Foods|The Effect of Iron Fortification of Complementary Foods on Iron Status and Infant Gut Microbiota in Kenya||Swiss Federal Institute of Technology|Yes|Completed|February 2010|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|160|||Both|24 Weeks|28 Weeks|No|||June 2013|June 6, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01111864||123120|
NCT01109251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hippocrate|Post CVA Persistent Hypertension Caring|Post CVA Persistent Hypetension, Interest of Caring by Tensional Auto-measures|Hippocrate|Central Hospital, Nancy, France|No|Recruiting|July 2011|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|20 Years|80 Years|No|||November 2013|November 12, 2013|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01109251||123321|
NCT01109043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084000-504|Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart Rate|b. p. m Study (Beats Per Minute): Heart Rate Development Whilst Treating Patients With Hypertension With Concor or Concor Plus||Merck KGaA||Completed|June 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|351|||Both|N/A|54 Years|No|Non-Probability Sample|Hypertensive subjects|November 2011|July 30, 2014|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01109043||123337|
NCT01109056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192371-019|Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium|||Allergan|No|Completed|June 2010|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|April 19, 2010|Yes|Yes||No|May 22, 2012|https://clinicaltrials.gov/show/NCT01109056||123336|
NCT01104311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STABLE-ICAS|Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis|Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis|STABLE-ICAS|Asan Medical Center|No|Active, not recruiting|April 2010|December 2015|Anticipated|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|156|||Both|40 Years|N/A|No|||June 2015|June 30, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104311||123700|
NCT01108848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1145_5002|Patient Registry Study of Berinert® in Normal Clinical Practice|Patient Registry for Berinert®, a C1-Esterase Inhibitor||CSL Behring|No|Completed|April 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|318|||Both|N/A|N/A|No|Non-Probability Sample|An attempt will be made to prospectively identify patients and enroll them into this        registry before treatment is required. In addition, retrospective chart/case review and        data collection may be conducted.|June 2014|June 5, 2014|April 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01108848||123352|
NCT01112553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002689|Treximet Migraine Brain Imaging Research Study|Evaluation of Brain Activation in Complete Responders and Partial Responders Following Acute Administration of Treximet (Sumatriptan and Naproxen)|TREX|Mclean Hospital||Terminated|April 2010|October 2012|Actual|||N/A|Observational|Observational Model: Cohort||1|Actual|2|Samples With DNA|Seven 5-mL blood samples will be drawn throughout the MRI session, and blood plasma will be      analyzed for the concentration of Treximet.|Both|18 Years|65 Years|No|Probability Sample|English-speaking males or females between the ages of 18 and 65, who suffer from acute        migraine (<14 migraine episodes/ month), will be recruited for this study.|October 2012|October 30, 2012|April 27, 2010||No|Study was closed due to low enrollment numbers.|No||https://clinicaltrials.gov/show/NCT01112553||123067|
NCT01108861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-100107|GORE VIABAHN® Versus Plain Old Balloon Angioplasty (POBA) for Superficial Femoral Artery (SFA) In-Stent Restenosis|The GORE VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Versus Plain Old Balloon Angioplasty (POBA) for the Treatment of Superficial Femoral Artery (SFA) In-Stent Restenosis|RELINE|Flanders Medical Research Program|No|Completed|May 2010|March 2014|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108861||123351|
NCT01109134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33|Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients|Prospective Randomized Controlled Clinical Study to Compare Tirofiban Intracoronary Bolus-Only vs Intravenous Bolus Plus Infusion in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention||Kosuyolu Heart Hospital|Yes|Completed|September 2008|August 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|25 Years|75 Years|No|||March 2010|April 21, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109134||123330|
NCT01108874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1241/09|Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Cesarean Section|Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Elective Cesarean Section||Federal University of São Paulo||Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|48|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 30, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01108874||123350|
NCT01109706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/3-ZE|Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.|Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.|PC-SCA-9|Nantes University Hospital|No|Recruiting|October 2010|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients of both sexes, 18 years old minimum, with an acute coronary syndrome, treated or        not with statins, admitted to cardiological intensive care unit.|November 2012|November 16, 2012|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01109706||123286|
NCT01109966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT0140PAICE|An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy|A Prospective, Double Blind Randomised Controlled Trial to Evaluate the Immunological Benefits and Clinical Effects of an Elimination Diet Using an Amino Acid Based Formula (AAF)||Nutricia Liverpool|No|Recruiting|June 2010|November 2014|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|228|||Both|N/A|8 Months|No|||July 2011|July 21, 2011|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01109966||123266|
NCT01110005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32118|A Trial of Intravenous Fluids During Labor|A Multi-Center, Two-Arm, Single-Blind Randomized Trial of IV Fluids During Labor|RARHY|Milton S. Hershey Medical Center|Yes|Active, not recruiting|April 2010|October 2016|Anticipated|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1524|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01110005||123263|
NCT01110291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XRP 6976A/6022|Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events|Activity of CYP3A and Genotypes of CYP3A5 and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients|Docetaxel|University of Turku|No|Completed|April 2003|March 2009|Actual|January 2004|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Blood samples for genotyping and phenotyping as well as analysis of docetaxel      concentrations.|Female|18 Years|60 Years|No|Probability Sample|Twenty patients with verified high risk breast cancer.|April 2010|April 26, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110291||123241|
NCT01110278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU eIRB 6005|Examining Bladder Control Using Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI)|Examining the Brain's Control Systems in Normal and Overactive Bladder Using DTI and Functional MRI||Oregon Health and Science University|No|Active, not recruiting|May 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|47|||Female|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women seeking care at Oregon Health and Science University in Portland, Oregon.|October 2014|October 16, 2014|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01110278||123242|
NCT01110629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14817|Study in Chronic Kidney Disease (CKD) Not on Dialysis|Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia||Bayer|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|143|||Both|20 Years|N/A|No|||October 2014|October 12, 2014|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110629||123215|
NCT01111227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-40|Inflammatory Cytokines Profile in Individuals Subjected to Surgical Procedures Using Propofol or Isoflurane|Inflammatory Cytokines Profile in Individuals Subjected to Surgical Procedures Using Propofol or Isoflurane.||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|50 Years|No|||April 2010|April 26, 2010|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01111227||123169|
NCT01111279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT-gpASIT004|Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis|Clinical Safety and Tolerability of gpASIT+TM Administered Subcutaneously in Absence or in Presence of DnaK Immunoregulating Adjuvant for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis||BioTech Tools S.A.|No|Completed|March 2010|November 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|50 Years|No|||February 2011|February 28, 2011|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01111279||123165|
NCT01111591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-GS-HBP2|Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer|Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer.||Seoul National University Hospital|Yes|Recruiting|November 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|220|||Both|19 Years|70 Years|No|||May 2015|May 22, 2015|March 31, 2009||No||No||https://clinicaltrials.gov/show/NCT01111591||123141|
NCT01112696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 221|An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor|An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor||Medtronic Diabetes|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|100|||Both|18 Years|75 Years|No|||July 2012|July 23, 2012|April 27, 2010||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT01112696||123056|
NCT01108419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU327|Evaluation of Dose-effect of a New Fermented Food in Healthy Adults|Evaluation of the Safety and Tolerance of a New Fermented Food in Healthy Adults||Danone Research||Completed|March 2010|June 2012|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment|4||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01108419||123385|
NCT01112059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F081024004|Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients|Implication of Cross-Protease Dysregulation in Cystic Fibrosis: A Randomized, Placebo Controlled Pilot Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult CF Patients Hospitalized for Pulmonary Exacerbations (Implications of Cross-Protease Dysregulation in Cystic Fibrosis)|DOXY|University of Alabama at Birmingham|Yes|Completed|November 2008|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|N/A|No|||January 2016|January 26, 2016|April 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112059||123105|
NCT01112826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSUCC-001|Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer|Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast Cancer|SYSUCC-001|Sun Yat-sen University|Yes|Recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|424|||Female|18 Years|70 Years|No|||February 2015|February 12, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01112826||123046|
NCT01108575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF IRB #723-2009|Effect of Inspiratory Muscle Training on Duration of Mechanical Ventilation Support|Inspiratory Muscle Strength Training in Ventilator Dependent Patients||University of Florida|Yes|Completed|May 2010|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108575||123373|
NCT01108588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-167|Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)|A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study Using Aspirin and Clopidogrel to Assess Reproducibility and Compare Platelet Function Assays||Merck Sharp & Dohme Corp.|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|April 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01108588||123372|
NCT01112839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA148791-01|Reducing Breast Cancer Recurrence With Weight Loss|Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial|ENERGY|University of California, San Diego|Yes|Completed|May 2010|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|692|||Female|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 17, 2015|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112839||123045|
NCT01108549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RiboseCFS03|Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study|Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study||Kona Research Center|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|257|||Both|18 Years|N/A|No|||April 2010|April 20, 2010|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01108549||123375|
NCT01108562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57366|Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion|Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion in Combination With Patient Controlled Analgesia: a Prospective Randomized, Double-blinded, Placebo-controlled Study||Loma Linda University|Yes|Withdrawn|February 2008|||August 2008|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108562||123374|
NCT01109407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100096|Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)|Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)||National Institutes of Health Clinical Center (CC)||Completed|April 2010|||||N/A|Observational|Time Perspective: Prospective|||Actual|225|||Both|18 Years|N/A|No|||August 2015|September 18, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109407||123309|
NCT01109420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100102|Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer|Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|7 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 28, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109420||123308|
NCT01109719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIITG-2|Critical Illness Outcomes Study|The Association of ICU Organization and Structure on in Patient Mortality|CIOS|National Institute of General Medical Sciences (NIGMS)|No|Active, not recruiting|July 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|6000|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients present in study ICU's on the days of enrollement|August 2010|August 23, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109719||123285|
NCT01110018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112008|GSK573719 IV Enabling Study|A Single-centre, Open-label, Sequential, Cross-over Study to Examine the Safety, Tolerability and Pharmacokinetics of 3 Ascending Single Intravenous Doses, a Single 1000μg Oral Dose and a Single 1000μg Inhaled Dose of GSK573719 in Healthy Male Volunteers.||GlaxoSmithKline|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|August 23, 2012|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01110018||123262|
NCT01112397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1060C00002|Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours|A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.||AstraZeneca|No|Terminated|April 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|April 23, 2010|No|Yes|Decision to stop development of AZD1480|No||https://clinicaltrials.gov/show/NCT01112397||123079|
NCT01108679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-471|Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users|Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|December 2009|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Whole blood, Urine|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects for this study will be drug users with a diagnosis of opioid dependence who are        initiating buprenorphine therapy at a DoSA clinic or at the CHCC. The study population is        expected to reflect the ethnic composition of the opioid-dependent population in the        Bronx. This population is composed of 40% women, and is 24% African-American, 58% Hispanic        and 17% Caucasian. Both males and females with opioid dependence who are initiating        buprenorphine will be recruited for the proposed study, and, based on our previous        studies, we expect to recruit high proportions of women and minorities.|April 2010|May 6, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108679||123365|
NCT01110655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSER 2009|The Efficacy of Oral Versus Intravenous Hypertonic Saline Administration in Runners With Exercise-Associated Hyponatremia|Incidence and Cause of Hyponatremia in Endurance Runners, Also to Determine if Oral Hypertonic Saline is as Efficacious as Intravenous Hypertonic Saline in the Correction of Below Normal Blood Sodium Concentrations in Runners With Hyponatremia Without Neurological Symptoms||Western States Endurance Run Research Foundation|No|Recruiting|June 2009|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 23, 2010|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110655||123213|
NCT01110668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107DTR01T|Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)|Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Previously Treated With Imatinib||Novartis||Completed|September 2008|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110668||123212|
NCT01110031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112855|Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects|An Open-Label, Single-Arm, Phase I Study to Evaluate the Effect of Ofatumumab on Cardiac Repolarization (QTc Duration) in Patients With Fludarabine-Refractory B-cell Chronic Lymphocytic Leukemia||GlaxoSmithKline|No|Completed|May 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110031||123261|
NCT01110044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112980|Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine|Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine||GlaxoSmithKline||Withdrawn|April 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|N/A|5 Days|Accepts Healthy Volunteers|||March 2015|March 26, 2015|April 22, 2010|Yes|Yes|Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|No||https://clinicaltrials.gov/show/NCT01110044||123260|
NCT01110980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOCISD 01-03-2010|Normalcy of Food Intake in Head and Neck Cancer Patients|Normalcy of Food Intake in Head and Neck Cancer Patients Receiving (Chemo)Radiotherapy Supported by Swallowing Therapy and Individual Dietary Counselling. (Supportive Care)|FOCISD|Radboud University|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|N/A|No|||October 2012|May 21, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110980||123188|
NCT01111916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI 02|Development Study Using Vaginal Tactile Imager|A Development Study Using Vaginal Tactile Imager to Assess the Elasticity Properties of the Vaginal Wall and Surrounding Connective Tissue||Artann Laboratories|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult women with normal pelvic anatomy|February 2014|February 24, 2014|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01111916||123116|
NCT01111929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECLAM|Emergency Contraception as a Back up of Lactational Amenorrhea Method(LAM)|Emergency Contraception as a Back up of Lactational Amenorrhea Method of Contraception|ECLAM|Assiut University|Yes|Active, not recruiting|January 2009|November 2012|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1174|||Female|18 Years|45 Years|No|||November 2011|November 25, 2011|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01111929||123115|
NCT01108692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS053|Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)|Investigation on Early Detection and Active Management of Supra-ventricular Arrhythmia With Telecardiology|SETAM|Biotronik France|Yes|Completed|July 2010|November 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|602|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108692||123364|
NCT01108757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-125|Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients|Prevention of Catheter-Associated Urinary Tract Infections in Patients Undergoing Incontinence and Reconstructive Pelvic Surgery: A Randomized Controlled Trial|PRECAUTION|The Cleveland Clinic|No|Terminated|April 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|79|||Female|21 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 22, 2013|April 21, 2010|Yes|Yes|Unfeasible because of low accrual|No||https://clinicaltrials.gov/show/NCT01108757||123359|
NCT01108770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-001|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia|Evaluation of Phenotypic and Genetic Properties in Male Subjects With Hypohidrotic Ectodermal Dysplasia and Their Family Members||Edimer Pharmaceuticals|No|Completed|July 2010|October 2010|Actual|July 2010|Actual|N/A|Observational|N/A||2|Actual|62|Samples With DNA|Blood samples|Male|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male subjects with HED or unaffected controls|August 2012|August 20, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108770||123358|
NCT01112566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRC-CS-2010-03|EASE MITRAL Expertise-based Assessment Study on Clinical Efficacy of Profile 3D in MITRAL Valve Annuloplasty|EASE MITRAL Expertise-based Assessment Study on Clinical Efficacy of Profile 3D in MITRAL Valve Annuloplasty||Medtronic Cardiovascular|No|Active, not recruiting|February 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|85 Years|No|Non-Probability Sample|The patient population includes all patients suffering from mitral valve disease,        indicated for a mitral valve repair procedure, either as a stand-alone procedure or        concomitant to a coronary artery bypass grafting, an aortic replacement or tricuspid valve        repair and/or the treatment of atrial fibrillation, and for which the surgeon considers        the implantation of a Profile 3D annuloplasty product most appropriate to reconstruct the        regurgitant valve.|February 2016|February 5, 2016|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112566||123066|
NCT01112579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEFEAT-HF|Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure|Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure|DEFEAT-HF|Medtronic Cardiac Rhythm Disease Management|Yes|Completed|April 2010|April 2015|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|April 16, 2010|No|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01112579||123065|
NCT01112293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03510|Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma|A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM))||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|April 2010|December 2014|Actual|October 2012|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Actual|14|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112293||123087|
NCT01108276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-071|Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy Device to Moist Wound Therapy|A Prospective, Randomized, Controlled Study Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy (NPWT) Device to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Wounds||Georgetown University|No|Withdrawn|May 2010|November 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|April 20, 2010||No|Study never started and therefore terminated.|No||https://clinicaltrials.gov/show/NCT01108276||123396|
NCT01108887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701068-526|An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.|Assessment of Adherence, Effectiveness & Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.|SMART|Merck KGaA||Completed|September 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|912|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with RMS naïve to treatment or currently being treated with Rebif multi-dose        injected by RebiSmart for no more than 6 weeks|September 2013|September 16, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108887||123349|
NCT01109160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZI002|Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation|A Prospective, Open-label Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation|AZI002|Katholieke Universiteit Leuven|No|Completed|April 2010|July 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109160||123328|
NCT01109173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-055|Confirmatory Study Nepafenac 0.3%|Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery||Alcon Research|No|Completed|June 2010|||May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|2120|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|April 21, 2010|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT01109173||123327|This study excluded patients who were under the age of 18, had uncontrolled glaucoma, were at risk of developing macular edema (eg, diabetic retinopathy), or of childbearing potential. Therefore, results may not be generalizable to these populations.
NCT01109433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100093|Immunogenetic Mechanisms in Behcet's Disease|Immunogenetic Mechanisms in Behcet's Disease||National Institutes of Health Clinical Center (CC)||Recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|N/A|N/A|No|||December 2015|December 31, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109433||123307|
NCT01109732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2192-1|Physical Activity, Function and Quality of Life in Older Patients After Endovascular Treatment|Physical Activity, Function and Quality of Life in Older Patients After Endovascular Treatment||Oslo University Hospital|Yes|Recruiting|February 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|N/A|No|||August 2011|August 23, 2011|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109732||123284|
NCT01109745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL29895.091.09|Effectiveness of the Pelican Instrument in Medical Care|Effectiveness of the Paediatric Electronic Quality of Life Instrument for Childhood Asthma in the Netherlands (Pelican) in Medical Care.|PELICANII|Radboud University|No|Completed|August 2011|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Actual|120|||Both|6 Years|12 Years|No|||March 2014|March 17, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109745||123283|
NCT01112670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0531|The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology|The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology||University of Colorado, Denver|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|33|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||October 2012|January 22, 2013|April 26, 2010|Yes|Yes||No|October 7, 2012|https://clinicaltrials.gov/show/NCT01112670||123058|Findings are only applicable to individuals with ABCB1 CGC/CGC, CGC/TTT, or TTT/TTT diplotypes.
NCT01108354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP13675ONB|The Serotonin Transporter in Attention Deficit Hyperactivity Disorder|The Serotonin Transporter in Attention Deficit Hyperactivity Disorder Investigated With Positron Emission Tomography||Medical University of Vienna|Yes|Completed|April 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|44|Samples With DNA|whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|40 participants including ten male adult ADHD patients, ten female adult ADHD patients and        20 age- and sex-matched healthy volunteers, free of any psychotropic treatments at        baseline|January 2014|January 2, 2014|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108354||123390|
NCT01109238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC 001P|A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma|Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma||Spectrum Health Hospitals|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|12 Months|21 Years|No|Non-Probability Sample|Relapsed and refractory Neuroblastoma|July 2013|July 19, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109238||123322|
NCT01109498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-AMT-011-01|Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]|A Study to Determine the Safety and Efficacy in Lipoprotein Lipase-Deficient Subjects After Intramuscular Administration of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein LipaseS447X||Amsterdam Molecular Therapeutics|Yes|Active, not recruiting|August 2007|June 2013|Anticipated|June 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||April 2010|September 29, 2011|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109498||123302|
NCT01110694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFILE_RBH_001|Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study|Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE_Brompton)Study|PROFILE|Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|September 2010|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|210|Samples With DNA|Whole blood, serum, bronchoalveolar lavage, surgical lung biopsy (when clinically indicated)|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from patients refered to the Interstitial Lung Disease Unit of        the Royal Brompton Hospital.|November 2014|November 12, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110694||123210|
NCT01111630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP_RCM_R01|Study of Erythropoietin (EPO) Administration Schedule|Compare the Hemoglobin and Hematocrit Variability Between Once & Three Times Weekly Erythropoietin Therapy for the Anemia in Patients With Maintenance Dialysis||JW Pharmaceutical|Yes|Completed|October 2009|January 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||May 2014|May 12, 2014|April 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01111630||123138|
NCT01111643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0023-08-HYMC-CTIL|Longitudinal Strain in Addition to Visual Assessment of Wall Motion for Ruling in Ischemia in the Emergency Room|||Hillel Yaffe Medical Center||Recruiting|April 2008|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|N/A|No|Probability Sample|Patients admitted to the ER because of chest pain with no prior history coronary artery        disease.|April 2010|April 26, 2010|April 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01111643||123137|
NCT01112410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09023JB-OPMS|Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis|A Randomised Double Blind 13 Week Crossover Trial of Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Patients With Bronchiectasis.||Belfast Health and Social Care Trust|No|Recruiting|January 2010|August 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2010|April 27, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112410||123078|
NCT01112423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB121-003|Safety Study of BMS-823778 in Subjects With Hypercholesterolemia|A Double-Blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Non-Diabetic Subjects With Primary Hypercholesterolemia on a Stable Dose of Statin Therapy With or Without Ezetimibe||Bristol-Myers Squibb|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112423||123077|
NCT01110057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113049|Efficacy Study in Lumbosacral Radiculopathy|A Randomised, Double Blind Study to Evaluate the Safety and Efficacy of the p38 Kinase Inhibitor, GW856553, in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy||GlaxoSmithKline|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|80 Years|No|||February 2012|February 16, 2012|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110057||123259|
NCT01107873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0085|Changes of Dorsalis Pedis Artery Flow Pattern After Caudal Block in Children: Observational Study Using a Duplex Sonography|||Yonsei University|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Male|1 Year|5 Years|No|Probability Sample|children patients who visit Severance hospital|October 2010|October 6, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107873||123427|
NCT01108783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 1003/RAE|A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine|Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis||Faes Farma, S.A.|No|Completed|April 2003|February 2004|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|720|||Both|12 Years|70 Years|No|||April 2012|April 4, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108783||123357|
NCT01112319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041-2010|The Effects of the Electro, Heat and Cold -Therapy During Physiotherapy Treatment in Osteoarthritis(OA) of KNEE|The Effects of the Electro, Heat and Cold -Therapy During Physiotherapy Treatment in OA of KNEE - Prospective Randomize Trial||Meir Medical Center||Withdrawn|March 2010|May 2012|Anticipated|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|60 Years|N/A|No|||September 2012|September 6, 2012|April 26, 2010|Yes|Yes|not patient recruitment|No||https://clinicaltrials.gov/show/NCT01112319||123085|
NCT01108263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-006|Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers|The Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers in High Risk Populations: A Prospective, Randomized, Controlled Trial||Georgetown University|No|Terminated|June 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|April 20, 2010||No|Sponsor Terminated|No|July 1, 2013|https://clinicaltrials.gov/show/NCT01108263||123397|
NCT01108302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAT.1429-07882-2|Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India|Assessing the Effectiveness, Safety and Feasibility of Expanding Use of Oxytocin in Uniject™ by Auxiliary Nurse Midwives to Prevent Postpartum Hemorrhage: A Community-based Cluster Randomized Trial in Bagalkot, India||Johns Hopkins Bloomberg School of Public Health|Yes|Withdrawn|September 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2011|January 6, 2012|April 2, 2010||No|PATH withdrew IRB approval|No||https://clinicaltrials.gov/show/NCT01108302||123394|
NCT01108601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-07-033|Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity|Transtympanic Administration of Lactate: An Innovative Otoprotection for Patients Receiving Cisplatin or Carboplatin Chemotherapy||McGill University Health Center|No|Recruiting|April 2008|||April 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|15 Years|N/A|No|||April 2010|April 20, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01108601||123371|
NCT01108900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481271|A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil|Non-Interventional, Prospective Study Of the Evaluation Of Patients Population With ED, Treated With Sildenafil|SURE|Pfizer|No|Completed|July 2010|October 2011|Actual|October 2011|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Male|18 Years|80 Years|No|Non-Probability Sample|- Patients, aged >18 years and having been switched to sildenafil after a previous        treatment with udenafil proved ineffective and/or was poorly tolerated. The evaluation of        udenafil ineffectivness should be performed after attempt intercourse 2 times a week over        the course of four weeks.|December 2011|December 16, 2011|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108900||123348|
NCT01108913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R015|Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Phase II Study to Evaluate the Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe COPD||Revotar Biopharmaceuticals AG||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|40 Years|N/A|No|||May 2011|May 6, 2011|April 21, 2010||||No||https://clinicaltrials.gov/show/NCT01108913||123347|
NCT01109186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/3-ZF|Anti-BK Virus Immune Response and Kidney Transplantation|Role of Specific Immune Cellular Response in the Control of BK Virus Infection: Prospective Study, Monocentric and Longitudinal During the First Nine Months After a Kidney Transplantation|BKv|Nantes University Hospital|No|Recruiting|May 2010|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Kidney-transplanted person|November 2012|November 16, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109186||123326|
NCT01109446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP RCT|Treatment of Lateral Epicondylitis: Platelet Rich Plasma Versus Steroid Versus Saline Solution|Treatment of Lateral Epicondylitis. Platelet Rich Plasma vs. Steroid vs. Saline Solution||University of Aarhus|No|Completed|January 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109446||123306|
NCT01109459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EY015893|Multimodal Physician Intervention to Detect Amblyopia|Multimodal Physician Intervention to Detect Amblyopia (Recruiting Title "Equipping Primary Care Physicians to Improve Care for Children")|EPPICC|University of Alabama at Birmingham|No|Completed|September 2004|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|136|||Both|N/A|N/A|No|||April 2010|April 22, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109459||123305|
NCT01109758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S282.1.002|Effects of Fenofibrate on Gene Expression in Healthy Volunteers|Effects of Fenofibrate on Gene Expression Activity and DNA Methylation Profile in Circulating Monocytes of Healthy Volunteers||Solvay Pharmaceuticals|No|Completed|March 2008|August 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||April 2010|April 22, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01109758||123282|
NCT01111604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13942|A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer|An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy||Eli Lilly and Company|Yes|Completed|August 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|157|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|April 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111604||123140|
NCT01108965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-C-HYDRO-2A-H|Study of Shunt Flow Sensor Accuracy in Extra-ventricular Drains.|A Flow Monitor for Pediatric Hydrocephalic Shunts||Transonic Systems Inc.|No|Enrolling by invitation|August 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|15|Samples With DNA|Cerebrospinal fluid samples are to be retained|Both|N/A|N/A|No|Non-Probability Sample|Hydrocephalus patients under the care of SUNY Upstate Medical University|May 2012|May 30, 2012|April 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01108965||123343|
NCT01108978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200911064M|Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease|Phase IV Study for Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease||Nang Kuang Pharmaceutical Co., Ltd.|Yes|Terminated|May 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|75 Years|No|||June 2011|June 7, 2011|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108978||123342|
NCT01109784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-1|Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).|Phase 3 Study of Prasugrel vs High Dose (150 mg) Clopidogrel in Clopidogrel Resistant Patients Post Coronary Angioplasty.||University of Patras|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||April 2010|August 23, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109784||123280|
NCT01110330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012910|An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot|A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|July 2007|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|583|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|April 22, 2010|Yes|Yes|Unexpected discordant results between the KOH microscopy and mycological culture tests at    three study sites in the UK.|No|February 26, 2013|https://clinicaltrials.gov/show/NCT01110330||123238|The study was terminated prematurely by the sponsor due to significant discrepancies between potassium hydroxide and mycological culture results.
NCT01111305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100101|A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection|A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 2010|May 2017|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||December 2015|February 5, 2016|April 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111305||123163|
NCT01111318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.13|Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function|Pharmacokinetics, Safety and Tolerability of BI 10773 50 mg Single Dose in Male and Female Subjects With Different Degrees of Liver Impairment (Child-Pugh Classification A, B and C) as Compared to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)||Boehringer Ingelheim||Completed|July 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|April 26, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01111318||123162|
NCT01111331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.18|Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers|Relative Bioavailability of Both BI 10773 and Warfarin and Pharmacodynamics of Warfarin After Co-administration Compared to Multiple Oral Doses of BI 10773 (25 mg Once Daily) and a Single Oral Dose of Warfarin (25 mg) Alone in Healthy Male Volunteers (an Open-label, Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|May 2010|||July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|April 26, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01111331||123161|
NCT01112163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EECP-VV|The Effect of Enhanced External Counter Pulsation on Left Ventricular Systolic and Diastolic Function|The Effect of Enhanced External Counter Pulsation on Left Ventricular Systolic and Diastolic Function||Herning Hospital|No|Enrolling by invitation|March 2010|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||March 2010|April 27, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112163||123097|
NCT01108367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HoLEPUI|Transient Urinary Incontinence After Holmium Laser Enucleation of the Prostate (HoLEP)|Predictor of Transient Urinary Incontinence Following Holmium Laser Enucleation of the Prostate||Seoul National University Hospital||Completed|November 2009|||March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|204|||Male|50 Years|N/A|No|Non-Probability Sample|men who underwent HoLEP for lower urinary tract symptoms (LUTS) with BPH refractory to        alpha blocker medication|May 2011|May 9, 2011|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108367||123389|
NCT01107886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680C00003|Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications|A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes|SAVOR- TIMI 53|AstraZeneca|Yes|Completed|May 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18206|||Both|40 Years|N/A|No|||July 2014|July 9, 2014|March 25, 2010|Yes|Yes||No|May 15, 2014|https://clinicaltrials.gov/show/NCT01107886||123426|
NCT01109615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018700-90|Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations|Phase II Study of Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations|PG|Vejle Hospital|Yes|Terminated|April 2010|March 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2012|April 17, 2012|April 20, 2010||No|Lacking effect of treatment|No||https://clinicaltrials.gov/show/NCT01109615||123293|
NCT01112332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042-2010|Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics|: Use of an Innovative Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics in Different Physiologic Conditions|SSW001|Meir Medical Center|No|Available|March 2010|||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||August 2012|August 9, 2012|April 26, 2010|No|Yes||||https://clinicaltrials.gov/show/NCT01112332||123084|
NCT01112605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC09155-09CTIL|Standard Deviation of the Distance Between the Sural Nerve and Achilles Tendon by Ultrasound|||Meir Medical Center|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|otherwise healthy persones, age 18-60, community sample.|July 2011|July 16, 2011|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01112605||123063|
NCT01112592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-10156-09CTIL|NETs Formation in Patients With Recurrent Pyogenic Infections (NETS)|The Ability of Neutrophils From Patients With Recurrent Infections to Produce Neutrophil Extracellular Traps (NET).|NETs|Meir Medical Center|No|Recruiting|May 2010|December 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients are referred subsequent to recurrent, persistent, or unusual infections and after        completing preliminary screening of the immune system and ruling out a humoral, cellular        or complement immune deficiency.|March 2012|February 26, 2013|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112592||123064|
NCT01108315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC4ext|Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice|Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice||BrightOutcome|No|Completed|January 2010|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|138|||Female|18 Years|N/A|No|||February 2012|February 2, 2012|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108315||123393|
NCT01108614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Drug Users Intervention|Injecting Drug Use Community Intervention Trial|A Randomized Community Intervention Trial on Reducing HIV Infection Among Drug Users Attending Methadone Maintenance Treatment(MMT) and Preventing Secondary Transmission From HIV Positive Clients to Their Sexual Partners in China||National Center for AIDS/STD Control and Prevention, China CDC|Yes|Recruiting|June 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|12000|||Both|20 Years|N/A|No|||April 2010|May 6, 2010|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108614||123370|
NCT01108926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 035|PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers|Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Efavirenz Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers||St Stephens Aids Trust|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 29, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108926||123346|
NCT01109199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX RCT Study|Effects of a Dietary Fibre Supplementation of a Low Calorie Diet on Appetite and Body Weight|A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a High Viscosity Dietary Fibre (PGX) Supplementation of a Low Calorie Diet on Appetite and Body Weight, in Overweight and Moderately Obese Females||Canadian Center for Functional Medicine||Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|20 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01109199||123325|
NCT01109212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004SC06084|The Effects of Bindarit in Diabetic Nephropathy|The Effects of the Association Bindarit + Irbesartan Versus Irbesartan Alone on Albuminuria on Patients With Diabetic Nephropathy. Placebo-controlled Study||Aziende Chimiche Riunite Angelini Francesco S.p.A|No|Completed|March 2007|December 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|70 Years|No|||April 2010|April 22, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01109212||123324|
NCT01110317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002362|A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate|Open-Label, Parallel, Randomized, Multiple-Dose Pharmacokinetic Study of Paliperidone After Intramuscular Injection of Paliperidone Palmitate in the Deltoid or Gluteal Muscle in Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|July 2005|March 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|65 Years|No|||April 2010|April 26, 2010|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110317||123239|
NCT01110681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33DA0605, Q-Med AB|Study to Evaluate Solesta for Treatment of Fecal Incontinence|An Open, Non-comparative, Post-marketing, Multi-center Study to Evaluate Efficacy and Safety of SolestaTM for the Treatment of Fecal Incontinence||Q-Med AB|No|Completed|November 2007|December 2010|Actual|November 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|80 Years|No|||November 2012|November 22, 2012|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01110681||123211|
NCT01111617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11062007-809|Applications of Realtime Functional Magnetic Resonance Imaging (fMRI )|Applications of Realtime fMRI Phase II||Stanford University||Enrolling by invitation|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01111617||123139|
NCT01112150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0063-09-HYMC-CTIL|Effect of Normatec Pump for Relief of Leg Edema|Effect of Normatec Pump for Relief of Leg Edema: Short- Intermediate- and Longer-term Outcomes||Hillel Yaffe Medical Center|No|Recruiting|April 2010|July 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|19 Years|N/A|No|||April 2010|April 27, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01112150||123098|
NCT01105416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0088-08|Emergency Department (ED) Adolescent Alcohol Prevention Intervention|Emergency Department Based Prevention Intervention to Delay Alcohol Use by Young Adolescents||Rhode Island Hospital|Yes|Completed|July 2010|June 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|196|||Both|12 Years|14 Years|No|||November 2014|November 3, 2014|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105416||123615|
NCT01105702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 07-712|Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma|Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study||New York University School of Medicine|Yes|Terminated|May 2010|April 2015|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|April 12, 2010|Yes|Yes|Due to slow accrual|No|October 5, 2015|https://clinicaltrials.gov/show/NCT01105702||123593|
NCT01105975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12468|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C|A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C||Eli Lilly and Company|Yes|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|430|||Both|18 Years|N/A|No|||July 2011|September 20, 2011|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105975||123572|
NCT01106248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-E044-110|QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors|An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors||Eisai Inc.|No|Completed|March 2009|||September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||March 2012|March 19, 2012|April 14, 2010|Yes|Yes||No|December 22, 2011|https://clinicaltrials.gov/show/NCT01106248||123551|
NCT01106508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEQ506X2101|A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors|A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors||Novartis||Completed|October 2010|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|April 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01106508||123531|
NCT01106794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPG-1|Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma|Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma||Children's Research Institute|No|Recruiting|April 2010|April 2020|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Cerebrospinal fluid, serum, urine, brainstem tumor and constitutional tissue from patients      with diffuse intrinsic pontine glioma or brainstem glioma will be collected.|Both|N/A|21 Years|No|Non-Probability Sample|Community sample|December 2015|December 11, 2015|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01106794||123509|
NCT01107080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017428|Fast Spectral Imaging Device for Tumor Margin Mapping|Fast Spectral Imaging Device for Tumor Margin Mapping||Duke University|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|54|||Female|18 Years|N/A|No|Non-Probability Sample|There are 2 groups of patients and each group contains 20 participants.|February 2013|February 6, 2013|April 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01107080||123487|
NCT01107301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912M74832|Vascular Effects of Attention Deficit Hyperactivity Disorder (ADHD) Medications in Youth|Vascular Consequences of ADHD Medication Use in Children and Adolescents||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|138|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Eighty youth who are taking ADHD stimulant medication and eighty of their healthy siblings        without ADHD.|September 2014|September 4, 2014|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01107301||123470|
NCT01107665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 09-53|Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma|A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma||University of California, Irvine|Yes|Recruiting|August 2010|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107665||123443|
NCT01109108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28757|Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage|Streptococcus Pneumonia: Herd Effects and Emergence of Potentially Virulent Serotypes PCV13_Impact of NP Colonization, Herd Effects and Emergence of Potentially Virulent Serotypes of Pneumococci||Boston Medical Center|No|Active, not recruiting|April 2010|April 2013|Anticipated|October 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|5000|Samples Without DNA|NP specimens and bacterial isolates of S. pneuomoniae and nontypable Haemophilus|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|children < 5 years of age receiving care at Primary Care center at BMC and as many        parent(s) as willing to particpate|November 2010|November 17, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109108||123332|
NCT01109121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3007GT|Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)|A Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Tranilast in Combination With Allopurinol in Patients With Moderate to Severe Gout (TAnGO)||Nuon Therapeutics, Inc.|No|Completed|June 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|112|||Both|18 Years|80 Years|No|||January 2011|January 5, 2011|April 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01109121||123331|
NCT01112345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701068-513|An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters|A Multicentre, Non Interventional, Non Randomized, Observational Study for the Assessment of Compliance and Persistence With Rebif® Therapy of Patients With Relapsing-Remitting Multiple Sclerosis as Well as for the Evaluation of Potential Factors Influencing These Parameters, in Real Life Clinical Practice||Merck KGaA||Completed|December 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with documented diagnosis of RRMS according to the McDonald criteria (2005)|July 2014|July 15, 2014|April 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01112345||123083|
NCT01112618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200061-500|A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in the Daily Practice|Pergoveris Non Interventional Study||Merck KGaA||Completed|January 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3247|||Female|N/A|N/A|No|Probability Sample|Subjects undergoing stimulation with Pergoveris for the ovarian stimulation with        intercourse for the optimum (VZO) or with IUI or in preparation for a technology of the        assisted conception such as IVF or ICSI.|April 2011|July 15, 2014|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01112618||123062|
NCT01108289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAT.1429-07882-1|Effect of Prophylactic Administration of Oxytocin in Uniject™ on Postpartum Hemorrhage at Home Births in Ghana|The Oxytocin Initiative: Determining the Effect of Prophylactic Administration of Oxytocin in Uniject™ by a Community Health Officer on Postpartum Hemorrhage at Home Births in Four Districts in Ghana||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1586|||Female|15 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01108289||123395|
NCT01110993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701068-516|An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)|Prospective, Non-interventional, Multicenter Study to Evaluate QoL and Influence of Cognitive Status on QoL in Patients With RRMS During 2 Years Treatment With RNF|MusiClock|Merck KGaA||Completed|November 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Probability Sample|Subjects with Multiple Sclerosis undergoing treatment with Rebif in Poland.|January 2014|January 31, 2014|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01110993||123187|
NCT01108627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3203534014|Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists|||Nemours Children's Clinic|Yes|Terminated|October 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|6 Years|18 Years|No|||May 2012|May 2, 2012|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01108627||123369|
NCT01108640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912006043|Continuous Glucose Monitoring in Critically Ill Surgical Patients|Continuous Glucose Monitoring in Critically Ill Surgical Patients||Yale University|No|Completed|April 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to a surgical intensive care unit and falling into one of the three        groups|June 2014|June 13, 2014|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01108640||123368|
NCT01108653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK sør-øst B:2009/719b|A Structuralised Sick-leave Program Compared to Usual Care Sick Leave Management in Patients After an Acute Myocardial Infarction|A Structuralised Sick-leave Program Compared to Usual Care Sick Leave Management in Patients After an Acute Myocardial Infarction||Oslo University Hospital||Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|N/A|65 Years|No|||January 2010|May 6, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01108653||123367|
NCT01108939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fe_Malaria_Benin|Study of Iron Absorption and Utilization in Asymptomatic Malaria|The Effect of Asymptomatic Malaria on Iron Absorption and Utilization From a Sorghum-based Meal in Adult Women in Benin||Swiss Federal Institute of Technology|No|Completed|February 2009|April 2010|Actual|September 2009|Actual|Phase 0|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Female|16 Years|35 Years|No|||June 2013|June 6, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108939||123345|
NCT01108952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-RE-687-CTIL|The Impact of Chemotherapy on Memory Function and the Development of Traumatic Symptoms in Children With Cancer|The Impact of Chemotherapy on Memory Function and the Development of Traumatic Symptoms in Children With Cancer||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|6 Years|25 Years|No|Non-Probability Sample|children with cancer|April 2010|April 21, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01108952||123344|
NCT01111292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01434|Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia|Myo-Inositol Chemoprevention in Colitis-Associated Dysplasia||National Cancer Institute (NCI)|Yes|Terminated|October 2010|||May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||February 2015|April 6, 2015|April 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111292||123164|
NCT01111877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-041|Natural History Study of Incidence of Otorrhea Following Tympanostomy Tube Insertion in Children 6 Months to 12 Years|||Alcon Research|No|Terminated|May 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|N/A||1|Actual|1389|||Both|6 Months|12 Years|No|Non-Probability Sample|Pediatric patients between the ages of 6 months and 12 years who are undergoing unilateral        or bilateral myringotomy with placement of tympanostomy tube.|January 2012|January 31, 2012|April 26, 2010||No|Management Decision|No||https://clinicaltrials.gov/show/NCT01111877||123119|
NCT01112384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I200|A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas|A Phase II Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas|IND200|Canadian Cancer Trials Group|Yes|Completed|March 2010|January 2014|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|16 Years|N/A|No|||January 2014|March 30, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01112384||123080|
NCT01105429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB122-002|Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes on Background Therapy of Metformin||Bristol-Myers Squibb|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|56|||Both|18 Years|65 Years|No|||November 2010|March 8, 2011|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105429||123614|
NCT01105715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS 112170|Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis|cLDL as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis|cLDL in RA|University of Arkansas|No|Completed|April 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|If a subject consents, any blood samples remaining after the tests planned for this study      will be stored indefinitely for potential future new studies. Any future new studies using      these blood samples will require prior approval by the UAMS Institutional Review Board      (IRB). A subject may request destruction of the stored samples at any time.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the UAMS Rheumatology Clinic at the UAMS Outpatient        Center, Little Rock, other UAMS outpatient clinics, or through advertisement at the UAMS        campus and/or the community.|June 2013|June 18, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105715||123592|
NCT01106261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reference No: 08/0390|A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer|A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer|PulMiCC|University College, London|Yes|Recruiting|April 2010|June 2025|Anticipated|June 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|N/A|No|||June 2015|June 10, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01106261||123550|
NCT01106807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18173|Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne|Exploratory Study to Evaluate the Efficacy and Safety of CD07223 1.5% Gel and 0.5% Gel in Subjects With Acne||Galderma|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|73|||Both|18 Years|35 Years|No|||April 2012|April 18, 2012|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106807||123508|
NCT01106820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEATE-1|Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and Effects on Fatigue and Quality of Life|Progressive Resistance Training vs. Relaxation for Breast Cancer Patients During Chemotherapy: A Randomized Controlled Intervention Trial to Evaluate the Biological Mechanisms and Effects of Resistance Training on Fatigue and Quality of Life|BEATE|German Cancer Research Center|No|Completed|April 2010|October 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Female|18 Years|N/A|No|||March 2015|March 12, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01106820||123507|
NCT01107093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914-007|Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge|A Prospective, Randomized, Double-blind, Cross-Over Study to Compare the Capacity to Prevent Follicular Rupture of CDB-2914 With Placebo, When Administered After the Ovulatory Process Has Been Triggered by the LH Surge||HRA Pharma|No|Completed|May 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|2||Actual|35|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2010|August 24, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01107093||123486|
NCT01107314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0528-H|Vasopressin Deficiency in Hemorrhagic Shock|Vasopressin Deficiency in Hemorrhagic Shock||The University of Texas Health Science Center at San Antonio|No|Completed|February 2010|April 2011|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|81|||Both|18 Years|N/A|No|Probability Sample|observational study - trauma patients admitted to University Hospital|March 2012|March 7, 2012|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107314||123469|
NCT01107327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI18327|Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated Venothromboembolism|FDG PET in Cancer Associated Venothromboembolism||University of Utah|Yes|Completed|August 2006|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be eligible either with provoked or unprovoked DVT.|October 2014|October 29, 2014|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01107327||123468|
NCT01107951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rituximab in PTI 001|Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP|Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for Adult Patients With Immune Thrombocytopenic Purpura.||Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|April 2010|January 2013|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|85 Years|No|||March 2013|March 21, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01107951||123421|
NCT01099813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOT-Light|Sepsis Pathophysiological & Organisational Timing|The Effect of Pathophysiological and Organisational Lead Times to Critical Care on Survival and Resource Utilisation|SPOT(Light)|Intensive Care National Audit & Research Centre|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15602|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Critical Care Units participating in the ICNARC CMP programme who        have been assessed at any time on a ward prior to ICU admission by a critical care        decision maker (e.g. the CCOT or any member of the medical staff on duty for the unit)|May 2014|May 21, 2014|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01099813||124043|
NCT01099826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR008425|Increasing Colorectal Cancer (CRC) Screening In Primary Care|Increasing CRC Screening in Primary Care Settings||Arizona State University|Yes|Completed|October 2004|January 2010|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|511|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 7, 2010|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01099826||124042|
NCT01112358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP26170 (INI25954)|An Exploratory Trial to Assess the Efficacy and Safety of Luveris in Women at Risk of Poor Response Undergoing Controlled Ovarian Stimulation (COS) Prior to Intracytoplasmic Sperm Injection (ICSI) With Gonal-f and Cetrotide|Lutropin Alfa (Luveris®) in Women at Risk of Poor Response Suppressed With Cetrorelix: an Exploratory Trial||Merck KGaA||Completed|November 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|N/A|38 Years|No|||April 2010|July 15, 2014|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112358||123082|
NCT01112371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90011_4023_1|Contractubex Treatment in Scars After Abdominal Caesarean Section|A Prospective, Single-center, Randomized, Parallel Group Trial to Investigate the Efficacy of Contractubex® Gel, Containing Extractum Cepae, Allantoin, and Heparin, in Scars After Abdominal Caesarean Section|ConMex|Merz Pharmaceuticals GmbH|No|Completed|February 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|50 Years|No|||April 2014|April 7, 2014|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01112371||123081|
NCT01112631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPSG01|Prospective Study of Quality of Life in Non-small Cell Lung Cancer (NSCLC) Patients Treated With/Without Postoperative Radiotherapy|Prospective Comparison of Quality of Life and Cardiopulmonary Morbidity After Surgery in Non-small Cell Lung Cancer Patients Treated With and Without Postoperative Radiotherapy||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Completed|April 2003|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|293|||Both|18 Years|N/A|No|Non-Probability Sample|It was assessed that during planned 3 years of accrual approximately 360 stage II patients        treated with surgery alone and approximately 240 stage III patients treated with surgery        and postoperative radiotherapy (PORT) would enter the study.The higher number of        inclusions of pN1 was planned, because of expected higher percentage of cancer related        deaths within two years in pN2 patients.        Patients with pN1 disease were followed in the thoracic surgery center and had no PORT.        Patients with pN2 disease were referred to PORT.|April 2010|September 19, 2011|April 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112631||123061|
NCT01108705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-047|Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment|A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib|BRISK-APS|Bristol-Myers Squibb|Yes|Terminated|May 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01108705||123363|
NCT01108718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIMC 015-09|Study of Mattress Type in Fibromyalgia|Study of Mattress Type in Fibromyalgia||Beth Israel Medical Center|No|Completed|July 2009|July 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Female|18 Years|N/A|No|||June 2013|June 10, 2013|March 23, 2010||No||No|February 3, 2012|https://clinicaltrials.gov/show/NCT01108718||123362|
NCT01112436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChunaAngUH|The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement|The Effect of Periarticular Injection of Multi-drug Regimen on Pain in Patient Receiving Partial Hip Replacement:Randomized Prospective Study.||Chung-Ang University Hospital|No|Recruiting|May 2010|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|258|||Both|N/A|N/A|No|||April 2010|June 23, 2011|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01112436||123076|
NCT01112709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK082383-01A1|Maintaining Resistance Training in Older Prediabetic Adults|Maintaining Resistance Training in Older Prediabetic Adults: Theoretical Approach||Virginia Polytechnic Institute and State University|Yes|Completed|January 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|170|||Both|50 Years|69 Years|No|||March 2014|March 19, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01112709||123055|
NCT01108380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-GS-HBP3|Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells|Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy||Seoul National University Hospital|Yes|Recruiting|January 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||December 2010|December 14, 2010|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108380||123388|
NCT01109771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/702|Absorbable Versus Permanent Mesh Fixation Trial in Laparoscopic Midline Ventral Hernia Repair|Absorbable Versus Permanent Mesh Fixation Trial in Laparoscopic Midline Ventral Hernia Repair (SORBET Trial)|SORBET|University Hospital, Ghent|No|Recruiting|April 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109771||123281|
NCT01110304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-337|Acromio-clavicular Dislocation Type III - Conservative Treatment Versus Surgical Hook Plate Treatment|Acromio-clavicular Joint Dislocation Type III. Conservative Treatment Compared to Surgical Management With 3.5mm Clavicle Hook Plate. A Prospective Randomized Study||Hopital de l'Enfant-Jesus|No|Recruiting|May 2007|February 2015|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|60 Years|No|||December 2012|December 19, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01110304||123240|
NCT01111890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-17|Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension|||Alcon Research|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||January 2012|July 27, 2015|April 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01111890||123118|
NCT01111903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REV (GINECO-OV214)|A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse|A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.|REV|ARCAGY/ GINECO GROUP|Yes|Completed|May 2009|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111903||123117|
NCT01112683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0934|Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome|A Sixteen-Week, Randomized, Double Blind, Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Young Adults With Down Syndrome||University of Colorado, Denver|Yes|Completed|July 2008|August 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|32 Years|No|||December 2012|December 26, 2012|April 23, 2010|Yes|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT01112683||123057|
NCT01106274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUMS-88191|The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy|Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking|C3R|Mashhad University of Medical Sciences|No|Completed|November 2008|September 2009|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|20|||Both|20 Years|80 Years|No|||October 2008|April 16, 2010|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106274||123549|
NCT01106287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0941-027|Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)|A Study of Higher Single Doses of MK-0941 in Type 2 Diabetics||Merck Sharp & Dohme Corp.|No|Completed|October 2009|March 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|April 16, 2010|No|Yes||No|July 3, 2012|https://clinicaltrials.gov/show/NCT01106287||123548|
NCT01106534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-374C|XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort|XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)|XVU-AV DAPT|Abbott Vascular|Yes|Completed|August 2009|July 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|870|||Both|N/A|N/A|No|||April 2015|April 8, 2015|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106534||123529|
NCT01107106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914-010|Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women|Prospective Observational Single Arm Open-Label Multicenter Study to Assess the Safety, Tolerability and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Adult Women||HRA Pharma|No|Completed|May 2010|February 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|579|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents and adult women seeking emergency contraception in family planning centers and        youth clinics in Sweden|May 2013|May 14, 2013|April 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01107106||123485|
NCT01107340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01.004.11|AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study|AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study||Medacta International SA||Recruiting|February 2010|February 2024|Anticipated|February 2024|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|N/A|N/A|No|||March 2013|March 15, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01107340||123467|
NCT01107353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIP-C75-PVFS-1|Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Imipramine Pamoate Capsules, 75 mg, Under Fasted Conditions||Roxane Laboratories|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|April 19, 2010||No||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01107353||123466|
NCT01108224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Camma 2003|Psychotherapy to Patients With Primary Breast Cancer - Psycho-social and Survival Outcome From a Randomised Trial|Psychosocial Group Intervention to Patients With Primary Breast Cancer - Psychosocial and Survival Outcome From a Randomised Study||Danish Cancer Society|No|Completed|January 2004|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|210|||Female|18 Years|70 Years|No|||January 2004|April 20, 2010|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01108224||123400|
NCT01100450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000083|Progressive Resistance Training in Patients With Class III Obesity|Pilot Study to Determine Feasibility, Acceptance, and Efficacy of a 12-week Progressive Resistance Training Exercise Protocol in Patients With Class III Obesity Preparing for Bariatric Surgery.||Beth Israel Deaconess Medical Center|Yes|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|6|||Both|18 Years|65 Years|No|||December 2013|December 19, 2013|October 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01100450||123996|
NCT01109511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|targiniqoxycodulleval|A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy|||Oslo University Hospital||Recruiting|April 2010|July 2011|Anticipated|April 2010|Actual|Phase 4|Interventional|N/A|2||||||Female|18 Years|70 Years||||April 2010|July 20, 2011|April 15, 2010||||No||https://clinicaltrials.gov/show/NCT01109511||123301|
NCT01109524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA225-346|Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer|Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study||Eli Lilly and Company|No|Completed|July 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|April 22, 2010|Yes|Yes||No|September 12, 2013|https://clinicaltrials.gov/show/NCT01109524||123300|
NCT01109797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12157|Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care|A Comparison of Two Models for Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care||University of Kansas Medical Center|No|Completed|April 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|16 Years|29 Years|No|||May 2014|May 23, 2014|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01109797||123279|
NCT01112176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-10-HYMC-CTIL|Effect of Heart Rate on Left Ventricular Performance|Effect of Heart Rate on Left Ventricular Performance||Hillel Yaffe Medical Center|No|Recruiting|April 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2010|April 27, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01112176||123096|
NCT01112644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3502|Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate Improvement of Symptoms of RLS in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms Who Take OXN PR Compared to Subjects Taking Placebo (PLA).||Mundipharma Research GmbH & Co KG|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01112644||123060|
NCT01112722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-13|Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis|A Multicenter, Randomized, Double Blind, Active Controlled, Parallel Group, Clinical Study, to Evaluate the Safety and Efficacy of Apitox vs Histamine in Subjects With Refractory Osteoarthritis Pain and Inflammation of the Knee||Apimeds, Inc.|Yes|Recruiting|December 2013|December 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|330|||Both|30 Years|85 Years|No|||February 2015|March 4, 2015|April 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112722||123054|
NCT01108666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01510|Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)|Phase I Dose Escalation Trial of Proton Beam Radiotherapy With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III NSCLC||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|March 2010|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Anticipated|72|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01108666||123366|
NCT01109472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X080401004|Improving Osteoporosis Care in a Home Health Setting|||University of Alabama at Birmingham|No|Completed|April 2009|November 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|1009|||Both|50 Years|N/A|No|||December 2013|December 20, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01109472||123304|
NCT01110967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Satellite Retrospective|Satellite™ PEEK Nucleus Replacement Retrospective Analysis|Satellite™ PEEK Nucleus Replacement Retrospective Analysis||Medtronic Spinal and Biologics|No|Completed|April 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who were implanted with a Satellite™ Nucleus Replacement device at the        participating sites are eligible for participation in the Satellite ™ Retrospective        Analysis.|January 2016|January 26, 2016|April 15, 2010||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01110967||123189|Due to the retrospective design, it was not possible to report on SF-36 results and Modic endplate changes results as limited data was available in the patient records.
NCT01104454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111576|Placenta and Cord Blood Analyses|Placenta and Cord Blood Analyses||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|March 2010|September 2016|Anticipated|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|Samples With DNA|placenta, umbilical cord and cord blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who are at least 7 months pregnant|September 2015|September 9, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104454||123689|
NCT01104740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/B/01|Dengue Seroprevalence Study in Blood Donors in the French West Indies|Dengue Seroprevalence Study in Blood Donors in the French West Indies|DengSeroprevAn|Etablissement Français du Sang, Martinique|No|Not yet recruiting|June 2010|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|770|Samples Without DNA|serum|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult, résidents in Martinique/ Guadeloupe (french west indies), aged 18 to 65 years        coming to give their blood in one of the building or mobile collection facilities of the        French Blood Establishment in French West Indies.|April 2010|April 14, 2010|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104740||123667|
NCT01104753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999907 CS07|A Study of Pentasa in Patients With Ulcerative Colitis|Non-interventional Post Marketing Safety Study Confirming Efficacy and Safety of Pentasa Slow Release Tablets in Patients With Ulcerative Colitis in Common Clinical Practice||Ferring Pharmaceuticals|No|Completed|September 2009|March 2011|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|338|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from ulcerative colitis|April 2011|April 6, 2011|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01104753||123666|
NCT01105078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI001AZ-AHK|Optimal Flow Rate During Cardiopulmonary Bypass|Optimal Flow Rate During Cardiopulmonary Bypass||Johann Wolfgang Goethe University Hospitals|No|Recruiting|May 2010|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105078||123641|
NCT01105091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-066A401|Epoprostenol for Injection in Pulmonary Arterial Hypertension|A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)|EPITOME-1|Actelion|No|Completed|March 2010|July 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||November 2012|November 29, 2012|April 15, 2010|No|Yes||No|July 20, 2012|https://clinicaltrials.gov/show/NCT01105091||123640|The EPITOME-1 study is an open label study without a primary endpoint. The sample size was determined based on feasibility and not a power calculation.
NCT01105988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008|Evaluating Tumor Pseudoprogression With FLT-PET and MRI|A Pilot Study to Evaluate Tumor Pseudoprogression With FLT-PET and MRI||Massachusetts General Hospital|Yes|Terminated|May 2011|October 2011|Actual|October 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|April 15, 2010||No|Funding ended|No||https://clinicaltrials.gov/show/NCT01105988||123571|
NCT01106001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM-042008-014|Study to Test the Efficacy of Periarticular Levo Bupivicaine Injection Following Primary Hip Arthroplasty|A Double Blind Randomized Control Trial on the Efficacy of Periarticular Levo Bupivicaine Injection Following Primary Hip Arthroplasty||Orthopaedic Research and Innovation Foundation|Yes|Completed|September 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||July 2008|April 16, 2010|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01106001||123570|
NCT01106300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/0167|Musculoskeletal Ultrasound Study in Critical Care: Longitudinal Evaluation|Assessment of Peripheral Muscle and Bone Mass in the Critically Ill and Its Response to External Muscle Stimulation|MUSCLE|University College, London|Yes|Completed|February 2009|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|63|Samples With DNA|quadricep muscle biopsy, blood and urine samples|Both|18 Years|N/A|No|Non-Probability Sample|All admission to CRitical care who are ventilated, and are likely to remain so for 48hrs        or more AND remain on ITU for 7 days|April 2014|December 17, 2015|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106300||123547|
NCT01106872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4761s|Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas|A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas||University of Iowa|Yes|Recruiting|September 2010|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|March 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01106872||123503|
NCT01106885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DK066166-01A1|Effective Care Management of Depressed Diabetes Patients (The Positive Steps Study)|Effective Care Management of Depressed Diabetes Patients||University of Michigan|No|Completed|May 2005|April 2011|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|339|||Both|21 Years|80 Years|No|||April 2015|April 24, 2015|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106885||123502|
NCT01106521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBSI Registry|A Registry Study of Permanent Breast Seed Implant|A Multicentre Registry Study of Permanent Breast Seed Implant (PBSI) for Early Stage Breast Cancers.||Sunnybrook Health Sciences Centre|Yes|Recruiting|March 2009|March 2024|Anticipated|March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|420|||Female|50 Years|N/A|No|||February 2013|February 28, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01106521||123530|
NCT01106833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0801|Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)|A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN Protocol #0801)||Medical College of Wisconsin|Yes|Active, not recruiting|April 2010|March 2019|Anticipated|March 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|N/A|N/A|No|||January 2016|January 7, 2016|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106833||123506|
NCT01107119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21528|Integrated Care Pathways in a Community Setting|Enabling Elderly Patients to Manage Their Own Lives - A Systematic Management Program for Home Care Services.||Norwegian University of Science and Technology|No|Completed|October 2009|October 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|304|||Both|70 Years|N/A|No|||February 2015|February 1, 2015|April 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01107119||123484|
NCT01107366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLANTIS BOLOGNA|ATLANTIS:Extensive Type A Dissections and Thoracic/ Thoraco-Abdominal Aneurysms Repair With LupiAe Hybrid TechNique|Extensive Type A Dissections and Thoracic/ Thoraco-Abdominal|ATLANTIS|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Withdrawn|June 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|April 20, 2010||No|The study never started since our Medical Ethic Commeettee did not approved it|No||https://clinicaltrials.gov/show/NCT01107366||123465|
NCT01112280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KASID polyp-01|Efficacy of Cap-assisted Chromoendoscopy as a Screening Test for Colorectal Neoplasm Using Web-based Research Network|Prospective Randomized Controlled Trial of Cap-Assisted ChromoEndoscopy(CapACE) Versus Conventional Colonoscopy(CC) for the Detection and 3-year Recurrence Rate of Colorectal Neoplasia|CapACE|Korean Association for the Study of Intestinal Diseases|Yes|Recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2000|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112280||123088|
NCT01101087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2009/BB|Taurolock for Preventing Bacterial Peritonitis During Renal Insufficiency|Efficacity of Taurolock in Preventing Primary Bacterial Peritonitis in Patients Undergoing Peritoneal Dialysis for Renal Insufficiency: a Randomized, Multicenter, Double Blind Study With Placebo||Centre Hospitalier Universitaire de Nīmes|Yes|Completed|July 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101087||123947|
NCT01101100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090403|Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis|A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Psoriasis||Amgen|No|Terminated|April 2010|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|181|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|April 1, 2010|Yes|Yes|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT01101100||123946|
NCT01110343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090965|Conventional vs Mindfulness Intervention in Parents of Children With Disabilities|Conventional Versus Mindfulness Intervention in Parents of Children With Disabilities|PSIP|Vanderbilt University|No|Completed|February 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|17 Years|85 Years|No|||April 2010|June 2, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01110343||123237|
NCT01110707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 25186|A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve|Lutropin Alpha in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve: Comparative Study, in Phase II, With Parallel Control||Merck KGaA||Completed|January 2005|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Female|35 Years|40 Years|No|||April 2010|July 15, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01110707||123209|
NCT01110720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-108-231|Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy|A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy||Allon Therapeutics|Yes|Completed|October 2010|December 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|313|||Both|41 Years|85 Years|No|||January 2013|January 15, 2013|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01110720||123208|
NCT01112657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200077-504|An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period|A Prospective, Observational Study On The Progression Of Clinically Isolated Syndrome (CIS) To Multiple Sclerosis Over A 2-year Period|NEO|Merck KGaA|No|Completed|November 2008|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|154|Samples Without DNA|Whole blood|Both|6 Years|60 Years|No|Non-Probability Sample|Subjects who have experienced a single, first clinical event potentially suggestive of MS        within the last 2 years from study entry.|November 2014|November 12, 2014|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01112657||123059|
NCT01108328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX Crossover Study|Evaluation of Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX)|A Prospective, Single Crossover, Randomized, Double Blind Placebo Controlled Trial Evaluating Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX) vs. Rice Flour Control, in Overweight and Moderately Obese Females.||Canadian Center for Functional Medicine||Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108328||123392|
NCT01108341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/2048|Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)|An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)||Teva Pharmaceutical Industries|No|Completed|May 2010|October 2011|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|April 14, 2010|Yes|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT01108341||123391|
NCT01109485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPN-P-2010-1|Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients|||Alcon Research|No|Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|7 Years|15 Years|No|||September 2011|May 11, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01109485||123303|
NCT01104467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11764A|Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke|Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke|DIAS-J|Lundbeck Japan K. K.|Yes|Completed|August 2010|||August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|20 Years|85 Years|No|||October 2015|October 14, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01104467||123688|
NCT01104480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP2010|Tocilizumab for Relapsing Polychondritis|Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis||McMaster Children's Hospital|No|Withdrawn|May 2010|May 2012|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|12 Years|15 Years|No|||May 2014|May 12, 2014|April 13, 2010|Yes|Yes|Tocilizumab was licenced in Canada for children, so the study was not necessary|No||https://clinicaltrials.gov/show/NCT01104480||123687|
NCT01104493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-VA-FluMist-1045|A Clinical Study to Assess the Safety of a New Influenza Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety of a New 6:2 Influenza Virus Reassortant||MedImmune LLC|No|Completed|May 2010|December 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2011|July 14, 2011|April 13, 2010|Yes|Yes||No|June 14, 2011|https://clinicaltrials.gov/show/NCT01104493||123686|
NCT01104779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-05|Safety and Efficacy of Cariprazine in Schizophrenia|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia||Forest Laboratories|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|459|||Both|18 Years|60 Years|No|||December 2012|December 6, 2012|April 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104779||123664|
NCT01105104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43HL097395-01A1|An Enhanced Medication Monitoring Program|An Enhanced Medication Monitoring Program||MedMinder Systems Inc.|Yes|Recruiting|September 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|55 Years|N/A|No|||November 2011|November 7, 2011|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105104||123639|
NCT01105117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-066A402|Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401|An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)|EPITOME-1 Ext|Actelion|No|Completed|May 2010|December 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|No|||November 2012|November 29, 2012|April 15, 2010|No|Yes||No|July 20, 2012|https://clinicaltrials.gov/show/NCT01105117||123638|
NCT01105468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC1|Breath Gas Analysis for the Diagnosis of Breast Cancer|Leistungsbewertungsprüfung: Atemluftanalyse für Die Diagnose Von Brustkrebs, für Die Überwachung Der Therapie Und für Die Voraussage Des Metastasenrisikos||Ionimed Analytik GmbH|No|Terminated|April 2010|April 2017|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|202|||Female|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|January 2013|January 11, 2013|April 8, 2010||No|Sponsor quit partnership in Oncotyrol-Center for Personalized Medicine, and consequential loss    of public funding.|No||https://clinicaltrials.gov/show/NCT01105468||123611|
NCT01105754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25281|A Multifaceted Prompting Intervention for Urban Children With Asthma|A Multifaceted Prompting Intervention for Urban Children With Asthma|PAIR-UP|University of Rochester|No|Completed|October 2008|December 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|638|||Both|2 Years|12 Years|No|||January 2016|January 15, 2016|April 15, 2010||No||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01105754||123589|
NCT01106014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-065A302|Selexipag (ACT-293987) in Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension|GRIPHON|Actelion|Yes|Completed|December 2009|October 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1156|||Both|18 Years|75 Years|No|||February 2016|March 16, 2016|April 2, 2010|Yes|Yes||No|February 2, 2016|https://clinicaltrials.gov/show/NCT01106014||123569|
NCT01106547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hysterektomistudiet|The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy|The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy: A Prospective, Double Blinded, Placebo Controlled Study||Holbaek Sygehus|Yes|Completed|August 2009|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|55|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 12, 2011|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01106547||123528|
NCT01106560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01.004.12 rev.01|A Randomised Trial Comparing Anterior Versus Posterior Approach in Total Hip Replacement|A Single Centre Prospective Randomised Controlled Clinical Trial Comparing Total Hip Arthroplasty Performed Either Through a Posterior Approach or a Direct Anterior Approach||Medacta International SA||Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||April 2015|April 14, 2015|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01106560||123527|
NCT01107158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2009/KM-01|LXRs, Cholesterol Metabolism and Uterine Dystocia|The Role of Two Nuclear Receptors for Oxysterols as a Molecular Cause of Uterine Dystocia: LXR Alpha and LXR Beta||Centre Hospitalier Universitaire de Nīmes|No|Terminated|April 2010|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|58|Samples With DNA|A whole blood sample is taken and DNA extracted using Qiagen kits.|Female|18 Years|N/A|No|Non-Probability Sample|The study population represents women undergoing a difficult, stagnating labor due to        either physical or uterine dystocia.|November 2015|November 19, 2015|April 14, 2010||No|Inclusion curve too slow.|No||https://clinicaltrials.gov/show/NCT01107158||123481|
NCT01106846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00026695|Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery|Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery||Northwestern University|No|Terminated|March 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Female|18 Years|65 Years|No|||July 2015|July 20, 2015|April 16, 2010|Yes|Yes|Resources not available to complete.|No|June 18, 2015|https://clinicaltrials.gov/show/NCT01106846||123505|Study was terminated early.
NCT01106859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZI-18|Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet|Assessment of Next-Morning Driving Performance After Middle of the Night Administration of Zolpidem Tartrate Sublingual Tablet 3.5 mg in Healthy Adult Volunteers: Single-center, Double-blind, Randomized, Placebo-controlled, Four-way Crossover Study||Transcept Pharmaceuticals|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|April 16, 2010|No|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT01106859||123504|No studies directly connect SDLP thresholds with an increased risk of an accident for an individual. Nor has a SDLP threshold been adopted by a regulatory body. Based on published literature, an SDLP change of 2.5 cm was used in the primary outcome.
NCT01107379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005010|Optimization and Refinement of Technique in In-Office Sinus Dilation 2|Optimization and Refinement of Technique in In-Office Sinus Dilation 2 (ORIOS 2)|ORIOS 2|Acclarent|No|Completed|April 2010|July 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|203|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with diagnosis of CRS and planned endoscopic sinus surgery.|September 2014|September 13, 2014|April 12, 2010|Yes|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT01107379||123464|
NCT01107392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-100|Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia|||Allergan|No|Completed|August 2010|June 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|315|||Male|45 Years|N/A|No|||February 2014|February 24, 2014|April 16, 2010|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01107392||123463|
NCT01107678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL16198|YMCA-Physical Activity and Nutrition|The YMCA After School Program of Physical Activity and Nutrition|YMCA-PAN|University of Kansas Medical Center|Yes|Completed|July 2007|June 2013|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|966|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01107678||123442|
NCT01111773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-204|Study Evaluating a Heated Lidocaine and Tetracaine Topical Patch in the Treatment of Patients With Patellar Tendinopathy|An Open-label Pilot Study Evaluating Synera® in the Treatment of Patients With Patellar Tendinopathy||ZARS Pharma Inc.|No|Completed|June 2010|May 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111773||123127|
NCT01111344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-1002-CU|Glizigen-Viudid-External Anogenital Warts in Children and Adolescents|Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents.||Catalysis SL|Yes|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|10 Years|18 Years|No|||May 2012|May 6, 2012|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111344||123160|
NCT01111357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/B/02|Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis|Study of HLA Polymorphisms in French West-Indian Patients With Rheumatoid Arthritis : A Case Control Study|HLAPRPA|Centre Hospitalier Universitaire de Fort-de-France|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|whole blood : collect of 10 ml of peripheric blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Martinique with at least 3 African-Caribbean grandparents|April 2010|December 20, 2010|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01111357||123159|
NCT01111656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75/07|Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b|SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study ("SWABIMS Follow Up-study")||University Hospital Inselspital, Berne|Yes|Completed|March 2007|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|67 Years|No|||September 2011|September 6, 2011|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01111656||123136|
NCT01111669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901|Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery|Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery: A Double Blind Randomized Controlled Trial||University of Alberta|No|Completed|August 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|17 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 25, 2012|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01111669||123135|
NCT01108133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-fMRI-PTSD|Neural and Pharmacological Correlates of Intrusions in Patients With Posttraumatic Stress Disorder|Neural and Pharmacological Correlates of Intrusions in Patients With Posttraumatic Stress Disorder||Central Institute of Mental Health, Mannheim|Yes|Recruiting|October 2010|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|20|||Female|18 Years|45 Years|No|||January 2013|January 29, 2013|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01108133||123407|
NCT01108146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPA-PTSD-1|Hydrocortisone in the Treatment of Intrusions in Patients With Posttraumatic Stress Disorder|Monocentric, Double-blind Placebo-Controlled, Randomized Cross-Sectional Clinical Trial of Hydrocortisone (10 and 30 mg/d) in Outpatients With Posttraumatic-Stress-Disorder (PTSD)||Central Institute of Mental Health, Mannheim|Yes|Completed|October 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Female|18 Years|45 Years|No|||January 2013|January 29, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01108146||123406|
NCT01109225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00537-50|Relation Between Aldosterone and Cardiac Remodeling After Myocardial Infarction|Multiparametric Study of Cardiac Remodeling After Myocardial Infarction Revascularized in Acute Phase : Relation With the Serum Concentrations in Aldosterone|REMI|Central Hospital, Nancy, France|No|Recruiting|April 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01109225||123323|
NCT01104168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035147|Diabetes in the Elderly: Retrospective Study|Diabetes Care in Nursing Home Residents||Emory University|No|Completed|May 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1409|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|older adults ages 65+ admitted to two large long-term care facilities|November 2013|November 12, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01104168||123711|
NCT01104181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09-HPV-001|Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test|Collection of Anal Specimens for Assessment of Anal Cancer Using the HC2 High-Risk DNA Test (QIAGEN)||Laser Surgery Care|Yes|Completed|March 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|300|||Both|18 Years|90 Years|No|||June 2011|June 21, 2011|March 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104181||123710|
NCT01104766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-04|Safety and Efficacy of Cariprazine in Patients With Schizophrenia|A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia||Forest Laboratories|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|617|||Both|18 Years|60 Years|No|||January 2012|January 9, 2012|April 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104766||123665|
NCT01105442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC2010-18|Local Anaesthesia Used During Fast-track Colonic Surgery: Evaluation of Bupivacaine and Levobupivacaine in Practice|Local Anaesthesia Used During Fast-track Colonic Surgery: Evaluation of Bupivacaine and Levobupivacaine in Practice||Martini Hospital Groningen|Yes|Completed|April 2010|July 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|14|||Both|N/A|N/A|No|Probability Sample|Martini Hospital Groningen|March 2010|July 20, 2011|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105442||123613|
NCT01105728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2632/09|Endoscopic Resection of Gastric Subepithelial Masses, EndoResect Study|Endoscopic Resection of Gastric Subepithelial Masses, EndoResect Study|EndoResect|Technische Universität München|No|Completed|April 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01105728||123591|
NCT01105741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-22684|Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)|Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)|MB|University of Calgary|No|Completed|June 2010|December 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples Without DNA|Serum, plasma and urine|Both|18 Years|N/A|No|Non-Probability Sample|Crohn's disease, active disease|February 2014|February 4, 2014|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01105741||123590|
NCT01105767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-055|Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees|Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees||Uniformed Services University of the Health Sciences|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30209|||Male|18 Years|42 Years|Accepts Healthy Volunteers|||May 2014|November 2, 2014|April 14, 2010||No||No|March 6, 2014|https://clinicaltrials.gov/show/NCT01105767||123588|
NCT01105780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017083|JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study|Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male and Female Caucasian and Male Japanese Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2010|August 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|April 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01105780||123587|
NCT01106313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02172010-5003|Insulin Resistance in Patients With Major Depression|Insulin Resistance in Patients With Major Depression||Stanford University||Active, not recruiting|July 2009|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|90|Samples With DNA|Optional buffy coat sample|Both|20 Years|65 Years|No|Non-Probability Sample|Men and women ages 20 to 65 years of age of any ethnic background, with a diagnosis of        depression, and whose depressive symptoms are currently in remission|June 2012|May 14, 2014|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01106313||123546|
NCT01106898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|371-09|Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery|A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients||University of Nebraska|Yes|Recruiting|March 2010|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Female|19 Years|N/A|No|||May 2013|May 14, 2013|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01106898||123501|
NCT01111136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0052|Stress Intervention for Chronic Urticaria|Effect of Psychological Stress Intervention for Patients With Chronic Urticaria||University of Mississippi Medical Center|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|64 Years|No|||November 2010|November 23, 2010|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01111136||123176|
NCT01107132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR495710ctil|Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus|Blood-retinal Barrier Imaging in Type 2 Diabetes Mellitus: a Window for Blood-brain Barrier Breakdown and Neuropsychiatric Sequela||Soroka University Medical Center|Yes|Not yet recruiting|May 2010|||||N/A|Observational|Observational Model: Cohort||1|Anticipated|100|Samples Without DNA|• Fluorescein Angiography        1. Investigation and documentation of the retinal and choroidal vascular systems integrity           by intravenous administration of sodium fluorescein        2. FA images are recorded in a central database with restricted accesses and are routinely           analyzed by the eye specialist|Both|18 Years|75 Years|No|Probability Sample|Type 2 Diabetes Mellitus Patient suffering from Non-Proliferative Diabetic Retinopathy        (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema|April 2010|April 19, 2010|April 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01107132||123483|
NCT01107145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAACT-PV|Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)|A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil|PAACT-PV|Centers for Disease Control and Prevention|Yes|Terminated|February 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Female|15 Years|N/A|No|||April 2012|April 12, 2012|April 19, 2010||No|Extremely slow enrollment|No||https://clinicaltrials.gov/show/NCT01107145||123482|
NCT01107691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL17623|Comparison of 1 vs 3 Sets of Resistance Training on Muscular Hypertrophy|Resistance Training Energy Balance & Weight Management||University of Kansas Medical Center|Yes|Completed|April 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|169|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01107691||123441|
NCT01107964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33794|Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome|Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome||Milton S. Hershey Medical Center|Yes|Completed|July 2010|||August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|April 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01107964||123420|
NCT01112306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-065A303|ACT-293987 in Pulmonary Arterial Hypertension|Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension||Actelion|Yes|Active, not recruiting|December 2009|February 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|670|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|April 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112306||123086|
NCT01101425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-10085|Male Breast Cancer: Understanding the Biology for Improved Patient Care|Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.||European Organisation for Research and Treatment of Cancer - EORTC|No|Recruiting|December 2010|||August 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Male|18 Years|N/A|No|Non-Probability Sample|Retrospective part: males with histologically proven invasive breast carcinoma diagnosed        since 1990 to 2010.        Prospective part: all men, with histologically proven invasive breast cancer, newly        presenting at the center irrespective of the stage of disease, initial diagnosis date or        treatment received.|October 2015|October 2, 2015|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01101425|10 Years|123921|
NCT01101438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA32|A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer|A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer||Canadian Cancer Trials Group|Yes|Active, not recruiting|July 2010|June 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3649|||Both|18 Years|74 Years|No|||March 2016|March 10, 2016|April 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01101438||123920|
NCT01101451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0263|Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery|Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy||Gynecologic Oncology Group|Yes|Recruiting|April 2010|||December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|534|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|April 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01101451||123919|
NCT01111942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB-SCCI 10-001-1|A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer|A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer||Southern Illinois University|Yes|Terminated|February 2010|January 2014|Actual|January 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|4|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|April 26, 2010|Yes|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT01111942||123114|
NCT01111955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB121-002|Safety Study of BMS-823778 in Subjects With Type 2 Diabetes|A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin||Bristol-Myers Squibb|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111955||123113|
NCT01104506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/2-A|Elaboration of a Pre-surgery Mapping Protocol of Primary Motor Cortex, Prior to an Implementation of a Stimulation of Primary Motor Cortex for Patients With Deafferentiation of Brachial Plexus Pain|Elaboration of a Pre-surgery Mapping Protocol of Primary Motor Cortex, Prior to an Implementation of a Stimulation of Primary Motor Cortex for Patients With Deafferentiation of Brachial Plexus Pain|CCPB|Nantes University Hospital|No|Terminated|April 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|December 13, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01104506||123685|
NCT01103921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715772|The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks|Effects of 2-weeks Fructose & HFCS Consumption on Dyslipidemia & Insulin Resistance|DRS|University of California, Davis|Yes|Completed|October 2008|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|4||Actual|214|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103921||123730|
NCT01104194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07.063|Effects of Fish-oil on Mood and Cognitive Functions of Healthy Individuals|The Effects of Omega-3 Fatty Acids Dietary Supplements (Fish-oil) on Mood and Cognitive Functions of Healthy Individuals||Leiden University Medical Center|No|Completed|September 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 8, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01104194||123709|
NCT01104207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7448-I|Transcranial Magnetic Stimulation for Tinnitus|Clinical Trial of Transcranial Magnetic Stimulation for Relief of Tinnitus||VA Office of Research and Development|No|Active, not recruiting|March 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|168|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104207||123708|
NCT01105455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH REB 09-0263-E|The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Pregnant Women at Risk for Gestational Diabetes|The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Pregnant Women at Risk for Gestational Diabetes||University of Toronto|No|Completed|March 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|103|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01105455||123612|
NCT01104831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:035|The Efficacy and Cost Effectiveness of Preoperative and Postoperative Cryotherapy in Proximal Tibia Fractures|The Efficacy and Cost Effectiveness of Preoperative and Postoperative Cryotherapy in Proximal Tibia Fractures|ARCTIC CAT|University of Manitoba|Yes|Recruiting|April 2010|November 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|17 Years|N/A|No|||April 2011|April 4, 2011|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104831||123660|
NCT01105169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100106|Personalized Prevention of Colorectal Cancer Trial|Investigational Nutrigenetic Studies for Cancer Prevention||Vanderbilt University||Recruiting|August 2010|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|250|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105169||123634|
NCT01106326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28198|A Pilot Study to Improve Preventive Asthma Care for Urban Adolescents|A Pilot Study to Improve Preventive Asthma Care for Urban Adolescents||University of Rochester|No|Completed|September 2009|September 2012|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Both|12 Years|15 Years|No|||July 2014|July 25, 2014|April 16, 2010||No||No|June 15, 2011|https://clinicaltrials.gov/show/NCT01106326||123545|
NCT01106573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBF2010-01|Associations Between Diabetes, Arterial Stiffness and Fibulin-1 in Patients Undergoing Heart- and Vascular Surgery?|Is There an Association Between the Presence of Diabetes, the Degree of Arterial Stiffness and a New Plasma Marker for Vascular Elasticity, Fibulin-1 in Patients Undergoing Heart- and Vascular Surgery?||Odense University Hospital|Yes|Not yet recruiting|June 2010|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1400|Samples With DNA|In this study we will collect serum, whole blood and urine|Both|18 Years|N/A|No|Non-Probability Sample|The cohort will be selected from patients undergoing planned heart and vascular surgery at        our department.|April 2010|April 19, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01106573||123526|
NCT01106586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0103|Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults||Gilead Sciences|Yes|Completed|April 2010|September 2014|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|708|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|April 14, 2010|Yes|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01106586||123525|There were no limitations affecting the analysis or results.
NCT01110564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RTR-DUM-2009/1|Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease|A Cross-sectional Observational Study to Investigate Daily Symptom Variability, Effects of Symptom on Morning Activities and Therapeutic Expectations of Patients and Physicians in Chronic Obstructive Pulmonary Disease - SUNRISE Study||AstraZeneca||Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|515|||Both|45 Years|N/A|No|Non-Probability Sample|Chronic Obstructive Pulmonary Disease (COPD)|January 2011|January 27, 2011|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110564||123220|
NCT01107405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|584|Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge|Efficacy of Loteprednol Etabonate Ophthalmic Base Compared to Loteprednol Etabonate Ophthalmic Suspension vs Placebo in a Modified Conjunctival Allergen Challenge(CAC) Model||Bausch & Lomb Incorporated|No|Completed|April 2010|August 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|101|||Both|10 Years|N/A|No|||February 2012|February 14, 2012|April 15, 2010|Yes|Yes||No|September 21, 2011|https://clinicaltrials.gov/show/NCT01107405||123462|
NCT01111487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-500|Activity of Inspiratory Muscles With the Use of Positive Pressure in Patients With Chronic Obstructive Pulmonary Disease|Inspiratory Muscle Recruitment in COPD Patients With the Use of Expiratory Positive Airways Pressure||Hospital de Clinicas de Porto Alegre|No|Completed|November 2009|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|70 Years|No|||September 2011|September 25, 2011|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111487||123149|
NCT01111760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2010-082|Radiation Dose From Computed Tomography Before and After Implementation of a High Pitch Dual Spiral Technique|Radiation Dose From Computed Tomography Before and After Implementation of a High Pitch Dual Spiral Technique|FLASH|William Beaumont Hospitals|No|Completed|May 2010|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|334|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|any patient receiving a coronary CT scan and a chest CT for pulmonary embolisms, pulmonary        nodules, aortic pathologies|April 2013|April 3, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01111760||123128|
NCT01112046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2009.625|Endoscopic Submucosal Dissection Versus Laparoscopic Resection for Early Colorectal Neoplasms|Endoscopic Submucosal Dissection Versus Laparoscopic Resection for Early Colorectal Neoplasms: A Prospective Randomized Trial||Chinese University of Hong Kong|No|Recruiting|April 2010|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01112046||123106|
NCT01101152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-2009036|Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers|Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Females and Males|DVS|University of Ottawa|No|Recruiting|April 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2010|August 4, 2011|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01101152||123942|
NCT01101165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1005|To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 40-mg Tablets to OxyContin® 40-mg Tablets||Purdue Pharma LP|No|Completed|February 2007|July 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|92|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|April 8, 2010|Yes|Yes||No|April 13, 2010|https://clinicaltrials.gov/show/NCT01101165||123941|
NCT01107574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-01-2004|Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative Medicine|Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia|FTTGO|Good Samaritan Regional Medical Center, Oregon|Yes|Completed|April 2004|April 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107574||123449|
NCT01107587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113518|Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants|Reactogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine 444563, in Healthy Infants||GlaxoSmithKline||Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|6 Weeks|16 Weeks|Accepts Healthy Volunteers|||February 2011|September 20, 2012|April 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01107587||123448|
NCT01107600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSPFBF-NB-02|Study on Immediate Loading of Immediately Placed Single Implants.|Study on Immediate Loading of Immediately Placed Single Implants in Extraction Sockets With Nobel Active™ Implants and Bio-oss®.||Hospital San Pietro Fatebenefratelli|Yes|Not yet recruiting|June 2010|June 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|25 Years|N/A|Accepts Healthy Volunteers|||April 2010|April 20, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01107600||123447|
NCT01107860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCT-003|Cone Beam Computed Tomography for Breast Imaging|Cone Beam Computed Tomography for Breast Imaging||Koning Corporation|Yes|Completed|January 2010|June 2013|Actual|December 2012|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|401|||Female|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be selected from the patient population at a community based        clinic, Elizabeth Wende Breast Care, LLC, which is located in Rochester, NY. Group I will        consist of subjects who have had mammograms read as BIRADS® 1 or 2. Group II will be        subjects who have had a diagnostic mammogram read as BIRADS® 4 or 5 prior to breast        biopsy.|June 2013|June 14, 2013|January 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01107860||123428|
NCT01103960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.29|An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy|8 Week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg+ Amlodipine 5 mg vs. Amlodipine 5mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy||Boehringer Ingelheim||Completed|July 2010|||August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||December 2013|June 17, 2014|April 13, 2010||||No|August 21, 2012|https://clinicaltrials.gov/show/NCT01103960||123727|
NCT01103973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070076|The Impact of Distress on the IVF Outcome|The Impact of Distress on the IVF Outcome||Boston IVF|No|Completed|March 2007|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||April 2010|April 14, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103973||123726|
NCT01104792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-11|Long-term Study of Cariprazine in Patients With Schizophrenia|Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia||Forest Laboratories|No|Completed|April 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|588|||Both|18 Years|60 Years|No|||March 2014|March 28, 2014|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01104792||123663|
NCT01104805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYSPI #6051|Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders|NIDA-CTN-0044: Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders Using the Therapeutic Education System (TES)|CTN-0044|New York State Psychiatric Institute|Yes|Completed|April 2010|September 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|507|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104805||123662|
NCT01105130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98110|L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors|A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated With Radiotherapy||Wake Forest NCORP Research Base|Yes|Completed|October 2010|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|140|||Male|18 Years|N/A|No|||July 2015|July 15, 2015|April 14, 2010||No||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01105130||123637|
NCT01105143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA 20100415|Effects of Negative Energy Balance on Muscle Mass Regulation|Effects of Negative Energy Balance on Muscle Mass Regulation||Charite University, Berlin, Germany|No|Not yet recruiting|August 2010|August 2013|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|40 Years|80 Years|Accepts Healthy Volunteers|||April 2010|April 15, 2010|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01105143||123636|
NCT01105156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEWLS29401|Outcomes of Gastric Band Fills as Found With a Patient Self-reported Questionnaire: The Vomiting, Eating, and Weight Loss (VEW) Questionnaire|Outcomes of Gastric Band Fills as Found With a Patient Self-reported Questionnaire. The VEW [Vomiting, Eating, and Weight Loss] Questionnaire||North Eastern Weight Loss Surgery|No|Not yet recruiting|April 2010|April 2010|Anticipated|April 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|361|||Both|16 Years|70 Years|No|Probability Sample|All patients who have received a Swedish Adjustable Gastric band at North Eastern Weight        Loss Surgery|April 2010|April 15, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01105156||123635|
NCT01104844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFT-MX-3|Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain|Multicentre, Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Analgesic Effects of Different Maxigesic Doses Versus Acetaminophen, Ibuprofen and Placebo for the Teeth Extraction Pain||AFT Pharmaceuticals, Ltd.|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|0|||Both|16 Years|40 Years|No|||July 2013|July 11, 2013|April 14, 2010|Yes|Yes|The study was withdrawn due to administrative reason|No||https://clinicaltrials.gov/show/NCT01104844||123659|
NCT01105481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M1106|Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients|Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients: A 14-week Randomized, Double-blind and Placebo-controlled Trial|M1106|National Health Research Institutes, Taiwan|No|Completed|May 2006|June 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|60 Years|No|||April 2010|April 14, 2010|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01105481||123610|
NCT01110551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0055|Tetravalent Chimeric Dengue Vaccine Trial|A Double-Blind Randomized, Placebo-Controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2010|December 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01110551||123221|
NCT01109940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2209E1|Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis|An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Moderate to Severe Ankylosing Spondylitis||Novartis||Completed|April 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|65 Years|No|||June 2014|June 5, 2014|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01109940||123268|
NCT01110200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113874|Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study|A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization||GlaxoSmithKline|No|Completed|April 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|639|||Both|40 Years|85 Years|No|||June 2013|July 10, 2014|April 22, 2010|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01110200||123248|
NCT01110824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVERCOME|Prevention of Left Ventricular Dysfunction During Chemotherapy|Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies|OVERCOME|Hospital Clinic of Barcelona|Yes|Completed|April 2008|March 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|70 Years|No|||November 2013|November 14, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110824||123200|
NCT01110837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09-3232|Repeat Dose Nasal Allergen Challenge|Repeat Dose Nasal Allergen Challenge: Development of a Model to Investigate the Cellular and Inflammatory Changes That Occur in Allergic Rhinitis||McMaster University|No|Recruiting|April 2010|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01110837||123199|
NCT01110863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-05-096|Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects|Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects||Northwell Health|No|Active, not recruiting|December 2005|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Blood cells, Bone Marrow|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Chronic Lymphocytic Luekemia|October 2015|October 5, 2015|December 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01110863||123197|
NCT01111162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Upenn HIV-H1N1-001|H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients|Evaluating the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Infected Patients||University of Pennsylvania|No|Completed|December 2009|December 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01111162||123174|
NCT01111500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-399|Immobilization After an Anterior Glenohumeral Joint Dislocation With a Bankart Lesion|First Time Anterior Glenohumeral Joint Dislocation With a Bankart Lesion in Young Patients: Which Type of Immobilization Should be Chosen? A Prospective Randomized Study||Hopital de l'Enfant-Jesus|No|Recruiting|July 2007|February 2015|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||December 2012|December 19, 2012|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01111500||123148|
NCT01111149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904M64601|Varenicline and Smoking Cessation in Schizophrenia|Varenicline and Smoking Cessation in Schizophrenia|VSCS|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|December 2009|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|75 Years|No|||July 2014|July 8, 2014|April 23, 2010|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01111149||123175|
NCT01111513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-413|The Influence of the Femoral Nerve Block on Quadriceps Strength|The Influence of the Femoral Nerve Block on the Quadriceps Strength After Total Knee Replacement||Hopital de l'Enfant-Jesus|No|Completed|November 2007|February 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01111513||123147|
NCT01111526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15618|Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease|A Phase I/II Trial Evaluating the Use of Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|April 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01111526||123146|
NCT01112072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEI-Intacs-CXL|Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia|Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia|CXL|Cornea and Laser Eye Institute|Yes|Recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|21 Years|N/A|No|||July 2015|July 27, 2015|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01112072||123104|
NCT01112085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINIMA-2|MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)|Phase 2 Study of Microdoses of Ranibizumab in Diabetic Macular Edema - the MINIMA 2 Study|MINIMA-2|Especialistas en Retina Medica y Quirurgica Grupo de Investigacion|Yes|Completed|April 2010|June 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||June 2014|June 13, 2014|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01112085||123103|
NCT01101503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|q9jhrvf3|The Effect of Intensive Multifactorial Therapy on Endothelial Function in Newly Diagnosed Type 2 Diabetes|The Metabolic Memorial Effect of Early Intensive Multifactorial Treatment in Diabetes||Wuhan General Hospital of Guangzhou Military Command|Yes|Recruiting|April 2010|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1000|||Both|40 Years|70 Years|No|||March 2010|July 4, 2013|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01101503||123915|
NCT01103934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-184-B|Vitamin D Plus Fluticasone Propionate|The Addition of Vitamin D to Fluticasone Propionate in the Management of Seasonal Allergic Rhinitis||University of Chicago|No|Completed|June 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|45 Years|No|||October 2014|October 6, 2014|April 13, 2010|Yes|Yes||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01103934||123729|
NCT01103947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoL IRB 09.0588|EcoAnaesthesia Facemask Versus Standard Facemask During Anesthesia Induction|A Comparison of the Efficiency of the New EcoAnaesthesia Facemask With a Standard Facemask During Induction of Anesthesia||University of Louisville|No|Enrolling by invitation|April 2010|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|40|||Both|18 Years|75 Years|No|||November 2012|November 12, 2012|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01103947||123728|
NCT01104220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102127|Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)|Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)||Washington University School of Medicine|No|Recruiting|April 2010|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|144|Samples With DNA|plasma and subcutaneous fat|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of subjects of all races and ethnic groups with an equal        number of men and women. Participants will be recruited by reviewing our database of        research subjects containing thousands of lean and obese research study volunteers and by        St. Louis metro area postings.|February 2016|February 4, 2016|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104220||123707|
NCT01104259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7161|Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer|Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer||University of Washington|Yes|Active, not recruiting|July 2010|||February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104259||123704|
NCT01104272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-1100-05|Subcutaneous Contouring Using High Intensity Focused Ultrasound|An Evaluation of the Treatment of Adipose Tissue Using a Focused Ultrasound Device in Subjects With Fitzpatrick IV-VI Skin Types||Medicis Technologies Corporation|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|18 Years|65 Years|No|||January 2011|January 17, 2011|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01104272||123703|
NCT01104233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20100320|Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) With LAP Protector|Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) With Rigid Spreading Versus Soft Spreading (Using LAP Protector)||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|March 2010|December 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|80 Years|No|Probability Sample|Patients with non-small cell lung cancer|March 2010|April 13, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01104233||123706|
NCT01104246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AND1001|Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men|An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of Testosterone Transdermal Systems in Hypogonadal Men||Watson Pharmaceuticals|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||October 2012|October 2, 2012|April 13, 2010|Yes|Yes||No|February 1, 2011|https://clinicaltrials.gov/show/NCT01104246||123705|
NCT01104519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-093|A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effects of Multiple Oral Doses of 2000 mg of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity in Subjects With Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|March 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|April 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104519||123684|
NCT01104532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0066|A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects|A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Sitagliptin After Separate and Concomitant Administration to Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|April 15, 2010|April 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01104532||123683|
NCT01104818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH085438|Siblings in Foster Care|Evaluation of Intervention for Siblings in Foster Care|SIBS|Portland State University|No|Not yet recruiting|May 2010|||April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|480|||Both|7 Years|15 Years|No|||April 2010|February 10, 2014|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01104818||123661|
NCT01105182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAHG20100201|Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors|A Prospective Study of Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors|FACPT|The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|November 2009|June 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|48|||Both|18 Years|80 Years|No|Probability Sample|Patients with pulmonary malignancies are not candidates for surgical resectionpatients.|December 2009|April 15, 2010|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01105182||123633|
NCT01119846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111598|A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics|A Study in Type 2 Diabetic Subjects of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound||GlaxoSmithKline|No|Completed|June 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|100|||Both|18 Years|60 Years|No|||March 2012|March 22, 2012|November 12, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119846||122511|
NCT01120613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-015A|Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study|Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study||Northwell Health|No|Withdrawn|April 2010|||August 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||May 2013|May 29, 2013|April 29, 2010|Yes|Yes|primary investigator left institution; not enough patients|No||https://clinicaltrials.gov/show/NCT01120613||122452|
NCT01120626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02042010-4923|Randomized Controlled Study of Donepezil in Fragile X Syndrome|Augmentation of the Cholinergic System in Fragile X Syndrome: A Double-Blind Placebo-Controlled Randomized Study of Donepezil||Stanford University|Yes|Completed|September 2009|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|12 Years|29 Years|No|||February 2016|February 18, 2016|May 7, 2010||No||No|November 19, 2015|https://clinicaltrials.gov/show/NCT01120626||122451|
NCT01117649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0803|Plasma Volume Replacement (PVR) Therapy With Colloid and Crystalloid Solutions|Prospective, Controlled, Double-blind, Randomized Multi-centric Study on the Efficacy and Safety of a Target Controlled PVR Therapy With a Hyperoncotic Balanced Hydroxyethyl Starch (HES) Solution Versus an Isooncotic Balanced HES Solution Compared to a Balanced Electrolyte Solution in Elective Surgery||B. Braun Melsungen AG|No|Completed|May 2010|July 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|80 Years|No|||September 2013|September 6, 2013|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01117649||122679|
NCT01121185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL-HCV1-10-02|Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C|A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation|MBL-HCV1|MassBiologics|Yes|Terminated|June 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|May 6, 2010|Yes|Yes|The study was terminated due to slower than anticipated subject accrual.|No||https://clinicaltrials.gov/show/NCT01121185||122408|
NCT01121484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-3364|Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)|A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder||Pfizer|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|439|||Female|40 Years|70 Years|No|||January 2012|March 30, 2012|May 3, 2010|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01121484||122385|Baseline characteristics are available for all treated participants (434) and not all randomized participants (439).
NCT01118143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT/TkNN|Oral Health Literacy Tailored Communication|Effects of Communication Tailored to Oral Health Literacy Level of Adult Dental Patients: A Randomized Controlled Trial||University of Tromso|Yes|Completed|June 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|179|||Both|20 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|April 28, 2010||No||No|August 27, 2012|https://clinicaltrials.gov/show/NCT01118143||122641|
NCT01117337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-ECN-04-08|Comparing Non-fixation of Mesh to Mesh Fixation in Laparoscopic Inguinal Hernia Repair|Comparing Non-fixation of Mesh to Mesh Fixation in Laparoscopic Total Extraperitoneal Inguinal Hernia Repair Under Spinal Anesthesia- A Randomized Controlled Trial||Moulana Hospital|Yes|Completed|September 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|104|||Both|16 Years|85 Years|No|||July 2008|August 9, 2010|May 3, 2010||No||No|July 7, 2010|https://clinicaltrials.gov/show/NCT01117337||122703|
NCT01152398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNIT-BR-003|A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy|A Phase I Safety and Immunogenicity Trial of MVA-BN®-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy||Bavarian Nordic, Inc.|No|Completed|June 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||August 2011|May 6, 2013|June 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01152398||120028|
NCT01152723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1068 (A6431123)|Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum|Single-dose Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum. A Study in Healthy Smokers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2008|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152723||120003|
NCT01152970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA024646 01A2|F.Y.I.: Flint Youth Injury Study|Substance Use Among Violently Injured Youth in Urban ER: Services & Outcomes|FYI|University of Michigan|No|Completed|November 2009|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|638|||Both|14 Years|24 Years|Accepts Healthy Volunteers|Probability Sample|Patients ages 14-24 seeking treatment at the Hurley Medical Center (HMC) Emergency        Department (ED) located in Flint, MI will be recruited for this study.|April 2014|April 9, 2014|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152970||119984|
NCT01148680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 08 31|Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment|Randomized Controlled Trial Comparing the Metabolic Efficiency of Allogeneic Pancreatic Islet Transplantation to Intensive Insulin Therapy for the Treatment of Type 1 Diabetes|TRIMECO|University Hospital, Grenoble|Yes|Recruiting|June 2010|December 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|64 Years|No|||December 2014|December 8, 2014|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148680||120311|
NCT01152359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-381|Considering Patient Diet Preferences to Optimize Weight Loss|Considering Patient Diet Preference to Optimize Weight Loss|DietChoice|VA Office of Research and Development|No|Completed|May 2011|August 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|N/A|74 Years|Accepts Healthy Volunteers|||September 2014|April 6, 2015|June 14, 2010||No||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01152359||120031|
NCT01152372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB122-003|Experimental Study to Validate the Modified Glucose Disposal Test|Experimental Medicine Study to Validate the Modified Glucose Disposal Test in Healthy Subjects and Subjects With Type 2 Diabetes||Bristol-Myers Squibb|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|65 Years|No|||August 2010|February 22, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01152372||120030|
NCT01119352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2710C00002|AZD7687 Multiple Ascending Dose Study|A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Multiple Ascending Doses in Overweight to Obese But Otherwise Healthy Male Subjects||AstraZeneca|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|45|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01119352||122548|
NCT01119365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10165|Bright Light as a Countermeasure for Circadian Desynchrony|Bright Light as a Countermeasure for Circadian Desynchrony||VA Palo Alto Health Care System|No|Recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119365||122547|
NCT01119937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A1302|Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of NVA237 (50µg o.d.) Using Tiotropium (18µg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|GLOW4|Novartis||Completed|May 2010|||November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Both|40 Years|N/A|No|||November 2012|December 12, 2012|May 5, 2010|Yes|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT01119937||122504|
NCT01119950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2208|Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, 2-period, Cross-over Study to Assess the Efficacy and Safety of Differing Doses of NVA237 Administered Either Once Daily or Twice Daily, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|388|||Both|40 Years|N/A|No|||March 2015|March 3, 2015|May 5, 2010|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT01119950||122503|
NCT01119638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR-BPSD-001|Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone|Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients|EscBPSD|Abarbanel Mental Health Center|Yes|Completed|April 2008|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|95 Years|No|||June 2015|June 23, 2015|May 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119638||122527|
NCT01119651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114574|A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers||GlaxoSmithKline|No|Completed|June 2010|September 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|9||Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|May 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01119651||122526|
NCT01119911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10086-09CTIL|Blood Sampling Through Peripheral Venous Catheter in Infants|Blood Sampling Through Peripheral Venous Catheter for Selected Basic Analytes in Infants||Meir Medical Center|No|Recruiting|May 2010|June 2012|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|24 Months|No|Probability Sample|All infants under 2 years of age, admitted to the Departments of Pediatrics and Pediatric        Surgery, Meir Medical Center, who have a functioning peripheral venous catheter and        require repeated blood sampling for diagnostic purposes.|March 2012|March 16, 2012|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01119911||122506|
NCT01120158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.31|Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer|Biweekly Paclitaxel Plus Bevacizumab as First Line Treatment for Older Patients With Metastatic Breast Cancer||Hellenic Oncology Research Group|No|Recruiting|September 2009|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01120158||122487|
NCT01120405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT #2010-018703-28|Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery|Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery: A Phase III Multicenter Randomized Controlled Study|CARVASAXe|Air Liquide Santé International|No|Completed|May 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|600|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|May 4, 2010||No||No|March 20, 2014|https://clinicaltrials.gov/show/NCT01120405||122468|
NCT01121198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0101|A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects|ASP1941 Phase I Study —Placebo-controlled, Single-dose and Repeated-dose Oral Administration Study in Healthy Adult Male Subjects—||Astellas Pharma Inc|No|Completed|December 2006|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|84|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2010|May 10, 2010|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01121198||122407|
NCT01121211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-001845/1|Hormonal Factors in the Treatment of Anorexia Nervosa|Hormonal Factors in the Treatment of Anorexia Nervosa||Massachusetts General Hospital|Yes|Completed|April 2010|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|45 Years|No|||February 2016|February 9, 2016|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121211||122406|
NCT01121224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|571|Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty|CSP #571 - Drug-eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Angioplasty (DIVA)|DIVA|VA Office of Research and Development|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|762|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121224||122405|
NCT01120366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURPRISE Study|Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation|Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation|SURPRISE|SURPRISE Study Group|Yes|Completed|October 2009|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|233|||Both|20 Years|75 Years|No|||January 2015|January 23, 2015|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120366||122471|
NCT01117350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_C_03680|Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure|A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide|EAGLE|Sanofi||Completed|July 2010|March 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|978|||Both|35 Years|75 Years|No|||March 2014|March 5, 2014|May 4, 2010|Yes|Yes||No|October 4, 2013|https://clinicaltrials.gov/show/NCT01117350||122702|
NCT01117662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200710602|Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients|Efficacy of Rituximab in Acute Cellular Rejection With B-cell Infiltrates in Renal Transplant Patients - Randomized Placebo Controlled Double Blind Trial|RIACT|Hannover Medical School|Yes|Active, not recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01117662||122678|
NCT01117896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5-5367|CPR Rescuer Fatigue on Chest Compression Effectiveness|Effect of Rescuer Fatigue on Chest Compression Effectiveness||Children's Hospital of Philadelphia|No|Completed|May 2007|July 2012|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|106|||Both|22 Years|65 Years|No|||October 2012|October 24, 2012|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117896||122660|
NCT01118156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0641|Suicide Classification System|Suicide Classification System||VA Eastern Colorado Health Care System|Yes|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mental Health professionals at the Denver and Grand Junction VA Medical Centers|May 2011|May 1, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01118156||122640|
NCT01118182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB08-0001|Use of a Traumatic Brain Injury (TBI) Screen in a Veteran Mental Health Population|Use of a Traumatic Brain Injury (TBI) Screen in a Veteran Mental Health Population: Prevalence, Validation, and Psychiatric Outcomes|TBI|VA Eastern Colorado Health Care System|No|Active, not recruiting|June 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Indivduals with a history of completing the 4 Traumatic Brain Injury (TBI) screening        questions during a mental health intake.|January 2016|January 13, 2016|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01118182||122638|
NCT01118468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1426|Systematic Assessment of Competitive Flow in Coronary Artery Bypass Grafts by Wave Intensity Analysis|Systematic Assessment of Competitive Flow in Coronary Artery Bypass Grafts by Wave Intensity Analysis||Imperial College London|Yes|Recruiting|January 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with previous bypass grafts undergoing angiography/ angioplasty who meet stduy        criteria|July 2011|July 28, 2011|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118468||122616|
NCT01118481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1428|Vasodilator Free Measure of Fractional Flow Reserve|ADenosine Vasodilator Independent Stenosis Evaluation Study (ADVISE)|ADVISE|Imperial College London|Yes|Recruiting|January 2010|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary stenosis without exclusion criteria|September 2011|September 5, 2011|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118481||122615|
NCT01152736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1073|Pharmacokinetics With a New Oral Nicotine Replacement Product and Nicorette® Gum|Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product and Nicorette® Gum. A Study in Healthy Smokers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|November 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152736||120002|
NCT01149005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-Insulin-HMO-CTIL|Cystic Fibrosis (CF) Exacerbation and Insulin Treatment|Evaluation of Glucose Tolerance and Insulin Treatment in Non Diabetic Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation||Hadassah Medical Organization|No|Not yet recruiting|June 2010|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|10 Years|N/A|No|||June 2010|June 22, 2010|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149005||120286|
NCT01149018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC-FMS-HMO-CTIL|Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia|A Randomized, Double-blind, Placebo-controlled Trial of Oral Tetrahydrocannabinol (∆-9-THC) in Patients With Fibromyalgia||Hadassah Medical Organization|No|Recruiting|June 2010|October 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2010|June 22, 2010|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149018||120285|
NCT01152931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULagosclinicaltrials|Antioxidant Micronutrients in Malaria|Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial|AMM|University of Lagos, Nigeria|No|Completed|August 2010|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|15||Actual|10|||Both|6 Months|5 Years|No|||August 2010|May 30, 2012|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152931||119987|
NCT01119924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB098-33|A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain|Phase IV Study for Evaluation the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain||Nang Kuang Pharmaceutical Co., Ltd.|Yes|Completed|December 2009|November 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|65 Years|No|||June 2011|June 7, 2011|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119924||122505|
NCT01120197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301.0|Study of Effect of Exercise With Osteoporosis and Vertebral Fracture|Study of Effect of Exercise on Health-related Quality of Life, Mobility and Balance in Osteoporotic Women With a History of Vertebral Fracture.||Ostfold Hospital Trust|Yes|Completed|May 2005|November 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Female|60 Years|N/A|No|||May 2014|May 5, 2014|May 6, 2010||No||No|May 23, 2012|https://clinicaltrials.gov/show/NCT01120197||122484|The numbers in our study were relatively small, and some caution is required in interpretation. Additionally, it cannot be ruled out that participants have become aware of the treatment allocation, and this could potentially have biased the results.
NCT01120457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA212-001|First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers|A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies||Bristol-Myers Squibb|No|Completed|August 2010|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|96|||Both|18 Years|N/A|No|||January 2015|March 5, 2015|May 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01120457||122464|
NCT01120418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|507|Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days|A Randomized, Contralateral Study To Evaluate Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered 0.6% ISV-403 Three Times Daily For Five Days||Bausch & Lomb Incorporated|No|Completed|May 2007|February 2008|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 10, 2012|May 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01120418||122467|
NCT01120431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1838-008|Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)|The INcreased Flow Utilizing Subcutaneously-Enabled Time-Motion (INFUSE-TM) Study: A Randomized, Open-label, Parallel-group, Multicenter Study Evaluating Efficacy and Time and Resources in the Emergency Department for Hylenex-facilitated Subcutaneous Rehydration Versus Oral Rehydration Therapy in Pediatric Patients With Mild to Moderate Dehydration|INFUSE-TM|Baxter Healthcare Corporation|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|2 Months|2 Years|No|||January 2011|January 28, 2011|May 7, 2010|Yes|Yes|Strategic business decision (not related to safety or efficacy concerns)|No||https://clinicaltrials.gov/show/NCT01120431||122466|
NCT01120444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDT-09-ADC004|Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients|A Single Center, Open-label, Randomized Study Examining the Glycemic Effects of ID vs SC Bolus Dosing of Insulin Lispro in Patients With Type 1 Diabetes||Becton, Dickinson and Company|No|Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|55 Years|No|||April 2011|April 15, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120444||122465|
NCT01121614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q2103/139|Mesenteric Vessel Sealing by Three Instruments|A Pilot Study to Compare Collateral Damage and Vessel Sealing Ability of LOTUS Ultrasonic Shears, Ethicon Harmonic Scalpel™ and LigaSure™ on Human Mesenteric Blood Vessels||Plymouth Hospitals NHS Trust|No|Completed|April 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 5, 2012|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01121614||122375|
NCT01121237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX575-503|MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5|An International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Haemodialysis Patients With Anaemia Treated With Biosimilar Epoetin Alfa|MONITOR-CKD5|Sandoz|Yes|Completed|February 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2088|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic kidney disease stage 5 with renal anemia and on haemodialysis|April 2015|April 8, 2015|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01121237||122404|
NCT01121510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 655-03|Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose Design 9 System|The QuickClose Design 9 System Study||CardioDex|Yes|Withdrawn|May 2010|May 2011|Anticipated|July 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2010|September 28, 2010|May 10, 2010||No|medical center difficulties in recruiting patients for the study in a timely fashion|No||https://clinicaltrials.gov/show/NCT01121510||122383|
NCT01121523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project Touch|Cue-based Tactile Stimulation and Infant Stress Reactivity|Effect of Cue-based Tactile Stimulation on Premature, Low Birth Weight Infants: Stress Reactivity.Immune Functioning, and Parenting||Penn State University|Yes|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|N/A|4 Months|Accepts Healthy Volunteers|||October 2015|October 19, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121523||122382|
NCT01121536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3074|Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder||Teva Pharmaceutical Industries|Yes|Completed|April 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|867|||Both|18 Years|65 Years|No|||January 2015|January 15, 2015|May 5, 2010|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01121536||122381|
NCT01117363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIV829|Effect of Three Weeks Consumption of Rye Porridge Breakfast|Effect of Three Weeks Consumption of Rye Porridge Breakfast on 24 h Appetite Profile, and Acute Effect on OCTT and Breath Hydrogen||Swedish University of Agricultural Sciences|No|Active, not recruiting|March 2010|July 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|26|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117363||122701|
NCT01117675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hospital Clinic|A New Telemedicine Approach for Chronic HIV/AIDS Patient Home Care|A New Telemedicine Approach for Chronic HIV/AIDS Patient Home Care||Hospital Clinic of Barcelona|No|Completed|January 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|83|||Both|18 Years|N/A|No|||April 2010|May 4, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117675||122677|
NCT01117688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102.09 (REK) - 3|Ureteroscopy With and Without Safety Guidewire|Ureteroscopy With and Without Safety Guidewire:. A Prospective, Randomized Study of the Results of Endoscopic Treatment of Urolithiasis.||Helse-Bergen HF|No|Withdrawn|May 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2011|March 31, 2015|May 4, 2010||No|Withdrawn. Not enough time to go through with the study.|No||https://clinicaltrials.gov/show/NCT01117688||122676|
NCT01117909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14919|Effects of Talocrural Joint Mobilizations in the Treatment of Subacute Lateral Ankle Sprains|Effects of Talocrural Joint Mobilizations in the Treatment of Subacute Lateral Ankle Sprains||University of Virginia|No|Recruiting|April 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||May 2011|May 26, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117909||122659|
NCT01118507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 09071|Trisomy of Chromosome 21 Diagnosis by High Output Sequencing|Trisomy of Chromosome 21 Diagnosis by High Output Sequencing of Foetal Circulating DNA in Mother Blood at First Trimester of Pregnancy.|SEQ21|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2010|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|976|Samples With DNA|fetal DNA in maternal blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|PREGNANT WOMEN|February 2011|January 2, 2014|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01118507||122613|
NCT01117935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-12870|Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer|Study of Hypofractionated Intensity Modulated External Beam Therapy for the Treatment of Patients With Adenocarcinoma of the Prostate||Virginia Commonwealth University|Yes|Active, not recruiting|May 2010|August 2017|Anticipated|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Male|18 Years|N/A|No|||February 2016|February 19, 2016|April 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01117935||122657|
NCT01118494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08dz1900603|Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.|||Fudan University|Yes|Recruiting|September 2009|June 2011|Anticipated|February 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|serum plasma urine supernatant urine sediment|Both|18 Years|80 Years|No|Non-Probability Sample|CKD（chronic kidney disease），in the stage of 3 or 4.|April 2010|May 5, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01118494||122614|
NCT01148706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASNG-LFNA-103-IL|Effectiveness of ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Procedures|Phase IV Study of the ActiSight Needle Guidance System Which Assist in Guiding a Rigid Interventional Instrument Percutaneously, to a Designated Point Within the Body by Means of CT Visualization|ASNG|ActiViews Ltd.|Yes|Completed|July 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2012|December 9, 2012|June 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01148706||120309|
NCT01148719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311040302|Triage of Reduced Exercise Tolerance in Frail Elderly|Triage of Reduced Exercise Tolerance in Frail Elderly|TREE|UMC Utrecht|No|Completed|May 2010|September 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|841|||Both|65 Years|N/A|No|||July 2014|July 4, 2014|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01148719||120308|
NCT01150240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PID_CH_Registry06|Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland|Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland||University of Zurich||Enrolling by invitation|October 2006|||December 2012|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|800|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Primary Immunodeficiency Disease (PID), followed in a PID centre, primary        care hospitals or private practice|June 2010|September 16, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150240||120191|
NCT01148654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807678|The Biomarker Study|Predicting Preterm Birth and Adverse Neonatal Outcomes With Novel Biomarkers: Identifying Those at Greatest Risk to Allow for Future Therapeutic Trials||University of Pennsylvania||Completed|May 2008|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1076|Samples With DNA|maternal serum, plasma, saliva; Neonatal saliva|Female|N/A|N/A|No|Non-Probability Sample|Women with singleton pregnancies between 22-0/7 and 33-6/7 weeks gestational age who        present to the Hospital of the University of Pennsylvania 'Perinatal Evaluation Center'        (PEC) complaining of PTL, PPROM, or CI. Group 2: Women who present to Labor and Delivery        and will deliver (or have just delivered) a single infant preterm (22-0/7 to 36-6/7 weeks)        at HUP.|January 2014|January 6, 2014|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148654||120313|
NCT01148667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/2006 1 531|Lactobacillus Rhamnosus GG: Interaction With Human Microbiota and Immunity|Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis||Turku University Hospital|No|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|18 Months|No|||June 2010|June 21, 2010|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148667||120312|
NCT01119677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108HV103|A Study of Avonex® to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers|A Randomized, Three-Arm, Dose-Blinded, Parallel-Group Study to Determine the Effect of Avonex® Dose Titration on the Severity and Incidence of Interferon Beta-1a-Related Flu Like Symptoms in Healthy Volunteers||Biogen|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers|April 2011|April 14, 2011|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01119677||122524|
NCT01119976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0983|Association Between the Menstrual Cycle and Weight Loss|Evaluation of the Association Between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women||University of Colorado, Denver|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01119976||122501|
NCT01120184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO22589|A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)|A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer||Hoffmann-La Roche||Active, not recruiting|July 2010|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1095|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|April 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01120184||122485|
NCT01120704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0049|Evaluation of Treatments to Improve Smoking Cessation Medication Adherence|Project 3: Identifying Optimal Strategies of Increasing Smokers' Adherence to Cessation Medications|Adherence|University of Wisconsin, Madison|Yes|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|32||Actual|544|||Both|18 Years|99 Years|No|||November 2015|November 12, 2015|May 3, 2010||No||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01120704||122445|
NCT01120665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRH01/989-7|Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women|Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women|TRH01/989-7|University of Sao Paulo General Hospital|Yes|Completed|February 2002|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|4||Actual|62|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120665||122448|
NCT01120678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13987|Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay|Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay||University of Virginia|No|Completed|February 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Samples of whole blood were obtained and processed to collect and retain only serum.|Both|N/A|N/A|No|Probability Sample|Infants in the Newborn Intensive Care Unit greater than three days of age undergoing        sepsis evaluation.|March 2011|March 4, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120678||122447|
NCT01121250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-1-0242|Spouse READI (Resilience Education And Deployment Information) Post Deployment Telephone Support Groups|Spouse READI (Resilience Education And Deployment Information) Post Deployment Telephone Support Groups|Spouse READI|Memphis VA Medical Center|No|Completed|October 2009|February 2015|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|228|||Female|N/A|N/A|No|||June 2015|June 5, 2015|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01121250||122403|
NCT01121263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0657|Hybrid Revascularization Observational Study|Hybrid Revascularization Observational Study||Icahn School of Medicine at Mount Sinai|Yes|Completed|May 2010|August 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|298|||Both|18 Years|N/A|No|Non-Probability Sample|Cohort 1 (Angiogram Review Group): All consecutive and consenting patients undergoing        diagnostic cardiac catheterization in a 3 month period.        Cohort 2 (Therapeutic Intervention Group): All patients (including those from cohort 1)        who meet either of the following: (a) undergo HCR with minimally invasive LIMA-LAD CABG        (HCR Group) OR (b) meet the proposed anatomic and clinical eligibility criteria defined        below and undergo multivessel PCI with DES (PCI Group).|February 2014|February 7, 2014|May 10, 2010||No||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01121263||122402|
NCT01121549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991091|A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer|A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer In Postmenopausal Hormone Receptors Positive Patients Following Of 2-3 Years of Initial Adjuvant Tamoxifen Therapy||Pfizer|No|Terminated|February 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|378|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women hormone-receptor positive invasive with early breast cancer,        following 2-3 years of initial adjuvant tamoxifen therapy|December 2013|December 4, 2013|March 30, 2010||No|See termination reason in detailed description.|No|December 4, 2013|https://clinicaltrials.gov/show/NCT01121549||122380|The study was prematurely terminated on 31 August 2012 due to unexpected high rate of participant withdrawal caused by Aromasin reimbursement policy change in Romania. There were no safety issues related to study termination.
NCT01117376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-88-01-36-1601|Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients|Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients Intolerant to Enteral Feeding||Shiraz University of Medical Sciences|No|Terminated|May 2010|August 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||May 2010|March 30, 2011|April 30, 2010|Yes|Yes|The study was prematurely terminated because of unavailibility of Methylnaltrexone in the    region|No||https://clinicaltrials.gov/show/NCT01117376||122700|
NCT01117389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV1|Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer|Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer||St. Jude Children's Research Hospital|Yes|Completed|May 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|587|||Female|9 Years|26 Years|No|Non-Probability Sample|Maternal participants and young adult females (18-26) enrolled from the ACT clinic will        provide contact information for acquaintances in their communities who have daughters (in        the young adult arm 18-26 years old peers) roughly the same age as the targeted ACT        patient. This will obtain a control sample demographically most like the cancer group.        Typically, this will take the form of having the participants access their cell phones,        and provide the contact information of the mothers (or 18-26 year old peers) who they        identify as potential acquaintance controls. This information will then be used as a means        to contact the potential acquaintance control participants. These participants will be        mothers with daughters between the ages of 9 and 17 years-of-age or 18-26 year old        females. Participants aged 18-26 years will now complete self-reported questionnaires as        part of this survey study.|August 2013|August 26, 2015|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01117389||122699|
NCT01117922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#09-007191|Philadelphia Preterm Prevention Project|Philadelphia Collaborative Preterm Prevention Project|PPP|Children's Hospital of Philadelphia|No|Completed|November 2004|September 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1136|||Female|18 Years|45 Years|No|||May 2010|March 11, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117922||122658|
NCT01118169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 09-0523|Personal Values, Interpersonal Needs, and Suicidal Ideation in a Veteran Population|Examining the Relationship Between Personal Values, Interpersonal Needs, and Suicidal Ideation in a Veteran Population||VA Eastern Colorado Health Care System|No|Completed|September 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|122|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Veterans receiving behavioral health services within the Denver VA Medical Center.|November 2011|November 8, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01118169||122639|
NCT01117948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR081101/CO14950|Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.|A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.||JSW Lifesciences|Yes|Terminated|September 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|219|||Both|50 Years|85 Years|No|||February 2013|February 1, 2013|May 4, 2010||No|Lack of Efficacy|No|May 21, 2012|https://clinicaltrials.gov/show/NCT01117948||122656|
NCT01118767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01TW007896|Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru|Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru|Cell-POS|Universidad Peruana Cayetano Heredia|No|Recruiting|May 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2010|June 15, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01118767||122593|
NCT01118780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12866|A Study of Duloxetine in Elderly Generalized Anxiety Disorder|Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder||Eli Lilly and Company|No|Completed|October 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|291|||Both|65 Years|N/A|No|||June 2013|June 25, 2013|May 5, 2010|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT01118780||122592|
NCT01149915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-407|Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias|A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias||Threshold Pharmaceuticals|No|Completed|June 2010|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149915||120216|
NCT01150227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIC-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2011|||||N/A|N/A|N/A||||||||||||||December 10, 2014|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01150227||120192|
NCT01148693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRC-88/19|Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting|Comparing Addition of Gentamicin vs. Placebo in Preventing Post ERCP Cholangitis in Non-calculus Stenting||Tehran University of Medical Sciences|Yes|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|114|||Both|N/A|N/A|No|||July 2011|September 18, 2011|June 19, 2010||No||No|February 18, 2011|https://clinicaltrials.gov/show/NCT01148693||120310|No limitation other than small sample size
NCT01148992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lofexidine-0001|Interactions Between Intravenous (IV) Cocaine and Lofexidine|Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine||National Institute on Drug Abuse (NIDA)|Yes|Terminated|August 2010|March 2011|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|50 Years|No|||April 2011|April 4, 2011|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01148992||120287|
NCT01119963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX0012|Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)|17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial|17PinPROM|Mednax Center for Research, Education and Quality|Yes|Completed|October 2011|October 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|152|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 17, 2014|February 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119963||122502|
NCT01120496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TRC|Nebulized Hypertonic Saline Treatment in Hospitalized Children With Moderate to Severe Viral Bronchiolitis|A Randomized Controlled Trial of Nebulized Hypertonic Saline Treatment in Hospitalized Children With Moderate to Severe Viral Bronchiolitis||Chongqing Medical University|Yes|Completed|November 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|1 Month|24 Months|No|||November 2008|May 10, 2010|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120496||122461|
NCT01120509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crux02|Crux Biomedical Vena Cava Filter Study - United States|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 2|RETRIEVE 2|Crux Biomedical|Yes|Completed|June 2010|January 2012|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||August 2012|June 26, 2014|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120509||122460|
NCT01120522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crux03|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3")|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3|RETRIEVE 3|Crux Biomedical|Yes|Completed|May 2010|January 2012|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2012|June 26, 2014|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120522||122459|
NCT01120470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-01|OGX-427 in Castration Resistant Prostate Cancer Patients|A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease||British Columbia Cancer Agency|No|Completed|September 2010|June 2014|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Male|18 Years|N/A|No|||May 2015|May 5, 2015|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120470||122463|
NCT01120483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onco400|Prevalence of Malnutrition in Oncologic Patients|Prevalence and Impact of Malnutrition in Hospitalised Patients||Charite University, Berlin, Germany|No|Completed|December 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Probability Sample|Patients will be selected in primary care clinics.|October 2006|May 10, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120483||122462|
NCT01120717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2307|A Study to Assess the Long-term Safety of QVA149|A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|ENLIGHTEN|Novartis|Yes|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|339|||Both|40 Years|N/A|No|||January 2013|January 28, 2013|May 5, 2010|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01120717||122444|
NCT01120691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2304|Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations|A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)|SPARK|Novartis||Completed|April 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2224|||Both|40 Years|N/A|No|||October 2013|October 29, 2013|May 5, 2010|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01120691||122446|
NCT01121302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3030C00001|Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects|A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability & PK of Single Ascending Dose (Part 1) & an Open-label Assessment of Effect of Food on the PK (Part 2)||AstraZeneca|Yes|Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01121302||122399|
NCT01120964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIT-002-01|Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol|Phase IB Double Blind, Randomized, Placebo Controlled Clinical Trial to Determine the Pharmacokinetics and Safety of a Revised Protocol of Intravenous L-Citrulline (Citrupress®) Versus Placebo in Children Undergoing Cardiopulmonary Bypass||Asklepion Pharmaceuticals, LLC|Yes|Completed|September 2010|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|22|||Both|N/A|6 Years|No|||January 2015|January 26, 2015|May 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120964||122425|
NCT01121562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181193|Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors|A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors||Pfizer|No|Completed|July 2010|November 2013|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||June 2014|June 18, 2014|May 10, 2010|Yes|Yes||No|July 1, 2012|https://clinicaltrials.gov/show/NCT01121562||122379|
NCT01121575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081006|A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer|A Phase 1, Open-label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Combined Oral C-met/Alk Inhibitor (Pf-02341066) And Pan-her Inhibitor (Pf-00299804) In Patients With Advanced Non-small Cell Lung Cancer||Pfizer|No|Completed|August 2010|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 10, 2010|No|Yes||No|February 11, 2015|https://clinicaltrials.gov/show/NCT01121575||122378|
NCT01121588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081013|An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)|Phase 1b Open-Label Study Of The Safety And Clinical Activity Of Crizotinib (PF-02341066) In Tumors With Genetic Events Involving The Anaplastic Lymphoma Kinase (ALK ) Gene Locus||Pfizer|No|Active, not recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|15 Years|N/A|No|||January 2016|January 4, 2016|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121588||122377|
NCT01121601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2010/94|CoSeal in Liver and Biliary Surgery in Prevention of Denovo Hepatic Adhesion|Effectiveness and Tolerance of CoSeal in the Prevention of Hepatic Adherences of Novo Post Operational Within the Framework of a Hepatic Surgery of Resection in Two Times for Hepatic Metastases: Study of Phase II/III.|COLIBIS|Centre Hospitalier Universitaire de Besancon|Yes|Terminated|August 2011|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||August 2015|August 4, 2015|May 4, 2010||No|Practices in surgery have evolved and the study has not interest yet|No||https://clinicaltrials.gov/show/NCT01121601||122376|
NCT01118208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-1-0723|Blister Packaging Medication to Increase Treatment Adherence and Clinical Response|Blister Packaging Medication to Increase Treatment Adherence and Clinical Response: Impact on Suicide-Related Morbidity and Mortality|BP|VA Eastern Colorado Health Care System|No|Completed|September 2009|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|303|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01118208||122636|
NCT01117701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102.09 (REK) - 4|Does a Safety Guidewire Increase the Forces Needed to Move the Ureteroscope up and Down the Ureter?|Does a Safety Guidewire Adjacent to the Ureteroscope Increase the Forces Needed to Move the Ureteroscope up and Down the Ureter?||Helse-Bergen HF|No|Completed|May 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2011|March 17, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117701||122675|
NCT01117714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-13245.8|Surgical Versus Non-surgical Staging of Lung Cancer|A Prospective Multicenter Study Comparing Endobronchial and Endoscopic Ultrasound-Guided FNA to Mediastinoscopy/Thoracoscopy in the Staging and Early Detection of Metastases in Lung Cancer||Medical University of South Carolina|Yes|Terminated|September 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|21 Years|N/A|No|||May 2010|August 4, 2011|March 25, 2010||No|Accrual was poor at two other sites and manuscript was published which describing another    study which accomplished the goals of this project.|No||https://clinicaltrials.gov/show/NCT01117714||122674|
NCT01118195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA 05-1100|Executive Dysfunction & Suicide: An Exploration Of Risk Factors In Traumatically Brain Injured Veterans|Executive Dysfunction & Suicide: An Exploration Of Risk Factors In Traumatically Brain Injured Veterans||VA Eastern Colorado Health Care System|No|Completed|January 2007|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|54|||Both|18 Years|74 Years|No|Non-Probability Sample|outpatient veterans with a history of traumatic brain injury|April 2011|April 21, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01118195||122637|
NCT01150526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2010-CS02|Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate|Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate||Metabolic Technologies Inc.|No|Completed|October 2010|July 2012|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|41|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150526||120169|
NCT01149304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD052|Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity|Evaluation of the Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity After Brachytherapy of Liver Metastases From Colorectal Carcinoma, Assessed in a Prospective Randomised Trial|ELDORADO|University of Magdeburg||Recruiting|June 2009|||June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Both|18 Years|80 Years|No|||June 2010|June 22, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01149304||120263|
NCT01149317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-306|Acupuncture for Chronic Pain|Acupuncture to Decrease Disparities in Outcomes of Pain Treatment|ADDOPT|Albert Einstein College of Medicine of Yeshiva University|No|Completed|May 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|235|||Both|21 Years|N/A|No|||January 2012|January 27, 2012|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01149317||120262|
NCT01149330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR.10.001|Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|Evaluation of Efficacy and Safety of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|Estudo Epiduo|Galderma Brasil Ltda.|No|Completed|July 2010|April 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|12 Years|35 Years|No|||March 2012|March 9, 2012|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149330||120261|
NCT01149343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113173|Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer|Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma||GlaxoSmithKline||Active, not recruiting|July 2010|December 2016|Anticipated|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|107|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149343||120260|
NCT01119391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091005|The Impact of Lifestyle Behaviors on In Vitro Fertilization (IVF) Outcome|The Impact of Lifestyle Behaviors on IVF Outcome||Boston IVF|No|Completed|July 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|118|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|Women about to undergo an in vitro fertilization cycle at Boston IVF|February 2016|February 3, 2016|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119391||122545|
NCT01119690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHMetS-03-AP|Hämeenlinna Metabolic Syndrome Research Program: Effects of Rapeseed Oil on Serum Lipids and Platelet Function|Hämeenlinna Metabolic Syndrome Research Program (HMS): Effects of Dietary Cold-pressed Turnip Rapeseed Oil and Milk Fat on Serum Lipids, Oxidized LDL, Arterial Elasticity and Platelet Function|HMS-03|Central Hospital of Kanta-Hame|No|Completed|September 2004|June 2008|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Male|31 Years|66 Years|No|||May 2010|May 6, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119690||122523|
NCT01119703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-131|Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)|A Phase I, Open-Label Observational Study to Develop a Prospective Predictor of Vaccine Hyporesponse in Healthy Elderly Subjects||Merck Sharp & Dohme Corp.|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|174|Samples With DNA|Cryopreserved peripheral blood mononuclear cells (PBMCs) obtained from whole blood samples.|Both|25 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adults 25 to 40 years old or 65 years and older|November 2015|November 30, 2015|May 5, 2010|No|Yes||No|October 16, 2012|https://clinicaltrials.gov/show/NCT01119703||122522|
NCT01126333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042739|Long-term Follow-up of Spare the Nephron (STN) Patients|Long-term Follow-up of Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients.|STN|University of Maryland|No|Active, not recruiting|June 2010|June 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|305|||Both|18 Years|N/A|No|Non-Probability Sample|Kidney transplant recipients who were previously enrolled in the Spare-the-nephron study.|June 2013|November 21, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126333||122013|
NCT01120210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017116|A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JNJ-39588146 in Subjects With Heart Failure||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|June 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|86 Years|No|||July 2013|July 8, 2013|May 6, 2010||No||No|September 6, 2012|https://clinicaltrials.gov/show/NCT01120210||122483|Data from the extended infusion sub-study were exploratory; therefore, results for outcome measures from the sub-study are not reported.
NCT01121003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocole 220/09|Effects of Fructose and Exercise on Hepatic Lipid Metabolism|Effects of a Weight Maintenance, High Fructose Diet and of Exercise on Hepatic Lipid Metabolism|FRUCTEXER|University of Lausanne|No|Completed|May 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|8|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2011|October 18, 2011|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01121003||122422|
NCT01121016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|moneb|Efficacy and Safety of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic Bronchitis|Randomized Double-blind Placebo-controlled Study of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic Bronchitis|NAEB|Guangzhou Medical University|Yes|Not yet recruiting|June 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|63|||Both|18 Years|70 Years|No|||September 2009|May 11, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01121016||122421|
NCT01120730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-BURN|Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury|Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury||University of Zurich|Yes|Completed|April 1997|March 2009|Actual|September 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||May 2010|May 7, 2010|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01120730||122443|
NCT01120990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hybrid BP Monitor Validation|Hybrid Blood Pressure Monitor Validation|Validation of a Hybrid Blood Pressure Monitor to Replace the Mercury Standard for Validation Studies According to Modified Criteria of the European Society of Hypertension International Protocol 2010|NISSEI|University of Athens|No|Completed|April 2010|July 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|51|||Both|25 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 14, 2012|May 6, 2010||No||No|December 3, 2010|https://clinicaltrials.gov/show/NCT01120990||122423|
NCT01120977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25274|Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study|Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study||University of Aarhus|No|Completed|May 2010|August 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|150|Samples With DNA|Blood sample to measure "Insulin like growth factor-1" (IGF-1)|Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects are healthy persons in the age 20-70 years, both males and females will be        recruited from the city Aarhus in Denmark.|November 2011|November 4, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120977||122424|
NCT01120938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09|Do Pacifiers Protect From Sudden Infant Death Syndrome (SIDS) Through an Increase in Upper Airway Patency?|Do Pacifiers Protect From Sudden Infant Death Syndrome (SIDS) Through an Increase in Upper Airway Patency?||Ziv Hospital|No|Recruiting|February 2010|December 2012|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|24 Months|No|Non-Probability Sample|primary care clinic, community sample|May 2010|May 25, 2010|May 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01120938||122427|
NCT01120951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATL01009|Clinical Assessment of the Use of the R8 Respiratory Rate Counter in Post-Operative Recovery in Adults and Adolescents|Clinical Assessment of the Use of the R8 Respiratory Rate Counter in Post-Operative Recovery in Adults and Adolescents||Anaxsys Technology Ltd|Yes|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Both|12 Years|N/A|No|Non-Probability Sample|Male or female patients aged 12 years and above following elective surgery under general        anaesthesia|May 2010|May 17, 2010|May 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01120951||122426|
NCT01121276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3824|A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 and Type 2 Diabetes||Novo Nordisk A/S|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|82|||Both|18 Years|65 Years|No|||February 2015|February 20, 2015|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01121276||122401|
NCT01121289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3808|A Trial Investigating NN1218 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|26|||Both|18 Years|65 Years|No|||December 2013|December 9, 2013|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01121289||122400|
NCT01117961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMTT# 2035-06|Promoting Healthy Weight Gain During Pregnancy|Promoting Healthy Weight Gain During Pregnancy||The Miriam Hospital|Yes|Completed|March 2007|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01117961||122655|
NCT01117974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU17637|Neck Liposuction for the Treatment of Obstructive Sleep Apnea|Neck Liposuction With Tumescent Anesthesia for the Treatment of Obstructive Sleep Apnea - A Pilot Study||Northwestern University|No|Withdrawn||June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|60 Years|No|||April 2013|April 15, 2013|March 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01117974||122654|
NCT01117753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSC19301|Research on Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders|Stage II Research on Outpatient Treatment for Adolescents With Comorbidity||Medical University of South Carolina|Yes|Completed|July 2009|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|10 Years|17 Years|No|||May 2013|April 10, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117753||122671|
NCT01117987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQTI571A2301E1|Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)|An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension|IMPRES Extn|Novartis|Yes|Terminated|April 2010|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|May 3, 2010|Yes|Yes|Novartis discontinued the development of imatinib in PAH due to requirement of regulatory    authorities for additional data to secure marketing approval in PAH.|No|April 2, 2015|https://clinicaltrials.gov/show/NCT01117987||122653|Within primary outcome measure (OM) #1, an additional death (>30 days post study completion) was included in the imatinib arm. The participant flow and secondary OM #2 reflect deaths that occurred up to and including 30 days post study completion.
NCT01118221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O7467-R|Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients|Rehabilitation of IPF Patients: Effects of Exercise and Oxidant Stress||VA Office of Research and Development|Yes|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|80 Years|No|||February 2015|February 13, 2015|April 27, 2010||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT01118221||122635|
NCT01118520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1644|Evaluation of Effect of Angiotensin-converting Enzyme (ACE) Inhibitors on Small Aneurysm Growth Rate|An Evaluation of the Effect of an Angiotensin-converting Enzyme (ACE) Inhibitor on the Growth Rate of Small Abdominal Aortic Aneurysms. A Double Blind Comparison With Similar Blood Pressure Lowering Medication (Calcium Channel Blockade)and Placebo|AARDVARK|Imperial College London|Yes|Completed|September 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|227|||Both|55 Years|N/A|No|||October 2011|August 4, 2015|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118520||122612|
NCT01118806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03|Vitamin D Levels in Residents in Medicine|Vitamin D Deficiency in Medical Residence in Israel||Meir Medical Center|No|Completed|May 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|106|||Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|medical staff, interns doing night shifts. nursing staff.|November 2011|November 21, 2011|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118806||122590|
NCT01118819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVDCNV1|Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies|Phase I Safety Study of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies||BioMed Valley Discoveries, Inc|Yes|Terminated|April 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 13, 2010|Yes|Yes|This study was terminated. An IT injection study of C. novyi-NT in patients with treatment    refractory solid tumor malignancies may be viewed at NCT01924689.|No||https://clinicaltrials.gov/show/NCT01118819||122589|
NCT01120275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02040|Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma|Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma||National Cancer Institute (NCI)||Active, not recruiting|October 2010|||May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120275||122478|
NCT01119417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091344|The Role of Endothelin in the Supine Hypertension of Autonomic Failure|The Role of Endothelin in the Supine Hypertension of Autonomic Failure||Vanderbilt University|No|Recruiting|May 2010|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|12|||Both|18 Years|85 Years|No|||December 2015|December 8, 2015|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119417||122543|
NCT01120236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02003|Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer|A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone Sensitive Metastatic Prostate Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Male|18 Years|N/A|No|||March 2015|June 25, 2015|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120236||122481|
NCT01120249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0931|S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery|EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study|S0931|Southwest Oncology Group|Yes|Recruiting|April 2011|||October 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1537|||Both|18 Years|120 Years|No|||December 2015|December 8, 2015|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120249||122480|
NCT01130415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Screening Method in Sacral Neuromodulation|Is the Method of Screening in Sacral Neuromodulation a Prognostic Factor for Long-term Success?||Maastricht University Medical Center|No|Completed|May 2002|July 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|64|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients who have been treated with sacral neuromodulation in our centre between 2002 and        2009|May 2010|May 25, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01130415||121705|
NCT01120743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No 28764|Correlation Between Release of Cytokines From Liver Graft and Hemodynamic Instability|Correlation Between Release of Cytokines From Liver Graft and Hemodynamic Stability During Liver Transplantation||Penn State University|No|Completed|August 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|Samples Without DNA|Blood samples were obtained. All blood samples were placed on ice and processed with      centrifugation. The plasma supernatant was frozen at -80º Celsius.|Both|18 Years|N/A|No|Non-Probability Sample|Study will include adult patients with end-stage liver disease accepted for liver        transplantation.|July 2009|May 7, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01120743||122442|
NCT01127074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 KV 9540|Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422)|Phase 1 Study: Induction of Systemic Immune Responses in Metastatic Breast Cancer Patients by Vaccination With a CD80-modified, Devitalized HLA-*A0201+ Breast Cancer Cell Line (KS24.22)|KS2422-vacc|University Hospital Tuebingen|No|Completed|March 2002|January 2010|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|80 Years|No|||May 2010|May 19, 2010|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01127074||121957|
NCT01121354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0906|Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX|A Phase I Multiple-Dose Two-Arm Study to Evaluate the PK and Safety of Cefazolin 2g for Inj. USP and Dextrose Inj. USP in the DUPLEX® Drug Delivery System and Cefazolin for Inj. 1.5g in Daily Doses of 6g in Healthy Adult Subjects|2 Cef|B. Braun Medical Inc.|No|Completed|December 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121354||122395|
NCT01121666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN3001|Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment|A Phase III Assessor-blinded Randomized Parallel Group Multi-centre Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA Versus Gonal-f) in Women for Assisted Reproductive Treatment||Finox AG|No|Completed|June 2010|March 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|410|||Female|20 Years|38 Years|No|||April 2013|April 9, 2013|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121666||122371|
NCT01121341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI/7|ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial|ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial: a Prospective Randomized Trial for Coronary Artery Bypass Grafting (CABG) Surgery.|ESOS|Azienda Ospedaliera San Giovanni Battista|Yes|Recruiting|May 2010|||June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2010|May 19, 2010|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01121341||122396|
NCT01121640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50CA083636-01|A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women|A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|November 2009|June 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1208|||Female|25 Years|80 Years|No|||September 2015|September 22, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121640||122373|
NCT01117402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 588|Tomotherapy in Postsurgery Recurrent Carcinoma Cervix|Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix||Tata Memorial Hospital|Yes|Recruiting|December 2008|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Female|18 Years|65 Years|No|||May 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117402||122698|
NCT01117727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I0003 - AT SMR Switch Control|Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology|Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology||University of Michigan|No|Terminated|January 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 11, 2015|May 4, 2010||No|Performance of BCI switch insufficient in pilot testing.|No|May 27, 2015|https://clinicaltrials.gov/show/NCT01117727||122673|
NCT01117740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0103|Pleural Catheters Versus Thoracoscopic Pleurodesis|Comparative Effectiveness of Indwelling Pleural Catheters Versus Thoracoscopic Pleurodesis for Treatment of Malignant Pleural Effusions||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2010|||April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|445|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, 18 years or older, with malignant pleural effusions, suitable for either pleural        catheter placement or thoracoscopic pleurodesis.|July 2015|July 16, 2015|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01117740||122672|
NCT01117415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-40|Cost Effectiveness Analysis of Cholecystectomy, Projected Long Term Outcomes and Complications Evaluation|Cost Effectiveness Analysis of Transgastric Cholecystectomy, Transvaginal Cholecystectomy, and Laparoscopic Cholecystectomy: Projected Long Term Outcomes and Complications Evaluation|NOTES|University Hospital Case Medical Center|Yes|Completed|April 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participants will be recruited from the University Hospitals Case Medical Center        Department of Surgery. The patient population in this study for the visual analog scale        measurement, standard gamble questionnaire, and time trade-off questionnaire will be        candidates of either sex, 18 years old or above, who have symptomatic cholelithiasis and        wish to undergo laparoscopic cholecystectomy for treatment. The patients will be asked to        participate in the study after evaluation by either the principal investigator,        co-investigators, or study coordinator. The investigator will discuss the study with the        patient and the study coordinator will participate in reviewing details and questions        regarding the study if necessary. Patients will be recruited until 40 participants are        enrolled.|June 2015|June 4, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01117415||122697|
NCT01118247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-REK NORD 44/206|Primary Uncemented Partly Ti-coated Total Hip Prosthesis With and Without HA, and Alumina-on-alumina Articulation|Primary Uncemented Total Hip Prosthesis With Pure Ti With and Without HA, and Alumina-on-alumina Articulation||University Hospital of North Norway|Yes|Active, not recruiting|April 2004|March 2023|Anticipated|March 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|70 Years|No|||June 2015|June 1, 2015|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01118247||122633|
NCT01118546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P051026|Physiopathology of Rapid Aspirin Desensitization|Physiopathology of Rapid Aspirin Desensitization in Patients With Coronary Artery Disease and a History of Hypersensitivity to Aspirin or NSAIDs||Assistance Publique - Hôpitaux de Paris|No|Completed|February 2007|June 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|86|Samples Without DNA|plasma and urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary artery disease and a history of aspirin hypersensitivity, requiring        treatment with aspirin , referred to an academic tertiary center for desensitization|February 2015|February 24, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01118546||122610|
NCT01118234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mabtenance|Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)|International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Active, not recruiting|December 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01118234||122634|
NCT01118533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K080902|Impact of Blades Used for Scheduled Orotracheal Intubation on Postoperative Sore Throat|A Prospective, Multicenter, Randomized and Single Bind Trial. Influence of Laryngoscope Blade Material on Postoperative PHARYNGEAL AND LARYNGEAL Morbidity Following Scheduled OroTracheal Intubation|MPLIT|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|712|||Both|18 Years|70 Years|No|||March 2015|March 26, 2015|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01118533||122611|
NCT01150487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002572|Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients|Paired Bone Marrow Aspirations to Assess the Variability of Allo-ELISPOT and Allo-Specificities Assays in Sensitized Renal Allograft Recipients||Mayo Clinic|Yes|Recruiting|June 2010|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150487||120172|
NCT01150500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT2-07-05|RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries|RESOLUTE JAPAN SVS: The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries|RJ-SVS|Medtronic Vascular|Yes|Active, not recruiting|June 2010|June 2016|Anticipated|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|20 Years|N/A|No|||November 2015|November 20, 2015|June 23, 2010||No||No|October 30, 2012|https://clinicaltrials.gov/show/NCT01150500||120171|
NCT01150513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-007|Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer|Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer||Chinese Academy of Medical Sciences|No|Recruiting|June 2010|June 2020|Anticipated|June 2020|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Female|18 Years|70 Years|No|Probability Sample|female, 18-70 years old, pathologically confired breast cancer, after tumor rescetion, no        other treatment except surgery|March 2013|March 13, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01150513||120170|
NCT01119989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocole 51/10|Effects of an Amino-acid Supplement on Hepatic Lipid Metabolism|Effects of a Supplementation With Amino-acids on Hepatic Lipid Metabolism|AMINOFRUCT|University of Lausanne|No|Completed|May 2010|December 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|9|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119989||122500|
NCT01120223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0412 INT|Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis|Safety and Efficacy of Calcipotriol Plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis||LEO Pharma|No|Completed|May 2010|October 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|12 Years|17 Years|No|||March 2015|March 25, 2015|April 9, 2010|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01120223||122482|
NCT01121679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09472|French Observatory on Hospitalizations in Cardiology of Patients of 80 Years and Over|French Observatory on Hospitalizations in Cardiology of Patients of 80 Years and Over|OCTOCARDIO|French Cardiology Society|Yes|Completed|October 2009|June 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|534|||Both|80 Years|N/A|No|Probability Sample|Patients aged 80 years and older and hospitalized in a cardiology department which        participate in this study.|June 2012|June 15, 2012|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01121679||122370|
NCT01126359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29398|Lidocaine Analgesia For Removal Of Wound Vac Dressings|Lidocaine Analgesia For Removal Of Wound Vacuum Assisted Closure Dressings: A Randomized Double Blinded Controlled Trial||University of Utah|No|Completed|August 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|May 17, 2010||No||No|January 22, 2013|https://clinicaltrials.gov/show/NCT01126359||122011|Overall subjectivity of pain and dosing of narcotic medications, all male cohort, timing of wound VAC changes, did not define the ideal lidocaine dosing for VAC changes or dosing method.
NCT01126567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F09-113|Exploratory Biomarker Study of Cerebrospinal Fluid in Healthy Volunteers|A Study of the Effects of Sampling Rate on Cerebrospinal Fluid (CSF) Biomarker Levels in Healthy Subjects||Abbott||Completed|December 2009|February 2010|Actual|January 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8|Samples With DNA|Whole blood, plasma, cerebrospinal fluid|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|May 2010|May 18, 2010|February 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01126567||121996|
NCT01126580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11375|A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)|The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)||Eli Lilly and Company|No|Completed|May 2010|June 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|807|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|May 18, 2010|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01126580||121995|
NCT01126593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708009|Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion|Efficacy of Continuous Subacromial Bupivacaine Infusion for Postoperative Analgesia After Arthroscopic Rotator Cuff Repair.||Orlando Health, Inc.|Yes|Completed|December 2008|February 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|96|||Both|18 Years|90 Years|No|||November 2014|November 6, 2014|May 18, 2010|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT01126593||121994|It is possible that different catheter infusion rates, different bupivacaine concentrations, and pain modulation agents different from bupivacaine could result in different findings.
NCT01127321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP209|A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus|A Phase 1, Double-blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in SLE||MedImmune LLC|No|Terminated|May 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|44|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|April 14, 2010|No|Yes|Business reasons|No|August 11, 2014|https://clinicaltrials.gov/show/NCT01127321||121938|The study was terminated early by the sponsor due to business reasons.
NCT01117454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100472|Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia|A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia||Vanderbilt University|Yes|Completed|December 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Both|5 Years|99 Years|No|||February 2016|February 11, 2016|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117454||122694|
NCT01121315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSE-DUM-2010/1|A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care|A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Glucose Lowering Drug Treatment in Primary Care|ROSE|AstraZeneca|No|Completed|May 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|58326|||Both|N/A|N/A|No|Non-Probability Sample|Eligible subjects are all type II diabetes patients, found in medical records at the        participating centres. Patient data from the period 1 January 1999 - 31 December 2009 will        be included in the observation. To ensure a representative selection of primary care        centers, selection of study sites will be based on the following criteria to ensure a        representative sample of the Swedish population: a mix of rural and urban areas, public        and private care providers, small, mid sized and large primary care centers.|May 2012|May 10, 2012|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121315||122398|
NCT01121328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#1|Autologous Umbilical Cord Blood Transfusion for Preterm Neonates|Autologous Umbilical Cord Blood Transfusion for Preterm and Low Birth Weight Neonates: A Pilot Feasibility Study||Ain Shams University|No|Recruiting|July 2011|September 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|N/A|30 Days|No|||April 2013|April 25, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01121328||122397|
NCT01121627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-10-0036-ctil|Computer-based Cognitive Training for Parkinson Disease|Effects of Computer-based Cognitive Training on Gait Function in Individuals With Parkinson Disease||Clalit Health Services|No|Completed|July 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|50 Years|80 Years|No|||August 2015|August 21, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121627||122374|
NCT01118000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDNSFC7001664|Study on the Cardioprotection and Humoral Mechanism of Limb Ischemia Preconditioning|Study on the Cardioprotection and Humoral Mechanism of Limb Ischemia Preconditioning||Sun Yat-sen University|Yes|Completed|September 2009|March 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||April 2010|July 27, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01118000||122652|
NCT01118273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13053|Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine|A Double-Blind, Randomized, Pilot Study Assessing the Analgesic and Hypnotic Effect of Naproxen Sodium and Diphenhydramine Combination in Dental Pain||Bayer|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|162|||Both|16 Years|45 Years|No|||May 2015|May 13, 2015|April 15, 2010|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01118273||122631|
NCT01118559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-019|A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150|Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150||Astellas Pharma Inc|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2010|May 5, 2010|May 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01118559||122609|
NCT01118572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177-CL-102|A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients|A Phase III Study of YM177 (Postoperative Pain) -- An Etodolac- and Placebo-controlled, Multicenter, Double-blind, Group Comparison Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients --||Astellas Pharma Inc|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|616|||Both|20 Years|N/A|No|||October 2014|October 14, 2014|May 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01118572||122608|
NCT01118884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171598|Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide for Uncooperative Children|Sedative Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide/Oxygen on Behavior Management of Uncooperative Children Receiving Dental Treatment||Shahid Beheshti University|Yes|Active, not recruiting|June 2009|May 2010|Anticipated|April 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|20|||Both|36 Months|96 Months|Accepts Healthy Volunteers|||April 2010|May 6, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01118884||122584|
NCT01118858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD058556-01A1|Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics|Exogenous and Endogenous Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics||Children's Mercy Hospital Kansas City|No|Active, not recruiting|April 2010|April 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|220|Samples With DNA|Blood or saliva for DNA testing. Blood samples will be obtained for safety labs throughout      the study.|Both|7 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive        impulsive, or inattentive type (ADD). (110 subjects)        Controls: Age and gender matched subjects who do not meet any of the exclusion criteria        (110 subjects)|July 2015|July 27, 2015|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01118858||122586|
NCT01118871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST1.0|The First Failure Study|A Randomised, Open Label, Prospective Study to Assess Two Different Therapeutic Strategies Following First Treatment Failure in HIV-1 Infected Subjects|FAST|Imperial College London|No|Terminated|May 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2010|March 23, 2015|May 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118871||122585|
NCT01119144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS/SUR/2010/1|Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial|Comparing the Reconstruction of the Orbit Fracture With a Poly Caprolactone / Tri-Calcium Phosphate ( PCL/TCP ) Implant vs. a Titanium Mesh Implant.|PCL/TCP|National University Hospital, Singapore|Yes|Recruiting|April 2010|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|70 Years|No|||April 2014|April 24, 2014|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119144||122564|
NCT01119157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUSECURE-OEK-H01|Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines|Comparison of the Cellular and the Humoral Immunogenicity as Well as the Safety of Different Trivalent Influenza Vaccines in Healthy Adults Between 18 and 60 Years of Age|FLUSECUOEKH1|National Centre for Epidemiology, Hungary|Yes|Active, not recruiting|November 2008|August 2010|Anticipated|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 6, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01119157||122563|
NCT01120548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07|Sleep Apnea Treatment During Cardiac Rehabilitation of Congestive Heart Failure Patients|SLEEP DISORDERED BREATHING DURING CARDIAC REHABILITATION A Study of the Improvement in Physical Performance of Patients With Heart Failure During Cardiac Rehabilitation Due to the Correction of Sleep Disordered Breathing|SATELIT-HF|French Cardiology Society|No|Completed|September 2010|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|85 Years|No|||March 2015|March 6, 2015|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120548||122457|
NCT01120561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM4884g|A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer|An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer||Genentech, Inc.||Approved for marketing|May 2010|||||Phase 2|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||May 2013|May 9, 2013|May 7, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01120561||122456|
NCT01150786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|884746|Effect of Selenium on Serum Adiponectin, Homocystein and Malnutrition-inflammation Complex Syndrome in Hemodialysis Patients|Effect of Selenium Supplementation on Serum Adiponectin and Homocystein||Shiraz University of Medical Sciences|Yes|Completed|April 2009|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||February 2012|February 13, 2012|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01150786||120150|
NCT01121367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KZ200910025007|Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema|Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema||Beijing Chao Yang Hospital|Yes|Completed|May 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||5|Actual|82|Samples Without DNA|whole blood, serum, sputum|Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with emphysema，pulmonary fibrosis , combined pulmonary fibrosis and emphysema|May 2010|June 23, 2011|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01121367||122394|
NCT01130129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR02/2009|The Effects of Plant Bioactives on Platelet Function|The Effects of Plant Bioactives on Platelet Function||Institute of Food Research|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130129||121726|
NCT01126372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40795|Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease|Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease||University of Utah|No|Completed|May 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|N/A|1 Month|No|Non-Probability Sample|Infants admitted into the NICU at PCMC (Salt Lake City, UT) with a prostaglandin-dependent        congenital heart defect (CHD).|August 2013|August 9, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126372||122010|
NCT01126346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97110|Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HOPE Program: Quality of Life Enhancement and Survivorship Care|HOPE|Comprehensive Cancer Center of Wake Forest University|No|Completed|May 2010|October 2013|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|N/A|N/A|No|||July 2014|July 21, 2014|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01126346||122012|
NCT01126866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-2007-11-02-1003|Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy|Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab)|APRIORI|National Center for Tumor Diseases, Heidelberg|Yes|Terminated|June 2009|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2011|July 14, 2011|May 12, 2010||No|recruiting inadequate|No||https://clinicaltrials.gov/show/NCT01126866||121973|
NCT01127100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuropathic pain 2010|Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain|Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial||Seoul National University Hospital|No|Enrolling by invitation|May 2010|January 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Both|20 Years|80 Years|No|||May 2015|May 24, 2015|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127100||121955|
NCT01121653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0073|Impact of Oral Magnesium on Neuropathic Pain|Impact of Oral Magnesium on Neuropathic Pain||University Hospital, Clermont-Ferrand||Completed|March 2006|June 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|||Actual|50|||Both|18 Years|N/A|No|||May 2010|May 10, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121653||122372|
NCT01117428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sym004-01|Sym004 in Patients With Advanced Solid Tumors|An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors||Symphogen A/S|Yes|Completed|March 2010|May 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117428||122696|
NCT01117441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIEOP-BFM ALL 2009|International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia|International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia||University of Schleswig-Holstein|Yes|Recruiting|June 2010|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|4750|||Both|1 Year|18 Years|No|||December 2014|December 2, 2014|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117441||122695|
NCT01117766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011015|Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain|A Randomized, Double Blind, Placebo Controlled, 2-Way Crossover Methodology Study Designed To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing (QST) In Patients With Neuropathic Pain Treated With Pregabalin Vs Placebo||Pfizer||Completed|December 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|31|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|May 4, 2010||No||No|September 1, 2010|https://clinicaltrials.gov/show/NCT01117766||122670|
NCT01118286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14296|Treatment of Hypertension With Adalat® in Combination With Other Drugs|AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy||Bayer|No|Completed|January 2010|September 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4497|||Both|18 Years|N/A|No|Non-Probability Sample|Previously untreated hypertensive adult patients starting with combination therapy        containing nifedipine or insufficiently controlled hypertensive patients receiving        nifedipine as an add-on to existing non-CCB containing antihypertensive therapy|June 2012|June 26, 2012|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118286||122630|
NCT01118299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL00921|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||February 2, 2015|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118299||122629|
NCT01128478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTX/08/11/107|MIld to MOderate Acute Pancreatitis: Early naSogastric Tube Feeding Compared With pAncreas Rest (MIMOSA)|Early Enteral Tube Feeding Compared With Pancreas Rest in Patients With Acute Pancreatitis: a Randomized Controlled Trial|MIMOSA|University of Auckland, New Zealand|Yes|Completed|May 2010|April 2012|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|N/A|No|||January 2013|January 5, 2013|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01128478||121850|
NCT01128725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-01|Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers|||Centre Hospitalier Universitaire de Nice|No|Recruiting|September 2010|December 2012|Anticipated|September 2010|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2010|March 23, 2012|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128725||121833|
NCT01128738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114078|GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Including an Open-label Phase to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Axillary Hyperhidrosis||GlaxoSmithKline|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|152|||Both|20 Years|75 Years|No|||May 2015|May 13, 2015|May 20, 2010|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01128738||121832|
NCT01119443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.677|Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers|A Multiple Dose Study With Increasing Dose for Pramipexole Extended Release (ER) Tablet (0.375 mg q.d. to 1.5 mg q.d.) in Two-way Cross-over Comparison to Investigate the Bioequivalence of 1.5 mg ER x 1 Tablet q.d. Versus 0.375 mg ER x 4 Tablets q.d. Under Fasted and Fed Conditions in Japanese Healthy Male Volunteers||Boehringer Ingelheim||Completed|April 2010|||June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||May 2014|June 3, 2014|May 5, 2010||||No|May 30, 2011|https://clinicaltrials.gov/show/NCT01119443||122541|
NCT01119456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13958|A Study of IMC-RON8 in Advanced Solid Tumors|Phase 1 Study of the Anti-Ron Receptor Monoclonal Antibody IMC-RON8 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available||Eli Lilly and Company|No|Completed|May 2010|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01119456||122540|
NCT01119742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTNF-0909|Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams to Lotrimin Ultra® Cream in Patients With Interdigital Tinea Pedis|BNF-0909|Taro Pharmaceuticals USA|No|Terminated|July 2010|July 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|428|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|May 6, 2010|No|Yes|Insufficient number of baseline eligible patient|No||https://clinicaltrials.gov/show/NCT01119742||122519|
NCT01119755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV|Seasonal Variation of Ambulatory Blood Pressure|Seasonal Variation of 24hour Ambulatory Blood Pressure Monitoring in Treated Hypertensives||University of Athens|No|Completed|January 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|40 Years|80 Years|No|Non-Probability Sample|TREATED HYPERTENSIVES REFERRED TO AN OUTPATIENT CLINIC|December 2011|December 8, 2011|April 21, 2010||No||No|December 8, 2011|https://clinicaltrials.gov/show/NCT01119755||122518|
NCT01120262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669307|Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin|Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy||National Cancer Institute (NCI)||Not yet recruiting|February 2010|||March 2010|Anticipated|N/A|Observational|N/A|||Anticipated|545|||Male|18 Years|N/A|No|||May 2010|March 5, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120262||122479|
NCT01120782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1476AI|Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types|||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2010|||February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|40 Years|No|||May 2015|May 5, 2015|May 4, 2010|Yes|Yes||No|November 4, 2011|https://clinicaltrials.gov/show/NCT01120782||122439|
NCT01120769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100001|Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction|Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction|APRIORI Pilot|Vanderbilt University|No|Withdrawn|July 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 6, 2010||No|Funding issue|No||https://clinicaltrials.gov/show/NCT01120769||122440|
NCT01121042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145/10|Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia|Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia||Bayside Health|Yes|Recruiting|July 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|May 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01121042||122419|
NCT01120795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 2000.175|Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy|Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes||Melbourne Health|No|Completed|February 2004|July 2006|Actual|January 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|No|||May 2010|May 27, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120795||122438|
NCT01129804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-050|Network Support for Alcohol Treatment 2|Network Support for Alcohol Treatment: Mechanisms and Effectiveness|Net Support 2|University of Connecticut Health Center|No|Active, not recruiting|September 2009|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|85 Years|No|||November 2015|November 30, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129804||121750|
NCT01130142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-926-03|A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer|A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer||Infinity Pharmaceuticals, Inc.|Yes|Completed|April 2010|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|April 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130142||121725|
NCT01130428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-026|Mechanical Bone Stimulation and Adenosine 5'-Triphosphate (ATP) Release in Humans|Pilot Study on the Effect of Mechanical Stimulation of Bone on ATP Release in Humans in Vivo||Maastricht University Medical Center|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2011|April 19, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130428||121704|
NCT01117831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD0108|An Analysis of Diabetes Control in Puerto Rico|An Analysis of Variables That Affect Quality of Diabetes Control in Puerto Rico||Center for Diabetes Control, Inc.|No|Enrolling by invitation|March 2010|February 2013|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|90 Years|No|Non-Probability Sample|This epidemiologic study will analyzed a 600 type 1 and 2 Diabetic patients under        medication. The populations to be analyzed is composed of female and male subjects under        therapy with anti diabetic medication. The population will be selected from four high        density cities in the Island of Puerto Rico. Puerto Ricans are considered as hispanic        populations with a mix of white hispanic, african people on a basis of indians ancestry.        Subjects will be invited to participate in the study.|May 2010|May 5, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117831||122665|
NCT01126606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_04937|Comparative Safety and Efficacy Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional|Single Center, Open, Cross-over, Phase III Study for Safety and Efficacy (Subjective and Instrumental) Comparative Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional for Intimate Use in Menopauses Woman.||Sanofi||Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|45 Years|65 Years|No|||December 2010|December 1, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126606||121993|
NCT01127373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-025|Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer|Pilot Study of Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer Patients Requiring Treatment of the Internal Mammary Lymph Nodes||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|May 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01127373||121934|
NCT01118650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBD0108|Concordance of the Quotient Attention Deficit Hyperactivity Disorder (ADHD) System Report With Teacher and Parent Assessments for Symptoms of ADHD|Concordance of the Quotient ADHD System Report With Teacher and Parent Assessments in School-Aged Children Receiving an Individualized Education Program (IEP) or 504 Accommodations in the Classroom Setting for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD)||BioBehavioral Diagnostics Company|No|Withdrawn|June 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|8 Years|14 Years|No|Non-Probability Sample|Public School based study for children ages 8 through 14 years of age who have been        identified and are currently receiving an Individualized Education Program (IEP) or 504        accommodations in the classroom setting for symptoms of Attention Deficit Hyperactivity        Disorder|April 2012|April 17, 2012|May 5, 2010|No|Yes|No interest from school district|No||https://clinicaltrials.gov/show/NCT01118650||122602|
NCT01126840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0160|Survivorship in Lynch Syndrome Families|Cancer Survivorship in Lynch Syndrome: Impact on Patients and Families||M.D. Anderson Cancer Center|No|Recruiting|December 2010|||July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|610|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Colorectal cancer (CRC) patients with Lynch-syndrome related CRC or with sporadic CRC;        along with first-degree relatives (FDRs), Siblings or adult children of recruited CRC        patients|January 2016|January 26, 2016|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126840||121975|
NCT01126853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSH 09-0220-E|Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders|A Pilot Study Evaluating the Combination Hepatitis A and B Vaccine (Twinrix®) in Healthy Healthcare Workers Who Meet the CDC Definition for Non-responders.||Mount Sinai Hospital, Canada|Yes|Recruiting|April 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||May 2010|May 18, 2010|April 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126853||121974|
NCT01117779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUC10-RNL02-01|Tracking Renal Tumors After Cryoablation Evaluation|Tracking Renal Tumors After Cryoablation Evaluation (TRACE) Registry|TRACE|Galil Medical|Yes|Recruiting|May 2010|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Academic medical centers and community-based physicians|October 2015|October 16, 2015|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117779||122669|
NCT01118013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-100601|Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant|Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation||Alliance for Clinical Trials in Oncology|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|69 Years|No|||July 2015|July 9, 2015|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118013||122651|
NCT01118260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-002672-42|Total Intravenous Anaesthesia (TIVA) Versus Spinal Anaesthesia in Patients Undergoing Transurethral Prostate Resection|TIVA Versus Spinal Anaesthesia in Patients Undergoing Transurethral Prostate Resection|TURPS|Asker & Baerum Hospital|No|Completed|January 2006|May 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Male|18 Years|N/A|No|||May 2010|May 5, 2010|April 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01118260||122632|
NCT01128153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680L00006|Saxagliptin Triple Oral Therapy|A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea||AstraZeneca|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|May 20, 2010|Yes|Yes||No|June 11, 2012|https://clinicaltrials.gov/show/NCT01128153||121874|
NCT01127919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK062148|Training Interventions and Genetics of Exercise Response (TIGER)|Training Interventions and Genetics of Exercise Response (TIGER)|TIGER|University of Texas at Austin|No|Recruiting|July 2010|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3200|Samples With DNA|Blood components and DNA|Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|The target for phase 2 of the TIGER study is a student, age 18-30, who has not engaged in        moderate physical activity more than 30 minutes per week for the previous 30 days and who        is not actively limiting his/her caloric intake by dieting. It is planned to enroll a        total of 3,200 subjects from student populations at the University of Houston (UH) and the        University of Alabama at Birmingham (UAB) and representative of the race/ethnicity        distribution of the respective campuses. Approximately 2,400 subjects will participate in        the exercise protocol (600/yr for four years). A control group (200/yr for four years)        will also be recruited that will not participate in the formal exercise for at least 35        weeks, but will be given the option of completing the formal exercise program after that        time.|May 2015|May 28, 2015|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127919||121892|
NCT01128166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MultiSENSE|Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices|Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients|MultiSENSE|Boston Scientific Corporation|Yes|Completed|June 2010|July 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|975|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with CRT-D devices(Heart Failure patients)|October 2015|October 19, 2015|May 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01128166||121873|
NCT01128179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-703|Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD|A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease||Shire||Completed|November 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||June 2013|June 16, 2014|May 20, 2010|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01128179||121872|
NCT01129037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0084BE|Goal Directed Fluid Therapy in Free Flap Reconstructive Surgery|Goal Directed Fluid Management and Patient Outcome in Free Flap Reconstructive Surgery for Head and Neck Oncology: a Feasibility Randomized, Controlled Trial||University Health Network, Toronto|No|Completed|July 2010|February 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|78|||Both|18 Years|80 Years|No|||April 2015|April 17, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01129037||121809|
NCT01129050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05042010-5842|Effects of Omega-3 Fatty Acids on Markers of Inflammation|ALA & EPA/DHA (w-3) Effects on Inflammatory Markers In Insulin Resistant Adults||Stanford University||Completed|April 2007|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 21, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01129050||121808|
NCT01128751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P41/09// A67/09|Elimination of Microemboli During Aortic Valve Replacement|ELMAR - Elimination of Microemboli During Aortic Valve Replacement. A Randomized Controlled Trial|ELMAR|University of Giessen|No|Recruiting|March 2010|||December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|N/A|No|||May 2010|May 21, 2010|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01128751||121831|
NCT01151670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97409|Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors|Use of Pioglitazone for the Prevention of Radiation-Induced Cognitive Dysfunction||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|August 2010|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151670||120084|
NCT01121081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7464-FP-CTIL|The Effect of Algae Dunaliella Bardawil on Psoriasis (2)|A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis Treated by Narrow Band UVB Therapy||Sheba Medical Center|No|Withdrawn|January 2010|January 2012|Anticipated|January 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||January 2013|January 23, 2013|April 11, 2010||No|no patients enrolled|No||https://clinicaltrials.gov/show/NCT01121081||122416|
NCT01129817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250.05.|Efficacy of Classification Based 'Cognitive Functional Therapy' in Patients With Non Specific Chronic Low Back Pain|Efficacy of Classification Based 'Cognitive Functional Therapy' in Patients With Non Specific Chronic Low Back Pain (NSCLBP) - A Randomized Controlled Trial||University of Bergen|Yes|Completed|March 2006|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2010|May 24, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01129817||121749|
NCT01130441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098047-3|Self-harming Behaviors Study of Adolescents in a Juvenile Detention House|Study on Self-harming Behaviors of Adolescents in a Juvenile Detention House||Far Eastern Memorial Hospital|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|277|||Both|11 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Youth admitted at juvenile detention center in Taiwan|January 2013|January 9, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130441||121703|
NCT01118078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN10B2|Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor|Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors||Children's Oncology Group|No|Recruiting|May 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|185|Samples With DNA|Archived tumor tissue samples|Both|N/A|16 Years|No|Non-Probability Sample|Up to 80 favorable histology Wilms tumors that relapse (RFHWT), 50 anaplastic Wilms tumors        (UHWT), 15 clear cell sarcomas of the kidney (CCSK), and 40 rhabdoid tumors (RT)|November 2015|November 5, 2015|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118078||122646|
NCT01127113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDO001|Inflammatory Cell Trafficking After Myocardial Infarction|Inflammatory Cell Labelling and Tracking With Magnetic Resonance Imaging After Myocardial Infarction||University of Edinburgh|No|Suspended|January 2010|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|66|||Both|18 Years|80 Years|No|||December 2014|December 3, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01127113||121954|
NCT01118377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO21125|A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas|A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas||Hoffmann-La Roche||Completed|May 2007|April 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|3 Years|17 Years|No|||February 2014|February 4, 2014|April 15, 2010|Yes|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01118377||122623|
NCT01118663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-NAC-001|Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection|A Multi-center, Double-blind, Randomized, Controlled Study to Determine the Efficacy and Safety of a New Formulation of Acetylcysteine Injection||Cumberland Pharmaceuticals|Yes|Terminated|September 2010|May 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|12 Years|N/A|No|||August 2014|August 1, 2014|May 4, 2010|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01118663||122601|
NCT01127360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008|LUCAS (Lucentis Compared to Avastin Study)|LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration|LUCAS|Oslo University Hospital|Yes|Completed|March 2009|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|420|||Both|50 Years|N/A|No|||January 2015|January 15, 2015|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127360||121935|
NCT01118923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9727d|Bronchial Challenge Test of Magnesium-treated Asthmatics|Metacholine-provocation of Mablet-treated Asthmatics||University of Aarhus|Yes|Completed|October 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|70 Years|No|||September 2013|September 3, 2013|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01118923||122581|
NCT01127906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1351003|Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin|A Randomized, Double-Blind, Double-Dummy, Placebo And Active Comparator Controlled 4-Period Cross-Over Study To Assess The Effect Of PF-04531083 On Heat Pain In The UVB-Induced Pain Model In Healthy Volunteers||Pfizer|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 22, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127906||121893|
NCT01127334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0069|Pilot Study Using Echocardiography to Evaluate Patients With Heart Failure and Dyssynchrony Who Have a CRT-D Device|Validation of a Robust Method for Kinematic Analysis of Ventricular Mechanical Dyssynchrony by Two Dimensional Echocardiography in Patients With Cardiac Resynchronization Devices for Chronic Systolic Heart Failure and Conduction System Disease||University of Mississippi Medical Center|No|Withdrawn|May 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiology and electrophysiology clinics|May 2010|April 2, 2012|May 19, 2010||No|Principal Investigator terminated study|No||https://clinicaltrials.gov/show/NCT01127334||121937|
NCT01127633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11935|Continued Safety Monitoring of Solanezumab in Alzheimer's Disease|Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease|EXPEDITION EXT|Eli Lilly and Company|Yes|Active, not recruiting|December 2010|November 2018|Anticipated|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1275|||Both|55 Years|N/A|No|||September 2015|September 17, 2015|May 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01127633||121914|
NCT01128530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32729463CSI2001|Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)|A Randomized, Controlled, Double-Blind, Double Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection||Furiex Pharmaceuticals, Inc|No|Completed|June 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|70 Years|No|||December 2011|December 9, 2011|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128530||121848|
NCT01120041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37124-C|Community-based Intergenerational Oral Health Study|Community-based Intergenerational Oral Health Promotion In Rural America|Baby Smiles|University of Washington|Yes|Recruiting|May 2010|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|400|||Female|15 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 10, 2011|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120041||122496|
NCT01128764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH083092|Integrated Treatment for Comorbid Depression and Obesity in Adolescents|Integrated Treatment for Comorbid Depression and Obesity in Adolescents||Brown University|Yes|Completed|December 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Both|12 Years|18 Years|No|||July 2014|July 28, 2014|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128764||121830|
NCT01128517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECF|Maternal Education on Complementary Feeding and Infant Outcome|Does Maternal Education on Complementary Feeding Have an Impact on Infant Nutritional Status in Low Middle-income Households? A Community Based Randomized Interventional Study in Karachi, Pakistan.||Aga Khan University|No|Completed|October 2008|May 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|175|||Both|3 Months|5 Months|No|||April 2010|May 21, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01128517||121849|
NCT01151384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE-DT-101|Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors|A Phase 1 Study of Liposome Encapsulated Docetaxel (LE-DT) in Patients With Advanced Solid Tumors|LE-DT|INSYS Therapeutics Inc|Yes|Completed|February 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2011|June 30, 2011|June 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01151384||120106|
NCT01151982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/00081|Primary Prevention of Major Depression Based on the Level and Profile of Risk of Primary Care Attenders: Cluster, Controlled, Randomised Trial|Primary Prevention of Major Depression Based on the Level and Profile of Risk of Primary Care Attenders: Cluster, Controlled, Randomised Trial|predictD-CCRT|The Mediterranean Institute for the Advance of Biotechnology and Health Research|No|Completed|October 2010|January 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|3326|||Both|18 Years|75 Years|No|||November 2014|November 17, 2014|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151982||120060|
NCT01151969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0505|Effectiveness of the "7H" Intervention to Reduce Frequent Attendance in Primary Care|Effectiveness of the "7H" Intervention to Reduce Frequent Attendance in Primary Care: Cluster Randomised Controlled Trial. The "7H" Study|"7H"|The Mediterranean Institute for the Advance of Biotechnology and Health Research|No|Completed|January 2010|June 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|527|||Both|14 Years|N/A|No|||March 2015|March 26, 2015|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01151969||120061|
NCT01130155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHGBVG04|IMPACT2: Monitoring Interventions to Improve Artemisinin-based Combination Therapy (ACT) Access and Targeting|IMPACT2: Monitoring Interventions to Improve ACT Access and Targeting|IMPACT2|London School of Hygiene and Tropical Medicine|Yes|Active, not recruiting|May 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||3|Anticipated|33900|||Both|3 Months|N/A|Accepts Healthy Volunteers|Probability Sample|For the household survey, all selected households in Mtwara, and Mwanza and Mbeya Regions        in Tanzania.        For the health facility survey patients presenting to selected health facilities with        fever or history of fever in the prior 24 hours.|June 2011|June 22, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130155||121724|
NCT01117545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-PTSD-5410|Psychological Symptom Change in Veterans After Six Sessions of EFT (Emotional Freedom Techniques)|Psychological Symptom Change in Veterans After Six Sessions of EFT (Emotional Freedom Techniques): A Randomized Controlled Trial||Soul Medicine Institute|No|Recruiting|May 2010|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117545||122687|
NCT01118988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD057421-01A2|Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents|Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents||University of California, Los Angeles|Yes|Completed|December 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|12 Years|18 Years|No|||February 2016|February 10, 2016|April 27, 2010||No||No|February 10, 2016|https://clinicaltrials.gov/show/NCT01118988||122576|
NCT01118065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT-LUMC-CRAD001CNL08T|Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer|A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma||National Cancer Institute (NCI)||Recruiting|May 2010|||May 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||May 2010|August 9, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118065||122647|
NCT01118962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0962|Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy|An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy||UCB Pharma|No|Completed|August 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|16 Years|65 Years|No|||March 2015|March 23, 2015|May 5, 2010|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT01118962||122578|
NCT01118975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040048|GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers|GCC 0845: Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells||University of Maryland|Yes|Terminated|March 2010|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|May 5, 2010|Yes|Yes|Lost sponsorship for study drug|No|March 20, 2014|https://clinicaltrials.gov/show/NCT01118975||122577|The most important limitation of this study is that the Phase II efficacy portion was terminated early by the sponsor.
NCT01119248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120100053|Pediatric Temperature Variation in the MRI Scanner Under General Anesthesia|Pediatric Temperature Variation in the MRI Scanner Under General Anesthesia||Rutgers, The State University of New Jersey|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|121|||Both|6 Months|8 Years|No|Probability Sample|Children 6 months to 8 years|January 2013|January 24, 2013|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119248||122556|
NCT01119261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COU-001A|EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol|EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol|EU-PACT|Utrecht Institute for Pharmaceutical Sciences|Yes|Completed|November 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|970|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01119261||122555|
NCT01118936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9727e|Daily Magnesium-treatment of Patients With Chronic Obstructive Pulmonary Disease|Daily Mablet-treatment of Patients With COPD||University of Aarhus|Yes|Completed|October 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|11|||Both|40 Years|70 Years|No|||September 2013|September 3, 2013|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01118936||122580|
NCT01127607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IITWW#2|Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?|Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?||Florida International University|No|Completed|November 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|55 Years|No|||June 2014|June 10, 2014|May 19, 2010|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01127607||121916|This study was limited by its small sample size. The validity and psychometrics of DPICS in adolescents is not well established, but removal of the adolescents had little impact on study results and actually strengthened some observed effects.
NCT01127620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 1503/RAP|Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension|A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg||Faes Farma, S.A.|No|Completed|May 2004|November 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|650|||Both|12 Years|70 Years|No|||September 2012|September 25, 2012|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127620||121915|
NCT01127347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-CMF-C-18-130-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2010|||||N/A|N/A|N/A||||||||||||||March 21, 2013|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01127347||121936|
NCT01127932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21DA026925-02|Developing an Intervention to Address Suicide Risk During Substance Use Disorder|||University of Michigan|No|Completed|April 2010|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|56|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127932||121891|
NCT01128192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOM230Novartis/VMRF|Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers|Phase 2, Double-Blind, Randomized, Single Center Trial to Assess the Mechanism(s) Responsible for the Effect of the Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers. Version #2 05/09/2009|Pasireotide|Veterans Medical Research Foundation|No|Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|September 15, 2009|Yes|Yes||No|July 26, 2013|https://clinicaltrials.gov/show/NCT01128192||121871|
NCT01120054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0170|Traumatic Brain Injury Among Homeless Veterans|Traumatic Brain Injury Among Homeless Veterans||VA Eastern Colorado Health Care System|No|Active, not recruiting|May 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2000|||Both|18 Years|89 Years|No|Non-Probability Sample|Homeless Veterans|January 2016|January 13, 2016|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120054||122495|
NCT01120301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTS-INT08-009|Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)|NeuroThera® Efficacy and Safety Trial - 3 (NEST-3) A Double-blind, Randomized, Sham-controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Efficacy of Transcranial Laser Therapy With the NeuroThera® Laser System for the Treatment of Acute Ischemic Stroke Within 24 Hours of Stroke Onset|NEST-3|PhotoThera, Inc|Yes|Completed|September 2010|||September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|40 Years|80 Years|No|||October 2012|November 14, 2013|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120301||122476|
NCT01129076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910104|Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma|Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma||National Institutes of Health Clinical Center (CC)||Completed|April 2010|January 2016||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|14 Years|N/A|No|||January 2016|January 8, 2016|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129076||121806|
NCT01151397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genotype 2,3 HCV +Vitamin D|Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?|Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve SVR in Genotype 2,3 Chronic Hepatitis C Patients?||Ziv Hospital|No|Not yet recruiting|August 2011|July 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2010|April 27, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01151397||120105|
NCT01151423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-0681-2.1/10|Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)|A Phase II, Single-blind, Randomised, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura|TITAN|Ablynx|Yes|Completed|September 2010|||April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||June 2015|July 22, 2015|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151423||120103|
NCT01152294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSR-DQ1-001|Measuring Quality of Decisions About Treatment of Menopausal Symptoms|Measuring Quality of Decisions About Treatment of Menopausal Symptoms||University of Massachusetts, Boston|No|Completed|June 2010|November 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|401|||Female|40 Years|60 Years|No|||July 2012|July 13, 2012|June 22, 2010||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT01152294||120036|Participants who answered less than half the knowledge questions do not have a total knowledge score (primary outcome).
NCT01152307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSR-DQ1-002|Measuring Quality of Decisions About Treatment of Depression|Measuring Quality of Decisions About Treatment of Depression||University of Massachusetts, Boston|No|Completed|June 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|405|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|June 22, 2010||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT01152307||120035|Those who answered fewer than half of the knowledge questions do not have a total knowledge score (primary outcome).
NCT01121744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC001:V.1.0:Dated 12/12/2008.|Supralimus-Core™ Pharmacokinetic (PK) Study|Supralimus-Core™ Pharmacokinetic (PK) Study: Evaluation of Pharmacokinetic (PK) and Safety of the Supralimus-Core™ Sirolimus Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions||Sahajanand Medical Technologies Pvt. Ltd.|Yes|Completed|April 2010|January 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121744||122365|
NCT01117532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-DEP-5410|Brief Group Intervention Using EFT (Emotional Freedom Techniques) for Depression in College Students|Brief Group Intervention Using EFT (Emotional Freedom Techniques) for Depression in College Students: A Randomized Controlled Trial||Soul Medicine Institute|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|16 Years|25 Years|Accepts Healthy Volunteers|||May 2010|May 28, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117532||122688|
NCT01117844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 24309|Proton Radiation For Meningiomas and Hemangiopericytomas|Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2010|||February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117844||122664|
NCT01119001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0004|A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis|A P300 Brain Computer Interface Keyboard to Control Assistive Technology for People With Amyotrophic Lateral Sclerosis||University of Michigan|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|May 5, 2010||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01119001||122575|
NCT01119014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAprotocolversion5-11 03 2010|Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis|Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis|TEA|University of Copenhagen|Yes|Active, not recruiting|May 2010|July 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01119014||122574|
NCT01118390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0072/09|Treatment of Leg Telangiectasias With Nd:YAG 1064nm|Treatment of Leg Telangiectasias With Nd:YAG 1064nm||Grupo de Cirurgia Vascular|Yes|Enrolling by invitation|August 2009|July 2010|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||August 2009|May 5, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01118390||122622|
NCT01118676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 POUM 01|Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer|Phase I Trial Evaluating Continuous Infusion of Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer||Institut Claudius Regaud|No|Completed|March 2010|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118676||122600|
NCT01119274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COU-001P|EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon|EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon|EU-PACT|Utrecht Institute for Pharmaceutical Sciences|Yes|Completed|November 2010|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|970|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01119274||122554|
NCT01119859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA19924|A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis|A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|326|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|April 1, 2010|Yes|Yes||No|September 18, 2012|https://clinicaltrials.gov/show/NCT01119859||122510|
NCT01120093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/29|Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.|Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator All Administered Twice Daily by Inhalation in Patients With Stable Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD).||Almirall, S.A.|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|79|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|May 7, 2010||No||No|August 14, 2012|https://clinicaltrials.gov/show/NCT01120093||122492|
NCT01120106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|levoTGA1|Levosimendan Administration in Neonates With Transposition of the Great Arteries|Perioperative Levosimendan Administration in Neonates With Transposition of the Great Arteries: Randomized Controlled Trial||Bambino Gesù Hospital and Research Institute|No|Completed|January 2009|September 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|N/A|30 Days|No|||June 2012|June 22, 2012|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120106||122491|
NCT01118949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0961|Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy|An Open-Label Pilot Study to Assess the Safety of Oral Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy||UCB Pharma|Yes|Completed|May 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|16 Years|65 Years|No|||March 2015|March 10, 2015|May 5, 2010|Yes|Yes||No|August 8, 2012|https://clinicaltrials.gov/show/NCT01118949||122579|
NCT01127087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000676|Oxazyme in Patients With Hyperoxaluria|A Pilot Study to Evaluate the Safety and Efficacy of Oxazyme (OC4) in Patients With Hyperoxaluria||Mayo Clinic|No|Completed|May 2010|October 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|May 14, 2010||No||No|November 21, 2012|https://clinicaltrials.gov/show/NCT01127087||121956|
NCT01119547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPOA-E|Patient Education Program for Osteoarthritis With Exercise Included|The Effect of Including Exercise in an Education Program for Patients With Osteoarthritis in Primary Health Care|PEPOA-E|Lund University|No|Not yet recruiting|September 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||April 2010|May 6, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01119547||122534|
NCT01119794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-NHL-227|Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab|Ofatumumab in Combination With Bortesomib in Patients With Relapsed or Refractory Low-Grade Non-Hodgkins Lymphoma||Brown University|Yes|Terminated|July 2010|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|May 6, 2010|Yes|Yes|lack of accrual|No|July 15, 2015|https://clinicaltrials.gov/show/NCT01119794||122515|
NCT01119807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeckIO2010|Intraosseous Versus Intravenous Vascular Access During Cardiac Arrest|Intraosseous Versus Intravenous Vascular Access During Cardiac Arrest||Carolinas Medical Center|Yes|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119807||122514|
NCT01120067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6281-I|Intensive Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)|Intensive Treatment of Chronic Pain and PTSD for OEF/OIF Veterans||VA Office of Research and Development|No|Active, not recruiting|August 2010|December 2015|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01120067||122494|
NCT01120314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP6537|Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment|An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function||Sanofi|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|48|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01120314||122475|
NCT01120327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amlodipine study|A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients|A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients||Seoul National University Hospital|Yes|Not yet recruiting|July 2010|December 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|212|||Both|20 Years|80 Years|No|||May 2010|May 7, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01120327||122474|
NCT01120574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR05/05/2007|Home Mechanical Ventilation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Hypercapnic Response|Home Mechanical Ventilation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Develop Nocturnal Hypercapnic Response Associated to Oxygen Therapy||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|October 2005|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Both|N/A|80 Years|No|||February 2014|February 21, 2014|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01120574||122455|
NCT01151410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2365E1|An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age|A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age||Novartis||Completed|August 2010|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|208|||Both|6 Years|17 Years|No|||January 2016|February 8, 2016|June 23, 2010|Yes|Yes||No|February 8, 2016|https://clinicaltrials.gov/show/NCT01151410||120104|
NCT01152047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/502|The Effect of Oxytocin on Gastric Emptying|The Effect of Oxytocin on Satiety in Patients With Dyspepsia||Skane University Hospital|No|Completed|May 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01152047||120055|
NCT01152060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00100504|Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial|an Open Parallel Clinical Trial in HBV-GN Patients||Nanchang University|No|Active, not recruiting|January 2010|November 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10|Samples Without DNA|not available|Both|18 Years|60 Years|No|Probability Sample|HBV-MN patients with heavy proteinuria in adults; HBsAg or HBeAg positive; HBV-DNA        negative|May 2010|June 28, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152060||120054|
NCT01121757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019069|Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma|A Phase 2 Study Evaluating the Efficacy of Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma||Duke University|No|Completed|April 2010|January 2016|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|February 11, 2010|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01121757||122364|
NCT01117558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-98010|Study of Metabolism and Cardiovascular Disease(CVD) in Women With Polycystic Ovary Syndrome (PCOS)|The Risk of Metabolic Syndrome and Cardiovascular Disease in Women With Polycystic Ovary Syndrome.||Taipei Medical University WanFang Hospital|No|Completed|May 2009|April 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Female|15 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Polycystic Ovary Syndrome(PCOS)|September 2013|September 10, 2013|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117558||122686|
NCT01118689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INK-128-002|Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia|A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia||Millennium Pharmaceuticals, Inc.|No|Completed|November 2010|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|May 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01118689||122599|
NCT01118702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017179|A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers|A Randomized, Open-label, Single-dose, Three-way Crossover Study to Determine the Relative Pharmacokinetic Profile of Oral Doses of CONCERTA Tablets, Ritalin-SR Tablets and Novo-Methylphenidate ER-CTablets Under Fasted Condition in Healthy Subjects||Janssen-Ortho Inc., Canada||Completed|May 2010|June 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118702||122598|
NCT01119625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113266|Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose|Evaluation of Immunological Persistence Following 3-dose Priming With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine in Study NCT00808444 and Safety and Immunogenicity Following a Booster Dose of the Same Vaccine||GlaxoSmithKline||Completed|July 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|238|||Both|18 Months|21 Months|Accepts Healthy Volunteers|||June 2012|June 14, 2012|April 22, 2010|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01119625||122528|
NCT01120132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOV1101/CLIN202|Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Administration of FOV1101-00 (Cyclosporine Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Mild Ongoing Ocular Allergic Inflammation||Fovea Pharmaceuticals SA|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|716|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01120132||122489|
NCT01119599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01410|RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma|Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study||National Cancer Institute (NCI)||Completed|May 2010|||June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|19 Years|N/A|No|||June 2015|September 28, 2015|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01119599||122530|
NCT01119612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD061232|Prenatal Iron Supplements: Safety and Efficacy in Tanzania|Prenatal Iron Supplements: Safety and Efficacy in Tanzania|MAL1|Harvard School of Public Health|Yes|Completed|September 2010|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01119612||122529|
NCT01119872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI-HUPA-1|Pilot Study of Positive-End Expiratory Pressure in Acute Respiratory Distress Syndrome|Randomized Controlled Pilot Study of Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome(ARDS): Individualized According to the Best Compliance or Fixed According to Fraction of Inspired Oxygen (FiO2) Applied|PEEP-HUPA|Hospital Universitario Principe de Asturias|No|Completed|January 2003|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||December 2002|May 7, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119872||122509|
NCT01119586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL10B2|Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia|Identifying Rare Genetic Variants Involved in High Risk Acute Lymphoblastic Leukemia (ALL) Via Pooled DNA Sequencing||Children's Oncology Group|No|Active, not recruiting|February 2013|||December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|DNA|Both|1 Year|30 Years|No|Non-Probability Sample|Patients With High-Risk Acute Lymphoblastic Leukemia|May 2015|January 12, 2016|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119586||122531|
NCT01127646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13070|A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents|Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)|EMD|Eli Lilly and Company|No|Terminated|June 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|6 Years|16 Years|No|||April 2012|November 26, 2012|May 19, 2010|Yes|Yes|Due to lack of availability of study participants to accommodate the study design|No|April 30, 2012|https://clinicaltrials.gov/show/NCT01127646||121913|This study (Study LYEN) was terminated after enrolling 23 participants due to lack of availability of study participants to accommodate the study design.
NCT01119209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-VF-20060072 - trochanteric|Postoperative Analgesia With Local Infiltration After Hip Fracture Of Intertrochanteric Type|Postoperative Analgesia With Local Infiltration After Hip Fracture Of Intertrochanteric Type||Odense University Hospital|Yes|Completed|February 2008|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|N/A|N/A|No|||March 2011|March 15, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01119209||122559|
NCT01119560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEPI07N1|Genetic Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])|Observational - Genetic Susceptibility Factors in the Etiology of Neuroblastoma Also Known as Neuroblastoma Epidemiology in North America (NENA)||Children's Oncology Group|Yes|Active, not recruiting|February 2012|||November 2032|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|700|Samples With DNA|buccal cells|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a primary diagnosis of neuroblastoma meeting other criteria.|February 2016|February 19, 2016|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119560||122533|
NCT01119573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000672415|Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer|Micro RNA's Associated With Lymph Node Metastasis in Endometrial Cancer||National Cancer Institute (NCI)||Not yet recruiting|May 2010|||June 2010|Anticipated|N/A|Observational|N/A|||Anticipated|100|||Female|N/A|N/A|No|||May 2010|June 17, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119573||122532|
NCT01119820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6467|Tissue Donation for Myoblast Culture|Tissue Donation for Myoblast Culture||University of California, Irvine|Yes|Completed|October 2008|June 2012|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Female|18 Years|N/A|No|||July 2013|July 18, 2013|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119820||122513|
NCT01120600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-053|A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men With Osteoporosis Treated With Vitamin D and Calcium||Merck Sharp & Dohme Corp.|Yes|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|294|||Male|40 Years|95 Years|No|||October 2015|October 14, 2015|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120600||122453|
NCT01120834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912010795|Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)|Phase I/II Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory DLBCL||Weill Medical College of Cornell University|No|Recruiting|September 2010|||April 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01120834||122435|
NCT01120587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193/2006|Videofluoroscopic of Deglutition Study of the Initiation of Pharyngeal Phase in Young Adults|The Start of Pharyngeal Phase of Swallowing in Healthy Individuals|VFD-IPP|Fortaleza University|Yes|Completed|January 2010|May 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|40 Young adults and healthy, individuals with ages ranging between 20 and 30 years        without, mean age 23.5 years, ranging between 20 and 30 years 87.5% (35/40) female 12.5%        (5/40) male.|January 2010|May 10, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01120587||122454|
NCT01151124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN01-CP-0001|Pilot Investigation of Stem Cells in Stroke|A Phase I Safety Trial of CTX0E03 Drug Product Delivered Intracranially in the Treatment of Patients With Stable Ischemic Stroke|PISCES|ReNeuron Limited|Yes|Active, not recruiting|June 2010|March 2023|Anticipated|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|60 Years|85 Years|No|||May 2015|May 18, 2015|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01151124||120125|
NCT01152073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.35|A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)|A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)||Healthy Drink Discoveries, Inc.|Yes|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|79|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152073||120053|
NCT01152086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hiking2010|The Effects of Regular Mountain Hiking on Hopelessness in Chronically Suicidal Patients||MOHS2010|Paracelsus Medical University|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|24|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152086||120052|
NCT01151683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG600|Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients|Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients|MG600|Rio de Janeiro State University|No|Completed|March 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|52|||Female|40 Years|65 Years|No|||January 2013|January 4, 2013|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151683||120083|
NCT01151995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0735|Effectiveness and Costs of Remote Monitoring for Clinical Trials|Effectiveness and Costs of Remote Monitoring for Clinical Trials||University of Colorado, Denver|No|Completed|August 2010|May 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|20||No biospecimens collected for this protocol|Both|18 Years|90 Years|No|Non-Probability Sample|Study population will be subjects who have already been enrolled in an ARDS or BARC/CLiC        clinical trial network study.|December 2012|December 17, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151995||120059|
NCT01118403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58222|Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients|Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients: A Randomized Trial|NAVPRO|Hospital Pablo Tobón Uribe|Yes|Suspended||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2011|May 27, 2013|May 4, 2010||No|He could not be started due to lack of funds|No||https://clinicaltrials.gov/show/NCT01118403||122621|
NCT01118715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRF-001|Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial|Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial||J&M Shuler|No|Active, not recruiting|April 2010|December 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|139|||Both|18 Years|85 Years|No|||February 2016|February 23, 2016|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01118715||122597|
NCT01119885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015454|Observational Study Investigating the Effectiveness of Fentanyl Matrix in Relieving Pain and Improving Function in Patients With Osteoarthritis of the Knee or Hip|Fentanyl Matrix for the Treatment of Pain Caused by Osteoarthritis of the Knee or Hip: Improvement of Pain and Function: Multicenter, Open-label, Prospective, Observational Study||Janssen Korea, Ltd., Korea||Completed|August 2008|January 2009|Actual|January 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|742|||Both|20 Years|N/A|No|Probability Sample|The study population is the patients who visit a center during the study period with the        complaint of chronic pain caused by osteoarthritis of the knee or hip, and are deemed to        fail to control pain in a proper way and need fentanyl matrix administration according to        the investigator's discretion|April 2014|April 24, 2014|January 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01119885||122508|
NCT01119287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-002|Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis|A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model||Alcon Research|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|180|||Both|18 Years|64 Years|No|||March 2013|February 27, 2014|May 4, 2010|Yes|Yes||No|January 28, 2013|https://clinicaltrials.gov/show/NCT01119287||122553|
NCT01120639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRN0012|PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform|A Phase I/II Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme||Stanford University|Yes|Active, not recruiting|April 2010|November 2020|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120639||122450|
NCT01120873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S06203|The Effect of Metamin 3D on the Lipid and Glucose in Subjects With Metabolic Syndrome|Phase 3 Study of 3D in Metabolic Syndrome||Taichung Veterans General Hospital|No|Completed|March 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|110|||Both|30 Years|75 Years|No|||May 2010|May 10, 2010|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01120873||122432|
NCT01120886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48699|Post-mortem Genetic Testing|Post-mortem Genetic Testing for Cardiac Ion Channelopathy in Unexplained Still Births||Thayyil, Sudhin|No|Completed|January 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Skin and muscle|Both|24 Weeks|42 Weeks|No|Probability Sample|Unexplained still births|April 2013|April 19, 2013|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120886||122431|
NCT01120899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100098|A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema|A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)|No|Completed|April 2010|February 2013|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|May 8, 2010|No|Yes||No|August 2, 2012|https://clinicaltrials.gov/show/NCT01120899||122430|
NCT01120353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCSS|Childhood Cancer Survivor Study|Childhood Cancer Survivor Study||St. Jude Children's Research Hospital|No|Recruiting|March 1994|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|50000|Samples With DNA|Blood, saliva and second tumor specimens|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Newly diagnosed with cancer between January 1, 1970 and December 31, 1999 at one of the        participating centers noted below or identified as sibling control.|March 2016|March 2, 2016|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120353||122472|
NCT01119534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-TRN-03(01/10)|Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin|Comparative Efficacy of the Suppository Composed by Guaiacol, Eucalyptol, Menthol and Camphor Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Not yet recruiting|May 2011|December 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|270|||Both|2 Years|6 Years|No|||January 2011|January 27, 2011|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01119534||122535|
NCT01119222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001388|Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers|A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers||Pfizer|No|Completed|July 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|19|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|May 5, 2010||Yes||No|October 12, 2010|https://clinicaltrials.gov/show/NCT01119222||122558|
NCT01120080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI R01 CA140256-01A1|Alcohol Counseling for Telephone Quitline Callers|Advancing Tobacco and Cancer Control: Reducing Alcohol Use to Promote Smoking Cessation||Yale University|Yes|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1948|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01120080||122493|
NCT01120340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sofar|Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares||DIV-01/04|SOFAR S.p.A.|No|Completed|October 2005|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|105|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01120340||122473|
NCT01117298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B22:A15:PGI/DM/EC/40/7.11.2007|A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma|A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Completed|November 2009|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||May 2010|May 7, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117298||122706|
NCT01117311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008825|Vagal Nerve Stimulation and Glucose Metabolism|The Effect of Vagal Nerve Stimulation on Enteroendocrine Secretion and Glucose Metabolism||Mayo Clinic|No|Completed|March 2011|November 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|9|||Both|35 Years|75 Years|No|||November 2013|November 14, 2013|May 4, 2010||No||No|August 21, 2013|https://clinicaltrials.gov/show/NCT01117311||122705|
NCT01117324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7637-AM-CTIL|Bone Density of Large Newborn Infants and Infants of Diabetic Mothers|Bone Density of Large Newborn Infants and Infants of Diabetic Mothers||Sheba Medical Center|No|Not yet recruiting|June 2010|||July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|7 Days|No|Probability Sample|Healthy term infants of birth weight 4 kg and above and infants of diabetic mothers|May 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117324||122704|
NCT01121159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orbita3|Prospective Multicenter Trial to Compare Preformed vs Non Preformed Orbital Implants|A Prospective Multicenter Study to Compare the Accuracy of Posttraumatic Orbital Reconstruction of the Medial Orbital Wall and/or the Orbital Floor With Preoperatively Preformed Versus Non-preformed Orbital Plates|Orbita 3|AO Clinical Investigation and Documentation|No|Completed|June 2010|October 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|185|||Both|18 Years|N/A|No|Non-Probability Sample|patients with fractures of the orbital floor and/or medial orbital wall in one of the        study centers|June 2015|June 25, 2015|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01121159||122410|
NCT01117584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0005|A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus|Phase IIb, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment With ASP1941 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|BALANCE|Astellas Pharma Inc|No|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|343|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117584||122684|
NCT01151436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.CIP.29089|Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers|Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers - Investigator and Subject Satisfaction|FRESH|Galderma|No|Completed|March 2010|February 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||May 2012|May 29, 2012|June 24, 2010||No||No|April 10, 2012|https://clinicaltrials.gov/show/NCT01151436||120102|
NCT01151722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRP22|Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage|Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage|ABeVi|University of Sao Paulo|No|Recruiting|December 2009|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|2|||Both|18 Years|80 Years|No|||February 2010|June 25, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151722||120080|
NCT01152710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139/03/06|Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer|Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer||Institute of Oncology Ljubljana|No|Completed|June 2004|April 2010|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|80 Years|No|||June 2010|June 28, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152710||120004|
NCT01151696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0918703|Pain and Anxiety Management of Traumatic Emergency in a Pre-hospital Setting|Prise en Charge Pharmacologique de l'anxiété et de la Douleur Chez Les Patients Qui Souffrent en Situation d'Urgence Traumatique pré-hospitalière : étude randomisée contrôlée en Double Aveugle||University Hospital, Toulouse|No|Completed|May 2010|January 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151696||120082|
NCT01151709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13808|Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management|Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management||University of Massachusetts, Worcester|No|Completed|August 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|838|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care practitioners, both family practice and internal medicine physicians from a        nationwide sample|March 2012|March 5, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151709||120081|
NCT01118416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020366|Risk Reduction Intervention for Vulnerable Young Adult Males|Risk Reduction Intervention for Vulnerable Young Adult Males|YMHP|Hunter College|Yes|Completed|June 2006|October 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|317|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118416||122620|
NCT01118429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0083/10|Use of Oxybutynin to Treat Axillary Hyperhidrosis|Use of Oxybutynin to Treat Axillary Hyperhidrosis||Grupo de Cirurgia Vascular|Yes|Completed|January 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|14 Years|55 Years|No|||March 2010|May 5, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01118429||122619|
NCT01118728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS11298|Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis|A Multicenter Uncontrolled Extension Study Evaluating the Long Term Safety and Efficacy of SAR153191 in Patients With Ankylosing Spondylitis (AS)|SUSTAIN|Sanofi|Yes|Terminated|June 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|223|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|May 5, 2010|Yes|Yes|Lack of benefit on efficacy|No||https://clinicaltrials.gov/show/NCT01118728||122596|
NCT01119027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09-04|Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills|Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills||University Hospital Case Medical Center|Yes|Terminated|September 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|83|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Surgeons and trainee surgeons attending laparoscopic colorectal training courses.|November 2012|December 12, 2014|April 29, 2010||No|slow accrual|No||https://clinicaltrials.gov/show/NCT01119027||122573|
NCT01119898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV05100031|Evaluation of the Safety and Efficacy of PENNSAID Gel in the Treatment of Osteoarthritis of the Knee|A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Clinical Study to Evaluate the Safety and Efficacy of PENNSAID Gel in the Symptomatic Treatment of Osteoarthritis of the Knee||Mallinckrodt|No|Completed|July 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|260|||Both|40 Years|85 Years|No|||April 2011|April 20, 2011|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119898||122507|
NCT01120379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-374B|XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)|XVU-LTF|Abbott Vascular|Yes|Completed|July 2008|December 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5034|||Both|N/A|N/A|No|Non-Probability Sample|Patients who agree to participate by signing the Institutional Review Board (IRB) approved        informed consent form, and who recieve only XIENCE V® EECSS during the index procedure.|May 2015|May 26, 2015|May 6, 2010|Yes|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT01120379||122470|
NCT01120652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR057338|Reducing Depressive Symptoms in Systemic Lupus Erythematosus|Reducing Depressive Symptoms in Systemic Lupus Erythematosus||University of Pittsburgh|No|Completed|November 2009|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01120652||122449|
NCT01120912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-INS-P1-01|Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients|A Single Center, Non-randomized, Single Blind, Placebo Controlled, Single Dose Study of the Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients - Phase 1 Study||Oshadi Drug Administration|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2011|April 16, 2012|May 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01120912||122429|
NCT01120925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Liver-002|Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients|Comparison of Therapeutic Outcome of Twice Transplantation of CD133+ and MNC BM Derived Stem Cells in Cirrhotic Patients: Clinical Trial, Double Blind, Phase I/II||Royan Institute|Yes|Completed|May 2010|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|16 Years|65 Years|No|||May 2010|April 24, 2014|May 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01120925||122428|
NCT01120119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLF-1 2005-000751-15|Efficacy of Calcitriol in Recent Onset Type 1 Diabetes|Clinical Study to Evaluate the Efficacy of 1,25(OH)2D3 (Calcitriol) Versus Placebo in Recent Onset Type 1 Diabetes(IMDIAB XIII)|IMDIABXIII|Campus Bio-Medico University|No|Completed||||||Phase 2|Interventional|N/A|2||||||Both|11 Years|40 Years|No|||March 2005|May 7, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120119||122490|
NCT01119235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1351005|A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.|A Phase 1, Open Label Study To Investigate The Pharmacokinetics Of Multiple Doses Of PF-04531083 Tablets In Healthy Volunteers||Pfizer|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 5, 2010|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01119235||122557|
NCT01119833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMI-1070-201|Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis||Pfizer|Yes|Completed|May 2010|December 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|12 Years|60 Years|No|||December 2013|February 6, 2014|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119833||122512|
NCT01120847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06302009-2920|Post Traumatic Stress Disorder (PTSD), Sleep Disordered Breathing And Genetics: Effects On Cognition|PTSD, Sleep Disordered Breathing And Genetics: Effects On Cognition||Stanford University|No|Recruiting|September 2004|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|blood or saliva|Both|55 Years|90 Years|No|Non-Probability Sample|US war Veterans with PTSD and possible sleep problems|December 2013|December 2, 2013|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120847||122434|
NCT01121172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012010|Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)|Serum Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)in Obese Children and Adolescents.||Aristotle University Of Thessaloniki|No|Completed|May 2010|January 2014|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|180|||Both|2 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|40 obese children 40 obese adolescents 50 lean children 50 lean adolescents|February 2014|February 20, 2014|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01121172||122409|
NCT01120860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06302009-2941|Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance|MRI and Decline of Aging Aviator Performance||Stanford University|No|Active, not recruiting|November 2002|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|active healthy pilots|June 2011|June 9, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120860||122433|
NCT01121458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dallas VA #09-041|Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed|Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE)|CARVE|North Texas Veterans Healthcare System|No|Completed|September 2009|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 7, 2013|February 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121458||122387|
NCT01121471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003H0122|Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)|Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)|WDS|Ohio State University|Yes|Completed|December 2004|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Female|18 Years|70 Years|No|||May 2010|May 10, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121471||122386|
NCT01121497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5759|The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy|||Rabin Medical Center|Yes|Not yet recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|160|||Both|18 Years|80 Years|No|||April 2010|May 11, 2010|May 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01121497||122384|
NCT01117597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVD20090991|Terrestrial Trunked Radio (TETRA) and Cognitive Functions in Healthy Subjects|Experimental Study on Possible Effects of Radiofrequency (RF) Signal Characteristics Used for the TETRA Standard on Cognitive Functions in Healthy Subjects|TETRA|Charite University, Berlin, Germany|Yes|Completed|April 2010|September 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|32|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||November 2014|November 6, 2014|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117597||122683|
NCT01151735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#33225|C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation|Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Determine the Efficacy of 1000u, and 1500u of C1-INH Compared to Placebo at the Time of Prodromal Symptoms in Preventing an Acute HAE Exacerbation.||Penn State University|No|Withdrawn|July 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||November 2012|November 29, 2012|June 25, 2010|Yes|Yes|PennState would not allow the study to move forward|No||https://clinicaltrials.gov/show/NCT01151735||120079|
NCT01151748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSEYE0001|Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma|Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma||Stanford University||Withdrawn|September 2010|March 2012|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|18 Years|No|||May 2012|May 10, 2012|March 4, 2010||No|Study abandoned; Could not obtain final SRC approval due to IND disagreements|No||https://clinicaltrials.gov/show/NCT01151748||120078|
NCT01152944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS069938-01|Mechanisms of Stroke in Intracranial Stenosis|Mechanisms of Stroke in Intracranial Stenosis and Stenting|MoSIS|University of Miami|No|Terminated|July 2010|December 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|30 Years|80 Years|No|Non-Probability Sample|Medical arm of the SAMMPRIS trial which includes recently symptomatic (<30 days) high        grade (70% or more)intracranial stenosis of the carotid, middle cerebral, vertebral or        basilar arteries.|February 2012|February 6, 2012|June 28, 2010||No|The affiliated study SAMMPRIS (Stenting and Aggressive Medical Management for Preventing    Recurrent stroke in Intracranial Stenosis) has stopped enrollment.|No||https://clinicaltrials.gov/show/NCT01152944||119986|
NCT01152957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090751|Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors|Miami Healthy Heart Initiative (MHHI) a Randomized Study of Behavioral Risk Factors for Cardiovascular Disease in Latino and Hispanic Patients With Poorly Controlled Diabetes|MHHI|University of Miami|No|Completed|July 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|300|||Both|35 Years|70 Years|No|||December 2013|December 11, 2013|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152957||119985|
NCT01152346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZFAST101|Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients|A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions||Bioniche Pharma USA LLC|No|Completed|April 2011|May 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|19|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01152346||120032|
NCT01118442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1424|Determination of the Acute Effects of Aortic Stenosis on Coronary Artery Haemodynamics|Determination of the Acute Effects of Aortic Stenosis on Coronary Artery Haemodynamics||Imperial College London|Yes|Recruiting|December 2009|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|6|Samples With DNA|Myocardial biopsy specimens|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing transcutaneous aortic valve insertion who meet study criteria|May 2010|May 5, 2010|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118442||122618|
NCT01118455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epilepsy (E)-06|Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures|An Open Randomized Trial to Assess the Efficacy and Safety of Vagus Nerve Stimulation (VNS) Versus New Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures||Cyberonics, Inc.|No|Terminated|October 2004|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|N/A|17 Years|No|||June 2014|June 25, 2014|May 5, 2010|Yes|Yes|Insufficient enrollment|No|March 1, 2011|https://clinicaltrials.gov/show/NCT01118455||122617|Study was terminated due to low enrollment.
NCT01119339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H553000-1001|Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis|An Investigator-blind, Controlled Study to Assess the Efficacy of Six Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test||Almirall, S.A.|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|20|||Both|18 Years|75 Years|No|||May 2015|May 28, 2015|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01119339||122549|
NCT01120171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/08.32|Myocet Plus Endoxan for Older Patients With Breast Cancer|Liposome-encapsulated Doxorubicin (Myocet) Plus Cyclophosphamide as First or Second Line Therapy for Older Patients With Metastatic Breast Cancer||Hellenic Oncology Research Group|No|Terminated|September 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|May 5, 2010||No|Due to poor accrual|No||https://clinicaltrials.gov/show/NCT01120171||122486|
NCT01120145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-5756|Assessment of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi|Assessment of the Efficacy and Effectiveness of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi||Centers for Disease Control and Prevention|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|1410|Samples With DNA|Blood spots will be collected from parasitemic patients to look at malaria prasite molecular      markers of resistance to sulphadoxine-pyrimethamine.|Both|N/A|N/A|No|Non-Probability Sample|Therapeutic efficacy study: Asymptomatic parasitemic pregnant women at 16-26 weeks of        gestation Birth outcomes study: Pregnant women presenting for delivery Characterizing        molecular markers of SP resistance study: Parasitemic outpatients|February 2013|February 5, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01120145||122488|
NCT01120392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNEP|Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease|Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease||Federal University of Bahia|No|Completed|May 2011|October 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||December 2011|December 6, 2011|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01120392||122469|
NCT01151527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022485|Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias|Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping||Duke University|No|Terminated|April 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|269|Samples With DNA|Tubes of blood will be drawn from the subject to extract RNA and DNA for laboratory      purposes.      Lung biopsy tissue (pathology slides) may be requested for specimen processing.      Also Bronchoscopy fluid may be requested.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of        Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected        individuals in a family).|June 2010|September 8, 2015|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151527||120095|
NCT01152762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07/42|Effectiveness of Standardized Respiratory Physiotherapy in Primary Care|Effectiveness of Standardized Respiratory Physiotherapy in Primary Care in Patients With Mild COPD and Its Economic Assessment||Jordi Gol i Gurina Foundation|No|Active, not recruiting|September 2007|July 2010|Anticipated|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|205|||Both|40 Years|74 Years|No|||June 2010|June 28, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152762||120000|
NCT01152775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-269-PSY|Evaluation of the Use of Multimedia to Enhance Patient and Family Understanding|Evaluation of the Use of Multimedia to Enhance Patient and Family Understanding||McGill University Health Center|Yes|Enrolling by invitation|April 2010|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|N/A|No|||April 2012|April 18, 2012|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01152775||119999|
NCT01152788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I202|Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma|A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma||Canadian Cancer Trials Group|No|Completed|June 2010|February 2015|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|June 28, 2010|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01152788||119998|
NCT01152476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T&A_EA|Emergency Agitation in T&A|||Seoul National University Bundang Hospital|Yes|Completed|April 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|42|||Both|2 Years|6 Years|No|||January 2011|January 5, 2011|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152476||120022|
NCT01152489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09501|A Test of the Effectiveness of a Device and Distraction for Pediatric Immunization Pain|Phase II Study of the Effectiveness of a Device and Distraction for Pediatric Immunization Pain in Multiple Age Groups||MMJ Labs LLC|No|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|345|||Both|4 Months|12 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|June 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01152489||120021|
NCT01148758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22909|A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer|Open-label, Exploratory, Pharmacodynamic (PD) Dose-finding Study of Intravenous RO5323441 in Patients With Metastatic Treatment-refractory Colorectal and Ovarian Cancer||Hoffmann-La Roche||Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|19 Years|N/A|No|||March 2016|March 1, 2016|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01148758||120305|
NCT01149668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-0405-CA|A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer|A Long-term Safety Study of the Pan-histone Deacetylase (HDAC) Inhibitor, PCI-24781, in Subjects With Cancer||Pharmacyclics|No|Completed|June 2010|April 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|June 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149668||120235|
NCT01150279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.1.3|Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up|Simplifying Medical Abortion Provision: Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up||Gynuity Health Projects||Completed|August 2009|||May 2014|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1200|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Women presenting to clinic seeking medical abortion|October 2015|October 1, 2015|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01150279||120188|
NCT01123031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-100118|Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)|Oral vs Intravenous Proton Pump Inhibitor（PPI） in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial||Changhua Christian Hospital|No|Active, not recruiting|April 2010|April 2011|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|65|||Both|N/A|N/A|No|||May 2010|January 18, 2011|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01123031||122266|
NCT01123369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEI 10-001|Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease|Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease||Medical University of South Carolina|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|8|||Both|12 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Approximately 60 subjects of both sexes of African American race with or without sickle        cell disease.|September 2010|September 13, 2010|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01123369||122240|
NCT01122706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058/10|Efficacy of Taiji Training as a Program for Stress Prevention|Efficacy of Taiji Training as a Program for Stress Prevention - a Randomized, Waiting List Controlled Longitudinal Study With Healthy Subjects||University of Bern|No|Completed|July 2010|June 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122706||122291|
NCT01123356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101376 OFT113297|Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab|Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab||Medical University of South Carolina|Yes|Completed|May 2010|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||July 2012|November 2, 2015|May 4, 2010|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01123356||122241|
NCT01149278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC09-01|Assessment of Two Levels of Arterial Pressure on Survival in Patients With Septic Shock||SEPSISPAM|University Hospital, Angers||Completed|March 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|800|||Both|18 Years|N/A|No|||June 2010|November 2, 2012|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01149278||120265|
NCT01149616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000345/1; BIDMC|Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery|Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery||Beth Israel Deaconess Medical Center|No|Completed|December 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149616||120239|
NCT01149590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/588|Scottish COmputed Tomography of the HEART Trial|Role of Multidetector Computed Tomography in the Diagnosis and Management of Patients Attending a Rapid Access Chest Pain Clinic|SCOT-HEART|University of Edinburgh|No|Recruiting|November 2010|January 2015|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|4138|||Both|18 Years|75 Years|No|||April 2013|April 17, 2013|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01149590||120241|
NCT01149603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G090176|The Destination Therapy Evaluation for Failing Fontan Study|The Destination Therapy Evaluation for Failing Fontan Study (DEFINe Study)|DEFINe|Providence Health & Services|Yes|Recruiting|July 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|June 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149603||120240|
NCT01149577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHOLZ0003|Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients|||Central Institute of Psychiatry, Ranchi, India|Yes|Completed|August 2007|April 2009|Actual|December 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Male|18 Years|45 Years|No|||June 2010|June 22, 2010|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01149577||120242|
NCT01149876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002803|Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots|A Single Blind, Placebo Controlled Trial to Evaluate Effects of a Study Medication, a Nu Skin Lightening Product With and Without Iontophoresis vs Tretinoin Cream vs Vehicle Control for Facial Hyperpigmentation||Massachusetts General Hospital|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|80|||Female|25 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 30, 2014|April 30, 2010||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01149876||120219|Scale of pigmentation didn't account for both change in color and number.
NCT01150201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis-ST-02|Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease|Phase 4 Study of the Renoprotective Efficacy of Aliskiren in Addition to Angiotensin II Receptor Blocker in Chronic Kidney Disease||The University of Hong Kong|No|Completed|July 2009|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||July 2015|July 2, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150201||120194|
NCT01150448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013300|A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia|An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of 150 mg eq. Paliperidone Palmitate in the Treatment of Subjects With Schizophrenia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|September 2007|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|65 Years|No|||May 2014|May 26, 2014|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01150448||120175|
NCT01150695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0006|Phase II Tularemia Vaccine Comparison|A Phase II, Multi-Center, Double-Blind, Randomized Trial Comparing the Safety and Immunogenicity of a Francisella Tularensis Live Vaccine Strain (LVS) Vaccine Produced by DynPort Vaccine Company (DVC-LVS) to a LVS Vaccine in Use by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID-LVS)||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|228|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|December 10, 2015|June 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01150695||120156|
NCT01150955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100058|Potential Beneficial Effects of Resveratrol|Potential Beneficial Effects of Resveratrol on Obesity, Metabolic Syndrome and Inflammation - Emphasis on Description of the Molecular Biology Underpinning the Interplay Between Calorie Restriction, SIRT1, STAT5 and the GH/IGF-I Axis||University of Aarhus|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150955||120138|
NCT01151215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00004|Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer|A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer (MINT).|MINT|AstraZeneca|Yes|Terminated|June 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|482|||Female|18 Years|N/A|No|||July 2014|July 15, 2014|June 15, 2010|Yes|Yes|Futility|No|January 29, 2014|https://clinicaltrials.gov/show/NCT01151215||120118|The final analysis for this study is the analysis that was sent to the study's IDMC, based on a data cut-off of 31 August 2012. At the data cut-off point the data was cleaned, but 9 adverse events were not coded. These events are not included here.
NCT01151228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0764-BE|Bedside Ultrasound Assessment of Gastric Content and Volume|Bedside Ultrasound Assessment of Gastric Content and Volume. Validating a Mathematical Model Using Gastroscopic Examination||University Health Network, Toronto|No|Completed|December 2009|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|6||Actual|108|||Both|18 Years|80 Years|No|||February 2013|February 8, 2013|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151228||120117|
NCT01151553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012235|Oxidative Stress Markers and Cardiac Resynchronization Therapy (CRT) Outcomes|Comparative of Markers of Oxidative Stress Present Pre and Post Cardiac Resynchronization Therapy Outcome Predictors||Emory University|No|Terminated|October 2008|July 2011|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|June 25, 2010||No|No funding, lost support staff. No data collected/processed|No|July 24, 2013|https://clinicaltrials.gov/show/NCT01151553||120093|Early termination leading to small numbers of subjects; lost funding and staff, no data collected/processed.
NCT01151865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2010/03891|Dexmedetomidine to Lessen Intensive Care Unit (ICU) Agitation|A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit|DahLIA|Austin Health|Yes|Completed|February 2011|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||January 2015|January 18, 2015|June 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151865||120069|
NCT01148784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-6158|Comparison of Doubled Quadrupled Versus Quadrupled Allograft Tissue Constructs for Anterior Cruciate Ligament (ACL) Reconstruction|A Prospective Randomized Comparison of Doubled Versus Quadrupled Allogenic Tissue Constructs for Anterior Cruciate Ligament Reconstruction||Oregon Health and Science University|No|Recruiting|June 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||March 2011|March 31, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148784||120303|
NCT01148797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2204|Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)|A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever|CONTROL FMF|Novartis||Completed|December 2010|||February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|4 Years|20 Years|No|||March 2014|March 5, 2014|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148797||120302|
NCT01148810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312A2202|Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis|A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis||Novartis|Yes|Terminated|June 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||July 2013|July 25, 2013|June 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01148810||120301|
NCT01149070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700623-506|An Observational Study to Evaluate Efficacy, Safety and Clinical Outcomes of Currently Used Pharmaceutical Therapies for Controlled Ovarian Stimulation in Assisted Reproductive Techniques|An Observational Program to Evaluate Efficacy, Safety and Clinical Outcomes of Currently Used Pharmaceutical Therapies for Controlled Ovarian Stimulation (COS) in Assisted Reproductive Techniques (ART)|ESCORT|Merck KGaA||Completed|June 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|10103|||Female|N/A|N/A|No|Non-Probability Sample|Female subjects undergoing ART|September 2014|September 12, 2014|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149070||120281|
NCT01152996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_314|Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study|A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder||Takeda|No|Completed|September 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1075|||Both|18 Years|77 Years|No|||April 2014|April 29, 2014|June 28, 2010|Yes|Yes||No|April 29, 2014|https://clinicaltrials.gov/show/NCT01152996||119982|
NCT01153009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_315|Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder||Takeda|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|614|||Both|18 Years|75 Years|No|||October 2013|October 25, 2013|June 28, 2010|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01153009||119981|
NCT01153022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT01UAM-H reflex|Effect of Joint Mobilization on Alpha Motoneuron Reflex Excitability|Effect of Joint Mobilization on Alpha Motoneuron Reflex Excitability in People With Spasticity: Controlled Clinical Trial|JM-HRreflex|Universidad Autónoma de Manizales, Colombia|No|Completed|February 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|60 Years|No|||June 2010|June 28, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01153022||119980|
NCT01149967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30284|Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Citalopram Hydrobromide 40 mg Tablets and Celexa 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 23, 2010|June 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149967||120212|
NCT01149980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30285|Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Citalopram Hydrobromide 40 mg Tablets and Celexa 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 23, 2010|June 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149980||120211|
NCT01149681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-B-020-10|Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis|Open-label, Phase II Clinical Trial of Aplidin® (Plitidepsin) in Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis||PharmaMar|No|Completed|July 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149681||120234|
NCT01150292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.555|Effects of Docosahexaenoic Acid (DHA) on Cardiovascular Disease on Diabetic Patients|Intake of Low Dose of Docosahexaenoic Acid: Effects on Platelet Functions and Redox Status in Diabetic Patients||Hospices Civils de Lyon|No|Completed|May 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|16|||Female|55 Years|75 Years|No|||February 2014|February 6, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150292||120187|
NCT01123928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOC-123|Guangdong Uptake of Surgery Trial|The Effect of Counseling in Cataract Screening: Guangdong Uptake of Surgery Trial|GUSTO|Sun Yat-sen University|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|434|||Both|50 Years|N/A|No|||February 2012|February 1, 2012|May 12, 2010||No||No|December 28, 2011|https://clinicaltrials.gov/show/NCT01123928||122198|One of the six participating hospitals did not adhere to protocol, and thus total number of subjects analyzed was smaller than originally anticipated.
NCT01123941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01_01TP|Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)|A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.||Novartis|No|Completed|May 2010|November 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|May 13, 2010||No||No|February 29, 2012|https://clinicaltrials.gov/show/NCT01123941||122197|
NCT01124188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG033575|ADAPT: Addressing Depression and Pain Together|Optimizing Care for Older Adults With Back Pain and Depression|ADAPT|University of Pittsburgh|Yes|Active, not recruiting|May 2010|April 2016|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|60 Years|N/A|No|||January 2016|January 5, 2016|May 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124188||122178|
NCT01123954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_21|Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers|Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers||Novartis||Completed|January 2010|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|33|||Both|1 Year|45 Years|Accepts Healthy Volunteers|||December 2011|December 13, 2011|March 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01123954||122196|
NCT01123642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7202-R|Project SERVE: Post Deployment Functioning|Functional Outcomes in OEF/OIF Veterans With PTSD and Alcohol Misuse||VA Office of Research and Development|No|Completed|October 2010|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|345|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Operation Enduring Freedom and Operation Iraqi Freedom Veterans|August 2015|August 12, 2015|May 5, 2010||No||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01123642||122220|
NCT01150734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/2009|Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation)|Transcranial Direct Current Stimulation (tDCS)-Boosted Changes in Muscle Evoked Potentials (MEP) in Depressed and Schizophrenic Patients Reveal Deficits in Neuromodulation||Ludwig-Maximilians - University of Munich|No|Completed|October 2009|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|15 depressed patients 15 schizophrenic patients 15 healthy volunteers|April 2011|April 21, 2011|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150734||120153|
NCT01149902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|631|Study of Chemo-Immunotherapy in Head and Neck Cancer Patients|Phase I Study of Chemo-Immunotherapy in Patients With Relapsed and Refractory Head and Neck Squamous Cell Carcinoma||University of Yamanashi||Recruiting|July 2010|||March 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|N/A|No|||June 2010|August 23, 2011|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149902||120217|
NCT01149889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-HU-002|Transcranial Direct Current Stimulation to Treat Major Depressive Disorder|An Open-label, Crossover Study on Major Depressive Disorder Using Transcranial Direct Current Stimulation||University of Sao Paulo|No|Completed|June 2010|December 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||December 2011|December 2, 2011|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149889||120218|
NCT01150461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P002232/7|Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy|Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy||Massachusetts General Hospital|No|Completed|February 2007|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2013|September 3, 2013|June 22, 2010||No||No|May 2, 2013|https://clinicaltrials.gov/show/NCT01150461||120174|
NCT01150708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100143|A Prospective Natural History Study of Patients With Syringomyelia|A Prospective Natural History Study of Patients With Syringomyelia||National Institutes of Health Clinical Center (CC)||Recruiting|June 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|180|||Both|18 Years|99 Years|No|||November 2015|January 29, 2016|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150708||120155|
NCT01150721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100149|Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection|Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection||National Institutes of Health Clinical Center (CC)||Completed|June 2010|||||N/A|Observational|Time Perspective: Prospective|||Actual|177|||Both|18 Years|99 Years|No|||December 2015|December 24, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150721||120154|
NCT01150968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10035736|An Educational Intervention to Improve Resident Comfort With Communication at the End of Life|An Educational Intervention to Improve Resident Comfort With Communication at the End of Life||University of California, San Francisco|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|166|||Both|18 Years|N/A|No|||February 2011|February 9, 2011|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150968||120137|
NCT01151241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0120-A|Early Discharge in Patients Undergoing Elbow Arthroscopy|Outpatient Versus Inpatient Continuous Brachial Plexus Block for Complex Arthroscopic Elbow Surgery: Safety and Functional Outcome||University Health Network, Toronto|No|Completed|July 2010|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||February 2015|February 20, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151241||120116|
NCT01151540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2080-J081-305|A Long Term Extension Study of E2080 in Lennox-Gastaut Patients|A Long Term Extension Study of E2080 in Lennox-Gastaut Patients||Eisai Inc.||Completed|November 2010|October 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|N/A|N/A|No|||February 2014|February 20, 2014|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01151540||120094|
NCT01153035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104603|Excision Followed by Radiofrequency Ablation for Breast Cancer|ABLATE Registry: Radiofrequency Ablation After Breast Lumpectomy (eRFA) Added To Extend Intraoperative Margins in the Treatment of Breast Cancer|ABLATE|University of Arkansas||Recruiting|June 2010|June 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|50 Years|100 Years|No|||January 2016|January 21, 2016|June 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01153035||119979|
NCT01148771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUTI003194HE|Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion|Comparative Pharmacokinetics, Safety, and Pharmacodynamics of Ertapenem 1 Gram Daily Administered as an IV Bolus Versus Standard 30 Minute Infusion to Healthy Adult Volunteers||Hartford Hospital|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 13, 2012|June 18, 2010|No|Yes||No|March 15, 2012|https://clinicaltrials.gov/show/NCT01148771||120304|
NCT01148823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Micro01|Time of Permanence of Dressing Following Breast Reconstruction|Influence of Time of Permanence of Dressing Following Breast Reconstruction on Skin Colonization and on Surgical Site Infection Rates||Federal University of São Paulo|No|Completed|June 2007|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|200|||Female|18 Years|70 Years|No|||February 2015|February 22, 2015|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148823||120300|
NCT01149083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01379|Veliparib With or Without Carboplatin in Treating Patients With Stage III or Stage IV Breast Cancer|Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|June 2010|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|71|||Female|18 Years|N/A|No|||February 2016|February 11, 2016|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149083||120280|
NCT01149356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-02181|RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer|A Phase I Dose Escalation Trial of RO4929097 Administered in Combination With Exemestane in Pre- and Postmenopausal Patients With ER + Metastatic Breast Cancer||National Cancer Institute (NCI)||Terminated|October 2010|April 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|June 22, 2010|No|Yes|Manufacturer discontinued drug development.|No||https://clinicaltrials.gov/show/NCT01149356||120259|
NCT01149655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-09-266|Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia|A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia|ATTAIN 266|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|July 2011|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|252|||Both|13 Years|17 Years|No|||April 2015|April 1, 2015|June 22, 2010|No|Yes||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01149655||120236|
NCT01149993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-496|Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation|Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation||Georgetown University|No|Withdrawn|June 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|No|||June 2014|June 6, 2014|June 21, 2010||No|FDA clinical hold, IND withdrawn.|No||https://clinicaltrials.gov/show/NCT01149993||120210|
NCT01123967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS064|Offering Proactive Tobacco Treatment|Improved Effectiveness of Smoking Cessation Programs for Minnesota Priority Populations||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2011|August 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2500|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123967||122195|
NCT01123707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-08-257|To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|ACES 257|Otsuka Pharmaceutical Development & Commercialization, Inc.||Terminated|November 2010|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|18 Years|66 Years|No|||August 2012|August 24, 2012|May 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01123707||122215|
NCT01123655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMA-007-08S|Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients|Phase 1 Trial of CII APL A12 in Rheumatoid Arthritis Patients||VA Office of Research and Development|Yes|Completed|October 2009|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|85 Years|No|||December 2015|December 2, 2015|May 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01123655||122219|
NCT01149928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08H3330006|Role of Cord Blood Hormones and Epinephrine in the Development of Transient Tachypnea of the Newborn|||Ankara University|No|Completed|September 2008|October 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|70|Samples Without DNA|Cord blood serum samples were stored.|Both|34 Weeks|40 Weeks|Accepts Healthy Volunteers|Probability Sample|Cesarean delivered, late preterm and term infants during the study period in Maternity        Center of Ankara University|October 2009|June 23, 2010|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01149928||120215|
NCT01149941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02279|Bioequivalence Study of Ibuprofen 200 mg Gel Capsules of Dr. Reddy's Laboratories Under Fasting Condition|Randomized, 2-way Crossover, Bioequivalence Study of Ibuprofen 200 mg Gel Capsules and Advil Liquigels 200 mg Gel Capsules Administered as 1 x 200 mg Gel Capsules in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|November 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 25, 2010|June 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149941||120214|
NCT01149954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02280|Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules of Dr. Reddy's Laboratories Limited Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules and Advil Liquigels 200 mg Gel Capsules Administered as 1 x 200 mg Gel Capsules in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2003|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 28, 2010|June 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149954||120213|
NCT01150981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12196|Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue|Effect of Rosiglitazone on In-vivo Angiogenic Potential of Human Adipose Tissue|RAPA|University of Massachusetts, Worcester|No|Completed|November 2006|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 25, 2012|June 17, 2010|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT01150981||120136|
NCT01150214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00039522|DECAAF: Delayed-Enhancement MRI (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation|DECAAF: DE-MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation|DECAAF|University of Utah|Yes|Completed|July 2010|September 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|339|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of those patients who have undergone catheter ablation        for atrial fibrillation.|September 2013|September 17, 2013|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01150214||120193|
NCT01151566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21982|Can Ultrasound Replace Computed Tomography (CT) Scan in Those Unable to Have Computed Tomography (CT) Contrast Agents|Can US With CEUS Replace the Nonenhanced CT Scan in Patients With Contraindication to CT Contrast Agent|CEUS_CT|Foothills Medical Centre|No|Completed|September 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|250|||Both|18 Years|95 Years|No|Probability Sample|Patients referred for unenhanced CT scan on the basis of renal compromise of CT contrast        agent sensitivity will be eligible for recruitment for our study.|March 2012|March 11, 2014|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01151566||120092|
NCT01151878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/127/2008|Glucomannan for Childhood Functional Constipation.|Glucomannan in Treating Childhood Functional Constipation: a Randomized, Double-blind, Placebo-controlled Trial.||Medical University of Warsaw|No|Completed|April 2009|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Years|16 Years|No|||October 2011|October 27, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01151878||120068|
NCT01152177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP009900012|Point Of Care Testing In Danish General Practice - Part II|Point-Of-Care Testing In Danish General Practice: A Randomised Controlled Trial - Part II|POCIP|Research Unit Of General Practice, Copenhagen|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|286|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||June 2010|July 29, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01152177||120045|
NCT01152190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13469|A Study in Benign Prostatic Hyperplasia|A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|September 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|97|||Male|45 Years|N/A|No|||March 2013|March 27, 2013|June 25, 2010|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01152190||120044|The primary and secondary efficacy analyses of resistive index (RI) and color pixel intensity (CPI) were based on centrally-read data.
NCT01152203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0979|Bendamustine and Bevacizumab for Advanced Cancers|A Phase I Study of Bendamustine and Bevacizumab for Patients With Advanced Cancers||M.D. Anderson Cancer Center|No|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|13 Years|N/A|No|||May 2014|November 16, 2015|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152203||120043|
NCT01152502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0076|Paracetamol Metabolism in Post Operative Conditions|Paracetamol Metabolism in Post Operative Conditions||University Hospital, Clermont-Ferrand||Completed|June 2008|June 2010|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Defined population|June 2010|June 28, 2010|June 28, 2010||||No||https://clinicaltrials.gov/show/NCT01152502||120020|
NCT01152515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4-2010-0022|A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients|A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients||Severance Hospital||Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||May 2010|March 10, 2011|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152515||120019|
NCT01153048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDMSFD01|Trial on an Educative Structured Intervention by Peer Educators to Improve HbA1c of Patients With Type 2 Diabetes in the Sikasso Region in Mali|Randomized Controlled Trial on an Educative Structured Intervention by Peer Educators to Improve HbA1c of Patients With Type 2 Diabetes in the Sikasso Region in Mali||Sante Diabete Mali|Yes|Active, not recruiting|June 2010|September 2011|Anticipated|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2|||150|||Both|30 Years|80 Years||||July 2011|July 20, 2011|June 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01153048||119978|
NCT01119469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WE 4654/2-1, WE 4654/2-3|Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis|Dysfunctional Illness-related Cognitions in Individuals With Hypochondriasis and Change Thereof||Goethe University|No|Completed|June 2010|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|65 Years|No|||August 2014|August 5, 2014|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119469||122539|
NCT01119508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0408|Ipilimumab + Temozolomide in Metastatic Melanoma|Phase II Study of Ipilimumab Plus Temozolomide in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2010|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|75 Years|No|||August 2015|August 5, 2015|May 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119508||122537|
NCT01149369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND - DK-GpCRC-4APRON|Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial|Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial|APRON|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|April 2013|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149369||120258|
NCT01120028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSU3C1|Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy|Open-label, Randomised Multicentre Study of CAMPATH-1H Versus Basiliximab Induction Treatment and Sirolimus Versus Tacrolimus Maintenance Treatment for the Preservation of Renal Function in Patients Receiving Kidney Transplants|3C|University of Oxford|Yes|Active, not recruiting|September 2010|February 2017|Anticipated|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|800|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01120028||122497|
NCT01120002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAM80-01|Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease|||Osaka City University||Recruiting|May 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|80 Years|No|||July 2011|July 21, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01120002||122499|
NCT01120015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ks1|Diacerein as Adjuvant to Diclofenac Sodium in Indian Patients of Osteoarthritis (OA) Knee|Phase 4 Study of Diacerein as Adjuvant to Diclofenac Sodium in Indian Patients of OA Knee||Government Medical College, Amritsar|No|Completed|January 2007|November 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|84|||Both|35 Years|60 Years|No|||May 2009|May 28, 2010|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120015||122498|
NCT01123668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009085|Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)|Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence||Duke University|No|Completed|July 2009|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|101|Samples With DNA|Samples With DNA|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|120 voluntary participants to yield 40 Adult Regular Smokers, including 20 diagnosed with        ADHD and 20 comparison controls.|August 2014|September 5, 2014|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123668||122218|
NCT01123681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORION-INDEX48|Intubation and Extubation Over 48 Hours Mechanical Ventilation|Observational Study of Intubation and Extubation Over 48 Hours Mechanical Ventilation|INDEX48|Okayama Research Investigator Organizing Network|No|Active, not recruiting|May 2010|||December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|20 Years|N/A|No|Probability Sample|Critically ill patients in an intensive care unit|November 2010|November 12, 2010|May 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01123681||122217|
NCT01123694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #5672|Xeroderma Pigmentosum Patient Experiences|Xeroderma Pigmentosum: A Survey of Patient Experiences||Henry Ford Health System|Yes|Recruiting|July 2009|July 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|15|||Both|N/A|N/A|No|Non-Probability Sample|Study population will be a convenience sample of XP patients from Camp Sundown, a camp for        children with XP.|May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123694||122216|
NCT01123980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3756|Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment|An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes|EasyMix|Novo Nordisk A/S|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|521|||Both|20 Years|80 Years|No|||October 2014|October 22, 2014|May 13, 2010|Yes|Yes||No|June 1, 2012|https://clinicaltrials.gov/show/NCT01123980||122194|
NCT01124461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1625|BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor|BIRN (Biomedical Informatics Research Network)Resources Facilitate the Personalization of Malignant Brain Tumor|CONDR|Washington University School of Medicine|Yes|Recruiting|January 2010|January 2015|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Brain tumor tissue, Whole Blood.|Both|18 Years|70 Years|No|Non-Probability Sample|Neurology clinic|March 2011|March 2, 2011|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124461||122157|
NCT01150253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.09.NRC|Effect of a Probiotic on Grass Pollen Allergic Rhinitis Subjects|Double Blind Randomised Comparison of Two Preparations, One Enriched in Probiotics and One Without Probiotics (Placebo) in Grass Pollen Allergic Rhinitis Patients, Using a Nasal Provocation Test||Nestlé|No|Completed|August 2006|March 2007|Actual|March 2007|Actual|N/A|Interventional|Intervention Model: Crossover Assignment|2||||||Both|18 Years|35 Years||||January 2014|January 13, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150253||120190|
NCT01150266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWOKE|Study for the Use of Alteplase in Patients Who Awaken With Stroke|Alteplase for Waking Onset STROKE|AWOKE|University of California, San Diego|Yes|Withdrawn|August 2011|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|22 Years|N/A|No|||September 2013|September 11, 2013|June 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01150266||120189|
NCT01151254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 06-0159 B|Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation|Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients||University Health Network, Toronto|No|Completed|September 2009|July 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|146|||Both|18 Years|90 Years|No|||February 2014|February 11, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01151254||120115|
NCT01150994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13420|Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)|Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)|ED-SAFE|University of Massachusetts, Worcester|Yes|Active, not recruiting|July 2010|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Anticipated|1440|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150994||120135|
NCT01151280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7055|WallFlex Biliary Post Liver Transplant IDE Pilot|A Multi-Center, Prospective Study the WallFlex Biliary RX Fully Covered Stent for the Treatment of Anastomotic Biliary Strictures in Post Liver Transplant Patients.||Boston Scientific Corporation|No|Completed|October 2009|December 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|June 21, 2010|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT01151280||120113|This was a small, pilot, feasibility study. Further prospective studies are needed to optimize duration of fully covered self-expanding metal stent indwell and assess predictors of treatment success.
NCT01151293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098011-3|Personality of Diabetic Patients Will Influence Their Medical compliance-a 5 Years Cohort Follow up With Type D Personality|Personality of Diabetic Patients Will Influence Their Medical compliance-a 5 Years Cohort Follow up With Type D Personality||Far Eastern Memorial Hospital|Yes|Completed|July 2009|||April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|80 Years||Non-Probability Sample|T2DM patients for OPD Age 18-80 y/o Inform consent|July 2009|June 25, 2010|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151293||120112|
NCT01151579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME 07-0011|Effect of Nebulized Bronchodilators on Heart Rate|Prospective Trial of Effect of Nebulized Bronchodilators on Heart Rate and Arrhythmias in Critically Ill Adult Patients||Genesys Regional Medical Center|No|Completed|December 2008|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|89|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 24, 2010|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01151579||120091|Potential limitations are its single-center site and that the design may not have adequately eliminated all carryover effects from the levalbuterol. However, the number of side effects without carryover would be even lower than we observed.
NCT01151891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE-2|Natural History of Pedal Puncture Wounds in Diabetics|The Natural History of Pedal Puncture Wounds in Diabetics: a Cross-sectional Survey in the Parish of St. James, Jamaica.||Cornwall Regional Hospital|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|188|||Both|15 Years|N/A|No|Non-Probability Sample|Diabetics attending 3 public hospital outpatient clinics, 6 public Health Center primary        care clinics and 2 private Internist's clinics.|January 2011|January 11, 2011|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01151891||120067|
NCT01151904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-COM004|Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients|||Allergan|No|Terminated|November 2009|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|June 5, 2010|Yes|Yes|Difficulty with patient recruitment|No|January 3, 2013|https://clinicaltrials.gov/show/NCT01151904||120066|Due to lack of enrollment, this study was discontinued early and the outcome measures were not analyzed.
NCT01152216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIM18EXT|An Extension of the CONCERT Protocol (DIM18)|An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease|CONCERT PLUS|Medivation, Inc.||Terminated|April 2010|||May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|672|||Both|50 Years|N/A|No|||August 2012|August 27, 2012|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01152216||120042|
NCT01152528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-7-27.3-1|Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery|VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY.||Common Sense|Yes|Not yet recruiting|July 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|248|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2010|June 28, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152528||120018|
NCT01152801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001L2101|Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer|A Phase Ib, Multi-center, Open-label Study to Evaluate the Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer Who Are Intolerant of or Who Have Progressed Despite Treatment With VEGF-targeted Therapies||Novartis||Completed|May 2010|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||June 2014|June 22, 2014|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152801||119997|
NCT01118910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W0319-501|Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of Intertrigo|Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of Intertrigo||Image Dermatology P.C.|No|Completed|April 2010|May 2011|Actual|November 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 3, 2011|May 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118910||122582|
NCT01119170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.51.INF|Safety of D-lactate Producing Probiotics|Safety Assessment of a Starter Formula Containing D-lactate Producing Probiotics||Nestlé|No|Completed|May 2010|August 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|N/A|1 Day|Accepts Healthy Volunteers|||April 2012|April 24, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01119170||122562|
NCT01119183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00006039|Improving Patient Understanding of Preeclampsia|Improving Patient Understanding of Preeclampsia||Northwestern University|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01119183||122561|
NCT01119521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0083|Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination|Phase I Study of Whether Preclearance of Latent M. Tuberculosis (MTB) Infection With Isoniazid (INH) Enhances Specific Immune Responses to MTB Following Subsequent BCG Revaccination in Healthy, HIV-Uninfected, Tuberculin Skin Test Positive Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 23, 2014|April 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01119521||122536|
NCT01119768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00127|Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients|A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen||AstraZeneca|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|75 Years|No|||September 2012|September 26, 2012|April 27, 2010||No||No|June 1, 2012|https://clinicaltrials.gov/show/NCT01119768||122517|
NCT01151072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1992|A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects|A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties of NN1250 After Different Routes of Administration in Healthy Subjects||Novo Nordisk A/S|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|June 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01151072||120129|
NCT01151085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501076|Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Vfend Drug Use Investigation (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|April 2006|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1002|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A1501076 prescribes the voriconazole (VFEND).|May 2013|May 14, 2013|June 24, 2010|No|Yes||No|May 14, 2013|https://clinicaltrials.gov/show/NCT01151085||120128|
NCT01120288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100113|A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases|A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|April 2010|September 2013|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|May 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01120288||122477|
NCT01131871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL096770|Innovative Approaches to Diet, Exercise and Activity|Enhanced Behavioral Intervention to Improve Long-Term Weight Loss in Young Adults|IDEA|University of Pittsburgh|Yes|Completed|September 2010|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|471|||Both|18 Years|35 Years|No|||August 2015|August 4, 2015|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01131871||121595|
NCT01149291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-314|A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism|A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism||AbbVie|No|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|511|||Both|18 Years|N/A|No|Non-Probability Sample|ESRD (End Stage Renal Disease) patients undergoing hemodialysis who at the time of entry        are receiving sVDRA's (Selective Vitamin D Receptor Activator) as it is prescribed in the        normal clinical setting and according to the approved SmPC (Summary of Product        Characteristics) for the prevention or treatment of secondary hyperparathyroidism.|January 2015|January 9, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149291||120264|
NCT01150747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10010159|Chlamydia Trachomatis Immunology and Vaccinology Study|Chlamydia Trachomatis Immunology and Vaccinology Study: Determination of Protective T Cell Responses to Chlamydia Trachomatis Infection||University of Pittsburgh|No|Completed|January 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|347|||Female|15 Years|35 Years|No|Non-Probability Sample|Women positive for chlamydia or at high risk of chlamydia infection.|December 2015|December 1, 2015|June 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01150747||120152|
NCT01150760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Premier clinical outcomes|Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database|Comparison of Clinical Outcomes in Bowel Resection Patients Receiving Alvimopan vs. Patients Not Receiving Alvimopan in the Premier Perspective/Care Science Database||Cubist Pharmaceuticals LLC|No|Completed|April 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|7050|||Both|18 Years|N/A|No|Probability Sample|Retrospective cohort study using the medical claims Premier/Care Science database. The        study time frame was from January 1, 2009 through December 31, 2009.|September 2010|July 16, 2015|June 23, 2010||No||No|August 17, 2010|https://clinicaltrials.gov/show/NCT01150760||120151|
NCT01151007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/E/11|KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009|Study of KRAS Mutation in 250 Cases of Colorectal Carcinoma and Study of the Incidence of the Disease in Martinique, From 2007 to 2009|KRAS|Centre Hospitalier Universitaire de Fort-de-France|Yes|Not yet recruiting|July 2010|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|250|Samples With DNA|Paraffin embedded block of colorectal carcinoma obtained after biopsy or surgery|Both|18 Years|N/A|No|Probability Sample|Patients who lived in martinique (a french west-indies island) with a colorectal carcinoma        diagnosed between january 1st, 2007 and december 31st, 2009|June 2010|June 25, 2010|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151007||120134|
NCT01151267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0017-B|Hypercapnic Spontaneous Hyperpnoea and Recovery From Sevoflurane Anesthesia|Hypercapnic Spontaneous Hyperpnoea and Recovery From Sevoflurane Anesthesia||University Health Network, Toronto|No|Completed|July 2009|October 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|80 Years|No|||February 2013|February 21, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01151267||120114|
NCT01151306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09105|The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)|The Cardiovascular and Inflammatory Effects of Statin Therapy in Patients With COPD||University of Nottingham|No|Completed|June 2010|August 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|45 Years|80 Years|No|||March 2014|March 21, 2014|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01151306||120111|
NCT01151592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VEN10034|Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)|Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)|ASSURED|Luitpold Pharmaceuticals|No|Withdrawn||||||Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 25, 2010||No|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT01151592||120090|
NCT01151917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC|Proteomics in Morbid Obesity After Bariatric Surgery|Identification of a Novel Factor(s) of Importance to Insulin Resistance -Repeated Blood Sampling Before and After Biliopancreatic Diversion|PROTOBESE|Catholic University of the Sacred Heart|No|Completed|June 2009|July 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Serum and plasma samples at fasting and after a meal|Male|25 Years|55 Years|No|Non-Probability Sample|Twenty male, morbidly obese subjects|January 2014|January 29, 2014|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01151917||120065|
NCT01152229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLACID|Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine|Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine|PLACID|Medstar Research Institute|No|Completed|April 2010|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone PCI and have reported no bleeding, nuisance bleeding or        alarming bleeding.|August 2011|August 1, 2011|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152229||120041|
NCT01152242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-168|Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)|A Two-Part Clinical Trial to Assess Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin||Merck Sharp & Dohme Corp.|No|Completed|August 2010|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|No|||July 2015|July 22, 2015|June 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01152242||120040|
NCT01152814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_25S|Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2010-2011, When Administered to Elderly Subjects||Novartis||Completed|June 2010|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|64|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|June 28, 2010||No||No|December 21, 2015|https://clinicaltrials.gov/show/NCT01152814||119996|
NCT01152827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0710-049-223|RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid|Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid|PheoCarcRAD001|Seoul National University Hospital|Yes|Completed|July 2008|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2010|May 19, 2015|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01152827||119995|
NCT01150032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.588|Bone Quality Lyon Orleans|Bone Quality and Improvement of Fracture Risk Prediction|QUALYOR|Hospices Civils de Lyon|No|Active, not recruiting|September 2010|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1605|Samples With DNA|Frozen plasma: for later genetic studies Frozen serum: for later studies on new potential      marker of bone remodelling|Female|50 Years|N/A|No|Non-Probability Sample|50 years old or older women with lowered Bone Mineral Density|December 2010|January 17, 2013|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150032||120207|
NCT01150058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B19|Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia|Preclinical Evaluation of Novel CD33-Targeting Therapeutics for Treatment of Acute Myeloid Leukemia (AML)||Children's Oncology Group|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|40|Samples With DNA|cell samples|Both|N/A|30 Years|No|Non-Probability Sample|Patients With Acute Myeloid Leukemia|May 2015|May 11, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150058||120205|
NCT01119196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100177|The Measurement of Insulin Resistance in Peritoneal Dialysis Patients|The Measurement of Insulin Resistance in Peritoneal Dialysis Patients||Vanderbilt University|Yes|Active, not recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|N/A|N/A|No|||January 2016|January 18, 2016|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119196||122560|
NCT01119482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHTM_5698|Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage|The Impact of Vaccination With a Serogroup A Meningococcal Conjugate Vaccine on Carriage of Serogroup A Meningococci in Mali and Niger|MenAfriCar|London School of Hygiene and Tropical Medicine|Yes|Completed|May 2010|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|33000|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 18, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01119482||122538|
NCT01150552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGYFLU XPD09-211|Studies of Avian Influenza Transmission to Humans in Egypt|Prospective Studies of Avian Influenza Transmission to Humans in Egypt||St. Jude Children's Research Hospital|No|Completed|June 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1000|Samples With DNA|Sera will be tested for human antibodies against AI viruses (types H4-H12) using a      microneutralization assay. Study sera will be examined for antibodies against human      influenza types H1 and H3 using a hemagglutination inhibition procedure.|Both|2 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Exposed subjects will be enrolled at the rural areas of Egypt where poultry production is        located. Controls will be enrolled in urban Cairo. Households will be selected from        neighborhoods without live bird markets close to the location of the NRC. All members of a        household will be enrolled. Cohort of exposed subjects will be assembled from villages        from 3 governorates in this area as well as 2 governorates south of Cairo where human        cases of AI were reported. Hence, 5 villages will make up 5 field sites. From each        village, the team will enroll 150 individuals with exposure to poultry. The control group,        i.e., individuals not occupationally exposed to poultry, will be enrolled from urban        Cairo, the capital of Egypt.|July 2014|July 11, 2014|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01150552||120167|
NCT01119781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105RI101|A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers|An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment||Biogen|No|Completed|May 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01119781||122516|
NCT01151098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3201S|Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study|An Open-Label, Multi-Center, Titration Study to Establish the Long-term Safety and Tolerability of Buprenorphine Transdermal Delivery System (BTDS) 5 mg, 10 mg, and 20 mg in Patients With Chronic Non-Malignant Pain Syndromes Responsive to Opioid Combination Therapy - a 28-Week Extension Study.||Purdue Pharma LP||Completed|April 2001|February 2002|Actual|February 2002|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|June 24, 2010|Yes|Yes||No|July 29, 2010|https://clinicaltrials.gov/show/NCT01151098||120127|
NCT01132300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Approval Pending|Efficacy Study Image Guided, Auto-Targeted Neurostimulation for the Treatment of Non-Specific Low Back Pain|An Open Trial Evaluating Efficacy of NeMa-st - A Computerized, Image Guided, Auto-Targeted Neurostimulation Device for the Treatment of Non Specific Low Back Pain||Bnai Zion Medical Center|No|Completed|July 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||May 2010|May 26, 2010|September 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01132300||121562|
NCT01123395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-10-1001|Bioavailability Study of Colcrys® in Apple Juice|A Pilot Bioavailability Study of Colcrys® Tablet 0.6 mg Versus Colcrys® Tablet 0.6 mg Crushed and Dissolved in Apple Juice Under Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 29, 2011|May 12, 2010|No|Yes||No|April 5, 2011|https://clinicaltrials.gov/show/NCT01123395||122238|
NCT01123408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2244|Clozapine and Olanzapine Treatment of Aggression|Clozapine and Olanzapine in the Treatment of Violence in Schizophrenic Patients||Nathan Kline Institute for Psychiatric Research|No|Completed|June 1999|July 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|60 Years|No|||May 2010|May 13, 2010|May 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01123408||122237|
NCT01133145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|knee Tx|Allogeneic Vascularized Knee Transplantation|Allogenic Vascularized Knee and Femur Transplantation Clinical Evaluation|kneeTx|University of Jena|No|Enrolling by invitation||June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|45 Years|No|||May 2010|May 27, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133145||121497|
NCT01133158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-BMD GELTAMO 08|R-BMD GELTAMO Relapsed Lymphoma|Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Active, not recruiting|July 2009|April 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||April 2015|April 16, 2015|February 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01133158||121496|
NCT01150474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008045|Postoperative Belladonna and Morphine Suppositories in Vaginal Surgery|Randomized Clinical Trial of Postoperative Belladonna and Morphine Suppositories in Vaginal Surgery||Mayo Clinic|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|June 23, 2010|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01150474||120173|
NCT01151345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7661002|Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. De C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. De C.V.|Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made By Pfizer, S.A. DE C.V., Versus Angiotrofin® 60 Mg Made By Amstrong Laboratorios De Mexico, S.A. DE C.V. Study In 26 Healthy Volunteers Of Both Genders Under Fasting Conditions||Pfizer|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|June 24, 2010||No||No|July 24, 2011|https://clinicaltrials.gov/show/NCT01151345||120109|
NCT01121380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-1021.01|A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021|A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single-Center Combined Single-Ascending Dose and Multiple-Ascending Dose, Parallel Groups, Study to Assess Safety, Tolerability and Pharmacokinetics of BL-1021 in Healthy Volunteers||BioLineRx, Ltd.|Yes|Terminated|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|8||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|May 10, 2010||No|Sponsor strategy change|No||https://clinicaltrials.gov/show/NCT01121380||122393|
NCT01117467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0501/7|Factors Affecting Medical Student Learning in Simulation Scenarios|Factors Affecting Medical Student Learning in Simulation Scenarios||University of Oxford|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|76|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117467||122693|
NCT01151319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-CORE 002|Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults|A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults|HIV-CORE 002|University of Oxford|Yes|Completed|October 2010|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|7||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 29, 2014|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151319||120110|
NCT01117792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN-01040|Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation|Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation||Boston Scientific Corporation|Yes|Completed|December 2008|August 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||May 2010|May 4, 2010|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01117792||122668|
NCT01118026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50801|Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma|Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)||Alliance for Clinical Trials in Oncology|No|Recruiting|September 2010|||July 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|123|||Both|18 Years|60 Years|No|||August 2015|August 25, 2015|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118026||122650|
NCT01118312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAACRC-11|Study of Asthma and Nasal Steroids|Study of Asthma and Nasal Steroids for the American Lung Association-Airways Clinical Research Centers|STAN|JHSPH Center for Clinical Trials|Yes|Completed|September 2010|June 2015|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|388|||Both|6 Years|N/A|No|||October 2015|October 29, 2015|April 28, 2010||No||No|September 24, 2015|https://clinicaltrials.gov/show/NCT01118312||122628|
NCT01118325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00065|An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease|A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patients With Stable Coronary Artery Disease||AstraZeneca|Yes|Completed|April 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|146|||Both|20 Years|80 Years|No|||June 2014|June 24, 2014|April 30, 2010|Yes|Yes||No|March 14, 2012|https://clinicaltrials.gov/show/NCT01118325||122627|
NCT01118585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D00960|Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)|Prospective Outcome Evaluation of Transoral Incisionless Fundoplication (TIF) for the Treatment of Gastroesophageal Reflux Disease (GERD): The TIF Registry Study||EndoGastric Solutions|No|Active, not recruiting|May 2010|December 2015|Anticipated|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|75 Years|No|||February 2015|August 31, 2015|April 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01118585||122607|
NCT01118897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 599|Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers|Concurrent Chemo-radiation Using Tomotherapy Based IMRT in Locally Advanced Gallbladder and Pancreatic Cancers :A Phase II Study||Tata Memorial Hospital|Yes|Completed|December 2008|June 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|75 Years|No|||May 2010|August 5, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01118897||122583|
NCT01150071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2271-1|Growth, Health and Development in Children Born Extremely Preterm|Growth, Health and Development in Children Born Extremely Preterm|PEP11|University of Bergen|No|Completed|August 2010|December 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|232|Samples Without DNA|On a subpopulation blood for inflammatory parameters will be collected|Both|10 Years|12 Years|No|Non-Probability Sample|All extremely preterm infants (gestational age < 28 weeks or birth weight < 1000 g born in        Norway in 1999 and 2000 and still living at age 11 years. Postal survey on outcome. In        addition a subgroup (80 out of 365)living in Western Norway will be examined with respect        to general health, lung function, mental development, quality of life and cerebral imaging        (fMRI)|June 2015|June 1, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150071||120204|
NCT01150318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040419|Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients|Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma|SAPIRA|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2006|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|18 Years|55 Years|No|||August 2013|August 6, 2013|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01150318||120185|
NCT01150565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-100-103|Safety Study of LiRIS in Interstitial Cystitis (IC) Patients|Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis||Allergan|No|Completed|July 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|18|||Female|18 Years|N/A|No|||November 2014|November 24, 2014|June 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01150565||120166|
NCT01150825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER_02_5023|Feasibility of High Frequency QRS Analysis in Patients With Acute Myocardial Infarction|Feasibility of High Frequency QRS Analysis in Patients With Acute Myocardial Infarction||BSP Biological Signal Processing Ltd.|No|Recruiting|June 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|40 Years|N/A|No|Non-Probability Sample|Patients presenting with confirmed AMI in the intensive cardiac care unit (ICCU) of Soroka        Medical Center (Beer Sheva, Israel), who are expected to undergo percutaneous coronary        intervention (PCI) will be asked to participate in the study. These include both        ST-elevation MI (STEMI) and non ST-elevation MI (NSTEMI) patients, with positive        biomarkers and clear ongoing electrocardiographic or clinical evidence of ischemia.|February 2011|February 6, 2011|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01150825||120148|
NCT01151111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0457-09-RMB|Relaxation Guided Imagery for Treatment of Parkinson's Disease|Pilot Study of Relaxation Guided Imagery for the Treatment of Motor Fluctuations in Parkinson's Disease's||Rambam Health Care Campus|No|Completed|May 2010|May 2014|Actual|May 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|30 Years|N/A|No|||May 2014|May 7, 2014|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01151111||120126|
NCT01132313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.21|Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection|Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II)||Boehringer Ingelheim||Completed|May 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|488|||Both|18 Years|75 Years|No|||December 2015|December 22, 2015|May 3, 2010||||No|October 29, 2015|https://clinicaltrials.gov/show/NCT01132313||121561|There were only 3 patients entered in part 4 of the trial, therefore no formal analyses of efficacy data were performed.
NCT01132326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa NOH304|Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)|A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension|NOH304|Chelsea Therapeutics|No|Completed|January 2009|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|350|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|September 9, 2009|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01132326||121560|
NCT01131546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-77|Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension|A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|December 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1080|||Both|18 Years|75 Years|No|||May 2011|May 30, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01131546||121620|
NCT01131559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adjunctive LDX in BP|Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression|Adjunctive Lisdexamfetamine in Bipolar Depression||Lindner Center of HOPE|No|Terminated|January 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|March 19, 2010||No|Sponsor halted study.|No||https://clinicaltrials.gov/show/NCT01131559||121619|
NCT01131572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB19223, 09-09-18-01|N-acetylcysteine in Bulimia Nervosa|||Lindner Center of HOPE||Terminated|February 2010|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||May 2013|May 8, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01131572||121618|
NCT01149642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPATOX|Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer|Phase III Multicenter, Randomised and Double-blind Study Comparing an Oral Immunomodulatory Solution Versus a Placebo in Preventing Severe Acute Mucositis in Head and Neck Cancer Patients Treated Surgically and Concomitantly With Radiochemotherapy|IMPATOX|Institut du Cancer de Montpellier - Val d'Aurelle||Completed|November 2009|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|75 Years|No|||March 2016|March 14, 2016|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149642||120237|
NCT01121393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.34|BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)|LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation||Boehringer Ingelheim||Active, not recruiting|April 2010|December 2016|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|April 21, 2010||||No|December 27, 2014|https://clinicaltrials.gov/show/NCT01121393||122392|
NCT01121692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-Wechsberg-AA018076|Venue-Based Couples CoOp in South Africa|Venue-Based Recruitment and HIV Prevention for Alcohol and Other Drug (AOD) Using Couples in South Africa|Couples CoOp|RTI International|No|Completed|May 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|600|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01121692||122369|
NCT01121705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-00437470|Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)|Multicenter Study on Efficacy of New Therapeutic Schedules With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV( Hepatitis C Virus) Infection|genotype-3|Casa Sollievo della Sofferenza IRCCS|No|Completed|January 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|65 Years|No|||June 2009|August 9, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01121705||122368|
NCT01117480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMOS-CANA-04-01|Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA|Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (REACH)|REACH|AbbVie||Completed|July 2005|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1013|||Both|18 Years|N/A|No|Probability Sample|Participants with moderate-to-severe rheumatoid arthritis|January 2016|January 27, 2016|May 4, 2010||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01117480||122692|
NCT01117805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HL094272-01|Women of Color and Asthma Control|Women of Color and Asthma Control||University of Michigan|Yes|Active, not recruiting|May 2010|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|420|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 6, 2012|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117805||122667|
NCT01118039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDM-SU-011248|Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer|A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy||National Cancer Institute (NCI)||Recruiting|July 2006|||December 2010|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||September 2012|August 6, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118039||122649|
NCT01118338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|648|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2010|||||N/A|N/A|N/A||||||||||||||August 10, 2012|April 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118338||122626|
NCT01118351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3808|Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer|Phase II Single Arm, Open Label, Single Institution Study of Continuous Sunitinib (Sutent) in Patients With High-Risk (BCG-Refractory) Superficial Transitional Cell Carcinoma (TCC) of the Bladder||Case Comprehensive Cancer Center|Yes|Completed|October 2008|September 2015|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118351||122625|
NCT01118598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0920 PCOS & Niacin|Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome|To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS)||Hull and East Yorkshire Hospitals NHS Trust|Yes|Completed|June 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|50 Years|No|||September 2012|September 10, 2012|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01118598||122606|
NCT01149772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-088|Adjusting to Chronic Conditions Using Education, Support, and Skills|Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill|ACCESS|VA Office of Research and Development|Yes|Completed|February 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|June 10, 2010||No||No|October 13, 2015|https://clinicaltrials.gov/show/NCT01149772||120227|There were some deaths and hospitalizations during the study, however, none of the adverse events reported were determined to be related to the study.
NCT01150331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070704|Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus|Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus|SAMU-KEPPRA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2009|October 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150331||120184|
NCT01150578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lexi-Echo2010|Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography|Lexi-Echo - a Rapid, Portable, Non-radiating Diagnostic Test for Myocardial Ischemia That is Accurate Relative to Simultaneously Obtained Nuclear SPECT MPI|Lexi-Echo|University of Arizona|No|Active, not recruiting|December 2011|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to a University of Arizona / Sarver Heart Center / University Medical        Center stress imaging laboratory and scheduled to receive a regadenoson SPECT nuclear        scan.|November 2015|November 3, 2015|March 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01150578||120165|
NCT01150838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13666|Determination of the Amount of Propofol Needed to Supplement 5% Sevoflurane for Intubation of Children Without Neuromuscular Blockade|Determination of the Amount of Propofol Needed to Supplement 5% Sevoflurane for Intubation of Children Without Neuromuscular Blockade,IRB-HSR# 13666||University of Virginia|No|Completed|July 2008|||June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|150|||Both|1 Year|11 Years|No|||August 2011|August 9, 2011|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01150838||120147|
NCT01150864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001069|Effects of Airway Conditioning Devices on Ventilator Associated Pneumonia:a Randomized Clinical Trial|Effects of Airway Conditioning Devices on Ventilator Associated Pneumonia:a Randomized Clinical Trial|AirconVAP|Università degli Studi dell'Insubria|No|Recruiting|April 2010|May 2012|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|190|||Both|18 Years|90 Years|No|||May 2010|June 24, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150864||120145|
NCT01132339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-011|Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)|Prospective Clinical Trial to Investigate Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)||Copenhagen University Hospital at Herlev|Yes|Completed|May 2010|October 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1467|||Both|18 Years|N/A|No|Non-Probability Sample|The population will be selected from Herlev Hospital, Department of Radiology. Patients        referred to an MR/CT-examination will be offered participation in this study.|January 2014|January 25, 2014|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01132339||121559|
NCT01124292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09240|Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis|Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders|TDS-1|Georgia Institute of Technology|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|May 10, 2010||No||No|May 2, 2013|https://clinicaltrials.gov/show/NCT01124292||122170|
NCT01132898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100118|Long-term Clinical Correlates of Traumatic Brain Injury|Long Term Clinical Correlates of TBI: Imaging, Biomarkers, and Clinical Phenotyping Parameters||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|350|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132898||121516|
NCT01132911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100119|A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas|A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|1 Year|21 Years|No|||April 2011|April 14, 2011|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01132911||121515|
NCT01132599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000674024|Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer|A Cancer Research UK Phase II Trial to Compare [11C]Choline and [18F]Choline Each Given as a Single Administration Via Intravenous Injection for Imaging Patients With Metastatic Prostate Cancer||Cancer Research UK||Withdrawn|May 2010|||June 2011|Actual|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Male|18 Years|N/A|No|||February 2012|February 27, 2012|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132599||121539|
NCT01132612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2211E1|AIN457 Regimen Finding Extension Study in Patients With Moderate to Severe Psoriasis|A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis||Novartis|No|Active, not recruiting|May 2010|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|276|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|May 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01132612||121538|
NCT01151020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001|TX2® Low Profile TAA Endovascular Graft|Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study|TX2® LP|Cook||Active, not recruiting|March 2010|December 2019|Anticipated|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 22, 2010|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01151020||120133|
NCT01151033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XR I|A Clinical Evaluation of the ProNOVA XR Polymer Free Drug Eluting Coronary Stent System|A Clinical Evaluation of the ProNOVA XR Polymer Free Drug Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions|EURONOVA|KCRI|No|Completed|November 2008|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||January 2011|January 19, 2011|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01151033||120132|
NCT01121406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.18|BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer|Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy||Boehringer Ingelheim||Completed|April 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|N/A|No|||July 2015|July 17, 2015|April 13, 2010||||No|July 17, 2015|https://clinicaltrials.gov/show/NCT01121406||122391|
NCT01121718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-039|NIR-Guided Sentinel Lymph Node Mapping in Melanoma|Real-Time NIR-Guided Sentinel Lymph Node Mapping in Melanoma||Dana-Farber Cancer Institute|Yes|Completed|September 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01121718||122367|
NCT01117493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06054JB-A|Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis|Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis||Belfast Health and Social Care Trust|No|Completed|September 2006|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||April 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117493||122691|
NCT01117506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX 000007|Coronary Obstruction Detection by Molecular Personalized Gene Expression|Coronary Obstruction Detection by Molecular Personalized Gene Expression|COMPASS|CardioDx|No|Completed|April 2010|May 2012|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|581|Samples With DNA|RNA PAXgene|Both|35 Years|90 Years|No|Probability Sample|The study will enroll a patient population that presents with stable chest pain syndrome        or anginal equivalent and referred for stress myocardial profusion imaging.|November 2014|November 25, 2014|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117506||122690|
NCT01117519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPSTER|Impact of Fluid Management Within a Goal-directed Hemodynamic Protocol on Acid-base Balance in Elective Trauma Surgery|Impact of a Balanced Infusion Solution Compound of 50% Crystalloid and 50% Colloid Versus an Unbalanced Infusion Solution of 100% Crystalloid Within a Goal-directed Hemodynamic Protocol on Acid-base Balance|HIPSTER|Charite University, Berlin, Germany|No|Completed|May 2010|November 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|60 Years|N/A|No|||November 2011|November 15, 2011|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117519||122689|
NCT01117818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF006|Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease|A Randomized, Controlled, Parallel Group, Double-blind, Multi-center, Phase II Study to Assess the Clinical- and Immunological Activity,as Well as the Safety and Tolerability of Different Doses/Formulations of AFFITOPE AD02 Administered Repeatedly to Patients With Early Alzheimer's Disease||Affiris AG|Yes|Completed|September 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|335|||Both|50 Years|80 Years|No|||December 2013|December 10, 2013|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01117818||122666|
NCT01118052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0170Q|EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Gynecologic Oncology Group|Yes|Active, not recruiting|November 2010|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118052||122648|
NCT01118364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00940-57|Effect of Cannabis on Simulated and Actual Driving in Healthy Subjects|Effect of Cannabis on Simulated and Actual Driving in Healthy Subjects||Assistance Publique Hopitaux De Marseille|No|Completed|May 2010|December 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|20|||Male|25 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118364||122624|
NCT01118611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000669923|Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors|A Cancer Research UK Phase I Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Aurora B Inhibitor GSK1070916A in Patients With Advanced Solid Tumors||Cancer Research UK||Completed|March 2010|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01118611||122605|
NCT01118624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-014|Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer|Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer||Spectrum Pharmaceuticals, Inc||Completed|March 2010|July 2012|Actual|April 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||May 2014|May 27, 2014|May 5, 2010|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01118624||122604|Sufficient patients were enrolled.
NCT01118637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15MH086852-01A1|Stepped Care in the Treatment of Trichotillomania|Stepped Care in the Treatment of Trichotillomania||American University|Yes|Completed|August 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2013|May 23, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118637||122603|
NCT01150019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET_Resistin|Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) (18FDG-PET)|Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18FDG-PET in Obese Person||Korea University|Yes|Completed|April 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|120|Samples Without DNA|Plasma, whole blood, serum|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participats who underwent a medical health check in the health promotion center in        Korea Guro University|April 2010|July 7, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01150019||120208|
NCT01150097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001H2304E1|Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients|Extension Study to the Multicenter, Open-label, Randomized, Controlled Study CRAD001H2304 to Evaluate the Long-term Efficacy and Safety of Concentration-controlled Everolimus in Liver Transplant Recipient||Novartis|Yes|Completed|March 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|284|||Both|20 Years|75 Years|No|||March 2015|March 12, 2015|April 23, 2010|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01150097||120202|
NCT01150383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UISM-4|SCOPE-Study: Salzburg Chronic Obstructive Pulmonary Disease- Exercise and Oxygen Study|The Effect of Supplemental Oxygen During Physical Exercise Training on Exercise Capacity in COPD Patients.|SCOPE|Paracelsus Medical University|No|Completed|July 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|N/A|No|||October 2013|October 30, 2013|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150383||120180|
NCT01150344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081222|Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria|Effectiveness and Safety Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria : a Multicentric Study|MalaRia|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2010|November 2015|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||October 2015|December 8, 2015|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01150344||120183|
NCT01150357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2365|Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age|A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age||Novartis||Completed|June 2010|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|267|||Both|6 Years|17 Years|No|||September 2015|September 15, 2015|June 23, 2010|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT01150357||120182|
NCT01150617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Limb ischemia|Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty|Effect of Normalization of Fasting Glucose by Intensified Insulin Therapy on the Incidence of Restenosis After Peripheral Angioplasty in Patients With Type 2 Diabetes.|LIMBISCH|IRCCS San Raffaele|No|Terminated|December 2008|May 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|30 Years|75 Years|No|||September 2012|September 12, 2012|June 23, 2010||No|end-point reached|No||https://clinicaltrials.gov/show/NCT01150617||120162|
NCT01150851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100716|Oxidative Stress in Chronic Kidney Disease: Diet and Exercise|Oxidative Stress in Chronic Kidney Disease: Diet and Exercise||Vanderbilt University|Yes|Completed|October 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|122|||Both|18 Years|75 Years|No|||July 2014|July 24, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150851||120146|
NCT01151137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11405|Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy|A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors|PALLAS|Sanofi|Yes|Terminated|July 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3236|||Both|65 Years|N/A|No|||October 2012|October 23, 2012|June 22, 2010|Yes|Yes|The study was stopped because of safety concerns|No|September 14, 2012|https://clinicaltrials.gov/show/NCT01151137||120124|Given that the study was prematurely discontinued after 3236 patients were randomized (30% of the initial planned number), p-values were provided for information without any adjustment for multiplicity.
NCT01124552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL017LCL|A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|A Phase 2, Double-Blind, Randomized, 4-Arm, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults||Revance Therapeutics, Inc.|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|180|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 24, 2013|May 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124552||122150|
NCT01132625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A1101|Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan|A Japanese Phase I, Multi-center, Open-label, Study of AUY922 Administered Intravenously on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies||Novartis||Completed|November 2008|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|20 Years|N/A|No|||February 2013|February 21, 2013|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132625||121537|
NCT01132937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100122|Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury|Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1020|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|October 10, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132937||121513|
NCT01121055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lorazepam in FB|Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy|Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy||Seoul National University Hospital|Yes|Recruiting|March 2010|December 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|372|||Both|18 Years|N/A|No|||May 2010|May 27, 2010|May 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01121055||122418|
NCT01121068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|monthly IGRA|Monthly Follow up of Interferon Gamma Releasing Assay (IGRA) Among Health-care Workers Treating Tuberculosis (TB) Patients|Monthly Follow up of Interferon Gamma Releasing Assay Among Health-care Workers Treating TB Patients||Seoul National University Hospital|No|Completed|May 2010|December 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Health care workers who are continuously exposed to TB patients|January 2014|January 3, 2014|May 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01121068||122417|
NCT01152268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBANK10|Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool|Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool||St. Jude Children's Research Hospital|Yes|Completed|July 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|282|||Male|13 Years|21 Years|No|Non-Probability Sample|Male Adolescents meeting eligibility criteria will be identified by updated clinic lists        that are available across all institutions included in this study. After the review of        clinic lists, medical record review, and report from oncologist regarding patient risk for        treatment-related infertility, patients meeting study criteria will be recruited        consecutively within the time constraints of the available staff. That is, for every        opportunity where there is staff available for recruitment, the study team will attempt to        enroll the first available patient meeting eligibility criteria.|March 2015|March 6, 2015|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152268||120038|
NCT01152593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC0033-10|Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections|||Hillel Yaffe Medical Center||Not yet recruiting|July 2010|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Female|N/A|N/A||||June 2010|June 28, 2010|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01152593||120013|
NCT01152606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO20652|A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin|An Observational Study of Cardiac Events in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin||Hoffmann-La Roche||Active, not recruiting|August 2007|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3942|||Both|18 Years|N/A|No|Probability Sample|HER2-positive Breast Cancer|September 2015|September 1, 2015|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01152606||120012|
NCT01152619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP22831|A Study of RO4989991 in Patients With Allergic Rhinitis|A Multi-center, Randomized, Observer-blind, Placebo-controlled Safety and Tolerability Study of Repeated Administration of Two Dose Levels of RO4989991 Administered Subcutaneously to Patients With Allergic Rhinitis||Hoffmann-La Roche||Completed|July 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01152619||120011|
NCT01153126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPO8110/2009-1092|Moderating the Negative Impact of Abnormal Screening Mammograms|Moderating the Negative Impact of Abnormal Screening Mammograms||University of Wisconsin, Madison|Yes|Completed|May 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|130|||Female|18 Years|N/A|No|||February 2014|February 27, 2014|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153126||119973|
NCT01148875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-03-2104|Mammography Reminders for Encouraging Women to Undergo Regular Mammography Screenings for Breast Cancer|Finding the M.I.N.C. for Mammography Maintenance||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|September 2004|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3547|||Female|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Women members of The North Carolina Teachers' and State Employees' Comprehensive Major        Medical Plan (SHP) who are age 40-75. They must be enrolled with the SHP for at least 24        months, not covered by COBRA or Medicare primary. Based on claims data, women will have        had their last mammogram 6-8 months ago.|January 2016|January 17, 2016|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148875||120296|
NCT01149109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeTeG|Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients|Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients|CeTeG|University Hospital, Bonn|Yes|Active, not recruiting|October 2010|December 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|70 Years|No|||June 2015|June 3, 2015|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149109||120278|
NCT01149122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-12-024|Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma|Phase III Study of Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib in Unresectable, Metastatic Biliary Tract Carcinoma||Samsung Medical Center|No|Completed|January 2009|June 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||January 2012|May 14, 2014|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01149122||120277|
NCT01149408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI42887|Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients|A Pilot Study of Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Who Can Tolerate Aggressive Therapy||University of Utah|Yes|Completed|February 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|60 Years|N/A|No|||October 2015|October 5, 2015|June 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149408||120255|
NCT01149421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13631|A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes|The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|June 2010|January 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|755|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|June 15, 2010|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01149421||120254|
NCT01149707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG09 PUR 0210 002|Safety, Tolerability, Biomarker and Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis|A 2-Week Exploratory Randomized, Double-Blind, Parallel-Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Clinical Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis||PurGenesis Technologies Inc.|No|Recruiting|June 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|75 Years|No|||June 2010|June 23, 2010|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149707||120232|
NCT01149720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-A-U157|Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors|An Open-Label, Phase 1, Randomized, Two-Treatment, Two-Period, Two-Way Crossover, Relative Bioavailability Study Of A Capsule And A Tablet Formulation Of ARQ 197 In Subjects With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Completed|July 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149720||120231|
NCT01150045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-80702|Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery|A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer||Alliance for Clinical Trials in Oncology|Yes|Recruiting|June 2010|||December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|2500|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|June 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01150045||120206|
NCT01149746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-824|Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 22, 2010|June 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149746||120229|
NCT01150396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/496|Prognosis of Extremely Premature Birth|Mortality and Morbidity of Infants Born With Gestational Age Less Than 28 Weeks|BabyPEP|University of Bergen|No|Recruiting|July 2010|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples Without DNA|Blood and amniotic fluid from mother Placenta Blood from umbilical cord and repeated blood      samples from the infant Repeated urine samples from infant repeated tracheal spirates from      the infant (while intubated)|Both|22 Weeks|27 Weeks|No|Non-Probability Sample|Infants born before 28 weeks' gestational age|June 2015|June 1, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150396||120179|
NCT01150084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN01150084|"Step by Step": A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees|"Step by Step": A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees||University of Birmingham|Yes|Active, not recruiting|September 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2009|June 25, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150084||120203|
NCT01150630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000675485|Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer|Randomized Phase II-III Trial of Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma|PACT-15|IRCCS San Raffaele|No|Recruiting|May 2010|December 2019|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|370|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150630||120161|
NCT01150591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32HL097383|Microaspiration in Pulmonary Fibrosis|The Role of Microaspiration in Idiopathic Pulmonary Fibrosis|ROMI|University of California, San Francisco|No|Completed|December 2009|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20||This is a prospective cohort study of patients with IPF. Subjects will undergo (1) an      assessment of the presence or absence of microaspiration (via bronchoscopy and BAL pepsin      level), (2) measurement of biomarkers of microaspiration (via esophageal function studies,      laboratory tests, pulmonary function, chest imaging, and survey), and (3) longitudinal      follow-up to document disease progression (via pulmonary function and survey).|Both|18 Years|100 Years|No|Non-Probability Sample|Patients with IPF|December 2015|December 1, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150591||120164|
NCT01150604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T32MH019391|Depression Management Project||DMP|University of California, San Francisco|No|Completed|June 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|547|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150604||120163|
NCT01151449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03135|Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer|A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|June 2010|||July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151449||120101|
NCT01124565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT001-CL025LCL|Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults||Revance Therapeutics, Inc.|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|May 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124565||122149|
NCT01124786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-101-001|A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)|A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma||Clovis Oncology, Inc.|Yes|Completed|May 2010|June 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|367|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|May 12, 2010|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT01124786||122132|Due to Primary endpoint showing lack of efficacy, development of CO-1.01 was stopped and secondary endpoints were not analyzed. However, patient enrollment completed normally.
NCT01125046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 09C2|Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas|Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas||Northwestern University|Yes|Active, not recruiting|July 2010|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01125046||122112|
NCT01121094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7502-OG-SMC|Fetal Parenchymatic Evaluation (Liver, Spleen) Using T2* Sequences|Fetal Parenchymatic Evaluation (Liver, Spleen) Using T2* Sequences.||Sheba Medical Center|No|Not yet recruiting|June 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will be offered to motheres undergoing fetal MRI for any indication.|May 2010|May 11, 2010|May 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01121094||122415|
NCT01152632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30930112/C190301|Acupuncture for Migraine: a Functional Magnetic Resonance Imaging (fMRI) Study|Acupuncture Treatment for Migraine: a Functional Magnetic Resonance Imaging Study||Chengdu University of Traditional Chinese Medicine|Yes|Completed|January 2010|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|100|||Both|17 Years|45 Years|No|||August 2012|November 25, 2014|June 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01152632||120010|
NCT01152281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|selectiveexposure|Selective Exposure in HIV Prevention|Study to Test Meta-intervention to Increase Retention in HIV Prevention Counseling||University of Illinois at Urbana-Champaign|Yes|Recruiting|May 2010|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|5||Anticipated|760|||Both|18 Years|35 Years|No|||June 2010|June 28, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152281||120037|
NCT01153139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124/2009BO1|Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression||TheBuS_D|University Hospital Tuebingen|No|Completed|April 2010|July 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|70 Years|No|||July 2013|July 13, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01153139||119972|
NCT01153152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO.2009128|Study of Pain Following Removal of Wisdom Teeth With Acute Pulpitis|||Wuhan University|Yes|Completed||September 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|20 Years|29 Years|No|Probability Sample|patients requiring surgical removal of a single upper wisdom tooth with acute pulpitis        were included in this prospective study|February 2009|June 28, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153152||119971|
NCT01148888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014574|The Effect of Magnesium Sulfate on Motor and Somatosensory Evoked Potentials in Children Undergoing Scoliosis Surgery|The Effect of Magnesium Sulfate on Motor and Somatosensory Evoked Potentials in Children Undergoing Scoliosis Surgery||The Hospital for Sick Children|No|Completed|June 2010|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|12 Years|18 Years|No|||November 2014|November 18, 2014|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148888||120295|
NCT01149135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METc 2008.184|Low Intensity 'Blue Light' Treatment of Seasonal Affective Disorder|Randomized and Controlled Study of the Effects of Low Intensity 'Blue Light'in the Treatment of Seasonal Affective Disorder||University Medical Center Groningen|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||October 2008|August 9, 2011|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149135||120276|
NCT01149434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI43102|Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers|Drug- Drug Interaction Study of JI-101 & Everolimus in Advanced Solid Tumors, Expansion Pharmacodynamic Study of JI-101 in Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers||University of Utah|Yes|Terminated|September 2010|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|June 22, 2010|Yes|Yes|Lack of drug efficacy|No|September 8, 2014|https://clinicaltrials.gov/show/NCT01149434||120253|
NCT01149733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-823|Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|November 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 18, 2010|June 22, 2010|No|Yes||No|August 18, 2010|https://clinicaltrials.gov/show/NCT01149733||120230|
NCT01149759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0663|Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy|A Study to Evaluate Reversal of the Pathological Epidermal Phenotype in Severe AD With Suppression of Immune Activation During Cyclosporine A Therapy||Rockefeller University|No|Completed|June 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|June 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149759||120228|
NCT01150656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B17|Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia|SCOR in Targeted Therapies for Infant Leukemias Project 2: Targeting Apoptosis in Leukemia in Infants||Children's Oncology Group|No|Active, not recruiting|June 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|2 Years|No|Non-Probability Sample|Patients With Acute Myeloid Leukemia|May 2015|May 11, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150656||120159|
NCT01150370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMT-01|A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings|A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings||Ministry of Health, Rwanda||Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Male|18 Years|54 Years|Accepts Healthy Volunteers|||December 2010|January 10, 2011|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150370||120181|
NCT01150890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090072|AMG 827 in Subjects With Moderate to Severe Crohn's Disease|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease||Amgen||Terminated|July 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|130|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|June 24, 2010|Yes|Yes|Per recommendation from DRT|No||https://clinicaltrials.gov/show/NCT01150890||120143|
NCT01151150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chronic Lyme|The Phenomenon of "Chronic Lyme"; an Observational Study|||Sorlandet Hospital HF|No|Completed|May 2010|May 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood, CSF|Both|18 Years|N/A|No|Non-Probability Sample|Patients are eligible if they themselves or their physician suspected that they suffer        from ongoing chronic Bb infection|June 2010|July 25, 2011|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151150||120123|
NCT01150877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00028|High Dose Vitamin D Study|Study of High-dose Vitamin D Supplementation in Stage-4 Colorectal Cancer Patients||University of British Columbia|No|Recruiting|January 2011|July 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01150877||120144|
NCT01152099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFCDLM-07|A Clinical Trial About the Contribution of Manual Lymph Drainage in Complex Physical Therapy for Patients With Lymphoedema Secondary to Mastectomy|A Randomized, Controlled Clinical Trial About the Contribution of Manual Lymph Drainage in Complex Physical Therapy for Patients With Lymphoedema Secondary to Mastectomy||Hospital Universitario de la Princesa|No|Recruiting|September 2007|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Female|18 Years|N/A|No|||June 2012|June 18, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01152099||120051|
NCT01152385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00016|Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients|A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients||AstraZeneca|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|224|||Both|20 Years|N/A|No|||July 2012|July 24, 2012|June 10, 2010|Yes|Yes||No|July 24, 2012|https://clinicaltrials.gov/show/NCT01152385||120029|
NCT01124578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT 2008-001|Study the Average Aerobic Bioburden Levels on Catheters After Use With Egret Catheter and the Predicate Device|Validate the Acceptability of Egret's Extended Use Product as Compared to the Existing Daily Change-out Product||Egret Medical Products Inc.|No|Completed|May 2008|March 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|200|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to Medical City who require ventilation|May 2010|May 14, 2010|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01124578||122148|
NCT01124591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113-09|Brief Intervention for Drug Misuse in the Emergency Department|Clinical Trial to Determine the Effect of a Brief Behavioral Intervention in Reducing Drug Misuse Among an Emergency Department Population|BIDMED|Rhode Island Hospital|Yes|Completed|June 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|1030|||Both|18 Years|64 Years|No|||June 2015|June 8, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01124591||122147|
NCT01124799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017158|TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light|Photosensitivity Trial. A Randomized, Double-blind, Double Dummy, Placebo- and Positive Controlled Phase I Trial to Evaluate the Photosensitizing Potential of TMC435 in Healthy Subjects.||Tibotec Pharmaceuticals, Ireland||Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124799||122131|
NCT01124812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19SIPI131-04/09|131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)|A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy in Patients With Inoperable, Locally-advanced (Stage III) NSCLC||Philogen S.p.A.|No|Terminated|May 2010|October 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2012|October 25, 2012|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01124812||122130|
NCT01125059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00027431|Methadone Versus Placebo in Spine Fusion|The Effect of Methadone on Perioperative Analgesia After Posterior Lumbar Fusion - A Randomized, Placebo-controlled, Double-blinded Study||Northwestern University|No|Withdrawn|May 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|May 11, 2010|Yes|Yes|Unable to fulfill recruitment|No||https://clinicaltrials.gov/show/NCT01125059||122111|
NCT01125072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-264|Use of Echocardiography in the Evaluation of Chest Pain in the Emergency Department|Use of Echocardiography in the Evaluation of Chest Pain in the Emergency Department||New York University School of Medicine|No|Active, not recruiting|June 2005|||December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|118|||Both|18 Years|N/A|No|Non-Probability Sample|All patients presenting to the emergency department with chest pain and are admitted to        rule out acute coronary syndrome|October 2015|October 26, 2015|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01125072||122110|
NCT01152008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU P 2010-05|Use of Laser Speckle to Study Cutaneous Blood Flow at Exercise in Healthy Subjects|Evaluation Chez Des Sujets Sains d'Une Nouvelle Technique d'étude de la Microcirculation cutanée|Speckle-move|University Hospital, Angers|No|Recruiting|June 2010|October 2010|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|July 2010|July 23, 2010|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01152008||120058|
NCT01152021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-05-0250|Comparing Safety and Efficacy of Dexmedetomidine and Propofol|Comparing Safety and Efficacy of Dexmedetomidine and Propofol in Patients Requiring Sedation for MRI Scanning||Children's Hospital Boston|Yes|Terminated|August 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|3 Years|11 Years|No|||July 2014|July 17, 2014|June 25, 2010|Yes|Yes|Publication of a similar study. Not ethical to continue.|No||https://clinicaltrials.gov/show/NCT01152021||120057|
NCT01152320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31552-E/A|Trial of Spirometry Fundamentals™ in the Primary Care Setting|Randomized Controlled Trial of Spirometry Fundamentals™ in the Primary Care Setting||University of Washington|No|Completed|March 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|52|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2010|June 28, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152320||120034|
NCT01152866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24662|An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)|An Observational Study Using Subcutaneous Ovidrel (Choriogonadotrophin Alfa) for Induction of Final Follicular Maturation and Early Luteinisation in Women Undergoing Ovarian Stimulation With Recombinant-human Follicle Stimulating Hormone (r-hFSH [Gonal-F®]).||EMD Serono||Completed|December 2003|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples With DNA|Blood samples|Female|N/A|N/A|No|Non-Probability Sample|Female subjects desiring pregnancy who had been unable to conceive and been diagnosed by a        physician who is familiar with infertility and its monitoring.|August 2013|August 4, 2013|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01152866||119992|
NCT01152879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRMC 10-03|Home Parenteral Nutrition in Cancer Patients|An Evaluation of Quality of Life Outcomes in Cancer Patients Receiving Home Parenteral||Southwestern Regional Medical Center|No|Completed|May 2010|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patient who are candidates for HPN will be identified by the Nutrition and Metabolic        Support Team. Patients will be appropriate for HPN as indicated by a safe home        environment, readiness for discharge, and reimbursement for the therapy at home.        Candidates for HPN include: Patients will a nonfunctioning gastrointestinal tract.        Patients that are moderately or severely malnourished (SGA B or C) with aniticipated        deterioration in nutritional status due to aggressive treatment. Patients who have        failured enteral feedings for nutrition support. Patients with life expectancy of greater        than 3 months.|February 2014|February 20, 2014|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01152879||119991|
NCT01152892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISAR ESRD 01 2010|Risk Stratification in End Stage Renal Disease (ESRD) - ISAR Study|Risk Stratification in End Stage Renal Disease (ISAR)|ISAR|Technische Universität München|No|Active, not recruiting|April 2010|May 2020|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|patients with end stage renal disease treated with chronic hemodialysis|January 2016|January 25, 2016|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152892||119990|
NCT01148576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTZJU201001|Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients|Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial||Zhejiang University|Yes|Recruiting|June 2010|February 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1200|||Both|18 Years|70 Years|No|||June 2010|June 21, 2010|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01148576||120318|
NCT01148901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06451|Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)|Hip Arthritis Associated With AS Efficacy and Safety of Early Treatment With Infliximab (Remicade®)|HACER|Merck Sharp & Dohme Corp.|No|Withdrawn|June 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|June 21, 2010|Yes|Yes|No patient enrolled after 6 months from the start. The decision to withdraw the study was    based on a feasibility reevaluation conducted with investigators.|No||https://clinicaltrials.gov/show/NCT01148901||120294|
NCT01149148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UmichiganHS|Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients|Effect of Regional Cerebral Oxygen Saturation Monitoring On Neurological Outcome In Patients Undergoing Aortic Arch Surgery||University of Michigan|No|Completed|November 2009|September 2011|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|25|||Both|18 Years|80 Years|No|||August 2012|April 27, 2015|June 21, 2010|Yes|Yes||No|March 26, 2012|https://clinicaltrials.gov/show/NCT01149148||120275|The study was discontinued after 25 subjects completed.
NCT01149161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02-017|Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma|Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study||Samsung Medical Center|Yes|Recruiting|May 2009|December 2017|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|801|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01149161||120274|
NCT01149447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFO-HUG-Study|Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale|Prospective Clinical Follow-up of Patients Presenting With Cryptogenic Stroke Treated With the Percutaneous Closure of a Patent Foramen Ovale|PFO-HUG|University Hospital, Geneva|Yes|Recruiting|January 2001|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Non-Probability Sample|all consecutive patients presenting with a cryptogenic stroke, in whom a successful        percutaneous closure of their PFO is performed|August 2011|August 15, 2012|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149447||120252|
NCT01151189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-030-485|Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)|A Phase II, Proof of Concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Protective Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in Healthy, HIV-infected Adults||Aeras|Yes|Completed|July 2011|September 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|650|||Both|18 Years|50 Years|No|||July 2015|July 29, 2015|June 24, 2010||No||No|June 30, 2015|https://clinicaltrials.gov/show/NCT01151189||120120|
NCT01150643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000675681|Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab|Identification of Biomarkers Predicting Responsiveness to Rituximab in Follicular Lymphoma||National Cancer Institute (NCI)||Not yet recruiting|August 2010|||September 2010|Anticipated|N/A|Observational|N/A|||Anticipated|559|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150643||120160|
NCT01151462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2009/2249b|Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.|Postnatal HCMV Infection in Very Preterm Infants. Implications on Acute and Chronic Morbidity, Growth and Neurodevelopmental Outcomes Part of the Study on "Nutrition, Growth and Development Among Very Preterm Infants".||Oslo University Hospital|Yes|Withdrawn|August 2010|May 2013|Actual|January 2013|Actual|N/A|Observational|N/A||1|Actual|0|Samples With DNA|Serum. Mothersmilk. Urine.|Both|N/A|N/A|No|Probability Sample|Premature infants with birth weight below 1,500 grams born at Oslo University Hospital and        Akershus University Hospital.|May 2013|October 21, 2015|June 25, 2010||No|The study was terminated prior to enrollment|No||https://clinicaltrials.gov/show/NCT01151462||120100|
NCT01151475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24698|Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE)|Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of HE||University of Aarhus|Yes|Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|75 Years|No|Non-Probability Sample|patients with hepatic encephalopathy|June 2012|June 18, 2012|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151475||120099|
NCT01151163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0154-10-TLV|Peripheral Arterial Tonometry (PAT) Evaluation of Sleep in Fibromyalgia|Evaluation of Sleep Disordered Breathing and Autonomic Dysfunction in Fibromyalgia Through Peripheral Arterial Tonometry||Tel-Aviv Sourasky Medical Center|No|Recruiting|January 2011|July 2012|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients suffering from fibromyalgia recruited from the Tel Aviv Sourasky Medical center        fibromyalgia clinic|February 2011|February 7, 2011|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151163||120122|
NCT01151761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0032|PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation|Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation||Stanford University|Yes|Terminated|January 2011|July 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|June 15, 2010||No|Poor accrual, lack of enthusiasm from referring physicians, unusual outcomes regarding 2    patients|No||https://clinicaltrials.gov/show/NCT01151761||120077|
NCT01152411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSL-AuBM-CRF|Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Chronic Renal Failure|Use of Autologous Bone Marrow Stem Cell Transplantation in the Treatment of Chronic Renal Failure in 5 Indian Patients - ABMST-CRF Study (Autologous Bone Marrow Stem Cell Transplantation-CRF)||International Stemcell Services Limited|Yes|Active, not recruiting|February 2010|November 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||March 2012|March 28, 2012|June 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01152411||120027|
NCT01152424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FeNO in AEP|Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia|Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia||Seoul National University Bundang Hospital|No|Active, not recruiting|July 2010|December 2011|Anticipated|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|All patients who visited the study hospital with bilateral pneumonic infiltration.|June 2011|June 7, 2011|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01152424||120026|
NCT01125605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|174A10PNAL|PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases|PASCONAL NERVENTROPFEN in the Treatment of Adults and Children Suffering From Nervous Diseases (e.g. Sleep Disorders Due to Nervousness)|174|Pascoe Pharmazeutische Praeparate GmbH|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|325|||Both|1 Year|N/A|No|Non-Probability Sample|Observational groups        Patients (adults and children 1-12 years of age) suffering from nervous diseases, e.g.        sleep-disturbances due to nervousness.|March 2015|March 24, 2015|May 10, 2010||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT01125605||122069|
NCT01124825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL IRB #09.0619|Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study|Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study||University of Louisville|No|Withdrawn|July 2011|October 2012|Actual|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|65 Years|No|||November 2012|November 12, 2012|May 12, 2010||No|No subjects enrolled. Funding withdrawn by sponsor.|No||https://clinicaltrials.gov/show/NCT01124825||122129|
NCT01124838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-880|Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate, Posterior, or Pan-Uveitis|Visual II|AbbVie|Yes|Completed|July 2010|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|May 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124838||122128|
NCT01125085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19SIPI131-01/09|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors|A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT) in Patients With Multiple Brain Metastases From Solid Tumors||Philogen S.p.A.|No|Completed|October 2009|June 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2014|February 24, 2014|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01125085||122109|
NCT01125098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM58J2XH|Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD|Comparison of a Serum Procalcitonin (PRO-CT) Guided Treatment Plan With the Standard Guideline Recommended Antibiotic Treatment Plan for Patients Hospitalized With a Diagnosis of Exacerbation of COPD||University of Modena and Reggio Emilia|No|Completed|October 2006|December 2011|Actual|July 2011|Actual|N/A|Observational|N/A||2|Actual|183|Samples Without DNA|Blood samples and sputum will be collected from COPD patients in order to measure serum      PRO-CT levels and inflammatory markers (cells and mediators), respectively.|Both|18 Years|95 Years|No|Non-Probability Sample|Patients with diagnosis of COPD according to GOLD guidelines|December 2014|December 9, 2014|April 13, 2010||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01125098||122108|
NCT01152034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-I-S-662|MAPS Group Therapy Model for Bipolar Disorder|Effect of Psychoeducational Group Therapy Model for Bipolar Disorder Patients||Mackay Memorial Hospital|Yes|Completed|July 2009|April 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01152034||120056|
NCT01152333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37919-D|The Role of GLP-1 in Satiety Perception in Humans|The Role of GLP-1 in Satiety Perception in Humans||University of Washington|Yes|Withdrawn|July 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|June 15, 2010|No|Yes|This study is delayed. It was not funded.|No||https://clinicaltrials.gov/show/NCT01152333||120033|
NCT01152645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-004|Study of ARQ 197 Monotherapy|Phase II Study of ARQ 197 Monotherapy for Previously Treated Advanced/Recurrent Gastric Cancer|ARQ 197-004|Kyowa Hakko Kirin Company, Limited||Completed|June 2010|||April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|20 Years|74 Years|No|||September 2012|September 6, 2012|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152645||120009|
NCT01152658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10008-2010CTIL|Partial Tear of Supraspinatus (SSP) and Treatment With Plasma Rich in Growth Factors (PRGF)|Double Blind Prospective Randomize Trail of Partial Tear of SSP and Treatment With PRGF|PrgfRC001IL|Meir Medical Center|No|Withdrawn|April 2010|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||March 2012|January 28, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01152658||120008|
NCT01148602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSP Innovation|The CLOQS Trial - Countdown Lights to Optimize Quality in Stroke|The CLOQS Trial - Countdown Lights to Optimize Quality in Stroke|CLOQS|Sunnybrook Health Sciences Centre|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3452|||Both|N/A|N/A|No|||December 2015|December 7, 2015|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01148602||120317|
NCT01148914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI-IMPACT|The Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation|The Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation|IMPACT|Texas Cardiac Arrhythmia Research Foundation|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|48|||Both|18 Years|75 Years|No|Probability Sample|Atrial fibrillation patients undergoing catheter ablation|June 2010|May 31, 2012|June 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01148914||120293|
NCT01149174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMDA/PRE-TUR/691836|Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer|Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.|EMDA/PRE-TUR|University of Rome Tor Vergata|Yes|Completed|January 1994|June 2009|Actual|December 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|352|||Both|18 Years|90 Years|No|||October 2011|October 3, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01149174||120273|
NCT01149460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40280|Valacyclovir 1000 mg Tablet Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Valacyclovir 1000 mg Tablet and Valtrex Administered as 1 x 1000 mg Tablet in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|September 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 18, 2010|June 21, 2010|No|Yes||No|August 18, 2010|https://clinicaltrials.gov/show/NCT01149460||120251|
NCT01149473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B046515|Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions|A Relative Bioavailability Study of Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|March 2004|April 2004|Actual|April 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 16, 2010|June 21, 2010|No|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT01149473||120250|
NCT01149486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-080|Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions|A Relative Bioavailability Study of 100/25 mg Losartan Potassium/Hydrochlorothiazide Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|January 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|June 21, 2010|No|Yes||No|August 16, 2010|https://clinicaltrials.gov/show/NCT01149486||120249|
NCT01149499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R04-1770|Valacyclovir 1000 mg Tablet Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Valacyclovir 1000 mg Tablet and Valtrex Following a 1 x 1000 mg Dose in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|January 2005|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 21, 2010|June 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149499||120248|
NCT01149785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081015|Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers|A Phase 1, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Doses Of Ketoconazole On The Single Dose Pharmacokinetics Of Crizotinib (PF-02341066) In Healthy Volunteers||Pfizer|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|June 21, 2010|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT01149785||120226|
NCT01149798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2010-02|A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer|A Single Institutional Phase II Clinical Trial of Abraxane Combined With Cisplatin in Metastatic Breast Cancer||Fudan University|No|Completed|June 2010|November 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Female|18 Years|70 Years|No|||August 2012|August 5, 2012|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01149798||120225|
NCT01151202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG NPP_P3|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup"|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup" in Acute Upper Respiratory Tract Infection and Chronic Inflammatory Bronchitis Patients: Double Blinded, Randomized, Active Drug Comparative, Parallel Designed, Multi-centered, Phase III Study||Ahn-Gook Pharmaceuticals Co.,Ltd|Yes|Completed|February 2010|June 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|236|||Both|24 Months|75 Years|No|||October 2010|October 3, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01151202||120119|
NCT01150903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481287|Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor|Prevalence and Incidence of Underlying Disease Diagnosed in Men With Erectile Dysfunction When Prescribed a PDE5i for the First Time||Pfizer|No|Completed|May 2010|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|98832|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with a PDE5 inhibitor prescription and within the age-match control.|April 2012|April 3, 2012|June 24, 2010||No||No|April 3, 2012|https://clinicaltrials.gov/show/NCT01150903||120142|
NCT01151176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-001|Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome|Phase IV Study of a Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome||Universidade Positivo|Yes|Suspended|August 2012|December 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||June 2012|June 17, 2012|March 4, 2010||No|Administrative problems makes changes in hospital staff New clinical research team will    restart|No||https://clinicaltrials.gov/show/NCT01151176||120121|
NCT01151787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPH03242010|Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine|Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial||Kennedy Medical Group|Yes|Terminated|July 2010|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|35|||Both|18 Years|65 Years|No|||July 2014|July 24, 2014|June 25, 2010|Yes|Yes|Study was never initiated under new location/provider group. Contract to continue was never    signed between TEVA and Kennedy Headache Center|No||https://clinicaltrials.gov/show/NCT01151787||120075|
NCT01151800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI 2006-128|Using Automated Calls To Improve Compliance With Acute Coronary Syndrome Best Practice Guidelines|Using Interactive Voice Response To Improve Disease Management and Compliance With Acute Coronary Syndrome Best Practice Guidelines||Ottawa Heart Institute Research Corporation|No|Completed|January 2006|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Actual|1608|||Both|18 Years|N/A|No|||June 2010|June 25, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151800||120074|
NCT01151774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120100024|Validation of Transesophageal Echocardiography (TEE) to Measure Renal Resistive Index and to Predict Renal Injury|Validation of Transesophageal Echocardiography With to Measure Renal Resistive Index and to Predict Acute Kidney Injury||Rutgers, The State University of New Jersey|No|Withdrawn|May 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|89 Years|No|Non-Probability Sample|The subject sample will consist of patients undergoing cardiac, vascular and major        abdominal surgeries.|February 2016|February 1, 2016|June 25, 2010||No|study entered twice, please see protocol 0120110047|No||https://clinicaltrials.gov/show/NCT01151774||120076|
NCT01152112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP 2009003|HOME Study: Hysteroscopic Office Myomectomy Evaluation|A Hysteroscopic Office Myomectomy Evaluation Using the MyoSure Tissue Removal System for the Removal of Uterine Fibroids and Polyps in the Treatment of Abnormal Uterine Bleeding (AUB)|HOME|Hologic, Inc.|No|Active, not recruiting|June 2010|March 2013|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|55 Years|No|||September 2012|September 10, 2012|June 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01152112||120050|
NCT01152437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.74|A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer|An Open Label, Partially Randomised Phase II Study to Investigate the Efficacy and Safety of BIBW 2992 in Patients With Metastatic Colorectal Cancer Who Never Received Prior Anti-EGFR (Epidermal Growth Factor Receptor) Treatment||Boehringer Ingelheim||Completed|June 2010|||March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|June 28, 2010||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01152437||120025|
NCT01125618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA8202|The Millennium Villages Project: Assessing the Impact on Child Survival and the Millennium Development Goals in Sub-Saharan Africa|A Pair-matched Community Intervention Trial to Assess the Impact of an Integrated Health and Development Intervention on Child Survival and the Millennium Development Goals in 10 Sub- Saharan African Countries|MVP|Columbia University|Yes|Recruiting|June 2006|January 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6000|||Both|15 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01125618||122068|
NCT01121822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT90|Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)||Sanofi|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121822||122359|
NCT01121783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lactisole|The Effect of Lactisole on the Responses to Glucose Solution|Study of the Effect of Lactisole on the Responses to Intragastric Glucose Solution||Salford Royal NHS Foundation Trust||Recruiting|May 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|May 10, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121783||122362|
NCT01122095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080414|Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis|Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis||University of California, San Diego|No|Recruiting|April 2010|April 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|Blood|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|case subjects, male or female, with typical psoriasis, with or without arthritis, ages 0        to 18 years of age and of all races and ethnicities control subjects, male or female,        normal, health, non-soriatic subjects, 0 to 18 years of age.|April 2010|May 28, 2010|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01122095||122338|
NCT01152684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT004676-01A1|Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border|Complementary & Alternative Care Behavior in HIV+ Latinos in the US-Mexico Border||University of California, San Diego|Yes|Recruiting|September 2009|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The population will be selected from 2 locations: 1. San Diego: San Ysidro Health        Center(SYHC) will serve as the recruitment site on the US side of the border. Latinos        comprise >90% of SYHC's patient population. SYHC provides HIV primary medical care to over        400 HIV-positive individuals. SYHC's HIV-positive Latino patient population includes        persons who may or may not be on ARVs and who participate in clinic services to varying        degrees. Previous studies with HIV-positive patients at SYHC indicate cross-border        mobility and bi-national care seeking behavior in this clinic population. 2.Tijuana: The        Agencia Familiar Binacional (AFABI;Binational Health Agency) opened the first HIV medical        and social services agency clinic in Tijuana. This clinic is in close proximity to the        municipal health clinic, where a large number of HIV-positive cases are diagnosed, and is        linked with other non-profit social services agencies for HIV-positive persons, many of        whom face barriers to ARVs.|March 2012|March 14, 2012|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152684||120006|
NCT01152905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225/2006|Effect of Nitrous Oxide on Cisatracurium Infusion Demands|Effect of Nitrous Oxide on Cisatracurium Infusion Demands. A Randomized Controlled Trial.||Turku University Hospital|No|Completed|April 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|70|||Both|18 Years|75 Years|No|Probability Sample|Patients undergoing elective surgery requiring general anesthesia with a duration of at        least 90 minutes.|November 2006|June 28, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152905||119989|
NCT01152671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP25311|A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers|A Multiple Center Randomized, Double-Blind, Single-Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics Following Oral Administration of RO5024048 in Healthy Japanese and Caucasian Subjects||Hoffmann-La Roche||Completed|June 2010|August 2010||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Double Blind (Subject, Investigator)|2||Actual|97|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01152671||120007|
NCT01148927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0619-CE|Quality of Life Study for Adult Patients With Acute Lymphoblastic Leukemia|A Pilot Study to Evaluate the Quality of Life of Long Term Survivors of Adult Acute Lymphoblastic Leukemia||University Health Network, Toronto||Completed|November 2009|October 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|N/A|No|Non-Probability Sample|Long-term survivors of adult acute lymphoblastic leukemia treated with modified Dana        Farber Cancer Institute ALL protocol (91-01).|January 2013|January 10, 2013|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148927||120292|
NCT01149187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUH-IGRA-01|Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules|Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules||Seoul National University Hospital|Yes|Recruiting|June 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|the investigaters will use the whole blood sample for interferon-gamma release assay.|Both|18 Years|N/A|No|Non-Probability Sample|Among the inpatients who got percutaneous needle biopsy for pulmonary nodule during the        study periods are going to be enrolled.|June 2010|June 22, 2010|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01149187||120272|
NCT01149512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014271|Outcomes of the Adjustable Gastric Band in a Publicly Funded Obesity Program|Outcomes of the Adjustable Gastric Band in a Publicly Funded Obesity Program||University of Alberta|No|Completed|September 2011|September 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All patients seen within the Weight Wise program and selected for surgical management, who        have undergone LAGB will be included in this analysis.|December 2011|December 20, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01149512||120247|
NCT01149811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVF-025-201|A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease|A Randomized, Double-Blind, Crossover Study Comparing the Safety and Tolerability of Two Dose Regimens of Oromucosal Fipamezole ODT in Adult Patients With Parkinson's Disease Who Are Receiving Levodopa|Fipamezole|Valeant Pharmaceuticals International, Inc.|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|27|||Both|30 Years|75 Years|No|Probability Sample|Patients with Parkinson's Disease on stable regimen of levodopa|June 2012|June 20, 2012|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149811||120224|
NCT01149824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPMC-APRL-6A|Placebo Controlled Study of Sublingual Salvinorin A|A Double Blind Placebo Controlled Ascending Dose Pharmacodynamic and Tolerability Study of 100 to 4000 µg of Sublingual Salvinorin A|6A|California Pacific Medical Center Research Institute||Completed|June 2009|October 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|8|||Both|21 Years|45 Years|No|||May 2013|May 29, 2013|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149824||120223|
NCT01150110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|432|Resilient Occlusal and Patients With Temporomandibular Disorder (TMD)|Evaluation of Resilient Occlusal Splints in the Control of Patients With Temporomandibular Disorder (TMD)||Federal University of Uberlandia|Yes|Completed|July 2007|July 2008|Actual|||Phase 0|Interventional|Primary Purpose: Treatment|||||||Both|19 Years|50 Years||||May 2007|June 23, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150110||120201|
NCT01150123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_06|Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women|A Phase Ib Randomized, Observer-Blind, Controlled, Single Center, Dose-Ranging Study of a Group B Streptococcus Vaccine in Healthy Women 18-40 Years of Age||Novartis||Completed|May 2010|October 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|678|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01150123||120200|
NCT01151839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IESC/T-186/2010|A Trial to Compare Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus|Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus - A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi||Recruiting|June 2010|||July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||June 2010|July 8, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151839||120071|
NCT01151852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-1001|Rechallenge of Imatinib in GIST Having no Effective Treatment|A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib|RIGHT|Asan Medical Center|No|Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 23, 2010||No||No|November 19, 2013|https://clinicaltrials.gov/show/NCT01151852||120070|
NCT01151488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045555|Nutrition, Exercise, and Breast Cancer Survivorship|Impact of Nutrition and Exercise on Glucose Metabolism, Inflammation, and Body Composition in Older Breast Cancer Survivors||Baltimore VA Medical Center|Yes|Active, not recruiting|May 2012|July 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|45 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151488||120098|
NCT01151501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT20100616|Noninvasive Positive Pressure Ventilation for Early Extubation of Acute Hypoxemic Respiratory Failure|Noninvasive Positive Pressure Ventilation for Early Extubation of Acute Hypoxemic Respiratory Failure|NPPV|Beijing Chao Yang Hospital|Yes|Not yet recruiting|July 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||June 2010|June 28, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151501||120097|
NCT01151826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4714|Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung Transplantation|Measurement of Physical and Biochemical Markers of Reperfusion Edema During Primary Graft Dysfunction Following Lung Transplantation. Assessment of Their Diagnosis and Prognosis Values||University Hospital, Strasbourg, France|No|Recruiting|July 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|N/A|No|Probability Sample|Lung transplant recipients cared for in Surgical Intensive Care Unit in Strasbourg        University Hospital, France|March 2011|March 1, 2011|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151826||120072|
NCT01152450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.420|A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma|A Phase II, Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Administered Once Daily (in the Evening) and Tiotropium 2.5 µg Administered Twice Daily Delivered by the Respimat® Inhaler for Four Weeks Versus Placebo in Patients With Moderate Persistent Asthma||Boehringer Ingelheim||Completed|July 2010|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|75 Years|No|||February 2013|May 7, 2014|June 28, 2010||||No|August 17, 2012|https://clinicaltrials.gov/show/NCT01152450||120024|
NCT01152125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSL-AuBM-OA|Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis|Use of Autologous Bone Marrow Stem Cell Transplantation for Therapeutic Chondrogenesis in Moderate to Severe Osteoarthritis - ABM & LAM ST-OA Study||International Stemcell Services Limited|Yes|Enrolling by invitation|January 2010|January 2012|Anticipated|August 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|70 Years|No|||June 2011|June 8, 2011|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152125||120049|
NCT01152983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIL - CL-001|Safety and Performance Evaluation of the Rapid Ring Device|Single Center, Open Label, Prospective, Non-comparative, Non-randomized Study to Assess the Safety and Performance of the Rapid Ring Device (Comparative Study to Assess the Pain Reduction)||RapiDx Ltd.|Yes|Not yet recruiting|August 2010|November 2010|Anticipated|November 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 28, 2010|June 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01152983||119983|
NCT01121835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_C_04589|Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study|A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents|GALAPAGOS|Sanofi||Completed|February 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|934|||Both|35 Years|N/A|No|||April 2013|April 2, 2013|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01121835||122358|
NCT01122121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP III/98/032|Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer|Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)||Takeda|Yes|Completed|March 2000|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Male|18 Years|80 Years|No|||July 2015|July 27, 2015|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01122121||122336|
NCT01122147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87034|Clinical Evaluation of Fluid Extract of Chamomilla Tincture for Oral Aphthae|Phase 1 Evaluation of Therapeutic Effect of Chamomilla Tincture Mouthwash on Oral Aphthae||Mashhad University of Medical Sciences||Completed|April 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|60 Years|No|||March 2010|August 1, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01122147||122334|
NCT01152697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reuter-L1473|Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic|A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness|CAE-L|University Hospital Case Medical Center|Yes|Completed|June 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|June 24, 2010||No||No|December 28, 2013|https://clinicaltrials.gov/show/NCT01152697||120005|
NCT01152918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 065|Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies|TLC-Plus: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States||HIV Prevention Trials Network|No|Completed|September 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|299038|||Both|N/A|N/A|No|||January 2016|January 20, 2016|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152918||119988|
NCT01148628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S065RDCX01|Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors|Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors||Southern Europe New Drug Organization|No|Active, not recruiting|October 2007|December 2011|Anticipated|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|N/A|75 Years|No|||September 2011|September 12, 2011|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01148628||120315|
NCT01148615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11382|A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors|A Phase I, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Docetaxel Administrated Every 3 Weeks in Chinese Patients With Advanced Solid Malignancies||Sanofi|No|Completed|July 2010|December 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148615||120316|
NCT01149200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-6499-12-CLP-004|Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominant IBS||Targacept Inc.|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01149200||120271|
NCT01149538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910M73517|Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure|Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2010|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|2 Years|5 Years|No|||September 2014|September 4, 2014|June 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149538||120245|
NCT01149525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/13|Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis|A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis|FACTSEP|University Hospital, Bordeaux|Yes|Active, not recruiting|June 2010|June 2014|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01149525||120246|
NCT01149837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND 14309|Evaluation of InnoLIA HTLV I/II Score|In Vitro Diagnostic Study for Supplemental Testing of Anti-HTLV-I/II Reactive Human Blood Specimens||Creative Testing Solutions|Yes|Enrolling by invitation|July 2013|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4500|Samples With DNA|human serum and/or human plasma|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Whole blood and HCT/P donor samples found repeatedly reactive for anti-HTLV-I/II using an        FDA approved donor screening test|March 2016|March 3, 2016|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149837||120222|
NCT01150136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H07-01140|Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study|Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study||University of British Columbia|No|Completed|October 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|57|||Both|N/A|17 Years|Accepts Healthy Volunteers|Probability Sample|Children with proven CF and known genotype, age 0-17 yr who are outpatients of the CF        Clinic at the British Columbia (B.C.) Children's Hospital|April 2015|April 21, 2015|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01150136||120199|
NCT01150409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-336|Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock|Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock||The Cleveland Clinic|Yes|Terminated|May 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|June 21, 2010||No|Difficulty in recruiting eligible subjects|No|August 25, 2015|https://clinicaltrials.gov/show/NCT01150409||120178|
NCT01152164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125/08|Quality of Life in Patients After Combined Modality Treatment of Rectal Cancer|Quality of Life in Patients After Combined Modality Treatment of Rectal Cancer||Institute of Oncology Ljubljana|No|Active, not recruiting|January 2008|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|167|||Both|18 Years|85 Years|No|Non-Probability Sample|consecutive patients with rectal cancer stage II and III, treated with capecitabine-based        preoperative radiochemotherapy from 1.1.2008 till 31.12.2009.|March 2012|March 23, 2012|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152164||120046|
NCT01151514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA-AKI referral|Referral Patterns for Hospital Acquired Acute Kidney Injury and Relevance to Renal Outcomes|Referral Patterns for Hospital Acquired Acute Kidney Injury and Relevance to Renal Outcomes|HA-AKI|Centre Hospitalier Universitaire Vaudois|Yes|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|18 Years|90 Years|No|Probability Sample|This study population consisted of patients who were hospitalized in the medical and        surgical departments as well as in the intensive care untis (ICU) of the University        Hospital of Lausanne (Centre Hospitalier Universitaire Vaudois [CHUV]) that is a tertiary        care academic medical center. Patients with AKI coming from ICU in the medicine or surgery        wards, and patients from medicine or surgery wards, who required a transfer to ICU during        the hospital stay, were also included whatever the cause of the transfer.|August 2010|June 25, 2010|June 23, 2010||||No||https://clinicaltrials.gov/show/NCT01151514||120096|
NCT01151813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811289|Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving|||University of Pennsylvania|Yes|Completed|July 2010|December 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|65 Years|No|||April 2014|April 2, 2014|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151813||120073|
NCT01152463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10.041|Sonography After Thoracic Surgery (SATS)|Sonography After Thoracic Surgery - SATS (CT0011)||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|June 2010|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|in-patient|June 2010|June 20, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01152463||120023|
NCT01152749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1075|Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum|Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum. A Study in Healthy Smokers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|December 2009|May 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|19 Years|50 Years|No|||July 2012|July 6, 2012|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01152749||120001|
NCT01149031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ahinoam110-HMO-CTIL|Low Level Laser Therapy for the Treatment of Provoked Vestibulodynia||LLLT|Hadassah Medical Organization||Terminated|June 2010|December 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 21, 2015|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01149031||120284|
NCT01149629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa NOH101|Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa|A Randomized, Open-Label, Three-Period, Three-Sequence, Single-Dose Crossover and Separate Three-Daily-Dose Treatment Period Study Comparing the Pharmacokinetic Profiles Following Oral Dosing of 300 mg of Droxidopa in the Fed Versus Fasted State, the Bioequivalence of Three 100 mg Capsules of Droxidopa Versus a Single 300 mg Capsule of Droxidopa, and 300 mg of Droxidopa Given Three Times at Four Hour Intervals in Healthy, Elderly Subjects||Chelsea Therapeutics|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 18, 2013|June 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149629||120238|
NCT01122134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR 07|Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment|Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Treatment of Severe Malaria in Ugandan Patients||Makerere University|No|Not yet recruiting|May 2010|September 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood samples collected for artesunate drug assays|Both|18 Years|65 Years|No|Non-Probability Sample|The target population for this study are patients aged 18 years and above. The accessible        population will be patients of 18 years and above who present to Mulago hospital with        severe malaria. The study population will include patients aged 18 years and above        presenting with severe malaria, who fulfill study eligibility criteria and are enrolled.|May 2010|May 10, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122134||122335|
NCT01122381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5043-R|Comparison of a Drug and Placebo in the Prevention of Migraine Headaches|Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine||VA Office of Research and Development|Yes|Terminated|December 2011|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|May 10, 2010|Yes|Yes|poor recruitment|No|June 5, 2015|https://clinicaltrials.gov/show/NCT01122381||122316|Early termination occurred due to inadequate recruitment of episodic migraineurs in a population meeting too many exclusion criteria; resulting in no subjects available for analysis.
NCT01123018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06302009-2900|Screening for Memory Studies|Screening for Memory Studies||Stanford University|No|Active, not recruiting|June 2007|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||1|Anticipated|2000|||Both|55 Years|N/A|Accepts Healthy Volunteers|Probability Sample|healthy older adults with memory concerns|August 2015|August 19, 2015|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01123018||122267|
NCT01125878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST 2010-027|Types of Resistant Starch and Their Effect on Appetite|Understanding Resistant Starch on Satiety in Premenopausal Women|NST|Institute for Food Safety and Health, United States|No|Active, not recruiting|August 2010|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01125878||122048|
NCT01125891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-09|Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors|Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors||Onconova Therapeutics, Inc.|No|Completed|January 2009|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||October 2014|October 4, 2014|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01125891||122047|
NCT01125904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081018|A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers|A Study In Trained Taste Panel Healthy Adult Volunteers To Investigate The Palatability Of Select Formulations Of Crizotinib Oral Liquid||Pfizer|No|Completed|June 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01125904||122046|
NCT01148641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201017829|Acceptability of LNS for Infants and Young Children in Guatemala|Acceptability of Lipid-based Nutrient Supplements (LNS) for Infants and Young Children in Guatemala||University of California, Davis|No|Recruiting|May 2010|October 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||June 2010|June 18, 2010|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148641||120314|
NCT01148966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7140|Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors|A Phase 1 and 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain||University of Washington|No|Terminated|June 2010|||April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|June 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01148966||120289|
NCT01149252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Psoriasis|Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis|Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis.||Trima, Israel Pharmaceutical Products|Yes|Terminated|January 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||December 2014|December 16, 2014|June 20, 2010||No|Difficulties arouse in recruiting new patients|No||https://clinicaltrials.gov/show/NCT01149252||120267|
NCT01148940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-539-001|Sickle Cell Trait and the Risk of Venous Thromboembolism|Sickle Cell Trait and the Risk of Venous Thromboembolism|SCT&DVT|Albert Einstein College of Medicine of Yeshiva University|No|Terminated|July 2010|March 2014|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant and postpartum women|April 2015|April 15, 2015|June 21, 2010||No|insufficent enrollment|No||https://clinicaltrials.gov/show/NCT01148940||120291|
NCT01148953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR01-001|Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis|A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Tolerability of a Single Dose of Intravenous ALN-TTR01 in Patients With TTR Amyloidosis||Alnylam Pharmaceuticals|No|Completed|June 2010|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148953||120290|
NCT01149551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|572|CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness|CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness||VA Office of Research and Development|No|Completed|February 2011|July 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|9356|Samples With DNA|Blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Case participants: Enrolled Veterans with a confirmed diagnosis of SZ and BP.        Control participants: Psychiatrically healthy Veterans enrolled in VA Million Veteran        Program.|April 2015|April 15, 2015|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01149551||120244|
NCT01149850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVF4535s|Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|April 2010|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|70 Years|N/A|No|||March 2016|March 4, 2016|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149850||120221|
NCT01150149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08145|Evaluating Modes of Influenza Transmission Between Humans|Evaluating Modes of Influenza Transmission Using a Human Challenge/Exposure Model||University of Nottingham|No|Withdrawn|March 2009|June 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|August 10, 2009||No|funding application unsuccessful|No||https://clinicaltrials.gov/show/NCT01150149||120198|
NCT01150162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037-POA-0901i|Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation|A Prospective Randomized, Multi-center Study to Assess the Safety and Efficacy of Mucosta (Rebamipide), in Combination With Omeprazole as Adjuvant Therapy in Gastric Ulcer Patients|MGES|Otsuka Pakistan Limited|No|Completed|October 2010|August 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|65 Years|No|||February 2013|February 1, 2013|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150162||120197|
NCT01150422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.4|The Acceptability and Feasibility of an Alternative to Routine Follow-up Visit After Medical Abortion in Vietnam|The Acceptability and Feasibility of an Alternative to a Routine Follow-up Visit After Medical Abortion in Vietnam||Gynuity Health Projects|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1500|||Female|13 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 29, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01150422||120177|
NCT01150669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B18|Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia|SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia||Children's Oncology Group|No|Recruiting|July 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|18|||Both|N/A|2 Years|No|Non-Probability Sample|Samples from infants with leukemia|November 2015|November 5, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150669||120158|
NCT01150916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CapPesq0074/10|B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites|B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites||University of Sao Paulo|No|Completed|June 2010|March 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|4||Actual|278|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150916||120141|
NCT01152138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCHISE|Closed Versus Open Cells Stent for Acute Myocardial Infarction|COCHISE Pilot Study: Closed vs Open Cells Stent for High Risk Percutaneous Coronary Interventions in ST Elevation Acute Myocardial Infarction|COCHISE|Policlinico Casilino ASL RMB|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01152138||120048|
NCT01152151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP00990001|Point Of Care Testing In Danish General Practice|Point-Of-Care Testing In Danish General Practice: A Randomised Controlled Trial|POCIP|Research Unit Of General Practice, Copenhagen|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|213|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||June 2010|July 29, 2014|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01152151||120047|
NCT01148732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003027R|Tracheal Rapid Ultrasound Exam (T.R.U.E) for Confirming Endotracheal Tube Placement in Emergency Intubation|Tracheal Rapid Ultrasound Exam (T.R.U.E) for Confirming Endotracheal Tube Placement in Emergency Intubation||National Taiwan University Hospital|No|Recruiting|February 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patient needed emergency intubation in emergency department|June 2010|June 21, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01148732||120307|
NCT01149044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTAL Trial|A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI|TOTAL Trial: A Randomized Trial of Routine Aspiration ThrOmbecTomy With PCI Versus PCI ALone in Patients With STEMI Undergoing Primary PCI|TOTAL|Population Health Research Institute|Yes|Completed|August 2010|October 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10732|||Both|19 Years|N/A|No|||October 2015|October 19, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149044||120283|
NCT01148745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI-0001|Iron Indices and Intravenous Ferumoxytol: Time to Steady State|Iron Indices and Intravenous Ferumoxytol: Time to Steady State||Dialysis Clinic, Inc.|No|Completed|March 2010|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|N/A|N/A|No|||March 2012|March 28, 2012|June 21, 2010|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT01148745||120306|
NCT01149057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22873|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS|An Open-Label Study to Evaluate the Efficacy and Safety Of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARDs and/or Biologic DMARDs||Hoffmann-La Roche||Completed|October 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 22, 2010|No|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01149057||120282|
NCT01122719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21002|Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen|The Best Trial - Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen|BEST|CID - Carbostent & Implantable Devices|Yes|Terminated|October 2010|January 2013|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|May 11, 2010||No|slow inclusion, due to difficulties in obtaining the patients consent for the 2 months    invasive follow-up, as required by protocol design.|No||https://clinicaltrials.gov/show/NCT01122719||122290|
NCT01122732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-242-B|Comparison of Pain Relief After Non Stimulating Interscalene Catheter Placement vs Stimulating Catheter Placement in Total Shoulder Arthroplasty.|Comparison of Pain Relief After US Guided Non Stimulating Interscalene Catheter Placement vs Stimulating Catheter Placement in Total Shoulder Arthroplasty;a Randomized Study||University of Chicago|No|Recruiting|August 2010|September 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|90 Years|No|Probability Sample|all subjects having total shoulder arthroplasty.|December 2012|December 20, 2012|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122732||122289|
NCT01123343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVS-2009-001|Clinical Evaluation of TrueVision System: LRI and Capsulorhexis Templates|CLINICAL EVALUATION OF THE TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY: LRI AND CAPSULORHEXIS TEMPLATES||TrueVision Systems, Inc|No|Completed|January 2010|December 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|May 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01123343||122242|
NCT01122368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-EC-0002|A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects|An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Double-blind Study|INTENSE|Astellas Pharma Inc|Yes|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|252|||Both|18 Years|N/A|No|||February 2012|March 3, 2014|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122368||122317|
NCT01148979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000871|Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.|Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive, Flexibly-Dosed Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment In Major Depressive Disorder (MDD) Partially Responsive to Selective Serotonin Reuptake Inhibitor (SSRI) or Selective Norepinephrine Reuptake Inhibitor (SNRI) Monotherapy||Mclean Hospital|No|Completed|September 2010|October 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148979||120288|
NCT01149239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0117|The Effect of Preoperative Anxiety Level on the Induction Dose of Propofol and Minimum Alveolar Concentration (MAC) Hour of Sevoflurane During Thyroidectomy|The Effect of Preoperative Anxiety Level on the Induction Dose of Propofol and MAC-hour of Sevoflurane During Thyroidectomy||Yonsei University|Yes|Completed|June 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Female|20 Years|65 Years|No|Probability Sample|female patients aged between 20-65 years and scheduled elective thyroidectomy|June 2011|June 9, 2011|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01149239||120268|
NCT01149265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL1376/001|Online Support Groups for Depression and Anxiety|Randomised Controlled Trial of an Existing Online Support Group for Depression and Anxiety||University College, London|No|Active, not recruiting|May 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 20, 2010|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149265||120266|
NCT01149564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-99|Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants|Comparison of Oral and Intravenous Ibuprofen for Treatment of Patent Ductus Arteriosus in Extremely Premature Infants: A Randomized Controlled Trial||China Medical University Hospital|Yes|Recruiting|December 2009|June 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|24 Hours|No|||June 2010|June 22, 2010|June 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01149564||120243|
NCT01149213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-HU-003|Follow-up Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder|An Open-label, Follow-up Study on Remitted Patients With Major Depressive Disorder Using Transcranial Direct Current Stimulation||University of Sao Paulo|No|Completed|June 2010|March 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|65 Years|No|||March 2012|March 24, 2012|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01149213||120270|
NCT01149226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0084|Effects of Chloral Hydrate on Induction, Maintenance, and Recovery From Sevoflurane Anesthesia in Day-case Pediatric Surgery|||Yonsei University|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|100|||Both|1 Year|5 Years|No|||June 2011|June 9, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01149226||120269|
NCT01149863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00034057|Alteration in Timing of Plerixafor Administration|WCI1680-09: Evaluation of Alterations in Time of Administration of Plerixafor (Mozobil ®, AMD3100) in Combination With G-CSF on Safety and CD34+ Cell Mobilization||Emory University|Yes|Completed|June 2010|||December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||May 2013|November 19, 2013|June 22, 2010|Yes|Yes||No|January 10, 2013|https://clinicaltrials.gov/show/NCT01149863||120220|
NCT01150175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-763|Direct Endomyocardial Injection of Autologous Bone Marrow Cells to Treat Ischaemic Heart Failure|Double-blind Placebo Controlled Trial on Direct Endomyocardial Injection of Autologous Bone Marrow Cells for Enhancement of Neovascularization in Patients With Ischaemic Heart Failure (END-HF)|END-HF|The University of Hong Kong|No|Recruiting|July 2008|December 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||June 2010|June 23, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150175||120196|
NCT01150188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139210|Effects of Amino Acids on Regional Lipid Metabolism|Effects of Amino Acids on Regional Lipid Metabolism|NH|University of Arkansas|No|Recruiting|June 2010|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01150188||120195|
NCT01150435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hummel 2010-1|Driving Ability of Drug Dependant Patients in Maintenance Therapy|Driving Ability of Drug Dependant Patients in Maintenance Therapy||Hummel, Christiane|No|Completed|February 2008|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|121|Samples Without DNA|Drug screen Urin|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|drug dependent patients in stable maintenance therapy|June 2010|June 24, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01150435||120176|
NCT01150682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000680598|Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer|Role of Sex Hormone and Insulin/IGF Axes in Endometrial Cancer Recurrence||National Cancer Institute (NCI)||Active, not recruiting|July 2010|||July 2015|Anticipated|N/A|Observational|N/A|||Anticipated|865|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2010|April 28, 2011|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150682||120157|
NCT01150929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050031|Rehabilitation After Total Knee Arthroplasty (TKA) - PFC Rotating Versus Fixed Bearing|Rehabilitation After Total Knee Arthroplasty - Rotating Platform Versus Fixed Bearing Polyethylene||University of Aarhus|No|Recruiting|March 2007|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|50|||Both|50 Years|75 Years|No|||February 2011|February 18, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01150929||120140|
NCT01150942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD287-BR-CT-301|Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea|A Multi-center, Active-control, Randomized, Double-blind Phase 3 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine 'KD-287(JEIMMUGEN INJ.) in Korean Healthy Children Aged 12~23 Months||Boryung Pharmaceutical Co., Ltd|Yes|Completed|August 2010|February 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|205|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||February 2011|January 29, 2014|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01150942||120139|
NCT01126008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-10-007|Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer|A Phase II Trial of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer||Samsung Medical Center||Recruiting|December 2009|December 2016|Anticipated|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||May 2013|June 3, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126008||122038|
NCT01121913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04ACL101|Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers|A Randomized, Four-way Crossover Pilot Study to Compare the Relative Bioavailability of Two Prototype Once-a-day Trazodone Hydrochloride Products and Two Marketed Reference Products Following an Equivalent Daily Dose Administration Under Fasting Conditions in Healthy Volunteers||Labopharm Inc.||Completed|March 2005|||April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|May 10, 2010||No||No|June 22, 2010|https://clinicaltrials.gov/show/NCT01121913||122352|
NCT01121926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04ACL108|A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady State|A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered Once Daily) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) at Steady State||Labopharm Inc.||Completed|January 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|May 10, 2010||No||No|June 22, 2010|https://clinicaltrials.gov/show/NCT01121926||122351|
NCT01125410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Med380104|Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis|Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis||Medinova AG|No|Completed|January 2007|February 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|321|||Female|18 Years|55 Years|No|||May 2010|May 17, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01125410||122084|
NCT01125657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-046|A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B|Pharmacokinetic Study of YM150 - The Verification ot the Bioequivalence Between YM150 Formulation-A and YM150 Formulation-B -||Astellas Pharma Inc|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|44|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2010|May 24, 2010|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01125657||122065|
NCT01125956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01164|Improving Diabetes Control Through Peer Counseling and Incentives|Improving Diabetes Control Through Peer Counseling and Incentives||University of Pennsylvania|Yes|Completed|July 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|50 Years|70 Years|No|||August 2012|August 14, 2012|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125956||122042|
NCT01125969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10022605|A Trial of Incentives and Peer Mentors to Improve Diabetic Outcomes|A Randomized Trial of Incentives and Peer Mentors to Improve Diabetic Outcomes||University of Pennsylvania|Yes|Active, not recruiting|March 2011|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|240|||Both|30 Years|70 Years|No|||December 2014|December 8, 2014|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01125969||122041|
NCT01122394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDP 09-414|Reducing Risk of Recurrence|Reducing Risk of Recurrences: Issues in Maintenance and Stability in Stroke (CDA 08-009)|RRR|VA Office of Research and Development|No|Completed|January 2010|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|21 Years|N/A|No|||August 2015|August 25, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122394||122315|
NCT01122407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091282|Pathophysiology of Cardiometabolic Risk Factors in African Americans|Obesity, Hypertension in African American Women, Neuro-metabolic Mechanism||Vanderbilt University|Yes|Recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|46|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122407||122314|
NCT01122420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100021|Online Resources to Manage Obesity and Health Risks in an Employee Wellness Program|Online Resources to Manage Obesity and Health Risks in an Employee Wellness Program||Vanderbilt University|Yes|Completed|May 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||August 2013|August 21, 2013|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122420||122313|
NCT01122745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-243-B|Single Shot vs Continuous Interscalene Block for Rotator Cuff Repair|Comparison of Pain Relief After Single Shot Interscalene Block With Continuous Interscalene Block for Arthroscopic Rotator Cuff Shoulder Surgery: A Randomized Study||University of Chicago|No|Completed|August 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|88|||Both|18 Years|90 Years|No|Probability Sample|All pateint undergoing arthroscopic rotator cuff surgrey and agreed to have regional block        for pain control|May 2014|May 29, 2014|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122745||122288|
NCT01123382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD059777|Electrical Stimulation for Hemiplegic Shoulder Pain|Electrical Stimulation for Hemiplegic Shoulder Pain||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|January 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|N/A|No|||December 2011|December 22, 2011|May 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01123382||122239|
NCT01147614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7887933|Brief Cognitive Behavioral Therapy (CBT) for Pediatric Anxiety and Depression in Primary Care|Brief CBT for Pediatric Anxiety and Depression in Primary Care|BCBT-PC|San Diego State University|Yes|Recruiting|September 2010|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|8 Years|16 Years|No|||June 2012|November 20, 2014|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147614||120392|
NCT01147952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15565|The Effect of Exercise on Peripheral Blood Gene Expression in Angina|||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Not yet recruiting|November 2010|||November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|30 Years|80 Years|No|||November 2010|November 3, 2010|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01147952||120366|
NCT01144312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0534|Population Pharmacokinetics of Fentanyl in Patients Undergoing Living Donor Liver Transplantation|Population Pharmacokinetics of Fentanyl in Patients Undergoing Living Donor Liver Transplantation||Asan Medical Center|No|Completed|September 2009|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|65 Years|No|||June 2010|June 21, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144312||120645|
NCT01123005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0032|Imaging and Biomarkers of Hypoxia in Solid Tumors|Imaging and Biomarkers of Hypoxia in Solid Tumors||Stanford University|Yes|Recruiting|December 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|blood and tumor samples|Both|18 Years|N/A|No|Non-Probability Sample|Any solid tumor malignancies of any stage meeting all of the following criteria: 1. Tumor        is accessible for minimally invasive biopsy (i.e., not requiring general anesthesia; e.g.,        FNA, core needle, punch, excision under local anesthesia) OR surgical resection is the        planned initial treatment regardless of participation in this study; 2. Minimum tumor        dimension is at least 1 cm (to ensure it is above the detection threshold of PET imaging).|February 2015|February 2, 2015|July 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01123005||122268|
NCT01123330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54DE1426101|Evaluation of a Brief Tailored Motivational Intervention to Prevent Early Childhood Caries|Detroit Research Center on Oral Health Disparities||Temple University||Completed|October 2001|October 2007|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2042|||Both|N/A|5 Years|Accepts Healthy Volunteers|||May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123330||122243|
NCT01124942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA116/09|MGuard Stent in ST-elevation Myocardial Infarction|MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial|GUARDIAN|Federico II University|No|Recruiting|March 2010|March 2013|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||April 2010|May 17, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01124942||122120|
NCT01124955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAAAU|Acupuncture Using Yamamoto's Method for the Treatment of Acute Nonspecific Low Back Pain|Acupuncture for Acute Nonspecific Low Back Pain: a Randomized, Controlled, Double-blind, Placebo Trial|ANLBP|Federal University of São Paulo|Yes|Completed|November 2009|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||November 2009|June 13, 2011|May 13, 2010||No||No|August 9, 2010|https://clinicaltrials.gov/show/NCT01124955||122119|
NCT01124929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abdominal TB_RCT (RNTCP-DOTS)|Treatment Duration for Abdominal Tuberculosis|A Multi-centric Study on Treatment of Abdominal Tuberculosis (Intestinal or Peritoneal): A Randomized Controlled Trial to Compare the 6 Months of Cat I Treatment With 9 Months of Cat I Treatment (Extension for 3 Months) in Abdominal Tuberculosis Under the Revised National Tuberculosis Control Program|RNTCP-DOTS|All India Institute of Medical Sciences, New Delhi|Yes|Completed|July 2008|April 2014|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01124929||122121|
NCT01125189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-010|Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients|A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection|HEPCAT|Bristol-Myers Squibb|No|Completed|July 2010|August 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|558|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|May 17, 2010|Yes|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01125189||122101|
NCT01125202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08040361|Intervention to Reduce Dietary Sodium in Hemodialysis|Intervention to Reduce Dietary Sodium in Hemodialysis|BalanceWise-HD|University of Pittsburgh|Yes|Recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2010|May 17, 2010|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01125202||122100|
NCT01125436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1KL2RR024990|A Trial of Vitamin D Therapy in Patients With Heart Failure|A Randomized Placebo Controlled Trial of Vitamin D Therapy in Patients With Heart Failure||University Hospital Case Medical Center|No|Active, not recruiting|July 2008|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|50 Years|N/A|No|||July 2011|July 1, 2011|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125436||122082|
NCT01124656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-06-TL-OPI536-005|Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes|A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of AD 4833-536 in Subjects With Type 2 Diabetes||Takeda|No|Terminated|September 2006|May 2007|Actual|May 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|May 13, 2010|Yes|Yes|Formulation issues.|No||https://clinicaltrials.gov/show/NCT01124656||122142|
NCT01124669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000670998|Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate|BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy||National Cancer Institute (NCI)||Not yet recruiting|June 2010|||July 2010|Anticipated|N/A|Observational|N/A|||Anticipated|80|||Both|18 Years|N/A|No|||May 2010|July 7, 2010|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01124669||122141|
NCT01121965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRIG #1|Early Vitrectomy for Impending Macular Hole|Early Vitrectomy for Impending Macular Hole. Multicenter Clinical Trial||Seoul Retina Investigator Group|Yes|Recruiting|November 2009|November 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|45 Years|N/A|No|||March 2011|March 28, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01121965||122348|
NCT01122173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP010|Use of the Hansen Medical System in Patients With Paroxysmal Atrial Fibrillation|A Prospective, Single Arm Study of the Hansen System for Introducing and Positioning RF Ablation Catheters in Subjects With Paroxysmal Atrial Fibrillation||Hansen Medical|Yes|Recruiting|July 2013|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01122173||122332|
NCT01122186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA023395|Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)|Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men|ACE|Hunter College|Yes|Completed|September 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Male|18 Years|N/A|No|||May 2013|May 30, 2013|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122186||122331|
NCT01122758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAIN|Chronic Obstructive Pulmonary Disease (COPD) History Assessment In SpaiN (CHAIN)|(COPD History Assessment In SpaiN): "Estudio Sobre la Evolución Multidimensional de la Enfermedad Pulmonar Obstructiva Crónica (EPOC)".|CHAIN|Cimera|No|Recruiting|December 2009|January 2016|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2400|Samples Without DNA|complete blood and serum samples|Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be selected from the outpatient clinics, pulmonary function labs, and /        or pulmonology wards of each participating center|November 2012|November 27, 2012|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122758||122287|
NCT01123044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 09-01|Transplantation of Cultivated Corneal Epithelial Sheet in Patients With Ocular Surface Disease|Transplantation of Cultivated Corneal Epithelial Sheet in Patients With Ocular Surface Disease|CLET|Ministry of Health, Malaysia|No|Not yet recruiting|August 2011|September 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|75 Years|No|||May 2010|July 7, 2011|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01123044||122265|
NCT01123057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R573/61/2007|Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia|Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia||Singapore National Eye Centre|No|Recruiting|August 2008|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2010|May 13, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01123057||122264|
NCT01123070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-TL011-101|TL011 in Severe, Active Rheumatoid Arthritis Patients|||Teva Pharmaceutical Industries||Completed|February 2010|May 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|80 Years|No|||May 2012|May 14, 2012|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01123070||122263|
NCT01131234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01428|Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors|A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)|No|Completed|May 2010|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2014|December 22, 2014|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01131234||121642|
NCT01145547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kw01|Continuous Glucose Monitoring to Measure Effect of Glycemic Index|The Effect of Glycemic Index on Post-prandial Glycemia (Breakfast vs. Lunch) in Patients With Type 1 Diabetes: Quantification With Continuous Glucose Monitoring||Legacy Health System|Yes|Completed|April 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|7|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|June 15, 2010||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01145547||120551|
NCT01148199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1219-10|Self-expandable Metallic Stent Versus Multiple Plastic Stents in Post Orthotopic Liver Transplantation Biliary Stenosis|Self-expandable Metalic Stent Versus Multiple Plastic Stents in Post OLT Biliary Stenosis: Prospective, Randomized, Controlled Trial.||Hospital Israelita Albert Einstein|No|Completed|August 2009|February 2016|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|No|||February 2016|February 17, 2016|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148199||120347|
NCT01148212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/2009|Safety and Tolerability of Transcranial Direct Current Stimulation (tDCS)|Safety and Tolerability of Transcranial Direct Current Stimulation (tDCS)||Ludwig-Maximilians - University of Munich|No|Completed|June 2009|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|15 healthy volunteers|January 2011|February 7, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148212||120346|
NCT01146184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-181|Single Incision Laparoscopic Cholecystectomy Using a Flexible Endoscope and Ethicon Manually Articulating Devices (MAD)|Single Incision Laparoscopic Cholecystectomy Using a Flexible Endoscope and Ethicon Manually Articulating Devices (MAD)|IRB#08-181|St. Luke's-Roosevelt Hospital Center|Yes|Withdrawn|November 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|18 Years|65 Years|No|||August 2015|March 4, 2016|June 1, 2010||No|the manufacturer never released the instruments|No||https://clinicaltrials.gov/show/NCT01146184||120502|
NCT01123902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC 05/06-69|Effectiveness of a Hand-held Fan for Breathlessness|Effectiveness of a Hand-held Fan for Breathlessness: a Randomised Phase II Trial||King's College London|No|Completed|June 2006|February 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||July 2006|May 13, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01123902||122200|
NCT01124149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-409|Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis|A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis||Shire||Completed|June 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|722|||Both|18 Years|N/A|No|||September 2013|June 6, 2014|May 13, 2010|No|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01124149||122181|
NCT01125215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUPYPM-01|Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy|Study of Topical Preparation of Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy||Mahidol University|No|Active, not recruiting|September 2009|December 2013|Anticipated|October 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|May 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01125215||122099|
NCT01124695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000672523|Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer|A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen||National Cancer Institute (NCI)||Recruiting|September 2010|||July 2016|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|240|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|May 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124695||122139|
NCT01126021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS09-634|Using Technology to Promote Mental Acuity|Using Technology to Promote Mental Acuity||University of Pennsylvania|No|Active, not recruiting|May 2010|March 2012|Anticipated|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|600|||Both|55 Years|80 Years|No|||January 2012|January 10, 2012|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126021||122037|
NCT01126034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn - 802142|Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention|Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention||University of Pennsylvania|No|Completed|March 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|85|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126034||122036|
NCT01125670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-047|A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet|Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet-||Astellas Pharma Inc|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||May 2010|May 24, 2010|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01125670||122064|
NCT01125683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00011|To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease|A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD||AstraZeneca|No|Terminated|June 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|40|||Both|55 Years|85 Years|No|||May 2011|May 11, 2011|May 13, 2010|Yes|Yes|Poor recruitment.|No||https://clinicaltrials.gov/show/NCT01125683||122063|
NCT01134471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ostene-project|Improvement of Hemostasis Techniques After Median Sternotomy|Improvement of Hemostasis Techniques After Median Sternotomy||Aarhus University Hospital|Yes|Enrolling by invitation|April 2009|May 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Male|60 Years|80 Years|Accepts Healthy Volunteers|||May 2010|June 1, 2010|May 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01134471||121395|
NCT01122199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-16; IUCRO-0287|Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors|Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors||Indiana University|Yes|Active, not recruiting|June 2010|December 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|May 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122199||122330|
NCT01122433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN-201005|Airway Management Study to Evaluate the C-MAC Video Laryngoscope as an Alternative to the Direct Laryngoscopy|Evaluation of the C-MAC Video Laryngoscope After Failed Direct Laryngoscopy||Johannes Gutenberg University Mainz||Completed|April 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2010|September 27, 2010|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01122433||122312|
NCT01122771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLCombo-BD-09|Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh|A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh||Drugs for Neglected Diseases|Yes|Completed|May 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|602|||Both|5 Years|60 Years|No|||January 2016|January 20, 2016|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122771||122286|
NCT01122784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rF1V-02b|Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant|A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 µg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers||DynPort Vaccine Company LLC, A CSC Company|Yes|Completed|July 2010|July 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|402|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 14, 2013|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01122784||122285|
NCT01123083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115494|Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2|DEFEND 2: Durable-Response Therapy Evaluation ForEarly- or New-Onset Type 1 Diabetes|DEFEND-2|GlaxoSmithKline|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|179|||Both|12 Years|17 Years|No|||December 2012|December 13, 2012|May 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01123083||122262|
NCT01131884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U of R 29563|Pilot Study of Fosamax in Spinal Cord Injury|Double Blind Placebo Controlled Trial to Evaluate Preservation of Bone Mineral Density of the Hip and Distal Femur by Biphosphate Therapy (Fosamax) Following Spinal Cord Injury||University of Rochester|No|Terminated|June 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1|||Both|18 Years|100 Years|No|||December 2015|December 25, 2015|May 25, 2010|Yes|Yes|Only 1 participant enrolled since the beginning of this study|No|December 4, 2012|https://clinicaltrials.gov/show/NCT01131884||121594|
NCT01145573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-65|Bone Health in Pregnancy|Testing the Calcium DRI During Pregnancy: A Study of Bone Health in Black and White Women|B-Hip|Children's Hospital & Research Center Oakland|Yes|Active, not recruiting|May 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 5, 2013|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01145573||120549|
NCT01145846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-022|Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)|A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia|AIvsAD|Cooperative Study Group A for Hematology|Yes|Recruiting|May 2010|April 2014|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|316|||Both|15 Years|65 Years|No|||June 2010|June 16, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01145846||120528|
NCT01145859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12892|Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects|Single-dose Pilot Study of Oral Rivaroxaban in Pediatric Subjects With Venous Thromboembolism||Bayer|Yes|Completed|November 2010|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|59|||Both|6 Months|18 Years|No|||August 2015|August 5, 2015|June 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01145859||120527|
NCT01146197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071242|Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics|Evaluation of Safety and Efficacity of Indometacin and Two Potassium Sparing Diuretics in Adult Patients Affected by Gitelman Syndrome|GITAB|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2010|January 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|33|||Both|18 Years|60 Years|No|||December 2009|December 9, 2013|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146197||120501|
NCT01146522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908A2212|Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia|A Multiple-dose, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCQ908 in Patients With Severe Hypertriglyceridemia and Chylomicronemia (Phenotypes I and V)||Novartis||Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|75 Years|No|||December 2012|December 28, 2012|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146522||120476|
NCT01123915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opal-HIV-1001|A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People|A Phase 1, Dose Escalating, Single Centre, Double Blind Study of the Safety and Immunogenicity of Opal-HIV-Gag Clade C in HIV Positive Subjects||Medicines Development Limited|Yes|Terminated|May 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|60 Years|No|||November 2011|November 8, 2011|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01123915||122199|
NCT01124162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30272|Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 22, 2010|May 13, 2010|No|Yes||No|June 21, 2010|https://clinicaltrials.gov/show/NCT01124162||122180|
NCT01124175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30273|Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|October 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 22, 2010|May 13, 2010|No|Yes||No|June 21, 2010|https://clinicaltrials.gov/show/NCT01124175||122179|
NCT01124721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816598|Effects of Cognitive Training on Academic Task Performance in Attention Deficit Hyperactivity Disorder (ADHD)|Pilot Testing of Cognitive Training on Academic Task Performance in Children With Attention-deficit/Hyperactivity Disorder|Cog-RAST|University of California, Davis|No|Recruiting|January 2008|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|7 Years|14 Years|No|||May 2010|May 13, 2010|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01124721||122137|
NCT01124968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eConsulta|eConculta: Impact of Virtual Visits in Primary Care|Before and After Study to Assess the Impact of the Use of Virtual Consultation on Frequency of Patient Attendance, and Satisfaction of Patients and Professionals|eConsulta|Institut Catala de Salut|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|16720|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|February 7, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01124968||122118|
NCT01124435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|935/03|Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients|Phase II Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients|carbo-cox2|Catholic University of the Sacred Heart|Yes|Completed|October 2003|December 2008|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|75 Years|No|||December 2008|June 3, 2010|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01124435||122159|
NCT01124448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBIOLAC|Global Effects of a Probiotic Strain on Lactating Women|Oral Administration of a Probiotic to Lactating Women: Microbiological, Immunological, Transcriptomics and Metabolomics Effects|PROBIOLAC|Universidad Complutense de Madrid|No|Completed|March 2011|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|May 14, 2010||No||No|July 3, 2014|https://clinicaltrials.gov/show/NCT01124448||122158|
NCT01125709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC0609|Comparative Study of Clinical Endpoint in DMD: Handheld Myometry (HHM) Versus CINRG Quantitative Measurement System (CQMS)|Comparative Study of Clinical Endpoint in DMD: HHM vs. CQMS||Cooperative International Neuromuscular Research Group|Yes|Completed|January 2010|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|30|||Male|6 Years|18 Years|No|Probability Sample|Participants will be selected from participating CINRG institution's neuromuscular        clinics.|January 2013|January 10, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125709||122061|
NCT01125722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10-0001|Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)|Pilot Clinical Trial to Study the Effectiveness of a Four-week Exposure to a Transcutaneous, High-frequency, Amplitude-modulated, Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence in Subjects With Idiopathic Overactive Bladder (OAB)||Ethicon Endo-Surgery|No|Completed|April 2010|March 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|May 14, 2010|Yes|Yes||No|April 9, 2012|https://clinicaltrials.gov/show/NCT01125722||122060|
NCT01125696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCCDPHP-5877|Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV|Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers|TiP|Centers for Disease Control and Prevention|Yes|Recruiting|May 2012|August 2016|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|20 Years|N/A|No|||June 2012|February 2, 2015|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01125696||122062|
NCT01134484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-BO2005|VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)|A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Active, not recruiting|May 2006|December 2015|Anticipated|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|65 Years|No|||July 2012|July 19, 2012|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134484||121394|
NCT01122212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S100-01 2010|Introduction of Protein S100 in Diagnostics in Minor Brain Injury Patients at Our Hospital|Introduction of Protein S100 in the Routine Diagnostics in Patients With Minor Head Injury|S100|Kantonsspital Münsterlingen|Yes|Completed|January 2010|January 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|128|Samples With DNA|venous blood (Serum)|Both|4 Years|N/A|No|Probability Sample|All patients older than 3 years entering the ED of the Kantonsspital Münsterlingen with        the history of a MHI during the last 6 hours and after getting informed consent|January 2012|April 17, 2015|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122212||122329|
NCT01122446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAPREV/2008|Diabetes Prevention - Immune Tolerance|A Double-blind, Randomized Investigator-initiated Study to Determine the Safety and the Effect of Diamyd® on the Progression to Type 1 Diabetes in Children With Multiple Islet Cell Autoantibodies|DIAPREV-IT|Lund University|Yes|Active, not recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|4 Years|18 Years|No|||March 2016|March 9, 2016|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122446||122311|
NCT01122797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-PNPLA3|Influence of Adiponutrin in Chronic Liver Disease|Study of Metabolism Influence in Human Alcoholic Liver Disease||Erasme University Hospital|Yes|Completed|January 2003|March 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|658|Samples With DNA|DNA extraction from whole blood sample. Piece of liver tissue in the alcoholic liver disease      group.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive patients undergoing transjugular liver biopsy for alcoholic liver disease will        be included in the study to determine the potential correlation between rs738409 PNPLA3        polymorphism and/or PNPLA3 mRNA expression.|December 2002|May 11, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122797||122284|
NCT01123096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5923|Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?|Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?||University of California, Irvine|Yes|Completed|September 2007|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Female|18 Years|N/A|No|Probability Sample|Patients with the primary complaint of stress incontinence with minimal or no urge        incontinence symptoms. They must be able to read English as the study involves use of        validated questionnaires which have only been validated in English.|June 2013|June 27, 2013|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01123096||122261|
NCT01145274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allopurinol_2010_1|A Pilot Study for Pharmacokinetic/Pharmacodynamic (PK/PD) Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient|A Pilot Study for PK/PD Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient|Allopurinol|Seoul National University Hospital||Recruiting|June 2010|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|80 Years|No|Non-Probability Sample|chronic kidney disease ( estimated GFR 30-60 ml/min )|August 2011|August 12, 2011|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145274||120571|
NCT01145560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0620C00003|A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock|A MultiCentre, Randomized, Double-blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of AZD9773 (CytoFab™) in Adult Patients With Severe Sepsis and/or Septic Shock||AstraZeneca||Completed|October 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|June 7, 2010|Yes|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01145560||120550|
NCT01145898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cosopt and OAG progression|Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data|Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data||Indiana University|No|Completed|June 2010|October 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|30 Years|N/A|No|Non-Probability Sample|Glaucoma patients|January 2014|January 17, 2014|June 15, 2010||No||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01145898||120524|Small numbers of participants at various time-points limited the power of analysis in our estimation, as did patients who changed medications and therefore further limited analysis options at various time-points.
NCT01145872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32AT004879-01A2|The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse|The Effects and Mechanisms of MBCT on Depressive Symptoms and Depression Relapse|MBCT|University of Denver|Yes|Completed|July 2010|April 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|55 Years|No|||December 2014|December 1, 2014|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01145872||120526|
NCT01146548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0720101|Fluoxetine in Multiple System Atrophy Patients|Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial|MSA-Fluox|University Hospital, Toulouse|No|Completed|May 2008|September 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|87|||Both|30 Years|80 Years|No|||February 2012|March 25, 2015|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146548||120474|
NCT01124708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5619-238-CRD-002|Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)|A Double-blind, Randomized, Placebo-controlled, Multicenter, Fixed Dose Titration Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)||Targacept Inc.|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|September 3, 2013|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124708||122138|
NCT01132261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-dietetic intake|Trial of a Brain Preservation Diet in Preventing Cognitive Decline in Old Age Hostel Residents|A Randonized Control Trial of a Brain Preservation Diet in Preventing Congnitive Decline in Odl Age Hostel Residents||Chinese University of Hong Kong||Completed|February 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|480|||Both|75 Years|N/A|No|||January 2009|May 27, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01132261||121565|
NCT01132547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0703|Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer|Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk||University of South Florida|Yes|Terminated|June 2010|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|22|||Both|2 Years|21 Years|No|||June 2015|June 4, 2015|May 26, 2010|Yes|Yes|The study was terminated due to slow accrual.|No|January 12, 2015|https://clinicaltrials.gov/show/NCT01132547||121543|
NCT01132560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000671157|Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ|A Correlative Science Study for ECOG E5194||National Cancer Institute (NCI)||Not yet recruiting|June 2010|||April 2011|Anticipated|N/A|Observational|N/A|||Anticipated|500|||Female|18 Years|N/A|No|||May 2010|July 7, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132560||121542|
NCT01132872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100110|PET Whole Body Distribution Studies Using [11C]CUMI|PET Whole Body Distribution Studies Using the 5-HT1A Agonist, [11C]CUMI||National Institutes of Health Clinical Center (CC)||Completed|April 2010|April 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|12|||Both|18 Years|65 Years|No|||April 2012|April 13, 2012|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01132872||121518|
NCT01125449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L500HD|Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease|Phase 2 Study of High Dose Ascorbic Acid in Solid Tumor Disease||Situs Cancer Research Center|Yes|Suspended|January 2011|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2012|August 25, 2012|May 16, 2010|Yes|Yes|Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche    (Ireland).|No||https://clinicaltrials.gov/show/NCT01125449||122081|
NCT01125462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700623-517|A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) Cycles|Post Marketing Assessment of GONAL-f Solution for Injection in a Prefilled Pen for Follicular Stimulation in IVF-ET Cycles: An Observational Study|POINT|Merck KGaA||Completed|February 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|61|Samples Without DNA|Plasma|Female|18 Years|43 Years|No|Non-Probability Sample|Pre-menopausal woman, between 18-43 years old requiring treatment with recombinant FSH for        controlled ovarian hyperstimulation for IVF or OI in Serbia|July 2012|July 15, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125462||122080|
NCT01133652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004389|Variation In Success of Intravenous (IV) Placement With Observation Using New Techniques|The VISION STUDY: Variation In Success of Intravenous (IV) Placement With Observation Using New Techniques|VISION|University of Alberta|No|Completed|May 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|399|||Both|N/A|16 Years|No|||August 2012|August 23, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01133652||121458|
NCT01121939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 135|Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers|Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers.||SCRI Development Innovations, LLC|No|Completed|May 2010|August 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|May 10, 2010|Yes|Yes||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01121939||122350|
NCT01121952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1965-31/4|The Effect of Manipulation on Dysfunction of the Talo-crural Joint|The Effect of Manipulation on Dysfunction of the Talo-crural Joint- a Clinical Randomised Trial||Scandinavian College of Chiropractic|Yes|Active, not recruiting|November 2009|April 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|19|||Female|16 Years|N/A|No|||April 2010|May 11, 2010|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01121952||122349|
NCT01122225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NESAKI08-267|Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury|Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury|NESAKI|Université Victor Segalen Bordeaux 2|No|Active, not recruiting|July 2009|June 2010|Anticipated|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Blood Sample (350 µl) at inclusion and then 24 and 48 hours after|Both|18 Years|N/A|No|Non-Probability Sample|patients of a medical intensive care presenting with a septic shock|April 2010|May 28, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122225||122328|
NCT01122459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RotAnaesFluid1|Evaluation of the Effect of Two Types of Fluid in the Recovery From Anaesthesia. Voluven 6% v Hartmanns|Evaluation of the Effects of Two Types of Fluid in the Recovery From Anaesthesia.||The Rotunda Hospital|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|July 20, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122459||122310|
NCT01135017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRONE_L_04316|Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers|A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers|HESTIA|Sanofi|Yes|Terminated|July 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|21 Years|N/A|No|||April 2013|April 5, 2013|May 28, 2010|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01135017||121353|Due to smaller-than-planned number of participants (112 instead of 424), results should be cautiously interpreted. However, the power to detect large treatment effect remained high and the posthoc power to detect a 60% reduction in AF burden was 99%.
NCT01130675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13493|Does Coffee Consumption Prevent or Shorten Postoperative Ileus After Colon Resection?|Does Coffee Consumption Prevent or Shorten Postoperative Ileus After Colon Resection? A Prospective Randomized Clinical Trial||University of Massachusetts, Worcester|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130675||121685|
NCT01130948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0054/1|Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects|Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects||University of Zurich|Yes|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|51|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 18, 2014|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130948||121664|
NCT01130961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OTH-IRE-2009/1|Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand|Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand||AstraZeneca|No|Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|104|Samples With DNA|Tissue|Both|N/A|N/A|No|Probability Sample|Lung cancer patients admitted in Chulalongkorn and Siriraj hospitals between January 2004        and December 2008 and treated with gefitinib for at least 3 months|October 2010|October 6, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01130961||121663|
NCT01145599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR-RET-2010-02|Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures|Identifying Progression of Retinal Disease in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures||European Vision Institute Clinical Research Network|No|Completed|September 2010|||October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|374|||Both|35 Years|75 Years|No|Non-Probability Sample|Type-2 diabetes, NPDR|November 2013|February 10, 2015|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145599||120547|
NCT01145885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.23|BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours|Investigation of the Metabolism, Excretion and Pharmacokinetics of an Openlabel Single Dose of 300 mg [14C]Volasertib Administered Intravenously in Patients With Various Solid Tumours With a Possible Extension Phase With Nonlabelled Drug||Boehringer Ingelheim||Completed|June 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Male|18 Years|70 Years|No|||October 2013|October 31, 2013|June 16, 2010||||No||https://clinicaltrials.gov/show/NCT01145885||120525|
NCT01146561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091044|Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Chronic Pancreatitis||Pfizer|No|Terminated|October 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||August 2012|August 23, 2012|May 24, 2010|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01146561||120473|
NCT01146210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B2|Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia|Identification of de Novo Fanconi Anemia Patients Using FANCD2 Western Blots||Children's Oncology Group|No|Recruiting|October 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|tumor tissue|Both|N/A|21 Years|No|Probability Sample|Patients treated on trials COG-2961 or COG-AAML03P1. Also patients at high risk of having        Fanconi anemia meeting other criteria.|November 2015|November 5, 2015|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146210||120500|
NCT01146223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B7|Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia|Observational - WT-1's Role in Leukemogenesis||Children's Oncology Group|No|Completed|September 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|bone marrow|Both|N/A|N/A|No|Non-Probability Sample|acute promyelocytic leukemia|May 2015|May 6, 2015|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146223||120499|
NCT01124201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1249/06|Lumbar Stabilization, Strengthening and Stretching in Chronic Low Back Pain|Lumbar Segmental Stabilization, Strengthening and Stretching in Chronic Low Back Pain: a Comparative Study||University of Sao Paulo General Hospital|Yes|Completed|February 2007|June 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|23 Years|53 Years|No|||March 2007|May 13, 2010|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124201||122177|
NCT01124474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100118|Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Spine Surgery|Evaluation of the Use of Arterial Pulse Waveform Contour Analysis for Goal Directed Therapy in Patients Undergoing Major Spine Surgery||Loma Linda University|No|Terminated|December 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|May 13, 2010|Yes|Yes|This study was stopped because of lack of posterior only major spine surgeries.|No||https://clinicaltrials.gov/show/NCT01124474||122156|
NCT01124487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A001/09|The Acute Effects of Oleic Acid Enriched-diets on Lipids, Insulin Sensitivity and Serum Inflammatory Markers|The Acute Effects of Oleic Acid Enriched-diets on Lipids, Insulin Sensitivity and Serum Inflammatory Markers||Malaysia Palm Oil Board|Yes|Completed|August 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|May 14, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01124487||122155|
NCT01132885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100112|Defining the Brain Phenotype of Children With Williams Syndrome|Defining the Brain Phenotype of Children With Williams Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|215|||Both|5 Years|55 Years|Accepts Healthy Volunteers|||November 2015|December 15, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132885||121517|
NCT01133132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2009-1127|Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors|ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors||University of Wisconsin, Madison|Yes|Completed|February 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|34|||Both|21 Years|N/A|No|||February 2016|February 3, 2016|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01133132||121498|
NCT01125228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880172|Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV|A Phase III Study With Long-Term Follow-Up of Zidovudine Versus Zidovudine and Alpha-Interferon Versus Alpha-Interferon in Patients With Early HIV Infection||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 1988|||||N/A|Observational|Time Perspective: Prospective|||Actual|180|||Both|18 Years|99 Years|No|||December 2015|January 20, 2016|May 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01125228||122098|
NCT01133353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVF-018-201|A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tetrabenazine MR in Subjects Aged 5 up to 17 Years With Tourette's Syndrome|TBZ-MR|Valeant Pharmaceuticals International, Inc.|Yes|Withdrawn|March 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|5 Years|16 Years|No|||November 2010|November 17, 2010|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133353||121481|
NCT01133366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPO2900509|A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin|A Drug-Drug Interaction Study to Assess the Effects of Multiple Doses of Mipomersen (200 mg SC) on Single-Dose Warfarin (25 mg) Pharmacodynamics and Pharmacokinetics in Healthy Adult Subjects||Sanofi|Yes|Completed|May 2010|July 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01133366||121480|
NCT01133951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMMU20100501|Helicobacter Pylori Eradication to Prevent Gastric Cancer|Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial||Second Military Medical University|Yes|Active, not recruiting|June 2010|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3000|||Both|30 Years|59 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01133951||121435|
NCT01126047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eCO|Exhaled Carbon Monoxide (eCO) for Diffusing Capacity (DLCO) Correction|Validation of Exhaled Carbon Monoxide for DLCO Correction||University of California, Los Angeles|No|Completed|May 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 7, 2011|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01126047||122035|
NCT01130688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM200905|Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.|Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia||University of Massachusetts, Worcester|No|Terminated|January 2010|December 2014|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2013|May 26, 2015|May 24, 2010|No|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01130688||121684|
NCT01130701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM2010-01|A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .|A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma|PMABIIS|University of Massachusetts, Worcester|No|Withdrawn|May 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2011|March 13, 2015|May 24, 2010||No|Study never went beyond FDA application for an IND #. FDAA required institutional DSMC which    this institution then lacked.|No||https://clinicaltrials.gov/show/NCT01130701||121683|
NCT01134783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908S71521|Choosing Healthy Options in College Environments and Settings|Evaluating Innovative Weight Reduction Strategies for College Students|CHOICES|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|441|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 30, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134783||121371|
NCT01135030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-09-03|Anterior Referencing Versus Posterior Referencing in Minimally Invasive Total Knee Arthroplasty|Anterior Referencing Vs. Posterior Referencing in Minimally Invasive Total Knee Arthroplasty|AR vs PR|Heekin Orthopedic Research Institute|No|Completed|October 2006|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|80 Years|No|||February 2012|February 3, 2012|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01135030||121352|
NCT01131247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVCI 09-15|PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab|PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB||Nevada Cancer Institute|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|May 25, 2010|Yes|Yes|PI left institution|No||https://clinicaltrials.gov/show/NCT01131247||121641|
NCT01131585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DDE13|Safety and Efficacy of Ranibizumab in Diabetic Macular Edema|A 12-month, Two-armed, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Laser Photocoagulation as Adjunctive to Ranibizumab Intravitreal Injections vs. Laser Photocoagulation Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema Followed by a 12 Month Follow up Period|RELATION|Novartis||Terminated|June 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|May 25, 2010||No|European drug approval.|No|July 12, 2012|https://clinicaltrials.gov/show/NCT01131585||121617|Early study termination due to European drug approval.
NCT01146236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCRCT|Sutures Versus Staples for Wound Closure in Orthopaedic Surgery|Sutures vs Staples for Wound Closure in Orthopaedic Surgery: A Randomized Controlled Trial||University of Manitoba|Yes|Recruiting|July 2010|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2560|||Both|18 Years|N/A|No|||April 2011|April 4, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01146236||120498|
NCT01146249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070401|Evaluation of the Sensorial Preference|Evaluation of the Sensorial Preference for Balance Control|PREFSENSOR|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2007|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects Vestibular patients Post stroke patients Patient with proprioception        disorder Old subjects with a history of falls|April 2010|June 16, 2010|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01146249||120497|
NCT01146574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-011-REN-001|A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.|A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).||Celgene Corporation|Yes|Completed|June 2010|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146574||120472|
NCT01146847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0908|Feasibility of Tight Blood Glucose Control With the Space TGC System in Surgical ICU Patients|Single-centre, Open Study to Investigate the Feasibility of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) in Surgical ICU Patients|DELIOS 03|B. Braun Melsungen AG|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2010|November 1, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01146847||120451|
NCT01124500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-020|Transdermal Methylphenidate for Cancer-Related Fatigue|Efficacy and Safety of Transdermal Methylphenidate for Cancer-Related Fatigue||Memorial Sloan Kettering Cancer Center||Withdrawn|May 2010|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|N/A|No|||August 2010|August 25, 2010|May 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01124500||122154|
NCT01124981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI1401_2010|Haemocomplettan® P During Elective Complex Cardiac Surgery|Efficacy and Safety of Haemocomplettan® P in Patients Experiencing Microvascular Bleeding While Undergoing Elective Complex Cardiac Surgery||Isala|Yes|Completed|February 2011|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124981||122117|
NCT01133964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B256|Dairy Proteins and Postprandial Appetite Regulation and Energy Expenditure|Dairy Proteins and Postprandial Appetite Regulation and Energy Expenditure|MAES|University of Copenhagen|No|Completed|October 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|22|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||September 2008|June 23, 2011|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133964||121434|
NCT01133977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-702|E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.||Eisai Inc.|No|Active, not recruiting|December 2012|August 2014|Anticipated|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133977||121433|
NCT01134250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-F16IL2TAXO-05/07|Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients|Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours||Philogen S.p.A.|No|Recruiting|June 2008|May 2016|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01134250||121412|
NCT01133119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013970|Use of Local Anesthetic (0.25% Bupivacaine) for Pain Control in Pediatric Cardiac Catheterization|Use of Local Anesthetic (0.25% Bupivacaine) for Pain Control in Pediatric Cardiac Catheterization: A Randomized Controlled Trial.||The Hospital for Sick Children|No|Completed|February 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|140|||Male|7 Years|18 Years|No|||August 2013|August 15, 2013|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01133119||121499|
NCT01133665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-206-B|Cetuximab and Lenalidomide in Head and Neck|Phase II Study of Cetuximab and Lenalidomide in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck||University of Chicago|Yes|Completed|February 2010|August 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|May 27, 2010|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01133665||121457|
NCT01133678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-069-B|Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck|Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck||University of Chicago|No|Active, not recruiting|May 2010|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|89 Years|No|||June 2015|June 22, 2015|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133678||121456|
NCT01135056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHCC06|Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)|Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)|SIRveNIB|Singapore General Hospital|Yes|Recruiting|July 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01135056||121350|
NCT01133938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OR-27052010|Predictive Factors for the Development of Osteonecrosis After the Treatment of the Developmental Dislocated Hip|Predictive Factors for the Development of Osteonecrosis After the Treatment of the Developmental Dislocated Hip. A Comparison of Early Open Reduction Versus Late Open Reduction With Combined Pemberton and Femoral Osteotomies||Orthopedic Hospital Vienna Speising|No|Completed|January 2009|May 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|79|||Both|1 Month|15 Years||Probability Sample|Consecutive series of patients hospitalized because of developmental dislocated hip        between 1198 and February 2007|May 2010|June 1, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01133938||121436|
NCT01134224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1978|A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes|A Trial Investigating the Pharmacodynamic Response of NN5401 in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|39|||Both|18 Years|70 Years|No|||November 2013|November 26, 2013|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134224||121414|
NCT01130727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTCOCOA-01|The Effect of Green Tea or Cocoa Extracts in Endothelial Dysfunction in Patients With Diabetes Mellitus|Randomized Clinical Trial, Placebo Controlled, With Parallel Groups to Investigate Whether Green Tea or Cocoa Extracts Improves Endothelial Dysfunction in Patients With Diabetes Mellitus and Nephropathy and Hypertension||University of Campinas, Brazil|No|Completed|May 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|N/A|No|||April 2012|April 17, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01130727||121681|
NCT01131013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 4022|A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Claudication||Cytokinetics|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|36|||Both|40 Years|N/A|No|||May 2011|September 16, 2013|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131013||121659|
NCT01134796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09103|Assessment of GRASP Medical Device to Improve Arm Coordination After Stroke|Assessment of GRASP II Medical Device to Improve Arm Coordination After Stroke||University of Nottingham|No|Terminated|September 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Stroke pateints and healthy volunteers (controls)|December 2015|December 1, 2015|May 28, 2010||No|failure to recruit|No||https://clinicaltrials.gov/show/NCT01134796||121370|
NCT01135043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acceptable_sputa|Simple Verbal Intervention for Adequately Collecting Sputum|The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing||Seoul National University Hospital|Yes|Recruiting|July 2009|September 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|188|||Both|18 Years|N/A|No|||May 2010|May 28, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01135043||121351|
NCT01130974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|639|A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens|A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens||Bausch & Lomb Incorporated|No|Completed|April 2010|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|May 25, 2010|Yes|Yes||No|March 15, 2013|https://clinicaltrials.gov/show/NCT01130974||121662|
NCT01131598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute lung injury in children|Acute Lung Injury in Children: Epidemiology and Natural History. PEDIATRIC ALIEN.|Acute Lung Injury in Spanish Children|ALIEN|Hospital de Cruces|No|Recruiting|January 2010|January 2011|Anticipated|June 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|1 Month|15 Years|No|Non-Probability Sample|All patients, age ranging from 1 month to 18 years old, meeting the American European        Consensus (AECC) definition of ALI and ARDS will be included regardless of etiology of        respiratory failure.|January 2010|May 27, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01131598||121616|
NCT01131897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA06179|Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Levetiracetam Tablets, 750 mg and Keppra® 750 mg Tablets of UCB Pharma in Healthy Adult Male Volunteers Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2003|November 2003|Actual|September 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131897||121593|
NCT01146262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/10-L|Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)|Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for AML Patients in First or Second CR|CD lam|Nantes University Hospital|No|Recruiting|November 2009|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|65 Years|75 Years|No|||June 2008|May 11, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146262||120496|
NCT01146275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GB0904|A 7-year Follow up of All Subjects Incuded in Protocol 31GB0106|A 7-year Follow up of All Subjects Incuded in Protocol 31GB0106||Q-Med AB||Completed|March 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Female|N/A|N/A|No|||November 2013|November 29, 2013|June 16, 2010||No||No|November 29, 2013|https://clinicaltrials.gov/show/NCT01146275||120495|
NCT01147159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-STD-001|Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus|Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus in Patients With Rhinoconjunctivitis With/ Without Asthma Sensitized to Betula Pendula, Dermatophagoides Pteronyssinus and Phleum Pratense An Open-label, Single-center Study||BIAL Industrial Farmacéutica S.A.||Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|68|||Both|18 Years|60 Years|No|||February 2012|February 2, 2012|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01147159||120427|
NCT01146860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARhiSi-2|Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis|A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Study to Assess the Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis||Bionorica SE|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|386|||Both|18 Years|75 Years|No|||June 2013|June 28, 2013|June 7, 2010||No||No|October 9, 2012|https://clinicaltrials.gov/show/NCT01146860||120450|Headache and facial pain are rated by investigator based on the description of the patient. This was done to ensure a uniform rating of symptom severity across the investigational sites but nevertheless subjective and open to error.
NCT01147146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0133|The Effects of Anesthetic Method on Cerebral Oxygen Saturation in Geriatric Patients Undergoing Transurethral Surgery|The Effects of Anesthetic Method on Cerebral Oxygen Saturation in Geriatric Patients Undergoing Transurethral Surgery||Yonsei University|Yes|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Primary Purpose: Prevention|||Actual|64|||Male|65 Years|N/A|No|||May 2011|May 12, 2011|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147146||120428|
NCT01132274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC210210|Radiation Exposure Reduction in Supraventricular Tachycardia Ablation|Near Zero Fluoroscopic Exposure During Catheter Ablation of Supraventricular Arrhythmias|NO-PARTY|Catholic University of the Sacred Heart|Yes|Completed|December 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Both|14 Years|50 Years|No|||April 2013|April 12, 2013|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01132274||121564|
NCT01132287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-50|An Evaluation of a Marketed Lubricated Eye Drop in Soft Contact Lens Wearers Who Experience Ocular Dryness|An Evaluation of a Marketed Lubricated Eye Drop in Soft Contact Lens Wearers Who Experience Ocular Dryness||Alcon Research|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|92|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|May 8, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01132287||121563|
NCT01132573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01436|Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia|A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995) Plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults With Relapsed and Refractory Disease||National Cancer Institute (NCI)||Completed|April 2010|||June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|21 Years|N/A|No|||April 2014|July 16, 2014|May 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01132573||121541|
NCT01132586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01375|Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia|Phase I Study of Lenalidomide and Conventional Chemotherapy in Acute Myeloid Leukemia||National Cancer Institute (NCI)|Yes|Completed|May 2010|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|64 Years|No|||November 2014|December 22, 2014|May 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01132586||121540|
NCT01133405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13733|A Safety Study of LY2886721 Single Doses in Healthy Subjects|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|0|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 4, 2010|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01133405||121477|
NCT01133418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24MH064478|Cognitive Training Trial|Efficacy of a Cognitive Training Intervention for Children With ADHD||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|September 2010|June 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|7 Years|12 Years|No|||December 2015|December 28, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01133418||121476|
NCT01133431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKD-19HPS10A|The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea|Clinical Study to Assess the Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea (Glimepiride) in Healthy Male Subjects: Single-blinded, Randomized, Crossover Study|CKD-501 DDI|Chong Kun Dang Pharmaceutical|No|Completed|May 2010|August 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2010|December 9, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133431||121475|
NCT01133990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7820-701|FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer||Eisai Inc.|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|N/A|No|||July 2012|May 21, 2013|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133990||121432|
NCT01134003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 2007-98|A Large Multi-Center Database of Women Who Have Had and Are Going to Have Surgical Correction of Their Pelvic Organ Prolapse Using the Gynecare Prolift System|A Large Multi-Center Database of Women Who Have Had and Are Going to Have Surgical Correction of Their Pelvic Organ Prolapse Using the Gynecare Prolift System||The Institute of Pelvic Medicine & Reconstructive Surgery, Allentown, Pennsylvania|No|Completed|January 2008|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Female|N/A|N/A||Probability Sample|women receiving surgery for their pelvic organ prolapse using the Gynecare mesh kit called        Prolift|May 2010|May 28, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134003||121431|
NCT01133379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOXDHY0001|Tooth Sensitivity Relief by Two Mouthrinses|Evaluation of the Efficacy of Two Potassium Oxalate Containing Mouthrinses for Relieving Dentinal Hypersensitivity||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|174|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|May 27, 2010|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01133379||121479|
NCT01134809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09106|Skeletal Muscle Wasting and Insulin Resistance Following Surgical Stress|Does Surgical Stress Impair Skeletal Muscle Protein and Carbohydrate Metabolism?|SIRSS|University of Nottingham|Yes|Completed|May 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients having major abdominal surgery|June 2015|June 5, 2015|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134809||121369|
NCT01134822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09116|Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)|Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)|PROFILE|University of Nottingham|No|Recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Blood(serum, plasma) & Lavage Fluid|Both|18 Years|85 Years|No|Probability Sample|Participants will be recruited from IPF clinics|February 2016|February 17, 2016|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01134822||121368|
NCT01134237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200908047M|Intrapleural Urokinase for Retained Hemothorax|Intrapleural Thrombolytic Treatment With Urokinase for Retained Hemothorax: A Prospective Double-blinded Randomized Multicenter Study|NTUH|National Taiwan University Hospital|Yes|Active, not recruiting|May 2010|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||May 2010|May 28, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134237||121413|
NCT01130740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-126|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care||VA Office of Research and Development|No|Completed|August 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|300|||Both|21 Years|N/A|No|||September 2014|April 6, 2015|May 24, 2010||No||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01130740||121680|
NCT01130987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002191|Implementing a Comprehensive Handoff Program to Improve Patient Safety|Implementing a Comprehensive Handoff Program to Improve Patient Safety||Brigham and Women's Hospital|No|Completed|July 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|92|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01130987||121661|
NCT01131000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-004|Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients|A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial To Evaluate The Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Adult Febrile Patients||Cumberland Pharmaceuticals|Yes|Completed|June 2002|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||May 2010|May 25, 2010|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131000||121660|
NCT01131260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-STAN|Fetal ST Segment and T Wave Analysis in Labor|A Randomized Trial of Fetal ECG ST Segment and T Wave Analysis as an Adjunct to Electronic Fetal Heart Rate Monitoring (STAN)|STAN|The George Washington University Biostatistics Center|Yes|Completed|November 2010|August 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|11108|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|May 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131260||121640|
NCT01131611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100508|Cognitive-Behavioral Physical Therapy|Cognitive-Behavioral Based Physical Therapy: Improving Surgical Spine Outcomes|CBPT|Vanderbilt University|Yes|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|21 Years|N/A|No|||July 2014|July 2, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01131611||121615|
NCT01131910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-019438-28|TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs|Efficacy of TBE-vaccine to Patients With Rheumatic Disease Who Are Treated With Methotrexate and/or TNF-alfa Blocking Drugs||Sormland County Council, Sweden|Yes|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|68|||Both|18 Years|N/A|No|||April 2010|May 24, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01131910||121592|
NCT01131923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-132|Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fasting Conditions|An Open-Label Randomized Single-Dose Bioequivalence Study of Amlodipine 10 mg Tablets and Norvasc ® 10 mg Tablets Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2002|December 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131923||121591|
NCT01131936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-133|Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fed Conditions|An Open-Label Randomized Single-Dose Bioequivalence Study of Amlodipine 10 mg Tablets and Norvasc ® 10 mg Tablets Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2002|November 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01131936||121590|
NCT01146873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE1145|Treatment Options for Protease Inhibitor-exposed Children|Treatment Options for Protease Inhibitor-exposed Children|NEVEREST-III|Columbia University|Yes|Completed|July 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|300|||Both|3 Years|N/A|No|||April 2015|April 22, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01146873||120449|
NCT01146886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1283.1|Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 10 mg to 1200 mg of BI 135585 XX Administered as a Solution to Healthy Male Volunteers (Trial Part 1), Followed by an Open, Randomised, Single-dose, Intra-individual Bioavailability Comparison of 200 mg BI 135585 XX as Tablet and as Solution (Trial Part 2)||Boehringer Ingelheim||Completed|June 2010|||September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|June 14, 2010||||No||https://clinicaltrials.gov/show/NCT01146886||120448|
NCT01147484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I197|A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer|A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer|IND197|Canadian Cancer Trials Group|Yes|Completed|May 2010|February 2015|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|N/A|No|||February 2015|February 13, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01147484||120402|
NCT01147744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112186|Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily|A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma While Treated With Short Acting Beta2-agonist.||GlaxoSmithKline|No|Completed|June 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|700|||Female|12 Years|N/A|No|||May 2014|July 16, 2015|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147744||120382|
NCT01147445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0066|Phase I Study of ETEC Vaccine|Phase I Study to Determine the Safety and Immunogenicity of an Oral ETEC Candidate Vaccine, Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) From Enterotoxigenic Escherichia Coli||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|February 13, 2014|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01147445||120405|
NCT01147458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0041007|A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee|A Phase 2 Randomized, Double-Blinded, Double-Dummy, Placebo And Active Controlled Two Cohort Two-Way Cross-Over, Multi-Centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A 5-Lipoxygenase (5-Lox) Inhibitor PF-04191834 Alone And In Combination With Naproxen In Patients With Flare-Enriched Osteoarthritis Of The Knee||Pfizer|No|Terminated|July 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|190|||Both|18 Years|75 Years|No|||May 2013|May 30, 2013|June 16, 2010|Yes|Yes|See termination reason in detailed description.|No|December 21, 2012|https://clinicaltrials.gov/show/NCT01147458||120404|The study was terminated early due to increases in hepatic enzymes for which a relationship to study drug could not be excluded and that could alter the potential benefit-risk for participants continuing in the study.
NCT01133392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13300|Bioequivalence of Two Lispro Formulations|Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|May 27, 2010|No|Yes||No|October 10, 2014|https://clinicaltrials.gov/show/NCT01133392||121478|
NCT01133691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2009-0147|Examination of Gastric Emptying in Children|Examination of Gastric Emptying With Magnetic Resonance Imaging and Ultrasonography||University Children's Hospital, Zurich|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy children aged 6 - 12 years old|January 2012|January 16, 2012|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01133691||121455|
NCT01133704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9902A|Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer|A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer||Dendreon||Completed|May 2000|May 2005|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Male|18 Years|N/A|No|||September 2010|September 2, 2010|May 27, 2010|Yes|Yes||No|June 1, 2010|https://clinicaltrials.gov/show/NCT01133704||121454|
NCT01125800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225X2104|A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB|A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma||Novartis|No|Completed|February 2011|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|76|||Both|12 Months|18 Years|No|||February 2016|February 4, 2016|May 12, 2010|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01125800||122054|The Phase I and Phase II patients are pooled and summarized by dose levels. One pediatric patient enrolled in the Phase II portion at the 680 mg/m2 dose was pooled with 21 pediatric patients enrolled in Phase I at the same dose
NCT01125813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENA-08|Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A|Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Hemophilia A||Octapharma|Yes|Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|32|||Male|12 Years|N/A|No|||March 2013|March 11, 2013|May 17, 2010|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT01125813||122053|
NCT01134497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON-804-10|Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer|A Randomised Phase II Study of Carboplatin With or Without the Addition of the ETAR Inhibitor ZD4054 as Treatment for Patients With Metastatic Breast Cancer|PLANET|Cardiff University|Yes|Not yet recruiting|September 2010|August 2013|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||May 2010|June 1, 2010|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134497||121393|
NCT01134263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD17|Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia|Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia||Sanofi|Yes|Completed|October 2010|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|712|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01134263||121411|
NCT01134510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1INH001CSMC|Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection|A Phase I/II Trial to Evaluate the Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Complement-Dependent, Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients"||Cedars-Sinai Medical Center|No|Completed|August 2011|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||July 2015|July 28, 2015|May 26, 2010|No|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01134510||121392|
NCT01134523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-006|Regimens Comparison for Breast Cancers of Positive Lymph Nodes|Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes||Chinese Academy of Medical Sciences|No|Recruiting|May 2010|May 2020|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Female|18 Years|70 Years|No|||March 2013|March 14, 2013|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01134523||121391|
NCT01134835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08028|PPAR-gamma: a Novel Therapeutic Target for Asthma?|PPAR-gamma: a Novel Therapeutic Target in Asthma?||University of Nottingham|No|Terminated|June 2010|July 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|May 28, 2010||No|safety concerns with pioglitazone|No||https://clinicaltrials.gov/show/NCT01134835||121367|
NCT01135082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 135|Pneumococcal Conjugate Vaccine (PCV) in HIV- Infected Children|The Immunogenicity and Safety of Pneumococcal Conjugate Vaccine in Human Immunodeficiency Virus - Infected Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|April 2010|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Both|2 Months|9 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135082||121348|
NCT01135069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAM-01|Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo|Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo||Spear Pharmaceuticals|No|Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|480|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|May 28, 2010|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01135069||121349|No unexpected problems.
NCT01130714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCIRB 09-0725|Resistance Training in Lung Cancer Patients on Chemotherapy|Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy||East Carolina University|No|Completed|January 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|15|||Both|21 Years|N/A|No|||August 2015|August 19, 2015|January 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01130714||121682|
NCT01123200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0002|An In-home Study of Brain Computer Interfaces|An In-home Study of Brain Computer Interfaces||University of Michigan|No|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01123200||122253|
NCT01131026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV-09-0015|Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication|A Monocentric, Open-label, Efficacy and Safety Evaluation Study of the Triple Therapy of 500 mg Levofloxacin, 1000 mg Amoxicillin and 30 mg Lansoprazole on Helicobacter Pylori Eradication in 60 Patients Infected With H. Pylori||Deva Holding A.S.|No|Completed|June 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2011|August 8, 2011|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01131026||121658|
NCT01123174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_25|Effectiveness of a Case Management Algorithm: ALGOS After a Suicide Attempt|Effectiveness of a "Case Management Algorithm" After a Suicide Attempt in Terms of Repetition of the Suicidal Behaviors and Medico-economic Impact|ALGOS|University Hospital, Lille|No|Completed|February 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|1040|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01123174||122255|
NCT01131273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDA026754A|HIV Risk Reduction in Subutex Injectors in Tbilisi|Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors||University of Pennsylvania|No|Active, not recruiting|June 2010|September 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|25 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 17, 2012|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01131273||121639|
NCT01123798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR080018-01|The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers|The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers||J&M Shuler|No|Completed|February 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Active duty OIF/OEF military personnel who have been air evacuated from theater to        Landstuhl Regional Medical Center (LRMC). Ambulatory, self-care volunteers from the LRMC        outpatient spine center will be identified to serve as controls for Cohort 1.|June 2011|June 14, 2011|February 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01123798||122208|
NCT01123811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-CIF-2005|Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer|An Open-label, Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FU/FA for Patients With Metastatic Gastric Cancer|GC-CIF-2005|Johannes Gutenberg University Mainz|No|Completed|May 2006|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|No|||March 2006|May 12, 2010|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01123811||122207|
NCT01124032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA 01-10|A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With ADHD Compared to Healthy Adults|||Shalvata Mental Health Center|Yes|Not yet recruiting|May 2010|||January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||May 2010|May 13, 2010|May 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124032||122190|
NCT01124266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-15|Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy|Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial||Soon Chun Hyang University|Yes|Completed|May 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|844|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2010|February 16, 2011|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01124266||122172|
NCT01124279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090226|Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects|A Phase I, Randomized, Open-Label, Single-Dose, 2-Part, 4-Treatment, 4-Way Crossover Study in Healthy Adult Subjects to Evaluate the Pharmacokinetics of Various AMG 853 Formulations When Administered Under Fasted and Fed Conditions||Amgen||Completed|May 2010|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|43|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 6, 2011|May 13, 2010||||No||https://clinicaltrials.gov/show/NCT01124279||122171|
NCT01147731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111681|A Drug Interaction Study With Albiglutide and Warfarin|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|January 22, 2011|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147731||120383|
NCT01148355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908435|Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Adolescent Smokers|Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Adolescent Smokers||National Institutes of Health Clinical Center (CC)||Completed|June 2008|January 2011||||N/A|Observational|Time Perspective: Prospective|||Anticipated|25|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||January 2011|January 15, 2011|June 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01148355||120335|
NCT01148368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-113|A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers|A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|June 2010|July 2011|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2010|January 6, 2012|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148368||120334|
NCT01132924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910108|A Follow-up of the Early Pregnancy Study Cohort.|A Follow-up of the Early Pregnancy Study Cohort||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|April 2010|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|221|||Female|45 Years|75 Years|No|||March 2016|March 8, 2016|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01132924||121514|
NCT01133171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-186|A Personalized Dashboard to Educate Veterans at Risk of Stroke|A Personalized Dashboard to Educate Veterans at Risk of Stroke||VA Office of Research and Development|No|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|77|||Both|N/A|N/A|No|||October 2015|October 28, 2015|May 26, 2010||No||No|March 31, 2015|https://clinicaltrials.gov/show/NCT01133171||121495|
NCT01125826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2536|Cell Culture of Glioma Specimens for in Vitro Preclinical Studies|Primary Cell Culture of Surgical Glioma Specimens for Invitro Preclinical Studies||Albany Medical College|No|Recruiting|April 2009|June 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|All subjects will be give permission for specimen storage by signing a separate permission      on the informed consent. All specimens will be stored at a tissue bank for an unspecified      amount of time.|Both|18 Years|N/A|No|Probability Sample|Patients 18 years of age or older undergoing surgical resection for gliomas.|April 2009|June 24, 2011|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01125826||122052|
NCT01125839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVOMS|Characterization and Differential Diagnosis of Vertebral Osteomyelitis|Clinical Features, Microbiological-, Radiological Characteristics, and Differential Diagnosis of Vertebral Osteomyelitis||Asan Medical Center|Yes|Completed|May 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|CT guided biopsy specimen|Both|16 Years|N/A|No|Probability Sample|All patients that have MRI findings sugggestive of vertebral osteomyelitis|September 2013|February 24, 2014|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01125839||122051|
NCT01133717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0831-BE|Cerebrovascular Reactivity in Obstructive Sleep Apnea (OSA) Subjects|Spatial and Temporal Response of Cerebrovascular Response in OSA||University Health Network, Toronto|No|Recruiting|February 2010|April 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Population|October 2010|December 16, 2014|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01133717||121453|
NCT01133730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0200-A|Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft|The Analgesic Efficacy of the Transversalis Fascia Plane Block in Iliac Crest Bone Graft Harvesting||University Health Network, Toronto|No|Recruiting|August 2010|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|85 Years|No|||May 2010|April 25, 2012|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01133730||121452|
NCT01133743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-CLL-PI-0411|Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia|An Open-Label Phase 2 Study of Lenalidomide (Revlimid) in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia (CLL)||University Health Network, Toronto|Yes|Active, not recruiting|May 2010|December 2019|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01133743||121451|
NCT01134016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOLANTA20090911|Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects|Determine MTD and to Evaluate PK, Safety/Tolerability and Efficacy Profiles of Antroquinonol (Hocena®) in NSCLC Patients Refractory to Conventional Treatment Modalities|Hocena|Golden Biotechnology Corporation|Yes|Completed|December 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|N/A|No|||November 2014|November 4, 2014|May 14, 2010|No|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT01134016||121430|
NCT01134276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1001-047-307|Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers|Prospective Study on the Comparison Between the Clinicopathological Outcomes According to the Methods of Preoperative Biliary Drainage in Periampullary Cancers Causing Obstructive Jaundice||Seoul National University Hospital|Yes|Completed|August 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Both|20 Years|85 Years|No|||June 2014|June 7, 2014|May 4, 2010||No||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01134276||121410|
NCT01134289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seoul National Univ Hospital|Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block|An Analysis of Photoplethysmographic Signal in Diagnostic Lumbar Sympathetic Block for Complex Regional Pain Syndrome|park001|Seoul National University Hospital|Yes|Recruiting|September 2009|||February 2010|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|25|||Both|19 Years|70 Years|No|||June 2010|June 4, 2010|May 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01134289||121409|
NCT01134536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016891|Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents|Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentadol Oral Solution for the Treatment of Postsurgical Pain in Children and Adolescents Aged From 6 to Less Than 18 Years||Janssen Research & Development, LLC|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|6 Years|17 Years|No|||July 2014|July 11, 2014|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01134536||121390|
NCT01122576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|651|Evaluation of 3 Intraocular Lenses Following Lens Extraction|A Three Arm Prospective Clinical Evaluation of Three FDA Approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction.||Bausch & Lomb Incorporated|No|Completed|June 2010|September 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|40 Years|N/A|No|||February 2014|February 12, 2014|May 11, 2010|Yes|Yes||No|September 13, 2013|https://clinicaltrials.gov/show/NCT01122576||122301|
NCT01135095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-DSPECT002|Low Dose One-Day Tc99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera For Detection of Coronary Disease|Validation of a Low-Dose One-Day TC99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera for Detection of Coronary Artery Disease||Spectrum Dynamics|No|Completed|June 2010|April 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|101|||Both|18 Years|90 Years|No|||April 2013|April 23, 2013|October 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01135095||121347|
NCT01123213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-6704|Characteristics Predictive of Pessary Success|Characteristics Predictive of Pessary Success||University of California, Irvine|Yes|Completed|January 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|158|||Female|N/A|N/A|No|Non-Probability Sample|All patients who have undergone a pessary fitting by physicians in the division of        Urogynecology between the years of 2000 to 20008 will be eligible.|June 2013|June 27, 2013|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123213||122252|
NCT01123226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AECC05052010|Trigger Point Therapy Versus Manipulation Correcting Thoracic Manipulable Lesion|Relative Effectiveness of Trigger Point Therapy Compared to Spinal Manipulation in Correcting a Thoracic Spinal Manipulable Lesion in Subjects With Mechanical Thoracic Back Pain: a Randomised Trial||Anglo-European College of Chiropractic|No|Not yet recruiting|September 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|No|||May 2010|May 13, 2010|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01123226||122251|
NCT01123187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 95/120|Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation|Phase 2 Study of Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation With Steroid Free Immunosuppression||University Hospital, Lille|Yes|Recruiting|March 2003|March 2015|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|65 Years|No|||February 2009|August 31, 2012|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01123187||122254|
NCT01123499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100095|Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers|Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01123499||122230|
NCT01123486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00013543|Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint|A Hydromorphone High Resolution Pharmacokinetic-Pharmacodynamic Fingerprint as the Basis for Identifying Sex Differences in Opioid Pharmacokinetics and Pharmacodynamics||Northwestern University|No|Withdrawn|January 2015|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|May 10, 2010|Yes|Yes|PI relocated to new university|No||https://clinicaltrials.gov/show/NCT01123486||122231|
NCT01124045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-004|Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery|A Phase IIIB, Multicenter, Randomized, Double-Masked, Parallel-Group, Active-Controlled Study of the Safety and Efficacy of Difluprednate Ophthalmic Emulsion, 0.05% (Durezol™) 4 Times Daily (QID) and Prednisolone Acetate Ophthalmic Suspension, 1.0% (Pred Forte™) QID for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age||Alcon Research|No|Completed|August 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|3 Years|No|||April 2013|April 30, 2013|May 13, 2010|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT01124045||122189|
NCT01124305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2010-0101|Knee Arthroplasty Performed With Conventional and Customized Instrumentation|A Prospective, Randomized Evaluation of Total Knee Arthroplasty Performed With Conventional and Customized Patient Instrumentation|CPI|Anderson Orthopaedic Research Institute|Yes|Completed|May 2010|November 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|N/A|N/A|No|||November 2013|November 25, 2013|May 12, 2010||No||No|October 18, 2012|https://clinicaltrials.gov/show/NCT01124305||122169|
NCT01147796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080607|Accuracy of the 64 Slices Computed Tomography for the Diagnosis of Left Atrial Appendage Thrombus|Accuracy of the 64 Slices Computed Tomography for the Diagnosis of Left Atrial Appendage Thrombus|THROMBI-SCAN|Assistance Publique - Hôpitaux de Paris|No|Terminated|July 2010|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|52|||Both|18 Years|N/A|No|||September 2013|March 6, 2015|June 18, 2010||No|defect of inclusion|No||https://clinicaltrials.gov/show/NCT01147796||120378|
NCT01147809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112765|Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag|A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin||GlaxoSmithKline|No|Completed|June 2010|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|108|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147809||120377|
NCT01148069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB 2009-A01336-51|Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers|Surgery Combined With IMRT-IGRT in Locally-advanced Prostate Cancers|TARGET|Rennes University Hospital|No|Active, not recruiting|June 2010|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Male|18 Years|N/A|No|||July 2015|July 6, 2015|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148069||120357|
NCT01148082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09112009-3880|School Response to Families Who Have Children With Cancer|School Response to Families Who Have Children With Cancer||Stanford University||Not yet recruiting|September 2010|||July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Prospective participants will be parents/caregivers who have had school-age children        treated for cancer within the last 5 years|June 2010|June 18, 2010|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148082||120356|
NCT01148342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999904394|Neurobiology and Pharmacokinets of Acute MDMA Administration|Neurobiology and Pharmacokinetics of Acute MDMA Administration||National Institutes of Health Clinical Center (CC)||Completed|February 2004|July 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|1||Anticipated|220|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|October 9, 2014|June 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01148342||120336|
NCT01148381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910457|Characterization of Phenotypic and Genotypic Regressors for Imaging|Characterization of Phenotypic and Genotypic Regressors for MRI||National Institutes of Health Clinical Center (CC)||Recruiting|June 2010|||||N/A|Observational|N/A|||Anticipated|2625|||Both|13 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 17, 2015|June 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01148381||120333|
NCT01133184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509-08-HMO|Improved Prevention of Perinatal Hepatitis B Transmission|The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers||Hadassah Medical Organization|Yes|Not yet recruiting|September 2010|September 2013|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|6343|||Both|N/A|40 Years|Accepts Healthy Volunteers|||January 2010|June 16, 2010|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01133184||121494|
NCT01133444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012742|Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia Under Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Completed|April 2002|May 2002|Actual|April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|July 9, 2010|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01133444||121474|
NCT01121770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021052|"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"|Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction|FONDA PK|Duke University|No|Completed|May 2010|February 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01121770||122363|
NCT01126138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25241|Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)|A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.||Chinese Academy of Medical Sciences|No|Recruiting|July 2010|August 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||May 2010|May 3, 2011|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126138||122028|
NCT01126151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA015737|Parent Interventions to Prevent Student Drinking|Parent Interventions to Prevent Student Drinking|ACT|Penn State University|No|Active, not recruiting|July 2006|July 2011|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1200|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2010|May 18, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126151||122027|
NCT01122043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R664/14/2009|The SNEC DSAEK EndoGlide Clinical Trial|The SNEC DSAEK EndoGlide Clinical Trial||Singapore Eye Research Institute|No|Recruiting|January 2010|January 2012|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|90 Years|No|Non-Probability Sample|Patients with Bullous Keratopathy|May 2010|December 1, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122043||122342|
NCT01122303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|520/2552(EC4)|Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye|Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye||Mahidol University|No|Active, not recruiting|December 2009|December 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|20|Samples Without DNA|Serum|Both|19 Years|N/A|No|Non-Probability Sample|SJS patients with dry eye and non-autoimmune dry eye patients who are treated at Siriraj        Hospital, Bangkok, Thailand|May 2010|May 11, 2010|May 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01122303||122322|
NCT01122589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISE 09-21|Working Inside for Smoking Elimination|Sustaining Tobacco Abstinence After Incarceration|WISE|Memorial Hospital of Rhode Island|No|Recruiting|February 2010|August 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 8, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122589||122300|
NCT01122901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02931|Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma|A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma||National Cancer Institute (NCI)||Active, not recruiting|December 2010|||July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|May 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01122901||122276|
NCT01122914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100100|A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis|A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis||National Institutes of Health Clinical Center (CC)||Terminated|April 2010|June 2024|Anticipated|June 2023|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|10 Years|30 Years|No|||April 2015|April 8, 2015|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122914||122275|
NCT01124071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2009/12124|Korean Diet Efficacy Clinical Trial|A 13 Week Study to Examine the Effectiveness of the Korean Diet on Weight, Blood Pressure, Metabolic Parameters and Disease Control in an Australian Overweight and Obese Population.||University of Sydney|No|Active, not recruiting|January 2010|April 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2010|May 13, 2010|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01124071||122187|
NCT01123512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEN005|The Kiva® System as a Vertebral Augmentation Treatment|The Kiva® System as a Vertebral Augmentation Treatment - A Safety and Effectiveness Trial|KAST|Benvenue Medical, Inc.|No|Completed|July 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|300|||Both|50 Years|N/A|No|||October 2014|October 1, 2014|May 11, 2010|Yes|Yes||No|August 6, 2014|https://clinicaltrials.gov/show/NCT01123512||122229|
NCT01123525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AdCard 2010|Adenosine Cardioplegia; Improved Cardioprotection?|Adenosine Instead of Supranormal Potassium in Crystalloid Cardioplegia, a Randomized Clinical Study||University Hospital of North Norway||Completed|April 2010|September 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|75 Years|No|||September 2011|September 29, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01123525||122228|
NCT01123538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-2006-004462-14|Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile|Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression|ProGEP|University Hospital of North Norway||Active, not recruiting|December 2008|October 2012|Anticipated|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 2, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01123538||122227|
NCT01123824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD11147|Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects|A Randomized, Double-blind, Double-dummy, Two Period, Two Treatment Cross-over Pharmacodynamic and Pharmacokinetic Study of Clopidogrel Given as 5-day Repeated Oral Doses (300 mg Loading Dose Followed by 75 mg/Day and 600 mg Loading Dose Followed by 150 mg/Day) in 4 Different Groups of CYP2C19 Genotyped Healthy Male and Female Subjects||Sanofi|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|May 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01123824||122206|
NCT01124058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007UHFMDvsLD|Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial|Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial.||University of Alberta|No|Recruiting|June 2010|||December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124058||122188|
NCT01125111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0210|The Clinical Study of Making the Evidence With Application of Da Vinci-Robot Assisted Low Anterior Resection in Rectal Cancer|The Clinical Study of Making the Evidence With Application of Da Vinci-Robot Assisted Low Anterior Resection in Rectal Cancer||Yonsei University||Completed|June 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|69|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patients who visit Severance Hospital for rectal cancer|May 2010|May 17, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01125111||122107|
NCT01124318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/09-AVVA RUS|A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults|Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Lactofiltrum, Orally Administered Tablets (Produced by AVVA RUS, JSC) to Treat Atopic Dermatitis in Adults|LF-AD-09|Avva Rus, JSC|Yes|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|60 Years|No|||September 2010|September 13, 2010|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124318||122168|
NCT01147523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolyzosKountouras|Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease|The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study|NAFLD|Aristotle University Of Thessaloniki|Yes|Completed|January 2010|December 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||January 2012|January 19, 2012|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147523||120399|
NCT01148095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2080C00002|To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers|A Single Centre Two Part Randomized Phase I Study to Assess the Pharmacokinetics of an ER Formulation of AZD2516 and to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Ascending Doses in Healthy Volunteers||AstraZeneca|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2011|February 6, 2011|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148095||120355|
NCT01148108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK286.2030|Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma|Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)||Telik|Yes|Completed|June 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||March 2013|March 13, 2013|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01148108||120354|
NCT01148121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113810|Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model|Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model||University of Arkansas|No|Completed|June 2010|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148121||120353|
NCT01125293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-280|Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia|Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Active, not recruiting|March 2010|January 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|March 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01125293||122093|
NCT01125566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.75|LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment|LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment||Boehringer Ingelheim||Active, not recruiting|June 2010|March 2016|Anticipated|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|508|||Female|18 Years|N/A|No|||January 2016|January 6, 2016|May 10, 2010||||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01125566||122072|The Data Monitoring Committee recommended termination of recruitment due to low likelihood of the study meeting its primary objectives.
NCT01122966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01-033|The Effect of Bevacizumab on the Trabeculectomy|The Effect of Intracameral and Subconjunctival Injections of Bevacizumab in Trabeculectomy With Antimetabolite|bevazicumab|Samsung Medical Center|Yes|Recruiting|March 2010|March 2012|Anticipated|March 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|70 Years|No|||May 2010|May 25, 2010|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01122966||122271|
NCT01126164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA012529|Parent Intervention to Reduce Binge Drinking|Parent Intervention to Reduce Binge Drinking|GOALS|Penn State University|No|Completed|September 2005|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|800|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||April 2010|May 18, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126164||122026|
NCT01122056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00277|Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis|Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis||University of British Columbia|No|Recruiting|May 2010|April 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|128|||Both|18 Years|65 Years|No|||February 2011|February 15, 2011|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122056||122341|
NCT01122069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCE-NSTEMI|Contrast Echocardiography in Non-ST Elevation Myocardial Infarction|Contrast Echocardiography in Assessment of Myocardial Perfusion in Patients With Non-ST Elevation Myocardial Infarction||University of Bergen|No|Completed|March 2008|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|N/A|No|Probability Sample|110 patients with acute non-ST elevation myocardial infarction|December 2007|May 11, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122069||122340|
NCT01122316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-06-086-02|Management of Diabetes With Metformin In Patients With Chronic Heart Failure|Management of Diabetes With Metformin In Patients With Chronic Heart Failure||University of California, Los Angeles|No|Completed|September 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|90 Years|No|||March 2012|March 29, 2012|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122316||122321|
NCT01122615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0037|Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)|Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer||M.D. Anderson Cancer Center|No|Completed|May 2010|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2014|November 16, 2015|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122615||122298|
NCT01122953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4121009|Bioequivalence Study Of PHENYTOIN Suspension Made By Pfizer, Versus EPAMIN® Made By McNeil LA LLC In Healthy Volunteers Under Fasting Conditions|Bioequivalence Study Of 5ml Dose Of PHENYTOIN 125mg/ 5ml Suspension Made By Laboratorios Pfizer, S.A. De C.V. Versus EPAMIN® 125 mg/5ml Made By McNeil LA LLC, Study In Healthy Volunteers Under Fasting Conditions||Pfizer|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 15, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01122953||122272|
NCT01123239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS# 2004-4025|Understanding and Improving Diabetes Care for Ethnic Minorities|Reducing Racial Disparities in Diabetes Care - The Coached Care Study|R2D2C2|University of California, Irvine|Yes|Completed|January 2006|March 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|540|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123239||122250|
NCT01122927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-09-267|Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.|A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia or Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features|ATTAIN 267|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Terminated|July 2010|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|524|||Both|10 Years|17 Years|No|||January 2016|January 8, 2016|May 6, 2010|No|Yes|The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational    Plan was met and provided 2 years of safety data.|No|August 5, 2015|https://clinicaltrials.gov/show/NCT01122927||122274|The study was terminated by the Sponsor as the European Medicines Agency P/99/2011Aripiprazole PIP which directed the sponsor to provide 2 years of safety data for at least 100 participants. The objective was met in April 2014.
NCT01122940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4121008|Bioequivalence Study Of Phenytoin Suspension Versus Epamin® In 34 Healthy Volunteers.|Bioequivalence Study Of 10ml Dose Of Phenytoin 0.75g/100ml Suspension Made By Laboratorios Pfizer, S.A. De C.V. Versus Epamin® 0.75g/100ml Made By McNeil LA LLC, Study In 34 Healthy Volunteers Under Fasting Conditions.||Pfizer|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 13, 2011|April 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122940||122273|
NCT01124370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Respicardia - Chronic Study I|Chronic Evaluation of Respicardia Therapy|Safety and Efficacy Evaluation of Respicardia Therapy for Central Sleep Apnea||Respicardia, Inc.|No|Completed|May 2010|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|May 13, 2010|Yes|Yes||No|July 13, 2015|https://clinicaltrials.gov/show/NCT01124370||122164|
NCT01124331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeOProM|Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis|Appropriate Levels of Oxygen Saturation for Extremely Preterm Infants: Prospective Individual Patient Data Meta-analysis|NeOProM|University of Sydney|Yes|Completed|March 2005|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4959|||Both|N/A|24 Hours|No|||February 2015|February 3, 2015|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124331||122167|
NCT01123837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100086|A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting|A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting||Loma Linda University|Yes|Completed|April 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|202|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123837||122205|
NCT01124851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-685|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness|A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ABT-652 Administered Once Daily to Subjects With an Excessive Daytime Sleepiness Disorder||Abbott|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|60 Years|No|||June 2011|June 30, 2011|April 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01124851||122127|
NCT01125124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1041/09|Safety and Effectiveness Study for Pleurodesis With Silver Nitrate in Malignant Pleural Effusion|Evaluation of Chest Pain, Effectiveness and Safety of Pleurodesis With Pleural Catheters and Silver Nitrate for Malignant Pleural Effusion.||University of Sao Paulo General Hospital|Yes|Recruiting|August 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||April 2010|May 14, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01125124||122106|
NCT01125358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13560|A Study in Schizophrenic Patients|A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia||Eli Lilly and Company|Yes|Terminated|May 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|20 Years|65 Years|No|||November 2012|January 11, 2013|May 17, 2010|Yes|Yes|The decision to stop the trial was based on efficacy results in the overall schizophrenia    participant population.|No||https://clinicaltrials.gov/show/NCT01125358||122088|
NCT01125345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009|Posterior Capsule Opacification (PCO) With Single Piece Hydrophobic Versus Hydrophillic Intraocular Lens (IOL)|A Prospective Controlled Clinical Trial to Evaluate the Posterior Capsule Opacification in Contralateral Eyes Implanted With Single Piece Hydrophobic AcrySof IOL and Single Piece Hydrophilic Acrylic IOLs||Iladevi Cataract and IOL Research Center|Yes|Completed|January 2006|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||May 2010|June 3, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125345||122089|
NCT01147835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|337-09|Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers|Effects of Herbal Lollipops on Streptococcus Mutans Levels and the Dental Caries Experience of Children With Asthma Taking beta2-adrenergic Agonist Drugs|Lollipops|University of Nebraska|Yes|Recruiting|October 2009|May 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Both|4 Years|16 Years|Accepts Healthy Volunteers|||June 2010|June 23, 2010|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01147835||120375|
NCT01148147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 93/09|Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty|Prevention of Cardiac and Vascular Periprocedural Complications in Patients Undergoing Coronary Angiography or Angioplasty: Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty. A Prospective Double-blind Randomized Trial.|PREVENT-ICARUS|Azienda Ospedaliero Universitaria Maggiore della Carita|Yes|Completed|November 2009|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|260|||Both|N/A|N/A|No|||September 2010|November 7, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01148147||120351|
NCT01147822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113078|Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma|A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma - A Substudy to VEG108844||GlaxoSmithKline|Yes|Active, not recruiting|May 2010|March 2018|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|May 20, 2010|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT01147822||120376|
NCT01148420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13530-01|DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding|Pilot Trial of Use of DMPA Injection and High Dose MPA Tablets in Outpatient||Women's Health Care Clinic, Torrance, California|Yes|Completed|January 2009|July 2012|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|June 21, 2010|Yes|Yes||No|July 19, 2012|https://clinicaltrials.gov/show/NCT01148420||120330|This was a single-arm, noncomparative pilot clinical trial. Impacts on bleeding beyond 5 days were not prospectively documented.
NCT01148433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999303 CS01|Quality of Life With TESTIM®|Quality of Life With TESTIM® in Testosterone Replacement Therapy for Male Patients With Hypogonadism|LIFE|Ferring Pharmaceuticals|No|Completed|May 2010|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|157|||Male|18 Years|N/A|No|Non-Probability Sample|Private practices|December 2011|December 21, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148433||120329|
NCT01125306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLAUCOMA/XAL EASE 1|Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom|||Meir Medical Center|No|Recruiting|June 2009|October 2012|Anticipated|August 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|May 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01125306||122092|
NCT01125319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/35|Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity|Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity||Assistance Publique Hopitaux De Marseille|No|Completed|March 2010|October 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125319||122091|
NCT01125579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162A07NPB|Effectiveness of NEURAPAS Balance in Children With Nervous Restlessness|NEURAPAS Balance in Children With Nervous Restlessness, e.g. Agitated Depression||Pascoe Pharmazeutische Praeparate GmbH|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|6 Years|11 Years|No|Non-Probability Sample|Children aged 6 - 11 (extremes included) suffering from nervous restlessness and/or        agitated depression according to ICD-10 F3 and DSM-IV "affective disorders"|May 2010|May 18, 2010|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01125579||122071|
NCT01125852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20090086|Supplementary Angiographic Embolization for Peptic Ulcer Bleeding|Supplementary Angiographic Embolization for Peptic Ulcer Bleeding: A Randomized Controlled Trial||Odense University Hospital|No|Completed|September 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01125852||122050|
NCT01122667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-038|Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)|A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function||Merck Sharp & Dohme Corp.|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122667||122294|
NCT01122680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.424|Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma|A Phase II Randomised, Double-blind, Placebo-controlled, Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 µg, 2.5 µg and 5 µg) Delivered Via Respimat® Inhaler Once Daily in the Evening in Adolescents (12 to 17 Yrs Old) With Moderate Persistent Asthma||Boehringer Ingelheim||Completed|May 2010|||April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|105|||Both|12 Years|17 Years|No|||July 2012|May 7, 2014|May 11, 2010||||No|April 10, 2012|https://clinicaltrials.gov/show/NCT01122680||122293|
NCT01122082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC123|Respiratory Quotient and Food Liking, Food Wanting and Food Consumption|Influence of Respiratory Quotient on Food Liking, Food Wanting, Macronutrient Selection and Food Consumption in Humans||University of Burgundy|No|Completed|October 2008|January 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|The participants wre 12 normal-weight men|January 2009|November 8, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122082||122339|
NCT01122329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GG-AC-1202|A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease|A Single-site Positron Emission Tomography (PET) Study of the Cerebral Metabolic Effects of AC-1202 (Axona®) Treatment in Mild-to-Moderate Alzheimer's Disease (AD)|AD|University of California, Los Angeles|Yes|Completed|October 2010|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|17|||Both|50 Years|90 Years|No|||March 2015|March 19, 2015|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122329||122320|
NCT01122602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15082|Evaluate Analgesic Efficacy of Fast Release Aspirin|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 650 mg in Postsurgical Dental Pain|TAROT|Bayer|No|Completed|April 2010|August 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|500|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122602||122299|
NCT01122628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009ORTH11|Long Term Follow up of the DVR-A Locking Plate|Long Term Follow Up Study Into The Use Of The DVR-A Locking Plate In The Treatment Of Distal Radial Fractures||Norfolk and Norwich University Hospitals NHS Foundation Trust|Yes|Enrolling by invitation|May 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|16 Years|N/A|No|Non-Probability Sample|Participants will be taken from a population consisting of all patients who have undergone        distal radial fracture treatement with a DVR-A locking plate at the norfolk and Norwich        University hospitals NHS Foundation Trust|May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122628||122297|
NCT01123577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCIP-CVD-ESBPM2010|Evaluation of Integrating Self Blood Pressure Monitoring Into Urban Primary Care Practices|Evaluation of Integrating Self Blood Pressure Monitoring Into Urban Primary Care Practices to Improve Ethnic/ Racial Disparities in Hypertension|ESBPM|New York City Department of Health and Mental Hygiene|No|Completed|May 2010|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|899|||Both|18 Years|N/A|No|||August 2012|August 13, 2012|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123577||122224|
NCT01123252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEA SAR 1|Seasonal Allergic Rhinitis Study|Evaluation of the Effect of Yoghurt-type Drink on Symptoms of Subjects Suffering Seasonal Allergic Rhinitis (SAR) [Rhinitis 2]|SAR|University of East Anglia|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|60|||Both|16 Years|N/A|No|||August 2012|August 22, 2012|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01123252||122249|
NCT01123551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Morphine|Efficacy Study of Nebulized Morphine and Intravenous Morphine in Post Traumatic Pain|Nebulized Morphine Versus Intravenous Morphine in the Management of Post Traumatic Pain in Emergency Department (ED)||University of Monastir|No|Completed|June 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|8 Years|50 Years|No|||July 2014|July 22, 2014|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01123551||122226|
NCT01124864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2206|A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.|A Phase II, Multi-center, Open-label Study of AUY922 Administered IV on a Once-weekly Schedule in Patients With Advanced Non-small-cell Lung Cancer Who Have Received at Least Two Lines of Prior Chemotherapy||Novartis|No|Completed|October 2010|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|153|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|May 14, 2010|Yes|Yes||No|July 7, 2015|https://clinicaltrials.gov/show/NCT01124864||122126|
NCT01124877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1281197|Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)|26 Week Open Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)||Pfizer|Yes|Withdrawn|July 2010|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|10 Years|17 Years|No|||January 2013|January 17, 2013|May 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124877||122125|
NCT01125384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10104-09CTIL|Comparison Between Two Methods of Throat Swabbing|Comparison Between Two Methods of Throat Swabbing||Meir Medical Center||Withdrawn|May 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|500|||Both|3 Years|45 Years|No|||August 2011|August 27, 2011|May 2, 2010||No|stopped due to protocol mistakes|No||https://clinicaltrials.gov/show/NCT01125384||122086|
NCT01125631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9951016|Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease|A Phase 1, Randomized, Placebo-Controlled, Double Blind, Multicenter Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|May 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|50 Years|N/A|No|||August 2011|August 11, 2011|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01125631||122067|
NCT01125371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAAGC018632|Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women|Computerized BI for Binge Drinking HIV At-Risk and Infected African-American Women||Johns Hopkins University|Yes|Active, not recruiting|October 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|439|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125371||122087|
NCT01148446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL ANZINTER3|R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL|A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)|ANZINTER3|Fondazione Italiana Linfomi ONLUS|No|Completed|January 2003|||January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|66 Years|80 Years|No|||June 2010|June 21, 2010|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148446||120328|
NCT01148459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112745|Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children|Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children||GlaxoSmithKline||Completed|July 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|6 Weeks|17 Months|No|||October 2013|October 16, 2014|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01148459||120327|
NCT01148134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0300-CE|Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL|Pharmacokinetic Profile of Vincristine Administered Along With Imatinib in the Induction Chemotherapy of Bcr-Abl (Philadelphia Chromosome) Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib in the Treatment of Bcr-Abl Negative ALL Patients||University Health Network, Toronto||Terminated|June 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Acute Lymphoblastic Leukemia will be selected from the Leukemia Clinic at        Princess Margaret Hospital.|January 2013|January 10, 2013|June 18, 2010||No|Analysis of the first 10 patients did not show anyt trend toward differences in PK profiles    between imatinib vs no imatinib groups.|No||https://clinicaltrials.gov/show/NCT01148134||120352|
NCT01144286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-090756-01|Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment|Multi-center, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study to Compare the Therapeutic Efficacy, Safety, and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate Pessaries in the Treatment of VVC||Ferrer Internacional S.A.|No|Completed|June 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|229|||Female|18 Years|65 Years|No|||August 2013|August 28, 2013|June 9, 2010||No||No|May 8, 2013|https://clinicaltrials.gov/show/NCT01144286||120647|
NCT01144299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114292|A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™/Influsplit SSW® 2010/2011 in People Aged 18 Years or Above||GlaxoSmithKline||Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 27, 2011|June 10, 2010|Yes|Yes||No|October 1, 2010|https://clinicaltrials.gov/show/NCT01144299||120646|
NCT01125332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009 10|Evaluation of Topic Anaesthesia for Laryngoscopy With Fibroscopy During Paediatric Ear Nose Throat (ENT)Consultation|Evaluation of Topic Anaesthesia for Laryngoscopy With Fibroscopy During Paediatric ENT Consultation||Assistance Publique Hopitaux De Marseille|No|Terminated|February 2010|November 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|4 Years|7 Years|No|||August 2014|August 29, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125332||122090|
NCT01125592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IonFootbath|Assessment of the Ability of Ionic Foot Bath (IonCleanse®) to Remove Heavy Metals Through the Feet and Its Potential Impact on Body Burden of Heavy Metals|Assessment of the Ability of Ionic Foot Bath (IonCleanse®) to Remove Heavy Metals Through the Feet and Its Potential Impact on Body Burden of Heavy Metals||The Canadian College of Naturopathic Medicine|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 14, 2011|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01125592||122070|
NCT01125865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-2010-04|Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture|Uncovered Self-expandable Metal Stent Versus DoubleLayer Plastic Stent for Malignant Hilar Stricture: a Prospective Randomized Multicenter Trial||Soon Chun Hyang University|Yes|Recruiting|May 2010|December 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2010|March 9, 2011|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01125865||122049|
NCT01123291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C406|Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial|Randomized Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial|ReACT|Kyoto University, Graduate School of Medicine|Yes|Active, not recruiting|May 2010|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3300|||Both|20 Years|N/A|No|||January 2016|January 7, 2016|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01123291||122246|
NCT01123304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb028-002|Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma|A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma||Morphotek|No|Terminated|May 2010|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|May 12, 2010|No|Yes|This study has been terminated due to lack of availability of investigational product.|No||https://clinicaltrials.gov/show/NCT01123304||122245|
NCT01123265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB - 32368|National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study|Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) as a Severity and Response Biomarker in Psoriatic Arthritis||University of Rochester|No|Completed|June 2010|June 2014|Actual|June 2014|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female population that are 18 years old and older.|September 2015|September 17, 2015|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01123265||122248|
NCT01123564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002AHU02T|Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion|A Randomized, Controlled, Two-center Phase II Study Assessing the Efficacy and Safety of Intravitreal Lucentis Injections in Patients With Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion|BRAVO|University of Pecs|No|Recruiting|August 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2010|May 13, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123564||122225|
NCT01123590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 003/09|Characteristics of Patients With Thymoma in Chulalongkorn Hospital|Characteristics of Patients With Thymoma Undergone Thymectomy in Chulalongkorn Hospital Between 2003-2007||Chulalongkorn University|Yes|Completed|November 2009|October 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|50|Samples Without DNA|PBMC|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with thymoma undergone thymectomy in Chulalongkorn hospital between 2003-2007|November 2010|November 21, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123590||122223|
NCT01124383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUQ: 118.05.07|The Impact of Anesthesia on the Absorption of Glycine in Operative Hysteroscopy: a Randomized Controlled Trial|The Impact of Anesthesia on the Absorption of Glycine in Operative Hysteroscopy: a Randomized Controlled Trial||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Completed|August 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|95|||Female|18 Years|70 Years|No|||April 2010|May 13, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124383||122163|
NCT01123850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001|CopiOs Posterolateral Fusion Procedure|A Prospective Study Assessing Clinical Outcomes and Radiographic Results After the Use of CopiOs(R) Bone Void Filler (BVF)Sponge in a Posterolateral Fusion Procedure (PLF).||Zimmer, Inc.|No|Terminated|June 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|21 Years|85 Years|No|||May 2015|May 11, 2015|May 12, 2010||No|Slow enrollment|No|April 24, 2015|https://clinicaltrials.gov/show/NCT01123850||122204|
NCT01124344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN166-002|Safety and Pharmacology Study of BMS-866949|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-866949 in Healthy Subjects||Bristol-Myers Squibb|Yes|Terminated|May 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|47|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|May 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01124344||122166|
NCT01124357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLA004.|A Study to Compare the Effectiveness of Two Different Outpatient Endometrial Ablation Techniques Used for Heavy Periods|A Randomised Control Trial To Compare the Effectiveness of Outpatient Endometrial Ablation Techniques (Novasure vs Thermachoice)in the Treatment of Menorhagia|COAT|Birmingham Women's NHS Foundation Trust|No|Completed|May 2006|October 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|81|||Female|25 Years|N/A|No|||May 2006|May 14, 2010|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01124357||122165|
NCT01124903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-12|Human Hydration Status Monitoring|Human Hydration Status Monitoring: Phase I||United States Army Research Institute of Environmental Medicine|No|Completed|January 2009|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01124903||122123|
NCT01125150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB5339|Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia|||Henry Ford Health System|Yes|Completed|February 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|9|||Both|11 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with both hyperinsulinemia and acanthosis nigricans.|May 2010|September 4, 2012|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01125150||122104|
NCT01124604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016999|An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants|Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Osteoarthritis of the Knee or Low Back Pain||Janssen Pharmaceutical K.K.|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|20 Years|N/A|No|||May 2013|May 10, 2013|April 22, 2010|Yes|Yes||No|March 6, 2013|https://clinicaltrials.gov/show/NCT01124604||122146|
NCT01124890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS S3|Southwest German Interventional Study in Acute Myocardial Infarction III|Southwest German Interventional Study in Acute Myocardial Infarction III|SIAM III|University Hospital, Saarland|No|Completed|July 1998|October 2009|Actual|October 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01124890||122124|
NCT01125943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVZAch|Bevacizumab and Endothelium Dependent Vasodilation|Bevacizumab and Endothelium Dependent Vasodilation||Radboud University||Completed|June 2010|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125943||122043|
NCT01121848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALI_L_04918|Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer|A Randomized Phase III Study of 5-Fluorouracil-based Regimen With or Without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have Previously Received Gemcitabine-based Chemotherapy||Sanofi||Completed|July 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01121848||122357|
NCT01125917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3015S|Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015|A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release Vs Buprenorphine Transdermal System (BTDS) 5 in Subjects With Moderate to Severe Low Back Pain: A 52-Week Open-label Extension Phase of BUP3015||Purdue Pharma LP|No|Terminated|June 2004|January 2008|Actual|September 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|354|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|May 17, 2010|Yes|Yes|Terminated early due to administrative reasons.|No|July 28, 2010|https://clinicaltrials.gov/show/NCT01125917||122045|BUP3015S was terminated early due to administrative reasons unrelated to efficacy or safety. There was full evaluation of safety but no evaluation of efficacy.
NCT01125930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Derm 616|Atralin Gel for the Treatment of Rosacea|Investigation of the Topical Retinoid, Atralin Gel 0.05% for the Treatment of Erythematotelangiectatic Rosacea||University of Michigan|No|Terminated|May 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|May 13, 2010|Yes|Yes|Due to slow recruitment and sponsor request study ended early|No|January 28, 2014|https://clinicaltrials.gov/show/NCT01125930||122044|Early termination of study due to slow recruitment and sponsor request resulted in smaller number of subjects analyzed.
NCT01144065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT-1|Hair Cortisol and Testosterone Levels in Patients With and Without Acute Myocardial Infarction(MI)|A Comparison of Hair Cortisol and Testosterone Levels in Patients With Acute MI and Controls With and Without Chronic Cardiovascular Disease or Diabetes||Meir Medical Center|No|Completed|August 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|180|Samples Without DNA|Heir samples for the measurement of cortisol and testosterone|Male|30 Years|N/A|No|Probability Sample|Cases:        Patient with acute MI admitted to the cardiology department at Meir Medical Center        Controls:        Control group 1:        patients with prior cardiovascular disease and/or diabetes:from intrnal medicine ward and        the outpatient clinic        Control group 2:        Patients without prior cardiovascular disease or diabetes:from intrnal medicine ward and        the outpatient clinic|May 2012|May 15, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01144065||120664|
NCT01144052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NC.09.01|Natalizumab De-escalation With Interferon Beta-1b|De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis||Ospedale Civico, Lugano|Yes|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|60 Years|No|||March 2014|March 13, 2014|June 11, 2010|Yes|Yes||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01144052||120665|
NCT01147341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERT-001|Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia|Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase||Schiff, Michael, M.D.|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|75 Years|No|||May 2014|May 29, 2014|June 17, 2010|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01147341||120413|
NCT01122342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0606|Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.|Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.||University of Vermont|Yes|Suspended|December 2006|January 2011|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||May 2010|May 12, 2010|May 12, 2010||No|Evaluating outcomes of current subjects pre further enrollment/dose reduction.|No||https://clinicaltrials.gov/show/NCT01122342||122319|
NCT01121796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HY100510|Influence of Vitamin D on Inflammatory Bowel Disease Remission|||Hillel Yaffe Medical Center||Not yet recruiting|June 2010|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||May 2010|May 10, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121796||122361|
NCT01122641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-013100-32|The Vascular Effects of Vildagliptin in Insulin Resistant Individuals|Does Modulating the Gut Hormones, Incretins, Modify Vascular Function, Thereby Reducing the Risk of Vascular Complications in Insulin Resistant Individuals?||Royal Devon and Exeter NHS Foundation Trust|No|Recruiting|May 2010|||August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122641||122296|
NCT01122654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3380-1|Growth and Tolerance of Cow Milk-Based Infant Formulas|Growth and Tolerance of Cow Milk-Based Infant Formulas||Mead Johnson Nutrition|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|405|||Both|N/A|16 Days|Accepts Healthy Volunteers|Probability Sample|Healthy, term infants|January 2012|January 27, 2012|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122654||122295|
NCT01123616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|triclosan-coated-suture|Abdominal Wall Closure With Triclosan-coated Suture (TCS09-10)|Abdomen Closure Using Triclosan Coated Absorbable Suture vs Uncoated Sutures of the Same Base Material||University of Pecs|Yes|Active, not recruiting|November 2009|June 2010|Anticipated|April 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1|||Both|18 Years|80 Years|No|||May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123616||122221|
NCT01122979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04737|Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.|National (Brazil), Phase IV, Multicentric, Open Label, Parallel, Comparative Study of the Use of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.|DINAMO|Sanofi|No|Completed|July 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122979||122270|
NCT01123278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TestoMet05|Testosterone Replacement in Metabolic Syndrome and Inflammation|Testosterone Replacement in Metabolic Syndrome and Inflammation of Fat Tissue|TERMSINFAT|University of Roma La Sapienza|Yes|Completed|January 2004|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Male|18 Years|75 Years|No|||October 2014|October 25, 2014|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01123278||122247|
NCT01124396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7002027|DSP-3025 A Phase 1 Study of Healthy Male Volunteers|A Double-blind, Placebo-controlled, Randomised Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Repeated Weekly Doses of DSP-3025 Administered Intranasally to Healthy Male Volunteers||Sumitomo Dainippon Pharma Co., Ltd.||Completed|April 2010|April 2012|Actual|August 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|24|||Male|20 Years|39 Years|Accepts Healthy Volunteers|Probability Sample||January 2014|January 7, 2014|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124396||122162|
NCT01124409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3DIGHNC|Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.|Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma||All India Institute of Medical Sciences, New Delhi|Yes|Active, not recruiting|December 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||June 2011|June 21, 2011|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124409||122161|
NCT01124084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99014|The Factors Affecting Intentions of Medical Staff to Use Personal Health Record in Northern Hospitals of Taiwan|The Factors Affecting Intentions of Medical Staff to Use Personal Health Record in Northern Hospitals of Taiwan||Taipei Medical University WanFang Hospital|No|Completed|March 2010|May 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1800|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Health care providers from three hospitals in Taipei|May 2010|May 13, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01124084||122186|
NCT01124097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-308|Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia|A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia||Bial - Portela C S.A.|No|Terminated|September 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|240|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|May 3, 2010||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01124097||122185|
NCT01124110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N011646 - 1465.RFP|Tobacco Tactics Website for Operating Engineers|Tobacco Tactics Website for Operating Engineers|BCBSM-OE|University of Michigan|No|Completed|January 2010|August 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|232|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124110||122184|
NCT01125176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002010897|Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL|A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL|THRiL|Weill Medical College of Cornell University|No|Recruiting|May 2012|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|April 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01125176||122102|
NCT01124617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017002|A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia|Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia||Janssen Pharmaceutical K.K.|No|Completed|June 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|20 Years|N/A|No|||December 2013|December 11, 2013|April 22, 2010||No||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01124617||122145|
NCT01124630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1008-A-U105|Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments|Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.||Daiichi Sankyo Inc.|No|Completed|May 2010|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124630||122144|
NCT01125137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #5890|Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar|Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar||Henry Ford Health System|Yes|Completed|February 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|January 10, 2011|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01125137||122105|
NCT01121874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-101|Suture Fixation System Versus Tendonous Reconstruction in Carpometacarpal (CMC) Arthroplasty|Suture Fixation System Versus Tendonous Reconstruction in Thumb Carpometacarpal Arthroplasty: a Randomized Controlled Trial||J&M Shuler|No|Active, not recruiting|April 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01121874||122355|
NCT01121861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R536/24/2007|Prospective Comparative Study of Refractive Outcome of STAAR and Alcon Toric Intraocular Lenses|Prospective Comparative Study of the Efficacy, Predictability, Safety and Stability of the STAAR and Alcon Toric Intraocular Lenses Implanted in Asian Eyes During Phacoemulsification Surgery||Singapore National Eye Centre|No|Completed|June 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||May 2010|May 11, 2010|May 10, 2010||||No||https://clinicaltrials.gov/show/NCT01121861||122356|
NCT01145534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPB-0346|Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes|Phase 1 Study for Testing Efficacy of Cissus Verticillata L Infusion in Controlling Glucose Concentration||Federal University of Paraíba|Yes|Completed|January 2009|October 2009|Actual|August 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|30 Years|80 Years|No|||August 2008|November 8, 2011|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145534||120552|
NCT01145833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081129|Guided Self-help for Families With an Overweight Child|Guided Self-help Treatment for Families With an Overweight Child|GSH|University of California, San Diego|Yes|Active, not recruiting|October 2009|October 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||June 2010|June 16, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145833||120529|
NCT01144650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDAT-072009-DAA-MC|Dapsone for Acute Ischemia Stroke Study|Clinical Trial Randomized, Placebo-controlled, Using Dapsone as a Neuroprotector During Acute Ischemia Stroke|DAISY|Cidat, S.A. de C.V.|Yes|Recruiting|July 2009|November 2010|Anticipated|August 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2010|June 14, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144650||120619|
NCT01144663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113369|Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines|Immunogenicity and Safety of GSK Biologicals' Meningococcal Vaccine (GSK 134612) When Co-administered With a Pneumococcal Conjugate Vaccine and in Infanrix Hexa™ in Healthy Infants||GlaxoSmithKline||Completed|July 2010|September 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|2095|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||April 2014|May 1, 2014|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144663||120618|
NCT01144936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-985-101|Study of VX-985 in Subjects With Chronic Hepatitis C|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-985 in Subjects With Genotype 1 Chronic Hepatitis C||Vertex Pharmaceuticals Incorporated|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|21|||Both|18 Years|64 Years|No|||March 2011|March 8, 2011|June 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01144936||120597|
NCT01121809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC-RAET-2009-1|Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily|Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (800 mg and 400 mg, Respectively) Compared With Standard Dosing (400 mg and 200 mg/12 h) in Patients With HIV Infection|RAET|Hospitales Universitarios Virgen del Rocío|Yes|Completed|April 2010|January 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||February 2011|February 7, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01121809||122360|
NCT01122108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale|A Randomized, Single-Blind, Single Research Site, Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale in Generally Healthy Subjects||Louisville Metabolic and Atherosclerosis Research Center|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2010|September 22, 2010|May 7, 2010|Yes|Yes||No|July 19, 2010|https://clinicaltrials.gov/show/NCT01122108||122337|Used generally healthy subjects, for who lipid-altering medication may not be indicated; Compared the BAS on the same day; Evaluated estimated equal cholesterol lowering doses of each BAS, rather than same g amt of active drug
NCT01122355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0530|Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol|||Yonsei University|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|20 Years|79 Years|No|||May 2010|May 28, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122355||122318|
NCT01124682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000671670|3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder|Image Guided Dose Escalated Adaptive Bladder Radiotherapy||National Cancer Institute (NCI)||Recruiting|May 2009|||April 2016|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2011|August 23, 2013|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01124682||122140|
NCT01123603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-923|Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata|Lower UTI Evaluation in Women With Uterine Leiomyomata|LOTUS|The Cleveland Clinic|No|Completed|May 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|860|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with urinary leakage and fibroids|January 2015|January 13, 2015|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123603||122222|
NCT01123876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-977|Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor|A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors||AbbVie|No|Completed|March 2010|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|April 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01123876||122202|
NCT01124123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILA 2909/BA|Oral Bioavailability of Bilastine|Study to Assess Oral Bioavailability of Bilastine (Estudio de Biodisponibilidad Oral de Bilastina)|BIOBI|Faes Farma, S.A.|No|Completed|May 2010|September 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124123||122183|
NCT01124422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113877|Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease|A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 Mcg Twice Daily Plus Tiotropium 18 Mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 Mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease|ESWT|GlaxoSmithKline|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|255|||Both|40 Years|N/A|No|||November 2011|January 19, 2012|May 13, 2010|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT01124422||122160|
NCT01123863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAIN2|The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2|The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2||St. Jude Children's Research Hospital|No|Completed|May 2010|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|248|||Both|3 Years|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patient group will consist of 3 year-old-children with SCD who are followed at the St.        Jude Children's Research Hospital Sickle Cell Center. The control group will consist of        3-year-old children attending day care in Memphis.|June 2015|June 12, 2015|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123863||122203|
NCT01124916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201805|Abdominal Colpopexy: Comparison of Endoscopic Surgical Strategies|Abdominal Colpopexy: Comparison of Endoscopic Surgical Strategies|ACCESS|Loyola University|Yes|Active, not recruiting|January 2010|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Female|18 Years|N/A|No|||October 2012|October 29, 2012|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01124916||122122|
NCT01121887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN046684 / LS04010116|Telephone-based Treatment for Smoking Cessation|Motivational Interviewing in Smoking Cessation: A Controlled Clinical Trial at the Swedish National Tobacco Quitline||Karolinska Institutet|Yes|Completed|January 2005|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1309|||Both|18 Years|N/A|No|||September 2008|May 11, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121887||122354|
NCT01121900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04ACL1-010|A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)|A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered as a Single Dose) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) Under Fasting Conditions||Labopharm Inc.||Completed|June 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|May 10, 2010||No||No|June 22, 2010|https://clinicaltrials.gov/show/NCT01121900||122353|
NCT01125163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0031|Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight (VLBW) Infants|Randomized Trial Comparing Iron Supplementation vs. Routine Iron Intake in Very Low Birth Weight (VLBW) Infants||The University of Texas Health Science Center, Houston|No|Recruiting|May 2010|May 2012|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|24 Weeks|32 Weeks|Accepts Healthy Volunteers|||November 2010|November 29, 2010|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01125163||122103|
NCT01125397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007135|Behavior Therapy Prior to Bariatric Surgery|The Potential Effectiveness of Behavior Therapy on Weight Loss Following Bariatric Surgery||Mayo Clinic|No|Completed|November 2009|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|25 Years|65 Years|No|||May 2013|May 8, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125397||122085|
NCT01125644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPK-843-03/01|Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis|Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study||Proaparts srl|Yes|Recruiting|May 2010|December 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||June 2011|June 6, 2011|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125644||122066|
NCT01122160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-069|Gastric pH and Anthocyanin Absorption|Gastric pH as a Possible Determinant of Anthocyanin Absorption||USDA Beltsville Human Nutrition Research Center|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|13|||Both|22 Years|59 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|May 10, 2010||No||No|December 17, 2012|https://clinicaltrials.gov/show/NCT01122160||122333|
NCT01146483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 09.252|Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin|Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01146483||120479|
NCT01146795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD8429|Neoadjuvant Therapy for Ovarian Cancer|Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer||Columbia University|Yes|Terminated|May 2010|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|May 21, 2010|Yes|Yes|Study encountered 7 cumulative protocol defined events in 30 patients during Stage II.|No||https://clinicaltrials.gov/show/NCT01146795||120455|
NCT01147055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081016|Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers|A Phase 1, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of Crizotinib (PF-02341066) In Healthy Volunteers||Pfizer|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|June 16, 2010|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT01147055||120435|
NCT01148524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P10E1|Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10|A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.||Novartis||Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|9||Actual|817|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|June 4, 2010|Yes|Yes||No|December 11, 2013|https://clinicaltrials.gov/show/NCT01148524||120322|
NCT01148537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1011|The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers|A Randomized, Double-blind, Placebo- & Positive-Controlled, Parallel Group, Dose Escalating Study to Evaluate the Effect of Buprenorphine Delivered by Buprenorphine Transdermal System at 10- and 40-mg Dose Levels on QT Intervals in Healthy Adult Volunteers||Purdue Pharma LP|No|Completed|July 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|132|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|June 21, 2010|Yes|Yes||No|July 28, 2010|https://clinicaltrials.gov/show/NCT01148537||120321|BUP1011 is a safety study. The comparison of buprenorphine vs placebo on QTc (interval corrected for heart rate) values is the primary outcome.
NCT01122693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eZono|Comparison Between Two Ultrasound Technologies for Ultrasound-guided Catheter Placement in Regional Anesthesia|A Prospective, Randomized Comparison Between Two Ultrasound Technologies for Ultrasound-guided Catheter Placement in Regional Anesthesia|eZono|Charite University, Berlin, Germany|Yes|Completed|January 2010|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|90|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01122693||122292|
NCT01122992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R489/38/2006|Prospective Evaluation of Limbal Relaxing Incision (LRI) in Conjunction With Phacoemulsification Surgery for Astigmatic Correction in Chinese Eyes|Prospective Evaluation of Limbal Relaxing Incision (LRI) in Conjunction With Phacoemulsification Surgery for Astigmatic Correction in Chinese Eyes||Singapore National Eye Centre||Recruiting|November 2006|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||May 2010|May 12, 2010|May 11, 2010||||No||https://clinicaltrials.gov/show/NCT01122992||122269|
NCT01123317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041288|Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia|Brain Blood Flow Changes Elicited by Oxytocin in Healthy and Schizophrenic Volunteers, an Assessment Using Positron Emission Tomography and 15-Oxygen Labeled Water||University of Maryland|Yes|Not yet recruiting|July 2010|January 2013|Anticipated|January 2011|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2010|May 12, 2010|May 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01123317||122244|
NCT01123889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59322|Treatment of the Rotator Cuff Disease With Platelet Rich Plasma Injection|Treatment of Rotator Cuff Syndrome With Injection of Autologous Platelet Rich Plasma||Loma Linda University|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|89 Years|No|||December 2013|December 24, 2013|April 20, 2010||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01123889||122201|
NCT01124136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708-0211|Neurostimulation of Spinal Nerves That Affect the Heart|Evaluation of the Effect of Neurostimulation in Patients With Symptomatic Heart Failure|Neurostim|The Methodist Hospital System|Yes|Recruiting|May 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01124136||122182|
NCT01125423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL2009-FFMS|Study of Fibromyalgia Treated With Milnacipran|An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran||Albany Medical College|No|Recruiting|May 2010|||May 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2010|June 23, 2011|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01125423||122083|
NCT01124643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-REP-060|Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease|An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease||Shire|No|Completed|April 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||March 2015|April 2, 2015|April 23, 2010|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01124643||122143|
NCT01125982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2171(REK)|Postoperative Fatigue and Nausea Related to Choice of Anaesthetic Regimens|Postanaesthetic Outcome and Assessment of Fatigue in Day-surgery Laparoscopic Cholecystectomy||Sykehuset Telemark|No|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|130|||Both|18 Years|70 Years|No|||November 2014|November 18, 2014|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01125982||122040|
NCT01125995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-02-016|Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer|A Randomized Phase III Trial for Timing of Radiation in Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer||Samsung Medical Center||Completed|June 2003|May 2013|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125995||122039|
NCT01130363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC2805|Fundic Gland Polyps and Proton Pump Inhibitor (PPI) Drugs|Determination of a Possible Association of Fundic Gland Polyps With the Use of Proton Pump Inhibitor Drugs||Columbia University|Yes|Terminated|October 2006|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|23|Samples With DNA|Blood draw: A fasting serum gastrin (FSG) level will be obtained to evaluate for      hypergastrinemia at a follow-up visit after EGD. Approximately 4 cc's of blood is required.      As many patients have been on long term PPI therapy, the FSG level is one method of      determining whether the patient is on super-therapeutic levels of PPI which may need to be      adjusted.      Biopsy specimens: Gastric fundic gland polyps found during endoscopy will have biopsies      taken of the polyp, adjacent normal gastric body or fundus, and from the antrum.      Histological evaluation of biopsy specimens: Biopsies will be stained with H&E as well as      neuroendocrine cell markers to assess for the presence of ECL cell hyperplasia.      Paraffin-fixed tissue will be stored for future biological analysis. This will only be done      after all clinically relevant analyses are completed and only if adequate tissue remains.|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Individuals found to have fundic gland polyps on endoscopic evaluation and are on proton        pump inhibitor (PPI), individuals found to have fundic gland polyps on endoscopic        evaluation but are not on PPI or patients on PPI but had no fundic gland polyps found on        endoscopic evaluation (control group).|June 2012|June 29, 2012|May 21, 2010||No|Poor Enrollment|No||https://clinicaltrials.gov/show/NCT01130363||121709|
NCT01126073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127-00|Niacin/Laropiprant and Endothelial Function|A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin||University Medical Centre Ljubljana|Yes|Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|35 Years|55 Years|No|||October 2011|October 5, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01126073||122033|
NCT01126086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP6207|Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment|An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 μg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function.||Sanofi|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|75 Years|No|||May 2014|May 7, 2014|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01126086||122032|
NCT01127854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007826|Pilot Study to Evaluate the Contribution of Gene Variants to Idiopathic Urolithiasis|Pilot Study to Evaluate the Contribution of Gene Variants to Idiopathic Urolithiasis||Mayo Clinic|No|Enrolling by invitation|December 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|900|Samples With DNA|Blood, Urine and DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Mayo Clinic in Jacksonville, FL|February 2016|February 12, 2016|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127854||121897|
NCT01127867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHO-0702|A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women|Docosahexaenoic Acid (DHA) Reduces Inflammation and Aromatase Expression in Subcutaneous Fat and Inflammation in the Rectosigmoid Mucosa in Obese Postmenopausal Women: A Pilot Study||Rockefeller University|No|Completed|May 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|17|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 16, 2013|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127867||121896|
NCT01123109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5983|3-D Endoanal Ultrasound: Normative Anatomy of the Anal Sphincter in Nulliparous Females|3-D Endoanal Ultrasound: Normative Anatomy of the Anal Sphincter in Nulliparous Females||University of California, Irvine|Yes|Completed|December 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|75|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 27, 2013|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01123109||122260|
NCT01129505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPG-92367|Preventing Childhood Obesity: A Two-pronged Approach Starting in Pregnancy and the First Year Postpartum|Preventing Childhood Obesity: Early Intervention During Pregnancy and First Year Postpartum for Overweight and Obese Women Using a Two-pronged Family-based Nutrition & Exercise Lifestyle Intervention Program (NELIP).||University of Western Ontario, Canada|No|Completed|March 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129505||121773|
NCT01123720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099M031|The Impact of Internationalize Medical Services to localPeople Seeking Medical Care|To Understand the Impacts of Internationalize Medical Services on Local People Seeking Medical Care, and to Establish Responsive Management Mechanism||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|December 2009|February 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Administrative staff in Hospital of Taiwan|May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123720||122214|
NCT01123733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98068|Breastfeeding Practice Evaluation in Taiwan|Breastfeeding Practice in Taiwan - Evaluation the Non-Baby-Friendly Hospitals Intervention Strategies to Breastfeeding Practice||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|October 2009|December 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Postpartum women who gave lived births in Taiwan|May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123733||122213|
NCT01117285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82315-98-090010|Implementation and Evaluation of the COTiD Program in the Netherlands|Implementation and Evaluation of an Effective Community Occupational Therapy in Dementia (COTiD) Program||Radboud University|Yes|Enrolling by invitation|October 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|180|||Both|N/A|N/A|No|||March 2010|May 20, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01117285||122707|
NCT01117870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRF-1|Assess the Effectiveness of Pulse RadioFrequency in Patients With Chronic Lumbar Radicular Pain|Randomized, Placebo Controlled, Double-blinded Trial to Assess the Effectiveness of Pulse RadioFrequency Treatment of Dorsal Root Ganglion in Patients With Chronic Lumbar Radicular Pain||McMaster University|No|Completed|July 2010|November 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2012|April 23, 2013|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117870||122662|
NCT01119300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COU-001W|EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin|EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin|EU-PACT|Utrecht Institute for Pharmaceutical Sciences|Yes|Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|455|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01119300||122552|
NCT01119313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 527 000-0917|Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema|A Phase II, Single-center, Randomized, Controlled, Double-blind Study to Assess Effects on Skin Conditions and Patient Reported Outcome of a Topical Formulation Containing LAS41002 on Lesional Skin in Patients With Atopic Eczema||Almirall, S.A.|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2010|July 9, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01119313||122551|
NCT01119326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503-2012|Autologous Fat Transfer for Scar Prevention and Remodeling|A Phase I/II Study of Autologous Fat Transfer for Scar Prevention and Remodeling||University of Florida|Yes|Recruiting|April 2010|September 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|57|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01119326||122550|
NCT01129167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD6885|Local Invasion of Pancreatic Cancer|Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma||Columbia University|Yes|Recruiting|September 2009|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1250|||Both|18 Years|85 Years|No|Non-Probability Sample|Study population will include patients who have been diagnosed with pancreatic        adenocarcinoma and who are undergoing surgical resection at CUMC.|February 2015|February 25, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129167||121799|
NCT01129440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR 09-014-E|Glass Ionomer Sealant and Fluoride Varnish Study to Prevent Early Childhood Caries|Glass Ionomer Sealant and Fluoride Varnish Randomized Clinical Trial|GIFVT|University of California, San Francisco|Yes|Active, not recruiting|June 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|597|||Both|2 Years|3 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129440||121778|
NCT01129661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-HDL-09-63|Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers|An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers||CSL Limited|No|Completed|June 2010|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||January 2011|January 20, 2011|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01129661||121761|
NCT01129674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11960|A Long-Term, Open-Label, Study on Schizophrenia|A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia||Eli Lilly and Company|No|Terminated|June 2010|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1210|||Both|18 Years|65 Years|No|||October 2012|January 11, 2013|May 21, 2010|Yes|Yes|The decision to stop the trial was based on efficacy results in the overall schizophrenia    participant population.|No||https://clinicaltrials.gov/show/NCT01129674||121760|
NCT01129960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-307|Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain|A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain||Bial - Portela C S.A.|No|Terminated|November 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|332|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|May 3, 2010||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01129960||121738|
NCT01129973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEICE01|Profile of Marketing Professional Audiologist Who Works in the Area of Audiology Clinic|Profile of Marketing Professional Audiologist Who Works in the Area of Audiology Clinic|Audiologist|Fortaleza University|Yes|Completed|January 2010|May 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|None Retained|no biospecimens are to be retained.|Both|24 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|replied to the questionnaire speech pathologists, of both sexes, active in the area of        audiology clinic, of the city of Fortaleza, Ceará.|January 2010|May 24, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01129973||121737|
NCT01130246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-CVD2233|VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome|VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes|VISTA-16|Anthera Pharmaceuticals|Yes|Terminated|May 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5189|||Both|40 Years|N/A|No|||October 2012|October 30, 2012|April 19, 2010|Yes|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01130246||121717|
NCT01130259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11614|An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer|An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in Patients With ER-, PR-, and HER2-Negative Metastatic Breast Cancer||Sanofi||No longer available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|N/A||||September 2013|September 14, 2013|May 24, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01130259||121716|
NCT01126502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01374|Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia|A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL)||National Cancer Institute (NCI)||Terminated|May 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2014|November 3, 2015|May 18, 2010|No|Yes|Administratively Complete.|No||https://clinicaltrials.gov/show/NCT01126502||122001|
NCT01129258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611004|Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes|A Phase 1 Placebo-Controlled Trial to Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses of PF-04991532 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)||Pfizer|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|110|||Both|18 Years|70 Years|No|||March 2011|March 8, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129258||121792|
NCT01129752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03172010-5264|Mothers With a History of Depression and Their 10-14 Year Old Daughters|The Neural Correlates of Mood and Cognitive Bias in a Population at Risk for Depression: Maternal Cognitive and Emotional Functioning||Stanford University||Completed|February 2004|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|240|Samples With DNA|All participants are asked to submit saliva samples during their second session using      sterile salivette containers in order to assess cortisol levels. There is no risk involved      in giving these samples.|Female|9 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Eligible mothers must read and speak English fluently and have a child between the ages of        9 and 15 years old. Mothers must either have no history of psychopathology or have a        history of depression during their child's lifetime.|June 2011|June 21, 2011|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129752||121754|
NCT01126528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU-IRB2481|Antenatal Vitamin D3 Supplementation in Bangladesh: Randomized Controlled Trial|The Effect of Antenatal Vitamin D Supplementation on Maternal-fetal Vitamin D Status and Neonatal Immune Function: a Randomized Controlled Trial in Bangladesh|AViDD-2|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|August 2010|May 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126528||121999|
NCT01122017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMU-400/435|A Modified (Retro-Tubercle) Opening Wedge High Tibial Osteotomy Versus the Conventional Technique|A Modified (Retro-Tubercle) Opening Wedge High Tibial Osteotomy Versus the Conventional Technique||hahid Beheshti University of Medical Sciences|No|Completed|January 2006|November 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|72|||Both|N/A|N/A|No|||April 2010|May 12, 2010|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01122017||122344|
NCT01122264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13085|A Study in Patients With Erectile Dysfunction|Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors||Eli Lilly and Company|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|770|||Male|18 Years|N/A|No|||September 2012|September 18, 2012|May 5, 2010|Yes|Yes||No|June 11, 2012|https://clinicaltrials.gov/show/NCT01122264||122325|
NCT01128426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-4002|Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers|Postlicensure Observational Safety Study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Administered in Routine Use to Infants and Toddlers||Pfizer|No|Completed|June 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53902|||Both|2 Months|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|60,000 infants total: at least 43,000 infants who receive all 3 primary series doses of        13vPnC plus 15,000 additional infants who receive less than 3 doses of 13vPnC|June 2014|June 12, 2014|May 20, 2010|Yes|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT01128426||121854|
NCT01128439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-4005|Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease|A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use||Pfizer|No|Completed|July 2010|April 2015|Actual|April 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|Primary Care Clinic|June 2015|June 9, 2015|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128439||121853|
NCT01122251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ZVCL001|Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension|A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dose Combinations in Patients With Essential Hypertension||LG Life Sciences|No|Completed|December 2009|July 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|441|||Both|20 Years|75 Years|No|||February 2011|February 17, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122251||122326|
NCT01122498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3202V1-1003|A Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Rotator Cuff Tears|A Phase 1, Randomized, Open-Label, Standard Of Care Control, Dose-Escalating, Multicenter, Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Full-Thickness Rotator Cuff Tears Treated By Means Of An Open Surgical Repair||Pfizer|No|Terminated|June 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|25 Years|75 Years|No|||February 2013|February 20, 2013|May 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01122498||122307|
NCT01130090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER- 08-131|Patient-ventilator Interactions in Long Term Non-invasive Ventilation: Influence of Back-up Frequency|Patient-ventilator Interactions in Long Term Non-invasive Ventilation (NIV): Influence of Back-up Frequency||Ligue Pulmonaire Genevoise|Yes|Completed|September 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|75 Years|No|||February 2011|February 23, 2011|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01130090||121728|
NCT01122836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1AT004411-02|Dosing Study of Massage for Neck Pain|Dosing Study of Massage for Neck Pain||Group Health Cooperative|Yes|Active, not recruiting|July 2010|March 2014|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|228|||Both|20 Years|64 Years|No|||January 2014|January 14, 2014|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122836||122281|
NCT01122849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3570674|Exploratory Subjective Sleep Study of a Prototype Nasal Dilator|Exploratory Subjective Sleep Study of a Prototype Nasal Dilator||GlaxoSmithKline|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122849||122280|
NCT01117610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAngUH|A Preemptive Epidural Ropivacaine for Postoperative Pain Relief in Degenerative Lumbar Spine Surgery|A Preemptive Epidural Ropivacaine for Postoperative Pain Relief in Degenerative Lumbar Spine Surgery: A Prospective Randomized Study||Chung-Ang University Hospital|No|Not yet recruiting|May 2010|April 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||May 2010|May 4, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117610||122682|
NCT01117623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11651|Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies|Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies||Bayer|No|Completed|February 2007|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|8||Actual|86|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 11, 2010|No|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01117623||122681|
NCT01117636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15120|Evaluate Analgesic Efficacy of Fast Release Aspirin|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 1000 mg in Postsurgical Dental Pain|TAROT|Bayer|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|514|||Both|16 Years|45 Years|No|||February 2016|February 16, 2016|May 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01117636||122680|
NCT01117883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007428|Sternal Wall Pressure in the Cath Lab|Effect of Gentle Sternal Chest Wall Pressure on Central Hemodynamic Measurements and Intrathoracic Pressure During Mechanical Ventilation in Children||Children's Hospital of Philadelphia|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|6 Months|7 Years|No|||July 2011|July 13, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01117883||122661|
NCT01129180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08067|Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma|Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Completed|May 2010|December 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129180||121798|
NCT01129713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEXIUM versus SECRETOL|Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.|Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).||Effexus Pharmaceutical|No|Recruiting|May 2010|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||August 2014|August 4, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01129713||121757|
NCT01129687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03052010-5142|Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy|Multicenter Prospective Analysis of Treatment Outcome in Patients With Large Acoustic Neuromas||Stanford University||Recruiting|March 2005|March 2025|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with large acoustic neuromas measuring 2.5cm in longest dimension in the        cerebellopontine angle.|August 2015|August 17, 2015|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01129687||121759|
NCT01130272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27018966IBS2001|Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea||Furiex Pharmaceuticals, Inc|No|Completed|May 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|807|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130272||121715|
NCT01126242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-142|Tape Versus Semirigid Versus Lace-up Ankle Support in the Treatment of Acute Lateral Ankle Ligament Injury.|Tape Versus Semirigid Versus Lace-up Ankle Support in the Treatment of Acute Lateral Ankle Ligament Injury.||Gelre Hospitals|No|Completed|May 2010|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|99 Years|No|||April 2010|February 12, 2016|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126242||122020|
NCT01127256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-S082-405|Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation|Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation||Eisai Inc.||Completed|May 2006|July 2009|Actual|May 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|15 Years|N/A|No|||May 2010|June 20, 2012|May 19, 2010||No||No|August 2, 2010|https://clinicaltrials.gov/show/NCT01127256||121943|Early termination leading to small numbers of subjects analyzed
NCT01122238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0203|Identifying Treatments to Motivate Smokers to Quit|Identifying Optimal, Translatable Smoking Cessation Intervention Components|Motivation|University of Wisconsin, Madison|Yes|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|16||Actual|517|||Both|18 Years|99 Years|No|||November 2015|November 12, 2015|May 7, 2010||No||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01122238||122327|
NCT01122563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQL-CRU.005-2009|A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment|Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 2: Responsiveness|RESORT-2|Astellas Pharma Inc|No|Completed|September 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Symptomatic OAB patients having urgency episodes|January 2011|January 11, 2011|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122563||122302|
NCT01122810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-07|Scanner and Transplant Heart Patients Protocol|Head to Head Comparison of Multidetector Coronary Tomography and Conventional Coronary Angiogram in the Setting of Systematic Screening of Coronary Vasculopathy After Orthotopic Heart Transplantation.||French Cardiology Society|No|Completed|June 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01122810||122283|
NCT01122537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APNSM|Characterization and Differential Diagnosis of Postneurosurgical Meningitis|Clinical Features, Microbiological Characteristics, and Differential Diagnosis of Postneurosurgical Meningitis||Asan Medical Center|Yes|Completed|May 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|16 Years|N/A|No|Probability Sample|All patient who develop meningitis after neurosurgical operation|September 2013|September 29, 2013|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122537||122304|
NCT01122862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z36420889|Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth|A Clinical Study to Evaluate the Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth||GlaxoSmithKline|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|August 22, 2013|May 11, 2010|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01122862||122279|
NCT01123421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUSS03|Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment|Portable Ultrasonometer for Osteoporosis Assessment: Retrospective Fracture Risk Validation Study, Version #1|BUSS03|Artann Laboratories|Yes|Completed|May 2010|February 2012|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|113|Samples Without DNA|Blood|Female|N/A|N/A|No|Probability Sample|Both groups|October 2012|October 11, 2012|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123421||122236|
NCT01123434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OCN-DUM-2009/2|Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.|A Non-interventional Study of Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Chinese Prostate Cancer Patients.||AstraZeneca|No|Completed|April 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Male|18 Years|N/A|No|Non-Probability Sample|Patients form urology surgery|January 2015|January 7, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01123434||122235|
NCT01123148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0001|A P300 Brain Computer Interface to Operate Power Wheelchair Tilt|A P300 Brain Computer Interface to Operate Power Wheelchair Tilt||University of Michigan|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 16, 2014|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01123148||122257|
NCT01123473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40071|Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer|Effectiveness of First Line Treatment With Lapatinib and ECF/X in Histologically Proven Adenocarcinoma of the Stomach or the Esophagogastric Junction, Metastatic or Not Amenable to Curative Surgery According to HER2 and EGFR Status: a Randomized Phase II Trial||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|December 2010|September 2014|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||August 2015|August 3, 2015|May 13, 2010|||company withdrew interest|No||https://clinicaltrials.gov/show/NCT01123473||122232|
NCT01118741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0972|Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)|A Multi-institutional Translational Clinical Trial of Disulfiram in Men With Recurrent Prostate Cancer as Evident by a Rising PSA||Johns Hopkins University|Yes|Completed|May 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||May 2014|May 15, 2014|April 29, 2010|Yes|Yes||No|December 13, 2013|https://clinicaltrials.gov/show/NCT01118741||122595|
NCT01119378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003|Study to Observe the Capability to Absorb Calcium as an Measure of Adequate Levels of Vitamin D|Calcium Absorption Efficiency As An Indicator For Vitamin D Sufficiency||Winthrop University Hospital|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|76|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119378||122546|
NCT01119040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-23|Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG "Rescue"|Prospective Evaluation of NOTES PEG "Rescue"|PEGRescue|University Hospital Case Medical Center|Yes|Terminated|November 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|May 6, 2010||No|Low accrual|No|October 14, 2010|https://clinicaltrials.gov/show/NCT01119040||122572|Study terminated early due to difficulty with patient accrual due to lack of patient population.
NCT01119053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01VNS2009|Effects of Vagus Nerve Stimulation (VNS) as a Treatment of Persistent Depression With Comorbid Personality Disorders (Impulse-VNS||Impuls-V|University Medical Center Goettingen|No|Recruiting|November 2009|November 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||November 2009|June 28, 2010|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119053||122571|
NCT01119066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-050|HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies|A Phase II Trial of Transplants From HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies and Other Lethal Hematologic Disorders||Memorial Sloan Kettering Cancer Center||Recruiting|May 2010|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|370|||Both|N/A|69 Years|No|||September 2015|September 28, 2015|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119066||122570|
NCT01129453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045057|Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection|Phase I Trial of a Live Oral Salmonella Enterica Serovar Paratyphi A Vaccine Harboring Mutations in guaBA and clpX||University of Maryland|Yes|Active, not recruiting|May 2010|April 2013|Anticipated|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129453||121777|
NCT01130311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AgaKhanU|Replacement of Vitamin D in Patients With Active Tuberculosis|A Randomized, Placebo-Controlled, Double-Blinded, 250-Subject Clinical Trial of Vitamin D Replacement in Patients With Pulmonary Tuberculosis|SUCCINCT|Aga Khan University|No|Completed|October 2009|December 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|259|||Both|15 Years|N/A|No|||June 2011|June 27, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01130311||121712|
NCT01130324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0113|VIBATIV Pregnancy Registry|VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry||Theravance Biopharma Antibiotics, Inc.|Yes|Recruiting|November 2009|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|N/A|N/A|No|Non-Probability Sample|Women exposed to VIBATIV during pregnancy and where outcome of pregnancy is unknown at        time of enrollment.|March 2014|January 2, 2015|May 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01130324|9 Months|121711|
NCT01129700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-458|Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer|Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer: Phase II Multi-institutional Study||National Cancer Center, Korea|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01129700||121758|
NCT01129986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENZ-DER-003-US|A Post Marketing Clinical Study Utilizing DermaStream and Saline in Venous Ulcers|A Post Marketing Clinical Study Utilizing DermaStream and Saline for Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremity||EnzySurge||Completed|June 2009|November 2011|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|September 2, 2013|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129986||121736|
NCT01129999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKH-Studie VT-HT|Cognitive-Behavioral Therapy and Hypnotherapy for Smoking Cessation|The Comparative Efficacy of Cognitive-Behavioral Therapy (CBT) and Hypnotherapy (HT) for Smoking Cessation.|CBT-HT|University Hospital Tuebingen|Yes|Completed|September 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 3, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01129999||121735|
NCT01130285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSC - 11|Validation of a Multi-gene Test for Lung Cancer Risk|Validation of a Multi-gene Test for Lung Cancer Risk||University of Toledo Health Science Campus|No|Active, not recruiting|May 2011|September 2019|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|403|Samples With DNA|Normal bronchial epithelial cell (NBEC) RNA. NBEC samples were obtained by bronchoscopic      brushing after informed consent to this project was obtained. RNA was extracted and frozen      in aliquots then archived. Two aliquots, were prepared for most subjects. In most cases,      there were more than 1 microgram of RNA per aliquot.|Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of subjects aged 50 to 90 and with 20 or more pack year        smoking history, who are determined not to have lung cancer at the time of enrollment or        within three months after the date of enrollment, and either a) volunteer for the study        driven bronchoscopy, or b) have standard of care clinical need for diagnostic bronchoscopy        (e.g. they may present with respiratory symptoms or abnormal test results consistent with        the need for bronchoscopy).|February 2016|February 2, 2016|May 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01130285||121714|
NCT01130298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S176.1.011|An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier|An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier||Abbott|No|Completed|May 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01130298||121713|
NCT01126255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213/08|Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus|Efficacy of a Topic Therapy With Progesterone Compared to the Conventional Therapy With Clobetasol Propionate in Patients With Vulvar Lichen Sclerosus. A Double Blind, Randomized Phase II Pilot Study.||University Hospital Inselspital, Berne|No|Terminated|March 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Female|18 Years|N/A|No|||October 2014|October 7, 2014|May 7, 2010||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT01126255||122019|
NCT01128413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFORT-10-0593|Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)|Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)|EFFORT|Washington University School of Medicine|No|Terminated|July 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|May 6, 2010||No|lack of resources|No|February 6, 2016|https://clinicaltrials.gov/show/NCT01128413||121855|Trial terminated early due to lack of resources leading to small numbers of subjects analyzed.
NCT01130051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-10-1002|Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce|A Pilot Bioavailability Study of Colcrys® Tablet 0.6 mg Versus Colcrys® Tablets 0.6 mg Crushed and Sprinkled on Applesauce Under Fasting Conditions||Mutual Pharmaceutical Company, Inc.|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 10, 2011|May 21, 2010|No|Yes||No|April 5, 2011|https://clinicaltrials.gov/show/NCT01130051||121731|
NCT01130064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2207|Efficacy of QAX576 in Asthma|A Multi-center, Randomized, Double Blind, Placebo-controlled, 'add-on' Study to Investigate the Efficacy and Safety of 24 Weeks Intravenous Treatment With QAX576 in Patients (≥18-75 Years) With Persistent Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting β2-agonists||Novartis||Completed|May 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|259|||Both|18 Years|75 Years|No|||April 2015|April 14, 2015|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130064||121730|
NCT01130077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08030085|A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas|A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas||University of Pittsburgh|Yes|Recruiting|February 2009|||February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|12 Months|21 Years|No|||January 2016|January 22, 2016|May 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01130077||121729|
NCT01125748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4777n|A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy|A Phase IV, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Persistency of Response With or Without Xolair After Long-term Therapy (XPORT)|XPORT|Genentech, Inc.||Completed|May 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|176|||Both|17 Years|70 Years|No|||October 2014|October 8, 2014|May 14, 2010|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT01125748||122058|
NCT01125761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECEMS21209|Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Withdrawn|November 2010|||November 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||April 2010|October 25, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125761||122057|
NCT01121991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 25244|A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies|A Phase III, Multicentre, Open-label Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone (Luveris) With r-hFSH on Follicular Development in Women Undergoing Ovarian Stimulation for ART||EMD Serono||Completed|September 2004|||September 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|18 Years|40 Years|No|||August 2013|August 2, 2013|May 10, 2010|No|Yes||No|February 17, 2011|https://clinicaltrials.gov/show/NCT01121991||122346|
NCT01123161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICTuS2/3|The Intravascular Cooling in the Treatment of Stroke 2/3 Trial|Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke|ICTuS2/3|University of California, San Diego|Yes|Terminated|June 2010|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|22 Years|82 Years|No|||May 2015|May 21, 2015|April 27, 2010|Yes|Yes|The ICTuS 2 portion of the trial has been halted and data will be analyzed. The study will    resume as ICTuS 3|No||https://clinicaltrials.gov/show/NCT01123161||122256|
NCT01122511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-021|Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration|||Allergan|No|Terminated|August 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|50 Years|N/A|No|||August 2012|August 1, 2012|May 11, 2010|Yes|Yes|The study was terminated early due to difficulties with patient recruitment.|No|August 1, 2012|https://clinicaltrials.gov/show/NCT01122511||122306|The study was terminated early due to difficulties with patient recruitment. No participants reached the 12 month time-point. Efficacy analyses were not performed.
NCT01122823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-Innov-4|Evaluation of the Online Chronic Disease Self-Management Project at Group Health|Evaluation of the Online Chronic Disease Self-Management Project at Group Health||Group Health Cooperative|Yes|Completed|February 2009|July 2012|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|406|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122823||122282|
NCT01127659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH testosterone grant|Testosterone Replacement in Men With Diabetes and Obesity|Effect of Hypogonadotrophic Hypogonadism and Treatment With Testosterone on Insulin Sensitivity, Inflammation, Body Composition and Sexual Function in Obese and Type 2 Diabetic Men||University at Buffalo|No|Completed|May 2010|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|144|||Male|30 Years|65 Years|No|||December 2015|December 1, 2015|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01127659||121912|
NCT01118754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-004|Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients|Phase I/II Prospective, Randomized, Double Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Compared to Placebo for the Treatment of Dry Eye Disease||Santen Inc.|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|132|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118754||122594|
NCT01119092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14787|The Effects of Gentle Movements at the Ankle in Individuals With Diminished Range of Motion|The Effects of Talocrural Joint Mobilizations in Individuals With Diminished Dorsiflexion Range of Motion After Ankle Sprain||University of Virginia|No|Recruiting|January 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|50 Years|No|||May 2011|May 26, 2011|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01119092||122568|
NCT01119664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02510; 811318|Combination Gene Transfer and Chemotherapy|A Pilot And Feasibility Trial Evaluating Two Different Chemotherapy Regimens In Combination With Intrapleural Adenoviral-Mediated Interferon-Alpha Gene Transfer For Malignant Pleural Mesothelioma||University of Pennsylvania||Active, not recruiting|April 2010|November 2025|Anticipated|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2014|April 16, 2015|May 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119664||122525|
NCT01130025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 0901 INT|Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer|Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT||LEO Pharma|Yes|Completed|August 2010|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|900|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130025||121733|
NCT01130038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032/2010k|Characteristic of Play: Comparison Between Children With Development Coordination Disorder ( DCD) and Children With Typical Development|||Meir Medical Center|No|Completed|August 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|N/A||2|Actual|64|||Both|4 Years|6 Years|Accepts Healthy Volunteers|Probability Sample|Children aged 4-6 years with Development Coordination Disorder ( DCD) and Children with        Typical Development (controlled group)|August 2011|August 27, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130038||121732|
NCT01129518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_06|Can we Reduce the Number of Vaccine Injections for Children?|An Open Label Randomised Controlled Study to Evaluate the Induction of Immune Memory Following Infant Vaccination With a Glycoconjugate Neisseria Meningitidis Serogroup C Vaccine and to Assess the Immunological Impact of Administering Routine Infant Immunisations in Consistent Versus Alternating Limbs|MALTA|University of Oxford|No|Completed|June 2010|||July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|404|||Both|2 Months|3 Months|Accepts Healthy Volunteers|||November 2015|November 6, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129518||121772|
NCT01129531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214868-002|A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia|||Allergan|Yes|Completed|June 2010|January 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|294|||Both|18 Years|80 Years|No|||September 2013|September 12, 2013|May 21, 2010|Yes|Yes||No|September 12, 2013|https://clinicaltrials.gov/show/NCT01129531||121771|
NCT01129544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND14067|Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector|Multi-institutional Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer||Children's Hospital Boston|Yes|Recruiting|April 2010|April 2030|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Male|N/A|N/A|No|||July 2014|July 23, 2014|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129544||121770|
NCT01130012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH16032005|Prevention of Gestational Diabetes|Feasibility of a Lifestyle Intervention in Early Risk Pregnancy in Preventing Deterioration in Glucose Tolerance?||Kuopio University Hospital||Completed|April 2005|December 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|440|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2010|December 14, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01130012||121734|
NCT01126788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002554|Comparative Physiologic Technology Study|Comparative Physiologic Technology Study||Massachusetts General Hospital|No|Recruiting|December 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|All patients referred to the MGH Vascular Labs for diagnostic testing for PAD|November 2010|November 23, 2010|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126788||121979|
NCT01126801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p001776|Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women|Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women||Massachusetts General Hospital|Yes|Terminated|May 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Female|40 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 16, 2013|May 11, 2010|Yes|Yes|Due to the challenge of identifying eligible participants, we decided to stop enrolling    subjects. Reviewed and approved by our DSMG and NIH Program Officer.|No||https://clinicaltrials.gov/show/NCT01126801||121978|
NCT01127035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLITALT2004|Sublingual Immunotherapy In Alternaria-Induced Rhinitis|STUDIO IN DOPPIO CIECO DISODIOCROMOGLICATO + PLACEBO vs DISODIOCROMOGLICATO + IMMUNOTERAPIA SPECIFICA SUBLINGUALE PER ALTERNARIA IN PAZIENTI CON RINITE ALLERGICA DOVUTA A SENSIBILIZZAZIONE AD ALTERNARIA||University of Genova|No|Completed|January 2006|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|14 Years|65 Years|No|||January 2008|June 4, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127035||121960|
NCT01128985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017200|A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Subjects With Type 2 Diabetes Mellitus||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|March 2010|July 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|39|||Both|25 Years|65 Years|No|||May 2013|May 27, 2013|May 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01128985||121813|
NCT01121978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRIG #2|Early Vitrectomy for Macular Tractional Maculopathy|Early Vitrectomy for Macular Tractional Maculopathy. Multicenter Clinical Trial||Seoul Retina Investigator Group|Yes|Recruiting|November 2009|November 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|N/A|No|||March 2011|March 28, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01121978||122347|
NCT01126099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1AG033133-01A1|Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease|Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease||Seattle Institute for Biomedical and Clinical Research|Yes|Completed|March 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||May 2015|May 19, 2015|May 17, 2010|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01126099||122031|
NCT01126112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-09-03|Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer|Phase II Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer|FRAIL|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|May 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|70 Years|N/A|No|||March 2015|March 23, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126112||122030|
NCT01122004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8877|The Effect of Gabapentin (Neurentin) and Pregabalin (Lyrica) in Pain Reduction After Photorefractive Keratectomy||PRK|hahid Beheshti University of Medical Sciences||Recruiting||||||Phase 1|Interventional|Primary Purpose: Treatment|2||||||Both|17 Years|N/A||||March 2010|May 10, 2010|April 12, 2010||||No||https://clinicaltrials.gov/show/NCT01122004||122345|
NCT01126619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-130|A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis|To Observe the Effectiveness and Safety of Anti-TNFs in Patients With Moderate to Severe Psoriasis||Abbott||Completed|May 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|University hospitals in Turkey|October 2012|October 19, 2012|May 18, 2010||No||No|September 7, 2012|https://clinicaltrials.gov/show/NCT01126619||121992|
NCT01126632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAC Study|Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial|Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial|CAC|Nova Scotia Health Authority|No|Withdrawn|June 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Endoscopy Clinic- Patients already receiving colonoscopies|January 2016|January 27, 2016|May 15, 2010||No|Caps became unavailable by manufacturer|No||https://clinicaltrials.gov/show/NCT01126632||121991|
NCT01126645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No. 2009-012576-27|Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer|Evaluation of Sorafenib in Combination With Local Micro-therapy Guided by Gd-EOB-DTPA Enhanced MRI in Patients With Inoperable Hepatocellular Carcinoma|SORAMIC|University of Magdeburg|Yes|Recruiting|December 2010|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|665|||Both|18 Years|85 Years|No|||December 2015|December 2, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126645||121990|
NCT01126658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG 371581|Evaluation the Intracranial Volume Pressure Response in Increased Intracranial Pressure|Evaluation of the Intracranial Volume Pressure Relationship in Increased Intracranial Pressure Patients by a Mathematic Manner||Chang Gung Memorial Hospital|Yes|Recruiting|December 2008|June 2010|Anticipated|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|41|||Both|18 Years|N/A|No|Non-Probability Sample|over 30 patients with severe brain injury and underwent bilateral external ventricular        drainage in situ.|May 2010|May 20, 2010|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126658||121989|
NCT01122277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|337 -09/2009-366-f-S|Rational Fluid Therapy in Germany|Klinisches Register RaFTinG - Rational Fluid Therapy in Germany|RaFTinG|Ludwig-Maximilians - University of Munich|No|Active, not recruiting|May 2010|October 2011|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in intensive care units with an indication for fluid/volume therapy|October 2010|July 7, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122277||122324|
NCT01122524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-0006|MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy|A Prospective, Multi-center Observational Study With Blinded, Nested Case:Control Analyses to Evaluate the Performance of the Verinata Health Prenatal Aneuploidy Diagnostic Test|MELISSA|Verinata Health, Inc.|No|Completed|June 2010|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10000||plasma|Female|18 Years|N/A|No|Probability Sample|Pregnant women undergoing chorionic villus sampling (CVS) or amniocentesis|October 2011|October 6, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122524||122305|
NCT01122875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFG4809g|A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma|An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma||Genentech, Inc.||Completed|November 2010|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122875||122278|
NCT01127399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00027264|Bariatric and Obstructive Lung Disease Study II|Effects of Obesity on Airway Caliber and Airway Smooth Muscle Tone|BOLD II|Johns Hopkins University|No|Active, not recruiting|September 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|120|Samples With DNA|Blood samples.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Bariatric Center at The Johns Hopkins University (Bariatric participants only), local        community (Baltimore and Central Maryland area; control participants only)|June 2011|June 24, 2011|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127399||121932|
NCT01127412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOIP-GECKO|Early Obesity Intervention Program Within GECKO Drenthe; a Randomized Controlled Trial|Early Obesity Intervention Program Within GECKO Drenthe; a Randomized Controlled Trial||University Medical Center Groningen|No|Completed|December 2006|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|228|||Both|N/A|2 Weeks|Accepts Healthy Volunteers|||May 2010|May 19, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127412||121931|
NCT01119079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090228|Study to Determine Whether the Instillation of 10ml Normal Saline Improves Epidural Analgesia During Labor|A Randomized, Prospective Study to Establish Whether the Instillation of 10ml of Epidural Normal Saline Improves the Quality Of Epidural Analgesia During Labor||Rutgers, The State University of New Jersey|No|Withdrawn|March 2010|September 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|45 Years|No|||April 2015|April 23, 2015|May 6, 2010||No|PI unable to recruit appropriate patients|No||https://clinicaltrials.gov/show/NCT01119079||122569|
NCT01119404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHMetS-02-AP|Hämeenlinna Metabolic Syndrome Research Program: Surrogate Indicators for Atherosclerosis|Hämeenlinna Metabolic Syndrome Research Program (HMS): Surrogate Indicators for Atherosclerosis in Men With Metabolic Syndrome, Coronary Heart Disease and Controls|HMS-02|Central Hospital of Kanta-Hame|No|Recruiting|June 2003|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|300|Samples Without DNA|serum, EDTA plasma, citrate plasma|Male|30 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|May 2010|May 10, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01119404||122544|
NCT01129726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100002|Fiberoptic Intubation and Transillumination-guided Fiberoptic Intubation：Success Rate and Time in Untrained Medical Personnel|Fiberoptic Intubation and Transillumination-guided Fiberoptic Intubation：Time and Success Rate in Untrained Medical Personnel||Second Military Medical University|Yes|Completed|May 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|100|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01129726||121756|
NCT01128140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37278-C|Efficacy Trial of Warrior Check-Up|Motivating Treatment Seeking and Behavior Change by Untreated Military Personnel Abusing Alcohol or Drugs||University of Washington|No|Completed|October 2010|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01128140||121875|
NCT01129791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05062010-5882|Effects of Raw Versus Other Milk Sources on Lactose Digestion|Comparison of Raw Milk Consumption vs. Other Milk Sources on Lactose Digestion in Healthy Individuals With Self-reported Lactose Intolerance||Stanford University||Completed|February 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 21, 2011|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129791||121751|
NCT01126268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0650|Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection|Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection||The University of Texas Health Science Center, Houston|No|Completed|April 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|9 Months|98 Years|No|||January 2016|January 20, 2016|April 19, 2010|No|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01126268||122018|
NCT01127269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04980|Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes|Practical Implementation of ADA/EASD Consensus Algorithm in Patients With Type 2 Diabetes: Timely Insulin Initiation and Titration|AFICIONADO|Sanofi|No|Completed|May 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|21 Years|80 Years|No|||July 2014|July 16, 2014|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127269||121942|
NCT01127568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/25|A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol|A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol||Douglas Mental Health University Institute|Yes|Recruiting|February 2010|June 2012|Anticipated|September 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2010|May 20, 2010|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01127568||121919|
NCT01127581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso-Obs-303|Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery|Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term|EXPEDITE|Ferring Pharmaceuticals|Yes|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1358|||Female|18 Years|N/A|No|||April 2014|April 15, 2014|May 19, 2010|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01127581||121918|
NCT01129492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 375/05|Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis|Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis: Randomized, Placebo Controlled Clinical Trial||University of Sao Paulo General Hospital|Yes|Completed|March 2006|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|20 Years|60 Years|No|||April 2009|May 21, 2010|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01129492||121774|
NCT01125514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2255|A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure|A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure||Novartis||Completed|May 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|75 Years|No|||August 2012|August 9, 2012|May 17, 2010||No||No|August 9, 2012|https://clinicaltrials.gov/show/NCT01125514||122076|
NCT01122290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10543 (Lboro)|Inducing Children's Emotional Eating|Inducing Preschool Children's Emotional Eating: Relationships With Parental Feeding Practices.||University of Birmingham|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Actual|64|||Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy 3-5 year old children in the UK (within approx. radius of 10 miles of Loughborough        University).|May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01122290||122323|
NCT01122550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQL-CRU.004-2009|Reproducibility Study of Overactive Bladder Symptom Score [OABSS]|Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 1: Reproducibility -|RESORT-1|Astellas Pharma Inc|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Symptomatic OAB patients having urgency episodes|August 2010|August 23, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01122550||122303|
NCT01122888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01455|Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme|Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib||National Cancer Institute (NCI)||Terminated|December 2009|April 2015|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|January 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01122888||122277|
NCT01126879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 09U2|Genistein in Treating Patients With Prostate Cancer|Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells||Northwestern University|Yes|Active, not recruiting|May 2010|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Male|18 Years|N/A|No|||June 2015|June 23, 2015|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126879||121972|
NCT01126892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ACO01|A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|ENACT|Novartis||Completed|January 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126892||121971|
NCT01127386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 09/040|Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome|Effect of Lenalidomide (Revlimid®) in Solid Tumour Patients With Inflammatory Cancer Cachexia Syndrome on Lean Body Mass and Muscle Strength: A Multicenter, Proof-of-concept Study of Fixed Dose or CRP-response-guided Dose of Lenalidomide in Relation to New Standard Basic Cachexia Management (Receiving Placebo).||Cantonal Hospital of St. Gallen|Yes|Recruiting|May 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2010|May 19, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01127386||121933|
NCT01127711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1706/2010-631-2|Cohort of Swedish Men|Cohort of Swedish Men|COSM|Karolinska Institutet|Yes|Completed|September 1997|||December 1997|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48850|Samples With DNA|Saliva Blood|Male|45 Years|79 Years|No|Non-Probability Sample|Men born between 1918 and 1952, living in central Sweden (Örebro and Västmanlands        counties)|February 2014|February 27, 2014|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127711||121908|
NCT01118793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC# 08-5083|Pilot Study on the Effect of High Clopidogrel Maintenance Dosing|PREDICT: Scripps Pilot Study on the Effect of High Clopidogrel Maintenance Dosing and Its Relationship to Cytochrome P450 2C19 Polymorphism Status|PREDICT|Scripps Health|No|Completed|December 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|Samples With DNA|Whole Blood|Both|18 Years|85 Years|No|Probability Sample|Scripps Health patients having decresed platlet inhibition on clopidogrel|May 2010|May 6, 2010|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01118793||122591|
NCT01119131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7051-W|Effects of Vitamin D in Parkinson's Disease (PD)|The Effects of Vitamin D on Balance in Persons With PD||VA Office of Research and Development|Yes|Completed|May 2011|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|50 Years|99 Years|No|||February 2016|February 8, 2016|April 23, 2010|No|Yes||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01119131||122565|
NCT01119716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6621-051|International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)|International Registry on Cardioversion of Atrial Fibrillation|RHYTHM-AF|Merck Sharp & Dohme Corp.|No|Completed|May 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4658|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in a hospital setting in Australia, Brazil, France, Germany, Italy, Netherlands,        Poland, UK, Spain, and Sweden from a cross section of different centers including        university and non-university hospitals.|October 2015|October 30, 2015|May 6, 2010||No||No|December 13, 2013|https://clinicaltrials.gov/show/NCT01119716||122521|
NCT01126827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBCT Randomized Study|Mindfulness-Based Cognitive Behavior Therapy for Bipolar Disorder|Mindfulness-Based Cognitive Behavior Therapy for Bipolar Disorder: A Randomized, Controlled Study|MBCT|Massachusetts General Hospital|No|Completed|January 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||July 2011|July 6, 2011|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01126827||121976|
NCT01130389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106037|CONDOR Study of Osteonecrosis of the Jaws (TMJ)|Trans-PBRN Case-control Study of Osteonecrosis of the Jaws||Dental Practice-Based Research Network|No|Completed|January 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|309|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The human subjects involved in this study were patients of dentists from the dental        practice-based research networks (DPBRN, PEARL, PRECEDENT) who identified (ONJ) cases and        chose to particpate in the study.|June 2011|June 14, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130389||121707|
NCT01130402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098026-3|A Real-time and Computerized Sonographic Reporting System in Predicting Malignant Cervical Lymphadenopathy|A Real-time and Computerized Sonographic Scoring System for Predicting Malignant Cervical Lymphadenopathy||Far Eastern Memorial Hospital|Yes|Completed|June 2009|September 2009|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|189|||Both|10 Years|83 Years|No|Non-Probability Sample|patients with previously untreated neck masses were referred for sonographic evaluation        and subsequent US-FNA after informed consent was obtained. Demographic data, including age        and sex, side, site, and number of lymphadenopathy was collected as well.|April 2009|May 25, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130402||121706|
NCT01130337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25189|A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer|An Open-label, Multi-center Study to Evaluate the Disease Free Survival Rate of a Perioperative Combination of Capecitabine (Xeloda), Trastuzumab (Herceptin) and Oxaliplatin (XELOX- Trastuzumab) in Patients With Resectable Gastric or Gastro-esophageal Junction Adenocarcinoma||Hoffmann-La Roche||Completed|July 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|May 25, 2010||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01130337||121710|
NCT01130103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH068173|Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack|Combination Treatment for PTSD After the WTC Attack||Research Foundation for Mental Hygiene, Inc.|No|Completed|March 2004|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|70 Years|No|||November 2012|November 30, 2012|May 24, 2010|Yes|Yes||No|July 9, 2012|https://clinicaltrials.gov/show/NCT01130103||121727|
NCT01127841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOTEL/09-01|Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line|Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.||Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas|No|Active, not recruiting|July 2009|December 2015|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01127841||121898|
NCT01125475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701068-521|A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects|A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study|SCANSMART|Merck KGaA|No|Completed|August 2010|||March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|18 Years|65 Years|No|Non-Probability Sample|Neurology Clinics at Danish and Norwegian hospitals (single treatment group)|September 2012|July 15, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125475||122079|
NCT01128101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-43|Effects of Spironolactone in Dialysis|Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients||UPECLIN HC FM Botucatu Unesp|Yes|Recruiting|March 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||September 2011|September 2, 2011|May 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01128101||121878|
NCT01128686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113973|Lamivudine(LAM) Good Responder Study|A Retrospective Cohort Study to Evaluate the Rate of Good Responses to Lamivudine (LAM) Treatment in naïve Chronic Hepatitis B (CHB) Patients With Certain Pre-treatment Characteristics|LAMGR|GlaxoSmithKline|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|20 Years|N/A|No|Probability Sample|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to        this investigation in General Hospital|June 2011|June 9, 2011|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128686||121836|
NCT01126060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-12-093|Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain|Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections||Samsung Medical Center||Completed|February 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|20 Years|80 Years|No|||November 2011|November 15, 2011|April 15, 2010||No||No|September 6, 2011|https://clinicaltrials.gov/show/NCT01126060||122034|realtive small number of patients to retrieve significant difference between two groups
NCT01125254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000002|Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major|Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major|AnloThal|University of Campinas, Brazil|No|Completed|September 2008|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|6 Years|90 Years|No|||January 2015|January 2, 2015|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01125254||122096|
NCT01125774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-065|Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)|A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine||Merck Sharp & Dohme Corp.|Yes|Completed|June 2010|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4548|||Female|18 Years|N/A|No|||June 2015|June 30, 2015|May 17, 2010|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01125774||122056|
NCT01126697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITT0908|Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies|PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies||Cooperative International Neuromuscular Research Group|Yes|Enrolling by invitation|February 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|8 Years|N/A|No|||February 2016|February 2, 2016|May 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126697||121986|
NCT01126385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DensiProbe Spine 2010|Pilot Study to Evaluate Feasibility of DensiProbe Spine Assessing Bone Strength in Spinal Surgery|A Prospective Case Series to Evaluate Handling and Feasibility of DensiProbe Spine Assessing Vertebral Bone Strength in Patients Undergoing Transpedicular Fixation of the Spine - a Pilot Study|DensiProbe|AO Clinical Investigation and Documentation|No|Completed|August 2010|August 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing transpedicular stabilization of the spine|January 2013|January 24, 2013|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126385||122009|
NCT01126671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-06-0271|Vitamin D Supplementation in Healthy Adolescents|Clinical Trial of Vitamin D Supplementation in Healthy Adolescents||Children's Hospital Boston|No|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||March 2013|March 8, 2013|May 18, 2010||No||No|March 8, 2013|https://clinicaltrials.gov/show/NCT01126671||121988|
NCT01126684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAY|Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion|EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL HYPERTENSION||Aristotle University Of Thessaloniki||Completed|June 2008|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||April 2010|May 19, 2010|May 19, 2010||||No||https://clinicaltrials.gov/show/NCT01126684||121987|
NCT01126905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010FAL1|Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal Patients|A Local Pilot Evaluation of Laboratory Monitoring of Renal Patients on Erythropoietin and /or Iron Therapy Using Mean Reticulated Haemoglobin Equivalent (RetHe) and Their Response to Therapy||NHS Tayside|Yes|Enrolling by invitation|June 2010|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|16 Years|85 Years|No|Non-Probability Sample|Renal Patients requested to participate in study (consent required)|May 2010|June 4, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01126905||121970|
NCT01127425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-20060067|Length of Hospital Stay, Nursing Hours and Recovery After Laparoscopic Versus Open Colon Resection Without Fast Track|Length of Hospital Stay, Nursing Hours and Recovery After Laparoscopic Versus Open Colon Resection Without Fast Track||University Hospital, Gentofte, Copenhagen|Yes|Terminated|July 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|40 Years|90 Years|No|||June 2006|June 4, 2010|February 17, 2010||No|Due to reorganisation in the hospital structure|No||https://clinicaltrials.gov/show/NCT01127425||121930|
NCT01127438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2083-A001-406|A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations|A Double-blind, Randomized, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations||Eisai Inc.|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|153|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|May 19, 2010|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT01127438||121929|
NCT01127126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0075/4|Bryophyllum Versus Placebo for Overactive Bladder|Treatment of the Overactive Bladder in Postmenopausal Women With Bryophyllum Pinnatum Versus Placebo (a Multicenter, Prospective, Double-blind Randomised, Placebo-controlled Clinical Pilot Study, Phase II Drug Study)||University of Zurich|Yes|Completed|December 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|90 Years|No|||January 2012|January 18, 2012|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01127126||121953|
NCT01119105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAB-BC-3781-2001|Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|A Phase II, Multi-center, Randomized, Double-blind Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection||Nabriva Therapeutics AG|Yes|Completed|May 2010|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|N/A|No|||July 2012|July 2, 2012|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01119105||122567|
NCT01119118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO09805|ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer|Pharmacodynamic Response Assessment With PET/MRI Imaging in Patients With Metastatic Prostate CAncer to Bone Treated With ZD4054||University of Wisconsin, Madison|Yes|Terminated|April 2010|November 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|N/A|No|||March 2013|March 18, 2013|May 5, 2010|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT01119118||122566|
NCT01118832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0868|Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi|Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|September 2009|||||N/A|Observational|Observational Model: Case-Only||1|Anticipated|30|||Both|10 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subject population will be identified in the Department of Dermatology Pigmented        Lesion Clinic at the Johns Hopkins Hospital Outpatient Center. Recruited patients will        only comprise those requesting a cutaneous pigmented lesion removed or patients that are        examined and found to have a pigmented lesion that is suspicious for malignancy at the        time of their visit, and thus recommended to have a skin biopsy for diagnosis following        the standard of care|May 2010|May 6, 2010|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01118832||122588|
NCT01119729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKZ 01GI0205|Cardiovascular Diseases in HIV-infected Subjects (HIV-HEART Study)|||University Hospital, Essen|Yes|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|803|||Both|18 Years|N/A||Non-Probability Sample|The study population included outpatients who were at least 18 years of age, had a known        HIV-infection and exhibited a stable disease status within 4 weeks before inclusion of the        trial. Patients were recruited during a 20-month period in a consecutive manner from        September 2004 to May 2006. Written informed consent was obtained from all participants|May 2010|May 7, 2010|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01119729||122520|
NCT01127880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLHN 2005-34|Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax|The Role of Antibiotics in the Reduction of Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax: A Prospective, Double-Blinded Study||St. Luke's Hospital, Pennsylvania|No|Completed|July 2005|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2009|May 20, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127880||121895|
NCT01127893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091032|Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis|A Phase 3, Multicenter, Randomized, Long Term Study Of The Safety Of The Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee||Pfizer|Yes|Terminated|June 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|May 20, 2010|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01127893||121894|
NCT01129284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD9539|Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)|The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)||Columbia University|No|Completed|December 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|May 21, 2010|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT01129284||121790|
NCT01126281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sant'orsola1|Efficacy and Safety of Floseal for the Haemostasis During Laparoscopic Cholecystectomy in Acute Cholecystitis (GLA)|THE USE OF FLOSEAL GELATIN MATRIX FOR THE HAEMOSTASIS DURING LAPAROSCOPIC CHOLECYSTECTOMY FOR ACUTE CHOLECYSTITIS; EFFICACY AND SAFETY EVALUATED IN A MULTICENTER, PROSPECTIVE, OPEN LABEL TRIAL WITH AN HISTORICAL CONTROL GROUP. (G.L.A. STUDY: GELATIN Matrix in Laparoscopic Cholecystectomy for Acute Cholecystitis)|GLA|University of Bologna||Not yet recruiting|August 2010|||August 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||May 2010|May 18, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126281||122017|
NCT01126294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0172-B|Perioperative Melatonin in Lumbar Laminectomy|Perioperative Analgesic and Anxiolytic Effect of Melatonin in Patients Undergoing Lumbar Laminectomy||University Health Network, Toronto|No|Recruiting|April 2010|September 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|84|||Both|18 Years|65 Years|No|||April 2010|May 18, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126294||122016|
NCT01125488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 97-04-03|Maintenance Therapy of Levonorgestrel-releasing Intrauterine System (LNG-IUS) to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery|Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|March 2008|September 2010|Anticipated|March 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|20 Years|45 Years|No|||June 2010|June 6, 2010|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01125488||122078|
NCT01125735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-093|MIST Therapy's Effectiveness in Wound Bed Preparation and Role of Bacterial Biofilm in Chronic, Non-healing Wounds|A Prospective, Randomized, Controlled Study of MIST Therapy's Effectiveness in Wound Bed Preparation and the Role of Bacterial Biofilm in Subjects Presenting With Chronic, Non-healing Wounds|Celleration|Georgetown University|No|Withdrawn|April 2011|April 2014|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|May 17, 2010|Yes|Yes|Contract negotiations were terminated and study never started.|No||https://clinicaltrials.gov/show/NCT01125735||122059|
NCT01125501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SomaL-028 (withdrawn)|Protandim and the Metabolic Syndrome|Protandim and the Metabolic Syndrome: A Preliminary Study to Define Protein Signatures That Change Along With Lowered Oxidative Stress Measured as F2 Isoprostanes or TBARS and Inflammation Measured as hsCRP||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Withdrawn|April 2010|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|28|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||July 2010|July 7, 2010|May 17, 2010||No|funding not available|No||https://clinicaltrials.gov/show/NCT01125501||122077|
NCT01125527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V37_06|Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children|A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose||Novartis||Completed|August 2009|April 2010|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|700|||Both|13 Months|59 Months|Accepts Healthy Volunteers|||December 2011|December 27, 2011|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01125527||122075|
NCT01125540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allergy02|The Role of Daily Disposable Contact Lenses in Ocular Allergy|The Role of Daily Disposable Contact Lenses in Ocular Allergy||Aston University|No|Completed|June 2007|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|May 17, 2010|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01125540||122074|
NCT01122030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007V9214|Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain|A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain||Shionogi Inc.|No|Completed|April 2010|||March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|72|||Both|18 Years|65 Years|No|||September 2011|September 13, 2011|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01122030||122343|
NCT01126944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/09-03|LVAD in Non Cardiac Transplant Candidates and Non Responders to Resynchronization|Study of Congestive Heart Failure Through the Evaluation of Cardiac Resynchronization Non-responders and Mechanical Assistance Therapy|CHECKMATE|Rennes University Hospital|Yes|Withdrawn|March 2010|December 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||September 2010|July 1, 2011|May 18, 2010||No|No patients recruted since recruiting is open|No||https://clinicaltrials.gov/show/NCT01126944||121967|
NCT01126918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH086582|Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students|Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students||Oregon Research Institute|Yes|Active, not recruiting|April 2010|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|432|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126918||121969|
NCT01126931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Appetite and Weight Loss|Wormwood in Chronic Progressive Disorders With Reduced Appetite|Pilot Trial With Wormwood to Improve Appetite in Cancer, Autoimmune Diseases, Depression and Old Age||University Hospital Freiburg|No|Recruiting|February 2006|December 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with reduced appetite and reduced quality of life as a result of chronic        progressive disorders such as cancer, autoimmune diseases (Crohn, IgA-Nephropathy), old        age and depression|February 2008|May 19, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126931||121968|
NCT01127464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC-0710|DCVax Plus Poly ICLC in Healthy Volunteers|A Randomized, Placebo-controlled, Dose-escalating, Double-blinded Phase I Study to Evaluate the Safety and Immunogenicity of Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) With Poly ICLC (Hiltonol) as Adjuvant in HIV-uninfected Healthy Volunteers||Rockefeller University|Yes|Completed|May 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|43|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|May 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01127464||121927|
NCT01127685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10043-2010CTIL|Weight-bearing Measuring Device Following Anterior Cruciate Ligament Reconstruction|The Use of a Biofeedback Insole Weight-bearing Measuring Device in Determining Weight-bearing Deficits Following Anterior Cruciate Ligament Reconstruction||Meir Medical Center||Completed|May 2010|July 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01127685||121910|
NCT01127984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOVE 1|Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator. The PHP Study.|Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator (ICD) During Dual Antiplatelet or Anticoagulant Therapy. A Prospective Randomized Trial. The PHP Study.|PHP|Careggi Hospital|Yes|Completed|December 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2010|February 10, 2011|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127984||121887|
NCT01127997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC10EISI0007|The Effect and Mechanisms of the Second-meal Phenomenon in Type 2 Diabetic Patients|The Effect and Mechanisms of the Second-meal Phenomenon in Type 2 Diabetic||The Catholic University of Korea|No|Completed|March 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|12|Samples Without DNA|plasma, serum|Both|35 Years|70 Years|No|Probability Sample|type 2 diabetic patients|May 2010|August 20, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127997||121886|
NCT01128010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD-CCL2|Role of CCL2 in Alcoholic Liver Diseases|||Erasme University Hospital||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive patients undergoing transjugular liver biopsy for alcoholic liver disease will        be include in the study to measure plasma levels and hepatic expression of CCL2. We        determine also the rs1024611 polymorphism of these patients. All these parameters are        correlated to severity of the disease.        The frequency of the presence of this polymorphism was also compared to a population of        healthy subjects.|December 2002|May 20, 2010|May 20, 2010||||No||https://clinicaltrials.gov/show/NCT01128010||121885|
NCT01118845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010001|Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma|A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma||SymBio Pharmaceuticals|Yes|Completed|April 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|20 Years|75 Years|No|||May 2013|May 29, 2013|May 1, 2010||No||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01118845||122587|
NCT01121029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN10-011|Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus|Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|May 2010|December 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|2 Years|35 Years|No|||December 2012|December 6, 2012|May 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121029||122420|
NCT01128712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEREG-001|Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin|An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin||Northeast Regional Epilepsy Group|No|Completed|April 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|75 Years|No|||September 2014|September 23, 2014|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128712||121834|
NCT01129739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZheng|Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes|Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat RA and RARS of MDS||Shandong University|Yes|Recruiting|May 2010|May 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||May 2010|May 24, 2010|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129739||121755|
NCT01126515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004120|Functional and Anatomical Magnetic Resonance Imaging (MRI) of Chronic Brain Injury and Hyperbaric Oxygen (HBO2) Study Subjects|MRI & CT Angiogram and Hyperbaric Oxygen in Chronic Stable Brain Injury|HYBOBI-MRI|Intermountain Health Care, Inc.|No|Completed|July 2007|June 2010|Actual|June 2010|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|Adults with chronic brain injury who are enrolled in the HYBOBI study.|March 2011|March 15, 2011|March 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01126515||122000|
NCT01127048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA-08-1-34|Prospan® Hustenzäpfchen - Investigation on Efficacy and Tolerability in Children|Investigation on Efficacy and Tolerability of Prospan® Hustenzäpfchen for the Symptomatic Treatment of Acute Bronchitis Accompanied by Coughing in Children||Engelhard Arzneimittel GmbH & Co.KG|Yes|Recruiting|October 2008|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1400|||Both|N/A|6 Years|No|||May 2010|June 14, 2011|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01127048||121959|
NCT01124994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 697/2009|Confocal Laser Endomicroscopy and Endoscopic Mucosal Resection|Endomicroscopy-targeted Endoscopic Mucosa Resection for Barrett's Oesophagus-associated Neoplasia||Medical University of Vienna|No|Completed|July 2011|December 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|90 Years|No|||January 2014|January 22, 2014|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01124994||122116|
NCT01126125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SwissFIT|Study of the Effect of Iodized Oil Supplementation During Infancy|Iodized Oil Supplementation During Infancy|INSIGHT|Swiss Federal Institute of Technology|Yes|Completed|May 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|241|||Both|N/A|40 Years|No|||November 2012|November 7, 2012|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126125||122029|
NCT01130454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-103-01|A Study for Evaluating the SCIO Biofeedback Device's Ability to Increase Body Wellness After One 45-minute Session|A Double-blind Placebo-controlled Study of the Application of the SCIO Universal Electrophysiological Biofeedback System for Statistical Evaluation of the SCIO's Ability to Increase Body Wellness After One 45-minute Session||Maitreya Kft.|No|Completed|September 2009|April 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 24, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01130454||121702|
NCT01126957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project Number: 1084480|Combined Ketamine/Propofol for Emergency Department Procedural Sedation|Combined Ketamine/Propofol for Emergency Department Procedural Sedation||University of Missouri-Columbia|No|Completed|May 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|1 Year|N/A|Accepts Healthy Volunteers|||March 2011|March 1, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01126957||121966|
NCT01127165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-S082-404|Low and High Dose Zonisamide in Children as Monotherapy|A Multi-center Comparative Trial of Low and High Dose Zonisamide in Children as Monotherapy||Eisai Inc.|No|Completed|March 2006|July 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|2 Years|15 Years|No|||May 2010|June 25, 2012|May 19, 2010||No||No|July 29, 2010|https://clinicaltrials.gov/show/NCT01127165||121950|
NCT01127178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7016-A001-101|Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors|Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors||Eisai Inc.|No|Completed|May 2012|February 2014|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2015|January 27, 2016|May 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01127178||121949|
NCT01127477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE06-008-CP3|Study to Obtain Volume Effect and Safety Data on 6 % Hydroxyethyl Starch 130/0.4 in Pediatric and Adult Patients Undergoing Major Elective Surgery|Examination of Volume Effect and Safety of 6 % Hydroxyethyl Starch 130/0.4 in Patients Undergoing Major Elective Surgery - an Uncontrolled, Open-labelled, Multi-centre Study||Fresenius Kabi|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||March 2012|June 25, 2012|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01127477||121926|
NCT01127750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2316|Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients|A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis||Novartis||Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2417|||Both|18 Years|65 Years|No|||January 2012|January 18, 2012|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127750||121905|
NCT01127139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-161|Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension|Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With VerapamilSR/ Trandolapril Fixed Combination (Tarka®) in Patients With Essential Hypertension in Routine Clinical Practice||Abbott|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3828|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg|March 2012|March 30, 2012|May 19, 2010||No||No|March 30, 2012|https://clinicaltrials.gov/show/NCT01127139||121952|
NCT01127152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHD 010-09|Assessment of Automatic Relays by Intensive Basis Advantage Compared With Manual Relays, on the Hypotension Risks, During Noradrenalin Administration|Assessment of Automatic Relays by Intensive Basis Advantage Compared With Manual Relays, on the Hypotension Risks, During Noradrenalin Administration|ARIBA|Centre Hospitalier Departemental Vendee|No|Completed|June 2009|April 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||June 2011|November 20, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01127152||121951|
NCT01127451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7272-701|Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma|A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma||Eisai Inc.|No|Active, not recruiting|June 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01127451||121928|
NCT01127698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1706/2010-631-1|Swedish Mammography Cohort|Swedish Mammography Cohort|SMC|Karolinska Institutet|Yes|Completed|March 1987|||December 1990|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|61433|Samples With DNA|Saliva Blood|Female|40 Years|74 Years|No|Non-Probability Sample|Women born between 1914 and 1948, living in central Sweden (Uppsala and Västmanlands        counties)|February 2014|February 27, 2014|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127698||121909|
NCT01128335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071B2201|Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients|A 24-month Randomized Multicenter Study Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of Sotrastaurin and Tacrolimus vs. a Tacrolimus/Mycophenolate Mofetil-based Control Regimen in de Novo Liver Transplant Recipients||Novartis||Completed|April 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|200|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128335||121861|
NCT01128348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700|A Patient Advocate and Literacy-Based Treatment of Asthma|A Patient Advocate and Literacy-Based Treatment of Asthma|HAP|University of Pennsylvania|Yes|Completed|September 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|100|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128348||121860|
NCT01119430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSP-2003-01|Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder|Fluoxetine Versus Fluoxetine Plus DU125530 in Latency of Antidepressant Response Shortening in Major Depressive Disorder||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Terminated|May 2004|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||May 2010|May 6, 2010|May 6, 2010||No|interim analysis suggested no differences with whole sample|No||https://clinicaltrials.gov/show/NCT01119430||122542|
NCT01129557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0863|Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease|Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease||Columbia University|Yes|Terminated|September 2009|December 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|May 21, 2010|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01129557||121769|
NCT01129011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PN400-302|Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen|6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers||POZEN|Yes|Completed|September 2007|October 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|May 20, 2010|Yes|Yes||No|May 27, 2010|https://clinicaltrials.gov/show/NCT01129011||121811|
NCT01129024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0914M0622|An Open-label Safety Study of S-888711|An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy||Shionogi Inc.|No|Completed|March 2010|||August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129024||121810|
NCT01124513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-STU27549|Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI|A Prospective Study of Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI|Melanin Index|Northwestern University|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|270|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01124513||122153|
NCT01125241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-2010|A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression|A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression: a Muli-center, Randomized, Double-blinded, Placebo-controlled Superiority Clinical Trial||Shanghai Zhongshan Hospital|Yes|Completed|September 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01125241||122097|
NCT01124734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 09-067|High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma|Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma||Milton S. Hershey Medical Center|Yes|Active, not recruiting|May 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01124734||122136|
NCT01124747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1585-CL-0011|A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug|An Open-Label Study to Evaluate the Disposition of 14C-Labeled ASP1585 in Healthy Male Volunteers||Astellas Pharma Inc|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 2, 2014|May 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01124747||122135|
NCT01125267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH064542-05|Promoting Adherence to Treatment in Schizophrenia|Promoting Adherence to Treatment in Schizophrenia||University of California, Los Angeles|No|Completed|April 2003|October 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|174|||Both|18 Years|50 Years|No|||May 2010|May 17, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125267||122095|
NCT01130168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-166|The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Crossover Study to Evaluate the Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Subjects and Patients With Hypertension||Merck Sharp & Dohme Corp.|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|38|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|May 19, 2010|No|Yes||No|February 23, 2012|https://clinicaltrials.gov/show/NCT01130168||121723|
NCT01130467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-098034-3|Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder|||Far Eastern Memorial Hospital||Recruiting|September 2009|||December 2011|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|One hundred and fifty children, aged 6-18 years old, are enrolled. ADHD children fulfill        the DSM-IV-TR criteria for the diagnosis of ADHD. ADHD children are evaluated by Chinese        version of SNAP-IV Rating Scale for rating ADHD-related symptoms before and after        medication. EEG and audiometric testing are required for every participant to exclude        dialeptic seizures and hearing impairment respectively. Urine pregnancy test is performed        to exclude pregnant participants. Each participant is evaluated by both pediatric        neurologists and child psychiatrists after enrollment to delineate possible underlying        comorbidities. Three groups of participants were assigned: normal control group, pure ADHD        group and ADHD with comorbidity group.|May 2010|August 8, 2010|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01130467||121701|
NCT01126970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002A2828|Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects|A Double-Blind, Multi-Center, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of 400 mg of Velneperit (S-2367) and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day With a Reduced Calorie Diet (RCD) in Obese Subjects||Shionogi Inc.|Yes|Completed|April 2010|||January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|486|||Both|18 Years|65 Years|No|||July 2011|September 13, 2011|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01126970||121965|
NCT01126983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|spinecareleads|Lead Migration in Spinal Cord Stimulation Trials: Comparing Non-suture vs Suture and Lead Anchor|Lead Migration in Spinal Cord Stimulation Trials: Comparing Non-suture vs Suture and Lead Anchor Securing Methods: A Randomized Single Blind Clinical Trial for Better Outcomes.||Spine Care, Oklahoma|No|Completed|May 2010|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|95 Years|No|||July 2010|July 7, 2010|May 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01126983||121964|
NCT01127191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901110|Effect of Prolonged Military Exercises With High Load Carriage, on Neuromuscular Fatigue and Physiological/Biomechanical Responses|||Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|March 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Lactatemia, based on subject's arterialized capillary blood samples analysis.|Male|30 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|military retreated from national army|July 2012|July 24, 2012|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01127191||121948|
NCT01127490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUL2009-FFMS|Study to Assess Mechanisms in Peripheral Tissue Innervation for Fibromyalgia|Duloxetine(Cymbalta) for Fibromyalgia: An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Duloxetine||Albany Medical College|No|Recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||December 2010|June 21, 2011|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01127490||121925|
NCT01127724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC105709KCTIL|Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis|Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis||Meir Medical Center|Yes|Terminated|June 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|N/A|No|||April 2013|November 18, 2014|May 20, 2010||No|difficulties in recruiting participants|No||https://clinicaltrials.gov/show/NCT01127724||121907|
NCT01127737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-090607|Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients|Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients|SCCs in OTRs|Northwestern University|No|Completed|September 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|75|||Both|18 Years|85 Years|No|||March 2015|March 17, 2015|May 19, 2010||No||No|April 13, 2011|https://clinicaltrials.gov/show/NCT01127737||121906|Small sample at a single center for a limited period of follow-upThe dermatologists' assessment of the participants' concerning lesions was not performed
NCT01128309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000947|Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain|Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain||Massachusetts General Hospital|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||May 2012|May 4, 2012|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01128309||121863|
NCT01128322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128HT09K|CKD-828 Primary Hypertension Trial(Dose-selection)|A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension||Chong Kun Dang Pharmaceutical||Completed|July 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Anticipated|430|||Both|18 Years|N/A|No|||April 2011|April 22, 2011|May 20, 2010||||No||https://clinicaltrials.gov/show/NCT01128322||121862|
NCT01128621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113132|A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263|A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263||GlaxoSmithKline|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|66|||Both|18 Years|65 Years|No|||March 2012|March 29, 2012|February 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128621||121841|
NCT01128634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113950|Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects|A Single-Centre, Randomised, Open-label Study to Evaluate the Effects of Steady-State Verapamil, a Moderate P-Glycoprotein and CYP3A4 Inhibitor, on the Pharmacokinetics of GSK573719 and GSK573719 in Combination With GW642444||GlaxoSmithKline|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|August 23, 2012|May 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01128634||121840|
NCT01128647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocole 59/09|Disposal of Oral Fructose During Exercise|Disposal of Oral Fructose During Exercise||University of Lausanne|No|Completed|April 2009|March 2010|Actual|December 2009|Actual|N/A|Observational|N/A||1|Actual|7|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, endurance trained male volunteers|February 2013|February 12, 2013|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128647||121839|
NCT01120535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crux04|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 4 (RETRIEVE 4)|RETRIEVE 4|Crux Biomedical|Yes|Completed|May 2010|January 2012|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2012|June 26, 2014|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01120535||122458|
NCT01120756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7467-I|Neural Bases of Cognitive Rehabilitation for Brain Injury|Neural Bases of Cognitive Rehabilitation for Brain Injury||VA Office of Research and Development|Yes|Recruiting|October 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|210|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120756||122441|
NCT01129570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE7604|Siliphos in Advanced Hepatocellular Carcinoma|Phase I Trial of Siliphos in Patients With Advanced Hepatocellular Carcinoma||Columbia University|Yes|Completed|February 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|April 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129570||121768|
NCT01123746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98088|Utility of Laboratory Testing for Children With Seizure in Emergency Department|||Taipei Medical University WanFang Hospital|No|Completed|October 2009|April 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|18 Years|No|Non-Probability Sample|500 patients who come to wanfang hospital due to seizure|May 2010|May 12, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123746||122212|
NCT01123759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA-CSREES 07-5110-03804|Healthful Seafood Consumption for Sensitive Populations|Consuming Fish to Reduce Mercury Intake While Optimizing Omega-3 Fatty Acid Status||Purdue University|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|71|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2010|May 13, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01123759||122211|
NCT01124214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00025471|Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study)|In Vivo Endomicroscopy (EM) for Improved Diagnosis of Barrett's Esophagus (BE) and Associated Neoplasia: A Multicenter Randomized Controlled Trial of Diagnostic Yield and Clinical Impact|CEBE|Johns Hopkins University|Yes|Completed|July 2010|June 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|68|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124214||122176|
NCT01124227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDinCHF|Peritoneal Dialysis in Congestive Heart Failure|Symptomatic Improvement by Peritoneal Dialysis in Patients With End Stage Congestive Heart Failure|PDinCHF|Martini Hospital Groningen|Yes|Recruiting|April 2010|April 2014|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01124227||122175|
NCT01124760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2690C00008|Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers|A Phase I, Single Center, Open Label, 2-consecutive-group, 2-period, 1-sequence Crossover Study to Assess the Effect of Diltiazem (Cardizem), a Moderate CYP3A4 Inhibitor, or Ketoconazole, a Potent CYP3A4 Inhibitor, on the Pharmacokinetics of a Single Intravenous Dose of 150mg of AZD9742.||AstraZeneca|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|23 Years|45 Years|Accepts Healthy Volunteers|||August 2010|August 2, 2010|May 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01124760||122134|
NCT01125007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FranciscanUC|Capacity of Biofilm Removal and Gingival Abrasion After Utilization Medium and Soft Toothbrushes|Biofilm Capacity Removal and Gingival Abrasion After Utilization Medium and Soft Toothbrushes||Franciscan University Center|Yes|Completed|January 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|25|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2009|May 17, 2010|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01125007||122115|
NCT01125020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008BAI60B03|Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation|||Shanghai Jiao Tong University School of Medicine||Recruiting|December 2008|December 2010|Anticipated|May 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2010|May 17, 2010|May 17, 2010||||No||https://clinicaltrials.gov/show/NCT01125020||122114|
NCT01125787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVCI 09-14|Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab|PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB||Nevada Cancer Institute|Yes|Terminated|May 2010|April 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|May 14, 2010|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT01125787||122055|
NCT01130181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITdAL@ICU - 19022010|VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients|Correction of Vitamin D Deficiency in Critically Ill Patients: a Randomized, Double-blind, Placebo-controlled Trial ("VITDAL@ICU")|VITdAL@ICU|Medical University of Graz|Yes|Completed|May 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01130181||121722|
NCT01130207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microbes and Bariatric Surgery|Microbes and Bariatric Surgery|Effects of Bariatric Surgery on the Gastro-intestinal Microflora||State University of New York - Upstate Medical University|No|Completed|May 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|34|Samples With DNA|Bacterial samples from dental plaque and feces, and serum|Both|18 Years|65 Years|No|Non-Probability Sample|Patients with obesity who are already accepted for treatment by bariatric surgery in        Syracuse NY|November 2014|November 17, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130207||121720|
NCT01126398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEFTOM|Trauma Expectation Factor Trauma Outcome Measure|The Role of Patient Expectations in Traumatic Orthopedic Outcomes: the Development of the Trauma Expectation Factor Trauma Outcome Measure (TEFTOM)||AO Clinical Investigation and Documentation|No|Completed|February 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|204|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who expericenced an ankle or pilon fracture presenting to the emergency room        or orthopedic department were asked to participate.|May 2010|May 18, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126398||122008|
NCT01127230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2010/03/14-S0001|Comparison Between Celution Preparation and Manual Preparation of Adipocyte Derived Regenerative Cells, Using Stromal Vascular Fraction Cell Counts (COMPARE)|Comparison Between Celution Preparation and Manual Preparation of Adipocyte Derived Regenerative Cells, Using Stromal Vascular Fraction Cell Counts (COMPARE)|COMPARE|Novena Medical Center|Yes|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|N/A||1|Anticipated|100|Samples With DNA|Lipoaspirate from liposuction.|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Liposuction Patients|July 2010|July 16, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127230||121945|
NCT01127204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12206 MONOD|Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age|Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, Côte d'Ivoire, Rwanda)||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|June 2011|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|3 Months|12 Months|No|||February 2016|February 19, 2016|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127204||121947|
NCT01127217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ALOS-303|Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension|The Multicenter, Randomized, Double Blind Phase 3 Clinical Trial to Compare Efficacy and Safety of Combination of Amlodipine and Losartan Compared to Amlodipine Monotherapy in Patients With Stage 2 Hypertension||Hanmi Pharmaceutical Company Limited|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||September 2010|September 12, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127217||121946|
NCT01127802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003017R|Changes of Functional Status, Symptoms Distress and Quality of Life in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|Changes of Functional Status, Symptoms Distress and Quality of Life in Patients Undergoing CABG Surgery||National Taiwan University Hospital|Yes|Enrolling by invitation|January 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|95 Years|No|Non-Probability Sample|patients undergoing elective CABG surgery|May 2010|May 20, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127802||121901|
NCT01127763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 09-0060|RAD001 Plus Carboplatin in Breast Cancer Patients|Phase II Trial of RAD001 Plus Carboplatin in Patients With Triple-Negative Metastatic Breast Cancer||New York University School of Medicine|Yes|Completed|June 2010|March 2013|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||March 2014|March 11, 2014|May 19, 2010|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01127763||121904|
NCT01128023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211897|Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)|Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)|Rb-ARMI|Ottawa Heart Institute Research Corporation|No|Active, not recruiting|April 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|||Both|18 Years|N/A|No|Probability Sample|Patients referred for a clinically indicated PET Rb-82 myocardial perfusion scan.|January 2016|January 4, 2016|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01128023||121884|
NCT01128036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPO0054|Comparison of Different Locations for Pulse Oximetry Probes in Cardiovascular (CV) Patients With Poor Peripheral Perfusion|Comparison of Different Locations for Pulse Oximetry Probes in Adult Cardiovascular Patients With Poor Peripheral Perfusion||Saint Luke's Health System|No|Terminated|May 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the CICU (Coronary Intensive Coronary Unit) with congestive heart        failure or cardiomyopathy|August 2011|August 8, 2011|May 20, 2010||No|Terminated due to software issues.|No||https://clinicaltrials.gov/show/NCT01128036||121883|
NCT01128361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11969|Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD)|Alzheimer's Disease Exercise Prevention Trial||University of Kansas Medical Center|Yes|Completed|May 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|55 Years|N/A|No|||April 2015|April 19, 2015|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01128361||121859|
NCT01128946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3500690|Enamel Remineralization Potential of Dentifrices in Situ|Comparison of Enamel Remineralization Potential of Dentifrices Incorporating Different Fluoride Salts Using an in Situ Caries Model||GlaxoSmithKline|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|83|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|May 20, 2010|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01128946||121816|
NCT01129297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_0620|A Biological Atlas of Severe Obesity (Biological Tissue Collection)|Influence of the Glycemic and Ponderal Status on Tissues Gene Expression (Biological Tissue Collection)|ABOS|University Hospital, Lille|Yes|Recruiting|June 2006|January 2025|Anticipated|January 2025|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|20000|Samples With DNA|-  Liver samples before and at 1 and 5 years after bariatric surgery        -  Muscle samples before and at 1 year after bariatric surgery        -  Subcutaneous fat samples before and at 3 month and 1 year after bariatric surgery        -  Visceral fat samples in the great omentum before bariatric surgery        -  Intestinal samples during gastric by-pass surgery        -  Blood samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruiting: Clinical Medical Center from the north of France|December 2015|December 1, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01129297||121789|
NCT01129830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRM 3|The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve|The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve||Virginia Center for Reproductive Medicine|Yes|Terminated|January 2010|September 2014|Actual|September 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Female|21 Years|44 Years|No|||September 2014|September 18, 2014|May 19, 2010||No|Suboptimal recruitment|No||https://clinicaltrials.gov/show/NCT01129830||121748|
NCT01129843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.SSD/WS/102/2008|Directly Observed Iron Supplementation to Treat Anemia|A Cluster Randomized Trial for Lowering Prevalence of Anemia in Rural Hilly Villages With Directly Observed Home Based Daily Iron Therapy(DOHBIT)|DOHBIT|Build Healthy India Movement|Yes|Completed|May 2010|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Female|13 Years|N/A|No|||May 2011|May 28, 2011|May 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01129843||121747|
NCT01124240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910259M|Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene|Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene|ExCentric|Northern Sydney and Central Coast Area Health Service|Yes|Recruiting|November 2009|January 2014|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124240||122174|
NCT01124253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endo001|Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)|Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer|Dengshan|Shanghai Jiao Tong University School of Medicine|Yes|Completed|July 2007|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|70 Years|No|||October 2009|May 14, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01124253||122173|
NCT01124006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-Intradiscal rhGDF-5-04|A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration|||DePuy Spine||Completed|January 2010|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 11, 2010|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01124006||122192|
NCT01128790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0550-BE|Pilot Study of Remote Ischemic Preconditioning in Heart Failure|Effect of Remote Ischemic Preconditioning on Exercise Capacity in Patients With Heart Failure: A Double Blind Randomized Control Trial||University Health Network, Toronto|No|Completed|October 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||December 2013|December 20, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01128790||121828|
NCT01125033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86-3893|Study of Vitamin C, Vitamin E and Their Combination to Treat Restless Legs Syndrome in Hemodialysis Patients|Efficacy of Vitamin C, Vitamin E and Their Combination for Treatment of Restless Legs Syndrome in Hemodialysis Patients: a Randomized Double-blind, Placebo-controlled Trial|ShirazUMS|Shiraz University of Medical Sciences|Yes|Completed|March 2008|February 2009|Actual|January 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|75 Years|No|||June 2011|June 16, 2011|May 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01125033||122113|
NCT01125280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 10-009|Prospective Multicenter Validation of a Severity Score of Strangulated Small Bowel Occlusion|Prospective Multicenter Validation of a Clinicoradiological Score for Predicting the Severity of Strangulated Small Bowel Occlusion||University Hospital, Geneva|No|Not yet recruiting|July 2010|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|16 Years|N/A|No|||May 2010|May 17, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01125280||122094|
NCT01125553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1980|A Comparison Between Two Formulations of NN5401 in Healthy Subjects|A Trial to Test for Bioequivalence Between Two NN5401 Formulations in Healthy Subjects||Novo Nordisk A/S|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|May 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01125553||122073|
NCT01129856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-003|Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye|Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for the Treatment of Dry Eye in the Controlled Adverse Environment (CAE) Model||Eyegate Pharmaceuticals, Inc.|No|Completed|June 2010|April 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|198|||Both|12 Years|N/A|No|||April 2011|April 25, 2011|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129856||121746|
NCT01126424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-008|A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability|A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study|SENIOR|Astellas Pharma Inc|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|26|||Both|75 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 13, 2012|April 29, 2010|Yes|Yes||No|July 5, 2012|https://clinicaltrials.gov/show/NCT01126424||122006|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01126710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-2010-01|Optical Detection of Intravenous Infiltration|Optical Detection of Intravenous Infiltration||CW Optics, Inc.||Completed|May 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|263|||Both|3 Years|N/A|No|Non-Probability Sample|Subjects recruited from the patient population at Virginia Commonwealth University Health        System will be enrolled in the Study.|February 2012|February 9, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126710||121985|
NCT01127243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08447a|Day-case Versus Inpatient Laparoscopic Supracervical Hysterectomy|Do Women Prefer to Stay in Hospital Following Hysterectomy? A Randomised Trial of Day-case Versus Inpatient Laparoscopic Supracervical Hysterectomy||Oslo University Hospital|No|Completed|June 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Female|N/A|N/A|No|||June 2009|May 19, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127243||121944|
NCT01127503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-MET-101|Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome|A Double-Blind, Placebo-Controlled, Multi-Center, Randomized Trial of the Safety and Efficacy of Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velo-Cardio-Facial Syndrome||Valeant Pharmaceuticals International, Inc.|No|Terminated|June 2010|September 2011|Anticipated|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|16 Years|65 Years|No|||September 2011|September 28, 2011|May 19, 2010|Yes|Yes|Enrollment, study-design and execution challenges.|No||https://clinicaltrials.gov/show/NCT01127503||121924|
NCT01127815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201004002R|Identify the Clinical Significance and Potential Implications of Peritoneal Washing Cytology (PWC) in Patients With Pancreatic Cancer|Identify the Clinical Significance and Potential Implications of PWC in Patients With Pancreatic Cancer||National Taiwan University Hospital|Yes|Active, not recruiting|March 2010|December 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case Control||1|Anticipated|300|Samples With DNA|peritoneal washing cells, postoperative drainage, and parts of tumor tissues|Both|20 Years|90 Years|No|Non-Probability Sample|operated in Surgical Department of National Taiwan University Hospital|May 2010|May 20, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127815||121900|
NCT01128062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHARMS-8310|Canthaxanthin Retinopathy: A Long-term Observation|||University of Cologne|No|Completed|December 1983|May 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a history of oral tanning agents should report at the University Eye        hospital for examination.|May 2010|May 20, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128062||121881|
NCT01127776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC9181-09CTIL|Bi-trimalleolar Fracture and APOS System Treatment|APOS System Effects in Post-operation Bi-trimalleolar Fracture of Ankle Prospective, Comparative Randomize Trial Study|APOS-IL 001|Meir Medical Center||Recruiting|October 2010|May 2012|Anticipated|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2012|March 16, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01127776||121903|
NCT01127789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910005R|The Use of Transcranial Direct Current Stimulation (tDCS) to Study Implicit Motor Learning on Patients With Brain Injury|The Use of Transcranial Direct Current Stimulation (tDCS) to Study Implicit Motor Learning on Patients With Brain Injury||National Taiwan University Hospital|Yes|Withdrawn|March 2010|November 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||November 2012|December 20, 2012|March 8, 2010||No|test device not approved to be used|No||https://clinicaltrials.gov/show/NCT01127789||121902|
NCT01128374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR024148 (CTSA)|The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes|The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 DiabetesS||The University of Texas Health Science Center, Houston|Yes|Completed|June 2010|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|134|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128374||121858|
NCT01128660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH-AP-001|Assessment of the Prescriber's and the Pharmacies Overview of Patient Medication by Use of the Fidelity Coefficient.|Assessment of the Prescriber's and the Pharmacies Overview of Patient Medication by Use of the Fidelity Coefficient.||University of Southern Denmark|No|Completed|June 2010|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|283388|||Both|N/A|N/A|No|Probability Sample|Residents of Region of Southern Denmark during 2009.|February 2013|February 1, 2013|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128660||121838|
NCT01126320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HST -AG -02|Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated Patients Using the AnapnoGuard System|Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated ICU Patients Using the AnapnoGuard System||Hospitech Respiration|No|Completed|December 2010|December 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|161|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01126320||122014|
NCT01129323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07081|Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia|Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia||City of Hope Medical Center|Yes|Withdrawn|November 2009|||September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|21 Years|No|||March 2012|March 23, 2012|April 21, 2010|No|Yes|This study did not accrue any subjects and due to this will be closed.|No||https://clinicaltrials.gov/show/NCT01129323||121787|
NCT01121432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003061R|Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)|Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)||National Taiwan University Hospital|No|Recruiting|April 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Mediastinal lymph nodes|Both|18 Years|N/A|No|Non-Probability Sample|The patients with mediastinal lymphadenopathy of unknow etiology|April 2010|May 11, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121432||122389|
NCT01121731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAHE001-CHC-01|A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C|Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C||Digna Biotech S.L.|Yes|Completed|May 2010|January 2013|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01121731||122366|
NCT01128543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112564|Lapatinib in Combination With Vinorelbine|A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer||GlaxoSmithKline|No|Completed|April 2009|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Female|18 Years|N/A|No|||November 2012|November 15, 2012|May 20, 2010|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT01128543||121847|
NCT01128777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH082164|Teens Coping With Parental Military Deployment|Mental Health Intervention for Teens Coping With Parental Military Deployment|Helping Hand|Brown University|Yes|Terminated|January 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|13 Years|17 Years|No|||July 2012|July 3, 2013|May 21, 2010||No|Terminated due to difficuly recruiting participants|No||https://clinicaltrials.gov/show/NCT01128777||121829|
NCT01128803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/9-P|Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response|Phase I/II Multicenter: Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response||Nantes University Hospital|No|Terminated|October 2009|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||November 2013|November 6, 2013|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128803||121827|
NCT01128816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVENT-HF trial|Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure|A Multi-Centre, Randomized Study to Assess the Effects of Adaptive Servo Ventilation (ASV) on Survival and Frequency of Hospital Admissions in Patients With Heart Failure (HF) and Sleep Apnea (SA)-The ADVENT-HF Trial|ADVENT-HF|Toronto Rehabilitation Institute|Yes|Recruiting|May 2010|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|860|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|April 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128816||121826|
NCT01124526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNHF-03.|Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma|Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma||Asociacion Espanola de Hematologia y Hemoterapia|Yes|Completed|September 2004|July 2008|Actual|July 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|75 Years|No|||May 2010|May 14, 2010|February 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01124526||122152|
NCT01124539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARN-AR67-IIS202|Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma|A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma||Arno Therapeutics|No|Active, not recruiting|December 2009|February 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||January 2014|December 8, 2014|May 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01124539||122151|
NCT01124773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|699|Memory Study of Youngest Women Enrolled in the Women's Health Initiative Hormone Therapy (HT) Arm|Women's Health Initiative Memory Study of Younger Women|WHIMS-Y|Wake Forest Baptist Health|Yes|Active, not recruiting|June 2009|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1362|||Female|50 Years|54 Years|Accepts Healthy Volunteers|Probability Sample|Women who enrolled into the HT arm of the Women's Health Initiative when age 50-54 at the        time of randomization.|June 2015|June 1, 2015|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01124773||122133|
NCT01129362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5A16|Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines|Surveillance for Rates of Pertussis Disease Among Persons Birth Through 59 Months of Age Receiving Pentacel® or Other Pertussis Vaccines||Sanofi|No|Active, not recruiting|May 2010|June 2016|Anticipated|February 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|19172|||Both|N/A|59 Months|Accepts Healthy Volunteers|Non-Probability Sample|Wisconsin residents younger than 60 months of age.|February 2016|February 11, 2016|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129362||121784|
NCT01129596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART05T|Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-|Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-||Eisai Inc.||Active, not recruiting|June 2010|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Hospital, Clinical. Japan|April 2015|April 7, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129596||121766|
NCT01129869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910127|Research Participant Perception of Care Project: Part II: Fielding and Validation of the Research Participant Perception Survey Derived From Focus Group-Identified Key Dimensions of the Research Participant Experience|Research Participant Perception of Care Project: Part II: Fielding and Validation of the Research Participant Perception Survey Derived From Focus Group-Identified Key Dimensions of the Research Participant Experience||National Institutes of Health Clinical Center (CC)||Completed|May 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|750|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01129869||121745|
NCT01126177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG005|Comparing Efficacy and Safety of Inhaled SNG001 to Placebo|A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses||Synairgen Research Ltd.|Yes|Completed|March 2010|January 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|65 Years|No|||February 2012|February 10, 2012|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126177||122025|
NCT01126190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUGR-003|Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)|A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Neugranin or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy|NEUGR-003|Teva Pharmaceutical Industries|Yes|Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|381|||Both|18 Years|N/A|No|||August 2013|August 28, 2013|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126190||122024|
NCT01126411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IA-2010-001|Immunoadsorption in Patients With Pulmonary Hypertension|Randomized, Prospective Investigation on the Effects of Immunoadsorption on Pulmonary Vascular Resistance in Patients With Pulmonary Hypertension||University Medicine Greifswald|No|Recruiting|October 2009|December 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2010|May 18, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01126411||122007|
NCT01126723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005|Effects of Tai Chi on Frailty in Elderly Adults|The Effects of Tai Chi on the Nonlinear Dynamics of Frailty in Elderly Adults||Hebrew Rehabilitation Center, Boston|No|Completed|September 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|70 Years|N/A|No|||February 2015|February 4, 2015|May 18, 2010||No||No|January 20, 2015|https://clinicaltrials.gov/show/NCT01126723||121984|
NCT01128088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURGN0008|The Stress Response in Laparoscopic Colorectal Surgery and Its Role in the Development of the Enhanced Recovery Program.|The Stress Response in Laparoscopic Colorectal Surgery and Its Role in the Development of the Enhanced Recovery Program.||University of Surrey|No|Completed|March 2010|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|133|||Both|18 Years|N/A|No|Probability Sample|Patients having colorectal resections at The Royal Surrey County Hospital|May 2014|May 20, 2014|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128088||121879|
NCT01127516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT105051|The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus|The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus to Vancomycin Among a Network of Academic Medical Center Hospitals||Virginia Commonwealth University|No|Completed|April 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Adult inpatients|July 2014|July 8, 2014|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127516||121923|
NCT01127529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400701|Ceprotin Treatment Registry|Ceprotin Treatment Registry||Baxalta US Inc.|No|Completed|June 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Both|N/A|N/A|No|Non-Probability Sample|Registry participants will be identified by working with Hemophilia Treatment Centers and        Thrombosis Centers known to have participants with severe congenital Protein C deficiency,        as well as by working with centers that use CEPROTIN in emergency care situations.|July 2015|July 10, 2015|April 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01127529||121922|
NCT01127542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09_DOG06_99|RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial|A Single Arm Phase II Study to Investigate the Use of Lenalidomide in the Treatment of Patients With Early Stage CLL Associated With Poor Prognostic Factors|RESPeCT|Christie Hospital NHS Foundation Trust|Yes|Terminated|May 2010|December 2011|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|May 19, 2010||No|Potential safety issue of second primary malignancies in patients treated with lenalidomide.|No||https://clinicaltrials.gov/show/NCT01127542||121921|
NCT01128673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090575Walsh|MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE)|MRI Thermal Imaging of Infants Undergoing Cooling for HIE||Vanderbilt University|Yes|Withdrawn|May 2010|June 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|0|||Both|N/A|1 Week|No|Non-Probability Sample|Infants with Hypoxic ischemic encephalopathy undergoing cooling|June 2015|June 1, 2015|May 20, 2010||No|No funding|No||https://clinicaltrials.gov/show/NCT01128673||121837|
NCT01128049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B&L 32280|Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation|Non-invasive Tear Film Dynamic Measurements in Normal, MGD (Meibomium Gland Dysfunction) and Aqueous Deficient Dry Eye(ADDE) Subjects After Saline Instillation||University of Rochester|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|15|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|May 19, 2010|Yes|Yes||No|May 25, 2015|https://clinicaltrials.gov/show/NCT01128049||121882|
NCT01128933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P05B02530|Renal Fractional Flow Reserve in Renal Artery Stenting|Prognostic Value of Renal Fractional Flow Reserve in Hypertensive Patients With Renal Artery Stenosis Qualified to Renal Artery Stenting|PREFFER|Institute of Cardiology, Warsaw, Poland|No|Completed|June 2006|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|75 Years|No|||May 2010|May 21, 2010|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128933||121817|
NCT01129063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKM11086|Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects|An Open-label, Two-treatment Crossover Pharmacokinetic Study of Clopidogrel Hydrogen Sulfate in Healthy Male and Female Subjects||Sanofi|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 27, 2010|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129063||121807|
NCT01129310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXOGoo1 25412|First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.|A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma.|IXOGoo1|AHS Cancer Control Alberta|Yes|Active, not recruiting|July 2010|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129310||121788|
NCT01129583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA8392|Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness|Intraoperative Injection of Botulinum Toxin A (Botox) for the Prevention of Post-Traumatic Elbow Stiffness: A Randomized Double Blind Placebo Controlled Study||Columbia University|No|Completed|November 2003|May 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|May 21, 2010||No||No|June 16, 2010|https://clinicaltrials.gov/show/NCT01129583||121767|Limited statistical power: Limitations in time and funding as well as difficulties in recruitingBlinding challenges: Weakness in the flexor muscles of patients receiving botulinum toxin injections was clinically apparent
NCT01121445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #041001|The Impact of Daily Sinus Irrigation on Nasal Symptoms in Continuous Positive Airway Pressure (CPAP) Users - A Pilot Study|||Bridgeport Hospital|No|Recruiting|May 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||May 2010|May 11, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01121445||122388|
NCT01117857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000956|Duloxetine for Menopausal Depression|Duloxetine for Menopausal Depression||Massachusetts General Hospital|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|40 Years|N/A|No|||August 2014|August 5, 2014|May 3, 2010||No||No|July 3, 2014|https://clinicaltrials.gov/show/NCT01117857||122663|
NCT01118091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100117|Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...|Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)|No|Completed|April 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|May 5, 2010|No|Yes||No|November 9, 2012|https://clinicaltrials.gov/show/NCT01118091||122645|
NCT01128556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-01-10|The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing|The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing||North Texas Institute for Clinical Trials|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 7, 2010|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128556||121846|
NCT01128829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0583/ 201102383|Sugar-replacement Sweeteners, and Blood Sugar Control|Regulation of Incretin Release by Non-nutritive Sweeteners in Humans|SIR|Washington University School of Medicine|Yes|Completed|May 2010|October 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|May 20, 2010||No||No|June 2, 2014|https://clinicaltrials.gov/show/NCT01128829||121825|
NCT01128842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3144A1-1122|A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor|A Phase 1, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Japanese Subject With Solid Tumors||Puma Biotechnology, Inc.|Yes|Completed|April 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|20 Years|N/A|No|||May 2012|May 10, 2012|May 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01128842||121824|
NCT01128855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114118|A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects|A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Subcutaneous Injections of GSK2402968 in Non-ambulant Subjects With Duchenne Muscular Dystrophy|DEMAND I|GlaxoSmithKline|Yes|Completed|July 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|20|||Male|9 Years|N/A|No|||July 2013|July 18, 2013|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128855||121823|
NCT01129089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917548-1|Acceptability of Nutrient Supplements Among Women and Children in Bangladesh|Acceptability of Lipid-based Nutrient Supplements (LNS) and Micronutrient Powder (MNP) for Women and Infants in Bangladesh||University of California, Davis|No|Completed|December 2009|February 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|144|||Both|6 Months|49 Years|No|||May 2010|May 20, 2010|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01129089||121805|
NCT01129375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT11146|Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects||Sanofi|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129375||121783|
NCT01129609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Investigational Plan #119|Talent Converter Post-Approval Study|Talent Converter Post-Approval Study||Medtronic Endovascular|No|Active, not recruiting|April 2010|April 2018|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects who are treated with the Talent Converter Stent Graft according to the        indications for use|January 2016|January 25, 2016|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129609||121765|
NCT01129895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unilever-0410-OL|Promoting Health by Self Experience (PHASE) Randomized Controlled Trial|Promoting Health by Self Experience (PHASE) Randomized Controlled Trial|PHASE|Unilever Israel|No|Recruiting|April 2010|May 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|650|||Both|21 Years|50 Years|No|||June 2010|June 2, 2010|May 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01129895||121743|
NCT01130194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #14228|Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma|A Pilot Phase II Study Of Sequential Treatment With Chemotherapy, Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Follicular Lymphoma|MasterPlan|St. Louis University|Yes|Completed|July 2006|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|80 Years|No|||May 2014|May 9, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130194||121721|
NCT01126437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.452|Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease|A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)||Boehringer Ingelheim||Completed|May 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|17183|||Both|40 Years|N/A|No|||May 2014|May 20, 2014|May 6, 2010||||No|May 20, 2014|https://clinicaltrials.gov/show/NCT01126437||122005|Prospectively defined outcome events, serious adverse events, adverse events leading to discontinuation, and investigator-determined drug-related adverse events were required for collection in this trial.
NCT01126450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8208|Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer|A Phase I, Open-Label Study To Determine The Maximum Tolerated Dose (Mtd) Of The Combination Of Lenalidomide And Cetuximab, And To Evaluate The Efficacy Of This Combination In Subjects With Wild Type K-Ras Metastatic Colorectal Carcinoma||Case Comprehensive Cancer Center|Yes|Terminated|October 2009|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|May 18, 2010|No|Yes|low accrual,loss of funding and results from EU study showing drug ineffective.|No||https://clinicaltrials.gov/show/NCT01126450||122004|
NCT01126736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-701|Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer||Eisai Inc.|No|Active, not recruiting|March 2010|May 2015|Anticipated|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||December 2014|January 23, 2015|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126736||121983|
NCT01126307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB # 10-0024-A|Study of Verapamil in Refractory Epilepsy|||University Health Network, Toronto|No|Not yet recruiting|June 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|60 Years|No|||March 2010|May 18, 2010|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126307||122015|
NCT01127295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 SEIN 09|Pharmacology of Adjuvant Hormonotherapy in Breast Cancer|Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer|PHACS|Institut Claudius Regaud|Yes|Active, not recruiting|May 2010|June 2019|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Female|18 Years|N/A|No|||March 2015|March 26, 2015|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01127295||121940|
NCT01128400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0873|Fat Perception in Humans (09-0873)|Inhibition of Lipolysis in Oral Cavity and Fat Perception in Humans|OT|Washington University School of Medicine|No|Completed|May 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|40|Samples With DNA|whole blood will be collected and frozen|Both|21 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 40 obese subjects will participate in this study. Subjects will be men and        women and will include all races and ethnic groups. The two groups (carriers and non-will        be matched as closely as possible in age, sex, body mass index (kg/m2) and race        distributions.|October 2013|June 2, 2014|May 20, 2010||No||No|June 2, 2014|https://clinicaltrials.gov/show/NCT01128400||121856|
NCT01128114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00080|Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy|A 4-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Broad Clinical Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy|RELEASE|AstraZeneca|No|Terminated|June 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|No|||April 2012|April 11, 2012|May 20, 2010|Yes|Yes|Poor recruitment|No|May 24, 2011|https://clinicaltrials.gov/show/NCT01128114||121877|In March 2011, considering the low patient inclusion rate (32 patients recruited so far whereas study objective was 125 patients for 85 completers), the study was ended prematurely earlier than the planned date. No analysis was conducted afterwards.
NCT01128127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 43 08|Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription Associated to Non-steroidal Anti-inflammatory Drugs (NSAIDs)|Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription for Gastropathy Prevention Due to Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Primary Health Care||Servicio Canario de Salud|No|Withdrawn|January 2013|June 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|0|||Both|N/A|N/A|No|||September 2012|September 13, 2012|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128127||121876|
NCT01128075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR701068-520|Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects|Multi-center, Two-arm Non-comparative, Observational, 96-week Phase IV Study to Evaluate Treatment Adherence When Using RebiSmart™ for Self-injection of Rebif® in Multi-dose Cartridges in Subjects With Relapsing Multiple Sclerosis (RMS)|MEASURE|Merck KGaA|No|Completed|August 2009|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|198|||Both|18 Years|65 Years|No|Probability Sample|Community and Academic MS clinics|July 2014|July 8, 2014|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128075||121880|
NCT01128387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0214|Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer|A Phase I/II Study of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation Preoperatively for Patients With Locally Advanced Esophageal Cancer||University of Wisconsin, Madison|Yes|Active, not recruiting|May 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128387||121857|
NCT01129232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1907 (REK)|Diabetes Virus Detection Project, Intervention With GAD-alum|A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis|DiViD|Oslo University Hospital|Yes|Recruiting|January 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|No|||April 2011|May 3, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01129232||121794|
NCT01129765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-002|Home Usability of a Nasal Lavage System in Children|Home Usability of a Nasal Lavage System in Children||Aardvark Medical Company|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|N/A|5 Years|No|Non-Probability Sample|The participants were selected from a primary care pediatric clinic.|July 2010|July 27, 2010|May 21, 2010|No|Yes||No|June 2, 2010|https://clinicaltrials.gov/show/NCT01129765||121753|
NCT01129336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446EUS147|Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients|A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis|MACS1295|Novartis||Completed|June 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Female|18 Years|N/A|No|||May 2014|May 9, 2014|May 20, 2010|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01129336||121786|
NCT01129349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-003|Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors|A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors||Onyx Pharmaceuticals|No|Completed|April 2010|March 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129349||121785|
NCT01121120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2009-001|Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients|Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells|TXA127-PBSC|US Biotest, Inc.|Yes|Active, not recruiting|June 2010|June 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|74|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|May 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121120||122413|
NCT01121133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-955|A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax|A Phase I Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of ABT-263 (Navitoclax)||Abbott|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2011|June 4, 2011|May 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01121133||122412|
NCT01121419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002039R|The Role of IMP3 Expression in Patients With Neuroblastoma|The Role of IMP3 Expression in Patients With Neuroblastoma||National Taiwan University Hospital|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|N/A|18 Years|No|Non-Probability Sample|From January 1990 to December 2009, 90 pediatric patients of NB treated at the National        Taiwan University Hospital, Taiwan|May 2010|May 20, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01121419||122390|
NCT01118104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK57|Sickness Absence Versus Physical, Mental, and Job-related Factors in Patients With Chronic Pulmonary Disease|Relationships Between Sickness Absence and Physical, Mental, and Job-related Factors in Patients With Chronic Pulmonary Disease||LHL Helse|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|318|||Both|18 Years|65 Years|No|||May 2012|May 14, 2012|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01118104||122644|
NCT01118117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIS2009-02|A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery|A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery|OSPREY|Terumo Medical Corporation|Yes|Active, not recruiting|July 2010|May 2016|Anticipated|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|276|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|May 4, 2010|Yes|Yes||No|June 18, 2015|https://clinicaltrials.gov/show/NCT01118117||122643|
NCT01128569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113090|Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response|A Randomised, Double-blind, Placebo-controlled, Three-way Crossover, Repeat Dose Pilot Study Comparing the Effect of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and Fluticasone Furoate on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma||GlaxoSmithKline|No|Completed|January 2010|December 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|65 Years|No|||September 2013|May 29, 2014|May 20, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01128569||121845|
NCT01129141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7452-I|Telephone Tinnitus Education for Patients With Traumatic Brain Injury (TBI)|Telehealth Tinnitus Intervention for Patients With TBI||VA Office of Research and Development|No|Completed|January 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01129141||121801|
NCT01129401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR08-SF-423|Stonewall Treatment Evaluation Project|Evaluation of a Harm Reduction Treatment for Methamphetamine-Using Men Who Have Sex With Men (MSM)|STEP|University of California, San Francisco|No|Completed|March 2010|May 2014|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Male|18 Years|N/A|No|||October 2014|October 23, 2014|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01129401||121781|
NCT01129102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-01-2|Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea|Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea||Nobelpharma|Yes|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|215|||Female|16 Years|N/A|No|||May 2014|May 15, 2014|May 21, 2010||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01129102||121804|
NCT01129115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11883|Dose Response Study of Aerobic Exercise in Older Adults|Dose Response Study of Exercise for Age-related Cognitive Changes||University of Kansas Medical Center|Yes|Completed|May 2010|April 2014|Actual|February 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|101|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|May 18, 2010||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01129115||121803|
NCT01129388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT11166|Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given With Omeprazole 80 mg/Day (12 Hours Apart on the Same Days) in Healthy Male and Female Subjects||Sanofi|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129388||121782|
NCT01129622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFWH-AI1|Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)|Phase II Study of the Effect of Acute Aromatase Inhibition on Breast MRI Postmenopausal Women|RFCLET2|Mount Sinai Hospital, Canada|No|Completed|October 2008|September 2010|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Female|40 Years|80 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|May 21, 2010||No||No|March 3, 2012|https://clinicaltrials.gov/show/NCT01129622||121764|The small sample size is a limitation.
NCT01129882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-10-270|An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia|An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia|ASPIRE|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Active, not recruiting|June 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|708|||Both|18 Years|65 Years|No|||July 2015|July 9, 2015|May 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129882||121744|
NCT01126203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT1|Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension|Randomized Multicentre Prospective Study of Selective Laser Trabeculoplasty (SLT) vs. Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension|SLT|University of Calgary|Yes|Completed|September 2006|October 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||May 2010|May 21, 2010|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126203||122023|
NCT01126463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP-RE-I|188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas|Phase 1 Study of Hepatic Intra-Arterial Administration of 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas|LIP-RE-I|Center Eugene Marquis|Yes|Recruiting|May 2010|January 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126463||122003|
NCT01126996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2009/06|Understanding the Persistence of Immunity After MenC Vaccines|An Observational Study Into the Maintenance of Seroprotection Against Meningococcal Serogroup C Disease Throughout Childhood Following a Single Dose of a Conjugated Meningococcal Serogroup C Vaccine Administered to Toddlers||University of Oxford|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|3 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children who participated in the U01-Td5I-303/ C01.183 study from 2001 to 2007 who        will be aged 11 to 13 years in 2010, all of whom would have received a single dose of a        MenC conjugate vaccine in 2000 as part of the nationwide immunisation campaign.|May 2013|May 7, 2013|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126996||121963|
NCT01127594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020406|Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion|A Multi-Center Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-Arterial Temozolomide for Patients With Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion||Duke University|No|Completed|July 2010|June 2014|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|May 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01127594||121917|
NCT01128699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VESC# 2010-142|Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma|Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma: a Randomized Controlled Clinical Trial||Vanak Eye Surgery Center|Yes|Recruiting|May 2010|July 2011|Anticipated|May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||May 2010|May 21, 2010|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01128699||121835|
NCT01128959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13181A|Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy|Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy||Lundbeck LLC|No|Completed|June 2010|||January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01128959||121815|
NCT01128972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z3480664|Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion|Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion||GlaxoSmithKline|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|April 30, 2010|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT01128972||121814|
NCT01129778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04302010-5803|Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus|Assessment of the Effects of Zegerid Powder for Oral Suspension 40 mg on 24-Hour and Nocturnal Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease and Barrett's Esophagus||Stanford University||Recruiting|November 2009|December 2010|Anticipated|July 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||May 2010|May 24, 2010|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129778||121752|
NCT01120808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04282010-5782|Prevention Trial Assessing Paper-Tape in Endurance Distances (PreTAPED)|Prevention Trial Assessing Paper-Tape in Endurance Distances (PreTAPED)||Stanford University|Yes|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01120808||122437|
NCT01121107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G090084|Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy|Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study|LAPTOP-HF|St. Jude Medical|Yes|Completed|April 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|486|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|May 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01121107||122414|
NCT01121146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2010-0100|Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty|A Prospective, Randomized Clinical Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty||Anderson Orthopaedic Research Institute||Completed|December 1998|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|236|||Both|N/A|N/A|No|||November 2014|November 3, 2014|May 10, 2010|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01121146||122411|
NCT01118130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00494|Pharmacogenomics of Drug Safety in Multiple Sclerosis|Canadian Pharmacogenomics Network for Drug Safety: Genetic Factors Associated With Multiple Sclerosis Treatment||University of British Columbia|No|Recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|300|Samples With DNA|Saliva|Both|18 Years|N/A|No|Non-Probability Sample|Multiple sclerosis (MS) patients attending MS clinics located at the University of British        Columbia Hospital, Winnipeg Health Sciences Centre, Dalhousie (Halifax, Nova Scotia) MS        clinic, London Health Sciences Centre (London, ON) and Hôpital Notre-Dame (Montréal).        Participants must have definite MS (Poser or McDonald criteria), with a        relapsing-remitting or secondary-progressive disease course, registered at one of the        above MS Clinics and prescribed a beta-interferon as an immunomodulatory drug for MS.|July 2015|July 16, 2015|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01118130||122642|
NCT01128868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF LCPs vs Trochanteric Nail|Proximal Femur Locking Compression Plates Versus Trochanteric Nails|Treatment of Reverse Oblique Intertrochanteric or Subtrochanteric Fractures With a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc) or Trochanteric Nails. A Multicenter Cohort Study||AO Clinical Investigation and Documentation|Yes|Completed|May 2011|July 2014|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128868||121822|
NCT01129414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT11208|Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (600 mg Loading Dose Followed by 150 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects||Sanofi|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129414||121780|
NCT01129128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10A1276|Three Arm Trial of Immune Effects of Echinacea|3-arm Randomized Controlled Trial Assessing the in Vivo Effect of an Echinacea Purpurea on Immune Markers in Adults||University of Washington|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|67|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|May 14, 2010||No||No|May 4, 2012|https://clinicaltrials.gov/show/NCT01129128||121802|Levels of TNF alpha, IL-6, IL-2 and Interferon gamma varied widely limiting chance of detecting differences.
NCT01129908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|odelia- HMO-CTIL|Saliva Composition and Oral Hygiene in Children With Celiac Disease Before and After the Change in Diet|Saliva Composition and Oral Hygiene in Children With Celiac Disease Before and After the Change in Diet||Hadassah Medical Organization||Completed|May 2010|July 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|3 Years|18 Years|No|Non-Probability Sample|chilren with celiac disease|July 2012|July 21, 2012|May 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01129908||121742|
NCT01129921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #G01|Comparative Study of Sham Versus Mild® Procedure in Patients Diagnosed With Symptomatic Lumbar Central Canal Stenosis|Comparative Study of Sham Versus Mild® (Minimally Invasive Lumbar Decompression) Procedure in Patients Diagnosed With Symptomatic Moderate to Severe Lumbar Central Canal Stenosis||Napa Pain Institute|No|Completed|April 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|April 30, 2010|Yes|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT01129921||121741|This was a small series with challenging patient retention, particularly in the sham arm.
NCT01130220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|708-2009|Study of the Health Information Needs of Brain Cancer Patients|Informed Brain Cancer Patients||University of Florida|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|27|||Both|18 Years|89 Years|No|Non-Probability Sample|Participants will be recruited during routine interactions with the investigators.|July 2012|July 24, 2012|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130220||121719|
NCT01126216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Paccis-RCT_2005|Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer|Randomised Phase-III-trial of Simultaneous Radiochemotherapy (RCT) of Locally Advanced Head and Neck Cancer in the Stages III and IV A-B: Comparing Dose Reduced Radiotherapy (63,6 Gy) With Paclitaxel/Cisplatin to Standard Radiotherapy (70,2 Gy) With 5-Fluorouracil/Cisplatin|Paccis-RCT|University of Erlangen-Nürnberg Medical School|Yes|Active, not recruiting|May 2010|June 2018|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|542|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01126216||122022|
NCT01126229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238-2009|Resveratrol for Improved Performance in the Elderly|A Pilot Study of Resveratrol Supplementation for Memory and Physical Performance|RIPE|University of Florida||Completed|November 2009|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|32|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 10, 2013|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01126229||122021|
NCT01126762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPHCI Fish 0344|Trial of Fish Intake Advice in Pregnancy|A Pilot Randomized Controlled Trial to Promote Healthful Fish Consumption in Pregnancy||Harvard Pilgrim Health Care|No|Completed|May 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|61|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 20, 2012|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01126762||121981|
NCT01126775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-1006-Gna-1000-I|Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie)|Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 Systematische Prävention Bei Hochrisikopatienten für Schlaganfall Und vaskulär (Mit)Bedingte Demenz: Identifizierung Und Behandlung Von Stummen Hirninfarkten.||INVADE gGmbH|No|Recruiting|April 2012|||November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|55 Years|N/A||Probability Sample|1000 participants of INVADE-2-study ("Intervention project on cerebrovascular diseases and        dementia in the district of Ebersberg, Bavaria")|January 2013|January 22, 2013|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01126775||121980|
NCT01127009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4909|Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)||Case Comprehensive Cancer Center|Yes|Completed|July 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||August 2015|August 12, 2015|May 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01127009||121962|
NCT01127022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSP No: 59370, 57100, 58222|Effect of Maternal Choline Intake on Choline Status and Health Biomarkers During Pregnancy and Lactation|Effect of Maternal Choline Intake on Maternal/Fetal Biomarkers of Choline Status||Cornell University|No|Completed|January 2009|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|82|||Female|21 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 17, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01127022||121961|
NCT01122472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMARC|Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP|Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line|REMARC|The Lymphoma Academic Research Organisation|No|Active, not recruiting|April 2009|September 2019|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|650|||Both|60 Years|80 Years|No|||April 2015|April 21, 2015|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01122472||122309|
NCT01122485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG201-PT-001|Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis|For an 8-week, Single Center, Randomized, Double Blind, Placebo Controlled Exploratory Clinical Study to Assess the Efficacy, Dose Response and Safety of PG201 Tablet in Patients With Osteoarthritis||ViroMed Co., Ltd. dba VM BioPharma|No|Completed|December 2006|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|82|||Both|40 Years|75 Years|No|||June 2011|June 13, 2011|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01122485||122308|
NCT01126814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0147-C|A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia|A Phase I-II Study Evaluating the Safety and Efficacy of Imatinib Mesylate (Gleevec) Combined With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive Acute Myeloid Leukemia||University Health Network, Toronto|No|Completed|July 2004|April 2010|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01126814||121977|
NCT01127282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin_H1N1|The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A|The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A: a Randomized-controlled Trial||Seoul National University Hospital|Yes|Recruiting|December 2009|August 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||May 2010|May 19, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01127282||121941|
NCT01129271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALI11209|Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-sequence, Two-period Crossover Study, to Investigate a Potential Food Effect on the Pharmacodynamic and Bioavailability of Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) in Healthy Male Subjects||Sanofi|No|Completed|April 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|72|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129271||121791|
NCT01128998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICR-CT2008-01|Sorafenib Plus S-1 in Advanced Solid Tumors|An Open-Label Phase I Dose-Escalation Study of Sorafenib Plus S-1 in Advanced Solid Tumors||National Health Research Institutes, Taiwan|No|Completed|November 2009|October 2015|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|75 Years|No|||August 2012|October 16, 2015|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01128998||121812|
NCT01130376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO930|Novel Interventions in HIV-1 Infection|A Randomised, Open Labelled, Phase I, Safety, Toxicity, and Exploratory Immunogenicity Evaluation of Therapeutic Immunisation +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy|IMIRC1003|Imperial College London|Yes|Terminated|September 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||September 2012|September 2, 2013|May 25, 2010||No|Data from the 12 patients recruited has now been analysed, and it has been determined that it    is sufficient to meet the study objectives.|No||https://clinicaltrials.gov/show/NCT01130376||121708|
NCT01120821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0702-375|Treatment of Polycythemia Vera With Gleevec|A Phase II Trial of the Treatment of Polycythemia Vera With Gleevec||Weill Medical College of Cornell University|No|Completed|August 2002|June 2007|Actual|January 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||May 2010|May 14, 2010|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01120821||122436|
NCT01117571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001|Multi-Center Study to Evaluate the ConforMIS iUni Knee Implant|A Prospective, Multi-Center Study to Evaluate the ConforMIS iUni® G2 Unicompartmental Knee Resurfacing Device|iUni|ConforMIS, Inc.|No|Active, not recruiting|April 2010|December 2020|Anticipated|August 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01117571||122685|
NCT01129154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luc 09-002|Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)|An Open Label Multicentric Phase II Study of Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)|PASCE|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|August 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|N/A|No|||August 2010|August 27, 2010|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01129154||121800|
NCT01129427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT11374|Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Pantoprazole 80 mg/Day in Healthy Male Subjects||Sanofi|No|Completed|August 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|66|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|May 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01129427||121779|
NCT01129635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00036655|Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging|Real-Time Intracardiac Impedograms of Left Ventricular Leads to Locate Sites of Latest Mechanical Delay in Cardiac Resynchronization Therapy||Emory University|Yes|Completed|June 2010|December 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|N/A|N/A|No|||January 2015|January 17, 2015|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01129635||121763|
NCT01129648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4208-202|Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout|A Randomized, Double-Blind, Multi-center, Placebo-Controlled, Combination Study to Evaluate the Urate-Lowering Activity, Safety, and Potential Pharmacokinetic Interaction of Oral BCX4208 and Allopurinol Administered in Subjects With Gout||BioCryst Pharmaceuticals|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|16||Actual|87|||Both|18 Years|69 Years|No|||January 2012|January 18, 2012|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129648||121762|
NCT01129934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-PH-701-CTIL|Morphine Versus Morphine-promethazine Combination for Acute Low Back Pain Relief in the Adult Emergency Department|Pharmacological Anxiolysis With Promethazine as an Adjunctive Therapy for Acute Low Back Pain in the Adult Emergency Department||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2010|January 2013|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||May 2010|May 23, 2010|April 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01129934||121740|
NCT01129947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRM4|The Use of DHEA in Women With Premature Ovarian Failure|The Use of DHEA in Women With Premature Ovarian Failure||Virginia Center for Reproductive Medicine|Yes|Withdrawn|May 2010|January 2013|Actual|January 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|40 Years|No|||January 2013|January 26, 2013|May 23, 2010||No|very poor patient recruitement|No||https://clinicaltrials.gov/show/NCT01129947||121739|
NCT01130233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 09-132|Randomized Trial on Robotic Assisted Resection for Rectal Cancer|Randomized Controlled Trial Comparing the Bladder and Sexual Functions of Patients Who Undergo Laparoscopic and Robotic Assisted Resection for Rectal Cancer||The University of Hong Kong|No|Recruiting|June 2009|December 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||May 2010|May 24, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01130233||121718|
NCT01126476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 23309|Proton Radiotherapy for Recurrent Tumors|Retreatment of Recurrent Tumors Using Proton Therapy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|February 2010|||February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126476||122002|
NCT01126749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-702|Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer||Eisai Inc.|No|Active, not recruiting|April 2010|September 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|May 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01126749||121982|
NCT01127555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUHHO 2010-2|Salvage mFOLFOX in BTC After Failure of Gemcitabine|Phase II Study of Salvage mFOLFOX(5-fluorouracil, Leucovorin, Oxaliplatin) in Patients With Unresectable Biliary Tract Cancer (BTC) Who Had Failed Gemcitabine||Chung-Ang University|No|Completed|April 2010|January 2013|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2013|October 6, 2013|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01127555||121920|
NCT01129245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN SFP3-7|The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation|The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation||Oregon Health and Science University|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|11|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|May 21, 2010|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01129245||121793|
NCT01127828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-05-008|Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes|Effects of Cultura Yoghurt on Symptoms Intestinal Flora and Immunological Changes in Patients With Irritable Bowel Syndrome(IBS)||Good Food Practice, Sweden|No|Completed|September 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2010|May 21, 2010|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01127828||121899|
NCT01139541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WalkStation1|Testing Strategies for Increasing Exercise|Testing Strategies for Increasing Exercise||Harvard University|Yes|Completed|June 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|224|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01139541||121009|
NCT01139567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WoundImager-2010-01|Tissue Perfusion and Blood Flow Monitoring Technology|Tissue Perfusion and Blood Flow Monitoring Technology|WoundImager|CW Optics, Inc.||Completed|June 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|56|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients who have chronic lower extremity wounds will be recruited from the patient        population at the Chippenham and Johnston-Willis Medical Center (CJW) for enrollment in        the study.|June 2013|June 28, 2013|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01139567||121008|
NCT01135264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5946/6970R|Cognitive-Motivational Behavior Therapy for Pathological Gamblers|Gambling Addiction: Treatment Mediators and Moderators||New York State Psychiatric Institute|No|Active, not recruiting|August 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||October 2015|October 5, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135264||121334|
NCT01136460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC052005CTIL|Genetic Testing in Primary Congenital Glaucoma Patients|Genetic Testing in Primary Congenital Glaucoma Patients||Carmel Medical Center|Yes|Recruiting|May 2006|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|400|Samples With DNA|blood samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary congenital glaucoma patients and their immediate relatives|September 2014|September 17, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136460||121243|
NCT01135862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIL-000-JR-08-TASMC|Platelet Administration To Patients With Traumatic Brain Injury Who Were Treated With Aspirin|Platelet Administration To Patients With Traumatic Brain Injury Who Were Treated With Aspirin||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|June 2010|June 2013|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2010|June 2, 2010|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01135862||121288|
NCT01170676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL092412|Promoting Asthma Wellness in Rural Communities|Promoting Asthma Wellness in Rural Communities||Georgia Regents University|Yes|Completed|August 2009|May 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|700|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01170676||118630|
NCT01170689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tsao-Tun Psychiatric Center|The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan|The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan||TsaoTun Psychiatric Center, Department of Health, Taiwan|Yes|Completed|March 2010|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|710|||Both|20 Years|72 Years|No|Probability Sample|710 adult schizophrenia patients living in the chronic ward in Tsau-Tun psychiatric center        during the first week in March 2010|July 2010|July 27, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170689||118629|
NCT01166659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMI-10-03|Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy||DUETTE|Transcend Medical, Inc.|No|Completed|June 2010|May 2014|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|21 Years|99 Years|No|||February 2016|February 24, 2016|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01166659||118938|
NCT01166672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15110|BCRL Prevention Pilot|Weight Loss to Prevent BCRL: A Pilot Study||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|July 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|20|||Female|18 Years|70 Years|No|Probability Sample|Women, aged 18-70, who are obese (BMI greater than or equal to 30), do not already have a        diagnosis of lymphedema, who are done with surgery, chemotherapy, and radiation therapy,        and who were diagnosed with breast cancer within the past 2 years will be invited to        participate.|October 2012|October 11, 2012|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166672||118937|
NCT01166893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2010-7322|Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential|Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential||University of California, Irvine|No|Recruiting|March 2010|February 2018|Anticipated|February 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Study population will be selected from University of California Irvine Medical Center Burn        Unit.|February 2016|February 8, 2016|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166893||118920|
NCT01166906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2009-7245|Pain Blocking During Drug Administration or Blood Collection With Needles|Pain Blocking During Drug Administration or Blood Collection With Needles||University of California, Irvine|No|Completed|March 2010|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic, community sample,|August 2015|August 5, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166906||118919|
NCT01167491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081238|Study of One Protein Implicated in Wegener Disease|Activating Receptors and DAP12 Protein in Wegener's Granulomatosis|DAP12WEGENER|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2010|September 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|138|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01167491||118874|
NCT01138072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113818|A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.|A Phase I, Single-center, Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.||GlaxoSmithKline|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|7||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 4, 2010|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138072||121122|
NCT01137591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD4090|Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever|Acetaminophen in Combination With N-Acetylcysteine (NAC) vs. Placebo in the Treatment of Fever: A Double-Blind, Randomized Control Study||Columbia University|No|Withdrawn|April 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|75 Years|No|||March 2015|March 3, 2015|June 3, 2010|Yes|Yes|Unable to recruit sufficient participants due to lack of funding; PI has left the institution.|No||https://clinicaltrials.gov/show/NCT01137591||121159|
NCT01138098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113954|Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children|Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in 11-12 Year Old Children, Previously Vaccinated With DTPa-HBV-IPV/Hib Vaccine in Study 217744/031||GlaxoSmithKline||Completed|June 2010|November 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|185|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||January 2012|January 23, 2014|May 27, 2010|Yes|Yes||No|November 10, 2011|https://clinicaltrials.gov/show/NCT01138098||121120|
NCT01137864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREQHOS 08023b|Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards|Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards: a Multicenter Randomized Controlled Trial.|ATBREFEMERG|Henri Mondor University Hospital|No|Completed|June 2010|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01137864||121138|
NCT01138124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114427|Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)|Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database||GlaxoSmithKline|No|Completed|March 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|54202|||Both|N/A|N/A|No|Probability Sample|The study cohort from which cases and controls are drawn is all subjects in the UK GPRD        1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are registered        in GPRD before that time, and at the time of registration if later than Jan 1, 1993.        Follow-up ends Dec 31, 2008, or earlier if the respective cancer is diagnosed, or if the        subject leaves the GPRD for any reason including death. There are several advantages to        the GPRD dataset for this study. It is a large dataset with detailed longitudinal        prescription data, and long term follow-up (mean 7 years) to allow for latency in        carcinogenicity. It provides good representation of the elderly who are disproportionately        affected by pancreatic and renal cancers, and routinely includes data recorded by general        practitioners on potential risk factors such as smoking and body mass index.|June 2011|June 23, 2011|June 3, 2010||No||No|December 16, 2010|https://clinicaltrials.gov/show/NCT01138124||121118|
NCT01138631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25940|Selection of Embryos by Time-lapse|Selection of Embryos for IVF Treatment by Time-lapse||University of Aarhus|Yes|Completed|June 2010|May 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Female|N/A|37 Years|No|||May 2011|May 9, 2011|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138631||121079|
NCT01138592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-003041|Pilot Study to Evaluate the Clinical Utility of Auscultation Software at Remote Locations|Pilot Study to Evaluate the Clinical Utility of 3M Littmann Scope-to-Scope Software for Real-time Assessment of Patients at Remote Clinic Locations by Centrally-located Medical Providers||3M|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Patients Hepatitis C Patients|June 2011|June 3, 2011|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138592||121082|
NCT01138891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB_2008|Sonication of Explanted Breast Implants for Detection of Subclinical Infection|||Centre Hospitalier Universitaire Vaudois|No|Completed|February 2006|June 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|121|Samples Without DNA|Breast implants|Both|N/A|N/A|No|Non-Probability Sample|Five plastic surgery clinics in Switzerland participated in this study (Basel, Luzern,        Dornach, Lausanne, Münchenstein).|June 2010|June 8, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01138891||121059|
NCT01138878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.4|HIV Testing in Non-traditional Settings Study|HIV Testing in Non-traditional Settings Study|HINTS|Chelsea and Westminster NHS Foundation Trust|No|Completed|July 2009|December 2011|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||4|Actual|6350|||Both|16 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|For patient pre-study and intra-study: All patients aged 16-65 (not know already to be HIV        positive) attending the healthcare setting (Primary Care centre, Emergency Department,        Acute Care Unit, Medical Outpatient Clinic) before or during the twelve week HIV testing        pilot programme        For Staff pre-study and post-study: All members of staff (HCP, Allied Health Professionals        and Admin/Clerical) working within the healthcare settings examined before and during the        implementation of the HIV testing programme|May 2010|April 11, 2012|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138878||121060|
NCT01139216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100CPT2|Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation|Effect of DAIKENCHUTO (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Female Patients With Functional Constipation||Tsumura USA|No|Completed|August 2010|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Female|18 Years|65 Years|No|||January 2013|January 8, 2013|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01139216||121034|
NCT01139580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114743|The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis|A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis||GlaxoSmithKline|No|Completed|May 2010|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|363|||Both|12 Years|N/A|No|||February 2012|February 23, 2012|June 6, 2010|Yes|Yes||No|August 18, 2011|https://clinicaltrials.gov/show/NCT01139580||121007|
NCT01139593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCRM 5|A Trial Comparing Qam With Qpm Dosing in Assisted Reproductive Technologies (ART)|A Prospective Randomized Trial Comparing Qam With Qpm Daily Dosing in Assisted Reproductive Technologies||Virginia Center for Reproductive Medicine|Yes|Completed|June 2010|December 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|128|||Female|21 Years|42 Years|No|Probability Sample|Infertile women between 21 and 44 years old|December 2015|December 8, 2015|June 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01139593||121006|
NCT01135277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0165|Immune Suppression and Ventilator Associated Pneumonias|Immune Suppression and Ventilator Associated Pneumonias|iVAP|Ohio State University|No|Enrolling by invitation|February 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Peripheral blood Bronchoalveolar lavage fluid|Both|18 Years|N/A|No|Non-Probability Sample|This study will be open to males and females, 18 years or older, who spend at least one        day on mechanic ventilation in the Ohio State University Medical Intensive Care Unit|December 2013|December 27, 2013|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01135277||121333|
NCT01135290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|828-101-09-016|Post Treatment Care After Chemical Peel or Laser Resurfacing|Evaluation of HP828-101 for Post Treatment Care Following a Chemical Peel or Laser Resurfacing||Healthpoint|No|Withdrawn|June 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|June 1, 2010|Yes|Yes|Business decision, formulation will not be pursued.|No||https://clinicaltrials.gov/show/NCT01135290||121332|
NCT01135563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000016324|Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including Central Nervous System Tumors|A Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including CNS Tumors||The Hospital for Sick Children|Yes|Completed|April 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|21 Years|No|||December 2013|December 2, 2013|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135563||121311|
NCT01135576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL2006/09519/ALI|Iron Fortified Beverages and Application in Women Predisposed to Anemia||FeDrink|National Research Council, Spain|No|Completed|November 2008|May 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|122|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01135576||121310|
NCT01135914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DCA05|Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)|A Canadian 12-month, Prospective, Randomized, Open-label, Multicenter, Laser-controlled Phase IIIb Study Assessing the Efficacy, Safety and Cost-efficacy of Ranibizumab as Combination and Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema.|RESPOND|Novartis||Completed|July 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|241|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|May 31, 2010||No||No|March 19, 2014|https://clinicaltrials.gov/show/NCT01135914||121284|
NCT01135927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1996|A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|20 Years|65 Years|No|||June 2015|June 12, 2015|May 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01135927||121283|
NCT01136187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEMI-RADIAL 16-9-2009|Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI)|ST Elevation Myocardial Infarction Treated by RADIAL or Femoral Approach - Randomized Multicenter Study Comparing Radial Versus Femoral Approach in Primary PCI. The STEMI-RADIAL Trial.|STEMI-RADIAL|Charles University, Czech Republic||Completed|October 2009|October 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|707|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136187||121263|
NCT01136720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-035|Clinical Trial to Evaluate the Safety and Clinical Utility of 18F-FDG Produced by the Molecular Imaging and Research Centre of Nova Scotia|Clinical Trial to Evaluate the Safety and Clinical Utility of18F-FDG Produced by the Molecular Imaging and Research Centre of Nova Scotia||Nova Scotia Health Authority|No|Recruiting|August 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|1 Year|N/A|No|Non-Probability Sample|The recruited subjects will be patients referred by medical and surgical specialists        involved in cancer management dementia epilepsy and cardiology|June 2010|June 23, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136720||121223|
NCT01136733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-205|A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment|An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment||Eisai Inc.||Active, not recruiting|August 2010|||June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|153|||Both|18 Years|99 Years|No|||November 2015|November 18, 2015|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136733||121222|
NCT01166685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPII|Safety and Efficacy Study Comparing 3 New Types of Coronary Stents|Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II)||University Hospital, Basel, Switzerland|Yes|Completed|April 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2291|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166685||118936|
NCT01166919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2009-7262|Pilot Study on the Use of the Matrix Radiofrequencyfor Treatment of Port Wine Stain Birthmarks|Pilot Study on the Use of the Matrix Radiofrequency for Treatment of Port Wine Stain Birthmarks||University of California, Irvine|Yes|Withdrawn|December 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|July 20, 2010||No|Laser company cannot provide laser unit for the study.|No||https://clinicaltrials.gov/show/NCT01166919||118918|
NCT01167725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000681540|Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer|Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma||National Cancer Institute (NCI)||Active, not recruiting|August 2010|||May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||January 2012|January 21, 2012|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167725||118856|
NCT01167244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA187-020|Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response|Phase 2 Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response||Bristol-Myers Squibb|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167244||118893|
NCT01168219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02053|Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia|Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML||National Cancer Institute (NCI)||Active, not recruiting|July 2010|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|74 Years|No|||March 2016|March 10, 2016|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168219||118818|
NCT01137604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-203|A Study in Subjects With Recurrent Malignant Glioma|An Open-Label, Three-Cohort, Phase 2 Study of E7080 in Subjects With Recurrent Malignant Glioma||Eisai Inc.||Terminated|August 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|N/A|No|||December 2013|December 20, 2013|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137604||121158|
NCT01137617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P 000425|Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients|Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients|SCS|Massachusetts General Hospital|No|Active, not recruiting|June 2010|June 2015|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Sixty subjects who already have an implanted SCS device for pain management at the MGH        Center for Pain Medicine and other Partners affiliated pain centers will be enrolled.|July 2014|July 2, 2014|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137617||121157|
NCT01138605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016768|TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV|Continued Access to DRV/Rtv in HIV-1 Infected Children and Adolescents (Rollover Patients From C212, C228, C230)||Janssen R&D Ireland|No|Recruiting|October 2010|December 2024|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|46|||Both|3 Years|99 Years|No|||March 2016|March 8, 2016|April 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138605||121081|
NCT01138618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.5 - 01 MARCH2010|Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)|Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)|CHEMPAQ|University of Aarhus|No|Completed|April 2010|May 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|85|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients treated with clozapine|November 2011|November 4, 2011|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01138618||121080|
NCT01138904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAUH-AGC-10-1|FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)|Randomized Phase II Study of FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Patients With Advanced or Relapsed Gastric Cancer||Dong-A University Hospital|No|Completed|September 2009|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|20 Years|N/A|No|||November 2014|November 2, 2014|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138904||121058|
NCT01138917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP001-5|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2010|||||N/A|N/A|N/A||||||||||||||February 19, 2015|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138917||121057|
NCT01135667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAILOR|Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI|Thrombocytes And IndividuaLization of ORal Antiplatelet Treatment After Percutaneous Coronary Intervention|TAILOR|Rigshospitalet, Denmark|Yes|Completed|September 2010|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01135667||121303|
NCT01139632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0030-10|The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease|The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease|0030-10|Ziv Hospital|Yes|Active, not recruiting|July 2010|March 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|1. Patients at intermediate risk for significant CAD was admitted to the hospital with             the diagnosis of chest pain or undergoing elective CT coronarography due to             suspection of coronary artery disease.          2. Male and female 18years or older.        Intermediate Risk patients for having significant CAD is deﬁned as:        a - chest pain or dyspnea in the presence of negative stress tests; b - the absence of        chest pain but positive stress tests; c - the absence of chest pain and of positive stress        tests but intermittent arrhythmias.        Age <18 years.|June 2010|April 5, 2011|June 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01139632||121003|
NCT01139242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1271|Increasing Colorectal Cancer Screening in Urban African American Communities Via Churches|Increasing CRC Screening in Urban African American Communities Via Churches|ACTS|University of North Carolina, Chapel Hill|No|Completed|February 2008|May 2010|Actual|August 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|955|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 7, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01139242||121032|
NCT01139229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH20070901|Hybrid-everted Versus Hand-sewn or Stapled Esophagogastrostomy in Prevention of Anastomotic Stricture|Phase III Study of Hybrid-everted Versus Hand-sewn of Stapled Esophagogastrostomy in Prevention of Anastomotic Stricture||Sichuan University|No|Completed|November 2007|September 2008|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|N/A|N/A|No|||March 2010|June 7, 2010|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01139229||121033|
NCT01139606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0034-10-HYMC|Vibration Training and Muscle Strength Development|The Effect of Resistance Training With Vibrating Weights on Muscle Strength Development and Everyday Functioning of Upper Limbs in Untrained Adults||Wingate Institute||Completed|June 2010|November 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01139606||121005|
NCT01135303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808119|Effectiveness of VistaO2 Device in Screening of Sleep Apnea/Hypopnea Syndrome|Effectiveness of VistaO2 Device in Screening of Sleep Apnea/Hypopnea Syndrome|VISTAO2|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|182|||Both|18 Years|80 Years|No|||July 2011|July 20, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01135303||121331|
NCT01136213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/01|Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study|Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study|SEROTAMS|University Hospital, Bordeaux|No|Recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|54|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited by neurologists specialized in movement disorders|January 2015|January 13, 2015|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01136213||121261|
NCT01136226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURA-RT-001|Evaluate Recovery of Testosterone for Patients Using Eligard|A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer|Eligard|Chesapeake Urology Research Associates|No|Completed|October 2003|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|50 Years|80 Years|No|||July 2013|July 16, 2013|June 2, 2010|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT01136226||121260|
NCT01136473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-10-0035-CTIL|Mechanism of Aphakic and Pseudophakic Glaucoma in Pediatric Patients|Mechanism of Aphakic and Pseudophakic Glaucoma in Pediatric Patients: Exploring the Pathophysiology Through Lens Epithelial Cell Culture and Isolation of Candidate Factors From Aqueous Humor||Carmel Medical Center|Yes|Completed|July 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|N/A|18 Years|No|Non-Probability Sample|children 0-18|February 2015|February 22, 2015|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01136473||121242|
NCT01136486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-015|Pain in Traumatic Brain Injury - Basile, MD|The Role of Persistent Pain on Neuro Psychological Functioning and Community Integration in Traumatic Brain Injury||Northwell Health|No|Completed|April 2003|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|history of traumatic brain injury|October 2015|October 22, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136486||121241|
NCT01167504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR03-2010|Factors Controlling the Formation of Salivary Films|Investigating the Formation of Salivary Films and How They Change in the Presence of Ingredients From Food and Oral Hygiene Products|SalFilm|Institute of Food Research|No|Completed|June 2010|August 2013|Actual|April 2013|Actual|N/A|Observational|N/A||1|Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Apparently normal healthy volunteers from the local community able to donate saliva        samples.|November 2013|November 14, 2013|July 20, 2010||No||No|August 21, 2013|https://clinicaltrials.gov/show/NCT01167504||118873|No adverse events were reported. The number of volunteers required gave acceptable statistics as anticipated. The study was completed on time
NCT01167517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00013359|Lactation Education Study in Mothers of Very Low Birth Weight Infants|Lactation Education Study in Mothers of Very Low Birth Weight Infants||Wake Forest Baptist Health|No|Recruiting|July 2010|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167517||118872|
NCT01167946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-451|Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata|Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata||King Saud University|Yes|Completed|January 2003|July 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|5 Years|N/A|No|||January 2003|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167946||118839|
NCT01167959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08-215|Hypothalamic Function Before and After Bariatric Surgery|Hypothalamic Morphology, Neuronal Activity and Systems Biology in Response to Food Intake in Obese Patients With Type 2 Diabetes Mellitus Compared to Obese and Lean Controls||Leiden University Medical Center|Yes|Completed|June 2009|May 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|48|Samples Without DNA|Blood/Sera Adipose tissue biopsies|Female|35 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Obese (type 2 diabetic or not) population from primary care (dietary intervention) and        hospital setting (bariatric surgery)|December 2012|December 20, 2012|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167959||118838|
NCT01168245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRX-NICE-PLA02|TMS Stimulation and Cognitive Training in Alzheimer Patients|Effects of a Combined TMS Stimulation and Cognitive Training in Alzheimer Patients: a Single-center, Randomized, Double-blind, Placebo-controlled Study||Neuronix Ltd|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|55 Years|85 Years|No|||March 2013|March 26, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168245||118816|
NCT01168505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 002/2009 - CEP 543/09|Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients|The Role of Intravenous Iron to Prevent Anemia in Women With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy||Instituto do Cancer do Estado de São Paulo|No|Recruiting|May 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168505||118796|
NCT01138345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0924|Biomarkers in Blood Samples From Older Breast Cancer Survivors|The Effect of Chemotherapy on Aging in Older Women With Breast Cancer as Measured by Expression of p16INK4a||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|January 2010|February 2014|Actual|January 2013|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|246|Samples With DNA|blood samples|Female|50 Years|N/A|No|Non-Probability Sample|Breast cancer survivors age 50 and older who have completed their breast cancer treatment.|February 2014|February 26, 2014|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138345||121101|
NCT01138358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000674580|Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease|Experiences of Episodic Breathlessness (EB) in Patients With Advanced Disease||National Cancer Institute (NCI)||Completed|January 2010|October 2012|Actual|August 2010|Actual|N/A|Observational|N/A|||Anticipated|50|||Both|18 Years|N/A|No|||June 2010|August 23, 2013|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138358||121100|
NCT01138956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLNAC|Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine|Study for Evaluation of the Immune Response of Visceral Leishmaniasis Patients Treated With Antimonial Pentavalent Associated to N-Acetylcysteine|VLNAC|Hospital Universitário Professor Edgard Santos|No|Recruiting|April 2010|December 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|2 Years|50 Years|No|||April 2010|June 7, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01138956||121054|
NCT01138969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS98-CT6-12|Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer|Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer and Gastrointestinal Bleeding||Kaohsiung Veterans General Hospital.|Yes|Completed|August 2008|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|165|||Both|N/A|N/A|No|||September 2015|September 6, 2015|June 7, 2010||No||No|December 31, 2012|https://clinicaltrials.gov/show/NCT01138969||121053|The patients without symptoms who refused follow-up endoscopy were regarded as having no recurrent ulcers. Because peptic ulcer may be asymptomatic, the cumulative number of recurrent peptic ulcer might be underestimated in both groups.
NCT01138930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|berberine2010|Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS)|Effect of Berberine on Hormonal and Metabolic Features in Obese Women With PCOS||Heilongjiang University of Chinese Medicine|Yes|Recruiting|June 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|35 Years|No|||May 2013|May 8, 2013|June 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138930||121056|
NCT01135329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1046|Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers|Reduced-intensity, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|August 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|6 Months|75 Years|No|||April 2014|April 16, 2014|June 1, 2010||No|The stopping rule was met and hence the study was closed|No||https://clinicaltrials.gov/show/NCT01135329||121329|
NCT01139619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OSE-DUM-2010/1|A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients|A Retrospective, Medical Record Study to Investigate the Current Situation of Biopsy Testing in the Swedish Inoperable Non Small Cell Lung Cancer Patient Population|MAPSY|AstraZeneca|No|Completed|October 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|136|||Both|N/A|N/A|No|Non-Probability Sample|Approximately 200 inoperable non small cell lung cancer patients recruited from centers in        Swedish University- and County hospitals.|February 2013|February 22, 2013|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01139619||121004|
NCT01135316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMI-Ablavar-401|Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR|A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice||Lantheus Medical Imaging|No|Completed|October 2009|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|Samples With DNA|whole blood, tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with moderate to severe kidney disease|May 2014|May 5, 2014|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01135316||121330|
NCT01135602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THoPA-O|Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study|Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study|THoPA-O|Chiang Mai University|No|Recruiting|July 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|60 Years|No|||June 2010|August 12, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01135602||121308|
NCT01135615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATAFGF23Sevelamer|Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)|Sevelamer, FGF-23 and Endothelial Dysfunction in CKD||Gulhane School of Medicine||Completed|January 2008|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|65 Years|No|||May 2010|July 20, 2011|June 2, 2010||||No||https://clinicaltrials.gov/show/NCT01135615||121307|
NCT01137019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMA A19/10|Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition|Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition: A Randomized Comparison of the Biolimus A9-eluting and Everolimus-eluting Coronary Stents|OPTIMA|Northern Hospital, Australia|Yes|Active, not recruiting|October 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2014|August 2, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137019||121200|
NCT01137032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT 0153-01-1|Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population|An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population||Fougera Pharmaceuticals Inc.|No|Suspended|June 2004|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|3 Months|N/A|No|||June 2014|June 25, 2014|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137032||121199|
NCT01137357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC 559-240908|Probiotics for Reduction Of Markers In Subjects With Allergy|Probiotics for Reduction Of Markers In Subjects With Allergy|PROMISA|Rijnstate Hospital|No|Completed|November 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|60|||Both|18 Years|50 Years|No|||June 2010|June 3, 2010|June 3, 2010||||No||https://clinicaltrials.gov/show/NCT01137357||121176|
NCT01137370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0911-066-301|The Impact of Vitamin D on Tuberculosis Among Koreans|The Impact of Vitamin D Level and Single Nucleotide Polymorphisms of Vitamin D Receptor Gene on the Development and Treatment Response of Tuberculosis||Seoul National University Hospital|No|Completed|January 2010|April 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|203|Samples With DNA|Serums for vitamin D measurement DNA for genotyping of vitamin D receptor gene|Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients diagnosed and treated as having a TB in Seoul National University Hospital|January 2014|January 3, 2014|June 3, 2010||No||No|January 3, 2014|https://clinicaltrials.gov/show/NCT01137370||121175|We did not evaluate the participants' dietary intake of vitamin D or their outdoor activities,and DEXA and PTH were not measured which indicate vitamin D insufficiency.
NCT01137045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC5301|Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG|An Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine(SPEEDA/TRCS SPEEDA) and Rabies Immunoglobulin||Queen Saovabha Memorial Institute|Yes|Recruiting|June 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|210|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137045||121198|
NCT01167283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APARD|Effect of Electrostimulation in Chronic Obstructive Pulmonary Disease (COPD)|Effect of Electromyostimulation in Severe Chronic Obstructive Pulmonary Disease|ExaEMS2005|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|July 2006|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|15|||Both|50 Years|80 Years|No|||July 2010|August 5, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01167283||118890|
NCT01159574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004011012|Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma|A Phase II Study of Dexamethasone (DECADRON®), Clarithromycin (BIAXIN®), and Pomalidomide (CC-4047®) for Subjects With Relapsed or Refractory Multiple Myeloma||Weill Medical College of Cornell University|Yes|Recruiting|August 2010|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2011|February 18, 2011|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159574||119481|
NCT01167972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OFR-DUM-2010/1|Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma|Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)|MUTACT|AstraZeneca|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Probability Sample|Patient with NSCLC adenocarcinoma confirmed by histologyPatient for whom a search for the        mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed|September 2012|September 7, 2012|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167972||118837|
NCT01168232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02056|Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus||National Cancer Institute (NCI)||Active, not recruiting|September 2010|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|N/A|No|||May 2014|June 10, 2014|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168232||118817|
NCT01160198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114204|A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.|A Multicentre, Randomized, Laboratory-blinded, Parallel-group Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.||GlaxoSmithKline|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|271|||Female|18 Years|55 Years|No|||March 2012|March 29, 2012|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01160198||119434|
NCT01160510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910137|Genetics of Mammographic Appearances and Patterns (The GenMap Study)|Genetics of Mammographic Appearances and Patterns (The GenMap Study)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2010|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|200|||Female|30 Years|50 Years|No|||January 2016|February 17, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160510||119411|
NCT01160523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910142|Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis|Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis||National Institutes of Health Clinical Center (CC)||Completed|June 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2200|||Both|9 Years|15 Years|No|||December 2015|March 9, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160523||119410|
NCT01139281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPSESDF-024-07|The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans|The Protective Effect of Ginkgo Biloba Extract on Cisplatin-Induced Ototoxicity in Humans Beings Evaluated by Distortion Product Otoacoustic Emissions||University of Brasilia|Yes|Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|15|||Both|18 Years|N/A|No|||May 2010|June 7, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01139281||121029|
NCT01139294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091087|Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics|Phase IV Randomized Study of Hylenex or Standard IV Hydration in the Pediatric Population With Moderate Dehydration|Hylenex|Vanderbilt University|Yes|Active, not recruiting|February 2010|April 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|75|||Both|2 Months|3 Years|Accepts Healthy Volunteers|||June 2010|June 7, 2010|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01139294||121028|
NCT01138137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-4229|N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer|Phase I Dose Escalation Study of N-acetylcysteine (NAC) Administered Intravenously (IV) in Conjunction With Intraperitoneal (IP) Administered Cisplatin and IV/IP Paclitaxel in Patients With Stage III or IV Ovarian Cancer||OHSU Knight Cancer Institute|Yes|Withdrawn|June 2010|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|75 Years|No|||April 2015|April 1, 2015|June 3, 2010|No|Yes|No funding was available for the cost of the IV N-acetylcysteine (NAC).|No||https://clinicaltrials.gov/show/NCT01138137||121117|
NCT01135368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO K019|Safety and Efficacy of Lansoprazole in Patients With Reflux Disease|Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study||Takeda|No|Completed|June 2002|September 2008|Actual|September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|506|||Both|18 Years|75 Years|No|||July 2012|July 25, 2012|June 1, 2010|Yes|Yes||No|July 25, 2012|https://clinicaltrials.gov/show/NCT01135368||121326|
NCT01139333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B4|Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia|Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples||Children's Oncology Group|No|Active, not recruiting|September 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|52|Samples With DNA|blood and tumor samples|Both|N/A|17 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia|May 2015|May 6, 2015|June 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01139333||121025|
NCT01139346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGC1004|Study of Oral Darinaparsin in Patients With Advanced Solid Tumors|Phase I Study of Oral Darinaparsin in Advanced Solid Tumors||Ziopharm|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01139346||121024|
NCT01139359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGL1003|Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma|A Phase I Dose Escalation Study of Darinaparsin in Combination With CHOP in Previously Untreated Patients With Lymphomas Who Are Scheduled to Receive CHOP Alone||Ziopharm|No|Withdrawn|June 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|June 4, 2010|Yes|Yes|Study enrollment was withdrawn as it is no longer the sponsor's intention to study this    indication under this protocol.|No||https://clinicaltrials.gov/show/NCT01139359||121023|
NCT01135940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00179|The Use of Dermabond Versus Standard Staple for Wound Closure in Children With Neuromuscular Scoliosis Undergoing Spinal Deformity Correction Surgery|The Use of Dermabond vs. Standard Staple for Wound Closure in Children With Neuromuscular Scoliosis Undergoing Spinal Deformity Correction Surgery: A Phase II Study||University of British Columbia|Yes|Recruiting|May 2010|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|19 Years|No|||January 2015|January 6, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135940||121282|
NCT01139268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090241|Identification of Viable Human Embryos Using Three Different Methods|Examination of Gene Expression, Time-lapse and Near-infrared Spectroscopy (NIR) to Identify Differences in Embryo Viability||University of Aarhus|Yes|Completed|June 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|N/A||1|Actual|161|Samples With DNA|biopsies from human embryos|Female|18 Years|37 Years|No|Non-Probability Sample|Women undergoing ART treament with single embryo transfer at the Fertility clinic, Aarhus        University hospital Skejby, due to infertility,|July 2013|July 17, 2013|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139268||121030|
NCT01135628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-83-09/10-1|Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy|Hyperproteic and Fiber-rich Diet Plus Probiotics (Lactobacillus Reuteri) and Nitazoxanide in the Treatment of Minimal Hepatic Encephalopathy.||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|August 2010|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|70 Years|No|||August 2014|August 18, 2014|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01135628||121306|
NCT01135641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/6-B|Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)|Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab|R-GVHD|Nantes University Hospital|Yes|Completed|June 2010|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135641||121305|
NCT01135888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED09|Short Term Effects and Risks of Physical Exercise in Subjects With Hypohidrotic Ectodermal Dysplasia|Short Term Effects and Risks of Physical Exercise in Subjects With Hypohidrotic Ectodermal Dysplasia (Christ-Siemens-Touraine Syndrome)||University Hospital Erlangen|Yes|Completed|April 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|28|Samples Without DNA|Serum|Male|7 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with X-chromosomally inherited hypohidrotic ectodermal dysplasia (HED) and        age-matched controls|July 2011|July 25, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01135888||121286|
NCT01135901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/696-2|Local Measures to Prevent Diabetes in the Værnes Region.|The VEND RISK-study. Preventing Diabetes Type 2 in Overweight Persons in the Værnes Region, Central-Norway.|VEND-RISK|Norwegian University of Science and Technology|No|Recruiting|April 2010|September 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|65 Years|No|||September 2015|September 30, 2015|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01135901||121285|
NCT01136200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREQHOS 08023|Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Surgical and Medical Wards|Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Surgical and Medical Wards: a Multicenter Randomized Controlled Trial.|ATBREFSURMED|Henri Mondor University Hospital|No|Completed|June 2010|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01136200||121262|
NCT01136252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAPA-01/EudraCT 2009-017429-21|Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Open-label Clinical Trial to Evaluate Safety and Efficacy of Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Non-responders to the Conventional Treatment With Ranibizumab||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|May 2010|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136252||121258|
NCT01136538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-VIN-028|Bioavailability Study of Valacycovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fed Condition|An Open Label, Balanced, Randomized, Two Treatment, Two-sequence, Two-period, Single-dose Crossover Comparative Bioavailability Study of 1000 mg Valacyclovir HCl Tablets of Dr. Reddys's and Valtrex (R) 1 gm Caplets of GlaxoSmithkline in Healthy Volunteers Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2007|May 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136538||121237|
NCT01136772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6017|A Comparison of Long-acting Injectable Medications for Schizophrenia|A Comparison of Long-Acting Injectable Medications for Schizophrenia|ACLAIMS|New York State Psychiatric Institute|Yes|Active, not recruiting|March 2011|July 2016|Anticipated|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|311|||Both|18 Years|65 Years|No|||September 2013|April 7, 2015|May 14, 2010|Yes|Yes||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01136772||121219|
NCT01159301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01435|Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia|A Phase I Study of Sorafenib in Combination With the Histone Deacetylase Inhibitor, Entinostat in Patients With Advanced Cancers||National Cancer Institute (NCI)||Terminated|June 2010|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|July 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159301||119502|
NCT01159899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC- AS3|Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee|Pilot Study of A One-Step Procedure for the Use of Autologous Bone Marrow Mesenchymal Stem Cells Stimulated by Proteins Scaffold to Heal Under Arthroscopy Full-Thickness Defects Articular Cartilage and Osteoarthrosis of the Knee.||University of Marseille|Yes|Recruiting|July 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|30 Years|75 Years|No|||January 2013|January 7, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01159899||119456|
NCT01159886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDLD001|Patient-posture and Ileal-intubation During Colonoscopy|Patient-posture and Ileal-intubation During Colonoscopy (PIC): a Randomized Controlled Open-label Trial|PIC|Postgraduate Institute of Medical Education and Research|No|Recruiting|June 2010|March 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|216|||Both|12 Years|N/A|No|||July 2010|July 9, 2010|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01159886||119457|
NCT01160185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114015|Meta-analysis of Efficacy of Topotecan|Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix||GlaxoSmithKline||Completed|June 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|1|||Female|21 Years|N/A|No|Non-Probability Sample|The search was designed to identify all clinical data published since the Cancer Care        Ontario systematic review in 2006. The Cancer Care Ontario systematic review searched        MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Library        (Cochrane Database of Systematic Reviews (2006 Issue 1), and Cochrane Controlled Trials        Register (2006 Issue 1)), the Canadian Medical Association Infobase, and the National        Guidelines Clearinghouse. The conference proceedings of the American Society of Clinical        Oncology (1995-2005) and the European Society of Medical Oncology (2002-2005) were also        searched. The search was conducted on 18 December 2008.|July 2010|July 8, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01160185||119435|
NCT01138150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK112035|Ictal and Interictal Inflammatory Markers in Migraine|Ictal and Interictal Inflammatory Markers in Migraine||Johns Hopkins University|No|Completed|September 2009|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|36|||Both|18 Years|55 Years|No|||August 2011|October 22, 2014|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138150||121116|
NCT01138943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1251/10|Chlorhexidine Mouthrinses and Plaque Control|Chlorhexidine Alcohol Base Mouthrinse Versus Chlorhexidine Formaldehyde Base Mouthrinse Efficacy on Plaque Control: Double Blind, Randomized Clinical Trials||Hôpital Militaire De Rabat|No|Completed|February 2007|April 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|20 Years|25 Years|Accepts Healthy Volunteers|||February 2007|May 13, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01138943||121055|
NCT01139658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.102|Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA|Observational Cohort Study on the Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA||Boehringer Ingelheim||Completed|August 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1676|||Both|18 Years|N/A|No|Probability Sample|Demographic, medical and chirurgical characteristics|November 2013|November 27, 2013|June 7, 2010||||No|September 6, 2013|https://clinicaltrials.gov/show/NCT01139658||121001|Data for the following secondary endpoints were not collected:Medical appointments with a general practitioner or specialist at visit 3, Frequency of medical appointments at visit 3, Prescription received at visit 3.
NCT01139671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0074|Comparison of Sufentanil and Remifentanil Infusion During General Anaesthesia for Removal of Wisdom Teeth in Ambulatory Surgery|Comparison of Sufentanil and Remifentanil Infusion During General Anaesthesia for Removal of Wisdom Teeth in Ambulatory Surgery|SUF-REM-DDS|University Hospital, Clermont-Ferrand||Completed|June 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|18|||Both|15 Years|35 Years|No|||July 2014|July 4, 2014|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01139671||121000|
NCT01137058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_UH1|Ubiquitous Healthcare for Elderly Patients With Type 2 Diabetes Mellitus|Clinical Efficacy of Ubiquitous Healthcare System for Elderly Patients With Type 2 Diabetes Mellitus||Seoul National University Bundang Hospital|Yes|Completed|June 2009|September 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|150|||Both|60 Years|85 Years|No|||May 2014|May 25, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137058||121197|
NCT01139307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B1|Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia|Development of Novel Therapeutics for AMKL||Children's Oncology Group|No|Completed|July 2009|||August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|Diagnosis of acute megakaryoblastic leukemia or diagnosis of Down syndrome when        cryopreserved specimens are available.|February 2016|February 19, 2016|June 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01139307||121027|
NCT01139320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B3|Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin|Pharmacogenetics of Mylotarg||Children's Oncology Group|No|Active, not recruiting|September 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|21 Years|No|Non-Probability Sample|Newly diagnosed acute myeloid leukemia treated with gemtuzumab ozogamicin on COG-AAML03P1.|May 2015|May 6, 2015|June 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01139320||121026|
NCT01136239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX/09-140|The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance of Chronic Obstructive Pulmonary disease-a Double Blinded Randomized Placebo Controlled Trial||Kwong Wah Hospital|Yes|Completed|February 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|133|||Both|40 Years|85 Years|No|||April 2015|April 8, 2015|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136239||121259|
NCT01139645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.AS1.24|The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism|The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism: A Prospective Single-Blind Matched Controlled Study||American University of Beirut Medical Center|Yes|Completed|October 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|58|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01139645||121002|
NCT01136499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTIM-LBH|Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure|Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study|ESTIM-LBH|Centre Leon Berard|No|Completed|January 2010|January 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||February 2013|March 5, 2013|March 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01136499||121240|
NCT01135342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05062010-5883|Adding Sleep Intervention to Traditional Diet and Exercise Approach to Weight Loss|Adding Sleep Intervention to Traditional Diet and Exercise Approach to Weight Loss||Stanford University||Completed|July 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 1, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135342||121328|
NCT01135355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09222008-1301|Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients|Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients at Risk for Respiratory Failure||Stanford University||Recruiting|July 2008|July 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|blood|Both|N/A|21 Years|No|Non-Probability Sample|Hematopoietic stem cell transplantation (HSCT) for any indication.|June 2010|June 15, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135355||121327|
NCT01135654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-09JMert-03-H|Alcohol Drinking as a Vital Sign|Alcohol SBIRT Implementation in an HMO: Non-Physician Providers Vs Physicians|ADVISE|Kaiser Permanente|No|Active, not recruiting|January 2010|December 2016|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|466000|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135654||121304|
NCT01136551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUPA - CR- HMO-CTIL|Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A|An Open-label, Three-period, Crossover Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Different Release Rate Controlled Release Formulations of Huperzine A (0.4mg)Compared to the Equivalent Dose of an Immediate Release Formulation.||Hadassah Medical Organization|Yes|Not yet recruiting|September 2010|April 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2010|June 2, 2010|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136551||121236|
NCT01138709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0196-09-A721|Vitala 12 Hour Wear Test With Convex Products|Phase II Vitala 12 Hour Wear Test With Convex Products||ConvaTec Inc.|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|27|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|June 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138709||121073|
NCT01139008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10159|Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between MetroGel® (Metronidazole Gel) 1% Versus Finacea® (Azelaic Acid) Gel 15% in Subjects With Healthy Skin||Galderma Laboratories, L.P.|No|Completed|June 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 21, 2012|June 4, 2010||No||No|June 28, 2011|https://clinicaltrials.gov/show/NCT01139008||121050|
NCT01139021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72P13E2|One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age|A Phase 3, Open-Label, Multi-Center, Extension Study of V72P13E1 to Assess Antibody Persistence at One Year After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting at 12 Months of Age and to Evaluate the Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age||Novartis|Yes|Completed|June 2010|September 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|508|||Both|23 Months|27 Months|Accepts Healthy Volunteers|||April 2015|April 9, 2015|June 4, 2010|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01139021||121049|
NCT01167738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000681691|Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer|A Randomized Phase II Study of Chemotherapy ± Metformin in Metastatic Pancreatic Cancer|PACT-17|IRCCS San Raffaele|No|Terminated|July 2010|April 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||April 2015|April 23, 2015|July 21, 2010||No|concern of detrimental effect|No||https://clinicaltrials.gov/show/NCT01167738||118855|
NCT01167751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Heart-001|Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction|Autologous Bone Marrow Derived Ac 133+ and Mono Nuclear Cells In-patient With Acute Myocardial Infarction During Coronary Artery Bypass Grafting (CABG): A Randomized Phase III Clinical Trial||Royan Institute|Yes|Completed|January 2008|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|20 Years|65 Years|No|||July 2010|July 15, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01167751||118854|
NCT01159587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11856|Prophylaxis Versus On-demand Therapy Through Economic Report|Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A. POTTER|POTTER|Bayer|No|Completed|July 2004|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|58|||Both|12 Years|55 Years|No|Probability Sample|Haemophilics|April 2011|April 12, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159587||119480|
NCT01159600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.23|Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea||Boehringer Ingelheim||Completed|July 2010|||February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|1504|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|July 8, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01159600||119479|
NCT01168778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32542-A|Improving Communication During Pediatric Visits for Acute Respiratory Illness|Improving Communication During Pediatric Visits for Acute Respiratory Illness||University of Washington|No|Completed|September 2007|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1313|||Both|19 Years|N/A|No|||July 2010|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168778||118775|
NCT01168791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM3001|Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma|A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.|PICASSO III|Ziopharm|Yes|Completed|July 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168791||118774|
NCT01160211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114299|A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer|A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies||Novartis|Yes|Recruiting|May 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|525|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160211||119433|
NCT01169155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00546|Critical Smoke Alarm Characteristics to Awaken Children From Stage 4 Sleep|Critical Smoke Alarm Characteristics to Awaken Children From Stage 4 Sleep||Nationwide Children's Hospital|No|Recruiting|August 2010|July 2018|Anticipated|July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|708|||Both|5 Years|84 Years|Accepts Healthy Volunteers|||January 2016|January 30, 2016|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01169155||118746|
NCT01138176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCM09|Whole Body Cooling Using Phase Changing Material|Phase II Randomized Control Trial of Whole Body Cooling in Neonatal Encephalopathy Using Phase Changing Material||Robertson, Nicola, M.D.|Yes|Active, not recruiting|July 2009|August 2011|Anticipated|January 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|N/A|24 Hours|No|||June 2010|June 3, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01138176||121114|
NCT01138371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044778|Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers|Inflammatory and Lipid Markers Pre- and Post-LDL Apheresis: A Multicenter Experience|INFLAME|Emory University|Yes|Completed|March 2011|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|Samples Without DNA|Blood samples only|Both|3 Years|70 Years|No|Probability Sample|This study focuses on people who are currently on stable LDL apheresis treatment for high        cholesterol.|December 2013|December 16, 2013|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138371||121099|
NCT01138384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I198|Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer|A Phase I/II Study of Foretinib in Combination With Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer||Canadian Cancer Trials Group|Yes|Completed|June 2010|February 2015|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||February 2015|February 13, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138384||121098|
NCT01138397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID34|Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)||Sanofi|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138397||121097|
NCT01138683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/539|Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration|Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration|CRUF|University Hospital, Ghent|No|Completed|February 2010|December 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138683||121075|
NCT01138696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/670|Long Term Follow-up of the "Stryker Dacron and Trevira Ligament" for Anterior Cruciate Ligament (ACL) Repair|Long Term Follow-up of the "Stryker Dacron and Trevira Ligament" for ACL Repair||University Hospital, Ghent|No|Recruiting|February 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|49 Years|75 Years|No|Non-Probability Sample|Patients that received a Stryker Dacron or Trevira ligament to replace there ACL.|December 2014|December 4, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01138696||121074|
NCT01138644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The "AFFORD" Study|Atrial Fibrillation/Flutter Outcome Risk Determination|The "AFFORD" Study: Atrial Fibrillation/Flutter Outcome Risk Determination|AFFORD|Vanderbilt University|No|Completed|June 2010|April 2015|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|519|Samples With DNA|whole blood for storing and conducting genetic testing.|Both|18 Years|N/A|No|Non-Probability Sample|Participants for this study will be those with AF who present to the ED for their care.        This study population will come from all walks of life and will not exclude any one group,        sex, ethnicity, etc.|April 2015|April 28, 2015|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01138644||121078|
NCT01138657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-877|Efficacy and Safety of Adalimumab in Subjects With Active Uveitis|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate-, Posterior-, or Pan-uveitis|VISUAL l|AbbVie|Yes|Completed|August 2010|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|May 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138657||121077|
NCT01138670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS-REK-2|Complications Following Pacemaker or Implantable Defibrillator Cardioverter (ICD) Implantation in Denmark|Complications Following Pacemaker or ICD Implantation in Denmark||University of Aarhus|No|Active, not recruiting|May 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5500|||Both|N/A|N/A|No|Probability Sample|All Danish patients receiving a cardiac device (pacemaker, cardiac resynchronization        therapy (CRT) or implantable defibrillator cardioverter (ICD)), or undergoing a        reoperation from May 2010 to April 2011.|November 2012|November 8, 2012|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01138670||121076|
NCT01137734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC1-1|CARDINAL Adjustable Annuloplasty Ring System For Treatment of Mitral Regurgitation|Valtech Cardinal Adjustable Semi-Rigid Annuloplasty Ring System For Treatment of Mitral Valve Regurgitation in Open Surgical Repair||Valtech Cardio Ltd|Yes|Completed|March 2010|January 2014|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||December 2014|December 22, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01137734||121148|
NCT01139723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNT4863g|A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors|A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors||Genentech, Inc.||Completed|June 2010|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01139723||120996|
NCT01139684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0014-10|Development of Field Test for Assessing the Human Anaerobic Capability|||Hillel Yaffe Medical Center||Not yet recruiting|September 2010|June 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Male|16 Years|18 Years|Accepts Healthy Volunteers|||June 2010|June 7, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139684||120999|
NCT01139697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cortest-chf-1|Hair Cortisol and Testosterone in Heart Failure|Hair Cortisol and Testosterone Levels and Their Correlation With Heart Failure Status in Patients With Chronic Congestive Heart Failure||Meir Medical Center|No|Completed|August 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|Samples Without DNA|Hair samples for the measurment of cortisol and testosterone|Male|18 Years|N/A|No|Non-Probability Sample|Patients with systolic heart failure from the out-patient clinic at the Meir Medical        Center|May 2012|May 15, 2012|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01139697||120998|
NCT01139710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10-114-10.CTIL|Sarcoidosis-associated Pulmonary Hypertension|||Meir Medical Center|Yes|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Non-Probability Sample|100 sarcoidosis patients|July 2011|March 12, 2013|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139710||120997|
NCT01136512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07040|Metformin Use and Vitamin B12 Deficiency|Metformin Use and Vitamin B12 Deficiency||Northwell Health|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|89|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient and hospitalized patients with type 2 diabetes mellitus|July 2013|July 29, 2013|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136512||121239|
NCT01136525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-VIN-027|Bioavailability Study of Valacyclovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two-sequence, Two-period, Single-dose Crossover Comparative Bioavailability Study of 1000 mg Valacyclovir HCl Tablets of Dr. Reddys's and Valtrex (R) 1 gm Caplets of GlaxoSmithkline in Healthy Volunteers Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2007|May 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 11, 2010|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136525||121238|
NCT01136759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-008|Tenofovir Gel in Pregnancy and Lactation|Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|232|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|June 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01136759||121220|
NCT01135953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC09344|Methods to Enhance Transcranial Direct Stimulation (tDCS)|Investigating Methods to Enhance the Excitatory Effects of Transcranial Direct Stimulation (tDCS)||The University of New South Wales|Yes|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Anticipated|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01135953||121281|
NCT01138722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/204|Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial|Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer|PEARL-1|University Hospital, Ghent|No|Terminated|May 2010|May 2017|Anticipated|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2011|August 24, 2011|June 4, 2010||No|Poor recruitment rate.|No||https://clinicaltrials.gov/show/NCT01138722||121072|
NCT01139749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|seb2010|Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea|Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea.||Federal University of São Paulo|Yes|Recruiting|October 2011|December 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 9, 2011|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01139749||120994|
NCT01139372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-006|An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop|An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop||Alcon Research|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139372||121022|
NCT01139385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-001|Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel Versus Conventional Method in Day Surgery|Comparative Study Between Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel Versus Conventional Method in Day Surgery: a Prospective Randomized Study|CLCHS|University of Roma La Sapienza|No|Completed|January 2008|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|218|||Both|N/A|65 Years|No|Probability Sample|patients with gallstone undergoing cholecystectomy in day surgery setting|December 2013|March 13, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01139385||121021|
NCT01139736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS Probiotics|Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome|Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome||Chinese University of Hong Kong|No|Completed|July 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|January 18, 2013|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01139736||120995|
NCT01169753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0638|Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients|Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia (CML) on Imatinib, Dasatinib, Nilotinib (or Any Other FDA Approved TKI for CML)||M.D. Anderson Cancer Center|Yes|Terminated|May 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|July 23, 2010|No|Yes|Slow Enrollment|No|November 4, 2015|https://clinicaltrials.gov/show/NCT01169753||118700|
NCT01169779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11321|Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin|Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period|GetGoal-M-Asia|Sanofi|Yes|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|391|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|July 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169779||118699|
NCT01169168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FibICU|Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome (SIRS), Sepsis or Chronicle Liver Disease on Intensive Care Units (ICU)|Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome, Sepsis, Chronicle Liver Disease or After Lysis on Intensive Care Units||Johann Wolfgang Goethe University Hospitals|No|Recruiting|April 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|Samples Without DNA|citrated plasma|Both|18 Years|80 Years|No|Non-Probability Sample|patients in intensive care units of the university hospital|July 2010|July 23, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169168||118745|
NCT01169129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3602010|Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resectable Brain Metastases|Surgery and Whole Brain Radiotherapy Versus Whole Brain Radiotherapy and Radiosurgery for 1-3 Resectable Brain Metastases: Phase III Prospective Pilot Study||Barretos Cancer Hospital|Yes|Withdrawn|July 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|64 Years|No|||February 2014|February 2, 2014|July 22, 2010||No|No participants enrolled.|No||https://clinicaltrials.gov/show/NCT01169129||118748|
NCT01169142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPCIRB0804|Study of Vitamin D in the Severely Mentally Ill|A Pilot Study of Vitamin D Supplementation in Bronx Psychiatric Patients||Bronx Psychiatric Center|No|Active, not recruiting|January 2010|December 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|70 Years|No|||July 2015|July 20, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01169142||118747|
NCT01138410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIB1-001|Study of a DNA Immunotherapy to Treat Melanoma|A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma||Scancell Ltd|No|Recruiting|May 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|May 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138410||121096|
NCT01145248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BilBiop_001|Comparison of Biliary Forceps Biopsy and Brush Cytology|A Combination of Endoscopic Transpapillary Brush Cytology and a Novel Method of Forceps Biopsy to Diagnose Proximal Biliary Malignancies||University of Ulm|No|Completed|January 2006|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|43|||Both|N/A|N/A|No|||May 2010|June 15, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145248||120573|
NCT01136564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-TL-2010|Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease|Reno- and Vascular Protective Effect of a Low-calcemic Vitamin-D-analogue (Paricalcitol) in Stage III-IV Chronic Kidney Disease||Regional Hospital Holstebro|Yes|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136564||121235|
NCT01138982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 238/2006:34|Effectiveness Study of a Swedish Youth Mentoring Program|A Randomized Effectiveness Trial of a One-to-one, Adult-to-youth Mentoring Program in Sweden||Karolinska Institutet|Yes|Completed|October 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|128|||Both|14 Years|14 Years|Accepts Healthy Volunteers|||March 2016|March 5, 2016|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01138982||121052|
NCT01138995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-L300-0801, Rev. B|Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop|Functional Ambulation: Standard Treatment vs. Electronic Stimulation Therapy (FASTEST)Trial in Chronic Post-Stroke Subjects With Foot Drop|L300|Bioness Inc|Yes|Completed|May 2010|February 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138995||121051|
NCT01137747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0913 / 201107117|Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia|A Phase I Trial of Carfilzomib in Adult Patients With Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia|AML ALL|Washington University School of Medicine|Yes|Active, not recruiting|October 2010|July 2016|Anticipated|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|June 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137747||121147|
NCT01137409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811004420|Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion|Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion||Yale University|No|Completed|August 2010|||December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|80 Years|No|Probability Sample|All patients with suspected or previously diagnosed coronary artery disease that are        clinically referred for either a treadmill exercise stress/rest SPECT study or an        adenosine vasodilatation stress/rest SPECT study will be considered for this protocol.        Efforts will be made to enroll equal numbers of men and women for this clinical study.|May 2015|May 19, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137409||121172|
NCT01135394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043497|Pharmacogenomics of Thiazolidinediones|Pharmacogenomics of Thiazolidinediones|PPAR|University of Maryland|Yes|Enrolling by invitation|March 2009|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|134|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135394||121324|
NCT01135407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0914|Visual Selective Attention in Parkinson's Disease|Role of the Cortico-basal Ganglia Loops in Visual Attention: Effects of Dopaminergic and Subthalamic Nucleus Stimulation in Parkinson's Disease|VSA-PD|University Hospital, Grenoble|No|Completed|October 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|36|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson's disease patients will be selected among those regularly treated in the Centres        that take part to the study. Healthy controls will be selected among patient family        circle, and the staff of the Centres where the research takes place.|June 2010|November 19, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135407||121323|
NCT01135381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS017786|IVR-Enhanced Care Transition Support for Complex Patients|E-Coaching: IVR-Enhanced Care Transition Support for Complex Patients||University of Alabama at Birmingham|Yes|Completed|February 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|511|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|June 1, 2010||No||No|April 10, 2013|https://clinicaltrials.gov/show/NCT01135381||121325|Limitations include generalizability. Our single healthcare system likely has unique characteristics. Readmission to the hospital is also a limited quality measure. There is currently no way to deem if readmissions are appropriate or avoidable.
NCT01135693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWYTNHS|Service Users' Perspective of Reasons for Detention Under Section 136 of the Mental Health Act 1983|A Qualitative Study of Service Users' Perspective of Reasons for Detention Under Section 136 of the Mental Health Act 1983 Using Grounded Theory||South West Yorkshire Partnership NHS Foundation Trust|Yes|Not yet recruiting|August 2010|January 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|Psychiatric patients who are detained under Section 136 of the Mental Health Act 1983 in        Wakefield district and subsequently admitted as inpatients to psychiatric wards at        Fieldhead Hospital, Wakefield.|June 2010|June 2, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01135693||121301|
NCT01135680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-010|Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100|Double-Blind Randomized Placebo-Control Trial to Evaluate Electrocardiogram Effects of HPN-100 as Defined by Clinical and Supratherapeutic Dose in Healthy Men and Women||Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|98|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|May 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01135680||121302|
NCT01136265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-238_10|PET/CT and Sentinel Node in Oral Cancer|Dual-time PET/CT and Sentinel Node Diagnostics Preoperatively in Patients With Oral Cancer|PETNode|Rigshospitalet, Denmark|No|Active, not recruiting|June 2010|June 2013|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|whole blood, primary cancer tissue, normal oral tissue|Both|18 Years|N/A|No|Non-Probability Sample|70 consecutive patients with biopsy-verified oral cancer without a suspicion of metastases        and without prior treated neck|June 2010|January 10, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136265||121257|
NCT01139398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L2009-06|Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia|Effect of Dietary Supplement Limicol on LDL-cholesterol Levels in Moderate Hypercholesterolaemia||Lescuyer Laboratory|Yes|Completed|May 2010|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139398||121020|
NCT01135160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSM 2010-1|Evaluation of Weight Bearing After Total Hip and Knee Replacement|Evaluation of Weight Bearing in Patients After Total Hip and Knee Replacement||Kantonsspital Münsterlingen|Yes|Recruiting|November 2014|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|all patients receiving TKA or THA at our institution between August 2010 and August 2011|April 2015|April 17, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01135160||121342|
NCT01135173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-100-03|Waterpipe Cessation Intervention Study|Pilot Test of a Cessation Intervention for Waterpipe Smokers||University of Memphis|Yes|Completed|November 2007|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||March 2010|June 9, 2010|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01135173||121341|
NCT01135446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-088|Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects|Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects|ULDS|AstraZeneca|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01135446||121320|
NCT01169181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6237|AMES + Brain Stimulation|AMES + Brain Stimulation: Treatment for Profound Plegia in Stroke|AMES|AMES Technology|Yes|Active, not recruiting|July 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|75 Years|No|||May 2013|May 17, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169181||118744|
NCT01168258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100169|Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema|Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema||National Institutes of Health Clinical Center (CC)||Terminated|July 2010|August 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|68|||Both|18 Years|N/A|No|||August 2013|February 19, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168258||118815|
NCT01168531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0506|The Effect of Pregabalin and Dexamethasone on Acute and Chronic Pain After Lumbar Spinal Surgery|The Effect of Pregabalin and Dexamethasone on Acute and Chronic Pain After Lumbar Spinal Surgery||Yonsei University|No|Completed|December 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|108|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||January 2011|August 18, 2011|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01168531||118794|
NCT01169454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016054|Ventriculostomy in Subarachnoid Hemorrhage (SAH): Intracranial Pressure (ICP) Open or Not?|Ventriculostomy in SAH: ICP Open or Not?|VISION 2|Duke University|No|Terminated|March 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with subarachnoid hemorrhage|April 2015|April 3, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169454||118723|
NCT01169792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0483|Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients|Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment||Yonsei University||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||Samples With DNA|Blood samples with DNA|Both|18 Years|N/A||Non-Probability Sample|Breast cancer survivors who underwent surgery at Severance hospital, Yonsei University        Health System.|October 2009|July 23, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169792||118698|
NCT01170026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R34 DA0029871|Individual and Family Motivational Interviews for Substance Using Truant Teens|Individual and Family Motivational Interviews for Substance Using Truant Teens||Brown University|Yes|Completed|August 2010|July 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|13 Years|16 Years|No|||July 2012|July 2, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01170026||118680|
NCT01136278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 353/09|Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)|Pharmacological Interaction Between Clonidine and 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)||University Hospital, Basel, Switzerland|Yes|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01136278||121256|
NCT01144949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIL1001|Study of Silodosin to Facilitate Passage of Urinary Stones|A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage||Watson Pharmaceuticals|No|Completed|June 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|June 14, 2010|Yes|Yes||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01144949||120596|
NCT01145235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GB0905|Swedish Macrolane Registry|||Q-Med AB||Recruiting|April 2010|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All clinics treating females with Macrolane in the breast will be asked to participate.|November 2013|November 8, 2013|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145235||120574|
NCT01137071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-Ov-01.10|Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer|A Phase II Trial of Hu3S193 Consolidation Therapy for Patients With Relapsing Platinum-sensitive Ovarian, Primary Peritoneal and Fallopian Tubes Adenocarcinoma, Who Achieved a Second Complete Response||Recepta Biopharma|No|Terminated|April 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|May 31, 2010|Yes|Yes|Total number of pts expected to be enrolled would not be met.|No||https://clinicaltrials.gov/show/NCT01137071||121196|
NCT01137084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100603|Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids|||Shanghai Jiao Tong University School of Medicine||Completed|January 2005|December 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||June 2010|June 3, 2010|June 3, 2010||||No||https://clinicaltrials.gov/show/NCT01137084||121195|
NCT01136785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-0547|Effects of Continuous Positive Airway Pressure (CPAP)Treatment on Glucose Control|Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes|CPAP|University of Chicago|No|Active, not recruiting|September 2009|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136785||121218|
NCT01137435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td533|Post Marketing Surveillance for ADACEL™ in South Korea|Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult)||Sanofi|No|Active, not recruiting|June 2010|November 2016|Anticipated|March 2016|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|659|||Both|11 Years|64 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137435||121171|
NCT01137760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-2009|Galactooligosaccharide, Immune Strength, and Digestive Health|Protocol 1: Galactooligosaccharide, Immune Strength, and Digestive Health in Academically Stressed University Students||University of Florida|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|427|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 1, 2012|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137760||121146|
NCT01137955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB6531(Y3M00)|Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease|Double-blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients With Celiac Disease||Columbia University|Yes|Completed|October 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||June 2010|January 19, 2011|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137955||121131|
NCT01137968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP14B012|Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)||Geron Corporation|No|Completed|May 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||March 2015|December 22, 2015|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137968||121130|
NCT01137721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCDMR4|State Of The Art Functional Imaging In Sickle Cell Disease|State Of The Art Functional Imaging In Sickle Cell Disease||St. Jude Children's Research Hospital|No|Recruiting|September 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|60|||Both|5 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|The potential research participants will be recruited, screened and consented from the        School-Age and Teen Sickle Cell Clinics by the referring St. Jude hematology        co-investigators. There will be no advertisement per se. Affiliate hematology        co-investigators will contact St. Jude hematology co-investigators about potentially        eligible research participants. Affiliate potential research participants will be        screened, and if appropriate, consented and tested at St. Jude institution.|September 2015|September 29, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137721||121149|
NCT01135706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0097|Fractal Analysis of the Pulmonary Arterial Tree in Pulmonary Hypertension|Fractal Analysis of the Pulmonary Arterial Tree in Pulmonary Hypertension.||Ohio State University|No|Completed|April 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having a right heart catheterization and CT pulmonary angiogram|October 2012|October 31, 2012|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01135706||121300|
NCT01135966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/157|Resistance Training in Patients With Chronic Obstructive Lung Disease (COPD): Whole Body Vibration Versus Conventional Resistance Training|Resistance Training in Patients With Chronic Obstructive Lung Disease (COPD): Whole Body Vibration Versus Conventional Resistance Training|REWORK|University Hospital, Ghent|No|Completed|April 2010|November 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|40 Years|80 Years|No|||December 2011|December 9, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01135966||121280|
NCT01138423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU-Vasc-14A|Treatment of Adiposity Related hypErTension (TARGET)|A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension|TARGET|UMC Utrecht|No|Completed|August 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|30 Years|70 Years|No|||February 2012|February 23, 2012|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138423||121095|
NCT01139411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT00538804|The Role of Parents in Adolescent Weight Loss|Parental Involvement as a Strategy to Enhance Adolescent Weight Control||The Miriam Hospital|Yes|Recruiting|August 2009|January 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|13 Years|17 Years|No|||June 2010|July 19, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139411||121019|
NCT01139424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Fritscher-Ravens|Closure of Anastomotic Leaks in the Stomach and Esophagus by Endoscopic Suturing|Safety and Efficacy of Closure of Postoperative Anastomotic Leaks in the Stomach and Esophagus by Endoscopic Suturing: A Prospective Pilot Study|GASTROSUTURE|University of Schleswig-Holstein|No|Not yet recruiting|June 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||May 2010|June 7, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01139424||121018|
NCT01139437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 258|Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/Δ1724 Lot PIV2#109C, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV2-Seropositive Children 15 to 59 Months of Age, and HPIV2-Seronegative Infants and Children 6 to 59 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|June 2010|April 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|7||Anticipated|90|||Both|6 Months|49 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|June 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01139437||121017|
NCT01135199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05302008-1189|Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis|Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study||Stanford University||Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|May 28, 2010|Yes|Yes|The FDA did not accept the sponsor's additional animal toxicology data to support the proposed    dosing in this protocol.|No||https://clinicaltrials.gov/show/NCT01135199||121339|
NCT01135472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08197|Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers|Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers||City of Hope Medical Center|Yes|Completed|March 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01135472||121318|
NCT01169194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-09-11-09|Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS): The Search for New Genes|Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)|MAAIS|Johns Hopkins University|Yes|Recruiting|June 2003|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|2400|Samples With DNA|Blood samples from each participant will be sent to the NIDDK repository for DNA      purification, sample distribution, establishment of cell lines. Serum samples will be sent      to Fisher Bioservices Repository.      All additional samples will be processed and stored at Dr. Brant's Johns Hopkins IBD      Genetics Laboratory with isolated lymphocytes and cell cultures made and stored at the Johns      Hopkins Cell Center with use restricted to the PI (Dr. Brant).|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient's of gastroenterology departments at medical centers.|July 2011|July 6, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01169194||118743|
NCT01168843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0027-10-BNZ|Computer Program for Evaluation of the Symmetry Between the Primary Sulci of the Two Fetal Brain Hemispheres and Midsagittal Fetal Head Biometry Using 3-dimensional Ultrasound Planes.|||Bnai Zion Medical Center||Not yet recruiting|October 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Female|20 Years|45 Years|No|Probability Sample|normal pregnancies in 2nd and 3rd trimester|July 2010|August 23, 2010|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168843||118770|
NCT01169441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2265-4|Lead Extract Study|EXTRACT Study (Data Collection on the Extraction of 2nd and 3rd Generation Defibrillation Leads)|EXTRACT|St. Paul Heart Clinic|No|Completed|November 2006|May 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are scheduled for an ICD lead extraction|May 2009|July 23, 2010|May 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01169441||118724|
NCT01170078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOE-10-08|A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|A Phase 1 Study Comparing the Pharmacokinetics of Epoetin Hospira and Epoetin Alfa (Amgen) When Administered Intravenously in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment||Hospira, Inc.|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|75 Years|No|||June 2015|June 12, 2015|July 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01170078||118676|
NCT01170104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUHHO 2009-1|Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)|Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma||Chung-Ang University|No|Recruiting|June 2009|June 2013|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||June 2009|June 22, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170104||118674|
NCT01169805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0176|Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery|Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery||Yonsei University|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|105|||Female|20 Years|65 Years|No|||November 2011|November 16, 2011|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169805||118697|
NCT01136798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-291-B|Impact of Exenatide on Sleep in Type 2 Diabetes|Impact of Exenatide on Sleep and Circadian Function in Type 2 Diabetes: A Pilot Study||University of Chicago||Recruiting|June 2010|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|April 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136798||121217|
NCT01137097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-07-101|Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC|Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study|LSLNB|Samsung Medical Center|Yes|Completed|June 2009|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|278|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137097||121194|
NCT01137110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1717|Comparison of Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After Subarachnoid Hemorrhage (SAH)|Comparison of Short Duration Levetiracetam to Extended Course Levetiracetam for Seizure Prophylaxis Following Subarachnoid Hemorrhage|DOPAST|Washington University School of Medicine|Yes|Recruiting|May 2010|January 2015|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|460|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01137110||121193|
NCT01137448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5T35DK007676-18|The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients|The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients||The University of Texas Health Science Center, Houston|No|Withdrawn|June 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|June 3, 2010||No|The site did not have enough funds to complete study arrengments and start to enrolling. The    site was not able to enroll subjects.|No||https://clinicaltrials.gov/show/NCT01137448||121170|
NCT01137461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TATV|Efficacy of Embryo Transfer Procedure Guided by Transvaginal Ultrasound Versus Abdominal Ultrasound in Oocytes Recipients|Evaluation of Efficacy of Embryo Transfer Procedure Guided by Transvaginal Ultrasound Versus Abdominal Ultrasound in Recipients of Oocytes. A Single-centre, Randomized Clinical Trial.||Fundació Privada Eugin|Yes|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|330|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 13, 2011|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137461||121169|
NCT01138020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6996-W|Cognitive Rehabilitation of Blast Traumatic Brain Injury (TBI)|Cognitive Rehabilitation of Blast-induced Traumatic Brain Injury|CRbTBI|VA Office of Research and Development|No|Recruiting|March 2011|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|50 Years|No|||December 2015|December 4, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01138020||121126|
NCT01137981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112885|Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects|Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects Associated With Exposure to GSK HIV Drugs During Pregnancy||ViiV Healthcare|No|Recruiting|February 1993|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1|||Female|N/A|N/A|No|Non-Probability Sample|Any pregnant, HIV positive woman exposed to antiretroviral drugs during pregnancy is        eligible to enroll. Registration is voluntary. Health professionals are strongly        encouraged to enroll their antiretroviral-exposed pregnant patients into the Registry as        early in the pregnancy as possible, preferably before prenatal testing is done.|February 2016|February 18, 2016|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01137981|31 Years|121129|
NCT01138202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 104|Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy|A Pilot Study of the Pharmacokinetics and Safety of Lopinavir/Ritonavir 400/100mg Bid Versus Lopinavir/Ritonavir 600/150 mg BID Combined With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|November 2010|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|60 Years|No|||February 2016|February 19, 2016|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138202||121112|
NCT01137942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMI2010-1|The Role of Cathepsin X in Infection With the Helicobacter Pylori|Helicobacter Pylori and Gastric Cancer - the Role of Cytokine Polymorphism, Cytokine Expression and Expression of TLR on Persistence of Helicobacter Pylori Infection and Development of Gastric Cancer.||University Medical Centre Ljubljana|Yes|Recruiting|November 2008|July 2010|Anticipated|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|14|Samples With DNA|Helicobacter pylori strains from patients are stored at -70oC.|Both|18 Years|65 Years|No|Non-Probability Sample|The investigators invited people who had problems with H. pylori(Hp) infection. They were        tested for Hp and if positive they were enrolled in the study.All patients were treated        with appropriate therapy.3 months after antibiotic therapy, the patients were re-examined.        The patients that had a positive test were invited to another re-evaluation.If H. pylori        sensitive to all antibiotics tested was isolated, we enrolled the patient in the study-7        patients. The investigators took the patient's first isolate and used it to prepare        antigens for the study. All patients in the control group, 7 patients, were successfully        cured with first attempt of antimicrobial therapy.Seven months after last patient        enrolled, all the participants will be re-evaluated to see if they are still infected with        Hp.|March 2010|July 9, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137942||121132|
NCT01138189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05272010-6188|Wavefront-guided Versus Wavefront-optimized LASIK for Nearsightedness|A Prospective Eye to Eye Comparison of LASIK Using Wavefront-guided Treatment Versus Wavefront-optimized Treatment||Stanford University|No|Active, not recruiting|April 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects age 21 and older with healthy eyes. Nearsightedness between -7.50 diopters and        -7.00 diopters with or without astigmatism of up to 3.50 diopters.|March 2014|April 2, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01138189||121113|
NCT01138735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18155|Epiduo Pediatric Acne Study|A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris||Galderma|No|Completed|June 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|285|||Both|9 Years|11 Years|No|||April 2013|April 4, 2013|June 4, 2010|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT01138735||121071|LOCF data were used for primary efficacy and secondary efficacy data.
NCT01139034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002029D|A Pilot Study of Shoulder Subluxation Treatment by Using the Self-Designed Surface Functional Electrical Stimulator|Rehabilitation Robot for Upper Limbs, Component Project 2: Hybrid of FES and Rehabilitation Robot for Treatment of Shoulder Subluxation||National Taiwan University Hospital|No|Recruiting|March 2010|March 2011|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|3|||Both|25 Years|65 Years|No|||June 2010|June 20, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139034||121048|
NCT01139463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|500-03/06-01/74, 2181-147-06|Study of Blood Lactate Levels in Patients Treated With Antipsychotics|Blood Lactate Levels in Patients Treated With Typical or Atypical Antipsychotics||University of Split|Yes|Completed|June 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Male|20 Years|50 Years|No|Non-Probability Sample|The population consists of patients from the psychiatric inpatient and outpatient sections        of a primary care hospital.|June 2010|June 7, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01139463||121015|
NCT01135186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03252010-5462|The Purpose of This Pilot Study is to Assess the Impact of KUVAN® (Sapropterin Dihydrochloride) on Gastric Relaxation in Women With Diabetic Gastroparesis.|Kuvan® (Sapropterin Dihydrochloride) for Improving Gastric Accommodation in Women With Diabetic Gastroparesis (KIGA-DG)||Stanford University||Recruiting|May 2010|March 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|65 Years|No|||June 2010|June 3, 2010|May 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01135186||121340|
NCT01135784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RZN 1|Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache|Human CT: Efficacy & Safety of MIGRA-ZEN RELIEF PLUS:Herbal Supp:Extracts Juniper Willow Goldenrod Dandelion Meadowsweet Whole Grape In Rx of Chronic Migraine Headache. Randomized, Double-Blind, Placebo Cont. Study P.II (PoC Study)|RZN|RZN Nutraceuticals, Inc.|No|Not yet recruiting|October 2011|July 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|June 13, 2011|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01135784||121294|
NCT01135797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS11315|Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials|Retrospective Safety Survey In Patients Included In Phase I-II NV1FGF Clinical Trials|TALISMAN S|Sanofi|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|164|||Both|18 Years|N/A|No|Non-Probability Sample|Patients participating in this observational study previously participated in one of the        phase I-II studies for the compound|April 2011|April 27, 2011|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01135797||121293|
NCT01169480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Massage Study - I|The Impact of Giving a Massage|The Impact of Giving a Massage on Perceived Depression, Anxiety and Stress of Massage Therapists: A Randomized Clinical Trial||Parker Research Institute|Yes|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|February 28, 2011|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01169480||118721|
NCT01169818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_R_04889|Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus|Asian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 Diabetes Mellitus|ATLAS|Sanofi||Completed|August 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|555|||Both|40 Years|75 Years|No|||July 2013|July 5, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169818||118696|
NCT01169207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-01-31-06|Johns Hopkins Crohn's Disease and Ulcerative Colitis Study|Johns Hopkins Crohn's Disease and Ulcerative Colitis Study||Johns Hopkins University|Yes|Recruiting|July 1996|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2500|Samples With DNA|whole blood, serum|Both|4 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|IBD patient's are primarily recruited at the Johns Hopkins inpatient and outpatient units.        However, individuals contact us by phone, mail or email after hearing about our study|July 2011|July 6, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169207||118742|
NCT01169220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-041|Bowel Preparation for Inpatient Colonoscopy|Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy||Santa Clara Valley Health & Hospital System|Yes|Recruiting|July 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2010|July 23, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01169220||118741|
NCT01170351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRC-301174|Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis|Comparing Efficacy and Tolerability of Cyclosporine-A vs. Prednisolone for Induction of Remission in Auto-immune Hepatitis||Tehran University of Medical Sciences|No|Recruiting|December 2005|December 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|65 Years|No|||July 2010|July 26, 2010|July 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01170351||118655|
NCT01166555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0151004|Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers|Phase I Pharmacokinetics And Tolerability Of PF-04236921 Following Subcutaneous Administration To Healthy Volunteers||Pfizer|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 19, 2010|May 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01166555||118946|
NCT01170585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006214-16|A Trial of Rosuvastatin in Systemic Lupus Erythematosus|A Randomised Placebo Controlled Trial of Rosuvastatin in Systemic Lupus Erythematosus||Imperial College London|Yes|Completed|July 2010|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|80 Years|No|||June 2015|June 22, 2015|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170585||118637|
NCT01136577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070604|Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn|Comparison of Light-emitting Diodes (LED) Phototherapy Versus Fluorescent Lamps Phototherapy for Treatment of Hyperbilirubinemia in Term Newborn|DELF|Assistance Publique - Hôpitaux de Paris|No|Terminated|January 2010|March 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|35 Weeks|N/A|No|||December 2012|December 10, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136577||121234|
NCT01136811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17002A|Safety and Efficacy of Computer Assisted Surgery for Use in Vascular Surgery Procedures|Safety and Efficacy of Computer Assisted Surgery for Use in Vascular Surgery Procedures||University of Chicago|Yes|Terminated|June 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|May 28, 2010|No|Yes|Study was terminated. P.I. left the institution before completing study|No||https://clinicaltrials.gov/show/NCT01136811||121216|
NCT01136824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-046|Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden|Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden||University of Pittsburgh|Yes|Completed|June 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy        protocol of doxorubicin plus ifosfamide (AI)|June 2015|June 1, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136824||121215|
NCT01137123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007044|Improve the Treatment of Thoracic Esophageal Cancer|A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer||Sun Yat-sen University|Yes|Recruiting|April 2010|December 2017|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|122|||Both|N/A|70 Years|No|||May 2015|May 19, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137123||121192|
NCT01137474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-073 ST|A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)||Bristol-Myers Squibb|No|Completed|July 2010|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|2996|||Both|18 Years|89 Years|No|||April 2014|April 1, 2014|June 3, 2010|Yes|Yes||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01137474||121168|Study originally had 2 additional arms, dapagliflozin 2.5 and 5 mg, but enrolment stopped after Protocol Amendment 8 (1-11-11) implemented. Because endpoints focused on comparison of dapagliflozin 10 mg with placebo, only these arms were summarized.
NCT01137773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL IRB #562.06|Normoglycemia and Neurological Outcome|Does Maintenance of Normoglycemia Change Neurological Outcome in Patients Recovering From Traumatic Brain Injury and Subarachnoid or Intraparenchymal Hemorrhage?||University of Louisville|No|Enrolling by invitation|January 2007|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|18 Years|80 Years|No|||November 2012|November 12, 2012|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137773||121145|
NCT01138254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98C1-045|Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients|The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|November 2008|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|No|||July 2011|July 12, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01138254||121108|
NCT01137994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113333|A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer|A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer||GlaxoSmithKline|No|Withdrawn|October 2011|March 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||March 2013|March 11, 2013|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137994||121128|
NCT01138007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113351|A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)|Study AK1113351, a Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) - a Multi-center, Placebo-controlled, Randomized, Double-blind, Parallel-comparison Study||GlaxoSmithKline|No|Completed|June 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|572|||Both|18 Years|64 Years|No|||September 2013|September 25, 2013|June 3, 2010||No||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01138007||121127|
NCT01138215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 111|The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children|The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|1 Year|15 Years|No|||June 2010|June 4, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138215||121111|
NCT01138436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEBO-VSU-PII-001 v2.0|A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers|A Phase II, Randomized, Controlled, Two-Center Pilot Study of the Safety and Efficacy of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Venous Leg Ulcers||Skingenix, Inc.||Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138436||121094|
NCT01138449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC356|Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)|Efficacy of Neonatal Vitamin A Supplementation in Improving Child Survival in Haryana, India: Generation of Evidence Necessary for Informing Global Policy||Society for Applied Studies|Yes|Completed|June 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44984|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||May 2015|May 29, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138449||121093|
NCT01138748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/205|Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers|Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers|PEARL-2|University Hospital, Ghent|No|Terminated|November 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138748||121070|
NCT01138761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1164097|Health Literacy for Children With Atopic Dermatitis and Their Caregivers|Health Literacy for Children With Atopic Dermatitis and Their Caregivers||University of Missouri-Columbia|No|Terminated|June 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|33|||Both|N/A|7 Years|No|||February 2012|January 3, 2013|June 4, 2010||No|Enrollment was significantly under target.|No||https://clinicaltrials.gov/show/NCT01138761||121069|
NCT01139047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10160|Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between MetroGel® (Metronidazole Gel) 1% vs Finacea® (Azelaic Acid) 15% in Subjects With Healthy Skin||Galderma Laboratories, L.P.|No|Completed|June 2010|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 21, 2012|June 4, 2010||No||No|June 28, 2011|https://clinicaltrials.gov/show/NCT01139047||121047|
NCT01139060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH082995|Organized Self-Management Support Services for Chronic Depression|Organized Self-Management Support Services for Chronic Depression|Stride|Group Health Cooperative|Yes|Completed|August 2009|||April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 15, 2013|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01139060||121046|
NCT01135485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007242|Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome|Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome||Children's Hospital of Philadelphia|No|Active, not recruiting|March 2010|August 2015|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|33|||Both|8 Years|18 Years|No|Probability Sample|Children and adolescents between 8 and 18 years of age|October 2014|October 13, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135485||121317|
NCT01135810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05252010-6143|Functional Magnetic Resonance Imaging (MRI) of Hypnosis and Mindfulness Meditation|Resting State Functional MRI Investigation of Hypnotic Trance and Mindfulness Meditation||Stanford University|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|102|Samples Without DNA|blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects who score in diverse ranges on hypnotic induction profiles or who are        experienced Mindfulness Meditators.|December 2013|December 2, 2013|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135810||121292|
NCT01135823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07292009-3461|Symptom Assessment With Patient Surveys|Symptom Assessment With Patient Surveys||Stanford University||Completed|July 2006|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|These patients will be pediatric oncology patients who have received chemotherapy within        the prior four weeks and being seen in the oncology clinic for an out-patient visit.|June 2010|June 2, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135823||121291|
NCT01169493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025144|Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)|Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)|PACE-RBBB|Duke University|Yes|Completed|January 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|16|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|July 22, 2010|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01169493||118720|We were unable to enroll adequately, and the study was underpowered to assess either the safety or efficacy of RV only, or BIV pacing in patients with right bundle branch block.
NCT01169506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nagymaci54|Sublingual Tonometry to Assess Tissue Perfusion in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A New Method of Sublingual Tonometry to Assess Tissue Perfusion in Patients With COPD and Healthy Individuals|subton|Szeged University|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2009|August 6, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169506||118719|
NCT01169831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045413|Regulation of Endothelial Progenitor Cells by Short-Term Exercise|Regulation of Endothelial Progenitor Cells by Short-Term Exercise|EPC-Ex|Baltimore VA Medical Center|Yes|Active, not recruiting|July 2011|November 2017|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|60|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169831||118695|
NCT01170065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.35|Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)|A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis||Boehringer Ingelheim||Active, not recruiting|June 2010|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|198|||Both|40 Years|N/A|No|||March 2016|March 21, 2016|July 6, 2010||||No||https://clinicaltrials.gov/show/NCT01170065||118677|
NCT01166568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-277-5|Trial of the PresView Implant for the Improvement of Near Vision in Patients With Presbyopia|A Prospective, Multicenter Clinical Trial Of the PresVIEW Scleral Implant (PSI) For the Improvement Of Near Visual Acuity In Presbyopic Patients||Refocus Group, Inc.|No|Completed|December 2003|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|360|||Both|50 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166568||118945|
NCT01166815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USARIEM C07-04|Zinc Supplementation to Reduce Diarrhea Rates in Adults in Western Kenya.|A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya.||United States Army Research Institute of Environmental Medicine|Yes|Completed|July 2007|January 2008|Actual|January 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166815||118926|
NCT01167101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-62|Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?|Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study||Kangdong Sacred Heart Hospital|Yes|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|290|||Both|20 Years|N/A|No|||September 2015|September 3, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167101||118904|
NCT01136590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRANEX2009|Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery|Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery||Hospital Universitari Vall d'Hebron Research Institute||Completed|September 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|70 Years|No|||February 2015|February 23, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136590||121233|
NCT01136837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYİEAH-3|The Prognostic Significance of a Fragmented QRS Complex After Primary Percutaneous Coronary Intervention|||Bursa Postgraduate Hospital|No|Completed|November 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|85|||Both|18 Years|80 Years||Non-Probability Sample|patients who presented to the hospital within 12 hours of the onset of chest pain who were        admitted to the coronary intensive care unit (ICU) with the diagnosis of acute STEMI and        who were administered primary PCI. Having acute STEMI for the first time was stipulated        for inclusion in the study.|November 2008|June 3, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136837||121214|
NCT01136850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70270|Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea|Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea|IPTp in PNG|University of Melbourne|Yes|Completed|November 2009|January 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|2793|||Female|16 Years|49 Years|Accepts Healthy Volunteers|||April 2013|April 20, 2013|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01136850||121213|
NCT01137487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRIREA1|Study of Impact of Not Measuring Residual Gastric Volume on Nosocomial Pneumonia Rates|Impact of Not Measuring Residual Gastric Volume on Nosocomial Pneumonia Rates in Mechanically Ventilated Patients Receiving Early Enteral Feeding: a Randomized-controlled Study|NUTRIREA1|Centre Hospitalier Departemental Vendee|Yes|Completed|May 2010|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|452|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01137487||121167|
NCT01138033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113517|Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors|A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects With Solid Tumors||GlaxoSmithKline|No|Recruiting|July 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|138|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138033||121125|
NCT01138540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gravity-VAP Trial|The Gravity-VAP (Ventilator-Associated Pneumonia) Trial|Prospective, Randomized, Multi-Center Trial of Lateral Trendelenburg Versus Semi-Recumbent Body Position in Mechanically Ventilated Patients For The Prevention of Ventilator-Associated Pneumonia|Gravity-VAP|Policlinico Hospital|Yes|Suspended|November 2010|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|800|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 4, 2010||No|NOT RECRUITING PARTICIPANTS, UNTIL COMPLETION OF THE SECOND INTERIM ANALYSIS|No||https://clinicaltrials.gov/show/NCT01138540||121086|
NCT01138241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 114|Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation|Incidence and Predictor of TDF Associated Nephrotoxicity and Pharmacokinetic of TDF in HIV-1 Infected Thai Patients: A Sub-study of HIV-NAT 006 Long Term Cohort||The HIV Netherlands Australia Thailand Research Collaboration|No|Active, not recruiting|March 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|700|Samples With DNA|PBMC collection|Both|18 Years|N/A|No|Non-Probability Sample|HIV-NAT 006 participants (TDF +non TDF)and ARV naive population        For TDF group, on TDF > 3 months HIV/HBV co-infected patients from COLD (Liver disease and        HIV/HBV coinfection in the era of HAART) and TDF surveillance study|March 2015|March 27, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138241||121109|
NCT01138228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF Validation|Does the VTS1000 Infra Red Vein Imager Allow Better Identification of Veins Than Normal Eyesight?|Validation of Vue Tek Digital Vein Viewing Device|VFvalidation|St. Luke's-Roosevelt Hospital Center|No|Completed|February 2010|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|106|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ages 4 weeks and above Light skin Dark skin Normal weight Obese weight|February 2010|June 4, 2010|March 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01138228||121110|
NCT01138462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocole 96/10|Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions|Universal Screening and Decolonization vs Standard Precautions for Control of Methicillin-resistant Staphylococcus Aureus (MRSA) in Nursing Homes: a Cluster, Randomised Controlled Study.||University of Lausanne Hospitals|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|157|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 22, 2014|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138462||121092|
NCT01138475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-234|Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery|A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery|ExtenD|William Beaumont Hospitals|No|Active, not recruiting|July 2010|October 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 12, 2014|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138475||121091|
NCT01138774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBEPALIP|Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) in Human Obesity|Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) on Adipose Tissue: Potential Application in Human Obesity|OBEPALIP|Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|January 2010|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|103|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||February 2012|May 27, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01138774||121068|
NCT01139086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003050R|Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF)|Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure||National Taiwan University Hospital|No|Recruiting|May 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|100|||Male|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chronic Heart Failure Coronary Disease Dilated Cardiomyopathy Control group without        diagnosis of any heart disease|June 2010|June 7, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139086||121044|
NCT01139450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0417|Study of 0417 Ointment in the Treatment of Atopic Dermatitis|Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0417 Ointment||Fougera Pharmaceuticals Inc.|No|Completed|January 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|899|||Both|8 Years|N/A|No|||September 2014|September 30, 2014|June 7, 2010|Yes|Yes||No|September 23, 2014|https://clinicaltrials.gov/show/NCT01139450||121016|
NCT01135498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19875|A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.|An Open-label Study of the Effect of First-line Treatment With Avastin+Xelox, Followed by Avastin+Tarceva, on Progression-free Survival in Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|November 2006|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|June 1, 2010||No||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01135498||121316|
NCT01135511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921072|A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease|A Phase II, Prospective, Randomized, Double Masked/Investigator Masked, Vehicle And Comparator (Sodium Hyaluronate Eye Drops) Controlled, Dose Ranging Study Of CP-690,550 Eye Drops In Subjects With Dry Eye Disease||Pfizer|No|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|285|||Both|20 Years|N/A|No|||March 2013|March 27, 2013|June 1, 2010|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01135511||121315|
NCT01136122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0304|Effects of PAP Treatment of OSA in Patients With Heart Failure|Effects of Positive Airway Pressure (PAP) Treatment of Obstructive Sleep Apnea (OSA) in Patients With Heart Failure|OSA-MRI|Ohio State University|No|Recruiting|April 2010|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|70|||Both|18 Years|75 Years|No|||September 2014|September 23, 2014|May 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01136122||121268|
NCT01136135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081113|Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection|Cardiac MRI for the Detection of Cellular Rejection in Patients With Heart Transplantation||Assistance Publique - Hôpitaux de Paris|No|Completed|February 2010|February 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|N/A|N/A|No|Non-Probability Sample|Patients who had undergone cardiac transplants|August 2015|August 31, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01136135||121267|
NCT01170117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6142/7117R|Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa|Olanzapine vs Placebo for Outpatients With Anorexia Nervosa||New York State Psychiatric Institute|Yes|Recruiting|August 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||April 2015|May 1, 2015|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170117||118673|
NCT01169844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2206E1|Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis|An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Psoriatic Arthritis||Novartis||Completed|June 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|July 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01169844||118694|
NCT01170091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.653|Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS|Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS||Boehringer Ingelheim||Completed|December 2007|||February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|651|||Both|18 Years|N/A|No|Probability Sample|General hospitals, primary care clinics|March 2014|March 14, 2014|July 26, 2010||||No|June 27, 2012|https://clinicaltrials.gov/show/NCT01170091||118675|
NCT01170611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREFACE-IPRE03|Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease|Prevention of Atrial Arrhythmia in Patients Without AV Conduction Disease||LivaNova||Completed|July 2004|January 2007|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|400|||Both|18 Years|N/A|No|||July 2010|July 26, 2010|July 22, 2010||Yes||||https://clinicaltrials.gov/show/NCT01170611||118635|
NCT01136603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS/SUR-PRAS/2010/2|TIGR vs Polypropylene (Permanent) Mesh: Randomised Trial|Abdominal Wall Closure After TRAM / DIEP Flap - Comparison of TIGR Mesh vs Polypropylene Mesh.||National University Hospital, Singapore|Yes|Recruiting|July 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|80 Years|No|||January 2014|January 27, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136603||121232|
NCT01137136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-035|Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea|Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea|CYP19|Samsung Medical Center|Yes|Suspended|June 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|N/A|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Postmenopausa women who underwent surgery for breast cancer|April 2014|April 18, 2014|June 2, 2010||No|Because of economic issue, we could just enrolled total 150 patients.|No||https://clinicaltrials.gov/show/NCT01137136||121191|
NCT01137149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA Adolescent Study|Behavioral Activation With Depressed Adolescents|Behavioral Activation Therapy With Adolescents||Seattle Children's Hospital|Yes|Enrolling by invitation|October 2006|January 2011|Anticipated|January 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|11 Years|18 Years|No|||June 2010|June 2, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01137149||121190|
NCT01137786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP-116|Kidney Damage in Patients With Normal eGFR|A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320||Bracco Diagnostics, Inc|No|Completed|December 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|49|||Both|18 Years|N/A|No|||April 2012|August 7, 2013|June 3, 2010|No|Yes||No|May 22, 2013|https://clinicaltrials.gov/show/NCT01137786||121144|
NCT01138046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113806|Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC|An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients||GlaxoSmithKline|No|Completed|April 2010|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||September 2014|September 29, 2014|March 18, 2010||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01138046||121124|
NCT01138527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU PCa-MAP|Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach|Prostate Cancer Localization With a Multiparametric MR Approach|PCa-MAP|Radboud University|No|Active, not recruiting|June 2010|December 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|fixed histopathology slides of resected prostates at local institutions: Not different from      clinical routine|Male|N/A|N/A|No|Probability Sample|Biopsy-proven patients with prostate cancer, planned for radical prostatectomy.|November 2015|November 9, 2015|June 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138527||121087|
NCT01138514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-716|Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd., Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to a Comparator Clindamycin / Benzoyl Peroxide Topical Gel, and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris||Perrigo Company|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1555|||Both|12 Years|65 Years|No|||June 2012|June 19, 2012|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138514||121088|
NCT01138800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-094|Assessing Chronic Pain Conditions in Patients (Pts) With and Without (w&wo) Interstitial Cystitis|Assessing Chronic Pain Conditions in Patients With and Without Interstitial Cystitis||William Beaumont Hospitals|No|Completed|May 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|666|||Female|18 Years|N/A|No|Probability Sample|Women over 18 years of age with IC identified from the investigators practice (cases);        women over 18 years of age without IC (controls)|November 2012|November 15, 2012|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138800||121066|
NCT01138488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1982|A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of NN5401 in Children, Adolescents and Adults With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|6 Years|65 Years|No|||September 2015|September 24, 2015|June 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138488||121090|
NCT01138501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3545|Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A|A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A|guardian™ 3|Novo Nordisk A/S|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Male|N/A|12 Years|No|||April 2015|April 8, 2015|May 28, 2010|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT01138501||121089|
NCT01138787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09030V|Cholesterol Absorption Inhibition Study|CASTELL = Cholesterol Absorption Study STErols (LL)|CASTELL|Unilever R&D|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|18|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||February 2011|June 15, 2011|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138787||121067|
NCT01139073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMorita-BB|A New Portable Monitor for Measuring Odorous Compounds in Oral, Exhaled and Nasal Air|||Okayama University|Yes|Completed|May 2009|April 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were recruited at the Clinic of Preventive Dentistry, Okayama University        Hospital.|June 2010|June 7, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139073||121045|
NCT01135225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2060|Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent|EVOLVE: A Prospective Randomized Multicenter Single-blind Non-inferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System (Evolution Stent System) for the Treatment of a De Novo Atherosclerotic Lesion|Evolve|Boston Scientific Corporation|Yes|Active, not recruiting|July 2010|May 2016|Anticipated|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|291|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01135225||121337|
NCT01135238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007747|Adrenalectomy for Solitary Adrenal Gland Metastases|The Use of Adrenalectomy in Patients With Solitary Adrenal Gland Metastases||Mayo Clinic|Yes|Completed|November 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|168|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing adrenalectomy for metastatic disease.|December 2011|December 14, 2011|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135238||121336|
NCT01135836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB No. 980705|Reducing Shoulder Tip Pain Following Laparoscopic Surgery|A Randomized, Controlled, Single Blind Study Comparing a Pulmonary Recruitment Maneuver Versus Intraperitoneal Infusion of Normal Saline to Reduce Shoulder Tip Pain After Gynecologic Laparoscopic Surgery||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|August 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|180|||Female|20 Years|80 Years|No|||June 2010|June 2, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01135836||121290|
NCT01136395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTx-RTx-LD-001|Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation|Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation - a Prospective Pilot Study||University of Giessen|Yes|Active, not recruiting|January 2010|October 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|N/A|No|||December 2014|December 28, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136395||121247|
NCT01170130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-09-0017-CTIL|Lidocaine Usage for Pupil Dilatation (Mydriasis)|Efficiency and Safety of Lidocaine Usage for Pupil Dilatation (Mydriasis) During Cataract Surgery||Carmel Medical Center|No|Completed|December 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|40 Years|80 Years|No|||February 2015|February 23, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01170130||118672|
NCT01170143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22700|Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer|A Randomized Study to Investigate the Efficacy and Safety of qw or q3w Trastuzumab, Paclitaxel and Carboplatin in Patients With IIB-IIIB HER2 Positive Breast Cancer|PCH|Fudan University|Yes|Recruiting|August 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|70 Years|No|||June 2009|July 26, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01170143||118671|
NCT01170598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML002|Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy|A Pilot Exercise RCT for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy: Pre-randomization Phase||Toronto Rehabilitation Institute|No|Completed|June 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|July 21, 2010||No||No|February 8, 2012|https://clinicaltrials.gov/show/NCT01170598||118636|Although as per study design, limitations include the lack of a control group due to non-randomization, a small sample size and lack of generalizability.
NCT01166542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 018|Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers|Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy||Oncolytics Biotech|Yes|Completed|June 2010|May 2014|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166542||118947|
NCT01170364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5821|Studying the Effects of Sibutramine on Eating Behavior|Studying the Effects of Sibutramine on Eating Behavior||New York State Psychiatric Institute|No|Terminated|February 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|60 Years|No|||February 2012|February 27, 2012|April 26, 2010|Yes|Yes|Terminated due to sibutramine being withdrawn from the market.|No||https://clinicaltrials.gov/show/NCT01170364||118654|
NCT01170377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141mina|Effect of Valproate on Propofol|The Effect of Valproate on the Required Dose of Propofol for Sedation in Patients With Mental Retardation||Okayama University|No|Completed|April 2007|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|16 Years|N/A|No|Probability Sample|Patients with mental reterdation|August 2010|October 20, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01170377||118653|
NCT01170624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUTOR - ITSY04|Clinical Status Monitoring in Implantable Cardiac Defibrillator (ICD) Patients by Physiological Diagnosis (PhD) Function|Clinical Status Monitoring in ICD Patients by Physiological Diagnosis (PhD) Function|TUTOR|LivaNova|Yes|Terminated|September 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|388|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|June 16, 2010||No|Field Safety Notice related to potential ventricular oversensing associated to the PhD feature    on Paradym ICDs|No||https://clinicaltrials.gov/show/NCT01170624||118634|
NCT01170637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1024.7|Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.|Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil® (200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Male and Female Volunteers (Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial).||Boehringer Ingelheim||Completed|July 2010|||September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|47|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 18, 2012|July 26, 2010||||No||https://clinicaltrials.gov/show/NCT01170637||118633|
NCT01136863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-906-02-11|Felodipine Event Reduction Study|Felodipine Event Reduction Study|FEVER|Chinese Academy of Medical Sciences|Yes|Completed|April 1998|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9800|||Both|50 Years|79 Years|No|||January 2005|June 23, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136863||121212|
NCT01136876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP-117|Kidney Damage in Patients With Moderate Fall in eGFR|A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320||Bracco Diagnostics, Inc|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|57|||Both|18 Years|N/A|No|||September 2013|November 11, 2013|June 2, 2010|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT01136876||121211|
NCT01137500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCHanaes001|Changes in Aortic Diameter During Laparoscopic Surgery|Ultrasonic Assessment of Changes in Aortic Diameter During Laparoscopic Surgery||Royal Surrey County Hospital|No|Not yet recruiting|August 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing elective laparoscopic procedures at the Royal Surrey County Hospital.        Recruitment done by Dr M Dickinson or Dr M Scott (COnsultant Anaesthetists). No        therapeutic promises are to be made as this is purely an observational study|June 2010|June 3, 2010|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137500||121166|
NCT01137799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016762|The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients|A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia||Janssen Pharmaceutica N.V., Belgium|No|Terminated|August 2009|March 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|47|||Male|18 Years|55 Years|No|||November 2012|November 7, 2012|June 3, 2010||No|Efficacy signals were insufficiently strong to justify recruitment of additional patients.|No||https://clinicaltrials.gov/show/NCT01137799||121143|
NCT01138566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP37925|Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae|Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae||Taipei Veterans General Hospital, Taiwan|Yes|Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Adult patients who admitted to the Taipei Veterans General Hospital, a 2900-bed        tertiary-care teaching hospital located in Taipei, Taiwan, with the diagnosis of        community-onset UTI caused by Enterobacteriaceae|April 2010|June 4, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138566||121084|
NCT01138267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT103|Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)|Impact of Pharmacogenomics on Antiretroviral Drugs (Atazanavir and Efavirenz) Concentration and Treatment Response in HIV-infected Adults Study-team||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|450|Samples With DNA|Patients are divided into 4 groups based on whether they need to redraw their blood.        1. have adequate samples stored and do not need additional blood draws.        2. have EFV or ATV blood concentrations samples stored but do not have samples for           genotyping. Need extra 5-ml sample.        3. have samples stored but the samples cannot be used to test for EFV or ATV blood           concentrations because the time of drug intake and blood drawn are unknown. Need to           redraw 5-ml sample.        4. have never had both drug concentration and genotyping done. Need to give 10 ml of blood           sample to perform both tests.|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected participants previously or currently enrolled in any HIV-NAT trials since        1996|February 2011|February 3, 2011|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138267||121107|
NCT01138553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD#100231|Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer|A Biomarker Study of Mifepristone in Early Stage Breast Cancer||University of California, San Diego|Yes|Terminated|June 2010|||June 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|June 4, 2010|No|Yes|Inadequate subject accrual|No||https://clinicaltrials.gov/show/NCT01138553||121085|
NCT01138839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1625|Dexamethasone Efficacy in HELLP I Syndrome|Dexamethasone Efficacy in HELLP I Syndrome, a Multicentric, Double-blind, Placebo-controlled, Randomized Clinical Trial||Universidad del Valle, Colombia|No|Recruiting|October 2009|December 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Female|10 Years|48 Years|No|||June 2010|June 4, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01138839||121063|
NCT01138813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-145|Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145)|Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism|MRS Tumor|Merck Sharp & Dohme Corp.|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples With DNA|Tissue|Both|18 Years|70 Years|No|Non-Probability Sample|Male and female patients aged 18-70 years old with newly diagnosed operable glioma of        grade II or higher|October 2015|October 9, 2015|June 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01138813||121065|
NCT01138826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531095|Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablet (ODT) And 10 Mg Amlodipine Besylate Tablets|Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 6-Sequence, 3-Period Crossover Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablets, Manufactured By Aurobindo Pharma Ltd., India To Amlodipine Besylate 10 Mg Tablets Manufactured by Pfizer Illertissen, Germany Under Fasted Conditions||Pfizer|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|March 8, 2010|Yes|Yes||No|June 21, 2011|https://clinicaltrials.gov/show/NCT01138826||121064|
NCT01139099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003068R|The Evaluation of Therapeutic Efficacy on the Integrated Group Psychotherapy for Patients With Schizophrenia|Department of Psychiatry of NTUH Yun-Lin Branch||National Taiwan University Hospital|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||November 2012|December 26, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139099||121043|
NCT01139476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910106|Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study|Study of Biomarkers of Exposure and Effects in Agriculture||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|2200|||Male|18 Years|100 Years|Accepts Healthy Volunteers|||August 2015|November 10, 2015|June 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01139476||121014|
NCT01135212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-302|The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb)||Boryung Pharmaceutical Co., Ltd|Yes|Completed|April 2010|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|290|||Both|19 Years|75 Years|No|||August 2012|August 22, 2012|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01135212||121338|
NCT01135524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3019S|Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase|A Randomized, Double-blind, Multicenter, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR® Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain: A 52-Week Extension Phase||Purdue Pharma LP|No|Terminated|April 2004|August 2005|Actual|August 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|196|||Both|40 Years|N/A|No|||September 2012|September 5, 2012|June 1, 2010|Yes|Yes|This study was terminated early for administrative reasons.|No|July 15, 2010|https://clinicaltrials.gov/show/NCT01135524||121314|This study was terminated early for administrative reasons.
NCT01136148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10004|Trial of a Medical and Mental Health Unit for Older People|Evaluation of a Medical and Mental Health Unit Compared With Standard Care for Older People Whose Emergency Admission to an Acute General Hospital is Complicated by Concurrent 'Confusion'.|TEAM|University of Nottingham|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|600|||Both|65 Years|120 Years|No|||December 2015|December 1, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136148||121266|
NCT01136161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUTISAPH2|Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection|Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection||Archivel Farma S.L.|Yes|Completed|June 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|95|||Both|18 Years|50 Years|No|||January 2013|January 23, 2013|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01136161||121265|
NCT01169883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09111001|Coping Peer Intervention for Adherence|Coping Peer Intervention for Adherence||Rush University Medical Center|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|107|||Both|11 Years|16 Years|No|||October 2012|October 23, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169883||118691|
NCT01169896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTGX01|Impact of Ventricular Pacing in Unselected ICD/CRT-D Patients|Impact of Ventricular Pacing in Unselected ICD/CRT-D Patients|FIRST|LivaNova|No|Completed|November 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|616|||Both|18 Years|N/A|No|Probability Sample|unselected ICD/CRT-D implanted patients|December 2015|December 2, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169896||118690|
NCT01170156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010REACHR01|Fluid Leakage Past Tracheal Tube Cuff : Effect of Suctioning Manoeuvre|Fluid Leakage Past Tracheal Tube Cuff : Effect of Suctioning Manoeuvre||Centre Hospitalier de Roanne|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|N/A|No|||March 2011|March 4, 2011|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01170156||118670|
NCT01170390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 5382|Oral Contraceptives and Body Mass Index|Improving Contraceptive Effectiveness in Obese Women||Oregon Health and Science University|Yes|Completed|September 2009|December 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|32|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|October 27, 2009|Yes|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT01170390||118652|
NCT01166854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2007-5832|Characterization of Familial Myopathy and Paget Disease of Bone|Phase 1 Study Non-invasive Use Diffuse Optical Spectroscopy Will Measure the Concentrations of Blood, Water, and Lipids (Fats, for Example) in Tissues||University of California, Irvine|No|Recruiting|June 2010|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Study Population will be selected from Dr. Kimonis outpatient clinic at University of        California Irvine.|February 2016|February 5, 2016|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166854||118923|
NCT01137162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0041|Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors|Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors||Stanford University||Terminated|August 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|skin biopsies and blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with adenocarcinoma|August 2012|August 7, 2012|June 1, 2010||No|Low Accrual|No||https://clinicaltrials.gov/show/NCT01137162||121189|
NCT01137175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-970216|Laboratory Diagnosis of of Rickettsial and Rickettsia-like Diseases|Laboratory Diagnosis of of Rickettsial and Rickettsia-like Diseases||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|January 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients suspect to be infected by Rickettsia pathogen|June 2011|September 28, 2012|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137175||121188|
NCT01137513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-49780|T-Wave Alternans in Patients With Suspected Acute Coronary Syndrome|T-Wave Alternans in Patients Acute Coronary Syndrome|TWA|Loma Linda University|Yes|Completed|July 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|252|||Both|18 Years|N/A|No|Probability Sample|18-100 Pt presenting with Chest Pain|May 2014|May 22, 2014|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137513||121165|
NCT01137526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-033|Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease||AbbVie|Yes|Completed|May 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|267|||Both|55 Years|90 Years|No|||January 2013|January 24, 2013|May 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137526||121164|
NCT01138059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2004-217|Reperfusion Therapy in Acute Ischemic Stroke With Unclear Onset|REperfusion Therapy in Acute Ischemic STroke With Unclear Onset by MRI Evaluation|RESTORE|Asan Medical Center|Yes|Completed|October 2006|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|83|||Both|18 Years|85 Years|No|Non-Probability Sample|Consecutive patients with acute ischemic stroke visiting the ER within 6 hours of the        detection of stroke symptoms will be screened for this study.|October 2006|June 4, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138059||121123|
NCT01138293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDIGREIF 001|Electronic Health Technology for Assessment of Physical Activity and Eating Habits in Children and Adolescents Who Are Overweight and Those With Obesity|||MEDIGREIF Inselklinik Heringsdorf|Yes|Completed|June 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||June 2010|June 25, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138293||121105|
NCT01138306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B5|Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia|Implications of s-SHIP Expression and SHIP Alterations in AML||Children's Oncology Group|No|Active, not recruiting|February 2013|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|149|Samples With DNA|tissue|Both|N/A|21 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia|May 2015|May 5, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138306||121104|
NCT01138865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/CPAP-OSAS/2009|Effect of CPAP on Biomarkers in Patients With OSA|Effect of Continuous Positive Airway Pressure (CPAP) on Cardiovascular Biomarkers in Patients With Obstructive Sleep Apnea.|CPAP|All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|March 2012|March 2015|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|65 Years|No|||June 2013|June 21, 2013|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138865||121061|
NCT01138852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHATpro1|Ampicillin/Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section|Ampicillin / Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section: a Randomized Study||Attikon Hospital|Yes|Completed|July 2004|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|176|||Female|N/A|N/A|No|||July 2004|June 4, 2010|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138852||121062|
NCT01139177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60-00857-01|SAMBA EU Femoropopliteal Trial|SAMBA EU Femoropopliteal Trial||NovoStent Corporation|No|Active, not recruiting|April 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|21 Years|N/A|No|||June 2010|June 7, 2010|June 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01139177||121037|
NCT01139125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAC09-04-276|An Open Trial of Cysteamine Treatment in Schizophrenia|An Open Trial of Cysteamine Treatment in Schizophrenia||Georgia Regents University|Yes|Terminated|September 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|60 Years|No|||November 2014|November 19, 2014|May 12, 2010|Yes|Yes|The study was stopped after 4 years of recruitment difficulties.|No|March 27, 2014|https://clinicaltrials.gov/show/NCT01139125||121041|Recruitment challenges for this study are the number of pills that the subjects are required to take during treatment and the reported foul body odor that the subjects complianed of and was also noted by the Investigator and research staff.
NCT01139112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201005034R|Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features|Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features||National Taiwan University Hospital|No|Completed|July 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|134|Samples With DNA|K. pneumoniae strains stored at -80oC|Both|N/A|N/A|No|Non-Probability Sample|Necrotizing fasciitis cases treated during 1997-2010 at National Taiwan University        Hospital|May 2012|November 14, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139112||121042|
NCT01139489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VU University medical center|Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's)|Stop Antibiotics on Procalcitonin Guidance Study|SAPS|VU University Medical Center|Yes|Completed|November 2009|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1575|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|March 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01139489||121013|
NCT01135537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013834|Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants|Pharmacokinetics and Pharmacodynamics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplant Recipients||The Hospital for Sick Children|No|Completed|November 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|21 Years|No|||November 2014|November 27, 2014|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01135537||121313|
NCT01135550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014713|Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation|A RANDOMIZED CONTROLLED MULTICENTER NON-INFERIORITY TRIAL OF TWICE DAILY LOW DOSE DEXAMETHASONE VERSUS USUAL DOSE DEXAMETHASONE FOR SYMPTOM CONTROL IN CHILDREN WITH A BRAIN TUMOUR UNDERGOING CRANIAL OR CRANIOSPINAL RADIATION||The Hospital for Sick Children|No|Active, not recruiting|June 2010|December 2014|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|25|||Both|2 Years|18 Years|No|||June 2014|June 17, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135550||121312|
NCT01136174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.31|Safety and PK Study of BIBF 1120 in Japanese Patients With IPF|A Double-blind, Randomised, Placebo-controlled (Within a Dose Group) Study to Evaluate Safety and Pharmacokinetics of Multiple Rising Doses of BIBF 1120 at 50 mg Bid (14 Days), 100 mg Bid (14 Days), and 150 mg Bid (28 Days) p.o., on Top of Standard Medical Care With Stratification According to Pirfenidone Use, in Japanese Patients With Idiopathic Pulmonary Fibrosis.||Boehringer Ingelheim||Completed|May 2010|||March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|4||Actual|50|||Both|40 Years|N/A|No|||December 2014|December 15, 2014|May 31, 2010||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01136174||121264|
NCT01170169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7566/05-06|Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study to Compare Omeprazole 40 mg DR Capsules Dr. Reddy's Laboratories Ltd.,With Prilosec® 40 mg Merck & Co.Inc., USA Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|January 2006|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 26, 2010|May 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01170169||118669|
NCT01170403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10642140004-06N4214-00410|Comprehensive Analyses of Multidetector-row Cardiac Computed Tomography Data in Koreans|Comprehensive Analyses of Multidetector-row Cardiac Computed Tomography Data of Over 15,000 Individuals in Korea||Seoul National University Bundang Hospital|No|Completed|January 2006|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|80 Years|No|Non-Probability Sample|Those who had undertook a computed tomographic angiography (CTA) with 64-slice MDCT from        January 2nd 2006 until August 21st 2008. Reasons for exam include screening in        asymptomatic subjects, diagnosis in patients with angina pectoris, follow up after        percutaneous coronary intervention or coronary artery bypass grafting, differential        diagnosis in chest pain and so on.|July 2014|July 7, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01170403||118651|
NCT01170650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-002|Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)|A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer|PROCEED|Endocyte|Yes|Suspended|April 2011|October 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Female|18 Years|N/A|No|||August 2015|August 3, 2015|July 7, 2010|Yes|Yes|DSMB decision|No||https://clinicaltrials.gov/show/NCT01170650||118632|
NCT01166607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC78371|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2010|||||N/A|N/A|N/A||||||||||||||November 30, 2014|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166607||118942|
NCT01166620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-244|Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics|Observational Real-world Evaluation of Cost of Infections of RA Patients on Biologics||Bristol-Myers Squibb|No|Completed|June 2010|March 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|4000|||Both|18 Years|N/A|No|Non-Probability Sample|Commercial health plan members|April 2012|April 12, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166620||118941|
NCT01166867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2009-7046|A Pilot Study Using Photo-plethysmographic (PPG) Camera|Photo-plethysmographic (PPG) Camera to Monitor Heart Rate, Respiration Rate and Oxygen Saturation in Infants.||University of California, Irvine|No|Completed|September 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|N/A|12 Months|Accepts Healthy Volunteers|Non-Probability Sample|infant|August 2015|August 4, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166867||118922|
NCT01166880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2009-7050|A Pilot Study Using Laser Speckle Imaging of Neonate Cerebral Vasculature|Imaging of Neonate Cerebral Vasculature||University of California, Irvine|No|Withdrawn|August 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|1 Month|Accepts Healthy Volunteers|Non-Probability Sample|new born|August 2015|August 5, 2015|July 20, 2010||No|Unable to find grant fundingsupport to continue builds the study device.|No||https://clinicaltrials.gov/show/NCT01166880||118921|
NCT01137188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-001|Effect of Weight Loss on Psoriasis|Effect of Weight Loss on Skin Manifestations, Inflammatory Markers and Risk Factor for Comorbidity in Obese Patients With Psoriasis - a Randomized Cross-over Study||University Hospital, Gentofte, Copenhagen|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|70 Years|No|||April 2012|April 3, 2012|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01137188||121187|
NCT01137552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070879|A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors|A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors||Amgen|No|Terminated|June 2010|April 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||February 2015|March 2, 2015|April 22, 2010|No|Yes|Part A, the dose escalation and primary objective of the study, was completed. Part B, the    dose expansion, was not conducted due to a business decision.|No||https://clinicaltrials.gov/show/NCT01137552||121162|
NCT01137812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017185|The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)|A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy||Janssen Research & Development, LLC||Completed|July 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|756|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|June 3, 2010|Yes|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01137812||121142|
NCT01138280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 96-12-21A|Heat Disinfection of HD Water Treatment System in Hemodialysis Patients|Effect of Heat Disinfection of HD Water Treatment System on Cardiovascular Events and Outcome in Hemodialysis Patients||Taipei Veterans General Hospital, Taiwan|Yes|Completed|March 2005|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|540|||Both|20 Years|80 Years|No|||January 2005|June 4, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01138280||121106|
NCT01138319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B6|Biomarkers in Patients With Acute Myeloid Leukemia|Mitochondrial Mutations and AML||Children's Oncology Group|Yes|Completed|February 2009|||March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|18|Samples With DNA|blood samples|Both|N/A|N/A|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia|May 2015|May 5, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138319||121103|
NCT01138332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B10|Biomarkers in Young Patients With Acute Myeloid Leukemia|Stat3 Signaling Pathway Aberrancies in Pediatric AML||Children's Oncology Group|No|Completed|September 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|||Both|N/A|21 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia|May 2015|May 5, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01138332||121102|
NCT01138579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP-LYM-01-V01|Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation|Phase I/II Dose-escalation Study of the Investigational Trifunctional Bispecific Anti-CD20 x Anti-CD3 Antibody FBTA05 in Combination With Donor Lymphocyte Infusion (DLI) in Patients With CD20 Positive Chronic Lymphocytic Leukemia (CLL), Low and High Grade Non-Hodgkin´s Lymphoma (NHL) After Allogeneic Stem Cell Transplantation|STP-LYM-01|Technische Universität München|Yes|Terminated|August 2010|April 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 4, 2010||No|Recruitment delayed, trial medication no loner available|No||https://clinicaltrials.gov/show/NCT01138579||121083|
NCT01139190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-NAP-002|Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults|A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage||PLx Pharma|Yes|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|76|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2011|February 15, 2011|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01139190||121036|
NCT01139203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH20100601|Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation|||Shanghai Jiao Tong University School of Medicine||Recruiting|August 2009|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|300|||Both|18 Years|65 Years|No|||August 2009|June 25, 2010|June 7, 2010||||No||https://clinicaltrials.gov/show/NCT01139203||121035|
NCT01139138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU-2009-0003/CRAD001CAU06T|Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer|A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT|PIE|The Queen Elizabeth Hospital|No|Active, not recruiting|June 2010|June 2017|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01139138||121040|
NCT01139151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1000|4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies|Phase I Study of 4'-Thio-araC in Patients With Advanced Hematologic Malignancies||M.D. Anderson Cancer Center|No|Completed|August 2010|November 2013|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|16 Years|N/A|No|||June 2014|June 16, 2014|June 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01139151||121039|
NCT01139164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101370|Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)|Allogeneic Hematopoietic Stem Cell Transplantation With Reduced-Intensity Pre-Transplant Conditioning for the Treatment of High-Risk Hematological Malignancies||Medical University of South Carolina|Yes|Terminated|June 2010|December 2015|Actual|September 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|1 Year|75 Years|No|||February 2016|February 11, 2016|June 4, 2010||No|Study halted prematurely due to low accrual.|No|February 11, 2016|https://clinicaltrials.gov/show/NCT01139164||121038|
NCT01139502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CogTherCogTrainWork|Cognitive Behaviour Therapy and Cognitive Training in Work Rehabilitation for Persons With Severe Mental Illness|Cognitive Therapy and Cognitive Training in Work Rehabilitation for Persons With Severe Mental Illness. A Randomised Controlled Trial||Oslo University Hospital|Yes|Completed|January 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|65 Years|No|||June 2013|October 15, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01139502||121012|
NCT01139515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1601126|Eletriptan Pharmacokinetics In Korean Males|An Open Label, Single And Repeat Dose Randomized Crossover Study To Estimate The Pharmacokinetics And Safety Of Eletriptan Hydrobromide Tablets In Healthy Korean Male Subjects||Pfizer|No|Completed|July 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 13, 2011|June 7, 2010|Yes|Yes||No|June 13, 2011|https://clinicaltrials.gov/show/NCT01139515||121011|
NCT01139528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASUUS 1529|Conservative or Operative Treatment of Fractures in the Neck of the 5th Metacarpal Bone|Conservative Treatment Versus Operative Treatment of Extra-articular Fractures in the Neck of the 5th Metacarpal Bone- A Prospective Randomized Trial|MC-studien|Oslo University Hospital|No|Completed|May 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01139528||121010|
NCT01135251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO-08-94/NT-11624/003|Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy|A Double Blind, Parallel-group, Randomized Placebo Controlled, Multicentre Exploratory Study of Dimiracetam in Treatment Induced Painful Neuropathy in Patients With HIV Infection||Neurotune AG|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|65 Years|No|||June 2010|June 1, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135251||121335|
NCT01135589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPHO 2010-02|Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation|Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation||Asan Medical Center|No|Recruiting|April 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|145|||Both|N/A|19 Years|No|||June 2010|September 27, 2010|May 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01135589||121309|
NCT01135875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-01|Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients|Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response||University of Florida|No|Completed|October 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|130|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited during routine interactions with the investigators.|October 2013|October 15, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01135875||121287|
NCT01135849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSVAR0038|B-Receptor Signaling in Cardiomyopathy|B-Receptor Signaling in Cardiomyopathy||Stanford University|Yes|Completed|November 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|Samples Without DNA|cheek swab or blood drawn for DNA extraction|Both|N/A|40 Years|No|Non-Probability Sample|Patients exposed to anthracycline who have had an echocardiogram at least six months after        initial exposure.|November 2015|November 16, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135849||121289|
NCT01136447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-101|Continuous Infraclavicular Blocks: Neurostimulation Versus Ultrasound|Success Rate of Infra-clavicular Blocks: Comparison of Ultrasound Versus Neurostimulation Guided Catheter Placement||Lawson Health Research Institute|No|Completed|January 2010|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|80 Years|No|||July 2013|July 8, 2013|April 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01136447||121244|
NCT01170416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP12|Testing Objective Methods for Template Matching Ventricular Tachycardia and Pacemapping|Quantitative Measurements Comparing Body Surface Potentials During Pacemapping and Spontaneous Ventricular Tachycardia||Nova Scotia Health Authority|No|Recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients will be recruited from consecutive patients referred for ablation of sustained        ventricular tachycardia with or without structural heart disease or Patients referred for        ablation of supraventricular tachycardia to the QEII Health Sciences Centre, in Halifax,        NS.|July 2010|June 21, 2011|July 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01170416||118650|
NCT01170663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13894|A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine|RAINBOW|Eli Lilly and Company|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|665|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 21, 2010|Yes|Yes||No|July 1, 2014|https://clinicaltrials.gov/show/NCT01170663||118631|One (1) participant was randomized to the placebo/paclitaxel group but received ramucirumab in error. For ITT population this participant was included in placebo/paclitaxel group and for the Safety population included in the ramucirumab group.
NCT01166633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-PTV-707|Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia|A Randomized , Open Label, Dose Titration Study to Evaluate the Effect of Pitavastatin Versus Atorvastatin in Patients With Hypercholesterolemia and Mild to Moderate Hepatic Damage|PITCH|JW Pharmaceutical|Yes|Completed|June 2009|February 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166633||118940|
NCT01166646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000-0551-202|Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis|||Therapeutics, Inc.|No|Completed|July 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166646||118939|
NCT01167231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13066|Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease|Acarbose in Cardiovascular Risk Management. Assessment of Clinical Efficacy and Safety of Acarbose and Its Effect on Selected Cardiovascular Risk Factors in Type 2 Diabetes Patients.|ABDOMEN|Bayer|No|Completed|May 2007|June 2008|Actual|March 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3310|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic diabetic patients not treated with acarbose for at least 3 months.|August 2010|August 24, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01167231||118894|
NCT01137565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090223|Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 853 in Adolescent (≥ 12 to <18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma||Amgen||Completed|June 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|23|||Both|12 Years|50 Years|No|||March 2014|March 3, 2014|April 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137565||121161|
NCT01137838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-238|Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents|Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents||Bristol-Myers Squibb|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1810|||Both|N/A|N/A|No|Non-Probability Sample|Commercial insurance claims database|May 2011|May 16, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137838||121140|
NCT01138085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113886|Safety, Pharmacokinetics (PK) of AKT and MEK Combination|A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795||GlaxoSmithKline|No|Completed|May 2010|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||June 2015|February 11, 2016|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138085||121121|
NCT01137851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-256|Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients|Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients Treated With Biologic Disease Modifying Antirheumatic Drug (DMARD) Therapies||Bristol-Myers Squibb|No|Completed|November 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3940|||Both|18 Years|65 Years|No|Probability Sample|Commercial health plan members|September 2010|September 30, 2010|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137851||121139|
NCT01138111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|312043|Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients|ß-amyloid Imaging With BAY94-9172 Positron Emission Tomography for Early Detection of Alzheimer's Disease in Patients With Mild Cognitive Impairment||Piramal Imaging SA|No|Completed|June 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|60 Years|N/A|No|||May 2014|May 22, 2014|April 1, 2010||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01138111||121119|
NCT01139255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0930|Pounds Off Digitally (POD): The Use of Podcasting and Mobile Media to Promote Weight Loss|The Use of Podcasting and Mobile Media to Promote Weight Loss and Increase Fruit and Vegetable Intake Among Overweight Adults|POD|University of North Carolina, Chapel Hill|No|Completed|June 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 2, 2011|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01139255||121031|
NCT01167296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-99-DR-27|Safety of Leaving Cook Balloon Uterine Stent in Uterus for One Month|||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Completed|July 2010|December 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 7, 2013|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167296||118889|
NCT01168284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910160|A Coping Effectiveness Training Intervention for Caregivers of Children With Autism Spectrum: A Feasibility Study|A Coping Effectiveness Training Intervention for Caregivers of Children With Autism Spectrum Disorders: A Feasibility Study||National Institutes of Health Clinical Center (CC)||Completed|July 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind|1||Anticipated|300|||Both|18 Years|100 Years|No|||February 2016|February 13, 2016|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168284||118813|
NCT01168297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910161|Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction|Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction||National Institutes of Health Clinical Center (CC)||Completed|July 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|900|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168297||118812|
NCT01167998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|orlucent-HMO-CTIL|Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions|Early Diagnosis of Malignant Melanoma Transformation in Pigmentary Skin Lesions||Hadassah Medical Organization|Yes|Recruiting|July 2010|||August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals above 18 years of age with pignented skin lesions indicated for        excision|July 2010|August 3, 2011|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167998||118835|
NCT01168011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 09-04|Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors|A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer||Onconova Therapeutics, Inc.|Yes|Completed|July 2010|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|July 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01168011||118834|
NCT01168804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBD|Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma|Bendamustine Plus Bortezomib Plus Dexamethasone in the Treatment of Stage II/III Relapsed or Refractory Multiple Myeloma|BBD|Austrian Forum Against Cancer|Yes|Completed|June 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168804||118773|
NCT01168817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14694|Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors|A Prospective, Randomized, Double-blind, Double-dummy, Placebo- and Active Controlled, Multicenter Study Assessing the Efficacy and Safety of the Combination BAY60-4552 / Vardenafil Compared to Vardenafil (20 mg) for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 (Phosphodiesterase 5) Inhibitors||Bayer|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|140|||Male|18 Years|64 Years|No|||November 2014|November 3, 2014|July 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01168817||118772|
NCT01140009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01356|Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011|A Randomized, Blinded, Placebo-controlled, Cross-over Study of the Safety and Immunogenicity of Trivalent, Inactivated Influenza Vaccine for 2010-2011|PCIRNRT06|University of British Columbia|Yes|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|324|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140009||120974|
NCT01140282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-12-1|Exercise Program for Early Breast Cancer Survivors|Combined Exercise Program for Early Breast Cancer Survivors||University of Southern California|Yes|Recruiting|May 2012|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||October 2015|October 24, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01140282||120953|
NCT01140295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-5004|Bowel Preparation for Colonoscopy in Children|Polyethylene Glycol Powder Solution vs Senna for Bowel Preparation for Colonoscopy in Children: A Prospective, Randomized, Investigator-Blinded Trial.||Children's Hospital of Philadelphia|No|Terminated|September 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|33|||Both|6 Years|21 Years|No|||April 2013|April 10, 2013|June 1, 2010|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT01140295||120952|Early termination due to poor efficacy in one of the study arms (senna preparation).
NCT01140516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPHA|Effectiveness of Antibiotics Versus Placebo to Treat Antenatal Hydronephrosis|Antibiotic prophyLaxis Versus Placebo in Infants Diagnosed With Hydronephrosis Antenatally|ALPHA|McMaster University|Yes|Recruiting|July 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|1 Month|7 Months|No|||March 2016|March 21, 2016|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140516||120935|
NCT01140815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2010-0103|Functional Performance of the Journey Deuce Bicompartmental Versus the Genesis II Total Knee System|A Prospective, Single-Center, Randomized Study Comparing the Functional Performance of the Journey Deuce Bicompartmental With the Genesis II Total Knee System|Deuce|Anderson Orthopaedic Research Institute|Yes|Completed|September 2007|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|65 Years|No|||July 2014|July 10, 2014|May 28, 2010||No||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01140815||120912|
NCT01140828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAN Study|A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury|A Double-blind Randomized Placebo Controlled Trial of Rabeprazole for Prevention of NSAID-associated Dyspepsia and Gastroduodenal Injury||Chinese University of Hong Kong|No|Completed|May 2009|June 2015|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01140828||120911|
NCT01167478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEFE026|Neurophysiological Reserve With Caffeine Manipulation|Neurophysiological Reserve: Peripheral and Central Effects of Caffeine Manipulation||University of Sao Paulo|No|Completed|March 2011|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|35 Years|No|||December 2014|December 4, 2014|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167478||118875|
NCT01167920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-575|Virtual Hypertension Clinic|Virtual Hypertension Clinic (VHC) Study|VHC|The Cleveland Clinic|No|Active, not recruiting|November 2009|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|25 Years|65 Years|No|||July 2013|July 29, 2013|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01167920||118841|
NCT01169077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0008|EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria|A Phase I, Randomized, Controlled Dosage-Escalation Study of the Safety and Reactogenicity of the EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria Administered Via Electroporation to Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|39|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 15, 2012|July 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01169077||118752|
NCT01169090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK-0403-2.01US|A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Phase 2 Dose Finding Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy||Kowa Research Institute, Inc.|No|Completed|July 2010|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|620|||Both|18 Years|75 Years|No|||August 2011|August 15, 2011|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169090||118751|
NCT01168466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMFFTD|Electroencephalography (EEG) Biofeedback Training to Improve Executive Functioning and Memory in Adults With a Dementing Illness|Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness.|QMFFTD|Quietmind Foundation|Yes|Completed|June 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|45 Years|85 Years|No|||July 2010|July 22, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168466||118799|
NCT01169662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24AE1|Effects of Dietary Nitrate From Vegetable/Fruit Juice on Cerebral Blood Flow Parameters|Effects of Dietary Nitrate From Vegetable/Fruit Juice on Cerebral Blood Flow Parameters||Northumbria University|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2010|October 11, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169662||118707|
NCT01169675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.92|BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours|BIBW 2992 Phase I Combination With Pemetrexed in Advanced Solid Tumours||Boehringer Ingelheim||Completed|July 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|53|||Both|18 Years|N/A|No|||January 2014|June 3, 2014|July 19, 2010|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01169675||118706|
NCT01157962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/207/09|Sentinel Concept in Early Stage Cervical Cancer|Prospective, Randomized and Multicentre Study for Investigation of Valence of Sentinel Lymph Nodes Concept in Patients With Cervical Cancer ≤ 2 cm||Charite University, Berlin, Germany|Yes|Recruiting|January 2010|January 2018|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|1600|||Female|18 Years|70 Years|No|||December 2009|June 30, 2011|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01157962||119603|
NCT01166958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0064|Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?|Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?||University of Wisconsin, Madison|Yes|Completed|September 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Female|60 Years|89 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|July 15, 2010|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01166958||118915|
NCT01168024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-6142|Contrast Media Reduction and Removal in Patients With CKD (PRESERV)|PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial||Osprey Medical, Inc|Yes|Terminated|December 2012|November 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|July 20, 2010|Yes|Yes|Study closed by sponsor prior to completing enrollment goal.|No||https://clinicaltrials.gov/show/NCT01168024||118833|
NCT01168856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV22688|An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens|A Long-term Monitoring Study to Evaluate the Persistence of Direct Antiviral (DAA) Treatment Resistant Mutations or the Durability of Sustained Virological Response (SVR) in Patients Treated With DAA Containing Regimens for Chronic Hepatitis C Infections (CHC)||Hoffmann-La Roche||Terminated|September 2010|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|734|None Retained|Serum specimens collected from patients with partial viral response or viral load rebound of      viral response to monitor for resistance mutations in viral RNA|Both|18 Years|N/A|No|Probability Sample|Chronic hepatitis C patients having received direct acting antiviral treatment in donor        protocol|February 2016|February 12, 2016|July 15, 2010|No|Yes|This study was terminated due to the decrease in percentage of participants.|No|December 30, 2015|https://clinicaltrials.gov/show/NCT01168856||118769|Investigators were notified of the early termination of study in Jan2015 due to the completion of assessment for resistance monitoring arm and were encouraged to complete scheduled visits until Apr2015 for participants enrolled in SVR durability arm.
NCT01169233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001304|Operational Evaluation of a Photic Countermeasure to Improve Alertness, Performance, and Mood During Nightshift Work on a 105-day Simulated Human Exploration Mission to Mars|Operational Evaluation of a Photic Countermeasure to Improve Alertness, Performance, and Mood During Nightshift Work on a 105-day Simulated Human Exploration Mission to Mars|Mars 105|Brigham and Women's Hospital|No|Completed|August 2008|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01169233||118740|
NCT01168544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC 712-050710|Daily Vitamin D Supplementation Compared to a Loading Dose and Monthly Supplementation in Elderly Nursing Home Residents|Vitamin D Supplementation in Elderly Nursing Home Residents: Daily Supplementation Compared to a Loading Dose an Monthly Supplementation, a Randomised Trial|VIDIV|Rijnstate Hospital|No|Completed|May 2011|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|65 Years|N/A|No|||January 2013|January 3, 2013|July 22, 2010||||No||https://clinicaltrials.gov/show/NCT01168544||118793|
NCT01143584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prlcab2020|Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.|Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|May 2010|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||May 2010|June 11, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01143584||120701|
NCT01143597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD053854|Improving Hand and Arm Function After Spinal Cord Injury (SCI)|Improving Hand and Arm Function After SCI||University of Miami|No|Completed|August 2007|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|16 Years|70 Years|No|||October 2013|October 9, 2013|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143597||120700|
NCT01140022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1095-31344|Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia|Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia||University of California, San Francisco|No|Completed|September 2007|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|346|||Female|18 Years|25 Years|No|Non-Probability Sample|Female patients 18-25 yo receiving care at urgent care or ED sites.|October 2014|October 1, 2014|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01140022||120973|
NCT01140035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R380T10586|Intensive Insulin Therapy in Deceased Donors|Intensive Insulin Therapy in Deceased Donors - to Improve Renal Allograft Function and Transplanted Allograft Outcomes||University of California, San Francisco|No|Completed|January 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2011|September 19, 2011|September 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01140035||120972|
NCT01140529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3005099|Dexmedetomidine for the Treatment of Delirium After Heart Surgery|A Prospective, Multi-centre, Randomised, Double-blind, Placebo-controlled Comparison of Intravenous Dexmedetomidine and Haloperidol in Treatment of Psychomotor Confusion After Heart Surgery|DexinDelir|Thorax-Kärlkliniken|No|Terminated|May 2010|June 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3|||Both|65 Years|N/A|No|||March 2010|January 25, 2012|June 7, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01140529||120934|
NCT01140542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-401|Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study|Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Phase IIb, Proof of Concept Clinical Study|FORTUNA|Nycomed||Completed|August 2006|March 2008|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|487|||Both|35 Years|70 Years|No|||May 2012|May 4, 2012|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140542||120933|
NCT01140841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVF-025-101|A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa|A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose-Escalation Study of Safety and Tolerability of Oromucosal Fipamezole ODT in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa|Fipamezole|Valeant Pharmaceuticals International, Inc.|Yes|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|30 Years|75 Years|No|Probability Sample|Patients with Parkinson's Disease on stable regimen of levodopa|August 2011|August 30, 2011|June 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140841||120910|
NCT01140854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD3838|Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery|Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery|HTN|Columbia University|No|Completed|January 2009|December 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|179|||Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients >60 years old will be recruited who are scheduled for elective simple spine        surgery (microdiskectomy or 1-2 level laminectomies without fusion) and lasting <5 hours        without blood transfusion.|June 2015|June 2, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01140854||120909|
NCT01167699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3501|Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain|An Open Study With OXN to Evaluate the Patient Preference for Pain Treatment With Respect to Quality of Life After WHO Stap I or Step II Analgesics for Patients With Moderate to Severe Non-malignant Pain||Mundipharma Pharmaceuticals B.V.||Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|174|||Both|18 Years|N/A|No|||July 2011|February 11, 2013|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167699||118858|
NCT01167712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03812|Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2010|||December 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|773|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167712||118857|
NCT01168479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU-FLAME|FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer|FLAME: Single Blind Randomized Phase III Trial to Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer|FLAME|UMC Utrecht|Yes|Active, not recruiting|September 2009|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|567|||Male|18 Years|N/A|No|||February 2015|February 1, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168479||118798|
NCT01168492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cme#2857|Analgesia During Pediatric Digestive Endoscopy: a Comparison of Two Protocols for Procedural Sedation|Analgesia During Pediatric Digestive Endoscopy: a Comparison of Two Protocols for Procedural Sedation||Université de Montréal|No|Completed|July 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|10 Years|19 Years|No|||December 2014|December 3, 2014|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168492||118797|
NCT01168713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-200|Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia|A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia||Cempra Inc|Yes|Completed|August 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168713||118780|
NCT01169103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000861|Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls|Effect of rhGH Administration on Visceral Adiposity and Markers of Cardiovascular Risk in Obese Adolescent Girls: Phase 2||Massachusetts General Hospital|Yes|Completed|March 2010|December 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Female|13 Years|21 Years|No|||April 2015|April 6, 2015|July 22, 2010|Yes|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01169103||118750|
NCT01169376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL10B1|Biomarkers in Young Patients With Neuroblastoma|Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Neuroblastoma||Children's Oncology Group|No|Active, not recruiting|July 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|380|||Both|N/A|30 Years|No|Non-Probability Sample|Patients registered on the COG-ANBL00B1 Neuroblastoma Biology Study|May 2015|May 6, 2015|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169376||118729|
NCT01169688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWKSC_2007_01|Preoperative Cataract Pupillary Dilation: Inpatient At The Ambulatory Surgery Center vs Outpatient Dilation Prior To Arrival At The Ambulatory Surgery Center|Preoperative Cataract Pupillary Dilation: Inpatient vs Outpatient||Northwest Kansas Surgery Center|No|Completed|December 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|||Actual|50|||Both|18 Years|N/A|No|||December 2007|July 22, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169688||118705|
NCT01166724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-702|Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-|Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- Clinical and Mechanistic Impact||The Cleveland Clinic|Yes|Recruiting|July 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|July 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166724||118933|
NCT01166737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR OP.4 DESKTOP III|Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer|A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer|DESKTOP III|AGO Study Group|Yes|Active, not recruiting|July 2010|December 2020|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|408|||Female|18 Years|N/A|No|||December 2015|December 22, 2015|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01166737||118932|
NCT01166971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09-050|A Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting Intraocular Lenses (IOLs)|A Randomized, Subject-masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting IOLs||Alcon Research|No|Completed|July 2010|||March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Both|21 Years|N/A|No|||November 2011|November 21, 2011|July 19, 2010|Yes|Yes||No|October 4, 2011|https://clinicaltrials.gov/show/NCT01166971||118914|
NCT01167777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCSA-VkPCRCTGC-200810-PRO|Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae|Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae||Siemens Healthcare Diagnostics Inc|No|Terminated|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2296|||Both|18 Years|99 Years|No|Non-Probability Sample|Symptomatic and asymptomatic male and female patients attending STD, family planning,        public health and women's health clinics, or other applicable centers, who are being        screened for CT or GC|November 2015|November 24, 2015|July 21, 2010||No|Siemens Management decided not to release the product in the USA.|No||https://clinicaltrials.gov/show/NCT01167777||118852|
NCT01168037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC090126|Medical & Economical Evaluation of Fenestrated & Branched Stent-grafts to Treat Complex Aortic Aneurysms|Medical and Economical Evaluation of Endovascular Therapy of Complex Aortic Aneurysms (Para- & Supra- Renal Abdominal Aortic Aneurysms, Type 4 THORACO-Abdominal Aneurysms) by Fenestrated & Branched Stent-grafts|Windows1|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|June 2009|June 2016|Anticipated|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|250|||Both|18 Years|N/A|No|Probability Sample|All patients with an Abdominal aortic aneurysm over 5 cm in diameter or with a diameter        increase over 1 cm in 1 year and a PSRAA defined by:          -  Infrarenal aortic neck < 15 mm          -  or extent of the aneurismal process to the suprarenal aorta|October 2015|October 18, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168037||118832|
NCT01168583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126-2010|Fluid Balance and Clinical Outcomes|Investigation of the Effect of Post-operative Fluid Balance on Inflammatory Mediators in Patients Undergoing Cardiovascular Surgery||University of Florida|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the hospital for elective cardiothoracic surgery.|September 2011|September 19, 2011|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168583||118790|
NCT01168596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091035|Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease|Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial)|REST|University of Florida|No|Completed|December 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|85 Years|No|||September 2012|December 10, 2013|February 19, 2010|Yes|Yes||No|June 14, 2013|https://clinicaltrials.gov/show/NCT01168596||118789|
NCT01168557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stress Echo - EIT|Stress Echo and Electric Impedance Tomography (EIT) Pilot Study|Stress Echo and Electric Impedance Tomography (EIT) Pilot Study to Investigate the Influence of Cardiac Output on Parameters of the EIT||RWTH Aachen University|No|Completed|July 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|N/A|No|||November 2013|November 26, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168557||118792|
NCT01168830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1007|First in Man Trial - BIOSOLVE-I|BIOTRONIKS-Safety and Clinical Performance Of the First Drug-Eluting Generation Absorbable Metal Stent In Patients With de Novo Lesions in NatiVE Coronary Arteries (BIOSOLVE - I)|BIOSOLVE-I|Biotronik AG|Yes|Completed|July 2010|December 2014|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|79 Years|No|||February 2015|February 4, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168830||118771|
NCT01143896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 10-044|Hepatitis C Translating Initiatives for Depression Into Effective Solutions|Hepatitis C Translating Initiatives for Depression Into Solutions|HEPTIDES|VA Office of Research and Development|Yes|Active, not recruiting|February 2012|September 2016|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|309|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143896||120677|
NCT01140048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0476-374|Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)|An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast||Merck Sharp & Dohme Corp.|No|Completed|October 2007|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|343|||Both|18 Months|6 Years|No|Non-Probability Sample|The study sample includes participants who completed all visits of Protocol 272 from        approximately 38 study sites worldwide. Participants enrolled in Protocol 272 were 3- to        24-month-old children with their first or second episode of "severe" RSV-induced        bronchiolitis.|March 2015|March 30, 2015|June 7, 2010||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01140048||120971|
NCT01140347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13895|A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib|A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)|REACH|Eli Lilly and Company|Yes|Completed|October 2010|March 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|565|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 2, 2010|Yes|Yes||No|March 13, 2015|https://clinicaltrials.gov/show/NCT01140347||120948|
NCT01139996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHUMC-2010-04-02|Use of Transdermal Clonidine in Trauma Patients|A Randomized Double Blinded Placebo Controlled Trial Of Transdermal Clonidine for Adjuvant Sedation in Ventilated Trauma Patients Experiencing Delirium||Memorial Health University Medical Center|Yes|Completed|May 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||August 2011|May 1, 2015|June 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01139996||120975|
NCT01140308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1AT005836-01|CoEnzyme Q10 in Statin Myopathy|CoEnzyme Q10 in Statin Myopathy||Hartford Hospital|Yes|Active, not recruiting|September 2009|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|135|||Both|20 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 6, 2012|June 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01140308||120951|
NCT01140555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-09-007|A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device|A Pilot Study to Determine the Optimal Procedure Steps to Obtain and Maintain Bilateral Uterine Artery Occlusion Using the GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device in Women With Uterine Fibroids||Ethicon, Inc.|No|Terminated|April 2010|July 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|25 Years|55 Years|No|||February 2011|February 16, 2011|June 8, 2010||No|Further internal evaluation of the device was required.|No||https://clinicaltrials.gov/show/NCT01140555||120932|
NCT01141153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSICA-2|Anticoagulation in Stent Intervention|Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation|MUSICA-2|Hospital Universitari Vall d'Hebron Research Institute|No|Active, not recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141153||120886|
NCT01168739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC08-606|Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response|Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response||University of New Mexico|Yes|Completed|September 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|9|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01168739||118778|
NCT01169116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3592010|Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis|Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis: Prospective Study||Barretos Cancer Hospital|Yes|Withdrawn|July 2010|||July 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||February 2014|February 2, 2014|July 22, 2010||No|No participants enrolled.|No||https://clinicaltrials.gov/show/NCT01169116||118749|
NCT01168726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protective Behaviors|Protective Behavioral Strategies and Brief Alcohol Interventions|Protective Behavioral Strategies and Brief Alcohol Interventions||University of Missouri-Columbia|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|365|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|July 20, 2010||No||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01168726||118779|
NCT01169701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AES07|24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients|Multicenter, Open-label, Randomized, 24 Months Follow-up, Two Arm Study to Compare the Efficacy of Everolimus in Improving the Cardiovascular Profile in a Regimen With Mycophenolic Acid vs. a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients.|EVITA|Novartis||Completed|August 2010|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|70 Years|No|||November 2015|November 6, 2015|July 22, 2010|Yes|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT01169701||118704|
NCT01169389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM/10/2008/18|Analgesic Control Following Knee Arthroscopy|Analgesic Control Following Knee Arthroscopy: Results of a Randomised , Double-blinded Trial Comparing a Hyaluronic Acid Supplement to Bupivacaine||Orthopaedic Research and Innovation Foundation|Yes|Completed|January 2009|June 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2008|July 29, 2010|July 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01169389||118728|
NCT01167543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-L-017|Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease|||University of California, San Francisco|No|Completed|September 2005|November 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|79|||Both|9 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric Specialty Clinics and General Pediatric Clinics at the University of California,        San Francisco|May 2010|July 21, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167543||118870|
NCT01167790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/02|Autofluorescence for the Screening of Precancerous and Malignant Lesions|Interest of Oral Tissue Autofluorescence for the Screening of Precancerous Lesions and Cancer in Population With Tobacco and Alcohol Abuse.|FLUOK|University Hospital, Bordeaux|No|Completed|July 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|180|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167790||118851|
NCT01168570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7713-AL-CTIL|Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level|Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level||Sheba Medical Center|No|Not yet recruiting|September 2010|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|20 FMF patients with AA amyloidosis demonstrated by positive biopsy of any target organs|August 2010|August 16, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168570||118791|
NCT01169246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTGX02-ASAP|Efficacy of the ATP Switch Automatic Programming in Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) Implanted Patients|Efficacy of the ATP Switch Automatic Programming in ICD and CRT-D Implanted Patients|ASAP|LivaNova|No|Terminated|November 2009|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1254|||Both|18 Years|N/A|No|Non-Probability Sample|ICD/CRT-D implanted patients population|February 2015|February 23, 2015|July 22, 2010||No|Low recruitement rate|No||https://clinicaltrials.gov/show/NCT01169246||118739|
NCT01169467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018317|Cerebral Perfusion Pressure Using Precedex and Other Sedatives|Cerebral Perfusion Pressure Using Precedex and Other Sedatives|C3PO|Duke University|No|Completed|October 2009|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|July 22, 2010|Yes|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01169467||118722|
NCT01139762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13529|A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms|A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|September 2010|May 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|696|||Male|45 Years|N/A|No|||January 2013|January 23, 2013|June 1, 2010|Yes|Yes||No|January 23, 2013|https://clinicaltrials.gov/show/NCT01139762||120993|
NCT01140880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC08-LA-710-FRI|Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men|Optimizing Access to Non-occupational Post Exposure Prophylaxis for HIV Using Contingency Management in Stimulant-Using Men Who Have Sex With Men||Friends Research Institute, Inc.|Yes|Completed|May 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|170|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|June 8, 2010|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT01140880||120907|
NCT01140893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT N° 2009-016384-11|Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes|Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.|EXEPUMP|University Hospital, Caen|Yes|Recruiting|November 2010|||May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|35 Years|70 Years|No|||January 2016|February 9, 2016|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01140893||120906|
NCT01140321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60/2003/Nerixia|Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI|A Randomized, Open-label Therapeutic Trial Evaluating the Efficacy and Safety of Neridronate (Nerixia®) in the Treatment of Osteoporosis in Patients With Thalassemia Major and Severe Thalassemia Intermedia.|Nerixia|Ente Ospedaliero Ospedali Galliera|No|Completed|January 2004|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2010|June 8, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140321||120950|
NCT01140568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091728|Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas|A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas||University of California, San Diego|Yes|Recruiting|May 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 6, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140568||120931|
NCT01141634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UToronto -25628|A Pilot Trial of Homeopathic Treatment for Attention Deficit Hyperactivity Disorder|A Pilot Trial of Homeopathic Treatment for Attention Deficit Hyperactivity Disorder in Children and Adolescents||University of Toronto|Yes|Completed|June 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|6 Years|16 Years|No|||March 2014|March 6, 2014|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141634||120850|
NCT01160809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia|Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Southern Ethiopia: a Cluster-randomized Controlled Trial||Malaria Consortium, Ethiopia|No|Completed|September 2008|January 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|6082|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2010|July 9, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01160809||119388|
NCT01160822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885C2201|To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee|A Randomized, Double Blind, Placebo and Naproxen Controlled, Multi-center, Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee||Novartis||Completed|April 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|169|||Both|40 Years|80 Years|No|||September 2012|September 28, 2012|July 9, 2010|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01160822||119387|
NCT01161069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9541002|A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Multiple Dose Escalation Study To Evaluate The Safety, Toleration, Pharmacokinetics Of PF-03049423 In Healthy Young Adult Volunteers And Healthy Elderly Volunteers||Pfizer|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 8, 2011|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01161069||119368|
NCT01169402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022822|Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)|Safety and Pharmacokinetics of Fluconazole Prophylaxis in Children Supported With Extracorporeal Membrane Oxygenation||Duke University|No|Active, not recruiting|July 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|18 Years|No|||February 2016|February 11, 2016|July 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01169402||118727|
NCT01161589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACTS S-ICD|First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data|First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data|FACTS|Boston Scientific Corporation|No|Completed|October 2005|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|142|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing a routine dual chamber, dual high voltage shocking coil T-ICD or CRT-D        insertion or replacement|July 2010|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161589||119328|
NCT01161875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nava Helmet #1|Impact of Neurally Adjusted Ventilator Assist (NAVA) Mode on Patient Ventilator Asynchrony Using Helmet|Study of the Benefit of the NAVA Mode Versus PSV Mode on Patient Ventilator Asynchrony During Non Invasive Ventilation With Helmet|NAVAHELMET|Pierre and Marie Curie University|No|Completed|November 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Probability Sample|Postoperative period|November 2009|August 4, 2011|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01161875||119306|
NCT01161888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMIT-1|Effect of Topical Imiquimod on Lentigo Maligna|Effect of Topical Imiquimod on Lentigo Maligna|LIMIT-1|University Hospital Birmingham NHS Foundation Trust|Yes|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|45 Years|N/A|No|||May 2010|June 18, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01161888||119305|
NCT01170000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0763 BJH|Timely End-of-Life Communication to Parents of Children With Brain Tumors|Timely End-of-Life Communication to Parents of Children With Brain Tumors||Barnes-Jewish Hospital|No|Recruiting|September 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The target sample size is 24 parents of 12 children diagnosed with a brain tumor. Our        sample size is sufficient to complete descriptive analyses of Aims 2 and 3, and adequate        precision for the estimation of effect sizes and preliminary tests of single-arm efficacy        in Aim 4.1. This study is powered for adequate estimation of effect sizes, not for        efficacy; that is, the study is powered to appropriately detect large effect sizes with        lower power for medium effect sizes. If 10% or fewer participants withdraw after COMPLETE        Session 1, we will be able to collect data from about 22 parents at least once. Twenty-two        parents will provide 61% power for detecting a difference of 0.5 times standard deviation        for a two-sided paired t-test with alpha of .05. The same test would have 70% power to        detect a difference of .55 standard deviation. This approach is typical and justifiable in        pilot feasibility studies to achieve 80% power for detecting only large effect sizes.|June 2011|June 27, 2011|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170000||118682|
NCT01167556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant 100003014|Family Motivational Intervention in Schizophrenia|Motivational Interviewing and Interaction Skills Training for Carers to Change Cannabis Use in Young Adults With Recent-onset Schizophrenia: Randomised Controlled Trial|FMI|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Enrolling by invitation|March 2006|February 2011|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|147|||Both|16 Years|40 Years|No|||February 2008|July 21, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167556||118869|
NCT01168310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-090|A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Pharmacodynamic Response of Fluticasone Propionate in Fixed-Dose Combination With Formoterol Fumarate in Subjects With COPD||Dey|No|Completed|August 2010|October 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|468|||Both|40 Days|N/A|No|||May 2013|May 17, 2013|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168310||118811|
NCT01168323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15310|Spaced Education to Optimize Prostate Cancer Screening|Spaced Education to Optimize Prostate Cancer Screening||Harvard University Faculty of Medicine|No|Completed|January 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|95|||Both|18 Years|N/A|No|||July 2010|August 6, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01168323||118810|
NCT01168336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BET 216|Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects|Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Escalating Doses of Extended Release and Standard Formulations of Betahistine as Monotherapy and as Adjunctive to Olanzapine in Healthy Subjects||OBEcure Ltd.|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 29, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01168336||118809|
NCT01168349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22733|An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)|Pharmaco-epidemiological Observational Study of the Clinical Benefit of NeoRecormon® in Cancer Patients With Anemia, According to Early Response to Treatment||Hoffmann-La Roche||Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1060|||Both|18 Years|N/A|No|Probability Sample|Anemic cancer patients receiving NeoRecormon (epoetin beta)|September 2015|September 1, 2015|July 21, 2010|No|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01168349||118808|
NCT01169259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-001217|Vitamin D and Omega-3 Trial (VITAL)|Vitamin D and Omega-3 Trial (VITAL)|VITAL|Brigham and Women's Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25874|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169259||118738|
NCT01169519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025220|Sildenafil in Single Ventricle Patients|Safety, Pharmacokinetics and Hemodynamic Efficacy of Sildenafil in Single Ventricle Patients||Duke University|Yes|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|3 Months|120 Months|No|||November 2012|October 10, 2013|July 7, 2010|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01169519||118718|
NCT01168869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 09-07|Myocardial Infarction as the First Manifestation of Coronary Heart Disease: Rates of Heralded and Unheralded Myocardial Infarction|Myocardial Infarction as the First Manifestation of Coronary Heart Disease: Rates of Heralded and Unheralded Myocardial Infarction. A CALIBER Study||London School of Hygiene and Tropical Medicine|Yes|Completed|September 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|9000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of patients registered at those GPRD practices that        agreed to the linkage with the MINAP database, and whose practices are "up to standard"        according to GPRD criteria. Practices taking part in the GPRD are chosen to be        representative of all UK practices, and 98% of people in the UK are registered with a GP.        Therefore the GPRD should be a representative sample of the UK population.|October 2015|October 1, 2015|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01168869||118768|
NCT01139775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13797|A Study in Non Small Cell Lung Cancer|A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed and Cisplatin in Patients With Stage IV Non-small Cell Lung Cancer||Eli Lilly and Company|No|Completed|February 2011|August 2014|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01139775||120992|
NCT01139788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13740|A Study of LY2624587 in Patients With Advanced Cancer|A Phase 1 Study of LY2624587 in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01139788||120991|
NCT01140906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13267A|Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults|A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/Day) in the Acute Treatment of Adult Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|May 2010|||September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|607|||Both|18 Years|75 Years|No|||December 2013|December 23, 2013|June 9, 2010||No||No|October 28, 2013|https://clinicaltrials.gov/show/NCT01140906||120905|
NCT01140919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2010|||||N/A|N/A|N/A||||||||||||||July 22, 2015|June 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01140919||120904|
NCT01140334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1DA028154-01|Treatment for Psychological and Drug Abuse Problems|Maximizing Effectiveness of Integrated Treatment Approaches||Johns Hopkins University|No|Completed|December 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|158|||Both|18 Years|65 Years|No|||September 2013|September 19, 2013|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01140334||120949|
NCT01140581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRONE_C_03668|Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation|A Randomized, International, Multi-center, Open-label Study to Document Optimal Timing of Initiation of Dronedarone Treatment After Conversion With Loading Dose of Amiodarone in Patients With Persistent Atrial Fibrillation Requiring Conversion of AF.|ARTEMIS Load|Sanofi|Yes|Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|402|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140581||120930|
NCT01140594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05192010-6082|Wavefront-guided Photorefractive Keratectomy (PRK) Versus Wavefront-guided Lasik for Myopia|A Prospective Randomized Eye to Eye Comparison of Fellow Eyes Undergoing Lasik With the IntraLase(TM) FS Versus PRK||Stanford University|No|Active, not recruiting|August 2006|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|34|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01140594||120929|
NCT01160536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910147|The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study|The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: An Exploratory Study||National Institutes of Health Clinical Center (CC)||Completed|June 2010|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|100|||Both|13 Years|N/A|No|||February 2016|February 17, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160536||119409|
NCT01169428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013688|Engaging Motivation for the Prevention of Weight Regain|Mindfulness Based Weight Loss Maintenance|EMPOWER|Duke University|Yes|Completed|July 2007|June 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 12, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169428||118725|
NCT01169415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024406|Effects of Steroid Tapering on Functional Capacity and Neurocognition|Effects of Dexamethasone Tapering Schedules on Functional Capacity and Neurocognition in Patients With Newly Diagnosed Glioblastoma Multiforme||Duke University|Yes|Withdrawn|June 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||May 2014|May 15, 2014|June 25, 2010|Yes|Yes|Funding not obtained|No||https://clinicaltrials.gov/show/NCT01169415||118726|
NCT01169714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1661003|A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.|An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Subjects||Pfizer|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2011|January 19, 2011|July 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01169714||118703|
NCT01161342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTV-1211142|Nutritional Status Among Older Adults. Risk Factors and Consequences of Malnutrition|Nutritional Status Among Older Adults. Risk Factors and Consequences of Malnutrition||Uppsala University|No|Completed|March 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1771|||Both|65 Years|N/A|No|Probability Sample|The included sample comprised 1771 patients 65 years and older, consecutively admitted        during fifteen months to two internal medicine wards (n = 706), two surgical wards (n =        681), and one orthopaedic ward (n = 384) at the Central hospital in Västerås, Sweden.|May 2011|August 25, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161342||119347|
NCT01170520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT 4953|Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents|The Addition of rTMS to the Therapy of Adolescents That Suffer From Treatment Resistant Depression: An Open Label Study||Shalvata Mental Health Center||Recruiting|August 2010|||September 2013|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|15 Years|18 Years|No|||January 2012|January 4, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170520||118642|
NCT01170754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-3350|Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy|A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy||Temple University|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01170754||118624|
NCT01157715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902001|A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD|A Randomized, Double-masked, Multicenter, Controlled Dose- and Interval-ranging Clinical Study of Intravitreal Injection of KH902 in Patients With Neovascular Age-related Macular Degeneration (the AURORA Study)|AURORA|Chengdu Kanghong Biotech Co.,Ltd.||Completed|May 2010|July 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|50 Years|N/A|No|||November 2014|November 5, 2014|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157715||119622|
NCT01168050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081237|Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.|Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification.|NILOMEL|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|July 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2011|February 7, 2011|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168050||118831|
NCT01168063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090210|Molecular Detection of Antibiotic Resistance and H Pylori Eradication|Medico-economic Evaluation of a Therapeutic Strategy Based on Molecular Detection of Antibiotic Resistance in the Management of H Pylori Infection|HELICOSTIC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2010|March 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1386|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168063||118830|
NCT01169272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SonR Study - ITSY05|Clinical Evaluation Of The SonR Atrial Lead In Paradym RF Device|Clinical Evaluation Of SonR Atrial Lead In Paradym RF Device SORIN GROUP'S New ICD Plateform||LivaNova|No|Completed|October 2010|June 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01169272||118737|
NCT01169532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-034|Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)||Fox Chase Cancer Center|Yes|Completed|October 2010|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169532||118717|
NCT01169857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05321|Velcade for Proliferative Lupus Nephritis|Velcade for Proliferative Lupus Nephritis||The Rogosin Institute|No|Withdrawn|August 2010|December 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|July 23, 2010|Yes|Yes|No participants were enrolled.|No||https://clinicaltrials.gov/show/NCT01169857||118693|
NCT01139801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009 ED|Cervical Ripening for Induction of Labor: Misoprostol Versus Oxytocin in Conjunction With Foley Balloon|||Aultman Health Foundation||Completed|September 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||January 2014|January 6, 2014|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139801||120990|
NCT01141192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910091|The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults|The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults|AVIS|Georgia Regents University|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|48|||Both|19 Years|60 Years|No|||June 2010|June 9, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01141192||120883|
NCT01140607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP6792|Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment|Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment||Sanofi|No|Completed|May 2010|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|56|||Both|18 Years|60 Years|No|||July 2015|July 20, 2015|May 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140607||120928|
NCT01140867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-S082-409|Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy|A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy||Eisai Inc.||Completed|February 2008|March 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|15 Years|N/A|No|||May 2011|September 8, 2011|May 19, 2010||No||No|August 5, 2011|https://clinicaltrials.gov/show/NCT01140867||120908|
NCT01169727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RTH-DUM-2009/2|Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand|Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand||AstraZeneca|No|Completed|July 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|684|||Both|41 Years|N/A|No|Non-Probability Sample|Primary care and Specialty care in 20 centers nationwide in Thailand|May 2012|May 30, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169727||118702|
NCT01169740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bilirubin 2010/413|Transcutaneous Measurement of Jaundice in the Newborn|Comparison of Transcutaneous or Laboratory Measurement of Bilirubin in the Newborn|TcBili|Norwegian University of Science and Technology|No|Completed|July 2010|October 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|N/A|28 Days|Accepts Healthy Volunteers|Non-Probability Sample|Newborn infants admitted to normal newborn nursery|October 2014|October 27, 2014|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169740||118701|
NCT01170546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950101002|Effects of Hamstring Training in Different Modes on Stabilizing Knee Joints With Anterior Drawer Laxity|Effects of Hamstring Training in Different Modes on Stabilizing Knee Joints With Anterior Drawer Laxity||Taipei Physical Education College|Yes|Completed|January 2006|April 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Male|15 Years|30 Years|Accepts Healthy Volunteers|||September 2010|November 15, 2010|July 23, 2010||No||No|August 2, 2010|https://clinicaltrials.gov/show/NCT01170546||118640|small size, participant: not real ACL-injured patient but knee with anterior laxity instead
NCT01166477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAI-CDV-2009-01|Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor|Ensayo clínico, Abierto, Aleatorizado Para Comparar la Calidad de Vida de Los Pacientes VIH+ Que Inician Monoterapia Con Comprimidos de LPV/r vs Triple Terapia Que Contenga un IP Potenciado|QoLKAMON|Sociedad Andaluza de Enfermedades Infecciosas|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|228|||Both|18 Years|N/A|No|||October 2009|March 19, 2013|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166477||118952|
NCT01170260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA RO1 AA013844-05|Alcohol, Marijuana, and Risky Sex: Group Interventions With Detained Adolescents|Alcohol, Marijuana, and Risky Sex: Group Interventions With Detained Adolescents|MARS|University of New Mexico||Recruiting|August 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|520|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||August 2011|August 16, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170260||118662|
NCT01170286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP01.09|Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy|Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects||DBV Technologies|Yes|Completed|July 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|6 Years|50 Years|No|||March 2012|March 22, 2012|July 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01170286||118660|
NCT01170767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.467/10|French Evaluation Group Avastin Versus Lucentis|French Evaluation Group Avastin Versus Lucentis|GEFAL|Hospices Civils de Lyon|Yes|Completed|June 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|501|||Both|50 Years|N/A|No|||February 2013|July 26, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170767||118623|
NCT01170780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dx3|Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair|Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair||University Hospital Koge|Yes|Completed|August 2010|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Male|18 Years|85 Years|No|||January 2012|January 26, 2012|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170780||118622|
NCT01166984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATB-001|AB103 Peptide Antagonist in Healthy Volunteers|Phase 1, Double Blind, Placebo-Controlled, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Clinical Trial of AB103, A Peptide Antagonist in Healthy Volunteers||Atox Bio Ltd|Yes|Completed|September 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|July 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01166984||118913|
NCT01166997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKOS Protocol Number 08|ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism|Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism|ULTIMA|EKOS Corporation|Yes|Completed|July 2010|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|80 Years|No|||June 2013|June 11, 2013|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166997||118912|
NCT01167309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 27847-S02|LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients|LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease||LEO Pharma|No|Completed|June 2010|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|72|||Both|18 Years|75 Years|No|||January 2012|January 20, 2012|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01167309||118888|
NCT01167816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VZ-PANC-PI-0244|Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer|Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer||University of Oklahoma|Yes|Terminated|July 2010|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|July 21, 2010|Yes|Yes|The study was terminated as the Prinicipal Investigator left the site- all previous subjects    enrolled are deceased|No||https://clinicaltrials.gov/show/NCT01167816||118849|
NCT01168882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGB638-1-08-02|Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies|Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies||Agennix|Yes|Withdrawn|November 2011|July 2015|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|July 20, 2010|Yes|Yes|Sponsor decision to not initiate clinical trial at this time|No||https://clinicaltrials.gov/show/NCT01168882||118767|
NCT01168895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14972|Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder|Randomized, Double-blind, Cross-over Study in COPD Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder||Bayer|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01168895||118766|
NCT01168947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052-10|Effect of Sodium Concentration of Priming and Rinsing Fluids on Weight Gain|Effect of Sodium Concentration of Priming and Rinsing Fluids on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients: a Prospective Pilot Study||Renal Research Institute||Completed|July 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168947||118762|
NCT01169285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-044|Efficiency and Efficacy of the Distress Thermometer in the Burn and Wound Population (Research Mentoring High Student Project)|Prospective Observational||Saint Elizabeth Regional Medical Center||Completed|May 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Burn Department Nurses and Burn Patients|May 2009|July 23, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169285||118736|
NCT01169298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-ATLL-001|A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma|A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma||Celgene|Yes|Completed|July 2010|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|N/A|No|||December 2015|December 16, 2015|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169298||118735|
NCT01169870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-07-278|Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients|A Randomized Phase II Trial of Genexol-PM vs Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients||National Cancer Center, Korea|No|Withdrawn|July 2007|October 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 1, 2012|February 8, 2010||No|withdrawn studies|No||https://clinicaltrials.gov/show/NCT01169870||118692|
NCT01139814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-001-01|Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies|Clinical Study to Evaluate the Effectiveness and Safety of the Catheter Robotics Amigo Remote Catheter System for Performing Right-Sided Electrophysiology Mapping Studies||Catheter Robotics, Inc.|No|Completed|June 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|181|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|June 7, 2010|Yes|Yes||No|March 1, 2013|https://clinicaltrials.gov/show/NCT01139814||120989|
NCT01141426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA002|Halifax Treatment Refractory Depression Trial|Halifax Treatment Refractory Depression Trial: A Randomized Controlled Trial of Intensive Short-Term Dynamic Psychotherapy (ISTDP) Compared to Secondary Care Treatment as Usual||Nova Scotia Health Authority|No|Active, not recruiting|September 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141426||120865|
NCT01141166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF2191|Octabaix Intervention Study|A Randomised Controlled Trial on Falls and Malnutrition Prevention in the Community in 85 Year Old Subjects||Jordi Gol i Gurina Foundation||Active, not recruiting|January 2009|||April 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|1||Anticipated|328|||Both|85 Years|85 Years|No|||June 2010|June 9, 2010|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01141166||120885|
NCT01141387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-534|Outcomes in MEasurement-Based Treatment|Clinical Outcomes in MEasurement-Based Treatment (COMET)|COMET|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|May 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|914|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|April 2011|November 7, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141387||120868|
NCT01170299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-FIBRE-STUDY|Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer|A Randomized Controlled Trial to Investigate the Role of Low or High 'Fibre' Diets in Patients Undergoing Pelvic Radiotherapy - The Fibre Study||National Cancer Institute (NCI)||Recruiting|October 2009|||April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|177|||Both|N/A|N/A|No|||July 2010|August 9, 2013|July 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01170299||118659|
NCT01170559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006628 BLT|Use of Loop Recorders for Diagnosis of Palpitations in A&E|Use of Implantable Loop Recorders as a Primary Investigation of Infrequent Undiagnosed ArrhythmIa Symptoms in the Emergency Department|LIAISE|Barts & The London NHS Trust|No|Active, not recruiting|April 2010|||August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|56|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170559||118639|
NCT01170013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA024207|Substance Use Prevention in Teen Psychiatric Patients|Substance Abuse Prevention for Preadolescents With Psychiatric Disorders|tCheckup|Brown University|Yes|Completed|August 2008|December 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|68|||Both|12 Years|16 Years|No|||July 2012|July 28, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01170013||118681|
NCT01170273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7574-R|Vitamin D in Vulnerable Adults (VIVA-VA)|Vitamin D in Vulnerable Adults|VIVA-VA|VA Office of Research and Development|No|Completed|August 2010|December 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|146|||Male|65 Years|95 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01170273||118661|
NCT01170533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2009-2|PPI and Clopidogrel Response|Effects of PPI Therapy on Clopidogrel-Induced Antiplatelet Effects: A Randomized Study||University of Florida|Yes|Completed|March 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|July 23, 2010||No||No|October 31, 2011|https://clinicaltrials.gov/show/NCT01170533||118641|
NCT01167010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF111|A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma|A Phase III, Randomized, Non-inferiority, Open-label, Comparative Study Between Foraseq® Inhalation Capsules, Eurofarma's Single Formoterol / Budesonide Inhalation Capsule and Single Alenia® Inhalation Capsule in Asthmatic Patients|UNIK|Eurofarma Laboratorios S.A.|Yes|Completed|April 2011|February 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|552|||Both|12 Years|N/A|No|||May 2011|May 4, 2012|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167010||118911|
NCT01167023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13806|Prasugrel Versus Placebo in Adult Sickle Cell Disease|A Double-Blind, Randomized, Multicenter Study of Prasugrel Compared to Placebo in Adult Patients With Sickle Cell Disease||Eli Lilly and Company|Yes|Completed|July 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|62|||Both|18 Years|55 Years|No|||April 2012|April 9, 2012|July 20, 2010|Yes|Yes||No|April 9, 2012|https://clinicaltrials.gov/show/NCT01167023||118910|
NCT01167322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-07-1|Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas|Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV)||Nobelpharma|Yes|Completed|August 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|18 Years|70 Years|No|||April 2012|April 26, 2012|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01167322||118887|
NCT01167803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2009/EN-01|Anesthesia for Obese Patients: Desflurane Versus Xenon|Coming Out of Anesthesia After Bariatric Surgery : Desflurane Versus Xenon|XENON|Centre Hospitalier Universitaire de Nīmes|No|Completed|December 2010|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167803||118850|
NCT01168362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10642140004-06N4214|Korea Atherosclerosis Study-3|Evaluation of Coronary Artery Disease With Multidetector-Row Cardiac Computed Tomography in Positive Cardiovascular Risk or Not|KAS3|Seoul National University Bundang Hospital|No|Completed|February 2006|May 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4000|Samples Without DNA|Biochemical paramteres including lipid, glucose, insulin, and other novel cardiometabolic      factors|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|positive cardiovascular risks or not|October 2013|October 24, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168362||118807|
NCT01168375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8742|The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy|The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy||hahid Beheshti University of Medical Sciences||Active, not recruiting||||||Phase 1|Interventional|N/A|2||||||Both|N/A|N/A|No|||March 2010|July 22, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01168375||118806|
NCT01168908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-00036602|Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy|Phase 2 Clinical Trial of Sildenafil for Cardiac Dysfunction in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy|REVERSE-DBMD|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Suspended|September 2010|August 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|50 Years|No|||February 2013|February 4, 2013|July 22, 2010||No|As recommended by the DSMB.|No||https://clinicaltrials.gov/show/NCT01168908||118765|
NCT01168921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0123|Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)|A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2010|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168921||118764|
NCT01168934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081010|A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers|A Phase 1, Single Dose, Randomized, Cross-Over Absolute Bioavailability Study In Healthy Volunteers Comparing Oral To Intravenous Administration Of Crizotinib (PF-02341066)||Pfizer|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|July 22, 2010|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT01168934||118763|
NCT01168960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RC1AA018986|Identifying Multiple Mechanisms of Change in Alcoholism Treatment|||State University of New York at Buffalo|Yes|Completed|January 2010|August 2012|Actual|August 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168960||118761|
NCT01168973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13852|A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy|A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy||Eli Lilly and Company|Yes|Active, not recruiting|December 2010|February 2017|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1253|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 16, 2010|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01168973||118760|Three participants randomized to placebo and docetaxel received 1 dose of ramucirumab in error. They are included in the placebo and docetaxel arm in the ITT population and are included in the ramucirumab and docetaxel arm in the Safety population.
NCT01168986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|340-2009|The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain|The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain||University of Florida|No|Recruiting|September 2009|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Both|18 Years|60 Years|No|||March 2015|March 17, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168986||118759|
NCT01169311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVHEPH0021|Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure|A Prospective, Multi-Center Investigation Of The Safety And Performance Of The Covidien EEA™ Hemorrhoid And Prolapse Stapling Set With DST Series™ Technology Im A Hemorrhoidopexy Procedure||Medtronic - MITG|No|Completed|July 2010|July 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|80 Years|No|||September 2014|September 30, 2014|July 22, 2010||No||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01169311||118734|
NCT01169558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20552|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.|An Expanded Access Program of Avastin in Patients With Metastatic Cancer of Colon or Rectum - Brazilian Extension Study||Hoffmann-La Roche||Completed|May 2006|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01169558||118715|
NCT01169545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-090|Cancer, Vulnerability, and Financial Quality of Life: A Mixed Methods Study|Cancer, Vulnerability, and Financial Quality of Life: A Mixed Methods Study||Georgetown University|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Any cancer patient over the age of 18 who can speak and understand English and can provide        informed consent|May 2015|May 14, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01169545||118716|
NCT01169571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-10-03|Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients|Phase 4, Open-Label Study Evaluating the Hemodynamic Effect of Differing Loading Regimens of Precedex in a Post-Surgical Intensive Care Patient Population||Hospira, Inc.|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|373|||Both|18 Years|N/A|No|Non-Probability Sample|Initially intubated and mechanically ventilated post-surgical adult male and female        subjects in an intensive care setting.|July 2015|July 23, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01169571||118714|
NCT01140633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001062|Novel Measures and Theory of Pediatric Antiretroviral Therapy Adherence in Uganda|Novel Measures and Theory of Pediatric Antiretroviral Therapy Adherence in Uganda||Massachusetts General Hospital|No|Completed|April 2010|August 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|Samples With DNA|Plasma samples with HIV viral DNA.|Both|1 Year|10 Years|No|Non-Probability Sample|young children receiving HIV antiretroviral therapy in a rural African setting|August 2013|August 30, 2013|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140633||120926|
NCT01141179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 27847-S03|The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847|The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847||LEO Pharma|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 1, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141179||120884|
NCT01141400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-587|The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use|The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|48865|||Both|18 Years|64 Years|No|Non-Probability Sample|Patients will be selected from the MarketScan Commercial Database between January 1, 2004        and September 30, 2008 (the last month of data available)|November 2010|November 7, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141400||120867|
NCT01170039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014592|The Effectiveness of Lubiprostone in Constipated Diabetics|A Randomized, Double Blind, Placebo-controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients||Emory University|No|Completed|September 2010|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|30 Years|80 Years|No|||February 2016|February 17, 2016|July 23, 2010|Yes|Yes||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01170039||118679|
NCT01170052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-No.: 2009-014844-13|Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)|Phase I/II Study With Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-hodgkin's Lymphoma (NHL) Not Eligible for High Dose Chemotherapy and Autologous/Allogeneic Stem Cell Transplantation||Charite University, Berlin, Germany|No|Withdrawn|May 2010|April 2014|Anticipated|April 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2010|March 15, 2011|July 14, 2010||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01170052||118678|
NCT01170572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007076|Longitudinal Study of Patients Following Long Bone Fracture|Longitudinal Study of Vitamin D Metabolism and Bone Healing in Adult Patients With Recent Long Bone Fracture||Barts & The London NHS Trust|No|Completed|March 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|Samples With DNA|Whole blood samples will be retained|Both|16 Years|N/A|No|Probability Sample|Patients presenting to the Accident and Emergency Department, Royal London Hospital,        Whitechapel with a long bone or clavicle fracture|November 2012|November 6, 2012|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170572||118638|
NCT01166490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASG5ME-002|A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma|A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma||Seattle Genetics, Inc.|No|Completed|July 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|July 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01166490||118951|
NCT01166776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12129|A Research Study Looking at Specific Tissue of the Umbilical Cord|Decellularization of Umbilical Cord Wharton's Jelly for Tissue Regenerative Applications Including Avascular Necrosis||University of Kansas Medical Center|No|Recruiting|June 2010|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|umbilical cord tissue|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant women at time of delivery|January 2016|January 15, 2016|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166776||118929|
NCT01167036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AECC 20091|Effectiveness of a Massage Instrument Compared to Placebo for Upper Trapezius Muscle Pain|Immediate Effectiveness of Instrument Assisted Soft Tissue Mobilization Compared to Placebo on the Sensitivity of Latent Upper Trapezius Trigger Points: A Randomized Double Blind, Placebo-controlled, Parallel-group Study||Anglo-European College of Chiropractic|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2009|July 21, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167036||118909|
NCT01166750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11154|Jointstrong Intervention for Juvenile Arthritis|Jointstrong Intervention for Juvenile Arthritis||University of Kansas Medical Center|No|Completed|April 2009|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|8 Years|12 Years|No|||May 2013|May 30, 2013|July 19, 2010||No||No|September 24, 2012|https://clinicaltrials.gov/show/NCT01166750||118931|It was difficult to find subjects with pain resulting in significantly fewer subjects entered in the study.
NCT01166763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11657|Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D|Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D||University of Kansas Medical Center|No|Completed|May 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Female|N/A|55 Years|No|||October 2015|October 30, 2015|July 16, 2010|No|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01166763||118930|Single arm pilot trial so all comparisons are within subject for change over the course of the study.
NCT01167348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tsaotun Psychiatric Center|The Effectiveness Of Auricular Acupressure On Body Weight Parameters On Patients With Schizophrenia|The Effectiveness Of Auricular Acupressure On Body Weight Parameters On Patients With Schizophrenia||TsaoTun Psychiatric Center, Department of Health, Taiwan|Yes|Recruiting|June 2010|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|86|||Both|20 Years|60 Years|No|||July 2010|July 22, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01167348||118885|
NCT01167569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220070054|Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients|Double-Blind, Randomized Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients|Vit C|Rutgers, The State University of New Jersey|No|Completed|October 2007|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|63|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01167569||118868|
NCT01167582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220090205|Myocardial Ischemia and Transfusion (MINT)|Myocardial Ischemia and Transfusion|MINT|Rutgers, The State University of New Jersey|Yes|Completed|September 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|March 17, 2010||No||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01167582||118867|This pilot trial was not designed to enroll enough patients to answer the transfusion dilemma currently facing clinicians in practice.
NCT01168609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS97-CT4-17|Left Atrial Distensibility and Left Ventricular Filling Pressure in Acute Myocardial Infarction|Usefulness of Left Atrial Distensibility to Assess Left Ventricular Filling Pressure and to Predict Prognosis in Acute Myocardial Infarction||Kaohsiung Veterans General Hospital.|Yes|Completed|December 2007|July 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|521|||Both|18 Years|N/A|No|Non-Probability Sample|Between December 2007 and March 2009, this study enrolled AMI patients who had received        cardiac catheterization for potential percutaneous coronary intervention (PCI). Myocardial        infarction was detected by the presence of at least two of the following criteria: chest        pain lasting more than 30 minutes, typical electrocardiographic changes, and elevated        creatinine kinase-MB fraction. Consecutive patients 18 years of age or older who presented        within 12 hours after the onset of symptoms were considered for enrollment. Patients who        had ST-segment elevation of 1 mm or more in two or more contiguous leads were classified        as ST-segment elevation MI. Others were classified as non ST-segment elevation MI. .|December 2007|July 22, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168609||118788|
NCT01168635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13169|Improving Asthma Outcomes Through Spirometry Distance Learning|Improving Asthma Outcomes Through Spirometry Distance Learning||Seattle Children's Hospital|Yes|Completed|June 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|660|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01168635||118786|
NCT01169597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-PDN001|Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients|Short Term Study on the Effect of a Fixed Dose of 12.5 mg of Prednisone as Starting Dose in Polymyalgia Rheumatica||University of Genova|No|Completed|January 2009|May 2010|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|50 Years|N/A|No|||June 2010|July 23, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01169597||118712|
NCT01169610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002699|Varenicline and Alcohol in Inpatient Addictions Program (IAP)|A 24-week Open-Label Feasibility Trial of Varenicline for Alcoholic Cigarette Smokers||Mayo Clinic|No|Terminated|January 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|70 Years|No|||July 2013|July 19, 2013|July 22, 2010|No|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01169610||118711|
NCT01169922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA RO1 AA017390-01|HIV Prevention With Adolescents: Neurocognitive Deficits and Treatment Response||SHARP|University of New Mexico||Active, not recruiting|October 2007|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||July 2011|August 5, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169922||118688|
NCT01169584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-IT-P009|Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients|A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors.||SillaJen, Inc.|Yes|Completed|August 2010|November 2014|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|21 Years|No|||January 2016|January 19, 2016|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169584||118713|
NCT01169909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-117|Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia|The Use of Ranibizumab to Control Pterygium Growth in Recurrences and in Non-surgical Primary Lesions.||University of New Mexico|No|Recruiting|August 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 9, 2011|July 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169909||118689|
NCT01140646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC09C4|Evaluation of SAMe for Hot Flashes|Phase II Evaluation of S-Adenosyl-L-Methionine (SAMe) for the Treatment of Hot Flashes|SAMe|Mayo Clinic|Yes|Completed|October 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||April 2014|April 10, 2014|June 8, 2010|Yes|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01140646||120925|
NCT01141205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-BIS NCP03/2009|HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease|Phase I Study: HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease|HIV-BIS|Statens Serum Institut|No|Completed|August 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|50 Years|No|||August 2013|August 2, 2013|June 9, 2010||No||No|June 13, 2012|https://clinicaltrials.gov/show/NCT01141205||120882|
NCT01141686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB98021|Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers|Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers||Taipei Medical University WanFang Hospital|No|Completed|May 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|90|Samples With DNA|DNA|Both|N/A|N/A|No|Non-Probability Sample|lung cancer patient in wanfang hospital|June 2010|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141686||120846|
NCT01141413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-255|Dose Escalation With Remicade® and Orencia®|Comparison of Dosing and Costs Between Rheumatoid Arthritis Patients Treated With Remicade® Versus Orencia®||Bristol-Myers Squibb|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|5451|||Both|18 Years|N/A|No|Non-Probability Sample|Commercial health plan members|April 2012|April 3, 2012|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141413||120866|
NCT01141946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10.046|Pleural Ultrasonography in Lung Cancer|Pleural Ultrasonography in Lung Cancer - PULC|CT0018|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|June 2010|October 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|June 2011|July 16, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01141946||120826|
NCT01166802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-005L|Development of a Questionnaire to Measure Hypervigilance for Visceral Pain|Development of a Questionnaire to Measure Hypervigilance for Visceral Pain||University of North Carolina, Chapel Hill|No|Completed|February 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|157|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with irritable bowel syndrome, age 18 or older, of any race or gender,        will be enrolled. These subjects will be recruited from the Functional GI & Motility        Disorder's Registry of Research Participants.|July 2010|July 19, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166802||118927|
NCT01166503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000005134|Early Versus Delayed Surgery for Infantile Esotropia|Early Versus Delayed Surgery for Infantile Esotropia: A Clinical Evaluation of Sensory and Motor Outcomes||The Hospital for Sick Children|No|Recruiting|May 2004|May 2017|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|3 Months|23 Months|No|Non-Probability Sample|Patients with infantile esotropia will be enrolled from The Hospital for Sick Children in        Toronto. Infants with characteristics that indicate low likelihood of spontaneous        resolution will be studied.|November 2015|November 16, 2015|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166503||118950|
NCT01166789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004L|Lubiprostone Effects on Visceral Pain Sensitivity|Lubiprostone Effects on Visceral Pain Sensitivity||University of North Carolina, Chapel Hill|No|Completed|February 2008|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|July 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01166789||118928|
NCT01167049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22199|Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis|Neoadjuvant Chemotherapy With Xeloda in Combination With Paclitaxel in Gastric Cancer With Liver Metastasis||Beijing Cancer Hospital|Yes|Recruiting|August 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2010|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167049||118908|
NCT01167335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2211|Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures|A 12-week, Randomized, Double-blind, Placebo-controlled Exploratory Study to Assess the Antiepileptic Activity of BGG492 Given Orally as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures||Novartis||Withdrawn|August 2010|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||April 2012|April 30, 2012|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167335||118886|
NCT01167361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD10-082 RESVPI|Epidemiology Of Respiratory Virus Infections In Children|Epidemiology Of Respiratory Virus Infections In Children||St. Jude Children's Research Hospital|No|Completed|September 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|350|Samples Without DNA|Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal      aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic      studies on this specimen will be performed as ordered and the results will be available to      the treating physicians after reporting. An aliquot from the leftover sample remaining after      clinical diagnostic testing will be used for FilmArrayTM analysis|Both|N/A|18 Years|No|Non-Probability Sample|Patients with an URTI or LRTI undergoing collection of respiratory secretions at St Jude        by nasopharyngeal wash, nasopharyngeal swab, tracheal aspirate or bronchoalveolar lavage        as ordered by the treating physician.|July 2011|October 30, 2012|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167361||118884|
NCT01168076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILS-01-007|Noninvasive Transcutaneous Glucometer Development|Noninvasive Transcutaneous Glucometer Development||InLight Solutions||Completed|December 2001|December 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Those with Type 1 and 2 diabetes|February 2008|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168076||118829|
NCT01168622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144-10|Impact of Race/Ethnicity on Platelet Function|Impact of Race/Ethnicity on Platelet Function||University of Nebraska|No|Completed|June 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|625|Samples With DNA|Blood or saliva samples will be collected for DNA extraction and genotyping of CYP2C19 and      other relevant genes.|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy people and coronary heart disease patients taking aspirin or aspirin and        clopidogrel or prasugrel|March 2013|March 12, 2013|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01168622||118787|
NCT01168648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ekhagastiftelsen 2001-5|Yoga for Stress Management in Health Care Personnel|Yoga for Stress Management in Health Care Personnel and Its Relation to the Hypothalamus-pituitary-adrenal(HPA)Axis||Karolinska Institutet|No|Completed|August 2003|May 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|71|||Both|18 Years|65 Years|No|||July 2010|July 22, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168648||118785|
NCT01168661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pickup 2003|Yoga, Mindfulness and Cognitive Psychotherapy as Treatment for Stress and Burnout|Yoga, Mindfulness and Cognitive Psychotherapy as Treatment for Stress and Burnout||Karolinska Institutet|No|Completed|August 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|90|||Both|16 Years|65 Years|No|||July 2010|July 22, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168661||118784|
NCT01169935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/S1102/31|Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)|In Vivo Tracking of Magnetically-labelled Human Mononuclear Cells Using MRI Scanning||University of Edinburgh|No|Completed|July 2010|||April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169935||118687|
NCT01170195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5459|Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms|Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms||F&C Licorice Ltd|No|Not yet recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Female|45 Years|60 Years|No|||July 2010|July 26, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170195||118667|
NCT01170182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7577/05-06|Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study to Compare Omeprazole 40 mg DR Capsules Dr. Reddy's Laboratories Ltd.,With Prilosec® 40 mg Merck & Co., Inc.,USA Under Fed Condition||Dr. Reddy's Laboratories Limited|No|Completed|February 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2010|July 26, 2010|May 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01170182||118668|
NCT01140932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kappelgaard, ERG|The Electroretinogram in Healthy and Glucose Intolerant Young Men|Electroretinographic Changes in Healthy Young Men Before and After Induction of Glucose Intolerance by Glucocorticoids Treatment, Hyperphagia and Lack of Exercise||Glostrup University Hospital, Copenhagen|Yes|Completed|February 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140932||120903|
NCT01140945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klinger-HMO-CTIL|Association Study Between Periodontal Disease and Male Infertility|Periodontal Status of Males Attending in Vitro Fertilization Clinic||Hadassah Medical Organization|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Male|20 Years|50 Years||Non-Probability Sample|Males attending in vitro fertiliztion clinic|January 2010|June 9, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01140945||120902|
NCT01141439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA4|Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management|A Retrospective Evaluation of the Effectiveness and Cost-effectiveness of HFA-BDP MDI (Qvar®) Compared With CFC-BDP MDI and FP MDI Used in the Management of Asthma in a Representative UK UK Primary Care Population|QvarAsthma|Research in Real-Life Ltd|Yes|Completed|January 2001|July 2010|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|815377|||Both|5 Years|60 Years|No|Non-Probability Sample|Primary care asthma patients receiving who either initiated ICS therapy as any of        extrafine HFA-BDP, CFC-BDP of FP via MDI at an index prescription date (IPD), or were on        existing ICs therapy (any) and had an increase in ICS dose at IPD as any of extrafine        HFA-BDP, CFC-BDP of FP via MDI|March 2013|March 13, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141439||120864|
NCT01141673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3-ITD KIT|Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia|Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia||Taipei Medical University WanFang Hospital|No|Recruiting|June 2010|June 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|DNA|Both|N/A|N/A|No|Non-Probability Sample|acute myeloid leukemia patient in wanfang hospital|April 2011|April 22, 2011|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141673||120847|
NCT01141699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB99006|A Study of Compliant Behaviors and Associated Factors of Women Breast Screening|A Study of Compliant Behaviors and Associated Factors of Women Breast Screening in the Shuang Ho Region of Taipei City.||Taipei Medical University WanFang Hospital|No|Completed|October 2009|December 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|191|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The women live in the Shuang Ho Region of Taipei City|September 2010|September 3, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141699||120845|
NCT01142206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7521B|The Leisure-time Activity and Nutrition Program|The Effects of Two Different Leisure-time Activity Prescriptions on Eating and Activity Behaviors During Behavioral Weight Loss Treatment|LEAN|University of Tennessee|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 28, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142206||120806|
NCT01170312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-123|Arthroscopic Surgery and Platelet Rich Plasma In Rotator Cuff Tear Evaluation|Arthroscopic Surgery and Platelet Rich Plasma In Rotator Cuff Tear Evaluation (A.S.P.I.R.E.): The Use of Platelet Rich Plasma Following Arthroscopic Repair of Rotator Cuff Tears, A Pilot Study|ASPIRE|McMaster University|No|Completed|September 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|70 Years|No|||October 2012|October 31, 2012|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01170312||118658|
NCT01170325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100157|A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG|A Study of Divalproex Sodium in Children With Autism Spectrum Disorder and Epileptiform EEG||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|3 Years|10 Years|No|||January 2011|December 30, 2011|July 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01170325||118657|
NCT01170338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.68|Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome|Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome||Newark Beth Israel Medical Center|No|Recruiting|January 2008|||July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2010|July 26, 2010|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01170338||118656|
NCT01167387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCI|Preoperative Carbohydrate Loading in Elective Surgery|PREOPERATIVE ORAL CARBOHYDRATE LOADING: EFFECTS ON THE GLUCOSE METABOLISM AND POSTOPERATIVE INFECTIONS||University of Milano Bicocca|Yes|Recruiting|June 2010|March 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|660|||Both|19 Years|90 Years|No|||May 2010|July 21, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167387||118882|
NCT01167400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS1259|Cybercycling for Cognitive Health|Cybercycling for Older Adults: Neuropsychological, Physiological and Behavioral Effects||Union College, New York|No|Completed|July 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|63|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 4, 2014|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167400||118881|
NCT01166516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-02704|IBV Valve System for the Treatment of Prolonged Air Leak Under HDE H060002 - Post Approval Study|A Prospective Study With the IBV Valve System for the Treatment of Prolonged Air Leak|HUD-PAS|Spiration, Inc.|No|Recruiting|April 2010|July 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|N/A|N/A|No|||February 2015|February 26, 2015|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01166516||118949|
NCT01167374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMETHEUS-01|Carbon Ion Radiotherapy for Hepatocellular Carcinoma|Phase I Study Evaluating the Treatment of Patients With Hepatocellular Carcinoma (HCC) With Carbon Ion Radiotherapy|PROMETHEUS-01|University Hospital Heidelberg|Yes|Recruiting|August 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||July 2010|August 3, 2011|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167374||118883|
NCT01167062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAM040-0109|Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones|Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study||ChaingMai University|Yes|Recruiting|June 2010|||April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2010|July 21, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01167062||118907|
NCT01167829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38636-D|ORAL T-8 Oral Testosterone for Male Hormonal Contraception|Pharmacokinetics of Modified Slow-Release Oral Testosterone Over 10 Days in Normal Men With Experimental Hypogonadism|Oral T8|University of Washington|No|Completed|July 2010|June 2012|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 23, 2013|July 20, 2010|Yes|Yes||No|September 25, 2012|https://clinicaltrials.gov/show/NCT01167829||118848|
NCT01168115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILS-07-386|Near-Infrared Spectroscopy for Blood Glucose Measurements|Near-Infrared Spectroscopy for Blood Glucose Measurements||InLight Solutions||Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Males and females between the ages of 18 and 65|January 2008|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168115||118826|
NCT01168414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-10-466-5929|A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|A Randomized, Comparison of the Effects of Ganfort and Duotrav on Intraocular Pressure in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Open Label/Evaluator-blind/Cross-over Study||Ministry of Health, Malaysia||Completed|August 2010|February 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|N/A|N/A|No|||July 2010|July 7, 2011|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168414||118803|
NCT01169324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100528004|Effect of Deep Brain Stimulation (DBS) on Sleep Architecture in Patients With Movement Disorders|Effect of DBS on Sleep Architecture in Patients With Movement Disorders.||University of Alabama at Birmingham|No|Active, not recruiting|July 2010|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|17|||Both|19 Years|N/A|No|||January 2016|January 12, 2016|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01169324||118733|
NCT01169337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02057|Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma|Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma||National Cancer Institute (NCI)|Yes|Recruiting|October 2010|||July 2026|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|No|||January 2016|March 24, 2016|July 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169337||118732|
NCT01169948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/R/CAR/17|320 Multidetector Computed Tomography Prior to Coronary Artery Bypass Surgery|320 Multidetector Computed Tomography in the Preoperative Assessment for Coronary Artery Bypass Graft Surgery||University of Edinburgh|No|Withdrawn|June 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients awaiting cardiac surgery.|March 2013|March 13, 2013|July 14, 2010||No|Not funded.|No||https://clinicaltrials.gov/show/NCT01169948||118686|
NCT01169961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003-10CTIL|Assessment of Iron Deposition in Major Organs of Hemodialysis Patients|Assessment of Iron Deposition in Major Organs of Hemodialysis Patients, Using T2*MRI and Novel Biomarkers of Free Iron Species||Wolfson Medical Center|No|Recruiting|February 2010|August 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|hemodialysis patients, who have elevated serum ferritin ( >2000ng/ml) and transferrin        saturation (TSAT) >30%|July 2010|July 23, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169961||118685|
NCT01170208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03985-10-A|Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes|Open-Label, Uncontrolled, Single-Arm, Single-Center, 16-Week Study Assessing Efficacy and Safety of Frequently Modified Insulin Therapy Using Dosage Recommending Device Software in 3-Groups of Subjects With Diabetes||HealthPartners Institute|No|Completed|June 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|21 Years|70 Years|No|||January 2014|November 30, 2015|July 22, 2010||No||No|September 5, 2013|https://clinicaltrials.gov/show/NCT01170208||118666|Study was limited by lack of a control group.
NCT01170429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-ZOC-0902i|Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA)|A Multicentered, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Procaterol Hydrochloride With Inhaled Glucocorticoid in Treatment Patients With Cough Variant Asthma (CVA)||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|July 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||June 2010|July 26, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170429||118649|
NCT01140958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pharmacoeconomic-01|A Retrospective Pharmacoeconomic Study of Lung Cancer|A Retrospective Pharmacoeconomic Study of Lung Cancer in Wan-Fang Hospital||Taipei Medical University WanFang Hospital|No|Active, not recruiting|March 2008|November 2010|Anticipated|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|91|||Both|N/A|N/A|No|Non-Probability Sample|lung cancer patients in WanFang Hospital|June 2010|June 9, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140958||120901|
NCT01140971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHVNCachoeirinha|Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor|TRANSCERVICAL FOLEY CATHETER (FOLEY) Versus INTRAVAGINAL MISOPROSTOL FOR CERVICAL RIPENING AND INDUCTION OF LABOR: A RANDOMIZED CLINICAL TRIAL.||Municipal Hospital Vila Nova Cachoeirinha|No|Completed|January 2006|January 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Female|19 Years|40 Years|No|||September 2009|June 9, 2010|June 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01140971||120900|
NCT01141452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA5|Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD|Retrospective, Real-life Evaluation of the Effectiveness, Cost-effectiveness and Direct Healthcare Costs of Qvar Pressurised Metered-dose Inhaler (pMDI) Compared With Beclometasone Dipropionate pMDI and Fluticasone pMDI in the Management of Chronic Obstructive Pulmonary Disease (COPD) in a Representative UK Primary Care Patient Population|QvarCOPD|Research in Real-Life Ltd|Yes|Completed|January 2001|July 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|815377|||Both|40 Years|80 Years|No|Non-Probability Sample|Primary care COPD patients who at an index prescription date either initiated ICS therapy        as extrafine HFA-BDP, CFC-BDP or FP via MDI or had an increase in baseline BDP-equivalent        ICS dose the index data as extrafine HFA-BDP, CFC-BDP or FP via MDI|March 2011|March 7, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141452||120863|
NCT01141712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0803|Autologous Transplant in HIV Patients (BMT CTN 0803)|High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN 0803)||Medical College of Wisconsin|Yes|Active, not recruiting|February 2011|May 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|15 Years|N/A|No|||January 2016|January 7, 2016|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01141712||120844|
NCT01141959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC-2373.00|Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients|Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients||Fred Hutchinson Cancer Research Center|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|Samples With DNA|plasma, DNA|Both|18 Years|N/A|No|Non-Probability Sample|Hematopoeitic cell transplant patients with haploidentical donors receiving        cyclophosphamide, fludarabine and mycophenolate mofetil.|March 2015|March 9, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141959||120825|
NCT01141725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2413.00|Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome|Safety and Clinical Activity of Treanda® (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Age >= 50 With Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome||Fred Hutchinson Cancer Research Center|No|Completed|September 2010|||November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|50 Years|N/A|No|||December 2012|December 7, 2012|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01141725||120843|
NCT01141972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001445|The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition|The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition|FLASH|Kaiser Permanente|No|Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Actual|23|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 28, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141972||120824|
NCT01166529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU protocol #0917 (eIRB 20311)|Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Management of Pain in Abdominal Non-pancreatic Malignancies|Endoscopic Ultrasound (EUS)-Guided Celiac Plexus Neurolysis (CPN) in the Management of Pain in Abdominal Non-pancreatic Malignancies||Northwestern University|Yes|Withdrawn|August 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|July 19, 2010||No|Unable to identify appropriate patients.|No||https://clinicaltrials.gov/show/NCT01166529||118948|
NCT01166828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 09-110|Pressure Ulcer Prevention for SCI Using a Tele Home Program|Pressure Ulcer Prevention for SCI Using a Tele Home Program|TELEPUPPS|VA Office of Research and Development|Yes|Withdrawn|January 2011|May 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|0|||Both|21 Years|80 Years|No|||June 2015|June 25, 2015|July 19, 2010||No|Project not funded - withdrawn by VA|No||https://clinicaltrials.gov/show/NCT01166828||118925|
NCT01167127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3504|Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain|An Open Study to Observe OXN Treatment for Patients With Moderate to Severe Non-malignant Pain||Mundipharma Pharmaceuticals B.V.||Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|No|||July 2012|February 11, 2013|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167127||118902|
NCT01167075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3941|A Study in Critically Ill Patients Investigating Tolerability and Efficacy of Low-volume Pharmaconutrition (Intestamin)|A Randomized, Prospective, Controlled, Double-blind, Single-center Pilot Study in Critically Ill Patients Investigating Tolerability and Efficacy of Low-volume Pharmaconutrition (Intestamin)|Intestamin|Hannover Medical School|No|Completed|February 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|75 Years|No|||December 2005|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167075||118906|
NCT01167088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTQ-LD-001|A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)|A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants With Raised Liver Enzymes Due to Non-Alcoholic Fatty Liver Disease (NAFLD)|MARVEL|Antipodean Pharmaceuticals, Inc.|No|Terminated|November 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|70 Years|No|||May 2011|May 28, 2011|July 19, 2010|Yes|Yes|This study has been terminated due to poor participant recruitment|No||https://clinicaltrials.gov/show/NCT01167088||118905|
NCT01167842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7016|Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer)|Analysis of Inherited Cancers||University of Washington|No|Recruiting|October 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|Samples With DNA|We will collect blood as a source for DNA from lymphocytes as well as tumor blocks as a      source for tumor DNA|Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic, Cancer center, University medical center|April 2014|April 8, 2014|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167842||118847|
NCT01167595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP uP cRCT|Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients|A Multicenter, Cluster Randomized Trial of Enhanced Protein-Energy Provision Via the Enteral Route Feeding Protocol in Critically Ill Patients: The PEP uP Protocol|PEP uP|Clinical Evaluation Research Unit at Kingston General Hospital|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1059|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167595||118866|
NCT01168388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirRRSH-001|Movement Disorder Survey in East China|Movement Disorder Survey in East China|MDS|Sir Run Run Shaw Hospital|Yes|Completed|April 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1600|||Both|N/A|N/A|No|Probability Sample|Patients seeking treatment in movement disorder clinics in east China during April 2010 to        August 2010.|April 2010|July 20, 2011|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168388||118805|
NCT01168401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV03-104|Bivalent Norovirus Vaccine Study|Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide (AlOH) in Adults||Takeda|Yes|Completed|September 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|102|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|July 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01168401||118804|
NCT01168128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERFECTIS|PERFormance Enhancement of the Canadian Nutrition Guidelines by a Tailored Implementation Strategy: The PERFECTIS Study|PERFormance Enhancement of the Canadian Nutrition Guidelines by a Tailored Implementation Strategy: The PERFECTIS Study|PERFECTIS|Clinical Evaluation Research Unit at Kingston General Hospital|No|Active, not recruiting|September 2009|August 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|280|||Both|18 Years|N/A|No|||July 2010|July 22, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168128||118825|
NCT01168427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reveal In-Office Implants|Reveal In-Office Implants|Reveal® In-Office Implants Study||Medtronic Cardiac Rhythm Disease Management|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|66|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|July 21, 2010|Yes|Yes||No|June 19, 2012|https://clinicaltrials.gov/show/NCT01168427||118802|
NCT01169623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10292 TUMS|Effect Of Educational Intervention Based On Supportive Leadership|Assessing The Effect Of Educational Intervention Based On Supportive Behaviour Leadership Model On Head Nurses' Performance In TUMS Hospitals: RCT In 2010|EEIBSL|University of Tehran|Yes|Completed|July 2010|August 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|110|||Both|N/A|N/A|No|||January 2010|January 4, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01169623||118710|
NCT01166698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3020C00001|Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group, 2-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects||AstraZeneca|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 8, 2011|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166698||118935|
NCT01166932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-44|Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia|COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study||UPECLIN HC FM Botucatu Unesp|No|Completed|April 2005|April 2009|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|104|||Both|2 Months|5 Years|No|||October 2010|October 29, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01166932||118917|
NCT01170442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC 2101039|Does Vitamin D Improve Glycemic Control in Type II DM?|Does Vitamin D Improve Glycemic Control in Type II DM? A Double Blind Randomized Controlled Trial||King Faisal Specialist Hospital & Research Center|No|Terminated|December 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|60 Years|No|||March 2015|March 31, 2015|July 25, 2010||No|In adequate enrollment|No||https://clinicaltrials.gov/show/NCT01170442||118648|
NCT01170702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00008429|Transverse Abdominis Plane (TAP) Block After Cesarean Delivery|The Postoperative Analgesic Efficacy of Varied Concentrations of Ropivacaine Used for the Transverse Abdominis Plane (TAP) Block After Cesarean Delivery||Northwestern University|No|Recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|200|||Female|18 Years|N/A|No|||August 2015|August 3, 2015|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170702||118628|
NCT01141010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJFY1021005|Effect of Psychological Interventions on Maternal Outcomes Undergoing Cesarean|Effect of Perioperative Psychological Interventions on Maternal Outcomes Undergoing Cesarean Delivery|PIMAC|Nanjing Medical University|Yes|Completed|May 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|365|||Female|19 Years|50 Years|No|||August 2010|August 24, 2010|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01141010||120897|
NCT01141023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPMI-001|Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression|The Parkinson's Progression Markers Initiative (PPMI)|PPMI|Michael J. Fox Foundation for Parkinson's Research|Yes|Recruiting|June 2010|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|680|||Both|30 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|June 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01141023||120896|
NCT01141244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02044|Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase 1 Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|June 2010|||November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|2 Years|21 Years|No|||December 2013|April 9, 2014|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01141244||120879|
NCT01141465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS30|Real-world Effectiveness of Combination Therapy in Asthma|A Retrospective Evaluation of the Effectiveness of Fixed-dose Combination Inhaled Corticosteroid /. Long-acting Beta Agonist (ICS/LABA) Therapy in the Management of Asthma in a Representative UK Primary Care Population||Research in Real-Life Ltd|Yes|Completed|January 2001|February 2010|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|815377|||Both|4 Years|80 Years|No|Non-Probability Sample|Primary care asthma patients receiving ICS therapy (any of BDP, extrafine HFA-BDP, BUD or        FP as pMDI, BAI or DPI) plus as needed SABA reliever therapy who underwent a change in        asthma therapy to combination ICS/LABA therapy as FP/SAL (MDI or DPI) or BUD/FOR (DPI) at        the same or at least twice the BDP-equivalent dose of ICS prescribed during baseline.|June 2010|June 9, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141465||120862|
NCT01141738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR009077-01|Problem-solving: A Stroke Caregiver Early Intervention|National Institute of Nursing Research #R01 NR09077-01: Problem-solving: A Stroke Caregiver Early Intervention|CPSI|Northwestern University|No|Active, not recruiting|April 2005|December 2016|Anticipated|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|362|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 20, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01141738||120842|
NCT01167114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-422|STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer|A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers||Massachusetts General Hospital|Yes|Active, not recruiting|August 2010|February 2013|Anticipated|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|January 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167114||118903|
NCT01166841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-181|The Effect of Percutaneous Superior Venae Cava Cannulation Clamping on Cerebral Near Infrared Spectroscopy in MICS|The Effect of Percutaneous Superior Venae Cava Cannulation Clamping on Cerebral Near Infrared Spectroscopy During Minimally Invasive Mitral Valve Surgery|NIRSinMICS|Lawson Health Research Institute|No|Completed|May 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|80 Years|No|||May 2013|May 14, 2013|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01166841||118924|
NCT01167608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220100120|Barriers to Mental Healthcare Utilization in Parkinson's Disease|Barriers to Mental Healthcare Utilization in Parkinson's Disease||Rutgers, The State University of New Jersey|No|Completed|June 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|883|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|People with Parkinson's disease.|March 2014|June 3, 2014|July 20, 2010||No||No|March 10, 2014|https://clinicaltrials.gov/show/NCT01167608||118865|Self-report biases (social desirability or recall); idiopathic PD could not be confirmed given the anonymous nature of study participation; results may not generalize to all people with PD; participants were self-selected (non-random sample)
NCT01167413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-JA-0423-CTIL|Frequency of Axial Spondyloarthropathy Among Patients Suffering From Fibromyalgia|Frequency of Axial Spondyloarthropathy Among Patients Suffering From Fibromyalgia - Application of the ASAS Classification Criteria||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|August 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited consecutively from the Fibromyalgia clinic as well as the        general rheumatological clinic of the Tel Aviv Sourasky medical center.|January 2010|August 5, 2010|January 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01167413||118880|
NCT01168089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILS-06-078|Near Infrared Spectroscopy for Blood Glucose Measurement in Critical Care Settings|Near Infrared Spectroscopy for Blood Glucose Measurement in Critical Care Settings||InLight Solutions|No|Completed|April 2008|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|i. Sample size is to include up to 50 subjects ii. Group will include nondiabetics as well        as people with Type I and Type II diabetes.        iii. Group will nominally be half male, half female. iv. Subjects must be 18 years or        older to participate.|February 2008|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168089||118828|
NCT01168102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILS-07-051|Noninvasive Blood Ethanol Measurement With Infrared Spectroscopy|Noninvasive Blood Ethanol Measurement With Infrared Spectroscopy||InLight Solutions||Completed|March 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inclusion Criteria:          1. Over the age of 21 but under the age of 70          2. No history of alcoholism -|February 2008|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168102||118827|
NCT01167855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112695|Reducing Asthma Disparities Through School-Based Telemedicine for Rural Children|Reducing Asthma Disparities Through School-Based Telemedicine for Rural Children||Arkansas Children's Hospital Research Institute|Yes|Recruiting|March 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1110|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167855||118846|
NCT01168674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9238|Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder|Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder : A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial||Tufts Medical Center|Yes|Completed|February 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||January 2013|January 14, 2013|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01168674||118783|
NCT01168999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|345-2009|The Mechanisms of Manual Therapy in the Treatment of Low Back Pain|The Mechanisms of Manual Therapy in the Treatment of Low Back Pain||University of Florida|No|Completed|September 2009|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|110|||Both|18 Years|60 Years|No|||October 2015|October 5, 2015|July 22, 2010||No||No|May 10, 2013|https://clinicaltrials.gov/show/NCT01168999||118758|
NCT01169012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0909|PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias|A Pharmacokinetic Study of Oral and Intravenous Clofarabine in Patients With High Risk Myelodysplasia and Acute Leukemias - Determination of Oral Bioavailability and the Effect of Cimetidine on Clofarabine Clearance||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|September 2010|July 2016|Anticipated|April 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|July 22, 2010|Yes|Yes|Drug supply discontinued by Collaborator.|No||https://clinicaltrials.gov/show/NCT01169012||118757|
NCT01169636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0065|Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma|Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2011|||January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|102|||Both|16 Years|N/A|No|||March 2016|March 21, 2016|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169636||118709|
NCT01169649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-067|Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)|A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)||Memorial Sloan Kettering Cancer Center|Yes|Completed|July 2010|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 21, 2010|Yes|Yes||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01169649||118708|
NCT01170715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDA0688|Psoriasis Inflammation and Systemic Co Morbidities|Psoriasis Inflammation and Systemic Co-Morbidities: Is it Preventable or Reversible?||Rockefeller University|No|Active, not recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Moderate to severe psoriasis|February 2016|February 16, 2016|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170715||118627|
NCT01170728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP008SU|Virtue® Male Sling Fixation Study|Virtue® Male Sling Fixation Study||Coloplast A/S|No|Terminated|July 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Male|18 Years|N/A|No|Non-Probability Sample|Subjects satisfying inclusion and exclusion criteria were enrolled.|August 2015|August 20, 2015|July 26, 2010||No|The study has been terminated due to lack of subject enrollment.|No||https://clinicaltrials.gov/show/NCT01170728||118626|
NCT01166711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEQUENT 1000|Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent|SeQuent 1000 - Treatment of Coronary Artery Disease With Bare Metal Stent Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent: Randomized Trial||Aesculap AG|No|Active, not recruiting|August 2010|October 2016|Anticipated|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166711||118934|
NCT01167257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL001|Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome|Comparative Study of the Efficacy and Safety of Liposome Encapsulated Botulinum Toxin-A (Lipotoxin) Versus Normal Saline Instillation in Treatment of Patients With Refractory Overactive Bladder Syndrome||Buddhist Tzu Chi General Hospital|No|Completed|May 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|July 20, 2010||No||No|September 10, 2014|https://clinicaltrials.gov/show/NCT01167257||118892|
NCT01167270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34493|The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study|The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study|INSIGHT|Penn State University|Yes|Enrolling by invitation|January 2012|June 2019|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|316|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 27, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167270||118891|
NCT01141751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00066|An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy|A Phase IV, Observational, Open-label, Multi-center Comparison Study of the Newly Developed and Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument With the Health-related QoL (MSQOL-54) Questionnaire in Subjects With Relapsing Forms of Multiple Sclerosis (RMS*) on Rebif® Therapy|COMPARE|Merck KGaA|No|Completed|September 2005|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|334|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with RMS who are eligible for Rebif therapy in Canada|June 2013|July 11, 2014|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141751||120841|
NCT01141998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bang-01|Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption|Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption||Hvidovre University Hospital|No|Completed|December 2009|March 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01141998||120822|
NCT01142011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGSI Belimumab in WM|A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia|A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia||Cancer Trials Australia|Yes|Recruiting|November 2009|January 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01142011||120821|
NCT01142479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPE-1-breast Ca|Compound Herbal Formula (TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy|The Effects of Compound Herbal Formula(TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy||Taipei City Hospital||Completed|May 2010|||April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|70 Years|No|||May 2014|May 28, 2014|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142479||120785|
NCT01142752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK091/10|Vaginal, Oral and Systemic Inflammation in Preterm Birth|Vaginal, Oral and Systemic Inflammation in Preterm Birth||University Hospital Inselspital, Berne|Yes|Active, not recruiting|November 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|65|Samples With DNA|Blood, vaginal smears, oral specimens|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women of more than 18 years of age.|May 2015|May 26, 2015|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01142752||120764|
NCT01142765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC039|Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP|A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP||University of Oxford|Yes|Completed|June 2010|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Anticipated|52|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01142765||120763|
NCT01166581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doncals Breast MRI study|Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates|Evaluation of Breast Magnetic Resonance Imaging (MRI) Impact on Mastectomy Rate at Summa Akron City Hospital||Summa Health System|No|Terminated|July 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Female|18 Years|85 Years|No|Probability Sample|early stage breast cancer cases between 2006-2009|February 2015|February 3, 2015|July 19, 2010||No|Not enough data collected to work with|No||https://clinicaltrials.gov/show/NCT01166581||118944|
NCT01167439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0027-09-HYMC|Dysphagia in Oculopharyngeal Muscular Dystrophy (OPMD)- Evaluation, Endoscopic Examination of Swallowing, Treatment and Long Term Follow up|Dysphagia in Oculopharyngeal Muscular Dystrophy. Evaluation, Endoscopic Examination of Swallowing, Treatment and Long Term Follow up.|OPMD|Hillel Yaffe Medical Center|No|Recruiting|July 2009|||July 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||December 2009|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167439||118878|
NCT01167452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA IRB A10-3592|Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations|Population Pharmacokinetic Analysis of Sulfamethoxazole and Trimethoprim in Normal Weight, Overweight, and Obese Volunteers||Texas Tech University Health Sciences Center|No|Completed|July 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|July 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167452||118877|
NCT01167140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-4000|Cryo-Touch II for the Treatment of Wrinkles|||MyoScience, Inc||Completed|July 2010|April 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|July 20, 2010|Yes|Yes||No|May 23, 2012|https://clinicaltrials.gov/show/NCT01167140||118901|
NCT01167426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM034|Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients|An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method.|ENCORE|Teva Pharmaceutical Industries|No|Completed|July 2010|December 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|148|||Both|18 Years|N/A|No|||August 2012|August 8, 2013|July 20, 2010|Yes|Yes||No|August 17, 2012|https://clinicaltrials.gov/show/NCT01167426||118879|
NCT01167621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/CHR/01|Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation|Assessment of Extravascular Lung Water and Hemodynamics Changes in Patients Treated by High Frequency Oscillation-ventilation for Refractory ARDS||Centre Hospitalier Universitaire de la Réunion|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Non-Probability Sample|Refractory Acute Respiratory Distress Syndrome (ARDS) patients admitted to the Intensive        Care Unit of Saint-Denis hospital (REUNION ISLAND)|July 2015|July 28, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167621||118864|
NCT01167868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00007|A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Fostamatinib Disodium in Healthy Japanese and White Subjects After Single and Multiple Ascending Doses||AstraZeneca||Completed|July 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|56|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 6, 2013|July 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01167868||118845|
NCT01169038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100552|Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis|Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis|CLEAR Lung|Vanderbilt University|Yes|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|75 Years|No|||October 2012|October 26, 2012|July 22, 2010|No|Yes||No|September 17, 2012|https://clinicaltrials.gov/show/NCT01169038||118755|
NCT01169051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100698|A Retrospective Analysis of Statin Use and Outcome After Thoracic Cancer Surgery|A Retrospective Analysis of Statin Use and Outcome After Thoracic Cancer Surgery||Vanderbilt University|Yes|Active, not recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|This study is a retrospective chart review of adult thoracic surgery patients who        underwent:          -  Esophagectomy          -  Pulmonary wedge resection          -  Pulmonary lobectomy          -  Pulmonary pneumonectomy        Data collected will be from January 1, 2007 forward.|July 2010|July 22, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01169051||118754|
NCT01169064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMFM-100785|Topical Silver for Prevention of Wound Infection After Cesarean Delivery|Topical Silver for Prevention of Wound Infection Post Cesarean Delivery: A Randomized Controlled Trial||Vanderbilt University|No|Terminated|July 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|524|||Female|18 Years|50 Years|No|||February 2013|February 5, 2013|July 22, 2010||No|Interim analysis showed no statistical significance achieved.|No||https://clinicaltrials.gov/show/NCT01169064||118753|
NCT01169350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01442|18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Scans in Assessing Oxygen in Tumor Tissue of Patients With Soft Tissue Sarcoma Undergoing Chemotherapy With or Without Radiation Therapy|A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Soft Tissue Sarcoma||National Cancer Institute (NCI)||Terminated|February 2010|||October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|July 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169350||118731|
NCT01170455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shanghai 9th People's Hospital|Nasal Intubation Using the Blind Intubation Device|Nasal Intubation Using the Blind Intubation Device:a Prospective,Randomized,Controlled Comparison With the Direct Laryngoscope|BID|Shanghai Jiao Tong University School of Medicine|Yes|Completed|September 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||September 2010|October 28, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01170455||118647|
NCT01158495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSVAR0009|Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing|Differentiating Outcome Measures in Infant and Early Childhood Lung Disease Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing||Stanford University||Completed|January 2009|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|3 Months|5 Years|No|Non-Probability Sample|infants/young children with cystic fibrosis, primary ciliary dyskinesia, or other chronic        lung disease, followed at our CF Center or Pulmonary Clinics|April 2013|April 1, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158495||119563|
NCT01166945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130933|Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children|Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children||University of Wisconsin, Madison|No|Recruiting|November 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|1 Year|10 Years|No|||February 2016|February 26, 2016|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166945||118916|
NCT01142037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS107|Development of a Biomarker for Dietary Furanocoumarins|Development of a Biomarker for Dietary Furanocoumarins||University of Minnesota - Clinical and Translational Science Institute|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 21, 2014|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142037||120819|
NCT01150539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 26038|Effects of Exercise for Overweight Women With Polycystic Ovary Syndrome|Effects of Physical Activity on Insulin Resistance and Adiposity in Polycystic Ovary Syndrome "Poly"|POLY|Pennington Biomedical Research Center|No|Completed|January 2007|June 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Female|18 Years|30 Years|No|||March 2016|March 24, 2016|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01150539||120168|
NCT01151046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-02-02-03 (ARD11588)|Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer|A Randomized Double-Blind Phase 2 Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+) Her2 Negative Breast Cancer||Merrimack Pharmaceuticals|Yes|Active, not recruiting|June 2010|June 2014|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Female|18 Years|N/A|No|||November 2013|November 21, 2013|June 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151046||120131|
NCT01151059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_19S|Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL® S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, When Administered to Non-elderly Adult and Elderly Subjects||Novartis||Completed|June 2010|July 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|138|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 27, 2012|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01151059||120130|
NCT01142492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP28157|A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)|Postmarketing Surveillance Study on the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis With Interferon Beta 1a (Rebif®)|TOURIMS|Merck KGaA||Completed|January 2005|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|403|Samples With DNA|Whole blood|Both|N/A|N/A|No|Probability Sample|A group of subjects with MS who were at the start of treatment with Rebif or switched to        Rebif from other forms of MS therapy.|March 2014|March 17, 2014|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142492||120784|
NCT01142505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/43/03|Wheeze and Intermittent Treatment|Parent-determined Oral Montelukast Therapy for Preschool Wheeze With Stratification for Arachidonate-5-Lipoxygenase (ALOX5) Promoter Genotype|WAIT|Queen Mary University of London|Yes|Completed|November 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1358|||Both|10 Months|5 Years|Accepts Healthy Volunteers|||April 2014|April 27, 2014|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142505||120783|
NCT01166594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136783|Use of Bevacizumab in Trabeculectomy Surgery|Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial||Sunnybrook Health Sciences Centre|No|Completed|June 2010|December 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166594||118943|
NCT01167465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diaper Rash|Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper Rash Prophylaxis|A Clinical Observation to Assess the Safety and Consumers' Satisfaction of Moussik vs Desitin Creamy Ointment in Prophylaxis of Diaper Rash. A Single Blind, Multicenter, Randomized, Cross-over Study||Trima, Israel Pharmaceutical Products|Yes|Withdrawn|January 2013|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|0|||Both|3 Months|18 Months|Accepts Healthy Volunteers|||December 2014|December 16, 2014|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167465||118876|
NCT01167673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bp004|The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel Syndrome|A Double Blind Placebo Controlled Cross Over Study for the Use of Coltect (Green Tea, Selenium and Curcumin) in Irritable Bowel Syndrome||Meir Medical Center|No|Recruiting|April 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2015|March 5, 2015|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167673||118860|
NCT01167153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489ACN02|Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients|A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment|EXAM|Novartis|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|564|||Both|18 Years|65 Years|No|||May 2012|May 31, 2012|July 20, 2010||No||No|April 19, 2012|https://clinicaltrials.gov/show/NCT01167153||118900|
NCT01167166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-19|Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)|A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms||Onconova Therapeutics, Inc.|No|Completed|July 2010|June 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167166||118899|
NCT01167881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.28|Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment||Boehringer Ingelheim||Completed|August 2010|August 2015|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1549|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 15, 2010||||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01167881||118844|
NCT01167894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8331|Bioequivalence Study of Simvastatin Tablets 80 mg of Dr. Reddy's Under Fasting Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Simvastatin 80 mg Tablets of Dr. Reddy's to be Compared With Zocor® 80 mg Tablets of Merck & Co. Inc., USA in Healthy Adult Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|January 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 21, 2010|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167894||118843|
NCT01167634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813407|University Of Pennsylvania Weight Loss Study|University Of Pennsylvania Weight Loss Study||University of Pennsylvania|No|Active, not recruiting|April 2011|December 2015|Anticipated|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|132|||Both|18 Years|70 Years|No|||September 2012|June 9, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01167634||118863|
NCT01168440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHLSUT09|Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease|A Single-arm, Phase II Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease|VHLSUT|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|No|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|90 Years|No|||September 2012|September 12, 2012|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01168440||118801|
NCT01168687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1815-29512-02|Effects of Levetiracetam (Keppra) on Alcohol Consumption|Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake||University of California, San Francisco|No|Completed|November 2008|November 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|October 6, 2008|Yes|Yes||No|January 16, 2013|https://clinicaltrials.gov/show/NCT01168687||118782|
NCT01169974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU P 2010-18|Use of Laser Speckle to Study Post Occlusive Reactive Hyperhemia in Healthy Subjects|Evaluation Chez Des Sujets Volontaires Sains de l'ischémie-reperfusion cutanée|SpeckleShake|University Hospital, Angers|No|Recruiting|July 2010|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|June 2012|June 28, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169974||118684|
NCT01169987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-129|Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life|Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life||AbbVie|No|Completed|May 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|198|||Both|18 Years|N/A|No|Probability Sample|Patients with psoriasis followed in university or peripheral hospitals or peripheral        private practices with experience in psoriasis patient care.|April 2015|April 7, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01169987||118683|
NCT01169363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000681533|Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy|Validation of AML Proteomic Signature Associated With Clinical Response to Ara-C Based Induction Therapy in Patients 60 Years of Age or Older Using Samples From ECOG Studies 3999, 3993 and 1490||National Cancer Institute (NCI)||Not yet recruiting|October 2009|||November 2009|Anticipated|N/A|Observational|N/A|||Anticipated|200|||Both|60 Years|N/A|No|||August 2010|August 27, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01169363||118730|
NCT01170741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA026771|Computer-Assisted Tailored Cue-card Health [CATCH] Study|A Tailored Cue Card HIV/STI Intervention for High Risk Groups Pilot Study|CATCH|RTI International|No|Completed|June 2010|June 2012|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|122|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 24, 2012|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170741||118625|
NCT01167530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGR 1269|Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer||RAD001|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|March 2008|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||July 2010|April 3, 2012|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167530||118871|
NCT01167764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-tranexamic acid|Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis|Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis: Multicenter, Prospective, Randomized, Double-blind Phase 3 Trial||Seoul National University Hospital|Yes|Withdrawn|July 2011|December 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|25 Years|75 Years|No|||January 2014|January 6, 2014|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167764||118853|
NCT01158742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RELIVE-06|Live Kidney Donor Study -Renal Function Study|Live Kidney Donor Study -Renal Function Study||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|402|||Both|N/A|N/A|No|Non-Probability Sample|individuals participating in DAIT RELIVE-04 who donated a kidney at the Mayo        Clinic-Rochester, University of Minnesota, or the University of Alabama|September 2012|September 13, 2012|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158742||119544|
NCT01158755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-201006.01|Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study|Comparison of Intensive Treatment Regimens and Standard Treatment Regimen for Tuberculous Meningitis: Pharmacokinetics, Pharmacodynamics and Tolerability Study||Universitas Padjadjaran|Yes|Completed|October 2010|June 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|15 Years|N/A|No|||June 2012|June 6, 2012|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158755||119543|
NCT01159002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmartPill|Evaluation of Gastrointestinal Motility With SmartPill|Clinical Evaluation of SmartPill Capsule for Investigation of Total Intestinal Transit Time and Intestinal Pathology in Critically Ill Patients||University of Louisville|No|Completed|November 2007|January 2009|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|70 Years|No|Non-Probability Sample|ICU patients with intracranial hemorrhage|July 2010|July 7, 2010|July 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159002||119525|
NCT01159015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|586|Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers|A Multi-center, Double-masked, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy, Normal Volunteers||Bausch & Lomb Incorporated|No|Completed|July 2010|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Actual|501|||Both|2 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 22, 2013|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159015||119524|
NCT01150812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2890C00001|Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects|A Phase I, Single-center, Single-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects||AstraZeneca|No|Terminated|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 16, 2010|June 21, 2010|No|Yes|The study pharmacodynamic stopping criteria were met after the first dosing group|No||https://clinicaltrials.gov/show/NCT01150812||120149|
NCT01139983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST10B4|DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers|Search for Novel Genes in Osteosarcoma Revealed by Analysis of Tumour Copy-Number Alterations and Constitutional Copy-Number Variations||Children's Oncology Group|No|Active, not recruiting|February 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|90|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Diagnosis of osteosarcoma|May 2015|May 6, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01139983||120976|
NCT01142245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOE|Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy|Phase 3 Study of Effect of Intravenous and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy (IOE Study)|IOE|Chinese University of Hong Kong|No|Completed|January 2008|July 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142245||120803|
NCT01142258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZD-001|Trazodone for Sleep Disorders in Alzheimer's Disease|Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study||Brasilia University Hospital|No|Completed|March 2010|August 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|N/A|No|||October 2012|October 12, 2012|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142258||120802|
NCT01142271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-DEO-09-297|Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy|Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy for Gastric Cancer Patients : Prospective Randomized Study||Ajou University School of Medicine|No|Recruiting|June 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|75 Years|No|||November 2011|November 4, 2011|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01142271||120801|
NCT01151644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEDMAC-H1N1|Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases|Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases||University of Sao Paulo|No|Active, not recruiting|April 2010|December 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5000|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2010|June 25, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151644||120086|
NCT01151657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFF080409-2|Probiotics for Irritable Bowel Syndrome|Probiotics for Irritable Bowel Syndrome||University of Southern Denmark|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|50 Years|No|||January 2009|October 24, 2011|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01151657||120085|
NCT01167179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDL-001-TVA|Nurse-led Follow-up Care for Head and Neck Cancer Patients|An Early Evaluation Study Testing Nurse-led Follow-up Care for Head and Neck Cancer Patients||Radboud University|No|Active, not recruiting|December 2008|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2011|November 24, 2011|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01167179||118898|
NCT01167686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|k008/2010|Effects of Gardemont S.A Food Supplement on Upper Respiratory Illness|Phase 2 Study of Gardemont S.A Food Supplement on Symptoms of Upper Respiratory Illness||Meir Medical Center|Yes|Recruiting|March 2010|December 2012|Anticipated|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|182|||Both|18 Years|80 Years|No|||March 2012|March 16, 2012|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167686||118859|
NCT01167647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10-087-10.CTIL|The Role of Routine Bacterial Culture Including Tuberculosis During Bronchoscopy: A Prospective Study|The Role of Routine Bacterial Culture Including Tuberculosis During||Meir Medical Center|Yes|Completed|July 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|All patients who will undergo a bronchoscopy examination at pulmonary department in Meir        Medical Center and will sign on informed consent.|March 2012|March 5, 2013|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167647||118862|
NCT01167660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pag-ThM2|Non Invasive Measurement of Coagulation in Term and Preterm Neonates|Non Invasive Measurement of Coagulation in Term and Preterm Neonates||Meir Medical Center|No|Recruiting|July 2010|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|N/A|2 Months|No|Non-Probability Sample|Term and preterm babies born in Meir Medical Center|June 2010|February 11, 2013|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01167660||118861|
NCT01168167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWG-HIVCENTER-Hopp1|Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation|Comparing the Dynamics of Different HIV-1 cDNA Species in CD4-positive T-cells and HIV-1 RNA in Plasma of Infected Individuals After Initiation of Antiretroviral Therapy With or Without Raltegravir||Goethe University|No|Completed|June 2010|May 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who begin cART in regular clinical routine with 2N(t)RTI plus either (n=10        patients) raltegravir or (n=10 patients) a boosted protease inhibitor/ alternatively an        NNRTI as third substance will be offered to participate in this non-interventional study.        Observation time is a period of 4 months after cART initiation.|March 2016|March 22, 2016|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168167||118822|
NCT01168141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08_CLPHA_54|Window Study of ZD4054 in Metastatic Prostate Cancer|Assessment of the Effects of the Specific Endothelin-A Antagonist ZD4054 on Prostate Cancer Biomarkers in Patients With Castrate-resistant Metastatic Disease||Christie Hospital NHS Foundation Trust|No|Enrolling by invitation|July 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Male|18 Years|N/A|No|||June 2010|July 22, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01168141||118824|
NCT01169025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00040229|Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients|Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients||University of Utah|Yes|Withdrawn|September 2012|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|July 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01169025||118756|
NCT01170234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUFTS-EOE-FENO|Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis|Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis||Tufts Medical Center|No|Completed|August 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|7 Years|65 Years|No|Non-Probability Sample|Gastroenterology outpatient clinic|February 2012|February 28, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170234||118664|
NCT01170221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-112|TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.|A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections|ABSSSI|Trius Therapeutics LLC|Yes|Completed|August 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|667|||Both|18 Years|N/A|No|||August 2014|August 31, 2014|July 23, 2010|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01170221||118665|
NCT01170468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC 2101040|Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals|Does Vitamin D Reduce Risk of Developing Type II DM in Prediabetics? A Double Blind Randomized Controlled Trial||King Faisal Specialist Hospital & Research Center|No|Active, not recruiting|December 2011|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|60 Years|No|||March 2015|March 31, 2015|July 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01170468||118646|
NCT01158222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8809|Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer|A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma||Case Comprehensive Cancer Center|Yes|Active, not recruiting|August 2010|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158222||119583|
NCT01168271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910156|Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali|Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali||National Institutes of Health Clinical Center (CC)||Recruiting|June 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|15000|||Both|N/A|45 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168271||118814|
NCT01158768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180/09.1|Questionnaire to Study Violence Against Women in the Climateric's Phase.|Questionnaire to Study Impacts in the Health of the Woman in the Climateric's Phase, Victim of Domestic and/or Sexual Violence||University of Sao Paulo General Hospital|Yes|Completed|January 2009|August 2009|Actual|July 2009|Actual|Phase 4|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|288|||Female|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women (during the ages of 40 to 65 years) who were or are victims of domestic and sexual        violence seeking attention at the outpatient clinic for Endocrines Gynecology and        Climactery - University of Sao Paulo General Hospital during 2009.|March 2009|January 27, 2011|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01158768||119542|
NCT01159028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-0578 (v) 08-8|Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS|A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome||Bio-Path Holdings, Inc.|Yes|Recruiting|June 2010|||April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||January 2016|January 11, 2016|July 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159028||119523|
NCT01143883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Silverlon 108010|Study Looking at the Effect of Silverlon on Post Operative Wound Infections|A Randomized Controlled Clinical Trial Evaluating the Efficacy of Silverlon® in Preventing Surgical Site Infection Following Colorectal Surgery||University of South Florida|Yes|Completed|June 2009|November 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|March 24, 2010||No||No|December 10, 2012|https://clinicaltrials.gov/show/NCT01143883||120678|Members of the surgical team were not blinded to the treatment group.
NCT01151358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERIT-NHL|Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy|Multicenter Prospective Evaluation of Patient- and Lesion Specific Prognostic Factors for Standard RadioImmunoTherapy With 90-Yttrium-labeled Anti-CD20 in Follicular Non-Hodgkin´s Lymphoma|MERIT-NHL|University Hospital, Saarland|Yes|Recruiting|May 2008|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Patients who suffer from a relapsed and/or refractory follicular non-Hodgkin´s lymphoma        (FL) or patients with partial remission after induction chemotherapy of FL|June 2010|June 25, 2010|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151358||120108|
NCT01151371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0917|Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens|||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2010|||April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|452|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|March 24, 2010|Yes|Yes||No|September 15, 2011|https://clinicaltrials.gov/show/NCT01151371||120107|
NCT01140802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD Microbe|Gut Microbiota in the Healthy Population, Inflammatory Bowel Disease Patients, and Their Relatives|A Study of the Gut Microbiota in the Healthy Population, Patients With Inflammatory Bowel Disease and Their Relatives (IBD Microbe Study||Chinese University of Hong Kong|Yes|Recruiting|March 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|72|Samples With DNA|Serum DNA will be collected and stored only if patients have provided consent separately.      All serum DNA blood samples will be anonymised. Genetic results will not be made available      to individual patients in a future date as there is no evidence to support genetic testing      for risk prediction in routine practice, but these large scale genetic results will be      useful to identify relevant future therapeutic targets for treatment of IBD. 10 ml of blood      will be collected in EDTA tubes and stored at minus 80 degrees C, These samples will be      transported to China for analysis at a later date.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Crohn's disease or ulcerative colitis patients as the case groups, Patients attend clinics        or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy as        the control group, and the first degree relatives of IBD patients as the relative group|February 2015|February 2, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140802||120913|
NCT01167192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201310089|Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer|Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters||Washington University School of Medicine|No|Active, not recruiting|February 2011|October 2017|Anticipated|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167192||118897|
NCT01167205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1005-072-319|Positive Effects of Haematococcus Astaxanthin on Oxidative Stress and Lipid Profile in Overweight and Obese Adults|||Seoul National University Hospital|Yes|Not yet recruiting|August 2010|March 2011||December 2010||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind||||30|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 20, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01167205||118896|
NCT01167218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09318|Study to Assess Platelet Dysfunction With Verify Now Assay|"In-vitro Characterization of Platelet Dysfunction in Common Hematological Disorders Using the Verify Now Assay"||Winthrop University Hospital|No|Completed|December 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|79|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|patients with platelet defects|August 2012|August 8, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01167218||118895|
NCT01167933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8340|Bioequivalence Study of Simvastatin Tablets, 80 mg of Dr. Reddy's Under Fed Conditions|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Simvastatin 80 mg Tablets of Dr. Reddy's to be Compared With Zocor® 80 mg Tablets of Merck & Co. Inc., USA in Healthy Adult Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|January 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|August 5, 2010|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01167933||118840|
NCT01168206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK3a_FIII_Janeiro/2010|Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy|Assessment of Quality of Life and the Toxicity of Chemotherapy in Patients With Malignancies in Clinical Stages III and IV Under Palliative Treatment With Chemotherapy or Hormone Therapy With or Without Nutritional Supplement TK3||Lavilabor Natural Products Ltd|No|Recruiting|December 2010|August 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|80 Years|No|||September 2011|September 8, 2011|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01168206||118819|
NCT01167907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol WFUHS 00013823|Evaluation of Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block After Ankle Surgery|Evaluation of a Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block for Postoperative Analgesia Following Ankle Surgery||Wake Forest School of Medicine|No|Recruiting|July 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|75 Years|No|||December 2015|December 11, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01167907||118842|
NCT01168154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReDiCo|Role Of Lactobacillus Reuteri DSM 17938 In The Non-Complicated Diverticular Disease|Phase 3 Study of Lactobacillus Reuterii in Patients With Symptomatic Non-complicated Diverticular Disease|ReDiCo|Casa Sollievo della Sofferenza IRCCS|Yes|Recruiting|February 2009|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|80 Years|No|||October 2008|June 27, 2011|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168154||118823|
NCT01168180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|527090004-4|Traditional Thai Massage and Scapulocostal Syndrome|Efficacy of Traditional Thai Massage on Patients With Scapulocostal Syndrome||Khon Kaen University|Yes|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|50 Years|No|||June 2011|August 13, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01168180||118821|
NCT01168193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Complications-HMO-CTIL|Evaluation of Surgical Complications|Evaluation of Surgical Complications Using a Novel Grading System - A Prospective Single Arm Study||Hadassah Medical Organization||Completed|January 2009|||December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2200|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168193||118820|
NCT01168453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoIJV|Changes in Anatomical Landmark Locations|Changes in the Relationship Between the Right Internal Jugular Vein and Anatomical Landmark After Head Rotation||Soonchunhyang University Hospital|No|Completed|May 2009|April 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for elective surgery under general anesthesia with endotracheal        intubation, were enrolled in the study between May 2009 and February 2010.|July 2010|August 6, 2010|July 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01168453||118800|
NCT01168700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kymes-Wakunaga-UDES|Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome|A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES"|Kymes|Universidad de Santander|No|Recruiting|November 2009|October 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|65 Years|No|||July 2010|July 21, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168700||118781|
NCT01170247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006786|Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients|Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation: A Prospective Randomized, Double-blinded, Placebo Controlled Study||University of Iowa|Yes|Terminated|January 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|2 Years|17 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|July 21, 2010|Yes|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT01170247||118663|
NCT01170494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC 2101041|Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels|Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels: A Randomized Controlled Trial||King Faisal Specialist Hospital & Research Center|No|Recruiting|December 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Anticipated|800|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|July 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01170494||118644|
NCT01170481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-128-f-S|Assessment of Retinal Nerve Fibre Layer by Optical Coherence Tomography in Uveitis Patients With Papilloedema|Retinal Nerve Fibre Layer in Uveitic Secondary Glaucoma||St. Franziskus Hospital|No|Completed|July 2009|April 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|50|||Both|18 Years|100 Years|No|Probability Sample|all patients with anterior or intermediate uveitis and papillooedema in fluoreszein        angiography.|November 2015|November 17, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01170481||118645|
NCT01170507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC 2101042|Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation|Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation: A Randomized Controlled Study||King Faisal Specialist Hospital & Research Center|No|Active, not recruiting|December 2011|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1080|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|July 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01170507||118643|
NCT01142856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001995|Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)|A Single Patient Treatment Protocol for Autologous Mesenchymal Stem Cell Intraspinal Therapy in Amyotrophic Lateral Sclerosis (ALS)||Mayo Clinic||Completed|June 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01142856||120756|
NCT01143064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHR-100-301|Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients With Severe Traumatic Brain Injury|SyNAPSe|BHR Pharma, LLC|Yes|Completed|June 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1195|||Both|16 Years|70 Years|No|||June 2014|June 11, 2014|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143064||120740|
NCT01143077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050289|A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents|A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents|SWITCHCore|Sunovion|Yes|Completed|June 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|244|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|June 10, 2010|Yes|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT01143077||120739|
NCT01143376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/447|High-intensity Intermittent Training for Obese Individuals|High-intensity Intermittent Training to Maximize Metabolic and Cardiovascular Protection in Obese Individuals||Norwegian University of Science and Technology|No|Completed|May 2010|January 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01143376||120716|
NCT01143701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH083665|Evaluation of an Intervention for Improving Community-based Pediatric Attention-Deficit Hyperactivity Disorder (ADHD) Care|Evaluation of an Intervention for Improving Community-based Pediatric ADHD Care||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|May 2010|June 2016|Anticipated|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Anticipated|576|||Both|6 Years|11 Years|No|||December 2015|December 28, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143701||120692|
NCT01143714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-024|A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers|A Vehicle-Controlled Study to Determine the Effect of Four Weeks of Debridement With Collagenase Santyl Ointment (Santyl) on the Healing of Diabetic Foot Ulcers||Healthpoint|No|Completed|June 2010|October 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|June 11, 2010|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT01143714||120691|
NCT01143727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-025|Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers|Comparison of SANTYL vs. Hydrogel in Debridement of Inflamed Diabetic Foot Ulcers||Healthpoint|No|Completed|July 2010|October 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|June 11, 2010|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT01143727||120690|
NCT01163981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Access 5|Ultrasound Guided Cannulation of Dialysis Fistulas|A Randomised Controlled Trial of the Effectiveness of Ultrasound Guidance in Cannulation of Dialysis Arteriovenous Fistulas and Grafts in a University Hospital Dialysis Unit||University of Hull|No|Not yet recruiting|November 2011|August 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2010|July 14, 2011|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01163981||119144|
NCT01163708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro-Nav-10|Prophecy Guide Outcomes in Total Knee Replacement Surgery|Phase IV Study - Prophecy Guide Outcomes in Total Knee Replacement Surgery||Global Orthopaedic Technology|No|Not yet recruiting|August 2010|December 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|188|||Both|65 Years|85 Years|No|||July 2010|July 27, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163708||119165|
NCT01164267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG 34|Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)|A Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus (RAD001) in Marginal Zone B-cell Lymphomas (MZL) EudraCT Number 2009-011725-14||International Extranodal Lymphoma Study Group (IELSG)|Yes|Completed|March 2010|||December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2012|November 21, 2013|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164267||119122|
NCT01164566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 60110|Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy|Prospective Evaluation of Esophageal Pathology Treatment of Head and Neck Carcinoma||Comprehensive Cancer Center of Wake Forest University|No|Terminated|December 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||April 2012|April 9, 2012|July 7, 2010||No|Inadequate Recruitment|No||https://clinicaltrials.gov/show/NCT01164566||119099|
NCT01164553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0018|Comparison of Flu Vaccine Doses in Children|A Randomized, Double-Blind, Phase I Study Comparing an Increased Dose(s) (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) With Standard Dose(s) (0.25 ml) TIV in Children 6-35 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2010|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|243|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||October 2012|April 25, 2013|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01164553||119100|
NCT01164826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-605/06-00|Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's and Relafen® 750 mg Tablets of Glaxosmithkline, in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2006|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 16, 2010|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164826||119079|
NCT01165125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105548|A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole|A Double-blind, Randomized, Placebo-controlled, Repeat Dose, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Administration of Fluticasone Furoate/GW642444M Inhalation Powder With Ketoconazole||GlaxoSmithKline|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|18|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2011|August 23, 2012|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01165125||119056|
NCT01164800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-029-TRAN-2006|Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healthy, Adult, Human Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2006|May 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 16, 2010|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164800||119081|
NCT01164813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-604/06-00|Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's and Relafen® 750 mg Tablets of Glaxosmithkline, in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2006|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 16, 2010|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164813||119080|
NCT01141296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feno-01|Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis|Randomized Controlled Study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis||University of Miami|No|Withdrawn|April 2011|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|75 Years|No|||March 2014|March 31, 2014|June 8, 2010|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01141296||120875|
NCT01141517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00538|Predictors of Teen Smoking-cessation|Predictors of Smoking Cessation Among Teen Smokers|NOT|Nationwide Children's Hospital|No|Recruiting|July 2008|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|13 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be adolescent smokers between the ages of 13-19 recruited from local        high-schools (Franklin county; Pike county, and Scioto County in Ohio), shopping malls,        and newspaper ads.|June 2010|June 21, 2011|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141517||120858|
NCT01141530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111481|Deep Sequencing of the Breast Cancer Transcriptome|Deep Sequencing of the Breast Cancer Transcriptome||University of Arkansas|Yes|Withdrawn|September 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|Samples With DNA|The informed consent process for biospecimen collection we expect to use in this research      has already been obtained by the UAMS Tissue Bank personnel as a part of the UARK 2005-06      protocol. Tissue is collected during biopsies or mastectomies after pathologist approval. We      will sequence small non-coding molecules (microRNA), messenger RNA, chromatin      immunoprecipated and bisulfite treated DNA.|Female|18 Years|N/A|No|Non-Probability Sample|This study is a retrospective tissue bank study analyzing tissue collected from a previous        clinical trial. No subjects will be enrolled. Tissue was collected during biopsies or        mastectomies after pathologist's approval.|December 2013|December 3, 2013|June 9, 2010||No|Study withdrawn due to inability to enroll subjects.|No||https://clinicaltrials.gov/show/NCT01141530||120857|
NCT01141816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIURCCCEUS|Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions|Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Renal Lesions: a Prospective, Blinded Study||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|January 2015|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141816||120836|
NCT01142076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19850701|Xinju Xiaogao Prescription Study on Overweight|Xinju Xiaogao Prescription and 10% of it in the Treatment of Adiposity (Stagnation of QI Causing Phlegm Retention)Clinical Study|XJXG|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|June 2010|March 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|60 Years|No|||December 2013|December 10, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01142076||120816|
NCT01142323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feno for PSC|Fenofibrate for PSC|Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis||University of Miami|No|Terminated|October 2010|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||March 2013|March 12, 2013|June 10, 2010|Yes|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT01142323||120797|
NCT01142570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5668|Effect of Enteral Nutrition Enriched in Protein and Based on Indirect Calorimetry Measurement in Chronically Critically Ill Patients|Effect of Enteral Nutrition Enriched in Protein and Based on Indirect Calorimetry Measurement in Chronically Critically Ill Patients||Rabin Medical Center|Yes|Active, not recruiting|September 2010|November 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|60|||Both|65 Years|90 Years|No|||January 2010|October 3, 2010|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01142570||120778|
NCT01143740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22890|A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery|An Exploratory Biomarker Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery||Hoffmann-La Roche||Completed|June 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143740||120689|
NCT01143090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050290|A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder|A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Protocol No. D1050290)|Switch Ext|Sunovion|Yes|Completed|August 2010|||November 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|June 10, 2010|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT01143090||120738|
NCT01143103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cough assist|Comparison Between Respiratory Therapy With Cough Assist Technique and Usual Respiratory Therapy in Intensive Care Patients Suffering of Neurologic Disorder|Comparison Between Respiratory Physiotherapy With Cough Assist Technique and Usual Respiratory Care in Intensive Care Patients Suffering of Neurologic Disorder||University Hospital, Geneva|No|Withdrawn|July 2010|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|90 Years|No|||June 2010|September 21, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01143103||120737|
NCT01143116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-ABC-0003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2010|||||N/A|N/A|N/A||||||||||||||September 27, 2012|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143116||120736|
NCT01140061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0873-020|Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)|A 3-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of MK-0873 Following Cumulative Patch and Repeated Max Area Applications in Healthy Subjects and Psoriasis Patients||Merck Sharp & Dohme Corp.|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|June 7, 2010|No|Yes||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01140061||120970|
NCT01140360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF/Gleevec DOD Trial|Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas|Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas|0908-09|Indiana University|Yes|Active, not recruiting|February 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|65 Years|No|||January 2016|January 26, 2016|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140360||120947|
NCT01140620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1V-SCH-CT02-09|Effects of Ketamine and Risperidone on Cognition|Effects of NMDA Receptor Antagonism on Cognitive Processes in Healthy Volunteers and Its Reversal by a Dopamine Antagonist: Comparison to Patients With Schizophrenia|Schiz_2|University of Manchester|No|Not yet recruiting|June 2010|December 2010|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Anticipated|87|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2010|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140620||120927|
NCT01164007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18727|A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.|An Open Label Study to Determine the Effect of Avastin in Combination With Dacarbazine on Overall Response Rate in Patients With Unresectable/Metastatic Melanoma||Hoffmann-La Roche||Completed|June 2006|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01164007||119142|
NCT01164033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25299|A Study of RO5045337 in Patients With Solid Tumors|An Open-Label, Randomized 3-Way Crossover, Study to Examine the Food-Effect on Pharmacokinetics of the Current Formulation and Relative Bioavailability of Two New Formulations for RO5045337 in Patients With Solid Tumors Including Lymphoma||Hoffmann-La Roche||Completed|August 2010|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01164033||119140|
NCT01164865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-58|Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers|The Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers||Alcon Research|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|78|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|July 15, 2010|Yes|Yes||No|September 13, 2012|https://clinicaltrials.gov/show/NCT01164865||119076|
NCT01165229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113077|Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older|Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older||GlaxoSmithKline||Completed|August 2010|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|14819|||Both|70 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165229||119048|
NCT01164579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921068|Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)|An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis||Pfizer|Yes|Completed|October 2010|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|109|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|July 15, 2010|Yes|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01164579||119098|
NCT01164852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ComplejoH 01|Aggressive Versus Expectant Management of Severe Preeclampsia Remote From Term|Expectant Management of Severe Preeclampsia at 28 to 33 Week`s Gestation:a Randomized Controlled Trial|MEXPRE-Latin|Complejo Hospitalario Dr. Arnulfo Arias Madrid|No|Completed|August 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|264|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2012|August 13, 2012|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164852||119077|
NCT01164514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-086|Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant|A Randomized, Partial-Blinded, Placebo-Controlled, Phase I Safety and Immunogenicity Study in Healthy Subjects of Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram Negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|November 2011|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|January 30, 2014|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01164514||119103|
NCT01164527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0015|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||September 24, 2015|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164527||119102|
NCT01164540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00093|Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis|A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism|Du Lac|AstraZeneca|No|Withdrawn|February 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|July 8, 2010||No|Due to discussion regarding the design of the study.|No||https://clinicaltrials.gov/show/NCT01164540||119101|
NCT01165177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110390|Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older|Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older||GlaxoSmithKline||Completed|August 2010|July 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|16167|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165177||119052|
NCT01140789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBD GWA|Chinese Patients With Inflammatory Bowel Disease|Genome Wide Association (GWA) Study in Chinese Patients With Inflammatory Bowel Disease||Chinese University of Hong Kong|Yes|Recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|3600|Samples With DNA|Blood        1. Up to 50ml of blood sample will be collected and stored at -80°C.        2. Some blood samples will be transported to Wuhan University for DNA extraction and           genetic analysis. Some will be used for targeted gene capture, NGS and validation in           Hong Kong. Some will be sent to Germany for transethnic response mapping. Some will be           transported to the UK and DNA will be extracted and genetic analysis will be performed           in the UK.           Stool        3. Stool samples will be collected and stored at -80°C. Some will be analysed with PCR for           norovirus and faecal calprotectin in Hong Kong. Some will be sent to Germany for           transethnic response mapping.Others will be stored for future analysis.           Biopsy        4. 5 biopsies from sigmoid will be collected, snap frozen and stored at -80°C, 1 routine           biopsy will also be collected for histology. Some will be sent to Germany for analysis.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Crohn's disease or ulcerative colitis patients as the case groups, Patients attend clinics        or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy as        the control group.|October 2015|October 5, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140789||120914|
NCT01141101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29160|Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus|Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus||Boston Medical Center|No|Recruiting|June 2010|June 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|MRSA isolates from the nose, axilla or perineum from mothers, infants and house hold      contacts and caregivers enrolled in the study will be retained only for the duration of the      study for use in molecular analysis for the purpose of this study.|Both|N/A|N/A|No|Non-Probability Sample|The exposed group will include 100 MRSA-colonized mothers and their babies. The unexposed        group will include 100 MRSA-negative mothers and their babies. The groups will be        conveniently selected from all mothers and infants meeting the inclusion and exclusion        criteria each month. Enrollment will continue until 100 babies and mothers in the        MRSA-positive mother group and 100 babies and mothers in MRSA-negative mother group are        enrolled. We estimate that enrollment will require approximately 18 months to complete.        Household contacts of infants will be enrolled. A contact is defined as any individual who        had or has had the same primary residences (who has lived in the same house for at least        one week) as the infant since the infant's birth. We will ask the infants mother to        identify the infants household contacts.        Infant care givers include any person who provides daily care to infant for at least 4        hours per day at least 3 days of week.|July 2011|July 11, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141101||120890|
NCT01141309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-060|Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer|Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01141309||120874|
NCT01141543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0756-C|Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection|Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients With AML Undergoing Allografting: Assessment of Feasibility and Efficacy||University Health Network, Toronto|Yes|Completed|May 2010|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|12|||Both|18 Years|61 Years|No|Probability Sample|The study will be performed on patients undergoing myeloablative allogeneic stem cell        transplants (PBSC or BM) from related or unrelated donors for the treatment of patients        with AML in remission.|July 2014|July 16, 2014|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01141543||120856|
NCT01141829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NADPHPM2010|NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)|NADPH Oxidase p22phox Polymorphisms and Oxidative Stress in Patients With Obstructive Sleep Apnea||Sociedad Española de Neumología y Cirugía Torácica|No|Recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with OSAS defined by an apnea hypopnea index (AHI)>10 h-1 will be included in the        study along with control subjects without OSAS. Participants were consequently studied at        the sleep unit of Hospital Universitario Son Dureta, (Palma de Mallorca, Spain).|January 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01141829||120835|
NCT01141842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSH-TCH-IIT-2010-1|Early Detection of Lung Tumors by Sniffer Dogs - Evaluation of Sensitivity and Specificity|Prospective Clinical Study to Determine the Predictive Value of Sniffer Dogs to Identify Lung Cancer in the Exhalation of Patients With and Without Pulmonary Disease||Schillerhoehe Hospital|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|3||Actual|230|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01141842||120834|
NCT01142089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2009-0201|Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea||Valeant Pharmaceuticals International, Inc.|No|Completed|May 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||April 2013|March 27, 2014|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01142089||120815|
NCT01142336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37373-B|Effects of Simvastatin on Biomarkers|Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects|SimBio|University of Washington|Yes|Completed|June 2010|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Both|45 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01142336||120796|
NCT01142583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000107|A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis|Canadian Assessment of the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis|CanTOR|Merck KGaA|No|Completed|July 2006|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|192|||Both|18 Years|55 Years|No|Non-Probability Sample|Subjects with either relapsing-remitting multiple sclerosis (RRMS) or a CIS were enrolled        from multiple sites across Canada.|March 2014|March 17, 2014|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142583||120777|
NCT01142596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06125|Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)|Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Phase 3 ; Protocol No. P06125)||Merck Sharp & Dohme Corp.|No|Completed|May 2010|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|20 Years|64 Years|No|||February 2016|February 19, 2016|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142596||120776|
NCT01143753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25247|A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours|An Open-label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-mutated Advanced Solid Tumours||Hoffmann-La Roche||Active, not recruiting|July 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143753||120688|
NCT01139827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET(FRS-CRP)|Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography|||Korea University Guro Hospital|Yes|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|178|||Both|16 Years|80 Years|No|Non-Probability Sample|The subjects underwent routine health checkups at Korea University Guro Hospital. Patients        with DM or gestational diabetes were not included.|February 2010|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01139827||120988|
NCT01139840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-15612|Relative Efficacy of Vitamins D2 and D3 in Adult Humans|Vitamin D Status: Relative Efficacy of Vitamins D2 and D3||Creighton University|No|Completed|January 2010|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139840||120987|
NCT01140074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB-501/2009|Efficacy of Zinc Sulfate With Probiotics for the Treatment of Acute Diarrhea in Children|Effectiveness and Efficacy of Zinc With Probiotics for the Treatment of Acute Diarrhea in Young Children|Zinc|University Hospital No 1 Wroclaw|Yes|Not yet recruiting|July 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|256|||Both|1 Month|36 Months|No|||June 2010|June 9, 2010|June 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01140074||120969|
NCT01140373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-036|Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)|Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)||Memorial Sloan Kettering Cancer Center||Recruiting|June 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Male|18 Years|N/A|No|||October 2015|October 28, 2015|June 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140373||120946|
NCT01164046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr: 2009-015336-15|Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism|Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism|Longheva|University Medical Center Groningen|Yes|Terminated|August 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|July 15, 2010||No|Due to slow inclusion of patients|No||https://clinicaltrials.gov/show/NCT01164046||119139|
NCT01164592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01a|Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation|SERVE-HF: Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation|MS|ResMed|Yes|Completed|August 2012|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|22 Years|N/A|No|||August 2015|August 4, 2015|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164592||119097|
NCT01164878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUVNeo-1|Cholestasis in Extreme Low Birth Weight Infants (ELBW)|Cholestasis in Extreme Low Birth Weight Infants (ELBW) - Possible Influences of a Change in Nutrition Policy||Medical University of Vienna|No|Completed|January 2010|July 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|122|||Both|N/A|1 Hour|No|Probability Sample|Preterm Infants below 1000 Gram birth weight|October 2012|October 19, 2012|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01164878||119075|
NCT01165242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114249|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults|Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years||GlaxoSmithKline||Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1013|||Both|10 Years|25 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165242||119047|
NCT01165489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Boushahri Medical Center|Discovering Laryngomalacia|Discovering Laryngomalacia||Boushahri Clinic Medical Center|Yes|Completed|January 2007|September 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1500|||Both|N/A|12 Months|Accepts Healthy Volunteers|Probability Sample|Primary Care Clinic|December 2009|July 19, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01165489||119028|
NCT01164839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTA-CMUXW|Evaluation of the Factors Affecting the Diagnostic Performance of Coronary Computed Tomography Angiogram (CTA) With Multi-slice Computed Tomography (MSCT)|Evaluation of the Factors Affecting the Diagnostic Performance of Coronary CTA With MSCT: a National Multicenter Trial||Capital Medical University|No|Recruiting|July 2010|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|20 Years|80 Years|No|Probability Sample|Consecutive eligible patients who undergo both coronary CTA and X-ray coronary angiography|July 2010|July 16, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01164839||119078|
NCT01165164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-014|An Evaluation of the Nighttime Retention of Effect of an Investigational Lubricant Eye Drop (FID 115958D)|||Alcon Research|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165164||119053|
NCT01165476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-121|Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities|An Evaluation of the Comparative Bioavailability of a Single Oral Dose of 1mg UT-15C (Treprostinil Diethanolamine) SR Tablets Manufactured by Two Independent Facilities Administered to Healthy Volunteers in the Fed State||United Therapeutics|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165476||119029|
NCT01141114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSGT-05-007-01-CPPB|Study of Patient Navigation to Promote Colon Cancer Screening|Randomized Controlled Trial of Patient Navigation to Increase Colorectal Cancer Screening Rates Among Community Health Center Patients||Cambridge Health Alliance|No|Completed|September 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|465|||Both|52 Years|75 Years|No|||June 2010|June 9, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141114||120889|
NCT01141322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-01-23A|Cholestatic Drug-induced Liver Injury|Cholestatic Drug-induced Liver Injury: Correlation With Genotypes of UGT1A1 and 1A7, and Treatment Effect of Ursodeoxycholic Acid|DILI|Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|August 2007|July 2010|Anticipated|April 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Both|N/A|N/A|No|||June 2010|June 8, 2010|January 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01141322||120873|
NCT01141556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236/09|Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery|Effects of High-dose Intravenous Selenium (Selenase®) on the Systemic Inflammatory Response Syndrome and Related Organ Dysfunction||University Hospital, Basel, Switzerland|No|Completed|December 2010|September 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141556||120855|
NCT01141569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03068|A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy|A Phase 2 Study of RO4929097 (IND 109291) in Patients With Advanced Renal Cell Carcinoma (RCC, NOS 10038415) That Has Progressed After VEGF/VEGFR Directed Therapy||National Cancer Institute (NCI)||Completed|June 2010|December 2013|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2013|May 22, 2015|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01141569||120854|
NCT01141855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008012|Smoking Termination Opportunity for inPatients|Effectiveness of Inpatient Initiated Varenicline Tartrate for Smoking Cessation, for Smoking Related Illnesses.|STOP|The Queen Elizabeth Hospital|Yes|Completed|May 2008|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|392|||Both|20 Years|75 Years|No|||April 2010|August 7, 2012|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01141855||120833|
NCT01142102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROG 10.01|Feasibility of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer|A Multicentre Feasibility Study of Online Adaptive Image Guided Radiotherapy for Muscle Invasive Bladder Cancer|BOLART|Trans-Tasman Radiation Oncology Group (TROG)|Yes|Completed|October 2010|June 2015|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01142102||120814|
NCT01142349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG031126|Cognitive Behavioral Therapy for Arthritis Pain and Insomnia in Older Adults|Cognitive Behavioral Therapy for Arthritis Pain and Insomnia in Older Adults|Lifestyles|University of Washington|No|Completed|January 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|367|||Both|60 Years|N/A|No|||December 2013|December 17, 2013|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01142349||120795|
NCT01143389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0243|Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia|Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia||Price Vision Group|Yes|Recruiting|May 2010|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|264|||Both|10 Years|N/A|No|||April 2015|April 27, 2015|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143389||120715|
NCT01143402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01411|Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye|Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|June 2010|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|159|||Both|18 Years|N/A|No|||December 2015|January 11, 2016|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143402||120714|
NCT01143428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100121|Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study|Oxidative Stress in Motor Neuron Disease: COSMOS-PLS Add-On Study||National Institutes of Health Clinical Center (CC)||Completed|May 2010|August 2015||||N/A|Observational|N/A|||Actual|10|||Both|20 Years|N/A|No|||August 2015|August 4, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143428||120713|
NCT01139866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C803-017e|An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery|A Multi-Center, Prospective, Observational, Extension Trial Following DURECT Protocol C803-017 to Investigate the Long-term Safety of SABER™-Bupivacaine Following Arthroscopic Shoulder Surgery||Durect|No|Completed|June 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|47|||Both|18 Years|N/A|No|Non-Probability Sample|All available subjects who received treatment in DURECT protocol C803-017.|July 2011|July 13, 2011|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01139866||120985|
NCT01139853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POINTS|Post-Operative Impact of Nasogastric Tubes on Rates of Emesis in Infants Diagnosed With Pyloric Stenosis|Post-Operative Impact of Nasogastric Tubes on Rates of Emesis in Infants Diagnosed With Pyloric Stenosis: A Prospective, Randomized Controlled Pilot Trial|POINTS|McMaster University|No|Completed|January 2010|January 2015|Actual|January 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|6 Months|No|||September 2015|September 25, 2015|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139853||120986|
NCT01140386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30835|Prevalence and Risk Factors of Venous Thromboembolism in Hospitalized Pediatric Patients||pediatric DVT|Penn State University|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Both|1 Month|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients aged <18 years old, who were hospitalized at MSHMC from January 1, 2000 -December        31, 2008 with documented VTE in one of three databases:          1. Vascular lab duplex ultrasound database          2. Inpatient hospital admission/discharge ICD-9 database          3. PTSF pediatric trauma database|June 2010|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140386||120945|
NCT01140659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/05|Objective Evaluation of Patients With Palmar Hyperhidrosis Submitted to Two Levels of Sympathectomy: T3 and T4.|Objective Evaluation of Patients With Palmar Hyperhidrosis Submitted to Two Levels of Sympathectomy: T3 and T4.||University of Sao Paulo|No|Completed|February 2007|February 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|15 Years|45 Years|Accepts Healthy Volunteers|||May 2010|June 21, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140659||120924|
NCT01164605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#37977|Pilot Study of Raltegravir Lipodystrophy IISP|Pilot Study on the Efficacy of a Two Drug, Raltegravir-based Regimen,(NRTI) Sparing Antiretroviral Treatment||Southern California Institute for Research and Education|No|Recruiting|October 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||May 2012|May 16, 2012|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164605||119096|
NCT01164891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25158|A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma|A Phase I, Open-label, Excretion Balance, Pharmacokinetic and Metabolism Study After Single Oral Dose of 14C-labeled RO5185426 in Previously Treated and Untreated Patients With Metastatic Melanoma||Hoffmann-La Roche||Completed|July 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 16, 2010||No||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01164891||119074|
NCT01164904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090107|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis|A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis||Amgen||Terminated|July 2010|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|July 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01164904||119073|
NCT01165255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114592|Bupropion and Specific Cardiovascular Malformations|Bupropion and Specific Cardiovascular Malformations||GlaxoSmithKline|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|7005|||Female|12 Years|49 Years|No|Non-Probability Sample|The study population will be the same as that used previously in the retrospective        epidemiologic study of infants born to women who were exposed to bupropion in their        estimated first trimester of pregnancy using data from a large US health plan affiliated        with i3 Drug Safety. 1,213 infants born to 1,140 women (1,142 pregnancies) were exposed to        bupropion during the first trimester. The comparison groups consisted of 4,753 infants        born to 4,617 women (4,649 pregnancies) exposed to other anti-depressants during the first        trimester, and 1,049 infants born to 1,009 women (1,009 pregnancies) exposed to bupropion        outside of the first trimester. All medical and prescription claims data along with dates        of health plan enrollment for these women were included. The other antidepressant sample        was frequency-matched to the bupropion cohort by year of birth, and was selected        irrespective of exposure to specific antidepressants.|June 2011|June 2, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01165255||119046|
NCT01165190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-012A|Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans|Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans|PIO|Arizona State University|No|Recruiting|May 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood, urine, and adipose tissue will be collected.|Both|18 Years|65 Years|No|Probability Sample|Both men and women, ages 18-65, any ethnicity.|July 2010|July 16, 2010|July 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165190||119051|
NCT01165203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112673|Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects|Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects||GlaxoSmithKline||Completed|September 2010|May 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|123|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165203||119050|
NCT01165216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-113|Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer|Phase 1 Study of Ipilimumab (BMS-734016) in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer||Bristol-Myers Squibb|No|Completed|September 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|20 Years|N/A|No|||June 2014|June 23, 2014|July 16, 2010|No|Yes||No|June 23, 2014|https://clinicaltrials.gov/show/NCT01165216||119049|
NCT01166061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG001|Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis|An Escalating, Multiple-dose Study in Grass Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Grass||Circassia Limited|No|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|65 Years|No|||May 2011|May 19, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01166061||118984|
NCT01141127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCML-2010-01|Tranexamic Acid (TXA) in Pediatric Cardiac Surgery|Tranexamic Acid (TXA) During Pediatric Cardiac Surgery: A Prospective Randomised Study Comparing Two Dosing Regimens|Exacyl|Centre Chirurgical Marie Lannelongue|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|18|||Both|12 Months|12 Years|No|||July 2014|July 21, 2014|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01141127||120888|
NCT01141335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-002|Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair|Lichtenstein's Repair of Inguinal Hernia With Polypropylene Mesh Versus Infinit® PTFE Mesh, a Prospective Randomized, Double-blind, Controlled Trial||University of Roma La Sapienza|No|Active, not recruiting|September 2009|September 2015|Anticipated|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||May 2013|May 21, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141335||120872|
NCT01141348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0055|The Weight-Wise Weight Loss Translation Study|Intensive Behavioral Weight Management in Public Health Settings: Weight-Wise|Weight-Wise|University of North Carolina, Chapel Hill|Yes|Completed|January 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|189|||Female|40 Years|64 Years|No|||June 2010|June 9, 2010|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01141348||120871|
NCT01141595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0578|Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders|Biomarkers of Central Nervous System Tetrahydrobiopterin Concentration and Response to Tetrahydrobiopterin Supplementation in Children With Idiopathic Cognitive Developmental Disorders||The University of Texas Health Science Center, Houston|Yes|Completed|July 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|2 Years|6 Years|No|||February 2014|February 28, 2014|June 8, 2010||No||No|January 15, 2013|https://clinicaltrials.gov/show/NCT01141595||120853|
NCT01141881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2202|Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema|Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema||Mashhad University of Medical Sciences|Yes|Terminated|May 2009|March 2010|Actual|January 2010|Anticipated|N/A|Interventional|Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||||||Both|N/A|N/A|No|||September 2008|October 7, 2010|June 10, 2010||No|occurrence of retinal hemorrhage , increase in macular edema of some patients in TPA group|No||https://clinicaltrials.gov/show/NCT01141881||120831|
NCT01142362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-001|Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults|Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)||Inovio Pharmaceuticals|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142362||120794|
NCT01142115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP063CC|Test of Discomfort and Malaise of Two Different Urine Catheters in Healthy Volunteers|Comparative Study of Two Different Urine Catheters.||Coloplast A/S|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|41|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 4, 2011|May 4, 2010||No||No|March 22, 2011|https://clinicaltrials.gov/show/NCT01142115||120813|
NCT01143129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECS-PNAF|Postoperative New-onset Atrial Fibrillation in Cardiac Surgery: DECS-PNAF Project|Postoperative New-onset Atrial Fibrillation in Cardiac Surgery: An Explanatory Study of the Prophylactic Effect of Corticosteroids (DECS-PNAF Project)|DECS-PNAF|UMC Utrecht|Yes|Completed|January 2011|January 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143129||120735|
NCT01143441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100125|Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)|Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2010|July 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|60 Years|No|||August 2015|October 1, 2015|June 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01143441||120712|
NCT01139879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0092|P400 for Stage II-IV Pressure Ulcers in Home and Extended Care|Assessment of the Incidence and Treatment of Stage II -IV Pressure Ulcers in the Home Care or Extended Care Environments Utilizing the P400 Mattress|P400|Hill-Rom|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 7, 2010||No||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01139879||120984|Small study with no comparative arm.
NCT01140087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040219|Face Transplantation|Maxillofacial Composite Tissue Allograft Transplantation: Face Transplant||University of Maryland|Yes|Recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|64 Years|No|||May 2015|May 27, 2015|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140087||120968|
NCT01140100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-3211|A Comparative Study of Depth of Anesthesia Monitored by Bispectral Index (BIS) Values|A Comparative Study of Depth of Anesthesia Monitored by BIS Values in Two Anesthesia Techniques||Shiraz University of Medical Sciences|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||January 2007|June 8, 2010|June 8, 2010||||No||https://clinicaltrials.gov/show/NCT01140100||120967|
NCT01140399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT code 2009-014|REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure|Impact of Different Therapeutic Approaches in Patients With Cardiorenal Syndrome in the Setting of Acute Decompensated Congestive Heart Failure (ADCHF)|REWORD-HF|Niguarda Hospital|Yes|Suspended|February 2011|||June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|80 Years|No|||March 2015|March 5, 2015|June 7, 2010||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01140399||120944|
NCT01140672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1261003|A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects|A Double Blind, 3rd Party Open, Placebo Controlled, Dose Escalating, Parallel Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04634817 In Healthy Volunteers||Pfizer||Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|June 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140672||120923|
NCT01140685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-LF-669-CTIL|Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air|||Tel-Aviv Sourasky Medical Center|No|Active, not recruiting|December 2009|||September 2010|Anticipated|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|70|Samples Without DNA|induced sputum, exhaled CO levels|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Fifty adult male and female patients who had been diagnosed with one or more of the four        study diseases and referred for sputum induction to the Pulmonary Laboratory in the        Tel-Aviv Sourasky Medical Center will be enrolled|March 2010|June 8, 2010|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01140685||120922|
NCT01164618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000015862|The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response|The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response||The Hospital for Sick Children|No|Active, not recruiting|May 2010|January 2014|Anticipated|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 14, 2013|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01164618||119095|
NCT01166139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10041|Nilotinib in the Treatment of Systemic Sclerosis|Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis||Hospital for Special Surgery, New York|Yes|Active, not recruiting|July 2010|||July 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166139||118978|
NCT01165268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-066|Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)|Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus||AstraZeneca|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|65|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 20, 2015|July 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165268||119045|
NCT01165749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05062010-5902|Exercise Study Including Patients With Hypertrophic Cardiomyopathy|A Randomized Trial of Moderate Intensity Exercise Training in Patients With Hypertrophic Cardiomyopathy||Stanford University||Recruiting|May 2010|April 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients diagnosed with hypertrophic cardiomyopathy|July 2010|July 19, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165749||119008|
NCT01141920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|da012347-4|Comparison of Two Counseling Induction Strategies|Comparison of Two Different Counseling Schedules on Treatment Response of New Admissions to Methadone Maintenance||Johns Hopkins University|No|Completed|September 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01141920||120828|
NCT01141140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF 2009-117|(Mis)Perceptions About Healthy Eating: Effects on Food Intake and Appetite in Men and Women|(Mis)Perceptions About Healthy Eating: Effects on Food Intake and Appetite in Men and Women|COLLATION|Laval University|No|Completed|September 2009|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|8||Actual|355|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141140||120887|
NCT01141361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POST-GPS|Feasibility of Home-based Measurement of Walking Capacity Using Global Positioning System in Peripheral Artery Disease|Feasibility of Home-based Measurement of Walking Capacity Using Global Positioning System in Patients With Peripheral Arterial Disease|POST-GPS|University Hospital, Angers|Yes|Completed|July 2009|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|251|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with peripheral arterial disease, defined by an ankle to brachial index below        0.90, or patients with vascular history and having vascular claudication|March 2013|March 15, 2013|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141361||120870|
NCT01141608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-U10-DA020024-04S1|Exercise as a Treatment for Substance Use Disorders Protocol|NIDA CTN Protocol 0037: Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)|STRIDE|University of Texas Southwestern Medical Center|Yes|Completed|June 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|65 Years|No|||December 2015|December 9, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141608||120852|
NCT01141868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31944EP|Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors|Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors||Milton S. Hershey Medical Center|No|Withdrawn|July 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|N/A|No|||June 2010|May 16, 2013|June 9, 2010||No|The study never opened due to technical upgrades that were needed for the SHUTi computer    system.|No||https://clinicaltrials.gov/show/NCT01141868||120832|
NCT01142609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1DA028189-01|Improving Substance Abuse Counseling Adherence Using Web-based Videoconferencing|Improving Substance Abuse Counseling Adherence Using Web-based Videoconferencing||Johns Hopkins University|No|Completed|December 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|85|||Both|18 Years|65 Years|No|||April 2013|April 2, 2013|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142609||120775|
NCT01142869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 062202-514|An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck|An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy, in the First-line Therapy of Recurrent/ Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)||Merck KGaA||Terminated|December 2009|April 2016|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|Samples With DNA|Whole Blood|Both|N/A|N/A|No|Non-Probability Sample|Patients with squamous cell carcinoma of head and neck|November 2014|November 7, 2014|June 10, 2010||No|The study was discontinued due to slow recruitment and subjects not completing follow up    period.|No||https://clinicaltrials.gov/show/NCT01142869||120755|
NCT01143142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|149891|Vax Facts Human Papillomavirus (HPV): Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV|Vax Facts HPV: Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV||University of Michigan|Yes|Completed|June 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|70|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 15, 2014|June 10, 2010||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01143142||120734|
NCT01143766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911-51|Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)|Premedication With Single Dose Gabapentin to Improve Patient Tolerance in ERCP: A Double-Blind Randomized Controlled Trial||Indiana University|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||November 2012|November 6, 2012|June 11, 2010||No||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01143766||120687|Limited sample size due to challenges with recruitment and transition to propofol-based anesthesia for sedation in ERCP. Study terminated at 50% enrollment for this reason.
NCT01139892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND09.282|The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES)|Canadian Study on the Endovascular Treatment of Unruptured Intracranial Aneurysms Versus Surgical Treatment. A Randomized Comparison of Clinical and Angiographic Results of Intracranial Aneurysms|CURES|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|June 2010|June 2025|Anticipated|June 2020|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|260|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|December 2015|December 2, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01139892||120983|
NCT01139905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 100|Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children|Pharmacokinetics of Low- Dose Lopinavir/Ritonavir Tablet Formulation HIV-1 Infected Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|1 Year|18 Years|No|||March 2015|March 24, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01139905||120982|
NCT01140113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Modified Ultrafiltration|Does Modified Ultrafiltration Improves Inflammatory Response and Cardiopulmonary Function After CABG Procedures?|Does Modified Ultrafiltration Improves Inflammatory Response and Cardiopulmonary Function After CABG Procedures?||University of Campinas, Brazil|Yes|Completed|July 2007|March 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|90 Years|No|||July 2013|July 21, 2013|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140113||120966|
NCT01140126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBI Protocol A101|Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults|A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults||United Biomedical|Yes|Completed|May 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|N/A|No|||July 2011|July 7, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140126||120965|
NCT01140412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001099|Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Open-Label, Fixed-Sequence, Crossover Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects||ViiV Healthcare|No|Terminated|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|June 7, 2010|Yes|Yes|The trial prematurely terminated on November 1, 2010, due to healthy volunteer participants    experiencing non-serious fosamprenavir-related skin rash.|No||https://clinicaltrials.gov/show/NCT01140412||120943|
NCT01140425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7691017|Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects|A Phase 1, Randomized, Multiple Dose, Placebo And Active Controlled, 4-Way Crossover Study To Evaluate The Effect Of A Multiple Oral Dose of PF-00232798 On Qt Intervals In Healthy Subjects||Pfizer|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|44|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 22, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140425||120942|
NCT01140698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7895-LL-SMC|Amino Acid Profile in the Fetus and the Neonate|||Sheba Medical Center|No|Not yet recruiting|July 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|N/A|6 Months|Accepts Healthy Volunteers|Probability Sample|Term and preterm newborn infants|June 2010|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140698||120921|
NCT01140711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-7649-10-DG-CTIL|Functional MRI Evaluation of Brain Response to Visual Food Stimulation in Morbidly Obese Patients Before and After Bariatric Surgery|||Sheba Medical Center|No|Completed|January 2011|||May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|30|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140711||120920|
NCT01165281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017188|A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain|A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain||Janssen Research & Development, LLC||Completed|August 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|343|||Both|20 Years|N/A|No|||December 2013|December 13, 2013|July 15, 2010||No||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01165281||119044|
NCT01165502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CellMed CM3.1-AC100/02|Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers|Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers||CellMed AG, a subsidiary of BTG plc.|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 18, 2011|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165502||119027|
NCT01165515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220/2007|Endostatin Serum Levels During Bicycle Stress Test|Endostatin Serum Levels During Bicycle Stress Test in Different Samples||Medical University of Vienna|Yes|Completed|January 2008|April 2013|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||13|Actual|240|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|200 patients, divided into sub-groups, always both genders will be tested for different        conditions (smoking, age, CMP, CHD,...)|May 2014|May 18, 2014|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01165515||119026|
NCT01141374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISNEP|Application of Auriculotherapy on Nursing Professional Stress Levels|Analysis of the Application of Different Forms in Auriculotherapy on Nursing Professional Stress Levels||University of Sao Paulo|No|Completed|January 2010|June 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|75|||Both|23 Years|61 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|June 4, 2010|Yes|Yes||No|August 20, 2011|https://clinicaltrials.gov/show/NCT01141374||120869|Study limitations: small sample sizeBias procedure with auricular seeds: the non-participation of the subject of research in self-massage of the points
NCT01141621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 022010-024|The Dallas Hereditary Spherocytosis Cohort Study|The Dallas Hereditary Spherocytosis Cohort Study||University of Texas Southwestern Medical Center|No|Terminated|May 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|Plasma|Both|N/A|21 Years|No|Non-Probability Sample|Center for Cancer and Blood Disorders outpatient clinics|May 2013|May 13, 2013|June 4, 2010||No|Insufficient staff to continue pursuing project|No||https://clinicaltrials.gov/show/NCT01141621||120851|
NCT01141894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-018087-10|Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral Fracture|Evaluation of Costs and Consequences of Alternative Strategies of Intraoperative Fluid and Pharmacological Optimization. A Randomized Clinical Trial|GDHT|Karolinska Institutet|Yes|Terminated|March 2010|October 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|70 Years|N/A|No|||January 2015|January 5, 2015|April 20, 2010||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT01141894||120830|
NCT01142141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095/2006|Manual Therapy in Postoperative Breast Cancer|Manual Therapy in Postoperative Breast Cancer||University of Campinas, Brazil|No|Completed|August 2006|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|136|||Female|18 Years|90 Years|No|||June 2010|June 9, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142141||120811|
NCT01142128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D.9612.L00058|Viokase 16, Viokase16 Plus Nexium and Nexium Alone|A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis|AZ|University of Florida|No|Terminated|February 2009|March 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|75 Years|No|||February 2013|February 20, 2013|June 9, 2010|Yes|Yes|Viokase was taken off market during study and remained off over a year.|No|October 19, 2012|https://clinicaltrials.gov/show/NCT01142128||120812|
NCT01142622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 02 2010 Ovarian Cyst|Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic Surgery|Do Peritoneal Nebulization of Ropivacaine Reduce the Use of Morphine After Short Gynecologic Laparoscopic Surgery?||San Gerardo Hospital|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|65 Years|No|||February 2013|February 22, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142622||120774|
NCT01142882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVPrev613|Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention|Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention||National Development and Research Institutes, Inc.|No|Recruiting|February 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142882||120754|
NCT01142895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDC-G4|Validation Study of G4 User Interface|Simulated Usability Trial of the T-Slim Ambulatory Insulin Infusion Pump|G4|Tandem Diabetes Care, Inc.|No|Completed|May 2010|||May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|33|||Both|22 Years|N/A|No|Probability Sample|Novice adult pumpers, experienced adult pumpers, and non-pumper adults|June 2010|June 10, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142895||120753|
NCT01143454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100126|Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System|Cardiovascular Disease Discovery Protocol||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|N/A|||Anticipated|1000|||Both|2 Years|100 Years|No|||December 2015|December 15, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143454||120711|
NCT01143779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0658|FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib|FLT-PET as an Imaging Biomarker in Patients Receiving the Combination of Cell Cycle Inhibitors Temsirolimus, Topotecan, and Bortezomib||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2010|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|June 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01143779||120686|
NCT01143792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005B0078|Evaluation of Treatments for Homeless Youths|Evaluation of Treatments for Homeless Youth: CRA, MET and Case Management||Ohio State University|No|Completed|September 2006|June 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|270|||Both|14 Years|20 Years|No|||April 2013|April 12, 2013|June 11, 2010||No||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01143792||120685|
NCT01140438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LADA|Treatment of Latent Autoimmune Diabetes of the Adult|Is "Beta Cell Rest" by Insulin Treatment Beneficial Compared to State-of-the Art Enhancers of Insulin Secretion in Preserving Beta Cell Function in Subjects With Latent Autoimmune Diabetes of the Adult (LADA)?|LADA|Norwegian University of Science and Technology|Yes|Active, not recruiting|March 2009|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|30 Years|75 Years|No|||April 2015|April 22, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140438||120941|
NCT01140139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermHIVImm|Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions|Active Immunotherapy Against HIV During Highly Active Anti-retroviral Therapy Followed by Repeated Treatment Interruptions|Vac09|Swedish Institute for Infectious Disease Control|Yes|Completed|September 2006|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|60 Years|No|||February 2006|June 8, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140139||120964|
NCT01140152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-06-058-02A|Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction|Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction||University of California, Los Angeles|Yes|Completed|July 2008|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|17|Samples With DNA|Ostomy effluent|Both|N/A|N/A|No|Non-Probability Sample|All Intestinal transplant recipients at UCLA, who are up to 8 weeks status-post transplant        and are undergoing surveillance endoscopy or who present with elevated stool outputs with        concern for acute rejection. Controls will consist of all primary ITx recipients of the        same follow-up criteria who are undergoing surveillance biopsies but are at their baseline        ostomy outputs.|February 2010|June 8, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140152||120963|
NCT01141218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 0938|Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes|Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes||Vanderbilt-Ingram Cancer Center|Yes|Terminated|July 2009|September 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|No|Non-Probability Sample|never-smokers with lung cancer|February 2013|April 2, 2013|June 9, 2010||No|slow accrual|No||https://clinicaltrials.gov/show/NCT01141218||120881|
NCT01141231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0547 MDA|Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer|A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2012|||November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|240|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141231||120880|
NCT01165827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERMANAVR-2010|German Aortic Valve Registry|National Prospective German Registry for Aortic Valve Therapy|GARY|German Aortic Valve Registry|Yes|Recruiting|July 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Aortic valve procedures from all German hospitals|February 2016|February 11, 2016|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165827||119002|
NCT01165840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAIRB97|Effect of Weight and/or Obesity on Dapsone Drug Concentrations|Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers||Texas Tech University Health Sciences Center|No|Completed|July 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165840||119001|
NCT01165320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-074|A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)|A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections||Merck Sharp & Dohme Corp.|No|Completed|July 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|3 Months|17 Years|No|||July 2015|July 20, 2015|July 15, 2010|No|Yes||No|March 20, 2014|https://clinicaltrials.gov/show/NCT01165320||119041|
NCT01165294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017368|The Effect of Ketamine on Attentiveness|Investigate the Effect of S-Ketamine, as Pharmacological Model of Schizophrenia, on the Attentiveness and Working Memory Simultaneously Measured With Functional Magnetic Resonance Imaging(fMRI)/Electroencephalogram(EEG)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2009|May 2010|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|35 Years|No|||August 2010|August 5, 2010|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01165294||119043|
NCT01165528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASVtrial|Adaptive Support Ventilation in Acute Respiratory Distress Syndrome (ARDS)|Adaptive Support Ventilation vs. Conventional Ventilation Strategy in the Management of Acute Respiratory Distress Syndrome:A Randomized Controlled Trial||Postgraduate Institute of Medical Education and Research|No|Recruiting|January 2010|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|N/A|No|||December 2009|July 19, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165528||119025|
NCT01165775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07082010-6490|Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy|Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy||Stanford University|No|Completed|July 2010|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant women receiving betamethasone|March 2015|March 30, 2015|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165775||119006|
NCT01141647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O7814-R|SCI-VIP: Predictive Outcome Model Over Time for Employment (PrOMOTE)|Predictive Outcome Model Over Time for Employment (PROMOTE)|PrOMOTE|VA Office of Research and Development|No|Completed|August 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141647||120849|
NCT01141660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU IRB# HM10692|Use of Laryngeal Mask Airway in Pediatric Adenotonsillectomy|Use of Laryngeal Mask Airway in Pediatric Adenotonsillectomy||Virginia Commonwealth University|No|Completed|December 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|2 Years|12 Years|No|||March 2011|February 21, 2012|June 7, 2010||No||No|November 10, 2010|https://clinicaltrials.gov/show/NCT01141660||120848|
NCT01141907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR011056|Nurse-Led Heart Failure Care Transition Intervention for African Americans: The Navigator Program|Nurse-Led Heart Failure Care Transition Intervention for African Americans||Johns Hopkins University|Yes|Completed|February 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|25|||Both|21 Years|N/A|No|||May 2012|May 25, 2012|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01141907||120829|
NCT01142154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP1104-02|Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome|A Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne Syndrome||DNage B.V.|Yes|Completed|June 2010|February 2011|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|2 Years|10 Years|No|||June 2011|June 22, 2011|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01142154||120810|
NCT01142375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leukemia-001|Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells|Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells||Taipei Medical University WanFang Hospital|No|Active, not recruiting|April 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Bone Marrow|Both|N/A|N/A|No|Non-Probability Sample|Acute Leukemia|June 2010|June 10, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142375||120793|
NCT01142908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 08-297|Cardiovascular Intervention Improvement Telemedicine Study|Cardiovascular Intervention Improvement Telemedicine Study||VA Office of Research and Development|No|Completed|November 2011|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|428|||Both|N/A|N/A|No|||May 2015|May 26, 2015|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01142908||120752|
NCT01143155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAILCAP|Failure and Cardiovascular Events in Community-acquired Pneumonia|Clinical Failure and Cardiovascular Events in Hospitalized Patients With Community-Acquired Pneumonia: The Failcap Study|FAILCAP|University of Milan|Yes|Completed|October 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|Samples Without DNA|Urine Sputum Blood Exhaled Breath Condensate Tracheal Aspirate Pleural effusion      Bronchoalveolar lavage Nasopharyngeal swabs|Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients admitted to any of the study centers will be screened for study        entry. Patients with a diagnosis of community-acquired pneumonia (including those with        health-care associated pneumonia) will be evaluated to define study entry criteria|December 2013|December 31, 2013|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01143155||120733|
NCT01143168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cellonis-CR-1.3|Stem Cell Therapy for Type 1 Diabetes Mellitus|A Pilot Study on Transplantation Therapy Using Autologous Bone Marrow Mononuclear Cells and Umbilical Cord Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus||Cellonis Biotechnology Co. Ltd.|Yes|Not yet recruiting|August 2010|December 2011|Anticipated|August 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|50 Years|No|||June 2010|June 11, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01143168||120732|
NCT01143181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-350|A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses|A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses||Chimerix||Completed|December 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|232|||Both|1 Month|N/A|No|||August 2013|August 28, 2013|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143181||120731|
NCT01143805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921077|A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form|A Phase 1, Open Label, Single Dose, Randomized, Cross Over Study To Estimate The Absolute Oral Bioavailability Of CP-690,550 In Healthy Subjects||Pfizer|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 6, 2010|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01143805||120684|
NCT01140191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-16049; S-10-0007|Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis|An Open-Label Clinical Study to Examine the Safety, Efficacy, and Pharmacokinetics of WR 279,396 (Paromomycin + Gentamicin Topical Cream) for the Treatment of Cutaneous Leishmaniasis at Walter Reed National Military Medical Center (WRNMMC)|WRNMMC|U.S. Army Medical Research and Materiel Command|No|Terminated|July 2010|September 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 7, 2010|Yes|Yes|This study was closed due to lack of enrollment (only one subject enrolled)|No||https://clinicaltrials.gov/show/NCT01140191||120960|
NCT01140204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-325-02|Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media|Restenosis Inhibition by Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media||University Hospital, Saarland|Yes|Completed|March 2003|June 2004|Actual|June 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|N/A|No|||June 2010|June 8, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140204||120959|
NCT01140451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-009e-CF|Extension Study of Ataluren (PTC124) in Cystic Fibrosis|A Phase 3 Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Cystic Fibrosis||PTC Therapeutics|Yes|Completed|August 2010|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|191|||Both|6 Years|N/A|No|||August 2013|March 1, 2016|June 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140451||120940|
NCT01140984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-08-HMO-CTIL|Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)|An Investigator Initiated Open Study to Evaluate the Efficacy and Safety of Intra Arterial Infusion for Treatment of Steroid Resistant Acute Hepatic Graft Versus Host Disease (AGVHD)||Hadassah Medical Organization|No|Terminated|September 2010|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2011|April 19, 2015|June 9, 2010||No|technical issues|No||https://clinicaltrials.gov/show/NCT01140984||120899|
NCT01140997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1006IFN|Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C|A Multi-center, Randomized, Open-label and Positive Controlled Phase II Clinical Trial to Assess Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C.|PEGIFN|Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|July 2010|March 2012|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|211|||Both|18 Years|65 Years|No|||June 2010|January 31, 2013|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140997||120898|
NCT01140724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC2008-0848|Personalizing Perioperative Analgesia in Children|Predicting Perioperative Opioid Adverse Effects and Personalizing Analgesia in Children||Children's Hospital Medical Center, Cincinnati|No|Recruiting|April 2008|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|DNA from blood is obtained and analyzed for genetic varaiations|Both|6 Years|15 Years|No|Non-Probability Sample|Children, 6-15 years of age, undergoing tonsillectomy or adenotonsillectomy at the        Cincinati Children's Hospital Medical Center (CCHMC), who have consented to participate in        an observational clinical study as approved by the CCHMC IRB, protocol # 2008-0848.|July 2015|July 29, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140724||120919|
NCT01165333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILENT-0902|Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma|Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study|CILENT-0902|Centre Oscar Lambret|Yes|Completed|August 2010|March 2015|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|6 Months|21 Years|No|||February 2016|February 15, 2016|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165333||119040|
NCT01165307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-007334-00|Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia|A Prospective Randomized Trial of Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia: Treatment Outcomes and Cost Utility Analysis|iTOM|Mayo Clinic|Yes|Completed|August 2009|October 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Female|30 Years|55 Years|No|||January 2016|January 7, 2016|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165307||119042|
NCT01165541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QM1|A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency|An Open-Label, Sequential Study of Quetiapine Fumarate Extended Release (XR) and Mirtazapine for the Treatment of Alcohol Dependency in Very Heavy Drinkers||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|64 Years|No|||February 2014|February 13, 2014|July 16, 2010||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01165541||119024|
NCT01165554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-067-007|Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels|A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem||GE Healthcare|No|Completed|May 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|203|||Both|55 Years|N/A|No|||November 2013|November 8, 2013|June 21, 2010|Yes|Yes||No|May 7, 2013|https://clinicaltrials.gov/show/NCT01165554||119023|
NCT01165788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT216|Social Adaptation in Long Term Survivors of Blood and Marrow Transplantation|Social Adaptation in Long Term Survivors of Blood and Marrow Transplantation||Stanford University|Yes|Active, not recruiting|November 2009|||November 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be identified from the comprehensive database of the Blood and Marrow        Transplant Division of Stanford Hospitals & Clinics. We will target lymphoma patients who        received an autologous BMT as adults (18 years or older). We estimate there are ~580        surviving who are between 2 and 22 years post-BMT.|March 2013|March 26, 2013|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165788||119005|
NCT01165801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKAM-1-2061|Size Progression of Macular Degeneration After Cataract Surgery|Size Progression of Non-Exudative Age-Related Macular Degeneration After Cataract Surgery||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|January 2002|July 2010|Actual|September 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 19, 2010|July 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01165801||119004|
NCT01165814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAMNAP|Naproxen Versus Tramadol for Post Cesarean Pain Control|Oral Naproxen Versus Oral Tramadol for Analgesia After Cesarean Delivery - A Randomized Controlled Trial||Bnai Zion Medical Center|No|Completed|August 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|120|||Female|N/A|N/A||||July 2010|July 19, 2010|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01165814||119003|
NCT01142193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-004|Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures||Upsher-Smith Laboratories||Completed|May 2010|January 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|249|||Both|18 Years|75 Years|No|||May 2014|May 19, 2014|June 9, 2010||Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01142193||120807|
NCT01142167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTC Study|A Comparison of an Ultra-thin and Standard Colonoscope in Achieving Caecal Intubation|A Study to Assess the Success Rate of Ultra-thin Colonoscopy Versus Conventional Colonoscopy for the First or Rescue Colonoscopy for Unsuccessful Procedures (UTC Study).||Chinese University of Hong Kong|Yes|Completed|October 2009|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|1121|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142167||120809|
NCT01142388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02045|Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer|Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2010|||July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|N/A|No|||January 2015|June 2, 2015|June 10, 2010|Yes|Yes||No|May 13, 2015|https://clinicaltrials.gov/show/NCT01142388||120792|
NCT01142635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08197M|Electromyographic (EMG) on the Anaesthesia Monitor|The Appearance of Electromyography on the Anaesthesia Monitor.||Tampere University Hospital|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|65 Years|No|||June 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142635||120773|
NCT01142648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09041M|Sugammadex and Brain Waves|The Effect of Sugammadex of EEG-derived Index Values||Tampere University Hospital|No|Completed|April 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|65 Years|No|||June 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142648||120772|
NCT01142674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-Cell Project|T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma|Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the International T-Cell Lymphoma Project||Associazione Angela Serra per la ricerca sul cancro|No|Recruiting|September 2006|December 2022|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples Without DNA|Formalin-fixed tissue for central diagnostic pathology review|Both|18 Years|N/A|No|Non-Probability Sample|Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell        lymphoma|January 2016|January 5, 2016|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142674||120770|
NCT01143194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-06-OREG|A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women|A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women||DSM Nutritional Products, Inc.|No|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|44|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143194||120730|
NCT01142921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARBS|The Patency Period of the New Plastic Anti-reflux Biliary Stent|||Chinese University of Hong Kong|No|Recruiting|November 2008|||November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2010|February 8, 2011|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01142921||120751|
NCT01143467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100128|Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy|Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy||National Institutes of Health Clinical Center (CC)||Completed|May 2010|November 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|26|||Male|18 Years|100 Years|No|||November 2015|November 7, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143467||120710|
NCT01139931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML10B9|Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia|Epigenetic Alterations in AML||Children's Oncology Group|No|Active, not recruiting|October 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|15|||Both|N/A|17 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia|May 2015|May 6, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01139931||120980|
NCT01140217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE0906|Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception|An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System|Simplify|Watson Pharmaceuticals|No|Completed|May 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1659|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 13, 2013|May 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01140217||120958|
NCT01140230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hanna Björnsson study 2|Outcomes After Repair of Acute Rotator Cuff Tears|Structural and Clinical Outcomes After Repair of Acute Rotator Cuff Tears|HBStud2|University Hospital, Linkoeping|Yes|Completed|August 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|42|||Both|42 Years|83 Years|No|Non-Probability Sample|A retrospective review of our computerized database identified 49 patients repaired at our        institution between May 2004 until May 2009 due to acute traumatic rotator cuff tears. 42        patients who fulfilled the inclusion criteria, were willing to participate in a follow-up        evaluation after written and oral informed consent.|September 2009|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140230||120957|
NCT01140464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH085645|Reaching Out to Adolescents With Depression|Adolescent Collaborative Care Treatment for Depression|ROAD|Seattle Children's Hospital|Yes|Completed|April 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|101|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01140464||120939|
NCT01140750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 07-283|Variability Analysis as a Predictor of Liberation From Mechanical Ventilation|Variability Analysis as a Predictor of Liberation From Mechanical Ventilation in Patients Admitted to the Respiratory Special Care Unit (ReSCU)||The Cleveland Clinic|No|Completed|August 2007|March 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that were admitted to the Respiratory Special Care Unit (ReSCU)|June 2010|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140750||120917|
NCT01141036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-08|Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients|Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients||Ziv Hospital|Yes|Completed|July 2008|February 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2010|June 9, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141036||120895|
NCT01140737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15195|A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas|A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas|Axi-STS|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|August 2010|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|152|||Both|16 Years|N/A|No|||May 2015|May 19, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140737||120918|
NCT01153412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-087|Effect of Osteopathic Manipulation on Postural Stability in the Elderly|Effect of Osteopathic Manipulation on Postural Stability in the Elderly||University of North Texas Health Science Center|No|Completed|August 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153412||119952|
NCT01153698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.118|Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery|Observational Cohort Study to Evaluate the Safety and Efficacy of Switching From Lovenox (Enoxaparin) 40mg to Pradaxa (Dabigatran Etexilate) 220mg in Patients Undergoing Elective Total Hip or Knee Replacement Surgery||Boehringer Ingelheim||Terminated|August 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|167|||Both|18 Years|N/A|No|Probability Sample|specialist care|May 2014|May 6, 2014|June 29, 2010||||No|November 30, 2012|https://clinicaltrials.gov/show/NCT01153698||119930|
NCT01153711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.47|Relative Bioavailability of of Olodaterol and Ketoconazole|Relative Bioavailability of 10 mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Ketoconazole (Tablet) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)||Boehringer Ingelheim||Completed|May 2010|||August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 28, 2014|June 29, 2010||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01153711||119929|
NCT01153724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.48|Relative Bioavailability of Olodaterol and Fluconazole|Relative Bioavailability of 10 mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Fluconazole (Hard Capsule) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)||Boehringer Ingelheim||Completed|May 2010|||July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|June 29, 2010||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01153724||119928|
NCT01166399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20P01|Behavioral Therapy Of Obstetric Sphincter Tears|BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study|BOOST|NICHD Pelvic Floor Disorders Network|Yes|Completed|July 2010|October 2012|Actual|June 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|362|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects in this trial will be primiparous women who underwent anal sphincter repair at        the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized        at the time of delivery as <50% tear through the anal sphincter (modified WHO 3a), >50%        (modified WHO 3b), or complete tear through the anal sphincter (4th degree).|September 2013|September 27, 2013|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166399||118958|
NCT01162187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER-09-02|Secondary Prevention in Acute Coronary Syndromes: A CALIBER Study|Secondary Prevention in Acute Coronary Syndromes: Long-term Survival in Relation to the Number and Combination of Evidence-based Therapies Prescribed Prior to Discharge (a CALIBER Study)||University College, London|No|Active, not recruiting|July 2003|June 2010|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400000|||Both|N/A|N/A|No|Non-Probability Sample|Individuals with data entered into the Myocardial Ischaemia National Audit Project (MINAP)        database in England and Wales.|July 2010|July 13, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01162187||119282|
NCT01162200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCC-02110|Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer|A Phase I Study of Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|October 2010|July 2020|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||March 2015|March 19, 2015|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01162200||119281|
NCT01142440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDF-918-2010|Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel|Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among Israeli Defence Force (IDF) Personnel|CAMBRA|Medical Corps, Israel Defense Force|No|Recruiting|June 2010|March 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142440||120788|
NCT01141933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSS-019126|Creating Meaning Following Cancer: An Intervention to Improve Existential and Global Quality of Life|Creating Meaning Following Cancer: An Cognitive-existential Intervention to Improve Existential and Global Quality of Life||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|February 2009|April 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|513|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141933||120827|
NCT01142180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAE2|Early Selective TAE to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis|Early Selective Angiographic Embolization to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis - a Randomized Controlled Trial||Chinese University of Hong Kong|Yes|Active, not recruiting|January 2010|December 2016|Anticipated|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142180||120808|
NCT01142401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03000|Fulvestrant With or Without Bortezomib in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|May 2010|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|118|||Female|18 Years|N/A|No|||February 2016|March 11, 2016|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01142401||120791|
NCT01142414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-22071-24071|Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence|Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence||European Organisation for Research and Treatment of Cancer - EORTC||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||January 2012|January 13, 2012|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142414||120790|
NCT01142661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-399|Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies|Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies||Eisai Inc.|No|Completed|August 2010|||August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||September 2013|September 19, 2013|June 10, 2010|Yes|Yes||No|April 29, 2013|https://clinicaltrials.gov/show/NCT01142661||120771|
NCT01143207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10206|PK of Depo SubQ Injected in the Upper Arm|Pharmacokinetics of Subcutaneous Depot Medroxyprogesterone Acetate Injected in the Upper Arm||FHI 360|No|Completed|May 2010|October 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2013|August 5, 2013|June 7, 2010||No||No|August 5, 2013|https://clinicaltrials.gov/show/NCT01143207||120729|
NCT01143818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S176.4.103|ESPRIT Study in Hypogonadal Men|Energy, Sexual Desire and Body PropoRtions wIth AndroGel®, Testosterone 1% Gel Therapy (ESPRIT) in Hypogonadal Men||Abbott|No|Completed|December 2007|August 2010|Actual|August 2010|Actual|Phase 4|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1053|||Male|18 Years|N/A|No|Non-Probability Sample|Community|October 2011|October 12, 2011|June 9, 2010||No||No|August 19, 2011|https://clinicaltrials.gov/show/NCT01143818||120683|
NCT01139918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6017|Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis|Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis||Innovaderm Research Inc.|No|Completed|June 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|105|||Both|18 Years|N/A|No|Non-Probability Sample|Study popululation description: Patients suffering from either: moderate psoriatic        arthritis and moderate psoriasis, mild psoriatic arthritis and moderate psoriasis or        moderate psoriatic arthritis and mild psoriasis, known from dermatologists participating        in the study.|July 2014|July 23, 2014|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01139918||120981|
NCT01143480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100129|Study of the Effect of Innate on the Inflammatory Response to Endotoxin|Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 2010|||||N/A|Observational|N/A|||Actual|67|||Both|18 Years|N/A|No|||October 2015|February 12, 2016|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143480||120709|
NCT01140165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A308|Cheese and Human Health|Effects of Hard Cheese and Butter on Markers of Cardiovascular Disease -A Randomized Controlled Dietary Human Intervention||University of Copenhagen|No|Active, not recruiting|January 2010|December 2011|Anticipated|June 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2009|June 8, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01140165||120962|
NCT01139944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z4102|Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer|Epigenetic Changes as Prognostic Markers in Patients With Early Stage Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Completed|July 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|99|Samples With DNA|tissue and blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with early stage non-small cell lung cancer and previously enrolled on        ACOSOG-Z0040 and Z0030.|July 2015|July 14, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01139944||120979|
NCT01141049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6123|Gabapentin for Abstinence Initiation in Alcohol Dependence|Gabapentin for Abstinence Initiation in Alcohol Dependence|GAINS|New York State Psychiatric Institute|Yes|Completed|August 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||July 2013|January 15, 2014|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141049||120894|
NCT01141270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN1001|Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application|Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application. A Randomised, Open Label, Cross Over Study||Polymun Scientific GmbH|No|Completed|January 2009|July 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||August 2010|August 3, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141270||120877|
NCT01141491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-0109DP001|Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free|A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free||MabVax Therapeutics, Inc.|No|Active, not recruiting|June 2010|September 2017|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|136|||Both|16 Years|N/A|No|||March 2016|March 8, 2016|June 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01141491||120860|
NCT01141257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pieris001|Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug|A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Angiocal® (PRS-050-PEG40) in Patients With Solid Tumors||Pieris AG|No|Completed|May 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01141257||120878|
NCT01141478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100104|Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria|Randomized Controlled Trial of Proton Beam Radiotherapy + Sorafenib vs. Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria||Loma Linda University|No|Recruiting|August 2010|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01141478||120861|
NCT01154257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/MRE09/44|Comparison of Swabs and Toothbrushes in Cleaning the Teeth of Mechanically Ventilated Patients|Comparison of Foam Swabs Versus Toothbrushes in Removing Dental Plaque From Orally Intubated Mechanically Ventilated Patients||Cardiff and Vale University Health Board|No|Enrolling by invitation|June 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2010|June 30, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01154257||119887|
NCT01154556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETRIeVE|RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice|Non-nucleoside Reverse Transcriptase Inhibitor Failure in a High HIV Caseload Australian Primary Care Practice||Holdsworth House Medical Practice||Completed|June 2010|February 2013|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|2044|||Both|N/A|N/A|No|Probability Sample|Demographic information will be collected from patient medical records for all patients        that have used previously, or are currently using an NNRTI as part of HIV treatment        therapy.|September 2015|September 17, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154556||119864|
NCT01154803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSF-nutcon02|Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection|Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Nigeria||Medecins Sans Frontieres|Yes|Completed|February 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2213|||Both|6 Months|59 Months|No|||October 2013|October 15, 2013|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154803||119845|
NCT01165580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22523|A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age|Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients < 4 Months of Age||Hoffmann-La Roche||Completed|May 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Both|N/A|124 Days|No|||March 2016|March 1, 2016|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165580||119021|
NCT01165593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01337|Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases|Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases||Kardium Inc.|No|Completed|November 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|96|||Both|N/A|N/A|No|Non-Probability Sample|Patients with atrial fibrillation who are deemed suitable for treatment of atrial        fibrillation by catheter-based ablation.|April 2015|April 15, 2015|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165593||119020|
NCT01165853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200412368|Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks|Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks on Hormones and Lipids|IPOP|University of California, Davis|Yes|Completed|July 2005|July 2012|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|40 Years|72 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165853||119000|
NCT01142219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-487 cep@hcpa.ufrgs.br|L-Arginine and Sickle Cell Disease|A Randomized, Controlled, Double-blind Clinical Trial of L-arginine as Adjuvant Therapy for Sickle Cell Disease||Hospital de Clinicas de Porto Alegre|Yes|Completed|September 2006|October 2009|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|1 Year|N/A|No|||June 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142219||120805|
NCT01142427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL08B1|Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|Yes|Recruiting|August 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|11750|Samples With DNA|Bone Marrow, Blood|Both|N/A|30 Years|No|Non-Probability Sample|Newly diagnosed acute leukemia|September 2015|September 30, 2015|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142427||120789|
NCT01142687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-05-113|Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis With a High Protein Very Low Calorie Diet|Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis Following 4 Weeks of Very Low Calorie Diet||University of California, Los Angeles|No|Completed|November 2008|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|58|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2009|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142687||120769|
NCT01142934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TegaCHGit01|Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections|A MULTICENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF TEGADERM CHG IN REDUCING CATHETER RELATED BLOOD STREAM INFECTIONS|TegaCHG|Catholic University of the Sacred Heart|Yes|Recruiting|October 2009|October 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1200|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01142934||120750|
NCT01143233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hipp2010|Suitability of an Infant Formula With Reduced Protein Content Based on a Partial Respectively Extensive Proteinhydrolysate With and Without Pro- and Prebiotics for the Particular Nutritional Use by Infants|Suitability of an Infant Formula With Reduced Protein Content Based on a Partial Respectively an Extensive Proteinhydrolysate With and Without Pro- and Prebiotics for the Particular Nutritional Use by Infants.|HippHA|HiPP GmbH & Co.|Yes|Completed|April 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|503|||Both|N/A|27 Days|Accepts Healthy Volunteers|||October 2014|October 24, 2014|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143233||120727|
NCT01143506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100131|Physiology of Volition Studied With Nerve Block|Physiology of Volition Studied With Nerve Block||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2010|January 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|May 9, 2012|June 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01143506||120707|
NCT01140178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 170910|A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx|A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.||Roswell Park Cancer Institute|Yes|Active, not recruiting|June 2010|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140178||120961|
NCT01140763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Histo-BC-001|Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer|Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer||Sysmex America, Inc.|Yes|Recruiting|August 2010|March 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Probability Sample|Patients with a previous diagnosis of breast cancer scheduled for sentinel lymph node        dissection.|August 2010|August 27, 2010|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140763||120916|
NCT01149382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUOA-03-ITP|Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients|Humoral Immune Response To Influenza Vaccine In Islet Cell In Transplant Recipients||University of Alberta|No|Completed|August 2010|December 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult islet cell transplant recipients|August 2012|August 17, 2012|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149382||120257|
NCT01149395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0417|Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn|Can Detection of Fragments of Cleaved E-cadherin in Tissue and/or Blood be of Value for Identifying and Monitoring Patients With PPI-responsive Heartburn?||University of North Carolina, Chapel Hill|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|75 Years|No|||June 2014|June 2, 2014|June 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01149395||120256|
NCT01149694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG08-PUR 0210-FIM001|A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers|A Randomized, Double-Blind, Parallel-Group, Single-Ascending Dose, Placebo-Controlled Safety and Tolerability Study of PUR 0110 Rectal Enema in Normal Healthy Volunteers||PurGenesis Technologies Inc.|No|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2010|June 23, 2010|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149694||120233|
NCT01150006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET_Adipokines|Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)|Correlation Between Various Adipokines and Vascular Inflammation Measured by 18FDG-PET In Healthy Male Subjects||Korea University|Yes|Completed|April 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|90|Samples Without DNA|whole blood, plasma, serum|Male|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male participats who underwent a medical health check in the health promotion        center in Korea Guro University|April 2010|June 28, 2010|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01150006||120209|
NCT01141764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014496|Cerebral Metabolic Changes Associated With Thalamic Stimulation|Cerebral Metabolic Changes Associated With Thalamic Stimulation||The Hospital for Sick Children|No|Terminated|March 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|85 Years|No|||November 2014|November 20, 2014|June 7, 2010||No|Very slow and infrequent recruitment, availability of the imaging procedure at Adult Centre|No||https://clinicaltrials.gov/show/NCT01141764||120840|
NCT01142024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2009-296|Polymorphism of Oxidative Stress Genes in the Pathogenesis and Antioxidant Prevention of Contrast Induced Nephropathy|Polymorphism of Oxidative Stress Relative Genes in Contrast Medium Induced Nephropathy:Implications in the Pathogenesis and the Effect of Antioxidant prevention-a Prospective,Randomized,Controlled Study||Huashan Hospital|Yes|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1000|||Both|18 Years|80 Years|No|||December 2009|June 23, 2011|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01142024||120820|
NCT01155583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1A09|Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Case Comprehensive Cancer Center|Yes|Recruiting|June 2010|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155583||119785|
NCT01155882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0767 / 201105335|Registry Study - Whipple at the Splenic Artery|Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study|WATSA|Washington University School of Medicine|No|Recruiting|September 2010|September 2021|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|25|||Both|18 Years|85 Years|No|Non-Probability Sample|Participants will be identified from PI's patient population or referrals from colleagues.|March 2016|March 8, 2016|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155882||119762|
NCT01155895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA15735|Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2004|April 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155895||119761|
NCT01155037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP-H1N1|Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults|Phase 2 Study to Evaluate the Safety of and the Immunogenicity to an Adjuvanted A(H1N1)v Influenza Vaccine in HIV-Infected Adults|VIP-H1N1|Oswaldo Cruz Foundation|No|Active, not recruiting|March 2010|April 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|450|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155037||119827|
NCT01156922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1321|B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome|B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Severely Affected Chronic Fatigue Syndrome Patients. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment for Patients in WHO Performance Status III-IV||Haukeland University Hospital|No|Active, not recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|66 Years|No|||November 2015|November 30, 2015|July 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156922||119682|
NCT01141985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT-001h|New Disposable Contact Lens Patient Interface For The Lensx Laser|Evaluation Of A New Disposable Contact Lens Patient Interface For The Lensx Laser In Cataract And Corneal Surgery||LenSx Lasers Inc.|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|110|||Both|24 Years|N/A|No|||October 2014|October 20, 2014|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01141985||120823|
NCT01142700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI451-004|A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I|A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I||Bristol-Myers Squibb|No|Withdrawn|July 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|70 Years|No|||March 2011|March 14, 2011|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01142700||120768|
NCT01142947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI079139|Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)|Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)|SAPPHIRE|Henry Ford Health System|Yes|Recruiting|October 2007|February 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|808|||Both|12 Years|56 Years|No|||August 2015|August 17, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01142947||120749|
NCT01143220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JASMINE 0709|Japanese Assessment of Indication Based Programming|Japanese Assessment of Indication Based Programming|JASMINE|Guidant Corporation|No|Completed|August 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|235|||Both|20 Years|N/A|No|Non-Probability Sample|The patient population comprises the standard patient population of the participating        sites indicated for the intended devices per local guidelines in the study centers.|August 2013|August 27, 2013|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143220||120728|
NCT01143493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100130|The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease|The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 2010|||||N/A|Observational|Time Perspective: Prospective|||Actual|272|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|February 12, 2016|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143493||120708|
NCT01142973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mdksu-mdct-001|The Clinical Course of Coronary Artery Disease in Coronary Multidetector Computed Tomographic Angiogram|Prognostic Role of Coronary Artery plaquEs in Patients With Suspected Coronary Artery Disease Using Multislice of Computed Tomography (PREDICT)|PREDICT|Inje University|No|Recruiting|September 2005|December 2010|Anticipated|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|5000|||Both|18 Years|85 Years|No|Non-Probability Sample|present typical/atypical chest pain|September 2010|September 10, 2010|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01142973||120747|
NCT01143246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-4001-HRS-301|A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin|Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial)||Ikaria|Yes|Completed|September 2010|May 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143246||120726|
NCT01143519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100134|Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage|Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 2010|||||N/A|Observational|N/A|||Actual|105|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|February 12, 2016|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143519||120706|
NCT01143831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1240|Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation|Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation||University of North Carolina, Chapel Hill|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|20 Years|85 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143831||120682|
NCT01149096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCT0631D|Collection of Bone Marrow From Donors Treated With or Without Filgrastim|A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631||Children's Oncology Group|Yes|Completed|June 2010|||December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|13|Samples With DNA|bone marrow|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients treated with or without Filgrastim.|February 2016|February 19, 2016|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01149096||120279|
NCT01142284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021-KOA-0901i|Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety|Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety in Peripheral Artery Disease Subjects Complicated With Coronary Artery Disease.||Korea Otsuka Pharmaceutical Co.,Ltd.|Yes|Recruiting|April 2010|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|224|||Both|40 Years|79 Years|No|||June 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142284||120800|
NCT01142804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-31708|WalkLink: Internet-based Walking Program|WalkLink:Internet-based Walking Program for Cardiovascular Disease Risk-Reduction|WalkLink|Milton S. Hershey Medical Center|Yes|Completed|August 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|308|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142804||120760|
NCT01143012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Group eczema education visits|Group Eczema Education Visits:Impact on Patient and Family Quality of Life|Group Eczema Education Visits:Impact on Patient and Family Quality of Life||Oregon Health and Science University|No|Recruiting|May 2010|||August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|2 Months|6 Years|No|||May 2010|August 1, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01143012||120744|
NCT01150305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 08041|Epidemiology of Non-syndromic Dominant Deafness|Genetic Epidemiology of Non-syndromic Dominant Deafness|SURDOM|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|183|Samples With DNA|Peripheral whole blood|Both|4 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|families with non syndromic dominant hearing impairment followed by the clinical        investigators|August 2013|August 6, 2013|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01150305||120186|
NCT01163656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007533|Comparing Use of the Glidescope Cobalt to Direct Laryngoscopy in Infants|A Prospective Comparison of the Glidescope Cobalt to Standard Direct Laryngoscopy in Infants||Children's Hospital of Philadelphia|No|Completed|July 2010|March 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|N/A|1 Year|No|||January 2013|January 24, 2013|July 13, 2010||No||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01163656||119169|
NCT01163929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12186|A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer|A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer||University of Kansas Medical Center|Yes|Withdrawn|July 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|65 Years|No|||October 2012|October 22, 2012|July 14, 2010|Yes|Yes|Study closed by Protocol Review Monitoring Committee because of lack of accrual|No||https://clinicaltrials.gov/show/NCT01163929||119148|
NCT01156181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-007|Effect of Cervical Discharge Removal During ET on Pregnancy Rate|Effect of Cervical Discharge Removal Before Embryo Transfer on ICSI Cycle Outcomes||Royan Institute|Yes|Completed|May 2009|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|492|||Female|18 Years|40 Years|No|||July 2010|September 20, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156181||119739|
NCT01153737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/1320|Manual Therapy Effectiveness in Comparison With Electric Nerve Stimulation (TENS) in Patients With Neck Pain|Primary Care Randomized Clinical Trial: Manual Therapy Effectiveness in Comparison With TENS in Patients With Neck Pain||Gerencia Atencion Primaria Area 3|Yes|Completed|May 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|60 Years|No|||February 2011|February 15, 2011|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153737||119927|
NCT01157221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200612088R|Prediction Frozen Shoulder Validation|Determining Shoulder Kinematics in the Prediction of Progress of Frozen Shoulder Syndrome: a Prediction Method, Validation of the Method, and Clinical Application||National Taiwan University Hospital|Yes|Completed|August 2006|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2010|July 2, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01157221||119659|
NCT01142986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DA012347|Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance|Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance||Johns Hopkins University|No|Completed|July 2010|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|223|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142986||120746|
NCT01142453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDHF PMS|An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients|Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its Monitoring||Merck KGaA||Completed|May 2005|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|231|Samples With DNA|Whole blood|Both|N/A|N/A|No|Probability Sample|Subjects with clinically ensured diagnosis and history of attacks or episodes of a MS and        on one of the permitted basis therapies at least since 6 months were enrolled for the case        series|June 2010|July 11, 2014|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142453||120787|
NCT01142713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-EG-0681-09-TLV-CTIL|The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study|The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study||Tel-Aviv Sourasky Medical Center||Not yet recruiting|August 2010|December 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142713||120767|
NCT01142726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-226|Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis|A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA||Bristol-Myers Squibb|No|Completed|December 2010|October 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|511|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 3, 2010|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01142726||120766|
NCT01142960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-ZH73|Effects of Vitamin C and Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population|Effects of Vitamin C and Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population||The Hong Kong Polytechnic University|Yes|Not yet recruiting|July 2010|December 2013|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|420|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||May 2010|June 11, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142960||120748|
NCT01139957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8199|Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer|Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants||Gynecologic Oncology Group||Active, not recruiting|June 2010|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1916|||Female|30 Years|N/A|No|Probability Sample|Woman at increased genetic risk of ovarian cancer|June 2015|June 3, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01139957||120978|
NCT01140243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030|Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital|Efficacy and Suitability of Infant Formula With a Special Fat Formulation for Premature Infants Following Discharge From Hospital Following Discharge From Hospital||Materna Laboratories|Yes|Completed|July 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|N/A|6 Weeks|Accepts Healthy Volunteers|||April 2012|May 27, 2013|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140243||120956|
NCT01140256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|585-Ped/ERC-06|Longitudinal Zinc Intakes and Exchangeable Zinc Pool Sizes in Breastfed Small for Gestational Age vs Appropriate for Gestational Age Infants in Pakistan|Longitudinal Zinc Intakes and Exchangeable Zinc Pool Sizes in Breastfed Small for Gestational Age vs Appropriate for Gestational Age Infants in Pakistan|EZP|Aga Khan University|No|Completed|January 2007|July 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|N/A|48 Hours|Accepts Healthy Volunteers|Non-Probability Sample|SGA and AGA infants born to healthy mothers.|July 2009|June 8, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01140256||120955|
NCT01143844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|804237|Assessing Fertility Potential in Female Cancer Survivors|Assessing Fertility Potential in Female Cancer Survivors||University of Pennsylvania|No|Recruiting|March 2006|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|400|Samples With DNA|Serum|Female|11 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with a history of cancer, or other conditions treated by chemotherapy, will be        identified through local survivorship programs or self-referral. In addition, two groups        of regularly menstruating unexposed subjects will be recruited through local advertising:        a group of similar-age subjects and another group in the late reproductive years. Exposed        and unexposed controls will be frequency matched with respect to age (within 2 years) at        enrollment. In addition,subjects will be balanced with respect to self reported        race/ethnicity. Enrollment is purposefully targeted and stratified for this study to        reflect the population in the pediatric and adult oncology practices.|March 2015|March 17, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143844||120681|
NCT01142050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cellonis-CR-2.3|Stem Cell Therapy for Type 2 Diabetes Mellitus|A Open Labeled and Self Controlled, Safety/Efficacy Assessed Pilot Study on Transplantation Therapy Using Bone Marrow Mesenchymal Stem Cells for Insulin Resistance of Type 2 Diabetes Mellitus||Cellonis Biotechnology Co. Ltd.||Not yet recruiting|August 2010|December 2011|Anticipated|August 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||June 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142050||120818|
NCT01143025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 01 2010|Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery|Peritoneal Nebulization of Ropivacaine for Postoperative Pain Control After Laparoscopic Cholecystectomy||San Gerardo Hospital|No|Completed|March 2010|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|75 Years|No|||May 2010|May 18, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01143025||120743|
NCT01143311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-05|Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma|||Centre Hospitalier Universitaire de Nice|No|Terminated|June 2010|April 2011|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|40 Years|N/A|No|||June 2010|May 31, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01143311||120721|
NCT01143610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115-2007|A New Therapeutic Approach for Root Coverage|A New Regenerative Therapeutic Approach for Root Coverage: a Randomized Clinical Trial||University of Sao Paulo|No|Completed|February 2008|February 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|April 30, 2010||No||No|October 29, 2011|https://clinicaltrials.gov/show/NCT01143610||120699|
NCT01143623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-SBC-2-DAN-03|Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults|Dose Response Effect of a Proprietary Probiotic Formula for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults||Changhai Hospital|No|Completed|May 2010|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|510|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||September 2011|September 19, 2011|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143623||120698|
NCT01143285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-APN-03|Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer|Chimiodiet Study:Impact of Early and Active Nutritional and Dietary Management on grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer.|CHIMIODIET|Centre Hospitalier Universitaire de Nice|No|Recruiting|April 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||December 2011|February 22, 2013|July 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01143285||120723|
NCT01143298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 27847-K01|LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects|LEO 27847 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects||LEO Pharma|No|Completed|June 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|December 10, 2013|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01143298||120722|
NCT01164488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25293|A Study of RO5190591 (Danoprevir) in Healthy Volunteers|A Two-Way Interaction Study Between RO5190591/RTV and Ketoconazole in Healthy Subjects||Hoffmann-La Roche||Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01164488||119105|
NCT01164202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000681319|Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer|A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)||National Cancer Institute (NCI)||Recruiting|July 2010|||July 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|190|||Both|18 Years|N/A|No|||July 2010|July 24, 2010|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164202||119127|
NCT01156402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030425PC062 03 (Meharry IRB)|Childhood Obesity Prevention Program for Hispanics|Culturally-Appropriate Childhood Obesity Prevention Program for Hispanic Families||Meharry Medical College|No|Active, not recruiting|May 2010|November 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|650|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01156402||119722|
NCT01165606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physiotherapy|Effects of Respiratory Physiotherapy in Critically Ill Patients Ventilated for More Than 48 Hours|||Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude|No|Completed||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A|No|||July 2010|July 19, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165606||119019|
NCT01165866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8031/08|Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis|Ondansetron Vs Metoclopramide in the Treatment of Vomiting in Gastroenteritis Patients: A Randomized Controlled Trial||Hamad Medical Corporation|Yes|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|1 Year|14 Years|No|||October 2010|October 25, 2010|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01165866||118999|
NCT01166165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-TL-2010-2|Effect of Vitamin D Replacement During Winter Months in Patients With Hypertension|Effect of Cholecalciferol on 24-hr ABPM and Vasoactive Hormones in Patients With Hypertension.||Regional Hospital Holstebro|Yes|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166165||118976|
NCT01151605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1934|The Suppression of Toll Like Receptors by Insulin|The Suppression of Toll Like Receptors by Insulin||Kaleida Health|No|Active, not recruiting|September 2008|December 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151605||120089|
NCT01151618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1018-FOTVal-SS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2010|||||N/A|N/A|N/A||||||||||||||December 28, 2010|June 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01151618||120088|
NCT01151631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICON-01|Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache|Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache|ICON|Leiden University Medical Center|Yes|Recruiting|October 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01151631||120087|
NCT01142232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005-06; IUCRO-0290|Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma|Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma||Indiana University|Yes|Recruiting|August 2010|June 2017|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142232||120804|
NCT01142466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 25874|A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone|Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone|REMAIN|Merck KGaA|No|Completed|December 2005|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||January 2014|January 26, 2014|June 10, 2010||No||No|April 7, 2011|https://clinicaltrials.gov/show/NCT01142466||120786|
NCT01142739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/20|Phosphorylation of ERK1/2 in Patients With Parkinson's Disease|A Descriptive Study of Lymphocytic Phosphorylation of ERK1/2 in Patients With Parkinson's Disease With Dyskinesias and in Controls|BIODYS (1)|University Hospital, Bordeaux|No|Completed|June 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|Samples With DNA|whole blood urine|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive eligible PD in- and outpatients selected at the university hospital of        bordeaux and subjects without known neurological disorder in a community sample.|July 2012|July 30, 2012|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01142739||120765|
NCT01152840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0710-050-223|Study of RAD001 in Adenoid Cystic Carcinoma|Phase II Study of RAD001monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma|ACCRAD001|Seoul National University Hospital|Yes|Completed|July 2008|December 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2010|May 19, 2015|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01152840||119994|
NCT01153061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-0201/10-TEF|Endoscopic Closure of Tracheoesophageal Fistulas With Occluder Device|Endoscopic Closure of Tracheoesophageal Fistulas With a Cardiac Septal Defect Occluder|TEFGoreHelex|University of Sao Paulo|Yes|Terminated|June 2010|December 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|14 Years|N/A|No|||March 2013|March 18, 2013|June 8, 2010||No|The study was terminated because the rate of prothesis dislocation was too high.|No||https://clinicaltrials.gov/show/NCT01153061||119977|
NCT01140477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|650|Toric Intraocular Lens Following Cataract Surgery|A Prospective Multicenter Clinical Trial To Evaluate the Effectiveness of A Toric Accommodating Posterior Chamber Silicone Intraocular Lens Designed To Provide Near, Intermediate, And Distance Vision And Reduce The Effects Of Preoperative Corneal Astigmatism On Postoperative Refraction Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|June 2010|October 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|June 8, 2010|Yes|Yes||No|August 7, 2014|https://clinicaltrials.gov/show/NCT01140477||120938|
NCT01153074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP01089/09-TBF|Bronchoscopic Closure of Bronchopleural Fistulas With Occlutech Figulla ASD N Occluder Device|Bronchoscopic Closure of Bronchopleural Fistulas With Occlutech Figulla ASD N Occluder Device||University of Sao Paulo|Yes|Recruiting|June 2010|January 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|14 Years|N/A|No|||March 2013|March 18, 2013|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153074||119976|
NCT01143324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MASTERS-D Study|A Prospective, Multicenter Observational Study on MAST™ (Minimal Access Spinal Technologies) Fusion Procedures for the Treatment of the Degenerative Lumbar Spine|A Prospective, Multicenter Observational Study on MAST™ (Minimal Access Spinal Technologies) Fusion Procedures for the Treatment of the Degenerative Lumbar Spine (MASTERS-D)|MASTERS-D|Medtronic Spinal and Biologics|No|Completed|June 2010|August 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|255|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population comprises individuals that have an indication for a single or        double level instrumented lumbar fusion for the treatment of the degenerative lumbar spine        causing back and/or leg pain.        Patients enrolled in this study will receive a single or double level instrumented fusion        using PLIF or TLIF techniques via a MAST™ procedure.|January 2016|January 26, 2016|June 11, 2010||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01143324||120720|Limitations of this study include the lack of a direct comparison of outcomes of minimally invasive surgery and open surgery, since it was designed as an observational trial and not designed as a randomized controlled trial.
NCT01143636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002048|Transcranial Direct Stimulation in Chronic Pelvic Pain|Investigation and Treatment of Central Nervous System Dysfunction in Chronic Pelvic Pain.||Spaulding Rehabilitation Hospital|No|Active, not recruiting|April 2010|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|68|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01143636||120697|
NCT01143649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p001808|Use of Transcranial Direct Current Stimulation (tDCS) Coupled With Constraint Induced Movement Therapy in Stroke Patient|Effects of Transcranial DC Stimulation Coupled With Constraint Induced Movement Therapy on Motor Function in Stroke Patients|tdcs|Spaulding Rehabilitation Hospital|No|Active, not recruiting|April 2010|||April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01143649||120696|
NCT01163942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flagship AA trial|Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)|A RANDOMIZED CONTROLLED STUDY IN NEWLY DIAGNOSED SEVERE APLASTIC ANEMIA PATIENTS RECEIVING ANTITHYMOCYTE GLOBULIN (ATG), CYCLOSPORIN A, WITH OR WITHOUT G-CSF|SAA-G-CSF|European Group for Blood and Marrow Transplantation|Yes|Terminated|March 2001|November 2010|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|205|||Both|N/A|N/A|No|||July 2010|April 2, 2015|July 14, 2010||No|Ceased production of the study drug, Lymphoglobulin. Recruitment of patients onto the trial    was too slow.|No||https://clinicaltrials.gov/show/NCT01163942||119147|
NCT01164475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ11809|Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms|A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg||Sanofi|No|Completed|October 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|78 Years|No|||February 2014|February 7, 2014|July 9, 2010|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT01164475||119106|
NCT01164501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.36|Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|July 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|741|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|July 15, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01164501||119104|In this trial, only patients with mild or moderate renal impairment were analysed. Patients with severe or no renal impairment were not analysed.
NCT01164748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL22080.060.08|Lymphatic Mapping After Previous Breast Surgery|Lymphatic Mapping After Previous Breast Surgery|LABS|Catharina Ziekenhuis Eindhoven||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Female|18 Years|N/A||Non-Probability Sample|We included patients that received BCT with SNB and/or ALND for primary breast cancer        located in the upper-outer quadrant of one breast at least 3 years before this analysis.        Patients were excluded if they had breast surgery for other reasons than breast cancer,        had recurrent breast cancer or had a former allergic reaction to 99mTc-colloidal-albumin.        44 patients were included and were divided into two groups according to previous surgical        treatment of the axilla, being the sentinel node biopsy group and the Axillary Lymph Node        Dissection group|July 2010|July 16, 2010|July 16, 2010||||No||https://clinicaltrials.gov/show/NCT01164748||119085|
NCT01164761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|074-05|Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions|A Two-way Open Label Crossover Experimental Evaluation of Relative Bioavailabilities of Ramipril 10 mg Capsules of Dr.Reddy's Laboratories and ALTACE@ 10 mg Capsules of King Pharmaceuticals in Healthy Adult Human Male Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2005|October 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 16, 2010|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164761||119084|
NCT01165619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200204347-BL|Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders|Detailed Clinical, Biochemical and Genetic Characterization in GnRH Deficiency Disorders||Massachusetts General Hospital|No|Terminated|June 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|50|Samples With DNA|serum, plasma, DNA|Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|The reproductive disorder populations will be recruited from the reproductive endocrine        clinic at the Mass General Hospital. The control populations will be recruited from Boston        and surrounding communities|May 2011|May 23, 2011|July 16, 2010||No|the Principal Investigator left the institution|No||https://clinicaltrials.gov/show/NCT01165619||119018|
NCT01162486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP-5779|Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers|Phase I Dose Escalation Study of the Pharmacokinetics, Safety and Tolerability of Rifapentine and the Effects of Increasing Doses of Rifapentine on Induction of Metabolizing Enzymes in Healthy Volunteers|TBTC S29B|Johns Hopkins University|Yes|Completed|April 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 1, 2013|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01162486||119259|
NCT01151956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBIMQ465-AK-08|Imiquimod and Actinic Keratoses: an Observational Study|Actinic Keratoses and 5% Topical Imiquimod: Lessons to Learn From a Prospective Non-Interventional Study by 93 Office-based Dermatologists||Federal University Teaching Hospital, Feldkirch, Austria|Yes|Completed|May 2008|May 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|463|||Both|N/A|N/A|No|Non-Probability Sample|patients with actinic keratoses who are routinely treated with topical 5% Imiquimod by        non-hospital based dermatologists|April 2008|June 30, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01151956||120062|
NCT01152567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSE-ATA-2010/1|Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension|Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension|ARBACE|AstraZeneca|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|50000|||Both|17 Years|N/A|No|Non-Probability Sample|Patient treated with ACE or candesartan in the period 1999 - 2007.|September 2011|September 26, 2011|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01152567||120015|
NCT01143259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intermountain Alvimopan1017978|Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use|A Randomized, Double Blind, Placebo Controlled Study to Study Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use||Intermountain Health Care, Inc.|No|Completed|May 2010|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||April 2014|August 25, 2014|May 24, 2010||No||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01143259||120725|
NCT01143532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100135|Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes|Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes||National Institutes of Health Clinical Center (CC)||Completed|May 2010|||||N/A|Observational|Time Perspective: Retrospective|||Actual|7|||Both|18 Years|N/A|No|||October 2015|February 18, 2016|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143532||120705|
NCT01143857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810580|Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement|Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement||University of Pennsylvania|Yes|Withdrawn|June 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 14, 2013|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143857||120680|
NCT01152541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPO-CXL-001|Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin|Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin||Cornea and Laser Eye Institute|No|Recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01152541||120017|
NCT01152554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00007|A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy||AstraZeneca|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|813|||Both|18 Years|65 Years|No|||March 2014|March 14, 2014|June 28, 2010|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT01152554||120016|
NCT01141504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2010-CS01|Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance|Effect of Oral ATP on Human Muscle Performance||Metabolic Technologies Inc.|No|Completed|June 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|16|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01141504||120859|
NCT01148836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-497|Coenzyme Q-10 and Pulmonary Arterial Hypertension|Coenzyme Q-10 in the Treatment of Pulmonary Arterial Hypertension||The Cleveland Clinic|No|Completed|January 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|March 19, 2010||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01148836||120299|Length of the trial and number of subjects enrolled were both study limitations.
NCT01142518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP28169|An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone|A Prospective Analysis of MS Patients After Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment|RETURN|Merck KGaA||Completed|July 2005|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|Samples With DNA|Blood samples|Both|N/A|N/A|No|Probability Sample|A group of MS subjects who will be treated with Rebif after being previously treated with        mitoxantrone|March 2014|March 17, 2014|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142518||120782|
NCT01142531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/10-02-13/3862|Effects of Bronchodilation on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent.|Effects of Bronchodilation on CT Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent: Comparisons Between CT Scans Obtained Before and After Bronchodilation and Relationships With Pulmonary Function Tests.||Erasme University Hospital|No|Completed|March 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|COPD patients aged 40 or more, with a smoking history of > 10 PY and a post-bronchodilator        FEV1/VC < 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory        infection in the 4 weeks before the begin of the study, concomitant pulmonary disease        (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active        malignancy or malignancy of any organ system within the past 5y.|July 2012|July 3, 2012|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01142531||120781|
NCT01142817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-001315|Metabolic and Psychological Changes Associated With Menopause Among Women With HIV|Metabolic and Psychological Changes Associated With Menopause Among Women With HIV||Massachusetts General Hospital|No|Completed|June 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|66|Samples Without DNA|Whole blood, serum|Female|45 Years|52 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female subjects in the perimenopausal transition will be recruited via referral by        infectious disease providers, newspaper advertisement, posted flyers, community based        programs at local AIDS Service Organizations and Partners subject recruitment broadcast at        Massachusetts General Hospital (MGH). The HIV negative control subjects will be recruited        through advertisements, flyers, and email announcements. Both HIV positive and negative        subjects will be recruited from the same neighborhoods to ensure similar demographic        characteristics.|August 2013|August 6, 2013|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142817||120759|
NCT01143038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080435|Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim|A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim||Amgen|No|Completed|November 2010|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|June 10, 2010|Yes|Yes||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01143038||120742|
NCT01143337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-435-J04|Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis|A Multicenter Randomized, Double-blind, Placebo-controlled Study of MP-435 in Combination With MTX in Patients With Rheumatoid Arthritis - Exploratory Study||Mitsubishi Tanabe Pharma Corporation|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|20 Years|75 Years|No|||October 2014|October 7, 2014|June 9, 2010||No||No|September 10, 2014|https://clinicaltrials.gov/show/NCT01143337||120719|
NCT01143350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-09|Non Pharmacological Treatment in Alzheimer's Disease and Associated Disorders|||Centre Hospitalier Universitaire de Nice||Terminated|March 2010|March 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|300|||Both|65 Years|N/A|No|||March 2010|May 31, 2011|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01143350||120718|
NCT01143662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1007IFN|Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B|A Multi-center, Randomized, Open-label and Positive Controlled Phase II Clinical Trial to Assess Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Patients With Chronic Hepatitis B||Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|July 2010|April 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|205|||Both|18 Years|60 Years|No|||June 2010|January 31, 2013|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143662||120695|
NCT01163994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-0510|Antibiotic Treatment of Multiple Erythema Migrans|Comparison of Ceftriaxone and Doxycycline for Treatment of Multiple Erythema Migrans||University Medical Centre Ljubljana|No|Recruiting|June 2010|||October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|720|||Both|15 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 30, 2014|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01163994||119143|
NCT01164020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creatine and Cognition|Creatine Supplementation and Cognition|||University of Sao Paulo|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|56|||Female|60 Years|N/A|No|||January 2013|January 17, 2013|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164020||119141|
NCT01164774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-05|Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions|A Two-way Open Label Crossover Experimental Evaluation of Relative Bioavailabilities of Ramipril 10 mg Capsules of Dr.Reddy's Laboratories and ALTACE@ 10 mg Capsules of King Pharmaceuticals in Healthy Adult Human Male Subjects Under Non-fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2005|November 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 16, 2010|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164774||119083|
NCT01164787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-028-TRAN-2006|Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healthy, Adult, Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2006|May 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 16, 2010|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164787||119082|
NCT01164449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0910|Usability of Blood Glucose Control With the Space TGC System in Medical ICU Patients|Monocentric, Open Study to Investigate the Usability of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) Over a Glucose Control Range of 4.4 to 8.3 mmol/L in Medical ICU Patients|DELIOS 4|B. Braun Melsungen AG|No|Completed|July 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164449||119108|
NCT01164462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO00439-48|Feasibility and Limitations of Offering Community Based Rapid HIV Testing to Men Who Have Sex With Men (MSM)||DRAG|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|March 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|357|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 26, 2012|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164462||119107|
NCT01164735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8013|Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression as Well as Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated With Anthracycline-Based Therapy||Gynecologic Oncology Group||Not yet recruiting|January 2100|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|169|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with Stage III, Stage IV, or recurrent endometrial cancer|June 2015|June 3, 2015|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01164735||119086|
NCT01151930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCB01A-01-B|Long-Term Compassionate Use Study for Continued Administration of SCB01A-01|Long-Term Compassionate Use Study for Continued Administration of SCB01A In Subjects Who Completed Treatment With SCB01A in the Previous Protocol # SCB01A-01||SynCore Biotechnology Co., Ltd.|No|Available|September 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 1|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||September 2015|September 9, 2015|June 23, 2010|No|Yes||||https://clinicaltrials.gov/show/NCT01151930||120064|
NCT01151943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/15|Comparison of Two Types of Pain Relief After Cesarean Delivery|Comparison of Two Methods of Pain Relief After Cesarean Delivery: Transversus Abdominis Plane (TAP) Block Versus Incisional Infiltration With Local Anesthetic|Cesar-Dol|Hopital Foch|No|Terminated|October 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|40 Years|No|||July 2012|July 12, 2012|June 24, 2010||No|The study has been halted prematurely beacuse of the occurence of convulsions in one case    after TAP block.|No||https://clinicaltrials.gov/show/NCT01151943||120063|
NCT01152255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6186-007|MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK6186 in HIV-1 Infected Patients||Merck Sharp & Dohme Corp.|No|Terminated|October 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|18|||Both|18 Years|55 Years|No|||October 2015|October 16, 2015|June 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01152255||120039|
NCT01148849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGAH22-01|Safety Study of MGAH22 in HER2-positive Carcinomas|A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available||MacroGenics|No|Active, not recruiting|July 2010|March 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01148849||120298|
NCT01148862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP235/Z25|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2010|||||N/A|N/A|N/A||||||||||||||September 10, 2012|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01148862||120297|
NCT01141283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3012S|Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase|Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Mod to Sev OA Pain of Hip or Knee: A 6-Month Open-label Extension Phase||Purdue Pharma LP|No|Completed|April 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|290|||Both|40 Years|75 Years|No|||August 2012|August 27, 2012|June 2, 2010|Yes|Yes||No|July 28, 2010|https://clinicaltrials.gov/show/NCT01141283||120876|
NCT01142297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0156H|Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes|A Randomized, Controlled Trial Comparing the Stability of SLA Implants and SLActive Implants Using Resonance Frequency Analysis for Patients With Type 2 Diabetes Mellitus||The University of Texas Health Science Center at San Antonio|No|Completed|July 2008|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|April 29, 2010|Yes|Yes||No|October 27, 2014|https://clinicaltrials.gov/show/NCT01142297||120799|
NCT01141777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAK-GLE_Spirulina|The Effects of Spirulina Platensis on Insulin Resistance in HIV-infected Patients|The Effects of Spirulina Platensis on Insulin Resistance in HIV-infected Patients||Yaounde Central Hospital|No|Completed|October 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|33|||Both|21 Years|N/A|No|||September 2010|January 3, 2011|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01141777||120839|
NCT01142830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-HSG 01-2009|Incidence of Pain After Craniotomy in Children|Prospective Multicenter Cohort Study Evaluating Incidence and Intensity of Postoperative Pain in Pediatric Patients After Craniotomy|Brainpain|San Gerardo Hospital|No|Completed|March 2009|December 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|1 Month|10 Years|No|Non-Probability Sample|330 paediatric patients undergoing major craniotomy from the following Italian Hospitals:        Policlinico Universitario Catania Ospedale Gaslini, Genova Ospedale Regina Margherita,        Torino Ospedale Gemelli, Roma Ospedale Meyer, Firenze Ospedale Civile di Padova Ospedale        Riuniti di Bergamo Ospedale San Gerardo di Monza|February 2013|February 22, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01142830||120758|
NCT01143051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-B|Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers|Phase I/II Study Epinephrine Inhalation Aerosol USP, an HFA-MDI Clinical Study-B for Assessment of Pharmacokinetics||Amphastar Pharmaceuticals, Inc.|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 7, 2010|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT01143051||120741|
NCT01143363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/444-7|Effect of High-intensity Intermittent Sprinting on Appetite Control on Obese Volunteers|Acute Effects of High-intensity Intermittent Sprinting vs. Moderate Intensity Continuous Cycling on Appetite Control on Obese Volunteers||Norwegian University of Science and Technology|No|Completed|May 2010|June 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01143363||120717|
NCT01143675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFOB-Hum|Influence of Local Bone Status on Complications After Surgical Treatment of Proximal Humerus Fractures|The Influence of Local Bone Status on Complications After Surgical Treatment of Proximal Humerus Fractures||AO Clinical Investigation and Documentation|No|Completed|March 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|148|||Both|50 Years|90 Years|No|Non-Probability Sample|Orthopedic and trauma clinics|June 2010|June 14, 2010|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143675||120694|
NCT01143688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P-002045|Characterization of Placebo Responses in Stable Asthma|Characterization of Placebo Responses in Stable Asthma||Brigham and Women's Hospital|No|Completed|January 2005|January 2009|Actual|January 2009|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|80 Years|No|||June 2010|June 11, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01143688||120693|
NCT01164215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0918|Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy|Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|February 2010|September 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|N/A|N/A|No|||October 2015|October 7, 2015|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01164215||119126|
NCT01163695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5337|The SUUBI Program: Asset-Ownership for Orphaned Children in Uganda|The SUUBI Program: Creating Asset-Ownership Opportunities and Health Promotion Among Orphaned Children in Uganda|SUUBI|Columbia University|No|Completed|June 2005|January 2009|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|286|||Both|11 Years|17 Years|No|||March 2014|March 13, 2014|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163695||119166|
NCT01164254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908152|Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-hour Recall|Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-Hour Recall (ACT24)||National Institutes of Health Clinical Center (CC)||Completed|May 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|25000|||Both|50 Years|75 Years|No|||December 2015|December 15, 2015|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164254||119123|
NCT01164228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000681614|Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery|A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features||Eastern Cooperative Oncology Group|No|Recruiting|June 2010|||June 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2012|July 24, 2014|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164228||119125|
NCT01164241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100148|Natural History of Diseases Associated With Allergic Inflammation: Atopic Dermatitis and Genetic and Congenital Diseases Associated With Atopic Pathways|Natural History of Atopic Dermatitis and Other Genetic/Congenital Diseases Associated With Allergic Inflammation||National Institutes of Health Clinical Center (CC)||Recruiting|June 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|2 Years|80 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164241||119124|
NCT01165112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOC 2502|Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma|A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)|TREC|University of Washington|No|Active, not recruiting|September 2010|||June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|June 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165112||119057|
NCT01165424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06333|A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)|A Study of Long-term (12-24 Weeks) Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No. P06333)||Merck Sharp & Dohme Corp.|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|3 Years|15 Years|No|||July 2015|July 1, 2015|May 28, 2010|No|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT01165424||119033|
NCT01141075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-012-MMA|Ataluren for Nonsense Mutation Methylmalonic Acidemia|A Phase 2 Study of Ataluren (PTC124®) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia||PTC Therapeutics|No|Suspended|June 2010|October 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|2 Years|N/A|No|||October 2011|October 31, 2011|June 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01141075||120892|
NCT01141088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-2010-02|Clinical Outcomes of Endoscopic Bilateral Stent-in-stent Placement Followed by Side-by-side Method With Newly Designed Metallic Stent for Malignant Hilar Biliary Strictures|||Soon Chun Hyang University|Yes|Recruiting|June 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||June 2010|March 9, 2011|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141088||120891|
NCT01152580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-88|Melatonin Osteoporosis Prevention Study|Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women|MOPS|Duquesne University|No|Completed|September 2008|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Female|45 Years|54 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|June 28, 2010||No||No|January 4, 2012|https://clinicaltrials.gov/show/NCT01152580||120014|Limitations to this study include small sample sizes, length of follow-up, and heterogeneity in terms of stage of perimenopause and prevalence of menopausal symptoms.
NCT01152853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1004-031-315|PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer|A Phase II Open Label Trial of PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer After Failure of At Least One Prior Chemotherapy Regimen|PF299804-AGC|Seoul National University Hospital|No|Completed|July 2010|September 2012|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||May 2015|November 17, 2015|June 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01152853||119993|
NCT01153100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1065|Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy|Effectiveness of a Subcutaneously Administered Long-acting Insulin Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment||University of Colorado, Denver|No|Completed|April 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|80 Years|No|||October 2012|October 2, 2012|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01153100||119975|
NCT01153113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMP hTERT DC Vaccine|Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines|Phase II Study of Active Immunotherapy With Mature, Human Telomerase Reverse Transcriptase Messenger RNA -Transfected, Autologous Dendritic Cells (DC) Administered In A Prime-Boost Format to Subjects With Metastatic Prostate Cancer||University of Florida|No|Withdrawn|January 2008|December 2010|Anticipated|December 2009|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||February 2011|November 30, 2011|March 31, 2010|Yes|Yes|IND has been withdrawn and the study is closed.|No||https://clinicaltrials.gov/show/NCT01153113||119974|
NCT01141790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 06/61338-5|Analysis of Vital, Facial and Muscular Responses Front to Music or Message in Coma, Vegetative State or Sedated Patients|Analysis of Vital, Facial and Muscular Responses Front to Music or Message in Coma, Vegetative State or Sedated Patients||University of Sao Paulo|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||||||Both|18 Years|70 Years|No|||June 2010|June 10, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01141790||120838|
NCT01141803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M198|Effect of Apple and Apple Pomace on Inflammation and Cholesterol Metabolism in Healthy Overweight|Isafruit: Nutrigenomics in Overweight||University of Copenhagen|No|Active, not recruiting|July 2008|October 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2009|June 10, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141803||120837|
NCT01142063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1891021|A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects|A Single Dose Bioequivalence Study Comparing The Commercial Tablet Formulation To The Clinical Tablet Of Neratinib In Healthy Subjects||Puma Biotechnology, Inc.|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|28|Samples Without DNA|Plasma|Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Cohorts will be selected from healthy volunteers.|May 2012|May 10, 2012|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142063||120817|
NCT01142310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122009-028|Reversing Corticosteroid Induced Memory Impairment|Reversing Corticosteroid Induced Memory Impairment||University of Texas Southwestern Medical Center|Yes|Completed|June 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|55|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142310||120798|
NCT01142544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0915-PED-ALI|Incidence of Acute Lung Injury in Children|Acute Lung Injury in Children: Epidemiology and Natural History: The Pediatric ALIEN Study|PED-ALIEN|Dr. Negrin University Hospital|Yes|Completed|February 2010|March 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|1 Month|18 Years|No|Non-Probability Sample|Children from 1 month to 18 years old, admmitted into ICU, and meeting the        American-European Consensus Conference definition for acute lung injury (ALI).|February 2013|February 23, 2013|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142544||120780|
NCT01142557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REBIJECT II|An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis|Therapy of the Chronic Multiple Sclerosis With Interferon-beta 1a (Rebif®)||Merck KGaA||Completed|June 2004|November 2005|Actual|November 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|522|||Both|N/A|N/A|No|Probability Sample|Subjects with clinically safe diagnosis of a chronic MS and ability to walk were recorded        in the case series.|June 2010|July 9, 2014|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01142557||120779|
NCT01142843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSantos-UFMG|Preliminary Evidence of the Efficacy of a Mouthwash Containing 5% Propolis for the Control of Plaque and Gingivitis|Clinical Preliminary Evidence of the Efficacy of a Mouthwash Containing 5% Propolis for the Control of Plaque and Gingivitis: Phase II Study|MGP|Federal University of Minas Gerais|Yes|Completed|August 2009|March 2010|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|60 Years|No|||May 2009|July 1, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142843||120757|
NCT01140269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABA-MCTG-0002|Rapid Detection of Staphylococcus Aureus in Burn Patients|Rapid, Quantitative, PCR-Based Detection Of Staphylococcus Aureus in Burn Sepsis Patients|PCR-Staph|American Burn Association|Yes|Enrolling by invitation|May 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|240|||Both|18 Years|N/A|No|||July 2013|January 14, 2015|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01140269||120954|
NCT01144104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917591-1|Activating Messages for Enhancing Primary Care Practice (AMEP2): Effectiveness Study|Targeted and Tailored Messages to Enhance Depression Care|AMEP2|University of California, Davis|Yes|Completed|June 2010|June 2014|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Actual|925|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144104||120661|
NCT01144702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/ASMQ/JURUA/2009|Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum|Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Uncomplicated Malaria by Plasmodium Falciparum, Juruá Valley, State of Acre, Brazil, 2009.||Oswaldo Cruz Foundation|No|Completed|November 2010|July 2014|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|6 Months|70 Years|No|||May 2015|May 15, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144702||120615|
NCT01145001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020718574|Enhancing a High School Based Smoking Cessation Program|Contingency Management for Smoking Cessation in Adolescent Smokers - Phase IV, Enhancing a High School Based Smoking Cessation Program||Yale University|Yes|Completed|November 2009|January 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|169|||Both|14 Years|19 Years|No|||June 2014|March 30, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145001||120592|
NCT01145612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-AT-MARFAN-01|Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome|A Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome.|LO-AT-MARFAN01|Forteza, Albert, M.D.|No|Active, not recruiting|October 2008|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|5 Years|60 Years|No|||June 2010|August 11, 2010|June 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01145612||120546|
NCT01145911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGPS|The Study of Ocular Hemodynamics With Glaucoma Progression|The Study of Ocular Hemodynamics With Glaucoma Progression|IGPS|Indiana University|No|Active, not recruiting|February 2008|July 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|123|||Both|30 Years|N/A|No|Non-Probability Sample|Glaucoma patients|February 2016|February 24, 2016|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145911||120523|
NCT01136382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589GC00001|A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo|Phase 2, Double-blind, Randomized, Parallel-group, Placebo-controlled, Multicenter Study, Comparing Budesonide pMDI 160 ug Bid With Placebo: a 6-week Efficacy and Safety Study in Children Aged 6 to <12 Years With Asthma|CHASE 1|AstraZeneca|No|Completed|July 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|304|||Both|6 Years|11 Years|No|||July 2014|July 30, 2014|June 1, 2010|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01136382||121248|
NCT01136369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSNA-BC-001|Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer|Clinical Evaluation of LS-03M/LS-04R for the Detection of Sentinel Lymph Node Metastasis From Breast Cancer||Sysmex America, Inc.|Yes|Completed|February 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|496|Samples With DNA|Samples of the tissue homogenate will be retained and may be used for for further testing.|Both|18 Years|N/A|No|Probability Sample|Patients with a previous diagnosis of breast cancer scheduled for sentinel lymph node        dissection.|June 2010|June 2, 2010|June 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01136369||121249|
NCT01137227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPIA 0501/09|Factors Associated With Physical Inactivity Among Adolescents|Factors Associated With Physical Inactivity Among Adolescents: a Systematic Review and Meta-analysis|FAPIA|University of Sao Paulo General Hospital|Yes|Active, not recruiting|April 2010|October 2010|Anticipated|August 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|264|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Samples of adolescents (age range 10-18y) without diseases and/or physical limitations.|April 2010|October 14, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01137227||121184|
NCT01137240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0016|Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders|Assessment and Prevalence of Gastrointestinal Dysfunction in Children With Mitochondrial Disorders (MD)||The University of Texas Health Science Center, Houston|Yes|Completed|June 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|3 Years|18 Years|No|Non-Probability Sample|children suffering form mitochondrial disorders.|February 2012|February 24, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137240||121183|
NCT01144585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1001-016-306|Effects of Remote Ischemic Preconditioning and Postconditioning on Lung Injury During Cardiopulmonary Bypass|Effects of Remote Ischemic Preconditioning and Postconditioning on Lung Ischemic-reperfusion Injury During Cardiopulmonary Bypass - Substudy of NCT00997217||Seoul National University Hospital|Yes|Completed|May 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|76|||Both|20 Years|80 Years|No|||June 2014|June 3, 2014|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01144585||120624|
NCT01142778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22229|A Study of Avastin (Bevacizumab) Added to Herceptin (Trastuzumab) Plus Docetaxel in the Neoadjuvant Setting in Patients With Early Stage HER2-Positive Breast Cancer|||Hoffmann-La Roche||Active, not recruiting|May 2010|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142778||120762|
NCT01142791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF033|Safety Study of ExAblate for the Treatment of Uterine Fibroids|A Phase IV Clinical Study To Evaluate the Safety of MR-Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques||InSightec|No|Completed|May 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Female|18 Years|N/A|No|||July 2014|July 28, 2014|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142791||120761|
NCT01147094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHMH0601|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2010|||||N/A|N/A|N/A||||||||||||||August 6, 2015|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147094||120432|
NCT01147107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHARP 001|Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection|Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C||University of Hawaii|Yes|Active, not recruiting|February 2014|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147107||120431|
NCT01147354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-4747|Effect of Selenium Supplementation on Inflammatory,Oxidative and Nutritional Markers in Hemodialysis Patients|Effect of Selenium Supplementation on Inflammatory,Oxidative and Nutritional Markers in Hemodialysis Patients||Shiraz University of Medical Sciences|Yes|Completed|April 2009|September 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||January 2012|January 31, 2012|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147354||120412|
NCT01147367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROG-SCCI-10-004-1|Physical Activity, Fatigue, Sleep, and Inflammation|Physical Activity Benefits After Breast Cancer: Exploring Cytokine Mechanisms|ABLE|University of Alabama at Birmingham|No|Completed|August 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|49|||Female|30 Years|70 Years|No|||March 2016|March 7, 2016|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147367||120411|
NCT01143571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910018|Evaluation of Skin, Colonic, and Oral Microbiome and Effect of Time and Antibiotic Treatment on Organism Diversity at Each Site|Evaluation of Skin, Colonic and Oral Microbiota and Effect of Time and Antibiotic Treatment on Organism Diversity at Each Site||National Institutes of Health Clinical Center (CC)||Completed|November 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||June 2015|March 10, 2016|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01143571||120702|
NCT01143870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811355|New Ways to Help Patients Improve Their Diabetes Control|Examining Ways to Increase Patient Understanding of Diabetes Control and Disease Severity Through Reinterpretation of Hemoglobin A1C Values With the Goal of Improved Diabetes Control||University of Pennsylvania|No|Active, not recruiting|April 2010|March 2011|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|177|||Both|18 Years|N/A|No|||June 2010|January 3, 2011|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01143870||120679|
NCT01148238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUTO|Autoimmune Diabetes: Markers of the Disease and Treatment of Latent Autoimmune Diabetes in Adults (LADA)|Autoimmune Diabetes: Disease Markers and Treatment of Latent Autoimmune Diabetes in Adults (LADA)||Norwegian University of Science and Technology|No|Withdrawn|August 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|Samples With DNA|Cytokines HLA T-reg|Both|30 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|10 patients with newly diagnosed diabetes type 1. 10 healthy age- and sex matched blood        donors.        10 patients with LADA. 10 healthy age- and sex matched blood donors. 10 patients with        diabetes type 1 older than 10 years. 10 healthy age- and sex matched blood donors.|December 2012|December 7, 2012|June 17, 2010||No|changed research plan|No||https://clinicaltrials.gov/show/NCT01148238||120344|
NCT01148251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eLipo-CTS DC78761|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2010|||||N/A|N/A|N/A||||||||||||||November 28, 2014|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01148251||120343|
NCT01148563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC29003|Louisiana State University Health Care Sciences Division (LSU HSCD) Tele-Health Projects: Adult CHF Patient Population|LSU HCSD Tele-Health Projects: Adult Systolic Heart Failure Patient Population|TeleHealth:CHF|Pennington Biomedical Research Center|Yes|Completed|March 2009|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|137|||Both|18 Years|N/A|No|||May 2011|October 28, 2011|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148563||120319|
NCT01148550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITOHEP 6003|Longitudinal Study of Mitochondrial Hepatopathies|Longitudinal Study of Mitochondrial Hepatopathies|MITOHEP|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|July 2010|||May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|67|Samples With DNA|Blood plasma and serum samples with DNA|Both|N/A|18 Years|No|Non-Probability Sample|A total of 67 children and young adults with suspected or documented hepatic RC defect or        FAO defect between birth and 18 years old from both genders and all races and ethnic        groups that meet inclusion/exclusion criteria as defined below.|September 2014|September 15, 2014|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148550||120320|
NCT01144390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShanghaiMHC|Effect Study of Optimized Intervention to Heroin Addicts|Barriers and Effect of Optimizing Intervention Protocols for Heroin Dependence in Community-based Methadone Maintenance Treatment (MMT): a Cohort Study||Shanghai Mental Health Center|No|Active, not recruiting|April 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||March 2011|March 10, 2011|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01144390||120639|
NCT01144988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT-Nr: 2009-015036-15|Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma|An Academic Prospective Single-arm Phase II Clinical Trial for Evaluation of Advanced Functional Neuroimaging Techniques and Molecular Markers in the Course of Anti-angiogenic Therapies in Malignant Gliomas|AVIRMA01-09|Medical University Innsbruck|Yes|Recruiting|March 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01144988||120593|
NCT01145924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD 08|Transbronchial Needle Forceps for Endobronchial Ultrasound|Transbronchial Needle Forceps for EBUS||Heidelberg University|Yes|Recruiting|January 2010|August 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|80 Years|No|||February 2010|June 16, 2010|June 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145924||120522|
NCT01145937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30756.041.10|PENTACON Trial: Partial ENdothelial Trepanation in Addition to Anterior Lamellar Keratoplasty in keratoCONus|Pentacon Trial: Partial ENdothelial Trepanation in Addition to Anterior Lamellar Keratoplasty in keratoCONus. A Prospective Multicenter Randomized Controlled Trial|PENTACON|UMC Utrecht|No|Terminated|March 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 14, 2010||No|during anticipated study duration trial power was not attained.|No||https://clinicaltrials.gov/show/NCT01145937||120521|
NCT01136681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR08-006|Wales Electronic Cohort for Children|Wales Electronic Cohort for Children (WECC)|WECC|Swansea University|Yes|Completed|April 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|900000|||Both|N/A|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|730,000 children born from 1990-2009, or subsequently resident, in Wales|December 2014|December 9, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136681||121226|
NCT01136668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014754|Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery|Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery: A Prospective Randomized Controlled Trial||The Hospital for Sick Children|Yes|Recruiting|April 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Months|18 Years|No|||May 2015|May 29, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136668||121227|
NCT01136941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1622|Trial of Zileuton CR in Children and Adults With Sickle Cell Disease|Phase I Trial of Zileuton CR in Children and Adults With Sickle Cell Disease|Zileuton|Children's Hospital Medical Center, Cincinnati|Yes|Completed|September 2010|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|12 Years|N/A|No|||June 2014|June 17, 2014|May 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01136941||121206|
NCT01136954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-313|A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)|An Open-label Extension Study Following a Double-blind, Randomized, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Pediatric Partial Onset Seizures||Eisai Inc.|No|Completed|July 2008|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|144|||Both|6 Years|18 Years|No|||November 2015|December 21, 2015|May 26, 2010||No||No|November 12, 2012|https://clinicaltrials.gov/show/NCT01136954||121205|
NCT01137253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091489|Autonomic Nervous System and Nitric Oxide Interactions|The Autonomic Nervous System, Nitric Oxide and TPA Interactions||Vanderbilt University|No|Active, not recruiting|June 2010|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|21|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137253||121182|
NCT01145794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|China-SHARE|Secondhand Smoke Exposure Reduction Study|Reducing Secondhand Smoke Exposure Among Young Children in Shanghai, China||Boston University|No|Completed|October 2008|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|348|||Both|18 Years|65 Years|No|||June 2011|June 23, 2011|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145794||120532|
NCT01145807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-067-III-01|TDT 067 Onychomycosis Study|A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks||Celtic Pharma Development Services|No|Active, not recruiting|April 2010|August 2012|Anticipated|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|738|||Both|18 Years|75 Years|No|||July 2012|July 31, 2012|March 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145807||120531|
NCT01146808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8413|Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver|Prevention of de Novo Hepatitis B Infection With Adefovir Dipivoxil (ADV) and Hepatitis B Vaccination in HBsAg Seronegative Recipients of Liver Grafts From Hepatitis B Core Antibody Positive (HBcAb+) Donors||Columbia University|No|Active, not recruiting|March 2006|July 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2012|January 12, 2012|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146808||120454|
NCT01147406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N6022-1H1-01|Safety and Tolerability Study of N6022 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of N6022 in Healthy Subjects||Nivalis Therapeutics, Inc.|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|June 14, 2010|No|Yes||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01147406||120408|
NCT01147666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-040|Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis|||FibroGen|Yes|Completed|March 2010|July 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|161|||Both|18 Years|75 Years|No|||March 2014|March 18, 2014|May 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147666||120388|
NCT01147380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100344|Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation|A Novel Immunotherapy for Liver Transplant Patients With Hepatocellular Carcinoma: Anti-tumor Effect of IL2-activated Donor Liver Natural Killer Cell|MIAMINK|University of Miami|Yes|Completed|June 2010|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|June 17, 2010|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01147380||120410|
NCT01147393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001010838|Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma|Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma||Weill Medical College of Cornell University|Yes|Recruiting|October 2010|||June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147393||120409|
NCT01147627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-201007-WJP|Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients|Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial||Sun Yat-sen University|No|Completed|August 2010|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|416|||Both|30 Years|70 Years|No|||June 2013|June 11, 2013|June 18, 2010||No||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01147627||120391|The open-label design, which could have introduced bias by affecting patients’ expectations and adherence to therapy.
NCT01147965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETBX-011|Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA|A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA||Etubics Corporation||Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|21 Years|75 Years|No|||March 2013|March 21, 2013|June 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01147965||120365|
NCT01144143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10702|Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab|Single Center, Randomized, Double-Blind, Placebo-Controlled Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab||University of Kansas Medical Center|Yes|Completed|July 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|16|||Both|35 Years|85 Years|No|||January 2011|January 11, 2011|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144143||120658|
NCT01144117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2009-011516-37|The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis|Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis|EPO-ProgMS|Rigshospitalet, Denmark|Yes|Recruiting|November 2009|April 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|56|||Both|19 Years|60 Years|No|||May 2010|August 4, 2011|June 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144117||120660|
NCT01144130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-011|Postoperative Sleep Disturbances After Fast Track Hip and Knee Replacement|Postoperative Sleep Disturbances After Fast Track Hip and Knee Replacement||Rigshospitalet, Denmark|Yes|Completed|May 2010|October 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|60 Years|N/A|No|Non-Probability Sample|Patients above 60 years undergoing hip/knee replacement surgery in a fest track set-up.|October 2010|September 19, 2011|June 14, 2010||||No||https://clinicaltrials.gov/show/NCT01144130||120659|
NCT01144715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS070646|Rehabilitation of the Stroke Hand at Home|An Innovative Home Stroke Rehabilitation and Monitoring System|HAAPI|Kinetic Muscles|No|Completed|June 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|21 Years|N/A|No|||October 2014|November 24, 2014|June 11, 2010||No||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01144715||120614|
NCT01145300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10.045|Biomarkers in Chronic Obstructive Pulmonary Disease (COPD)|Relationship Between Exhaled Markers and Airway Pathology in Smokers With and Without Airflow Obstruction||Leiden University Medical Center|No|Completed|June 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|Samples With DNA|blood|Both|40 Years|80 Years|No|Non-Probability Sample|Patients with and without COPD scheduled for lung resection for lung cancer.|January 2012|January 25, 2012|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145300||120569|
NCT01145313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-582|Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder|Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|October 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|501|||Both|18 Years|64 Years|No|Probability Sample|The population is identified as patients diagnosed with MDD who are treated with        antidepressants and subsequently augment with atypical antipsychotic therapy.|August 2010|November 7, 2013|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145313||120568|
NCT01146587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-LK-PT|Comparative Study of GangTrainer GT1, Lokomat and Conventional Physiotherapy|Robot Assisted Therapy for Acute Stroke Patients: a Comparative Study of GangTrainer GT I, Lokomat System and Conventional Physiotherapy|galop|Research Department for Neurorehabilitation South Tyrol|No|Suspended|August 2010|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|79 Years|No|||June 2015|June 4, 2015|June 14, 2010||No|GangTrainer GT1 is not state of the art anymore for the principal Invesigator|No||https://clinicaltrials.gov/show/NCT01146587||120471|
NCT01136408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.49|A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin|Open Label, Randomised Exploratory Dose Response Study in Pharmacodynamics and Safety of BIBR 1048 (110 mg Twice Daily (b.i.d.) and 150 mg b.i.d.) for 12 Weeks in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin||Boehringer Ingelheim||Completed|November 2005|||September 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|174|||Both|20 Years|N/A|No|||February 2014|February 18, 2014|May 19, 2010||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT01136408||121246|
NCT01136928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00038067|Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers|Phase I Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers||Johns Hopkins University|Yes|Active, not recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|May 9, 2011|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136928||121207|
NCT01136980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D01010|Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study|A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD Compared With Sham and Placebo Controls|RESPECT|EndoGastric Solutions|No|Completed|April 2011|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|80 Years|No|||July 2015|July 7, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136980||121203|
NCT01137877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK66|Growth and Tolerance of Healthy Term Infants to a New Infant Formula|Growth and Tolerance of Healthy Term Infants to a New Infant Formula||Abbott Nutrition|Yes|Terminated|May 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|399|||Both|N/A|11 Days|Accepts Healthy Volunteers|||November 2010|November 24, 2010|June 3, 2010||No|The control product was recalled.|No||https://clinicaltrials.gov/show/NCT01137877||121137|
NCT01146496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Safe Storage Protocol Sep09|A Community Trial to Determine Whether 'Safe Storage' Reduces Pesticide Self-poisoning in Rural Asia|A Community Trial to Determine Whether 'Safe Storage' Reduces Pesticide Self-poisoning in Rural Asia||University of Edinburgh|Yes|Active, not recruiting|December 2010|June 2016|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|190000|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146496||120478|
NCT01146509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-A001-213|An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis|An Open-Label, Multicenter, One-Year Extension Of The Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis||Eisai Inc.||Completed|January 2003|March 2007|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|65 Years|No|||December 2012|December 6, 2012|April 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146509||120477|
NCT01146821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-FOILED|Fish OIL Optimal dosE Determination Study|Multi-centre, Open-label, Phase II Clinical Trial for Determination of the Optimal Dose of Fish Oil in Patients With Severe Sepsis|FOILED|University Hospital Carl Gustav Carus|No|Recruiting|October 2013|June 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|21|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01146821||120453|
NCT01148017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P14E1|Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine|A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine||Novartis|No|Completed|July 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|433|||Both|37 Months|63 Months|Accepts Healthy Volunteers|||October 2015|October 19, 2015|June 16, 2010|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01148017||120361|
NCT01148030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11319|Impact of Pre-surgical Nasal Bacterial Reduction on Postoperative Surgical Site Infections / Standard Care Change|||3M|No|Terminated|June 2010|July 2012|Actual|July 2012|Actual|Phase 4|Observational|N/A||1|Actual|333|||Both|2 Years|N/A|No|Probability Sample|Emergent Hip Fractures|February 2014|February 28, 2014|June 18, 2010|Yes|Yes|Outcome measures for pre-intervention were much lower than anticipated.|No||https://clinicaltrials.gov/show/NCT01148030||120360|
NCT01147991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000675266|Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer|A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens||Cancer Research UK||Completed|March 2005|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01147991||120363|
NCT01148004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100124|The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers|The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|May 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|60 Years|No|||July 2013|November 27, 2013|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148004||120362|
NCT01147640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625A-012|Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections||Cubist Pharmaceuticals LLC|No|Completed|June 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|90 Years|No|||January 2016|January 6, 2016|June 17, 2010|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT01147640||120390|
NCT01147653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00017801|A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy|Is Autologous Umbilical Cord Blood Reinfusion Beneficial in Children With Cerebral Palsy: A Randomized, Blinded, Placebo-Controlled, Crossover Study||Duke University|No|Active, not recruiting|June 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|12 Months|6 Years|No|||February 2016|February 4, 2016|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147653||120389|
NCT01147978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K070101|Proactive Communication Strategy in Intensive Care Unit and Post Traumatic Stress Symptoms|Impact of a Proactive Strategy of Communication With Patients Hospitalized in ICU and Their Families With the Aim of Reducing Their Anxious and Depressive Symptoms and Their Post Traumatic Stress Symptoms|FAMIREAXV|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2009|November 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|303|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01147978||120364|
NCT01144429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603-PG-PSC-173|Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma|Randomized, DB, Parallel Group, MC Study to Evaluate the Efficacy and Safety of Four Doses of Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depigoid Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma||Leti Pharma GmbH|Yes|Completed|June 2010|May 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|344|||Both|18 Years|70 Years|No|||June 2011|June 7, 2011|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01144429||120636|
NCT01144403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22489|A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.|A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma||Hoffmann-La Roche||Completed|June 2010|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144403||120638|
NCT01144416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06029|Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)|A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)|PURSUE|Merck Sharp & Dohme Corp.|Yes|Completed|June 2010|April 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1424|||Female|35 Years|42 Years|No|||June 2015|June 3, 2015|June 11, 2010|Yes|Yes||No|November 27, 2012|https://clinicaltrials.gov/show/NCT01144416||120637|
NCT01145027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|do200812|Cephalic Phase Insulin Secretion and Capillary Recruitment in Healthy Men|Relations Among Cephalic Phase of Insulin Secretion, Body Composition, Dietary Intake and Microvascular Reactivity in Healthy Young Men||Rio de Janeiro State University|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|39|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2010|October 20, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145027||120590|
NCT01145625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINALO3004|Clinical Trial in Females With Female Pattern Hair Loss|A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625)||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|322|||Female|18 Years|N/A|No|||May 2014|May 19, 2014|June 15, 2010|Yes|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01145625||120545|
NCT01145638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-CIA-01|A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)|A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)||Pharmacosmos A/S|No|Completed|October 2010|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|N/A|No|||April 2015|November 2, 2015|June 15, 2010|Yes|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01145638||120544|
NCT01145651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2009|||||N/A|N/A|N/A||||||||||||||October 7, 2010|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145651||120543|
NCT01145950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ECCL001|Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®|A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers||LG Life Sciences|No|Completed|June 2010|January 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145950||120520|
NCT01146288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ObesAceta 1|Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration|Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration||Rabin Medical Center|No|Completed|July 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Male|18 Years|55 Years|No|||June 2015|June 2, 2015|June 16, 2010||No||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01146288||120494|
NCT01147172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA0701|Safety Study of Cosmetic Tissue Augmentation in People of Color|A Post Approval, Multicenter, Open-Label, Longitudinal, Uncontrolled Safety Study of Cosmetic Tissue Augmentation Product (ELEVESS™) in the Treatment of Nasolabial Folds in People of Color||Anika Therapeutics, Inc.|No|Completed|March 2009|August 2010|Actual|December 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|April 3, 2015|June 3, 2010|Yes|Yes||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01147172||120426|
NCT01147471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU-20100582|Flail Chest - Rib Fixation Study|Flail Chest: Early Operative Fixation Versus Non-operative Management - a Prospective Randomized Study||Virginia Commonwealth University|Yes|Terminated|September 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|21 Years|75 Years|No|||August 2015|August 4, 2015|June 7, 2010||No|Insufficient enrollment|No|August 4, 2015|https://clinicaltrials.gov/show/NCT01147471||120403|Subject enrollment too low leading to insufficient data to analyze.
NCT01136421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Magnesium sulfate|Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease|||University of Monastir|No|Completed|January 2005|June 2007|Actual|June 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|40 Years|N/A|No|||May 2010|June 2, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136421||121245|
NCT01136694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-230|Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)|Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)||Bristol-Myers Squibb|No|Completed|May 2009|December 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|695|||Both|18 Years|N/A|No|Non-Probability Sample|Commercial health plan members|February 2012|February 9, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136694||121225|
NCT01137630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K40-3|Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp|A Multicenter, Randomised Double Blind, Placebo Controlled Study of Efficacy, Safety and Tolerability of Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp.||Moberg Derma AB|No|Completed|February 2007|May 2007|Actual|May 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|65 Years|No|||June 2010|June 3, 2010|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137630||121156|
NCT01137890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA027065|Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse|Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse||Johns Hopkins University|No|Completed|June 2010|August 2013|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|19|||Both|21 Years|45 Years|No|||January 2014|January 28, 2014|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137890||121136|
NCT01146535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCR09025|Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment|Pilot Study of Interferon Alpha Lozenges Plus Oseltamivir in the Treatment of Influenza A Infection||Amarillo Biosciences, Inc.|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|65 Years|No|||August 2013|August 19, 2013|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146535||120475|
NCT01146834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005011049|Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma|A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma||Weill Medical College of Cornell University|Yes|Recruiting|March 2011|December 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146834||120452|
NCT01147120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT004544-01A2|Chronic Low Back Pain and Primary Health Care|CAM Referral and Outcomes: Chronic Low Back Pain in Urban and Rural Primary Care||University of Kentucky|Yes|Completed|September 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|21 Years|N/A|No|||June 2014|June 3, 2014|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01147120||120430|
NCT01148303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARX_ISP_IL1001|Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache|Randomized, Placebo Controlled Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache||Hartford Hospital|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|220|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 7, 2011|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01148303||120339|
NCT01148290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/2010|Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence|A Comparison Between Tension-free Vaginal Tape and Bulking Agent for the Treatment of Post-vulvectomy Urinary Incontinence: a Randomized Controlled Trial||University Magna Graecia||Completed|May 2009|April 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|95 Years|No|||April 2013|April 5, 2013|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148290||120340|
NCT01143922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOUS|Role of Intraoperative Ultrasound in Gastrointestinal (GI) Malignancies|||All India Institute of Medical Sciences, New Delhi||Recruiting|August 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|10 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients with GI tract malignancies undergoing surgery|January 2010|June 14, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01143922||120675|
NCT01148264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKSH 079|Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis|Efficacy of Olanzapine in Break-through Emesis After Prophylaxis With Dexamethasone, 5-HT3 Receptor Antagonists and Aprepitant Compared to Metoclopramide|COMFORT|Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|July 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|86|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148264||120342|
NCT01148277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propofol vs Midazolam|Propofol and Remifentanyl Versus Midazolam and Fentanyl for Diagnostic Colonoscopy in Patients With Compensated Cirrhosis Child A-B|Propofol and Remifentanyl Versus Midazolam and Fentanyl for Diagnostic Colonoscopy in Patients With Compensated Cirrhosis Child A-B||Ziv Hospital|Yes|Not yet recruiting|August 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||June 2010|April 5, 2011|June 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01148277||120341|
NCT01143909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw-80823109710069|Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients|Transfusion of Fresh Frozen Plasma in Non-bleeding ICU Patients|TOPIC|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|May 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|81|||Both|18 Years|N/A|No|||June 2010|June 14, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01143909||120676|
NCT01145040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFC-UK10|NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation|NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study|NOMOTHETICOS|Ruhr University of Bochum|Yes|Enrolling by invitation|June 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|100|||Both|14 Years|N/A|No|Probability Sample|Outpatients with "open-loop" thyrotropic feedback control (disconnection at the site of        the thyroid)|February 2015|February 12, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145040||120589|
NCT01145053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.463|Drug Use Survey of RESPIMAT in Patients With COPD|Long Time Survey of RESPIMAT in Daily Clinical Use||Boehringer Ingelheim||Completed|May 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|361|||Both|15 Years|N/A|No|Non-Probability Sample|300|February 2014|February 27, 2014|June 15, 2010||||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01145053||120588|
NCT01144728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLMET_L_04718|Initiation and Titration of Amaryl|AMIT Study - Amaryl M Initiation and Titration Study|AMIT KZ|Sanofi||Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|35 Years|75 Years|No|||January 2011|January 28, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144728||120613|
NCT01145014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1284.1|To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Phase I - Study to a) Assess Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses 2 mg to 600 mg of BI 660848 Administered as Oral Drinking Solution (Powder in Bottle) in Healthy Male Volunteers, b) to Explore the Relative Oral Bioavailability of an Immediate Release Tablet Formulation and c) to Assess the Impact of a High Fat Meal on the Oral Bioavailability of the Oral Drinking Solution (Powder in Bottle).||Boehringer Ingelheim||Terminated|May 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|12||Actual|72|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|May 5, 2010||||No||https://clinicaltrials.gov/show/NCT01145014||120591|
NCT01146301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06.44A|Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery|Does the Magnitude of Platelet Inhibition Inversely Correlate With the Number of TCD-detected Microemboli in Asymptomatic Patients Undergoing Carotid Artery Stenting Prior to Cardiac Surgery Who Are Being Pre-treated With 300 mg or 600 mg Loading Dose of Clopidogrel?|IMPACT|R&D Cardiologie|Yes|Completed|March 2008|April 2010|Actual|March 2010|Actual|Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|90 Years|No|||June 2010|June 21, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01146301||120493|
NCT01146314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18-06038-001|A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children|A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children|FBI|Nemours Children's Clinic|No|Completed|September 2006|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|8 Years|11 Years|No|||April 2013|April 30, 2013|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146314||120492|
NCT01146600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044170|Clarithromycin for the Treatment of Hypersomnia|Clarithromycin for the Treatment of Hypersomnia||Emory University|No|Completed|July 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|June 15, 2010|Yes|Yes||No|September 28, 2013|https://clinicaltrials.gov/show/NCT01146600||120470|
NCT01146613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-DTRR-2010-LITTEN-003|Varenicline for Alcohol Dependence|A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy of Varenicline Tartrate for Alcohol Dependence in Very Heavy Drinkers|NCIG 003|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||Completed|February 2011|July 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|June 16, 2010|Yes|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT01146613||120469|
NCT01146899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE4956|FluAlert: Influenza Vaccine Alerts for Providers in the Electronic Health Record|FluAlert: Influenza Vaccine Alerts for Providers in the Electronic Health Record||Columbia University|No|Completed|December 2009|June 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|6145|||Both|6 Months|75 Years|No|||June 2014|June 22, 2014|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146899||120447|
NCT01147757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0129|Effect of Intraoperative Remifentanil Infusion Rate on Postoperative Tolerance and Analgesic Consumption in Pediatric Laparoscopic Ureteroneocystostomy|||Yonsei University|No|Recruiting|June 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|4||Anticipated|60|||Both|1 Year|5 Years|No|||December 2011|December 5, 2011|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147757||120381|
NCT01147770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRG-45|Prolongation of Progesterone Supplementation in Antagonist Cycles and Pregnancy Outcomes|The Effect of Progesterone Supplementation During Early Gestations in Patients Treated With Rec FSH/GnRH Antagonist:a Randomized Controlled Trial||Universitair Ziekenhuis Brussel|Yes|Completed|September 2008|June 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Female|18 Years|39 Years|No|||July 2013|July 1, 2013|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147770||120380|
NCT01147783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anae-Vie-SimbabyCT|Airway Anatomy of the SimBaby|A Comparison of Pediatric Airway Anatomy With the SimBaby High-Fidelity Simulator||Medical University of Vienna|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|1 Month|12 Months|Accepts Healthy Volunteers|Non-Probability Sample|infants undergoing routine head MRI|June 2010|July 2, 2010|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147783||120379|
NCT01136993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M1010NL0002|Finnish Telestroke Pilot 2007-2009|Finnish Telestroke Pilot 2007-2009||Helsinki University Central Hospital|No|Recruiting|May 2007|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|109|||Both|N/A|N/A|No|Probability Sample|All teleconsultations on stroke thrombolysis decision between the Hub (HUCH) and the 5        Spokes during 2 years time period.|June 2010|June 3, 2010|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01136993||121202|
NCT01137006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13945|An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma|An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated||ImClone LLC|No|Completed|June 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|June 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137006||121201|
NCT01136707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-266|Predictors of Adherence to Orencia|Predictors of Adherence to Orencia||Bristol-Myers Squibb|No|Completed|December 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|422|||Both|18 Years|N/A|No|Non-Probability Sample|Commercial health plan members|August 2010|August 20, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136707||121224|
NCT01136967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-206|An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma|An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma||Eisai Inc.|No|Completed|August 2010|November 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|99 Years|No|||February 2016|February 16, 2016|June 2, 2010|Yes|Yes||No|March 13, 2015|https://clinicaltrials.gov/show/NCT01136967||121204|
NCT01137643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0824|Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer|Tissue Procurement For Hematolymphoid Conditions||UNC Lineberger Comprehensive Cancer Center|No|Recruiting|July 2009|||July 2040|Anticipated|Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|15000|Samples With DNA|Tumor tissue, blood, bone marrow, urine, ascites|Both|18 Years|N/A|No|Non-Probability Sample|Hematologic malignancies|November 2013|November 18, 2013|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137643||121155|
NCT01147133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOSER-GENERIC|Comparison of Generic and Original Formulation of Clopidogrel|Comparison of the Generic and Original Formulation of Clopidogrel Regarding the Potency of Platelet Inhibition in Patients After PCI|DOSER-GENERIC|University of Pecs|No|Completed|November 2009|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|75|||Both|N/A|N/A|No|||January 2013|January 28, 2013|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01147133||120429|
NCT01147419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-vascular surgery|Comparison of Stent and Prothesis Bypass in Superficial Femoral Artery|The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions|SPACIAL|Peking Union Medical College Hospital|Yes|Recruiting|June 2010|June 2015|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|80 Years|No|||July 2010|July 6, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01147419||120407|
NCT01147679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG034499|Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls|Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls||University of California, Los Angeles|No|Recruiting|January 2010|July 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|99|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients evaluated by Dr. Mario Mendez at the UCLA Frontotemporal Dementia Clinic|October 2011|October 27, 2011|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01147679||120387|
NCT01144182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-412|Veterans Affairs Lowering Readmission in Heart Failure|VALOR (Veterans Affairs Lowering Readmissions) in Heart Failure Study|VALOR in HF|VA Office of Research and Development|No|Completed|October 2010|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|21 Years|N/A|No|||August 2015|October 15, 2015|June 10, 2010||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01144182||120655|
NCT01143948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC-T2D|Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial|Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes|VIRDICT|Cairo University|Yes|Not yet recruiting|January 2011|May 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|60 Years|No|||February 2010|June 14, 2010|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01143948||120673|
NCT01144169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 10-029|Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma|A Phase IB Study of Hydroxychloroquine Prior to Nephrectomy in Patients With Primary Renal Cell Carcinoma||University of Pittsburgh|Yes|Terminated|October 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|19 Years|N/A|No|||January 2016|January 4, 2016|June 10, 2010|Yes|Yes|barriers to accrual including delay until surgery and additional pre-operative visits|No||https://clinicaltrials.gov/show/NCT01144169||120656|
NCT01143935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liver volume estimation|Estimation of Standard Liver Volume in the Indian Population|Estimation of Standard Liver Volume in the Indian Population||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|January 2009|December 2010|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|10 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing CT scans for non hepatobiliary conditions. Autopsy cases in whom there        is no liver disease or trauma.|January 2010|June 14, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01143935||120674|
NCT01144442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS114|WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer|WCC# 59: Pilot Study of Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence||Masonic Cancer Center, University of Minnesota|Yes|Completed|August 2010|September 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|16 Years|90 Years|No|||February 2016|February 23, 2016|May 26, 2010|No|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT01144442||120635|The primary weakness of this study is the small sample size.
NCT01144156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gal002|Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy|Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy||Rabin Medical Center|No|Not yet recruiting||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2010|June 14, 2010|June 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144156||120657|
NCT01145352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881Y1-4689|Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]|Enbrel-JIA Use Results Survey [All-Case Surveillance]|Enbrel-JIA|Pfizer|No|Completed|July 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|113|||Both|5 Years|16 Years|No|Probability Sample|All patients who administrated ENBREL for active polyarticular juvenile idiopathic        arthritis (restricted to the case of lack of effect by other treatment) during registered        period (2.5 year).|August 2014|August 20, 2014|June 9, 2010|No|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT01145352||120565|
NCT01145365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100063|Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas|A Prospective Multicenter Trial Evaluating the Benefit of INitial Surgically Established Drainage Prior to Medical Therapy for the Treatment for Crohn's Perianal Fistulas||Vanderbilt University|No|Recruiting|December 2010|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145365||120564|
NCT01145378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHM0602|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2010|||||N/A|N/A|N/A||||||||||||||August 6, 2015|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145378||120563|
NCT01145326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUDEM 2010-1|Functional Microarray Augmentation of Skin Treatment With Lidocaine|Functional Microarray Augmentation of Skin Treatment With Lidocaine (FAST Lidocaine)|FAST|University of Oklahoma|No|Suspended|January 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|June 14, 2010||No|The device is undergoing further study in China, per FDA requirements.|No||https://clinicaltrials.gov/show/NCT01145326||120567|
NCT01145339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF099|A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI)|A Phase III, Non-Inferiority, Randomized, Double-Blind, Parallel-Group, Multicentre, Single-Dose, Comparative Clinical Study of Lactase Eurofarma (Test Drug) and Lactaid® (Comparative Drug), Assessing the Efficacy and Safety in the Treatment of Patients With Lactose Intolerance (Hypolactasia)|EF099|Eurofarma Laboratorios S.A.|Yes|Completed|July 2011|March 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|60 Years|No|||October 2011|June 22, 2012|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145339||120566|
NCT01146912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF0137|TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations|TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Population||Columbia University|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|30537|||Both|6 Months|50 Years|No|||September 2015|September 6, 2015|June 16, 2010||No||No|August 8, 2012|https://clinicaltrials.gov/show/NCT01146912||120446|
NCT01147185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSCI-DR|Effectiveness of Automated Locomotor Training in Patients With Acute Incomplete Spinal Cord Injury: A Multicenter Trial|Effectiveness of Automated Locomotor Training in Patients With Acute Incomplete Spinal Cord Injury: A Multicenter Trial||University of Zurich|No|Recruiting|February 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01147185||120425|
NCT01147497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00021303|Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in Intrauterine Device Insertion for Nulliparous Women|miso|Emory University|Yes|Completed|June 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|78|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|June 15, 2010||No||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01147497||120401|
NCT01147510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-GEN-CT4-10-095|Asthma Control in Elderly Patients With Montelukast|A Randomized Controlled Study of Montelukast Plus Low Dose Inhaled Budesonide Versus Medium Dose Inhaled Budesonide on Asthma Control in Elderly Patients|ACEM|Ajou University School of Medicine|No|Completed|July 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|60 Years|75 Years|No|||November 2013|November 10, 2013|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01147510||120400|
NCT01137305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Katja Maschuw, MD|Soft Skills and Surgical Performance|Do Soft Skills Predict Surgical Performance? Do Soft Skills Predict Surgical Performance? A Prospective Randomized Controlled Single Center Educational Trial Evaluating Predictors of Skill Acquisition in Virtual Reality Laparoscopy|SSPSP|Philipps University Marburg Medical Center|No|Completed|June 2008|May 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|1||Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2010|June 16, 2010|June 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137305||121179|
NCT01137266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL2073208008|Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Disability in Patients With Osteoarthritis|Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Disability in Patients With Osteoarthritis||Maxima Medical Center|No|Completed|July 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||July 2009|October 7, 2010|January 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01137266||121181|
NCT01137292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501082|Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection|Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-Comparative Study|Ve-RIFI|Pfizer|No|Completed|April 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|177|||Both|2 Years|N/A|No|Non-Probability Sample|Male or female patients older than 2 years with invasive fungal infections.|August 2011|August 31, 2011|June 2, 2010|No|Yes||No|July 12, 2010|https://clinicaltrials.gov/show/NCT01137292||121180|
NCT01137903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM-2010|Efficacy of Surgical Treatment of Osteomyelitis in Diabetic Foot Ulcers|Prospective Randomized Clinical Trial Comparing Efficacy Surgical Versus Medical Treatment of Osteomyelitis in Diabetic Foot Ulcers||Universidad Complutense de Madrid|Yes|Recruiting|April 2010|November 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||May 2010|June 4, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01137903||121135|
NCT01147432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0141006|Acute Response Capsaicin Flare Study|A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Modified Cross-Over Study To Examine The Acute Effect Of PF-04427429 On Capsaicin Flare Response In Healthy Volunteers Using EMLA Cream As Positive Control||Pfizer|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 19, 2011|June 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01147432||120406|
NCT01147692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108366|A Drug Interaction Study of Simvastatin and Albiglutide|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects||GlaxoSmithKline|Yes|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|January 22, 2011|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147692||120386|
NCT01147705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009CV16|Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease|Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease|APOSA-PAD|University of Dundee|No|Completed|February 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|35 Years|85 Years|No|||March 2016|March 24, 2016|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01147705||120385|
NCT01148043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL32030.101.10|Pharmacological Treatment In Osteoarthritis|Pharmacological Treatment In Osteoarthritis|FABIO|Maasstad Hospital|No|Completed|July 2010|September 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|40 Years|N/A|No|||April 2015|April 10, 2015|June 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01148043||120359|
NCT01145092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P15656|Effects of Six Months of Moderate Resistance- Versus Endurance-Training on Muscle ATP Synthesis in First-Degree Relatives of Patients With Type 2 Diabetes|Effects of Six Months of Moderate Resistance- Versus Endurance-Training on Muscle ATP Synthesis in First-Degree Relatives of Patients With Type 2 Diabetes|RECO2|Landsteiner Institut|No|Completed|February 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2010|June 15, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145092||120585|
NCT01144468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP3BSS|Effects of Exemestane on Bone Strength|Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer|MAP3BSS|University Health Network, Toronto|No|Active, not recruiting|April 2007|June 2019|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|354|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women randomized to the MAP.3 study from 5 participating locations were consecutively        approached for participation in this companion study.|December 2014|December 23, 2014|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01144468||120633|
NCT01144455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-404|Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma|A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma||Threshold Pharmaceuticals|Yes|Completed|June 2010|December 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144455||120634|
NCT01144741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000063|Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome: a Retrospective, Cohort Survey|STOP-FSS|Freeman-Sheldon Research Group, Inc.|No|Recruiting|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|20|Samples With DNA|Any specimens received as part of records review, such as pathology microscope slides or      frozen sections, will be retained as per institutional policy.|Both|N/A|N/A|No|Non-Probability Sample|Patients world-wide are welcome, so long as they have a qualifying diagnosis.|October 2014|October 21, 2014|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144741||120612|
NCT01145664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907001-3|A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease|||Beijing YouAn Hospital|Yes|Recruiting|May 2010|||August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|390|||Both|1 Year|13 Years|No|||May 2010|June 16, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01145664||120542|
NCT01146652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS11210|Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)|A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)||Sanofi|Yes|Active, not recruiting|June 2010|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|N/A|No|||September 2015|October 5, 2015|June 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146652||120466|
NCT01146925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRMD-001-2001|Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury|A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury||CorMedix|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2011|June 23, 2011|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146925||120445|
NCT01147198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSFOCB1|Ready to Use Supplementary Food in Moderate Childhood Malnutrition|Effectiveness of a Ready-to-Use-Supplementary-Food for the Treatment of Moderate Childhood Malnutrition||Medecins Sans Frontieres|No|Completed|April 2007|April 2008|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|570|||Both|6 Months|5 Years|No|||March 2007|January 23, 2012|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147198||120424|
NCT01146938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-112|A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers|A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers||Boryung Pharmaceutical Co., Ltd|Yes|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|18|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||December 2010|January 2, 2012|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01146938||120444|
NCT01147211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001017M|Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)|A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation||National Taiwan University Hospital|No|Active, not recruiting|September 2010|December 2013|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|20 Years|N/A|No|||April 2013|May 1, 2013|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147211||120423|
NCT01136746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13698|Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin|Randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients Without Known History of Diabetes: The HMH Trial|HMH|Eli Lilly and Company|Yes|Terminated|March 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|June 2, 2010|Yes|Yes|Low enrollment|No|September 12, 2012|https://clinicaltrials.gov/show/NCT01136746||121221|Due to low enrollment, this trial was terminated early, leading to small numbers of participants analyzed or some outcome measures not being able to be analyzed at all.
NCT01137318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH088845-01|Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)|Combined Cognitive Remediation and Behavioral Intervention for Treatment of ADHD||Queens College, The City University of New York|No|Active, not recruiting|September 2009|July 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|84|||Both|7 Years|11 Years|No|||November 2012|November 10, 2012|February 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01137318||121178|
NCT01138163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 0902|Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer||Peregrine Pharmaceuticals|Yes|Completed|June 2010|May 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01138163||121115|
NCT01147718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111680|A Drug Interaction Study of Albiglutide and Digoxin|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects||GlaxoSmithKline|Yes|Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|April 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147718||120384|
NCT01148056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-157|Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer|A Phase II Study of Neoadjuvant Short Course Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer: An Analysis of Quality of Life and Biomarkers of Response||Massachusetts General Hospital|Yes|Terminated|March 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|June 18, 2010||No|The study was closed to enrollment due to slow accrual.|No||https://clinicaltrials.gov/show/NCT01148056||120358|
NCT01143974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-008|Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer|Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer||Chinese Academy of Medical Sciences|No|Completed|June 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|70 Years|No|||March 2013|March 13, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01143974||120671|
NCT01143961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/MRE09/54|Bedside Measurement of Ventilation With or Without a One-way Valve During Lung Lavage|Measurement of Changes in Ventilation and Catheter Placement During Non-directed Bronchoalveolar Lavage Using Electrical Impedance Tomography With and Without a One-way Valve||Cardiff and Vale University Health Board|No|Enrolling by invitation|June 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2010|June 14, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01143961||120672|
NCT01145391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0646|Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial|Health Promotion Outreach To Overcome Clinical Inertia In The Treatment Of Patients With Poorly-Controlled Hypertension||University of Colorado, Denver|No|Completed|November 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|591|||Both|18 Years|79 Years|No|||October 2012|October 24, 2012|June 15, 2010||No||No|October 10, 2011|https://clinicaltrials.gov/show/NCT01145391||120562|Adherence measures were not included. Patients with and without a formal diagnosis of hypertension were enrolled, but might require different intervention strategies.
NCT01144754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0071|Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT|A Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP With or Without Radiotherapy||Stanford University|Yes|Terminated|February 2009|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Male|18 Years|N/A|No|Non-Probability Sample|Previously untreated patients with DLBCL of the breast.|May 2012|May 24, 2012|June 14, 2010||No|Low Accrual|No||https://clinicaltrials.gov/show/NCT01144754||120611|
NCT01145066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|not yet assigned|Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects|Modulation of Biomarkers and Gene Expression by Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects.||Wake Forest Baptist Health|No|Completed|May 2009|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|80|||Both|21 Years|N/A|No|||March 2012|March 1, 2012|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145066||120587|
NCT01145079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0115|A New Strategy Regarding Discontinuation of Dual Antiplatelet|A New Strategy Regarding Discontinuation of Dual Antiplatelet; Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET Trial)||Yonsei University|Yes|Completed|May 2009|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|982|||Both|20 Years|85 Years|No|||March 2013|March 4, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145079||120586|
NCT01145963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT 2010-042|Pasta Formulations and Their Effect on Appetite|Understanding Pasta Formulations on Satiation in Healthy Weight Women|SAT|Institute for Food Safety and Health, United States|No|Active, not recruiting|June 2010|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145963||120519|
NCT01146327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0961010|A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects|A Phase 1, Parallel, Randomized Trial To Assess The Effect Of Time Of Dosing On The Pharmacodynamics, Pharmacokinetics, Safety And Tolerability Of Multiple Oral Doses Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects||Pfizer|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|June 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01146327||120491|
NCT01146340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042-2010|Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer|Phase I/II Study of Dose-Escalated Hypofractionated Radiotherapy for Low- and Intermediate-Risk Prostate Cancer (PHART6)||Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|May 2010|||February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 9, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01146340||120490|
NCT01146626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV +Vitamin D|Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?|Does Vitamin D Supplement Improve SVR in Chronic Hepatitis C (Genotype 2,3) in naïve Patients Treated With Peginterferon Alpha and Ribavirin||Ziv Hospital|No|Not yet recruiting|August 2011|May 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||June 2010|April 27, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146626||120468|
NCT01146639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rek 4.2008.802|DynaCT in Preoperative Imaging Before Insertion of Stentgraft|Usefulness of DynaCT Compared to Multidetector CT as Preoperative Imaging Before Insertion of Aortic Stentgraft.|DynaCT|Norwegian University of Science and Technology|Yes|Completed|August 2008|June 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|60 Years|N/A|No|||June 2010|June 17, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146639||120467|
NCT01146366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0020|Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)|Utility of Routine Cervical Mediastinoscopy in Clinically Staged T2N0M0 and Select T1N0M0 Non-Small Cell Lung Cancers by FDG-PET and CT Scans||Washington University School of Medicine|No|Completed|January 2008|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|111|||Both|18 Years|N/A|No|Non-Probability Sample|Patients being evaluated by a thoracic surgeon for surgical resection of clinical stage I        non-small cell lung cancer|December 2014|December 10, 2014|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01146366||120488|
NCT01146665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011650|Pilot Study of a Computer-Based Intervention for Alcohol Misuse in the Emergency Department|Pilot Study of a Computer-Based Intervention for Alcohol Misuse in the Emergency Department||University of Alberta|No|Completed|July 2010|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01146665||120465|
NCT01146951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2080-J081-304|A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)|A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients||Eisai Inc.||Completed|June 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|4 Years|30 Years|No|||January 2014|January 29, 2014|June 14, 2010||No||No|May 13, 2013|https://clinicaltrials.gov/show/NCT01146951||120443|
NCT01146964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003|Comparison of Manual Super Small Incision Cataract Surgery and Phacoemulsification|Comparison of Manual Super Small Incision Cataract Surgery and Phacoemulsification||Wenzhou Medical University|Yes|Completed|May 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|N/A|No|||January 2014|January 2, 2014|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146964||120442|
NCT01147237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XILLION|Xience/Promus for Long Coronary Lesion Registry|A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease|XILLION|Society for Advancement of Coronary Intervention Research|Yes|Enrolling by invitation|February 2010|December 2012|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|450|||Both|18 Years|85 Years|No|||June 2010|June 17, 2010|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147237||120421|
NCT01147536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-100-38|Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence|A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage)for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence||Agenus, Inc.|No|Terminated|January 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|January 29, 2010|Yes|Yes|Sponsor's business decision|No||https://clinicaltrials.gov/show/NCT01147536||120398|
NCT01137331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K301-I|K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp|A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp||Moberg Derma AB|No|Completed|February 2008|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|70 Years|No|||June 2010|June 3, 2010|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137331||121177|
NCT01137929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genes-APN|Bacterial and Host Genetic Risk Factors in Acute Pyelonephritis|Bacterial and Host Genetic Risk Factors That Predispose Children to Acute Pyelonephritis and Renal Scarring||Children's Research Institute|No|Withdrawn|November 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|0|Samples With DNA|Urine samples: Urine is routinely collected at the time of presentation with fever to      diagnose UTI and an aliquot of this urine sample will be frozen for microbial genomic and      metagenomic sequencing and analysis, that will allow us to identify      unique/pathogenic/virulence factors in the genomes of these bacterial species when compared      to non-pathogenic strains that have been subject to whole genome sequencing.      Blood: DNA samples will be obtained at the time of renal scanning from the study subjects.      The genomic DNA is used in PCR reactions and the resulting PCR products are screened for      single nucelotide polymorphisms. Although we will be performing a genome wide association      study, we will be particularly curious as to the behavior of SNP's among certain previously      described candidates for the risk of renal scarring such as TLR2, TLR4, TGF-beta, and      TNF-alpha. DNA samples will be stored for possible use in other future association studies.|Both|2 Months|24 Months|No|Probability Sample|We will identify infants ≤ 2 years to be of particular risk for UTIF and renal scarring by        virtue of a variety of risk factors, including age, gender, race, and underlying genetic        risk factors and bacterial phenotypes.|October 2014|October 1, 2014|June 3, 2010||No|Difficulty identifying eligible candidates|No||https://clinicaltrials.gov/show/NCT01137929||121133|
NCT01144195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACROSS-08-01|A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy|An Open-label, Phase II Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy|ACTIVE|Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials|No|Active, not recruiting|September 2009|||December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2010|November 9, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01144195||120654|
NCT01144481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROVISTII|Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases|Prospective Identification of Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases|PROVISTII|University Health Network, Toronto|No|Completed|February 2009|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|serum and urine|Female|N/A|N/A|No|Probability Sample|female breast cancer patients with metastases to any site|January 2015|January 6, 2015|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01144481||120632|
NCT01144494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220-10-FB|Aqueous Humor Dynamics and Brimonidine|Circadian Rhythms of Aqueous Humor Dynamics in Subjects With Ocular Hypertension Using Brimonidine|Brimonidine|University of Nebraska|No|Not yet recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|N/A|No|||June 2010|June 14, 2010|June 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01144494||120631|
NCT01144767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04262010-5762|Computer-Based Physical Activity Advice for Ethnic Minority Aging Adults|Computer-Based Physical Activity Advice for Ethnic Minority Aging Adults||Stanford University|No|Completed|November 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Actual|40|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144767||120610|
NCT01144780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07092009-3060|Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry|Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry||Stanford University||Recruiting|September 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|blood and bone marrow|Both|18 Years|N/A|No|Non-Probability Sample|Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).|August 2010|August 9, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144780||120609|
NCT01145105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-09-0078-ctil|Neural Dynamics Technique for the Treatment of Chronic Radicular Low Back Pain|Efficacy of Neural Dynamics Technique in the Treatment of Chronic Low Back Pain With Radiation to the Leg||Clalit Health Services|No|Completed|June 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|65 Years|No|||July 2011|November 9, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01145105||120584|
NCT01145677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THoPA-R|Efficacy of Topiramate for Hospitalized Patients With Alcoholism|Efficacy of Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Randomized, Placebo-Controlled Trial|ETHoPA-R|Chiang Mai University|No|Completed|June 2010|June 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|60 Years|No|||June 2010|June 22, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01145677||120541|
NCT01145690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOFIE-5YFU|Five Year Follow-up of Internet-based Cognitive Behaviour Therapy (CBT) for Social Anxiety Disorder (SAD)|Five Year Follow-up of Internet-based Cognitive Behaviour Therapy for Social Anxiety Disorder|SOFIE-5YFU|Karolinska Institutet|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|The sample is constituted by all 80 participants who received Internet-based CBT in 2005        within the context of a RCT in Sweden.|June 2010|October 25, 2010|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145690||120540|
NCT01145976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-021|Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia|Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia|CyATG-FluATG|Cooperative Study Group A for Hematology|Yes|Recruiting|March 2010|February 2016|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|15 Years|65 Years|No|||September 2012|September 6, 2012|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01145976||120518|
NCT01146353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00023343|Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy|Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy||Midwestern University|No|Withdrawn|February 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients are male or female patients ≥18 years of age who are hospitalized,        undergoing CVVH or CVVHD, and receiving peramivir.        Eligible patients will additionally have the following: blood flow rate will be required        to be ≥100 mL/ min with an ultrafiltrate +/- dialysis flow rate greater than or equal to        3000mL/hr, and the continuous renal replacement therapy must be scheduled to run for the        full duration of the dosing interval (full 24 hours).        Written informed consent in a form approved by the Northwestern University and the        Midwestern University Institutional Review Boards will be granted by the patient.|June 2010|April 6, 2015|June 16, 2010||No|Peramivir EUA terminated by FDA.|No||https://clinicaltrials.gov/show/NCT01146353||120489|
NCT01146678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDR11578|Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1|A Randomized, Cross-over, Open, Euglycemic Clamp Study on the Relative Bioavailability and Activity of 0.6 U/kg Insulin Glargine and 20 μg Lixisenatide, Given as On-site Mix Compared to Separate Simultaneous Injections in Subjects With Type 1 Diabetes Mellitus||Sanofi|No|Completed|June 2010|January 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|65 Years|No|||March 2011|March 1, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146678||120464|
NCT01146691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2008:233|Effect of Around the Clock Intensivist Coverage on Intensive Care Unit (ICU) Outcomes|The Effect of Alternative Attending Physician Staffing Models on Outcomes for Intensive Care Unit Patients, Families, and Health Care Workers||University of Manitoba|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|627|||Both|17 Years|N/A|No|Non-Probability Sample|All patients admitted to the participating Intensive Care Units during the study period|June 2010|June 16, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146691||120463|
NCT01146704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7219-R|Gastrointestinal Hormonal Regulation of Obesity|Gastrointestinal Hormonal Regulation of Obesity||VA Office of Research and Development|No|Recruiting|September 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|198|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01146704||120462|
NCT01146977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-020|Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)|Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission|CBF(+)AML|Cooperative Study Group A for Hematology|No|Recruiting|January 2010|December 2015|Anticipated|January 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|43|||Both|15 Years|65 Years|No|||June 2010|June 17, 2010|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01146977||120441|
NCT01147224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-9709-401-DE|ATEM (Alvesco Non-interventional Study)|Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component|ATEM|Nycomed|No|Completed|March 2010|August 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|Outpatients|May 2012|May 4, 2012|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147224||120422|
NCT01147250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11319|Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome|ELIXA|Sanofi|Yes|Completed|June 2010|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6076|||Both|30 Years|N/A|No|||February 2016|February 16, 2016|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147250||120420|
NCT01147263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-JA-0678-09-CTIL|Palpitations and Tachycardia in Fibromyalgia Syndrome|Prevalence and Mechanism of Palpitations and Tachycardia in Fibromyalgia Syndrome||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2010|June 2012|Anticipated|June 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients attending a fibromyalgia clinic, fullfilling ACR 1990 criteria for        classification of fibromyalgia|June 2010|June 17, 2010|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147263||120419|
NCT01147549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00016|Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers|An Open-Label, Single-Centre, Phase I Study to Assess the Excretion, Metabolism and Plasma Pharmacokinetics Following a Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers|ADME|AstraZeneca|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|4|||Male|50 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 2, 2010|June 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01147549||120397|
NCT01147848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113091|HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents|A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents||GlaxoSmithKline|No|Completed|June 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|810|||Both|12 Years|N/A|No|||September 2013|July 10, 2014|May 27, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01147848||120374|
NCT01137656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|686|Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis|Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis||University of Pittsburgh|Yes|Completed|April 2010|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|53|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 10, 2015|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137656||121154|
NCT01137669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0016|ZOSTAVAX® in Renal Transplant Patients|Phase I Trial of ZOSTAVAX® Prior to Renal Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)||Terminated|September 2010|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|99 Years|No|||October 2015|October 22, 2015|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01137669||121153|
NCT01137682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230C2402|Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly|A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly|PAOLA|Novartis||Active, not recruiting|July 2010|December 2016|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|May 27, 2010|Yes|Yes||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01137682||121152|
NCT01137916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BDE70|Study to Evaluate Imatinib in Desmoid Tumors|Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss||Heidelberg University|Yes|Active, not recruiting|June 2010|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137916||121134|
NCT01168752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 0932-101|Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma|Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma||Debiopharm International SA|No|Completed|April 2010|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168752||118777|
NCT01168765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SPH-10-0015|Tu Salud Si Cuenta: UT Community Outreach Program for Community-based Diabetes Prevention and Control.|Tu Salud Si Cuenta: UT Community Outreach Program for Community-based Diabetes Prevention and Control|UTCO|The University of Texas Health Science Center, Houston|No|Completed|June 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01168765||118776|
NCT01148316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPq-HCFMUSP - 259|Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.|Adaptive Treatment Strategies for Children and Adolescents With Psychiatric Disorders in the Context of Public Health: "Medicine in Practice"|SMART|University of Sao Paulo|Yes|Completed|August 2010|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01148316||120338|
NCT01148329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2057|PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study|PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the PROMUS™ Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice|PE-Prove|Boston Scientific Corporation|No|Active, not recruiting|June 2010|March 2016|Anticipated|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1010|||Both|N/A|N/A|No|Non-Probability Sample|All patients who are candidates for Coronary artery stenting, signed the Informed Consent        Form and are eligible to receive a PROMUS™ Element™ stent will be evaluated for enrollment        in this study.|August 2013|August 9, 2013|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148329||120337|
NCT01144208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFOB-Rad|The Influence of Local Bone Status on Complications After Surgical Treatment of Distal Radius Fractures|The Influence of Local Bone Status on Complications After Surgical Treatment of Distal Radius Fractures||AO Clinical Investigation and Documentation|No|Completed|February 2007|April 2010|Actual|April 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|244|||Both|50 Years|90 Years|No|Probability Sample|participating clinics will identify all eligible patients who meet the inclusion and        exclusion|June 2010|June 15, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144208||120653|
NCT01144260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAFETINIB-P2-CLL-01|Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|A Pilot Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)||CytRx|No|Completed|June 2010|April 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01144260||120649|
NCT01144533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM-10-01|Comparative Analysis of Intra-articular Injection of Steroid and/or Sodium Hyaluronate in Adhesive Capsulitis|Comparative Analysis of Intra-articular Injection of Steroid and/or Sodium Hyaluronate in Adhesive Capsulitis: A Randomized, Double-blind, Placebo-controlled Trial||Seoul National University Hospital|No|Completed|June 2010|December 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01144533||120628|
NCT01144793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07102008-1246|Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias|A Pilot/Observational Study Using a Biomarker Monitoring System to Evaluate Protein Profiles of Neutropenic Fever/Infection in Patients With Acute or Chronic Leukemias Undergoing Chemotherapy or Other Biologic Treatment||Stanford University||Active, not recruiting|April 2008|May 2009|Anticipated|May 2008|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Acute or Chronic Leukemias|June 2010|June 15, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144793||120608|
NCT01145131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-065|Dietary Interventions for Muscle Mass|Dietary Interventions for Muscle Mass||Maastricht University Medical Center|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2011|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145131||120582|
NCT01145404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-2008-11-01-1015|Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer|Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial|GastroLap|National Center for Tumor Diseases, Heidelberg|Yes|Terminated|June 2010|October 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|May 21, 2010||No|Changes of SoC for third line therapy resulting in poor recruitment|No||https://clinicaltrials.gov/show/NCT01145404||120561|
NCT01145417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081251|Pregabalin Trial In HIV Neuropathic Pain|An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)||Pfizer|No|Terminated|July 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|217|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|June 7, 2010|Yes|Yes|See termination reason in detailed description.|No|May 7, 2013|https://clinicaltrials.gov/show/NCT01145417||120560|The parent double blind trial A0081244 (NCT01049217) was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated.
NCT01145703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040570|Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly|Effects of Vitamin D Supplementation With and With Out Exercise on Metabolic and Physical Consequences of Vitamin D Deficiency in the Elderly|VitD|Baltimore VA Medical Center|Yes|Terminated|May 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|39|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|June 16, 2010||No|Investigator terminated study due to low enrollment of eligible subjects|No||https://clinicaltrials.gov/show/NCT01145703||120539|
NCT01145989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I191|A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma||Canadian Cancer Trials Group|No|Completed|June 2010|November 2015|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145989||120517|
NCT01146002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guanfacine learning study|Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine|Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine||Neurology Group of Bergen County, P.A.|No|Completed|June 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|June 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146002||120516|
NCT01146379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0230|Does More Practice Improve Arm Movement After Stroke?|Dose Response of Movement Practice During Stroke Rehabilitation||Washington University School of Medicine|Yes|Completed|May 2010|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|85|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01146379||120487|
NCT01146717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032009-065|Aerobic Exercise Training in Mild Cognitive Impairment Study|Mild Cognitive Impairment:Cerebrovascular Dysfunction and Exercise|AETMCI|University of Texas Southwestern Medical Center|Yes|Active, not recruiting|March 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|102|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146717||120461|
NCT01146990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17P-FU-004|A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth|A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth||Lumara Health, Inc.|No|Recruiting|June 2010|October 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|584|||Both|22 Months|25 Months|No|Non-Probability Sample|Children whose mothers received 17P and those who received vehicle in the 17P Efficacy        Trial|December 2015|December 9, 2015|June 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01146990||120440|
NCT01148160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCZ-IPA-HEM-2010|Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy|The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis||Asan Medical Center|No|Terminated|August 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|-  Venous blood sampling will be carried out at steady state for therapeutic drug           monitoring(trough sampling:right before the dose)        -  Genotyping will be performed using peripheral blood.|Both|15 Years|N/A|No|Non-Probability Sample|Patients with hematologic malignancies who were given voriconazole to treat invasive        (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine,        Seoul, Korea|April 2014|April 9, 2014|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01148160||120350|
NCT01148472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10990|Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder|A Double-blind, Randomised, Multicenter, Comparative Study of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|September 2005|November 2006|Actual|September 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|294|||Both|18 Years|65 Years|No|||June 2010|June 21, 2010|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01148472||120326|
NCT01137383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRC.86.90|Pegaferon and Ribavirin for Hepatitis C|Safety and Efficacy of Locally Manufactured Pegylated Interferon in Hepatitis C Patients||Tehran University of Medical Sciences|No|Completed|December 2007|February 2010|Actual|December 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|15 Years|65 Years|No|||June 2010|June 28, 2010|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137383||121174|
NCT01137396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911005989|Modafinil, Sleep Architecture and Cocaine Relapse|Modafinil, Sleep Architecture and Cocaine Relapse||Yale University|No|Recruiting|April 2010|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|25 Years|50 Years|No|||July 2012|January 21, 2015|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137396||121173|
NCT01137695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEFCon2|Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus|Symlin® Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus||North Jersey Endocrine Consultants, LLC|No|Active, not recruiting|May 2010|April 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|80 Years|No|||October 2011|October 13, 2011|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137695||121151|
NCT01137708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921071|CP-690,550 And Oral Contraception Drug-Drug Interaction Study|A Phase 1, Randomized, Open Label, 2-Way Crossover Study To Assess The Effect Of Multiple Dose CP-690,550 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids In Healthy Female Subjects||Pfizer|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 5, 2010|May 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137708||121150|
NCT01135979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07AN007|Assessment of the Sympathetic Nervous System Blockade of the Upper Limb After a Brachial Plexus Block in Patients With End Stage Renal Failure|Assessment of the Sympathetic Nervous System Blockade of the Upper Limb After a Brachial Plexus Block in Patients With End Stage Renal Failure||University of Nottingham|No|Withdrawn|February 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with end stage renal failure who are due to have a forearm fistula created|March 2013|March 5, 2013|June 2, 2010||No|Unable to recruit|No||https://clinicaltrials.gov/show/NCT01135979||121279|
NCT01135992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3839|Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)|A Trial Assessing the Implications of Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™: SIMPLIFY)|BEGIN™|Novo Nordisk A/S|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|May 31, 2010|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01135992||121278|
NCT01143987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010.084-T|Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism|Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism||Chinese University of Hong Kong|No|Completed|June 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01143987||120670|
NCT01144221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1764|Bone Marrow Derived Mononuclear Cells for Ischemic Cardiomyopathy|Protocol on an Evaluative Study on Bone Marrow Derived Mononuclear Cells for Optimization of Biventricular Pacing in Patients With Chronic Ischemic Left Ventricular Dysfunction|Alster-Star|Asklepios proresearch|No|Recruiting|May 2010|||May 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||August 2012|August 10, 2012|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144221||120652|
NCT01144234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InvolvMaleUg|Male Involvement in Antenatal Care and the Prevention Programme of Mother-to-child Transmission of HIV in Uganda|Facility-based Intervention to Increase Male Involvement in Antenatal Care and the Prevention Programme of Mother-to-child Transmission of HIV in Eastern Uganda|InvolvMaleUg|Centre For International Health|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1060|||Both|15 Years|N/A|No|||January 2013|January 12, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144234||120651|
NCT01144546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0809-037-256|Passive Leg Raising Test to Predict Hypotension During Induction of Anesthesia in Patients Undergoing Cardiac Surgery|Passive Leg Raising Test to Predict Hypotension During Induction of Anesthesia in Patients Undergoing Cardiac Surgery||Seoul National University Hospital|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Both|18 Years|80 Years|No|||June 2010|June 14, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01144546||120627|
NCT01144507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFLD PUSH|Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis|Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)|PUSH|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|January 2009|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|800|Samples With DNA|During this study, blood and urine specimens will be obtained, de-identified and shipped to      and stored at the NIDDK repositories for use in future CFLD ancillary studies. This      "biobanking" is a critical aspect of this longitudinal study to facilitate the creation of a      resource of DNA and other specimens from a meaningful number of patients with CFLD. In      addition, obtaining and storing DNA or EBV-transformed leukocytes (from which DNA can be      extracted) will allow future studies to investigate genetic causes and influences (modifier      genes) in CFLD.|Both|3 Years|12 Years|No|Non-Probability Sample|The study population will consist of males and females 3 through 12 years of age with        Cystic Fibrosis and pancreatic insufficiency who are enrolled in the CFF or Toronto CF        registry studies. All racial and ethnic groups will be included.|December 2015|December 17, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144507||120630|
NCT01144520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0270|Leukocyte Dysfunction in Diabetic Patients.|Leukocyte Dysfunction in Diabetic Patients.||Ohio State University|No|Active, not recruiting|March 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|N/A||4|Anticipated|200|Samples With DNA|Blood|Both|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the population who visit the Ohio State University (OSU)        Hospitals and Comprehensive Wound Center (CWC), OSU Wexner Medical Center diabetic clinics        and Bariatric clinic.|January 2015|January 23, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144520||120629|
NCT01145144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc07204-2006ctil|Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment|||Meir Medical Center||Completed|January 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|42 Years|No|||June 2010|June 15, 2010|May 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01145144||120581|
NCT01145157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMET AU03 (INT.CR.LAU3)|A Comparison Between Signature Total Knee Arthroplasty (TKA) to Conventional TKA and Computer Assisted TKA|A Comparison Between 'Signature™ Personalised Patient Care' to Conventional Total Knee Arthroplasty and Computer Assisted Navigation and a Cost Benefit Analysis for the Australian Market||Biomet, Inc.|No|Completed|July 2010|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||July 2014|June 22, 2015|June 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145157||120580|
NCT01145118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-10-0037-ctil|Reliability of Functional Outcome Measures in Plantar Fascitis Patients|Reliability of Functional Outcome Measures in Plantar Fascitis Patients||Clalit Health Services|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|21 Years|65 Years|No|Probability Sample|Individuals referred to community physiotherapy center for plantar Fasceitis treatment.|January 2012|January 21, 2012|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01145118||120583|
NCT01145716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC Linkoping TFCC volar expl|Exploration of Wrist Soft Tissue Injuries Associated With Wrist Fractures|Exploration of Acute TFCC-injuries in Association With Distal Radius Fractures||Linkoeping University|No|Completed|August 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|65 Years|No|||November 2009|May 19, 2011|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01145716||120538|
NCT01145729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21|Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure|Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure||Minneapolis Veterans Affairs Medical Center|No|Active, not recruiting|June 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|12 Months|36 Months|Accepts Healthy Volunteers|||March 2010|June 16, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01145729||120537|
NCT01146015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S201.3.130|Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2010/2011. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects||Abbott|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 24, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01146015||120515|
NCT01146028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01220|Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Tizanidine Hydrochloride 4mg Tablets and Zanaflex® 4mg Tablets Administered As 1 x 4mg Tablet in Healthy Adult Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|September 2001|November 2001|Actual|September 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|January 12, 2012|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146028||120514|
NCT01146392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RSE-DUM-2010/1|An Investigation of the Past 10 Yrs Health Care for Primary Care Patients With Chronic Obstructive Pulmonary Disease|A Retrospective Epidemiological Study to Map Out Patients With Chronic Obstructive Pulmonary Disease (COPD) and Describe COPD Health Care in Real-Life Primary Care During the First Ten Years of the 21th Century|PATHOS|AstraZeneca|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|27394|||Both|N/A|N/A|No|Non-Probability Sample|Eligible subjects are all COPD patients, found in medical records at the participating        swedish primary care clinics. Primarily patients with diagnosis code J44 (ICD-10) stated        in the medical record will be investigated. Patient data from the period 1 January 1999 -        31 December 2009 will be included in the observation.|June 2014|June 17, 2014|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146392||120486|
NCT01146418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06031|Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)|Follow-up Protocol to Collect the Outcome and Safety of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Study P06029 (Phase 3; Protocol No. P06031)||Merck Sharp & Dohme Corp.|No|Completed|June 2010|April 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|307|||Female|35 Years|42 Years|No|||January 2016|January 4, 2016|June 11, 2010|Yes|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01146418||120484|
NCT01147276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lund University Diabetes 002|Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes|Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Patients With Type 1 Diabetes||Lund University|Yes|Completed|September 2010|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|65 Years|No|||September 2012|September 21, 2012|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147276||120418|
NCT01147289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 102|Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain|A Phase III, Randomized, Multicenter, Open Label Clinical Trial: Efficacy and Safety of the Injectable Association of Dexamethasone, Dipyrone, and Hydrocobalamin in Lumbar Sciatic Pain|Dextra|Eurofarma Laboratorios S.A.|No|Completed|February 2011|April 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01147289||120417|
NCT01147861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114187|A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics|A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.||GlaxoSmithKline|No|Completed|July 2010|October 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|39|||Both|20 Years|70 Years|No|||May 2011|May 12, 2011|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01147861||120373|
NCT01147874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A6-4728|Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice|Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice|PREPARE|Pfizer|No|Completed|August 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1013|||Both|18 Years|N/A|No|||April 2012|May 18, 2012|June 17, 2010||No||No|May 18, 2012|https://clinicaltrials.gov/show/NCT01147874||120372|
NCT01144338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5551C00003|Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus|Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.||AstraZeneca|Yes|Active, not recruiting|June 2010|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14000|||Both|18 Years|130 Years|No|||January 2016|January 5, 2016|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144338||120643|
NCT01144611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-002-2009|Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery|A Randomized, Double-blind, Placebo-controlled Phase IIIa Study on bIAP, an Anti-inflammatory Moiety, in Patients Undergoing Combined Aortic Valve Replacement and Coronary Artery Bypass Grafting|APPIRED-II|Alloksys Life Sciences B.V.|No|Completed|April 2010|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|N/A|No|||June 2011|February 24, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144611||120622|
NCT01145222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS 7056-004|Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy|A Phase IIb Study Evaluating the Safety and Efficacy of Multiple Doses of CNS 7056 Compared to Midazolam in Patients Undergoing Colonoscopy||Paion UK Ltd.|No|Completed|May 2010|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|162|||Both|18 Years|70 Years|No|||August 2011|August 4, 2011|May 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145222||120575|
NCT01167985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191062 HMO-CTIL|A Clinical Study: the Antibacterial Effect of Insoluble Antibacterial Nanoparticles (IABN) Incorporated in Dental Materials for Root Canal Treatment|Clinical Study: Evaluation of the Antibacterial Effect of Insoluble Antibacterial Nanonparticles Incorporated in Dental Materials for Endodontic Treatment|IABN|Hadassah Medical Organization|No|Recruiting|July 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 20, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01167985||118836|
NCT01168518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLEA01-FINE|An Observational Study on the Sorin Group New Brady Leads XFine and Beflex|Performance of the New Generation of Sorin Group Brady Leads In a Normal Hospital Practice|XFine & Beflex|LivaNova|No|Completed|July 2008|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2254|||Both|18 Years|N/A|No|Probability Sample|Any patient implanted with an endocavitary pacing lead (atrial and/or ventricular)        connected to a single, double or triple chamber pacemaker or defibrillator.|September 2014|September 26, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01168518||118795|
NCT01135719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04302009-2458|A Comparison of Fellow Eyes Undergoing LASIK or PRK With a Wavefront-guided Excimer Laser Versus a Wavefront-optimized Excimer Laser|A Prospective Randomized Comparison of Fellow Eyes Undergoing LASIK or PRK With a Wavefront-guided Excimer Laser Versus a Wavefront-optimized Excimer Laser||Stanford University|No|Active, not recruiting|April 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|May 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01135719||121299|
NCT01136304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URFLSD-2010-01|Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)|Retrospective and Prospective Validation of a Disease Severity Score System (DS3) for Adults With Type 1 Gaucher Disease (GD1)||University Research Foundation for Lysosomal Storage Diseases, Inc.|No|Completed|April 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|173|Samples With DNA|Whole blood Buccal smears|Both|18 Years|N/A|No|Non-Probability Sample|Consenting adult patients with type 1 Gaucher disease who are cared for at one of the        participating research sites and who are enrolled in the International Collaborative        Gaucher Group Gaucher Registry|May 2015|May 29, 2015|May 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01136304||121254|
NCT01136317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD10/1-P|Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects||Oberab|Nantes University Hospital|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|N/A|3||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136317||121253|
NCT01144000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBC134ACH03T|Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection|Efficacy and Safety of Daptomycin (With or Without Rifampin) in the Treatment of Staphylococcal Hip, Knee and Shoulder Prosthetic Joint Infection|Dapto-Studie|Centre Hospitalier Universitaire Vaudois|Yes|Not yet recruiting|June 2012|June 2016|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||June 2012|June 24, 2012|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144000||120669|
NCT01144013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 024|Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring|A Double-Blind, Randomised, Placebo-Controlled Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess Delivery of Dapivirine From the Matrix Vaginal Ring Containing 25 MG of Dapivirine||International Partnership for Microbicides, Inc.|Yes|Completed|August 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|16|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2010|June 14, 2010|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01144013||120668|
NCT01144026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYMON-10001|Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects|Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects|THYMON-10001|Thymon, LLC|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|June 12, 2010|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT01144026||120667|
NCT01144247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA 07-09-008|Cellular Immunotherapy Study for Brain Cancer|A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas|alloCTL|Jonsson Comprehensive Cancer Center|Yes|Withdrawn|July 2010|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2015|October 28, 2015|June 11, 2010|No|Yes|Closed without Enrollment|No||https://clinicaltrials.gov/show/NCT01144247||120650|
NCT01145183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA018197-05|Pharmacogenetics of Doxazosin for Cocaine Dependence|H-26605: Pharmacogenetics of Doxazosin for Cocaine Dependence||Baylor College of Medicine|Yes|Completed|March 2010|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|84|||Both|18 Years|64 Years|No|||January 2016|January 25, 2016|June 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145183||120578|
NCT01144806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1400-Ped-ERC-09|Evaluation of Energy Expenditure, Body Composition and Recovery Rates in Children With Severe Acute Malnutrition|Evaluation of Energy Expenditure, Body Composition and Recovery Rates in Children With Severe Acute Malnutrition (SAM) Receiving Community-based Nutritional Rehabilitation Therapy||Aga Khan University|No|Completed|June 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|6 Months|3 Years|No|||February 2012|February 23, 2012|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01144806||120607|
NCT01144819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23374|Platelet Inhibition in the Acute Phase of STEMI|Platelet Inhibition in the Acute Phase of ST-segment Elevation Myocardial Infarction||University of Aarhus|No|Completed|October 2009|August 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|Samples With DNA|Blood sample 1:        -  Whole blood (Platelet aggregation tests and flowcytometry)        -  Serum        -  S-Thromboxane B2        -  S-Trombopoeitin        -  S-P-selectin        -  Plasma        -  DNA        -  RNA      Blood sample 2:        -  Whole blood        -  Plasma      Blood sample 3:        -  Whole blood        -  Plasma      Blood sample 4:        -  Whole blood (Platelet aggregation tests and flowcytometry)        -  Serum        -  S-Thromboxane B2        -  S-Trombopoeitin        -  S-P-selectin        -  Plasma        -  DNA        -  RNA|Both|18 Years|N/A|No|Non-Probability Sample|Residents of the Central Denmark Region.|September 2013|September 6, 2013|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01144819||120606|
NCT01145170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF090|Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma|Use of Nimotuzumab and Radiotherapy in the Treatment of Pediatric Patients With Diffuse Intrinsic Brainstem Glioma|POLARIS|Eurofarma Laboratorios S.A.|Yes|Completed|March 2011|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|3 Years|18 Years|No|||January 2012|July 24, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145170||120579|
NCT01145768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00006|To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days|A Phase 1, Single Center, Double-blind, Randomized, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TC-5214 (S-Mecamylamine) After Administration of Single and Multiple Ascending Doses for up to 8 Days in Healthy Male and Female Subjects||AstraZeneca|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|June 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01145768||120534|
NCT01145430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03161|Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer|Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer||National Cancer Institute (NCI)|Yes|Recruiting|June 2010|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|June 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01145430||120559|
NCT01145443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-05-00307|Multicenter Intensivist Weekend Scheduling Study|A Multicenter Study of the Effect of Intensive Care Unit Attending Physician Work Schedules on Outcomes Relevant to Society||University of Manitoba|No|Completed|June 2005|September 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|1945|||Both|17 Years|N/A|No|Non-Probability Sample|All patients admitted to the participating Intensive Care Units during the study period|June 2010|June 15, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01145443||120558|
NCT01145755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0475C00020|6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder|A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020||AstraZeneca||Terminated|May 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|131|||Both|18 Years|65 Years|No|||September 2012|September 27, 2012|May 27, 2010|Yes|Yes||No|August 28, 2012|https://clinicaltrials.gov/show/NCT01145755||120535|
NCT01146041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30479|Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Rivastigmine 1.5 mg Capsules and Exelon Administered as 1 x 1.5 mg Capsule in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|February 2004|April 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 16, 2010|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146041||120513|
NCT01146054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0007|Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma|Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma||Stanford University|Yes|Active, not recruiting|October 2009|September 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01146054||120512|
NCT01146067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30496|Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions|Bioequivalence Study of Rivastigmine 1.5 mg Capsules (Test)of Dr.Reddy's Laboratories Limited Versus Exelon (Reference),Administered as 1 x 1.5 mg Capsule Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|January 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|January 12, 2012|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146067||120511|
NCT01146405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|918/09|Memory During Anesthesia: the Role of Stress Hormones|||Catholic University of the Sacred Heart|No|Recruiting|June 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|110|Samples Without DNA|Whole blood and serum.|Both|18 Years|70 Years|No|Probability Sample|Patients sheduled for minor elective laparoscopic surgery|October 2009|February 8, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01146405||120485|
NCT01147003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2207|Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures|A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures||Novartis||Completed|June 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|65 Years|No|||March 2013|March 6, 2013|June 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147003||120439|
NCT01147016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000675211|Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery|A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers||Barbara Ann Karmanos Cancer Institute|Yes|Suspended|July 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|120 Years|No|||February 2016|February 18, 2016|June 17, 2010|Yes|Yes|Primary co-investigator leaving the institution & funding transfer.|No||https://clinicaltrials.gov/show/NCT01147016||120438|
NCT01147042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100123|Assessment of the Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease|Assessment of the Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease||National Institutes of Health Clinical Center (CC)||Terminated|May 2010|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||December 2014|September 24, 2015|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147042||120436|
NCT01147939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-306|Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)|A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia|CLAVELA|Clavis Pharma|Yes|Completed|June 2010|June 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|381|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|April 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147939||120367|
NCT01144923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00036062|Conservative Therapy Versus Epidural Steroids for Cervical Radiculopathy|Randomized, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Conservative Management With Medications and Physical Therapy in Patients With Cervical Radiculopathy||Johns Hopkins University|Yes|Completed|June 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|169|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144923||120598|
NCT01135732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10438|Cytological Evaluation of Biliary Epithelium After Endoscopic Sphincterotomy|Cytological Evaluation of Biliary Epithelium After Previous Endoscopic Sphincterotomy for Benign Disease||University of Athens|Yes|Completed|October 2006|||June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|56|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing ERCP and ES for benign disease|October 2009|November 15, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135732||121298|
NCT01136005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esperanz-001|Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)|Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of Papulopustular Eruption in Patients Receiving Epidermal Growth Factor Receptor Inhibitors (EGFRI): BeCet|BeCet|Waterland Hospital|No|Recruiting|September 2010|June 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136005||121277|
NCT01135420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAC 09-055|Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes|Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes||VA Office of Research and Development|No|Active, not recruiting|April 2011|June 2015|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|270|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01135420||121322|
NCT01135433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0106|A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients|A Phase 3, Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone||Astellas Pharma Inc|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|June 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01135433||121321|
NCT01136291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|exerciseobesitypregnancy|Physical Exercise Influence Among Overweight and Obese Pregnant Women|Physical Exercise Influence on Maternal, Perinatal Outcomes and Quality of Life Among Overweight and Obese Pregnant Women:||University of Campinas, Brazil|No|Completed|August 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|82|||Female|18 Years|N/A|No|||March 2011|March 20, 2011|May 21, 2010||No||No|December 10, 2010|https://clinicaltrials.gov/show/NCT01136291||121255|
NCT01136616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS/SUR-PRAS/2010/3|CT Analysis of Structural Buttresses in the Traumatised Nose|CT Analysis of Structural Buttresses in the Traumatised Nose - A Basis for Decision Making for Early Open Rhinoplasty and Biomechanical Study of Nasal Structural Support||National University Hospital, Singapore|Yes|Completed|May 2009|May 2013|Actual|May 2013|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|67|||Both|21 Years|80 Years|No|Non-Probability Sample|67 consecutive patients admitted for facial fractures and who undergo routine CT scans of        the face with our protocol of axial and coronal sections taken at 0.6mm and gantry 0 are        to be studied. The CT scans are evaluated to assess the position, comminution and        displacement of the 5 said buttresses.|April 2014|April 1, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136616||121231|
NCT01136629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS/SUR-PRAS/2010/4|Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion|Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion.||National University Hospital, Singapore|Yes|Recruiting|June 2008|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|160|||Both|21 Years|80 Years|No|Non-Probability Sample|Subjects age 21 to 80 year old, who have elected to undergo a plastic surgery will be        enrolled. Patients will be from Chinese, Malay, Indian or Caucasian ancestry. Patients        will be female or male with hyper-pigmented spots.|January 2014|January 26, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136629||121230|
NCT01148394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-1|Enhanced Recovery After Colorectal Surgery|Impact of the Introduction of a Multimodal Rehabilitation Programme for Colorectal Patients. A Prospective Randomized Trial.||University of Valencia|No|Completed|January 2009|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|N/A|No|||June 2010|June 21, 2010|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148394||120332|
NCT01148407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 0806|Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer|Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer||University of Vermont|No|Recruiting|June 2010|August 2013|Anticipated|August 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|30|Samples Without DNA|plasma, serum and platelet activated blood samples|Both|18 Years|N/A|No|Probability Sample|Patients with a malignancy diagnosis.|April 2011|April 21, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148407||120331|
NCT01144273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol ver 1.1|Transversus Abdominis Plane Block From Abdominal Approach|Transversus Abdominis Plane Block From Intraabdominal Approach in Patients Undergoing Total Abdominal Hysterectomy: a Randomized Controlled Trial||United Christian Hospital|Yes|Recruiting|May 2010|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||June 2010|June 29, 2010|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144273||120648|
NCT01145482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-05-0007|Mechanisms of Insulin Facilitation of Memory|Mechanisms of Insulin Facilitation of Memory||University of Texas at Austin|Yes|Completed|July 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|21 Years|N/A|No|||October 2014|October 30, 2014|June 15, 2010|No|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01145482||120555|
NCT01144832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51638|Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists|IBS Treatment With H1-receptor Antagonists||Katholieke Universiteit Leuven|No|Completed|October 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|May 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144832||120605|
NCT01144845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTPS-18|Chronic Pain Following Thoracic Surgery|Study of Persistent Postsurgical Pain Following Thoracic Surgery in Patients With Pulmonary Malignancies|PTPS-18|University of Aarhus|No|Completed|April 2010|October 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|702|||Both|N/A|N/A|No|Probability Sample|Patients who underwent thoracic surgery due to pulmonary malignancies at the Department of        Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Skejby, Denmark|August 2011|August 27, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144845||120604|
NCT01145781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|649|Trial to Evaluate Single- and Double-freeze Cryotherapy in the Prevention of Cervical Neoplasia|RANDOMISED INTERVENTION TRIAL TO EVALUATE SINGLE- AND DOUBLE- FREEZE CRYOTHERAPY IN THE PREVENTION OF CERVICAL NEOPLASIA||Tata Memorial Hospital|No|Recruiting|January 2010|||January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|440|||Female|25 Years|64 Years|No|||June 2010|June 16, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01145781||120533|
NCT01145456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01433|Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors|A Phase I Study of R04929097 in Combination With Gemcitabine in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|June 2010|||November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2013|February 21, 2014|June 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01145456||120557|
NCT01145742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-232|Controlling Hypertension in Diabetes- Feasibility Study|A Collaborative Approach to Control Hypertension in Diabetes|COACH-D|Albert Einstein College of Medicine of Yeshiva University|No|Completed|November 2006|September 2009||September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Health Services Research|2||Actual|56|||Both|30 Years|N/A|No|||June 2010|June 17, 2010|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145742||120536|
NCT01146431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/1051/2009|Memory During Inhalation Anesthesia Performed With or Without Bispectral Index (BIS) in Patients Undergoing Thyroidectomy|||Catholic University of the Sacred Heart||Recruiting|June 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|18 Years|70 Years|No|Probability Sample|Patients undergoing general anesthesia for thyroidectomy|January 2010|February 8, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01146431||120483|
NCT01146444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL0814-SPRG0801/KHMR|Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)|Investigation of the Efficacy of Different Sunscreens in Patients With Photosensitive Cutaneous Lupus Erythematosus||Spirig Pharma Ltd.|Yes|Completed|November 2009|November 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2013|March 8, 2016|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01146444||120482|
NCT01146730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Workcoping2010|At Work and Coping - Effect Study of Workcoping for Patients With Anxiety and Depression|At Work and Coping - Effect Evaluation of Center for Workcoping for Patients With Anxiety and Depression|AWaC|Uni Research|Yes|Active, not recruiting|June 2010|December 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1202|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01146730||120460|
NCT01146132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRP-Santé|Nutrition and Physical Activity in Patients With Cerebrovascular Disease|Nutrition and Physical Activity in Patients With Cerebrovascular Disease|ALVINA|Public Research Centre Health, Luxembourg|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|119|||Both|30 Years|N/A|No|||October 2012|October 4, 2012|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01146132||120506|
NCT01146145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P020401|Efficacity, Safety and Cost of Intravenous Morphine Titration Alone or Combined to Ketamine|Efficacity, Safety and Cost of Intravenous Morphine Titration Alone or Combined to Ketamine|KEMO|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2003|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|75 Years|No|||June 2010|June 16, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146145||120505|
NCT01147601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6114|Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas|Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas: A Prospective Double Blinded Placebo Controlled Study||Oregon Health and Science University|Yes|Recruiting|March 2010|||March 2011|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|1 Month|8 Months|No|||June 2010|June 18, 2010|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01147601||120393|
NCT01147926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD555-302|Evaluation of Prucalopride in Male Subjects With Chronic Constipation.|A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Prucalopride in Male Subjects With Chronic Constipation||Shire|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|374|||Male|18 Years|N/A|No|||August 2014|March 4, 2015|June 17, 2010||No||No|August 29, 2014|https://clinicaltrials.gov/show/NCT01147926||120368|
NCT01148511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002ATR01|Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)|Comparison of Safety, Effectiveness, and Quality-of-life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to AMD|SALUTE|Novartis||Completed|February 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|50 Years|N/A|No|||May 2013|May 23, 2013|June 21, 2010||No||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01148511||120323|
NCT01144624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0620C00005|A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock|A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous Infusions of AZD9773 (CytoFab™) in Japanese Patients With Severe Sepsis and/or Septic Shock||AstraZeneca|Yes|Completed|July 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|N/A|No|||September 2014|September 26, 2014|June 7, 2010|Yes|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT01144624||120621|
NCT01146158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070154|Axillary Reverse Mapping for Breast Carcinomas|Individualisation of the Lymphatic Arm Drainage During Axillary Dissection for Breast Carcinomas.|SENTIBRAS|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Female|18 Years|70 Years|No|||May 2009|April 7, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01146158||120504|
NCT01146171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA196-007|Japanese Phase 1 Study of BMS-844203 (CT322)|A Phase I Multiple Ascending Dose Study of BMS-844203 (CT-322) Monotherapy in Japanese Patients With Solid Tumors||Bristol-Myers Squibb|No|Withdrawn|November 2013|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|N/A|No|||February 2012|February 6, 2012|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01146171||120503|
NCT01135459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33457/2047|A Study to Evaluate the Efficacy and Safety of CEP-33457 in Patients With Systemic Lupus Erythematosus|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus||Teva Pharmaceutical Industries||Completed|June 2010|June 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|70 Years|No|||September 2013|September 9, 2013|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01135459||121319|
NCT01136018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0016|A Prospective Evaluation of Iodinated Contrast Flow Patterns in Caudal Epidurography With Intentional Lateral Caudal Approach|||Yonsei University||Completed|April 2010|April 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|22|||Both|20 Years|N/A|No|Non-Probability Sample|24|April 2011|April 18, 2011|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01136018||121276|
NCT01136031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0703-042-201|Paclitaxel and Irinotecan in Advanced Gastric Cancer|A Phase I/II Trial of Second-line Chemotherapy With Paclitaxel and Irinotecan in Fluoropyrimidine- and Platinum-Pretreated Advanced Gastric Cancer|TI-2ndAGC|Seoul National University Hospital|No|Completed|January 2008|August 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|70 Years|No|||May 2010|May 19, 2015|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01136031||121275|
NCT01136057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-046|Blood and Plasma Collection For Use in Future Clinical Trials|A Pilot Study for Collection of High-Titer Anti-Influenza A Plasma||National Institute of Allergy and Infectious Diseases (NIAID)|No|Active, not recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood will be collected from participants.|Male|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will include people who have recovered from influenza, received a seasonal        influenza vaccine, or have both recovered from influenza and received a seasonal influenza        vaccine.|December 2015|December 14, 2015|May 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01136057||121273|
NCT01136330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFM-13286|DM1 Heart Registry - DM1 Respiratory Registry|Cardiac and Respiratory Prognostic Factors in Patients With Myotonic Dystrophy Type 1|DM1-Heart-R|Institut de Myologie, France|No|Completed|May 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|914|||Both|18 Years|N/A|No|Non-Probability Sample|Myotonic dystrophy type 1|February 2012|February 17, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136330||121252|
NCT01136889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG957|PEssary Plus Physiotherapy for Pelvic Organ Prolapse (PEPPY)|A Feasibility Study for a Randomised Controlled Trial of Pelvic Floor Muscle Training Combined With Vaginal Pessary for Women With Pelvic Organ Prolapse.|PEPPY|Glasgow Caledonian University|No|Completed|April 2008|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Female|16 Years|N/A|No|||January 2011|January 18, 2011|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01136889||121210|
NCT01144039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VI_echo_01_2006|Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair|Glutamate Infusion in Hypertrophied Ventricle After Aortic Valve Replacement - a Randomized Trial||Medical University of Vienna|No|Completed|February 2006|September 2008|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|27|||Both|19 Years|90 Years|No|||September 2008|June 15, 2010|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144039||120666|
NCT01144858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|past-1001-ryth|Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation|Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation|CLAAAF|Clinique Pasteur|No|Terminated|January 2009|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|80 Years||Probability Sample|40 consecutive patients who underwent first-time radiofrequency catheter ablation for pAF.        pAF was defined as continuous AF lasting longer than 1 month, resistant to either        electrical or pharmacological cardioversion|October 2008|June 15, 2010|June 15, 2010||No|40 patients|No||https://clinicaltrials.gov/show/NCT01144858||120603|
NCT01144871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1095-31348|Parental Knowledge and Attitudes of Confidential Sexually Transmitted Infections (STI) Services for Teens|Parental Knowledge and Attitudes of Confidential STI Services for Teens||University of California, San Francisco|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|1216|||Both|N/A|N/A|No|Non-Probability Sample|Parents/Guardians who have adolescents between 12-17 years of age|October 2014|October 25, 2014|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144871||120602|
NCT01146457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000197|The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia|The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia||Beth Israel Deaconess Medical Center|No|Terminated|July 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|89|||Female|18 Years|50 Years|No|||January 2015|January 28, 2015|June 14, 2010||No|Principal Investigator|No||https://clinicaltrials.gov/show/NCT01146457||120481|
NCT01146743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS_GB1|Prospective Trial for Endoscopic Ultrasound Guided Gallbladder Drainage for Acute Cholecystitis in High Risk Patients|Prospective Randomized Controlled Trial for Endoscopic Ultrasound Guided and Percutaneous Transhepatic Gallbladder Drainage for Acute Cholecystitis in High Risk Patients||Asan Medical Center|No|Completed|June 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||March 2011|March 16, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01146743||120459|
NCT01145469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000674957|Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy|Genome Wide Association Study Evaluating Genetic Factors Related to the Efficacy and Tolerability of Fludarabine Treatment in Patients With CLL||National Cancer Institute (NCI)||Not yet recruiting|July 2010|||August 2010|Anticipated|N/A|Observational|N/A|||Anticipated|225|||Both|18 Years|N/A|No|||June 2010|August 3, 2010|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145469||120556|
NCT01146756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09_DOG07_104|MEK Inhibitor and Thoracic Radiotherapy Trial|Phase I Trial of the MEK Inhibitor AZD6244 in Combination With Thoracic Radiotherapy in Non-small Cell Lung Cancer|MEKRT|Christie Hospital NHS Foundation Trust|No|Recruiting|May 2010|August 2017|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01146756||120458|
NCT01146080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG-001-09|Optical Coherence Tomography for EVERolimus Eluting STent|Optical Coherence Tomography for EVERolimus Eluting STent (OCTEVEREST)|OCTEVEREST|A.O. Ospedale Papa Giovanni XXIII|Yes|Completed|February 2010|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146080||120510|
NCT01146093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-138|Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Pravastatin 80 mg Tablets in Healthy Volunteers||Dr. Reddy's Laboratories Limited|No|Completed|November 2002|March 2003|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|January 12, 2012|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146093||120509|
NCT01144598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-087|Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey|Time to DMARD Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey||Abbott|No|Completed|February 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|356|||Both|18 Years|N/A|No|Non-Probability Sample|As this study is non-randomized, the normal study population and design requirements for        power calculations are not met. Therefore, the results of the following should be        interpreted as indicative only. Subjects will be recruited from rheumatology outpatient        clinics of university hospitals and/or private offices.        Patients diagnosed with rheumatoid arthritis who had received at least one        disease-modifying anti-rheumatic drug, who are already employed at a paid work and are        able to provide disease history data will be included.|September 2012|September 21, 2012|May 28, 2010||No||No|August 17, 2012|https://clinicaltrials.gov/show/NCT01144598||120623|
NCT01146769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMTIMS-01|Early Pelvic Floor Muscle Training Improves Pelvic Floor Muscle Strength in Patient After Low Anterior Resection|Early Pelvic Floor Muscle Training Improves Pelvic Floor Muscle Strength in Patient After Low Anterior Resection||Kwong Wah Hospital|No|Recruiting|April 2010|April 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2010|June 17, 2010|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01146769||120457|
NCT01146782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10753|Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea|The ATLAST Trial - A Multicenter, Prospective Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)|ATLAST|ApniCure, Inc.|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|367|||Both|18 Years|80 Years|No|||May 2014|May 28, 2014|June 15, 2010|Yes|Yes||No|January 13, 2014|https://clinicaltrials.gov/show/NCT01146782||120456|
NCT01148186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-2009MOP-201314-KTE|An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults|The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults||Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|Yes|Terminated|June 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|300|||Both|65 Years|N/A|No|||May 2013|May 14, 2013|June 21, 2010||No|Study funding period reached conclusion. Sample size sufficient to complete the analysis on    benzodiazepines.|No||https://clinicaltrials.gov/show/NCT01148186||120348|
NCT01144637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POX-MVA-013|A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects|A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects||Bavarian Nordic|Yes|Completed|February 2013|June 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|4005|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01144637||120620|
NCT01141062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|998933A|Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|HIFU|Philips Healthcare|No|Completed|June 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|59 Years|No|||December 2012|December 3, 2012|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01141062||120893|
NCT01145261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5846|The Relationship Between Emotional Regulation Strategies And Cognitive Behavioral Treatment Effectiveness In Childhood Anxiety Disorders: A Longitudinal Prospective Study|The Relationship Between Emotional Regulation Strategies And Cognitive Behavioral Treatment Effectiveness In Childhood Anxiety Disorders: A Longitudinal Prospective Study||Rabin Medical Center||Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|54|||Both|10 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The anxious group: children who will present to the Anxiety Disorder Outpatient Clinic at        Schneider Children's Hospital in Israel.|November 2014|November 12, 2014|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145261||120572|
NCT01135758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE09-144/Psy 09-22|Study of Depression-Ketamine-Brain Function|Pilot Study Probing the Antidepressant Effects of 0.5 mg/kg Intravenous Ketamine in Drug-resistant Depressed Patients (Unipolar Depression): Efficacy, Safety, Brain Function||University Hospital, Geneva|No|Terminated|June 2010|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||December 2015|December 4, 2015|June 2, 2010||No|End of funding of study|No||https://clinicaltrials.gov/show/NCT01135758||121296|
NCT01135771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003106|Performance Study Using the OptiScanner on Healthy Diabetics|Performance Study Using the OptiScanner on Healthy Diabetics||Profil Institut für Stoffwechselforschung GmbH|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|60|||Both|18 Years|65 Years|No|||June 2010|June 2, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01135771||121295|
NCT01135745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD PMCF Study 1.02.7003|Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF)|Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF)||Medtronic International Trading Sarl|Yes|Active, not recruiting|April 2010|March 2016|Anticipated|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01135745||121297|
NCT01136044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUG111|Clinical Experience With a Tensor Fasciae Latae Perforator Flap Based on Septocutaneous Perforators|Clinical Experience With a Tensor Fasciae Latae Perforator Flap Based on Septocutaneous Perforators||Medical University of Graz|No|Completed|January 2008|May 2010|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|16 Years|71 Years|No|||June 2010|June 2, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01136044||121274|
NCT01136343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99001|Comparison of Predictive Factors Related to Coronary Artery Disease Among Different Menopausal Status and Effect of a Life Style Management Program on Risk Factors Modification Among Middle-aged Women|Comparison of Predictive Factors Related to Coronary Artery Disease Among Different Menopausal Status and Effect of a Life Style Management Program on Risk Factors Modification Among Middle-aged Women||Taipei Medical University WanFang Hospital|No|Recruiting|February 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|130|||Female|40 Years|64 Years|No|||December 2010|December 1, 2010|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01136343||121251|
NCT01136642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910459|Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray|Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray||National Institutes of Health Clinical Center (CC)||Completed|January 2010|November 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind|1||Anticipated|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|March 14, 2014|June 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01136642||121229|
NCT01136902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kappelgaard, vessel|Measuring Retinal Vessel Caliber in Relation to Dark Adaptation and Blood Glucose Level|Measuring Retinal Vessel Caliber in Relation to Dark Adaptation and Blood Glucose Level||Glostrup University Hospital, Copenhagen|Yes|Completed|August 2009|September 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|Samples Without DNA|Venous blood sample. Na+, K+, Crea, HbA1c. Capillary glucose measurement. Samples will be      analysed and destructed according to normal laboratory practice at the Glostrup Hospital.|Both|17 Years|80 Years|No|Non-Probability Sample|Subjects with diagnosed Type 2 diabetes mellitus with none or minimal diabetic        retinopathy.|December 2010|December 7, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01136902||121209|
NCT01137214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2010:026|Outcome and Treatment of Complex Sleep Apnea|Outcome and Treatment of Complex Sleep Apnea||University of Manitoba|Yes|Withdrawn|June 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||October 2010|February 11, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01137214||121185|
NCT01144559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Femoral Sensory and Motor|Continuous Femoral Nerve Blocks: Relative Effects of Basal Infusion and Bolus Doses on Sensory and Motor Function|Continuous Femoral Nerve Blocks: Relative Effects of Basal Infusion and Bolus Doses on Sensory and Motor Function||University of California, San Diego|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 29, 2010|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144559||120626|
NCT01144572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OCN-ARI-2010/1|Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment|A Prospective, Multicenter, Non-interventional Study to Evaluate Quality of Life in Chinese Postmenopausal HR(+) EBC Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment|BC Qol NIS|AstraZeneca|No|Completed|July 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|494|||Female|50 Years|70 Years|No|Probability Sample|The eligible patients will be recruited when they start their upfront AIs adjuvant        treatment within 7 days.|February 2014|February 13, 2014|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144572||120625|
NCT01144351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND002-MS103|A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis|A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis||Elan Pharmaceuticals||Terminated|March 2010|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|June 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01144351||120642|
NCT01147302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-201|A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection|A Randomized Double-Blind Placebo-Controlled Pilot Study to Evaluate the Safety and Effect of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-Mediated Rejection in Recipients of Donor-Sensitized Kidney Transplants||Shire|No|Completed|November 2010|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||March 2014|July 22, 2015|June 16, 2010|Yes|Yes||No|June 16, 2015|https://clinicaltrials.gov/show/NCT01147302||120416|
NCT01147315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/10-H|ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution|10 Patients Bicentric Prospective Study of Hybrid Bone Substitution With Calcium-phosphate Ceramic Biomaterial and Autologous Bone Marrow for Mandibular Osteoradionecrosis (ORN) Treatment|ORN|Nantes University Hospital|Yes|Active, not recruiting|November 2009|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147315||120415|
NCT01147029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000675271|GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy|A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors||Cancer Research UK||Terminated|January 2008|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|June 17, 2010||No|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT01147029||120437|
NCT01147887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017176|A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers|An Open-Label Study to Assess the Effect of Multiple-Dose JNJ26489112 on the Cytochrome P450 Enzymes Using a 3-Probe Substrate Drug Combination in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|June 2010|August 2010|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147887||120371|
NCT01147562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBBL0001|Biomarker Discovery and Validation in Lung Cancer|Biomarker Discovery and Validation in Lung Cancer|LCS|Public Research Centre Health, Luxembourg|No|Recruiting|October 2009|October 2019|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147562||120396|
NCT01147575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OENB11758|Effects of Creatine Supplementation in Rett Syndrome|Effects of Creatine Supplementation in Rett Syndrome: A Randomized, Placebo-controlled Trial||Medical University of Vienna|No|Completed|January 2005|January 2009|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Female|3 Years|24 Years|No|||May 2010|June 18, 2010|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147575||120395|
NCT01147588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612C00034|Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel|An Open-label, Randomized, 4-treatment, 3-period, Crossover Interaction Study, Evaluating the Effect of Esomeprazole 40 mg, Omeprazole 80 mg or Lansoprazole 60 mg on the Pharmacodynamics and the Pharmacokinetics of Clopidogrel in Healthy Volunteers||AstraZeneca|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|149|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01147588||120394|
NCT01148485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09016|Community-acquired Methicillin-Resistant Staphylococcus Aureus Carriage Among Athletes|Community-acquired Methicillin-Resistant Staphylococcus Aureus Carriage Among Athletes: a Study in Limousin. : CA-MRSA|PSARM-S|University Hospital, Limoges|No|Completed|January 2011|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|Athletes of Limousin practicing sport.|June 2010|October 31, 2013|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01148485||120325|
NCT01148498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13572|A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's|Plasma Amyloid Beta Species After a Single Solanezumab Infusion in Nondemented Individuals and Those With Mild Dementia of the Alzheimer's Type||Eli Lilly and Company|No|Completed|August 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|55|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2012|September 18, 2012|June 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01148498||120324|
NCT01145508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02048|Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2010|January 2017|Anticipated|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|N/A|No|||November 2015|January 14, 2016|June 15, 2010|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01145508||120553|
NCT01145196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100140|Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene|Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|February 19, 2016|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145196||120577|
NCT01145209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100141|A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2010|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|99 Years|No|||February 2016|February 18, 2016|June 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01145209||120576|
NCT01145495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02047|Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma|A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)||National Cancer Institute (NCI)||Active, not recruiting|June 2010|||December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||December 2015|January 22, 2016|June 15, 2010|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01145495||120554|
NCT01147328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708160258-08|Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization|Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization|VHR|Weill Medical College of Cornell University|No|Not yet recruiting|June 2011|December 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|157000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with concurrent controls who have consented to have their clinical data        viewed by their providers using the VHR portal provided by RHIOs. Providers who are        participating in the Regional Health Information Exchange (RHIO).|January 2011|January 11, 2011|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01147328||120414|
NCT01140776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSNA-BC-NEO-001|Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy|OSNA Neoadjuvant Feasibility Study in Breast Cancer Patients||Sysmex America, Inc.|Yes|Terminated|November 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Samples of the tissue homogenate will be retained and may be used for for further testing.|Both|18 Years|N/A|No|Probability Sample|Patients with a previous diagnosis of breast cancer scheduled for sentinel lymph node        dissection after receiving neoadjuvant hormonal/chemotherapy.|June 2011|June 6, 2011|June 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01140776||120915|
NCT01144676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 013|A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring|A Double-Blind, Randomised, Placebo-Controlled Pharmacokinetic and Safety Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring and to Evaluate the Safety of a Matrix Vaginal Ring Containing 25 MG of Dapivirine||International Partnership for Microbicides, Inc.|Yes|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|45|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|October 5, 2010|June 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01144676||120617|
NCT01144689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808004113|Mindfulness Training for Smoking Cessation|Assessing Mindfulness Training as a Mechanistic Probe for Stress-Induced Brain Activation and Relapse Prevention for Tobacco Addiction||Yale University|Yes|Completed|February 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|60 Years|No|||July 2013|July 9, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144689||120616|
NCT01144962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10.102|Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease||Leiden University Medical Center|Yes|Completed|June 2010|December 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|21|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01144962||120595|
NCT01136083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003064R|Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients|Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients||National Taiwan University Hospital|No|Completed|September 2010|August 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|75 Years|No|||November 2011|August 12, 2013|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01136083||121271|
NCT01136096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9261701067|Effects of Exercise Behavior Modification on Plasma Adiponectin and Insulin Resistance in High Risk Subjects of Diabetes|Effects of Exercise Behavior Modification on Plasma Adiponectin and Insulin Resistance in High Risk Subjects of Diabetes||National Taiwan University Hospital|Yes|Completed|January 2004|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|216|||Both|20 Years|70 Years|No|||June 2010|June 2, 2010|May 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01136096||121270|
NCT01136070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-053|A Prospective Study of Body Image, Social Avoidance and Distress and Psychological Functioning in Burn Patients|A Prospective Study of Body Image, Social Avoidance and Distress and Psychological Functioning in Burn Patients||Saint Elizabeth Regional Medical Center|No|Recruiting|June 2010|June 2013|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|19 Years|N/A|No|Non-Probability Sample|Burn patients in community hospital with an estimated follow-up time of at least 3 months        post-burn.|March 2011|March 1, 2011|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01136070||121272|
NCT01136655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589GC00002|A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy|A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children|CHASE 2|AstraZeneca|No|Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|54|||Both|6 Years|11 Years|No|||October 2013|October 30, 2013|June 1, 2010|Yes|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT01136655||121228|
NCT01137539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIWH08-001|TVT-SECUR as an Office-based Procedure|TVT-SECUR as an Office-based Procedure - A Pilot Study|TVTSOffice|Michigan Institution of Women's Health PC|No|Completed|October 2008|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|21 Years|89 Years|No|||October 2012|October 5, 2012|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01137539||121163|
NCT01144884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18808040|Identify Patients With Neck Pain Likely to Benefit From Education and Exercise|Development of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Education and Exercise||University of Central Florida|No|Completed|August 2009|||December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01144884||120601|
NCT01144897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET ACE 01|PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy|PET Acetate for Docetaxel Response Assessment in Hormone-Refractory Prostate Cancer||University of Iowa|Yes|Active, not recruiting|June 2010|May 2014|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||June 2011|June 16, 2011|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144897||120600|
NCT01142999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEEP|Feasibility Study of Barrier Enhancement for Eczema Prevention|Feasibility Study of Barrier Enhancement for Eczema Prevention (BEEP)|BEEP|Oregon Health and Science University|No|Active, not recruiting|May 2010|September 2012|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|46|||Both|N/A|6 Months|No|||June 2010|August 4, 2011|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01142999||120745|
NCT01147900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113055|Evaluation of Boostrix™10 Years After Previous Booster Vaccination|Evaluation of GSK Biologicals' Boostrix™ in Healthy Adults, 10 Years After Previous Booster Vaccination||GlaxoSmithKline||Completed|June 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|180|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||August 2013|October 24, 2013|May 20, 2010|Yes|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT01147900||120370|
NCT01147913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F32MH088065-01|Computerized Information-Processing Bias Retraining in Depressed Adolescents|Computerized Information-Processing Bias Retraining in Adolescents With Depression: A Controlled Trial||Massachusetts General Hospital|Yes|Completed|March 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|14 Years|21 Years|No|||May 2012|May 2, 2012|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01147913||120369|
NCT01148173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL-ZNS-Rezidiv|High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas|Combined Systemic and Intrathecal Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation for CNS Relapse of Aggressive Lymphomas||Charite University, Berlin, Germany|Yes|Recruiting|October 2007|October 2012|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||November 2007|June 21, 2010|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01148173||120349|
NCT01144325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSchest2010001|Minimally Invasive Esophagectomy (MIE) in Prone Versus Left Decubitus Position|Minimally Invasive Esophagectomy in Prone or Left Decubitus Position: A Prospective Randomized Clinical Trial From A Single Institution||Fudan University|Yes|Recruiting|July 2010|December 2016|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|2|||Both|35 Years|70 Years|No|||February 2011|March 7, 2011|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01144325||120644|
NCT01139970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01457|Veliparib and Temozolomide in Treating Patients With Acute Leukemia|A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias||National Cancer Institute (NCI)|No|Active, not recruiting|May 2010|||March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|June 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01139970||120977|
NCT01145820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_09-111|Fruit And Vegetables and OUtcomes After Removal of Impacted TEeth|Efficacy of Adjunctive Juice Plus in Reducing Post-operative Morbidity and Improving Quality of Life After Lower Third Molar Surgery: a Randomized Controlled Clinical Trial|FAVOURITE|University of Birmingham|No|Completed|June 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|246|||Both|18 Years|60 Years|No|||October 2013|October 8, 2013|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01145820||120530|
NCT01140490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8020|Sub-total Parathyroidectomy Reduces Vascular Calcification in Haemodialysis Patients|Sub-total Parathyroidectomy Reduces Vascular Calcification in Haemodialysis Patients||Guangdong General Hospital|Yes|Recruiting|January 2009|December 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|80 Years|No|||January 2009|March 10, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01140490||120937|
NCT01140503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03302010-5522|A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis|An Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Dermatomyositis||Stanford University|Yes|Terminated|February 2010|September 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|April 6, 2010|Yes|Yes|Slow recruitment of participants|No|January 28, 2015|https://clinicaltrials.gov/show/NCT01140503||120936|Study was terminated early due to low enrollment. Therefore we only have data on 5 participants.
NCT01144364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17638|A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)|A Randomized, Open-label Study of MabThera Maintenance Therapy Compared With no Further Therapy After a Brief Induction With Chemotherapy Plus MabThera on Failure-free Survival in Treatment-naïve Elderly Patients With Advanced Follicular Lymphoma||Hoffmann-La Roche||Completed|January 2004|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|234|||Both|60 Years|75 Years|No|||December 2014|December 3, 2014|June 11, 2010||No||No|September 12, 2014|https://clinicaltrials.gov/show/NCT01144364||120641|
NCT01144377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11953|A Study of LY2541546 in Women With Low Bone Mineral Density|A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women With Low Bone Mineral Density: An Evaluation of the Dose Response Relationship Using Bone Mineral Density||Eli Lilly and Company|Yes|Completed|August 2010|February 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|153|||Female|45 Years|85 Years|No|||April 2013|April 3, 2013|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144377||120640|
NCT01144975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052118|Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus|A Randomized Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy||XOMA (US) LLC|No|Completed|May 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|75 Years|No|||May 2012|May 15, 2012|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01144975||120594|
NCT01145287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Burden-1|Impact of the Diagnosis of Celiac Disease|Impact of the Diagnosis of Celiac Disease||Tampere University Hospital|No|Recruiting|February 2007|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Both|N/A|N/A|No|Non-Probability Sample|All new members with biopsy-proven celiac disease joining the Finnish Celiac Society.|February 2014|February 18, 2014|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01145287||120570|
NCT01145586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF099-2|A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia|A Phase III, Non-Inferiority, Randomized, Blind, Parallel-Group, Multicentre, Multiple-Dose, Comparative Clinical Study of Lactase Eurofarma and Lactaid®, Assessing the Efficacy and Safety in the Treatment of Patients With Lactose Intolerance"|LAILAII|Eurofarma Laboratorios S.A.|Yes|Completed|June 2011|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|60 Years|No|||June 2010|June 26, 2012|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01145586||120548|
NCT01136109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0143|A Study to Evaluate the Effect of Mechanical Ventilation on the Inferior Vena Cava Collapsibility Index|A Prospective Pilot Study to Evaluate the Effect of Mechanical Ventilation on the Inferior Vena Cava Collapsibility Index|IVCCI|Ohio State University|No|Completed|October 2009|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|||Both|18 Years|N/A|No|Probability Sample|InpatientSample|January 2016|January 15, 2016|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01136109||121269|
NCT01136356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-08045-9|A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals|A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals||Johns Hopkins University|No|Active, not recruiting|July 2010|June 2016|Anticipated|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|60 Years|No|||April 2015|April 16, 2015|June 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01136356||121250|
NCT01136915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOP-118|Kidney Damage In Patients With Severe Fall In eGFR|A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Severe Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320||Bracco Diagnostics, Inc|No|Terminated|November 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|15|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|June 2, 2010|No|Yes|slow enrollment|No|November 25, 2013|https://clinicaltrials.gov/show/NCT01136915||121208|
NCT01137201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPN 2009/415|Internal Hernia After Laparoscopic Gastric Bypass|Internal Hernia After Laparoscopic Gastric Bypass||University Hospital Orebro|Yes|Completed|May 2010|November 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2507|||Both|N/A|N/A|No|||December 2015|December 2, 2015|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01137201||121186|
NCT01137578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-077|Pediatric Catheter-related Thrombosis Imaging Study|Pilot Study for Assessing Diagnostic Techniques for Central Venous Catheter-related Venous Thromboembolism|AESOP|Bristol-Myers Squibb|Yes|Completed|February 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|151|||Both|N/A|18 Years|No|||November 2014|November 25, 2014|June 3, 2010|No|Yes||No|November 19, 2014|https://clinicaltrials.gov/show/NCT01137578||121160|
NCT01137825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0916|Registry of Older Patients With Cancer|Carolina Senior: UNC Registry for Older Cancer Patients||UNC Lineberger Comprehensive Cancer Center|No|Recruiting|September 2009|December 2018|Anticipated|December 2016|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|65 Years|N/A|No|Non-Probability Sample|Oncology Patients or those with a presumed cancer diagnosis|December 2015|December 7, 2015|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01137825||121141|
NCT01144091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10059-2010|Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography|Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography||Meir Medical Center|Yes|Withdrawn|December 2012|December 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|0|||Both|18 Years|75 Years|No|||September 2012|April 7, 2015|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01144091||120662|
NCT01146106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-139|Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions|Single Dose Two-Way Crossover Fasting Bioequivalence Study of Pravastatin 80 mg Tablets in Healthy Volunteers||Dr. Reddy's Laboratories Limited|No|Completed|December 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 16, 2010|February 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01146106||120508|
NCT01146119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVX-004|Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)|A Phase II, Randomized, Two Stage, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers||BiondVax Pharmaceuticals ltd.|No|Completed|July 2010|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|200|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|June 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01146119||120507|
NCT01147068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC22 GLA-SE|Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults|A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49||Protein Sciences Corporation|Yes|Completed|June 2010|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|392|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|June 16, 2010|Yes|Yes||No|October 24, 2012|https://clinicaltrials.gov/show/NCT01147068||120434|The absence of a treatment group receiving a SE- or GLA-alone adjuvanted vaccine formulation is a limitation to the study conclusion.
NCT01147081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V44_14S|Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Begrivac®, Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011 When Administered to Adult and Elderly Subjects||Novartis|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|142|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 4, 2012|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01147081||120433|
NCT01143272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNI-2009-01|Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea|Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea - Randomised, Double-blind, Placebo-controlled Trial|SacBo|Bernhard Nocht Institute for Tropical Medicine|Yes|Terminated|June 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|477|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|June 11, 2010||No|Masked independent interim analysis: completion of the trial was unlikely.|No||https://clinicaltrials.gov/show/NCT01143272||120724|
NCT01144078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-2010|Exercise Intensity, Glycemic Control and Abdominal Fat in People With Type 2 Diabetes: A Pilot Study|||University of Alberta|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|55 Years|75 Years|No|||January 2012|January 2, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01144078||120663|
NCT01143545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100138|Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas|Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas||National Institutes of Health Clinical Center (CC)||Completed|May 2010|March 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|120 Years|No|||January 2016|February 4, 2016|June 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01143545||120704|
NCT01143558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100139|Searching for Persistence of Infection in Lyme Disease|Searching for Persistence of Infection in Lyme Disease||National Institutes of Health Clinical Center (CC)||Completed|May 2010|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|June 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01143558||120703|
NCT01144910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-317/09|The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children|A Prospective, Open Label, Single-center Study of the Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children.|BHR|Johann Wolfgang Goethe University Hospitals|No|Suspended|May 2011|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|104|Samples With DNA|whole blood, serum, sputum|Both|3 Years|5 Years|No|Non-Probability Sample|patients from the outpatient Department of Allergology, Pneumology and Cystic fibrosis,        children's hospital, Goethe-University, Frankfurt, Germany|September 2012|September 19, 2012|June 1, 2010||No|2006 data will be analyzed. Due to few capacities 2011 to 2016 will be supended.|No||https://clinicaltrials.gov/show/NCT01144910||120599|
NCT01148225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-327|A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis|A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis|VISUAL III|AbbVie|Yes|Active, not recruiting|November 2010|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|May 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01148225||120345|
NCT01146470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-NV-0176-CTIL|The Influence of Red Grape Cells on Blood Pressure Vascular Function in People With Hypertension|A Single-Center, Double-blind, Random, Parallel Controlled Study|RGC|Tel-Aviv Sourasky Medical Center|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|50|||Both|35 Years|70 Years|No|||June 2010|February 17, 2013|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01146470||120480|
NCT01153633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-H 0901|Trial on the Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Pilot, Randomised, Double-blind, Controlled Clinical Trial on the Combined Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel in the Reduction in Size and Change in Bioburden of Hard-to-heal Venous Leg Ulcers||B. Braun Ltd. Centre of Excellence Infection Control|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|June 28, 2010||No||No|May 29, 2012|https://clinicaltrials.gov/show/NCT01153633||119935|Most likely the non-statistical significant results are due to the small sample size. No sample size calculation and statistical analysis was planned a priori because it was a pilot study.
NCT01153646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03161|Gene Transfer for HIV Using Autologous T Cells|A Pilot Study of Safety and Feasibility of T-Cell Immunotherapy Using Lentivirus Vector-Expressed RNAi in Autologous T-Cells of HIV-1 Infected Patients Who Have Failed Anti-Retroviral Therapy|Gene Transfer|City of Hope Medical Center|Yes|Terminated|April 2010|January 2011|Actual|January 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|18 Years|60 Years|No|||January 2011|January 18, 2011|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153646||119934|
NCT01185860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22660|A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1|A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1||Hoffmann-La Roche||Completed|August 2009|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01185860||117470|
NCT01185873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25290|A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment|The Effect of Hepatic Impairment on the Pharmacokinetics of RO5190591/Ritonavir: A Multiple-Center, Open-Label Study Following Multiple Oral Doses of RO5190591/Ritonavir to Subjects With Mild, Moderate, or Severe Hepatic Impairment and Healthy Subjects With Normal Hepatic Function||Hoffmann-La Roche||Completed|February 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185873||117469|
NCT01186120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0036|Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-V:Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents|LONG-DES-V|CardioVascular Research Foundation, Korea|Yes|Completed|August 2010|August 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01186120||117450|
NCT01187160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809623|Transoral Robotic Surgery (TORS) for Sleep Apnea|A Pilot Study Assessing Surgical Exposure During Transoral Robotic Surgery (TORS) for Sleep Apnea Using the da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA)||University of Pennsylvania|No|Recruiting|October 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01187160||117370|
NCT01178021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL0903|Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan|Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan|VRA|University of Oxford|No|Recruiting|January 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|6 Months|N/A|No|||August 2013|August 27, 2013|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01178021||118070|
NCT01177709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091/C22|Metformin for Weight Loss in Schizophrenia|Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication||Nathan Kline Institute for Psychiatric Research|No|Terminated|May 2000|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|70 Years|No|||May 2012|May 16, 2012|April 23, 2010|No|Yes|PI moved to differetnt6 institution. Decided to concentrate on different studies.|No||https://clinicaltrials.gov/show/NCT01177709||118093|
NCT01177722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L24|A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants|Lot-to-Lot Consistency Study of DTaP-IPV-Hep B-PRP-T Vaccine Administered at 2-4-6 Months of Age in Healthy Latin American Infants Concomitantly With Prevenar™ and Rotarix™||Sanofi|Yes|Completed|August 2010|December 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1375|||Both|55 Days|65 Days|Accepts Healthy Volunteers|||April 2014|April 3, 2014|August 6, 2010||No||No|February 22, 2014|https://clinicaltrials.gov/show/NCT01177722||118092|
NCT01178008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acup-003|Pilot Study on the Use of Acupuncture for Postpartum Depression|Pilot Study on the Use of Acupuncture for Postpartum Depression||The University of Hong Kong|No|Completed|May 2010|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||January 2013|January 14, 2013|August 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01178008||118071|
NCT01178333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|678|Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study|Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study (HIT-RADIO Study)|HIT-RADIO|New England Research Institutes|Yes|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|668|||Both|N/A|N/A|No|Probability Sample|Subjects with a positive heparin PF-4 antibody test drawn between 1/21/2008 and 9/25/2008|March 2013|May 6, 2015|August 6, 2010||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01178333||118046|
NCT01188291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC070029CTIL|Retinal Nerve Fiber Layer Thickness Measurements in Patients With Sleep Apnea Syndrome|Retinal Nerve Fiber Layer Thickness Measurements Using Optical Coherence Tomography in Patients With Sleep Apnea Syndrome||Carmel Medical Center|No|Completed|September 2007|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|166|||Both|18 Years|N/A|No|Probability Sample|Study group composed of patients with Obstructive Sleep Apnea / Hypopnea syndrome.|August 2010|March 9, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01188291||117283|
NCT01187706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007087R|A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors|A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors||National Taiwan University Hospital|No|Recruiting|August 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|140|||Female|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study used a cross-sectional design. By using the method of purposive sampling, the        70 gynecological cancer patients who had completed the active treatments for six months        will be recruited from the oncology and gynecology clinics of a medical center in the        Northern Taiwan area. The 70 healthy controls without any cancer will be recruited from        clinic and from friends and colleagues.|August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187706||117328|
NCT01187940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09BS22|Evaluating PEGASUS - a Group Intervention for Young People With an Autism Spectrum Disorder|Evaluating Psychoeducation for People With Autism Spectrum Disorder||Institute of Child Health|No|Not yet recruiting|September 2010|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|9 Years|14 Years|No|||August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187940||117310|
NCT01188265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-95-110|Add-on Dextromethorphan in Bipolar Disorders|Dextromethorphan Enhances the Therapeutic Efficacy of Valoproate in Bipolar Disorder Patients|DM|National Cheng-Kung University Hospital|Yes|Completed|June 2007|June 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|65 Years|No|||September 2013|September 16, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188265||117285|
NCT01188499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL32711-POC-0078-PTL|Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors||TetraLogic Pharmaceuticals|No|Completed|October 2010|March 2014|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|176|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01188499||117267|
NCT01188512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT06-04|First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine|A Phase 1, Single Centre, Dose-escalating, Placebo-controlled Study of a Genetically Modified B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Male Volunteers||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|August 2010|January 2012|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|48|||Male|19 Years|31 Years|Accepts Healthy Volunteers|||January 2012|January 27, 2012|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188512||117266|
NCT01188785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLSG12D|Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas|Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas||Silenseed Ltd|Yes|Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01188785||117245|
NCT01184651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU ORP#30695|Tweens to Teens Project at Penn State|"Gender Development in Early Adolescence: Prenatal Hormones and Family Socialization"|T2T@PSU|Penn State University|No|Recruiting|August 2009|August 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|300|Samples With DNA|Samples of saliva will be collected from participants with CAH for genetic testing (specific      mutations of CYP21 gene) and to obtain hormone levels.|Female|10 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will study girls with the 21-hydroxylase deficiency (21-OHD) form of congenital adrenal        hyperplasia (CAH) aged 10 to 13. Parents of participants are also included.|May 2010|August 23, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01184651||117562|
NCT01184989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.86|Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate|An Open Label, Non-comparative, Pharmacokinetic and Pharmacodynamic Study to Evaluate the Effect of Dabigatran Etexilate on Coagulation Parameters Including a Calibrated Thrombin Time Test in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Primary Unilateral Elective Total Knee or Hip Replacement Surgery||Boehringer Ingelheim||Completed|August 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|142|||Both|18 Years|N/A|No|||April 2014|June 3, 2014|August 16, 2010||||No|March 3, 2014|https://clinicaltrials.gov/show/NCT01184989||117536|
NCT01184963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-364|High Versus Normal Protein Diet in Polycystic Ovary Syndrome (PCOS)|Effect of High-protein or Normal-protein Diet on Weight Loss, Body Composition, Hormone and Metabolic Profile in Women With Polycystic Ovary Syndrome From South Brazil: A Randomized Study||Federal University of Rio Grande do Sul|No|Completed|March 2008|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|14 Years|35 Years|Accepts Healthy Volunteers|||December 2009|August 18, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184963||117538|
NCT01184976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-001|Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males|Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)||GeneOne Life Science, Inc.|Yes|Completed|August 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Male|20 Years|39 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01184976||117537|
NCT01185262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC-LENAR-08|Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia|Phase I Study of the Activity and Safety of Lenalidomide and Rituximab as Non-chemotherapy Therapy for Patients With Recurrent and Refractory Chronic Lymphocytic Leukemia|LLC-LENAR-08|MD Anderson International Spain SA|No|Completed|April 2009|September 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01185262||117516|
NCT01186380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEE-002|Safety of the PET-512MC Transesophageal Transducer|Safety of the PET-512MC Transesophageal Transducer (TEE)|TEE|Toshiba America Medical Systems, Inc.|Yes|Completed|August 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patients ages 18 and above|November 2010|November 19, 2010|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186380||117430|
NCT01186640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPLL2|Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)|Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia||German CLL Study Group|No|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186640||117410|
NCT01186887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-645|A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction|A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament Reconstruction||Ottawa Hospital Research Institute|No|Completed|February 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01186887||117391|
NCT01178034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1643P|Early Identification of Warfarin Maintenance Dosage|Early Identification of Warfarin Maintenance Dose in Patients With Atrial Fibrillation: a Randomized Trial Evaluating a New Genotype-based Versus Usual Care Initiation of Treatment||University of Padova|Yes|Completed|October 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Both|18 Years|N/A|No|||October 2012|October 21, 2012|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01178034||118069|
NCT01178346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-4519|Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies|Health-Related Quality-of-Life and Health-Care Resource Utilization Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies||Nabi Biopharmaceuticals|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|500|||Both|18 Years|65 Years|No|||May 2012|May 8, 2012|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01178346||118045|
NCT01178359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35739-B|Pilot Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients|Phase 1 Hospital Based Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients||University of Washington|Yes|Recruiting|January 2010|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|August 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01178359||118044|
NCT01178684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH 014|Epidermal Nerve Fiber Density, Fat and Mitochondrial Parameters in Thai HIV+ Patients on d4T and HIV- Patients|Study of Epidermal Nerve Fiber Density, Subcutaneous Fat, and Mitochondrial Parameters in Thai HIV-positive Patients on Long-term Stavudine Treatment and in Thai HIV-negative Patients||South East Asia Research Collaboration with Hawaii|No|Completed|May 2010|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||4|Actual|113|Samples Without DNA|Plasma PBMC Urine CBC|Both|18 Years|N/A|No|Non-Probability Sample|Seventy five HIV-positive patients on long-term d4T treatment (25 with symptomatic        peripheral neuropathy, 25 without peripheral neuropathy and 25 with asymptomatic        peripheral neuropathy) and 50 HIV-negative subjects without peripheral neuropathy will be        recruited from the Thai Red Cross AIDS Research Centre and the Queen Savang Vadhana        Memorial Hospital.|September 2014|September 25, 2014|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01178684||118019|
NCT01178931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBSM-0010|Dydrogesterone Versus Intravaginal Progesterone in the Luteal Phase Support|Oral Dydrogesterone Versus Vaginal Progesterone Gel in the Luteal Phase Support: Randomized Controlled Trial||University of Zagreb|Yes|Completed|October 2010|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|853|||Female|18 Years|45 Years|No|||January 2014|January 27, 2014|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178931||118000|
NCT01187992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFN/02/03/AL|Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease|Full-dose Atorvastatin Versus Conventional Medical Therapy After Non-ST-elevation Acute Myocardial Infarction in Patients With Advanced Non-revascularisable Coronary Artery Disease|APRIRE|San Filippo Neri General Hospital|Yes|Terminated|September 2003|April 2007|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|290|||Both|18 Years|N/A|No|||May 2010|August 24, 2010|August 24, 2010||No|Interim analysis showed significant effect in favour of full-dose atorvastatin.|No||https://clinicaltrials.gov/show/NCT01187992||117306|
NCT01188278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-291|Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey|Treatment With Second Generation TYROSINE KINASE INHIBITORS (2G TKI) Post Imatinib Failure: Factors Predicting Response and Predictive Value of Response||Bristol-Myers Squibb|No|Completed|July 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|173|||Both|18 Years|N/A|No|Non-Probability Sample|Hematology centers (hospitals) which have necessary historical data available|October 2013|October 7, 2013|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188278||117284|
NCT01187953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro-3002|Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx|Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant|LCPTacro3002|Veloxis Pharmaceuticals|Yes|Completed|September 2010|March 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|543|||Both|18 Years|70 Years|No|||May 2015|May 12, 2015|August 23, 2010|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01187953||117309|
NCT01188252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14484|Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies||Bayer|No|Active, not recruiting|August 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01188252||117286|
NCT01184326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-166|Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer|An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|September 2010|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|August 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01184326||117587|
NCT01184664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qmul250510|Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study)|Effects of a Combination of Varenicline and Transdermal Nicotine Patch on Post-quitting Urges to Smoke|CONVICT|Queen Mary University of London|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 10, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184664||117561|
NCT01185002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-111|Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen|Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen||Given Imaging Ltd.|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|80|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2011|June 9, 2011|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185002||117535|
NCT01185288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-071|A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)|A Multicenter, Double-Blind, Randomized, Parallel-Arm Study to Determine the Effect of Methotrexate Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis Treated With Adalimumab (MUSICA)|MUSICA|AbbVie|No|Completed|September 2010|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|309|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|August 18, 2010|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01185288||117514|
NCT01185301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-073|Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)|A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)|CONCERTO|AbbVie|No|Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|395|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|August 18, 2010|Yes|Yes||No|September 11, 2013|https://clinicaltrials.gov/show/NCT01185301||117513|
NCT01185574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201255|Vitamin D for Improving Metabolic Control and Depressive Symptoms|Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study||Loyola University|Yes|Completed|October 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||July 2013|July 10, 2013|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185574||117492|
NCT01185587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1187|Sodium Channel Splicing in Heart Failure Trial|Sodium Channel Splicing in Heart Failure Trial|SOCS-HEFT|University of Illinois at Chicago|No|Completed|February 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|147|Samples Without DNA|Whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Heart Failure and Device Clinics|April 2014|April 21, 2014|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185587||117491|
NCT01185275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0716|A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)|A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)|BTR|Washington University School of Medicine|No|Recruiting|August 2010|August 2018|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|190|Samples With DNA|DNA and RNA extraction, serum, plasma and sputum|Both|18 Years|65 Years|No|Non-Probability Sample|Subject Population - Severe Refractory Asthma|December 2014|December 20, 2014|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01185275||117515|
NCT01185548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13076|A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma|The Effect of Tasisulam on the CYP2C9-Mediated Metabolism of Tolbutamide: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma||Eli Lilly and Company|No|Terminated|July 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|August 18, 2010|No|Yes|Terminated based on safety results from another trial|No||https://clinicaltrials.gov/show/NCT01185548||117494|
NCT01185561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108324|A Pychoeducational Intervention for Women With Diabetes|A Pychoeducational Intervention for Women With Diabetes|SWEEP|Loyola University|Yes|Completed|January 2007|April 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Female|18 Years|75 Years|No|||August 2010|August 18, 2010|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185561||117493|
NCT01186133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-035|Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice|Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice|IRIS-DES|CardioVascular Research Foundation, Korea|Yes|Recruiting|January 2009|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||16|Anticipated|25000|||Both|18 Years|N/A|No|Probability Sample|consecutive patients amenable to PCI|October 2015|October 14, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186133||117449|
NCT01156415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178C2399|Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)|A 52-week, Multi-center, Open-label Study of the Safety and Tolerability of Agomelatine Sublingual Tablets in Patients With Major Depressive Disorder (MDD)||Novartis||Terminated|June 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|837|||Both|18 Years|71 Years|No|||March 2013|March 6, 2013|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156415||119721|
NCT01156207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC20110101|Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure|Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor|VACHF|Taipei Veterans General Hospital, Taiwan|No|Not yet recruiting|July 2010|||July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|90 Years|No|||June 2010|July 1, 2010|June 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01156207||119737|
NCT01156649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL102151|Effects of Positive Airway Pressure (PAP) in Children With Obstructive Sleep Apnea (OSA)|Neurobehavioral Effects of Positive Airway Pressure (PAP) Therapy in Children With Obstructive Sleep Apnea|OSA|University of Arizona|Yes|Recruiting|July 2010|June 2015|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|12 Years|No|||April 2013|April 2, 2013|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156649||119703|
NCT01156662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAMI-2009|Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction|Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction|ETAMI|Ajou University School of Medicine|Yes|Active, not recruiting|March 2009|April 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|80 Years|No|||April 2013|April 13, 2013|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156662||119702|
NCT01186900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008198-01H|Comparison of Ultrasound-Guided Needle Aspiration and Open Incision and Drainage for Cutaneous Abscesses|Comparison of Ultrasound-Guided Needle Aspiration and Open Incision and Drainage in the Management of Cutaneous Abscesses||Ottawa Hospital Research Institute|No|Terminated|June 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|August 4, 2011|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186900||117390|
NCT01178372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS002|Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis|Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy|HE|Govind Ballabh Pant Hospital|Yes|Recruiting|September 2008|September 2010|Anticipated|||Phase 4|Interventional|N/A|2||||||Both|18 Years|75 Years|No|||September 2009|August 9, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178372||118043|
NCT01178697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8886|Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)|Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion||hahid Beheshti University of Medical Sciences||Recruiting|January 2010|December 2010|Anticipated|September 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||||||Both|N/A|N/A||||January 2010|August 9, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01178697||118018|
NCT01178944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 169210|Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer|Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates||Roswell Park Cancer Institute|Yes|Completed|September 2010|November 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01178944||117999|
NCT01178957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-0004|Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia|Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia||University of Aarhus|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples With DNA|Blood Samples|Male|18 Years|50 Years|No|Non-Probability Sample|Type 1 diabetics|August 2013|August 5, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01178957||117998|
NCT01179230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HELL001671HE|Rubidium-82 Position Emission Computed Tomography (PET) Versus Gated, Rest / Stress Technetium 99-m SPECT|A Prospective Comparison of Gated, Rest/Stress Rubidium-82 Position Emission Computed Tomography (PET) vs. Gated, Rest / Stress Technetium 99-m SPECT|PETvsSPECT|Hartford Hospital|No|Completed|January 2005|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|136|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with intermediate to high likelihood of CAD referred for cardiac catheterization,        either on outpatient or inpatient basis|July 2012|March 19, 2015|June 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179230||117977|
NCT01188577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-B2|Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics|Epinephrine Inhalation Aerosol USP, an HFA-MDI CLINICAL STUDY-B2 FOR ASSESSMENT OF PHARMACOKINETICS (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)||Amphastar Pharmaceuticals, Inc.|No|Completed|August 2010|January 2011|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2014|October 21, 2014|August 24, 2010|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01188577||117261|
NCT01154270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSMIC|CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC|Combined Therapy of Malignant Salivary Gland Tumours With IMRT and Carbon Ions: COSMIC|COSMIC|Heidelberg University|No|Active, not recruiting|June 2010|September 2013|Anticipated|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|80 Years|No|||April 2013|April 23, 2013|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154270||119886|
NCT01188525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-04|Pharmacokinetic Study to Characterize Individual Metabolic Profile|Pharmacokinetic of Ten Parent Drugs and Their Metabolits in Order to Characterise Individual Metabolic Profile|CIME1|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|August 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188525||117265|
NCT01188538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29084|Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel|Anti P. Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel in the Treatment of Subjects With Acne Vulgaris||Galderma|No|Completed|March 2010|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2011|July 13, 2011|August 24, 2010||No||No|June 9, 2011|https://clinicaltrials.gov/show/NCT01188538||117264|
NCT01154816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL0921|Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia|A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias||Children's Oncology Group|Yes|Completed|February 2011|||January 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|1 Year|21 Years|No|||March 2014|August 31, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154816||119844|
NCT01155050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC29032|Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population|Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population||Pennington Biomedical Research Center|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|240|||Both|18 Years|N/A|No|||April 2011|October 28, 2011|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155050||119826|
NCT01154582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVONUTRIAL|Nutritional Quality of Egg Proteins and Effect on Satiety|||Institut National de la Recherche Agronomique|Yes|Completed|February 2009|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Basic Science|2||Actual|43|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2010|July 12, 2010|June 30, 2010||||No||https://clinicaltrials.gov/show/NCT01154582||119862|
NCT01154829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-088|Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)|Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes|PECANS|University of Copenhagen|No|Active, not recruiting|December 2008|May 2016|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01154829||119843|
NCT01185886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000682702|Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia|Translational Research - Observational Study for Identification of New Possible Prognostic Factors and Future Therapeutic Targets in Children With Acute Lymphoblastic Leukemia (ALL)||National Cancer Institute (NCI)||Recruiting|May 2011|||November 2014|Anticipated|N/A|Observational|N/A|||Anticipated|800|||Both|1 Year|17 Years|No|||May 2011|May 24, 2011|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01185886||117468|
NCT01185899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor505310ctil|Usefulness of High-frequency QRS Analysis in the Evaluation of Patients With Chest Pain|The Usefulness of High-frequency QRS Analysis in the Evaluation of Patients Presenting to the Emergency Department With Chest Pain||Soroka University Medical Center|No|Completed|August 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|324|||Both|18 Years|N/A|No|Non-Probability Sample|Patients arriving to the emergency department of Soroka University Medical Center with        chest pain that is suspected of being due to acute coronary syndrome|November 2015|November 18, 2015|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185899||117467|
NCT01186146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0186|Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)|Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events|DES-LATE|CardioVascular Research Foundation, Korea|Yes|Completed|August 2010|October 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5000|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01186146||117448|
NCT01156194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArBel.2010|Homeopathic Remedy for the Third Stage of Delivery|Effect of a Homeopathic Remedy on the Third Stage of Delivery: a Prospective, Randomized, Double-Blind Study.||Shaare Zedek Medical Center|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 19, 2012|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156194||119738|
NCT01155947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859093|Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|May 2008|July 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|37 Years|67 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155947||119757|
NCT01155960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859094|Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|May 2008|July 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|37 Years|67 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155960||119756|
NCT01156714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7158-R|Exercise and Cognitive Training in Parkinson's Disease|Effects of Exercise and Cognitive Training on Executive Function in Parkinson's Disease||VA Office of Research and Development|Yes|Active, not recruiting|October 2010|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|121|||Both|40 Years|90 Years|No|||February 2016|February 16, 2016|March 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01156714||119698|
NCT01156675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPR003|Study Evaluating the Safety and Effectiveness of the FLEXUS(TM) Interspinous Spacer|A Prospective Randomized Clinical Investigation of the FLEXUS(TM) Interspinous Spacer: A Pivotal Study||Globus Medical Inc||Terminated|June 2008|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|215|||Both|50 Years|N/A|No|||September 2015|September 9, 2015|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156675||119701|
NCT01156688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1069|A Prospective Randomized Comparison Trial on the Use of Mifepristone With Sublingual or Buccal Misoprostol for Medical Abortions of Less Than 9 Weeks Gestation|A Prospective Randomized Comparison Trial on the Use of Mifepristone With Sublingual or Buccal Misoprostol for Medical Abortions of Less Than 9 Weeks Gestation||The University of Hong Kong|Yes|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|N/A|No|||August 2011|August 3, 2011|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01156688||119700|
NCT01187498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3083-R|Behavioral Treatment of Overactive Bladder in Men|Behavioral Treatment of Overactive Bladder in Men|MOTIVE|VA Office of Research and Development|No|Completed|January 2005|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Male|19 Years|N/A|No|||December 2013|April 22, 2014|August 20, 2010||No||No|October 28, 2013|https://clinicaltrials.gov/show/NCT01187498||117344|Results can only be generalized to men without evidence of obstruction as determined by uroflowmetry, post-void residual urine (PVR) volume, and a trial of an alpha-blocker.
NCT01187511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100046|Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety|Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study||National Institutes of Health Clinical Center (CC)||Completed|January 2010|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|44|||Female|21 Years|65 Years|No|||August 2015|September 12, 2015|August 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187511||117343|
NCT01187173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100475|The Fibrosis-Lymphedema Continuum in Head and Neck Cancer|The Fibrosis-Lymphedema Continuum in Head and Neck Cancer||Vanderbilt University|No|Completed|July 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|Blood from blood draws|Both|21 Years|N/A|No|Non-Probability Sample|The targeted population consists of patients with carcinoma of the head and neck. Subjects        will be recruited from newly diagnosed patients with carcinoma of the head and neck        undergoing treatment at the VICC, Vanderbilt Cool Springs Clinic, and the Nashville        Veterans Administration (VA) Medical Center.|June 2015|June 5, 2015|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187173||117369|
NCT01187485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13183B|A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer|A Randomized Phase I Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer||University of Chicago|No|Completed|June 2004|February 2009|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Male|18 Years|N/A|No|||January 2014|January 16, 2014|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01187485||117345|
NCT01187732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82310-97-1074|Washing Without Water: Cost-effectiveness of a Rapidly Spreading Nursing Intervention in Bedridden Patients'|WASHING WITHOUT WATER Cost-effectiveness of a Rapidly Spreading Nursing Intervention om Bedridden Patients'|WWW|Radboud University|Yes|Recruiting|April 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|576|||Both|45 Years|N/A|No|||June 2012|June 19, 2012|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187732||117326|
NCT01188590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-220|Transcutaneous Carbon Dioxide Monitoring Post Cardiac Surgery: Incidence and Severity Resp Insufficiency|Pilot Study: Transcutaneous Carbon Dioxide Monitoring Post Cardiac Surgery: Incidence and Severity of Respiratory Insufficiency||Baylor Research Institute|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|85 Years|No|Probability Sample|Cardiovascular surgical patients at Baylor University Medical Center|January 2016|January 11, 2016|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188590||117260|
NCT01188603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511.146|Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)|Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder||Sprout Pharmaceuticals, Inc|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|N/A|N/A|No|||May 2014|May 15, 2014|August 24, 2010|Yes|Yes||No|May 4, 2011|https://clinicaltrials.gov/show/NCT01188603||117259|
NCT01153750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-Glivec-012|Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct|Phase II Study to Evaluate the Efficacy of a Chemotherapy Combination With Imatinib (Glivec®) and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct||University Hospital Dresden|No|Completed|April 2007|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||April 2010|June 29, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01153750||119926|
NCT01153763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113710|A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma|A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma||GlaxoSmithKline|Yes|Active, not recruiting|August 2010|February 2016|Anticipated|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||April 2015|November 19, 2015|May 27, 2010|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01153763||119925|
NCT01154608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANCREATITE|Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis|||Institut National de la Recherche Agronomique|Yes|Completed|April 2005|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Primary Purpose: Basic Science|2||Actual|11|||Both|18 Years|N/A|No|||May 2010|June 30, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154608||119860|
NCT01154569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002390|Absorption of Drugs Post-Bariatric Surgery (Absorb-Azithromycin)|Absorption of Drugs Post-Bariatric Surgery (Absorb-Azithromycin)|Absorb-Azithro|University of Alberta|No|Completed|June 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|60 Years|No|||July 2011|July 28, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01154569||119863|
NCT01154283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSA-9611|Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients|A Randomized Crossover Study of Standard, Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in Amyotrophic Lateral Sclerosis (ALS) Patients||University of Michigan|No|Completed|January 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|19 Years|N/A|No|||July 2013|July 9, 2013|June 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154283||119885|
NCT01154296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK3153|HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.|Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032|Aware|Columbia University|Yes|Completed|April 2010|February 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|5012|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|June 29, 2010||No||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01154296||119884|
NCT01154595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGENT0410|Effectiveness of a Ready-to-Use-Food (RUF) Supplement to Prevent Acute Child Malnutrition|Effectiveness and Cost-effectiveness of a Ready-to-Use-Food (RUF) Supplement to Prevent Acute Malnutrition in Children Between 6-36 Months in Urban Chad|PREAMA|Action Contre la Faim|Yes|Completed|June 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2000|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||October 2011|October 10, 2011|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154595||119861|
NCT01155622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypothermia_32vs34|Trial of Different Hypothermia Temperatures in Patients Recovered From Out-of-hospital Cardiac Arrest|Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest||Hospital Universitario La Paz|No|Completed|March 2008|May 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01155622||119782|
NCT01155271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGIR-03|OBese Patients With Obstructive Sleep Apnea Syndrome(OSAS) and EXercise Training|Comparison of 3 Exercise Training Modalities in Obese Patient With Sleep Apnea Syndrome Treated by Continue Positive Airway Pressure : a Randomized Controlled Study|OBEX1|AGIR à Dom|Yes|Active, not recruiting|July 2010|December 2018|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||June 2015|June 9, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155271||119809|
NCT01155284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPAIR-T1D|Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes|Combination Therapy With Sitagliptin (DPP 4 Inhibitor) and Lansoprazole (PPI) Inhibitor) to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes|REPAIR-T1D|Sanford Health|Yes|Active, not recruiting|August 2010|September 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|11 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|June 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155284||119808|
NCT01155596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-3276B|Negative Pressure Ventilation Imapcts Weaning Ventilator In Medical Intensive Care Units (ICUs)|Phase 2 Study of Negative Pressure Ventilation That Imapcts Weaning Ventilator in Medical Intensive Care Units||Chang Gung Memorial Hospital|Yes|Recruiting|March 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|120|||Both|20 Years|N/A|No|||June 2010|July 1, 2010|May 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155596||119784|
NCT01155908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA15736|Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Non-fasting (Fed) Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|April 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155908||119760|
NCT01155921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA19885|Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Ltd. and Janssen Pharmaceutica Products, LP. (Risperdal M-TABTM)1 mg Risperidone Orally Disintegrating Tablets in Healthy Adult Male Volunteers Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155921||119759|
NCT01155934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA21566|Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Ltd. and Janssen Pharmaceutica Products, LP. (Risperdal M-TABTM)1 mg Risperidone Orally Disintegrating Tablets in Healthy Adult Male Volunteers Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155934||119758|
NCT01155609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7101|L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer|L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study||University of Washington|No|Completed|September 2010|October 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|June 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01155609||119783|
NCT01156727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 10-047|Linking National Guard Veterans With Need to Mental Health Care|Linking National Guard Veterans With Need to Mental Health Care||VA Office of Research and Development|No|Completed|July 2010|May 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|3015|||Both|18 Years|N/A|No|Non-Probability Sample|SURVEY: Michigan Army National Guard soldiers who have returned from OEF/OIF deployments        between August 2010 and December 2012.        INTERVIEW: Michigan Army National Guard soldiers and key B2B stakeholders.|July 2015|July 31, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01156727||119697|
NCT01187186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0063|A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941|A Phase 1, Open-Label, Single-Dose Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941||Astellas Pharma Inc|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||October 2010|October 5, 2010|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01187186||117368|
NCT01187199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0486|Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer|Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer||M.D. Anderson Cancer Center|No|Recruiting|August 2010|||August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|278|||Both|N/A|N/A|No|||December 2015|December 3, 2015|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01187199||117367|
NCT01187212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-1002|Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation|A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer|STARGATE|Asan Medical Center|No|Completed|August 2010|August 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|195|||Both|18 Years|75 Years|No|||October 2014|October 10, 2014|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01187212||117366|
NCT01187225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0930/09|Fibrinogen Concentrate In Children After Cardiac Surgery|Fibrinogen Concentrate to Treat Bleeding in Children Undergoing Cardiac Surgery With Pump: a Randomised Controlled Clinical Trial|FiCCS|University of Sao Paulo|No|Completed|August 2010|November 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|N/A|18 Years|No|||January 2013|January 2, 2013|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01187225||117365|
NCT01187524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100144|The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry|The Natural History of Reproductive and Overall Health in Women With a Pre-Mutation in the FMR1 Gene: Creation of a Patient Registry||National Institutes of Health Clinical Center (CC)||Terminated|August 2010|May 2013||||N/A|Observational|N/A|||Actual|7|||Female|18 Years|N/A|No|||May 2013|January 14, 2014|August 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01187524||117342|
NCT01187745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009520-01H|Study to Look for Artifact on Computed Tomography (CT) Representing Kidney Stones|Evaluation of Twinkling Artifact Compared to Computed Tomography for Evaluation of Kidney Stones||Ottawa Hospital Research Institute|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Probability Sample|Adults with flank pain in the emergency department, suspected to have kidney stones.|June 2011|June 27, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187745||117325|
NCT01188005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|439|Inflammatory Mediators in Obstructive Sleep Apnoea Syndrome; Mechanisms of Production and the Effect of Long Term Antioxidants Administration|Inflammatory Mediators in Obstructive Sleep Apnoea Syndrome; Mechanisms of Production and the Effect of Long Term Antioxidants Administration||University of Athens|Yes|Recruiting|August 2010|October 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|N/A|N/A|No|||August 2010|August 24, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01188005||117305|
NCT01188317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25330|A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of Ibuprofen on Top of Multiple Doses of 150 µg Aleglitazar Once Daily on Renal Function, Renin-angiotensin System, and Pharmacokinetics of Both Compounds in Healthy Subjects||Hoffmann-La Roche||Completed|June 2010|September 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|August 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01188317||117281|
NCT01153438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810104|Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes|Role of Endogenous Glucagon-like Peptide-1 (GLP-1) in Improved Glucose Tolerance After Two Different Types of Bariatric Surgery||University of Pennsylvania|Yes|Recruiting|April 2011|May 2013|Anticipated|December 2012|Anticipated|Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|16|Samples Without DNA|Extra blood will be stored for the potential analysis of additional hormones.|Both|18 Years|N/A|No|Non-Probability Sample|Individuals with type 2 diabetes who are medically approved and have insurance approval to        undergo gastric bypass or gastric banding at the University of Pennsylvania.|January 2011|April 26, 2011|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153438||119950|
NCT01154309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020159|Group CBT for Depression and AOD Disorders|Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders|BRIGHT2|RAND|Yes|Completed|September 2006|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 10, 2011|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154309||119883|
NCT01154621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2690C00007|Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects|A Phase I, Double-blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability, and Pharmacokinetics of a Single Dose of AZD9742 in Healthy Elderly Male and Female Volunteers||AstraZeneca|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 2, 2010|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154621||119859|
NCT01153997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1810-3733|Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers|A Randomised, Placebo-controlled Single-dose, Parallel-group, Double-blind Trial Evaluating Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Japanese Subjects||Novo Nordisk A/S|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|June 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153997||119907|
NCT01155076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-SUS-03-NU-01|Effects of a Vitality Dietary Supplement on Physical and Mental Function in Middle-aged Adults|Effects of a Proprietary Ginseng, Cordyceps, and Pomegranate Supplement on Physical and Mental Function in Middle-aged Adults: a Double-blind, Randomized, Placebo-controlled Trial||Pharmanex|No|Completed|July 2010|November 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|116|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155076||119824|
NCT01155089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAS-T1-PVFD-1|Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|May 2006|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01155089||119823|
NCT01155310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-07-C3-009|Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|An International Phase III Randomised Trial Comparing in Severe Exacerbations of Chronic Obstructive Pulmonary Disease the Efficacy of Helium/Oxygen Versus Air/Oxygen Administered During Spontaneous Breathing and Intermittent Non-Invasive Ventilation.|ECHO/ICU|Air Liquide Santé International|No|Terminated|May 2010|June 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|446|||Both|35 Years|N/A|No|||October 2014|October 6, 2014|June 25, 2010||No|the observed event rate is lower than expected by the protocol hypothesis.|No||https://clinicaltrials.gov/show/NCT01155310||119806|
NCT01155323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0926|Two Week Cross-Over Study Comparing Two Daily Disposable Contact Lenses|Proclear 1 Day Lens vs 1-Day Acuvue Moist Daily Disposable Contact Lens Crossover Study||Johnson & Johnson Vision Care, Inc.||Completed|March 2010|||June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|39 Years|No|||May 2015|May 5, 2015|June 30, 2010|Yes|Yes||No|August 29, 2011|https://clinicaltrials.gov/show/NCT01155323||119805|
NCT01155102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAS-T1-PVFS-1|Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|April 2006|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01155102||119822|
NCT01155336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVZ114193|The Effects of Lovaza® in Acute Myocardial Infarction|The Effects of Lovaza® on Platelet Function and Cardiac Electrophysiology in Acute Myocardial Infarction|OmegaMI|University of Rochester|Yes|Terminated|June 2010|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|80 Years|No|||March 2013|March 8, 2013|June 25, 2010|Yes|Yes|Only 5 individuals were able to be recruited.|No|February 5, 2013|https://clinicaltrials.gov/show/NCT01155336||119804|no adverse events
NCT01155349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF105832|Brain Fitness in Parkinson's Disease|Cognitive Speed of Processing Training Among Persons With Parkinson's Disease||University of South Florida|No|Completed|July 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|87|||Both|40 Years|N/A|No|||December 2012|December 7, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155349||119803|
NCT01155063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991092|Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients|A Non-Interventional Observational Study Evaluating The Effects Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy On Safety In Postmenopausal And Hormone Receptors Positive Early Breast Cancer Patients||Pfizer|No|Terminated|September 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|89|||Female|18 Years|60 Years|No|Non-Probability Sample|Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are        Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy|September 2012|September 25, 2012|June 28, 2010|No|Yes|See Detailed Description|No|August 17, 2012|https://clinicaltrials.gov/show/NCT01155063||119825|The study was prematurely discontinued, therefore not all data was analyzed and only one outcome measure timeframe was presented.
NCT01155297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-45|Effect of PT on QL, FC, PWV and Biochemical Markers in CRF on Conservative Treatment|Effect of Physical Training on Quality of Life, Functional Capacity, Pulse Wave Velocity and Biochemical Markers in Patients With Chronic Renal Failure on Conservative Treatment||UPECLIN HC FM Botucatu Unesp|Yes|Not yet recruiting|June 2010|November 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|68|||Both|18 Years|60 Years|No|||June 2010|June 29, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155297||119807|
NCT01156233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBB_ANA_ TET|Tube Tip Position in Orally Intubated 0-4year Old Children: Assessment of the Precision of Two Clinical Techniques|Endotracheal Tube Tip Position in Orally Intubated 0-4 Year Old Children: Comparative Assessment of the Precision of Two Clinical Techniques||University Hospital, Basel, Switzerland|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|N/A|4 Years|No|||February 2013|February 9, 2013|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01156233||119735|
NCT01156246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1691C00005|Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers|An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/1000 mg) in Healthy Male and Female Volunteers||AstraZeneca|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01156246||119734|
NCT01156428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908010598|Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease|Transcriptional Profiling of Kidney Tissue Obtained From Patients With Newly Identified Proteinuria, Nephrotic Syndrome or Nephritic Syndrome||The Rogosin Institute|No|Active, not recruiting|July 2010|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|119|Samples Without DNA|Whole blood, serum, urine, kidney tissue|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subject with pre-existing clinical indication for a kidney biopsy including, but not        limited to, nephritic syndrome, nephritic syndrome or proteinuric disease state.|February 2016|February 26, 2016|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156428||119720|
NCT01156701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113502|Prophylactic Efficacy of Relenza Against Influenza A and B|Prophylactic Efficacy of Relenza Against Influenza A and B||GlaxoSmithKline|No|Completed|July 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||4|Actual|171705|||Both|N/A|N/A|No|Non-Probability Sample|The study will use data from the NHI database which includes only those individuals who        have both medical and pharmacy benefits, and therefore captures most outpatient        prescription drug exposures and health provider encounters. From October 2006 through        April 2009, we will count patients receiving prophylactic Relenza, defined as a dispensing        of Relenza to a person who meets 2 criteria: (1) not having had a diagnosis of influenza        associated with medical care on the day of dispensing or in the preceding 3 days, and (2)        a household member has had a diagnosis of influenza associated with medical care on the        day of the prophylactic dispensing or within the preceding 3 days. Household members will        be defined as persons within the NHI database sharing a common family identifier code.|June 2011|June 2, 2011|April 22, 2010||No||No|January 28, 2011|https://clinicaltrials.gov/show/NCT01156701||119699|
NCT01156740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRN-A-00-96-90006-00|Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings|Treatment of Pharyngitis Study (TOPS): A Randomized Equivalence Trial of Intramuscular Penicillin G vs. Oral Amoxicillin Antibiotics for the Treatment of Streptococcal Pharyngitis in Children in Developing Countries|TOPS|Johns Hopkins University|Yes|Completed|August 2001|April 2003|Actual|April 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|558|||Both|2 Years|12 Years|No|||December 2009|July 2, 2010|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156740||119696|
NCT01186939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA PH GL 2003 CL 001 E|An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)|AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)||Celgene|No|Completed|April 2007|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2010|April 2, 2012|August 20, 2010|No|Yes||No|August 26, 2010|https://clinicaltrials.gov/show/NCT01186939||117387|
NCT01187537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIG/09052|Effects of Continuous Nerve Block vs Single Injection Block With PCA vs PCA on Pain and Function After Knee Replacement|Effects of Continuous Femoral Nerve Block Versus Single-Injection Femoral Nerve Block With Intravenous Patient Controlled Analgesia Versus Intravenous Patient Controlled Analgesia on Knee Pain and Function After Total Knee Replacement|PCA|Tan Tock Seng Hospital|Yes|Recruiting|July 2009|May 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|40 Years|90 Years|No|||August 2010|August 23, 2010|August 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01187537||117341|
NCT01187758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-01-2357-GRY-CTIL|Israeli Judicious Antibiotic Prescription Study|Can Change in Physicians' Prescribing Habits Decrease Carriage of Resistant Bacteria in the Community?|IJAP|Sheba Medical Center|No|Completed|February 2002|December 2007|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5700|||Both|N/A|5 Years|Accepts Healthy Volunteers|||August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187758||117324|
NCT01188018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00023726|Testing Counseling Styles to Motivate Smokers to Quit|Can Motivational Interviewing be Effective for Smoking Cessation?||University of Missouri, Kansas City|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|255|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 3, 2012|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188018||117304|
NCT01188031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-0302|A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions|A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Fasting Conditions||Actavis Inc.|No|Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188031||117303|
NCT01188330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLSP/IPC 2009-003|Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival|Randomized Study Comparing the Interest of a Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival of Elderly Patients With Acute Myeloid Leukaemia. MLSP/IPC 2009-003|MLSP|Institut Paoli-Calmettes|No|Recruiting|March 2010|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|70 Years|N/A|No|||October 2013|October 30, 2013|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188330||117280|
NCT01188356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGST04-EMERALD Study|EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients|AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients|EMERALD|LivaNova|No|Active, not recruiting|March 2010|January 2019|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4350|||Both|18 Years|N/A|No|Probability Sample|The sponsor plans the enrolment of a total of 2188 subjects in this clinical        investigation.|June 2015|June 1, 2015|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188356||117278|
NCT01154322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-09-09|Pediatric Nasal Mask Usability Study|Pediatric Nasal Mask Usability Study||ResMed|No|Completed|June 2010|November 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|2 Years|7 Years|No|||January 2013|January 18, 2013|June 15, 2010|Yes|Yes||No|November 7, 2012|https://clinicaltrials.gov/show/NCT01154322||119882|
NCT01154842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-perk|Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients|Serum Fibroblast Growth Factor-23 (FGF-23) Levels Are Independently Associated With Left Ventricular Mass and Myocardial Performance Index in Maintenance Haemodialysis Patients||Diskapi Teaching and Research Hospital|Yes|Active, not recruiting|December 2009|June 2010|Anticipated|May 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|128|Samples With DNA|Human plasma to measure FGF-23 levels|Both|18 Years|N/A|No|Non-Probability Sample|Adult hemodialysis patients (age>18 years old)|January 2010|July 12, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154842||119842|
NCT01154634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3830C00001|Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers||AstraZeneca|No|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 17, 2012|June 15, 2010|Yes|Yes||No|January 27, 2012|https://clinicaltrials.gov/show/NCT01154634||119858|
NCT01154855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00029568|Periodontal Disease and Circulatory Microbial Components|Circulatory Microbial Components and Immune Regulators of Patients With Periodontal Disease and Rheumatoid Arthritis|CirCo|University of Michigan|Yes|Completed|January 2010|May 2015|Actual|May 2015|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|Samples With DNA|Dental plaque samples evaluated for microbial DNA|Both|35 Years|N/A|Accepts Healthy Volunteers|Probability Sample|40 adult subjects comprised of two populations: 1) healthy (n=20) and 2) severe        periodontal disease (n=20)|December 2015|December 11, 2015|March 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01154855||119841|
NCT01155375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-CKD-251|A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease|A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease||AMAG Pharmaceuticals, Inc.|Yes|Active, not recruiting|April 2011|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|288|||Both|6 Months|17 Years|No|||September 2014|September 15, 2014|June 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155375||119801|
NCT01155388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-CKD-252|A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-Dependent Chronic Kidney Disease|A Randomized, Open Label, Active Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-dependent Chronic Kidney Disease||AMAG Pharmaceuticals, Inc.|Yes|Terminated|April 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|6 Months|17 Years|No|||December 2013|December 12, 2013|June 30, 2010|Yes|Yes|Study AMAG-FER-CKD-252 was combined with Study AMAG-FER-CKD-251 and is currently recruiting    under study AMAG-FER-CKD-251.|No||https://clinicaltrials.gov/show/NCT01155388||119800|
NCT01155973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/90354|Educore Project: Effect of a Visual Learning Method for Improving Blood Pressure Control|Educore Project: A Clinical Trial, Randomised by Clusters, to Assess the Effect of a Visual Learning Method on Blood Pressure Control in the Primary Health Care Setting|EDUCORE|Gerencia de Atención Primaria, Madrid|Yes|Completed|June 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|452|||Both|40 Years|65 Years|No|||April 2013|April 3, 2013|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155973||119755|
NCT01156220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPT0901|Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers|Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers||Universitätsklinikum Hamburg-Eppendorf|No|Not yet recruiting|January 2012|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||April 2011|April 11, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156220||119736|
NCT01156259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-LYM-004|30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy|Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy||Chinese Academy of Medical Sciences|Yes|Recruiting|April 2010|May 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|15 Years|N/A|No|||April 2010|July 1, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01156259||119733|
NCT01156441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAS-SIU-10-003-1|Medical Versus Surgical Management of Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention|Medical Versus Surgical Management of Patients With Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention for Myocardial Infarction: A Pilot Prospective Randomized Trial||Southern Illinois University|No|Withdrawn|July 2010|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|75 Years|No|||June 2014|June 12, 2014|June 30, 2010||No|no patients enrolled|No||https://clinicaltrials.gov/show/NCT01156441||119719|
NCT01153828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113149|EU PV for Retapamulin-Prescribing|Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union||GlaxoSmithKline|No|Completed|November 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Retrospective||5|Actual|1|||Both|N/A|N/A|No|Probability Sample|The GPRD contains detailed information for a sample of patients from representative        general practices throughout the United Kingdom. Patient data included in the GPRD were        drawn from the computer systems used by general practitioners to maintain the clinical        records within their practices and contain all records deemed relevant to patient care.        Prescriptions of Altabax, Altargo, Mupirocin and Fucidin will be captured.|May 2013|June 6, 2013|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01153828||119920|
NCT01153841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113151|Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam|Primary Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, in Healthy Infants in Vietnam When Co-administered With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine||GlaxoSmithKline||Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||January 2012|July 23, 2012|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01153841||119919|
NCT01187238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-HN-001|The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma|A Randomized Multicenter Phase II Study of Intensity-modulated Radiotherapy Combined With Chemotherapy Versus Intensity-modulated Radiotherapy Alone for Stage II Nasopharyngeal Carcinoma||Chinese Academy of Medical Sciences|Yes|Completed|July 2010|August 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|70 Years|No|||September 2014|September 9, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01187238||117364|
NCT01188070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB000032005|Caregiver Stress: Interventions to Promote Health and Wellbeing|Caregiver Stress: Interventions to Promote Health and Wellbeing||Emory University|Yes|Completed|January 2010|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|354|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 3, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01188070||117300|
NCT01187771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL106410|Apnea, Bariatric Surgery Versus Continuous Positive Airway Pressure (CPAP) Trial|A Randomized Trial of Bariatric Surgery for the Treatment of Sleep Apnea|ABC|Brigham and Women's Hospital|Yes|Completed|November 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187771||117323|
NCT01188044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG Validation Lungwena|Validating Accelerometers to Study Physical Activity of Toddlers|Validating the Use of Accelerometers for the Study of Physical Activity Among Young Malawian Toddlers||University of Tampere|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|16 Months|18 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children|January 2011|January 5, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188044||117302|
NCT01188057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-0303|A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Non-fasting Conditions||Actavis Inc.|No|Completed|July 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188057||117301|
NCT01188343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC04|Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers|Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan.||Sanofi|Yes|Completed|August 2010|December 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|542|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||July 2014|July 25, 2014|August 24, 2010||No||No|June 25, 2014|https://clinicaltrials.gov/show/NCT01188343||117279|
NCT01184469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB 10-0007|Prospective Observational Study of Peri-implantation Serum hCG Levels|Prospective Observational Study of Peri-implantation Serum hCG Levels||Fertility Center of Las Vegas|No|Completed|August 2010|May 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|451|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|IVF patients|October 2012|October 12, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184469||117576|
NCT01184482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tykerb-itux 1|Lapatinib and Cetuximab in Patients With Solid Tumors|A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors|TYKERB-ITUX 1|Georgetown University|Yes|Completed|June 2010|September 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|August 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01184482||117575|
NCT01154036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653C-162|MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)|A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin||Merck Sharp & Dohme Corp.|No|Completed|July 2010|October 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|1547|||Both|18 Years|79 Years|No|||October 2015|October 30, 2015|June 29, 2010|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT01154036||119904|
NCT01154010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-020|PEMF: an Adjunct Therapy for Anterior Uveitis|PEMF an Adjunct Therapy for Anterior Uveitis|PEMF|Massachusetts Eye and Ear Infirmary|No|Completed|August 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|85 Years|No|||May 2015|May 13, 2015|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154010||119906|
NCT01154023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29NR004951|Behavioral Intervention for Insomnia in Older Adults|Behavioral Intervention for Insomnia in Older Adults||Carl T. Hayden VA Medical Center|No|Completed|September 2000|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|179|||Both|55 Years|N/A|Accepts Healthy Volunteers|||June 2010|June 29, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01154023||119905|
NCT01154335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 124|Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer|A Phase I Study of Everolimus (mTOR Inhibitor) and OSI-906 (Dual IGFR and IR Tyrosine Kinase Inhibitor) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer||SCRI Development Innovations, LLC|No|Completed|July 2010|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|June 29, 2010|No|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01154335||119881|
NCT01154348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011N0913|Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus|A Phase 1b, Randomized, Placebo-Controlled Study to Assess the Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus||Shionogi Inc.|Yes|Completed|June 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|65 Years|No|||September 2011|September 13, 2011|June 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154348||119880|
NCT01154868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00035937|Clinical and Histological Evaluation of Healos® for Alveolar Ridge Augmentation|Clinical and Histological Evaluation of Healos® for Alveolar Ridge Augmentation||University of Michigan|No|Withdrawn|August 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|June 29, 2010|No|Yes|Sponsor withdrew funding of study.|No||https://clinicaltrials.gov/show/NCT01154868||119840|
NCT01154881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1987|A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes|A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|49|||Both|18 Years|70 Years|No|||September 2015|September 24, 2015|June 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154881||119839|
NCT01155115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000013966|Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia|Inflammatory and Microbiologic Markers in Sputum in Response to Pulmonary Exacerbation: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia||The Hospital for Sick Children|Yes|Completed|January 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|6 Years|18 Years|No|||May 2015|May 21, 2015|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155115||119821|
NCT01156480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH09-196|Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants|Anti-inflammatory Treatment at the Onset of NEC in Preterm Infants- a Pilot Study|steroids/NEC|NorthShore University HealthSystem Research Institute|Yes|Terminated|September 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|N/A|6 Months|No|||April 2014|April 15, 2014|July 1, 2010||No|low enrollment|No|January 8, 2014|https://clinicaltrials.gov/show/NCT01156480||119716|This study was terminated due to low enrollment. We had a drop in our incidence of NEC, so there were very few eligible infants. One subject that was enrolled was soon thereafter thought NOT to have NEC, so that subject never received study drug.
NCT01155362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA001-002|A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease|A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease||Celgene|Yes|Completed|August 2010|April 2014|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|75 Years|No|||July 2014|July 14, 2014|May 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155362||119802|
NCT01155635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-417|Carvedilol Post-intervention Long-term Administration in Large-scale Trial|Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial|CAPITAL-RCT|Kyoto University, Graduate School of Medicine|Yes|Completed|July 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|801|||Both|N/A|N/A|No|||December 2015|January 5, 2016|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01155635||119781|
NCT01155986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|761541|Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative Pain|Lidocaine 5% Medicated Plaster for the Topical Treatment of Localized Chronic Postoperative Neuropathic Pain.||Grünenthal GmbH|No|Terminated|August 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|July 1, 2010||No|Trial was stopped due to difficult enrolment|No||https://clinicaltrials.gov/show/NCT01155986||119754|
NCT01155999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1225-PIIIB-02/08|Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.|||Laboratoires Thea||Completed|December 2008|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|286|||Both|N/A|18 Years|No|||September 2011|October 24, 2014|June 30, 2010||No||No|October 24, 2014|https://clinicaltrials.gov/show/NCT01155999||119753|
NCT01156012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2345-PIII-12/08|Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients|||Laboratoires Thea||Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|404|||Both|18 Years|90 Years|No|||December 2014|January 9, 2015|June 30, 2010||No||No|November 12, 2014|https://clinicaltrials.gov/show/NCT01156012||119752|
NCT01153269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAL 1 HO|Long-term Effectiveness and Safety in Hepatitis-co-infected Patients|Long-term Effectiveness and Safety in Hepatitis-co-infected Patients||Abbott|No|Completed|May 2001|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample, Human Immunodeficiency Virus-infected patients with Hepatitis B or C        co-infections|November 2011|November 16, 2011|February 26, 2010||No||No|November 16, 2011|https://clinicaltrials.gov/show/NCT01153269||119963|
NCT01156454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111743|Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling|Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling (GPS)|GPS|University of Arkansas|No|Completed|November 2009|January 2012|Actual|January 2011|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Males or females of all races and ethnicities, must be equal to or greater than 18 years        of age, scheduled for breast cancer surgery that includes sentinel node biopsy and/or        axillary dissection|June 2012|June 12, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01156454||119718|
NCT01156467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK:26/2010|Neurally Adjusted Ventilatory Assist (NAVA) in Ventilatory Care of Premature Infants|Neurally Adjusted Ventilatory Assist (NAVA) in Ventilatory Care of Premature Infants||University of Oulu|No|Completed|April 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|9 Weeks|No|||June 2013|June 10, 2013|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156467||119717|
NCT01153854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INP14/2005-Raceca-001|Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico|Efficacy, Safety and Cost-effectiveness Analysis of Impact of Racecadotril as an Adjunct in the Treatment of Acute Diarrhea in Mexican Children|Raceca-Mex|National Institute of Pediatrics, Mexico|Yes|Completed|January 2007|December 2009|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|454|||Both|1 Month|24 Months|No|||June 2010|June 29, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153854||119918|
NCT01187550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27709|Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®|A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen®||Merck KGaA||Completed|March 2007|April 2009||September 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|214|||Both|N/A|N/A|No|||January 2014|January 20, 2014|August 22, 2010||No||No|May 9, 2012|https://clinicaltrials.gov/show/NCT01187550||117340|
NCT01188369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1616|Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy|Effects of Levosimendan on Systolic Deformation and Diastolic Function in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy||University of Aarhus|Yes|Terminated|September 2010|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|90 Years|No|||August 2012|August 3, 2012|August 10, 2010|Yes|Yes|Terminated prematurely due to high incidence of postoperative atrial fibrillation. The study    has not been unblinded.|No||https://clinicaltrials.gov/show/NCT01188369||117277|
NCT01188629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26670|Conversational IT for Better, Safer Pediatric Primary Care|The Personal Health Care Partner Project, Conversational IT for Better, Safer Pediatric Primary Care|PHP|Boston Medical Center|Yes|Completed|July 2007|August 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|475|||Both|N/A|11 Years|No|||November 2015|November 16, 2015|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188629||117257|
NCT01188642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2007/64|Effects of Physical Training and Nutrition Education on Adipocytokines in Severely Obese Teenagers||OBAPA|Centre Hospitalier Universitaire de Besancon|No|Completed|March 2009|||June 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||32|||Both|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|obese teenagers|August 2010|August 24, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01188642||117256|
NCT01188655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881X1-4456|Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis|Observational Non-Interventional Study With Enbrel in Patients With Ankylosing Spondylitis||Pfizer|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|89|||Both|18 Years|N/A|No|Non-Probability Sample|The patient cohort in this non-interventional study will reflect the kind of patients seen        in routine clinical practice and will not be specifically pre-selected as it is the case        in clinical studies.|September 2011|September 8, 2011|August 24, 2010|No|Yes||No|March 29, 2011|https://clinicaltrials.gov/show/NCT01188655||117255|
NCT01154660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0734|Effects of Increased Tidal Volume on Internal Jugular Vein Cross-sectional Area|Effects of Increased Tidal Volume on Internal Jugular Vein Cross-sectional Area||Yonsei University|Yes|Completed|July 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|25 Years|75 Years|No|||April 2011|April 18, 2011|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154660||119856|
NCT01154894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KunioYui|Dietary Fatty Acids Improve Social Impairment in Autism Spectrum Disorders|Double-blind Randomized Placebo-controlled Trail|Fatty acid|Ashiya University|No|Completed|February 2009|December 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|13|||Both|6 Years|29 Years|No|||December 2008|June 22, 2011|June 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154894||119838|
NCT01154361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMACE|AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study|A Multicenter Study, Randomized, Double-blind With 2 Groups as Prove of Concept for the Treatment of ACEI Induced Angioedema With Subcutaneous Icatibant||Technische Universität München||Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|18 Years|84 Years|No|||December 2011|December 22, 2011|June 29, 2010||||No||https://clinicaltrials.gov/show/NCT01154361||119879|
NCT01154647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-020498-17|Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes|Unraveling Impaired Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes: a Series of Experiments Targeting Brain Neurotransmission||Vrije Universiteit Brussel|No|Not yet recruiting|September 2010|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|70|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||April 2010|June 30, 2010|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01154647||119857|
NCT01156051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSHTR-TR-0901|Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia|Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia||Children's Specialized Hospital|Yes|Terminated|June 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|6 Years|12 Years|No|||July 2014|July 21, 2014|July 1, 2010|Yes|Yes|extended beyond completion date; chose to close out rather than renew IRB review|No|May 31, 2014|https://clinicaltrials.gov/show/NCT01156051||119749|
NCT01156272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009|Post Market ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm|3f 19mm IDE Study Rev D||Medtronic Cardiovascular|No|Withdrawn|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who were previously implanted with the ATS 3f Aortic Bioprosthesis Model 1000        (size 19mm) between the dates 1-Jan-2009 and 31-Dec-2009 and who meet the eligibility        criteria.|August 2015|August 4, 2015|June 28, 2010||No|Study terminated prematurely.|No||https://clinicaltrials.gov/show/NCT01156272||119732|
NCT01155648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-504|Pressure Support During Chest Wall Compression|Increasing Pressure Support During Chest Wall Compression is Useful During Respiratory Therapy?||Hospital de Clinicas de Porto Alegre|No|Completed|May 2008|May 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|66|||Both|18 Years|N/A|No|||June 2010|July 1, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01155648||119780|
NCT01155661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11318|A Safety Study in Patients With Major Depressive Disorder|Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment||Eli Lilly and Company|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|N/A|No|||January 2013|April 30, 2013|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155661||119779|
NCT01157052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25408|Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients|Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients||AHS Cancer Control Alberta|No|Not yet recruiting|January 2015|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|15|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01157052||119672|
NCT01156025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTGV550-PII-11/06|Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis|Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients)||Laboratoires Thea|Yes|Completed|March 2009|June 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|No|||July 2010|July 1, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01156025||119751|
NCT01156038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|599/2552(EC4)|Atopy Patch Test in Normal Population : Pilot Study|Atopy Patch Test in Normal Population : Pilot Study||Mahidol University|Yes|Completed|February 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2010|July 1, 2010|May 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01156038||119750|
NCT01153282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 14110|Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer|Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|June 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|N/A||1|Anticipated|30|||Female|21 Years|70 Years|No|Probability Sample|The semi-structured interviews will be conducted with breast cancer patients of the Rena        Rowan Breast Center of the Abramson Cancer Center of the University of Pennsylvania. A        purposive sampling strategy in which study participants are recruited based on a        particular characteristic of experience of interest, will be used to select breast cancer        patients (N=30). Participants will be recruitedwith the goal of having a balanced sample        of women who experience documented CIPN (per Common Toxicity Criteria for Adverse Events        CTCAE - grading criteria, details below) and those who received a taxane but did not have        documented CIPN.|January 2016|January 25, 2016|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153282||119962|
NCT01153516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122009-049|Diabetes and Gastric By- Pass|Unraveling the Mechanisms of Rapid Improvement in Diabetes Following Gastric By-Pass Surgery||University of Texas Southwestern Medical Center|No|Completed|June 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|whole blood samples, plasma, serum, urine,|Both|18 Years|65 Years|No|Non-Probability Sample|Bariatric surgery clinical roster or by the treating physician in the bariatric surgery        clinic.        This study does NOT pay for the By-pass surgery, eligible participants should have planned        their surgery by their own physician, at their own expense.|January 2013|January 22, 2013|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01153516||119944|
NCT01153867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-048|Schema Focused Therapy for Chronic Depression|Schema-Focused Therapy for Chronic Depression: Efficacy and Mechanisms of Change||Maastricht University Medical Center|No|Completed|January 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153867||119917|
NCT01188109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00034258|Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision|Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision||Emory University|Yes|Terminated|July 2010|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|July 23, 2010|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01188109||117297|
NCT01187784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McNallyKeehn|Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and Anxiety|Effectiveness of Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and Anxiety||Alliant International University|No|Completed|May 2009|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|7 Years|14 Years|No|||August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187784||117322|
NCT01187797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA408109|Effects of Emotional Stimulation on the Stress Levels of Healthy Persons|Evaluation of the Effects of a Body-centered Emotional Stimulation in Healthy Persons||Charite University, Berlin, Germany||Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2010|October 22, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01187797||117321|
NCT01188083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007471|Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis|Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis|Sweet Bev|Emory University|No|Completed|June 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|53|||Both|11 Years|18 Years|No|||November 2013|November 20, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01188083||117299|
NCT01188096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Poly ICLC|A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas|A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas|Poly-ICLC|University of California, San Diego|Yes|Recruiting|August 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|21 Years|No|||December 2014|April 14, 2015|August 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188096||117298|
NCT01188382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydrocephalus100|Reference Values of Cerebrospinal Fluid Outflow Resistance and Intracranial Pressure in Healthy Elderly|Reference Values of Cerebrospinal Fluid Outflow Resistance and Intracranial Pressure in Healthy Elderly||Umeå University|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|60 Years|82 Years|Accepts Healthy Volunteers|Probability Sample|Healthy elderly|June 2010|August 24, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01188382||117276|
NCT01188395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-98-002|Bipolar Disorder With Alcoholism in Han Chinese|||National Cheng-Kung University Hospital|Yes|Recruiting|August 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|105|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Bipolar disorders|August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188395||117275|
NCT01184820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13401|Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration|An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A||Bayer|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|65 Years|No|||October 2014|October 31, 2014|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01184820||117549|
NCT01185184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921113|Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers|A Phase 1, Randomized, 3-Period, Open Label, Single Dose, Cross Over Study To Evaluate The Pharmacokinetics And Safety Of Two Controlled Release Formulations Of CP-690,550||Pfizer|No|Completed|August 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|21 Months|55 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|August 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01185184||117522|
NCT01155440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-06-023(1)|Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine|Restoration of Bowel Function After Laparoscopic Colorectal Surgery: Effect of Intravenous Lidocaine||McGill University Health Center|No|Completed|June 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||November 2011|November 24, 2011|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155440||119796|
NCT01155401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GRU-NEX-2009/2|Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding|Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding||AstraZeneca|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|November 2011|November 7, 2011|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01155401||119799|
NCT01155414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK75|Tolerance of Healthy Term Infants Fed Infant Formulas #4|Tolerance of Healthy Term Infants Fed Infant Formulas||Abbott Nutrition|Yes|Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|168|||Both|N/A|8 Days|Accepts Healthy Volunteers|||November 2010|October 31, 2011|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01155414||119798|
NCT01155674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 09-311|Innate Immune Functions of Immature Neutrophils|Innate Immune Functions of Immature Neutrophils||University Hospital, Geneva|No|Recruiting|May 2010|October 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|No samples retained|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Patients with severe sepsis or septic shock          -  Patients with a noninfectious systemic inflammatory response syndrome (SIRS)          -  Healthy donors|February 2010|July 1, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01155674||119778|
NCT01156493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090579|Hydrolized Protein Formula for Premature Infants|Randomized Trial of Hydrolyzed Protein Premature Formula||University of Miami|No|Completed|July 2010|September 2015|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|137|||Both|N/A|6 Months|No|||November 2015|November 2, 2015|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156493||119715|
NCT01156506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKD02|Focus Group Interviews of Patients With Permanent or Temporary Enterostomas|Patient Perspectives on Living With an Enterostoma and Rehabilitation||Herlev Hospital|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|N/A||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Department of surgery|December 2012|December 11, 2012|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01156506||119714|
NCT01156519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/12-I|Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC)|Detection of Infra-clinic Cortisol Adenoma (ACIC) in a Population of Android Obese With High Metabolic Risk: Contribution of Salivary Cortisol at 23 Hours|ACIC|Nantes University Hospital|No|Terminated|June 2010|March 2014|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|514|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|June 29, 2010||No|Number of patients with a serum cortisol > 18 ng/ml reached|No||https://clinicaltrials.gov/show/NCT01156519||119713|
NCT01156753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX011-03|A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer|A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer|EMERGE|Celldex Therapeutics|Yes|Completed|July 2010|November 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156753||119695|
NCT01156766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0077|Metaphyseal Distal Radius Fractures|Locking Plate Versus Pins for Surgical Treatment of Posteriorly Tilted Distal Radius Fracture||University Hospital, Clermont-Ferrand||Completed|June 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|60 Years|N/A|No|||June 2013|June 11, 2013|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156766||119694|
NCT01157065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-067|Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration|Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD|RACE|Alcon Research|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|50 Years|N/A|No|||April 2013|April 19, 2013|July 2, 2010|Yes|Yes||No|April 19, 2013|https://clinicaltrials.gov/show/NCT01157065||119671|
NCT01157078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00002|A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Therapy||AstraZeneca|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|65 Years|No|||March 2014|March 14, 2014|June 24, 2010|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT01157078||119670|
NCT01157312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-290s|Minimal Stimulation or Clomiphene Citrate in Treatment of Polycystic Ovary Syndrome|Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome||Mansoura University|Yes|Completed|August 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Female|20 Years|39 Years|No|||July 2010|July 16, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157312||119652|
NCT01157325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMU10-201|Cesarean Rate in Parturients Without Neuraxial Analgesia|Comparison of the Cesarean Rate Between Parturients Who Received Neuraxial Analgesia and Those Who Did Not|CRINA|Nanjing Medical University|Yes|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Female|19 Years|40 Years|No|||July 2011|July 26, 2011|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157325||119651|
NCT01153295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFF080408-1|"Functional Bowel Disorder. Investigation in General Practice"|"Functional Bowel Disorder. Investigation in General Practice"||University of Southern Denmark|No|Completed|December 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|153|||Both|18 Years|50 Years|No|||December 2008|October 24, 2011|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153295||119961|
NCT01153308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-11612|Outcomes of Bariatric Surgery/UMMMC Bariatric Surgery Registry|Outcomes of Bariatric Surgery (UMMMC Bariatric Surgery Registry)||University of Massachusetts, Worcester|No|Completed|April 2005|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4785|||Both|18 Years|80 Years|No|Non-Probability Sample|UMMMC Bariatric Surgery Patients|August 2015|August 17, 2015|March 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01153308||119960|
NCT01153529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|575|Post-Deployment Afghanistan/Iraq Trauma Related Inventory of Traits (PATRIOT): Phase 1 (Feasibility Study)|CSP #575 - Post-Deployment Afghanistan/Iraq Trauma Related Inventory of Traits (PATRIOT): Phase 1 (Feasibility Study)|PATRIOT|VA Office of Research and Development|Yes|Completed|September 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|OEF/OIF Veterans|May 2014|May 16, 2014|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153529||119943|
NCT01153880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113158|United States Pharmacovigilence Retapamulin-Prescribing|Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the United States||GlaxoSmithKline|No|Completed|December 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Retrospective||6|Actual|1|||Both|N/A|N/A|No|Probability Sample|Members with enrollment and phamacy benefits eligibility in the Integrated Health Care        Information Services (IHCIS) National Managed Care Benchmarked Database will be assessed        annually for prescription sales claims for five years post-launch of retapamulin. The        IHCIS is a US national managed care database which is Health Insurance Portability and        Accountability Act (HIPAA) compliant and features encrypted member and provider        identifiers.|May 2013|June 6, 2013|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153880||119916|
NCT01188421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-018125|Medications Development for Drug Abuse Disorders|Medications Development for Drug Abuse Disorders||Johns Hopkins University|No|Active, not recruiting|October 2010|July 2016|Anticipated|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|60 Years|No|||February 2016|February 15, 2016|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188421||117273|
NCT01184859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS36|Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo|A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-group, Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo in Water-loaded Male and Female Japanese Nocturia Patients (Single Dose), and to Study the Efficacy of 4 Different Dose Levels of Minirin Melt and Placebo After 28 Days of Dosing (Multiple Doses)|NOC|Ferring Pharmaceuticals|No|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|116|||Both|55 Years|75 Years|No|||April 2012|April 24, 2012|August 18, 2010||No||No|April 24, 2012|https://clinicaltrials.gov/show/NCT01184859||117546|
NCT01188408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE-DT 201|Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer|A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer||INSYS Therapeutics Inc|Yes|Terminated|June 2010|||September 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||June 2011|June 2, 2011|August 19, 2010|No|Yes|Study shut-down in 12/2010 when NeoPharm merged with Insys.|No||https://clinicaltrials.gov/show/NCT01188408||117274|
NCT01188668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061026|Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects|An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects||Pfizer|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 1, 2011|August 24, 2010|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT01188668||117254|
NCT01184534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0397|Multimedia Patient Education|Increasing Patient Preparedness for the Procedural Experience and Improving Qualitative Outcomes Through Patient Education||M.D. Anderson Cancer Center|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|UT MD Anderson Cancer Center Patients scheduled for a computed tomography (CT) guided lung        biopsy|February 2013|February 11, 2013|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184534||117571|
NCT01185210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fructose: Double Blind|Investigation of Alanine in Fructose Intolerance: A Dose Ranging Study|Investigation of Alanine in Fructose Intolerance: A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study||University of Iowa|No|Recruiting|September 2007|December 2010|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|70 Years|No|||March 2011|March 7, 2011|September 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01185210||117520|
NCT01185483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESD-HYBRID-AFDA|Endoscopic Submucosal Dissection in Upper Gastrointestinal Canal With HybridKnife|Endoscopic Submucosal Dissection in Upper Gastrointestinal Canal With HybridKnife||Odense University Hospital|No|Recruiting|November 2009|February 2011|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients referred to the Endoscopic Section at the Department of Surgery, Odense        University Hospital, with a mucosal or submucosal tumor in the esophagus or stomach.|August 2010|September 3, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185483||117499|
NCT01155453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120B2101|A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.||Novartis||Completed|April 2010|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|113|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|June 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155453||119795|
NCT01155687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuropeAid/127054/C/SER/MULTI|Psychosocial Counseling in Afghanistan|||University of Konstanz|Yes|Completed|September 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|61|||Both|14 Years|N/A|No|Probability Sample|Afghan people at primary care clinic seeking help because of mental health problems|June 2010|August 8, 2011|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155687||119777|
NCT01155700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025B1301|Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)|A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment||Novartis||Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|6 Years|15 Years|No|||September 2012|September 20, 2012|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155700||119776|
NCT01156064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07CX201|Confocal Laser Endomicroscopy in Digestive Diseases|Confocal Laser Endomicroscopy in Digestive Diseases||Chinese PLA General Hospital|Yes|Recruiting|August 2008|December 2011|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|biopsy tissue|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients of a tertiary referral hospital|July 2010|November 22, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01156064||119748|
NCT01156285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC110|Acute Anterior Uveitis: Psychic Burden and Pain|Acute Anterior Uveitis: Psychic Burden and Pain||Hospital Hietzing|No|Recruiting|May 2010|June 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|80 Years|No|Probability Sample|Patients with acute attack of anterior uveitis|November 2011|November 27, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156285||119731|
NCT01156298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-09-AVX|Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance|Phase IV, Multi-center, Non-treatment, Observational, Registry Study to Determine Long Term Effects of AVONEX® Therapy on EDSS, MRI, QoL, and Cognition.|CHAMPIONS CONT|Biogen|No|Terminated|June 2010|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|383|||Both|18 Years|85 Years|No|Non-Probability Sample|Approximately 383 patients participated in CHAMPS, the original AVONEX® placebo trial,        will be approached for study participation. The patient population will be divided into        two cohorts.        Cohort 1: Patients that participated in CHAMPS and CHAMPIONS 10 will be approached for        study participation at approximately twenty-four CHAMPIONS Continuation investigative        sites. Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with        MRI lesions consistent with MS. Patients are eligible regardless of whether they have        converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will        have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and        SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI        will be performed each patient's 15 year anniversary date. See Schedule of Assessments,        section 12.        Cohort 2: Patients that participated in CHAMPS will be located and approached for s|August 2012|August 2, 2012|July 1, 2010||No|low enrollment|No||https://clinicaltrials.gov/show/NCT01156298||119730|
NCT01156311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109MS201|BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis|An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)|EXPLORE|Biogen|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|55 Years|No|||July 2015|July 21, 2015|July 1, 2010|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01156311||119729|
NCT01156532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-261|Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy|Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy||AbbVie||Terminated|November 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with moderate to severe psoriasis who receive adalimumab therapy according to        standard clinical practice at Peruvian hospitals/clinics.|August 2014|August 8, 2014|July 1, 2010||No|This study was prematurely terminated due to low enrollment and not for safety reasons.|No|August 8, 2014|https://clinicaltrials.gov/show/NCT01156532||119712|Although a sample of 75 participants was originally planned, only 30 participants were enrolled in this study. The limited sample size can result in a potential sampling bias that cannot be tested.
NCT01156779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3091_DM_I|Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating, Phase I Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of DA-3091 After Subcutaneous Injection in Healthy Male Subjects|SR-Exenatide|Dong-A ST Co., Ltd.|Yes|Completed|July 2010|||April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156779||119693|
NCT01156545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-489|BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC|A Randomized Open Label Phase II Trial Comparing BIBW2992 Plus Simvastatin With BIBW2992 Plus Best Supportive Care in Previously Treated Patients With Advanced (Stage IIIB/IV) Non-adenocarcinomatous Non-small Cell Lung Cancer (NSCLC)||National Cancer Center, Korea|No|Recruiting|October 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||September 2011|October 18, 2012|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156545||119711|
NCT01157091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10030|Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer|A Phase II Study of Pazopanib in VEGF-TKI Refractory Metastatic Renal Cell Carcinoma (MRCC)||City of Hope Medical Center|Yes|Active, not recruiting|November 2010|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01157091||119669|
NCT01157338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1123|Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization|Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization||Shiraz University of Medical Sciences|Yes|Completed|October 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|52 Years|68 Years|No|||July 2010|July 6, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157338||119650|
NCT01153321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3320C00001|Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)|A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation||AstraZeneca|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|71|||Both|40 Years|N/A|No|||March 2015|March 23, 2015|June 28, 2010|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT01153321||119959|
NCT01153568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08032|Vitamin D and Osteoporosis Prevention in Elderly African American Women|Vitamin D and Osteoporosis Prevention in Elderly African American Women: A 4-year Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Vitamin D Status in Elderly African American Women|NIHD|Winthrop University Hospital|Yes|Active, not recruiting|August 2010|April 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Female|60 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153568||119940|
NCT01153542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX10-770-011|Study of VX-770 on Desipramine|An Open-Label Phase 1 Study to Examine the Effect of VX 770 on Desipramine in Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153542||119942|
NCT01153555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRST|Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy|Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy: The FIRST Study|FIRST|Volcano Corporation|No|Completed|September 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients required to have an intermediate coronary lesion (stenosis 40-80% by visual        estimate) in one or more native, major epicardial coronary artery with reference diameter        ≥2.5mm (visual estimate)|January 2015|February 27, 2015|June 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01153555||119941|
NCT01154153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICA_L_04286|Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [>=2 to < 12 Years of Age] With Allergic Rhinitis (AR).||Sanofi||Completed|June 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|2 Years|12 Years|No|||June 2012|June 21, 2012|June 22, 2010|Yes|Yes||No|September 21, 2011|https://clinicaltrials.gov/show/NCT01154153||119895|
NCT01154166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111528|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa||GlaxoSmithKline|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|347|||Both|30 Years|N/A|No|||June 2012|August 16, 2012|June 29, 2010||No||No|May 10, 2012|https://clinicaltrials.gov/show/NCT01154166||119894|
NCT01184872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCBC134A2404|Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections|An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With Complicated Skin and Soft Tissue Infections (cSSTI)||Novartis||Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|65 Years|N/A|No|||July 2012|July 9, 2012|February 18, 2010||No||No|March 22, 2012|https://clinicaltrials.gov/show/NCT01184872||117545|
NCT01184885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09G.474|A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy|A Pilot Study of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) With Sirolimus for the Treatment of Adult Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies||Thomas Jefferson University|Yes|Completed|July 2010|April 2013|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|August 17, 2010||No||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01184885||117544|
NCT01184898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10D.21|Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)|A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia||Thomas Jefferson University|Yes|Active, not recruiting|July 2010|September 2016|Anticipated|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|August 17, 2010||No||No|August 12, 2014|https://clinicaltrials.gov/show/NCT01184898||117543|
NCT01188681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16201|Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia|A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia||Emergent Product Development Seattle LLC|Yes|Completed|September 2010|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|79|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|August 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188681||117253|
NCT01184547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-034|Effects of a Community Based Exercise Program in Adults With Severe Burns|"Effects of a Community Based Exercise Program in Adults With Severe Burns"|COMBEX|The University of Texas Medical Branch, Galveston|Yes|Recruiting|April 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|60 Years|No|||May 2015|May 27, 2015|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01184547||117570|
NCT01184833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14323|Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis|Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis|BREAK|Bayer|No|Completed|September 2008|August 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|852|||Both|18 Years|N/A|No|Probability Sample|Adult patients with relapsing form of multiple sclerosis treated with Betaferon under        routine practice setting.|June 2013|June 24, 2013|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01184833||117548|
NCT01184846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgPro10_3001|Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy|A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)||CSL Behring|Yes|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||March 2013|August 27, 2013|August 18, 2010|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01184846||117547|
NCT01186302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHO A65550|Comparison of the Safety and Efficacy of Medical Abortion Provided by Physicians and Midlevel Providers in Nepal|Comparison of the Safety, Efficacy, and Feasibility of Medical Abortion Provided by Physicians and Non-physicians in Nepal: a Randomized Controlled, Equivalence Trial.||World Health Organization|No|Completed|April 2009|July 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1104|||Female|16 Years|50 Years|No|||August 2010|August 20, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186302||117436|
NCT01155154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-130|Antibiotic Prophylaxis for Simple Hand Lacerations|Antibiotic Prophylaxis for Prevention of Infection in Emergency Department Patients With Simple Hand Lacerations||State University of New York - Downstate Medical Center|No|Terminated|February 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|73|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|June 29, 2010||No||No|January 3, 2014|https://clinicaltrials.gov/show/NCT01155154||119818|
NCT01155713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2116|Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors|A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors||Novartis|No|Completed|July 2010|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155713||119775|
NCT01155726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-371-C-101|The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies|The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies|ARGON|Alcon Research|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|134|||Both|17 Years|N/A|No|||April 2012|June 26, 2012|June 30, 2010|Yes|Yes||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01155726||119774|
NCT01156077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-111|Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients|A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients||Trius Therapeutics LLC|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|12 Years|17 Years|No|||September 2011|September 26, 2011|June 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156077||119747|
NCT01155739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141/08, Propéritonite|Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections|Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales||University of Lausanne Hospitals|Yes|Completed|June 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|162|||Both|18 Years|N/A|No|Probability Sample|hospitalized patients with SIRS due to peritonitis or intra-abdominal infections|December 2014|December 18, 2014|July 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01155739||119773|
NCT01156090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI Outcomes 04|A Retrospective Cohort Study of Infusion Reactions Due to Vectibix|A Retrospective Cohort Study of Infusion Reactions Due to Vectibix||SCRI Development Innovations, LLC|No|Completed|June 2010|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|141|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have received Vectibix (Panitumumab) in offices and clinics located in        Tennessee, North Carolina, South Carolina, and North Georgia.|August 2015|August 27, 2015|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01156090||119746|
NCT01156805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVALL|Assessment of an School-based Intervention in Eating Habits and Physical Activity in Schoolchildren: the AVall Study|Assessment of an School-based Intervention in Eating Habits and Physical Activity in Schoolchildren: the AVall Study.|AVALL|Hospital de Granollers|No|Active, not recruiting|September 2006|September 2012|Anticipated|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|598|||Both|5 Years|6 Years|No|||July 2010|July 7, 2010|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156805||119691|
NCT01157117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AADCRC-MSSM-01|OIT and Xolair® (Omalizumab) in Cow's Milk Allergy|Oral Immunotherapy Combined With Humanized Monoclonal Anti-IgE Antibody Xolair® (Omalizumab)in the Treatment of Cow's Milk Allergy||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|August 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|76|||Both|7 Years|35 Years|No|||April 2015|April 14, 2015|July 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01157117||119667|
NCT01156792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114255|Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeterol 50mcg Inhalation Powder Twice Daily to Fluticasone Propionate 100mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects ≥ 12 Years of Age||GlaxoSmithKline|No|Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|160|||Female|12 Years|N/A|No|||September 2014|September 4, 2014|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156792||119692|
NCT01157351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015625|15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated|A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated||Janssen Scientific Affairs, LLC|No|Completed|May 2010|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|450|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|May 3, 2010|Yes|Yes||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01157351||119649|
NCT01157364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-041D|Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension|||Allergan|No|Active, not recruiting|August 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|109|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01157364||119648|
NCT01153594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERI-2|Early Re-Intervention Experiment 2|Early Re-Intervention (ERI) Experiment 2|ERI2|Chestnut Health Systems|Yes|Completed|February 2004|June 2009|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|N/A|No|||June 2010|June 29, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153594||119938|
NCT01153893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113199|Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria|Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Nigerian Children||GlaxoSmithKline||Completed|October 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|105|||Both|15 Months|21 Months|Accepts Healthy Volunteers|||September 2012|October 20, 2014|June 29, 2010|Yes|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT01153893||119915|Data were reanalyzed because an issue was discovered with the informed consent obtained for one child after the original statistical analysis. The child’s parent requested GlaxoSmithKline not to use the data of their child.
NCT01153581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512000875a|Sex Hormones and Orthostatic Tolerance|Sex Hormones and Orthostatic Tolerance||Yale University|No|Completed|February 2006|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|62|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01153581||119939|
NCT01153906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113522|Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination|Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination in Females Aged 9-25 Years in the US||GlaxoSmithKline||Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1516|||Female|9 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Females between the ages of 9-25 years|September 2014|November 26, 2014|June 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153906||119914|
NCT01154140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081014|A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung|Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.|PROFILE 1014|Pfizer|Yes|Active, not recruiting|January 2011|August 2016|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|343|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 29, 2010|Yes|Yes||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01154140||119896|
NCT01154179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNE-A01322|Appropriate Controlled Feeding: a Single Blinded Prospective Randomised Study|Appropriate Controlled Feeding: a Single Blinded Prospective Randomised Study||Scarborough General Hospital|Yes|Completed|April 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154179||119893|
NCT01184911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC5972|Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda|Assessment of the Efficacy of Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda|SP IPTp|University of California, San Francisco|No|Withdrawn|October 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Female|N/A|N/A|No|||March 2015|March 3, 2015|August 17, 2010||No|Research plan changed; no longer conducting clinical trial.|No||https://clinicaltrials.gov/show/NCT01184911||117542|
NCT01184924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1048|Evaluation of the Arthritis Foundation Tai Chi Program|Evaluation of the Arthritis Foundation Tai Chi Program||University of North Carolina, Chapel Hill|No|Completed|September 2008|August 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|358|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 4, 2013|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01184924||117541|
NCT01185223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 22371|Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation|Multicenter, Randomized Study Comparing Oral Valganciclovir Versus Intravenous Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation|CONVINCE|Pierrel Research Europe GmbH|No|Terminated|September 2010|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|212|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185223||117519|
NCT01185496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-900220|Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus|Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus||DexCom, Inc.|No|Completed|August 2010|November 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|64|||Both|6 Years|17 Years|No|Probability Sample|This clinical study population will consist of a minimum of 64 and up to 80 subjects with        a previous diagnosis of type 1 diabetes mellitus. It is desirable to achieve an equal        number of subjects enrolled into each of the following four subgroups as defined in the        FDA guideline for Age Ranges of Pediatric Subgroups:          -  Female children* 6-12 years-old          -  Female adolescents** 13-17 years-old          -  Male children 6-12 years-old          -  Males adolescents 13-17 years-old|June 2011|June 10, 2011|August 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185496||117498|
NCT01185769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD141/09|Study of Tocotrienol Absorption and Distribution Under Different Fat Status|Mechanism of Absorption and Distribution of Tocotrienols Under Different Food Status||Malaysia Palm Oil Board|Yes|Completed|September 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|22 Years|25 Years|Accepts Healthy Volunteers|||August 2010|August 19, 2010|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01185769||117477|
NCT01185782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP26648|SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women|Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study||Merck KGaA|Yes|Completed|February 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|300|||Female|20 Years|39 Years|No|||December 2013|December 2, 2013|August 11, 2010||No||No|September 26, 2011|https://clinicaltrials.gov/show/NCT01185782||117476|
NCT01185795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-001|Efficacy of Cardioviva™ Probiotic Yogurt Formulation|Efficacy of a Microencapsulated Probiotic Yogurt Formulation as a Health Promoting Agent||Micropharma Limited|No|Completed|September 2008|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|74 Years|No|||June 2012|June 29, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185795||117475|
NCT01186315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00011730|Post-traumatic Stress Disorder (PTSD), Addiction, and Virtual Reality|Developing a Computer-Based Intervention to Enhance Behavioral Treatments for PTSD and Addiction||Duke University|Yes|Completed|December 2008|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||August 2014|August 19, 2014|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186315||117435|
NCT01155492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07100403|Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease|Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease||Rush University Medical Center|No|Completed|September 2007|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|43|Samples With DNA|Colonic mucosa biopsies|Both|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with Parkinson's disease Age- and gender-matched controls|May 2013|May 29, 2013|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01155492||119792|
NCT01155466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04938|A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)|A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)||Merck Sharp & Dohme Corp.|Yes|Completed|July 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|778|||Both|30 Years|85 Years|No|||January 2016|January 13, 2016|June 30, 2010|Yes|Yes||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01155466||119794|
NCT01155479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05664|A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (P05664 AM5)|A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease (Phase 3 Protocol No. P05664)||Merck Sharp & Dohme Corp.|Yes|Terminated|July 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1022|||Both|30 Years|85 Years|No|||October 2014|October 23, 2014|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155479||119793|
NCT01155752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#33344|Pulmozyme in Cystic Fibrosis With Sinusitis|Z4770s, Use of Recombinant Human DNASE in Cystic Fibrosis Patients With Chronic Sinusitis to Prevent Acute Sinusitis Exacerbations and Improve Symptoms and Outcomes - A Pilot Study||Penn State University|No|Not yet recruiting|July 2013|June 2015|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|12 Years|65 Years|No|||November 2012|November 29, 2012|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155752||119772|
NCT01156324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100765|The Impact of an Online Stress Management Program on In Vitro Fertilization (IVF) Outcome|The Impact of an Online Stress Management Program on IVF Outcome||Boston IVF|No|Withdrawn|July 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|June 29, 2010||No|Loss of funding.|No||https://clinicaltrials.gov/show/NCT01156324||119728|
NCT01156558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10FA01|Early Outcome Assessment of Revision Total Knee Arthroplasty Using Metaphyseal Sleeves|Early Outcome Assessment of Revision Total Knee Arthroplasty Using Metaphyseal Sleeves||Rothman Institute Orthopaedics|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Sequential assessment of 100 patients who have received a revision knee surgery for which        metaphyseal sleeve was used in femoral and/or tibial side starting August 2007. Patients        must meet inclusion/exclusion criteria for enrollment.|March 2011|March 30, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156558||119710|
NCT01156818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSI-MUL-GEN-WMF-01|Wheezometer™ Exploratory (WM) Field Study|Wheezometer™ Exploratory (WM) Field Study||KarmelSonix Ltd.|No|Recruiting|July 2010|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|8 Years|80 Years|No|Non-Probability Sample|Asthma patients|July 2010|June 8, 2011|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156818||119690|
NCT01157130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVCI 10-09|Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory|Prescriptive Exercise Intervention During Active Treatment for Early Stage Breast Cancer Patients: A Breast Cancer Rehabilitation & Exercise Laboratory||Nevada Cancer Institute|Yes|Recruiting|July 2010|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|N/A|No|||July 2011|July 19, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01157130||119666|
NCT01157390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-004|Tolerance and Efficacy of Wondersun Infant Formula in Formula-fed Chinese Term Infants|Tolerance and Efficacy of Wondersun Infant Formula in Formula-fed Chinese Term Infants: an Open Label, Controlled Trial||Sun Yat-sen University|No|Completed|February 2010|June 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|75|||Both|N/A|14 Days|Accepts Healthy Volunteers|||February 2012|February 7, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01157390||119646|
NCT01157104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6844-002|A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)|A Phase I, Double-Blind, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX320 and IDX184 in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|June 2010|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|July 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157104||119668|
NCT01157377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214868-004|Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence|||Allergan|Yes|Completed|October 2010|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|160|||Both|18 Years|75 Years|No|||February 2014|February 4, 2014|July 1, 2010|Yes|Yes||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01157377||119647|
NCT01153607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14708|Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers|Open-label, Non-randomized, Multicenter Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of BAY1006578 for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimers Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of BAY1006578 in Healthy Volunteers||Piramal Imaging SA|No|Completed|June 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|24|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 18, 2013|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01153607||119937|
NCT01153919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-HEM-07-5|Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia|A Double-Blind, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who Are Not Candidates for Antiviral Treatment With Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia||University of Southern California|No|Suspended|March 2010|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||October 2015|October 24, 2015|June 24, 2010|Yes|Yes|Interim analysis|No||https://clinicaltrials.gov/show/NCT01153919||119913|
NCT01154192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081696|Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)|Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)||University of California, San Diego|Yes|Completed|August 2011|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|24|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|June 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154192||119892|
NCT01184937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182014/V52|Effect of Patient Education on Kidney Recipients Knowledge, Coping and Quality of Life|Effect of Patient Education on Kidney Recipients Knowledge, Coping and Quality of Life. A Randomized Controlled Trial.||Oslo and Akershus University College of Applied Sciences|Yes|Completed|October 2007|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|159|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01184937||117540|
NCT01185236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1007-100-324|Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes|A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes||Seoul National University Hospital|Yes|Not yet recruiting|September 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|20 Years|80 Years|No|||August 2010|August 18, 2010|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185236||117518|
NCT01185509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-207|Trastuzumab and Vinorelbine in Advanced Breast Cancer|A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells||Dana-Farber Cancer Institute|Yes|Terminated|October 2010|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|August 18, 2010|Yes|Yes|Not enough confirmed responses to continue treatment.|No||https://clinicaltrials.gov/show/NCT01185509||117497|
NCT01186068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V-101-ROSE-202|Dose Response Study of Patients With Erythematous Rosacea|A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Dose-Response Profile of V-101 Cream in Subjects With Erythematous Rosacea||Vicept Therapeutics, Inc.|No|Completed|August 2010|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|175|||Both|18 Years|N/A|No|||August 2010|November 22, 2010|August 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186068||117454|
NCT01177982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA14979-06|Reinforcement-Based Treatment for Pregnant Drug Abusers|Reinforcement-Based Treatment for Pregnant Drug Abusers|HOME II|National Institute on Drug Abuse (NIDA)|No|Completed|July 2009|May 2015|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|8||Actual|220|||Female|18 Years|46 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177982||118073|
NCT01155778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-SAN-055|Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients|A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan N-Sulfatase (rhHNS) Intrathecal Administration Via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)||Shire Human Genetic Therapies, Inc.|Yes|Completed|June 2010|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|3 Years|N/A|No|||September 2012|September 28, 2012|June 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155778||119770|
NCT01155791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0033|Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer|A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer||Stanford University||Terminated|April 2010|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|June 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01155791||119769|
NCT01155765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-2|Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis|Prasugrel in Comparison to High Clopidogrel Dose for Inhibition of Platelet Reactivity as Assessed With a Point-of-Care Platelet Function Assay in Patients Undergoing Chronic Hemodialysis Presenting Resistance to the Usual Clopidogrel Dose||University of Patras|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|85 Years|No|||April 2010|November 15, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01155765||119771|
NCT01156103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H48814-32411-0|Reducing Pediatric Obesity Through After-school Programs|Reducing Pediatric Obesity Through After-school Programs||University of California, San Francisco|No|Completed|August 2009|December 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01156103||119745|
NCT01156337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G.F. Ingrassia Hospital,Italy|Sodium Management in Acute and Chronic Heart Failure|Sodium Management in Acute and Chronic Phases in Patients With New York Heart Association Class III (Class C) Heart Failure. Short and Long Term Findings.|SMAC-HF|Ospedale G. F. Ingrassia|Yes|Completed|September 2000|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|N/A|No|Non-Probability Sample|Patients in III NYHA class HF|August 2007|November 18, 2011|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156337||119727|
NCT01156571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CAN-10-01|A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)|A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)|CHAMPION|The Medicines Company||Completed|September 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11145|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|June 29, 2010|Yes|Yes||No|April 22, 2013|https://clinicaltrials.gov/show/NCT01156571||119709|
NCT01156831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-18-12/08|PET-CT Based Radiotherapy in Esophageal Cancer Patients|Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients||Maastricht Radiation Oncology|Yes|Completed|November 2007|May 2013|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic|December 2014|December 5, 2014|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156831||119689|
NCT01156844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2223|Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Repeated-dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Three Different Dosing Regimens of Inhaled Indacaterol Maleate in Patients With Persistent Asthma||Novartis||Completed|March 2010|||July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|191|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|June 30, 2010|Yes|Yes||No|July 22, 2011|https://clinicaltrials.gov/show/NCT01156844||119688|
NCT01157143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10105|Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation|Phase I, Double Blind, Parallel-Group, Multi-center, Gene Expression (Synthesis of FGF-1 mRNA) and Tolerability Study of Increasing Single Dose of NV1FGF Administered by Intra-Muscular Injection in Subjects With Severe Peripheral Artery Occlusive Disease (PAOD) Planned to Undergo Amputation Above the Ankle||Sanofi|No|Completed|January 2002|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||July 2010|July 2, 2010|July 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157143||119665|
NCT01157156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10106|Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease|A Phase I, Multi-Center, Open Label, Safety and Tolerability Study of Single and Repeated Administrations of Escalating Dose(s) of NV1FGF Administered by Intra-Muscular Injection in Patients With Severe Peripheral Artery Occlusive Disease||Sanofi|No|Completed|June 1999|September 2001|Actual|September 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||July 2010|July 2, 2010|July 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157156||119664|
NCT01157403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ldb201001|Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes|Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes||Third Military Medical University|Yes|Recruiting|July 2010|August 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Both|10 Years|40 Years|No|||June 2013|June 15, 2013|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01157403||119645|
NCT01153334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0277|Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)|||Yonsei University|Yes|Recruiting|July 2010|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|20 Years|N/A|No|||March 2014|March 4, 2014|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153334||119958|
NCT01153620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-CIC-G-H-0901|The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds|Randomized, Double-blind, Controlled Clinical Trial on the Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds|Lavasept 2|B. Braun Ltd. Centre of Excellence Infection Control|Yes|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|61|||Both|18 Years|N/A|No|||April 2012|April 5, 2012|June 29, 2010||No||No|October 21, 2011|https://clinicaltrials.gov/show/NCT01153620||119936|
NCT01153932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114117|Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy|A Phase II, Double Blind, Exploratory, Parallel-group, Placebocontrolled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy||GlaxoSmithKline|Yes|Completed|September 2010|September 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Male|5 Years|N/A|No|||August 2013|August 21, 2014|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153932||119912|
NCT01154504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1781/07|The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study|The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study||Federal University of São Paulo|Yes|Suspended|April 2010|December 2012|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01154504||119868|
NCT01176825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH081335|Cognitive-Behavior Therapy for Young Adults With Bipolar Disorder|Reducing High-Risk Behaviors Among Bipolar Patients Transitioning to Adulthood||Massachusetts General Hospital|Yes|Completed|September 2007|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|24 Years|No|||April 2012|April 25, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176825||118161|
NCT01185249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-010|Congestive Heart Failure Weight Study|Time of Day and Accurate Weights for Patients With Congestive Heart Failure (CHF)||Central DuPage Hospital|Yes|Completed|August 2009|May 2011|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|66|||Both|18 Years|85 Years|No|||June 2013|June 19, 2013|August 18, 2010||No||No|December 3, 2012|https://clinicaltrials.gov/show/NCT01185249||117517|Pilot study with small sample size in one patient population.
NCT01185522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22457|An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)|PEPS: Pharmaco-Epidemiological Study of imPact of Tocilizumab Treatment in Real Life on RA patientS Fatigue||Hoffmann-La Roche||Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|719|||Both|18 Years|N/A|No|Probability Sample|Patients with inadequate response to DMARDs or anti-TNF receiving RoActemra/Actemra        according to standard of care|November 2015|November 2, 2015|August 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01185522||117496|
NCT01185808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D in CRSwNP|Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps|Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps|VDinCRS|Medical University of South Carolina|No|Not yet recruiting|October 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|14 Years|N/A|No|||May 2013|May 20, 2013|July 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185808||117474|
NCT01186081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC Rectal Pre Vs Post 2004|Comparison of Preoperative and Postoperative Radiotherapy and Capecitabine in Locally Advanced Rectal Cancer|Comparison of Preoperative and Postoperative Radiotherapy and Capecitabine in Locally Advanced Rectal Cancer||Asan Medical Center|No|Completed|March 2004|August 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|19 Years|75 Years|No|||August 2010|August 20, 2010|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01186081||117453|
NCT01177995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24MH082471|Russian Labor Migrant HIV Prevention Trial|Fostering an AIDS Research and Training Center Infrastructure in Russia (Labor Migrant HIV Prevention Trial)||Medical College of Wisconsin|No|Completed|October 2008|August 2013|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|207|||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177995||118072|
NCT01155804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP2010|Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery|Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery||Center for Research on Reproductive Health of Campinas|No|Recruiting|June 2009|October 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|192|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||April 2010|June 30, 2011|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01155804||119768|
NCT01156116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-249-A|Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk|Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk||University of Chicago|Yes|Completed|October 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|45 Years|75 Years|No|||May 2015|May 22, 2015|June 23, 2010||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01156116||119744|
NCT01156350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0075|Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma|Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma|Rice NK|University Hospital, Clermont-Ferrand||Not yet recruiting|September 2011|September 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|18 Years|No|||January 2011|January 18, 2011|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01156350||119726|
NCT01156584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tg 511-08-01|A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma|A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma||Tocagen Inc.|Yes|Active, not recruiting|June 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01156584||119708|
NCT01156857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL09-026|PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata|A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding.|PEARLIII|PregLem SA|Yes|Completed|July 2010|February 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|209|||Female|18 Years|48 Years|No|||June 2013|January 14, 2016|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156857||119687|
NCT01157169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-A63-AU|Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|August 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|July 2, 2010|No|Yes||No|August 18, 2010|https://clinicaltrials.gov/show/NCT01157169||119663|
NCT01157182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3251|Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects||Teva Pharmaceuticals USA|No|Completed|February 2007|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|July 2, 2010|No|Yes||No|September 15, 2010|https://clinicaltrials.gov/show/NCT01157182||119662|
NCT01157429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tulane-09-00450|D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents|D-cycloserine Adjunctive Treatment for PTSD in Adolescents||Tulane University School of Medicine|Yes|Active, not recruiting|June 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|13 Years|18 Years|No|||June 2012|June 29, 2012|July 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157429||119643|
NCT01157416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1MH088969-01|Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth|Effect of D-cycloserine on Treatment of PTSD in Youth||Tulane University School of Medicine|Yes|Active, not recruiting|June 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|7 Years|12 Years|No|||June 2012|June 29, 2012|July 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157416||119644|
NCT01153347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00004|A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind Parallel Group Placebo-Controlled Phase III,Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy||AstraZeneca|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|2409|||Both|18 Years|65 Years|No|||March 2014|March 14, 2014|June 23, 2010|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT01153347||119957|
NCT01153360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0086|Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery|Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery||Yonsei University|Yes|Completed|June 2010|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|20 Years|75 Years|No|||July 2012|July 23, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153360||119956|
NCT01153945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|097-2010|Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum|Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum||Meir Medical Center|Yes|Withdrawn|February 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|N/A||3|Actual|0|||Both|20 Years|80 Years|No|Non-Probability Sample|Thyroid cancer patients before/after radioactive iodine total body scan or treatment        admitted to the Endocrinology Institute, Meir Medical Center|August 2011|April 6, 2015|June 29, 2010||No|The sponsor stopped the study.|No||https://clinicaltrials.gov/show/NCT01153945||119911|
NCT01154205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7598-DL-CTIL|Sheba Medical Center Home Monitoring Clinic Registry|Sheba Medical Center Home Monitoring Clinic Registry||Sheba Medical Center|No|Not yet recruiting|June 2010|January 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with an ICD or CRTD.|June 2010|June 29, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154205||119891|
NCT01154218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081011|Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers|A Phase 1, Single Dose Bioequivalence And Food Effect Study In Healthy Volunteers Comparing The Commercial Image Capsules To The Immediate Release Tablets And Powder In Capsule Formulations Of Crizotinib (PF-02341066), And The Commercial Image Capsule In The Fasted To Fed State||Pfizer|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|June 29, 2010|No|Yes||No|September 12, 2011|https://clinicaltrials.gov/show/NCT01154218||119890|
NCT01186107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0220|Comparison of Zotarolimus-Eluting Stent vs Sirolimus-Eluting Stent for Diabetic Patients|Randomized Comparison of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus|ESSENCE-DM2|CardioVascular Research Foundation, Korea|Yes|Completed|August 2010|July 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186107||117451|
NCT01176838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007317|A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients|A Prospective Study on Newly Diagnosed Breast Cancer Patients: A 5 Year Follow Up on Quality of Life||Wake Forest School of Medicine|No|Terminated|November 2008|August 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Female|18 Years|N/A|No|Non-Probability Sample|The study population will consist of females ages 18 and over that have been newly        diagnosed with breast cancer.|September 2015|September 17, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176838||118160|
NCT01176851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0915-PR-0031|Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers|Pharmacokinetic, Randomized, Open-label, Single-dose, 3-way Cross-over Study of Intravenous and Inhaled Glycopyrrolate With or Without Charcoal Block Ingestion in Healthy Volunteers.|Gly1|Chiesi Farmaceutici S.p.A.|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2010|October 26, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176851||118159|
NCT01177072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHSPH-3034|Study of Effectiveness of Mental Health Interventions Among Torture Survivors in Southern Iraq|Study of Effectiveness of Mental Health Interventions Among Torture Survivors in Southern Iraq||Johns Hopkins Bloomberg School of Public Health|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|342|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01177072||118142|
NCT01177410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGIB2051|Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea|A Phase II, Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week Study to Assess the Efficacy and Safety of Mesalamine Granules 750 mg and 1,500 mg Capsules Administered Once Daily in the Treatment of Irritable Bowel Syndrome With Diarrhea||Valeant Pharmaceuticals International, Inc.|No|Completed|July 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|July 30, 2010|Yes|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT01177410||118116|
NCT01177683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM08-141|Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma|A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141||Hoosier Cancer Research Network|Yes|Recruiting|July 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01177683||118095|
NCT01178671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH091336|Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial|Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD)||Research Foundation for Mental Hygiene, Inc.|No|Completed|July 2010|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|July 29, 2010|Yes|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT01178671||118020|small sample due to low recruitment
NCT01155830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39121|Inflammatory Cytokine Quantification in Infants|Inflammatory Cytokine Quantification in Infants With Documented Sepsis, Congenital Diaphragmatic Hernia and/or ECMO Therapy||University of Utah|No|Completed|June 2010|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|21|||Both|N/A|2 Months|No|Non-Probability Sample|Infants admitted into the NICU at the University of Utah Health Sciences Centers and        Primary Children's Medical Center.|December 2014|May 1, 2015|June 22, 2010||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01155830||119766|
NCT01187121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139855|Evaluating A Drug Testing and Graduated Sanctions Program in Delaware|Evaluating A Drug Testing and Graduated Sanctions Program in Delaware|DYT|University of Delaware|No|Active, not recruiting|June 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Delaware Probationers who fail a urine screen are randomly assigned to either intensive        supervision probation (ISP)(n=400) or the Decide Your Time program(n=400).|August 2010|August 20, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187121||117373|
NCT01156129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228-10|Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery|Interventions to Decrease the Impact of Post-Operative Ileus After Liver Transplant or Resection Surgery||University of Nebraska|No|Enrolling by invitation|September 2010|December 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|19 Years|N/A|No|||August 2011|August 2, 2011|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01156129||119743|
NCT01156363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22299|A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous and Intravenous MIRCERA® for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia||Hoffmann-La Roche||Completed|October 2010|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|July 1, 2010||No||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01156363||119725|
NCT01156597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-009A|Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes|Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes||University of Miami|Yes|Completed|April 2008|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|35 Years|70 Years|No|||November 2014|November 11, 2014|July 2, 2010|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT01156597||119707|
NCT01188759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501095|Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects|A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years||Pfizer|Yes|Withdrawn|May 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|17 Years|No|||May 2012|May 10, 2012|August 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188759||117247|
NCT01188772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7977-0422|Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients|A Multi-center, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1, and an Open Label Assessment of PSI-7977 in Patients With HCV Genotypes 2 or 3||Gilead Sciences|Yes|Completed|August 2010|May 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|147|||Both|18 Years|70 Years|No|||April 2014|April 2, 2014|August 23, 2010|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01188772||117246|
NCT01184638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJMU-2010-07022|Long-term Outcome of General Anesthesia on Dysgnosia|Long-term Outcome Followed-up of the Cognitive Disorders After General Anesthesia|LOGAND|Nanjing Medical University|Yes|Recruiting|August 2010|August 2020|Anticipated|August 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|10000|||Both|10 Years|80 Years|No|||January 2014|January 11, 2014|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01184638||117563|
NCT01184950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10019|Virtual Reality Laparoscopy Training|Prospective Randomized Trial of Virtual Reality Simulator Training in an Obstetrics and Gynecology Residency||TriHealth Inc.|No|Completed||||||N/A|Interventional|N/A|2||||||Both|N/A|N/A||||August 2010|August 18, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01184950||117539|
NCT01153386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-122|Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine|An Evaluation of the Pharmacokinetic Linearity and Comparative Bioavailability of a Single Oral Dose of 0.5 mg, 1 mg and 2.5 mg UT-15C (Treprostinil Diethanolamine) SR Tablets in Healthy Volunteers in the Fed State||United Therapeutics|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 20, 2010|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153386||119954|
NCT01153373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13419|Dynamic Assessment and Referral System - Evaluation|The Dynamic Assessment and Referral System for Substance Abuse: Evaluation|DARSSA|University of Massachusetts, Worcester|Yes|Completed|June 2010|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|758|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 8, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01153373||119955|
NCT01185535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081110362101197410300047|Effects of Topical Anesthesia With Pressure Nebulized 2% Lidocaine During Awake Intubation|Effects of Topical Anesthesia With Pressure Nebulized 2% Lidocaine During Awake Intubation||Sun Yat-sen University|Yes|Active, not recruiting|January 2010|December 2010|Anticipated|August 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2010|August 19, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01185535||117495|
NCT01185847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP22349|A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-label Phase Ib/II Study of RO5083945 in Combination With Cisplatin and Gemcitabine/Pemetrexed Versus Cisplatin and Gemcitabine/Pemetrexed in Patients With Advanced or Recurrent Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy||Hoffmann-La Roche||Completed|November 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01185847||117471|
NCT01186354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021370|Understanding of Genetic Risk Information for Type 2 Diabetes|Implications of Health and Genetic Literacy for Genomic Medicine||Duke University|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 12, 2012|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01186354||117432|
NCT01186367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-147|Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer|Exercise Intensity Trial (EXCITE): A Randomized Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer|Excite|Memorial Sloan Kettering Cancer Center|No|Recruiting|August 2010|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|174|||Female|21 Years|80 Years|No|||March 2016|March 2, 2016|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186367||117431|
NCT01177436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11|Prostate Cancer Antigen 3 (PCA-3) Gene Project|PCA-3 Gene Project||Assistance Publique Hopitaux De Marseille|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Male|18 Years|N/A|No|||August 2014|August 28, 2014|October 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01177436||118114|
NCT01177085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mush2|Substituting Mushrooms for Meat to Control Body Weight|Substituting Mushrooms for Meat: A Controlled Clinical Trial to Control Body Weight||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2010|December 8, 2010|November 5, 2008||No||No||https://clinicaltrials.gov/show/NCT01177085||118141|
NCT01177098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-050|Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|||Allergan|No|Completed|October 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|561|||Both|18 Years|N/A|No|||March 2013|March 22, 2013|August 4, 2010|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01177098||118140|
NCT01177423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08|Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block|Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block||Assistance Publique Hopitaux De Marseille|No|Completed|October 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|37|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01177423||118115|
NCT01177696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRS270A08|Intervention in Groups of Family Caregivers in Primary Health Care|VALIDATION OF AN INTERVENTION EFFECTIVE IN GROUPS OF FAMILY CAREGIVERS OF DEPENDENT PATIENTS FOR THEIR APPLICATION IN CENTRES OF PRIMARY HEALTH CARE.|IGFC|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Active, not recruiting|September 2008|September 2010|Anticipated|June 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2010|August 5, 2010|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01177696||118094|
NCT01179204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-052|Prediction of Pain in Total Knee Arthroplasty|Is Preoperative Pain Response Upon Tonic Heat Stimulation Predictive for Pain After Total Knee Arthroplasty?||Hvidovre University Hospital|No|Completed|August 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|Blood-samples|Both|18 Years|N/A|No|Probability Sample|Patients operated with total knee arthroplasty (TKA)|September 2012|September 25, 2012|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179204||117979|
NCT01179217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUSCC09-01|A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia|A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA||Emmaus Medical, Inc.|No|Completed|May 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|5 Years|N/A|No|||June 2014|June 24, 2014|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179217||117978|
NCT01187407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12182|A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment|A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment||Eli Lilly and Company|Yes|Completed|March 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1178|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|August 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187407||117351|
NCT01187693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006053R|The Outcome Effect of Shoe Lift for Individuals With Low Back Pain and Pronated Foot Due to Anatomical Leg Length Discrepancy|The Outcome Effect of Shoe Lift for Individuals With Low Back Pain and Pronated Foot Due to Anatomical Leg Length Discrepancy||National Taiwan University Hospital|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||January 2011|January 20, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187693||117329|
NCT01156142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N09C6|Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy|A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|December 2010|||May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|162|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156142||119742|
NCT01188239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT02/10|A Structured Protocol to Evaluate Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette) Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette)|Twelve Weeks Study Investigating the Efficacy and Safety of a Widely Marketed Electronic Nicotine Delivery Device (E-Cigarette): 6 Weeks on High Dose Nicotine and 6 Weeks on Low Dose Nicotine Cartridges in Smokers||Universita degli Studi di Catania|Yes|Completed|April 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Regular smokers from Catania in Italy recruited following the placement of an        advertisement in a local newspaper.|January 2013|January 7, 2013|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01188239||117287|
NCT01188486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0040|Pulmonary Interstitial Lymphography in Early Stage Lung Cancer|Pulmonary Interstitial Lymphography in Early Stage Lung Cancer||Stanford University||Suspended|August 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|August 23, 2010||No|Interim analysis|No||https://clinicaltrials.gov/show/NCT01188486||117268|
NCT01186172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETHCVC|Ethanol Lock for the Salvage of Infected Long-term Vascular Access|Lock Con Etanolo Per il Salvataggio di Dispositivi Vascolari a Lungo Termine. Un Trial Clinico Multicentrico Controllato Randomizzato||IRCCS Policlinico S. Matteo|No|Recruiting|June 2010|June 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|1 Year|N/A|No|||January 2012|January 4, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01186172||117446|
NCT01186406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025180|Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)|Phase II Trial for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Concurrent Radiation Therapy, Temodar and Avastin, Then Followed by Avastin and Temodar Post-Radiation||Duke University|Yes|Active, not recruiting|April 2011|June 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||June 2015|January 20, 2016|August 19, 2010|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01186406||117428|
NCT01186419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-201|Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload|A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, With a 72 Week Dosing Extension||Shire|No|Completed|August 2010|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|60 Years|No|||May 2013|June 3, 2015|August 19, 2010|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01186419||117427|Only data from all subjects (ie, total) are presented because dose adjustments that occurred after Week 24 obviated the meaningful interpretation of data presented by the original 16 and 32 mg/kg/day dose groups.
NCT01186432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV4 FH-1.2|Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)|||Forsight Vision4|No|Completed|August 2010|April 2014|Actual|May 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|N/A|No|||March 2015|March 4, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186432||117426|
NCT01186679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSL-AuBM-SCI|Safety and Efficacy of Autologous Bone Marrow Stem Cells in Treating Spinal Cord Injury|Surgical Transplantation of Autologous Bone Marrow Stem Cells With Glial Scar Resection for Patients of Chronic Spinal Cord Injury and Intra-thecal Injection for Acute and Subacute Injury - A Preliminary Study|ABMST-SCI|International Stemcell Services Limited|Yes|Completed|January 2008|August 2010|Actual|February 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|55 Years|No|||August 2010|August 20, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186679||117407|
NCT01186913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RDCRN PIDTC-6901|Natural History Study of SCID Disorders|A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|August 2010|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|265|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diagnosis of SCID or SCID variants treated at Consortium Centers from        1968-2010|March 2016|March 16, 2016|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186913||117389|
NCT01186926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-003|Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea|Australian Prospective Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea||Apnex Medical, Inc.|Yes|Completed|March 2009|May 2013|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|70 Years|No|||December 2011|April 14, 2015|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186926||117388|
NCT01159613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDL + HCV|Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?|Do Low HDL Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?||Ziv Hospital|Yes|Completed|April 2008|January 2009|Actual|October 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|chronic HCV genotype 1 naïve patients|July 2010|July 8, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159613||119478|
NCT01159626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9131010|Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects|A Phase 1, Randomized, Subject- and Investigator-blind, Sponsor-open, Placebo-controlled, Single- and Multiple-dose Escalation Study to Investigate the Pharmacokinetics, Safety and Tolerability of PF-03463275 in Healthy Male Japanese and Western Subjects||Pfizer|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 19, 2011|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159626||119477|
NCT01159912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112059|Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents|A Randomised, Double-blind, Double-dummy, Placebo Controlled (With Rescue Medication), Multicenter Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.||GlaxoSmithKline|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|350|||Both|12 Years|N/A|No|||January 2014|January 30, 2014|July 8, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01159912||119455|
NCT01161394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1851|Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study|Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study||University at Buffalo|Yes|Completed||October 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||July 2010|December 14, 2015|July 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161394||119343|
NCT01161667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARA-T25-PVFS-1|Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fasted Conditions||Roxane Laboratories|No|Completed|September 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161667||119322|
NCT01161680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00983|Breathing and Bones Initiative|A Prospective Baseline Assessment of the Risk of Osteoporosis in Patients With Chronic Obstructive Lung Disease and Outcomes After 2 Years; a Pilot Study||University of British Columbia|No|Completed|July 2010|May 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|65 Years|N/A|No|Non-Probability Sample|Patients will be drawn from specified respirology clinics: The Lung Centre (VCH) and The        Pacific Lung Centre (PHC)|April 2015|April 15, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01161680||119321|
NCT01179464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/70|Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells|Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells||VU University Medical Center|No|Completed|August 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|N/A|No|||May 2013|June 13, 2013|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01179464||117959|
NCT01184339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP2009-B|Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives|Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives||MicroPhage, Inc.|Yes|Completed|August 2009|August 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1165|Samples With DNA|Approximately 100 uL of deidentified blood culture sample per test sample run.|Both|18 Years|N/A|No|Non-Probability Sample|Hospital patients with at least one positive blood culture.|August 2010|August 17, 2010|March 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01184339||117586|
NCT01184677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProSeal LMA 3 vs 4|ProSeal Laryngeal Mask Airway (LMA) Size 3 vs 4 in Non-paralyzed Female Patients|Comparison of the Size 3 ProsealTM Laryngeal Mask Airway Versus Size 4 in Anaesthetized, Non-paralyzed Women: A Randomised Controlled Trial||Seoul National University Bundang Hospital|Yes|Completed|August 2010|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|154|||Female|18 Years|80 Years|No|||August 2012|August 24, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01184677||117560|
NCT01184690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBE-S vs D|Single-Operator Versus Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders|Prospective Trial Comparing Single-Operator and Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders|DBE|Shanghai Changzheng Hospital|Yes|Enrolling by invitation|August 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|16 Years|70 Years|No|||August 2010|August 18, 2010|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01184690||117559|
NCT01185327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0066-10-HYMC-CTIL|Do Isreali Infants of Ethiopian Origin Mother Regurgitate More Than Other Infants?|Do Isreali Infants of Ethiopian Origin Mother Regurgitate More Than Other Infants?||Hillel Yaffe Medical Center|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|220|||Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Infants born at Hillel Yaffe medical center during 2009|June 2011|June 5, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185327||117511|
NCT01185340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12183|A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor|A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment||Eli Lilly and Company|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|793|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|August 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185340||117510|
NCT01185600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090685|Microparticles in Stored RBC as Potential Mediators of Transfusion Complications|Microparticles in Stored Red Blood Cells (RBC) as Potential Mediators of Transfusion Complications (II): Clinical Study||University of Miami|Yes|Completed|July 2010|May 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185600||117490|
NCT01185626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVT 2010-4743|ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers|ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers. A Pragmatic Cluster Randomized Controlled Trial|ROGYcare|University of Tilburg|Yes|Recruiting|April 2011|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|300|||Female|18 Years|N/A|No|||August 2011|August 24, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185626||117488|
NCT01185613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-09-024-EU-AB|Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|FACT-AF|St. Jude Medical|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185613||117489|
NCT01186185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006240|Fludrocortisone for Sudden Hearing Loss|Mineralocorticoid Treatment for Sudden Sensorineural Hearing Loss||Oregon Health and Science University|No|Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|89 Years|No|||April 2015|April 21, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186185||117445|
NCT01186198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-802|A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions|A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions|CROSS|Abbott Vascular|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|18 Years|N/A|No|Non-Probability Sample|Up to 4 sites in the United States (US). At each site, at least two different qualified        physicians will perform the index procedures. Approximately 30% of the enrolled subjects        will be females.|February 2012|February 28, 2012|August 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186198||117444|
NCT01186445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIAMI-2008-09|Morphine In Acute Myocardial Infarction|Evaluation of the Cardioprotective Effect of Intracoronary Injection of Morphine During Reperfusion in Acute Myocardial Infarction|MIAMI|French Cardiology Society|Yes|Active, not recruiting|January 2011|October 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186445||117425|
NCT01186705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-068|Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer|A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer||Memorial Sloan Kettering Cancer Center|Yes|Terminated|August 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2015|October 17, 2015|August 20, 2010|Yes|Yes|Lack of accrual|No|April 7, 2015|https://clinicaltrials.gov/show/NCT01186705||117405|
NCT01186965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022132|Ehealth: Second Life Impacts Diabetes Education & Self-Management|Ehealth: Second Life Impacts Diabetes Education & Self-Management|SLIDES|Duke University|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|21 Years|75 Years|No|||March 2015|March 4, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186965||117385|
NCT01159938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13087|A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes|The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes||Eli Lilly and Company|No|Completed|October 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|72|||Male|45 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 21, 2014|June 17, 2010|Yes|Yes||No|February 21, 2014|https://clinicaltrials.gov/show/NCT01159938||119453|
NCT01160237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114454|Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM|Immunogenicity and Safety of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM||GlaxoSmithKline||Terminated|August 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 21, 2012|July 8, 2010|Yes|Yes|The study was terminated for logistic reasons not related to safety or efficacy of the    vaccine.|No|February 21, 2012|https://clinicaltrials.gov/show/NCT01160237||119431|Only 7 subjects were enrolled in either the Pandemrix Group or the Fluarix Group and none in the Control Group since the study was terminated prematurely. Therefore most outcome measures (except unsolicited AEs and SAEs) were not analysed.
NCT01160250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4811g|A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|A Single-Arm, Open-Label, Expanded Access Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma||Genentech, Inc.||Approved for marketing|July 2010|April 2012|Actual|April 2012|Actual|Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||August 2015|August 4, 2015|July 8, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01160250||119430|
NCT01159314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00037146|Baerveldt Plate Area Comparison (BPAC)|Baerveldt Plate Area Comparison (BPAC)|BPAC|Johns Hopkins University|Yes|Recruiting|June 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159314||119501|
NCT01159327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-476|Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy|A Randomized Phase II Study of Sorafenib Maintenance in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC) After Response to Induction Chemotherapy||National Cancer Center, Korea|No|Terminated|December 2010|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Months|N/A|No|||November 2015|November 9, 2015|July 8, 2010||No|low enrolling participants|No||https://clinicaltrials.gov/show/NCT01159327||119500|
NCT01160874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/17|Sleepiness and Driving Performances in Adults With Attention-Deficit/ Hyperactivity Disorder (ADHD)|Sleepiness and Performances Degradation in Adults Presenting an Attention-Deficit/ Hyperactivity Disorder (ADHD)|SOMTDA/H|University Hospital, Bordeaux|No|Completed|July 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 24, 2013|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160874||119383|
NCT01161108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010842|Trial of Melatonin to Improve Sleep in Children With Epilepsy and Neurodevelopmental Disabilities|A Randomized Controlled Trial Pilot Project to Evaluate the Efficacy of Melatonin in Children With Insomnia, Intractable Epilepsy and Neurodevelopmental Disabilities||The Hospital for Sick Children|Yes|Completed|July 2010|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|5 Years|17 Years|No|||December 2014|December 1, 2014|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161108||119365|
NCT01161121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rega-9I06|Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab|Utilization of Lexiscan (Regadenoson)in the Cardiac Catheterization Lab to Achieve Maximal Hyperemia for Coronary Physiologic Assessment With Fractional Flow Reserve||St. Louis University|Yes|Recruiting|July 2010|August 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161121||119364|
NCT01188551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00377|Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement|Pain Management Following Myringotomy and Tube Placement: Intranasal Dexmedetomidine Versus Fentanyl||Nationwide Children's Hospital|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|100|||Both|N/A|N/A|No|||February 2014|February 17, 2014|August 24, 2010|Yes|Yes||No|June 26, 2013|https://clinicaltrials.gov/show/NCT01188551||117263|
NCT01188564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1310|Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks|A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE||Pharming Technologies B.V.|No|Completed|January 2011|March 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|13 Years|N/A|No|||July 2015|August 3, 2015|August 24, 2010|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01188564||117262|
NCT01184352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR734|Glider PTCA Balloon Catheter Registry|Registry for PCI With the TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter||TriReme Medical, LLC|No|Completed|July 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|125|||Both|18 Years|N/A|No|Probability Sample|Patients treated by Physicians using the Glider PTCA Balloon Catheter who are willing to        participate in the Glider Registry.|December 2012|December 5, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01184352||117585|
NCT01184365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01037|Spinal Cord Injury Energy Management Program|Spinal Cord Injury Energy Management Program||University of British Columbia|No|Completed|August 2010|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|19 Years|65 Years|No|||March 2014|March 14, 2014|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01184365||117584|
NCT01185054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000017642|Is Electrolyte Maintenance Solution Required in Low-Risk Children With Gastroenteritis?|Is Electrolyte Maintenance Solution Required in Low-Risk Children With Gastroenteritis?||The Hospital for Sick Children|Yes|Completed|November 2010|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|624|||Both|6 Months|60 Months|No|||May 2015|May 22, 2015|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185054||117531|
NCT01185067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00029626|Physiological Effects of Grape Seed Extract in Diastolic Heart Failure|GRAPe Seed Extract and Ventriculovascular Investigation in Normal Ejection-Fraction Heart Failure|GRAPEVINE-HF|University of Michigan|No|Recruiting|August 2010|June 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|50 Years|N/A|No|||December 2013|December 9, 2013|August 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185067||117530|
NCT01185080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0540C00014|Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848|A Double-blind, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Investigate the Efficacy, Tolerability, and Safety of Different Dosing Regimens of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients Out of Pollen Season in a Nasal Allergen Challenge Model||AstraZeneca|No|Completed|September 2010|January 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|55 Years|No|||December 2015|December 2, 2015|August 11, 2010||No||No|August 31, 2015|https://clinicaltrials.gov/show/NCT01185080||117529|
NCT01185353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13854|A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy||Eli Lilly and Company|No|Completed|October 2010|March 2014|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|270|||Both|18 Years|75 Years|No|||April 2014|April 9, 2014|August 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185353||117509|
NCT01185366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0628|Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma|Everolimus Versus Sunitinib Therapy in Patients With Advanced Non-clear Cell Renal Cell Carcinoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2010|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|August 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185366||117508|
NCT01185639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 62110|Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer|Phase II Study of Stereotactic Body Radiation Therapy (SBRT) After First-Line Chemotherapy for Metastatic NSCLC||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|August 2010|August 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|90 Years|No|||October 2015|October 26, 2015|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185639||117487|
NCT01185652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR803|A Study on Smoking-related Lung Function Abnormalities and Correlation With Serum Biomarkers in Chinese|A Study on Smoking-related Lung Function Abnormalities and Correlation With Serum Biomarkers in Chinese||The University of Hong Kong|Yes|Recruiting|May 2010|September 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|10 ml Peripheral blood will be collected upon recruitment for storage and later extraction      of DNA and serum biomarkers|Both|18 Years|N/A|No|Non-Probability Sample|In 2001 - 2003, we conducted a study to recruit 1089 non-smokers for establishing local        reference lung function values, and 694 smokers for investigating the diagnostic        definition of airflow obstruction. The cohort was derived from a random population sample        and the characteristics of the two cohorts have been described in detail in previous        communications. All subjects will be invited to return for spirometry testing (at one of        the participating hospitals of their choice) and an interview. We would compare their lung        function parameters 7 years ago with the repeat measurements obtained in this study.|May 2011|May 12, 2011|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185652||117486|
NCT01185925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444-14|Exercise Oscillatory Breathing and Sildenafil in Heart Failure|PDE5-Inhibition With Sildenafil Reverses Exercise Oscillatory Breathing in Chronic Heart Failure: a Long-Term Cardiopulmonary Exercise Testing Placebo-Controlled Study||University of Milan||Completed|April 2008|June 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|30 Years|80 Years|No|||May 2008|August 4, 2011|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01185925||117465|
NCT01186458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG LYM08-134|Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma|A Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma: Hoosier Oncology Group LYM08-134||Hoosier Cancer Research Network|Yes|Terminated|October 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 19, 2010|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01186458||117424|
NCT01186692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D03909|Melody® Transcatheter Pulmonary Valve Post-Approval Study|Implantation of the Medtronic Melody Transcatheter Pulmonary Valve (TPV) in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Post-Market Approval Study||Medtronic Cardiovascular|No|Active, not recruiting|July 2010|July 2017|Anticipated|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|N/A|N/A|No|||October 2015|October 26, 2015|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186692||117406|
NCT01186952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRL-01-2010|Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes|Effects of an Exercise Program Combined or Not With Nutritional intErvention on Total Fat, Epicardial Fat and Metabolic Profile of Obese and Overweight Adults With tyPe 2 Diabetes (The PEP-2 Study)|PEP-2|Institut de Recherches Cliniques de Montreal|No|Active, not recruiting|September 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|30 Years|75 Years|No|||January 2016|January 26, 2016|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186952||117386|
NCT01186978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025164|Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma|Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma|DLBCL|Duke University|No|Recruiting|October 2010|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186978||117384|
NCT01187251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tinnitus and mp3 players|Incidence of Tinnitus Amongst Teenagers and Young Adults mp3 Users|||Faculdade de Medicina de Valenca|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|15 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|teenagers and young adults (15 to 30 years old)|February 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187251||117363|
NCT01159951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112263|Analysis of Trends Over Time of Hepatitis Related Incidence in Panama|Time Trend Analysis of the Incidence of Hepatitis- Related Outcomes (Viral Hepatitis A and Unspecified Viral Hepatitis) Reported to the Surveillance System of Panama, 2000-2010||GlaxoSmithKline||Completed|January 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|None Retained|No samples retained|Both|N/A|N/A|No|Probability Sample|The target population to be studied will be all subjects reported with hepatitis related        outcomes to the Epidemiologic Surveillance System of the Ministry of Health of Panama,        between 2000 and 2010.|November 2011|November 10, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159951||119452|
NCT01159964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113174|Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery|Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer||GlaxoSmithKline||Terminated|July 2010|September 2014|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|July 8, 2010|Yes|Yes|Study termination due to negative Phase III of another study product from same technology    platform.|No||https://clinicaltrials.gov/show/NCT01159964||119451|
NCT01159977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008232|Trial Evaluating the Effect of Facilitated Small Group Sessions on Physician Well-Being, Job Satisfaction, and Professionalism|||Mayo Clinic|No|Completed|June 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|74|||Both|N/A|N/A|No|||November 2012|November 14, 2012|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159977||119450|
NCT01160562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910155|Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity|Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity||National Institutes of Health Clinical Center (CC)||Completed|June 2010|January 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|4000|||Both|N/A|25 Years|No|||January 2013|October 23, 2014|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160562||119407|
NCT01160575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910158|A Semi-Factorial Cluster-Randomized Trial to Estimate the Effect Size of Community Mobilization and VCT Vans on the Adoption of Voluntary Counseling and Testing (VCT) Services in Andhra Pradesh, India: THE MCVCT STUDY|A Semi-Factorial Cluster-Randomized Trial to Estimate the Effect Size of Community Mobilization and VCT Vans on the Adoption of Voluntary Counseling and Testing (VCT) Services in Andhra Pradesh, India: THE MCVCT STUDY||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2010|September 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|No|||September 2014|October 23, 2014|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160575||119406|
NCT01160887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1652|Diabetes Peripheral Neuropathy and Small-fibre Nerve Damage: A Comparative Study|Is Diabetic Peripheral Neuropathy Accompanied by Internal Nerve Damage? A Comparative, Clinical Experimental Study of Peripheral and Visceral Nerve Damage in Diabetic Patients and Healthy Controls||Haukeland University Hospital|No|Completed|June 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients with verified diabetic neuropathy.|July 2013|July 8, 2013|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160887||119382|
NCT01161433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32583-E/B|A Practical Model to Transform Childhood Asthma Care - Spirometry Training in the Primary Care Setting|Implementing Evidence-based Quality Improvement Strategies to Improve Asthma Care for Children||University of Washington|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|36|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||July 2010|July 9, 2010|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01161433||119340|
NCT01161407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genzyme - 0907-07|Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease|Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease||Indiana University|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|35 Years|N/A|No|||July 2014|July 22, 2014|July 12, 2010||No||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01161407||119342|Due to the characteristic short treatment periods of balance studies, the results may not reflect the effects of chronic treatment with calcium carbonate on mineral balance.
NCT01161420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inspire 4|Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)|Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea|STAR|Inspire Medical Systems, Inc.|Yes|Active, not recruiting|July 2010|March 2017|Anticipated|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|929|||Both|22 Years|N/A|No|||March 2016|March 15, 2016|July 9, 2010|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT01161420||119341|
NCT01188304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25329|A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of 150 µg Aleglitazar Once Daily in Healthy Subjects Treated With 325 mg Aspirin Once Daily on Renal Function, Renin-angiotensin System and Platelet Aggregation||Hoffmann-La Roche||Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01188304||117282|
NCT01184716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12394|The Effect of Vitamin D Fortification of Bread and Milk in Danish Families|The Effect of Vitamin D Fortification of Bread and Milk in Danish Families|VitMaD|Technical University of Denmark|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|782|||Both|4 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 6, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184716||117557|
NCT01185093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCECP|St. Jude Cancer Education for Children Program: Evaluation at 4th-Grade Level|St. Jude Cancer Education for Children Program: Evaluation at 4th-Grade Level||St. Jude Children's Research Hospital|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|481|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of schools that agree to participate in the St. Jude Cancer Education        for Children Program. 2-3 public schools and 2-3 private schools will be selected in order        to achieve a fair representation of the Mid-South area. Based on average class sizes, this        study expects to enroll at least 200 public school students and about 100 private school        students.|February 2012|February 13, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185093||117528|
NCT01185392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT Survey|European Cardiac Resynchronisation Therapy Survey|European Cardiac Resynchronisation Therapy Survey||Helse Stavanger HF|No|Completed|November 2008|January 2012|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2438|||Both|N/A|N/A|No|Non-Probability Sample|All consecutive patients successfully implanted with a new CRT-P, CRT-D or upgrades during        the inclusion period were eligible. The successful procedure itself identified the patient        as a survey candidate. Patients screened but not successfully implanted were not entered        into the survey. Ethics approval and written informed consent were obtained in countries        where required.|June 2012|July 27, 2015|August 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01185392||117506|
NCT01185379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31N1|The Effects of Efalex Active 50+ on Cognitive Performance, Well-being and Cerebral Hemodynamics in Healthy Older Adults|Investigation of the Effects of Efalex Active 50+ on Cognitive Performance, Well-being and Cerebral Hemodynamics in Healthy Adults Aged 50-70 Years Reporting Subjective Memory Deficits||Northumbria University|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|261|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||November 2010|September 25, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185379||117507|
NCT01185665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vubmtmoensTENS|Predicting Outcome of Transcutaneous Electrical Nerve Stimulator (TENS) in Failed Back Surgery Syndrome|||Universitair Ziekenhuis Brussel|Yes|Not yet recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2010|August 19, 2010|August 19, 2010||||No||https://clinicaltrials.gov/show/NCT01185665||117485|
NCT01185938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552010|Statin Contrast Induced Nephropathy Prevention|Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial|PRATO-ACS|Centro Cardiopatici Toscani|Yes|Completed|July 2010|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|90 Years|No|||October 2012|October 18, 2012|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01185938||117464|
NCT01186471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017263|The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients|A Double-Blind, Placebo-Controlled, Randomized Three-Way Crossover Study to Investigate The Effect of Nicotine on Arousal, Standard Cognitive Tasks And Social Cognition in Patients With Schizophrenia (Smoking and Non-Smoking)||Janssen Pharmaceutica N.V., Belgium||Completed|May 2010|March 2011|Actual|||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|32|||Both|18 Years|55 Years|No|||March 2012|March 19, 2012|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186471||117423|
NCT01186718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOA 09-05-581|Interexaminer Reliability, Outcomes for Manipulation of Cervical Dysfunction, 3-D Kinematics|Three-dimensional Study of Cervical Kinematics||Michigan State University|Yes|Completed|September 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Two study groups: Control = subjects with symmetric cervical motion; Experimental =        subjects with asymmetric cervical motion.|November 2011|November 28, 2011|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186718||117404|
NCT01187563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-RA-1008|A Study of Tocilizumab in Patients With Rheumatoid Arthritis|A Phase 4, Open-label, Repeat-Dose Study of the Safety and Pharmacodynamic Profile of Tocilizumab and Concomitant Methotrexate in Patients With Rheumatoid Arthritis||Regeneron Pharmaceuticals|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|Adult rheumatoid arthritis patients with indication for treatment with tocilizumab.|October 2011|October 12, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187563||117339|
NCT01187576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPF FaR 001|A Multi-professional Team Intervention on Physical Activity Referrals in Primary Care Patients With Cardiovascular Risk Factors—the Dalby Lifestyle Intervention Cohort (DALICO) Study|A Multi-professional Team Intervention on Physical Activity Referrals in Primary Care Patients With Cardiovascular Risk factors-the Dalby Lifestyle Intervention Cohort Study (DALICO) Study|DALICO|Region Skane|No|Recruiting|November 2010|||June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|200|||Both|18 Years|95 Years|No|||October 2012|October 15, 2012|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187576||117338|
NCT01160302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-081|Curcumin Biomarker Trial in Head and Neck Cancer|An Exploratory Biomarker Trial of the Food Substances Curcumin C3 Complex® in Subjects With Newly Diagnosed Head and Neck Squamous Cell Carcinoma||Louisiana State University Health Sciences Center Shreveport|Yes|Completed|June 2010|January 2016|Actual|January 2016|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|33|||Both|18 Years|90 Years|No|||March 2016|March 1, 2016|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160302||119426|
NCT01160263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080402|Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls|Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT|DOSERAL|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|16|||Both|39 Years|66 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160263||119429|
NCT01160276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081105|Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients|An Open Non Randomized Comparative Study Exploring Drug Interaction Between Colchicine and Calcineurin Inhibitors in 2 Groups (Ciclosporin Group and Tacrolimus Group) of Renal Graft Recipients|COLCHINCAL|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160276||119428|
NCT01160900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sperimental Registry n°844|FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.|Phase III Study, Multivessel Percutaneous Treatment During Myocardial Infarction|FIT|Azienda Ospedaliera San Camillo Forlanini|Yes|Active, not recruiting|July 2010|July 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|85 Years|No|||July 2010|July 12, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01160900||119381|
NCT01160913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTCESAR|Optimal Site of Administration for Continuous Wound Infusion After Cesarean Section|Evaluation of Optimal Anatomical Layer for Continuous Wound Infusion of Local Anesthetics Combined With NSAIDs Through a Multiorifice Catheter for Postoperative Pain Intensity After Elective Cesarean Delivery||Association pour la Recherche et la Formation en Anesthésie Analgésie Réanimation|No|Completed|October 2007|December 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|N/A|No|||September 2007|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01160913||119380|
NCT01161134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1CX04001|Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition|Comparative Bioavailability Study of Meloxicam 15 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics) Vs. Mobic® 15 mg Tablets (Boehringer Ingelheim Pharmaceuticals Inc.,Usa) in Healthy Male And/Or Female Volunteers Under Fasting Conditions-P1cx04001||Dr. Reddy's Laboratories Limited|No|Completed|September 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2004|July 12, 2010|July 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161134||119363|
NCT01161147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1CX04002|Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition|Comparative Bioavailability Study of Meloxicam 15 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics) Vs. Mobic® 15 mg Tablets (Boehringer Ingelheim Pharmaceuticals Inc.,Usa) in Healthy Male And/Or Female Volunteers Under Fed Conditions- P1CX04002||Dr. Reddy's Laboratories Limited|No|Completed|October 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2004|July 12, 2010|July 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161147||119362|
NCT01161160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114495|Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old|An Observer-blind Safety and Immunogenicity Study of GSK Biologicals' A/California/7/2009 (H1N1)V-like Vaccines GSK234074A and GSK234072A in Children 3 to Less Than 10 Years Old||GlaxoSmithKline||Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|209|||Both|3 Years|9 Years|Accepts Healthy Volunteers|||May 2011|March 8, 2012|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161160||119361|
NCT01161732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0065|Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis|Randomized Comparison of Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis|RECOVERY|Asan Medical Center|Yes|Active, not recruiting|April 2010|April 2022|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|20 Years|80 Years|No|||June 2015|June 24, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161732||119317|
NCT01161719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816003|Effectiveness Study of Videoconferencing on Teaching Parent Training Skills to Parents of Children With Attention Deficit Hyperactivity Disorder (ADHD)|The Effectiveness of Videoconferencing on Teaching Parent Training Skills to Parents of Children With ADHD||University of California, Davis|Yes|Completed|April 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|6 Years|14 Years|No|||January 2016|January 25, 2016|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01161719||119318|
NCT01184378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRD-08-15|Tolerance and Digestibility of a New Formula in Healthy Infants|Study of Tolerance and Lipid Digestibility of a Formula in Healthy 3 Months Infants||Lactalis|Yes|Completed|November 2008|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|2 Months|4 Months|Accepts Healthy Volunteers|||January 2011|January 25, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184378||117583|
NCT01184391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVA-0771|Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg|Single-Dose Fasting Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets (500 mg; Mylan) and Depakote Tablets (500 mg; Abbott) in Healthy Adult Male And Female (Not of Childbearing Potential) Volunteers||Mylan Pharmaceuticals||Completed|July 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 17, 2010|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01184391||117582|
NCT01184729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP MN 002|6 Minute Propulsion Test Sensitivity to Increased Aerobic Capacity|6 Minute Propulsion Test Sensitivity to Increased Aerobic Capacity||University of Miami|No|Completed|November 2008|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|65 Years|No|Non-Probability Sample|Community sample of persons with spinal cord injury|July 2014|July 21, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01184729||117556|
NCT01185119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H80-CP-O015|Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET|The Effect of Native GLP-1 on Glucose Metabolism in the CNS During Hyperglycemia in Healthy Young Men Assessed by PET||University of Aarhus|No|Completed|June 2010|March 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 21, 2011|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185119||117527|
NCT01185405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVORI|Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients|Prediction and Adjustment of Voriconazole Plasma Level in Critically Ill Patients||Asan Medical Center|Yes|Withdrawn|August 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|N/A|No|||September 2013|September 29, 2013|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185405||117505|
NCT01185678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15253|Data on Oral Contraceptives Compliance in Non Stop Regimen|Observation of Compliance With Dosage in Women Using Oral Contraceptives Designed for the Non Stop Use, (it Means 28 Pills for 28-days Cycle).|DOC Non Stop|Bayer|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8416|||Female|18 Years|50 Years|No|Probability Sample|Gynecological practices ptients - starters or current users.|June 2013|June 25, 2013|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01185678||117484|
NCT01185691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-248-SDR|Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients|RELIEF I: Investigating the Role of IMPELLA 2.5 System In Acutely Decompensated Chronic Heart Failure Patients. A Prospective, Single Center Feasibility Study|RELIEF I|Abiomed Inc.|No|Terminated|July 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|80 Years|No|||May 2013|May 1, 2013|August 19, 2010||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01185691||117483|
NCT01185951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENDOSHOCK-2010|TENDOSHOCK-2010 Combination Therapy for Athletic Tendinopathies|TENDOSHOCK-2010 - Combined Sclerosing Therapy, Extracorporeal Shockwave Therapy, Eccentric Training and Topical Glyceryl Trinitrate for Athletic Tendinopathies|TENDOSHOCK|Hannover Medical School|No|Active, not recruiting|January 2007|December 2010|Anticipated|August 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|N/A|No|||August 2010|August 19, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185951||117463|
NCT01185964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14055|A Study of IMC-3G3 in Soft Tissue Sarcoma|A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma||Eli Lilly and Company|No|Active, not recruiting|October 2010|March 2016|Anticipated|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|146|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185964||117462|
NCT01186211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB2010262-01H|Feasibility of Outpatient Total Knee Arthroplasty|Feasibility of Outpatient Total Knee Arthroplasty||Ottawa Hospital Research Institute|No|Recruiting|November 2010|January 2019|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The first 20 patients (baseline) will be treated in hospital so we can gauge the potential        of inpatient stay and our criteria will be refined. The next group of 20 (intermediate)        will be geared toward overnight stay and finally the last 120 patients (full intervention)        will be geared for same day discharge using the successful protocol already in place for        unicompartment knee arthroplasty (UKA) at TOH.|May 2015|May 20, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186211||117443|
NCT01186991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAM4861g|Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer|A Randomized, Phase II, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer||Genentech, Inc.||Active, not recruiting|March 2011|||March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|205|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186991||117383|
NCT01187264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7557/PG/2Trg/07|Dose Ranging Study to Compare the Efficacy and Safety of Methotrexate in Plaque Type Psoriasis|Efficacy and Safety of Methotrexate in 2 Fixed Doses of 10mg or 25mg Orally Once Weekly in Patients With Severe Plaque Type Psoriasis: a Prospective, Randomized, Double Blind, Dose Ranging Study||Postgraduate Institute of Medical Education and Research|Yes|Completed|August 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||September 2009|August 24, 2010|August 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187264||117362|
NCT01187810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOC2008-01|Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL|A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058"||South Plains Oncology Consortium|Yes|Recruiting|August 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|21 Years|No|||December 2014|December 9, 2014|August 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187810||117320|
NCT01160315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ErasmeUH|Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure|A Prospective Open Randomized Trial on the Efficacy of Gonadotropin-releasing Hormone Agonist Depot-Triptorelin- to Prevent Chemotherapy Induced Premature Ovarian Failure in Lymphoma Patients.|Erasme-POF|Erasme University Hospital|No|Completed|July 2002|October 2015|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|118|||Female|18 Years|45 Years|No|||October 2015|October 29, 2015|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01160315||119425|
NCT01160588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH086517|Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents|Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents||University of Michigan|Yes|Completed|July 2010|March 2015|Actual|March 2015|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|156|Samples With DNA|saliva|Both|7 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants with one or more of the following anxiety disorders (diagnosed by our study):        Generalized Anxiety Disorder, Social Anxiety Disorder, Separation Anxiety Disorder.|May 2015|May 26, 2015|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160588||119405|
NCT01160926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09_DOG03_184|Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial|Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy|DREAMtherapy|Christie Hospital NHS Foundation Trust|No|Terminated|July 2010|September 2016|Anticipated|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 7, 2010||No|2 DLTs had been reported from first 4 patients on lowest possible dose cohort.|No||https://clinicaltrials.gov/show/NCT01160926||119379|
NCT01161173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21474|An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (TEAM)|A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting||Hoffmann-La Roche||Completed|April 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Both|18 Years|N/A|No|Probability Sample|NSCLC patients with PD after 1st line chemotherapy|July 2015|July 1, 2015|July 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01161173||119360|
NCT01161186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#10451|Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma|A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma||University of California, San Francisco|Yes|Completed|July 2010|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161186||119359|
NCT01157546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-10-012|TAP Block for Open Radical Prostatectomy.|Continuous Transversus Abdominis Plane (TAP) Block for Open Radical Prostatectomy. A Double Blind Randomized Study.||McGill University Health Center|Yes|Terminated|August 2010|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Male|18 Years|N/A|No|||March 2015|March 16, 2015|June 30, 2010||No|Low recruitment rate. In our center, open radical prostatectomies have been almost completely    replaced by robotic prostatectomies.|No||https://clinicaltrials.gov/show/NCT01157546||119634|
NCT01157559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-Zeldox in FEP|Efficacy and Safety With Ziprasidone in First-episode Psychosis|Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study||Chonbuk National University Hospital|No|Completed||May 2010|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|14 Years|45 Years|No|||January 2007|July 6, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01157559||119633|
NCT01157572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACTNR: 2007-000518-34|Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation|Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation|BAR|Oslo University Hospital|No|Completed|August 2010|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|70 Years|No|||September 2014|September 24, 2014|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01157572||119632|
NCT01188616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24963|IT-Supported Early Treatment Of Childhood Overweight|Automated Self-management System to Promote Healthy Eating and Activity in Overweight Children|HEAT|Boston Medical Center|Yes|Completed|July 2005|||May 2010|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||||||Both|9 Years|12 Years|No|||August 2010|August 24, 2010|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188616||117258|
NCT01184404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03603|Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery|Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery|BOCA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|September 2011|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01184404||117581|
NCT01184417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlamedaCountyMC|Phenobarbital for Acute Alcohol Withdrawal|Phenobarbital Versus Placebo for Acute Alcohol Withdrawal||Alameda County Medical Center|Yes|Completed|January 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|65 Years|No|||March 2012|March 7, 2012|August 17, 2010|No|Yes||No|February 18, 2012|https://clinicaltrials.gov/show/NCT01184417||117580|
NCT01184742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-001|6 Minute Push & 30 Second Sprint Tests Reliability & Relationship to Fitness, Participation, & Environmental Assessments|6 Minute Push and 30 Second Sprint Tests Reliability and Relationship to Fitness, Participation, and Environmental Assessments||University of Miami|No|Completed|March 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|56|||Both|18 Years|65 Years|No|Non-Probability Sample|Community sample of persons with spinal cord injury.|November 2011|July 21, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01184742||117555|
NCT01184755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|526|RCT of Effects of Device-guided Breathing on Ambulatory BP|RCT of Device-guided Breathing Effects on Ambulatory BP|RESPeRate|Rutgers, The State University of New Jersey|Yes|Completed|May 2008|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|630|||Both|18 Years|80 Years|No|||April 2015|April 11, 2015|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184755||117554|
NCT01184768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2010-2|HBA1c and Diagnosis of Type 2 Diabetes|HBA1c and Diagnosis of Type 2 Diabetes||University of Tromso|No|Completed|January 2008|November 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|3509|Samples Without DNA|serum|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|random sample of subjects living in Tromso and who participated in the 6 th Tromsø study|July 2011|July 19, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01184768||117553|
NCT01185717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100JC401|JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)|Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients|JEMS|Biogen|No|Completed|September 2010|June 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|7726|||Both|N/A|N/A|No|Non-Probability Sample|Multiple Sclerosis (MS) patients will be enrolled in Europe, Canada, and Australia.        Patient enrollment from each country will be commensurate with the distribution of MS        patients among all participating countries.|May 2014|May 29, 2014|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01185717||117481|
NCT01185444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS97-CT9-12|Efficacy of Three Weekly Injections of a Bacterial-- Sourced Hyaluronate on Pain and Function in Patients With Knee Osteoarthritis (OA)|Efficacy of 3 Weekly Injections of a Bacterial-- Sourced Hyaluronate on Pain and Physical Function in Patients With Knee Osteoarthritis—a Randomized Controlled Clinical Trial||Kaohsiung Veterans General Hospital.|Yes|Completed|February 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|40 Years|80 Years|No|||December 2008|August 19, 2010|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01185444||117502|
NCT01185990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD 10 - 01|Tinnitus Measured by MEG and Synchronous Neural Interaction™ Test: Template Development|Moderate to Severe Tinnitus as Measured by MEG and the Synchronous Neural Interaction™ Test: Template Development Study||Orasi Medical, Inc.|No|Recruiting|August 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with chronic, moderate to severe unilateral tinnitus|March 2011|March 22, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185990||117460|
NCT01185704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200088-501|Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)|A Phase IIIb Randomized Open-label Study to Compare the Estradiol Level on the Releasing Day in Two Regimen of Cetrotide® 0.25 mg Used From Day 1 or From Day 7 of the Menstrual Cycle (Day 0 or Day 6 of Stimulation) in Polycystic Ovarian (PCO) Women in ART (IVF/ICSI).|ATTAC-PCO|Merck KGaA|No|Completed|November 2008|February 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Female|18 Years|35 Years|No|||January 2014|January 20, 2014|August 10, 2010||No||No|March 25, 2013|https://clinicaltrials.gov/show/NCT01185704||117482|
NCT01185977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090713201|Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)|Biomarkers of Antidepressant Treatment in Adolescents With Major Depression||University of California, Los Angeles|No|Completed|April 2010|||October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|14 Years|18 Years|No|||July 2014|July 2, 2014|April 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01185977||117461|
NCT01186224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHANTASTIC|Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)|A Comparison of Plerixafor/G-CSF With Chemotherapy/G-CSF for Stem Cell Mobilisation|PHANTASTIC|University of Liverpool|Yes|Recruiting|May 2010|May 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2010|August 20, 2010|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01186224||117442|
NCT01187277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB200810|Robotic Versus Conventional Training on Hemiplegic Gait.|A Randomized Controlled Trial on Hemiplegic Gait Rehabilitation: Robotic Locomotor Training Versus Conventional Training in Subacute Stroke.|BB200810|Prasat Neurological Institute|Yes|Completed|January 2011|July 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||July 2012|July 15, 2012|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187277||117361|
NCT01187290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chest1001|Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases|Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase II Trial||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|August 2010|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||August 2010|August 23, 2010|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01187290||117360|
NCT01187589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLS-02|PulseHaler Drug Deposition Study in Chronic Obstructive Pulmonary Disease Patients|Preliminary Assessment of the Effect of PulseHaler™ With Albuterol on Lung Deposition of Aerosol and on Pulmonary Functions in COPD Patients||Respinova LTD|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|40 Years|85 Years|No|||September 2011|September 22, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187589||117337|
NCT01188122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HST -AG -01|Optimal Endotracheal Cuff Pressure During Hospitalization in Intensive Care Units Using AnapnoGuard 100 System|Optimal Endotracheal Cuff Pressure During Hospitalization in Intensive Care Units Using AnapnoGuard 100 System||Hospitech Respiration|No|Completed|April 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|N/A|No|||August 2010|August 23, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188122||117296|
NCT01160640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10010112|The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)|The Importance of Anti-anaerobic Therapy for Acute PID||University of Pittsburgh|Yes|Completed|November 2010|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|233|||Female|15 Years|40 Years|No|||December 2015|December 1, 2015|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160640||119401|
NCT01160601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1001|Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer|A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients With Previously Untreated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer||Peregrine Pharmaceuticals|No|Completed|June 2010|September 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160601||119404|
NCT01160614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR1020|Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients|An Open-label Study to Characterize the Pharmacokinetics and Safety of Oxycodone Hydrochloride q12h Controlled-Release (ORF) Tablets in Pediatric Patients Aged 6 to 16 Years Inclusive, Who Require Opioid Analgesia||Purdue Pharma LP|No|Completed|July 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|6 Years|16 Years|No|||October 2012|October 11, 2012|July 8, 2010|Yes|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT01160614||119403|
NCT01161199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H52899-34904-01|The Use of Leukapheresis to Support HIV Pathogenesis Studies|The Use of Leukapheresis to Support HIV Pathogenesis Studies||University of California, San Francisco|No|Recruiting|July 2010|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|CD4+ T cells Plasma|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients on long-term antiretroviral therapy, untreated patients, and elite        controllers will be studied.|August 2015|August 14, 2015|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161199||119358|
NCT01161446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36706-D|Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)|Comparisons of Public Health Screening Methods for Acute and Early HIV Infection: Home Self-Testing for HIV Infection||University of Washington|Yes|Completed|July 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|230|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161446||119339|
NCT01158365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACAC_L_05401|Dermacyd in Odor Reducing.|Single Center, Open, Cross-over, Phase III Study for Comparative Evaluation of Safety Use and Efficacy in the Odor Reduce and Vaginal Moisturize Increase for Intimates Use Products Dermacyd Femina Delicata, Dermacyd Femina Breeze, Dermacyd Teen Sweet Flower, Dermacyd Teen Fresh Mix and Dermacyd Femina Comparing to the Control Product Glycerine Vegetal Soap Granado Traditional.||Sanofi||Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 3, 2011|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158365||119572|
NCT01158378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBMT-080453|Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures|A Pivotal Clinical Trial Examining the Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures||HyperBranch Medical Technology, Inc|Yes|Completed|June 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|75 Years|No|||February 2014|February 26, 2014|July 6, 2010|Yes|Yes||No|February 26, 2014|https://clinicaltrials.gov/show/NCT01158378||119571|
NCT01184781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-02|Project PREVAM : Prospective Comparison of Capsule Endoscopy Pillcam II™ Versus Colonoscopy|Prospective Comparison of Capsule Endoscopy Pillcam II™ Versus Colonoscopy for the Detection of Adenomatous Polyps and Cancer in a High Risk Population||Centre Hospitalier Universitaire de Nice|No|Recruiting|August 2010|November 2013|Anticipated|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|210|||Both|18 Years|N/A|No|||May 2010|April 23, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01184781||117552|
NCT01184495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-168|Efficacy Study of Two Formulations of Erythropoietin|Comparison of the Efficacy of Erythropoietin Produced in the Institute of Technology in Immunobiology of the Oswald Cruz Foundation (BioMaguinhos/FioCruz/MS) and Erythropoietin Industrialized in Patients With Chronic Renal Failure||Hospital de Clinicas de Porto Alegre|Yes|Completed|April 2008|January 2009|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||August 2010|August 17, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184495||117574|
NCT01184430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Algebra|Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery|Monocentric Pilot Study of Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery|Algebra|Charite University, Berlin, Germany|Yes|Not yet recruiting|August 2013|December 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184430||117579|
NCT01184443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGDM24|Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents|Evaluation of the Efficacy and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Children and Adolescents: An Open-label Trial||Children's Hospital of Eastern Ontario|Yes|Terminated|August 2010|March 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|11 Years|17 Years|No|||September 2014|September 3, 2014|August 13, 2010||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01184443||117578|
NCT01184456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHF-GAN01|A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System|A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System||AIDS Healthcare Foundation|Yes|Recruiting|August 2010|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||August 2010|August 17, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184456||117577|
NCT01185418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBIRB0226-22|Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer|Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer: a Double-blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, Amisulpride, Risperidone and Aripiprazole||Chonbuk National University Hospital|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Prospective||5|Actual|80|||Both|18 Years|38 Years|Accepts Healthy Volunteers|Probability Sample|Recruited volunteers among normal adults aged from 18 to 38 who responded advertisements        for research subjects. Then selected subjects from the applicants using various screening        tests - physical and neurological examination including confirming vital signs after        examining physical health and sleep habits of volunteers|March 2009|August 19, 2010|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185418||117504|
NCT01185431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCF2_2010_YM|The Effects of a Ficus Carica on Improvement in Bowl Movements in Female Volunteer With Functional Constipation|Randomized, Double-Blind, Placebo-Controlled, Parallel Trial in Female Volunteers With Functional Constipation, to Evaluate the Improvement in Bowl Movement of Ficus Carica||Chonbuk National University Hospital|Yes|Completed|July 2010|August 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|19 Years|40 Years|No|||February 2012|February 6, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01185431||117503|
NCT01186029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|359-09-FB|Comparison of Adding EMEND to PONV/PDNV Treatment Regimen|A Comparison Study to Determine the Increased Efficacy of Adding EMEND to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting||University of Nebraska|Yes|Not yet recruiting|October 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|300|||Both|19 Years|N/A|No|||August 2010|August 19, 2010|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186029||117457|
NCT01186003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0483|Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy|Effectiveness of a Subcutaneously Administered Long-Acting Insulin Detemir Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment||University of Colorado, Denver|No|Enrolling by invitation|August 2010|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|80 Years|No|||January 2016|January 15, 2016|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186003||117459|
NCT01186016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226-09-FB|Developing Genetic Education for Smoking Cessation|Developing Genetic Education for Smoking Cessation||University of Nebraska|Yes|Completed|February 2010|July 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|19 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 17, 2013|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01186016||117458|
NCT01186237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC0004|Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study|Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study||Stanford University|Yes|Recruiting|June 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01186237||117441|
NCT01186484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017137|Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer|Phase 1 Study of JNJ-212082 (Abiraterone Acetate) in Patients With Castration-Resistant Prostate Cancer||Janssen Pharmaceutical K.K.|No|Completed|June 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|20 Years|99 Years|No|||October 2015|October 30, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186484||117422|
NCT01186497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014821|A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers|Relative Bioavailability of Rabeprazole Sodium Sprinkle Capsule Formulation Using Different Dosing Vehicles Following Single-dose Administration in Healthy Adult Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 21, 2013|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186497||117421|
NCT01186731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol LE-DT 202|Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer|A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer||INSYS Therapeutics Inc|Yes|Completed|April 2010|December 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||August 2012|September 11, 2012|August 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186731||117403|
NCT01186757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9111002|Multiple Dose Healthy Volunteer Study of PF-03715455.|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Inhaled Doses Of PF-03715455 In Healthy Subjects|MD-MULTI DOSE|Pfizer|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 11, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01186757||117401|
NCT01187602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15099|Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer|A Pilot Study of Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer|sncRNA|University of Virginia|Yes|Recruiting|August 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|103|Samples Without DNA|plasma|Female|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women in Gynecologic clinics|December 2014|December 4, 2014|August 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01187602||117336|
NCT01187823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-447|The Effect of Adaptive Servo Ventilation and Oxygen Therapy in Central Sleep Apnea Patients|Comparison of Adaptive Servo Ventilation(Bipap® Auto SV Advanced) and Oxgen Therapy in Chronic Heart Failure Patients Complicated With Central Sleep Apnea||Kyoto University, Graduate School of Medicine|No|Completed|December 2010|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|20 Years|80 Years|No|||July 2014|April 13, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187823||117319|
NCT01184560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OPS|Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine|A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine||Gachon University Gil Medical Center|Yes|Completed|February 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|50 Years|No|||October 2009|August 18, 2010|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01184560||117569|
NCT01160666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090208|Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome|A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS (BAFF) Antibody, in Subjects With Primary Sjögren's Syndrome|BELISS|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2010|June 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 1, 2012|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160666||119399|
NCT01160952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-I-08-CN-041-C|Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation|Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation||Guangzhou General Hospital of Guangzhou Military Command|Yes|Recruiting|May 2009|March 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|14 Years|60 Years|No|||July 2010|July 23, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01160952||119377|
NCT01160939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYYUNIFESP|Assessment and Monitoring of Patients in Medium-term Heart Transplant Candidates Undergoing Low-intensity Exercise|Assessment and Monitoring of Patients in Medium-term Heart Transplant Candidates Undergoing Low-intensity Exercise||Federal University of São Paulo|Yes|Completed|November 2004|November 2008|Actual|November 2006|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|||Actual|21|||Both|35 Years|75 Years||||November 2009|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01160939||119378|
NCT01161459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1004|Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid|Research Institute of Nephrology, Jinling Hospital||Nanjing University School of Medicine|Yes|Completed|June 2010|October 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||May 2014|May 29, 2014|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161459||119338|
NCT01161745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANETHDEPT-001|PD-1/PD-L1 Pathway Study on Septic Patients|PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients||Changhai Hospital|No|Completed|December 2008|April 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|39|Samples Without DNA|peripheral venous blood from septic patients and healthy controls, anticoagulate with      EDTA-K2|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients who develop sepsis|June 2010|July 13, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01161745||119316|
NCT01161758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT0004|Study on the Effect of Cervical Mobilization on Motor Function and Pressure Pain Threshold in Pain Free Individuals|A Crossover Study on the Effect of Cervical Mobilization on Motor Function and Pressure Pain Threshold in Pain Free Individuals||Curtin University of Technology|No|Completed|April 2005|December 2005|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2005|July 13, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01161758||119315|
NCT01158391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC_BMDX_002|Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding|Trial of Patterned Oral Somatosensory Entrainment||KC BioMediX, Inc|Yes|Active, not recruiting|May 2010|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|28 Weeks|34 Weeks|Accepts Healthy Volunteers|||February 2016|February 21, 2016|June 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01158391||119570|
NCT01158404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13284|Notch Inhibitor in Advanced Cancer|Phase 1 Study of a Notch Inhibitor in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|July 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|July 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01158404||119569|
NCT01184508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13313|A Study in Migraine Prevention|A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study of LY2300559 in Patients With Migraine||Eli Lilly and Company|No|Terminated|January 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|87|||Both|18 Years|65 Years|No|||October 2012|October 25, 2012|August 17, 2010|Yes|Yes|Elevation of ALT and AST in some patients.|No||https://clinicaltrials.gov/show/NCT01184508||117573|
NCT01184521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00364|Masimo CO-Oximeter Study|Use of the Masimo Rainbow SET Pulse CO-Oximeter in Patients Undergoing Isovolemic Hemodilution||Nationwide Children's Hospital|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients requiring isovolemic hemodilution during surgery.|January 2012|January 27, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184521||117572|
NCT01185197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis-ST-03|Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study|Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome||The University of Hong Kong|No|Recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||July 2015|July 2, 2015|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01185197||117521|
NCT01185132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-APBI|Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy|A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy|2009-APBI|Rocky Mountain Cancer Centers|No|Recruiting|July 2009|July 2028|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|40 Years|N/A|No|||June 2014|June 24, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185132||117526|
NCT01185145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB #20040075|Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy|A Phase II Study of Accelerated Partial Breast Radiotherapy With Either a Novel Breast Brachytherapy Technique - Mammosite or Intensity Modulated Radiotherapy|APBI|Rocky Mountain Cancer Centers|No|Active, not recruiting|February 2004|August 2024|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|291|||Both|40 Years|N/A|No|||July 2013|July 10, 2013|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185145||117525|
NCT01185158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11588A|A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma|A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma||University of Chicago|No|Completed|May 2002|November 2010|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|August 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185158||117524|
NCT01185171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12019A|Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer|Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer||University of Chicago|Yes|Active, not recruiting|January 2003|September 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|August 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01185171||117523|
NCT01186263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD050|Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy|Exploratory Study to Assess the Predictive Value of 99mTc-labeled Albumin Spheres for the Intrahepatic Distribution of 90Y SIR Spheres in Patients With Liver Metastases of Colorectal Tumors|EXPLOSIVE|University of Magdeburg|No|Completed|July 2010|August 2013|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|24|||Both|18 Years|85 Years|No|||September 2014|September 3, 2014|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01186263||117439|
NCT01186250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05282010-6202|Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation|Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation||Stanford University|Yes|Active, not recruiting|July 2010|December 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186250||117440|
NCT01186510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PulPer-001-Sch|Lung Perfusion With Oxygenated Blood During Aortic Clamping|Lung Perfusion With Oxygenated Blood During Aortic Clamping|PulPer-001-Sch|Johann Wolfgang Goethe University Hospitals|No|Completed|August 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||June 2013|June 3, 2013|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186510||117420|
NCT01186744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921111|A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi-Site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|Yes|Completed|September 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|666|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|August 20, 2010|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01186744||117402|Clinical interpretation regarding sub-phenotypes of psoriasis (e.g., scalp psoriasis) should not be made based on the reported assessments by body regions. For example, the body region of head does not reflect solely scalp psoriasis.
NCT01187004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82755|Extracardiac Complications After Cardiac Surgery|Extracardiac Complications After Cardiopulmonary by Pass in Cardiac Surgery||University of Turin, Italy|Yes|Completed|April 2007|December 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|164|||Both|18 Years|85 Years|No|Probability Sample|patients undergoing major cardiac surgery with cardiopulmonary by pass|February 2013|February 5, 2013|August 19, 2010||No||No|August 8, 2011|https://clinicaltrials.gov/show/NCT01187004||117382|The main limitation of the trial was the observational nature and the relatively small number of patients
NCT01187316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-R6YV8|Treatment of Temporomandibular Disorders|Massage and Transcutaneous Electrical Nerve Stimulation Therapies for Temporomandibular Disorders in Adolescents||University of Pernambuco|No|Completed|April 2007|September 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Female|14 Years|24 Years|Accepts Healthy Volunteers|||March 2007|August 24, 2010|August 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187316||117358|
NCT01188148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPMM HR-98-025|Series Studies of Bipolar Disorder-Valproate add-on Memantine|Series Studies of Bipolar Disorder-Valproate add-on Memantine Treatment|MM|National Cheng-Kung University Hospital|Yes|Completed|August 2009|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|65 Years|No|||August 2009|September 16, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188148||117294|
NCT01188434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA021603|Integrating Interventions for Maternal Substance Abuse|Integrating Interventions for Maternal Substance Abuse and Child Neglect|ITSAN|Oregon Social Learning Center|No|Completed|September 2007|August 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Female|N/A|N/A|No|||April 2015|April 27, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188434||117272|
NCT01188694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37340-G|Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)||HELP|University of Washington|Yes|Active, not recruiting|September 2009|April 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|65 Years|No|||December 2012|December 18, 2012|July 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01188694||117252|
NCT01188707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU0928|A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer|A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer||Herlev Hospital|Yes|Terminated|December 2010|August 2012|Anticipated|March 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|August 24, 2010|Yes|Yes|Dose over MTD reached|No||https://clinicaltrials.gov/show/NCT01188707||117251|
NCT01188720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-07-0043|Sexual Health on Antidepressants Through Physical Exercise|Sexual Health on Antidepressants Through Physical Exercise|SHAPE|University of Texas at Austin|No|Completed|November 2010|August 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|52|||Female|18 Years|N/A|No|||May 2015|May 26, 2015|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01188720||117250|
NCT01161472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221086|A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects|A 4 Way Placebo And Active Controlled Study To Evaluate The Effects Of Fesoterodine On Cognitive Function In Healthy Elderly Subjects||Pfizer|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|20|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 25, 2012|July 12, 2010|No|Yes||No|May 25, 2012|https://clinicaltrials.gov/show/NCT01161472||119337|
NCT01161771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-RES-09-004|Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye|||Allergan|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|50 Years|N/A|No|Non-Probability Sample|Patients undergoing cataract extraction and limbal relaxing incision|July 2012|July 17, 2012|July 6, 2010||No||No|December 13, 2011|https://clinicaltrials.gov/show/NCT01161771||119314|
NCT01161212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regulaps2006|REGULarity of Physical ActivitieS (REGUL'APS)|Physical Activity, Health-related Quality of Life and Corpulence Among French Schoolchildren|REGUL'APS|University of Nancy|Yes|Completed|September 2005|September 2006|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1600|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2010|July 23, 2010|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161212||119357|
NCT01157598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-037|Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection|Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection||Samsung Medical Center||Recruiting|September 2009|||September 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|56|||Both|19 Years|80 Years|No|||July 2010|July 6, 2010|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01157598||119630|
NCT01157884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-001-YH|Change of Body Composition After Kidney Transplantation in Korea|||Seoul National University Hospital|No|Completed|September 2009|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|None Retained|serum: total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, C-reactive protein      (CRP)|Both|20 Years|N/A|No|Probability Sample|recieved kidney transplantation in the Seoul National University Hospital|January 2012|January 3, 2012|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01157884||119609|
NCT01158118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1154 / 201108083|Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors|A Phase II Trial Evaluating the Safety and Efficacy of Plerixafor and Sargramostim (GM-CSF) for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal, HLA-Matched Allogeneic Sibling Donors||Washington University School of Medicine|No|Active, not recruiting|April 2011|December 2016|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158118||119591|
NCT01158144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH03|Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)|A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|October 2009|December 2013|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|65 Years|No|||July 2010|July 6, 2010|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01158144||119589|
NCT01185457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRVShoulder|Effect of Interscalene Block on Heart Rate Variability (HRV)|Effect of Interscalene Block on Heart's Autonomic Nervous System With Heart Rate Variability Measurement||Larissa University Hospital|No|Completed|June 2010|September 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|50|||Both|20 Years|45 Years|No|Probability Sample|Patients for elective shoulder surgery|October 2012|October 26, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185457||117501|
NCT01185743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLA_ZIPRA|Antipsychotics and Gene Expression in Soft Tissues|Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study||Medical University of Vienna|No|Suspended|July 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|August 19, 2010||No|interim analysis|No||https://clinicaltrials.gov/show/NCT01185743||117479|
NCT01184794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008JTW01|Postoperative Pain Control Using ON-Q Painbuster Pump|Postoperative Pain Control Using Continuous Infusion of Levobupivacaine in Women Undergoing Pelvic Operative Laparoscopy: A Randomised Controlled Trial||Ashford and St. Peter's Hospitals NHS Trust|No|Completed|August 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|16 Years|75 Years|No|||November 2013|November 12, 2013|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01184794||117551|
NCT01184807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266-09-801-01|Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors|A Phase 1, Open-label, Non-randomized, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors||Otsuka Beijing Research Institute|No|Completed|December 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|21 Years|N/A|No|||March 2014|March 24, 2014|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184807||117550|
NCT01186523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL15226|Long-term Exercise, Weight Loss and Energy Balance|Long-term Exercise, Weight Loss and Energy Balance||University of Kansas Medical Center|Yes|Completed|July 2005|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|136|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 8, 2012|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186523||117419|
NCT01186536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL16583|Whey Protein, Resistance Training, and Changes in Body Composition|Whey Protein Supp. w/ Resistance Training; Effects on Body Comp. of Young Adults.||University of Kansas Medical Center|Yes|Completed|June 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|85|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01186536||117418|
NCT01187030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200766101|Appropriateness of Frozen Plasma Use in Canada|Appropriateness of Frozen Plasma Use in Canada||Ottawa Hospital Research Institute|No|Completed|May 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2580|||Both|16 Years|N/A|No|Non-Probability Sample|Patients at 10 academic medical centres (17 hospitals) across Canada|May 2012|May 22, 2012|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187030||117380|
NCT01187043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZP-204|Determination of the Lowest, Safe and Effective Dose of Proellex|A Single-Blind, Placebo Run-in, Phase I/II Study Comparing Five Oral Doses of Proellex®||Repros Therapeutics Inc.|Yes|Completed|August 2010|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|52|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|August 20, 2010|Yes|Yes||No|June 23, 2014|https://clinicaltrials.gov/show/NCT01187043||117379|
NCT01186770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 3201|A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral Methylnaltrexone (OM) for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic, Non-Malignant Pain||Valeant Pharmaceuticals International, Inc.|Yes|Completed|September 2010|May 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|700|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186770||117400|
NCT01187017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100177|A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia|A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)|Yes|Completed|August 2010|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|2 Years|N/A|No|||February 2016|February 3, 2016|August 20, 2010|Yes|Yes||No|June 5, 2014|https://clinicaltrials.gov/show/NCT01187017||117381|
NCT01187303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1432|Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)|Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)||University of Cologne|No|Completed|May 2011|September 2015|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|75 Years|No|||October 2015|October 30, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01187303||117359|
NCT01187849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 245/09|Metformin to Prevent Metabolic Complications in Glucocorticoid Excess|Metformin to Prevent Metabolic Complications in Glucocorticoid Excess||University Hospital, Basel, Switzerland|Yes|Recruiting|August 2010|December 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|66|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187849||117317|
NCT01188135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH090160|Antidepressant Adherence Via AD_IVR|Antidepressant Adherence Via Telephonic Interactive Voice Recognition (IVR)|AD_IVR|Kaiser Permanente|Yes|Completed|February 2011|November 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6058|||Both|21 Years|75 Years|No|||March 2015|March 12, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188135||117295|
NCT01188161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-06|Postural Effects of Being Rotated in a Whole Body Gyroscope|The Effects of Whole Body Rotations in the Pitch and Yaw Planes on Postural Stability|Gyro|Carrick Institute for Graduate Studies|Yes|Completed|July 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy volunteers without a history of vertigo or dizziness|August 2010|August 23, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01188161||117293|
NCT01188447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009142-01H|Evaluation of the Safety of C-Spine Clearance by Paramedics|Evaluation of the Safety of C-Spine Clearance by Paramedics||Ottawa Hospital Research Institute|Yes|Recruiting|January 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|3000|||Both|16 Years|N/A|No|||July 2015|July 23, 2015|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01188447||117271|
NCT01161797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMC-ENDO-0801|1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus|Correlation Between 1,5-anhydroglucitol and Postprandial Hyperglycemia by Continuous Glucose Monitoring System and Clinical Usefulness of 1,5-anhydroglucitol in Well-controlled Diabetic Patients||Kyunghee University Medical Center|No|Completed|February 2008|July 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|Samples Without DNA|serum (HbA1c, fructosamine, 1,5-anhydroglucitol)|Both|18 Years|65 Years|No|Probability Sample|Well-controlled patients with type 2 diabetes with HbA1c<7%|September 2010|September 29, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01161797||119312|
NCT01161784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMU RO52/2009|The Effects of a Probiotic Fermented Milk on Functional Constipation in Adults|The Effects of a Probiotic Fermented Milk on Functional Constipation in Adults||International Medical University|Yes|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||July 2010|July 13, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01161784||119313|
NCT01157585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBIRB0912-141|Efficacy and Safety of Paliperidone ER in First Episode Psychosis|Efficacy and Safety of Paliperidone ER in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study||Chonbuk National University Hospital|No|Completed|February 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|59 Years|No|||July 2015|July 30, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01157585||119631|
NCT01157897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1692|Study of VMP001 and AS01B in Healthy Malaria-Naïve Adults|Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GSK Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults||U.S. Army Medical Research and Materiel Command|Yes|Completed|July 2010|December 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|July 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157897||119608|
NCT01158131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p002118|Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)|Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)||Brigham and Women's Hospital|No|Completed|November 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|75|||Female|18 Years|45 Years|No|||December 2012|December 21, 2012|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01158131||119590|
NCT01158703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2009.120|Aspirin and Plavix Following Coronary Artery Bypass Grafting|Aspirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG)|ASAP-CABG|Brooke Army Medical Center|Yes|Terminated|July 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 3, 2015|July 7, 2010|Yes|Yes|poor recruitment and reduction in CT surgery support|No|February 23, 2015|https://clinicaltrials.gov/show/NCT01158703||119547|The study did not recruit enough patients due to strict exclusion criteria and low volume of consenting patients resulting in a sample size that was insufficient for power analysis.
NCT01185756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM : 08085|MIBG Scintigraphy as a Tool for Selecting Patients Requiring Implantable Cardioverter Defibrillator (ICD)|Can we Better Select Patients With Heart Failure for a Primary Prevention Indication of Implantable Cardioverter Defibrillator (ICD)? Evaluation of the Diagnostic Value of 123I Meta-iodobenzylguanidine (MIBG)|MISTIC|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|September 2010|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|330|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01185756||117478|
NCT01185470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100|The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain|THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN||Medallion Therapeutics, Inc.|Yes|Active, not recruiting|February 2011|June 2016|Anticipated|January 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|21 Years|N/A|No|||April 2015|April 6, 2015|August 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185470||117500|
NCT01186276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07292010-6626|Dietary Maneuvers to Reduce Production of Colon-Derived Uremic Solutes|Dietary Maneuvers to Reduce Production of Colon-Derived Uremic Solutes||Stanford University||Enrolling by invitation|July 2010|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186276||117438|
NCT01185730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 09065|Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics|Evaluation of Prognostic Factors and Therapeutic Targets in Pulmonary Arterial Hypertension|EFORT|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01185730||117480|
NCT01187368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020-1601-001-P01|EVAHEART LVAS Bridge-to-Transplant Pivotal Study|A Prospective Study to Evaluate the Safety and Efficacy of the EVAHEART LVAS for Use as a Bridge-to-Transplant||Evaheart, Inc.|Yes|Suspended|July 2010|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 19, 2010|Yes|Yes|Data Adjudication|No||https://clinicaltrials.gov/show/NCT01187368||117354|
NCT01187329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-526|The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose|The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose||The Cleveland Clinic|Yes|Completed|October 2010|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|40 Years|84 Years|No|||June 2014|June 12, 2014|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01187329||117357|
NCT01187615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14458|Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer|An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 "Regorafenib", Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer||Bayer|No|Terminated|August 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|July 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01187615||117335|
NCT01187628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15074|Long-term Study in Chronic Kidney Disease (Extension From Study 14817)|An Open-label, Long-term Extension Study of Lanthanum Carbonate 750 to 2,250 mg in Hyperphosphatemia in Patients With Chronic Kidney Disease Not on Dialysis (52 Weeks Extension From Study 14817)||Bayer|No|Completed|September 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|20 Years|N/A|No|||April 2015|April 2, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187628||117334|
NCT01187836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP120027.2001|Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure|A Randomized, Double-Blind, Placebo-Controlled, Adaptive, Ascending Dose-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Invasive Hemodynamics of TRV120027 in Patients With Stable Heart Failure||Trevena Inc.||Completed|December 2010|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|79 Years|No|||April 2012|April 13, 2012|August 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187836||117318|
NCT01187862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB-94/10|Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes|Single-center, Randomized, Five-way Crossover Study to Investigate Low-dose Combinations of Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol, Chlorzoxazone and Midazolam ("Basel Cocktail") for Simultaneous Phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in Healthy Male Subjects||University Hospital, Basel, Switzerland||Completed|July 2010|||February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187862||117316|
NCT01187875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806M37445|Resistant Starch and Satiety|Satiety Response of Resistant Starches||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2009|June 2011|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|20|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01187875||117315|
NCT01188733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005739|Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis|Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis||Mayo Clinic|Yes|Completed|June 1998|December 2000|Actual|July 2000|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|39|||Both|18 Years|75 Years|No|||August 2010|August 24, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188733||117249|
NCT01184612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30225613|Effects of Motivational Interviewing in Prison|Motivational Interviewing Delivered by Existing Prison Staff: A Randomized Controlled Study of Effectiveness on Substance Use After Release||Karolinska Institutet|No|Completed|April 2004|July 2008|Actual|March 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|296|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2003|August 18, 2010|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01184612||117565|
NCT01184625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exercise|Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation|Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation||Karolinska Institutet|No|Recruiting|January 2008|August 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 24, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184625||117564|
NCT01184573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBT01|Novel Breath Test to Detect Early Stage Chronic Pancreatitis|Phase 1 Study of the Pancreatic Breath Test to Detect Early Stage Chronic Pancreatitis Utilizing the Secretin Stimulation Test||Metabolic Solutions Inc.|Yes|Completed|May 2011|September 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50|Samples Without DNA|Breath samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Two study population groups. The case group will have evidence of mild to moderate chronic        pancreatitis. The control group will be healthy without evidence of chronic disease.|February 2014|February 6, 2014|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184573||117568|
NCT01184586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DupuyShock-2010|Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010)|Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) - a Randomized Trial|DupuyShock|Hannover Medical School|No|Recruiting|November 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2011|December 1, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184586||117567|
NCT01184599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCGH-746|A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy|||Kagawa University|Yes|Recruiting|June 2010|||March 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|75 Years|No|||May 2010|June 23, 2011|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01184599||117566|
NCT01176500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100173|A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors|A Pilot, Open-Label, Proof-of-Concept Study of the Use of [18F]Fluciclatide PET/CT Imaging in the Evaluation of Anti-Angiogenic Therapy in Solid Tumors||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2010|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||November 2011|March 8, 2012|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176500||118186|
NCT01161511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XmAb5574-01|Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia|A Phase 1 Study of XmAb®5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Xencor, Inc.|No|Completed|September 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161511||119334|
NCT01161810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABA-MCTG-0003|The Relationship of Rehabilitation Therapy Time To The Prevention of Burn Scar Contracture|Burn Patient Acuity Demographics, Scar Contractures and Rehabilitation Treatment Time Related to Patient Outcomes (ACT)|ACT|American Burn Association|No|Completed|July 2010|September 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|386|||Both|18 Years|N/A|No|Non-Probability Sample|Primary diagnosis of acute burn injury|January 2015|January 14, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161810||119311|
NCT01157611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-05-065|The Effect of Online Based Mentoring Program on the Blood Glucose and Satisfaction Score in Type 1 Diabetes Patients|The Effect of Online Based Mentoring Program on the Blood Glucose and Satisfaction Score in Type 1 Diabetes Patients||Samsung Medical Center|Yes|Completed|July 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01157611||119629|
NCT01157624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nasalo2|Application of Nasal Cannula With Oxygen Versus Air During Eye Surgery Under Local Anaesthetic|||University of Malaya|Yes|Completed|May 2010|December 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|100|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2011|August 15, 2011|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01157624||119628|
NCT01157650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/CROH|Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue|Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue||Clinica Universidad de Navarra, Universidad de Navarra|No|Active, not recruiting|June 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2013|May 6, 2013|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01157650||119627|
NCT01157910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36-2009|Bacterial Assessment of Middle Ear Fluid in Children Undergoing Ventilation Tube Placement Surgery|An Epidemiological and Bacteriological Assessment of Middle Ear Fluid in Children Undergoing Ventilation Tube Placement Surgery||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2010|November 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|1 Year|15 Years|No|Non-Probability Sample|Children suffering from chronic otitis media who are scheduled for surgery.|July 2010|July 6, 2010|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01157910||119607|
NCT01158157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-006|Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV)|Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous||Cangene Corporation|Yes|Completed|August 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|July 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158157||119588|
NCT01158430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001001|Acceptance and Commitment Group Therapy (ACT) for Patients With Health Anxiety|Treatment of Patients With Health Anxiety. A Randomized Controlled Trial of Acceptance and Commitment Therapy (ACT) Group Treatment Compared to a Waiting List|ACT|University of Aarhus|No|Completed|March 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|20 Years|60 Years|No|||April 2013|April 12, 2013|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01158430||119567|
NCT01159275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 085|Lopinavir (LPV) Dose Reduction|Pharmacokinetics of Pediatric Aluvia® (Lopinavir /Ritonavir 100/25 mg) and Generic Lopinavir/Ritonavir Tablet Formulation (200/50 mg) in Clinically and Virologically Stable HIV-1 Infected Thai Adults||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|July 2009|March 2010|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2010|July 8, 2010|June 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01159275||119504|
NCT01186289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00020165|Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery|Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery||Duke University|Yes|Withdrawn|October 2010|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|50 Years|N/A|No|||February 2011|October 11, 2015|August 19, 2010|Yes|Yes|Principal Investigator decided not to pursue enrollment due to changes in standard of care.|No||https://clinicaltrials.gov/show/NCT01186289||117437|
NCT01186549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12610000610033|The Effect of Combined Ephedrine and Lidocaine Pretreatment on Pain and Hemodynamic Changes Due to Propofol Injection|Title: The Effect of Combined Ephedrine and Lidocaine Pretreatment on Pain Due to Propofol Injection in Patients Undergoing Elective Surgery Under General Anaesthesia||Qazvin University Of Medical Sciences|No|Completed|August 2010|November 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|165|||Both|20 Years|60 Years|No|||October 2012|October 10, 2012|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186549||117417|
NCT01187381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25235|An Observational Study of the Mean Duration of Herceptin (Trastuzumab) Treatment in Patients With Early or Metastatic HER2-positive Breast Cancer (HERODOT)|Multicenter, Single-arm, Observational Study of Mean Duration of Trastuzumab Treatment for Early and Metastatic Breast Cancer in Romanian Population (HERODOT Study)||Hoffmann-La Roche||Active, not recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Female|18 Years|N/A|No|Probability Sample|Female patients with early or metastatic HER2-positive breast cancer|December 2015|December 1, 2015|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01187381||117353|
NCT01187394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009769 01|Plasma Utilization Following Cardiac Surgery|Plasma Utilization Following Cardiac Surgery|PUCS|Ottawa Hospital Research Institute|No|Completed|February 2011|May 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|970|||Both|16 Years|N/A|No|Non-Probability Sample|Patients at six 6 Canadian Centres|May 2012|May 22, 2012|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187394||117352|
NCT01186783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKSH-067|Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine|Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by the "Funny Channel" Current (If) Inhibitor Ivabradine|MODIfY|Martin-Luther-Universität Halle-Wittenberg|Yes|Recruiting|May 2010|May 2012|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||September 2010|September 7, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01186783||117399|
NCT01187056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-41-1446|The RISAP-study: a Complex Intervention in Risk Communication and Shared Decision-making in General Practice|The RISAP-study: a Complex Intervention in Risk Communication and Shared Decision-making in General Practice|RISAP|University of Aarhus|Yes|Completed|November 2007|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|179|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187056||117378|
NCT01187342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSTPSYDIS|Post Stroke Psychological Distress|Depression and Posttraumatic Stress Disorder in Stroke Patients: an Observational Study of Neuro-psychiatric, Cognitive, and MR-Changes Over Time After Stroke|POSTPSYDIS|Charite University, Berlin, Germany|No|Recruiting|October 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Blood|Both|18 Years|85 Years|No|Non-Probability Sample|Adult patients with acute ischemic stroke in MCA/AchA territory within 48 hours of onset|February 2016|February 8, 2016|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01187342||117356|
NCT01187355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-074|Alcon Multi-Purpose Disinfecting Solution Versus Renu Fresh Multi-Purpose Solution in Symptomatic Contact Lens Wearers|SiH MPDS FID 114675A Compared to Renu Fresh MPS in Symptomatic Contact Lens Wearers||Alcon Research|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|591|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|August 20, 2010|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT01187355||117355|
NCT01187641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3370|Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer|Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer||Royal Marsden NHS Foundation Trust|No|Recruiting|August 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|62|||Both|18 Years|N/A|No|Non-Probability Sample|patients with colon cancer|August 2010|August 26, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187641||117333|
NCT01188460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009902|A Cognitive-Behaviour Therapy (CBT) Self-Management Approach for Insomnia in Chronic Pain: A Randomized Control Trial|A Cognitive-Behaviour Therapy (CBT) Self-Management Approach for Insomnia in Chronic Pain: A Randomized Control Trial||Ottawa Hospital Research Institute|No|Completed|April 2010|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01188460||117270|
NCT01188746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-059|Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites|Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188746||117248|
NCT01176253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08078|Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)|Detection of Human Beta Cell Death in T1DM by Methylation Specific PCR||City of Hope Medical Center|Yes|Completed|July 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Type I Diabetic, newly diagnosed, >18 years of age|April 2015|April 29, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176253||118205|
NCT01176539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-00005|Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitor|How Does the New Kai R Spot 100 Respiratory Monitor Compare to the Currently Used Respiratory Monitor for Measuring Respiratory Rate During Overnight Sleep Studies?||Kai Medical, Inc.|No|Completed|March 2010|March 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects at the Sleep Center at Stanford Universoty|June 2011|June 6, 2011|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176539||118183|
NCT01176513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-148-002|GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer|GE148-002: A Phase 2, Open-label, Single-Center, Study to Assess GE-148 (18F) Injection Positron Emission Tomography(PET) Imaging to Detect Localized Prostate Cancer||GE Healthcare|No|Terminated|July 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Male|18 Years|N/A|No|||January 2014|January 21, 2014|August 5, 2010|No|Yes|Lack of Subject enrollment|No|September 20, 2013|https://clinicaltrials.gov/show/NCT01176513||118185|
NCT01176526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910172|The Role of Social Comparisons in Coping and Quality of Life Following a Prostate Cancer Diagnosis|The Role of Social Comparisons in Coping and Quality of Life Following a Prostate Cancer Diagnosis||National Institutes of Health Clinical Center (CC)||Completed|July 2010|January 2016||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|602|||Male|18 Years|70 Years|No|||January 2016|January 28, 2016|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176526||118184|
NCT01161524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-235|A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures||Eisai Inc.|Yes|Active, not recruiting|October 2010|September 2014|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|12 Years|18 Years|No|||February 2014|February 26, 2014|July 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161524||119333|
NCT01161537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX10-770-107|Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation|A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 ≥40% Predicted||Vertex Pharmaceuticals Incorporated|Yes|Completed|October 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|13|||Both|12 Years|N/A|No|||July 2014|July 1, 2014|July 9, 2010|Yes|Yes||No|February 27, 2014|https://clinicaltrials.gov/show/NCT01161537||119332|
NCT01161836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEX11505|An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)|An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi) Administered at Cycle 1 as a 60-minute Intravenous Infusion to Patients With Advanced Solid Tumors Followed by Extended Treatment With BSI-201 With or Without Additional Chemotherapy||Sanofi|No|Completed|July 2010|June 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Both|18 Years|65 Years|No|||September 2013|September 23, 2013|July 12, 2010|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01161836||119309|
NCT01161823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|451/2009|Influence of Nebivolol on Postmenopausal Women|Effect of Nebivolol on Climacteric Disorders in Postmenopausal Women. A Randomized, Open Label Trial||Medical University of Vienna|Yes|Recruiting|January 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Female|N/A|N/A|No|Probability Sample|60 Postmenopausal women|April 2010|January 11, 2016|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01161823||119310|
NCT01157663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/345|The Effect of Balance Training in People With Functional Ankle Instability (FAI)|The Effect of Balance Training in People With Functional Ankle Instability||University Ghent|No|Completed|December 2010|December 2013|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01157663||119626|
NCT01157923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005816ctil|MD Logic Pump Advisor- Adults Study|Evaluation of Automated Insulin Pump Settings Using the MD-Logic Pump Advisor-Adults Sub Study||Rabin Medical Center|No|Active, not recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|135|||Both|18 Years|65 Years|No|||November 2015|November 26, 2015|June 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01157923||119606|
NCT01158976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-190A|Effect of Omega-3 Supplementation During Pregnancy on Regulation of Stress|Impact of Omega-3 Intake During Pregnancy on Maternal Stress and Infant Outcome|NAPS|University of Chicago|Yes|Completed|December 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|66|||Female|20 Years|34 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01158976||119527|
NCT01159288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGR Dex2|Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes|Phase II Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes on Patients With Unresectable Non Small Cell Lung Cancer Responding to Induction Chemotherapy|CSET 1437|Gustave Roussy, Cancer Campus, Grand Paris||Recruiting|December 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|70 Years|No|||July 2010|April 3, 2012|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159288||119503|
NCT01186042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|396-10-FB|Chronic HIV Infection and Aging in NeuroAIDS (CHAIN)|Chronic HIV Infection and Aging in NeuroAIDS (CHAIN)|CHAIN|University of Nebraska|No|Recruiting|August 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|Samples Without DNA|plasma|Both|20 Years|75 Years|No|Non-Probability Sample|University of Nebraska Medical Center HIV Clinic|August 2010|August 19, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01186042||117456|
NCT01186055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811325|Brain Activity and Smoking Cessation|Neural Mechanisms Underlying Smoking Relapse (Center for Interdisciplinary Research on Nicotine Addiction - CIRNA)||University of Pennsylvania|No|Completed|April 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|80|Samples With DNA|1. A 2ml saliva sample for DNA collection & genotyping (Oragene™).        2. A 5ml saliva sample to assess nicotine metabolites (e.g. cotinine and           3-hydroxycotinine).|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|100 treatment seeking smokers ages 18 to 65 who report smoking at least 10 cigarettes per        day for at least the last 6-months.|July 2013|July 11, 2013|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186055||117455|
NCT01186796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003036|Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women|Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women||Mayo Clinic|Yes|Completed|June 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|30|||Female|50 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|August 16, 2010|No|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01186796||117398|Strengths and limitations of the study include the potentially confounding effects of body composition (not studied here except at the level of BMI), underlying physical fitness of subjects, size of the cohort, and the brevity of the study (2 months)
NCT01187069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-41-3065|A Practice-nurse Addressed Intervention to Improve Type 2 Diabetes Care|A Practice-nurse Addressed Intervention to Improve Type 2 Diabetes Care. A Pragmatic Cluster Randomised Controlled Trial in Primary Health Care||University of Aarhus|Yes|Completed|August 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|40 Years|74 Years|No|||August 2012|August 17, 2012|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01187069||117377|
NCT01179165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83FU18-09|Noninvasive Methods in Diagnosing Coronary Heart Disease in Diabetic Patients|Application in High Risk Groups of Recently Developed Noninvasive Methods in Diagnosing Coronary Heart Disease.A Community Based Study.||Norwegian University of Science and Technology|No|Completed|January 2011|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|104|Samples Without DNA|Routine laboratory tests, parameters to caracterize diabetes controle, inflammatory markers.|Both|40 Years|75 Years|No|Non-Probability Sample|Type 2 diabetes without known cardiac disease between 40 and 75 years of age|February 2014|February 27, 2014|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01179165||117982|
NCT01187654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Heart-002|Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient|Comparison the Therapeutic Outcomes of Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Patient With Acute Myocardial Infarction Underwent PCI Procedure||Royan Institute|Yes|Completed|May 2009|December 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|75 Years|No|||August 2010|December 25, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01187654||117332|
NCT01187888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08P02|Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)|PROSPERA|Ludwig-Maximilians - University of Munich|Yes|Terminated|January 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|80 Years|No|||April 2013|April 23, 2013|August 20, 2010||No|IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available    for the study(pre-treatm.with Rasagiline=exclusion criterion|No||https://clinicaltrials.gov/show/NCT01187888||117314|
NCT01187901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00039278|A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients|Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients|FAPEST|University of Utah|Yes|Active, not recruiting|April 2010|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|69 Years|No|||June 2014|June 20, 2014|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187901||117313|
NCT01188174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 09/6-C|Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure|Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure|setric|Nantes University Hospital|Yes|Completed|July 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|55 Years|No|||December 2014|December 4, 2014|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01188174||117292|
NCT01188187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGX-011-11|Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer|A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer|SYNERGY|Teva Pharmaceutical Industries||Completed|October 2010|April 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1023|||Male|18 Years|N/A|No|||April 2014|April 28, 2014|August 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188187||117291|
NCT01188200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK79|Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes|Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes||Abbott Nutrition|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||July 2010|August 24, 2010|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188200||117290|
NCT01188473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAS-SIU-10-005|Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus|Safety and Efficacy of Early Initiation of Noninvasive Positive Pressure Ventilation in Pediatric Patients Admitted With Status Asthmaticus||Southern Illinois University|No|Withdrawn|January 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|18 Years|No|||December 2014|December 18, 2014|August 23, 2010||No|Pilot early noninvasive ventilation on all children who met the criteria was effective.|No||https://clinicaltrials.gov/show/NCT01188473||117269|
NCT01175967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1015|Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer|Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|June 2010|May 2015|Actual|May 2015|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Female|65 Years|N/A|No|Non-Probability Sample|Patients who undergo surgery for presumed ovarian cancer, and those diagnosed with ovarian        cancer who undergo surgery and chemotherapy treatment|October 2015|October 9, 2015|August 4, 2010||No|Unable to meet accrual due to changing practice patters|No||https://clinicaltrials.gov/show/NCT01175967||118227|
NCT01176864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERK-2|Double- Versus Single-balloon Enteroscopy for Obscure Small-bowel Bleeding|Prospective Trial Comparing Push-and-Pull Enteroscopy With the Single- and Double-Balloon Techniques in Patients With Obscure Small-Bowel Bleeding|DBE;SBE|Shanghai Changzheng Hospital|Yes|Enrolling by invitation|July 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|16 Years|70 Years|No|||July 2010|August 5, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01176864||118158|
NCT01177111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD060712|Impact of Sunflower Seed Oil Massage on Neonatal Mortality and Morbidity in Nepal|Impact of Sunflower Seed Oil Massage on Neonatal Mortality and Morbidity in Nepal|NOMS|Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|November 2010|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|29260|||Both|N/A|28 Days|Accepts Healthy Volunteers|||April 2015|April 15, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177111||118139|
NCT01176552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1114-6557|Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer|Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma||Kidney Cancer Research Bureau|Yes|Completed|May 2004|May 2010|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|80 Years|No|||August 2010|August 22, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01176552||118182|
NCT01158170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH06|Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)|A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001)||Zhejiang Cancer Hospital|Yes|Recruiting|June 2010|December 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|75 Years|No|||July 2010|July 6, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01158170||119587|
NCT01158443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH090843|Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS|Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS||Research Foundation for Mental Hygiene, Inc.|Yes|Completed|July 2010|March 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|70 Years|No|||March 2014|March 12, 2014|July 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01158443||119566|
NCT01158716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.7.7.2010|Remote Ischemic Preconditioning in ad Hoc Percutaneous Coronary Interventions|Remote Ischemic Preconditioning in ad Hoc Percutaneous Coronary Interventions: a Randomized Clinical Study||Cardiovascular Research Society, Greece|Yes|Completed|July 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|85 Years|No|||March 2014|March 1, 2014|July 7, 2010||No||No|March 1, 2014|https://clinicaltrials.gov/show/NCT01158716||119546|
NCT01158989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PillCam|Clinical Evaluation Gastrointestinal Motility With PillCam|Clinical Evaluation of Endoscopic Video Capsule for Investigation of Small Intestine Transit Time and Intestinal Pathology in Critically Ill Patients||University of Louisville|No|Completed|May 2006|June 2008|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|16|||Both|18 Years|70 Years|No|Non-Probability Sample|Critically ill patients (i.e., all were intubated, mechanically ventilated and sedated)        and healthy patients scheduled for an outpatient procedure.|July 2010|July 7, 2010|July 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01158989||119526|
NCT01164410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 09-378|The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children|The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children||The Cleveland Clinic|No|Completed|August 2009|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|5 Years|21 Years|No|Non-Probability Sample|Forty-five patients undergoing colonoscopy in the Department of Pediatric Gastroenterology        at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.|July 2010|July 15, 2010|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164410||119111|
NCT01186562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006M83756|Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant|A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|August 2010|June 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186562||117416|
NCT01186809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract number: 2008-003185-26|Cytokine Induced Killer (CIK) Cells In Leukemia Patients|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)Cells After Allogeneic Stem Cell Transplantation|CIK2|A.O. Ospedale Papa Giovanni XXIII|Yes|Recruiting|July 2009|September 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||April 2015|April 20, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01186809||117397|
NCT01186822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF6mo|A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease|A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease.||Medical Acoustics LLC|No|Completed|September 2010|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|30 Years|80 Years|No|||January 2015|January 29, 2015|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186822||117396|
NCT01187082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLATRA 01|Grouptraining for Overactive Bladder in Adults|A Clinical, Randomized, Comparative, Non-blinded Study on the Effect of Bladdertraining in Groups Compared to Individual Bladdertraining for Female Patients With Overactive Bladder.||University of Aarhus|No|Completed|December 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|91|||Female|18 Years|N/A|No|||February 2011|March 9, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01187082||117376|
NCT01187095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWI-2008-41-1869|Involuntary Childlessness and Stress Management|A Randomized Controlled Intervention Study: The Effect of Expressive Writing on Psychosocial Stress and Pregnancy Results With Couples Undergoing In Vitro Fertility(IVF) Treatment Due to Involuntary Childlessness.||University of Aarhus|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|298|||Both|18 Years|45 Years|No|||February 2013|February 27, 2013|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01187095||117375|
NCT01179438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003036M|Effect of Dexmedetomidine on Microcirculation in Patients Undergoing Extracorporeal Shock Wave Lithotripsy|Effect of Dexmedetomidine on Microcirculation in Patients Undergoing Extracorporeal Shock Wave Lithotripsy||National Taiwan University Hospital||Withdrawn|August 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2010|December 6, 2012|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179438||117961|
NCT01187667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/May|Evaluation of Delirium Prevention in Critically Ill Patients|Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium||Radboud University|No|Completed|August 2010|October 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|650|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted in the ICU of a tertiary care clinic|August 2012|August 9, 2012|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187667||117331|
NCT01187680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-RTB-0002|Efficacy of Sprayable PEG Barrier in Gynecologic Laparoscopy|Polyethylene Glycol Adhesion Barrier Reduces Adhesions After Gynecologic Laparoscopy; a Prospective Randomized Controlled Pilot Study||Radboud University|No|Terminated|October 2002|July 2009|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|40 Years|No|||August 2010|December 28, 2010|July 19, 2010||No|Financial and organisational reasons|No||https://clinicaltrials.gov/show/NCT01187680||117330|
NCT01187914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00042859|Effect of Structural Remodeling on Scar Formation as Assessed by DE-MRI of the Left Atrium|RADAR: Effect of Structural Remodeling on Scar Formation as Assessed by DE-MRI of the Left Atrium Following Open-Irrigation Cooled-Tip Radiofrequency Catheter Ablation of Paroxysmal Atrial Fibrillation|RADAR|University of Utah|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40|||Both|18 Years|89 Years|No|Non-Probability Sample|Forty patients ages 18-89 years, who have had an open irrigation cooled-tipped RF ablation        procedure for PAF. Patients must participate in 3-, 6-, and 12-months follow-up post        ablation. PAF is defined by >2 documented episodes of AF that terminate spontaneously        within 7 days. AF has to be documented by means of electrocardiography, holter monitor,        loop recorder, or echocardiography.|February 2012|February 9, 2012|August 3, 2010||No||No|September 23, 2011|https://clinicaltrials.gov/show/NCT01187914||117312|The sample size was too small to see any significant relationship.
NCT01187927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114332|Drug Use Investigation for Cervarix®|Drug Use Investigation for Cervarix®||GlaxoSmithKline|No|Completed|September 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1230|||Female|10 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Japanese women who received Cervarix® for the first time|January 2015|January 22, 2015|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01187927||117311|
NCT01188213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/05|Efficacy of Methylsulfonylmethane Supplementation on Osteoarthritis of The Knee: A Randomized Controlled Study|||Assaf-Harofeh Medical Center|No|Completed||||||N/A|Interventional|N/A|1||||||Both|40 Years|70 Years||||May 2005|August 24, 2010|August 21, 2010||||No||https://clinicaltrials.gov/show/NCT01188213||117289|
NCT01188226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101960|Wear Characteristics of Denture Teeth|Evaluation of Wear Characteristics of Nano-Hybrid Denture Teeth||University of California, Los Angeles|No|Enrolling by invitation|August 2010|||December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|85 Years|No|||August 2010|August 24, 2010|August 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188226||117288|
NCT01175720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lga030183|Clinical Comparison Between Two Surgical Techniques for the Treatment of Gingival Recessions|Clinical Comparison Between Two Surgical Techniques With Acellular Dermal Matrix Graft in the Treatment of Gingival Recessions||University of Sao Paulo|No|Completed|August 2010|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 11, 2011|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175720||118246|
NCT01175733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080686|Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer|Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer|Vectibix|VU University Medical Center|No|Active, not recruiting|July 2010|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175733||118245|
NCT01176565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207M17921|Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)|Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)|ATACH-II|University of Minnesota - Clinical and Translational Science Institute|Yes|Suspended|January 2011|July 2017|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1280|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|August 4, 2010||No|Pre-planned interim analysis.|No||https://clinicaltrials.gov/show/NCT01176565||118181|
NCT01176578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047188|Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes|Exercise Training, CACs, and Vascular Function in Older Veterans With IGT (Impaired Glucose Tolerance)|EPC-DM|Baltimore VA Medical Center|Yes|Recruiting|July 2011|||September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|70|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176578||118180|
NCT01177449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-1825B|The Effect of Prolotherapy on Balance and Lumbar Flexibility in the Patients With a Sacralized L5 Vertebra|The Effect of Prolotherapy on Balance and Lumbar Flexibility in the Patients With a Sacralized L5 Vertebra||Chang Gung Memorial Hospital|No|Completed|April 2008|August 2010|Actual|November 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|16 Years|50 Years|No|||August 2010|August 5, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177449||118113|
NCT01177124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA131080-01A2|Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors|Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors||University of South Florida|Yes|Completed|February 2009|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|300|||Female|21 Years|N/A|No|||February 2014|February 25, 2014|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177124||118138|
NCT01177137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DC007422|Tinnitus Retraining Therapy Trial|Tinnitus Retraining Therapy Trial|TRTT|Johns Hopkins Bloomberg School of Public Health|Yes|Active, not recruiting|July 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|228|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177137||118137|
NCT01158196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-200-M/keloid project|Safety and Efficacy of Infrared Diode Laser on Improvement of Scar and Prevention of Recurrence of Excised Keloid|Effect of Infra-red Diode Laser on Improvement of Surgical Scar and on the Prevention of Excised Keloids Recurrence-Pilot Study||Ekkyo|No|Recruiting|June 2010|June 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|70 Years|No|||July 2010|July 7, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158196||119585|
NCT01158456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P01CA138338|Metabolism of NNK Among African Americans|Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking: Project 5: Metabolism of NNK Among African Americans|Project 5|University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|December 2010|March 2015|Anticipated|November 2014|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Venous blood sample (approximately 40 ml) will be drawn from each study participant at the      baseline visit. Approximately 33 ml will be used immediately for the study, and the      remaining two 3-ml volumes will be reserved for future use. The various components of the      blood including buffy coat (white blood cells), red blood cells, plasma, and serum will be      separated immediately after their collection, labelled using a unique subject number, and      stored in a -80C freezer. Urine samples and oral cells will be collected from study subjects      at various time points. All these samples will be labelled using a unique subject number,      and stored at a -80C freezer.|Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be classified as African American if they report themselves, biological        parents and both sets of biological grandparents as African American or African descent.        Similar criteria will be applied to European Americans (e.g., self, both parents and four        grandparents of European American or European descent). Subjects will be evenly divided by        gender.|October 2013|October 17, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158456||119565|
NCT01158729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped-ATIII CPB 001|Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates|Antithrombin III Supplementation Prior to Cardiopulmonary Bypass for Neonates||Medical College of Wisconsin|Yes|Terminated|August 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|8|||Both|N/A|30 Days|No|||January 2014|January 16, 2014|June 17, 2010|No|Yes|Grant funding expired, poor patient enrollment|No||https://clinicaltrials.gov/show/NCT01158729||119545|
NCT01163864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q607|Affect Regulation Training for Pregnant Smokers|Affect Regulation Training for Pregnant Smokers||State University of New York at Buffalo|Yes|Recruiting|September 2007|November 2011|Anticipated|November 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2011|March 7, 2011|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01163864||119153|
NCT01164150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 09-06|Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06|Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer|ICORG 09-06|ICORG- All Ireland Cooperative Oncology Research Group||Suspended|March 2010|December 2033|Anticipated|December 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164150||119131|
NCT01164423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0905|Feasibility of Blood Glucose Control With the Space TGC System in Medical ICU Patients|Monocentric, Open Study to Investigate the Feasibility of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) in Medical ICU Patients|DELIOS 01|B. Braun Melsungen AG|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2011|February 8, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164423||119110|
NCT01186575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38465-E/G|Text Messaging to Improve Adherence to Clinic Visits and Reduce Early Resumption of Sexual Intercourse After Male Circumcision|Text Messaging to Improve Adherence to Post-Operative Clinic Appointments and Reduce Early Resumption of Sexual Intercourse After Adult Male Circumcision: A Randomized Controlled Trial||University of Washington|No|Completed|August 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1200|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 15, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186575||117415|
NCT01186588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017227|A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function|An Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of 300 mg JNJ-28431754 (Canagliflozin) in Subjects With Various Degrees of Impaired Hepatic Function Compared With Subjects With Normal Hepatic Function||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 27, 2013|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186588||117414|
NCT01178645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BuEAM-BCL except for DLBCL|Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma|Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma||Seoul National University Hospital|No|Recruiting|July 2010|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|15 Years|65 Years|No|||August 2014|August 22, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01178645||118022|
NCT01178879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNRS-20100030-2|Randomised Trial of Telehealth Consultations for Nursing Care of Chronic Obstructive Pulmonary Disease (COPD) Patients|Effectiveness of Nurse Lead Telehealth Consultations in Patients With Chronic Obstructive Pulmonary Disease (COPD)||University of Southern Denmark|No|Completed|May 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|40 Years|N/A|No|||June 2013|June 27, 2013|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178879||118004|
NCT01179152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hermanasthma|Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic|Childhood Asthma and Return to School: the September Epidemic Exacerbation in Israel.A Controlled Trial of the Effectiveness of Preventive Treatment With Symbicort or Budicort Turbuhaler||Meir Medical Center|No|Recruiting|September 2010|October 2012|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|225|||Both|6 Years|18 Years|No|||March 2012|March 16, 2012|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179152||117983|
NCT01175460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH08|S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer|Phase I Study of S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer||Zhejiang Cancer Hospital|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|70 Years|No|||March 2012|March 4, 2012|July 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175460||118266|
NCT01179425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR# 19292|Sex Differences in Attentional Bias in Marijuana-dependent Individuals|Sex Differences in Attentional Bias and Cognitive Functioning in Response to Stress in Marijuana-dependent Individuals||Medical University of South Carolina|No|Completed|August 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 13, 2011|November 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01179425||117962|
NCT01179737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107X2201|Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)|A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)||Novartis|Yes|Terminated|July 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|August 3, 2010|Yes|Yes|Study was terminated due to serious adverse event (SAE)|No|January 14, 2014|https://clinicaltrials.gov/show/NCT01179737||117938|
NCT01175434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32479|School-Based Preventive Asthma Care Technology: A Trial Using a Novel Technology to Improve Adherence|School-Based Preventive Asthma Care Technology: A Randomized Control Trial Using a Novel Technology to Improve Adherence|SB-PACT|University of Rochester|No|Completed|August 2010|August 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|3 Years|10 Years|No|||December 2013|December 31, 2013|April 16, 2010||No||No|January 14, 2013|https://clinicaltrials.gov/show/NCT01175434||118268|
NCT01176006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100174|Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency|Related and Unrelated Donor Hematopoietic Stem Cell Transplant of DOCK8 Deficiency||National Institutes of Health Clinical Center (CC)||Recruiting|July 2010|December 2022|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|80|||Both|6 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|August 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176006||118224|
NCT01176266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-010-10|Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)|An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)||Alexion Pharma GmbH|Yes|Active, not recruiting|July 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|N/A|5 Years|No|||March 2016|March 14, 2016|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176266||118204|
NCT01176604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0770|Humanitarian Device Exemption (HDE) Treatment Protocol|Protocol For Use of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma||M.D. Anderson Cancer Center|No|Recruiting|August 2010|||August 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176604||118178|
NCT01177150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012454|A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers|A First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of JNJ 28431754 in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 10, 2010|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01177150||118136|
NCT01177462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG590021G|Transformation of Somatosensory and Visual Coordinate Systems|The Transformation of Coordinates Between Somatosensory and Visual Systems: a Neurophysiological Study||Chang Gung Memorial Hospital|Yes|Recruiting|March 2011|||December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit 40 normal healthy adult subjects (equal to and more than 18 years old);        the exclusion criteria are subjects with brain pathology, peripheral neuropathy and limb        amputation. We will also recruit 50 stroke patients, the including criteria are stroke        patients with stable medical condition and being capable of receiving the evaluations. In        this group, stroke patients with peripheral neuropathy, and unstable medical condition.|September 2013|September 23, 2013|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01177462||118112|
NCT01177735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2010-01|Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma|Phase II Trial of Pomalidomide in GEP-defined High-risk Multiple Myeloma That is Relapsing or Refractory to Prior Therapy||University of Arkansas|Yes|Completed|October 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|May 14, 2010|Yes|Yes||No|November 25, 2014|https://clinicaltrials.gov/show/NCT01177735||118091|
NCT01163331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000338/1|Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing Therapy for PD-related Voice/Speech Impairment|Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing|SING-PD|Beth Israel Deaconess Medical Center|No|Completed|March 2010|||August 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|30 Years|80 Years|No|||June 2011|June 20, 2011|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163331||119194|
NCT01163617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-088|The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients|A Multicenter, Randomized, Open-Label Study of the Injection Time and Usability of the Physiolis Syringe and Autoinjector in Injection-Experienced Rheumatoid Arthritis Patients||AbbVie|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|8||Actual|85|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|May 4, 2010|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01163617||119172|
NCT01163877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-2009-N-19|Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma|Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma.||Swiss Federal Institute of Technology|No|Completed|April 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|43|||Both|12 Years|16 Years|No|||October 2013|October 11, 2013|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163877||119152|
NCT01164163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1011|INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease|A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms||Children's Oncology Group|Yes|Completed|September 2010|||October 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|1 Year|21 Years|No|||October 2014|October 22, 2014|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164163||119130|
NCT01160835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561705022|Comparison of Quadriceps-sparing Minimally Invasive and Medial Parapatellar Total Knee Arthroplasty|Comparison of Quadriceps-sparing Minimally Invasive and Medial Parapatellar Total Knee Arthroplasty||National Taiwan University Hospital|No|Completed|May 2005|November 2007|Actual|February 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|30 Years|90 Years|No|||June 2010|July 9, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01160835||119386|
NCT01160848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC TA205/10|Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients|A Clinical Study of Photoactive Porphyrins (PAP) Levels in Acne-affected Skin After Topical Visonac Application in Patients With Moderate to Severe Facial Acne Vulgaris||Photocure|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|12 Years|35 Years|No|||April 2014|April 22, 2014|July 8, 2010|Yes|Yes||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01160848||119385|
NCT01178307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0267|Symptom Inventory for Gastrointestinal Stromal Tumors|Symptom Burden in Patients With Gastrointestinal Stromal Tumors (GISTs)||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2010|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|188|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|UT MD Anderson Cancer Center Sarcoma and Surgical Oncology Clinics GIST Patients, their        caregivers, doctors and nurses who are 18 years or older.|February 2016|February 18, 2016|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01178307||118048|
NCT01178892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MsFLASH-02|MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation|MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation||Fred Hutchinson Cancer Research Center|Yes|Completed|November 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|355|||Female|40 Years|62 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178892||118003|
NCT01179178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGOTTriad|A Dangerous Triad in Ageing and in Chronic Obstructive Pulmonary Disease (COPD) - Reduced Muscle Mass, Impaired Muscle Function and Malnutrition|A Dangerous Triad in Ageing and in COPD - Reduced Muscle Mass, Impaired Muscle Function and Malnutrition||Göteborg University|No|Completed|March 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|65 Years|81 Years|Accepts Healthy Volunteers|Probability Sample|Outpatients (COPD) and older adults living in Gothenburg|January 2006|August 10, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179178||117981|
NCT01175785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2378.00|Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies|Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|August 2010|||August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|6 Months|45 Years|No|||October 2015|October 30, 2015|August 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175785||118241|
NCT01185015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200101-500|A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization|A Clinical Trial to Assess the Efficacy of Sigmart in Patients With Recurrent Angina After Coronary Revascularization|SIGMART|Merck KGaA||Withdrawn|January 2011|||January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||July 2012|July 1, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01185015||117534|
NCT01179750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-089|The Use of Ultrasonic Coagulating Shears Compared to Monopolar Electrocautery in Open Gastric Cancer Surgery|The Use of Ultrasonic Coagulating Shears Compared to Monopolar Electrocautery in Open Gastric Cancer Surgery||Samsung Medical Center|No|Recruiting|January 2010|June 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|256|||Both|20 Years|75 Years|No|||December 2010|December 14, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01179750||117937|
NCT01175447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH07|S-1 and Radiotherapy in Elderly Patients With Esophageal Cancer|A Phase I Study of S-1 With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer||Zhejiang Cancer Hospital|Yes|Completed|February 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|70 Years|85 Years|No|||March 2012|March 4, 2012|July 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175447||118267|
NCT01175746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2009-0196|The Effect of Nicardipine on Kidney Function During Orthognathic Surgery Under Hypotensive Anesthesia|||Yonsei University|Yes|Completed|August 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|46|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 11, 2013|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175746||118244|
NCT01175759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34/2009|Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss|Evaluation of the Efficacy and Safety of the EVE- Skin-Test Panel in Detecting Sensitivity to Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss||EVE Medical Systems Ltd.||Recruiting|June 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||June 2010|August 4, 2010|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01175759||118243|
NCT01175980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02981|Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma|A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)||National Cancer Institute (NCI)||Active, not recruiting|August 2010|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175980||118226|
NCT01175993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100150|Effects of Rapid-Resisted Exercise and Bright Light Therapy on Ambulatory Adults With Traumatic Brain Injury|Effects of Rapid-Resisted Exercise on Ambulatory Adults With Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Completed|June 2010|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|44 Years|No|||December 2015|December 30, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01175993||118225|
NCT01176877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU32316|Assessing and Improving Patient Knowledge About Keloid Scars (Keloids)|Assessing and Improving Patient Knowledge About Keloids||Northwestern University|No|Completed|August 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|July 30, 2010||No||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01176877||118157|limitation of the study is the accrual of a majority of participants from keloid patients at a single academic center.
NCT01177163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014881|A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Type-2 Diabetes Mellitus Subjects Not Optimally Controlled (A1C >=7.0%) on Fixed Doses of Insulin Therapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|May 2008|March 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|65 Years|No|||May 2013|May 27, 2013|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01177163||118135|
NCT01177176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1HL099668|Smoking Interventions for Hospital Patients|Smoking Interventions for Hospital Patients: A Comparative Effectiveness Trial|Helping HAND|Massachusetts General Hospital|No|Completed|July 2010|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|397|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01177176||118134|
NCT01186393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715352|STUDY: Effects of Potatoes in a Weight Loss Program|CCRC: Assessing the Role of Glycemic Index in Body Weight Management and Glucose Control|BBFUSPB|University of California, Davis|No|Completed|May 2007|March 2014|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186393||117429|
NCT01177748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-ER-SAMBA|Stroke Arrhythmia Monitoring Database||SAMBA|University of Erlangen-Nürnberg Medical School|No|Completed|June 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|501|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from acute cerebral injury treated on a specialized Stroke Unit|March 2012|March 30, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177748||118090|
NCT01177761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFZ-EFOPS16|16 Year Follow-up of the Erlangen Fitness and Prevention Study.|Effects of Exercise on Fracture Risk, Bone Mineral Density and Falls in Postmenopausal Women. A 16 Year Follow-up of the Erlangen Fitness and Prevention Study.|EFOPS|University of Erlangen-Nürnberg Medical School|No|Active, not recruiting|October 1998|December 2023|Anticipated|December 2023|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|48 Years|N/A|No|||May 2015|May 27, 2015|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177761||118089|
NCT01163344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000029|Dance Exercise as Novel Complementary Therapy for Parkinson's Disease|Dance Exercise as Novel Complementary Therapy for Parkinson's Disease|DANCE-PD|Beth Israel Deaconess Medical Center|No|Active, not recruiting|July 2010|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|40 Years|79 Years|No|Probability Sample|To qualify for this study, subject must have been diagnosed with Parkinson's Disease for 3        years or more, be less than 80 years of age, and have problems with gait and balance|November 2015|November 17, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163344||119193|
NCT01163357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09171|Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma|Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma||City of Hope Medical Center|Yes|Recruiting|January 2011|||November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|27|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|July 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01163357||119192|
NCT01163630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00009|Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg|A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination Capsule of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg||AstraZeneca|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|July 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01163630||119171|
NCT01163890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG033125-01A1|Preventing Mid- and Later-Life Work Limitations|Preventing Mid- and Later-Life Work Limitations: Community-Based Depression Care||Tufts Medical Center|No|Completed|September 2009|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|431|||Both|45 Years|N/A|No|||April 2014|April 7, 2014|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163890||119151|
NCT01163903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP-IT-01|Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours|A Phase I Study Evaluating the Proton Pump Inhibitor Pantoprazole in Combination With Doxorubicin for Advanced Cancer Patients With an Extension Cohort of Patients With Solid Tumours||University Health Network, Toronto|Yes|Completed|July 2010|May 2015|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01163903||119150|
NCT01164436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-AO0258-45|Cohort of HIV Associated Lymphomas|French Cohort of HIV Associated Lymphomas|ANRS CO16|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Active, not recruiting|June 2008|December 2017|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|65 Years|No|Non-Probability Sample|The recruitment of 80 cases per year is expected. The length of inclusions is 5 years. The        follow-up will be of 5 years. Clinical, pathological and biological data at diagnosis and        during follow-up will be collected. This will allow characterizing the lymphoma, the HIV        infection, the antitumoral treatments and the outcome of lymphoma. Biological samples will        be centralized to collect cell, DNA, RNA, plasma, serum and tumour collection.|September 2015|September 29, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01164436||119109|
NCT01164722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-076|Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia|A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults||AIDS Malignancy Consortium|Yes|Active, not recruiting|April 2011|July 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|27 Years|N/A|No|||October 2015|October 1, 2015|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164722||119087|
NCT01160549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910152|Study of Pregnancy Hormone Concentrations in Urban and Nomadic Mongolian Women|Study of Pregnancy Hormone Concentrations in Urban and Nomadic Mongolian Women||National Institutes of Health Clinical Center (CC)||Completed|June 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|50 Years|No|||January 2016|February 18, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160549||119408|
NCT01178320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|627|Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)|Carotid Plaque Characteristics by MRI in AIM-HIGH||University of Washington|Yes|Completed|March 2008|February 2015|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|230|||Both|45 Years|N/A|No|Probability Sample|Participants in the main AIM-HIGH study (NCT00120289)|December 2015|December 1, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01178320||118047|
NCT01178658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BuEAM-NK/T|Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma|Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With T Cell or NK Cell Lymphoma||Seoul National University Hospital|No|Recruiting|July 2010|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|15 Years|65 Years|No|||August 2014|August 22, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01178658||118021|
NCT01179191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-01-10-4003|Conversion to Embeda With Rescue Trial|A Multi-Center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion|ConvERT|Pfizer|No|Terminated|August 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|684|||Both|21 Years|N/A|No|||October 2012|October 9, 2012|July 30, 2010|Yes|Yes|See termination reason in detailed description.|No|July 30, 2012|https://clinicaltrials.gov/show/NCT01179191||117980|The study was prematurely terminated due to drug supply issues.
NCT01179451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10040-10CTIL|Late Cardial Assessment in Children Who Were Diagnosed With Post Streptococcal Reactive Arthritis - a Long Term Study|Late Cardial Assessment in Children Who Were Diagnosed With Post Streptococcal Reactive Arthritis - a Long Term Study||Meir Medical Center||Completed|September 2010|August 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|146|||Both|N/A|18 Years|No|Non-Probability Sample|out patient rheumatology clinic|March 2012|February 19, 2013|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179451||117960|
NCT01175213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160902|Tolerability and Safety of Immune Globulin Subcutaneous Solution and rHuPH20 in Primary Immunodeficiency Diseases (PID)|Long-Term Tolerability and Safety of Immune Globulin Subcutaneous (IGSC)Solution Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases||Baxter Healthcare Corporation|No|Completed|July 2010|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|4 Years|N/A|No|||September 2014|September 15, 2014|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175213||118285|
NCT01185028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100183|A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures|An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders||National Institutes of Health Clinical Center (CC)||Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|August 18, 2010||No||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01185028||117533|
NCT01185041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF02032|Watermelon Supplementation and Arterial Stiffness|Effects of Oral L-citrulline/L-arginine in Watermelon on Central Blood Pressure and Arterial Stiffness in Individuals With Obesity-related High Blood Pressure||Florida State University|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|45 Years|70 Years|No|||March 2012|March 17, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01185041||117532|
NCT01175772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0082-09-EMC|Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy|Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy With Metronomic/Oral Chemotherapy (Cytophosphan Combined With Low-dose Methotrexate)and COX-2 Inhibition (Celecoxib)||HaEmek Medical Center, Israel|Yes|Terminated|August 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|20 Years|80 Years|No|||June 2015|June 21, 2015|August 1, 2010||No|Due to change in the national policy of medications|No||https://clinicaltrials.gov/show/NCT01175772||118242|
NCT01176019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-291|An Interactive Informed Consent and Education Program for Pregnant Women|An Interactive Informed Consent and Education Program for Pregnant Women||Northwestern University|Yes|Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 5, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01176019||118223|
NCT01176279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGLIC-2007-03|Arterial Catheter to Monitor Glycemia|Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels|CAT-GLIC|Consorci Hospitalari de Vic|Yes|Recruiting|April 2008|December 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2010|August 5, 2010|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176279||118203|
NCT01176591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811184|HBPL Study of the Impact of the NK1 Antagonist Aprepitant|Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving||University of Pennsylvania|Yes|Terminated|September 2010|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|60 Years|No|||April 2014|April 2, 2014|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176591||118179|
NCT01176890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Truncated mealtest (AP)|Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects|The Significance of Intact Vagal Innervation for the GLP-1 Induced Inhibition of Gastric Emptying, Appetite and Food Intake||University Hospital, Gentofte, Copenhagen|No|Active, not recruiting|July 2008|December 2012|Anticipated|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 6, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176890||118156|
NCT01186159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COX-2|The Correlation of COX-2 Expression in Human Polymorphonuclear Leukocytes/Macrophages (PMNL/MP) and Postoperative Pain|The Correlation of COX-2 Expression in Human Polymorphonuclear Leukocytes/Macrophages and Postoperative Pain||Huazhong University of Science and Technology|Yes|Completed|November 2010|September 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|90|||Both|20 Years|55 Years|No|||April 2015|April 16, 2015|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186159||117447|
NCT01186666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080703|Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease|BIOmarkers of CORonary Events-2 : Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease|BIOCORE-2|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2010|August 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|85|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01186666||117408|
NCT01186653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcadMedCTU030406|Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)|Effect of High Dose Inhaled Budesonide and Fluticasone on Adrenal Function in Patients With Moderate to Severe COPD||Hull and East Yorkshire Hospitals NHS Trust|No|Completed|October 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|85 Years|No|||August 2010|September 3, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186653||117409|
NCT01163643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|637|Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome|A Randomized, Double-Masked, Parallel-Group, Vehicle Controlled, Multicenter, Exploratory Study Assessing the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome||Bausch & Lomb Incorporated|No|Completed|July 2010|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|350|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163643||119170|
NCT01163916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-272|Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care|A Multi-Center Post Marketing Observational Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed HUMIRA® (Adalimumab) as Part of Routine Clinical Care in Russia||Abbott|No|Completed|January 2008|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|252|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis        prescribed adalimumab as part of Routine Clinical Care in Russia.|December 2012|December 5, 2012|February 26, 2010||No||No|November 8, 2012|https://clinicaltrials.gov/show/NCT01163916||119149|
NCT01164176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0542|Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer|An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer||Yonsei University|No|Completed|March 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2014|November 26, 2014|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164176||119129|
NCT01164189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26091|Bevacizumab in Recurrent Grade II and III Glioma|Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial|TAVAREC|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Active, not recruiting|February 2011|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164189||119128|
NCT01160224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114312|Oral GW766944 (Oral CCR3 Antagonist)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare GW766944 (an Oral CCR3 Receptor Antagonist) Versus Placebo in Patients With Asthma and Sputum Eosinophilia.||GlaxoSmithKline|No|Completed|September 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|75 Years|No|||April 2012|April 5, 2012|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01160224||119432|
NCT01161641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX-ODSH-2009-PLE|Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery|" An Open Label Pilot Study Evaluating Safety and Evidence of Therapeutic Effect of IV Admin of 2-0, 3-0 Desulfated Heparin, Treatment of Exacerbation of Protein Losing Enteropathy (PLE) Associated With Single Ventricle Palliative Surgery"||Cantex Pharmaceticals|No|Terminated|July 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|6 Years|N/A|No|||August 2015|August 5, 2015|July 9, 2010|No|Yes|Extremely slow accural due to rarity of medical condition studied.|No||https://clinicaltrials.gov/show/NCT01161641||119324|
NCT01161654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARA-T25-PVFD-1|Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|August 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2010|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161654||119323|
NCT01178905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM CMV inactivation|Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants|Clinical Evaluation of a Gentle But Safe Ultrashort-term Heat Inactivation Procedure of Raw Breast Milk (BM) Containing Virulent Cytomegalovirus for Preventing CMV-infection of Preterm Infants||University Hospital Tuebingen|No|Completed|August 2010|||October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Prevention|1||||||Both|23 Weeks|40 Weeks||||February 2013|April 23, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01178905||118002|
NCT01178918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOPA-H1N1-01|Non-specific Response to H1N1 Vaccine|Enhanced Non-Specific T Lymphocytes Response to Influenza A (H1N1) AS03-Adjuvanted Vaccine||The University Clinic of Pulmonary and Allergic Diseases Golnik|No|Active, not recruiting|November 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers from consecutive recipients of H1N1 influenza vaccine at the University        Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.|August 2010|August 9, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01178918||118001|
NCT01175226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA798-202|A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection|RHINO|Biota Scientific Management Pty Ltd|Yes|Completed|August 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|70 Years|No|||September 2013|September 12, 2013|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175226||118284|
NCT01175239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06MI10|Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)|Gene Therapy for SCID-X1 Using a Self-inactivating (SIN) Gammaretroviral Vector||Great Ormond Street Hospital for Children NHS Foundation Trust||Recruiting|April 2011|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|N/A|16 Years|No|||September 2015|September 11, 2015|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01175239||118283|
NCT01175473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY10931|Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes|An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin||Sanofi|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|74 Years|No|||April 2014|April 9, 2014|August 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175473||118265|
NCT01175486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201004014IA|Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy|The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy||Taipei Veterans General Hospital, Taiwan|No|Recruiting|July 2010|December 2015|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|30 Years|80 Years|No|||June 2010|January 4, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01175486||118264|
NCT01184703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-project_1|Low Glycemic Index Diet in Patients With Type 1 Diabetes|Effects of a Low Glycemic Index Diet on HbA1c and Lipids in Patients With Type I Diabetes|LGID1|Steno Diabetes Center|No|Completed|June 2007|December 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|65|||Both|20 Years|65 Years|No|||August 2010|September 2, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184703||117558|
NCT01176032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AES02|ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling|The "ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK)" Study|ALLMARK|Novartis||Completed|June 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|75 Years|No|||July 2014|July 22, 2014|August 2, 2010|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01176032||118222|
NCT01185314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00086|To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|A Molecular Epidemiology Study in Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) of Adeno Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status|PIONEER|AstraZeneca|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1270|||Both|20 Years|N/A|No|||August 2011|August 5, 2011|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01185314||117512|
NCT01176292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2010-0104|Comparison of High Flex and Standard Rotating Platform Total Knee Arthroplasty (TKA)|A Prospective Comparison of Rotating Platform Cruciate Substituting Total Knee Arthroplasty With Rotating Platform High-Flex Cruciate Substituting Total Knee Arthroplasty||Anderson Orthopaedic Research Institute|No|Completed|August 2007|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|142|||Both|40 Years|75 Years|No|||July 2015|July 31, 2015|July 26, 2010|Yes|Yes||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01176292||118202|
NCT01176305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAV1|Venous Thromboembolism in Pregnant and Puerperal Women in Denmark 1995-2005|Venous Thromboembolism in Pregnant and Puerperal Women in Denmark 1995-2005||Hillerod Hospital, Denmark|Yes|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Female|15 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Danish Women 15 to 49 years old in the period January 1995 through December 2005, free of        previous VTE and current use of oral contraceptives.|October 2009|August 5, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176305||118201|
NCT01176617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn811675|Assessing Arrhythmias After Ablation Using Implantable Recorders|Assessment of Arrhythmia Burden in Patients Undergoing Atrial Fibrillation Using an Implantable Loop Recorder (ILR) Versus Conventional Monitoring Strategy|ABACUS|University of Pennsylvania|Yes|Completed|June 2012|January 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|44|||Both|18 Years|N/A|No|||June 2012|August 14, 2014|August 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176617||118177|
NCT01185912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2006|Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia|||Turku University Hospital|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Transmyocardial needle biopsies|Both|60 Years|90 Years|No|Probability Sample|20 patients (male and female) undergoing elective aortic valve replacement surgery due to        aortic valve stenosis or combined aortic valve disease in Turku University Hospital,        Department of Surgery.|May 2015|May 19, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01185912||117466|
NCT01160029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40332|Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition|RANDOMIZED, 2-WAY CROSSOVER, BIOEQUIVALENCE STUDY OF NATEGLINIDE 120 mg TABLET AND STARLIX@ ADMINISTERED AS 1 x 120 mg TABLET IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS||Dr. Reddy's Laboratories Limited|No|Completed|October 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2004|July 12, 2010|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160029||119447|
NCT01159704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0823|Peer Leaders as HIV Risk Reduction Change Agents Among Injection Drug Users (IDUs) in Ukraine|Peer Leaders as HIV Risk Reduction Change Agents Among Injection Drug Users (IDUs) in Ukraine||University of Colorado, Denver|Yes|Active, not recruiting|July 2010|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|5250|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 4, 2015|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159704||119471|
NCT01159678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01032|Online Psychoeducation for Sexual Dysfunction in Cancer Survivors|Online Psychoeducation for Sexual Dysfunction in Cancer Survivors|OPES|University of British Columbia|Yes|Completed|October 2010|April 2014|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|19 Years|70 Years|No|||June 2015|June 11, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01159678||119473|
NCT01160003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113209|A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.|A Randomised, Double-blind, Placebo-controlled, Dose Ascending, 3-way Crossover Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.|SIG|GlaxoSmithKline|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|March 10, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01160003||119448|
NCT01183923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00035087|Dietary Interventions in Asthma Treatment: Sprouts Study|Dietary Interventions in Asthma Treatment: Sprouts Study||Johns Hopkins University|Yes|Suspended|November 2010|||November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|49 Years|No|||September 2015|September 5, 2015|August 17, 2010||No|reworking protocol|No||https://clinicaltrials.gov/show/NCT01183923||117617|
NCT01184170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0708|Metabolically Normal and Metabolically Abnormal Obesity|Metabolically Normal and Metabolically Abnormal Obesity||Washington University School of Medicine|Yes|Completed|August 2010|February 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|71|||Both|18 Years|65 Years|No|||April 2015|April 28, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01184170||117599|
NCT01181128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|997HA301|Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A|A-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A||Biogen|Yes|Completed|November 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|165|||Male|12 Years|N/A|No|||June 2015|June 4, 2015|August 12, 2010|No|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01181128||117831|
NCT01182298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100159|Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection|Study to Evaluate the Genetic, Epigenetic, and Proteomic Expression in Latino Participants With and Without HIV Coinfection Receiving Treatment for Hepatitis C|LATHCV|National Institutes of Health Clinical Center (CC)||Terminated|July 2010|March 2013|Actual|March 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Plasma and serum storage.|Both|18 Years|N/A|No|Non-Probability Sample|latino with or without HIV infection undergoing Hepatitis C treatment|September 2014|September 26, 2014|August 13, 2010|Yes|Yes|small number of patients enrolled|No|April 23, 2014|https://clinicaltrials.gov/show/NCT01182298||117741|Early termination due to small numbers of subjects enrolled as the options for HCV treatment changed significantly since the start of the study planning.
NCT01161706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614971|Clinical Investigation on the Effects of a Vegetable Juice Treatment|The Use of a Commercial Vegetable Juice as a Practical Means to Increase Vegetable Intake: A Randomized Controlled Trial||University of California, Davis|Yes|Completed|July 2007|February 2009|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|90|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161706||119319|
NCT01157520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNAP_Sectio|Study to Detect Hypotensive Episodes During Spinal Anesthesia for Cesarean Section Using a Noninvasive Continuous Device|Hypotensive Episodes During Cesarean Section Detected by a Continuous Non-invasive Arterial Pressure Measurement Device Are Missed by the Oscillometric Blood Pressure Measurement||University of Schleswig-Holstein|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Female|18 Years|45 Years||Probability Sample|elective Cesarean section under spinal anesthesia|July 2010|July 8, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157520||119636|
NCT01157468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/E/12|Catalytic Antibodies and Lupus in Martinique|Study of Catalytic Antibodies in a Cohort Population of Martinique|LUMAB2|Centre Hospitalier Universitaire de Fort-de-France|Yes|Not yet recruiting|August 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|180|Samples With DNA|-  For the "case" means the research will be done on a blood sample of 7 ml, reclassified           from treatement to research, collected from the blood sampling usually prescribed by           doctors to treat the patient come to be diagnosed a lupus or for continuing care.        -  For the "control" means research will be done on a blood sample of 7 ml collected from           people coming to donate blood at thethe French Blood Establishment of Martinique.      The volume does not exceed the maximum amount allowed by French regulations for blood      donation.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cases are patients with Systemic Lupus Erythematosus treated at the Centre Hospitalier of        Fort de France (Martinique): patients with a quiescent lupus and patients with an active        lupus.        Controles are people coming to donate blood samples at the French Blood Establishment of        Martinique.|July 2010|July 6, 2010|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01157468||119640|
NCT01157481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEMAND-01|Diastolic Heart Failure Management by Nifedipine|Diastolic Heart Failure Management by Nifedipine|DEMAND|Demand Investigators|Yes|Active, not recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Both|20 Years|N/A|No|||January 2016|January 21, 2016|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01157481||119639|
NCT01157793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP24632|A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood|A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in GHD Subjects During the Transition Phase From Childhood to Adulthood||Merck KGaA|No|Completed|September 2003|February 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|14 Years|25 Years|No|||July 2010|July 9, 2014|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01157793||119616|
NCT01158534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE8805|Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery|A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining||Case Comprehensive Cancer Center|Yes|Completed|March 2006|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|July 6, 2010|Yes|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT01158534||119560|
NCT01158547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR3001|Efficacy Study of CLR3001 in Depression|A Pilot Placebo Controlled, Double-Blind, Randomized Parallel Group Study to Evaluate the Efficacy of Treatment With CLR3001 in Depression||Clera Inc.|No|Completed|April 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|86|||Both|18 Years|65 Years|No|Non-Probability Sample|Community sample|February 2015|February 2, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158547||119559|
NCT01158573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36879|Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity|Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity||University of Michigan|Yes|Recruiting|July 2010|May 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|160|Samples Without DNA|Subjects will provide 30 cc of blood, a urine sample and we will collect 1-2 ml. of exhaled      breath condensate for analysis.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|UM Housing Residents/Student Dorms UM Human Research Recruiting Registry (e.g., ENGAGE -        http://www.med.umich.edu/engage/) Department or unit-specific research recruiting registry        (provide UM IRB project number below) Other UM subject pools (describe below) Patients or        their medical records from the UM Health System or any other UM health care provider        (e.g., School of Dentistry, University Health Service, University Center for Language and        Literacy)|July 2010|July 7, 2010|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158573||119557|
NCT01158794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENIOS|Genes Influencing Iron Overload State|Genes Influencing Iron Overload State||St. Jude Children's Research Hospital|No|Active, not recruiting|August 2010|July 2019|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|Samples With DNA|The total volume of blood transfused (in ml/kg) will be collected and stored in the study      database. Cumulative transfused blood volume (in ml/kg) will be captured. Serum samples will      be stored frozen at -20°C until the time of analysis. In addition to the protocol-specific      testing of specimens, study participants will be offered the option of allowing any leftover      purified DNA, serum, or blood cells to be saved or shared for future analyses. Leftover      purified genomic DNA, serum, and blood cells from subjects enrolled in the GENIOS protocol      will be de-identified prior to storage or any future testing and/or sharing.|Both|N/A|N/A|No|Non-Probability Sample|Study participants will be patients who receive medical care at St. Jude Children's        Research Hospital and have developed iron overload secondary to multiple transfusions.        Patients will be approached during regular outpatient visits and will be invited to        participate in this study if they meet the inclusion/exclusion criteria and consent to        participate in the study. Non-sickle cell patients with transfusional iron overload        includes patients with thalassemia, bone marrow failure syndromes, and patients who have        received multiple blood transfusions due to marrow aplasia secondary to the use of        chemotherapeutic agents. About 40 participants with sickle cell disease are targeted.        About 10 participants with non-sickle cell disease are targeted.|January 2016|January 29, 2016|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158794||119540|
NCT01158807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN# 6203|Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia|Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia (RDCRN# 6203, Protocol Version Date 07Jan10)|BVMN6203|St. Michael's Hospital, Toronto|No|Recruiting|April 2010|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|3500|Samples With DNA|blood and/or saliva|Both|N/A|N/A|No|Non-Probability Sample|HHT individuals with a history of brain arteriovenous malformation. HHT individuals        without a history of brain arteriovenous malformation.|November 2015|November 16, 2015|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158807||119539|
NCT01159717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 129/09|CT Versus CEUS Findings of Complex Cystic Renal Lesions|Complex Cystic Renal Lesions: Evaluation of Computed Tomography Findings With Contrast Enhanced Ultrasound in Terms of the Bosniak Classification System.||University Hospital, Basel, Switzerland|No|Completed|January 2007|July 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing a CT procedure.|July 2010|July 12, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159717||119470|
NCT01160393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070216|Atrial Fibrillation After Cardiac Surgery-comparing Conventional and Miniaturized Bypass Systems|Atrial Fibrillation After Cardiac Surgery - Prospective, Randomized Study Comparing Conventional and Miniaturized Bypass Systems||Kuopio University Hospital|No|Recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|330|||Both|N/A|N/A|No|||March 2016|March 10, 2016|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01160393||119419|
NCT01160042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8313|Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fasting Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Metformin Hydrochloride 1000 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics, India) to be Compared With Glucophage® (Metformin Hydrochloride) 1000 mg Tablets (Bristol-Myers Squibb, USA) in 52 + (2 Standby) Healthy, Adult, Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|January 2005|April 2005|Actual|April 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2005|July 22, 2010|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160042||119446|
NCT01160328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000309|Influence of Male Hormones on Regional Fat Metabolism|Influence of Male Hormones on Regional Fat Metabolism||Mayo Clinic|No|Completed|June 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|39|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01160328||119424|
NCT01160341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-072010|Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism|Phase 4 Study of About the Effect of Testosterone Treatment on the Components of Metabolic Syndrome||Gulhane School of Medicine|No|Completed|August 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|312|||Male|18 Years|26 Years|Accepts Healthy Volunteers|||January 2010|July 9, 2010|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160341||119423|
NCT01160627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN in STEMI|Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction|Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction||Odense University Hospital|Yes|Completed|April 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|720|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160627||119402|
NCT01160367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR010733-02|Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life|Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life||Johns Hopkins University|No|Recruiting|August 2009|June 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|264|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 9, 2010|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160367||119421|
NCT01179906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS research incubator study|Lifestyle Modifications and the Progression of Chronic Kidney Disease|Effect of Lifestyle Interventions on the Progression of Kidney Disease in Patients With Chronic Kidney Disease||Springfield College|No|Completed|January 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Both|20 Years|70 Years|No|||January 2006|August 10, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179906||117925|
NCT01180205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017010-68|Telmisartan, Amlodipine and Flow Mediated Dilation|A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure|TEAMSTAprotect|Johannes Gutenberg University Mainz|Yes|Active, not recruiting|August 2010|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|576|||Both|35 Years|N/A|No|||April 2010|July 11, 2011|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01180205||117902|
NCT01182025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907001-4|A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease|||The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine|Yes|Recruiting|June 2010|December 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|360|||Both|1 Year|14 Years|No|||August 2010|August 16, 2010|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182025||117762|
NCT01172054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX128-01|Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults|A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults ≥65 Years of Age|VAX128-01|VaxInnate Corporation|Yes|Completed|July 2010|November 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|292|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 30, 2012|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01172054||118525|
NCT01172067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-09-063-AP-HF|QuickOpt Chronic Study|Clinical Impact of Cardiac Resynchronization Therapy on Heart Failure Patients With QuickOpt and Echo Optimization||St. Jude Medical|Yes|Active, not recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172067||118524|
NCT01182311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100187|Duration of Long-term Immunity After Hepatitis B Virus Immunization|Duration of Long-Term Immunity After Hepatitis B Virus Immunization||National Institutes of Health Clinical Center (CC)||Completed|August 2010|||||N/A|Observational|Time Perspective: Prospective|||Actual|205|||Both|18 Years|N/A|No|||March 2015|April 8, 2015|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182311||117740|
NCT01182324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910171|The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor|The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor||National Institutes of Health Clinical Center (CC)||Completed|July 2010|June 2013||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|160|||Both|18 Years|N/A|No|||June 2013|October 23, 2014|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182324||117739|
NCT01172288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCSC1004006637|N-acetylcysteine (NAC) for Children With Tourette Syndrome|Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome||Yale University|No|Completed|July 2010|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|8 Years|17 Years|No|||July 2014|July 21, 2014|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01172288||118507|
NCT01172951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS-08-43-GR|Nutrigenomics Investigation of the Body's Metabolic Response to 2 Different Meal Challenges|A Nutrigenomics Study of Post-prandial Metabolic Responses in Individuals of Varying Body Weight: An Assessment of the Body's Response to Meals Containing Different Levels of Fat and Carbohydrate|MECHE|University College Dublin|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2011|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172951||118457|
NCT01157832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-0219-09|Evaluation of the Acute Effect of Water-Pipe Smoking on the Respiratory System|||Rambam Health Care Campus|Yes|Completed|November 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal People who have smoked Water-pipe, at least once before.|June 2013|June 10, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157832||119613|
NCT01157806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0109|Palliative Radiochemotherapy Against Palliative Surgery in Stage IV Rectal Cancer With Unresectable Metastases|Palliative Radiotherapy Followed by Chemotherapy Against Palliative Surgery in Patients With Rectal Cancer With Unresectable Synchronous Distant Metastases||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|January 2010|June 2012|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2011|February 14, 2011|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01157806||119615|
NCT01157819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-002-000|Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis|Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro (0.3% Ciprofloxacin Otic Foam) Compared to Twice-Daily Dosing of Ciloxan (0.3% Ciprofloxacin Otic Solution) in Patients With Acute External Otitis|Once-a-day|Otic Pharma|Yes|Completed|July 2010|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||March 2011|March 14, 2011|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01157819||119614|
NCT01158001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080513|Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder|Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder||Veterans Medical Research Foundation|No|Completed|May 2009|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|211|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|February 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01158001||119600|
NCT01158014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-5033-GB-CTIL|Fibrin Glue vs. Suture in Pterygium Surgery|Fibrin Glue vs. Vicryl Suture in Pterygium Surgery With Conjunctival Auto-graft||Sheba Medical Center|No|Recruiting|January 2010|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|100 Years|No|||November 2015|November 30, 2015|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01158014||119599|
NCT01158287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-41 ICORG|Sorafenib. ICORG 06-41, V4|Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients||ICORG- All Ireland Cooperative Oncology Research Group||Completed|February 2009|||November 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||January 2014|December 30, 2014|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158287||119578|
NCT01159132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 127|Pharmacokinetics of Low Dose Raltegravir|Pharmacokinetics of Low Dose Raltegravir||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|N/A|No|||October 2011|October 29, 2011|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01159132||119515|
NCT01158820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810981|Alternative Sedation During Bronchoscopy|A Randomized, Placebo-controlled, Concealed Allocation Comparison of Respiratory Depression and Coughing During Bronchoscopy With Dexmedetomidine-ketamine as an Adjunct to Fentanyl-midazolam Sedation|DEX|University of Pennsylvania|Yes|Completed|June 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01158820||119538|
NCT01160055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113368|Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian Children|Identification and Characterisation of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Egypt||GlaxoSmithKline||Withdrawn|October 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|Middle ear fluid, Urine.|Both|3 Months|5 Years|No|Non-Probability Sample|Children aged >= 3 months to < 5 years visiting ear, nose and throat specialists for the        treatment of acute otitis media.|April 2015|April 9, 2015|July 1, 2010||No|Key aspects linked to sample management and analysis were not met during feasibility    assessment limiting the ability of the study to reach its objectives.|No||https://clinicaltrials.gov/show/NCT01160055||119445|
NCT01160354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0536|Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)|Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit||M.D. Anderson Cancer Center|No|Terminated|August 2010|March 2016|Actual|March 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|60 Years|N/A|No|||March 2016|March 23, 2016|July 8, 2010|Yes|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01160354||119422|
NCT01160380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/6270|A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma|A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma||Oncotherapeutics|No|Completed|June 2010|May 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||October 2014|November 5, 2014|July 7, 2010||No||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01160380||119420|
NCT01160653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNF1|Cognitive & Motor Training After Stroke For Everyday Walking Restoration|Cognitive and Motor Training After Stroke for Everyday Walking Restoration||VA Office of Research and Development|No|Withdrawn|August 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 21, 2014|April 26, 2010|No|Yes|Never funded|No||https://clinicaltrials.gov/show/NCT01160653||119400|
NCT01179919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002|Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects|||Albany College of Pharmacy and Health Sciences|No|Completed|July 2010|December 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|January 28, 2013|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179919||117924|
NCT01180218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreaUGuroH_1|Complete Lesion Versus Culprit Lesion Revascularization|Comparison of Complete Lesion Versus Culprit Lesion Revascularization in Acute ST Elevation Myocardial Infarction Patients With Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention|COCUA|Korea University Guro Hospital|No|Available|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180218||117901|
NCT01180491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K101-50|A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis|||Moberg Derma AB|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|N/A|||Actual|75|||Both|18 Years|N/A||||June 2013|June 25, 2013|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180491||117880|
NCT01180803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVAL- CLIN A00690-39|Efficacy of Oxygen Therapy Delivered by Systems Using Oxygen-Saving Valves in COPD Patients|||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|No|Recruiting|July 2010|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|45 Years|80 Years|No|||December 2015|December 29, 2015|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180803||117856|
NCT01180816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-292A|Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA|Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma||Northwell Health|No|Active, not recruiting|August 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180816||117855|
NCT01171560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|096/2010|Evaluation of the EZ Blocker|Prospective Randomized Clinical Trial for Single-Lung-Ventilation Comparing Double-Lume Tube and the EZ-Blocker®||Medical University of Vienna|No|Recruiting|June 2010|August 2010|Anticipated|July 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||May 2010|August 11, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171560||118563|
NCT01172613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/2553(EC3)|Optimal Concentration of Dermatophagoides Pteronyssinus (Dp) Allergen Extract for Skin Prick Test (SPT) of Thai Population|Optimal Concentration of Allergen Extract of Dermatophagoides Pteronyssinus to be Used in Diagnostic Allergy Skin Prick Test Among Thai Population|DSPT|Siriraj Hospital|No|Recruiting|June 2010|||December 2010|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|110|||Both|15 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|allergic rhinitis patients in Siriraj hospital (tertiary care) control group: healthy        subjects from community sample|July 2010|July 29, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172613||118482|
NCT01172626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPA20100716|Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment|Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment|EGBPPVPA|Sun Yat-sen University|Yes|Not yet recruiting|August 2010|July 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Whole blood for DNA extraction as well as for pharmacokinetic studies|Both|4 Years|60 Years|No|Non-Probability Sample|patients receiving treatment with valproate sodium|July 2010|July 29, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172626||118481|
NCT01157845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VirginiaCU HM12041|Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis|Use of the BreathID Methacetin Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients Awaiting Liver Transplantation||Virginia Commonwealth University|No|Completed|March 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|165|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|July 2, 2010|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01157845||119612|
NCT01157507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-B-PD-P|Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome|Botulinum A Toxin Intravesical Injections Versus Bladder Overdistension in the Treatment of Patients With Painful Bladder Syndrome: A Prospective Randomized Study||University Of Perugia|Yes|Enrolling by invitation|January 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|80 Years|No|||December 2009|April 19, 2011|February 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01157507||119637|
NCT01158313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCN-DYS|Bedside Screening Method for Patients With Potential Swallowing Impairment|Development and Validation of Clinician-administered Bedside Screening Method for Patients With Potential Swallowing Impairment|CABS|Nestlé|No|Completed|July 2010|August 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|120 Patients suspected of having symptoms of swallowing impairment will be enrolled in the        study as well as 14 healthy volunteers|October 2013|October 29, 2013|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01158313||119576|
NCT01158027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7999-OK-CTIL|Evaluating Walking Kinetic of Children Who Suffer Central Nervous System (CNS) Damage|Evaluating Walking Kinetic of Children Who Suffer Central Nervous System (CNS)||Sheba Medical Center|No|Not yet recruiting|October 2011|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|8 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|Fifteen children post-TBI and fifteen typically control.|October 2011|October 17, 2011|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01158027||119598|
NCT01158040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8014-HS-CTIL|Intrapartum Maternal Glycemic Control Using Insulin Pump Versus Insulin Drip - Cohort Observational Trial|Intrapartum Maternal Glycemic Control Using Insulin Pump Versus Insulin Drip Cohort Retrospective and Prospective Observational Trial||Sheba Medical Center|No|Not yet recruiting|August 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|88|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Women suffering from pregestational diabetes mellitus type-1, and are being treated for a        minimum of 3 months in the high risk pregnancy clinic in Sheba medical center.|July 2010|July 28, 2010|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01158040||119597|
NCT01158300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000680634|PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors|Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors||Pediatric Brain Tumor Consortium|Yes|Completed|November 2010|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|3 Years|21 Years|No|||May 2015|May 1, 2015|July 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01158300||119577|
NCT01159145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00009|Study to Assess the Pharmacodynamics/Pharmacokinetics After Repeated Dosing of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects|A Randomised, Single Blind, Two-way Cross-over, Single-centre Study to Assess the Pharmacodynamics (Intragastric pH) and Pharmacokinetics After Repeated Oral Administration of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects||AstraZeneca|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Anticipated|42|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 19, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159145||119514|
NCT01159158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40331|Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition|RANDOMIZED, 2-WAY CROSSOVER, BIOEQUIVALENCE STUDY OF NATEGLINIDE 120 mg TABLET AND STARLIX@ ADMINISTERED AS 1 x 120 mg TABLET IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS||Dr. Reddy's Laboratories Limited|No|Completed|February 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2007|July 12, 2010|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159158||119513|
NCT01158833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDGEE_2010_classdipl|Validity of the Kinematic Classification of Gait in Diplegic Children With Cerebral Palsy (CP)|Validity of the Kinematic Classification of Gait in Diplegic Children With Cerebral Palsy||University of Modena and Reggio Emilia|No|Completed|April 2010|November 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|86|||Both|12 Years|17 Years|No|Non-Probability Sample|We retrospectively studied children with diplegia and CP who are followed by the Unit for        Severe Disability in the Developmental Age at the Hospital of Reggio Emilia (Italy);|June 2014|June 26, 2014|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158833||119537|
NCT01159119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-012|A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain|Single Center Randomized Single Blind Crossover Group Active Control Study to Evaluate Safety and Efficacy of EUR-1066 a Pancreatic Enzyme Product in Patients With Chronic Pancreatitis Exocrine Pancratic Insufficiency,Chronic Abdominal Pain|EUR-1066|Forest Laboratories|No|Not yet recruiting|August 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|N/A|No|||July 2010|July 7, 2010|July 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159119||119516|
NCT01160965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version1.0|Ropivacaine 0.75% Versus Levobupivacaine 0.5% for Conversion of Labour Epidural|Ropivacaine 0.75% Versus Levobupivacaine 0.5% for Conversion of Labour Epidural to Surgical Anaesthesia for Emergency Caesarean Section.|RoLe|Guy's and St Thomas' NHS Foundation Trust|Yes|Withdrawn|August 2012|August 2014|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|50 Years|No|||December 2011|December 28, 2011|July 7, 2010|Yes|Yes|Not able provide staff for recruting at present|No||https://clinicaltrials.gov/show/NCT01160965||119376|
NCT01160978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1020SIMVASTATIN|Donor Simvastatin Treatment in Organ Transplantation|Donor Simvastatin Treatment in Organ Transplantation|SIMVA|Helsinki University Central Hospital|Yes|Enrolling by invitation|June 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01160978||119375|
NCT01160679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NKR-SER-2010/1|Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia|Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia|PLEASURE|AstraZeneca|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|231|||Both|20 Years|N/A|No|Non-Probability Sample|Department of psychiatry of 25 hospitals|August 2011|August 17, 2011|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01160679||119398|
NCT01160692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11954|A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment|A Randomized, Placebo-controlled, Parallel Group, Double Blind Study to Evaluate the Cognitive Effects and Tolerance of a Multi-Vitamin/Mineral Preparation Containing Gingko in Elderly Subjects With Age Associated Memory Impairment||Bayer|No|Completed|February 2006|July 2008|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 30, 2010|October 8, 2009||No||No||https://clinicaltrials.gov/show/NCT01160692||119397|
NCT01161225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR009837|Teen Asthma Project|Peer-Assisted Asthma Self-Management Program for Adolescents|TAP|University of Rochester|Yes|Completed|March 2007|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|126|||Both|13 Years|20 Years|No|||December 2014|December 9, 2014|July 9, 2010||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01161225||119356|
NCT01180504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVAR-IMRT-02|Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer|Consolidation Intensity-Modulated Whole Abdominal Radiotherapy for High-Risk Patients With Ovarian Cancer Stage FIGO III|OVAR-IMRT-02|University Hospital Heidelberg|Yes|Recruiting|August 2010|August 2016|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||August 2010|August 11, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180504||117879|
NCT01180790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH625-003|Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects|A Phase IIa, Randomized, Double-blind (Subject and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Subjects With Chronic Hepatitis C Virus Genotype 1||Achillion Pharmaceuticals||Completed|September 2010|April 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|122|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|August 11, 2010|Yes|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01180790||117857|
NCT01181778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06557|Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)|Observational, Prospective, Multicenter Study to Evaluate the Educational Counseling Effects in the Choice of Different Combined Hormonal Contraceptives|ECOS|Merck Sharp & Dohme Corp.|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1919|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women ≥ 18 years of age and < 40 years of age who consult their physician for        information on contraception choices|October 2015|October 1, 2015|August 12, 2010|No|Yes||No|July 21, 2013|https://clinicaltrials.gov/show/NCT01181778||117781|
NCT01174173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00030314|Ranolazine and Pulmonary Hypertension|Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension||Northwestern University|No|Completed|June 2010|October 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|80 Years|No|||April 2015|April 22, 2015|July 23, 2010|Yes|Yes||No|March 9, 2015|https://clinicaltrials.gov/show/NCT01174173||118364|This study was a small pilot Interventional study to test safety and tolerability of ranolazine in 11 patients with sx WHO Group 1 PAH patients.
NCT01174407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK08010-VK|Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration|Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration||Rudolf Foundation Clinic|No|Active, not recruiting|September 2008|August 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|55 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with exudative age-related macular degeneration, over 55|August 2010|August 2, 2010|November 19, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174407||118346|
NCT01172301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104738|Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis|Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis||Texas A&M University|No|Completed|July 2008|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|14|||Both|10 Years|21 Years|No|||August 2015|August 7, 2015|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01172301||118506|
NCT01172093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW07-060|A Study on the Prevalence of Obstructive Sleep Apnea in Patients With Type II Diabetes Mellitus|Prevalence and Recognition of Obstructive Sleep Apnea in Chinese With Type 2 Diabetes Mellitus||The University of Hong Kong|Yes|Completed|January 2007|December 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|177|Samples Without DNA|Plasma and serum samples were collected from subjects for batch assays for further research      purposes|Both|18 Years|75 Years|No|Non-Probability Sample|All Chinese subjects with type 2 diabetes mellitus being followed up at the diabetic        clinic of a University affiliated hospital|July 2010|July 28, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01172093||118522|
NCT01158105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-037|Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)|Phase 2 Study of Bortezomib (Velcade) for the Treatment of Steroid Refractory Chronic Graft-vs-Host Disease||Baylor Research Institute|Yes|Active, not recruiting|June 2010|January 2017|Anticipated|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158105||119592|
NCT01158053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFC-001|Vascular Evaluation for Revascularization: Defining the Indications for Coronary Therapy: A Pilot Study|A Prospective, Global, Multicenter, Non-Randomized, Non-Blinded Study in Patients With Intermediate Coronary Lesions to Examine the Correlation Between Fractional Flow Reserve (FFR) and Intravascular Ultrasound With Virtual Histology (VH-IVUS)|VERDICT|Volcano Corporation|No|Completed|September 2010|January 2015|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|291|||Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled to undergo a diagnostic cardiac catheterization|June 2015|December 8, 2015|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158053||119596|
NCT01158066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD and CAC|Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification|Association Between NAFLD and Coronary Artery Calcification||Ziv Hospital|Yes|Not yet recruiting|August 2011|March 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|45 Years|75 Years|No|||June 2010|April 5, 2011|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01158066||119595|
NCT01158326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-542|Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu|Evaluation of Efficacy and Safety of Oral Solution Paracetamol, Maleate Chlorpheniramine and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu: a Double-blind||Hospital de Clinicas de Porto Alegre|Yes|Completed|August 2010|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|12 Years|60 Years|No|||November 2011|November 24, 2011|February 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01158326||119575|
NCT01158599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-315|This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population|An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population||Valneva Austria GmbH|No|Completed|June 2010|October 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 22, 2012|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158599||119555|
NCT01158586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCEA-LEVO-ROPI|Postoperative Patient Controlled Epidural Analgesia After Total Knee Arthroplasty With 2ug/ml Fentanyl Combine With 0.2% Ropivacaine or 0.2% Levobupivcaine|||United Christian Hospital|Yes|Recruiting|April 2010|December 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2010|July 7, 2010|July 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158586||119556|
NCT01158846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biva/Pra versus Abcix/clop|Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI|Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention||Istituto Clinico Sant'Ambrogio|No|Not yet recruiting|August 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||June 2010|July 7, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01158846||119536|
NCT01159730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-201-030|Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers||Vascular Biogenics Ltd. operating as VBL Therapeutics|Yes|Completed|October 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|320|||Both|18 Years|75 Years|No|||November 2011|November 15, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159730||119469|
NCT01159743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-031|A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine|A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine|LYNX|AbbVie|No|Completed|July 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|346|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients visiting Spanish HIV clinics.|January 2013|January 16, 2013|July 8, 2010||No||No|September 28, 2012|https://clinicaltrials.gov/show/NCT01159743||119468|
NCT01159405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeeCure GP-001|The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer|A Pilot Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide (99mTc-GP) in Patients With Breast Cancer||SeeCure LLC|No|Recruiting|June 2010|April 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|9|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|July 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159405||119494|
NCT01161238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30863-E/B|Amputee Residual Limb Volume Fluctuation|Measuring and Controlling In-Socket Residual Limb Volume Fluctuation||University of Washington|No|Completed|May 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|people with lower limb amputation that are ambulatory|April 2014|April 24, 2014|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161238||119355|
NCT01161251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMI-ARA PACIS|Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study.|Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study.|ARAPACIS|University of Roma La Sapienza|Yes|Completed|July 2010|December 2014|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2027|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|The investigators plan to include in the study n = 3,000 AF patients, with competitive        recruitment between centers involved in the study. The sample size was calculated assuming        an expected prevalence of 19% at time zero, and in order to obtain a confidence interval        95% to prevail at time zero whose distance from the edge is less than or equal to 1.4%.        This sample size yields a power greater than 99.9% for the secondary endpoint, assuming an        event rate of 19% for patients with ABI <=0.9, and 10% for patients with ABI >0.9.An        interim analysis showed an ABI prevalence, calculated by exact confidence intervals, of        21% in patients with AF, it is considered to interrupt the enrollment, as the observed        prevalence is greater than two percentage points higher than that assumed. The sample size        is amended as follows: a sample of 2,027 patients leads to the expected prevalence of 21%        with a confidence interval width of 3.5. This sample size has no impact on the power of        the secondary objective.|February 2015|March 8, 2016|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161251||119354|
NCT01161485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0518|Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users|Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users||University of Colorado, Denver|Yes|Recruiting|August 2010|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161485||119336|
NCT01181414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARE III - 2010|Spanish Atrial Fibrillation And Resynchronization Study|Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation.|SPAREIII|Hospital Clinic of Barcelona|Yes|Completed|October 2010|January 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01181414||117809|
NCT01181427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-116|Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects|A Blinded, Randomized, Placebo-Controlled Study in Healthy and HCV Genotype 1-infected Adults, to Evaluate the Safety, Tolerability, Antiviral Activity, Pharmacokinetics (Including the Effect of Food) and Resistance Profile of Single and Multiple Doses of ABT-267||Abbott|No|Completed|August 2010|January 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|137|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01181427||117808|
NCT01181440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABH-DG-04-04-0694|Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers|A Prospective, Multicenter, Randomized, Single-Blind Clinical Investigation of Dermagraft(R) in Patients With Plantar Diabetic Foot Ulcers||Shire Regenerative Medicine, Inc.||Completed|September 1994|January 1997|Actual|January 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|281|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|August 12, 2010||Yes||||https://clinicaltrials.gov/show/NCT01181440||117807|
NCT01181167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-B-J304|A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty|A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)||Daiichi Sankyo Inc.||Completed|May 2009|March 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|610|||Both|20 Years|84 Years|No|||February 2015|February 3, 2015|August 12, 2010||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01181167||117828|
NCT01172080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000113|Utility Analysis of an Endoscopy Follow-up System|Utility Analysis of an Endoscopy Follow-up System||Beth Israel Deaconess Medical Center|No|Completed|January 2009|October 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|830|||Both|N/A|85 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172080||118523|
NCT01172405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBU-CAF-01/09|Efficacy and Safety Study to Compare Ibuprofen + Caffeine With Ibuprofen Alone in the Treatment of Headache|A Clinical Multicenter, Phase III, Randomized, Double-blind, Prospective and Comparative Trial to Evaluate the Efficacy and Safety of the Combination of Ibuprofen + Caffeine in the Treatment of Headache Attacks, Compared to Ibuprofen Alone.||Mantecorp Industria Quimica e Farmaceutica Ltd.|Yes|Not yet recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|65 Years|No|||July 2010|July 28, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172405||118498|
NCT01172730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13495|The Use of Ultrasound to Measure Depth of Thoracic Epidural Space|Use of Ultrasound to Measure Depth of Thoracic Epidural Space Compared With Blind Technique||University of Massachusetts, Worcester|No|Completed|May 2010|||April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having a thoracic epidural catheter for post operative pain|April 2013|April 9, 2013|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01172730||118474|
NCT01171833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J In 2010-1|Ventilatory Effect on Speed of Anesthesia Under Various Inhaled Anesthetics|Effect of Ventilation on Speed of Induction of Anesthesia in Desflurane, Sevoflurane, and Isoflurane||DongGuk University|Yes|Completed|June 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|36|||Both|20 Years|60 Years|No|||August 2012|August 9, 2012|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01171833||118542|
NCT01172171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLH-01|The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction|Intracoronary Injection of Melatonin for Patients With ST-elevation Myocardial Infarction: a Placebo Controlled Randomized Study||Herlev Hospital|Yes|Recruiting|June 2013|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172171||118516|
NCT01172392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-019367-11|A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B|A Randomized, Multicenter, Unblinded, Phase III Study Assessing the Loss of HbsAg at W96 After a 48-week Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (HbeAg Negative) Under Treatment and Responders (Undetectable Viral Load) to a Nucleoside(s) or Nucleotide(s) Analog(s) Treatment for at Least 12 Months. ANRS HB 06 Pegan|PEGAN|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|January 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|75 Years|No|||February 2013|March 28, 2013|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172392||118499|
NCT01157533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0887|Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients|Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients||M.D. Anderson Cancer Center|No|Terminated|June 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|July 5, 2010||No|Low Accrual.|No|February 13, 2013|https://clinicaltrials.gov/show/NCT01157533||119635|
NCT01158911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4530|Uric Acid and Long-term Outcomes in Chronic Kidney Disease|Does Uric Acid Promote Progression of Kidney Disease and Development of Cardiovascular Disease in Patients With Chronic Kidney Disease?||Tufts Medical Center|No|Completed|February 2007|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|838|||Both|18 Years|70 Years|No|Non-Probability Sample|838 participants of the randomized arm of the Modification of Diet in Renal Disaese (MDRD)        Study conducted between 1989-1993|October 2006|July 7, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158911||119532|
NCT01158079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-VSP02-002|Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment|A Multi-center, Open-Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment||Alnylam Pharmaceuticals|No|Completed|July 2010|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|December 11, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01158079||119594|
NCT01158092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC-SI-CIP-002|Trial Comparing Treatment With SInergy™ System to Conservative Treatment for Chronic Sacroiliac Joint Pain|A Randomized Controlled Trial Comparing Cooled Radiofrequency Denervation to Conservative Treatment as a Treatment for Sacroiliac Joint Pain Using the SInergy™ System|SI-RCT-Ross|Baylis Medical Company||Terminated|July 2010|||March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158092||119593|
NCT01158625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100084|Nighttime Dosing of Antihypertensive Drugs in Type 2 Diabetes|Nighttime Dosing of Antihypertensive Drugs in Type 2 Diabetes||University of Aarhus|No|Completed|August 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|30 Years|75 Years|No|||April 2013|April 3, 2013|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01158625||119553|
NCT01158638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StepCount|Utilizing Tailored Step-Count Feedback to Enhance Physical Activity in the Elderly|Utilizing Tailored Step-Count Feedback to Enhance Physical Activity in the Elderly|StepCount|University of Wisconsin, Milwaukee|Yes|Active, not recruiting|August 2009|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|160|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158638||119552|
NCT01158612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-039|The Effect of Local Injectet GH on the Collagen Synthesis in the Ligamentum Patella|The Effect of Local Injectet GH on the Collagen Synthesis in the Ligamentum Patella||University of Aarhus|No|Completed|August 2010|August 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|12|||Male|55 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 4, 2011|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158612||119554|
NCT01158859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC09-014|Effect of Preoperative Pregabalin on Propofol Induction Dose|Effect of Preoperative Pregabalin on Propofol Induction Dose||Université de Sherbrooke|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158859||119535|
NCT01158885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2009-002|Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia|Clofarabine With Cytarabine for MRD Positive Leukemia||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|August 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|1 Year|21 Years|No|||October 2012|October 24, 2012|June 30, 2010|Yes|Yes|Study terminated for lack of accrual.|No||https://clinicaltrials.gov/show/NCT01158885||119534|
NCT01160406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI-DSAB-2010|Screening for Atrial Fibrillation, After Ischemic Stroke|Improving Screening for Silent Atrial Fibrillation, After Ischemic Stroke||Karolinska Institutet|No|Completed|June 2007|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Patients from hospital strokewards.|June 2011|June 22, 2011|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160406||119418|
NCT01159418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKSD00702|LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors|A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors||Southern Europe New Drug Organization|No|Active, not recruiting|June 2008|March 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|75 Years|No|||September 2011|September 12, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159418||119493|
NCT01160705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-08 ICORG|Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2|Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Recruiting|November 2009|||February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Male|18 Years|N/A|No|Non-Probability Sample|Hormone refractory Prostate Cancer patients who are due to receive their first treatment        with Docetaxel.|February 2016|February 15, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160705||119396|
NCT01160718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 21/08|Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy|Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) ½ Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|August 2010|December 2015|Anticipated|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|89|||Female|18 Years|N/A|No|||January 2015|January 13, 2015|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160718||119395|
NCT01160991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeuOlanAmi|Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism|Effects of the Serotonin 2A Receptor on Insulin Sensitivity and Secretion: a Double-blind Controlled Comparison of Olanzapine vs. Amisulpride:||Central Institute of Mental Health, Mannheim|No|Completed|May 2004|October 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 2, 2010|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160991||119374|
NCT01161264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V78_08S|Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects|A Phase III, Multicenter, Uncontrolled, Open Label Study to Evaluate Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects||Novartis||Completed|July 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|July 4, 2012|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161264||119353|
NCT01161498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006/09|Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer|A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEX^GM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck||BioVex Limited|Yes|Terminated|February 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 12, 2010|Yes|Yes|The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN).|No|November 12, 2015|https://clinicaltrials.gov/show/NCT01161498||119335|
NCT01180842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911-104|Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF)|Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With CF||Children's Hospitals and Clinics of Minnesota|No|Completed|March 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||February 2014|February 13, 2014|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01180842||117853|
NCT01180855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-046R|Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia|Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia: A Randomized, Double-Blind, Placebo Controlled Study (Investigator Initiated Study)|CBT|University of Arizona|Yes|Active, not recruiting|August 2007|September 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|64 Years|No|||August 2010|August 11, 2010|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180855||117852|
NCT01171339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Muth|Prioritising and Optimising Multi-medication in Multimorbidity|Prioritising and Optimising Multiple Medications in Elderly Multimorbid Patients in General Practice. - A Pragmatic Cluster-randomised Controlled Trial.|PRIMUM|Goethe University|Yes|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|505|||Both|60 Years|N/A|No|||March 2016|March 1, 2016|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171339||118580|
NCT01171157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112868|Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling Elderly With Influenza Like Illness in Brazil|An Observational Case Control Study of Effectiveness of Influenza Vaccination and Burden of Illness in Community-dwelling Elderly With Influenza-like Illness in Southern Brazil||GlaxoSmithKline||Terminated|May 2009|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4|Samples With DNA|One nose/throat swab|Both|65 Years|N/A|No|Probability Sample|Adults aged 65 years and over, consulting a physician for an influenza-like illness during        the influenza season.|May 2015|May 7, 2015|July 15, 2010||No|In the context of the World Health Organization's (WHO) Phase 6 pandemic influenza declaration    the conduct of the study was deemed no longer feasible|No||https://clinicaltrials.gov/show/NCT01171157||118594|
NCT01171599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA128019|PACE-CALL: A Weight Control Intervention for Survivors of Childhood Leukemia|PACE-CALL: A Weight Control Intervention for Survivors of Childhood Leukemia|PACE-CALL|University of California, San Diego|No|Completed|August 2008|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|7 Years|18 Years|No|||June 2012|June 8, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171599||118560|
NCT01171612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR2009017|Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery|Evaluation and Monitoring of Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery|RegistStents|Corporacion Parc Tauli|Yes|Completed|June 2009|July 2012|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|483|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary stents undergoing noncardiac surgery with admission between May        2010 and April 2012|September 2013|September 16, 2013|July 23, 2010||No||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01171612||118559|This is a prospective and observational study
NCT01172977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EvKB Barzu|Neurological Complications at Stroke Patients With Diabetes Mellitus|Neurological Complications at Stroke Patients With Diabetes Mellitus During the First Six Months After a Cerebral Ischemia|SDM|Evangelisches Krankenhaus Bielefeld gGmbH|Yes|Completed|August 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Stroke patients on the Stroke Unit with hyperglycemia with cerebral ischemia within the        last 24 hours|June 2011|June 21, 2011|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172977||118455|
NCT01183832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORACLES|Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects|Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects|ORACLES|Centre Oscar Lambret|No|Active, not recruiting|August 2005|October 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|490|||Female|N/A|N/A|No|Non-Probability Sample|Patients are post-menopausal women treated for a breast concer|August 2014|August 21, 2014|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183832||117624|
NCT01157858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995 ANLIIT|Everolimus and LongActing Octreotide Trial in Polycystic Livers|Everolimus Added to Long Acting Octreotide as a Volume Reducing Treatment of Polycystic Livers|ELATE|Radboud University|Yes|Completed|June 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||June 2015|June 26, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157858||119611|
NCT01157871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT6141|Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication|Double-blind, Randomized, Placebo-controlled, Parallel Group and Dose-finding, Multicentric, Safety and Efficacy Study With Intramuscular Injections of NV1FGF in Subjects With Intermittent Claudication|TALISMAN 211|Sanofi|Yes|Completed|June 2004|August 2005|Actual|August 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|36|||Both|40 Years|N/A|No|||July 2010|July 6, 2010|July 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157871||119610|
NCT01158924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-Intradiscal rhGDF-5-02|A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration|A Phase I/IIa, Multicenter, Open-label, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration||DePuy Spine|No|Completed|March 2010|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 1, 2010||No||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01158924||119531|
NCT01158339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK No 2010/48-2|Dare to Move: Treatment of Movement Phobia in Patient With Low Back Pain|Dare to Move: Treatment of Movement Phobia in Patient With Low Back Pain A Randomized Controlled Study of Two Methods Comparing the Role of Exposure in Session|Ryggbra|Norwegian University of Science and Technology|Yes|Active, not recruiting|January 2010|January 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||January 2016|January 20, 2016|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01158339||119574|
NCT01158352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005547ctil|Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children|Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children|Formula|Rabin Medical Center|No|Completed|November 2010|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|3 Years|8 Years|No|||November 2014|November 6, 2014|June 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01158352||119573|
NCT01159444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPJ/2010|What do built-in Softwares in Home Ventilators Tell us?|What do built-in Softwares in Home Ventilators Tell us? An Observational Study of 150 Patients on Home Ventilation||Ligue Pulmonaire Genevoise|No|Completed|February 2007|July 2010|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated for at least 3 months in the Geneva Canton Area, followed by the Division        of Pulmonary Diseases of Geneva University Hospital, under home ventilation with bi-level        positive pressure home ventilators with integrated software for data recording, in stable        clinical condition|July 2010|July 8, 2010|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01159444||119491|
NCT01158898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI ASM8-207|Efficacy of TPI ASM8 During a 14-Day Allergen Challenge|A Double-Blind,Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma||Pharmaxis|No|Completed|November 2010|February 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|55 Years|No|||November 2013|November 14, 2013|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01158898||119533|
NCT01159171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18523|A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.|Phase II Study of the Combination of Bevacizumab (rhuMab VEGF) and Oxaliplatin Plus Capecitabine (XELOX) in Patients With Advanced Colorectal Cancer||Hoffmann-La Roche||Completed|January 2006|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|July 7, 2010|No|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT01159171||119512|
NCT01159431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNS-TDP-01|External Trigeminal Nerve Stimulation for Epilepsy|Randomized Double Blind Study of External Trigeminal Nerve Stimulation for Intractable Epilepsy||Olive View-UCLA Education & Research Institute|Yes|Completed|January 2008|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||May 2013|May 6, 2013|July 7, 2010||No||No|February 1, 2013|https://clinicaltrials.gov/show/NCT01159431||119492|Due to sample size and high variability in seizure frequency, median change did not achieve significance. To constrain variability, the RRATIO was used to assess seizure frequency. The RRATIO demonstrated within groups differences, p=0.04 ANOVA.
NCT01160419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-FLOT|Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer|||Ludwig-Maximilians - University of Munich||Active, not recruiting|December 2009|May 2014|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||December 2009|October 27, 2010|October 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01160419||119417|
NCT01160068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8322|Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fed Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Metformin Hydrochloride 1000 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics, India) to be Compared With Glucophage® (Metformin Hydrochloride) 1000 mg Tablets (Bristol-Myers Squibb, USA) in 48 + (2 Standby) Healthy, Adult, Human Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|February 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2005|July 12, 2010|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160068||119444|
NCT01160081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113564|Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis|Sero-prevalence of Hepatitis A Varicella-Zoster Virus, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis in Mexico||GlaxoSmithKline||Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3658|Samples With DNA|Serum samples|Both|1 Year|70 Years|Accepts Healthy Volunteers|Probability Sample|The study population will include a random sample of 4000 subjects of subjects who        participated in the 2006 National Health and Nutrition Survey (ENSANUT).|November 2010|January 22, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01160081||119443|
NCT01160731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-09 ICORG|Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I Dose Finding Study of the Pan-DAC Inhibitor Panobinostat (LBH589) in Combination With Etoposide and Cisplatin in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer - An ICORG In-House Study||ICORG- All Ireland Cooperative Oncology Research Group||Withdrawn|November 2009|||October 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|December 30, 2014|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160731||119394|
NCT01161004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/01|Recovery Effect of Sugammadex Measured by Bispectral and Neurosense Indices|Pilot Study of EEG Signs of Awakening Secondary to Injection of Sugammadex: Evaluation by Recording Bispectral Index and NeuroSENSE (Prospective, Double-blind Study)|Sugarecovery|Hopital Foch|No|Recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161004||119373|
NCT01161017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine06CTIL|Mechanism-based Choice of Therapy for Pain: Can Successful Prevention of Migraine be Coupled to a Psychophysical Pain Modulation Profile?|Mechanism-based Choice of Therapy for Pain: Can Successful Prevention of Migraine be Coupled to a Psychophysical Pain Modulation Profile?||Rambam Health Care Campus|No|Active, not recruiting|July 2008|||December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2007|July 12, 2010|July 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01161017||119372|
NCT01161277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016222-14|Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning|Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning: A Pharmacological fMRI Study|Arip_200901|Oslo University Hospital|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01161277||119352|
NCT01171820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-369 Diabetic Sub-study|SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)|SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions||Abbott Vascular|Yes|Completed|November 2006|July 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|April 1, 2010|Yes|Yes||No|August 31, 2010|https://clinicaltrials.gov/show/NCT01171820||118543|
NCT01173003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.1.7|Expansion Study of a Simplified Regimen of Medical Abortion Thru 63 Last Menstrual Period (LMP) in Tunisia|An Open Label Study of 400 mcg Sublingual Misoprostol Following Mifepristone 200 mg for Abortion up to 63 Days LMP||Gynuity Health Projects||Completed|June 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|688|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173003||118453|
NCT01173861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-0887|Effectiveness of a Cancer Center Based Physical Activity Intervention|Effectiveness of a Cancer Center Based Physical Activity Intervention||East Carolina University|No|Completed|March 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Female|18 Years|N/A|No|||July 2012|July 12, 2012|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01173861||118388|
NCT01171846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVPROL Study RG1271|A Study of the Effects of Physiotherapy to Prevent Pelvic Organ Prolapse|A Multicentre Randomised Controlled Trial of Pelvic Floor Muscle Training to Prevent Pelvic Organ Prolapse in Women|PREVPROL|Glasgow Caledonian University|No|Completed|August 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|337|||Female|N/A|N/A|No|||March 2015|March 16, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01171846||118541|
NCT01171885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0003.0.419.419-0|Bilateral Superficial Cervical Block for Thyroidectomy|Evaluation of the Postoperative Analgesic Efficacy of Bilateral Superficial Cervical Block for Thyroidectomy and Mini Incision Under General Balanced Anesthesia: a Randomized, Triple Masked, Placebo Controlled Trial.||Lifecenter Hospital|Yes|Recruiting|July 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||May 2009|July 28, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01171885||118538|
NCT01184105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSD502-PE-007|A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation|A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Study to Evaluate Systemic and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites, 2,6-Dimethylaniline (2,6-DMA) and O-Toluidine, in Female Healthy Volunteer Subjects Following Daily Application of 60 mg PSD502 or Placebo to the Vagina and Cervix for 7 Days||Plethora Solutions Ltd|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 2, 2015|August 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01184105||117604|
NCT01158651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOD W81XWH-05-1-0615|Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas|A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas|NFC-RAD001|University of Alabama at Birmingham|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|23|||Both|1 Year|21 Years|Accepts Healthy Volunteers|||February 2016|March 6, 2016|July 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158651||119551|
NCT01158690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/093|Intimate Partner Violence and Pregnancy, a Perinatal Care Intervention Study|Intimate Partner Violence and Pregnancy, a Randomised Controlled Trial on the Effect of a Resource Card on the Incidence of Intimate Partner Violence|MOM|University Ghent|No|Recruiting|June 2010|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|150|||Female|18 Years|N/A|No|||December 2014|December 4, 2014|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158690||119548|
NCT01159249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1308|Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes|A Multicenter, Open Label, Long-Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes||Novartis||Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|245|||Both|20 Years|N/A|No|||May 2012|May 20, 2015|July 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159249||119506|
NCT01159184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098083-3|Stressors, Coping Methods and Social Support in Diabetic Patients|Stressors, Coping Methods and Social Support in Diabetic Patients||Far Eastern Memorial Hospital|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|301|||Both|30 Years|80 Years|No|Non-Probability Sample|1. Type 2 diabetes          2. Aged 30-80 year old          3. under oral hypoglycemic agents          4. clear consciousness|January 2010|March 26, 2012|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159184||119511|
NCT01159197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-97-D-093|Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis|Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis and Its Impacts on Their Inflammatory Cytokines, Oxidative Stress and Autonomic Dysfunction||Far Eastern Memorial Hospital|Yes|Recruiting|August 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||November 2008|August 4, 2010|May 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159197||119510|
NCT01159470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|472010.ctil|The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children|CRP Velocity as a Marker for Bacterial Infections in Children|CRPv|Shaare Zedek Medical Center|Yes|Not yet recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|5 Years|No|Probability Sample|children < 5 years of age presenting to the Emergency Department with fever|July 2010|July 8, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159470||119489|
NCT01159769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-10-13|Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis|||Alcon Research|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|215|||Both|12 Years|N/A|No|||March 2012|March 5, 2012|July 8, 2010|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT01159769||119466|
NCT01159756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-10-01|To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure|||Alcon Research|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|468|||Both|18 Years|N/A|No|||January 2012|April 7, 2012|July 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159756||119467|
NCT01160094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113780|Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)|Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)|TYCO|GlaxoSmithKline|No|Recruiting|February 2010|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|276|||Female|18 Years|N/A|No|Non-Probability Sample|All cases of ErbB2 positive metastatic breast cancer, receiving approved standard        treatment with lapatinib-capecitabine, after trastuzumab-containing regimen progression in        community setting. Patients from private and public settings.|April 2015|April 20, 2015|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01160094||119442|
NCT01160120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 118|Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz|Generic Fixed Dose Combination (FDC) of Tenofovir(TDF) /Lamivudine(3TC)/Efavirenz (EFV) Tablets 300/300/600 mg||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|June 2010|June 2015|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160120||119440|
NCT01160432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5703433|Naloxone Methadone Combination (NAMEKO)|The Safety and Tolerability of Methadone/Naloxone Combination in Opioid Substitution Treatment|NAMEKO|Kuopio University Hospital|No|Withdrawn|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||July 2013|July 3, 2013|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160432||119416|
NCT01160445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100145|Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer|Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer||National Institutes of Health Clinical Center (CC)|No|Terminated|June 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|July 9, 2010|Yes|Yes|The study was terminated because we were not able to obtain the study drug.|No|November 7, 2012|https://clinicaltrials.gov/show/NCT01160445||119415|
NCT01161550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1181 / 201108160|Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML|Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML|CLAG ATRA AML|Washington University School of Medicine|No|Completed|November 2010|August 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||July 2013|July 22, 2013|July 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01161550||119331|
NCT01157676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120408|Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial|Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial||University of Miami|Yes|Active, not recruiting|March 2009|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|350|||Both|18 Years|N/A|No|Probability Sample|Bladder cancer patients who are a candidate for radical cystectomy.|November 2015|November 4, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01157676||119625|
NCT01157936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPERURICEMIA 2010|Hyperuricemia on Hypertension and Metabolic Syndrome|Effect of Hyperuricemia Treatment on Hypertension and Metabolic Syndrome||Instituto Nacional de Cardiologia Ignacio Chavez|Yes|Completed|July 2010|August 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01157936||119605|
NCT01171105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3030C00002|Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects|A Phase I, Double-blind, Randomized, Placebo-controlled', Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD5213 After Administration of Multiple Ascending Doses for 10 Days in Healthy Male and Non-fertile Female Volunteers||AstraZeneca|Yes|Completed|July 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171105||118598|
NCT01173874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENETS01|Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone|Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone||University of California, Los Angeles|Yes|Recruiting|July 2010|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|55 Years|No|||October 2012|October 3, 2012|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01173874||118387|
NCT01174966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-ICU-LDW-OCT|Assessment of Transcutaneous Oxygen Tension/Oxygen Challenge Test in Intensive Care Unit (ICU) Patients|Assessment of Transcutaneous Oxygen Tension and Oxygen Challenge Test in Adult Intensive Care Patients|ICUPtO2OCT|Peking Union Medical College Hospital|Yes|Recruiting|September 2009|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|95 Years|No|Probability Sample|The subjects were sequentially admitted to the Department of Critical Care department of        Peking Union Medical College Hospital from sept. of 2009 till the end of this study.|August 2010|August 3, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174966||118304|
NCT01183845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2008-2|Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease|A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease|CAPSCOL|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|April 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|N/A|No|||August 2011|April 26, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01183845||117623|
NCT01172106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/HD11/4572U|Impact of Family Psychoeducation on Psychosis|The Role of Psychoeducation on Perceived Social Support of Postpartum Others With a Psychotic Illness||Makerere University|Yes|Recruiting|August 2008|October 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Female|13 Years|50 Years|No|||July 2010|July 28, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172106||118521|
NCT01172119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08EU01|BioFreedom FIM Clinical Trial.|A Prospective, Single Blinded, Randomized Study to Evaluate the Safety and Effictiveness of a Low and Standard Dose Biolimus A9TM Drug-Eluteing Coronary Stent Delivery System Compared With a TaxusTM LiberteTM Control Arm for Treatment of Stenotic Lesions in Native Coronary Arteries.||Biosensors Europe SA|Yes|Completed|August 2008|July 2014|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|N/A|No|||September 2014|September 6, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172119||118520|
NCT01179815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 025/10|Swiss Diabetes Pilot-Study|Swiss Diabetes Pilot-Study, a Prospective Cohort Study of Patients With Type 1 and Type 2 Diabetes in Switzerland|SwissDiab|University Hospital Inselspital, Berne|Yes|Recruiting|January 2010|January 2099|Anticipated|January 2099|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|All patients with diabetes above age 18 are eligible for this study, irrespective of        duration of diabetes or treatment. Diabetes will be defined according to the current        diagnosis criteria suggested by the American Diabetes Association (fasting plasma glucose        ≥ 7mmol/L, occasional plasma glucose ≥11.1mmol/L (plus typical symptoms), a 2hour plasma        glucose of ≥11.1mmol/L after a 75g oral glucose tolerance test, or a HbA1c ≥ 6.5%), but        patients under treatment with ≥2 oral hypoglycemic agents (OHA) and/or insulin in the        absence of proof of a diagnosis by fasting, random plasma glucose or oral glucose        tolerance test will also be included. The type of diabetes will be diagnosed clinically in        most cases. In equivocal cases classification will be based on previously reported        criteria with the assistance of laboratory test results.|November 2015|November 23, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179815||117932|
NCT01158664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/649|What is the Influence of a Different Thread Pitch Design on Bone Remodelling Around Conical Southern Oral Implants?|A Prospective Multicenter Randomized Controlled Clinical Study on Conical Southern Implants With Different Thread Pitch||University Hospital, Ghent|No|Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158664||119550|
NCT01158677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/117|Short Term Outcome After Meniscectomy|Short Term Outcome After Meniscectomy||University Hospital, Ghent|No|Recruiting|July 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|all the meniscectomy patients (male & female, all ages)|December 2014|December 4, 2014|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158677||119549|
NCT01159262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-09-08|Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age|A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥28 Weeks to ≤44 Weeks Gestational Age||Hospira, Inc.|Yes|Completed|July 2010|August 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|28 Weeks|44 Weeks|No|||July 2015|July 23, 2015|June 30, 2010|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01159262||119505|
NCT01159522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCB01A-01|A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy|A Phase 1 Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy||SynCore Biotechnology Co., Ltd.|Yes|Active, not recruiting|April 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|June 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159522||119485|
NCT01159834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vaccine HCB 01|Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)|Proposal for HPV Vaccination of Women in the City of Barretos. A Pioneering Project Designed by the Pio XII Foundation - Barretos Cancer Hospital.||Barretos Cancer Hospital|No|Completed|September 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1574|||Female|10 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study included young girls enrolled in public and private schoolgirls, attending the        6th and 7th grades of the elementary school. Pregnant and breastfeeding adolescents and        girls who did not attend classes (although enrolled at school) were excluded. Considering        the inclusion criteria, 19 schools were candidates to the project (13 public and 6        private). The list provided by each school accounted for 1,615 girls, out of which, 41        were not eligible for the study. Thus, 1,574 girls were considered as potential candidates        to the vaccination program.|January 2012|January 23, 2012|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01159834||119461|
NCT01159210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220901|Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal|An International, Multi-centre, Prospective, Open-Label, Non-Randomised, Uncontrolled Study to Assess the Efficacy and Safety of Prothromplex Total in Oral Anticoagulant Reversal in Patients With Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X)||Baxalta US Inc.|No|Completed|July 2010|June 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|16 Years|N/A|No|||September 2012|June 26, 2015|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159210||119509|
NCT01159457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15364.ct.il|Comparison of Engerix B Vaccine Versus Sci-B-Vac Vaccine in Celiac Patients|Engerix B Versus Sci-B-Vac Immunization in a Celiac Population of Non-responders to Primary Hepatitis B Immunization Series - a Randomized Controlled Trial||Shaare Zedek Medical Center||Recruiting|April 2011|January 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|1 Year|20 Years|No|||April 2011|April 14, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159457||119490|
NCT01159223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV - NAT 110|Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)|A Multicenter Randomized Study to Compare the Efficacy and Safety of Lower Dose Atazanavir /Ritonavir (ATV/r 200/100 OD) Versus Standard Dose (ATV/r 300/100 mg OD) in Combination With 2NRTIs in Well Virology Suppressed HIV-infected Adults||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Active, not recruiting|May 2011|June 2016|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|559|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159223||119508|
NCT01159236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0765|Molecular Triaging of Newly Diagnosed Breast Cancer|Molecular Triaging of Newly Diagnosed Breast Cancer for Preoperative Therapies||M.D. Anderson Cancer Center|Yes|Withdrawn|September 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|N/A|No|||July 2012|July 27, 2012|July 7, 2010|No|Yes|Recent developments lead to re-evaluation of study.|No||https://clinicaltrials.gov/show/NCT01159236||119507|
NCT01159782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0712/59|Mechanisms of Rhinovirus Induced Asthma Exacerbations|Human Model of Rhinovirus Induced Acute Asthma Exacerbations||Imperial College London|Yes|Recruiting|October 2009|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 22, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159782||119465|
NCT01159483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701001|First-In-Human Study Of PF-04958242 In Healthy Volunteers|A Phase I, First-In-Human, Randomized, Subject And Investigator-Blind, Sponsor Open, Single Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-04958242 In Healthy Adult Volunteers||Pfizer|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 25, 2010|July 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159483||119488|
NCT01160107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-302|Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients|A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients|RP_MPR|Fondazione Neoplasie Sangue Onlus|Yes|Active, not recruiting|July 2008|August 2017|Anticipated|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|65 Years|N/A|No|||February 2016|February 5, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160107||119441|
NCT01161030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|almond1|Almonds and Diabetes Management|Almond Ingestion at Meal-time Reduces Postprandial Glycemia and Chronic Ingestion Reduces Hemoglobin A1c in Individuals With Well-controlled Type 2 Diabetes||Arizona State University|No|Completed|August 2008|November 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||July 2010|July 12, 2010|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161030||119371|
NCT01161290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nield005|Real-Time Telehealth to Promote Self-care Management for Chronic Obstructive Pulmonary Disease|A Randomized Controlled Trial Using Real-Time Interactive Audio/Visual Telehealth to Promote Self-care Management for United States Veterans With Chronic Obstructive Pulmonary Disease: a Pilot Study|E-Breathe|VA Greater Los Angeles Healthcare System|No|Completed|September 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|||Actual|22|||Both|45 Years|N/A|No|||July 2010|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161290||119351|
NCT01157689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-eff 2010|Artemether-Lumefantrine Effectiveness in Guinea-Bissau|The Routine Use of Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum at the Bandim Health Centre||Bandim Health Project|No|Active, not recruiting|March 2010|June 2014|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Capillary blood samples for drug concentration analysis and for PCR for identifying the      malaria parasites|Both|N/A|15 Years|No|Non-Probability Sample|Children diagnosed as having malaria at Bandim Health Center in Bissau. Of these all        children with a positive malaria film and/or a positive rapid diagnostic test will be        included in an observational follow-up study.|March 2013|March 16, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157689||119624|
NCT01157949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1007-1|A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)|A Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® for the Prevention of Cardiac Allograft Vasculopathy in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients.||Cedars-Sinai Medical Center||Not yet recruiting|November 2010|||November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|70 Years|No|||May 2010|July 7, 2010|July 7, 2010||||No||https://clinicaltrials.gov/show/NCT01157949||119604|
NCT01158183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14838|Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis|Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon β-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis|ROBUST|Bayer|No|Completed|July 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|226|||Both|18 Years|65 Years|No|Non-Probability Sample|"real world" population|July 2010|July 7, 2010|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158183||119586|
NCT01171352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006189|Predicting Hypotension During Dialysis in the ICU|Predicting Hypotension During Dialysis in the ICU||Oregon Health and Science University|No|Recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End        Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole        determinant for that level of care, will be invited to participate. The patient must have        acute or chronic needs for dialytic support during their ICU stay in order to qualify for        the study. Dialysis support may be provided by intermittent HD sessions, or continuous        venovenous hemodiafiltration (CVVHDF) depending on the underlying hemodynamic stability of        the patient.|July 2010|March 3, 2011|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171352||118579|
NCT01174979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-09|Caroverin and Inner Ear Diseases|Double Blind, Placebo-controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Transtympanic Treatment of Tinnitus With Caroverine||Phafag AG|Yes|Suspended|January 2011|||August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|August 2, 2010||No|due to less patient the study was suspended|No||https://clinicaltrials.gov/show/NCT01174979||118303|
NCT01170845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|531|Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy|A Pilot Study of Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy|NEIE|Yokohama City University Medical Center|No|Completed|March 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|31|||Both|55 Years|77 Years|No|||March 2007|July 26, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170845||118617|
NCT01170858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0379|Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal Dialysis|||Yonsei University|No|Completed|August 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01170858||118616|
NCT01183858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22162|A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)|A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)||Hoffmann-La Roche||Completed|October 2010|February 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|August 16, 2010||No||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01183858||117622|
NCT01172639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CareRA|Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.|A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.||Universitaire Ziekenhuizen Leuven|Yes|Completed|February 2009|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|400|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172639||118480|
NCT01179828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 213/09|Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)|Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain|Predictio|University Hospital Inselspital, Berne|Yes|Recruiting|July 2010|December 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|150|||Both|18 Years|80 Years|No|||December 2012|December 27, 2012|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179828||117931|
NCT01179841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00006553|Intervention for Toddlers at Risk for Autism Spectrum Disorders (ASD)|A Comprehensive Approach to Intervention for Toddlers at Risk for ASD||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|January 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|11 Months|21 Months|No|||February 2016|February 8, 2016|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01179841||117930|
NCT01158417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1935|Resveratrol in Type2 Diabetes and Obesity|Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects||Kaleida Health|No|Active, not recruiting|December 2008|August 2014|Anticipated|April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|102|||Both|20 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 17, 2012|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158417||119568|
NCT01159847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFSD DPP-Ⅳ LADA|Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA)|Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA)|DPP-ⅣLADA|European Foundation for the Study of Diabetes|Yes|Enrolling by invitation|January 2010|December 2012|Anticipated|July 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|70 Years|No|||January 2010|July 9, 2010|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01159847||119460|
NCT01158937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#08-316|Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients|Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patient With Exacerbation of Pulmonary Infection||St. Michael's Hospital, Toronto|No|Terminated|May 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|July 7, 2010||No|Inadequate enrolment and lack of resources|No||https://clinicaltrials.gov/show/NCT01158937||119530|
NCT01159821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017242|A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers|An Open-Label Study to Assess the Effect of CYP2D6 Inhibitor Paroxetine on the Single-Dose Pharmacokinetics of JNJ-31001074 in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|August 2010|October 2010|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|July 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159821||119462|
NCT01159496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2081003|Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760)|A Randomized Investigator And Subject-Blind, Sponsor Open, Placebo Controlled Phase 1 Study To Characterize The Safety, Tolerability, And Pharmacokinetics Of Ascending Multiple Doses Of PF-05212377 (SAM-760) Administered Orally To Healthy Young And Elderly Subjects|MAD|Pfizer|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2011|March 9, 2011|July 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159496||119487|
NCT01159509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8021-AM-CTIL|The Effect of Hypertrophic Pyloric Stenosis (HPS) on Sodium Intake in Childhood|||Sheba Medical Center|No|Not yet recruiting|September 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|7 Years|13 Years|No|Non-Probability Sample|Children ages 7-13 years. Status post HPS in infancy|July 2010|July 8, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159509||119486|
NCT01159795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0707/24|Studying Innate Immune Responses in Infants With Bronchiolitis|Investigating Type I and Type III Interferon Responses in Infants With Respiratory Syncytial Virus||Imperial College London|Yes|Suspended|October 2010|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Blood plasma - cytokines Blood EDTA - DNA Blood PAXgene tube - RNA Nasal lining fluid -      cytokines Nasal mucosal lining - RNA|Both|6 Weeks|1 Year|Accepts Healthy Volunteers|Probability Sample|Infants presenting with bronchiolitis presenting to St Mary's Hospital, London|April 2012|April 23, 2012|July 6, 2010||No|Awaiting further funding|No||https://clinicaltrials.gov/show/NCT01159795||119464|
NCT01159808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-001|A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects|A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects||Bristol-Myers Squibb|Yes|Completed|May 2010|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|July 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159808||119463|
NCT01161563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRE1001|Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration|Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer||Watson Pharmaceuticals|No|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|118|||Male|18 Years|N/A|No|||September 2013|September 5, 2013|July 9, 2010|Yes|Yes||No|June 10, 2013|https://clinicaltrials.gov/show/NCT01161563||119330|
NCT01161329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr2009/067|Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach|Description of Physical and Psychosocial Problems One Year After Stroke and the Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach||Uppsala University|Yes|Active, not recruiting|September 2009|December 2014|Anticipated|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|65 Years|85 Years|No|||January 2013|January 15, 2013|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161329||119348|
NCT01161849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lali2010|Peritoneal/ Serum Lactate Ratio in Relaparotomy|Peritoneal/Serum Lactate Ratio in Relaparotomy|lactate|Ospedale S. Giovanni Bosco|Yes|Completed|August 2010|December 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|No|Probability Sample|Patients admitted to our surgery department for the post operative period after major        abdominal surgery (neoplastic and non neoplastic) or urgent laparotomy for traumatic or        non traumatic acute abdomen.|July 2010|January 3, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01161849||119308|
NCT01161576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810010013|Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis|Direct CNS Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human CLN2 cDNA to Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)||Weill Medical College of Cornell University|Yes|Recruiting|August 2010|August 2032|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|2 Years|18 Years|No|||October 2015|December 9, 2015|March 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01161576||119329|
NCT01161862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29293|Integration of Continuous Glucose Monitoring Into a Bi-Hormonal Closed-Loop Artificial Pancreas for Automated Management Of Type 1 Diabetes|Integration of Continuous Glucose Monitoring Into a Bi-Hormonal Closed-Loop Artificial Pancreas for Automated Management of Type 1 Diabetes|CL2|Boston University|Yes|Completed|July 2010|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|12 Years|N/A|No|||October 2013|October 21, 2013|July 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161862||119307|
NCT01157702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|721001|Yearly Strain Variation Study, 2010/2011|An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2010/2011, in an Adult and Elderly Population||Baxter Healthcare Corporation|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 23, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157702||119623|
NCT01158209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113367|An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt|An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women >= 18 Years of Age, in Egypt||GlaxoSmithKline||Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|490|Samples With DNA|Endocervical samples|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women >= 18 attending out-patient departments of primary, secondary or tertiary care        centres for gynaecological examination and agreeing to provide a cervical sample for human        papillomavirus testing.|October 2011|July 12, 2012|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01158209||119584|
NCT01158482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06252010-6416|Filter Initial & Long Term Evaluation After Placement and Retrieval Registry|FILTER - Filter Initial & Long Term Evaluation After Placement and Retrieval (Including Laser-Assisted Retrieval) Registry|FILTER|Stanford University|No|Recruiting|June 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|No specific criteria. Anyone who will be undergoing IVC Filter Placement/Retrieval will be        eligible.|May 2015|May 18, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158482||119564|
NCT01172691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-085|Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts|Randomized, Blinded, Controlled Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts.||Baylor Research Institute|No|Active, not recruiting|July 2010|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|2|||Both|17 Years|70 Years|No|||March 2015|March 13, 2015|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172691||118477|
NCT01172704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC HIV Prevention|HIV/AIDS, Severe Mental Illness and Homelessness|HIV/AIDS, Severe Mental Illness and Homelessness||Boston Medical Center|Yes|Completed|October 2010|January 2016|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|240|||Both|19 Years|N/A|Accepts Healthy Volunteers|||August 2014|January 11, 2016|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01172704||118476|
NCT01172717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31701|Study of Panitumumab in the Treatment of Carcinoid Syndrome|Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome||Boston Medical Center|Yes|Withdrawn|July 2013|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|July 28, 2010|Yes|Yes|Study never began|No||https://clinicaltrials.gov/show/NCT01172717||118475|
NCT01183546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7149-I|Biomechanical Validation of the Transfer Assessment Instrument (TAI)|Biomechanical Validation of the Transfer Assessment Instrument (TAI)||VA Office of Research and Development|No|Completed|August 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|To initially evaluate the transfer measurement system and protocol, individuals without        disability will be recruited (preliminary phase). After validating and evaluating the        reliability and sensitivity of the measurement system, individuals with paraplegia and        tetraplegia will be recruited (final phase).|February 2016|February 11, 2016|July 16, 2010||No||No|January 8, 2016|https://clinicaltrials.gov/show/NCT01183546||117646|
NCT01183559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC IRB 07-017|A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery|Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, GE Junction and Gastric Cancer: A Phase I Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery (IRUSZACT0064)||Fox Chase Cancer Center|Yes|Recruiting|August 2008|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||February 2011|February 8, 2011|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183559||117645|
NCT01183884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-160|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma: A Phase II Study||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Months|N/A|No|||September 2015|September 21, 2015|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183884||117620|
NCT01179854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2Р/КИ/Б|Remegal Different Doses in Patients With Refractory Partial Seizures|Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures||Valexfarm|Yes|Completed|September 2009|September 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||December 2012|December 5, 2012|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01179854||117929|
NCT01184118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0265|DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?|Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea? DREAM-A Pilot Study|DREAM|University of Wisconsin, Madison|Yes|Completed|March 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|65 Years|No|||April 2011|April 28, 2011|August 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01184118||117603|
NCT01180166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-010|Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer|Phase II Study of Nimotuzumab and Concurrent Radiotherapy and Capecitabine for Inoperable Locally Advanced or Recurrent Gastric Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|May 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||September 2013|September 17, 2013|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01180166||117905|
NCT01158950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-12-461|A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors|A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors||University of California, San Francisco|No|Active, not recruiting|March 2010|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|154|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|July 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158950||119529|
NCT01158963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POC-004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2010|||||N/A|N/A|N/A||||||||||||||December 10, 2014|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158963||119528|
NCT01159860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol No. 33895|Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?|Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?||Milton S. Hershey Medical Center|No|Active, not recruiting|July 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2010|August 24, 2011|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01159860||119459|
NCT01159873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C37251/1080|Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women||Teva Pharmaceutical Industries||Terminated|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Female|40 Years|74 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|July 8, 2010||No|Study has been stopped by sponsor decision|No||https://clinicaltrials.gov/show/NCT01159873||119458|
NCT01159535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31183-J|Mindfulness Based Relapse Prevention: Efficacy and Mechanisms|Mindfulness Based Relapse Prevention: Efficacy and Mechanisms|MBRP|University of Washington|Yes|Active, not recruiting|October 2009|July 2012|Anticipated|May 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|70 Years|No|||June 2011|June 13, 2011|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01159535||119484|
NCT01160471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100153|Noninvasive Imaging of Heart Failure: A Pilot Study|Noninvasive Imaging of Heart Failure||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2010|||||N/A|Observational|Time Perspective: Prospective|||Actual|62|||Both|18 Years|N/A|No|||January 2016|February 2, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160471||119413|
NCT01160133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-67|To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops|||Alcon Research|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||January 2012|April 7, 2012|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160133||119439|
NCT01160458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100146|Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy|Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|June 2010|June 2016|Anticipated|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|July 9, 2010|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01160458||119414|
NCT01160744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13916|A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination With Platinum-based Chemotherapy Versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)||Eli Lilly and Company|Yes|Active, not recruiting|September 2010|May 2016|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|280|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|July 8, 2010|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01160744||119393|
NCT01160757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U/S1-SPOT|A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions|A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions||Arizona State University|Yes|Completed|October 2008|||July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 9, 2010|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160757||119392|
NCT01166438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDN 17|Anticholinergic vs. Botox Comparison Study|Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence|ABC|NICHD Pelvic Floor Disorders Network|Yes|Completed|March 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|249|||Female|21 Years|N/A|No|||September 2013|September 27, 2013|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166438||118955|
NCT01162252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005082|Improving Psoriasis Through Health and Well-Being|Improving Psoriasis Through Health and Well-Being||University of Rochester|Yes|Completed|March 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01162252||119277|
NCT01162499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007372|Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia|Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia After Nissen Fundoplication: Studies With the GLP-1 Receptor Antagonist Exendin-(9-39)||Children's Hospital of Philadelphia|No|Completed|April 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|7|||Both|6 Months|18 Years|No|||March 2015|March 12, 2015|May 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162499||119258|
NCT01162746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10032011|Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Comparison of Intravitreal Dexamethasone With Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Monotherapy in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration A Prospective, Randomized, Clinical Study||Medical University of Vienna||Recruiting|October 2011|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|N/A|No|||April 2015|April 7, 2015|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162746||119239|
NCT01163058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-01/2010|Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer|Retrospective Analysis Evaluating Molecular Factors of Primary Resistance to Tyrosine Kinase Inhibitors in Metastatic Non Small Cell Lung Cancer Patients||Istituto Clinico Humanitas|No|Active, not recruiting|June 2010|July 2011|Anticipated|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|non small cell lung cancer patients treated with gefitinib or erlotinib|July 2010|July 27, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01163058||119215|
NCT01163071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA601|A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas||Celgene Corporation|No|Terminated|March 2011|September 2014|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2011|November 3, 2011|June 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163071||119214|
NCT01173549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017224|A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers|A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2010|September 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|26|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 30, 2011|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173549||118412|
NCT01183572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0055/07|Trial of Pre-Pregnancy Supplements|Trial of Pre-Pregnancy Supplements|TOPPS|Harvard School of Public Health|Yes|Completed|August 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|802|||Female|15 Years|29 Years|Accepts Healthy Volunteers|||September 2012|September 8, 2012|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01183572||117644|
NCT01184131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0146|NCRR ARRA Development-Workforce Development|Implementation and Evaluation of Formal Training for Mentors of K-Series Mentored Career Awards||University of Wisconsin, Madison|No|Recruiting|September 2009|September 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2010|August 17, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01184131||117602|
NCT01180179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNH_RCT|PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers|Proton-Pump Inhibitor Versus Histamine-2 Receptor Antagonist on the Rebleeding Rate in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers: A Double-Blind Randomized Controlled Trial||Chinese University of Hong Kong|Yes|Recruiting|June 2010|May 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|228|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01180179||117904|
NCT01159548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0034B|Efficacy of Low Dose Promethazine for Postoperative Nausea and Vomiting|||Women's College Hospital|No|Terminated|July 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|400|||Female|18 Years|60 Years|No|||July 2011|July 26, 2011|July 7, 2010||No|Population of interest was no longer available|No||https://clinicaltrials.gov/show/NCT01159548||119483|
NCT01164670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0011|Evaluation of the Reproducibility of Jumping Mechanography|Evaluation of the Reproducibility of Jumping Mechanography in Older Adults and Comparison With Current Functional Assessment Tools|Jump|University of Wisconsin, Madison|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|96|Samples Without DNA|Serum will be collected for measurement of laboratory studies (serum chemistries, TSH and      25[OH]D),|Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ambulatory community dwelling adults who are able to stand without assistance. Both men        and women age ≥ 70 years from the Madison Wisconsin area. Specifically, participants will        be enrolled using the following strata in each gender group: low vitamin D/low functional        status (12 men and 12 women), normal vitamin D/low functional status (12 men and 12        women), low vitamin D/high functional status (12 men and 12 women), and normal vitamin        D/high functional status (12 men and 12 women). Low vitamin D will be defined as 25(OH)D        concentrations < 25 ng/ml, normal vitamin D status will be defined as 25(OH)D        concentration of 30 ng/ml or greater. Functional status will be based on screening short        physical performance battery (SPPB) score dichotomized at <9 vs. 9 and above.|March 2011|October 1, 2015|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164670||119091|
NCT01160146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0296|Geisinger Education Intervention Study in Obesity Protocol|Geisinger Education Intervention Study in Obesity Protocol|GEISO|Geisinger Clinic|No|Completed|August 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|289|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Geisinger's General Internal Medicine Primary Care Clinic Geisinger's Family Medicine        Primary Care Clinic|July 2015|August 14, 2015|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160146||119438|
NCT01160484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-0533|Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma|A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma||Oncotherapeutics|No|Completed|September 2009|September 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|July 7, 2010||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01160484||119412|
NCT01160770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13109A|Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome|Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome|LGS|Lundbeck LLC|No|Completed|December 2005|||February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|267|||Both|2 Years|60 Years|No|||March 2013|March 22, 2013|June 18, 2010|Yes|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT01160770||119391|
NCT01160783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-04-0136|Genetic Contributions to Autism Spectrum Disorders|Genetic Contributions to Autism Spectrum Disorders||Children's Hospital Boston|No|Suspended|April 2007|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|1500|Samples With DNA|Whole blood, DNA and RNA and/or Saliva, DNA|Both|18 Months|N/A|No|Non-Probability Sample|Children with a diagnosis of an Autism Spectrum Disorder (autism, pervasive developmental        disorder (PDD), or Asperger's syndrome) and their parents and/or siblings|August 2013|August 7, 2013|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160783||119390|
NCT01161303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUHT-III-KSB|An Investigation of Tumor Necrosis Factor (TNF)-Alpha in Asthma Using Biopsy Explants and Primary Bronchial Epithelial Cell Cultures|Study to Investigate the Role of TNF-alpha in Asthma Using Biopsy Explants and Primary Bronchial Epithelial Cell Cultures||University Hospital Southampton NHS Foundation Trust.|No|Completed|July 2000|June 2003|Actual|June 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|12|Samples With DNA|-  bronchial brushings and biopsies        -  Blood|Both|18 Years|65 Years|No|Non-Probability Sample|Primary care clinic|July 2010|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161303||119350|
NCT01161043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP232|New Glucose Sensor Pediatric|An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects||Medtronic Diabetes|No|Completed|July 2010|November 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|7 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric subjects, ages 7-17 inclusive, Type 1 diabetes|March 2011|September 19, 2011|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161043||119370|
NCT01161056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-081A|Genes and Phenotype (GAP) A National Resource for Genotype-Phenotype Studies of Immunological and Inflammatory Pathways|Genes and Phenotype (GAP) A National Resource for Genotype-Phenotype Studies of Immunological and Inflammatory Pathways|GAP|Northwell Health|No|Completed|May 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|N/A||1|Actual|5000|Samples With DNA|Blood sample will be processed to isolate DNA and peripheral blood mononuclear cells, which      will be stored in our Biorepository.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Controls|September 2015|September 9, 2015|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01161056||119369|
NCT01161316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-09-04|Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours|Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-line Treatment in Patients With Metastatic Colorectal Cancer (mCRC) and Wild-type KRAS Tumours|MACRO-2|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|August 2010|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|70 Years|No|||July 2015|July 24, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161316||119349|
NCT01162512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU-2010-01|Telephone Physical Activity Intervention in Obese Youth|Telephone-Based Physical Activity Intervention in Obese Youth|TPAI|East Carolina University|No|Active, not recruiting|July 2010|December 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162512||119257|
NCT01162759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-08DMagi-01|Home Blood Pressure Monitoring Project|Home Blood Pressure Monitoring Program|HBPM|Kaiser Permanente|No|Completed|July 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|348|||Both|18 Years|85 Years|No|||April 2012|April 4, 2012|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162759||119238|
NCT01163084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-01737|Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer|A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate||National Cancer Institute (NCI)||Active, not recruiting|July 2010|||January 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Male|18 Years|N/A|No|||March 2016|March 10, 2016|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163084||119213|
NCT01163370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|creatine and bone|Creatine Supplementation and Bone Mass|||University of Sao Paulo|No|Completed|July 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Female|60 Years|N/A|No|||November 2011|November 9, 2011|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163370||119191|
NCT01163383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-02-4159|131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma|I-Metaiodobenzylguanidine (131 I-MIBG) Therapy for Refractory Neuroblastoma and Paraganglioma/Pheochromocytoma Expanded Access Protocol||Children's Hospital of Philadelphia|No|Available|March 2005|July 2015|Anticipated|July 2015|Anticipated|N/A|Expanded Access|N/A|||||||Both|1 Year|N/A|No|||November 2015|November 23, 2015|July 13, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01163383||119190|
NCT01163396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASL606LIOM01|First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer|Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer|FOIB|Gruppo Oncologico del Nord-Ovest|Yes|Completed|July 2007|April 2010|Actual|April 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01163396||119189|
NCT01174680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM@CAD|Cardiogoniometry for Early Diagnosis of Coronary Artery Disease Symptomatik|Cardiogoniometry Zur Früherkennung CAD Symptomatik||Stiftung Institut fuer Herzinfarktforschung|No|Not yet recruiting|December 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|460|||Both|18 Years|N/A|No|||August 2010|August 3, 2010|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01174680||118325|
NCT01183598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA19847|A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment|Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment||Hoffmann-La Roche||Completed|August 2006|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183598||117642|
NCT01183871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011|Cerebral Oxygenation After Lung Resection|Changes in Cerebral Oxygenation in Patients With Pulmonary Dysfunction After Lung Resection||King Faisal University|Yes|Completed|February 2010|February 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|4||Anticipated|120|||Both|18 Years|60 Years|No|||March 2012|March 22, 2012|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01183871||117621|
NCT01184144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0066|Endometriosis: Immunomodulation|Effect of Pioglitazone on Peritoneal Cytokines in Women With Endometriosis||University of Wisconsin, Madison|No|Withdrawn|August 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Female|18 Years|45 Years|No|||April 2012|October 1, 2015|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01184144||117601|
NCT01184157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0256|Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections|Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections in Long-Acting Reversible Contraceptive Users||Washington University School of Medicine|No|Completed||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||||||Female|14 Years|45 Years||||August 2010|August 17, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184157||117600|
NCT01179867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN 0000086616 - 222163|Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge|Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge||McGill University|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3714|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 19, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179867||117928|
NCT01180153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaBJCH_SOX_BTC|Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)|An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma||Beijing Cancer Hospital|Yes|Not yet recruiting|August 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|74 Years|No|||August 2010|August 11, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01180153||117906|
NCT01180738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWSTTvsOWT_UIndy|Body Weight Supported Treadmill Training vs. Overground Walking Training in Persons With Chronic Stroke|Comparison of Short Bursts of Body Weight Supported Treadmill Training vs. Overground Walking Training in Persons With Chronic Stroke||University of Indianapolis|No|Completed|August 2010|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|80 Years|No|||January 2013|January 28, 2013|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01180738||117861|
NCT01159561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15812|Western Equine Encephalitis Vaccine|Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults|WEE|U.S. Army Medical Research and Materiel Command|No|Completed|February 2010|March 2012|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159561||119482|
NCT01164683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 10-066|A Pilot Study of CPAP Adherence Promotion by Peer Buddies With Sleep Apnea|A Pilot Study of CPAP Adherence Promotion by Peer Buddies With Sleep Apnea|CPAPPs|VA Office of Research and Development|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|21 Years|85 Years|Accepts Healthy Volunteers|||February 2013|April 6, 2015|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164683||119090|
NCT01165034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0808/17|Development of King's College Hospital Breathlessness Service|Development,Effectiveness and Cost-effectiveness of a New Respiratory and Palliative Care Out-patient Breathlessness Support Service||King's College London|Yes|Active, not recruiting|July 2010|May 2013|Anticipated|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|110|||Both|16 Years|90 Years|No|||April 2013|April 8, 2013|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01165034||119063|
NCT01160159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071012|Arterial Microcirculation, Macrocirculation and Thrombophilias|Arterial Microcirculation, Macrocirculation and Thrombophilias|MICMAC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2010|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|240|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups of 80 women will be compared: healthy volunteers and women with thrombophilia.|February 2010|July 9, 2010|February 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01160159||119437|
NCT01160172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113949|A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults|A Partially Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal 4-component Investigational Vaccine (GSK2392102A) in Healthy Adults||GlaxoSmithKline||Completed|July 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|88|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|July 11, 2013|July 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01160172||119436|
NCT01165346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKNO-HEP-0703|Stereotaxic Irradiation of Hepatocellular Carcinoma|Stereotaxic Irradiation of Hepatocellular Carcinoma : Phase II Study|CKNO-HEP|Centre Oscar Lambret|Yes|Active, not recruiting|August 2009|March 2018|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165346||119039|
NCT01165359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5277|Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults|A Randomized, Double-Blind, Phase 1b Study to Assess the Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Treatment-Naive HCV Mono-Infected Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2010|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|30|||Both|18 Years|65 Years|No|||March 2014|March 5, 2014|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165359||119038|
NCT01160796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVA|Lcr35® for Bacterial Vaginosis Prevention|Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial||Laboratoires Lyocentre|No|Completed|June 2010|April 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|352|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160796||119389|
NCT01165879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA5347|Measuring Uterine Electrical Activity Throughout Pregnancy and Labor Measuring Uterine Electrical Activity Throughout Pregnancy and Labor|||OB-Tools Ltd.|No|Recruiting|May 2010|||May 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|100|||Female|18 Years|60 Years|No|Probability Sample|Pergnant women which are admitted to Meir Medical Center with complaints of uterine        contractions starting.|July 2010|June 9, 2011|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01165879||118998|
NCT01166191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRONC 45.1,5|Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)|Concurrent Chemo-radiotherapy With IMRT for Stage I-III Small Cell Lung Cancer||Maastricht Radiation Oncology|No|Recruiting|May 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166191||118974|
NCT01158508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-08-081-01|Remote Ischemic Preconditioning in Subarachnoid Hemorrhage|Prophylactic Remote Ischemic Preconditioning for Cerebral Vasospasm Following Subarachnoid Hemorrhage|RIPC-SAH|University of California, Los Angeles|No|Completed|April 2010|July 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||December 2014|December 1, 2014|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01158508||119562|
NCT01158781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT074749|Restoration of Life Role Participation Through Cognitive and Motor Training for TBI|Restoration of Life Role Participation Through Integrated Cognitive and Motor Training for Individuals With TBI||Malcom Randall VA Medical Center|Yes|Recruiting|May 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|October 13, 2009||No||No||https://clinicaltrials.gov/show/NCT01158781||119541|
NCT01159041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH082861|Systems of Support Study for Childhood Depression|Evaluation of Family Focused Treatment for Childhood Depression|SOS|Boston University|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|7 Years|13 Years|No|||July 2015|July 20, 2015|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01159041||119522|
NCT01159639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8.1-10/41-2|Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting|Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting||University of Zagreb|No|Completed|June 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||June 2010|August 27, 2013|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159639||119476|
NCT01159925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112158|Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamanian Children|Epidemiologic Surveillance to Assess Trends in Acute Hepatitis A Among Children in Panama||GlaxoSmithKline||Completed|July 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|42|Samples With DNA|Serum|Both|1 Month|15 Years|No|Probability Sample|Children aged >1 month and <15 years of age being seen for possible acute hepatitis A        during the study time period at the selected sentinel hospitals of Panama|November 2012|November 21, 2012|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159925||119454|
NCT01183299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLR-2005049|Salty Life 7 Study: Effect of High Salt Intake on Several Physiological Systems in Immobilisation|Influence of a High Salt Intake on Sodium Retention, Bone Metabolism and Acid-base Balance in Immobilised Test Subjects|SL7|DLR German Aerospace Center|No|Completed|April 2005|April 2006||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|8|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2011|July 7, 2011|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01183299||117665|
NCT01183910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021775|A Novel Oral Natural Extract for the Treatment of Senile Purpura|A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Safety and Efficacy of a Novel Oral Natural Extract for the Treatment of Senile Purpura||Nexgen Dermatologics, Inc.|Yes|Active, not recruiting|November 2008|August 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|75|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 6, 2011|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183910||117618|
NCT01180192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gungorduk09|Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage|Phase 3 Study of Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage||Erzincan Military Hospital||Recruiting|May 2010|September 2010|Anticipated|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||May 2010|February 11, 2011|August 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01180192||117903|
NCT01179880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6005-J081-101|A Study of E6005 in Japanese Patients With Atopic Dermatitis|A Phase 1/2 Study of E6005 in Japanese Patients With Atopic Dermatitis||Eisai Inc.||Completed|September 2010|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|20 Years|65 Years|No|||January 2014|January 31, 2014|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01179880||117927|
NCT01181362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0886-AE|Comparing Head and Neck Endoscopy Procedures|A Feasibility Study Comparing Head And Neck Endoscopy Procedures In The Upright And Supine Positions||University Health Network, Toronto|Yes|Completed|September 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181362||117813|
NCT01164696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13455|A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin|A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin||Bayer|No|Completed|August 2007|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with relapsed or refractory FL who have been treated with 90Y-Zevalin in        Belgium within the first 24 months after ethics approval|August 2010|August 23, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01164696||119089|
NCT01164709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 65/08|Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer|Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies||Swiss Group for Clinical Cancer Research|No|Completed|July 2010|November 2013|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01164709||119088|
NCT01165047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0|Nitric Oxide, GeNO Nitrosyl Delivery System|An Open Label, Non-Randomized Pilot Study to Evaluate the Safety and Performance of the GeNO Nitrosyl Delivery System in Subjects Being Evaluated for Orthotopic Heart Transplantation (OHT), or Left Ventricular Assist Device (LVAD) Implantation||Aurora Health Care|Yes|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|July 16, 2010|Yes|Yes||No|August 7, 2014|https://clinicaltrials.gov/show/NCT01165047||119062|
NCT01161355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00021|Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject|An Exploratory Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9668 With Respect to an Intra-venous Microdose of [14C]AZD9668 in Healthy Male Subjects||AstraZeneca|No|Completed|June 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01161355||119346|
NCT01165008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS 01|Anakinra in Myositis|Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies||Karolinska Institutet|No|Completed|September 2003|September 2008|Actual|||Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||||||Both|18 Years|80 Years|No|||February 2005|July 16, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165008||119065|
NCT01165021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13621|A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer|An Exploratory Phase 2 Study of Pemetrexed/Cisplatin as Pre-operative Chemotherapy in the Treatment of Stage IIIAN2 Nonsquamous Non-Small Cell Lung Cancer||Eli Lilly and Company|No|Active, not recruiting|November 2010|March 2016|Anticipated|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|July 14, 2010|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT01165021||119064|Due to difficulties identifying suitable participants and enrollment delays, entries were closed after 19 of planned 33 participants signed consent. Results based on 19 participants who received ≥1 dose of chemotherapy. View results with caution.
NCT01165892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0567|Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)|Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using a Single Dose of Gadofosveset (Ablavar)||Washington University School of Medicine|No|Completed|July 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years or older with pulmonary embolism|December 2014|December 8, 2014|July 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165892||118997|
NCT01165632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1078|Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma|A Pilot Study of Utility of 18F-FDOPA-PET for Neurosurgical Planning and Radiotherapy Target Delineation in Glioma Patients: Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Brain Tumors||Mayo Clinic|Yes|Active, not recruiting|July 2010|||July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165632||119017|
NCT01166451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD033487|The Anemia Control Program: High or Low Iron Supplementation|Iron Deficiency Anemia and Infant Behavior: Preventive Trial||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Completed|September 1991|March 2004|Actual|August 1994|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|835|||Both|6 Months|6 Months|No|||October 2011|October 17, 2011|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166451||118954|
NCT01166464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA027142|Examining a Text Message Intervention for Smoking Cessation|Examining a Text Message Intervention for Smoking Cessation||The Miriam Hospital|No|Completed|July 2009|October 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 31, 2014|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01166464||118953|
NCT01162265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICT|Prognostic Value of Interferon Gamma Release Assays in Predicting Active Tuberculosis Among Individuals With, or at Risk of, Latent Tuberculosis Infection|Prognostic Value of Interferon Gamma Release Assays in Predicting Active Tuberculosis Among Individuals With, or at Risk of, Latent Tuberculosis Infection|PREDICT|Public Health England|Yes|Active, not recruiting|August 2010|June 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|Samples With DNA|A biobank will be established from samples collected in this study, subject to routine HTA      requirements in the UK. This has full ethical approval and is included in the consent to      take part in the study.|Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Those who are close contacts of active tuberculosis cases or those who have are new        entrants to the UK from high incidence countries (>40/100000).|October 2015|October 19, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162265||119276|
NCT01158521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE4809|Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer|A Phase II Study of Pazopanib to Enable Partial Nephrectomy||Case Comprehensive Cancer Center|Yes|Completed|June 2010|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01158521||119561|
NCT01159054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001049|Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid|Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid||Brigham and Women's Hospital|No|Terminated|July 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|July 7, 2010|Yes|Yes|The funding source is not going to fund this anymore. Only two subjects completed the study    therefore meaningful analysis not possible.|No||https://clinicaltrials.gov/show/NCT01159054||119521|
NCT01159067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09187|Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload|Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation||City of Hope Medical Center|Yes|Terminated|July 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|July 6, 2010|No|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT01159067||119520|
NCT01159340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Icare-0021|Icare Versus Haag-Streit Applanation Tonometer|Design Compliance Testing of the Icare One Rebound Tonometer According to the American National Standard ANSI Z80.10-2001 and International Standard ISO 8612.2 for Tonometers||Icare Finland Oy|No|Completed|May 2009|November 2009|Actual|||N/A|Observational|N/A||1|Actual|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were eligible for the study if they had no exclusion criteria specified in the        ANSI/ISO standard. One eye from 260 subjects was selected for the study. The minimum        sample size according to the ANSI standard is 150. In order to aid enrollment of at least        40 eyes in each pressure range (7-16 mmHg, >16 to <23 mmHg and 23 mmHg or higher),        subjects were invited to participate on the basis of prior knowledge of their IOP range.        One eye of each subject was selected for the study by an investigator, based on the        history of the patient, results of an external examination of the eye with slit lamp,        keratometry readings, and prior knowledge of the IOP range.|July 2010|July 8, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01159340||119499|
NCT01183078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012034|Distal Locking Using an Electromagnetic Field Guided Computer Based Real Time System for Orthopaedic Trauma Patients|Distal Locking Using an Electromagnetic Field Guided Computer Based Real Time System for Orthopaedic Trauma Patients|Sure Shot|Wake Forest School of Medicine|No|Completed|August 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183078||117682|
NCT01183312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00044836|Flumazenil for the Treatment of Primary Hypersomnia|A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors||Emory University|No|Completed|September 2010|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|August 9, 2010|Yes|Yes||No|January 11, 2013|https://clinicaltrials.gov/show/NCT01183312||117664|EEG power was specified as a secondary outcome measure. Second-by-second manual artifact removal has been necessary to ensure interpretable data. This artifact removal is in progress and results will be reported separately.
NCT01179893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0280-B|Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis|A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis||University Health Network, Toronto|No|Completed|March 2007|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||August 2010|August 9, 2010|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179893||117926|
NCT01180751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2010:014|18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology|18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology||University of Manitoba|Yes|Enrolling by invitation|July 2010|December 2013|Anticipated|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|N/A|No|||July 2013|August 14, 2013|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180751||117860|
NCT01181115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108MS301|Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)|An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis|Avonex China|Biogen|No|Completed|April 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|55 Years|No|||November 2011|September 12, 2013|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01181115||117832|
NCT01180452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2008-4|Endoscopic Detection of Dysplasia in Crohn 's Disease Patient|Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients|DYDJI|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|January 2010|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|107|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01180452||117883|
NCT01180465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPO-102-CL-09|A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity|A Multi-center, Randomized, Double-masked, Placebo-controlled, Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity||Neothetics, Inc|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|160|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180465||117882|
NCT01181752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01479|Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana|Educational Intervention, Observing Participants' Proficiency of Eye Drop Instillation||University of British Columbia|No|Not yet recruiting|February 2012|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People in Ghana needing proficiency of eye drop instillation in postoperative cataract        surgery|February 2012|February 28, 2012|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181752||117783|
NCT01161082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1001|Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single to Multi-Dose Study of Safety, Tolerability, and Bioeffect of Subcutaneously Administered REGN727 in Patients With and Without Concomitant Atorvastatin||Regeneron Pharmaceuticals|No|Completed|June 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|72|||Both|18 Years|65 Years|No|||November 2011|January 24, 2015|July 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01161082||119367|
NCT01161368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECOG/BC.1.2.001|A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients|A Phase II Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients Pretreated With Chemotherapy or Hormonal Treatment in Combination With Lapatinib for Metastatic Disease||Central European Cooperative Oncology Group|Yes|Terminated|September 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||May 2014|August 11, 2015|May 27, 2010||No|poor recruitment|No||https://clinicaltrials.gov/show/NCT01161368||119345|
NCT01165645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1083|Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma|Lopinavir/Ritonavir as an Immunomodulator to Enhance Vaccine Responsiveness||Mayo Clinic|Yes|Withdrawn|November 2010|||May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|July 14, 2010|No|Yes|no patients enrolled|No||https://clinicaltrials.gov/show/NCT01165645||119016|
NCT01161901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0078|Impact of Inflammation Biomarkers on the Acute Respiratory Distress Syndrome (ARDS) Definition|Impact of Inflammation Biomarkers on the Acute Respiratory Distress Syndrome Definition in Intensive Care Unit||University Hospital, Clermont-Ferrand||Completed|June 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|134|||Both|18 Years|N/A|No|Non-Probability Sample|Defined population|July 2014|July 4, 2014|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01161901||119304|
NCT01166204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRONC CONCURR MLD/BRONC MLD|Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)|Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With IMRT for Stage I-III Non-small Cell Lung Cancer to an Individualised MLD||Maastricht Radiation Oncology|No|Recruiting|May 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166204||118973|
NCT01157975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060913|Study the Relationship Between Obesity and Hepatitis C Replication|A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.||University of California, San Diego|No|Active, not recruiting|October 2008|September 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2011|February 11, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157975||119602|
NCT01158235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-109-02|A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)|A Randomised, Double-blind, Placebo-controlled, Ascending Dose Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)||Lytix Biopharma AS|Yes|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Anticipated|24|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158235||119582|
NCT01159080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AKR07T|Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients|Organ Function Preservation by the Combination Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients: OPTIMUM Study|OPTIMUM|Asan Medical Center|No|Recruiting|July 2010|July 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01159080||119519|
NCT01159353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_C_01160|Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart|A Randomized, Double Blind Study to Assess the Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart||Sanofi|No|Completed|September 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|70 Years|No|||July 2010|July 15, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159353||119498|
NCT01159652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63-SR-10|Hypnotic Medications and Memory: Effect of Drug Exposure During the Night|Hypnotic Medications and Sleep-dependent Memory Consolidation: the Effect of Variable Drug Exposure During the Night||St. Luke's Hospital, Chesterfield, Missouri|No|Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|4||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159652||119475|
NCT01182805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-SPEED|Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function|Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function|RF-SPEED|University of Michigan|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|August 12, 2010|Yes|Yes||No|June 25, 2012|https://clinicaltrials.gov/show/NCT01182805||117702|
NCT01183091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040411|Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of AF|Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of the Atrial Fibrillation|EVABLAF|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2005|October 2010|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|503|||Both|18 Years|79 Years|No|Non-Probability Sample|Description of the patients experiencing a first AF ablation|September 2012|September 19, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183091||117681|
NCT01183325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/291|Prospective Evaluation of the Proceed Ventral Patch With and Without Laparoscopic Evaluation|Multicentric Evaluation of the Proceed Ventral Patch for Umbilical and Small Primary Ventral Hernias Less Than 3cm Diameter With One Year Follow-up||University Hospital, Ghent|No|Completed|September 2009|September 2013|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01183325||117663|
NCT01183585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25262|A Study of RO4917838 With Rosuvastatin in Healthy Volunteers|A Single Center, Open-label, Fixed Sequence, Two-period Study to Investigate the Effect of RO4917838 on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers||Hoffmann-La Roche||Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01183585||117643|
NCT01180478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004660|Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer|A Multi-center, International Study to Compare Use of Narrow Band Imaging (NBI) Versus White Light(WL) During Transurethral Resection of Bladder Tumors (TURB) to Asses Recurrence of Bladder Cancer in Terms of Safety and Efficacy||Clinical Research Office of the Endourological Society|No|Completed|August 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180478||117881|
NCT01181375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 06-0379-CE|Predictive Assays In Cervix Cancer|Predictive Assays in Cervix Cancer: Assessment of Hypoxia, Interstitial Fluid Pressure, and Tissue and Plasma Biomarkers of Hypoxia (CXTF10)||University Health Network, Toronto|Yes|Active, not recruiting|August 2006|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|500|||Female|18 Years|N/A|No|||June 2015|June 12, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181375||117812|
NCT01181089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104MS101|Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)|A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis||Biogen|Yes|Withdrawn|September 2010|||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|57 Years|No|||January 2012|September 12, 2013|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01181089||117834|
NCT01181102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-B-J302|A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty|A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)||Daiichi Sankyo Inc.|Yes|Completed|March 2009|February 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|716|||Both|20 Years|84 Years|No|||February 2015|February 3, 2015|August 12, 2010||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01181102||117833|
NCT01182012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVD-SMI-2009-03|Reduction of Cardiovascular Risk in Severe Mental Illness|Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs|RISCA-TMS|Consorci Hospitalari de Vic|Yes|Recruiting|August 2010|December 2012|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|391|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182012||117763|
NCT01160861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP4840g|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis|A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis||Genentech, Inc.||Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|No|||January 2012|January 2, 2012|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01160861||119384|
NCT01161095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCP.2010.0074|A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period|||United States Naval Medical Center, Portsmouth|Yes|Recruiting|August 2010|September 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 29, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161095||119366|
NCT01161602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pumo-10-001|A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Dose Levels of Pumosetrag in Patients With Symptoms Associated With Gastroesophageal Reflux Disease (GERD) Receiving a Standard Refluxogenic Meal||Edusa Pharmaceuticals, Inc.||Completed||May 2011||||Phase 2|Interventional|N/A|4||||||Both|18 Years|70 Years|No|||September 2011|September 20, 2011|July 12, 2010||||||https://clinicaltrials.gov/show/NCT01161602||119327|
NCT01161615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-7EAT-1006|MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder||MEDRx USA, Inc.|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|350|||Both|14 Years|N/A|No|||June 2012|June 28, 2012|July 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161615||119326|
NCT01161628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 893|Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)|Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease||Northside Hospital, Inc.|No|Active, not recruiting|April 2011|February 2016|Anticipated|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||January 2016|January 27, 2016|July 12, 2010|Yes|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01161628||119325|
NCT01157728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071102|Early Cognitive Impairment in Multiple Sclerosis|Early Cognitive Impairment in Multiple Sclerosis: a Multimodal MRI Study Evaluating the Relative Contribution of Cortical and White Matter Tract Injury|CogniSEP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|69|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Relapsing remitting Multiple Sclerosis patients          -  Age: 18-40 years          -  Evolving between 3 and 5 years          -  EDSS<5|May 2010|July 30, 2012|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157728||119621|
NCT01157741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-033|Community-based Follow-up of Severely Malnourished Children|Efficacy of Community-based Follow-up, Food Supplementation and Psychosocial Stimulation in the Home-management of Young Severely Malnourished Bangladeshi Children: a Randomized Intervention Trial||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|October 2003|June 2008|Actual|June 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Actual|507|||Both|6 Months|24 Months|No|||December 2003|July 7, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157741||119620|
NCT01157988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISL-2007|90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma|Phase II Study of 90Y-ibritumomab Tiuxetan Treatment as a Consolidation After 6th R-CHOP Chemotherapy in Patients With Limited-stage, Bulky Diffuse Large B Cell Lymphoma||Chonnam National University Hospital|Yes|Completed|January 2007|||January 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2006|July 7, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157988||119601|
NCT01158248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000675699|Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer|A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB||National Cancer Institute (NCI)||Recruiting|February 2010|||March 2013|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|N/A|N/A|No|||July 2010|July 8, 2010|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01158248||119581|
NCT01159093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-00-7352|Giving Immunizations Through Vaccine Education|Using Health Information Technology to Improve Healthcare Quality in Primary Care Practices and in Transitions Between Care Settings|GIVE|Children's Hospital of Philadelphia|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|23675|||Female|11 Years|17 Years|No|||August 2011|March 11, 2015|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01159093||119518|
NCT01159106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-PI-3132|The Use of Neurally Adjusted Ventilatory Assist (NAVA) Versus Pressure Support During Asynchrony in Children|The Use of NAVA vs. Pressure Support During Asynchrony in Children|NAVAChildren|Hospital Universitario La Paz|No|Recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|1 Month|18 Years|No|||July 2010|July 8, 2010|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01159106||119517|
NCT01159366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00402675|Incidence of Occluded Culprit Arteries and Impact of Coronary Collaterals on Outcome in Patients With NSTEMI|Substudy of the Leipzig Immediate Versus Early and Late Percutaneous Coronary Intervention Trial in NSTEMI - LIPSIA-NSTEMI TRIAL||University of Jena|Yes|Completed|July 2006|January 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|602|||Both|18 Years|90 Years|No|||July 2010|July 9, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159366||119497|
NCT01159379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1131/09|Safety of Ertapenem in Beta-lactam Allergic Patients.|Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams||Catholic University of the Sacred Heart|Yes|Not yet recruiting|January 2011|December 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|16 Years|75 Years|No|||January 2010|January 4, 2011|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01159379||119496|
NCT01159665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-010|The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)|An Open-Label, Ascending-Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects Scheduled for Primary Pars Plana Vitrectomy|MIVI-10|ThromboGenics|No|Completed|July 2010|January 2011|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|38|||Both|18 Years|N/A|No|||April 2014|December 2, 2014|July 7, 2010||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT01159665||119474|
NCT01159990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 084|Antigenic Competition in HIV Preventive Vaccines|A Randomized, Double Blind Phase 1b Trial to Examine the Influence of Antigenic Competition on the Immunogenicity of HIV-1 Gag/Pol: A Comparison of rAd5 Gag/Pol Env A/B/C to rAd5 Gag/Pol||National Institute of Allergy and Infectious Diseases (NIAID)|No|Active, not recruiting|January 2011|||August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|July 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01159990||119449|
NCT01160289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11888|A Study of LY900010 in Erectile Dysfunction|A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction||Eli Lilly and Company|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|378|||Male|45 Years|70 Years|No|||December 2011|February 10, 2012|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01160289||119427|
NCT01183338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWI-US11-006|Accuracy of Continuous SpO2 Measurement in Adults|SpO2 Accuracy Validation of Sotera Wireless Pulse Oximetry Systems During Non-Motion and Motion Conditions of Induced Hypoxia as Compared to Arterial Blood CO-Oximetry|SPO2|Sotera Wireless, Inc.|No|Withdrawn||||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy adult volunteers, male or female, of any ethnic background. To the extent possible        while still achieving timely enrollment, subjects should vary from one another in their        physical characteristics. Each subject must also meet all of the inclusion and exclusion        criteria prior to study entry and give informed consent to participate in this study.|June 2011|June 21, 2011|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183338||117662|
NCT01183611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT008|The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates|The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates Born to Mother With Positive for Both HBsAg and HBeAg, Positive for HBsAg But Negative for HBeAg, Negative for HBsAg, HBeAg, HBeAb and HBcAb||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|April 2007|September 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|7||Anticipated|1740|||Both|N/A|24 Hours|No|||September 2010|September 16, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01183611||117641|
NCT01183624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCTPAI3001|A Controlled Study of an Herbal Topical Patch in Treating Osteoarthritis (OA) of the Knee|A Multi-Center, Randomized, Double-Blind, Parallel, Placebo Control Study of a Traditional Chinese Medicine Topical Analgesic Patch in the Treatment of Osteoarthritis of the Knee||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|626|||Both|40 Years|70 Years|No|||January 2016|January 6, 2016|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01183624||117640|
NCT01183897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-161|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow: A Phase II Study||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Months|N/A|No|||September 2015|September 18, 2015|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183897||117619|
NCT01180764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00040562|Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia|Effects of Lovaza Monotherapy vs. Placebo on Composition and Function of HDL and Other Lipoproteins, and on Other Lipid-Related Parameters||University of Utah|No|Withdrawn|August 2010|October 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|35 Years|75 Years|No|||July 2011|February 4, 2016|May 17, 2010|Yes|Yes|Withdrawn for administrative reasons.|No||https://clinicaltrials.gov/show/NCT01180764||117859|
NCT01180777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1579AP|Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP)|Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP) Contact Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|July 2010|||August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|95|||Female|18 Years|40 Years|No|||May 2015|May 6, 2015|August 3, 2010|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01180777||117858|
NCT01181401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No. 2010-019347-18|InductionChemo-Radio-Antibody-Treatment|Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck|ICRAT|Charite University, Berlin, Germany|Yes|Recruiting|August 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||August 2010|August 26, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181401||117810|
NCT01181388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64456541|Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients|Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients|SUIT-AMI|Beijing Anzhen Hospital||Recruiting|April 2010|October 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||June 2010|August 12, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181388||117811|
NCT01181765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100747|The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy|The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)|ICE|Janssen Inc.|No|Completed|June 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181765||117782|
NCT01182649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM_DES02|Everolimus Stent in Patients With Coronary Artery Disease (CAD)|Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease|RACES|San Giuseppe Moscati Hospital|No|Completed|March 2007|June 2010|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|85 Years|No|||May 2010|August 16, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01182649||117714|
NCT01182909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099046-F|Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC)|Far Eastern Memorial Hospital||Far Eastern Memorial Hospital|No|Recruiting|August 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We propose a case-control study of 2000 NPC cases (both retrospective [n=800] and        prospective [n=1,200]) and 2,000 age-gender-matched hospital controls in northern Taiwan|September 2011|September 16, 2011|August 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01182909||117695|
NCT01157494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDGEE_2010_hand_class|Validity of Manipulation Taxonomy of Spastic Hemiplegic Cerebral Palsy (CP) Forms|Validity of Manipulation Taxonomy of Spastic Hemiplegic Cerebral Palsy Forms Proposed by Ferrari A et.al.||University of Modena and Reggio Emilia|No|Completed|April 2010|July 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|||Both|5 Years|18 Years|No|Non-Probability Sample|We retrospectively studied children with hemiplegia and CP who are followed by the Unit        for Severe Disability in the Developmental Age at the Hospital of Reggio Emilia (Italy).|April 2010|July 6, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157494||119638|
NCT01161693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01157|The Effects of a Head Elevated Ramped Position During Elective Cesarean Delivery After Combined Spinal Epidural (CSE) Anesthesia|The Effects of a Head Elevated Ramped Position During Elective Cesarean Delivery After Combined Spinal Epidural (CSE) Anesthesia||University of British Columbia|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Female|19 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 9, 2011|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161693||119320|
NCT01161381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1001|Evaluation Of Patients With Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) Based on Nonlinear Analysis Of Respiratory Signals|Evaluation Of Patients With Suspected Obstructive Sleep Apnea - Hypopnea Syndrome Using Two Models Based on Nonlinear Analysis Of Respiratory Signals||Aristotle University Of Thessaloniki|No|Completed|November 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred to the Sleep Unit of a tertiary hospital in northern Greece during the        years 2005-2008 and who accepted to sign the informed consent form were included in the        study. One out of every five consecutive patients was selected in order to ensure        randomization.|December 2005|July 12, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161381||119344|
NCT01157780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128695|Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation|Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation||University of Tennessee|No|Recruiting|October 2008|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|1 Year|No|||June 2011|June 16, 2011|March 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01157780||119617|
NCT01158261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-08-004|The Evicel Post-Authorization Surveillance Study|A Prospective, Single-Arm, Observational, Non-interventional Study for EVICEL ™ Fibrin Sealant (Human) When Used as an Adjunct to Haemostasis in Vascular Surgery||Ethicon, Inc.|No|Completed|June 2010|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects requiring elective vascular procedures|July 2015|July 22, 2015|July 6, 2010|No|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01158261||119580|Limitations of the study include the small number of centers involved and the observational nature of the design.
NCT01158274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02918|RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors|A Phase 1 Study of RO4929097 (NSC749225) in Combination With Capecitabine in Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|June 2010|||August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2014|November 6, 2014|July 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01158274||119579|
NCT01157754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-GV-05-2009-01|Oral Contraceptive Pill and GnRH Antagonist Versus Long Protocol in IVF Patients|Cycle Planning With OCP in GnRH Antagonists Cycles Versus Long Protocol in Good Prognosis IVF Patients|Larganta|IVI Madrid|No|Completed|June 2009|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Female|18 Years|38 Years|No|||April 2015|April 21, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157754||119619|
NCT01157767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-062|Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation|A Feasibility Study of the Effects of a Directed Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Female|18 Years|N/A|No|Non-Probability Sample|Potential research subjects may be identified in advance by a member of the patient's        treatment team, the principal investigator, or research team at Memorial Sloan-Kettering        Cancer Center (MSKCC).|April 2015|April 28, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157767||119618|
NCT01158560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McFlu2 10-313|A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections|McFlu2 COLD3 Prevention: A Randomized, Placebo-controlled, Double Blind Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections in McMaster University Students||St. Joseph's Healthcare Hamilton|Yes|Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|600|||Both|17 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 2, 2012|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01158560||119558|
NCT01159392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-0152|Alveolar Recruitment in Brain Injury|Effects of Recruitment Maneuvers in Patients With Acute Brain Injury and Acute Lung Injury||Hospital Clinic of Barcelona|No|Completed|February 2001|November 2003|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with brain injury (Glasgow Coma Score<13) admitted into the Trauma and Surgical        Intensive care unit (ICU) at the Hospital Clinic, Barcelona.|February 2001|July 8, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01159392||119495|
NCT01159691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0970|Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch|A Multicentric, Non-interventional Study on Switching From Oral Parkinson Therapy to Neupro® in Patients With Idiopathic Parkinson's Disease With Gastrointestinal Symptoms|NON-GI|UCB Pharma|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Parkinson's Disease (PD) suffering from gastrointestinal complaints under        oral anti-parkinson treatment; treated in Germany by neurological outpatient centers        (clinic/ practice of neurologist).|May 2013|May 13, 2013|July 8, 2010|No|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT01159691||119472|
NCT01162889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2281001|Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People|Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ATR-107 Administered Subcutaneously And Intravenously To Healthy Subjects||Pfizer|No|Terminated|June 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|11||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|June 9, 2010|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01162889||119228|
NCT01163734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-270-0101|Ranolazine in Diastolic Heart Failure|A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction|RALI-DHF|Gilead Sciences|No|Completed|April 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Both|40 Years|N/A|No|||March 2011|July 11, 2012|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01163734||119163|
NCT01163500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S07240|Coenzyme Q10 in Relation of the Lipid Peroxidation, Antioxidant Enzyme Activities in Coronary Artery Disease Patients|||Taichung Veterans General Hospital|Yes|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|59|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 10, 2013|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01163500||119181|
NCT01164280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-2-083 (5266)|Effect of Pulse Rate Changes on Clinical Outcome|The Effect of Pulse Rate Changes on Clinical Outcome in Sacral Neuromodulation||Maastricht University Medical Center|No|Completed|July 2008|January 2010|Actual|December 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||July 2010|July 15, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01164280||119121|
NCT01154439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML1208|Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Study Investigating the Combination of RAD001 With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|AML1208|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|October 2010|June 2016|Anticipated|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|61 Years|75 Years|No|||July 2015|July 9, 2015|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154439||119873|
NCT01154452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01412|Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma|A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas||National Cancer Institute (NCI)|Yes|Completed|June 2010|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||November 2014|May 22, 2015|June 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154452||119872|
NCT01154465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOL09-PR-DUPONT|A Trial to Study the Influence of Ultrasound Guidance on the Complications of Central Catheter|Impact of Ultrasound Guided Central Venous Catheterization on Complications in Obese Patients in Intensive Care Unit||Centre Hospitalier Universitaire, Amiens|No|Recruiting|July 2010|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|450|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154465||119871|
NCT01154764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG100649-1-03|Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649|A Randomized, Open, Crossover Clinical Study to Investigate the Effects of Ketoconazole on the Pharmacokinetics of CG100649 in Healthy Male Volunteers||CrystalGenomics, Inc.|No|Completed|October 2009|December 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01154764||119848|
NCT01154998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H1102/46|Case-Control Study of Fibrotic Interstitial Lung Disease (ILD) and Cardiac Disease / Interventions.|Case-Control Study of Fibrotic Interstitial Lung Disease and it's Association With Cardiac Disease or Cardiac Intervention.||St George's Healthcare NHS Trust|No|Not yet recruiting|July 2010|April 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|360|||Both|18 Years|N/A|No|Non-Probability Sample|Cases - patients with IPF or UIP. Controls - hospital clinic attenders.|June 2010|June 30, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154998||119830|
NCT01186328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2009-007|EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)|T2009-007: A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) [IND 108753]||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|August 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|1 Year|21 Years|No|||May 2015|May 14, 2015|August 19, 2010|No|Yes|The company (Enzon Pharmaceuticals)providing the drug EZN-3042 decided to end its development    of EZN-3042.|No||https://clinicaltrials.gov/show/NCT01186328||117434|
NCT01186601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15329|Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer|Open-label Study for an Exploration of Tumor Accumulation of the 18F Labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to </= 0.1 mg Total Quantity) in Patients With Prostate Cancer or Other Malignant Tumors||Piramal Imaging SA|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|90 Years|No|||November 2014|November 11, 2014|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01186601||117413|
NCT01186835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-stu24810|Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone|Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone: A Split-face, Rater-blinded Randomized Control Trial||Northwestern University|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186835||117395|
NCT01187108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0078|Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru|Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness|CoCMS|University of Colorado, Denver|Yes|Completed|June 2013|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|85|||Male|18 Years|N/A|No|||May 2015|May 13, 2015|August 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187108||117374|
NCT01165138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106827|Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics|HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents||GlaxoSmithKline|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|612|||Both|12 Years|N/A|No|||August 2013|July 16, 2015|July 15, 2010|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01165138||119055|
NCT01165151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK081607-01A1|Impact of Group Size in Weight Loss Interventions|Improving Weight Loss Maintenance Through Alternatives Schedules of Treatment||Florida State University|Yes|Completed|July 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 4, 2015|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165151||119054|
NCT01165450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nex001|Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects|Phase 2, Randomized, Double-masked, Vehicle-controlled, Dose-escalation Study Evaluating Efficacy/Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) Resulting From Corneal Epithelial Debridement During Diabetic Vitrectomy Surgery, Herpes Simples Virus (HSV) Keratitis, Herpes Zoster Virus (HZV) Keratitis, Corneal Burns, Post-photorefractive Keratectomy (Post-PRK), or Post-corneal Transplant Surgery.|NTX-PED-001|University of California, San Francisco|Yes|Terminated|November 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|July 15, 2010|Yes|Yes|Drug manufacturer could not supply study drug.|No|April 7, 2015|https://clinicaltrials.gov/show/NCT01165450||119031|The study was terminated prematurely due to discontinued supply of study drug, and data were never analyzed; PI has left the institution and data are no longer available.
NCT01165996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2908|Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome|A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome||Case Comprehensive Cancer Center|Yes|Completed|July 2010|August 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|July 14, 2010|Yes|Yes||No|January 2, 2013|https://clinicaltrials.gov/show/NCT01165996||118989|
NCT01166295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRK.008a.2010|Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia|Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia|BSTK|Analgesic Solutions|No|Recruiting|July 2010|November 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|40 Years|85 Years|No|Non-Probability Sample|Community sample patients with postherpetic neuralgia who voluntarily participate and meet        eligibility criteria|August 2010|August 3, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01166295||118966|
NCT01162070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.566/19|Evaluation of a Standardized Strategy for Uveitis Etiological Diagnosis|Uveitis: Medico-economical and Clinical Evaluation of a Standardized Strategy for an Etiological Diagnosis|ULISSE|Hospices Civils de Lyon|Yes|Active, not recruiting|June 2010|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|894|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162070||119291|
NCT01162044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER-PTSD-HMO-CTIL|Examining an Emergency Room Intervention for the Prevention of Post Traumatic Stress Disorder (PTSD)|Interrupting Traumatic Memories: An Emergency Room Intervention for the Prevention of PTSD||Hadassah Medical Organization|Yes|Not yet recruiting|November 2010|September 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 13, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162044||119293|
NCT01162057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42-2008|The Effect of Hemodialysis on Hearing|The Effect of Hemodialysis on Hearing in Hemodialysis Patients||Hillel Yaffe Medical Center||Not yet recruiting|August 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing regular thrice-weekly hemodyalysis|July 2010|July 13, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162057||119292|
NCT01162590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113545|Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults|Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Adults||GlaxoSmithKline||Completed|March 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01162590||119251|
NCT01163201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS018|T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies|Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|January 2014|January 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|55 Years|No|||March 2014|March 4, 2014|May 26, 2010|Yes|Yes|Replaced by a new study|No||https://clinicaltrials.gov/show/NCT01163201||119204|
NCT01163513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 09-01|Coronary Mortality in South Asians: Aetiologic and Prognostic Effects|Cardiovascular Disease Research Using Linked Bespoke Studies and Electronic Records|CALIBER|University College, London|Yes|Active, not recruiting|August 2009|December 2010|Anticipated|December 2009|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Anticipated|100000|||Both|30 Years|N/A|No|Non-Probability Sample|ACS registry data (MINAP) - with hospital admission databases (Hospital Episode Statistics        (HES)|July 2010|February 18, 2011|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01163513||119180|
NCT01163526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0031|Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies|Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies||Stanford University||Recruiting|September 2010|September 2016|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing        age, must take precautions not to become pregnant.|July 2014|July 21, 2014|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163526||119179|
NCT01163747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA25256|A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)|A Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Tocilizumab on Vaccination in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate||Genentech, Inc.||Completed|September 2010|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|64 Years|No|||November 2012|November 12, 2012|July 14, 2010|Yes|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT01163747||119162|
NCT01163760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0706|Clinical Evaluation of Two Daily Disposable Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2007|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|50|||Both|21 Years|39 Years|No|||May 2015|May 5, 2015|September 29, 2008|Yes|Yes||No|October 1, 2008|https://clinicaltrials.gov/show/NCT01163760||119161|The integrity of the subject reported data is suspect and not reflective of lens’ performance due to a significant protocol deviation. Upon completion of the study it was found that subjects were unmasked and their data should be considered biased.
NCT01164059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeSSy_200901|Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia|Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia|NeSSy|University of Bremen|Yes|Completed|February 2010|March 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|65 Years|No|||June 2015|June 19, 2015|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01164059||119138|
NCT01164293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079/2553(EC1)|Atopy Patch Test in Children With Food Allergy-related Gastrointestinal Symptoms|Prevalence of Positive Reactions in Atopy Patch Test in Children With Food Allergy-related Gastrointestinal Symptoms|APT|Mahidol University|Yes|Completed|April 2010|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|1 Month|18 Years|No|||September 2015|September 17, 2015|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164293||119120|
NCT01154478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpWP5|Effects of Dietary Polyphenols and ω-3 Fatty Acids on Cardiovascular Risk Factors in High Risk Subjects|Effects of Polyphenols and Omega-3 Fatty Acids on Cardiovascular Rik Factors (Focusing on Postprandial Lipids Metabolism) in Subjects With High Risk for Type 2 Diabetes and Cardiovascular Diseases|Etherpaths|Federico II University|No|Completed|January 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|86|||Both|40 Years|70 Years|No|||June 2013|June 18, 2013|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01154478||119870|
NCT01186094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0086|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: (LONG-DES-IV)|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: Sirolimus vs. Zotarolimus-eluting Stent|LONG-DES-IV|CardioVascular Research Foundation, Korea|Yes|Completed|May 2009|June 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|502|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|October 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01186094||117452|
NCT01186848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU34376|Fractional Laser and Ultrasound for Striae Distensae|Comparison of Fractional Photothermolysis Alone Versus Fractional Photothermolysis Plus Intense Focused Ultrasound for Treatment of Striae Distensae: A Prospective Randomized Control Trial.||Northwestern University|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|August 19, 2010|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT01186848||117394|
NCT01187134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1.1|Medical Education for Sepsis Source Control and Antibiotics|Medical Education for Sepsis Source Control and Antibiotics|MEDUSA|Center for Sepsis Control and Care, Germany|Yes|Completed|July 2011|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|4138|||Both|N/A|N/A|No|||March 2014|March 21, 2014|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187134||117372|
NCT01187420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0470|Bilateral Bispectral Index (BIS) Study|Real Time Monitoring for Cerebral Vasospasm Using Bilateral Processed Electroencephalogram (EEG)|BIS|Icahn School of Medicine at Mount Sinai|No|Completed|June 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Neurosurgical ICU patients with Subarachnoid Hemorrhage|July 2011|July 5, 2011|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01187420||117350|
NCT01187966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-1015/016/III/2006|Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease|A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic||Newron|Yes|Completed|January 2007|February 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|669|||Both|30 Years|80 Years|No|||August 2010|August 23, 2010|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01187966||117308|
NCT01165463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200908789|Iowa Healthy and Active Minds Study|RCT of Two Speed of Processing Modes to Prevent Cognitive Decline in Older Adults|IHAMS|University of Iowa|Yes|Completed|September 2009|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|681|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 24, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01165463||119030|
NCT01165723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0141007|A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated|A Randomised, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group Study To Evaluate the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses PF-04427429 Administered Intravenously To Healthy Adult Volunteers||Pfizer|No|Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|July 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165723||119010|
NCT01165710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016327|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)||Janssen Scientific Affairs, LLC|No|Completed|June 2010|December 2014|Actual|November 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10179|||Both|18 Years|99 Years|No|Non-Probability Sample|Enrolling physicians will include cardiologists, internists, and electrophysiologists from        both academic and private practice who preferably have experience in registry        participation.|March 2016|March 8, 2016|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165710||119011|
NCT01166022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE8200|Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)|Randomized, Controlled Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)||Columbia University|No|Active, not recruiting|December 2010|December 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|8 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01166022||118987|
NCT01162083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1570|Identifying an Ideal Cardiopulmonary Exercise Test Parameter|Identifying the Ideal Parameter of the Cardiopulmonary Exercise Test to Distinguish Between the Cardiovascular and Respiratory Components of Functional Limitation and to Detect Relevant Physiological Changes in Function|PVA|Imperial College London|No|Completed|October 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Current patients under tertiary care for cardiac or respiratory disease. Valvular patients        will be stable patients under follow-up to judge optimal timing for intervention on        clinical grounds at which point they will become applicable to the study.|August 2011|February 15, 2016|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162083||119290|
NCT01162603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOBS-SAF-01|Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)|Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions|SAF-24H-IOP|Azienda Ospedaliera Spedali Civili di Brescia|No|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|45 Years|N/A|No|||May 2013|May 5, 2013|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162603||119250|
NCT01162356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100073|Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study|A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy|PROVE|Vanderbilt University||Active, not recruiting|July 2010|January 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients presenting to ophthalmology practice requiring pars plana vitrectomy|June 2015|June 1, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162356||119269|
NCT01163214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003312|Management of Postoperative Pain After Total Knee Replacement.|Prospective Randomized Study Comparing Regional Anesthetic Blocks and Periarticular Infiltration for the Management of Postoperative Pain After Total Knee Replacement.||Mayo Clinic|No|Completed|July 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|79 Years|No|||November 2014|November 3, 2014|July 14, 2010|Yes|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01163214||119203|Participants and staff could not be blinded to the treatment arm received; participants' pain was evaluated at rest and not with activity; the study was not powered to identify certain rare events such as falls.
NCT01163539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN0002|Cyberknife Radiosurgery and Quality of Life|Cyberknife Radiosurgery and Quality of Life||Stanford University|Yes|Active, not recruiting|September 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patient must have cancer metastases to the spine. They may have had previous surgical or        not surgical treatments. Benign tumors will not be assessed.|July 2012|July 16, 2012|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163539||119178|
NCT01163773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2004-039|Milk Consumption and the Metabolic Syndrome in Menopausal Women|Milk Consumption and the Metabolic Syndrome in Menopausal Women|MILK|Laval University|No|Completed|October 2004|June 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 15, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163773||119160|
NCT01163786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 09H7|A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD|A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD||Northwestern University|Yes|Active, not recruiting|July 2010|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||November 2015|November 18, 2015|July 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163786||119159|
NCT01164072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT01/10|Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette)|Randomised Controlled Trial Investigating the Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) in Smokers||Universita degli Studi di Catania|Yes|Completed|April 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Regular smokers from Catania in Italy recruited following the placement of an        advertisement in a local newspaper.|January 2013|January 7, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01164072||119137|
NCT01164306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA118066|The Impact of a Tobacco Control Intervention in African-American Families|The Impact of a Tobacco Control Intervention in African-American Families||Georgia Regents University|Yes|Completed|September 2007|May 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|688|||Both|8 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 29, 2015|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01164306||119119|
NCT01164319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFERAWCLP-022|"UNMASKING Study" For Atrial Fibrillation Recurrences Typing in Early Postoperative Period|Typing of the Atrial Fibrillation Recurrences in Early Postoperative Period After Pulmonary Veins Isolation Through Continous Subcutaneous Monitoring.||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|February 2008|November 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|150|||Both|18 Years|70 Years|No|||April 2012|April 23, 2012|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164319||119118|
NCT01154491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAHFRAC-01|Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period|Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period.|PAHFRAC|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Completed|June 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|303|||Both|65 Years|N/A|No|||July 2015|July 27, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01154491||119869|
NCT01186614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|project 160/10|Refractory Out-Of-Hospital Cardiac Arrest Treated With Mechanical CPR, Hypothermia, ECMO and Early Reperfusion|Refractory Out-Of-Hospital Cardiac Arrest Treated With Mechanical CPR, Hypothermia, ECMO and Early Reperfusion|CHEER|Bayside Health|Yes|Recruiting|November 2010|December 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|59 Years|No|||March 2014|March 6, 2014|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186614||117412|
NCT01186874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OARSIS20100808|Epidemiology Research on Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) in Adult ICU in Shanghai|||Tongji University|Yes|Recruiting|September 2010|November 2011|Anticipated|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|16 Years|N/A|No|Non-Probability Sample|All consecutive patients with ALI/ARDS who are admitted to the study ICUs|July 2010|October 25, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01186874||117392|
NCT01187147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR415|Effects of Green Tea Extract (GTE) on Systemic Oxidative and Antioxidative Status in Chinese Patients With Stable Asthma|Effects of Green Tea Extract (GTE) on Systemic Oxidative and Antioxidative Status in Chinese Patients With Stable Asthma||The University of Hong Kong|Yes|Completed|January 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|70 Years|No|||August 2010|August 20, 2010|August 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187147||117371|
NCT01187433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD30|Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America|Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America||Sanofi|Yes|Completed|August 2010|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|9 Years|16 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|August 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01187433||117349|
NCT01187446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0078|Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides|A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)||Stanford University|Yes|Terminated|December 2010|February 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|August 20, 2010||No|Business decision|No||https://clinicaltrials.gov/show/NCT01187446||117348|
NCT01187459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01391|Vitamin D in Pediatric Crohn's Disease|Vitamin D in Pediatric Crohn's Disease||University of British Columbia|Yes|Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|87|||Both|8 Years|18 Years|No|||February 2012|February 10, 2012|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187459||117347|
NCT01153984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22606|A Study of Tarceva (Erlotinib) in Patients With Advanced and/or Metastatic Non-small Cell Lung Cancer With EGFR Positive Mutation (BIOTEC)|Biomarkers Impact On the Response to Treatment With Erlotinib in First Line Non-small Cell Lung Cancer With EGFR Positive Mutation - BIOTEC||Hoffmann-La Roche||Completed|June 2011|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153984||119908|
NCT01165736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3071001|To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity|An Exploratory, Open Label, Randomized, Parallel Group Study To Investigate The Pharmacokinetics Of Single Intravenous And Oral Micro Doses Of PF-05186462, PF-05089771, PF-05241328 And PF-05150122 In Healthy Male Subjects||Pfizer|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 23, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165736||119009|
NCT01166048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPDP-01|Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component|Randomized Double-blind Study Comparing the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component||Medical University of Vienna|Yes|Completed|May 2010|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||July 2014|July 29, 2014|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01166048||118985|
NCT01166035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEXO0309|Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors|Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors|TEXO|Medical University Innsbruck||Recruiting|March 2010|December 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||May 2010|July 19, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166035||118986|
NCT01166308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINDERELLA|Carbon Ion Radiotherapy for Recurrent Gliomas|Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial|CINDERELLA|University Hospital Heidelberg|Yes|Recruiting|August 2010|August 2015|Anticipated|July 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|436|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166308||118965|
NCT01162369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# Pending|Brief Delirium Assessments in Non-Intensive Care Unit (ICU) Patients|Validation of Brief Delirium Assessments in Non Critically Ill Hospitalized Patients||Vanderbilt University|No|Recruiting|August 2010|August 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|65 Years|N/A|No|Non-Probability Sample|The participants will be those who are Vanderbilt University Hospital inpatients aged 65        years or older. There will be no selection bias in regards to race or gender. Only those        who meet the inclusion/exclusion criteria will be considered for study inclusion.|August 2011|August 1, 2011|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162369||119268|
NCT01162616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP_Fe_Study Sorghum|Polyphenols in Sorghum and Iron Absorption|Is There a Dose-dependant Effect of Sorghum Polyphenols on Human Iron Absorption and Can it be Overcome by Sodium Iron EDTA or by Adding Vitamin C or Laccase?||Swiss Federal Institute of Technology||Completed|August 2010|April 2012|Actual|March 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162616||119249|
NCT01162629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RED001|Vertical Augmentation With Osteon at Dental Implant Placement|An Evaluation of Vertical Augmentation of Alveolar Bone With Osteon at Dental Implant Placement||Research and Education in Dentistry|No|Not yet recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Private specialist dental implant clinic|July 2010|July 14, 2010|July 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162629||119248|
NCT01162902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC Trial|Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation|Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation||Seoul National University Hospital|Yes|Not yet recruiting|September 2013|December 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|30 Years|80 Years|No|||December 2013|December 15, 2013|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01162902||119227|
NCT01163227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAQW051A2205|Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.||Novartis||Completed|May 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|57|||Both|18 Years|55 Years|No|||March 2013|March 6, 2013|July 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163227||119202|
NCT01163578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0405628|Biomarkers in Transplant Recipients|Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection||University of Pittsburgh|Yes|Recruiting|March 2005|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|blood, saliva, intestinal and liver biospy samples, urine, stool|Both|N/A|N/A|No|Non-Probability Sample|Individuals who are listed and or recipients of solid organ or bone marrow        transplantation.|January 2016|January 13, 2016|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01163578||119175|
NCT01163552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLR IRB#09-207|Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity|Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies||St. Luke's-Roosevelt Hospital Center|No|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|75 Years|No|||June 2014|June 12, 2014|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163552||119177|
NCT01163565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004394|A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery|A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery||University of Alberta|Yes|Completed|April 2010|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|85 Years|No|||December 2014|December 2, 2014|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163565||119176|
NCT01164332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL972-01/2010 (AMET)|Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects|Investigation of the Sensitivity of Different Methods to Detect NRL972 in Healthy Volunteers During and After a 2-hour Intravenous Infusion of 10 and 30mg NRL972||Norgine|No|Completed|July 2010|November 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2011|June 9, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01164332||119117|
NCT01164345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7481-AN-CTIL|Mozobil for Autologous Stem Cell Mobilization|Plerixafor (Plerixafor AMD 3100) + Recombinant Human G-CSF (rhG-CSF) for Autologous Peripheral Blood Stem Cell Transplantation (AutoSCT) in Hard to Mobilise Patients: a Phase IIB Study||Sheba Medical Center|No|Completed|June 2010|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01164345||119116|
NCT01164085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091196|Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study|Intravitreal Ketorolac for Chronic Uveitis:A Phase I Investigational Safety Study|INCITE|Vanderbilt University|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|90 Years|No|||December 2013|December 30, 2013|April 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01164085||119136|
NCT01164930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R03CA144751-02|Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer|Impact of Acceptance and Commitment Therapy on Salivary Cortisol in Breast Cancer|ACT|San Jose State University|No|Active, not recruiting|January 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|N/A|N/A|No|||July 2011|July 20, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164930||119071|
NCT01185821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312A2201E1|Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis|A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis||Novartis||Active, not recruiting|August 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|186|||Both|18 Years|56 Years|No|||March 2016|March 7, 2016|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01185821||117473|
NCT01185834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-335-C-015|Assessment of Lotrafilcon A Contact Lenses|Assessment of Lotrafilcon A Contact Lenses||Alcon Research||Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|118|||Both|N/A|N/A|No|||December 2011|June 26, 2012|August 18, 2010|Yes|Yes||No|December 20, 2011|https://clinicaltrials.gov/show/NCT01185834||117472|
NCT01157234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYS-MD-42|Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients|Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients||University of Florida|No|Completed|July 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 2, 2010|Yes|Yes||No|January 25, 2016|https://clinicaltrials.gov/show/NCT01157234||119658|Small numbers of subjects analyzed in a single center limits precision and generalizability of results.Technical limitations prevented measurements of asymmetric dimethyl-arginine and arginine leading to absence of analysis for these outcomes.
NCT01187979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA 007|Reducing HIV in Adolescents|A Proof of Concept Cluster Randomised Controlled Trial to Evaluate the Impact of a Cash Incentivised Prevention Intervention to Reduce HIV Infection in High School Learners in Rural KwaZulu-Natal, South Africa|RHIVA|Centre for the AIDS Programme of Research in South Africa|No|Completed|September 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3217|||Both|13 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 3, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01187979||117307|
NCT01166321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARCIE|Carbon Ion Radiotherapy for Atypical Meningiomas|Treatment of Patients With Atypical Meningiomas Simpson Grade 4 and 5 With a Carbon Ion Boost in Combination With Postoperative Photon Radiotherapy: A Phase II Trial|MARCIE|University Hospital Heidelberg|Yes|Not yet recruiting|August 2010|||July 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2010|July 30, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166321||118964|
NCT01162096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06U.328|Reduced Intensity Haploidentical Transplant for Hematological Malignancies|A Two Step Approach To Non-Myeloablative Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies||Thomas Jefferson University|Yes|Completed|September 2006|April 2012|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|July 12, 2010|Yes|Yes||No|January 7, 2015|https://clinicaltrials.gov/show/NCT01162096||119289|Outcome measures were only analyzed for the 17 patients who were >= 66 years of age and <= 77 years of age.
NCT01162109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zinc1017|Zinc Therapy in Critical Illness|Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis||University of Vermont|Yes|Recruiting|September 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 23, 2014|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01162109||119288|
NCT01162122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_27|Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects|A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older||Novartis||Completed|August 2010|November 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|7109|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 16, 2014|July 13, 2010|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01162122||119287|
NCT01162382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WUSM3621222|Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder: A Functional Connectivity Magnetic Resonance Imaging (fcMRI) Study||Washington University School of Medicine|Yes|Suspended|January 2010|June 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|35|||Both|18 Years|50 Years|No|||March 2012|March 12, 2012|November 30, 2009|Yes|Yes|Protocol currently undergoing changes. Will be relisted at later date.|No||https://clinicaltrials.gov/show/NCT01162382||119267|
NCT01162395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3760C00001|Open Label Prostate Cancer Study|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients With Metastatic Castration-Resistant Prostate Cancer.||AstraZeneca|No|Completed|August 2010|October 2015|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Male|20 Years|130 Years|No|||January 2016|January 11, 2016|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01162395||119266|
NCT01162421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W12-122|A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis|Radiographic, Clinical and Patient Outcomes in a Multicenter, Open Label Phase IV Randomized Trial of Earlier Adalimumab Introduction Therapy Versus Later Introduction as Per Standard of Care After Initial Methotrexate Failure in Early Rheumatoid Arthritis Patients|RADAR|AbbVie||Completed|May 2010|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01162421||119264|
NCT01162642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007C0109|Green Tea Anticancer Mechanisms in Smokers|Green Tea Anticancer Mechanisms in Smokers||Ohio State University|No|Completed|June 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|43|||Both|23 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01162642||119247|
NCT01162915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-SCI-I|Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury|Phase I, Single Center, Trial to Asses Safety and Tolerability of the Intrathecal Infusion of Ex-vivo Expanded Bone-marrow Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury||TCA Cellular Therapy|Yes|Suspended|July 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||September 2013|May 7, 2014|July 13, 2010|No|Yes|Suspended due to lack of funding.|No||https://clinicaltrials.gov/show/NCT01162915||119226|
NCT01163799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 00029396|A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients|A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients||Northwestern University|Yes|Terminated|July 2010|August 2012|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 1, 2013|July 14, 2010|Yes|Yes|Noted increased risks, greater than expected for standard of care therapy.|No||https://clinicaltrials.gov/show/NCT01163799||119158|
NCT01164098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100498|Rituximab to Prevent Recurrence of Proteinuria|The Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGS||University of Miami|No|Active, not recruiting|March 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|7 Years|65 Years|No|||January 2016|January 12, 2016|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164098||119135|
NCT01164644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0065|The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery|The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery||University of Wisconsin, Madison|No|Completed|June 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|89 Years|No|||February 2016|February 9, 2016|July 15, 2010|Yes|Yes||No|December 26, 2012|https://clinicaltrials.gov/show/NCT01164644||119093|
NCT01164631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP - 06/57695-7|Pharyngeal Size in Patients With Obstructive Tonsils Under Orthodontic Treatment|Improvement of Pharyngeal Size in Patients With Obstructive Tonsils Treated With Bioajusta X Orthodontic Appliance - Randomized Clinical Trial||University of Sao Paulo General Hospital|Yes|Completed|November 2006|November 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|6 Years|9 Years|No|||June 2012|June 21, 2012|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01164631||119094|
NCT01164917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100011|Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled, Single Dose, Two-period, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of AMG 811 in Subjects With Discoid Lupus Erythematosus||Amgen||Terminated|August 2010|March 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|70 Years|No|||September 2014|September 12, 2014|July 15, 2010|||The 16 subjects enrolled in the study should enable Amgen to adequately assess safety and    tolerabili|No||https://clinicaltrials.gov/show/NCT01164917||119072|
NCT01165567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091104/06-2009-123/89|The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease|Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy||Seoul National University Boramae Hospital|No|Active, not recruiting|December 2009|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|212|||Both|20 Years|85 Years|No|||July 2010|July 19, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01165567||119022|
NCT01186341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018346|BraveNet Multi-Center Study on Integrative Medicine Treatment Approaches for Pain|BraveNet Multi-Center Study on Integrative Medicine Treatment Approaches for Pain|SIMTAP|Duke University|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|418|||Both|18 Years|N/A|No|Non-Probability Sample|Patients attending one of the nine Integrative Medicine Clinics of the BraveNet research        network.|June 2011|March 24, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01186341||117433|
NCT01153204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE Satisfaction - 2010|Satisfaction, Confidence and Naturalness in Men With Psychogenic Erectile Dysfunction (ED)|Satisfaction With the Treatment, Confidence and Naturalness in Engaging in Sexual Activity in Men With Psychogenic Erectile Dysfunction: Randomized Controlled Trial of Three Therapeutic Approaches.||Federal University of São Paulo|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Male|25 Years|50 Years|No|||June 2010|June 29, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153204||119968|
NCT01187719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 09.02|The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance|The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)|VITA 2|Radboud University|Yes|Completed|May 2010|September 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|66|||Female|18 Years|N/A|No|||September 2012|September 17, 2012|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01187719||117327|
NCT01153776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070118|CT Coronary Angiography After Arterial Switch Operation|CT Coronary Angiography for the Detection of Reimplanted Coronary Lesions in Patients Who Had Undergone Arterial Switch Operation for Transposition of the Great Arteries|SCANTGV|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2008|October 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|42|||Both|4 Years|30 Years|No|||February 2011|December 18, 2013|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153776||119924|
NCT01165762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06232010-6408|Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.|Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion in HLA Haplotype Match Living Donor Kidney Transplantation||Stanford University|Yes|Recruiting|July 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|60 Years|No|||November 2014|November 20, 2014|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165762||119007|
NCT01166074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ig_6001_R_D|Retrospective Chart Review of Subcutaneous IgG Use in Infants|Retrospective Chart Review Study: Subcutaneous IgG in Children Under 2 Years of Age||CSL Behring|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|27|||Both|N/A|2 Years|No|Non-Probability Sample|Children under 2 years of age|February 2011|February 10, 2011|July 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01166074||118983|
NCT01166087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|586/05|Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg Delayed Release Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2006|September 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|July 20, 2010|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166087||118982|
NCT01166334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IR#7181|WebQuit Online Smoking Cessation Study|WebQuit Online Smoking Cessation Study|WebQuit|Fred Hutchinson Cancer Research Center|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|721|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 10, 2013|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166334||118963|
NCT01166347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW004|A Clinical Trial to Evaluate the HeartWare® Ventricular Assist System|A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (VAS) for Destination Therapy of Advanced Heart Failure|ENDURANCE|HeartWare, Inc.|Yes|Active, not recruiting|August 2010|May 2017|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||October 2014|February 25, 2015|July 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166347||118962|
NCT01162434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoB1112|Brain MRI (Magnetic Resonance Imaging) Scans of Patients With Treatment Resistant Depression (TRD) and Healthy Controls|Volumetric Brain MRI (Magnetic Resonance Imaging) Comparison of Patients With Treatment Resistant Depression (TRD) Undergoing Deep Brain Stimulation (DBS) With Age, Sex and Education Matched Healthy Controls||University of Bristol|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|21|||Both|26 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have received Deep Brain Stimulation (DBS) for Treatment Resistant Depression        at Frenchay Hospital, UK., and healthy volunteers who are matched to the DBS patients,        sampled from the local area.|August 2011|July 11, 2012|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162434||119263|
NCT01162135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10G.87|Digoxin for Recurrent Prostate Cancer|A Pilot Phase II Study of Digoxin in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA||Thomas Jefferson University|Yes|Completed|September 2010|May 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Male|18 Years|N/A|No|||July 2014|July 25, 2014|July 12, 2010||No||No|April 23, 2014|https://clinicaltrials.gov/show/NCT01162135||119286|
NCT01162408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|The Study of Clinical Value of Acute Physiologic and Chronic Health Evaluation (APACHE) Scoring System in Medical Intensive Care Unit|||Sun Yat-sen University|No|Not yet recruiting|July 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|N/A|No|Probability Sample|Patients admitted between July 2010 and July 2013 to the medical intensive care unit of        the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China.|July 2010|July 13, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162408||119265|
NCT01162941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-019|Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)|Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)||Cooperative Study Group A for Hematology|No|Recruiting|February 2010|January 2012|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||July 2010|July 14, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01162941||119224|
NCT01162928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0804|Parenteral Nutrition With Intravenous and Oral Fish Oil for Intensive Care Patients|Assessment of the Benefit From Combined Administration of Oral and Intravenous Nutrition - Enriched With Omega-3 Fatty Acids - for Intensive Care Patient||B. Braun Melsungen AG|No|Recruiting|May 2013|January 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||July 2015|July 21, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01162928||119225|
NCT01163812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-2005181|Clinical Trial for Laparoscopic D2 Gastrectomy|A Phase-II Clinical Trial of Laparoscopy-Assisted Distal Gastrectomy With D2 Lymph Node Dissection for Gastric Cancer|NCC181|National Cancer Center, Korea|Yes|Completed|April 2006|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|75 Years|No|||July 2010|July 16, 2010|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01163812||119157|
NCT01164111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-034|Preoperative Resistance Training in Patients Scheduled for Total Hip Arthroplasty|Preoperative Resistance Training in Patients Scheduled for Total Hip Arthroplasty - a Prospective Randomized Study in Patients With Osteoarthritis||University of Southern Denmark|Yes|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|90 Years|No|||October 2015|October 8, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01164111||119134|
NCT01164358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002|Long Term Observation of Patient Satisfaction Post INTRACOR Treatment Based on Patient Perception and Diagnostic Data|Long Term Observation of Patient Satisfaction Post INTRACOR Treatment Based on Patient Perception and Diagnostic Data||Technolas Perfect Vision GmbH|Yes|Completed|July 2010|October 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|105|||Both|18 Years|N/A|No|Probability Sample|Just patients who have been already enrolled in the previous study "Intrastromal        Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia        sub-group: treatment pattern 5-Rings" or "Intrastromal Presbyopia Correction by Means of        Femtosecond Laser (study # 0905)"|October 2013|October 18, 2013|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164358||119115|
NCT01164943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-FB-04-2010-01|Aneuploidy Rate and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH|Aneuploidy Rate Impact in Oocyte From Egg Donation Cycle With Different Stimulation Protocol: Recombinant FSH vs Human FSH||IVI Madrid|No|Terminated|July 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|February 24, 2016|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01164943||119070|
NCT01164956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-146|Methylphenidate for Cancer-Related Fatigue|Methylphenidate for Cancer-Related Fatigue: A Pilot N-of-1 Study||Dana-Farber Cancer Institute|Yes|Suspended|July 2010|August 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|1||Anticipated|24|||Both|7 Years|21 Years|No|||April 2013|April 24, 2013|July 6, 2010|No|Yes|Pending Amendment|No||https://clinicaltrials.gov/show/NCT01164956||119069|
NCT01164969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMI2010-2|Mixed Strain H. Pylori Infection in Patients Who Have Problems With Eradication of H. Pylori|Multi Locus Sequence Typing (MLST) Used as Tool to Confirm Ability of Susceptible Helicobacter Pylori Strains to Gain Resistance to Clarithromycin During Eradication Therapy Independently of Mixed Strain Helicobacter Pylori Infection||University Medical Centre Ljubljana|Yes|Completed|November 2008|July 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Isolated PBMC cell from patients, isolated H. pylori|Both|18 Years|65 Years|No|Non-Probability Sample|The investigators invited people who were not able to eradicate H. pylori although at        their first visit they had H. pylori sensitive to all antibiotics tested. At first visit        all patients had stomach biopsy sample taken and H. pylori isolated and therapy        prescribed. If they did not eradicate bacteria after 2 months they were again invited to        control visit to define the problem and appropriate therapy prescribed. They were again        invitation to control visit at the end of June 2010 to see the outcome of therapy.|July 2010|July 16, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01164969||119068|
NCT01186627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Test-Apgar Follow-Up|Trial to Evaluate a Specified Type of Apgar (TEST-APGAR) Follow Up Study|Trial to Evaluate a Specified Type of Apgar (TEST-APGAR) Follow-Up Study||Technische Universität Dresden|No|Recruiting|April 2010|December 2012||April 2012||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|2 Years|2 Years|No|Probability Sample|Former preterm infants with a gestational age below 32 weeks which have been included in        the TEST-APGAR Study are now screened at a corrected age of 2 years after birth.|October 2010|October 13, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01186627||117411|
NCT01186861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-205|Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy|A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC||Astellas Pharma Inc|Yes|Completed|December 2010|March 2015|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01186861||117393|
NCT01153217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSTEOTENOFOVIR|Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density|MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY||Germans Trias i Pujol Hospital|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153217||119967|
NCT01153191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#10-046|Effectiveness for Interventions to Minimize Surgical Site Infections|Developing Evidence of Effectiveness for Adjuvant Interventions Designed to Minimize Surgical Site Infections||Dallas VA Medical Center|No|Enrolling by invitation|August 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|95 Years|No|||November 2011|November 3, 2011|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153191||119969|
NCT01153789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081114|Study of Oculomotor Dysfunction Leading to Children Vertigo|Evaluation and Medical Care of Oculomotor Dysfunction Leading to Vertigo in Children|VERVE|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2010|August 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|183|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||August 2013|December 3, 2014|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153789||119923|
NCT01166100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|587/05|Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg DR Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2006|August 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|July 20, 2010|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166100||118981|
NCT01166113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO0023|Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide|A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide|PCP|Fondazione Neoplasie Sangue Onlus|No|Active, not recruiting|July 2010|July 2018|Anticipated|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01166113||118980|
NCT01166360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS_RS_2008-2009 - GDF_TNT|The Usefulness of Growth Differentiation Factor 15 (GDF-15) for Risk Stratification in Cardiac Surgery|The Prognostic Relevance of Cerebral Oxygen Saturation, NTproBNP and Preoperative Creatinine Clearance in Cardiac Surgical Patients; Amendment 4: the Prognostic Relevance of Growth Differentiation Factor 15 (GDF-15) and High Sensitive Troponin-t (hsTnT)||University of Luebeck|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2000|Samples Without DNA|Plasma and urine samples|Both|18 Years|N/A|No|Probability Sample|Consecutive patients undergoing primary cardiac surgery at a University hospital.|March 2011|March 14, 2011|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166360||118961|
NCT01162148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rab581710ctil|Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation|Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation||Rabin Medical Center|No|Not yet recruiting|September 2010|September 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|50|||Both|18 Years|70 Years|No|||June 2010|July 13, 2010|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01162148||119285|
NCT01162447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAR.YC.2008.0276|Comparison of Bone Morphogenetic Protein-4 (BMP-4) and 7 Levels Between Control and Polycystic Ovarian Syndrome (PCOS) Patients.|Comparison of Bone Morphogenetic Protein-4 and -7 Levels (BMP-4 and 7) in the Serum, Ovarian Follicle Aspirates and Ovarian Organ Culture Supernatants Between Healthy Controls and Patients With Polycystic Ovarian Syndrome (PCOS).||V.K.V. American Hospital, Istanbul|No|Enrolling by invitation|February 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples With DNA|Blood samples, ovarian tissue samples, ovarian follicular fluid samples|Female|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who present to the women's health center of American Hospoital for complaints due        to polcystic ovarian syndrome will be enrolled. Age-matched healthy subjects will be        chosen for comparison.|February 2010|July 13, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162447||119262|
NCT01162655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009:110|Cognitive-Behavioural Therapy (CBT) for Insomnia Via Internet or Telehealth|Delivery of Cognitive-Behavioral Treatment for Insomnia Via Telehealth or Internet||University of Manitoba|Yes|Completed|April 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|No|||July 2013|July 29, 2013|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01162655||119246|
NCT01162668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41165|Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employees|Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employees||University of Mississippi Medical Center|No|Enrolling by invitation|April 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|200 obese patients with Mississippi State Employee Insurance who undergo bariatric surgery        as part of Obesity Treatment Program|May 2012|May 15, 2012|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162668||119245|
NCT01162954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA6034_DES_I|Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Local Tolerability After Administration of Eye Drop DA-6034 in Healthy Volunteers(Phase I)||Dong-A ST Co., Ltd.||Completed|September 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|20 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01162954||119223|
NCT01162967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHAGASAZOL01|Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole|PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE|CHAGASAZOL|Hospital Universitari Vall d'Hebron Research Institute|No|Completed|September 2010|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|N/A|No|||September 2013|September 9, 2013|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01162967||119222|
NCT01163240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2414|Epidemiological Study in Children and Adolescents With Chronic Hepatitis B|A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B|EPIC B|Novartis||Completed|June 2009|||September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1640|||Both|2 Years|18 Years|No|Probability Sample|Eligible patients will be identified in the treatment centers by the investigators. These        patients can include those patients being referred to the practice or patients currently        being seen by the investigator who are male or female, children or adolescents with        chronic hepatitis B, aged 2 to < 18 years . Patients visiting the center during the 2 year        enrolment period may be eligible for the study. This visit will constitute the data        captured for the "current disease state" in the questionnaire. Patients will be recruited        from Asian and Western countries.|September 2011|September 26, 2011|July 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01163240||119201|
NCT01164124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 08-019|Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants|Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants|PAS|Vermont Oxford Network|Yes|Completed|February 2008|August 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|N/A|14 Days|No|||July 2010|July 15, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01164124||119133|
NCT01163838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481002|Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of RN316 In Healthy Adult Subjects With Hypercholesterolemia||Pfizer|No|Withdrawn|August 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|July 14, 2010|No|Yes|Study was redesigned based on FDA feedback.|No||https://clinicaltrials.gov/show/NCT01163838||119155|
NCT01163851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481003|Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin|A Phase 1 Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Rn316 In Combination With Atorvastatin In Hypercholesterolemic Subjects||Pfizer|No|Completed|July 2010|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|July 14, 2010|No|Yes||No|April 20, 2015|https://clinicaltrials.gov/show/NCT01163851||119154|All determinations of primary or secondary outcomes were arbitrary as study did not specify primary or secondary outcome measures.
NCT01164371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER-09-05|Gender Differences in the Development, Treatment and Prognosis of Coronary Disease: A CALIBER Study|Gender Differences in the Development and Prognosis of Coronary Disease Where Initial Disease Manifestation is Stable Angina, Myocardial Infarction or Unheralded Coronary Death: A CALIBER Study Using Linked GPRD-MINAP Data||University College, London|Yes|Completed|July 2010|November 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1758584|||Both|35 Years|N/A|No|Non-Probability Sample|The study population will include all adults aged 35 or over in General Practice Research        Database (GPRD), registered with an up-to-standard practice with at least 1 year of        continuous follow-up.        Further details on defining up-to-standard practices within GPRD are available from        http://www.gprd.com/home/|January 2014|January 8, 2014|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01164371||119114|
NCT01164657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/214|A Swedish Trial of Birth on a Birthing Seat|A Swedish Randomized Controlled Trial of Birth on a Birthing Seat||Helsingborgs Hospital|No|Completed|November 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|68|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2009|July 16, 2010|March 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01164657||119092|
NCT01164982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPTO 02|Investigation Evaluating Handling of Mepitel® One Used in Acute Wounds in Home Care|An Open Non-controlled Proof of Concept Investigation Evaluating the Handling of a Soft Silicone Wound Contact Layer, Mepitel® One Used in Acute Wounds in Home Care||Molnlycke Health Care AB|No|Withdrawn|March 2010|November 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||December 2010|April 27, 2015|July 16, 2010||No|No resources available at the clinic|No||https://clinicaltrials.gov/show/NCT01164982||119067|
NCT01164995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10MKO / MK1775-009|Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer|Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line Treatment|M10MKO|The Netherlands Cancer Institute|No|Recruiting|July 2010|September 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Female|18 Years|N/A|No|||September 2012|September 11, 2012|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01164995||119066|
NCT01187472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12145B|Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer|Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer||University of Chicago|No|Completed|March 2003|December 2010|Actual|December 2010|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|35|||Both|59 Years|N/A|No|Non-Probability Sample|Subjects enrolled on a previous head and neck cancer treatment protocol|January 2013|January 15, 2013|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01187472||117346|
NCT01153230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-4|Frequencies of Histo-pathological Findings in Patients With Paraquat Toxicity|Study of Frequencies of Histo-pathological Findings in Paraquat Poisoned Patients||Isfahan University of Medical Sciences|Yes|Completed|December 2002|November 2008|Actual|November 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|42|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|forty two poisoned patients|November 2008|June 29, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153230||119966|
NCT01153243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#07-061|Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes|Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease?||John H. Stroger Hospital|No|Active, not recruiting|April 2007|June 2011|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|117|||Both|N/A|N/A|No|||March 2009|April 6, 2011|March 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01153243||119965|
NCT01153451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS018229-01|An Automatic Notification System for Test Results Finalized After Discharge|An Automatic Notification System for Test Results Finalized After Discharge||Brigham and Women's Hospital|No|Completed|October 2010|July 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|441|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01153451||119949|
NCT01153802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112773|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses ofGSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands||GlaxoSmithKline|No|Completed|April 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153802||119922|
NCT01166126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02846|Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV|Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma||National Cancer Institute (NCI)||Terminated|October 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2012|April 29, 2014|July 12, 2010|Yes|Yes||No|March 29, 2013|https://clinicaltrials.gov/show/NCT01166126||118979|The study was terminated due to overall low accrual and a high rate of screening failures. Accrual goal was 38 participants and only 4 participants were actually treated.
NCT01166373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16P01S|The Extended Operations And Pelvic Muscle Training In The Management Of Apical Support Loss Study|Long-Term Effectiveness Of Sacrospinous Ligament Fixation (SSLF) Versus Uterosacral Ligament Suspension (ULS) With and Without Perioperative Behavioral Therapy/Pelvic Muscle Training: The Extended Operations And Pelvic Muscle Training In The Management Of Apical Support Loss Study|E-OPTIMAL|NICHD Pelvic Floor Disorders Network|Yes|Active, not recruiting|April 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|218|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166373||118960|
NCT01166386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HD052922-01A2|Acute Neurobehavioral Program for Improving Functional Status After TBI|An Acute Neurobehavioral Program for Improving Functional Status After TBI||Virginia Commonwealth University|Yes|Recruiting|March 2008|September 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||March 2012|March 12, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166386||118959|
NCT01162161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sphingo-AC|Role of Sphingolipids in Pulmonary Edema|Role of Sphingolipids in Pulmonary Edema|09-045|RWTH Aachen University|No|Completed|July 2010|May 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||3|Actual|45|||Both|18 Years|N/A|No|Probability Sample|3 groups        first group: patients with a lung oedema because of a pneumonia (about 30 patients)        second group: patients with a lung oedema because of cardiac insufficiency (about 25        patients)        third group: patients without any lung oedema (about 15 patients)|September 2015|September 22, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162161||119284|
NCT01162174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816212-1|Pilot Study of Oligonol Supplementation to Promote Cardiovascular Health|Effects of Oligonol on Vascular Function and Inflammation in Healthy Men: A Double-Blind, Dose-Finding Study||University of California, Davis|No|Completed|August 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|July 13, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162174||119283|
NCT01163279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB1021|Maintaining Autonomy as we Age: A Strategy Training Approach to Ameliorating the Effects of Age-related Executive Dysfunction.|Maintaining Autonomy as we Age: Investigating the Application of a Strategy Training Approach for Ameliorating the Effects of Age-related Executive Dysfunction - Part II||Baycrest||Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Actual|19|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||March 2012|March 21, 2012|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163279||119198|
NCT01163292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-069|Special Investigation (Follow up Survey of the Study of Adalimumab (D2E7)for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859(NCT00870467)|Humira 40 mg/0.8 mL Syringe for Subcutaneous Injection - Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)]|HOPE 3|AbbVie|No|Completed|March 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|220|||Both|20 Years|N/A|No|Non-Probability Sample|The participants were patients who continued treatment with adalimumab until the end of        the treatment period in the NCT00870467(M06-859) study.|December 2013|December 11, 2013|July 14, 2010||No||No|October 18, 2013|https://clinicaltrials.gov/show/NCT01163292||119197|
NCT01162681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-SLE3321|PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus|A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus|PEARL-SC|Anthera Pharmaceuticals|Yes|Completed|July 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|547|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162681||119244|
NCT01163253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921061|A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|Yes|Recruiting|September 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3200|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163253||119200|
NCT01163266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_316|Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder||Takeda|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|462|||Both|18 Years|75 Years|No|||October 2013|October 25, 2013|July 14, 2010|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01163266||119199|
NCT01163604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLH|Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting|Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting|APORIAS|Jinling Hospital, China|Yes|Completed|August 2010|August 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|80 Years|No|||October 2015|October 21, 2015|June 28, 2010|Yes|Yes||No|October 25, 2014|https://clinicaltrials.gov/show/NCT01163604||119173|
NCT01154790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG100649-1-04|Phase I Study on Multiple Oral Dosing of CG100649|A Randomized, Double-blind Study Evaluating the Upper Gastrointestinal Safety on Multiple Doses of CG100649 in Healthy Subjects||CrystalGenomics, Inc.|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||June 2010|January 26, 2016|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01154790||119846|
NCT01164137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMPA#2026|Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care|Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care: to Develop and Test a Community-based Medication Reconciliation Program and a Risk Prediction Model That Identifies High-risk Patient Groups|CMR|Westview Physician Collaborative|Yes|Completed|November 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|156|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 12, 2013|July 14, 2010||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT01164137||119132|
NCT01164384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BamiHepC-Study|A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.|||University of Zurich||Not yet recruiting|October 2010|February 2013||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2010|July 15, 2010|July 8, 2010||||No||https://clinicaltrials.gov/show/NCT01164384||119113|
NCT01164397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CME-CRE-2010/1|Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients|Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin to Reduce the Cholesterol Levels in Outpatients in a Realistic Environment. A Retrospective Study||AstraZeneca|No|Completed|April 2009|December 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|268|||Both|18 Years|N/A|No|Non-Probability Sample|Care clinic private practice|January 2012|January 17, 2012|May 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01164397||119112|
NCT01157455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEEDS|A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization|Clinical Trial Program of a Medical Instrument Product|SEEDS|CCRF Consulting Co., Ltd.|Yes|Recruiting|May 2010|June 2013|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1900|||Both|18 Years|75 Years|No|||April 2010|July 8, 2010|July 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01157455||119641|
NCT01156935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0073-10-WOMC|Effects of Laugh-yoga Intervention on Mood and Quality of Life Among Oncologic Patients in a Oncologic Clinic Setting.|Effects of Laugh-yoga Intervention on Mood and Quality of Life Among Oncologic Patients||Wolfson Medical Center||Not yet recruiting|July 2010|December 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|90 Years|No|||July 2010|July 9, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156935||119681|
NCT01156948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WenzhouMC|Misoprostol For Nulliparous Women Before Hysteroscopy|Comparison of Vaginal Versus Oral Misoprostol for Nulliparous Women Prior to Operative Hysteroscopy||Wenzhou Medical University|Yes|Recruiting|May 2008|December 2011|Anticipated|August 2010|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|16 Years|40 Years|Accepts Healthy Volunteers|||May 2008|July 7, 2010|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156948||119680|
NCT01153256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg_rocu|Intubating Condition After Magnesium Pre-treatment|The Influence of Magnesium Sulphate Pretreatment on Intubating Conditions During Rapid Sequence Induction||Seoul National University Bundang Hospital||Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|168|||Both|20 Years|65 Years|No|||January 2012|January 6, 2012|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01153256||119964|
NCT01153464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810106|Effectiveness of Extended Treatment for Drug Dependence (ETDD) in the City Study|Effectiveness of Extended Treatment for Drug Dependence - City Supplement||University of Pennsylvania|No|Completed|October 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||August 2011|December 21, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01153464||119948|
NCT01154049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sm14-CT001P1|Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis|Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis||Oswaldo Cruz Foundation|Yes|Active, not recruiting|March 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154049||119903|
NCT01154374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEBO-DFU-PILOTII-001|A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)|A Phase II, Randomized, Controlled, Two-Center Pilot Study of the Safety and Efficacy of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Diabetic Foot Ulcers||Skingenix, Inc.||Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|79 Years|No|||July 2013|July 23, 2013|June 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154374||119878|
NCT01162460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-311|Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study||Bial - Portela C S.A.|No|Active, not recruiting|December 2010|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162460||119261|
NCT01162694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBGMS vs CGMS|Comparing Internet Blood Glucose Monitoring System and Continuous Glucose Monitoring System|Protocol: Comparing the Effect of Using an Internet-Based Glucose Monitoring System Versus the Continuous Glucose Monitoring System on HbA1c Levels in Type 2 DM||Endocrine Research Society|No|Suspended|July 2010|||February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|25 Years|70 Years|No|||September 2014|September 9, 2014|June 4, 2010||No|Study was expanded and included in another study.|No||https://clinicaltrials.gov/show/NCT01162694||119243|
NCT01162980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-150-BMB (SWITCHBACK)|The Angiotensin Converting Enzyme (ACE) Inhibitor SwitchBack Study|The ACEi SwitchBack Study||McGill University Health Center|No|Recruiting|July 2010|July 2012|Anticipated|January 2012|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|heart failure patients followed in heart failure clinics in Canada|July 2010|July 14, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162980||119221|
NCT01162993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-120|Effect of Spinal Cord Stimulation (SCS) in Painful Diabetic Polyneuropathy|Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy: a Multicenter Randomised Controlled Trial (PDP Study)|PDP|Maastricht University Medical Center|Yes|Active, not recruiting|April 2010|January 2018|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||October 2015|October 19, 2015|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01162993||119220|
NCT01162473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007320|Milk Oral Immunotherapy in Children to Treat Food Allergy|A Study of the Efficacy of Milk Oral Immunotherapy in Children||Children's Hospital of Philadelphia|No|Completed|June 2010|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|6 Years|17 Years|No|||May 2015|May 11, 2015|July 13, 2010||No||No|April 22, 2015|https://clinicaltrials.gov/show/NCT01162473||119260|The small sample size constrains the statistical significance of this study. While useful in indicating potential trends, the results of this pilot study should be cautiously interpreted.
NCT01162707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-06-03|Wireless, Intermittent Monitoring of Right Heart Pressures in HF|A Multi-Center, Non-Randomized, Prospective Trial to Evaluate the Safety and Feasibility of Wireless, Intermittent Monitoring of Right Heart Pressures in Adult Heart Failure Subjects||CardioMEMS|Yes|Completed|December 2006|September 2012|Actual|November 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162707||119242|
NCT01162720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FairfieldHJCD|Short- Versus Long-duration Tourniquet Use During Total Knee Replacement (TKR)|Feasibility of Tourniquet Use During Cement Fixation Only for TKR Surgery||Fairfield Hospital, Australia|Yes|Terminated|November 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|65|||Both|18 Years|N/A|No|||March 2011|March 29, 2011|July 6, 2010||No|The risk of donor blood transfusion was unacceptably high in the Short Duration Group|No||https://clinicaltrials.gov/show/NCT01162720||119241|
NCT01163006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-084|Soluble Dietary Fibres in the Prevention of Type 2 Diabetes Mellitus|Soluble Dietary Fibres as Dietetic Aid to Reduce the Risks of Type 2 Diabetes Mellitus||Maastricht University Medical Center|No|Recruiting|March 2010|||March 2011|Anticipated|N/A|Interventional|N/A|4||Anticipated|60|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||July 2010|July 14, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163006||119219|
NCT01163591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.470-T|To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy|A Phase II, Open-Label, Cross-Sectional, Study to Compare eZscan, With Standard Methods of Screening for Diabetic Nephropathy, As a Tool for Detection of Type 2 Diabetic Nephropathy||Chinese University of Hong Kong|No|Completed|January 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|||Both|21 Years|75 Years|No|Non-Probability Sample|Type 2 diabetes mellitus patients with and without diabetic nephropathy|October 2015|October 9, 2015|November 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01163591||119174|
NCT01163825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NsG0202-001|Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients|An Open Label, Dose-Escalation Study of Encapsulated Cell Biodelivery of Nerve Growth Factor to the Cholinergic Basal Forebrain of Alzheimer´s Disease Patients|NsG0202|NsGene A/S|Yes|Active, not recruiting|January 2008|||December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|50 Years|80 Years|No|||July 2010|July 15, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163825||119156|
NCT01153958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200059-504|Colposeptine for the Treatment of Bacterial Vaginosis|The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study||Merck KGaA|No|Terminated|July 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Female|18 Years|45 Years|No|||January 2014|January 20, 2014|June 28, 2010||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT01153958||119910|
NCT01155570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-077|Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)|Special Investigation (All Cases Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis)||AbbVie||Completed|February 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|752|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who receive Humira for the treatment of psoriasis vulgaris or psoriatic        arthritis|September 2013|September 30, 2013|June 30, 2010||No||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01155570||119786|
NCT01155856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-021|The Virtual Hospital - a Clinical Trial|Consecutive, Randomized Controlled Multicenter Trial, Investigating the Feasibility and Safety of a Telemedicine Based Treatment Regimen in Patients With Chronic Obstructive Pulmonary Disease (COPD), Compared to Conventional Hospital Treatment|TVH|Frederiksberg University Hospital|Yes|Active, not recruiting|June 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|45 Years|N/A|No|||June 2012|June 19, 2012|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01155856||119764|
NCT01155869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 10-079|Pilot Study of Depot NTX in Homeless Veterans|Pilot Study of Depot Naltrexone in Alcohol-Dependent, Homeless Veterans||VA Office of Research and Development|No|Terminated|August 2010|June 2012|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|7|||Both|18 Years|64 Years|No|||June 2014|June 16, 2014|June 30, 2010|No|Yes|Poor enrollment|No|September 17, 2013|https://clinicaltrials.gov/show/NCT01155869||119763|Only 15 of 215 alcohol-dependent, homeless veterans would consider a study that included an intramuscular injection of XR-NTX. Of 3 given XR-NTX, only 1 returned for injection #2. Aversion to injection likely contributed to poor acceptability.
NCT01156623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-3639A3|Endobronchial Ultrasound Guided Transbronchial Aspiration (EBUS-TBNA) in Non Small Cell Lung Cancer (NSCLC) in a Tuberculosis-endemic Country|Value of EBUS-TBNA for Mediastinal Lymph Nodes in Non-small Cell Lung Cancer in a Tuberculosis-endemic Country||Chang Gung Memorial Hospital|Yes|Completed|June 2010|August 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|36|||Both|20 Years|N/A|No|||February 2015|February 11, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01156623||119705|
NCT01156636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|444-10|Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure|Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study||University of Milan|Yes|Completed|January 2006|December 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Male|N/A|N/A|No|||June 2009|June 14, 2012|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156636||119704|
NCT01156961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25081|A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)|Post Registration Observational Program for Patients With Locally Recurrent or Metastatic Breast Cancer Who Receive Bevacizumab (Avastin) in Combination With Paclitaxel for the First-line Treatment||Hoffmann-La Roche||Withdrawn|October 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 2, 2010|No|Yes|Absence of patient's recruitment in the study due to administrative reasons|No||https://clinicaltrials.gov/show/NCT01156961||119679|
NCT01156974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3096-1E|Care Guides in the Primary Care Office (Phase II)|Care Guides: Can Trained Laypersons Help Manage Chronic Disease? A Randomized Trial.||Allina Hospitals and Clinics|No|Completed|July 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2135|||Both|18 Years|79 Years|No|||January 2015|January 14, 2015|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156974||119678|
NCT01157247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSRAA-CMA:007/03|Intravenous Fentanyl or Local Anesthetic Infiltration for Pain Reducing During Spinal Needle Insertion|||Croatian Society of Regional Anesthesia and Analgesia|Yes|Completed|April 2009|July 2010|Actual|June 2010|Actual|N/A|Interventional|Primary Purpose: Treatment|4||Actual|88|||Both|35 Years|55 Years|No|||June 2010|July 6, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157247||119657|
NCT01154907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIBE-FGS|Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa|Prevention of HIV and Improved Diagnosis of Adolescent Genital Disease in Bilharzia Endemic KwaZulu-Natal, South Africa|VIBE-FGS|Oslo University Hospital|Yes|Enrolling by invitation|April 2010|December 2018|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|6500|Samples Without DNA|Urine, stool, blood, in the adults also vaginal lavage and Pap smears|Female|10 Years|20 Years|No|Probability Sample|A random sample of school girls in Ugu district, KwaZulu Natal, South Africa|March 2012|March 20, 2012|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154907||119837|
NCT01154920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0885|Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2010|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|June 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154920||119836|
NCT01153477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810112|Effectiveness of Enhanced Treatments for Drug Dependence|Effectiveness of an Enhanced Adaptive Continuing Care Model for Cocaine Dependence|EETDD|University of Pennsylvania|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||August 2011|December 21, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01153477||119947|
NCT01153490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-159B|Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine|Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine|CD|Feinstein Institute for Medical Research|Yes|Recruiting|July 2010|June 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||June 2010|May 27, 2011|June 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01153490||119946|
NCT01166152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TokyoUAT_21_11|Development of a New Diagnosis and Intervention Method for Developmental Disorders|Development of a New Diagnosis and Intervention Method for Developmental Disorders|DIDD|Tokyo University of Agriculture and Technology||Recruiting|August 2010|March 2013|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|N/A|50 Years|Accepts Healthy Volunteers|||July 2010|July 20, 2011|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166152||118977|
NCT01166412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN009|A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)|CCN009: A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate the Effects on the Mechanisms of Contraceptive Efficacy and, Secondarily, to Assess the Pharmacokinetic Profile and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)|CCN009|Health Decisions|Yes|Completed|December 2010|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||February 2014|February 19, 2016|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166412||118957|
NCT01162213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200916915-2|Pilot Study of Lychee Fruit Extract to Promote Cardiovascular Health|Effects of Lychee Fruit Extract on Vascular Function and Inflammation in Postmenopausal Women: a Double-Blind, Crossover Study||University of California, Davis|No|Completed|April 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|August 19, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162213||119280|
NCT01162226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R42NS061502-02|Computer-Based Balance Training for People With Parkinson's Disease|"PD Wii: Computer-based Gait and Balance Training for Parkinson's Patients".||University of California, San Francisco|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|62|||Both|N/A|N/A|No|||April 2012|April 17, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01162226||119279|
NCT01155011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134795|Multilevel Intervention for Physical Activity in Retirement Communities|MIPARC - Multilevel Intervention for Physical Activity in Retirement Communities|MIPARC|University of California, San Diego|Yes|Completed|January 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|307|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155011||119829|
NCT01155843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT006202|Neural Mechanisms in Asthma|Neural Mechanisms by Which Chronic Stress Regulates Inflammation in Asthma||University of Wisconsin, Madison|Yes|Completed|October 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|December 2014|September 30, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155843||119765|
NCT01163019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2DS-CP-ED-MSS-IERG|2D Strain Echocardiography for Diagnosing Chest Pain in the Emergency Room|Utility of 2D Strain Echocardiography in Triage of Patients With Chest Pain in the Emergency Department|2DSPER|Technion, Israel Institute of Technology|No|Completed|September 2010|September 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|700|||Both|45 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency department with a chief complaint of chest pain|October 2014|October 27, 2014|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01163019||119218|
NCT01163305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL016|PET-CT and Circulating Tumor Cells in Colorectal Cancer|Identifying an Early Indicator of Drug Efficacy in Patients With Advanced Colorectal Cancer - a Prospective Evaluation of Circulating Tumor Cells, Positron-emission Tomography Scan and RECIST Criteria||Chinese University of Hong Kong|No|Recruiting|June 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|96|Samples With DNA|circulating tumor cells|Both|18 Years|N/A|No|Probability Sample|patients with metastatic colorectal cancer|January 2016|January 28, 2016|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01163305||119196|
NCT01154543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Famvir™ 500 in HIV|Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes|A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes.||Holdsworth House Medical Practice||Completed|March 2008|February 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|N/A|N/A|No|Non-Probability Sample|50-60 patients attending Holdsworth House Medical Practice in Darlinghurst, Sydney, New        South Wales with documented HIV-1 infection who are taking Famciclovir 500mg bd as        suppressive therapy for management of genital HSV infection who agree to participate in        this study will be enrolled after signing HREC approved informed consent.|March 2013|March 19, 2013|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154543||119865|
NCT01156168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000681004|Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab|VEGF Gene Amplification/Deletion and Haplotype as Biomarkers for Bevacizumab in Breast Cancer||National Cancer Institute (NCI)||Not yet recruiting|April 2010|||May 2010|Anticipated|N/A|Observational|N/A|||Anticipated|363|||Both|18 Years|N/A|No|||June 2010|September 18, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156168||119740|
NCT01156389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-010-10|Pyronaridine/Artesunate -Ritonavir Drug Drug Interaction Study|Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers||Medicines for Malaria Venture|No|Completed|July 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 18, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156389||119723|
NCT01156896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF0995|Malaria and the Safety of Iron Supplements and Iron Fortification|Malaria and Iron Intervention Safety: Absorption and NTBI|MIA|Columbia University|No|Completed|July 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|23|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156896||119684|
NCT01157208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0600|Nutrition for Chronic Daily Headache|Dietary Interventions for Chronic Daily Headache (CDH): A Feasibility Study,||University of North Carolina, Chapel Hill|Yes|Completed|July 2009|December 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|67|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01157208||119660|
NCT01156987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS055|Improved Breast MRI With SWIFT|Improved Breast Dynamic Contrast Enhanced-magnetic Resonance Imaging (DCE-MRI) With Sweep Imaging With Fourier Transform (SWIFT)||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|August 2009|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156987||119677|
NCT01157000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017197|A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers|An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-28431754 (Canagliflozin) Administered as a 300-mg Oral Tablet and an Intravenous Microdose of 10 mcg 14C-canagliflozin in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2010|June 2010|Actual|||Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01157000||119676|
NCT01157260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ewha AST-120|The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease|The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease||Ewha Womans University|Yes|Not yet recruiting|September 2010|December 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|70 Years|No|||March 2010|July 6, 2010|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01157260||119656|
NCT01153503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022010-002|Ultrasound-guided Transversus Abdominis Plane Block After Hysterectomy|Ultrasound-guided Transversus Abdominis Plane Block After Abdominal Hysterectomy: a Prospective Randomized Controlled Trial|TAP|University of Texas Southwestern Medical Center|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|75|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||May 2010|December 2, 2014|June 28, 2010|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01153503||119945|
NCT01153815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112958|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity||GlaxoSmithKline|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|75 Years|No|||May 2012|October 4, 2012|June 17, 2010||No||No|April 19, 2012|https://clinicaltrials.gov/show/NCT01153815||119921|
NCT01155128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-0001-FB|Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease|Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial||Federal University of Pelotas|No|Enrolling by invitation|September 2011|December 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155128||119820|
NCT01155427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-186|Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)|A Systematic Review of Literature on Common Antiretroviral Treatments Against Hepatitis B Virus (HBV)||Bristol-Myers Squibb|No|Completed|May 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort||5|Actual|100|||Both|16 Years|N/A|No|Non-Probability Sample|Clinical trial enrollees|June 2010|June 30, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155427||119797|
NCT01153165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10015LH-OPMS|Study of Treatment of Depression in Refractory Asthma|Pilot Study of Treatment of Depression in Refractory Asthma||Belfast Health and Social Care Trust|No|Recruiting|November 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||February 2012|February 1, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01153165||119970|
NCT01153425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803763|Nuclear MRI(NMR)in Women at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide|NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide|TERIZOL|University of Pennsylvania|No|Completed|July 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|34|||Female|60 Years|N/A|No|||November 2011|January 31, 2013|June 1, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01153425||119951|
NCT01162239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA002538|Maintaining Nonsmoking|Maintaining Nonsmoking||University of California, San Francisco|Yes|Active, not recruiting|May 2010|July 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|271|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 14, 2015|June 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162239||119278|
NCT01163032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-3201|Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder|A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon Versus Placebo in Totally Blind Subjects With N24HSWD Followed by an OLE Phase||Vanda Pharmaceuticals|No|Completed|August 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|75 Years|No|||October 2014|October 15, 2014|July 2, 2010|Yes|Yes||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01163032||119217|
NCT01163318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-070|Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis|Special Investigation (Long-term Treatment in Patients With Rheumatoid Arthritis)||AbbVie||Completed|December 2009|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|552|||Both|15 Years|N/A|No|Non-Probability Sample|Participants who received adalimumab in accordance with its indications for treatment and        dosage regimens.|May 2015|May 28, 2015|July 14, 2010||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01163318||119195|
NCT01155557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2009-081|The Effect of Specific Strength-Training on Tension-Type Headache in Children 9-17 Years|Strength Capacity of Neck and Shoulder Muscles in Children and Adolescents 9-17 Years With Tension Type Headache and the Effect of Specific Strength-Training on Tension-Type Headache||Herlev Hospital|No|Completed|August 2009|August 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|9 Years|18 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01155557||119787|
NCT01156376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOXDHY0003|Oral Irritation Study of Two Experimental Mouthrinses|Determination of the Oral Irritation and Sensitization Potential of Two Experimental Potassium Oxalate Containing Mouthrinses||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|June 30, 2010|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01156376||119724|
NCT01156610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000405|Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations|Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations||Brigham and Women's Hospital|No|Completed|November 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|706|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 4, 2014|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01156610||119706|
NCT01157442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009:315|Study of Cell Phone SMS Messages for Prevention of Maternal to Child Transmission of HIV|Harnessing Mobile Phone Usage for HIV and Horizontal Health Systems Improvement: PMTCT||University of Manitoba|No|Recruiting|July 2010|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|856|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||July 2010|March 22, 2011|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01157442||119642|
NCT01155024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-10700-V1|Clinical Evaluation of Direct Manufactured Prosthetic Sockets|Clinical Evaluation of Direct Manufactured Prosthetic Sockets||Ohio Willow Wood|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|June 29, 2010||No||No|October 26, 2011|https://clinicaltrials.gov/show/NCT01155024||119828|Early termination by four participants for reasons unrelated to the interventions lead to smaller numbers completing the 3 month trial period for the direct manufactured socket.
NCT01155258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-09-6|Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors|Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.||University of Southern California|No|Active, not recruiting|June 2010|December 2015|Anticipated|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155258||119810|
NCT01162785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0938|Phase IB Intravesical Administration of SCH 721015|Phase 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2011|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|9|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01162785||119236|
NCT01163097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070278|Study to Characterize the Effect of Heparin on Palifermin Activity|An Open-label, Randomized, Parallel-Design Study to Characterize the Effect of Heparin on Palifermin Activity in Healthy Adult Subjects||Swedish Orphan Biovitrum|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|July 14, 2010|No|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT01163097||119212|
NCT01156909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1318|B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome|B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment||Haukeland University Hospital|No|Completed|October 2010|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|66 Years|No|||August 2014|August 29, 2014|July 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01156909||119683|
NCT01153971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18324|A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas|An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma||Hoffmann-La Roche||Completed|July 2005|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|65 Years|No|||June 2015|June 24, 2015|June 14, 2010||No||No|August 4, 2014|https://clinicaltrials.gov/show/NCT01153971||119909|
NCT01154244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113417|Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea|Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea|SURPRISE|GlaxoSmithKline|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1439|||Both|18 Years|N/A|No|Probability Sample|Newly diagnosed Type II DM, Drug naive|January 2011|January 22, 2011|June 29, 2010||||No||https://clinicaltrials.gov/show/NCT01154244||119888|
NCT01157013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09/90721|Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma|The Role of Positron Emission Tomography (PET) Imaging in the Evaluation of Response to Sorafenib Treatment in Advanced Hepatocellular Carcinoma.||Hospital Miguel Servet|No|Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||July 2010|July 2, 2010|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01157013||119675|
NCT01157273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/UNIFESP 0707/05|Evaluation of Physiological and Vocal Parameters in Volunteers of Both Genders Submitted to an Anxiogenic Task|Psychophysiological and Vocal Affections in Subjects Submitted to a Public Speaking Mock Test||Federal University of São Paulo|Yes|Completed|February 2009|July 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thirty individuals participated in the study, being 18 (60.0%) female and 12 (40.0%) male.        They were between 19 and 42 years old and their schooling ranged from fundamental school        (primary and middle school) to post-graduation.        All the volunteers were in good health, had no history of psychiatric problems or alcohol        and/or drug abuse, and did not report any vocal problems. Subjects excluded from the        sample were chronic smokers; had paralysis or neurological diseases; had problems in the        upper airways or allergic rhinitis at the moment of the experiment; used stimulant,        psychotropic, anxiolytic, phytotherapic or antidepressant substances, and those who had        ingested alcohol or coffee on the day of the experiment.|July 2010|July 6, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157273||119655|
NCT01157286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAOS1|Obstructive Apnea in Patients Submitted to Partial Laryngectomy|Obstructive Apnea in Patients Submitted to Partial Laryngectomy||Hospital do Servidor Publico Estadual|No|Recruiting|June 2010|October 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|PATIENTS OVER 18 YEARS, SUBMITED IN THE LAST 15 YEARS TO PARTIAL LARINGECTOMY IFNO        TRACHEOSTOMY IS PRESENT|July 2010|July 6, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157286||119654|
NCT01154673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041009|Intense Acute Infection Study|Randomized, Double-blinded, Controlled Trial Assessing the Effect of Intensive Treatment With HAART and the Integrase Inhibitor, Raltegravir, and the CCR5 -Receptor Antagonist, Maraviroc, on HIV-1 Pro-viral DNA and Reservoir Decay in HIV-1-infected Individuals Initiating Antiretroviral Therapy During the Acute Phase of Infection||University of Toronto|Yes|Completed|November 2011|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||May 2015|May 29, 2015|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154673||119855|
NCT01154686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23977|Working Memory Training in College Students With Attention-Deficit Hyperactivity Disorder/Learning Disabilities|Working Memory Training in College Students With ADHD/LD||University of Toronto|No|Recruiting|September 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|35 Years|No|||June 2010|June 30, 2010|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01154686||119854|
NCT01154933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1930|Exeantide in Type 2 Diabetes on Insulin|The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin||Kaleida Health|No|Completed|April 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|63|||Both|20 Years|75 Years|No|||December 2012|December 14, 2012|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154933||119835|
NCT01155141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08182009-3600|Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH|Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH||Stanford University||Completed|September 2009|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|16 Years|65 Years|No|||August 2014|August 20, 2014|June 29, 2010||No||No|August 1, 2014|https://clinicaltrials.gov/show/NCT01155141||119819|
NCT01166178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HDE40|Zoledronic Acid in MS-patients With Osteoporosis|A 1-year, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Zoledronic Acid 5 mg (Aclasta®) on Bone Mineral Density in Patients With Multiple Sclerosis Followed by a 1-year Open-label Treatment Phase|EXALT|Novartis||Terminated|October 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||October 2013|October 24, 2013|July 19, 2010||No||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01166178||118975|Study termination due to small number of participants recruited lead to lack of power for analysis of all outcome measures.
NCT01166425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-2005-07-2|Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.|A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.|Lithium2|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|June 2010|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|7 Years|17 Years|No|||May 2013|October 8, 2013|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01166425||118956|
NCT01163045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2 - Cavicchi|Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerve Versus Neurostimulation|Intraoperative Neuromonitoring and Neurostimulation of the Recurrent Laryngeal Nerve Versus Neurostimulation Alone in Thyroid Surgery: a Randomized Clinical Trial||University of Bologna|Yes|Completed|January 2008|January 2010|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|84 Years|Accepts Healthy Volunteers|||June 2010|July 14, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01163045||119216|
NCT01154777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFB6-18Autism|Collaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism|COLLABORATIVE STUDY OF NEUROFEEDBACK TRAINING OF 6-18YEAR OLDS WITH AUTISM||Institute for Personal Excellence, P.A.|No|Not yet recruiting|July 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||October 2010|October 3, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154777||119847|
NCT01156155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|342-10-FB|Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis|Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis||University of Nebraska|No|Completed|July 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|617|Samples With DNA|Blood specimens (serum, plasma and DNA)will be collected during a one time visit. Also      bacterial samples will be collected from the gums of the subject's mouth.|Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|UNebraskapatients Omaha VA Medical Center|May 2014|June 30, 2014|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01156155||119741|
NCT01156870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED10499|First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor|Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors||Sanofi|No|Active, not recruiting|September 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01156870||119686|
NCT01156883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1308|Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia|Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment|LAL1308|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|April 2010|February 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|34 Years|No|||April 2015|April 21, 2015|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01156883||119685|
NCT01157195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F071227003|Home-Based Automated Therapy of Arm Function After Stroke Via Tele-Rehabilitation|Home-Based Automated Therapy of Arm Function After Stroke Via Tele-Rehabilitation||University of Alabama at Birmingham|Yes|Active, not recruiting|June 2010|August 2017|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|19 Years|N/A|No|||September 2015|September 15, 2015|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01157195||119661|
NCT01153659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-A001-038|A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets|A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Effect on 24-hour, Intragastric pH Following Daily Oral Dose Administration of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40-mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets to H. Pylori-Negative Healthy Subjects in a 5-day Treatment Regimen||Eisai Inc.||Completed|July 2010|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01153659||119933|
NCT01153672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6856|Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy|A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy||University of Washington|No|Active, not recruiting|November 2010|July 2017|Anticipated|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|June 22, 2010|No|Yes||No|October 31, 2014|https://clinicaltrials.gov/show/NCT01153672||119932|
NCT01153685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110628|Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years|Immunogenicity and Safety Study of GSK Biologicals' (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years.||GlaxoSmithKline||Completed|July 2010|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 13, 2011|June 29, 2010|Yes|Yes||No|July 26, 2011|https://clinicaltrials.gov/show/NCT01153685||119931|
NCT01162525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pTNS|Percutaneous Tibial Nerve Stimulation for Patients With Fecal Incontinence|Percutaneous Tibial Nerve Stimulation (pTNS) for Patients With Fecal Urge Incontinence||Cantonal Hospital of St. Gallen|No|Recruiting|January 2010|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||March 2016|March 10, 2016|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162525||119256|
NCT01162772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|575/2008|Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects|Influence of a Modern Oral Anti-diabetic Medication on Endothelial Dysfunction and Cardiovascular Risk in Diabetic Women and Men: Gender Aspects||Medical University of Vienna||Recruiting|January 2010|||October 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|25 Years|70 Years|No|Non-Probability Sample|In this study 40 female and 40 male subjects with T2DM, who take metformin as an oral        anti-diabetic mono therapy according to the guidelines of the ÖDG.|July 2010|July 15, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162772||119237|
NCT01163123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9902|Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan|Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan||Mennonite Christian Hospital|No|Enrolling by invitation|May 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|312|Samples Without DNA|The sera from volunteer was collected to detect IgG, IgM and anti-NS1 antibody against      Japanese encephalitis virus|Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers were recruited from 2 villages in Hualien county Taiwan. There were at least        one patient who had confirmed diagnosis of Japanese virus encephalitis in past 2 years.        Many pig farms were located in these 2 villages also. The volunteers are either living or        working in the villages during 2010 summer. We had blood test for IgM, IgG for Japanese        virus encephalitis before and after the summer season to identify possible subclinical        infection. At the same time, mosquito were analyzed by RT-PCR periodically to identify        possible virus in the community.|July 2010|July 15, 2010|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163123||119210|
NCT01163110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCA04-04|Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy|Phase II Dose of Escalation Design to Investigate the Therapeutic Role of RNA Fragments in the Protection of Platelet Production During Chemotherapy||Midwestern Regional Medical Center|No|Completed|March 2004|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163110||119211|
NCT01163409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|exercisefibro|Exercise, Acupuncture and Fibromyalgia|Acupuncture and Physical Activity in Patients With Fibromyalgia||University of Sao Paulo|No|Enrolling by invitation|June 2010|June 2014|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|60|||Both|10 Years|17 Years|No|||June 2010|January 18, 2012|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01163409||119188|
NCT01163422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09/307|Right Ventricular Resynchronization Therapy|Long-term Right Ventricular Resynchronization Therapy for Chronic Thromboembolic Pulmonary Hypertension|RVRT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Enrolling by invitation|July 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2009|July 14, 2010|July 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01163422||119187|
NCT01157026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT369|A Pilot Clinical Trial With Tocotrienol on Breast Cancer|Effectiveness of Tocotrienol-rich Fraction Combined With Tamoxifen in the Management of Women With Early Breast Cancer: A Pilot Clinical Trial|BC|Malaysia Palm Oil Board|No|Completed|November 2001|January 2010|Actual|November 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Female|40 Years|60 Years|No|||July 2010|July 2, 2010|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01157026||119674|
NCT01157039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25070|A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin|A Phase II Trial of Glutamin to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin.||AHS Cancer Control Alberta|No|Withdrawn|October 2011|||September 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||October 2011|February 23, 2016|July 2, 2010||No|abandoned|No||https://clinicaltrials.gov/show/NCT01157039||119673|
NCT01157299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-PI-800|Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO|Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO|PreloaDren|Hospital Universitario La Paz|Yes|Recruiting|September 2009|September 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|1 Month|18 Years|No|Non-Probability Sample|Pediatric patients admitted to the PICU equipped with a femoral arterial catheter and a        central venous catheter or who require advanced hemodinamic monitoring|June 2010|July 6, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01157299||119653|
NCT01154699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001733/1|Positive Airway Pressure for the Treatment of Asthma|Positive Airway Pressure for the Treatment of Asthma||Brigham and Women's Hospital|No|Completed|July 2010|December 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|75 Years|No|||July 2015|July 20, 2015|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01154699||119853|
NCT01154946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAC|Clinical Implication of DAC (Detrusor After-contraction)|A New Approach to Clinical Implication of Detrusor After-contraction (DAC)|DAC|Seoul National University Hospital|Yes|Completed|January 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|2309|||Both|18 Years|N/A|No|Non-Probability Sample|2,309 patients more than 18 years old with neurogenic or non-neurogenic voiding        dysfunction who performed urodynamic studies|June 2010|June 30, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154946||119834|
NCT01155167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT0061169|Topical Radial Artery Vasodilation|The Effect of Topical Administration of Lidocaine/Nitroglycerin Combination Versus Placebo on Radial Artery Access in Patients Undergoing Cardiac Catheterization Via the Radial Artery||University of California, San Francisco|No|Completed|July 2010|August 2012|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|June 29, 2010|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01155167||119817|
NCT01162733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30029|Loading Vancomycin Doses in the Emergency Department|A Randomized Prospective Study of Vancomycin Dosing in the Emergency Department: Will a Loading Dose of 30mg/kg Lead to a More Rapid Attainment of Therapeutic Levels?|Loaded|Christiana Care Health Services|Yes|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|July 13, 2010||No||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01162733||119240|
NCT01154517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3617|Utility of the History and Physical Exam in the Emergency Department|Utility of the History and Physical Exam in the Emergency Department||Henry Ford Health System|No|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|128|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency Department Patients|July 2009|June 30, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154517||119867|
NCT01154530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOTES01|Chlorhexidine Mouthwash and Bacterial Contamination During Endoscopy|Chlorhexidine Mouthwash and Bacterial Contamination During Endoscopy. Implementation of Chlorhexidine Mouthwash Before Transgastric NOTES||Herlev Hospital|Yes|Completed|January 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|August 16, 2011|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154530||119866|
NCT01155245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH 08-321-AE|Teriparatide (PTH) and Bone Strength in Postmenopausal Women|Study on the Effect of 24 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Postmenopausal Women With Osteoporosis||University Health Network, Toronto|No|Active, not recruiting|June 2008|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Female|N/A|N/A|No|Non-Probability Sample|community dwelling postmenopausal women with osteoporosis and women with atypical femur        fractures|December 2014|December 23, 2014|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155245||119811|
NCT01165905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-10|Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors|Phase I Dose Escalation Study of Gemcitabine and 24 Hour Infusion of ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors||Onconova Therapeutics, Inc.|No|Completed|January 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2011|December 29, 2011|July 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165905||118996|
NCT01165918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor491210CTIL|Derivation of New Human Embryonic Stem Cell Lines: Identification of Instructive Factors for Germ Cells Development|Basic Research. Unveiling Factors That Contribute to Germ Cell Differentiation||Soroka University Medical Center|No|Not yet recruiting|October 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|4 Days|Accepts Healthy Volunteers|Non-Probability Sample|any donated embryo|June 2010|July 18, 2010|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01165918||118995|
NCT01165931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14550|Coronary Vasomotor Response After Riociguat Exposure|A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease|CORONARIES|Bayer|No|Withdrawn|May 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|90 Years|No|||October 2013|October 21, 2013|July 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01165931||118994|
NCT01166217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0961009|A Single Dose Study Of PF-04620110 In Healthy Subjects|A Phase 1, Cross-over, Single-dose, Open-label Study to Estimate the Relative Bioavailability of Three Different Formulations of Pf-04620110 Under Fed/Fasted Conditions in Healthy Adult Subjects||Pfizer|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 18, 2010|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01166217||118972|
NCT01166230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC B305/E10|Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB|An Open, Non-interventional, Retrospective, Comparative, Multicenter Follow-up Study in Patients Included in the Previously Completed Clinical Study PCB305/04, to Assess Longer-term Recurrence Rates in Patients After Hexvix® (Cysview®)Fluorescence Cystoscopy/Transurethral Resection of the Bladder (TURB) or White Light Cystoscopy/TURB||Photocure|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|551|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-invasive papillary bladder cancer, enrolled in the previously completed        pivotal phase III study PC B305/04, who were followed for recurrence will be included in        this study.|November 2013|November 14, 2013|July 19, 2010||No||No|August 5, 2013|https://clinicaltrials.gov/show/NCT01166230||118971|
NCT01153399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OGR-DUM-2010/1|A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).|An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)-REASON STUDY.|REASON|AstraZeneca|No|Completed|October 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|589|||Both|N/A|N/A|No|Probability Sample|Patients with Non Small Cell Lung Cancer|November 2015|November 19, 2015|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01153399||119953|
NCT01161914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISU302-2008|The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease|A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease||ISU Abxis Co., Ltd.||Not yet recruiting|January 2011|||August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|18|||Both|2 Years|75 Years|No|||July 2010|July 13, 2010|July 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01161914||119303|
NCT01161927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-04|Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions|A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Non-fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|July 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 13, 2010|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161927||119302|
NCT01154231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3090X1-4415|BeneFIX Drug Use Results Survey [All-Case Surveillance]|Benefix(Registered) Intravenous 500 1000 2000 Drug Use Results Survey (All-case Surveillance)||Pfizer|No|Completed|February 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|314|||Both|N/A|N/A|No|Probability Sample|Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are        administered this drug.|September 2015|September 14, 2015|June 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154231||119889|
NCT01162798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.02.US.INF|Preterm Infant Growth|Growth of Preterm Infants Consuming Formula||Nestlé|No|Completed|September 2010|September 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|150|||Both|N/A|1 Month|No|||November 2014|November 3, 2014|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162798||119235|
NCT01163682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE7054|Acupuncture Study for the Prevention of Taxane Induced Myalgias and Neuropathy|Randomized Sham Controlled Trial of Weekly Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy||Columbia University|No|Active, not recruiting|December 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Female|21 Years|N/A|No|||May 2015|May 20, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163682||119167|
NCT01163435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912093M|Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication|Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication - A Prospective, Comparative Study||National Taiwan University Hospital|No|Completed|August 2010|October 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|618|||Both|18 Years|N/A|No|||December 2013|December 1, 2013|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01163435||119186|
NCT01163669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080093|A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients|A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients||The Cleveland Clinic|No|Completed|July 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|kidney transplant recipients|January 2012|August 12, 2013|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163669||119168|
NCT01154062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114155|A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration|An Open-label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Exploratory Efficacy and Pharmacodynamics of Oral Pazopanib Administered for 28 Days to Neovascular Age-related Macular Degeneration Patients||GlaxoSmithKline|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|50 Years|N/A|No|||June 2011|June 9, 2011|June 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154062||119902|
NCT01154387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTI-121|Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection|A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation||Tolera Therapeutics, Inc|Yes|Active, not recruiting|July 2010|June 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|85|||Both|18 Years|60 Years|No|||June 2013|June 10, 2013|June 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154387||119877|
NCT01154400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109237|Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients|Grant Title: Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in COPD||Texas A&M University|No|Completed|May 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|12|||Both|45 Years|N/A|No|||October 2012|October 11, 2012|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01154400||119876|
NCT01154413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP3984/07|Implementation of a Diabetes Management Protocol as Compared to Conventional Management in a Heart Hospital's Non-Intensive Care Unit: Randomized Clinical|Implementation of a Diabetes Management Protocol as Compared to Conventional Management in a Heart Hospital's Non-Intensive Care Unit: Randomized Clinical Trial||Instituto de Cardiologia do Rio Grande do Sul|No|Completed|December 2007|May 2009|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A||||June 2010|June 29, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154413||119875|
NCT01154959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTB01|Latency in Pulmonary Tuberculosis|Characterization of Immune Responses in Treatment-induced Latency in Pulmonary Tuberculosis||Tuberculosis Research Centre, India|No|Recruiting|February 2010|February 2015|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Both|18 Years|N/A|No|||June 2011|June 15, 2011|June 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154959||119833|
NCT01155180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P000190|Leptin in the Maintenance of Reduced Body Weight|Leptin in the Maintenance of Reduced Body Weight||Beth Israel Deaconess Medical Center||Active, not recruiting|July 2008|December 2015|Anticipated|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|June 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155180||119816|
NCT01165060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09/278|The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)|Effect of Bezafibrate on Very Long Chain Fatty Acid Metabolism in Men With X-linked Adrenoleukodystrophy (X-ALD)|BEZA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|July 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||July 2010|August 9, 2011|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165060||119061|
NCT01165671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEOPATRA|Carbon Ion Radiotherapy for Primary Glioblastoma|Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma|CLEOPATRA|University Hospital Heidelberg|Yes|Recruiting|July 2010|||June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01165671||119014|
NCT01166243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-10-001|The Fibrin Pad Liver Study|A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery||Ethicon, Inc.|Yes|Completed|July 2010|October 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01166243||118970|
NCT01161953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|670-02 PBC|Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)|Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC).||Mayo Clinic|Yes|Recruiting|March 2002|December 2025|Anticipated|December 2025|Anticipated|Phase 1|Observational|Observational Model: Family-Based||1|Anticipated|1500|Samples With DNA|Blood and stool samples are collected.|Both|18 Years|90 Years|No|Non-Probability Sample|Subjects who are patients at Mayo Clinic and are seen in the department of        Gastroenterology and Hepatology are recruited by mail and carry a diagnosis of PBC.        Subjects who are not Mayo Clinic patients are encouraged to contact the study coordinator        by phone or email to request enrollment.|September 2015|September 15, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161953||119300|
NCT01161966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40577|Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|A Randomized. Single-Dose, Two-Way Crossover Relative Bioavailability Study of Zonisamide Formulations in Fasted Normal, Healthy Men and Women||Dr. Reddy's Laboratories Limited|No|Completed|January 2005|March 2005|Actual|February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2005|July 13, 2010|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161966||119299|
NCT01161940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090-04|Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|July 2004|September 2004|Actual|September 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 13, 2010|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161940||119301|
NCT01162278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCC-02210|Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases|Dose Escalating Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|July 2010|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01162278||119275|
NCT01162291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW-M-MRI01|Comparison of Intramuscular Distribution of Different Injection Volumes Via Diffusion Tensor Imaging (DTI)|Comparison of Intramuscular Distribution of Different Injection Volumes Via Diffusion Tensor Imaging (DTI)-A Pilot Trial||Medical University of Vienna|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|8|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteer|January 2012|January 28, 2012|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162291||119274|
NCT01163448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-013|Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer|Phase I Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer||Memorial Sloan Kettering Cancer Center||Withdrawn|July 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||March 2015|March 4, 2015|July 14, 2010|No|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01163448||119185|
NCT01162824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOVA-8|Blood Markers for Inflammation and Coronary Artery Vasoreactivity Testing in Patients With Chest Pain and Normal Coronary Arteries|Correlation Between Abnormal Coronary Vasoreactivity Testing, Expansion of CD4+CD28null T Cells and Biomarkers for Inflammation and Endothelial Dysfunction in Patients With Angina Despite Angiographically Normal Coronary Arteries.|ACOVA|St George's Healthcare NHS Trust|No|Recruiting|January 2011|December 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|35 Years|N/A|No|||February 2011|February 22, 2011|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162824||119233|
NCT01163955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 10-90|A Postural Study Comparing Sitting on the Floor Versus Sitting in a Chair While Playing Video Games.|A Postural Analysis of Children Playing Video Games Sitting on the Floor vs. Sitting in a Chair: A Randomised Controlled Trial||Glinn and Giordano Physical Therapy|No|Completed|July 2010|December 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|56|||Both|5 Years|15 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|July 15, 2010||No||No|June 2, 2011|https://clinicaltrials.gov/show/NCT01163955||119146|
NCT01163968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|177-09-FB|Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM)|Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM)|MOMENTUM|University of Nebraska|Yes|Completed|June 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 5, 2014|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01163968||119145|
NCT01163461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6572-R|Phonomotor Treatment of Word Retrieval Deficits in Individuals With Aphasia|Real Word Effects in Phonological Treatment for Word Retrieval||VA Office of Research and Development|No|Completed|September 2010|September 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||July 2015|July 9, 2015|July 14, 2010||No||No|September 29, 2014|https://clinicaltrials.gov/show/NCT01163461||119184|
NCT01154075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1112|Medication Adherence in Children Who Had a Liver Transplant|Medication Adherence in Children Who Had a Liver Transplant|MALT|Icahn School of Medicine at Mount Sinai|Yes|Completed|August 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|401|Samples Without DNA|liver tissue samples (from biopsies performed for clinical, not investigational, reasons)|Both|1 Year|18 Years|No|Non-Probability Sample|Pediatric patients receiving liver transplantation|October 2015|October 22, 2015|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154075||119901|
NCT01154426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01473|ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors|Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies||National Cancer Institute (NCI)||Completed|May 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2014|June 30, 2015|June 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154426||119874|
NCT01154712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244|Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling|Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling||BeerYaakov Mental Health Center|No|Recruiting|June 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||January 2010|July 12, 2010|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154712||119852|
NCT01155193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-410|Prospective, Study for the Use of Palivizumab (Synagis) in High Risk Children in Germany|Documentation of Safety and Efficacy of Synagis in Preterm Infants||AbbVie|No|Recruiting|November 2007|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|24 Years|No|Non-Probability Sample|Each community Pediatrician in care of preterm infants and/or children with congenital        heart disease can participate in this study.|January 2016|January 13, 2016|March 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01155193||119815|
NCT01155505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S095LEPT01|Lenalidomide and Paclitaxel in Advanced Solid Tumors|Phase Ib of CC-5013 and Paclitaxel in Patients With Advanced Solid Tumors||Southern Europe New Drug Organization|No|Active, not recruiting|November 2009|March 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|75 Years|No|||September 2011|September 12, 2011|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01155505||119791|
NCT01165073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGVOC1|Short Term Feeding for Asian Patients With Liver Cirrhosis|Short Term Feeding for Hospitalised Asian Patients With Liver Cirrhosis - a Randomised Trial of Naso-gastric vs Oral Feeding||University of Malaya|No|Completed|March 2008|May 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||July 2010|February 27, 2011|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165073||119060|
NCT01165086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoodED101|Reducing Dietary Energy Density by Incorporating Vegetables in Order to Decrease Energy Intake|||Penn State University||Completed|November 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|1||Actual|48|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 9, 2011|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165086||119059|
NCT01165099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4874|Acupuncture for Pain Relief During Induced Labour in Nulliparae|Acupuncture for Pain Relief During Induced Labour in Nulliparae: a Randomised Controlled Study||University of Oxford|No|Completed|August 2005|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|105|||Female|18 Years|N/A|No|||July 2010|July 16, 2010|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01165099||119058|
NCT01165684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-3786|Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen|A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy|Full STEP™|Novo Nordisk A/S|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|July 16, 2010|Yes|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT01165684||119013|A higher proportion of subjects did not complete the trial in the basal-bolus arm (52 subjects, 26.0%) than in the step-wise arm (28 subjects, 13.9%).
NCT01165957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2010-0102|A Comparison of Wear Among Mobile and Fixed Bearing Knee Replacements|A Comparison of Volumetric Wear Among DePuy Mobile and Fixed Bearing Knee Tibial Inserts||Anderson Orthopaedic Research Institute|No|Completed|June 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Retrieved polyethylene tibial inserts archived as part the Anderson Orthopaedic Research        Institute's implant retrieval program.|July 2012|July 30, 2012|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01165957||118992|
NCT01165372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02MA|Study of Malaria Treatment at Phuoc Long Hospital, Binh Phuoc Province, Vietnam|Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam||Oxford University Clinical Research Unit, Vietnam|Yes|Completed|August 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|166|||Both|10 Years|N/A|No|||September 2011|September 14, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01165372||119037|
NCT01165658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0164|Hypofractionated Proton Radiation Therapy|Phase I Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2010|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165658||119015|
NCT01161979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40578|Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions|A Randomized. Single-Dose, Two-Way Crossover Relative Bioavailability Study of Zonisamide Formulations in Normal, Healthy Men and Women Following a Standard Meal||Dr. Reddy's Laboratories Limited|No|Completed|January 2005|March 2005|Actual|February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2005|July 13, 2010|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01161979||119298|
NCT01161992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|670-02 PSC|Genomics of Primary Sclerosing Cholangitis (PSC)|P.R.O.G.R.E.S.S.: PSC Resource Of Genetic Risk, Environment and Synergy Studies.||Mayo Clinic|No|Recruiting|March 2002|December 2025|Anticipated|December 2025|Anticipated|Phase 1|Observational|Observational Model: Cohort||1|Anticipated|1500|Samples With DNA|Blood sample will be drawn at local facility and sent to Mayo Clinic by mail. Stool sample      will be collected and sent back to Mayo Clinic by mail. All study related charges will be      charged to the study.|Both|5 Years|90 Years|No|Non-Probability Sample|Subjects who are patients at Mayo Clinic and are seen in the department of        Gastroenterology and Hepatology are recruited by mail and carry a diagnosis of Primary        Sclerosing Cholangitis (PSC). Subjects who are not Mayo Clinic patients are encouraged to        contact the study coordinator by phone or email to request enrollment.|September 2015|September 15, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01161992||119297|
NCT01162317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6924-W|AcuSleep in Mild Traumatic Brain Injury (TBI)|Novel Approaches to Sleep Difficulties: Application in Mild TBI|AcuTBI|VA Office of Research and Development|No|Active, not recruiting|July 2011|December 2015|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|55 Years|No|||October 2015|October 20, 2015|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01162317||119272|
NCT01162304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29813|Open-Label Trial Comparing Oxycodone Medications|Open-Label Trial Comparing Oxycodone Medications for Effectiveness and Satisfaction (OUTCOMES)|OUTCOMES|University of Rochester|Yes|Terminated|March 2010|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|80 Years|No|||January 2014|June 25, 2015|April 27, 2010|Yes|Yes|unable to enroll subjects meeting Eligibility criteria|No|March 26, 2015|https://clinicaltrials.gov/show/NCT01162304||119273|
NCT01162538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021178-12|To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients|The Main Objective of This Study is to Evaluate the Virologic Effectiveness at M6 of Regimen Containing Raltegravir in Treatment Naive HIV Subtype Non B or B Infected Subjects|Ral'inNONB|Centre Hospitalier Intercommunal Robert Ballanger|No|Not yet recruiting|September 2010|March 2012|Anticipated|March 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|It's a pilot open label, multicentric, national, prospective and descriptive study to        evaluate effectiveness and safety of regimen containing Raltegravir (400mg x 2) in 40        treatment naive HIV non B infected subjects versus in 20 treatment naive HIV B infected        sujects.        The patients will be matched according to:          -  basal viral load (< 10 000 copies/ml, ≥100 000 copies/ml)          -  rate of basal CD4 (<200 cell/mm3, ≥ 200 cell/mm3)|May 2010|July 13, 2010|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01162538||119255|
NCT01162850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070050|Oral Polypodium Leucotomos for Melasma|A Randomized Double-Blind Placebo Controlled Study Evaluating the Effectiveness and Tolerability of Oral Polypodium Leucotomos in Patients With Melasma||University of Miami|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2008|August 4, 2011|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01162850||119231|
NCT01162863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-028LUB|Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation|A Pilot Study to Assess the Effects of Lubiprostone on Gastrointestinal and Colonic Motility and pH in Patients With the Irritable Bowel Syndrome and Constipation (IBS-C)||University of Michigan||Completed|November 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162863||119230|
NCT01163149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-009-10|Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)|A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, Pharmacokinetic of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults With Hypophosphatasia (HPP)||Alexion Pharma GmbH|Yes|Active, not recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|13 Years|65 Years|No|||May 2015|May 11, 2015|June 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163149||119208|
NCT01163162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003-15|The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate|The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate|Paricalcitol|Indiana University|No|Completed|August 2010|June 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|16|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|July 14, 2010||No||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01163162||119207|
NCT01163474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 10-060|Telemedicine in Cardiac Surgery: A Pilot Study|Telemedicine in Cardiac Surgery: A Pilot Study||VA Office of Research and Development|No|Completed|October 2010|September 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|July 14, 2010||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01163474||119183|
NCT01154088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114248|Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds|Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Mencevax™ ACWY in Healthy Subjects Aged 18-25 Years||GlaxoSmithKline||Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1173|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2012|November 15, 2012|June 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154088||119900|
NCT01154101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114296|Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis||GlaxoSmithKline|Yes|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|80 Years|No|||February 2012|November 15, 2012|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01154101||119899|
NCT01154725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKD01|The Effect of Patient Education and Rehabilitation on Quality of Life in Patients With Permanent Stomas|Effect of Patient Education and Rehabilitational Interventions on Health Related Quality of Life of Patients With Permanent Stomas Regardless of Cause||Herlev Hospital|No|Completed|August 2010|March 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01154725||119851|
NCT01154972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010ON03|Preoperative Localisation of the Sentinel Lymph Node in Breast Cancer|Preoperative Identification of the Sentinel Lymph Node in Breast Cancer, Using Ultrasound and Radio-isotope/Percutaneous Gamma Probe||NHS Tayside|No|Recruiting|April 2010|November 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|N/A|N/A|No|||June 2010|July 12, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154972||119832|
NCT01155206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0394-A|Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon|Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon|Glucagon|University Health Network, Toronto|No|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|9|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2007|November 30, 2015|June 25, 2008||No||No||https://clinicaltrials.gov/show/NCT01155206||119814|
NCT01155518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-JF-13|Hypogonadism in Young Men With Type 2 Diabetes|Effect of Hypogonadotropic Hypogonadism and Replacement With Clomiphene Citrate and Testosterone on Insulin Sensitivity, Body Composition, Inflammation, Sexual Function and Spermatogenesis in Young Type 2 Diabetic Men||State University of New York at Buffalo|No|Terminated|June 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|5|||Male|18 Years|40 Years|No|||March 2016|March 9, 2016|June 30, 2010|Yes|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01155518||119790|
NCT01165944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1343|Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus|Effectiveness of Pramlintide on Control of Post-Transplant Diabetes Mellitus||University of Colorado, Denver|No|Withdrawn|August 2009|August 2011|Anticipated|August 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|70 Years|No|||October 2012|October 2, 2012|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01165944||118993|
NCT01165970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-01/2008-005451-23|Effect of Saliva Substitutes on Dental Hard Tissues in Situ|Vergleichende, Randomisierte, Kontrollierte Und Doppelblinde In-situ-Studie Zur Wirkung Von Speichelersatzmitteln Auf Schmelz Und Dentin|T-01|Charite University, Berlin, Germany|Yes|Terminated|January 2009|December 2012|Anticipated|March 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||November 2011|November 12, 2011|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01165970||118991|
NCT01166269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILIT|Study to Asses Efficacy of Intralymphatic Immunotherapy|Intralymphatic Specific Immunotherapy - as a New Treatment Form for Grass-pollen Allergic Subjects|ILIT|Rigshospitalet, Denmark|Yes|Completed|July 2010|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|60 Years|No|||November 2012|November 7, 2012|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01166269||118968|
NCT01162005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-Tacrobell|Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children|||Seoul National University Hospital|No|Withdrawn|July 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|18 Years|Accepts Healthy Volunteers|||July 2010|November 17, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162005||119296|
NCT01162018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0020|Acupuncture for Sleep Disruption in Cancer Survivors|Acupuncture for Sleep Disruption in Cancer Survivors||Stanford University|Yes|Completed|February 2011|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Female|18 Years|N/A|No|||May 2013|May 30, 2013|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01162018||119295|
NCT01162811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J. nr. 2007-58-0015.).|Visualization and Structured Attention Behaviour for Pain and Anxiety Reduction During Ablation of Atrial Fibrillation|Visualization and Structured Attention Behaviour -- Does it Reduce the Patient's Experience of Pain Intensity and Anxiety During Ablation of Atrial Fibrillation?||Rigshospitalet, Denmark|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||November 2009|July 20, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01162811||119234|
NCT01163136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007447|Decision Making in Serious Pediatric Illness|Decision Making in Serious Pediatric Illness|DSPI|Children's Hospital of Philadelphia|No|Active, not recruiting|July 2010|November 2016|Anticipated|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|358|||Both|18 Years|N/A|No|Non-Probability Sample|Parents of children of age < 18 years or cognitively impaired such that their parents make        all medical decisions on their behalf; and of either gender and any race/ethnicity who are        patients at The Children's Hospital of Philadelphia (CHOP) admitted to the neonatal,        pediatric, or cardiac intensive care unit (CICU), neonatal intensive care unit (NICU), or        pediatric intensive care unit (PICU), or who have been referred to the Pediatric Advanced        Care Team (PACT) for palliative care services.|December 2015|December 15, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01163136||119209|
NCT01162551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007444|Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma|Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma||Children's Hospital of Philadelphia|Yes|Recruiting|May 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|N/A|25 Years|No|||March 2016|March 15, 2016|June 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162551||119254|
NCT01162564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-10-002|Flexible Composite Next Generation Tissue Separating Mesh in Laparoscopic Incisional/Ventral Hernia Repair|Single-Arm, Prospective, Multi-Center Observational Study of a Flexible Composite Next Generation Tissue Separating Mesh(NG-TSM)to Assess Ease of Use and Early Outcomes in Laparoscopic Incisional/Ventral Hernia||Ethicon, Inc.|No|Completed|June 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for planned laparoscopic procedure to repair an abdominal        incisional/ventral hernia that requires the addition of reinforcing or bridging material        to obtain the desired surgical result|April 2011|April 25, 2011|July 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01162564||119253|
NCT01163188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01ER0801|Social Adjustment and Quality of Life After Very Preterm Birth|Social Adjustment and Quality of Life After Very Preterm Birth: Risk and Resiliency From Infancy to Adulthood||University Hospital, Bonn|Yes|Completed|September 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|520|Samples Without DNA|hair|Both|24 Years|28 Years|No|Probability Sample|Very low birthweight (< 1500g birthweight) and/ or very preterm children (< 32 weeks of        gestation) and a control group of term born children from the Bavarian Longitudinal Study|August 2014|August 8, 2014|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01163188||119205|
NCT01163175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2005-233|Study of the Impact of Trans Fatty Acids From Dairy Products on Cardiovascular Risk Factors|Study of the Impact of Trans Fatty Acids From Dairy Products n Cardiovascular Risk Factors|TRANS|Laval University|No|Completed|May 2006|November 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|February 10, 2011|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01163175||119206|
NCT01163487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0031|Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers|Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers||Stanford University|Yes|Active, not recruiting|August 2010|February 2016|Anticipated|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|July 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01163487||119182|
NCT01163721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0107|Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Exploratory Study to Access the Metabolic Effects of Ranolazine When Added to Ongoing Non-Insulin Antidiabetic Therapy in Subjects With Type 2 Diabetes Mellitus||Gilead Sciences|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||July 2013|July 19, 2013|July 14, 2010|Yes|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01163721||119164|
NCT01154114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480848/028|Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment||GlaxoSmithKline|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 11, 2011|June 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01154114||119898|
NCT01154127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2310|Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD|GLOW3|Novartis||Completed|June 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|40 Years|N/A|No|||April 2012|April 10, 2012|June 29, 2010|Yes|Yes||No|February 8, 2012|https://clinicaltrials.gov/show/NCT01154127||119897|
NCT01154738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/18|Lidocaine and Closed-Loop Anesthesia System|Influence of Lidocaine on a Closed-Loop Anesthesia System|LoopLido|Hopital Foch|No|Recruiting|January 2011|April 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01154738||119850|
NCT01154751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEV Technologies, Inc.|Data Registry Following Patients Using Supera Stent in the Femoral Arteries|Supera Treatment Registry Observing Neointimal Growth|STRONG|IDev Technologies, Inc.|No|Active, not recruiting|November 2008|August 2015|Anticipated|August 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01154751||119849|
NCT01154985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCH-02-001|Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)|A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH||Mochida Pharmaceutical Company, Ltd.|Yes|Completed|June 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|243|||Both|18 Years|N/A|No|||October 2014|November 13, 2014|June 29, 2010|Yes|Yes||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01154985||119831|
NCT01155219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTG1030-PIV-12/07|Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.|Safety and Efficacy Assessment of Geltim LP® 1 mg/g (Unpreserved Timolol Gel - TG1030) in Ocular Hypertensive or Glaucomatous Patients Stabilized by Xalatan® With Ocular Intolerance Signs.|T1030|Laboratoires Thea|No|Completed|July 2008|December 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|90 Years|No|||July 2010|October 24, 2014|June 30, 2010||No||No|October 24, 2014|https://clinicaltrials.gov/show/NCT01155219||119813|
NCT01155232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTH 04-0655AE|Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis|Effect of 24 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Men and Women With Osteoporosis||University Health Network, Toronto|No|Recruiting|November 2004|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|community dwelling men and women with osteoporosis|November 2015|November 30, 2015|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01155232||119812|
NCT01155531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-4450-C-401|Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects|A Phase I, Single Center, Open Label, Intra Subject, Dose Escalation Study to Evaluate Safety and Tolerability of Sertraline Plus Telenzepine in Overweight Healthy Subjects||Theracos|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|March 4, 2015|June 22, 2010|Yes|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT01155531||119789|
NCT01155544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-160B|Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole|Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole|SIP|Feinstein Institute for Medical Research|Yes|Not yet recruiting|June 2011|June 2014|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|44 Years|No|||June 2010|May 27, 2011|July 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01155544||119788|
NCT01155817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT222|Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease|A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease||Stanford University|Yes|Active, not recruiting|August 2010|July 2014|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|N/A|No|||May 2013|May 5, 2013|June 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01155817||119767|
NCT01165385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEP 07/0908 - PACIFIK|Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors|An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors|PACIFIK|UNICANCER|Yes|Completed|June 2010|October 2014|Actual|October 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||November 2014|November 14, 2014|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01165385||119036|
NCT01165398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-20090107|Comprehensive Evaluation of a Central Line Simulation Course|Comprehensive Evaluation of a Central Line Simulation Course||Lehigh Valley Hospital|No|Completed|December 2008|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|383|||Both|N/A|N/A|No|Non-Probability Sample|Lehigh Valley Health Network residents, physician assistants, and nurse practitioners who        place central lines and attend the central lines simulation course|April 2012|April 25, 2012|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01165398||119035|
NCT01165411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Registry|Developing and Maintaining a Central Venous Catheter Registry|Developing and Maintaining a Central Venous Catheter Registry||Lehigh Valley Hospital|No|Enrolling by invitation|August 2008|January 2016|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4530|||Both|N/A|N/A|No|Non-Probability Sample|All patients that have CVCs and PICC lines placed at LVH|August 2010|August 2, 2010|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01165411||119034|
NCT01165697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0137|Establishment of Biomarkers for Fabry Disease|Establishment of Biomarkers for Fabry Disease||Ohio State University|No|Recruiting|July 2010|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Initially any Fabry patient, age 18 and above who has a confirmed diagnosis of Fabry        disease by previously identifying plasma or leukocyte α-galactosidase A (α-gal A)        deficiency, will be recruited from all participating physician practices. Those who        present with evidence of angiopathy (with specific attention to the target organs: renal,        cardiac, or ocular) will be recruited for the study.|May 2013|May 20, 2013|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01165697||119012|
NCT01165983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000233|The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes|The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes||Beth Israel Deaconess Medical Center|Yes|Completed|November 2009|||January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|124|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|December 15, 2009|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01165983||118990|
NCT01165437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF IRB 10-513|Validation of a Novel Oscillometric-Based Algorithm for Determination of the Ankle-Brachial Index|Validation of a Novel Oscillometric-Based Algorithm for Determination of the Ankle-Brachial Index||Summit Doppler Systems, Inc.|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|161|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to the non-invasive vascular laboratory or another outpatient clinic        in the Heart and Vascular Institute at Cleveland Clinic.|February 2011|February 22, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01165437||119032|
NCT01166256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFNCinAHRF|Comparison Between High-flow Nasal Cannula System and Non-invasive Ventilation in Acute Hypoxemic Respiratory Failure|Prospective, Open-labeled, Randomized Controlled Trial of Comparison Between High-flow Nasal Cannula System and Non-invasive Ventilation in Acute Hypoxemic Respiratory Failure||Asan Medical Center||Recruiting|July 2010|||July 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||July 2010|July 20, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166256||118969|
NCT01166009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMDP IRB-1999-0021|Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries|Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries||Center for International Blood and Marrow Transplant Research|No|Recruiting|July 2002|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|99999999|||Both|N/A|N/A|No|Non-Probability Sample|Recipients and Donors that are involved with a stem cell transplantation process.|May 2014|February 2, 2015|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01166009||118988|
NCT01166282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-328|A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis|A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis||AbbVie|No|Completed|September 2010|November 2015|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|6 Years|17 Years|No|||November 2015|November 13, 2015|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01166282||118967|
NCT01162031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMTPLL0001|Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia|Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia||Stanford University|Yes|Withdrawn|June 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|July 12, 2010||No|Low accrual|No||https://clinicaltrials.gov/show/NCT01162031||119294|
NCT01162330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5286|The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment|The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment After Their Neonatal Screen (BEST)|BEST|Newcastle-upon-Tyne Hospitals NHS Trust|No|Completed|August 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|411|||Both|N/A|21 Days|No|Non-Probability Sample|This population this study examines is infants in Newcastle and South West London who are        referred for more hearing tests after their neonatal hearing screen.        This cohort of patients will be offered screening tests for congenital CMV infection.|October 2015|October 7, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162330||119271|
NCT01162343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081408|Delirium in the Emergency Department: Novel Screening|Delirium in the Emergency Department: Novel Screening||Vanderbilt University|No|Active, not recruiting|July 2009|May 2013|Anticipated|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|406|||Both|65 Years|N/A|No|Non-Probability Sample|The participants will be those who are Vanderbilt University Emergency Department patients        65 years or older. There will be no selection bias in regards to race or gender. Only        those who meet the inclusion/exclusion criteria will be considered for study inclusion.|July 2012|July 26, 2012|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162343||119270|
NCT01162577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|Oklahoma Weight Concerns Quitline: a Randomized Cessation Trial|Oklahoma Weight Concerns Quitline: a Randomized Cessation Trial|OKRCT|Alere Wellbeing|Yes|Completed|March 2008|September 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 13, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01162577||119252|
NCT01162837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAT-0110|Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne|An Evaluation of the Safety and Effectiveness of the BEAM Device in the Treatment of Mild-to-moderate Acne||Oregon Aesthetic Technologies|No|Completed|June 2010|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Both|15 Years|N/A|No|||May 2012|May 1, 2012|July 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01162837||119232|
NCT01162876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-09-003|A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus|A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus||Kyowa Hakko Kirin Company, Limited|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|20 Years|65 Years|No|||January 2014|January 6, 2014|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01162876||119229|
NCT01171430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081236|"WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival|Assessment of Dynamic Contrast Enhanced Whole Body MRI (DCE-WB-MRI) as Independent Prognostic Factor for Disease-free Survival in Multiple Myeloma (After Intensification Therapy and Autologous Stem Cell Transplantation Suppressed by Amendment n°3)|EVALICEMM|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|July 2010|July 2019|Anticipated|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Both|18 Years|70 Years|No|||November 2014|November 13, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171430||118573|
NCT01171664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105781-2|Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects|A Bi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of STAHIST in Adult Subjects With a History of Seasonal Allergic Rhinitis|STA-2|Magna Pharmaceuticals, Inc.|Yes|Completed|September 2010|January 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||September 2010|March 24, 2014|July 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171664||118555|
NCT01171677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYULMC - 10-01156|Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits|Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits||New York University School of Medicine|Yes|Completed|July 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|N/A|No|||January 2013|January 30, 2013|July 27, 2010||No||No|October 22, 2012|https://clinicaltrials.gov/show/NCT01171677||118554|Overall small sample size, limited exercise intensity and capacity, missed exercise classes, dropout because of placement, work schedules and non-study-related medical conditions.
NCT01203306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2006-004748-22|Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors|Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors|XELBEVOCT|University of Turin, Italy|Yes|Recruiting|January 2006|December 2010|Anticipated|May 2009|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|80 Years|No|||July 2010|September 15, 2010|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203306||116142|
NCT01203553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 094/10|Prophylactic Mesh Implantation for the Prevention of Incisional Hernia|Mesh Implantation for Prophylaxis of Incisional Hernia|ProphMesh|University Hospital Inselspital, Berne|No|Active, not recruiting|January 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Population with a high risk for incisional hernia formation|December 2015|December 10, 2015|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01203553||116123|
NCT01203839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-114|Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer|A Phase II Study of Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203839||116101|
NCT01204099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-866-002|Study of PX-866 and Docetaxel in Solid Tumors|Phase 1/2 Study of PX-866 and Docetaxel in Patients With Solid Tumors||Oncothyreon Inc.|Yes|Completed|September 2010|February 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|223|||Both|18 Years|N/A|No|||April 2015|May 19, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204099||116081|
NCT01204112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921056|Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers|A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers||Pfizer|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 21, 2010|September 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01204112||116080|
NCT01203085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC-6603|Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT|Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth|INC-6603|University of Iowa|No|Recruiting|April 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|21 Years|No|Non-Probability Sample|Patients who are 21 years of age and under who are also enrolled in the 6601 study and        have performed all tasks to complete the CMT Peds Scale will be recruited for        participation. Participation entails allow the information collected in the 6601 study be        used for validation in the current study.|May 2015|May 14, 2015|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01203085||116159|
NCT01203527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPRU Tamiflu|A Study of the Pharmacology of Tamiflu in Pregnancy|A Study of the Pharmacology of Oseltamivir (Tamiflu-Roche) in Pregnancy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|March 2007|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort||4|Actual|63|Samples With DNA|Blood and urine|Female|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant and non-pregnant women|August 2013|October 8, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203527||116125|
NCT01203540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBKE_SNUBH&BM_01|Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients|Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients||Laboratoires Thea|No|Completed|October 2010|January 2011|Actual|||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|21|||Both|20 Years|N/A|No|||January 2012|January 27, 2012|September 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01203540||116124|
NCT01204645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKT|Karolinska Cardiorenal Theme-centre and StockholmHeartbank|Stockholmheartbank and Karolinska Cardiorenal Theme-centre, From Genome to Clinical Practice in Patients With Acute Coronary Syndrome and Impaired Kidney Function|KKT|Danderyd Hospital|Yes|Recruiting|May 2010|January 2021|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|10000|Samples With DNA|Blood and plasma.|Both|N/A|N/A|No|Probability Sample|1. All patients admitted to one of the four major emergency hospitals in Stockholm, for             an acute coronary event.          2. All patients admitted to one of the four major emergency hospitals in Stockholm, for             an elective coronary angiography|April 2013|April 25, 2013|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204645||116040|
NCT01204970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220109292|Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients|Confocal Laser Micro-endoscopy: New Insights in COPD and Lung Transplant Recipients||Katholieke Universiteit Leuven||Recruiting|September 2010|December 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|80 Years|No|Probability Sample|Patients referred for a bronchoscopic procedure will be asked to undergo CLME. 3 pools        will be made: COPD patients according to their pulmonary function test, lung transplant        recipients and patients with normal spirometric results. In all groups the difference        between active smokers and no-smokers will be made.|August 2013|August 5, 2013|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01204970||116015|
NCT01205269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1883C00004|The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Double-blind, Placebo-controlled, Randomised, Multi-centre, 3-way Cross-over, Single-dose Phase II Study to Investigate the Local and Systemic Effects of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|28|||Both|40 Years|N/A|No|||February 2014|February 24, 2014|September 15, 2010|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT01205269||115993|
NCT01204372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GATE 1|Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma|Phase II Trial Evaluating the Combination of Gemcitabine, Trastuzumab and Erlotinib as First-line Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma|GATE 1|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|June 2010|April 2015|Anticipated|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204372||116060|
NCT01173939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0035|Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments|Primary Prevention of MACE With Standard and Intensive Statin Treatment in Hypercholesterolemia Patients With Concomitant Diabetes and Hypertension|POSITIVE|Positive Trial Group||Terminated|July 2010|||June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10000|||Both|50 Years|N/A|No|||November 2010|May 30, 2011|July 27, 2010||No|With recommendation from IDMC, Steering Committee terminated this trial due to ethical    concerns raised by J-ART study.|No||https://clinicaltrials.gov/show/NCT01173939||118382|
NCT01174485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEFEUSP-LIPO|Effects of Liposuction and Exercise Training on Metabolism, Lipid Profile and Adiposity in Women|Effects of Liposuction and Exercise Training on Metabolism, Lipid Profile and Adiposity in Women||University of Sao Paulo|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Female|20 Years|36 Years|Accepts Healthy Volunteers|||April 2011|May 11, 2011|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01174485||118340|
NCT01174771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCaliforniaLA|Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration|Noninvasive Cortical Stimulation (rTMS) for Motor and Non-Motor Features of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD)||University of California, Los Angeles|No|Completed|October 2008|February 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|30|||Both|35 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The purpose of this study is to learn more about how transcranial magnetic stimulation        (TMS) affects motor and non-motor function in patients with Progressive Supranuclear Palsy        (PSP) or Cortical Basal Ganglionic Degeneration (CBGD)—forms of parkinsonism.|May 2014|May 7, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01174771||118319|
NCT01175044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10031106|Dilute Betadine Lavage in the Prevention of Postoperative Infection|Efficacy of a Dilute Betadine Lavage in the Prevention of Postoperative Infection in Revision Total Knee Arthroplasty||Rush University Medical Center|No|Recruiting|August 2010|August 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|90 Years|No|||August 2014|August 29, 2014|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175044||118298|
NCT01175005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCH 10-042|Procalcitonin Levels in Patients With Fever and a Central Line|Procalcitonin as a Marker of Serious Infection in Patients With Fever and a Central Venous Catheter||Phoenix Children's Hospital|Yes|Completed|May 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|N/A|18 Years|No|Non-Probability Sample|Patients with fever and a central venous catheter who are 18 years of age and younger will        be enrolled and will have PCT levels drawn in the Emergency Department.|May 2011|May 5, 2011|July 28, 2010||No||No|March 29, 2011|https://clinicaltrials.gov/show/NCT01175005||118301|
NCT01170910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.550/3|Pulsatile Perfusion Preservation in Kidney Transplantation From Expanded Criteria Donors|Interest of Pulsatile Perfusion Preservation on Outcomes in Kidney Transplantation From Expanded Criteria Donors|IMPULSION|Hospices Civils de Lyon|Yes|Recruiting|April 2010|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170910||118612|
NCT01171209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016824-29|REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients|REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients|REPAIR|Rigshospitalet, Denmark|Yes|Completed|July 2010|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|55 Years|No|||November 2012|November 29, 2012|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01171209||118590|
NCT01171690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000901|Teriparatide for Postsurgical Hypoparathyroidism|Pilot Study of Teriparatide for Postsurgical Hypoparathyroidism||Mayo Clinic|Yes|Terminated|November 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||December 2014|December 19, 2014|July 27, 2010|No|Yes|Funding problems|No|December 2, 2014|https://clinicaltrials.gov/show/NCT01171690||118553|
NCT01171950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED-001|CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients|CentriMag Ventricular Assist System (VAS): Treatment of Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients||Thoratec Corporation|Yes|Withdrawn|June 2009|||December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|5 Years|16 Years|No|||March 2016|March 18, 2016|July 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171950||118533|
NCT01171963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113808|Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants|Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants||GlaxoSmithKline||Completed|August 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3340|||Both|6 Weeks|16 Weeks|Accepts Healthy Volunteers|||October 2013|December 19, 2013|July 28, 2010|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT01171963||118532|
NCT01203124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0540C00016|A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers|A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker||AstraZeneca|No|Completed|November 2010|February 2012|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203124||116156|
NCT01203319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KT0003|The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines|The Immunogenicity and Safety of 60mcg and 30mcg Recombinant Hepatitis B Vaccines in People Aged 16 and Older Who Failed to Respond to Routine Administration of 10mcg Recombinant Hepatitis B Vaccines||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|November 2006|March 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|1091|||Both|16 Years|N/A|No|||April 2012|April 21, 2012|September 15, 2010||No||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01203319||116141|
NCT01203566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC 2009.347|A Randomised Controlled Trial on LESS Versus Conventional Laparoscopic Appendicectomy.|A Double-blinded Randomised Controlled Trial of Laparoendoscopic Single-site Access (LESS) Versus Conventional Three-port Appendicectomy.||Chinese University of Hong Kong|Yes|Completed|October 2009|April 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||September 2010|July 19, 2011|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203566||116122|
NCT01203579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003048|Chest Computed Tomography (CT) Screening Study With Antibody Testing|Different Strategies Using Autoantibodies and/or CT in the Detection of Lung Cancer||Mayo Clinic|No|Withdrawn|September 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Current or Former Smokers with >20 pack year history and or family history of lung cancer.        Ages 50-75 years old|June 2012|June 20, 2012|September 15, 2010|Yes|Yes|Due to lack of funding|No||https://clinicaltrials.gov/show/NCT01203579||116121|
NCT01204385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111337|Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Saudi Arabia|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Saudi Arabia||GlaxoSmithKline||Completed|June 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|Samples Without DNA|Middle ear fluid and urine|Both|3 Months|5 Years|No|Non-Probability Sample|Subjects aged ≥ 3 months and < 5 years of age, diagnosed as having AOM|January 2014|January 9, 2014|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204385||116059|
NCT01204658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113994|Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants|Safety, Reactogenicity & Immunogenicity of GSK Biologicals' Pneumococcal Vaccine 2189242A When Co-administered With DTPa-HBV-IPV/Hib Vaccine in Healthy Infants||GlaxoSmithKline||Completed|September 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|576|||Both|6 Weeks|14 Weeks|Accepts Healthy Volunteers|||May 2013|May 1, 2014|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204658||116039|
NCT01204671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114269|Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)|Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.||GlaxoSmithKline||Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|4659|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|October 15, 2015|September 16, 2010|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01204671||116038|Concerns arose about data integrity for a Romanian site (102 subjects) after completion of analysis. These data were not excluded from this reporting as they did not reveal irregularities and GSK does not plan to use them towards regulatory filing.
NCT01204684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000202|Dendritic Cell Vaccine for Patients With Brain Tumors|A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|September 2010|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|70 Years|No|||January 2016|February 1, 2016|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204684||116037|
NCT01205282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002|Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD) (PIO)|A Pilot Dose Finding Study of Pioglitazone in Children With ASD||Anagnostou, Evdokia, M.D.|No|Active, not recruiting|April 2013|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|35|||Both|5 Years|12 Years|No|||February 2016|February 9, 2016|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01205282||115992|
NCT01204983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26923|Quality Improvement Project - Evaluation of Current Standard of Care for Feeding Practices in the NICU|Quality Improvement Project - Evaluation of Current Standard of Care for Feeding Practices With Donor Human Milk Products in the NICU|NICU|Baylor College of Medicine|No|Recruiting|July 2010|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Premature, very low birth weight infants only|January 2016|January 13, 2016|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204983||116014|
NCT01174225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00798|IUD Insertion Post First Trimester Abortion|Contraception Satisfaction and Effectiveness: A Randomized Controlled Trial||University of British Columbia|Yes|Active, not recruiting|September 2010|July 2018|Anticipated|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|534|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 29, 2015|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174225||118360|
NCT01174498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cMPsPAI01|Pilot Study of the Effect of Transcutaneous Stimulation of the Vagus Nerve on Pain Perception and Parameters of the Autonomic Nervous System|Controlled, Randomized Study of Pain Perception and Psychophysiological Reactions of the Autonomic Nervous System Under Transcutaneous, Electrical Stimulation of the Vagus Nerve in Healthy Volunteers||cerbomed GmbH|No|Completed|November 2009|September 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 7, 2011|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174498||118339|
NCT01174784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI CTO 10001|Chronic Total Occlusion Crossing With the Wildcat Catheter|A Non-randomized Study of the Avinger Wildcat Used to Cross Femoropopliteal CTOs|CONNECT|Avinger, Inc.||Completed|August 2010|June 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|19 Years|N/A|No|||July 2013|July 29, 2013|August 2, 2010|No|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01174784||118318|
NCT01175057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medina Pilot Study|MeDiNa Pilot Study for Evaluation of the MeDiNa Concept of Homely Rehabilitation After Myocardial Infarction|Pilot Study for Evaluation of the MeDiNa Concept of Homely Rehabilitation of Patients With Acute Myocardial Infarction||RWTH Aachen University|No|Completed|September 2011|September 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|18|||Both|60 Years|N/A|No|Non-Probability Sample|Patients of the Medical Clinic I, RWTH Aachen University Hospital, Pauwelsstaße 30, 52074        Aachen, post stationary after myocardial infarction and who are at least 60 years old|March 2013|March 21, 2013|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175057||118297|
NCT01175018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA 10SDG3030051|Anakinra to Prevent Adverse Post-infarction Remodeling (2)|Anakinra to Prevent Adverse Post-infarction Remodeling (2)|VCU-ART2|Virginia Commonwealth University|No|Completed|July 2010|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||July 2013|July 6, 2013|July 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175018||118300|
NCT01175031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-1002-PRS1ED-MS|Comparison of Breathing Event Detection by a CPAP Device to Clinical Polysomnography|Validation of Breathing Event Detection of the Philips Respironics Sleep Therapy System REMstar Auto A-Flex Compared to Clinical Polysomnography||Philips Respironics|No|Completed|September 2010|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|55|||Both|21 Years|80 Years|No|||October 2013|October 9, 2013|July 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175031||118299|
NCT01171222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saarland University|Health Status and Cardiovascular Stress of Veteran Soccer Players|Health Status and Cardiovascular Stress of Veteran Soccer Players||Saarland University|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|40 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|veteran soccer players from Saarland County, Germany|July 2010|August 26, 2011|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01171222||118589|
NCT01171443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102-10CTIL|The Pathophysiology of Bortezomib Induced Peripheral Neuropathy|Is There a Role of Oxidative Stress in the Pathophysiology of Bortezomib Induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients?|BIPN|Wolfson Medical Center|No|Not yet recruiting|August 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|A total of 30 newly diagnosed patients (age > 18 years) with multiple myeloma (stage3        Durie and Salmon, ECOG-performance status <2), who are candidates for bortezomib therapy        will be enrolled in the study (duration of the study 6 months).|July 2010|July 27, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171443||118572|
NCT01171703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-DCLI-I|Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I)|Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I)|DCLI-I|Peking Union Medical College Hospital|Yes|Enrolling by invitation|November 2010|July 2016|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|55 Years|75 Years|No|||July 2010|December 20, 2012|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01171703||118552|
NCT01171976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002D2304|Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus|A 2 Year Randomized, Single-masked, Multicenter, Controlled Phase IIIb Trial Assessing the Efficacy and Safety of 0.5 mg Ranibizumab in Two "Treat and Extend" Treatment Algorithms vs. 0.5 mg Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus|RETAIN|Novartis||Completed|September 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|373|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|July 27, 2010||No||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01171976||118531|
NCT01171989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113978|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children||GlaxoSmithKline||Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|391|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||December 2011|December 1, 2011|July 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171989||118530|
NCT01203605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuSOS 1.1|European Surgical Outcomes Study|European Surgical Outcomes Study: A Multi-centre, International Seven Day Evaluation of Patient Care and Clinical Outcomes for Patients Undergoing Non-cardiac Surgery|EuSOS|Queen Mary University of London|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46985|||Both|16 Years|N/A|No|Probability Sample|In-patient adult non-cardiac surgery|June 2011|September 4, 2012|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203605||116119|
NCT01204151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09132010-6849|Teaching Math Skills to Individuals With Fragile X Syndrome|Evaluating a Brief Intensive Intervention for Individuals With Fragile X Syndrome||Stanford University||Recruiting|September 2008|July 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|10 Years|23 Years|No|||September 2010|September 16, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204151||116077|
NCT01204125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11419|Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients|Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC)|SOLTI NEOPARP|Sanofi|No|Active, not recruiting|September 2010|February 2017|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|141|||Female|18 Years|N/A|No|||November 2015|November 26, 2015|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204125||116079|
NCT01204398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.31|Telmisartan+Amlodipine Fixed Dose Combination in Hypertension|An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension||Boehringer Ingelheim||Completed|November 2010|||July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|80 Years|No|||December 2013|June 17, 2014|September 16, 2010||||No|July 20, 2012|https://clinicaltrials.gov/show/NCT01204398||116058|
NCT01204697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21869|A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)|A Randomized Phase II Trial of Erlotinib or Intermittent Dosing of Erlotinib and Docetaxel in Male Former-smokers With Locally Advanced or Metastatic Squamous NSCLC in Second-line Setting After Failure on Chemotherapy||Hoffmann-La Roche||Completed|November 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|September 16, 2010|No|Yes||No|October 15, 2015|https://clinicaltrials.gov/show/NCT01204697||116036|
NCT01204710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13938|A Study of IMC-3G3 in Prostate Cancer|A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy||Eli Lilly and Company|Yes|Completed|October 2010|October 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Male|18 Years|N/A|No|||January 2014|January 22, 2014|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204710||116035|
NCT01205295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBH-12-1106|Patient Anxiety and Concern as Predictors for the Perceived Quality and Efficacy of Treatment|Patient Anxiety and Concern as Predictors for the Perceived Quality and Efficacy of Treatment||Kolding Sygehus|Yes|Recruiting|September 2010|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Probability Sample|Hip and shoulder patients from the Department of Orthopaedic Surgery, Kolding Hospital, a        part of Lillebaelt Hospital, Denmark and Department of Orthopaedics and Traumatology,        Odense University Hospital, Denmark.|September 2010|June 22, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01205295||115991|
NCT01173978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYS-CLAMP|Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance|Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Induced by Steroid Treatment, Relative Physical Inactivity and High Calorie Diet||Glostrup University Hospital, Copenhagen|Yes|Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2010|June 20, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01173978||118379|
NCT01174238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10852|A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852)|A Two Arm Phase II Trial of Sequential Axitinib and Carboplatin/Paclitaxel in Melanoma With Correlative FLT PET Scans (3'Deoxy-3'-18F-Fluorothymidine Positron Emission Tomography Scans)(CC# 10852)||University of California, San Francisco|Yes|Completed|July 2010|December 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174238||118359|
NCT01174511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0124-10-HMO-ctil|Evaluation of A-1 Cool Cream Efficacy for Treatment Atopic Dermatitis|Clinical Trial Study for Evaluation of A-1 Cool Cream Efficacy for Treatment Patients With Atopic Dermatitis||Hadassah Medical Organization|Yes|Not yet recruiting|July 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2010|July 3, 2011|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174511||118338|
NCT01174797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60-0001-001|Evaluation of Microvolt T-Wave Alternans(MTWA) Testing for the Detection of Active Ischemia|Evaluation of Microvolt T-Wave Alternans Testing for the Detection of Active Ischemia in Patients With Known or Suspected Coronary Artery Disease: A Feasibility Study|MTWA-CAD|Cambridge Heart Inc.||Completed|June 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|186|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with known or suspected CAD who are scheduled to undergo routine exercise MPI or        stress echocardiography testing for the detection of active ischemia in a cardiology        practice or hospital setting.|May 2013|May 23, 2013|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174797||118317|
NCT01170962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-011|Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment|A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy|HEPCAT|Bristol-Myers Squibb|No|Completed|August 2010|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|512|||Both|18 Years|70 Years|No|||September 2015|September 11, 2015|July 16, 2010|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT01170962||118608|
NCT01170975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPK103|Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules|An Open-label, Single-dose, Randomized, Crossover Study to Determine the Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsule in Solid Tumor Cancer Subjects||Genta Incorporated|No|Completed|June 2010|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|75 Years|No|||July 2012|July 20, 2012|July 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01170975||118607|
NCT01170923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 08-351|FDG-PET Scan Response Guided Chemotherapy Strategy for Advanced Non-small Cell Lung Cancer|Standard Chemotherapy Strategy Versus Changing Chemotherapy Strategy as to FDG-PET Response After 1st Cycle of Standard Chemotherapy for Advanced Non-small Cell Lung Cancer||Asan Medical Center|No|Active, not recruiting|September 2008|||August 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01170923||118611|
NCT01171235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFYY-H&N-1|Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma|Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma||Southern Medical University, China|Yes|Enrolling by invitation|July 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|blood and tissue samples|Both|15 Years|75 Years|No|Non-Probability Sample|all of nasopharyngeal carcinoma, hypopharyngeal carcinoma or laryngeal carcinoma visited        at ENT department of NanFang hospital|March 2009|July 27, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171235||118588|
NCT01171248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFIL-H-B-2009-056|Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 Diabetes|Central and Peripheral 24h BP and the Association to Autonomic Neuropathy and Diabetic Nephropathy in Type 1 Diabetic Patients|PROFIL|Steno Diabetes Center|No|Completed|September 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|650|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|type 1 diabetic patients (600 patients) non-diabetic controls (50)|September 2011|September 21, 2011|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171248||118587|
NCT01171456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1017118|Early Intervention for Gestational Diabetes|Early Medical Intervention in Women at Risk for Gestational Diabetes||Intermountain Health Care, Inc.|No|Withdrawn|April 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|45 Years|No|||January 2013|January 15, 2013|July 13, 2010||No|Insufficient funding for enrollment of patients. The invesitgators realized the study could    not be performed.|No||https://clinicaltrials.gov/show/NCT01171456||118571|
NCT01171716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708005744|The Body's Response to Changes in Dietary Protein and Meal-Frequency In Men|||Purdue University|Yes|Completed|September 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|13|||Male|21 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171716||118551|
NCT01172002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-20100330|Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis|A Randomized Multicenter Trial Comparing Leflunomide and Azathioprine as Remission-Maintaining Treatment for Proliferative Lupus Glomerulonephritis.||RenJi Hospital|Yes|Recruiting|March 2010|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||August 2010|August 10, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01172002||118529|
NCT01172249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLI/P/09-1|Non-inferiority Study of the Glucosamine Sulfate + Chondroitin Sulfate Association Capsule in Comparison to the CONDROFLEX® Product in Osteoarthrosis of the Knee|Non-inferiority Study of the Glucosamine Sulfate + Chondroitin Sulfate Association Capsule in Comparison to the CONDROFLEX® Product in Osteoarthrosis of the Knee||Mantecorp Industria Quimica e Farmaceutica Ltd.|No|Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|55 Years|80 Years|No|||July 2010|July 28, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01172249||118510|
NCT01172522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS910510|Topical Treatment of Under Eye Dark Circles and Swelling|A Pilot Randomized Double Blind Study to Assess the Safety and Efficacy of 1% Ibuprofen/ 1%Fexofenadine Topical Cream for the Treatment of Dark Circles Under the Eyes||The Connecticut Sinus Center, PC|Yes|Completed|September 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 16, 2015|July 28, 2010|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01172522||118489|
NCT01203618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-003-007|Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas|Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma||Morphotek|Yes|Withdrawn|February 2011|August 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 1, 2013|July 28, 2010|No|Yes|Trial terminated due to focus of primary therapeutic areas.|No||https://clinicaltrials.gov/show/NCT01203618||116118|
NCT01204450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0901|Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma|A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors||UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|November 2009|March 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|2 Years|18 Years|No|||October 2015|October 8, 2015|September 16, 2010|No|Yes|Funding has become unavailable|No||https://clinicaltrials.gov/show/NCT01204450||116054|
NCT01203852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01GM074492-06|Pharmacogenomic Evaluation of Antihypertensive Responses 2|Pharmacogenomic Evaluation of Antihypertensive Responses 2|PEAR2|University of Florida|Yes|Completed|August 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|839|||Both|18 Years|65 Years|No|||July 2015|July 30, 2015|September 15, 2010|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01203852||116100|
NCT01203865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0303-10-TLV|Prevalence of Fibromyalgia in Israel|Prevalence of Fibromyalgia in Israel||Tel-Aviv Sourasky Medical Center|No|Recruiting|October 2010|March 2012|Anticipated|November 2011|Anticipated|N/A|Observational|N/A||1|Anticipated|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Telephone survey - general population over age 18 Rheumatology patients - patients        attending the rheumatology clinic for any reason|October 2011|October 10, 2011|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203865||116099|
NCT01204138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08312010-6811|Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA|Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA|CATARA|Stanford University||Withdrawn|September 2010|December 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|September 10, 2010|No|Yes|decision of sponsor to withdraw before initiation; 0 patients enrolled|No||https://clinicaltrials.gov/show/NCT01204138||116078|
NCT01204411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/Nig/2010/PaluMadaua|Efficacy of Artesunate-amodiaquine (AS-AQ) in Children With Malaria and Severe Acute Malnutrition, Madaoua, Niger 2010|Efficacy of the Artesunate-amodiaquine Combination for Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Between 6 and 59 Months of Age With Severe Acute Malnutrition in Madaoua, Tahoua Region, Niger||Epicentre|No|Withdrawn||||||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Months|59 Months|No|||November 2012|November 29, 2012|September 16, 2010||No|The ethics committee did not approve the pharmacokinetic part of the study.|No||https://clinicaltrials.gov/show/NCT01204411||116057|
NCT01205581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUHD|Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV|Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV||St. Jude Children's Research Hospital|No|Completed|September 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|85|||Both|3 Years|21 Years|No|||July 2014|September 5, 2014|September 17, 2010|Yes|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01205581||115969|
NCT01204996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016462|A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors|An Open-label, Multicenter, Phase 1b Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors||Centocor, Inc.||Completed|May 2010|November 2011|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|53|||Both|18 Years|N/A|No|||May 2012|May 29, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204996||116013|
NCT01174251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H61125-34760-01|The Effect of General Anesthesia on the Risk for Arrhythmia|The Effect of General Anesthesia on the Risk for Arrhythmia -A Pilot Study|10-02725|University of California, San Francisco|No|Completed|December 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|18 Years|N/A|No|Probability Sample|A simple random sample will be chosen among all patients scheduled for general anesthesia        in the UCSF affiliations Mt. Zion Hospital and Moffit/Long Hospital meeting all inclusion-        and exclusion criteria.|October 2013|October 7, 2013|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174251||118358|
NCT01175096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001KCN01|Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor|A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor||Guangdong General Hospital|Yes|Active, not recruiting|July 2010|January 2012|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2010|August 3, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175096||118294|
NCT01175109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15120|Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma|Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma||University of Virginia|No|Active, not recruiting|October 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2012|December 26, 2012|July 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175109||118293|
NCT01170988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUSS001AHK|Coronary Flow Rate Measurement in T-Grafts|Comparison of Coronary Flow Reserve in Two Different Bypass Techniques (T-graft Technique Versus Isolated Graft Technique) Using Magnetic Resonance Technology (MRT)||Johann Wolfgang Goethe University Hospitals|No|Completed|August 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|80 Years|No|||August 2014|August 5, 2014|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01170988||118606|
NCT01171014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#08‐SPUS‐o6‐FON‐01|Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms|A Three‐Arm, Placebo Controlled, Double‐Blind, Single Center Study to Evaluate the Impact of Probiotic Strain Bifidobacterium Lactis HN019 on Intestinal Well‐Being, Colonic Transit Time and Digestive Discomfort||Fonterra Research Centre|No|Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|100|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 27, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01171014||118605|
NCT01170936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILUVIT1|Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses|An Open-label Pilot Study to Assess the Efficacy and Safety of a Single Dose Regime of Canakinumab (ACZ885) in Patients With Active, Refractory Urticarial Vasculitis|ILUVIT|Charite University, Berlin, Germany|Yes|Completed|July 2010|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170936||118610|
NCT01170949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIARCU 01/2008|Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria|Randomised, Double-blind, Placebo-controlled Study|MIARCU|Charite University, Berlin, Germany|Yes|Terminated|September 2008|April 2010|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|101|||Both|18 Years|N/A|No|||October 2008|July 27, 2010|January 12, 2010||No|Study medication expired|No||https://clinicaltrials.gov/show/NCT01170949||118609|
NCT01171469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS053|Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor|Phase I Study of Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Recurrent or Progressive Malignant Gliomas||Masonic Cancer Center, University of Minnesota|Yes|Completed|September 2010|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|N/A|N/A|No|||June 2013|June 11, 2013|July 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01171469||118570|
NCT01171482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2010-010|Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma|An Open Label, Phase 2 Trial Comparing Sorafenib and 5-fluorouracil/Mitomycin in Hepatocellular Carcinoma With Pulmonary Metastasis||Seoul National University Hospital|No|Recruiting|November 2010|July 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||November 2014|November 26, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01171482||118569|
NCT01171729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-10-030|Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer|A Phase I/IIa Study of Autologous Cell-based Vaccine Therapy With CreaVax-PC in Hormone-Refractory Metastatic Prostate Cancer Patients With PSA Relapse to Evaluate the Safety and Efficacy||Samsung Medical Center|Yes|Completed|July 2006|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|N/A|No|||July 2010|August 10, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171729||118550|
NCT01172015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00396-33|NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults|NK-ITP STUDY : NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURPURA OF ADULTS.||Assistance Publique Hopitaux De Marseille|No|Completed|September 2010|June 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01172015||118528|
NCT01172262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMW04292010|Task-Based Functional MRI (fMRI) in Patients With Severely Bothersome Tinnitus|Task-Based Functional MRI (fMRI) Exploration of the Cortical Attention Network in Patients With Severely Bothersome Tinnitus||Washington University School of Medicine|No|Withdrawn|February 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|60 Years|No|Non-Probability Sample|This is an observation study focusing on people who have tinnitus and are severely        bothered. Recruit a total of 10 participants, preference given to those who live close to        63110.|July 2011|July 29, 2011|July 23, 2010||No|Study did not recieve funding, currenlty undergoing protocol revision.|No||https://clinicaltrials.gov/show/NCT01172262||118509|
NCT01204164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG02-101|Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies|Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies|TG02-101|Tragara Pharmaceuticals, Inc.|No|Recruiting|August 2010|August 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204164||116076|
NCT01204177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14899|Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.|A Phase II Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)|BASIL|Bayer|No|Completed|December 2010|August 2013|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204177||116075|
NCT01204476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-02196|Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma|Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|October 2010|||May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|September 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01204476||116053|
NCT01204424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKK-SVP-10 Prot. 1.4|Clinical Investigation to Assess the Safety and Feasibility of the Crestal, Minimal-invasive Sinus Floor Augmentation With the Pressure Chamber Drill (DKK) and the Sinus Vibration Pump (SVP)|Klinische Prüfung Zur Untersuchung Der Sicherheit Und Machbarkeit Des Crestalen, Minimal-invasiven Kieferknochenaufbaus (Sinuslift) Mit Der Druck-kammerknochenfräse (DDK) Und Der Sinusvibrationspumpe (SVP)|DKK SVP|Jeder GmbH|Yes|Recruiting|September 2010|June 2011|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||September 2010|September 16, 2010|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204424||116056|
NCT01204437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 52|Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast|An Investigational Randomized Study on Epirubicin Plus Cyclophospamide (EC) or Cyclophosphamide Plus Methotrexat Plus 5-fluorouracil (CMF) Versus Nab-paclitaxel Plus Capecitabine as Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast|ICE-II|German Breast Group|Yes|Completed|March 2009|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|400|||Both|65 Years|N/A|No|||February 2016|February 9, 2016|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01204437||116055|
NCT01204723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14392|Medications Development for the Treatment of Cannabis Related Disorders|Medications Development for the Treatment of Cannabis Related Disorders|MTC|University of Virginia|Yes|Completed|August 2009|April 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|63|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204723||116034|
NCT01205009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hCGpoorresp-HMO-CTIL|Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders|||Hadassah Medical Organization||Not yet recruiting|April 2011|||March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|40 Years|45 Years|No|||September 2010|March 1, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01205009||116012|
NCT01205321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14269|PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers|Open-label, Multi Center PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 68Ga Labeled PET Tracer BAY86-7548 Following a Single Intravenous Administration of 140 MBq (Corresponding to ≤ 28 µg Mass Dose) in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers||Piramal Imaging SA|No|Completed|November 2010|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|19|||Male|45 Years|N/A|No|||January 2013|January 18, 2013|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205321||115989|
NCT01205594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14296|IRB-HSR# 14296 The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Systemic Blood Pressure in Patient Undergoing CABG Surgery|IRB-HSR# 14296 The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Systemic Blood Pressure in Patient Undergoing CABG Surgery||University of Virginia|No|Completed|May 2009|||May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|18 Years|N/A|No|||August 2011|August 9, 2011|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205594||115968|
NCT01174537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDV-HUJ-HMO-CTIL|New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma|Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities||Hadassah Medical Organization|No|Withdrawn|July 2011|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|3 Years|75 Years|No|||August 2010|June 10, 2015|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174537||118336|
NCT01174810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/0391|Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study|An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.||University College, London|No|Active, not recruiting|July 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|70 Years|No|||March 2012|March 22, 2012|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174810||118316|
NCT01174823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00041|Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis Patients|||Bausch & Lomb Incorporated|No|Completed|June 2010|December 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|12 Years|N/A|No|||December 2013|December 4, 2013|August 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174823||118315|
NCT01175122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 10-004|Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza|Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||February 2013|February 8, 2013|August 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175122||118292|
NCT01175135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241012|An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia|A Phase 2, Multicenter, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of PF-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control||Pfizer|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|259|||Both|18 Years|65 Years|No|||April 2013|April 9, 2013|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175135||118291|
NCT01175070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDME 001 PID 6180|Intravitreal Macugen for Ischaemic Diabetic Macular Oedema|A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study)|MIDME|University of Oxford|Yes|Completed|January 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175070||118296|
NCT01175083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114056|Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Pneumococcal Vaccine 1024850A When Administered to Children Between 8 Weeks and 2 Years of Age||GlaxoSmithKline||Completed|June 2011|May 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|300|||Both|8 Weeks|23 Months|Accepts Healthy Volunteers|||December 2014|December 4, 2014|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175083||118295|
NCT01171287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erica 02|Effects of Right Lower Limb Orthopedic Immobilization on Braking Function|Effects of Right Lower Limb Orthopedic Immobilization on Braking Function : An On-the-Road Experimental Study by Healthy Volunteers||Université de Sherbrooke|No|Completed|September 2008|April 2014|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|14|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01171287||118584|
NCT01171261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ 64439|Testing Health Games for Adolescent Physical Activity|Health Games Research: Advancing Effectiveness of Interactive Games for Health||University of California, San Diego|No|Completed|May 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|63|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||June 2012|June 8, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171261||118586|
NCT01171495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRC 51016|Impact of Nutrition Intervention on HIV/AIDS Infected Patients|Phase 3 Study That Assesses the Impact of a Nutrition Intervention on HIV/AIDS Infected Patients: Kingston, Jamaica|INI|Caribbean Health Research Council|Yes|Completed|April 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|50 Years|No|||February 2010|July 27, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171495||118568|
NCT01171768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-05-043|The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis|The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis||Samsung Medical Center||Completed|June 2008|December 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|52|||Both|20 Years|90 Years|No|Non-Probability Sample|patients visited Samsung Medical Center for the treatment of benign inflammatory disease        such as bronchiectasis, aspergilloma, peumonia and post-tuberculosis destroyed lung|July 2011|July 20, 2011|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01171768||118547|
NCT01171742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-09-096|Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Living Donor Liver Transplantation|Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Adult Living Donor Liver Transplantation Using Right Hemiliver Grafts||Samsung Medical Center|Yes|Active, not recruiting|July 2008|August 2010|Anticipated|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171742||118549|
NCT01171755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-11-008|Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer|A Phase II Study of Gemcitabine and TS-1 in Patients With Previously Untreated Metastatic or Recurrent Biliary Tract Cancer|GetBil|Samsung Medical Center|Yes|Terminated|February 2008|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||January 2012|May 20, 2014|July 27, 2010||No|The objective response rate by more than two people are confirmed.|No||https://clinicaltrials.gov/show/NCT01171755||118548|
NCT01172275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCSC1004006623|N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder|Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Pediatric Obsessive-Compulsive Disorder||Yale University|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|17 Years|No|||March 2016|March 18, 2016|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01172275||118508|
NCT01172574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112|Motor Control Exercise in Osteoporotic Women|Motor Control Exercise Can Reduce Pain and Improve Postural Alignment in Osteoporotic Women With Vertebral Fractures: a Randomized Controlled Trial||National and Kapodistrian University of Athens|No|Completed|November 2006|January 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|60 Years|80 Years|No|||January 2008|July 29, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172574||118485|
NCT01204190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15264|Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.|Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation During Treatment With Three Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol (EE) and 2.10 mg Gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles||Bayer|No|Completed|September 2010|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|173|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204190||116074|
NCT01204203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090917002 (UAB 0901)|Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)|A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma|UAB 0901|University of Alabama at Birmingham|Yes|Active, not recruiting|June 2009|April 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|19 Years|N/A|No|||February 2016|February 23, 2016|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204203||116073|
NCT01196442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13098|Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer|An Expanded Trial of MC5-A Calmare Therapy in the Treatment of Cancer Pain Syndromes and Chronic Chemotherapy-Induced Peripheral Neuropathy Including Pain and Numbness||Virginia Commonwealth University|Yes|Completed|September 2010|January 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|39|||Both|18 Years|N/A|No|||August 2013|August 21, 2013|September 3, 2010|No|Yes||No|October 11, 2012|https://clinicaltrials.gov/show/NCT01196442||116665|
NCT01196455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO18646|Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer|Phase II Clinical Study of Capecitabine in Combination With Mitomycin C as First-Line Treatment in Patients With Metastatic Breast Cancer||Croatian Cooperative Group for Clinical Research in Oncology|No|Recruiting|March 2006|||April 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|18 Years|N/A|No|||August 2010|September 7, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01196455||116664|
NCT01196468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Indicator Diseases Survey|HIV Indicator Diseases Survey Across Europe - UK Arm|HIV Indicator Diseases Survey Across Europe||Chelsea and Westminster NHS Foundation Trust|Yes|Recruiting|July 2010|February 2014|Anticipated|July 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||5|Anticipated|2000|None Retained|Salivary or serological HIV test|Both|16 Years|N/A|No|Non-Probability Sample|Adults (16 years and over), not known already to be HIV-positive, presenting for care in        designated healthcare settings with one of five "indicator diseases." Sequential patients        will be offered HIV tests, and if they accept, asked to provide additional information via        focussed interview (sub-study).|October 2009|April 11, 2012|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01196468||116663|
NCT01204736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7515-R|Comparing Outcomes of Elbow Extension Tendon Transfers|A Comparison of Two Surgical Procedures That Restore Elbow Extension||VA Office of Research and Development|No|Completed|August 2011|December 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|14|||Both|18 Years|60 Years|No|Non-Probability Sample|Three groups of subjects will be recruited to participate in the experiments: individuals        that have had the posterior deltoid to triceps tendon transfer, individuals that have the        biceps to triceps tendon transfer, and individuals with SCI between C5-C7 who have not had        tendon transfers. Nominally, we plan to recruit 15 subjects from each group.|February 2016|February 8, 2016|September 15, 2010||No||No|December 2, 2015|https://clinicaltrials.gov/show/NCT01204736||116033|
NCT01205022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10038|Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Phase I Trial of Radioimmunotherapy (Y-90 M5A) in Combination With FOLFIRI and Bevacizumab Chemotherapy for Metastatic Colorectal Carcinoma||City of Hope Medical Center|Yes|Completed|April 2011|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|September 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01205022||116011|
NCT01205334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26901-COGLI|Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme|Phase I/II Administration of CMV (Cytomegalovirus)-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)|COGLI|Baylor College of Medicine|Yes|Terminated|November 2010|March 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|N/A|No|||August 2013|August 17, 2013|September 17, 2010|Yes|Yes|poor accrual|No||https://clinicaltrials.gov/show/NCT01205334||115988|
NCT01205607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14299|IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance|IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance||University of Virginia|No|Enrolling by invitation|May 2009|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2010|September 17, 2010|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205607||115967|
NCT01174550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019865|PROspective Multicenter Imaging Study for Evaluation of Chest Pain|PROspective Multicenter Imaging Study for Evaluation of Chest Pain - The PROMISE Trial|PROMISE|Duke University|Yes|Completed|July 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|10003|||Both|45 Years|N/A|No|||January 2016|February 2, 2016|August 2, 2010|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01174550||118335|
NCT01174836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0807|Patient and Physician Attitudes About Informed Consent for Emergency Department (ED) Computerized Axial Tomography (CT) Scans|Patient and Physician Attitudes About Informed Consent for Emergency Department (ED) Computerized Axial Tomography (CT) Scans|CT Consent|Lehigh Valley Hospital|Yes|Completed|August 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|77|||Both|N/A|N/A|No|||April 2012|April 25, 2012|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174836||118314|
NCT01171534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1162817|Closure of Fasciotomy Wounds: A Prospective, Observational Study of a Continuous External Tissue Expander|Closure of Fasciotomy Wounds: A Prospective, Observational Study of a Continuous External Tissue Expander||University of Missouri-Columbia|No|Terminated|July 2010|February 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|July 27, 2010|Yes|Yes|Study determined not to be feasible to continue.|No|September 8, 2014|https://clinicaltrials.gov/show/NCT01171534||118565|
NCT01171027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOTES® Trial|Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy|Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy||Natural Orifice Surgery Consortium for Assessment and Research|Yes|Recruiting|July 2010|September 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01171027||118604|
NCT01171300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52399|Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients|Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients||Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|October 2010|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|94|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01171300||118583|
NCT01171521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1162777|Management of Complex Wounds Using a Constant Tension External Tissue Expander|Management of Complex Wounds Using a Constant Tension External Tissue Expander||University of Missouri-Columbia|No|Terminated|July 2010|September 2015|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|July 27, 2010|Yes|Yes|enrollment did not meet projections and numerous lost to follow-up|No|September 12, 2014|https://clinicaltrials.gov/show/NCT01171521||118566|enrollment was less than predicted and no subject completed the intended 12-month followup. Only SF-12 and pain data were collected for enrolled patients. There was also one screen failure.
NCT01171274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-4358|Effects of Hatha Yoga on Chronic Neck Pain|Randomisierte Kontrollierte Studie Zum Einfluss Von Hatha Yoga Auf Sensorische Schwellen, Kinästhetik Und Körperbild Bei Patienten Mit Chronischen Nackenschmerzen||Universität Duisburg-Essen|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|60 Years|No|||February 2011|February 18, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171274||118585|
NCT01171781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-037|A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma|A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma||Samsung Medical Center||Recruiting|November 2009|June 2014|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171781||118546|
NCT01172041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0026|The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging|Investigating the Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging||Stanford University|Yes|Completed|July 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Diagnosis of AJCC Stage I-III lung cancer of any histology to be treated using        radiotherapy at Stanford Cancer Center|July 2013|July 8, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01172041||118526|
NCT01172028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0108-04|Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients||University of Arizona|Yes|Completed|September 2005|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2014|December 2, 2015|July 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01172028||118527|
NCT01173159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-2314|Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis|Compassionate Use of a Fish Oil-derived Intravenous Fat Emulsion (Omegaven) to Reverse Parenteral Nutrition (PN) Induced Cholestasis||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|July 2010|July 2025|Anticipated|July 2025|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|1 Month|18 Years|No|||July 2015|July 28, 2015|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173159||118441|
NCT01205360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abcd 2|Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia|A Randomized, Control Study to Evaluate Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia||Pravara Institute of Medical Sciences University|Yes|Withdrawn|August 2010|October 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2010|May 4, 2015|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205360||115986|
NCT01173445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12203|Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma|A Pilot Study on the Assessment of Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma||University of Kansas Medical Center|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|None Retained|Blood samples will be collected at the following times:        -  one draw prior to treatment initiation        -  one draw after completion of two treatment cycles        -  one draw at the time of disease progression|Both|18 Years|N/A|No|Probability Sample|Eligible subjects will be approached for participation during regular Cancer Center clinic        visits.|October 2011|October 19, 2011|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01173445||118420|
NCT01196182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701|Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)|Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)|CHD GENES|New England Research Institutes|Yes|Recruiting|November 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Blood; possibly saliva and tissue.|Both|N/A|N/A|No|Non-Probability Sample|While all patients with pediatric cardiovascular disease and adults with congenital heart        disease are of interest, the study will initially focus on four CHD anatomic        classifications:          -  Atrial septal defects          -  Conotruncal abnormalities          -  Left-sided obstructive lesions          -  Heterotaxy        Whenever possible, the study will recruit "trios" of participants--children, mothers and        fathers-- as well as extended family members when appropriate and feasible.|September 2014|April 16, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196182||116685|
NCT01196767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0080|Ropivacaine Though Laterosternal Catheters After Cardiac Surgery|Postoperative Analgesia After Cardiac Surgery: Effects of a Continuous Infusion of Ropivacaine Through Laterosternal Catheters||University Hospital, Clermont-Ferrand||Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|90 Years|No|||April 2013|April 2, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01196767||116640|
NCT01196780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25228|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)|MabThera Post Marketing Observational Study in TNF-IR Patients to Assess Efficacy and Safety of REPeated Courses in routinE ClinicAl pracTice||Hoffmann-La Roche||Active, not recruiting|February 2010|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1240|||Both|18 Years|N/A|No|Probability Sample|Patients with an inadequate response to prior anti-TNF therapy|March 2016|March 1, 2016|September 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01196780||116639|
NCT01204749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090508|TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer|A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers||Amgen|Yes|Active, not recruiting|October 2010|November 2017|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|919|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204749||116032|
NCT01204762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-005|Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen|Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients With Chronic Hepatitis B Virus Infection Who Are HBeAg-positive|LIRA-B|Bristol-Myers Squibb|No|Completed|November 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|197|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204762||116031|
NCT01205035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4875s|High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia|High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia [HD-LIPT]|HD-LIPT|Eye Center of Northern Colorado, P.C.|Yes|Completed|October 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|September 16, 2010|No|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT01205035||116010|
NCT01205048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.CIP.18156|Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds|A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel Classic Lidocaine Versus Juvederm® Ultra in the Treatment of Moderate to Severe Facial Wrinkle Folds||Galderma|No|Completed|September 2010|April 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205048||116009|
NCT01205347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Statin_InsulinSensitivity|Effect of Statin Treatment on Insulin Sensitivity During Myocardial Infarction|Phase 4 Study of the Effect of Statin Treatment on Insulin Sensitivity During Myocardial Infarction||Brasilia Heart Study Group|No|Completed|October 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|65 Years|No|||September 2013|September 8, 2013|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205347||115987|
NCT01197547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U8088|Registry Study of Genesys HTA for Treatment of Menorrhagia|Genesys HTA Post Approval Registry A Multi-center, Single-arm, Prospective Registry of the Genesys HTA System for the Treatment of Menorrhagia|Genesys HTA|Boston Scientific Corporation|No|Completed|November 2010|August 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1014|||Female|18 Years|N/A|No|||February 2013|February 4, 2013|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01197547||116580|
NCT01171053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-S|Internet-delivered CBT for Irritable Bowel Syndrome|Internet-delivered Exposure and Mindfulness Based Therapy for Irritable Bowel Syndrome - A Randomized Controlled Trial||Karolinska Institutet|No|Completed|June 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||July 2010|July 27, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01171053||118602|
NCT01171066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA14010|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2010|||||N/A|N/A|N/A||||||||||||||April 11, 2013|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171066||118601|
NCT01171079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORC-100|Use of an Oxidized Regenerated Cellulose After Thyroid Surgery: A Prospective, Randomized Study|Use of an Oxidized Regenerated Cellulose After Thyroid Surgery: A Prospective, Randomized Study|ORC|Seoul National University Hospital||Completed||||||N/A|Interventional|N/A|1||||||Both|18 Years|70 Years||||July 2010|July 27, 2010|July 26, 2010||||No||https://clinicaltrials.gov/show/NCT01171079||118600|
NCT01174849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|605810|Pneumococcal Vaccines Early and in Combination|A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes|PREVIX_COMBO|Menzies School of Health Research|Yes|Recruiting|August 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|425|||Both|N/A|38 Days|Accepts Healthy Volunteers|||April 2015|April 7, 2015|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174849||118313|
NCT01171040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS99-015|Left Atrial Distensibility to Predict Prognosis in Consecutive Patients|Studies on Assessment of Left Atrial Distensibility to Predict Late Prognosis in Consecutive Patients Received Echocardiographic Examination||Kaohsiung Veterans General Hospital.|Yes|Recruiting|July 2009|July 2012|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients received echocardiographic examinations|July 2009|March 7, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171040||118603|
NCT01203930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-08|A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL|A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Gilead Sciences|No|Active, not recruiting|October 2010|July 2017|Anticipated|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|65 Years|N/A|No|||February 2016|February 22, 2016|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203930||116094|
NCT01203943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-930-IPF-001|A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)||Celgene|Yes|Terminated|January 2011|August 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|28|||Both|50 Years|N/A|No|||September 2013|September 5, 2013|September 15, 2010|Yes|Yes|The benefit/ risk profile does not support continuation of this study.|No||https://clinicaltrials.gov/show/NCT01203943||116093|
NCT01171508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVH-02|Circadian Disturbances After Breast Cancer Surgery|Circadian Disturbances After Breast Cancer Surgery|CIRCA|Herlev Hospital|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|Urine|Female|30 Years|70 Years|No|Non-Probability Sample|Department of Breast Surgery at Herlev University Hospital in Copenhagen|March 2013|March 7, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01171508||118567|
NCT01204788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0468|Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia|A Prospective Randomized Comparative Study of the Effect on Infections of Radiated Prophylactic White Cell Transfusions Versus Therapeutic Radiated White Cell Transfusions||M.D. Anderson Cancer Center|Yes|Terminated|September 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5|||Both|2 Years|N/A|No|||May 2015|May 28, 2015|September 15, 2010||No|Low Recruitment|No|May 28, 2015|https://clinicaltrials.gov/show/NCT01204788||116029|
NCT01172587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA024740-01A2|Secondary Effects of Parent Treatment for Drug Abuse on Children|Secondary Effects of Parent Treatment for Drug Abuse on Children||Old Dominion University|Yes|Recruiting|July 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|480|||Both|6 Years|65 Years|No|||April 2012|April 6, 2012|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01172587||118484|
NCT01172925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-TIDAL|Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer|Randomized Phase II Crossover Study of Tiotropium For Dyspnea in Advanced Non-Small Cell Lung Cancer|TIDAL|McMaster University|Yes|Recruiting|November 2010|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01172925||118459|
NCT01205373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.7|A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers|A Phase I Trial to Investigate the Metabolism and Pharmacokinetics of an Open-label Single Dose of 400 mg [14C]BI 671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers.||Boehringer Ingelheim||Completed|September 2010|||October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|September 17, 2010||||No||https://clinicaltrials.gov/show/NCT01205373||115985|
NCT01204801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102-00-301|Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors|Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast|Medifocus301|Medifocus, Inc.|No|Recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204801||116028|
NCT01205087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OKT3-NASH-HMO-CTIL|Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome|Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial||Hadassah Medical Organization|Yes|Completed|September 2010|April 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|75 Years|No|||June 2011|June 22, 2011|May 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01205087||116006|
NCT01205386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR1055-01|Crosser Enters The Right Arterial Lumen|Crosser Enters The Right Arterial Lumen|CENTRAL|C. R. Bard|No|Completed|February 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CTO who are indicated for recanalization.|September 2012|September 6, 2013|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01205386||115984|
NCT01196481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS PHT-04|Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.|A Prospective,Open Labeled, Randomized Controlled Trial Comparing Carvedilol + VSL# 3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.||Institute of Liver and Biliary Sciences, India|No|Completed|December 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|75 Years|No|||December 2015|December 22, 2015|September 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01196481||116662|
NCT01196793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH 24062010 V1 4|Hospital Admissions in Children Aged 3 Months to 5 Years Presenting With Fever to the Emergency Department|Evaluation of Medical and Non-medical Factors Associated With Admission of Children Aged 3 Months to 5 Years Presenting to the Urban Paediatric Emergency Department With Febrile Illness in the United Kingdom and in Switzerland||Imperial College Healthcare NHS Trust|No|Not yet recruiting|November 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5600|||Both|3 Months|5 Years||Probability Sample|Children aged 3 months to 5 years presenting to an urban paediatric emergency department        with fever|September 2010|September 7, 2010|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01196793||116638|
NCT01196741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/09/105|Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer|A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|SaPPrOC|University College, London|Yes|Completed|March 2011|January 2014|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|107|||Female|18 Years|N/A|No|||January 2014|April 17, 2015|September 1, 2010||No||No|September 18, 2014|https://clinicaltrials.gov/show/NCT01196741||116642|
NCT01196754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0079|Pharmacokinetic of Sevoflurane During a 48h Sedation in Intensive Care Unit With AnaConDa®|Pharmacokinetic of Sevoflurane During a 48h Sedation in ICU With AnaConDa®|Anaconda|University Hospital, Clermont-Ferrand||Completed|March 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Primary Purpose: Screening|1||Actual|12|||Both|18 Years|N/A|No|||September 2010|September 7, 2010|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01196754||116641|
NCT01197053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091102|Epicutaneous Immunotherapy in Peanut Allergy in Children|ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut|ARACHILD|Assistance Publique - Hôpitaux de Paris|Yes|Completed|August 2010|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|5 Years|17 Years|No|||October 2015|October 18, 2015|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197053||116618|
NCT01197066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-KOA-0802i|Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis|A Phase Ⅲ Multicenter, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate, in Patients With Active Rheumatoid Arthritis Who Participated in Study 101-KOA-0801i||Korea Otsuka Pharmaceutical Co.,Ltd.|No|Active, not recruiting|March 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01197066||116617|
NCT01197313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9561709097|Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers|Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers||National Taiwan University Hospital|Yes|Completed|December 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|80 Years|No|||September 2010|September 7, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197313||116598|
NCT01197560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-DLC-001|Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma||Celgene|Yes|Active, not recruiting|September 2010|March 2018|Anticipated|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|July 29, 2010|Yes|Yes||No|July 31, 2014|https://clinicaltrials.gov/show/NCT01197560||116579|
NCT01197872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF008.5|Clinical Use of Parental Support To Detect Single Gene Mutations|Phase II: Clinical Use of Parental Support To Detect Single Gene Mutations||Natera, Inc.|No|Completed|September 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|240|Samples With DNA|Whole blood, cheek swab/saliva samples, sperm samples, embryo biopsy samples|Both|N/A|N/A|No|Non-Probability Sample|Couples in which both parents are carriers or one parent is affected by an inherited        condition that they are at risk of passing on to their offspring. These couples must be        planning to use In Vitro Fertilization (IVF) and Preimplantation Genetic Diagnosis (PGD).|July 2013|July 12, 2013|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01197872||116555|
NCT01202942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805584|Use and Harm Exposure in New Low Nicotine Cigarettes|Smoking Topography and Harm Exposure in a New Potentially Reduced Exposure Product||University of Pennsylvania|Yes|Completed|July 2007|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|246|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2012|December 17, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202942||116169|
NCT01171313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-C-069|A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects|A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations||XenoPort, Inc.|No|Completed|July 2010|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|35|||Both|30 Years|80 Years|No|||February 2013|February 4, 2013|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171313||118582|
NCT01203176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-08-0073 CTIL|Incidence of Malignant and Premalignant Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women|Incidence of Malignant and Pre-malignant Findings in Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women||Carmel Medical Center|No|Recruiting|September 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1400|||Female|18 Years|80 Years|No|||December 2013|December 2, 2013|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01203176||116152|
NCT01203410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0004|Prediction of Jaundice in Term Infants|BilirubinProduction in Healthy Term Infants as Measured by Carbon Monoxide in Breath||NICHD Neonatal Research Network|No|Completed|November 1991|November 1992|Actual|November 1992|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|535|||Both|N/A|8 Hours|Accepts Healthy Volunteers|Probability Sample|Term infants.|June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203410||116134|
NCT01171807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crocodex|Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis|PHASE 2 STUDY OF DEXAMETHASONE 21-PHOSPHATE LOADED INTO AUTOLOGOUS ERYTHROCYTES IN STEROID-DEPENDENT ULCERATIVE COLITIS PATIENTS|Crocodex|Casa Sollievo della Sofferenza IRCCS|Yes|Recruiting|April 2003|December 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2003|June 27, 2011|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01171807||118544|
NCT01203956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC-C001|DeVilbiss AutoAdjust With SmartFlex Comparative Study|A Multi Center, Prospective, Randomized, Double Blind, Crossover Study to Compare the DeVilbiss AutoAdjust With and Without the Smartflex Device Modification; "AutoAdjust With SmartFlex Study"||DeVilbiss Healthcare LLC|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|August 31, 2010|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01203956||116092|
NCT01203969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC IRB 2010-007|Safety and Efficacy of Single Port Laparoscopic Surgery in Colon Cancer|||Kyunghee University Medical Center||Completed|June 2010|April 2012|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|N/A|85 Years|No|||February 2016|February 2, 2016|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203969||116091|
NCT01171794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12012009-4443|Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)|Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)||Stanford University||Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|89|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171794||118545|
NCT01205061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.CIP.18159|Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds|A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel Classic Lidocaine Versus Juvederm® Ultra in the Treatment of Moderate to Severe Facial Wrinkles and Folds||Galderma|No|Completed|September 2010|April 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205061||116008|
NCT01205074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METH-EX-610- HMO - CTIL|¹³C-Methacetin Breath Test (MBT) Methodology Study|¹³C-Methacetin Breath Test (MBT) Methodology Study||Hadassah Medical Organization||Active, not recruiting|September 2010|||||Phase 2/Phase 3|Interventional|N/A|6||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|August 27, 2012|September 16, 2010||||No||https://clinicaltrials.gov/show/NCT01205074||116007|
NCT01205945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC IRB 2010-019|The Effect of Abdominal Aortic Aneurysm Screening on Mortality in Asian Population|The Effect of Abdominal Aortic Aneurysm Screening on Mortality in Asian: A Randomized, Controlled Trial||Kyunghee University Medical Center|No|Recruiting|August 2010|August 2017|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12000|||Both|50 Years|85 Years|No|Non-Probability Sample|Popultaion who reside in Korea as an Asian|September 2010|September 20, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01205945||115941|
NCT01196494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STENTCSPT01|Study of Intraoperative Colonic Irrigation Versus Stent Placement in Obstructive Left-Sided Colonic Cancer|Prospective, Controlled, Randomized Study of Intraoperative Colonic Irrigation vs. Stent Placement in Obstructive Left-Sided Colonic Cancer||Corporacion Parc Tauli|No|Terminated||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|18 Years|N/A||||January 2005|September 7, 2010|September 7, 2010||||No||https://clinicaltrials.gov/show/NCT01196494||116661|
NCT01197352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10040186|Pilot Study of a Text Message Platform to Reduce Risky Drinking in Young Adults|Pilot Study of a Computer-driven Platform That Uses Text Messages to Collect Drinking Information and Deliver Personalized Motivational Messages to At-risk Young Adults|PART|University of Pittsburgh|Yes|Completed|August 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Actual|45|||Both|18 Years|24 Years|No|||May 2012|May 18, 2012|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01197352||116595|
NCT01197079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP 37875|Utilization of Human Papillomavirus (HPV) Vaccine Among Young Men Who Have Sex With Men (MSM) and Parents of Boys (Aged 9 to 18 Years)|Survey Study of the Awareness, Acceptance, and Barriers to Utilization of Human Papillomavirus (HPV) Vaccine Among Young Men Who Have Sex With Men (MSM) and Parents of Boys (Aged 9 to 18 Years)||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|August 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|800|||Male|9 Years|26 Years|Accepts Healthy Volunteers|Probability Sample|Young men who have sex with men (MSM) that obtain medical care from a        Gay/Lesbian/Bisexual/Transgender community health clinic        Parents of boys aged 9 to 18 years who obtain their medical care from several public        health clinics or who obtain their medical care from private pediatrician offices in        Chicago|July 2011|July 14, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197079||116616|
NCT01197092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-101-01|The Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II|A Study Evaluating the Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II||Center for Integrative Medicine, Germany|No|Recruiting|November 2010|January 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||September 2010|November 15, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197092||116615|
NCT01197326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUD33108|The Prevention of Failure to Rescue Using Early Warning Scoring|The Use of IntelliVue Patient Monitor MP5 Rel. G.1 for the Prevention of "Failure to Rescue" Using Early Warning Score|VitalCare|Philips Healthcare|No|Completed|August 2009|June 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|414|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We plan to observe a non-probability, convenience sample of patients which will consist        primarily of acutely ill hospitalized adult patients (at least 18 years of age). We will        also enroll 1-2 pediatric units to be used as pilot data, since there is less available        empiric data published in the literature. Study participants will be recruited from all        eligible patients during the enrollment period who are having vital signs monitoring        performed as Standard of Care.|October 2015|October 20, 2015|September 3, 2010||No||No|December 17, 2012|https://clinicaltrials.gov/show/NCT01197326||116597|
NCT01197573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIRB: 10-365|Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy|Enhancing DCD Utilization With Thrombolytic Therapy||The Cleveland Clinic|Yes|Recruiting|April 2010|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|135|||Both|18 Years|N/A|No|||February 2013|February 12, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197573||116578|
NCT01197586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_spb_ma|Evaluation of Surfactant Protein B in the Differential Diagnostics of Dyspnea|||Universitätsmedizin Mannheim|Yes|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|80 Years|No|Probability Sample|patients presenting with the symptom "dyspnea" in a university hospital emergency room|June 2013|June 21, 2013|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197586||116577|
NCT01197898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-029|Wound Edge Changes Following Treatment With Santyl|Evaluation of the Edge of Non-Healing Cutaneous Ulcers Following Debridement With Collagenase Santyl Ointment||Healthpoint|No|Completed|December 2010|October 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|August 26, 2010|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT01197898||116553|
NCT01193621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0692|Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers|Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers||Asan Medical Center|No|Completed|January 2008|January 2012|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|12|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193621||116879|
NCT01202968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chhwang2|Effect of Pre-emptive Transcutaneous Neuro-muscular Electrical Stimulation for Dysphagia in Long Term Intubated Patients|Effect of Pre-emptive Transcutaneous Neuro-muscular Electrical Stimulation for Dysphagia in Long Term Intubated Patients||Ulsan University Hospital|Yes|Withdrawn|December 2010|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|0|||Both|N/A|N/A|No|||December 2013|December 22, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01202968||116167|
NCT01203189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|seb derm 2010|Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo|Seborrheic Dermatitis of the Scalp in Populations Practicing Less Frequent Hair Washing: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo||St. Louis University|Yes|Completed|September 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Female|18 Years|89 Years|Accepts Healthy Volunteers|||June 2013|June 1, 2013|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203189||116151|
NCT01203423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0009|Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study|Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study|PPHN|NICHD Neonatal Research Network|No|Completed|October 1993|December 1994|Actual|December 1994|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|385|||Both|N/A|7 Days|No|Probability Sample|The infants were screened within the first 24 hours and were followed until enrollment        criteria were met or until they reached 7 days of age, whichever occurred first.|June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203423||116133|
NCT01203670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHYTHEA-e437-950|Renal and Digestive Tolerance of a Food Supplement, Phytalgic, in Elderly Volunteers - A Multicentric Open Trial|Renal and Digestive Tolerance of a Food Supplement, Phytalgic, in Elderly Volunteers - A Multicentric Open Trial||Phythea|No|Completed||December 2009|Actual|||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|70 Years|87 Years|No|||September 2010|September 21, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203670||116114|
NCT01203683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-09-0004|Testing the Effectiveness of a Computer-based Program for Depression|Attention Training for Major Depressive Disorder||University of Texas at Austin|Yes|Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|55 Years|No|||October 2013|October 9, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203683||116113|
NCT01203982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-20060060|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima Media Thickness and Its Relation to Plaque Components of the Coronary Arteries in Patients With ST-Segment Elevation Acute Myocardial Infarction||Odense University Hospital|Yes|Completed|November 2007|June 2009|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|81 Years|No|||September 2010|September 16, 2010|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203982||116090|
NCT01204489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL 10109|Lifestyle Intervention for Toddlers Pilot Study|Lifestyle Intervention for Toddlers at Finnish Welfare Clinics|LIFT|National Institute for Health and Welfare, Finland|No|Completed|September 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|148|||Both|6 Months|6 Months|Accepts Healthy Volunteers|||June 2011|June 20, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204489||116052|
NCT01204775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-058|Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patients With Type 2 Diabetes||Bristol-Myers Squibb|Yes|Active, not recruiting|June 2011|April 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|9|||Both|10 Years|17 Years|No|||February 2016|February 9, 2016|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204775||116030|
NCT01204216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09100601|Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c|Does Variation in Mean Red Cell Age Impact HbA1C Interpretation?||University of Cincinnati|Yes|Recruiting|September 2010|September 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|35|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204216||116072|
NCT01204229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AA1AA017291A1|Motivational and Cognitive Intervention for College Drinkers|Motivational and Cognitive Intervention for College Drinkers|MCID|University of Cincinnati|No|Recruiting|May 2010|||May 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|25 Years|No|||April 2011|April 21, 2011|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204229||116071|
NCT01204502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06MI04|Suicide Gene Therapy Trial|Phase I/II Clinical Trial of T-cell Suicide Gene Therapy Following Haploidentical Stem Cell Transplantation||Great Ormond Street Hospital for Children NHS Foundation Trust||Terminated|January 2011|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|N/A|16 Years|No|||September 2013|September 17, 2013|September 16, 2010||No|Changes in the clinical practice|No||https://clinicaltrials.gov/show/NCT01204502||116051|
NCT01205100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)60/2009|Treatment of Abdominal Distension by Biofeedback - a Randomized Controlled Trial|Feedback-assisted Treatment of Abdominal Distension - a Randomized Controlled Trial||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|November 2010|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||May 2015|November 9, 2015|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01205100||116005|
NCT01205399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE006|A Retrospective Study With Prospective Follow-Up of Complex Ventral Hernia Repair Utilizing the AlloMax Surgical Graft|A Single Arm, Multi-Center, Retrospective Study With Prospective Follow-Up of Complex Ventral Hernia Repair Utilizing the AlloMax Surgical Graft|AlloMax|C. R. Bard|No|Completed|September 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|78|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have undergone a ventral hernia repair using the AlloMax Surgical Graft at        least 9 months in the past.|October 2012|October 10, 2012|September 17, 2010||No||No|July 5, 2012|https://clinicaltrials.gov/show/NCT01205399||115983|Study was designed to use existing data. Limitations include: limited data generalizability given the retrospective, single arm, observational study design.
NCT01205659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8611|Allergy and Ashthma in Children Who Were Fed Supplemented Infant Formula|Allergy and Asthma in Children Who Were Fed Supplemented Infant Formula (3-7 Years of Age)||Mead Johnson Nutrition|No|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|||||Both|3 Years|7 Years||Probability Sample|Children who participated in randomizaed trials of supplemented infant formula conducted        by The Retina Foundation of the Southwest during infancy|September 2010|September 17, 2010|September 17, 2010||||No||https://clinicaltrials.gov/show/NCT01205659||115963|
NCT01205958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHU 20091458|The Effect of East-West Collaborative Medicine on Chronic Cervical Pain|Clinical Trial to Evaluate the Effect of East-West Collaborative Medicine on Chronic Cervical Pain: a Pilot Study||Kyunghee University Medical Center|Yes|Recruiting|December 2009|February 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|45|||Both|25 Years|55 Years|No|||September 2010|September 20, 2010|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01205958||115940|
NCT01197118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCC-GC001|Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer|Phase 2 Study of Chemoradiotherapy for Advanced Gastric Cancer||Huazhong University of Science and Technology|No|Not yet recruiting|September 2010|May 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||September 2010|September 8, 2010|April 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01197118||116613|
NCT01193647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29048|Genetic Factors Affecting Risks for Rotator Cuff Disease|Genetic Factors Affecting Risks for Rotator Cuff Disease||University of Utah|Yes|Enrolling by invitation|July 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|400|Samples With DNA|DNA will be retained|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The initial set of study participants for this study will be recruited through the        clinical practice of the PI. Patients will be categorized based upon MRI confirmation of a        rotator cuff tear. All patients being treated for shoulder pain with a positive MRI for a        rotator cuff tear which was performed as a normal part of a clinical exam will be included        as possible participants (tear group). All patients being treated for shoulder pain with a        negative MRI for rotator cuff tearing (MRI performed for normal part of clinical exam)        will undergo an MRI of the opposite shoulder to confirm the absence (or presence) of        rotator cuff pathology and be categorized based upon the findings (either tear or no tear        group).|February 2016|February 3, 2016|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193647||116877|
NCT01197105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG 2612|Evaluation Study of a Mouthwash Based on Schinus Terebinthifolius to Treat Gingivitis in Children|Clinical Evaluation of a Mouthwash Based on Schinus Terebinthifolius (Aroeira) Used by Children With Gingivitis||Federal University of Paraíba|Yes|Recruiting|September 2010|||September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|60|||Both|10 Years|12 Years|No|||September 2010|September 8, 2010|September 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01197105||116614|
NCT01197339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC008290|Hybrid Model of Vocal Inflammation and Tissue Mobilization|Hybrid Model of Vocal Inflammation and Tissue Mobilization||University of Pittsburgh|No|Completed|September 2010|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|45|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197339||116596|
NCT01197885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-IMAB-001-02|Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer|International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus||Ganymed Pharmaceuticals AG|Yes|Completed|September 2010|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01197885||116554|
NCT01193959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC/OSS-02/2010|Pemetrexed in Advanced Non-small Cell Lung Cancer|Retrospective Study of Molecular Predictors of Sensitivity and Resistance to Pemetrexed in Advanced Non-Small Cell Lung Cancer||Istituto Clinico Humanitas|No|Active, not recruiting|September 2010|September 2011|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|33|||Both|18 Years|N/A|No|Non-Probability Sample|Non-small cell lung cancer patients treated with single agent pemetrexed|September 2010|October 11, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01193959||116853|
NCT01193972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005126|Decision Aid Development for Smokers|Decision Aid Development for Cigarette Smokers Undergoing Surgery: Specific Aim 1||Mayo Clinic|No|Completed|September 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|46|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193972||116852|
NCT01203709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTWC/CREC/837/10|Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis|Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study||Tuen Mun Hospital|Yes|Completed|August 2010|February 2013|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||March 2014|March 3, 2014|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203709||116111|
NCT01203722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1055|Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies|Reduced Intensity, Partially HLA Mismatched Allogeneic BMT for Hematologic Malignancies Using Donors Other Than First-degree Relatives||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2010|December 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Months|75 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203722||116110|
NCT01203995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710-65B|Remote Information Counseling for Elders|Remote Information Counseling for Elders|RICE|Indiana University|No|Completed|August 2010|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|64|||Both|40 Years|N/A|No|||March 2013|March 29, 2013|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01203995||116089|
NCT01204255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13108|Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers|Absorption of "ABH Gel" (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) From the Skin of Normal Volunteers||Virginia Commonwealth University|Yes|Completed|November 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 26, 2013|September 15, 2010|No|Yes||No|July 11, 2011|https://clinicaltrials.gov/show/NCT01204255||116069|
NCT01204268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC-BRAIN-2009|The Neuroprotection of Sevoflurane Preconditioning on Intracranial Aneurysm Surgery|The Neuroprotection of Sevoflurane Preconditioning on Perioperative Ischemia-reperfusion Injury During Intracranial Aneurysm Surgery||Xijing Hospital|Yes|Recruiting|August 2009|October 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|80|||Both|18 Years|70 Years|No|||August 2009|September 16, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204268||116068|
NCT01203696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aml-Clo-protocol-v1|Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease|Effect of Amlodipine on Platelet Inhibition by Clopidogrel in Patients With Ischemic Heart Disease- a Prospective Randomized Controlled Trial||Ruttonjee Hospital|No|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203696||116112|
NCT01204242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13957|IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence|IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence||University of Virginia|Yes|Enrolling by invitation|August 2009|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|80 Years|No|||August 2011|August 9, 2011|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204242||116070|
NCT01204814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-009|HIV-1 Resistance at Screening for HIV Prevention Studies|Prevalence of HIV-1 Drug Resistance Within a Female Screening Population for HIV Prevention Trials||Microbicide Trials Network|Yes|Completed|August 2010|July 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|1074|Samples With DNA|Blood Plasma|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women of reproductive age who are interested in participating in HIV prevention trials|April 2015|April 10, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204814||116027|
NCT01205126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017437|An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain|A Randomized, Double-Blind, Active Controlled, Multi-center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Once-daily Compared With Oxycodone HCL Controlled-release Twice Daily in Subjects With Cancer Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2009|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|70 Years|No|||December 2013|December 31, 2013|August 5, 2010|Yes|Yes||No|September 13, 2013|https://clinicaltrials.gov/show/NCT01205126||116004|
NCT01205672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0927|Metformin and Endometrial Cancer|Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2010|||September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|80 Years|No|||December 2015|December 14, 2015|September 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01205672||115962|
NCT01197625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-005|Vaccine Therapy in Curative Resected Prostate Cancer Patients|Trial of Vaccine Therapy in Curative Resected Prostate Cancer Patients Using Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin||Oslo University Hospital|No|Active, not recruiting|September 2010|September 2023|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|75 Years|No|||March 2016|March 11, 2016|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197625||116574|
NCT01197638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ablations Register|German Ablation Quality-Register|Deutsches Ablations-Qualitätsregister||Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|June 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|all consecutive patients with an performed or attempted electrophysiological ablation|September 2010|September 7, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01197638||116573|
NCT01193660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTUBSC|Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy|Double-blind Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Allogenic Umbilical Cord Blood and Erythropoietin for Children With Cerebral Palsy||Sung Kwang Medical Foundation|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|10 Months|10 Years|No|||March 2012|March 1, 2012|August 29, 2010||No||No|October 11, 2011|https://clinicaltrials.gov/show/NCT01193660||116876|
NCT01193673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35439|Discovering the Gene(s) Causing Developmental Dysplasia of the Hip (DDH)|Discovering the Gene(s) Causing Developmental Dysplasia of the Hip||University of Utah|No|Enrolling by invitation|January 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|DNA samples are kept|Both|7 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients who have been diagnosed with hip dysplasia and their family members.|February 2016|February 16, 2016|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193673||116875|
NCT01197599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-003|Acute Tendon and Nerve Responses to Exercise|Acute Tendon and Nerve Responses to Exercise||University of Miami|No|Completed|December 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample of persons with spinal cord injury or healthy volunteers.|July 2014|July 21, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01197599||116576|
NCT01197911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25240|A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar|The Effect of Hepatic Impairment on the Pharmacokinetics of Aleglitazar: A Multiple-centre, Open-label Study Following a Single Oral Dose of Aleglitazar to Subjects With Mild or Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function.||Hoffmann-La Roche||Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|38|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|September 8, 2010|Yes|Yes||No|November 20, 2015|https://clinicaltrials.gov/show/NCT01197911||116552|
NCT01193634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITSY03 - PARADYM RF STUDY|Clinical Evaluation Of The PARADYM RF Device|Clinical Evaluation Of The PARADYM RF Device SORIN GROUP'S New IDC Platform||LivaNova|No|Completed|October 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|75|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193634||116878|
NCT01194505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACLObturator|Ultrasound Guided Obturator Nerve Block for Anterior Cruciate Ligament Reconstruction (ACL)|Comparison of Posterior Lumbar Plexus Block Plus Sciatic Nerve Block With Sciatic Plus Femoral Plus Obturator Nerve Block for Anterior Cruciate Ligament Reconstruction||Larissa University Hospital|No|Completed|June 2010|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|92|||Both|18 Years|50 Years|No|||April 2014|April 27, 2014|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194505||116811|
NCT01194817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2010-0105|A Prospective, Randomized Study Comparing Cemented and Cementless Total Knee Replacement|A Prospective, Randomized Study Comparing Cemented and Cementless Total Knee Replacement: Results of a New Modular Trabecular Metal Tibial Component Using the NexGen System||Anderson Orthopaedic Research Institute|No|Active, not recruiting|April 2010|December 2026|Anticipated|December 2026|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|N/A|75 Years|No|||February 2013|February 1, 2013|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194817||116787|
NCT01195116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 31154|Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis|Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis||University of Rochester|Yes|Completed|May 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|August 13, 2010|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01195116||116765|
NCT01204008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zseyhds2|Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy|A Prospective Randomized Trails for Primary Disc Herniation With Radiculopathy:Conservative Versus Aggressive Discectomy||Sun Yat-sen University|Yes|Recruiting|September 2009|December 2015|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|40 Years|No|||August 2007|September 16, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01204008||116088|
NCT01204281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC 10-48|Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients|High-assistance Proportional Assist Ventilation (PAV) vs. Assist-Control Ventilation (ACV) in Early Stage of Critically Ill Patients||Althaia Xarxa Assistencial Universitària de Manresa|Yes|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|90 Years|No|||November 2012|November 23, 2012|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204281||116067|
NCT01204541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-120-0013|A Single-Center Pilot Study to Assess Macular Function|||ORA, Inc.||Completed|September 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|24|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of subjects will be enrolled:          1. Normal healthy subjects aged 20-29 years          2. Normal healthy subjects aged 60-90 years          3. Subjects with early dry AMD|February 2012|February 13, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204541||116048|
NCT01204554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/223b.2008/3837 (REK)|Microcirculation in Perforator Flaps. Enhancing Tissue Survival|Microcirculation in Perforator Flaps. Enhancing Tissue Survival||Oslo University Hospital|Yes|Recruiting|September 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2010|September 16, 2010|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01204554||116047|
NCT01204853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321052|A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients|A Phase 3, Multi-Center, Open Label Study To Evaluate The Safety And Efficacy Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension||Pfizer|Yes|Terminated|August 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|16 Years|80 Years|No|||October 2011|October 26, 2011|August 6, 2010||No|Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,    specifically new emerging evidence of hepatic injury.|No|October 26, 2011|https://clinicaltrials.gov/show/NCT01204853||116024|
NCT01204866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036-08-05-A|Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use|A Phase I, Open Label, Controlled Study of Valortim® (MDX-1303) and Its Selected Formulation Components When Introduced Percutaneously in Subjects Who Have and Have Not Been Exposed to Valortim Administered Intravenously||PharmAthene, Inc.|Yes|Completed|July 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204866||116023|
NCT01204515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25755|Abdominal Symptom Phenotype Study in Children|Abdominal Symptom Phenotype: Pathways to New Biomarkers|ASPPNB|Baylor College of Medicine|No|Completed|June 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|45|Samples With DNA|We will be banking DNA for future analysis. The samples will be retained according to the      legal and ethical laws.|Female|7 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are studying only girls in this exploratory study because IBS is more common in girls        than boys and the results of these studies can be compared with the results from studies        of IBS in adults where the overwhelming number of patients are women.        Girls who meet the Rome III criteria for IBS or healthy girls with no complaints of        stomach pain.|February 2013|February 4, 2013|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204515||116050|
NCT01204528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDRA|Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease|Diastolic Dysfunction, Microcirculation Disturbance, Sympathetic Activation and Inflammation in Moderate Kidney Failure and in Diabetic Nephropathy: Disease Modification With Vitamin-D Receptor Activation. A Double-blind, Placebo-controlled, Randomised Trial - the SOLID Trial|SOLID|Danderyd Hospital|Yes|Completed|September 2010|July 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|20 Years|N/A|No|||September 2013|September 4, 2013|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01204528||116049|
NCT01204827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AIL02T|Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test|Follow Up of Patients With HBeAg Negative Chronic Hepatitis B Virus Infection Treated With Sebivo (Telbivudine) Using the 13C Methacetin Breath Test (BreathID®)||Hadassah Medical Organization||Withdrawn||||||Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|75 Years||||June 2011|August 27, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204827||116026|
NCT01204840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFC-001|Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)|Co-treatment With Recombinant Growth Hormone (GH) in Poor Responders Treated by in Vitro Fertilization (IVF-ET)||Ottawa Fertility Centre|Yes|Completed|September 2010|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01204840||116025|
NCT01205139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017392|TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir|A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, TMC278 and Tenofovir Disoproxil Fumarate (TDF), at Steady State||Tibotec Pharmaceuticals, Ireland|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 23, 2012|September 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01205139||116003|
NCT01205685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 09112|Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer|A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva®, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|May 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|September 17, 2010|Yes|Yes|PI closed study early, all patients experienced severe toxicities and progressed|No|June 7, 2012|https://clinicaltrials.gov/show/NCT01205685||115961|
NCT01205412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112710|An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain|An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women in the Kingdom of Bahrain||GlaxoSmithKline||Completed|October 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|552|Samples With DNA|Endocervical samples|Female|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women ≥ 20 years of age, attending out-patient health services for routine cervical        screening and women ≥ 16 years of age presenting for post-natal check up in the Kingdom of        Bahrain.|November 2012|November 21, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01205412||115982|
NCT01205425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N N403 295736|Computed Tomography Coronary Angiography Before Stent Implantation|Role of Computed Tomography Coronary Angiography in Optimalization of Percutaneous Coronary Interventions With Stent Implantation.||Institute of Cardiology, Warsaw, Poland|No|Completed|September 2009|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|60|||Both|N/A|N/A|No|||July 2011|July 4, 2011|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01205425||115981|
NCT01205711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000685062|Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer|A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy|FOLFERA|Cardiff University|Yes|Completed|April 2010|September 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205711||115959|
NCT01205724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7088-3776|Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A|A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A|pathfinder™1|Novo Nordisk A/S|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Male|18 Years|65 Years|No|||February 2015|February 20, 2015|September 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01205724||115958|
NCT01206478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12261|Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age|A PHASE II, RANDOMIZED-CONTROLLED, MULTICENTER TRIAL OF AMITRIPTYLINE FOR CHRONIC ORAL FOOD REFUSAL IN CHILDREN 9 MONTHS TO 8 YEARS OF AGE||University of Kansas Medical Center|Yes|Completed|August 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|9 Months|8 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206478||115900|
NCT01206257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15454|The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)|This is an International, Prospective, Non-interventional Study, Company Sponsored, Multi-center Study. Patients Undergo Coronary Angiography or PCI Procedure With Ultravist. The Primary Objective is to Evaluate the Safety and Tolerability.|TRUST|Bayer|No|Completed|August 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17513|||Both|N/A|N/A|No|Probability Sample|Patients who plan to undergo coronary angiography or PCI procedure with ultravist will be        enrolled|June 2013|June 10, 2013|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206257||115917|
NCT01194271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0135|Neoadjuvant Ipilimumab in Prostate Cancer|A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.||M.D. Anderson Cancer Center|No|Completed|September 2010|||October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194271||116829|
NCT01194284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C23003|Surveillance Study of Patients With Newly Diagnosed Osteosarcoma|Observational, Noninterventional Surveillance Study of Patients With Newly Diagnosed Osteosarcoma||Millennium Pharmaceuticals, Inc.|Yes|Active, not recruiting|December 2011|November 2021|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|2 Years|40 Years|No|Non-Probability Sample|The study population consists of patients with high-grade osteosarcoma who are candidates        for treatment with mifamurtide within the context of prevailing standard oncology        practice.|January 2014|January 31, 2014|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194284||116828|
NCT01193985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-WK-6|Safety and Performance Study of TIGR Matrix Surgical Mesh in Inguinal Hernia Repair|Safety and Performance Study of TIGR Matrix Surgical Mesh in Inguinal Hernia Repair||Novus Scientific|No|Completed|April 2009|March 2011|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||April 2011|April 19, 2011|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193985||116851|
NCT01194245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-117-205|Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus|A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 1 Diabetes||Halozyme Therapeutics|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|August 31, 2010|Yes|Yes||No|August 1, 2014|https://clinicaltrials.gov/show/NCT01194245||116831|
NCT01194791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LENDEXAL|Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed|A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation|LENDEXAL|PETHEMA Foundation|Yes|Active, not recruiting|October 2010|December 2016|Anticipated|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|January 16, 2016|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194791||116789|
NCT01194804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E07-001|E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients|Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol||Alexion Pharmaceuticals|No|Completed|April 2008|March 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|12 Years|N/A|No|||December 2011|December 5, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01194804||116788|
NCT01194843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPO-Hepatectomy|Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations|A Double-blind Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Per and Post Hepatectomy Infiltrations for Adult Pain Management|DPO|Centre Leon Berard|No|Completed|March 2009|April 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|85|||Both|18 Years|N/A|No|||January 2014|April 20, 2015|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194843||116785|
NCT01203748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-09-102-ID-AB|Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study|Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study|Star AF II|St. Jude Medical|Yes|Completed|November 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|589|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203748||116108|
NCT01204021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG028748-01-SST|Managing Stress and Social Ties for Health Aging|Managing Stress and Social Ties for Health Aging||University of California, Los Angeles|No|Completed|May 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01204021||116087|
NCT01204034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML-DOC-1003|Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Open-label, Prospective Exploratory Study to Assess the Effects of Formoterol and Beclometasone Dipropionate Combination Therapy on Central and Peripheral Airway Dimensions in COPD Patients||University Hospital, Antwerp|No|Completed|September 2010|June 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|40 Years|N/A|No|||June 2012|June 29, 2012|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204034||116086|
NCT01204294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.78|Comprehensive Add on Study in Japan|An Open Label, Randomised, Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Background Mono-therapy With an Approved Antidiabetic Drug||Boehringer Ingelheim||Completed|September 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|574|||Both|20 Years|N/A|No|||February 2014|February 27, 2014|September 16, 2010||||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01204294||116066|
NCT01204307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-1896C|Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation|A Phase III Study to Investigate the Differential Influence of Prior Chemotherapy on the Efficacy of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (IIIB, IV) With or Without EGFR Gene Mutation||Chang Gung Memorial Hospital|Yes|Completed|January 2010|June 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|75 Years|No|||September 2010|July 27, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204307||116065|
NCT01205152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-003-08|Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)|Extension Study of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children With Hypophosphatasia (HPP)||Alexion Pharma GmbH|Yes|Active, not recruiting|April 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|6 Months|42 Months|No|||May 2015|May 11, 2015|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205152||116002|
NCT01205165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103814|An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)|An Open Label, Multicenter Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)||GlaxoSmithKline|No|Completed|December 2004|April 2006|Actual|April 2006|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||November 2010|January 22, 2011|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205165||116001|
NCT01205438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13653|A Study of LY2127399 in Patients With Systemic Lupus Erythematosus|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)||Eli Lilly and Company|Yes|Completed|January 2011|March 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1124|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205438||115980|
NCT01205698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6007|Glycemic Index of Foods|Glycemic Index of Foods||Mead Johnson Nutrition||Completed|June 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|N/A|4||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2010|September 17, 2010|September 17, 2010||||No||https://clinicaltrials.gov/show/NCT01205698||115960|
NCT01206205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0805603|Frontline Therapy in de Novo Multiple Myeloma Patients Under 65|IFM2008: Frontline Therapy in de Novo Multiple Myeloma Patients Under 65, (a Phase 2 Multicenter Trial)|IFM2008|University Hospital, Toulouse|Yes|Completed|August 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||June 2014|June 11, 2014|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01206205||115921|
NCT01205191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFP5/08|Cell Phone-supported Cognitive Behavioural Therapy|Effectiveness Study of Cell Phone-supported Cognitive Behavioural Therapy for Anxiety Disorders in Frontline Settings|LINNEA|Linkoeping University|Yes|Recruiting|April 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|400|||Both|18 Years|25 Years|No|||September 2010|June 14, 2011|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01205191||115999|
NCT01206218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREC-AGC|Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer|Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer|BREC-AGC|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||Not yet recruiting|October 2010|||October 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||September 2010|September 20, 2010|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206218||115920|
NCT01205984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS-0655-IF|Systemic Methylprednisolone in Chronic Rhinosinusitis|Efficacy and Tolerability of Systemic Methylprednisolone in Children and Adolescents With Chronic Rhinosinusitis||Ondokuz Mayıs University|Yes|Completed|July 2007|April 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|6 Years|17 Years|No|||September 2010|September 20, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01205984||115938|
NCT01171625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-08|Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX|Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis in the Aortic Position, Model 3300TFX||Edwards Lifesciences|No|Active, not recruiting|October 2007|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|225|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01171625||118558|
NCT01171898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR103304|Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)|An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer||Aragon Pharmaceuticals, Inc.|No|Active, not recruiting|July 2010|December 2017|Anticipated|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|23|||Male|18 Years|N/A|No|||January 2016|January 27, 2016|July 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171898||118537|
NCT01197924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07PHN01|MEDIR Medulloblastome|Médulloblastome of the Child and After-effects Cognitive: Study Anatomo-functional by IRM of the Working Memory|MEDIR|University Hospital, Grenoble|No|Recruiting|October 2007|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|80|||Both|8 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|child Treaties for a médulloblastome after the 6 years age|September 2010|September 8, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197924||116551|
NCT01193699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11012010|Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera|An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera|PEGINVERA|AOP Orphan Pharmaceuticals AG|No|Active, not recruiting|August 2010|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|90 Years|No|||February 2015|February 26, 2015|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193699||116873|
NCT01193998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-310|Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department|Analysis of the Impact of Using a Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department||St. Michael's Hospital, Toronto|Yes|Completed|September 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|186|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193998||116850|
NCT01194258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-117-206|Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus|A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 2 Diabetes||Halozyme Therapeutics|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|August 31, 2010|Yes|Yes||No|August 1, 2014|https://clinicaltrials.gov/show/NCT01194258||116830|
NCT01194518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC992314B006048MY3|Exploring Life Experience and Lifestyle Intervention Program Among Patients With Chronic Kidney Disease: A Longitudinal Study|Exploring Life Experience and Lifestyle Intervention Program Among Patients||National Cheng Kung University|Yes|Active, not recruiting|August 2010|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Primary Purpose: Prevention|1||||||Both|20 Years|N/A||||September 2010|September 16, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01194518||116810|
NCT01194830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.75|Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study|A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study||Boehringer Ingelheim||Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|234|||Both|18 Years|80 Years|No|||December 2013|December 12, 2013|September 2, 2010||||No|September 26, 2012|https://clinicaltrials.gov/show/NCT01194830||116786|Eight randomized subjects were excluded from all analysis due to overall data integrity issues at the site
NCT01203449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0012|Development of Standards for the New Ballard Maturation Score|Development of Standards for the New Ballard Maturation Score|Ballard|NICHD Neonatal Research Network|No|Completed|June 1994|March 1996|Actual|March 1996|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1090|||Both|N/A|48 Hours|Accepts Healthy Volunteers|Probability Sample|Infants born in the NICHD Neonatal Research Network during the study period.|June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203449||116131|
NCT01203462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-402|The PRIDE Study Probiotics on Regulation and Improving Digestive hEalth|A Probiotic Double-blind Randomized Placebo Crossover Trial of Colonic Transit Time in Adult Females, The PRIDE Study The Study to Determine the Effects of Probiotics on Regulation and Improving Digestive hEalth|PRIDE|Georgetown University|Yes|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|February 8, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203462||116130|
NCT01204047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-007|Wheelchair Mobility Assessment of Individuals With Spinal Cord Injury|Wheelchair Propulsion Function and Physical Capacity in Persons With Spinal Cord Injury||University of Miami|No|Completed|March 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample|July 2014|July 21, 2014|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204047||116085|
NCT01204320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo003|A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR)||COMPACT-ISR|Ospedale San Donato|No|Terminated|January 2008|||January 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||October 2009|September 16, 2010|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204320||116064|
NCT01204333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOACT|Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis|Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (TOACT)|TOACT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|September 2011|January 2018|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204333||116063|
NCT01204580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLMET_L_04735|ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination|ADIponectin and ADMA Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination (Amaryl-M)|DIAGRAM|Sanofi||Completed|December 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|40 Years|60 Years|No|||April 2012|April 2, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204580||116045|
NCT01204567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/184a|The Influence of Exercise on Mental Health After Discharge From Hospital|The Aim of the Study is to Evaluate the Effect of Aerobic Fitness Training on Mental Health (Health-related Quality of Life), Cognitive and Physical Capacity in Older People Discharged From Hospital.||Oslo University Hospital|Yes|Completed|January 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|116|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 23, 2012|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01204567||116046|
NCT01204879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-010S-2|Reinforcing Exercise in Substance Abusing Patients|Reinforcing Exercise in Substance Abusing Patients||University of Connecticut Health Center|No|Completed|April 2010|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01204879||116022|
NCT01205178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110027|G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)|A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects With Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium Vivax Malaria Patients With Glucose-6-phosphate Dehydrogenase Deficiency||GlaxoSmithKline|No|Completed|July 2009|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|192|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|March 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01205178||116000|
NCT01205464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151:2004/25331|Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis|Immunomodulatory and Clinical Effects of Doxycycline on Persistent Symptoms After Treatment of Neuroborreliosis: A Double-blind, Randomised, Crossover Study||Linkoeping University|Yes|Completed|February 2005|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|85 Years|No|||February 2005|September 17, 2010|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205464||115978|
NCT01205451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114609|A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity|A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity||GlaxoSmithKline||Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|18 Years|76 Years|No|||October 2012|November 15, 2012|September 3, 2010||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT01205451||115979|
NCT01205737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL-TL011-102|A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects|A Phase Ib, Double Blind RCT to Evaluate and Compare the PK, PD and Safety of MabThera® With TL011, in Combination With CHOP, in Subjects With CD20+ DLBCL||Teva Pharmaceutical Industries|Yes|Completed|September 2010|September 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|80 Years|No|||October 2013|October 21, 2013|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205737||115957|
NCT01171911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJESS20103079|Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery|Nanjing First Hospital, Nanjing Medical University||Nanjing Medical University|Yes|Not yet recruiting|October 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|75 Years|No|||April 2010|July 28, 2010|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171911||118536|
NCT01194011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99010|Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment|Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment||Taipei Medical University WanFang Hospital|No|No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||June 2010|August 31, 2010|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194011||116849|
NCT01194531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF006-D3|Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer|IPSO Trial - Impact of Parental Support on Pregnancy Outcomes: A Multi-Center, Randomized, Open-Label Study to Evaluate the Implantation and Pregnancy Rates Following 24 Chromosome Aneuploidy Screening With Parental Support in Patients Undergoing In Vitro Fertilization (IVF)|IPSO|Natera, Inc.|No|Terminated|September 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|59|||Female|35 Years|42 Years|No|||November 2014|November 12, 2014|August 2, 2010||No|Slow enrollment and Natera is transitioning to a new PGS testing platform.|No|November 5, 2014|https://clinicaltrials.gov/show/NCT01194531||116809|
NCT01194544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99033|The Relationship Between Dietary Habit and Gastroesophageal Flap Valve Abnormality|The Relationship Between Dietary Habit and Gastroesophageal Flap Valve Abnormality||Taipei Medical University WanFang Hospital|No|Recruiting|August 2010|December 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|healthy subjects|March 2011|March 6, 2011|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01194544||116808|
NCT01194856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-418|Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression|A Randomized Study to Evaluate the Effect of Switching From Efavirenz to Atazanavir/ Ritonavir on Lipoatrophy and Mitochondrial Dysfunction in HIV-infected Subjects With Good Virologic Suppression||The Cleveland Clinic|Yes|Terminated|October 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|80 Years|No|||February 2012|February 28, 2012|September 2, 2010||No|Closed due to low enrollment|No||https://clinicaltrials.gov/show/NCT01194856||116784|
NCT01194869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00019781|Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer|Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer||Emory University|Yes|Terminated|June 2010|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|September 1, 2010|Yes|Yes|Slow accrual, availability of other clinical options|No||https://clinicaltrials.gov/show/NCT01194869||116783|
NCT01195155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC-UCD-ATN3|Transcriptomic Profile of Adipose Tissue Following n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation|Transcriptomic Profile of Subcutaneous Adipose Tissue of Young Women With PCOS Followin 6 Weeks Supplementation With n-3 PUFA Versus Olive Oil Placebo||The Adelaide and Meath Hospital|No|Completed|December 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|10|||Female|18 Years|40 Years|No|||July 2008|September 3, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195155||116762|
NCT01203033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU 1910|Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)|Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From Acute Myeloid Leukemia (AML) Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)||West Virginia University|Yes|Recruiting|September 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed or relapsed AML patients at the Mary Babb Randolph Cancer Center|September 2011|September 26, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01203033||116162|
NCT01195428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15377|Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)|Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome||University of Oklahoma|Yes|Withdrawn|October 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|September 2, 2010||No|Minimal enrollment|No||https://clinicaltrials.gov/show/NCT01195428||116741|
NCT01203761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-IM-0301-CTIL|The Experience of Loneliness Among Patients During the Perioperative Period|The Experience of Loneliness Among Ear, Nose and Throat (ENT) Surgical Patients During the Perioperative Period||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2010|November 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|600|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population includes 3 groups:          1. ENT surgical patients in the preoperative period          2. ENT surgical patients in the postoperative period          3. Family members of ENT patients, perioperatively|September 2010|September 15, 2010|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01203761||116107|
NCT01174186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4682724|Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing|Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing|INTASAH|Regionshospitalet Silkeborg|Yes|Completed|October 2010|March 2014|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|45 Years|No|||November 2014|November 18, 2014|July 16, 2010|Yes|Yes||No|April 12, 2014|https://clinicaltrials.gov/show/NCT01174186||118363|15 participants in each group is not many, but the number was selected based on an a priori analysis.NSAID wash-out period of 4 weeks was chosen as best estimate. Loading dose of adalimumab was given to calprotectin elevated group
NCT01174420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAE-CT-DEU-2009-01|Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany|A Prospective Randomized Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy||Aeon Astron Europe B.V.|No|Recruiting|November 2009|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2011|May 5, 2011|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174420||118345|
NCT01174693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAESTRO-001|Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping|Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping|MAESTRO|Gangnam Severance Hospital|Yes|Completed|March 2010|March 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|795|||Both|20 Years|N/A|No|||March 2015|March 16, 2015|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01174693||118324|
NCT01204892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27128|Pain After Laparoscopic Cholecystectomy With Bilateral Tranversus Abdominis Plane (TAP) Block Versus Local Anesthetic Infiltration|Postoperative Pain After Laparoscopic Cholecystectomy in Patients Receiving Bilateral Ultrasound-guided Transverse Abdominis Plane Block Compared With Local Anesthetic Infiltration of Trochar Insertion Sites With Ropivacaine 0.5%||Baylor College of Medicine|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|64 Years|No|||July 2012|July 11, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204892||116021|
NCT01205204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abcd123|Comparison of Different Doses of Clonidine to Fentanyl as an Adjuvant to Bupivacaine 0.5% for Spinal Anesthesia|A Randomized Clinical Study to Compare Different Doses of Clonidine to Fentanyl as an Adjuvant to Hyperbaric Bupivacaine 0.5% for Spinal Anesthesia in Patients Undergoing LSCS||Pravara Institute of Medical Sciences University|Yes|Withdrawn|August 2010|November 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|September 15, 2010||No|This study was registered with Clinical Trials.gov by mistake.|No||https://clinicaltrials.gov/show/NCT01205204||115998|
NCT01170884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-COM-09-013|Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®|||Allergan||Completed|December 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|July 26, 2010|Yes|Yes||No|December 7, 2011|https://clinicaltrials.gov/show/NCT01170884||118614|
NCT01171170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVALT12|Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer|A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12|NVALT12|Dutch Society of Physicians for Pulmonology and Tuberculosis|No|Recruiting|September 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||July 2011|July 26, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171170||118593|
NCT01205750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0132|Hepatic Insulin Sensitivity and Very Low Density Lipoprotein Triglyceride (VLDL-TG) Kinetics|Basal and Insulin Mediated VLDL-triglyceride Kinetics in Obesity; Relationship With Hepatic Insulin Sensitivity||University of Aarhus|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01205750||115956|
NCT01171391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-007|VA106483 Dose Response in Females|An Open Label, Dose Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Female Subjects||Vantia Ltd|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Female|40 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 30, 2010|July 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01171391||118576|
NCT01171404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CEU-DUM-2009/1|Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge|Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients|EPICOR|AstraZeneca|No|Completed|September 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10568|||Both|18 Years|N/A|No|Probability Sample|Patients hospitalized within 24 hours of onset of symptoms and diagnosed with unstable        angina (UA), STEMI or non-STEMI(NSTEMI). Patients will be invited to participate by the        hospital (Academic or Community) which is going to discharge the patient.        Participating investigators will belong to hospitals (Academic, Community, with/without        cathlab, etc), in the proportion representing the reality of where this kind of patients        are managed in each country.|April 2013|April 16, 2013|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171404||118575|
NCT01206283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030531674|A Study Comparing Modified Lund Concept and Cerebral Perfusion Pressure-targeted Therapy in Secondary Brain Ischaemia.|Modified Lund Concept Versus Cerebral Perfusion Pressure-targeted Therapy: A Randomized Controlled Study in Patients With Secondary Brain Ischaemia.||University of Sarajevo|Yes|Completed|January 2006|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|70 Years|No|||September 2010|September 20, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206283||115915|
NCT01206270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160/10|Androgen for Leydig Cell Proliferation|Androgen Treatment in Leydig Cell Proliferation|ALCeP|University of Roma La Sapienza|Yes|Completed|June 2009|October 2014|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|60 Years|No|||October 2014|October 25, 2014|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01206270||115916|
NCT01206504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGAWN1-EA1|Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure|Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus||MacroGenics||No longer available||||||N/A|Expanded Access|N/A|||||||Both|8 Years|N/A||||July 2011|July 5, 2011|September 17, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01206504||115898|
NCT01206517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06522|A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)|A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder||Merck Sharp & Dohme Corp.|No|Completed|July 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|10 Years|17 Years|No|||October 2015|October 29, 2015|September 17, 2010|No|Yes||No|November 20, 2012|https://clinicaltrials.gov/show/NCT01206517||115897|
NCT01194882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUBIN_L_05335|Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes|Evaluation of Insuman Implantable 400 IU/ml in Patients With Type 1 Diabetes Treated With the Medtronic MiniMed Implantable Pump System Using Insuplant 400IU/ml||Sanofi||Active, not recruiting|November 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|458|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194882||116782|
NCT01195168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC-UCD-CS|Cardiovascular Risk Markers in Polycystic Ovary Syndrome (PCOS)|Assessment of Cardiovascular Risk in PCOS-a Cross Sectional Study of Women With PCOS Compared With Controls Matched for Age, Body Mass Index and, or Insulin Resistance|CS|The Adelaide and Meath Hospital|No|Completed|November 2006|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|201|Samples Without DNA|Plasma|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with PCOS and a control population of women matched for age and body mass index        (BMI) and insulin resistance|July 2008|September 3, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195168||116761|
NCT01195181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPCOVE protocol|Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.|Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response.||Azienda Ospedaliera di Padova|Yes|Completed|September 2005|August 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|506|||Both|18 Years|65 Years|No|||September 2010|September 3, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01195181||116760|
NCT01203046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP 01|Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days|SP1 - Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days||Pinango, Silvia M. L., M.D.|No|Completed|December 2010|October 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|12 Years|65 Years|No|||August 2012|August 8, 2012|September 14, 2010||No||No|February 10, 2012|https://clinicaltrials.gov/show/NCT01203046||116161|Presented limitations because patients with penetrating abdominal trauma usually had associated bone fractures or haemodynamic instability.Identifying other predisposing factors is not reached since the sample size was restricted to only two groups.
NCT01203072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-04|A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty|A Phase 2b, Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Dose-finding Study of the Oral Factor Xa Inhibitor DU-176b Compared With Placebo for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS J-1)||Daiichi Sankyo Inc.|Yes|Completed|July 2006|July 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|523|||Both|20 Years|84 Years|No|||January 2015|January 15, 2015|September 14, 2010|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01203072||116160|
NCT01203280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200800018|Icing Effects on Neck Functions of the Boxers|Icing Effects on Neck Functions of the Boxers||Taipei Physical Education College|Yes|Completed|January 2009|July 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||December 2008|September 15, 2010|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203280||116144|
NCT01173887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-003|Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15|Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease)||Kyowa Hakko Kirin Company, Limited||Completed|July 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|20 Years|N/A|No|||March 2013|March 26, 2013|July 30, 2010||||No||https://clinicaltrials.gov/show/NCT01173887||118386|
NCT01174199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPCI I 150709|Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer|A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination With the HDAC Inhibitor Vorinostat in Patients With Metastatic Prostate Cancer||Roswell Park Cancer Institute|Yes|Active, not recruiting|February 2012|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||March 2016|March 14, 2016|July 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01174199||118362|
NCT01174433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2040P|Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)|Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)|SAFE-TRY|University of Padua|Yes|Completed|September 2009|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|241|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01174433||118344|
NCT01174446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250901|Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients|Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B||Baxalta US Inc.|Yes|Completed|July 2010|July 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|12 Years|65 Years|No|||September 2013|June 26, 2015|August 2, 2010|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01174446||118343|
NCT01174706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1LM010424-01|Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients|Impact of Information Prescriptions on Medication Adherence in ED Patients||Johns Hopkins University|No|Recruiting|November 2010|December 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|4||Anticipated|3800|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01174706||118323|
NCT01174719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAHes|Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery|Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery||Medical University of Vienna|Yes|Completed|March 2006|April 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|240|||Both|20 Years|80 Years|No|||April 2015|April 6, 2015|August 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174719||118322|
NCT01174992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-09-001|A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair|A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair||Ethicon, Inc.|No|Completed|July 2010|October 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|139|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|August 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01174992||118302|
NCT01170871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-08-2|Ixabepilone and Pemetrexed/Solid Tumors|Phase I Clinical Trial of Ixabepilone and Pemetrexed in Advanced Solid Tumors||University of Southern California|No|Withdrawn||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|November 4, 2009|No|Yes|Sponsor withdrew support|No||https://clinicaltrials.gov/show/NCT01170871||118615|
NCT01170897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-109-102|Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors||Halozyme Therapeutics|No|Completed|July 2010|January 2014|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Both|18 Years|N/A|No|||September 2012|January 27, 2014|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01170897||118613|
NCT01171183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P50DA018197|Carvedilol for Psychostimulant Dependence|Clinical Efficacy of Carvedilol for Psychostimulant Dependence||University of Arkansas|Yes|Completed|August 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|45 Years|No|||July 2015|July 29, 2015|July 27, 2010|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01171183||118592|Small numbers of participants analyzed. Primary outcome measure based on successfully transition to outpatient phase of the study.
NCT01171196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTC-1117|Questionnaires to Identify Chinese Patients at Risk for Obstructive Sleep Apnea|Validation of Questionnaires to Identify Chinese Patients at Risk for Obstructive Sleep Apnea||The University of Hong Kong|Yes|Completed|July 2010|August 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|378|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are referred to have a diagnostic polysomnography (PSG) will be recruited        from the Sleep Disorders Centre, Department of Medicine, Queen Mary Hospital.|November 2015|November 5, 2015|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171196||118591|
NCT01171417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ODE-FAS-2009/1|A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer|An Epidemiological Prospective Cohort Study to Describe Treatment Patterns of Fulvestrant And ExemeSTane in Postmenopausal Patients With Advanced HR+ Breast Cancer Under Real-life Conditions in GERmany|ACT-FASTER:|AstraZeneca|No|Completed|August 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|570|||Female|18 Years|N/A|No|Probability Sample|660 patients in 140 sites in Germany. 100 specialists and 40 hospitals. Each site should        enrol 4-20 patients|February 2014|February 26, 2014|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01171417||118574|
NCT01171638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR080018-02|The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome|The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome||J&M Shuler|Yes|Not yet recruiting|September 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|15 Years|65 Years|No|Non-Probability Sample|Critically injured patients (Cohort 1) or patients with severe lower extremity injuries        (Cohort 2), admitted to one of the participating sites, who meet the eligibility criteria        described below.|June 2011|June 14, 2011|July 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171638||118557|
NCT01171651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-HEP016|A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma|A Phase 2 Open-Label Pilot Safety Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by IV Infusion Followed by Intratumoral Injection Prior to Standard Sorafenib Treatment in Patients With Unresectable Primary Hepatocellular Carcinoma||SillaJen, Inc.|No|Completed|August 2009|December 2015|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2011|January 19, 2016|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01171651||118556|
NCT01206530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07210|FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer|A Phase I/II Pharmacodynamic Study of Hydroxychloroquine in Combination With FOLFOX Plus Bevacizumab to Inhibit Autophagy in Colorectal Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2010|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206530||115896|
NCT01206543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cranio 15|1.5T Intraoperative MR Imaging in Craniopharyngiomas|Intraoperative Use of a MR Tomography System Combined With Neuronavigation - Analysis of the Craniopharyngioma Subgroup ("Intraoperative Nutzung Eines Kernspintomographie-Systems in Direkter Kopplung Mit Einem Neuronavigations-System")||Hofmann, Bernd, M.D.||Completed|April 2002|August 2006|Actual|September 2005|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|3 Years|75 Years||||September 2010|September 21, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206543||115895|
NCT01206803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GR 3422/3-1|Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients|Polymorphisms of FSH Receptor, LH Receptor, LH and Ovarian Response to FSH in Controlled Ovarian Stimulation Using a GnRH Antagonist Protocol||University of Schleswig-Holstein|No|Completed|September 2010|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|294|Samples With DNA|Serum samples for analysis of gonadotropins and Anti-Muellerian Hormone EDTA samples for DNA      extraction|Female|18 Years|45 Years|No|Probability Sample|Female patients with an indication for IVF or ICSI|January 2016|January 4, 2016|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206803||115875|
NCT01206816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.20|An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours|An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBW 2992 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|October 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|September 21, 2010||||No||https://clinicaltrials.gov/show/NCT01206816||115874|
NCT01202773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13732|A Study in Patients With Rheumatoid Arthritis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to One or More TNF-α Inhibitors (FLEX V)|FLEX V|Eli Lilly and Company|Yes|Completed|January 2011|January 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|555|||Both|18 Years|N/A|No|||March 2014|April 14, 2014|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202773||116182|
NCT01206777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10001|Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies|Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|89 Years|No|||February 2015|February 26, 2015|September 10, 2010|Yes|Yes||No|October 28, 2014|https://clinicaltrials.gov/show/NCT01206777||115877|
NCT01206790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET-2010-KN|Immunological Changes Through Narrative Treatment of Post-Traumatic Stress Disorder (PTSD) in Torture Victims|Immunological Changes Through Narrative Treatment of PTSD in Torture Victims||University of Konstanz|Yes|Completed|June 2009|January 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|16 Years|60 Years|No|||February 2012|February 21, 2012|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206790||115876|
NCT01202747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF002|Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction|Pilot Study for Evaluation of LipiFlow Screening Methods||TearScience, Inc.|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|September 14, 2010|Yes|Yes||No|September 16, 2011|https://clinicaltrials.gov/show/NCT01202747||116184|
NCT01202760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12978|A Rheumatoid Arthritis Study in Patients|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)|FLEX O|Eli Lilly and Company|Yes|Completed|January 2011|July 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|1002|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202760||116183|
NCT01203826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-008-10|Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)|Extension Study of Protocol ENB-006-09 Evaluating the Long-term Safety and Efficacy of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)||Alexion Pharma GmbH|Yes|Active, not recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|5 Years|13 Years|No|||May 2015|May 26, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203826||116102|
NCT01204086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-95-06|Pharmacogenomics Studies of Antidepressants|||National Cheng-Kung University Hospital|No|Recruiting|March 2007|February 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|65 Years|No|||September 2010|September 15, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204086||116082|
NCT01203293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5SC1MH90599-2|Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector|CBT for Latinos With Generalized Anxiety Disorder in the General Medical Sector||University of Puerto Rico|No|Completed|September 2009|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|65 Years|No|||August 2014|August 26, 2014|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01203293||116143|
NCT01173913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N10BOM|Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir|Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir||The Netherlands Cancer Institute|No|Recruiting|September 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||December 2010|December 23, 2010|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01173913||118384|
NCT01173926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3857|Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes|A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties Between NN5401 and NN1250 and Between NN5401 and Insulin Aspart in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|July 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173926||118383|
NCT01174212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10020102|Effect of Prophylactic Antibiotics on Intra-Operative Culture Results|Effect of Prophylactic Antibiotics on Intra-Operative Culture Results||Rush University Medical Center|Yes|Completed|July 2010|July 2012|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|90 Years|No|||August 2012|August 29, 2012|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01174212||118361|
NCT01174459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.678|Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome|Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome||Boehringer Ingelheim||Completed|August 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|571|||Both|15 Years|N/A|No|Non-Probability Sample|500|August 2014|August 28, 2014|August 2, 2010||||No|July 9, 2014|https://clinicaltrials.gov/show/NCT01174459||118342|
NCT01174472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9462/14-4-2010|Drug Eluting Balloon Angioplasty for Dialysis Access Treatment|Drug Eluting Versus Conventional Balloon Angioplasty for the Treatment of Failing Dialysis Access. A Prospective Randomized Single-Center Trial.||University of Patras|No|Completed|March 2010|January 2012|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||January 2012|January 20, 2012|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01174472||118341|
NCT01174732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A006-CL-B|Dose-Ranging Study of A006 DPI, in Adult Asthma Patients|Phase II Study Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Cross-over and Dose-ranging Study of A006 DPI, Albuterol Inhalation Powder, in Adult Asthma Patients||Amphastar Pharmaceuticals, Inc.|No|Completed|July 2010|January 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|26|||Both|18 Years|55 Years|No|||January 2012|January 23, 2012|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174732||118321|
NCT01174758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5029|Development of an Instrumented System to Measure Mobility in Parkinson's Disease|Development of an Instrumented System to Measure Mobility in Parkinson's Disease||Oregon Health and Science University||Completed|October 2009|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|160|||Both|50 Years|80 Years|No|Non-Probability Sample|Movement Disorders Clinic at OHSU in Portland Oregon.|October 2014|October 31, 2014|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174758||118320|
NCT01195623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETKI 96-169|The Long-term Value of Preoperative Duplex Before Surgery for Varicose Veins|Randomized Clinical Trial of Routine Preoperative Duplex Imaging Before Varicose Vein Surgery; Long-term Follow-up||Uppsala University Hospital|No|Completed|November 1997|August 2010|Actual|September 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|293|||Both|20 Years|75 Years|No|||February 2013|February 13, 2013|September 3, 2010||No||No|June 14, 2012|https://clinicaltrials.gov/show/NCT01195623||116726|The rate of hand-held Doppler device use was not known and may have influenced the results, however even now many Swedish surgeons plan varicose vein surgery clinical tests only
NCT01195896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPWT 02|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a New Negative Pressure Wound Therapy (NPWT) System to be Used in the Treatment of Acute Non-infected Wounds and Post Surgical Infected Wounds|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a New Negative Pressure Wound Therapy (NPWT) System to be Used in the Treatment of Acute Non-infected Wounds and Post Surgical Infected Wounds.||Molnlycke Health Care AB|No|Completed|September 2010|September 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195896||116705|
NCT01176812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9251|Dermal Fillers Patient Satisfaction|Dermal Filling Agents: Patient Satisfaction||Wake Forest School of Medicine|No|Withdrawn|May 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|0|||Both|21 Years|80 Years|No|Non-Probability Sample|Subjects who have an interest in combating the effects of facial aging with injectible        dermal fillers.|February 2011|September 17, 2015|August 5, 2010||No|Difficult to recruit subjects in the area.|No||https://clinicaltrials.gov/show/NCT01176812||118162|
NCT01176214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEANING-Study2010|WEANING-Study: "Weaning by Early Versus lAte Tracheostomy iN supratentorIal iNtracerebral Bleedings|Weaning by Early Versus lAte Tracheostomy iN supratentorIal iNtracerebral Bleedings|WEANING|University of Erlangen-Nürnberg Medical School|No|Terminated|July 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|7|||Both|18 Years|85 Years|No|||April 2014|April 25, 2014|July 26, 2010||No|slow recruitment of patients|No||https://clinicaltrials.gov/show/NCT01176214||118208|
NCT01177397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-223-ST-001|Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma|A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma||Celgene|No|Active, not recruiting|July 2010|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|173|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177397||118117|
NCT01182376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00040931|SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI|SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI|SOAR|University of Utah|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|August 11, 2010|Yes|Yes||No|September 10, 2015|https://clinicaltrials.gov/show/NCT01182376||117735|
NCT01182688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.023|Prospective Review of Procalcitonin After Cardiac Surgery|Prospective Review of Procalcitonin After Cardiac Surgery||Tampa Bay Heart Foundation|No|Completed|May 2009|||September 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|105|||Both|18 Years|N/A|No|Probability Sample|All patients having Elective CABG + / - Aortic / Mitral valve patients Off pump and on        pump cases|October 2009|August 16, 2010|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01182688||117711|
NCT01178268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-387|XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)|XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)||Abbott Vascular|No|Completed|August 2010|September 2014|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|546|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01178268||118051|
NCT01182948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1578|Effects of Different Types of Exercise in Type 2 Diabetes|Comparison of Aerobic and Resistance Training Effects on Glycemic Control in Type 2 Diabetes|RAED2|Universita di Verona|No|Completed|January 2009|||December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|70 Years|No|||August 2011|August 24, 2011|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01182948||117692|
NCT01204632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-008|Cardiometabolic Risk, Obesity and Cardiovascular Disease in People With Spinal Cord Injury|Cardiometabolic Risk, Obesity and Cardiovascular Disease in People With Spinal Cord Injury||University of Miami|No|Completed|March 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|65 Years|No|Non-Probability Sample|Community sample of healthy persons with spinal cord injury|February 2016|February 17, 2016|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204632||116041|
NCT01206062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704|Systolic Blood Pressure Intervention Trial|Systolic Blood Pressure Intervention Trial|SPRINT|Wake Forest Baptist Health|Yes|Active, not recruiting|October 2010|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|9250|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206062||115932|
NCT01206075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36078-B|Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major|A Pilot Study to Assess the Safety and Efficacy of Mozobil ± G-CSF in Mobilizing Hematopoietic Stem Cells (CD34+ Cells) in Adults With Beta-thalassemia Major||University of Washington|Yes|Completed|October 2010|December 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|50 Years|No|||December 2014|December 27, 2014|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206075||115931|
NCT01206335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-201|Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia|A Phase II Open Label Study With OHR/AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies||Ohr Pharmaceutical Inc.|Yes|Active, not recruiting|September 2010|February 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||November 2012|November 26, 2012|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206335||115911|
NCT01206348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-0104-28|Combination Treatment for Moderate to Severe Acne|A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin||Medicis Global Service Corporation|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|12 Years|30 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206348||115910|
NCT01203358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0003|Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome|Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome|Surfactant 1|NICHD Neonatal Research Network|Yes|Completed|January 1991|January 1992|Actual|January 1992|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|617|||Both|N/A|6 Hours|No|||June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203358||116138|
NCT01203371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APS 001/2010|Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS|PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF NAFTOPIDIL AND TAMSULOSIN TO TREATMENT THE SYMPTOMS OF LOWER URINARY TRACT IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA||Apsen Farmaceutica S.A.|Yes|Not yet recruiting|January 2011|January 2012|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Male|50 Years|90 Years|No|||September 2010|September 15, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203371||116137|
NCT01203163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-PO-PHORC07-01|Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes|Case Analysis on Real Life Incidence of PDT Safety Outcomes: Multicentre, Observational Post-marketing Safety Surveillance Registry of Patients Exposed to Photodynamic Therapy With Porfimer Sodium: The CALIPSO Registry|CALIPSO|Pinnacle Biologics Inc.|No|Withdrawn||||||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients suffering from esophageal cancer, lung cancer, or HGD in Barrett's esophagus and        scheduled to undergo PDT with porfimer sodium|May 2012|May 7, 2012|September 15, 2010||No|Sponsor cancelled the study|No||https://clinicaltrials.gov/show/NCT01203163||116153|
NCT01195922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100180|Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma|A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer||National Institutes of Health Clinical Center (CC)||Completed|August 2010|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|80 Years|No|||December 2014|November 10, 2015|September 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01195922||116704|
NCT01195948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100191|Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis|Peptide B27PD (Optiquel®) as Corticosteroid-sparing Therapy for Chronic Non-infectious Uveitis (BOOTS)||National Institutes of Health Clinical Center (CC)|Yes|Completed|August 2010|February 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|September 3, 2010|Yes|Yes||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01195948||116703|The protocol was completed early due to lack of efficacy. The Data Safety Monitoring Committee (DSMC), along with the PI, reviewed an interim data report and agreed that Optiquel® was not efficacious and did not cause a proliferative response.
NCT01196195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KONCERT protocol, version 1.6|KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)|KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)|KONCERT|PENTA Foundation|Yes|Completed|August 2010|August 2013|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|N/A|18 Years|No|||October 2013|October 25, 2013|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196195||116684|
NCT01181180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR496510CTIL|The Effect of Fluids Consumption on Balance and Gait Function in Old Adults|The Effect of Fluids Consumption in the Elderly on Balance and Gait Function - A Single Blind Randomized Control Trial||Soroka University Medical Center|Yes|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|44|||Both|65 Years|95 Years|Accepts Healthy Volunteers|||July 2010|June 18, 2012|May 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01181180||117827|
NCT01181453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABH-DG-04-07-0798|Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers|A Prospective, Multicenter, Randomized, Single-Blind, Phase III, Clinical Investigation of Dermagraft(R) in Patients With Plantar Diabetic Foot Ulcers||Shire Regenerative Medicine, Inc.||Completed|December 1998|March 2000|Actual|March 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|314|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|August 12, 2010||Yes||||https://clinicaltrials.gov/show/NCT01181453||117806|
NCT01177059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016027|Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial|A Long Term Follow-up Protocol to Evaluate the Safety and Survival of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection||Janssen-Cilag Pty Ltd|No|Active, not recruiting|December 2004|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|37|||Both|18 Years|45 Years|No|||March 2016|March 15, 2016|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177059||118143|
NCT01181791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090924|Effects of Lactobacillus Reuteri in Premature Infants|Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns|Reuteri|University of Miami|Yes|Active, not recruiting|July 2010|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|N/A|6 Months|No|||January 2016|January 26, 2016|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01181791||117780|
NCT01181804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06992|Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)|A Definitive Bioequivalence Study of a New Boceprevir (SCH 503034) Tablet Formulation Compared to the Current Capsule Form in Healthy Male and Female Subjects.||Merck Sharp & Dohme Corp.|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|177|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|August 12, 2010|No|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT01181804||117779|
NCT01182389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1631|A Study of Early Robotic Ablation by Substrate Elimination of Ventricular Tachycardia|A Prospective Randomised Study of Early Robotic Ablation by Substrate Elimination of Ventricular Tachycardia|ERASE-VT|Imperial College London|Yes|Active, not recruiting|October 2011|December 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182389||117734|
NCT01182662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kongdx|Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia|Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat SAA||Shandong University|Yes|Recruiting|August 2010|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||August 2010|August 30, 2010|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182662||117713|
NCT01183247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|187/07|An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens|An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens for de Novo Renal Transplant Recipients: A Comparison of a Sirolimus / EC-MPS (Myfortic) / Tacrolimus Regimen, an Everolimus / EC-MPS / Tacrolimus Regimen and a EC-MPS / Tacrolimus Prednisone Regimen|SterFreePlus|University Hospital, Basel, Switzerland|No|Completed|July 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|75 Years|No|||August 2010|August 16, 2010|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183247||117669|
NCT01205555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-GYN-10-02|Combining LHu With Ultrasound Monitoring in IUI|Combining Urinary Luteinizing Hormone Testing With Ultrasound Monitoring in Intrauterine Insemination Cycles||OVO R & D|No|Recruiting|January 2011|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|500|||Female|18 Years|39 Years|No|||February 2016|February 1, 2016|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205555||115971|
NCT01205529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 100800|Certain People With Atrial Fibrillation May Have Changes on Ecg When Given Procainamide That May be Related to a Genetic Difference|Prospective Evaluation of a Potential Sodium Channel-Related Endophenotype|Proc|Vanderbilt University|Yes|Recruiting|November 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|750|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205529||115973|
NCT01205542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIMS03|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function|VIMS03|National Research Centre for the Working Environment, Denmark||Completed|September 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 3, 2011|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205542||115972|
NCT01205854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA2010-1|Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial|Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen|ARCTIC|Diakonhjemmet Hospital|Yes|Completed|September 2010|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01205854||115948|
NCT01206881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO5903, EudraCT 2008-007951-29|Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer|A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer||Herlev Hospital|Yes|Completed|March 2009|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|75 Years|No|||June 2011|June 30, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01206881||115869|
NCT01206894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10.119|Pre-Operative Assessment of Chest Wall Invasion in NSCLC Using Pre-Operative, Surgeon Performed Ultrasound|Pre-Operative Assessment of Chest Wall Invasion in Non-Small Cell Lung Cancer (NSCLC)Using Pre-Operative, Surgeon Performed Ultrasound|CT0010|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2010|September 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01206894||115868|
NCT01202851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0976|Relaxation for Women With Breast Cancer Undergoing Radiotherapy|Biobehavioral Effects of Relaxation for Women With Breast Cancer Undergoing Radiotherapy||M.D. Anderson Cancer Center|No|Recruiting|February 2011|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|600|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202851||116176|
NCT01202864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008059|Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)|Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)|ERICH|University of Cincinnati|No|Enrolling by invitation|August 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|6000|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Our purpose is to enroll 1000 cases of ICH among whites, 1000 cases of ICH among blacks,        and 1000 cases of ICH among Hispanics.        3000 controls matched to cases by race/ethnicity, age (+/- 5 years), gender, and        geographic location.|May 2015|May 27, 2015|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202864||116175|
NCT01195051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910-19|Medication Reconciliation Technology to Improve Quality of Transitional Care|Medication Reconciliation Technology to Improve Quality of Transitional Care|MedMatch|Indiana University|Yes|Completed|November 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|4818|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01195051||116770|
NCT01203384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0913-PR-0038|Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects|CT02|CERESPIR|Yes|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|September 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01203384||116136|
NCT01203397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPSEMS0110|Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate In The Superficial Varicose Veins Treatment|PHASE III OF SAFETY AND EFFICACY STUDY OF TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G IN THE SUPERFICIAL VARICOSE VEINS TREATMENT||EMS|Yes|Suspended|September 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||March 2013|March 1, 2013|September 15, 2010||No|Study suspended by decision strategically.|No||https://clinicaltrials.gov/show/NCT01203397||116135|
NCT01195961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100194|Facilitating Numerical Processing With Transcranial Stimulation in Developmental Dyscalculia|Facilitating Numerical Processing With Transcranial DC Stimulation in Developmental Dyscalculia||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2010|July 2011||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|December 30, 2011|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195961||116702|
NCT01195974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113394|A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.|A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Drospirenone and Ethinyl Estradiol When Co-administered With GSK2248761 in Healthy Adult Female Subjects||ViiV Healthcare|No|Terminated|September 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|3||Actual|13|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|September 3, 2010|No|Yes|In a Phase II study in HIV-infected patients there were a number of seizures, although exact    causality could not be assessed phase 1 activity was terminated.|No||https://clinicaltrials.gov/show/NCT01195974||116701|
NCT01196208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-010|A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001|An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma||Seattle Genetics, Inc.|No|Available||August 2017|Anticipated|||N/A|Expanded Access|N/A|||||||Both|6 Years|N/A|No|||July 2015|July 31, 2015|September 3, 2010|No|Yes||||https://clinicaltrials.gov/show/NCT01196208||116683|
NCT01181479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL12|Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System|Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.||Agile Therapeutics|No|Completed|August 2010|March 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1504|||Female|17 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01181479||117804|
NCT01181466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C10-002PLV|AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema|A Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema||Aeris Therapeutics|Yes|Completed|August 2010|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|N/A|No|||October 2011|October 20, 2011|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01181466||117805|
NCT01182051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-00019444|A Study of Family-based Cognitive-behavioral Therapy for Chronic Pediatric Headache and Anxiety|A Pilot Study of Family-based Cognitive-behavioral Therapy for Treating Chronic Pediatric Headache/Migraine and Comorbid Anxiety||Johns Hopkins University|No|Completed|March 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|7 Years|17 Years|No|||May 2013|May 22, 2013|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01182051||117760|
NCT01183806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-01|Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients|Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients||Federal University of Bahia|No|Completed|July 2010|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|55 Years|N/A|No|||March 2012|March 19, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183806||117626|
NCT01183819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE5848|Cognitive Control and Physical Exercise|Cognitive Control and Physical Exercise: A Multi-Modal Intervention||Columbia University|Yes|Terminated|February 2010|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|August 16, 2010||No|insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01183819||117625|
NCT01183260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIMM1007WB|Evaluation of the Trabecular Metal™ Revision Hip Cup Using Bone Mineral Density (DEXA)|Evaluation of the Trabecular Metal™ Acetabular Revision Cup Using Dual-Energy X-ray Absorptiometry (DEXA)||The Cleveland Clinic|Yes|Active, not recruiting|August 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|85 Years|No|||February 2016|February 11, 2016|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183260||117668|
NCT01183494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-277-B|A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients|A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients||University of Chicago|Yes|Active, not recruiting|December 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01183494||117650|
NCT01182961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-NG-0113-CTIL|The Use of Virtual Reality for the Gait Training of Elderly Fallers|Gait Training Intervention to Evaluate the Efficacy of Using Virtual Reality to Decrease Fall Risk in the Elderly Population|VR-Fallers|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|September 2010|April 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||August 2010|August 27, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01182961||117691|
NCT01183481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RINV Prophylaxis|Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study|Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study||Sunnybrook Health Sciences Centre|No|Terminated|January 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|19|||Both|N/A|N/A|No|||November 2014|November 17, 2014|August 4, 2010|No|Yes|Study was stopped due to inadequate accrual.|No|June 24, 2013|https://clinicaltrials.gov/show/NCT01183481||117651|Small number of subjects results in early termination of study
NCT01183780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13856|A Study in Second Line Metastatic Colorectal Cancer|A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine||Eli Lilly and Company|Yes|Active, not recruiting|December 2010|June 2016|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1072|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 4, 2010|Yes|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01183780||117628|
NCT01205308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125/2009|Plant Stanols and Type 1 Diabetes|Effects of Plant Stanol Esters on Serum Lipids, Precursors of Cholesterol Synthesis and Plant Sterols in Type 1 Diabetics on Stabile Statin Drug Use||University of Eastern Finland|No|Completed|January 2010|March 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|72 Years|No|||April 2012|April 16, 2012|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01205308||115990|
NCT01205841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52510|A Prospective Study Comparing Different Clinical Decision Rules in Adult and Pediatric Ankle Trauma|A Prospective Study Comparing Different Clinical Decision Rules in Adult and Pediatric Ankle Trauma|LEFO|Katholieke Universiteit Leuven|No|Not yet recruiting|September 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1500|||Both|5 Years|N/A|No|||September 2010|September 20, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01205841||115949|
NCT01206049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020385-13|Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations|Randomized Phase II Trial of Combination Chemotherapy With Panitumumab or Bevacizumab for Patients With Inoperable Cholangiocarcinoma Without KRAS Mutations|GOC-B-P|Vejle Hospital|Yes|Recruiting|September 2010|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206049||115933|
NCT01206608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402-C-210|Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty|A Randomized, Double-Blind, Active-Control Study to Evaluate the Safety and Efficacy of a Single Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Augmentation Mammoplasty||Pacira Pharmaceuticals, Inc|No|Completed|March 2008|December 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|40 Years|No|||July 2013|July 3, 2013|September 19, 2010|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT01206608||115890|
NCT01206920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071029|Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort|Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort|DC Cohort|George Washington University|No|Recruiting|January 2011|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Study participants will include men, women and children receiving HIV/AIDS care at major        publicly-funded, government and academic medical centers in the District of Columbia.|February 2016|February 18, 2016|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206920||115866|
NCT01202877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0374|PKC412 and 5-Azacytidine|A Combination of PKC412 and 5-Azacytidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Completed|March 2011|||July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202877||116174|
NCT01202890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1001|Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer|Phase IB Study of Lenalidomide (Revlimid®) With Liposomal Doxorubicin (Doxil®) and Bevacizumab (Avastin®) for Patients With Platinum Resistant Ovarian Cancer.||New Mexico Cancer Care Alliance|No|Terminated|September 2010|May 2012|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|N/A|N/A|No|||January 2014|January 7, 2014|September 14, 2010|Yes|Yes|Terminated due to inadequate rate of accrual.|No||https://clinicaltrials.gov/show/NCT01202890||116173|
NCT01202903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025A2313|Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy|A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of Xolair® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy||Novartis|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|616|||Both|18 Years|75 Years|No|||March 2015|March 16, 2015|September 14, 2010||No||No|October 24, 2014|https://clinicaltrials.gov/show/NCT01202903||116172|
NCT01195337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0763|Social Contextual Influences on Physical Activity|Social, Contextual, and Environmental Determinants of Physical Activity in Sedentary Minority Adults||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2010|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|380|||Both|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|300 black or Latino participants in the greater Houston, Texas area.|February 2016|February 15, 2016|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195337||116748|
NCT01195636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPF-002-201|A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Systemic Exposure of Topical XPF-002 in Subjects With Postherpetic Neuralgia|XEN402|Xenon Pharmaceuticals Inc.|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|80 Years|No|||September 2013|September 20, 2013|August 31, 2010|Yes|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT01195636||116725|
NCT01195324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017440|A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers|An Open-Label Drug Interaction Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Administered Alone and in Combination With Multiple-Dose JNJ-28431754 (Canagliflozin) in Healthy Male and Female Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195324||116749|
NCT01195610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B 260|Dietary Intervention With Shop Model - SHOPUS|A Six Month Randomized Controlled Dietary Intervention Study of the New Nordic Diet vs Average Danish Diet in Adults (18-65y) Using the Shop Model for Optimal Dietary Adherence|SHOPUS|University of Copenhagen|No|Completed|August 2010|July 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|July 29, 2014|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195610||116727|
NCT01196221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP-R|Technical Innovation Protocol for MR & US Plaque Imaging: Reproducibility.|Technical Innovation Protocol for Carotid Plaque Imaging by 3.0 Tesla MRI, MRS and Ultrasound: Reproducibility.||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|November 2009|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|The population will consist of patients with carotid artery plaques that cause 30% to 70%        lumen stenosis. The degree of stenosis will be assessed by the peak systolic velocity end        end diastolic velocity near the stenosis measured by ultrasound duplex.        The researchers choose to investigate patients with 30% to 70% carotid artery stenosis for        the following reasons: 1. Treatment of patients with carotid artery plaques is based on        the amount of lumen stenosis. A stenosis of more than 70% is generally treated surgically        by endarterectomy. Doing repeated measurements is only possible in patients not treated        surgically. 2. Patients with 30% to 70% carotid artery stenosis are, despite their drug        treatment, still at high risk for cardiovascular events.|September 2010|September 7, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01196221||116682|
NCT01196507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS PHT-02|Early Primary Prophylaxis of Esophageal Varices|A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis.||Institute of Liver and Biliary Sciences, India|No|Completed|November 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|75 Years|No|||December 2013|August 31, 2015|September 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01196507||116660|
NCT01196806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTMED02-0910|Comparison of Measurement of Arterial Blood Pressure by L&T NIBP Module With Invasive Arterial Blood Pressure in Neonates|Comparison of Measurement of Arterial Blood Pressure by L&T NIBP Module With Invasive Arterial Blood Pressure in Neonates||Larsen & Toubro Limited|No|Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|N/A|30 Days|Accepts Healthy Volunteers|Non-Probability Sample|Total 20 numbers Neonates in NICU were studied during this study.|September 2010|September 7, 2010|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01196806||116637|
NCT01181492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HuazhongU|Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery|Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery||Huazhong University of Science and Technology|Yes|Completed|November 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|N/A||3|Actual|176|Samples With DNA|176 blood samples were extracted|Both|20 Years|65 Years|No|Non-Probability Sample|176 Chinese patients receiving elective lower abdominal surgery under general anesthesia|August 2013|August 28, 2013|August 11, 2010|Yes|Yes||No|December 4, 2012|https://clinicaltrials.gov/show/NCT01181492||117803|The preoperative and postoperative data were not all integrallty recorded in a relative short period and entered into Excel.
NCT01181505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-78|STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study|STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study|HNF4a|Inje University|No|Completed|January 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|31|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||November 2008|August 12, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181505||117802|
NCT01181817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vubmtmoensSCS|Evaluation of the Brain Activity During Spinal Cord Stimulation in Failed Back Surgery Syndrome Using Functional MRI and MRS|Evaluation of the Brain Activity During Spinal Cord Stimulation (SCS) in Failed Back Surgery Syndrome Using Functional Magnetic Resonance Imaging (fMRI) and Magnetic ResonanceSpectroscopy (MRS)||Universitair Ziekenhuis Brussel|Yes|Recruiting|September 2008|September 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2008|August 17, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01181817||117778|
NCT01182064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCJWJ1|Acute Myocardial Infarction by Penetrating Cardiac Trauma|Relationship of Echocardiographic and Coronary Angiographic Findings in Patients With Acute Myocardial Infarction Secondary to Penetrating Cardiac Trauma||Universidad de Antioquia|No|Completed|April 2007|April 2008|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|51|||Both|14 Years|80 Years|No|Probability Sample|The study included patients admitted to the emergency department of the San Vicente de        Paul University Hospital with a penetrating stab cardiac injury without previous injuries|March 2007|August 13, 2010|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182064||117759|
NCT01182077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK05|A Study to Assess Drug Interaction of ASP015K and Midazolam|A Phase 1, Open Label, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP015K and Midazolam After Separate and Concomitant Administration to Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 11, 2010|August 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01182077||117758|
NCT01183507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|410-2009|Task Specific Exercise for the Prevention of Disability|Task Specific Exercise for the Pre-Clinically Disabled|TSE|University of Florida|Yes|Active, not recruiting|April 2010|August 2016|Anticipated|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|71|||Both|60 Years|N/A|No|||April 2015|April 16, 2015|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183507||117649|
NCT01184092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921075|A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)|Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, Cross-Over, Bioequivalence Study Comparing Phase 2b, Phase 3 And Commercial Image Tablet Formulations Of Tasocitinib (CP-690,550) Under Fasted Conditions||Pfizer|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Anticipated|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 12, 2010|August 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01184092||117605|
NCT01182974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1662CTIL|Paracetamol Toxicity in Septic Patients|Paracetamol-induced Liver Toxicity in Septic Patients||Barzilai Medical Center|No|Suspended|August 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2011|March 1, 2011|August 16, 2010||No|Difficulty in patient enrollment|No||https://clinicaltrials.gov/show/NCT01182974||117690|
NCT01184079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP#38206|Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting|Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting||University of Pittsburgh|No|Completed|October 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Male|18 Years|26 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|August 11, 2010||No||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01184079||117606|Drop-out rates higher in the Alternate group; however, sample size was met for all HPV types. The effect of the Alternate dosing schedule on long-term clinical outcomes is unknown. One syncopal episode related to phlebotomy prior to vaccination.
NCT01206101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3619|Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation|A 52 Week Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center, Multinational Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Determine If The Early Use Of Liraglutide As An Adjunct To Standard Care Increases The Proportion Of Subjects Achieving Insulin Independence After First Transplantation||Novo Nordisk A/S|No|Terminated|March 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|September 20, 2010|Yes|Yes|The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well    as challenges relating to trial execution and study completion.|No|June 2, 2014|https://clinicaltrials.gov/show/NCT01206101||115929|Due to the premature termination of the trial prior to islet cell transplantation in any randomised subject, no results are available.
NCT01206361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111145|Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom|Persistence Of Use Of Topical Prostaglandin Fixed Dose Combination In The United Kingdom Primary Care: An Observational Study In Thin||Pfizer|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2015|||Both|18 Years|N/A|No|Non-Probability Sample|patients who had received a prescription for either Xalacom, Ganfort and DuoTrav, > 18        years old, diagnosed with glaucoma or ocular hypertension, registered at the primary care        practice for > 12 months|June 2011|June 28, 2011|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01206361||115909|
NCT01205568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0502027R|Cutting Balloon Study|Safety and Efficacy of the Cutting Balloon to Treat Resistant Pulmonary Artery Stenosis|CB|Children's Hospital Boston|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|65|||Both|N/A|N/A|No|||September 2010|September 17, 2010|September 17, 2010|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01205568||115970|
NCT01206374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-027SLRHC|Questionnaire and Laboratory Data on Vitiligo Vulgaris|Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris||St. Luke's-Roosevelt Hospital Center|Yes|Completed|August 2010|September 2014|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients willing to sign consent, complete questionnaire and/ or laboratory studies.|May 2015|May 22, 2015|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206374||115908|
NCT01206621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB051|Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED|Assessment of the Utility of Vibration Response Imaging (VRI) in Evaluating Dyspnea Patients Presenting to the Emergency Department||Deep Breeze|No|Recruiting|August 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|530|None Retained|Blood drawn for BNP testing|Both|41 Years|N/A|No|Probability Sample|Patients presenting to the ED with acute dyspnea who are greater than 40 years of age and        consisting of both male and females|September 2010|May 12, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206621||115889|
NCT01206907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3319-301|Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects|AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER EFFECTIVENESS, SAFETY AND TOLERABILITY STUDY OF OXYMORPHONE HCl IMMEDIATE-RELEASE ORAL LIQUID IN OPIOID-TOLERANT PEDIATRIC SUBJECTS WITH CHRONIC PAIN REQUIRING AN AROUND THE CLOCK OPIOID||Endo Pharmaceuticals|Yes|Withdrawn|October 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|6 Years|No|||August 2012|August 15, 2012|September 17, 2010|Yes|Yes|The study is no longer required for the PREA for this product.|No||https://clinicaltrials.gov/show/NCT01206907||115867|
NCT01206933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWUIRB #061012|The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System|The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System.||George Washington University|No|Completed|July 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Four groups of subjects will be included in this study, with 5 participants in each group:          1. detectable HIV RNA (Ribonucleic Acid) and detectable HCV RNA          2. undetectable HIV RNA (treated) and detectable HCV RNA          3. undetectable HIV RNA (treated) and undetectable HCV RNA          4. undetectable HCV RNA (mono-infected)          5. detectable HCV RNA (mono-infected)          6. detectable HIV RNA (mono-infected)|September 2010|February 8, 2016|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01206933||115865|
NCT01202916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8422|Quality of Life Among Children With Congenital Heart Disease|Quality of Life Among Children With Congenital Heart Disease||University Hospital, Montpellier|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|316|||Both|8 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  children with congenital heart disease          -  healthy children|February 2012|February 10, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202916||116171|
NCT01202929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.0057|Correlation of High Resolution Esophageal Manometry With Symptoms|Correlation of High Resolution Esophageal Manometry With Symptoms||University of Louisville|No|Terminated|February 2010|March 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from patients referred to the University Medical Associates        motility lab for high resolution manometry|August 2011|August 4, 2011|September 14, 2010||No|Principal investigator has left the Institution|No||https://clinicaltrials.gov/show/NCT01202929||116170|
NCT01195350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-47|Blood Pressure Level and Prognosis in Acute Stroke|Relationship Between Blood Pressure Level and Lethality in Acute Phase of Stroke : Observational Prospective Study.||UPECLIN HC FM Botucatu Unesp|No|Recruiting|February 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|266|||Both|18 Years|N/A|No|Non-Probability Sample|Acute isquemic or hemorragic stroke admitted in ICU.|July 2011|July 4, 2011|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01195350||116747|
NCT01195363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20070253H|Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder|A Randomized, Double-Blind, Placebo Controlled Study Of Quetiapine SR (QTP) As Adjunctive Treatment In Mixed States (MS) Of Bipolar Disorder||The University of Texas Health Science Center at San Antonio|Yes|Completed|April 2007|June 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||August 2015|August 6, 2015|September 2, 2010|Yes|Yes||No|April 3, 2013|https://clinicaltrials.gov/show/NCT01195363||116746|Overall limitations were screen failures and lost to follow-ups which led to not reaching recruitment goals.
NCT01195376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235A1101|A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors|A Phase I Study of BEZ235, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors||Novartis||Completed|October 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|20 Years|N/A|No|||August 2013|August 26, 2013|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01195376||116745|
NCT01195649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15242|Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy|Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy||Bayer|No|Completed|December 2010|August 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Taiwanese patients|October 2014|October 11, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01195649||116724|
NCT01197131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 1.0/18/06/2010|Urinary Steroid Metabolites in Autism|Investigation of Urinary Steroid Metabolites in Children With Autism Spectrum Disorder||Intersci Research Association, Austria|No|Active, not recruiting|September 2010|March 2016|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|160|Samples Without DNA|noninvasive overnight urine (morning urine)|Both|5 Years|15 Years|No|Non-Probability Sample|Children , age 5-15 years with autism and autism spectrum disorder resident in Austria        without other severe or psychiatric disorders.|September 2015|September 28, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197131||116612|
NCT01197365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA-LENI-09|Safety and Efficacy of an Infant Formula Supplemented With Galacto-oligosaccharides, Beta-palmitate and Acidified Milk|Double-blind Randomized Controlled Study for the Evaluation of Nutritional Outcomes of a Cow's Milk Based Infant Formula Containing Galacto-oligosaccharides, Beta-palmitate and Acidified Milk||Heinz Italia SpA|No|Completed|August 2010|December 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|148|||Both|N/A|21 Days|No|||February 2015|February 2, 2015|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197365||116594|
NCT01197612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00029273|Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis|Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis||University of Michigan|Yes|Recruiting|September 2010|||||Phase 3|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||August 2010|September 8, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01197612||116575|
NCT01182402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5703432|Electronic Compliance Monitoring in Opioid Substitution Treatment|Electronic Compliance Monitoring in Opioid Substitution Treatment|EHSO|Kuopio University Hospital|No|Completed|September 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|37|||Both|18 Years|N/A|No|||March 2011|March 21, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01182402||117733|
NCT01182415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-444|High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma|Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma||Massachusetts General Hospital|Yes|Active, not recruiting|June 2010|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|April 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182415||117732|
NCT01181830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF_Mg_fam_MetS|Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome|Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome||Universita di Verona|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 15, 2013|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181830||117777|
NCT01181843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMC IRB 2010.200|Incidence of Respiratory Depression in Cesarean Section|A Prospective, Observational, Double-blind (Black-Box) Study Evaluating Incidence, Severity and Predictive Factors of Respiratory Depression During Postoperative Neuraxial Opioid Analgesia in Obstetric Patients After Cesarean Delivery Using Current Standard Intermittent Postoperative Monitoring Compared to Continuous Pulse Oximetry / Capnography||Wake Forest School of Medicine|Yes|Terminated|July 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Female|18 Years|55 Years|No|Probability Sample|subjects having an elective cesearean section and having as their anesthetic either a        spinal or epidural and receiving duramorph|August 2015|August 31, 2015|August 12, 2010||No|departmental financial support withdrawn|No||https://clinicaltrials.gov/show/NCT01181843||117776|
NCT01182987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRC 09-002|SCAN Memory Program Evaluation Study|SCAN Memory Program Evaluation Study|SMPES|VA Greater Los Angeles Healthcare System|No|Recruiting|October 2009|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|N/A|No|||August 2010|August 16, 2010|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01182987||117689|
NCT01183273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29043|Randomized Trial Comparing Laparoscopic Roux-en-y Gastric Bypass to Micro-laparoscopic Roux-en-y Gastric Bypass|Prospective Randomized Trial Comparing Laparoscopic Roux-en-y Gastric Bypass to Micro-laparoscopic Roux-en-y Gastric Bypass||Danbury Hospital|No|Completed|March 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01183273||117667|
NCT01183286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44HL088826-03|CFfone: A Cell Phone Support Program for Adolescents With Cystic Fibrosis|CFfone: A Cell Phone Support Program for Adolescents With Cystic Fibrosis||Dawkins Productions, Inc.|Yes|Not yet recruiting|September 2010|||April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|146|||Both|11 Years|20 Years|No|||August 2010|August 16, 2010|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01183286||117666|
NCT01183533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0195|Safety of Intravenous Thrombolysis for Wake-up Stroke|Safety of Intravenous Thrombolysis for Wake-up Stroke|Wake-Up Stroke|The University of Texas Health Science Center, Houston|Yes|Completed|July 2010|January 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|No|||November 2014|November 24, 2014|August 16, 2010|Yes|Yes||No|October 28, 2014|https://clinicaltrials.gov/show/NCT01183533||117647|The single-arm / open-label design suffers from limitations such as possible bias in patient selection and outcome assessment. However, adverse events were adjudicated by the DSMB. Small trial size warrants caution; further studies are necessary.
NCT01179477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD561|QuickFlex Micro Post Approval Study|QuickFlex® μ Model 1258T Left Heart Pacing Lead Post Approval Study|QuickFlex PAS|St. Jude Medical|No|Active, not recruiting|August 2010|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1930|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an approved indication per ACC/AHA/HRS guidelines for implantation of a        CRT-D system|December 2014|December 9, 2014|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179477||117958|
NCT01179490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010002|Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma|A Multicenter, Open-Label, Phase 2 Study of SyB L-0501 (Bendamustine Hydrochloride) for Patients With Multiple Myeloma||SymBio Pharmaceuticals|Yes|Terminated|September 2010|||September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|79 Years|No|||March 2013|March 15, 2013|August 2, 2010||||No|December 2, 2012|https://clinicaltrials.gov/show/NCT01179490||117957|
NCT01183793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-CIR-02|Magnetic Resonance (MR) Enterography Assessment of Post Operative Small Bowel Length in Short Bowel Syndrome Patients|MR Enterography Assessment of Post Operative Small Bowel Length in Short Bowel Syndrome Patients||Centre Hospitalier Universitaire de Nice|No|Recruiting|July 2010|July 2012|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|85 Years|No|||June 2010|August 17, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01183793||117627|
NCT01205867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0540C00009|Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects|An Open, Non-controlled, Non-randomised, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD 8848 Administered Intranasally to Male and Female Butyrylcholinesterase Deficient Subjects and to Sex and Age Matched Controls||AstraZeneca|No|Completed|September 2010|January 2012|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01205867||115947|
NCT01206088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AKR02|Tasigna in Glivec-resistant or Intolerant Patients in CML|A Phase IV Study for Nilotinib in Patients With Imatinib-resistant or Intolerant Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase.||Novartis|No|Completed|February 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206088||115930|
NCT01206114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1N1-495-10THL|Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11|Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11||National Institute for Health and Welfare, Finland|No|Completed|September 2010|September 2014|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2351|Samples With DNA|nasal/oral swabs, serum samples|Both|18 Years|76 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participation in the study will be offered to all participants of the cohort study        "Evaluation of a vaccination campaign with A(H1N1)v pandemic vaccines: a prospective        cohort study" AH1N1-483-09THL, who still live in the study area (city of Tampere) and who        have complied to the SMS or phone follow-up. The eligibility criteria of the original        study AH1N1-483-09THL were: full legal competence; community-dwelling; age 18 to 75 years,        written informed consent obtained; able to communicate fluently in Finnish or Swedish and        able to adhere to all protocol required study procedures without any special burden or        risk. Originally, 3500 persons participated in the study|September 2014|September 24, 2014|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206114||115928|
NCT01206387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS-0808|Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis|A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis||Taro Pharmaceuticals USA|No|Completed|August 2010|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|September 20, 2010|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01206387||115907|
NCT01206400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pioglitazonetestosterone|Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study|Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|September 2010|January 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Male|25 Years|50 Years|No|Probability Sample|30 eugonadal men with type 2 diabetes mellitus|September 2010|June 28, 2011|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206400||115906|
NCT01206413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPQ500404/2003-8|A Randomized Clinical Trial of Home-based Exercise Combined With a Slight Caloric Restriction on Obesity Prevention Among Women|A Randomized Clinical Trial of Home-based Exercise Combined With a Slight Caloric Restriction on Obesity Prevention Among Women||Rio de Janeiro State University|Yes|Completed|October 2003|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|203|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 20, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206413||115905|
NCT01206634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-9427-B2716-21C|Regenerative Injection Therapy and Osteoarthritis|Effect of Regenerative Injection Therapy on Function and Pain in Patients With Knee Osteoarthritis||Réseau de Santé Vitalité Health Network|No|Completed|October 2007|October 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|90 Years|No|||September 2010|September 20, 2010|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206634||115888|
NCT01194700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAI008|Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers|Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers||University of Dundee|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2009|September 17, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194700||116796|
NCT01195064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2009-A00916-51, CHU 0921|Endothelial Function Study Before Cardiovascular Surgery|Endothelial Function Study Before Cardiovascular Surgery in COPD and/or SAS Patients|COPD-OSAS|University Hospital, Grenoble|Yes|Recruiting|April 2010|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|Samples With DNA|Urinary, blood and adipose tissue samples will be collected for measurement of different      parameters of inflammation and oxidative stress.|Both|18 Years|80 Years|No|Probability Sample|Patients presenting with chronic obstructive pulmonary disease (COPD) and/or obstructive        sleep apnea syndrome (OSAS) or control patients without these pathologies, before planned        cardiovascular surgery.|March 2016|March 23, 2016|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01195064||116769|
NCT01195701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10063|Clitoral Location in Relation to Sexual Function Using Pelvic Imaging|Clitoral Location in Relation to Sexual Function Using Pelvic MRI: A Case-Control Study||TriHealth Inc.|No|Completed|July 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|35|Samples Without DNA|Blood hormone levels|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sexually active premenopausal females aged 18-55 years old presenting to private        gynecology practice|November 2014|November 24, 2014|September 3, 2010||No||No|April 29, 2014|https://clinicaltrials.gov/show/NCT01195701||116720|
NCT01196234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2009-0677|Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer|Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study|PRIDE|Asan Medical Center|No|Completed|December 2009|December 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01196234||116681|
NCT01195662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-077 ST|A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication||AstraZeneca|No|Completed|October 2010|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2245|||Both|18 Years|89 Years|No|||December 2015|December 2, 2015|September 3, 2010|Yes|Yes||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01195662||116723|Totality of data from dapagliflozin development program as of 1 NOV 2011 showed 10 mg dapagliflozin dose provided optimal efficacy, was safe and well tolerated for the general Type 2 diabetes population, allowing the 5 mg arm to be discontinued.
NCT01195675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.16|Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects|Assessment of the Effect of 25 mg and 200 mg of BI 10773 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Five-period Crossover Phase-I-study With Moxifloxacin as Positive Control||Boehringer Ingelheim||Completed|August 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|September 3, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01195675||116722|
NCT01197651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aortenstent|Aortic-Stent-Register|Aortenstent-Register||Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|October 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients being treated in one of the participating hospitals because of a        disease of the distal thoracal aorta|May 2011|June 9, 2011|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197651||116572|
NCT01197937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29372|Relationship of Realize Mysuccess Usage to Outcomes of Bariatric Surgery|Relationship of Realize Mysuccess Usage to Outcomes of Bariatric Surgery||University of Pennsylvania|No|Completed|August 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25000|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants will be men and women, 18-65 years old, with a BMI of 40-70 kg/m2 (or 35-70        kg/m2 in the presence of co-morbidities) who have registered in the RMS system and have        log into the system at least once postoperatively.|December 2013|December 10, 2013|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01197937||116550|
NCT01193686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-134|Peer Visitation for OEF/OIF Veterans|Evaluating a Peer Visitor Program for OIF/OEF Veterans With Polytrauma||VA Office of Research and Development|Yes|Completed|November 2010|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||October 2014|April 6, 2015|August 31, 2010||No||No|December 11, 2014|https://clinicaltrials.gov/show/NCT01193686||116874|We had great difficulty recruiting Recipients of Peer Visitors, i.e., Veterans who wished to receive mentorship from our trained peer visitors. This rendered our sample size too small for planned analyses.
NCT01182740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-183|Comparison of Endotracheal Intubation Success Rates Using Video Laryngoscopes in Entrapped Patients - a Manikin Study|Comparison of Endotracheal Intubation Success Rates Using Video Laryngoscopes in Entrapped Patients - a Manikin Study||University of Cologne|No|Completed|August 2010|November 2010|Actual|||N/A|Observational|Time Perspective: Prospective||6|Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|experienced emergency physicians|August 2010|November 10, 2010|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182740||117707|
NCT01183000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1789|Closure of Peritoneum at Cesarean Section and Postoperative Adhesion|Effects of Closure Versus Non-closure of the Visceral and Parietal Peritoneum at Cesarean Section on Adhesions: A Prospective Randomized Study|cs adhesions|Barzilai Medical Center||Completed||||||N/A|Interventional|Primary Purpose: Prevention|2||||||Female|18 Years|N/A||||August 2010|August 16, 2010|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01183000||117688|
NCT01182701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR007883|Cognitive Behavioral Intervention in Diabetes Self-Management|Cognitive Behavioral Intervention in Diabetes Self-Management||University of Hawaii|Yes|Completed|August 2004|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|207|||Both|18 Years|76 Years|No|||August 2010|August 13, 2010|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01182701||117710|
NCT01182714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foley-01|A Prospective Randomized Control Trial Comparing Immediate and 24-hours Delayed Catheter Removal Following Hysterectomy|A Prospective Randomized Trial to Compare Immediate and 24-hours Delayed Catheter Removal Following Total Abdominal Hysterectomy||The University of Hong Kong|Yes|Completed|November 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|N/A|N/A|No|||August 2010|August 18, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01182714||117709|
NCT01183520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC017|Effect of High Omega-3 Fish Intake on Lipid Peroxidation|Effect of High Omega-3 Fish Intake on Lipid Peroxidation||USDA Grand Forks Human Nutrition Research Center|No|Completed|September 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 24, 2013|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183520||117648|
NCT01175512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL097973-01|Stress, Hormones, and Eating|Novel Interventions to Reduce Stress Induced Non-homeostatic Eating|SHE|University of California, San Francisco|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|44|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 7, 2013|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175512||118262|
NCT01175824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13493|Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies|Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone||Eli Lilly and Company|No|Completed|April 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|478|||Both|18 Years|75 Years|No|||January 2014|January 24, 2014|August 3, 2010|Yes|Yes||No|November 12, 2013|https://clinicaltrials.gov/show/NCT01175824||118238|
NCT01179789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/079/09|New E-Service for a Dietary Approach to the Elderly|Open Label, Randomized Study of the Impact of Diet on Gut Microbiota, Inflammageing and Oxidative Stress in Elderly People. Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene. German Part of a Multicentric European Study|RISTOMED|Charite University, Berlin, Germany|No|Completed|October 2009|June 2011|Actual|August 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|48|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01179789||117934|
NCT01175252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112368|Trends Over Time (1990-2010) of Diarrhoea-related Hospitalizations and Deaths in Children < 5 Years of Age in Brazil|Time Trend Analysis of Diarrhea-related Hospitalizations and Deaths in Children < 5 Years of Age in Brazil, 1990-2010||GlaxoSmithKline||Completed|December 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|5 Years|No|Non-Probability Sample|All children <5 years of age being hospitalized due to gastroenteritis between 1998 and        2010 and deceased due to gastroenteritis between 1990 and 2009 in Brazil.|November 2012|November 8, 2012|August 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175252||118282|
NCT01205880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1500|Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis|Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis||Emer, Jason, M.D.|Yes|Completed|December 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 20, 2010|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205880||115946|
NCT01205893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#REDCLN-178|Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA|Study to Confirm the Safety and Efficacy of the Reducer on Patients With Refractory Angina|COSIRA|Neovasc Inc.|Yes|Completed|September 2010|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01205893||115945|
NCT01206127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239-08/344c(REK)-1|DSAEK- Postoperative Positioning and Transplant Dislocation|DSAEK- Postoperative Positioning and Transplant Dislocation||Oslo University Hospital|No|Recruiting|September 2010|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2010|September 20, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206127||115927|
NCT01206426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-288-B|Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer|Identification of Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer||University of Chicago|Yes|Active, not recruiting|October 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood (germline) and tumor tissue samples will be used to perform genetic analysis. The      purpose of this analysis is to determine whether a set of "cisplatin susceptibility"      polymorphisms predict complete pathologic response to cisplatin-based chemotherapy and to      identify novel determinants which may predict response to cisplatin-based chemotherapy.      Samples will be biobanked for future analysis of genetic determinants.|Both|18 Years|89 Years|No|Probability Sample|Eligible patients who are about to begin neoadjuvant cisplatin‐based chemotherapy for        urothelial cancer and who have consented to IRB approved protocols #15550B and/or TRIDOM        (IRB #14104B).|January 2016|January 6, 2016|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01206426||115904|
NCT01194453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HANSOH20090601|Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer|A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study|AP/GP|Sun Yat-sen University|Yes|Completed|November 2009|August 2012|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|288|||Both|18 Years|75 Years|No|||November 2013|November 4, 2013|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01194453||116815|
NCT01194713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWAKE32920|Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics|Losing Sleep Over Alzheimer's Disease? Effects of Sleep Deprivation on Cerebrospinal Fluid Amyloid-beta Dynamics|AWAKE|University Medical Center Nijmegen||Completed|March 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194713||116795|
NCT01194726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2422PAIN|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2009|||||N/A|N/A|N/A||||||||||||||January 13, 2015|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194726||116794|
NCT01194739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-053|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2009|||||N/A|N/A|N/A||||||||||||||July 30, 2014|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194739||116793|
NCT01195077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dietary Algae and HIV|Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?|Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?|HIV|University of South Carolina|No|Completed|February 2003|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195077||116768|
NCT01195389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF #6178-P67865|Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease|A Randomized, Single-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety and Efficacy of the Application of Magnetic Fields Using the Resonator for the Treatment of Alzheimer's Disease in Addition to Standard of Care||pico-tesla Magnetic Therapies, LLC|Yes|Recruiting|December 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|N/A|No|||June 2011|July 7, 2011|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01195389||116744|
NCT01196520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910133|Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)|Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)||National Institutes of Health Clinical Center (CC)||Recruiting|May 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|6750|||Both|N/A|15 Years|Accepts Healthy Volunteers|||April 2015|May 8, 2015|September 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01196520||116659|
NCT01195987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-290|Immune Dysregulation in Hepatitis C Patients With or Without Arthritis|Immune Dysregulation in Hepatitis C Patients With or Without Arthritis||The Center for Rheumatic Disease, Allergy, & Immunology|No|Recruiting|June 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hepatitis positive patients with and without osteoarthritis, with a group of Hepatitis C        negative and no osteoarthritis to serve as controls.|September 2010|September 7, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195987||116700|
NCT01197664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 54110|Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery|A Pilot Study of Paricalcitol Synergism in Conjunction With Standard-of-Care Chemo-Radiation for Resectable Rectal Cancers||Comprehensive Cancer Center of Wake Forest University|No|Terminated|August 2010|April 2014|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|September 2, 2010||No|Study terminated due to funding issues|No||https://clinicaltrials.gov/show/NCT01197664||116571|
NCT01194297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25914|Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants|Immune Responses in Preterm and Full-Term Infants Following Live, Attenuated Influenza Vaccination||University of Rochester|No|Terminated|August 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3|||Both|24 Months|35 Months|Accepts Healthy Volunteers|||August 2014|August 4, 2014|August 31, 2010||No|Insufficient enrollment|No|July 1, 2013|https://clinicaltrials.gov/show/NCT01194297||116827|
NCT01182753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS.P.12C|Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base|Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base, Clinical Phase III Study|CSP12C|Heidelberg University|No|Recruiting|August 2010|August 2022|Anticipated|August 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|80 Years|No|||August 2010|August 16, 2010|August 12, 2010||||No||https://clinicaltrials.gov/show/NCT01182753||117706|
NCT01183013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1264.3|30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks|A Randomised, Double-blind Parallel Group Study to Compare the Efficacy and Safety of Initial Combination Therapy With Linagliptin 5 mg + Pioglitazone 15 mg, 30 mg, or 45 mg, vs. Monotherapy With Pioglitazone (15 mg, 30 mg, or 45 mg) or Linagliptin 5 mg Once Daily for 30 Weeks, Followed by a Blinded Trial Period on Linagliptin 5 mg + Pioglitazone 30 or 45 mg Versus Pioglitazone Monotherapy 30 or 45 mg or Linagliptin 5 mg for up to 54 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control on Diet and Exercise||Boehringer Ingelheim||Completed|August 2010|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|936|||Both|18 Years|80 Years|No|||October 2014|October 9, 2014|August 16, 2010||||No|March 12, 2014|https://clinicaltrials.gov/show/NCT01183013||117687|The study (Part B treatment only) was stopped early by protocol amendment #5, although Part A (time frame for all efficacy outcomes) proceeded to completion
NCT01183026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPECT|V/Q SPECT for Diagnosis of Pulmonary Embolism|Performance of V/Q SPECT for the Diagnosis of Pulmonary Embolism||University Hospital, Brest|No|Completed|January 2004|December 2006|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Pulmonary embolism suspicion|August 2010|August 16, 2010|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183026||117686|
NCT01183039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00209-46|Effects of Training in Healthy Sedentary Subjects|Cellular Effects of Training in Healthy Sedentary Subjects||5 Santé|Yes|Completed|May 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|50 Years|75 Years|No|||September 2012|September 3, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183039||117685|
NCT01175265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|Effects of Breathing Retraining in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effects of Breathing Retraining on Pulmonary Function, Exercise Capacity, Quality of Life and Cardiac Autonomic Function in Patients With COPD||University Hospital, Essen|Yes|Completed|November 2008|April 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|85 Years|No|||April 2010|August 3, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01175265||118281|
NCT01175278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15839|Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures|A Pilot Study of Vertebral Augmentation With Kyphoplasty Versus Nonsurgical Management in Multiple Myeloma Patients With Mildly Symptomatic Vertebral Body Compression Fractures||H. Lee Moffitt Cancer Center and Research Institute|Yes|Withdrawn|July 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|21 Years|N/A|No|||January 2012|January 11, 2012|August 3, 2010||No|No enrollment|No||https://clinicaltrials.gov/show/NCT01175278||118280|
NCT01175525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Treatment of Acute Stroke With Cromolyn(Single Dose)|||Wolfson Medical Center||Not yet recruiting||||||Phase 3|Interventional|Intervention Model: Parallel Assignment|2||||||Both|20 Years|90 Years|No|||August 2010|August 2, 2010|August 2, 2010||Yes||||https://clinicaltrials.gov/show/NCT01175525||118261|
NCT01176058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851023|A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis|A Phase Iiib, Open-label, Randomized, Multi-center Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole, In The Treatment Of Subjects With Candidemia And/or Other Forms Of Invasive Candidiasis||Pfizer|No|Terminated|December 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|17|||Both|18 Years|N/A|No|||August 2015|October 6, 2015|August 3, 2010|Yes|Yes|See termination reason in detailed description.|No|October 29, 2012|https://clinicaltrials.gov/show/NCT01176058||118220|Due to small enrollment, the per-protocol population was not determined, and analysis was performed on the mITT population.
NCT01176071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP 37367|Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis|An Observational Assessment of the Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome in the Setting of Invasive Aspergillosis in Patients With an Underlying Hematological Disorder||University Hospital, Gasthuisberg|No|Active, not recruiting|July 2010|January 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Probability Sample|hematology patients with proven or probable invasive aspergillosis|July 2010|August 4, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176071||118219|
NCT01205906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINT-100510|Comparison of an Internet-based Guided Self-help and a Group Therapy for Chronic Tinnitus|Comparison of the Efficacy of an Internet-based Self-help Training and a Well-established Outpatient Group Therapy for the Treatment of Chronic Tinnitus: A Randomized Controlled Trial|MINT|Johannes Gutenberg University Mainz|No|Completed|May 2010|March 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205906||115944|
NCT01198132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701068-524|A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly|A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing- Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly|CHOLINE|Merck KGaA|Yes|Completed|January 2010|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|129|||Both|18 Years|65 Years|No|||September 2015|September 8, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198132||116536|
NCT01193881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-01975|RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer|Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Terminated|August 2010|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01193881||116859|
NCT01193894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUPE2|Trial on Profermin and Fresubin in Ulcerative Colitis|A Randomized Trial on Profermin and Fresubin for Dietetic Treatment of Active Ulcerative Colitis|CUPE2|Nordisk Rebalance A/S|Yes|Completed|August 2010|December 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01193894||116858|
NCT01193907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01_04TP|Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)|A Phase 2, Randomized, Observer-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the Novartis Vaccines Institute for Global Health (NVGH) Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age||Novartis|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|88|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|September 1, 2010||No||No|March 6, 2012|https://clinicaltrials.gov/show/NCT01193907||116857|
NCT01194180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB023|A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A|A Phase 1 Study to Evaluate a BCG Challenge Model as a Method of Assessing Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A, Alone and in Combination||University of Oxford|Yes|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|August 29, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01194180||116836|
NCT01194466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Iowa 2031062|Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)|The Influence of TENS on Mucositis Pain and Function in Head and Neck Cancer Patients: A Randomized and Placebo-Controlled Double Blind Clinical Trial||University of Iowa|Yes|Active, not recruiting|May 2011|August 2015|Anticipated|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|90 Years|No|||May 2014|May 27, 2014|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194466||116814|
NCT01194765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL10-01|Distance-Based Cognitive-Behavioural Therapy for High Anxiety Sensitivity: A Randomized Controlled Trial|Distance-Based Cognitive-Behavioural Therapy for High Anxiety Sensitivity: A Randomized Controlled Trial||Dalhousie University|No|Completed|January 2011|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01194765||116791|
NCT01195090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09MMHIS047|Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea|Efficacy of Adding Sitagliptin or Pioglitazone to Patients With Type 2 Diabetes Insufficiently Controlled With Metformin and Sulfonylurea|JAS|Mackay Memorial Hospital|Yes|Completed|October 2009|April 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|20 Years|80 Years|No|||September 2012|September 9, 2012|September 2, 2010||No||No|April 18, 2012|https://clinicaltrials.gov/show/NCT01195090||116767|The reasons for withdrawal:lost to follow-up:2 in pioglitazone and 2 in sitagliptin protocol violation:4 in pioglitazone and 3 in sitagliptin edema:1 in pioglitazone, ALT >3 times ULN:1 in pioglitazone gastrointestinal events:1 in sitagliptin
NCT01195688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1279.1|Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1-700 mg) of BI 638683 Powder in Bottle (PiB) in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|September 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|63|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|September 3, 2010||||No||https://clinicaltrials.gov/show/NCT01195688||116721|
NCT01195714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH09-7B|Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years|PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOUSLY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA||The Lymphoma Academic Research Organisation|No|Completed|May 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|81 Years|N/A|No|||April 2015|April 7, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195714||116719|
NCT01195727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-079|Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter|Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter||Bristol-Myers Squibb|Yes|Terminated|July 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|8|||Both|12 Years|17 Years|No|||December 2012|December 27, 2012|September 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01195727||116718|
NCT01196832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/05|Role of Fibrocytes in Chronic Obstructive Pulmonary Disease|Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease|FIREBROB|University Hospital, Bordeaux|No|Recruiting|March 2011|November 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male or female aged more than 40 years          -  Chronic obstructive pulmonary disease (CODP) patients recruited during             hospitalization in Intensive care unit or as outpatients in the clinical             investigation centre of the CHU de Bordeaux.          -  Control group: subjects without any history of lung disease and with normal lung             function testing recruited following a normal lung function testing in the clinical             investigation centre of the CHU de Bordeaux.|October 2014|October 29, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01196832||116635|
NCT01196819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Target I|Randomized MicroPort's Firehawk DES Versus Xience V|A Prospective Multicenter Randomized Trial Assessing the Safety and Effectiveness of FIREHAWK BiodeGradable Polymer TArget Release Rapamycin-Eluting STent vs. XIENCE V Everolimus-Eluting Stent for the Treatment of Coronary Artery Disease: TARGET I Trial||Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Active, not recruiting|September 2010|September 2016|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|510|||Both|18 Years|75 Years|No|||April 2014|April 15, 2014|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01196819||116636|
NCT01194024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABA-MCTG-0004|Scoring System for Inhalation Injury|Burn Multicenter Proposal: Development of an Inhalation Injury Scoring System to Predict Severity of Inhalation Injury||American Burn Association|No|Enrolling by invitation|November 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|bronchioalveolar lavage specimens, blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Study population includes all patients admitted to a participating burn center and who are        intubated withing 24 hours of injury|July 2013|January 14, 2015|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194024||116848|
NCT01205763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98086|Evaluation of Effects of Clavicular Hook Plate on Subacromial Space|Evaluation of Effects of Clavicular Hook Plate on Subacromial Space||Taipei Medical University WanFang Hospital|No|Completed|December 2007|January 2009|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|N/A|N/A|No|Non-Probability Sample|The patient received surgical treatment for AC joint dislocation of unstable distal        clavicle fracture|September 2010|September 17, 2010|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205763||115955|
NCT01205997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12610000757011|Comparison of Postoperative Analgesic Effect of Intrathecal Magnesium and Fentanyl Added to Bupivacaine in Patients Undergoing Lower Limb Orthopedic Surgery|The Effects of Intrathecal Magnesium and Fentanyl Added to Bupivacaine on Postoperative Analgesic Requirement in Patients Undergoing Lower Limb Orthopedic Surgery||Qazvin University Of Medical Sciences|Yes|Completed|August 2010|January 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|20 Years|60 Years|No|||October 2012|October 10, 2012|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205997||115937|
NCT01178970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OU IRB 14759|The Effects of Lower Body Resistance Training on Balance and Fall Prevention in the Elderly|The Effects of Lower Body Resistance Training on Balance and Fall Prevention in the Elderly||University of Oklahoma|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment|||Actual|25|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 9, 2010|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01178970||117997|
NCT01179243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 702|Prevalence of Microcirculatory Alterations in Intensive Care Patients|Observation of the Prevalence of Sublingual Microcirculatory Alterations With SDF Imaging in Intensive Care Patients||Medical Centre Leeuwarden|No|Completed|September 2011|May 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|intensive care patients|October 2012|October 31, 2012|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01179243||117976|
NCT01183052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00426-51|Mitochondrial Dysfunction and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD) Patients|Mitochondrial Respiratory Chain and Peripheral Muscle Dysfunction in COPD Patients||5 Santé|Yes|Completed|June 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|50 Years|75 Years|No|||September 2012|September 3, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183052||117684|
NCT01179256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|curcumin|Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma|Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma|CURCUMIN|University of South Florida|Yes|Completed|March 2009|March 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|60 Years|No|||August 2009|August 10, 2010|August 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01179256||117975|
NCT01175291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16145|FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer|Randomized, Double Blind Phase II Study of FOLFOX/Bevacizumab Combined With MK-0646 Versus FOLFOX/Bevacizumab Combined With Placebo in First-Line Treatment of Metastatic Colorectal Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Withdrawn|September 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|August 2, 2010|Yes|Yes|treatment deemed ineffective so accrual was closed|No||https://clinicaltrials.gov/show/NCT01175291||118279|
NCT01179503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG029364-03S1|Vitamin D Supplementation and Physical Function in Older Adults|Vitamin D Supplementation, Skeletal Muscle Gene Expression, and Physical Performance in Older Adults||Wake Forest School of Medicine|Yes|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|70 Years|89 Years|Accepts Healthy Volunteers|||February 2011|August 3, 2011|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179503||117956|
NCT01179516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_317|Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder||Takeda|No|Completed|August 2010|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|469|||Both|18 Years|75 Years|No|||October 2013|October 25, 2013|August 9, 2010|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01179516||117955|
NCT01175850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P990|Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease|Randomized Trial of IN.PACT Admiral(TM) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease|INPACT SFA I|Medtronic Endovascular|Yes|Active, not recruiting|September 2010|June 2016|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|85 Years|No|||January 2016|January 25, 2016|August 3, 2010||No||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01175850||118236|
NCT01175538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS001|Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis|Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose||Govind Ballabh Pant Hospital|Yes|Recruiting|January 2008|September 2010|Anticipated|June 2010|Anticipated|Phase 4|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|70 Years|No|||October 2009|August 4, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175538||118260|
NCT01197846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00079|Efficacy of Quetiapine XR Versus Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder|Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder||Centro de Investigación Biomédica en Red de Salud Mental|No|Completed|September 2010|July 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||September 2012|September 18, 2012|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01197846||116557|
NCT01197859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCSH-1901|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2008|||||N/A|N/A|N/A||||||||||||||September 9, 2010|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01197859||116556|
NCT01193920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_08|Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age|A Phase Ib/II Randomized, Observer-Blind, Controlled, Single Centre Study of a Trivalent Group B Streptococcus Vaccine in Healthy Non-Pregnant Women Leading Into a Dose-Ranging Study in Pregnant Women in South Africa||Novartis||Completed|October 2010|December 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|380|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|September 1, 2010||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01193920||116856|
NCT01193933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL-2009|Multicenter Clinical Trial for Adult Ph-negative ALL. Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity|Multicenter Clinical Trial for Adult Ph-negative ALL. Evaluation of the Impact of the Prolonged L-asparaginase Therapy During Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity.||National Research Center for Hematology, Russia|No|Recruiting|November 2008|December 2014|Anticipated|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|15 Years|55 Years|No|||April 2014|April 4, 2014|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193933||116855|
NCT01194193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1600C00002|Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of the m-Tor Kinase Inhibitor AZD8055 Using Intermittent Dosing Schedules in Patients With Advanced Solid Malignancies and Lymphomas||AstraZeneca|No|Withdrawn||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|August 18, 2010|No|Yes|Amendment to study compound development programme|No||https://clinicaltrials.gov/show/NCT01194193||116835|
NCT01195103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000721|Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery|A Prospective Randomized Study to Assess the Efficacy and Safety of Bolus-dose Lusedra (Fospropofol Disodium) 6.5 mg/kg or 10 mg/kg Versus a Placebo (With Midazolam Rescue) for Minimal-to-moderate Sedation in Patients Undergoing Procedural Sedation for Regional Anesthesia Blocks Prior to Orthopedic Surgery||Mayo Clinic|No|Terminated|February 2011|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|85 Years|No|||June 2012|June 25, 2012|September 1, 2010|Yes|Yes|Funding terminated by funding source.|No|February 27, 2012|https://clinicaltrials.gov/show/NCT01195103||116766|The study was terminated early because funding was terminated by the funding source.
NCT01195402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR-01|Ambulatory Interdisciplinary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)|Low Intensity Pulmonary Outpatient Rehabilitation in Moderate to Severe COPD|AIR|Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2004|February 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|80 Years|No|||September 2010|September 3, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195402||116743|
NCT01196533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMIL-MHUS-V1.0|A Comparative Clinical Trial to Assess the Accuracy of the TensorTip, a Novel Non Invasive Device for the Measurement of Physiological Parameters and Blood Parameters|A Comparative Clinical Trial to Assess the Accuracy of the TensorTip, a Novel Non Invasive Device for the Measurement of Physiological and Blood Chemistry Parameters||Cnoga Medical Ltd.|No|Completed|August 2010|August 2014|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Actual|94|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|February 8, 2015|August 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196533||116658|
NCT01196546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237ATH01|Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)|Multi-center, Open-label, 24-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin 50/500 or 50/1000 mg Twice Daily in Patients With T2DM Inadequately Controlled With Metformin||Novartis||Completed|March 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|August 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01196546||116657|
NCT01197157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEAR trial|Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients|Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients With Genotype 4: A Placebo-controlled Randomized Trial||National Liver Institute, Egypt|Yes|Completed|September 2010|April 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|60 Years|No|||September 2014|September 27, 2014|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01197157||116610|
NCT01197144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR20100114|Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab|Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)|PARADE|Karolinska Institutet|No|Recruiting|October 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|September 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01197144||116611|
NCT01197378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP103-04|Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)|A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis||Raptor Pharmaceuticals Inc.|No|Active, not recruiting|August 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|N/A|N/A|No|||June 2015|January 28, 2016|September 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01197378||116593|
NCT01205776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-389|EXCEL Clinical Trial|Evaluation of XIENCE PRIME™ Everolimus Eluting Stent System (EECSS) or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization|EXCEL|Abbott Vascular|Yes|Active, not recruiting|September 2010|December 2019|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1905|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205776||115954|
NCT01205789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-389 UR|EXCEL Clinical Trial (Universal Registry)||EXCEL|Abbott Vascular|Yes|Completed|October 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 1000 consecutive subjects enrolled which includes approximately 100        consecutive subjects with intermediate lesions|November 2012|November 30, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01205789||115953|
NCT01206010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qmul010610|Tailoring Varenicline to Individual Needs (TVIN Study)|Effects of a Tailored Dose of Varenicline on Post-quitting Urges to Smoke|TVIN|Queen Mary University of London|No|Completed|July 2011|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 24, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01206010||115936|
NCT01178983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7334-RP-CTIL|Efficacy of Telerehabilitation Intervention Program Using Telebiofeedback Among Computer Operators|||Sheba Medical Center|No|Recruiting|August 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 20, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178983||117996|
NCT01179269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202499|Stage IIIB/IV Non-Small Cell Lung Cancer|Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer||Loyola University|Yes|Recruiting|June 2011|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|August 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179269||117974|
NCT01175863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAVOR|Fractional Flow Reserve (FFR) Versus Intravascular Ultrasound (IVUS) in Intermediate Coronary Artery Disease|Fractional Flow Reserve- And Intra-vascular Ultrasound-Guided Percutaneous Coronary Intervention With Drug-Eluting Stents in Intermediate Coronary Artery Lesion (FAVOR Study)|FAVOR|Ajou University School of Medicine|Yes|Terminated|February 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|75 Years|No|||February 2014|February 11, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175863||118235|
NCT01175551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810707|Direct Measurements of Cervical Remodeling for Predicting Preterm Birth|Direct Measurements of Cervical Remodeling for Predicting Preterm Birth||University of Pennsylvania|No|Completed|November 2009|May 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1207|Samples With DNA|maternal serum, maternal cervical vaginal fluid|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All pregnant women screened at Penn OB/GYN Associates or Helen O. Dickens Center at less        than 18 weeks gestational age with a documented singleton pregnancy who agree to        participate in the study (group 1); Nulliparous women (no previous pregnancy greater than        15 weeks)less than 18 weeks gestational age (group 2)|January 2014|January 6, 2014|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01175551||118259|
NCT01176383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPCRU1|Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers|A Protocol for an Randomised Controlled Trial of Smoking Cessation Success Rate With or Without a Genetic Test, "Respiragene", to Assess Lung Cancer Risk - an Exploratory Study||Sussex NHS Research Consortium|Yes|Completed|September 2011|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|67|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01176383||118195|
NCT01176110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMI101|Thermal Management in Patients With Interventional Minimally Invasive Valve Replacement|A Randomized Pilot Study for Thermal Management in Patients With Interventional Minimally Invasive Valve Replacement|TIMI|Charite University, Berlin, Germany|Yes|Completed|July 2010|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2010|May 18, 2011|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01176110||118216|
NCT01176370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 02977 Rev - B|The Purpose of the Study is to Evaluate Whether the Use of C-Pulse™ as Treatment for Patients in Moderate to Severe Heart Failure (HF) is Associated With Reasonable Assurance of Safety and Performance|A Prospective Study to Assess the Safety and Indications of Performance of the C-Pulse™ System in Relieving Heart Failure Symptoms in Patients With ACC/AHA Stage C, NYHA Class III-ambulatory Class IV Heart Failure.||Sunshine Heart Inc.|Yes|Active, not recruiting|March 2010|October 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||March 2015|March 31, 2015|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176370||118196|
NCT01198145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N08C9|Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy|Phase III, Randomized, Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|April 2011|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198145||116535|
NCT01194206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3209|Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant|Downstaging of Hepatocellular Carcinoma by Stereotactic Body Radiotherapy for Non-Resectable and Non-Transplantable Tumors: Phase 2 Study||Case Comprehensive Cancer Center|Yes|Withdrawn|August 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||April 2012|April 17, 2012|September 1, 2010|Yes|Yes|Study being rewritten|No||https://clinicaltrials.gov/show/NCT01194206||116834|
NCT01194219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-008|Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis|ESTEEM 1|Celgene|No|Active, not recruiting|September 2010|October 2016|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|844|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|August 31, 2010|Yes|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01194219||116833|
NCT01194479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1005006832|Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.|The Effect of the Beta 2 Agonist, Formoterol, on Recovery From Hypoglycemia||Yale University|No|Recruiting|August 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|55 Years|No|||June 2013|June 27, 2013|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194479||116813|
NCT01194752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-071|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2009|||||N/A|N/A|N/A||||||||||||||December 22, 2010|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194752||116792|
NCT01196247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU2C-001|A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer|Stand Up to Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated With Metastatic Pancreatic Cancer||Translational Drug Development|No|Completed|September 2010|February 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196247||116680|
NCT01196845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-CHUG-25|Inflammation and Oxidative Stress of Adipose Tissue in Sleep Apnea Syndrome|Inflammation and Oxidative Stress of Adipose Tissue in Obese and Non-obese Patients Having Sleep Apnea Syndrome|ADISAS|University Hospital, Grenoble|No|Recruiting|July 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|80|||Male|18 Years|69 Years|No|||August 2015|August 19, 2015|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01196845||116634|
NCT01197950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136-08|Acupuncture to Reduce Labour Pain|A Randomized Controlled Trial of Acupuncture to Reduce Labour Pain||University of Skövde|No|Completed|October 2008|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|303|||Female|N/A|N/A|No|||February 2012|February 3, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01197950||116549|
NCT01197391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R728-CL-0915|Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneous REGN 728 in Healthy Volunteers||Regeneron Pharmaceuticals|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 9, 2012|August 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01197391||116592|
NCT01205802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHV_Goretex_LDLT|Usability of Ringed Polytetrafluoroethylene Graft for Venous Vascular Reconstruction of Living Donor Liver Transplantation|Prospective Study on Usability of Ringed Polytetrafluoroethylene Graft for Venous Vascular Reconstruction of Living Donor Liver Transplantation|MHVLDLT|Asan Medical Center|No|Enrolling by invitation|August 2010|July 2012|Anticipated|July 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||September 2010|September 20, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01205802||115952|
NCT01178723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC10JW0080CTIL|The Effects of Breakfast Size on Hormonal Profile in Adults With Type 2 Diabetes Mellitus|||Wolfson Medical Center|Yes|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|48|||Both|30 Years|70 Years|No|||August 2010|August 8, 2010|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178723||118016|
NCT01178996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST1472-DM-03-004|Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.|A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + Peginterferon Alpha-2a Plus Ribavirin With Peginterferon Alpha-2a + Ribavirin + Placebo||sigma-tau i.f.r. S.p.A.|No|Completed|December 2004|July 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|552|||Both|18 Years|70 Years|No|||August 2010|August 9, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178996||117995|
NCT01179009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0000|Treatment Resistant Depression (Pilot)|A Safe Ketamine-Based Therapy for Treatment Resistant Depression||Washington University School of Medicine|Yes|Recruiting|April 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|August 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179009||117994|
NCT01179282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|intradermal positive dust mite|Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients|Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients.|DUSTMITE|University of South Florida|No|Completed|June 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179282||117973|
NCT01179529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMBITIOUS|Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage|Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair®) Treatment in Atopic Dermatitis|AMB-WEI-1052-I|Technische Universität München|No|Completed||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Both|18 Years|70 Years|No|||January 2012|January 9, 2012|August 2, 2010||||No||https://clinicaltrials.gov/show/NCT01179529||117954|
NCT01179542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc10134-2010ctil|The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR|The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR.||Meir Medical Center|No|Not yet recruiting|September 2010|||October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Only the Placenta aftr delivery or abortion|August 2010|August 10, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179542||117953|
NCT01175590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|631|Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle|A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days||Bausch & Lomb Incorporated|No|Completed|June 2010|February 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|518|||Both|1 Year|N/A|No|||March 2013|March 19, 2013|August 3, 2010|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01175590||118256|
NCT01176123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00366|Cognitive Behavioral Therapy for Trauma-Related Insomnia in Veterans|Comparing Telemedicine to In Person Delivery of Cognitive Behavioral Therapy for Trauma-Related Insomnia in Rural Veterans|CBT-I Telemed|Southeast Louisiana Veterans Health Care System|No|Not yet recruiting||||||N/A|Interventional|Primary Purpose: Treatment|2||||||Both|N/A|N/A|No|||August 2010|August 4, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176123||118215|
NCT01176136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0479|Organizational Skills Interventions for Children With Attention Deficit Hyperactivity Disorder (ADHD)|Organizational Skills Interventions for Children With ADHD||Children's Hospital Medical Center, Cincinnati|Yes|Completed|September 2010|June 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|11 Years|15 Years|No|||July 2013|July 29, 2013|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01176136||118214|
NCT01176149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSES-01|Role Of Self-monitoring of Blood Glucose and Intensive Education in Patients With Type 2 Diabetes Not Receiving Insulin|Role Of Self-monitoring of Blood Glucose and Intensive Education in Patients With Type 2 Diabetes Not Receiving Insulin: a Pilot Study|ROSES|Consorzio Mario Negri Sud|No|Completed|March 2007|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|45 Years|75 Years|No|||August 2010|August 5, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176149||118213|
NCT01176396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF A113385|CAMBRA - PBRN Caries Management By Risk Assessment In A Practice-Based Research Network|CAMBRA - PBRN Caries Management By Risk Assessment In A Practice-Based Research Network|CAMBRA-PBRN|University of California, San Francisco|No|Recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|900|||Both|12 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176396||118194|
NCT01176708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transplant isoglycemia (AP)|Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion|The Significance of Intact Liver Innervation for the Glucose and GLP-1 Induced Insulin Secretion||University Hospital, Gentofte, Copenhagen|No|Recruiting|July 2009|December 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 5, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176708||118170|
NCT01193946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001008857|Assessment of Dietary Protein Needs of Older Women|Assessment of Dietary Protein Needs of Older Women||Purdue University|No|Completed|May 2010|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples With DNA|plasma samples|Female|80 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Female Age range: 80 yrs and older Body mass index between 22-30 Weight stable 4.5 kg        weight gain or loss within the last 6 month Non-smoking within the last 6 month Ambulatory        Clinically normal blood profiles within 10% of clinical normalcy. No diseases or not        taking medications known to influence protein or energy metabolism, Willingness and        ability to consume food provided and not allergic to phenylalanine|January 2013|January 16, 2013|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01193946||116854|
NCT01194492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018529-21|Albumin Kinetics in Generalized Inflammation|Albumin Kinetics in Generalized Inflammation - an Exploratory Study on Patients Before and After Major Abdominal Surgery||Karolinska Institutet|Yes|Completed|September 2010|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|40 Years|N/A|No|||February 2014|February 17, 2014|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01194492||116812|
NCT01194778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-078|Comparison of Efficacy of Different Dosages Vitamin K2|Comparison of Efficacy of Different Dosages Vitamin K2||Maastricht University Medical Center|No|Completed|October 2009|August 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|82|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 2, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01194778||116790|
NCT01196026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114451|Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™|Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine Fluarix™ in Children Previously Vaccinated With GSK Biologicals' H1N1 Vaccine Pandemrix™||GlaxoSmithKline||Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|162|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||October 2012|January 31, 2013|September 3, 2010|Yes|Yes||No|March 12, 2012|https://clinicaltrials.gov/show/NCT01196026||116697|
NCT01196000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07158|Laparoscopic Surgery or Robotic-Assisted Laparoscopic Surgery in Treating Patients With Rectal Cancer That Can Be Removed By Surgery|Laparoscopic Versus Robotic-Assisted Surgery for Rectal Cancer||City of Hope Medical Center|Yes|Withdrawn|December 2011|||July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|September 3, 2010|No|Yes|The study has never been opened to accrual at COH. Study to be closed at COH due to the lack    of qualified robotic colorectal surgeons.|No||https://clinicaltrials.gov/show/NCT01196000||116699|
NCT01196013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO05908|A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia|A Phase I, Open-label, Multi-center Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia||Sanofi|Yes|Completed|August 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|1 Year|21 Years|No|||March 2014|March 17, 2014|September 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01196013||116698|
NCT01196559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG GY10-10|Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer|A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma.||The Catholic University of Korea|Yes|Completed|January 2011|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|20 Years|75 Years|No|||February 2015|February 14, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196559||116656|
NCT01196572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7897-ZD-CTIL|Efficiency of Cold vs. Laser Internal Urethrotomy Treatment of Urethral Strictures|Cold vs. Laser Internal Urethrotomy Treatment of Urethral Strictures|IU|Sheba Medical Center|No|Recruiting|September 2010|September 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|N/A|No|||August 2011|August 7, 2011|September 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01196572||116655|
NCT01197170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0504|Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance|Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance||M.D. Anderson Cancer Center|No|Recruiting|September 2010|||September 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|281|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|September 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01197170||116609|
NCT01197677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Euro CMR|European CMR Registry|European Cardiovascular Magnetic Resonance Registry||Stiftung Institut fuer Herzinfarktforschung|No|Active, not recruiting|April 2009|April 2012|Anticipated|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20000|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients undergoing CMR (enrolled into the "European clinical practice"-part        of the registry Consecutive patients with suspected coronary artery disease or with        hypertrophic cardiomyopathy (enrolled into the specific protocols "suspected-CAD" or        "HCM-SCD").|September 2010|September 7, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197677||116570|
NCT01205217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113957|Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer|Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer.|ELATE|GlaxoSmithKline|No|Withdrawn|December 2010|December 2010|Anticipated|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||February 2012|March 1, 2012|September 17, 2010|Yes|Yes|Data presented at SABCS 2010 showing that dual blockade is superior to monotherapy|No||https://clinicaltrials.gov/show/NCT01205217||115997|
NCT01205477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE09-009|Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment|Phase 2 Double-blinded, Placebo-controlled, Clinical Trial for Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment||Universidad Autonoma de Nuevo Leon|Yes|Completed|September 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|90 Years|No|||June 2009|September 17, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01205477||115977|
NCT01193712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL26963.060.09|Endocardial Pacing in On-table Non-responders in Cardiac Resynchronization Therapy|Non-Responders in Cardiac Resynchronization Therapy||Catharina Ziekenhuis Eindhoven|No|Withdrawn|August 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|August 25, 2010||No|too limited number of eligible patients|No||https://clinicaltrials.gov/show/NCT01193712||116872|
NCT01202799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV05100070|Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel|A Phase 1, Randomized, Single Center, Open-Label, Multiple-Dose, Three-Way Crossover Study to Evaluate the Pharmacokinetics, Bioavailability and Safety of PENNSAID Gel in Comparison With Sandoz 75 mg Diclofenac Sodium Delayed Release Tablet and PENNSAID (Diclofenac Sodium Topical Solution) in Healthy Volunteers||Mallinckrodt|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|September 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202799||116180|
NCT01202812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10F.161|A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)|Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)||Thomas Jefferson University|Yes|Not yet recruiting|October 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|10 Years|19 Years|No|||October 2010|October 22, 2010|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202812||116179|
NCT01178736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCF-2011-BRA-IND-CAM|Early Detection of Cancers in Low Resource Countries|Efficacy of a Combined Program for Early Detection of Breast and Gynecological Cancers in Low Resource Countries||Woman's Cancer Foundation|No|Not yet recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|36000|||Female|30 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Brazil has two rural hospitals serving a population of roughly 46,000 people (Nova        Andradina) inside Mato Grosso do Sul, which has a population of over 2 million. Cambodia        has a population of over 1 million inside the Phnom Penh metropolitan area. India has a        population of more than 1.3 million inside the state of Goa. According to the NFHS-2,        nearly 30 percent of rural Goan women live 10 or more kilometers away from a primary        health center.|August 2010|August 8, 2010|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01178736||118015|
NCT01175304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)40/2009|Study of Sleep Habits and Prevalence of Sleepiness in a Health Care Environment in Barcelona|Study of Sleep Habits and Prevalence of Sleepiness in a Health Care Environment in Barcelona||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|500|||Both|18 Years|65 Years|No|Non-Probability Sample|Community sample of 500 consecutive tertiary hospital workers in the city of Barcelona        (Spain), attending annual checkups at the Hospital's medical department.|July 2011|July 4, 2011|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01175304||118278|
NCT01175317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-2-089|Improvement of Fluid Balance in Patients Undergoing Surgery of the Colon and Rectum|Does Hemodynamic Optimization During and After Colorectal Surgery Result in Improved Intestinal Perfusion, Sustained Intestinal Barrier and Improved Postoperative Recovery?|HOC|Maastricht University Medical Center|Yes|Completed|April 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|July 29, 2010||No||No|November 5, 2013|https://clinicaltrials.gov/show/NCT01175317||118277|Tolerance of esophageal Doppler probe postoperatively was low. Therefore, optimization based on cardiac output could only be achieved within 3 hours in most patients.
NCT01175564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4131C00002|To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects|A Phase I, Single Centre, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose and Multiple Doses of TC-5214 (S-Mecamylamine) in Healthy Male Japanese Subjects||AstraZeneca|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|July 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175564||118258|
NCT01175577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP|Feeding the Rainbow to Investigate Endothelial Dysfunction|Evaluating the Effects of Mixed-Carotenoids on Biomarkers of Endothelial Dysfunction|FRIED|Bastyr University|No|Completed|October 2009|August 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175577||118257|
NCT01175889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE MS 1|Megadyne Ace Incision/Dissection Study|Megadyne ACE Incision/Dissection Study|ACE|Megadyne Medical Products Inc.|No|Active, not recruiting|August 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|60 Years|No|||October 2012|October 24, 2012|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175889||118233|
NCT01176422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12016|Telomere and Telomerase|Telomere and Telomerase||University of Kansas Medical Center|No|Terminated|September 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|Two teaspoons of blood will be collected - one teaspoon before subject begins treatment for      disease and one teaspoon will be collected when subject completes treatment.|Both|18 Years|N/A|No|Probability Sample|Patients will be selected from the BMT/Hematology clinic in the Cancer Center.|October 2011|October 14, 2011|August 3, 2010||No|lack of resources; no patient enrollment|No||https://clinicaltrials.gov/show/NCT01176422||118192|
NCT01175876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC2010|The Effect Of Remote Limb Ischemic Preconditioning For Carotid Artery Stenting|The Effect Of Remote Limb Ischemic Preconditioning For Carotid Artery Stenting||Capital Medical University|Yes|Recruiting|July 2010|||December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|80 Years|No|||August 2010|August 5, 2010|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175876||118234|
NCT01176409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALIANT-001|Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?|VALacyclovir for Inflammation AttenuatioN Trial Pilot (VALIANT Pilot)|VALIANT Pilot|University Health Network, Toronto|No|Recruiting|September 2010|September 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||December 2010|December 22, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176409||118193|
NCT01176721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02VNS2009|Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia|Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia: a Randomized, Controlled, Double Blind, Two-armed Clinical Trial|02VNS2009|cerbomed GmbH|Yes|Completed|March 2010|February 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||September 2012|September 11, 2012|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176721||118169|
NCT01176968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6141116|Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction|A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction|REMINDER|Pfizer|Yes|Completed|September 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1013|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176968||118150|
NCT01194232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-2067|Sildenafil Trial in Children and Young Adults With CF|Randomized Controlled Study of Sildenafil in Children and Young Adults With Mild to Moderate Cystic Fibrosis Lung Disease||Children's Hospital Medical Center, Cincinnati|Yes|Withdrawn|August 2012|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|8 Years|21 Years|No|||December 2012|December 10, 2012|September 1, 2010|Yes|Yes|Funding, MedWatch change to study drug|No||https://clinicaltrials.gov/show/NCT01194232||116832|
NCT01195129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13861|HydroCoil Cerebral Aneurysm Treatment Trial|HydroCoil Cerebral Aneurysm Treatment Trial|HCAT|University of Virginia|Yes|Terminated|December 2008|June 2015|Anticipated|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|21 Years|90 Years|No|||December 2014|December 11, 2014|September 2, 2010||No|Due to results shown by the Cerecyte Clinical Trial, HCAT stopped enrolling.|No||https://clinicaltrials.gov/show/NCT01195129||116764|
NCT01195740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006296|Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters|Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters||Children's Hospital of Philadelphia|No|Completed|July 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|17 Years|No|||December 2012|December 13, 2012|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195740||116717|
NCT01196039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP4843g|A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma||Genentech, Inc.||Completed|December 2010|January 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196039||116696|
NCT01196052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO22857|A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer|A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Cancer||Hoffmann-La Roche||Completed|October 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|September 3, 2010|Yes|Yes||No|May 27, 2014|https://clinicaltrials.gov/show/NCT01196052||116695|
NCT01196260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dake Chu-200401|Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III|Clinical Trial on Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III Among Chinese Population||State Key Laboratory of Cancer Biology|Yes|Recruiting|January 2004|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|8000|||Both|18 Years|90 Years|No|||October 2014|October 10, 2014|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196260||116679|
NCT01196273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-4085|Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up|HIV-HEART STUDY: A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk in HIV-infected Patients||University Hospital, Essen|Yes|Completed|December 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1424|Samples Without DNA|Stored blood samples|Both|18 Years|N/A|No|Non-Probability Sample|The study population included outpatients who were at least 18 years of age, had a known        HIV-infection and exhibited a stable disease status within 4 weeks before inclusion of the        trial. Written informed consent was obtained from all participants.|September 2010|June 27, 2012|May 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01196273||116678|
NCT01197404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR011906|Affect Management for Early Adolescents|Affect Management Intervention for Early Adolescents With Mental Health Problems||Rhode Island Hospital|No|Completed|August 2009|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|420|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197404||116591|
NCT01204593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_R_05033|baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus|Phase IV, Multicenter, International, Non-comparative, Open Label Study of Efficacy and Safety of Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in Patients With T1 Diabetes Previously Uncontrolled on Any Insulin Regimen.|SUBSTITUTE|Sanofi|No|Completed|November 2010|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|206|||Both|18 Years|60 Years|No|||March 2014|March 14, 2014|September 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01204593||116044|
NCT01204905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045769|R5 Integrase Study in HIV-1 Naive Patients|Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naïve HIV-1 Infected Patients||University of Maryland|Yes|Recruiting|September 2010|September 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||November 2012|November 8, 2012|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204905||116020|
NCT01204918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC#0903004917|Efficacy and Tolerability of Riluzole in Treatment Resistant Depression|Efficacy and Tolerability of Riluzole in Treatment Resistant Depression||Yale University|Yes|Active, not recruiting|June 2011|August 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||January 2014|February 2, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204918||116019|
NCT01205230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113971|VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK|An Open-Label Study to Evaluate the Effects of Ketoconazole and the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Repeat Doses of Pazopanib in Subjects With Solid Tumor Malignancies||GlaxoSmithKline|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|August 12, 2010|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01205230||115996|
NCT01205243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114382|ZIAGEN® Post-marketing Surveillance|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ZIAGEN® Administered in Korean Patients According to the Prescribing Information||ViiV Healthcare|No|Completed|November 2010|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|671|||Both|N/A|N/A|No|Probability Sample|Patients administrated ZIAGEN® at the site|September 2015|September 21, 2015|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205243||115995|
NCT01205490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102026|Changes in Cerebral Blood Flow With Spinal Manipulative Therapy vs. Voluntary Motion|Changes in Cerebral Blood Flow With Spinal Manipulative Therapy vs. Voluntary Motion||Canadian Memorial Chiropractic College||Not yet recruiting|July 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|||Anticipated|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205490||115976|
NCT01203332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 096|Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults|Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults||Westat|No|Completed|July 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||3|Actual|1917|||Both|13 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescent and young adult Hispanic/Latino MSM and heterosexual men and women, aged 13-24        years, who meet all eligibility requirements for enrollment into the AVT or SSNIT        component of the study.|March 2016|March 3, 2016|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203332||116140|
NCT01203592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004529|Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes|Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes||Mayo Clinic|No|Completed|September 2010|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|2 Years|N/A|No|||December 2015|December 31, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203592||116120|
NCT01179555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURE-1837|Confronting Unequal Eye Care in Pennsylvania|Confronting Unequal Eye Care in Pennsylvania||Wills Eye|Yes|Active, not recruiting|October 2010|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|206|||Both|65 Years|N/A|No|||November 2013|November 26, 2013|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179555||117952|
NCT01179568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5971|A Study of Medication With or Without Psychotherapy for Complicated Grief|Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL)|HEAL|New York State Psychiatric Institute|Yes|Completed|March 2010|July 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|395|||Both|18 Years|95 Years|No|||February 2015|August 27, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01179568||117951|
NCT01175330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAFPAF-042|Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting|Randomized Trial of Fish Oil Infusion to Prevent Atrial Fibrillation After Cardiac Surgery||Meshalkin Research Institute of Pathology of Circulation|Yes|Terminated|August 2010|August 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||March 2015|March 23, 2015|August 3, 2010||No|Interim analysis did not reveal of anticipated benefits of intervention|No||https://clinicaltrials.gov/show/NCT01175330||118276|
NCT01176760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Truncated isoglycemia|Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects|The Significances of Intact Vagal Innervation for the Glucose and GLP1 Induced Insulin Secretion||University Hospital, Gentofte, Copenhagen|No|Active, not recruiting|August 2009|December 2012|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176760||118166|
NCT01176773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S15-002|Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancement|||Allergan||Completed|August 2010|January 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|October 6, 2014|March 23, 2010|Yes|Yes||No|June 7, 2012|https://clinicaltrials.gov/show/NCT01176773||118165|
NCT01176162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081211|Aldosterone Resistance in Preterm Infants|PREMALDO : Aldosterone Resistance in Preterm Infants : Assessment by a Non Invasive Measurement of Urinary Aldosterone|PREMALDO|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2010|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|170|Samples Without DNA|-  Urinary samples will be collected onto a gauze compress, during the first 24 hours of           life, at day three, and at 1, 3, 6 and 12 months.        -  A blood sample will be obtained from systematic umbilical cord blood collection at           birth and during the Guthrie test at day three|Both|24 Weeks|41 Weeks|No|Non-Probability Sample|Every newborn without congenital malformation will be included, after written parental        consent was obtained|April 2014|April 28, 2014|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01176162||118212|
NCT01177007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J09150, NA_00035790|Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors|Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|August 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01177007||118147|
NCT01177358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX-001|Botox in the Healing of Surgical Wounds of the Neck|Botulinum Toxin A in the Healing of Surgical Wounds of the Neck: a Randomized, Prospective, Placebo-controlled Trial||Nova Scotia Health Authority|No|Recruiting|September 2011|July 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|September 15, 2014|July 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177358||118120|
NCT01176734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cMPsTIN01|The Treatment of Tinnitus With Transcutaneous Non-invasive Vagus Nerve Stimulation|The Treatment of Tinnitus With Transcutaneous Non-invasive Vagus Nerve stimulation-a Controlled Randomized Pilot Study Assessing Safety, Compatibility and Clinical Performance||cerbomed GmbH|No|Completed|January 2010|March 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||April 2013|April 29, 2013|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176734||118168|
NCT01176747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0815-PR-0011|Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients|In-vivo Deposition Measurement of Beclometasone and Formoterol After Inhalation of a Single Dose of the Combination BDP Plus Formoterol NEXT DPI in Healthy Volunteers, Asthmatic and COPD Patients.||Chiesi Farmaceutici S.p.A.|No|Completed|August 2010|October 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2011|April 13, 2011|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176747||118167|
NCT01195415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03746|Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer|Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine||National Cancer Institute (NCI)|Yes|Active, not recruiting|June 2010|||July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||April 2015|September 9, 2015|September 2, 2010|Yes|Yes||No|September 9, 2015|https://clinicaltrials.gov/show/NCT01195415||116742|
NCT01195753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD05|Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders|Open, Prospective, Historic-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Infusion of Liver Cell Suspension (HHLivC) in Children With Urea Cycle Disorders.||Cytonet GmbH & Co. KG|Yes|Terminated|December 2010|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|5 Years|No|||February 2016|February 5, 2016|March 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01195753||116716|
NCT01196585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082010/2|Ultrasonography Guided Pleural Biopsy Versus Computed Tomography Guided Pleural Biopsy|ULTRASONOGRAPHY GUIDED PLEURAL NEEDLE BIOPSY VERSUS COMPUTED TOMOGRAPHY GUIDED ABRAMS PLEURAL NEEDLE BIOPSY FOR DIAGNOSIS OF PATIENTS WITH PLEURAL EFFUSIONS: A RANDOMIZED CONTROLLED TRIAL||Eskisehir Osmangazi University|Yes|Completed|April 2009|April 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|20 Years|85 Years|No|||September 2010|May 16, 2011|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01196585||116654|
NCT01196598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1978/07|Pelvic Floor Muscle Training and Hypopressive Exercises for Pelvic Organ Prolapse|Impact of Pelvic Floor Muscle Training and Hypopressive Exercises in Women With Pelvic Organ Prolapse: Randomized Controlled Trial||Federal University of São Paulo|No|Active, not recruiting|January 2008|January 2011|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|84|||Female|40 Years|70 Years|No|||August 2010|September 7, 2010|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01196598||116653|
NCT01196858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1426(REK)|Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland|Duration of Untreated Psychosis (DUP) and Pathways to Care in Patients With First- and Multiple Episodes of Psychosis in Nordland - a Study of the Components of DUP in a Rural Mental Health System||University Hospital of North Norway|No|Completed|September 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|62|||Both|16 Years|35 Years|No|Non-Probability Sample|This study is a naturalistic cohort study. All patients registrered in a 3 year period        with the acute and/or rehabilitation units will be invited to participate.        The eight units (acute and rehabilitation) will be able to provide a potential sample size        of 150 participants over the 3-year period of the study. We are confident of minimal        attrition and assume that we will achieve at least 85% follow up. This means that we can        expect to have collected data on approximately 120 people.|January 2014|January 6, 2014|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01196858||116633|
NCT01204606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM-10-02|Arthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA)|Arthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA): A Randomized, Double-blind, Placebo-controlled Trial||Seoul National University Hospital|No|Completed|September 2010|||March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|45 Years|85 Years|No|||March 2013|March 11, 2013|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204606||116043|
NCT01204931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERD SISAP|Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?|Can We Predict Who Has GERD? Systematic Evaluation of Role of pH Monitoring and the Specific Physiologic pH Parameters in Defining GERD, Bravo, Impedence and SISAP||Vanderbilt University|No|Completed|November 2010|June 2015|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|254|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult subjects presenting to Vanderbilt University Medical Center Gastroenterology        outpatient clinic with symptoms consistent with gastroesophageal reflux disease (GERD)|September 2015|January 19, 2016|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01204931||116018|
NCT01204944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3347C0-108795/1|Swiss Transplant Cohort Study|Swiss Transplant Cohort Study|STCS|University of Zurich|Yes|Recruiting|May 2008|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|100 Years|No|Probability Sample|All transplanted indivduals in Switzerland|December 2015|December 2, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204944||116017|
NCT01202786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCO1miRviewmets|Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)|An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel||Teva Pharmaceutical Industries|No|Completed|May 2010|April 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|Samples Without DNA|Formalin Fixed Paraffin Embedded tumor tissue|Both|18 Years|N/A|No|Probability Sample|Patients who present with histologically-confirmed metastatic cancer in whom an initial        work-up which consists of detailed medical history, physical examination, basic laboratory        studies, histopathological review of biopsy material, and CT scan of the chest abdomen and        pelvis fail to identify the primary site.|August 2012|August 14, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202786||116181|
NCT01205503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0431-F1V|Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release|Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release||University of Kentucky|Yes|Completed|September 2010|April 2015|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 17, 2010|Yes|Yes||No|September 18, 2015|https://clinicaltrials.gov/show/NCT01205503||115975|We did not measure any cognitive outcomes. We did not measure levels of anti-inflammatory cytokines, which could play a role in pathophysiology of Chemotherapy induced cognitive impairment (CICI). Small sample size, needs future trials to confirm.
NCT01205516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2010-Meth|Methadone in Neuropathic Pain|||Nova Scotia Health Authority|No|Recruiting|January 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205516||115974|
NCT01203345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0002|Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection|Randomized Clinical Trial of Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection in Very-Low-Birth-Weight Infants|IVIG|NICHD Neonatal Research Network|Yes|Completed|January 1988|March 1991|Actual|March 1991|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2416|||Both|N/A|72 Hours|Accepts Healthy Volunteers|||September 2010|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203345||116139|
NCT01179321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|malscreen05/185|Malnutrition Screening in Acute Aged Care|Malnutrition Screening and Intervention in Hospitalised Older Patients: A Randomised Controlled Trial||Prince of Wales Hospital, Sydney||Completed|April 2006|||||N/A|Interventional|N/A|2||||||Both|N/A|N/A|No|||March 2006|August 10, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179321||117970|
NCT01179581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-101|First-in-Human Single Ascending and Multiple Dose of GLPG0634|Double-blind Placebo-controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG0634 in Healthy Subjects||Galapagos NV|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|48|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||March 2011|March 23, 2011|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179581||117950|
NCT01175343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03069|RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer||National Cancer Institute (NCI)|Yes|Completed|July 2010|August 2015|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||June 2015|December 23, 2015|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175343||118275|
NCT01175356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL09P1|Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin|A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma||Children's Oncology Group|Yes|Active, not recruiting|October 2010|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|1 Year|30 Years|No|||January 2016|January 14, 2016|August 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175356||118274|
NCT01175603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHMI ICTR 2009|Preventing Postpartum Depression in African American Home Visiting Clients|||Johns Hopkins University|No|Active, not recruiting|October 2009|October 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|91|||Female|14 Years|50 Years|Accepts Healthy Volunteers|||June 2010|August 4, 2010|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175603||118255|
NCT01175616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00041936|Creatine Augmentation in Veterans With SSRI-Resistant Major Depression|Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder||University of Utah|Yes|Completed|September 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175616||118254|
NCT01176786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10667|Reusable Versus Disposable Draping System in Breast Reconstruction Surgery|The Effect of Reusable Versus Disposable Draping on Implant Based Breast Reconstruction Infection Rates: a Prospective Randomized Study||Wake Forest School of Medicine|No|Completed|September 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|107|||Female|18 Years|N/A|No|||September 2013|September 5, 2013|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176786||118164|
NCT01177020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC1069A|The Role of Pro-angiogenic Immune Cells in Human Pregnancies|||Hillel Yaffe Medical Center||Recruiting|August 2010|December 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|300|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Placentas after delivery or abortion|August 2010|August 5, 2010|May 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01177020||118146|
NCT01177033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN 39997806|Angioplasty or Bypass Surgery in Intermittent Claudication|ABC-Trial - Angioplasty or Bypass Surgery in Intermittent Claudication:|ABC|Institut für Klinisch-Kardiovaskuläre Forschung GmbH|Yes|Recruiting|August 2010|December 2014|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|470|||Both|50 Years|85 Years|No|Probability Sample|Patients with Intermittent Claudication, due to complex lesions of the superficial femoral        artery|May 2010|August 5, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177033||118145|
NCT01177371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWRU1494T|High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma|High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma||Case Comprehensive Cancer Center|Yes|Completed|March 1988|February 2010|Actual|February 2000|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|N/A|No|||August 2010|August 5, 2010|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177371||118119|
NCT01177618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1437|Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study|Genetic Epidemiology of Severe, Early-Onset Chronic Obstructive Pulmonary Disease||Brigham and Women's Hospital|No|Recruiting|July 1994|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Anticipated|2000|Samples With DNA|DNA, Serum, Plasma, Buccal Brushings, and Urine|Both|N/A|N/A|No|Non-Probability Sample|Severe, early-onset COPD subjects and their relatives|January 2016|January 11, 2016|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177618||118100|
NCT01195142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC-UCD-ATCS|Adipose Tissue Gene Expression Profiles in Women With Polycystic Ovary Syndrome (PCOS) Versus Controls|Adipose Tissue Gene Expression Profiles in Women With PCOS Versus Controls Matched for BMI||The Adelaide and Meath Hospital|No|Completed|December 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|10|Samples Without DNA|Plasma|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with PCOS and a control population of women matched for age and body mass index        (BMI)|July 2008|September 3, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195142||116763|
NCT01196065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25180|A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine|A Single Center, Open-label, Fixed Sequence, Two-period Study to Investigate the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of RO5313534 After Single Dose Administration in Healthy Volunteers and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine||Hoffmann-La Roche||Completed|September 2010|November 2010||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196065||116694|
NCT01196286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-BN-07|Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis|Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis||University of Arizona|No|Active, not recruiting|June 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|35 Years|No|||November 2015|November 30, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196286||116677|
NCT01204060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#10-3322|Effect of Allergen Challenge on Inflammation Induced by Toll-like Receptor Stimulation in a Nasal Model|Effect of Allergen Challenge on Inflammation Induced by Toll-like Receptor Stimulation in a Nasal Model.||McMaster University|No|Recruiting|September 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01204060||116084|
NCT01204346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRossouw|Mentalization - Based Treatment: Adolescents With Co-morbid Depression and Personality Disorder|Mentalization - Based Treatment for Young People Presenting With Co-morbid Depression and Symptoms of Emerging Personality Disorder: Prospective Controlled Trial.|MBT|North East London Foundation Trust|No|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Both|12 Years|17 Years|No|||July 2011|October 2, 2014|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204346||116062|
NCT01204619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEACH|Trial on Education And Clinical Outcomes for Home PD Patients (TEACH)|||Seoul National University Hospital|No|Recruiting|December 2010|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|N/A|No|||June 2012|June 6, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204619||116042|
NCT01206829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2156 (REK)|Hearing Impairment, Cognitive Therapy and Coping|Hearing Impairment, Tinnitus, Mental Health and Vocational Coping. A Randomized, Controlled Study of a Cognitive Therapy Program to Reduce Social Safety Seeking.||Oslo University Hospital|No|Active, not recruiting|October 2010|December 2013|Anticipated|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|70 Years|No|||June 2013|June 13, 2013|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206829||115873|
NCT01206569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFKLN|Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis|Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis||Chinese University of Hong Kong|No|Completed|September 2010|February 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|80 Years|No|||December 2012|December 3, 2012|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206569||115893|
NCT01203098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-B-J209|A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty|A Phase 2b, Randomized, Multi-Dose Efficacy,Safety Study of the Oral Factor Xa Inhibitor DU-176b Versus Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-2)||Daiichi Sankyo Inc.|Yes|Completed|July 2008|June 2009|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|264|||Both|20 Years|84 Years|No|||February 2015|February 6, 2015|September 14, 2010||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01203098||116158|
NCT01203111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_R_05048|Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs|Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs|CHANGING|Sanofi||Completed|December 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|75 Years|No|||August 2012|August 29, 2012|September 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01203111||116157|
NCT01179594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV22597|A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.|A Phase IV, 2x2 Factorial, Double Blind Study of 48 Versus 96 Weeks of PEGASYS 180µg, With or Without 24 Weeks of Entecavir in Adult Patients With HBeAg Negative Chronic Hepatitis B.||Hoffmann-La Roche||Withdrawn||November 2014|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 10, 2010||No|This study was canceled for operational reasons.|No||https://clinicaltrials.gov/show/NCT01179594||117949|
NCT01175629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|569|Veteran Health Study|CSP #569 - A Twin Study of the Course and Consequences of PTSD in Vietnam Era Veterans||VA Office of Research and Development|Yes|Completed|January 2010|March 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|7568|||Male|N/A|N/A|No|Non-Probability Sample|All subjects are members of the Vietnam Era Twin Registry, and are males born between        1939-1957.|June 2014|June 30, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175629||118253|
NCT01175642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSYC-085-08|Cognitive Remediation and Functional Skills Training in Schizophrenia|Specificity and Generalizability of Cognitive Remediation and Functional Skills Training in Schizophrenia||National Alliance for Research on Schizophrenia and Depression|No|Recruiting|July 2007|September 2010|Anticipated|August 2010|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|65 Years|No|||August 2010|August 4, 2010|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175642||118252|
NCT01175902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cosopt-IOP/OPP|Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma|To Prove the Non-inferiority of Cosopt Compared to Xalatan in the Aspects of Intraocular Pressure and Ocular Perfusion Pressure in Subjects With Normal Tension Glaucoma||The Catholic University of Korea|Yes|Completed|March 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|July 26, 2010|Yes|Yes||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01175902||118232|
NCT01176799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR01/09/10|Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor|Phase II Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor||National University Hospital, Singapore|Yes|Recruiting|August 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|73|||Female|18 Years|N/A|No|||June 2015|June 17, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176799||118163|
NCT01177046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160-2002|Development of a Multi-attribute Health Index: to Measure the Quality of Labour Analgesia: The QLA Index|Development of a Multi-attribute Health Index to Measure the Quality of Labour Analgesia: Psychometric Development of a Quality of Neuraxial Labour Analgesia Scale||Sunnybrook Health Sciences Centre||Recruiting|July 2010|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|60 Years|No|Non-Probability Sample|Women who received neuraxial labour analgesia during the current pregnancy|July 2015|July 30, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01177046||118144|
NCT01177384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-130|Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)|A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Acarbose Monotherapy||Merck Sharp & Dohme Corp.|Yes|Completed|January 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|June 30, 2010|Yes|Yes||No|March 10, 2014|https://clinicaltrials.gov/show/NCT01177384||118118|
NCT01177631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97068|Proteomic Analysis of Human Hepatocellular Carcinoma|Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis||Far Eastern Memorial Hospital|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|June 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01177631||118099|
NCT01177644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSV4 FH-1|Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD|||Forsight Vision4||Withdrawn|January 2011|||July 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|N/A|No|||August 2012|August 21, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177644||118098|
NCT01177930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6004|Evaluation of the Health Related Quality of Life and Disease Prevalence of Children From Spain at 6-8 Years of Age Who Participated in a Qualifying Infant Formula Study at Birth|||Mead Johnson Nutrition||Completed|October 2009|||May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|6 Years|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children 6 - 8 years of age|June 2011|June 21, 2011|August 6, 2010||||No||https://clinicaltrials.gov/show/NCT01177930||118077|
NCT01195766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-ESHAP-LH-2009|Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma|Phase II-study Using Ofatumumab and ESHAP Followed by Autologous Trasplant of Hemopoietic Precursors for the Treatment of Classic Hodgkin's Lymphoma on Relapse, Partial Response or Refractory to First Line Treatment||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Completed|July 2010|May 2015|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195766||116715|
NCT01203774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0788|Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital|"Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients Discharged From the Hospital"||University of Colorado, Denver|No|Completed|September 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|22 Years|70 Years|No|||December 2015|December 23, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203774||116106|
NCT01203787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-2010-19|Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)|Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery||University of Florida|No|Completed|December 2010|March 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|20 Years|75 Years|No|||February 2015|February 13, 2015|September 10, 2010|Yes|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01203787||116105|
NCT01204073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C24002|A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-Label, Dose-Escalation, Phase 1 Study of TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Completed|October 2010|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|September 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01204073||116083|
NCT01204359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007022|The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions|"5010 Clinical Research Programme"of Sun Yat-sen University||Sun Yat-sen University|Yes|Recruiting|July 2007|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|627|||Both|8 Years|90 Years|No|||May 2015|May 22, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01204359||116061|
NCT01206556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1085|IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody|Duration of Human Papilloma Virus (HPV) Type-Specific Antibody After Administration of Quadrivalent HPV Vaccine (QHPV) to HIV-1 Infected Children Previously Enrolled in IMPAACT P1047|HPV|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Completed|May 2010|August 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|N/A|N/A|No|Non-Probability Sample|This will be limited to subjects who were enrolled into IMPAACT P1047 and who completed        the scheduled vaccine doses for their designated arm.|March 2015|March 30, 2015|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206556||115894|
NCT01206309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 6501|Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation|Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|March 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1118|Samples With DNA|blood and urine specimens|Both|N/A|N/A|No|Probability Sample|Patients who are preparing for or have recently received an allogeneic hematopoietic cell        transplant|November 2015|November 24, 2015|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206309||115913|
NCT01202825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017035|TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients|Phase I, First-in-human Trial in Healthy Volunteers to Examine Increasing Single and Repeated Oral Doses of TMC647055, Followed by a Repeated-dose Part in Chronic HCV-genotype 1 Infected Patients to Examine TMC647055 Given Alone or in Combination With TMC435||Tibotec Pharmaceuticals, Ireland|No|Completed|April 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|10||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|September 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202825||116178|
NCT01206868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-06342a|Prophylactic Fenestration of the Peritoneum in Kidney Transplantation|Prospective Open Randomized Study to Evaluate the Efficiency of Prophylactic Fenestration of the Peritoneum in Kidney Transplantation in Preventing the Occurrence of Postoperative Lymphoceles|PROFFEN|Oslo University Hospital|No|Completed|March 2007|May 2009|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||March 2007|September 21, 2010|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206868||115870|
NCT01206842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1538 (REK)|Social Cognition Training in Schizophrenia|Social Cognition Training in Schizophrenia||Oslo University Hospital|No|Recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|55 Years|No|||April 2015|April 20, 2015|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01206842||115872|
NCT01203137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1009-014-331|Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation|||Seoul National University Hospital|No|Completed|January 2009|||February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|21 Years|80 Years|No|Non-Probability Sample|We prospectively recruited consecutive patients with isolated (without any other valvular        dysfunction) severe TR who underwent corrective surgery.|December 2012|December 11, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01203137||116155|
NCT01203878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09US05N375-Gold|Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy|An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy||Tennessee Clinical Research Center|No|Terminated|September 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|September 15, 2010|No|Yes|Unable to reach target enrollment of 60 subjects|No|November 13, 2014|https://clinicaltrials.gov/show/NCT01203878||116098|Early termination (slow enrollment) leading to small numbers of subjects analyzed; missing measurement(s) on a patient
NCT01203891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20021714|Single Photon Emission Computed Tomography of the Normal Human Brain|Single Photon Emission Computed Tomography of the Normal Human Brain||Amen Clinics, Inc.|Yes|Completed|January 2003|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|97|||Both|10 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study seeks to recruit 100 subjects between ages 10 and 90 for SPECT brain imaging.|September 2010|September 17, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203891||116097|
NCT01175369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12308|School-based Asthma Therapy: Stage 2 Effectiveness Study|School-Based Asthma Therapy: Stage 2 Effectiveness Study|SBAT|University of Rochester|No|Completed|August 2006|January 2012|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|530|||Both|3 Years|10 Years|No|||August 2013|July 25, 2014|June 23, 2010||No||No|January 14, 2013|https://clinicaltrials.gov/show/NCT01175369||118273|
NCT01176435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912M75653|Trial of L-DOPA as a Treatment to Improve Vision in Albinism|Clinical Trial to Evaluate Levodopa as Treatment to Improve Vision in Individuals With Albinism||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|47|||Both|3 Years|60 Years|No|||December 2014|December 9, 2014|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176435||118191|
NCT01177670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0210001|Adiana Post-Approval Clinical Study (APACS)|Adiana Post-Approval Clinical Study|APACS|Hologic, Inc.|No|Terminated|August 2010|April 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|169|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women, 18 - 45 years old, at risk for pregnancy, that are seeking permanent contraception        using the Adiana Permanent Contraception System.|October 2012|October 19, 2012|August 5, 2010||No|Hologic made business decision to no longer sell or manufacture Adiana device.|No|September 18, 2012|https://clinicaltrials.gov/show/NCT01177670||118096|After determining Adiana was not financially viable and would not become so, Hologic decided to discontinue manufacturing & sales. Hologic decided to terminate the study. All subjects were notified of termination and withdrawn by April 30, 2012.
NCT01182337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-Intradiscal rhGDF-5-03|A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration|A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration||DePuy Spine|No|Completed|June 2010|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 11, 2010||No||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01182337||117738|
NCT01182350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI 10-321|Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)|Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2011|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|53|||Both|3 Years|18 Years|No|||October 2015|October 17, 2015|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182350||117737|
NCT01177657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111562|Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in Brazil|Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalized Children Born After 6 March 2006 and at Least 12 Weeks of Age, in Belem, Brazil||GlaxoSmithKline||Completed|May 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|1944|Samples Without DNA|Stool sample|Both|12 Weeks|N/A|No|Non-Probability Sample|Gastroenteritis Cohort: Cases will include children born after 6 March 2006, at least 12        weeks of age and hospitalized for rotavirus severe gastroenteritis the study        clinics/hospitals, during the designated study period, Hospital control cohort: Children        hospitalized for non gastroenteritis causes, Neighbourhood control cohort: Children        without any symptoms of gastroenteritis or severe gastroenteritis.|November 2012|November 15, 2012|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01177657||118097|
NCT01178242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0427/08|Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome.|Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome.||Federal University of São Paulo|Yes|Enrolling by invitation|December 2008|December 2010|Anticipated|April 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|10 Years|58 Years|No|||December 2008|August 9, 2010|January 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01178242||118053|
NCT01203488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0015|Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants|Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight|Vitamin A|NICHD Neonatal Research Network|Yes|Completed|January 1996|July 1999|Actual|July 1997|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|807|||Both|N/A|96 Hours|No|||June 2015|June 3, 2015|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203488||116128|
NCT01203800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0056-09-WOMC|Evaluation of Blood Brain Barrier Permeability in Chronic Stroke|Evaluation of Blood Brain Barrier Permeability in Chronic Stroke||Wolfson Medical Center|No|Completed|September 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female patients at any age with a history of a large stroke in the territory of        the middle cerebral artery, occurring 1-2 years ago or between 2-5 years ago.|February 2016|February 8, 2016|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203800||116104|
NCT01203813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R18HS018226-02|A Risk Based Approach to Improving Chronic Kidney Disease Management|A Risk Based Approach to Improving Chronic Kidney Disease Management||Brigham and Women's Hospital|Yes|Completed|May 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|10000|||Both|18 Years|85 Years|No|||February 2013|February 14, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203813||116103|
NCT01205256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14145|IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction|IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction||University of Virginia|No|Completed|March 2009|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|11|||Both|12 Years|19 Years|No|||March 2016|March 1, 2016|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205256||115994|
NCT01205815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL 09109|Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment|||Vanderbilt-Ingram Cancer Center||Recruiting|June 2010|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients with melanoma.|August 2012|August 24, 2012|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205815||115951|
NCT01206296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCI 2009-455|Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma|A Phase 2 Study of Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma||Washington Hospital Center|Yes|Terminated|August 2010|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|September 20, 2010|Yes|Yes|Study suspended|No||https://clinicaltrials.gov/show/NCT01206296||115914|
NCT01206855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Celleration-NU-01|Effectiveness Study of MIST Therapy After Cosmetic Surgery Procedures of the Face and Body|Use of MIST Ultrasound Therapy to Minimize Edema, Bruising and Scarring After Cosmetic Surgery Procedures of the Face and Body||Celleration, Inc.|No|Completed|October 2010|December 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3440|||Both|18 Years|75 Years|No|||October 2014|October 6, 2014|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206855||115871|
NCT01202838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP125/2008|Bioactive Glass Composite Implants in Cranial Bone Reconstruction|Bioactive Glass Composite Implants in Cranial Bone Reconstruction||Turku University Hospital|No|Recruiting|June 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|patients of Turku university hospital needing cranial bone defect reconstruction|September 2010|September 14, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01202838||116177|
NCT01203150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-006|Effects of Exercise in People With Paraplegia|Exercise Treatment of Obesity-Related Secondary Conditions in Adults With Paraplegia||University of Miami|Yes|Completed|October 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|65 Years|No|||March 2015|March 23, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203150||116154|
NCT01203904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D525AL00001|Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation|Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation for Long Term Use in Pediatrics|PEACE-Peds|AstraZeneca||Completed|September 2010|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Pulmicort Turbuhaler for the firtst time due to bronchial asthma and        children of >= 5 years and < 15 years old age at the start of study treatment|December 2015|December 15, 2015|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01203904||116096|
NCT01203917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791AC00014|Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC|An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer|IFUM|AstraZeneca|No|Active, not recruiting|September 2010|April 2016|Anticipated|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1060|||Both|18 Years|130 Years|No|||February 2016|February 1, 2016|September 7, 2010|Yes|Yes||No|August 5, 2013|https://clinicaltrials.gov/show/NCT01203917||116095|
NCT01175928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NormaTec_90513134-01|Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy|Phase 2 Study of the NormaTec PCD in the Treatment of Diabetic Peripheral Neuropathy||NormaTec Industries LP|No|Active, not recruiting|October 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|August 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175928||118230|
NCT01175941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-01/2010 (MANO)|Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence|A Double-blind, Randomized, Placebo-controlled, Cross Over Study in Patient Volunteers With Faecal Incontinence to Evaluate the Effect on Rectal Compliance, Rectal Sensitivity, Recto-anal Inhibitory Reflex, Sphincter Pressures, Safety and Tolerability of a Daily Rectal Application of a 10 mg NRL001 Suppository for Seven Consecutive Days||Norgine|No|Completed|August 2010|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|40 Years|85 Years|No|||November 2012|November 2, 2012|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01175941||118229|
NCT01176175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908/I/PRO|Progesterone Microspheres Pharmacokinetic - Pharmacodynamic (PK-PD) Study|Randomized, Controlled, Open-label, Parallel, Clinical Trial to Assess Pharmacokinetics and Endometrial Effect of an Injectable Formulation of Progesterone Microspheres in Doses of 50 mg, 100 mg, 200 mg and 300 mg, in Postmenopausal Women.||Productos Científicos S. A. de C. V.|No|Completed|August 2010|February 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176175||118211|
NCT01176188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-069-PED|A Nursing Intervention to Enhance Child Comfort and Psychological Well-Being During and Following PICU Hospitalization|A Nursing Intervention to Enhance Comfort and Promote Psychological Well-Being in Children During and Following PICU Hospitalization: A Pilot Study||McGill University Health Center|No|Completed|August 2010|July 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|6 Years|17 Years|No|||September 2015|September 23, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176188||118210|
NCT01176201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S337.1.005|14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man|An Open-Label Study to Determine ADME of 14C Labeled SLV337 After a Single Dose of an Oral Suspension||Abbott|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 25, 2011|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01176201||118209|
NCT01176448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN-1001M75732|Laser Resurfacing Versus Dermabrasion for Scar Revision|A Comparison Evaluation of Fractional Laser Therapy and Dermabrasion for Scar Revision||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|April 2010|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 25, 2013|June 21, 2010|Yes|Yes||No|November 9, 2011|https://clinicaltrials.gov/show/NCT01176448||118190|
NCT01176461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15400|Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558|A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|August 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|16 Years|N/A|No|||October 2015|October 27, 2015|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176461||118189|
NCT01182038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/739|The Swedish Birth Seat Trial|The Swedish Birth Seat Trial||Helsingborgs Hospital|Yes|Completed|November 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1002|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01182038||117761|
NCT01182363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H28906|Reducing Risk After an Adverse Pregnancy Outcome|Reducing Risk After an Adverse Pregnancy Outcome: Addressing Maternal Depression During Internatal Periods||Boston Medical Center|No|Completed|August 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|188|||Female|N/A|N/A|Accepts Healthy Volunteers|||August 2014|August 26, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01182363||117736|
NCT01182675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01000701|Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim|Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease Utilizing Alemtuzumab and Mobilization With Plerixafor & Filgrastim||University of California, San Francisco|No|Terminated|August 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|N/A|3 Years|No|||November 2014|November 6, 2014|August 9, 2010||No|Insufficient evidence of efficacy|No|October 28, 2014|https://clinicaltrials.gov/show/NCT01182675||117712|
NCT01177969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34HD065274-01|Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents|CBT for Anxiety Disorders in Autism: Adapting Treatment for Adolescents||University of South Florida|Yes|Completed|November 2009|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|August 5, 2010||No||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01177969||118074|Modest sample size Lack of objective measures of anxiety that go beyond diagnostic interview or checklist measures
NCT01178281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MF-002|Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence|A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell Transfusion Dependence|RESUME|Celgene|Yes|Active, not recruiting|September 2010|May 2018|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|July 15, 2010|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01178281||118050|
NCT01178294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBI-1-301|Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A|Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies||Baxalta US Inc.|Yes|Completed|November 2010|October 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|August 6, 2010|Yes|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01178294||118049|Due to the low number of subjects available for evaluation, statistical tests could only be performed for the primary outcome measure. The results of all other outcome measures are descriptive.
NCT01182935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2010-3|Elevated Triglyceride Levels and Later Type 2 Diabetes|Elevated Triglyceride Levels and Later Type 2 Diabetes||University of Tromso|No|Completed|April 2010|November 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3509|Samples Without DNA|serum|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|participants in the 4 Tromsø study 1994 and with elevated serum triglyceride levels|July 2011|July 19, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01182935||117693|
NCT01203501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0016|In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants|In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants|MgSO4|NICHD Neonatal Research Network|No|Completed|July 1996|June 2000|Actual|June 1998|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1339|||Both|N/A|14 Days|Accepts Healthy Volunteers|Probability Sample|All infants with birth weights 401 through 1500 grams admitted to the NICU within 14 days        of age are eligible for the study. In addition, all inborn, liveborn infants in the same        weight range (401-1500 gms) who die prior to admission to the NICU are enrolled        posthumously.|June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203501||116127|
NCT01203514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0017|The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants|The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Preterm Infants 401-1250 Grams: Two Multi-Center, Randomized, Double-Masked, Placebo Controlled Studies|EPO|NICHD Neonatal Research Network|Yes|Completed|August 1997|August 2000|Actual|August 1998|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|318|||Both|N/A|96 Days|Accepts Healthy Volunteers|||June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203514||116126|
NCT01204957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USCIRB#060701|Brown Seaweed as a Breast Cancer Preventive|Brown Seaweed as a Breast Cancer Preventive||University of South Carolina|No|Completed|October 1998|March 1999|Actual|March 1999|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01204957||116016|
NCT01205828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-268|ABT-888 and Temozolomide for Liver Cancer|Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib||Georgetown University|Yes|Active, not recruiting|August 2010|July 2014|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|September 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205828||115950|
NCT01206322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21-DK088446301|Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes|Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes||Beth Israel Deaconess Medical Center|Yes|Completed|May 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|30|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|August 20, 2010|Yes|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01206322||115912|
NCT01206023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nano-MS-10|Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples|Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis by Respiratory Samples|MS-NANOSE|Carmel Medical Center|Yes|Completed|November 2010|November 2012|Actual|November 2011|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|71|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients of the Multiple Sclerosis Clinic, Carmel Medical Center, Israel will be invited        to participate.        Healthy volunters accompanying patients to the clinic will be invited to participate as        control subjects.|February 2015|December 8, 2015|September 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01206023||115935|
NCT01206036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-II-007|CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)|Phase I/II Study With Temsirolimus Versus no add-on in Patients With Castration Resistant Prostate Cancer (CRPC) Receiving First-line Docetaxel Chemotherapy|CEPTAS|Central European Society for Anticancer Drug Research|No|Completed|July 2010|October 2015|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||January 2016|January 26, 2016|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01206036||115934|
NCT01206582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000129|A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)|A Pilot Study of Hemin Therapy for Gastroparesis||Mayo Clinic|No|Completed|May 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|September 20, 2010|Yes|Yes||No|November 21, 2015|https://clinicaltrials.gov/show/NCT01206582||115892|
NCT01206595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402-C-203|Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy|A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De-Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sustained Release Encapsulated Bupivacaine (SKY0402) Administered as a Nerve Block in the Management of Postoperative Pain in Subjects Undergoing Bunionectomy||Pacira Pharmaceuticals, Inc|No|Completed|March 2005|December 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||November 2011|April 15, 2012|September 19, 2010|Yes|Yes||No|November 30, 2011|https://clinicaltrials.gov/show/NCT01206595||115891|
NCT01203631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8555-3797|Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease|A Randomised, Double-blind, Parallel-group, Placebo Controlled Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease||Novo Nordisk A/S|No|Completed|February 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|75 Years|No|||October 2014|October 8, 2014|September 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01203631||116117|
NCT01203644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKY0402-C-201|Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair|A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of a Single Dose of Sustained Release Encapsulated Bupivacaine (SKY0402) in the Management of Postoperative Pain in Subjects Undergoing Inguinal Hernia Repair||Pacira Pharmaceuticals, Inc|No|Completed|December 2004|December 2006|Actual|January 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Male|18 Years|N/A|No|||November 2011|April 15, 2012|September 15, 2010|Yes|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT01203644||116116|
NCT01203657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-TCC01|UCLA Tai Chi in a Community Setting Study|Tai Chi, Vitality and Activity in a Community Setting||University of California, Los Angeles|Yes|Recruiting|January 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 15, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203657||116115|
NCT01182103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC99-2628-B-182-002-MY2|Epigenetic Regulation of BDNF in Major Depression|Epigenetic Regulation of Brain-Derived Neurotropic Factor (BDNF) in Patients With Major Depression||Chang Gung Memorial Hospital|No|Completed|August 2010|May 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|110|Samples With DNA|Blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|This 2-year study will be conducted in our clinical setting. By a semi-structured        interview for DSM-IV criteria, a total of 160 subjectes (80 healthy controls and 80        patients with major depression) will be recruited in this study. In the first year        (recruiting 40 healthy controls and 40 patients with major depression), the data of BDNF        DNA methylation in all subjects will be collected. In the second year (recruiting another        40 healthy controls and 40 patients with major depression), the data of BDNF histone        modification in all subjects will be collected and the mechanism of epigenetic regulation        of BDNF in major depression will be discussed.|July 2014|July 24, 2014|August 11, 2010||No||No|June 7, 2013|https://clinicaltrials.gov/show/NCT01182103||117756|Limited funding prevented all samples from receiving all analyses.
NCT01182116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 08-178|Quality of Life in Patients That Undergo J Pouch or Side to End Coloanal Anastomosis for Rectal Cancer|A Randomized, Controlled Trial to Compare the Functional Outcome and Quality of Life in Patients With Low Rectal Cancer Who Undergo a J Pouch or a Side to End Coloanal Anastomosis||The Cleveland Clinic|Yes|Recruiting|March 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|75 Years|No|||July 2013|July 29, 2013|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01182116||117755|
NCT01178710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|statinstudy1|Effect of Simvastatin on Cardiac Function|The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial||Sun Yat-sen University|Yes|Completed|September 2010|July 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|151|||Both|10 Years|N/A|No|||July 2012|July 25, 2012|August 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01178710||118017|
NCT01189877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-121|Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins|Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins||Memorial Sloan Kettering Cancer Center||Completed|August 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|89 Years|No|||October 2012|October 10, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189877||117162|
NCT01190449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-50901|Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma|A Phase II Trial of Ofatumumab (CALGB IND #) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|August 2011|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190449||117118|
NCT01200043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-2845|Metabolic Impact of Fructose Restriction in Obese Children|Metabolic Impact of Fructose Restriction in Obese Children|SUCRE|University of California, San Francisco|Yes|Active, not recruiting|July 2010|June 2015|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|8 Years|18 Years|No|||February 2015|February 18, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01200043||116392|
NCT01200316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0129|Rocking Motion: Physiologic Effect on the Surgical Stress Response|Rocking Motion: Physiologic Effect on the Surgical Stress Response||M.D. Anderson Cancer Center|No|Recruiting|February 2012|||February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01200316||116371|
NCT01200329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0142|High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease|High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic Cell Support for Patients With Relapsed/Refractory Hodgkin's Disease||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2011|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|12 Years|70 Years|No|||April 2015|April 10, 2015|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200329||116370|
NCT01200342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0188|Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma|Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma||M.D. Anderson Cancer Center|No|Terminated|December 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|September 9, 2010|Yes|Yes|Pharmaceutical company no longer manufacturing investigational product.|No|November 13, 2015|https://clinicaltrials.gov/show/NCT01200342||116369|
NCT01200654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06 049 02|Population Pharmacokinetics of Linezolid|Population Pharmacokinetics of Linezolid in Intensive Care Units Patients Treated for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections||University Hospital, Toulouse|No|Completed|November 2007|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200654||116345|
NCT01202071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-040|A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)|A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers||Eisai Inc.||Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|September 14, 2010||No||No|October 26, 2012|https://clinicaltrials.gov/show/NCT01202071||116236|
NCT01183468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN041AI Part 1|A Research Trial of Aralast in New Onset Diabetes (RETAIN)|Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus (ITN041AI)|RETAIN|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|October 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|17|||Both|8 Years|35 Years|No|||January 2015|January 14, 2015|August 16, 2010|Yes|Yes|Due to lack of mechanistic signal and competing industry studies|No|January 6, 2015|https://clinicaltrials.gov/show/NCT01183468||117652|This (Part 1) was the drug dosing portion of the study; however, due to lack of a mechanistic signal and competing industry studies, the study was terminated and the trial portion (Part II, NCT01183455) was withdrawn.
NCT01179763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-12-089|Thickness of Retinal Layers in Amblyopia|Analysis of Spectral Domain Optical Coherence Tomography Measurements in Amblyopia||Samsung Medical Center|Yes|Completed|April 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|4 Years|19 Years|No|Non-Probability Sample|patients in tertiary hospital|August 2010|August 10, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01179763||117936|
NCT01176318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erd090908|Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|A Double Blind, Placebo Controlled Multicentre Study of the Effects of Standard Care Plus Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)||Hull and East Yorkshire Hospitals NHS Trust|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|80 Years|No|||July 2010|January 9, 2012|August 4, 2010||No|pharmaceutical grant was withdrawn, thus no financial support to conduct the study.|No||https://clinicaltrials.gov/show/NCT01176318||118200|
NCT01181258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS083|Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies|Lymphodepleting Chemotherapy With Rituximab and Allogeneic Natural Killer Cells for Patients With Refractory Lymphoid Malignancies (MT2009-15)||Masonic Cancer Center, University of Minnesota|Yes|Completed|August 2010|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||January 2016|January 21, 2016|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01181258||117821|
NCT01180920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00038150|The Importance of Periostin in Periodontal Health and Disease|The Importance of Periostin in Periodontal Health and Disease||University of Michigan|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|Samples With DNA|Each patient will be have 5ml of blood collected at 3 different visits. Saliva, and gingival      crevicular fluid will also be collected at 7-8 visits during the study. Gingival tissue will      be collected on the day of surgery.|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will have a sample size of 22 subjects: 11 periodontally healthy and 11 with        periodontal disease.|December 2014|December 1, 2014|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180920||117847|
NCT01181232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STCR-0901-TW|A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients|A Randomized, Active Control, Parallel Study to Evaluate the Efficacy and Safety of Zolpidem MR (Stilnox CR) Versus Zolpidem (Stilnox) in Patients With Primary Insomnia||Astellas Pharma Inc|No|Completed|October 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|132|||Both|18 Years|64 Years|No|||August 2014|September 9, 2014|August 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01181232||117823|
NCT01181245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-MC3019-028|A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer|A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer||FibroGen|Yes|Completed|December 2008|June 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|May 4, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01181245||117822|
NCT01177774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1700|Assessment of Children With Tic Onset in the Past 6 Months|Predictive Biomarkers of Conversion to Tourette Syndrome in Children With New-Onset Tics|NewTics|Washington University School of Medicine|No|Recruiting|August 2010|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|saliva|Both|5 Years|17 Years|No|Non-Probability Sample|A convenience sample of 36 children age 5-17 who have tics now but whose first-ever tic        occurred within the past 6 months. Subjects will be a convenience sample from community        and clinical sources.|December 2014|December 8, 2014|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177774||118088|
NCT01177787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wonik201007|Clinical Efficacy of Cryolipolysis on the Fat of Thigh in Korean Women|Clinical Efficacy of Local Fat Reduction on the Thigh of Korean Women Through Cryolipolysis||Wonik Trade Company, Korea|No|Active, not recruiting|July 2010|October 2010|Anticipated|August 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 5, 2010|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177787||118087|
NCT01178398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0613|Understanding Fish Consumption Habits During Pregnancy|A Qualitative Study of Fish Consumption During Pregnancy||Harvard Pilgrim Health Care|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 18+ who are currently pregnant and who consume <2 weekly fish servings|August 2010|August 9, 2010|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01178398||118041|
NCT01178411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-299|An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols|An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols||ArQule|No|Enrolling by invitation|August 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||May 2015|May 12, 2015|July 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01178411||118040|
NCT01199159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|misohys001|Preoperative Misoprostol in Reducing Blood Loss in Total Abdominal Hysterectomy (TAH)|A Pilot Study of the Preoperative Misoprostol in Reducing Operative Blood Loss During Hysterectomy||The University of Hong Kong|No|Completed|January 2007|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Female|N/A|N/A|No|||September 2010|September 9, 2010|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01199159||116459|
NCT01199133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO64.08|Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children|A Randomised,Double-blind,Placebo-controlled,Multi National,Phase III Trial to Assess the Efficacy and Safety of 300 IR Sublingual Immunotherapy Administered as Allergen-based Tablets Once Daily to Adolescents and Children Above the Age of 5 Years, Suffering From House Dust Mite Allergic Rhinitis||Stallergenes|Yes|Terminated|October 2009|September 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|471|||Both|5 Years|17 Years|No|||December 2011|December 20, 2011|September 9, 2010||No|Following the DSMB recommendation. Study population being insufficiently symptomatic to enable    differentiation between treatment and placebo. No safety concerns|No||https://clinicaltrials.gov/show/NCT01199133||116461|
NCT01199146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC# 085514|Abiraterone Post Ketoconazole for Prostate Cancer|A Phase II Study of Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC) and Prior Therapy With Ketoconazole||University of California, San Francisco|Yes|Active, not recruiting|September 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199146||116460|
NCT01199471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-563|Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane|A Multi-center Registry to Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane||Abbott||Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4000|||Both|18 Years|70 Years|No|Non-Probability Sample|Chinese patients undergoing surgery requiring general anesthesia with endotracheal        intubation or laryngeal mask airway|January 2012|January 24, 2012|August 31, 2010||No||No|November 30, 2011|https://clinicaltrials.gov/show/NCT01199471||116435|Types of surgery not restricted/stratified in the study and no standard practice in China on inhalation and intravenous anesthesia methods may skew/bias results. Gaps in study design and multiple outcome parameters make drawing conclusions difficult.
NCT01199731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113399|Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection|A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance|SONNET|ViiV Healthcare|No|Terminated|October 2010|December 2015|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||March 2012|April 19, 2012|September 9, 2010|Yes|Yes|Study placed on Clinical Hold|No||https://clinicaltrials.gov/show/NCT01199731||116415|
NCT01200875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08032010-6646|Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections|Effect of Intramuscular and Intratendinous Platelet-Rich Plasma Injections on Systemic Concentrations of Performance-Enhancing Growth Factors||Stanford University|Yes|Recruiting|July 2010|July 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Blood serum, blood plasma, and platelet-rich-plasma (PRP)|Both|N/A|N/A|No|Non-Probability Sample|Patients receiving intramuscular or intratendinous platelet-rich-plasma (PRP) for        treatment of muscle or tendon injury.|June 2011|June 10, 2011|September 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01200875||116328|
NCT01201174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-01CTIL|Hemolysis in Patients With Hereditary Spherocytosis (HS)|Oxidative Stress Contributes to Hemolysis in Patients With Hereditary Spherocytosis (HS) and Can be Ameliorated by Fermented Papaya Preparation (FPP)||Wolfson Medical Center|No|Not yet recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|5 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 13, 2010|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201174||116305|
NCT01191853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090239|Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines|Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees at Baseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines||National Institutes of Health Clinical Center (CC)||Completed|September 2009|||||N/A|Observational|Time Perspective: Prospective|||Actual|203|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|August 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01191853||117013|
NCT01191866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0406|Psychosocial Interventions in the Treatment of Youth With Type 1 Diabetes Mellitus|Intensive Individual and Familial Psychosocial Interventions in the Treatment of Children and Adolescents With Type 1 Diabetes Mellitus||Assaf-Harofeh Medical Center|No|Recruiting|September 2009|||September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh        Pediatric Diabetes Clinic will be eligible for inclusion in the study.|August 2010|August 30, 2010|August 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01191866||117012|
NCT01192113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGAZSY091109|Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)|An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection||Eisai Inc.||Completed|April 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|1072|||Both|18 Years|75 Years|No|||November 2012|November 5, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01192113||116993|
NCT01192126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662|A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens|A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens||Bausch & Lomb Incorporated|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|102|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|August 30, 2010|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01192126||116992|
NCT01184066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|706367|The ACTS Intervention to Reduce Breast Cancer Treatment Disparity|The ACTS Intervention to Reduce Breast Cancer Treatment Disparity||University of Pittsburgh|Yes|Recruiting|January 2010|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Female|18 Years|N/A|No|||March 2011|March 8, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01184066||117607|
NCT01180075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2120|Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population|Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population||University of North Carolina, Chapel Hill|No|Completed|May 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|85|Samples With DNA|Blood samples for determining drug concentrations and for future genetic testing of drug      metabolizing enzymes and transporters will be stored for up to 5 years.|Both|18 Years|N/A|No|Non-Probability Sample|HIV Positive patients on a stable regimen consisting of either        efavirenz/tenofovir/emtricitabine or atazanavir boosted with        ritonavir/tenofovir/emtricitabine|December 2014|December 1, 2014|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180075||117912|
NCT01176682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GEU-DUM-2010/1|Observational Study on Non-steroid Anti-inflammatory Drugs (NSAIDs) Treated Patients With Arthritic Disorder|European Real Life Study on NSAIDs Treated Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS): Assessment of Pain Relieve, Gastrointestinal (GI) Symptoms, Adherence and Health Resource Consumption|EVIDENCE|AstraZeneca|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1149|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk        factors. The patients will be asked to participate by their treating doctors at GP        centres, specialist centres or hospitals.        Participating investigators will belong to a variety of centres representing the reality        of how and where these patients are managed in each country.|June 2012|June 5, 2012|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01176682||118172|
NCT01176630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10311|Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population|Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population||Winthrop University Hospital|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|N/A|No|Non-Probability Sample|All study subjects are on maintenance hemodialysis|February 2012|February 24, 2012|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176630||118176|
NCT01176643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN10-037|Development and Evaluation of Modified Yoga in Systemic Lupus Erythematosus (SLE)|Development and Evaluation of an Adapted Yoga Program as Adjunct Therapy for Persons With Systemic Lupus Erythematosus (SLE): a Pilot Study||McGill University Health Center|No|Completed|August 2010|August 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|57|||Both|18 Years|65 Years|No|||September 2013|September 23, 2013|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01176643||118175|
NCT01181583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-VR-DEP2009-1|Tailored Internet-delivered Cognitive Behaviour Therapy for Symptoms of Depression and Comorbid Problems|Efficacy Testing of a Tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Symptoms of Depression and Comorbid Problems|TAYLOR1|Linkoeping University|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A||||December 2010|December 27, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01181583||117796|
NCT01181908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113476|Alcohol Interaction Study|A Study to Investigate the Psychomotor and Cognitive Effects of Alcohol When Co-administered With GSK1144814 or Matching Placebo in Healthy Subjects.||GlaxoSmithKline|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|December 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01181908||117771|
NCT01181921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015586|The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease|Phase IV Study for the Assessment of Modulating Effect of Galantamine (Reminyl PRC) on Circadian Rhythm in Patients With Moderate Alzheimer's Disease||Janssen-Cilag, S.A.|No|Terminated|May 2011|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|August 12, 2010||No|The recruitment rate was very low (one screening failure and one early withdrawal patient)|No|April 4, 2012|https://clinicaltrials.gov/show/NCT01181921||117770|
NCT01178086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22610|An Observational Study on MabThera/Rituxan (Rituximab) in Patients With Chronic Lymphocytic Leukemia|Non-interventional Study on Rituximab in the Therapy of Chronic Lymphocytic Leukemia (CLL NIS)||Hoffmann-La Roche||Completed|February 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|703|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic lymphocytic leukemia on chemotherapy receiving MabThera/Rituxan|March 2016|March 1, 2016|August 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01178086||118065|
NCT01178099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13746|An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults|A Pharmacokinetic and Pharmacodynamic Assessment of Prasugrel in Healthy Adults and Adults With Sickle Cell Disease||Eli Lilly and Company|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|August 6, 2010|No|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT01178099||118064|
NCT01178060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 08-240|The Effectiveness of Personalized Stroke Risk Communication|The Effectiveness of Personalized Stroke Risk Communication - A Pilot Randomized Controlled Trial|RiskCom|Durham VA Medical Center|No|Completed|September 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|90|||Both|55 Years|N/A|No|||August 2010|August 20, 2010|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01178060||118067|
NCT01199172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8567|Prevention and Treatment of Voice Problems in Teachers|Prospective Study of Prevention and Treatment of Voice Problems in Teachers|Prevention|University of Pittsburgh|Yes|Completed|October 2009|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|140|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|October 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01199172||116458|
NCT01199185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UO1HL096628|Treating Adults at Risk for Weight Gain With Interactive Technology|Targeted Approaches to Weight Control for Young Adults|TARGIT|University of Tennessee|Yes|Active, not recruiting|August 2009|October 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|330|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199185||116457|
NCT01199198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0862|Tolvaptan in Hyponatremic Cancer Patients|Randomized Placebo-Controlled Trial of Tolvaptan in Hyponatremic Patients With Cancer||M.D. Anderson Cancer Center|Yes|Completed|May 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||September 2013|January 7, 2015|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199198||116456|
NCT01200056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 07-266 (IRB HKU)|Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment|A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound|VENUS|The University of Hong Kong|Yes|Completed|August 2007|June 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||February 2013|February 27, 2013|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01200056||116391|
NCT01199484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOTI-CMA|Specific Oral Tolerance Induction to Cow's Milk Allergy|Specific Oral Tolerance Induction as an Useful Treatment in Two-year-old Children With Cow's Milk Allergy.||Valencia University General Hospital|Yes|Completed||||||N/A|Interventional|N/A|||||||Both|24 Months|36 Months|No|||September 2010|September 10, 2010|September 9, 2010||||No||https://clinicaltrials.gov/show/NCT01199484||116434|
NCT01199757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114812|A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures|A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures||GlaxoSmithKline|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|540|||Both|N/A|N/A|No|Probability Sample|Inclusion criteria for physicians:          -  Qualified after 1965          -  See 3 or more AR patients per week          -  Personally responsible for treatment decisions for patients with AR          -  Gave consent to participate to complete all tasks for the study duration             90 Primary Care Physicians and 45 allergists, each prospectively recruit 4             consecutive patients with SAR who provided consent to participate, for a total of 540             patients. Each physician completed a patient record form for 2 patients on             fluticasone furate, 1 patient on mometasone furate and 1 patient on fluticasone             propionate.|January 2011|April 7, 2011|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199757||116413|
NCT01200628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_0632|DEPITAC : Short Screening Scale for Psychotraumatic Disorders After Motor Vehicle Accident|Construction and Validation of a Short Screening Scale for Psychotraumatic Disorders for Inpatients Hospitalized in Surgical Unit Following a Road Traffic Accident|DEPITAC|University Hospital, Lille|No|Completed|June 2007|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|274|||Both|18 Years|N/A|No|Non-Probability Sample|We include 250 road traffic accident victim hospitalized in surgical department (less than        2 weeks). Patients are hospitalized in 5 different hospitals (3 in Lille, 1 in Douai, 1 in        Paris).|June 2015|June 16, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01200628||116347|
NCT01200641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12610000727044|Evaluation of Anxiolysis and Pain Associated With Retrobulbar Eye Block for Cataract Surgery : Melatonin Versus Gabapentin|Evaluation of Anxiolysis and Pain Associated With Retrobulbar Eye Block for Cataract Surgery : Melatonin Versus Gabapentin ( A Randomized, Double-blind, Placebo-controlled Study)||Qazvin University Of Medical Sciences|Yes|Completed|September 2010|January 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|35 Years|85 Years|No|||October 2012|October 10, 2012|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200641||116346|
NCT01200368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851056|Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants|A Phase 3, Randomized, Active-controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-label DTaP in Healthy Japanese Infants||Pfizer|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|551|||Both|3 Months|6 Months|Accepts Healthy Volunteers|||July 2014|July 25, 2014|August 31, 2010|Yes|Yes||No|September 12, 2012|https://clinicaltrials.gov/show/NCT01200368||116367|
NCT01201512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|129134|CONDOR Temporomandibular Muscle and Joint Disorders (TMJD) Survey|Primary Care Management for TMJD Pain||Dental Practice-Based Research Network|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|503|||Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The questionnaire was administered to all enrolled DPBRN dentist practitoner-investigators        (general dentists or specialists), defined as those who had completed a DPBRN Enrollment        Questionnaire who were 22 years or older.|June 2011|June 14, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201512||116279|
NCT01191268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11376|A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)|The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)||Eli Lilly and Company|No|Completed|November 2010|September 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|884|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|August 27, 2010|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01191268||117057|
NCT01191567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/2023-31|Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life|Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life||Karolinska Institutet|Yes|Recruiting|September 2010|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01191567||117035|
NCT01191879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRNA-MI-1|A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction|A Comparison of p53-induced Genes Activation as Possible Markers Differentiating Between Patients Presenting With Acute Myocardial Infarction and Controls||Meir Medical Center|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|79|||Male|18 Years|N/A|No|Non-Probability Sample|Aacute MI group- Patients with acute ST elevation MI planned for emergency primary PCI        Controls: Patients undergoing non-invasive evaluation of possible myocardial ischemia|October 2012|October 30, 2012|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01191879||117011|
NCT01179776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-PS-02|Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)|A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin® in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)||Thrombologic ApS|No|Completed|September 2010|June 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||June 2011|June 1, 2011|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179776||117935|
NCT01180647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU IRB Number: 09-0372|Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail|Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail||New York University School of Medicine|Yes|Completed|May 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||July 2013|July 22, 2013|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180647||117868|
NCT01176903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0916-PR-0032|Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration|Randomized, Double-blind, Placebo-controlled, Cross-over Study to Investigate the Bronchodilator Efficacy and Safety After Single and Repeated Administrations of Different Doses of Glycopyrrolate Via pMDI in Moderate to Severe COPD Patients.|GLY2|Chiesi Farmaceutici S.p.A.|No|Completed|August 2010|August 2011|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|65|||Both|40 Years|75 Years|No|||December 2011|December 14, 2011|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176903||118155|
NCT01177488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DoD Acierno|Innovative Service Delivery for Secondary Prevention of PTSD|Innovative Service Delivery for Secondary Prevention of PTSD in At-Risk OIF-OEF Service Men and Women||Charleston Research Institute|No|Completed|March 2008|February 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|21 Years|N/A|No|||September 2015|September 11, 2015|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01177488||118110|
NCT01177475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00666-51|Effect of Intake in Bioactive Molecules From Natural or Pasteurised Milk on Gut Maturation in Very Premature Newborns|Effect of Intake in Bioactive Molecules From Natural or Pasteurised Milk on Gut Maturation in Very Premature Newborns||Assistance Publique Hopitaux De Marseille|No|Completed|February 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|55|||Both|N/A|1 Week|No|||September 2015|September 29, 2015|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01177475||118111|
NCT01179035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transitions001|Evaluation of Transitions Clinic: A Post-Release Clinic for Recently Released Parolees With Chronic Medical Conditions|The Impact of Parolee-Targeted Care Versus Expedited Usual Care on Health Care Utilization and Recidivism||Transitions Clinic|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|2||Actual|150|||Both|18 Years|N/A||||August 2010|August 9, 2010|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01179035||117992|
NCT01178424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093/2010|My Depression Wellness Toolkit Study|My Depression Wellness Toolkit Study||Centre for Addiction and Mental Health|No|Active, not recruiting|August 2010|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||October 2015|October 5, 2015|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178424||118039|
NCT01178437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cMPsE01|Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy|Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy - a Prospective Pilot Study Regarding Safety, Effectiveness and Clinical Performance||cerbomed GmbH|No|Completed|August 2009|January 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|75 Years|No|||March 2011|March 7, 2011|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01178437||118038|
NCT01200355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-038|Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome|A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome||Memorial Sloan Kettering Cancer Center||Recruiting|September 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200355||116368|
NCT01199523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-077|A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females|A Phase 1, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Crossover Study to Evaluate the Effect of Repeat Oral Doses of Mirabegron on Cardiac Repolarization in Healthy Male and Female Adult Subjects||Astellas Pharma Inc|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|352|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199523||116431|
NCT01199783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCBC134ADE02T|Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment|Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment||Ruhr University of Bochum|No|Terminated|July 2011|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|80 Years|No|||March 2012|May 4, 2015|April 29, 2010||No|Patient number to be enrolled not reachable in prospected time frame, decision to stop the    study prematurely was made.|No||https://clinicaltrials.gov/show/NCT01199783||116411|
NCT01200381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T94|INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients With Remotely Monitored Implanted Cardioverter Defibrillators (ICD) SysTems|INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients With Remotely Monitored ICD SysTems|InContact|St. Jude Medical|No|Completed|February 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|210|||Both|18 Years|80 Years|No|||November 2014|November 21, 2014|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200381||116366|
NCT01200069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120100189|IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia|Intravenous Ibuprofen for Post-Electroconvulsive Therapy Myalgia||Rutgers, The State University of New Jersey|No|Terminated|July 2010|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|80 Years|No|||March 2015|March 10, 2015|August 19, 2010||No|unable to increase to target enrollment|No||https://clinicaltrials.gov/show/NCT01200069||116390|
NCT01200901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nelson AZ-IIT|Quetiapine in Melancholic Depression|Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response||University of Cincinnati|No|Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01200901||116326|
NCT01191580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5996/7033R|Interpersonal Therapy for Depression in Breast Cancer|Interpersonal Therapy for Depression in Breast Cancer||New York State Psychiatric Institute|No|Active, not recruiting|October 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|90 Years|No|||December 2014|September 8, 2015|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01191580||117034|
NCT01191593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-PJ-10|The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty|The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty||Rigshospitalet, Denmark|Yes|Completed|September 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|40 Years|85 Years|No|||August 2013|August 21, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01191593||117033|
NCT01191892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000684016|Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer|A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin||Wales Cancer Trials Unit|Yes|Recruiting|June 2010|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|August 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01191892||117010|
NCT01192165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113486|Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel|An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors||GlaxoSmithKline||Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|169|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192165||116989|
NCT01180348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOXBER0610|Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines|Randomized Study of Clinical Non-inferiority of Medicine Botulift (Laboratório Químico Farmacêutico Bergamo Ltd.) Compared to Botox ® (Allergan Inc.) in the Improvement of Wrinkles in the Facial Region.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|August 2011|September 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|192|||Female|18 Years|65 Years|No|||March 2016|March 3, 2016|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180348||117891|
NCT01176045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP00087|TearLab Refractive Surgery Dry Eye Study|Measurement of Refractive Surgery Induced Dry Eye Using Tear Osmolarity Testing||TearLab Corporation|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|128|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients scheduled to undergo refractive surgery with no previous diagnosis of dry eye        disease.|February 2016|February 2, 2016|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01176045||118221|
NCT01177800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013804|A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Infliximab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis||Xian-Janssen Pharmaceutical Ltd.|No|Completed|February 2009|September 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|65 Years|No|||September 2014|September 4, 2014|August 5, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01177800||118086|
NCT01177813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.20|Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise||Boehringer Ingelheim||Completed|July 2010|||March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|986|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|July 29, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01177813||118085|
NCT01177826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111426|Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children|Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix™) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium||GlaxoSmithKline||Completed|February 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|643|Samples Without DNA|Stool samples|Both|14 Weeks|5 Years|No|Non-Probability Sample|The confirmed cases are children born after 01 October 2006, at least 14 weeks of age,        hospitalized for SGE during the designated study period and whose stool samples have been        tested positive for RV by polymerase chain reaction (PCR). The controls are those children        hospitalised or visiting the hospital outpatient clinic for non-GE causes at the study        hospitals during the same time-period as the case and will be included after matching by        age.|January 2014|January 9, 2014|August 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01177826||118084|
NCT01178112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0258|Trientine and Carboplatin in Advanced Malignancies|Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Completed|July 2010|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|56|||Both|N/A|N/A|No|||August 2014|November 16, 2015|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01178112||118063|
NCT01177189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6910-R|Oxidative Stress Links Aging, Activity and Mobility Limitation|Oxidative Stress Links Aging, Activity and Mobility Limitation||VA Office of Research and Development|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01177189||118133|
NCT01177202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1758|Study of the Safety and Immunogenicity of H1N1 Vaccine|A Phase I Dose-Escalation Study to Investigate the Safety and Immunogenicity of the Fusion Protein Recombinant Influenza A (HAC1) Vaccine Derived From Influenza A/California/04/09 (H1N1) in Healthy Adults||Walter Reed Army Institute of Research (WRAIR)|No|Completed|September 2010|October 2012|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01177202||118132|
NCT01177215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-ADAPTALGO-2010|Investigation of an Adaptive Treatment Algorithm for Post-op Thoracic Patients to Reduce the Length of Drainage|Implementation of an Adaptive Algorithm to Improve Chest Tube Therapy in Patients With Pulmonary Leaks Following Thoracic Surgery|AATD|Medela AG|Yes|Terminated|July 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|18 Years|N/A|No|Non-Probability Sample|Thoracic Surgery Patient|May 2013|May 5, 2013|August 4, 2010||No|Interim analysis showed that the tested protocol did not improve treatment|No||https://clinicaltrials.gov/show/NCT01177215||118131|
NCT01177501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 050603|Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma|Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months|ITOV04|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|April 2009|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|65 Years|No|||November 2012|November 16, 2012|August 6, 2010||No|choice of the principal investigator|No||https://clinicaltrials.gov/show/NCT01177501||118109|
NCT01177228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13002|Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis|A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN0002 Following Multiple Intravenous Doses in Patients With Ulcerative Colitis||Millennium Pharmaceuticals, Inc.|No|Completed|May 2007|September 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|70 Years|No|||June 2014|June 19, 2014|August 5, 2010|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT01177228||118130|
NCT01177514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GABA1|The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy|The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy A Prospective, Randomized, Double Blinded, Placebo Controlled Study||Codet Vision Institute|Yes|Completed|April 2010|November 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01177514||118108|
NCT01178073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112565|A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)|AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)|AMBITION|GlaxoSmithKline|Yes|Completed|October 2010|August 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|610|||Both|18 Years|75 Years|No|||May 2015|May 28, 2015|July 15, 2010|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01178073||118066|
NCT01178762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709013R|The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis|The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis||National Taiwan University Hospital|Yes|Completed|September 2007|December 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|N/A|N/A|No|||September 2010|October 5, 2010|August 31, 2008||No||No|August 12, 2010|https://clinicaltrials.gov/show/NCT01178762||118013|
NCT01179295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15091|Japanese BAY86-9766 Monotherapy Phase I Study|Phase 1 Study of Single Agent BAY86-9766 in Japanese Patients With Advanced or Refractory Solid Tumors||Bayer|Yes|Completed|November 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||May 2013|May 7, 2013|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179295||117972|
NCT01199211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI-6212|Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism|Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism in Healthy Female Volunteers Training for a Marathon||University of California, San Francisco|Yes|Active, not recruiting|February 2011|January 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|100|Samples With DNA|Plasma|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample. Participants will be recruited by invitation to volunteer in the study.|May 2015|May 6, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199211||116455|
NCT01199224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-846|To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors|A Phase 1, Single-Dose, Randomized, Group Sequential Cross-Over Study Evaluating the Bioavailability and Food Effect of Three Formulations of Veliparib on Pharmacokinetics in Subjects With Solid Tumors||Abbott|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|N/A|No|||December 2010|February 3, 2011|July 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199224||116454|
NCT01199237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10722-35629-01|Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block|Effect of Anesthetic Choice (Sevoflurane Versus Desflurane) on Speed and Sustained Nature of Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block||University of California, San Francisco|No|Completed|August 2010|August 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|65 Years|No|||May 2014|May 7, 2014|August 23, 2010||No||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01199237||116453|
NCT01199536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GRU-NEX-2009/1|Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers|Observational Study to Evaluate Helicobacter Pylori Eradication at the End of Routine Triple Eradication Therapy With Duodenal Ulcer Relapses Control.||AstraZeneca|No|Completed|November 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|59|Samples Without DNA|Blood samples for Hematology (whole blood) and Chemistry (serum), gasric mucosa biopsies      taken during esophagogastroduodenoscopy (EGDS) in routine practice of Moscow Medical Academy      n/a I.M. Sechenov, Moscow State Medical and Stomatological University, Central Clinical      Hospital of Presidential Administration|Both|18 Years|N/A|No|Non-Probability Sample|Hospital patients|November 2013|November 22, 2013|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199536||116430|
NCT01200082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|487-10-EP|Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases|||University of Nebraska|No|Not yet recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples Without DNA|lood samples will be collected from healthy volunteers at their 1st visit. Urine samples      will be obtained from healthy controntrols and patients with hepatobiliary diseases over      time.|Both|19 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Controls: Subjects with no apparemt hepatobiliary diseases Patient Populaton:        Subjects visiting the hepatology clinic in UNMC as part of their treatment of hepatobiliry        diseases|October 2010|October 15, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01200082||116389|
NCT01200693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC-002|Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|Z-SEA-SIDE|Catholic University of the Sacred Heart|No|Completed|November 2008|March 2012|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|85 Years|No|||February 2013|February 13, 2013|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200693||116342|
NCT01200706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR0127/2006|Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Pneumonia|Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Community-acquired Pneumonia|PNEUMOPACEf|Federal University of Bahia|No|Completed|November 2006|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|820|||Both|2 Months|59 Months|No|||September 2010|July 19, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01200706||116341|
NCT01200667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0990004864|uPHI: Wireless Body Area Network Core Technology|uPHI: Wireless Body Area Network Core Technology|uPHI|Taipei Medical University WanFang Hospital|Yes|Active, not recruiting|July 2010|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|380|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Emergency patient with chest pain.          -  Emergency patients were implementation of 12-lead EKG during observation.          -  Out-patient services of Cardiology with arrhythmia.          -  Adults over 20 years old.|September 2010|September 14, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200667||116344|
NCT01200680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910188|Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes|Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes||National Institutes of Health Clinical Center (CC)||Recruiting|August 2010|||||N/A|Observational|N/A|||Anticipated|400|||Both|6 Years|100 Years|No|||March 2016|March 22, 2016|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01200680||116343|
NCT01201200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eco2|Right Ventricular Function in Patients With Obstructive Sleep Apnea|Right Ventricular Function in Patients With Obstructive Sleep Apnea Assessed by Real-time Three-dimensional Echocardiography||Associação Fundo de Incentivo à Pesquisa|Yes|Completed|June 2007|November 2007|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|106|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Initially, 56 patients with obstructive sleep apnea (OSA) and 50 non-OSA controls        underwent real-time three-dimensional echocardiography. 30 Patients with moderate and        severe OSA underwent to continuous positive airway pressure treatment over 6 months.        Echocardiogram will be repeated on the third and sixth months from the treatment onset.|June 2010|May 7, 2012|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201200||116303|
NCT01191554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FW2009006|Dose-ranging Study of Tranexamic Acid in Valve Surgery|Comparison of Two Tranexamic Acid Dose Regimens on Postoperative Bleeding and Transfusion Needs in Primary Valve Surgery||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Completed|September 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|70 Years|No|||November 2012|November 2, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01191554||117036|
NCT01192178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113872|Fall Epidemic Viral Pediatric Study|A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season.||GlaxoSmithKline|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|339|||Both|4 Years|11 Years|No|||August 2014|April 6, 2015|July 15, 2010|Yes|Yes||No|September 29, 2011|https://clinicaltrials.gov/show/NCT01192178||116988|
NCT01192191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114156|A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD|A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|187|||Both|40 Years|N/A|No|||May 2015|May 7, 2015|August 30, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01192191||116987|
NCT01192438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-364A|Laser Based Focal Ablation of Low Grade Prostate Cancer|A Pilot Study to Evaluate Magnetic Resonance Thermal Image-guided Laser-Induced Interstitial Thermal Therapy for Focal Ablation of Prostate Cancer||University of Chicago|Yes|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|45 Years|N/A|No|||March 2014|March 26, 2014|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01192438||116968|
NCT01192451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08SC01|Prospective Cohort of Respiratory Insufficiency Outcome|Prospective Cohort of Patients With Chronic Obstructive Pulmonary Disease (COPD) Undergoing Domiciliary Noninvasive Positive Pressure Ventilation|RIO|University Hospital, Grenoble|Yes|Recruiting|December 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|COPD patients undergoing domiciliary noninvasive ventilation|September 2010|September 10, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192451||116967|
NCT01180088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA001|Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy|Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy: A Randomized Trial|AA|Azienda Ospedaliera Ordine Mauriziano di Torino|No|Not yet recruiting|August 2010|August 2011|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||August 2010|August 10, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01180088||117911|
NCT01175798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2275|Impact of Vitamin D Repletion in Hemodialysis Patients|Immunologic Impact of Vitamin D Repletion in Hemodialysis Patients: A Randomized Controlled Trial||Mehrotra, Anita, M.D.|Yes|Completed|August 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|August 3, 2010||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01175798||118240|
NCT01175811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13492|A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus|A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin||Eli Lilly and Company|No|Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|80 Years|No|||October 2013|October 29, 2013|August 3, 2010|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01175811||118239|
NCT01176916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991093|Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China|A Prospective Non-Interventional Study Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin(Registered)||Pfizer|No|Recruiting|February 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|550|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women with primary breast cancer with estrogen receptor positive switching        to adjuvant Aromasin® endocrine therapy following adjuvant Tamoxifen therapy for 2-3 years|March 2016|March 7, 2016|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176916||118154|
NCT01177527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-233|Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders|Medical Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders||Dana-Farber Cancer Institute|No|Recruiting|December 2009|December 2020|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Peripheral blood Bone marrow samples|Both|18 Years|N/A|No|Non-Probability Sample|Participant's will be identified through several mechanisms:          1. Primary recruitment will occur via Internet advertising through patient websites             including but not limited to the International Waldenstrom's Macroglobulinemia             Foundation (IWMF), the Leukemia and Lymphoma Society and the Multiple Myeloma             Research Foundation (MMRF) websites.          2. Investigators who identify patients at Dana-Farber Cancer Institute (DFCI) who do not             wish to continue their treatment plan at DFCI can approach these patients to             participate in this study|March 2016|March 8, 2016|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177527||118107|
NCT01176929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OST08017|Randomized Controlled and Prospective Trial of a Cohort of People Who Made a Suicide Attempt|Effectiveness of Telephone Contact and Professional Coordination for Preventing Recurrent Suicidal Acts|OSTA|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2009|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|320|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176929||118153|
NCT01177241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP450CLBP1|Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids|Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids||NEMA Research, Inc.|Yes|Completed|September 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|10000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with chronic low back pain on opioids|April 2012|April 28, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177241||118129|
NCT01177254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP450OA1|Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions|Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions||NEMA Research, Inc.||Completed|September 2010|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|10000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|retrospective chronic low back pain patients taking opioids|April 2012|April 28, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177254||118128|
NCT01178749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200708003R|Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments|Exploration of Symptom Experience and Related Factors for Patients With Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments: Development of a Prediction Model||National Taiwan University Hospital|Yes|Recruiting|September 2007|July 2011|Anticipated|July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|390|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic Hepatitis C inpatients|August 2010|August 9, 2010|April 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01178749||118014|
NCT01179022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10-137-10.CTIL|Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions|Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions||Meir Medical Center|Yes|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|50 patients that undergo bronchoscopy with the use of APC|March 2012|March 12, 2013|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01179022||117993|
NCT01179061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/S1101/18|Investigating the Inotropic Potential of Apelin|Investigating the Inotropic Potential of Apelin in Healthy Volunteers and Patients With Chronic Stable Heart Failure|INO-apelin|University of Edinburgh|No|Recruiting|August 2010|||August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|January 13, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179061||117990|
NCT01179347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.438|Tiotropium Bromide in Cystic Fibrosis|A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.||Boehringer Ingelheim||Completed|September 2010|||March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|464|||Both|N/A|N/A|No|||October 2013|November 27, 2013|August 10, 2010||||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01179347||117968|
NCT01179048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX2211-3748|Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation|A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events|LEADER®|Novo Nordisk A/S|No|Completed|August 2010|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9341|||Both|50 Years|N/A|No|||December 2015|December 18, 2015|August 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01179048||117991|
NCT01179308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-610|The Effect of Adding Intraoperative Regional Anesthesia on Cancer Recurrence in Patients Undergoing Lung Cancer Resection|The Effect of Adding Intraoperative Regional Anesthesia on Cancer Recurrence in Patients Undergoing Lung Cancer Resection||The Cleveland Clinic|No|Terminated|August 2010|August 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|67|||Both|18 Years|85 Years|No|||May 2015|May 15, 2015|August 10, 2010||No|The principal investigator decided to close this study site.|No||https://clinicaltrials.gov/show/NCT01179308||117971|
NCT01199809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP22713|A Study of RO5310074 in Patients With Psoriatic Arthritis|A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis||Hoffmann-La Roche||Completed|February 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||July 2013|July 1, 2013|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199809||116410|
NCT01200095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99045|Posterior Cruciate Ligament Reconstruction Using Knot/Press-fit Technique|Non-hardware Posterior Cruciate Ligament Reconstruction Using Knot/Press-fit Technique With Periosteum-Evenloping Hamstrings Tendon Autograft||Taipei Medical University WanFang Hospital|No|Completed|January 2003|December 2008|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|15 Years|60 Years|No|Non-Probability Sample|Patients with PCL tear who received surgery|September 2010|September 10, 2010|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01200095||116388|
NCT01200108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acti-AICS-001|AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma|A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Tolerability, Safety and Efficacy of AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma Requiring Chronic Oral Corticosteroid Treatment||Activaero GmbH|Yes|Completed|March 2010|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|N/A|4||||||Both|18 Years|65 Years|No|||November 2011|November 14, 2011|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200108||116387|
NCT01200394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7331011|A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Evaluate The Efficacy And Safety Of Once-Daily Administration Of A Phosphodiesterase 5 Inhibitor (PF-00489791) In Adults With Type 2 Diabetes And Overt Nephropathy||Pfizer|No|Completed|October 2010|August 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200394||116365|
NCT01190904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 06-0648|Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes|Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes|HEART-MEND|Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|January 2010|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|568|Samples Without DNA|Inflammatory markers; Hormones: testosterone, estradiol, SHBG|Male|18 Years|75 Years|No|Non-Probability Sample|Men with diabetes mellitus (DM) and coronary artery disease (CAD) following        catheterization.|November 2015|November 24, 2015|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01190904||117083|
NCT01190332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7918|Conventional Versus Rendezvous Technique of Intraoperative Endoscopic Retrograde Cholangiopancreatography|||Mansoura University||Completed|October 2007|March 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|98|||Both|18 Years|80 Years|No|||February 2010|August 26, 2010|July 6, 2010||||No||https://clinicaltrials.gov/show/NCT01190332||117127|
NCT01200914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORE-001|Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins|Placement of Covered Stents to Treat Hemodialysis Access Stenosis in the Cephalic Arch and Central Veins||University Health Network, Toronto|No|Terminated|January 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2015|December 5, 2015|September 10, 2010||No|poor recruitment|No||https://clinicaltrials.gov/show/NCT01200914||116325|
NCT01201187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YY-162|Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD|Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162) in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks|yuyu|Yuyu Pharma, Inc.|Yes|Completed|March 2010|April 2011|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|6 Years|12 Years|No|||September 2010|January 9, 2012|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201187||116304|
NCT01190917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO #09-0859|Neural and Behavioral Outcomes of Social Skills Groups in Children With Autism Spectrum Disorder (ASD)|Acute and Sustained Effects of Social Skills Intervention on Neural and Behavioral Outcomes in Children With ASD||Icahn School of Medicine at Mount Sinai|No|Completed|September 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|8 Years|11 Years|No|||October 2012|October 1, 2012|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01190917||117082|
NCT01192204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009C0086|Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention|Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention||Ohio State University|No|Completed|October 2010|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|41|||Both|21 Years|80 Years|No|||November 2013|August 12, 2015|August 30, 2010|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01192204||116986|While we initially planned to include microvascular densities and COX-2 analyses, there were insufficient tissue samples to collect these data. Therefore as we do not have these data we can not report them.
NCT01192464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26617-CAR CD 30|EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma|Phase I Study of the Administration of EBV CTLs Expressing CD30 Chimeric Receptors for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CAR CD 30)|CARCD30|Baylor College of Medicine|Yes|Active, not recruiting|March 2011|October 2033|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|N/A|No|||March 2016|March 9, 2016|August 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01192464||116966|
NCT01192789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|665-Ped/ERC-06|Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of Age|Cluster Randomized Trial of Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of Age in Hala and Matiari District, Pakistan||Aga Khan University|Yes|Completed|February 2008|May 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4070|||Both|2 Months|59 Months|No|||March 2010|October 12, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192789||116941|
NCT01175499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00166|Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract|Accuracy of Endoscopic Diagnosis of Carcinoma of the UpperAerodigestive Tract: A Tandem Trial of Direct Rigid Endoscopy and Transnasal Flexible Endoscopy With Narrowband Imaging|TNFE-NBI|University of California, San Francisco|No|Withdrawn|July 2010|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|July 20, 2010|Yes|Yes|Unable to obtain funding to continue recruitment; no accrual|No||https://clinicaltrials.gov/show/NCT01175499||118263|
NCT01176656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CUS-DUM-2010/1|Hypoglycemia: Physician and Patient Perspectives|Hypoglycemia: Physician and Patient Perspectives||AstraZeneca|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with T2DM will be identified from a large U.S. administrative claims database        using a claims-based algorithm for T2DM. Patients and their associated physicians will be        recruited via mail into the survey portion of this study. Survey results will be linked to        actual patient care using the claims records.|September 2011|September 12, 2011|August 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176656||118174|
NCT01176669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2010-03|Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients|A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Metastatic Triple-Negative Breast Cancer||Fudan University|No|Completed|June 2010|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|70 Years|No|||September 2015|September 8, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01176669||118173|
NCT01176357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96039|Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues|Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues Between Patients With Coronary Artery Diseases and With Valvular Diseases||Far Eastern Memorial Hospital|Yes|Recruiting|January 2008|||December 2008|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|Samples Without DNA|Adipose tissue biopsy samples from mediastinal fat, epicardial fat, subcutaneous fat in      thoracic region or abdominal region and subcutaneous fat in leg were obtained soon after      sternotomy or thoracotomy before the initiation of cardiopulmonary bypass.|Both|18 Years|N/A|No|Probability Sample|Patients with CAD or with valve diseases proposed to have cardiac operations|August 2010|August 4, 2010|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01176357||118197|
NCT01177540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7373-G000-202|Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects|A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects||Eisai Inc.||Completed|March 2011|July 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|1 Year|16 Years|No|||October 2013|October 21, 2013|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177540||118106|
NCT01177553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#105690|Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery|Randomized Clinical Trial: Expectant Management vs. Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation And Absent or Reverse Diastolic Flow in the Umbilical Artery||University of South Florida|Yes|Completed|May 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|August 5, 2010|No|Yes||No|September 21, 2012|https://clinicaltrials.gov/show/NCT01177553||118105|
NCT01178125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSG-PPS-303|A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy|A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-102) for the Prevention of Pregnancy in Women||Teva Pharmaceutical Industries|No|Completed|August 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2858|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|August 6, 2010|Yes|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT01178125||118062|
NCT01178138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110371|Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin|Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin|MATMA|University of Arkansas|Yes|Completed|December 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|August 4, 2010|Yes|Yes||No|July 31, 2014|https://clinicaltrials.gov/show/NCT01178138||118061|24 enrolled, 3 started study (1 withdrew after 5 sessions, 1 after 3 sessions; both for personal reasons), 1 completed. Data were collected on sessions completed.
NCT01178450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01PTHi|Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation|A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation||Hospital Universitari de Bellvitge|No|Completed|January 2010|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||April 2015|April 27, 2015|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01178450||118037|
NCT01178463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0065-09|Spermatogonial Stem Cells in Azoospermic Patients: a Comparison Between Obstructive and Non-obstructive Azoospermia|||Hillel Yaffe Medical Center|Yes|Active, not recruiting|January 2010|October 2010|Anticipated|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|25|||Male|18 Years|N/A|No|Probability Sample|Infertile male patients treated at the Hillel Yaffe Medical Center IVF Unit|August 2010|August 9, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178463||118036|
NCT01178476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyposafe-hypo-02|Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device|Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device||Hypo-Safe A/S|Yes|Withdrawn|November 2009|March 2011|Anticipated|January 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|70 Years|No|||August 2010|March 7, 2014|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01178476||118035|
NCT01178489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-FSP|Recovery at the Post Anaesthetic Care Unit After Hip and Knee Arthroplasty|Recovery at the Post Anaesthetic Care Unit After Fast-track Hip and Knee Arthroplasty||Hvidovre University Hospital|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|170|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing primary, unilateral, total hip or knee arthroplasty|September 2011|September 21, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178489||118034|
NCT01179607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0002-BEL-C201|Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia|A Randomized, Double Blind, Placebo Controlled, Phase II, Dose-titration Trial to Explore the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of M0002 in Cirrhotic Subjects With Ascites and Hypo- or Normonatraemia.||Movetis|No|Completed|June 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||July 2010|August 10, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179607||117948|
NCT01179334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15096|Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.|An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension|PATENT PLUS|Bayer|No|Completed|August 2010|May 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|75 Years|No|||January 2014|January 24, 2014|August 10, 2010|Yes|Yes||No|November 6, 2013|https://clinicaltrials.gov/show/NCT01179334||117969|
NCT01200121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-SUP-0108|Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers|Double-blind, Placebo-controlled, Randomized Phase II-study Investigating the Efficacy of Bevacizumab for Symptom Control in Patients With Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers||AIO-Studien-gGmbH|Yes|Completed|February 2010|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01200121||116386|
NCT01200407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1581001|Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients|An Open Label, Non-interventional Study Of The Safety, Tolerability, And Efficacy Of Amlodipine And Olmesartan Medoxomil (Normetec) In Filipino Patients With Hypertension: A Post Marketing Surveillance Study||Pfizer|No|Terminated|June 2010|January 2014|Actual|January 2014|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|615|||Both|18 Years|65 Years|No|Non-Probability Sample|Filipino Hypertensive patients ages 18-65 years old|March 2016|March 17, 2016|August 25, 2010||No|The requirement for Post Marketing Surveillance was lifted by the Philippine FDA|No||https://clinicaltrials.gov/show/NCT01200407||116364|
NCT01190579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDIC|Dual Source CT Angiography for Detection of Coronary Artery Stenoses|Multicenter Evaluation of Coronary Dual Source CT Angiography in Patients With Intermediate Risk of Coronary Artery Stenoses|MEDIC|University of Erlangen-Nürnberg Medical School|Yes|Recruiting|August 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|398|||Both|30 Years|80 Years|No|Non-Probability Sample|Patients with Chest Pain and an Intermdiate Likelihood for Coronary Artery Stenoses|August 2010|August 26, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01190579||117108|
NCT01190605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0131|Evaluating Factors That Impact Loss to Follow-up Among Postpartum HIV-infected Women in Mississippi|Evaluating Factors That Impact Loss to Follow-up Among Postpartum HIV-infected Women in Mississippi||University of Mississippi Medical Center|No|Completed|July 2010|July 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|53|||Female|18 Years|45 Years|No|Non-Probability Sample|Women in Mississippi with HIV infection who have been pregnant and received perinatal HIV        care at University of Mississippi Medical Center are eligible to participate in a        questionnaire study on the factors that affect entry into HIV care after delivery|December 2014|December 5, 2014|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190605||117106|
NCT01191255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-304|A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis|A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis||Keryx Biopharmaceuticals|Yes|Completed|October 2010|February 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|441|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|August 26, 2010|Yes|Yes||No|October 4, 2014|https://clinicaltrials.gov/show/NCT01191255||117058|
NCT01191281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT00395147|Improving Food Security and Nutrition to Promote ART Adherence in Latin America|Improving Food Security and Nutrition to Promote ART Adherence in Latin America||RAND|No|Completed|January 2010|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|400|||Both|18 Years|65 Years|No|||October 2012|October 17, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01191281||117056|
NCT01192477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017428|Ozone Cardiovascular Effects in Genetically Susceptible People|Ozone Cardiovascular Effects in Genetically Susceptible People|OZCARD|University of Rochester|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192477||116965|
NCT01192815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2309|Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck|A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck||Case Comprehensive Cancer Center|Yes|Terminated|January 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|70 Years|No|||October 2012|October 30, 2012|August 30, 2010|Yes|Yes|Funding unavailable|No||https://clinicaltrials.gov/show/NCT01192815||116939|
NCT01176331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOU-8487358664|Outcomes of 20 and 23-gauge Combined Transconjunctival Pars Plana Vitrectomy|Outcomes of 20 and 23-gauge Combined Transconjunctival Pars Plana Vitrectomy||Kocaeli University||Completed||||||Phase 4|Observational|Time Perspective: Retrospective||1|||||Both|44 Years|80 Years||Non-Probability Sample|Patients who were in the range 44 to 80 years, who had to undergo vitrectomy operation        with different diagnosis were included in the study. Each participant had a complete        ophthalmological examination which included best-corrected visual acuity (BCVA), slit lamp        examination with and without pupil dilation, intraocular pressure (IOP) measurement with        applanation tonometry and stereoscopic evaluation of the ocular fundus before decision of        operation.|July 2010|August 5, 2010|August 3, 2010||||No||https://clinicaltrials.gov/show/NCT01176331||118199|
NCT01176344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIDEO605501|VItamin D Effect on Osteoarthritis Study|Does Vitamin D Supplementation Prevent Progression of Knee Osteoarthritis? A Randomised Controlled Trial|VIDEO|Menzies Institute for Medical Research|No|Completed|August 2010|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|413|||Both|50 Years|79 Years|No|||September 2015|September 7, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176344||118198|
NCT01176097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2920C00001|To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes|A Randomized, Single-Blind, Placebo-Controlled, Single-Center, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Fasting After Single Ascending Oral Doses of AZD5658 in Type 2 Diabetes Mellitus Patients||AstraZeneca||Completed|July 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|65 Years|No|||February 2012|February 1, 2012|July 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176097||118217|
NCT01177267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP450OA3|Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions(DDI) Among Osteoarthritis Patients|Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Osteoarthritis Patients Taking Opioid Analgesics and Associated Economic Outcomes||NEMA Research, Inc.|Yes|Completed|September 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1||10000|||Both|18 Years|65 Years|No|Non-Probability Sample|retrospective database analysis|April 2012|April 28, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177267||118127|
NCT01177280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYP450cLBP4|Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes|||NEMA Research, Inc.||Completed|September 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1||10000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|chronic low back pain patients|April 2012|April 28, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177280||118126|
NCT01177566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1450|Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.|Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.||Emer, Jason, M.D.|Yes|Completed|September 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|2 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 5, 2010|August 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177566||118104|
NCT01177579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006969|Human Biomarkers for Assessing Copper Deficiency|Human Biomarkers for Assessing Copper Deficiency and Repletion: A Pilot Study||Purdue University|No|Recruiting|November 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177579||118103|
NCT01177865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000682206|Study of Treatment Choice in Patients With Localized Prostate Cancer|Evaluating Patient Preferences for the Treatment of Localized Prostate Cancer - A Discrete Choice Experiment||National Cancer Institute (NCI)||Recruiting|September 2010|||September 2012|Anticipated|N/A|Interventional|Primary Purpose: Health Services Research|||Anticipated|432|||Male|45 Years|80 Years|No|||November 2010|August 23, 2013|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177865||118081|
NCT01177839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910/193|Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore|Prospective, Hospital-based, Multicentre Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore||GlaxoSmithKline||Completed|May 2002|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|178|||Both|N/A|24 Months|No|Non-Probability Sample|All subjects < 24 months of age seen on an in- or out-patient basis with a diagnosis of        intussusception during at least a one year period beginning at study start.|November 2012|November 21, 2012|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177839||118083|
NCT01177852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-NTS-03(02/10)|Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis|Multicenter Clinical Trial, Phase III, Controlled, Open, Parallel Group, Randomized, Comparing the Fixed Dose Combination of Diphenhydramine + Dropropizine + Pseudoephedrine and the Combined Use of Dropropizine and Fixed Dose Combination of Pseudoephedrine Hydrochloride + Brompheniramine Maleate Used Orally for Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2 to 12 Years Old, Suffering From Non-productive Cough and Acute Rhinitis.||Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|October 2011|||April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|962|||Both|2 Years|12 Years|No|||July 2011|July 12, 2011|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177852||118082|
NCT01178151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCmedonc010|Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome|Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome|EVAMP|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Withdrawn|October 2010|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|July 26, 2010||No|No patients|No||https://clinicaltrials.gov/show/NCT01178151||118060|
NCT01178164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/04|Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains|Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains|DOUFAB|University Hospital, Bordeaux|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|137|||Both|6 Years|65 Years|No|||April 2013|April 3, 2013|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01178164||118059|
NCT01178775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200807050R|Development and Validation of Perceived Fatigue Meaning Scale on Walking Program|Development and Validation of Perceived Fatigue Meaning Scale and Its Effect on Individualized Patient Education and Walking Program for Managing Fatigue in Patients With Cancer|PFMS|National Taiwan University Hospital|Yes|Recruiting|September 2008|December 2011|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|105|||Both|20 Years|N/A|No|||August 2010|August 9, 2010|April 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01178775||118012|
NCT01175655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 28105|A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation|A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation|MSC in OB|The Prince Charles Hospital|Yes|Active, not recruiting|February 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||April 2015|April 30, 2015|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01175655||118251|
NCT01179620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEX839BDE06|Certoparin in Renal Patients Undergoing Hemodialysis|A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis|MEMBRANE|Novartis||Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|109|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01179620||117947|
NCT01175915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907001-3-1|A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease|||Jiangsu Kanion Pharmaceutical Co., Ltd|Yes|Recruiting|May 2010|August 2010|Anticipated|August 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|1 Year|13 Years|No|||August 2010|August 4, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01175915||118231|
NCT01190306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-001|Safety Study of the VEGA UV-A System to Treat Keratoconus|Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus||Topcon Medical Systems, Inc.|No|Terminated|August 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Both|12 Years|N/A|No|||January 2013|January 28, 2013|August 25, 2010|Yes|Yes|The sponsor terminated the study prior to data analysis for financial reasons.|No|December 13, 2012|https://clinicaltrials.gov/show/NCT01190306||117129|
NCT01190566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-MR Breast Cancer|PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer|PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients||Seoul National University Hospital|No|Completed|May 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|57|None Retained|Core biopsy specimens of breast cancer|Female|18 Years|70 Years|No|Probability Sample|Breast cancer patients who are candidates for neoadjuvant chemotherapy, pre-treatment MRI        and PET scan, post-treatment MRI and PET scan for evaluation of chemotherapy response        monitoring and residual disease|June 2015|June 11, 2015|August 25, 2010||No||No|December 30, 2013|https://clinicaltrials.gov/show/NCT01190566||117109|
NCT01190618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-176|Surgical Outcomes of Vaginal Prolapse Repair With Elevate|Surgical Outcomes of Vaginal Prolapse Repair With the Elevate Prolapse Repair Kit||William Beaumont Hospitals|No|Active, not recruiting|August 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|Women having vaginal repair with Elevate prolapse repair kit|December 2015|December 7, 2015|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190618||117105|
NCT01190592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11935|Resistance Training With Milk Supplementation in Adolescents|Effects of Resistance Training With Milk Supplementation on Body Composition in Middle School Children||University of Kansas Medical Center|Yes|Completed|October 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||June 2011|June 20, 2011|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190592||117107|
NCT01190930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL0932|Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma|Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)||Children's Oncology Group||Recruiting|August 2010|||March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|9022|||Both|1 Year|30 Years|No|||March 2016|March 18, 2016|August 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190930||117081|
NCT01191619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1006/104-004|Comparison of Two Insertion Techniques of Proseal Laryngeal Mask Airway by Unskilled Personnel in Children|Comparison of Two Insertion Techniques of Proseal Laryngeal Mask Airway by Unskilled Personnel in Children||Seoul National University Bundang Hospital|Yes|Recruiting|July 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|134|||Both|3 Years|9 Years|No|||July 2010|August 30, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01191619||117031|
NCT01191905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSGAM-001|Effects of HIgh Volume COntinuous REnal Replacement Therapy in Patients With Septic Acute Kidney Injury|Effects of HIgh Volume COntinuous REnal Replacement Therapy in Patients With Septic Acute Kidney Injury|HICORES|Seoul National University Hospital|Yes|Completed|January 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|20 Years|80 Years|No|||August 2015|August 18, 2015|August 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01191905||117009|
NCT01192490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00002301|Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices|Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices|10-053|University of Tennessee|Yes|Recruiting|August 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|210|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2011|June 15, 2011|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01192490||116964|
NCT01192503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14630|Safety and Efficacy of Rasagiline in Restless Legs Syndrome|Safety and Efficacy of Rasagiline in Restless Legs Syndrome|RAS-RLS|University of Virginia|No|Terminated|September 2010|August 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|August 23, 2010|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01192503||116963|
NCT01188863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-102-DM|Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Open-Label, Three-Way Crossover Study of Two Oral Formulations of LX4211 in Subjects With Type 2 Diabetes Mellitus||Lexicon Pharmaceuticals|No|Completed|September 2010|||October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|65 Years|No|||March 2011|March 29, 2011|August 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188863||117239|
NCT01175837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC09C3|Short-Term Fasting Before Chemotherapy in Treating Patients With Cancer|Short-Term Fasting Prior to Systemic Chemotherapy: A Pilot Feasibility Study||Mayo Clinic|No|Active, not recruiting|August 2010|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01175837||118237|
NCT01176084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lowcarbex_v1|Low Carb Diets & Exercise for Cardiovascular Disease (CVD) Reduction|The Efficacy of a Low Carbohydrate Diet, With and Without Exercise, on Cardiovascular Disease Risk in Obese Men||University of Surrey|No|Completed|January 2004|February 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||July 2010|August 19, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01176084||118218|
NCT01177293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531096|Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablets, Manufactured By Aurobindo Pharma Ltd., India To 10 Mg Amlodipine Besylate Capsules, Manufactured By Pfizer France Under Fasted Conditions||Pfizer|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 1, 2011|March 10, 2010|Yes|Yes||No|June 28, 2011|https://clinicaltrials.gov/show/NCT01177293||118125|
NCT01177319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSH|Glutathione (GSH) In The Treatment of Parkinson's Disease|Glutathione (GSH) In The Treatment of Parkinson's Disease||University of South Florida|No|Completed|September 2003|March 2007|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2007|August 6, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177319||118123|
NCT01177891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM08084|Genetic Analysis of Familial Cases of Premature Ovarian Failure|Genetic Analysis of Familial Cases of Premature Ovarian Failure|FAMIOP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Actual|110|Samples With DNA|Blood Sample|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Caucasian population|March 2015|March 25, 2015|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01177891||118080|
NCT01178190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-AMC|The Role of Narrow Band Imaging Videobronchoscopy in Lung Cancer|The Diagnostic Yield of Narrow Band Imaging Videobronchoscopy in Lung Cancer|NBI|Asan Medical Center|Yes|Completed|July 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|||Both|19 Years|N/A|No|Non-Probability Sample|suspected endobroncheal lesion on chest CT|June 2010|August 9, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01178190||118057|
NCT01178203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAU-1083|The Effects of Three Oral Medications on Post-operative Pain Following Endodontic Treatment|||Azad University of Medical Sciences|Yes|Completed|July 2010|August 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||||||Both|20 Years|60 Years||||July 2010|August 9, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178203||118056|
NCT01178177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPA -HEM vs SOT-2010|Radiologic Features of Invasive Pulmonary Aspergillosis|Retrospective Analysis of Radiologic Features of Invasive Pulmonary Aspergillosis in Transplant Recipients and Neutropenic Patients.Transplant Recipients and Neutropenic Patients||Asan Medical Center|Yes|Completed|January 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|130|||Both|16 Years|N/A|No|Probability Sample|All adult patients who are diagnosed with invasive pulmonary aspergillosis (IPA)between        January 2008 and February 2010.|May 2013|May 14, 2013|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178177||118058|
NCT01178502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-025|PGx Study to Develop and Validate the Predictive Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy|Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy in Korean Patients||Inje University|No|Completed|March 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|405|Samples With DNA|Blood samples were taken from patients for genotyping about 8ml|Both|20 Years|N/A|No|Probability Sample|the patients taking warfarin|May 2013|May 30, 2013|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178502||118033|
NCT01178515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Milk, Cardiovas risk, children|Low Fat Milk Intake and Cardio Vascular Risk (CVR) Indicators in Children|Impact of Low Fat Milk Intake on Cardiovascular Risk Indicators in Children 6-13 Years of Age||Instituto Nacional de Salud Publica, Mexico|Yes|Completed|September 2010|May 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|650|||Both|6 Years|13 Years|Accepts Healthy Volunteers|||June 2011|June 24, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178515||118032|
NCT01179074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEMSRT-1|Role of Radiotherapy Following Oesophageal Stenting in Cancer|Palliative Stenting With or Without Radiotherapy for Inoperable Oesophageal Carcinoma: a Randomised Trial||All India Institute of Medical Sciences, New Delhi|No|Completed|April 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|84|||Both|N/A|N/A|No|||February 2010|August 10, 2010|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01179074||117989|
NCT01179087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B32220109109|Sleep Disordered Breathing and Lung Transplantation|Sleep Disordered Breathing and Lung Transplantation||Katholieke Universiteit Leuven|No|Recruiting|August 2010|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|70 Years|No|Probability Sample|Patients undergoing lung transplantation|August 2013|August 5, 2013|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179087||117988|
NCT01175395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1067|20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)|An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD|20089/Combo|University of Illinois at Chicago|No|Completed|September 2010|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|55 Years|N/A|No|||October 2014|October 13, 2014|August 2, 2010|Yes|Yes||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01175395||118271|
NCT01175668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-10-196|Clonidine for Neonatal Abstinence Syndrome Study|Comparison of Clonidine Versus Phenobarbital as an Adjunct Therapy for Neonatal Abstinence Syndrome||Baystate Medical Center|Yes|Terminated|July 2010|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|N/A|15 Days|No|||November 2013|November 18, 2013|July 14, 2010|Yes|Yes|Based on the planned interim analysis results at 50% recruitment, after IRB reviewed the    results, further enrollment was stopped.|No|September 3, 2013|https://clinicaltrials.gov/show/NCT01175668||118250|One of the major limitations to our study was the inability to blind the two groups for the study medications.
NCT01175681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ischemia|Effect of Remote Ischemia Preconditioning on Myocardial Injury in Patients Undergoing Heart Valve Surgery|Effect of Remote Ischemia Preconditioning on Myocardial Injury in Patients Undergoing Heart Valve Surgery||Sun Yat-sen University|Yes|Completed|December 2007|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|73|||Both|N/A|N/A|No|||July 2010|July 20, 2011|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175681||118249|
NCT01189695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIDI-MONO|Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure|A Randomized Controlled Study Compares the 48 Weeks Results of HIV-1 RNA Between Ritonavir-boosted Lopinavir Monotherapy and Ritonavir-boosted Lopinavir + Optimized Background Regimens in HIV-1 Infected Patients Who Have HIV-1 RNA <50 Copies/ml More Than 6 Months While Receiving Salvage PI-based Regimen and Previously Failed NNRTI-based Regimen|BIDI-MONO|Bamrasnaradura Infectious Diseases Institute|No|Completed|December 2010|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|60 Years|No|||May 2013|May 10, 2013|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01189695||117176|
NCT01190020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LUB-106|Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.|Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation||University of Iowa|No|Recruiting|February 2009|||August 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||February 2011|February 9, 2011|August 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01190020||117151|
NCT01190033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIZT2010|Study Of The Efficacy Of Neurolysis In Functional Recovery From Chronic Nonspecific Low Back Pain|STUDY OF THE EFFICACY OF NEUROLYSIS IN FUNCTIONAL RECOVERY FROM CHRONIC NONSPECIFIC LOW BACK PAIN||University of Sao Paulo|Yes|Recruiting|August 2010|July 2013|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||March 2013|March 22, 2013|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01190033||117150|
NCT01190319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715153|Study: Effects of Strawberries on Blood Pressure|Effect of Strawberry Powder on Blood Pressure in Individuals With Pre-Hypertension|CSCBP|University of California, Davis|No|Active, not recruiting|September 2007|May 2012|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|25 Years|65 Years|No|||May 2012|May 1, 2012|October 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01190319||117128|
NCT01190943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST10B5|DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma|Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma||Children's Oncology Group|No|Active, not recruiting|August 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Tissue|Both|N/A|120 Years|No|Non-Probability Sample|Patients With Osteosarcoma|May 2015|September 30, 2015|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190943||117080|
NCT01191294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-011510|Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma|Development and Evaluation of a Simulation Training Module to Identify Lesions Requiring Further Visual Screen or Skin Biopsy for Melanoma||Northwestern University|Yes|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|270|||Both|18 Years|89 Years|No|||September 2014|September 24, 2014|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191294||117055|
NCT01191606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1005-100-003|Pressure-controlled Versus Volume-controlled Ventilation During Protective One Lung Ventilation|Pressure-controlled Versus Volume-controlled Ventilation During Protective One Lung Ventilation for Thoracic Surgery||Seoul National University Bundang Hospital|Yes|Recruiting|June 2010|December 2010|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|34|||Both|20 Years|70 Years|No|||May 2010|August 30, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01191606||117032|
NCT01191918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zlu001|The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania|A Double-Blind, Placebo-Controlled Evaluation of The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania||Shanghai Mental Health Center|Yes|Completed|May 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||August 2010|August 30, 2010|August 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01191918||117008|
NCT01193400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-CLOFARA-CA09|Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years|Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine and Low-dose Cytarabine for the Treatment of AML Patients Age Greater Than or Equal to 60 Years||PETHEMA Foundation|Yes|Terminated|September 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|60 Years|N/A|No|||April 2014|April 4, 2014|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193400||116896|
NCT01189136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0061|Treatment for Acute Postoperative Voiding Dysfunction|Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of Acute Postoperative Voiding Dysfunction|PTNS|Women and Infants Hospital of Rhode Island|No|Completed|July 2006|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Female|18 Years|95 Years|Accepts Healthy Volunteers|||June 2015|June 12, 2015|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01189136||117218|
NCT01189487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9231001|The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)|A Multicenter, Unblinded, Non-Comparative Study Of Unasyn-S 12 G/Day Evaluating The Safety And Efficacy In Japanese Adult Subjects With Community Acquired Pneumonia||Pfizer|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|16 Years|79 Years|No|||July 2012|July 9, 2012|August 16, 2010|Yes|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT01189487||117191|
NCT01189825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-12-0059|Efficacy of Exercise for Sexual Side Effects of Antidepressants|Effects of Acute Exercise on Sexual Arousal in Women Taking a Selective Serotonin Reuptake Inhibitor (SSRI) or Selective Serotonin/Norepinephrine Reuptake Inhibitor||University of Texas at Austin|No|Completed|June 2009|August 2012|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|48|||Female|18 Years|N/A|No|||February 2013|February 25, 2013|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189825||117166|
NCT01176695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0802|Efficacy and Safety of a Fish Oil Containing Lipid Emulsion|A Randomized, Double Blind, Controlled, Parallel Group, Multicenter Study on the Efficacy and Safety of a Fish Oil Containing Lipid Emulsion vs. a Medium and Long Chain Lipid Emulsion in Patients Undergoing Elective Abdominal Surgery of Moderate Severity||B. Braun Melsungen AG|No|Completed|April 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|85 Years|No|||January 2012|January 9, 2012|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01176695||118171|
NCT01176942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMS-01|Probiotics and Endotoxemia|Probiotics and Endotoxemia in Humans|PROMS-01|Danisco||Completed|May 2010|May 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 8, 2014|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01176942||118152|
NCT01177332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-024|Elevated Circulating FFA and Intrahepatic Lipid Content|Effects of Acute Elevation of Circulating Fatty Acids on Hepatic Lipid Accumulation and Metabolism in Healthy Overweight and Obese Men||Maastricht University Medical Center|No|Completed|April 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01177332||118122|
NCT01178567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10-117-10.CTIL|Comparison of Pulmonary Complications Related to Sleeve Gastrectomy and Gastric Banding|Comparison of Pulmonary Complications Related to Laparoscopic Sleeve Gastrectomy and Laparoscopic Adjustable Gastric Banding||Meir Medical Center|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|307|||Both|18 Years|N/A|No|Non-Probability Sample|300 sleeve gastectomy patients|May 2013|May 6, 2013|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178567||118028|
NCT01178801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002032R|Sharable Knowledge Mining Platform|Sharable Knowledge Mining Platform for Clinical Data Extraction, and Medical Knowledge and Mining Services Sharing||National Taiwan University Hospital|No|Recruiting|March 2010|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|patients with liver cancer. (ICD9 Code is 155.0)|July 2010|August 9, 2010|May 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01178801||118010|
NCT01179100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019834|How Lidocaine Affects Outcomes In Orthopedic Surgery Patients|The Effects Of Lidocaine Infusion On The Recovery Of Cognitive Function Following General Anesthesia In Elderly Patients Undergoing Orthopedic Surgeries Requiring A Minimum Two Day Hospitalization||Cedars-Sinai Medical Center|No|Withdrawn|June 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|0|||Both|65 Years|N/A|No|||September 2015|September 3, 2015|April 23, 2010||No|Patient population require high amount of opioids.|No||https://clinicaltrials.gov/show/NCT01179100||117987|
NCT01178528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTG001-07|Heart Rate Reduction in Heart Failure|Effect of Ivabradine, Carvedilol or Their Combination in Patients With Heart Failure|CARVIVA-HF|IRCCS San Raffaele|Yes|Completed|September 2009|October 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|121|||Both|35 Years|N/A|No|||September 2014|September 29, 2014|April 19, 2010||No||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01178528||118031|
NCT01178541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K111/2010|Simultaneous Measurement of Both Fetal's Lateral Ventricles of the Brain|Simultaneous Measurement of Both Fetal's Lateral Ventricles of the Brain||Meir Medical Center|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|low risk pregnant women|March 2012|February 18, 2013|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178541||118030|
NCT01178788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017441-63|Progestagens for the Tertiary Prophylaxis of Preterm Delivery|Progestagens for the Tertiary Prophylaxis of Preterm Delivery in Women With Short Cervix. A Randomized Multicentre Trial|PROTECT|University of Modena and Reggio Emilia|Yes|Recruiting|January 2011|June 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|480|||Female|N/A|N/A|No|||January 2011|February 2, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178788||118011|
NCT01175382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK082548-01A1|Combined Behavioral and Drug Treatment of Overactive Bladder in Men|Combined Behavioral and Drug Treatment of Overactive Bladder in Men|COBALT|University of Alabama at Birmingham|No|Completed|July 2010|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|432|||Male|40 Years|N/A|No|||August 2015|August 26, 2015|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175382||118272|
NCT01179672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13649|A Study in Participants With Diabetic Peripheral Neuropathic Pain in China|Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo||Eli Lilly and Company|No|Completed|April 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|August 10, 2010|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT01179672||117943|
NCT01176227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)|The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Irritable Bowel Syndrome (IBS)||The Canadian College of Naturopathic Medicine|Yes|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|64 Years|No|||March 2011|March 31, 2011|May 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01176227||118207|
NCT01176474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15651|Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma|A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|16 Years|N/A|No|||February 2016|February 29, 2016|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01176474||118188|
NCT01189708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG08/006|Prevention of Incisional Hernia After Elective Open Abdominal Aortic Aneurysm (AAA) Repair|Prevention of Incisional Hernia After Elective Open Abdominal Aortic Aneurysm Repair||Cantonal Hospital of St. Gallen|No|Terminated|March 2008|April 2011|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|February 20, 2008||No|Treatment without success, low enrollment, one serious adverse event|No||https://clinicaltrials.gov/show/NCT01189708||117175|
NCT01190046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033547|Chronic Muscle Disuse in the Elderly|Muscle Disuse and Contractile Dysfunction in the Elderly||University of Vermont|No|Recruiting|October 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|56|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||December 2010|December 1, 2014|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190046||117149|
NCT01190345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVASTEM/IPC 2009-001|Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer|Phase II" Proof of Concept " Trial Evaluating Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab in Combination With Chemotherapy in Breast Cancer|AVASTEM|Institut Paoli-Calmettes|No|Active, not recruiting|May 2010|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Female|18 Years|N/A|No|||March 2013|March 19, 2013|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01190345||117126|
NCT01190631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-10-008|An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation Following Intraocular Lens (IOL) Implantation|An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation After SN60WF IOL Implantation||Alcon Research|No|Completed|July 2010|||November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|100|||Both|40 Years|80 Years|No|||November 2012|November 27, 2012|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190631||117104|
NCT01191307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006C|Assess Specific Kinds of Children Challenges for Neurologic Devices Study|Assess Specific Kinds of Children Challenges for Neurologic Devices Study||Food and Drug Administration (FDA)|Yes|Recruiting|March 2009|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||5|Anticipated|100|||Both|7 Years|15 Years|No|Non-Probability Sample|Primary Dystonia Criteria; Between ages 7 and 15 years of age, Approved medical device for        Primary Dystonia, Neurologic device implanted within the past 12 months, Signed assent        form document from the child. Epilepsy Criteria; Between ages 12 and 15 years of age;        Neurologic device implantation or surgical (in-hospital) adjustment within the past 12        months; Approved medical device. Signed assent form document from the child. Pediatric        Hydrocephalus Criteria; Between ages 7 and 15 years of age, Approved medical device,        Neurologic shunt implantation or surgical (in-hospital) adjustment within the past 12        months, Signed assent form document from the child. Spinal Cord Injury Criteria; Between        ages 14 and 15 years of age, Approved medical device, Neurologic device implanted within        the past 12 months,Signed assent form document from the child. Deaf or Hearing Impaired        Criteria; Between ages 7 and 15* years of age, Approved medical device, Signed assent form        document from the child.|August 2010|August 26, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01191307||117054|
NCT01191632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S081/2008|Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases|Randomised Controlled Phase I/II Trail to Evaluate the Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation Therapy in Resectable Colorectal Liver Metastases Patients||Heidelberg University|No|Recruiting|March 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|50 Years|90 Years|No|||October 2010|October 21, 2010|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01191632||117030|
NCT01191645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS002|Opioid Effects on Swallowing and Esophageal Sphincter Pressure|Can Opioid Induced Effects on Esophageal Motility and Lower Esophageal Sphincter be Counteracted by a Dopamine Receptor Antagonist?||University Hospital Orebro|Yes|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 31, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01191645||117029|
NCT01192217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEPACTS-01|Video-assisted Thoracic Surgery (VATS) Versus Axillary Mini-thoracotomy for the Treatment of Recurrent Spontaneous Pneumothorax|A Prospective Randomized Study of a Modified Two-port Thoracoscopic Technique Versus Axillary Minithoracotomy for the Treatment of Recurrent Spontaneous Pneumothorax.||AHEPA University Hospital|No|Completed|January 2006|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|N/A|N/A|No|||January 2009|August 31, 2010|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01192217||116985|
NCT01192009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/02896-6|Leucine Supplementation and Skeletal Muscle Disuse|Leucine and Skeletal Muscle Disuse: Clinical Anti-Atrophic Effectiveness and Related Mechanisms||University of Sao Paulo|Yes|Completed|April 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192009||117001|
NCT01189149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115/08|Intravenous Fluids Versus Naso/Orogastric-tube Feeding in Hospitalized Infants With Bronchiolitis|Intravenous Fluids vs. Naso/Orogastric-tube Feeding in Hospitalized Infants With Acute Viral Bronchiolitis: a Randomized, Controlled, Prospective Clinical Trial||Bnai Zion Medical Center|No|Completed|December 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|N/A|6 Months|No|||December 2009|February 5, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01189149||117217|
NCT01190423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20550|Treatment for Young Adults With Anorexia Nervosa|Family-Based Treatment for Weight Restoration in Young Adults With Anorexia Nervosa||Temple University|Yes|Recruiting|July 2010|March 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|30 Years|No|||January 2011|March 26, 2013|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190423||117120|
NCT01176955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8982|A Novel Method to Improve Acne Outcomes|A Novel Method for Improving Acne Outcomes||Wake Forest School of Medicine|No|Completed|May 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|13 Years|18 Years|No|||November 2011|November 9, 2011|August 5, 2010|Yes|Yes||No|July 1, 2011|https://clinicaltrials.gov/show/NCT01176955||118151|
NCT01177306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS-IST-001|Inuniv and Working Memory|Phase 4 Study of the Effect of Extended Release Guanfacine on Working Memory in Children With ADHD||Schweickert, Lori A., M.D.|Yes|Completed|July 2010|May 2014|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|8 Years|12 Years|No|||July 2014|July 25, 2014|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01177306||118124|
NCT01177345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36813|Burden of Cervical Cancer in Tanzania|Survey Assessment and Projection of the Social and Economic Burdens of Cervical Cancer in Tanzania||Kilimanjaro Christian Medical Centre, Tanzania|Yes|Not yet recruiting|October 2010|December 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|105|||Female|30 Years|75 Years|No|Non-Probability Sample|Women diagnosed with cervical cancer at the Reproductive Health Clinic at Kilimanjaro        Christian Medical Centre (KCMC) and satellite cervical cancer screening clinics in rural        areas affiliated with KCMC.|September 2010|September 3, 2010|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01177345||118121|
NCT01177592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1714|Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)|Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)|TARGET-PCI|LifeBridge Health|No|Terminated|July 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|85 Years|No|||March 2014|March 18, 2014|August 6, 2010||No|Lack of financial support|No||https://clinicaltrials.gov/show/NCT01177592||118102|
NCT01177605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3376-1 (8575)|Assessment of Efficacy and Tolerance of a Follow-On Milk Containing a Mixture of Prebiotics Fed to Young Children in Salvador, Bahia, Brazil|||Mead Johnson Nutrition|No|Completed|September 2006|||March 2007|Actual|N/A|Interventional|N/A|2||||||Both|9 Months|48 Months|Accepts Healthy Volunteers|||August 2011|August 31, 2011|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01177605||118101|
NCT01178580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10-138-10.CTIL|Procoagulant Activity in Patients With Community Acquired Pneumonia, Pleural Effusion and Empyema|Procoagulant Activity in Patients With Community Acquired Pneumonia, Pleural Effusion and Empyema||Meir Medical Center|Yes|Completed|November 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Probability Sample|all patients that will be admitted with CAP to the pulmonary department in Meir Medical        Center and have no exclusion criteria will be included in the study|September 2011|September 5, 2011|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178580||118027|
NCT01178814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2696|Revlimid in Transfusion Dependent Patients|A Prospective Trial of Revlimid® in Transfusion Dependent Patients With Non-del (5q) Low/Intermediate-1 Risk Myelodysplastic Syndrome||Columbia University|Yes|Active, not recruiting|July 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|21 Years|N/A|No|||January 2016|January 15, 2016|August 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01178814||118009|
NCT01178827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-SXR-09-005|Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial|||Allergan|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|60 Years|N/A|No|||January 2016|January 28, 2016|August 9, 2010|Yes|Yes||No|March 23, 2012|https://clinicaltrials.gov/show/NCT01178827||118008|
NCT01179360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT-90867|Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Clinical Value of Combined [18F]Fluoro-2-deoxy-D-glucose (FDG) PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Potentially Operable Locally Advanced Head and Neck Squamous Cell Carcinoma.|ECLYPS|University Hospital, Antwerp|No|Active, not recruiting|February 2011|June 2016|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|173|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced, N2 and N3 HNSCC|December 2014|December 17, 2014|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179360||117967|
NCT01179633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP001|Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid|||Oplon-Pure Science Ltd.|Yes|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||August 2010|August 10, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01179633||117946|
NCT01179646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP796|Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets|A Pharmacokinetic Study to Determine the Bioequivalence of a Test 40 mg Pantoprazole Delayed-Release Tablet, Compared to a Marketed 40 mg Pantoprazole Delayed-Release Tablet (Protonix, Wyeth Pharmaceuticals) When Administered to Healthy Adult Subjects in the Fasted State||Kremers Urban Development Company|No|Completed|June 2004|August 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 10, 2010|August 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01179646||117945|
NCT01179659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP872|Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets Under Fed Conditions|A Pharmacokinetic Study to Assess the Bioequivalence of a Single-Dose of KUDCO and Wyeth Pharmaceuticals (Protonix) 40 mg Pantoprazole Sodium Delayed-Release Tablet When Administered to Healthy Adult Volunteers Under Fed Conditions||Kremers Urban Development Company|No|Completed|September 2005|March 2006|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2010|August 10, 2010|August 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01179659||117944|
NCT01179685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-043|Diagnostic Utility of Pleural Fluid MAGE Assay in Patients With Pleural Effusion From Primary Lung Cancer|Diagnostic Utility of Pleural Fluid MAGE Assay in Patients With Pleural Effusion From Primary Lung Cancer||Samsung Medical Center||Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179685||117942|
NCT01175694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brachy-APBI-03|Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer|Phase II Study - Dose Optimization PDR/HDR Brachytherapy Alone for Early Breast Cancer||University Hospital Erlangen|No|Recruiting|January 2010|January 2015|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|50 Years|N/A|No|||June 2010|August 19, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01175694||118248|
NCT01176487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-34 ICORG|Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34|A Clinical Trial Using 3-Dimensional Conformal Radiation Therapy to Reduce the Toxicity of Palliative Radiation for Lung Cancer||ICORG- All Ireland Cooperative Oncology Research Group||Active, not recruiting|June 2010|||December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|February 12, 2016|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176487||118187|
NCT01190358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917488|Grape Seed Extract and Postprandial Oxidation and Inflammation|Grape Seed Extract and Postprandial Oxidation and Inflammation: A Pilot Study in People With the Metabolic Syndrome.|GSEMetS|University of California, Davis|No|Active, not recruiting|August 2010|June 2012|Anticipated|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|12|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190358||117125|
NCT01190644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-011-ST-001|Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors|A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors||Celgene|No|Terminated|June 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|July 21, 2010|Yes|Yes|Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from    manufacturer. No alternatives available for use.|No||https://clinicaltrials.gov/show/NCT01190644||117103|
NCT01191658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-07-2252|Can Neck Circumference Measurements Less Than 43cm or Greater Than 43cm Predict Difficulty of Tracheal Intubation?|Can Neck Circumference Measurements Less Than 43cm or Greater Than 43cm Predict Difficulty of Tracheal Intubation?||CAMC Health System|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|adult patients who require tracheal intubation for general anesthesia and surgery|July 2011|July 14, 2011|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191658||117028|
NCT01191671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMEB001|Language and Deglutition in Children|Feeding and Sociolinguist Profile in Children|LDC|Fortaleza University|Yes|Completed|May 2009|December 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|89|||Both|1 Year|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|89 children, 41 children in public kindergarten and 48 children in daycare facilities.|May 2009|August 30, 2010|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01191671||117027|
NCT01191931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR2P00113|Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)|Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)|PHS-02|Advanced Medical Diagnostics s.a.|Yes|Completed|February 2008|June 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|Samples Without DNA|paraffin blocks of prostate specimens|Male|18 Years|N/A|No|Non-Probability Sample|Patients with histologically proven prostate cancer (positive biopsy) and who are planned        to undergo radical prostatectomy.|October 2012|October 26, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01191931||117007|
NCT01192230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EndoDocNSCLC|Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients|A Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients||Fudan University||Recruiting|June 2009|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||August 2010|September 15, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01192230||116984|
NCT01200849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00005495|Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use|Enhanced Spanish Drug Label Design to Promote Patient Understanding and Use||Northwestern University|Yes|Completed|October 2010|January 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|420|||Both|30 Years|N/A|No|||November 2014|November 17, 2014|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01200849||116330|
NCT01176981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000018144|Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma|Assessing the Safety, Feasibility, Cost Effectiveness and Patient Satisfaction of Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma||The Hospital for Sick Children|Yes|Recruiting|October 2010|December 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|6 Years|18 Years|No|||February 2016|February 8, 2016|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01176981||118149|
NCT01178216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genentech-Ritux2010|Use of Immune Globulin (IVIG) Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation|Use of Immune Globulin Intravenous (Human), 10% (IVIG), Plus Rituximab as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation||Cedars-Sinai Medical Center|No|Recruiting|September 2013|September 2018|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|70 Years|No|||August 2015|August 31, 2015|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01178216||118055|
NCT01178554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83423-0|The Clinic Treatment Project|Child System and Treatment Enhancement Projects (Child STEPs); The Clinic Treatment Project - Phase II|CTP|Judge Baker Children's Center|Yes|Completed|June 2005|June 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|203|||Both|7 Years|13 Years|No|||March 2011|March 15, 2011|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01178554||118029|
NCT01179126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROSS-AMI|Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease|Complete Revascularization Or streSS Echo in Patients With Multivessel Disease and ST-segment Elevation Acute Myocardial Infarction|CROSS-AMI|Complexo Hospitalario Universitario de A Coruña|No|Recruiting|September 2010|||September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||September 2013|September 2, 2013|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179126||117985|
NCT01179386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hermanadhd|Expectation of Driving Performance in Young Adults With ADHD Assessed by Driving Simulator and Seat Pressure Mapping|Expectation of Driving Performance in Young Adults With ADHD Assessed by Driving Simulator and Seat Pressure Mapping||Meir Medical Center|No|Not yet recruiting|November 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|15 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 adolescents aged 15-18 years ,diagnosed as suffering from ADHD and being treated with a        methylphenidate medication that is used in Israel 30 adolescents aged 15-18, without ADHD        will the control group|August 2011|August 27, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01179386||117965|
NCT01179399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C22001|Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies|A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Terminated|September 2010|January 2013|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|August 9, 2010|No|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT01179399||117964|
NCT01179113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019850|Esmolol Infusion During Laminectomy: Effect on Quality of Recovery|Esmolol Infusion for Maintaining Hemodynamic Stability During Single or Double Level Lumbar Laminectomy: Effect on Quality of Recovery.||Cedars-Sinai Medical Center|No|Terminated|June 2011|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|33|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|August 10, 2010||No|The preliminary result didn't show any benefit.|No||https://clinicaltrials.gov/show/NCT01179113||117986|
NCT01179373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003|Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease|Phase 2 Study of Trans Cranial Magnetic Stimulation as Additional Therapy Patients With Alzheimer's Disease||Brainsway|No|Active, not recruiting|August 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|45|||Both|50 Years|85 Years|No|||September 2014|September 15, 2014|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01179373||117966|
NCT01180283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIST 002|Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes.|Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patient With Type II Diabetes. Multicentric Study.||Cristália Produtos Químicos Farmacêuticos Ltda.||Completed|January 2009|April 2010||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Male|18 Years|65 Years|No|||August 2010|August 10, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01180283||117896|
NCT01175954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEREG-002|Cognitive and Behavioral Effects of Lacosamide|Phase IV Study of Cognitive and Behavioral Effects of Lacosamide as Adjunctive Therapy in Patients With Partial Epilepsy||Northeast Regional Epilepsy Group|No|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|70 Years|No|||September 2014|September 23, 2014|July 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01175954||118228|
NCT01176240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa NOH306 (306A / 306B)|A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease|A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease|306A/306B|Chelsea Therapeutics|Yes|Completed|June 2010|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|July 30, 2010|Yes|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01176240||118206|
NCT01180868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-02-049|The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases|The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases||Jonsson Comprehensive Cancer Center|No|Completed|May 2008|||November 2011|Actual|N/A|Observational|N/A||3|Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with cancer, patients with autoimmune dosorders, and healthy subjects.|July 2012|July 27, 2012|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180868||117851|
NCT01181193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR504110CTIL|Vitamin D for Treatment of Glioblastoma Multiforme|High-Dose Vitamin D in Combination With Chemoradiotherapy in the Treatment of Glioblastoma Multiforme||Soroka University Medical Center|No|Recruiting|March 2011|March 2014|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||August 2010|March 27, 2011|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01181193||117826|
NCT01190657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P216|Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer|A Multiple-center, Self-controlled Open Study to Evaluate Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer||Eisai Inc.|No|Completed|May 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1184|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190657||117102|
NCT01190670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK16|A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus|A Phase 1, Open Label, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 12, 2010|August 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01190670||117101|
NCT01190969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNSS 2010|A Trial of Oral Nutritional Supplements on Nutritional Status and Clinical Outcomes|A Randomized Controlled Trial of Oral Nutritional Supplements on Nutritional Status and Clinical Outcomes in Malnourished Elderly||Singapore General Hospital|Yes|Withdrawn|September 2010|November 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|120|||Both|65 Years|85 Years|No|||June 2011|June 15, 2011|August 26, 2010||No|difficulty in recruiting elderly subjects|No||https://clinicaltrials.gov/show/NCT01190969||117079|
NCT01190982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEP-ETU 202|Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer|A Multicenter, Open-Label, Phase II Study of LEP-ETU for Efficacy and Safety in Patients With Metastatic Breast Cancer||INSYS Therapeutics Inc|Yes|Completed|March 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Female|18 Years|N/A|No|||August 2012|August 23, 2012|August 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01190982||117078|
NCT01189526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVOIVRI|Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)|A Randomized Trial Comparing Intravitreal Ranibizumab and Macular Laser Photocoagulation for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion||Seoul Retina Investigator Group|Yes|Recruiting|January 2009|August 2011|Anticipated|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2010|August 25, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189526||117188|
NCT01189552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA026424|Depression Treatment for Low Income Substance Users|Depression Treatment for Urban Low Income Minority Substance Users|LET'S ACT|University of Maryland|Yes|Recruiting|October 2010|March 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|243|||Both|18 Years|65 Years|No|||May 2011|May 9, 2011|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01189552||117187|
NCT01191411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012011-152|Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs|Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs.||University of Texas Southwestern Medical Center|No|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|5970|||Both|54 Years|64 Years|No|||September 2014|October 29, 2014|August 27, 2010||No||No|October 13, 2014|https://clinicaltrials.gov/show/NCT01191411||117046|
NCT01191424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1017-PR-0034|A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.|A Multicenter, Multinational, Single-Dose, Open Label, Randomized, 2-Way Crossover, Clinical Pharmacology Study of CHF 1535 100/6 Next™ DPI (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg) Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescents and Adult Patients|ADONE|Chiesi Farmaceutici S.p.A.|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|12 Years|65 Years|No|||November 2011|November 16, 2011|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191424||117045|
NCT01193075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC-6601|Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others|Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Type (CMT1B), 2A (CMT2A), 4A (CMT4A), 4C (CMT4C), and Others|INC-6601|University of Iowa|Yes|Recruiting|April 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|5000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who present to a participating site and have Charcot Marie Tooth disease (CMT)        will be recruited for participation.|May 2015|May 14, 2015|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01193075||116919|
NCT01193387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3769|Comparison of Two Identical NN1250 Formulations in Healthy Volunteers|A Trial to Test for Bioequivalence Between Identical NN1250 Formulations, IM1 and IM2, in Healthy Subjects||Novo Nordisk A/S|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|August 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01193387||116897|
NCT01201135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDF-15CTIL|GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis|The Impact of Growth Differentiating Factor (GDF) 15 in Sickle Cell Disease and Hereditary Spherocytosis|GDF 15|Wolfson Medical Center|No|Not yet recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|80|||Both|5 Years|N/A|No|Non-Probability Sample|The study will contain 40 patients with Sickle cell disease and 40 patients with        hereditary spherocytosis.        After ICF (Informed Consent Form) has been signed by the patients the following laboratory        tests will be taken once during the study:          1. GDF 15( 3ml of serum) (at the laboratory of hematology at Wolfson Medical             Center/Israel)          2. Hepcidine (3ml of serum) (at the laboratory of Prof. T. Ganz, USA). The blood samples             should be taken at least one week apart from blood transfusion.        In case of infection or acute inflammation , blood samples should be taken only one week        after resolution of these conditions.|September 2010|September 12, 2010|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201135||116308|
NCT01201460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123961|DPBRN Blood Sugar Testing in Dental Patients|Blood Sugar Testing in Dental Patients||Dental Practice-Based Research Network|No|Completed|April 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|498|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The human subjects direclty involved in this study were the patients who had sought dental        treatment in the (DPBRN) practitioner-investigators' practices.|June 2011|June 14, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201460||116283|
NCT01200836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100165|Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol|Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol||National Institutes of Health Clinical Center (CC)||Completed|June 2010|||||Phase 1|Observational|Time Perspective: Prospective|||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200836||116331|
NCT01201109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/354|Carpal Tunnel Release in Diabetic Patients|Five Years Follow-up After Carpal Tunnel Release in Diabetic and Non-diabetic Patients||Skane University Hospital|No|Enrolling by invitation|November 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|66|||Both|18 Years|80 Years|No|Non-Probability Sample|Prospective series of matched diabetic and non-diabetic patients who were operated for        carapl tunnel syndrome 5 years ago.|September 2010|September 27, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201109||116310|
NCT01176994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0016-09|Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.|Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.||Hillel Yaffe Medical Center|Yes|Not yet recruiting|December 2010|May 2012|Anticipated|May 2011|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2010|August 5, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01176994||118148|
NCT01178229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|via aerea 01|Physiotherapy on the Airway of Bruxist Children|AWARNESS THROUGH MOVEMENT PHYSIOTERAPEUTIC TECHNIQUE INCREASED THE AIRWAY DIMENSIONS OF BRUXIST CHILDREN: A SINGLE BLIND RANDOMIZED CLINICAL TRIAL.||CES University|No|Completed|January 2006|November 2007||June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|3 Years|6 Years|No|||July 2006|August 9, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01178229||118054|
NCT01178606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10094-2010CTIL|Measurement of Echogenic Area in the Border of the Fetal Ventricles|||Meir Medical Center|No|Withdrawn|September 2010|February 2011|Actual|February 2011|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Actual|0|||Both|22 Weeks|37 Weeks|Accepts Healthy Volunteers|Probability Sample|pregnant women 22-37GA, singleton normal pregnancy|August 2013|August 27, 2013|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178606||118025|
NCT01179139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P002050|Pathogenesis of Chronic Sinusitis in Relationship to Tobacco Smoke Exposure|Pathogenesis of Chronic Sinusitis in Relationship to Tobacco Smoke Exposure|FAMRI|Massachusetts General Hospital|No|Completed|December 2003|April 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|97|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||July 2011|July 12, 2011|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01179139||117984|
NCT01179412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKC2004|Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine|Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine||Mahidol University|No|Completed|July 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|7 Years|N/A|No|||August 2010|August 10, 2010|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01179412||117963|
NCT01179711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-06-027|Under-correction in Refractive Accommodative Esotropia|The Maximal Tolerable Reduction in Hyperopic Correction in Patients With Refractive Accommodative Esotropia: A 6-month Follow-up Study||Samsung Medical Center|Yes|Completed|June 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|24 Months|18 Years|Accepts Healthy Volunteers|||August 2010|August 10, 2010|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01179711||117940|
NCT01179698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-08-058|Navigation Surgery for Bone and Soft Tissue Tumor|Navigation Surgery for Bone and Soft Tissue Tumor||Samsung Medical Center|No|Recruiting|January 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2010|August 10, 2010|July 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01179698||117941|
NCT01175408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Monitoring and Acquisition T2D|Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin|Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin||Endocrine Research Society|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|100|||Both|25 Years|70 Years|No|||September 2014|September 9, 2014|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175408||118270|
NCT01180608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vubmtmoensLIIRA|Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain|Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain in Patients With Diabetic Polyneuropathy Using Proton MR Spectroscopy||Universitair Ziekenhuis Brussel|Yes|Not yet recruiting|September 2010|September 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2010|August 11, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180608||117871|
NCT01180582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2009-039|Roentgen Stereophotogrammetric Analysis (RSA) and Dual Energy X-ray Absorptiometry (DEXA) to Evaluate Fixation of Periapatite Coated Triathlon Total Knee Arthroplasty (TKA) Components|Prospective Clinical Study Using Roentgen Stereophotogrammetric Analysis (RSA) and DEXA to Evaluate Fixation of Periapatite Coated Triathlon Total Knee Arthroplasty Components||Dalhousie University|No|Completed|April 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|21 Years|80 Years|No|||March 2014|March 28, 2014|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180582||117873|
NCT01180595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-010|Roentgen Stereophotogrammetric Analysis (RSA) Trial Comparing Trabecular Metal Monoblock and Modular Tibial Components|Randomized Control Study Using Roentgen Stereophotogrammetric Analysis (RSA) to Compare the Fixation of the Trabecular Metal Monoblock and the Trabecular Metal Modular Total Knee Arthroplasties||Dalhousie University|No|Active, not recruiting|February 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|80 Years|No|||August 2015|August 6, 2015|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180595||117872|
NCT01181206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUM-Chir-002/2010|Covering of the Abdominal Wall in Laparotomies: Differences in Surgical Site Infections Between an Approved Abdominal 3M™ Steri-Drape™ Wound Edge Protector and Standard Woven Swabs at Technische Universität München|Standard-Bauchwandabdeckung Mit Bauchtüchern vs. Abdeckung Mittels ringförmiger Folie: Eine Doppelblinde Randomisiert-kontrollierte Studie|BaFo|Technische Universität München|No|Completed|August 2010|February 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|516|||Both|18 Years|N/A|No|||December 2012|June 17, 2014|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181206||117825|
NCT01190995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pain and Neurobehaviour|Role of Repeated Painful Procedures in Preterm Neonates on Short Term Neurobehavioural Outcome|A Randomised Controlled Trial to Evaluate the Role of Repeated Painful Procedures in Preterm Neonates on Short Term Neurobehavioural Outcome||Lady Hardinge Medical College|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|106|||Both|N/A|28 Days|No|||November 2011|November 23, 2011|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190995||117077|
NCT01191320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-202|Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus|A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment||Repros Therapeutics Inc.|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Male|20 Years|80 Years|No|||June 2014|June 27, 2014|August 27, 2010|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01191320||117053|
NCT01191333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|556|The Effectiveness of rTMS in Depressed VA Patients|CSP #556 - The Effectiveness of rTMS in Depressed VA Patients||VA Office of Research and Development|Yes|Recruiting|July 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|80 Years|No|||March 2016|March 3, 2016|August 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01191333||117052|
NCT01191346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTC-G1|Radiation Planning Study for High Grade Brain Tumors|3T Versus 1.5T MR Approaches in Target Definition for Malignant Gliomas: Is There a Significant Difference in Tumor Extent and Radiation Treatment Volume?||University of Cincinnati||Recruiting|June 2010|||June 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with high grade glioma planning to receive radiation therapy|February 2011|February 11, 2011|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01191346||117051|
NCT01192269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116-10|Cheek Cells - Non-invasive Fatty Acid Status Marker|Buccal Cheek Cells - a New Non-invasive Fatty Acid Status Marker||Ludwig-Maximilians - University of Munich|No|Completed|August 2010|June 2012|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2012|July 2, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01192269||116981|
NCT01191736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-070|Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice|Comparison of the Effectiveness of Ultra-Brief and Brief Hands-Only CPR Video Training With and Without Psychomotor Skill Practice for Lay Responders: a Controlled Randomized Study||Maricopa Integrated Health System|No|Completed|September 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|7||Actual|336|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 2, 2011|August 27, 2010||No||No|September 17, 2010|https://clinicaltrials.gov/show/NCT01191736||117022|
NCT01191749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0187|Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)|Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL)||M.D. Anderson Cancer Center|No|Terminated|August 2010|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||December 2013|December 18, 2013|August 27, 2010|Yes|Yes|Low Accrual|No||https://clinicaltrials.gov/show/NCT01191749||117021|
NCT01200602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0896|Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy|A Randomized Megestrol Acetate/Placebo Controlled Trial in Pediatric Patients With Malignancies With Weight Loss/Anorexia||Mayo Clinic|Yes|Terminated|March 2011|January 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1|||Both|N/A|21 Years|No|||October 2015|October 29, 2015|September 10, 2010|Yes|Yes|The study closed due to slow accrual.|No|March 29, 2013|https://clinicaltrials.gov/show/NCT01200602||116349|
NCT01201720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG0905|Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"|Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Liver Failure"||Instituto Grifols, S.A.|No|Completed|March 2011|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01201720||116263|
NCT01200888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09092010-6830|Controlled Ventilation CT in CF Infants|Differentiating Outcome Measures in Infants/Young Children With Cystic Fibrosis Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing||Stanford University|No|Recruiting|September 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|2 Months|5 Years|No|Non-Probability Sample|Young children with cystic fibrosis at Packard Children's Hospital.|December 2012|December 14, 2012|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200888||116327|
NCT01201122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0052-10-WOMC|Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis|Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC.|MUPPIT|Wolfson Medical Center|Yes|Completed|September 2010|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|6 Years|18 Years|No|||December 2015|December 6, 2015|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201122||116309|
NCT01201447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119275|DPBRN Prevalence of Questionable Occlusal Caries Lesions|Prevalence of Questionable Occlusal Caries Lesions||Dental Practice-Based Research Network|No|Completed|August 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|2624|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participants directly involved in this study were the patients who have sought dental        treatment in the DPBRN practitioner-investigators' practices.|March 2011|March 3, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201447||116284|
NCT01177904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-GK-01-2009-02|Early Progesterone Cessation After in Vitro Fertilization|Early Progesterone Cessation After in Vitro Fertilization||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|January 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|40 Years|No|||March 2011|March 16, 2011|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01177904||118079|
NCT01177917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3371-4|Evaluation of Mineral Absorption in Infants Fed Infant Formula|||Mead Johnson Nutrition|No|Completed|August 2006|October 2008|Actual|September 2008|Actual|N/A|Interventional|N/A|2||||||Both|56 Days|70 Days|Accepts Healthy Volunteers|||August 2010|August 6, 2010|August 6, 2010||||No||https://clinicaltrials.gov/show/NCT01177917||118078|
NCT01178840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONRAD-108|Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom|A Randomized Cross-Over Study of Vaginal Semen Exposure and Clinical Failure Comparing the PATH Woman's Condom and the FC2 Female Condom|CONRAD-108|CONRAD|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|505|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|December 11, 2013|August 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01178840||118007|
NCT01178853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.03US|Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers|Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers||Kowa Research Institute, Inc.|No|Completed|July 2010|April 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|August 9, 2010|Yes|Yes||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01178853||118006|
NCT01183754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200603|Use of a Point-of-Care Platelet Function Assay for the Prediction of Atherothrombotic Events|Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events After Implantation of Drug-Eluting Stents: ASAN-VerifyNow Registry|ASAN-VERIFY|CardioVascular Research Foundation, Korea|Yes|Completed|March 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3000|Samples With DNA|Blood sampling for genotyping (genetic subgroup analysis)|Both|18 Years|N/A|No|Probability Sample|The study population included consecutive patients with de novo coronary artery disease        who underwent an initial PCI with drug-eluting stents and had VerifyNow test at the Asan        Medical Center (Seoul, Korea)|March 2006|January 31, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01183754||117630|
NCT01184040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-249-1|Extending Contingency Management's Benefits With Progressively Increasing Variable Interval Prize Reinforcement|Extending Contingency Management's Benefits With Progressively Increasing Variable Interval Prize Reinforcement||University of Connecticut Health Center|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01184040||117609|
NCT01184274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I203|A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia|A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia||Canadian Cancer Trials Group|No|Completed|September 2010|January 2014|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|12 Months|18 Years|No|||January 2014|January 16, 2014|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184274||117591|
NCT01179724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-06-030|Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial|Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial||Samsung Medical Center||Recruiting|July 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|206|||Both|18 Years|80 Years|No|||June 2009|August 10, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179724||117939|
NCT01175421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/02449|Multidimensional System as Predictor of Outcomes in Obstructive Sleep Apnea: The OSA-SCORE|Development and Validation of a Multidimensional System as Predictor of Outcomes in Obstructive Sleep Apnea: The OSA-SCORE|OSA-SCORE|Hospital Miguel Servet|No|Completed|May 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1100|||Both|18 Years|70 Years|No|Non-Probability Sample|Sleep Clinic|August 2010|March 19, 2015|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175421||118269|
NCT01175707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-009|Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting|A Phase 4, Prospective, Randomized, Open-label Study to Compare Use of Cubicin With Vancomycin Administered Intravenously in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Confirmed Gram-positive Bacteria in a Home Infusion Setting||Cubist Pharmaceuticals LLC|No|Terminated|July 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|80|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 20, 2010||No|Business decision|No|April 5, 2013|https://clinicaltrials.gov/show/NCT01175707||118247|The study was terminated prematurely.
NCT01181518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-140|Tamoxifen Pharmacogenetics in Asian Breast Cancer Women|Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients|Tamoxifen|Inje University|No|Recruiting|August 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|Samples With DNA|Blood samples for genotyping and pharmacokinetic analysis|Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients who underwent surgery at Busan Paik Hospital, Inje University|May 2013|May 31, 2013|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181518||117801|
NCT01181531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090686|Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis|A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis||Amgen|No|Completed|October 2010|October 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|August 12, 2010||No||No|December 3, 2013|https://clinicaltrials.gov/show/NCT01181531||117800|
NCT01181544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gambro PI 2012|A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis|Heparin Dose Reduction During Hemodialysis With the Gambro Revaclear and Revaclear MAX Hemodialyzers: Pilot Study I and II||Gambro Renal Products, Inc.|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181544||117799|
NCT01180881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009A058394|Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment|Neurobehavioral Functioning and Utilization of Special Education Services in Pediatric Brain and CNS Tumor Patients After Proton Radiation Treatment: A Longitudinal Study||Massachusetts General Hospital|Yes|Active, not recruiting|October 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|2 Years|25 Years|No|Non-Probability Sample|Pediatric patients who received proton radiation therapy at MGH|April 2015|April 6, 2015|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180881||117850|
NCT01182090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPerugia|Surgical Correction of Pelvic Organ Prolapse|OPEN SURGERY VS LAPAROSCOPY IN SURGERY OF PELVIC ORGAN PROLAPSE||University Of Perugia|No|Completed|August 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|75 Years|No|||July 2010|May 19, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182090||117757|
NCT01191008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6641056|Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension|Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|October 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|661|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A6641056 prescribes the Xalacom® Combination        Eye Drops.|September 2015|September 30, 2015|August 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01191008||117076|
NCT01191021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H54427-35579|Monitoring Exhaled Propofol to Individualize General Anesthesia|Pilot Study to Estimate Central Propofol Effect by Measuring Exhaled Propofol Concentrations|EPIGA|University of California, San Francisco|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 4, 2013|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01191021||117075|
NCT01193114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008B0309|Stage 1 Treatment Development With Homeless Mothers|Stage 1 Treatment Development With Homeless Mothers and Their 2-6 Year Old Children||Ohio State University|No|Completed|April 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||January 2013|January 26, 2013|February 2, 2010||No||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01193114||116916|
NCT01191099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016||Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance|Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance||University of Zurich|Yes|Recruiting|August 2010|August 2020|Anticipated|August 2012|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|prostate|Male|N/A|N/A|No|Non-Probability Sample|Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with        radical prostatectomy at the Department of Urology, University Hospital of Zurich|November 2011|November 7, 2011|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01191099||117070|
NCT01191112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK87|Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population|Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population||Abbott Nutrition|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|1 Year|13 Years|No|||March 2015|March 2, 2015|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191112||117069|
NCT01191944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.671|Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients|A Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With Levodopa||Boehringer Ingelheim||Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|475|||Both|30 Years|N/A|No|||October 2014|October 22, 2014|August 30, 2010|Yes|Yes||No|December 19, 2012|https://clinicaltrials.gov/show/NCT01191944||117006|
NCT01191957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GITMO AMLR2|Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML|Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission.|GITMO-AMLR2|Gruppo Italiano Trapianto di Midollo Osseo|Yes|Completed|January 2008|October 2014|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Both|40 Years|65 Years|No|||September 2015|September 2, 2015|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01191957||117005|
NCT01200615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025622648|The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects|The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects||Shalvata Mental Health Center|Yes|Not yet recruiting|October 2010|October 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|66 Years|No|||September 2010|September 10, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01200615||116348|
NCT01201161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RANITRA|Ranibizumab for Diabetic Traction Retinal Detachment|The Effect of Intravitreous Ranibizumab on Intra-Operative Bleeding During Pars Plana Vitrectomy for Diabetic Traction Retinal Detachment|RANITRA|University of Sao Paulo|No|Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|80 Years|No|||January 2010|September 13, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201161||116306|
NCT01201733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5270900044|Traditional Thai Massage and Brain Electrical Activity|The Immediate Effect of Traditional Thai Massage on Brain Electrical Activity in Patients With Scapulocostal Syndrome||Khon Kaen University|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|50 Years|No|||September 2010|August 13, 2012|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201733||116262|
NCT01177943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13554|A Bioequivalence (BE) Study in Healthy Subjects|LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects||Eli Lilly and Company|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 20, 2011|August 6, 2010|No|Yes||No|September 20, 2011|https://clinicaltrials.gov/show/NCT01177943||118076|
NCT01177956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62241_055|A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck|Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Asian Subjects|CHANGE|Merck KGaA|Yes|Completed|December 2009|November 2012|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|June 2, 2010||No||No|July 3, 2012|https://clinicaltrials.gov/show/NCT01177956||118075|
NCT01178255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP-HOM10|Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)|Homeopathy for Depression: a Randomized, Partially Double-blind, Placebo Controlled, Four Armed Study DEP-HOM|DEP-HOM|Charite University, Berlin, Germany|Yes|Terminated|August 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|65 Years|No|||July 2012|July 9, 2012|August 9, 2010||No|recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01178255||118052|
NCT01178866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC517/04|Laboratory Outcome Predictors in Coronary Surgery|Markers of Tissue Perfusion as Predictors of Complicated Evolution in Patients With Left Ventricular Dysfunction Submitted to Coronary Artery Bypass Surgery||University of Sao Paulo|Yes|Completed|January 2006|March 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|N/A|No|Probability Sample|Adults undergoing coronary artery bypass surgery requiring the use of CPB|January 2008|August 9, 2010|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178866||118005|
NCT01184053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0920|Trisenox® in Women With Metastatic Endometrial Cancer|A Phase II Trial of Trisenox in Women With Recurrent or Metastatic Endometrial Adenocarcinoma|NRR|UNC Lineberger Comprehensive Cancer Center|Yes|Terminated|March 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|July 22, 2010|No|Yes|Accrual was very low. No subject had been enrolled in a year.|No||https://clinicaltrials.gov/show/NCT01184053||117608|
NCT01184300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-9427-U0143-43C|ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation|ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)|RAPID GENE|Ottawa Heart Institute Research Corporation|No|Completed|August 2010|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||November 2011|November 10, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184300||117589|
NCT01184313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mikkola2010|Acute Lung Injury After Aortic Valve Surgery|Acute Lung Injury After Aortic Valve Surgery||University of Oulu||Not yet recruiting|September 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|elective aortic valve surgery patients in Oulu University hospital|August 2010|September 2, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184313||117588|
NCT01184287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30-800|A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer|A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer||Tamir Biotechnology, Inc.|Yes|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 17, 2010|Yes|Yes|Program discontinued|No||https://clinicaltrials.gov/show/NCT01184287||117590|
NCT01179997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT-opt|Tissue Doppler Imaging (TDI) Versus Electrocardiography (ECG) Interventricular Pacing Delay Optimization in Cardiac Resynchronization Therapy (CRT)|||Hospital Clinic of Barcelona|Yes|Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|N/A|N/A|No|||May 2010|February 26, 2014|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01179997||117918|
NCT01180010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 08-0294-CE|Low Dose Chest Computed Tomography (CT) Screening|Low-Dose Chest CT for Lung Cancer Screening in Survivors of Hodgkin's Disease||University Health Network, Toronto|No|Active, not recruiting|August 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated for Hodgkin's Lymphoma|June 2015|June 16, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180010||117917|
NCT01181557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-D176768|A Questionnaire to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma|Prospective Evaluation of Quality of Life in Patient With Rectal Cancer||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Completed|September 2008|December 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|236|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients admitted to hospital for rectal cancer, Italian resident older than 18 years,        without history of psychiatric illness, or preoperative radiotherapy, dived in two cohorts        patient with stoma after surgery and patients without stoma after surgery|July 2008|August 12, 2010|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01181557||117798|
NCT01181570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6016|Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea|Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea||Innovaderm Research Inc.|No|Completed|September 2010|September 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||October 2011|October 27, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181570||117797|
NCT01181856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB022|Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route|Safety and Immunogenicity of Candidate Tuberculosis (TB) Vaccine MVA85A Administered by the Intramuscular Route and the Intradermal Route: a Phase I Randomised Active Controlled Trial||University of Oxford|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181856||117775|
NCT01181869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|observatoire antadir|Database of Patients Treated With Respiratory Support|Observatoire de l'ANTADIR - Database of Patients Registered as Treated With Respiratory Support in a Multicenter Homecare Federation for Patients Wirh Respiratory Problems|observatory|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|Yes|Recruiting|January 1983|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|120000|||Both|N/A|N/A|No|Non-Probability Sample|Patients requiring respiratory support, in the ANTADIR homecare federation|April 2012|April 12, 2012|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181869||117774|
NCT01182428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-377 sub-study|XIENCE V: SPIRIT WOMEN Sub-study|A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions||Abbott Vascular|Yes|Completed|September 2008|July 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|455|||Female|18 Years|N/A|No|||July 2012|July 23, 2012|July 13, 2010|Yes|Yes||No|May 3, 2012|https://clinicaltrials.gov/show/NCT01182428||117731|
NCT01182727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00046612|Salsalate for Insulin Resistance in Schizophrenia|Salsalate for the Treatment of Insulin Resistance in People With Schizophrenia||University of Maryland|Yes|Completed|August 2010|December 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||May 2013|May 7, 2013|August 13, 2010|Yes|Yes||No|January 28, 2013|https://clinicaltrials.gov/show/NCT01182727||117708|
NCT01192854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XY3-III-CLV-1001A02.4|An Study of Efficacy and Safety of Clevudine|A Multi-center, Randomized, Double-blind, Positive-control, Phase III Trial of the Efficacy and Safety of Clevudine||Eisai Inc.||Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|288|||Both|18 Years|65 Years|No|||July 2011|May 13, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192854||116936|
NCT01188889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.093|RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.|An Open Label, Time-To-Event Continuous Reassessment Method, Phase I/II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib (Gleevec) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) With Persistent Molecular Disease.||University of Michigan Cancer Center|Yes|Withdrawn|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|August 25, 2010|Yes|Yes|Unable to obtain sufficient funding.|No||https://clinicaltrials.gov/show/NCT01188889||117237|
NCT01189188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/RGG-03|Ultrasound Guidance for Radial Arterial Blood Sampling|Ultrasound Guidance for Radial Arterial Blood Sampling||Centre Hospitalier Universitaire de Nīmes|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|74|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189188||117214|
NCT01189201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1275.3|Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food|Relative Bioavailability Investigations of a 25 mg BI 10773 / 5 mg Linagliptin Fixed Dose Combination (FDC) Tablet (Formulation A1) Including the Comparison With Its Mono-components, the Comparison With a Second FDC Tablet (Formulation A3), and the Investigation of Food (an Open-label, Randomised, Single Dose, Crossover, Phase I Trial in Healthy Male and Female Volunteers)||Boehringer Ingelheim||Completed|August 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|August 25, 2010||||No|March 10, 2015|https://clinicaltrials.gov/show/NCT01189201||117213|
NCT01191359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-B-02|Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch|A Multicentre Randomised Phase II Clinical Pilot Study to Compare the Pharmacodynamic Efficacy and Tolerability of the Sublingual and the Vestibular Administration Route for SLITonePLUS® Birch||ALK-Abelló A/S|No|Completed|January 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||February 2013|February 7, 2013|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191359||117050|
NCT01191372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC19499-001|First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients|First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients||Baxalta US Inc.|No|Terminated|September 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|17|||Male|18 Years|75 Years|No|||April 2013|June 26, 2015|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01191372||117049|
NCT01191684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10105|Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer|A Phase I Study of an MVA Vaccine Targeting P53 in Cancer||City of Hope Medical Center|Yes|Completed|October 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2013|August 21, 2013|August 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01191684||117026|
NCT01192828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1376|Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine|Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine||University of Colorado, Denver|No|Active, not recruiting|January 2010|June 2016|Anticipated|January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|8 Years|49 Years|No|||January 2016|January 27, 2016|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192828||116938|
NCT01193062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1661004|Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274|A Phase 1 Investigator And Subject-Blind Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Doses Of PF-04995274 On Sapp-Alpha Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology||Pfizer|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 11, 2011|August 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01193062||116920|
NCT01200862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGS649A2204|Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men|An Open-label Dose Finding Study Followed by a Parallel Group, Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Pharmacodynamics of 12 Week BGS649 Treatment in Obese, Hypogonadotropic Hypogonadal Men|OHH|Novartis||Terminated|August 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Male|30 Years|65 Years|No|||June 2014|June 19, 2014|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200862||116329|
NCT01201499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-IM-0073-CTIL|Comparing the Outcome of Two Intraoperative Analgesia Techniques After Hepato-pancreato-biliary Surgery|The Impact of Two Different Intraoperative Analgesia Techniques on Post-operative Outcome After Hepato-pancreato-biliary Surgery||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|November 2010|January 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|90 Years|No|||September 2010|September 13, 2010|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201499||116280|
NCT01201473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126171|CONDOR Impact of Dental Practice-Based Research Network|CONDOR Impact of Dental Practice-Based Research Network (PIRG)|CONDOR PIRG|Dental Practice-Based Research Network|No|Completed|July 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|687|||Both|22 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The questionnaire was administered to all DPBRN practitioner-investigators (including both        dentists and hygienists) 22 years of age or older.|June 2011|June 14, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201473||116282|
NCT01201486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS-CH1|Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester|Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester.||Helse Stavanger HF|No|Completed|October 2006|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|6781|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant women for routine examination in the 2nd trimester.|September 2010|July 27, 2015|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201486||116281|
NCT01178593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA716E0126|Group Hypnosis for Irritable Bowel Syndrome|GUT-FOCUSED GROUP HYPNOSIS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME - A RANDOMISED CONTROLLED TRIAL|IBS|Medical University of Vienna|No|Completed|April 2008|July 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||December 2011|December 11, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01178593||118026|
NCT01178619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10095-2010CTIL|Sonographic Differences in Brain Measurements Between Normal and Intrauterine Growth Restriction (IUGR) Fetuses|||Meir Medical Center||Withdrawn|September 2010|August 2012|Actual|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control||3|Actual|0|||Both|28 Weeks|37 Weeks|Accepts Healthy Volunteers|Probability Sample|pregnant women 28-37 GA, singleton, otherwise normal fetuses|August 2013|August 27, 2013|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178619||118024|
NCT01183455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN041AI Part II|A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II|Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus (ITN041AI)- Part II|RETAIN|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn|October 2010|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|35 Years|No|||December 2014|December 30, 2014|August 16, 2010|Yes|Yes|Sponsor decision-lack of mechanistic signal and competing industry studies|No||https://clinicaltrials.gov/show/NCT01183455||117653|
NCT01180062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0476-F1V|Safety Study of Latanoprost Slow Release Insert|A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|Latanoprost SR|University of Kentucky|Yes|Terminated|January 2011|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 10, 2010|Yes|Yes|Study terminated early due to manufacturer not replenishing study site supply of inserts,    despite repeated requests for more inserts.|No||https://clinicaltrials.gov/show/NCT01180062||117913|
NCT01180322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 12-09|Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine|Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine|azacitidine|University of Ulm|Yes|Active, not recruiting|November 2010|October 2016|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|336|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01180322||117893|
NCT01180621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCIRN RT-07|Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children|PCIRN Evaluation of Seasonal Trivalent Influenza Vaccine for 2010-2011 in Young Children in the First Year After the H1N1 Pandemic||Dalhousie University|Yes|Completed|September 2010|April 2011|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|12 Months|59 Months|Accepts Healthy Volunteers|||June 2011|June 21, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180621||117870|
NCT01180023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKeller01|Membrane Sweeping in Group B Streptococcus (GBS) Positive Patients|Membrane Sweeping in GBS Positive Patients at 37 Weeks Gestation: A Randomized Controlled Trial||George Washington University|Yes|Completed|April 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01180023||117916|
NCT01180036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003372|MEmbranous Nephropathy Trial Of Rituximab|"A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"|MENTOR|Mayo Clinic|Yes|Active, not recruiting|November 2011|October 2017|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|80 Years|No|||October 2015|November 23, 2015|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180036||117915|
NCT01180049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-4438|Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma|A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (Temsr) Regimens In Subjects With Relapsed, Refractory Mantle Cell Lymphoma||Pfizer|Yes|Recruiting|March 2011|July 2017|Anticipated|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180049||117914|
NCT01180296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVH-MP-Pilot-RCT|Oral Progesterone for Prevention of Preterm Birth|Prevention of Recurrent Preterm Birth With Micronized Progesterone||Fetal Medicine Foundation|No|Completed|November 2006|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Female|18 Years|45 Years|No|||March 2012|March 2, 2012|August 10, 2010||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT01180296||117895|
NCT01180309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLeite|Lingual Frenum and Articulation of Phonemes|Lingual Frenum and Possible Alterations in the Articulation of Phonemes||Fortaleza University|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|16|||Both|7 Years|N/A||Probability Sample|The total study population consisted of subjects with complete phonological system, ie        more than seven years of chronological age, both male and female, accompanied in the field        of Dentistry, University of Fortaleza - UNIFOR.|August 2010|August 11, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01180309||117894|
NCT01178047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ras-PDS-1|Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease|A Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD)|Ras-PDS-1|University of Zurich|No|Terminated|September 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|40 Years|N/A|No|||October 2012|October 3, 2012|August 6, 2010||No|payments stopped by grant provider|No||https://clinicaltrials.gov/show/NCT01178047||118068|
NCT01178385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-2010|Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders|Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders||University of South Florida|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||December 2012|February 25, 2013|August 5, 2010||No||No|December 12, 2012|https://clinicaltrials.gov/show/NCT01178385||118042|Modest sample size was modest.Only ~75% of families in the treatment as usual arm had some form of active intervention.Short follow-up interval that only included treatment responders in the CBT arm.
NCT01181882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00030668|Fish Oil and Aspirin With Type 2 Diabetes|The Effects of Fish Oil and Aspirin on Cardiovascular Risk in Type 2 Diabetes|R-21|University of Rochester|Yes|Completed|August 2010|November 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|40 Years|80 Years|No|||October 2013|October 7, 2013|August 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01181882||117773|
NCT01181895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112060|Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistentasthma||GlaxoSmithKline|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|348|||Both|12 Years|N/A|No|||August 2013|October 31, 2013|July 15, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01181895||117772|
NCT01182441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT1004|Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy|Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy|PREVAIL|Boston Scientific Corporation|Yes|Active, not recruiting|November 2010|August 2017|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|475|||Both|18 Years|N/A|No|||March 2013|January 26, 2015|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182441||117730|
NCT01182454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Citizen-658|Clinical Test Report for Blood Pressure Meter of CH-658|||Citizen Systems Japan Co., Ltd.|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|96|||Both|22 Years|62 Years|Accepts Healthy Volunteers|Probability Sample|community sample|August 2010|August 13, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182454||117729|
NCT01188902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walnut-2010|The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women|The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women||Ludwig-Maximilians - University of Munich|No|Completed|August 2010|August 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01188902||117236|
NCT01188915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROPER/IPC 2010-001|Personalised Program for Women Treated for Hodgkin Disease|Personalised Program for Women Treated for Hodgkin Disease : Risk Evaluation of Breast Cancer and Intensive Screening Program for Women at High Risk of Breast Cancer. PROPER/IPC 2010-001|PROPER|Institut Paoli-Calmettes|No|Recruiting|July 2010|July 2026|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|145|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188915||117235|
NCT01190137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A09-M108-09A|Study Comparing Two Isoforms of Vitamin D Supplements for Infants|Bio-equivalency Study of the Effects of Vitamin D2 and Vitamin D3 Supplements on 25-hydroxyvitamin D Levels in Exclusively Breast Fed Canadian Infants||McGill University|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|N/A|6 Weeks|Accepts Healthy Volunteers|||March 2012|March 1, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190137||117142|
NCT01190150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999304 CS01|Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding|Randomized, 2-way Crossover, Pharmacokinetic Study of Lysteda (Xanodyne Modified-Immediate Release Tranexamic Acid) Tablets at 2 Doses in Fasting Adolescent Females With Evidence of Heavy Menstrual Bleeding|PREA|Ferring Pharmaceuticals|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Female|12 Years|16 Years|No|||July 2012|July 10, 2012|August 26, 2010|Yes|Yes||No|May 30, 2012|https://clinicaltrials.gov/show/NCT01190150||117141|
NCT01199744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114045|Relenza® Sentinel Site Monitoring Program in Japan|Collection of Patients' Background InformationRelenza® Sentinel Site Monitoring Program in Japan|SSMP|GlaxoSmithKline||Completed|November 2009|April 2010|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1575|||Both|N/A|N/A|No|Probability Sample|1600 cases (of which 90 shall be pregnant women)|November 2011|November 17, 2011|September 9, 2010||No||No|March 17, 2011|https://clinicaltrials.gov/show/NCT01199744||116414|
NCT01200030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHSC_NG|Effects of Home-based Program in Improving Sitting Balance and Upper Limb Functions in Patients With Stroke|||The Hong Kong Polytechnic University|No|Recruiting|August 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|36|||Both|45 Years|80 Years|No|||September 2010|September 10, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200030||116393|
NCT01200303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEH-03-OPQ-001|Evaluation of Computer-assisted, Non-cathartic CT Colonography|Prospective Evaluation of Computer-Assisted, Non-Cathartic CT Colonography for Detection of Adenomatous Colonic Polyps in a Screening Cohort|ncCTC|Massachusetts General Hospital|No|Completed|June 2005|January 2011|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|605|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01200303||116372|
NCT01201148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10231|Open Pilot Trial of TES for Depression|A Study of Transcranial Electrical Stimulation (TES) for the Treatment of Depression||The University of New South Wales|Yes|Completed|September 2010|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|85 Years|No|||November 2015|November 30, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01201148||116307|
NCT01201772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2010-49|Prasugrel Re-load Strategies|Impact of Prasugrel Re-load on Platelet Aggregation in Patients on Chronic Prasugrel Therapy||University of Florida|Yes|Completed|August 2010|September 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|65|||Both|18 Years|74 Years|No|||December 2011|January 17, 2013|September 3, 2010||No||No|January 9, 2013|https://clinicaltrials.gov/show/NCT01201772||116259|
NCT01201759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090361|Effects of Salsalate on Prandial-Induced Vascular Inflammation After Spinal Cord Injury (SCI)|Effects of Salsalate on Prandial-Induced Vascular Inflammation After SCI||University of Miami|No|Completed|July 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|September 8, 2010||No||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01201759||116260|
NCT01178632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR4009|Therapeutic Effect of an Herbal Medicine on Anxiety|A Double-blind, Randomized, Controlled, Phase III Study of an Herbal Medicine Association for Generalized Anxiety Disorder||Millet Roux|Yes|Not yet recruiting|October 2010|July 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|65 Years|No|||August 2010|August 9, 2010|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01178632||118023|
NCT01183221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0857|The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders|The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders||Bartz, Jennifer, Ph.D.|Yes|Recruiting|June 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|35|||Both|18 Years|45 Years|No|||August 2010|August 13, 2010|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183221||117671|
NCT01183234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD544-101|SPD544 High Strength Bioequivalence Study|Phase 1,Randomized,Open-Label,Two Period Single Dose Crossover Bioequivalence Study of Two Capsule Strengths of SPD544 In Healthy Volunteers.||Shire|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 31, 2011|August 16, 2010||No||No|July 27, 2011|https://clinicaltrials.gov/show/NCT01183234||117670|
NCT01183767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNIMUD|Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy|Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy|SUNIMUD|Charite University, Berlin, Germany|No|Active, not recruiting|December 2010|September 2018|Anticipated|September 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|5 Years|10 Years|No|||January 2016|January 27, 2016|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01183767||117629|
NCT01180335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET1376|Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer|Randomized Trial Comparing Standard Neoadjuvant Chemotherapy to Genomic Driven Chemotherapy Regimen in Patients With Breast Cancer|REMAGUS04|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Completed|January 2009|December 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Female|18 Years|N/A|No|||August 2010|March 15, 2012|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01180335||117892|
NCT01180933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01111|Fish Oil and Folate Supplementation During Pregnancy|Dietary Supply of Docosahexaenoic Acid (DHA) and 5-methyl-tetrahydro-folate (MTHF) During the Second Half of Pregnancy and Early Infancy|NUHEAL|Ludwig-Maximilians - University of Munich|No|Completed|November 2001|March 2013|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|315|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||June 2014|July 29, 2014|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180933||117846|
NCT01180634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpex-207|MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis|A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin™) In Stable Cystic Fibrosis Patients||Forest Laboratories|Yes|Completed|November 2010|September 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|330|||Both|12 Years|N/A|No|||July 2013|July 11, 2013|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180634||117869|
NCT01180894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0705|IV Iron for the Anemia of Traumatic Critical Illness|A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness|IATCI|Denver Health and Hospital Authority|Yes|Completed|June 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180894||117849|
NCT01180907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-07-071|The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases|The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study||Jonsson Comprehensive Cancer Center|No|Completed|November 2007|||November 2011|Actual|N/A|Observational|N/A||3|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with cancer, autoimmune diseases and healthy subjects|July 2012|July 27, 2012|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180907||117848|
NCT01181219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-TE UNN2010|Transepithelial Corneal Collagen Cross-linking (CXL) in Treatment of Keratoconus|Behandling av Keratoconus Med "Cornea Collagen Cross-linking" Uten Hornhinneepitelfjerning||University Hospital of North Norway|No|Completed|July 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|40 Years|No|||May 2012|December 11, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181219||117824|
NCT01174914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOFLDNMALIHIVb|Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+|Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression||The Ojai Foundation|Yes|Completed|March 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|171|||Both|18 Years|60 Years|No|||August 2010|August 2, 2010|August 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174914||118308|
NCT01171378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_018|Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome|Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome|CHOP-OR|University of Oxford|No|Active, not recruiting|April 2011|April 2016|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01171378||118577|
NCT01171586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA138730|mDiet: A Text Message Intervention for Weight Loss|mDiet: A Text Message Intervention for Weight Loss||University of California, San Diego|No|Completed|May 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|318|||Both|21 Years|60 Years|No|||December 2014|December 3, 2014|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01171586||118561|
NCT01171118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17789|Phamacological Reversal of Airway Instability During Sedation|Phamacological Reversal of Airway Instability During Sedation|PHYSO|University of Rochester|Yes|Completed|August 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|July 26, 2010|Yes|Yes||No|March 8, 2013|https://clinicaltrials.gov/show/NCT01171118||118597|Study done on healthy non OSA male patients. Has to be confirmed with patients suffering from moderate to severe OSA.
NCT01172184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC99-2314-B-075B-007|Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation|Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation||Kaohsiung Veterans General Hospital.|Yes|Completed|July 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|111|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with severe mitral regurgitation are admitted for surgical intervention and are        willing to participate in this study.|June 2010|May 9, 2011|July 28, 2010||No||No|March 3, 2011|https://clinicaltrials.gov/show/NCT01172184||118515|LV filling pressure was obtained using fluid-filled pigtail catheters.Although micromanometer-tipped catheters would have been ideal, the method we used to measure LV filling pressure is standard in the clinical setting and is well validated.
NCT01173029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0204/21.07.08|Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events|Observational Study of the Polymorphisms of the Renin-angiotensin-aldosterone System and Their Relation to Resistant Systemic Arterial Hypertension and Adverse Cardiovascular Events|GENHART|Universidade Gama Filho|No|Completed|June 2001|December 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|92|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects of both genders in investigation for resistant systemic arterial hypertension at        the Hypertension Unit, whose arterial pressure control was not achieved by primary care        assistance despite regular use of three anti-hypertensive drugs, including one diuretic.        All subjects received standard drug therapy, aiming at achieving outpatients clinics        pressure <140/90mmHg and were re-evaluated up to four weeks later, including 24h        ambulatory arterial pressure monitoring.|April 2013|April 13, 2013|July 29, 2010||No||No|April 21, 2011|https://clinicaltrials.gov/show/NCT01173029||118451|Drugs prescribed were at the discretion of attending physician. The impact of anti-hypertensive drugs on the outcomes was not assessed.
NCT01202721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAV-15JUNE2010|Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)|Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)|BAV|Hamilton Health Sciences Corporation|Yes|Active, not recruiting|June 2011|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202721||116186|
NCT01173016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS090|Administration of IV Laronidase Post Bone Marrow Transplant in Hurler|Pilot Study of Administration of Intravenous Laronidase Following Allogeneic Transplantation for Hurler Syndrome||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|May 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|14 Years|No|||February 2016|February 23, 2016|July 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173016||118452|
NCT01173952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-06-026|Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Versus Radical Retropubic Prostatectomy|Prospective Evaluation of Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Vs. Radical Retropubic Prostatectomy||Samsung Medical Center|Yes|Not yet recruiting|August 2010|January 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|||Male|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with prostate cancer|June 2010|July 30, 2010|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01173952||118381|
NCT01173965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3873|Endometrial Ablation With Non-hysteroscopic Methods|Treatment of Dysfunctional Uterine Bleeding With Second Generation Ablation Devices: Microwaves (MEA®) vs Bipolar Impedance Control System (Novasure®)||Aristotle University Of Thessaloniki|No|Completed|January 2008|February 2011|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Female|30 Years|49 Years|No|||September 2009|July 11, 2012|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01173965||118380|
NCT01182922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-I|Information About a Doctor or a Possibility of Choosing Doctor's Gender and Attendance to Screening Colonoscopy|Is the Information About a Doctor or Possibility of Choosing Doctor's Gender Associated With Attendance to Screening Colonoscopy: Randomized Study With Three Types of Invitations.||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Completed|August 2010|August 2011|Actual|March 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|5100|||Both|55 Years|64 Years|No|||November 2011|November 17, 2011|August 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01182922||117694|
NCT01183195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2010|||||N/A|N/A|N/A||||||||||||||November 15, 2011|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183195||117673|
NCT01183442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENM-DA012|Vitamin D Supplementation in CAD and Postchallenge Hyperglycemia|Effects of Vitamin D Supplementation in Coronary Artery Disease Patients With Postchallenge Hyperglycemia and Vitamin D Deficiency on Endothelial Function and Insulin Sensitivity||Medical University of Graz|No|Terminated|June 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|40 Years|75 Years|No|||April 2015|April 16, 2015|August 16, 2010||No|unable to recruit|No||https://clinicaltrials.gov/show/NCT01183442||117654|
NCT01183741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOW-US10-003|Accuracy of Non-Invasive Blood Pressure Measurement in Adults|Clinical Evaluation of the Sotera VisiTM System for Measurement of Systolic and Diastolic Blood Pressures in Adults|NIBP|Sotera Wireless, Inc.|No|Withdrawn|September 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 3|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|12 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Eligible subjects are adults of any ethnic background who consent to spot-check blood        pressure measurements and in whom paired blood pressure measurements with the ViSi will be        feasible during a single visit. Subjects need to be greater than 12 years of age on the        date of measurement and need to meet all the other inclusion and exclusion criteria.|June 2011|June 21, 2011|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183741||117631|
NCT01174095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0905010396|Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy|A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA||Weill Medical College of Cornell University|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|31|||Both|60 Years|85 Years|No|Non-Probability Sample|These subjects have clinically significant coronary artery disease (CAD) and have received        direct myocardial injection of AdGVVEGF121.10 expressing the human vascular endothelial        growth factor (VEGF) 121 cDNA to induce therapeutic angiogenesis.|July 2015|July 29, 2015|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174095||118370|
NCT01174355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0801/001|A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)|A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)||NeuroDerm Ltd.|No|Active, not recruiting|October 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|55 Years|No|||November 2012|November 5, 2012|August 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01174355||118350|
NCT01173848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cleveland Clinic|Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients|A Randomized Study to Evaluate the Effectiveness of Cholecalciferol Versus Ergocalciferol Following Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines for Vitamin D Therapy in Stages 3 & 4 Chronic Kidney Disease (CKD) Patients|UPGRADE|The Cleveland Clinic|No|Recruiting|July 2010|||September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|July 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173848||118389|
NCT01174667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AECC 290710|Massage of the Low Back Muscles Assessed With Ultrasound Scanning|Effect of Fascial Release on Connective Tissue Structure in Human Subjects With Chronic Low Back Pain as Determined by Ultrasound Imaging: a Randomized Controlled Trial||Anglo-European College of Chiropractic|No|Not yet recruiting|September 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|64 Years|No|||July 2010|August 3, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174667||118326|
NCT01170832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00036408|To Evaluate if Wide Blood Sugar Fluctuations Lead to Injury of Heart Function and Heart Nerves|Cardiac Autonomic Neuropathy and Myocardial Dysfunction in Type 1 Diabetes||University of Michigan|Yes|Recruiting|May 2010|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|Samples With DNA|We will collect approximately 15 ml of whole blood for DNA sampling and storage.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Type 1 diabetics who have been diagnosed between 5-10 years and do not have any        complications that are associated with Diabetes|December 2014|December 2, 2014|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170832||118618|
NCT01172158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Dicle University|SMS Reminder for Forgotten Ureteral Stents|A Solution for Medical and Legal Problems Arising From Forgotten Ureteral Stents: Reminder Short Message Service (SMS)|sms&FUS|Dicle University|Yes|Enrolling by invitation|May 2010|August 2011|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|||Both|1 Year|80 Years|No|Non-Probability Sample|First an institutional subscription agreement was signed between our university and a        mobile phone cell company which is supporting SMS sending program. In the By making        software plug-in to our hospital's patient follow up program, two programs were        integrated. According to this integration, after stent insertion, in case of entering the        numerical code corresponding of ''ureteral stent application'' procedure during the stage        of epicrisis preparation, the patient follow up system warns the official recording the        epicrisis to enter the stent removal time. Patient follow up system transfers this        information to SMS sending program. After several weeks of the procedure, if the stent        needs to be removed, the software automatically sends a warning message to the patient and        the physician.|July 2010|July 28, 2010|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172158||118517|
NCT01172366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTE12|A Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application|A Phase I Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application of 2% Testosterone Metered Dose (MD) Lotion®||Acrux DDS Pty Ltd|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|N/A||1|Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male and female volunteers|August 2010|September 2, 2010|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01172366||118501|
NCT01172379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-E044-204|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias||Eisai Inc.|No|Completed|May 2004|||February 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4|||2|||Both|30 Years|75 Years|No|||August 2014|August 21, 2014|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01172379||118500|
NCT01172431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WestChinaH|Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency|A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension||West China Hospital|Yes|Completed|September 2010|December 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|65 Years|85 Years|No|||June 2014|June 23, 2014|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01172431||118496|
NCT01172444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESA-ULP3125|Clinical Trial With Mesalamine 1g Suppositories|AN INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ESTABLISH THERAPEUTIC EQUIVALENCE OF 1000 mg MESALAMINE RECTAL SUPPOSITORIES AND CANASA® RECTAL SUPPOSITORIES (1000 mg MESALAMINE, USP) IN THE TREATMENT OF MILD TO MODERATE ULCERATIVE PROCTITIS||Sandoz Inc.|No|Terminated|June 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|158|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|July 28, 2010|Yes|Yes|Enrollment difficulties|No||https://clinicaltrials.gov/show/NCT01172444||118495|
NCT01206491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99035|Development of Intervention Model for Osteoporosis and Fall Prevention in Taiwan|Development of Intervention Model for Osteoporosis and Fall Prevention in Taiwan||Taipei Medical University WanFang Hospital|No|Active, not recruiting|September 2010|July 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|35|||Both|50 Years|90 Years|No|Non-Probability Sample|we will recruit patients form outpatient services at WanFang Hospital or the people who        live near WanFang Hospital.|October 2010|October 5, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206491||115899|
NCT01206751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99008|Multi-detector Computer Tomography Protocol Project: Chest Imaging Technique and Case Presentation|Multi-detector Computer Tomography Protocol Project: Chest Imaging Technique and Case Presentation||Taipei Medical University WanFang Hospital|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|30|||Both|N/A|N/A|No|Probability Sample|Patients with complete clinical images|September 2010|September 21, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206751||115879|
NCT01202734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017464|A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers|An Open-label, Single-Ascending-Dose Study to Investigate the Pharmacokinetics and Safety of CONCERTA in Healthy Japanese Adult Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2010|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|September 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202734||116185|
NCT01173328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP/HUCFF/UFRJ 187/07|Effects of Pursed-lip Breathing on Exercise Tolerance and Dynamic Hyperinflation in COPD|Effects of Pursed-lip Breathing on Exercise Tolerance and Dynamic Hyperinflation in Chronic Obstructive Pulmonary Disease||Universidade Federal do Rio de Janeiro|Yes|Completed|March 2007|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|40 Years|N/A|No|||August 2008|July 30, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01173328||118429|
NCT01173601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11316|A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder|A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment||Eli Lilly and Company|Yes|Completed|November 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1344|||Both|18 Years|N/A|No|||October 2013|January 7, 2014|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01173601||118408|
NCT01173627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9204-06-840|Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 Mcg) Compared to Actiq® 400 Mcg, Cephalon, Inc.|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Oral Transmucosal Test Troche Formulation of Fentanyl Citrate (400 Mcg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Actiq 400 Mcg, Cephalon, Inc.) in Normal Human Subjects Under Fasting Conditions||Mallinckrodt|No|Completed|August 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|July 30, 2010|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173627||118406|
NCT01173640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38328-D|Resveratrol and Midazolam Metabolism|Resveratrol and Midazolam Metabolism||University of Washington|Yes|Completed|July 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 27, 2012|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173640||118405|
NCT01172600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-446|Effect of Nitrous Oxide in Treating Neuropathic Pain: A Study in Chronic Low Back Pain Patients|Effect of Nitrous Oxide in Treating Neuropathic Pain: A Pilot Study in Chronic Low Back Pain Patients||The Cleveland Clinic|No|Active, not recruiting|July 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|72|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01172600||118483|
NCT01173172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNCT_090514|Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer|A Phase I/II Trial of Boron Neutron Capture Therapy (BNCT) for Recurrent Head and Neck Cancer at Tsing-Hua Open Pool Reactor|BNCT|Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|July 2010|October 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||April 2010|July 30, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173172||118440|
NCT01173198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFG-002-WFO|An Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients|A Prospective Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients||Innovative Medical|No|Completed|November 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|37|||Both|21 Years|35 Years|No|||June 2012|June 13, 2012|February 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173198||118439|
NCT01173458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12216|Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)|A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)||University of Kansas Medical Center|No|Active, not recruiting|July 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Blood samples will be collected before treatment begins, at completion of treatment, and      every 6 to 8 weeks during follow-up visits.|Both|18 Years|N/A|No|Probability Sample|Eligible patients will be approached during their regularly scheduled Cancer Center        appointments.|May 2014|May 22, 2014|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01173458||118419|
NCT01173471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4250C00001|A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure|A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure||AstraZeneca|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|50|||Both|18 Years|80 Years|No|||January 2014|January 20, 2014|July 29, 2010||No||No|August 2, 2013|https://clinicaltrials.gov/show/NCT01173471||118418|
NCT01173744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0076-10-WOMC|Comparison of Gamma Nail Versus Dynamic Hip Screw for the Treatment of Unstable Intertrochanteric Fractures|||Wolfson Medical Center||Recruiting|July 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||July 2010|June 16, 2011|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01173744||118397|
NCT01173757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1661002|To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers|A Phase I, Healthy Volunteer Determination Of 5HT4 Receptor Occupancy Of PF-04995274, Using PET With Ligand [11C]PF-05127401.||Pfizer|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173757||118396|
NCT01174108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100154|Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells|Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells||National Institutes of Health Clinical Center (CC)||Recruiting|July 2010|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|4 Years|80 Years|No|||February 2016|March 11, 2016|July 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174108||118369|
NCT01174121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100166|Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer|A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab||National Institutes of Health Clinical Center (CC)||Recruiting|July 2010|December 2019|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|290|||Both|18 Years|70 Years|No|||January 2016|February 10, 2016|July 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174121||118368|
NCT01174134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3375-1|The Effects of Study Products Containing Varying Quantities of Docosahexaenoic Acid (DHA)|||Mead Johnson Nutrition|No|Completed|July 2006|||May 2007|Actual|N/A|Interventional|N/A|3||||||Both|18 Months|36 Months|Accepts Healthy Volunteers|||August 2011|August 31, 2011|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174134||118367|
NCT01174368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003010955|Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T|An Open-Label, Phase II Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T||The Rogosin Institute|Yes|Recruiting|June 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|August 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174368||118349|
NCT01174394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 10-211|Electroacupuncture Combined With Antidepressants for Post-stroke Depression|A Randomized, Assessor-blind, Controlled Trial of Electroacupuncture Combined With Antidepressants in Treating Patients With Post-stroke Depression||The University of Hong Kong|Yes|Completed|May 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|35 Years|80 Years|No|||April 2013|April 30, 2013|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01174394||118347|
NCT01171144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111757|Trends Over Time (1990-2010) of Diarrhoea-related Incidence, Hospitalizations and Deaths in Children of Panama|Time Trend Analysis of Diarrhoea-related Incidence, Hospitalizations, and Deaths in Children < 5 Years of Age in Panama by Monitoring Secondary Data Sources From 1990-2010||GlaxoSmithKline||Completed|January 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|None Retained|No samples are retained.|Both|N/A|59 Months|No|Non-Probability Sample|All children <5 years of age reported with gastroenteritis, gastroenteritis related        hospital discharges and gastroenteritis related deaths in Panama, between 1990 and 2010.|September 2011|September 15, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01171144||118595|
NCT01173289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-09-436|Study of External Beam Radiotherapy to Thyroid Carcinoma|A Phase II Study of External Beam Radiotherapy for Locoregionally Advanced or Recurrent Differentiated Thyroid Carcinoma||National Cancer Center, Korea|No|Completed|December 2009|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01173289||118432|
NCT01172197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002136-15|Comparison of Levobupivacaine and Ropivacaine for Femoral Neural Block|A Randomised Single Blind Study Comparing the Molar ED50 of Levobupivacaine and Molar ED50 of Ropivacaine When Administered as a Femoral Perineural Infusion for Pain Relief After Total Knee Replacement||NHS Tayside|No|Suspended|January 2009|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|80 Years|No|||May 2010|July 29, 2010|July 28, 2010|Yes|Yes|Protocol amendment|No||https://clinicaltrials.gov/show/NCT01172197||118514|
NCT01172457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epiduroscopy trial|The Effect of Epiduroscopy and Ozone Therapy in Patients With Failed Back Surgery Syndrome|A Randomized, Double-Blind Study to Evaluate the Effect of Epiduroscopy and Ozone Therapy in Patients With Failed Back Surgery Syndrome|Epiduroscopy|University of Sao Paulo|No|Completed|May 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||August 2013|August 28, 2013|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172457||118494|
NCT01172470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13881B|Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients|Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients||University of Chicago|No|Completed|June 2005|July 2010|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|July 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01172470||118493|
NCT01172418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #20057672|Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols|Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Accompanied by Maintenance Therapy With Prograf® and Myfortic®||University of Miami|Yes|Completed|February 2006|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|June 10, 2010||No||No|August 1, 2014|https://clinicaltrials.gov/show/NCT01172418||118497|
NCT01172743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904010340|Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)|Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)||Weill Medical College of Cornell University|No|Recruiting|June 2009|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes      will be obtained. The goal is to find single nucleotide polymorphims (SNP), small changes in      single genes that affect disease risk, to see if they correlate with diabetes. Serum will be      stored for future studies, for a period of 6 years, to look at levels of proteins. Subjects      who consent to participate in this study will have their serum stored for up to 6 years,      inorder to be used for future studies on genomics.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Diabetes group will be taken from (1)individuals visiting the Medicine Department at the        Hamad Medical Corporation(HMC), Qatar for standard clinical care, (2)outpatient adult        individuals seen at the HMCdiabetes clinics, (3)individuals who have participated in the        following IRB protocol #s:0608008703, #0602008388 and HMC protocol #231, (4)ndividuals who        attend clinics at the Qatar Diabetes Association (QDA), and (5)Individuals who work at the        governmental ministries of Qatar. Controls will be obtained from volunteers without a        history of diabetes. Family members of patients may be asked to participate in the study.|December 2015|December 16, 2015|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172743||118473|
NCT01172756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14554|A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction|Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts|DILATE|Bayer|Yes|Terminated|July 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|39|||Both|18 Years|90 Years|No|||November 2014|November 3, 2014|July 19, 2010||No|Recruitment was only stopped after the statistical power of the study was reached and the    study objectives could be met despite the premature discontinuation.|No||https://clinicaltrials.gov/show/NCT01172756||118472|
NCT01172769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN001|Efficacy Study of Temsirolimus to Treat Head and Neck Cancer|A Single Arm, Open-label Multicenter Phase II Trial of Temsirolimus in Patients With Relapsed/Recurrent Squamous Cell Cancer of the Head and Neck (HNSCC)|TEMHEAD|Hannover Medical School|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01172769||118471|
NCT01173315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFarvid|The Impact of Vitamins and Minerals Supplementation on Neuropathy and Nephropathy Complications|The Impact of Vitamins and Minerals Supplementation on Neuropathy and Nephropathy Complications in Type 2 Diabetic Patients: a Randomised Clinical Trial||hahid Beheshti University of Medical Sciences||Completed|June 2007|September 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|30 Years|70 Years||||April 2006|July 30, 2010|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01173315||118430|
NCT01173614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECR-CCRS-2010-01|Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes|Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes|Gullstrand|European Vision Institute Clinical Research Network|No|Active, not recruiting|January 2011|April 2016|Anticipated|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Normal subjects|January 2016|January 21, 2016|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173614||118407|
NCT01173991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIOCAR|Carbohydrate Counting in Adults With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion|Clinical Assessment of Carbohydrate Counting in Adult Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion: a Randomized Controlled Study (GIOCAR)|GIOCAR|IRCCS San Raffaele|No|Completed|October 2008|January 2010|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||July 2010|August 2, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01173991||118378|
NCT01174004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-020|A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis|A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease||ACADIA Pharmaceuticals Inc.|No|Completed|July 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|199|||Both|40 Years|N/A|No|||February 2014|February 6, 2014|July 30, 2010|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01174004||118377|
NCT01172964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08002|A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas|A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas||City of Hope Medical Center|Yes|Completed|August 2010|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|13 Years|N/A|No|||March 2015|March 2, 2015|July 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01172964||118456|
NCT01173211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0005|2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women|A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Seasonal 2010-2011 Inactivated Trivalent Influenza Vaccine in Pregnant Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|183|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||March 2013|December 4, 2014|July 29, 2010|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT01173211||118438|
NCT01173224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0104|Influenza Antiviral DAS181-F03|A Phase I C Clinical Study With Influenza Antiviral DAS181-F03: Double-Blind, Randomized, Placebo-Controlled, Single Dose and Multiple Dose Escalation Study in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2010|September 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|July 18, 2013|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173224||118437|
NCT01173484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0569|Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification|Idiopathic Gastroparesis Registry to Define Severity, Treatment Response, and Prognosis Using a Predominant-Symptom Classification||University of Louisville|No|Terminated|June 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|15|Samples Without DNA|Serum|Both|16 Years|80 Years|No|Non-Probability Sample|Subjects presenting to the University of Louisville Motility Center with newly diagnosis        of idiopathic gastroparesis|August 2011|August 4, 2011|July 29, 2010||No|Principal investigator has left the Institution|No||https://clinicaltrials.gov/show/NCT01173484||118417|
NCT01173770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC3680-01|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ADC3680B in Healthy Volunteers|A Double-Blind Randomized, Placebo-Controlled, Dose Escalating Study to Assess The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ADC3680B Administered Orally to Healthy Volunteers and to Investigate Food Effects on Pharmacokinetics After Single Oral Doses of ADC3680B||Pulmagen Therapeutics|No|Completed|July 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|52|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|February 1, 2011|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173770||118395|
NCT01173783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEVICE|Deutsches Device Qualitätsregister|Deutsches Device Qualitätsregister||Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|March 2007|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8000|||Both|N/A|N/A|No|Non-Probability Sample|all consecutive patients with an intended implantation of an ICD / CRT.|July 2010|July 30, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173783||118394|
NCT01172132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 08235|The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"|Long Term Outcomes in Critically Ill Haematological Patients. The Use of Intensive Care in Critically Ill Cancer Haematological Patients||Assistance Publique - Hôpitaux de Paris|No|Completed|November 2009|November 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1011|||Both|18 Years|N/A|No|Probability Sample|Patients with heamatological malignancy adressed to ICU|November 2011|November 19, 2012|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01172132||118519|
NCT01172145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F32MH075583-01|Treatment of Apathy in Alzheimer's Disease With Modafinil|Treatment of Apathy in Alzheimer's Disease With Modafinil||Brown University|No|Completed|July 2005|September 2007|Actual|||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|65 Years|95 Years|Accepts Healthy Volunteers|||September 2010|February 9, 2011|July 28, 2010|Yes|Yes||No|August 4, 2010|https://clinicaltrials.gov/show/NCT01172145||118518|
NCT01172990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANCE Pilot Study|Direct Angioplasty for Non ST Elevation Acute Coronary Events: DANCE Pilot Study|Direct Angioplasty for Non ST Elevation Acute Coronary Events: DANCE Pilot Study|DANCE|Royal Brompton & Harefield NHS Foundation Trust|Yes|Terminated|October 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|108|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|July 26, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01172990||118454|
NCT01174953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12052|High Risk Prostate Cancer Prevention Study|High Risk Prostate Cancer Prevention Study||University of Kansas Medical Center|Yes|Completed|July 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Male|55 Years|95 Years|Accepts Healthy Volunteers|||December 2013|December 30, 2013|July 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174953||118305|
NCT01170819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1229|Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening.|Double Balloon Catheter Versus Vaginal PGE2 for Pre-induction Cervical Ripening: a Randomized Study.||Università degli Studi dell'Insubria|No|Completed|June 2010|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Female|18 Years|N/A|No|||December 2011|December 9, 2011|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01170819||118619|
NCT01171872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-09-09-07|Gene Expression in Inflammatory Bowel Disease|Gene Expression in Inflammatory Bowel Disease||Johns Hopkins University|Yes|Recruiting|November 1999|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|600|Samples With DNA|whole blood, serum, tissue|Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who are to undergo upper or lower gastrointestinal endoscopies or a surgical        resection as part of their normal medical care and deemed necessary by their physicians.        Patient's are primarily recruited at the Johns Hopkins inpatient and outpatient units.        However, individuals contact us by phone, mail or email after hearing about our study.|July 2011|July 6, 2011|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01171872||118539|
NCT01182766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15597|New Treatment for Alcohol and Nicotine Dependence|High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers||University of Virginia|Yes|Recruiting|September 2011|September 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|294|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182766||117705|
NCT01183065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-112|Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)|A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)||Memorial Sloan Kettering Cancer Center||Completed|August 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 11, 2010|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01183065||117683|
NCT01171924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-101-102|A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors|A Phase Ib Open Label, Expansion Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors||Curis, Inc.|No|Completed|July 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 27, 2010|No|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01171924||118535|
NCT01171937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-06-033|Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior|Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels of Repetitive Behavior|ProjectV|University of California, Los Angeles|Yes|Recruiting|September 2008|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|8 Years|16 Years|No|||January 2016|January 11, 2016|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01171937||118534|
NCT01172782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|minware2|The Analgesic Effect of Intrathecal Hydromorphone Injection on Spinal Anesthesia|||Korea University Anam Hospital|Yes|Completed|July 2009|July 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|60|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||January 2010|June 23, 2011|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01172782||118470|
NCT01172795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-Cognitive tests|Diffuse Noxious Inhibitory Controls (DNIC): Nociceptive Modulation and Interaction With Neurocognitive Performance in Chronic Pain|||Vrije Universiteit Brussel||Recruiting|July 2010|August 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thirty patients with FM, 30 patients with WAD and 30 healthy pain-free control subjects        will be enrolled. All three groups will be comparable for age, gender, education level and        socioeconomic status; both patient groups will be comparable for illness duration. Sample        size was calculated based on a power analysis (0.80), based on the assumption of a 20%        difference of DNIC functioning after neurocognitive testing.|July 2010|July 29, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172795||118469|
NCT01173055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-SAV-09|A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia|A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia||University of Michigan|No|Completed|June 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|22|||Female|18 Years|70 Years|No|||February 2015|February 3, 2015|July 29, 2010||No||No|August 5, 2014|https://clinicaltrials.gov/show/NCT01173055||118449|
NCT01173042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE105|Effects of Peanut Consumption on Postprandial Inflammation, Glucose and Triglycerides|Pilot Study of the Effect of Peanut Consumption on Postprandial Inflammatory Status, Glucose and Triglycerides|PKEPEANUT|Penn State University|No|Completed|August 2009|February 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|6|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||July 2010|July 29, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01173042||118450|
NCT01173354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105558|EAA Intake to Optimize Protein Anabolism in COPD|Essential Amino Acid Intake to Optimize Protein Anabolism in Elderly COPD Patients||Texas A&M University|No|Active, not recruiting|January 2009|June 2017|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|34|||Both|45 Years|N/A|No|||November 2015|November 2, 2015|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173354||118427|
NCT01173367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-23090|Anti-pyretic Therapy in Critically Ill Adults|Assessment of the Safety of Anti-pyretic Therapy in Critically Ill Adults||University of Calgary||Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||February 2012|February 21, 2012|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173367||118426|
NCT01174264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-03099|Evaluation of Food Effect on Pharmacokinetics of Vismodegib|Evaluation of Food Effect on Pharmacokinetics of GDC-0449, an Inhibitor of Hedgehog Signaling||National Cancer Institute (NCI)||Active, not recruiting|October 2009|||December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Both|19 Years|N/A|No|||February 2015|February 16, 2016|July 30, 2010|Yes|Yes||No|February 16, 2016|https://clinicaltrials.gov/show/NCT01174264||118357|
NCT01174524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedleyHGF|Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme|Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme||Hospital Geral de Fortaleza|No|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|15 Years|46 Years|Accepts Healthy Volunteers|||January 2009|August 2, 2010|December 29, 2008||No||No||https://clinicaltrials.gov/show/NCT01174524||118337|
NCT01173510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-184|A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells|A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells||Community Research Initiative of New England|Yes|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|July 29, 2010|Yes|Yes|This study was not feasible due to facility budget and contractual issues.|No||https://clinicaltrials.gov/show/NCT01173510||118415|
NCT01173523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-048|Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer|A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|July 2010|||August 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01173523||118414|
NCT01174381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIM/AC/4|The Use of a Community-based Organization to Change Lifestyle Characteristics Related to Non Communicable Diseases|The Use of a Community-based Organization to Change Lifestyle Characteristics Related to Non Communicable Diseases: A Community Based Intervention Study Among 25-60 Year Olds||University of Kelaniya|No|Completed|August 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|440|||Both|25 Years|60 Years|No|||May 2015|May 26, 2015|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174381||118348|
NCT01174927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAM2010_01|Effects of Diacetylmorphine (DAM) on Brain Function and Stress Response|The Effects of Diacetylmorphine (Heroin) on Human Brain Functions and Stress Response||University Hospital, Basel, Switzerland|Yes|Completed|March 2010|February 2012|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174927||118307|
NCT01173497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11608|A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis|A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis||Sanofi||Completed|July 2010|July 2013|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|21 Years|N/A|No|||February 2016|February 17, 2016|July 28, 2010|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01173497||118416|
NCT01173796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI-PROPOSE|Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes|Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes|PROPOSE|Texas Cardiac Arrhythmia Research Foundation|No|Completed|March 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|75 Years|No|||July 2012|July 10, 2012|June 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173796||118393|
NCT01172652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUP0005-17504|Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)|A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder|Pfizer Anxiety|VA Palo Alto Health Care System|Yes|Completed|April 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 16, 2012|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01172652||118479|
NCT01172665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16103A|Celiac Disease Database|University of Chicago Celiac Disease Database||University of Chicago|No|Recruiting|September 2008|||September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|3500|||Both|N/A|70 Years|No|Non-Probability Sample|Both pediatric and adult patients of The University of Chicago Medical Center who have        been diagnosed with celiac disease or gluten sensitivity.|December 2013|December 2, 2013|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172665||118478|
NCT01173536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4871g|A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects|A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Parallel-Group Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects||Genentech, Inc.||Completed|August 2010|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|61|||Female|45 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 17, 2011|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173536||118413|
NCT01173835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902004736|Incentive-based Intervention for Smoking Cessation and Prevention in High Schools|Incentive-based Intervention for Smoking Cessation and Prevention in High Schools|Rise Above|Yale University|Yes|Completed|July 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1651|||Both|13 Years|N/A|Accepts Healthy Volunteers|||June 2012|July 2, 2012|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173835||118390|
NCT01181934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017251|The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.|A Double-Blind, Placebo-Controlled, Randomized Three-Way Crossover Study to Investigate The Effect of Nicotine on Arousal, Standard Cognitive Tasks And Social Cognition in Young and Elderly Healthy Subjects||Janssen Pharmaceutica N.V., Belgium||Completed|May 2010|February 2011|Actual|||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 19, 2012|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181934||117769|
NCT01182467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE8300|Use of PET-CT in the Management of Crohn's Disease|Pilot Study in the Use of Positron Emission Tomography-Computed Tomography (PET-CT)in the Management of Crohn's Disease||Columbia University|No|Terminated|February 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|21 Years|65 Years|No|Non-Probability Sample|All adults between ages of 21-65 who have previously been diagnosed with Crohn's disease|April 2015|April 9, 2015|August 12, 2010||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT01182467||117728|
NCT01182480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 10-0257|Chronic Care Management/Patient Relationship Management Proof of Concept|Chronic Care Management/Patient Relationship Management Proof of Concept||Denver Health and Hospital Authority|No|Completed|May 2010|May 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|47|||Both|18 Years|76 Years|No|||October 2014|October 29, 2014|August 11, 2010||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT01182480||117727|Insufficient power (# appointments) to detect changes in attendance rates; technical issues with self-efficacy data resulting in inability to compare pre- and post- intervention; intervention period insufficient to assess impact on glycemic control.
NCT01182779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT-1|Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base|Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III Study-|HIT-1|Heidelberg University|Yes|Recruiting|July 2010|August 2023|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|319|||Both|18 Years|80 Years|No|||July 2010|August 16, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01182779||117704|
NCT01182792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMS|Chronic Mountain Sickness, Systemic Vascular Function|Chronic Hypoxemia and Systemic Vascular Function|CMS|University of Lausanne Hospitals||Active, not recruiting|October 2008|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|10 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 5, 2013|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01182792||117703|
NCT01172223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAPADO-Study|Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer|Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early|LAPADO|Sana-Klinikum Lichtenberg|No|Recruiting|September 2007|September 2016|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||July 2010|July 29, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172223||118512|
NCT01172236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-LF100-2010|Supplementation With Lactoferrin in Preterm Newborns|Supplementation With Lactoferrin in Preterm Newborns|lactoprenew|University of Siena||Not yet recruiting|January 2011|January 2013|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1300|||Both|23 Weeks|32 Weeks|No|||April 2010|July 28, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172236||118511|
NCT01172210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5973/6951R|Examining Common Substrates of Eating and Alcohol Use Disorders|Examining Common Substrates of Eating and Alcohol Use Disorders||New York State Psychiatric Institute|No|Completed|July 2009|June 2014|Actual|June 2014|Actual|N/A|Observational|N/A||3|Actual|61|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who call the main clinic line at the Eating Disorders Research Unit at        NYSPI/CUMC.|April 2013|August 20, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172210||118513|
NCT01172496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-123|A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers|A Comparative Bioavailability Study of UT-15C SR (Treprostinil Diethanolamine, Sustained Release) Oral Tablets and UT-15C (Treprostinil Diethanolamine) Administered as an Oral Solution in Healthy Volunteers||United Therapeutics||Completed|August 2010|||August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|October 8, 2010|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01172496||118491|
NCT01172483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2009|Effectiveness of Community-Based Physiotherapy Versus General Practice|Effectiveness of Community-Based Physiotherapy in Chronic Disorders Versus General Practice in Primary Care. Multicenter Randomized Control Trial|ECACOM|University of Malaga|Yes|Recruiting|December 2009|March 2017|Anticipated|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2013|December 3, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172483||118492|
NCT01172808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.418|Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma||Boehringer Ingelheim||Completed|August 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|1071|||Both|18 Years|75 Years|No|||January 2014|June 3, 2014|July 26, 2010||||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01172808||118468|
NCT01172821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.419|Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma||Boehringer Ingelheim||Completed|August 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|1032|||Both|18 Years|75 Years|No|||January 2014|June 3, 2014|July 26, 2010||||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01172821||118467|
NCT01173341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09110|Cardiotoxicity of Cancer Therapy (CCT)|Cardiotoxicity of Cancer Therapy: Mechanisms and Predictors||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|July 2010|||July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|||Female|18 Years|N/A|No|Probability Sample|Subjects with breast cancer will enter the cohort prior to chemotherapy initiation and be        evaluated at baseline and at regular intervals during the first approximately 15 months        after chemotherapy is initiated. Furthermore, given that our goals are to grow our        understanding of the late effects of these regimens, we will follow patients once yearly        after 1st year of exposure to cancer therapy for a total of 5 years from when they began        treatment.|January 2016|January 25, 2016|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173341||118428|
NCT01173653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100411|Smoking Cessation Invention in the Emergency Department (ED)|A Randomized Controlled Trial of Directed Smoking Cessation Intervention in the Emergency Care Population||Vanderbilt University|No|Completed|July 2010|January 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|199|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|July 29, 2010||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT01173653||118404|This is a preliminary study with a convenience sample of patients at a single academic medical center. A larger multicenter trial targeting consecutive ED patients who smoke will be essential to validate the applicability of our findings.
NCT01172314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112254|Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients|Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients||Texas A&M University|No|Active, not recruiting|July 2010|February 2017|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|47|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01172314||118505|
NCT01172327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-1U48/DP0019361 SIP 09-028|Self-Directed Exercise Program for Adults With Arthritis|Evaluation of a Self-directed, Packaged Physical Activity Program for Adults With Arthritis||University of South Carolina|No|Completed|September 2009|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|401|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 14, 2013|May 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01172327||118504|
NCT01174147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0991-093|A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)|Brazilian Network of Candidemia: a Laboratory-based Surveillance Study on Candida Bloodstream Infections in 10 Medical Centers||Merck Sharp & Dohme Corp.||Completed|April 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|436|||Both|N/A|N/A|No|Non-Probability Sample|Adult and pediatric patients hospitalized in participating medical centers (tertiary care        hospitals) in Brazil|October 2015|October 5, 2015|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174147||118366|
NCT01174940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12047|Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease|A Study of Extracorporeal Photopheresis With UVADEX® in the Setting of a Standard Myeloablative Conditioning Regimen in Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for the Prevention of Graft Versus Host Disease||University of Kansas Medical Center|Yes|Active, not recruiting|June 2010|December 2015|Anticipated|September 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2014|March 31, 2015|July 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174940||118306|
NCT01170806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0008|Study of Fat Malabsorption by Lipiblock Versus Xenical|Study of Pharmacodynamic Equivalence of Two Commercial Formulations of Orlistat (Lipiblock vs Xenical) on Intestinal Lipases Inhibition||University of Campinas, Brazil|No|Completed|October 2009|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 28, 2011|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01170806||118620|
NCT01171859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOXYTUDCA2010|Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis|A Single Center, Twelve-month, Open-label, Prospective Study Followed by a Six-month Withdrawal Period to Evaluate the Efficacy, Tolerability, Safety and Pharmacokinetics of Doxycycline in Combination With Tauroursodeoxycholic Acid in Transthyretin Amyloidosis||IRCCS Policlinico S. Matteo|Yes|Completed|July 2010|October 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171859||118540|
NCT01173263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-226|Effect of Bispectral Index (BIS) Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients|Effect of BIS Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients||The Cleveland Clinic|Yes|Terminated|July 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1|||Both|18 Years|80 Years|No|||March 2014|March 4, 2014|July 21, 2010||No|recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01173263||118434|
NCT01173276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTEMIS|Intrauterine Insemination In HIV-Discordant Couples|Intrauterine Insemination In HIV-Discordant Couples|ARTEMIS|Boston Medical Center|No|Terminated|September 2009|October 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|50 Years|No|||January 2012|February 19, 2016|July 28, 2010||No|The field has changed, and we have decided to develop a PrEP program.|No||https://clinicaltrials.gov/show/NCT01173276||118433|
NCT01174160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6621-010|A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)|A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation||Cardiome Pharma|No|Completed|August 2010|October 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|85 Years|No|||November 2015|November 9, 2015|July 30, 2010|No|Yes||No|October 9, 2015|https://clinicaltrials.gov/show/NCT01174160||118365|
NCT01182493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUR05 / CEP234|OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy|OpT2mise Glucose Control in Type 2 DM With Insulin Pump Therapy|OpT2mise|Medtronic|Yes|Completed|December 2010|August 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|495|||Both|30 Years|75 Years|No|||February 2016|February 17, 2016|August 11, 2010||No||No|February 17, 2016|https://clinicaltrials.gov/show/NCT01182493||117726|
NCT01182506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-105|Rehabilitation of Cognitive Changes in Breast Cancer Survivors|Rehabilitation of Cognitive Changes in Breast Cancer Survivors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182506||117725|
NCT01182519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-115|Lung Inflammation and Lung Metastases From Breast Cancer|Association of Smoking, Lung Inflammation and Lung Metastases From Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|Urine and Blood|Female|18 Years|N/A|No|Non-Probability Sample|All patients who meet the above inclusion and exclusion criteria will be approached by a        member of the study team and be asked to participate.|September 2015|September 21, 2015|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182519||117724|
NCT01172535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1083|A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines|A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|November 2010|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|N/A|N/A|No|||November 2015|November 16, 2015|July 28, 2010|No|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01172535||118488|
NCT01172548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BIC08|Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)|A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec®) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)|INV555|Novartis||Completed|August 2008|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|132|||Both|18 Years|N/A|No|||March 2015|March 1, 2015|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01172548||118487|
NCT01172873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5828|D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD|Open-Label Exploratory Investigation of D-Cycloserine Augmentation to Cognitive Behavioral Therapy With Exposure and Response Prevention for Adults and Adolescents Diagnosed With Obsessive Compulsive Disorder - A Feasibility Study||New York State Psychiatric Institute|No|Completed|September 2008|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|12 Years|17 Years|No|||January 2014|August 15, 2014|April 20, 2009||No||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01172873||118463|Due to small sample size of treatment groups, analyses comparing groups were not conducted. Therefore, we cannot conclude that findings were due to D-cycloserine (DCS) augmentation.All participants received treatment from the same therapist.
NCT01172509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS_biomarker_Rbac_normals1|TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers|Transcranial Magnetic Stimulation (TMS) Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers for R-baclofen Effects in Normal Volunteers||Gonzalez-Heydrich, Joseph, M.D.|Yes|Terminated|October 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|6|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2015|August 20, 2015|July 28, 2010|Yes|Yes|too much variability in the TMS measures|No||https://clinicaltrials.gov/show/NCT01172509||118490|
NCT01172834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-09-IS-0258-09-TLV-CTIL|The Possible Influence of Health Promotion Coaching on Health Related and Organizational Outcomes Among Nurses|The Possible Influence of Health Promotion Coaching on Health Related and Organizational Outcomes Among Nurses||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2011|December 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|120|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2010|July 29, 2010|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01172834||118466|
NCT01172847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP22770|A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers|An Open-label, Multiple Dose, Randomized, Three-period Crossover Study in Healthy Subjects to Evaluate the Effect of Co-administration of Oseltamivir (Ro 64-0796) 75 mg Twice Daily and Rimantadine 100 mg Twice Daily on the Pharmacokinetic Properties of Oseltamivir and Rimantadine.||Hoffmann-La Roche||Completed|August 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|February 19, 2016|July 29, 2010|Yes|Yes||No|January 5, 2016|https://clinicaltrials.gov/show/NCT01172847||118465|
NCT01172860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT:2012-001248-23|Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System|Treatment of Inoperable Colorectal Cancer With Electrochemotherapy Through an Endoscopic System|CCEE EndoVe|Mercy University Hospital, Cork, Ireland|Yes|Active, not recruiting|January 2014|December 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172860||118464|
NCT01173094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-DCLI-II|Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II)|DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II)|DCLI-II|Peking Union Medical College Hospital|Yes|Enrolling by invitation|August 2010|July 2016|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|55 Years|75 Years|No|||July 2010|December 20, 2012|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173094||118446|
NCT01173068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Domain E/10/312|An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.|A Prospective Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.||National University Hospital, Singapore|Yes|Recruiting|August 2010|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|21 Years|70 Years|No|Non-Probability Sample|Adults OPAT patients diagnosed with complicated urinary tract infections and whom require        IV Ertapenem will be enrolled over a period of 1-2 years.|April 2014|April 1, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173068||118448|
NCT01173081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3D-US-X026|The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures|The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures||Ohio Orthopedic Center of Excellence|No|Recruiting|July 2010|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173081||118447|
NCT01174017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01685|Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate|A Study Assessing the Ability of AnchorSeed Iodine-125 Sources to Hold Fast in Tissue When Implanted for Treatment of Localized Prostate Cancer|FAST|British Columbia Cancer Agency|No|Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Male|40 Years|80 Years|No|||February 2013|February 8, 2013|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174017||118376|
NCT01173237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 00160287000-10|Efficacy Evaluation of Surfactant Administration Via Laryngeal Mask Airway|Efficacy Evaluation of Surfactant Administration for Respiratory Distress Syndrome Treatment Via Laryngeal Mask Airway. A Randomized Controlled Trial||Federal University of Minas Gerais|Yes|Not yet recruiting|July 2011|July 2013|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|8 Hours|No|||July 2010|June 27, 2011|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01173237||118436|
NCT01173250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251068|Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?|||Mansoura University||Completed||||||N/A|Interventional|N/A|2||||||Both|N/A|N/A||||October 2010|August 13, 2010|July 30, 2010||||No||https://clinicaltrials.gov/show/NCT01173250||118435|
NCT01174641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSA 2010/3|Test of Trans-cranial Magnetic Stimulation (TMS) Intervention on Unilateral Neglect|A Randomised Double-blind Test of TMS Intervention on Unilateral Neglect||University of Birmingham|Yes|Not yet recruiting|October 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|90 Years|No|||August 2010|August 2, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174641||118328|
NCT01174654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA019420-01A1|Development of a Methamphetamine Early Intervention|Development of a Methamphetamine Early Intervention||University of Washington|No|Completed|December 2006|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|127|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 12, 2012|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174654||118327|
NCT01171131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0334|A Pilot Study to Identify Biomarkers Associated With Chronic Traumatic Brain Injury|A Pilot Study to Identify Biomarkers Associated With Chronic TBI|Chronic TBI|The University of Texas Health Science Center, Houston|No|Recruiting|April 2010|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|180|Samples Without DNA|Saliva sample Blood sample (plasma)|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|TIRR Clinics|December 2015|December 10, 2015|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01171131||118596|
NCT01180361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08310|Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance|Atherosclerosis in RA and Lupus: Restoring Cholesterol Balance||Winthrop University Hospital|No|Recruiting|September 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|160|Samples Without DNA|plasma|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Lupus patients, rheumatoid arthritis patients, psoriatic arthritis patients, healthy        volunteers in Nassau County NY|December 2015|December 22, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180361||117890|
NCT01171365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09115|Small Particle Steroids in Refractory Asthma|Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma|SPIRA|University of Nottingham|No|Completed|January 2010|December 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||January 2014|January 30, 2014|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01171365||118578|
NCT01172340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK074666|Diet and Exercise for Underserved Women|Behavioral/Support Intervention for Diet and Exercise Among Underserved Women||University of South Carolina|Yes|Completed|August 2007|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|180|||Female|25 Years|50 Years|No|||February 2012|February 2, 2012|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172340||118503|
NCT01172353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSaoLucas|Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy|Hydration With Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy: A Multicenter Clinical Trial||Hospital Sao Lucas da PUCRS||Completed|July 2004|February 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|301|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|July 28, 2010||No||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01172353||118502|
NCT01181271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI Protocol No.: 10-057|Tandem Auto-Allo Transplant for Lymphoma|Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas||Massachusetts General Hospital|Yes|Active, not recruiting|August 2010|February 2016|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||July 2015|July 28, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181271||117820|
NCT01181596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICU-TECH RM9L-RS|NICU-TECH RM9L-RS Probe ME Feasibility Study|NICU-TECH RM9L-RS Probe ME Feasibility Study||GE Healthcare||Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|32|||Both|23 Weeks|6 Months||||January 2012|February 9, 2012|August 12, 2010||||No||https://clinicaltrials.gov/show/NCT01181596||117795|
NCT01181609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18559|A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum|An Open-label Study of Avastin in Combination With Chemotherapy Regimens as Second-line Treatment in Patients With Metastatic Colon or Rectal Cancer||Hoffmann-La Roche||Completed|June 2005|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|July 30, 2010|No|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT01181609||117794|
NCT01182207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-0632|Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Non-Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|July 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|33|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|August 12, 2010|No|Yes||No|September 15, 2010|https://clinicaltrials.gov/show/NCT01182207||117748|
NCT01182129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMWS06|4 mg Nicotine Polacrilex Gum and Swedish Portion Snus|Nicotine Delivery and Subjective Effects of 4 mg Nicotine Polacrilex Chewing Gum Compared With Swedish Portion Snus|SMWS06|Contract Research Organization el AB|Yes|Completed|March 2006|January 2007|Actual|January 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2010|August 11, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01182129||117754|
NCT01182142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT-06.CAP|Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients|Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients||Kidney Cancer Research Bureau|No|Completed|September 2007|August 2010|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|80 Years|No|||August 2010|August 22, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01182142||117753|
NCT01182155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0043|Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation|Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation: A Feasibility Study||Stanford University|Yes|Completed|August 2010|March 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lung tumors who are undergoing radiation therapy|August 2013|August 20, 2013|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182155||117752|
NCT01182194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-0631|Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.|A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|August 12, 2010|No|Yes||No|September 15, 2010|https://clinicaltrials.gov/show/NCT01182194||117749|
NCT01182818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD01/2010|Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease|FASEP Fabry and Stroke Epidemiological Protocol RISK FACTORS IN ISCHEMIC STROKE PATIENTS WITH FABRY DISEASE AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|FASEP|University of Rostock|Yes|Completed|September 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|Samples With DNA|Fabry diagnostic will be done centrally: blood samples will be stored for analysis of      a-galactosidase in blood, Gb3 as well as lyso-Gb3. In all cases direct analysis of the gene      will be done, especially in females where due to the Lyonisation effect a-galactosidase      activity might be normal in blood although the patient might suffer from Fabry disease.|Both|18 Years|60 Years|No|Probability Sample|Adult patients with acute ischemic cerebrovascular event of any ischemic etiology|June 2012|June 13, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01182818||117701|
NCT01183104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|START-J|START-J: SiTAgliptin in eldeRly Trial in Japan|Efficacy and Safety Comparison of Sitagliptin and Glimepiride in Elderly Japanese Patients With Type 2 Diabetes|START-J|Japan Association for Diabetes Education and Care|Yes|Completed|August 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|305|||Both|60 Years|N/A|No|||March 2015|March 31, 2015|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183104||117680|
NCT01183117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-01|A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease|A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease||Johnson & Johnson K.K. Medical Company|No|Completed|July 2010|August 2014|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|20 Years|N/A|No|||March 2015|March 31, 2015|August 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01183117||117679|
NCT01172561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0488|Community Awareness Resources and Education - Project 1|Reducing Cervical Cancer in Appalachia|CARE|Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|March 2005|||May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|280|||Female|18 Years|N/A|No|||September 2015|September 3, 2015|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01172561||118486|
NCT01172899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL26279.068.09|Bariatric Surgery in Children.|The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery|BASIC|Maastricht University Medical Center|Yes|Recruiting|July 2010|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|16 Years|No|||December 2015|December 18, 2015|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01172899||118461|
NCT01172886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|icapasso|Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer|Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer||Sbarro Health Research Organization|No|Recruiting|January 2008|||December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|777|Samples Without DNA|Blood samples|Female|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women and women operated for breast cancer|February 2010|July 29, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172886||118462|
NCT01173120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-174 (Sub study)|Methotrexate - Inadequate Response Device Sub-Study|Sub-study-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate|MTX-IR|Bristol-Myers Squibb|No|Completed|November 2009|July 2010|Actual|February 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||January 2012|January 9, 2012|July 28, 2010|Yes|Yes||No|May 3, 2011|https://clinicaltrials.gov/show/NCT01173120||118444|
NCT01173107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colchicine_2010_1|A Pilot Study for PK/PD Parameter of Colchicine in Chronic Kidney Disease Patient.|||Seoul National University Hospital||Completed|December 2010|||December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|80 Years|No|||December 2010|December 27, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173107||118445|
NCT01173406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTC-1113|Education Programme on Continuous Positive Airway Pressure Treatment|The Efficacy of a Brief Motivational Enhancement Education Programme on Continuous Positive Airway Pressure Adherence in Obstructive Sleep Apnea: A Randomised Controlled Trial||The University of Hong Kong|Yes|Completed|May 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01173406||118423|
NCT01173380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715715-4|Soy Nut Study on Markers of Health|Effects of Soy on Metabolite Markers of Health||University of California, Davis|No|Completed|August 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|21 Years|N/A|No|||September 2015|September 2, 2015|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01173380||118425|
NCT01173393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|435/09 B|Rapid Infusion of Cold Normal Saline During CPR for Patients With Out-of-hospital Cardiac Arrest|The RINSE Trial: Rapid Infusion of Cold Saline During CPR for Patients With Cardiac Arrest|RINSE|Ambulance Victoria|Yes|Completed|July 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|1220|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01173393||118424|
NCT01174277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12179|Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.|Immunological Changes in Chronic Graft Versus Host Disease Treated With Extracorporeal Photopheresis||University of Kansas Medical Center|Yes|Active, not recruiting|August 2010|December 2015|Anticipated|September 2015|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood samples will be collected at study entry and at 2, 4, 6 and 12 months following      treatment|Both|7 Years|N/A|No|Probability Sample|Patients who have undergone allogeneic HSCT and are being managed for chronic Graft versus        Host Disease by the University of Kansas Blood and Marrow Transplantation Program, and the        Children's Mercy Hospital BMT program, will be invited to take part in the study.|December 2014|December 15, 2014|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01174277||118356|
NCT01174290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15AG034915-01A1|Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol|Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study||Northeastern University|Yes|Recruiting|September 2010|||August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|84 Years|No|||April 2012|April 27, 2012|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01174290||118355|
NCT01173809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI-SPECULATE|Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation|Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation|SPECULATE|Texas Cardiac Arrhythmia Research Foundation|No|Completed|October 2010|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|75 Years|No|||August 2014|August 20, 2014|July 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173809||118392|
NCT01173822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRBC-1|Processed Residual Pump Blood in Cardiac Surgery: The PRBC Trial|Processed Residual Pump Blood in Cardiac Surgery: The PRBC Trial|PRBC|McMaster University|Yes|Completed|December 2004|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||July 2010|July 30, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01173822||118391|
NCT01180101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-380|Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease|Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease||The Cleveland Clinic|No|Active, not recruiting|August 2010|December 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|19 Years|N/A|No|||July 2013|January 6, 2014|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180101||117910|
NCT01180374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001006240|The Effects of Cannabidiol and ∆-9-THC in Humans|Cannabidiol Modulation of ∆-9-THC's Psychotomimetic Effects in Healthy Humans||Yale University|Yes|Recruiting|June 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|75|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180374||117889|
NCT01180660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00032300|IV Lidocaine on Postoperative Pain and QOR on Morbid Obese Patients Undergoing Bypass Surgery|The Effect of Systemic Intraoperative Lidocaine on Postoperative Pain and Quality of Recovery on Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery||Northwestern University|No|Completed|June 2010|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|51|||Both|18 Years|70 Years|No|||July 2014|July 15, 2014|July 19, 2010|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01180660||117867|We did not evaluate if the opioid sparing properties of systemic lidocaine resulted in a lower incidence of adverse respiratory events (hypoxemia/hypoventilation). We were underpowered to detect significant differences in certain parts of the qor-40.
NCT01180946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001126/1|Vitamin D Deficiency in Adolescent Girls|Vitamin D Deficiency in Adolescent Girls||Massachusetts General Hospital|Yes|Completed|September 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|90|||Female|9 Years|18 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180946||117845|
NCT01181622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08643|A Safety and Tolerability Study of Denufosol in 2-4 Year Olds|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC® Star in Patients 2 to 4 Years of Age With Cystic Fibrosis|REACH-1|Merck Sharp & Dohme Corp.|Yes|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|2 Years|4 Years|No|||December 2014|December 29, 2014|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01181622||117793|
NCT01181635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/494 (REK)|Can Psychotherapy Reduce Sickness Absence?|Can Psychotherapy Reduce Sickness Absence?||Lovisenberg Diakonale Hospital|No|Active, not recruiting|August 2010|July 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181635||117792|
NCT01182220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-241-B|Comparison of Ultrasound Guided Low Epidural Catheter Placement With Standard Epidural Catheter Placement|Comparison of Ultrasound Guided L5/S1 Epidural Catheter Placement With Standard Epidural Catheter Placement: A Randomized Trial||University of Chicago|No|Recruiting|January 2013|October 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Female|18 Years|40 Years|No|Probability Sample|active laboring patient without any complication requesting epdiural for pain control|May 2013|May 25, 2013|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01182220||117747|
NCT01181947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDTEV20112009|VALIANT CAPTIVIA Post-market Registry|VALIANT CAPTIVIA Post-market Registry A Multi-center, Post-market, Non Interventional, Prospective Study|VCOUS|Medtronic Endovascular|No|Terminated|February 2010|August 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|The Valiant Thoracic Stent Graft with the Captivia Delivery System is indicated for        treatment of diseases of the descending thoracic aorta including but not limited to        aneurysms and dissections. The Valiant Thoracic Stent Graft is indicated for exclusion of        the aneurysm, the false lumen or site of rupture and restoration of blood flow through the        stent graft lumen. The device is intended for use in subjects who are candidates for        conventional surgical repair, and in subjects who are not candidates for conventional        surgical repair due to pre-existing risk factors.        Study enrolment is open to subjects who in the opinion of the investigator are candidates        for endovascular TAA repair with the Valiant Captivia Thoracic Stent Graft System        according to the instructions for use (IFU).|January 2015|January 22, 2015|August 10, 2010||No|CIP was amended to include long-term FU but, not all sites accepted it so the nr. of pts    participating in the extended FU will be small.|No|December 17, 2014|https://clinicaltrials.gov/show/NCT01181947||117768|
NCT01183351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MID|Multidisciplinary Intervention for Challenging Behaviour (Agitation) in Patients With Dementia|Pilot Study of a Multidisciplinary Intervention for Challenging Behaviour (Agitation) in Patients With Dementia|TID|Sykehuset Innlandet HF|Yes|Completed|May 2011|August 2012|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||May 2011|December 11, 2014|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01183351||117661|
NCT01183364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-07|A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors|A Phase 1, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies||Synta Pharmaceuticals Corp.|No|Completed|July 2010|May 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|August 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01183364||117660|
NCT01183637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE Pilot|Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions Pilot Trial|Initial Safety and Effectiveness Study of the Kensey Nash Corp. Cartilage Repair Device for Knee Cartilage Lesion Repair|EAGLE Pilot|Kensey Nash Corporation|Yes|Terminated|June 2010|May 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|21 Years|N/A|No|||May 2015|May 7, 2015|July 28, 2010|Yes|Yes|Study enrollment rate was far slower than anticipated. Study was stopped for business    purposes.|No||https://clinicaltrials.gov/show/NCT01183637||117639|
NCT01183650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13910|A Study of Tadalafil in Benign Prostatic Hyperplasia|A Study to Evaluate the Pharmacokinetics of Tadalafil Administered Once Daily in Japanese and Non-Japanese Subjects With Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|July 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Male|45 Years|N/A|No|||April 2012|April 19, 2012|August 13, 2010|No|Yes||No|April 19, 2012|https://clinicaltrials.gov/show/NCT01183650||117638|
NCT01172912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITA-MIL-INT-38-10|High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy|Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment||National Cancer Institute (NCI)||Recruiting|October 2010|||October 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Male|18 Years|N/A|No|||August 2011|August 9, 2013|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01172912||118460|
NCT01173133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLA-001|Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery|Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery||Spectros Corporation|Yes|Recruiting|April 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing surgical breast reconstruction.|January 2011|January 30, 2011|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173133||118443|
NCT01173146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCA-002|Imaging of Residual Tumor During Prostatectomy|Imaging of Residual Prostate Cancer During Prostatectomy Using ProstaFluor®, a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent FDA Trial||Spectros Corporation|Yes|Not yet recruiting|December 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|96|||Male|N/A|N/A|No|Non-Probability Sample|Subjects undergoing prostatectomy for prostate cancer.|January 2011|January 30, 2011|July 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173146||118442|
NCT01173419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-201|Comparison Study for Safety and Efficacy of Two Devices for the Treatment of the Great Saphenous Vein|A Multi-Center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Subjects Comparing the NeverTouch Versus the RF ClosureFAST Methods of Treatment of the Great Saphenous Vein|RECoN|Angiodynamics, Inc.|No|Withdrawn|July 2010|February 2012|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||July 2012|July 12, 2012|July 28, 2010|Yes|Yes|Business decision to reevaluate clinical needs.|No||https://clinicaltrials.gov/show/NCT01173419||118422|
NCT01173679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-325|Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma||Massachusetts General Hospital|Yes|Terminated|July 2010|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2012|January 5, 2015|July 28, 2010|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01173679||118402|
NCT01173666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-1|Stenting of Renal Artery Stenosis in Coronary Artery Disease Study|Renal Artery Stenosis in Coronary Artery Disease: Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing Cardiac and Renal Outcomes. The Rationale and Study Design of a Prospective,Randomized Trial: the RASCAD Study|RASCAD|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|Yes|Recruiting|April 2006|April 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|85 Years|No|||July 2010|July 30, 2010|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01173666||118403|
NCT01174303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1981|A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN5401 in Young Adults and Geriatric Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|August 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01174303||118354|
NCT01175148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU11010|Atorvastatin for the Prophylaxis of Acute Graft-versus-host Disease in Patients Undergoing Matched Sibling Allogeneic Transplantation|Phase II Study Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft-versus-host Disease in Patients Undergoing Matched Sibling Hematopoietic Stem Cell Transplantation||West Virginia University|Yes|Active, not recruiting|July 2010|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|75 Years|No|||January 2013|January 11, 2013|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175148||118290|
NCT01179802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 005/10|Exercise-induced Changes in Cardiac Function & Morphology|Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology||University Hospital Inselspital, Berne|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||February 2011|February 14, 2011|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179802||117933|
NCT01180387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMN-Repository|Reproductive Medicine Network Biologic Specimen Repository|Reproductive Medicine Network Biologic Specimen Repository||Yale University|No|Completed|September 2010|January 2015|Actual|November 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|1640|Samples With DNA|The RMN plans to collect baseline serum samples (5 cc) and DNA for storage and eventual DNA      extraction. The whole blood will also be collected by the clinical sites.      As part of the RMN effort, pregnancies conceived as part of the study protocols are entered      into a pregnancy registry if the subjects consent to be part of the registry. Saliva samples      from the child conceived as part of the protocols, as well as the parent from whom the DNA      was not collected as part of the original protocols will be collected at that time. The      newborn's saliva will be collected with up to 5 saliva sponges, the tips of which are cut      off and stored using an Oragene® kit. The adults will be asked to provide 2 cc of saliva,      which will be stored with the same kits. These saliva samples will be stored at -20°C.      Two of the RMN studies involve assessing semen parameters. As part of this protocol, we      anticipate collecting semen samples from male subjects.|Both|N/A|N/A|No|Non-Probability Sample|Current patients of the ongoing and future RMN clinical protocols, who consents to        participate in this repository.|March 2015|March 2, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01180387|1 Week|117888|
NCT01180686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AECC 30610|Comparison of a Multiple Thrust Instrument to a Single Thrust Instrument in Treating the Low Back|Comparative Effectiveness of the Multiple Thrust Impulse Instrument and the Activator IV Single Thrust Instrument in Correcting a Lumbar Spinal Manipulable Lesion and Improving Lumbar Erector Spinae Flexion-relaxation|AECC|Anglo-European College of Chiropractic|No|Not yet recruiting|September 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|64 Years|No|||June 2010|August 11, 2010|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01180686||117865|
NCT01180959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0260|Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy|A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Received First-line Sorafenib Therapy (AVF4572)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|April 2011|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180959||117844|
NCT01171573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ollier-002|Investigating Genes in Patients With Polymyositis and Dermatomyositis|Identification of Disease Susceptibility Genes Associated With Development and Clinical Characteristics of Primary Inflammatory Muscle Diseases, PM, DM and IBM.|AOMIC|Salford Royal NHS Foundation Trust|Yes|Recruiting|January 2001|January 2020|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|DNA and serum|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Potential participants will be identified at their routine attendance of myositis clinics        at participating centres, by the study PI. Before recruitment, each prospective candidate        will be given a full explanation of the study, provided with a patient information sheet        (PIS) and consent form to read, and given the opportunity to ask any questions that may        arise. Once all questions have been answered and the Principal Investigator is assured        that the individual understands what is required, informed consent can then be sought.|May 2015|May 18, 2015|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171573||118562|
NCT01180673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P60MD000206|Counseling Older Adults to Control Hypertension|Counseling Older Adults to Control Hypertension|COACH|New York University School of Medicine|Yes|Completed|February 2008|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|251|||Both|60 Years|N/A|No|||November 2013|November 12, 2013|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01180673||117866|
NCT01181284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-001716|Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)|Modulating Effects of Lisinopril on Sildenafil Activity in PAH (MELISSA)|MELISSA|Mayo Clinic|No|Completed|May 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|75 Years|No|Probability Sample|Participants will be currently diagnosed with Pulmonary Arterial Hypertension (PAH).        Lisinopril versus placebo will be added to participants already recieving a stable dose of        Sildenafil.|February 2012|February 3, 2012|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01181284||117819|
NCT01181648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-111|Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life|Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life||Memorial Sloan Kettering Cancer Center||Recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Potential research subjects will be identified through a Dataline query. While Dataline        should capture most eligible patients, potential subjects can also be identified by a        member of the Head and Neck DMT.|January 2016|January 13, 2016|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181648||117791|
NCT01182545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-10-2007|The Effects of Hyperventilation Prior to CO2 Insufflation During Laparoscopic Cholecystectomy|A Prospective Randomized Study of the Effects of Hyperventilation Prior to Carbon Dioxide Insufflation on Hemodynamic Changes During Laparoscopic Cholecystectomy||King Faisal University|Yes|Completed|December 2008|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|45 Years|No|||November 2010|November 18, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182545||117722|
NCT01182168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-106|Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies|Phase I Trial of Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|August 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01182168||117751|
NCT01182181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1042|Anastrozole 1 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Anastrozole 1 mg Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|August 2005|September 2005|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 15, 2010|August 12, 2010|No|Yes||No|October 15, 2010|https://clinicaltrials.gov/show/NCT01182181||117750|
NCT01183936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Margins Melanoma|Trial of Surgical Excision Margins in Thick Primary Melanoma|A Randomised Trial of Surgical Excision Margins for Thick Primary Cutaneous Melanoma (>2 mm). A Multicenter Trial Comparing 2-cm vs 4-cm||Karolinska Institutet|No|Completed|January 1992|December 2006|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|936|||Both|N/A|75 Years|No|||June 1991|August 17, 2010|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01183936||117616|
NCT01183949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT7519M/0004|Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma|A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma||Astex Pharmaceuticals|No|Completed|November 2010|March 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|August 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183949||117615|
NCT01183962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-15602|Vitamin D and T-Regulatory Cells in Coronary Artery Disease|Vitamin D and T-Regulatory Cells in Coronary Artery Disease||Creighton University|No|Terminated|February 2010|||August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|30 Years|80 Years|No|||August 2011|August 3, 2011|August 17, 2010||No|slow enrollment, funding ended|No||https://clinicaltrials.gov/show/NCT01183962||117614|
NCT01184183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02-2136|Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy|Prospective Randomized Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy||CAMC Health System|No|Recruiting|September 2009|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|The population includes Carotid Endarterectomy (CEA), surgical removal of the blockage in        the neck artery patients.|February 2013|February 18, 2013|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184183||117598|
NCT01173718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVG 08-06|Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access|Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access (ACUSEAL, AVG 08-06)|ACUSEAL|W.L.Gore & Associates|Yes|Completed|July 2010|February 2013|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|July 29, 2010|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT01173718||118399|
NCT01173731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2217|Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias||Novartis||Completed|October 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|N/A|N/A|No|||March 2016|March 22, 2016|July 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01173731||118398|
NCT01174069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHS0701|Natural Orifice Transgastric Endoscopic Surgical Removal of the Gallbladder|Clinical Outcomes Trial of Laparoscopic Assisted Transgastric Endoscopic Cholecystectomy|NOTESchole|The Oregon Clinic|No|Recruiting|May 2007|October 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||October 2012|October 3, 2012|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174069||118372|
NCT01173432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW07-178|Exploring the Role of Adipocyte Fatty Acid Binding Protein in the Association of Obstructive Sleep Apnea and Metabolic Dysfunction|Randomized Controlled Trial of the Effect of Continuous Positive Airway Pressure on Adipocyte Fatty Acid Binding Protein and Other Metabolic Markers in Obstructive Sleep Apnea||The University of Hong Kong|Yes|Recruiting|June 2008|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2010|July 30, 2010|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01173432||118421|
NCT01173692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0096|Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.|Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2010|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01173692||118401|
NCT01173705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #100919|Factors Involved in Obesity-related Inflammation and Insulin Resistance|Genetic and Nutritional Factors Involved in Obesity-related Inflammation and Insulin Resistance||Vanderbilt University|No|Enrolling by invitation|June 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|120|Samples With DNA|Whole blood, omentum biopsy, subcutaneous fat biopsy, muscle biopsy (abdominal wall)|Both|18 Years|65 Years|No|Non-Probability Sample|Normal weight and obese subjects who are undergoing elective bariatric or abdominal        surgery|March 2016|March 2, 2016|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173705||118400|
NCT01174030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18161|Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea||Galderma|No|Completed|August 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|269|||Both|18 Years|N/A|No|||January 2014|January 24, 2014|July 30, 2010|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01174030||118375|
NCT01174043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-12; IUCRO-0300|Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia|Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia||Indiana University|Yes|Completed|July 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|July 30, 2010|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT01174043||118374|
NCT01175161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID-0925|Postpartum Intrauterine Device Study|A Pilot Study Of A Randomized Trial Comparing Two Different Time Frames For Copper T380A Intrauterine Contraception Insertion; Immediately Postpartum Compared To 4-6 Weeks Postpartum In Lilongwe, Malawi|PPIUD|University of North Carolina, Chapel Hill|Yes|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|115|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 6, 2011|August 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01175161||118289|
NCT01206946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED.KY.11|Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants|Effect of Antenatal Steroids for Women at Risk of Late Preterm Delivery on Neonatal Respiratory Morbidity||American University of Beirut Medical Center|Yes|Recruiting|September 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|700|||Female|18 Years|49 Years|No|||September 2010|June 22, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206946||115864|
NCT01206959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth 4|Clinical Test for Armed-used Blood Pressure Monitor With Preformed Cuff(Monitor When Being Inflated)|||Andon Health Co., Ltd|No|Completed||||||N/A|Observational|Time Perspective: Prospective||1|Actual|88|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|hospital population, including patient and accompanies.|June 2015|June 23, 2015|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206959||115863|
NCT01180114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD2525|Economic Empowerment Program Suubi-Maka|SUUBI MAKA ("Hope for Families"): A Family-Based Economic Empowerment Model for Orphaned Children in Uganda|Suubi-Maka|Columbia University|No|Completed|August 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|300|||Both|11 Years|16 Years|No|||November 2012|November 22, 2012|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01180114||117909|
NCT01180400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00003|A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy||AstraZeneca|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|295|||Both|18 Years|65 Years|No|||March 2014|March 14, 2014|August 5, 2010|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT01180400||117887|
NCT01180699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUOA-02|Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients|A Randomized Controlled Trial Comparing Intradermal vs. Intramuscular Trivalent Inactivated Influenza Vaccine in Adult Solid Organ Transplant Recipients||University of Alberta||Completed|October 2010|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|229|||Both|18 Years|59 Years|No|||May 2015|May 26, 2015|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180699||117864|
NCT01181011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.30|Telmisartan, Amlodipine and Combination in Healthy Subjects|A Single-centre, Randomized, Open-label, Three-period Crossover Pharmacokinetic Study of 80 mg Telmisartan / 5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Chinese Subjects||Boehringer Ingelheim||Completed|August 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|August 10, 2010||||No|November 21, 2011|https://clinicaltrials.gov/show/NCT01181011||117840|
NCT01180972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2010-1159|Effects of Environmental Opportunities and Barriers on Physical Activity, Fitness, and Health in Hispanic Children in Wisconsin|Effects of Environmental Opportunities and Barriers on Physical Activity, Fitness, and Health in Hispanic Children in Wisconsin||University of Wisconsin, Madison|No|Completed|August 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|214|||Both|12 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Middle - school age children in grades 5-8|October 2012|December 9, 2013|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180972||117843|
NCT01181297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3369-2|Double Blind Controlled Trial of an Extensively Hydrolyzed Formula With a Probiotic vs. an Extensively Hydrolyzed Formula Without a Probiotic|||Mead Johnson Nutrition||Completed|January 2003|November 2004|Actual|November 2004|Actual|N/A|Interventional|N/A|2||||||Both|N/A|14 Years||||August 2010|August 12, 2010|August 12, 2010||||No||https://clinicaltrials.gov/show/NCT01181297||117818|
NCT01181661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA029162|Internet-based Group Contingency Management to Promote Smoking Abstinence|Internet-based Group Contingency Management to Promote Smoking Abstinence||National Development and Research Institutes, Inc.|No|Completed|August 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||September 2014|September 23, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181661||117790|
NCT01181674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMIT Pilot|Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)|Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial||Population Health Research Institute|No|Completed|January 2011|September 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|83|||Both|30 Years|80 Years|No|||October 2015|October 20, 2015|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181674||117789|
NCT01181960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017107|Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations|Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations||Janssen Scientific Affairs, LLC|No|Completed|August 2010|November 2013|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1066|||Both|18 Years|64 Years|No|Non-Probability Sample|Potential participants will be identified by treating clinicians at the site. The study        will enroll participants treated at participating sites for schizophrenia and bipolar I        disorder. The study does not involve administration of a study drug, but will        naturalistically follow partticipants in these medication cohorts at the time of        enrollment: clinician ordered initiation or switch to LAT within past 4 weeks, clinician        ordered initiation or switch to oral antipsychotic within past 4 weeks, continuous users (        greater than or equal to 6 months) of Risperdal long acting injectable, continuous users        (greater than or equal to 1 month) of Invega Sustenna.|February 2014|February 11, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181960||117767|
NCT01183377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85-01-41-3488|Frequency of Female Athlete Triad Among Elite Female Athlete of Iran in Different Sport in 2007|Screening of Menstrual Disorder in Elite Feamle Athlete in Iran||Tehran University of Medical Sciences|Yes|Terminated|October 2006|March 2009|Anticipated|February 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|250|||Female|13 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population: Professional Iranian female athletes who are members in national teams        or federations sports and champion team in Tehran|August 2010|August 16, 2010|August 13, 2010||No|the study terminated last week|No||https://clinicaltrials.gov/show/NCT01183377||117659|
NCT01183390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-1043|Anastrozole 1 mg Tablets Under Fed Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Anastrozole 1 mg Tablets Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|September 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 15, 2010|August 13, 2010|No|Yes||No|October 15, 2010|https://clinicaltrials.gov/show/NCT01183390||117658|
NCT01182532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907001-3|A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease|||The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine|Yes|Completed|May 2010|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3000|||Both|1 Year|14 Years|No|||July 2012|July 20, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01182532||117723|
NCT01182831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-GIA-201001|Trial Comparing Two Techniques of Celiac Plexus Neurolysis for Treatment of Pain in Carcinoma Pancreas|A Randomized Trial Comparing Fluoroscopy Guided Percutaneous Technique Versus Endoscopic Ultrasound Guided Technique of Celiac Plexus Neurolysis for Treatment of Pain in Carcinoma Pancreas||Asian Institute of Gastroenterology, India|Yes|Recruiting|January 2010|January 2011|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2010|August 27, 2010|August 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182831||117700|
NCT01183975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-FR-004|Swedish Adjustable Gastric Banding Observational Cohort Study|Prospective National Cohort Study on Swedish Adjustable Gastric Band (SAGB) for Gastroplasty (Étude de Cohorte Nationale Prospective de l'Implant Annulaire Ajustable Pour Gastroplastie SAGB)||Ethicon Endo-Surgery (Europe) GmbH|Yes|Completed|September 2007|April 2012|Actual|April 2012|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|517|||Both|18 Years|N/A|No|Probability Sample|The study population is that of morbidly obese patients currently treated in France by        gastroplasty (gastric banding with an SAGB). The CEPP notices define the indications in        which this treatment is covered by health insurance.|August 2014|August 6, 2014|August 17, 2010||No||No|April 9, 2014|https://clinicaltrials.gov/show/NCT01183975|36 Months|117613|
NCT01184196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008|ChloraPrep Versus Betadine for Elective Knee Replacement Surgery|A Comparison of Chlorhexadine Gluconate Versus Povidone Iodine Surgical Preparation in Skin Bacterial Colony Counts for Elective Knee Replacement Surgery||Central DuPage Hospital|No|Terminated|November 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|August 16, 2010||No|ChloroPrep Wipes no longer available|No||https://clinicaltrials.gov/show/NCT01184196||117597|
NCT01184209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WueAC17/07|Prospective Study on the Incidence of Adrenal Crisis in Patients With Chronic Adrenal Insufficiency|Prospective Cohort-study on the Incidence of Adrenal Crisis in Patients With Chronic Adrenal Insufficiency||University of Wuerzburg|Yes|Completed|February 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|444|||Both|18 Years|N/A|No|Probability Sample|adult patients with chronic secondary or primary adrenal failure|January 2014|January 3, 2014|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184209||117596|
NCT01205919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TITUS-110510|Internet-based Guided Self-help for Chronic Tinnitus|Efficacy of an Internet-based Guided Self-help Training for Chronic Tinnitus: A Randomized Controlled Trial|TITUS|Johannes Gutenberg University Mainz|No|Completed|May 2010|October 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01205919||115943|
NCT01174316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0808/56|Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Acute Exacerbation of Respiratory Failure|Autotitrating Non-invasive Ventilation (NIV) Versus Standard NIV; a Randomised Crossover Trial in Patients With Acute Exacerbation of Chronic Respiratory Failure||ResMed|No|Enrolling by invitation|August 2010|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2010|April 30, 2014|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174316||118353|
NCT01174563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25200|A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Patients With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy|A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy||Hoffmann-La Roche||Active, not recruiting|February 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01174563||118334|
NCT01174056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDCF-2010060|Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging|Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone||Washington University School of Medicine|Yes|Completed|July 2011|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|39|||Both|19 Years|44 Years|Accepts Healthy Volunteers|||April 2014|April 22, 2014|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01174056||118373|
NCT01206972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14398|Dose-confirmatory Bridging Study in Total Knee Replacement|Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement||Bayer|No|Completed|October 2010|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|302|||Both|20 Years|N/A|No|||July 2013|July 15, 2013|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206972||115862|
NCT01202955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|808250|Pilot Study of Tolcapone in Smokers|Pilot Study of Tolcapone Effects on Abstinence-Induced Cognitive Symptoms in Smokers||University of Pennsylvania|Yes|Completed|July 2008|June 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|55 Years|No|||May 2011|May 4, 2011|August 19, 2010|Yes|Yes||No|October 6, 2010|https://clinicaltrials.gov/show/NCT01202955||116168|
NCT01180127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5804|Mars Flavanol Exercise and Cognitive Function Study|Study of the Impact of a Flavanol Containing Food Product and Exercise on Cognitive Function and Brain Structure||New York State Psychiatric Institute|No|Completed|December 2009|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Actual|41|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2014|January 14, 2015|May 21, 2010||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01180127||117908|
NCT01180140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seamguard Study|Use of Seamguard to Prevent Leak and Bleeding in Gastrointestinal Surgery|Use of Seamguard to Prevent Digestive Leak and Bleeding on Lineal Stapled Anastomoses: a Prospective Randomized Clinical Trial||Hospital Universitario de Canarias|Yes|Completed|March 2006|June 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|113|||Both|18 Years|90 Years|No|||August 2010|August 10, 2010|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01180140||117907|
NCT01180712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 10/S0802/27|Study of Oral Anthocyanins on Insulin Resistance|Study of Oral Anthocyanins on Insulin Resistance||University of Aberdeen|Yes|Recruiting|June 2010|November 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Male|40 Years|70 Years|No|||November 2015|November 12, 2015|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180712||117863|
NCT01181024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP25195|A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1|A Single Ascending Dose Tolerability and Pharmacokinetic Study of RO5303253 With a Pilot Food-effect Investigation in Healthy Subjects and Exploratory Pharmacokinetic, Pharmacodynamic, and Safety Assessments in Chronic Hepatitis C Genotype 1 Patients Following 5 Days of Oral Administration||Hoffmann-La Roche||Completed|April 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator)|3||Actual|82|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181024||117839|
NCT01180985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1636BD|Dispensing Evaluation of a Galyfilcon A Prototype Lens and a Marketed Contact Lens|||Johnson & Johnson Vision Care, Inc.|No|Completed|June 2010|||July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|39 Years|No|||May 2015|May 6, 2015|August 11, 2010|No|Yes||No|November 7, 2011|https://clinicaltrials.gov/show/NCT01180985||117842|
NCT01180998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-201004|Clinical Evaluation of Two Toric Contact Lenses in Current Non-toric Lens Users|||Johnson & Johnson Vision Care, Inc.|No|Completed|June 2010|||October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|210|||Both|16 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|August 11, 2010|Yes|Yes||No|November 29, 2011|https://clinicaltrials.gov/show/NCT01180998||117841|
NCT01181973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6291026|Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects|An Open-label, Randomized, Phase 1, Single-Dose Crossover Study to Evaluate Safety, Tolerability and Relative Bioavailability of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered in Healthy Subjects||Pfizer|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|August 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01181973||117766|
NCT01182233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30850|Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation|Evaluation of a Method Designed to Improve Outcome of HD Chemotherapy and AHSCT for Patients With Myeloma: Total Marrow Irradiation Administered Via Helical Tomotherapy Plus High-Dose Melphalan and Amifostine Before AHSCT2||University of Rochester|No|Terminated|June 2010|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|70 Years|No|||April 2015|April 3, 2015|August 3, 2010||No|low enrollmenet|No||https://clinicaltrials.gov/show/NCT01182233||117746|
NCT01183403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2008-3|CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease|Value of Contrast-enhanced Ultrasonography and Magnetic Resonance Enterography to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease Complicated by Symptomatic Small Bowel Stricture|CREOLE|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Completed|January 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|patients with ileal Crohn's disease complicated by symptomatic stricture after failure of        corticosteroids and/or immunosuppressives|June 2015|June 21, 2015|September 11, 2009||No||No||https://clinicaltrials.gov/show/NCT01183403||117657|
NCT01183130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5703434|Compliance Monitoring in Real Time During Opioid Substitution Treatment|Compliance Monitoring in Real Time During Opioid Substitution Treatment||Kuopio University Hospital|No|Withdrawn|August 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||August 2011|March 31, 2015|August 9, 2010||No|The technology planned to be used in the study got outdated and therefore the study will not    be conducted according to the initial protocol.|No||https://clinicaltrials.gov/show/NCT01183130||117678|
NCT01183663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0108|Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)|A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2010|||August 2025|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|180|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|August 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01183663||117637|
NCT01183676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIVA-0772|Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg|Single-Dose Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets (500 mg; Mylan) and Depakote Tablets (500 mg; Abbott) in Healthy Adult Male And Female (Not of Childbearing Potential) Volunteers||Mylan Pharmaceuticals||Completed|July 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 13, 2010|September 24, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183676||117636|
NCT01179932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charting Pilot|Anesthesia Charting Fidelity Study|Acute Anesthesia Charting Fidelity Quality Assessment Pilot Study||University Hospital Case Medical Center|No|Not yet recruiting|August 2010|August 2011|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Deidentified patients undergoing a cardiac surgical procedure or undergoing select        electrophysiologic procedures as well as the corresponding clinical staff caring for them.|July 2010|August 10, 2010|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01179932||117923|
NCT01180231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 168-10|Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity|Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity||Baker IDI Heart and Diabetes Institute||Recruiting|September 2010|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Subject)|4||Anticipated|77|||Male|18 Years|30 Years|No|||November 2013|November 3, 2013|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180231||117900|
NCT01205620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15084|IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery|IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery||University of Virginia|No|Enrolling by invitation|August 2010|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2010|September 17, 2010|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01205620||115966|
NCT01205633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCSVI Registry|Multi-center Registry for CCSVI Testing and Treatment|Multi-center Registry for CCSVI Testing and Treatment|CCSVI|Hubbard Foundation|No|Suspended|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients suspected of obstructions in the veins draining the central nervous system which        may adversely affect CNS function|September 2012|September 15, 2012|September 17, 2010||No|9/12/12 FDA stopped enrollment pending device exemption(IDE)application.|No||https://clinicaltrials.gov/show/NCT01205633||115965|
NCT01205932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14397|Dose-confirmatory Bridging Study in Total Hip Replacement|Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement||Bayer|No|Completed|September 2010|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|402|||Both|20 Years|N/A|No|||July 2013|July 17, 2013|September 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01205932||115942|
NCT01206140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02532|Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery|Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas||National Cancer Institute (NCI)|Yes|Completed|October 2010|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||January 2015|September 4, 2015|September 18, 2010|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01206140||115926|
NCT01206439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC- 09-12-31-04|An Advanced Echocardiographic Evaluation of Nebivolol|An Advanced Echocardiographic Evaluation of Nebivolol||University of Cincinnati|No|Terminated|September 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|20 Years|60 Years|No|||October 2015|October 22, 2015|April 2, 2010|Yes|Yes|Slow enrollment|No|August 24, 2015|https://clinicaltrials.gov/show/NCT01206439||115903|
NCT01174862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|288/09|Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery|Comparative Cohort Study on the Outcome of Patients With Normal and Reduced Acetylsalicylic Acid Responsiveness Undergoing Coronary Artery Bypass Surgery||University Hospital, Basel, Switzerland|No|Completed|June 2010|June 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|304|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective CABG surgery (on-pump and off pump surgery)|March 2015|March 9, 2015|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174862||118312|
NCT01203436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0010|Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity|Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity|STOP-ROP|NICHD Neonatal Research Network|Yes|Completed|February 1994|March 1999|Actual|March 1999|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|649|||Both|N/A|48 Hours|No|||June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203436||116132|
NCT01180413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26169|Intensive Vasodilator Therapy in Patients With Essential Hypertension|Effects of Intensive Vasodilating add-on Therapy on Peripheral Vascular Resistance and Coronary Flow Reserve in Patients With Essential Hypertension|Vasomore|Aarhus University Hospital|Yes|Completed|December 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|25 Years|80 Years|No|||April 2012|April 18, 2012|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180413||117886|
NCT01180426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR-2797-045|Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia|The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat||Chroma Therapeutics|Yes|Active, not recruiting|June 2010|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|60 Years|N/A|No|||February 2012|February 14, 2012|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01180426||117885|
NCT01181037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc10039-2010ctil|Bipolar H.A Versus Trochanteric Antegrade Nail for Treatment of Displaced Subcapital Femoral Fractures|||Meir Medical Center|No|Recruiting|June 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|40 Years|85 Years|No|Non-Probability Sample|200 patients sustained a displaced subcapital femoral fracture and were operated on by        colsed reduction and internal fixation with T.A.N nail or Bipolar hemiarthroplasty|March 2012|March 16, 2012|May 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01181037||117838|
NCT01181050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8555-3796|Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)|A Randomised, Single-dose, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0142-0002 in Subjects With Active Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|August 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||June 2014|June 10, 2014|August 12, 2010|Yes|Yes||No|April 25, 2013|https://clinicaltrials.gov/show/NCT01181050||117837|As per protocol, this clinical proof-of-principle trial investigated a limited number of participants and doses (single-dose regimen).
NCT01181323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0007|Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women|A Randomized, Double-Blind Trial, Comparing the Safety in Mothers and Their Infants and Immunogenicity in Mothers of Live Attenuated Influenza Vaccine (LAIV) to Inactivated Trivalent Influenza Vaccine (TIV) When Administered to Breast Feeding Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||April 2013|January 15, 2015|August 12, 2010|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01181323||117816|
NCT01181336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-v-001|Phase 1b Influenza Vaccine Study in Healthy Subjects|A Single Centre, Randomised, Double Blind, Phase 1 Study of the Safety, Tolerability, and Immunogenicity of an Influenza Vaccine Candidate (FLU-v)||PepTcell Limited|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|48|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181336||117815|
NCT01181726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3252|Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects.||Teva Pharmaceuticals USA|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|August 11, 2010|No|Yes||No|September 15, 2010|https://clinicaltrials.gov/show/NCT01181726||117785|
NCT01181310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3134-005|Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)|A Five-Period, Placebo-Controlled, Crossover Study to Evaluate the Effect of Donepezil and MK-3134 on Reversal of Cognitive Impairment Associated With a Single-Dose of Scopolamine.||Merck Sharp & Dohme Corp.|No|Completed|June 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|31|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|August 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01181310||117817|
NCT01182844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vs09.2008|Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota|Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota||Medical University of Graz|Yes|Completed|April 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182844||117699|
NCT01183143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 25040|Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization|A Multicentre, Open-label, Non-comparative Phase IIIb Study to Evaluate the Acceptability of GONAL-f® Prefilled Liquid Formulation Administered by Pen in an Outpatient Setting for Ovarian Stimulation|Prestyje|Merck KGaA||Completed|May 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|215|||Female|18 Years|43 Years|No|||March 2014|March 17, 2014|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183143||117677|
NCT01184001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921076|A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects|A Phase 1, Randomized, 2-Period, 2-Sequence, Open Label, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On Pharmacokinetics Of Tasocitinib (CP-690,550) Tablets In Healthy Subjects||Pfizer|No|Completed|September 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2010|October 12, 2010|August 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01184001||117612|
NCT01184248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEK14152010|The Effect of Sound Stimulation on Pure-tone Hearing Threshold|The Effect of Sound Stimulation on Pure-tone Hearing Threshold||Earlogic Korea, Inc.||Completed|May 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2011|September 7, 2011|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01184248||117593|
NCT01183689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|703|Study of Novel Approaches for Prevention|Study of Novel Approaches for Prevention|SNAP|Wake Forest School of Medicine|Yes|Active, not recruiting|August 2010|May 2019|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|599|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01183689||117635|
NCT01180530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS328-3741|Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes|A Multicentre, Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction of Insulin Therapy in Children and Adolescents With Diabetes Mellitus|REMIND™|Novo Nordisk A/S|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|358|||Both|2 Years|18 Years|No|Non-Probability Sample|Any child or adolescent with type 1 diabetes who has just started using NovoPen Echo® is        eligible. The selection of the patients will be at discretion of the individual physician.|June 2012|June 20, 2012|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01180530||117877|
NCT01180829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088/2010|Pilot Study of Text Message Brief Interventions for Problem Drinkers|Pilot Study of Text Message Brief Interventions for Problem Drinkers||Centre for Addiction and Mental Health|No|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|91|||Both|19 Years|N/A|No|||August 2012|August 29, 2012|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01180829||117854|
NCT01181141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-B-J303|Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery|A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)||Daiichi Sankyo Inc.|No|Completed|October 2008|February 2010|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Both|20 Years|N/A|No|||February 2015|February 3, 2015|August 12, 2010||No||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01181141||117830|
NCT01181154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080704|Rituximab in Auto-Immune Hemolytic Anemia|Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial|RAHIA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|March 2011|July 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181154||117829|
NCT01205646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU 2006-066|PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer|Pilot Trial to Evaluate Change in Positron Emission Tomography Scanning (PET) as a Surrogate for Zoledronate (Zometa) Efficacy in Patients With Metastatic Prostate Cancer||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|September 2010|||August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|11|||Male|N/A|N/A|No|||March 2015|March 25, 2015|September 17, 2010|Yes|Yes||No|April 18, 2014|https://clinicaltrials.gov/show/NCT01205646||115964|Small sample size.
NCT01206699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/3-N|Involvement of Transverso-sacral- Neo- Articulations or of Transverso-iliac Articulations in Chronic Lumbago|Involvement of Transverso-sacral- Neo- Articulations or of Transverso-iliac Articulations in Chronic Lumbago: Prospective Multicentric , Double-Blinded, Randomized of the Efficacy of corticoïd Infiltration Versus Physiological Solution Infiltration||Nantes University Hospital|No|Terminated|September 2010|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2010|November 2, 2015|September 21, 2010||No|after 4 years of recruitment only 16 patients have been included. Due to this low rate of    recruitment it was decided to stop the study|No||https://clinicaltrials.gov/show/NCT01206699||115883|
NCT01206153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWu|Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients|Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients: a Double Blind, Placebo-controlled Study||Central South University|Yes|Completed|June 2008|March 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|84|||Female|18 Years|40 Years|No|||February 2008|September 20, 2010|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206153||115925|
NCT01206166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP-UP|Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)|A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)|TOP-UP|Clinical Evaluation Research Unit at Kingston General Hospital|No|Active, not recruiting|June 2011|December 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01206166||115924|
NCT01206452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12153|Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes|Use of Oral Steroids Before Circumferential Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation to Improve Outcomes||University of Kansas Medical Center|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206452||115902|
NCT01206673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/07-I|Macrophagic Activation and Immunophenotypic Profile of Patients With Gaucher's Disease|Evaluation of Macrophagic Activation and Immunophenotypic Profile of Patients With Gaucher's Disease.|Gaucher|Nantes University Hospital|No|Completed|December 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||December 2011|December 1, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206673||115885|
NCT01206647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-SAX-001|Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus|Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus||ikfe-CRO GmbH|No|Active, not recruiting|February 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||September 2010|September 21, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01206647||115887|
NCT01206660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSXS-0914|Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis|A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis||Taro Pharmaceuticals USA|No|Completed|August 2010|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|September 20, 2010|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01206660||115886|
NCT01203735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR507910CTIL|Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer|Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Vinorelbine and Cisplatin for Inoperable Locally Advanced Non-Small-Cell Lung Cancer||Soroka University Medical Center|No|Recruiting|February 2011|February 2015|Anticipated|February 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||September 2010|March 27, 2011|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203735||116109|
NCT01203475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0013|Growth Observational Study|Growth Observational Study|Growth|NICHD Neonatal Research Network|No|Completed|August 1994|August 1995|Actual|August 1995|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1660|||Both|N/A|24 Hours|Accepts Healthy Volunteers|Probability Sample|Premature infants born at NICHD Neonatal Research Network centers during the study period.|June 2015|June 3, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203475||116129|
NCT01180439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 09-047|Patient-Ventilator Interactions in Chronic Obstructive Pulmonary Diseases (COPD) Under Non-Invasive Ventilation|Patient-Ventilator Interactions During Sleep Under Non-Invasive Ventilation in Severe Stable COPD||Ligue Pulmonaire Genevoise|No|Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|8|||Both|18 Years|N/A|No|||August 2010|August 11, 2010|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01180439||117884|
NCT01180725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dried Plum|Investigation of Dried Plums in the Treatment of Adults With Constipation|||University of Iowa||Completed||||||Phase 4|Interventional|N/A|||||||Both|18 Years|75 Years||||August 2010|August 11, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180725||117862|
NCT01181349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07535|Incidence of Incomplete Postoperative Neuromuscular Recovery From Anesthesia (P07535)(Completed)|Incidence of Postoperative Residual Neuromuscular Blockade - A Multicenter, Observational Study in Portugal|INSPIRE|Merck Sharp & Dohme Corp.|No|Completed|July 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|350|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Portuguese participants undergoing different types of elective surgical procedures        requiring general anesthesia with neuromuscular blocking agents|October 2015|October 12, 2015|July 23, 2010|No|Yes||No|February 29, 2012|https://clinicaltrials.gov/show/NCT01181349||117814|
NCT01181713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBK-OcuFResis|Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use|Antibiotic Resistance of Ocular Surface Flora After Continued Use of Topical Antibiotics Post Intravitreal Injections||Sunnybrook Health Sciences Centre|No|Active, not recruiting|June 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|168|||Both|65 Years|N/A|No|Non-Probability Sample|Patient recruitment would be from the Sunnybrook Health and Sciences Centre Department of        Ophthalmology|December 2011|December 2, 2011|February 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01181713||117786|
NCT01182285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100041|A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin|A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2010|September 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|100 Years|No|||May 2015|December 18, 2015|August 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01182285||117742|
NCT01182246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXP-CT-001|AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer|Safety, Pharmacokinetics and Efficacy of AXP107-11 in Combination With Standard Gemcitabine (Gemzar®) Treatment in Patients With Locally Advanced or Metastatic, Unresectable, Adenocarcinoma of the Pancreas, Stage III-IV: A Prospective, Open Label, Multi-centre, Sequential Phase Ib/IIa Study||Axcentua Pharmaceuticals AB|Yes|Recruiting|November 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01182246||117745|
NCT01181687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1268 (REK)|Psychometric Testing of the Norwegian Version of the Comfort Behavioral Scale|Psychometric Testing of the Norwegian Version of the Comfort Behavioral Scale||Sykehuset Telemark|No|Completed|January 2011|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|40 Weeks|3 Years|No|Non-Probability Sample|Children admitted to Telemark Hospital (level II hospital) and meeting the inclusion and        exclusion criteria specified|February 2013|February 12, 2013|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01181687||117788|
NCT01181700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0871015|A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers||Pfizer|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Actual|42|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 21, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181700||117787|
NCT01182857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100151|Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents|Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2010|September 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|5 Months|50 Years|No|||September 2014|October 4, 2014|August 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01182857||117698|
NCT01183156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR13002404|Re-invitation to Screening Colonoscopy: a Randomized Study|Re-invitation to Screening Colonoscopy: a Randomized Controlled Trial of Reminding Letter and Educational Intervention on Attendance in Nonresponders to Initial Invitation to Screening Colonoscopy|REINVITE|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Recruiting|August 2010|March 2011|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|55 Years|64 Years|No|||February 2011|February 14, 2011|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01183156||117676|
NCT01179945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05-0202|Effects of a Food Preservative on Glucose Homeostasis|Effects of a Food Preservative on Glucose Homeostasis||Children's Hospital Boston|No|Completed|August 2010|December 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|13|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179945||117922|
NCT01179971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charite-n-3-n-6|n-3 and n-6 Fatty Acids in Rheumatoid Arthritis|Incorporation of n-3 Long Chain Polyunsaturated Fatty Acids and Gamma Linolenic Acid in Plasma Lipids, Cholesteryl Esters, and Erythrocyte Membranes and Their Influence on Disease Activity in Patients With Rheumatoid Arthritis||Charite University, Berlin, Germany|No|Completed|December 2008|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|80 Years|No|||August 2010|August 25, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01179971||117920|
NCT01183702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004H002|Corneal Biomechanics With Hydration in Normal and LASIK Eyes|Analysis of Corneal Biomechanics Based Upon Central and Peripheral Corneal Thickness in Normal and Post Refractive Surgery Eyes||Ohio State University|Yes|Active, not recruiting|February 2004|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|44|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01183702||117634|
NCT01180556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sor493009ctil|Effect of Probiotics in Childhood Abdominal Pain|The Effect of Probiotics in Childhood Abdominal Pain||Soroka University Medical Center|Yes|Completed|March 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|6 Years|15 Years|No|||March 2016|March 20, 2016|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01180556||117875|
NCT01180569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-022|Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma|Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma||Memorial Sloan Kettering Cancer Center||Withdrawn|August 2010|May 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180569||117874|
NCT01206465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238-10|Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors|A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors||University of Nebraska|Yes|Recruiting|September 2010|||September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|19 Years|N/A|No|||August 2011|August 15, 2011|September 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01206465||115901|
NCT01202669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-30|Heart Rate Changes in Subjects With Epilepsy|Heart Rate Changes in Subjects With Epilepsy During an Epilepsy Monitoring Unit Admission||Cyberonics, Inc.|No|Completed|August 2010|July 2014|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|98|||Both|N/A|N/A|No|Non-Probability Sample|Epilepsy patients indicated for epilepsy monitoring unit stay.|August 2014|August 6, 2014|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01202669||116190|
NCT01202981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42093|Impact of Glistenings in AcrySof Intraocular Lenses on Visual Quality|Impact of IOL Glistenings on Visual Quality and Function in Patients Implanted With a Single-Piece AcrySof IOL That Exhibits Glistening Formation||University of Utah|No|Completed|July 2010|June 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Enrollment will be stratified into two patient groups based on time since surgery: (1) one        to two years post-operative, and (2) two to three years post-op.|December 2014|December 9, 2014|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202981||116166|
NCT01206686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810589|The Effect of Time-Slot Scheduling on Flu Vaccination Rates|Effect of Time-Slot Scheduling on Flu Vaccination Rates||University of Pennsylvania|No|Not yet recruiting|September 2010|April 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|5||Anticipated|50000|||Both|18 Years|N/A|No|||September 2010|September 20, 2010|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01206686||115884|
NCT01203202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC PE 02|Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation|A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped Clinical Study to Evaluate the Tolerability and to Determine the Adequate Dosage of PED-1 and PED-2 in Male Patients With Premature Ejaculation||Symyoo|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|104|||Male|20 Years|65 Years|No|||October 2012|October 1, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01203202||116150|
NCT01173302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUPH-ER-1|Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose|Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose||Peking University People's Hospital|Yes|Enrolling by invitation|May 2010|September 2010|Anticipated|August 2010|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|160|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2010|July 30, 2010|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01173302||118431|
NCT01181063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103005|Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers|Pharmacokinetic Pilot Study on Budesonide/Formoterol Easyhalers and Symbicort Turbuhaler; an Open, Randomised, Single Centre, Single Dose Study With Crossover Design in Healthy Subjects|Reco-Pilot|Orion Corporation, Orion Pharma|No|Completed|August 2010|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01181063||117836|
NCT01181076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-09136c|Individualized Nutrition for Adult Recipients of Allogeneic Stem Cell Transplants - Effect on Quality of Life|Individualized Nutrition for Adult Recipients of Allogeneic Stem Cell Transplants - Effect on Quality of Life|NASQ|Oslo University Hospital|Yes|Recruiting|August 2010|January 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 2, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01181076||117835|
NCT01182597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003039M|Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis|Oral Versus Intravenous Proton Pump Inhibitor Treatment in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis: a Prospective Randomized Comparative Study||National Taiwan University Hospital|No|Recruiting|August 2010|||August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182597||117718|
NCT01182558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100161|The Effect of Prior Muscle Activation on the Compound Muscle Action Potential (CMAP)|The Effect of Prior Muscle Activation on the Compound Muscle Action Potential (CMAP)- Implications for Routine Nerve Conduction Studies (NCS) and Serial NCS||Loma Linda University|No|Active, not recruiting|October 2010|June 2016|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182558||117721|
NCT01183416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-158|High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation|High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation in Patients With High-Risk Neuroblastoma: A Phase II Study||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Months|N/A|No|||September 2015|September 21, 2015|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183416||117656|
NCT01183715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2911001|A Single Dose Study Of PF-05161704 In Healthy Volunteers|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-05161704 After Administration Of Single Escalating Oral Doses Under Fed And Fasted Conditions In Healthy Volunteers||Pfizer|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|August 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01183715||117633|
NCT01179984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-09-006|Bard® LifeStent® Vascular Stent Delivery System Study|Bard® LifeStent® Vascular Stent Delivery System Study||C. R. Bard|No|Active, not recruiting|June 2010|October 2013|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects with lifestyle-limiting claudication or ischemic rest pain that are candidates        for percutaneous transluminal angioplasty (PTA) and stenting with lesion(s) in the        infra-inguinal segment (superficial femoral artery (SFA) and/or proximal popliteal        artery).|February 2012|February 13, 2012|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01179984||117919|
NCT01174576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CofSt|Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake|Acute Effects of Caffeinated and Decaffeinated Coffee Consumption on Energy Intake, Appetite, Inflammation and Glucose Metabolism||Harokopio University|No|Completed|February 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|16|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|July 26, 2010||No||No|September 4, 2012|https://clinicaltrials.gov/show/NCT01174576||118333|the results cannot be generalized to other population groups, as participants were selected according to specific criteria.
NCT01184222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-API-07|Efficacy Evaluation Of Great Occipital Nerve Electrical Stimulation On Rebound Headache|EFFICACY EVALUATION OF GREAT OCCIPITAL NERVE ELECTRICAL STIMULATION ON REBOUND HEADACHE AFTER WITHDRAWAL IN MEDICATION OVERUSE HEADACHE OCCURING IN MIGRAINE PATIENTS (SENGO-CAM Study)||Centre Hospitalier Universitaire de Nice|No|Recruiting|November 2010|December 2012|Anticipated|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2010|February 20, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01184222||117595|
NCT01184235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Act3|Multidimensional Measurement of Psychopharmacological Treatment Response|Actigraphic, Observational, Psychometric and Biological Measurement of Psychopharmacological Treatment Response||Child Psychopharmacology Institute|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|44|||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children and adults, male or female receiving or anticipating pharmacological intervention        and their non-affected first degree relatives will be invited to participate based on        institutional actiwatch availability. Since children are the focus of the Child        Psychopharmacology Institute they will be the primary recruitment focus, however, adult        subjects may include non-affected first degree relatives or others who represent        designated cohort groups and will be accepted based on actiwatch availabilty.|January 2014|January 2, 2014|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01184235||117594|
NCT01180244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113|The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients|The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients||McLaren Regional Medical Center|No|Completed|January 2002|July 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|65 Years|No|||May 2014|May 30, 2014|August 10, 2010|Yes|Yes||No|March 19, 2014|https://clinicaltrials.gov/show/NCT01180244||117899|
NCT01180257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-10-048 rev 1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2010|||||N/A|N/A|N/A||||||||||||||January 26, 2012|August 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01180257||117898|
NCT01180270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVV_CD1|Static Graviceptive Functions in Patients With Cervical Dystonia (CD)|Experimental Pilot Trial Assessing Static Graviceptive Function in Patients With Cervical Dystonia||Medical University of Vienna|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|outpatient botulinum toxin clinic of the department of neurology, medical university of        Vienna healthy subjects, residents of vienna|January 2012|January 28, 2012|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01180270||117897|
NCT01180543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP002|Acne Treatment With Active Oplon's Patches|Phase II- Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid||Oplon-Pure Science Ltd.|Yes|Completed|August 2010|December 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||June 2011|June 9, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01180543||117876|
NCT01171326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-10LND /FX2010-01|Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients|A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo||Foamix Ltd.|No|Completed|August 2010|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|2 Years|N/A|No|||December 2010|December 9, 2013|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01171326||118581|
NCT01171547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1632|Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration|Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Find Study||University of Zurich|Yes|Recruiting|February 2010|||February 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||July 2010|July 27, 2010|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01171547||118564|
NCT01206725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2009.365|Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction|The Effect of Aerobic Interval Training on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction||Norwegian University of Science and Technology|Yes|Completed|September 2010|May 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01206725||115881|
NCT01206179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-004|Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell|Effect of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Reconstructing Human Bone Defects||Royan Institute|Yes|Completed|March 2009|May 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|12 Years|75 Years|No|||June 2008|December 13, 2011|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206179||115923|
NCT01206192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 10-095|Differential Effects of Intimate Partner Violence (IPV) on Mental Health|The Differential Effects of Intimate Terrorism and Situational Couple Violence on the Mental Health of Abused Chinese Women||The University of Hong Kong|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|600|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Shelter residents and community sample|December 2014|December 2, 2014|September 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01206192||115922|
NCT01206712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN-FORST-001|Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients|Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients - Investigation on Postprandial Excursions of Proinsulin and PAI-1 Levels||ikfe-CRO GmbH|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|106|||Both|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|-  Group 1 (n=20): Healthy subjects          -  Group 2 (n=20): T2DM patients treated with continuous SU + MET therapy as             individually prescriped by the primary care physicians          -  Group 3 (n=20): T2DM patients treated with continuous LANTUS + MET therapy as             individually prescriped by the primary care physicians          -  Group 4 (n=20): T2DM patients treated with continuous DPP-4 + MET therapy as             individually prescriped by the primary care physicians|September 2010|September 21, 2010|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206712||115882|
NCT01202682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-34|Heart Rate Changes During Normal Activity, Exercise, and Sleep in Normal Healthy Subjects With and Without Epilepsy|Heart Rate Changes During Normal Activity, Exercise, and Sleep in Normal Healthy Subjects With and Without Epilepsy||Cyberonics, Inc.|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal, healthy population.|September 2010|January 20, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202682||116189|
NCT01203215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJF044224|Examining Two Print-based Exercise Interventions for Women|Evaluating Self-Help Programs for Exercise Adoption and Maintenance in Women|WWP|Temple University|No|Completed|June 2002|December 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|280|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|November 4, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01203215||116149|
NCT01181739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-00776|Computed Tomography (CT) Colonography Versus Optical Colonoscopy|The Effect of Experience and Training on the Accuracy of CT (Computed Tomography) Colonography in Comparison With Optical Colonoscopy in the Detection of Colonic Neoplasia||University of British Columbia|No|Recruiting|October 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|Colonic Mucosal Biopsy specimens obtained at the time of colonoscopy|Both|19 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients 19 - 65 years of age at with a recognized indication for optical colonoscopy,        including those high risk for colorectal cancer.|April 2013|April 9, 2013|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181739||117784|
NCT01182883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100175|A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2010|April 2012|Anticipated|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|21 Years|No|||April 2012|May 9, 2012|August 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01182883||117696|
NCT01181986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-CT-31|The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes|Exenatide and Postprandial Endothelial Dysfunction: Effects and Mechanisms||Carl T. Hayden VA Medical Center|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|76|||Both|35 Years|70 Years|No|||May 2014|May 12, 2014|August 13, 2010|Yes|Yes||No|December 26, 2013|https://clinicaltrials.gov/show/NCT01181986||117765|
NCT01182259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTWu002|The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study|||E-DA Hospital||Recruiting|October 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Newly diagnosed TB patient in E-DA hospital|August 2010|August 13, 2010|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182259||117744|
NCT01182272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000682840|Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery|Proof-of-Concept Phase II Study to Evaluate the Anti-Tumor Activity of Sorafenib Along With Pathological and Molecular Changes in Tumor Samples From Patients With Resectable Hepatocellular Carcinoma||National Cancer Institute (NCI)||Recruiting|May 2010|||June 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2010|August 13, 2010|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01182272||117743|
NCT01182571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808050R|Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients|Exploration of Fatigue ,Uncertainty ,Depression and Quality of Life in Heart Transplantation Recipients||National Taiwan University Hospital|Yes|Completed|October 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|127|||Both|18 Years|N/A|No|Non-Probability Sample|The outpatients who undergone heart transplantation were recruited from the Department of        Cardiac Surgery|August 2010|August 27, 2010|August 24, 2009||No||No||https://clinicaltrials.gov/show/NCT01182571||117720|
NCT01182584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200811040R|Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease|Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy||National Taiwan University Hospital|Yes|Recruiting|December 2009|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|16 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Graves' disease patients with or without ophthalmopathy and dermopathy|December 2010|December 21, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182584||117719|
NCT01183728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TerCel001|Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells|Regeneration of Articular Cartilage in Grade II, III and IV Knee Osteoarthritis by Intraarticular Injection of Autologous Bone Marrow Stem Cells Expanded ex Vivo With a GMP Procedure Developed by IBGM-Valladolid (MSV)|KDD&MSV|Red de Terapia Celular|Yes|Completed|May 2010|September 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|76 Years|No|||January 2015|January 7, 2015|August 13, 2010||No||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01183728||117632|
NCT01184014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04000-10-C|Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia|Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia||HealthPartners Institute|No|Completed|August 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||November 2013|November 30, 2015|August 16, 2010||No||No|September 13, 2013|https://clinicaltrials.gov/show/NCT01184014||117611|
NCT01174589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-145|Training of Patients With Hip Fracture|Strength Training of Patients With Hip Fracture - a Randomized Clinical Trial||Lolland Community, Denmark|No|Completed|September 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|60 Years|N/A|No|||August 2014|August 6, 2014|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01174589||118332|
NCT01179958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6211/7140R|Cognitive Benefits of Aerobic Exercise Across the Age Span|Cognitive Benefits of Aerobic Exercise Across the Age Span||New York State Psychiatric Institute|Yes|Active, not recruiting|August 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|260|||Both|20 Years|68 Years|Accepts Healthy Volunteers|||August 2015|October 5, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01179958||117921|
NCT01180517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1003|The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations|The Paclitaxel-Eluting PTCA-Balloon Catheter for the Treatment of Coronary Bifurcations|PEPCAD-BIF|Heart Centre Rotenburg|Yes|Completed|November 2010|February 2016|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01180517||117878|
NCT01171092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11803|A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma|A Pilot Trial to Assess Mobilization of Hematopoietic Progenitor Cells With a Combination of Bortezomib and G-CSF in Patients Undergoing Autologous Transplant for Myeloma and Lymphoma||University of Kansas Medical Center|Yes|Active, not recruiting|September 2010|March 2015|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|November 5, 2014|July 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01171092||118599|
NCT01202695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS.AVP.001|Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)|A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers||Emergent BioSolutions|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202695||116188|
NCT01202708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 1997|||||N/A|N/A|N/A||||||||||||||July 30, 2013|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202708||116187|
NCT01206738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010PS10|Developing and Evaluating Interventions to Reduce Inappropriate Prescribing of Antibiotics in Primary Care|Developing and Evaluating Interventions to Reduce Inappropriate Prescribing by General Practitioners of Antibiotics for Upper Respiratory Tract Infections: an RCT to Compare Paper-based and Web-based Modelling Experiments|WIME|University of Dundee|No|Completed|November 2010|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|270|||Both|N/A|N/A|No|||July 2014|July 22, 2014|September 21, 2010||No||No|January 30, 2014|https://clinicaltrials.gov/show/NCT01206738||115880|
NCT01203228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-002011-24|Dose-reduced Versus Standard Conditioning in MDS/sAML|Dose-reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study (RICMAC)|RICMAC|European Group for Blood and Marrow Transplantation|Yes|Terminated|May 2004|February 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|65 Years|No|||April 2015|April 2, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203228||116148|
NCT01203241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LARA-PAF|Benefit of Left Atrial Roof Ablation in Paroxysmal Atrial Fibrillation|||Hospital Clinic of Barcelona||Completed|June 2009|December 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||December 2013|December 11, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203241||116147|
NCT01203254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-010727-91|Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease|Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease|COBAM|Klinikum der Universitaet Muenchen, Grosshadern|No|Terminated|October 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|No|||April 2013|April 17, 2013|September 15, 2010||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01203254||116146|
NCT01173562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017419|A Safety Study of Mebendazole in Children 2 to 10 Years of Age|An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|397|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||March 2014|March 11, 2014|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173562||118411|
NCT01173575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J&P009SAN/2009|Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection|Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection||Infectopharm Arzneimittel GmbH|No|Recruiting|August 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Any subject with bacterial infection considered suitable for routine antimicrobial therapy        with FOM may be included into this analysis.|February 2016|February 5, 2016|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173575||118410|
NCT01173900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITU-001|Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls|Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls||London School of Hygiene and Tropical Medicine|Yes|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5532|||Female|9 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 5, 2011|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01173900||118385|
NCT01181999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25393|Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma|Phase II Trial of Rituximab (R) Augmentation Following R-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma (DLBCL)||Chonnam National University Hospital|Yes|Recruiting|August 2010|September 2014|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|70 Years|N/A|No|||July 2010|September 21, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01181999||117764|
NCT01183208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSD502-PE-006|A Safety and Tolerability Study of Administration of PSD502|A Phase I, Single-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Pharmacokinetic and Safety Study to Evaluate Systemic Exposure and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites 2,6 DiMethylAlanine (2, 6, DMA) and O-Toluidine; and the Safety and Tolerability of PSD502 in Female Healthy Volunteer Subjects Following Daily Application to the Vagina and Cervix for Seven Days With Three Different Doses of PSD502 or Placebo||Plethora Solutions Ltd|No|Completed|December 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|September 2, 2015|January 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01183208||117672|
NCT01182610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACORN ARCHESO0611|Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma|A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma||Accelerated Community Oncology Research Network|No|Terminated|April 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|August 13, 2010|Yes|Yes|Safety concern in a similar trial enrolling the same patient population|No|October 30, 2012|https://clinicaltrials.gov/show/NCT01182610||117717|This study was closed due to notification and preliminary results from a trial including panitumumab as part of combination chemotherapy for gastroesophageal cancer. The study was closed by mutual consent from the PI, Sponsor, and Funder.
NCT01182870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2010-1|Vitamin D and the Influenza Epidemic|Vitamin D and the Influenza Epidemic||University of Tromso|No|Completed|April 2010|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|569|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01182870||117697|
NCT01183169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2210|Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study on Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders to Previous Peg-IFN Alfa-2 Plus Ribavirin Treatment||Novartis|Yes|Completed|August 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|459|||Both|18 Years|70 Years|No|||March 2015|March 19, 2015|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183169||117675|
NCT01184027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 11226|Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment|Impact of Nutrition and Swallowing Function in a Randomized Controlled Trial of Head and Neck Cancer Patients During the Course of Treatment||University of Alberta|No|Not yet recruiting|October 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|Advanced Head and Neck Cancer Patients|March 2011|March 1, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184027||117610|
NCT01174082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0660|Donor Lymphocyte Infusion for Myeloma|Randomized Phase II Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogeneic Transplant||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2010|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|July 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174082||118371|
NCT01184261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000432|Integrated Behavioral Intervention for Cigarette Smoking and Binge Drinking in Young Adults|Integrated Intervention for Cigarette Smoking and Binge Drinking for Young Adults||Mayo Clinic|Yes|Completed|August 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01184261||117592|
NCT01174602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6010|Inpatient Exposure Therapy and Response Prevention & Cognitive Remediation Therapy for Anorexia Nervosa|Randomized Controlled Trial of Inpatient Exposure Therapy and Response Prevention for Anorexia Nervosa||New York State Psychiatric Institute|No|Completed|November 2009|October 2014|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|45 Years|No|||January 2015|January 28, 2015|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01174602||118331|
NCT01174875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/09/021|Developmental Pathways to Health and Disease: Metabolic, Neurodevelopmental and Related Outcomes.|Growing Up in Singapore Towards Healthy Outcomes|GUSTO|National University Hospital, Singapore|No|Active, not recruiting|June 2009|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1247|Samples With DNA|During pregnancy; Mother: blood, buccal and hair samples. At delivery; cord, cord blood and      placenta. During infancy; Stool, nasal, buccal samples from the children breast milk from      breastfeeding mothers|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant mothers who are attending the first trimester antenatal visit at the public        maternity units in KKH and NUH.|January 2014|January 2, 2014|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01174875||118311|
NCT01170793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/16|Medicine Abuse Headache|Medication Overuse Headaches: the Impact of Educative Telephone Coaching Administered by Nurses Prior to the Medical Appointment in a Tertiary Consultation Center: a Comparative Randomized Trial|CAM-ET|University Hospital, Bordeaux|No|Completed|August 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|88|||Both|18 Years|N/A|No|||December 2012|December 26, 2012|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01170793||118621|
NCT01175174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1038-sputum|Clinical, Airway Inflammatory, and HRA Phenotypes, in Preschool Children With Acute Asthmatic Attack Presenting to the ED.|Clinical, Airway Inflammatory, and HRA Phenotypes, in Preschool Children With Acute Asthmatic Attack Presenting to the ED.||Wolfson Medical Center|No|Completed|January 2009|September 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|1 Year|6 Years|No|Probability Sample|Children, age: 1-6 years old presenting to the emergency room (ER) with acute wheezing        episode.|September 2011|September 4, 2011|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175174||118288|
NCT01175187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1077|Intrapartum Fever and Histopathological Placental Findings|Intrapartum Fever and Histopathological Placental Findings||Wolfson Medical Center|Yes|Enrolling by invitation|April 2009|October 2010|Anticipated|March 2010|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|200||degree and location of inflamation|Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|200 normal deliveries|August 2010|August 8, 2010|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01175187||118287|
NCT01175200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOSAPI|Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.|Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study.|DOSAPI|Ascopharm Groupe Novasco|Yes|Completed|September 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|75 Years|No|||July 2012|July 3, 2012|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01175200||118286|
NCT01205971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-011-E|Tooth Smart Healthy Start: Oral Health Advocates in Public Housing|Oral Health Advocates in Public Housing||Boston University|Yes|Active, not recruiting|January 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3720|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|September 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01205971||115939|
NCT01206231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRS-DUM-2010/1|An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia|An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia||AstraZeneca|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|330|||Both|18 Years|N/A|No|Non-Probability Sample|Speciality care clinics|November 2011|November 7, 2011|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206231||115919|
NCT01206244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM20100465|Diurnal Variation of Tear Meniscus and Tear Osmolarity|Diurnal Variation of Tear Meniscus and Tear Osmolarity||University of Miami|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal subjects vs. dry eye patients|June 2013|June 11, 2013|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01206244||115918|
NCT01206764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001LIC01|A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.|An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE).||Novartis|No|Recruiting|November 2009|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01206764||115878|
NCT01202994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43306|Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET|Practice Effects and Amyloid Imaging Using 18F-PIB (18F-39-F-6-OH-BTA1) Known as [18FGE067]) or Flutemetamol PET and FDG-PET||University of Utah|Yes|Enrolling by invitation|May 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|24|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202994||116165|
NCT01203007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2259|Diet Intervention in Food Sensitive Patients With IgA Nephropathy|A Pilot Study of 6 Months Diet Intervention in Food Sensitive Patients With IgA Nephropathy|DIIGA|Uppsala University Hospital|No|Not yet recruiting|September 2010|March 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2010|September 16, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01203007||116164|
NCT01203020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU 11310|Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation|Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study||West Virginia University|Yes|Recruiting|September 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|70 Years|No|||December 2014|December 8, 2014|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01203020||116163|
NCT01203267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXK200801|Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer|Phase 2 Study of Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer Patients||Shanghai Jiao Tong University School of Medicine|No|Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Female|18 Years|70 Years|No|||November 2007|September 15, 2010|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01203267||116145|
NCT01173588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEE-001-2007|Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function.|Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function: A Randomized, Double-blind, Longitudinal Controlled Study in Mexican Adult.||Instituto Lala|Yes|Completed|June 2007|February 2008|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2010|July 29, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01173588||118409|
NCT01182623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT2009/046|The Value of Polyp Surface Pattern Recognition in the Identification of Neoplasia: a Prospective Study|Polyp Surface Pattern Recognition in the Identification of Neoplastic Polyps||Portsmouth Hospitals NHS Trust|No|Recruiting|December 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|260|Samples With DNA|All polyps are sent for histological analysis as per standard protocol. This is not      additional for the study and part of routine NHS practice. They will be kept and stored as      per standard NHS protocols.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing colonoscopy where one or more polyps are found.|August 2010|August 17, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01182623||117716|
NCT01182636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70716202|Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris|A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of Adapalene Gel 0.1% (PLIVA Research & Development Ltd.) Compared to Differin® (Adapalene 0.1%) Topical Gel (Galderma Laboratories) in Patients With Acne Vulgaris||Teva Pharmaceuticals USA|No|Completed|July 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|3||Actual|601|||Both|12 Years|40 Years|No|||November 2010|November 22, 2010|August 13, 2010||Yes||No||https://clinicaltrials.gov/show/NCT01182636||117715|
NCT01172938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSA-002|Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis|PALACE-1|Celgene|Yes|Active, not recruiting|June 2010|November 2016|Anticipated|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|504|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|July 6, 2010|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01172938||118458|
NCT01183182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACST-2010-1|Safety and Effectiveness Study for a Needle Guidance System in Lung Biopsies|Confirmation of Clinical Effectiveness and Safety of CT-guided Percutaneous Lung Aspiration and Biopsy Performed With the Aid of the ActiSightTM Needle Guidance System||ActiViews Ltd.|No|Completed|August 2010|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|48|||Both|18 Years|N/A|No|||March 2011|December 20, 2012|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01183182||117674|
NCT01183429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-159|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma: A Phase II Study||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|August 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Months|N/A|No|||March 2015|March 16, 2015|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01183429||117655|
NCT01174329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation|Difference in Salivary Flow in Patients With Salivary Gland Hypofunction of the Following Application of Neuro-electrostimulation|SALELECTROSTIM|Universidad Autonoma de Nuevo Leon|No|Recruiting|August 2010|||December 2010|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|75 Years|No|||July 2010|August 17, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01174329||118352|
NCT01174342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099-2010mmc|Effect of Child Delivery on Intraocular Pressure|The Effect of Child Delivery on the Intraocular Pressure||Meir Medical Center|No|Completed|August 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|45 Years|No|Non-Probability Sample|Healthy women candidate for chlid delivery|January 2013|January 9, 2013|August 1, 2010||No||No|November 26, 2012|https://clinicaltrials.gov/show/NCT01174342||118351|The number of participants was small due to difficulties in recruitment.
NCT01174615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM200901|Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth|Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth in Patients With Malignancy or Hematologic Disorders||University of Massachusetts, Worcester|No|Recruiting|September 2009|December 2100|Anticipated|December 2099|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|Tissue/cells from patients' samples.|Both|18 Years|N/A|No|Non-Probability Sample|Patients over the age of 18 with blood and/or bone disorders (leukemia, myeloproliferative        disorders, lymphoma etc.) with alterations of their blood counts.|October 2015|October 27, 2015|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01174615||118330|
NCT01174628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-93627|Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism|The ELOPE Study: Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism|ELOPE|Sir Mortimer B. Davis - Jewish General Hospital|Yes|Active, not recruiting|June 2010|February 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|platelet-poor plasma|Both|18 Years|N/A|No|Probability Sample|Patients seen in the Emergency Department, in-patient wards, out-patient clinics or        anticoagulation clinics.|November 2014|November 24, 2014|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01174628||118329|
NCT01174888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09111|Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia|Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|August 2010|||April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|August 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01174888||118310|
NCT01174901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoHead|Copeptin for Risk Stratification in Non-traumatic Headache in the Emergency Setting - The CoHead Study|Copeptin for Risk Stratification in Non-traumatic Headache in the Emergency Setting - The CoHead Study|CoHead|University Hospital, Basel, Switzerland|No|Completed|October 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples Without DNA|7.5 ml of EDTA blood, 7.5 ml of serum, 4.3 ml of citrate blood|Both|18 Years|N/A|No|Probability Sample|Patients presenting to emergency department or walk-in clinic|May 2014|May 23, 2014|August 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01174901||118309|
NCT01222481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0433|Comprehensive Assessment of Head and Neck Cancer Survivors|A Comprehensive Assessment of Adult Head and Neck Cancer Survivors (A Pilot Study)|CAHNCA|Washington University School of Medicine|No|Completed|July 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|40 Years|N/A|No|Non-Probability Sample|Participants will be recruited from the Washington University Physicians Faculty Practice        clinics of Adult Otolaryngology, Medical Oncology and Radiation Oncology|February 2012|February 29, 2012|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222481||114674|
NCT01222858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RC1HL100002-02|Innovative Technology To Improve Patient Adherence To Weight Loss Recommendations|Innovative Technology to Improve Patient Adherence to Weight Loss Recommendations||The Miriam Hospital|Yes|Completed|August 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|70 Years|No|||July 2014|July 7, 2014|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222858||114645|
NCT01222871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00540|Treatment of Early Nasal Polyposis With Topical Triamcinolone|Treatment of Early Nasal Polyposis With Topical Triamcinolone||Steward St. Elizabeth's Medical Center of Boston, Inc.|No|Terminated|July 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||June 2012|January 2, 2014|October 14, 2010||No|not enough particpants|No||https://clinicaltrials.gov/show/NCT01222871||114644|
NCT01223144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/10|Decision-making and Emotion Recognition in Essential Tremor|Decision-making and Emotion Recognition in Essential Tremor|EMOTREM|University Hospital, Bordeaux|No|Completed|September 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 7, 2012|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223144||114623|
NCT01223755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRENA-II|Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency|EFFECTS OF SIROLIMUS ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND SEVERE RENAL INSUFFICIENCY|SIRENA-II|Mario Negri Institute for Pharmacological Research|No|Terminated|September 2010|July 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|80 Years|No|||February 2013|February 22, 2013|October 12, 2010||No|safety and efficacy reason|No||https://clinicaltrials.gov/show/NCT01223755||114579|
NCT01223768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-12-00 C|Acetyl-L-Carnitine In Severe Hepatic Encephalopathy|||University of Catania||Completed|July 2002|December 2005||||N/A|Interventional|N/A|2||||||Both|40 Years|65 Years||||December 2000|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223768||114578|
NCT01223742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-12-00 B|Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy|ORAL ACETYL-L-CARNITINE THERAPY REDUCES FATIGUE IN HEPATIC ENCEPHALOPATHY||University of Catania|Yes|Completed|June 2002|December 2006||||N/A|Interventional|N/A|2||||||Both|40 Years|65 Years||||December 2000|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223742||114580|
NCT01224314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010010|Potassium in Haemodialysis Fluids and Haemodynamics|Haemodynamic Consequences of Changing Potassium Concentrations in Haemodialysis Fluids||Ospedale Regionale di Locarno|No|Completed|September 2007|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2007|October 19, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224314||114537|
NCT01220674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|491-10-FB|Pilot Testing a New Computer-based Screening Tool to Detect Cognitive Impairment|Pilot Testing a New Computer-based Screening Tool to Detect Cognitive Impairment||University of Nebraska|No|Not yet recruiting|November 2010|||October 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community||2|Anticipated|300|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Community-dwelling adults without significant cognitive impairment|October 2010|October 13, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220674||114813|
NCT01220973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080811|Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer|Phase II Trial of Atorvastatin and Celecoxib in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer.||Rutgers, The State University of New Jersey|No|Active, not recruiting|February 2009|||November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Male|18 Years|N/A|No|||March 2015|March 18, 2015|October 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220973||114790|
NCT01189916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00023311|Transrectal NOTES Appendectomy - Feasibility Study|Transrectal - Natural Orifice Translumenal Endoscopic Surgery (NOTES)||Northwestern University|No|Completed|August 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189916||117159|
NCT01189240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02509|RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma|Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma||National Cancer Institute (NCI)|Yes|Terminated|December 2010|February 2015|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|13|||Both|18 Years|N/A|No|||October 2015|November 13, 2015|August 25, 2010|Yes|Yes|Company decided to stop development of drug - 7/31/12|No|May 5, 2015|https://clinicaltrials.gov/show/NCT01189240||117210|This is Phase 1/Phase 2 Study. It closed prematurely by Roche, study still in Phase 1. Roche halted pt enrollment in ALL clinical trials w/ RO4929097 & cease production of drug & development. Phase 2 of this study was never activated.
NCT01190189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113621|Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study||GlaxoSmithKline||Recruiting|April 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|600|||Female|26 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 17, 2016|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190189||117138|
NCT01191216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02528|1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors|A Phase 1 Study of 1-Methyl-D-tryptophan (NSC-721782) in Combination With Docetaxel in Metastatic Solid Tumors||National Cancer Institute (NCI)||Completed|September 2010|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||April 2014|July 23, 2014|August 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01191216||117061|
NCT01191229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tecnis One-Piece MF IOL|Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens Aspheric Optic (AO)|Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens AO||Innovative Medical||Completed|July 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01191229||117060|
NCT01190852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-03065-3283|Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays|Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays Single-centre, Randomised, Open-label, Three-period, Six-sequence Cross-over Trial (William's Design)||MEDA Pharma GmbH & Co. KG|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190852||117087|
NCT01191515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Mast Study|Prospective Evaluation of Near and Intermediate Visual Outcomes With Monofocal Intraocular Lenses: The Mast Study|Prospective Evaluation of Near and Intermediate Visual Outcomes With Monofocal Intraocular Lenses: The Mast Study||Innovative Medical|No|Recruiting|August 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prospective evaluation of 200 patients male or female at least 18 years of age who have        previously undergone phacoemulsification (the break-up and removal of a cataract) between        one and 36 months earlier|June 2012|June 13, 2012|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191515||117039|
NCT01191203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00037535|Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi|Prospective Assessment of Acceptability and Adherence Associated With Use of the Copper Intrauterine Device (CuT380A-IUCD) Compared to Depo-medroxyprogesterone Acetate (DMPA) Among HIV Positive Women in Lilongwe, Malawi||Emory University|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|45 Years|No|||October 2013|October 23, 2013|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01191203||117062|
NCT01191489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-3116|High-flow Conditioned Oxygen Therapy Versus Non-invasive Ventilation: Prevention of Post-extubation Failure|Comparison Between High-flow Conditioned Oxygen Therapy and Non-invasive Ventilation in Prevention of Post-extubation Respiratory Failure. A Randomized Controlled Trial||Hospital Infanta Sofia|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1042|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191489||117041|
NCT01191502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMF-09-002|Comparative Study of Photopic and Mesopic Distance, Intermediate and Near Visual Acuity, and Spectacle Independence|Comparative Study of Photopic and Mesopic Distance Intermediate and Near Visual Acuity, and Spectacle Independence With Binocular Implantation of the Tecnis Multifocal (TMF) Intraocular Lens or Crystalens HD (CHD) Intraocular Lens||Innovative Medical|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Evaluate visual acuity in different lighting conditions (daylight and night time) and        distances (distance, near and intermediate), and the independence of glasses, in patients        who have had binocular implantation of the Tecnis Multifocal IOL or the Crystalens™ HD        Accommodating IOL.|October 2011|October 5, 2011|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191502||117040|
NCT01191151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OrthoIllustrated SOS #1|OrthoIllustrated Web Based Orthopaedic Sports Medicine Registry|Orthopaedic Sports Medicine, Arthroscopy, and Related Surgery Registry Using the Web-based OrthoIllustrated Surgical Outcome System||Arthrex, Inc.|No|Recruiting|September 2010|||June 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12500|||Both|12 Years|N/A|No|Non-Probability Sample|Cohort will be selected from clinic patients scheduling surgery or nonoperative treatment|September 2014|September 11, 2014|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191151||117066|
NCT01191164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA-H09-01053|Pilot Study of Partial Breast Irradiation Utilizing Permanent Breast Seed Implant to Treat Breast Cancer|A Prospective Study to Evaluate the Feasibility of Partial Breast Irradiation Utilizing Permanent Breast Seed Implant in British Columbia||British Columbia Cancer Agency|No|Not yet recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Female|N/A|60 Years|No|||August 2011|August 23, 2011|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01191164||117065|
NCT01191177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02-0066|Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease|An Initial Trial of Enteral Fish Oil Supplementation in the Treatment of Parenteral Nutrition-associated Liver Disease in Patients With Short Bowel Syndrome||Children's Hospital Boston|Yes|Recruiting|January 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|21 Years|No|||November 2011|November 10, 2011|August 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01191177||117064|
NCT01222494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0425|Healthy Bodies, Healthy Kids|Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children||Washington University School of Medicine|Yes|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01222494||114673|
NCT01222845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32W4|Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge|Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge||Northumbria University||Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|13|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 1, 2012|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01222845||114646|
NCT01222884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-CKD-03|A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D|A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With Intravenous Iron Sucrose in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)||Pharmacosmos A/S|No|Completed|June 2011|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|N/A|No|||June 2015|November 2, 2015|October 15, 2010|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01222884||114643|
NCT01223157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/14|Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index|Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index|SALIVENDO|University Hospital, Bordeaux||Completed|October 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 27, 2011|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223157||114622|
NCT01223781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|510-10-TLV|Biofeedback-based Motor Learning to Ameliorate Freezing of Gait|Biofeedback-based Motor Learning to Ameliorate Freezing of Gait||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|January 2011|May 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|85 Years|No|||October 2010|October 18, 2010|October 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01223781||114577|
NCT01224301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00439262|School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities|Monroe COunty School Kids Influenza Prevention Project|MCSkipp|Monroe County Department of Public Health|No|Completed|September 2009|January 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|25366|||Both|4 Years|13 Years|No|||April 2012|April 3, 2012|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224301||114538|
NCT01224067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB-0094/11/04|Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults|A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults||Cambridge Health Alliance|No|Active, not recruiting|March 2006|November 2010|Anticipated|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||October 2010|October 18, 2010|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224067||114556|
NCT01224080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF-002|Use of Adiana Tubal Occlusive Devices in Women With Hydrosalpinx Prior to In Vitro Fertilization|||Reproductive Science Center||Recruiting|October 2010|||October 2011|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|21 Years|43 Years|Accepts Healthy Volunteers|||October 2010|October 18, 2010|October 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224080||114555|
NCT01224093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25372|An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)|A Multicentre, Observational, Prospective Study to Assess the Safety Profile of Rituximab in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (B-CLL)||Hoffmann-La Roche||Completed|October 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|219|||Both|18 Years|N/A|No|Probability Sample|Patients with B cell-lineage chronic lymphocytic leukaemia (B-CLL)|March 2016|March 1, 2016|October 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01224093||114554|
NCT01211925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|440/III-3|Distal Venous Arterialisation of Ischemic Limb|Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb||Clinical Centre of Serbia|No|Active, not recruiting|September 2009|July 2011|Anticipated|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|95 Years|No|||September 2010|September 29, 2010|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01211925||115483|
NCT01211938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 1542-JANORL2|Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract|Randomized Phase 2 Trial Evaluating the Acute Toxicity of Two Protocols of Reirradiation After Surgery in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract - Single-fraction Radiotherapy With Concomitant 5FU and Hydrea Administered Every Other Week - Continuous Hyperfractionated Radiotherapy With Concomitant Cetuximab|JANORL2|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|April 2010|||April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Both|18 Years|70 Years|No|||March 2014|March 31, 2014|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01211938||115482|
NCT01224587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1840M00017|Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions|Characterisation of Gastrointestinal Transit of Four New Developed Gel Matrix Tablets With Different Erosion Rates by Means of MMM Measurement Under Fasting and Fed Conditions|MMM|AstraZeneca|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|5|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 3, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01224587||114516|
NCT01224860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSTANT|Telmisartan Versus Losartan in Kidney Transplantation|A Prospective, Randomized, Open Label Blinded End Point (Probe), Crossover Study to Compare the Effects of Telmisartan and Losartan on Metabolic Profile of Renal Transplant Patients|COSTANT|Mario Negri Institute for Pharmacological Research|No|Completed|January 2009|January 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||February 2014|February 24, 2014|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224860||114495|
NCT01224873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-019|Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET|Diagnosis of Sceletal Metastases in c. Mammae: 18F-NaF-PET/Lowdose-CT Versus 99mTc HDP Bone Scintigraphy||Rigshospitalet, Denmark|Yes|Recruiting|October 2010|September 2013|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Female|18 Years|N/A|No|Non-Probability Sample|breast cancer patients who are treated at Rigshospitalet, DK|October 2010|January 10, 2011|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224873||114494|
NCT01189929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M18-002|A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer|A Phase 1b Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer||OncoMed Pharmaceuticals, Inc.|Yes|Active, not recruiting|August 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|N/A|No|||September 2015|September 29, 2015|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189929||117158|
NCT01190215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114452|Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM|Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine FluarixTM in Adolescents Previously Vaccinated With GSK Biologicals' H1N1 Vaccine PandemrixTM||GlaxoSmithKline||Completed|October 2010|July 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|77|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||August 2012|August 23, 2012|August 26, 2010|Yes|Yes||No|January 12, 2012|https://clinicaltrials.gov/show/NCT01190215||117136|
NCT01190202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114001|Epidemiology Study of Malaria Transmission Intensity in Africa|Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa||GlaxoSmithKline||Completed|March 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|13380|Samples With DNA|Whole blood|Both|6 Months|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects at least 6 months of age will be enrolled in catchment areas of a Phase III trial        of the candidate malaria vaccine in sub-Saharan Africa (study 110021 (NCT00866619));        participants of study 110021 are excluded from this epidemiology study.|September 2015|September 28, 2015|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190202||117137|
NCT01190228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC15|Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV|Assessment of the Memory Immune Response, Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV and Long-Term Follow-Up||Sanofi|Yes|Active, not recruiting|August 2010|June 2016|Anticipated|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|505|||Both|36 Months|42 Months|Accepts Healthy Volunteers|||October 2015|October 26, 2015|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190228||117135|
NCT01190891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111411-1|Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome|A Manual Physical Therapy Approach Versus Subacromial Corticosteroid Injection for Treatment of Shoulder Impingement Syndrome: a Randomized Clinical Trial||Madigan Army Medical Center|No|Active, not recruiting|May 2010|December 2013|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01190891||117084|
NCT01191242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154-08|Methadone Monitoring for Insights Into Adverse Events|Methadone Monitoring for Insights Into Adverse Events|MEMORIES|Intermountain Health Care, Inc.|No|Completed|August 2010|May 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|Samples With DNA|Plasma and DNA|Both|18 Years|N/A|No|Non-Probability Sample|Subjects initiating methadone treatment for opioid addiction who meet elibitility        criteria.|April 2012|April 4, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01191242||117059|
NCT01191528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH2ESCAP|The Comparison of Pulse Oximetry, End-tidal Capnometry, and Integrated Pulmonary Index (IPI)|The Comparison of Pulse Oximetry, End-tidal Capnometry, and Integrated Pulmonary Index in Adult Post-operative Patients||Allenmore Hospital|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Convenience sample post-operative in-patients admitted to 2 East at Allenmore        Hospital/multicare Health system a 75 bed community facility.|December 2010|December 10, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01191528||117038|
NCT01191827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-011-07F|fMRI Cholinergic Mechanisms in Schizophrenia|fMRI Cholinergic Mechanisms in Schizophrenia||VA Office of Research and Development|Yes|Completed|October 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|40|||Both|18 Years|60 Years|No|Non-Probability Sample|Subjects with schizophrenia|May 2015|May 12, 2015|August 27, 2010||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01191827||117015|
NCT01191840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025497|Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection|A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci|Bacteremia|Duke University|Yes|Recruiting|February 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01191840||117014|
NCT01192087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCEPT|Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy|Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study|ACCEPT|Heidelberg University|Yes|Recruiting|June 2012|July 2017|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|70 Years|No|||April 2013|April 23, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192087||116995|
NCT01191801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOS-AML-301|Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)|VALOR|Sunesis Pharmaceuticals|Yes|Active, not recruiting|October 2010|||June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|675|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|August 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01191801||117017|
NCT01222507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0829|Processing Speed as an Objective Measure of Tinnitus|Processing Speed as an Objective Measure of Tinnitus|BST|Washington University School of Medicine|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|60|||Both|18 Years|80 Years|No|Non-Probability Sample|Tinnitus subjects recruited from speciality clinic and community at large.|September 2012|September 18, 2012|October 15, 2010||No||No|September 18, 2012|https://clinicaltrials.gov/show/NCT01222507||114672|
NCT01223443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VELETI II|Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents|Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents as a New Approach to MainTaining VeIn Graft Patency and Reducing Cardiac Events|VELETI II|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Yes|Active, not recruiting|October 2010|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||February 2014|May 13, 2014|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223443||114601|
NCT01223456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CPH-DUM-2010/1|Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use|A Descriptive Study of the Efficacy and Safety of ONGLYZA (Saxagliptin) Under Conditions of Actual Use in the Philippines|ONGLYZA PMS|AstraZeneca|No|Terminated|October 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|542|||Both|18 Years|N/A|No|Non-Probability Sample|several private and government hospitals|October 2013|October 7, 2013|October 14, 2010|No|Yes|Inability to recruit adequate number of patients within the specified time period.|No||https://clinicaltrials.gov/show/NCT01223456||114600|
NCT01215591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maimonides Project 07/10/VA5|Trial of Weaning of Nasal Continuous Positive Airway Pressure (CPAP)|Randomized Controlled Trial of Gradual Versus Sudden Weaning From Nasal CPAP in Preterm Neonates||Maimonides Medical Center|No|Completed|January 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|24 Weeks|32 Weeks|No|||October 2012|October 22, 2012|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01215591||115202|
NCT01211639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101JC403|Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy|Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy||Biogen|No|Terminated|October 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|24|Samples With DNA|Whole Blood collection for genetic analysis Urine collection for archiving and future      research use Plasma, Serum, and Peripheral Blood Mononuclear Cells (PBMC) collection for      archiving and future research use|Both|18 Years|N/A|No|Non-Probability Sample|This study will be conducted in subjects who have confirmed Progressive Multifocal        Leukoencephalopathy (PML) while being treated with natalizumab.|January 2015|January 15, 2015|September 16, 2010|Yes|Yes|Due to lack of enrollment.|No||https://clinicaltrials.gov/show/NCT01211639||115505|
NCT01215890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-RF|Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease|A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients||University of Alberta||Completed||||||Phase 4|Interventional|N/A|2||||||Both|18 Years|N/A|No|||October 2010|October 5, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215890||115179|
NCT01211626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA773-601|Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study in Healthy Volunteers and Patients With Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANA773 Tosylate||Hoffmann-La Roche|Yes|Completed|June 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 12, 2012|September 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01211626||115506|
NCT01212484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0011|Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia|Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia||New York University School of Medicine|No|Completed|December 2009|October 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|12 Years|N/A|No|||April 2013|April 5, 2013|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212484||115440|
NCT01212497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Virtual Coach for Mindfulness Meditation Training|Virtual Coach for Mindfulness Meditation Training||Psychometrix Associates|No|Completed|January 2010|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 29, 2010|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212497||115439|
NCT01212783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH087499-01A1|Treatment of Maternal Depression in Home Visitation: Mother and Child Impacts|Treatment of Maternal Depression in Home Visitation: Mother and Child Impacts|MIDISII|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|October 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Female|16 Years|45 Years|No|||February 2013|July 8, 2014|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212783||115417|
NCT01190540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42657-EG|Integrated Infectious Disease Capacity-Building Evaluation|Cost Effectiveness of Building Capacity of Mid-level Practitioners in Sub-Saharan Africa for the Care and Prevention of HIV, Tuberculosis, Malaria and Related Infectious Diseases|IDCAP|University of Washington|No|Completed|November 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|72|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190540||117111|
NCT01190865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-021|Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds|A Phase I Study Investigating the Survival of HP802-247 Allogeneic Cells in Excisional Acute Cutaneous Wounds||Healthpoint|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 1, 2011|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190865||117086|
NCT01223196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20080452|Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes|Effect of Pioglitazone on Tissue Inhibitor of Metalloproteinases 3 (TIMP-3) and TNF (Tumor Necrosis Factor)-α Converting Enzyme (TACE) in Skeletal Muscle and Their Circulating Substrates.|PIO-TACE|The University of Texas Health Science Center at San Antonio|No|Completed|August 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|70 Years|No|||December 2015|December 9, 2015|July 21, 2010|Yes|Yes||No|February 19, 2013|https://clinicaltrials.gov/show/NCT01223196||114619|
NCT01191541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAPL2010|Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)|Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia in Children: Remission Induction With All-transretinoic Acid (ATRA) and Arsenic Trioxide (As2O3). Consolidation With Daunorubicin(DNR)+Ara-c or DNR Alone.|Ara-C|Chinese Academy of Medical Sciences|Yes|Recruiting|May 2010|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Year|16 Years|No|||August 2010|August 30, 2010|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01191541||117037|
NCT01192100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1173258|The Beneficial Effects of a Protein-rich Breakfast on Appetite Control & Cognition in Overweight and Obese Adolescents|The Beneficial Effects of a Protein-rich Breakfast on Appetite Control & Cognition in Overweight and Obese Adolescents||University of Missouri-Columbia|Yes|Completed|September 2010|August 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Female|15 Years|20 Years|Accepts Healthy Volunteers|||January 2013|January 26, 2013|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01192100||116994|
NCT01192360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000016503|Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease|Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease||The Hospital for Sick Children|No|Recruiting|September 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|N/A|No|||September 2010|September 14, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192360||116974|
NCT01191814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100513025|Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression|Multicenter Randomized Trial COmparing Covered Metal and Plastic Stents for Preoperative Biliary Decompression in Pancreatic Cancer||Florida Hospital|Yes|Recruiting|July 2010|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|19 Years|85 Years|No|||April 2015|April 15, 2015|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01191814||117016|
NCT01214681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates|Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates||Newcastle University|No|Active, not recruiting|May 2010|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|75|||Both|16 Years|85 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214681||115271|
NCT01223170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNN-NST-eRehab-01|eRehab: Can Information and Communication Technology (ICT) Enhance Self-management of Cardiovascular Disease?|eRehab: Can Information and Communication Technology (ICT) Enhance Self-management of Cardiovascular Disease?|eRehab|University Hospital of North Norway|No|Completed|January 2012|December 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|69|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01223170||114621|
NCT01223183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09080375|Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis|Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis||University of Pittsburgh|Yes|Completed|September 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|No|||June 2013|June 14, 2013|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01223183||114620|
NCT01223469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-001 147|TOCCATA - Touch+™ for Catheter Ablation|A Prospective Safety, Performance and Preliminary Effectiveness, Multi-centre, Clinical Investigation Using the Irrigated TactiCath™ Percutaneous Ablation Catheter for the Treatment of Supra-Ventricular Tachyarrhythmia Using RF Ablation|TOCCATA|St. Jude Medical|Yes|Completed|September 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|75 Years|No|||May 2014|May 7, 2014|October 18, 2010||No||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01223469||114599|
NCT01211652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-PFR-DUM-2010/1|Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France|Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France||AstraZeneca|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|8186|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community sample|January 2013|January 28, 2013|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01211652||115504|
NCT01211951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCT1201|A Study of KCT-0809 in Patients With Dry Eye Syndromes|A Randomized, Double Blind, Placebo Controlled, Exploratory Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4|||160|||Both|20 Years|N/A|No|||June 2011|June 30, 2011|September 26, 2010||||No||https://clinicaltrials.gov/show/NCT01211951||115481|
NCT01211366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32600|Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions|Post-operative Infusion of Intra-operative Cell Salvage Reduces Allogeneic Blood Product Transfusions and Volume Resuscitation in Pediatric Cardiac Surgery and Improves Clinical Outcomes|cell salvage|University of Rochester|Yes|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|N/A|N/A|No|||February 2012|February 10, 2012|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211366||115526|
NCT01211964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 22811-S01|LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects|LEO 22811 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects||LEO Pharma|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01211964||115480|
NCT01211977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100182|A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease|A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD)||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2010|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2011|September 26, 2015|September 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01211977||115479|
NCT01211990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100192|An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States|An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States||National Institutes of Health Clinical Center (CC)||Completed|August 2010|May 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|22|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||May 2013|January 12, 2016|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01211990||115478|
NCT01212237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003010928|Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy|Phase I Study of Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy||Weill Medical College of Cornell University|No|Recruiting|September 2010|October 2016|Anticipated|October 2014|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with brain tumors (astrocytoma, meningioma, low grad glioma)|December 2012|December 20, 2012|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01212237||115459|
NCT01212250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS PHT-003|Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis|A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis||Institute of Liver and Biliary Sciences, India|No|Recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|132|||Both|18 Years|75 Years|No|||February 2016|March 1, 2016|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01212250||115458|
NCT01212263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MansouraIFC1|Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS|Clomiphene Citrate Co-treatment With Low Dose HP Urinary FSH vs. HP Urinary FSH Step-up Protocol for Clomiphene-citrate Resistant PCOS Anovulatory Infertility: Randomized Controlled Trial||Mansoura Integrated Fertility Center|No|Completed|January 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Female|18 Years|38 Years|No|||May 2013|May 29, 2013|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212263||115457|
NCT01212510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/170/HP|Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer|Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer|Coca-Colon|University Hospital, Rouen|No|Active, not recruiting|October 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|95 Years|No|||January 2016|January 22, 2016|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212510||115438|
NCT01212796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GET-ALO-2010-01|Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH|Second and Further Allogeneic Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH||Grupo Espanol de trasplantes hematopoyeticos y terapia celular|Yes|Not yet recruiting|September 2010|June 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|350|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who underwent 2 or more allogeneic transplants in Spanish hospitals between the        beginning of monitoring and the end of 2009, end of follow-up.|September 2010|September 30, 2010|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01212796||115416|
NCT01212809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUVE_COSMO_1-10-01|Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles|A Prospective, Open Label, Randomized, Comparative, Split-Face Study Evaluating Reconstituted JUVÉDERM® Ultra Injectable Gel Versus COSMODERM® 1 Human Based Collagen Implant for the Treatment of Vertical Lip Rhytids and Radial Cheek Lines|JUVE_COSMO_1|Fagien, Steven, M.D., PA|No|Completed|September 2010|June 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|25 Years|70 Years|No|||September 2011|September 9, 2011|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212809||115415|
NCT01190267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05897|Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)|A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia||Merck Sharp & Dohme Corp.|Yes|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|204|||Both|12 Years|17 Years|No|||August 2015|August 4, 2015|August 25, 2010|No|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01190267||117132|
NCT01190553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0166-10-RMC|Pilot Study of Maintenance Therapy With Intravenous AMANTADINE|Maintenance Therapy of Intravenous Amantadine in Patients With Idiopathic Parkinson Disease Who Are Not Optimally Treated With Anti Parkinson Medications||Rabin Medical Center|No|Not yet recruiting|November 2010|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|80 Years|No|||August 2010|October 10, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190553||117110|
NCT01190878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-303-001|Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers|A Randomized Double-masked 14-day Study to Compare the Ocular Safety, Tolerability, and Efficacy of Differing Dosing Regimens of ISV-303 to Vehicle and Xibrom™ in Post Cataract Surgery Volunteers||InSite Vision|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|169|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190878||117085|
NCT01222936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S075LBH501|LBH Phase II in Small Cell Lung Cancer (SCLC)|A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Patients With Advanced Small Cell Lung Cancer (SCLC)||Southern Europe New Drug Organization|No|Completed|May 2008|August 2010|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||October 2010|October 14, 2010|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01222936||114639|
NCT01223482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011-017|A Study Looking at Women's Experiences After a Miscarriage|An Investigation of Women's Experiences Following Karyotyping Products of Conception After a Miscarriage||California State University, Stanislaus|Yes|Recruiting|October 2010|June 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|400|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The investigators are targeting woman based on the inclusion and exclusion criteria        provided below.|September 2010|December 16, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223482||114598|
NCT01223521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH2010224|Systematic Provision of Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion. A Randomized, Prospective Trial.|Systematic Provision of Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion. A Randomized, Prospective Trial.||Helsinki University Central Hospital|No|Active, not recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|700|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223521||114597|
NCT01223794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98101|Fall Risk Assessment for Inpatient|Fall Risk Assessment for Inpatient||Taipei Medical University WanFang Hospital|No|Completed|February 2010|December 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1000|||Both|18 Years|N/A|No|Probability Sample|all in surgical & Medical in-patient|April 2011|April 21, 2011|October 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01223794||114576|
NCT01224106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN25203|A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for an Additional Two Years of Treatment||Hoffmann-La Roche||Active, not recruiting|November 2010|November 2021|Anticipated|November 2021|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|799|||Both|50 Years|85 Years|No|||March 2016|March 1, 2016|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224106||114553|
NCT01224119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMX-200|A Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery|A Multi-Center, Randomized, Pilot Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery||BioSurface Engineering Technologies, Inc|Yes|Active, not recruiting|January 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||March 2012|March 7, 2012|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224119||114552|
NCT01224327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCHC005|Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients|The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients.||Qingdao University|Yes|Not yet recruiting|October 2010|December 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||September 2010|October 19, 2010|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224327||114536|
NCT01192347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-702|French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia|A Phase 4, Observational Study to Explore How Different Treatment Regimens Affect Continuation With Treatment in the First 6 Months Following Initiation of XAGRID Into Adult Patients' Essential Thrombocythemia Therapy|FOX|Shire|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|177|||Both|18 Years|N/A|No|Non-Probability Sample|See Eligibility Criteria|February 2014|February 14, 2014|August 26, 2010||No||No|July 24, 2013|https://clinicaltrials.gov/show/NCT01192347||116975|
NCT01192659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-102|Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes|Identification of Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes: An Analysis of Data From the SAVOR Study||Bristol-Myers Squibb|No|Completed|May 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|16492|||Both|40 Years|N/A|No|Non-Probability Sample|Patients enrolled in the Saxagliptin Assessment of Vascular Outcomes Recorded in Diabetes        Mellitus study, which is a randomized, placebo-controlled phase 4 study of cardiovascular        outcomes). 12,000 patients with type 2 diabetes and either a history of a cardiovascular        event or multiple risk factors for vascular disease. Patients will be distributed as        follows: at least 30% in North America, approximately 30% in Europe, and the remainder in        South America, Asia, Australia, and South Africa.|February 2016|February 23, 2016|August 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01192659||116951|
NCT01215292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38692-K|ITT4 Intratesticular Hormonal Milieu in Man (ITT4)|Mechanisms of Control of the Intratesticular Hormonal Milieu in Man|ITT4|University of Washington|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|46|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|March 3, 2014|October 4, 2010|Yes|Yes||No|August 20, 2013|https://clinicaltrials.gov/show/NCT01215292||115225|
NCT01214954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090231|Early Rehabilitation After Total Hip Replacement|Early Rehabilitation After Toal Hip Replacement. -Effect of Supervised Progressive Resistance Training||University of Aarhus|Yes|Completed|September 2010|November 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|73|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01214954||115250|
NCT01214967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hood-R03HD058075|Problem Solving Education and Neonatal Intensive Care Unit (NICU) Mothers|Empowering Low Income Mothers With Preterm Infants: a Randomized Controlled Trial|Project Solve|Boston Medical Center|Yes|Completed|October 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|50|||Female|15 Years|N/A|No|||October 2010|October 5, 2010|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01214967||115249|
NCT01215279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3320C00002|AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)|A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD||AstraZeneca|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|63|||Both|40 Years|80 Years|No|||October 2014|October 17, 2014|September 30, 2010|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT01215279||115226|
NCT01215578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070145|Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors|A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.|NET|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|October 2008|December 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|September 23, 2010||No|lack of recruitement|No||https://clinicaltrials.gov/show/NCT01215578||115203|
NCT01211379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DP001566-01|The FLU-FOBT Program in Primary Care Settings Where Disparities Persist|The FLU-FOBT Program: Translation of an Evidence-Based Colorectal Cancer Screening Program to Primary Care Settings Where Disparities Persist||University of California, San Francisco|No|Completed|October 2009|August 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1372|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2010|October 14, 2010|September 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01211379||115525|
NCT01211392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|Detektion Von Knochenmarksveränderungen: Vergleich Von MRT Und DECT|||University of Zurich||Not yet recruiting|October 2010|December 2012||||Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with bone marrow changes|September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211392||115524|
NCT01211665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101JC404|Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)|High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab|IRIS|Biogen||Terminated|September 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|July 29, 2010|Yes|Yes|This study was stopped prematurely due to lack of enrollment within a 1-5-year period.|No|July 23, 2014|https://clinicaltrials.gov/show/NCT01211665||115503|
NCT01212549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|524270910|Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma|Open Label, Randomized Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma of the Skin|IMCXvsCIMT|University of Ioannina|Yes|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|80 Years|No|||August 2011|August 31, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212549||115435|
NCT01212276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-028-001|A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma|A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma||Morphotek|No|Terminated|December 2010|September 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|September 29, 2010|No|Yes|Sponsor terminated protocol|No||https://clinicaltrials.gov/show/NCT01212276||115456|
NCT01212523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/2007/2476|Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance|Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension.||University Hospitals Bristol NHS Foundation Trust|No|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|10|||Both|3 Months|16 Years|No|||December 2011|December 14, 2011|November 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01212523||115437|
NCT01212536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/2009/3387|Airtraq Versus Conventional Laryngoscopy in Children|Randomised Controlled Trial of the Airtraq Optical Laryngoscope and Conventional Laryngoscopy in Children||University Hospitals Bristol NHS Foundation Trust|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Both|N/A|6 Years|No|||December 2011|December 14, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01212536||115436|
NCT01189981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHK 3341|Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease|Effect of Internet, Mobil Applications and SMS-based Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease|PReVaiL|Rigshospitalet, Denmark|Yes|Completed|October 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|158|||Both|13 Years|16 Years|No|||September 2014|September 30, 2014|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189981||117154|
NCT01222533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.458|Tiotropium Respimat Pharmacokinetic Study in COPD|A Multicenter, Randomised, Placebo- and Active-controlled, 5 Way, Crossover Trial to Characterise the Pharmacokinetics and Evaluate the Bronchodilator Efficacy and Safety of Once-daily Tiotropium Delivered (Double-blind) From the Respimat Inhaler as Solution for Inhalation (1.25, 2.5, 5 mcg or Placebo) and as Inhalation Powder (18mcg) From the HandiHaler (Open Label) After 4 Week-treatment Periods in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|October 2010|||November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|154|||Both|40 Years|N/A|No|||August 2013|May 7, 2014|October 15, 2010||||No|November 13, 2012|https://clinicaltrials.gov/show/NCT01222533||114670|
NCT01222546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-001EU|Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors|Phase I, Open-label, Multi-center, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Activity of CH5132799 Administered Orally as a Monotherapy in Patients With Advanced Solid Tumors||Chugai Pharma Europe Ltd.|No|Completed|August 2010|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222546||114669|
NCT01222910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217_VALAC_09|A Relative Bioavailability Study of Valacyclovir Hydrochloride Tablets 1gm Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period,Two-sequence,Single-dose, Crossover, Bioequivalence Study Comparing Valacyclovir Hydrochloride Tablets 1 Gram of Ohm Laboratories Inc. (a Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With VALTREX® Caplets 1 Gram (Containing Valacyclovir Hydrochloride 1 Gram) of GlaxoSmithKline in Healthy, Adult, Male, Human Subjects Under Fasting Condition||Ranbaxy Inc.|No|Completed|May 2009|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 15, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222910||114641|
NCT01222923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-254|Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions|Single Dose Two-way Crossover Fed Bioequivalence Study of Risperidone 1 mg ODT Tablets in Healthy Volunteers||Ranbaxy Inc.|No|Completed|October 2004|January 2005|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 15, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222923||114640|
NCT01223222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-109-03|A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection|A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection||Lytix Biopharma AS|No|Completed|September 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|No|||February 2011|February 15, 2011|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223222||114617|
NCT01223235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-099|Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab|A PILOT STUDY OF A POLYVALENT VACCINE-KLH CONJUGATE + OPT-821 GIVEN IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN SECOND OR GREATER COMPLETE OR PARTIAL CLINICAL REMISSION||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|October 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||August 2015|August 14, 2015|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01223235||114616|
NCT01223209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-315-02|A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma|A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma||Lytix Biopharma AS|No|Completed|August 2010|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223209||114618|
NCT01223547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOLUSCAL|Study of the Effects of Carbohydrate Counting|The Effect of Carbohydrate Counting and Bolus Calculation Using an Electronic Calculator in Carbohydrate Counting-naïve Persons With Non-optimally Treated Type 1 Diabetes||Hvidovre University Hospital|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|64|||Both|18 Years|65 Years|No|||January 2014|January 26, 2014|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223547||114595|
NCT01223534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QFT-ECC-01|QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.|Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT)|OPTIMIST|Hospital Universitari de Bellvitge|Yes|Active, not recruiting|July 2010|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|870|||Both|18 Years|85 Years|No|||December 2015|December 21, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223534||114596|
NCT01223807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uspferd|Effects of a Diaphragmatic Breathing Training Program in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of a Short-term Diaphragmatic Breathing Training Program in COPD Patients: a Randomized Controlled Trial||University of Sao Paulo|Yes|Completed|June 2008|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|80 Years|No|||June 2008|October 18, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223807||114575|
NCT01192672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4764-8|Use of Expressive Writing in Irritable Bowel Syndrome (IBS)|Use of Expressive Writing in Irritable Bowel Syndrome (IBS)||Boston University|No|Active, not recruiting|September 2008|November 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|383|||Both|18 Years|80 Years|No|||August 2010|August 31, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01192672||116950|
NCT01224340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sahlgrenska Hospital|Active and Passive Distraction in Children Undergoing Wound Dressings|||Sahlgrenska University Hospital, Sweden||Completed|May 2008|||June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|60|||Both|5 Years|12 Years||||May 2007|October 19, 2010|October 13, 2010||||No||https://clinicaltrials.gov/show/NCT01224340||114535|
NCT01214993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114819|A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects|A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects||ViiV Healthcare|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|October 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214993||115247|
NCT01215604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10156-2010CTIL|Involvement of Translation Initiation Factors in the Immune Response in the Elderly|Characterization of the Involvement of Translation Initiation Factors in the Immune Response to Acute Infection in the Elderly and Very Elderly||Meir Medical Center|Yes|Recruiting|October 2010|October 2012|Anticipated|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Blood samples of elderly patients diagnosed with acute infection will be collected at      admittance to Meir hospital and on recovery (24-48 hours without fever and leukocytosis)|Both|65 Years|N/A|No|Probability Sample|patient aged >65 years admitted to internal medicine or geriatric departments due to acute        infection with fever and leukocytosis.|March 2012|March 16, 2012|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215604||115201|
NCT01215903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRUL-85742|Fish Gelatin Supplement and Omega-3 Supplement in Obese or Overweight Subjects With Insulin Resistance|The Beneficial Effects of Fish Nutrients on the Obesity-linked Metabolic Syndrome and Cardiovascular Risk Profile||Laval University|Yes|Completed|November 2007|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Both|40 Years|70 Years|No|||October 2010|October 22, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215903||115178|
NCT01212003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100195|Training Protocol on the Natural History of Tuberculosis|Training Protocol on the Natural History of Tuberculosis||National Institutes of Health Clinical Center (CC)||Recruiting|August 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|2 Years|N/A|No|||March 2016|March 15, 2016|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212003||115477|
NCT01212861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060410|Surgical Treatment of Refractory Open Angle Glaucoma|Surgical Treatment of Refractory Open Angle Glaucoma - A Prospective, Open-Label, Pilot Study||iScience Interventional Corporation|No|Completed|August 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212861||115411|
NCT01212289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005011027|Use of ROTEM® in Pediatric Cardiac Surgical Patients|The Use of Rotational Thromboelastometry ROTEM® to Characterize Coagulation Abnormalities in Pediatric Cardiac Surgical Patients: A Prospective Pilot Study|PedsROTEM|Weill Medical College of Cornell University|No|Completed|September 2010|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|23|Samples Without DNA|For each group, a small amount of blood will be obtained for ROTEM® analysis after induction      of anesthesia but before skin incision and again following cardiopulmonary bypass, 5 minutes      following protamine administration.|Both|1 Year|6 Years|No|Non-Probability Sample|Minors from the ages 1-6 years old receiving cardiac surgery using a cardiopulmonary        bypass machine|February 2016|February 16, 2016|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01212289||115455|
NCT01213381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11451|Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors|A Phase I Study Evaluating the Safety and Pharmacokinetics of SAR240550 Administered Twice Weekly in Patients With Advanced Solid Tumors.||Sanofi|No|Completed|September 2010|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|N/A|No|||May 2013|May 23, 2013|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213381||115371|
NCT01213602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAB-ANE-2010-01|Bilateral Bispectral Index (BIS)-Monitoring in Trauma Surgery|Bilateral Bispectral Index Changes During Knee Replacement Surgery With and Without Femoral Block||Hospital Universitari de Bellvitge|Yes|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|85|||Both|50 Years|90 Years|No|Non-Probability Sample|ASA physical status I-III patients scheduled for total knee arthoplasty|February 2011|July 22, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213602||115354|
NCT01212835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTROBESE 005|Effect of RING on Gastroesophageal Reflux (GERD) After RYGBP|The Use of a Silastic Ring in Open Gastric Bypass for Morbid Obesity and Its Association With Gastroesophageal Reflux Disease|RING|Clinica Gastrobese|No|Terminated|October 2010|January 2014|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|58 Years|No|||December 2015|December 21, 2015|September 29, 2010||No|lack of follow up|No||https://clinicaltrials.gov/show/NCT01212835||115413|
NCT01212848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-TMS|Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation|A Pilot Safety and Feasibility Study of High Dose Left Prefrontal Transcranial Magnetic Stimulation (TMS) to Rapidly Stabilize Suicidal Patients With PTSD||INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Active, not recruiting|October 2010|October 2013|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|70 Years|No|||April 2013|April 24, 2013|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212848||115412|
NCT01213095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CISL-MZL-10-4(ML25403)|Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)|R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma||Dong-A University Hospital|Yes|Active, not recruiting|September 2010|September 2015|Anticipated|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|20 Years|N/A|No|||November 2014|November 2, 2014|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213095||115393|
NCT01222039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2008-004014-27|Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.|Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.|CMM/EICH/2008|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Active, not recruiting|October 2010|December 2015|Anticipated|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||October 2015|October 20, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222039||114708|
NCT01222559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cod16HS13|Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects|Prospective, Randomised, Open Label, Multicentre Phase-III Clinical Trial to Compare the Efficacy and Safety of the Treatment With the Autologous Chondrocyte Transplantation Product co.Don Chondrosphere (ACT3D-CS) With Microfracture in Subjects With Cartilage Defects of the Knee With a Defect Size Between 1 an 4 cm2||co.don AG|Yes|Active, not recruiting|October 2010|December 2020|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|50 Years|No|||February 2015|February 12, 2015|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222559||114668|
NCT01222572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-240|Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer|Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer||Dana-Farber Cancer Institute|Yes|Terminated|December 2010|October 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 8, 2010|Yes|Yes|Slow accrual due to restrictive eligibility criteria|No|August 25, 2014|https://clinicaltrials.gov/show/NCT01222572||114667|Study was closed due to poor accrual after enrollment of 1 patient and results of trial are not interpretable.
NCT01223248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-154|Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy|A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|October 2010|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223248||114615|
NCT01223560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiaCon Study 01|Collection of Information-Rich Type 1 Diabetes Data|||Hvidovre University Hospital|Yes|Completed|October 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Prevention|||Actual|12|||Both|18 Years|70 Years|No|||October 2010|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223560||114594|
NCT01223573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMC1234|Neonatal Pulse Oximetry Compared With Apgar Scores|Newborn Pulse Oximety as a Predictor for Newborn Status and Future Outcome As Compared With the Apgar Score|newborn O2 sat|Kern Medical Center||Active, not recruiting|August 2010|||December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|newborns delivered at KMC OBGYN dept|August 2010|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223573||114593|
NCT01223820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasal Capsaicin treatment|Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin.|Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin.||Universitaire Ziekenhuizen Leuven|Yes|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 30, 2011|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223820||114574|
NCT01224145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-011|Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant in Men After Laparoscopic Inguinal or Umbilical Herniorrhaphy|A Phase II, Single-dose, Open-label Study to Investigate the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Laparoscopic Inguinal or Umbilical Herniorrhaphy||Innocoll|No|Completed|December 2010|September 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||October 2011|April 29, 2013|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224145||114550|
NCT01224158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBRGBP0016|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2010|||||N/A|N/A|N/A||||||||||||||October 4, 2011|October 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224158||114549|
NCT01224132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JID-2010-0484|Effect of Probiotics in the Atopic Dermatitis|Effect of Probiotics in the Treatment of Children With Atopic Dermatitis||Yuzuncu Yıl University|No|Completed|October 2007|April 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|8 Weeks|8 Weeks|Accepts Healthy Volunteers|||May 2008|October 18, 2010|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224132||114551|
NCT01224353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM2010001|Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy|Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Thioctacid Oral Tablet 600mg Once Daily in Chinese Diabetic Patients With Distal Symmetric Polyneuropathy||NovaMed Pharmaceuticals Inc.|Yes|Not yet recruiting|November 2010|July 2011|Anticipated|May 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||October 2010|October 19, 2010|October 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01224353||114534|
NCT01215344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 1020|First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade|Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Based Therapy||Vanderbilt-Ingram Cancer Center|Yes|Active, not recruiting|November 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||July 2015|July 15, 2015|October 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215344||115221|
NCT01215643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2211|Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN α2a in Chronic Hepatitis C Genotype 2 and 3 naïve Patients|A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNα2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients.||Novartis||Completed|October 2010|||May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|340|||Both|18 Years|70 Years|No|||June 2014|June 5, 2014|October 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215643||115198|
NCT01215305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GGR-DUM-2010/1|A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece|A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of GERD in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece. The 'GERDQ-XS' Study|GERDQ-XS|AstraZeneca||Completed|October 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|No|Probability Sample|Patients with upper GI symptoms|April 2011|April 5, 2011|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215305||115224|
NCT01215318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR: 2010-0014|Etiology and Prevention of Urinary Contamination of Vaginal Tampons During (18F)-FDG PET/CT Examinations|||University of Zurich||Completed|February 2010|July 2010||||N/A|Observational|Observational Model: Case-Only||1|Anticipated|60|||Female|20 Years|48 Years|No|Non-Probability Sample|Prevention of FDG uptake in vaginal tampons|October 2010|October 4, 2010|October 4, 2010||||No||https://clinicaltrials.gov/show/NCT01215318||115223|
NCT01215617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1539-5|The Effect of Aerobic Interval Training on Obstructive Sleep Apnea|The Effect of Aerobic Interval Training on Obstructive Sleep Apnea, Cardiovascular and Pulmonary Function in Obese Patients||Norwegian University of Science and Technology|No|Completed|October 2010|October 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|75 Years|No|||May 2014|May 22, 2014|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01215617||115200|
NCT01215630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2010/1512-2|Cardiovascular Fitness and Venous Function in Trained and Untrained Subjects|Cardiovascular Fitness and Venous Function in Trained and Untrained Subjects||Norwegian University of Science and Technology|No|Completed|October 2010|May 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|30|Samples Without DNA|Blood samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men and women, aged 18-75 yrs|January 2013|January 9, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01215630||115199|
NCT01212874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100218|Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery|Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass(CPB) in Cardiac Surgery: a Randomized, Controlled Trial||Loma Linda University|Yes|Completed|December 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|85 Years|No|||September 2014|September 9, 2014|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212874||115410|
NCT01212887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000685060|Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer|A Cancer Research UK Phase I Trial of Adoptive Transfer of Autologous Tumor Antigen-Specific T Cells With Preconditioning Chemotherapy and Intravenous IL2 in Patients With Advanced CEA Positive Tumors||Cancer Research UK||Terminated|August 2007|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|September 30, 2010||No|due to safety concerns and lack of efficacy|No||https://clinicaltrials.gov/show/NCT01212887||115409|
NCT01213108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFÅ 2007/44|Effects of the Örebro Prevention Program on Youth Drinking|||Karolinska Institutet|Yes|Completed|March 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1752|||Both|13 Years|16 Years|Accepts Healthy Volunteers|||September 2010|September 30, 2010|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213108||115392|
NCT01213121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH 11-2010-040|Neurophysiologic Changes in Patients With Bipolar Depression|Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression||Seoul National University Bundang Hospital|Yes|Recruiting|September 2010|October 2015|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213121||115391|
NCT01213394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25073|Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients|A 6-month, Prospective, Open-label, Randomized, Controlled, Pilot Study Evaluating the Efficacy, Safety and Toxicity of an Optimized Immunosuppressive Regimen of CellCept (Mycophenolate Mofetil, MMF) and Reduced Doses of Both Calcineurin-inhibitors and Prednisone in Renal Transplant Recipients With an Increased 10-year Coronary Heart Disease Risk|MMCR|St. Michael's Hospital, Toronto|No|Terminated|October 2010|December 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Both|30 Years|N/A|No|||April 2012|April 18, 2012|September 28, 2010||No|Poor recruitment.|No||https://clinicaltrials.gov/show/NCT01213394||115370|
NCT01213901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00462|Optimizing Insulin Absorption and Insulin Injection Technique in Older Adults|Optimizing Insulin Absorption and Insulin Injection Technique in Older Adults||University of British Columbia|No|Completed|September 2010|March 2014|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|1||Actual|20|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01213901||115331|
NCT01214187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL105371|Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis|Phase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary Fibrosis||Brigham and Women's Hospital|Yes|Active, not recruiting|July 2011|May 2015|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|85 Years|No|||May 2015|May 11, 2015|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214187||115309|
NCT01222351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6045 (Bayer)|Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172|BAY 94-9172 PET/CT in Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease||New York State Psychiatric Institute|Yes|Recruiting|December 2010|July 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|65 Years|N/A|No|||October 2015|October 14, 2015|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222351||114684|
NCT01222312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S417|Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel|Multicenter Randomized Phase II Study for the Therapy of Locally Advanced or Metastatic NSCLC (Stage IIIB/IV) With Cisplatin/Docetaxel or Oxaliplatin/Docetaxel|Taxelox|Krankenhaus Nordwest|Yes|Completed|August 2008|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||November 2011|November 28, 2011|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01222312||114687|
NCT01222325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1183/06|Comparison Between Two Shock Wave Regimens for Treating Urinary Stones|Comparison Between Two Shock Wave Regimens Using Frequencies of 60 and 90 Impulses Per Minute for Urinary Stones||University of Sao Paulo General Hospital|No|Completed|June 2008|August 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|6 Years|80 Years|No|||August 2009|October 14, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01222325||114686|
NCT01222338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|imm01|Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients|Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients||Lisichansk Regional Tuberculosis Dispensary|Yes|Completed|January 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|70 Years|No|||August 2012|August 2, 2012|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01222338||114685|
NCT01222949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST3073/ST3074-DM09-007|A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™|A Phase I, Pharmacokinetic Trial, in Healthy Asian and Caucasian Volunteers for Investigating the Pharmacokinetic Profiles of Eurartesim™ (40 mg Dihydroartemisinin (DHA)/320 mg Piperaquine (PQ) Phosphate.||sigma-tau i.f.r. S.p.A.|No|Completed|February 2010|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01222949||114638|
NCT01223859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lefa|Pretreatment Assessment of Oropharynx Ans Soft Palate Radiofrequency Surgery - a Multi-center Study|The Impact of Pretreatment Assessment of Oropharynx on Interstitial Soft Palate Radiofrequency Surgery Outcome - a Multi-center Study in Patients With Habitual Snoring||Helsinki University|No|Completed|January 2008|March 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2007|October 18, 2010|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223859||114572|
NCT01223586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H22-42|Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome|Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome|Ex JAPAN-ACS|Kyoto University|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|238|||Both|20 Years|N/A|No|Non-Probability Sample|Cohort of participants of JAPAN-ACS trial who completed the study|April 2012|April 21, 2012|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223586||114592|
NCT01223599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|non|Rhomboid Flap Versus Primary Closure After Excision of Sacrococcygeal Pilonidal Sinus. (A Prospective Randomized Study)|Rhomboid Flap Versus Primary Closure|non|Mansoura University|Yes|Withdrawn|April 2008|March 2010||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|140|||Both|15 Years|43 Years|No|Non-Probability Sample|both sex different age april 2008-march 2010|October 2010|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223599||114591|
NCT01223833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51575|A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen|A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen|LOGRIBMET|Universitaire Ziekenhuizen Leuven|No|Completed|April 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|296|Samples Without DNA|serum|Female|18 Years|N/A|No|Probability Sample|Postmenopausal early breast cancer patients scheduled to start adjuvant hormonal therapy        with any of the third generation aromatase inhibitors or tamoxifen in University Hospitals        Leuven.|November 2010|July 24, 2013|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01223833||114573|
NCT01224171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C13011|Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease|A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease|GEMINI III|Millennium Pharmaceuticals, Inc.|Yes|Completed|November 2010|April 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|416|||Both|18 Years|80 Years|No|||June 2014|June 19, 2014|October 18, 2010|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT01224171||114548|
NCT01224379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Köln-1223|Comparison of Standard Fusion With "Topping Off"-System in Lumbar Spine|Clinical Trial of the Efficacy of Hybrid Systems(Topping Off)in Comparison to the Conventional Spondylodesis in Fusion-surgery in the Lumbal Spine: a Prospective, Randomised Study|Topping-off|University of Cologne|Yes|Not yet recruiting|January 2011|October 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|N/A|No|||September 2010|October 19, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224379||114532|
NCT01224652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-ST10-01|Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy|A Randomized, Multicenter Phase III Study to Assess the Efficacy of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy||Korean Cancer Study Group|Yes|Recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|518|||Both|18 Years|N/A|No|||October 2010|October 19, 2010|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01224652||114511|
NCT01212016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100196|Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders|Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders||National Institutes of Health Clinical Center (CC)||Terminated|August 2010|May 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|162|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212016||115476|
NCT01215656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L. fermentum infections|Effect of a Follow on Formula With Lactobacillus Fermentum on the Incidence of Infections|||Puleva Biotech|Yes|Completed|May 2008|||January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|188|||Both|6 Months|7 Months|Accepts Healthy Volunteers|||October 2010|October 6, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215656||115197|
NCT01211405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-8|Study Comparing Three Doses of MDMA Along With Psychotherapy in Veterans With Posttraumatic Stress Disorder|Randomized, Triple-Blind, Phase 2 Pilot Study Comparing 3 Different Doses of MDMA in Conjunction With Manualized Psychotherapy in 24 Veterans, Firefighters and Police Officers With Chronic Posttraumatic Stress Disorder (PTSD)||Multidisciplinary Association for Psychedelic Studies|No|Active, not recruiting|September 2010|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|N/A|No|||May 2015|September 17, 2015|August 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211405||115523|
NCT01211678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999RA002|Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients|Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients (BATTER-UP)|BATTER-UP|Biogen|No|Completed|June 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|301|Samples With DNA|Whole blood, serum, plasma.|Both|18 Years|N/A|No|Non-Probability Sample|Participants who meet American College of Rheumatology (ACR) criteria for rheumatoid        arthritis (RA) and who, in the opinion of their treating rheumatologist, are not        adequately treated with existing therapy and should begin treatment with either an anti        TNF agent for the first time or with a different anti-TNF agent.|June 2014|June 6, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211678||115502|
NCT01211691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB004-01|Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)|Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies||KaloBios Pharmaceuticals|No|Suspended|September 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|September 24, 2010|Yes|Yes|KaloBios to Wind Down Operations|No||https://clinicaltrials.gov/show/NCT01211691||115501|
NCT01213134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98TMU-WFH-13|Evaluating the Implementation of Portfolio Assessment in Resident Training Program|Evaluating the Implementation of Portfolio Assessment in Resident Training Program||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|February 2010|August 2012|Anticipated|May 2010|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|residents tutors|September 2010|September 30, 2010|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213134||115390|
NCT01213147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2063|Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders|The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial||Yazd Medical University|Yes|Completed|April 2009|May 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|159|||Female|38 Years|45 Years|No|||September 2010|September 30, 2010|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01213147||115389|
NCT01214512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10097/2010k-CTIL|Performance Evaluation of the Micromedic CD24 in Vitro Diagnostic Assay|Performance Evaluation of the Micromedic CD24 Western Blot and ELISA in Vitro Diagnostic Assay||Meir Medical Center|No|Completed|January 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|229|Samples Without DNA|Fresh blood samples are collected and separated. Plasma is collected and stored and rest is      discarded of. Leukocytes are separated, lysed and the supernatant is stored. As DNA is      retained in the pellet, which is discarded, no DNA is retained in the samples stored.|Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects aged 50 years and above that are referred to colonoscopy assessment|March 2013|March 10, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01214512||115284|
NCT01213615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rev B February 4, 2010|Hancock II Ultra Porcine Bioprosthesis Hemodynamic Study|||Medtronic Cardiovascular|No|Completed|August 2008|May 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|179|||Both|18 Years|N/A|No|Non-Probability Sample|The patient population includes all patients who require aortic valve replacement for        heart valve disease (acquired or congenital) and who are candidates for a bioprosthetic        valve. Patients will be informed about the aspects of this study and will be asked to give        their Informed Consent.|October 2015|October 29, 2015|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01213615||115353|
NCT01213914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-09-046|Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)|The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure|RESCUE|United States Army Institute of Surgical Research|Yes|Recruiting|August 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213914||115330|
NCT01215084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218HV101|A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers|A Single-Dose, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers||Biogen|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 7, 2014|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01215084||115241|
NCT01222364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0023|Delayed Cord Clamping in VLBW Infants|Delayed Cord Clamping in VLBW Infants Pilot Study||NICHD Neonatal Research Network|Yes|Completed|June 2000|December 2000|Actual|December 2000|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|N/A|1 Minute|Accepts Healthy Volunteers|||June 2015|June 3, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222364||114683|
NCT01222585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024571|Metronidazole Pharmacokinetics (PK) in Premature Infants|Safety and Pharmacokinetics of Multiple Dose Metronidazole in Premature Infants|PTN_METRO|Duke University|Yes|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|N/A|90 Days|No|||January 2014|January 7, 2014|October 6, 2010|No|Yes||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01222585||114666|
NCT01222598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS38|A Study of Minirin Melt in Patients With Nocturia|Minirin Melt Tolerance With Nocturia in the Common Practice Conditions in Czech Republic||Ferring Pharmaceuticals|No|Completed|September 2008|March 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|588|||Both|18 Years|64 Years|No|Non-Probability Sample|Primary care clinic|October 2012|October 5, 2012|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01222598||114665|
NCT01222962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST3073/ST3074-DM09-008|Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers|Study of the Effect of Food on the Pharmacokinetics of DHA and PQP After Single Oral Administration of Eurartesim™ in Healthy Male Adult Volunteers||sigma-tau i.f.r. S.p.A.|No|Completed|March 2010|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01222962||114637|
NCT01222975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-257|Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions|Single Dose Two-way Crossover Fasted Bioequivalence Study of Risperidone 1 mg ODT Tablets in Healthy Volunteers||Ranbaxy Inc.|No|Completed|October 2004|December 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 15, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222975||114636|
NCT01223625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-200600|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function||Odense University Hospital|No|Completed|November 2007|June 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|81 Years|No|||July 2007|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223625||114589|
NCT01223872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICCREACH1038|Childhood Cancer Survivors' Knowledge of Diagnosis,Treatment and Risk of Late Effects: Specialized Survivorship Clinic|Childhood Cancer Survivors' Knowledge of Their Diagnosis, Treatment, and Risk of Late Effects: The Impact of Care in a Specialized Survivorship Clinic||Vanderbilt University|No|Active, not recruiting|August 2010|August 2016|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Cohort||3|Anticipated|160|||Both|N/A|21 Years|No|Non-Probability Sample|Fifty new cancer patients in the REACH for Survivorship clinic, fifty returning cancer        patients in the REACH for Survivorship clinic, and one hundred routine care cancer        patients are expected to enroll in this study.|June 2013|June 11, 2013|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223872||114571|
NCT01224184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5UR6PS000665-04|Young Women's CoOp Study|Adapting the Women's CoOp for At-Risk Teens|YWC|RTI International|No|Completed|May 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|237|||Female|16 Years|19 Years|No|||October 2013|October 16, 2013|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01224184||114547|
NCT01223885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-MK-2|Camel's Milk as a Safe Alternative in Cow's Milk Allergy|||Meir Medical Center|No|Completed|December 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2012|October 7, 2015|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01223885||114570|
NCT01224418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGRA-08-01-KOR|A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate|Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study||Astellas Pharma Inc|No|Completed|May 2008|August 2009|Actual|August 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||October 2010|October 19, 2010|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01224418||114529|
NCT01224678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-70806|Vitamin D and Breast Cancer Biomarkers in Female Patients|Vitamin D and Breast Cancer Biomarkers||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|October 2010|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|250|||Female|N/A|55 Years|No|||July 2015|July 9, 2015|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224678||114509|
NCT01224392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RectumSIB|Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer|Randomized Trial of Preoperative Radiotherapy With an Integrated Simultaneous Boost Compared to Chemoradiotherapy for T3-4 Rectal Cancer|RectumSIB|Universitair Ziekenhuis Brussel|No|Recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|95 Years|No|||April 2013|April 29, 2013|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01224392||114531|
NCT01224405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-019004-24|Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy|Androgen Deprivation Withdrawal Versus Maintenance and Intermittent Chemotherapy Versus Continuous in Prostate Cancer Patients With Castrate Resistant Disease|PON-PC-02|University of Turin, Italy|Yes|Active, not recruiting|April 2010|April 2016|Anticipated|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|600|||Male|18 Years|N/A|No|||June 2010|October 19, 2010|September 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224405||114530|
NCT01211730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00005806|Study of Glycemic Control on Liver Transplantation Outcomes|Prospective, Randomized, Open-Label, Controlled Study to Evaluate the Safety and Efficacy of Intensive Glycemic Control on Outcomes Following Liver Transplantation||Northwestern University|No|Active, not recruiting|April 2009|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|80 Years|No|||October 2015|October 5, 2015|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211730||115498|
NCT01212302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOCLAplan01|Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)|Optimizing Therapy With Aspirin and Clopidogrel. The BOchum CLopidogrel and Aspirin Plan to Improve Dual Antiplatelet Therapy.|BOCLAplan|Ruhr University of Bochum|No|Completed|October 2008|April 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|500|||Both|18 Years|80 Years|No|||September 2010|August 11, 2011|September 29, 2010||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT01212302||115454|
NCT01212315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Effects of Triclosan-coated Sutures in Cardiac Surgery|Triclosan-coated Sutures in Cardiac Surgery:Effects on Leg Wound Infections and Costs||Sahlgrenska University Hospital, Sweden|Yes|Completed|March 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|392|||Both|18 Years|85 Years|No|||December 2012|December 19, 2012|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212315||115453|
NCT01212562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75090409|Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery|Open Label, Phase 3 Study of the Efficacy of Combination of Imiquimod and Cryosurgery in the Treatment of Primary Basal Cell Carcinomas of the Skin|IMCX|University of Ioannina|Yes|Completed|April 2007|August 2011|Actual|April 2010|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|Blood samples with anticoagulant at -20C|Both|18 Years|N/A|No|Non-Probability Sample|Patients with basal cell carcinoma|August 2011|August 31, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212562||115434|
NCT01212575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NDK-SER-2010/2|A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia|A Retrospective, Non-interventional Study to Evaluate the Use of Seroquel XR and Seroquel IR in the Clinical Practice of Outpatients With Schizophrenia||AstraZeneca|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|186|||Both|18 Years|65 Years|No|Probability Sample|Patients with a diagnosis of schizophrenia who are registered at an outpatient district        psychiatric clinic|March 2011|March 4, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01212575||115433|
NCT01213927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI09020|National Cohort of Uncomplicated Alcoholic Cirrhosis|CIRRAL: Hepatocellular Carcinoma in Patients With Uncomplicated Alcoholic Cirrhosis: Incidence and Predictive Factors. A Multicentric Prospective Cohort|CIRRAL|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2010|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|At enrollement, 20 ml of blood will be collected for freezing and storage of serum and      plasma, and constitution of a DNA library|Both|18 Years|N/A|No|Non-Probability Sample|French primary care hospitals|September 2015|November 30, 2015|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213927||115329|
NCT01214213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MULTI2009|Non-Specific Chronic Back Pain; Insight From Spatial Aspects of Lumbar Spinal Muscle Activation|NON-SPECIFIC CHRONIC BACK PAIN; INSIGHT FROM SPATIAL ASPECTS OF LUMBAR SPINAL MUSCLE ACTIVATION||Oslo University Hospital||Enrolling by invitation|September 2009|||January 2012|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Chronic non-spesific low back pain and healthy control subjects|April 2011|April 14, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214213||115307|
NCT01215136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCRN GU10-147|First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma|Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147||Hoosier Cancer Research Network|Yes|Active, not recruiting|December 2010|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|October 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215136||115237|
NCT01214785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR03|Cluster Randomised Trial of Improved Sanitation in Rural Orissa, India|Assessing the Effect of Improved Rural Sanitation on Diarrhoea and Intestinal Nematode Infections: a Cluster Randomised Controlled Trial in Orissa, India||London School of Hygiene and Tropical Medicine|No|Active, not recruiting|September 2010|June 2017|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01214785||115263|
NCT01214798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SecondQinhuangdao201010|A Case of Sesamoid Displacement Causing the First Metacarpophalangeal Joint Locking|Study of the Second Hospital of Qinhuangdao|SDL|The Second Hospital of Qinhuangdao|Yes|Completed|January 2008|April 2010|Actual|January 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|||Both|20 Years|70 Years|No|Non-Probability Sample|1 person|October 2010|October 4, 2010|October 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01214798||115262|
NCT01215097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.65|Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy|A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 Over 24 Weeks in T2D Patients With Insufficient Glycaemic Control Despite Metformin Therapy||Boehringer Ingelheim||Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|80 Years|No|||June 2013|December 5, 2013|September 28, 2010||||No|April 16, 2013|https://clinicaltrials.gov/show/NCT01215097||115240|
NCT01215110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC207-CL001|Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis|A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of TMC207 in Adult Patients With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis.||Global Alliance for TB Drug Development|No|Completed|April 2010|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|68|||Both|18 Years|65 Years|No|||October 2010|October 4, 2010|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215110||115239|
NCT01222988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002960|Improving Maintenance Following Very Low Calorie Diet: The Sustain Lost Weight (SLW) Intervention|||Mayo Clinic|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|80 Years|No|||January 2013|January 15, 2013|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01222988||114635|
NCT01222611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA 6710|HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir|Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir|FOSTER-C|Fundacion SEIMC-GESIDA|Yes|Completed|March 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||September 2013|May 29, 2014|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222611||114664|
NCT01222624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXMab25101|PankoMab-GEX™: Dose Escalation Study|Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX™ in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy||Glycotope GmbH|Yes|Completed|November 2009|May 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222624||114663|
NCT01222637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXMab52101|CetuGEX™: Dose Escalation Study|Dose-escalation, PK- and Safety Study With Single Agent CetuGEX™ in Patients With EGFR Positive Locally Advanced and/or Metastatic Cancer||Glycotope GmbH|Yes|Completed|August 2010|October 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222637||114662|
NCT01223612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYKP1015|Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation|Diabetic Macula Oedema. A Prospective Randomised Study Comparing the Detailed Functional and Anatomical Changes of Repeated Pan Anti-VEGF Therapy With Ranibizumab Versus Conventional Macular Laser Therapy.|LUCIDATE|Moorfields Eye Hospital NHS Foundation Trust|Yes|Completed|October 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||July 2011|February 19, 2013|October 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01223612||114590|
NCT01224704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911008|Water Deprivation Protocol|Assessment of Thirst and Role of Water/Electrolytes Homeostasis During Water Deprivation in Obesity||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|88|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|August 25, 2015|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224704||114507|
NCT01220557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH062010|Evaluation of a Treatment and Education Programme for Type 1 Diabetic Patients (PRIMAS)|Prospective Randomized Trial for the Evaluation of a Treatment and Education Programme for Type 1 Diabetic Patients (PRIMAS)|PRIMAS|Forschungsinstitut der Diabetes Akademie Mergentheim|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|75 Years|No|||August 2014|August 8, 2014|October 12, 2010||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01220557||114822|
NCT01220817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM 2007-001|Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study|Safety and Efficacy of POMx in Men With Prostate Cancer: An 18-Month, Randomized, Double-Blind, Dose-Finding Study of the Effects of Two (2) Doses of Pomegranate Juice Extract Capsules (1 or 3 Capsules/Day) on Rising Prostate Specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer||POM Wonderful LLC|No|Completed|October 2007|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Male|18 Years|N/A|No|||April 2012|April 5, 2012|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220817||114802|
NCT01224197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017482|TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers|Phase I, Open Label, Randomized Study to Examine the Pharmacokinetics, Safety and Tolerability of Different Oral Doses of TMC435 After Single and Repeated Dosing in Healthy Chinese Subjects||Tibotec Pharmaceuticals, Ireland|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224197||114546|
NCT01224431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-014|Needle-Free Jet Injection of Lidocaine During Lumbar Puncture|Needle-Free Jet Injection of Lidocaine for Local Anesthesia During Lumbar Puncture: A Randomized Controlled Trial||Phoenix Children's Hospital|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|90 Days|No|||June 2011|June 14, 2011|September 30, 2010||No||No|April 5, 2011|https://clinicaltrials.gov/show/NCT01224431||114528|
NCT01224691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110006|TGF-(Beta) and Susceptibility to RSV|The Role of TGF-Beta in Asthmatic Epithelial Cell Susceptibility to RSV Infection||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|February 12, 2016|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224691||114508|
NCT01212900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100214|Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression|The RIGHT Study: Risk Stratification With Image Guidance of HMG Coa Reductase Inhibitor Therapy||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|242|||Both|50 Years|99 Years|No|||March 2016|March 24, 2016|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01212900||115408|
NCT01212328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTRN 022342347-29072010248|A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia|Developing and Testing Integrated, Multi-factorial Cardiovascular Disease Risk Reduction Strategies in South Asia (CARRS Translation Trial)|CARRS|Public Health Foundation of India|Yes|Recruiting|October 2010|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1120|||Both|35 Years|N/A|No|||September 2011|September 2, 2011|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01212328||115452|
NCT01213160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2610C00002|Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients With Advanced Solid Malignancies||AstraZeneca|Yes|Completed|November 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|25 Years|N/A|No|||August 2013|August 1, 2013|September 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01213160||115388|
NCT01212588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011002977|Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)|Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse||Indiana University|Yes|Recruiting|September 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|64 Years|No|||February 2016|February 4, 2016|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212588||115432|
NCT01214811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxB Ag 01|Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing|Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing||Molnlycke Health Care AB|No|Completed|September 2010|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2011|February 28, 2013|October 4, 2010||No||No|January 22, 2013|https://clinicaltrials.gov/show/NCT01214811||115261|
NCT01215123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25100|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer|Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study||Hoffmann-La Roche||Completed|January 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|28|||Both|18 Years|N/A|No|Probability Sample|Breast cancer patients with first line treatment with Avastin|January 2016|January 25, 2016|September 27, 2010||No||No|January 25, 2016|https://clinicaltrials.gov/show/NCT01215123||115238|
NCT01214538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX10-07|Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children|Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children||NasVax Ltd|No|Recruiting|October 2010|July 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Plasma|Both|3 Months|3 Years|No|Probability Sample|100 subjects with acute otitis media infection will be enrolled. The expectation is for        ≥50 children with pneumococcal culture-positive MEF (Middle Ear Fluid) and ≥50 children        with culture-negative MEF to be enrolled|September 2011|September 26, 2011|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01214538||115282|
NCT01214824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-PMR-NAV-09005|Use of the FreeStyle Navigator Continuous Glucose Monitoring System to Enhance Education and Glycaemic Control|Use of the FreeStyle Navigator Continuous Glucose Monitoring System to Enhance Education and Glycaemic Control||Abbott Diabetes Care|No|Completed|November 2010|June 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|No|||June 2013|June 21, 2013|October 4, 2010||No||No|March 1, 2013|https://clinicaltrials.gov/show/NCT01214824||115260|After an enrolment review recruitment was ceased on 02 Sep 11 with only 32/50 enrolled subjects. The screening/recruitment phase had been 12 weeks but was significantly extended. Only 7/32 subjects had completed 6 month HbA1c when recruitment ceased.
NCT01215409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14328|Real Life Safety and Efficacy of Vardenafil|Vardenafil in Routine Treatment of Erectile Dysfunction||Bayer|No|Terminated|February 2008|November 2008|Actual|November 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|372|||Male|18 Years|N/A|No|Non-Probability Sample|Primary care clinics|May 2014|May 16, 2014|September 28, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01215409||115216|
NCT01215422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-01|Success of Pediatric Anesthesiologists in Learning to Use Videolaryngoscopes|Anesthesiologists Learning to Use Videolaryngoscopes in Children||University of Alberta|No|Completed|January 2007|July 2011|Actual|July 2011|Actual|Phase 3|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|646|||Both|N/A|17 Years|No|Non-Probability Sample|Children being intubated for surgery|October 2012|October 5, 2012|October 4, 2010||No||No|February 3, 2012|https://clinicaltrials.gov/show/NCT01215422||115215|Level of success could only be determined for the 8 anesthesiologists who completed minimum 18 intubations with the GS or KS video laryngoscope. Only 6 of 14 completed the whole study so had data could be used in comparing the two scopes.
NCT01215734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 1057|Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients|Randomized Double-Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Stem Cell Hematopoetic Transplant Recipients||Vanderbilt-Ingram Cancer Center|Yes|Completed|October 2010|September 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|October 5, 2010|Yes|Yes||No|February 4, 2013|https://clinicaltrials.gov/show/NCT01215734||115191|
NCT01222663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-67-PMX|Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock|Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock|ABDO-MIX|Meditor SAS|Yes|Completed|October 2010|December 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01222663||114660|
NCT01223261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0027|Observational Study of Surgical Treatment of Necrotizing Enterocolotis|Observational Study of Surgical Treatment of Necrotizing Enterocolotis or Isolated Intestinal Perforation|NEC Surgery|NICHD Neonatal Research Network|No|Completed|March 2001|March 2004|Actual|September 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|156|||Both|N/A|6 Weeks|No|Probability Sample|Extremely Low Birth Weight (ELBW) infants (those with birth weights <1000 g) born at        participating NRN Centers diagnosed by a pediatric surgeon and neonatologist as having        either necrotizing enterocolitis (NEC) or intestinal perforation (IP) requiring surgical        intervention.|June 2015|June 3, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01223261||114614|
NCT01223001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHI 05-096|Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury|Prevention of Depression and Enhancement of Cognitive Recovery Following Traumatic Brain Injury With Duloxetine|Duloxetine|Rehabilitation Hospital of Indiana|Yes|Terminated|September 1996|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|75 Years|No|||November 2014|December 15, 2014|October 15, 2010||No|Most potential subjects had already been prescribed Cymbalta.|No|November 6, 2014|https://clinicaltrials.gov/show/NCT01223001||114634|All subjects excluded (n=6) had already been prescribed Duloxetine. Completion of the study by the remaining 4 per group was not achieved due to noncompliance.
NCT01223274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0028|Delivery Room CPAP in Extremely Low Birth Weight Infants|Delivery Room Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) in Extremely Low Birth Weight (ELBW) Infants|DR-CPAP|NICHD Neonatal Research Network|Yes|Completed|July 2002|January 2003|Actual|January 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|N/A|10 Minutes|No|||June 2015|June 3, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01223274||114613|
NCT01224457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0029|Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.|Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.||Yonsei University|No|Completed|May 2008|May 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Both|N/A|1 Year|No|||January 2012|January 26, 2012|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224457||114526|
NCT01224470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0405|The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate|The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate||Yonsei University|No|Completed|November 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|51|||Male|20 Years|N/A|No|||April 2011|April 27, 2011|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224470||114525|
NCT01221103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT5909|Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)|Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly||Southern Europe New Drug Organization||Recruiting|April 2010|June 2012|Anticipated|April 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|60 Years|N/A|No|||September 2011|September 12, 2011|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221103||114780|
NCT01221116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSI-study|Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery|Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery||Ullevaal University Hospital|No|Terminated|January 2003|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|85 Years|No|||January 2003|November 1, 2010|October 13, 2010||No|The study was stopped due to difficulties in including patients|No||https://clinicaltrials.gov/show/NCT01221116||114779|
NCT01221350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UdeG-FSL-2010|Effects of Lipoic Acid on Oxidative, Inflammatory and Functional Markers in Asthmatic Patients|Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.||Centro Universitario de Ciencias de la Salud, Mexico|No|Completed|November 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|55|||Both|18 Years|75 Years|No|||October 2013|October 16, 2013|October 14, 2010||No||No|April 23, 2013|https://clinicaltrials.gov/show/NCT01221350||114761|
NCT01221363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00289237|Reduction of Sitting Time: Sedentarism Intervention Trial|Reduction of Sitting Time - a Randomized Controlled Intervention Study|SIT|Glostrup University Hospital, Copenhagen|No|Completed|November 2010|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|171|||Both|18 Years|69 Years|No|||January 2015|January 19, 2015|October 14, 2010||No||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01221363||114760|
NCT01221376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571ABR23T|Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)|Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)||Hospital Santa Marcelina|No|Active, not recruiting|February 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|18 Years|No|||March 2013|March 25, 2013|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221376||114759|
NCT01221649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHC2|Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan (J-HomeCARE II)|Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan||Biotronik Japan, Inc.|No|Completed|June 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|198|||Both|18 Years|N/A|No|||February 2012|October 8, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01221649||114738|
NCT01213420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/567|Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Site After Wound Closure|A Prospective, Randomized Controlled, Double Blinded, Clinical Multicentre Trial of the Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure||University Hospital, Ghent|No|Completed|January 2010|September 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|N/A|N/A|No|||June 2012|June 13, 2012|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213420||115368|
NCT01213654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VATS-IC-2010|Inter Costal Catheters for Video-Assisted Thoroscopic (VATS) Lobectomy|Pain Relief After VATS Lobectomy Using Interoperatively Placed Inter Costal Catheters.||Rigshospitalet, Denmark|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Consenting lung cancer patients due for elective surgery|October 2010|October 1, 2010|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213654||115350|
NCT01213407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBM-Vax|Dendritic Cell Cancer Vaccine for High-grade Glioma|First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells|GBM-Vax|Trimed Biotech GmbH|No|Recruiting|March 2010|December 2012|Anticipated|March 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|3 Years|70 Years|No|||October 2010|October 1, 2010|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01213407||115369|
NCT01213667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPONSE2010|Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD|Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations|RESPONSE|University of Cologne|No|Active, not recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|60 Years|N/A|No|||May 2015|May 28, 2015|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213667||115349|
NCT01213628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Buk1|Local CO2 Increases Core and Wound Temperature|Intraoperative Local Insufflation of Humidified Warmed CO2 Increases Core and Open Wound Temperatures? - A Randomized Clinical Trial||Karolinska University Hospital|No|Completed|March 2007|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||October 2010|October 1, 2010|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213628||115352|
NCT01213641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2401|Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients|An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients|B-Confident|Novartis||Recruiting|November 2009|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with CAPS and treated with canakinumab. Patients treated with        canakinumab for other autoinflammatory diseases may be included where allowed per local        regulations.|March 2015|March 5, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213641||115351|
NCT01214837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_36|Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life|A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life.||Novartis||Completed|October 2010|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|751|||Both|55 Days|89 Days|Accepts Healthy Volunteers|||September 2014|September 30, 2014|September 27, 2010|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT01214837||115259|
NCT01214850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_29|Novartis Vaccine and Diagnostics Carriage Trial|A Phase 3 Observer Blind Randomized, Multi-center, Controlled Study to Evaluate the Effect of Novartis Vaccine's Meningococcal B Recombinant and MenACWY Conjugate Vaccines on Pharyngeal Carriage of N. Meningitidis in Young Adults||Novartis||Completed|September 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2968|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|September 30, 2010|Yes|Yes||No|September 4, 2013|https://clinicaltrials.gov/show/NCT01214850||115258|
NCT01214863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-007|AcrySof Toric Clinical Results|Clinical Results With the AcrySof Toric Intraocular Lens (IOL)||Alcon Research|No|Completed|August 2007|||April 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|144|||Both|18 Years|N/A|No|Non-Probability Sample|Study population chosen from physician's patients implanted with the AcrySof Toric        intraocular lens (IOL)|October 2010|September 27, 2012|August 7, 2008||No||No||https://clinicaltrials.gov/show/NCT01214863||115257|
NCT01215162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1681-02|Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer|Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer||Mayo Clinic|Yes|Completed|January 2003|January 2013|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|N/A|No|||April 2014|April 2, 2014|August 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01215162||115235|
NCT01215149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI B003/ IPCAVD-004|Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults|A Phase 1 Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Safety and Immunogenicity of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adult Volunteers||International AIDS Vaccine Initiative|Yes|Completed|October 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|12||Actual|218|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|October 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215149||115236|
NCT01215435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3858|Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone|An Open Labelled, Randomised, Parallel Trial; Efficacy and Safety Comparison of Two Different Biphasic Insulin Aspart 30 Treatment Initiation Regimens Followed by Intensification in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs Alone in Iran||Novo Nordisk A/S|No|Completed|March 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|October 1, 2010|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01215435||115214|
NCT01215747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-503012|Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis|International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis||C.T. Development America, Inc.|Yes|Completed|November 2010|March 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|261|||Both|18 Years|80 Years|No|||March 2016|March 9, 2016|October 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215747||115190|
NCT01223638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0128-08-EMC|The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism|||HaEmek Medical Center, Israel||Withdrawn|September 2010|June 2015|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|2 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients aged 2-30 years with congenital hypothyroidism which are being followed at the        Pediatric Endocrine Department at Ha'Emek Medical Center.|July 2015|July 6, 2015|October 3, 2010|Yes|Yes|written here by mistake|No||https://clinicaltrials.gov/show/NCT01223638||114588|
NCT01223014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2600C00008|Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers|An Open Label, Single Dose, Phase I Study to Evaluate the Excretion of Radioactivity, the Metabolic Profile, Pharmacokinetics, Safety and Tolerability Following Single Oral Administration of [14C]AZD2423 to Healthy Male Volunteers|ADME|AstraZeneca|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|6|Samples With DNA|Pharmacogenetic samples|Male|50 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic/community sample|February 2011|February 6, 2011|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223014||114633|
NCT01224444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS-21237|Complete Histologic Resection of Adenomatous Polyps?|Complete Histologic Resection of Adenomatous Polyps? (Complete Adenoma REsection Trial - CARE Trial)|CARE|White River Junction VAMC|Yes|Completed|May 2008|January 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|269|Samples Without DNA|Biopsies will be taken from resection margins: 2 biopsies will be obtained from opposite      margins for polyps 5-9mm, and 4 biopsies will be taken for polyps 10-20mm from all four      quadrants of the resection margins.|Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants eligible for recruitment are patients who present for a colonoscopy to the        VAMC or DHMC Gastroenterology department conducting this study. Upon arrival for a        scheduled colonoscopy patient records will be reviewed to determine eligibility.|December 2014|December 30, 2014|October 19, 2010||No||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01224444||114527|
NCT01224210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ambrisentan Portopulm Study|Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial|Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial|Portopulm|Tufts Medical Center|Yes|Recruiting|March 2010|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224210||114545|
NCT01224483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02-048|Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients|Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Patients With PNH||Samsung Medical Center|No|Recruiting|August 2010|December 2010|Anticipated|November 2010|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|350|||Both|1 Year|N/A|No|Probability Sample|Korean PNH patients: diagnosis confirmed by Ham's test or Flow cytometry|October 2010|October 19, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224483||114524|
NCT01224743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Griffin Hospital IRB #2004-22|Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome|Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome: A Randomized, Controlled, Crossover Trial||Griffin Hospital|No|Completed|December 2004|March 2008|Actual|March 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|64|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 19, 2010|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01224743||114504|
NCT01224717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTH134A2102|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women|A Phase I, Partially Blinded, Randomized, Placebo Controlled, Active Comparator Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Post-menopausal Women After Daily Oral Doses of PTH134||Novartis||Completed|September 2010|||April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Female|45 Years|80 Years|No|||May 2011|May 12, 2011|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224717||114506|
NCT01224730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 147|A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies|A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies||AEterna Zentaris|Yes|Active, not recruiting|January 2012|May 2012|Anticipated|May 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224730||114505|
NCT01220570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-050|The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)|A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer||Merck Sharp & Dohme Corp.|No|Completed|September 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Female|18 Years|N/A|No|||January 2015|January 19, 2015|October 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01220570||114821|
NCT01220830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100915_CIP_MS_V1.0|Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis|Efficacy of Rotational Field Quantum Nuclear Magnetic Resonance (RFQMR) Based Tissue Engineering in the Treatment of Multiple Sclerosis|RFQMR|The Centre for Advanced Research & Development, India|Yes|Active, not recruiting|September 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|60 Years|No|||September 2011|September 16, 2011|October 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01220830||114801|
NCT01220843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amiens FRENCH|FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease|Randomized Placebo Controlled Double-blind Trial in CKD Patients Not on Dialysis to Evaluate the Effect of Sevelamer Carbonate in the Control of FGF-23 Serum Levels and Its Consequences in the Evolution of PTH, Calcitriol and Mineral Metabolism Parameters Levels|FRENCH|Centre Hospitalier Universitaire, Amiens|Yes|Completed|October 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||February 2012|September 2, 2013|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220843||114800|
NCT01213693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTEICSBV01|Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD|Long-term Effects of Inhaled Corticosteroids (ICS) Treatment on Sputum Bacterial and Viral Loads in Chronic Obstructive Pulmonary Disease (COPD) Patients||Università degli Studi di Ferrara|No|Completed|May 2009|November 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|50 Years|80 Years|No|||December 2013|December 27, 2013|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213693||115347|
NCT01213680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-PK-IBD-02|Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease|Open-label Pharmakokinetic Study of Iron Isomaltoside 1000 (Monofer)Administered by 500 mg IV Injection or 1000 mg Intravenous Infusion to Patients With Inflammatory Bowel Disease (PK-IBD-02)||Pharmacosmos A/S|No|Completed|February 2012|November 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213680||115348|
NCT01213940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-131|Vascular Endothelium Changes After Bariatric Surgery (Endothelial Progenitor Cells)|Vascular Endothelium Changes After Bariatric Surgery|EPC|University of South Alabama|No|Recruiting|September 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213940||115328|
NCT01213953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98025|Isolation and Authentication of Mesenchymal Stem Cell-like Progenitor Cells From the Degenerated Intervertebral Disc of Lumbar Spine|Isolation and Authentication of Mesenchymal Stem Cell-like Progenitor Cells From the Degenerated Intervertebral Disc of Lumbar Spine||Taipei Medical University WanFang Hospital|No|Active, not recruiting|September 2010|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|The biospecimen is the tissue waste after the surgery of discectomy.|Both|20 Years|N/A|No|Probability Sample|The patients received the surgery of discectomy for the degenerative disc.|October 2010|October 18, 2010|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213953||115327|
NCT01214525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10144-2010CTIL|The Improvement in Uroflow and Postvoid Residual Urine After Urethral Meatotomy in Children With Meatal Stenosis|The Improvement in Uroflow and Postvoid Residual Urine After Urethral Meatotomy in Children With Meatal Stenosis||Meir Medical Center|No|Recruiting|October 2010|June 2012|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Male|2 Years|12 Years|No|Non-Probability Sample|Toilet trained children, before puberty, scheduled for urethral meatotomy for the        treatment of urethral meatal stenosis.|March 2012|March 16, 2012|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01214525||115283|
NCT01214226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-006944-78|Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis|Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis|CorpentoxHAA|University Hospital, Lille|No|Completed|December 2007|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|70 Years|No|||September 2010|May 31, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214226||115306|
NCT01214239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.66|Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control|A Randomized, db, Placebo Controlled Parallel Group Efficacy and Safety Study Over 24 Weeks in T2D Patients in China||Boehringer Ingelheim||Completed|October 2010|||May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|80 Years|No|||May 2013|December 5, 2013|September 28, 2010||||No|May 24, 2013|https://clinicaltrials.gov/show/NCT01214239||115305|
NCT01214252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVPERH0046|A Retrospective Study Evaluating the Use of Permacol Surgical Implant in the Repair of Abdominal Wall Defects|||Medtronic - MITG|No|Completed|October 2010|January 2012|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|343|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone surgical repair of their abdominal wall defects with Permacol        Surgical Implants with at least 12 months(-30days)follow-up|April 2014|April 8, 2014|September 30, 2010||No||No|June 21, 2012|https://clinicaltrials.gov/show/NCT01214252||115304|
NCT01214265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMK0708C|A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive Bladder|A Pilot Clinical Study to Evaluate the Initial Feasibility of Neuromodulation Therapy in Treating Patients With Overactive Bladder Via Magnetic Stimulation of the Posterior Tibial Nerve||EMKinetics, Inc|No|Completed|October 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||October 2010|October 22, 2010|October 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214265||115303|
NCT01222728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100193|Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients|Using Positron Emission Tomography (PET) to Predict Intracranial Tumor Growth in Neurofibromatosis Type II (NF2) Patients||National Institutes of Health Clinical Center (CC)||Completed|September 2010|June 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|5|||Both|18 Years|50 Years|No|||June 2015|June 4, 2015|October 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01222728||114655|
NCT01222741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100216|Studies of Disorders With Increased Susceptibility to Fungal Infections|Studies of Disorders With Increased Susceptibility to Fungal Infections||National Institutes of Health Clinical Center (CC)||Recruiting|September 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|850|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|March 3, 2016|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222741||114654|
NCT01222754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100219|Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas|A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2010|January 2017|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|1 Year|21 Years|No|||December 2015|February 12, 2016|October 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01222754||114653|
NCT01223118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2010-02|Evaluation of the Impact of Vitrification on Oocytes|Evaluation of the Impact of Vitrification on the Reproductive Performance and Potential of Human Oocytes||Reproductive Medicine Associates of New Jersey|No|Completed|August 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01223118||114625|
NCT01223352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-373|Pulmonary Arterial Hypertension in Children|An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension|FUTURE 3|Actelion||Completed|January 2011|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|3 Months|12 Years|No|||August 2014|August 22, 2014|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223352||114607|
NCT01215448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-10-0054-CTIL|Wheatgrass Juice / Lifestyle Recommendations / Cancer Patients' Quality of Life / Chemotherapy Treatment|Impact of Wheatgrass Juice and Lifestyle Recommendations on Cancer Patients' Quality of Life During Chemotherapy Treatment|4001|Carmel Medical Center|Yes|Completed|October 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|17|||Both|18 Years|95 Years|No|||June 2014|June 16, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01215448||115213|
NCT01215461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-001-10|Factors Associated With Mortality in Neonates|Evaluation of Factors Associated With Mortality in Neonates||Mednax Center for Research, Education and Quality|No|Completed|September 2010|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|645|||Both|22 Weeks|44 Weeks|No|Non-Probability Sample|Neonates for whom healthcare was provided.|May 2013|May 13, 2013|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215461||115212|
NCT01215760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFonseca|Sensory Reeducation in Peripheral Nerve Injuries of Hand|Proposal of Sensory Reeducation in Peripheral Nerve Injuries of Median and Ulnar Nerves of the Hand: RANDOMIZED CONTROLLED CLINICAL STUDY|HandtherRCT|University of Sao Paulo|Yes|Completed|March 2009|December 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01215760||115189|
NCT01223651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0505/73|Performance of Continuous Glucose Monitoring Systems at Altitude|Performance of Continuous Glucose Monitoring Systems at Altitude.||The Royal Bournemouth Hospital|No|Terminated|January 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 18, 2010||No|Suspended awaiting Ministry of Defence ethics approval.|No||https://clinicaltrials.gov/show/NCT01223651||114587|
NCT01223664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYS-1012|Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis|The Efficacy of Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis Resulting From Chronic Hepatitis B||Sun Yat-sen University|Yes|Active, not recruiting|October 2010|November 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|65 Years|No|||October 2010|October 18, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01223664||114586|
NCT01223898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2128|To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib|An Open-label, Two-period, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics of Midazolam in CML Patients Who Are Resistant and/or Intolerant Against at Least One Prior Therapy With a BCR-ABL Tyrosine Kinase Inhibitor||Novartis||Completed|June 2010|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|19|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223898||114569|
NCT01223950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067-10-HYMC|Monitoring the Prevalence of E.R Admissions and Hospitalizations as a Result of Drug Related Problems (DRPs)|||Hillel Yaffe Medical Center|No|Completed|August 2010|||September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12350|||Both|18 Years|N/A|No|Non-Probability Sample|18 years of age and above) admitted to the E.R and subsequently to hospital wards of the        Hillel Yaffe medical center, Hadera, Israel.|October 2010|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223950||114565|
NCT01224236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT of Iron Supplementation|Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants|Randomized Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight (VLBW) Infants||The University of Texas Health Science Center, Houston|No|Completed|July 2010|February 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|N/A|8 Weeks|No|||June 2015|June 17, 2015|October 14, 2010||No||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01224236||114543|
NCT01224223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYELOID|Myeloid Suppressors in Inflammation|Myeloid Suppressors in Inflammation||University of South Florida|No|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|20|||Both|18 Years|60 Years|No|Probability Sample|Ages eligible for study: 18 to 60 years Genders eligible for study: male and female Signed        and dated written informed consent is obtained prior to study blood draw.        Subjects being actively treated for chronic moderate to severe asthma based on National        Heart Lung and Blood Institute guidelines (figure 1). Subjects must carry the diagnosis of        asthma (made by a physician) for a minimum of six months.        Subjects within the first seven days of an acute asthma exacerbation, as determined by the        referring physician.Able to give informed consent.|October 2010|June 27, 2012|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224223||114544|
NCT01224756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TI-NF-1001|Efficacy of Tinoridine in Treating Pain and Inflammation in Adults|Safety and Efficacy of Tinoridine in the Treatment of Pain and Inflammation in Patients With Acute Tonsillitis and/or Acute Pharyngitis: a Randomized, Double-blind Study Versus Placebo||Takeda|Yes|Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|342|||Both|18 Years|60 Years|No|||January 2012|January 11, 2012|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224756||114503|
NCT01224769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETRO-BENDA|Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders|A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders||Gruppo Italiano Studio Linfomi|No|Completed|September 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|109|||Both|18 Years|N/A|No|Probability Sample|All patients with relapsed or refractory chronic lymphoproliferative disorders treated        with bendamustine +/- rituximab|October 2010|October 20, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01224769||114502|
NCT01220583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1008|Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery|A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors||Radiation Therapy Oncology Group|Yes|Recruiting|January 2011|||October 2023|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220583||114820|
NCT01220596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25206|Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.|A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.|POTENT|Hanyang University|Yes|Recruiting|June 2010|June 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|N/A|No|||June 2011|July 1, 2011|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01220596||114819|
NCT01220856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REP0110|Reparixin in Pancreatic Islet Transplantation|A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus||Dompé Farmaceutici S.p.A|No|Completed|July 2010|June 2014|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||June 2014|June 27, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01220856||114799|
NCT01221142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HfICHiC|Pilot Study of Hypothermia for Intracerebral Hemorrhage in Croatia|||University of Rijeka|Yes|Not yet recruiting|January 2011|June 2012||September 2011||Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||20|||Both|18 Years|80 Years|No|||October 2010|December 27, 2010|October 13, 2010||||No||https://clinicaltrials.gov/show/NCT01221142||114777|
NCT01221402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-029|Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis|Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial|ALPINE-SVG|North Texas Veterans Healthcare System|Yes|Active, not recruiting|October 2010|||October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221402||114757|
NCT01213446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-BIO-08-52|Study of Biostate® in Children With Von Willebrand Disease|A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects With Von Willebrand Disease||CSL Behring|Yes|Completed|August 2010|August 2013|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|12 Years|No|||November 2013|November 12, 2013|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213446||115366|
NCT01213719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|betaine supplementation|Effects of Betaine Supplementation on Strength and Muscle Creatine Content|Effects of Betaine Supplementation Combined or Not With Creatine Supplementation on Muscle Creatine Content and Strength||University of Sao Paulo|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|40|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213719||115345|
NCT01213966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_10_002|Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection|Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection||Medicines for Malaria Venture|Yes|Completed|October 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|60 Years|No|||November 2014|November 17, 2014|October 1, 2010||No||No|July 22, 2013|https://clinicaltrials.gov/show/NCT01213966||115326|
NCT01213979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-PK-CIA-04|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)(PK-CIA-04)|PK-CIA-04|Pharmacosmos A/S|No|Completed|February 2012|July 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213979||115325|
NCT01214005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA026829|Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls|Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls|WREN|Brown University|No|Completed|June 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 26, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214005||115323|
NCT01214551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1551-4|Exercise-induced Bronchoconstriction Diagnostics: Impact of a Repeated Exercise Challenge Test|Exercise-induced Bronchoconstriction Diagnostics: Impact of a Repeated Exercise Challenge Test||Norwegian University of Science and Technology|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|16 Years|45 Years|No|Non-Probability Sample|Subjects referred to Klinikk for allergi og luftveissykdommer|November 2011|November 15, 2011|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01214551||115281|
NCT01223131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11681|Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.|A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus® (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Mellitus Aged at Least 6 Years to Less Than 18 Years|Lantus-P-CN|Sanofi|No|Completed|February 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|6 Years|17 Years|No|||March 2014|March 31, 2014|October 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223131||114624|
NCT01223391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005203|Abdominal Compression in Orthostatic Hypotension|The Efficacy of Adjustable Lower Abdominal Compression in Neurogenic Orthostatic Hypotension||Mayo Clinic|No|Completed|October 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||May 2014|May 9, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01223391||114604|
NCT01223365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/3080|Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time|A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time||Teva Pharmaceutical Industries||Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|294|||Both|18 Years|80 Years|No|||May 2013|May 2, 2013|October 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223365||114606|
NCT01223378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|659|Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension||Bausch & Lomb Incorporated|No|Completed|December 2010|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|355|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|October 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223378||114605|
NCT01223703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-PUFA-02|PUFAs and Left Ventricular Function in Heart Failure|Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy|CS-PUFA-02|Università degli Studi di Brescia|Yes|Completed|November 2007|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|75 Years|No|||January 2012|January 27, 2012|October 18, 2010|Yes|Yes||No|April 11, 2011|https://clinicaltrials.gov/show/NCT01223703||114583|Our investigation was a single-center trial with a small sample size and a limited number of clinical events. Therefore, our results cannot be generalized to HF patients.
NCT01223313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN008|A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom|A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom||Health Decisions|Yes|Completed|January 2011|September 2015|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|500|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 19, 2016|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223313||114610|
NCT01223911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8209-3607|A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|January 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|75 Years|No|||January 2015|January 22, 2015|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223911||114568|
NCT01223924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-2008-1|Single-dose Escalation Trial of M2ES in Healthy Volunteer|Randomized ，Placebo-controlled,Single-dose Escalation Trial of M2ES in Healthy Volunteer||Protgen Ltd|Yes|Completed|May 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 18, 2010|October 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01223924||114567|
NCT01189890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-251|Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)|A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|August 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|480|||Both|65 Years|85 Years|No|||June 2015|June 30, 2015|August 25, 2010|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT01189890||117161|
NCT01224496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHF/TCM002/2008|Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders|Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders||Singapore General Hospital|Yes|Completed|July 2009|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|38|||Both|13 Years|85 Years|No|||May 2012|May 14, 2012|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01224496||114523|
NCT01190462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUT-LUMC-838|Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer|Safety and Efficacy of the Addition of Simvastatin to Cetuximab in K-ras Mutant Advanced or Metastatic Colorectal Cancer Patients. A Single-Arm, Multicenter, Phase II Study Using a Simon Two Stage Design.||National Cancer Institute (NCI)||Recruiting|August 2010|||August 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||April 2011|August 9, 2013|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190462||117117|
NCT01220609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02656|Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy|A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2010|||July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||January 2015|September 30, 2015|October 12, 2010|Yes|Yes||No|September 30, 2015|https://clinicaltrials.gov/show/NCT01220609||114818|
NCT01220869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS43|A Study of Degarelix in Taiwanese Patients With Prostate Cancer|An Open-label, Multi-centre Registration Trial, Investigating Efficacy and Safety of Degarelix One-month Dosing Regimen in Taiwanese Patients With Prostate Cancer Requiring Androgen Ablation Therapy||Ferring Pharmaceuticals|Yes|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Male|20 Years|N/A|No|||December 2013|December 6, 2013|October 13, 2010|No|Yes||No|October 14, 2013|https://clinicaltrials.gov/show/NCT01220869||114798|
NCT01221428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCKJ004|Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis||Qingdao University|Yes|Active, not recruiting|September 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||July 2010|October 14, 2010|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221428||114755|
NCT01213732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19TNFαILP-01-08|Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma|Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma.||Philogen S.p.A.|No|Completed|October 2008|September 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213732||115344|
NCT01214018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2009/CB-04|Evaluation of Post-traumatic Stress Among the Nearest Relatives of Brain-dead Organ Donors|Evaluation of Post-traumatic Stress Among the Nearest Relatives of Brain-dead Organ Donors: Comparison With the Nearest-relatives of Brain-dead Patients Who Were Not Organ Donors for Medical or Legal Reasons, or Because of Donation Opposition||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|May 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|273|||Both|16 Years|N/A|No|Non-Probability Sample|Study participants are the nearest relatives of brain-dead patients|October 2015|November 4, 2015|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214018||115322|
NCT01213706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090748|Effect of Whole Body Periodic Acceleration on Airway Endothelial Function|Effect of Whole Body Periodic Acceleration on Airway Endothelial Function in Healthy Smokers, Non-smokers and Asmathics||University of Miami|No|Completed|October 2009|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|October 1, 2010|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01213706||115346|
NCT01213992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-PK-CKD-03|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-Dialysis Dependent Chronic Kidney Disease (PK-CKD-03)|PK-CKD-03|Pharmacosmos A/S|No|Completed|March 2012|November 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213992||115324|
NCT01222468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1976|Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons|A Randomized Double-Blinded Crossover Trial Assessing the Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons||University of Manitoba|No|Completed|June 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||February 2015|February 24, 2015|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01222468||114675|
NCT01222767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM104-B-003-10|Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy|Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy||PharmaMar|No|Completed|December 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|16 Years|N/A|No|||June 2012|June 4, 2012|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222767||114652|
NCT01224041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGRA-09-02-KOR|Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate|Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study||Astellas Pharma Inc|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|October 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01224041||114558|
NCT01224275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/553|Group Based Care Versus Individual Care|Group Based Care Versus Individual Care- Effects on Parents Satisfaction and Health||Karolinska Institutet|No|Recruiting|August 2008|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1150|||Both|N/A|N/A|No|||September 2008|June 24, 2011|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224275||114540|
NCT01224535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amaranth|Improving Iron Status of Children: Potential of Amaranth|Improving Iron Status of Children in a Semi-arid Area of Kenya: the Potential of Amaranth Grain Flour||Wageningen University|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|270|||Both|12 Months|59 Months|Accepts Healthy Volunteers|||October 2010|September 28, 2011|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224535||114520|
NCT01223716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS#2003-11-83|An Active Approach to Treat Amblyopia: Video Game Play|Does Video Game Play Induce Plasticity in the Visual System of Adults With Amblyopia?||University of California, Berkeley|No|Completed|December 2004|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Both|5 Years|75 Years|Accepts Healthy Volunteers|||May 2008|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223716||114582|
NCT01224015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-104|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines|||Allergan|No|Completed|May 2011|February 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|684|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|October 18, 2010|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01224015||114560|
NCT01224028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGNS-10-01-KOR|A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients|Double-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA Nephropathy||Astellas Pharma Inc|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||August 2014|August 20, 2014|October 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01224028||114559|
NCT01223690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A06-269|Clarithromycin as Immunomodulator for the Management of Sepsis|A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis||University of Athens|Yes|Completed|July 2007|April 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|N/A|No|||October 2010|August 3, 2011|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01223690||114584|
NCT01223677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-50105-96-635|Rumination-focused CBT Training for the Prevention of Depression and Anxiety|Randomized Controlled Trial Evaluating Two Versions of a Rumination-focused CBT Training for the Presence of Depression and Anxiety in Adolescents and Young Adults||VU University of Amsterdam|Yes|Completed|October 2010|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|251|||Both|15 Years|22 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01223677||114585|
NCT01223937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS40|Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablet for the Treatment of Nocturia in Adult Females|COMFORT|Ferring Pharmaceuticals|No|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|268|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|October 18, 2010|Yes|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01223937||114566|
NCT01189591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0150|Slow-wave Sleep Deprivation in Depression|Slow-wave Sleep Deprivation as a Possible Treatment for Major Depressive Disorder||University of Wisconsin, Madison|No|Completed|June 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|35 Years|No|||May 2014|May 20, 2014|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189591||117184|
NCT01189604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0092C00001|Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests|A Multi-centre, Single-blind, Randomised, Parallel Group, Phase IIb Dose Rate Range Finding Study to Find Maintenance Dose Rate Range of ICI35,868 for the Minimal-to-moderate Sedation on Gastrointestinal Endoscopic Tests (Including Endoscopic Polypectomy)||AstraZeneca|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|123|||Both|20 Years|N/A|No|||December 2011|December 15, 2011|August 25, 2010|Yes|Yes||No|November 9, 2011|https://clinicaltrials.gov/show/NCT01189604||117183|
NCT01189903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR01/18/10|Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients|Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients||National University Hospital, Singapore||Active, not recruiting|January 2011|||August 2013|Actual|Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|||||||Both|21 Years|N/A|No|||January 2014|January 26, 2014|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189903||117160|
NCT01190163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999901 CS01|Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction|Phase IV, Multicenter, Open Label, Randomized Trial to Compare the Effectiveness and Safety of the Dinoprostone Vaginal Pessary vs. Oxytocin for Women Requiring Cervical Ripening Prior to Induction of Labor|SOFTNES|Ferring Pharmaceuticals|No|Terminated|June 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Female|18 Years|N/A|No|||August 2012|August 22, 2012|August 26, 2010||No|Study was early terminated due to problems enrolling adequate number of patients|No||https://clinicaltrials.gov/show/NCT01190163||117140|
NCT01190475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGS649A2105|BGS649 Monotherapy in Moderate to Severe Endometriosis Patients|A Randomized, Double-blind, Double-dummy, Placebo-controlled Study of Oral BGS649 Monotherapy Assessing Safety and Tolerability in Patients With Moderate to Severe Endometriosis||Novartis||Completed|July 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Female|18 Years|40 Years|No|||September 2012|September 10, 2012|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190475||117116|
NCT01190488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0819|Feasibility Of An Advanced Care Decision Aid Among Patients And Physicians_Matlock|Feasibility Of An Advanced Care Decision Aid Among Patients And Physicians||University of Colorado, Denver|No|Completed|November 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190488||117115|
NCT01190800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 08009|Capacity Assessment in Persons With Alzheimer's Disease|Decision Capacity Assessment in Persons With Alzheimer's Disease: Approach by Capacity to Appoint a Proxy, to Consent to Treatment and to Vote|MACAP|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|400|None Retained|None Retained|Both|18 Years|N/A|No|Non-Probability Sample|persons with Alzheimer's disease|June 2014|October 13, 2014|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190800||117091|
NCT01191125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK94|Evaluation of an Oral Nutritional Supplement Containing AN777|Evaluation of an Oral Nutritional Supplement Containing AN777 in Malnourished and Frail Subjects||Abbott Nutrition|Yes|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Both|65 Years|90 Years|No|||March 2013|March 5, 2013|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191125||117068|
NCT01191138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-GIS-20090|Gastric Emptying After Infracolic or Supracolic Gastrojejunostomy Following Pancreaticoduodenectomy|Randomized Control Trial Comparing Gastric Emptying Following Infracolic vs Supracolic Gastrojejunostomy After Whipples Pancreaticoduodenectomy||Asian Institute of Gastroenterology, India|Yes|Completed|January 2009|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|N/A|No|||June 2012|June 19, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01191138||117067|
NCT01221987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110430|Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer|A Cross-sectional, Hospital-based, Epidemiological Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) and/or Cervical Intraepithelial Neoplasia (CIN) II and/or CIN III in Sri Lanka||GlaxoSmithKline||Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|40|Samples With DNA|Tissue samples of invasive cervical cancer|Female|21 Years|N/A|No|Non-Probability Sample|Females > 21 years of age, diagnosed with invasive cervical cancer or cervical        intraepithelial neoplasia - moderate or severe|May 2011|April 26, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221987||114712|
NCT01214031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR0005|Prospective Study for Evaluating Colon Polyp Histology With in Vivo Probe Based Confocal Laser Endomicroscopy|Prospective Study for Evaluating Colon Polyp Histology With in Vivo Probe Based Confocal Laser Endomicroscopy||Midwest Biomedical Research Foundation|No|Not yet recruiting|September 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|70|||Both|18 Years|85 Years|No|||April 2012|April 6, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214031||115321|
NCT01223404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042696|Nicotinic Modulation of the Default Network|Nicotinic Modulation of the Default Network of Resting Brain Function||University of Maryland|Yes|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01223404||114603|
NCT01214278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWLUH-002|Bioavailability of Different n-3 Fatty Acid Formulations|Relative Bioavailability of Different n-3 Fatty Acid Formulations in Humans||Gottfried Wilhelm Leibniz Universität Hannover|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 6, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01214278||115302|
NCT01214291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G300213|Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer|Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy|TREAT2|GTx|Yes|Withdrawn|March 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|0|||Male|50 Years|80 Years|No|||November 2013|November 13, 2013|October 1, 2010|Yes|Yes|cost of conducting the study and increased burden on the clinical trial professionals make it    impossible for us to proceed with the development of the drug.|No||https://clinicaltrials.gov/show/NCT01214291||115301|
NCT01214304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20100154H|Aromatherapy to Reduce Pain and Anxiety During Cervical Colposcopy|Aromatherapy With Lavender Oil to Reduce Pain and Anxiety During Cervical Colposcopy: A Randomized, Controlled Trial|Lavender Colpo|Mike O'Callaghan Federal Hospital|No|Completed|February 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|262|||Female|18 Years|N/A|No|||November 2013|November 21, 2013|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01214304||115300|
NCT01222780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100220|To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer|Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer||Spectrum Pharmaceuticals, Inc|Yes|Completed|September 2010|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|2 Years|20 Years|No|||May 2015|May 26, 2015|October 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01222780||114651|
NCT01224054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0009|Food and Gastrointestinal Habits After Bariatric Surgery|Food Tolerance in Patients Submitted to Bariatric Surgery||University of Campinas, Brazil|No|Completed|July 2008|August 2010|Actual|December 2009|Actual|N/A|Observational|N/A||3|Actual|34|||Both|24 Years|62 Years|No|Non-Probability Sample|It was studied 34 patients (15 males, 19 female), ranging from 24 to 62 years old, who        underwent bariatric surgery: gastric bypass (n=15), biliopancreatic diversion (n=9) or        metabolic surgery: duodenal exclusion (n=10) with more than six months of follow-up        postoperatively.|October 2010|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224054||114557|
NCT01224288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0845|Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble|Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Companion to Protocol 2010-0085||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2011|||January 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224288||114539|
NCT01224808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-BIO-09-64|Extension Study of Biostate in Subjects With Von Willebrand Disease|An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects With Von Willebrand Disease Who Completed Clinical Studies CSLCT-BIO-08-52 or CSLCTBIO-08-54||CSL Behring|Yes|Completed|October 2010|March 2014|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||April 2014|April 8, 2014|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01224808||114499|
NCT01220648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ADE10|Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)|An Open Label, Nonrandomized, Single-center, Phase I Trial of Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) With Nilotinib in Combination With Low Dose Interferon-alpha (IFN) - NICOLI Study -|NICOLI|Novartis||Completed|April 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01220648||114815|
NCT01224821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104731|Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies|Multicenter, Phase II Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies|RIT-II-001|GlaxoSmithKline||Completed|December 1995|January 2010|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||May 2012|May 24, 2012|October 19, 2010|Yes|Yes||No|March 22, 2012|https://clinicaltrials.gov/show/NCT01224821||114498|
NCT01189214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opioid MM-2009|Psychopharmacotherapy in Multiple Substances Abuse|Psychopharmacotherapy in Multiple Substances Abuse / Dependence - the Pharmacological and Immunological Approach to the New Indication of Memantine|MM opioid|National Cheng-Kung University Hospital|Yes|Completed|March 2009|June 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|65 Years|No|||August 2010|February 27, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01189214||117212|
NCT01223963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GB0902|Macrolane Retrospective Study|A Multi-center Retrospective Chart Review of Medical Records on the Use of Macrolane Volume Restoration Factor for Breast Enhancement||Q-Med AB|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|93|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women that have had breast enhancement in clinics in Sweden (and UK).|November 2012|November 22, 2012|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223963||114564|
NCT01223976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222-10|Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis|Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2010|August 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2010|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223976||114563|
NCT01189565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-19772|Continuous Postoperative Pulse Oximetry in Patients Presenting for Total Hip and Total Knee Replacement|Continuous Postoperative Pulse Oximetry in Patients Presenting for Total Hip and Total Knee Replacement||Medical University of South Carolina||Completed|March 2010|||March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Joint Replacement|August 2010|May 21, 2013|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189565||117186|
NCT01190501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07 326 03|Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism|Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism||University Hospital, Toulouse|Yes|Completed|June 2009|June 2015|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|96|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190501||117114|
NCT01190514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061035|Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)|Phase 1, Open-Label, Randomized, Single-Dose, 4-Treatment, 4-Period Crossover Bioequivalence Study Comparing 25 Mg and 50 Mg Formulations of DVS-233 SR and Investigate Food Effect on 50 Mg Formulations of DVS-233 SR Tablet Under Fed and Fasted Conditions||Pfizer|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 21, 2011|August 24, 2010||No||No|December 21, 2011|https://clinicaltrials.gov/show/NCT01190514||117113|
NCT01190176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113617|Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects|Gynaecological Follow-up of a Subset of HPV-015 Study Subjects||GlaxoSmithKline||Recruiting|September 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|111|||Female|28 Years|N/A|No|||October 2015|February 4, 2016|August 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190176||117139|
NCT01191190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100429|Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|CRC027|University of California, San Diego|Yes|Completed|August 2010|August 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 26, 2010|No|Yes||No|August 24, 2015|https://clinicaltrials.gov/show/NCT01191190||117063|
NCT01191476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-564|Compare Pharmaceutical Economics and Efficacy of Sevoflurane With Low Fresh Gas Flow Balanced Anesthesia, Propofol Target Controlled Infusion Anesthesia and Propofol Induction Sevoflurane Maintenance Anesthesia|A Prospective, Randomized, Open-label Multicenter Study Comparing the Pharmaceutical Economics and Effectiveness of Sevoflurane With Low Fresh Gas Flow Balanced Anesthesia, Propofol Target Controlled Infusion Anesthesia and Propofol Induction Sevoflurane Maintenance Anesthesia in Laparoscopic Surgeries in China||Abbott|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|336|||Both|18 Years|65 Years|No|||May 2012|May 31, 2012|August 27, 2010||No||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01191476||117042|
NCT01190774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Denanx0103|Anxiety Assessment Intervention in Dental Patients|An Investigation Into Patients' State Anxiety Reduction Following the Administration of a Dental Anxiety Questionnaire in the Dental Treatment Setting|ANXDEN|University of St Andrews|Yes|Completed|September 2003|September 2004|Actual|April 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Actual|182|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2003|August 27, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190774||117093|
NCT01190787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138MMY2069|Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone|A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients||Stichting Hemato-Oncologie voor Volwassenen Nederland|Yes|Active, not recruiting|July 2010|May 2016|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190787||117092|
NCT01191463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGUST_2|The Efficacy of a Local Vitamin-C Rich Fruit (Guava) in Improving Iron Absorption From Mungbean Based Meals and Its Effect on Iron Status of Rural Indian Children (6-10 Years)|The Efficacy of a Local Vitamin-C Rich Fruit (Guava) in Improving Iron Absorption From Mungbean Based Meals in Indian Children (6-10 Years)|MUGUST_2|Wageningen University|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|300|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||September 2010|September 28, 2011|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191463||117043|
NCT01191788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA014699-03|Building Recovery By Improving Goals, Habits, and Thoughts|Group Cognitive Behavioral Therapy (CBT) For Depression in Clients With Alcohol and Other Drug (AOD) Disorders|BRIGHT|RAND|Yes|Completed|August 2006|March 2010|Actual|July 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|299|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 22, 2012|June 29, 2010||No||No|October 24, 2011|https://clinicaltrials.gov/show/NCT01191788||117018|
NCT01222819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5981|SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients|Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial|G-CSF|Rabin Medical Center|Yes|Terminated|January 2011|April 2013|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|90 Years|No|||February 2013|February 3, 2013|October 14, 2010||No|Significant difference in time to neutrophil recovery (primary outcome). Physycians' refusal    to continue the study|No||https://clinicaltrials.gov/show/NCT01222819||114648|
NCT01222832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00534|Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge|Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge After Functional Endoscopic Sinus Surgery||Steward St. Elizabeth's Medical Center of Boston, Inc.|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|226|||Both|18 Years|N/A|No|||July 2011|January 2, 2014|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222832||114647|
NCT01222208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-106-GEN|Oral Versus Parenteral Nutrition Support to Improve Protein Balance in Colorectal Surgical Patients|Oral Versus Parenteral Perioperative Nutrition Support to Improve Protein Balance: Stable Isotope Study in Colorectal Surgical Patients||McGill University Health Center|No|Completed|March 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|85 Years|No|||February 2012|February 3, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222208||114695|
NCT01223430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH IRB 100105|Simultaneously Using Traditional Chinese Medicine (Si-Ni-Tang) to Treat Septic Shock Patients|Simultaneously Using Traditional Chinese Medicine (Si-Ni-Tang) to Treat Septic Shock Patients - a Double Blind, Prospective, Randomized Controlled Study||Changhua Christian Hospital|Yes|Terminated|September 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|20 Years|85 Years|No|||May 2012|May 21, 2012|October 18, 2010||No|The IRB considered our trial risky. Although there were debates between investigators and IRB,    we terminated our trial in accordance with the suggestion of IRB.|No||https://clinicaltrials.gov/show/NCT01223430||114602|
NCT01222793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910460|Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia|Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia||National Institutes of Health Clinical Center (CC)||Completed|September 2010|May 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|October 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01222793||114650|
NCT01222806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911442|Pilot Study of Repetitive Transcranial Magnetic Stimulation in Cocaine Craving|Pilot Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Cocaine Craving||National Institutes of Health Clinical Center (CC)||Withdrawn|October 2010|May 2013||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||May 2013|March 14, 2014|October 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01222806||114649|
NCT01223729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-12-00 A|Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy|Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy||University of Catania|Yes|Completed|April 2002|November 2005||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2|||67|||Both|34 Years|67 Years||||December 2000|October 18, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01223729||114581|
NCT01224561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0701047|Adaptation of Lipid and Energy Metabolism During a Lipid Overnutrition in Constitutional Thinness|Adaptation of Lipid and Energy Metabolism During a Lipid Overnutrition in Constitutional Thinness|Surnutrition|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|March 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|26|Samples With DNA|muscle tissue fat tissue|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Constitutionnal thinness women and healthy volonteers(women)|May 2011|May 4, 2011|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224561||114518|
NCT01224574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 01 029|To Assess the Predictive Value of D-dimer Level on the Occurrence of Cardiovascular Events|Place Des D-dimères Dans la Prise en Charge Des Patients en Fibrillation Auriculaire : Evaluation de la Valeur prédictive Des D-dimères Sur la Survenue d'événements Thromboemboliques|COAGFAII|Hopital Lariboisière|No|Completed|January 2001|July 2007|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|425|Samples Without DNA|No biospecimens are to be retained|Both|18 Years|N/A|No|Non-Probability Sample|Patients with atrial fibrillation encountered in usual care|September 2010|October 19, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01224574||114517|
NCT01224847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-415|Intravitreal Injection Anesthesia - Comparison of Different Topical Agents|Intravitreal Injection Anesthesia - Comparison of Different Topical Agents.||Lawson Health Research Institute|No|Completed|October 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|92|||Both|50 Years|N/A|No|||April 2012|April 17, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01224847||114496|
NCT01224548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCCR-WNS2|Multicenter Worksite Nutrition Study|Multicenter Worksite Nutrition Study|WNS2|Physicians Committee for Responsible Medicine|Yes|Completed|October 2010|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|292|||Both|18 Years|70 Years|No|||January 2013|January 23, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01224548||114519|
NCT01224834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO63.08 HUN|Safety and Tolerability Study of Ragweed SLIT Tablets|Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets Given in Single Rising Doses and in Multi Dose Regimens to Subjects With an Allergy to Ragweed Pollen.||Stallergenes|No|Completed|January 2009|October 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||October 2010|November 5, 2010|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01224834||114497|
NCT01188941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-001379/26|Linkage and Retention: A Randomized Trial to Optimize HIV/TB Care in South Africa|Linkage and Retention: A Randomized Trial to Optimize HIV/TB Care in South Africa|Sizanani|Massachusetts General Hospital|Yes|Completed|August 2010|April 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|1899|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01188941||117233|
NCT01189578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR# 20276|Brain Imaging of Cocaine Craving in Recreational Cocaine Users|Neural Correlates of Craving and Impulsivity in Recreational Cocaine Users||Medical University of South Carolina|Yes|Completed|August 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|9|||Both|18 Years|65 Years|No|Non-Probability Sample|community sample|October 2012|October 25, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189578||117185|
NCT01189227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP C-11|Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery|A Phase III Study Evaluating the Role of Perioperative Chemotherapy in Patients With Potentially Resectable Hepatic Colorectal Metastases||NSABP Foundation Inc|Yes|Terminated|August 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|August 25, 2010|Yes|Yes|The study was terminated due to low accrual.|No|February 5, 2013|https://clinicaltrials.gov/show/NCT01189227||117211|
NCT01190527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007.123|Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer|Using FDG-PET Acquired During the Course of Radiation Therapy to Individualize Adaptive Radiation Dose Escalation in Patients With Non-Small Cell Lung Cancer|HUM15709|University of Michigan Cancer Center|Yes|Active, not recruiting|August 2008|August 2015|Anticipated|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|April 1, 2010||No||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01190527||117112|
NCT01190839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017080|A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence|Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence||Janssen Biotech, Inc.|Yes|Terminated|November 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|297|||Both|18 Years|99 Years|No|||December 2015|January 5, 2016|August 12, 2010|Yes|Yes|Study is terminated as per Sponsor's Decision.|No|October 16, 2014|https://clinicaltrials.gov/show/NCT01190839||117088|
NCT01190813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS 17|Levodopa for the Treatment of Residual Amblyopia|A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17)|ATS17|Jaeb Center for Health Research|Yes|Completed|September 2010|April 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|7 Years|12 Years|No|||February 2016|February 22, 2016|August 17, 2010|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01190813||117090|
NCT01190826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASM-024/II/STA-02|Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma|Single-Center, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of a Single Dose of ASM-024 Administered by Inhalation to Subjects With Stable Moderate Asthma||Asmacure Ltée|No|Completed|August 2010|February 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|55 Years|No|||March 2012|March 14, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190826||117089|
NCT01202656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09012010-02|Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)|G-CSF(Granulocyte Colony Stimulating Factor) and Embryo Implantation and Pregnancy Following IVF (in Vitro Fertilization)||Center for Human Reproduction|Yes|Completed|September 2010|June 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|September 14, 2010||No||No|May 18, 2014|https://clinicaltrials.gov/show/NCT01202656||116191|The study results are applicable only to women undergoing routine IVF. Most of the women in this trial had normal endometrial thickness at randomization.
NCT01198405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-5010-2008|Study of Enahnced External Counterpulsation to Treat Coronary Heart Disease|A Prospective,Randomized,Open-labeled,and Blind Endpoint Study of Enhanced External Counterpulsation for Patients With Coronary Heart Disease|PROBE-EECP|Sun Yat-sen University|Yes|Recruiting|September 2008|September 2013|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|1050|||Both|18 Years|75 Years|No|||January 2008|September 9, 2010|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01198405||116515|
NCT01198665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-01-001|RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas|A Phase I/II Study of RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas|RADCHOP|Samsung Medical Center|Yes|Completed|July 2010|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|20 Years|70 Years|No|||March 2015|March 1, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198665||116495|
NCT01198964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37183-D|Brain Computer Interfaces for Functional Recovery From Brain Injury|Brain Computer Interfaces for Functional Recovery From Brain Injury|BCI|University of Washington|No|Recruiting|September 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|8|||Both|18 Years|N/A|No|Non-Probability Sample|Age 18 and older male and female epileptic patients who are referred for surgical        implantation of electrodes.|October 2010|October 20, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198964||116473|
NCT01199354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEM-01|Skin Sparing Mastectomy and Immediate Breast Reconstruction With Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy (M-RIC)|Phase II Study: Assessing the Feasibility and Morbidity of Skin Sparing Mastectomy and Immediate Breast Reconstruction With Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma.|M-RIC|Clinique Clementville||Recruiting|July 2010|July 2017|Anticipated|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Female|18 Years|75 Years|No|||June 2011|June 8, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01199354||116444|
NCT01199367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2450-US-002|Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer|A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumors Overexpress HER2||Kyowa Hakko Kirin Pharma, Inc.|No|Terminated|December 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|September 8, 2010|No|Yes|The results of the dose escalation phase did not identify a well-tolerated dose that would    permit further study in Phase 2.|No||https://clinicaltrials.gov/show/NCT01199367||116443|
NCT01199614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0544|HEXT (Hypo Studies EXTended)|HEXT: The Hypoparathyroidism Studies, Extended: the Effect of PTH on the Skeleton in Hypoparathyroidism|HEXT|Columbia University|Yes|Active, not recruiting|December 2009|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|85 Years|No|||February 2016|February 8, 2016|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199614||116424|
NCT01199601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD1784|Blood-borne Infection Screening in an Afghan Antenatal Population|Pilot Educational Intervention to Determine Effect of Intrapartum Testing and Concentrated Postpartum Counseling on Birth Spacing, Breastfeeding, and Infant Vaccination Completion in a Kabul Urban Population.||Columbia University|No|Completed|June 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1291|||Both|14 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|September 9, 2010||No||No|September 4, 2013|https://clinicaltrials.gov/show/NCT01199601||116425|
NCT01199887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IW001-01|Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis|A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||ImmuneWorks|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|35 Years|75 Years|No|||July 2013|July 26, 2013|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199887||116404|
NCT01200472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCOST Version 22-Oct-09|Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis|A Phase 2, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel-group,Efficacy Study of Apremilast (CC-10004)in Subjects With Erosive Hand Osteoarthritis||University of Erlangen-Nürnberg Medical School|Yes|Completed|August 2010|October 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01200472||116359|
NCT01200485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0284|Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2|A Randomized Phase 2 Study to Evaluate the Efficacy of Rasburicase in Patients at Risk for TLS During Two Cycles of Chemotherapy||M.D. Anderson Cancer Center|Yes|Active, not recruiting|April 2011|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|N/A|N/A|No|||September 2015|September 11, 2015|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200485||116358|
NCT01200498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0319|Study of SB939 in Subjects With Myelofibrosis|A Phase 2, Prospective, Open-Label Study to Determine the Safety and Efficacy of SB939, A Histone Deacetylase Inhibitor, in Subjects With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (PMF; Post-Polycythemia Vera (PV) Myelofibrosis (MF), Or Post- Essential Thrombosis (ET) MF||M.D. Anderson Cancer Center|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2013|December 13, 2013|September 9, 2010|Yes|Yes||No|December 13, 2013|https://clinicaltrials.gov/show/NCT01200498||116357|
NCT01200758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO22334|A Study of MabThera (Rituximab) Subcutaneous Vs. MabThera (Rituximab) Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma|A Two-stage Phase III, International, Multi-center, Randomized, Controlled, Open-label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV||Hoffmann-La Roche||Active, not recruiting|February 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|September 10, 2010|No|Yes||No|July 7, 2015|https://clinicaltrials.gov/show/NCT01200758||116337|
NCT01220687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1976|Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation|Administration of Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation Protocol: A Pilot Trial|iNO|University of Oklahoma|No|Recruiting|April 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|N/A|2 Minutes|No|||November 2015|November 18, 2015|October 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01220687||114812|
NCT01212770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSA-004|PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis and a Qualifying Psoriasis Lesion|PALACE 3|Celgene|Yes|Active, not recruiting|September 2010|February 2017|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|505|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|September 29, 2010|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01212770||115418|
NCT01213576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FED-311207|Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi|Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study|FED|London School of Hygiene and Tropical Medicine|No|Terminated|January 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|September 30, 2010||No|Introduction of National Mass Drug Administration Campaign and failure to identify appropriate    participants.|No|February 10, 2015|https://clinicaltrials.gov/show/NCT01213576||115356|
NCT01213862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS and HCPA 09111|Home Based Intervention Led by Nurse in Brazil|Home Visit Impact on Knowledge of Disease, Self-Care Skills and Quality of Life of Heart Failure Patients: Randomized Clinical Trial|HFHELENI|Hospital de Clinicas de Porto Alegre|Yes|Completed|August 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01213862||115334|
NCT01214161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE9330|Intracervical Lidocaine Gel for IUD Insertional Pain|Intracervical Two Percent Lidocaine Gel as an Analgesic During Intrauterine Device Insertion: A Randomized Controlled Trial||Columbia University|No|Active, not recruiting|September 2010|June 2013|Anticipated|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 6, 2012|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01214161||115311|
NCT01211418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040827|Integrative Meditation (IM) for Cocaine Addiction|Treatment of Cocaine Addiction With Integrative Meditation||University of Maryland|Yes|Recruiting|March 2009|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||September 2010|September 28, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211418||115522|
NCT01214720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17706|A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer|A Randomized, Double-blind Study of the Effect of Avastin Plus Gemcitabine and Erlotinib Compared With Placebo Plus Gemcitabine and Erlotinib on Overall Survival in Patients With Metastatic Pancreatic Cancer||Hoffmann-La Roche||Completed|July 2005|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|607|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|October 4, 2010||No||No|July 23, 2014|https://clinicaltrials.gov/show/NCT01214720||115268|
NCT01215019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004-10|Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain Injury|20% Mannitol vs 3% Hypertonic Saline in the Treatment of Intracranial Hypertension in Patients With Traumatic Brain Injury: A Double-blinded, Randomized Trial||Indiana University|Yes|Withdrawn|October 2010|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||April 2013|April 1, 2013|October 4, 2010|Yes|Yes|Lack of funding; not subjects enrolled|No||https://clinicaltrials.gov/show/NCT01215019||115246|
NCT01198158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02603|Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy|Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2010|||June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||January 2016|March 24, 2016|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198158||116534|
NCT01198418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTG 592|A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)|A Randomized Controlled Clinical Trial of an Internet-based Prevention Intervention to Reduce STI in High-risk HIV Infected MSM||California Collaborative Treatment Group|No|Completed|November 2010|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|181|||Male|18 Years|N/A|No|||March 2014|March 31, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198418||116514|
NCT01198678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Slovenia-UMC-001|Feasibility Study to Assess the Safety and Functionality of the GluSense Continuous Glucose Monitor in Diabetic Patients|Feasibility Study to Assess the Safety and Functionality of the GluSense-LTone 2e3 Continuous Glucose Monitor in Diabetic Patients||GluSense Ltd|Yes|Completed|November 2010|February 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|50 Years|No|||December 2010|March 29, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198678||116494|
NCT01198977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4972-W|Telehealth-Based Exercise Program to Treat Fatigue in MS|Telehealth-Based Exercise Program to Treat Fatigue in MS|MS-FIT|VA Office of Research and Development|No|Active, not recruiting|October 2009|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|80 Years|No|||January 2016|January 29, 2016|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198977||116472|
NCT01199380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA018730|Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms|Stage II Trial of Novel Behavioral Activation Intervention for Smoking Cessation||University of Maryland|No|Recruiting|October 2010|June 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||December 2010|December 7, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01199380||116442|
NCT01199627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA-CRT|Tranexamic Acid Versus Placebo for the Reduction of Blood Loss in Total Hip Replacement Surgery|Tranexamic Acid Versus Placebo for the Reduction of Blood Loss in Total Hip Replacement Surgery - Randomized, Controlled and Double-masked Trial|TXA-CRT|Basque Health Service|No|Completed|March 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|114|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01199627||116423|
NCT01199913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100193|POCD in Elderly Patients Following Desflurane or Sevoflurane General Anesthesia|Incidence of Postoperative Cognitive Dysfunction in Elderly Patients Following Desflurane or Sevoflurane General Anesthesia: A Randomized, Controlled Trial||Loma Linda University|No|Completed|August 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|110|||Both|65 Years|N/A|No|Non-Probability Sample|Adult patients, male and female, 65 years or older scheduled for elective surgery        requiring general anesthesia.|September 2014|September 8, 2014|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199913||116402|
NCT01200199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-002|Validity of Electronic Diary for Monitoring Varicose Veins Symptoms|Performance of Daily Electronic Diary to Capture Venous Symptoms Before and After Intervention for Great Saphenous Vein Incompetence||BTG International Inc.|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|75 Years|No|Non-Probability Sample|Varicose veins|March 2013|March 7, 2013|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01200199||116380|
NCT01200212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 43|A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer|A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer|TABEA|German Breast Group|Yes|Terminated|July 2009|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|432|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|September 10, 2010||No|A planed interim analysis shows no benefits, but higher adverse event rates for the    experimental arm.|No||https://clinicaltrials.gov/show/NCT01200212||116379|
NCT01200511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09-052|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2010|||||N/A|N/A|N/A||||||||||||||December 5, 2011|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200511||116356|
NCT01200524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2600C00012|A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..|A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..||AstraZeneca|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|133|||Both|18 Years|80 Years|No|||April 2014|April 8, 2014|September 10, 2010|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01200524||116355|
NCT01200784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6520-9961-03|Nicotinamide in Hemodialysis Patients With Hyperphosphatemia|Dose Finding Study of Nicotinamide in Hemodialysis Patients With Hyperphosphatemia|DONATO|Medice Arzneimittel Pütter GmbH & Co KG||Completed|August 2010|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|252|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200784||116335|
NCT01213043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T6004-201/Version 2|Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency|A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin®-C in Subjects With Alpha1-Antitrypsin Deficiency|SPARK|Grifols Therapeutics Inc.|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||April 2013|April 8, 2013|September 29, 2010|Yes|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01213043||115397|
NCT01213329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00011048|Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab|Immunophenotyping and Functional Profiles of Peripheral Lymphocytes in Renal Transplant Recipients After T-cell Depletion With Alemtuzumab (Anti-CD52 Monoclonal Antibody)-Potential Implications for Safe Immunosuppressive Minimization||Northwestern University|No|Terminated|February 2006|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|65 Years|No|||April 2013|April 18, 2013|September 30, 2010||No||No|May 3, 2011|https://clinicaltrials.gov/show/NCT01213329||115375|Processing of blood samples was inconsistent and lab results were questionable. Research blood specimens were in addition to Standard of Care (SOC) required blood. Most research visits were planned at the same time as SOC visits.
NCT01214746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-FHC-2010-1|The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man|The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man|STAR|Regional Hospital Holstebro|Yes|Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2011|August 15, 2011|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01214746||115266|
NCT01213875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRGS and HCPA 09112|A Multifaceted Nurse-based Strategy Reduces HEart FaiLure Morbidity in PatiENts Admitted for Acute Decompensated Heart Failure in Brazil|A Multifaceted Nurse-based Strategy Reduces HEart FaiLure Morbidity in PatiENts Admitted for Acute Decompensated Heart Failure in Brazil|HELEN II|Hospital de Clinicas de Porto Alegre|No|Completed|August 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|N/A|No|||January 2014|January 1, 2014|November 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01213875||115333|
NCT01215669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GID33|Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea|Immunogenicity and Safety of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea||Sanofi|No|Completed|October 2010|April 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215669||115196|
NCT01215682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7762-GDR-CTIL|Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers|Vitamin D Supplementation, Upper Respiratory Tract Infections, Immune and Physical Functions in Adolescent Swimmers||Sheba Medical Center|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|82|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215682||115195|
NCT01215331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-057|Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?|Gestational Diabetes Mellitus: Insulin or Oral Hypoglycemic Agents?|DG5|Université de Sherbrooke|Yes|Completed|August 2010|September 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215331||115222|
NCT01211704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20081123|Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism|Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism: A Double-blind, Placebo-controlled, Randomized, Parallel Groups, Multi-center Study.||University of Miami|No|Withdrawn|October 2010|February 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||November 2014|November 19, 2014|September 28, 2010||No|lack of funding|No||https://clinicaltrials.gov/show/NCT01211704||115500|
NCT01198171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8022|Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer|The Relationship of Racial Genetic Admixture With Endometrial Cancer Outcomes||Gynecologic Oncology Group||Not yet recruiting|January 2100|||January 2100|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|243|||Female|N/A|N/A|No|Non-Probability Sample|Patient with endometrial cancer|May 2015|May 27, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198171||116533|
NCT01198431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPUS-B261|Effects of Impaired Sleep on Energy Balance|Effects of Impaired Sleep on Energy Balance: A Randomized, 2-Condition, Crossover Study in Adolescents|SLOPUS|University of Copenhagen|No|Completed|October 2009|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Male|15 Years|19 Years|Accepts Healthy Volunteers|||September 2010|August 9, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198431||116513|
NCT01198444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14340|To Evaluate Compliance to Treatment Regimen (Rate of Deviations From the Prescribed Regimen) in Polish Females Treated With Different Low Dose Oral Contraceptives|Prospective, Open-label Observational Survey Evaluating Patients Compliance to Administration Regimen During Low Dose Combined Oral Contraceptive Use in Everyday Praxis Data on Oral Contraceptives Compliance - DOC Study|DOC|Bayer|No|Completed|December 2007|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11884|||Female|18 Years|50 Years|No|Probability Sample|Gynecological practices patients - starters or current users.|November 2011|October 31, 2011|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01198444||116512|
NCT01198691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10018-10-016|A Comparison of Metallic Staples Versus Absorbable Staples After a Cesarean Section (C-Section)|Closure of Pfannenstiel Skin Incisions After Cesarean Delivery: A Comparison of Metallic Staples Versus Absorbable Staples||TriHealth Inc.|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 13, 2014|September 2, 2010||No||No|March 13, 2014|https://clinicaltrials.gov/show/NCT01198691||116493|Low response rate to patient surveys at discharge and at 6 weeks postpartum.
NCT01198990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908010566|SCALE: Small Changes and Lasting Effects|SCALE: Small Changes and Lasting Effects|SCALE|Weill Medical College of Cornell University|Yes|Active, not recruiting|October 2009|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|312|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 19, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198990||116471|
NCT01199393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|snp|Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer|Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer||Beijing Cancer Hospital|Yes|Completed|August 2010|May 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|153|Samples With DNA|about 4ml peripheral vein blood|Female|18 Years|75 Years|No|Non-Probability Sample|female patients with metastatic breast cancer|July 2015|July 27, 2015|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01199393||116441|
NCT01199939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017149|A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients|A Multicenter, Single Arm, Open-Label Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients|INROADS|Tibotec, Inc|No|Completed|May 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||October 2013|October 4, 2013|September 9, 2010|Yes|Yes||No|October 4, 2013|https://clinicaltrials.gov/show/NCT01199939||116400|
NCT01199926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSSI-VitD (0801006402)|Effect of Vitamin D Supplementation on Muscle Mass and Function|Impact of Vitamin D Supplementation on Strength and Lean Mass Accumulation During an Exercise Intervention||Purdue University|No|Completed|August 2008|February 2010|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|September 9, 2010||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01199926||116401|
NCT01200225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22790|An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)|Prospective Observational Study to Asses the Insulin Resistance (IR) and Its Impact on Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegasys and Copegus||Hoffmann-La Roche||Completed|February 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1155|||Both|18 Years|N/A|No|Probability Sample|Patients with inadequate response or intolerant to DMARDs and anti-TNF|March 2016|March 1, 2016|September 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01200225||116378|
NCT01200537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022374|Optimizing Ovulation Induction in the Poor Responder|Optimizing Ovulation Induction in the Poor Responder: a Randomized Clinical Trial of Luteal Phase Estradiol Versus Combined Oral Contraceptive Pill on Ovarian Morphology and Biomarkers Prior to Ovulation Induction||Duke University|No|Withdrawn|October 2010|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|August 23, 2010|Yes|Yes|Change in staffing|No||https://clinicaltrials.gov/show/NCT01200537||116354|
NCT01201005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-Vest 104.08|B Vitamin Status in Premature and Small for Gestational Age(SGA) Infants|B VITAMIN STATUS IN PREMATURE AND SMALL FOR GESTATIONAL AGE INFANTS||Haukeland University Hospital|No|Completed|July 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Both|5 Months|7 Months|Accepts Healthy Volunteers|||September 2010|September 13, 2010|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201005||116318|
NCT01213056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0378|Mindfulness-Based Cognitive Therapy for the Treatment of Chronic Headache Pain|Mindfulness-Based Cognitive Therapy for the Treatment of Chronic Headache Pain||University of Alabama, Tuscaloosa|No|Completed|April 2010|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|19 Years|N/A|No|||November 2015|November 30, 2015|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01213056||115396|
NCT01213342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0014|Omega-3 Fatty Acid Supplements and Dry Eye|Omega-3 Fatty Acid Supplementation and Dry Eye||Ohio State University|No|Terminated|May 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|September 30, 2010||No|Researchers left institution|No||https://clinicaltrials.gov/show/NCT01213342||115374|
NCT01215383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036-10|The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy|The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy||Ziv Hospital|No|Recruiting|November 2010|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|psychiatric patients before and during antipsychotic therapy|February 2013|February 19, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01215383||115218|
NCT01215695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL IRB #10.0300|Video-laryngoscope With a Novel Video-stylet for Difficult Intubation|Feasibility of a Combined Use of a Video-laryngoscope With a Novel Video-stylet for Predicted Difficult Intubation||University of Louisville|No|Recruiting|August 2010|December 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215695||115194|
NCT01215357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY201|Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble|Ecopipam Treatment of Pathological Gambling||Psyadon Pharma|No|Completed|October 2010|August 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|75 Years|No|||February 2013|February 28, 2013|October 4, 2010|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01215357||115220|This was an open label trial of ecopipam for the treatment of pathological gambling. A significant effect of drug treatment was demonstrated. These data need to be verified with a double-blind, placebo controlled trial.
NCT01215370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016||Pea Protein and Postprandial Response (PEA)|Effect of Arginine-rich Dietary Protein on Postprandial Metabolism, Inflammation and Endothelial Function|PEA|Wageningen University|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|18|||Male|45 Years|70 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01215370||115219|
NCT01211717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100233|The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients|The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients||Loma Linda University|No|Completed|October 2010|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||April 2011|April 21, 2011|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211717||115499|
NCT01198457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14561|Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment|BONA (Adherence of Patients to Bonefos Therapy). Prospective Observational Non-interventional Study of Adherence of Patients to Bonefos Medication in Relation to Analgesic Effect and Incidence of Skeletal Events|BONA|Bayer|No|Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|147|||Both|18 Years|N/A|No|Non-Probability Sample|Random group of patients in oncology clinic|September 2012|September 6, 2012|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01198457||116511|
NCT01198470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G090143|TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study|A Prospective Clinical Investigation of the TRIUMPH Lumbar Disc: A Pilot Study||Globus Medical Inc|No|Active, not recruiting|September 2010|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||August 2015|August 4, 2015|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198470||116510|
NCT01198704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM07237|Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)|Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma|EFAPRE|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|January 2009|July 2019|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|372|Samples Without DNA|Blood and serum sample (28 ml at M0, M3, M6) Tissues (one pretransplant, hepatic explant,      potential resection)|Both|18 Years|70 Years|No|Non-Probability Sample|Patient notified on the waiting list for hepatic transplant|November 2014|November 13, 2014|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01198704||116492|
NCT01198717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-404|Pediatric Disease Registry in Essential Thrombocythaemia (ET)|Multicentre Paediatric Disease Registry in Essential Thrombocythaemia||Shire|No|Completed|September 2010|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|||Both|6 Years|17 Years|No|Non-Probability Sample|Paediatrics aged between 6 years and 17 years|March 2016|March 14, 2016|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198717||116491|
NCT01199016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-4010|Effect of Prevnar 13 on Ear Infections in Children|"a Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children||Pfizer|No|Active, not recruiting|September 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|360|Samples Without DNA|Middle Ear Fluid for microbiologic analysis Nose and throat swab for microbiologic analysis|Both|6 Months|30 Months|No|Non-Probability Sample|Healthy children aged approximately 6 to 36 months of age.|December 2015|December 14, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01199016||116470|
NCT01199029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0861004|Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate|An Open Label Study Evaluating The Effect Of Single Doses Of Pf-04308515 And Prednisone On Carbohydrate Metabolism Utilizing An Oral Glucose Tolerance Test In Healthy Adult Subjects||Pfizer|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 15, 2010|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199029||116469|
NCT01199406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intense Trial|Pain Reduction After Cholecystectomy|Combined Preincisional Infiltration and Intraperitoneal Instillation of Levobupivacaine for Postoperative Pain Reduction After Laparoscopic Cholecystectomy; A Double-blind Placebo-controlled Randomised Clinical Trial|INTENSE|Meander Medical Center|Yes|Completed|July 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||September 2010|September 10, 2010|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199406||116440|
NCT01199640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN120204-063|Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis|A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis||Millennium Pharmaceuticals, Inc.|No|Completed|May 2005|October 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||September 2010|September 9, 2010|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199640||116422|
NCT01199653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYH6267|Study Comparing Plate Stabilization to Conservative Treatment in Midshaft Clavicle Fractures|Nonoperative Versus Operative Treatment of Midshaft Clavicle Fractures - A Randomized Controlled Trial||Helsinki University Central Hospital|No|Completed|August 2004|November 2009|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||September 2010|September 10, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01199653||116421|
NCT01199952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT 10-01978|RCT: Can a Single Counseling Phone Call Improve Contraception After an Abortion?|A Randomized Controlled Trial: Contraceptive Counseling After an Abortion|PPR|University of California, San Francisco|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|234|||Female|15 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 28, 2014|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199952||116399|
NCT01200238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-137|STA-9090(Ganetespib) in Metastatic Ocular Melanoma|A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|June 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|January 19, 2016|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200238||116377|
NCT01200251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9459|Study of Bimatoprost Gel on Eyelash Growth|The Role of Bimatoprost Eyelash Gel in Chemotherapy-induced Madarosis: an Analysis of Efficacy and Safety||Duke University|No|Completed|February 2007|December 2008|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|80 Years|No|||September 2010|July 14, 2014|September 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01200251||116376|
NCT01200797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02519|SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin|A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma||National Cancer Institute (NCI)|Yes|Terminated|July 2010|February 2013|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Female|18 Years|N/A|No|||May 2015|May 7, 2015|September 10, 2010|Yes|Yes|Slow accrual was the reason for study termination.|No|October 7, 2013|https://clinicaltrials.gov/show/NCT01200797||116334|The death reported in the SAE section was not related to study drug.
NCT01201031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98105|Reduction of Nosocomial Vancomycin -Resistant Enterococci (VRE) Colonization and Infection by Active Surveillance and Intervention of Infection Control|Reduction of Nosocomial VRE Colonization and Infection by Active Surveillance and Intervention of Infection Control (no)||Taipei Medical University WanFang Hospital|No|Completed|April 2010|February 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Anticipated|80|||Both|20 Years|N/A|No|Probability Sample|patients admitted to RCC unit , and these patients received active surveillance of VRE        colinization|March 2011|March 14, 2011|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201031||116316|
NCT01201044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO201001|Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized, Two Arm Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)|DO201001|Third Military Medical University|No|Recruiting|January 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||December 2009|September 13, 2010|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01201044||116315|
NCT01213069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2009/CB-01|Staff Opinions and Knowledge Concerning Organ and Tissue Harvesting: an Investigation Among the Patient Care Personnel in the South-Mediterranean Region of France|Staff Opinions and Knowledge Concerning Organ and Tissue Harvesting: an Investigation Among the Patient Care Personnel in the South-Mediterranean Region of France||Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1859|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Health care personnel in South-Mediterranean France|March 2015|March 24, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213069||115395|
NCT01213082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201018281-1|Prospective Randomized Trial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)|Phase I/II Prospective, Randomized, Double-blinded Study of Intravitreal Anti-VEGF Therapy Combined With Proton Beam Radiation Versus Sham Irradiation in Treating Exudative Age-related Macular Degeneration|PBAMD2|University of California, Davis|No|Active, not recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|50 Years|N/A|No|||December 2015|December 2, 2015|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01213082||115394|
NCT01213355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2081009|Scopolamine Challenge Study|A Randomized, Double-Blind, Sponsor Unblinded, Placebo Controlled, 5-Way, Crossover Study To Evaluate The Effects Of Single Oral Administrations of PF-05212377 (SAM-760), A 5-HT6 Antagonist, On Scopolamine Induced Deficits In Psychomotor And Cognitive Function In Healthy Young Adults||Pfizer|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|September 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01213355||115373|
NCT01213888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01900|Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy|Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy||University of British Columbia|No|Terminated|November 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|3|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 1, 2013|September 30, 2010||No|Low enrollment & superior treatments available for diabetic macular edema including anti-VEFG    therapies such as bevacizumab and ranibizumab.|No||https://clinicaltrials.gov/show/NCT01213888||115332|
NCT01211756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytocin Depression|Oxytocin Add-on for Stable Depressed Patients|Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antidepressant Medication in Depressed Patients.||University of California, San Diego|No|Suspended|October 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|September 28, 2010|No|Yes|Break in funding|No||https://clinicaltrials.gov/show/NCT01211756||115496|
NCT01212614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2010-0293|Measurement of Gastric Secretion by MRI Under Inhibition by ProtonPump Inhibitors in Healthy Subjects & in GERD Patients|A Study for Measurement of Gastric Secretion by Magnetic Resonance Imaging (MRI) Under Inhibition of Gastric Secretion by Proton Pump Inhibitors in Healthy Subjects and Patients With Reflux Disease||University of Zurich||Completed|October 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||September 2012|September 11, 2012|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212614||115430|
NCT01212029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100198|Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging|Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging||National Institutes of Health Clinical Center (CC)||Recruiting|August 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 1, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212029||115475|
NCT01212042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100200|Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections|Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections||National Institutes of Health Clinical Center (CC)||Recruiting|September 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|2 Years|N/A|No|||April 2015|September 24, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212042||115474|
NCT01212055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100201|Apheresis of Patients With Immunodeficiency|Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells From Patients With DOCK8 Deficiency, LAD-1, and GATA2 Deficiency||National Institutes of Health Clinical Center (CC)||Recruiting|August 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|6|||Both|15 Years|40 Years|No|||November 2015|December 15, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212055||115473|
NCT01211431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2008/GA-01|Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine|Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine: Comparison of the Quality of Analgesia, Side Effects, and the Incidence of Residual Scar Pain||Centre Hospitalier Universitaire de Nīmes|No|Withdrawn|September 2010|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||March 2015|March 24, 2015|September 28, 2010||No|No inclusions.|No||https://clinicaltrials.gov/show/NCT01211431||115521|
NCT01211444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-004|US Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea|US Prospective Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea||Apnex Medical, Inc.|Yes|Completed|July 2010|August 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|70 Years|No|||October 2011|April 14, 2015|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01211444||115520|
NCT01198483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-6-CI-2010|Microincision Versus Smallincision Combined Surgery|Microincision Cataract Surgery Combined With 23-gauge Vitrectomy Versus Smallincision Cataract Surgery Combined With 23-gauge Vitrectomy||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Recruiting|August 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01198483||116509|
NCT01198769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114351|Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.|Immunogenicity, Reactogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.||GlaxoSmithKline||Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||March 2012|June 7, 2012|September 9, 2010|Yes|Yes||No|March 22, 2012|https://clinicaltrials.gov/show/NCT01198769||116487|
NCT01198730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C08215|Screen of DM by OGTT in Subjects Receiving CAG or MDCT for CAD|Screen of Diabetes Mellitus by Oral Glucose Tolerance Test in Subjects Receiving Catheterization or Multi-detector Computed Tomography (MDCT) for Coronary Artery Disease||Taichung Veterans General Hospital|No|Recruiting|April 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|70 Years|No|||September 2015|September 1, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198730||116490|
NCT01198743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P040433|Presence of Circulating Tumor DNA in Colorectal Cancer|Search for the Presence of Genetic Alteration in the Plasma of Patients With Stage II-III Colorectal Cancers: Prognosis Impact|ALGECOLS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2005|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|serum and tissue|Both|18 Years|85 Years|No|Non-Probability Sample|defined population : patients suffer from colorectal cancers in stage II-III|April 2010|October 22, 2014|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01198743||116489|
NCT01199042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-1001-ASVWO-MS|Bipap autoSV Advanced in Central Apnea Patients|BiPAP autoSV Advanced in Central Apnea Patients, ST-1001-ASVWO-MS||Philips Respironics|No|Completed|September 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|21 Years|75 Years|No|||August 2013|August 21, 2013|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199042||116468|
NCT01199055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-A108|CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)|Phase 1b Study of CS-7017 in Combination With Carboplatin/Paclitaxel in Chemotherapy-naïve Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)||Daiichi Sankyo Inc.|No|Completed|March 2010|July 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||July 2011|July 11, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01199055||116467|
NCT01199068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS7017-A-A110|CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)|Phase 1b Study of CS-7017 in Combination With Erlotinib in Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Who Failed First-line Therapy||Daiichi Sankyo Inc.|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01199068||116466|
NCT01199419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1|Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP|Cost-effectiveness of Percutaneous Coronary Intervention With TAXUS Stents in Patients With Multivessel Coronary Artery Disease Compared With Aortocoronary Bypass Surgery 5 Years After Intervention||Medical University of Vienna||Completed|January 2004|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|207|||Both|18 Years|N/A|No|Probability Sample|Patients, treated with multivessel disease requiring revascularization were consecutively        included in this study.|July 2014|July 16, 2014|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199419||116439|
NCT01199666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF4263|Text Message Reminder-Recalls For Early Childhood Vaccination|Text 4 Health-Kids: Text Message Reminder-Recalls For Early Childhood Vaccination||Columbia University|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|2586|||Both|9 Months|50 Years|No|||July 2014|July 24, 2014|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199666||116420|
NCT01199679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-016|Rubber Band Ligation and Mucosectomy for Gastroesophageal Reflux Disease (GERD)|Evaluation of Distal Esophageal and Cardia Rubber Band Ligation and Mucosectomy in the Treatment of Subjects With Gastroesophageal Reflux Disease|GERD|Cook||Terminated|June 2011|March 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199679||116419|
NCT01200563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-86000|Comparative Effectiveness Study of MIST Therapy Versus Negative Pressure Wound Therapy|Comparative, Prospective, Randomized Study of MIST Therapy vs NPWT vs MIST Therapy in Conjunction With NPWT on the Rate of Healing and Its Economic Value in the Treatment of Full Thickness Wounds in a LTACH and SNF||Celleration, Inc.|No|Withdrawn|August 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|September 10, 2010|Yes|Yes|Study site compliance|No||https://clinicaltrials.gov/show/NCT01200563||116352|
NCT01200550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GBA-DUM-2010/1|The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients|An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease (GERD)||AstraZeneca|No|Completed|September 2010|November 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1233|||Both|18 Years|N/A|No|Probability Sample|Patients previously diagnosed with GERD (disease duration =3 years) or newly diagnosed        patients that are currently not treted with proton pump inhibitors, for whom GP or        specialist (in primary care unit) have previosly decided to initiate or change treatment        for GERD.|April 2012|April 16, 2012|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01200550||116353|
NCT01200810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02527|Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer|A Randomized Phase II Study of Peripheral Androgen Blockade With Bicalutamide Followed by Placebo or Treatment With the Gamma Secretase Inhibitor RO4929097 in Men With Rising PSA After Definitive Local Therapy for Adenocarcinoma of the Prostate||National Cancer Institute (NCI)|No|Terminated|August 2010|November 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|N/A|No|||August 2014|October 20, 2014|September 10, 2010|Yes|Yes|Drug was no longer available|No|October 20, 2014|https://clinicaltrials.gov/show/NCT01200810||116333|Early termination leading to small numbers of subjects analyzed.
NCT01200823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100162|Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies|Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies||National Institutes of Health Clinical Center (CC)||Recruiting|June 2010|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|2 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 3, 2016|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200823||116332|
NCT01201070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antithrombin III|Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery|Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery|ATIII|University of Bari|Yes|Recruiting|September 2009|November 2011|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|90|||Both|18 Years|80 Years|No|||July 2010|September 14, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01201070||116313|
NCT01201395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111010|DPBRN Longitudinal Study of Repaired or Replaced Dental Restorations|Longitudinal Study of Repaired or Replaced Dental Restorations||Dental Practice-Based Research Network|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9813|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participants directly involved in this study are the particpants who have sought        dental treatment in the practitioner-investigators' practices and participated in the        DPBRN "Reasons for replacement or repair of dental restorations" study.|September 2011|September 16, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201395||116288|
NCT01212822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-GI-029|Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer|Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer||Fox Chase Cancer Center|Yes|Active, not recruiting|April 2011|||October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212822||115414|
NCT01213589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDTVIRTUE001|The VIRTUE Post Marketing Surveillance Registry|The VIRTUE Post Marketing Surveillance Registry - VALIANT Thoracic Stent Graft Evaluation For the Treatment of Descending Thoracic Aortic Dissections|VIRTUE|Medtronic Endovascular|Yes|Completed|December 2006|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to        stent-graft operation will be enrolled in the registry.|October 2013|October 21, 2013|October 1, 2010||No||No|October 21, 2013|https://clinicaltrials.gov/show/NCT01213589||115355|
NCT01214174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-01|Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients|A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Treating Inflammation in Cataract Surgery Patients||ICON Bioscience Inc|No|Terminated|October 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|40 Years|N/A|No|||September 2013|September 16, 2013|September 21, 2010|Yes|Yes|Study C11-01 started|No|June 24, 2013|https://clinicaltrials.gov/show/NCT01214174||115310|Early termination leading to small numbers of subjects analyzed
NCT01214759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT-NPEP|Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)|A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV)||The University of Texas Health Science Center, Houston|Yes|Completed|May 2011|August 2015|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|103|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|September 30, 2010|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01214759||115265|This is a pilot study with a small sample size.
NCT01215032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-244|Metformin in Castration-Resistant Prostate Cancer|Prospective Study of Metformin in Castration-Resistant Prostate Cancer||Massachusetts General Hospital|Yes|Terminated|September 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|N/A|N/A|No|||January 2015|January 14, 2015|October 4, 2010|No|Yes|slow accrual, competing clinical trials|No||https://clinicaltrials.gov/show/NCT01215032||115245|
NCT01215045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-004|Visual Performance of Bilateral AcrySof ReSTOR Aspheric +4|||Alcon Research|No|Completed|June 2007|May 2008|Actual|May 2008|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study participants taken from physician's patient pool implanted with the AcrySof ReSTOR        +4 Intraocular Lens (IOL)|October 2010|October 4, 2010|August 12, 2008||No||No||https://clinicaltrials.gov/show/NCT01215045||115244|
NCT01215058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-PFR-DUM-2010/2|Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer|Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal Bleeding Ulcer or a Symptomatic Ulcer With Non-steroidal Anti-inflammatory Drug (NSAID) in France||AstraZeneca|No|Withdrawn|October 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Hospital sample|October 2010|October 21, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01215058||115243|
NCT01212926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/23|Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain|Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain|CA2D|University Hospital, Bordeaux|No|Active, not recruiting|September 2010|April 2015|Anticipated|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|65 Years|No|||May 2014|May 9, 2014|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212926||115406|
NCT01212913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_04867|Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)|Comparison of a Basal Plus (Insulin Glargine/Insulin Glulisine) Regimen to Biphasic Insulin (InsulinAspart/Insulin Aspart Protamine 30/70) in T2DM Patients Who Require Insulin Intensification After Basal Insulin Optimization.|B to B|Sanofi|No|Completed|August 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|18 Years|N/A|No|||July 2013|July 5, 2013|September 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01212913||115407|
NCT01212341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG4101_P1|Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor|A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor|MG4101|Seoul National University Hospital|Yes|Completed|September 2010|March 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|September 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01212341||115451|
NCT01212601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ICN-DUM-2010/1|Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice|A Multicenter, Observational, Non-interventional Registry Designed to Collect Clinical Data in Chinese Patients Who Have Received CUBICIN® Treatment Under Condition of Actual Usage in Clinical Practice||AstraZeneca|No|Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|203|||Both|N/A|N/A|No|Non-Probability Sample|Chinese patients received CUBICIN treatment|November 2012|November 23, 2012|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01212601||115431|
NCT01199081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRONE_C_04629|Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation|A Randomized, International, Multi-center, Open-label Study to Document Pharmacokinetics and Optimal Timing of Initiation of Dronedarone Treatment Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Whatever the Reason for the Change of Treatment.|ARTEMIS AF LT|Sanofi|Yes|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199081||116465|
NCT01199094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRP5-HBM|Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5|Clinical Assessment of Patients With High Bone Mass Due to Mutation in Low Density Lipoprotein l Receptor 5||Odense University Hospital|No|Completed|January 2009|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|38|Samples With DNA|Serum, plasma, DNA as well as fat and skin biopsies|Both|8 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Case-control study on almost 40 individuals|August 2010|September 9, 2010|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199094||116464|
NCT01199432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCP06|Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer|A Phase Ⅳ Randomized Clinical Trial of Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer||Peking University|Yes|Completed|October 2010|December 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|501|||Female|18 Years|65 Years|No|||June 2014|June 9, 2015|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199432||116438|
NCT01199692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPL201006A|Characterization of Metabolic Biomarkers in Varying Subjects|Characterization of Metabolic Biomarkers in Subjects of Varying Age, Gender, Ethnicity, Body Mass Distribution, Dietary Habits, Exercise Habits, Medication Requirements, and Disease State Burden||CPL Associates|No|Recruiting|August 2010|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||8|Anticipated|250|Samples With DNA|Blood, stool, urine|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects of varying age, gender, ethnicity, body mass distribution, dietary habits,        exercise habits, medication requirements and disease state burdens|January 2016|January 29, 2016|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199692||116418|
NCT01199965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0004-CL-P203|Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers|An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004) in Smoking and Non-Smoking Adult Volunteers||Allergan|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|August 5, 2010|No|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01199965||116398|
NCT01199978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-218|Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma|Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma||Massachusetts General Hospital|Yes|Recruiting|September 2010|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199978||116397|
NCT01200264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025452|Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy|Open-Label Study to Assess the Safety and Efficacy of Apremilast in Patients With Chronic Plaque Psoriasis Who Have Failed One Course of Biologic Therapy.||Duke University|No|Withdrawn|September 2010|September 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||September 2010|July 14, 2014|September 10, 2010|Yes|Yes|Contract never executed; withdrawn by sponsor|No||https://clinicaltrials.gov/show/NCT01200264||116375|
NCT01200589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113676|Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy|Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy|HOMER|Novartis|Yes|Recruiting|October 2010|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|516|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200589||116350|
NCT01195779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114294|Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children|Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months||GlaxoSmithKline||Terminated|September 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|14||Actual|4|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||June 2012|June 15, 2012|September 3, 2010|Yes|Yes|The study was terminated for logistic reasons not related to safety or efficacy of the    vaccine.|No|March 22, 2012|https://clinicaltrials.gov/show/NCT01195779||116714|
NCT01201057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-013|Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)|A Double-blind, Multi-center, Randomized, Placebo Controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel®) Administered Vaginally in the Treatment of Bacterial Vaginosis||Starpharma Pty Ltd||Completed|August 2010|May 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|132|||Female|18 Years|45 Years|No|||April 2012|April 18, 2012|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201057||116314|
NCT01201083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA022116 - A1|Study of Recently HIV Infected Men and Transmission Behaviors|Transmission Behavior in Partnerships of Newly HIV Infected Southern Californians|MetroMates|University of California, Los Angeles|No|Recruiting|February 2009|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|We collect a sample of blood/plasma and have a repository (blood) and for future analysis.      After noting that subject has consented to main study as well as consenting to have his      blood stored for later research purposes, appropriate research staff will direct the      phlebotomist to draw and additional tube of blood (approximately 7mls of blood) into a      purple cap (EDTA) tube. After processing, each sample will be securely stored at the      participating site under appropriate conditions .|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|STI/HIV testing and treatment clinic|July 2010|September 13, 2010|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01201083||116312|
NCT01201408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111015|DPBRN Longitudinal Study of Dental Restorations Placed on Previously Un-restored Surfaces|Longitudinal Study of Dental Restorations Placed on Previously Un-restored Surfaces||Dental Practice-Based Research Network|No|Completed|November 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9291|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participants directly involved in this study are the participants who have sought        dental treatment in the practitioner-investigators' practices and particpated in the DPBRN        "Reasons for placing the first restoration on permanent tooth surfaces" study.|September 2011|September 16, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201408||116287|
NCT01213368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI10939|Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation|Double Blind, Randomized, Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Dronedarone (SR33589B) at 300, 400, or 600 mg BID for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation||Sanofi|Yes|Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|181|||Both|20 Years|N/A|No|||October 2013|October 12, 2013|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01213368||115372|
NCT01215071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB 25/02|Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA|Prospektiv Randomisierte Studie Zum Vergleich Einer Ausgedehnten Mit Einer eingeschränkten Pelvinen Lymphadenektomie Bei Der Operativen Therapie Des Harnblasenkarzinoms||Association of Urogenital Oncology (AUO)|Yes|Active, not recruiting|March 2006|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01215071||115242|
NCT01212354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESC-928-MOL-0000-I|Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT|Phase III A Prospective, Randomized, Rater-blinded, Multicentre Interventional Clinical Trial. Do Selective Radiation Dose Escalation and Tumour Hypoxia Status Impact the Locoregional Tumour Control After Radiochemotherapy of Head & Neck Tumours?|Escalox|Technische Universität München|Yes|Recruiting|July 2015|September 2025|Anticipated|January 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|70 Years|No|||February 2016|February 8, 2016|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212354||115450|
NCT01212627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG-Phase 1-233|Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer|BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer||Brown University|Yes|Terminated|September 2010|April 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|September 29, 2010|Yes|Yes|Determination to stop enrollment made due to funding|No|May 20, 2015|https://clinicaltrials.gov/show/NCT01212627||115429|
NCT01211457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC682-11|Study of Sapacitabine in Acute Myeloid Leukemia (AML)|A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia||Cyclacel Pharmaceuticals, Inc.|No|Active, not recruiting|June 2010|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|70 Years|N/A|No|||November 2011|March 25, 2014|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211457||115519|
NCT01211743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1948-06|Oxidative Stress in Standard Laparoscopic vs Single Port Cholecystectomy|Study of Oxidative Stress in Standard Laparoscopic vs Single Port Cholecystectomy for Uncomplicated Cholelithiasis (Lap vs SILS)||G. Hatzikosta General Hospital|Yes|Completed|June 2010|September 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|30 Years|65 Years|No|||September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211743||115497|
NCT01212653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS_2010|Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS)|Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS|AS|Chinese University of Hong Kong|Yes|Completed|October 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||September 2014|September 10, 2014|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212653||115427|
NCT01212666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-ME-10|The Efficacy of Adductor-Canal-Block (ACB) in Patients After Anterior Cruciate Ligament (ACL) Reconstruction|The Effect of Adductor-Canal-Block (ACB) in Patients After Anterior Cruciate Ligament (ACL) Reconstruction in Day Case Surgery||Glostrup University Hospital, Copenhagen|Yes|Completed|May 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||September 2012|September 9, 2012|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01212666||115426|
NCT01213186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beijing302-001|Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients|Phase 2 Study of UC-MSC in Restoring CD4 T Cell Counts and Reducing Immune Activation in HIV-infected Patients Underlying Long-term Antiviral Therapy: a Multicenter, Does-escalating, Randomized, Double-blind, Controlled Trial.||Beijing 302 Hospital|Yes|Recruiting|January 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|65 Years|No|||May 2013|May 26, 2013|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01213186||115386|
NCT01213173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4022L00008|Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients|A Randomised, Open Label, Parallel Group, Multicentre, Phase IV Study on the Effect of 8 Weeks Succinate Metoprolol (Betaloc ZOK®) (95 - 190 mg) on Heart Rate in the Stable Angina Patients||AstraZeneca|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|75 Years|No|||August 2014|August 26, 2014|September 30, 2010||No||No|November 8, 2012|https://clinicaltrials.gov/show/NCT01213173||115387|The sample size was insufficient for the secondary endpoints. Besides, the treatment prior to study did not correlate well with 47.5 mg metoprolol succinate, but with some higher dose. last the quality control of the study needs further improvement.
NCT01199107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS10-106|Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)|||Southern Methodist University||Completed|September 2010|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|54 Years|No|||December 2014|December 8, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01199107||116463|
NCT01199445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH2010/SP02|Efficacy of Vitamin A in Fortified Extruded Rice in School Children|Efficacy of Vitamin A in Fortified Extruded Rice in School Children in Satun, Thailand||Swiss Federal Institute of Technology|No|Completed|August 2010|March 2011|Actual|November 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|50|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||June 2012|January 5, 2016|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01199445||116437|
NCT01199705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB06_002CR|Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)|A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency||CSL Behring|No|Completed|September 2010|November 2011|Actual|August 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|75 Years|No|||March 2013|November 25, 2014|September 8, 2010|Yes|Yes||No|January 1, 2013|https://clinicaltrials.gov/show/NCT01199705||116417|
NCT01199991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000462|Comparison of Xtreme CT and DXA Bone Densitometry|||Massachusetts General Hospital||Active, not recruiting|August 2010|||August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers|June 2012|June 4, 2012|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01199991||116396|
NCT01200004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0076|Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide|A Phase I Study of Epigenetic Immunomodulation Through the Use of Azacitidine, Lenalidomide, and Grifola Frondosa in Patients With Advanced Malignancy||M.D. Anderson Cancer Center|No|Terminated|April 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1|||Both|13 Years|N/A|No|||July 2013|July 31, 2013|September 9, 2010|No|Yes|Slow Accrual.|No||https://clinicaltrials.gov/show/NCT01200004||116395|
NCT01200277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZTilburg1|A Trial of Vertebroplasty for Painful Acute Osteoporotic Vertebral Fractures|A Randomised Sham Controlled Trial of Vertebroplasty for Painful Acute Osteoporotic Vertebral Fractures|VertosIV|Elisabeth-TweeSteden Ziekenhuis|No|Completed|January 2011|January 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|95 Years|No|||November 2014|November 17, 2014|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01200277||116374|
NCT01200576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10225|A Prospective Observational Study of the Clinical Performance of Zarin in Madagascar|A Prospective Observational Study of the Clinical Performance of Zarin in Madagascar||FHI 360|No|Completed|October 2010|March 2012|Actual|February 2012|Actual|N/A|Observational|N/A||1|Actual|621|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|healthy women of any age|March 2013|March 28, 2013|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200576||116351|
NCT01195792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111850|A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.|A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects With Over-Eating Behaviours.||GlaxoSmithKline|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|60 Years|No|||March 2012|August 23, 2012|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195792||116713|
NCT01196078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20322|A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan||Hoffmann-La Roche||Completed|February 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|70 Years|N/A|No|||June 2015|June 29, 2015|September 3, 2010|No|Yes||No|July 23, 2014|https://clinicaltrials.gov/show/NCT01196078||116693|
NCT01196312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA023384|Anxiety Sensitivity Treatment for Heroin Users|Novel Intervention for Drug Use and HIV Risk Among Anxiety Sensitive Heroin Users|ASTH-HR|University of Maryland||Recruiting|October 2009|September 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|60|||Both|18 Years|65 Years|No|||September 2010|September 3, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01196312||116675|
NCT01196299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040713|Imaging of Traumatic Brain Injury|Prognostic Value of MR Imaging Markers in the Assessment of Traumatic Brain Injury Patients|Imaging of TBI|University of Maryland|No|Recruiting|March 2009|June 2013|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted with head trauma ranging from mild to severe.|September 2010|September 21, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196299||116676|
NCT01214200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-0927-HINPPV-MS|High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)|High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV) for Stable Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients|HINPPV|Philips Respironics|No|Active, not recruiting|August 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|80 Years|No|||October 2012|October 23, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01214200||115308|
NCT01214499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMR-SC-02|Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina|Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina||Hospital Universitario de la Princesa|No|Recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2010|November 27, 2010|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01214499||115285|
NCT01214473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332-10 FB|Probiotics for Prevention Neonatal Infection|Prevention of Neonatal Infection in the Indian Community Setting Using Probiotics||University of Nebraska|Yes|Terminated|June 2007|November 2013|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4556|||Both|N/A|3 Days|Accepts Healthy Volunteers|||August 2014|August 23, 2014|September 30, 2010||No|DSMB stopped the study due to early effectiveness|No||https://clinicaltrials.gov/show/NCT01214473||115287|
NCT01214486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|506-10-FB|Measurement of Plasma and Intracellular Concentrations of Raltegravir|Measurement of Plasma and Intracellular Concentrations of Raltegravir in Patients Infected With Human Immunodeficiency Virus||University of Nebraska|No|Recruiting|October 2010|June 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|19 Years|N/A|No|||November 2010|November 12, 2010|September 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214486||115286|
NCT01211470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL PMX63-203|Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus|Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus||PolyMedix, Inc.|Yes|Completed|October 2010|March 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|84 Years|No|||May 2012|May 16, 2012|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211470||115518|
NCT01212068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100211|Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy|Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy||National Institutes of Health Clinical Center (CC)||Completed|September 2010|||||N/A|Observational|Time Perspective: Retrospective|||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|May 8, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212068||115472|
NCT01212640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRALI STUDY. SEMICYUC|GROUP FOR TRALI STUDY. SEMICYUC.|GROUP FOR TRALI STUDY. SEMICYUC.||Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Not yet recruiting|October 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|N/A|No|Non-Probability Sample|All patients transfused in eleven spanish intensive care units (UCI) from October 1, until        November 30, 2010. Patients with less of 18 years old, or transfused six hours before be        included in this study or seriousness patients with a length of stay <24 hrs will be        excluded.|September 2010|September 29, 2010|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212640||115428|
NCT01212952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1082|Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|MC1082: A Phase I/II Trial of Pomalidomide (CC-4047), Bortezomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Mayo Clinic|Yes|Active, not recruiting|September 2011|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212952||115404|
NCT01212939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 5100239|Revitalization of Teeth With Necrotic Pulps and Open Apexes Using Platelet-Rich Plasma|Revitalization of Teeth With Necrotic Pulps and Open Apexes Using Platelet-Rich Plasma||Loma Linda University|No|Terminated|October 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|6 Years|89 Years|No|Non-Probability Sample|All patients between the ages of 6-89|April 2014|April 3, 2014|September 29, 2010||No|No advantage seen during continued animal studies. Difficult recruitment.|No||https://clinicaltrials.gov/show/NCT01212939||115405|
NCT01213199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29088|Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars|Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.||Galderma|No|Completed|March 2011|September 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|50 Years|No|||March 2015|March 9, 2015|September 30, 2010|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT01213199||115385|
NCT01213433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|016-2010|Amodiaquine+Artesunate for Uncomplicated Malaria Treatment|Amodiaquine+Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso|ASAQ-MAL|Centre Muraz|No|Completed|October 2010|April 2011|Actual|November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|6 Months|N/A|No|||July 2015|July 29, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213433||115367|
NCT01213212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRESO|Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk|Preventing Renal Functional Abnormalities Predisposing to Chronic Kidney Disease in Abdominal Obesity: A Randomized, Parallel-Group, Pilot Study of Calorie REstriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk|CRESO|Mario Negri Institute for Pharmacological Research|No|Completed|September 2009|February 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|73|||Both|40 Years|80 Years|No|||February 2013|February 20, 2013|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213212||115384|
NCT01199458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT nr: 2010-020697-41|The Effect of an Opioid on the Lower Esophageal Sphincter During Anesthesia Induction|The Effect of Alfentanil on the Lower Esophageal Sphincter During Anesthesia Induction - a Study in Volunteers||University Hospital Orebro|Yes|Recruiting|September 2010|October 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2010|September 10, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01199458||116436|
NCT01199718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C4-09-001|Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma||Cylene Pharmaceuticals|No|Recruiting|September 2010|September 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199718||116416|
NCT01200017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-10082|Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant|An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients||University of California, San Francisco|No|Available|September 2010|September 2020|Anticipated|September 2015|Anticipated|N/A|Expanded Access|N/A|||||||Both|N/A|30 Years|No|||October 2014|October 18, 2014|September 9, 2010|No|Yes||||https://clinicaltrials.gov/show/NCT01200017||116394|
NCT01200290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13710|A Study in Patients With End-Stage Renal Disease|An Exploratory/Proof of Concept Investigation of the Safety and Pharmacodynamics of LY2127399 in HLA-Presensitized Patients With End-Stage Renal Disease Awaiting Transplantation||Eli Lilly and Company|No|Completed|April 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|September 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200290||116373|
NCT01195441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACTNUMMER 2009-017833-23|Prediction and Prevention of Preeclampsia by First Trimester Ultrasound|Prediction and Prevention of Preeclampsia by First Trimester Ultrasound|Screen-tox|Norwegian University of Science and Technology|Yes|Completed|September 2010|October 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|602|Samples With DNA|Blood samples Urine|Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|November 2013|November 29, 2013|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01195441||116740|
NCT01195454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD11627|Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®|||Sanofi|No|Completed|August 2010|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||October 2011|October 28, 2011|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195454||116739|
NCT01196091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13656|A Study of LY2127399 in Patients With Systemic Lupus Erythematosus|A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)||Eli Lilly and Company|Yes|Completed|December 2010|June 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1164|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|September 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196091||116692|
NCT01196624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeershevaMHC - 4733CTIL|Repetitive Transcranial Magnetic Stimulation With Or Without Traumatic Stimuli in Post Traumatic Stress Disorder (PTSD)|Efficacy of Repetitive Transcranial Magnetic Stimulation Right Versus Left, With or Without Traumatic Stimuli in the Treatment of Posttraumatic Stress Disorder (PTSD) and Its Flashbacks|BSPTSDTMS2010|Beersheva Mental Health Center|No|Completed|November 2008|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|11|||Both|18 Years|65 Years|No|||February 2013|February 5, 2013|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01196624||116651|
NCT01197729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTAMI|OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry|OPTAMI (Optimierte Therapie Des Akuten Myokard-Infarktes) - Register|OPTAMI|Stiftung Institut fuer Herzinfarktforschung|No|Completed|October 2005|February 2010|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|3248|||Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic|September 2010|September 7, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197729||116566|
NCT01196910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBR-0014-00|Deep Transcranial Magnetic Stimulation (DTMS) as a Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Adults|Test Efficiency of Deep Transcranial Magnetic Stimulation (DTMS) Using an H-coil for Dorso-Lateral Prefrontal Cortex (HLPFC) to Treat Attention Deficit Hyperactivity Disorder (ADHD) in Adults||Brainsway|No|Recruiting|July 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|65 Years|No|||September 2014|September 15, 2014|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01196910||116629|
NCT01196923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-2858|Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation|Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation||CardioFocus||Completed|September 2010|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||June 2012|June 19, 2012|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01196923||116628|
NCT01197196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0068-10|Behavioral Weight Loss as a Treatment for Migraine in Obese Women|Behavioral Weight Loss as a Treatment for Migraine in Obese Women||The Miriam Hospital|Yes|Recruiting|July 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197196||116607|
NCT01215396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-584|Impact of Varying Doses of Amino Acids on Exercise, Muscular and Mental Performance|Impact of Varying Doses of Amino Acids on Exercise, Muscular and Mental Performance||McMaster University|Yes|Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2010|November 1, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215396||115217|
NCT01214772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1378|The Effect of Heparin in Treatment IVF-ET Failure|the Effect of Unfractionated Heparin in Treatment of IVF-ET Failure||Yazd Medical University|Yes|Completed|May 2009|June 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|86|||Female|19 Years|35 Years|No|||October 2010|October 1, 2010|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214772||115264|
NCT01212133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3865|A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India|A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India|Lead-In|Novo Nordisk A/S|No|Completed|November 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1386|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with type 2 diabetes, including newly-diagnosed subjects, who are considered to        need treatment with liraglutide are eligible for the study|November 2014|November 13, 2014|September 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01212133||115467|
NCT01212081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910462|Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality|Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality||National Institutes of Health Clinical Center (CC)||Completed|September 2010|November 2012||||N/A|Observational|Time Perspective: Prospective|||Anticipated|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|February 19, 2014|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212081||115471|
NCT01212094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100212|Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)|Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|65 Years|No|||September 2015|October 6, 2015|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212094||115470|
NCT01212107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13843|A Study of LY2874455 in Patients With Advanced Cancer|A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.||Eli Lilly and Company|Yes|Completed|December 2010|February 2015|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Actual|94|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|September 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01212107||115469|
NCT01212120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2009/JPL-02|The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections|The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections||Centre Hospitalier Universitaire de Nīmes|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|278|Samples With DNA|The DNA samples correspond to the bacteria present in the nose and feet of diabetic      patients.|Both|18 Years|N/A|No|Non-Probability Sample|Adult type 1 or 2 diabetic patients with grade 2-4 foot or ankle ulcers (first event or        recurrence)|March 2015|March 26, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212120||115468|
NCT01212367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 18508; 808806|Intrapleural Gene Transfer for Pleural Mesothelioma|A Pilot Study of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Alpha (SCH 721015, Ad.hIFN-a2b) Gene Transfer for Malignant Pleural Mesothelioma|IFN-alpha|Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|February 2009|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|September 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01212367||115449|
NCT01221454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYS-LF|Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure|Efficacy of Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Failure Resulting From Chronic Hepatitis B||Sun Yat-sen University|Yes|Active, not recruiting|October 2010|November 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|65 Years|No|||October 2010|October 15, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01221454||114753|
NCT01213225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gerivsnot12month|Geriatric Education and Its Effect on Certain Aspects of Hospital Care of the Nursing Home Patients - 12 Month Retrospective Study|Geriatric Education and Its Effect on Certain Aspects of Hospital Care of the Nursing Home Patients - 12 Month Retrospective Study||Maimonides Medical Center|No|Completed|December 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|65 years of age and older|August 2011|August 17, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01213225||115383|
NCT01213459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111336|Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia|An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women >= 15 Years of Age, in the Kingdom of Saudi Arabia||GlaxoSmithKline||Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|420|Samples With DNA|Cervical samples|Female|15 Years|N/A|No|Non-Probability Sample|Women >=15 years of age attending out-patient departments of primary, secondary or        tertiary care centers for routine cervical screening, in the Kingdom of Saudi Arabia.|November 2012|November 21, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213459||115365|
NCT01213472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112406|Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma|Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma||GlaxoSmithKline||Active, not recruiting|January 2011|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01213472||115364|
NCT01194310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phako/ELT-12m|Longtime Efficiency of Combined Cataract-Surgery and Excimer-Laser-Trabeculotomy in Glaucoma Surgery|||University of Zurich||Terminated|January 2009|May 2010||||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|August 2010|September 17, 2010|August 31, 2010||||No||https://clinicaltrials.gov/show/NCT01194310||116826|
NCT01196104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-162|Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler|A Phase 3b, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder, Using the Gen2 Inhaler, in Combination With Insulin Glargine Versus Insulin Aspart in Combination With Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Over a 16-week Treatment Period||Mannkind Corporation|No|Terminated|September 2010|March 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||October 2014|October 21, 2014|August 30, 2010|Yes|Yes|For Business Reasons|No|July 22, 2014|https://clinicaltrials.gov/show/NCT01196104||116691|- Early termination of trial leading to small numbers of subjects analyzed.
NCT01194557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTUGA3|Introducing Rapid Diagnostic Tests Into the Private Health Sector|Introducing Rapid Diagnostic Tests Into the Private Health Sector in Uganda: a Randomised Trial Among Registered Drug Shops to Evaluate Impact on Antimalarial Drug Use||DBL -Institute for Health Research and Development|Yes|Completed|September 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2600|||Both|1 Month|N/A|No|||October 2012|October 11, 2012|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194557||116807|
NCT01194895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-2010-LV|A Trial to Evaluate the Impact of Lung-protective Intervention in Patients Undergoing Esophageal Cancer Surgery|Impact of Intraoperative Protective One-lung Ventilation in Patients Undergoing Esophagectomy : a Prospective Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Completed|August 2010|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|101|||Both|18 Years|80 Years|No|||March 2013|March 13, 2013|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01194895||116781|
NCT01195194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRES|Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.|Pilot Study of Selection of Either Calcineurin Inhibitor(CNI)-Based or CNI-free Immunosuppressive Regimen Depending on the Result of Pre-transplantation Donor-specific T-cell Reactivity Measured by Enzyme-linked Immunosorbent Spot(ELISPOT) in Standard-risk Kidney Recipients.|SIRES|Hospital Universitari de Bellvitge|Yes|Completed|March 2008|June 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||February 2014|February 24, 2014|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01195194||116759|
NCT01195467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 036|Atripla to Raltegravir Switch Study for CNS Toxicity|A Phase III, Open-label, Single Centre, Single-arm, Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Raltegravir|SSAT036|St Stephens Aids Trust|No|Completed|October 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|September 3, 2010||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01195467||116738|
NCT01195480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/09/0050|CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)|Immunotherapy With CD19ζ Gene-modified EBV-specific CTLs After Stem Cell Transplant in Children With High-risk Acute Lymphoblastic Leukaemia|CD19TPALL|University College, London|Yes|Terminated|May 2012|January 2021|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|N/A|18 Years|No|||August 2013|December 7, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195480||116737|
NCT01195493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/552|Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care|Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care|Listerine|University Hospital, Ghent|No|Active, not recruiting|February 2010|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195493||116736|
NCT01195805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2010.03.SKM|The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables|The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study.|hass|Regional Hospital Holstebro|Yes|Completed|August 2010|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|25|||Both|40 Years|70 Years|No|||March 2013|August 19, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195805||116712|
NCT01197443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071669|Parents as the Agent of Change for Childhood Obesity|Parents as the Agent of Change for Childhood Obesity|PAAC|University of California, San Diego|Yes|Completed|November 2010|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01197443||116588|
NCT01197742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sweetheart|Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction|Sweetheart: Risiko-Management Von Diabetikern Mit Akutem Myokardinfarkt|Sweetheart|Stiftung Institut fuer Herzinfarktforschung|No|Completed|October 2007|September 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2772|||Both|N/A|N/A|No|Non-Probability Sample|all consecutive patients with acute (no older than 24 h) ST-Elevation Myocardial        infarction or acute (no older than 24 h) Non-ST-Elevation Myocardial infarction.|September 2010|September 7, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197742||116565|
NCT01197989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEPSO2|Efficacy Study of TEPSO® Socks in Improving Palmoplantar Pustulosis|Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Pustulosis||Lenzi Egisto S.P.A.|No|Terminated|March 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||September 2012|September 24, 2012|September 8, 2010||No|Unable to recruit suitable subjects within a reasonable time period.|No||https://clinicaltrials.gov/show/NCT01197989||116546|
NCT01198002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11352|A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate Therapy (FLEX M)|FLEX M|Eli Lilly and Company|Yes|Completed|December 2010|January 2014|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|990|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198002||116545|
NCT01211483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U31287-A-U201|Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer|Randomized, Placebo-controlled, Double-blind Phase 1b/2 Study of U3 1287 (AMG 888) in Combination With Erlotinib in EGFR Treatment Naïve Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Chemotherapy||Daiichi Sankyo Inc.|No|Completed|August 2010|November 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|222|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211483||115517|
NCT01215708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278/06|Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus|Effect of Tamsulosin and Nifedipine on the Elimination of Fragments After Extracorporeal Shock Waves Lithotripsy in Patients With Kidney Stones - a Prospective, Double-blind and Randomized Study||University of Sao Paulo General Hospital|No|Active, not recruiting|August 2006|December 2010|Anticipated|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|N/A|No|||September 2010|October 5, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215708||115193|
NCT01215721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5720-2|Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)|Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy||University of California, Irvine|Yes|Completed|October 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|N/A|No|||December 2013|December 4, 2013|October 5, 2010||No||No|December 4, 2013|https://clinicaltrials.gov/show/NCT01215721||115192|One limitation of this study was finding a reasonable Control group. This is problematic as symptoms that definitively identify detrusor overactivity preoperatively don’t exist; hence we used pad usage 7 dys post catheter removal as a surrogate.
NCT01224782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-269|Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)|Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) Stage 3 or 4 in the Conditions of Routine Clinical Practice. A Multi-country, Multi-center Post Marketing Observational Study in Routine Clinical Use in Eastern European Countries.||AbbVie|No|Completed|October 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|N/A||1|Actual|994|||Both|18 Years|N/A|No|Non-Probability Sample|Zemplar capsules will be prescribed in usual manner in accordance with the terms of the        local marketing authorization with regards to dose, population and indication as well as        local guidelines. The decision to prescribe or not prescribe Zemplar capsules would be        made prior to entry of a subject in the study.        Medical doctors with experience in treatment of patients with chronic kidney disease (CKD)        stage 3 or 4 and secondary hyperparathyroidism (SHPT) will observe each enrolled patient        for a period of 12 months.        Follow-up of patients should enable 6 patient visits during this period.|September 2014|September 12, 2014|September 27, 2010||No||No|August 13, 2014|https://clinicaltrials.gov/show/NCT01224782||114501|
NCT01212380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09108|Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)|A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL)||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2010|||October 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212380||115448|
NCT01212679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGF-TBI|Effects of Intranasal Nerve Growth Factor for Traumatic Brain Injury|Pilot Study of Intranasal Nerve Growth Factor for Traumatic Brain Injury(TBI)||Jinling Hospital, China|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|65 Years|No|||October 2015|October 22, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01212679||115425|
NCT01221701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH073867|Treatment of Depression in Mothers in Home Visitation|Treatment of Depression in Mothers in Home Visitation|MIDIS|Children's Hospital Medical Center, Cincinnati|Yes|Completed|October 2006|February 2013|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Female|16 Years|45 Years|No|||March 2013|March 15, 2013|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221701||114734|
NCT01221714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS08-001|Toxicity and Safety Evaluation of an Omega-3 Fatty Acid and a Multivitamin and Antioxidant Nutritional Preparation|Toxicity and Safety Evaluation of an Omega-3 Fatty Acid and a Multivitamin and Antioxidant Nutritional Preparation||AmeriSciences LP|Yes|Terminated|October 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|Samples Without DNA|Blood samples will be drawn at baseline and three months to monitor hematology, blood      chemistry, and urinalysis values for major changes. CBC, Chem-17, uric acid, lipid panel,      PT/PTT, and urinalysis will be evaluated under fasting conditions.|Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 160-200 healthy volunteers at five to six study centers (25-50) per center)        will be evaluated.|January 2016|January 6, 2016|October 14, 2010||No|Ameriscience went bankrupt.|No||https://clinicaltrials.gov/show/NCT01221714||114733|
NCT01196325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0258-BE|Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy|Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy.|VEGF|University of Toronto|No|Recruiting|July 2009|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|64|||Both|35 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type 2 diabetic patients with clinically sight-threatening Diabetic Macular Edema will be        recruited from the Retina Clinics of Toronto Western Hospital.|January 2013|January 23, 2013|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196325||116674|
NCT01196637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOS-US BP JAOA|Thoracic Outlet Syndrome: Case Reports and Analysis With Ultrasound Imaging|Thoracic Outlet Syndrome: Case Reports and Analysis - Ultrasound Imaging and Pathomechanics of Brachial Plexus Compression||EMG Labs of Arizona Arthritis & Rheumatology Associates|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|6|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with upper limb symptoms of pain, numbness, tingling, or weakness,        aggravated by arm abduction; Adult patients with no upper limb symptoms|September 2010|September 8, 2010|September 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01196637||116650|
NCT01196936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08218|Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors|Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial|LDTam|University of Alabama at Birmingham|Yes|Recruiting|September 2010|May 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|230|||Female|25 Years|N/A|No|||October 2015|October 27, 2015|September 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196936||116627|
NCT01197222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|940|Evaluation of Safety and Efficacy of Using EndoClear-Endoscopic Lens Cleaning Device|Evaluation of Safety and Efficacy of Using EndoClear-Endoscopic Lens Cleaning Device||The Oregon Clinic|Yes|Completed|March 2009|March 2010|Actual|March 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|85 Years|No|||March 2009|September 8, 2010|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01197222||116605|
NCT01197235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH B- 0811/063-001|Effect of Darbepoetin in Contrast-induced Nephropathy|Prevention of Contrast-Induced Nephropathy by Darbepoetin in Patients With Chronic Kidney Disease||Seoul National University Bundang Hospital|No|Terminated|May 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|September 8, 2010||No|difficult to enroll targeted participants|No||https://clinicaltrials.gov/show/NCT01197235||116604|
NCT01198067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0972|Pomalidomide for Relapse/Refractory Waldenstrom's|Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom Macroglobulinemia||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2010|||October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|September 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01198067||116541|
NCT01197456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD POISE|Predictors of Ovarian Insufficiency in Young Breast Cancer Patients|Predictors of Ovarian Insufficiency Through Serial Exams in Young Breast Cancer Patients (POISE Study)|POISE|University of California, San Diego|No|Recruiting|September 2008|||June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Serum DNA|Female|18 Years|45 Years|No|Non-Probability Sample|Newly diagnosed breast cancer patients|June 2015|June 4, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197456||116587|
NCT01197755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00003|Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist|(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist|OSKIRA - 3|AstraZeneca|Yes|Completed|September 2010|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|323|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|September 8, 2010|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT01197755||116564|
NCT01211496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042318|The Effect of Velocity Training in Functionally Limited Elderly|High Velocity Resistance Training in Older Men and Women||University of Missouri-Columbia|No|Completed|June 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|52|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2010|October 1, 2010|December 2, 2008||No||No||https://clinicaltrials.gov/show/NCT01211496||115516|
NCT01211769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/01641-6|Effects of Omegas 3 and 6 on Alcohol Dependence|Alcohol Dependence: Study of the Possible Reduction of Compulsion by Association of Naltrexone With Poly-unsaturated Fatty Acids (PUFAs)||Federal University of São Paulo|No|Completed|February 2006|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|80|||Male|30 Years|50 Years|No|||September 2010|September 2, 2010|December 5, 2008||No||No|December 5, 2008|https://clinicaltrials.gov/show/NCT01211769||115495|
NCT01224795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX1812-304|A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.|A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.||BioCryst Pharmaceuticals|Yes|Terminated|October 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|12 Years|N/A|No|||December 2014|December 15, 2014|October 19, 2010|Yes|Yes|This study was terminated for administrative reasons|No||https://clinicaltrials.gov/show/NCT01224795||114500|
NCT01220635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34 MH083706|Middle School Matters Study|Prevention of Depression Within Salient Adolescent Contexts|MSM|Seattle Children's Hospital|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|N/A|N/A|No|||February 2014|February 13, 2014|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01220635||114816|
NCT01220622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSP-SOP-040|Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes|Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE)|NICE|Ministry of Science and Technology of the People´s Republic of China|Yes|Recruiting|October 2010|July 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|656|||Both|30 Years|80 Years|No|||October 2010|October 13, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220622||114817|
NCT01220882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120080287|Evaluation of Skeletal Maturity for Slipped Capital Femoral Epiphysis|Skeletal Age Assessment From the Olecranon For Slipped Capital Femoral Epiphysis||Rutgers, The State University of New Jersey|Yes|Recruiting|October 2008|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|8 Years|16 Years|No|||December 2013|December 24, 2013|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01220882||114797|
NCT01220895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-2009-01|Alternate Donor Study of Pre-Emptive Cellular Therapy|A Prospective Phase II Study to Investigate the Efficacy and Safety of Pre-emptive Cytomegalovirus Adoptive Cellular Therapy in Patients Receiving Allogeneic Haematopoietic Stem Cell Transplant From an Unrelated Donor|CMV-ACE/ASPECT|Cell Medica Ltd|Yes|Completed|October 2010|January 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|36|||Both|16 Years|N/A|No|||May 2014|May 14, 2014|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01220895||114796|
NCT01222000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-02|Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous|TREATMENT OF THE RECESSIVE NONBULLOUS CONGENITAL ICHTHYOSIS BY THE EPIGALLOCATECHINE CUTANEOUS||Centre Hospitalier Universitaire de Nice||Not yet recruiting|October 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|8 Years|N/A|No|||October 2010|October 15, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01222000||114711|
NCT01221155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72152|Extending Ultrasound Elastography to Manual Treatment Methods|Extending Ultrasound Elastography to Manual Treatment Methods||Canadian Memorial Chiropractic College|No|Completed|December 2007|December 2011|Actual|||N/A|Observational|Observational Model: Cohort||1|Actual|101|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: Fifteen healthy volunteers from Canadian Memorial Chiropractic College (CMCC)        community.        Group 2: 30 Subjects (15 healthy volunteers and 15 chronic low back pain)|September 2012|September 21, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01221155||114776|
NCT01221441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGC09201|Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee|A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-β1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee||TissueGene, Inc.|Yes|Completed|May 2011|October 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|70 Years|No|||January 2016|January 19, 2016|October 13, 2010|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT01221441||114754|
NCT01222234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11936|Impact of Vitamin D Therapies on Chronic Kidney Disease|Impact of Vitamin D Therapies on Monocyte Function in Chronic Kidney Disease||University of Kansas Medical Center|No|Completed|October 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|21 Years|90 Years|No|||September 2012|September 24, 2012|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01222234||114693|
NCT01195506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99025|Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)|Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)||Taipei Medical University WanFang Hospital|No|Active, not recruiting|September 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|60 Years|No|Probability Sample|patients who were diagnosed acute myeloid leukemia|October 2010|October 5, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195506||116735|
NCT01195519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99039|The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis|The Study Will Investigate the Quality of Life in PD or HD Patients||Taipei Medical University WanFang Hospital|Yes|Recruiting|September 2010|September 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|95|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|peritoneal dialysis and hemodialysis patients|April 2011|April 22, 2011|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195519||116734|
NCT01195818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081110|Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients|Effect of RAS Inhibitors on Albuminuria, Hyperfiltration and Endothelial Dysfunction in a Sickle Cell Disease Population.|RAND|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2010|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|53|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195818||116711|
NCT01195831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL 0802 CN|Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis|Multicentre, Randomized, Investigator-Blinded, Parallel-group Study to Assess the Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis.||LEO Pharma|No|Completed|September 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|65 Years|No|||March 2015|March 25, 2015|September 3, 2010||No||No|March 26, 2012|https://clinicaltrials.gov/show/NCT01195831||116710|
NCT01196117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|481-04|Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea|Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea||Medical College of Wisconsin|No|Completed|November 2004|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|90 Years|No|||April 2014|April 8, 2014|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196117||116690|
NCT01196676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3600C00001|Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451|A Phase I, Randomized, Double- Blind, Placebo- Controlled, Single-center Study, to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 Following Single Ascending Oral Dose Administration in Healthy Subjects|AZD4451 SAD|AstraZeneca|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|63|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 29, 2011|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01196676||116647|
NCT01196338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ankle|Early Weightbearing and Mobilization Versus Non-Weightbearing and Mobilization in Unstable Ankle Fractures|Early Weightbearing and Mobilization Versus Non-Weightbearing and Immobilization After ORIF of Unstable Ankle Fractures: a Randomized Controlled Trial||University of Toronto|No|Recruiting|September 2010|June 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|N/A|N/A|No|||September 2010|June 9, 2011|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01196338||116673|
NCT01196975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112963|A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults|Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older||GlaxoSmithKline||Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|1707|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 21, 2012|September 7, 2010|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT01196975||116624|Analyses of duration for solicited local and general and unsolicited adverse events were not performed. Relationship to vaccination was not computed for medically-attended adverse events. Joint pain data were collected in Canada and Mexico only.
NCT01196650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 10 003|Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep|A Double Blind, Polysomnographic, Three-Way Crossover Study to Compare the Efficacy of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep||Intec Pharma Ltd.||Completed|September 2010|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|No|||September 2010|May 2, 2011|September 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01196650||116649|
NCT01196949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC08132010A|Comparing Manipulation and Rehabilitation to Rehabilitation Only, in the Management of Chronic Ankle Instability|The Effectiveness of Combined Manipulation and Rehabilitation Versus Rehabilitation Only, in the Management of Chronic Ankle Instability||Cleveland Chiropractic College|No|Recruiting|August 2010|November 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|45 Years|No|||September 2010|September 24, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01196949||116626|
NCT01193790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43-2001|Evaluation of Coblation Channeling in Treating Chronic Tonsillitis|||Hillel Yaffe Medical Center||Not yet recruiting|January 2011|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|14 Years|70 Years|No|||September 2010|September 17, 2010|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193790||116866|
NCT01193803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC076057|Molecular Microbiology in Osteo-arthritis Infection|Interest of Molecular Biology for Diagnostic of Osteo-arthritis Infections. EE Observational Prospective Study|MOLOS|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2008|June 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Actual|229|Samples Without DNA|Detection of bacteria will be performed on sample provided from the osteoarticular      infections like articular fluids, synovial biopsies, bone biopsies, intervertebral disc,      paravertebral or epidural abscess, articular capsul...|Both|18 Years|N/A|No|Non-Probability Sample|Suspected diagnosis of osteoarticular infections included discitis, septic arthritis and        prosthetic joint infection and control patients.|May 2014|May 30, 2014|April 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193803||116865|
NCT01194115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Surgical Site Infection C-Sect|Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery|Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery|SSI|University of Cincinnati|No|Enrolling by invitation|September 2010|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|475|||Female|13 Years|N/A|No|||November 2011|November 10, 2011|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194115||116841|
NCT01194102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSNRC-2010|Fit for Function: A Community Wellness Program for Persons With Stroke|Fit for Function: A Community Wellness Program for Persons With Stroke|FFF|McMaster University|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|61|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194102||116842|
NCT01211509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLK002|Montelukast in Bronchiolitis Obliterans Syndrome|A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation|MLK002|Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2010|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||March 2015|March 4, 2015|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211509||115515|
NCT01211522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG035117-01A1|The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study|MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction|MIND-USA|Vanderbilt University|Yes|Recruiting|December 2011|July 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|561|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211522||115514|
NCT01211782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-10-006|AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)|A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)|ALERT|Accera, Inc.|No|Withdrawn||||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|55 Years|85 Years|No|||December 2012|December 3, 2012|September 24, 2010|Yes|Yes|Study never started. Study was redesgined.|No||https://clinicaltrials.gov/show/NCT01211782||115494|
NCT01221467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCam06|Closing the Loop in Youth With Type 1 Diabetes in the Home Setting|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy, Safety and Utility of Real-time Continuous Subcutaneous Glucose Monitoring Combined With Overnight Closed-loop Glucose Control in the Home Setting in Comparison With Real-time Continuous Subcutaneous Glucose Monitoring Alone in Adolescents With Type 1 Diabetes on Subcutaneous Insulin Infusion Pump Therapy.||University of Cambridge|Yes|Completed|June 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|12 Years|18 Years|No|||September 2013|September 22, 2013|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221467||114752|
NCT01221480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHO002|What Influences Patient Outcome in Obstructive Airway Disease?|Beta-Blockers Reduce Mortality and Exacerbations When Added to Stepwise Inhaled Therapy for COPD Without Adverse Effects on Lung Function.||University of Dundee|No|Completed|August 2010|October 2010||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|5977|||Both|50 Years|N/A|No|Probability Sample|COPD patients within NHS Tayside, UK|October 2010|October 19, 2010|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221480||114751|
NCT01220908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0006|Evaluation of the PneumRx Lung Volume Reduction Coil to Treat Emphysema|Evaluation of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema||PneumRx, Inc.|No|Completed|January 2008|March 2012|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|35 Years|N/A|No|||December 2010|March 11, 2014|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01220908||114795|
NCT01220921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neuropoint SD|Neurosurgery Patient Outcomes in Treating Spinal Disorders|Neurosurgery Patient Outcomes in Treating Spinal Disorders|Neuropoint SD|Greenwich Hospital|No|Completed|September 2010|September 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|198|||Both|18 Years|80 Years|No|||December 2015|December 3, 2015|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01220921||114794|
NCT01221168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProGene|Epidemiologic and Genetic Study on Familial Prostate Cancer|ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial||Centre de Recherche sur les Pathologies Prostatiques|No|Recruiting|October 1996|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|DNA extracted from blood/saliva or urine Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men with or without prostate cancer are recruited in different departments of urology or        care centers in France.        For hereditary prostate cancer, patients and their family members are referred by all        urologists from France.|February 2015|February 11, 2015|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221168||114775|
NCT01222013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571ABR22T|Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)|Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)||Hospital Santa Marcelina|No|Suspended||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|18 Years|No|||March 2013|March 25, 2013|October 15, 2010||No|Study was suspended before recruitment, due to logistic issues.|No||https://clinicaltrials.gov/show/NCT01222013||114710|
NCT01222260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ7800|Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis|Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis||Columbia University|Yes|Recruiting|June 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222260||114691|
NCT01221727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101131|The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam|The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam, a Cytochrome P450 3A4/P-gp (CYP3A4) Substrate, in Postmenopausal Osteoporotic Women||Amgen|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|45 Years|75 Years|No|||July 2014|July 18, 2014|October 14, 2010|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01221727||114732|
NCT01222221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000686559|Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma||Cancer Research UK||Completed|July 2010|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222221||114694|
NCT01195532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A29GLI60-1|An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects|An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects||Taipei Medical University WanFang Hospital|No|Recruiting|January 2010|January 2011|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Case-Crossover||2|Anticipated|40|Samples Without DNA|Plasma|Male|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Health subjects|September 2010|September 3, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195532||116733|
NCT01196130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0091|Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol|Assessment of Targeted Therapy Against Colorectal Cancer (ATTACC) Screening Protocol||M.D. Anderson Cancer Center|No|Recruiting|August 2010|||August 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Blood (16 mL) collected and archived tumor samples (primary tumor or metastatic site) from      prior surgeries or biopsies.|Both|18 Years|N/A|No|Non-Probability Sample|Patients previously treated with systemic chemotherapy for metastatic colorectal cancer.|October 2015|October 14, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196130||116689|
NCT01196364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-Kids21595_EXR2|Activity at 25% Above the Ventilation Threshold on Appetite and Food Intake in Boys|Effect of Activity at 25% Above the Ventilation Threshold on Appetite and Food Intake After a Glucose Drink in Normal Weight Boys|HIE|University of Toronto|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|19|||Male|9 Years|14 Years|Accepts Healthy Volunteers|||September 2010|September 3, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196364||116671|
NCT01196663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-thermometer-CTIL|Comparison of the Performance of TMS-thermometer With Standard Esophageal or Urine Bladder Thermometer|Clinical Evaluation of TMS (Temperature Monitoring System) Performance||Rambam Health Care Campus|No|Recruiting|April 2008|||December 2008|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|1 Month|N/A|No|||July 2010|September 21, 2010|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01196663||116648|
NCT01196962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSIS|Safety Study of Subclavian and Internal Jugular Venous Catheterization|A Randomize Controlled Trial to Compare the Complications of Subclavian and Internal Jugular Venous Catheterization in Critically Ill Patients||E-DA Hospital|Yes|Recruiting|November 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|300|||Both|20 Years|N/A|No|||August 2011|November 22, 2012|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01196962||116625|
NCT01197248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR Trial|Randomized Controlled Trial of Cystocele Plication Risks ("CPR Trial"): A Pilot Study|Randomized Controlled Trial of Cystocele Plication Risks ("CPR Trial"): A Pilot Study|CPR|Mount Sinai Hospital, Canada|No|Completed|February 2009|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|75 Years|No|||August 2011|August 2, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01197248||116603|
NCT01197469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008CV17|Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?|Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension?||University of Dundee|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|35 Years|85 Years|No|||November 2012|November 5, 2012|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01197469||116586|
NCT01197482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ 109/09|Inhaled Steroids and Control of Severe Asthma|Inhaled Steroids and Control of Severe Asthma: Comparison of the AKITA Technology Versus Conventional MDI (INHALE)|INHALE|University of Giessen|No|Recruiting|September 2010|December 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Probability Sample|Patients with severe persistent asthma|December 2015|December 14, 2015|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01197482||116585|
NCT01197495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JULIDO-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2010|||||N/A|N/A|N/A||||||||||||||April 7, 2015|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01197495||116584|
NCT01197768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F080428013|A Multi-Component Behavioral Nutrition Intervention for Homebound Elderly|A Multi-Component Behavioral Nutrition Intervention for Homebound Older Adults|MCBNIHE|University of Alabama at Birmingham||Completed|September 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|65 Years|N/A|No|||October 2011|October 12, 2011|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01197768||116563|
NCT01198054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LENA-LMA-5|LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)|PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5||PETHEMA Foundation|Yes|Terminated|January 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|July 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198054||116542|
NCT01193816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 070106|Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning|Assessment of Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning|Sevralox|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2011|July 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||July 2012|July 17, 2014|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01193816||116864|
NCT01194128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR009573|Facilitating Caregiver Adaptation to Patient Institutionalization|Intervention to Facilitate Family Caregiver Adaptation to Nursing Home Transition|FACTS|University of Pittsburgh|Yes|Completed|January 2008|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Both|21 Years|N/A|No|||November 2015|November 30, 2015|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194128||116840|
NCT01194401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22928|An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)|A Prospective, Non-interventional Multi-center Observational Study to Evaluate the Long-term Effectiveness and Safety of Tocilizumab in Patients With Active Rheumatoid Arthritis in Daily Practice||Hoffmann-La Roche||Active, not recruiting|February 2010|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3404|||Both|18 Years|N/A|No|Probability Sample|Patients with inadequate response or intolerant to DMARDs and anti-TNF|March 2016|March 1, 2016|September 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01194401||116819|
NCT01223989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP 753|Bread in Overweight/Obesity Treatment|Evaluation of the Utility of an Hypocaloric Diet With or Without Bread in Overweight/Obesity Treatment||Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|No|Completed|March 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Female|18 Years|N/A|No|||October 2010|October 18, 2010|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01223989||114562|
NCT01224002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910215|A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine|A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2010|November 2012||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|65 Years|No|||November 2012|November 20, 2012|October 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224002||114561|
NCT01211795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 79,629|Topical Intra-Oral Ketoprofen for Migraine Prevention|Phase III Double Blind Randomized Placebo Controlled Trial Using 20% Intra-Oral Ketoprofen Gel for Migraine Prevention.||Behar, Caren, M.D.|Yes|Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|67|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 4, 2011|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211795||115493|
NCT01211808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV203-002|Effect of Diltiazem on Pharmacokinetics of BMS-914392|Effect of Diltiazem on the Pharmacokinetics of BMS-914392 and on Heart Rate After Single-dose Administration of BMS-914392 in Healthy Subjects||Bristol-Myers Squibb|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 1, 2011|September 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01211808||115492|
NCT01221194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW - 7R01DK070046-04|Therapeutic Stockings to Prevent Foot Ulcers|Therapeutic Stockings to Prevent Foot Ulcers||University of Texas Southwestern Medical Center|No|Recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2010|October 13, 2010|October 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221194||114773|
NCT01221493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-320|EBUS Guided Cryo Biopsy of Solitary Pulmonary Nodules|||Heidelberg University|Yes|Recruiting|April 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|40 Years|80 Years|No|||March 2010|October 14, 2010|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221493||114750|
NCT01221740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-00977/1|Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran|Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran||Brigham and Women's Hospital|No|Recruiting|August 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||October 2010|January 18, 2011|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221740||114731|
NCT01221753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-038|Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study|A Phase II Study of Docetaxel/Cisplatin/5-Fluorouracil (TPF) Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Using a Modified Radiation Dose in Patients With Newly Diagnosed HPV Positive, Locally Advanced Squamous Cell Carcinoma of the Oropharynx||Dana-Farber Cancer Institute|Yes|Withdrawn|September 2010|September 2015|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|September 21, 2010|Yes|Yes|Due to slow accrual|No||https://clinicaltrials.gov/show/NCT01221753||114730|
NCT01222520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.36|Telmisartan 80mg Non-responder Trial|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg+ Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 80 mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg Monotherapy||Boehringer Ingelheim||Completed|October 2010|||June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|174|||Both|20 Years|N/A|No|||January 2014|June 17, 2014|October 15, 2010||||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01222520||114671|
NCT01222247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL98354-HD36801-ALPS|Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial|Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial|ALPS|The George Washington University Biostatistics Center|Yes|Completed|October 2010|October 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|2831|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222247||114692|
NCT01196351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-Kids21595_EXR1|Activity at Ventilation Threshold on Appetite and Food Intake in Boys|Effect of Activity at the Ventilation Threshold on Appetite and Food Intake After a Glucose Drink in Normal Weight, Overweight and Obese Boys|VeT|University of Toronto|No|Completed|October 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|35|||Male|9 Years|14 Years|Accepts Healthy Volunteers|||September 2010|September 3, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196351||116672|
NCT01196390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02601|Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer|A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|||August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|591|||Both|18 Years|N/A|No|||November 2015|March 24, 2016|September 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196390||116669|
NCT01196988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113275|Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children|Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children||GlaxoSmithKline||Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3027|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||April 2013|March 23, 2015|September 7, 2010|Yes|Yes||No|December 17, 2012|https://clinicaltrials.gov/show/NCT01196988||116623|
NCT01197001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-ALOS-101|A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan|A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|August 2010|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 26, 2011|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197001||116622|
NCT01197014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-ALOS-102|A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan|A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|September 2010|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 26, 2011|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197014||116621|
NCT01197261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN2503|OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)|An Exploratory, Randomised, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Assess the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets (OXN PR) Compared to Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome.||Mundipharma Research GmbH & Co KG||Completed|September 2010|June 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|N/A|No|||July 2013|July 23, 2013|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197261||116602|
NCT01197508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00005|A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.|A Multicenter, Randomized, Double-Blind Parallel Group Placebo-Controlled Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressants in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy||AstraZeneca||Completed|September 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|696|||Both|18 Years|65 Years|No|||March 2014|March 14, 2014|September 8, 2010|Yes|Yes||No|June 26, 2012|https://clinicaltrials.gov/show/NCT01197508||116583|
NCT01197781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00011|Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers|An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers When Fostamatinib Disodium 150 mg is Administered Alone and in Combination With Verapamil||AstraZeneca||Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 19, 2010|September 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01197781||116562|
NCT01197794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00008|Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients|A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients|Sweapea|AstraZeneca|No|Completed|October 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|1144|||Both|18 Years|N/A|No|||October 2013|October 11, 2013|September 8, 2010|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT01197794||116561|
NCT01198080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-003|Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head|Bone Marrow Derived CD133+ Stem Cells Transplantation in Femoral Head Osteonecrosis||Royan Institute|Yes|Completed|August 2009|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||April 2009|August 27, 2013|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198080||116540|
NCT01194141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0652|Exercise Training in Barth Syndrome|Safety and Efficacy of Aerobic Exercise Training in Barth Syndrome||Washington University School of Medicine|Yes|Completed|July 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|15 Years|30 Years|No|||December 2013|December 18, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01194141||116839|
NCT01194167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCC-H1|Study of Eltrombopag in Platelet Refractory Thrombocytopenia|A Phase II Study of Eltrombopag in Platelet Refractory Thrombocytopenia||University of Cincinnati||Withdrawn|August 2010|||August 2012|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 8, 2012|August 25, 2010|Yes|Yes|Inability to identify eligible patients|No||https://clinicaltrials.gov/show/NCT01194167||116837|
NCT01194414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA22762|A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind, Parallel Group Study Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis||Hoffmann-La Roche||Completed|September 2010|June 2013|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1262|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|September 1, 2010|Yes|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT01194414||116818|
NCT01194635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000683306|Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy|Molecular Correlates of Response to C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck (E3303): A Phase II Trial of Eastern Cooperative Oncology Group||National Cancer Institute (NCI)||Not yet recruiting|September 2010|||February 2012|Anticipated|N/A|Observational|N/A|||Anticipated|69|||Both|18 Years|N/A|No|||September 2010|September 2, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194635||116801|
NCT01194648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000684020|High-Intensity Focused Ultrasound in Treating Patients With Localized Prostate Cancer|A Multi-Center Prospective Single Arm Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound (Sonablate 500) for Localized Prostate Cancer||National Cancer Institute (NCI)||Recruiting|November 2010|||June 2014|Anticipated|Phase 2|Interventional|Primary Purpose: Treatment|1||Anticipated|272|||Male|N/A|N/A|No|||November 2010|August 23, 2013|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194648||116800|
NCT01224262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIQC10-001|A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001|A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older.|LIfT|Liquidia Technologies, Inc.||Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|152|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 25, 2013|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224262||114541|
NCT01224249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCS-53227244|Selenium Status Measured in Blood After a Higher Intake of Fish and Shellfish - a Randomized Dietary Intervention Study|Selenium Status Measured in Blood After a Higher Intake of Fish and Shellfish - a Randomized Dietary Intervention Study||Danish Cancer Society|Yes|Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|102|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||August 2011|September 28, 2011|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224249||114542|
NCT01224509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP3 receptors|The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors|Cervical Prostaglandin EP3 Receptor mRNA Expression 48 Hours After Administration of Mifepristone|EP3|University of Southern California|No|Terminated|September 2004|March 2005|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Female|18 Years|N/A|No|||October 2010|October 19, 2010|October 18, 2010|No|Yes|Longer than expected recruitment period.|No||https://clinicaltrials.gov/show/NCT01224509||114522|
NCT01221766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-163|Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease|The Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease||Dana-Farber Cancer Institute|Yes|Completed|September 2010|October 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|The research subject population is children who have received hematopoietic stem cell        transplant and developed chronic graft-versus-host disease. All children seen at the        pediatric GVHD clinic at the Dana-Farber Cancer Institute will be recruited.|March 2015|March 27, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221766||114729|
NCT01221506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 34809|Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)|Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|October 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|October 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221506||114749|
NCT01222286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2101-203|Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma|Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)|KIRMONO|Innate Pharma|No|Completed|September 2010|January 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||April 2014|April 11, 2014|October 8, 2010|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01222286||114689|
NCT01222299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00032|Safety and Efficacy of Bepotastine Besilate Nasal Product in Seasonal Allergic Rhinitis Patients|||Bausch & Lomb Incorporated|Yes|Completed|May 2010|August 2010|Actual|August 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|89|||Both|18 Years|65 Years|No|||December 2013|December 4, 2013|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222299||114688|
NCT01213810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCS 610|Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study|||University of Zurich|Yes|Withdrawn|December 2010|June 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01213810||115338|
NCT01213823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851024|Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins|Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins||Pfizer|No|Terminated|September 2008|May 2011|Actual|May 2011|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|536|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|Acute-care inpatients aged 18 years or older, with at least one dose of echinocandin        antifungal therapy during the hospitalization and a primary or secondary ICD-9 discharge        diagnosis of invasive candidiasis / candidemia identified in the Premier's PerspectiveTM        Comparative Database (PCD) from 01 June 2006 to 30 June 2008.|January 2016|January 4, 2016|September 30, 2010|No|Yes|The study was terminated on May 5, 2011, due to methodological issues. The decision to    terminate the study was not based on any safety or efficacy concerns.|No|April 9, 2012|https://clinicaltrials.gov/show/NCT01213823||115337|Study results were invalidated due to lack of temporality, a critical methodological element of the study that was never established for the majority of the cases of severe hepatic injury.
NCT01222273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09090370|Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis|Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis||University of Pittsburgh|No|Completed|September 2010|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|16 Years|N/A|No|||June 2012|January 8, 2016|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222273||114690|
NCT01196689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00021|Pharmacokinetics in Adolescents|An Open, Single Centre, Phase I Study in Male Adolescents With Asthma, Aged 12 to 17 Years, to Assess Pharmacokinetics of Orally Administered AZD1981 Tablets 100 mg Twice Daily for 61/2 Days|PEAK|AstraZeneca|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Male|12 Years|17 Years|No|||March 2011|March 4, 2011|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01196689||116646|
NCT01197274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186/2553(EC4)|Comparison of Simple Blood Lancet(Vitrex®)With DuoTip as Skin Prick Test Devices Among Mite-sensitized Subjects|Comparison of Simple Blood Lancet(Vitrex®)With DuoTip as Devices for Skin Prick Test Among Mite-sensitized Subjects||Siriraj Hospital|Yes|Completed|June 2010|August 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|42|||Both|12 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who have positive skin prick testing to Der p 10,000 AU/ml (wheal size 3 mm at        least)|June 2010|September 8, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197274||116601|
NCT01197521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00001|Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.|(OSKIRA-1): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|OSKIRA - 1|AstraZeneca|Yes|Completed|September 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|923|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|September 8, 2010|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT01197521||116582|
NCT01197807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 001|Oronasopharyngeal Suction Versus Simple Nose and Mouth Wiping in Term Newborns|Newborn Resuscitation: A Randomized Controlled Trial of Oronasopharyngeal Suction Versus Simple Nose and Mouth Wiping in Term Newborns|TermWIPE|University of Alabama at Birmingham|Yes|Completed|November 2010|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|506|||Both|N/A|1 Minute|No|||August 2012|August 12, 2012|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01197807||116560|
NCT01197820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/11|Hepatic and Renal Thermography Using Magnetic Resonance Imaging|Hepatic and Renal Thermography Using Magnetic Resonance Imaging|THeR-IRM|University Hospital, Bordeaux|No|Terminated|September 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01197820||116559|
NCT01198093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-02-008|Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD)|Clinical Research Center for Dementia of South Korea (CREDOS)|CREDOS|Samsung Medical Center|Yes|Recruiting|November 2005|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Serum, plasma and DNAs were prepared|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Patient populatin who is suffering from memory impairment          2. Normal subjects matched with age and gender|September 2012|September 26, 2012|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198093||116539|
NCT01198119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-CAB-0907|Excision Limits of Oral Cavity Tumor by Narrow Band Imaging|Excision Limits of Oral Cavity Tumor by NARROW BAND IMAGING (NBI): Feasibility Trial||Centre Oscar Lambret|No|Terminated|July 2010|July 2012|Actual|March 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|September 8, 2010||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01198119||116537|
NCT01193829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK05/16/10|Development of Circulating Tumour Cell Molecular Diagnostics Using a Novel Microfluidic Device|||National University Hospital, Singapore|No|Recruiting|September 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30||Blood will be collected for circulating tumor cells (CTC) using previously optimized methods      described by Tan et al. DNA will be extracted from CTC and matching tumor samples (for aim      1) and tested for somatic lung mutations by direct sequencing (2). Germline DNA will be      analysed for genes related to putative genetic risks for NSCLC and, for treatment      toxicities, for genes related to gefitinib and other chemotherapy metabolic pathways.|Both|21 Years|N/A|No|Non-Probability Sample|Hospital patients|April 2014|April 24, 2014|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193829||116863|
NCT01193868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-01989|RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy|Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Terminated|September 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2013|October 15, 2015|September 1, 2010|Yes|Yes|Study drug production halted.|No|October 15, 2015|https://clinicaltrials.gov/show/NCT01193868||116860|The study closed June 2012 with the NCI discontinuation production of the study drug RO4929097.
NCT01194427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J09144|A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer|A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Terminated|March 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Female|18 Years|N/A|No|||May 2013|May 15, 2013|March 25, 2010|No|Yes|Difficulty meeting patient accrual goals|No|March 18, 2013|https://clinicaltrials.gov/show/NCT01194427||116817|Unable to recruit participants to complete the study.
NCT01194440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1022|Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms|A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial||Sidney Kimmel Comprehensive Cancer Center|No|Completed|February 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|59|||Female|18 Years|N/A|No|||May 2014|May 12, 2014|August 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01194440||116816|
NCT01194661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100185|Neural Dynamics and Connectivity in Response Inhibition and Traumatic Brain Injury|Neural Dynamics and Connectivity in Response Inhibition and Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Recruiting|August 2010|||||N/A|Observational|N/A|||Anticipated|285|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|February 9, 2016|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194661||116799|
NCT01194674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100186|Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema|Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema|MIME|National Institutes of Health Clinical Center (CC)|No|Terminated|January 2011|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|September 2, 2010|No|Yes|Lack of enrollment.|No|July 10, 2012|https://clinicaltrials.gov/show/NCT01194674||116798|The study was terminated early due to lack of enrollment.
NCT01194687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910107|Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses|Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses||National Institutes of Health Clinical Center (CC)||Completed|April 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|100|||Both|18 Years|99 Years|No|||October 2015|November 3, 2015|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194687||116797|
NCT01195038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPIP501-01b|Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults|A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine||UMN Pharma Inc.|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|87|||Both|21 Years|41 Years|Accepts Healthy Volunteers|||February 2011|February 7, 2011|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195038||116771|
NCT01220934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22834|An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer|Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES)||Hoffmann-La Roche||Active, not recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|443|||Both|18 Years|N/A|No|Probability Sample|Gastric cancer patients receiving Herceptin in routine clinical practice|March 2016|March 1, 2016|September 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01220934||114793|
NCT01220947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV22776|A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection|||Hoffmann-La Roche||Completed|November 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|5||Actual|421|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220947||114792|
NCT01224522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11025-2|Axial Alignment in Patients Operated Using the Visionaire Patient Matched Cutting Blocks|PATIENT-MATCHED INSTRUMENTATION Versus (vs) STANDARD INSTRUMENTATION: A RANDOMIZED CLINICAL TRIAL COMPARING POSTOPERATIVE AXIAL ALIGNMENT and COMPONENT POSITION|Visionaire|Smith & Nephew, Inc.|No|Terminated|March 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|40 Years|75 Years|No|||April 2015|April 13, 2015|October 14, 2010||No|protocol deviations|No||https://clinicaltrials.gov/show/NCT01224522||114521|
NCT01213030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX4-FMISO|Clinical Evaluation of the New Hypoxia Imaging Agent HX4|Clinical Evaluation of the New Hypoxia Imaging Agent HX4||Siemens Molecular Imaging|Yes|Completed|June 2009|May 2010|Actual|January 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|12|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|August 14, 2009||No||No||https://clinicaltrials.gov/show/NCT01213030||115398|
NCT01222026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr 214/2008|Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate|Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I||Medical University of Vienna|No|Completed|September 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222026||114709|
NCT01213537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0706/5|Cardiac Resynchronisation Study|A Study of the Effect of Cardiac Resynchronisation Therapy (CRT) on Chemosensitivity in Patients With Chronic Heart Failure With and Without Sleep Disordered Breathing.||Imperial College London|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|182|||Both|18 Years|N/A|No|Probability Sample|Patients with Chronic Heart Failure who fulfil the current national guidelines for CRT        insertion (see inclusion criteria)|October 2015|October 21, 2015|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213537||115359|
NCT01214694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B090010--02|Internet-based Interacting Together Everyday, Recovery After Childhood TBI (I-InTERACT)--RRTC|Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions--Internet-based Interacting Together Everyday, Recovery After Childhood TBI|I-InTERACT|Children's Hospital Medical Center, Cincinnati|Yes|Completed|October 2009|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|117|||Both|3 Years|9 Years|No|||March 2016|March 7, 2016|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214694||115270|
NCT01222897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216_VALAC_09|A Relative Bioavailability Study of Valacyclovir Hydrochloride Tablets 1gm Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Valacyclovir Hydrochloride Tablets 1 Gram of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With VALTREX® Caplets 1 Gram (Containing Valacyclovir Hydrochloride 1 Gram) of GlaxoSmithKline in Healthy, Adult, Male, Human Subjects Under Fed Condition.||Ranbaxy Inc.|No|Completed|May 2009|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 15, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222897||114642|
NCT01214096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-01-302|Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure|A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure||Zensun Sci. & Tech. Co., Ltd.|Yes|Suspended|July 2010|June 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||July 2012|July 18, 2012|September 28, 2010||No|The same protocol has been launched in United States.|No||https://clinicaltrials.gov/show/NCT01214096||115316|
NCT01197027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN062|Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection|Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection|HPTN062|HIV Prevention Trials Network|No|Completed|February 2010|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197027||116620|
NCT01197287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAK423A2101|Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-blind, Placebo-controlled Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of QAK423 in Healthy Subjects and COPD Patients and Multiple, Titrated Dosing in COPD Patients||Novartis||Completed|May 2004|||February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|76|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2010|September 16, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197287||116600|
NCT01197300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446H2337E1|1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions|A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions.||Novartis||Recruiting|October 2010|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|6 Years|19 Years|No|||March 2016|March 3, 2016|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197300||116599|
NCT01197534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00002|Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.|(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs|OSKIRA - 2|AstraZeneca|Yes|Completed|September 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|913|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|September 8, 2010|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT01197534||116581|
NCT01197833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV017|Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities|A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolve™ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities|017|BTG International Inc.|Yes|Completed|September 2010|December 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|117|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|September 8, 2010|Yes|Yes||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01197833||116558|
NCT01198106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|792-2008-IDF-CTIL|A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness|A Double-blind Randomized Placebo Controlled Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness||Medical Corps, Israel Defense Force|No|Recruiting|September 2009|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|100|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||September 2010|September 8, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198106||116538|
NCT01193842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02508|Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas|A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)|No|Recruiting|October 2010|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2016|March 18, 2016|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193842||116862|
NCT01193855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000684018|Dutasteride in Treating Patients With Prostate Cancer|Single Site, Phase II, Double Blind, Randomized, Placebo Controlled Study of the Effect of Dutasteride (Avodart) 0.5mg on the Volume and Characteristics of Prostate Cancer, as Assessed by Multifunctional Magnetic Resonance Imaging (MRI) With Lower Risk Prostate Cancer Suitable for Active Surveillance. (MAPPED TRIAL)||National Cancer Institute (NCI)||Recruiting|June 2010|||January 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|42|||Male|N/A|80 Years|No|||August 2011|August 23, 2013|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193855||116861|
NCT01194154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22916|A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)|A Randomized Controlled, Single-blind, Proof-of-concept-study to Investigate the Protective Effects of Early Treatment With C.E.R.A. in Patients With Chronic Kidney Disease on Renal Disease Progression (PRIMAVERA-Study)||Hoffmann-La Roche||Completed|September 2010|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|August 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194154||116838|
NCT01198652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04|Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program|Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program||Glenveigh Medical|No|Terminated|September 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|300|||Female|N/A|N/A|No|Non-Probability Sample|Patients who have received treatment with the BD-OTS as part of their standard of care in        hospital.|March 2013|March 4, 2013|September 9, 2010|No|Yes|Study discontinued following 57 subjects enrolled over 2 years|No||https://clinicaltrials.gov/show/NCT01198652||116496|
NCT01199315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1950C00013|A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 in Young and Elderly Healthy Japanese Volunteers After Oral Single and Repeated Doses||AstraZeneca|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2011|February 16, 2011|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199315||116447|
NCT01199328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00011|Study to Evaluate the Interaction Between Aspirin and Nexium|A Phase I, Open, Two-way Crossover, Drug-drug Interaction Study Evaluating the Effect of Esomeprazole on the Pharmacodynamics of Acetylsalicylic Acid After 5 Days of Treatment||AstraZeneca|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2010|November 18, 2010|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199328||116446|
NCT01199341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00017|A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin|A Phase I, Open Label, Randomised, Parallel Group Study of Repeated Oral Doses of AZD1981 (100 mg Twice Daily and 400 mg Twice Daily) for Two Weeks and Single Doses of Warfarin (25 mg) to Evaluate the Pharmacokinetic Interaction of AZD1981 and Warfarin and the Effect of AZD1981 on Warfarin Pharmacodynamics in Healthy Male Volunteers||AstraZeneca|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 8, 2011|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199341||116445|
NCT01199874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATH HS534|Immunogenicity of Rotavirus Vaccine|The Immunogenicity of Rotavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding Around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine||PATH|No|Completed|April 2011|June 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|1140|||Both|6 Weeks|18 Weeks|Accepts Healthy Volunteers|||August 2013|August 28, 2013|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199874||116405|
NCT01200160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-055|Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America|Post-Marketing Observational Study on the Effectiveness and Safety of Niaspan® in the Treatment of Lipid Abnormalities in Latin America||Abbott||Completed|February 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|May 2014|May 15, 2014|September 10, 2010||No||No|April 29, 2013|https://clinicaltrials.gov/show/NCT01200160||116383|Expected sample size was not achieved due to supply issues with the new formulation in Mexico and the local decision in Colombia to cancel marketing the product in the country.
NCT01220661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-485|Safety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery|Phase 2 Study of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery||National Cancer Center, Korea|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|312|||Both|18 Years|80 Years|No|||December 2011|December 11, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220661||114814|
NCT01221181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2403|Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy|Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy||Columbia University|Yes|Active, not recruiting|August 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||February 2014|February 5, 2014|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221181||114774|
NCT01213550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-DIS-27|Effects Of Chlorhexidine Mouthrinse On Peridontopathogens: A Randomized, Placebo-Controlled Study|||Ege University|No|Completed|March 2006|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|N/A|2||Actual|50|||Both|18 Years|45 Years||||October 2010|October 1, 2010|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213550||115358|
NCT01213836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00082|Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia|A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR®) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroquel XR®) Dosed Once Daily in the Evening in Patients With Stable Schizophrenia|eXtRa|AstraZeneca|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|50 Years|No|||May 2012|June 21, 2012|October 1, 2010|Yes|Yes||No|May 15, 2012|https://clinicaltrials.gov/show/NCT01213836||115336|
NCT01213316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-145|A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)|A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany|WIP|Merck Sharp & Dohme Corp.|No|Completed|October 2010|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|451|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with confirmed HIV-1 infection|May 2015|May 11, 2015|September 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01213316||115376|
NCT01214408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-576|Effect of Digene Total (Buffered Pantoprazole) on 24 Hour Gastric Potential Hydrogen (pH) in Patients From Acid Peptic Disorder After Single and Repeated Dosing.|Effect of Digene Total on 24 Hrs Ambulatory Gastric ph in Pts Suffering From Acid Peptic Disorder After Single and Repeated Dosing.||Abbott|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||December 2012|December 26, 2012|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01214408||115292|
NCT01214421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08-271|Open-Label Tolvaptan Study in Subjects With ADPKD|Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|TEMPO 4/4|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Active, not recruiting|May 2010|March 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1500|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|September 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214421||115291|
NCT01214434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC0903|Promiseb Topical Cream for Cradle Cap|A Double Blind, Placebo-Controlled, Pilot Study to Estimate the Efficacy and Tolerability of Twice Daily Promiseb Topical Cream in Pediatric Subjects With Cradle Cap (Seborrheic Dermatitis)||Promius Pharma, LLC|No|Completed|March 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|N/A|N/A|No|||July 2013|September 17, 2013|September 28, 2010||No||No|July 8, 2013|https://clinicaltrials.gov/show/NCT01214434||115290|Small number of subjects enrolled and analyzed.
NCT01214447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/10|Validity and Reproducibility of OSND (Objective Score of Nutrition on Dialysis) as a Nutritional Marker in End-stage Renal Disease|||Assaf-Harofeh Medical Center||Recruiting|October 2010|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|300 stable chronic hemodialysis patients receiving maintenance hemodialysis treatment in        our dialysis unit (nephrology division, Assaf Harofeh Medical Center) and in 2 satellite        hemodialysis units (Nephromor, Rishon Lezion and Afek, Ramla).|September 2010|October 4, 2010|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01214447||115289|
NCT01214109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.665|Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers|A Multiple Dose Bioequivalence Study of Pramipexole With Increasing Doses (0.375mg to 1.5mg q.d.) of Oral Extended Release (ER) Tablet in Two-way Cross-over Comparison of 0.375mg Extended Release Tablet q.d. Versus 0.125mg Immediate Release (IR) Tablet t.i.d and 1.5 mg Extended Release Tablet q.d. Versus 0.5mg Immediate Release Tablet t.i.d. in Chinese Healthy Male Volunteers||Boehringer Ingelheim||Completed|December 2010|||January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2014|June 17, 2014|October 1, 2010||||No|January 25, 2012|https://clinicaltrials.gov/show/NCT01214109||115315|
NCT01214395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-199|Nasal Tea Tree Oil for the Prevention of Infections in PD Patients|An Investigator Blinded Controlled Study of the Nasal Application of 5% Tea Tree Oil (TTO) for the Prevention of Catheter-associated Infections in Renal Dialysis Patients||PathWest Laboratory Medicine WA|No|Completed|June 2010|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|5|||Both|18 Years|80 Years|No|||June 2012|June 22, 2012|October 4, 2010||No||No|May 14, 2012|https://clinicaltrials.gov/show/NCT01214395||115293|
NCT01197040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071226|Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome|Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome|MSN|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2009|June 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197040||116619|
NCT01201785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFJ 2008-88|Aspirin Dosing in Diabetic Patients|Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease||University of Florida|Yes|Completed|January 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|75 Years|No|||March 2012|March 5, 2012|September 3, 2010||No||No|October 31, 2011|https://clinicaltrials.gov/show/NCT01201785||116258|
NCT01202084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 065|A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients|A Phase III, Randomized, Open-label, Non-inferiority Study Comparative of Formoterol/Fluticasone Eurofarma 12/250 µg, Foraseq® 12/400 µg and Fluticasone 500 µg in Asthma Patients||Eurofarma Laboratorios S.A.|Yes|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|222|||Both|12 Years|N/A|No|||May 2012|June 17, 2015|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202084||116235|
NCT01202370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-MULTI-09-MCC|A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies|A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies||University of Kentucky|Yes|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202370||116213|
NCT01202383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH224|Double-blinded Trial of Household-based Chlorination in India|Household-based Chlorination of Drinking Water to Prevent Diarrhoeal Disease: a Randomized, Placebo-controlled Trial in India Using Sodium Dichloroisocyanurate (NaDCC) Tablets||London School of Hygiene and Tropical Medicine|Yes|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2163|||Both|N/A|N/A|No|||June 2013|June 18, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202383||116212|
NCT01202643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09012010-01|Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF|G-CSF and Endometrial Growth, Embryo Implantation and Pregnancy Following FET or Donor ET||Center for Human Reproduction|Yes|Terminated|September 2010|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|September 14, 2010||No|Insufficient recruitment|No|May 18, 2014|https://clinicaltrials.gov/show/NCT01202643||116192|
NCT01198379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTCGHTN01|Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients|Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|Yes|Recruiting|February 2010|February 2013|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|80 Years|No|||February 2010|September 23, 2010|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01198379||116517|
NCT01198392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005L02859|Trial of S-1 Plus Cisplatin in Gastric Cancer|A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer||Sun Yat-sen University|Yes|Recruiting|September 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|75 Years|No|||August 2008|July 22, 2011|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01198392||116516|
NCT01198938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN090334B|Postoperative Melatonin Administration and Delirium Prevention in Patients Undergoing Vascular and Cardiac Surgery|Postoperative Melatonin Administration and Delirium Prevention in Patients Undergoing Vascular and Cardiac Surgery||University Health Network, Toronto|No|Completed|August 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|100|||Both|60 Years|N/A|No|||February 2013|February 21, 2013|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198938||116474|
NCT01199900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9391006|Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism|An Open Label Study Evaluating The Effect Of Single Doses Of PF-04171327 And Prednisone On Carbohydrate Metabolism Utilizing An Oral Glucose Tolerance Test In Healthy Adult Subjects||Pfizer|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 16, 2010|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199900||116403|
NCT01200173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU206|Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers|Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers||Danone Research||Completed|October 2006|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Basic Science|2||||||Both|3 Years|6 Years|Accepts Healthy Volunteers|||September 2010|October 5, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200173||116382|
NCT01200186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15217|Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction|Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction||Bayer|No|Completed|October 2010|October 2014|Actual|February 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3258|||Female|18 Years|50 Years|No|Non-Probability Sample|Women in gynecological practice|October 2015|October 15, 2015|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01200186||116381|
NCT01221207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTSW - 7R01DK074483-04|Instant Total Contact Cast to Heal Diabetic Foot Ulcers|Instant Total Contact Cast to Heal Diabetic Foot Ulcers|ITCC|University of Texas Southwestern Medical Center|Yes|Recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||October 2010|October 15, 2010|October 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221207||114772|
NCT01221519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00033|A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients|Randomized, Open, 4-way Crossover, Single Center, Phase I Relative Bioavailability Study in Type 2 Diabetes Mellitus Patients to Measure the Extent and Rate of Absorption of AZD1656 From Different Tablet Formulations||AstraZeneca|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|October 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221519||114748|
NCT01220960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-049-PSY|Art Therapy Intervention for Breast Cancer Patients|A Mixed Methods Approach to Evaluating How Art Therapy Can Benefit Women Recently Diagnosed With Breast Cancer||McGill University Health Center|Yes|Completed|August 2010|October 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Female|18 Years|N/A|No|||October 2013|October 24, 2013|October 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01220960||114791|
NCT01221532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHHE2010|Support From Hospital to Home for Elders: A Randomized Controlled Study|Support From Hospital to Home for Elders: A Randomized Controlled Study|SHHE|University of California, San Francisco|No|Completed|July 2010|July 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|699|||Both|55 Years|N/A|No|||July 2013|July 5, 2013|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221532||114747|
NCT01213563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/808|Management of Type 2 Diabetes After Gastric Bypass Surgery|Protocol Driven Management of Type 2 Diabetes After Gastric Bypass Surgery||Imperial College London|No|Completed|January 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|70 Years|No|||October 2010|February 26, 2016|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213563||115357|
NCT01213849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102932|Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler|An Open-label, Randomised, 3-way Crossover Single Dose Study to Demonstrate Dose Proportionality of Fluticasone Furoate (FF) and Equivalence of Vilanterol (VI) When Administered as FF/VI Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subjects.||GlaxoSmithKline|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213849||115335|
NCT01214122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0520C00013|A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin|A Phase I, Open Label, Fixed Sequence, Single Centre Study in Healthy Volunteers to Investigate the Effects of Repeated Oral Doses AZD9668 on the Pharmacokinetics and Pharmacodynamics of a Single Dose of Warfarin||AstraZeneca|No|Withdrawn|November 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01214122||115314|
NCT01214135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NSE-SER-2010/1|A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia|A Retrospective, Non-interventional Study to Evaluate the Use of Seroquel XR and Seroquel IR in the Clinical Practice of Inpatients With Schizophrenia|SPIN|AstraZeneca|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|300|||Both|18 Years|65 Years|No|Non-Probability Sample|Approximately 300 patients with schizophrenia who have been hospitalized during the study        period (1st of July 2009 - 30th of September 2010).|January 2011|January 10, 2011|September 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214135||115313|
NCT01214148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0904|First in Man Experience With a Drug Eluting Stent in De Novo Coronary Artery Lesions|A Prospective, Multi-centre, Single Treatment Clinical Trial With Follow-up Investigations at 1, 4, 9, 12, 24 and 36 Months|BIOFLOW-I|Biotronik AG|Yes|Completed|July 2009|July 2013|Actual|April 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||August 2013|August 8, 2013|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01214148||115312|
NCT01214460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10111|Impact of Medical Emergency Team and EMS in Tampere University Hospital|Impact of Medical Emergency Team and EMS on ICU Readmissions and Sudden Cardiac Arrests in Tampere University Hospital||Tampere University Hospital|Yes|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|10000|||Both|18 Years|N/A|No|Probability Sample|All adult EMS or in-hospital patients with deteriorating vital signs or patients in risk        in Tampere University Hospital|May 2015|May 29, 2015|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01214460||115288|
NCT01214733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25321|A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis|An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214733||115267|
NCT01214980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-86003|Split Thickness Donor Site Healing With MIST Study|A Prospective, Randomized, Controlled Pilot Study of the MIST Therapy System for the Treatment of Split Thickness Donor Sites||Celleration, Inc.|No|Completed|February 2012|July 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|October 4, 2010|Yes|Yes||No|December 11, 2014|https://clinicaltrials.gov/show/NCT01214980||115248|Participants were not blinded to study treatment.
NCT01214707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-31|Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy|Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy||Cyberonics, Inc.|No|Completed|September 2010|||October 2011|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with epilepsy already scheduled for an EMU stay.|March 2012|March 13, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214707||115269|
NCT01201525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/218|Pulsed Dye Laser Treatment of Recent Surgical Scars|Pulsed Dye Laser Treatment of Recent Surgical Scars: A Prospective Single Blinded Within Patient Controlled Randomized Trial||University Hospital, Ghent|No|Completed|November 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2011|August 9, 2011|December 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01201525||116278|
NCT01216371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN 20/04|Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)|Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO|SMAT|Association of Urogenital Oncology (AUO)|Yes|Recruiting|October 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||February 2012|February 10, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216371||115142|
NCT01216384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.15|Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers|A Randomised, Double-blind (Within Dose Groups), Parallel Group, Placebocontrolled Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Rising Doses (50 mg, 200 mg, 400 mg) of BI 671800 HEA in Chinese Healthy Male Volunteers and Multiple Rising Doses (50 mg b.i.d., 200 mg b.i.d., 400 mg b.i.d.) of BI 671800 HEA in Japanese Healthy Male Volunteers||Boehringer Ingelheim||Completed|October 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|73|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|October 1, 2010||||No||https://clinicaltrials.gov/show/NCT01216384||115141|
NCT01207622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-P-001823|Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD|Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD)||Massachusetts General Hospital|Yes|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|15 Years|30 Years|No|||March 2013|March 4, 2013|September 22, 2010|Yes|Yes|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01207622||115812|
NCT01208714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPR-METRAS|Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study)|Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney.|METRAS|University Hospital Padova|Yes|Not yet recruiting|December 2010|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|November 3, 2010|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208714||115729|
NCT01208727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-504|Post Cond No Reflow|The POSTCONDITIONING and THE NO REFLOW Phenomenon in Acute Myocardial Infarction||Hospices Civils de Lyon|No|Completed|April 2009|March 2011|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||September 2010|May 7, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208727||115728|
NCT01217853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/10|24h Continuous Intraocular Pressure (IOP) Monitoring vs Goldmann Applanation Tonometry|Comparison of 24-hour Continuous IOP Monitoring With a Contact Lens-based Sensor to Goldmann Applanation Tonometry||Sensimed AG|No|Completed|August 2010|August 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|40 Years|70 Years|No|Probability Sample|Male or female patients 40 to 70 years old and diagnosed with primary open angle glaucoma.|August 2011|August 2, 2011|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217853||115029|
NCT01208883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/510|A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer|A FEASIBILITY STUDY ON CONTINUOUS ADAPTIVE [18F]FDG-PET-GUIDED RADIOTHERAPY FOR HEAD AND NECK CANCER||University Hospital, Ghent|No|Completed|September 2010|March 2012|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208883||115717|
NCT01209143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4593g|A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists|A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists||Genentech, Inc.||Completed|November 2010|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|September 23, 2010|No|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01209143||115697|
NCT01219023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021480|Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil|Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil|JADE|Duke University|No|Completed|June 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|90 Years|No|||October 2012|October 29, 2012|October 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01219023||114939|
NCT01219309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ö761-03|Omega-3/Omega-6 Fatty Acids for Attention-Deficit/Hyperactivity Disorder (ADHD): A Trial in Children and Adolescents|Omega-3/Omega-6 Fatty Acids for ADHD. A Randomized Placebo-controlled Trial in Children and Adolescents||Göteborg University|Yes|Completed|August 2004|April 2007|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|8 Years|18 Years|No|||April 2010|October 12, 2010|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01219309||114917|
NCT01219010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017452|A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma|A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma||Janssen Research & Development, LLC||Completed|October 2010|March 2014|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01219010||114940|
NCT01219322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7458-IK-CTIL|Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Anesthetized Children|Intravenous Bicarbonate Identifies the Correct Position of Intravenous Catheter||Sheba Medical Center|No|Recruiting|October 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 27, 2010|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01219322||114916|
NCT01201369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORCA-2|A Study to Examine the Implantation Characteristics of Two Drug-Eluting Stents|Comparison of Rates of Strut Malapposition Between Everolimus and Sirolimus Eluting Stents - A Randomised Optical Coherence Tomography Study|ORCA-2|Royal Brompton & Harefield NHS Foundation Trust|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||July 2011|July 11, 2011|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01201369||116290|
NCT01200992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3348-303|Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer|A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer|EMBARC-RF|Bioniche Life Sciences Inc.|Yes|Terminated|November 2010|December 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|September 12, 2010|Yes|Yes|Lack of Recruitment|No|August 29, 2014|https://clinicaltrials.gov/show/NCT01200992||116319|
NCT01201317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2600C00005|A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy|A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo||AstraZeneca|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|134|||Both|18 Years|80 Years|No|||April 2014|April 8, 2014|September 13, 2010|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01201317||116294|
NCT01201603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS 100058|The Effects of Orange Juice on Insulin Sensitivity and Plasma Lipids|The Effects of Orange Juice on Insulin Sensitivity and Plasma Lipids||University of Nottingham|No|Completed|July 2010|November 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|36|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 24, 2014|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201603||116272|
NCT01202201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114131|A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in Japan|A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in Children <6 Years of Age in Japan||GlaxoSmithKline||Completed|September 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13767|||Both|N/A|6 Years|No|Non-Probability Sample|Children <6 years of age hospitalized with acute gastroenteritis or rotavirus        gastroenteritis in any of the participating hospitals|March 2011|March 31, 2011|September 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202201||116226|
NCT01202214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR2114661|Repeat Dose Safety Study for Compound to Treat Asthma|A Randomized, Single-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK1440115 After a Single Dose and 7 Days of Repeat Dosing in Healthy Volunteers||Accenture|Yes|Completed|September 2010|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 28, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01202214||116225|
NCT01198236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpoIV-CHA-IIS-0802|Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection|Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection||Zhejiang University|Yes|Completed|July 2008|November 2010|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Both|18 Years|65 Years|No|||October 2011|October 13, 2011|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01198236||116528|
NCT01198223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUMS 1234|Effect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis|Comparison of Therapeutic Effect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis||Qazvin University Of Medical Sciences|Yes|Completed|July 2010|October 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|40 Years|N/A|No|||September 2010|October 15, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01198223||116529|
NCT01198496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPECT 1|Recurrent Stroke Prevention Clinical Outcome Study|Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke|RESPECTS|Biomedis International Ltd.|Yes|Recruiting|October 2010|December 2019|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5000|||Both|50 Years|85 Years|No|||September 2010|July 29, 2012|August 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01198496||116508|
NCT01198756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113314|A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children||GlaxoSmithKline||Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|3109|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||February 2013|November 30, 2015|September 9, 2010|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01198756||116488|
NCT01217034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLOG 1001 trial|Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib|Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS)|TACTICS|Japan Liver Oncology Group|Yes|Recruiting|October 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|228|||Both|20 Years|N/A|No|||October 2010|October 6, 2010|October 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01217034||115092|
NCT01217606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-062|Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|January 2011|June 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|October 7, 2010|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01217606||115048|
NCT01207908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1491|Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy|IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy||Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|November 2010|June 2013|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|5 Years|N/A|No|||June 2012|June 12, 2012|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207908||115791|
NCT01217021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNI-558-01|Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558|An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate Efficacy & Safety of MNI-558 Positron Emission Tomography for Detection/Exclusion of Cerebral Amyloid Beta in Patients w/ Alzheimer Disease Compared to Healthy Volunteers|MNI-558|Institute for Neurodegenerative Disorders|No|Completed|September 2010|March 2011|Actual|March 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 22, 2011|October 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217021||115093|
NCT01209416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2010-0157|The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin|The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin||University of Aarhus|No|Active, not recruiting|June 2012|October 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|8|||Male|18 Years|65 Years|No|||August 2012|December 2, 2014|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209416||115676|
NCT01209455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC Forearm 0910|Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects|Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects||University of Edinburgh|No|Recruiting|January 2011|September 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|24|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||September 2010|July 18, 2011|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209455||115673|
NCT01209949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10179|Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris|Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris||Galderma Laboratories, L.P.|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|16 Years|25 Years|No|||January 2012|January 18, 2012|September 24, 2010||No||No|December 13, 2011|https://clinicaltrials.gov/show/NCT01209949||115635|
NCT01219569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120070222|Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry|The Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry||Rutgers, The State University of New Jersey|No|Completed|August 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|35|||Both|18 Years|70 Years|No|Non-Probability Sample|subjects undergoing orthopedic surgery in the supine position|August 2013|April 23, 2015|April 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01219569||114897|
NCT01210183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProvingCartilageGrowth|Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose|Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose Injections Without Weight Bearing Restriction: A Double Arthroscopic Assessment||Universidad Nacional de Rosario|Yes|Completed|July 2010|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|6|||Both|40 Years|N/A|No|||May 2014|May 19, 2014|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210183||115617|
NCT01210196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shire/CS01|Sophisticated Assessment of Disease Burden in Patients With Fabry Disease|Sophisticated Assessment of Disease Burden in Patients With Fabry Disease - The SOPHIA in Fabry Disease Study|SOPHIA|Shire|Yes|Completed|October 2010|||September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|36|||Both|25 Years|N/A|No|Non-Probability Sample|Male and female patients with a genetically confirmed Fabry disease.|March 2014|March 25, 2014|September 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01210196||115616|
NCT01219829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD5381|Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma|Refining the Molecular Progression From Intraductal to Invasive Pancreatic Cancer: Correlating Genetic Profiles and Clinicopathological Phenotypes in Sporadic and Familial Pancreatic Adenocarcinoma||Columbia University|Yes|Active, not recruiting|August 2008|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|5|Samples With DNA|-  Tissue: Pancreatic resection specimens will be obtained from our Pancreatic Cancer           Tissue Bank and evaluated by a single pathologist, blinded to patients' clinical           information. Specimens will be examined for PanIN lesions, specifically number and           grade of lesions, the presence of multifocality and lesion location in relation to           tumor.        -  Molecular Analysis: In patients with multifocal PanIN disease outside tumor location,           molecular analysis will be conducted to determine clonality of these PanIN lesions. In           any patient who underwent a second resection for recurrent Pancreatic ductal           adenocarcinoma , the recurrent tumor will also be studied. All neoplastic lesions of           interest will be laser-microdissected from paraffin-embedded slides.        -  ROMA analysis: Genomic DNA from PanIN lesions and tumor will be isolated, using           representational oligonucleotide microarray analysis (ROMA) or somatic mutation           analysis. ROMA analysis will be performed by Cold Spring Harbor Laboratory.|Both|18 Years|85 Years|No|Non-Probability Sample|We are interested in studying two "high-risk" patient groups:          1. patients who underwent surgery for pancreatic cancer and developed tumor recurrence             after surgery and          2. patients with a strong family history of pancreatic cancer or with a genetic syndrome             that puts them at risk for pancreas cancer.|July 2015|July 2, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01219829||114878|
NCT01201629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1620|Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm|Does Transcranial Direct Current Stimulation Improve Functional Motor Recovery in the Affected Arm-Hand in Patients After an Acute Ischemic Stroke: A Randomized Control Trial||University of Oklahoma|No|Terminated|January 2009|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|19 Years|90 Years|No|||February 2016|February 18, 2016|September 7, 2010||No|Slow accrual over 6 year period|No||https://clinicaltrials.gov/show/NCT01201629||116270|
NCT01201356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2399|Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis|A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis||Novartis||Recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5000|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201356||116291|
NCT01201616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS030426a|The Effects of Diet on Mood, Cognition and Appetite|The Effects of a High Fat, Low Carbohydrate or a Low Fat, High Carbohydrate Diet on Mood Cognition and Appetite||University of Nottingham|No|Completed|July 2010|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201616||116271|
NCT01201876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118680|DPBRN Reasons for Replacement or Repair of Dental Restorations|Reasons for Replacement or Repair of Dental Restorations||Dental Practice-Based Research Network|No|Completed|November 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|6368|||Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Practitioner investigators must have been enrolled in the DPBRN, completed the "Assessment        of caries diagnosis & caries treatment" study; and do at least some restorative dentistry        in their practices. The human subjects directly involved in this study were patients who        had sought dental treatment in the DPBRN practitoners' practices.|June 2011|June 14, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201876||116251|
NCT01201889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01000-T36|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2010|||||N/A|N/A|N/A||||||||||||||June 27, 2013|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201889||116250|
NCT01202513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSMCH230810|Topical Bimatoprost Solution 0.03%in Stable Vitiligo|Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study||Gian Sagar Medical College and Hospital|Yes|Withdrawn|August 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|10 Years|40 Years|No|||July 2010|August 2, 2011|September 14, 2010||No|regulatory reasons|No||https://clinicaltrials.gov/show/NCT01202513||116202|
NCT01198522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19IL2GEM-01/07|Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients|Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer||Philogen S.p.A.|No|Terminated|June 2007|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|70 Years|No|||October 2014|November 19, 2014|September 8, 2010||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01198522||116506|
NCT01198535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02905|Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer|Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer||National Cancer Institute (NCI)||Terminated|September 2010|||July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2012|May 15, 2015|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01198535||116505|
NCT01198509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0658|Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)|Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)||New York University School of Medicine|Yes|Completed|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|178|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|September 8, 2010|Yes|Yes||No|September 3, 2014|https://clinicaltrials.gov/show/NCT01198509||116507|Interpretation of results is limited by very small sample size. It should be noted that this was intended as a proof-of-concept study, and not a fully-powered clinical trial.
NCT01198782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-42|Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%|||Alcon Research|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01198782||116486|
NCT01217866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-44206615|A Retrospective Review of Enseal Laparoscopic Vaginal Assisted Hysterectomy (LAVH) Versus Traditional LAVH|A Retrospective Analysis of a Complete Enseal Laparoscopic Vaginal Assisted Hysterectomy Versus a Traditional Suture Laparoscopic Vaginal Hysterectomy||Womens Care|No|Completed|August 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|79|||Female|35 Years|75 Years|No|Non-Probability Sample|patients who underwent Laparoscopically Assisted Vaginal Hysterectomy (LAVH)|December 2012|December 19, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217866||115028|
NCT01216397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.6|Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers|Relative Bioavailability of Two Different Batches of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet (FDC) in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial)||Boehringer Ingelheim||Completed|September 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||February 2014|June 18, 2014|October 4, 2010||||No|February 3, 2012|https://clinicaltrials.gov/show/NCT01216397||115140|
NCT01216709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iron absorption in infants|Iron Absorption From Infant Formula and Iron Drops in Infants (MJAU-studien)|Iron Absorption From Iron-fortified Infant Formula and Iron Drops in Infants (MJAU-studien)|MJAU|Umeå University|No|Recruiting|October 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|72|||Both|6 Months|7 Months|Accepts Healthy Volunteers|||June 2012|June 13, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216709||115116|
NCT01217580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.091.C|Pain Relief Study of Ultrasound Guided Transverse Abdominis Plane(TAP)Block|Analgesic Efficacy of Ultrasound Guided Transversus Abdominis Plane Block After Cesarean Delivery in Patients With a BMI > 30|TAP|Ochsner Health System|Yes|Withdrawn|October 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||October 2011|October 25, 2011|October 7, 2010|Yes|Yes|The study was not feasible to perform at one institution with the amount of subjects that were    needed to complete it.|No||https://clinicaltrials.gov/show/NCT01217580||115050|
NCT01218217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-IMPH-SQ109-01|Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB|A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|SQ109EBA|Ludwig-Maximilians - University of Munich||Completed|November 2010|May 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|90|||Both|18 Years|64 Years|No|||January 2013|January 11, 2013|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218217||115001|
NCT01208597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99011|The Effectiveness of Adopting Humanized Service Program on Transvaginal Ultrasound About Women's Service Quality and Satisfaction|The Effectiveness of Adopting Humanized Service Program on Transvaginal Ultrasound About Women's Service Quality and Satisfaction.||Taipei Medical University WanFang Hospital|No|Completed|February 2010|June 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|100|||Female|20 Years|N/A|No|Non-Probability Sample|adult women|September 2010|September 23, 2010|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208597||115738|
NCT01209468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Treatment of Sleep Apnea With Oral Appliances|A Randomized Clinical Trial of the Treatment of Obstructive Sleep Apnoea Using Oral Appliances||The University of Hong Kong|No|Recruiting|June 2008|December 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 24, 2010|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209468||115672|
NCT01209156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBR111 001|Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions|A Phase 1 Evaluation of the Kinetics, Clearance and Cerebral Distribution of One Novel PBR PET Imaging Agent, 18F-PBR-111 Following Intravenous Administration in Healthy Subjects and Alzheimer Disease Patients|PBR111|Institute for Neurodegenerative Disorders|No|Completed|March 2010|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 8, 2013|September 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209156||115696|
NCT01209429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100150|Importance of the GH/IGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction|Importance of the GH/IGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction||University of Aarhus|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|10|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209429||115675|
NCT01209442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0274.cc|Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme|A Pilot Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) and Bevacizumab for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)||University of Colorado, Denver|Yes|Active, not recruiting|August 2010|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209442||115674|
NCT01209689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA22908|A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy|A Randomized, Double-blind, Parallel Group Placebo-controlled Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab (TCZ) Versus Placebo in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy||Hoffmann-La Roche||Terminated|October 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|113|||Both|18 Years|N/A|No|||December 2012|December 11, 2012|September 24, 2010|Yes|Yes|Clinical development program terminated due to failure to achieve efficacy|No|December 11, 2012|https://clinicaltrials.gov/show/NCT01209689||115655|
NCT01210248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO 51/10|Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status|||Assaf-Harofeh Medical Center||Recruiting|September 2010|||January 2012||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|THE RESEARCH WILL INVOLVE PATIENTS THAT TAKE CLOPIDOGREL AND READY TO GIVE INFORMED        CONSENT FOR GENETIC TESTING.|May 2010|September 27, 2010|September 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01210248||115612|
NCT01210482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K5-4406|Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Basis Plan For Postmarketing Surveillances, Etc. Of New Ethical Drugs For Torisel||Pfizer|No|Completed|August 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1022|||Both|N/A|99 Years|No|Probability Sample|Patients treated with Torisel (patients with metastatic and/or radically unresectable or        advanced renal cell carcinoma).|October 2015|October 12, 2015|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210482||115594|
NCT01210495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061058|Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma|A Multicenter, Global, Randomized, Double-Blind Study Of Axitinib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced Hepatocellular Carcinoma Following Failure Of One Prior Antiangiogenic Therapy||Pfizer|Yes|Active, not recruiting|December 2010|May 2016|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 22, 2010|Yes|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT01210495||115593|
NCT01201928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-164|Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166|A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes||Mannkind Corporation|No|Terminated|October 2010|March 2012|Actual|March 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3|||Both|18 Years|80 Years|No|Non-Probability Sample|Interested subjects enrolled in one of three parent trials; MKC-TI-161, MKC-TI-162 or        MKC-TI-166|December 2012|December 5, 2012|August 27, 2010|No|Yes|Parent trials were either not initiated or terminated|No||https://clinicaltrials.gov/show/NCT01201928||116247|
NCT01201941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002606/2|Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru|Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru||Brigham and Women's Hospital|No|Completed|November 2004|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1849|||Both|N/A|N/A|No|Non-Probability Sample|The study population includes those individuals with pulmonary TB who have a risk factor        for MDR-TB in the region of Lima Ciudad.        Risk factors:          -  Confirmed mdr-tb by previous dst          -  Failure, default or relapse from a treatment containing 2nd line drugs          -  Patient who will initiate treatment with 2nd line drugs          -  Patient who has received at least 30 days of any second-line drug          -  Contact with confirmed mdr-tb, contact in treatment for mdr-tb, or contact who has             previously been treated with 2nd line drugs|September 2010|September 14, 2010|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01201941||116246|
NCT01201902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1116|A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine|Randomized, Open, Clinical Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine GC1116 With Adjuvant in Healthy Adults||Green Cross Corporation|No|Completed|October 2009|July 2010|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|592|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 17, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201902||116249|
NCT01201915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHH4812g|A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma|A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)||Genentech, Inc.||Completed|October 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|21 Years|N/A|No|||May 2014|May 22, 2014|September 10, 2010|Yes|Yes||No|May 22, 2014|https://clinicaltrials.gov/show/NCT01201915||116248|
NCT01202227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081252|An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain|An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)||Pfizer|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|August 31, 2010|Yes|Yes||No|January 10, 2013|https://clinicaltrials.gov/show/NCT01202227||116224|
NCT01202240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921054|Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers|A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers||Pfizer|No|Completed|September 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 15, 2011|September 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202240||116223|
NCT01198249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0295|Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension|A Randomized, Open Label, Multiple Dose, Crossover Study to Investigate Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide(HCTZ) in Subjects With (Pre)Hypertension||Yonsei University|No|Completed|September 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|23|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 25, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198249||116527|
NCT01198262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-23059|Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections|GeneXpert in Studying Staphylococcus Aureus Infections at the Michael E. DeBakey Medical Center, Houston, Texas||VA Medical Center, Houston|No|Completed|April 2008|August 2010|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|260|||Both|18 Years|N/A|No|Probability Sample|The study population includes adult and geriatric patients at the Michael E. DeBakey VA        Medical Center for have suspected blood and wound infections.|October 2008|September 9, 2010|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01198262||116526|
NCT01197963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0122|A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2|A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2||The University of Texas Health Science Center, Houston|Yes|Terminated|September 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|21 Years|55 Years|No|||June 2015|June 11, 2015|September 7, 2010||No|IRB temporarily halted enrollment|No||https://clinicaltrials.gov/show/NCT01197963||116548|
NCT01198795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCT-MD-55|Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder|An Open-label Long-term Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder||Forest Laboratories|No|Completed|September 2010|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|7 Years|11 Years|No|||January 2014|January 31, 2014|September 9, 2010|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01198795||116485|
NCT01199120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UACJ-ICSA-VPortillo-01|Cognitive Effects of Omega-3 Supplements in Children With Mild to Moderate Malnutrition|Cognitive Effects of Omega-3 Supplements in Children With Mild to Moderate Malnutrition||Universidad Autonoma de Ciudad Juarez|No|Completed|March 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|75|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||September 2010|September 9, 2010|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01199120||116462|
NCT01208584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306/09|Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions|Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions||University Hospital, Basel, Switzerland|No|Completed|August 2008|October 2013|Actual|October 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A          -  Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12)             ASIA A          -  Volunteers without any neurological deficits|March 2015|March 10, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208584||115739|
NCT01217307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPS-III 2010B257|Metformin to Reduce Heart Failure After Myocardial Infarction|Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.|GIPS-III|University Medical Center Groningen|Yes|Active, not recruiting|January 2011|May 2015|Anticipated|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217307||115071|
NCT01218503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAIN-T32|The Neural Correlates of Food Choice Decision-making in Obesity and Weight Loss|The Neural Correlates of Food Choice Decision-making in Obesity and Weight Loss (CHOICES)|CHOICES|The Miriam Hospital|No|Recruiting|March 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|90|||Female|35 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218503||114979|
NCT01209117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114435|A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435|A Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435||ViiV Healthcare|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 8, 2011|September 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209117||115699|
NCT01209169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sapphire|Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury|Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury||Astute Medical, Inc.|No|Completed|September 2010|February 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|890|||Both|21 Years|N/A|No|Non-Probability Sample|Adult ICU patients at risk for AKI.|February 2013|February 21, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209169||115695|
NCT01209182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSB-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2010|||||N/A|N/A|N/A||||||||||||||September 23, 2010|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209182||115694|
NCT01209702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA22823|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs|A Ph II/III Seamless, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Reduction in Signs and Symptoms and Inhibition of Structural Damage During Treatment With Tocilizumab Versus Placebo in Patients With Ankylosing Spondylitis Who Have Failed Non-steroidal Anti-inflammatory Drugs and Are naïve to TNF Antagonist Therapy NSAIDs||Hoffmann-La Roche||Terminated|September 2010|December 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|306|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|September 24, 2010|Yes|Yes|Recruitment halted: Failed to achieve efficacy|No|November 26, 2012|https://clinicaltrials.gov/show/NCT01209702||115654|
NCT01209975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT-blood flow study|Retinal Vascular Reactivity in Subjects With Newly Diagnosed Glaucoma Before and After Selective Laser Trabeculoplasty|Retinal Vascular Reactivity in Response to Isoxic Hypercapnia in Subjects With Newly Diagnosed Glaucoma||University of Toronto|No|Recruiting|November 2008|||November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|40 Years|75 Years|No|Non-Probability Sample|patient with untreated primary open angle glaucoma|September 2010|September 27, 2010|June 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209975||115633|
NCT01210235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGPB-09-010-01-CPPB|FLU-FIT Program at Kaiser Permanente Northern California|FLU-FIT Program at Kaiser Permanente Northern California||University of California, San Francisco|No|Completed|October 2009|April 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|7465|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|September 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01210235||115613|
NCT01210521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB1116133|Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients|Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients||Florida Atlantic University|Yes|Withdrawn|September 2010|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|70 Years|No|||October 2015|October 9, 2015|September 27, 2010|Yes|Yes|Sponsor terminated study due to inability to enroll subjects.|No||https://clinicaltrials.gov/show/NCT01210521||115591|
NCT01209962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2008.034|A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response|A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response||University of Michigan Cancer Center|Yes|Active, not recruiting|May 2008|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologic or cytologic proof of pancreatic cancer, for whom the treatment        plan, at the time of enrollment, is neoadjuvant chemoradiotherapy followed by surgical        resection.|May 2015|May 14, 2015|April 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01209962||115634|
NCT01196884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIT|Immune Thrombocytopenia (ITP) Immune-Genetic Assessment|IMMUNE-GENETIC ASSESSMENT OF PRIMARY ITP IN ADULT|UNIT|Azienda Ospedaliero Universitaria Udine, SOC Clinica Ematologica||Not yet recruiting|September 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|190|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|September 2010|September 8, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01196884||116631|
NCT01196897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT1000|Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)|Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients|EVOLVE|Boston Scientific Corporation|Yes|Completed|May 2009|November 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||August 2012|December 7, 2015|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01196897||116630|
NCT01202253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8851028|Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom|A Study To Describe The Early Clinical Experience With Anidulafungin In Patients With Liver Disease At King's College Hospital NHS Trust, London||Pfizer|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|90 Years|No|Non-Probability Sample|Subjects admitted with candidiasis infections to the Liver Unit at King's College Hospital        (United Kingdom) who are prescribed anidulafungin.|March 2014|March 25, 2014|September 13, 2010|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01202253||116222|Protocol-specified endpoint, percentage of participants with presumed eradication of infecting species, was not presented as a separate outcome measure because the ‘presumed eradication’ was considered same as favorable clinical response.
NCT01202266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2911002|A Multiple Dose Study Of PF-05161704 In Healthy Volunteers|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Pf-05161704 After Administration Of Multiple Escalating Oral Doses In Healthy Volunteers||Pfizer|No|Terminated|August 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 9, 2011|September 13, 2010|No|Yes|The study was terminated on October 29, 2010 due to gastrointestinal adverse events.|No||https://clinicaltrials.gov/show/NCT01202266||116221|
NCT01202526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISBypass|The Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity in Type 2 Diabetes|||Hvidovre University Hospital|No|Completed|September 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples Without DNA|serum, plasma, urine, muscle, subcutaneous fat, visceral fat|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from the outpatient clinic of endocrinology and gastrosurgical        clinic at Hvidovre University Hospital|October 2013|October 24, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01202526||116201|
NCT01197690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|602/2552(EC1)|Association Between Fractional Exhaled Nitric Oxide and Asthma Control|Association Between Fractional Exhaled Nitric Oxide and Asthma Control|FeNO_AS|Mahidol University|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|62|||Both|7 Years|60 Years|No|Non-Probability Sample|atopic asthmatic patients in Department of Pediatrics, Siriraj hospital (tertiary care)|September 2015|September 17, 2015|July 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01197690||116569|
NCT01194570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA25046|A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis|A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis||Hoffmann-La Roche||Active, not recruiting|March 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|741|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|August 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01194570||116806|
NCT01193725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDO-09-8014|Exposure Therapy for Active Duty Soldiers With Post Traumatic Stress Disorder|Comparing Virtual Reality Exposure Therapy to Prolonged Exposure in the Treatment of Soldiers With PTSD|VRPE|National Center for Telehealth and Technology|Yes|Completed|March 2009|November 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|162|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01193725||116871|
NCT01194037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-143IFN-SC-US-001|A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C|A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C||HanAll BioPharma Co., Ltd.|No|Completed|June 2011|June 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|65 Years|No|||February 2014|February 24, 2014|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194037||116847|
NCT01194050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22816|An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer|Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)||Hoffmann-La Roche||Completed|June 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|289|||Both|18 Years|N/A|No|Probability Sample|Non small cell lung cancer patients|March 2016|March 1, 2016|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194050||116846|
NCT01217879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15379|COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia|Cough Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop Previous ACE-i Treatment Due to Cough|COUGH|Bayer|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|980|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic hypertensive patients with cough caused by the ACE-I regardless any        other factors.|November 2012|November 14, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217879||115027|
NCT01218204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113779|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin||GlaxoSmithKline|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|16||Actual|171|||Both|18 Years|75 Years|No|||August 2013|April 27, 2015|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218204||115002|
NCT01209130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCT4862g|A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma|An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma||Genentech, Inc.||Completed|October 2010|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209130||115698|
NCT01208311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4539|Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound|Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound.||Feinstein Institute for Medical Research|No|Suspended|December 2004|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|30|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Collect endoscopic ultrasound images form normal subjects, alcoholic liver patients and        patients with hepatitis C Cirrhosis.|June 2015|June 23, 2015|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208311||115760|
NCT01209195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-04-01-04|A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers|A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers||Merrimack Pharmaceuticals|No|Completed|October 2010|July 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209195||115693|
NCT01209715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114279|Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD|Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD||University of Miami|No|Withdrawn|October 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|0|||Both|18 Years|65 Years|No|||July 2014|July 31, 2014|September 24, 2010|Yes|Yes|Due to the ubiquitous use of ICS in the treatment of COPD in 2012, it was hard to find the    study population.|No||https://clinicaltrials.gov/show/NCT01209715||115653|
NCT01209728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-183|Effects of Insomnia on Simulated Driving (MK-0000-183-00)|A Randomized Clinical Trial to Study the Effects of Simulated Driving on Primary Insomniacs||Merck Sharp & Dohme Corp.|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|1||Actual|76|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209728||115652|
NCT01209741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-038|Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)|An Open Label, Randomized, 3-Period Crossover Study to Evaluate the Comparative Bioavailability of Variably Aged MK-0974 Capsules Administered Orally as Single Doses in Healthy Male and Female Subjects||Merck Sharp & Dohme Corp.||Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|September 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209741||115651|
NCT01209988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_UR_010|Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy|A Prospective Randomized Study Examining the Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-Assisted Laparoscopic Radical Prostatectomy||Asan Medical Center|No|Recruiting|April 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Male|N/A|N/A|No|||September 2010|September 27, 2010|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01209988||115632|
NCT01210001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.19|Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin|A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin||Boehringer Ingelheim||Completed|September 2010|||April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|499|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|September 27, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01210001||115631|
NCT01210261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAP001|New Versus Existing Auto-titrating CPAP Device to Treat Obstructive Sleep Apnea in Adults|New Versus Existing Auto-titrating CPAP Device to Treat Obstructive Sleep Apnea in Adults: Randomised Non-inferiority Double Blinded Trial.|APAP|Compumedics Limited|Yes|Completed|May 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01210261||115611|
NCT01210547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912M75577|Three-dimensional Assessment of Craniofacial Structures|Assessment of Dental, Skeletal Pattern, and Soft Tissue Using Three-dimensional Images||University of Minnesota - Clinical and Translational Science Institute|Yes|Suspended|September 2010|July 2016|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Current patients attending the University of Minnesota School of Dentistry Orthodontic        Clinic, and who voluntarily agreed to participate in this study.|November 2015|November 2, 2015|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210547||115589|
NCT01210755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 10 09|Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics|Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Specific and Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers|REVNEWANTICO|University Hospital, Grenoble|Yes|Completed|November 2010|June 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210755||115573|
NCT01201382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH087481|Depression Prevention Initiative - A Study of Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) in School Settings|Depression Prevention Initiative - A Study of IPT-AST in School Settings||Rutgers University|Yes|Active, not recruiting|October 2010|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|12 Years|17 Years|No|||October 2015|October 26, 2015|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201382||116289|
NCT01197703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Euro CT|European Cardio Computer Tomography Registry|European Cardio CT Registry||Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|June 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20000|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients that are studies by computed tomography of the heart for clinical        indications|September 2010|September 7, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197703||116568|
NCT01197716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|German CPU-Register|German Chest Pain Unit (CPU)-Register|Deutsches CPU-Register. Unterstützt Durch Die Deutsche Gesellschaft für Kardiologie.||Stiftung Institut fuer Herzinfarktforschung|No|Recruiting|December 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25000|||Both|N/A|N/A|No|Non-Probability Sample|Patients admitted to a chest pain unit in a primary care clinic|September 2010|September 8, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01197716||116567|
NCT01197183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200007-502|Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France|Survey for the Initial Treatment of Hypothyroidism in France|ORCHIDEE|Merck KGaA||Completed|October 2008|September 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1285|Samples With DNA|Whole blood|Both|35 Years|60 Years|No|Non-Probability Sample|Independent, hospital and mixed practice endocrinologists and general practitioners        enrolled 1000 subjects.|September 2010|February 3, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01197183||116608|
NCT01197417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECARN 025|Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis|Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis|MAGiC|Medical College of Wisconsin|Yes|Completed|December 2010|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|208|||Both|4 Years|21 Years|No|||December 2015|December 21, 2015|August 31, 2010|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01197417||116590|
NCT01194323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BENCH|Biology in Patients With Reflux Esophagitis|Biology in Patients With Reflux Esophagitis and Mucosal Impedance|BENCH|Vanderbilt University|No|Active, not recruiting|November 2010|December 2016|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Total RNA and proteins will be extracted from de-identified samples. Genes' and proteins'      expression will be processed and analyzed at Vanderbilt Core Facilities.|Both|18 Years|N/A|No|Non-Probability Sample|Male and female volunteers ages 18 years and older; able to give informed consent; no use        of acid suppressive therapy within 14 days prior to procedure; no history of Barret's        esophagus, gastric surgery, alcoholism, or significant motility condition; no        contraindications to biopsy, including taking anticoagulants or allergies to local        anesthetic.|December 2015|January 19, 2016|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01194323||116825|
NCT01195220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-381|Project AWARE: Using the Emergency Department (ED) to Prevent Sexually Transmitted Infections (STIs) in Youth|Project AWARE: Using the ED to Prevent STIs in Youth|AWARE|North Bronx Healthcare Network|No|Withdrawn|December 2011|May 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Actual|0|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|September 3, 2010||No|We could not obtain proper funding to complete this study.|No||https://clinicaltrials.gov/show/NCT01195220||116757|
NCT01195233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUMS 1350|Comparative Analysis of BioXtra on Xerostomia|Comparison Study of BioXtra Spray and Mouth Rinse in Patient With Radiation-induced Xerostomia|BioXtra|Qazvin University Of Medical Sciences|Yes|Completed|July 2010|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2010|April 18, 2011|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01195233||116756|
NCT01195246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-18|Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis|An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected||Dynavax Technologies Corporation|No|Completed|December 2010|August 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|155|||Both|18 Years|N/A|No|||August 2015|February 26, 2016|September 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01195246||116755|
NCT01194908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00029718|Re-expression of ER in Triple Negative Breast Cancers|Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients With Triple Negative Metastatic Breast Cancer||Emory University|Yes|Terminated|July 2010|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2015|January 18, 2015|September 1, 2010|No|Yes|Slow accrual|No|January 18, 2015|https://clinicaltrials.gov/show/NCT01194908||116780|
NCT01194934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXA12C101|NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers|A Single Center, Open-label, Repeated Dose, Phase I Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics and the Effect on Mobilization of Hematopoietic Stem Cells of NOX-A12 Alone and in Combination With Filgrastim|SNOXA12C101|NOXXON Pharma AG|Yes|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194934||116779|
NCT01195207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017095|A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Intravenous Study in Healthy Subjects and a Multiple-Dose Intravenous Study in Asthmatic Subjects to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of CNTO 3157||Centocor, Inc.||Completed|June 2010|January 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|79|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195207||116758|
NCT01207687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02987|Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)|Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma||National Cancer Institute (NCI)||Completed|October 2010|||February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|12 Years|N/A|No|||December 2013|April 1, 2014|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207687||115807|
NCT01207700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO1-HV-98215/SJRI - DCT/SPREAD|Secondary Prevention of coRonary Events After Discharge From Hospital (SPREAD)|A Randomized, Open Trial Comparing Post Discharge Interventions to Standard Care|SPREAD|St. John's Research Institute|Yes|Completed|August 2011|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|806|||Both|45 Years|N/A|No|||November 2014|November 27, 2014|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01207700||115806|
NCT01208870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1083316-1-52205|Translating Habituation Research to Interventions for Pediatric Obesity|Translating Habituation Research to Interventions for Pediatric Obesity|EAT|State University of New York at Buffalo|No|Recruiting|October 2009|March 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|281|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208870||115718|
NCT01208896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/09|Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma|Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma|RITALLO|University Hospital, Bordeaux|Yes|Recruiting|February 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|65 Years|No|||July 2015|July 22, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208896||115716|
NCT01208974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090299|Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction|A Phase I Trial Assessing the Safety and Feasibility of Prophylactic Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Immediate Reconstruction in Patients With In-Situ or Invasive Breast Cancer||University of Miami|Yes|Recruiting|October 2009|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208974||115710|
NCT01209234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-7710|Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance|Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance|CLEAR|University of California, Irvine|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2200|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209234||115690|
NCT01210014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUMS320|Systemic Zinc Sulphate in Treatment of Recurrent Aphthous Ulcerations:A Doubleblind, Placebo Controled Study|Zinc Sulphate in Treatment of Recurrent Aphthous Stomatitis||Qazvin University Of Medical Sciences|Yes|Completed|April 2008|August 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|10 Years|N/A|No|||September 2010|September 27, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01210014||115630|
NCT01210274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-10|Characterization of the Mechanisms of Resistance to Azacitidine|Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia||Centre Hospitalier Universitaire de Nice|No|Recruiting|September 2010|September 2013|Anticipated|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|bone marrow samples|Both|18 Years|N/A|No|Probability Sample|Patients with myelodysplastic syndromes or acute myeloid leukemia with multilineage        dysplasia treated with Azacitidine|September 2010|August 6, 2012|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210274||115610|
NCT01210287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010HBV|Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP|Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study|IHBVRL|Fudan University|Yes|Active, not recruiting|October 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|110|||Both|18 Years|75 Years|No|||January 2014|January 7, 2014|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210287||115609|
NCT01210560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-285|Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD|A Multi-center, Parallel-group, Randomized, Double-blind, Placebo-masked, Multiple Dose Trial of Modified-release (MR) and Immediate-release (IR) Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|25|||Both|18 Years|50 Years|No|||February 2012|February 20, 2012|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210560||115588|
NCT01210768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYLD0914|A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients|A Phase II Randomized Study of Pegylated Liposomal Doxorubicin, Cyclophosphamide Versus Epirubicin-Cyclophosphamide as Adjuvant Chemotherapy in Her2-negative Stage I and II Breast Cancer Patients||TTY Biopharm|No|Recruiting|June 2010|August 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|254|||Female|20 Years|70 Years|No|||June 2013|June 4, 2013|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01210768||115572|
NCT01201642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XijingNeuro-2010|Prednisone and Acupuncture for the Treatment of Facial Neuritis: a Multiple Center, CER in China|Prednisone Acetate and Acupuncture for the Treatment of Facial Neuritis: a Multiple Center, Comparative Effectiveness Research in China||Xijing Hospital|Yes|Recruiting|September 2010|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|1800|||Both|18 Years|75 Years|No|||August 2014|August 18, 2014|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01201642||116269|
NCT01194076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0082590|Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)|Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD|5dayOCD|Mayo Clinic|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|7 Years|17 Years|No|||May 2012|May 29, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01194076||116844|
NCT01197976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEPSO1|Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis|Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Psoriasis||Lenzi Egisto S.P.A.|No|Completed|March 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||September 2011|September 26, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197976||116547|
NCT01193738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01373-54|Osteopathy and Obstructive Sleep Apnea Syndrome|a Single Blind Cross Over Trial to Compare Osteopathic Compression of Pterygopalatine Node to Placebo Compression in Obstructive Sleep Apnea Syndrome.||Groupe Hospitalier Pitie-Salpetriere|No|Completed|September 2010|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193738||116870|
NCT01193751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apgar in asphyxiated infants|Apgar-Score in Asphyxiated Infants Under Resuscitation|Prospective Multicenter Study to Evaluate the Validity of the Specified Apgar-score in Asphyxiated Infants Under Resuscitation||Technische Universität Dresden|No|Recruiting|September 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|37 Weeks|N/A|No|Non-Probability Sample|Asphyxiated newborns >37 weeks of gestation receiving resuscitative interventions|September 2010|February 17, 2011|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193751||116869|
NCT01194063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107954|Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease|Use of Omegaven for Parenteral Nutrition Associated Liver Disease||Kapiolani Medical Center For Women & Children|Yes|Recruiting|September 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||April 2015|April 6, 2015|June 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01194063||116845|
NCT01194947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8015-AS-CTIL|Classification and Longitudinal Follow-up of Common Melanocytic Nevi With in Vivo Reflectance Confocal Microscopy|||Sheba Medical Center|No|Not yet recruiting|September 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|patients visiting the pigmented lesion clinic for skin cancer surveillance|September 2010|September 2, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194947||116778|
NCT01194960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV2/001/09|TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)|A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer||Oxford BioMedica|No|Terminated|August 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Male|18 Years|N/A|No|||February 2012|November 26, 2012|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194960||116777|
NCT01194973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-004|An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome|An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome||Alexion Pharmaceuticals|Yes|Completed|July 2010|February 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|August 31, 2010|Yes|Yes||No|April 7, 2015|https://clinicaltrials.gov/show/NCT01194973||116776|
NCT01195259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114769|Malignancy Meta Analysis for BRL49653|A Meta Analysis of Malignancy Serious Adverse Events in the ADOPT, 49653/048, and RECORD, 49653/231, Studies, Comparing Metformin With Rosiglitazone.||GlaxoSmithKline|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1|||Both|N/A|N/A|No|Probability Sample|5135 subjects with type 2 diabetes mellitus from the intention to treat (ITT) populations        of 2 randomised, controlled studies (2576 metformin/2559 rosiglitazone)|October 2013|October 24, 2013|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01195259||116754|
NCT01195545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38048-D|Veritas Laparoscopic Paraesophageal Hiatal Hernia (PEH) Repair Pilot Trial|Veritas Laparoscopic PEH Repair Pilot Trial||University of Washington|No|Active, not recruiting|May 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|August 5, 2011|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01195545||116732|
NCT01216722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070787|Study of Resistance Strengthening Versus Ambulation Post-Liver Transplant|Comparison of Targeted Lower Extremity Strengthening and Usual Care Progressive Ambulation in Subjects Post Liver Transplant: A Randomized Controlled Trial||University of Miami|No|Completed|October 2007|July 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|80 Years|No|||July 2010|October 6, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216722||115115|
NCT01217320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cr in rheumato|Creatine Supplementation in Pediatric Rheumatology|Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis||University of Sao Paulo|No|Recruiting|January 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|18 Years|No|||January 2012|January 12, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217320||115070|
NCT01208324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809690|Estrogen and Serotonin on Changing Brain Chemistry|Interaction of Estrogen and Serotonin in Modulating Brain Activation in Menopause||University of Pennsylvania|Yes|Recruiting|September 2009|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|150|||Female|48 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208324||115759|
NCT01208610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99015|The Effectiveness of Adopting Humanized Service Program on Transabdominal Ultrasound About Pregnant Women's Service Quality and Satisfaction|The Effectiveness of Adopting Humanized Service Program on Transabdominal Ultrasound About Pregnant Women's Service Quality and Satisfaction||Taipei Medical University WanFang Hospital|No|Completed|February 2010|June 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|200|||Female|20 Years|N/A|No|Non-Probability Sample|pregnant women|September 2010|September 23, 2010|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208610||115737|
NCT01207986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO 781-38|Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study|Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study|EP48 HIV CHEST|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|February 2011|August 2014|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|450|||Both|40 Years|85 Years|No|||July 2015|July 17, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01207986||115785|
NCT01207999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109117|Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer|Human Papillomavirus (HPV) Type Distribution in Adult African Women Diagnosed With Invasive Cervical Cancer||GlaxoSmithKline||Completed|October 2007|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|591|Samples With DNA|Cervical specimen|Female|21 Years|N/A|No|Non-Probability Sample|Women aged ≥ 21 years at the time the cervical specimen is taken, diagnosed with cervical        lesion macroscopically suggestive of invasive cervical cancer, scheduled for cervical        biopsy as per routine procedure.|November 2012|November 21, 2012|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01207999||115784|
NCT01208909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-XYZ-002|Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)|Combined Approach to GBM-resection by 5-ALA and Intraoperative MRI||University of Zurich|No|Recruiting|August 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|tumor samples for pathophysiology|Both|20 Years|70 Years|No|Non-Probability Sample|patients with Glioblastoma multiforme (GBM)|February 2010|October 21, 2010|April 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01208909||115715|
NCT01208922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIT-1/AID|Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea|A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers|ERASE|Dr. Falk Pharma GmbH|Yes|Recruiting|October 2010|April 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|776|||Both|18 Years|85 Years|No|||October 2015|October 22, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208922||115714|
NCT01209247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR09005|Emergence of Fluoroquinolone Resistance in Commensal Flora|Emergence of Fluoroquinolone Resistance in the Commensal Flora of Patients Receiving Fluoroquinolone Treatment.|FQEMERG|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2010|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|571|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209247||115689|
NCT01209767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU34401|Cryolipolysis and Subcision for Treatment of Cellulite|Comparison of the Efficacy Between Cryolipolysis and Subcision for Treatment of Cellulite: A Prospective Randomized Control Trial.||Northwestern University|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|September 24, 2010|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT01209767||115649|
NCT01209494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEALTH-F2-2009-241526|An Arrhythmia Risk Stratification and Genetic Trial|The EU TrigTreat Clinical Study: An Advanced Diagnostics and Observational Trial for Arrhythmia Risk Stratification and Correlation With Genotype|EUTrigTreat|University Medical Center Goettingen|Yes|Completed|January 2010|September 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|672|Samples With DNA|Whole blood specimens for genetic analyses|Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard indications for ICD treatment according to ACC/AHA/ESC guidelines        with and without myocardial infarction in their history are eligible for the study|December 2015|December 1, 2015|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209494||115670|
NCT01209754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-016|EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)|HIV Prevention Agent Pregnancy Exposure Registry: EMBRACE Study|EMBRACE|Microbicide Trials Network|Yes|Recruiting|October 2009|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|950|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of female participants who become or became pregnant        during HIV prevention agent trials, or who have or had planned exposures in pregnancy        safety studies, and the infants resulting from those pregnancies. Mother participants must        still be pregnant, or have had a pregnancy outcome diagnosis less than one year before        screening/enrollment, and infant participants must be less than one year old. The study        may include HIV-uninfected and -infected participants. Mothers may participate in EMBRACE        without participation of their infants; however, infants whose mothers have not enrolled        in EMBRACE will not participate.|September 2014|September 17, 2014|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209754||115650|
NCT01210027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2006.067|A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion|A Pilot Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion||University of Michigan Cancer Center|Yes|Recruiting|November 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have one of the following: primary hepatocellular cancer, hepatobiliary        cancer, or metastatic disease to the liver.|December 2015|December 4, 2015|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01210027||115629|
NCT01196611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIC 0521.0.203.000-09|Effectiveness of Two Therapeutic Approaches in Female Teachers With Voice Disorders|Effectiveness of Two Therapeutic Approaches in Female Teachers With Voice Disorders||Federal University of São Paulo|Yes|Enrolling by invitation|September 2010|September 2012|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Female|21 Years|50 Years|No|||September 2010|September 7, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196611||116652|
NCT01196871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-013|Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease|An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease.||Amicus Therapeutics|No|Completed|February 2011|October 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Male|18 Years|65 Years|No|||December 2013|December 19, 2013|September 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196871||116632|
NCT01193777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-10-06A|L-Carnitine Administration in Early Sepsis|||Carolinas Healthcare System|Yes|Terminated|September 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|August 30, 2010|Yes|Yes|Study stopped to open expanded phase II study|No||https://clinicaltrials.gov/show/NCT01193777||116867|
NCT01194336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR 1650|Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance|Evaluation of Three Potential CNS Pretreatments for Soman Exposure - Huperzine A, Donepezil, and Galantamine - on Human Performance||U.S. Army Medical Research and Materiel Command|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|84|||Both|18 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults (18-39 years) males and females, military or civilian|November 2012|November 27, 2012|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194336||116824|
NCT01194349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PED 001, Version 2.990526|The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection|The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection||Taipei Medical University WanFang Hospital|No|Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|1 Year|18 Years|No|Non-Probability Sample|Pediatric hospitalized patients less than 18 year-old.|May 2010|September 1, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01194349||116823|
NCT01194583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT03/10|Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) Without Nicotine Cartridges|Randomised Controlled Trial Investigating the Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) Without Nicotine Cartridges in Smokers||Universita degli Studi di Catania|Yes|Completed|April 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Regular smokers from Catania in Italy recruited following the placement of an        advertisement in a local newspaper.|January 2013|January 7, 2013|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194583||116805|
NCT01194596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R07/040|Effectiveness of Smoking Cessation Advice Combined With Spirometric Results in Adult Smokers (ESPITAP)|Effectiveness of Smoking Cessation Advice Combined With a Detailed Discussion of the Spirometric Results With the Primary Care Practitioner on the Smoking Habit in Adult Smokers (ESPITAP)|ESPITAP|Jordi Gol i Gurina Foundation|No|Active, not recruiting|June 2008|July 2011|Anticipated|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|596|||Both|35 Years|70 Years|No|||April 2011|April 6, 2011|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194596||116804|
NCT01194986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3030C00003|Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration|An Open-label Positron Emission Tomography Study to Evaluate Use of Histamine H3 Receptor Radioligand [11C]AZ12807110 and to Determine Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration to Healthy Volunteers||AstraZeneca|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|13|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|September 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01194986||116775|
NCT01195857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR701068-512|Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration|Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration||Merck KGaA|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with relapsing remitting multiple sclerosis who are currently receiving Rebif        treatment and using the Rebiject II injection device who are under regular review by a        Multiple Sclerosis nurse.|February 2014|February 3, 2014|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01195857||116708|
NCT01195558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005099|Patient Registry of Blind Subjects With Sleep-related Problems|Development of a Patient Registry of Blind Subjects With Sleep-related Problems||Vanda Pharmaceuticals|No|Recruiting|April 2010|||April 2030|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|General population of blind individuals|December 2015|December 7, 2015|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195558||116731|
NCT01195844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-031|Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).|Rotavirus Gastroenteritis in Children Up to 5 Years of Age. Surveillance Performed in Hospitals From Four Brazilian Regions.||Merck Sharp & Dohme Corp.|No|Terminated|August 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|230|||Both|N/A|5 Years|No|Non-Probability Sample|Children less than 5 years of age from four Brazilian cities with diarrhea attributed to        rotavirus infection.|February 2015|February 23, 2015|September 3, 2010||No|Inadequate recruitment|No|November 8, 2012|https://clinicaltrials.gov/show/NCT01195844||116709|
NCT01217593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.116.C|Ultrasound vs. Predetermined Distance Techniques for Paravertebral Nerve Block in Patients Having Breast Surgery|A Comparison Of Ultrasound and Predetermined Distance Techniques For Paravertebral Space Localization In Breast Surgery: A Randomized Prospective Trial||Ochsner Health System|No|Recruiting|October 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|25 Years|85 Years|No|||March 2014|March 20, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217593||115049|
NCT01208298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCOWDH1001|Study to Evaluate Using a Cold Sore Patch to Treat Herpes Labialis|Study to Evaluate the Safety and Performance of Compeed® Cold Sore Patch Night in the Treatment of Herpes Labialis||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|18 Years|70 Years|No|||October 2011|October 4, 2011|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208298||115761|
NCT01208337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB0701088|Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation|Pharmacodynamics, Pharmacogenomics, and Preliminary Safety and Efficacy of Alemtuzumab Induction and Tacrolimus in Pediatric Intestinal Transplantation (IND # 100496)||University of Pittsburgh|Yes|Active, not recruiting|April 2007|November 2014|Anticipated|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|4 Months|25 Years|No|||August 2011|August 5, 2011|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208337||115758|
NCT01208961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM-EPA-001|Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation|A Randomized, Open-label, Four-Way Crossover Study to Compare the Relative Bioavailability of a Single Dose of Epanova® With Lovaza® After a Low-Fat and High-Fat Meal|ECLIPSE|AstraZeneca|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 19, 2015|September 23, 2010|Yes|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01208961||115711|
NCT01208623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC99-2314-B-038-024-|A Large Series of Clinical and Imaging Investigation to Patients With Chronic Lower Limb Edema With Unclear Etiology|A Large Series of Clinical and Imaging Investigation to Patients With Chronic Lower Limb Edema With Unclear Etiology||Taipei Medical University WanFang Hospital|No|Active, not recruiting|August 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|Between April 2008 and Dec 2009, a total of approximately 300 patients with chronic lower        limb edema who had had bilateral iliac digital venography and surgery at our institution        will be reviewed. All patients underwent surgery by one senior vascular surgeon for lower        limb conditions within one month after the venographic examination.|September 2010|September 23, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01208623||115736|
NCT01208636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton9|Environmental & Genetic Influences on Vitamin D Status|Environmental & Genetic Influences on Vitamin D Status||Creighton University|No|Completed|August 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|40|Samples With DNA|Blood was obtained for genetic testing of selected 13 candidate genes important for vitamin      D metabolism|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will include 50 "healthy" unrelated community dwelling males or females.        The subjects will be between ages 18-60.|September 2010|September 23, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01208636||115735|
NCT01209481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-48|Impact of Educational Group Intervention on the Consumption of Fruit and Vegetables|Impact of Educational Group Intervention on the Consumption of Fruit and Vegetables by Adult People Attended to Primary Health Care.|fvphc|UPECLIN HC FM Botucatu Unesp|No|Not yet recruiting|September 2010|March 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01209481||115671|
NCT01210040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.55|Long-term Iron Supplements and Malaria Risk in Early Pregnancy: a Randomized Controlled Trial|Malaria Risk Prior to and During Early Pregnancy in Nulliparous Women Receiving Long-term Weekly Iron and Folic Acid Supplementation (WIFS): a Non-inferiority Randomized Controlled Trial|PALUFER|Liverpool School of Tropical Medicine|Yes|Completed|April 2011|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|1959|||Female|15 Years|24 Years|Accepts Healthy Volunteers|||March 2014|March 18, 2014|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210040||115628|
NCT01209793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R846-HV-1007|Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety and Tolerability of Intravenously Administered REGN846 (SAR302352) in Healthy Volunteers||Regeneron Pharmaceuticals|Yes|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|September 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209793||115647|
NCT01210313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG C07|Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma|Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma||Austrian Breast & Colorectal Cancer Study Group|No|Completed|October 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|subjects with localised colorectal carcinoma|March 2014|March 6, 2014|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01210313||115607|
NCT01210586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA008075-07|Tobacco Cessation in Postmenopausal Women|Tobacco Cessation in Postmenopausal Women - Part I & Part II||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 1999|January 2008|Actual|January 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Female|40 Years|79 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210586||115586|
NCT01210820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTO-102-ISAK|Feasibility of iFS™ for Intrastromal Arcuate Keratotomy (ISAK) Procedures|A Prospective Single Center Study To Evaluate the Feasibility of Intrastromal Arcuate Keratotomy Performed With the IntraLase iFS™ Femtosecond Laser System||Abbott Medical Optics|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|21 Years|N/A|No|||April 2013|April 25, 2013|September 24, 2010||No||No|January 22, 2013|https://clinicaltrials.gov/show/NCT01210820||115568|This evaluation was performed on a small number of subjects and should be repeated in a larger number of subjects.
NCT01197209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTG-REIC-PC001|Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer|A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer||Momotaro-Gene Inc.|Yes|Withdrawn|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|20 Years|75 Years|No|||August 2013|August 21, 2013|September 3, 2010|Yes|Yes|Suspended due to change in development plans and investigator|No||https://clinicaltrials.gov/show/NCT01197209||116606|
NCT01197430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|980035|Vertical Stability Training Effects on the Eye-Hand Coordination of Female Volleyball Players|||Taipei Physical Education College|Yes|Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|||Actual|23|||Female|17 Years|21 Years|Accepts Healthy Volunteers|||November 2009|September 8, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01197430||116589|
NCT01194609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RadImmune Cx-1001|A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer|A Pilot Study of Radiation-Immune Cell Combination Therapy in Recurrent or Persistent Cervical Cancer||Korea Cancer Center Hospital|Yes|Terminated|September 2010|April 2012|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|75 Years|No|||May 2014|May 7, 2014|September 2, 2010||No|No further enrollment after two patients|No||https://clinicaltrials.gov/show/NCT01194609||116803|
NCT01194089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002241|Nicotine Administration and Post-operative Opioid Use With Bariatric Surgery|A Randomized, Double Blind, Study to Evaluate the Efficacy of Nasal Nicotine Spray to Reduce Post-Operative Opioid Requirements in Nonsmokers in Elective Laparoscopic Bariatric Surgical Patients||Mayo Clinic|No|Completed|August 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|95|||Female|18 Years|60 Years|No|||June 2015|June 10, 2015|September 1, 2010|Yes|Yes||No|May 13, 2015|https://clinicaltrials.gov/show/NCT01194089||116843|
NCT01194362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-161|A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease|A Study to Establish Genomic Bio Signatures of Ascending Aortic Aneurysms in Patients With Bicuspid and Tricuspid Aortic Valve Disease With Aortic Stenosis||Baylor Research Institute|No|Recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|105|Samples With DNA|Blood and Tissue|Both|18 Years|N/A|No|Probability Sample|Hospital facility|March 2015|March 12, 2015|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01194362||116822|
NCT01194375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-IDP-107-P2-02|A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris|||Dow Pharmaceutical Sciences||Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|180|||Both|12 Years|N/A|No|||June 2012|June 20, 2012|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194375||116821|
NCT01195571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age|A Dose Escalation Study to Assess the Safety and Immunogenicity of Four Live Attenuated Human Cytomegalovirus(HCMV) Vaccines in Healthy Adults Without Prior Immunity.||CMV Research Foundation|Yes|Completed|September 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01195571||116730|
NCT01196156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 27143|Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone|An Observational Phase IV Study for Prospective Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone|SGA|Merck KGaA|No|Active, not recruiting|September 2005|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|443|||Both|N/A|N/A|No|Non-Probability Sample|Children with growth disorder (current height <-2.5 SD and height adjusted to parental        stature <-1 SD) in children born SGA with a weight and/or length at birth below -2 SD,        that has not experimented a growth catch-up (growth speed <0 SD during the last year) at 4        years old or afterwards.|July 2015|July 15, 2015|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01196156||116687|
NCT01196143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700623-503|A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation|Non-interventional Observational Study to Evaluate the Baseline FSH, Ovarian Volume and AFC (Antral Follicle Count) as Prognostic Factors of the Outcome of the In-vitro Fertilization/Intracytosolic Sperm Injection (IVF/ICSI) in Infertile Patients Who Receive r-FSH (GONAL-f®) for Controlled Ovarian Hyperstimulation||Merck KGaA||Completed|October 2008|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|356|Samples Without DNA|Plasma, serum, urine|Female|20 Years|43 Years|No|Non-Probability Sample|Subjects undergoing COH for IVF/ICSI-treatment with Gonal-f in Greece.|February 2014|February 3, 2014|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01196143||116688|
NCT01196377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100725|Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study|Personalized Medicine, Biomarker-based Study of Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study|OARS|Vanderbilt University|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Both|5 Years|17 Years|No|||June 2012|June 19, 2012|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196377||116670|
NCT01207713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZhejiangU|A Modified Orbital Implantation Technique in Enucleation|Evaluation of the Functional and Cosmetic Outcome of Enucleation With Rectus End-to-end Suturing Surgical Technique in Coralline Hydroxyapatite Orbital Implants||Second Affiliated Hospital, School of Medicine, Zhejiang University|No|Completed|April 2009|December 2009|Actual|October 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|45|None Retained|The investigators reviewed surgical records from July 2005 to March 2009, to identify      patients who had received hydroxyapatite orbital implants after primary enucleation by a      single surgeon|Both|3 Years|73 Years|No|Non-Probability Sample|The patients who had received hydroxyapatite orbital implants after primary enucleation by        a single surgeon from July 2005 to March 2009|September 2010|September 22, 2010|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01207713||115805|
NCT01208012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lira-Vasc-001|Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus|Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus||ikfe-CRO GmbH|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|30 Years|65 Years|No|||March 2011|March 14, 2011|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01208012||115783|
NCT01209208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUG-1/LMC|Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis|Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Study on the Efficacy and Tolerability of a 8-week Treatment With Budesonide vs. Mesalazine vs. Placebo in Patients With Lymphocytic Colitis||Dr. Falk Pharma GmbH|Yes|Recruiting|May 2010|April 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|90 Years|No|||October 2015|October 22, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209208||115692|
NCT01208077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol: HFH DEM 002|PREMIUM Registry: PRognostic HEModynamIc Profiling in the AcUtely Ill EMergency Department Patient|PROGNOSTIC HEMODYNAMIC PROFILING IN THE ACUTELY ILL EMERGENCY DEPARTMENT PATIENT|PREMIUM|Henry Ford Health System|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|514|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Potential subjects will be screened and enrolled from the Emergency Department|August 2015|August 3, 2015|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01208077||115778|
NCT01209221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25342|A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers|A Phase 1 Placebo-controlled, Randomized, Observer-blind Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5271983 in Healthy Subjects.||Hoffmann-La Roche||Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209221||115691|
NCT01208662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-106|Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65|A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age|DFCI 10-106|Dana-Farber Cancer Institute|Yes|Recruiting|September 2010|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208662||115733|
NCT01209000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6801|Nephrotic Syndrome Study Network|Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network|NEPTUNE|University of Michigan|Yes|Recruiting|April 2010|June 2019|Anticipated|June 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|600|Samples With DNA|Renal tissue core (from clinically indicated kidney biopsy procedure) Blood products Urine      products DNA/RNA specimens (declining consent does not forego participant eligibility)      Finger/toe nail clippings|Both|N/A|80 Years|No|Non-Probability Sample|Adult patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or        proteinuric renal disease or pediatric participants not previously biopsied, who present        for patient care at the participating clinical centers will be the primary study        population targeted for enrollment into the NEPTUNE study. Potential participants willing        to receive their biopsy care, and subsequent follow-up study visits at one of these sites        are also welcome to participate.|December 2015|December 1, 2015|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01209000||115708|
NCT01209273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-01|Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis|Prospective, Observational and Multi-center Study of a Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis|EQlips|Kyungpook National University|Yes|Completed|October 2010|September 2015|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|260|Samples Without DNA|blood 24hr urine PD dialysate|Both|20 Years|N/A|No|Probability Sample|Incident PD patients in Korea|September 2015|September 11, 2015|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209273||115687|
NCT01209507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0190.cc|Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy|A Prevalence Study of Adrenal Suppression After Adjuvant Corticosteroid Administration During Gynecologic Cancer Chemotherapy||University of Colorado, Denver|No|Active, not recruiting|November 2010|December 2016|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Female|18 Years|N/A|No|Non-Probability Sample|The study will be open to all women over the age of 18 scheduled to begin standard of care        chemotherapy for a gynecologic malignancy, either every 3 weeks (carboplatin and taxol) or        weekly (cisplatin). The study is restricted by gender due to the population of interest        being women with gynecologic malignancies.|March 2016|March 1, 2016|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209507||115669|
NCT01209520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080779|Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy|Pilot Study Targeting Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer As Part of Adjuvant Therapy and Preventive Strategy||University of Miami|Yes|Completed|July 2009|||December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|September 22, 2010|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT01209520||115668|Study data were not analyzed due to insufficient number of evaluable patients.
NCT01209780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_18|Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age|A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age||Novartis||Completed|September 2010|September 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3116|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|September 24, 2010|Yes|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01209780||115648|Due to GCP non-compliance at the Mexico site, data of 312 subjects (3-8 year olds) enrolled from this site were excluded from the final immunogenicity and safety analysis.
NCT01209806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09D.472|The Effects of Moviprep With Simethicone on Colonic Bubbles|The Effects of Moviprep With Simethicone on Colonic Bubbles||Thomas Jefferson University|No|Completed|November 2009|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|140|||Both|18 Years|N/A|No|||November 2014|December 5, 2014|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01209806||115646|
NCT01210053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yang-001|Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|This Phase II Trial is Studying Sunitinib to See How Well it Works When Given as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer Which is Previously Treated With Combination Chemotherapy.||Third Military Medical University|Yes|Recruiting|September 2010|March 2012|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2010|September 27, 2010|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210053||115627|
NCT01210326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-009|The Comparison of Diagnostic TESE and TESA in Non-obstructive Azoospermic|The Comparison of Diagnostic Testicular Sperm Extraction(TESE) and Testicular Sperm Aspiration(TESA) in Non-obstructive Azoospermic Patients a Randomized Clinical Trial Study||Royan Institute|Yes|Completed|September 2009|September 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Male|20 Years|50 Years|No|||August 2008|July 14, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210326||115606|
NCT01193764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100520 - Intramural - Berman|Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris|Double Blind Placebo Controlled Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris||University of Miami|Yes|Recruiting|September 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2010|September 1, 2010|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193764||116868|
NCT01198015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL32481.068.10|Creatine Metabolism in Rett Syndrome|Metabolic Evaluation of Nutrition in Rett Syndrome: Creatine Metabolism||Maastricht University Medical Center|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|13|Samples With DNA|Whole blood, serum, leucocytes, erythrocytes, fibroblasts.|Female|3 Years|20 Years|No|Non-Probability Sample|The study population (identical to the population in the preliminary research project)        consists of a well-defined group of thirteen Dutch RTT girls with complete clinical,        molecular, neurophysiological and metabolic work-up.|February 2011|February 16, 2011|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01198015||116544|
NCT01195012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM-H-22657|Pilot RCT of an Obesity Intervention for Primary Care Pediatrics: Helping HAND|Pilot Randomized Controlled Trial for Feasibility of an Obesity "Prevention Plus" Intervention for Primary Care Pediatrics: Helping HAND|Helping HAND|Baylor College of Medicine|Yes|Completed|June 2008|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized|2||Actual|40|||Both|5 Years|8 Years||||September 2010|September 2, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01195012||116773|
NCT01194999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC-2010-04|Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence|Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence||Barrie Urology Associates|Yes|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Female|N/A|N/A|No|||August 2012|August 21, 2012|September 2, 2010|Yes|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT01194999||116774|The V8 questionnaire used for patient surveying has been validated, but forms of such a nature present potential over and under reporting of symptoms. Loss to follow-up presents an issue, although we anticipate those lost experienced improvements.
NCT01195285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-423|Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic Cholecystectomy|Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic Cholecystectomy: A Randomized Prospective Trial||Saint Luke's Health System|No|Terminated|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|80 Years|No|||August 2011|April 27, 2012|September 2, 2010|Yes|Yes|Investigator decisions based on slow enrollment.|No||https://clinicaltrials.gov/show/NCT01195285||116752|
NCT01195272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25243|A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.|A 52 Week, Single Center, Open-label Study to Evaluate Neutrophil Function and Survival Effects of Tocilizumab (TCZ) in Patients With Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy||Hoffmann-La Roche||Completed|August 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|September 2, 2010|No|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01195272||116753|
NCT01195870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR701068-514|Assessment of Patient Use of a New Device: RebiSmart|Assessment of Patient Use of a New Device: RebiSmart||Merck KGaA|No|Completed|July 2009|October 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients, who are under regular review by a Multiple Sclerosis nurse, with relapsing        remitting multiple sclerosis who have been prescribed Rebif and have chosen to use the        RebiSmart device for drug administration.|February 2014|February 14, 2014|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01195870||116707|
NCT01196702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006749|Lymphocyte Immunophenotyping in Common Variable Immunodeficiency|Investigation of the Lymphocyte Surface Expression of Patients With Primary Immunodeficiency (Common Variable Immunodeficiency (CVID)), Compared to Controls||Barts & The London NHS Trust|No|Recruiting|March 2010|July 2011|Anticipated|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||7|Anticipated|210|Samples With DNA|Blood serum samples kept for one year in secure laboratory.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients selected from medical clinics in the order of attendance with common        variable immunodeficiency, bronchiectasis, on long-term immunoglobulin treament and        granulomatous disease. Must be able to give consent for testing of B-cell immunophenotype.        Healthy control samples taken from colleagues.|September 2010|September 7, 2010|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01196702||116645|
NCT01208025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2-082|ParisK: Validation of Imaging Techniques|The Assessment of the Plaque at RISK by Non-invasive (Molecular) Imaging and Modelling (ParisK): Prospective Clinical Study for Diagnosis Efficacy for High Risk Plaque and Stroke.|ParisK|Maastricht University Medical Center|No|Active, not recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|244|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with neurological symptoms due to ischemia in the carotid artery territory and        with a carotid stenosis between 30-69% according to the ECST criteria will be included.|May 2015|May 26, 2015|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01208025||115782|
NCT01208376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCS 625|Prevalence of Liver Fibrosis and Progression of Liver Fibrosis|Prevalence of Liver Fibrosis and Progression of Liver Fibrosis in HIV-infected, Hepatitis C (HCV) and Hepatitis B (HBV) Seronegative Patients With Chronic Alanine Aminotransferase (ALT) Elevation||University of Zurich|No|Recruiting|October 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|HIV-infected, hepatitis B and C seronegative Patients With Chronic alanine        aminotransferase (ALT) Elevation|December 2014|December 9, 2014|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208376||115755|
NCT01208389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAV2-hRPE65v2-102|Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2|A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study||Spark Therapeutics|Yes|Active, not recruiting|November 2010|November 2026|Anticipated|November 2026|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|8 Years|N/A|No|||February 2015|February 2, 2015|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208389||115754|
NCT01208987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710-59|Improving Laboratory Follow-up by Delivering an Enhanced Medication List to Outpatient Physician Practices|||Indiana University|No|Suspended|December 2008|January 2011|Anticipated|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|4449|||Both|19 Years|N/A||||September 2010|September 23, 2010|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208987||115709|
NCT01208792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071209|Auto-immunity and Pulmonary Arterial Hypertension|Auto-immunity and Prognosis of Pulmonary Arterial Hypertension|Auto-HTAP|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2010|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|629|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01208792||115723|
NCT01209533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100637|Inhaled Iloprost in Mild Asthma|Inhaled Iloprost in Mild Asthma||Vanderbilt University|Yes|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|60 Years|No|||August 2011|August 1, 2011|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209533||115667|
NCT01209819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0262|Bone Mineral Density in Adults With Hyperphenylalaninemia|Bone Mineral Density in Adults With Hyperphenylalaninemia||The University of Texas Health Science Center, Houston|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with PKU or benign HPA followed at The University of Texas Health Science Center at        Houston will be invited to participate in the study. In addition, adults with PKU or        benign HPA in the State of Texas will be invited to participate.|June 2015|June 11, 2015|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209819||115645|
NCT01210339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00010|An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel|An Open-label, Randomized, Single-center, 2-way Cross-over Interaction Study, Evaluating the Effect of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg on the Pharmacodynamics and the Pharmacokinetics of Clopidogrel on Days 1 and 9 in Healthy Volunteers||AstraZeneca|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 6, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210339||115605|
NCT01210352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3319-302|Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects|An Open-Label, Non-randomized, Multicenter, Ascending Dose by Age, Single- and Multiple-Dose Evaluation of the Effectiveness, Safety, and Tolerability of Oral Liquid Oxymorphone HCl Immediate-Release Oral Liquid for Acute Postoperative Pain in Pediatric Subjects||Endo Pharmaceuticals|Yes|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|2 Years|12 Years|No|||March 2016|March 14, 2016|September 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01210352||115604|
NCT01210612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSC-12|The Effect of Five-Toed Socks on Postural Control Among Active Individuals Who Have Chronic Ankle Instabilities|The Effect of Five-Toed Socks on Postural Control Among Active Individuals Who Have Chronic Ankle Instabilities||University of Toledo Health Science Campus|No|Recruiting|September 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2010|December 15, 2010|June 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01210612||115584|
NCT01198028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0888|Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin|Phase II Study of Erlotinib, an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin||M.D. Anderson Cancer Center|Yes|Active, not recruiting|March 2011|||March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198028||116543|
NCT01194388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCESS-09012010|Axium Coil in Completing Endovascular Aneurysm Surgery Study|Axium Coil in Completing Endovascular Aneurysm Surgery Study: A Single-center, Prospective Observational Registry|ACCESS|ev3|No|Active, not recruiting|September 2010|||December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|90 Years|No|Non-Probability Sample|All patients presenting with an intracranial aneurysm will be evaluated by the neuro        interventional team, in accordance with institutional practice, to establish an        appropriate treatment plan based on the patient's medical condition and available        diagnostic screening prior to recruitment.|September 2010|September 1, 2010|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01194388||116820|
NCT01195311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 24360-101|A Dose-escalation Study in Subjects With Advanced Malignancies|A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies||Incyte Corporation|No|Completed|July 2010|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|August 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01195311||116750|
NCT01195298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22373|Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer|Phase II Clinical Study of Bevacizumab in Combination With Capecitabine as First-line Treatment in Elderly Patients With Metastatic Breast Cancer||South Eastern European Research Oncology Group|No|Recruiting|May 2010|||August 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|70 Years|N/A|No|||August 2010|September 3, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01195298||116751|
NCT01195584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Senker|Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease|Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease||General Hospital Amstetten|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|72|||Both|18 Years|N/A|No|Probability Sample|All patients who underwent minimal access spinal surgery for degenerative lumbar disease        fusion surgery.|March 2015|March 16, 2015|September 3, 2010||No||No|August 16, 2011|https://clinicaltrials.gov/show/NCT01195584||116729|The study is retrospective and all patients during the timeframe (who signed the patient informed consent) have been included into the study.
NCT01195883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1051|Effect of Goal- Directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity|||The Cleveland Clinic|Yes|Recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1112|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01195883||116706|
NCT01200719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-102|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) Enhances Neurological Function Recovery Among Post-stroke Patients||Fudan University|Yes|Completed|November 2006|September 2009|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|312|||Both|40 Years|79 Years|No|||October 2006|September 13, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200719||116340|
NCT01196403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000684060|Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer|Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer.||National Cancer Institute (NCI)||Recruiting|January 2009|||December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||September 2010|March 31, 2011|September 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01196403||116668|
NCT01196416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02524|Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma|Phase Ib/II Study of the Gamma-Secretase Inhibitor (GSI) RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Completed|August 2010|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||May 2015|August 27, 2015|September 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196416||116667|
NCT01196429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02653|Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer|A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary||National Cancer Institute (NCI)|Yes|Completed|August 2010|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Female|18 Years|N/A|No|||November 2015|November 20, 2015|September 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01196429||116666|
NCT01196715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS201001|Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes|REGIME: A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha, With or Without Recombinant Human Granulocyte Colony Stimulating Factor, Versus Best Supportive Care in Patients With Low-risk Myelodysplastic Syndromes (MDS).|REGIME|Barts & The London NHS Trust|Yes|Not yet recruiting|November 2010|November 2015|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|360|||Both|18 Years|N/A|No|||July 2010|March 14, 2012|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01196715||116644|
NCT01196728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CellMed CM3.1-AC100/03|Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes|Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes||CellMed AG, a subsidiary of BTG plc.|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|16|||Both|18 Years|75 Years|No|||December 2010|December 3, 2010|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01196728||116643|
NCT01208935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-IRP-322|Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence|Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence||National Institute on Drug Abuse (NIDA)||Completed|August 1999|August 2004|Actual|June 2004|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|157|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208935||115713|
NCT01208948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMP 77.1.99|Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema|Alpha Lipoic Acid in the Treatment of Diabetic Retinopathy|RETIPON|Ludwig-Maximilians - University of Munich|Yes|Completed|July 2000|December 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|520|||Both|45 Years|68 Years||||September 2010|September 23, 2010|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208948||115712|
NCT01207765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zevalin|Fixed Dose Radioimmunotherapy (Zevalin) for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma|A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma||Tufts Medical Center|No|Completed|April 2008|June 2013|Actual|January 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||December 2014|December 8, 2014|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207765||115801|
NCT01208090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-058A201|ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis|Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis||Actelion||Completed|October 2010|November 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|326|||Both|18 Years|60 Years|No|||January 2013|January 23, 2013|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208090||115777|
NCT01208103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0626|Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater|Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2011|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208103||115776|
NCT01208675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TiDiS-2010|Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach|Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach||Skåne University Hospital|No|Recruiting|September 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|Cerebrospinal fluid, plasma, DNA, mRNA|Both|60 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Community sample|April 2013|April 17, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208675||115732|
NCT01209260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MarcusHsu|Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access|Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access (TRAVERSE-LA): A Randomized Controlled Trial|TRAVERSE-LA|University of California, San Francisco|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|September 9, 2010||No||No|December 5, 2013|https://clinicaltrials.gov/show/NCT01209260||115688|
NCT01209286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT103-206|Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)|An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)||Amgen Research (Munich) GmbH|Yes|Active, not recruiting|October 2010|December 2016|Anticipated|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|September 23, 2010||No||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01209286||115686|
NCT01218451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|670901|NeisVac-C Single Prime Study in Infants|A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants||Pfizer|Yes|Completed|September 2010|June 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|956|||Both|8 Weeks|11 Weeks|Accepts Healthy Volunteers|||May 2015|May 20, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218451||114983|
NCT01209546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP 2010-2|Study of the Effect of FLUTTER® VRP1 (PEP and Oscillating High Frequency).|Study of the Effect of FLUTTER VRP1 in Patients With Bronchiectasis.|FLUTTER®VRP1|University of Sao Paulo|Yes|Terminated|July 2007|December 2010|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|30|||Both|20 Years|85 Years|No|||September 2010|June 26, 2012|July 12, 2010||No|The protocol finished.|No||https://clinicaltrials.gov/show/NCT01209546||115666|
NCT01210365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF083|Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema|Safety and Efficacy of the Combination of Furosemide 40 mg + Amiloride Hydrochloride 10 mg in the Reduction of Edema of Cardiac Origin in Patients With Congestive Heart Failure Functional Class II (NYHA)||Eurofarma Laboratorios S.A.|Yes|Suspended|January 2011|||February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|June 25, 2013|August 9, 2010||No|The company decided to suspended the study because the investigational product will change.|No||https://clinicaltrials.gov/show/NCT01210365||115603|
NCT01211223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Facultad Odontologia, U Chile|Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.|Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.|Metro + Amoxi|University of Chile|No|Recruiting|January 2010|March 2012|Anticipated|March 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|36|||Both|35 Years|65 Years|No|||September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211223||115537|
NCT01207596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-NP2010|Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain|Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain: An Open Label Study||International Clinical Research Institute|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||May 2012|May 17, 2012|September 20, 2010|Yes|Yes||No|October 4, 2011|https://clinicaltrials.gov/show/NCT01207596||115814|
NCT01194622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-03065-3282|Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays|Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays Single-centre, Randomised, Open-label, Three-period, Six-sequence Cross-over Trial (William's Design)||MEDA Pharma GmbH & Co. KG|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01194622||116802|
NCT01199861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2320|Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)|A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)||Novartis||Completed|August 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|55 Years|No|||May 2012|May 15, 2012|September 9, 2010||No||No|May 15, 2012|https://clinicaltrials.gov/show/NCT01199861||116406|
NCT01200134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015543-16|HYPONCO - Hypoxia in Brain Tumors|Hypoxia Diagnosis and Evaluation Using F-MISO PET and Biomarkers in Brain Tumors|HYPONCO|University Hospital, Caen|Yes|Completed|October 2010|July 2012|Actual|June 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200134||116385|
NCT01195597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT00/10|Smoking Cessation and Reduction With an Electronic Nicotine Delivery Device (ENDD)|Effect of an Electronic Nicotine Delivery Device (ENDD) on Smoking Cessation and Reduction: a Pilot Study||Universita degli Studi di Catania|Yes|Completed|February 2010|July 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|September 3, 2010||No||No|May 22, 2012|https://clinicaltrials.gov/show/NCT01195597||116728|
NCT01196169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0310.7f|Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty|Daptomycin Use For Prophylaxis In Prosthetic Joint Surgery, A Randomized Prospective Study Comparing The Efficacy Of Daptomycin Versus Vancomycin For Peri-Operative Antibiotic Prophylaxis In MRSA Colonized Adult Patients Undergoing Primary Elective Hip, Knee or Shoulder Arthroplasty||Mountain Home Research & Education Corporation|Yes|Terminated|October 2010|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|90 Years|No|||January 2014|January 31, 2014|June 4, 2010|Yes|Yes|The study is closed to accrual. Enrollment of new patients stopped at the request of CUBIST    Pharmaceuticals due to slow rate of enrollment.|No||https://clinicaltrials.gov/show/NCT01196169||116686|
NCT01200433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-715|The Effects of Dexmedetomidine and Propofol on Cerebral Blood Flow and Brain Oxygenation During Deep Brain Stimulation|||The Cleveland Clinic|No|Active, not recruiting|October 2010|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|44|||Both|18 Years|80 Years|No|||October 2013|December 17, 2013|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200433||116362|
NCT01201798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-034|Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis|A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis||Alcon Research|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|2 Years|N/A|No|||October 2012|October 15, 2012|September 13, 2010|Yes|Yes||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01201798||116257|
NCT01200927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183-02|Sitting Postural Control in Infants With Cerebral Palsy|INVESTIGATION OF THE DYNAMICS OF SITTING POSTURAL CONTROL IN INFANTS WITH CEREBRAL PALSY||University of Nebraska|No|Completed|December 2004|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||Actual|35|||Both|5 Months|24 Months|No|||September 2010|September 13, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200927||116324|
NCT01200940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100163|Metabolic Effects of Non-Nutritive Sweeteners|Metabolic Effects of Non-Nutritive Sweeteners||National Institutes of Health Clinical Center (CC)||Recruiting|June 2010|June 2020|Anticipated|June 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Both|6 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|September 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01200940||116323|
NCT01201213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007AN01|Bupivacaine, Levobupivacaine and Ropivacaine After Intrathecal and Extradural Injection in Labour|Median Effective Concentration of Bupivacaine, Levobupivacaine and Ropivacaine After Intrathecal and Extradural Injection for Pain Relief in the First Stage of Labour||NHS Tayside|No|Suspended|September 2009|August 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|162|||Female|18 Years|45 Years|No|||January 2010|September 13, 2010|September 13, 2010|Yes|Yes|Audit pre regulatory inspection|No||https://clinicaltrials.gov/show/NCT01201213||116302|
NCT01201226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrimordialFollicleActivat.CTIL|Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive?|Can Dormant Ovarian Follicles From Perimenopausal Women Become Gonadotropin Responsive by Incubation With PTEN Inhibitor and PI3K Activating Peptide?||The Baruch Padeh Medical Center, Poriya|No|Not yet recruiting|November 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Female|45 Years|51 Years|Accepts Healthy Volunteers|||September 2010|September 13, 2010|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201226||116301|
NCT01208064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-08092|Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy|Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study.||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|July 2011|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|120 Years|No|||January 2016|January 21, 2016|September 22, 2010||No|based on IDMC decision|No||https://clinicaltrials.gov/show/NCT01208064||115779|
NCT01208129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903|Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks||Promius Pharma, LLC|No|Terminated|September 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|458|||Both|18 Years|70 Years|No|||July 2013|July 8, 2013|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208129||115774|
NCT01208688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-36|FES Therapy:Restoring Voluntary Grasping Function in Chronic SCI|FES Therapy:Restoring Voluntary Grasping Function in Chronic SCI||Toronto Rehabilitation Institute|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208688||115731|
NCT01217567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cicatricestudiet|Subcuticular Suture Versus Staples for Closure of the Skin After Caesarean Section.|Subcuticular Suture Versus Staples for Closure of the Skin After Caesarean Section: A Prospective Randomized Single-blinded Case-Control Study With the Case as it's Own Control.||Holbaek Sygehus|No|Completed|March 2010|January 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 7, 2012|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217567||115051|
NCT01210898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70P5E1|Immunogenicity and Safety of V70P5 Revaccination Subjects|A Phase IIIB, Observer-Blind, Randomized, Parallel Groups, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of a Sub-unit Adjuvanted or a Non-adjuvanted Influenza Vaccines in Healthy Children Previously Vaccinated in the V70P5 Study||Novartis||Completed|September 2010|December 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|13||Actual|197|||Both|18 Months|96 Months|Accepts Healthy Volunteers|||January 2012|January 27, 2012|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01210898||115562|
NCT01210911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCmedonc10/003|Metformin Combined With Chemotherapy for Pancreatic Cancer|A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gemcitabine, Erlotinib and Metformin in Patients With Locally Advanced and Metastatic Pancreatic Cancer|GEM|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|August 2010|April 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||September 2010|May 19, 2014|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210911||115561|
NCT01207349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM01-23|Type 2 Diabetes Secondary Prevention|Type 2 Diabetes Secondary Prevention Trial at the Reunion Island|RP2|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|August 2002|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|398|||Both|18 Years|N/A|No|Non-Probability Sample|type 2 diabetic patients|January 2012|January 27, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01207349||115833|
NCT01207362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-648-09|Assessing and Improving Balance Using Platform Perturbations|Assessing and Improving Balance Using Platform Perturbations||Kessler Foundation|No|Active, not recruiting|August 2009|December 2010|Anticipated|August 2010|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|4|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adults|September 2010|September 21, 2010|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207362||115832|
NCT01207843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|idr-3d-001|Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias|Verbesserung Der Radiologischen Diagnose Von Hepatolienaler Candidiasis während Der Therapie Der Leukämie||University of Zurich|No|Completed|October 2009|May 2013|Actual|April 2011|Actual|Phase 4|Observational|Time Perspective: Retrospective||1|Actual|88|||Both|16 Years|80 Years|No|Probability Sample|patients with suspected hepatolienal candidiasis.|August 2014|August 18, 2014|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207843||115795|
NCT01208181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-107|A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)|A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK‑0663/Etoricoxib in Patients With Rheumatoid Arthritis||Merck Sharp & Dohme Corp.|No|Completed|September 2010|July 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1404|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|September 22, 2010|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01208181||115770|
NCT01208194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGN1703-C02|Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma|Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy|IMPACT|Mologen AG|Yes|Completed|June 2010|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01208194||115769|
NCT01195025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VkVR|Volume Kinetics for Starch Solution and Acetated Ringers|Volume Kinetics for Starch Solution and Acetated Ringers||University Hospital, Linkoeping|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|10|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|August 31, 2010||No||No|March 12, 2014|https://clinicaltrials.gov/show/NCT01195025||116772|
NCT01200953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100197|Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases|Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|August 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|2 Years|N/A|Accepts Healthy Volunteers|||March 2015|September 24, 2015|September 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01200953||116322|
NCT01200966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100199|Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates|Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 2010|||||N/A|Observational|N/A|||Actual|96|||Both|21 Years|N/A|No|||January 2016|February 24, 2016|September 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01200966||116321|
NCT01200147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schatzki-2010|Effectiveness of Rupture of Schatzki's Ring Using Biopsy Forceps Versus SIngle Dilation|Effectiveness of Rupture of Schatzki's Ring Using Biopsy Forceps Versus SIngle Dilation||Nova Scotia Health Authority|Yes|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|80 Years|No|||September 2010|September 10, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200147||116384|
NCT01200420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC3649-203|Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (Miravirsen) Administered to Treatment-Naïve Subjects With Chronic Hepatitis C (CHC) Infection||Santaris Pharma A/S|Yes|Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||January 2012|January 26, 2012|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01200420||116363|
NCT01201538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-024|A Study of Nilotinib in Growing Vestibular Schwannomas|A Phase II Study of Nilotinib in Growing Vestibular Schwannomas||University Health Network, Toronto|No|Terminated|October 2010|October 2013|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 13, 2010||No|Study PI passed away We had trouble recruiting for the drug arm|No||https://clinicaltrials.gov/show/NCT01201538||116277|
NCT01201811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-MDS-001|Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)|A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes.||Celgene|No|Completed|November 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|September 13, 2010|Yes|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01201811||116256|
NCT01201824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10.115|Thoracoscopic Localization of Pulmonary Nodules Using Direct Intracavitary Thoracoscopic Ultrasound|Thoracoscopic Localization of Pulmonary Nodules Using Direct Intracavitary Thoracoscopic Ultrasound|CT0007|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2010|March 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|93|||Both|18 Years|N/A|No|||May 2015|November 24, 2015|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201824||116255|
NCT01202097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF113|A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients With Asthma|A PHASE III, RANDOMIZED, OPEN-LABEL, NON-INFERIORITY COMPARATIVE STUDY BETWEEN SERETIDE® 50/250 µG AND SALMETEROL/FLUTICASONE SINGLE INHALATION CAPSULE 50/250 µG EUROFARMA IN PATIENTS WITH ASTHMA|CAINAS SF|Eurofarma Laboratorios S.A.|Yes|Completed|August 2011|May 2012|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|334|||Both|12 Years|N/A|No|||September 2010|May 4, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202097||116234|
NCT01202396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-10-2-033|The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis|The Interaction Between the Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis: a Multifactorial Approach||Maastricht University Medical Center||Not yet recruiting|November 2010|November 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|In the prospective study the following biospecimens will be collected: faeces, serum,      plasma, leucocytes, urine, intestinal biopsies and mucus|Both|18 Years|65 Years|No|Non-Probability Sample|Consecutive patients undergoing proctocolectomy with the construction of an ileal pouch        anal anastomosis will be asked to participate in the study|September 2010|September 14, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01202396||116211|
NCT01202409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0458|CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater|Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater||M.D. Anderson Cancer Center|Yes|Recruiting|November 2010|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202409||116210|
NCT01208142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.001|Toe Walker Gait Trial|Dynamic Splinting for Toe Walking: a Randomized, Controlled Study With Gait Analysis|TW|Dynasplint Systems, Inc.|No|Terminated|September 2010|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|1 Year|18 Years|No|||August 2013|August 8, 2013|September 22, 2010||No|Unrelated to trial|No||https://clinicaltrials.gov/show/NCT01208142||115773|
NCT01208402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024224|Esmolol for Treatment of Perioperative Tachycardia|Safety and Efficacy of Esmolol for the Treatment of Peri-operative Tachycardia in Patients at Risk for Post Operative Adverse Ischemic Outcomes||Duke University|No|Terminated|September 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|76|||Both|41 Years|N/A|No|||November 2014|November 25, 2014|September 10, 2010|Yes|Yes|Baxter has terminated the study for inadequate enrollment rate accrual.|No|November 13, 2014|https://clinicaltrials.gov/show/NCT01208402||115753|
NCT01208415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-625-P1|PRESERVE-Zenith® Iliac Branch System Clinical Study|PRESERVE-Zenith® Iliac Branch System Clinical Study||Cook||Active, not recruiting|January 2011|May 2017|Anticipated|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208415||115752|
NCT01208701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-FHC-2010-3|The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy|The Effect of Atorvastatin on the NO-system in Patients With Type 2 Diabetes and Nephropathy|STAD|Regional Hospital Holstebro|Yes|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|N/A|No|||August 2015|August 19, 2015|September 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01208701||115730|
NCT01208519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7-N° 241796|SATURN 04 Nosocomial Acquisition Study|Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria in Hospitalised Patients (SATURN 04)|SATURN|Catholic University of the Sacred Heart|Yes|Active, not recruiting|November 2010|January 2015||November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|16680|Samples Without DNA|Nasal and rectal swabs|Both|18 Years|N/A|No|Non-Probability Sample|All patients will be screened at hospital admission and hospital discharge during the        study period. Patients colonised with MRSA and/or ESBL-producing gram-negative bacteria        before starting antibiotic therapy will be excluded from follow-up cultures and analysis.        Patients starting antibiotic therapy per os and/or intravenously will be sampled at        antibiotic start (t0, within one hour) and at the following intervals: day 3 (t1), 7 (t2),        15 (t3), 30 (t4). Screening will be performed in outpatient clinics after patients'        discharge from the hospital.|November 2012|February 12, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208519||115744|
NCT01208532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDC29_Kor|Validation Study of the Korean Version of the EORTC QLQ-HDC29|Quality of Life in Patients With Stem Cell Transplant After High Dose Chemotherapy: Validation Study of the Korean Version of the EORTC QLQ-HDC29||Seoul National University Hospital|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|226|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients who are diagnosed with hematologic malignancies and who are planned to recieve        high-dose chemotherapy followed by allo or auto stem cell transplantation in Seoul        National University Hospital, Korea|April 2015|April 21, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208532||115743|
NCT01218178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/479/CE/2010|Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction|BIcarbonato di Sodio e N-Acetilcisteina Nella Prevenzione Della Nefropatia da Mezzo di Contrasto Nell'infaRto mIocardico acutO(Registro BINARIO)|BINARIO|Catholic University of the Sacred Heart|No|Completed|June 2008|October 2011|Actual|October 2011|Actual|Phase 3|Observational|Observational Model: Case Control||2|Actual|520|||Both|18 Years|89 Years|No|Probability Sample|• Consecutive patients admitted from ER of the Policlinico Agostino Gemelli and Casilino        of Rome with a ST-Segment Elevation Myocardial Infarction undergoing urgent PCI|March 2015|March 12, 2015|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01218178||115004|
NCT01218191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSA-2|Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage.|Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage Assessed With Cardiac 18F-FDG PET and 123I-MIBG Scintigraphy: a Prospective Observational Study.|HSA-2|Direction Centrale du Service de Santé des Armées|Yes|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|patients presenting a SAH|February 2012|February 17, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01218191||115003|
NCT01210066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21DA027558|Pain, Opioids and Pro-Inflammatory Immune Responses|Pain, Opioids and Pro-Inflammatory Immune Responses||University of California, Los Angeles|Yes|Recruiting|July 2010|August 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|44|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 4, 2012|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210066||115626|
NCT01210079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DA 05463|Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?|Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?||University of California, Los Angeles|No|Completed|September 2002|May 2010|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|55 Years|No|||February 2012|March 11, 2012|September 27, 2010||No||No|December 5, 2011|https://clinicaltrials.gov/show/NCT01210079||115625|Baseline hyperalgesia not established. Duration of trial only 5 weeks. Findings can only be generalized to methadone-maintained patients who are able to abstain from illicit drug use over an extended period of time.
NCT01210092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-182-2|Comparison of Different Video Laryngoscopes in a Manikin With Immobilized Cervical Spine|Comparison of Different Video Laryngoscopes in a Manikin With Immobilized Cervical Spine||University of Cologne|No|Completed|August 2010|January 2011|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||6|Anticipated|25|||Both|25 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|anaesthesiologists|September 2011|September 21, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210092||115624|
NCT01207115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-889|A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee|A Global Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Osteoarthritis Pain of the Knee||AbbVie|Yes|Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|322|||Both|40 Years|75 Years|No|||January 2013|January 2, 2013|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207115||115851|
NCT01207128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2010-14|Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis|A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer||University of Arkansas|Yes|Withdrawn|February 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|September 21, 2010|Yes|Yes|None enrolled|No||https://clinicaltrials.gov/show/NCT01207128||115850|
NCT01207856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/07|Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis|Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis and Assessment by Neuroimaging|REACTIV|University Hospital, Bordeaux|No|Completed|May 2011|February 2016|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01207856||115794|
NCT01207869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-104|Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia|Intratracheal Instillation of Umbilical Cord-derived Mesenchymal Stem Cells as a Rescue Treatment for Severe Bronchopulmonary Dysplasia||China Medical University Hospital|Yes|Active, not recruiting|July 2010|July 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|N/A|6 Months|No|||September 2010|September 22, 2010|September 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01207869||115793|
NCT01208740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2010|Metformin in Patients With PCOS and Predictors of Poor Ovarian Response Ongoing In-vitro Fertilization|Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response||University Magna Graecia|Yes|Terminated|January 2009|March 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Female|35 Years|45 Years|No|||May 2011|May 23, 2011|May 24, 2010||No|Concerns about safety at the first interim analysis|No||https://clinicaltrials.gov/show/NCT01208740||115727|
NCT01208753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0555-CL-102|Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of GLPG0555 in Healthy Subjects.||Galapagos NV|No|Completed|September 2010|February 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208753||115726|
NCT01199588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEX-ULC-007|A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers|A Randomized, Parallel Group, Dose-Ranging, Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nexagon® in the Treatment of Subjects With a Venous Leg Ulcer|NOVEL2|CoDa Therapeutics Inc.|Yes|Completed|May 2011|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199588||116426|
NCT01201239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAL-001|Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients|An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir（RAL）in Treatment-experienced HIV-1 Infected Adult Chinese Patients||Shanghai Public Health Clinical Center|Yes|Not yet recruiting|September 2010|October 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||September 2010|September 13, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201239||116300|
NCT01201252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110846|Study to Estimate the Disease Burden of Acute Rotavirus Gastroenteritis in Children < 5 Years in United Arab Emirates|An Observational, Hospital-based Surveillance to Estimate the Disease Burden of Acute Rotavirus (RV) Gastroenteritis (GE) in Children < 5 Years of Age in United Arab Emirates (UAE).||GlaxoSmithKline||Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|717|Samples With DNA|Stool|Both|N/A|5 Years|No|Non-Probability Sample|Children < 5 years of age hospitalised with acute gastroenteritis|November 2012|November 15, 2012|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201252||116299|
NCT01201551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|088-Mom-2010|Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature|Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature||University Hospital, Basel, Switzerland|No|Completed|June 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|48 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201551||116276|
NCT01201837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-001-CLIN-002|Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial|CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome|CHI SQUARE|Cerenis Therapeutics, SA|Yes|Completed|March 2011|March 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|507|||Both|N/A|75 Years|No|||January 2014|January 29, 2014|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201837||116254|
NCT01202110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020850|Early Propranolol After Traumatic Brain Injury: Phase II|A Phase II, Dose Escalation, Single Center Study on the Effects of Early Propranolol on Heart Rate, Blood Pressure, and Cerebral Perfusion Pressure in Subjects Who Present With Moderate to Severe Traumatic Brain Injury.|EPAT: Phase II|Cedars-Sinai Medical Center|Yes|Recruiting|June 2010|May 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2010|June 21, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202110||116233|
NCT01202123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999906 CS10|Post Marketing Surveillance of MENOPUR|Post Marketing Surveillance of MENOPUR||Ferring Pharmaceuticals|No|Completed|December 2008|February 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2501|||Female|18 Years|N/A|No|Probability Sample|Infertile women|February 2014|February 20, 2014|September 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202123||116232|
NCT01202422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081198|An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule|An Open-Label, Multiple-Dose, Randomized, 3-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 165 Mg And 330 Mg Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal And 150 Mg Of The Immediate Release Formulation Administered Twice Daily||Pfizer|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 9, 2010|September 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202422||116209|
NCT01208467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8017|Prognostic Biomarkers in Patients With Endometrial Cancer|Validating The Prognostic Role of ATR Mutation in Patients With Endometrioid Endometrial Cancer||Gynecologic Oncology Group||Not yet recruiting|January 2100|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2824|||Female|N/A|N/A|No|Non-Probability Sample|Patients with endometrial cancer|June 2015|June 3, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208467||115748|
NCT01208428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026533|Cognitive Behavioral Treatments for Depression in Chronic Illness|Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness||Duke University|Yes|Completed|April 2011|August 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|85 Years|No|||March 2015|March 13, 2015|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208428||115751|
NCT01208441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02487|RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer|A Phase Ib Neoadjuvant Study of the Gamma Secretase Inhibitor (RO4929097) in Combination With the Aromatase Inhibitor Letrozole in Post-Menopausal Women With Stage II/III Hormone Receptor-Positive Breast Cancer||National Cancer Institute (NCI)||Terminated|November 2010|||December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||September 2013|September 27, 2013|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208441||115750|
NCT01208454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02522|Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma|Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma||National Cancer Institute (NCI)||Completed|December 2010|||September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|N/A|30 Years|No|||November 2015|November 23, 2015|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208454||115749|
NCT01207154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0724/40|Feasibility of Using Depth-of-sedation Measuring Equipment (BIS) to Guide Awake Fibreoptic Intubation|BIS-guided Conscious Sedation for Awake Intubation||Oxford University Hospitals NHS Trust|No|Suspended|December 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|79 Years|No|Non-Probability Sample|Patients requiring elective maxillofacial, ENT or cervical spine neurosurgery who also        require awake fibreoptic intubation|May 2013|May 30, 2013|September 21, 2010||No|Difficulty in Recruitment due to lack of investigators and suitable patients|No||https://clinicaltrials.gov/show/NCT01207154||115848|
NCT01209013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-PO-PHOEST07-01|Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE)|Multicenter, Prospective, Open-label, Single-arm Phase IIIb/IV Clinical Study on the Safety of Photodynamic Therapy With Porfimer Sodium for Injection for the Ablation of High-grade Dysplasia in Barrett's Esophagus|Oedisse|Pinnacle Biologics Inc.|No|Withdrawn||||||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|September 17, 2010|Yes|Yes|Sponsor cancelled the study|No||https://clinicaltrials.gov/show/NCT01209013||115707|
NCT01210625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutrabiotix|Starch-entrapped Microspheres [Nutrabiotix Fiber] for Gut Health|A Randomized, Double Blind, Controlled, Dose Ranging Trial to Compare Nutrabiotix Fiber to Psyllium Fiber in Patients Experiencing Constipation.|NTX|Rush University Medical Center|No|Active, not recruiting|July 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|120|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210625||115583|
NCT01218984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-004|ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids|A Randomized, Single-Dose Opiate Challenge Study of Medisorb® Naltrexone in Opioid-Using Adults||Alkermes, Inc.|No|Completed|March 2002|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 3, 2011|October 8, 2010|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT01218984||114942|
NCT01219257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011110|Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy|Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting First Time or Switching to a New Biological Therapy; the ULSpABiT Study.|ULSPABIT|Diakonhjemmet Hospital|No|Completed|September 2011|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|Samples With DNA|At the first visit, one glass with blood will be frozen for later genetical analyzes, all      related to questions regarding SpA.|Both|18 Years|85 Years|No|Non-Probability Sample|SpA patients with high disease activity|January 2016|January 19, 2016|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01219257||114921|
NCT01200732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES/F.501(134)/EC/07/MC|Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome|Clinical Efficacy of Phosphodiesterase-5 Inhibitor Tadalafil in Eisenmenger Syndrome - A Randomised, Placebo Controlled, Double Blind, Crossover Study||Govind Ballabh Pant Hospital|No|Completed|February 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||August 2010|September 13, 2010|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01200732||116339|
NCT01200446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005001346|Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Docosahexaenoic Acid (DHA) as a Nutritional Treatment for Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma||Indiana University|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|40 Years|No|||May 2011|May 25, 2011|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01200446||116361|
NCT01200459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090640|SMART: A Social and Mobile Weight Control Program for Young Adults|SMART: A Social and Mobile Weight Control Program for Young Adults|SMART|University of California, San Diego|Yes|Completed|May 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|404|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200459||116360|
NCT01200745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHU 20100675|Efficacy of Topical Capsaicin on Chronic Neck Pain|Efficacy of Topical Capsaicin on Chronic Neck Pain ; Double-blinded Randomized Trial||Kyunghee University Medical Center|Yes|Not yet recruiting|September 2010|February 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2010|September 13, 2010|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01200745||116338|
NCT01201265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25420|A Study of Avastin (Bevacizumab) in Combination With Gemcitabine and Carboplatin as First Line Treatment in Patients With Triple Negative Metastatic Breast Cancer|Multi Centre, Pilot Phase II Trial Assessing the Efficacy and Safety of Bevacizumab + Gemcitabine + Carboplatin as First Line Treatment for Patients Diagnosed With Triple Negative Metastatic Breast Cancer.||Hoffmann-La Roche||Completed|February 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|September 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01201265||116298|
NCT01201278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI2010-001|PK/PD Study of Intranasal Insulin in Type I Diabetes|A Phase 1, Randomized, 3-Way Crossover, Investigator Initiated Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Two Doses of Intranasally Administered Regular Human Insulin Compared to a Single Dose of a Subcutaneously Injected Rapid Acting Insulin Analog (Humalog®) in Subjects With Type I Diabetes||Hompesch, Marcus, M.D.|No|Not yet recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|65 Years|No|||June 2011|June 15, 2011|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201278||116297|
NCT01201564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPOM-46/10|Comparative Study Matching Intraperitoneal Onlay Mesh (IPOM) and Sublay Mesh to Treat Umbilical Hernia|Prospective Randomized Multicenter Trial Comparing Laparoscopic (IPOM) vs. Sublay Mesh Plasty for Umbilical Hernia in Adults||University Hospital, Basel, Switzerland|No|Recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01201564||116275|
NCT01201577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09GA014|Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals|Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals||University of Nottingham|No|Completed|October 2009|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|40|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201577||116274|
NCT01202162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00036200|A Comparison of Desflurane vs. Sevoflurane and the Time to Awakening and the Incidence and Severity of Cough|A Comparison of Desflurane vs. Sevoflurane on Time to Awakening and the Incidence and Severity of Cough After Ambulatory Surgery Using Laryngeal Mask Airway||Northwestern University|No|Completed|February 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|85|||Both|18 Years|65 Years|No|||October 2013|October 29, 2013|September 13, 2010|Yes|Yes||No|April 8, 2013|https://clinicaltrials.gov/show/NCT01202162||116229|Our study is only valid if interpreted within the context of its limitations. We have only evaluated female subjects undergoing ambulatory hysteroscopic surgery which limits the generalizability of our results.
NCT01202136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00026447|The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study|The Clinical,Radiologic, Pathologic and Molecular Marker Characteristics of Premalignant and Malignant Pancreatic Cysts Study|PCyst|Johns Hopkins University|No|Active, not recruiting|October 2012|September 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Blood, pancreatic cyst fluid|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred to Johns Hopkins for evaluation of pancreatic cysts|April 2015|April 10, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01202136||116231|
NCT01202149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0879|Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis|Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis||Frankel, Amylynne, M.D.|Yes|Completed|March 2010|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|2 Years|N/A|No|||April 2011|April 14, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202149||116230|
NCT01202435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081215|An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule|An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 82.5 Mg Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 25 Mg Of The Immediate Release Formulation Administered Three Times Daily||Pfizer|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|September 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202435||116208|
NCT01202448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-091|Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma|Prospective Cohort Study With Risk-adapted Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma|PROCESS|Samsung Medical Center|Yes|Completed|August 2010|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|600|||Both|20 Years|N/A|No|||March 2015|March 1, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01202448||116207|
NCT01210131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX4 in small cell lung cancer|Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)|Individualized Hypoxia-guided Radiotherapy Combined With Standard Cisplatin-etoposide in Stage I-III SCLC|HX4 in SCLC|Maastricht Radiation Oncology|No|Withdrawn|July 2013|August 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|August 26, 2013|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210131||115621|
NCT01210391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.43.PED|Growth of Infants Fed an Extensively Hydrolyzed Infant Formula|Assessment of Growth of Infants Fed a 100% Whey Extensively Hydrolyzed Formula.||Nestlé|No|Completed|November 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|282|||Both|N/A|4 Months|Accepts Healthy Volunteers|||June 2014|June 25, 2014|September 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01210391||115601|
NCT01210404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8121023|Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance|Open Label Single Sequence Study To Estimate The Effect Of Filibuvir (PF-00868554) On S-And R-Methadone In Subjects Receiving Chronic Methadone Treatment And To Evaluate The Pharmacokinetics Of Filibuvir||Pfizer|No|Completed|February 2011|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|September 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01210404||115600|
NCT01209052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112483|First Time in Human Study With GSK1325756|A Single-centre, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerabilty, Pharmacokinetics, and Pharmacodynamics of Single, Oral, Ascending Doses and Repeat Oral Doses of GSK1325756 in Healthy Male Subjects.||GlaxoSmithKline|No|Completed|October 2009|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|58|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|August 23, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209052||115704|
NCT01209338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655|Acceptability and Feasibility of Human Papilloma Virus Vaccine|Acceptability and Feasibility of Human Papilloma Virus Vaccine||Tata Memorial Hospital|No|Recruiting|November 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1000|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 27, 2010|June 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01209338||115682|
NCT01209832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13074|A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients|The Effect of Tasisulam on CYP3A-mediated Metabolism of Midazolam: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Tumors or Lymphoma||Eli Lilly and Company|No|Terminated|September 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|September 23, 2010|No|Yes|Terminated based on safety results from another trial|No||https://clinicaltrials.gov/show/NCT01209832||115644|
NCT01218789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-3202|Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception|Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception||Vanda Pharmaceuticals|No|Recruiting|September 2010|||September 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|75 Years|No|||January 2015|January 6, 2015|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218789||114957|
NCT01217840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10012010-6989|Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents|The Effect of Vitamin D on Cytokines and Cardiometabolic Risk in Obese Adolescents||Stanford University|No|Completed|September 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|11 Years|17 Years|No|||February 2015|February 13, 2015|October 7, 2010||No||No|February 13, 2015|https://clinicaltrials.gov/show/NCT01217840||115030|
NCT01218750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46/WIM/2008|Triple Therapy for Diffuse Diabetic Macular Edema|Combined Phako-Vitrectomy With ILM Peeling, Retinal Endophotocoagulation, and Intraoperative Use of Bevacizumab for Diffuse Diabetic Macular Edema|TTDDME|Military Institute of Medicine, Poland|Yes|Recruiting|December 2008|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||September 2010|October 18, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01218750||114960|
NCT01218763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITHO02|CANadian Clinical Evaluation of SpiderFlash Arrhythmia DETECTion in SpiderFlash™ Device|CANadian Clinical Evaluation of the Automatic Arrhythmia DETECTion in SpiderFlash™ Device|CAN-DETECT|Sorin Group Canada|No|Recruiting|April 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|101|||Both|N/A|N/A|No|Non-Probability Sample|Candidates may come from the investigator's general population, who require DR ICD or        CRT-D therapy for primary or secondary ICD indication and meet all study eligibility        criteria.|April 2010|June 10, 2011|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218763||114959|
NCT01218464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302-003|Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure|Phase Ⅰ/Ⅱ Study of Human Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs) for Treatment of Liver Failure||Beijing 302 Hospital|Yes|Recruiting|March 2009|March 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||May 2013|May 30, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218464||114982|
NCT01218776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISACS-TC 1|International Survey of Acute Coronary Syndromes in Transitional Countries|International Survey of Acute Coronary Syndromes in Transitional Countries|ISACS-TC|University of Bologna|No|Recruiting|September 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24000|Samples With DNA|whole blood, serum, white cells,|Both|18 Years|N/A|No|Probability Sample|Subjects admitted with a diagnosis of acute coronary syndromes.|January 2016|January 23, 2016|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218776||114958|
NCT01200771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07005 FUO TEP|Impact of the PET in the Diagnosis Strategy of FUO or Inflammatory Syndrome in Immunocompetent Patients FUO-TEP|Impact of the PET-scan in the Diagnosis Strategy of Fever Unknown Origin or Inflammatory Syndrome in Immunocompetent Patients|FUO-TEP|University Hospital, Limoges|No|Completed|May 2008|February 2014|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|116|||Both|18 Years|N/A|No|||October 2012|February 17, 2014|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01200771||116336|
NCT01201291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5070218|Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury|Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury|BRAINOXY|Kuopio University Hospital|Yes|Terminated|November 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|65 Years|No|||December 2013|December 20, 2013|September 13, 2010||No|Due to slow recruitment the study was terminated|No||https://clinicaltrials.gov/show/NCT01201291||116296|
NCT01201304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEstudyUW|Comparison of Methods for the Delivery of Interoceptive Exposure|Comparison of Methods for the Delivery of Interoceptive Exposure||University of Wyoming|No|Enrolling by invitation|January 2010|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2012|January 26, 2012|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01201304||116295|
NCT01201850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0418|The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors|The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors||University of Colorado, Denver|No|Recruiting|July 2010|February 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|25 Years|No|||February 2016|February 11, 2016|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201850||116253|
NCT01202175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100353|Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension|Effects of the Novel Beta-adrenergic Antagonist Nebivolol (Bystolic) on Prehypertensive Subjects at Genetic Risk of Hypertension: Implications for Inflammation, Endothelial Dysfunction, and Oxidative Stress.||University of California, San Diego||Completed|July 2010|June 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||May 2014|May 24, 2014|June 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01202175||116228|
NCT01202188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2303|A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|SHINE|Novartis||Completed|September 2010|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|2144|||Both|40 Years|N/A|No|||August 2013|August 26, 2013|September 13, 2010|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01202188||116227|
NCT01202461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-07-209|Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)|Three-year Result of Triple Therapy of Vitrectomy, Intravitreal Triamcinolone and Macular Laser Photocoagulation for Intractable Diabetic Macular Edema||Samsung Medical Center|No|Completed|August 2010|September 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|20 Years|80 Years|No|||September 2010|September 14, 2010|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202461||116206|
NCT01202474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_04884|Apidra Children & Adolescents Study|A Study of Effectiveness and Safety of Apidra in Combination With Lantus Therapy in Basal-bolus Insulin Regimen in Inadequately Controlled Children and Adolescents With Type 1 Diabetes in the Russian Federation.||Sanofi||Completed|May 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|6 Years|17 Years|No|||December 2012|December 17, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202474||116205|
NCT01198184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02529|Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors|Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers||National Cancer Institute (NCI)||Completed|August 2010|October 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||October 2013|May 29, 2014|September 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01198184||116532|
NCT01210937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-CAS|Early Warning and Optimization Strategy in Carotid Endarterectomy|Early Warning and Optimization Strategy in Carotid Endarterectomy||Peking Union Medical College Hospital|Yes|Active, not recruiting|January 2010|December 2014|Anticipated|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|40 Months|80 Years|No|||September 2010|December 20, 2012|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01210937||115559|
NCT01211249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0259-CL-201|GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis|Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate||Galapagos NV|Yes|Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|70 Years|No|||April 2011|April 22, 2011|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211249||115535|
NCT01211262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMCgp100/01|Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma|A Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma||Immunocore Ltd|Yes|Active, not recruiting|September 2010|September 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211262||115534|
NCT01208220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Healthpoint-123-Collagenase|Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers|The Effects of Collagenase Santyl Ointment and Negative Pressure Wound Therapy(Npwt) for the Treatment of Chronic Pressure Ulcers.||Louisiana State University Health Sciences Center Shreveport|Yes|Terminated|June 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|April 16, 2010|Yes|Yes|Low enrollment of qualified subjects|No|September 24, 2013|https://clinicaltrials.gov/show/NCT01208220||115767|No adverse events noted or reported
NCT01217294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN10AN280|Study Comparing a Nerve Block With Spinal Opiate to Provide Pain Relief for Hip Replacement Surgery|Intrathecal Opioid Versus Ultrasound Guided Fascia Iliaca Plane Block for Analgesia After Primary Hip Arthroplasty||University of Glasgow|No|Completed|May 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|85 Years|No|||April 2014|April 8, 2014|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217294||115072|
NCT01209676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 03610|IMCgp100 in Advanced Unresectable Melanoma|A Phase 0, Exploratory Study of the Pharmacodynamics of a Single Intratumoral Dose of IMCgp100, a Monoclonal Receptor Anti-CD3 scFv Fusion Protein, in Subjects With Advanced Unresectable Melanoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 0|Interventional|Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209676||115656|
NCT01218477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-323|Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)|Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI||Bristol-Myers Squibb|No|Completed|January 2011|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|October 8, 2010|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01218477||114981|Because the smoothened inhibitor program was terminated, Bristol-Myers Squibb closed this study and prepared the limited efficacy data in a synoptic clinical study report .
NCT01218490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC 07/12-H|Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer|Pelvic and Aortic-cava Lymphadenectomy Randomized Phase III for Advanced Ovarian Cancer|CARACO|Institut Cancerologie de l'Ouest|No|Recruiting|December 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|450|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218490||114980|
NCT01218165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/062/10|Low Grade Inflammation, Gut Microbiota and Barrier Function in Elderly Humans|The Inflammaging Network: Bridging Low Grade Inflammation With Gut Microbiota and Intestinal Barrier Function in Elderly Humans||Charite University, Berlin, Germany|No|Completed|May 2010|May 2011|Actual|November 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218165||115005|
NCT01219283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-2009-01|Study of the Efficacy of 24 Chromosome Preimplantation Genetic Diagnosis (PGD)|A Prospective Randomized Clinical Trial to Determine the Efficacy of 24 Chromosome Preimplantation Genetic Diagnosis||Reproductive Medicine Associates of New Jersey|No|Completed|August 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|334|Samples With DNA|Blood samples from the male and female partners. Buccal swabs from infants.|Female|21 Years|43 Years|Accepts Healthy Volunteers|Probability Sample|500 patients attempting conception through IVF who have a maximum of one prior failed IVF        cycle.|March 2015|March 25, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219283||114919|
NCT01219296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-01|Retrospective Database Studies|Retrospective Database Studies From Reproductive Endocrinology Practice Looking at Relationships Between Demographics, Stimulation Protocols and Outcomes, Retrieval and Transfer Outcomes, Number and Quality of Oocytes and Embryos Retrieved and Transferred, Pregnancy Rates and Pregnancy Outcomes.||Reproductive Medicine Associates of New Jersey|No|Completed|June 2002|November 2015|Actual|October 2015|Actual|N/A|Observational|N/A||1|Actual|1|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing infertility treatment in our practice.|November 2015|November 16, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219296||114918|
NCT01219556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14916|Xirtam H Combination In the Treatment of Hypertension Evaluation Study.|Prospective, Multicentric, Large Scale Observational Study to Evaluate the Effectiveness & Safety of Xirtam H in Indian Patients Suffering From Hypertension.|XCITE|Bayer|No|Completed|November 2010|February 2013|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8704|||Both|18 Years|N/A|No|Probability Sample|Hypertension|January 2014|January 25, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01219556||114898|
NCT01201018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-DRS-P1-01|Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment|A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment - A Phase I Study||Oshadi Drug Administration|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|21 Years|N/A|No|||June 2012|June 20, 2012|September 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01201018||116317|
NCT01201343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 25206|Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients|Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients|SEPTIME|Merck KGaA|Yes|Completed|January 2005|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|September 13, 2010||No||No|March 15, 2012|https://clinicaltrials.gov/show/NCT01201343||116292|
NCT01200979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100205|Assessment of Alterations in Immune Function During Pregnancy and Post Parturition|Assessment of Alterations in Immune Function During Pregnancy and Post Parturition||National Institutes of Health Clinical Center (CC)||Completed|September 2010|||||N/A|Observational|Time Perspective: Prospective|||Actual|41|||Both|18 Years|45 Years|No|||January 2016|February 12, 2016|September 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01200979||116320|
NCT01201330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106030|DPBRN Retrospective Cohort Study of Osteonecrosis of the Jaw|Retrospective Cohort Study of ONJ||Dental Practice-Based Research Network|No|Completed|January 2007|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|572606|||Both|41 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients older than 40 with a history of jaw osteonecrosis and control patients with        exposure to biphosphonates were included.|June 2011|June 14, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201330||116293|
NCT01201590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000165377|The Effects of Cocoa Flavanols on Insulin Resistance in an 'At-risk' Population|The Effects of Cocoa Flavanols on Insulin Resistance in at 'At-risk' Population||University of Nottingham|No|Completed|March 2009|October 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|32|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01201590||116273|
NCT01201863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 IHA 11650|Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy|Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy||Craig Hospital|Yes|Completed|September 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Male|16 Years|65 Years|No|||August 2014|August 11, 2014|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01201863||116252|
NCT01202500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016528-30|Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis|Multicentre, Randomised Study to Determine the Relative Efficacy of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis|TOSCANE|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|July 2010|September 2016|Anticipated|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|486|||Both|3 Months|6 Months|No|||September 2010|June 2, 2014|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01202500||116203|
NCT01202487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6138378804|Gluing Lacerations Utilizing Epinephrine|Pretreatment of Lacerations With Topical LET (Lidocaine-Epinephrine-Tetracaine) Reduces Pain During Tissue Adhesive Repair in Children: Double-blind, Randomized, Controlled Trial of Efficacy|GLUE|Children's Hospital of Eastern Ontario|Yes|Completed|April 2011|April 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|222|||Both|N/A|17 Years|No|||April 2013|April 9, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202487||116204|
NCT01198197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100204|PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A|PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [(11)C]NOP-1A||National Institutes of Health Clinical Center (CC)||Completed|September 2010|February 2014|Actual|||Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|41|||Both|18 Years|50 Years|No|||September 2014|September 6, 2014|September 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01198197||116531|
NCT01198210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12610000658011|The Effect of Peritonsillar Infiltration of Ketamine and Dexamethasone for Postoperative Pain Relief in Children Following Adenotonsillectomy|Comparison of Peritonsillar Infiltration of Ketamine and Dexamethasone for Postoperative Pain Relief in Children Following Adenotonsillectomy||Qazvin University Of Medical Sciences|Yes|Recruiting|July 2010|December 2013|Anticipated|November 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|160|||Both|3 Years|12 Years|No|||May 2013|May 6, 2013|September 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198210||116530|
NCT01207388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT103-203|Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)|A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST)|BLAST|Amgen Research (Munich) GmbH|Yes|Active, not recruiting|November 2010|January 2019|Anticipated|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|September 21, 2010||No||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01207388||115830|
NCT01190683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/NP-216/2010|Vitamin D and Muscle Strength and Surface (Electromyography) EMG|Skeletal Muscle Strength,Bone Mineral Homeostasis and Th1 and Th2 Cytokines Expression in Asian Indians With Chronic Hypovitaminosis D Before and After Oral Cholecalciferol Supplementation||Indian Council of Medical Research|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|170|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2010|June 14, 2011|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190683||117100|
NCT01190696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-5|Titanium Elastic Nailing Versus Hip Spica Cast in Treatment of Femoral Fractures in Children|Study of Surgical Method Versus Casting for Treatment of Femoral Fracture in Children||Isfahan University of Medical Sciences|Yes|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||February 2009|August 27, 2010|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190696||117099|
NCT01221129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF-GCRC-772|Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)|Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)||University of Florida|No|Completed|October 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|Samples With DNA|Blood cells in clotted blood|Male|21 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|UF campus community|September 2011|September 16, 2011|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221129||114778|
NCT01221389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB#2010077-01H|Study Using Plasma for Patients Requiring Emergency Surgery|Study Using Plasma for Patients Requiring Emergency Surgery: A Randomized Pilot Trial of Early Plasma for Patients Undergoing Emergency Surgery for Hemorrhagic Shock|SUPPRES|Ottawa Hospital Research Institute|No|Recruiting|March 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01221389||114758|
NCT01222182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000986|Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)|Statin Therapeutic Interchange by Pharmacist Collaborative Practice Process||Mayo Clinic|No|Completed|September 2009|June 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|260|||Both|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|225 insured eligible subjects, 35 Primary Care Internal Medicine (PCIM) physicians|May 2012|May 25, 2012|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01222182||114697|
NCT01222195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0657|Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)|Phase II Study of Lenalidomide and Darbepoetin Alfa in Myelodysplastic Syndrome (Low to Intermediate-1 Risk Category Excluding 5q Deletion)||M.D. Anderson Cancer Center|Yes|Terminated|February 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|October 14, 2010|Yes|Yes|Low accrual.|No|March 30, 2011|https://clinicaltrials.gov/show/NCT01222195||114696|
NCT01222455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00010|A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function|An Open-label, Single-center Study to Assess the Pharmacokinetics of R406 in Subjects With Hepatic Impairment and in Healthy Subjects Following Administration of a Single Dose of Fostamatinib Disodium 150 mg||AstraZeneca||Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 5, 2011|October 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01222455||114676|
NCT01192542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1636BE|Pilot Evaluation of a New Galyfilcon A Lens Prototype and Enfilcon A Lens|Dispensing Evaluation of a New Galyfilcon A Prototype and Avaira Lenses||Johnson & Johnson Vision Care, Inc.|No|Completed|August 2010|||September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|39|||Both|18 Years|39 Years|No|||May 2015|May 6, 2015|August 30, 2010|No|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT01192542||116960|
NCT01192880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN25308|A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25308)|A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.||Hoffmann-La Roche||Completed|November 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|625|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192880||116934|
NCT01189279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-053|Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia|||Allergan|No|Completed|October 2010|February 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|64 Years|No|||June 2013|June 24, 2013|August 25, 2010|Yes|Yes||No|June 24, 2013|https://clinicaltrials.gov/show/NCT01189279||117207|
NCT01189292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 10/082/2B|Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery|Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery|tPONV|Cantonal Hospital of St. Gallen|No|Completed|January 2011|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|152|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|July 19, 2010||No||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01189292||117206|all patients received a bilateral superficial cervical plexus block during surgery which could explain the very low postoperative pain scores compared to other similar studies
NCT01193478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-256-0102|A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Escalating, Multiple, Oral Doses of GS 5885 in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection||Gilead Sciences|Yes|Completed|August 2010|December 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|71|||Both|18 Years|65 Years|No|||January 2013|January 18, 2013|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193478||116890|
NCT01193491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-493-02|Dose Escalation of IPI-493 in Hematologic Malignancies|A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies With Client Proteins of Hsp90||Infinity Pharmaceuticals, Inc.|No|Terminated|June 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|June 28, 2010|Yes|Yes|Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on Retaspimycin    HCL|No||https://clinicaltrials.gov/show/NCT01193491||116889|
NCT01202357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM-RCT|Optimal Duration of Early Intervention for Psychosis|Community Case Management for Early Psychosis: is Two Year an Optimal Duration? A Randomized Controlled Study||The University of Hong Kong|No|Not yet recruiting|July 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|35 Years|No|||September 2010|September 13, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01202357||116214|
NCT01192685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29098|Transcranial Magnetic Stimulation in Major Depression With EEG and Near Infrared Spectroscopy (NIRS) Monitoring|Transcranial Magnetic Stimulation in Major Depression With EEG and NIRS Monitoring||Boston University|Yes|Active, not recruiting|December 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|65 Years|No|||May 2013|May 14, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192685||116949|
NCT01192698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-05-09A|Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus|Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus||Carolinas Healthcare System|Yes|Completed|October 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||March 2014|March 31, 2014|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192698||116948|
NCT01192997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIME|Comparison of Two Meningococcal ACWY Conjugate Vaccines|A Phase 2/3, Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY (Menveo) or GSK Meningococcal ACWY Conjugate Vaccine in Adolescents Primed With Meningitec, Menjugate or Neisvac-C in Preschool Vaccination|PRIME|Public Health England|No|Completed|June 2012|March 2014|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|91|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192997||116925|
NCT01193010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000444|Computer Assisted Planing of Corrective Osteotomy for Distal Radius Malunion|Computer-Assisted Versus Non-Computer Assisted Preoperative Planning of Corrective Osteotomy for Extra-Articular Distal Radius Malunions: A Multi-Center Randomized Controlled Trial||Massachusetts General Hospital|No|Enrolling by invitation|August 2010|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01193010||116924|
NCT01192984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0761-004|Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma|Phase II Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma||Kyowa Hakko Kirin Company, Limited||Completed|September 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Primary Purpose: Treatment|1||Actual|38|||Both|20 Years|N/A|No|||September 2014|September 11, 2014|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192984||116926|
NCT01189435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-097|Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib|A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib||Memorial Sloan Kettering Cancer Center|Yes|Terminated|August 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|21 Years|N/A|No|||October 2015|October 17, 2015|August 25, 2010|Yes|Yes|Lack of accrual|No|April 7, 2015|https://clinicaltrials.gov/show/NCT01189435||117195|
NCT01189721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2010-0102|Effect of Propofol on Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Thyroid Surgery|Effect of Propofol on Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Thyroid Surgery||Gangnam Severance Hospital||Recruiting|August 2010|July 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|20 Years|65 Years|No|||August 2010|August 26, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189721||117174|
NCT01189747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-098|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines|||Allergan|No|Completed|October 2010|July 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|August 25, 2010|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01189747||117172|
NCT01190384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201018072|The Effect of Whole Beans on Inflammation and Satiety|Bean Consumption: A Pilot Study in Overweight Men and Women on Immuno-metabolic and Food Intake Endpoints|BEAN|University of California, Davis|No|Active, not recruiting|August 2010|August 2012|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|12|||Both|21 Years|N/A|No|||May 2012|May 8, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190384||117123|
NCT01190709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-6|Study of Tibial Shaft Fracture Fixation: Intramedullary Nailing Comparing With Dynamic Compression Plate|Study of Surgical Methods for Treatment of Tibial Fractures||Isfahan University of Medical Sciences|Yes|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|August 27, 2010|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190709||117098|
NCT01190722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001HV|A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain|A Randomized Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain||Karolinska Institutet|Yes|Withdrawn|November 2010|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||July 2010|March 30, 2015|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01190722||117097|
NCT01221415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.127.A|A Comparison of Ultrasound and Nerve Stimulator Techniques for Nerve Localization in Regional Anesthesia|A Comparison of Ultrasound and Nerve Stimulator Techniques for Nerve Localization in Regional Anesthesia||Ochsner Health System|Yes|Completed|January 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Prospective||6|Anticipated|220|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients 18 years of age or older undergoing outpatient knee arthroscopy or lower leg/foot        surgery as well as shoulder arthroscopy.|October 2011|October 26, 2011|July 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01221415||114756|
NCT01221675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/9-O|TF2- Small Cell Lung Cancer Radio Immunotherapy|Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)||Centre René Gauducheau|No|Recruiting|June 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01221675||114736|
NCT01192022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-2402-040-SP|TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery|A Randomized, Open Label, Parallel-group, Multi-center Trial to Compare the Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery||Takeda|Yes|Completed|August 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|253|||Both|N/A|N/A|No|||October 2015|October 22, 2015|August 27, 2010|Yes|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01192022||117000|
NCT01192282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131/2010|Typing of Human Papilloma Virus (HPV) From Female Genital Warts|Clinico-Pathological HPV DNA Typing Study of Women With Genital Warts Presenting to Groote Schuur Hospital Over a One Year Period, Evaluated by HIV Status, Psychological Impact and Costs to the Health Care System||University of Cape Town|No|Completed|April 2010|August 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|156|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All female patients with Genital Warts presenting to Groote Schuur Hospital, Cape Town|January 2013|January 18, 2013|August 31, 2010||No||No|December 15, 2012|https://clinicaltrials.gov/show/NCT01192282||116980|Thirty (19.2%) specimens had to be rejected due to contamination that occurred during the analysis process. During the HPV DNA analysis, there were protocols for different aspect of controls during the analysis which needed to be negative.
NCT01192555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26652-ATOMIC|Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma|A Phase I/II Study Using Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)|ATOMIC|Baylor College of Medicine|Yes|Active, not recruiting|September 2010|September 2026|Anticipated|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|N/A|N/A|No|||August 2015|August 26, 2015|August 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192555||116959|
NCT01192568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG09002|Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder|A Multi-Center, Double-Blind, Placebo-Controlled, Dose-Titration Study Evaluating the Efficacy, Safety, PD and PK of Oxybutynin Chloride Topical Gel for Detrusor Overactivity Associated With a Neurological Condition in Pediatric Subjects||Watson Pharmaceuticals|No|Suspended|June 2011|June 2020|Anticipated|August 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|6 Years|16 Years|No|||May 2015|May 28, 2015|August 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01192568||116958|
NCT01188954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doxy 10-006|Doxycycline Versus Standard Care to Prevent Seroma Formation|Randomized Clinical Trial of Doxycycline Versus Standard Care to Prevent Seroma Formation at Femoral Artery/Vein Cannulation Site After Cardiopulmonary By-Pass||Northwell Health|Yes|Withdrawn|January 2010|November 2012|Actual|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|85 Years|No|||April 2015|April 10, 2015|June 22, 2010||No|The recruitment process was slower than expected.|No||https://clinicaltrials.gov/show/NCT01188954||117232|
NCT01189955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|harmonic total thyroidectomy|the Use of Harmonic Scalpel Versus Knot Tying for Total Thyroidectomy|The Use of Harmonic Scalpel Versus Knot Tying for Total Thyroidectomy: A Prospective Randomized Study|HS|Mansoura University|Yes|Completed|February 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|N/A|N/A|No|||February 2008|August 26, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189955||117156|
NCT01190241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/124|Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study|Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study|TSAP|VU University Medical Center|No|Active, not recruiting|August 2010|||May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190241||117134|
NCT01189617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOYNAP0011|Safety Study for an All-in-One Body and Personal Lubricant|A Single-center, Medically Supervised, Safety Evaluation Study of an All-in-One Body and Lubricant Product||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|June 2010|August 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 9, 2013|August 25, 2010|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT01189617||117182|
NCT01192373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M20090230|Modulation of Free Fatty Acids in Heart Failure Patients With Diabetes: "Effect on Left Ventricular Function"|Short Term Modulation of Circulating Free Fatty Acids in Heart Failure Patients With Type 2 Diabetes: "Effect on Myocardial Lipid Content, Left Ventricular Function and Exercise Capacity"|Metamod3|University of Aarhus|Yes|Completed|September 2010|March 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|30 Years|85 Years|No|||January 2013|January 18, 2013|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01192373||116973|
NCT01192386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHINO2010|Eosinophil Markers and Development of Disease in Allergic Rhinitis|Eosinophil Markers and Development of Disease in Allergic Rhinitis. A 15-year Follow-up of Patients With Grass Pollen Induced Hayfever.||University of Aarhus|No|Completed|May 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|N/A||1|Actual|29|||Both|N/A|N/A|No|Non-Probability Sample|Follow-up on participants in Allergic Rhinitis study 1995.|August 2010|August 31, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192386||116972|
NCT01192399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C07-001|C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients|Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients||Alexion Pharmaceuticals|No|Completed|November 2007|October 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|12 Years|N/A|No|||April 2012|April 4, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192399||116971|
NCT01192711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTD003|Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice|An Open Label, Multicentre, Randomized Study of Insulin Glargine + Prandial Insulin Glulisine Associated With a Telemedicine System for Carbohydrates Counting vs. Insulin Glargine + Prandial Insulin Glulisine Associated With Common Practice|DID3|Consorzio Mario Negri Sud|No|Recruiting|May 2009|||October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||September 2010|September 1, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192711||116947|
NCT01192724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCD|Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation|A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation|ABCD|Yonsei University|Yes|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|630|||Both|18 Years|N/A|No|||January 2013|January 9, 2013|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192724||116946|
NCT01188811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7493-W|Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)|Lipoic Acid for Neuroprotection in Secondary Progressive MS||VA Office of Research and Development|Yes|Completed|October 2010|August 2015|Actual|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|40 Years|70 Years|No|||February 2016|February 11, 2016|August 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01188811||117243|
NCT01193283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100176|Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia|Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)|Yes|Completed|August 2010|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|2 Years|N/A|No|||October 2015|October 13, 2015|August 31, 2010|Yes|Yes||No|October 13, 2015|https://clinicaltrials.gov/show/NCT01193283||116903|
NCT01189773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2633|Combined Analgesia to Control Pain in Children Seen in Emergency Department (ED) for a Trauma of a Limb|Efficacy and Security of Combined Analgesia (Opioid and Anti-inflammatory Agent) to Control Pain in Children Seen in the Emergency Department for a Trauma of a Limb||St. Justine's Hospital|No|Completed|February 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|6 Years|18 Years|No|||May 2010|August 26, 2010|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01189773||117170|
NCT01189786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27251-EXCESS|Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection|Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection (EXCESS)|EXCESS|Baylor College of Medicine|Yes|Recruiting|October 2010|November 2021|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|N/A|70 Years|No|||December 2015|December 1, 2015|August 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01189786||117169|
NCT01189760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-099|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines|||Allergan|No|Completed|September 2010|September 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|917|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|August 25, 2010|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01189760||117171|
NCT01190098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB-SLEEP|Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy|Searching for "Sleep Friendly" Therapies for a Sleepy Population: A Double-Blind, Placebo-Controlled, Randomized Trial to Assess the Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy||The Cleveland Clinic|Yes|Active, not recruiting|August 2010|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|August 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190098||117145|
NCT01190397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2420-PI-CE-07/10|Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy|Phase I, Prospective, Comparative Study, Investigator Masked , Monocentric Measuring Warming Efficiency and Safety of Blephasteam® Versus Warm Compresses in Eyelid Therapy||Laboratoires Thea|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|4 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 3, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190397||117122|
NCT01190410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0012|Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol|An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035||UCB Pharma|Yes|Active, not recruiting|August 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|6 Years|17 Years|No|||November 2015|November 19, 2015|August 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01190410||117121|
NCT01192529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGENAT-SUPR|Evaluation of a Diet in Patients With Senile Dementia|Clinical Evaluation of an Specific Diet for People With Dementia Disease|SUPRESSI|Vegenat, S.A.|No|Recruiting|October 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|184|||Both|70 Years|N/A|No|||February 2011|June 21, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192529||116961|
NCT01192035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/CNES/2010|PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial|PI or NNRTI as First-line Treatment of HIV in a West African Population With Low Adherence - the PIONA Trial|PIONA|University of Aarhus|Yes|Completed|May 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||November 2014|May 28, 2015|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192035||116999|
NCT01221688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 09/9-G|Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer|Evaluation of Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer|GANEA 2|Institut Cancerologie de l'Ouest|No|Recruiting|July 2010|||July 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|858|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01221688||114735|
NCT01221974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF1|Use of Essure® Micro-inserts in Women With Hydrosalpinx Prior to In Vitro Fertilization: A Prospective, Multicenter, International Feasibility Study|||Reproductive Science Center|No|Completed|July 2008|||July 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Female|21 Years|38 Years|Accepts Healthy Volunteers|||October 2010|October 15, 2010|October 4, 2010||Yes||||https://clinicaltrials.gov/show/NCT01221974||114713|
NCT01192893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-07|Role of Oxytocin in Post-menopausal Osteoporosis: Evaluation on the Population of the OPUS Cohort|||Centre Hospitalier Universitaire de Nice|No|Completed|July 2011|October 2013|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1000|Samples Without DNA|OPUS is a prospective study of postmenopausal women recruited in the general population      between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin      (Germany), Kiel (Germany), Paris (Hôpital Cochin, France), and Sheffield (UK)).      Investigations were approved at each institution according to the Declaration of Helsinki.      Written consent was obtained from all subjects. Each center recruited approximately 500      postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79.      Ninety-nine percent of subjects were of white ethnicity.|Female|55 Years|79 Years|No|Probability Sample|OPUS is a prospective study of postmenopausal women recruited in the general population        between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin        (Germany), Kiel (Germany), Paris (Hôpital Cochin, France), and Sheffield (UK)).        Investigations were approved at each institution according to the Declaration of Helsinki.        Written consent was obtained from all subjects. Each center recruited approximately 500        postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79.        Ninety-nine percent of subjects were of white ethnicity.|August 2015|August 13, 2015|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192893||116933|
NCT01193166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017110|Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital|A Twelve-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital||Ortho-McNeil Janssen Scientific Affairs, LLC|No|Withdrawn|August 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|0|||Both|18 Years|65 Years|No|||July 2013|July 4, 2013|August 30, 2010|Yes|Yes|This study was stopped due to an internal reconsideration of priorities of the product    portfolio.|No||https://clinicaltrials.gov/show/NCT01193166||116912|
NCT01193504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25324|Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification|Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification||Innovative Medical|No|Recruiting|September 2010|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193504||116888|
NCT01188967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-19378-5|Effectiveness of GSK598809, a Selective D3 Antagonist, Added to Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation and Prevention of Very Early Relapse to Smoking|A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation and Prevention of Very Early Relapse to Smoking||Massachusetts General Hospital|Yes|Completed|August 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|65 Years|No|||September 2014|September 16, 2014|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188967||117231|
NCT01189669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC-UCD-PCOS|n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS)|Long Chain (LC) n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS): A Cross-over, Placebo Controlled Dietary Intervention Study||The Adelaide and Meath Hospital|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|25|||Female|18 Years|40 Years|No|||July 2008|September 10, 2010|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01189669||117178|
NCT01189630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-01-2010|Medtronic Observational Study in the "Real World" of Implantable Electronic Cardiac Devices|Medtronic Observational Study in the "Real World" of Implantable Electronic Cardiac Devices|OBSERVE|Medtronic Comercial Ltda.|Yes|Enrolling by invitation|December 2010|December 2015|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|3500|||Both|18 Years|95 Years|No|Non-Probability Sample|Patients eligible to participate in this study are among those having an approved        indication for the implantation of Implantable Cardiac Pacemakers (IPG), Cardiac        Resynchronization Pacemakers (CRT-P), Implantable Cardioverter Defibrillator (ICD) with or        without Cardiac Resynchronization Pacemakers (CRT-D).|March 2011|March 29, 2011|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189630||117181|
NCT01192139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-111|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN) Coadministered to Healthy Subjects in a Fed Condition||AstraZeneca|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|August 30, 2010|No|Yes||No|March 11, 2011|https://clinicaltrials.gov/show/NCT01192139||116991|
NCT01192152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-112|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR Coadministered to Healthy Subjects in the Fed State and Steady State Pharmacokinetic Assessment of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR||AstraZeneca|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|April 22, 2015|August 30, 2010|No|Yes||No|March 9, 2011|https://clinicaltrials.gov/show/NCT01192152||116990|
NCT01192750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000683281|Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab|Retrospective Analysis of ERCC1 Expression in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Received Cisplatin or Cisplatin and Cetuximab||National Cancer Institute (NCI)||Not yet recruiting|September 2010|||October 2010|Anticipated|N/A|Observational|N/A|||Anticipated|79|||Both|18 Years|N/A|No|||August 2010|August 31, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192750||116944|
NCT01193296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AFR02|Glycemic Holter Study (Continuous Glucose Monitoring) -|Prospective, Randomized, Open-label Study With Blinded Endpoint (PROBE Design) to Compare the 72 hr Glycemic Profiles Obtained by Continuous Subcutaneous Glucose Monitoring (CSGM) in Type 2 Diabetic Patients at Baseline With Metformin Monotherapy and After an 8-week Period With the Addition of Either Vildagliptin or Sitagliptin in Patients Insufficiently Controlled by Metformin After at Least 3 Months of Monotherapy|OPTIMA|Novartis||Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|79 Years|No|||May 2012|May 3, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193296||116902|
NCT01189110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 08-371|Auriculotherapy for Smoking Cessation: Pilot|Auriculotherapy for Smoking Cessation||VA Office of Research and Development|Yes|Completed|August 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|19 Years|N/A|Accepts Healthy Volunteers|||August 2013|April 6, 2015|August 24, 2010||No||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01189110||117220|It is possible that the pressure alone applied to these points provided a therapeutic effect and therefore was not a true placebo.Other stimulation frequencies or intensities may have produced a different outcome condition.
NCT01189097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-95-139|Combined Therapy of Methadone and Dextromethrophan|Combined Therapy of Methadone and Dextromethrophan: A Novel Strategy for the Treatment of Opioid Dependence|DM|National Cheng-Kung University Hospital|Yes|Recruiting|April 2008|September 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|1500|||Both|18 Years|65 Years|No|||August 2010|August 25, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01189097||117221|
NCT01189812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP-DP-09201|Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders||Columbia Northwest Pharmaceuticals|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||August 2011|August 22, 2011|March 18, 2010|Yes|Yes||No|March 28, 2011|https://clinicaltrials.gov/show/NCT01189812||117167|
NCT01189851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IORT|Intraoperative Radiotherapy for Early Stage Breast Cancer|Intraoperative Radiotherapy (IORT) for the Management of Carcinoma of the Breast: Use of Mammography, Ultrasonography,and Contrast-Enhanced Magnetic Resonance Imaging (CE-MRI) to Identify Candidates for IORT|IORT|Hoag Memorial Hospital Presbyterian|No|Active, not recruiting|June 2010|September 2018|Anticipated|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|48 Years|N/A|No|||August 2015|August 18, 2015|June 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01189851||117164|
NCT01190111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-13|Study on Interleukin-7 (CYT107) in HIV Patients|An Open-label, Multicenter Study of Subcutaneous Intermittent Recombinant Interleukin-7 (CYT107) in Chronically HIV-infected Patients With CD4 T-lymphocyte Counts Between 101-400 Cells/mm3 and Plasma HIV RNA< 50 Copies/mL After at Least 12 Months of HAART|Inspire 2|Cytheris SA|Yes|Terminated|January 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|August 23, 2010|No|Yes|CYTHERISSA filed for banckcuptcy in June 2013.Subjects treated by CYT 107 were followed up for    at the least 3 months.|No||https://clinicaltrials.gov/show/NCT01190111||117144|
NCT01191710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProgRise001|Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles|Is the Clinical Outcome Affected by the Incidence of Progesterone Elevation on the Day of hCG Triggering When Agonist Protocol is Compared to Antagonist Protocol for IVF||Universitair Ziekenhuis Brussel|No|Active, not recruiting|January 2007|January 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|21 Years|39 Years|No|||January 2009|September 14, 2010|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191710||117024|
NCT01191723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0004-CL-P103|QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo|A Randomized, Double Blind, Placebo Controlled, Three- Period Crossover Study Comparing the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo on QT Intervals in Healthy Adults||Allergan|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|August 27, 2010|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01191723||117023|
NCT01192048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB09-00339|Genetics of Congenital Heart Disease|Genetics Testing of Individuals and Families With Congenital Heart Disease||Nationwide Children's Hospital|No|Recruiting|December 2009|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood samples will be collected in vacuum tubes containing acid citrate dextrose (ACD).      Lymphocytes from blood drawn in appropriate anticoagulant (ACD) may be stored for subsequent      immortalization. DNA will be extracted from these samples for analysis.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|cardiology clinic sample, community sample|February 2016|February 1, 2016|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192048||116998|
NCT01191450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 114|Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension|A Study to Evaluate the Safety and Efficacy of Chlorthalidone in Combination With Amiloride as a Treatment for Elderly Patients With Arterial Hypertension|CARD|Eurofarma Laboratorios S.A.|No|Recruiting|August 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|60 Years|N/A|No|||January 2012|January 31, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01191450||117044|
NCT01191762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhelpsK|Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease|The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism||Phelps, Kenneth R., M.D.|No|Completed|April 2010|April 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 30, 2014|August 27, 2010|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01191762||117020|All intended measurements were made. The desired number of participants was recruited.
NCT01191775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-10091 (PNT2258-01)|A Study of PNT2258 in Patients With Advanced Solid Tumors|A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors||ProNAi Therapeutics, Inc|No|Completed|August 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01191775||117019|
NCT01192906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN25309|A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)|A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.||Hoffmann-La Roche||Completed|December 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|624|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192906||116932|
NCT01192919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM TLK|Tumour Registry Lung Cancer (TLK)|Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.||iOMEDICO AG|No|Active, not recruiting|January 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|patients with lung cancer requiring therapy|February 2016|February 26, 2016|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192919||116931|
NCT01193179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-10-005|A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes|Long-term Co-administration Study of OPC-262 in Patients With Type 2 Diabetes Mellitus||Kyowa Hakko Kirin Company, Limited|No|Completed|July 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|20 Years|N/A|No|||January 2014|January 6, 2014|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01193179||116911|
NCT01193192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-002|A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy|A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy||Pamlab, Inc.|No|Terminated|July 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|30|||Female|21 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant Women Who Received Neevo®/NeevoDHA® or Another Standard Prenatal Vitamin|November 2011|November 22, 2011|August 30, 2010|No|Yes|Inadequate number of charts available for Test Group|No||https://clinicaltrials.gov/show/NCT01193192||116910|
NCT01193517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0625|Azacitidine and CAPOX in Metastatic Colorectal Cancer|Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2010|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193517||116887|
NCT01193530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0738|The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer|The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2011|||June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193530||116886|
NCT01189656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71007.02|A Clinical Study on Therapeutic Double-plasmid Hepatitis B Virus (HBV) DNA Vaccine in Patients With HBeAg-positive Chronic Hepatitis B|A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on Specific-Population to Evaluate the Safety and Efficacy of Therapeutic Double-plasmid HBV DNA Vaccine in HBeAg-positive Patients With Chronic Hepatitis B||The 458 Hospital of Chinese PLA|Yes|Active, not recruiting|January 2009|December 2010|Anticipated|November 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||February 2009|August 26, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189656||117179|
NCT01189942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M18-003|A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer|A Phase 1b Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer||OncoMed Pharmaceuticals, Inc.|Yes|Active, not recruiting|September 2010|May 2013|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|21 Years|N/A|No|||December 2011|December 15, 2011|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189942||117157|
NCT01221779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATS01EO0801|Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation|Chronic Aphasia - Improved by Intensive Training and Electrical Brain|CATS|Charite University, Berlin, Germany|Yes|Recruiting|January 2011|December 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2013|August 26, 2013|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221779||114728|
NCT01190254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05896|Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)|An 8-week, Placebo-controlled, Double-blind, Randomized, Fixed-dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia||Merck Sharp & Dohme Corp.|Yes|Completed|September 2010|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|306|||Both|12 Years|17 Years|No|||August 2015|August 4, 2015|August 25, 2010|Yes|Yes||No|March 10, 2014|https://clinicaltrials.gov/show/NCT01190254||117133|
NCT01189968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M18-004|A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer|A Phase 1b Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) as 1st-line Treatment in Subjects With Non-Squamous Non-Small Cell Lung Cancer||OncoMed Pharmaceuticals, Inc.|Yes|Active, not recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||September 2015|September 29, 2015|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189968||117155|
NCT01192412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-00882|The CHIPS Trial (Control of Hypertension In Pregnancy Study)|The CHIPS Trial (Control of Hypertension In Pregnancy Study)||University of British Columbia|Yes|Completed|April 2009|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|987|||Female|N/A|N/A|No|||February 2015|February 4, 2015|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192412||116970|
NCT01192425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-001|Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes|P06-001: (EX)Amination of (P)NH, by (L)Evel (O)f CD59 on (RE)d and White Blood Cells, in Bone Marrow Failure Syndromes|EXPLORE|Alexion Pharmaceuticals|No|Completed||||||N/A|Observational|Time Perspective: Prospective||1|Actual|5580|||Both|10 Years|N/A|No|Probability Sample|Patients at least 10 years of age with aplastic anemia, myelodyplastic syndromes or other        bone marrow failure syndromes.|August 2010|August 31, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192425||116969|
NCT01193335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851037|Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.|A Phase 4, Open-label Trial Describing The Safety, Tolerability, And Immunogenicity Of The 13 Valent Pneumococcal Conjugate Vaccine In Preterm Compared To Term Infants||Pfizer|Yes|Completed|October 2010|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|42 Days|98 Days|No|||January 2015|January 21, 2015|August 31, 2010|Yes|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT01193335||116901|
NCT01189123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080925|Cell Mediated Immunity in Older Adults|Evaluation of Cell-mediated Immunity and Antibody Response to Influenza Vaccination and Correlates of Protection in Seniors|CMI|Vanderbilt University|No|Completed|August 2010|August 2013|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|105|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2014|April 3, 2014|August 23, 2010|No|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01189123||117219|Due to cost and time limitations, a random sample from each treatment group were pulled for CMI testing. Hence not all samples were tested.
NCT01189461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751036|Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema|An Open Label, One Year, Non-Comparative Study To Evaluate The Safety And Tolerability Of Intravitreous Pegaptanib Sodium In Patients With Diabetic Macular Edema||Pfizer|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|July 23, 2010||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01189461||117193|
NCT01189448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081234|Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy|Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy|TOXOGEST|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|November 2010|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Female|18 Years|N/A|No|||November 2013|November 7, 2013|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189448||117194|
NCT01189864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL (12 & older)|Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas||Cxlusa||Recruiting|June 2010|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|||Both|12 Years|N/A|No|Probability Sample|Primary care clinic.|August 2015|August 26, 2015|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01189864||117163|
NCT01190436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200006-512|A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes|A Study on the Efficacy of Bisoprolol and Its Influence on Selected Biochemical Parameters in Filipino Hypertensive Patients With Diabetes||Merck KGaA|No|Completed|December 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|August 26, 2010||No||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01190436||117119|
NCT01190748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40463|Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions||Actavis Inc.|No|Completed|November 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 27, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190748||117095|
NCT01192256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/WMW01/28|Studies Examining the Importance of Smoking After Being Diagnosed With Lung Cancer|Does Smoking Status After Being Diagnosed With Lung Cancer Influence Outcome? An Observational Cohort Study.|LungCast|Hywel Dda Health Board|Yes|Recruiting|March 2010|March 2019|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2400|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with newly diagnosed lung cancer|February 2016|February 18, 2016|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01192256||116982|
NCT01192061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N N402 165637|Autonomic Nervous System Activity and Normal Tension Glaucoma|Autonomic Nervous System Activity, Peripheral Microcirculation and Retrobulbar Hemodynamics in Normal Tension Glaucoma Patients.|ANS|Military Institute of Medicine, Poland|No|Completed|February 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|97|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|NTG group: out-patient clinic of the Ophthalmology Department of the Military Medical        Institute (MMI), control group: hospital stuff, family and friends of hospital stuff and        patients|January 2011|January 24, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192061||116997|
NCT01192295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR3001|Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids|An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics||Purdue Pharma LP|Yes|Completed|November 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|6 Years|16 Years|No|||August 2015|August 26, 2015|August 30, 2010|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01192295||116979|
NCT01192581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vuloven001|Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection as Adjunctive Therapy in Subjects With Internal Carotid Artery Hypoperfusion|Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection as Adjunctive Therapy in Subjects With Internal Carotid Artery Hypoperfusion||Xijing Hospital|Yes|Recruiting|August 2010|October 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|75 Years|No|||June 2010|October 28, 2010|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192581||116957|
NCT01192932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/10-02-13/3863|Effects of Nycthemeral Variations on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent in Chronic Obstructive Pulmonary Disease (COPD)|Effects of Nycthemeral Variations on CT Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent in COPD: Comparisons Between CT Scans Obtained in the Morning and in the Afternoon and Relationships With Pulmonary Function Tests||Erasme University Hospital|No|Completed|March 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|40 Years|N/A|No|Non-Probability Sample|COPD patients aged 40 or more, with a smoking history of > 10 PY, a post-bronchodilator        FEV1/VC < 0.7 and an optimal treatment according to GOLD guidelines will be included.        Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before        the begin of the study, concomitant pulmonary disease (tuberculosis, significant        bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any        organ system within the past 5 years.|July 2012|July 3, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192932||116930|
NCT01193543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2010-4|Effect of Calanus Oli on Intra-abdominal Fat, Glucose Tolerance and Lipids in Man|Effect of Calanus Oli on Intra-abdominal Fat, Glucose Tolerance and Lipids in Man||University of Tromso|No|Completed|December 2010|August 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 3, 2012|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01193543||116885|
NCT01188980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005328|Early Increase in Blood Supply in Patients With Barrett's Esophagus|Detectable Esophageal Early Increase in Blood Supply (EIBS) in Patients With Barrett's Esophagus|EIBS in BE|Mayo Clinic||Completed|June 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Control Population: Patients with no Barrett's metaplasia scheduled for upper endoscopy at        Mayo Clinic Jacksonville.        Experimental Population: Patients with biopsy-proven Barrett's esophagus and previously        scheduled for upper endoscopy at Mayo Clinic Jacksonville.|April 2014|April 8, 2014|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188980||117230|
NCT01189305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA025618|Behavioral Couples Therapy for Female Drug-Abusing Patients|Behavioral Couples Therapy for Female Drug-Abusing Patients|CPW-D|Harvard University|No|Completed|July 2009|February 2015|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 19, 2015|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01189305||117205|
NCT01189318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00042|Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder|Effects of Seroquel XR (Quetiapine Fumarate Extended-Release) on Sleep Architecture in Patients With Major Depressive Disorder||Ewha Womans University|Yes|Withdrawn|March 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01189318||117204|
NCT01189643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-091|Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor|A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor||Memorial Sloan Kettering Cancer Center||Recruiting|August 2010|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|1 Year|29 Years|No|||February 2016|February 15, 2016|August 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01189643||117180|
NCT01189331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1007-193-325|CT Coronary Angiography and Computational Fluid Dynamics|Non-invasive Functional Assessment of Coronary Stenoses Using CT Coronary Angiography and Computational Fluid Dynamics||Seoul National University Hospital|Yes|Recruiting|August 2010|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||December 2013|December 1, 2013|August 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01189331||117203|
NCT01189344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1039/07|Levothyroxine (L-T4) Absorption After Bariatric Surgery|Levothyroxine Absorption in Morbidly Obese Patients Before and After Roux-en-Y Bariatric Surgery|RYS|University of Sao Paulo|No|Completed|September 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|N/A|No|||June 2007|August 25, 2010|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01189344||117202|
NCT01222052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 42|6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients|Randomized Multicenter Study Comparing 6xFEC With 3xFEC-3xDoc in High-risk Node-negative Patients With Operable Breast Cancer: Comparison of Efficacy and Evaluation of Clinico-pathological and Biochemical Markers as Risk Selection Criteria|NNBC3-Europe|Martin-Luther-Universität Halle-Wittenberg|Yes|Active, not recruiting|January 2002|February 2019|Anticipated|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4150|||Female|18 Years|70 Years|No|||September 2012|September 3, 2012|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222052||114707|
NCT01221805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 10 18|STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism|STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism|DiET|Diagnostica Stago|No|Active, not recruiting|November 2011|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2426|Samples Without DNA|plasma samples (at least 1 aliquot 0.5 ml) will be collected at the initial visit of      patients with low or moderate PTP|Both|N/A|80 Years|No|Non-Probability Sample|The study population will be recruited from prospective, consecutive, ambulatory        outpatients (presenting at the emergency unit or outpatient clinic) suspected of having        venous thromboembolism|January 2016|January 20, 2016|October 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221805||114726|
NCT01192763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02523|RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer|A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer||National Cancer Institute (NCI)||Terminated|August 2010|||January 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|August 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01192763||116943|
NCT01192776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0043|Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)|Optimizing Cooling Strategies at < 6 Hours of Age for Neonatal Hypoxic-Ischemic Encephalopathy||NICHD Neonatal Research Network|Yes|Active, not recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|726|||Both|N/A|6 Hours|No|||October 2015|November 6, 2015|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192776||116942|
NCT01193023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG-matped 09-253|Patient-ventilator Asynchrony During Mechanical Invasive Assisted-ventilation in Pediatric Patients|Patient-ventilator Asynchrony During Mechanical Invasive Assisted-ventilation in Pediatric Patients|NavPed-Inv|University Hospital, Geneva|Yes|Recruiting|June 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|N/A|12 Years|No|||August 2010|August 31, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193023||116923|
NCT01188824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-137|The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)|The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)||China Medical University Hospital|Yes|Completed|September 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|801|||Both|50 Years|N/A|No|||July 2013|September 30, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01188824||117242|
NCT01192841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1137|Bacterial Contamination of Workwear|Physician Dress Code And Microbial Colonization Of The White Coat: Does Physician Dress Code Alter Bacterial Colonization Rate On The Clothing Of Physicians?||Denver Health and Hospital Authority|Yes|Completed|April 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2010|August 30, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192841||116937|
NCT01189474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2420-PIV-CE-02/10|Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases|Phase IV Multicentric Study, 140 Patients Suffering of Meibomian Glands Dysfunction.|ESPOIR Ext|Laboratoires Thea|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|4 Years|N/A|No|||October 2012|October 2, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189474||117192|
NCT01189799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DA020085|Motivational Therapy for Substance Users With Depression|Motivational Therapy for Substance Users With Depression|Aftercare|University of California, Los Angeles|Yes|Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A||||August 2010|August 26, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01189799||117168|
NCT01191398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012008-058|Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation|Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation||University of Texas Southwestern Medical Center|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|52|||Both|6 Months|18 Years|No|||March 2014|March 20, 2014|August 27, 2010|Yes|Yes||No|December 11, 2013|https://clinicaltrials.gov/show/NCT01191398||117047|
NCT01193439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082010/1|Safety of Thoracoscopy in Patients With High Risk|Safety of Thoracoscopy in Patients With High Risk||Eskisehir Osmangazi University|Yes|Completed|January 2002|December 2010|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|355|||Both|20 Years|85 Years|No|Non-Probability Sample|Patients who require thoracoscpic investigation|September 2012|September 24, 2012|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01193439||116893|
NCT01193452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL-eCRC|S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer|A Randomized Phase II Study of Comparing S-1/Leucovorin With sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer||Fudan University|No|Recruiting|August 2010|February 2012|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|65 Years|N/A|No|||August 2010|September 1, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193452||116892|
NCT01192074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1147418|Use of Ultrasound in Obstetric Neuraxial Analgesia and Anesthesia Data Base|Use of Ultrasound in Obstetric Neuraxial Analgesia and Anesthesia Data Base||University of Missouri-Columbia|Yes|Recruiting|January 2010|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients in labor Pregnant patients scheduled for cesarean section|January 2010|August 30, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01192074||116996|
NCT01192308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KINETAM|PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)|PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)|KINETAM|Radboud University|No|Completed|July 2010|May 2012|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Female|18 Years|N/A|No|||May 2012|May 21, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192308||116978|
NCT01192594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906005268|Milestones of Adjustment Post-Psychosis|Outcomes of Psychiatric Case Manager Training on Medication Adherence, Progression Through the Four Phases of the MAPP Recovery Model, and Quality of Life in Patients With Schizophrenia|MAPP|Yale University|Yes|Recruiting|November 2009|September 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 7, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192594||116956|
NCT01193556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK VP-00075|PEAK PlasmaBlade TnA Versus Traditional Electrosurgery in Subcapsular Tonsillectomy|A Prospective, Randomized, Double-blinded, Controlled Study to Evaluate Use of the PEAK PlasmaBlade TnA in Subcapsular Tonsillectomy|PRECISE|Medtronic Surgical Technologies|No|Terminated|July 2010|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|51|||Both|3 Years|N/A|No|||November 2012|November 29, 2012|August 31, 2010|Yes|Yes|Termination due to acquisition of PEAK Surgical by Medtronic|No|November 29, 2012|https://clinicaltrials.gov/show/NCT01193556||116884|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.
NCT01188993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09003|Transpulmonary Thermodilution and Transesophageal Echocardiography in Early Septic Shock|Hemodynamic Assessment With Transpulmonary Thermodilution and Transesophageal Echocardiography in Patients With Early Septic Shock|HEMOSEPSIS|University Hospital, Limoges|Yes|Recruiting|January 2011|December 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|153|||Both|18 Years|N/A|No|||August 2010|October 31, 2013|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01188993||117229|
NCT01189006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-Schizo|Add-On Therapy to Risperidonein Schizophrenia|A Double-blind, Placebo-Controlled, Randomized Study of the Efficacy of Dextromethorphan as Add-On Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia|DM|National Cheng-Kung University Hospital|Yes|Completed|January 2005|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|161|||Both|18 Years|65 Years|No|||August 2010|February 27, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01189006||117228|
NCT01190280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS06|Indications for Gallbladder Surgery in Gallstone Disease|Indications for Gallbladder Surgery in Gallstone Disease||Haraldsplass Deaconess Hospital|No|Completed|October 1991|August 2010|Actual|August 2010|Actual|Phase 3|Observational|N/A||8|Actual|500|Samples Without DNA|Resected gallbladders for histological and bacteriological investigation|Both|18 Years|80 Years|No|Non-Probability Sample|Patients admitted to a hospital for either acute cholecystitis or uncomplicated        symptomatic gallstone disease randomized to observation or operation. Patients from a        population screening study for gallstones performed in 1983. Patients operated for        gallstone disease in 1983.|August 2010|August 26, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190280||117131|
NCT01221818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6007-A001-001|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects||Eisai Inc.||Completed|September 2010|||October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221818||114725|
NCT01192802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Albendazole-001|Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora|Effect of Intestinal Helminths on Gut Microflora||Albert Schweitzer Hospital|No|Completed|August 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|200|||Both|4 Years|14 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192802||116940|
NCT01193036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0551|Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems|Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems||M.D. Anderson Cancer Center|No|Terminated|August 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|MD Anderson Hospital and the Melanoma and Skin Center|January 2015|January 7, 2015|August 30, 2010||No|Low accrual.|No||https://clinicaltrials.gov/show/NCT01193036||116922|
NCT01193348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-003|An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome|An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome|aHUS|Alexion Pharmaceuticals|Yes|Completed|September 2010|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|1 Month|18 Years|No|||April 2015|April 13, 2015|August 31, 2010|Yes|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT01193348||116900|
NCT01193361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-012|Ph IIA Study (SOC +/- NS5B)|A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|HEPCAT|Bristol-Myers Squibb|No|Completed|October 2010|November 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|August 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193361||116899|
NCT01188837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-CCC08132010|Comparing Manipulation, Rehabilitation and Combination of the Two in the Treatment of Knee Osteoarthritis|The Relative Effectiveness of Three Full Kinetic Chain Treatment Protocols for Osteoarthritis of the Knee: Manual Therapy, Rehabilitation and a Combination Thereof||Cleveland Chiropractic College|No|Completed|September 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|144|||Both|38 Years|80 Years|No|||August 2012|August 8, 2012|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01188837||117241|
NCT01188850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-002|Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100|Phase I, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Previously Immunized With VGX-3100||Inovio Pharmaceuticals|No|Completed|July 2010|||October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|46 Years|No|||December 2011|December 8, 2011|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01188850||117240|
NCT01193413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Changhai-100829|Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis|Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis: a Marker of Infected Necrosis and Indicator of Treatment|STREM-1|Changhai Hospital|Yes|Completed|July 2008|November 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|The FNA fluid specimens were performed under ultrasound or CT guidance, using a 18G needle      attached to a 15 ml eppendorf tube. One percent xylocaine was used for local anaesthesia.      Under real-time visualization, the needle was directed into the tissue part of the necrosis      or pseudocyst.|Both|18 Years|90 Years|No|Non-Probability Sample|All patients 18 years of age or older who were hospitalized in our medical pancreatic        intensive care unit (PICU) for least two weeks were enrolled in the study if there was a        clinical suspicion of secondary infection of necrotic tissue.|September 2009|September 1, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01193413||116895|
NCT01193426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-API-01|Diagnostic of Spontaneous Bacterial Peritonitis|Evaluation of IL-6 and IL-8 Interleukin Rates to Diagnose Spontaneous Bacterial Peritonitis||Centre Hospitalier Universitaire de Nice|No|Recruiting|September 2010|November 2013|Anticipated|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Ascitic fluid obtained by paracentesis|Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients with cirrhosis admitted to the five participating center Patients        were hospitalized or treated in an ambulatory setting for treatment of ascites or        complications of cirrhosis.|August 2010|May 31, 2011|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193426||116894|
NCT01188876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-113|Phase II of Carbo/Pralatrexate in Rec. Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer|Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|August 2010|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|August 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01188876||117238|
NCT01190124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CohortHIV2008PT|Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients|Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients: a Retrospective Analysis of a Portuguese Cohort Treated Within the Expanded Access Program||Doroana, Maria Manuela, M.D.|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|151|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected adult portuguese patients who started treatment with raltegravir since the        Early Access Program and Compassionate Use Program (from March 2007 to December 2008)|April 2011|April 20, 2011|August 25, 2010||No||No|January 3, 2011|https://clinicaltrials.gov/show/NCT01190124||117143|
NCT01190761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40464|Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions||Actavis Inc.|No|Completed|December 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 27, 2010|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190761||117094|
NCT01191983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25276|A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy|A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Diabetic Nephropathy With CKD Stages III-IV Not on Dialysis, Not Currently Treated With ESA.||Hoffmann-La Roche||Recruiting|August 2010|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01191983||117003|
NCT01191996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS416-201|Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis|A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis||Innate Immunotherapeutics|No|Completed|August 2010|November 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01191996||117002|
NCT01198808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBT-1|Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker|Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters||Technische Universität München|No|Active, not recruiting|August 2010|||December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Peripheral blood|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|The study population will consist of patients with muscle-invasive bladder cancer, who are        referred to the university hospital: Krankenhaus rechts der Isar der Technischen        Universität München|January 2012|January 16, 2012|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198808||116484|
NCT01198821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16123|Gem-TABS in Unresectable Pancreatic Carcinoma|A Phase I Study of Oral Sodium Bicarbonate in Patients With Unresectable Pancreatic Carcinoma Treated With Gemcitabine||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2011|November 21, 2013|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198821||116483|
NCT01192633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVP-SAR|Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma|Phase Ⅱ Study of Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma|GVPS|Fudan University|No|Recruiting|January 2009|January 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|75 Years|No|||August 2010|August 31, 2010|March 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01192633||116953|
NCT01192646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBLSS TRIAL|Home Based Life Saving Skills Training in a Rural Area in Tanzania|IMPACT OF HOME BASED LIFE SAVING SKILLS TRAINING IN A RURAL AREA IN TANZANIA IN FACILITY DELIVERY, PREPARATION OF BIRTH PLANS AND COST-EFFECTIVENESS. AN INTERVENTION CLUSTER RANDOMIZED TRIAL.|HBLSS|Muhimbili University of Health and Allied Sciences||Not yet recruiting|August 2011|December 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|28|||Both|15 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 31, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192646||116952|
NCT01192321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09-047|Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric IOL Implantation Compared to Monofocal IOL Implantation|Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric Intraocular Lens (IOL) Implantation Compared to Monofocal IOL Implantation||Alcon Research|No|Terminated|June 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|N/A|No|||October 2012|October 19, 2012|August 30, 2010|No|Yes|Business decision to close study based on low enrollment|No||https://clinicaltrials.gov/show/NCT01192321||116977|
NCT01192334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chhwang1|Changes of the Single Limb Standing Balance After Total Knee Arthroplasty in Degenerative Osteoarthritis|Observational Study for Changes of the Single Limb Standing Balance After Total Knee Arthroplasty in Degenerative Osteoarthritis||Ulsan University Hospital|Yes|Completed|September 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Probability Sample|patients to be scheduled to take a elective unilateral total knee arthroplasty|December 2013|December 22, 2013|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192334||116976|
NCT01192607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA3741|Endoscopic Treatment During Endodontic Procedures|Endoscopic Treatment During Endodontic Procedures||Barzilai Medical Center|No|Recruiting|April 2007|December 2011|Anticipated|November 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 1, 2011|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192607||116955|
NCT01192620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006596|Pediatric Appendicitis Pathway Study|Pediatric Appendicitis Pathway Study||Oregon Health and Science University|Yes|Recruiting|October 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|3 Years|18 Years|No|Non-Probability Sample|A consecutive sample of all patients ages 3 through 18 presenting to the Oregon Health and        Science University (OHSU) emergency department (ED) for suspicion of appendicitis during        the hours in which study staff are available will be prospectively enrolled.|May 2012|May 1, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192620||116954|
NCT01193205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|050/2010|20 Weeks DBT Group Skills Training Study|Evaluating the Effectiveness of Dialectical Behaviour Skills Training for Suicidality in Borderline Personality Disorder||Centre for Addiction and Mental Health|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|60 Years|No|||October 2012|January 18, 2013|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193205||116909|
NCT01189682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01184-53|Impact of Tegaderm HP and CHG in Major Catheter Related Infections and Dressing Detachment|Impact of Tegaderm HP and Tegaderm CHG in Major Catheter Related Infections and Dressing Detachment in ICU Patients a Prospective Randomized Study|DRESSING2|University Hospital, Grenoble|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1960|||Both|18 Years|N/A|No|||September 2012|October 18, 2013|May 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189682||117177|
NCT01189994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMRJH-001|Trial of Acupuncture in the Treatment of Fibromyalgia|Pragmatic Randomized Controlled Trial of Acupuncture Effectiveness in the Treatment of Fibromyalgia||Santa Casa da Misericordia do Rio de Janeiro Hospital|No|Recruiting|September 2010|December 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||September 2010|September 3, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189994||117153|
NCT01190007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3841064|Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients|A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia||Pfizer|No|Completed|August 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|159|||Both|20 Years|N/A|No|||December 2012|December 19, 2012|August 5, 2010|No|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT01190007||117152|
NCT01221792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVD-PT-10203|Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)|A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Carvedilol Versus Placebo in the Treatment of Post Traumatic Stress Disorder||Columbia Northwest Pharmaceuticals|No|Active, not recruiting|October 2010|August 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||June 2011|June 6, 2011|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221792||114727|
NCT01222065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-04-0101|Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis|Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis|PSOCT|University of Texas at Austin|Yes|Completed|August 2007|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|85|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|45 normal volunteers and 40 glaucoma patients (known visual field defects)with equal sex        distribution between the ages of 40 and 80 will be recruited for this study by H. Grady        Rylander, M.D. at The Eye Institute of Austin and grouped by age into the following        categories: 40-49, 50-59, 60-69, 70-79. Every effort will be made to equalize the number        of patients in each age category and to recruit volunteers representing the race        distribution in our community. Maps of RNFLT, phase retardation, and RNFL birefringence        will be acquired from individuals within each age category.|March 2012|March 26, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222065||114706|
NCT01193049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-175|A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)|A Two-Part, Randomized Clinical Trial to Study the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics||Merck Sharp & Dohme Corp.|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|55 Years|No|||September 2015|September 3, 2015|August 30, 2010|No|Yes||No|June 27, 2012|https://clinicaltrials.gov/show/NCT01193049||116921|
NCT01193374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD050996|The Healthy Families Project|Promoting Healthy Families Through Enhanced Primary Care|HF|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|February 2007|August 2009|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|149|||Both|4 Years|10 Years|No|||May 2011|May 23, 2011|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193374||116898|
NCT01191970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Szabo|Epidural Analgesia, Beta-Endorphin Concentrations in Colostrum, and Infant Neurobehavior as Breast-Feeding Predictors|Investigating Potential Determinants of Breast-Feeding Probability: Epidural Analgesia, Beta-Endorphin Concentrations in Colostrum, and Infant Feeding Behavior||MetroHealth Medical Center|No|Not yet recruiting|October 2010|March 2012|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500||Colostrum samples collected 2x/d for duration of postpartum hospital stay, which is, on      average, 2d.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study is open to all women, aged 18 and over, who are inpatients on the postpartum        floor of MetroHealth Medical Center following the vaginal delivery of a single, healthy        neonate. A neonate is "healthy" if neither of the following two conditions exists: 1)        admission to the neonatal intensive care unit (NICU) following delivery and 2)        pathologies, in either mother or baby, that would be reasonably expected to impede normal        breast-feeding activity.|September 2010|December 17, 2010|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191970||117004|
NCT01189162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31/09|High Flow Nasal Cannula (HFNC) Versus Nasal Intermittent Mandatory Ventilation (NIMV)for Respiratory Distress Syndrome (RDS): a Randomized, Controlled, Prospective Study|High Flow Nasal Cannula Versus Nasal Intermittent Mandatory Ventilation for Respiratory Distress Syndrome: a Randomized, Controlled, Prospective Study||Bnai Zion Medical Center|No|Recruiting|January 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||August 2015|August 11, 2015|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01189162||117216|
NCT01189175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1272.5|Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823|Relative Bioavailability of a Single Oral Dose of BI 113823 (50 mg qd) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Bid) in Healthy Male Volunteers (an Open Label, Two Periods, Fixed-sequence, Clinical Phase I Study)||Boehringer Ingelheim||Completed|August 2010|||September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|August 25, 2010||||No||https://clinicaltrials.gov/show/NCT01189175||117215|
NCT01189500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061027|Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects|An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Tamoxifen When Co-Administered In Healthy Post-Menopausal Female Subjects||Pfizer|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Female|45 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 1, 2011|August 25, 2010|Yes|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT01189500||117190|
NCT01189513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0576|SCH-900105 in Recurrent Glioblastoma|A Phase I Evaluation of SCH 900105 With Correlative Tissue Studies in the Treatment of Adult Patients With Recurrent Glioblastoma||M.D. Anderson Cancer Center|No|Withdrawn|August 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|August 25, 2010|No|Yes|Sponsor decision.|No||https://clinicaltrials.gov/show/NCT01189513||117189|
NCT01191073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/655|Manually Versus Digitally Fabricated Removable Partial Dentures|A Study on the Fit and Behaviour of Computer-aided Design and Rapid Prototyping Fabrication of Removable Partial Dentures||University Ghent|No|Recruiting|June 2011|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01191073||117072|
NCT01191086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-005|Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures|Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study||Upsher-Smith Laboratories||Completed|October 2010|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|August 26, 2010|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01191086||117071|
NCT01198548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 176910|High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer|A Phase II Clinical Trial of High Dose Vitamin D3 Supplementation in Combination With FOLFOX + Bevacizumab in the 1st Line Treatment of Metastatic Colorectal Cancer||Roswell Park Cancer Institute|Yes|Terminated|August 2010|June 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|79 Years|No|||June 2014|June 23, 2014|September 8, 2010||No|Lack of funding|No|January 28, 2014|https://clinicaltrials.gov/show/NCT01198548||116504|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.
NCT01198847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-2010|Early Stockholm Obesity Prevention Program|A Randomised Controlled Trial for Overweight and Obese Parents to Prevent Childhood Obesity|EarlySTOPP|Karolinska Institutet|Yes|Recruiting|January 2010|March 2016|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|250|||Both|1 Year|1 Year|Accepts Healthy Volunteers|||June 2011|June 22, 2011|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01198847||116481|
NCT01192958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFLU|A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza|A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza|Snuffles|Public Health England|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|||||Both|6 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects from primary care who are participating in the clinical service evaluation.|December 2009|August 31, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01192958||116928|
NCT01224600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 0704|EValuation of Systemic Atherothrombosis in Patients With ARTerial Disease of the Lower Limbs|EValuation of Systemic Atherothrombosis in Patients With ARTerial Disease of the Lower Limbs|EVART|Institut de l'Atherothrombose|Yes|Completed|January 2008|March 2014|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1056|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed PAD < 1 year symptomatic or asymptomatic without any hystory        of previous coronary nor cerebrovascular event|March 2015|March 5, 2015|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01224600||114515|
NCT01192945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-0905|Non-interventional Study With Azacitidin (Vidaza®)|Piaza - Non-interventional Study on the Efficacy and Safety of Azacitidin (Vidaza®) in Patients With Myelodysplastic Syndromes (MDS, INT-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder)|Piaza|iOMEDICO AG|No|Completed|July 2010|November 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are not suitable for transplantation of hematopoietic stem cells and have one        of the following diseases: myelodysplastic syndrome (MDS) with intermediate risk 2 or high        risk according to the International Prognostic Scoring System (IPSS), chronic        myelomonocytic leukemia (CMML) with 10-29% marrow blasts without myeloproliferative        disorder, acute myeloid leukemia (AML) with 20-30% blasts and multilineage dysplasia        according to classification of the World Health Organisation (WHO).|August 2015|November 12, 2015|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192945||116929|
NCT01189019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4928|HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration|High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study|HiPED|Pacific Eye Associates|Yes|Active, not recruiting|August 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|N/A|No|||April 2012|April 10, 2012|August 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01189019||117227|
NCT01189032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00890404|Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye|Dose-Response Study of DE-089 Ophthalmic Solution in Patients With Dry Eye -Late Phase II Confirmatory Study-||Santen Pharmaceutical Co., Ltd.||Completed||||July 2006|Actual|Phase 2|Interventional|N/A|3||Actual|320|||Both|20 Years|N/A||||August 2014|August 8, 2014|August 24, 2010||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01189032||117226|
NCT01189357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/358|Revision Meniscal Transplants; Lateral and Medial|Revision Meniscal Transplants; Lateral and Medial||University Hospital, Ghent|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|failed meniscal transplantation|July 2011|July 13, 2011|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189357||117201|
NCT01189370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11277|Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer|A Phase II Study of the Efficacy and Tolerability of the Dose Escalation of Sorafenib in Advanced Renal Cell Cancer||University of Kansas Medical Center|Yes|Active, not recruiting|June 2008|June 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||December 2013|December 30, 2013|August 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01189370||117200|
NCT01221246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-002|Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours|A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window|GMAIS|Genervon Biopharmaceuticals, LLC|No|Recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|October 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221246||114769|
NCT01221545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1020C00044|A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After High Single Ascending Oral Supratherapeutic Doses of AZD1656 in Male Type 2 Diabetes Mellitus (T2DM) Patients||AstraZeneca|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Male|20 Years|60 Years|No|||February 2011|February 16, 2011|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221545||114746|
NCT01221259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2212-A001-001|A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects||Eisai Inc.|No|Completed|January 2010|November 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|May 20, 2013|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221259||114768|
NCT01221558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-01|Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men|Effects of Lycopene Supplementation on Oxidative Stress and Markers of Endothelial Function in Healthy Men||Yonsei University|Yes|Completed|July 2009|September 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|126|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||June 2009|October 14, 2010|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221558||114745|
NCT01222078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113390|Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus|Evaluation of the Safety and Tolerability of Re-dosing With Intravenous (iv) Otelixizumab in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus||GlaxoSmithKline|No|Terminated|November 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|45 Years|No|||March 2015|March 12, 2015|October 7, 2010||No|A Phase 3 study recently reported and demonstrated that the dose of otelixizumab in OTX113390    is not effective.|No||https://clinicaltrials.gov/show/NCT01222078||114705|
NCT01189838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098055-3|The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma|The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma||Far Eastern Memorial Hospital|No|Recruiting|January 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|100|Samples With DNA|Surgical resection of tumor|Both|18 Years|90 Years|No|Probability Sample|We will retrospectively review adult patients (age>18 years) with TCC who received surgery        at Far Eastern Memorial Hospital and National Taiwan University Hospital from 2004 to        2008.|January 2010|October 5, 2010|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01189838||117165|
NCT01191034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luc 10-002|Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma|Phase I/II Study of Peptide Vaccination Associated With Tumoral Immunomodulation With Proinflammatory Cytokines and Imiquimod in Patients With Advanced Metastatic Melanoma||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|August 2010|August 2012|Anticipated|August 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||August 2010|August 27, 2010|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01191034||117074|
NCT01191060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 110 01|Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years|Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age|IFM/DFCI2009|University Hospital, Toulouse|Yes|Active, not recruiting|October 2010|September 2020|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|700|||Both|18 Years|65 Years|No|||August 2015|August 18, 2015|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01191060||117073|
NCT01192516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7557-R|Effectiveness of Tailored Activity Pacing for Symptomatic Osteoarthritis|Effectiveness of Tailored Activity Pacing for Symptomatic Osteoarthritis|AIM|VA Office of Research and Development|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|195|||Both|50 Years|N/A|No|||March 2015|March 18, 2015|August 25, 2010||No||No|February 13, 2015|https://clinicaltrials.gov/show/NCT01192516||116962|Although overall effects were not found by group over time, additional data analyses will be conducted to determine if there were positive effects for specific subgroups of people.
NCT01193088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC-6602|Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2|Genetics of Charcot Marie Tooth Disease (CMT) - Modifiers of CMT1A, New Causes of CMT|INC-6602|University of Iowa|Yes|Recruiting|April 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1050|Samples With DNA|DNA extracted from whole blood. Filter cards with blood spots.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients participating in Inherited Neuropathies Consortium (INC)-6601 and meeting        eligibility criteria for this study will be recruited.|May 2015|May 14, 2015|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01193088||116918|
NCT01201954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SACAROSE01|Pain Relief of Newborn Preterm Infants During Endotracheal Suctioning|Pain Relief of Newborn Preterm Infants During Endotracheal Suctioning: a Randomized Clinical Trial|PRPS|Universidade Federal de Pernambuco|No|Completed|March 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|N/A|36 Weeks|No|||September 2010|April 25, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01201954||116245|
NCT01202279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-MUCD-001|Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Mucinex D for Symptomatic Therapy in Patients With Acute Upper Respiratory Tract Who Seek Treatment|Wait and See|Reckitt Benckiser LLC|No|Completed|October 2009|July 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1189|||Both|18 Years|75 Years|No|||October 2012|October 4, 2012|September 13, 2010|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT01202279||116220|
NCT01202539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00006460|Real-time Assessment of Frameless Intrafraction Motion|Use of Real-time Infrared Reflective Marker Tracking and Surface Texture Mapping to Assess the Integrity of a Novel Thermoplastic Mask System for Frameless Immobilization||Oregon Health and Science University|Yes|Active, not recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Potential subjects will be recruited by the Oregon Health and Science University study        investigators.|September 2010|September 15, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01202539||116200|
NCT01198275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-PUFA-01|n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation|N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.||Azienda Ospedaliera Spedali Civili di Brescia|Yes|Completed|January 2006|May 2008|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|199|||Both|18 Years|80 Years|No|||January 2012|January 19, 2012|September 9, 2010|Yes|Yes||No|April 13, 2011|https://clinicaltrials.gov/show/NCT01198275||116525|The effect of n-3 PUFAs on the recurrence of Atrial Fibrillation (AF) in patients with persistent AF not on amiodarone and a renin-angiotensin-aldosterone system (RASS) inhibitor cannot be inferred from our findings
NCT01198561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-08-072|Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression|Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression : Effect of TMS on Depression, Cognitive Function, and Regional Cerebral Glucose Metabolism||Samsung Medical Center|Yes|Recruiting|February 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|serum, plasma and DNAs|Both|N/A|N/A|No|Non-Probability Sample|Patients with major depressive disorder, who were not responsive to antidepressants|December 2015|December 30, 2015|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198561||116503|
NCT01198834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-7EAT-1005|MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains|A Randomized, Multi-Center, Double-Blind, Factorial, Comparator and Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains||MEDRx USA, Inc.|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|600|||Both|14 Years|N/A|No|||June 2012|June 28, 2012|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198834||116482|
NCT01199770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SET 2010-043|Pasta Formulations, Portion Sizes and Their Effect on Appetite|Understanding Pasta Formulations and Portion Size on Satiety in Healthy Weight Women|SET|Institute for Food Safety and Health, United States|No|Active, not recruiting|September 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199770||116412|
NCT01224613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1002|Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine|A Randomized Controlled Trial To Compare The Immunogenicity Of Self-Administered And Nurse-Administered Intradermal Influenza Vaccine||Dalhousie University|No|Completed|November 2010|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|276|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 14, 2011|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01224613||114514|
NCT01224366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23135|Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus|A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.||Novartis||Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|448|||Both|18 Years|80 Years|No|||September 2012|September 4, 2012|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224366||114533|
NCT01193218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.38|Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus|A Double-blind, Randomised, Parallel Group Efficacy and Safety Study of BI 10773 (5 mg, 10 mg, 25 mg, and 50 mg) Compared to Placebo When Administered Orally Once Daily Over 12 Weeks, as Monotherapy, in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Diet and Exercise, Followed by a 40 Week Randomised Extension Study to Assess Long Term Safety of BI 10773 (10 mg and 25 mg)||Boehringer Ingelheim||Completed|September 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|547|||Both|20 Years|80 Years|No|||May 2014|May 16, 2014|August 31, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01193218||116908|
NCT01220700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triclosan|Antimicrobial Coated Sutures in Paediatric Surgery|Antimicrobial Coated Sutures in Paediatric Surgery||University of Oulu|No|Completed|September 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1635|||Both|N/A|18 Years|No|||February 2015|February 5, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220700||114811|
NCT01220986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDDC10/H0403/32|Liver Regeneration After Liver Resection|An Observational Study of Liver Regeneration After Right Hepatectomy: Understanding the Molecular Primers of Liver Regeneration||Nottingham University Hospitals NHS Trust|Yes|Recruiting|August 2010|August 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Liver tissue & serum|Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing right hepatectomy for colorectal liver metastases.|October 2010|October 13, 2010|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01220986||114789|
NCT01220999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2010-002|An Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer|A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.||Ludwig Institute for Cancer Research|No|Completed|October 2010|September 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220999||114788|
NCT01221220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08302010-6809|Environmental Strategies & Behavior Change to Reduce Overeating in Obese Children|Environmental Strategies & Behavior Change to Reduce Overeating in Obese Children||Stanford University|No|Active, not recruiting|September 2010|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221220||114771|
NCT01221233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD005|Investigation of Trunk Muscle Size and Function in Older Adults With Chronic Low Back Pain|Lumbar Stabilization Exercises and Neuromuscular Electrical Stimulation: An Investigation of Muscle Size and Function in Older Adults With Chronic Low Back Pain||University of Delaware|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|60 Years|85 Years|No|||June 2013|June 17, 2013|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221233||114770|
NCT01221012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|883-2009-CLIT|Heat Stress and Physiological Strain of Permeable vs. Impermeable CB Protective Garment|||Medical Corps, Israel Defense Force||Recruiting|December 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control||5|Anticipated|12|||Male|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Twelve young (20-30 yr) male subjects will voluntarily participate in this study|March 2012|March 28, 2012|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221012||114787|
NCT01221272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0103|Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging|A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging||Gilead Sciences|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|October 13, 2010|Yes|Yes||No|July 1, 2014|https://clinicaltrials.gov/show/NCT01221272||114767|
NCT01222091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10062010-7050|Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids|Effect of Beta Blockade on Opioid-Induced Hyperalgesia in Humans||Stanford University||Recruiting|February 2009|March 2011|Anticipated|January 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 15, 2010|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222091||114704|
NCT01222377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-09-14|Endoscopic Breast Surgery in Treating Patients With Breast Cancer|Endoscopic Breast Surgery Feasibility Study||University of Southern California|Yes|Terminated|September 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|15 Years|N/A|No|||February 2014|February 5, 2014|October 14, 2010|No|Yes|P.I. left|No||https://clinicaltrials.gov/show/NCT01222377||114682|
NCT01222650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSO1201|A Comparative Study of KSO-0400 in BPH Patients With LUTS|A Randomized, Double-blind, Placebo-controlled, Multicentre Study of KSO-0400 in BPH Patients With LUTS||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4|||400|||Male|50 Years|N/A|No|||June 2011|June 30, 2011|October 15, 2010||||No||https://clinicaltrials.gov/show/NCT01222650||114661|
NCT01190735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-219243|Caffeine for Motor Manifestations of Parkinson's Disease|Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.||McGill University Health Center|No|Completed|August 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190735||117096|
NCT01191697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-457|CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer|Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|February 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|August 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01191697||117025|
NCT01193101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2219|Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension||Novartis||Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|389|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|August 26, 2010||No||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01193101||116917|
NCT01202292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 070087|Group Motivational Intervention in Overweight/Obese Patients.|Group Motivational Intervention in Overweight/Obese Patients in Primary Prevention of Cardiovascular Disease in the Primary Healthcare Area.|IMOAP|Jordi Gol i Gurina Foundation|Yes|Recruiting|January 2008|December 2010|Anticipated|October 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|1200|||Both|30 Years|70 Years|No|||September 2010|September 30, 2010|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01202292||116219|
NCT01202552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIC 5301|Two-site Intradermal Influenza Vaccination in Elderly|Two-site Intradermal Influenza Vaccination in Elderly||Queen Saovabha Memorial Institute|Yes|Recruiting|October 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|180|||Both|60 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01202552||116199|
NCT01198288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Effects of Home-based Pulmonary Rehabilitation in Patients With Severe or Very Severe Chronic Obstructive Pulmonary Disease (COPD)|Randomised Controlled Trial on the Effects of Home-based Pulmonary Rehabilitation in Patients With Severe or Very Severe COPD||Associazione Riabilitatori Insufficienza Respiratoria|No|Recruiting|September 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|182|||Both|N/A|N/A|No|||January 2012|January 30, 2012|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01198288||116524|
NCT01199497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-NTS-03(08/10)|Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute Rhinitis|Multicenter Clinical Trial Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms in Subjects Above 12 Years of Age, Suffering From Non-productive Cough and Acute Rhinitis.||Ache Laboratorios Farmaceuticos S.A.||Not yet recruiting|August 2011|January 2013|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|208|||Both|12 Years|N/A|No|||May 2011|May 3, 2011|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199497||116433|
NCT01199510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-05|Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery|||Alcon Research|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199510||116432|
NCT01199250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8020|Biomarkers in Samples From Patients With Endometrial Cancer|Specialized Program of Research Excellence (SPORE) in Endometrial Cancer||Gynecologic Oncology Group||Not yet recruiting|January 2100|||January 2100|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|3600|||Female|N/A|N/A|No|Non-Probability Sample|Patients with endometrial cancer|May 2015|May 27, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199250||116452|
NCT01199549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAO09C01|Bioavailability Study of Different Dietary Antioxidants in Volunteers|Phase 1 Bioavailability Study of Different Dietary Antioxidants in Volunteers||Cambridge Theranostics Ltd|No|Completed|September 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|N/A||3|Actual|90|Samples Without DNA|serum|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Cambridgeshire|September 2010|September 9, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01199549||116429|
NCT01199822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13940|Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors|A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-3G3 Administered in a 2-week, or 3-week Schedule to Japanese Patients With Advanced Solid Tumors||ImClone LLC|No|Completed|September 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|N/A|No|||November 2011|February 8, 2012|September 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199822||116409|
NCT01224626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951139|Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)|Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)(Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|May 2006|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|41|||Both|N/A|N/A|No|Non-Probability Sample|The patients who are prescribed to Zyvox (linezolid).|May 2012|May 29, 2012|October 18, 2010|No|Yes||No|March 28, 2012|https://clinicaltrials.gov/show/NCT01224626||114513|
NCT01220505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-058|Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System|A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System||Biomet, Inc.|No|Active, not recruiting|September 2010|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|All subjects with a spinal defomrity with a Risser score of a minimum of 3 where the        physician has determined that the patient requires a spinal fusion of the thoracic or        lumbar spine are eligible for entry into the post market surveillance.|September 2015|February 29, 2016|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220505||114826|
NCT01224886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGIR|Age and Insulin Resistance|Insulin Resistance of Aging, Ectopic Lipid Depositions and Oxidative Capacity: Effects of Exercise and Obesity|AGIR|University of Lausanne|No|Recruiting|October 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01224886||114493|
NCT01224899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SymBlock Trial|Surgical Sympathetic Blockade in Heart Failure|Left Cervico-Thoracic Sympathetic Blockade by Clipping in Systolic Heart Failure: A Randomised Controlled Trial|SymBlock|University of Sao Paulo|No|Completed|December 2006|July 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||October 2010|October 19, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224899||114492|
NCT01224912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU-vandenBout-2|Internet Delivered Self-Help CBT for Insomnia|Phase 3 Study of Internet-based Self-help for Insomnia: Factors That Are Associated With Success of the Intervention||Utrecht University|Yes|Completed|October 2010|October 2012|Actual|December 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|479|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 7, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224912||114491|
NCT01220713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N66001-09-2-2060|Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI)|Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI): A Randomized, Double-Blinded, Sham Controlled, Variable Dose, Prospective Trial|HBOT|Virginia Commonwealth University|Yes|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|19 Years|60 Years|No|||August 2013|August 26, 2013|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01220713||114810|
NCT01221584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-DUM-2010/1|Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia|Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia|CEPHEUS|AstraZeneca|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Subject on lipid lowering drug treatment for at least 3 months, with no dose change for a        minimum of 6 weeks..|February 2012|February 29, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221584||114743|
NCT01221597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-803|Study of AA4500 in the Treatment of Peyronie's Disease|A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease||Endo Pharmaceuticals|No|Completed|September 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|418|||Male|18 Years|N/A|No|||March 2015|March 24, 2015|October 8, 2010|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01221597||114742|
NCT01221831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES-C02|Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2|A Randomised Open-label Multi-centre Comparative Study to Evaluate Cycle Control of 2 Dosages of Estetrol Combined With Either P1 or P2, Compared to a Combined Oral Contraceptive Containing E2V and DNG|FIESTA|Estetra|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|396|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221831||114724|
NCT01222104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903|Angio-Seal Interventional Radiology (IR) Registry|Clinical Registry of St. Jude Medical Angio-Seal™ Vascular Closure Devices Following Interventional Radiology Procedures||St. Jude Medical|No|Completed|October 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|634|||Both|N/A|N/A|No|Probability Sample|Patients who undergo a diagnostic and/or interventional radiology procedure through        percutaneous femoral artery access and meet the registry selection criteria.|December 2014|December 15, 2014|October 5, 2010||No||No|April 28, 2014|https://clinicaltrials.gov/show/NCT01222104||114703|Major and minor vascular complications were collected as Serious Adverse Event and Other Adverse Events as defined in the protocol.
NCT01222117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T05018-2004|A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion|A Phase 2, Randomized, Open-label (With Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Compared to Plasminogen Activator and Placebo In Patients With Acute Lower Extremity Native Artery or Bypass Graft Occlusion||Grifols Therapeutics Inc.|Yes|Active, not recruiting|December 2010|February 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Anticipated|230|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|October 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222117||114702|
NCT01222390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G10-0056|Tissue Expander Breast Reconstruction Study on Breast Volume and Shape Change|The Contour Profile® Tissue Expander in Immediate Breast Reconstruction: A Three-Dimensional Look Into Shape and Volume Changes|CPX3|Northwestern University|Yes|Completed|November 2010|April 2014|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|25 Years|85 Years|No|||November 2014|November 14, 2014|October 13, 2010||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01222390||114681|The number of subjects studied is small; projection measurements may have been subject to human error.
NCT01223027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2302|Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma|An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies||Novartis|Yes|Completed|March 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|564|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|September 30, 2010|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01223027||114632|
NCT01191385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14611|GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start|Non Interventional Study in Patients With Diagnosis of HCC in Whom a Decision to Treat With Sorafenib Has Not Been Made at Time of Study Enrollment||Bayer|No|Withdrawn|November 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with unresectable HCC in whom a decision to treat with sorafenib has not been        made at time of study enrollment and who were never treated with sorafenib in the past|March 2015|March 17, 2015|August 27, 2010|No|Yes|Study is officially cancelled bevore FPFV.|No||https://clinicaltrials.gov/show/NCT01191385||117048|
NCT01192243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iressa combined with Pem/Cis|Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients|Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small||Fudan University|Yes|Recruiting|December 2009|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|70 Years|No|||September 2010|September 2, 2010|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01192243||116983|
NCT01201655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chenyong|Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis|Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis||Xijing Hospital|Yes|Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|5000|||Both|20 Years|90 Years|No|Probability Sample|post-hepatitic cirrhosis with portal hypertension and hypersplenism patients|January 2010|September 13, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201655||116268|
NCT01201668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133265|DPBRN Persistent Pain and Root Canal Therapy|Persistent Pain and Root Canal Therapy||Dental Practice-Based Research Network|No|Completed|August 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|19 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants directly involved in this study are the patients who have sought dental        treament in the practitioner-investigators' practices. The practitioner-investigators will        be endodontists and general dentists.|September 2011|September 16, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201668||116267|
NCT01198301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEP|Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy|Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy||Beijing Cancer Hospital|Yes|Completed|August 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|Samples Without DNA|the tissue will be obtained by core niddle biopsy.|Female|18 Years|75 Years|No|Probability Sample|female patients with metastatic breast cancer treated by Docetaxel-based chemotherapy|July 2015|July 22, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01198301||116523|
NCT01198574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIVA|Sub-clinical Inflammation and Iron Supplementation|The Role of Sub-clinical Inflammation on the Iron Status of Myanmar Anaemic Adolescent Schoolgirls During Iron and Vitamin A Supplementation|SCI&Anaemia|Indonesia University|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|402|||Female|12 Years|19 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|September 8, 2010||No||No|December 31, 2011|https://clinicaltrials.gov/show/NCT01198574||116502|
NCT01198860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBsAg 07-10 - Private Clinic|Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B|Tenofovir Disoproxil Fumarat 300 mg - Phyllanthus Cantoniensis Hornem 300mg - Herba Adenosmatis Caerulei 150mg - Herba Eclipta 150mg, Vitamin C 500 mg Daily is Effective in the Long-term Treatment of Chronic and Acute Hepatitis B.|HBV|Triệu, Nguyễn Thị, M.D.|Yes|Available|September 2010|May 2015|Actual|May 2015|Actual|Phase 3|Expanded Access|N/A|||||||Both|18 Years|60 Years|No|||May 2015|November 19, 2015|September 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198860||116480|
NCT01198587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01-0022|Oral Zinc for the Treatment of Acute Diarrhea in US Children|A Double Blind Randomized Placebo Controlled Trial of Oral Zinc for Children With Acute Diarrhea in a Developed Nation.||Children's Hospital Boston|Yes|Active, not recruiting|November 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|6 Months|6 Years|No|||June 2014|June 21, 2014|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01198587||116501|
NCT01199835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B251|The Effects of Dairy Products on Energy Balance|The Effects of Dairy Products on Energy Balance|MEPEB|University of Copenhagen||Completed|June 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01199835||116408|
NCT01199848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRB 2010-033|A Study of Strawberries and Disease Risk|Effect of Strawberry on Oxidative Stress- and Inflammatory-mediated Insulin Resistance (IR) in Humans: Combating a Major Risk Factor for Diabetes and Cardiovascular Disease Through Diet|STRB|Institute for Food Safety and Health, United States|No|Active, not recruiting|September 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199848||116407|
NCT01220518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 1.1|Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)|Randomized, Double-blind, Parallel-group, Phase 1 Study||Celltrion|Yes|Completed|October 2010|June 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|75 Years|No|||March 2013|March 11, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01220518||114825|
NCT01224639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-DEN-102|Safety and Immunogenicity Study to Assess DENVax, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever|Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults||Takeda|No|Completed|October 2010|November 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|96|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|October 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01224639||114512|
NCT01220726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX0621|Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction|Randomized Double-blind Placebo Controlled Trial of Intradetrusor Injections of Botox for the Treatment of Refractory Overactive Bladder Secondary to Benign Prostatic Obstruction-BTX0621||Weill Medical College of Cornell University|No|Recruiting|June 2009|||June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|40 Years|90 Years|Accepts Healthy Volunteers|||October 2010|October 12, 2010|June 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220726||114809|
NCT01221025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHHparecoxib1|Effect Study of Parecoxib to Treat Emergence Delirium and Postoperative Pain|Effects of Parecoxib on Emergence Delirium and Postoperative Pain in Elderly Patients Undergoing Abdominal Surgery After General Anesthesia||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|September 2010|June 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|900|||Both|65 Years|90 Years|No|||October 2010|March 24, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01221025||114786|
NCT01221285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-18|Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium|A Biomarker-Based Pilot Study of Cockroach Subcutaneous Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-18)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|55 Years|No|||June 2014|June 5, 2014|October 13, 2010|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01221285||114766|
NCT01221571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFM13-101|A Study to Assess AFM13 in Patients With Hodgkin Lymphoma|A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma||Affimed GmbH|Yes|Completed|October 2010|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||February 2011|June 25, 2013|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221571||114744|
NCT01221610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1003|BIOLUX P-I First in Man Study|A Prospective, Multi-centre, Randomized Controlled, First in Man Study to Assess the Safety and Performance of the Passeo-18 Lux Paclitaxel Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Patients With Stenosis and Occlusion of the Femoropopliteal Arteries (BIOLUX P-I).||Biotronik AG|Yes|Completed|October 2010|January 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|N/A|No|||February 2015|February 6, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221610||114741|
NCT01221623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-804|Study of AA4500 in the Treatment of Peyronie's Disease|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease||Endo Pharmaceuticals|No|Completed|October 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|418|||Male|18 Years|N/A|No|||March 2015|March 24, 2015|October 8, 2010|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01221623||114740|
NCT01221844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP2010|Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies|Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women||Clinica Fabia Mater|No|Completed|February 2010|May 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|20 Years|45 Years|No|||June 2011|June 24, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01221844||114723|
NCT01222130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MQ-00-6-300-01206-0-00|Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants|CIDRZ 1234 - Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants|IDX|University of North Carolina, Chapel Hill|No|Completed|July 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1126|||Both|N/A|60 Weeks|No|Probability Sample|HIV-infected mothers and their exposed infants seek care in a primary care setting in        Lusaka, Zambia|September 2014|September 16, 2014|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01222130||114701|
NCT01222403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_26|A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older|A Multicenter, Post-marketing Surveillance Study to Monitor the Safety of Novartis Vaccine MF59-adjuvanted Influenza Subunit Vaccine FLUAD® and Sandoz Korea Vaccine MF59-adjuvanted Influenza Subunit Vaccine VANTAFLU® Administered According to the Prescribing Information in Korean Subjects Aged 65 Years or Older at the Time of Vaccination.||Novartis||Completed|October 2010|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|767|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|October 12, 2010||No||No|September 9, 2015|https://clinicaltrials.gov/show/NCT01222403||114680|
NCT01223040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-64|An Open-Label, Single-Center Study Evaluating the Effect of Systane Balance on Video Ocular Protection Index (OPI) and Blink Patterns in Patients Diagnosed With Dry Eye|||Alcon Research|No|Completed|August 2010|||September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2012|April 7, 2012|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223040||114631|
NCT01223053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLP-110-002|Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Confirmatory Phase 3 Study to Assess the Efficacy and Safety of TDLP-110 (Ketotransdel®, Ketoprofen 10% Cream) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury||Imprimis Pharmaceuticals, Inc.||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||September 2012|September 4, 2012|October 8, 2010|Yes|Yes|Revised Development Program|No||https://clinicaltrials.gov/show/NCT01223053||114630|
NCT01201096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-LEBE|Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)|Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors|NEO-LEBE|University of Jena|No|Recruiting|September 2010|September 2018|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|60 Years|No|Non-Probability Sample|All patients with liver metastasis of neuroendocrine tumors of the small bowel, colon,        pancreas or stomach. Primary tumor removed.|September 2010|September 22, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201096||116311|
NCT01201421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118678|DPBRN Patient Satisfaction With Dental Restorations|Patient Satisfaction With Dental Restorations||Dental Practice-Based Research Network|No|Completed|November 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|5932|||Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Practitioner investigators must have been enrolled in the DPBRN, completed the "Assessment        of caries diagnosis & caries treatment" study; and do at least some restorative dentistry        in their practices. The human subjects directly involved in this study were patients who        had sought dental treatment in the DPBRN practitioners' practices.|June 2011|June 14, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201421||116286|
NCT01201967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-001414|A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients|A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC)|MOSAIC|Massachusetts General Hospital|No|Completed|September 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 7, 2010||No||No|May 12, 2014|https://clinicaltrials.gov/show/NCT01201967||116244|
NCT01201980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRS-DUM-2010/2|An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension|An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension and to Evaluate Patients' Quality of Life||AstraZeneca|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Speciality care clinics|January 2012|January 9, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01201980||116243|
NCT01202565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-165|Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice|Effectiveness of Adalimumab (Humira) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice||AbbVie|No|Completed|September 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|506|||Both|18 Years|N/A|No|Non-Probability Sample|Per this PMOS protocol, the study population will consists of adult patients with moderate        to severe plaque psoriasis who have failed to respond to, have a contraindication to, or        are intolerant of other systemic therapies including cyclosporine, methotrexate or PUVA        (photochemotherapy combining psoralen with ultraviolet A treatment), and exhibit a        significant psoriatic affection of the scalp and/or nails.|July 2014|July 15, 2014|September 14, 2010||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01202565||116198|
NCT01198314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCLTIT|Withdrawal of Immunosuppression in Long Term Stable Liver Transplant Recipients|Gradual Withdrawal of Immunosuppression in Long Term Stable Liver Transplant Recipients Using Immunologic Profile Predicting Operational Tolerance|tolerance|The Catholic University of Korea|Yes|Recruiting|July 2010|March 2013|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2010|September 9, 2010|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01198314||116522|
NCT01198600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-373-C-006|Ocular Comfort and the "Aging" Lens (ERBIUM)|Ocular Comfort and the "Aging" Lens (ERBIUM)||Alcon Research|No|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|78|||Both|17 Years|N/A|No|||July 2012|July 26, 2012|September 9, 2010|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01198600||116500|The current study design and sample size was not able to uncover clinically meaningful differences between survivors and strugglers. There is considerable individual variation in lens performance with age, which requires further investigation.
NCT01198873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRONE_L_04315|Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement|A Placebo-Controlled, Double-Blind, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement|ODYSSEUS|Sanofi|No|Terminated|September 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|21 Years|N/A|No|||January 2013|January 10, 2013|September 9, 2010|Yes|Yes||No|January 10, 2013|https://clinicaltrials.gov/show/NCT01198873||116479|Due to the early termination of the study, results should be cautiously interpreted. Indeed the number of participants was lower than planned (76 instead of 334) and the treatment period was shorter than planned (6 months instead of 12 months).
NCT01224665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1011|S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer|A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer||Southwest Oncology Group|Yes|Recruiting|August 2011|||August 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Both|18 Years|120 Years|No|||December 2015|December 8, 2015|October 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01224665||114510|
NCT01220739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StELLAR|Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery|Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery|StELLAR|University of California, San Diego|Yes|Terminated|June 2011|April 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|80 Years|No|||April 2013|April 20, 2013|October 13, 2010|Yes|Yes|Device sponsor no longer in business.|No||https://clinicaltrials.gov/show/NCT01220739||114808|
NCT01221038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|923-2010-CTIL|Standardization of a Heat Tolerance Test for Young Women as a Basis for Heat Tolerance Tests in Female Soldiers|Preliminary Study for Standardization of Heat Tolerance Test for Young Women||Medical Corps, Israel Defense Force|No|Recruiting|February 2011|||November 2011|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|30|||Both|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|young health women|June 2011|July 12, 2011|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221038||114785|
NCT01221051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUGSB-8290|Third Stage of Labor a Swedish Randomized Controlled Trial|A Comparison of Active and Expectant Management of the Third Stage of Labor||Göteborg University|No|Completed|November 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1800|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 30, 2012|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01221051||114784|
NCT01221298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-267|A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)|An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Completed|October 2010|April 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||December 2014|December 29, 2014|October 13, 2010|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01221298||114765|
NCT01221636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-278|Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept|A Study to Compare the Pharmacokinetics of Abatacept (BMS-188667) Drug Product Using Active Pharmaceutical Ingredient Manufactured With a High Concentration of Metals Relative to the Active Pharmaceutical Ingredient Manufactured With a Low Concentration of Metals||Bristol-Myers Squibb|No|Withdrawn|October 2010|February 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|August 31, 2015|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221636||114739|
NCT01221857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC P#01.01.020|Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies|Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hematological Malignancies||Gamida Cell ltd|Yes|Completed|November 2010|May 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|8 Years|65 Years|No|||February 2014|February 24, 2014|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221857||114722|
NCT01221870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOB203|Tesetaxel as First-line Therapy for Metastatic Breast Cancer|A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer||Genta Incorporated|No|Recruiting|November 2010|January 2013|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|81|||Female|18 Years|N/A|No|||July 2012|July 20, 2012|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221870||114721|
NCT01222702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-061A201|ACT-179811 in Patients With Clostridium Difficile Infection|Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection|CDI|Actelion|Yes|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222702||114657|
NCT01223092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-10|Study of Gene Associations and Infertility|Genes and Gene Polymorphisms Associated With Infertility: Utilization of DNA Characteristics to Better Understand Reproductive Competence||Reproductive Medicine Associates of New Jersey|No|Enrolling by invitation|February 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|whole blood serum, follicular fluid and sperm|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing infertility treamtnet|November 2015|November 16, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01223092||114627|
NCT01201434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7702-BW-CTIL|Effect of Probiotics on Sputum Inflammation and Pulmonary Infections in Patients With Cystic Fibrosis|The Effect of Probiotics on Sputum Bacteria, Sputum Inflammation, and Pulmonary Infections in Patients With Cystic Fibrosis: A Double-blind Placebo-controlled Trial||Sheba Medical Center|No|Terminated|October 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|12|||Both|5 Years|40 Years|No|||July 2014|July 21, 2014|August 31, 2010||No|Severe allergic reaction in one patient|No||https://clinicaltrials.gov/show/NCT01201434||116285|
NCT01201681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133266|DPBRN Peri-operative Pain and Root Canal Therapy|Peri-operative Pain and Root Canal Therapy||Dental Practice-Based Research Network|No|Completed|July 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|19 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants directly involved in this study are patients who have sought dental        treatment in the practitioner-investigators' practices. The practitioner-investigators        will be endodontists and general dentists.|September 2011|September 16, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201681||116266|
NCT01201694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0276|Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)|Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Completed|October 2011|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|13 Years|N/A|No|||January 2015|January 7, 2015|September 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01201694||116265|
NCT01202305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03606|The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies|The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies||University of California, San Francisco|No|Recruiting|April 2011|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|Inguinal LN|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|We propose a study in which inguinal lymph node biopsies will be performed on HIV-infected        and uninfected subjects, with the goals of: 1) quantifying and characterizing residual        virus in lymph nodes and 2) quantifying and comparing lymph node architecture in untreated        subjects, HAART-suppressed subjects, elite controllers, and HIV-negative subjects. This        research study will permit a lymph node biopsy to be performed and peripheral blood to be        obtained from patients with HIV disease. Subjects with HIV or without HIV infection who        have no contraindications to lymph node biopsy will be invited to participate in this        study.|June 2015|June 26, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01202305||116218|
NCT01202578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005013|Evaluation of the Tympanostomy Tube Delivery System|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media|inVENT-OR|Acclarent|No|Completed|September 2010|December 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|6 Months|N/A|No|||June 2014|June 10, 2014|September 13, 2010|Yes|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT01202578||116197|
NCT01198327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00040287|Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion|Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab|RETAIN|Johns Hopkins University|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|August 31, 2010|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01198327||116521|
NCT01198340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKAFEMORAL-2010|Evaluation of Optimal Dose of Local Anesthetics for Patient Controlled Continuous Femoral Nerve Block|Evaluation of Optimal Dose of Local Anesthetics for Patient Controlled Continuous Femoral Nerve Block With Sciatic Nerve Block After Total Knee Arthroplasty||Okayama University|Yes|Recruiting|September 2010|June 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||August 2010|July 20, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198340||116520|
NCT01198912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/384|Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial|Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.|DOXYPOSTOP|University Hospital, Ghent|No|Recruiting|November 2010|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198912||116476|
NCT01198886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006010|The Vitality, Independence, and Vigor in Elders Study I Clinical Trial|Vitality, Independence, and Vigor in Elders Study (VIVE Study): Effects of an Exercise and Nutrition Program on Functionality in the Elderly|VIVE-1|Tufts University|Yes|Completed|September 2010|May 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|121|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 11, 2015|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01198886||116478|
NCT01198899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/035|Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy|Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy||University Hospital, Ghent|No|Completed|July 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|540|||Both|18 Years|N/A|No|Non-Probability Sample|patients with left ventricular hypertrophy|January 2012|January 11, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01198899||116477|
NCT01199562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09038|Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant|Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function||City of Hope Medical Center|Yes|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|153|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|September 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01199562||116428|
NCT01199575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC022|Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)||University of California, San Diego|Yes|Active, not recruiting|August 2010|June 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199575||116427|
NCT01190293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 033|PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen|A Pilot Evaluation of the Pharmacokinetics, Efficacy and Safety of Switching From Efavirenz to Maraviroc Administered at 600mg Then 300mg Twice-daily in Patients Suppressed on an Efavirenz-containing Regimen as Initial Therapy|SSAT033|St Stephens Aids Trust|No|Completed|January 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||April 2012|April 11, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01190293||117130|
NCT01220752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMRT-HIT-SNT|Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12)|Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12)|IMRT-HIT-SNT|Heidelberg University|No|Recruiting|November 2010|November 2016|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||April 2013|April 23, 2013|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220752||114807|
NCT01221064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUGSO-001|Effect of Early vs Late Drainage Removal in Women After Radical Mastectomy With Axillary Clearance|Prospective Randomised Clinical Trial Comparing the Effect of Early and Late Drainage Removal in Female Patients After Radical Mastectomy With Axillary Clearance|CHLONKA|Medical University of Gdansk|Yes|Recruiting|October 2010|May 2014|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Female|18 Years|75 Years|No|||January 2012|January 30, 2012|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221064||114783|
NCT01221077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-207|Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene|A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene||Astellas Pharma Inc|Yes|Completed|December 2011|September 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|October 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221077||114782|
NCT01221090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071304|Diabetes Self-Management Models to Reduce Health Disparities|Employing Diabetes Self-Management Models to Reduce Health Disparities in Texas|P20-P2|Scott and White Hospital & Clinic|Yes|Completed|January 2009|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|376|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 7, 2013|October 13, 2010||No||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01221090||114781|Differential dropout across interventions. Failure to obtain 50% minority and 50% non-minority participants, preventing further analyses regarding race/ethnicity differences in outcome. Could only provide information in an exploratory manner.
NCT01221311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G100118|Covered Metallic Stents for First-Line Treatment of Benign Bile Duct Strictures|Use of Fully-covered, Self-expandable Metallic Stents for First-line Treatment of Benign Bile Duct Strictures||Medical University of South Carolina|Yes|Active, not recruiting|January 2011|October 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221311||114764|
NCT01221324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG10/126|Diagnostic Value of C-reactive Protein and White Blood Cell Counts for Early Detection of Inflammatory Complications After Open Resection of Colorectal Cancer|||Cantonal Hospital of St. Gallen|No|Completed|November 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Given indication for resection of colorectal cancer|February 2012|February 10, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221324||114763|
NCT01221883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER DIAZEPAM PTSD- HMO-CTIL|Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam|Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD).||Hadassah Medical Organization|No|Active, not recruiting|May 2013|December 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|67 Years|No|||March 2013|March 19, 2013|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221883||114720|
NCT01223066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GB0906|Macrolane Prospective Survey|A Multi-center, Non-interventional, Prospective Study to Monitor Long Term Safety in Female Subjects After Treatment With Macrolane Volume Restoration Factor 20 and/or Macrolane Volume Restoration Factor 30 in the Breasts.||Q-Med AB|No|Withdrawn|September 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participating clinics will ask women who have been treated with Macrolane in the breasts        in clinical practice, to participate in this survey.|November 2012|November 22, 2012|October 15, 2010||No|no patients recruited|No||https://clinicaltrials.gov/show/NCT01223066||114629|
NCT01223105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2009-02|Oocyte Cryopreservation by Slow Freezing and Vitrification|Longitudinal Evaluation of Vitrification of Human Oocytes||Reproductive Medicine Associates of New Jersey|No|Terminated|July 2009|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|October 8, 2010||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01223105||114626|
NCT01223287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0032|Physiologic Definition of Bronchopulmonary Dysplasia|Physiologic Definition of Bronchopulmonary Dysplasia|PhysiologicDef|NICHD Neonatal Research Network|No|Completed|May 2005|September 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|410|||Both|36 Weeks|37 Weeks|No|Probability Sample|Premature infants on mechanical ventilation at 36 weeks of life.|June 2015|June 16, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01223287||114612|
NCT01223300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00007523|Osteoporosis Research Registry|Osteoporosis Research Registry||Northwestern University|No|Enrolling by invitation|November 2008|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Two (10 ml) blood samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with osteoporosis or at risk for osteoporosis. Also, healthy controls.|October 2015|October 7, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01223300||114611|
NCT01201707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2794|Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis|The Effectiveness of Endovascular Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis||Community Care Physicians, P.C.|Yes|Terminated|August 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|60 Years|No|||November 2013|November 25, 2013|September 10, 2010||No|Inability to enroll adequate number of patients|No||https://clinicaltrials.gov/show/NCT01201707||116264|
NCT01201993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN2010|Clinical and Laboratory Characteristics of Patients Admitted With Syncope; Diagnosis and Follow up After These Patients|Observational Study Following After Patients Admitted With Syncope||Carmel Medical Center|No|Suspended|August 2010|June 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Admitted patients the medical ward|September 2010|June 19, 2011|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01201993||116242|
NCT01202006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL31024.041.10|Strategy to Recognize and Initiate Treatment of Chronic Heart Failure|A Combined Diagnostic-therapeutic Strategy to Optimize Management of Patients With Previously Unrecognized Heart Failure in Primary Care|STRETCH|UMC Utrecht|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|585|||Both|65 Years|N/A|No|||July 2015|July 7, 2015|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202006||116241|
NCT01202331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02169|Tripartite International Research for the Elimination of Trachoma|Tripartite International Research for the Elimination of Trachoma|TIRET|University of California, San Francisco|Yes|Completed|November 2010|May 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|29000|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 5, 2015|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01202331||116216|
NCT01202591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2610C00003|Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients|A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW)|GLOW|AstraZeneca|No|Completed|December 2010|October 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|127|||Female|18 Years|99 Years|No|||January 2016|January 13, 2016|September 14, 2010|Yes|Yes||No|September 7, 2015|https://clinicaltrials.gov/show/NCT01202591||116196|Enrolment to the Part B was terminated on 27 March 2014. Slow recruitment led to concerns that enrolment would not be completed in a realistic timeframe. This led to a business decision to terminate the enrolment.
NCT01198613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR002|ToleroMune Ragweed Exposure Chamber Study|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Two Doses of ToleroMune Ragweed in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber||Circassia Limited|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|275|||Both|18 Years|65 Years|No|||October 2011|October 6, 2011|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01198613||116499|
NCT01199289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090203|A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects With Inadequately Controlled Asthma||Amgen|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|315|||Both|18 Years|65 Years|No|||April 2015|April 28, 2015|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199289||116449|
NCT01199302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100008|Safety Study in Subjects With Crohn's Disease|A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease||Amgen||Terminated|December 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|N/A|N/A|No|||December 2015|December 14, 2015|September 9, 2010|Yes|Yes|Per recommendation from DRT|No||https://clinicaltrials.gov/show/NCT01199302||116448|
NCT01199263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02654|Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC # 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|||September 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||October 2015|March 24, 2016|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01199263||116451|
NCT01189383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-273|IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma|IL15-DC Vaccine in Patients With High Risk Melanoma - Exploratory Phase I/II Trial||Baylor Research Institute|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|75 Years|No|||January 2016|January 12, 2016|August 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01189383||117199|
NCT01220531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025966|Thymus Transplantation Safety-Efficacy|Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836||Duke University|Yes|Recruiting|December 2010|December 2023|Anticipated|December 2021|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|N/A|N/A|No|||December 2015|December 10, 2015|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220531||114824|
NCT01220765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 29266.041.09|Capnography During Nurse Administered Propofol Sedation|Assessment of Capnography in Monitoring Patients During Nurse Administered Deep Sedation With Propofol||UMC Utrecht|No|Completed|April 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|440|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2010|June 9, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220765||114806|
NCT01220778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERSS-2010-951-P|Effects of Physical Activity During Pregnancy on the Newborn's Cognitive Function|Effects of Physical Activity During Pregnancy on the Newborn's Cognitive Function, the Healthy Mom, Bright Child Randomized Trial||Université de Montréal|No|Recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||||||Female|20 Years|35 Years||||September 2010|October 13, 2010|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01220778||114805|
NCT01220791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medrol005|Methylprednisolone Addition in IVF Treatment of Infertile Couples|Methylprednisolone vs. Placebo to Control Late Follicular Progesterone Elevation in GnRH-Antagonist IVF Cycles||Universitair Ziekenhuis Brussel|No|Recruiting|January 2009|December 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Female|21 Years|36 Years|No|||October 2010|October 13, 2010|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01220791||114804|
NCT01222416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 09108|PET/CT Evaluation of Treatment Response in Breast Cancer|Positron Emission Tomography (PET)-Computed Tomography (CT) PET/CT Evaluation of Treatment Response in Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|October 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|September 29, 2010||No|Study objectives were met|No||https://clinicaltrials.gov/show/NCT01222416||114679|
NCT01221337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-09|Heparin Free Haemodialysis With Haemodialyzers "VIE" Versus "EVODIAL"|Comparative Study of Two Haemodialyzers "VIE 2.1" Versus "EVODIAL2.2" in a Strategy of Heparin-free Haemodialysis (HFH)||Centre Hospitalier Universitaire de Nice|No|Completed|October 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|N/A|No|||October 2010|March 23, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221337||114762|
NCT01222676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITA-MIL-IRCCS-INT-52/10|Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder|A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder||National Cancer Institute (NCI)||Recruiting|October 2010|||October 2013|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2010|August 9, 2013|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01222676||114659|
NCT01222689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01266|Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase 2 Study of AZD6244 Plus Erlotinib for the Second-Line Treatment of Advanced Pancreatic Adenocarcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2010|||April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||April 2014|July 28, 2014|October 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222689||114658|
NCT01222429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBNI-1|Practice Based Nutrition Intervention|Practice-Based Nutrition Intervention||Physicians Committee for Responsible Medicine|No|Completed|October 2010|February 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01222429||114678|
NCT01193127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-001|Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)|||Omeros Corporation|No|Completed|July 2010|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|223|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|August 23, 2010|Yes|Yes||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01193127||116915|
NCT01193140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-273|To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors|An Extension Study to Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors.||Abbott|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193140||116914|
NCT01223079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20052361|Use of r-hLH (Luveris) in Donors Previously Treated With r-hFSH (Gonal F)|Use of r-hLH (Luveris) Late Follicular Phase for Controlled Ovarian Stimulation (COS) in Donor Patients Previously Treated With r-hFSH (Gonal F)in a Long Luteal Downregulated Cycle With GnRH Agonist. A Cross-over Study||Reproductive Medicine Associates of New Jersey|No|Completed|December 2005|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|21 Years|32 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01223079||114628|
NCT01202019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-005|Effects of Exercise in People With Tetraplegia|Effects of Exercise on Post-Prandial Lipemia and Fat Oxidation After Tetraplegia||University of Miami|No|Completed|March 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|55 Years|No|||July 2014|July 21, 2014|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202019||116240|
NCT01202318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H60373-35400-01|Comparative Evaluation of Stroke Triage Algorithms for Emergency Medical Dispatchers|Pilot Prospective Cohort to Determine the Comparative Diagnostic Accuracy of Card 28 to Card 28 and Cincinnati Stroke Scale.|MeDS|University of California, San Francisco|No|Withdrawn|May 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|The target study population consists of all 911 callers with symptoms suggestive of stroke        in the participating county. Specifically, the accessible population for this study is the        group of patients whose 911 calls are answered and interrogated by the emergency medical        dispatchers at the County Communication Center, Santa Clara.|June 2012|June 13, 2012|September 13, 2010||No|The study design was changed to a prospective cohort study due to difficulties in using a    randomized approach in an emergency setting|No||https://clinicaltrials.gov/show/NCT01202318||116217|
NCT01202604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NGR-DUM-2010/1|A Study Evaluating the Efficacy of Administered Maintenance Treatments in Bipolar Disorder I and II.|Prospective, Observational Study for the Maintenance Treatment of Patients With Bipolar Disorder I and II in Greece.||AstraZeneca|No|Completed|September 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|294|||Both|18 Years|65 Years|No|Probability Sample|Outpatients diagnosed with bipolar disorder I or II (as per DSM-IV), who have received        therapy with at least one atypical antipsychotic for the acute episode and whose treating        physician has considered they have entered the maintenance phase.|December 2011|December 19, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202604||116195|
NCT01202617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NHU-SER-2010/1|Seroquel XR in the Long Term Treatment of Schizophrenia|Seroquel XR in the Long Term Treatment of Schizophrenia Focus on Affective Symptoms|SereNIS|AstraZeneca|No|Completed|September 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1606|||Both|18 Years|70 Years|No|Non-Probability Sample|Psychiatric outpatients|October 2011|October 21, 2011|September 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01202617||116194|
NCT01198353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG-KOR-017-2009|Effectiveness of Ziprasidone for Patients With Schizophrenia|Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder||Soonchunhyang University Hospital|Yes|Completed|September 2010|December 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|55 Years|No|||November 2014|November 18, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198353||116519|
NCT01198925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/414|Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion|Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion||University Hospital, Ghent|No|Recruiting|September 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||December 2014|December 4, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01198925||116475|
NCT01199276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-08-C2-020|Hip Fracture Surgery in Elderly Patients|An International, Multi-center, Randomized, Controlled Trial Evaluating The Effect of Xenon on Post-operative Delirium in Elderly Patients Undergoing Hip Fracture Surgery|HIPELD|Air Liquide Santé International|No|Completed|September 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|256|||Both|75 Years|N/A|No|||July 2015|July 24, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01199276||116450|
NCT01189045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00735|Understanding Changes in Heart Function After Exercise in People With Stroke|Beyond VO2peak: Understanding Exercise-induced Changes in Cardiovascular Function After Stroke||University of British Columbia|No|Completed|September 2010|April 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|80 Years|No|||June 2014|June 11, 2014|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01189045||117225|
NCT01189396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A006-CL-C|Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006|A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients||Amphastar Pharmaceuticals, Inc.|No|Completed|July 2010|January 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|55 Years|No|||January 2012|January 23, 2012|August 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01189396||117198|
NCT01189409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H0901329|Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients|A Randomized, Double Blind, Double-dummy, 2-treatment, 2-period Crossover Comparison of Sennosides and Polyethylene Glycol in Treatment of Opioid-induced Constipation in Outpatients With Cancer||British Columbia Cancer Agency|No|Recruiting|June 2010|||July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|64|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01189409||117197|
NCT01220544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BELEHAPLO-1412001|Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells|Transplantation of Hematopoetic Stem Cells and Infusion of CD56+CD3- NK Cells From Haploidentical Donors for Patients With Hematological Malignancies||Charite University, Berlin, Germany|Yes|Recruiting|July 2001|October 2011|Anticipated|October 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|54 Years|No|||October 2010|October 13, 2010|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01220544||114823|
NCT01220804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/SAU-BEB/103151/2008|Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography|Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography||Association for Innovation and Biomedical Research on Light and Image|No|Completed|November 2010|March 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR) (study        population) and healthy volunteers (control population).|September 2011|December 17, 2013|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220804||114803|
NCT01221662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IRB-282|Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome|Complementary Therapy of Siwu Tang on Patients With Brain Hypoperfusion Syndrome||China Medical University Hospital|Yes|Recruiting|July 2010|November 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|80 Years|No|||October 2010|October 14, 2010|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01221662||114737|
NCT01221935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-4431|Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder|A Retrospective Study To Evaluate The Current Utilization Of Desvenlafaxine Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder||Pfizer|No|Completed|September 2009|January 2010|Actual|January 2010|Actual|Phase 4|Observational|Time Perspective: Retrospective||4|Actual|2701|||Both|18 Years|N/A|No|Non-Probability Sample|patient charts from psychiatrists and primary care physicians (PCPs) treating patients        suffering from major depressive disorder (MDD).|January 2011|January 25, 2011|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01221935||114716|
NCT01222156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGCI HS01|Accuracy and Safety Study of the Magnetecs CGCI System for Intracardiac Mapping|Remote Intracardiac Catheter Target Acquisition Using the Magnetecs Catheter Guidance Control and Imaging (CGCI) System|RICTAM|Magnetecs Corporation|Yes|Recruiting|October 2010|December 2010|Anticipated|December 2010|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|85 Years|No|||October 2010|October 15, 2010|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222156||114699|
NCT01222715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02607|Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma|A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma||National Cancer Institute (NCI)||Active, not recruiting|October 2010|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|29 Years|No|||January 2016|March 7, 2016|October 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222715||114656|
NCT01193153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016618|A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder||Janssen Scientific Affairs, LLC|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|667|||Both|18 Years|65 Years|No|||December 2014|December 22, 2014|August 30, 2010|Yes|Yes||No|December 22, 2014|https://clinicaltrials.gov/show/NCT01193153||116913|
NCT01223326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/NAC|N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection|A Randomized Controlled Trial of N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection Performed Under Ischemic Preconditioning and Intermittent Portal Triad Clamping||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|January 2003|December 2007|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|70 Years|No|||June 2012|June 7, 2012|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01223326||114609|
NCT01223339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8835-041|Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)|A Phase 1, Randomized, Double Blind, Placebo-Controlled, Parallel Cohort, Single Dose Escalation And Multiple Dose Study In Japanese Healthy Subjects, And Open Label, Single Dose Escalation Study In Western Healthy Subjects To Investigate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729||Merck Sharp & Dohme Corp.|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01223339||114608|
NCT01201746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PU-D/314/Acad|Influence of Periodontal Treatment on Systemic Inflammatory Mediators|Influence of Periodontal Treatment on Systemic Inflammatory Mediators:hsC-reactive Protein, Fibrinogen and White Blood Cells in CHD Patients|Perio-CHD|Sheikh Zayed Federal Postgraduate Medical Institute|Yes|Completed|July 2008|May 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|31 Years|N/A|No|||September 2010|September 15, 2010|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01201746||116261|
NCT01202032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARASOL|Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors|Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors|PARASOL|Centre Leon Berard|Yes|Active, not recruiting|July 2010|January 2014|Anticipated|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2013|December 24, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01202032||116239|
NCT01202045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Projet # 10-111|Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients|Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients With Indirect Signs of Pulmonary Arterial Hypertension||Université de Sherbrooke|No|Withdrawn|September 2010|October 2011|Anticipated|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Systemic slerosis patients with indirect signs of arterial pulmonary hypertension:          -  Effort dyspnea (NYHA >= 2/4)          -  DLCO < 60%          -  FVC% / DLCO% > 1.6          -  SPAP > 40 mmhg and < 55 mmhg|July 2013|July 3, 2013|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01202045||116238|
NCT01202344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0335-BE|Computer Prediction of Restenosis Following Peripheral Angioplasty|Computer Prediction of Restenosis Following Peripheral Angioplasty||University Health Network, Toronto||Recruiting|September 2010|||September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 5, 2015|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01202344||116215|
NCT01198366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-029-402|Study of AERAS-402 in Healthy Infants|A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis||Aeras|Yes|Completed|September 2010|April 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|487|||Both|112 Days|182 Days|Accepts Healthy Volunteers|||October 2015|October 12, 2015|September 7, 2010||No||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01198366||116518|
NCT01198626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32729463CAP2001|Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia|A Randomized, Controlled, Double Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia (CABP) With a PORT Score of II or Greater||Furiex Pharmaceuticals, Inc|No|Terminated|October 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|85 Years|No|||December 2011|December 5, 2011|September 7, 2010|Yes|Yes|Enrollment would not have been met prior to the end of the pneumonia season. Termination is    based on slow enrollment and not related to safety or efficacy.|No||https://clinicaltrials.gov/show/NCT01198626||116498|
NCT01198639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/30|One-year Mortality After Surgery and Low Bispectral Index|One-year Mortality According to the Method of Total Intravenous Anesthesia. A Prospective, Randomized and Multicenter Study||Hopital Foch|Yes|Recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4200|||Both|50 Years|85 Years|No|||June 2015|June 16, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01198639||116497|
NCT01193257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21005|Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy||Millennium Pharmaceuticals, Inc.|Yes|Completed|November 2010|July 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1099|||Male|18 Years|N/A|No|||October 2015|October 15, 2015|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193257||116905|
NCT01193270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0044|Vitamin E for Extremely Preterm Infants|Single-Dose Vitamin E for Prevention of Mortality and Morbidity in Extremely Preterm Infants: Pilot Study||NICHD Neonatal Research Network|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|93|||Both|N/A|4 Hours|Accepts Healthy Volunteers|||November 2015|November 10, 2015|August 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01193270||116904|
NCT01193569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP2818|A Study of Survival and Outcome After Stroke|The SOS Study: A Study of Survival and Outcome After Stroke|SOS|Penumbra Inc.|No|Active, not recruiting|September 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|85 Years|No|Probability Sample|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom        onset and with an imaging-defined large cerebral vessel occlusion and a known infarct        volume will be enrolled and followed for 90-days.|March 2016|March 14, 2016|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193569||116883|
NCT01193582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1841008|A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria|A Phase 4, Open-label Trial to Assess the Safety, Tolerability and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination.|6114A1-4000-CN|Pfizer|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|505|||Both|121 Days|72 Months|Accepts Healthy Volunteers|||September 2013|September 17, 2013|August 31, 2010|Yes|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT01193582||116882|
NCT01193595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11379|Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors|An Open-label, Non-randomized, Dose Escalation, Safety and Pharmacokinetic Phase I Study of Ombrabulin (AVE8062) in Combination With Bevacizumab Administered by Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.||Sanofi|No|Completed|September 2010|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193595||116881|
NCT01189058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22163|Modulation of Brain Plasticity After Perinatal Stroke|Modulation of Brain Plasticity After Perinatal Stroke: The PLASTIC CHAMPS Trial|PLASTIC CHAMPS|University of Calgary|Yes|Active, not recruiting|August 2010|March 2014|Anticipated|February 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|64|||Both|6 Years|18 Years|No|||October 2013|October 21, 2013|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01189058||117224|
NCT01189071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1119697|Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain|Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain||University of Missouri-Columbia|No|Recruiting|August 2009|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|August 24, 2010|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01189071||117223|
NCT01190059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT-001-TOR|Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation|Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation|HELP|XVIVO Perfusion|Yes|Completed|August 2008|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|22|||Both|18 Years|N/A|No|||November 2010|November 12, 2010|August 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01190059||117148|
NCT01221896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|choline2010-HMO-CTIL|Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma|||Hadassah Medical Organization||Not yet recruiting|January 2011|||January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with elevated PTH in search of a PTA|October 2010|October 14, 2010|October 14, 2010||||No||https://clinicaltrials.gov/show/NCT01221896||114719|
NCT01221909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-DCR-TA|Tranexamic Acid in Dacryocystorhinostomy|Single Dose Tranexamic Acid for Dacryocystorhinostomy|TA-DCR|HaEmek Medical Center, Israel||Not yet recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2010|October 14, 2010|September 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01221909||114718|
NCT01221922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C67-10-A|Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI|A Study of the RevLite Q-Switched Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG) Laser for the Treatment of Acne Scars in Fitzpatrick Skin Types III-VI||Cynosure, Inc.|No|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01221922||114717|
NCT01222143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107YCA03T|Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia|A Phase I/II Study Evaluating the Safety and Efficacy of Nilotinib Combined With Mitoxantrone, Etoposide, and High-Dose Cytarabine (NOVE-HiDAC) Induction Chemotherapy Followed by Consolidation Therapy for Poor-Risk Patients With C-kit Positive Acute Myeloid Leukemia (AML) up to Age 65||University Health Network, Toronto|Yes|Terminated|October 2010|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||June 2015|June 19, 2015|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01222143||114700|
NCT01221948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5001|Vercise Implantable Stimulator for Treating Parkinson's Disease|VANTAGE STUDY Vercise™ Implantable Stimulator for Treating Parkinson's Disease|VANTAGE|Boston Scientific Corporation|Yes|Active, not recruiting|October 2010|December 2018|Anticipated|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|21 Years|75 Years|No|||July 2015|November 23, 2015|October 8, 2010||No||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01221948||114715|
NCT01221961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021287|Masimo Radical-7 Monitor a Useful Adjuvant During Major Spine Surgery|A Study to Determine the Agreement Between Masimo Monitor and Standard of Care||Cedars-Sinai Medical Center|No|Terminated|October 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|62|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing major spine surgery|November 2013|November 13, 2013|October 15, 2010||No|We completed the 62% of the cases, enough data to get a conclusion of the study.|No||https://clinicaltrials.gov/show/NCT01221961||114714|
NCT01222169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKBB_ANA_LR 6|Laryngeal Reflex Study Under Propofol Anesthesia: Effect of Intravenous Lidocaine|Impact of Intravenous Lidocaine on Laryngeal Reflex Responses in Pediatric Patients Anesthetized With Propofol|LR6|University Hospital, Basel, Switzerland|Yes|Completed|September 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|25 Months|84 Months|No|||October 2015|October 29, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01222169||114698|
NCT01222442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0570C00004|To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart|A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 μg and 1200 µg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers||AstraZeneca|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 15, 2011|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01222442||114677|
NCT01192867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN25310|A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)|A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.||Hoffmann-La Roche||Completed|December 2010|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|629|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01192867||116935|
NCT01189253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62091|Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma|TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma||European Organisation for Research and Treatment of Cancer - EORTC||Terminated|May 2011|June 2015|Anticipated|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|133|||Both|18 Years|N/A|No|||August 2013|August 7, 2014|August 25, 2010||Yes|Results of step1: none of the experimental arms fulfills expectations and the study will not    continue as a phase III.|||https://clinicaltrials.gov/show/NCT01189253||117209|
NCT01189266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02600|Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma|A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2010|||November 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|37 Months|21 Years|No|||March 2016|March 10, 2016|August 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01189266||117208|
NCT01193465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|humidity|Temperature and Humidity Among Different Anesthesia Work-station|Comparison of Heat and Humidity Conservation Among Different Anesthesia Workstation and Different Flow Rate.|humidity|Korea University Anam Hospital|No|Recruiting|January 2010|October 2010|Anticipated|September 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|60|||Both|18 Years|70 Years|No|||July 2010|September 1, 2010|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01193465||116891|
NCT01188928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 80185-G23|LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)|A Phase 3 Study Comparing Once Daily Treatment With Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension With Betamethasone 0.5 mg/g (as Dipropionate) in the Topical Suspension Vehicle, Calcipotriol 50 mcg/g in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Subjects With Psoriasis Vulgaris on Non-scalp Regions of the Body (Trunk and/or Limbs)||LEO Pharma|No|Completed|September 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1152|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|August 25, 2010|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT01188928||117234|
NCT01202058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC09-01|An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)|An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent.|NEVO II|Cordis Corporation|No|Terminated|August 2010|October 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|September 14, 2010||No|The NEVO™ stent will not be commercialized. Cordis decided to close the study after 1 years.    This decision took the absence of safety signals into account.|No||https://clinicaltrials.gov/show/NCT01202058||116237|
NCT01202630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-SUS-05-BIK-02|BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection|A Triple-blind, Randomized, Placebo-controlled, Multi-center Study on the Effect of BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection||Bio-K Plus International Inc.|No|Suspended|June 2010|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|September 14, 2010||No|The site is unable to recruit patients.|No||https://clinicaltrials.gov/show/NCT01202630||116193|
NCT01192971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HENGRUI20100510|A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma|Single Arm, Open-label, Multi-center, Phase II Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma|HCC|Jiangsu HengRui Medicine Co., Ltd.|Yes|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|75 Years|No|||April 2015|April 2, 2015|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01192971||116927|
NCT01192737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-24|"COhort Study on A/H1N1 FLU During PREGnancy"|Cohort Study to Evaluate Clinical Expression and Maternofetal Consequences of A/H1N1 Influenza in Pregnant Women|COFLUPREG|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|October 2009|November 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|919|Samples Without DNA|Serum, cord blood|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women|April 2012|April 16, 2012|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01192737||116945|
NCT01193231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACVL-001|A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing|A Single Center, Randomized, Contralateral, 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing||Durrie Vision|No|Completed|August 2010|April 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|10|||Both|18 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Male or female patients, 18-39 yrs of age, in good general health Patient is schedule to        undergo bilateral PRK surgery The difference between the two eyes ≤ 2 D Refractive error        -1 to -8 diopters (spherical equivalent) at baseline|February 2012|February 13, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01193231||116907|
NCT01193244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21004|Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer||Millennium Pharmaceuticals, Inc.|Yes|Completed|October 2010|March 2015|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1560|||Male|18 Years|N/A|No|||October 2015|October 19, 2015|August 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01193244||116906|
NCT01188798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUDSIB|Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies|Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies||St. Jude Children's Research Hospital|Yes|Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Months|21 Years|No|||February 2012|March 14, 2013|August 24, 2010|Yes|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT01188798||117244|This study was terminated prematurely. The Data Safety and Monitoring Board (DSMB) requested major scientific study changes. This was deemed infeasible by institutional leadership and study was terminated. Therefore, no final results exist to report.
NCT01189084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBI Protocol V118-obs|Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease|An Observational Study to the Patients With Alzheimer's Disease Who Previously Received UB311-Treatment in the V118-AD Trial||United Biomedical|No|Completed|April 2010|July 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|Samples Without DNA|Periodic blood samples collected for serum and measurement of anti-Amyloid-beta antibody      levels.|Both|50 Years|80 Years|No|Non-Probability Sample|Enrolled subjects who received UB 311-treatment in the initial UBI Protocol V118 (Protocol        V118-AD) Phase I trial are eligible for continued follow-up to week 48|July 2011|July 12, 2011|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01189084||117222|
NCT01193608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2601001|Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease|A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|88|||Both|50 Years|89 Years|No|||November 2013|November 19, 2013|August 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01193608||116880|
NCT01189422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA031-06|Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Teplizumab (MGA031) in Adults With Type 1 Diabetes Mellitus|SUBCUE|MacroGenics|No|Terminated|August 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|1|||Both|18 Years|35 Years|No|||September 2015|September 22, 2015|August 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01189422||117196|
NCT01189734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCBDEIOES|Comparison Between Laparoscopic Common Bile Duct Exploration and Intraoperative ERCP for Management of Common Bile Duct Stones|||Mansoura University||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|248|||Both|12 Years|90 Years||||February 2010|August 26, 2010|August 25, 2010||||No||https://clinicaltrials.gov/show/NCT01189734||117173|
NCT01190072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSI-DUM-2010/1|Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)|LIPID-LOWERING THERAPY FOR SECONDARY PREVENTION IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) A 10-week, Open-label, Non-interventional Study of Total Cholesterol/LDL-cholesterol Management in Real Life in Coronary Patients Hospitalised for Elective PCI||AstraZeneca|No|Terminated|September 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Secondary care clinic|January 2013|January 28, 2013|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01190072||117147|
NCT01190085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005000183|Effects of Ghrelin on Alcohol Cue Reactivity and Craving|Effects of Ghrelin on Alcohol Cue Reactivity and Craving||Brown University|Yes|Completed|April 2011|||November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|45|||Both|18 Years|70 Years|No|||April 2014|April 30, 2014|August 26, 2010|Yes|Yes||No|December 1, 2013|https://clinicaltrials.gov/show/NCT01190085||117146|Small proof-of-concept study
NCT01190371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEMRI_CT_2010/0013|Have Malaria Infections in Kenya Become Less Responsive to Artemisinin Treatment?|Confirmation of Artemisinin Tolerance in Malaria Parasites Trial in Kilifi|CATMAP|KEMRI-Wellcome Trust Collaborative Research Program|No|Active, not recruiting|April 2011|August 2016|Anticipated|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|175|||Both|6 Months|10 Years|No|||December 2015|December 4, 2015|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01190371||117124|
NCT01230203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-APN-01|Computed Tomography Scan Versus Color Duplex Ultrasound for Surveillance of Endovascular Repair of Abdominal Aortic Aneurysm. A Prospective Multicenter Study|Computed Tomography Scan Versus Color Duplex Ultrasound for Surveillance of Endovascular Repair of Abdominal Aortic Aneurysm. A Prospective Multicenter Study|ESSEA|Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2010|April 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|18 Years|N/A|No|||October 2010|October 28, 2010|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230203||114087|
NCT01230814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0070|Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women|A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|234|||Female|18 Years|45 Years|No|||September 2014|September 26, 2014|October 28, 2010|Yes|Yes||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01230814||114042|
NCT01230541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-00110|Effect of Udenafil on Spermatogenesis|Effect of Udenafil on Spermatogenesis: A Double-blind, Randomized, Placebo-controlled, Parallel-group Study||Warner Chilcott|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|239|||Male|25 Years|64 Years|Accepts Healthy Volunteers|||November 2011|November 29, 2011|October 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230541||114063|
NCT01230775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOP13007|Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia|A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia|ARETA|AOP Orphan Pharmaceuticals AG|Yes|Active, not recruiting|December 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|280|||Both|18 Years|60 Years|No|||December 2015|December 31, 2015|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230775||114045|
NCT01231113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 8/DHAPPQ/MIP|Efficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in Ghana|Efficacy, Safety and Tolerability of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Falciparum Malaria in Pregnancy: an Open-label, Randomised Controlled, Non-inferiority Trial|DHAPPQ/MIP|Kwame Nkrumah University of Science and Technology|Yes|Completed|July 2011|February 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|417|||Female|15 Years|45 Years|No|||February 2016|February 23, 2016|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231113||114020|
NCT01231347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060540|Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas|GAMMA|Amgen|Yes|Terminated|April 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|800|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|October 14, 2010|Yes|Yes|Planned independent DMC Interim review: ended for futility w/no safety concerns|No||https://clinicaltrials.gov/show/NCT01231347||114002|
NCT01231360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p001107RP|The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease (PAD)|The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease||Brigham and Women's Hospital|No|Recruiting|October 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 20, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231360||114001|
NCT01231646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-266A|Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?|Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?||Northwell Health|No|Completed|October 2010|July 2015|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|38|||Female|18 Years|50 Years|No|Non-Probability Sample|Patients in epilepsy and/or psychiatric clinics|October 2015|October 23, 2015|October 28, 2010||No||No|August 24, 2015|https://clinicaltrials.gov/show/NCT01231646||113979|
NCT01231880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCDC-SBMC|School Based Malaria Control in Ugandan Schoolchildren|School-based Malaria Control: Impact of Intermittent Preventive Treatment on Malaria Morbidity and Cognitive Function in Ugandan School Children|SBMC|Makerere University|Yes|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|740|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231880||113961|
NCT01231867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09_042|Cohort Study of Clopidogrel and Proton Pump Inhibitors|Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study||London School of Hygiene and Tropical Medicine|Yes|Completed|December 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|24471|||Both|N/A|N/A|No|Non-Probability Sample|All patients registered in the GPRD from 1998 to date and receiving clopidogrel in        combination with aspirin and with at least 12 months up to standard observation before the        first prescription for clopidogrel will be eligible for inclusion. Data will be restricted        to 1998 onwards as this is the year clopidogrel was licensed in the UK.|May 2015|May 1, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01231867||113962|
NCT01232205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|asip02|Antioxidant Supplementation in Pregnant Women|Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status|ASIP1|Showa University|No|Completed|June 2001|March 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|168|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2009|November 2, 2010|November 1, 2010||No||No|November 2, 2010|https://clinicaltrials.gov/show/NCT01232205||113936|
NCT01232504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-09-01|Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT|Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial||Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|September 2009|June 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|206|||Both|N/A|N/A|No|||October 2014|October 27, 2014|October 25, 2010||No||No|January 26, 2014|https://clinicaltrials.gov/show/NCT01232504||113913|The limitations of the current study included the lack of blinding and placebo group.
NCT01208259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29MH138403|The Psychological Treatment of Overweight Binge Eaters Minority Supplement|A Randomized Comparison of Group-Behavioral Therapy and Group Interpersonal Psychotherapy for the Treatment of Overweight Individuals With Binge-Eating Disorder Minority Supplement||Washington University School of Medicine||Completed|April 1997|March 1999|Actual|March 1999|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01208259||115764|
NCT01242540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10020252|Brain Activation During Accommodation to Painful Stimulation With FMRI|Brain Activation During Accommodation to Painful Stimulation With Functional Imaging of Pain||University of Pittsburgh|Yes|Active, not recruiting|November 2010|October 2016|Anticipated|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will come from the general surrounding community.|December 2015|December 1, 2015|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242540||113147|
NCT01242553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iVue 100-2009|Clinical Validation Study for iVue|Clinical Validation Study for iVue||Optovue|No|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers with various ocular pathology or no ocular pathology.|November 2010|November 16, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242553||113146|
NCT01243151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481009|Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of PF-04950615 (RN316) In Healthy Adult Subjects With Hypercholesterolemia||Pfizer|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|68|||Both|18 Years|80 Years|No|||July 2012|July 9, 2012|November 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01243151||113102|
NCT01243164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02385|Efficacy of Wheelchair Skills Training on Confidence Using a Manual Wheelchair|Efficacy of the Wheelchair Skills Training Program for Improving Confidence With Using a Manual Wheelchair in Younger and Older Able-bodied Adults: A Pilot RCT||University of British Columbia|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Both|19 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 10, 2014|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01243164||113101|
NCT01242865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006367|Self Help Intervention to Decrease Stress|Self Help Intervention to Decrease Stress: A Pilot Trial||Mayo Clinic|No|Completed|December 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2013|April 24, 2013|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01242865||113123|
NCT01243138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581186|Africa and Middle East Cardiovascular Epidemiological Study|Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region|ACE|Pfizer|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|4386|None Retained|Whole Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subject selection would be from clinics in a primary care setting|June 2012|June 25, 2012|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01243138||113103|
NCT01239628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-48-52120-152|A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke|A National, Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities up to 3 Years Follow up of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity Post-CVA (Cerebrovascular Accident)|DECIDE|Ipsen|No|Terminated|December 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a history of stroke, suffering from upper limb spasticity|February 2016|February 26, 2016|November 10, 2010||No|Participant enrolment was lower than expected|No||https://clinicaltrials.gov/show/NCT01239628||113370|
NCT01239303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC10-3-064|Effects of Citrulline on Gut Functioning During Excercise|Effects of Citrulline on Gut Functioning During Excercise||Maastricht University Medical Center|Yes|Enrolling by invitation|December 2010|February 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239303||113395|
NCT01230216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C464|Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound|Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound|PREVUS|Kyoto University, Graduate School of Medicine|Yes|Terminated|December 2010|April 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|20 Years|79 Years|No|||January 2016|January 7, 2016|October 28, 2010||No|Slow patients enrollment|No||https://clinicaltrials.gov/show/NCT01230216||114086|
NCT01230229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFA stenting and QoL|Primary Stenting vs Conservative Treatment in Claudicants - a Study on Quality of Life|Primary Stenting vs Conservative Treatment in Claudicants - a Study on Quality of Life||Lund University|No|Active, not recruiting|January 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230229||114085|
NCT01230515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC SUPP 0566|Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol|||Vanderbilt-Ingram Cancer Center|No|Completed|January 2006|March 2008|Actual|November 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|65|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Hospice Staff Caregiver Patient Referring Physician|September 2012|September 7, 2012|October 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230515||114065|
NCT01230528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PED 002 Version.2/990603|Childhood Reactive Thrombocytosis|Childhood Reactive Thrombocytosis (RT)|RT|Taipei Medical University WanFang Hospital|No|Completed|July 2009|June 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|N/A|18 Years|No|Probability Sample|The investigators will enroll all pediatric hospitalized patients with platelet counts        more than (500x109/l) at complete blood counts examination.The association of reactive        thrombocytosis and clinical manifestation will be analyzed.|October 2010|October 28, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230528||114064|
NCT01230554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654|Product Performance of a Daily Disposable Contact Lens|A Study to Assess the Product Performance of a Daily Disposable Contact Lens||Bausch & Lomb Incorporated|No|Completed|August 2010|November 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|212|||Female|15 Years|38 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|October 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230554||114062|
NCT01230840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-15249|Effect of Wheat Dextrin on Calcium and Magnesium Absorption|Effect of Wheat Dextrin on Calcium and Magnesium Absorption|Benefiber|Creighton University|No|Completed|October 2009|October 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|19 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 28, 2010|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230840||114040|
NCT01230827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017089|A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)|A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy||Janssen Research & Development, LLC|Yes|Terminated|December 2010|May 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|173|||Both|2 Years|18 Years|No|||November 2015|November 25, 2015|October 28, 2010|Yes|Yes|Trial has failed to meet primary - and major secondary endpoints|No|September 23, 2014|https://clinicaltrials.gov/show/NCT01230827||114041|
NCT01231126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051/09|Evaluation the Blood Loss in Pregnancies With Misoprostol-induced Labour|Evaluation the Blood Loss in Pregnancies With Misoprostol-induced Labour||Maternidade Escola Assis Chateaubriand|Yes|Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|161|||Female|14 Years|40 Years|No|||January 2009|November 15, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231126||114019|
NCT01231373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV016|Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence|A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"|VANISH-2|BTG International Inc.|Yes|Completed|November 2010|August 2014|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|235|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|October 22, 2010|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT01231373||114000|
NCT01231906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS1031|Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma|A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma||Children's Oncology Group|Yes|Suspended|November 2010|||September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|693|||Both|N/A|50 Years|No|||February 2016|February 19, 2016|October 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231906||113959|
NCT01231893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 406|Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury|Transplantation of Autologous Olfactory Ensheathing Cells for Treatment of Complete Human Spinal Cord Injuries- a Phase I Clinical Trial.||Wroclaw Medical University|No|Recruiting|May 2008|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|16 Years|65 Years|No|||October 2010|October 29, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231893||113960|
NCT01232530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHO/TDR - A70283|Pharmacovigilance for ACTs in Africa|Pharmacovigilance for Artemisinin-based Combination Treatments in Africa|PVACT|Centre Muraz|No|Completed|June 2010|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|3176|Samples With DNA|Blood spot on filter paper for PCR analysis|Both|N/A|N/A|No|Probability Sample|Initially, a census of the population living in Nanoro department and around        (approximately 50,000 people) will be carried out. The complete census database will be        utilized to estimate the incidence of malaria episodes and to determine whether there is        any clustering of malaria episodes as well as AEs. Such census will be updated by a team        of 8 field workers who will visit each single household every 4 months, for at least 3        years to identify newly pregnant women and to collect information on vital events such as        births and deaths. Of the 50,000 people in the census database, approximately 25,000 will        be under active surveillance while the other 25,000 will be under passive surveillance.|July 2015|July 29, 2015|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232530||113911|
NCT01232517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.NV0804|NeuroVision® Dynamic Screw Test Study|A Prospective Evaluation of the Dynamic Function of the NeuroVision® System for the Placement of Lumbar Pedicle Screws||NuVasive|No|Completed|March 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Surgical candidates for posterior instrumented lumbar fusion surgery|April 2015|April 29, 2015|October 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01232517||113912|
NCT01240785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246/2005|Metformin Versus Insulin in Gestational Diabetes|Metformin Versus Insulin in Gestational Diabetes. A Randomized Controlled Single Center Trial.||Turku University Hospital|No|Completed|June 2006|December 2012|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|221|||Female|N/A|N/A|No|||November 2014|November 21, 2014|November 3, 2010||No||No|December 4, 2013|https://clinicaltrials.gov/show/NCT01240785||113281|
NCT01241435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12602|A Study of LY2216684 in Subjects With Impaired Hepatic Function|The Effect of Impaired Hepatic Function on the Pharmacokinetics of LY2216684||Eli Lilly and Company|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|November 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241435||113231|
NCT01243177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0993|Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older|A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.|SP0993|UCB Pharma|No|Completed|April 2011|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|888|||Both|16 Years|N/A|No|||January 2016|January 25, 2016|November 16, 2010|Yes|Yes||No|January 25, 2016|https://clinicaltrials.gov/show/NCT01243177||113100|
NCT01207401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00020958|Paracervical Block Before Intrauterine Device (IUD) Insertion|Pain Control for Intrauterine Device Insertion: A Randomized Trial of 1% Lidocaine Paracervical Block||Northwestern University|Yes|Completed|July 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 2, 2013|September 21, 2010||No||No|July 25, 2012|https://clinicaltrials.gov/show/NCT01207401||115829|
NCT01238718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lidocaine3|Use of Lidocaine in Rapid Sequence Induction|Impact of Lidocaine on Anesthetic Depth During Rapid Sequence Induction||University of Athens||Completed|October 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|76|||Both|20 Years|70 Years|No|||November 2010|August 23, 2011|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01238718||113438|
NCT01238731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKB_001_2010|Persistent Pulmonary Artery Hypertension After Valve Replacement|Persistence of Severe Pulmonary Artery Hypertension in Patients After vaLve replacemenT|SALT|University Hospital, Bonn|No|Not yet recruiting|January 2011|March 2012|Anticipated|January 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with proven PH before valve replacement by right heart catherterization will be        screened for study entry.|November 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01238731||113437|
NCT01239043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA75|Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination|Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29||Sanofi|No|Completed|November 2010|February 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|139|||Both|56 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 18, 2012|November 8, 2010|Yes|Yes||No|May 14, 2012|https://clinicaltrials.gov/show/NCT01239043||113413|
NCT01239056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreatic Pseudocyst|Evaluation of Pancreatic Pseudocyst Drainage With a Metal Stent|Prospective Evaluation of the Clinical Utility of Pseudocyst Drainage With Metal Stent||University of Florida|No|Completed|August 2009|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a medical indication for endoscopic drainage of pancreatic pseudocyst        and are referred for the procedure as part of their standard medical care will be        considered for the study.|August 2015|August 21, 2015|November 5, 2010||No||No|July 24, 2015|https://clinicaltrials.gov/show/NCT01239056||113412|
NCT01238705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709TCYA068|Combined Antihypertensive Therapy and Sexual Dysfunction|Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension||LanZhou University|Yes|Recruiting|April 2008|November 2010|Anticipated|October 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|60 Years|No|||November 2010|November 10, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01238705||113439|
NCT01239875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS1081|Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma|LS1081, "A Pilot Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation or Intradermally for Patients With B-Cell Non-Hodgkin's Lymphoma"||Mayo Clinic|Yes|Terminated|November 2010|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|90 Years|No|||March 2015|November 25, 2015|October 27, 2010|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01239875||113351|
NCT01229956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B3|Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia|Promoter Methylation in MLL-Rearranged Childhood AML||Children's Oncology Group|No|Active, not recruiting|November 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|32|Samples With DNA|Tissue|Both|1 Year|18 Years|No|Non-Probability Sample|Patients With Acute Myeloid Leukemia.|May 2015|May 11, 2015|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229956||114106|
NCT01230242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3689|Postplacental Mirena IUD Insertion and Estimating Expulsion Rates.|Experimental Study Examining Mirena IUD Insertion and Estimating Rates of Expulsion Immediately After Placental Delivery.||Maine Medical Center Research Institute|Yes|Suspended|August 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|August 1, 2011|October 28, 2010|Yes|Yes|Suspended to determine if Mirena device could be charged to patient insurance|No||https://clinicaltrials.gov/show/NCT01230242||114084|
NCT01230853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAN2401-A001-101|A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study|A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease||Eisai Inc.|No|Completed|August 2010|February 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|50 Years|N/A|No|||February 2013|May 20, 2013|October 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230853||114039|
NCT01231139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARITY|The Paracetamol AfteR Traumatic Brain InjurY Study|A Multi-centre Phase 2b Randomised Controlled Trial Investigating the Efficacy and Safety of Intravenous Paracetamol in Reducing Core Body Temperature After Traumatic Brain Injury|PARITY|South East Sydney and Illawarra Area Health Service|Yes|Completed|October 2010|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||October 2014|October 26, 2014|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231139||114018|
NCT01231386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09147|MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer|MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer||City of Hope Medical Center|Yes|Recruiting|April 2010|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|165|Samples With DNA|Tissue and Blood Procurement. Breast cancer tissues from core biopsies (as available,      preferably fresh frozen or RNA-later preserved, but in case of lack of availability,      formalin-fixed paraffin-embedded [FFPE] core or tissue samples) which have been collected or      will be collected under IRB#05091 or 05015.|Female|18 Years|N/A|No|Probability Sample|Female, Breast Cancer, > 18 years, regardless of histology, treatment phase, or stage.        However, only patients with Stage II-III disease from IRB #05015 will be accrued, in order        to assure that sufficient tumor tissue will be available.|November 2015|November 4, 2015|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01231386||113999|
NCT01231659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001JIL05|Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane||Novartis||Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231659||113978|
NCT01231919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02612|MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia|A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia||National Cancer Institute (NCI)||Completed|January 2011|||April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|1 Year|21 Years|No|||April 2013|April 28, 2014|October 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01231919||113958|
NCT01232218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRLP-10-010|Treatment Protocol for Hemiplegic Shoulder Pain|Effectiveness of a Three-Dimensional Scapular-Humeral Mobilization Technique on Hemiplegic Shoulder Pain|TPHSP|Toronto Rehabilitation Institute|No|Completed|October 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01232218||113935|
NCT01232543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405-01-04|Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis|An Open-Label Evaluation of the Adrenal Suppression Potential of Product 0405 in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects|0405-01-04|Fougera Pharmaceuticals Inc.|No|Completed|November 2010|November 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|3 Months|17 Years|No|||April 2012|April 9, 2012|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01232543||113910|
NCT01232556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1931008|A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy|An Open-Label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin Administered In Combination With Rituximab Compared To Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates For Intensive High-Dose Chemotherapy||Pfizer|Yes|Terminated|April 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|October 27, 2010|Yes|Yes|The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected    safety issues were identified.|No||https://clinicaltrials.gov/show/NCT01232556||113909|
NCT01232790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904005039|A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia|A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia|NAC|Yale University|No|Completed|February 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|60 Years|No|||November 2015|November 4, 2015|February 25, 2010||No||No|January 24, 2013|https://clinicaltrials.gov/show/NCT01232790||113891|
NCT01241448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13031|A Study of LY2409021 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of LY2409021 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|January 2011|March 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|260|||Both|18 Years|70 Years|No|||April 2012|May 24, 2012|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241448||113230|
NCT01241461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13871|A Study of LY2584702 in Solid Tumors|A Phase 1 Study of LY2584702 in Japanese Patients With Solid Tumors||Eli Lilly and Company|Yes|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|N/A|No|||November 2011|November 17, 2011|November 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241461||113229|
NCT01207414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO522DUS01|Switching to Iloperidone From Other Antipsychotics in Schizophrenia|A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24 mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole|i-FANS|Novartis||Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|501|||Both|18 Years|64 Years|No|||February 2013|February 4, 2013|September 19, 2010|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01207414||115828|
NCT01207635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAB02-0400|Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer|Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer||M.D. Anderson Cancer Center|No|Completed|November 2002|January 2006|Actual|January 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|None Retained|Blood drawn; and, fluids collected from ductal lavage.|Female|N/A|N/A|No|Non-Probability Sample|Breast cancer patients receiving standard Arimidex treatment.|July 2012|July 27, 2012|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207635||115811|
NCT01207648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200136-024|Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)|Retrospective Cohort Study of Rebif® Use in Pediatric MS Patients|REPLAY|EMD Serono|No|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|307|||Both|N/A|18 Years|No|Non-Probability Sample|Every eligible subject at participating centers: subjects who have received one or more        injections of Rebif® for treatment of a demyelinating event before the age of 18 and        before the 30th June 2009.|April 2015|April 27, 2015|September 21, 2010||No||No|April 8, 2013|https://clinicaltrials.gov/show/NCT01207648||115810|
NCT01207921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010719|Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma|A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma||Washington University School of Medicine|No|Recruiting|April 2011|October 2018|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207921||115790|
NCT01208233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9541004|Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke|A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke||Pfizer|Yes|Terminated|December 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|181|||Both|18 Years|85 Years|No|||January 2016|January 22, 2016|September 22, 2010|Yes|Yes|See termination reason in detailed description.|No|February 19, 2015|https://clinicaltrials.gov/show/NCT01208233||115766|The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.
NCT01239342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-02270|Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer|A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma||National Cancer Institute (NCI)|No|Active, not recruiting|January 2011|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239342||113392|
NCT01239030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-BP-EF002|Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD|A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD)||Rhodes Pharmaceuticals, L.P.|No|Completed|November 2010|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|236|||Both|6 Years|18 Years|No|||January 2013|January 22, 2013|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239030||113414|
NCT01229969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-060390|A Pilot Study of the Wii Fit as a Low-Cost Virtual Reality System to Evaluate Balance Ability in Older Adults|A Pilot Study of the Wii Fit as a Low-Cost Virtual Reality System to Evaluate Balance Ability in Older Adults|WiiFit|Atlanta VA Medical Center|No|Completed|August 2009|March 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 23, 2013|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229969||114105|
NCT01230255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH09.068.04|Percutaneous Catheter Decompression in the Treatment of Elevated Intra-abdominal Pressure|Percutaneous Catheter Decompression in the Treatment of Elevated Intra-abdominal Pressure||Orlando Regional Medical Center|Yes|Completed|January 2007|August 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|15 Years|N/A|No|||October 2010|October 28, 2010|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230255||114083|
NCT01230879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8268|Effect of Ageing on Airway Remodeling|Study of Bronchoalveolar Lung Remodeling in Subjects From 60 Years Free of Progressive Lung Disease: Structure-function Analysis||University Hospital, Montpellier|Yes|Terminated|July 2009|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|101|||Both|60 Years|95 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01230879||114037|
NCT01231152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OB10|The Impact of Obesity on Children and Adolescents.|The Relation of Obesity With Metabolic Disorders, Inflammation Markers and Arterial Blood Pressure With Preclinical Target-organ Damage in Children and Young Adolescents.||University of Athens|No|Recruiting|September 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|8 Years|18 Years|No|Non-Probability Sample|Children and adolescents referred for increased body weight.|May 2012|May 24, 2012|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231152||114017|
NCT01231399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10064|Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer|Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma||City of Hope Medical Center|Yes|Active, not recruiting|February 2012|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|19 Years|N/A|No|||February 2016|February 10, 2016|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231399||113998|
NCT01231672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2008/GL-03|Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients With Septic Shock|Evaluation and Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients Entering Intensive Care Units for Septic Shock|SEPSICOAG|Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|780|||Both|18 Years|N/A|No|Non-Probability Sample|Severe septic shock patients entering intensive care units in the participating centers.|March 2015|March 26, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231672||113977|
NCT01241682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL24050.000.08|Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma|Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma|PMR-MM-002|Erasmus Medical Center|Yes|Completed|October 2009|October 2012|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|N/A|N/A|No|||February 2014|February 26, 2014|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01241682||113212|
NCT01241695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCOS-002-CFS|Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients|||Fresenius Kabi|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|40|||Both|40 Years|N/A|No|||November 2010|June 29, 2012|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01241695||113211|
NCT01232231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E23134|Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting|Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus in the Outpatient Setting: a Randomized Controlled Study||University of Calgary|No|Completed|July 2010|November 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 14, 2013|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232231||113934|
NCT01232244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXMDissek|Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.|||University Hospital, Gentofte, Copenhagen|No|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|N/A||1|Actual|15|Samples With DNA|blood samples|Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young males|December 2013|December 9, 2013|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232244||113933|
NCT01242293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0062-10-EMC|Intrapartum Hydration|||HaEmek Medical Center, Israel|Yes|Completed|November 2010|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Female|18 Years|50 Years|No|||February 2016|February 20, 2016|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242293||113166|
NCT01242579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 025|A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium|A Double-Blind, Randomised, Placebo-Controlled Phase I Trial to Compare the Pharmacokinetics of Maraviroc and Dapivirine Following Application of Maraviroc Vaginal Vaginal Gel, 0.1% 2.5g, Dapivirine Vaginal Gel, 0.05%, 2.5g and Maraviroc 0.1% + Dapivirine 0.05% Vaginal Gel, 2.5g Formulations, and to Assess Their Safety as Compared to the Matching Placebo Vaginal Gel, 2.5g in Healthy, HIV-Negative Women||International Partnership for Microbicides, Inc.|Yes|Withdrawn|January 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 8, 2011|November 15, 2010|Yes|Yes|In order to focus efforts on the combination ring formulation, IPM decided not to move forward    with this trial.|No||https://clinicaltrials.gov/show/NCT01242579||113144|
NCT01232803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-007|Rectal Safety and Acceptability Study of Tenofovir 1% Gel|A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel||CONRAD|Yes|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 19, 2013|November 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01232803||113890|
NCT01233063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44AG032241-03|Diet and Activity Promotion Among Older Working Adults|Diet and Activity Promotion Among Older Working Adults|ALIVE|Berkeley Analytics, Inc.|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|610|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 28, 2014|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01233063||113870|
NCT01207661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-002|Articular Cartilage Resurfacing With Mesenchymal Stem Cells In Osteoarthritis Of Knee Joint|Mesenchymal Stem Cells Transplantation for Articular Cartilage Resurfacing in Patient With Osteoarthritis of Knee Joint||Royan Institute|Yes|Completed|August 2009|November 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||April 2009|January 2, 2012|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01207661||115809|
NCT01207934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0643|Recombinant Human Leptin Therapy Effects on Insulin Action|Recombinant Human Leptin Therapy Effects on Insulin Action|Leptin|Washington University School of Medicine|Yes|Completed|August 1998|July 2000|Actual|July 2000|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|18|||Both|25 Years|75 Years|No|||June 2015|June 11, 2015|September 21, 2010|Yes|Yes||No|June 6, 2011|https://clinicaltrials.gov/show/NCT01207934||115789|
NCT01208246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31522|Impact of Pelvic Floor Musculature on Peripartum Outcomes|Impact of Pelvic Floor Musculature on Peripartum Outcomes: A Prospective Study|PregUS|University of Rochester|No|Completed|April 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Prenatal visits|February 2014|February 19, 2014|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208246||115765|
NCT01208545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99000287|Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs|Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs||NeuroMetrix, Inc.|No|Active, not recruiting|July 2008|||July 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients presenting to an oncology clinic for treatment of breast cancer, colon cancer, or        non-Hodgkins lymphoma, or treatment of advanced gastroesophageal cancer|September 2010|September 22, 2010|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208545||115742|
NCT01239667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pla123|Rehabilitative Care to Patients With Heart Failure|Rehabilitative Care to Patients With Heart Failure||University College Sjælland|Yes|Recruiting|September 2010|February 2012|Anticipated|May 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|194|||Both|18 Years|N/A|No|||October 2010|November 10, 2010|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01239667||113367|
NCT01230268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT2010-05|A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Mulberry Fruit Extract|A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Mulberry Fruit Extract|C3G|Seoul St. Mary's Hospital|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2010|December 13, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230268||114082|
NCT01230281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT2010-06|A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Black Bean Seed Coat Extract|A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Black Bean Seed Coat Extract|C3G|Seoul St. Mary's Hospital|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2010|December 13, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230281||114081|
NCT01230567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-10-0032 CTIL|Comparison Between the Histological and Clinical Diagnosis of Non Healing Wounds|Comparison Between the Histological and Clinical Diagnosis of Non Healing Wounds||Carmel Medical Center|Yes|Completed|October 2010|April 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|85 Years|No|Probability Sample|Patients suffering from non healing wounds, which do not respond well to six weeks of        adequate treatment.|April 2013|April 9, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230567||114061|
NCT01230580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIVOT|Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)|A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART|PIVOT|Medical Research Council|Yes|Active, not recruiting|November 2008|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|587|||Both|18 Years|N/A|No|||October 2010|October 9, 2012|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230580||114060|
NCT01240759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010N0921|Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy|A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy||Shionogi Inc.|Yes|Completed|October 2010|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|218|||Both|18 Years|75 Years|No|||April 2013|April 9, 2013|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240759||113283|
NCT01231165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-5 2008|Treatment of Coronary Heart Disease With Amiloride|Comparative Randomized Single-blind Trial of Amiloride in Coronary Heart Disease||University of Carabobo|No|Completed|February 2009|February 2011|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|35 Years|75 Years|No|||April 2012|June 8, 2012|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231165||114016|
NCT01241071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-UCH-88|Effects of Myofascial Release on Pain, Disability and Electromyography of Erector Spinae in Chronic Low Back Pain|Effects of a Myofascial Release Protocol on Pain, Disability and Activation Pattern of Erector Spinae in Patients With Chronic Low Back Pain||Cardenal Herrera University|No|Not yet recruiting|January 2011|January 2012|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241071||113259|
NCT01241084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lr_Asthma|Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on Asthmatic Children|Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on the Airways Allergic Inflammation of Asthmatic Children||Federico II University|Yes|Completed|June 2009|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|6 Years|14 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241084||113258|
NCT01241370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKFE-RET-001|Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects|Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects||ELAB-Logistics|No|Completed|May 2009|April 2010|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|78|||Both|30 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|It is planned to recruit up to 60 obese male and female subjects, stratified according to        the following,        20 non-diabetic subjects with HOMAs ≤ 2, BMI < 28 kg/m² 20 non-diabetic subjects with        HOMAs > 2, BMI ≥ 28 kg/m² 20 type 2 diabetic patients|November 2010|November 15, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01241370||113236|
NCT01242007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNBC-11102010|Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients|Lung Function Impairment and Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients||University of Nancy|Yes|Completed|April 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|58|||Both|18 Years|N/A|No|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242007||113187|
NCT01241994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/2004/U/Oss|Automatic Adaptive System Dialysis (AASD)|Automatic Adaptive System Dialysis (AASD) for Dialysis Related Hypotension and Intolerance: a Prospective Long-term Multicenter Study||St. Orsola Hospital|No|Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||January 2004|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241994||113188|
NCT01242605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-04|ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer|ABC-04 a Phase 1B Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer|ABC-04|University College, London|Yes|Active, not recruiting|February 2012|January 2015|Anticipated|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01242605||113142|
NCT01240499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOIX-170|Effects of a Health-At-Every-Size Approach on Weight Management in Premenopausal Overweight Women|Intervention s'Inspirant du Nouveau Paradigme en matière de Gestion de Poids Chez Des Femmes préménopausées présentant un Surplus de Poids|CHOIX|Laval University|No|Completed|September 2003|September 2008|Actual|September 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|144|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01240499||113303|
NCT01241760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013711|VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection|A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection||Janssen Infectious Diseases BVBA|Yes|Completed|December 2010|November 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|744|||Both|18 Years|70 Years|No|||May 2014|May 14, 2014|October 28, 2010|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01241760||113206|
NCT01241773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017494|TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir|A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, Efavirenz and Raltegravir, at Steady State||Tibotec Pharmaceuticals, Ireland||Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01241773||113205|
NCT01242085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04061991|Preoperative Alignment of Total Knee Replacement|Alignment of Total Knee Components Using Standard or Custom Instrumentation||VA Palo Alto Health Care System|No|Completed|November 2010|January 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|90 Years|No|||May 2013|May 9, 2013|November 15, 2010||No||No|February 19, 2013|https://clinicaltrials.gov/show/NCT01242085||113181|none except small sample sizes
NCT01208571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1883|The Effect of a Interdisciplinary Alcohol Cessation Intervention|The Effect of an Interdisciplinary "Booster" Session in Primary Care Following Brief Intervention in Hospitals - a Randomized Clinical Trial||Helse Stavanger HF|No|Recruiting|April 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208571||115740|
NCT01208831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225X1101|An East Asian Study of LDE225|An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors||Novartis||Completed|October 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208831||115720|
NCT01208844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPS06230812Exp.|Study of Physical Health for Women With Posttraumatic Stress or Depression|Cardiovascular Risk in Relation to Posttraumatic Stress Disorder in Young Women||Nova Southeastern University|No|Completed|June 2008|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|59|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample, psychology clinics|April 2015|April 27, 2015|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01208844||115719|
NCT01209104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113722|Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors|A Single-dose, Open, Randomized, Crossover Investigation of Age, Gender, Food-effect and Proton-pump Interaction on the Pharmacokinetics of GSK1325756 in Healthy Adult Subjects and a Single-dose, Double Blind, Parallel-group, Placebo- Controlled Investigation of the Pharmacokinetics of GSK1325756||GlaxoSmithKline|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209104||115700|
NCT01208558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU2010/332|Grain Exercise Trial|Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss|GET|Lund University|No|Active, not recruiting|August 2010|November 2014|Anticipated|November 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||September 2011|May 17, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208558||115741|
NCT01208805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52573|Spinal Cord Evoked Potentials as a Tool to Investigate Sensorimotor Processing|Spinal Cord Evoked Potentials in Candidates for Dorsal Column Stimulation|SCEPTISM|Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|November 2010|July 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with epidural elektrodes for intractable pain (spinal cord stimulation)|September 2010|September 23, 2010|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208805||115722|
NCT01230294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S275-2010|New Echocardiographic Methods for Right Ventricular Function.|Evaluation of New Echocardiographic Methods for Measurement of Right Ventricular Function.|NEW-RV|Heidelberg University|Yes|Active, not recruiting|October 2010|||October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  patients with pulmonary aterial hypertension          -  patients with chronic heart failure of the left ventricle affecting the right heart          -  patients without structural heart disease who underwent an echocardiographic             examination for other reasons (control group)|July 2015|July 6, 2015|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230294||114080|
NCT01230593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-469|Chalazion Conservative Treatment Trial|A 5-year Multicenter Prospective Randomized Trial Comparing Three Conservative Chalazion Treatments||McMaster University|No|Completed|November 2010|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|160|||Both|18 Years|N/A|No|||February 2016|February 20, 2016|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230593||114059|
NCT01230866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU002-10|Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer|A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate||Proton Collaborative Group|Yes|Recruiting|November 2010|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Male|18 Years|N/A|No|||December 2015|December 7, 2015|October 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230866||114038|
NCT01241396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017410|A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure|An Observational Study of the Treatment of Multiple Myeloma in Routine Clinical Practice||Janssen Pharmaceutica N.V., Belgium|No|Completed|October 2010|November 2014|Actual|October 2014|Actual|Phase 4|Observational|Observational Model: Case-Only||1|Actual|2395|||Both|18 Years|N/A|No|Probability Sample|The study will focus on enrolling consecutively, patients who are initiating any new line        of therapy for Multiple Myeloma, regardless of the line of treatment. Because this is a        non-interventional study, intended to provide a picture of routine clinical practice, no        guidance will be given on any aspect of treatment, patient clinical management or        treatment dose selection.|June 2015|June 24, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01241396||113234|
NCT01241409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014830|A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers|Pivotal Study to Assess the Bioequivalence of the To-be-Marketed Sprinkle Capsule Formulation and the Phase 3 Sprinkle Capsule Formulation of Rabeprazole Sodium in Fasted Condition and to Assess the Effect of Food on the To-be-Marketed Formulation in Healthy Adult Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|78|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 28, 2012|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241409||113233|
NCT01241097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sxse|Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe|Comparison of the Effect on Endothelial Function of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe||Federal University of Bahia|Yes|Recruiting|March 2010|December 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241097||113257|
NCT01241383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081217|Effect of Bosentan in Scleroderma Renal Crisis|Effect of Bosentan in the Course of Scleroderma Renal Crisis|ScS-REINBO|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|December 2010|April 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01241383||113235|
NCT01241708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001295|Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma|Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma|(Mel/MelVel)|Hackensack University Medical Center|Yes|Recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|75 Years|No|||August 2015|August 21, 2015|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241708||113210|
NCT01242618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TpP-I-2010-002|Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule|Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule Following Resection of a Non Melanoma Skin Cancer- a Phase I Clinical Trial.||University Hospital, Basel, Switzerland|No|Completed|October 2010|||February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242618||113141|
NCT01242631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CDE21T|Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer|A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer|RADIT|Hannover Medical School|No|Completed|November 2010|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|N/A|No|||February 2015|February 24, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242631||113140|
NCT01242306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREDENTIAL|Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions|Head-to-Head Comparison of Endothelial Dysfunction (Bare Metal Stent vs Sirolimus Eluting Stent) in the Same Patient With Multiple Coronary Artery Lesions|CREDENTIAL|Azienda Ospedaliera San Camillo Forlanini|Yes|Completed|March 2009|December 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|90 Years|No|||April 2009|November 16, 2010|November 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242306||113165|
NCT01242319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-01|Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice|Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice||Memorial Hospital of Rhode Island|Yes|Completed|September 2002|August 2008|Actual|August 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|5218|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|stratified random sample of practices within those who agreed to participate; Cluster        sampling of patients from practices|September 2002|November 16, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242319||113164|
NCT01241149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP# 10.0090|Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery|Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery.||United States Naval Medical Center, Portsmouth|Yes|Recruiting|November 2010|||November 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|17 Years|N/A|No|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241149||113253|
NCT01242423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/160/06|Healing of Burns and the Effect of Shockwave Therapy on the Recovery of Skin Grafts|Accelerated Healing of Second Degree Burns and the Effect of Musculoskeletal Shockwave Therapy on the Recovery of Skin Graft Donor Sites||Unfallkrankenhaus Berlin|No|Completed|November 2006|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|80 Years|No|||November 2010|November 17, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242423||113156|
NCT01241123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP# 10-0061|The Influence of Ambulation on the Return of Bowel Function After Colorectal Surgery|The Influence of Ambulation on the Return of Bowel Function After Colorectal Surgery: Traditional Care Versus Early Mobilization Protocol||United States Naval Medical Center, Portsmouth|Yes|Recruiting|November 2010|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|98|||Both|17 Years|N/A|No|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241123||113255|
NCT01241136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP# 10.0041|Open Wide Excision Versus Minimal Surgery for Pilonidal Disease|Open Wide Excision Versus Minimal Surgery for Pilonidal Disease: A Randomized Control Trial Evaluating for Early Recurrence and Patient Satisfaction||United States Naval Medical Center, Portsmouth|Yes|Recruiting|November 2010|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|106|||Both|17 Years|N/A|No|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241136||113254|
NCT01241422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017533|A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model|A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|55 Years|No|||December 2015|December 18, 2015|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01241422||113232|
NCT01241747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR09-035|Exercise for Women With Peripheral Arterial Disease|Exercise for Women With Peripheral Arterial Disease||University of Oklahoma|No|Recruiting|July 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Female|60 Years|N/A|No|||December 2014|December 2, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241747||113207|
NCT01209403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGFHD1-2010|Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients|Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients||University of Aarhus|Yes|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01209403||115677|
NCT01208818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081226|Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy|Treatment of Renal Failure Due to Myeloma Cast Nephropathy: Comparison of Two Different Chemotherapy Regimens and Evaluation of Optimized Removal of Monoclonal Immunoglobulin Light Chains Using a High Permeability Hemodialysis Membrane.|MYRE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|June 2011|September 2017|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|284|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208818||115721|
NCT01240148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3780C00005|Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy Volunteers||AstraZeneca||Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 11, 2011|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01240148||113330|
NCT01240460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11605|Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection|An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection||Sanofi||Completed|January 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 26, 2012|November 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240460||113306|
NCT01240473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-008|A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh|A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|April 2007|July 2009|Actual|March 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|5 Years|64 Years|Accepts Healthy Volunteers|||November 2010|November 12, 2010|November 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01240473||113305|
NCT01233115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC387715/HTRA1 & combined PDT|LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy|LOC387715/HTRA1 Variants and the Response to Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy||Kyungpook National University|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|70|Samples With DNA|Genomic DNA was extracted from peripheral blood. The two SNPs (rs10490924 in the LOC387715      locus and rs11200638 in HTRA1 gene) were analyzed by LC480 Real time PCR (Roche, Basel,      Switzerland) at D&P Biotech (Daegu, Korea).|Both|60 Years|80 Years|No|Non-Probability Sample|The authors did a retrospective chart review of 70 patients with PCV who were treated at        the Department of Ophthalmology, Kyungpook National University Hospital in Daegu, Korea.|August 2011|August 28, 2011|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233115||113866|
NCT01241721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 09096|Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer|Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer||Swedish Medical Center|No|Active, not recruiting|September 2010|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241721||113209|
NCT01241734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001132 - RV-DLBCL-PI-0463|Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL|Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)|RICER|Hackensack University Medical Center|Yes|Active, not recruiting|June 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|N/A|No|||February 2014|February 2, 2014|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241734||113208|
NCT01242020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811310|Microvascular Flow Assessment Repeatability Study: The MARS Study|Microvascular Flow Assessment of the Periadventitial Adipose Tissue, Subcutaneous Adipose Tissue and Skeletal Muscle Using Contrast Enhanced Ultrasound (CEU); A Repeatability Study|MARS|University of Pennsylvania|No|Terminated|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|6|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|November 24, 2015|October 22, 2010|Yes|Yes|Unable to reliably reproduce, visualize, or quantify microvascular flow in the subcutaneous    tissue, the skeletal muscle or peri-adventitia|No||https://clinicaltrials.gov/show/NCT01242020||113186|
NCT01242332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 52 -234-08-1-2|Perioperative Administration of Pregabalin in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction|Perioperative Administration of Pregabalin in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction: Does it Help to Relieve Postoperative Pain?||Prince of Songkla University|Yes|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||May 2009|November 16, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242332||113163|
NCT01242345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capno-Interventional 2011|Capnography During Upper GI Endoscopy|Clinical Value of Advanced Patient Monitoring With Capnography and Analysis of the Integrated Pulmonary Index During Interventional Upper Gastrointestinale Endoscopy||Ruhr University of Bochum|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 20, 2011|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242345||113162|
NCT01229774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eto-Dic-01|Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty|Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty, a Prospective, Double Blind, Phase III Study||University of Regensburg|No|Completed|February 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|55 Years|85 Years|No|||September 2010|September 12, 2014|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229774||114120|
NCT01229787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIIRespiratory1|The Relation Between Obesity, Adipose Tissue Content of Fatty Acids and Systemic and Airway Inflammation|The Relation Between Obesity, Adipose Tissue Content of Fatty Acids and Systemic and Airway Inflammation||Cyprus International Institute for Environment and Public Health|Yes|Completed|January 2007|December 2009|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|5384|||Both|15 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Part I took place in 2007 and children 15-16 and 16-17 years across Cyprus were invited to        participate. The targeted population were 19849 children that participated in an earlier        study in years 2001-3 and had anthropometric measurements, assessment of        cardio-respiratory fitness and serum lipids taken at that time. The subjects of the second        part of the study were selected from the 5384 subjects that had participated in the first        part and had matched data on current and past BMI. We targeted subjects for part two of        the study with the following criteria:1. Current Wheezers: All active asthmatics across        all BMI subgroups. Definition of Current Wheezer: Positive answer to the question in ISAAC        questionnaire: "Have you had wheezing in the past 12 months?" 2. Never Wheezers: 700        controls selected in a random way across all BMI groups. Definition of Never Wheezer:        Negative answers to both of the following two questions: "Have you ever had wheezing?" and        "Have you ever had asthma?"|July 2009|October 27, 2010|October 27, 2010||||No||https://clinicaltrials.gov/show/NCT01229787||114119|
NCT01230047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1018|Mindfulness and Lifestyle Interventions for Depression and Anxiety: A Pilot Study|Evaluation of a Psychoeducational Intervention Teaching Mindfulness and Lifestyle Interventions for Clinical Depression and Anxiety (A Pilot Study)||Arizona State University|No|Active, not recruiting|October 2010|October 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||October 2010|October 27, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01230047||114099|
NCT01242904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-460|Use of a Bimodal Solution for Peritoneal Dialysis|Randomized Controlled Trial of Bimodal Solution for Peritoneal Dialysis: 24-Hour UF Efficiency Using Bimodal PD Solutions During the Long Dwell||Lawson Health Research Institute|No|Recruiting|June 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2011|August 3, 2011|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242904||113120|
NCT01242917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL004_354|A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy|CARAT-2|ChemoCentryx|Yes|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|159|||Both|18 Years|75 Years|No|||February 2012|February 8, 2012|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242917||113119|
NCT01242111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-100|A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)||BioMarin Pharmaceutical|No|Terminated|November 2010|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||August 2015|August 28, 2015|October 28, 2010||No||No|July 10, 2015|https://clinicaltrials.gov/show/NCT01242111||113179|
NCT01242137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|169/09|Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide|||Assaf-Harofeh Medical Center||Recruiting|October 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|20 Years|90 Years|No|Non-Probability Sample|Diabetes type 2 patients treated with metformin and glibenclamide.|October 2010|November 15, 2010|November 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01242137||113177|
NCT01242059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PureNet_23281|Yellow Pea Fractions and Short-term Food Intake, Subjective Appetite and Glycemic Response|Effect of Yellow Pea Fractions on Short-term Food Intake at 120 Minutes, Subjective Appetite and Glycemic Response in Young Adult Males||University of Toronto|No|Completed|January 2009|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|20|||Male|20 Years|29 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01242059||113183|
NCT01242072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM1004|Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies|A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice||Ziopharm|No|Active, not recruiting|November 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242072||113182|
NCT01242384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECEP-RETARD TRIAL|Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women After Threatened Preterm Labor(PECEP-RETARD)|Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women After Threatened Preterm Labor|PECEP-RETARD|Maternal-Infantil Vall d´Hebron Hospital|Yes|Completed|June 2008|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|500|||Female|18 Years|45 Years|No|||July 2014|July 25, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01242384||113159|
NCT01242397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiRBi- Acosta|Mitral Insufficiency Reduction With Biventricular Pacing|Prospective.Randomized, Blinded, Crossover Chronic IDE Study of the Effects of Pacing on Mitral Regurgitation in Patients Without Standard Indications for Cardiac Resynchronization Therapy|MiRBi|Trinity Medical Center, Illinois|Yes|Not yet recruiting|January 2011|January 2013|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2009|December 1, 2010|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242397||113158|
NCT01242657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDCU48/CCU310821|Quit and Fit: Teen Smoking Cessation|Quit and Fit: Exploring the Effects of Physical Activity on Teen Smoking Cessation||West Virginia University|No|Completed|October 2006|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|3||Actual|236|||Both|14 Years|18 Years|No|||December 2010|December 9, 2010|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01242657||113138|
NCT01242670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|880801|Ross River Virus (RRV) Vaccine Study|A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older||Nanotherapeutics, Inc.|Yes|Completed|April 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1968|||Both|16 Years|N/A|Accepts Healthy Volunteers|||January 2013|October 7, 2015|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242670||113137|
NCT01242033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24774|Effect of Acute Red Raspberry Consumption on Post-prandial Oxidative Stress|An Acute Intervention Study Investigating the Effect of Red Raspberry Consumption on Post-prandial Oxidative Stress||University of Toronto|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|8|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||November 2010|December 3, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01242033||113185|
NCT01242046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-07-0070|Effects of Caffeine on Women's Sexual Arousal|The Effects of Caffeine on Female Genital Arousal||University of Texas at Austin|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 15, 2010||No|Key personnel were reassigned to different project|No||https://clinicaltrials.gov/show/NCT01242046||113184|
NCT01240486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1073|IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int'l Sites|IMPAACT P1073: Study Of Immune Reconstitution Inflammatory Syndrome (IRIS) For International Sites Initiating Highly Active Antiretroviral Therapy (HAART) In Infants And Children < 72 Months Of Age||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|No|Completed|November 2010|October 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|207|||Both|N/A|72 Months|No|Probability Sample|This is a prospective, clinical observational and pathogenesis study of HIV-infected        infants and children stratified into 2 age groups: ≥ 4 weeks to ≤ 12 months of age; and >        12 to < 72 months of age who will enroll into P1073 at a timepoint ≤ 1 week prior to        initiating HAART|May 2014|May 16, 2014|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240486||113304|
NCT01231971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-039-ADNI2|Alzheimer's Disease Neuroimaging Initiative 2|Alzheimer's Disease Neuroimaging Initiative 2|ADNI2|University of Southern California|Yes|Active, not recruiting|January 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|650|Samples With DNA|blood, urine, cerebrospinal fluid|Both|55 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Community Sample|February 2016|February 23, 2016|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01231971||113954|
NCT01240772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIC/10/01|Randomized Controlled Trial Comparing Transanal Doppler-guided Arterial Ligation With Mucopexy and Stapled Haemorrhoidopexy|Cost-effectiveness of New Surgical Treatments for Haemorrhoidal Disease - Randomized Controlled Trial Comparing Transanal Doppler-guided Arterial Ligation With Mucopexy and Stapled Haemorrhoidopexy (Longo's Technique)|LIGALONGO|Nantes University Hospital|No|Completed|December 2010|February 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|407|||Both|18 Years|75 Years|No|||August 2014|August 22, 2014|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240772||113282|
NCT01232322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5257L00014|Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation|Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation for Long-term Use in Pediatrics||AstraZeneca|No|Completed|October 2006|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|633|||Both|6 Months|5 Years|No|Non-Probability Sample|Patients treated with Pulmicort respules for the first time due to bronchial asthma and        children of >=6months and <5 years old age at the start of study treatment|January 2013|January 23, 2013|October 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01232322||113927|
NCT01241110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinicalTrials.gov|To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment|Phase 4 Study of Azitromicin in the Treatment of PID|CTO|Guilan University of Medical Sciences|Yes|Completed|January 2010|September 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|N/A|N/A|No|||October 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241110||113256|
NCT01232842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B4|Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia|Assessment of Stem Cell Heterogeneity in AML in Co-Culture Systems Using X Chromosome Inactivation Patterns||Children's Oncology Group|No|Active, not recruiting|October 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|Tissue|Female|N/A|120 Years|No|Non-Probability Sample|Diagnosed with acute myeloid leukemia.|May 2015|September 30, 2015|October 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01232842||113887|
NCT01233128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGF & LOC387715/HTRA1|Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy|Association of Vascular Endothelial Growth Factor and LOC387715/HTRA1 Polymorphisms With the Response to Intravitreal Ranibizumab Injections in Polypoidal Choroidal Vasculopathy||Kyungpook National University|Yes|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|121|Samples With DNA|Genomic DNA was extracted from peripheral blood with the Qiagen QIAamp Blood Kit (Qiagen,      Valencia, CA).|Both|60 Years|80 Years|No|Non-Probability Sample|The authors did a retrospective chart review of 70 patients with PCV who visited the        Department of Ophthalmology, Kyungpook National University Hospital in Daegu, Korea.|April 2012|April 6, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233128||113865|
NCT01233414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH081148|Randomized Trial of Parent Training for Young Children With Autism|Randomized Trial of Parent Training for Young Children With Autism|RUBI|Yale University|Yes|Active, not recruiting|September 2010|March 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|3 Years|7 Years|No|||July 2014|July 7, 2014|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01233414||113843|
NCT01233700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR011149|Brief Intervention to Prevent Poor Psychosocial Outcomes in Living Donors|Brief Nursing Intervention to Prevent Poor Psychosocial Outcomes in Living Donors||University of Pittsburgh|No|Completed|March 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|113|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01233700||113822|
NCT01233973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000180|Using Videos to Improve Understanding of the Delivery of End-of-life Medical Care in Non-hospital Settings|||Massachusetts General Hospital|No|Completed|July 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|101|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 28, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233973||113801|
NCT01233986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABYSS|Association of Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)|Prospective, Matched Case Control, Multicenter, Observational Study for the Association of Serum Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)||Hallym University Medical Center|Yes|Recruiting|May 2010|October 2011|Anticipated|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|112|Samples Without DNA|Serum level of apolipoprotein B-48|Both|20 Years|N/A|No|Probability Sample|Tertiary Hospital|November 2010|October 4, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01233986||113800|
NCT01230073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-004|Treatment Satisfaction in Implantable Cardioverter Defibrillator Recipients|Treatment Satisfaction With Remote Monitoring in Implantable Cardioverter Defibrillator Recipients|SAN REMO 2|Deutsches Herzzentrum Muenchen|No|Active, not recruiting|February 2011|December 2015|Anticipated|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||June 2015|June 19, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01230073||114097|
NCT01230359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8225/08|Early Nutritional Intervention in Patients With Autism Spectrum Disorders|EARLY NUTRITIONAL INTERVENTION IN PATIENTS WITH AUTISM SPECTRUM DISORDERS||Hamad Medical Corporation|Yes|Completed|April 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|2 Years|10 Years|No|||July 2011|July 18, 2011|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230359||114076|
NCT01230346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08237|Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer|Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas||City of Hope Medical Center|Yes|Recruiting|December 2010|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|475|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01230346||114077|
NCT01241526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-07-C4-008|The COPD Patient Management European Trial (COMET)|An International Phase IV Randomised Trial for Medical and Medico-economic Evaluations of Home-based Disease Management Program in Patients With Gold III/IV Chronic Obstructive Pulmonary Disease.|COMET|Air Liquide Santé International|Yes|Completed|September 2010|October 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|346|||Both|35 Years|N/A|No|||January 2016|January 13, 2016|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01241526||113224|
NCT01242124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-ECC-001|Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy|Randomized Study of Intrathoracic Side-to-side Stapled Esophagogastric Anastomosis Versus Circular-Stapled Technique in Ivor-Lewis Oesophagectomy||Tianjin Medical University Cancer Institute and Hospital|No|Active, not recruiting|January 2011|December 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||September 2010|December 21, 2015|November 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01242124||113178|
NCT01242098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004/11|Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management|Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management|Fos/Ser_switch|Research in Real-Life Ltd|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|137|||Both|18 Years|80 Years|No|Probability Sample|Patients receiving ICS/LABA therapy as FP/SAL (Seretide® 125) who, at an index        prescription date (IPD) receive a routine asthma review* and either:        (i) Switched to BDP/FOR (Fostair®)at same or lower BDP-equivalent ICS dose;        OR,        (ii) Continues on FP/SAL (Seretide® 125) for the duration of the outcome period at the        same or lower BDP-equivalent ICS dose prescribed at baseline.|June 2012|June 7, 2012|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01242098||113180|
NCT01242410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pessary in twins TRIAL|Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix in Twins|Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix in Twins|PECEP-TWINS|Maternal-Infantil Vall d´Hebron Hospital|Yes|Completed|January 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|137|||Female|18 Years|45 Years|No|||July 2014|May 9, 2015|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01242410||113157|
NCT01242683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10112010-7069|Vivamos Activos Fair Oaks Program for Weight Loss in Low Income Latinos|Case-Management & Environmental Support to Sustain Weight Loss & Reduce CHD Risk|VAFO|Stanford University|Yes|Completed|May 2008|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|207|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242683||113136|
NCT01242995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thin Scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) With Cholangiopancreatoscopy Using a Thin Scope|Prospective Evaluation of the Clinical Utility of the Thin Scope/Anchoring Balloon Cholangiopancreatoscopy System for Disorders fo the Pancreatobiliary System||University of Florida|No|Withdrawn|May 2015|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a medical indication for Endoscopic Retrograde Cholangiopancreatography        (ERCP) with cholangioscopy and/or pancreatoscopy and are referred for the procedure as        part of their standard medical care will be considered for this study.|May 2015|May 6, 2015|November 16, 2010||No|The device was withdrawn from clinical use|No||https://clinicaltrials.gov/show/NCT01242995||113114|
NCT01238562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1004CSF|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients|A Randomized, Open-label, Single-dose, Dose-escalation, Self-controlled Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YPEG-Filgrastim in Cancer Patients Receiving Chemotherapy|Filgrastim|Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|April 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|30|||Both|18 Years|70 Years|No|||March 2010|January 31, 2013|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01238562||113450|
NCT01242956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-001|Video-based Training for Rehabilitation of Upper Limb Functions After Stroke|Video-based Training for Rehabilitation of Upper Limb Functions After Stroke: a New Treatment Exploiting the Mirror Neuron System||RWTH Aachen University|Yes|Terminated|September 2011|September 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|80 Years|No|||September 2015|September 22, 2015|November 16, 2010||No|Problem to recruit sufficient patient number|No||https://clinicaltrials.gov/show/NCT01242956||113116|
NCT01242982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOSL-2010|Subcapital and Shaft Fractures of the 5. Metacarpal|Prospective Randomised Study of Subcapital and Shaft Fractures of the 5. Metacarpal. Comparison Conservative Treatment and Operation||St. Olavs Hospital|Yes|Terminated|January 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|November 16, 2010||No|problems to include patients, patients not showing up at check-up|No||https://clinicaltrials.gov/show/NCT01242982||113115|
NCT01232309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSN-CS-001|Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)||Stratum Nutrition|Yes|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|135|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|October 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01232309||113928|
NCT01232335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589IC00001|Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation|Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation for Long-term Use|ENSURE|AstraZeneca|No|Completed|January 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Symbicort for the first time due to bronchial asthma|May 2013|May 28, 2013|October 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01232335||113926|
NCT01232348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589IL00001|Symbicort Turbuhaler 30/60 Clinical Experience Investigation|Symbicort Turbuhaler 30/60 Clinical Experience Investigation|SURE|AstraZeneca|No|Completed|January 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3643|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Symbicort for the first time due to bronchial asthma|December 2011|December 6, 2011|October 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01232348||113925|
NCT01232595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFF571X2201|Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections|Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections||Novartis|No|Completed|October 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|109|||Both|18 Years|90 Years|No|||March 2015|March 24, 2015|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01232595||113906|
NCT01232855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B5|Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia|Regulation of S100A10 by the PML-RAR-alpha Oncoprotein||Children's Oncology Group|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Tissue|Both|N/A|120 Years|No|Non-Probability Sample|Patients With Acute Promyelocytic Leukemia|May 2015|September 30, 2015|October 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01232855||113886|
NCT01233453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL25754.101.08|Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent|Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study|COMPARE-II|Maasstad Hospital|Yes|Active, not recruiting|January 2009|December 2015|Anticipated|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2700|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01233453||113840|
NCT01233427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-68|Infant Feeding Study.09-68|The Infant Feeding Experience of New Mothers - a Descriptive Pilot Study.||Children's Hospital Medical Center, Cincinnati|No|Completed|June 2009|October 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|breastfeeding moms|August 2014|August 22, 2014|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233427||113842|
NCT01233440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL654_2001|Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B|An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B||CSL Behring|Yes|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Male|12 Years|65 Years|No|||January 2012|January 26, 2012|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233440||113841|
NCT01233713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Colon_Perf_RCT|Hartmann's Versus Primary Anastomosis in Left-sided Colon Perforation|Hartmann's Versus Primary Anastomosis in Left-sided Colon Perforation - A Prospective Randomized Multicenter Trial|ColonPerfRCT|University of Zurich|Yes|Completed|May 2006|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|95 Years|No|||May 2012|May 25, 2012|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233713||113821|
NCT01233999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015510|Botulinum Toxin in the Treatment of Raynaud's|Botulinum Toxin in the Treatment of Raynaud's||Emory University|Yes|Completed|October 2010|March 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|89 Years|No|||March 2014|March 15, 2014|November 2, 2010|Yes|Yes||No|July 17, 2013|https://clinicaltrials.gov/show/NCT01233999||113799|Pilot study with limited numbers to analyze
NCT01230060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|658|One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction|A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of a Bausch + Lomb One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction||Bausch & Lomb Incorporated|No|Completed|October 2010|August 2011|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|October 27, 2010|Yes|Yes||No|May 16, 2013|https://clinicaltrials.gov/show/NCT01230060||114098|
NCT01230099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0601 0001 01 ME|Informing Decisions in Chronic Critical Illness: A Randomized Control Trial (RCT)|Informing Decisions in Chronic Critical Illness: A Randomized Control Trial (RCT)||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|622|||Both|21 Years|N/A|No|||October 2015|October 28, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01230099||114095|
NCT01230385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271049|Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects|Randomized, Open-Label, Parallel Group Study To Investigate The Safety And Tolerability Of Multiple Dose Lersivirine (Proposed Phase 3 Formulation) For 21 Days In Healthy Subjects||Pfizer|No|Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|75|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 16, 2011|October 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230385||114075|
NCT01230671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-059-PSY|The Physical and Psychological Benefits of Yoga and Breast Cancer|The Physical and Psychological Benefits of Yoga in Patients With Breast Cancer: A Feasibility Study||McGill University Health Center|No|Completed|August 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|80|||Female|18 Years|70 Years|No|||October 2013|October 24, 2013|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230671||114053|
NCT01230398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA021110|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2011|||||N/A|N/A|N/A||||||||||||||September 26, 2014|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230398||114074|
NCT01242163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0481-10CTIL|Application of Chemical Sensors for Diagnosis of Inflammatory Bowel Diseases and Irritable Bowel Syndrome by Respiratory Samples|Application of Chemical Sensors for Diagnosis of Inflammatory Bowel Diseases and Irritable Bowel Syndrome by Respiratory Samples||Rambam Health Care Campus|No|Not yet recruiting|December 2010|December 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Experiated lung air|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with Inflammtory bowel Diseases and IBS|October 2010|November 22, 2010|November 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01242163||113175|
NCT01241812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01492|Biomarkers and Knee Osteoarthritis|Biomarkers and Knee Osteoarthritis: Associations With Joint Load and Effects of Exercise||University of British Columbia|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|85 Years|No|||October 2011|October 12, 2011|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01241812||113202|
NCT01241825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01726|The Effect of Chewing Gum on Small Bowel Transit Time|The Effect of Chewing Gum on Small Bowel Transit Time: a Prospective Randomized Trial.||University of British Columbia|No|Completed|September 2010|July 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|122|||Both|19 Years|N/A|No|||September 2014|September 26, 2014|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01241825||113201|
NCT01242696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2059|TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)|PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS® Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice|TE-Prove|Boston Scientific Corporation|No|Active, not recruiting|November 2010|July 2017|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1014|||Both|N/A|N/A|No|Non-Probability Sample|All subjects who are candidates for coronary artery stenting, signed the Informed Consent        Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in        this study.|December 2013|December 19, 2013|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242696||113135|
NCT01243008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXO-01|Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation|A Single Centre, Randomized, Investigator Blinded, Placebo-controlled Ascending Dose Study to Assess the Local Safety, the Skin and Plasma Concentration of Azithromycin Dermal Formulation During Repeated Applications on the Skin of Healthy Volunteers|IXO-01|University of Zurich|Yes|Completed|April 2010|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2010|November 18, 2010|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01243008||113113|
NCT01238575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH083707|Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder|Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder||Yale University|Yes|Completed|December 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|5 Years|14 Years|No|||September 2015|October 30, 2015|October 29, 2010|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01238575||113449|
NCT01243021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH98765|Validation of an Early Warning Score Based Triage System in the Emergency Department|Nurse Administered Early Warning Score System Can be Used for Emergency Department Triage||Bispebjerg Hospital|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Both|N/A|N/A|No|Probability Sample|When arriving at the emergency department patients are divided into on of three groups        (red, blue nd white) according to the severity of their condition based on common regional        guidelines. Red patients are the most servelery ill or injured patients. A random sample        of "red" patients are included in this study|November 2010|November 17, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243021||113112|
NCT01238549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7566-R|Extending Veteran Participation in the Validation of the Spinal Cord Injury-Quality Of Life/Computerized Adaptive Test (SCI-QOL/CAT)|Extending Veteran Participation in the Validation of the SCI-QOL/CAT||VA Office of Research and Development|No|Active, not recruiting|May 2012|December 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|89 Years|No|Non-Probability Sample|Veterans at the James J. Peters VAMC or the James A. Haley VA Hospital with spinal cord        injury|March 2016|March 15, 2016|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238549||113451|
NCT01232621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-278|The Approach Study|A Randomized Pilot Study of Different Methods of Approaching Substitute Decision Makers Regarding Research Participation in the Intensive Care Unit: The Approach Study||St. Michael's Hospital, Toronto|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|138|||Both|N/A|N/A|No|||January 2013|January 4, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01232621||113904|
NCT01232608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1060-1|Exercise Training in Patients With Coronary Heart Disease and Type 2 Diabetes|Exercise Training in Patients With Coronary Heart Disease and Type 2 Diabetes|EXCADI|Oslo University Hospital|Yes|Completed|June 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|80 Years|No|||April 2013|April 4, 2013|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01232608||113905|
NCT01232868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046787|Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly|Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly||Emory University|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|66|||Both|25 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 27, 2015|October 23, 2010|Yes|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01232868||113885|Long period of time required for detailed analysis of gene expressions in different participants
NCT01233479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000673892|Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy|Immunologic Profile of Patients With Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy||Pediatric Brain Tumor Consortium||Withdrawn|May 2010|||July 2011|Anticipated|N/A|Interventional|Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|4 Years|21 Years|No|||October 2012|October 19, 2012|November 2, 2010||No|This non-therapeutic study was registered in error. The PRS team doesn't delete studies once    registered, so they recommended changing the status to Withdrawn|No||https://clinicaltrials.gov/show/NCT01233479||113839|
NCT01233726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR2009|Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia|Effects of a Complete Diet Rich in Monounsaturated Fatty Acids and Slow Absorption Carbohydrate Administration in Critically Ill Patients With Stress Hyperglycemia. Open Study, Blind Randomised, Multicenter and Controlled.||Vegenat, S.A.|No|Completed|April 2010|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|160|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01233726||113820|
NCT01229501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001282|Fat Biology, Sleep Disorders, and Cardiovascular Disease|Fat Biology, Sleep Disorders, and Cardiovascular Disease||Mayo Clinic|No|Enrolling by invitation|March 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum and plasma.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|With sleep disordered breathing, Without sleep disordered breathing, With cardiovascular        disease, Without cardiovascular disease, Sleep disordered breathing using CPAP.|April 2015|April 27, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229501||114141|
NCT01229813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 25359|Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.||ACT2|Lund University Hospital|No|Completed|October 2010|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|233|||Both|18 Years|N/A|No|||November 2013|April 10, 2015|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229813||114117|
NCT01230112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-289|The Role of ITGAM in Systemic Lupus Erythematosus|TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus||Northwell Health|No|Completed|December 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|Samples With DNA|Blood and DNA will be collected and retained|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal Control Subjects with genotype of interest registered in the Genotype and Phenotype        Registry|July 2013|July 29, 2013|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230112||114094|
NCT01229800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGI-2010-01|Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial|Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial|SPEN|Inje University|Yes|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|207|||Both|18 Years|64 Years|No|||August 2010|October 27, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229800||114118|
NCT01230086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-005|Trop-Shock DFT-testing Versus None|hs Troponin Release in Relation to Different ICD-Implantation Procedures|Trop-Shock|Deutsches Herzzentrum Muenchen|No|Completed|August 2010|June 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|195|||Both|N/A|N/A|No|||July 2013|July 3, 2013|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01230086||114096|
NCT01230411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/IVIb/01|A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack|A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack||Thomas Jefferson University|No|Recruiting|June 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|October 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230411||114073|
NCT01230424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH NIAMS R01-AR057802|Effect of Steroid Injections in a Knee With Osteoarthritis|Effect of Intra-articular Steroids on Structural Progression of Knee OA: A Randomized Controlled Trial|IACS for KOA|Tufts Medical Center|Yes|Completed|March 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|45 Years|N/A|No|||December 2015|December 14, 2015|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230424||114072|
NCT01230684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00038554|Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair|Comparison of Contrast Enhanced Ultrasound and the Gold Standard Computed Tomographic Angiography in Detection of Endoleak Following Endovascular Abdominal Aortic Aneurysm Repair.||University of Michigan|No|Terminated|December 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|October 28, 2010|No|Yes|Due to low enrollment|No||https://clinicaltrials.gov/show/NCT01230684||114052|
NCT01230697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|662010|Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)|Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib. Multicenter Cohort Study|SORHORM|University of Turin, Italy|Yes|Recruiting|June 2010|September 2011|Anticipated|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Serum analites involved in phosphate homeostasis|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced renal cells carcinoma and hepatocarcinoma|July 2010|October 28, 2010|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230697||114051|
NCT01242202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0108|A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients|A Phase 3, Open-Label, Non-comparative Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Combination With an α-Glucosidase Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With an α-glucosidase Inhibitor Alone.||Astellas Pharma Inc|No|Completed|October 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01242202||113173|
NCT01242215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0109|A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients|A Phase 3, Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone||Astellas Pharma Inc|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|243|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01242215||113172|
NCT01241838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1717|The Effect of Heart Rate on Cardiac Index in Patients With Left Ventricular Hypertrophy|The Effect of Heart Rate on Cardiac Index in Patients With Left Ventricular Hypertrophy||University of Aarhus|No|Terminated|February 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|11|||Both|30 Years|90 Years|No|||August 2012|August 3, 2012|November 15, 2010||No|Insufficient no of patients eligible for enrollment.|No||https://clinicaltrials.gov/show/NCT01241838||113200|
NCT01242436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52920|Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis|Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis||Universitaire Ziekenhuizen Leuven|No|Completed|January 2011|December 2014|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Female|N/A|N/A|No|||April 2015|April 9, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242436||113155|
NCT01242722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELEVATE 2.0|Evaluation of Left Ventricular Autothreshold, Phase Two|Evaluation of Left Ventricular Autothreshold, Phase Two|ELEVATE 2|Boston Scientific Corporation|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be a sample of patients with COGNIS CRT-D devices and bipolar LV        leads.|October 2012|October 2, 2012|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242722||113134|
NCT01242449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021618-42|Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer|A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer|OVINTRA|Vejle Hospital|Yes|Completed|November 2010|October 2014|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||March 2015|May 20, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242449||113154|
NCT01243034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100717|Waist Circumference Measurements in Schizophrenic Patients|Variability of Waist Circumference Measurements at 3 Sites and Its Relationship With Cardiovascular Risk Factors in Patients With Schizophrenia||Changhua Christian Hospital|No|Not yet recruiting|November 2010|October 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|65 Years|No|Non-Probability Sample|schizophrenia outpatients|October 2010|November 17, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243034||113111|
NCT01238874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA CRT Study|Latin America Cardiac Resynchronization Therapy Study|Latin America Cardiac Resynchronization Therapy Study|LatAmCRT|Medtronic Latin America||Enrolling by invitation|February 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|21 Years|N/A|No|||March 2011|March 28, 2011|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238874||113426|
NCT01238588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002213|The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan|The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan||Brigham and Women's Hospital|No|Recruiting|November 2010|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|50 Years|N/A|No|||October 2015|October 5, 2015|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238588||113448|
NCT01232634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000010841|Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles|External Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles. MRI Correlation.||The Hospital for Sick Children|No|Recruiting|September 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|72|||Male|7 Years|18 Years|No|Non-Probability Sample|Children attending the Hemophilia clinics at the participating institutions (Universidade        de São Paulo, Universidade Federal de São Paulo and Universidade Estadual de Campinas),        who have a history of ankle or knee bleed(s), will be recruited to take part in this        study.|October 2010|November 1, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232634||113903|
NCT01232881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOG COE-03|Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study||Hoosier Cancer Research Network|Yes|Terminated|August 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|27|Samples Without DNA|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed      paraffin embedded tissue block.      Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after      the last dose of lonafarnib.|Both|18 Years|N/A|No|Probability Sample|The study population will be limited to patients with advanced breast cancer receiving        treatment with lonafarnib.|April 2011|April 27, 2011|November 1, 2010||No|funding terminated|No||https://clinicaltrials.gov/show/NCT01232881||113884|
NCT01232894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BIL01|12-week Open-label Evaluation of Efficacy and Safety of Indacaterol|A 12 Week, Multi-center, Randomized, Open Label Study, eValuating the Efficacy and Safety of Treatment Regimens That Include ONbrez (Indacaterol) in Patients With Moderate to Severe COPD (MOVE-ON Study)|MOVE-ON|Novartis|No|Completed|March 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|40 Years|N/A|No|||November 2013|November 18, 2013|November 1, 2010||No||No|May 21, 2013|https://clinicaltrials.gov/show/NCT01232894||113883|
NCT01233141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICLI-2010|Viennese Registry on Patients With Chronic Critical Limb Ischemia|Phase IV Hospital Based Registry to Explore the Outcome of Chronic Critical Limb Ischemia||Medical University of Vienna|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|whole blood, serum, plasma, urine|Both|N/A|N/A|No|Non-Probability Sample|tertiary care centre|November 2010|July 27, 2011|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233141||113864|
NCT01229540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08ZCGYSF01700|Clinical Research on Retinal Neovascularization of Diabetic Retinopathy|||Tianjin Medical University||Terminated||||||N/A|Interventional|N/A|1||||||Both|45 Years|74 Years|Accepts Healthy Volunteers|||September 2008|October 26, 2010|October 26, 2010||||No||https://clinicaltrials.gov/show/NCT01229540||114138|
NCT01229553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5975|Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients|Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients at the CF Center at SUNY Upstate Medical University, Syracuse, NY.||State University of New York - Upstate Medical University|No|Withdrawn|January 2011|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Months|23 Months|No|||May 2015|June 10, 2015|October 26, 2010||No|protocol was never implemented as procedures became standard of care|No||https://clinicaltrials.gov/show/NCT01229553||114137|
NCT01233739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIZACONDRO|Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.|Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Measurement With Sensory and Quantitive Functional Tests and Concordance Analysis With Subjective Scales of Pain.||Hospital Clinic of Barcelona|No|Recruiting|March 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|45 Years|75 Years|No|||February 2013|February 21, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233739||113819|
NCT01229514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB07-00456|Functional Magnetic Resonance Imaging (fMRI) Findings in Children With Early Exposure to General Anesthesia|A Comparison of Functional Magnetic Resonance Imaging (fMRI) Findings in Children With and Without a History of Early Exposure to General Anesthetics||Nationwide Children's Hospital|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|10 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children from Nationwide Children's Hospital|June 2012|August 1, 2012|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229514||114140|
NCT01229527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCSA/Remi 2009|Comparison Between Two Different Dosages of Remifentanil During Colonoscopy|Comparison Between Two Different Dosages of Remifentanil Administered by PCSA (Patient Controlled Sedation and Analgesia) and Meperidine During Colonoscopy: A Randomized Double-Blind Trial||Ospedale San Raffaele||Completed|April 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|3||Actual|90|||Both|18 Years|N/A|No|||January 2012|January 2, 2012|October 26, 2010||No||No|September 19, 2011|https://clinicaltrials.gov/show/NCT01229527||114139|
NCT01230437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-36765-IISP|Montelukast and Nasal Epithelial Cell Inflammatory Responses in Asthma and Rhinitis|The Effect of Montelukast on Inflammatory Responses of Nasal Epithelial Cells Cultured From Patients With Asthma, With and Without Concomitant Allergic Rhinitis||University of Aberdeen|Yes|Not yet recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|10 Years|60 Years|No|Non-Probability Sample|For the primary study the investigators will identify 40 patients (aged 10-60) with with        stable physician confirmed mild/moderate asthma (Steps 1-4 of BTS/SIGN guidelines [3])        with <10 pack-year smoking histories. Twenty of the subjects will have asthma and        concomitant allergic rhinitis (asthma/AR) and 20 will have asthma alone.|October 2010|October 28, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230437||114071|
NCT01230125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|663|Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery|Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|November 2010|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230125||114093|
NCT01231009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN-01-JG|The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis|The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis: a Prospective Randomized Controlled Clinical Trial||Aristotle University Of Thessaloniki|Yes|Recruiting|January 2010|January 2013|Anticipated|January 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2010|October 29, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231009||114027|
NCT01231022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DILI|Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)|Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer|MBC|Beijing Cancer Hospital|Yes|Completed|August 2010|June 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|52|None Retained|patients' blood sample|Female|18 Years|70 Years|No|Non-Probability Sample|female patients with metastatic breast cancer|July 2015|July 27, 2015|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01231022||114026|
NCT01230710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25478|A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression|A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy||Hoffmann-La Roche||Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|October 28, 2010|No|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01230710||114050|
NCT01242228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0110|A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients|A Phase 3, Open-Label, Non-comparative Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Combination With an DPP-4 Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With a DPP-4 Inhibitor Alone.||Astellas Pharma Inc|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01242228||113171|
NCT01242475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESEC-03|A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG|A Phase IIa Specificity Trial of the Diagnostic Agent C-Tb, When Given Intradermally by the Mantoux Technique to Healthy Volunteers Previously Vaccinated With BCG|TESEC-03|Statens Serum Institut|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|151|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242475||113152|
NCT01242150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCHNN16011968|Noninvasive Continuous Positive Airway Pressure (NCPAP) in Children|Noninvasive Continuous Positive Airway Pressure by Helmet or Facial Mask in Children: a Multicenter Randomized Controlled Study|NCPAP|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Completed|December 2008|December 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|1 Month|24 Months|No|||January 2014|January 21, 2014|November 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01242150||113176|
NCT01242462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB NEO 002|Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial|Feasibility of Mid-frequency Ventilation in Newborn Infants With Respiratory Distress Syndrome (RDS): Crossover Pilot Trial||University of Alabama at Birmingham|Yes|Completed|October 2011|May 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|N/A|7 Days|No|||May 2014|May 29, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242462||113153|
NCT01242735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-001|Exercise and Health Intervention for Patients With Obsessive Compulsive Disorder (OCD)|Testing the Efficacy of an Exercise Intervention for Patients With OCD||Butler Hospital|Yes|Completed|November 2010|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||July 2015|July 21, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242735||113133|
NCT01243047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL012|Intermittent Versus Continuous Tarceva Study|Intermittent Versus Continuous Erlotinib With Concomitant Modified 'Xelox' (q3W) in First-line Treatment of Metastatic Colorectal Cancer||Chinese University of Hong Kong|No|Completed|September 2007|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243047||113110|
NCT01238601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Imaging Study of Implants|Upright Magnetic Resonance Imaging (MRI) Study - Breast Implant Shell Geometry and Edge Scalloping|Breast Implant Shell Geometry and Edge Scalloping: A Study Using the Upright MRI Machine||Ideal Implant Incorporated||Completed|July 2007|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|18|||Female|20 Years|50 Years||Non-Probability Sample|Women 20-50 who previously had primary breast augmentation or replacement of existing        breast implants.|November 2010|November 10, 2010|November 9, 2010||||No||https://clinicaltrials.gov/show/NCT01238601||113447|
NCT01238614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLM-CHICA-K-MD|Universal Screening for Maternal Depression With the CHICA System|Universal Screening for Maternal Depression With the CHICA System||Indiana University|No|Completed|October 2007|September 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Actual|3250|||Female|N/A|N/A|No|||November 2010|November 9, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238614||113446|
NCT01232920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00235|First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial|First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial|FAST|University of California, San Francisco|Yes|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|16 Years|N/A|No|||December 2015|December 1, 2015|November 1, 2010||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01232920||113881|
NCT01232907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01570|The Effects of L-carnitine on Fatigue in Spinal Cord Injury|The Effects of L-carnitine on Fatigue in Spinal Cord Injury||University of British Columbia|No|Completed|October 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|19 Years|65 Years|No|||October 2014|October 6, 2014|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232907||113882|
NCT01233154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.27.NRC|Effect of a L. Paracasei Strain on Grass Pollen Allergic Rhinitis Subjects|||Nestlé|No|Completed|October 2007|June 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233154||113863|
NCT01233492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000687653|Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme|A Cancer Research UK Pharmacokinetic Study of BPA in Patients With High Grade Glioma to Optimize Uptake Parameters for Clinical Trials of BNCT||Cancer Research UK||Terminated|October 2007|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|45 Years|75 Years|No|||October 2013|October 7, 2013|November 2, 2010||No|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT01233492||113838|
NCT01229566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRGG-963-002|Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia||Trygg Pharma, Inc.|No|Active, not recruiting|October 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|79 Years|No|||November 2010|November 23, 2011|October 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229566||114136|
NCT01229579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1291-Peds/ERC-09|Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan|Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan: a Randomized, Controlled Trial||Aga Khan University|No|Completed|May 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|320|||Both|N/A|14 Days|No|||October 2010|March 31, 2011|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01229579||114135|
NCT01229826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002112|Magnetic Resonance Elastography (MRE) of Uterine Fibroids|Magnetic Resonance Elastography (MRE) of Uterine Fibroids|MRE|Mayo Clinic|No|Completed|October 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|134|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female individuals between the years of 18 and 65 whose doctor has suggested magentic        resonance imaging of the uterus for treatment of uterine fibroids.|September 2015|September 1, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01229826||114116|
NCT01230138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP187-201|Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis|A Randomised, Double Blind, Placebo Controlled Efficacy and Safety Trial of Different Doses/Dose Regimens of FP187 Compared to Placebo in Moderate to Severe Plaque Psoriasis (Pivotal Registration Study)||Forward-Pharma GmbH|No|Completed|September 2010|May 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|252|||Both|18 Years|90 Years|No|||December 2012|December 9, 2012|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01230138||114092|
NCT01230151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-0002|Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease|Sustained Affect of GUIDE (SAGE):A Software Evaluation Study|SAGE|Intelect Medical, Inc.|No|Withdrawn|December 2010|||December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|N/A|N/A|No|||February 2011|February 17, 2011|October 27, 2010||No|Sponsor (Intelect Medical, Inc.) was acquired by Boston Scientific and study was canceled.|No||https://clinicaltrials.gov/show/NCT01230151||114091|
NCT01230450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI-TOT|Feasibility of Comparing Two Surgical Treatment of Female Urodynamic Stress|Feasibility of Comparing Two Surgical Treatment of Female Urodynamic Stress Incontinence (SITOT)|SITOT|University of Aberdeen|Yes|Completed|November 2009|October 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Female|20 Years|N/A|No|||January 2013|January 23, 2013|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230450||114070|
NCT01230723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S03210|Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography|RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT|ZES/EES-OCT|Deutsches Herzzentrum Muenchen|No|Active, not recruiting|October 2010|July 2012|Anticipated|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230723||114049|
NCT01231035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECLOSE 2-ACS|REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)|REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry|RECLOSE2-ACS|Careggi Hospital|Yes|Completed|September 2008|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1789|||Both|18 Years|N/A|No|Probability Sample|patients with acute coronary syndrome who received invasive treatment and for whom        platelet reactivity after clopidogrel treatment will be prospectively assessed.|July 2011|July 22, 2011|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231035||114025|
NCT01231061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYM008|Spinal met_radiosurgery/SBRT Study|Randomized Phase II Study of Image-Guided Radiosurgery / SBRT for Localized Spine Metastasis||Chinese University of Hong Kong|No|Completed|November 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231061||114024|
NCT01231256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN97/177|Preventive Health Consultations With Young Adults With Multiple Problems|A Study on Preventive Health Consultations in General Practice With Young Adults With Multiple Problems; a Randomised Controlled Study||University of Southern Denmark|No|Terminated|February 1998|December 2015|Anticipated|November 2001|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|495|||Both|20 Years|45 Years|No|||January 2013|October 13, 2014|October 29, 2010||No|Stopped as planned in 2001, follow up in 2010-11|No||https://clinicaltrials.gov/show/NCT01231256||114009|
NCT01231269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51160|Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma|Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma||Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2010|July 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|No|||September 2010|January 15, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231269||114008|
NCT01242241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22091|Propofol in Obese Children|Propofol in Obese Children||Baylor College of Medicine|No|Recruiting|April 2008|December 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Years|17 Years|No|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242241||113170|
NCT01242488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0056|Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy|Randomized, Double-blind, Placebo-controlled, Dose Ranging Study With an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects With Rheumatoid Arthritis Having Previously Failed TNF-blocker Therapy||UCB Pharma|Yes|Completed|November 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|221|||Both|18 Years|N/A|No|||January 2013|August 26, 2014|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242488||113151|
NCT01242761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0092-10-HYMC|Ultrasound as a Diagnostic Tool for Rotator Cuff Tears|Ultrasound as a Diagnostic Tool for Rotator Cuff Tears: Accuracy of Results From the Community Versus Results From a Hospital-based Ultrasound Service and Surgical Findings||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients with symptomatic rotator cuff tears|November 2010|November 16, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242761||113131|
NCT01242748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS35A|A Degarelix Trial in Patients With Prostate Cancer|An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy||Ferring Pharmaceuticals|Yes|Terminated|October 2010|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|288|||Male|18 Years|N/A|No|||May 2015|May 13, 2015|November 16, 2010|Yes|Yes|Inadequate recruitment resulting in a too low patient number for collection of long term    efficacy data.|No|February 26, 2015|https://clinicaltrials.gov/show/NCT01242748||113132|
NCT01243073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP14B015|Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera|A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy|ET/PV|Geron Corporation|No|Completed|December 2010|April 2015|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243073||113108|
NCT01238640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1072|Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab|Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab. A Study in Healthy Smokers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|August 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|84|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|November 9, 2010|Yes|Yes||No|March 11, 2011|https://clinicaltrials.gov/show/NCT01238640||113444|
NCT01243060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEY-1413|Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance|Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance||Northern California Institute of Research and Education|Yes|Completed|May 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|203|||Both|19 Years|39 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243060||113109|
NCT01233193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMM01-FAR-10|The Effect of Pharmacist Intervention on Blood Pressure Control|Pharmacist Intervention Effect on the Medication Adherence and Blood Pressure Control in Treated Patients|AFenPA|Universidad de Granada|No|Active, not recruiting|February 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|18 Years|N/A|No|||February 2010|March 18, 2011|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01233193||113860|
NCT01233167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRRSH-CVD-001|Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation|Benefits and Risks Evaluation of Different Anti-platelet Strategies Beyond a 12-month Period Inpatients Receiving Sirolimus Drug-eluting Stent Implantation|EASTS|Sir Run Run Shaw Hospital|Yes|Not yet recruiting|August 2011|May 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|5232|||Both|18 Years|N/A|No|||October 2010|July 19, 2011|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233167||113862|
NCT01233752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-SM-07-PCA-Gene|Association Between Clinical Effect of Morphine With PCA After Surgery and Pharmacogenetics|Association Between Clinical Effect of Morphine in Patients With PCA After Major Surgery and Pharmacogenetics: Prospective Observational Clinical Study.|PCA-Gene|IRCCS Policlinico S. Matteo|Yes|Completed|July 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|224|Samples With DNA|genes OPRM1, COMT, UGTs, ESR1|Both|18 Years|75 Years|No|Probability Sample|Pazients scheduled for major abdominal or urological surgery with postoperative pain        control by PCA morphine administration|July 2013|July 18, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233752||113818|
NCT01229592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC07/90653|Ethanol in the Prevention of Central Venous Catheter Infections|Clinical Study of Ethanol Lock-therapy in the Prevention of Non-tunnelled, Short Term Central Venous Catheter Associated Infections||Hospital General Universitario Gregorio Marañon|No|Terminated|December 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|October 18, 2010||No|The non significative reduction of CRBSI adverse events,the need for a high frecuency of    catheter manipulations|No||https://clinicaltrials.gov/show/NCT01229592||114134|
NCT01229839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC_S010|Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC|Chemoembolization of Unresectable Hepatocellular Carcinoma With or Without Mixing the Chemotherapy With Lipiodol: Effectiveness and Safety. A Prospective and Randomized Clinical Trial.||Sun Yat-sen University|Yes|Recruiting|August 2013|August 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|668|||Both|18 Years|70 Years|No|||November 2015|March 11, 2016|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01229839||114115|
NCT01229852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-CFS-FM-1|Treatment of Fibromyalgia Using Deep Shaped-Field Transcranial Magnetic Stimulation a Clinical Feasibility Study|Treatment of Fibromyalgia Using Deep Shaped-Field (DSF) Transcranial Magnetic Stimulation (TMS): A Clinical Feasibility Study||Cervel Neurotech, Inc.|No|Completed|August 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|65 Years|No|||May 2014|May 15, 2014|October 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01229852||114114|
NCT01229865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-111-103|Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer|||Vascular Biogenics Ltd. operating as VBL Therapeutics|Yes|Active, not recruiting|December 2010|June 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|October 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229865||114113|
NCT01230164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-016|Comparison of Four Different Aberrometers for Evaluation of Higher Order Visual Aberrations|Comparison of Four Different Aberrometers for Evaluation of Higher Order Visual Aberrations||Massachusetts Eye and Ear Infirmary|No|Completed|August 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal subjects over the age of 18 with visual abberations.|December 2011|December 19, 2011|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230164||114090|
NCT01231074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 0900237|Reducing Antipsychotic-Induced Weight Gain in Children With Metformin|Reducing Antipsychotic-Induced Weight Gain in Children With Metformin|GFMS|Nationwide Children's Hospital|No|Recruiting|February 2010|May 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|10 Years|17 Years|No|||June 2010|October 29, 2010|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231074||114023|
NCT01231087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastrocirurgia|Energy Expenditure Pre and Post Bariatric Surgery|Energy Expenditure in Patients Pre and Post Bariatric Surgery||Gastrocirurgia, Brazil|No|Completed|January 2008|October 2010|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|75 Years|No|Non-Probability Sample|Obese petiets|October 2010|October 29, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231087||114022|
NCT01230736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-243|Safety and Efficacy of Changing to DuoTrav From Prior Therapy|Assessing the Safety and Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients Uncontrolled on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed)||Alcon Research|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||April 2012|July 18, 2012|October 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230736||114048|
NCT01231581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113487|Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer|A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer||GlaxoSmithKline|Yes|Completed|August 2010|February 2013|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|August 30, 2010|No|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01231581||113984|
NCT01231594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114144|A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors|A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors||GlaxoSmithKline|No|Recruiting|November 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01231594||113983|
NCT01231282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52777|Technique Optimization and Anatomy of the Human Body With Whole-body Diffusion-weighted MRI: Study With Healthy Volunteers|Technique Optimization and Anatomy of the Human Body With Whole-body Diffusion-weighted MRI: Study With Healthy Volunteers||Universitaire Ziekenhuizen Leuven|No|Recruiting|November 2010|April 2013|Anticipated|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|January 15, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231282||114007|
NCT01243125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1001|Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation|A Multicenter, Double-blind, Crossover Design, Pilot Study to Evaluate the Effect of NVC-422 Catheter Irrigation on Urinary Catheter Patency||NovaBay Pharmaceuticals, Inc.|No|Completed|November 2010|August 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|67|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243125||113104|
NCT01242501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-113|Brief HIV Prevention Counseling for STI Patients in South Africa|Randomized Trial of a Brief HIV Risk Reduction Counseling Intervention for Sexually Transmitted Infections Clinic Patients in Cape Town, South Africa||University of Connecticut|No|Completed|August 2005|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|617|||Both|18 Years|N/A|No|||November 2010|November 16, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01242501||113150|
NCT01242774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589G2101|Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)|A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)||Novartis||Completed|October 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|65 Years|No|||May 2015|May 5, 2015|October 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242774||113130|
NCT01243086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARP2SJHH|OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab|OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab|STAR|McMaster University|No|Recruiting|March 2011|March 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01243086||113107|
NCT01238653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-LC-2009-02|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures||Pathfinder Therapeutics|Yes|Terminated|November 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject scheduled for a laparoscopic procedure where liver surface visualization and        surface swabbing is feasible with standard port placement.|August 2012|August 7, 2012|November 8, 2010||No|Slow enrollment with limited population for study parameters.|No||https://clinicaltrials.gov/show/NCT01238653||113443|
NCT01238926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-545|Vitamin B6, B12, Folic Acid and Exercise in Parkinson's Disease|Effects of Vitamin Supplementation and Strength Training in Parkinson's Disease||New York Institute of Technology|No|Active, not recruiting|May 2008|November 2010|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|50 Years|80 Years|No|||November 2010|November 10, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238926||113422|
NCT01238939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6012113US|Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer|A Phase I Study of NK012 in Combination With Infusional 5-fluorouracil and Leucovorin in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Colorectal Cancer||Nippon Kayaku Co.,Ltd.||Completed|August 2010|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|November 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238939||113421|
NCT01233206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2010|Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles|Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization||University Magna Graecia|Yes|Completed|May 2009|January 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|35 Years|No|||June 2011|June 9, 2011|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01233206||113859|
NCT01233505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02543|Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors||National Cancer Institute (NCI)||Terminated|October 2010|||October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2013|April 1, 2014|November 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01233505||113837|
NCT01233765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_10-077|Analysis of Neutrophil Response in Chronic Periodontitis|Analysis of Neutrophil Response in Chronic Periodontitis (Including the Project Entitled 'Pro-Inflammatory Cytokine Production by Neutrophils in Periodontitis Patients')||Birmingham Community Healthcare NHS|No|Not yet recruiting|September 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will comprise 20 competent adult volunteers (>18 years old) recruited        from patients attending for clinical examination following referral for a specialist        opinion for periodontal disease, and will be recruited on the basis of clinical need. In        addition, 20 periodontally-healthy controls will be recruited from staff or students of        the School of Dentistry and Biomaterials and Birmingham Dental Hospital.|July 2010|July 21, 2011|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233765||113817|
NCT01233778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE COMIT|Canola Oil Multicentre Intervention Trial (COMIT)|Canola and Flax Oils in Modulation of Vascular Function and Biomarkers of Cardiovascular Disease Risk|COMIT|Penn State University|No|Completed|October 2010|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|5||Actual|43|||Both|20 Years|65 Years|No|||March 2013|March 14, 2013|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233778||113816|
NCT01230190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAMBOO|Management of Eczema by Specific Probiotic Strains|Beyond Conventional Treatment of Atopic Eczema in Infants: Management By Specific prObiOtic Strains|BAMBOO|Agentschap NL|Yes|Withdrawn|March 2011|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|15 Months|Accepts Healthy Volunteers|||March 2011|January 11, 2016|October 28, 2010||No|Because of safety issues/support concerning the multispecies probiotic mixture|No||https://clinicaltrials.gov/show/NCT01230190||114088|
NCT01229878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7539-P|Vitamin D Supplementation on Physical and Cognitive Function-Pilot Study|Vitamin D Supplementation on Physical and Cognitive Function-Pilot Study||VA Office of Research and Development|No|Recruiting|December 2011|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|89 Years|No|||February 2016|February 11, 2016|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229878||114112|
NCT01230177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801134|Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)|Enbrel Qw Special Investigation (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3|||Both|N/A|N/A|No|Probability Sample|Among the patients with rheumatoid arthritis (only for patients with an inadequate        response to prior conventional therapy), the patients who will have changed regimen from        10 mg twice a week administration to 25 mg once a week administration.|November 2013|November 5, 2013|October 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230177||114089|
NCT01230463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23237|Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose.|Intraoperative Ketorolac Dose of 15 mg Versus the Standard 30 mg on Early Postoperative Pain After Spine Surgery: A Randomised, Blinded, Non-Inferiority Trial||University of Calgary|Yes|Recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||October 2010|October 27, 2010|October 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230463||114069|
NCT01230476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-832|Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma|Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma||University of Malaya|No|Terminated|May 2010|||May 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||May 2013|May 29, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01230476||114068|
NCT01231100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCUE2|Hand-carried Ultrasound Echocardiography in the Hospital|Effects of Hand-carried Ultrasound Echocardiography by Hospitalists Among Inpatients Referred for Standard Echocardiography: a Randomized Trial||John H. Stroger Hospital|No|Completed|July 2008|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|453|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01231100||114021|
NCT01231308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002010906|Roux-en-Y-Gastric Bypass vs. Lifestyle Modification and Medical Therapy in the Treatment of Type 2 Diabetes|Roux-en-Y-Gastric Bypass (RYGB) Versus Lifestyle Modification Plus Medical Therapy in the Treatment of Type 2 Diabetes in Overweight-to-Moderately Obese Patients: A Randomized Clinical Trial||Weill Medical College of Cornell University|Yes|Recruiting|October 2010|October 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|65 Years|No|||December 2012|December 20, 2012|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01231308||114005|
NCT01231295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2009/POK-01|Isotopic Imaging for Prodromal Alzheimer's Disease|Evaluating the Performance of Isotopic Brain Imaging of Glucose Metabolism Via PET (18F-FDG) and Perfusion SPECT (99mTc-ECD) for the Diagnosis of Prodromal Stage Alzheimer's Disease|ISALP|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|February 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|143|Samples With DNA|3 x 10ml of blood and 3 ml lumbar puncture for Abeta1-40, A1beta-42, Abetan-40, Abetan-42,      sAPPalpha, Tau, pTau, and DNA extraction for the ApoE4 gene|Both|70 Years|N/A|No|Non-Probability Sample|The study population consists of elderly patients over 70 years of age who consult for        memory problems. These patients are further split into two groups based on the clinical        validation of memory complaints.|November 2015|November 5, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231295||114006|
NCT01231828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A90591-34|Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.|Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. Impact of Lactulose and Carnitine Treatment.|AutoSop-Foie|University Hospital, Caen|Yes|Completed|September 2009|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|55|||Both|18 Years|80 Years|No|||February 2013|February 26, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01231828||113965|
NCT01231815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-007746-58|Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner|Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner|RECOPE|University Hospital, Caen|No|Recruiting|November 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231815||113966|
NCT01242566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P060102|Temozolomide in Elderly Patients With KPS < 70|Phase II Trial of Temozolomide in Elderly Patients With Glioblastoma and Poor Performance Status (KPS<70).|TAG|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2007|September 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|70 Years|N/A|No|||November 2009|November 16, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242566||113145|
NCT01242514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00005|Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)|(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis|OSKIRA-X|AstraZeneca|No|Terminated|January 2011|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1917|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|November 10, 2010|Yes|Yes|AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to    Rigel Pharmaceuticals.|No|December 18, 2013|https://clinicaltrials.gov/show/NCT01242514||113149|
NCT01242527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM-EPA-003|Epanova® for Lowering Very High Triglycerides|Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia|EVOLVE|Omthera Pharmaceuticals, Inc|No|Completed|January 2011|April 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|399|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|November 15, 2010|Yes|Yes||No|June 26, 2013|https://clinicaltrials.gov/show/NCT01242527||113148|
NCT01242813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2203|Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).|An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).||Novartis||Completed|October 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|4 Years|N/A|No|||January 2016|January 5, 2016|November 16, 2010|Yes|Yes||No|November 2, 2015|https://clinicaltrials.gov/show/NCT01242813||113127|
NCT01242787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVCL008|Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B|A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Completed LG-BVCL007 Study|LB80380|LG Life Sciences|No|Active, not recruiting|August 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|66 Years|No|||April 2012|April 13, 2012|November 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01242787||113129|
NCT01242800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000688097|Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer|A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer||Eastern Cooperative Oncology Group|No|Recruiting|February 2011|||June 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|880|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|November 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242800||113128|
NCT01243099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSR-01|Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions|Des Re-Endothelization for In-StEnt ResTenosis. The DESERT Study|DESERT|S.M. Misericordia Hospital|No|Completed|November 2010|July 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|31|||Both|18 Years|90 Years|No|Non-Probability Sample|Paziente affected by either stable coronary artery disease or silent myocardial ischemia|July 2013|July 22, 2013|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01243099||113106|
NCT01238666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-LC-2010-01|Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures||Pathfinder Therapeutics|Yes|Completed|November 2010|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject scheduled for a laparoscopic procedure where liver surface visualization and        surface swabbing is feasible with standard port placement.|March 2012|March 12, 2012|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238666||113442|
NCT01238952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6012121US|Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer|A Phase I Study of NK012 in Combination With Carboplatin in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Triple Negative Metastatic Breast Cancer||Nippon Kayaku Co.,Ltd.||Completed|July 2010|March 2013|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||March 2013|November 12, 2014|November 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238952||113420|
NCT01239212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101335|Dosing of Levetiracetam (Keppra) in Neonates|Pharmacokinetics and Safety of 50 mg/kg IV Levetiracetam (Keppra) in Full Term and Preterm Neonates||Children's Hospital Medical Center, Cincinnati|Yes|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|30 Days|No|||August 2015|August 5, 2015|October 28, 2010|Yes|Yes||No|February 26, 2014|https://clinicaltrials.gov/show/NCT01239212||113400|
NCT01233804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0557|Opting In vs Opting Out|Opting In vs Opting Out: Impact on Influenza Vaccination in Pregnant Women||The University of Texas Health Science Center, Houston|No|Completed|November 2010|August 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|280|||Female|18 Years|N/A|No|||June 2013|June 26, 2013|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01233804||113814|
NCT01233518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-901-001|Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography|Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography|DeFACTO|HeartFlow, Inc.|Yes|Completed|October 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|285|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01233518||113836|
NCT01233791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10025-10-021|Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.|Diazepam Vaginal Suppositories as a Treatment Option for High Tone PElvic Floor Dysfunction: A Randomized Controlled Trial.||TriHealth Inc.|Yes|Completed|November 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|65 Years|No|||July 2015|July 9, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233791||113815|
NCT01230788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00039682|Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia|A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)|Rituximab|Emory University|Yes|Terminated|September 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|1 Year|30 Years|No|||November 2014|November 26, 2014|October 23, 2010|Yes|Yes|Lack of enrollment|No|July 30, 2014|https://clinicaltrials.gov/show/NCT01230788||114044|The one subject was enrolled became a screen failure as she started a prohibited medication prior to going on study.
NCT01230801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM-001|Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease|A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant Human GAA) in Patients With Late-onset Pompe Disease||BioMarin Pharmaceutical|No|Completed|December 2010|February 2014|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|13 Years|N/A|No|||May 2015|May 15, 2015|October 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230801||114043|
NCT01231334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-ACZ1001|A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne|||Allergan|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|286|||Female|18 Years|40 Years|No|||June 2012|June 25, 2012|October 28, 2010|Yes|Yes||No|June 25, 2012|https://clinicaltrials.gov/show/NCT01231334||114003|
NCT01231620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114373|A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza|A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza|ZORO|GlaxoSmithKline|Yes|Completed|January 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|626|||Both|16 Years|N/A|No|||February 2016|February 8, 2016|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231620||113981|
NCT01231841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF7922|Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia|Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA)||The Cleveland Clinic|Yes|Completed|March 2005|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|N/A|No|||March 2013|March 25, 2013|October 29, 2010|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT01231841||113964|
NCT01231321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W06-406|A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis|An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira®) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis||Abbott|Yes|Completed|December 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||April 2011|April 20, 2011|October 28, 2010||No||No|February 25, 2011|https://clinicaltrials.gov/show/NCT01231321||114004|
NCT01231607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114263|Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia|A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia||GlaxoSmithKline|No|Completed|October 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|917|||Male|20 Years|50 Years|No|||August 2013|August 29, 2013|October 28, 2010||No||No|August 30, 2012|https://clinicaltrials.gov/show/NCT01231607||113982|
NCT01232491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3785|Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes|A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin (Levemir DIET)|DIET™|Novo Nordisk A/S|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|611|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|October 29, 2010|Yes|Yes||No|November 14, 2012|https://clinicaltrials.gov/show/NCT01232491||113914|
NCT01232127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-398|Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection|Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine on the Pharmacokinetics of Atazanavir in HIV-Infected Subjects Receiving Atazanavir With Ritonavir and Tenofovir||Bristol-Myers Squibb|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|25|||Both|18 Years|65 Years|No|||August 2012|August 27, 2012|October 29, 2010|Yes|Yes||No|July 23, 2012|https://clinicaltrials.gov/show/NCT01232127||113942|
NCT01232140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATCH study|CRP-guided Antibiotic Treatment in COPD Exacerbations Admitted to the Hospital|CRP-guided Antibiotic Treatment in Patients Hospitalized With Acute Exacerbations of COPD Patients. A Randomized Controlled Intervention Trial.|CATCH|Medical Center Alkmaar|No|Recruiting|July 2011|July 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|40 Years|N/A|No|||March 2012|March 21, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232140||113941|
NCT01207167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MASALA|Mediators of Atherosclerosis in South Asians Living in America|Mediators of Atherosclerosis in South Asians Living in America|MASALA|University of California, San Francisco|No|Active, not recruiting|September 2010|||March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|906|||Both|40 Years|79 Years|No|Probability Sample|South Asians (individuals from India, Pakistan, Nepal, Bangladesh, and Sri Lanka) adults        between the ages of 40 and 79 years without cardiovascular disease living in the San        Francisco Bay Area and Chicago Area.|May 2015|May 14, 2015|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207167||115847|
NCT01238692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-CROC-02|A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)|A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma||Jewish General Hospital|Yes|Active, not recruiting|November 2010|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||December 2014|September 3, 2015|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01238692||113440|
NCT01239004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Welchol-Niaspan 001|Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy|A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia|CERTAIN|Radiant Research|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||January 2012|January 5, 2012|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239004||113416|
NCT01242826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3881|Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects|A Trial Investigating the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 (BIAsp 50) in Healthy Chinese Subjects||Novo Nordisk A/S|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|No|||May 2015|May 28, 2015|November 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01242826||113126|
NCT01243112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090520|Effectiveness Study of Different Local Anesthetic Mixtures|Onset and Duration of Effect of Lidocaine, Bupivacaine, and Lidocaine/Bupivacaine Mixture With Epinephrine.|CA|Scott and White Hospital & Clinic|No|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|25|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|November 17, 2010|Yes|Yes||No|September 15, 2011|https://clinicaltrials.gov/show/NCT01243112||113105|
NCT01238679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701002|Multiple Dose Tolerance Study For PF-04958242|A Phase I, Randomized, Subject And Investigator-Blind, Sponsor Open, Multiple Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Healthy Adult Volunteers||Pfizer|No|Terminated|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2012|November 2, 2010||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01238679||113441|
NCT01238978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AFR03|Phase 4 Study in the Elderly Patients With T2DM|A Multicenter, Prospective, Randomized, Open-label, Parallel Group Study to Investigate the Clinical Benefit on Hypoglycemia Frequency of 24 Weeks Treatment With Galvus Versus Usual Care (Any OAD of Another Class Added to Metformin Within SmPc) in Older Patients With Type 2 Diabetes Insufficiently Controlled by Metformin Monotherapy.|GLYCEMIA|Novartis||Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|65 Years|80 Years|No|||May 2012|May 3, 2012|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238978||113418|
NCT01238991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2571001|Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease|A Phase Iia, Multicenter, Treatment Assigned, Open-label, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease||Pfizer|Yes|Terminated|December 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Both|52 Years|87 Years|No|||December 2014|December 12, 2014|October 21, 2010|No|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01238991||113417|Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.
NCT01239277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-080|Combined Nutrient Intake and Muscle Protein Synthesis|Combined Nutrient Intake and Muscle Protein Synthesis||Maastricht University Medical Center|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|48|||Male|70 Years|85 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2011|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239277||113396|
NCT01238965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3C-08-1|Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy|Phase I Clinical Trial With LBH589 and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU Based Chemotherapy||University of Southern California|Yes|Terminated|October 2010|April 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 3, 2010|Yes|Yes|Adverse Events|No||https://clinicaltrials.gov/show/NCT01238965||113419|
NCT01229930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000687338|Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery|CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer||National Cancer Institute (NCI)||Completed|June 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|||Anticipated|130|||Female|18 Years|N/A|No|||October 2010|August 23, 2013|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229930||114108|
NCT01229605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tufts BR01|Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer|Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer, A Collaborative Trial||Tufts Medical Center|No|Withdrawn|October 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||December 2011|December 8, 2011|October 18, 2010|Yes|Yes|Study was not a good fit for the patient population seen at this hospital.|No||https://clinicaltrials.gov/show/NCT01229605||114133|
NCT01229891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11024|Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink in Diabetic Patients|Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink on Glycemic, Metabolic, Inflammatory, Immunity and Oxidative Stress Markers in Type 2 Diabetes||National Nutrition and Food Technology Institute|Yes|Completed|October 2009|September 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|90|||Both|30 Years|60 Years|No|||December 2011|December 10, 2011|October 27, 2010||No||No|November 6, 2011|https://clinicaltrials.gov/show/NCT01229891||114111|
NCT01229904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 10-075|Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy|Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy||VA Office of Research and Development|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2011|April 6, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229904||114110|
NCT01229917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valio-73|Rhinovirus Study With Lactobacillus Rhamnosus GG|||Valio Ltd||Completed||||||Phase 4|Interventional|N/A|||||||Both|18 Years|65 Years|No|||July 2011|July 6, 2011|October 26, 2010||||No||https://clinicaltrials.gov/show/NCT01229917||114109|
NCT01230489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1771097|The Efficacy of "MediHoney" to Facilitate Catheter Exit-Site Surgical Wound Healing|The Efficacy of "MediHoney" to Facilitate Catheter Exit-Site Surgical Wound Healing and Prevention of Wound Bacterial Colonization: A Randomized, Open-label, Controlled, Clinical Trial||University of Missouri-Columbia|No|Enrolling by invitation|January 2011|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|90 Years|No|||June 2015|June 8, 2015|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230489||114067|
NCT01230502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW H-2010-0121|Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation|Donor Specific Regulation (DSR) Guided Tacrolimus Withdrawal to Myfortic Monotherapy in Liver Transplantation||University of Wisconsin, Madison|Yes|Terminated|November 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|October 27, 2010|Yes|Yes|insufficient study population to meet study objective|No|February 24, 2014|https://clinicaltrials.gov/show/NCT01230502||114066|
NCT01230749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017401|A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Randomized, Placebo- and Active Comparator-Controlled, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of JNJ-41443532 in Subjects With Type 2 Diabetes Mellitus||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|89|||Both|25 Years|65 Years|No|||October 2013|October 17, 2013|October 22, 2010|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01230749||114047|
NCT01230762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR005041|An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation|An Open Label Study of the Long-term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation||Alza Corporation, DE, USA||Completed||April 2005|Actual|||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1774|||Male|18 Years|N/A|No|||January 2011|May 18, 2011|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230762||114046|
NCT01231633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST CRVO 1118147|Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)|Comparative Study of Initial Ozurdex (Dexamethasone Implant) Versus Avastin (Bevacizumab) in the Treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO)||Long Island Vitreoretinal Consultants|No|Completed|September 2010|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231633||113980|
NCT01231854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-TOCYDD-044|Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.|Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis. A Randomized Controlled Investigator-initiated Double-blind Trial.|TocyDD|Technische Universität Dresden|No|Terminated|November 2010|March 2013|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||June 2014|June 2, 2014|October 29, 2010||No|delayed start of the trial, both treatment options already have market authorizations, study    medication expired|No||https://clinicaltrials.gov/show/NCT01231854||113963|
NCT01232153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREOXY|Preoxygenation Before Prehospital Tracheal Intubation With NIV Versus Balloon|Preoxygenation Before Prehospital Tracheal Intubation With NIV Versus Balloon. A Multicenter Randomized Controlled Trial in Mobile Medical Emergency Rescue Service|PREOXY|Hopital of Melun|Yes|Active, not recruiting|September 2015|March 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|230|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232153||113940|
NCT01232166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW464/2003|Which is the Best Bedside Test to Detect Endobronchial Intubation?|Endotracheal Tube Insertion Depth Better Detects Endobronchial Intubation Than Bilateral Auscultation or Observation of Chest Movements - a Prospective Randomised Trial||Medical University of Vienna||Completed|March 2004|June 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|8||Actual|160|||Both|19 Years|75 Years|No|||October 2010|November 1, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232166||113939|
NCT01232179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88100|Comparison of Two Laser Therapy Methods for PDR|Comparison Between Result and Side Effects of Treatment of Prolifrative Diabetic Retinopaty by Conventional and Extended Targeted Pan Retinal Photocoagolation|PDR|hahid Beheshti University of Medical Sciences||Recruiting|October 2010|May 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|N/A|N/A|No|||October 2010|November 1, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232179||113938|
NCT01232192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AACP09|Study of Antenatal Model to Prevent Preterm Delivery|Study of Antenatal Model to Prevent Preterm Delivery: Early Detection and Treatment of Bacterial Vaginosis|AACP|Showa University|No|Recruiting|January 2009|March 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|220|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||March 2009|November 1, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232192||113937|
NCT01232751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 32375.081.10|Effects of Isoflavones on Gene-expression|The Effect of Isoflavone Supplement Intake on Gene-expression in Postmenopausal Women|ISO|Wageningen University|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|30|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01232751||113894|
NCT01207427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2402-001|Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain||Cubist Pharmaceuticals LLC|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|131|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|September 21, 2010|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01207427||115827|
NCT01207440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-10-201|PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)|A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia|PACE|Ariad Pharmaceuticals|Yes|Active, not recruiting|September 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|449|||Both|18 Years|N/A|No|||December 2015|February 12, 2016|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207440||115826|
NCT01239017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R475-PN-1004|A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee|A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Single Dose Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee||Regeneron Pharmaceuticals|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|0|||Both|40 Years|75 Years|No|||March 2015|March 16, 2015|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239017||113415|
NCT01239316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02546|Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma|A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma||National Cancer Institute (NCI)||Completed|November 2010|August 2015|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|3 Years|21 Years|No|||April 2015|December 10, 2015|November 10, 2010|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT01239316||113394|
NCT01219699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719X2101|A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene|A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene||Novartis||Active, not recruiting|October 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01219699||114888|
NCT01220271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11585|A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma|Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma||Eli Lilly and Company|No|Active, not recruiting|April 2011|April 2016|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220271||114844|
NCT01220284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKSD00701|Satraplatin and Vinorelbine in Advanced Solid Tumors|Dose-finding Study of Satraplatin in Combination With Oral Vinorelbine in Patients With Advanced Solid Tumors||Southern Europe New Drug Organization|No|Active, not recruiting|February 2008|February 2011|Anticipated|November 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|75 Years|No|||September 2010|October 11, 2010|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220284||114843|
NCT01220297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT209|Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation||Stanford University|Yes|Terminated|September 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|2 Years|60 Years|No|||October 2011|October 7, 2011|November 24, 2009||No|Low accrual|No||https://clinicaltrials.gov/show/NCT01220297||114842|
NCT01216943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-049|Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension|A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost/0.15% Brimonidine/0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, and Are on Twice-daily 0.2% Brimonidine/0.5% Timolol Ophthalmic Solution (Dual Combination) Therapy||Allergan|No|Completed|November 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|126|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|October 6, 2010|Yes|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01216943||115098|
NCT01217190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OND/CR/020/08-09|Cross-over Bioequivalence Fasting Study to Compare Ondansetron Oral Soluble Film (OSF)With Zofran Orally Disintegrating Tablets(ODT)|An Open-Label Randomized, Single Oral Dose, Two Way Crossover Bioequivalence Study to Compare Ondansetron OSF 8mg (Manufactured by MonoSol RX, USA) With Zofran ODT (Containing Ondansetron 8mg) (Manufactured by Cardinal Health Blagrove, Swindon, Wiltshire, UK, SN58RU for Glaxo Smithkline, Research Triangle Park NC 27709, Made in England) in 48 Healthy, Adult, Human Study Participants Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|September 2008|||September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|July 25, 2011|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217190||115080|
NCT01217489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0308/12|Study Into the Use of Electrical Impedance Mammography in the Diagnosis and Characterisation of Breast Disease|Use of Non-invasive Electrical Impedance Mammography in the Detection, Diagnosis and Characterisation of Breast Lesions|Signascan|Oxford University Hospitals NHS Trust|Yes|Terminated|August 2009|September 2013|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|N/A|No|Non-Probability Sample|Participants to be included will be women referred for NHS investigation of symptomatic        breast lump, following self-examination or picked up by GP. They will generally be in the        age range 40-60 years but no eligible patients over 18 yrs will be excluded from the study        on the basis of age.|February 2013|February 5, 2013|August 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01217489||115057|
NCT01217775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH80 CL019|Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder|A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder|PH80-PMD|Pherin Pharmaceuticals, Inc.|Yes|Not yet recruiting|March 2016|July 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1400|||Female|18 Years|43 Years|No|||December 2015|December 1, 2015|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217775||115035|
NCT01217762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLH001|Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|A Pilot Study to Evaluate the Safety and Tolerability of the IRay Stereotactic Radiosurgery System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)||Oraya Therapeutics, Inc.|No|Active, not recruiting|July 2008|October 2014|Anticipated|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|62|||Both|50 Years|N/A|No|||January 2012|January 18, 2012|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01217762||115036|
NCT01219231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|exercise_neuromod|Effects of Physical Activity on the Brain in Impaired Glucose Tolerance (IGT)|Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons?||Charite University, Berlin, Germany|Yes|Completed|August 2010|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|46|||Both|50 Years|65 Years|No|||March 2016|March 15, 2016|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219231||114923|
NCT01219244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nutrition_memory_01|Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)|Enhancing Memory Functions in Patients With Mild Cognitive Impairment by Dietary Interventions and in Combination With Exercise and Cognitive Training - Proof of Concept and Mechanisms||Charite University, Berlin, Germany|Yes|Recruiting|August 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|330|||Both|50 Years|80 Years|No|||March 2016|March 15, 2016|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219244||114922|
NCT01211535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-59|Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers|Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers||Alcon Research|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|104|||Both|18 Years|N/A|No|||October 2012|October 15, 2012|September 28, 2010|Yes|Yes||No|October 15, 2012|https://clinicaltrials.gov/show/NCT01211535||115513|
NCT01211548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-573|Coronary CT Angiography in Aneurysms Repaired With Open or Endovascular Approach|Coronary CT Angiography in Aneurysms Repaired With Open or Endovascular Approach|CARE|The Cleveland Clinic|Yes|Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01211548||115512|
NCT01219777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09149|Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian|Phase I Evaluation of Intravenous Carboplatin With Weekly Paclitaxel and Bevacizumab in Patients Undergoing Neoadjuvant Chemotherapy for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer||Ohio State University Comprehensive Cancer Center|Yes|Completed|September 2010|May 2015|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Female|18 Years|90 Years|No|||May 2015|June 3, 2015|October 11, 2010|Yes|Yes||No|May 6, 2015|https://clinicaltrials.gov/show/NCT01219777||114882|
NCT01219790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/2-S|ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma|STUDY OF PHASE ID'ACIDE ZOLEDRONIC ASSOCIATED WITH A STRONG DOSE Hypofractionated Radiotherapy in Bone Metastases Vertebral Prostate Adenocarcinoma||Centre René Gauducheau|No|Recruiting|October 2010|||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|30|||Male|18 Years|N/A|No|||October 2010|October 12, 2010|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01219790||114881|
NCT01232764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25048|Pressure Ulcer Multi-disciplinary Teams Via Telemedicine (PUMTT): A Trial in Long Term Care|Pressure Ulcer Multi-disciplinary Teams Via Telemedicine (PUMTT): A Cluster Pragmatic Randomised Controlled Trial in Long Term Care|PUMTT|University of Toronto|Yes|Completed|October 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|137|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232764||113893|
NCT01233245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14192|BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program|BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program||Bayer|No|Completed|April 2004|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1077|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, who were recruited at neurologic practices or specialized neurological centers,        were eligible for selection if they had relapsing-remitting MS (RRMS) or        secondary-progressive MS (SPMS)|November 2012|November 14, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01233245||113856|
NCT01233258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14319|A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A|A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)|Leopold II|Bayer|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|80|||Male|12 Years|65 Years|No|||August 2015|August 12, 2015|November 2, 2010|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01233258||113855|
NCT01233570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33000332|Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease|Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease||University of Aberdeen|No|Completed||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|N/A|No|||November 2010|November 2, 2010|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233570||113832|
NCT01233830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2600C00004|Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers|A Phase I, Single Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Administration of Multiple Ascending Doses for 12 Days in Young and Elderly Healthy Japanese Volunteers||AstraZeneca|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|19|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||April 2011|April 11, 2011|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01233830||113812|
NCT01229631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MULTI-NSA-10-001|The Effect of Daily Dietary Intake of Dried Juice Concentrates of Fruit, Vegetables and Berries Upon Outcomes of Chronic Periodontitis|The Effect of Daily Dietary Intake of Dried Juice Concentrates of Fruit, Vegetables and Berries (Juice Plus+) Upon Periodontal Outcomes in Chronic Periodontitis: A Multicentre Randomised Controlled Trial|ENURGISE|Birmingham Community Healthcare NHS|No|Active, not recruiting|December 2010|March 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|75 Years|No|||September 2014|September 24, 2014|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229631||114131|
NCT01229943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02609|Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery|Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors||National Cancer Institute (NCI)||Active, not recruiting|October 2010|||December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||October 2015|January 13, 2016|October 27, 2010|Yes|Yes||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01229943||114107|
NCT01219712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hip-Op 101a|Optimization Study of Cardiac Risk Patients With Hip Fracture|Preoperative Optimization of the High-Risk Patient Undergoing Hip Fracture Surgery||University Hospital, Linkoeping|Yes|Not yet recruiting|January 2011|February 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||September 2010|October 12, 2010|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01219712||114887|
NCT01219933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25252|A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)|An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE)||Hoffmann-La Roche||Completed|January 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|October 11, 2010|No|Yes||No|August 26, 2014|https://clinicaltrials.gov/show/NCT01219933||114870|
NCT01216592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISLCOPD01|Airway Inflammation, Symptoms and Lung Function in COPD|Correlations Between Airway Inflammation, Symptoms and Lung Functions in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)||Università degli Studi di Ferrara|No|Completed|January 2009|July 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples With DNA|Sputum cells.|Both|40 Years|75 Years|No|Probability Sample|Moderate to severe COPD patients (according to GOLD guidelines) will be enrolled in the        study|December 2011|December 4, 2011|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216592||115125|
NCT01216605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X01A-DO1312/1-1|Oxytocin and Emotion Recognition|||University Hospital Freiburg|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|56|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|October 6, 2010||||No||https://clinicaltrials.gov/show/NCT01216605||115124|
NCT01217216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC28036|Cancer Survival Through Weight Loss and Exercise|Cancer Survival Through Weight Loss and Exercise (CASTLE)|CASTLE|Pennington Biomedical Research Center|Yes|Completed|May 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|52|||Female|30 Years|75 Years|No|||November 2012|November 2, 2012|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01217216||115078|
NCT01217229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-03|Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma|A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma||Plexxikon|No|Completed|December 2010|||May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|October 4, 2010|Yes|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT01217229||115077|
NCT01217788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH94B CL022|Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia|Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia|PH94B-SAD|Pherin Pharmaceuticals, Inc.|Yes|Completed|February 2008|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||May 2011|May 9, 2011|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217788||115034|
NCT01217801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OND/CR/021/08-09/01906|Two Way Crossover Bioequivalence Study to Compare Ondansetron Orally Dissolving Filmstrip 8mg With Zofran Orally Disintegrating Tablets in 48 Participants Under Fed Conditions|An Open-label Randomized, Single Oral Dose, Two Way Crossover Bioequivalence Study to Compare Ondansetron Orally Dissolving FilmStrip (ODFS) 8mg (Manufactured by MonoSol Rx, USA) With Zofran Orally Disintegrating Tablets [ODT® (Containing Ondansetron 8 mg)] (Manufactured by Cardinal Health Blagrove, Swindon, Wiltshire, UK, SN58RU for Glaxo SmithKline, Research Triangle Park, NC 27709, Made in England) in 48 Healthy, Adult, Human Study Participants Under Fed Conditions.||Par Pharmaceutical, Inc.||Completed||||||Phase 3|Interventional|N/A|2||||||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|October 7, 2010||Yes||No||https://clinicaltrials.gov/show/NCT01217801||115033|
NCT01218126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113006|Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).|A Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).||GlaxoSmithKline|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|605|||Both|40 Years|N/A|No|||July 2014|July 16, 2015|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218126||115008|
NCT01218425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3-056|Dopaminergic Modulation of Cognition and Psychomotor Function|Dopaminergic Modulation of Cognition and Psychomotor Function||Maastricht University Medical Center|No|Completed|November 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01218425||114985|
NCT01218087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08120584|Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU|Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU||Children's Hospital Boston|No|Terminated|April 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|88|||Both|N/A|10 Days|No|||July 2015|July 29, 2015|September 30, 2010||No|Study discontinued by DSMB due to loss of equipoise.|No|March 17, 2015|https://clinicaltrials.gov/show/NCT01218087||115011|During the second interim analysis, safety monitors recommended early closure due to loss of study equipoise. Clinical staff had been reporting observable differences in infant head shapes for the two study groups.
NCT01218100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-25|Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension|A Randomized, Double-blind, Parallel-Group Study to Evaluate the Effects of First-Line Treatment With a Free Combination of Nebivolol and Lisinopril Compared With Placebo and the Monotherapy Components on Blood Pressure in Patients With Stage 2 Diastolic Hypertension||Forest Laboratories|No|Completed|October 2010|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|664|||Both|18 Years|64 Years|No|||May 2012|May 18, 2012|October 7, 2010|Yes|Yes||No|May 18, 2012|https://clinicaltrials.gov/show/NCT01218100||115010|
NCT01218113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111679|Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons|Efficacy and Safety of HIV Vaccine 732462 in ART-naïve HIV-1 Infected Persons||GlaxoSmithKline||Completed|November 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|191|||Both|18 Years|55 Years|No|||September 2015|December 3, 2015|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218113||115009|
NCT01215786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|207281-004|Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma|||Allergan|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|October 5, 2010|Yes|Yes||No|December 8, 2011|https://clinicaltrials.gov/show/NCT01215786||115187|
NCT01215799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAFETINIB-P2-HRPC-01|Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer|A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer|PROACT|CytRx|Yes|Completed|August 2010|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|18 Years|N/A|No|||December 2011|December 14, 2011|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215799||115186|
NCT01215812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098013-3|Analysis of Cases of Sexual Assault in Taiwan|||Far Eastern Memorial Hospital||Completed|August 2009|August 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|500|||Female|20 Years|N/A|No|Non-Probability Sample|sexual assault|September 2011|December 1, 2015|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215812||115185|
NCT01215825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098097-3|The Doses of Systemic Steroid in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)|The Therapeutic Impact of Various Doses of Systemic Steroid in Acute Exacerbation of Chronic Obstructive Pulmonary Disease||Far Eastern Memorial Hospital|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|164|||Both|N/A|N/A|No|Non-Probability Sample|From January 2008 to December 2008, patients were admitted and diagnosed as having chronic        obstructive pulmonary disease with acute exacerbation (code ICD-9: 491.21)|January 2010|October 6, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215825||115184|
NCT01211821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV203-003|Effect of BMS-914392 on Pharmacokinetics of Metoprolol|Effect of BMS-914392 on the Pharmacokinetics of Metoprolol and on Heart Rate After Co-administration of BMS-914392 and Metoprolol in Healthy Subjects||Bristol-Myers Squibb|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 1, 2011|September 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01211821||115491|
NCT01211834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-TCZ301|Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and the Safety During Treatment With Tocilizumab vs Placebo in Combination With Traditional DMARD Therapy in Patients With Moderate to Severe Active RA and an Inadequate Response to Current DMARD Therapy||JW Pharmaceutical|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2010|November 1, 2010|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01211834||115490|
NCT01232777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)|Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)|BLOCK-ROP|Vision Research Foundation|Yes|Withdrawn|June 2012|July 2018|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|30 Weeks|36 Weeks|No|||October 2013|October 16, 2013|October 26, 2010|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01232777||113892|
NCT01233024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003E78714|Satiety Response of Four Dietary Fibers|Satiety Response of Fructo-oligosaccharide (FOS), Inulin, Soluble Corn Fiber (SCF), and Resistant Starch (RS) in Overweight Woman and Relationship to Fermentation||University of Minnesota - Clinical and Translational Science Institute|No|Completed|November 2010|February 2012|Actual|February 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01233024||113873|
NCT01233271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0907|Feasibility of Blood Glucose Control With the Space TGC System in Postoperative Cardiac Surgery Patients in the ICU|Single-centre, Open Study to Investigate the Feasibility of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) Over an Extended Glucose Control Range (4.4 to 8.3 mmol/L) for a Maximum of 48 Hours in Postoperative Cardiac Surgery Patients in the ICU|DELIOS 02|B. Braun Melsungen AG|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233271||113854|
NCT01233583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pRGF/009/10|Regulatory T-cells in Psoriasis Patients as Targets for Therapy|Enumeration and Functional Evaluation of Regulatory T-cells in Psoriasis Patients Before and After Treatment With: Calcipotriol/Betamethasone, Acitretin, Narrow-Band UVB and Anti-TNF Alpha Therapy (Etanercept, Adalimumab and Infliximab)||University of Aberdeen|Yes|Completed|June 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|38|Samples Without DNA|Whole Blood Skin biopsy|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients and control in this study will be identified and recruited from the department of        Dermatology by clinical members of the study team.|December 2014|December 2, 2014|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233583||113831|
NCT01233843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2007-02|Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.|A Phase III Randomized Multicenter Study,Comparing an Induction Chemotherapy Followed by Irradiation and Concurrent Erbitux Versus Chemoradiotherapy for Patients With Locoregional Advanced Head and Neck Cancers|2007/02|Groupe Oncologie Radiotherapie Tete et Cou|Yes|Active, not recruiting|May 2009|May 2019|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|370|||Both|18 Years|70 Years|No|||January 2014|January 2, 2014|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01233843||113811|
NCT01233856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/06/VA05|Omega-3 Fatty Acids as an Adjunctive Therapy for Treatment in Attention-Deficit Hyperactivity Disorder (ADHD)|Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD||Maimonides Medical Center||Recruiting|June 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|30|||Both|6 Years|15 Years|No|||August 2011|August 25, 2011|November 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01233856||113810|
NCT01229644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-BRE-001|A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas|A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas||Arog Pharmaceuticals, Inc.||Terminated|April 2011|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|October 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229644||114130|
NCT01216020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eudract 2010-021552-26|Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer|Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC)|CTXMAB+RT|Azienda USL 4 Prato|Yes|Terminated|October 2010|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|October 6, 2010||No|insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01216020||115169|
NCT01216293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR_104|Effect of Dexlansoprazole on Bone Homeostasis|Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dexlansoprazole 60 mg Delayed Release Capsules and Esomeprazole 40 mg Delayed Release Capsules on Bone Homeostasis in Healthy Postmenopausal Female Subjects||Takeda|No|Completed|January 2011|February 2015|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|247|||Female|N/A|75 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01216293||115148|
NCT01216956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIASPAN-C05-36|Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia|Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia||Centre de Recherche en Nutrition Humaine Rhone-Alpe|No|Completed|September 2006|March 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|65 Years|No|||October 2010|October 6, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01216956||115097|
NCT01217502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kalorama 1|Self-management for Dual Sensory Impaired|Self-management for Dual Sensory Impaired Older People and Their Caregivers: an Effective Approach?||Radboud University|Yes|Completed|November 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|89|||Both|55 Years|N/A|No|||November 2014|November 21, 2014|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01217502||115056|
NCT01217515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-AF-09|Diltiazem Hydrochloride Cream for Anal Fissure|A Randomised,Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Diltiazem Hydrochloride Cream in Subjects With Anal Fissure||S.L.A. Pharma AG|No|Completed|October 2010|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|465|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|October 6, 2010||No||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01217515||115055|
NCT01217528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T76|Reduction of Inappropriate Implantable Cardioverter Defibrillator (ICD) Therapies in Primary Prevention Patients|Reduction of Inappropriate ICD Therapies in Patients With Approved Indication for Primary Prevention of Sudden Cardiac Death|DECREASE|St. Jude Medical|Yes|Completed|August 2009|January 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|543|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01217528||115054|
NCT01218139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEGIUS_001|Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients|Analysis of Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients||Katholieke Universiteit Leuven|No|Active, not recruiting|September 2007|December 2010|Anticipated|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|population of NF1 patients, seen by prof. Eric Legius, who are having surgery to remove a        tumor|October 2010|October 8, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218139||115007|
NCT01214876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIGHTMAL|Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires|||Radboud University|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples With DNA|Plasma samples Human DNA samples Parasite DNA samples|Both|1 Year|N/A|Accepts Healthy Volunteers|Probability Sample|Randomly selected individuals living in Abedi, Apac District, Uganda.|August 2010|March 3, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01214876||115256|
NCT01215175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V114-001|Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001 EXT1)(COMPLETED)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar™ in Healthy Adults and Toddlers||Merck Sharp & Dohme Corp.|Yes|Completed|September 2009|January 2011|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|150|||Both|12 Months|45 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|October 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215175||115234|
NCT01218971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-003-EXT|ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)|A Multicenter Double-Blind Extension of Alkermes Study ALK21-003 to Evaluate the Long-Term Safety of Medisorb® Naltrexone||Alkermes, Inc.|No|Completed|August 2002|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||December 2010|December 8, 2010|October 8, 2010|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT01218971||114943|
NCT01212172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-7704|Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction|Side-by-Side Comparison of 810 nm Diode Laser Technology With Low Fluence-High Repetition Rate vs Low Fluence-Vacuum Assist - A Split - Extremity Efficacy , Safety and Tolerability Study||University of California, Irvine|Yes|Completed|September 2010|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|January 7, 2016|September 22, 2010||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01212172||115464|
NCT01212185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0172|Oxytocin Treatment of Alcohol Withdrawal|Oxytocin Treatment of Alcohol Withdrawal||University of North Carolina, Chapel Hill|Yes|Completed|July 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 12, 2014|September 28, 2010|No|Yes||No|December 14, 2013|https://clinicaltrials.gov/show/NCT01212185||115463|
NCT01211561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1122|Colon Cancer Prevention Using Selenium|||University of Illinois at Chicago||Not yet recruiting|December 2010|December 2016|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2010|September 28, 2010|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211561||115511|
NCT01211847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT013|Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind DCCR-Fenofibrate Combination Extension||Essentialis, Inc.|No|Completed|October 2010|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 9, 2014|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211847||115489|
NCT01233050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-05-012087|Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery|A Randomized Double-Blind Study of 2% Chlorhexidine Gluconate / 70% Isopropyl Alcohol vs Iodine Povacrylex [0.7% Available Iodine] / 74% Isopropyl Alcohol for Perioperative Skin Preparation in Open Elective Colorectal Surgery||University of Pennsylvania|Yes|Completed|December 2010|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|802|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 13, 2015|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233050||113871|
NCT01233037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007M86679|Markers of Endothelial Function and Exercise CapaciTy in Patients With Left Ventricular Assist Devices (EFECT LVAD)|Observational Study Assessing Markers of Endothelial Function and Exercise CapaciTy in Patients With Left Ventricular Assist Devices|EFECT-LVAD|University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|October 2010|June 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Some of the blood collected at each visit will stored by the investigator for up to 5 years.      Samples will be kept in our laboratory for up to 5 years as plasma, after which they will be      destroyed. Samples will be identified only by a code number, only the principal investigator      and his research staff will have access to the code. The results of the future tests will      not be communicated to subjects in this study.      The samples are stored in the form of plasma from Peripheral blood for additional markers of      endothelial function (Soluble thrombomodulin, IL-6, etc.)|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the University of Minnesota Cardiology Practice prior to        clinically-indicated LVAD implantation.|December 2015|December 1, 2015|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233037||113872|
NCT01233310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-302|Evaluation of Small Bowel Colon Capsule for Bowel Visualization in Crohn's Disease Patients|Evaluation of Small Bowel Colon Capsule for Bowel Visualization in Crohn's Disease Patients|SBC-CD|Given Imaging Ltd.|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Crohn's disease clinic|August 2012|August 22, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233310||113851|
NCT01233284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.380|Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.|A Phase II Randomised, Double-blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Three Doses of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (1.25, 2.5 and 5.0 Mcg Once Daily) Versus Placebo in Patients With Moderate Persistent Asthma.||Boehringer Ingelheim||Completed|November 2010|||January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|149|||Both|18 Years|75 Years|No|||September 2013|November 27, 2013|November 2, 2010||||No|December 14, 2012|https://clinicaltrials.gov/show/NCT01233284||113853|
NCT01233297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018592-16|Antibiotic Treatment of Recurrent Episodes of Asthma in Children|Antibiotic Treatment of Recurrent Episode of Asthma in Children - a Randomised, Case-controlled Study Within the COPSAC2010 Cohort (Asthma Begins in Childhood)|AB-studie|Copenhagen Studies on Asthma in Childhood|Yes|Active, not recruiting|November 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|1 Year|3 Years|No|||July 2015|July 27, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233297||113852|
NCT01233596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-FNO-2010|Monocanalicular Versus Bicanalicular Intubation in the Treatment of Congenital Nasolacrimal Duct Obstruction|Monocanalicular Versus Bicanalicular Intubation in the Treatment of Congenital Nasolacrimal Duct Obstruction|MCI_vs_BCI|University Hospital Ostrava|Yes|Completed|January 2006|December 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|10 Months|36 Months|No|||March 2015|March 3, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233596||113830|
NCT01233869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871019|Bosutinib For Autosomal Dominant Polycystic Kidney Disease|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)||Pfizer|Yes|Completed|December 2010|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|172|||Both|18 Years|50 Years|No|||February 2016|February 10, 2016|October 28, 2010|Yes|Yes||No|August 26, 2015|https://clinicaltrials.gov/show/NCT01233869||113809|
NCT01233882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871020|Bosutinib In Subjects With Renal Impairment|An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults||Pfizer|No|Completed|December 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 29, 2012|October 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01233882||113808|
NCT01229657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-senU|Evaluation of Anatomic and Visual Outcomes of Initially Closed Macular Holes|Study of the Anatomic and Visual Outcomes in Patients With Initially Closed Macular Holes After Vitreoretinal Surgery||Sun Yat-sen University|Yes|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|79|||Both|N/A|N/A|No|Probability Sample|Patients with initially closed macular holes after vitreoretinal surgery and with one to        seven years of follow-up|October 2010|October 27, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229657||114129|
NCT01229670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-3605B|Effects of Aerobic Interval and Continuous Exercise Trainings in Patients With Chronic Heart Failure|Effects of Aerobic Interval and Continuous Exercise Trainings on Cardiovascular Hemorheological Characteristics and Atherothrombosis/Angiogenesis-related Variables in Patients With Chronic Heart Failure||Chang Gung Memorial Hospital|Yes|Recruiting|July 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01229670||114128|
NCT01216319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-009|Evaluation of the Cook Biodesign Plastic Surgery Matrix|A Single Arm Multicenter Study Evaluating the Cook(R) Biodesign(R) Plastic Surgery Matrix|NRC|Cook||Completed|September 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|October 5, 2010|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01216319||115146|
NCT01216618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080106/A|Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies|Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies||Insuline Medical Ltd.|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||June 2011|September 3, 2014|October 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216618||115123|
NCT01216631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015810-23|Seronegative Oligoarthritis of the Knee Study (SOKS)|Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee|SOKS|University of Leeds|Yes|Recruiting|September 2010|September 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||September 2010|October 6, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216631||115122|
NCT01216982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-10023|Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders|Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders: A Mood Resilience Trial||United States Department of Defense||Active, not recruiting|November 2010|June 2011|Anticipated|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|256|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 8, 2011|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216982||115096|
NCT01217242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD060764|Activity and Participation in Ambulatory Cerebral Palsy|Cross-sectional Descriptive Study to Quantify to What Extent Activity Capacity, Performance and Body Composition Predict Day to Day Life Participation in Ambulatory Children With CP.|APCP|Seattle Children's Hospital|No|Completed|August 2009|December 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|128|||Both|2 Years|9 Years|No|Non-Probability Sample|Children with cerebral palsy (CP) or developmental movement disorder before age two who        are able to walk|January 2012|January 4, 2012|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01217242||115076|
NCT01217814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT11575|Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers|A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis (RA) Who Have Failed Previous TNF-α Antagonists||Sanofi|Yes|Terminated|November 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|75 Years|No|||November 2012|November 9, 2012|October 7, 2010|Yes|Yes|The study was delayed and timelines impacted so that it would not allow completion in a    reasonable timeframe for informing the future clinical development|No||https://clinicaltrials.gov/show/NCT01217814||115032|
NCT01214564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-033|Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis|A Phase 2a, Multi-Centre, Open-Label Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis on Non-head Locations||Peplin|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2011|January 23, 2011|October 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214564||115280|
NCT01215201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|452-09-EP|Diode Laser Study for Periodontal Maintenance Patients|Adjunctive Non-Surgical Therapy of Inflamed Periodontal Pockets Using Diode Lasers During Maintenance Therapy||University of Nebraska|Yes|Active, not recruiting|May 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|110|||Both|30 Years|N/A|No|||October 2010|October 4, 2010|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01215201||115232|
NCT01215188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V114-003|A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM2)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13™ in Healthy Infants||Merck Sharp & Dohme Corp.|Yes|Completed|October 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1152|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2014|December 29, 2014|October 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215188||115233|
NCT01215474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZ-NSCLC 18+|Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC|||Provitro GmbH||Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|500|||Both|N/A|N/A|No|Non-Probability Sample|Patients who were biopsied and/or received surgery for NSCLC diagnostics|October 2010|June 15, 2011|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215474||115211|
NCT01215773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268.59|Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.|Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given 200 mg b.i.d. or 400 mg b.i.d. Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.||Boehringer Ingelheim||Completed|October 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|September 29, 2010||||No||https://clinicaltrials.gov/show/NCT01215773||115188|
NCT01215487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-03255|A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib|A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid in Chronic Phase Receiving Treatment With Imatinib||University of British Columbia|No|Recruiting|October 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Specimens of whole blood will be collected, and used for measurement of sensitivity of the      patient's individual pretreatment colony-forming cells (CFCs) to IM exposure in vitro, the      level of expression of BCR-ABL, OCT1, ABCB1/MDR and ABCG2 transcripts in their CD34+ cells      and the frequency of mutant BCR-ABL transcripts in the same cells. The cells are cultured      for 3 weeks|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be selected from patients referred to the primary hospital site for        treatment and assessment. The patients will be approached by the physicians and or the        study research nurse to consider participation in the study. Patients may be selected by        participating off-site hospital centres and may be enrolled at those collaborating        centres.|March 2015|March 27, 2015|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01215487||115210|
NCT01215500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13619B|Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer|A Study of Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer||University of Chicago|No|Active, not recruiting|January 2005|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|August 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215500||115209|
NCT01212198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNDP-KMC-0505|Korea National Diabetes Program|Clinical Research Center For Type 2 Diabetes Mellitus - Observational Cohort Study of Type 2 Diabetes Mellitus|KNDP|Kyunghee University Medical Center|Yes|Recruiting|May 2005|March 2014|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|6000|Samples With DNA|whole blood, serum, and urine|Both|20 Years|N/A|No|Probability Sample|Korean patients with type 2 diabetes, Koreans at high risk for diabetes, Korean patients        with gestational diabetes|September 2010|October 22, 2010|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212198||115462|
NCT01212419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC #28122|SWC on aEEG in Post-surgical Neonates on Morphine and Midazolam|Effects of Morphine and Midazolam on Sleep-wake Cycling in Amplitude-integrated Electroencephalography in Post-surgical Neonates > 32 Weeks' Gestational Age||Royal Children's Hospital|Yes|Completed|March 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Both|32 Weeks|50 Weeks|No|Non-Probability Sample|newborns > 32 weeks' gestational age post abdominal surgery|September 2010|September 30, 2010|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212419||115445|
NCT01233076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-337-C-034|Clinical Comparison of Two Daily Disposable Contact Lenses in a Population of Daily Disposable Contact Lens Wearers|||Alcon Research||Completed|October 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||January 2012|June 26, 2012|November 1, 2010|Yes|Yes||No|August 5, 2011|https://clinicaltrials.gov/show/NCT01233076||113869|
NCT01233323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETECT PS|Detection of Phrenic Nerve Stimulation Using Sensors' Signals|Detection of Phrenic Nerve Stimulation Using Accelerometer and Electrogram Signals Study|DETECT PS|Guidant Corporation||Completed|February 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with a COGNIS™ CRT-D device|September 2012|September 10, 2012|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233323||113850|
NCT01233609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13371|Trial of Oral Valproic Acid for Retinitis Pigmentosa|A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa|VPA|Foundation Fighting Blindness Clinical Research Institute|Yes|Completed|November 2010|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233609||113829|
NCT01233622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23152|Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride|A Multi-center, Randomized, Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin 50 mg Bid as add-on Therapy to Metformin Plus Glimepiride in Patients With Type 2 Diabetes|Vildagliptin|Novartis||Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|80 Years|No|||September 2012|September 4, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233622||113828|
NCT01233895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED6420|Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma|Open Label Study of the Anti Insulin-like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent (Dose Escalation, Part 1) and in Combination With Velcade® (Combination, Part 2) in Patients With Recurrent, Refractory Multiple Myeloma (MM)||Sanofi|No|Completed|September 2006|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2010|November 2, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01233895||113807|
NCT01233908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7609-DF-CTIL|Diagnosis of Posttraumatic Stress Disorder Following Primary Rhegmatogenous Retinal Detachment|Diagnosis of Posttraumatic Stress Disorder Following Primary Rhegmatogenous Retinal Detachment||Sheba Medical Center|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|547|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects eligible for the study were subjects, above 18 years of age, who underwent        surgical correction for primary rhegmatogenous retinal detachmentat the Goldschleger Eye        Institute, from January 1, 2004 to September 31, 2009, and were followed up for at least 1        month|November 2010|November 2, 2010|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233908||113806|
NCT01229683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Madison Block|Effects of Interscalene Brachial Plexus Nerve Blocks on the Hand and Forearm|Effects of Interscalene Brachial Plexus Nerve Blocks on the Hand and Forearm||University of California, San Diego|No|Completed|October 2010|March 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will consist only of patients undergoing orthopedic shoulder surgery.|March 2012|March 6, 2012|October 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229683||114127|
NCT01229696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Popliteal Bifurcation|Continuous Popliteal Nerve Blocks: Effect of Perineural Catheter Tip Location Relative to the Sciatic Nerve Bifurcation on Postoperative Analgesia|Continuous Popliteal Nerve Blocks: Effect of Perineural Catheter Tip Location Relative to the Sciatic Nerve Bifurcation on Postoperative Analgesia||University of California, San Diego|No|Completed|October 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|October 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229696||114126|
NCT01229982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 11|A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma|A Phase 2 Study Evaluating Safety and Efficacy of the Latanoprost Punctal Plug Delivery System (L PPDS)in Subjects With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||September 2013|September 16, 2013|October 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229982||114104|
NCT01216644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLOT4|5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer|A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach||Krankenhaus Nordwest|Yes|Active, not recruiting|July 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|714|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|June 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01216644||115121|
NCT01216995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANCE|Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)|A Phase II Trial of Safety and Efficacy of ADRCs Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction - The ADVANCE Study|ADVANCE|Cytori Therapeutics|Yes|Completed|September 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|80 Years|No|||November 2014|November 19, 2014|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216995||115095|
NCT01217541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50022|Collaboration Between Department of Old Age Psychiatry and Nursing Homes|Collaboration Between Department of Old Age Psychiatry and Nursing Homes|SAM-AKS|Sykehuset Innlandet HF|Yes|Completed|September 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|700|||Both|N/A|N/A|No|||December 2014|December 11, 2014|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01217541||115053|
NCT01217827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08102010-6708|Implantable Cardioverter-Defibrillator Use in the VA System|Implantable Cardioverter-Defibrillator (ICD) Utilization in a Potentially Eligible VA Population||Stanford University||Completed|April 2010|December 2013|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|March 4, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217827||115031|
NCT01218152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEGIUS_002|Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs|Analysis of Circulating Tumor DNA in Plasma of Neurofibromatosis Type 1 Patients With MPNSTs Using Microarray CGH||Katholieke Universiteit Leuven|No|Active, not recruiting|October 2010|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|cancer patients who are seen in the UZLeuven oncology clinic NF1 patients who are seen in        Germany by Prof. Mautner|October 2010|October 8, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218152||115006|
NCT01218438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170904|Phase 2/3 Study of IGSC, 20% in PIDD|A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)||Baxalta US Inc.|No|Completed|January 2013|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|2 Years|N/A|No|||April 2015|June 26, 2015|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218438||114984|
NCT01214889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I49|Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.|Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Versus Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given Simultaneously at Separate Sites With PRP~T Conjugate Vaccine (ACTHIB™) as a Three-dose Primary Vaccination at 2, 4 and 6 Months of Age in South Korean Infants||Sanofi|No|Completed|September 2010|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|370|||Both|56 Days|70 Days|Accepts Healthy Volunteers|||April 2012|April 13, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214889||115255|
NCT01214902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chamudotctil|Constraint Induced Movement Therapy (CIMT) in Babies Home Program|||Shaare Zedek Medical Center|Yes|Recruiting|May 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|7 Months|18 Months|No|||June 2010|June 20, 2011|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01214902||115254|
NCT01215838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI-2009-1|MRI of the Liver With Eovist|Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)||University of Washington|No|Terminated|August 2010|January 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known hepatocellular carcinoma undergoing MRI of the liver in the UWMC        Radiology Clinic.|October 2013|October 11, 2013|September 28, 2010||No|Unable to meet enrollment expectations.|No||https://clinicaltrials.gov/show/NCT01215838||115183|
NCT01215851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-001-(J-M-Pa-Z)|Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)|A Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Alone, TMC207 Plus Pyrazinamide,TMC207 Plus PA-824,PA-824 Plus Pyrazinamide and PA-824 Plus Pyrazinamide and Moxifloxacin, in Adult Patients With Newly Diagnosed, Smear-Positive Pulmonary Tuberculosis.||Global Alliance for TB Drug Development|No|Completed|October 2010|September 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|85|||Both|18 Years|65 Years|No|||September 2012|September 21, 2012|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01215851||115182|
NCT01211574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2044-10|Pilot Study Testing Professional, Peer, and Mentor Health Coaches for Weight Loss|||The Miriam Hospital||Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211574||115510|
NCT01211587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR701165-024|A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease|A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment||Newron|Yes|Completed|September 2010|||April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|45 Years|80 Years|No|||June 2012|March 28, 2013|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211587||115509|
NCT01211860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK015|Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects|A Multiple-Dose Pharmacokinetic Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects With Elevated Fasting Triglyceride Levels||Essentialis, Inc.|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211860||115488|
NCT01212757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSA-003|PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis|PALACE2|Celgene|Yes|Active, not recruiting|September 2010|January 2017|Anticipated|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|488|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|September 29, 2010|Yes|Yes||No|April 21, 2014|https://clinicaltrials.gov/show/NCT01212757||115419|
NCT01242592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMP/H/01|Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis|Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis: Randomized Placebo Controlled Trial||NMP Medical Research Institute|Yes|Completed|February 2005|June 2008||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|60 Years|No|||November 2010|November 16, 2010|November 16, 2010||||No||https://clinicaltrials.gov/show/NCT01242592||113143|
NCT01233336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.52/VII/10|Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction|Hepatocyte Growth Factor as an Early Marker of Myocardial Injury and Prognostic Factor of Cardiovascular Events in Log-term Follow up in Patients With Acute Coronary Syndrome||Institute of Cardiology, Warsaw, Poland|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|Samples Without DNA|plasma for HGF concentration|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with acute coronary syndrome admitted to CCU due to symptoms of ACS.|February 2013|February 4, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233336||113849|
NCT01233635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0507061|Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)|Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)||University of Pittsburgh||Terminated|November 2005|November 2007|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|228|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 2, 2010||No|inadequate enrollment rate|No||https://clinicaltrials.gov/show/NCT01233635||113827|
NCT01233648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0601113|Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)|Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)||University of Pittsburgh||Completed|June 2006|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233648||113826|
NCT01233921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2437.00|Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer|A Preliminary Study to Evaluate the Effects of Palifermin in Patients at Risk of Chronic Graft-versus-host Disease||Fred Hutchinson Cancer Research Center|No|Completed|September 2010|||July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|6|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|November 2, 2010|No|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT01233921||113805|
NCT01229709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8935-35834-01|Mindfulness Based Tinnitus Reduction (MBTR): A Symptom Perception Shift Program|Phase 2 Mindfulness Based Tinnitus Reduction (MBTR) Study: A Symptom Perception Shift Program|MBTR|University of California, San Francisco|Yes|Completed|January 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 26, 2014|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229709||114125|
NCT01229995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M17719-104|Randomized Controlled Clinical Trial of CAD/CAM and Conventionally Fabricated Singl Implant Abutments.|A Comparison of Zirconia CAD/CAM and Conventionally Fabricated Single Implant Abutments and Restorations in the Esthetic Zone: a Randomized Controlled Clinical Trial.||Harvard School of Dental Medicine|Yes|Active, not recruiting|May 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study|1||Actual|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 27, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01229995||114103|
NCT01230008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|katty7|Radiotherapy in Primary Mediastinal Lymphoma|Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP|pml|Instituto Mexicano del Seguro Social|No|Completed|June 2002|December 2009|Actual|June 2007|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|198|||Both|18 Years|65 Years|No|Probability Sample|Patients with primary mediastinal lymphoma treated in an tertiary medical center|June 2009|October 27, 2010|October 27, 2010||||No||https://clinicaltrials.gov/show/NCT01230008||114102|
NCT01216657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S379 SUMA|Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma|An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma||Krankenhaus Nordwest||Terminated|March 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|April 12, 2010||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT01216657||115120|
NCT01216670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-CARRYINGONforHF|Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure|Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure|CARRYINGON|Medtronic Italia|No|Completed|February 2011|May 2014|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|N/A|No|Probability Sample|Hf patients without indication to permanent device implant (PM/ICD/CRT)|February 2013|October 12, 2015|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01216670||115119|
NCT01217554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K09158ctil|Kinematical Evaluation of Lumbar Rotation in Chronic Low Back Pain|Kinematical Evaluation of Lumbar Rotation in Neutral Position and Full Flexion in Sitting and Standing in Patients With Non-specific Chronic Low Back Pain||Clalit Health Services|No|Completed|February 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Male|40 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Individuals referred to physiotherapy for LBP|February 2012|February 8, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217554||115052|
NCT01214317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|389050|Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis|Study of Combinative Effect of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Patients With Aggressive Multiple Sclerosis|IMPAMS|Isfahan University of Medical Sciences|Yes|Active, not recruiting|January 2010|February 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|55 Years|No|||August 2010|August 16, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01214317||115299|
NCT01214330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20100177H|Clinician-Collected Versus Patient-Collected Cervical Pap Smears|A Pilot Study for a Non-Inferiority Trial of Clinician-Collected Versus Patient-Collected Cervical Papanicolaou Smears|SoloPaP|Mike O'Callaghan Federal Hospital|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 20, 2014|September 30, 2010|Yes|Yes||No|October 10, 2014|https://clinicaltrials.gov/show/NCT01214330||115298|Limitations:Higher socioeconomic status of participants
NCT01214577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-036|Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin|A Phase 2a, Multi-Centre, Single Arm Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin on the Face||Peplin|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|30 Years|65 Years|No|||January 2011|January 23, 2011|October 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214577||115279|
NCT01215513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS42A|Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients|An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy||Ferring Pharmaceuticals|No|Completed|September 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|127|||Male|18 Years|N/A|No|||April 2013|April 4, 2013|October 5, 2010|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01215513||115208|
NCT01215526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS46|A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer|Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands|FAST-NL|Ferring Pharmaceuticals|No|Completed|October 2010|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|274|||Male|N/A|N/A|No|Non-Probability Sample|Patients with advanced prostate cancer|August 2015|August 18, 2015|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215526||115207|
NCT01215864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T10-10646|Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors|A Multicenter Phase I Study of TCD-717 Given by 4-Hour Intravenous Infusion in Patients With Advanced Solid Tumors||Traslational Cancer Drugs Pharma, SL||Completed|January 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215864||115181|
NCT01211899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|f2000tj2|4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock|Incidence and Prognosis of Disseminated Intravscular Coagulation in Patients Severe Sepsis and Septic Shock; Association With 4G/5G Polymorphism of PAI-1 Gene||Hallym University Medical Center|Yes|Not yet recruiting|September 2010|||September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|Blood sample for 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1)|Both|18 Years|N/A|No|Probability Sample|Patients admitted to the ICU for severe sepsis or septic shock|September 2010|October 4, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01211899||115485|
NCT01211600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10D.199|Cesarean Trial of Staples vs. Sutures|Cesarean Randomized Control Trial Of Sutures vs. Staples (CROSS)|CROSS|Thomas Jefferson University|No|Active, not recruiting|June 2010|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|936|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 4, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211600||115508|
NCT01211873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-050|Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions|Safety and Efficacy Evaluation of DOTAREM® in Magnetic Resonance Imaging (MRI) in Patients With Central Nervous System (CNS) Lesions.|SENTIO|Guerbet|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|416|||Both|2 Years|N/A|No|||April 2014|April 29, 2014|September 28, 2010|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01211873||115487|
NCT01211886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|f2000tj1|Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)|Utility of BNP in Patients With Type IV Cardio-renal Syndrome Admitted to the ICU: a Prospective Observational Study||Hallym University Medical Center|Yes|Not yet recruiting|September 2010|||August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|83|Samples Without DNA|Serum sample for BNP level|Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic kidney disease admitted to the ICU for acute heart failure (i.e.,        type IV cardio-renal syndrome)|September 2010|October 4, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01211886||115486|
NCT01217372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMONE|Nephrolithiasis Prevention by Lemon Juice|A Prospective, Randomized, Open Blind Endpoint (Probe) Trial to Assess the Possibility to Prevent Stone Recurrence by Lemon Juice Supplementation in Patients With Recurrent Calcium Oxalate Nephrolithiasis (LIMONE Study)|LIMONE|Mario Negri Institute for Pharmacological Research|No|Recruiting|January 2009|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|202|||Both|18 Years|80 Years|No|||October 2015|October 9, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01217372||115066|
NCT01217385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000674337|Diffuse Optical Spectroscopy Imaging in Monitoring and Predicting Response in Patients With Locally Advanced Breast Cancer Undergoing Chemotherapy Before Surgery|Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)|ACRIN 6691|American College of Radiology Imaging Network|Yes|Active, not recruiting|March 2011|||June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|No|||October 2013|October 14, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217385||115065|
NCT01243216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1167437|Does Ultrasound of the Spine Improve Labor Epidurals/Spinal Anesthesia in Obstetric Patients?|The Utility of Pre-procedure Ultrasound for Neuraxial Analgesia/Anesthesia in Obstetric Patients||University of Missouri-Columbia|Yes|Recruiting|October 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||September 2010|November 17, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01243216||113097|
NCT01242878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/0270|MACS Study - Microparticles and Coagulation in Sickle Cell Disease|MACS Study - Microparticles and Coagulation in Sickle Cell Disease: An Observational Study to Measure the Levels of Circulating Microvesicles and Coagulation Activation Parameters in Patients With Sickle Cell Disease in the in- and Out-patient Setting.|MACS|University College, London|No|Not yet recruiting|December 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|360|Samples Without DNA|plasma will be retained following appropriate informed written consent for further ethically      approved studies as stipulated on the consent forms|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is an observational case-control study in adults and children with sickle cell        disease. The cases are any child or adult attending the study centres with a confirmed        diagnosis of sickle cell disease that meet the eligibility criteria. The controls are        ethnically matched volunteers who meet the appropriate eligibility criteria for controls        and who do not have sickle cell disease and will be recruited from the same study sites.|November 2010|November 17, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242878||113122|
NCT01242891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCOR® Continued Access|Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device Under a Continued Access Protocol|A Prospective, Multi-center, Single Arm Study to Assess the Safety and Probable Benefit of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device (EXCOR® Pediatric)Under a Continued Access Protocol.|CAP|Berlin Heart, Inc||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|16 Years||||March 2012|March 2, 2012|November 16, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01242891||113121|
NCT01243190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0241|Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)|Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2011|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243190||113099|
NCT01243203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA30517W|Smoking Cessation Program in the Preadmission Clinic: The Use of a Teachable Moment|||University Health Network, Toronto|No|Completed|November 2007|November 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|300|||Both|18 Years|N/A|No|||November 2013|December 17, 2013|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01243203||113098|
NCT01238744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B271|Flaxseed Mucilage and Satiety|Effect of Flaxseed Mucilage Drinks and Tablets on Satiety and Energy Intake|MUCISAT|University of Copenhagen|No|Active, not recruiting|August 2009|December 2010|Anticipated|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|45|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01238744||113436|
NCT01239069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30-002|Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease|A Phase II, Prospective, Randomized, Observer-masked, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of Two Concentrations Compared to Placebo for the Treatment of Dry Eye Disease||Santen Inc.||Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|140|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239069||113411|
NCT01239355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02549|MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy|A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy||National Cancer Institute (NCI)||Terminated|December 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2013|September 3, 2015|November 10, 2010|Yes|Yes|Early termination for discouraging results|No|June 10, 2015|https://clinicaltrials.gov/show/NCT01239355||113391|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results
NCT01239368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110016|Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma|Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|August 2019|Anticipated|November 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|75 Years|No|||January 2016|March 3, 2016|November 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01239368||113390|
NCT01239680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-18|Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy|Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy.||University of Missouri, Kansas City|No|Completed|January 2011|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|21 Years|65 Years|No|||May 2014|May 14, 2014|October 12, 2010||No||No|December 30, 2013|https://clinicaltrials.gov/show/NCT01239680||113366|Many subjects excluded due to being unstable after initial resuscitation, having altered mental status, inability to speak English, <21 years of age, or blood alcohol in excess of 80mg/dl. No waiver of consent.
NCT01239914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COACT|CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)|CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)|COACT|The Catholic University of Korea|Yes|Recruiting|January 2005|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|11000|Samples With DNA|Whole blood, serum and DNA|Both|18 Years|N/A|No|Non-Probability Sample|all comers who admitted cardiovascular center for coronary stent implantation|July 2010|August 24, 2012|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01239914||113348|
NCT01239927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRTHRAPDP|Hartmann vs R/A in Peritonitis by Perforated Diverticulitis|Hartmann vs Resection With Anastomosis and Diverting Stoma for Peritonitis Caused by Perforated Left-sided Colon Diverticulitis: a Multicenter Prospective Randomized Study.||Ente Ospedaliero Ospedali Galliera|Yes|Completed|January 2000|July 2010|Actual|July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|100|||Both|N/A|N/A|No|||July 2010|November 12, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01239927||113347|
NCT01217255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000020214|Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World|Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World: The Sao Paulo - Toronto Hemophilia Study||The Hospital for Sick Children|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Male|7 Years|18 Years|No|Probability Sample|Participants will be a representative (random) sample of individuals from the        comprehensive hemophilia treatment centres at HCFMUSP and SickKids. Boys between the ages        of 7 and 18 years (inclusive) will be identified from the clinic ledgers at each of the        centres. Using a computer generated random number list, proportionately stratified for        Hemophilia A and B, and for moderate and severe disease (based on the baseline clinic        proportions)|December 2013|December 17, 2013|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217255||115075|
NCT01214044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD-132|Circadian Effects of Escitalopram|Circadian Effects of Escitalopram||Oregon Health and Science University|Yes|Recruiting|May 2008|||May 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|65 Years|No|||October 2010|October 1, 2010|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01214044||115320|
NCT01214915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-308|Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia|A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment||Shire||Completed|November 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|20 Years|N/A|No|||September 2013|September 27, 2013|October 4, 2010|No|Yes||No|July 24, 2013|https://clinicaltrials.gov/show/NCT01214915||115253|
NCT01215214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT10_CYP3A|Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics|Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics||Seoul National University Hospital|No|Completed|October 2010|January 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 19, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01215214||115231|
NCT01215539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 6A/09|Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients|A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS.||Hellenic Cooperative Oncology Group|No|Completed|September 2010|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01215539||115206|
NCT01215552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-0712-006|Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712|A PET Study: Single-dose, Open-label Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712||Dart NeuroScience, LLC|No|Terminated|September 2010|January 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|3|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||May 2011|May 27, 2011|September 24, 2010|No|Yes|The experimental design was not sufficient to answer the proposed questions. A new study    design is now being considered.|No||https://clinicaltrials.gov/show/NCT01215552||115205|
NCT01211912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003283|Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-being|Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-being||Mayo Clinic|No|Completed|September 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|56|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211912||115484|
NCT01212211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00778-31|Hyponatremia in the Elderly: Benefit From a Change in Drug Therapy?|Hyponatremia in the Elderly: Benefit From a Change in Drug Therapy?|NATRIPHAR|University Hospital, Caen|No|Completed|December 2010|May 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|18|||Both|65 Years|N/A|No|||May 2012|May 22, 2012|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01212211||115461|
NCT01212224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS37|A Study of Minirin Melt in Patients With Nocturia|Retrospective Safety Study in 12 Months Treatment Nocturia With Minirin Melt in Clinical Practice in Czech Republic||Ferring Pharmaceuticals|No|Completed|January 2010|December 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|2187|||Both|18 Years|64 Years|No|Non-Probability Sample|primary care clinic|January 2014|January 3, 2014|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01212224||115460|
NCT01212458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.03|Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study|||University of Zurich||Completed|October 2010|January 2013|Actual|January 2013|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|24|||Male|18 Years|65 Years|No|Non-Probability Sample|healthy volunteers|March 2014|March 14, 2014|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212458||115442|
NCT01212471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00007|A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease|||Bausch & Lomb Incorporated|No|Completed|September 2010|December 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|840|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212471||115441|
NCT01243229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35848|Genetic Analysis of Congenital Diaphragmatic Disorders|Genetic Analysis of Congenital Diaphragmatic Disorders||University of Utah|No|Recruiting|October 2010|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|400|Samples With DNA|Blood or buccal swabs|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Newborns, children and adults affected by congenital disorders of the diaphragm, such as        congenital diaphragmatic hernia, eventration and hiatal hernia.|July 2015|July 13, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01243229||113096|
NCT01243242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL008|Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)|Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder||Alcobra Ltd.|No|Completed|February 2011|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|50 Years|No|||April 2012|April 17, 2012|November 17, 2010||No||No|October 30, 2011|https://clinicaltrials.gov/show/NCT01243242||113095|
NCT01238757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG-matped 09-054|Patient-ventilator Asynchrony During Mechanical Non-Invasive Assisted-ventilation in Pediatric Patients (NavPed-NI)|Patient-ventilator Asynchrony During Mechanical Non-Invasive Assisted-ventilation in Pediatric Patients|NavPed-NI|University Hospital, Geneva|Yes|Recruiting|June 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|N/A|5 Years|No|||August 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01238757||113435|
NCT01239082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|577|Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)|CSP #577 - Colonoscopy vs. Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer|CONFIRM|VA Office of Research and Development|Yes|Recruiting|April 2012|September 2027|Anticipated|September 2027|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50000|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 18, 2016|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01239082||113410|
NCT01239381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-139|Individualized Stereotactic Body Radiotherapy of Liver Metastases|Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases||Massachusetts General Hospital|Yes|Active, not recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01239381||113389|
NCT01239394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-271|Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma|Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma||Massachusetts General Hospital|Yes|Active, not recruiting|November 2011|July 2015|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239394||113388|
NCT01239693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iLiNS-DYAD-M|Supplementing Maternal and Infant Diet With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS)|A Research Plan for a Randomised, Single-blind, Parallel Group Controlled Trial in Rural Malawi, Testing the Health Effects of Supplementing Maternal Diet During Pregnancy and Lactation and Infant Diet From 6 to 18 Months of Age With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS)|iLiNS-DYAD-M|University of Tampere|Yes|Active, not recruiting|February 2011|December 2015|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1391|||Both|15 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 1, 2015|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239693||113365|
NCT01239940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIBS IV|RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)|RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial|RIBS IV|Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular|Yes|Recruiting|January 2010|||July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|310|||Both|20 Years|85 Years|No|||November 2010|June 23, 2011|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01239940||113346|
NCT01240161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000554|Personalized Translational Platform for Biomarker Discovery in Brain Tumors|Personalized Translational Platform for Biomarker Discovery in Brain Tumors||Brigham and Women's Hospital|No|Recruiting|December 2009|December 2015|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients presenting to BWH/DFCI emergency department (ED), inpatient, or neurology/        neurosurgery/ radiation oncology clinics with newly diagnosed brain masses (suspected high        grade gliomas) will be consented and enrolled in this study after adequate explanation of        the risks and benefits of the study.|December 2013|December 13, 2013|November 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240161||113329|
NCT01213758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AarhusLiverRadGal|Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT|Radiation Induced Change of Liver Function Measured by Uptake of the Galactose Analogue FDGal and PET/CT||University of Aarhus|No|Recruiting|June 2010|May 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|85 Years|No|||March 2012|March 21, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213758||115342|
NCT01217268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESAM|Use of Telemedicine in Collaboration Between a Psychogeriatric Unit and Nursing Homes|Use of Telemedicine in Collaboration Between a Psychogeriatric Unit and Nursing|TESAM|Sykehuset Innlandet HF|No|Recruiting|October 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|15|||Both|N/A|N/A|No|||May 2011|May 5, 2011|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01217268||115074|
NCT01217281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143|The Effect of Non-surgical Periodontal Treatment in the Renal Function of Patients With Chronic Kidney Disease: RCT|The Effect of Non-surgical Periodontal Treatment in the Renal Function of Patients With Chronic Kidney Disease: A Randomized Clinical Trial||University of Athens|No|Recruiting|June 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217281||115073|
NCT01214590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAS-02|Preliminary Assessment of the Efficacy of the VascuActive™ Device on Diabetic Peripheral Neuropathy|Preliminary Assessment of the Efficacy of the VascuActive™ Device on Diabetic Peripheral Neuropathy||VascuActive LTD|No|Recruiting|March 2011|||February 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01214590||115278|
NCT01214603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13370|A Study in Participants With Acute Leukemia|A Phase 2 Study of LY2090314 in Participants With Acute Leukemia||Eli Lilly and Company|No|Completed|November 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||February 2013|April 30, 2013|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214603||115277|
NCT01214928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJH PSI 001|Hemodialysis Vitamin D Pilot|Oral Cholecalciferol (Vitamin D3) Therapy in Prevalent Hemodialysis Patients: A Randomized Placebo Controlled Pilot Study||St. Joseph's Healthcare Hamilton|Yes|Completed|January 2011|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2011|July 19, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01214928||115252|
NCT01215227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06153|An Active-Controlled Extension Study to P04938 and P07037 (P06153 AM3)|A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)||Merck Sharp & Dohme Corp.|Yes|Terminated|November 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|841|||Both|30 Years|85 Years|No|||October 2015|October 6, 2015|October 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215227||115230|
NCT01215240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-LR-001|Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure|Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure||University of Alberta|Yes|Completed|September 2010|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|30 Days|No|||June 2015|June 22, 2015|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01215240||115229|
NCT01211613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10040327|Chiropractic Manipulation and Medical Care for Low Back Pain|A Comparison of Chiropractic Manipulation Methods and Standard Medical Care for Low Back Pain||University of Pittsburgh|Yes|Completed|November 2010|October 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|107|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|September 28, 2010||No||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01211613||115507|
NCT01216163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-09-14|Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain|Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain||Pfizer|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|218|||Both|16 Years|40 Years|No|||July 2012|July 13, 2012|October 5, 2010|Yes|Yes||No|July 12, 2012|https://clinicaltrials.gov/show/NCT01216163||115158|
NCT01216462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFN/117/09/AL|Registry of Acute Coronary Syndromes in the Lazio Region of Italy|First Prospective Observational Registry of the Lazio Regional Network for Acute Coronary Syndromes|NET-SCA|San Filippo Neri General Hospital|Yes|Recruiting|January 2010|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Whole blood|Both|N/A|N/A|No|Probability Sample|Consecutive patients with ACS admitted to CCU of 15 hospitals of the Lazio Region of        Italy.|May 2015|May 20, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216462||115135|
NCT01216475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R788/72/2010|Randomized, Non-inferiority Trial Comparing SMILE and LASIK|Comparison of Small Incision Lenticule Extraction (SMILE) and VisuMax Femtosecond Laser In Situ Keratomileusis (FemtoLASIK): A Randomized, Non-inferiority Trial||Singapore National Eye Centre|Yes|Recruiting|February 2012|March 2015|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 15, 2012|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01216475||115134|
NCT01216761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N010316 - 1932.II|A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions|Blood Culture Contamination: A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions||University of Michigan|No|Completed|May 2008|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3879|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|October 6, 2010||No||No|October 7, 2011|https://clinicaltrials.gov/show/NCT01216761||115112|It is possible for subjects to have multiple blood culture sets obtained during the study.Thus, the # of blood culture sets will not equal the # of subjects. Also, cross-over assignment occurred at the hospital floor level - not the subject level.
NCT01216774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52680|The Role of Mechanical Stress and Muscle Fatigue in Strength Gains|||Universitaire Ziekenhuizen Leuven||Completed|September 2010|||December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|36|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||September 2010|June 15, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216774||115111|
NCT01217073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-006|A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)|A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|No|Completed|October 2010|April 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|685|||Both|18 Years|70 Years|No|||November 2015|November 25, 2015|October 6, 2010|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01217073||115089|
NCT01217086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 3.1|Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)|Randomized, Double-blind, Parallel-group, Phase 3 Study||Celltrion|Yes|Completed|October 2010|July 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|617|||Both|18 Years|75 Years|No|||March 2013|March 11, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01217086||115088|
NCT01217411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02533|RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer|Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative||National Cancer Institute (NCI)||Terminated|October 2010|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||October 2011|January 22, 2015|October 7, 2010|Yes|Yes|Slow accrual coupled with discontinuation of study drug.|No|January 22, 2015|https://clinicaltrials.gov/show/NCT01217411||115063|Due to small number of patients enrolled on study, researchers were unable to make meaningful conclusions from the data.
NCT01230645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH003|RV568 - Viral Challenge With RSV|A Randomized, Single-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Intranasal RV568 (400μg) Administered Twice Daily to Adult Male Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus||Respivert Ltd|No|Completed|October 2010|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230645||114055|
NCT01230658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STV IRB R2009-111|Prophylactic Enoxaparin Dosing in Roux-en-Y Gastric Bypass Surgery Patients at St. Vincent Carmel|Prophylactic Enoxaparin Dosing in Roux-en-Y Gastric Bypass Surgery Patients at the St. Vincent Carmel Bariatric Center of Excellence||St. Vincent Carmel Hospital|No|Completed|January 2010|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 years or older undergoing primary roux-en-Y gastric bypass surgery at St.        Vincent Carmel Bariatric Center of Excellence.|November 2012|November 5, 2012|October 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01230658||114054|
NCT01230944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/2004|Conventional Nissen Fundoplication Versus Laparoscopic Nissen Fundoplication|Conventional Nissen Fundoplication vs. Laparoscopic Nissen Fundoplication: a Prospective Randomized Study, Long-term Follow-up||Turku University Hospital|No|Completed|December 2004|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|80 Years|No|||October 2010|October 28, 2010|June 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01230944||114032|
NCT01238770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3107000|Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer|A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer||University Hospital Heidelberg|Yes|Completed|November 2010|October 2015|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||February 2016|February 8, 2016|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01238770||113434|
NCT01238783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-061|Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis|||Alcon Research|No|Withdrawn|January 2011|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|5 Years|N/A|No|||November 2011|November 29, 2011|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01238783||113433|
NCT01238796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9809-CL-1407|A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin|A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin||Theravance Biopharma Antibiotics, Inc.|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|45|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|November 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238796||113432|
NCT01230918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI Protocol #2009641-01H|Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis|Technetium-NC100692 SCintigraphy to Detect avB3 Integrin Expression as a mARker of Fibrosis in Hypertrophic Cardiomyopathy and Acute Coronary Syndrome: the SCAR Study|SCAR|Ottawa Heart Institute Research Corporation|No|Recruiting|May 2011|September 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230918||114034|
NCT01230931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0654|Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel)|Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat||The University of Texas Health Science Center, Houston|No|Recruiting|October 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||June 2012|June 12, 2012|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230931||114033|
NCT01231191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV Acetaminophen|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures|Cadence|University of California, San Diego|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|October 27, 2010|Yes|Yes|study not funded|No||https://clinicaltrials.gov/show/NCT01231191||114014|
NCT01231438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS2010GOLA01|Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.|An Open, Randomized, Crossover Phase 2 Pilot Study of Treatment of Stage 3B Renal Failure With Active Vitamin D or a Phosphate Binder to Evaluate the Effect on the FGF23 and PTH Levels.||Helse Stavanger HF|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|October 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231438||113995|
NCT01231451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 038|Depot Contraception With and Without Lopinavir/Ritonavir|The Pharmacokinetics of Depot Medroxyprogesterone Acetate (DMPA) in the Absence and Presence of Lopinavir/Ritonavir in HIV-1 Infected Women||St Stephens Aids Trust|No|Withdrawn|December 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Female|18 Years|45 Years|No|||November 2010|November 25, 2010|October 29, 2010||No|Ethics board said the study could not be fully justified.|No||https://clinicaltrials.gov/show/NCT01231451||113994|
NCT01231711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24633-1|Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention|Improving Quality-of-life and Depressive Symptoms for OEF/OIF Combat Veterans: Assessing the Benefits of Interactive, Internet-based Psychotherapy and Peer-to-peer Support||Prevail Health Solutions, LLC|No|Completed|September 2009|June 2010|Actual|February 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|No|||October 2010|October 29, 2010|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231711||113974|
NCT01213771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS2008|Health and Coping Prior to Ovarian Cancer Surgery|Health and Coping Prior to Ovarian Cancer Surgery||University of Aarhus|No|Completed|September 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|279|||Female|18 Years|90 Years|No|||June 2011|June 15, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213771||115341|
NCT01213745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3454|The Use of a Quality of Life Questionnaire in Patients With Lung Cancer|A Prospective Randomised Controlled Study to Investigate the Effectiveness of Using a Quality of Life Questionnaire to Target Interventions to Improve Quality of Life in Patients With Lung Cancer||Royal Marsden NHS Foundation Trust|No|Recruiting|September 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|138|||Both|18 Years|N/A|No|||October 2010|October 20, 2010|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213745||115343|
NCT01214616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.84|BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours|An Open-label Phase I Study of Once Daily Oral Treatment With BIBW 2992 in Combination With Weekly Vinorelbine Intravenous Injection in Japanese Patients With Advanced Solid Tumours||Boehringer Ingelheim||Completed|October 2010|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|74 Years|No|||June 2014|June 24, 2014|October 4, 2010||||No|May 9, 2014|https://clinicaltrials.gov/show/NCT01214616||115276|MTD was not determined and below Cohort 2 due to DLTs likely related to vinorelbine. After the revised dose criteria for afatinib and vinorelbine were implemented, Cohort 3 was established as a recommended dose.
NCT01214629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11618|A Study for Patients With Advanced Cancer|A Phase I Study of LY2523355 in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|July 2007|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|October 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214629||115275|
NCT01214642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11619|A Dose-Escalation Study for Patients With Advanced Cancer|A Phase 1 Dose-Escalation Study of LY2523355 in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|May 2008|June 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Years|N/A|No|||July 2012|July 13, 2012|October 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214642||115274|
NCT01215565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070134|Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma|A Multicenter National Phase II Open Study Coupled With Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Hepatocellular Carcinoma.|Fibrolam|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|October 2009|May 2012|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|September 24, 2010||No|lack of inclusion|No||https://clinicaltrials.gov/show/NCT01215565||115204|
NCT01215877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOBL204|Tesetaxel for Previously Treated Patients With Bladder Cancer|A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium||Genta Incorporated|No|Recruiting|September 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||November 2011|July 9, 2012|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215877||115180|
NCT01220479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|snf n°63164|Exercise Training Intervention in Children With Type 1 Diabetes|Impact of an Exercise Training Program on Bone Development and Cardiovascular Disease Risk Factors in Children With Type 1 Diabetes Mellitus|Diabex|University Hospital, Geneva|No|Completed|September 2001|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|59|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||October 2010|October 13, 2010|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01220479||114828|
NCT01216488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB09-060|Comparison Between Two Different Volumes of Anesthesia Drug in Forearm Surgery|Comparison of Axillary Block Under Ultrasound With 40 or 25 ml of Xylocaine 1.5% Adrenalin in Forearm or Arm Surgery.|COMBAX|University Hospital, Brest|Yes|Completed|January 2010|June 2011|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01216488||115133|
NCT01216787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02512|RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery|A Pilot Trial to Evaluate the Molecular Effects of RO4929097 as Neoadjuvant Therapy for Resectable Stage IIIB, IIIC or IV Melanoma||National Cancer Institute (NCI)|Yes|Withdrawn|September 2010|||November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|October 6, 2010|No|Yes|Study drug not available.|No||https://clinicaltrials.gov/show/NCT01216787||115110|
NCT01216800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000686212|Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors|A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors||National Cancer Institute (NCI)||Recruiting|August 2008|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||October 2010|October 6, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216800||115109|
NCT01217099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TRC2|Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children|A Prospective, Open-label Trial of Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children|MPP|Chongqing Medical University|Yes|Terminated|May 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|3 Years|11 Years|No|||May 2007|October 7, 2010|October 6, 2010|Yes|Yes|terminated|No||https://clinicaltrials.gov/show/NCT01217099||115087|
NCT01217424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000686459|Reflexology or Aromatherapy Massage in Relieving Symptoms in Patients With Cancer|Is Reflexology as Effective as Aromatherapy Massage for Symptom Relief in an Outpatient Oncology Population?||National Cancer Institute (NCI)||Recruiting|October 2010|||September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2010|August 23, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217424||115062|
NCT01230970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-55-58064-005|Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer|A Phase II, Open-label, Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 Administered for 14 Days Prior to Surgery to Postmenopausal Women With Newly Diagnosed Primary Invasive Oestrogen Receptor Positive Breast Cancer||Ipsen|No|Terminated|May 2011|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Female|55 Years|80 Years|No|||October 2013|October 10, 2013|October 20, 2010||No|The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the    primary endpoint will not be reached.|No||https://clinicaltrials.gov/show/NCT01230970||114030|
NCT01230957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-030-012|Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults|Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection||Sanofi|No|Completed|October 2010|March 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|661|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230957||114031|
NCT01231204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVB Catheter Study|Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks|Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks||University of California, San Diego|No|Active, not recruiting|October 2010|March 2016|Anticipated|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|October 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231204||114013|
NCT01231464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113342|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis||GlaxoSmithKline||Completed|September 2009|July 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|365|||Both|12 Years|65 Years|No|||March 2011|March 24, 2011|October 28, 2010||No||No|January 22, 2011|https://clinicaltrials.gov/show/NCT01231464||113993|
NCT01231477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEO4531|Cytokines and Sevoflurane During Surgery|Effects of Inhalation Anaesthesia With Sevoflurane on Cytokine Response in Patients Submitted to Otorhinolaryngological Surgery||UPECLIN HC FM Botucatu Unesp|Yes|Completed|July 2009|June 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Thirty adult patients ASA I physical status were allocated in 2 grups: 15 volunteers, not        submitted to anesthesia and surgery, and 15 patients scheduled for tympanoplasty or        septoplasty anesthetized with sevoflurane at 2,5%. Blood samples were drawn at 4 moments:        before induction of anaesthesia, before surgery, at 120 minutes after anaesthesia        induction, and on the postoperative first day. Blood samples from volunteers were drawn        only once.|October 2010|October 29, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231477||113992|
NCT01231724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-224-A|Topical Allstate and Nasal Allergen Challenge|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical Allstate in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (CETALY0001)||University of Chicago|No|Withdrawn|November 2011|April 2012|Anticipated|February 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||May 2013|May 30, 2013|October 28, 2010|Yes|Yes|study halted prematurely, prior to enrollment of first participant|No||https://clinicaltrials.gov/show/NCT01231724||113973|
NCT01231984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBC-10-SQUIR05|Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles|Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fine™ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fine™ Short 8mm x 31G Pen Needle or the BD Ultra Fine™ 12.7mm x 29G Pen Needle||Becton, Dickinson and Company|No|Completed|October 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|293|||Both|18 Years|80 Years|No|||May 2014|May 27, 2014|October 29, 2010|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT01231984||113953|
NCT01214070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6687-R|Functional Vision in TBI|Functional Vision Consequences of Rehabilitation for TBI Vision Loss||VA Office of Research and Development|No|Terminated|June 2012|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|110|||Both|20 Years|79 Years|No|||November 2013|November 22, 2013|September 14, 2010||No|Administrative Closure|No||https://clinicaltrials.gov/show/NCT01214070||115318|
NCT01214057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0014|Total Intravenous Anesthesia (TIVA) vs. Inhaled Anesthesia for Endoscopic Sinus Surgery.|Preliminary Study to Assess the Effects of Total Intravenous Anesthesia With Propofol/Remifentanyl Compared to Sevoflurane/Remifentanyl for Endoscopic Sinus Surgery: Novel Approach.||The University of Texas Health Science Center, Houston|Yes|Terminated|May 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|August 4, 2010||No|the study was terminated for patient recruitment difficulty and interim power analysis|No||https://clinicaltrials.gov/show/NCT01214057||115319|
NCT01214343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILIUS Phase III trial|Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC|Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma||Ministry of Health, Labour and Welfare, Japan|Yes|Recruiting|October 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|20 Years|N/A|No|||October 2010|June 14, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01214343||115297|
NCT01215253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HL096607|Ranolazine Implantable Cardioverter-Defibrillator Trial|Late Sodium Current Blockade in High-Risk ICD Patients|RAID|University of Rochester|Yes|Active, not recruiting|September 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|1012|||Both|21 Years|N/A|No|||December 2015|December 30, 2015|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215253||115228|
NCT01215266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB 31/05 RUTT 204|Sorafenib in Urothelium Cancer of Bladder|Prospektiv, Randomisierte, Doppelblinde, Multizentrische Phase-II- Studie Zum Vergleich Der Wirksamkeit Einer Chemotherapie Mit Gemcitabin Plus Cisplatin Und Sorafenib (BAY 43-9006) Versus Gemcitabin Plus Cisplatin Und Plazebo in Der Therapie Des Lokal Fortgeschrittenen Bzw. Metastasierten Urothelkarzinoms AB 31/05 - RUTT 204 - SUSE||Association of Urogenital Oncology (AUO)|Yes|Terminated|October 2006|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|October 1, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01215266||115227|
NCT01219842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sahlgrenska Academy|Invasive Revascularization or Not in Intermittent Claudication|Invasive Revascularization or Not in Intermittent Claudication|IRONIC|Sahlgrenska University Hospital, Sweden|No|Active, not recruiting|March 2010|December 2017|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|30 Years|80 Years|No|||October 2015|October 5, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219842||114877|
NCT01220141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7025-3601|Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B|Prospective Observational Study on NovoSeven® Room Temperature Stable (VII25) in Patients With Haemophilia A or B||Novo Nordisk A/S|No|Completed|November 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Male|N/A|N/A|No|Probability Sample|Male patients with haemophilia A or B with inhibitors treated with room temperature stable        NovoSeven® (activated recombinant human factor VII).|April 2015|April 15, 2015|October 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01220141||114854|
NCT01220102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEENA|Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne|Efficacy of Epiduo and Adherence of Patients Between 12 to 20 Years Using This Drug First Time in the Monotherapy of Moderate Inflammatory Acne|TEENA|Galderma Laboratorium GmbH|No|Completed|May 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3113|||Both|12 Years|20 Years|No|Probability Sample|About 2.700 patients with moderate inflammatory acne, aged 12 to 20 will be selected from        about 324 dermatology practices|February 2016|February 15, 2016|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220102||114857|
NCT01220115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS38|A 5-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients|A 5-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease Patients|FISCO|Novartis|No|Completed|January 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|498|||Both|2 Years|N/A|No|Non-Probability Sample|Patients with Sickle cell disease age 2 years and older|May 2015|May 18, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220115||114856|
NCT01216176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080325|A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer|A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer||University of Miami|Yes|Recruiting|October 2008|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|72|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|October 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216176||115157|
NCT01216189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/247-31/3|Sexual Function and Wellbeing in Females Diagnosed With Rectal Cancer|||Karolinska Institutet|Yes|Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Female|18 Years|N/A|No|Probability Sample|Females with rectal cancer stadium I-III, planned for abdominal surgery, with or without        preoperative radiotherapy.|February 2016|February 25, 2016|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216189||115156|
NCT01216215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SaudiGenAsthma|Novel Gentic Variations Contributing to Asthma Susceptability in Saudi Arabia|Novel Gentic Variations Contributing to Asthma Susceptability in Saudi Arabia||King Saud University|Yes|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2000|||Both|3 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This is a multi-center observational study. Asthmatic patients attending major hospitals        in Riyadh with clear and well defined inclusion criteria (see below for details, Appendix        I) will be recruited. We anticipate recruiting 1000 asthmatic patients and comparable        number of control subjects. The controls will be recruited from people attending blood        bank for donation or other patients attending different clinics with history excluding        atopic diseases and asthma. Ethical approval for this study will be obtained from CMRC        ethical committee of the KKUH as well as other involved centers|April 2014|April 13, 2014|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216215||115154|
NCT01216501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK-02/2010|Sevoflurane and Isoflurane for RF or Cryo Ablation in Children.|Comparison of Electrophysiological Effects of Sevoflurane and Isoflurane-based Anesthesia in Children Undergoing RF Ablation or Cryoablation for SVT Treatment. A Randomized Double Blind Study.||Schneider Children's Medical Center, Israel|No|Terminated|November 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|8 Years|14 Years|No|Non-Probability Sample|Patients who are scheduled for elective radiofrequency ablation or cryoablation to        interrupt abnormal foci and/or accessory pathways at Schneider Children's Medical Center        of Israel (SCMCI).|November 2014|November 19, 2014|October 6, 2010||No|Recruiting was not as anticipated.|No||https://clinicaltrials.gov/show/NCT01216501||115132|
NCT01216813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000686456|Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer|The Rehabilitation Needs of People Who Have Had an Upper Gastrointestinal or a Gynecological Cancer||National Cancer Institute (NCI)||Recruiting|August 2010|||December 2010|Anticipated|N/A|Observational|N/A|||Anticipated|30|||Both|18 Years|N/A|No|||October 2010|August 23, 2013|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216813||115108|
NCT01217112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMD1092|GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes|A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes||GW Research Ltd|No|Completed|October 2010|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|62|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|October 7, 2010||No||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01217112||115086|
NCT01217697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017479|Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer|An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|November 2010|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2334|||Both|18 Years|99 Years|No|||February 2016|February 3, 2016|October 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217697||115041|
NCT01230983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9404|Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma|Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study|T-Cell #4|Children's Oncology Group|Yes|Completed|June 1996|October 2004|Actual|September 2001|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|573|||Both|N/A|21 Years|No|||June 2013|June 4, 2013|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230983||114029|
NCT01231217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTCD-01|Green Tea in Crohn's Disease|||University Hospital Heidelberg|No|Recruiting|October 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2010|October 29, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01231217||114012|
NCT01231490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111293|Acute Osteoarthritis Experimental Model Study.|A Double Blind, Randomised, Placebo Controlled Methodological Cross-over Study to Investigate the Senstivity of a Novel Study Design and Endpoints to Treatment Effects of Naproxen in Osteoarthritis||GlaxoSmithKline|No|Completed|September 2008|March 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|53|||Both|N/A|N/A|No|||January 2011|January 27, 2011|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231490||113991|
NCT01231503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111315|Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants|Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine 257049 When Administered on Different Schedules to Infants in Africa||GlaxoSmithKline|Yes|Completed|January 2011|December 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|8||Actual|480|||Both|N/A|7 Days|Accepts Healthy Volunteers|||November 2015|November 23, 2015|October 14, 2010|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT01231503||113990|
NCT01231737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)|Efficacy of Prulifloxacin vs Phosphomycin in the Prophylasy of Urinary Tract Infection||University Of Perugia|Yes|Enrolling by invitation|November 2010|February 2012|Anticipated|February 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|96|||Female|18 Years|75 Years|No|||October 2009|October 29, 2010|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01231737||113972|
NCT01231997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0431|Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients|Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients|DA8159_RI_I|Asan Medical Center|No|Completed|November 2009|||November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|27|||Male|19 Years|64 Years|Accepts Healthy Volunteers|||October 2010|November 1, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01231997||113952|
NCT01232010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0445|Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients|Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients|SK3530_RI_I|Asan Medical Center|No|Completed|November 2009|||December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|12|||Male|19 Years|64 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232010||113951|
NCT01232361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1080|IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents|IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents|IMPAACT P1080|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|No|Enrolling by invitation|September 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90|Samples With DNA|Non-viable PBMC pellets for DNA genotypic analysis|Both|6 Years|25 Years|No|Non-Probability Sample|HIV-1 infected and uninfected children and adolescents ages ≥6 to <25 years who are        currently receiving methylphenidate or amphetamine/dextroamphetamine for treatment of        attention deficit hyperactivity disorder (ADHD)|July 2015|July 13, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232361||113924|
NCT01214655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12119|A Study for Patients With Acute Leukemia|Phase 1 Study of LY2523355 in Patients With Acute Leukemia||Eli Lilly and Company|No|Terminated|June 2008|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|October 1, 2010|No|Yes|Primary objective has been met and in the absence of clinically meaningful remissions|No||https://clinicaltrials.gov/show/NCT01214655||115273|
NCT01214668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12887|Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors|A Phase 1b, Multicenter, Dose-Escalation Study of LY573636-sodium in Combination With Liposomal Doxorubicin in Patients With Advanced Solid Tumors||Eli Lilly and Company|Yes|Completed|January 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|October 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01214668||115272|
NCT01214356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03DK089120|Impact of Vitamin D on Diabetic Kidney Disease in African Americans|Impact of Vitamin D on Diabetic Kidney Disease in African Americans||Medical University of South Carolina|Yes|Recruiting|February 2010|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|N/A|No|||October 2010|June 13, 2011|October 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214356||115296|
NCT01219582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14954|GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients|Open, Prospective, Multicentric, Single-arm, Non-interventional Study to Evaluate the Effectiveness & Safety of Oral Glucobay®-M Tablets in Type 2 Diabetes Patient|GLOBE|Bayer|No|Completed|October 2010|December 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9364|||Both|18 Years|N/A|No|Probability Sample|Type 2 Diabetes|November 2013|November 11, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01219582||114896|
NCT01220154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09115|Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer|Phase I Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel and Bevacizumab in Patients With Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2010|||March 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220154||114853|
NCT01219881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0174|Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery|A Randomized, Double-Blind, Double-Arm Trial Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery Under General Anesthesia With a Laryngeal Mask Airway (LMA)||Ohio State University|Yes|Completed|September 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Actual|75|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2013|January 2, 2013|September 27, 2010||No||No|October 30, 2012|https://clinicaltrials.gov/show/NCT01219881||114874|Nine patients which were screen failures and not included in final analysis. Patients assessed for SOMCT score every 15 minutes in the PACU, which did not allow for an exact time for the return to cognition endpoint.
NCT01220492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beijing302-002|Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis|Phase 1/2 Study of UC-MSC Treatment for the Evaluation the Efficacy and Safety in Patients With Liver Cirrhosis||Beijing 302 Hospital|Yes|Recruiting|May 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|65 Years|No|||May 2013|May 30, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01220492||114827|
NCT01220180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081138|Lyrica (Pregabalin) Korean Post Marketing Surveillance Study|Post Marketing Surveillance Study For Observing Safety And Efficacy Of Lyrica||Pfizer|No|Completed|July 2006|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Actual|4175|||Both|N/A|N/A|No|Non-Probability Sample|Korean adult patients with epilepsy, neuropathic pain or fibromyalgia, prescribed        pregabalin for within label use|November 2011|November 3, 2011|October 7, 2010|No|Yes||No|November 3, 2011|https://clinicaltrials.gov/show/NCT01220180||114851|It is highly likely that Adverse Events were under reported for this study as it was a Non Interventional study.
NCT01215929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110743|Studying Amphetamine Withdrawal in Humans|Amphetamine Withdrawal Paradigm in Humans||University of Arkansas|Yes|Completed|October 2009|May 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|21 Years|65 Years|No|||July 2014|July 14, 2014|October 1, 2010|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT01215929||115176|
NCT01216202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1860-31/2|Sexual Function and Wellbeing in Males Diagnosed With Rectal Cancer|||Karolinska Institutet|Yes|Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|N/A|No|Probability Sample|Men with rectal cancer stadium I-III, planned for abdominal surgery with or without        preoperative radiotherapy.|February 2016|February 25, 2016|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216202||115155|
NCT01216514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008074|Serologic Markers for Inflammatory Bowel Disease During Clinical Forms With Weak or Strong Evolution Capacities|Differential Characteristics of All Serologic Markers for Chronic Inflammatory Bowel Diseases During Clinical Forms With Weak or Strong Evolution Capacities||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|194|Samples Without DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|community sample|November 2011|November 2, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216514||115131|
NCT01216826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CBR07T|Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma|Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma||Hospital Santa Marcelina|No|Recruiting|March 2011|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|21 Years|No|||August 2013|August 5, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216826||115107|
NCT01216839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001CBR08T|Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas|Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas||Hospital Santa Marcelina|No|Recruiting|March 2011|December 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|21 Years|No|||March 2013|March 25, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216839||115106|
NCT01216852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOSA-01|Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment Bioequivalency Study of Losartan Potassium Tablets 100 mg Under Fasted Conditions||Roxane Laboratories|No|Completed|August 2004|August 2004|Actual|August 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216852||115105|
NCT01217437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02605|Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors|Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2010|||September 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|21 Years|No|||December 2015|March 22, 2016|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217437||115061|
NCT01217450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02915|Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors|A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|October 2012|May 2014|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2013|May 28, 2014|October 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217450||115060|
NCT01230996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000687340|Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer|DEPICT: A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer||National Cancer Institute (NCI)||Recruiting|July 2010|||July 2013|Anticipated|Phase 1/Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Female|18 Years|65 Years|No|||October 2010|October 28, 2010|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230996||114028|
NCT01231230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060346|Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway|Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway||University of Miami|No|Completed|May 2007|August 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|14|||Both|18 Years|65 Years|No|||November 2014|December 3, 2014|October 25, 2010|Yes|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01231230||114011|
NCT01231516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111762|A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults|A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults|SAILING|ViiV Healthcare|No|Active, not recruiting|October 2010|November 2015|Anticipated|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|724|||Both|18 Years|N/A|No|||March 2014|March 20, 2014|October 21, 2010|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01231516||113989|
NCT01231750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 060559|Efficacy of Topical Capsaicin Cream for Stable Angina|A Randomized, Placebo-Controlled, Cross-Over Study to Assess the Safety and Efficacy of TOPical CAPsaicin With Stable Angina (TOPCAP)|TOPCAP|University of Cincinnati|Yes|Terminated|October 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|80 Years|No|||June 2015|June 23, 2015|October 28, 2010|Yes|Yes|Unable to identify study population to achieve number expected|No|June 25, 2013|https://clinicaltrials.gov/show/NCT01231750||113971|
NCT01232023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0103|Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent|Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent||Asan Medical Center|No|Recruiting|January 2010|||December 2010|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|12|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||October 2010|November 9, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232023||113950|
NCT01232036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0195|Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018|A Clinical Trial to Compare the Pharmacokinetic and Pharmacodynamic Characteristics and Safety After Oral Administration of Glucophage With Those After Oral Administration of HL-018 in Healthy Male Volunteers||Asan Medical Center|No|Completed|May 2010|October 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|28|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||October 2010|November 1, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232036||113949|
NCT01232374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-ESO-1001|Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma|A Clinical Study of Nimotuzumab in Combination With Concurrent Chemotherapy and Radiation for Patients With Local Advanced Esophageal Squamous Cell Carcinoma||Biotech Pharmaceutical Co., Ltd.|Yes|Active, not recruiting|September 2010|January 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||August 2015|August 19, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01232374||113923|
NCT01219036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07094LH-A|The Use of Fractional Exhaled Nitric Oxide in the Identification of Non-adherence in Difficult Asthma|The Use of Fractional Exhaled Nitric Oxide (FeNO) and Induced Sputum in the Identification of Non-adherence in Difficult to Control Asthma||Belfast Health and Social Care Trust|Yes|Completed|October 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|16 Years|N/A|No|||February 2012|February 1, 2012|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219036||114938|
NCT01214941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54/180/2010|Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol|||Turku University Hospital|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|April 12, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01214941||115251|
NCT01219855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP101-CL-2008|Safety and Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Vitamin D Insufficiency and Secondary Hyperparathyroidism (SHPT)|A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism||OPKO Health, Inc.|Yes|Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|78|||Both|18 Years|85 Years|No|||September 2014|September 16, 2014|October 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01219855||114876|
NCT01219868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-001|Physician-nurse Team to Reduce Emergency Department (ED) Overcrowding|Impact of Physician-nurse Team on ED Length of Stay||University Hospital, Geneva|No|Completed|October 2010|March 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|8000|||Both|16 Years|N/A|No|||March 2013|March 19, 2013|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01219868||114875|
NCT01220128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113172|Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer|Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer|INDUCT|GlaxoSmithKline||Terminated|April 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 7, 2010|Yes|Yes|Study termination due to negative Ph III of another study product from same technology    platform.|No||https://clinicaltrials.gov/show/NCT01220128||114855|
NCT01220167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OND/CR/051/08/09|Three-way Crossover Comparative Water-effect Bioavailability to Compare Ondansetron ODFS 8mg With and Without Water With Zofran ODT 8mg Without Water in 18 Healthy Participants Under Fasting Conditions|An Open-label Randomized, Single Oral Dose, Three-way Crossover Comparative Water-effect Bioavailability Study to Compare Ondansetron Orally Dissolving Filmstrop (ODFS)8mg (MonoSol Rx USA) With and Without Water With Zofran Orally Dissolving Tablets (ODT) (Containing Ondansetron 8mg) (Glaxo SmithKline, USA) Without Water in 18 Adult, Healthy Human Study Participants Under Fasting Conditions.||Par Pharmaceutical, Inc.||Completed|August 2008|August 2008|Actual|August 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|July 25, 2011|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220167||114852|
NCT01220193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTVue 100 - 2009|Evaluation of RTVue in Corneal Measurement|Evaluation of RTVue in Corneal Measurement||Optovue||Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|196|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Various ocular conditions to include normal, pathology, post refractive surgery and        cataract.|February 2011|February 16, 2011|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220193||114850|
NCT01215916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11158|A Phase 1 Study in Patients With Solid Tumors|A Phase 1b Study of LY573636-sodium in Combination With Alimta (Pemetrexed) in Patients With Solid Tumors||Eli Lilly and Company|No|Completed|February 2008|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01215916||115177|
NCT01215942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13419|An Open Label Study for Patients With Rheumatoid Arthritis|A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA)||Eli Lilly and Company|Yes|Completed|June 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1505|||Both|18 Years|N/A|No|||March 2014|April 14, 2014|October 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01215942||115175|
NCT01215955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13460|Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes|Two Approaches to Escalate Lispro Therapy in Patients With Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone (AUTONOMY)|AUTONOMY|Eli Lilly and Company|No|Completed|December 2010|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1117|||Both|18 Years|85 Years|No|||April 2014|April 3, 2014|September 30, 2010|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01215955||115174|Five (5) randomized participants (3 Study B Q1D, 2 Study B Q3D) from 1 site were excluded from efficacy and safety analyses due to quality issues and validity of the data at that site.
NCT01216228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC 2010-10-06|Food Patterns, Inflammation Markers of Cardiovascular Disease Risk and Incidence of CVD|||Skane University Hospital|No|Completed|March 1991|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A||Non-Probability Sample|The Malmö Diet and Cancer Cohort (MDC), a large-scale, population-based, prospective        cohort study, was designed in the early 1990s to identify dietary and lifestyle risk        factors related to the incidence of cancer. Men aged 46-73 years (n =11 063) and women        aged 45-73 years (n = 17 035) living in Malmö, the third largest city in Sweden, at that        time, were examinedinvited to participate. Baseline examinations took place at the MDC        CentreCenter at the Skåne Malmö University Hospital in Malmö between March 1991 and        October 1996.|October 2006|October 6, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216228||115153|
NCT01216865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCDF001|Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot||Qingdao University|Yes|Not yet recruiting|January 2011|July 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||January 2009|October 12, 2010|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216865||115104|
NCT01217125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-005978-30|Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis|CLINICAL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF RAPAMYCIN IN ANGIOMYOLIPOMAS IN PATIENTS WITH TUBEROUS SCLEROSIS||Fundacio Puigvert|No|Completed|October 2008|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|10 Years|N/A|No|||March 2012|March 7, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217125||115085|
NCT01217138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232-05/25/2009|Make up for the Epinephrine Autoinjector|Make up for the Epinephrine Autoinjector: Effect on Its Use by Untrained Users||Gazi University|No|Completed|June 2009|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|164|||Both|21 Years|26 Years|Accepts Healthy Volunteers|||October 2010|October 7, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217138||115084|
NCT01217151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDT NICOM|Perioperative Hemodynamic Optimization Using the NICOM Device|Perioperative Hemodynamic Goal-directed Optimization Using the Noninvasive NICOM™ Monitoring Device in Major Abdominal Surgery||Hospital Universitario La Paz|No|Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|142|||Both|18 Years|90 Years|No|||September 2010|November 19, 2012|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217151||115083|
NCT01218048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 08-013|ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma|Phase II Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Followed by Adjuvant Therapy With Concurrent Chemoradiotherapy or Radiotherapy With or Without Cetuximab for Locally Advanced Head and Neck Squamous Cell Carcinoma||University of Pittsburgh|Yes|Active, not recruiting|February 2011|October 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218048||115014|
NCT01231542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113099|Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers|Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers||ViiV Healthcare|No|Completed|May 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 21, 2011|October 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01231542||113987|
NCT01231555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113404|Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)|Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 Administered With Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|SIGNET|ViiV Healthcare|Yes|Terminated|November 2010|June 2013|Anticipated|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231555||113986|
NCT01231243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAL001|Clinical Effectiveness of In-office Bleaching Activated With a LED/Laser Device|Color Change and Sensitivity Level for In-office Bleaching With and Without a LED/Laser Device||Universidade Estadual de Ponta Grossa|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2011|December 5, 2011|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231243||114010|
NCT01231529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113097|GSK1349572 Hepatic Impairment Study|A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (ING113097)||ViiV Healthcare|No|Completed|November 2010|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2011|July 26, 2011|October 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01231529||113988|
NCT01231763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10080621 (UPittsburgh IRB#)|Acceptability Study of Vaginal Films for HIV Prevention|Film Acceptability Characterization and Evaluation|FACE|University of Pittsburgh|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|84|||Female|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 18-30 years from the Pittsburgh, Pennsylvania area who express interest in the        study. Enrollment is expected to achieve racial and ethnic demographics representative of        Allegheny County, Pennsylvania in terms of approximately 0.2 percent American Indian and        Alaska Native, 2.5 percent Asian, and 1.5 percent Hispanic or Latino (7). Allegheny County        is 82.8 percent white and 13.2 percent black or African American (7). For enrollment in        this study, we would like to achieve at least 40 percent black or African American in        order to collect a more diverse set of film microbicide preferences. The remainder of        enrollment is expected to be white.|February 2011|February 8, 2011|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231763||113970|
NCT01232049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0577|Drug Interaction and Safety Between Pitavastatin and Valsartan (CWP-PTV-101)|A Randomized, Open-label, Multiple Dose, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety Between Pitavastatin and Valsartan in Healthy Male Subjects||Asan Medical Center||Completed|October 2010|||March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2010|June 24, 2011|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232049||113948|
NCT01232387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0920|Identification of Early Predictors of Fetomaternal Hemorrhage|Identification of Early Predictors of Fetomaternal Hemorrhage And Development Of An Automated Screening Strategy For At-Risk Pregnancies||Icahn School of Medicine at Mount Sinai|No|Completed|May 2011|September 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|39|Samples Without DNA|Whole blood, placenta|Both|N/A|60 Years|No|Non-Probability Sample|A convenience sample of women admitted to the Mount Sinai Medical Center labor floor will        be selected for this pilot study. Eligible women will be those admitted for term delivery        (delivery between 37 0/7 and 41 6/7 weeks from the last menstrual period).|September 2013|September 19, 2013|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232387||113922|
NCT01232647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract number - 2010-02258712|Vitamin K as Additive Treatment in Osteoporosis|The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis|VITKANDOP|Guy's and St Thomas' NHS Foundation Trust|No|Not yet recruiting|April 2011|September 2013|Anticipated|June 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Female|55 Years|85 Years|No|||October 2010|November 1, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232647||113902|
NCT01219348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU 1006 - IDO|IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.|IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.|IDOvaccine|Herlev Hospital|Yes|Completed|June 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01219348||114914|
NCT01219335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-02|Discarded Materials Study|Evaluation of Non-viable Oocytes, Extra Spermatozoa, Developmentally Arrested Non-viable Embryos, Granulosa Cells, Serum, Follicular Fluid, and Conditioned IVF Media for Optimization of Laboratory Technology in Assisted Reproduction||Reproductive Medicine Associates of New Jersey|No|Recruiting|April 2003|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Discarded non-viable oocytes, granulosa cells, spermatozoa, developmentally arrested      embryos, serum, follicular fluid, and conditioned IVF media.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing infertility treatment|November 2015|November 16, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219335||114915|
NCT01219608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eums1388|Iranian Intensive Care Unit (ICU) Glutamine Study|Iranian Intensive Care Unit (ICU) Glutamine Study||hahid Beheshti University of Medical Sciences|Yes|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|60|||Both|18 Years|60 Years|No|||October 2010|June 13, 2011|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01219608||114894|
NCT01219621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGXD04|Comparison of AAIsafeR and DDD Modes in Non-selected Patients|A Prospective Canadian Multi-Center Randomized Study; Spontaneous AtrioVEntricular Conduction PReservation|CAN-SAVE R|Sorin Group Canada|No|Completed|April 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|N/A|No|||September 2006|October 12, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219621||114893|
NCT01220206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM 2010-003|POMx In the Treatment of Erectile Dysfunction|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of POM Wonderful Pomegranate Extract Capsules In Male Subjects With Moderate to Severe Erectile Dysfunction||POM Wonderful LLC|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Male|21 Years|70 Years|No|||October 2012|October 4, 2012|October 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220206||114849|
NCT01215968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13598|A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus|A Study to Evaluate the Effect of LY2189265 on Gastric Emptying Using Scintigraphy in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|75 Years|No|||October 2014|October 3, 2014|October 5, 2010|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01215968||115173|
NCT01216241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPNEUT|Daptomycin Versus Placebo in Patients With Neutropenia and Fever|A Single Center, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Daptomycin Versus Placebo in Patients With Neutropenia and Fever.||University of Rochester|Yes|Terminated|April 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|October 4, 2010|Yes|Yes|The study has shown futility and the objectives could not be reached without enrolling a very    large number of subjects.|No|November 6, 2013|https://clinicaltrials.gov/show/NCT01216241||115152|It was felt that this study had shown futility and objectives could not be reached without enrolling a very large number of subjects in a reasonable time frame.
NCT01216527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007048|Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer|A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery for Locally Advanced Squamous Cell Esophageal Carcinoma||Sun Yat-sen University|No|Recruiting|June 2007|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|70 Years|No|||November 2014|November 23, 2014|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216527||115130|
NCT01216540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000184|Vancomycin-Associated Nephrotoxicity|Occurrence and Economic Impact of Nephrotoxicity Associated With Vancomycin Exposure||University at Buffalo|No|Not yet recruiting|November 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|A simple random sample of 400 patients treated with greater than 48 hours of intravenous        vancomycin exposure during hospitalization during the time period from July 1, 2009        through June 30, 2010|October 2010|October 8, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216540||115129|
NCT01216553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/2010|Home Oxygen Therapy in Bronchiolitis|Home Oxygen Therapy in the Ambulatory Treatment of Bronchiolitis|O2-Rx|Meir Medical Center|Yes|Not yet recruiting|October 2011|August 2014|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|135|||Both|8 Weeks|24 Months|No|||July 2011|July 10, 2011|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216553||115128|
NCT01216566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-0030-10|Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|December 2010|May 2011|Anticipated|April 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||October 2010|October 6, 2010|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01216566||115127|
NCT01216878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOSA-02|Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment Bioequivalency Study of Losartan Potassium Tablets 100 mg Under Fed Conditions||Roxane Laboratories|No|Completed|September 2004|September 2004|Actual|September 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 6, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216878||115103|
NCT01216891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAISE Connection|Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis|Recovery After an Initial Schizophrenia Episode (RAISE): The RAISE Connection Program Duration of Untreated Psychosis (DUP)||Research Foundation for Mental Hygiene, Inc.|Yes|Active, not recruiting|October 2010|August 2016|Anticipated|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|15 Years|35 Years|No|||May 2015|May 20, 2015|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216891||115102|
NCT01217723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBMTG 0801|Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation|A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors||McMaster University|Yes|Recruiting|April 2010|January 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|198|||Both|16 Years|70 Years|No|||September 2010|October 7, 2010|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217723||115039|
NCT01217736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTP-27999-005|Direct Renin Inhibition and the Kidney|Direct Renin Inhibition and the Kidney||Vitae Pharmaceuticals, Inc.|Yes|Completed|September 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|22|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|October 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217736||115038|
NCT01231568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113468|An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor|An Open-Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation-Positive Tumor||GlaxoSmithKline|No|Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|23|||Both|18 Years|N/A|No|||May 2014|August 27, 2015|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01231568||113985|
NCT01231776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100926|Acupuncture Improves Sleep in Patients Undergoing Cardiopulmonary Bypass|Study of Acupuncture of Traditional Chinese Medicine||Xijing Hospital|Yes|Recruiting|September 2010|February 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|65 Years|No|||September 2010|February 21, 2011|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231776||113969|
NCT01232062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD+DC-CIK|Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients|Study of High-dose Chemotherapy Combined With Adoptive Cellular Therapy With Dentritic and Cytokine-induced Killer Cells in Triple Negative Breast Cancer Patients|DC-CIK|Beijing Cancer Hospital|Yes|Completed|August 2010|October 2013|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|46|None Retained|about 4ml peripheral vein blood，paraffin section on metastatic tissue，|Female|18 Years|45 Years|No|Probability Sample|female patients with metastatic breast cancer|July 2015|July 22, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232062||113947|
NCT01232400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM31297|Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage|Adrenergic Blockade After Subarachnoid Hemorrhage|ABASH|University of Michigan|Yes|Withdrawn|July 2014|August 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|November 1, 2010|No|Yes|Funding withdrawn. Design not feasible.|No||https://clinicaltrials.gov/show/NCT01232400||113921|
NCT01232660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 039|Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)|The Immunological Impact of Adding Hydroxychloroquine in Patients With Discordant CD4+ Cell Responses to Suppressive HAART: A Phase I Pilot Study.|SSAT039|St Stephens Aids Trust|No|Recruiting|October 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||February 2014|February 10, 2014|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232660||113901|
NCT01232673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-99/OVZ/08/006-Dot|Autologous Bone Marrow Stem Cell Transfer in Patients With Chronical Critical Limb Ischemia and Diabetic Foot|Autologous Bone Marrow Stem Cell Transfer in Patients With Chronical Critical Limb Ischemia and Diabetic Foot||University Hospital Ostrava|Yes|Completed|October 2008|December 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232673||113900|
NCT01232933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-0120|Use of the VasoNova VPS System During PICC Placement in an Algorithm Confirmation Study Using Fluoroscopy|Use of the VasoNova VPS System During PICC Placement in an Algorithm Confirmation Study Using Fluoroscopy||VasoNova, Inc.|No|Completed|June 2010|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|83|||Both|18 Years|N/A|No|||November 2010|November 1, 2010|June 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01232933||113880|
NCT01233180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-4434|Effects of Gua Sha and Thermotherapy on Chronic Neck Pain|Randomized Controlled Trial Comparing Gua Sha Massage and Thermotherapy for Chronic Neck Pain: Effects on Pain Intensity, Haptic Perception and Body Image.||Universität Duisburg-Essen|No|Completed|September 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||February 2011|February 22, 2011|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233180||113861|
NCT01219062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si391/2010|Postoperative Pain Control After Hip Hemiarthroplasty: Intrathecal Morphine vs Periarticular Infiltration of Bupivacaine|Comparative of Postoperative Pain Control at 24 and 48 Hours Between Intrathecal 0.1 mg. of Morphine or Local Infiltration of 20 ml. of 0.25% Bupivacaine in Patients Post Hip Hemiarthroplasty Under Spinal Anesthesis||Mahidol University|No|Recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|90 Years|No|||October 2010|October 12, 2010|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01219062||114936|
NCT01219595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0107|Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women|Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women||University of Wisconsin, Madison|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|65|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219595||114895|
NCT01219894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045456|Intravascular Optical Coherence Tomography Imaging - Length of Anti-Platelet Therapy After Drug Eluting Stent Placement|Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement|FDI-DAPT-ZES|Emory University|Yes|Withdrawn|November 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|N/A|80 Years|No|Probability Sample|Patients undergoing percutaneous transluminal coronary intervention (PTCI) for treatment        of de novo native vessel coronary artery disease with a single DES (EndeavorTM,        zotarolimus, Medtronic Vascular) will be enrolled in this study.|November 2013|November 18, 2013|October 8, 2010||No|Number of patients to meet individual IDE requirements was not obtained.|No||https://clinicaltrials.gov/show/NCT01219894||114873|
NCT01215981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010NTLS050|Influenza Vaccine Post Allogeneic Transplant|MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?||Masonic Cancer Center, University of Minnesota|Yes|Terminated|September 2010|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|73|||Both|6 Months|N/A|Accepts Healthy Volunteers|||May 2012|May 16, 2012|October 5, 2010||No|Lack of patients and no longer influenza vaccine season.|No||https://clinicaltrials.gov/show/NCT01215981||115172|
NCT01220245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|721-070910|SuperB Trial: SUrgical Versus PERcutaneous Bypass|Heparin-bonded Endoluminal Versus Surgical Femoropopliteal Bypass; a Multicentre Randomized Controlled Trial|SuperB|Rijnstate Hospital|No|Active, not recruiting|October 2010|July 2020|Anticipated|July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220245||114846|
NCT01215994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEPA|Estimation of Glomerular Filtration Rate (GFR) in Patients With Type 2 Diabetes Mellitus.|Comparative Study of New Formulae of GFR Estimation Based on Creatinine, Cystatin C and Cr51-EDTA.||AHEPA University Hospital|No|Recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|600|Samples Without DNA|serum, urine|Both|18 Years|85 Years|No|Non-Probability Sample|diabetic patients treated in the primary care clinic|April 2015|April 19, 2015|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01215994||115171|
NCT01216254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKEBN/219/2010|Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation|Prospective, Randomized Clinical Trial Comparing Pain Sensation, Seroma Formation and Quality od Life Following BCT With SLND in Breast Cancer Patients Operated With Classic Versus High-frequency Electrocoagulation.||Medical University of Gdansk|Yes|Recruiting|October 2010|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||January 2012|January 30, 2012|October 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216254||115151|
NCT01216267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB16279|Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples|Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples||University of Western Ontario, Canada|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01216267||115150|
NCT01216917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s52701|The Influence of Ageing on Muscle Quality|||Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|45|||Male|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|elderly men (65+)|November 2011|October 3, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216917||115100|
NCT01217164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUARTEJLMB-001|Strategy to Minimize In-hospital Malnutrition in Premature Babies|Strategy to Minimize In-hospital Malnutrition in Premature Babies|SPN|Hospital Universitario Pedro Ernesto|Yes|Completed|October 2008|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|64|||Both|N/A|43 Weeks|Accepts Healthy Volunteers|||October 2008|October 7, 2010|August 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217164||115082|
NCT01217177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C24128|A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer|A Phase I Study of Oral Administration of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for the Treatment of Locally Advanced Cervix Cancer|PHOENIX I|Novartis||Completed|December 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Female|N/A|N/A|No|||April 2015|April 1, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217177||115081|
NCT01217463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFM-CL3-001|The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study|A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment With Trafermin 0.01% Spray in Patients With Diabetic Foot Ulcer of Neuropathic Origin|TRANS-South|Olympus Biotech Corporation|Yes|Completed|November 2010|February 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|October 7, 2010||No||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01217463||115059|
NCT01218932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTM1001|Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects|Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects|PQCQ|University of Oxford|No|Completed|October 2010|March 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218932||114946|
NCT01218919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-10-017-ID-DB|Post Market (Brio™ System) Deep Brain Stimulation (DBS) PD Study|A CLINICAL EVALUATION OF A RECHARGEABLE DEEP BRAIN STIMULATION SYSTEM AS AN ADJUNCTIVE TREATMENT FOR REDUCING SOME OF THE SYMPTOMS OF ADVANCED, LEVODOPA-RESPONSIVE PARKINSON'S DISEASE THAT ARE NOT ADEQUATELY CONTROLLED WITH MEDICATION||St. Jude Medical|Yes|Withdrawn|October 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with advanced, levodopa-responsive Parkinson's disease that are not adequately        controlled with medication        Eligible subjects in this study will be screened to confirm that they meet the strict        guidelines for advanced, levodopa-responsive Parkinson's disease that are not adequately        controlled with medication|February 2015|February 27, 2015|October 8, 2010|No|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT01218919||114947|
NCT01219179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-10-22|Use of Sterile Water Feeds for Treatment of Hypernatremia in Extremely Low Birth Weight Infants|The Use of Enteral Sterile Water Feeds for the Treatment of Hypernatremia in Extremely Low Birth Weight Infants||Case Western Reserve University|Yes|Completed|November 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|N/A|28 Weeks|No|||February 2013|February 26, 2013|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219179||114927|
NCT01232101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMS-01|Covered or Uncovered Bile Duct Stents|Covered and Uncovered Self Expandable Metallic Stents Are Equally Efficacious in Bile Duct Strictures. Results of a Randomized Study.||Göteborg University|Yes|Completed|March 2007|August 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|N/A|N/A|No|||March 2007|November 1, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232101||113944|
NCT01232114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB523002|Safety Study of a Chinese Herbal Formula Simotang Oral Liquid for the Treatment of Functional Dyspepsia|Phase 2 Study of of a Chinese Herbal Formula Simotang Oral Liquid for the Treatment of Functional Dyspepsia|SMT|Hunan University of Traditional Chinese Medicine|Yes|Recruiting|October 2010|October 2010|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|65 Years|No|Probability Sample|patients with functional dyspepsia primary care clinic were studied|October 2010|November 1, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01232114||113943|
NCT01231789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC-Cardiac-Neuroprotection|The Neuroprotection of Remote Ischemic Preconditioning (RIPC) on Cardiac Surgery in Multicenter|The Neuroprotection of Remote Ischemic Preconditioning on Cardiac Surgery in Multicenter||Xijing Hospital|No|Recruiting|June 2009|August 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|70 Years|No|||June 2009|August 19, 2012|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01231789||113968|
NCT01231802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHX-03-202|Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer|A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer||Adherex Technologies, Inc.|No|Recruiting|April 2011|January 2013|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||July 2012|July 16, 2012|October 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231802||113967|
NCT01232075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clomid/extended letr/unexp.inf|Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination|Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination||Cairo University|Yes|Completed|September 2008|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|214|||Female|18 Years|37 Years|No|||July 2011|July 11, 2011|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232075||113946|
NCT01232088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Standardized Drug Labelling|Questionnaire of the Section Perioperative Intensive Care of the European Society of Intensive Care Medicine (ESICM) on Standardized Drug Labelling|Questionnaire of the Section Perioperative Intensive Care of the European Society of Intensive Care Medicine (ESICM) on Standardized Drug Labelling||Charite University, Berlin, Germany|No|Completed|November 2010|September 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|482|||Both|18 Years|100 Years|No|Probability Sample|Members of the European Society of Intensive Care Medicine (ESICM)|October 2015|October 30, 2015|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232088||113945|
NCT01232413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0058|A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Repeat Oral Doses of ASP1941 on Cardiac Repolarization in Healthy Male and Female Adult Subjects||Astellas Pharma Inc|No|Completed|September 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|88|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 24, 2011|October 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01232413||113920|
NCT01232426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mallet2010|A Randomized Controlled Trial of the Treatment of Mallet Fractures|A Randomized Controlled Trial of the Treatment of Mallet Fractures: Conservative Versus Operative Using One Meniscus Arrow®||Conmed Linvatec Benelux|No|Recruiting|March 2011|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||August 2012|August 17, 2012|October 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01232426||113919|
NCT01232686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 3746/ HST954-10|Snow Disease Surveillance System Study|Snow Disease Surveillance System Study|Snow|University Hospital of North Norway|No|Enrolling by invitation|October 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 2, 2011|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01232686||113899|
NCT01232946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105005578|Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake|Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake||Indiana University|Yes|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|3||Anticipated|27|||Both|18 Years|50 Years|No|||April 2015|April 8, 2015|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01232946||113879|
NCT01219374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-08|Study of Ovum Donors After Donation|A Longitudinal Prospective Study of Ovum Donors After Donation||Reproductive Medicine Associates of New Jersey|No|Completed|December 2006|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|500|||Female|21 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Anonymous egg donors|January 2013|January 22, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219374||114912|
NCT01219387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-09|Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old|Evaluation of Serum Anti-Mullerian Hormone (AMH) and Inhibin B Levels as Early Predictors of a Successful IVF Cycle in Women Over 38 Years Old.||Reproductive Medicine Associates of New Jersey|No|Completed|February 2006|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|Samples Without DNA|serum|Female|38 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing IVF treatment who are over the age of 38 years.|January 2013|January 22, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219387||114911|
NCT01219361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-05|Evaluation of Donated Human Embryos Following in Vitro Fertilization|Evaluation of Donated Human Embryos for Study of Normal and Abnormal Differentiation and Development Following in Vitro Fertilization.||Reproductive Medicine Associates of New Jersey|No|Enrolling by invitation|July 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Donated embryos|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients will cryopreserved embryos who do not want to discard them or donate them to        another couple|November 2015|November 16, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219361||114913|
NCT01220219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081226|An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers|An Open-Label, Multiple-Dose, Randomized, 3-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 82.5 Mg And 165 Mg Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal And 75 Mg Of The Immediate Release Formulation Administered Twice Daily||Pfizer|No|Completed|November 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2011|October 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01220219||114848|
NCT01220232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271048|Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects|Open-Label, Fixed-Sequence, Crossover Study To Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects||Pfizer|No|Completed|November 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220232||114847|
NCT01220258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08641|A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)|A Single-Center, Open-Label Study to Characterize Eyelid Margin Erythema, Markers of Clinical Inflammation and Levels of Inflammatory Mediators in the Lid Margins and Conjunctivae of Untreated Healthy Volunteers and Subjects Diagnosed With Posterior Blepharoconjunctivitis Following Dosing With Azithromycin Ophthalmic Solution, 1% for Four Weeks||Merck Sharp & Dohme Corp.|No|Terminated|November 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 13, 2013|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220258||114845|
NCT01216579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARD002|Steroid Titration Against Mannitol IN Asthma|Titrating Inhaled Steroid Dose Against Mannitol Hyper-responsiveness or BTS Outcomes: Comparative Effects on Asthma Exacerbations Over 1 Year||University of Dundee|No|Completed|March 2004|||February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|164|||Both|16 Years|65 Years|No|||March 2008|October 6, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216579||115126|
NCT01216904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSG PDF MCRA 07012010|Nicotine Treatment of Impulsivity in Parkinson's Disease|Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study||University of Vermont||Recruiting|October 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216904||115101|
NCT01216930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-LS-DK-01|Molecular Screening for Lynch Syndrome in Southern Denmark|Molecular Screening for Lynch Syndrome in Southern Denmark||Vejle Hospital|No|Completed|October 2010|September 2015|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|N/A|N/A|No|Non-Probability Sample|All colorectal cancer patients in the geographical region of southern Denmark|September 2015|September 11, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216930||115099|
NCT01218061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/11|Therapeutic Innovation in Type 2 DIABetes (IT-DIAB)|IT-DIAB (Therapeutic Innovation in Type 2 Diabetes) : Prospective Follow-up of a Cohort of Patients With Pre-diabetes Over 5 Years|IT-DIAB|Nantes University Hospital|No|Active, not recruiting|June 2010|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|366|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218061||115013|
NCT01218373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSH-CLTRPR-01|The Clinical Evaluation of Continuous Assistance Offered to Older People Living Independently.|Health Monitoring and sOcial Integration environMEnt for Supporting WidE ExTension of Independent Life at HOME (HOMESWEETHOME)|HOMESWEETHOME|Him SA|Yes|Not yet recruiting|December 2010|July 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2010|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 11, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01218373||114989|
NCT01218672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE1006|A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia|A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study)||American Medical Systems|No|Active, not recruiting|April 2011|January 2015|Anticipated|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Male|40 Years|80 Years|No|||October 2012|October 29, 2014|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218672||114966|
NCT01218685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUTVAC-Influenza A (H1N1) 2.0|Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants|Evaluation Aof Safety and Immunogenicity of Non-adjuvanted Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants, Produced by Butantan Institute||Butantan Institute|Yes|Completed|April 2010|April 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Actual|1152|||Both|6 Months|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers with chronic and or immunocompromised disease, elderly and pregnant in follow -        up at the institutions participants in the study will be recruited.|February 2013|February 5, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218685||114965|
NCT01218711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-067|Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Fixed Dose Combination (FDC) of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years||||October 2010|October 8, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218711||114963|
NCT01218737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9890X-001|Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation|Double-Masked, Randomized, Parallel Group Study for Evaluation of Non-Inferiority of 0.3%Gatifloxacin/1.0% Prednisolone Association Compared With Their Isolated Administration in the Prevention of Ocular Infection/Inflammation After LASIK Surgery||Federal University of São Paulo|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2010|October 14, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218737||114961|
NCT01218945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bone-ZH09|Development of Bone Grafts Using Adipose Derived Stem Cells and Different Scaffolds|Development of Bone Grafts Using Adipose Derived Stem Cells and Different Scaffolds: Impact of Pre-engineered Capillaries in Critical Size Grafts||University of Zurich|No|Completed|November 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|33|Samples With DNA|Human adipose-derived stem cells from human fat|Both|18 Years|70 Years|No|Non-Probability Sample|Patients admitted for reconstructive surgery|June 2013|June 18, 2013|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01218945||114945|
NCT01219192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2ES2010-2|Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure|Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure||Protgen Ltd|Yes|Recruiting|August 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|N/A|No|||October 2010|October 27, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219192||114926|
NCT01218958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-003|ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol-Dependent Adults||Alkermes, Inc.|No|Completed|February 2002|September 2003|Actual|September 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|624|||Both|18 Years|N/A|No|||December 2010|December 9, 2010|October 8, 2010|Yes|Yes||No|November 5, 2010|https://clinicaltrials.gov/show/NCT01218958||114944|
NCT01232478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCARE|I Change Adherence & Raise Expectations|I Change Adherence & Raise Expectations|iCARE|Johns Hopkins University|No|Completed|October 2009|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|641|||Both|11 Years|20 Years|No|||March 2015|March 30, 2015|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01232478||113915|
NCT01232439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12511|A Study of Brain Receptor Occupancy in Healthy Subjects|Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 5, 2011|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01232439||113918|
NCT01232452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13973|A Study in Non-Small Cell Lung Cancer|An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Carcinoma||Eli Lilly and Company|Yes|Active, not recruiting|April 2011|March 2016|Anticipated|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01232452||113917|
NCT01232465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-249A|Impact of Sperm DNA Integrity on In Vitro Cycles|Impact of Sperm DNA Integrity on In Vitro Cycles|TBA on IVF|Northwell Health|No|Completed|October 2010|September 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|420|Samples Without DNA|slide smears will be kept to observe overall DNA integrity of sperm sample|Male|N/A|N/A|No|Probability Sample|couples undergoing IVF treatement at the Center for Human Reproduction, North Shore        University Hospital, Manhasset NY|March 2014|March 14, 2014|October 28, 2010||No||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01232465||113916|
NCT01232699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-124|Internet Obesity Treatment Enhanced With Motivational Interviewing|Internet Obesity Treatment Enhanced With Motivational Interviewing|iReach2|University of Vermont|Yes|Completed|December 2010|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|495|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 15, 2014|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232699||113898|
NCT01232712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAXIL-001|A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies|A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies||Vaxil Therapeutics Ltd.|No|Completed|September 2010|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01232712||113897|
NCT01232959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001167|Feasibility of Transvaginal Cholecystectomy|Feasibility of Transvaginal Cholecystectomy|TVC|Mayo Clinic|Yes|Withdrawn|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|October 28, 2010|No|Yes|Subjects not interested|No||https://clinicaltrials.gov/show/NCT01232959||113878|
NCT01232972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-203A|Oocyte Cryopreservation|Oocyte Cryopreservation|egg freezing|Northwell Health|No|Terminated|October 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|23|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||April 2013|April 22, 2013|October 29, 2010||No|Study technique has been declared part of standard care|No||https://clinicaltrials.gov/show/NCT01232972||113877|
NCT01233219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-SM-08-MorfinaContinua-Gene|Association Between Clinical Effect of Continuous Morphine Administration After Surgery and Pharmacogenetics|Association Between Clinical Effect of Continuous Morphine Administration in Patients After Major Surgery and Pharmacogenetics: Perspective Observational Clinical Study||IRCCS Policlinico S. Matteo|Yes|Recruiting|November 2010|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|genes OPRM1, COMT, UGTs, ESR1|Both|18 Years|75 Years|No|Probability Sample|Pazients scheduled for major abdominal or urological surgery with postoperative pain        control with continuous morphine administration|January 2012|January 19, 2012|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233219||113858|
NCT01233557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/S0802/36|Biomarkers of Bone Resorption in Metastatic Prostate Cancer|Measurement of Biomarkers of Bone Resorption in Patients With Hormone Sensitive Bone Metastases From Prostate Cancer Treated With Antiandrogen Therapy and Bisphosphonates||University of Aberdeen|No|Completed|September 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Male|40 Years|80 Years|No|Non-Probability Sample|men with hormone sensitive prostate cancer with bone metastases|November 2015|November 4, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233557||113833|
NCT01233531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 068|Effects of Cash Transfer for the Prevention of HIV in Young South African Women|Effects of Cash Transfer for the Prevention of HIV in Young South African Women||HIV Prevention Trials Network|Yes|Completed|March 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2537|||Female|13 Years|20 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233531||113835|
NCT01219686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 09-054, Psy 09-004|EScitalopram PIndolol ONset of Action|Antidepressant Effect of Escitalopram: Delay of Onset. Clinical Randomized Double-blinded Study With Three Parallel Treatment Groups (Escitalopram 20mg vs Escitalopram 30mg vs Escitalopram 20 mg + Pindolol 15 mg/Day|ESPION|University Hospital, Geneva|Yes|Terminated|October 2010|June 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|October 7, 2010||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01219686||114889|
NCT01219647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 4174A5/2|Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis|Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis|CogEx|University of California, Los Angeles|No|Completed|July 2010|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|60 Years|No|||December 2014|December 5, 2014|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219647||114892|
NCT01219660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091703|Obstructive Sleep Apnea (OSA) Anesthesia and Positive Airway Pressure|Obstructive Sleep Apnea (OSA) Anesthesia and Positive Airway Pressure|OSA|University of California, San Diego|No|Enrolling by invitation|December 2009|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|75|||Both|19 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Primary Care Clinic|October 2010|October 12, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219660||114891|
NCT01219673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0517|Symptom Burden in Head and Neck Cancer|A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Head and Neck Cancer||M.D. Anderson Cancer Center|Yes|Terminated|March 2013|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|1|||Both|18 Years|65 Years|No|||January 2015|January 15, 2015|October 11, 2010|Yes|Yes|Low accrual.|No|January 15, 2015|https://clinicaltrials.gov/show/NCT01219673||114890|Analysis was not possible due to early termination with only one participant accrued.
NCT01219920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASL601LIOM03|FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer|Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer||Gruppo Oncologico del Nord-Ovest|Yes|Completed|November 2001|November 2009|Actual|November 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219920||114871|
NCT01216007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01501|A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia|A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia||University of British Columbia|Yes|Completed|October 2010|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|30|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||October 2012|October 26, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01216007||115170|
NCT01216280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI-2009-UC1|Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis|Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis||Natrogen Therapeutics International, Inc|No|Active, not recruiting|July 2010|September 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|70 Years|No|||July 2010|June 24, 2011|September 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216280||115149|
NCT01217203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2101-202|Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse|Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse|KIRIMID|Innate Pharma|No|Completed|September 2010|February 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||February 2014|February 27, 2014|October 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217203||115079|
NCT01217476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFM-CL3-002|The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study|A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment With Trafermin 0.01% Spray in Patients With Diabetic Foot Ulcer of Neuropathic Origin|TRANS-North|Olympus Biotech Corporation|Yes|Completed|December 2010|March 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|October 7, 2010||No||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01217476||115058|
NCT01217749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1109-CA|Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL|An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia|PCYC-1109-CA|Pharmacyclics|Yes|Completed|December 2010|May 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|71|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|October 7, 2010|No|Yes||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01217749||115037|
NCT01218074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-04|Platelets Antiaggregation Control Enhancement (PACE) Study|Platelets Antiaggregation Control Enhancement Study: an Independent Randomized Blind Prospective Study|PACE|Cardiochirurgia E.H.|Yes|Recruiting|December 2010|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|N/A|No|||February 2013|February 13, 2013|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01218074||115012|
NCT01218386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-019924-30|Pretreatment With Estradiol Valerate|Programmation of GnRH Antagonist Cycles With Estradiol Valerate: Impact on the Stimulation in IVF/ICSI.||Universitair Ziekenhuis Brussel|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|35 Years|No|||March 2012|March 27, 2012|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218386||114988|
NCT01218399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10042010-7010|Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations|A Randomized, Blinded, Single-center Study in Mild to Moderate Asthmatics Over the Age of 12 Years Who Have a Viral-mediated Exacerbation and Are Treated With Symbicort (160 mcg Budesonide/4.5 Formoterol, 2 Inhalations BID) or Pulmicort Flexhaler (160 mcg Budesonide, 2 Inhalations BID).||Stanford University||Completed|September 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|12 Years|65 Years|No|||March 2014|March 14, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218399||114987|
NCT01218698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-065|Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition|An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|45 Years||||October 2010|October 8, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218698||114964|
NCT01218724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-068|Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Fixed Dose Combination (FDC) of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years||||October 2010|October 8, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218724||114962|
NCT01218412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-84E|Web-based Physical Activity Program|Investigation of Web-based Motivational Interviewing to Increase Physical Activity Participation Among Adults||Karnes, Sasha|Yes|Recruiting|October 2014|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|132|||Both|21 Years|55 Years|No|||April 2014|April 3, 2015|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01218412||114986|
NCT01219504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-17|Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing In Vitro Fertilization (IVF)|Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing IVF||Reproductive Medicine Associates of New Jersey|No|Completed|April 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|200|Samples With DNA|Blood samples on female and male patients. Buccal swabs on infant(s).|Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|200 infertile couples undergoing IVF will be enrolled in the study.|January 2013|January 22, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219504||114902|
NCT01219205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_128|Major and Macular Branched Retinal Venous Occlusion|Intravitreal Bevacizumab for Macular Edema Secondary to Major and Macular Branch Retinal Vein Occlusion||Hallym University Medical Center|Yes|Completed|March 2008|August 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|20 Years|80 Years|No|||October 2010|October 12, 2010|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01219205||114925|
NCT01233011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01389|Evaluation of the Intubating Laryngeal Airway in Children|Evaluation of the Intubating Laryngeal Airway in Children - Phase 3||University of British Columbia|Yes|Completed|December 2010|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|None Retained|No biospecimens.|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy male and female pediatric subjects presenting for surgery through Surgical Day        Care Unit.|March 2015|March 13, 2015|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233011||113874|
NCT01232725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200708746|Donor Human Milk and Neurodevelopmental Outcomes in Very Low Birthweight (VLBW) Infants|Clinical Epidemiologic and Biologic Studies of Donor Human Milk and Breastfeeding||University of Iowa|Yes|Active, not recruiting|August 2009|July 2016|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|24 Months|No|||January 2015|January 19, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01232725||113896|
NCT01232738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11922|Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)||University of Kansas Medical Center|Yes|Active, not recruiting|December 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|80 Years|No|||November 2012|November 15, 2012|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01232738||113895|
NCT01232985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIC-AD-001|Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults|An Open-Label Pilot Study to Determine the Efficacy and Tolerability of a Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis With Associated Pruritus in Adults||Oculus Innovative Sciences, Inc.|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||May 2012|May 29, 2012|October 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01232985||113876|
NCT01232998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8711|Emergency Department Patient Satisfaction Survey in the Imam Reza Hospital , Tabriz ,Iran, 2008|||Tabriz University|Yes|Completed|June 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|504|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|community sample|April 2008|November 1, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232998||113875|
NCT01233232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00002|A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|CIRRUS|AstraZeneca||Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|109|||Both|40 Years|80 Years|No|||August 2015|August 27, 2015|November 2, 2010|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01233232||113857|
NCT01233544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAS 01|Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases|The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial|RAS01|University of Aarhus|No|Recruiting|September 2010|December 2016|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|90 Years|No|||June 2012|June 18, 2012|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233544||113834|
NCT01233817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39995|Progressive Strength Training in Spinal Muscular Atrophy|Pilot Study of Progressive Strength Training in Spinal Muscular Atrophy||University of Utah|Yes|Active, not recruiting|June 2010|||June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|5 Years|21 Years|No|||February 2013|February 5, 2013|October 19, 2010||No||No|December 5, 2012|https://clinicaltrials.gov/show/NCT01233817||113813|This was a pilot study with only one arm, the treatment arm. This is an inherent limitation.
NCT01229618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|085517|Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer|A Phase 1 Ascending-dose Study to Assess the Safety and Tolerability and Imaging Potential of Hyperpolarized Pyruvate (13C) Injection in Subjects With Prostate Cancer||University of California, San Francisco|Yes|Completed|October 2010|August 2013|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|31|||Male|18 Years|N/A|No|||August 2014|October 1, 2015|October 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01229618||114132|
NCT01219413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-4/Aliskiren/01|Influence of Aliskiren on Proteinuria|The Effect of Aliskiren on Proteinuria in Chronic Nondiabetic Kidney Disease: a Double Blind Cross-over Randomized Controlled Trial|ALIPRES|Medical University of Gdansk|Yes|Completed|March 2009|September 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219413||114909|
NCT01219907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7266|Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer|Phase I Study of Adoptive T-Cell Therapy With HER-2/Neu (HER-2)-Specific Memory CD8+ T Lymphocytes Obtained Following In Vivo Priming With a Peptide Vaccine in Patients With Advanced Stage HER-2-Positive Breast Cancer||University of Washington|No|Withdrawn|June 2012|||June 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01219907||114872|
NCT01225575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cod 16HS14|Assessment of Efficacy and Safety of 3 Different Doses of co.Don Chondrosphere to Treat Large Cartilage Defects|Prospective, Randomised, Open Label, Multicentre Phase II Clinical Trial to Investigate the Efficacy and Safety of the Treatment of Large Cartilage Knee Defects(4-10 cm²) With 3 Diff. Doses of the ACT Product co.Don Chondrosphere®||co.don AG|Yes|Active, not recruiting|October 2010|November 2017|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|50 Years|No|||February 2013|July 11, 2014|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01225575||114440|
NCT01225601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 04141|Prospective Evaluation of Adult Pulmonary Langerhans Cell Histiocytosis|Epidemiology of Adult Adult Pulmonary Langerhans Cell Histiocytosis - A Multicenter Cohort Study|LCHA1|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2006|September 2010|Actual|May 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Pulmonary Langerhans cell histiocytosis|March 2015|March 11, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01225601||114439|
NCT01225198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AutismVitaminStudy2008|Vitamin/Mineral Supplement for Children and Adults With Autism|New Vitamin/Mineral Supplement for Children and Adults With Autism - National Study||Arizona State University|No|Completed|May 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|3 Years|60 Years|Accepts Healthy Volunteers|||October 2010|October 19, 2010|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01225198||114469|
NCT01225211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX09-809-102|Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation|A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated|Yes|Completed|October 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|10||Actual|312|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|October 15, 2010|Yes|Yes||No|August 1, 2015|https://clinicaltrials.gov/show/NCT01225211||114468|
NCT01225848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 14809|Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy Patients With Advanced Urothelial Carcinoma|Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy Patients With Advanced Urothelial Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|February 2010|October 2013|Actual|December 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225848||114420|
NCT01225861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241437|Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK|||Mundipharma Research Limited|No|Completed|November 2010|January 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Non-Probability Sample|Patients experiencing pain. They may be from primary or secondary care.|May 2014|May 14, 2014|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225861||114419|
NCT01226147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM80-F01|Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis|||Kinki University||Recruiting|September 2010|February 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|75 Years|No|||July 2011|July 21, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226147||114398|
NCT01227070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH IRB 11798|Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma|Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma||Seattle Children's Hospital|No|Completed|January 2006|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|80|Samples Without DNA|Exhaled breath condensate|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|children ages 6-18 years hospitalized for an asthmat exacerbation, similar aged healthy        control children|October 2010|October 20, 2010|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01227070||114328|
NCT01227395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661097|Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients|Drug Use Investigation On Zithromac Tablets 600mg In HIV Patients (Post Marketing Commitment Plan)||Pfizer|No|Completed|July 2002|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|476|||Both|N/A|N/A|No|Probability Sample|The subjects whom an investigator involving A0661097 prescribes the Azithromycin Tablets        600mg (Zithromac Tablets 600mg).|April 2013|April 18, 2013|October 7, 2010|No|Yes||No|March 4, 2013|https://clinicaltrials.gov/show/NCT01227395||114303|
NCT01227408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-08-7|Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer|Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer||University of Southern California|Yes|Withdrawn|February 2009|||February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||May 2014|May 19, 2014|January 8, 2009|Yes|Yes|Sponsor withdrew due to funding issues|No||https://clinicaltrials.gov/show/NCT01227408||114302|
NCT01227694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCEL-M-09-01|Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis|Articular Cartilage Regeneration in Gonarthrosis Grade II and III by Articular Infiltration of Xcel-m-condro-alpha.||Banc de Sang i Teixits|No|Completed|October 2010|January 2013|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||November 2015|December 10, 2015|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227694||114280|
NCT01227707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18522|A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.|An Open-label Study to Assess the Effect of Combination Treatment With Avastin and Xeloda, Plus Pre-operative Standard Radiotherapy, on Response Rate in Patients With Locally Advanced Rectal Cancer.||Hoffmann-La Roche||Completed|November 2005|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|October 22, 2010|No|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT01227707||114279|
NCT01220011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K090601|Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery|A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery|TTTS1|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2011|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220011||114864|
NCT01216072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DUS01|A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis|A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)|EPOC|Novartis||Completed|August 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1053|||Both|18 Years|65 Years|No|||January 2014|January 14, 2014|September 7, 2010|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01216072||115165|
NCT01212393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2008-02|Prevention of Venous Thromboembolism Disease in Emergency Departments|Prevention of Venous Thromboembolism Disease for Acutelly Ill Medical Patients Admitted to Hospital : Systematic Analysis of Thrombosis Risk Factors and Remember of Prevention Treatment Indications in Emergency Departments.|PREVENU|University Hospital, Angers|Yes|Completed|September 2009|June 2013|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|20000|None Retained|observational study at the patient level - cluster randomized study|Both|40 Years|N/A|No|Probability Sample|Eligible centers: Emergency departments previously implicated in research on venous        thromboembolism.        Eligible patients: patients over 40 years old admitted in participating emergency        departments for non traumatic reason|May 2014|May 21, 2014|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212393||115447|
NCT01212692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00039100|Effects of Mental Stimulation in Patients With Mild Cognitive Impairment|A Theoretically Based Memory Training Intervention in Mild Cognitive Impairment||Johns Hopkins University|No|Completed|October 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|50 Years|100 Years|No|||December 2015|December 8, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01212692||115424|
NCT01212705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW2126/10|Effect of Adaptive Servoventilation on Cardiac Function in Chronic Heart Failure and Cheyne-Stokes Respiration|Effect of Adaptive Servoventilation on Cardiac Function, Exercise Tolerance and Quality of Life in Patients With Chronic Heart Failure and Cheyne-Stokes Respiration||Military Institute of Medicine, Poland||Recruiting||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A||||September 2010|September 30, 2010|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01212705||115423|
NCT01212978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCW-MEW2|Overcoming Inactivity in Older Adults: Impact on Vascular Homeostasis|Overcoming Inactivity in Older Adults: Impact on Vascular Homeostasis||Medical College of Wisconsin|No|Completed|September 2010|||July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|114|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212978||115402|
NCT01212991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-03|A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer|A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy|PREVAIL|Medivation, Inc.|Yes|Active, not recruiting|September 2010|||September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1717|||Male|18 Years|N/A|No|||February 2016|February 12, 2016|September 29, 2010|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT01212991||115401|
NCT01213251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRomPT|Post-Myocardial Infarction Remodeling Prevention Therapy|Post-Myocardial Infarction Remodeling Prevention Therapy|PRomPT|Medtronic Cardiac Rhythm Disease Management|Yes|Active, not recruiting|December 2010|||April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|250|||Both|18 Years|N/A|No|||February 2014|April 23, 2014|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01213251||115381|
NCT01228877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ad/Ab exercise|The Effect of 16 Weeks of Hip Adduction and Abduction Resistance Exercise|The Effect of 16 Weeks of Hip Adduction and Abduction Resistance Exercise Training on Strength and Density of the Proximal Femur|Ad/Ab|University of California, San Francisco|No|Completed|December 2010|September 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 14, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01228877||114189|
NCT01229150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100218|Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...|Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|September 2010|September 2016|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|89|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 26, 2010|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT01229150||114168|
NCT01225237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-501|A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients|Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome||Astellas Pharma Inc|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|296|||Male|20 Years|64 Years|No|||October 2014|October 14, 2014|October 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01225237||114466|
NCT01225250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS-END-001|Safety and Efficacy Study of Polydioxanone (PDS) Plates in Rhinoplasty|An Open-Label, Randomized, 2-Arm Parallel Study Comparing the Efficacy, Ease of Use, and Safety of PDS Plated Cartilagenous Grafting Versus Non-Plated Cartilagenous Grafting as Performed Through Endonasal Rhinoplasty||DeNova Research|No|Active, not recruiting|November 2010|May 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||February 2015|February 10, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225250||114465|
NCT01225263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000118|Statin/Vitamin D & Migraine Study|Combined Statin and Vitamin D Therapy for Prophylactic Treatment of Episodic Migraine||Beth Israel Deaconess Medical Center|No|Completed|September 2010|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|89|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|September 30, 2010|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT01225263||114464|
NCT01225224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-HV03|Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers|Phase I Study of ASP015K: Single-Dose and Multiple-Dose Oral Administration in Healthy Nonelderly Men||Astellas Pharma Inc|No|Completed|November 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|72|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||October 2010|October 19, 2010|October 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01225224||114467|
NCT01225874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9900|Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL|ALinC 17, Classification ©), B-precursor Induction Treatment (I)||Children's Oncology Group|Yes|Completed|December 1999|||March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3762|||Both|N/A|21 Years|No|||February 2016|February 19, 2016|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225874||114418|
NCT01225887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0229K|Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma||Gynecologic Oncology Group|Yes|Active, not recruiting|October 2011|||November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|October 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225887||114417|
NCT01227018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 1016|PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer|Phase II Study of STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer||Vanderbilt-Ingram Cancer Center|Yes|Terminated|December 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|October 20, 2010|Yes|Yes|interim analysis found the study drug to be ineffective|No|June 23, 2014|https://clinicaltrials.gov/show/NCT01227018||114332|
NCT01227031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98089|Pharmacogenomic Study of Androgenetic Alopecia|Pharmacogenomic Study of Androgenetic Alopecia||Taipei Medical University WanFang Hospital|No|Not yet recruiting|October 2010|July 2011|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|DNA extraction from blood sample|Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Androgenetic alopecia (pattern hair loss)|October 2010|November 10, 2010|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01227031||114331|
NCT01226459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINALO3005|Clinical Trial in Females for Female Pattern Hair Loss|A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia)||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|404|||Female|18 Years|N/A|No|||June 2014|June 3, 2014|October 20, 2010|Yes|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01226459||114374|
NCT01226472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW-0761-002|Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001|Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|August 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2013|August 26, 2013|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01226472||114373|
NCT01226485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13200|A Study in Advanced Cancer|A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer||Eli Lilly and Company|No|Active, not recruiting|September 2010|May 2016|Anticipated|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226485||114372|
NCT01226498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000961|Effects of Blood Transfusion in Healthy Volunteers|Effects of Duration of Stored Red Blood Cell Transfusion on Physiological Parameters and Inflammatory Mediators in Healthy Adult Volunteers||Massachusetts General Hospital|Yes|Completed|July 2010|February 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 29, 2014|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01226498||114371|
NCT01226511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12929|A Study in Pediatric Participants With Generalized Anxiety Disorder|A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder||Eli Lilly and Company|No|Completed|June 2011|June 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|281|||Both|7 Years|17 Years|No|||January 2014|January 17, 2014|October 12, 2010|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01226511||114370|Nine (9) randomized participants (5 duloxetine, 4 placebo) from 1 site were excluded from efficacy and safety analyses due to major quality issues at that site.
NCT01226810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|024-10-RMB_parathyroid|The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration|A Novel Approach to Ultrafast Parathyroid SPECT Imaging Using a Solid State CZT SPECT Camera||Rambam Health Care Campus|No|Not yet recruiting|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients referred for the parathyroid scan.|October 2010|October 21, 2010|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226810||114347|
NCT01227083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-GEN-OBS-10-178|2nd_Computerized Asthma Specific Quality of Life(cAQOL)|Comparison of the Responsiveness of Two Different Asthma-specific QOL Measures (AQLQ and cAQOL) in Korean Patients With Persistent Asthma|2nd_cAQOL|Ajou University School of Medicine|No|Completed|October 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|N/A||2|Actual|150|Samples With DNA|Sub-group of ADRB2 and NK2R genotypes|Both|20 Years|70 Years|No|Probability Sample|asthma control patient|November 2013|November 10, 2013|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227083||114327|
NCT01227421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM08-3001|Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza|A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza||Romark Laboratories L.C.|No|Completed|December 2010|May 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|624|||Both|12 Years|65 Years|No|||January 2014|January 8, 2014|October 21, 2010|Yes|Yes||No|May 30, 2012|https://clinicaltrials.gov/show/NCT01227421||114301|
NCT01227720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1076|Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products.|Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products - A Study in Healthy Smokers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|August 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|104|||Both|19 Years|50 Years|No|||July 2012|July 6, 2012|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227720||114278|
NCT01212146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0818G|Probiotic-enriched Artichoke in Functional Constipation|A Randomized Double-blind, Crossover Clinical Trial to Assess the Efficacy of Lactobacillus Paracasei Enriched Artichokes in the Treatment of Functional Constipation|PAFC|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|No|Completed|September 2010|March 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||December 2011|December 23, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212146||115466|
NCT01212406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT001|Vitamin D in Bronchiolitis Obliterans Syndrome|A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation|VIT001|Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2010|August 2015|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||October 2013|November 10, 2015|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01212406||115446|
NCT01212718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOGT5|Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase|Stratified and Randomized Multi-center Phase II - to Determine Potential Benefit of Treating Patients With Advanced Colorectal Cancer According to the Intratumoral TS RNA Levels|FOGT5|University of Ulm|Yes|Completed|July 2001|September 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|75 Years|No|||September 2010|September 30, 2010|September 9, 2010||||No||https://clinicaltrials.gov/show/NCT01212718||115422|
NCT01213511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEPA_CTS-02|Neurocognitive Outcome After Coronary Artery Bypass Surgery Using Minimal Versus Conventional Extracorporeal Circulation|Neurocognitive Outcome After Coronary Artery Bypass Surgery Using Minimal Versus Conventional Extracorporeal Circulation||AHEPA University Hospital|No|Completed|January 2009|June 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|N/A|N/A|No|||November 2013|November 27, 2013|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213511||115361|
NCT01213264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06556|Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)|Observational Project on the Current Neuromuscular Monitoring Practice (Including Extubation Practice) Via TOF-ratio (Train-of-four) Measurements in Different Types of Surgery After Administration of Neuromuscular Blocking Agents With or Without Reversal (Protocol No. P06556)||Merck Sharp & Dohme Corp.|No|Completed|September 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|659|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult patients (18-65 years old) who are undergoing different types of surgical procedures        (short, intermediate, or long in duration), requiring general anesthesia with a        non-depolarizing NMBA, with or without NMB reversal.|February 2015|February 26, 2015|September 9, 2010||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01213264||115380|
NCT01228890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-464-A|Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)|Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)|CATCH-IT|University of Chicago|No|Withdrawn|September 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|13 Years|17 Years|No|||December 2012|December 13, 2012|October 25, 2010||No|no one enrolled; PI left institution|No||https://clinicaltrials.gov/show/NCT01228890||114188|
NCT01224938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarker sputum airway study1|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 1.|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 1.|BioSput-Air|Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2010|September 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|395|Samples Without DNA|lysed sputum cells|Both|6 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|330 asthmatics (300 adults, 30 children) will be recruited from the outpatient clinic of        the university hospital of Leuven. 115 healthy subjects (100 adults, 15 children) will be        recruited among students and co-workers from the KULeuven and UZ Leuven.|September 2013|September 25, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224938||114489|
NCT01225276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGAM-03|Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP|Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients|POINT|Octapharma|Yes|Terminated|October 2011|October 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|No|||June 2015|October 16, 2015|October 6, 2010|Yes|Yes|Study Terminated.priority changes in product development.|No||https://clinicaltrials.gov/show/NCT01225276||114463|
NCT01225822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.19|BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery|BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery||Boehringer Ingelheim||Completed|November 2002|||August 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|5||Actual|1973|||Both|18 Years|N/A|No|||February 2014|May 8, 2014|October 20, 2010||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT01225822||114422|
NCT01225835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999906 CS11|Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)|Effect of Highly Purified Menotrophin and Recombinant Follicle Stimulating (rFSH, Follitrophin Alpha) in Subfertile Female Patients Undergoing IVF on Progesterone Serum Levels During the Follicular Phase and Their Possible Use as Predictors for the Success Rate of Ongoing Pregnancies|PREDICT|Ferring Pharmaceuticals|No|Completed|October 2010|June 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Female|34 Years|42 Years|No|||February 2014|February 17, 2014|October 7, 2010||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01225835||114421|
NCT01226160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/Q0603/100/01|Pilot Randomised Controlled Trial of Posturing Following Surgery for Full-thickness Macular Hole|Pilot Randomised Controlled Trial of Posturing Following Surgery for Full-thickness Macular Hole||Moorfields Eye Hospital NHS Foundation Trust|Yes|Completed|January 2005|October 2010|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|16 Years|N/A|No|||August 2006|October 21, 2010|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226160||114397|
NCT01226758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-v-002|Influenza Vaccine Challenge Study in Healthy Subjects|A Randomised Double-blind, Placebo-controlled, Phase 1b Trial to Evaluate the Safety, Tolerability and Protective Efficacy of the Influenza Vaccine Candidate, FLU-v, in an Influenza Challenge Model||PepTcell Limited|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226758||114351|
NCT01226524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-HMO-CTIL|The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)|||Hadassah Medical Organization|No|Terminated|February 2011|August 2014|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|1 Year|18 Years|No|||March 2011|August 17, 2015|October 21, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01226524||114369|
NCT01226797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9421016|Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate The Efficacy And Safety Of Oral PF-04136309 500 Mg BID In Subjects With Chronic HCV Infection And Raised Aminotransferases||Pfizer|No|Terminated|December 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||March 2012|March 19, 2012|October 21, 2010||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01226797||114348|
NCT01226550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.368|Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan|Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan||Hospices Civils de Lyon|Yes|Completed|June 2007|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|64 Years|No|||December 2011|December 28, 2011|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226550||114367|
NCT01226823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERTO|Ursodeoxycholic Acid And Cholestasis Of Pregnancy|Intrahepatic Cholestasis Of Pregnancy: Clinical Impact Of Ursodeoxycholic Acid Treatment|CERTO|University of Bologna|No|Not yet recruiting|November 2010|||November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Female|18 Years|N/A|No|||May 2010|October 21, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01226823||114346|
NCT01227096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC3090091-6|Randomized Controlled Trial of the Effects of Electroacupuncture Preconditioning in Children Undergoing Cardiac Surgery|National Natural Science Foundation of China||Fourth Military Medical University|Yes|Active, not recruiting|October 2010|July 2011|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|60|Samples Without DNA|blood serum|Both|2 Years|12 Years|No|Probability Sample|2-12 years old children undergoing all types of open-heart surgery were included.|October 2010|June 22, 2011|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227096||114326|
NCT01227434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10105|A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma|A Phase II Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma|PD0332991|University of California, San Francisco|Yes|Terminated|September 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|October 15, 2010|Yes|Yes||No|May 18, 2015|https://clinicaltrials.gov/show/NCT01227434||114300|
NCT01228487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTH-OA-1|Influence of Oxidative Dysbalance on Secondary Osteoarthritis|Biomechanical Factors of Secondary Osteoarthritis: Oxidative and Nitrosative Stress as Predictive Factors of Joint Destruction||Heinrich-Heine University, Duesseldorf|No|Recruiting|October 2010|November 2013|Anticipated|November 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Arthroscopical obtained wash- out preparations of synovial space Synovial biopsies Blood      serum samples|Both|18 Years|70 Years|No|Non-Probability Sample|University clinic, patients, residents of Düsseldorf, Germany and surrounding cities|July 2011|July 25, 2011|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228487||114219|
NCT01212159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12832|Telephone Based Management of Hyperlipidemia|Telephone Based Management of Hyperlipidemia Utilizing a Self Monitoring Testing Device||Temple University|No|Completed|November 2010|August 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|80 Years|No|||September 2015|September 24, 2015|September 28, 2010||No||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01212159||115465|Recruiting did not reach goal due to change in FDA approval for simvastatin use requiring protocol modification.
NCT01213004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-146|Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers|Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2010|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01213004||115400|
NCT01213277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1c Discordance|A1c Discordance in Diabetes Patients|Differences in Hemoglobin Glycation Rate in Diabete Mellitus Patients||Endocrine Research Society|No|Suspended|October 2010|||May 2011||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|25|||Both|25 Years|70 Years|No|||September 2010|July 25, 2011|September 30, 2010||No|a pilot study of 7 patients did not reveal a temperature dependent difference in glycation    rates|No||https://clinicaltrials.gov/show/NCT01213277||115379|
NCT01213290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR0007|A Randomized Controlled Trial Of Endoscopic Ultrasound-Guided Fine-Needle Aspiration With And Without A Stylet|A Randomized Controlled Trial Of Endoscopic Ultrasound-Guided Fine-Needle Aspiration With And Without A Stylet : A Pilot Study||Kansas City Veteran Affairs Medical Center|No|Active, not recruiting|September 2009|March 2010|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|85 Years|No|||September 2010|September 30, 2010|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213290||115378|
NCT01214083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-014-09F|N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence|N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence||VA Office of Research and Development|No|Active, not recruiting|October 2010|September 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01214083||115317|
NCT01213784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M20090047|Optimized Glycemic Control in Heart Failure Patients With DM2:"Effect on Left Ventricular Function and Skeletal Muscle"|Optimized Glycemic Control in Type 2 Diabetics With Heart Failure:"Effect on Left Ventricular Function and Skeletal Muscle"|HFDM|University of Aarhus|Yes|Completed|September 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||June 2013|March 5, 2015|August 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01213784||115340|
NCT01214369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88288|Anesthetic Efficacy of X-tip Intraosseous Injection|Anesthetic Efficacy of X-tip Intraosseous Injection Following Mandibular Nerve Block in Molars With Acute Irreversible Pulpitis||Mashhad University of Medical Sciences|Yes|Recruiting|October 2010|January 2011|Anticipated|November 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2010|October 26, 2010|September 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01214369||115295|
NCT01224925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UiT-IKO-MTA-001|RCT of Pulp Capping Over Carious Exposures Comparing Mineral Trioxide Aggregate (MTA) With Dycal|Randomized Controlled Trial of Pulp Capping Over Carious Exposures Comparing MTA With Dycal||University of Tromso|No|Completed|October 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|55 Years|No|||December 2015|December 10, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224925||114490|
NCT01224951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarker sputum airway study2|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2|BioSput-Air|Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|January 2011|July 2015|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||March 2015|March 27, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224951||114488|
NCT01225640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1171003|PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay|A Phase 2a, Open-Label, Randomized Study In Treatment-Naive, Sputum Smear Positive Subjects With Drug-Sensitive Pulmonary Tuberculosis To Assess Early Bactericidal Activity (EBA) And Whole Blood Activity (WBA) Of PNU-100480 (PF-02341272)||Sequella, Inc.|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|65 Years|No|||December 2015|December 14, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225640||114436|
NCT01225614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081221|Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive|Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1)|DYVINE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|October 2010|December 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225614||114438|
NCT01226173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC IRB Protocol # 2009-037|Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol|Study of Bio-Rad Laboratories Platelia Dengue NS1 Ag Assay in Blood Donors.||Bio-Rad Laboratories|No|Completed|March 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|182353|Samples With DNA|EDTA plasma samples contained in plasma preparation tubes (PPTs) that have been frozen      within 24 hours of collection and following centrifugation (under the same centrifugation      conditions as used for PPTs used for nucleic acid testing, NAT) will be the primary samples      for prospective testing.|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The initiation of the dengue NS1 Ag IND study began on March 8th, 2010 with a study        population of donations collected by the American Red Cross in Puerto Rico and the study        population was expanded to Monroe County blood collections of the Community Blood Centers        of Florida, Inc in August 2010. Testing of collections may be further expanded to include        other non-ARC sites in Puerto Rico, or to sites in the continental US with documented        local dengue virus transmission. Testing may also include retrospective testing of a        repository of samples retained from Puerto Rico during the 2009 epidemic season.Testing        will be performed from donors who have read information sheets specific to this study        (Dengue Research Study Donor Information).|September 2012|September 20, 2012|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01226173||114396|
NCT01226537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01225588|Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients|Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients||Hamad Medical Corporation|Yes|Not yet recruiting|November 2012|December 2014|Anticipated|November 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|60 Years|No|||November 2012|November 7, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226537||114368|
NCT01226563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-5001-VENREM-201|IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction|A Placebo Controlled , Multicenter, Randomized, Double Blind Trial to Evaluate the Safety and Effectiveness of IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction - Preservation I Trial|PRESERVATION 1|Bellerophon|Yes|Active, not recruiting|April 2012|August 2020|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|October 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01226563||114366|
NCT01227733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR06/25/10|Comparative Genomic and Genetic Analysis of Paired Primary Breast - Metastatic Tumor Specimens Using High-throughput Platforms|||National University Hospital, Singapore|No|Active, not recruiting|August 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Female|N/A|N/A|No|Non-Probability Sample|Up to 10 archival breast tumor blocks will be obtained from the Department of Pathology,        NUH - half of these blocks will be from patients who were diagnosed before year 2000, and        the other half of the blocks will be from patients diagnosed between year 2000-2005        (control specimens). Basic tumor and patient information will be collected without patient        identifiers - grade, stage, ER/PR/HER2 status, treatment received, outcome data. 8-10        ten-micron sections will be cut from each tumor block. RNA will be extracted from the        tumor sections using the Roche High Pure FFPE RNA Micro Kit. RNA will be profiled using        the Illumina Veracode assay and the Affymetrix Quantigene assay. RNA extraction and gene        expression profiling will be performed by collabroators at the Genome Institute of        Singapore.|January 2014|January 21, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227733||114277|
NCT01227928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114012|Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women|A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655||GlaxoSmithKline|Yes|Completed|September 2010|January 2014|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Female|18 Years|N/A|No|||February 2015|February 12, 2015|October 21, 2010|Yes|Yes||No|April 18, 2013|https://clinicaltrials.gov/show/NCT01227928||114262|
NCT01227941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-4827-011|MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)|A Phase Ib Dose Escalation Study of MK-4827 in Combination With Pegylated Liposomal Doxorubicin (Doxil™ or Caelyx™) in Patients With Advanced Solid Tumors With a Cohort Expansion in Patients With Platinum Resistant/Refractory High Grade Serous Ovarian Cancer||Merck Sharp & Dohme Corp.|No|Terminated|November 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|October 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01227941||114261|
NCT01228240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19/3-3/2073|The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co. in Glycemic Control of Diabetic Patients|||Zanjan University of Medical Sciences||Completed|December 2008|September 2009|Actual|July 2009|Actual|N/A|Interventional|N/A|1||||||Female|30 Years|80 Years||||November 2008|October 25, 2010|October 25, 2010||||No||https://clinicaltrials.gov/show/NCT01228240||114238|
NCT01228253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-05|Effects of Treatment of PTSD on Reduced Recall for Fear Extinction|Effects of Treatment of Post-traumatic Stress Disorder on Reduced Recall for Fear Extinction||Centre Hospitalier Universitaire de Nice|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228253||114237|
NCT01225731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05495|A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)|Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)||Merck Sharp & Dohme Corp.|Yes|Completed|October 2010|October 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|14||Actual|355|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|October 7, 2010|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT01225731||114429|
NCT01226615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/IV-RMF-01|Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI)|Randomized, Double-blind, Placebo-controlled Study to Asses the Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis by Functional Magnetic Resonance Imaging||Bioiberica||Active, not recruiting|October 2010|December 2012|Anticipated|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|40 Years|75 Years|No|||October 2012|October 1, 2012|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01226615||114362|
NCT01212731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 08310|Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study|Detection of Vascular and Neuronal Changes Following Proton and/or Photon Radiotherapy in Patients Receiving Skull Base and/or Brain Radiation||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2010|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|Eligible subjects will include patients with malignancies of the skull base or patients        with low grade glioma who require radiotherapy. 10 subjects receiving photon treatment        plans and 20 subjects receiving proton treatment plans with malignancies involving the        base skull and a total of 40 patient with low grade glioma will be prospectively enrolled.|January 2016|January 25, 2016|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01212731||115421|
NCT01213303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iuliano_AVIS|Cardiovascular Risk Factors, Lipid Metabolism and Oxidative Stress|Relation Between Fatty Acids and Oxidative Stress Markers With Cardiovascular Risk Factors in a Healthy Population||University of Roma La Sapienza|Yes|Active, not recruiting|May 2009|December 2021|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|500|Samples Without DNA|Collection of plasma and serum samples|Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of healthy blood donors|December 2015|December 10, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213303||115377|
NCT01213524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014002|Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia|Biological and Behavioral Mechanisms of Smoking in Schizophrenia||Brown University|No|Completed|September 2005|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 26, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213524||115360|
NCT01213797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2006/0116|IMTAP : Impact of the Suicide Attempt on the Nearly Entourage in Term of Traumatic Stress and Medico-economic Impact|Impact of the Suicide Attempt on the Close Entourage: Traumatic Stress and Medico-economic Concerns, in Medium and Long Term|IMTAP|University Hospital, Lille|No|Completed|March 2006|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|372|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|500 families; 500 committing suicide and approximately 900 close relatives.|July 2011|October 24, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01213797||115339|
NCT01218516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-003-009|A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung|A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum Containing Doublet in Chemotherapy-Naїve Subjects With Stage IV Adenocarcinoma of the Lung||Morphotek|Yes|Completed|April 2011|November 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218516||114978|
NCT01218529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 42/09|Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors|Lapatinib and Whole Brain Radiotherapy for Patients With Brain Metastases From Lung and Breast Tumors. A Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG).||Hellenic Cooperative Oncology Group|No|Completed|October 2010|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218529||114977|
NCT01214382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DK085066-01|Pharmacokinetic Properties of Sertraline Before and After Gastric Bypass Surgery|A Prospective, Longitudinal Comparison of the Pharmacokinetic Properties of Sertraline Before and After Roux-en-Y Gastric Bypass||North Dakota State University|Yes|Active, not recruiting|October 2010|December 2015|Anticipated|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|60 Years|No|||May 2015|May 8, 2015|September 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01214382||115294|
NCT01229215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFD4870g|A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy|A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy||Genentech, Inc.||Completed|February 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|143|||Both|60 Years|89 Years|No|||March 2016|March 1, 2016|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229215||114163|
NCT01225289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-03-27-9576|Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients|The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis||Tehran University of Medical Sciences|Yes|Completed|October 2009|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|45 Years|No|||February 2014|February 12, 2014|September 6, 2010||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01225289||114462|
NCT01225926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-003|A Comparison of Aspheric Toric Intraocular Lens (IOL) Implantation Versus Aspheric Non-Toric Lens Implantation|A Randomized, Prospective, Multi-Center, Patient-Masked, Bilateral Comparison of Aspheric Toric Intraocular Lens (IOL) Implantation Versus Aspheric Non-Toric Lens Implantation||Alcon Research|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|N/A|No|||September 2013|September 24, 2013|October 20, 2010|Yes|Yes||No|July 22, 2013|https://clinicaltrials.gov/show/NCT01225926||114415|This study was considered a pilot study and did not have an expectation to meet any of the study endpoints.
NCT01225627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Golnik-COPD-DC-1|Discharge Coordinator Intervention in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effects of Discharge Coordinator Intervention on Hospitalizations and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease: a Randomized Controlled Clinical Trial||The University Clinic of Pulmonary and Allergic Diseases Golnik|Yes|Completed|November 2009|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|253|||Both|35 Years|N/A|No|||April 2013|April 8, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01225627||114437|
NCT01226186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0505/77|Self Medication With Oral Morphine After Total Knee Arthroplasty.|Self Medication With Oral Morphine After Total Knee Arthroplasty. A Randomised Controlled Trial Comparing Self Medication With Standard Nurse Dispensing. Is There a Difference in Morphine Consumption, Pain, Patient Satisfaction or Safety?||The Royal Bournemouth Hospital|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226186||114395|
NCT01226199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLR2 and TLR4 in COPD tissue|The Expression of TLR2 and TLR4 in the Lung of Chronic Obstructive Pulmonary Disease (COPD) Patients|The Expression of TLR2 and TLR4 in the Lung of COPD Patients||Seoul National University Bundang Hospital|No|Recruiting|October 2010|March 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Lung tissues are retained till the study ends.|Both|N/A|N/A|No|Probability Sample|All patients who will have lung resection for the therapeutic cause.|June 2011|June 7, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226199||114394|
NCT01226225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT-090870|A Multicentre Trial on the Effectiveness of Physical Rehabilitation of Patients With Coronary Artery Disease: Aerobic Interval Training Versus Moderate Continuous Training.||SAINTEX-CAD|University Hospital, Antwerp|No|Recruiting|November 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|75 Years|No|||August 2010|November 9, 2010|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01226225||114392|
NCT01227447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO 3589/2-1|Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Human Urinary Outflow Tract|Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Continent and Incontinent Human Urinary Outflow Tract||Ludwig-Maximilians - University of Munich|No|Recruiting|January 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|200||Human tissue from the urinary outflow tract (bladder base and urethra) of patients      undergoing cystectomy or radical prostatectomy (for cancer treatment) with pre-operatively      documented voiding disorders/incontinence - in particular SUI|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Human tissue from the urinary outflow tract (bladder base and urethra) of patients        undergoing cystectomy or radical prostatectomy (for cancer treatment) with pre-operatively        documented voiding disorders/incontinence - in particular SUI|March 2012|March 2, 2012|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227447||114299|
NCT01228500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEI-001|The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial|The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial||Integra LifeSciences Corporation|Yes|Withdrawn|January 2008|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228500||114218|
NCT01228513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15267|Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)|Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)||Bayer|No|Completed|November 2010|April 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|263|||Both|18 Years|55 Years|No|||December 2015|December 17, 2015|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228513||114217|
NCT01229384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BronchPAP|Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions|Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions|BPAP|Phoenix Children's Hospital|Yes|Recruiting|October 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|2 Months|24 Months|Accepts Healthy Volunteers|||June 2012|June 8, 2012|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229384||114150|
NCT01225744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07_DOG03_133|Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy|A Phase II Study Evaluating the Use of Concurrent Cetuximab, Irinotecan, Oxaliplatin and UFT in the First Line Treatment of Patients With Metastatic Colorectal Cancer|eSCOUT|Christie Hospital NHS Foundation Trust|Yes|Completed|April 2009|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225744||114428|
NCT01212432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPTO_CH08|Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study|||University of Zurich||Recruiting|December 2009|March 2010|Anticipated|March 2010|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|90 Years|No|||July 2010|October 15, 2010|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01212432||115444|
NCT01212445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18129|Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)|A Randomized, Open-Label, Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation||Bayer|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|154|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|September 29, 2010||No||No|November 20, 2012|https://clinicaltrials.gov/show/NCT01212445||115443|
NCT01212744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-004|Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)|A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Dose Levels of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria||BioMarin Pharmaceutical|Yes|Completed|March 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|16 Years|70 Years|No|||July 2015|July 23, 2015|September 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01212744||115420|
NCT01213017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRF-UCB-5-16-2010|The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients|The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients|PICS|Oklahoma Medical Research Foundation|No|Completed|September 2010|April 2012|Actual|January 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|September 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01213017||115399|
NCT01217892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1691C00003|Evaluation of Dapagliflozin Taken Twice-daily|A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy||AstraZeneca|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|400|||Both|18 Years|77 Years|No|||October 2014|October 16, 2014|October 7, 2010|Yes|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT01217892||115026|For participants who did not complete 16 weeks LOCF (last observation carried forward) was used.
NCT01218230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEC08205|Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia|A Clinical Trial to Study the Efficacy and Safety of Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia|INGECT|L.V. Prasad Eye Institute|No|Withdrawn|December 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|October 8, 2010||No|Funding did not come through as the product was sold to another company.|No||https://clinicaltrials.gov/show/NCT01218230||115000|
NCT01218815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.0/2010|Complete Infarct Related Artery Revascularization|Complete Infarct Related Artery Revascularization in Acute Myocardial Infarction Patients - CORAMI Trial|CORAMI|Fundacja Ośrodek Badań Medycznych|No|Terminated|October 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|October 1, 2010||No|Due to very low enrollment rate the study was terminated.|No||https://clinicaltrials.gov/show/NCT01218815||114955|
NCT01218802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR012642-01|Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks|Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation||University Hospital Case Medical Center|Yes|Completed|February 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|147|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|October 8, 2010||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01218802||114956|
NCT01229228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAP2-08-03|Study of Naproxen Capsules to Treat Dental Pain|A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Naproxen [Test] Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars||Iroko Pharmaceuticals, LLC|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|254|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|May 15, 2012|October 25, 2010|Yes|Yes||No|November 22, 2011|https://clinicaltrials.gov/show/NCT01229228||114162|
NCT01225653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Latano-2|Topical Application of Latanoprost in Diabetic Retinopathy|Topical Application of Latanoprost in Diabetic Retinopathy|Latano-2|University of Aarhus|Yes|Completed|November 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|36 Years|No|||December 2014|December 17, 2014|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225653||114435|
NCT01225666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-4-003|MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)|A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA)||Opko Biologics|Yes|Completed|August 2010|April 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|52|||Both|23 Years|60 Years|No|||April 2015|April 5, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225666||114434|
NCT01225328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1032|Participation Restrictions in Breast Cancer Survivors|Participation Restrictions in Young-Middle Adult Rural Breast Cancer Survivors||Dartmouth-Hitchcock Medical Center|Yes|Completed|October 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Female|18 Years|59 Years|No|||February 2014|December 18, 2014|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225328||114459|
NCT01225341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSV-BOT-01-09|Botulinum Toxin A for Herpes Labialis|A Double-Blind, Randomized, Placebo Controlled, Crossover Study to Assess the Safety and Efficacy of Botulinum Toxin A Injections as a Preventative Measure for Herpes Labialis.||DeNova Research|No|Completed|August 2010|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|64 Years|No|||February 2015|February 10, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225341||114458|
NCT01225354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD-IMP-001|Injectable Filler for Cheek Flattening|An Open-label, Prospective, Postmarket Study to Assess Altering First Impressions and Self-esteem Following Radiesse® Injections.||DeNova Research|No|Completed|August 2010|October 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Female|30 Years|65 Years|No|||September 2012|September 27, 2012|October 19, 2010|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01225354||114457|
NCT01225913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070934A|Mechanism(s) of Airflow Limitation During Exacerbation of Asthma|Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers||Gelb, Arthur F., M.D.|Yes|Recruiting|October 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|10 Years|80 Years|No|||March 2015|March 13, 2015|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225913||114416|
NCT01226212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010GA03|Can Synbiotic Use Effect Gut Bacteria and the Immune Response in Older People|Can Synbiotic Use Improve Dysbiosis in the Gut Microbiome and Modify Inflammatory Processes in Older People||University of Dundee|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||April 2013|May 2, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01226212||114393|
NCT01227109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Procalcitonin-one|Procalcitonin as a Marker of Infection in Cancer Patients|Procalcitonin as a Marker of Infection in Cancer Patients||Herlev Hospital|No|Not yet recruiting|February 2011|October 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|Samples Without DNA|Blood will be drawn for CRP and procalcitonin analysis|Both|N/A|N/A|No|Non-Probability Sample|Two groups of 40 patiens each, one with bacterial infection, the other without any signs        or symptoms of infection|October 2010|October 22, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227109||114325|
NCT01227122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00111-38|NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure|Plasmatic Level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Predictive Marker of Acute Kidney Failure in Patients With Preoperative Chronic Kidney Failure Undergoing Cardiac Surgery.|NGAL-CKF|Hopital Jean Minjoz|Yes|Recruiting|August 2010|September 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients with a chronic kidney failure, undergoing cardiac surgery.|March 2013|March 1, 2013|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227122||114324|
NCT01227746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA03/17/10|A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.|||National University Hospital, Singapore|No|Recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|21 Years|N/A|No|Non-Probability Sample|Asian patients with advanced gastro-intestinal stromal tumors (GIST) treated with        imatinib.|January 2014|January 21, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227746||114276|
NCT01227954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0933|Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases||Radiation Therapy Oncology Group|Yes|Active, not recruiting|March 2011|||June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227954||114260|
NCT01229072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPBLA0108|Safe Use of Heparin Sodium Laboratory Blausiegel Compared to Liquemine ® Laboratory Roche in Patients With Chronic Renal Failure.|Clinical Study to Assess the Safety of the Use of the Drug Heparin Sodium Produced by the Laboratory Blausiegel Compared in Parallel to the Product Liquemine ® Laboratory Roche in Patients With Chronic Renal Failure.|Heparin|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Suspended|July 2008|||July 2008|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2008|October 26, 2010|October 1, 2008||No||No||https://clinicaltrials.gov/show/NCT01229072||114174|
NCT01225458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCDE|Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)|Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)|BCDE|Centre Hospitalier Universitaire de Nice|No|Completed|July 2008|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Both|75 Years|N/A|No|||September 2015|September 29, 2015|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225458||114449|
NCT01226264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s52647|Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence|Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence.|s52647|Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|November 2010|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|N/A|N/A|No|||December 2015|December 1, 2015|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226264||114389|
NCT01226277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4914g|A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma|An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered Daily in Patients With Refractory Solid Tumors or Lymphoma||Genentech, Inc.||Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226277||114388|
NCT01226290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL02413|Fibroid Ablation Study|Symptom Effectiveness Study of VizAblate™ Intrauterine Ultrasound-Guided RF Ablation (IUUSgRFA) in the Ablation of Uterine Fibroids|FAST-EU|Gynesonics|No|Terminated|January 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Female|28 Years|N/A|No|||March 2015|March 13, 2015|October 20, 2010|Yes|Yes|Investigational device changes; adequate enrollment achieved|No||https://clinicaltrials.gov/show/NCT01226290||114387|
NCT01217346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 09-127|A Prevalence Study of Obstructive Sleep Apnea in Subjects With Chest Pain, Positive Exercise Treadmill Test and Normal Coronary Angiogram|||The University of Hong Kong|Yes|Terminated|February 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|70 Years|No|Non-Probability Sample|Subjects with chest pain, positive exercise treadmill test and normal coronary angiogram|August 2013|August 1, 2013|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01217346||115068|
NCT01217359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2040|Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling|Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling||University of North Carolina, Chapel Hill|No|Completed|May 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|22|||Both|18 Years|65 Years|No|||December 2013|December 2, 2013|September 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217359||115067|
NCT01217619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25444|Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.|A Single Arm, One Center, Phase Ⅱ Study of Erlotinib as Neoadjuvent Treatment in Patients With Endobronchial Ultrasound Confirmed Stage ⅢA N2 NSCLC With EGFR Mutation in Exon 19 or 21|ML25444|Shanghai Chest Hospital|No|Active, not recruiting|March 2011|January 2017|Anticipated|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2015|February 28, 2015|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217619||115047|
NCT01218243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009S208|An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia|An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|September 2010|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Male|50 Years|70 Years|No|||May 2013|May 18, 2013|October 8, 2010|Yes|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01218243||114999|
NCT01218542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00045035|Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc|Whole Brain Radiation Therapy With Simultaneous Boost to Gross Metastatic Tumor Volume Using Volumetric Modulated Arc Therapy (RapidArc)||Emory University|Yes|Recruiting|April 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|September 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01218542||114976|
NCT01218555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00031088|Study of Everolimus (RAD001) in Combination With Lenalidomide|Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma||Emory University|Yes|Active, not recruiting|September 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01218555||114975|
NCT01219049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1144|L-Tyrosine Supplementation in Patients With Fibromyalgia|L-Tyrosine Supplementation in Patients With Fibromyalgia||Icahn School of Medicine at Mount Sinai|No|Terminated|January 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||March 2012|March 7, 2012|October 8, 2010||No|Due to FDA comments, changes required unavailable resources. There are no results for this    study.|No||https://clinicaltrials.gov/show/NCT01219049||114937|
NCT01224964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarker sputum airway study3|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3|BioSput-Air|Universitaire Ziekenhuizen Leuven|Yes|Terminated|January 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|65 Years|No|||October 2014|October 22, 2014|October 18, 2010||No|A lot of patients recruited in our center were already on montelukast treatment. It was not    possible to recruit sufficient patients for the study.|No||https://clinicaltrials.gov/show/NCT01224964||114487|
NCT01225302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W12-076|A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase 1 Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment||Abbott|Yes|Completed|September 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|N/A|No|||July 2012|July 13, 2012|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01225302||114461|
NCT01225003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52302|Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas|Diffusion Kurtosis Imaging en MR Spectroscopy in Grading and the Characterization of Tumour Infiltration in Gliomas||Universitaire Ziekenhuizen Leuven||Completed|July 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|standard neurosurgical procedure to obtain specimens; standard histopathological examination|Both|18 Years|N/A|No|Probability Sample|patients diagnosed with a gliomatuous brain tumor, prior to treatment|October 2010|September 28, 2011|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225003||114484|
NCT01225016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1007|Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound|Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound||University of Alabama at Birmingham|Yes|Withdrawn|October 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|19 Years|N/A|No|||January 2012|January 27, 2012|October 14, 2010|Yes|Yes|Due to lack of funding and issues with ability to complete all procedures, it was decided that    this study could not be carried out and therefore withdrawn.|No||https://clinicaltrials.gov/show/NCT01225016||114483|
NCT01225939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2350C00007|A Study Conducted Over 3 Periods to Look at the Drug in the Body|A Randomised, Open-label, Three-way Cross-over, Phase I Study in Healthy Subjects to Assess the Pharmacokinetics of AZD8329 After Single Doses of the Oral Solid Formulation and the Oral Solution||AstraZeneca|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 1, 2011|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01225939||114414|
NCT01225952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|656|Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction|A Three Arm Prospective Clinical Evaluation of Three FDA-approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction||Bausch & Lomb Incorporated|No|Completed|July 2010|July 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|93|||Both|40 Years|N/A|No|||December 2012|December 11, 2012|October 19, 2010|Yes|Yes||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01225952||114413|
NCT01225978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002147|Refining Information Technology Support for Genetics in Medicine|Refining Information Technology Support for Genetics in Medicine|RISGIM|Brigham and Women's Hospital|No|Active, not recruiting|September 2009|December 2014|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|None Retained|None Retained|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The subjects in this study will be treating clinicians, geneticists, genetic counselors,        and pathologists who are involved in ordering or processing genetic tests relating to        cardiomyopathy, hearing loss, and cancer genotyping tests.|January 2014|January 23, 2014|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225978||114411|
NCT01225991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-10|Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis|An Open-label Trial of Milnacipran for the Treatment of Pain in Rheumatoid Arthritis (RA) in Older Adults||University of California, Los Angeles|Yes|Completed|November 2010|June 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|50 Years|N/A|No|||September 2014|September 15, 2014|October 20, 2010||No||No|August 12, 2014|https://clinicaltrials.gov/show/NCT01225991||114410|
NCT01226589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23851|Pharmacist Discharge Medication Reconciliation Study|The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute||AHS Cancer Control Alberta|Yes|Completed|October 2007|October 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226589||114364|
NCT01226602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00067|Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.|A Randomized, Double-blind, Placebo Controlled, Crossover, Single Centre Phase I Study to Assess the Effect of Ticagrelor on Adenosine-induced Coronary Blood Flow Velocity in Healthy Male Subjects||AstraZeneca|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226602||114363|
NCT01226849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGH652|Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma|An Open-Label, Pilot Study To Investigate Feasibility and Safety Of Using Bortezomib, Rituximab, Ifosfamide, Carboplatin, Etoposide As Salvage Regime In Previously Treated Patients With Diffuse Large B-Cell Lymphoma|SGH652|Singapore General Hospital|Yes|Recruiting|November 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|21 Years|N/A|No|||June 2015|June 18, 2015|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01226849||114344|
NCT01228266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMM-EM|Mesenchymal Stem Cell Transplantation in MS|Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study|CMM-EM|Hospital Clinic of Barcelona|No|Terminated|December 2010|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|50 Years|No|||February 2014|February 12, 2014|October 25, 2010||No|Ended the recruitment in June 2012 for low enrollement accrual|No||https://clinicaltrials.gov/show/NCT01228266||114236|
NCT01225107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-052|Effect of Cranberry Extract on Infections in Burn Patients|A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Cranberry Extract on the Incidence of Infections in Burn Patients||Saint Elizabeth Regional Medical Center|No|Not yet recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|19 Years|N/A|No|||July 2011|July 19, 2011|August 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225107||114476|
NCT01226030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-2008-2|Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors|Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors||Protgen Ltd|Yes|Recruiting|September 2009|June 2011|Anticipated|April 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|65 Years|No|||October 2010|October 20, 2010|October 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01226030||114407|
NCT01226875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-225|Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi|Multicentred, Randomized Control Trial Comparing Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi||St. Michael's Hospital, Toronto|No|Recruiting|January 2011|November 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226875||114342|
NCT01217632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-3019-801|A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection||FibroGen|No|Active, not recruiting|August 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|75 Years|No|||January 2015|January 6, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01217632||115046|
NCT01217905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2710C00004|Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687|A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Single and Multiple Ascending Doses in Healthy Male Japanese Subjects|JSMAD|AstraZeneca|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|October 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217905||115025|
NCT01217918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631027|Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects|APhase 1, Placebo-Controlled, Randomized, Parallel Group, Subject- And Investigator-Blind, Sponsor-Open Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PH-797804 Following Multiple Escalating Oral Doses In Healthy Japanese Adult Subjects||Pfizer|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 14, 2011|October 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217918||115024|
NCT01217944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002F2301|Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia||Novartis||Completed|October 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|277|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|October 6, 2010||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT01217944||115022|
NCT01218269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHospital - 90415|U-clip Pilot Study in Plastic Surgery|A Prospective Evaluation of U-clips for Arterial Microvascular Anastomoses||Scott and White Hospital & Clinic|No|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|February 28, 2011|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218269||114997|
NCT01218256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UISM-2-2010|Secondary Prevention in Type 2 Diabetes: Comparison of Two Different Resistance Exercise Training Protocols|Combined Resistance and Endurance Training in Patients With Type 2 Diabetes: A Pilot-study to Assess the Effects of 2 Different Resistance Protocols on Muscle Mass, Strength and Glycemic Control.||Paracelsus Medical University|No|Completed|July 2007|May 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|30 Years|80 Years|No|||June 2007|October 8, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218256||114998|
NCT01218841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 310/04|Pure Fish Oil Parenteral Lipid Emulsion in Patients With Gastrointestinal Cancer|Clinical and Immunological Benefits of the Infusion of Pure Fish Oil Lipid Emulsion in Surgical Patients With Gastrointestinal Cancer.||University of Sao Paulo|Yes|Completed|November 2005|November 2008|Actual|November 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|75 Years|No|||October 2010|October 8, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218841||114953|
NCT01218828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-RCCL-5718|Prevention of Contrast Renal Injury With Different Hydration Strategies|Hydration With Different Sodium Chloride Protocols for the Prevention of Contrast Medium-induced Nephropathy in Patients Undergoing Coronary Angiography: a Randomized Trial|POSEIDON|Kaiser Permanente|Yes|Completed|October 2010|January 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|396|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218828||114954|
NCT01225315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-060A202|Study of ACT-129968 in Adult Patients With Partly Controlled Asthma.|A Multi-center, Double-blind, Placebo-controlled, Parallel-group Study to Establish Proof-of-concept and Explore the Efficacy of Different Doses of ACT-129968 in Adult Patients With Partly Controlled Asthma|CONTROL|Actelion|Yes|Completed|October 2010|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|438|||Both|18 Years|65 Years|No|||June 2013|June 13, 2013|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225315||114460|
NCT01225042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N132716.081.10|The Effect of Probiotics on E. Coli Gastroenteritis|The Effect of Probiotics on E. Coli Gastroenteritis|PRETEC|NIZO Food Research|No|Completed|October 2010|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01225042||114481|
NCT01225055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00033380|Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury|Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury||Northwestern University|No|Active, not recruiting|October 2010|August 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|21 Years|N/A|No|||October 2015|October 7, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225055||114480|
NCT01225679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|512947|Late-onset Congenital Central Hypoventilation Syndrome and the Mutation of Phox2B Gene|Late-onset, Insidious Course and Invasive Treatment of Congenital Central Hypoventilation Syndrome in a Case With the Phox2B Mutation|CCHS|Associação Fundo de Incentivo à Pesquisa|No|Completed|July 2010|September 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|Samples With DNA|Human|Male|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|familial case in which the father (proband) presented late-onset CCHS with an expansion        mutation of the Phox2B gene that was confirmed by genetic analysis.|February 2014|February 5, 2014|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01225679||114433|
NCT01225965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL-015|Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung|An Efficacy and Feasibility Study to Investigate the Effect of Ectoin® Inhalation Solution (EIL) in Subjects With Inflammation and Airway Obstruction Followed by a Long Term Study Extension on the Prevention of Lung Function Decline|EFECT|Bitop AG|Yes|Completed|October 2010|September 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Female|75 Years|80 Years|No|||August 2012|August 6, 2012|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225965||114412|
NCT01226836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/0152|Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD): the Development and Feasibility of an Education Package|Pulmonary Rehabilitation in COPD: the Development and Feasibility of an Education Package||University of Ulster|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|N/A|N/A|No|||November 2012|November 8, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226836||114345|
NCT01227460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRK-SI-100|Effects of Sitagliptin (Januvia®) on Blood Glucose Control in Patients With Type 1 Diabetes|Effects of Sitagliptin (Januvia®) on Blood Glucose Control in Patients With Type 1 Diabetes and CGM Substudy of the Investigator Initiated Study Protocol Effects of Sitagliptin (Januvia) on Glucagon Suppression and GLP-1 Levels in Patients With Type 1 Diabetes; CGM Substudy||University of Colorado Denver School of Medicine Barbara Davis Center|Yes|Completed|November 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|140|||Both|18 Years|70 Years|No|||May 2014|May 19, 2014|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227460||114298|
NCT01228812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR_AP|Physical Activity Behavior of Rheumatoid Arthritis Patients and Healthy Controls|An Observational Study of Physical Activity Behavior of Swiss Rheumatoid Arthritis Patients and Healthy Matched Controls||University of Lausanne|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|||||Both|40 Years|80 Years||Probability Sample|Patients from the RA patients group will be selected in the Rheumatology Department of the        Centre Hospitalier universitaire Vaudois in Lausanne. Healthy matched controls will be        randomly selected from a cohort study conducted in Lausanne.|October 2010|October 26, 2010|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01228812||114194|
NCT01228825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC2760/06/005|Pharmacokinetics of Cefuroxime in Cardiac Surgery With Cardiopulmonary Bypass|Evaluation of Plasma Concentrations and Pharmacokinetics of Cefuroxime Administered Prophylactically in Patients Undergoing Coronary Surgery With Cardiopulmonary Bypass||University of Sao Paulo|No|Completed|May 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|19|Samples With DNA|Blood samples were collected sequentially after the administration of initial bolus of      cefuroxime every 15 minutes during the first hour, then within two, three and six hours.      Samples were also collected every 15 minutes during CPB. Group Off-Pump had equivalent      collections, considering the time after heparinization and anastomosis initiation. Four      other blood samples were collected at times considered as high risk for bacterial      contamination, i.e.      chest incision, beginning of anastomosis, after protamine administration, and chest suture.      After each bolus of 750 mg, samples were collected within 30 minutes, one, three, and six      hours.|Both|18 Years|75 Years|No|Non-Probability Sample|Twenty patients scheduled for coronary surgery were enrolled in the study.|October 2010|October 26, 2010|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01228825||114193|
NCT01236768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL13|Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm|An Open-Label, Randomized, Phase 3 Study of the Contraceptive Efficacy and Safety of Agile Transdermal Contraceptive Delivery System (TCDS) in Comparison to an Oral Contraceptive Containing 150 Mcg Levonorgestrel And 30 Mcg Ethinyl Estradiol|ATI-CL13|Agile Therapeutics|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|407|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236768||113587|
NCT01237054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110020|Imaging in MGUS, SMM and MM|A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM)||National Institutes of Health Clinical Center (CC)|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|November 6, 2010|No|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01237054||113565|
NCT01237301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04034-10-C|Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes|Comparison of Clinical Decisions and Outcomes Employing a Treat to Target Design for Subjects With Type 2 Diabetes Randomized to Either SMBG or CGM|REACT3|HealthPartners Institute|Yes|Completed|October 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|75 Years|No|||November 2013|November 30, 2015|November 2, 2010||No||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01237301||113546|
NCT01217398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000683852|Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye|Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma||National Cancer Institute (NCI)||Recruiting|October 2009|||October 2012|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||August 2012|August 23, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217398||115064|
NCT01217645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6702C00030|Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration|A Phase I, Open-label, Single-Centre Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration to Healthy Male Subjects|AZD6765|AstraZeneca|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01217645||115045|
NCT01217931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0085|Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial|Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2011|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217931||115023|
NCT01218282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExTCOPD01|Exercise Training in Chronic Obstructive Pulmonary Disease (COPD)|Different Methods of Home Exercise Training in COPD Patients||Università degli Studi di Ferrara|No|Completed|January 2008|March 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|80|||Both|40 Years|85 Years|No|||October 2010|October 26, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218282||114996|
NCT01218295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMTCOPD2|Inspiratory Muscle Training With Normocapnic Hyperpnea in Chronic Obstructive Pulmonary Disease (COPD)|Efficacy of Inspiratory Muscle Training by Means of Spirotiger® in COPD Patients.||Università degli Studi di Ferrara|No|Recruiting|May 2009|July 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||October 2010|October 8, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218295||114995|
NCT01218568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS HE-01|Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial|Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial||Institute of Liver and Biliary Sciences, India|Yes|Completed|October 2010|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||June 2012|April 2, 2013|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01218568||114974|
NCT01219088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si392/2010|Intrathecal Morphine,Femoral Nerve Block,Periarticular Bupivacaine Infiltration for Pain After Intramedullary Hip Screw|Post Operative Pain Control Among Intrathecal 0.1 mg Morphine, Femoral Nerve Block, or Periarticular Infiltration of 20 mL of 0.25% Bupivacaine in Patients Post Intramedullary Hip Screw||Mahidol University|No|Recruiting|September 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|90 Years|No|||August 2011|August 3, 2011|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01219088||114934|
NCT01219075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-10-6|Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer|Soy Treatment for High-risk Women||University of Southern California|No|Active, not recruiting|June 2010|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|110|||Female|30 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 20, 2015|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01219075||114935|
NCT01229280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDBEQ_DFNLP/ELEA_010|Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.|Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.||Center for Clinical Pharmacology Research Bdbeq S.A.|No|Not yet recruiting|December 2010|February 2011|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 26, 2010|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229280||114158|
NCT01225432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2008.050dt|The Effect of Gait Training Using Virtual Reality and Real-Time Feedback on Physiological and Functional Gait Performance in Persons With a Traumatic Lower Extremity Amputation|The Effect of Gait Training Using Virtual Reality and Real-Time Feedback on Physiological and Functional Gait Performance in Persons With a Traumatic Lower Extremity Amputation|VRVO2|Brooke Army Medical Center|No|Enrolling by invitation|August 2007|||September 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 20, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225432||114451|
NCT01227174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-142|Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery|Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery||Atlantic Center for Oral and Maxillofacial Surgery|Yes|Not yet recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|169|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 21, 2010|October 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01227174||114320|
NCT01225406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 113|Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children|Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|August 2010|December 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|56|Samples Without DNA|Plasma and PBMC|Both|N/A|18 Years|No|Non-Probability Sample|Thai children aged < 18 years old who are on or are switching to third line antiretroviral        therapy|March 2015|March 26, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01225406||114453|
NCT01225692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2004-014|Brain Trauma Outcomes in Nova Scotia Study|Brain Trauma Outcomes in Nova Scotia|BTOS|Queen Elizabeth II Health Sciences Centre|No|Completed|February 2004|June 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Health Services Research|||Actual|52|||Both|N/A|N/A||||October 2010|October 20, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01225692||114432|
NCT01226056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S075SORD01|Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets|Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets||Southern Europe New Drug Organization|No|Suspended|March 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2010|October 20, 2010|October 18, 2010||No|toxicity (protocol amendment under approval)|No||https://clinicaltrials.gov/show/NCT01226056||114405|
NCT01226069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/09/481|Effectiveness of Topical Glycerine Sulphate Paste, Hirudoid Cream and Nil Application on Superficial Phlebitis|To Investigate the Effectiveness of Topical Glycerine Sulphate, Hirudoid Cream and Nil Application in Treating Peripheral Cannula Related Phlebitis||Tan Tock Seng Hospital|Yes|Completed|November 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|147|||Both|21 Years|N/A|No|||October 2010|October 20, 2010|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226069||114404|
NCT01227967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-I-0210|Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications|A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications|IRC003|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|September 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227967||114259|
NCT01227980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110010|Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^|Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics||National Institutes of Health Clinical Center (CC)|No|Completed|October 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|21 Years|65 Years|No|||December 2015|December 30, 2015|October 22, 2010|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01227980||114258|
NCT01236248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2130|Drug Abuse Prevention Among Girls Through a Mother-Daughter Intervention|Drug Abuse Prevention Among Girls Through a Mother-Daughter Intervention||Columbia University|Yes|Completed|December 2004|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|916|||Female|11 Years|13 Years|Accepts Healthy Volunteers|||November 2010|March 20, 2013|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236248||113627|
NCT01236521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-128|Care Management for the Effective Use of Opioids|Care Management for the Effective Use of Opioids (CAMEO)|CAMEO|VA Office of Research and Development|Yes|Completed|December 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236521||113606|
NCT01226914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVICEL|A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy|A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy||Medical University of South Carolina|No|Completed|June 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|1||Anticipated|120|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|October 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01226914||114339|
NCT01227213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMAVA|The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma|The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma||Radboud University|No|Completed|November 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|Samples Without DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|30 patients with metastatic renal cell carcinoma starting treatment with sunitinib|October 2015|October 29, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227213||114317|
NCT01227525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|535-07-FB|Assessing the Benefits of the Vibraject Attachment|Assessing Pain Behaviors of Children Receiving Local Anesthesia Using VibraJect Attachment|Vibraject|University of Nebraska|No|Completed|August 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|4 Years|8 Years|No|||October 2010|October 25, 2010|April 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01227525||114293|
NCT01217658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0392|Measuring and Reducing Excessive Infant Crying|Measuring and Reducing Excessive Infant Crying: A Randomized Trial|UTHealth THB|The University of Texas Health Science Center, Houston|No|Completed|January 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|N/A|5 Weeks|No|||December 2015|December 4, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217658||115044|
NCT01217957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16005|A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|November 2010|June 2017|Anticipated|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|65|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|September 24, 2010|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01217957||115021|
NCT01218308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114541|A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children|Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine, GSK2282512A, (FLU Q-QIV) When Administered in Children||GlaxoSmithKline||Completed|December 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|5220|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|October 7, 2010|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01218308||114994|
NCT01218581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|adenomyosis|Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis|Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial||Mansoura University|Yes|Completed|December 2005|January 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Female|N/A|N/A|No|||December 2005|October 8, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218581||114973|
NCT01219400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103|Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes|Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes||Lund University|Yes|Completed|January 2012|December 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|75 Years|No|||September 2014|September 29, 2014|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219400||114910|
NCT01225367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES_DOP05|The Use of a Ultra-sound of the Lung to Diagnose Lung Diseases|Detection and Characterization of Cardio-pulmonary Patho-physiological States and Diseases by Ultrasound Transthoracic Doppler||Echosense Ltd.|No|Completed|August 2010|August 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|primary care clinic|May 2011|August 12, 2015|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225367||114456|
NCT01225380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-196-0123|A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0123)||Gilead Sciences|Yes|Completed|October 2010|September 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|324|||Both|18 Years|70 Years|No|||December 2013|December 20, 2013|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225380||114455|
NCT01225393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT4864g|A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis|A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patient With Active Rheumatoid Arthritis||Genentech, Inc.||Completed|November 2010|||July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|211|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225393||114454|
NCT01227187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1K-MC-1003|Safety and Dose Finding Study of Xigris in Hemodialysis Patients|Safety and Dose Finding Study of Xigris (Drotrecogin Alfa Activated) as an Anti-coagulant in End Stage Renal Disease (ESRD) Patients Treated With Hemodialysis (HD)|Xigris1003|George Washington University|No|Completed|October 2008|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227187||114319|
NCT01226004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRRA01|Multi-Institutional Registry for Prostate Cancer Radiosurgery|Multi-Institutional Registry for Prostate Cancer Radiosurgery. An IRB Approved Observational Trial|RPCR|Florida Robotic Radiosurgery Association|Yes|Recruiting|July 2010|July 2020|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Male|18 Years|90 Years|No|Non-Probability Sample|Men over 18 who have early or intermediate risk prostate cancer and have chosen to undergo        radiosurgical treatment|March 2015|March 9, 2015|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226004||114409|
NCT01226238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deprexis-HH-HL-WL|Online Self-help for Depressed Patients Awaiting Psychotherapy|||University of Luebeck||Terminated|October 2010|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|65 Years|No|||June 2014|June 25, 2014|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226238||114391|
NCT01226576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCa004|Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study|Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study||InSightec|No|Recruiting|October 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Male|50 Years|75 Years|No|||March 2016|March 7, 2016|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226576||114365|
NCT01226251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100914|New "in Vitro" Diagnostic Test for Oral Malodour|New "in Vitro" Diagnostic Test for Oral Malodour: First Prototype Evaluation|Striptest|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|January 2011|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Hundred consecutive adult subjects consulting the bad breath clinic who meet the inclusion        criteria.        Number of volunteers extended to 150 in March 2012 (Amendment Research Agreement)|October 2012|October 1, 2012|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01226251||114390|
NCT01236261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMICOMED-GEIH 0109|Prospective Population Study on Candidemia in Spain|Prospective Population Study on Candidemia in Spain (Estudio Poblacional Prospectivo Sobre Candidemia en España)|CANDIPOP|Fundacion SEIMC-GESIDA|Yes|Completed|March 2013|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|730|Samples Without DNA|Fungal strains obtained from blood cultures.|Both|N/A|N/A|No|Non-Probability Sample|All patients with Candida sp or other fungal isolate obtained from a blood sample        (fungemia episode)|April 2013|April 22, 2013|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236261||113626|
NCT01226355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FW2009-183|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Coronary Stent System|Clinical Trial Program of a Medical Instrument Product||Medfavour (Beijing) Medical Co., Ltd|Yes|Active, not recruiting|April 2009|November 2014|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|75 Years|No|||May 2012|May 20, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226355||114382|
NCT01226654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00006060|Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis|Quantitative MR Imaging and Proton Spectroscopy in MS||New York University School of Medicine|Yes|Recruiting|August 1991|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|7 Years|110 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226654||114359|
NCT01226667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS2009001|Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia|Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia|Flexdose|Osteoporosis Medical Center, Beverly Hills, CA|No|Completed|July 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|174|||Female|18 Years|65 Years|No|||July 2012|July 30, 2012|October 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01226667||114358|
NCT01226927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 18880|The Efficacy of Automated Intermittent Boluses for Continuous Femoral Nerve Block: a Prospective, Randomized Comparison to Continuous Infusions|The Efficacy of Automated Intermittent Boluses for Continuous Femoral Nerve Block: a Prospective, Randomized Comparison to Continuous Infusions||Medical University of South Carolina|No|Completed|April 2009|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|80 Years|No|||October 2010|October 21, 2010|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226927||114338|
NCT01226953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V37_07E1|Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants|A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants||Novartis||Completed|October 2010|March 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|660|||Both|365 Days|569 Days|Accepts Healthy Volunteers|||December 2011|December 27, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226953||114337|
NCT01227226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06|Tear Osmolarity Over Time With Artificial Tears|||Hom, Milton M., OD, FAAO|Yes|Enrolling by invitation|October 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|4||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 4, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227226||114316|
NCT01227239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JACCRO CC-04|Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting|A Phase I/II Study of S-1 and Oxaliplatin Combined With Radiation for Preoperative Locally Advanced Rectal Carcinoma. (SHOGUN Trial)||Japan Clinical Cancer Research Organization|Yes|Active, not recruiting|September 2010|August 2016|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|80 Years|No|||November 2012|November 26, 2012|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01227239||114315|
NCT01227538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME/2010/3452|Towards Simple and Non-invasive Assessment of Residual Beta-cell Function in Type 1 Diabetes|Towards Simple and Non-invasive Assessment of Residual Beta-cell Function in Type 1 Diabetes||University Hospitals Bristol NHS Foundation Trust|No|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|45 Years|No|Non-Probability Sample|Subjects with Type 1 diabetes diagnosed in the last 5 years|January 2016|January 6, 2016|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227538||114292|
NCT01217671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamada-AAT (inhaled) 007|International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema|A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema||Kamada, Ltd.|Yes|Active, not recruiting|December 2009|December 2014|Anticipated|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01217671||115043|
NCT01217684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 6404|Test-retest Reliability of a Standard Protocol on the Biodex Dynamometer|||Universitaire Ziekenhuizen Leuven||Completed|October 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|60|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|older adults|June 2012|June 14, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217684||115042|
NCT01217970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShoptawPI_ibudilast|Safety Interaction Trial Ibudilast and Methamphetamine|Phase I Safety Interaction Trial of Ibudilast With Methamphetamine||University of California, Los Angeles|Yes|Completed|January 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|11|||Both|18 Years|55 Years|No|||December 2013|December 2, 2013|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01217970||115020|
NCT01217983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-056 Med 10-019|Utility of Renal Biomarkers in Cirrhosis|Utility of Renal Biomarkers in Cirrhotic Patients||University Hospital, Geneva|Yes|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|105|Samples Without DNA|Plasma, serum, urine and ascitis|Both|18 Years|N/A|No|Probability Sample|All patients admitted for cirrhotic ascitis in the University Hospital of Geneva.|October 2012|October 29, 2012|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217983||115019|
NCT01218594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-EN-RT|Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer|Phase I/II Clinical Trial of Recombinant Human Endostatin in Combination With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer|DP-EN-RT|Sun Yat-sen University|Yes|Active, not recruiting|May 2009|December 2015|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||August 2012|September 17, 2012|June 1, 2010||No||No|August 19, 2012|https://clinicaltrials.gov/show/NCT01218594||114972|This was a single-arm study, no comparison between Endostar to CCRT and CCRT alone was performed. It is not clear whether the observed improvement in survival is a result of the addition of Endostar or patient selection.The patient samples are small.
NCT01218607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZL-S52480|Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.|BOsentan for Mild Pulmonary Vascular Disease in Asd Patients (the BOMPA Trial): a Double-blind, Randomized Controlled, Pilot Trial|BOMPA|Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218607||114971|
NCT01218620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02916|Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors|Randomized Drug Interaction Study of RO4929097 for Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|September 2010|December 2014|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|17|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|October 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01218620||114970|
NCT01218633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003435|Dose-response Study of Exendin-9,39 on Glucose Metabolism|A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.||Mayo Clinic|No|Completed|May 2011|December 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|11|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218633||114969|
NCT01218854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100217|A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy|A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy||National Institutes of Health Clinical Center (CC)||Recruiting|September 2010|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|45|||Both|18 Years|100 Years|No|||November 2015|December 15, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218854||114952|
NCT01218867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110013|CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer|Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes||National Institutes of Health Clinical Center (CC)||Completed|October 2010|February 2016|Actual|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||February 2016|March 1, 2016|October 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218867||114951|
NCT01218880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2ES2010-1|Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer|Phase I Study of M2ES Combined Gemcitabine in Patients With Advanced Pancreatic Cancer||Protgen Ltd|Yes|Recruiting|June 2010|December 2011|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|21|||Both|18 Years|60 Years|No|||September 2010|October 18, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218880||114950|
NCT01218893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw1|Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|ZonMw1|Radboud University|Yes|Completed|April 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218893||114949|
NCT01219101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-010|The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination|Evaluate the Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination||Royan Institute|Yes|Completed|March 2011|February 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Female|25 Years|30 Years|No|||March 2009|November 5, 2014|October 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01219101||114933|
NCT01229332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0611/002|A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients|A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations||NeuroDerm Ltd.||Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|N/A|No|||December 2011|December 4, 2011|October 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01229332||114154|
NCT01228292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/27/179|Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.|Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.||University Hospital, Antwerp|Yes|Not yet recruiting|January 2011|January 2013|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2010|October 25, 2010|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228292||114234|
NCT01228539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPTSD-10-118-2|Breaking the Cycle IV: Military PTSD (MPTSD) Treatment Study|Breaking the Cycle IV: Military PTSD (MPTSD) Treatment Study|MPTSD|University of Connecticut Health Center|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Male|18 Years|N/A|No|||May 2013|May 9, 2013|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01228539||114215|
NCT01225484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-315 ex 09/10|Perioperative Analgesia After Knee Arthroplasty|Perioperative Analgetic Therapy After Knee Arthroplasty||Landeskrankenhaus Feldbach|No|Recruiting|October 2010|October 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|123|||Both|18 Years|80 Years|No|||April 2015|April 8, 2015|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225484||114447|
NCT01227148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS95-070|Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein Catabolism in Critically Ill Patients|Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein||Kaohsiung Veterans General Hospital.|Yes|Completed|April 2006|December 2006|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||April 2006|October 22, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01227148||114322|
NCT01235936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0004|Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia|Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4||Akebia Therapeutics|No|Completed|October 2010|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|79 Years|No|||September 2012|September 27, 2012|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235936||113651|
NCT01226095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-162|Evaluation of the Effectiveness, Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients|A Prospective, Multi-center, Post-marketing Observational Study to Evaluate the Effectiveness and Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients||Abbott||Completed|June 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|519|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinics|January 2012|September 16, 2013|September 7, 2010||No||No|November 4, 2011|https://clinicaltrials.gov/show/NCT01226095||114402|
NCT01226368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/B/09|Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.|Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.|HP2V-AG|Centre Hospitalier Universitaire de Fort-de-France|No|Completed|December 2010|March 2014|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|455|Samples With DNA|cervix cells|Female|18 Years|N/A|No|Non-Probability Sample|Adult HIV-Infected women followed in one of the center participating in the study and who        has accepted the use of Nadis® medical files.|October 2014|October 29, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226368||114381|
NCT01226966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3815|Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes|Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes|EVIDENCE|Novo Nordisk A/S|No|Completed|September 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3152|||Both|18 Years|N/A|No|Non-Probability Sample|Patients starting or having recently started liraglutide treatment for less than one week,        and satisfying the study inclusion and exclusion criteria.|October 2014|October 15, 2014|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226966||114336|
NCT01227252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13734|A Safety Study of LY2886721 Multiple Doses in Healthy Subjects|Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|42|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 9, 2011|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01227252||114314|
NCT01227291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYL040012_II|SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg|Study With SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With IOP >= 21 mm Hg.||Sylentis, S.A.|Yes|Completed|October 2010|September 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227291||114311|
NCT01227265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07037|Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)|A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)||Merck Sharp & Dohme Corp.|Yes|Completed|November 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|476|||Both|30 Years|85 Years|No|||September 2015|September 3, 2015|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227265||114313|
NCT01227278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP196|A Study to Evaluate the Effectiveness of a Drug (MEDI-563) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe COPD and Sputum Eosinophilia||MedImmune LLC|No|Completed|November 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|421|||Both|40 Years|85 Years|No|||April 2014|April 3, 2014|October 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227278||114312|
NCT01227564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2571010|Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease|A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.||Pfizer|Yes|Completed|February 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|50 Years|80 Years|No|||January 2016|January 28, 2016|October 22, 2010|Yes|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01227564||114290|In 2013 Pfizer and Janssen Alzheimer Immunotherapy Alliance made the decision that ACC-001 would not be further developed in mild to moderate AD.
NCT01217996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COGTRN|Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors|Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors||St. Jude Children's Research Hospital|No|Completed|October 2010|November 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|8 Years|16 Years|No|||April 2014|April 28, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01217996||115018|
NCT01218009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-306|A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing|A Multi-Center 52-Week Study to Assess the Safety of an Albuterol Dry-powder Inhaler in Subjects With Asthma||Teva Pharmaceutical Industries|No|Terminated|October 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Both|12 Years|N/A|No|||May 2015|May 1, 2015|October 7, 2010|Yes|Yes|Change to study required.|No|May 1, 2015|https://clinicaltrials.gov/show/NCT01218009||115017|
NCT01218321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0582-09-HMO-CTIL|The Effect of Anti-epileptic Drugs on Mitochondrial Activity|Phase 1 Study for Measuring the Effect of Antiepileptic Drugs on Mitochondrial Activity||Hadassah Medical Organization|Yes|Not yet recruiting|January 2011|June 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|White blood cells from peripheral blood samples|Both|3 Years|18 Years|No|Probability Sample|Children, ages 3 to 18 years old who start new antiepileptic drug treatment for the first        time for new onset epilepsy|October 2010|October 7, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218321||114993|
NCT01218347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT10_Rosuvastatin_OATP1B1|Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles|Influence of OATP1B1 Genotype on the Pharmacokinetics,Lipid Lowering Effect, and Lipid Profiles After Rosuvastatin Administration|OATP|Seoul National University Hospital|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2011|January 4, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01218347||114991|
NCT01219140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM 2010-001|Pomegranate Extract Biomarker Study in Osteopenic Women|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of Pomegranate Extract Capsules in Post-Menopausal Subjects With Decreased Bone Mineral Density||POM Wonderful LLC|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Female|45 Years|65 Years|No|||October 2010|October 8, 2010|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219140||114930|
NCT01219725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG2508/06/08|Cardiovascular Prophylaxis for Postmenopausal Women|Can a Moderate Intensity Exercise Training Programme Improve Cardiac Function and Known Cardiovascular Risk Factors in Middle-aged Women?||University of Leeds|No|Recruiting|July 2005|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||May 2009|October 27, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219725||114886|
NCT01218906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD34|Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia|Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia||Sanofi|No|Completed|August 2010|March 2012|Actual|November 2011|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|2 Years|14 Years|Accepts Healthy Volunteers|Probability Sample|Participants aged 2 to 14 years in 5 countries in Asia: Malaysia, Indonesia, Thailand, the        Philippines and Viet Nam.|March 2012|March 27, 2012|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01218906||114948|
NCT01219114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-IPH-DUM-2010/1|Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use|A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines||AstraZeneca|No|Withdrawn|October 2010|November 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|several private and government tertiary hospitals|September 2011|September 27, 2011|October 10, 2010|Yes|Yes|Inability to recruit patients within the specified time period. No patients have been enrolled    in the study.|No||https://clinicaltrials.gov/show/NCT01219114||114932|
NCT01219426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/3-F|A Transversal Study for the French Validation of Two Assessment Tools of Gambling Related Cognitions.|A Transversal Study for the French Validation of Two Assessment Tools of Gambling Related Cognitions.||Nantes University Hospital|No|Completed|March 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|||||Both|18 Years|N/A||Non-Probability Sample|To be more than 18 years old (the legal age to gamble in France)|May 2011|May 19, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219426||114908|
NCT01225081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0107|A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients|A Phase 3, Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone||Astellas Pharma Inc|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|20 Years|N/A|No|||January 2016|January 18, 2016|October 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01225081||114478|
NCT01225419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0082|Mobilization by Plerixafor of Haematopoietic Stem Cells in Children|Mobilization by Plerixafor of Haematopoietic Stem Cells in Children|MEP1|University Hospital, Clermont-Ferrand||Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|18 Years|No|||July 2014|July 4, 2014|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01225419||114452|
NCT01229111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02535|Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers|A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers||National Cancer Institute (NCI)||Active, not recruiting|October 2010|||July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2013|December 6, 2013|October 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229111||114171|
NCT01226316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3610C00001|Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.||AstraZeneca|No|Recruiting|December 2010|April 2018|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|130 Years|No|||March 2016|March 11, 2016|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226316||114385|
NCT01225770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2010001|Gargling With Green Tea for Prophylaxis of Influenza Infection in Teenagers|Effects of Gargling With Green Tea on Preventing Influenza Infection Among High School Students: A Randomized Clinical Study||University of Shizuoka|No|Recruiting|November 2010|August 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|640|||Both|15 Years|20 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225770||114426|
NCT01226017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1589|A Possible Effect of Oxytocin During Interaction Between Humans and Animals|A Possible Effect of Oxytocin During Interaction Between Humans and Animals|Oxytocin2010|Norwegian University of Life Sciences|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Female|20 Years|30 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226017||114408|
NCT01235949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112921|Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment|Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines||GlaxoSmithKline||Completed|November 2010|December 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|18||Actual|850|||Both|12 Weeks|16 Weeks|Accepts Healthy Volunteers|||September 2013|September 25, 2013|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235949||113650|
NCT01226108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aktin study|The Akloma Tinnitus Patch in Patients With Manifested Tinnitus|The Akloma Tinnitus Patch in Patients With Manifested Tinnitus (the Aktin Study)|Aktin|Akloma Bioscience AB|No|Completed|October 2010|||August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||September 2011|September 23, 2011|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226108||114401|
NCT01226381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0083|Interaction Between tropisétron / granisétron - paracétamol|Comparative Study of the Influence of Two Antagonist Receptors 5-HT3, tropisétron and granisétron, on the Analgesic Effect of Paracétamol||University Hospital, Clermont-Ferrand||Completed|July 2010|May 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01226381||114380|
NCT01226394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 1539-ProphyloCHIP|Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients|Multicentric Phase III Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" HIPEC (Hyperthermic Intraperitoneal Chemotherapy) in Colorectal Patients Initially Treated With Surgery and Adjuvant Chemotherapy Who Have a High Risk of Developing Colorectal Peritoneal Carcinomatosis|ProphyloCHIP|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|April 2010|June 2019|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|70 Years|No|||January 2014|January 16, 2014|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226394||114379|
NCT01226680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921066|A Study Of Tasocitinib In Dry Eye Subjects|A Phase II, Randomized, Double Masked, Parallel Group, Vehicle Controlled, Multiple-Dose Study Of Tasocitinib (CP-690,550) In Subjects With Dry Eye Disease||Pfizer|No|Withdrawn|December 2010|November 2011|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||December 2010|December 21, 2010|October 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01226680||114357|
NCT01227304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMOOCH-1|SMOOCH - Small Volume Challenges to Predict Volume Responsiveness: Prospective Interventional Study||SMOOCH|Technische Universität München||Recruiting|July 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2010|October 22, 2010|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227304||114310|
NCT01227577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AUS28|CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib|A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|MACS1428|Novartis|No|Completed|November 2010|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 21, 2010|No|Yes||No|November 19, 2015|https://clinicaltrials.gov/show/NCT01227577||114289|
NCT01227590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2629-34853|Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)|Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)|AP6142|University of California, San Francisco|No|Completed|February 2010|September 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227590||114288|
NCT01227824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113086|A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily|A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|SPRING-2|ViiV Healthcare|No|Active, not recruiting|October 2010|June 2015|Anticipated|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|827|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|October 14, 2010|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01227824||114270|
NCT01217710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001171|Promoting Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) Through New Technology and Health Coaching|Next Generation Technology for Chronic Care Self Management||Mayo Clinic|No|Completed|April 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|38|||Both|40 Years|N/A|No|||May 2015|May 11, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217710||115040|
NCT01218022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-064|Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fasting Condition|An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fasting Condition||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years||||October 2010|November 1, 2010|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218022||115016|
NCT01218035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94/180/2006|Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis||Turku University Hospital|Yes|Completed|May 2007|June 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|49|||Female|20 Years|N/A|No|||June 2011|June 15, 2011|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218035||115015|
NCT01218334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ineedMD 06-777|A Comparative Trial of Standard 12 Lead ECG to the 12 Lead ECG Glove to Assess Cardiac Electrical Function|A Randomized, Single Blind, Comparative Trial of Standardized 12 Lead ECG to the 12 Lead ECG Glove for the Assessmant of Cardiac Electrical Function|HandEKG|New York University School of Medicine|No|Completed|June 2008|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiology Patients|April 2013|April 5, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218334||114992|
NCT01219439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-14|Evaluation of Discarded Laboratory Pathological Specimens and Media|Laboratory Evaluation of IVF Discarded Pathological Specimens and Media for Optimization of Techniques for Assisted Reproduction||Reproductive Medicine Associates of New Jersey|No|Enrolling by invitation|July 2007|December 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Samples with DNA: Non-viable oocytes, spermatozoa, granulosa cells and follicular fluid      Samples without DNA: seminal fluid, serum and conditioned IVF media|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing infertility treatment.|November 2015|November 16, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219439||114907|
NCT01219959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51067|Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients|Multi-center, Prospective, Randomized Trial to Demonstrate Improved Metabolic Control of Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in the Treatment of Diabetic CAPD Patients||Baxter Healthcare Corporation|Yes|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||August 2011|August 4, 2011|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219959||114868|
NCT01219946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RGR-DUM-2010/1|A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)|A Cross Sectional Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease and the Limitations of Patients' Activities in Primary Care.|COPD Language|AstraZeneca|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|700|||Both|45 Years|75 Years|No|Probability Sample|Patients with Chronic Obstructive Pulmonary Disease|March 2012|March 20, 2012|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219946||114869|
NCT01220310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09242008-1309|Doctors and Web-based Self-management Support Pilot Study|Doctors and Web-based Self-management Support Pilot Study.||Stanford University||Completed|October 2008|August 2009|Actual|August 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 11, 2010|August 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220310||114841|
NCT01220336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CEPC|Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions||HCPC|University of California, San Francisco|No|Completed|April 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|441|||Both|18 Years|75 Years|No|||October 2014|October 17, 2014|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220336||114839|
NCT01226888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-037|Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer|Prospective Study of Changes in Brown Adipose Tissue (BAT) Activity in Men Receiving Androgen Deprivation Therapy (ADT) With a GnRH Agonist or Antagonist for Prostate Cancer||Massachusetts General Hospital|Yes|Terminated|September 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|Samples With DNA|fine needle aspirate biopsies of subcutaneous fat|Male|N/A|N/A|No|Non-Probability Sample|Men initiating androgen deprivation therapy with a GnRH agoinist or antagonist|November 2012|November 2, 2012|October 4, 2010||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT01226888||114341|
NCT01229410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-036|Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy|||Allergan|No|Completed|December 2010|October 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|October 20, 2010|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT01229410||114148|
NCT01229423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAT-KOR-01|Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects|||Allergan|No|Completed|November 2009|October 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Female|18 Years|N/A|No|||December 2011|December 16, 2011|October 25, 2010|Yes|Yes||No|December 16, 2011|https://clinicaltrials.gov/show/NCT01229423||114147|
NCT01225146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4820s|Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)|A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)|RAVE2|Greater Houston Retina Research|No|Terminated|October 2010|||October 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 26, 2012|October 14, 2010|Yes|Yes|The collaborator, Genentech, stopped supplying the study drug to the site.|No||https://clinicaltrials.gov/show/NCT01225146||114473|
NCT01225159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUB.EC 51-1008-08-1-1|Tight Glycaemic Control During Cardiac Surgery|Safety and Efficacy of Tight Glycaemic Control During Cardiac Surgery|TGC|Prince of Songkla University|Yes|Terminated|September 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|15 Years|N/A|No|||November 2015|November 15, 2015|July 29, 2010||No|Hypoglycaemia is significantly higher in TGC|No|April 14, 2014|https://clinicaltrials.gov/show/NCT01225159||114472|
NCT01226862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSA Telestroke|Advancing Telestroke Care: A Prospective Observational Study|Advancing Telestroke Care: A Prospective Observational Study|ATC|National Stroke Association, United States|Yes|Completed|December 2010|December 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|508|||Both|18 Years|N/A|No|Non-Probability Sample|600 subjects meeting inclusion and exclusion criteria will be enrolled consecutively over        approximately 12 months and followed for 90 days post-stroke.|December 2013|December 4, 2013|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226862||114343|
NCT01227135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000686729|Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia|CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR).||University of Glasgow|Yes|Recruiting|March 2010|||March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||November 2011|November 29, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227135||114323|
NCT01235325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRB RP/2006/38|The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients|The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease||University College Cork|Yes|Completed|July 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|70 Years|No|||November 2010|November 5, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235325||113697|
NCT01235338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-117|Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers|A Phase 1, Open-label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR, Administered Alone and in Combination in Healthy Adult Subjects||Shire|No|Completed|November 2010|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|November 2, 2010|No|Yes||No|November 4, 2011|https://clinicaltrials.gov/show/NCT01235338||113696|
NCT01226693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631028|A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804|A Phase 1, Randomized, Open Label, Single Dose, 3 Treatment, Two Period, Balanced Incomplete Block Study In Healthy Fasted Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of A 6 Mg Dose Of The PH-797804 Material Sparing Tablet (MST) And Two Modified Versions Of The MST Formulation With And Without The Solubilizing Agent Sodium Lauryl Sulphate (SLS)||Pfizer|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|18|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 9, 2011|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226693||114356|
NCT01226979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J0977|Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer|Phase II Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer|HDRBT|Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2010|September 2020|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|100 Years|No|||September 2015|September 24, 2015|September 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01226979||114335|
NCT01226992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN # 08-0440|Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin|Phase II/III Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin for Recurrent Clostridium Difficile Infection (CDI)||University Health Network, Toronto|Yes|Terminated|October 2010|October 2014|Actual|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|December 4, 2014|October 20, 2010||No|Unavailable study resources|No||https://clinicaltrials.gov/show/NCT01226992||114334|
NCT01227317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIODINER BRAHMS France|BIOmarkers of Dyspnea IN Emergency Room|Prognostic Value of Novel Biomarkers in Patients With Shortness of Breath Attending an Emergency Department|BIODINER|ThermoFisher Scientific Brahms Biomarkers France|Yes|Completed|April 2010|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|444|Samples Without DNA|plasma|Both|18 Years|N/A|No|Probability Sample|Severe acute SOB Suspicion of CAP, Acute Heart failure, AE COPD or PE|December 2011|December 6, 2011|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227317||114309|
NCT01227603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14027|Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions|Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Volunteers Under Fasting Conditions in an Open Label, Randomized, 4-way-crossover Design||Bayer|No|Completed|November 2010|July 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227603||114287|
NCT01227616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-CKD-401|A Phase IV Trial of Repeated Doses of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients With Chronic Kidney Disease on Hemodialysis|Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis|FACT|AMAG Pharmaceuticals, Inc.|No|Active, not recruiting|May 2013|September 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227616||114286|
NCT01218360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06484|Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)|Observational Study on Disease Severity, Evaluation Tools and the Long Term Impact of Each Treatment Strategy in the Daily Clinical Practice in Patients With Moderate to Severe Active Crohn's Disease (Protocol P06484)||Merck Sharp & Dohme Corp.|No|Completed|November 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants with diagnosed active Crohn's Disease who are inadequately controlled with        their current therapy|March 2015|March 18, 2015|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01218360||114990|
NCT01218646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QIV03|Study of Quadrivalent Influenza Vaccine Among Adults|Safety and Immunogenicity Trial Among Adults Administered Quadrivalent Influenza Vaccine||Sanofi|No|Completed|October 2010|April 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|739|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 13, 2013|October 8, 2010|Yes|Yes||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01218646||114968|
NCT01218659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-012|Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease|A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT||Amicus Therapeutics|Yes|Completed|December 2010|May 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|16 Years|74 Years|No|||June 2015|June 25, 2015|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01218659||114967|
NCT01219127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0438C|The Regeneration Effects of Derma-PACE Shockwave in Chronic Diabetic Ulcers|The Regeneration Effects of Derma-PACE Shockwave in Chronic Diabetic Ulcers||Chang Gung Memorial Hospital|No|Active, not recruiting|February 2009|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|N/A|No|||February 2009|October 12, 2010|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01219127||114931|
NCT01219738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071068|Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide|Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide||University of Miami|No|Completed|July 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|20|||Both|18 Years|65 Years|No|||January 2015|January 7, 2015|October 12, 2010|Yes|Yes||No|November 12, 2014|https://clinicaltrials.gov/show/NCT01219738||114885|
NCT01220349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/27|Alteration of Myocardial Deformations in Diabetes: Relationship to Micro-angiopathy|Early Detection of Diabetic Cardiomyopathy by Analysis of Myocardial Deformations by Two-dimensional Speckle Tracking Strain Echocardiography and Relationship to Micro-angiopathy|ECHO-DIAB|University Hospital, Bordeaux|No|Completed|January 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|18 Years|45 Years|No|||April 2013|April 18, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01220349||114838|
NCT01220323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-SB-396-CTIL|Transcranial Direct Current Stimulation for Chronic Pain Relief|Transcranial Direct Current Stimulation for Chronic Pain Relief||Tel-Aviv Sourasky Medical Center||Not yet recruiting|November 2010|||November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||October 2010|October 11, 2010|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01220323||114840|
NCT01216033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111InABY025|Exploratory Study of Breast Cancer With ABY025|An Exploratory Study to Evaluate the Distribution of [111In]ABY-025 Uptake for SPECT Imaging in Subjects With Metastatic Breast Cancer|ABY0125|Biomedical Radiation Sciences|Yes|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Female|20 Years|N/A|No|||April 2013|April 12, 2013|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216033||115168|
NCT01216306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K07CA131178|Reducing Television Viewing To Prevent Obesity in Hispanic Preschool Children|Reducing Television Viewing To Prevent Obesity in Hispanic Preschool Children||Seattle Children's Hospital|No|Completed|October 2010|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|252|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||December 2013|December 4, 2013|September 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01216306||115147|
NCT01216332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC PED 1067|Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients|Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High Dose Trivalent Inactivated Influenza Vaccine in Pediatric Patients With Acute Lymphoblastic Leukemia||Vanderbilt University|Yes|Enrolling by invitation|October 2010|April 2012|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|3 Years|17 Years|No|||October 2011|October 31, 2011|October 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216332||115145|
NCT01228019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-119|Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of TREDAPTIVE Tablet in Usual Practice||Merck Sharp & Dohme Corp.|No|Terminated|December 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1166|||Both|18 Years|N/A|No|Probability Sample|Korean participants with hypercholesterolemia or mixed dyslipidemia treated with niacin        (+) laropiprant (TREDAPTIVE) for the first time|April 2015|April 1, 2015|October 22, 2010|No|Yes|In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a    significant increase in incidence of some types of non-fatal SAEs|No|March 25, 2014|https://clinicaltrials.gov/show/NCT01228019||114255|Study enrollment stopped early due to termination of all TREDAPTIVE studies. Data obtained for participants enrolled prior to termination was analyzed and reported.
NCT01228032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027782|The Health Outcomes Management and Evaluation (HOME) Study|Improving Primary Care of Patients With Mental Disorders|HOME|Emory University|Yes|Completed|April 2010|December 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01228032||114254|
NCT01235052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2008/20|Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer|Prognostic Evaluation of Fluor 18 Labelled FLUROMISONIDAZOLE (18F-FMISO) Positon Emission Tomography-Computed Tomography (PET-CT) in Head and Neck Squamous Cell Carcinomas|MISORL|University Hospital, Bordeaux|Yes|Completed|June 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|1||Actual|16|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|October 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01235052||113718|
NCT01225523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZY-01|Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus|Perioperative Versus Preoperative Chemotherapy With Surgery in Patients With Locoregional Squamous Carcinoma of Esophagus||Xi’an Jiaotong University College of Medicine||Completed|January 1997|January 2010|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|October 20, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225523||114444|
NCT01225796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00044216|Study of Sodium Bicarbonate in Kidney Transplant Recipients|Randomized Trial of Sodium Bicarbonate in Renal Transplant Recipients With Low-normal Serum Bicarbonate Levels||University of Utah|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|29|||Both|21 Years|75 Years|No|||March 2016|March 7, 2016|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01225796||114424|
NCT01226420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-230|Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease|A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease||Dana-Farber Cancer Institute|Yes|Terminated|October 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||August 2013|August 11, 2013|October 21, 2010|Yes|Yes|Discontinuation of drug supply from Astellas.|No|January 28, 2013|https://clinicaltrials.gov/show/NCT01226420||114377|
NCT01226433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10227|Family Planning Through Dairy Cooperatives|Providing Family Planning Services Sustainably Through Dairy Cooperatives in Kenya||FHI 360|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|N/A||1|Actual|319|||Female|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females aged 18-49|March 2013|March 28, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01226433||114376|
NCT01226706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-08-04|Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence|Efficacy of Botulinum Toxin A Intradetrusor Injections for the Treatment of Non-neurogenic Urinary Urge Incontinence- A Randomized Double-Blind Control Trial||Regina Qu'Appelle Health Region|No|Completed|June 2008|October 2012|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|17 Years|80 Years|No|||May 2015|May 4, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01226706||114355|
NCT01226719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 134|FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only|A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only||SCRI Development Innovations, LLC|No|Completed|December 2010|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|October 15, 2010|Yes|Yes||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01226719||114354|
NCT01227005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-07-1-0229|Early Whole Blood in Patients Requiring Transfusion After Major Trauma|Early Whole Blood in Patients Requiring Transfusion After Major Trauma||The University of Texas Health Science Center, Houston|Yes|Completed|May 2011|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|October 20, 2010||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01227005||114333|First, we failed to specifically exclude patients with severe TBI from our initial protocol. Finally, we did not use an objective scoring system to randomize patients and, therefore, did not always include patients who would have received an MT.
NCT01227330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU HSIRB 1174637|Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults|Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults||University of Missouri-Columbia||Completed|October 2010|February 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|43|||Both|60 Years|N/A|No|||December 2015|December 21, 2015|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01227330||114308|
NCT01227629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.20|PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin|Dose Exploration in Patients With Atrial Fibrillation||Boehringer Ingelheim||Completed|September 2003|||November 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|10||Actual|502|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|October 22, 2010||||No|November 18, 2010|https://clinicaltrials.gov/show/NCT01227629||114285|
NCT01227642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-147|Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy|Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy|USA|Beth Israel Medical Center|Yes|Completed|February 2007|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|N/A|No|||March 2016|March 11, 2016|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227642||114284|
NCT01219153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ext letro/GnRHant|Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET|Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Patients With Poor Ovarian Response Undergoing IVF-ET, a Randomized Controlled Trial||Cairo University|Yes|Completed|September 2008|December 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Female|30 Years|42 Years|No|||July 2011|July 11, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219153||114929|
NCT01219166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG10/140/U|Is Routine Cholecystectomy Reasonable in All Patients Receiving a Bypass Procedure: a Comparative Cohort Study|||Cantonal Hospital of St. Gallen|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|437|||Both|18 Years|N/A|No|Non-Probability Sample|Given indication for laparoscopic Roux-en-Y-gastric bypass|October 2010|December 9, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219166||114928|
NCT01219452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCKX002|Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy|Effects of Intramuscular Injection of Umbilical Cord Mesenchymal Stem Cell on the Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy||Qingdao University|Yes|Not yet recruiting|October 2010|December 2012|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|14 Years|No|||May 2010|October 27, 2010|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01219452||114906|
NCT01219972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 04118|Pulmonary Complications of Allografts|Prospective Cohort Study of Late Pulmonary Complications in Patients Who Received Allogeneic Hematopoietic Stem Cells Transplantation: Estimation of Incidence and Identification of Distinct Nosologic Entities|ALLOPULM|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2006|February 2010|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|245|||Both|N/A|N/A|No|Non-Probability Sample|Patients who underwent a allogeneic blood stem cell transplantation, alive at 100 days        post-transplantation|September 2010|November 19, 2012|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01219972||114867|
NCT01219985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI07-PR-MEYER|Benefits Study of Respiratory-gated Positron Emission Tomography Acquisitions of the Liver|Benefits Study of a Respiratory Gating Protocol for 18F-FDG PET: Application on the Liver|RespiTEP|Centre Hospitalier Universitaire, Amiens|No|Completed|April 2008|June 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|October 12, 2010||No||No|June 29, 2012|https://clinicaltrials.gov/show/NCT01219985||114866|
NCT01220362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093/10|Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study|Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study||University Hospital Inselspital, Berne|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|N/A|No|||December 2011|December 14, 2011|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220362||114837|
NCT01220375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236/09|PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma|PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma. A Pilot Phase II Study.|PAV|University Hospital Inselspital, Berne|Yes|Completed|April 2010|October 2013|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|70 Years|No|||April 2014|April 16, 2014|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220375||114836|
NCT01216046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX10-809-006|Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multiple-Dose, Dose-Escalation, Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 16, 2012|September 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01216046||115167|
NCT01216345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC 01|Cetuximab + Gemox in Biliary Tract Cancer|Cetuximab Plus Gemcitabine-Oxaliplatin (GEMOX) in Patients With Unresectable Advanced or Metastatic Biliary Tract Cancer: a Phase II Study||Association of Research on the Biology of Liver Tumors|No|Completed|October 2006|October 2009|Actual|October 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2010|October 6, 2010|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216345||115144|
NCT01228851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30775|Balance Training in Parkinson's Disease Using the Wii Balance Board|A Pilot Study of the Effects of Balance Training Using the Wii Balance Board on Balance and Ambulation in Adults With Parkinson's Disease||Rehabilitation Institute of Chicago|No|Completed|August 2010|February 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2011|July 26, 2011|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01228851||114191|
NCT01229163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911464|Automated Prize-based Contingency Management to Increase Counseling Attendance in Opiate-Replacement-Therapy Patients|Automated Prize-Based Contigency Management to Increase Counseling Attendance in Opiate-Replacement-Therapy Patients||National Institutes of Health Clinical Center (CC)||Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|February 19, 2014|October 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01229163||114167|
NCT01234506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHPD-150212|Oxidative Stress and Nutritional Supplementation Intervention Study|Community Alliance for Quality of Life in Long Term Care: Oxidative Stress and Nutritional Supplementation Intervention Study|Oxi-Stress|University of Saskatchewan|No|Completed|October 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|21|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||July 2013|July 30, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234506||113760|
NCT01234519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS-108-046|A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy|A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy||AEterna Zentaris|Yes|Terminated|November 2010|November 2015|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2013|January 14, 2014|November 2, 2010|Yes|Yes|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01234519||113759|
NCT01225705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKB-2009-MED-I-JKR-01|Safety Study of Raltegravir in HIV/HCV Co-infected Patients|An Open, Prospective Study to Compare the Safety and Efficacy of Raltegravir vs. Atazanavir / Ritonavir, Both in Combination With Tenofovir DF and Emtricitabine, in the Treatment of HIV-infection in ART Naive Subjects With HCV Co-infection.||University Hospital, Bonn|No|Withdrawn|October 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2010|June 2, 2015|October 20, 2010||No|no pts recruited|No||https://clinicaltrials.gov/show/NCT01225705||114431|
NCT01225718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC PED1061|Ceftriaxone in Non-neutropenic Fever|Ceftriaxone in Non-neutropenic Fever||Vanderbilt University|No|Active, not recruiting|August 2010|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|360|||Both|N/A|22 Years|No|Non-Probability Sample|All patients diagnosed with and treated for malignancy, Langerhans cell histiocytosis ,or        Hemophagocytic lymphohistiocytosis between 2007 through 2010 at Monroe Carrell Jr.        Children's Hospital at Vanderbilt under the age of 23 at diagnosis.|June 2013|June 11, 2013|October 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01225718||114430|
NCT01225536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 736-101|Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations|A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations||ArQule|No|Completed|October 2010|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01225536||114443|
NCT01225549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2340C00005|The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen|A Double-blind, Double-dummy, Randomised, Placebo-controlled, 4-way, Crossover, Multi-centre Phase II Study With Budesonide as an Active Control to Evaluate the Efficacy and Safety of 2 Doses of Inhaled AZD5423 Over 7 Days in Patients With Mild Allergic Asthma Challenged With an Inhaled Allergen|Allergen|AstraZeneca||Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|27|||Both|18 Years|60 Years|No|||March 2015|March 31, 2015|October 15, 2010|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01225549||114442|Of the 27 patients enrolled, 20 (74.1%) patient were randomised to receive a treatment sequence consisting of 4 different treatment in random order. 19 patients completed each individual treatment period and 17 patients completed all 4 treatment
NCT01225809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF003E|AD01 Follow up Extension Visit|Observational Follow-up Extension Study-visit to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD01 Applied During AFFiRiS001 in Patients With Alzheimer's Disease||Affiris AG|Yes|Completed|September 2010|January 2011|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|17|||Both|N/A|N/A|No|Non-Probability Sample|Patients having participated in AFFiRiS 001 and AFF003 and having received ≥1 vaccination        with AFFITOPE AD01|January 2011|January 25, 2011|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01225809||114423|
NCT01226407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG200745-1-01|Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile|Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer||CrystalGenomics, Inc.|No|Recruiting|September 2010|February 2013|Anticipated|February 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|20 Years|69 Years|No|||October 2012|December 27, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226407||114378|
NCT01226446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021967-34|Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders|Multicenter Open and Prospective Trial Assessing the Efficacy of Vitamin D Supplementation in Addition to Pegylated Interferon Plus Ribavirin in Null-Responders Patients With Chronic Viral Hepatitis C Genotype 1 or 4|ANRS VITAVIC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|November 2010|January 2013|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||June 2012|August 8, 2014|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226446||114375|
NCT01226732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 143|A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors|A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors||SCRI Development Innovations, LLC|No|Completed|November 2010|June 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|23|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|October 18, 2010|No|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01226732||114353|
NCT01226745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4641POU007 (EMR200559-002)|A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis|A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis|DreaMS|EMD Serono|Yes|Terminated|October 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|343|||Both|18 Years|55 Years|No|||July 2015|July 15, 2015|October 19, 2010|Yes|Yes|Merck Serono has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The    decision was not related to any safety and efficacy findings.|No||https://clinicaltrials.gov/show/NCT01226745||114352|
NCT01227655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-302|Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.|Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study.|BIPARKII|Bial - Portela C S.A.|Yes|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|427|||Both|30 Years|83 Years|No|||September 2015|September 21, 2015|October 22, 2010||No||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01227655||114283|
NCT01227668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-603|Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder|Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder||Bristol-Myers Squibb|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|215|||Both|6 Years|17 Years|No|||March 2014|March 31, 2014|October 22, 2010|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01227668||114282|
NCT01227863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNPUNI0610|Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis|Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|February 2011|||February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2010|October 22, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01227863||114267|
NCT01228162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nr. 5615 Hanover Med. School|Influence of Muscle Relaxation With Rocuronium Bromide During General Anaesthesia on Muscle Trauma and Postoperative Analgetic Consumption in Patients With Total Hip Prosthesis Implantation|||Klinikum Hildesheim GmbH|Yes|Completed|September 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|55 Years|80 Years|No|||June 2013|June 22, 2013|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228162||114244|
NCT01228175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA025074|Effectiveness of Varenicline: Testing Individual Differences|Effectiveness of Varenicline: Testing Individual Differences|Varenicline|The Mind Research Network|Yes|Active, not recruiting|March 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|55 Years|No|||August 2015|August 20, 2015|September 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228175||114243|
NCT01227369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111720|Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment|Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment|BRAVO|GlaxoSmithKline|No|Completed|June 2008|November 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|4376|||Female|18 Years|N/A|No|Probability Sample|According to 2006 national health insurance data, a total of osteoporosis women (ICD-10        code: M81) are about 244,190 in Korea According to recent market research data, 95% of        osteoporosis women use bisphosphonate in Korea.        With considering 95% market share of bisphosphonate in osteoporosis market, there are        231,714 Korean osteoporosis women. Applying for 2% extracting fraction in this study,        total size of study population are 4,634.|February 2011|February 17, 2011|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01227369||114305|
NCT01227681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCSP-01|Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease|A Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease||Buddhist Tzu Chi General Hospital|Yes|Active, not recruiting|June 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|36|||Both|40 Years|65 Years|No|||January 2013|January 3, 2013|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227681||114281|
NCT01219465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCT1DM003|Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes||Qingdao University|Yes|Active, not recruiting|September 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|35 Years|No|||September 2010|October 12, 2010|October 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01219465||114905|
NCT01219478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99028|Research of the Correlation Between Metabolic Syndrome, Retinal Thickness and Visual Acuity|Research of the Correlation Between Metabolic Syndrome, Retinal Thickness and Visual Acuity||Taipei Medical University WanFang Hospital|No|Completed|January 2009|December 2009|Actual|||N/A|Observational|Time Perspective: Retrospective||4|Actual|100|||Both|65 Years|N/A|No|Non-Probability Sample|Patients who were over 60 y/o were divided into four groups according to their MRs of        hypertension, hyperlipidemia or hyperglyceremia.|December 2010|December 19, 2010|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01219478||114904|
NCT01219751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOSG_AMC_0801|Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma|Phase II Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma||Asan Medical Center|No|Active, not recruiting|June 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||September 2010|June 16, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219751||114884|
NCT01219998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC08103|NGAL, an Early Predictive Marker of Acute Kidney Injury After Cardiac Surgery in Neonates and Infants|Evaluation of the Predictive Ability of Urinary NGAL as an Early Marker of Acute Kidney Injury Following Cardiac Surgery in Neonates and Infants|NGAL|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2010|November 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|205|Samples Without DNA|Blood and urine samples are collected during the early postoperative period, stored, than      NGAL concentrations are measures on the ARCHITECT platform.|Both|N/A|12 Months|No|Non-Probability Sample|heterogeneous populations of children undergoing cardiac surgery|May 2013|May 22, 2013|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01219998||114865|
NCT01216683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2408|Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma|A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma||Eastern Cooperative Oncology Group|No|Recruiting|December 2010|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|N/A|No|||June 2014|March 13, 2015|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216683||115118|
NCT01216696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-2009-11-02-53|Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1|Phase II Trial of Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1|CTLA4 NY-ESO-1|National Center for Tumor Diseases, Heidelberg|Yes|Active, not recruiting|November 2010|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216696||115117|
NCT01216059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU29486|Text Messaging and Atopic Dermatitis|The Use of Text Messages to Improve Adherence to Health Maintenance Behaviors in Adolescents With Atopic Dermatitis||Northwestern University|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Both|10 Years|17 Years|No|||November 2012|November 29, 2012|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01216059||115166|
NCT01213485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22643|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease on Dialysis (HORTENSIA)|Observational Cohort Study in Chronic Kidney Disease Patients on Dialysis Initiating Treatment With Mircera During the Correction and Maintenance Phase||Hoffmann-La Roche||Completed|March 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|419|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic kidney disease on dialysis|March 2016|March 1, 2016|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01213485||115363|
NCT01229176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01_02TP|Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants|A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants||Novartis|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|200|||Both|6 Weeks|45 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|October 25, 2010||No||No|March 5, 2014|https://clinicaltrials.gov/show/NCT01229176||114166|
NCT01229449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL0811|Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study|A Double-blind, Parallel-group, Placebo-controlled, Randomised, Single Dose Study to Compare Ibuprofen + Acetaminophen; Ibuprofen + Codeine (Nurofen Plus®) and Acetaminophen + Codeine (Panadeine® Extra) in Postoperative Dental Pain.||Reckitt Benckiser LLC|No|Completed|January 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|678|||Both|16 Years|N/A|No|||October 2010|October 26, 2010|October 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229449||114145|
NCT01229462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190342-035|Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension|||Allergan|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|75 Years|No|||August 2012|August 15, 2012|October 26, 2010|Yes|Yes||No|August 15, 2012|https://clinicaltrials.gov/show/NCT01229462||114144|
NCT01234792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1070|Single-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.|Single-Dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products - A Study in Healthy Smokers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|May 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234792||113738|
NCT01225562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5132C00001|Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin|A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction|PEGASUS|AstraZeneca||Completed|October 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|21379|||Both|50 Years|130 Years|No|||December 2015|December 18, 2015|July 9, 2010|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01225562||114441|
NCT01226121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHtSC-Delay 101|Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture|A Post Market, Open-Label Study of the Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture||Indiana Hand to Shoulder Center|No|Terminated|December 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 16, 2014|October 20, 2010|No|Yes|difficulty enrolling additional patients|No|April 21, 2014|https://clinicaltrials.gov/show/NCT01226121||114400|Study was terminated early due to slow enrollment
NCT01226134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|965-Med/ERC-08|Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia|Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia|EIGEAPFD|Aga Khan University|No|Recruiting|February 2009|May 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||July 2010|October 21, 2010|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226134||114399|
NCT01227343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810278|Nicotine and Brain Imaging Research Study|Sex, GABA and Nicotine: A 1H-MRS Study||University of Pennsylvania|No|Recruiting|March 2010|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|54|Samples Without DNA|Whole blood, plasma, urine|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women and men from the greater Philadelphia and surrounding areas who are ages 18-50 will        be considered for enrollment into this study.|June 2015|June 19, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227343||114307|
NCT01227356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NordCML002|A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia|A Randomized Study Comparing Imatinib And Imatinib/Pegylated Interferon Alpha-2B in Newly Diagnosed Non-high Risk Chronic Myeloid Leukemia Patients in Complete Hematological Remission After Imatinib Induction Therapy||Uppsala University|No|Completed|September 2004|November 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|95 Years|No|||October 2010|October 22, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227356||114306|
NCT01226771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eu-nr 2010-018332-41|Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1||RibaC|Göteborg University|Yes|Completed|September 2010|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226771||114350|
NCT01226784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF 2010 stud GLS|The Effects of Training and Relaxation on Fibromyalgia.|||Karolinska Institutet||Enrolling by invitation|October 2010|||May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|240|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01226784||114349|
NCT01227044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC0909005730|Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention|Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention|DAWN|Yale University|Yes|Active, not recruiting|April 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|October 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227044||114330|
NCT01227057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSRD-068-10S|Hoarding Older Adults|Treatment of Late Life Compulsive Hoarding||VA Office of Research and Development|Yes|Completed|November 2010|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|60 Years|85 Years|No|||September 2015|September 4, 2015|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01227057||114329|
NCT01227382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpyBite|Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods|Prospective Evaluation of the Accuracy of Spybite Biopsy Forceps for the Tissue Diagnosis of Lesion of the Pancreatobiliary System. ( Part of the "The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Treatment of Pancreaticobiliary Disorders" Study)||University of Florida|No|Completed|November 2006|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|October 18, 2010||No||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01227382||114304|
NCT01227889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113683|A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma|A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma||GlaxoSmithKline|Yes|Active, not recruiting|December 2010|September 2016|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|N/A|No|||August 2015|September 3, 2015|October 21, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01227889||114265|
NCT01219218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR-AZM-NL|Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris|Shockwave Treatment for Advanced Angina in Maastricht (SWAAM). A Pilot Study||Medispec|No|Completed|January 2009|June 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2013|February 17, 2013|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01219218||114924|
NCT01219491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-16|Egg Donor Recipient Characteristics Preferences|Do Egg Donor Recipient Characteristics Change Over Time?||Reproductive Medicine Associates of New Jersey|No|Completed|December 2007|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|131|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are planning to undergo an egg donor cycle are eligible|March 2013|March 4, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219491||114903|
NCT01219764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.AS1.25|A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection|A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection||American University of Beirut Medical Center|Yes|Completed|October 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|80 Years|No|||January 2014|January 24, 2014|May 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01219764||114883|
NCT01216085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571AKR23|An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints|An Exploratory Single Center Study of High-dose Treatment of Glivec® in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study|CML|Novartis|No|Completed|August 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01216085||115164|
NCT01216358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000464|Boston Migraine and Contraception Study|The Boston Migraine and Contraception Study|BMAC|Planned Parenthood League of Massachusetts|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|171|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Health female adults, patients of Planned Parenthood League of Massachusetts|May 2012|May 8, 2012|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216358||115143|
NCT01212965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/93|Selenium in the Treatment of Complicated Lymphatic Malformations|Pilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults||Medical College of Wisconsin|Yes|Terminated|September 2010|November 2012|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|14 Years|30 Years|No|||April 2013|April 22, 2013|September 24, 2010|Yes|Yes|The investigators chose to terminate the study due to participant attrition. Of the limited    data evaluable, none of the patients experienced adverse events.|No||https://clinicaltrials.gov/show/NCT01212965||115403|
NCT01217008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP35A007|Safety Study of GRNOPC1 in Spinal Cord Injury|A Phase 1 Safety Study of GRNOPC1 in Patients With Neurologically Complete, Subacute, Spinal Cord Injury||Asterias Biotherapeutics, Inc.|Yes|Completed|October 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||January 2014|January 6, 2014|October 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01217008||115094|
NCT01213238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0413|Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab|A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2010|||September 2022|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01213238||115382|
NCT01213498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-FHC-2010-2|The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy|The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy|STAN|Regional Hospital Holstebro|Yes|Completed|May 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|N/A|No|||August 2015|August 19, 2015|September 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01213498||115362|
NCT01229189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D Study|Evaluation of the Effectiveness of Vitamin D Supplementation to Pregnant Women and Their Infants in Pakistan.|Evaluation of the Effectiveness of Vitamin D Supplementation to Pregnant Women and Their Infants in Pakistan||Aga Khan University|Yes|Completed|February 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|460|||Female|15 Years|49 Years|No|||March 2012|March 7, 2012|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229189||114165|
NCT01229475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-003|Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation|Stepwise Approach Versus Linear Ablation for Repeat Procedure in Patients With Recurrence of Persistent Atrial Fibrillation|REDO-AF|Deutsches Herzzentrum Muenchen|No|Recruiting|October 2010|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||February 2013|February 28, 2013|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229475||114143|
NCT01229488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006001474 IND|System for Ocular Oxygen Measurement|||Indiana University|No|Withdrawn|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|October 26, 2010|No|Yes|I withdrew from this study|No||https://clinicaltrials.gov/show/NCT01229488||114142|
NCT01239537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/03|Swine Flu (Influenza A H1N1) Follow on Vaccine Study|A Multi-centre, Open-label, Clinical, Phase 4 Trial, Following on From a Head-to-head Comparison Study of Two H1N1 Influenza Vaccines in Children, to Compare Firstly, the Persistence of Antibody Against the A/California/7/2009 (H1N1) Virus and Secondly the Immunogenicity and Reactogenicity of One Dose of a Non-adjuvanted Trivalent Seasonal Influenza Vaccine, in Children Who Had Received a Two-dose Immunisation Regimen of Celvapan or Pandemrix.||University of Oxford|Yes|Completed|November 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|560|||Both|17 Months|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|We intend to recruit all interested participants who completed the original NIHR funded        study (NCT00980850)(1) (n=937) into groups 1 & 2 outlined in table one above. It is        anticipated that approximately 66% of these participants are likely to take part in this        follow-on study; therefore the study population for groups 1 & 2 is likely to be        approximately 560 children. As the option of only having a blood sample taken at visit 1        will be made available to participants in this study, there will be two cohorts of        participants: the 'persistence' cohort (consenting to the baseline blood test alone) and        the 'booster' cohort (consenting to the baseline blood test, seasonal influenza vaccine        and post-immunisation blood test).|May 2013|May 7, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239537||113377|
NCT01239849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKimlipid|Korean AMADEUS Study|A Multicenter, Eight Weeks Treatment, Single Step Titration, Open Label Study Assessing the Percentage of Korean Diabetic Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Dose 10mg, 20mg, 40mg||The Catholic University of Korea|Yes|Recruiting|February 2009|February 2011|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|80 Years|No|||February 2009|November 12, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239849||113353|
NCT01240070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINDIT2000|Multifactorial Intervention in Type 2 Diabetes - Italy|Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes|MINDIT|University of Parma|Yes|Active, not recruiting|January 2002|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1461|||Both|50 Years|70 Years|No|||October 2010|August 11, 2011|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240070||113336|
NCT01240330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VenousHealth-001|Vasculaire Compression System Increases Flow Velocity in the Femoral Vein|Evaluation of the Effect of the Vasculaire Compression System on Flow Velocity in the Femoral Vein||Venous Health Systems, Inc.|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 2, 2011|November 10, 2010||No||No|November 22, 2010|https://clinicaltrials.gov/show/NCT01240330||113316|
NCT01240668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-10-292|Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia|An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized With Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization|HN Registry|Otsuka America Pharmaceutical|No|Completed|September 2010|August 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5028|||Both|18 Years|N/A|No|Probability Sample|The prospective registry study population will consist of up to 1500 patients at        approximately 150 sites from the USA who are hospitalized and identified as having        hypervolemic or euvolemic hyponatremia with serum sodium ≤130 mmol/L. Also up to 1005        patients at approximately 67 sites from Europe (United Kingdom, Germany, France, Italy,        Spain, Denmark, and Sweden)who are identified as having hyponatremia ≤130mmol/L secondary        to SIADH. A similar distribution of patients with a serum sodium <125 mmol/L and patients        with a serum sodium between 125-130 mmol/L will be collected.|May 2015|May 13, 2015|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240668||113290|
NCT01241357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE5051|High-Tc Susceptometer to Monitor Transfusional Iron Overload|High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device)||Columbia University|No|Recruiting|March 2011|October 2016|Anticipated|August 2016|Anticipated|Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|190|||Both|5 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Potential participants who are eligible for this study include: (i) patients scheduled for        clinically indicated liver transplantation or liver biopsy, (ii) patients with        transfusional iron overload followed in adult and pediatric hematology, and (iii) healthy        individuals participating as control subjects.|February 2016|February 27, 2016|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241357||113237|
NCT01241968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR-RCT-DE|Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease|Randomized, Placebo Controlled, Double Blind Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device||Medispec|No|Active, not recruiting|June 2009|April 2013|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2013|February 17, 2013|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241968||113190|
NCT01210664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSFDC411AI|T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs|A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes|Treg|University of California, San Francisco|Yes|Active, not recruiting|November 2010|December 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|45 Years|No|||December 2014|December 8, 2014|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210664||115580|
NCT01242254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902004|A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD|An Open Label, Multicenter, Randomized, Uncontrolled Study Assessing the Safety and Efficacy of KH902 in Patients With Choroidal Neovascularization Due to Neovascular Age-related Macular Degeneration(HOPE Study)|HOPE|Chengdu Kanghong Biotech Co.,Ltd.|No|Completed|August 2009|February 2011|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|45 Years|N/A|No|||July 2011|March 25, 2014|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01242254||113169|
NCT01241981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010ON15|Digital Breast Tomosynthesis in Younger Symptomatic Women|Digital Breast Tomosynthesis (DBT): Sensitivity for Cancer and Accuracy in Assessing Extent of Malignant Disease in Symptomatic Women Below 60 With Clinical or Ultrasound Signs Compatible With Malignancy||NHS Tayside|No|Recruiting|March 2011|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|N/A|59 Years|No|Probability Sample|Women under 60 years of age with clinical or ultrasound suspicion of breast cancer|October 2011|October 3, 2011|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241981||113189|
NCT01242280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PE08001|Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding.|Esophageal Stent is More Effective Than Tamponade Controlling Refractory Esophageal Variceal Bleeding: a Randomized Controlled Trial||Hospital Clinic of Barcelona|No|Completed|January 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01242280||113167|
NCT01220063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/9-R|RSHF in Colorectal Cancer|CLINICAL MULTICENTER STUDY OF PHASE II AND RADIOBIOLOGY ASSESSING Hypofractionated Stereotactic Radiotherapy With Irinotecan (Campto) IN THE TREATMENT OF LIVER METASTASIS AND / OR PULMONARY, Unoperated or Recurrent After Surgery of a Colorectal Cancer||Centre René Gauducheau|No|Recruiting|October 2007|||October 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment||||48|||Both|18 Years|N/A|No|||October 2010|October 12, 2010|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220063||114860|
NCT01220076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/11-A|Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+|Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+|TAM|Institut Cancerologie de l'Ouest|No|Recruiting|September 2009|||September 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|265|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220076||114859|
NCT01220089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0719|Adaptation of the Diabetes Prevention Program for Primary Care|Adaptation of the Diabetes Prevention Program for Primary Care||University of Colorado, Denver|Yes|Completed|October 2010|August 2015|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01220089||114858|
NCT01220453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999169 CS01|Compliance and Efficacy in the Use of PICOPREP®|Compliance and Efficacy in the Use of PICOPREP® for Bowel Cleansing|CLEAR|Ferring Pharmaceuticals||Completed|October 2010|July 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2165|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample|October 2012|October 5, 2012|October 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01220453||114830|
NCT01220466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-108-IDSN|Performance and Acceptability of iDesign|A Prospective Study to Evaluate the Performance and Acceptability of the iDesign Advanced WaveScan Study(tm) System||Abbott Medical Optics|No|Completed|October 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|September 24, 2010|No|Yes||No|February 15, 2013|https://clinicaltrials.gov/show/NCT01220466||114829|
NCT01211015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCPD ER stress|Endoplasmic Reticulum Stress in Chronic Respiratory Diseases|Endoplasmic Reticulum (ER) Stress in Patients With Various Chronic Pulmonary Diseases||Chonbuk National University||Recruiting|July 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|blood|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|1. Control group               -  healthy control (volunteer)          2. Disease group               -  chronic pulmonary lung diseases including asthma, COPD, ILD, and lung cancer|September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211015||115553|
NCT01210729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReFlow01|Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke|Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke (ReFlow Study)|ReFlow|Saarland University|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|85 Years|No|||September 2010|December 1, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210729||115575|
NCT01211041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99026|The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia|The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia||Taipei Medical University WanFang Hospital|No|Recruiting|July 2010|July 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|case with candidemia of Candida albicans and candida caused the disease .|April 2011|April 21, 2011|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211041||115551|
NCT01207245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10076|Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis|Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis (CRITIC) A Randomized Pharmacokinetic Comparison of Tobramycin in Cystic Fibrosis|CRITIC|University of Nottingham|Yes|Completed|May 2011|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|5 Years|N/A|No|||June 2015|June 22, 2015|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207245||115841|
NCT01211340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160518|The ACTIVE Intervention to Improve Hospice Care|The ACTIVE Intervention to Improve Hospice Care||University of Missouri-Columbia|Yes|Recruiting|September 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|554|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 28, 2011|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01211340||115528|
NCT01211353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA020180-01|Personalized Drinking Feedback Interventions|Personalized Drinking Feedback Interventions for OEF/OIF Veterans||University of Missouri-Columbia|No|Completed|January 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|325|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211353||115527|
NCT01208649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H80-MC-O008|Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)|Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)||Ruhr University of Bochum|No|Completed|July 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2010|September 23, 2010|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208649||115734|
NCT01239238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2-064|Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study|Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study|RASTER|Maastricht University Medical Center|No|Completed|November 2010|March 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|6 Years|17 Years|No|Probability Sample|This study is carried out in two hospitals in the Netherlands (Maastricht University        Medical Centre, Maastricht; and Orbis Medical Centre, Sittard).|November 2013|November 14, 2013|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01239238||113398|
NCT01239251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-183|GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy|Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy||Memorial Sloan Kettering Cancer Center||Terminated|November 2010|November 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|||Female|60 Years|N/A|No|Non-Probability Sample|Breast Cancer Medicine practice outpatients|March 2015|March 4, 2015|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239251||113397|
NCT01239576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-100|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2010|||||N/A|N/A|N/A||||||||||||||February 16, 2016|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239576||113374|
NCT01239563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxford/OTC/TIKT|Thymoglobulin Induction in Kidney Transplant Recipients|THYMOGLOBULIN INDUCTION AND STEROID-FREE IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION FROM DECEASED DONORS AFTER CARDIAC DEATH-AN OPEN LABEL RANDOMISED CONTROLLED TRIAL TO EVALUATE THE ROLE OF THYMOGLOBULIN AS INDUCTION IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTS FROM DECEASED DONORS AFTER CARDIAC DEATH|TIKT|University of Oxford|Yes|Not yet recruiting|January 2011|May 2016|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||November 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239563||113375|
NCT01239589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NEU-SER-2010/1|European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes|European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes Treated With Immediate Release Quetiapine or Extended Release Quetiapine||AstraZeneca|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1280|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with Bipolar Disorder (ICD-10).admitted due to a acute manic episode        and treated with quetiapine IR or quetiapine XR during the hospitalization period|March 2011|March 28, 2011|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239589||113373|
NCT01240083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-TB1|Effectiveness of Theta-burst Stimulation (TBS) in Patients With Major Depression|Effectiveness of Theta-burst Stimulation (TBS) Versus Tonic High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)in Patients With Major Depression||University of Regensburg|No|Completed|April 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|70 Years|No|||October 2013|October 14, 2013|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240083||113335|
NCT01240343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-057|Creation of the Biobank Related to Eye Disease|Creation of the Biobank Related to Eye Disease|BioBank|William Beaumont Hospitals|No|Enrolling by invitation|June 2009|June 2024|Anticipated|June 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|blood, urine other body fluids (i.e. vitreous)|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All pediatric and adult patients (age 0-99)who are being seen in the eye Dr. office and or        having eye surgery|February 2016|February 1, 2016|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01240343||113315|
NCT01240356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOTBUST-HF|CLOTBUST Hands-Free|Combined Lysis of Thrombus in Brain Ischemia With Transcranial Ultrasound and Systemic T-PA- Hands-Free. A Phase I/II Pilot Safety Trial|CLOTBUST-HF|The University of Texas Health Science Center, Houston|Yes|Enrolling by invitation|December 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 10, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01240356||113314|
NCT01240681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2010-IMPACT|Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|A Pilot Study of Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|IMPACT|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|April 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|32|||Female|18 Years|N/A|No|||March 2015|March 10, 2015|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01240681||113289|
NCT01240694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33457/3075|A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus|An Open-Label Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus||Teva Pharmaceutical Industries||Terminated|December 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|18 Years|70 Years|No|||September 2013|September 9, 2013|October 15, 2010|Yes|Yes|Business Decision; there were no safety issues|No||https://clinicaltrials.gov/show/NCT01240694||113288|
NCT01241006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-08103G|Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma|A Randomized Double-Blind Controlled Trial of Single Oral Dose Dexamethasone Versus Five Days of Oral Prednisone in Acute Mild to Moderate Adult Asthma||Alameda County Medical Center|Yes|Completed|January 2011|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|376|||Both|18 Years|55 Years|No|||January 2016|January 5, 2016|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241006||113264|
NCT01210144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMP 28364|EXpression PRofile Endometrium Samples Study|Open Label Pilot Study on Gene Expression Profiling of the Endometrial Tissue in Patients Undergoing Assisted Reproductive Technology [ART: In Vitro Fertilization (IVF)/ Intracytoplasmic Sperm Injection (ICSI)] With GONAL-f®|EXPRESS|Merck KGaA|No|Terminated|August 2008|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Female|18 Years|35 Years|No|||December 2013|December 2, 2013|August 11, 2010|No|Yes|Study terminated due to recruitment failure|No|August 30, 2012|https://clinicaltrials.gov/show/NCT01210144||115620|Gene expression of the endometrium could not be analyzed due to poor quality of biopsy samples (poor mRNA quality) and poor recruitment in the study.
NCT01210417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179_06/2010|Trauma Heart to Arm Time||THAT|Niguarda Hospital|Yes|Completed|September 2010|May 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|All trauma victims enrolled by our Helicopter Emergency Medical System (HEMS)|February 2012|February 20, 2012|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210417||115599|
NCT01210963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/08|Central Corneal Thickness With SENSIMED Triggerfish|Central Corneal Thickness After Overnight IOP Monitoring With SENSIMED Triggerfish|09/08|Sensimed AG|No|Completed|September 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Glaucoma and ocular hypertension patients, at least 18 years old and with stable        IOP-lowering treatment (if any).|March 2011|March 17, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210963||115557|
NCT01210950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-006|Distraction Osteogenesis in Limb-length Discrepancy With Mesenchymal Cell Transplantation|Autologous Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Distraction Osteogenesis in Patients With Limb-length Discrepancy||Royan Institute|Yes|Completed|September 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||April 2008|April 24, 2014|September 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01210950||115558|
NCT01211275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL25655.031.08|Axitinib in Malignant Mesothelioma|A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy|N08CPA|The Netherlands Cancer Institute|No|Recruiting|May 2009|September 2010|Anticipated|September 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2010|September 28, 2010|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01211275||115533|
NCT01210716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCRP- 0210|Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device|Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device||Fenwal, Inc.|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|37|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|September 26, 2010|Yes|Yes||No|March 13, 2012|https://clinicaltrials.gov/show/NCT01210716||115576|
NCT01211028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405402|Adipose CELL Derived Regenerative Endothelial Angiogenic Medicine|Safety of Autologous Adipose Derived Stroma/Stem Cells to Treat Critical Leg Ischemia.|ACELLDREAM|University Hospital, Toulouse|No|Completed|January 2009|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|40 Years|N/A|No|||March 2015|March 27, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01211028||115552|
NCT01206985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0081|Paracétamol PMB by Sublingual et Buccal Routes|Pharmacodynamic Study of 125 mg of Paracetamol Permucosal Administered by Sublingual and Buccal Route||University Hospital, Clermont-Ferrand||Completed|October 2010|March 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01206985||115861|
NCT01208350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812193|Testing Strategies to Encourage Weight Loss in an Employer Setting|Testing Strategies to Encourage Weight Loss in an Employer Setting||University of Pennsylvania|No|Completed|March 2011|August 2014|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2014|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208350||115757|
NCT01207505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001083|Emotion Regulation Group Therapy for Bipolar Disorder|Emotion Regulation Group Therapy for Bipolar Disorder||Massachusetts General Hospital|No|Completed|July 2010|December 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|65 Years|No|||April 2015|April 9, 2015|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01207505||115821|
NCT01239602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-200|The Variation of Movement Related Cortical Potential, Cortico-cortical Inhibition, and Motor Evoked Potential in Intracerebral Implantation of Antologous Peripheral Blood Stem Cells(CD34)in Old Ischemic Stroke|||China Medical University Hospital||Recruiting|October 2010|October 2010|Anticipated|October 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|36|||Both|30 Years|N/A|No|Probability Sample|36 patients suffered from old cerebral infarction (middle cerebral artery territory as        documented on the T2 weight image [T2WI] of MRI) between 6 months and 5 years of onset who        had initial scores on the National Institute of Health stroke scale (NIHSS) of between 9        and 20.|November 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239602||113372|
NCT01239615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK-20100061|Test-retest Stability of MR-parameters. A Neuroimaging Pilot-study in Healthy Volunteers|Test-retest Stability of MR-parameters. A Neuroimaging Pilot-study in Healthy Volunteer||Aarhus University Hospital|No|Withdrawn|January 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|healthy volunteers|October 2015|October 12, 2015|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239615||113371|
NCT01239862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP5772008|Safety of Stem Cells Intrabronchial Instillation for Silicosis|Phase-1 Study of Autologous Bone Marrow Cells Intrabronchial Instillation for Patients Silicosis|SilicStemCell|Universidade Federal do Rio de Janeiro|Yes|Completed|August 2009|December 2013|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|50 Years|No|||May 2015|May 26, 2015|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239862||113352|
NCT01240369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-206|Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma|||China Medical University Hospital|Yes|Active, not recruiting|October 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Anticipated|250|||Both|50 Years|80 Years|No|Probability Sample|ESCC and NSCLC patients|November 2010|November 12, 2010|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240369||113313|
NCT01240707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK S-O, Ref 2010/1340, part A|Pathophysiologic Changes in the Respiratory System After Fire Smoke Inhalation|Pathophysiologic Changes in the Respiratory System After Fire Smoke Inhalation||Oslo University Hospital|No|Recruiting|November 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|January 12, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01240707||113287|
NCT01241019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2010-018627-25|Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia|Safety and Efficacy of Oral Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia: a Pilot Study of the Neonatal Neuroprotection of Asphyxiated Tuscan Infants (NeoNATI) Network|NeoNATI|Azienda Ospedaliero, Universitaria Meyer|No|Completed|February 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|36 Weeks|N/A|No|||December 2013|December 12, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01241019||113263|
NCT01241331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI1100-201|BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris|A Randomized, Controlled Evaluation of the Safety and Efficacy of a Topical Treatment for Moderate-Severe Facial Acne Vulgaris||Braintree Laboratories|No|Completed|November 2010|||April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|233|||Both|12 Years|45 Years|No|||September 2012|September 27, 2012|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241331||113239|
NCT01241344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX001-202|The Adv Halt Trial|A Randomized, Placebo-Controlled Multi-Site Phase 2 Study Evaluation the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation in Adults and Children|Adv|Chimerix||Completed|November 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|3 Months|75 Years|No|||October 2013|October 31, 2013|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241344||113238|
NCT01241656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1317|Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1|Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment (DESI)- Study 1||University of North Carolina, Chapel Hill|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|2521|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241656||113214|
NCT01241045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AubshamsU|Study of Effect of Vaginal ph and Acidification of Vaginal Misoprostol on Its Efficacy for Induction of Midtrimester Abortion|EFFECT OF VAGINAL Ph AND ACIDIFICATION OF VAGINAL MISOPROSTOL ON ITS EFFICACY FOR INDUCTION OF MID-TRIMESTERIC ABORTION||Ain Shams University|Yes|Not yet recruiting|November 2010|December 2010|Anticipated|November 2010|Anticipated|Phase 4|Observational|Observational Model: Ecologic or Community||1|Anticipated|100|||Female|15 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|November 2010|November 15, 2010|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241045||113261|
NCT01210677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI-03|Cardiac Sarcoidosis Response To Steroids Trial|CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial|CASTOR|Ottawa Heart Institute Research Corporation|No|Withdrawn|April 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|September 27, 2010|Yes|Yes|No funding obtained.|No||https://clinicaltrials.gov/show/NCT01210677||115579|
NCT01207193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-005|Treatment Of Bone Cyst With Bone Marrow Mesenchymal Cell Transplantation|Effect of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Reconstructing Bone Defects.||Royan Institute|Yes|Completed|October 2009|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|12 Years|75 Years|Accepts Healthy Volunteers|||March 2009|December 13, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207193||115845|
NCT01211288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090730003|Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients|Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients||University of Alabama at Birmingham|No|Active, not recruiting|May 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|19 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|In good general health with the following requirements:        Hemoglobin >8g/dl Absolute neutrophil count >750/mm3 Platelet count>75,000cells/mm3 AST< 5        times the upper limit of normal (ULN) Bilirubin< 2.5 times ULN Alkaline phosphate < 5        times ULN Creatinine< 2.5 mg/ml Non- smoker (quit smoking at least 6 months) Controlled -        If type II diabetes Controlled - if hypertension Non bisphosphate user Non- bruxer Misch        Available Bone classification divisions A, B, C Misch Bone Density classification D1, D2,        D3 Minimal available bone width 5mm Minimal available bone height 10mm Minimum bone graft        with freeze dried demineralised bone upon implant placement Extraction site has to be        healed up for minimum 6 months before implant placement        Implant supported restorations are limited to the following edentulous areas:        Mandibular arches, excluding 3rd molar areas Maxillary anterior and premolar areas|May 2015|May 29, 2015|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211288||115532|
NCT01207180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0978|Discharge Planning for Elderly Patients in the Emergency Department: Use of a Brief Phone Call After Discharge to Improve Medication Utilization and Physician Follow-up|Discharge Planning for Elderly Patients in the Emergency Department: Use of a Brief Phone Call After Discharge to Improve Medication Utilization and Physician Follow-up||University of North Carolina, Chapel Hill|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|157|||Both|65 Years|N/A|No|||November 2011|November 17, 2011|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01207180||115846|
NCT01210209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000683940|Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives|GENEWING - A Genome Wide Association Study in Ewing Sarcoma||National Cancer Institute (NCI)||Recruiting|September 2009|||September 2011|Anticipated|N/A|Observational|N/A|||Anticipated|600|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2010|August 23, 2013|September 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01210209||115615|
NCT01210222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0229L|Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer|A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium||Gynecologic Oncology Group|Yes|Active, not recruiting|June 2011|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|September 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210222||115614|
NCT01210508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 5797|Analysis of Tokuhashi Score|A Prospective Analysis of the Tokuhashi Score and Its Effectiveness in Guiding Treatment and Predicting Survival in Patients With Metastases Spread to the Spine||State University of New York - Upstate Medical University|No|Terminated|March 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Both|10 Years|N/A|No|Non-Probability Sample|Patients seen in the Orthopedic Spine office, that have been diagnosed with metastases to        the spine.|September 2013|May 22, 2015|January 26, 2010||No|low enrollment|No||https://clinicaltrials.gov/show/NCT01210508||115592|
NCT01208051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02530|Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer|Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2010|||August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||November 2015|January 20, 2016|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208051||115780|
NCT01207271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS018440|A Comparison of Cognitive and Dynamic Therapy for Depression in Community Settings|A Comparison of Cognitive and Dynamic Therapy for MDD in Community Settings||University of Pennsylvania|Yes|Active, not recruiting|November 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|65 Years|No|||May 2015|May 27, 2015|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207271||115839|
NCT01208363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COWPEA|Improving Iron Status Through Consumption Of Iron Fortified Cowpea: An Intervention Study|Improving Iron Status Through Consumption Of Iron Fortified Cowpea: An Intervention Study||Wageningen University|No|Completed|September 2010|July 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2011|September 28, 2011|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208363||115756|
NCT01207284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LaBiMPH-001|Influence of Physical Therapy for Foot and Ankle in the Gait of Individuals With Diabetic Neuropathy|Influence of Physical Therapy Intervention on the Foot and Ankle in Gait Biomechanics in Individuals With Diabetic Neuropathy: a Randomized Clinical Trial||University of Sao Paulo General Hospital|No|Completed|August 2010|June 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|45 Years|65 Years|No|||September 2013|September 26, 2013|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01207284||115838|
NCT01207518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guide Cluster RCT|Cluster RCT - Evaluating Effectiveness of a Guide and Tools for Influenza Immunization Campaign Planners|Cluster RCT Evaluating the Effectiveness of "Successful Influenza Immunization Campaigns in Healthcare Organizations: A Guide for Campaign Planners, Part of Optimizing Healthcare Workers Interpandemic Vaccine Uptake Study||Ottawa Hospital Research Institute|No|Recruiting|August 2010|August 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 27, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207518||115820|
NCT01207531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301PLAGH-2010915|MiRNAs Evaluate the Prognosis of Sepsis|miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study|METPS|Chinese PLA General Hospital|Yes|Recruiting|July 2010|April 2011|Anticipated|November 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|human serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|within 24 hours after admited in ICU|September 2010|September 22, 2010|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01207531||115819|
NCT01240096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S50181|Mirtazapine Versus Placebo in Functional Dyspepsia|Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss||Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2006|December 2011|Anticipated|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|75 Years|No|||November 2010|November 12, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240096||113334|
NCT01240109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0369|Effect of Remifentanil on Cough During Emergence From General Anesthesia : Trial to Compare Between Sevoflurane Anesthesia and Propofol Anesthesia|Effect of Remifentanil on Cough During Emergence From General Anesthesia : Randomized Trial to Comparison Between Sevoflurane Anesthesia and Propofol Anesthesia||Yonsei University|Yes|Completed|September 2010|February 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|70|||Female|20 Years|70 Years|Accepts Healthy Volunteers|||May 2011|May 12, 2011|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01240109||113333|
NCT01240382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00890602|Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye|Double-masked Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Multi-center Study, in Comparison to 0.1% Sodium Hyaluronate Ophthalmic Solution) - Phase III Confirmatory Study -||Santen Pharmaceutical Co., Ltd.||Completed||||February 2008|Actual|Phase 3|Interventional|N/A|2||Actual|332|||Both|20 Years|N/A||||August 2014|August 8, 2014|November 12, 2010||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01240382||113312|
NCT01239641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2610|High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids|Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study||Chongqing Medical University|Yes|Recruiting|September 2010|July 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|220|||Female|18 Years|45 Years|No|||November 2010|November 12, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239641||113369|
NCT01239888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPRC 2010CK|Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study|Phase IB Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression||The Alfred|No|Recruiting|January 2012|||November 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|15|||Female|18 Years|45 Years|No|||January 2012|January 15, 2012|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239888||113350|
NCT01240122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBR-109-9608|Short-Term Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions|||Abbott Medical Optics||Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 7, 2012|November 8, 2010||No||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01240122||113332|
NCT01240395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBCT-MCS|Mindfulness-based Cognitive Therapy for Individuals With Multiple Chemical Sensitivity|||The Danish Research Centre for Chemical Sensitivities||Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|65 Years|No|||February 2014|February 17, 2014|November 10, 2010||||No||https://clinicaltrials.gov/show/NCT01240395||113311|
NCT01240408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-003|E7080 Food Effect Study in Healthy Subjects|E7080 Food Effect Study in Healthy Subjects||Eisai Inc.|No|Completed|July 2010|||November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|March 3, 2015|November 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240408||113310|
NCT01240421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-398|An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory|An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory||Eisai Inc.||Approved for marketing|March 2011|November 2014|Anticipated|March 2015|Anticipated|N/A|Expanded Access|N/A|||||||Female|18 Years|N/A||||May 2015|May 21, 2015|October 1, 2010|No|Yes||||https://clinicaltrials.gov/show/NCT01240421||113309|
NCT01240720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-F16SIPI131-06/07|A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer|A Phase I/II Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer||Philogen S.p.A.|No|Completed|September 2008|April 2013|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01240720||113286|
NCT01240733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0829-VSOM-MS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2010|||||N/A|N/A|N/A||||||||||||||November 12, 2010|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240733||113285|
NCT01241032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0086|Phase I Study to Investigate the Alcohol Interaction of DA8159|A Randomized, Open, Crossover Clinical Study to Investigate the Effects of Alcohol on the Pharmacokinetics of Udenafil Tablet in Healthy Male Volunteers|DA8159_DIA_I|Asan Medical Center|No|Completed|June 2006|||February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|24|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241032||113262|
NCT01241058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bespghan|Registry of Pediatric Patients Diagnosed With Crohn's Disease in Belgium|Belgian Registry of Pediatric Crohn's Disease|Belcro|Belgian Society for Pediatric Gastroentrology Hepatology and Nutrition|No|Completed|May 2008|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|257|||Both|1 Year|18 Years|No|Non-Probability Sample|subjects under 18 yrs of age diagnosed with Crohn's disease, living in Belgium|January 2016|January 17, 2016|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241058||113260|
NCT01210976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08039M|The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery|The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting||Tampere University Hospital|No|Completed|January 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|90 Years|No|||September 2011|September 20, 2011|September 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210976||115556|
NCT01211301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100625001|Medifast 5 & 1 Plan|Randomized Controlled Trial of the Medifast 5 & 1 Plan||University of Alabama at Birmingham|Yes|Completed|October 2010|April 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211301||115531|
NCT01239953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIBS V|RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)|RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial|RIBS V|Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular|Yes|Active, not recruiting|January 2010|||July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Both|20 Years|85 Years|No|||February 2012|February 24, 2012|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01239953||113345|
NCT01207453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-16|Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis|Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis||Brigham and Women's Hospital|Yes|Completed|January 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|24 Years|N/A|No|||November 2014|November 7, 2014|September 21, 2010||No||No|October 16, 2014|https://clinicaltrials.gov/show/NCT01207453||115825|
NCT01207674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/9-F|Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers (JEU)|Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers.||Nantes University Hospital||Active, not recruiting|April 2009|September 2016|Anticipated|November 2011|Actual|N/A|Interventional|N/A|||Actual|622|||Both|18 Years|65 Years||||March 2015|March 10, 2015|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01207674||115808|
NCT01207947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13931|LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers|LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers||Bayer|No|Completed|October 2007|March 2010|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|491|||Male|18 Years|N/A|No|Non-Probability Sample|Erectile dysfunction patients of 18 years-old or older and also the patients with        combination use of alpha-blockers.|January 2015|January 19, 2015|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01207947||115788|
NCT01210742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0604/33|The Efficacy of Viscosupplementation for Early Knee Osteoarthritis|The Efficacy of Hylan G-F 20 (Synvisc One) Injections in the Routine Management of Patients With Early Osteoarthritis of the Knee -a Randomised Controlled Trial (Pilot)|EVOKE|University of Oxford|Yes|Recruiting|May 2011|October 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||June 2012|June 15, 2012|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01210742||115574|
NCT01211067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-0015-1109|Study of Histological Findings of the Internal Inguinal Ring in Patients With Indirect Inguinal Hernia|Histological Findings of the Internal Inguinal Ring in Patients With Indirect Inguinal Hernia||Cirujanos la Serena|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|72|Samples Without DNA|A 1 cm tissue sample of the internal inguinal ring taken during elective hernioplasty|Male|15 Years|N/A|No|Non-Probability Sample|Patients with indirect inguinal hernia submitted to elective surgery with the Lichtenstein        hernioplasty technique|September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211067||115549|
NCT01211080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB 3|Off Label Use of Propranolol for Infancy Hemangiomas|Open-label, Uncontrolled Study of the Off Label Use of Propranolol for Infancy Hemangiomas to Identify Side Effects|PIHS|Hannover Medical School|No|Completed|August 2008|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Both|1 Month|8 Months|No|Probability Sample|Tertiary and Secondary Pediatric Surgery Referral unit Secondary Care Pediatrics Unit|November 2014|November 9, 2014|September 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01211080||115548|
NCT01207037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071228|Prognostic Factors of Acute Splenic Sequestration|Study of Prognostic Factors of Acute Splenic Sequestration in a Cohort of Sickle Cell Disease (SCD) Children Diagnosed at Birth|SSADREPA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|August 2010|April 2016|Anticipated|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|58|||Both|3 Months|6 Months|No|||January 2016|January 29, 2016|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01207037||115857|
NCT01207050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-604-08|Effect of Rozerem on Sleep Among People With Traumatic Brain Injury|Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury||Kessler Foundation|No|Active, not recruiting|September 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207050||115856|
NCT01207778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-153|Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin|Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin|BRITE|University of New Mexico|No|Recruiting|March 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|136|||Both|6 Months|47 Months|Accepts Healthy Volunteers|Non-Probability Sample|All infants previously enrolled in NCT00334737, a randomized masked study of darbepoetin        administration in preterm infants, are eligible for the study. We anticipate enrolling 75        of the original 102 infants from that study. In addition we will enroll 25 preterm infants        who did not receive Epo treatment during hospitalization, and 36 term infants matched for        age, gender and ethnicity to the preterm group.|September 2014|September 9, 2014|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207778||115800|
NCT01207544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS2009113001|Fitball Program Versus Task-oriented Motor Program on Improving Postural Control in Developmental Coordination Disorder|The Effectiveness of Fitball Program Versus Task-oriented Motor Program on Improving Postural Control and Motor Proficiency in Children With Developmental Coordination Disorder||The Hong Kong Polytechnic University|Yes|Completed|April 2010|December 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|6 Years|12 Years|No|||November 2012|November 26, 2012|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01207544||115818|
NCT01239329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL32655.068.10|Malnutrition in People With Complex Multiple Disabilities|Understanding of Malnutrition in People With Complex Multiple Disabilities||Maastricht University Medical Center|No|Recruiting|February 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|125|Samples Without DNA|Blood as well as urine samples will be collected. Urine samples are important concerning      measurement of body composition according to the Deuterium dilution method. A blood sample      will be collected for measurement of nutrients.|Both|18 Years|N/A|No|Non-Probability Sample|125 people with complex multiple disabilities, living in a care institution participating        in the Governor Kremers Centre (GKC).|February 2011|February 16, 2011|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239329||113393|
NCT01239654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APICE OCT Study (Project 4)|Activity of Platelets After Inhibition and Cardiovascular Events Optical Coherence Tomography Study|Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study|APICE-OCT|IRCCS San Raffaele|Yes|Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239654||113368|
NCT01240135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-030|Clinical Performance of a Silicone Hydrogel Lens With Use of FID 114675A|Clinical Performance of a Marketed Silicone Hydrogel Contact Lens When Used With Silicone Hydrogel MPDS FID 114675A||Alcon Research|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|89|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|November 10, 2010|Yes|Yes||No|June 8, 2012|https://clinicaltrials.gov/show/NCT01240135||113331|
NCT01240434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cierrlaparosc001|Randomized Prospective Trial on the Occurrence of Laparoscopic Trocar Site Hernias|Estudio Prospectivo Aleatorizado Simple Ciego Sobre la Incidencia de Hernias Incisionales en Los Orificios de Los trócares de Laparoscopia: Cierre aponeurótico Superficial Frente a cicatrización aponeurótica Sin Cierre||Hospital General Universitario Gregorio Marañon|No|Completed|March 2006|October 2008|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|195|||Both|N/A|N/A|No|||March 2006|November 12, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240434||113308|
NCT01240447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-RACO-02-08|Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients|A Prospective, Randomised, Open Label Phase II Study of Active Specific Immunotherapy With Racotumomab Versus Support Treatment in Patients With Advanced Non-small Cell Lung Cancer||Laboratorio Elea S.A.C.I.F. y A.|No|Completed|September 2009|June 2014|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|21 Years|N/A|No|||July 2014|July 9, 2014|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01240447||113307|
NCT01240746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QIV04|Study of Quadrivalent Influenza Vaccine Among Children|Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine||Sanofi|No|Completed|November 2010|February 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|4363|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|November 11, 2010|Yes|Yes||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01240746||113284|
NCT01209351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-003|Effect of Teduglutide on Gastric Emptying in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dosing, Parallel Group Study to Assess the Effects of Teduglutide (ALX-0600) on Gastric Emptying in Healthy Subjects||Shire|No|Completed|October 2010|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|November 10, 2015|September 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209351||115681|
NCT01209364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35GA0608|Durolane Versus Methylprednisolone in Knee Osteoarthritis|Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects With Osteoarthritis of the Knee||Q-Med AB|No|Completed|March 2007|November 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|442|||Both|35 Years|80 Years|No|||August 2007|November 6, 2012|September 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209364||115680|
NCT01209585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-INDP-1056|A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis|Study to Evaluate Biomarkers in Blood and Synovial Fluid in Subjects With Rheumatoid Arthritis||MedImmune LLC|No|Completed|March 2011|March 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|23|||Both|18 Years|75 Years|No|Non-Probability Sample|Male or Female Adults aged 18-75 years old|July 2013|July 23, 2013|September 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209585||115663|
NCT01209598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-094|PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma|A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|September 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209598||115662|
NCT01209897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA120799-02|Testing Different Theories of Smoking Cessation: An Intervention Study|Testing Alternative Stage Models of Smoking Cessation: An Intervention Study|Stage Models|University of Hawaii|Yes|Completed|February 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|1826|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 11, 2012|August 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01209897||115639|
NCT01208272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29MH051384|Psychological Treatment of Overweight Binge Eaters|A Randomized Comparison of Group-Behavioral Therapy and Group Interpersonal Psychotherapy for the Treatment of Overweight Individuals With Binge-Eating Disorder||Washington University School of Medicine||Completed|April 1994|March 1999|Actual|March 1998|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2010|September 22, 2010|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01208272||115763|
NCT01240187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-E044-037|A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects|A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 x2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects||Eisai Inc.||Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 13, 2013|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240187||113327|
NCT01240512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001612|DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension|Daylight: The Effect of Vitamin D Supplementation on Blood Pressure in Vitamin D Deficient Individuals With Pre-Hypertension|DAYLIGHT|Massachusetts General Hospital|Yes|Completed|December 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|534|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240512||113302|
NCT01240174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001247|Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis|Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis||Brigham and Women's Hospital|No|Active, not recruiting|March 2011|July 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|400|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2014|June 29, 2014|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01240174||113328|
NCT01210534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0036|Physiological Brain Atlas Development|Physiological Brain Atlas Development||Ohio State University|No|Recruiting|August 2010|August 2025|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|7 Years|90 Years|No|Non-Probability Sample|All patients who are undergoing DBS implantation surgery at the Ohio State University.|February 2016|February 2, 2016|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210534||115590|
NCT01211093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20091016003-01|Acute Effects of Whole Body Vibration in Chronic Stroke|The Acute Effects of Whole Body Vibration Training With Different Frequencies on Neuromotor Performance in Individuals With Stroke||The Hong Kong Polytechnic University|Yes|Recruiting|November 2009|July 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01211093||115547|
NCT01207258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA018705-01A1|Brief Intervention for Problem Drinking and Partner Violence|A Randomized Control Trial of Brief Intervention for Problem Drinking and Partner Violence||University of Pennsylvania|Yes|Active, not recruiting|September 2010|January 2015|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Female|18 Years|64 Years|No|||December 2014|December 11, 2014|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207258||115840|
NCT01207752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCO 10-6|The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction|Evaluation of the Efficacy of an Ocular Emulsion on the Signs and Symptoms of Meibomian Gland Dysfunction||Southern California College of Optometry|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207752||115802|
NCT01208038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1646|Testosterone Patch's Effects on the Cardiovascular System and Libido|Pilot Study: Evaluating the Effect of 300 Micrograms Testosterone Patches in Addition to Hormone Replacement Therapy on Arterial Compliance, Insulin Resistance and Sexual Desire.||Imperial College Healthcare NHS Trust|No|Not yet recruiting|October 2010|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Female|45 Years|70 Years|No|||September 2010|September 22, 2010|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208038||115781|
NCT01206998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VagPro 27515|Vaginal Progesterone as a Treatment for Women Active Preterm Labor|Vaginal Progesterone in Patients With Active Preterm Labor|VagPro|University of Rochester|Yes|Withdrawn|July 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||September 2012|September 28, 2012|September 20, 2010|Yes|Yes|Withdrawal of support of the drug company for drug and placebo|No||https://clinicaltrials.gov/show/NCT01206998||115860|
NCT01207011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0702035|Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer|A Randomised, Open-Label Phase 3 Trial Comparing Amrubicin Versus Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy||Sumitomo Dainippon Pharma Co., Ltd.||Completed|October 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Both|20 Years|74 Years|No|||July 2015|August 27, 2015|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207011||115859|
NCT01207024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071225|Assessment of Knee Arthrosis After Bariatric Surgery|Assessment of Knee Arthrosis in Severely Obese Patients After Bariatric Surgery.|BASIK|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2009|September 2014|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|59 Years|No|Non-Probability Sample|Inclusion Criteria:          -  bariatric surgery          -  IMC >= 35        Exclusion Criteria:          -  those of bariatric surgery          -  contra-indication to MRI          -  pregnancy|December 2014|December 19, 2014|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01207024||115858|
NCT01207557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPA 90189|A Randomized Controlled Trial of the Effectiveness of the Ottawa Influenza Decision Aid|A Randomized Controlled Trial of the Effectiveness of the Ottawa Influenza Decision Aid - A Component of the "Optimizing Healthcare Workers Interpandemic Vaccine Uptake in Acute and Long-term Care" CIHR Project|OIDA|Ottawa Hospital Research Institute|No|Completed|August 2009|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 24, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207557||115817|
NCT01207570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20091207001|Endermotherapy for Children With Developmental Disabilities|Effect of Endermotherapy on Passive Ankle Range of Motion in Children With Developmental Disabilities||The Hong Kong Polytechnic University|Yes|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|2 Years|6 Years|No|||October 2011|October 7, 2011|September 17, 2010||No||No|August 8, 2011|https://clinicaltrials.gov/show/NCT01207570||115816|
NCT01208116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009A055|A Prospective Study on Predictive Value of Non-Invasive Atherosclerotic Measurements in Elderly Chinese|A Prospective Study on Predictive Value of Non-Invasive Atherosclerotic Measurements in Elderly Chinese||Tianjin Medical University General Hospital||Recruiting|April 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1290|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with an age>=60 years, who are designated for healthcare in Tianjin Medical        University General Hospital will be enrolled in the study and there is no restriction on        gender. Medical histroy are recorded precisely. The protocol was approved by our        Institutional Ethics Committee and all subjects give informed consent before        participating.|September 2010|September 22, 2010|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208116||115775|
NCT01239901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1HL099412-01|Iron Mediated Vascular Disease in Sickle Cell Anemia Patients|Iron-mediated Vascular Disease in Sickle Cell Disease.||Children's Hospital Los Angeles|Yes|Active, not recruiting|December 2009|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|Red Blood Cells (RBCs), Peripheral Blood Mononuclear Cells (PBMCs), Plasma, Serum, and Urine|Both|13 Years|N/A|No|Non-Probability Sample|Our large and well-established sickle cell Center has strong ties to the SCD community in        a large metropolitan area (Los Angeles), placing us in an ideal position to rapidly accrue        sufficient subjects to study the prevalence of iron overload and determine the relation        between directly measured iron loading, vascular responsiveness and clinically relevant        biomarkers of vascular function.|March 2016|March 17, 2016|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01239901||113349|
NCT01209377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA1475/2-1|Study of Eye Movement Desensitization and Reprocessing (EMDR) Working Mechanism|Randomized Controlled Study of Eye Movement Desensitization and Reprocessing (EMDR) Working Mechanism||Technische Universität München|No|Recruiting|April 2010|April 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|192|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|June 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01209377||115679|
NCT01209611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30730092|Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in Accelerating Tissue Expansion and Skin Regeneration|Phase 1/2 Study of Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in Accelerating Soft Tissue Expansion||Shanghai Jiao Tong University School of Medicine||Recruiting|September 2010|December 2014|Anticipated|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||April 2014|April 21, 2014|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01209611||115661|
NCT01209910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120|Effects of Free Water Protocol on Inpatients in a Neurological Rehabilitation Setting|Effects of Free Water Protocol on Inpatients in a Neurological Rehabilitation Setting||University of Manitoba|Yes|Completed|August 2010|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01209910||115638|
NCT01210157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL_LGALS3BP|Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure|GALectin-3 Binding Protein for Risk Assessment in Coronary arTery dIsease and Chronic Heart Failure|GALACTIC|Heidelberg University|No|Completed|June 2008|August 2010|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|373|Samples Without DNA|Serum, plasma|Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing coronary angiography.|September 2010|September 27, 2010|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01210157||115619|
NCT01210443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321053|Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients|A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension||Pfizer|Yes|Terminated|November 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|16 Years|80 Years|No|||June 2011|November 10, 2011|August 11, 2010||No|Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,    specifically new emerging evidence of hepatic injury.|No|November 10, 2011|https://clinicaltrials.gov/show/NCT01210443||115597|
NCT01210430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01HL074873-06A2|Local Vasoconstriction in Postural Tachycardia Syndrome|Local Vasoconstriction in Postural Tachycardia Syndrome||New York Medical College|Yes|Completed|July 2010|June 2015|Actual|June 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Anticipated|90|||Both|14 Years|29 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|August 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210430||115598|
NCT01239966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00397-32|Pulmonary And Renal Support During Acute Respiratory Distress Syndrome|Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With the Acute Respiratory Distress Syndrome and Acute Renal Failure|PARSA|Hôpital Européen Marseille|No|Completed|November 2010|June 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 21, 2016|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01239966||113344|
NCT01241175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4286|The Effect of Intravenous Magnesium Sulfate on Intraocular Pressure Following Tracheal Intubation|||Shiraz University of Medical Sciences|No|Completed||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|18 Years|38 Years|No|||March 2009|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241175||113251|
NCT01241188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESEC-04|A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)|A Phase IIb Sensitivity Trial of the Diagnostic Agent C-Tb, When Given Intradermally by the Mantoux Technique to Adult Patients Recently Diagnosed With Active TB|TESEC-04|Statens Serum Institut|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|253|||Both|18 Years|65 Years|No|||April 2015|April 16, 2015|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241188||113250|
NCT01240798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 09-10|Depression and Anxiety in the Aetiology and Prognosis of Specific Cardiovascular Disease Syndromes: a CALIBER Study|Depression and Anxiety in the Aetiology and Prognosis of Specific Cardiovascular Disease Syndromes: a CALIBER Study Using Linked GPRD-MINAP-HES Data||University College, London|Yes|Active, not recruiting|January 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include all adults (18+) in GPRD registered in up-to-standard        practices with at least 1 year of up to standard follow up. Analyses will focus on the        ~200 practices which have consented to linkage with HES and MINAP. Essentially we will        define an aetiological cohort - whole population - free of any coronary syndrome at start        of follow up. Patients within this cohort are followed for the aetiologic endpoint of a        first specific coronary syndrome (see below). This aetiologic endpoint is the prognostic        start-point; such patients will then be followed for subsequent specific coronary        syndromes and death. We will focus analyses on patients with at least a year follow up        data before and their endpoint. As in a conventional cohort study we will define according        to exposure history.|January 2010|November 22, 2010|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240798||113280|
NCT01211106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZDA1-03-W10|Integrated vs Sequential Treatment for PTSD and Addiction|Integrated vs Sequential Treatment for PTSD and Addiction Among OEF/OIF Veterans||VA Office of Research and Development|Yes|Active, not recruiting|February 2011|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||December 2015|December 15, 2015|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01211106||115546|
NCT01210781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBS|Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation|Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation||University of Zurich|Yes|Enrolling by invitation|September 2009|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|consecutive patients implanted with DBS electrodes at our institution|December 2014|December 19, 2014|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210781||115571|
NCT01211119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99022|Novel One-step Repair of Knee Meniscal Tear Using Platelet-rich Fibrin|Novel One-step Repair of Knee Meniscal Tear Using Platelet-rich Fibrin||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|January 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|20 Years|45 Years|No|||April 2011|April 21, 2011|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01211119||115545|
NCT01210794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNL/CTC08-09|The Influence of Different Food Componente on Zinc Absorption in Young Adults Consuming Zinc Fortified Porridges Prepared From Maize, Beans and Sorghum: a Series of Six Similar Randomized, Single-blind Studies|||University of Zurich||Completed|March 2009|June 2010||||N/A|Observational|N/A||1|Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Study not related to a disease. Nutrition study without drug drug administration.        Investigation on the influence of different food components on zinc absorption in young        adults consuming zinc fortified porridges prepared from maize, beans and sorghum.|January 2012|January 9, 2012|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210794||115570|
NCT01210807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIOL-105-TMF1|Clinical Evaluation of the One-Piece Tecnis Multifocal Intraocular Lens (IOL)|Clinical Evaluation of the One-Piece Tecnis Multifocal IOL, Model ZMB00||Abbott Medical Optics|No|Completed|November 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 17, 2010||No||No|May 15, 2013|https://clinicaltrials.gov/show/NCT01210807||115569|
NCT01211132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR0006|Cap Assisted Colonoscopy for the Detection of Colon Polyps|Prospective Randomized Controlled Study of Cap Assisted Colonoscopy for the Detection of Colon Polyps||Kansas City Veteran Affairs Medical Center|No|Recruiting|September 2009|November 2010|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|462|||Both|21 Years|85 Years|No|||September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211132||115544|
NCT01207310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11RT0009|Pager-Assisted Smoking Cessation Treatment|Pager-Assisted Smoking Cessation Treatment|Pager|University of California, San Francisco|No|Completed|May 2003|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2011|September 15, 2011|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207310||115836|
NCT01207817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090181|Effect of Ambient Light on the Parameters of the Pupillary Light Reflex|Effect of Ambient Light on the Parameters of the Pupillary Light Reflex||Rutgers, The State University of New Jersey|No|Completed|September 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volinteers|September 2010|September 22, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01207817||115797|
NCT01207830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA 2.2|Feasibility Trial of ValenTx Endo Bypass System of the ValenTx Endo Bypass System in Obese Subjects|A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Subjects||ValenTx, Inc.|No|Completed|March 2010|February 2012|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207830||115796|
NCT01207791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA CTN Protocol 0047|Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments|Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments|SMART-ED|University of New Mexico|Yes|Completed|October 2010|March 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1285|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207791||115799|
NCT01207804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM|Feasibility Trial of ValenTx Endo Bypass System|A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Patients||ValenTx, Inc.|No|Completed|August 2008|May 2009|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|No|||March 2016|March 15, 2016|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207804||115798|
NCT01209065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113068|GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir|See Detailed Description Section as Official Study Title is Too Long to Fit in This Field||GlaxoSmithKline|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 22, 2011|August 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209065||115703|
NCT01209637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMW 04|Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CAD|Impact of Intensive Exercise Training Compared to Inactive Controls on Coronary Collateral Circulation and Plaque Composition in Patients With Significant Stable Coronary Artery Disease||University of Leipzig|No|Recruiting|March 2010|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||September 2011|September 2, 2011|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209637||115659|
NCT01209650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.47|LUX Lung Special Access Scheme Australia Named Patient Use (NPU)|Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment||Boehringer Ingelheim||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 24, 2010||||No||https://clinicaltrials.gov/show/NCT01209650||115658|
NCT01209923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stayhealthy 01|Validation of the Stayhealthy BC1 Body Comp Analyzer|Validation of the BC1 Bioelectrical Impedance Body Comp Analyzer||University of Southern California|No|Completed|May 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|180|||Both|10 Years|80 Years|Accepts Healthy Volunteers|||July 2010|September 24, 2010|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01209923||115637|
NCT01210170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20071188|Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma|Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma||University of Miami|No|Completed|October 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|7||Actual|22|||Both|18 Years|65 Years|No|||November 2014|November 17, 2014|September 27, 2010|Yes|Yes||No|September 5, 2014|https://clinicaltrials.gov/show/NCT01210170||115618|
NCT01210456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREKIT-001|Efficacy Trial of N-Acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-Induced Acute Kidney Injury|The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|PREKIT|Tokushukai Medical Group|No|Enrolling by invitation|October 2009|November 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|458|||Both|20 Years|N/A|No|||September 2014|September 13, 2014|July 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01210456||115596|
NCT01207206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-SB-392-CTIL|Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients|Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients||Tel-Aviv Sourasky Medical Center|No|Recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2010|October 31, 2011|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207206||115844|
NCT01210690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01357|Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution|Observational Sentinel Sites Study in Infants Younger Than 12 Months Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution in Usual Clinical Practice||UCB Pharma|No|Completed|January 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|||Both|1 Month|11 Months|No|Non-Probability Sample|Patients coming to day clinic for consultation by specialist|November 2014|November 18, 2014|September 23, 2010|No|Yes||No|November 11, 2014|https://clinicaltrials.gov/show/NCT01210690||115578|
NCT01240811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09100199|Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception|Impact of Intrauterine Contraception on the Immune Environment of the Female Genital Tract|CHIC|University of Pittsburgh|No|Completed|November 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|November 11, 2010||No||No|January 15, 2013|https://clinicaltrials.gov/show/NCT01240811||113279|We identified a need for methods optimization prior to proceeding with a large definitive study to determine contraceptive hormone induced changes in genital tract immune cell populations.
NCT01241162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34183|Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma|A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed Neuroblastoma and Sarcoma.||University of Louisville|Yes|Active, not recruiting|August 2010|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|1 Year|24 Years|No|||February 2016|February 8, 2016|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241162||113252|
NCT01241487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAA489AEG02|A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy|An 8 Weeks Open Label National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy||Novartis|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|21 Years|N/A|No|||June 2011|June 7, 2011|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241487||113227|
NCT01241500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-21|Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts|Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine|ONTIME|Onconova Therapeutics, Inc.|Yes|Active, not recruiting|November 2010|November 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241500||113226|
NCT01241474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofAberdeen RINH HNU800|Effect of Fish Oil on Insulin Sensitivity|Chronic Long-chain n-3 PUFA Supplement and Insulin Action in Human Subjects With Impaired Glucose Regulation||University of Aberdeen|Yes|Completed|February 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|34|||Both|40 Years|69 Years|No|||August 2012|August 6, 2012|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01241474||113228|
NCT01210300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99038|Exploring Taiwanese Womens' Decision-making Regarding Vaginal Birth After Caesarean Section|Exploring Taiwanese Womens' Decision-making Regarding Vaginal Birth After Caesarean Section||Taipei Medical University WanFang Hospital|No|Completed|June 2010|September 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Female|20 Years|N/A|No|Non-Probability Sample|pregnant women|April 2011|April 22, 2011|September 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01210300||115608|
NCT01210573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002M77542|Prospective Observation of Exercise Parameters in Advanced Heart Failure|Prospective Observation of Exercise Parameters in Advanced Heart Failure||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with, or suspected to have, advanced heart failure and who meet inclusion and        exclusion criteria are eligible for participation. Those who have undergone LVAD        implantation, heart transplantation or are on the transplant list, and those with        biventricular pacemaker who meet study criteria are also eligible for study participation.        Patients diagnosed with pulmonary hypertension and therefore at risk for developing right        sided heart failure may also be included.|December 2014|December 16, 2014|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210573||115587|
NCT01207063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRONC CONC MLD/BRONC MLD/ADA|Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)|Adaptive Radiotherapy for Stage II-III Non-small Cell Lung Cancer||Maastricht Radiation Oncology|Yes|Active, not recruiting|March 2011|September 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01207063||115855|
NCT01207076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010LS030|AHN-12 Biodistribution in Advanced Leukemia|Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 In Patients With Advanced Leukemia HM2010-05||Masonic Cancer Center, University of Minnesota|Yes|Terminated|December 2013|July 2016|Anticipated|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|12 Years|N/A|No|||May 2015|May 15, 2015|September 21, 2010|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01207076||115854|
NCT01207297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiCTR-TKMS-1000960|Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis|Tacrolimus Versus Cyclophosphamide as Treatment for Diffuse Proliferative or Membranous Lupus Nephritis: Prospective Cohort Study||Zhejiang University|Yes|Completed|March 2003|June 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|64 Years|No|||September 2010|August 22, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207297||115837|
NCT01207583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4596|Prevenar (PCV-7) Post-Licensure Safety Study In Russia|Prevenar Post-Licensure Safety Study in Russia: Frequency Of Fever Post Vaccination||Pfizer|No|Completed|December 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|3 Months|23 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants and Children from 3 months to 23 months at enrollment|July 2012|July 26, 2012|September 21, 2010||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01207583||115815|
NCT01208779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORS-DUM-2010/1|Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer|An Epidemiological, Non-interventional Study to Evaluate Patient Compliance in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer||AstraZeneca|No|Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|90|||Female|18 Years|N/A|No|Non-Probability Sample|Oncology centers|July 2013|July 16, 2013|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208779||115724|
NCT01209039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111587|A Repeat Dose Positron Emission Tomography Study With GSK1144814|A Healthy Volunteer Repeat Dose Study to Evaluate; the Safety, Tolerability, Pharmacokinetics, Effects on the Pharmacokinetics of Midazolam and the Neurokinin 1 Receptor Occupancy of GSK1144814|NK1 NK3 PET|GlaxoSmithKline|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2010|January 22, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01209039||115705|
NCT01208155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00016|Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets|An Open-label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of 4 Different Fostamatinib Tablets||AstraZeneca|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208155||115772|
NCT01208168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904|Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks||Promius Pharma, LLC|No|Terminated|September 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|468|||Both|18 Years|70 Years|No|||July 2013|July 8, 2013|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208168||115771|
NCT01209390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMCM-2010-01|A Prospective, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects|A Prospective, Open Label, Multi-centre, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects|OMCM|TiGenix n.v.|No|Terminated|September 2010|April 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients will be recruited in selected centres, primary or secondary care, first line or        referral treatment.|September 2011|September 19, 2011|August 6, 2010||No|Slow recruitment rate|No||https://clinicaltrials.gov/show/NCT01209390||115678|
NCT01209624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111135|Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma|Prospective, Observational Study to Investigate the Long-term Effect of Xalatan® on Intraocular Pressure (IOP) and on Maintenance of Visual Field in Patients With Normal Tension Glaucoma (NTG)|NTG-X-PERT|Pfizer|No|Completed|August 2006|September 2009|Actual|September 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|902|||Both|18 Years|N/A|No|Non-Probability Sample|Glaucoma subjects|June 2011|July 7, 2011|September 23, 2010||No||No|September 29, 2010|https://clinicaltrials.gov/show/NCT01209624||115660|Outcome measures for this observational non-interventional study were not designated as primary or secondary measures.
NCT01210469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|787/06|Effectiveness of Two Treatments on Posture and Balance in Elderly Women With Osteoporosis|Effectiveness of Two Treatments on Posture and Balance in Elderly Women With Osteoporosis: a Randomized Clinical Trial||University of Sao Paulo General Hospital|Yes|Completed|July 2007|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|50|||Female|65 Years|80 Years|No|||March 2008|October 5, 2010|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210469||115595|
NCT01210703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcPh.1|Acoustic Pharyngometry in Obstructive Sleep Apnea Syndrome Patients, With Indication of Continuous Positive Air Pressure|Evaluation of Effect of Continuous Positive Air Pressure (CPAP) on Upper Airway Dimensions, by Acoustic Pharyngometry (AP), in Severe Obstructive Sleep Apnea Syndrome (OSAS) and Primary Snore Patients|APOSAS|University of Sao Paulo General Hospital|No|Active, not recruiting|May 2009|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|65 Years|No|Probability Sample|Patients with Severe Sleep Obstructive Apnea Syndrome and Primary Snorers, who have        already made a polysomnography (in apneics, polysomnography for CPAP titulation, too).|September 2010|October 14, 2010|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210703||115577|
NCT01210989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD- Hepaguard|Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis|A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis||Chinese University of Hong Kong|Yes|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||February 2014|February 20, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01210989||115555|
NCT01211002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sim201002|Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)|The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) )||Simcere Pharmaceutical Co., Ltd|Yes|Not yet recruiting|October 2010|December 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|75 Years|No|||September 2010|September 28, 2010|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01211002||115554|
NCT01207466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-415-C-001 sub 2|Evaluation of Two Daily Disposable Contact Lenses for Wearers With Astigmatism|||Alcon Research|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|95|||Both|N/A|N/A|No|||January 2012|June 27, 2012|September 21, 2010|Yes|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT01207466||115824|
NCT01207960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-137-f-S|Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Dental Phobia|A Randomized Wait-list Control Study of the Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Patients With Dental Phobia|EMDR-DP|University Hospital Muenster|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||May 2012|May 3, 2012|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01207960||115787|
NCT01207973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1272.2|Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Multiple Rising Oral Doses (50, 100, 200 and 350 mg qd and 100 mg Bid for 12 Days) of BI 113823 as Tablet in Male and Female Patients With Osteoarthritis of the Knee (Randomised, Double-blind, Placebo-controlled Within the Dose Groups, Clinical Phase I)||Boehringer Ingelheim||Terminated|September 2010|||January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|36|||Both|35 Years|65 Years|No|||November 2013|November 4, 2013|September 22, 2010||||No||https://clinicaltrials.gov/show/NCT01207973||115786|
NCT01241201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9067|Intestinal Barrier Function and Probiotics.|A Study Proposal to Investigate the Sequels of Mucosal Inflammation Caused by ETEC Infection - the Effects of Probiotics.||TNO|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|32|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 20, 2011|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01241201||113249|
NCT01241786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VZ-CLL-PI-0146|Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL|A Phase II, Single Arm Study Examining the Combination of Lenalidomide and Azacitidine (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)||Hackensack University Medical Center|Yes|Terminated|July 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|November 15, 2010|Yes|Yes|anticipated results not seen and population not seen|No||https://clinicaltrials.gov/show/NCT01241786||113204|
NCT01241799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-01481|Yield of Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS-FNA) With and Without the Use of a Stylet in the Biopsy Needle|A Prospective, Single Blinded, Randomized, Controlled Study to Compare the Yield of Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS-FNA) With and Without the Use of a Stylet in the Biopsy Needle||University of British Columbia|Yes|Completed|December 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|72|||Both|18 Years|N/A|No|||November 2010|November 22, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01241799||113203|
NCT01210833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10k112/2010CTIL|Using HandTutor With Traumatic Hand Injuries: Characterizing the System|Using HandTutor With Traumatic Hand Injuries: Characterizing the System||Meir Medical Center|No|Completed|October 2010|December 2014|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|June 3, 2015|August 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01210833||115567|
NCT01211145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1220C00001|Zomig - Treatment of Acute Migraine Headache in Adolescents|A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents|TEENZ|AstraZeneca|No|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1653|||Both|12 Years|17 Years|No|||January 2015|January 26, 2015|September 28, 2010|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01211145||115543|
NCT01211158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gandolfatto|Ketofol vs Propofol for Emergency Department Procedural Sedation and Analgesia|A Randomized Double-blind Trial to Evaluate Ketamine-propofol Combination vs. Propofol Alone for Procedural Sedation and Analgesia in the Emergency Department.||Lions Gate Hospital|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|284|||Both|14 Years|N/A|No|||November 2011|November 16, 2011|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211158||115542|
NCT01211171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14881|COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland|COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH|COUGH|Bayer|No|Completed|May 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2498|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic hypertensive patients with cough caused by the ACE-i regardless any        other factors.|February 2014|February 11, 2014|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211171||115541|
NCT01211184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STS1|Fluid and Nutrition in Elective Hip Surgery|Fluid and Nutrition in Elective Hip Surgery||Sodertalje Hospital|No|Completed|May 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2011|June 28, 2013|September 28, 2010||No||No|September 12, 2011|https://clinicaltrials.gov/show/NCT01211184||115540|A few glucose tolerance tests had to be discarded because of hemolysis in the samples taken for analysis of insulin.
NCT01207089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2350C00010|To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329|A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD8329 After Administration of Multiple Ascending Doses in Abdominally Obese But Otherwise Healthy Male Subjects|AZ8329|AstraZeneca||Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|45|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 9, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01207089||115853|
NCT01207609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-9-001|Laparoscopic Gastric Plication Operation for Patients With Severe or Morbid Obesity|A Prospective Study to Evaluate the Safety and Efficacy of the Laparoscopic Gastric Plication Operation for Patients With Severe or Morbid Obesity||Ponce, Jaime, M.D.|No|Completed|November 2010|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|60 Years|No|||February 2016|February 1, 2016|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207609||115813|
NCT01209572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU767|Modelling of Energy Expenditure From Heart Rate, Accelerometry and Other Physiological Parameters|Modelling of 24h Energy Expenditure From Heart Rate, Actimetry and Other Parameters Recorded Under Free-living Conditions|Modelheart|Institut National de la Recherche Agronomique|Yes|Completed|January 2009|September 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209572||115664|
NCT01209884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB# 10-5416|Metabolomics of Aging: Sub-study of the Healthy Elderly Active Longevity (HEAL) Study|Metabolomics of Aging: Sub-study of the Healthy Elderly Active Longevity (HEAL) Cohort|Metabolomics|Scripps Translational Science Institute|No|Completed|February 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|Samples Without DNA|Blood sample will be collected from each subject after informed consent is obtained      Blood collection      Approximately 10mL of blood will be collected. The blood will be collected for the purpose      of isolating plasma, as follows:      1 X 10mls Sodium (Na) Heparin tube      Blood will be drawn by hospital/clinic phlebotomy services, a nurse or a medical assistant.      Blood will be collected from each subject one time.      Once aliquoted, the plasma will be catalogued in a central registry (LIMS database) and then      stored. Metabolite extraction and protein precipitation will be performed to remove proteins      and extract the maximum number of metabolites. The samples will be maintained at 4 degrees      Celcius in the autosampler and then analyzed.|Male|80 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|General outpatient and community population|January 2014|January 7, 2014|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209884||115640|
NCT01209936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stayhealthy 02|Hydration Factor Study for the Stayhealthy BC3|Pilot Study for the Validation of the BC3 Bioelectrical Impedance Hydration Factor||University of Southern California|No|Completed|September 2009|July 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|15|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||September 2010|September 24, 2010|September 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209936||115636|
NCT01242930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP14B013|Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma|A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma||Geron Corporation|No|Completed|November 2010|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242930||113118|
NCT01242943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19SIPI131-07/07|Radioimmunotherapy With 131I-L19SIP in Patients With Cancer|A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER||Philogen S.p.A.|No|Terminated|November 2008|May 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|75 Years|No|||November 2011|November 21, 2011|November 16, 2010||No|With the determination of the RD and a well established understanding of the safety and    tolerability profile, the main endpoints of the study have been met.|No||https://clinicaltrials.gov/show/NCT01242943||113117|
NCT01243255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CPL-DUM-2010/1|Polish Survey on the Efficacy of the Hypercholesterolemia Treatment|Centralized Pan-European Survey on the Undertreatment of Hypercholesterolemia. Polish Survey on the Efficacy of the Hypercholesterolemia Treatment|CEPHEUS|AstraZeneca|No|Completed|December 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1500|Samples Without DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|April 2012|April 3, 2012|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243255||113094|
NCT01243268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.40|A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy|A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy||Boehringer Ingelheim||Recruiting|December 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|19 Years|N/A|No|Probability Sample|Korean patients wtih essential hypertension|March 2016|March 16, 2016|November 17, 2010||||No||https://clinicaltrials.gov/show/NCT01243268||113093|
NCT01238809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-DUM-2010/1|Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France|Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France||AstraZeneca|No|Withdrawn|June 2011|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|7300|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community sample|June 2011|June 6, 2011|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238809||113431|
NCT01238822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH074770|Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Response Variability in Children With ADHD||Children's Hospital Medical Center, Cincinnati|No|Completed|June 2006|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|96|||Both|7 Years|11 Years|No|||April 2012|April 2, 2012|November 9, 2010||No||No|July 14, 2011|https://clinicaltrials.gov/show/NCT01238822||113430|
NCT01239095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-089|Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection|Perioperative Administration of Oral Green Tea Extract/Milk Thistle Extract to Colorectal Cancer Patients Undergoing Colorectal Cancer Resection, a Phase 1 Study||St. Luke's-Roosevelt Hospital Center|No|Recruiting|July 2011|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||November 2015|November 19, 2015|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239095||113409|
NCT01239108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-1776-02|Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias|A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias||Astex Pharmaceuticals||Withdrawn|October 2010|April 2012|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||November 2010|September 6, 2012|November 5, 2010|No|Yes|The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe    to continue clinical development of this molecule.|No||https://clinicaltrials.gov/show/NCT01239108||113408|
NCT01239407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000954|Culturally-focused Consultation for Asian Americans and Latino Americans|Culturally Focused Psychiatric Consultation Service for Asian American and Latino American Primary Care Patients With Depression|CFP|Massachusetts General Hospital|No|Completed|December 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||April 2012|October 29, 2014|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239407||113387|
NCT01239706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23036|Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1|A Phase IIa, Single Centre, Open Label Study to Characterize the Safety of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1||University of Calgary|Yes|Recruiting|November 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239706||113364|
NCT01239719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECEMS11209|Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|March 2011|December 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||January 2011|January 27, 2011|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01239719||113363|
NCT01240889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-15912|Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*|Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*|Roche|Creighton University|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 8, 2012|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01240889||113273|
NCT01240824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14585|Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer|A Phase I Trial to Determine the Safety, Tolerability and Maximum Tolerated Intravesical Dose of Aminophylline With BCG in Patients With Non-invasive Bladder Cancer|BCG|University of Virginia|Yes|Completed|July 2010|February 2011|Actual|February 2011|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|40 Years|N/A|No|||April 2014|April 10, 2014|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240824||113278|
NCT01240837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33657|Effect of Palm Sugar on Blood Glucose Concentrations|Investigation of the Glycaemic Index of Arenga Pinnata Palm Sugar|LIPS|Wageningen University|No|Completed|November 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|21|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240837||113277|
NCT01240850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM79BKPY|Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial|Medical Therapy in Idiopathic Retroperitoneal Fibrosis: a Multicenter, Randomized, Controlled Trial of Prednisone vs Low-dose Prednisone Plus Methotrexate|FIPREDEX|University of Parma|No|Recruiting|May 2007|December 2013|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||November 2010|November 12, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240850||113276|
NCT01241214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-060B202|Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis|A Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group, Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis|SAR|Actelion|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|579|||Both|18 Years|70 Years|No|||January 2012|January 6, 2012|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241214||113248|
NCT01241513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-13|Induced Changes in Ventilatory Responsiveness and Altitude Exposure|Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization||United States Army Research Institute of Environmental Medicine|Yes|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241513||113225|
NCT01210599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0782|A Pilot Trial of IV Pamidronate for Low Back Pain|A Pilot Trial of Intravenous Pamidronate for Low Back Pain||Pappagallo, Marco, M.D.|Yes|Completed|April 2004|October 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|44|||Both|21 Years|N/A|Accepts Healthy Volunteers|||September 2010|October 12, 2010|September 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01210599||115585|
NCT01210846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-10-112|A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors|An Open-Label Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors||AVEO Pharmaceuticals, Inc.|No|Completed|October 2010|July 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2011|September 23, 2011|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210846||115566|
NCT01210859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URSTDETRUSITOL|Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents|Effects of Antimuscarinic Drugs on OAB Symptoms After Insertion of Ureteral Stents||Meir Medical Center||Withdrawn|September 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|patients which underwent ureteral stent insertion|September 2013|September 25, 2013|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01210859||115565|
NCT01207102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019321|Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer|A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for "Triple Negative" (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer||Duke University|No|Terminated|August 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||August 2014|December 8, 2014|September 10, 2010|Yes|Yes|Low enrollment and there is insufficient data to publish.|No|December 8, 2014|https://clinicaltrials.gov/show/NCT01207102||115852|
NCT01207323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAF4873g|A Study of the Safety and Pharmacokinetics of MEHD7945A in Patients With Locally Advanced or Metastatic Epithelial Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients With Locally Advanced or Metastatic Epithelial Tumors||Genentech, Inc.||Active, not recruiting|November 2010|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207323||115835|
NCT01207336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-27|Combined tDCS+PNS After Acute Stroke|Effect of Combined Anodal tDCS and Peripheral Nerve Stimulation on Motor Recovery in Acute Stroke||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|September 2010|||September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|35 Years|85 Years|No|||April 2012|April 5, 2012|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207336||115834|
NCT01208506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8828-3837|First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis|First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|64|||Both|18 Years|75 Years|No|||February 2012|February 28, 2012|September 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208506||115745|
NCT01208766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOVON 95 MM|Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma|A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma|HO95|Stichting Hemato-Oncologie voor Volwassenen Nederland|Yes|Active, not recruiting|January 2011|April 2021|Anticipated|April 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1500|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01208766||115725|
NCT01210651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H49362-35940-01|Treating Depression With Yoga|Treating Depression With Yoga: A Randomized Controlled Pilot Trial With Adults and Adolescents||University of California, San Francisco|No|Completed|May 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|14 Years|N/A|No|||August 2010|January 31, 2011|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01210651||115581|
NCT01209078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113414|GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection|A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection||GlaxoSmithKline|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|September 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209078||115702|
NCT01209091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113547|Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden|Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden||GlaxoSmithKline|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A hundred members of the general public will be recruited in the Netherlands and in Sweden        to participate in time trade off (TTO) interviews. In Sweden in order to try to match the        socio-demographic profile of women suffering from HER2+ MBC, recruitment will be aimed at        females aged over 50. In the Netherlands participants will be from both genders, and of        mixed age, ethnicity, education and employment status categories. In Sweden, interviews        will be conducted in Stockholm, Tyresö and Malmo. In the Netherlands, interviews will be        conducted in Rotterdam, Amsterdam and Colmschate.|February 2016|February 1, 2016|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01209091||115701|
NCT01242644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-230|Comparison of a Pain Pump Versus Injectable Medication for Analgesia in Knee Arthroscopy|Comparison of a Pain Pump Versus Injectable Medication for Analgesia in Knee Arthroscopy||University of South Alabama|No|Completed|October 2006|June 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|49|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01242644||113139|
NCT01239433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK S-O, Ref 2010/1340, part B|Pathophysiologic Changes in the Respiratory System During Therapeutic Interventions|Pathophysiologic Changes in the Respiratory System During Therapeutic Interventions||Oslo University Hospital|No|Recruiting|May 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients in the Intensive Care Unit (ICU) on mechanical ventilation where daily        endotracheal suctioning is performed to remove secretions.        Most of the patients have ARDS/ ALI.|May 2011|January 12, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239433||113385|
NCT01239732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22923|A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer|Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma||Hoffmann-La Roche||Completed|December 2010|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1041|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|November 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01239732||113362|
NCT01239979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|388417|Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease|Evaluation of the Association Between Myeloperoxidase Levels and Cardiovascular Risk Factors in Patients With Coronary Artery Disease||Isfahan University of Medical Sciences|No|Completed|January 2009|November 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|150|Samples Without DNA|Plasma|Both|35 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|All subjects are diagnosed angiographically following chest pain, clinical manifestations        or suspected changes on ECG at Isfahan Cardiovascular Research Center in Iran|January 2009|December 21, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01239979||113343|
NCT01240200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046366|Satisfaction of Treatment Among Elderly Patients With Insulin Therapy|Satisfaction of Treatment Among Elderly Patients With Insulin Therapy Using Pens for a Basal Insulin Treatment (STEP IT UP a BIT)||Emory University|Yes|Completed|January 2011|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|65 Years|N/A|No|||October 2014|October 29, 2014|November 9, 2010|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01240200||113326|
NCT01240213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAC110024|Vitamin D, Diet and Activity Study|Vitamin D, Weight Loss, and Breast Cancer Biomarkers|ViDA|Fred Hutchinson Cancer Research Center|Yes|Completed|October 2010|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|218|||Female|50 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 5, 2013|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01240213||113325|
NCT01240525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/10/0241|Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers|Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers|ProT4|University College, London|Yes|Recruiting|November 2011|November 2019|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|69 Years|No|||December 2015|December 7, 2015|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240525||113301|
NCT01241227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLV-0403|Prognosis Value of Transient Elastography and Non-invasive Markers of Fibrosis in Patients With Chronic Liver Disease|Prognosis Value of Transient Elastography and Non-invasive Markers of Fibrosis in Patients With Chronic Liver Disease. A Prospective Follow-up of 4,935 Person-years|PVTE|Association HGE CHU Bordeaux Sud|Yes|Completed|April 2003|February 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1830|||Both|18 Years|N/A|No|Non-Probability Sample|We included all consecutive patients with an age over eighteen and a chronic hepatitis C        of any severity. The determination of chronic hepatitis C was made using standard        diagnostic criteria: serological detection of hepatitis C antibodies and positive serum        HCV-RNA by PCR for more than 6 months. Exclusion criteria were chronic hepatitis B virus        infection and all other causes of chronic liver disease. Patients with HIV infection were        included.|November 2010|November 15, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01241227||113247|
NCT01241240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-063|Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|November 12, 2010|Yes|Yes||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01241240||113246|
NCT01241539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.121|Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis|Open Label, Non Randomized, Multiple Dose Phase I Study to Investigate the Elimination, Pharmacokinetics, Pharmacodynamics and Safety of Dabigatran Etexilate (Pradaxa) Under Steady State Conditions Before, During and After Haemodialysis in Patients With End Stage Renal Disease (ESRD) Undergoing Regular Haemodialysis||Boehringer Ingelheim||Completed|November 2010|||May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|7|||Both|21 Years|60 Years|No|||February 2014|February 24, 2014|November 15, 2010||||No|May 10, 2012|https://clinicaltrials.gov/show/NCT01241539||113223|
NCT01241552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3415A-001|A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)|MODIFY I|Merck Sharp & Dohme Corp.|Yes|Completed|October 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1453|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241552||113222|
NCT01210872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGFL-QDV|Quality-Of-Life Assessment in Patients With Head and Neck Cancer Treated With Radiation Therapy|Impact of Quality of Life Assessment in Routine Oncology Practice for Head and Neck's Cancer Patients, Treated by Radiotherapy: Impact on the Satisfaction With Care, the Health Related Quality of Life and on the Toxicity||National Cancer Institute (NCI)||Recruiting|September 2009|||September 2013|Anticipated|N/A|Observational|N/A|||Anticipated|200|||Both|18 Years|70 Years|No|||September 2010|August 6, 2013|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01210872||115564|
NCT01210885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_02|Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents|Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB Plus MenACWY Formulations||Novartis||Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|6||Actual|495|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||October 2011|October 21, 2011|September 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01210885||115563|
NCT01211197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.5|Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability|Relative Bioavailability of a 12.5 mg BI 10773 / 1000 mg Metformin Fixed Dose Combination Tablet Compared With Its Monocomponents and Administered With and Without Food (an Open-label, Randomised, Single-dose, Three-way Crossover, Phase I Trial in Healthy Volunteers)||Boehringer Ingelheim||Completed|October 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|September 28, 2010||||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01211197||115539|
NCT01211210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU01|Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer|A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer|FOWARC|Sun Yat-sen University|Yes|Active, not recruiting|June 2010|June 2020|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|495|||Both|18 Years|75 Years|No|||November 2013|May 21, 2015|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211210||115538|
NCT01210118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBAL001|Interventions of Smoking Cessation During Pregnancy|The Effectiveness of High and Low Intensity Intervention for Smoking Cessation During Pregnancy||Hellenic Anticancer Society|Yes|Completed|November 2009|February 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|92|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 7, 2013|September 23, 2010||No||No|January 23, 2013|https://clinicaltrials.gov/show/NCT01210118||115622|
NCT01210638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYM-T10-PVFS-1|Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxymorphone Hydrochloride IR 10 mg Tablets, With a Naltrexone Block, Under Fasted Conditions||Roxane Laboratories|No|Completed|June 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210638||115582|
NCT01211236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC04-130|Maggot Therapy for Wound Debridement|Maggot Therapy for Wound Debridement: a Randomized Multicentric Double-blind Trial|MAGGOT|University Hospital, Caen|Yes|Completed|February 2006|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|90 Years|No|||September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211236||115536|
NCT01209312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0931|Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes|Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes||University of Colorado, Denver|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|21|||Both|7 Years|21 Years|No|||November 2012|November 20, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209312||115684|
NCT01209325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-072|Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males|AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males||AIDS Malignancy Consortium|No|Active, not recruiting|June 2011|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|149|||Male|13 Years|26 Years|No|||December 2015|December 23, 2015|September 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01209325||115683|
NCT01216098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01551|Impact of Doula Support on Childbirth Outcomes for Women Undergoing a Vaginal Birth After Cesarean (VBAC)|Impact of Doula Support on Intrapartum Outcomes for Women Undergoing a Vaginal Birth After Cesarean (VBAC)||University of British Columbia|Yes|Completed|October 2010|February 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|82|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01216098||115163|
NCT01209663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-010|Intermediate Care - Effect on Mortality Following Emergency Abdominal Surgery|Intermediate Care - Effect on Mortality Following Emergency Abdominal Surgery|InCare|Copenhagen University Hospital at Herlev|Yes|Terminated|October 2010|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|September 24, 2010||No|30th November 2012. Please see breif summary.|No||https://clinicaltrials.gov/show/NCT01209663||115657|
NCT01239121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-146|Regional Data Exchange to Improve Medication Safety|Implementing a Regional Data Exchange Tool to Improve Medication Use and Safety||VA Office of Research and Development|No|Active, not recruiting|February 2012|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|400|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01239121||113407|
NCT01239420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK S-O A Ref 2010/1116a|Norwegian Cardio-Respiratory Arrest Study|Norwegian Cardio-Respiratory Arrest Study (NORCAST)|NORCAST|Oslo University Hospital|No|Recruiting|September 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Serum, plasma, blood (PaxGene). For future identification of biochemical markers in      prognostication after cardiorespiratory arrest. For future identification of biochemical      markers for cardiac arrest (primarily serum, but also on mRNA-level).|Both|18 Years|N/A|No|Probability Sample|Patients admitted after pre-hospital cardio/respiratory arrest.|May 2011|January 12, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239420||113386|
NCT01239446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0390-10-RMB_BRODOV|Hybrid SPECT/CTCA for the Assessment of the Presence and Hemodynamic Significance of CAD in Asymptomatic Patients.|Hybrid Single-Photon Emission Computed Tomography/Computed Tomography Coronary Angiography for the Assessment of the Presence and Hemodynamic Significance of CAD in Asymptomatic Patients After Mediastinal Irradiation for Hodgkin Lymphoma.||Rambam Health Care Campus|No|Not yet recruiting|January 2011|||January 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|65 Years|No|||November 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239446||113384|
NCT01239459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP11432|Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment|An Open-label Pharmacokinetic and Tolerability Study of Teriflunomide Given as a Single 14 mg Dose in Subjects With Severe Renal Impairment, and in Matched Subjects With Normal Renal Function||Sanofi|No|Completed|November 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|75 Years|No|||February 2012|February 28, 2012|November 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01239459||113383|
NCT01239745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5991094|Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer|A Non-Interventional Study With Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy||Pfizer|No|Terminated|April 2011|October 2011|Actual|October 2011|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|46|||Female|N/A|N/A|No|Non-Probability Sample|Estrogen receptor positive early breast cancer patients|October 2012|October 11, 2012|November 3, 2010||No|See termination reason in detailed description.|No|October 11, 2012|https://clinicaltrials.gov/show/NCT01239745||113361|The study was prematurely discontinued, therefore not all data was analyzed.
NCT01239992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-Niacin-2010|Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia|Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia||Ludwig-Maximilians - University of Munich|No|Terminated|June 2011|July 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|19 Years|70 Years|No|||March 2014|March 12, 2014|November 12, 2010||No|negative endpoint study resulting in withdrawal of study drug|No|December 2, 2013|https://clinicaltrials.gov/show/NCT01239992||113342|
NCT01240226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4931g|A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet|An Open-Label, 2-Part Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet||Genentech, Inc.||Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|November 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240226||113324|
NCT01240239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59305|Comparison of Telemedicine Evaluation to Standard Evaluation Methods for Pre-Anesthesia Consultation|Comparison of Telemedicine Evaluation to Standard Evaluation Methods for Pre-Anesthesia Consultation||Loma Linda University|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|200|||Both|18 Years|89 Years|No|Probability Sample|Subjects scheduled for ENT surgery.|January 2014|January 8, 2014|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01240239||113323|
NCT01240252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003382|Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance|Molecular Regulation of Muscle Glucose Metabolism in Man, Protocol 4||Mayo Clinic|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|14|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 3, 2013|September 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240252||113322|
NCT01240538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02617|Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors|A Phase 1 Dose Escalation Study of Reolysin, a Replication Competent Reovirus, in Pediatric Patients With Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)||Completed|December 2010|||April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|3 Years|21 Years|No|||January 2014|May 9, 2014|November 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240538||113300|
NCT01240577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110026|An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas|An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|October 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2013|October 10, 2014|November 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240577||113297|
NCT01240590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110027|A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)|A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)||National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|November 2010|December 2016|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|27|||Both|18 Years|90 Years|No|||November 2015|November 27, 2015|November 11, 2010|Yes|Yes||No|October 26, 2015|https://clinicaltrials.gov/show/NCT01240590||113296|The phase II portion was not completed because it was impossible to recruit.
NCT01240603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911017|Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia|Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia||National Institutes of Health Clinical Center (CC)||Completed|October 2010|September 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|415|||Both|1 Year|N/A|No|||September 2013|September 24, 2015|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240603||113295|
NCT01240902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCV-US-2009-01|Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement|Medtronic CoreValve® U.S. Pivotal Trial||Medtronic Cardiovascular|Yes|Active, not recruiting|November 2010|August 2020|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1453|||Both|N/A|N/A|No|||January 2016|February 8, 2016|November 10, 2010|Yes|Yes||No|March 6, 2015|https://clinicaltrials.gov/show/NCT01240902||113272|
NCT01241565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVEGTT0027|ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection|A Prospective, Multi-Center Evaluation of the ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection||Medtronic - MITG|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|October 18, 2010||No||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01241565||113221|
NCT01241851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0093-10-HYMC|Effect of Acute Exercise on Cognitive Functions|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2011|December 2011|Anticipated|July 2011|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Prevention|3||Anticipated|40|||Both|40 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 15, 2010|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241851||113199|
NCT01241864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-479-A|Islet Transplantation in Type 1 Diabetic Kidney Allograft|Islet Transplantation in Type 1 Diabetic Kidney Allograft||University of Chicago|Yes|Recruiting|December 2010|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|68 Years|No|||October 2015|October 13, 2015|November 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241864||113198|
NCT01208480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000685975|Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer|A Phase II Trial of Neoadjuvant Bevacizumab, Docetaxel and Carboplatin for Triple Negative Breast Cancer (Neat Trial)||Severance Hospital|No|Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|N/A|No|||April 2012|April 9, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01208480||115747|
NCT01208493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04.26.INF|Dietary Protein in the Very-low-birth-weight Infant|Dietary Protein in the Very-low-birth-weight Infant: Effects of the Level of Dietary Protein on Growth and Feeding Tolerance||Nestlé|Yes|Terminated|September 2007|April 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|N/A|10 Weeks|Accepts Healthy Volunteers|||December 2011|March 25, 2015|September 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01208493||115746|
NCT01209299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000683300|Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate|Integrated Molecular Signature for the Prediction of Response to Carboplatin/Paclitaxel-Based Chemotherapy in Metastatic Melanoma||National Cancer Institute (NCI)||Not yet recruiting|September 2010|||December 2011|Anticipated|N/A|Observational|N/A|||Anticipated|80|||Both|18 Years|N/A|No|||September 2010|July 1, 2011|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209299||115685|
NCT01210924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pediatric treatment 2010|Chinese Network of Pediatric Antiretroviral Therapy|Chinese Study of Pediatric Antiretroviral Therapy|CN-PART|National Center for AIDS/STD Control and Prevention, China CDC|Yes|Recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|plamsa, PMBC, whole blood|Both|N/A|15 Years|No|Non-Probability Sample|Pediatric HIV-infected patients receiving triple antiretroviral drugs|November 2013|November 20, 2013|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210924||115560|
NCT01207375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ndcnidrr2007|Improving New Learning and Memory in Traumatic Brain Injury|Improving New Learning in Traumatic Brain Injury: A Randomized Clinical Trial||Kessler Foundation|Yes|Completed|January 2008|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|59 Years|No|||April 2015|April 1, 2015|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207375||115831|
NCT01216410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012142|Prevention of Intraoperative Nausea and Vomiting During Cesarean Section|The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section||Duke University|No|Completed|December 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|306|||Female|18 Years|45 Years|No|||July 2014|August 4, 2014|October 6, 2010|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT01216410||115139|
NCT01242358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capno-PEG 2010|Capnography During Percutaneous Endoscopic Gastrostomy (PEG)|Clinical Value of Advanced Patient Monitoring Using Capnography With Analysis of the Integrated Pulmonary Index During Percutaneous Endoscopic Gastrostomy.|PEG|Ruhr University of Bochum|No|Recruiting|June 2010|March 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 20, 2011|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242358||113161|
NCT01242371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI/SPHS 2010-01|Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia|A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia||Sheppard Pratt Health System|Yes|Completed|August 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|65 Years|No|||January 2014|January 7, 2014|November 16, 2010||No||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01242371||113160|Did not perform more detailed measures of gastrointestinal functioning or obtain a more complete history of participants’ gastrointestinal symptoms and associated treatment
NCT01239472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR14T|Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant|Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant||Santa Casa de Misericórdia de Belo Horizonte|No|Recruiting|January 2011|November 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|65 Years|No|||June 2012|June 5, 2012|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239472||113382|
NCT01239485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCLSG-0901, SNUCH-RAL-0901|Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents|Phase I Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents||Seoul National University Hospital|Yes|Recruiting|November 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|21 Years|No|||November 2013|November 17, 2013|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01239485||113381|
NCT01239758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A031-06|Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy||Acceleron Pharma, Inc.|Yes|Terminated|October 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Male|4 Years|N/A|No|||January 2013|January 30, 2013|November 1, 2010|Yes|Yes|This study was terminated based on preliminary safety data.|No||https://clinicaltrials.gov/show/NCT01239758||113360|
NCT01239771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00013|A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects|A Phase I, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of TC-5214 Given as Multiple Ascending Oral Doses in Medically Stable Elderly Subjects||AstraZeneca|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2011|June 27, 2012|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01239771||113359|
NCT01240005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCCIK002|Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma|A Phase I/II Evaluation of Cytokine Induced Killer Cells Stimulated by DC(DCIK) Immunotherapy in Patients With Renal Cell Carcinoma||Qingdao University|No|Not yet recruiting|January 2011|September 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2010|November 12, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240005||113341|
NCT01240265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004130|Vitamin D Supplementation in Breastfeeding Women|Maternal Oral Vitamin D Supplementation Via Daily or Monthly Regimens and the Effect on Levels of Vitamin D in Human Milk and Infant Serum||Mayo Clinic|No|Completed|December 2010|August 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|1 Month|50 Years|Accepts Healthy Volunteers|||April 2013|April 26, 2013|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240265||113321|
NCT01240551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110021|F-18 Sodium Fluoride in Prostate Cancer|A Pilot Study of F-18 Sodium Fluoride PET/CT for Metastatic Burden Qualification in Prostate Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|October 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|November 11, 2010|No|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01240551||113299|
NCT01240564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110023|The Nephrotic Syndrome Study Network (NEPTUNE)|The Nephrotic Syndrome Study Network (NEPTUNE)||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|750|||Both|18 Years|N/A|No|||February 2014|November 11, 2014|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01240564||113298|
NCT01240863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/3079|Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time|A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time||Teva Pharmaceutical Industries||Completed|November 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|391|||Both|18 Years|80 Years|No|||May 2013|May 2, 2013|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240863||113275|
NCT01241578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOSNewInvestigator2009|Improving Behavioral Weight Loss Via Electronic Handheld Device|Improving Behavioral Weight Loss Via Electronic Handheld Device||The Miriam Hospital|No|Completed|February 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||April 2015|April 6, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01241578||113220|
NCT01241877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-068|Astaxanthin Supplementation in Cyclists|||Maastricht University Medical Center|No|Recruiting|November 2010|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2011|April 19, 2011|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241877||113197|
NCT01242176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.51|Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers|Relative Bioavailability of 25 mg BI 10773 (Final Formulation) Compared to 25 mg BI 10773 XX (Trial Formulation 2) Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|November 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|November 10, 2010||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01242176||113174|
NCT01209026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102936|Corrected QT (QTc) Study With Flucticasone Furoate and GW642444|A Randomised, Placebo-controlled, Four-way Crossover Repeat Dose Study to Evaluate the Effect of the Inhaled Fluticasone Furoate (FF)/GW642444M Combination on Electrocardiographic Parameters, With Moxifloxacin as a Positive Control, in Healthy Subjects||GlaxoSmithKline|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01209026||115706|
NCT01209858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-E044-029|A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects|A Open-label Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects||Eisai Inc.||Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01209858||115642|
NCT01209871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0465|Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma|Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma With DNA Vaccines Encoding Antigen-Chemokine Fusion||M.D. Anderson Cancer Center|No|Recruiting|February 2015|||February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|September 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209871||115641|
NCT01210105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-182-3|Ice-pick Intubation With Video Laryngoscopes in a Manikin With Restricted Access to the Airway|Comparison of Different Video Laryngoscopes in Ice-pick Position in an Manikin With Restricted Access to the Airway||University of Cologne|No|Completed|September 2010|December 2010|Actual|November 2010|Actual|N/A|Observational|Time Perspective: Prospective||6|Anticipated|25|||Both|25 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|anaesthesiologists|September 2011|September 21, 2011|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01210105||115623|
NCT01207141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0608006|rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation|Pharmacodynamics, Pharmacogenomics, and Preliminary Safety and Efficacy of rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation||University of Pittsburgh|Yes|Active, not recruiting|August 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|110|None Retained|Blood|Both|N/A|21 Years|No|Non-Probability Sample|Children 0- 21 years receiving liver transplantation|January 2016|January 13, 2016|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01207141||115849|
NCT01207895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 0993|Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer|Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|March 2010|July 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207895||115792|
NCT01208207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-108|A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)|A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis||Merck Sharp & Dohme Corp.|No|Completed|September 2010|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1015|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|September 22, 2010|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT01208207||115768|
NCT01220388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/138/HP|Effects of L-lysine on Adrenal Secretion|Pilot Study of the Action L-lysine on Aldosterone and Cortisol Secretion in Healthy Volunteers.|L-Lysine|University Hospital, Rouen|No|Completed|October 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220388||114835|
NCT01220401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU1107|Efficacy of a Brief Nightmare Treatment for Veterans|Efficacy of a Brief Nightmare Treatment for Veterans||University of Tulsa|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|October 11, 2010||No||No|March 29, 2014|https://clinicaltrials.gov/show/NCT01220401||114834|
NCT01220414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0087|Attenuation of Pain in Men and Women|Attenuation of Pain in Men and Women: Mechanisms of Exercise-Induced Analgesia||University of Wisconsin, Madison|Yes|Recruiting|September 2010|||January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|October 15, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01220414||114833|
NCT01217047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00036348|Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury|CURE-SCI. Clinical Utilization of CNS Growth Factor Release in Response to Electrical Stimulation Following Spinal Cord Injury.|CURE-SCI|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|October 2010|January 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|65 Years|No|||April 2013|April 15, 2013|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01217047||115091|
NCT01243281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biochem2010/01|Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B|A Randomized Design Study to Compare the Efficacy of Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B: Role of Host and Viral Factors Associated With Treatment Response||Chulalongkorn University|Yes|Recruiting|March 2011|December 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|126|||Both|18 Years|65 Years|No|||June 2011|June 26, 2011|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243281||113092|
NCT01238835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-06|Prevail TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (TransApical)|Prevail TA Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (TransApical)|PrevailTA|Edwards Lifesciences|Yes|Active, not recruiting|September 2009|February 2016|Anticipated|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|218|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01238835||113429|
NCT01238848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE-14-2010|Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis|A Randomized Controlled Trial to Evaluate Efficacy of Nebulized Hypertonic Saline vs. Normal Saline in the Treatment of Hospitalized Children With Bronchiolitis|Hypertonic|Hospital General de Niños Pedro de Elizalde|Yes|Completed|December 2010|May 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|1 Month|2 Years|No|||July 2012|July 16, 2012|November 9, 2010||No||No|July 16, 2012|https://clinicaltrials.gov/show/NCT01238848||113428|not obtained the estimated number of patients because many of them were left out of the study due to torpid evolution. So physitians decided to took them out of the study
NCT01238861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP220|Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma|A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma||MedImmune LLC||Completed|December 2010|August 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|965|||Both|18 Years|75 Years|No|||September 2014|September 16, 2014|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01238861||113427|
NCT01239498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8246-DF-CTIL|Saline Injection - Assisted Anesthesia in Eyelid Surgery|Saline Injection - Assisted Anesthesia in Eyelid Surgery||Sheba Medical Center|No|Recruiting|November 2010|December 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 7, 2011|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01239498||113380|
NCT01239511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCD09004A|Phase IIb Study of STA-2 in Patients With Chronic Stable Angina|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Dose-Response and Safety of STA-2 in Patients With Chronic Stable Angina||Sinphar Pharmaceutical Co., Ltd|Yes|Completed|November 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|186|||Both|20 Years|N/A|No|||August 2014|August 13, 2014|November 10, 2010|No|Yes||No|August 13, 2014|https://clinicaltrials.gov/show/NCT01239511||113379|
NCT01239173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM06075/ P060226|Emotional Memory Reactivation in Posttraumatic Stress Disorder|Reliving the Traumatic Event in Posttraumatic Stress Disorder: An Emotional Memory Reactivation Pathology? An fMRI Study|VIVITRAU|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|September 2010|February 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|5|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|July 25, 2012|October 25, 2010||No|Study stopped by promoter for lack of inclusion|No||https://clinicaltrials.gov/show/NCT01239173||113403|
NCT01239784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014278|Neurodevelopmental Rehabilitation for Toddlers With Complex Heart Defects|Neurodevelopmental Rehabilitation for Toddlers With Complex Heart Defects||The Hospital for Sick Children|No|Completed|October 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|12 Months|24 Months|No|||August 2013|August 25, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239784||113358|
NCT01240018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B257II|ProSat - Long Term Effect of Probiotics on Satiety|Probiotics and Satiety - Acute Effects and Persistence of Acute Effects|ProSat|University of Copenhagen|No|Completed|September 2009|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|June 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01240018||113340|
NCT01240278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004506|Histology of Functional Density in Postmenopausal Breast|Pilot Study to Examine Histological Characteristics of Mammographic Density With Molecular Breast Imaging: Part 1 - Postmenopausal Women||Mayo Clinic|No|Enrolling by invitation|November 2010|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|core biopsy samples of dense breast tissue|Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women with mammographically dense breasts who demonstrate either photopenic or marked        background parenchymal uptake on MBI.|May 2015|May 8, 2015|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240278||113320|
NCT01240876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C37247/1083|Study to Evaluate the Safety and Efficacy of CEP-37247 Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation|A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety and Efficacy of CEP-37247 Administered at Single Doses of 0.5, 1, 3, 6, or 12 mg by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation||Teva Pharmaceutical Industries||Completed|January 2011|April 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|70 Years|No|||May 2014|May 8, 2014|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240876||113274|
NCT01240928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 1029|MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer|A Phase Ib Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||August 2013|August 18, 2013|October 26, 2010|Yes|Yes|Funding not available, study did not open to accrual and will not open in future|No||https://clinicaltrials.gov/show/NCT01240928||113270|
NCT01240941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE1029|Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer|Phase II Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Withdrawn|February 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||August 2013|August 18, 2013|October 26, 2010|Yes|Yes|Funding was not available|No||https://clinicaltrials.gov/show/NCT01240941||113269|
NCT01240954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-I-01|Comparison of Different Up-dosing Schedules With Osiris|||ALK-Abelló A/S||Terminated|December 2010|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|November 11, 2010||No|CA approval not obtained|No||https://clinicaltrials.gov/show/NCT01240954||113268|
NCT01241253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTS0020|Glycemic Response of Bean-and-rice Meals in Type 2 Diabetes Mellitus|Glycemic Response of Bean-and-rice Meals in Persons With Type 2 Diabetes Mellitus||Arizona State University|No|Completed|November 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|35 Years|70 Years|No|||November 2010|November 12, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01241253||113245|
NCT01241266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GCN-DUM-2010/1|China Survey of Peptic Ulcer Bleeding|China Survey of Peptic Ulcer Bleeding|PUB|AstraZeneca|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1044|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized Patients|December 2011|December 29, 2011|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01241266||113244|
NCT01241591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921080|A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|Yes|Completed|November 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1101|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|November 12, 2010|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01241591||113219|Clinical interpretation regarding sub-phenotypes of psoriasis (e.g., scalp psoriasis) should not be made based on the reported assessments by body regions. For example, the body region of head does not reflect solely scalp psoriasis.
NCT01241604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-0830-ASV3-ST-SS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2009|||||N/A|N/A|N/A||||||||||||||November 12, 2010|June 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01241604||113218|
NCT01241890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-3-111|Prevention of CF Exacerbation in Childhood: PREVEC Study|Prevention of CF Exacerbation in Childhood (PREVEC): Early Recognition of Inflammation by Non-invasive Biomarkers in Exhaled Breath (Condensate)|PREVEC|Maastricht University Medical Center|No|Completed|October 2011|July 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|49|||Both|5 Years|18 Years|No|Probability Sample|Children with Cystic Fibrosis|July 2015|July 16, 2015|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241890||113196|
NCT01241903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-208-F1V|Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions|Early Use of Rosuvastatin (Crestor) in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions||University of Kentucky|Yes|Completed|June 2011|February 2014|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|80 Years|No|||May 2014|May 21, 2014|November 12, 2010|No|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01241903||113195|
NCT01209559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-156|A Comparative Study of the Air-Q ILA and the ILMA for Ventilation and Intubation|||Nova Scotia Health Authority||Suspended|January 2011|||January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Healthy ASA class I and II patients scheduled for elective surgery under general        anesthesia requiring the use of the LMA.|August 2015|August 12, 2015|September 23, 2010||No|Study never initiated.|No||https://clinicaltrials.gov/show/NCT01209559||115665|
NCT01209845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909005766|Ketamine for Low Mood States in the ER|Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients||Yale University|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|August 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01209845||115643|
NCT01210378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nitroglycerin in NSCLC|Nitroglycerin in Non-small Cell Lung Cancer|Nitroglycerin as a Sensitizer in the Treatment of Non Small Cell Lung Cancer: a Phase II Trial|Nitroglycerin|Maastricht Radiation Oncology|No|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01210378||115602|
NCT01220024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN-CB-010|Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy|A Phase II, Randomized, Single Dose, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety Profile of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Open Laparotomy Herniorrhaphy||Innocoll|No|Completed|December 2010|October 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|N/A|No|||April 2013|September 2, 2014|September 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01220024||114863|
NCT01220037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-080|Resistance Exercise in Healthy Men|The Effect of Age and Dietary Protein Intake on Myocellular Characteristics Following a Single Bout of Resistance Exercise in Healthy Men||Maastricht University Medical Center|No|Completed|April 2010|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|34|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||October 2013|October 25, 2013|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01220037||114862|
NCT01220427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mi-RNA HR-Pca|Micro-RNA Expression Profiles in High Risk Prostate Cancer|Micro-RNA Expression Profiles in High Risk Prostate Cancer||Wuerzburg University Hospital|No|Terminated|June 2007|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|300|||Male|35 Years|80 Years|No|Probability Sample|University hospital, community hospital|August 2010|March 2, 2016|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01220427||114832|
NCT01216423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-FOP|Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale|Is There a Link Between Venous Thromboembolism and Stroke in Patient With Patent Foramen Ovale ? Research for Stroke in Hospitalized Patients With Pulmonary Embolism.|EPIC-FOP|University Hospital, Brest|Yes|Terminated|November 2009|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|313|||Both|18 Years|N/A|No|Probability Sample|Consecutive series of hospitalized patients with pulmonary embolism|March 2016|March 22, 2016|September 29, 2010||No|The study stooped because the answer to the primary objective is possible.|No||https://clinicaltrials.gov/show/NCT01216423||115138|
NCT01216111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan TNBC Adjuvant CT|Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer|A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients||Fudan University||Available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|65 Years||||June 2010|October 6, 2010|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216111||115162|
NCT01217333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCRP 12BB-3900|Telephone-Based Decision Support for Rural Patients|Telephone-Based Decision Support for Rural Patients||University of California, San Francisco|No|Completed|October 2007|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|74|||Female|18 Years|N/A|No|||October 2012|October 16, 2012|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01217333||115069|
NCT01208285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX10-770-013|Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects|A Phase 1 Non-Randomized, Open-Label Study to Assess the Safety and Pharmacokinetics of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 11, 2011|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01208285||115762|
NCT01238887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress|Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress||University of Florida|Yes|Terminated|July 2011|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|17|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|August 6, 2010||No|Some capsules used in this study were been found to be cracked and leaking.|No||https://clinicaltrials.gov/show/NCT01238887||113425|
NCT01239186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 08027|Identification and Characterization of the Methylation Abnormalities on Whole Genome Among Infertile Men|Identification and Characterization of the Methylation Abnormalities on Whole Genome Among Infertile Men|METHYLHOMME|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2009|December 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|Samples With DNA|Sample of sperm collected by automasturbation|Male|18 Years|45 Years|No|Probability Sample|Men from 18 to 45 years old, presenting an idiopathic oligozoospermia lower than 10        million sperm cells / ml and include in a program of medically assisted conception|August 2013|August 6, 2013|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01239186||113402|
NCT01239524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06075|The Significance of Latissimus Dorsi Flap Innervation in Delayed Breast Reconstruction|The Significance of Latissimus Dorsi Flap Innervation in Delayed Breast Reconstruction||Tampere University Hospital|Yes|Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Female|20 Years|70 Years||||November 2010|November 10, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239524||113378|
NCT01239797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-004|Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma|Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)|ELOQUENT - 2|Bristol-Myers Squibb|Yes|Active, not recruiting|March 2011|March 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|N/A|No|||December 2015|March 11, 2016|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239797||113357|
NCT01240031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMS-2010-29293/19069|Effect of Energy- and Protein-rich Foods on Physiological Functions and Quality of Life in Undernourished Patients|Framework for Developing Appetising, Energy- and Protein-rich Foods for Patients at Nutritional Risk: Effect on Physiological Functions and Quality of Life||University of Copenhagen||Recruiting|April 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2010|November 12, 2010|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240031||113339|
NCT01240291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/10/QRBW/131|The Clinical Role of Intravenous Glutamine in Trauma Patients Receiving Enteral Nutrition|Effect of Intravenous GLutamine Supplementation IN Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomized, Placebo-controlled Clinical Trial|GLINT|Royal Brisbane and Women's Hospital|No|Recruiting|March 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|85 Years|No|||May 2012|May 22, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01240291||113319|
NCT01240967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00008|To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function|An Open-Label, Multi-Center, Phase I Study To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 (S-Mecamylamine) in Subjects With Renal Impairment With Subjects With Normal Renal Function||AstraZeneca|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label|1||Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|November 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240967||113267|
NCT01240980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB125-001|Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)|A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus||Bristol-Myers Squibb|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|104|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|March 14, 2012|November 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240980||113266|
NCT01240993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DA017294|Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers|Fostering Mothers' Emotionally-Responsive Parenting||Yale University|Yes|Recruiting|July 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|21 Years|45 Years|No|||January 2014|January 23, 2014|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01240993||113265|
NCT01241279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|657|Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses|A Two Arm Prospective, Randomized, Double-Masked Clinical Evaluation of Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses||Bausch & Lomb Incorporated|No|Terminated|October 2010|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|40 Years|N/A|No|||November 2014|November 25, 2014|November 12, 2010|Yes|Yes|Terminated due to low enrollment|No|May 17, 2013|https://clinicaltrials.gov/show/NCT01241279||113243|Study terminated early due to lack of enrollment
NCT01241292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-005|Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone|Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan||Bristol-Myers Squibb|No|Active, not recruiting|January 2011|August 2016|Anticipated|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|20 Years|N/A|No|||January 2016|January 22, 2016|November 4, 2010|No|Yes||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01241292||113242|
NCT01241617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Juntendo-530|ENDO GIA Stapler With Duet Tissue Reinforcement System (TRS) Used in Pulmonary Resections|Randomized Trial Between Buttressed and Non Buttressed Stapling in Pulmonary Lobectomy||Medtronic - MITG|No|Terminated|August 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|79 Years|No|||January 2012|January 22, 2012|July 30, 2010||No|Covidien is conducting a voluntary recall of DuetTRS™ use in the thoracic cavity. IFU is    revised to contraindicate use in adult and pediatric thoracic surgeries|No||https://clinicaltrials.gov/show/NCT01241617||113217|
NCT01241916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003P001441|A Prospective Randomized Trial of Static-Progressive Versus Dynamic Splinting for Post-Traumatic Elbow Stiffness|A Prospective Randomized Trial of Static-Progressive Versus Dynamic Splinting for Post-Traumatic Elbow Stiffness||Massachusetts General Hospital|Yes|Completed|August 2003|September 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|November 15, 2010||No||No|April 16, 2012|https://clinicaltrials.gov/show/NCT01241916||113194|Evaluation of <80% of enrolled patients at planned follow-up times; musculoskeletal injury patients are difficult to maintain in protocol. Some violations where enrollment/evaluation points were slightly outside the planned range of acceptable times.
NCT01219517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-00-18|Validation of the Accuracy of DNA Fingerprinting Using Polar Bodies and Embryonic Cells|Validation of the Accuracy of DNA Fingerprinting Using Polar Bodies and Embryonic Cells||Reproductive Medicine Associates of New Jersey|No|Completed|January 2008|December 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Female|21 Years|43 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219517||114901|
NCT01219803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100727|Trial of Different Dosages' Ge Gen Qin Lian Decoction in the Treatment of Type 2 Diabetes|Dosage-efficacy Relationship Clinical Trial of Ge Gen Qin Lian Decoction||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|August 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|240|||Both|30 Years|65 Years|No|||May 2012|May 5, 2012|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219803||114880|
NCT01219816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/05-O|Multi-centric Study|Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study.|CHEPRALL|Nantes University Hospital|Yes|Recruiting|November 2010|May 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219816||114879|
NCT01216436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019239|Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma|Phase 1 Study of Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects With Metastatic Melanoma||Duke University|No|Terminated|January 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|2|||Both|18 Years|N/A|No|||April 2014|May 22, 2015|February 1, 2010|No|Yes|The PI retired|No||https://clinicaltrials.gov/show/NCT01216436||115137|
NCT01216449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-39|Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults|Pharmacodynamics of Intravenous Citalopram in the Elderly: a Functional Magnetic Resonance Imaging Analysis||Rotman Research Institute at Baycrest|Yes|Active, not recruiting|April 2009|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Male|20 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 26, 2015|October 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01216449||115136|
NCT01216735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070896|Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers|Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers||University of Miami|No|Completed|September 2008|September 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|32|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|October 6, 2010|Yes|Yes||No|September 5, 2014|https://clinicaltrials.gov/show/NCT01216735||115114|
NCT01207479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0196-09-A725|A Multi-Center Feasibility Study to Assess the Safety and Performance of The VitalaTM Continence Control Device With Natura Moldable Skin Barriers|A Multi-Center, Open-Label, Feasibility Study to Assess the Safety and Performance of the VitalaTM Continence Control Device When Worn With SUR FIT Natura® Moldable TechnologyTM Skin Barrier Products Over a 12 Hour Period||ConvaTec Inc.|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|28|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01207479||115823|
NCT01238627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1064-A6431115|Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg|Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg - A Study in Healthy Smokers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|50 Years|No|||July 2012|July 6, 2012|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238627||113445|
NCT01239134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRX518-001|Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors|A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies|TRX518-001|GITR, Inc.|No|Recruiting|October 2010|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239134||113406|
NCT01239147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.02.CPW / OP71709.UPC.CPW|Effects of Whole Grain on Weight Maintenance|Effect of Whole Grain Inclusion in the Diet on Abdominal Fat Regain After a Weight Loss Diet||Cereal Partners Worldwide|Yes|Completed|October 2010|April 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|186|||Female|20 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 26, 2013|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01239147||113405|
NCT01239810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBOSTZKM1|Intra-articular Hyaluronic Acid in Mild to Moderate Knee Osteoarthritis|Effect of Intra-articular Hyaluronic Acid on Articular Cartilage Morphology and Composition in Mild to Moderate Knee Osteoarthritis|Ostenil|Technische Universität München|No|Completed|June 2005|December 2008|Actual|November 2006|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|34|||Both|18 Years|95 Years|No|Probability Sample|referred from visiting orthopaedic surgeons to our academic outpatient clinic|December 2010|December 8, 2010|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239810||113356|
NCT01239823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2009120009|Platform Exercise Training|Platform Exercise Training for Women at Risk for Knee Osteoarthritis||University of Iowa|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01239823||113355|
NCT01240044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTNB 2010|Respiratory Therapy and Newborn Pain: Comparison Between Techniques|Study of Respiratory Therapy and Newborn Pain That Made a Comparison Between Physiotherapeutical Techniques||University of the State of Santa Catarina|Yes|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|N/A|28 Days|Accepts Healthy Volunteers|||October 2010|June 18, 2013|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01240044||113338|
NCT01240304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112748|A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas|A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemotherapy With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas||University of Arkansas|No|Recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|November 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240304||113318|
NCT01240616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911461|Nicotinic Modulation of the Default Network of Resting Brain Function|Nicotinic Modulation of the Default Network of Resting Brain Function||National Institutes of Health Clinical Center (CC)||Completed|October 2010|December 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|43|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 25, 2014|November 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240616||113294|
NCT01240629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-09-9|Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer||University of Southern California|Yes|Suspended|November 2010|November 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Male|18 Years|N/A|No|||May 2015|May 21, 2015|June 30, 2010|Yes|Yes|Drug shortage|No||https://clinicaltrials.gov/show/NCT01240629||113293|
NCT01240915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3041001|A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis|A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis||Pfizer|Yes|Completed|February 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 10, 2010|Yes|Yes||No|November 20, 2015|https://clinicaltrials.gov/show/NCT01240915||113271|
NCT01241318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZamCAT|Zambia Chlorhexidine Application Trial|Impact of Chlorhexidine Cord Cleansing for Prevention of Neonatal Mortality in Zambia|ZamCAT|Boston University|Yes|Completed|February 2011|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|77535|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 28, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01241318||113240|
NCT01241305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5510|One-Time DNA Study for Vasculitis|VCRC Genetic Repository One-Time DNA Protocol||University of Pennsylvania|Yes|Recruiting|October 2010|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|Samples With DNA|Two 10 ml tubes of blood will be collected for DNA extraction.|Both|7 Years|N/A|No|Non-Probability Sample|Individuals with giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa,        granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and eosinophilic        granulomatosis with polyangiitis (Churg-Strauss). Enrollment will be sequential and        patients will have disease in various stages and of different duration.|September 2015|September 4, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01241305||113241|
NCT01241630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090113 - 2|Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Clinical Outcome|Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Clinical Outcome||University of Aarhus|Yes|Completed|November 2009|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2012|May 9, 2014|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01241630||113216|
NCT01241929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000826|Using Videos in Advance Care Planning for Patients With Advanced Cancer|A Pilot Study of Using Video Images in Advance Care Planning in Patients With Advanced Cancer||Massachusetts General Hospital|No|Completed|April 2009|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|21 Years|N/A|No|||July 2012|July 9, 2012|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241929||113193|
NCT01242839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT08L06UC|Randomized Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing|Randomized Multicentric Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing|UNICOL|Organ, Tissue, Regeneration, Repair and Replacement|No|Recruiting|April 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|128|||Both|18 Years|75 Years|No|||April 2014|April 8, 2014|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01242839||113125|
NCT01242852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|inSIGHT|SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle|SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle|inSIGHT|UMC Utrecht|Yes|Completed|May 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|750|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01242852||113124|
NCT01218997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-006|ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)|A Randomized, Open Label, Long-Term, Multi-Center Study of the Safety of Medisorb® Naltrexone||Alkermes, Inc.|No|Completed|August 2003|March 2005|Actual|March 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|436|||Both|18 Years|N/A|No|||December 2010|December 27, 2010|October 8, 2010|Yes|Yes||No|November 8, 2010|https://clinicaltrials.gov/show/NCT01218997||114941|
NCT01219270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyponatremia-GUGH|Radiocontrast Media Induced Hyponatremia|Radiocontrast Media Induced Hyponatremia After Percutaneous Coronary Intervention: Observational Study||Gachon University Gil Medical Center|No|Recruiting|October 2010|June 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who receive contrast media during percutaneous coronary intervention|October 2010|October 13, 2010|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01219270||114920|
NCT01219530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2010-01|Follow Up of Gestational Carriers and Intended Parents|Follow Up of Gestational Carriers and Intended Parents||Reproductive Medicine Associates of New Jersey|No|Withdrawn|April 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|0|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients participating in the gestational carrier program, either as a gestation carrier        or an intended parent.|January 2013|January 22, 2013|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01219530||114900|
NCT01219543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1060C00004|A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.|A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 in Asian Patients With Advanced Solid Malignancies and Asian Patients With Child-Pugh A to B7 Advanced Hepatocellular Carcinoma (HCC) in the Escalation Phase, Estimated Glomerular Filtration Rate(EGFR) or ROS Mutant NSCLC and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour With Biopsy Available in the Expansion Phase.||AstraZeneca||Terminated|November 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|October 11, 2010|No|Yes|Compound development discontinued|No||https://clinicaltrials.gov/show/NCT01219543||114899|
NCT01216124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan TNBC Neo CT|Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients|A Prospective, Open and Unicentric Phase II Clinical Trial of Docetaxel Combined With Oxaliplatin for Triple Negative Local Advanced Breast Cancer Patients (TNLABC)||Fudan University||Available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|65 Years||||September 2009|October 6, 2010|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01216124||115161|
NCT01216137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1108|Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control Trial|The Effects of Vestibular Rehabilitation on MS-related Fatigue and Upright Postural Control: a Randomized Controlled Trial||University of Colorado, Denver|No|Completed|January 2007|October 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|65 Years|No|||January 2013|January 25, 2013|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01216137||115160|
NCT01216748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070583|Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway|Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway||University of Miami|No|Completed|January 2010|August 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|December 15, 2014|October 6, 2010|Yes|Yes||No|September 2, 2014|https://clinicaltrials.gov/show/NCT01216748||115113|
NCT01217060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0333|Trimodality Management of T1b Esophageal Cancers|Phase IIB Study of Trimodality Management of Clinical T1bN0M0 Cancers of the Esophagus||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2010|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01217060||115090|
NCT01207232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810589-1|The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates|The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates||University of Pennsylvania|No|Completed|October 2009|April 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|3272|||Both|18 Years|N/A|No|||September 2010|September 21, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01207232||115842|
NCT01207492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-179|Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor|A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2010|April 2018|Anticipated|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 21, 2010|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT01207492||115822|
NCT01239199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 070802|Is the Exhaled Nitric Oxide in Infants a Predictive Marker of Asthma ?|Is the Exhaled Nitric Oxide in Infants a Predictive Marker of Asthma?|NOnourisson|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|86|||Both|6 Months|36 Months|No|||February 2014|February 26, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01239199||113401|
NCT01239160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flexitouch 1010|Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphedema|At Home Evaluation of Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphoedema(ACE: At Home Compression Evaluation)|ACE|Centre for Research & Implementation of Clinical Practice|Yes|Recruiting|November 2010|July 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|262|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01239160||113404|
NCT01239836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-200909-CUK-202417|Effectiveness of Continence Promotion Interventions Among Community-dwelling Older Women|Self-management, Constructivism or Both as Knowledge Transfer Strategies for Reducing the Cost and Impact of Urinary Incontinence Among Community-dwelling Senior Women in the United Kingdom||Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|No|Completed|September 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|259|||Female|60 Years|N/A|No|||May 2013|May 14, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01239836||113354|
NCT01240057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 6277|Tracheal Occlusion To Accelerate Lung Growth (TOTAL) Trial for Severe Pulmonary Hypoplasia|Randomized Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) Versus Expectant Management During Pregnancy in Fetuses With Left Sided and Isolated Congenital Diaphragma Hernia and Severe Pulmonary Hypoplasia.|TOTAL|University Hospital, Gasthuisberg|Yes|Recruiting|December 2010|October 2017|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|148|||Female|18 Years|50 Years|No|||August 2011|August 4, 2011|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01240057||113337|
NCT01240317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02621|eVent in the Human Patient Simulator|eVENT: An Expert System for Detecting Critical Events During Anesthesia (Human Patient Simulator Study)||University of British Columbia|Yes|Completed|December 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|anesthesiologists, anesthesia residents and fellows|November 2011|November 24, 2011|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01240317||113317|
NCT01240642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2112|An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404|A Multi-center, Open-label, Dose-escalation Study in Patients With Advanced Cacner to Determine the Effect of the ASA404 Infusion Rate and Co-administration With the Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokinetics of Free and Total ASA404||Novartis||Terminated|January 2010|||December 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01240642||113292|
NCT01240655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCL161A2104|A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors|A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors||Novartis|No|Completed|April 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|100 Years|No|||January 2016|January 5, 2016|November 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01240655||113291|
NCT01241942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-001 Vitrolife|Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability|Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|December 2010|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|November 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241942||113192|
NCT01241955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001820/1|Temporal Intervention Trial of a CPR Video in the ICU|A Temporal Intervention Trial of a CPR Video in the ICU||Massachusetts General Hospital|No|Recruiting|February 2011|||February 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 4, 2011|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01241955||113191|
NCT01241643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-107-14|Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders|A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in HIV-infected Patients With CD4 Counts Remaining Between 101-350 Cells/µL After at Least 2 Years of HAART and Plasma HIV RNA < 50 Copies/mL for 18 Months.|Inspire 3|Cytheris SA|Yes|Terminated|September 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|November 15, 2010||No|Terminated [CYTHERISSA filed for banckcuptcy in June 2013.Subjects treated by CYT107 were    followed up for at the least 3 months.]|No||https://clinicaltrials.gov/show/NCT01241643||113215|
NCT01241669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5555-A001-023|Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity|A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Multiple Doses of E5555 on the Pharmacokinetics of Metformin (a Substrate for OCT2 Transporter) and on Renal Function in Healthy Subjects||Eisai Inc.||Completed|October 2010|||August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01241669||113213|
NCT01242267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-00001215|Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT|A Phase I/II Study of Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Advanced Multiple Myeloma|Thal/Mel/Vel|Hackensack University Medical Center|Yes|Active, not recruiting|April 2010|November 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|75 Years|No|||August 2015|October 16, 2015|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01242267||113168|
NCT01220050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPLE|Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism|A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH SECONDARY HYPERPARATHYROIDISM|APPLE|Mario Negri Institute for Pharmacological Research|No|Completed|September 2009|February 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||February 2013|February 21, 2013|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01220050||114861|
NCT01220440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3208|Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD|Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD||Ostfold Hospital Trust||Completed|January 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|36|||Both|9 Years|14 Years|No|||October 2010|October 13, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01220440||114831|
NCT01216150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICARE Study|Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding in Coronary Surgical Patients|Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding and Platelets Functions in Coronary Surgical Patients Treated Prophylactically With Tranexamic Acid: the ICARE Study.|ICARE|Groupe Hospitalier Pitie-Salpetriere|No|Completed|December 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|During the planned 11 months of investigation, all patients undergoing isolated first-time        coronary artery by-pass grafting will be enrolled. Patients admitted for emergency        procedure, following failed percutaneous transluminal coronary angioplasty and off-pump        coronary surgery, will be excluded. Because antithrombotic therapy management may differ        during the postoperative period, we will exclude patients in whom a mechanical support or        intra-aortic balloon pump will be required for a difficult weaning from cardiopulmonary        bypass. Finally, we will exclude all patients who will not have received any oral        antiplatelet agents within 5 days prior surgery, those who will have been preoperatively        exposed to platelet glycoprotein IIb/IIIa inhibitors, and those with history of        haematological disease. Patients treated with aspirin and clopidogrel and in whom        clopidogrel will be stopped more than 5 days before surgery will also be excluded.|October 2010|June 22, 2011|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01216150||115159|
NCT01211314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU1952|Antihypertensive Efficacy of Fixed Combination Drug|Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements||Meir Medical Center|Yes|Suspended|January 2011|April 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||August 2011|August 27, 2011|September 28, 2010|Yes|Yes|sponsor decision|No||https://clinicaltrials.gov/show/NCT01211314||115530|
NCT01211327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZ Ghent 003|Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda|Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial||University Hospital, Ghent|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|366|||Both|5 Years|N/A|No|||September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211327||115529|
NCT01211054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCPD old PFT|Epidemiologic Analysis for the Prevalence of Chronic Airway Diseases in Old Population|Epidemiologic Analysis for the Prevalence of Chronic Airway Diseases in Old Population in Korea||Chonbuk National University||Active, not recruiting|July 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|For old people aged 60 yrs or more, the investigators will analyze their respiratory        symptoms, spirometric data, smoking history, and atopic history in Korea.|September 2010|September 28, 2010|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01211054||115550|
NCT01207219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YEP_2010|Yoga and Aerobic Exercise in Psychosis|The Impacts of Yoga and Aerobic Exercise on Neuro-cognitive Function and Symptoms in Early Psychosis - A Single-blind Randomized Controlled Clinical Trial|YEP|The University of Hong Kong|Yes|Completed|November 2010|October 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|140|||Female|18 Years|55 Years|No|||December 2014|December 8, 2014|September 16, 2010||No||No|June 17, 2014|https://clinicaltrials.gov/show/NCT01207219||115843|Lack of a healthy control group; a measurement bias may exist in the HKLLT because the same word list was used for baseline and 12 weeks.
NCT01207726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02901|Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery|Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-Azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care||National Cancer Institute (NCI)||Terminated|September 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||July 2013|April 30, 2015|September 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207726||115804|
NCT01207739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLEASE|Persistent Lyme Empiric Antibiotic Study Europe|Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease|PLEASE|Radboud University|Yes|Active, not recruiting|September 2010|June 2014|Anticipated|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|280|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01207739||115803|
NCT01239225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc2010137-09ctil|Prevalence of Abdominal Aortic Aneurysm in Patients Undergoing Coronary Angiography|||Meir Medical Center|No|Completed|September 2009|||March 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A||||October 2010|November 10, 2010|November 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01239225||113399|
NCT01239550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KDN2010|Insulin Detemir in Obesity Management|Making an "Obese"Brain(and Body)Lean: Insulin Detemir,Monoamines,and Reward|IDIOM|Vanderbilt University|Yes|Active, not recruiting|April 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|240|||Both|31 Years|60 Years|No|||June 2015|June 23, 2015|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01239550||113376|
NCT01238900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benign Biliary Strictures|Evaluation of the Use of Metal Stents as Part of the Treatment of Benign Biliary Strictures|Prospective Evaluation of the Clinical Utility of Placement of Metal Stent for Benign Biliary Strictures||University of Florida|No|Completed|May 2009|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a medical indication for endoscopic therapy of benign biliary stictures        and are referred for the procedure as part of their standard medical care will be        considered for the study.|August 2015|August 31, 2015|November 5, 2010||No||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01238900||113424|Fifty-six percent of our patients had prior therapy for their benign biliary stricture; therefore they were not treatment naive. High prevalence of CP-related strictures which are known to be more difficult to treat.
NCT01238913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benign esophageal lesions|Use of Metal Stents on Benign Esophageal Lesions|Prospective Evaluation of the Clinical Utility of the Endoscopic Placement of Mental Stent for Benign Esophageal Lesions||University of Florida|No|Withdrawn|September 2015|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a medical indication for endoscopic placement of esophageal metal stent        and are referred for the porcedure as part of their standard medical care will be        considered for the study.|September 2015|September 29, 2015|November 5, 2010||No|No one met the inclusion/exclusion criteria|No||https://clinicaltrials.gov/show/NCT01238913||113423|
NCT01253915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C113|The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine||Capnia, Inc.|No|Terminated|January 2012|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||October 2013|October 30, 2013|December 2, 2010|No|Yes|Low enrollment and lack of funding for study|No||https://clinicaltrials.gov/show/NCT01253915||112281|
NCT01254136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 7839-204|Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer|A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.||Incyte Corporation|No|Terminated|October 2010|October 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||January 2012|January 20, 2012|December 1, 2010|Yes|Yes|Incyte has suspended development of the compound.|No||https://clinicaltrials.gov/show/NCT01254136||112264|
NCT01251744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113134|Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus|Study of Maternal-foetal Cytomegalovirus (CMV) Transmission||GlaxoSmithKline||Completed|December 2010|June 2015|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|159|||Female|18 Years|N/A|No|||July 2015|September 24, 2015|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251744||112448|
NCT01252030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telemonitoring 2|Telemonitoring During Phase 2-3 Cardiac Rehabilitation|Impact of Telemonitoring Intervention on Physical Activity, CVD Risk Factors, During Phase 2-3 Cardiac Rehabilitation|TeleRehabII|Jessa Hospital|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|80|||Both|40 Years|80 Years|No|||April 2015|April 6, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252030||112426|
NCT01252043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010044R|Retrospective Review of CT and MR in Pediatric Patients With Cholestasis|Retrospective Review of Computed Tomography and Magnetic Resonance Images in Pediatric Patients With Cholestasis||National Taiwan University Hospital|Yes|Recruiting|October 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|80|||Both|N/A|18 Years|No|Non-Probability Sample|younger than 18 years of age|November 2010|November 30, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01252043||112425|
NCT01251458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC022|Hepatocellular Carcinoma (HCC)_Torisel_|Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression||Chinese University of Hong Kong|No|Completed|October 2009|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251458||112470|
NCT01251731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-A001-006|Single and Multiple Dose Asian Bridging Study|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Single-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of 10, 40, and 80 mg E5501 Followed by a Selected Dose for Multiple Dosing Administered to Healthy Japanese, Chinese, and Caucasian Subjects||Eisai Inc.||Completed|July 2010|||January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|November 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01251731||112449|
NCT01252004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFSETT|French Observatory Syndromes Tako-Tsubo|French Observatory Syndromes Tako-Tsubo|OFSETT|French Cardiology Society|No|Completed|November 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|121|||Both|18 Years|N/A|No|Non-Probability Sample|Patients newly diagnosed for a Tako-Tsubo Syndrome. Recruitment will be from the centers        of coronary angiography and coronary angioplasty in high volume.|September 2013|September 27, 2013|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252004||112428|
NCT01252017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006057M|Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation|Cytomegalovirus (CMV) Reactivation in Post-allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) Patients: Salvage and Prophylactic Treatments of Nilotinib||National Taiwan University Hospital|No|Recruiting|November 2010|June 2014|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|36|||Both|18 Years|N/A|No|||November 2012|December 26, 2012|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01252017||112427|
NCT01248364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.39|A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects|An Open-label, Phase II Study to Determine Acute (After the First Dose Administration) and Chronic (After 28 Days of Treatment) Effects of the Sodium-glucose Co-transporter-2 (SGLT-2) Inhibitor Empagliflozin (BI 10773) (25 mg Once Daily) on Pre and Postprandial Glucose Homeostasis in Patients With IGT and, Type 2 Diabetes Mellitus and Healthy Subjects||Boehringer Ingelheim||Completed|November 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 29, 2014|November 24, 2010||||No|August 29, 2014|https://clinicaltrials.gov/show/NCT01248364||112704|
NCT01248390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14853.22|"Interactive Metronome Technology for Blast-Related Traumatic Brain Injury"|"A Randomized, Controlled, Trial of Interactive Metronome Technology for Remediation of Cognitive Difficulties Following Blast-Related Traumatic Brain Injury"||The Defense and Veterans Brain Injury Center|No|Active, not recruiting|August 2010|December 2015|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01248390||112702|
NCT01248988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114469|Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea|Safety of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal-protein D-diphtheria Toxoid-tetanus Toxoid Conjugate (10PN-PD-DiT) Vaccine, Synflorix When Administered According to the Approved Prescribing Information in Korea||GlaxoSmithKline||Completed|December 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|622|||Both|6 Weeks|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infants and children who receive at least one dose of Synflorix as a part of routine        practice at a private clinic or hospital.|October 2015|January 14, 2016|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248988||112657|
NCT01257542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6531001|Acute Cough Study In Children|A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose, Pilot Study To Evaluate Efficacy Of Dextromethorphan Hydrobromide On Acute Cough In A Pediatric Population||Pfizer|No|Terminated|December 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|6 Years|11 Years|No|||August 2012|August 21, 2012|December 7, 2010|Yes|Yes|See termination reason in detailed description.|No|August 21, 2012|https://clinicaltrials.gov/show/NCT01257542||112002|Due to methodological issues during study conduct, the study was terminated after only less than 50% of the targeted enrollment was achieved.
NCT01257555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-116-CF-I|Evaluation of a Photopneumatic System for the Treatment of Acne|||Valeant Pharmaceuticals|Yes|Completed|December 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|All genders and ethnic backgrounds. No subjects from vulnerable categories (i.e. minors,        pregnant women, etc).|March 2012|March 22, 2012|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257555||112001|
NCT01258101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML17087|A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3|Randomized, Multicenter Study to Compare Pegylated Interferon Alfa (PEG-IFN) in Combination With Two Different Doses of Ribavirin in Patients With Chronic Hepatitis C and Subtype 2/3||Hoffmann-La Roche||Completed|May 2003|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|393|||Both|18 Years|65 Years|No|||October 2015|October 1, 2015|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258101||111959|
NCT01258348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10407|A Phase 1b Trial in Patients With Renal Cell Cancer|A Phase 1b Study of LY573636-sodium in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Cancer||Eli Lilly and Company|No|Completed|July 2008|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2012|April 13, 2012|December 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258348||111940|
NCT01258660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91509|Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate|A Randomized, Double-blind, Double-dummy, 2-parallel Arms Clinical Trial to Assess the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and to Compare the Profile of Circulating Folate Metabolites During 24 Weeks of Treatment With an Oral Contraceptive Containing Ethinylestradiol, Drospirenone and L-5-methyltetrahydrofolate (SH T04532A and SH T04532C) or Yasmin (SH T04532D and SH T04532PC) Co-administered With Folic Acid (SH K04532B) Followed by 20 Weeks of Open-label Treatment With Yasmin Only (Folate Elimination Phase) in Women Seeking Contraception||Bayer|No|Completed|December 2006|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 15, 2013|December 10, 2010||No||No|April 19, 2011|https://clinicaltrials.gov/show/NCT01258660||111916|
NCT01258959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retro-Parabulbar|Anaesthesia for Ophthalmic Surgery: How "Retro" is the Peribulbar Block?|Anaesthesia for Ophthalmic Surgery: How "Retro" is the Peribulbar Block?||Sunnybrook Health Sciences Centre|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|100 consecutive patients (men and women) of at least 18 years of age undergoing an        ophthalmic procedure on the posterior section of the eye under local anaesthesia, i.e.        with a peribulbar block.|December 2010|June 8, 2011|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01258959||111893|
NCT01258608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200149|Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma|A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma||GlaxoSmithKline|Yes|Active, not recruiting|February 2011|March 2016|Anticipated|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258608||111920|
NCT01258621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANCREAS-LDP2010|Learning Curve for Laparoscopic Distal Pancreatectomy|Learning Curve for Laparoscopic Distal Pancreatectomy in a High-volume Hospital||Università Vita-Salute San Raffaele|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||August 2010|December 10, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258621||111919|
NCT01258634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-186-B|A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response|A Pilot Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response||University of Chicago|No|Terminated|July 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|2 Years|35 Years|No|||December 2013|December 9, 2013|September 30, 2010|No|Yes|PI no longer affiliated with institution; only 2 subjects enrolled|No||https://clinicaltrials.gov/show/NCT01258634||111918|
NCT01250392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0001|The Effect of Active Choice on Nurse Visit Participation|The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening and Nurse Visit Participation||National Bureau of Economic Research, Inc.|Yes|Completed|December 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|3500|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250392||112550|
NCT01250405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA2009-0008|Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients|Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients|ECIRA|Laval University|No|Completed|May 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|23|||Both|18 Years|80 Years|No|||April 2014|April 4, 2014|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01250405||112549|
NCT01250379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22998|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)|A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment||Hoffmann-La Roche||Completed|February 2011|March 2015|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|494|||Female|18 Years|N/A|No|||January 2016|January 12, 2016|November 25, 2010|No|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01250379||112551|
NCT01250093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nantou|Acupuncture Compared With "Sham" Acupuncture for Treatment of Chronic Neck Myofascial Pain|||China Medical University Hospital||Completed|March 2008|January 2009|Actual|December 2008|Actual|N/A|Interventional|N/A|||||||Both|18 Years|85 Years|No|||October 2008|November 29, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01250093||112573|
NCT01250366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-002|Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects|A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects||Bristol-Myers Squibb|Yes|Completed|October 2010|June 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|70|||Both|18 Years|65 Years|No|||July 2012|July 11, 2012|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01250366||112552|
NCT01250626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-139|Establish the Caring Model of Children With Chronic Kidney Disease and End-stage Renal Disease: To Set up Childhood Glomerular Filtration Rate (GFR) Formula in Taiwan|||China Medical University Hospital||Active, not recruiting|August 2010|||||Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric OPD, age < 18 y/o.|August 2010|November 30, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250626||112533|
NCT01250639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-164|Type 2 Diabetes Mellitus Collaborative Genetic Study on Non-aboriginal Taiwanese|Type 2 Diabetes Mellitus Collaborative Genetic Study Room|T2D2|China Medical University Hospital|Yes|Recruiting|August 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|serum,urine|Both|20 Years|N/A|No|Probability Sample|Type 2 Diabetes Mellitus|November 2010|November 30, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250639||112532|
NCT01251159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000688223|Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia|Somatic Mutations in Stem and Progenitor Cells in AML||National Cancer Institute (NCI)||Not yet recruiting|September 2010|||October 2010|Anticipated|N/A|Observational|N/A|||Anticipated|30|||Both|16 Years|60 Years|No|||November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251159||112492|
NCT01251757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS019341-01|Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies|Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)|PATIENT|Kaiser Permanente|Yes|Completed|August 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|19845|||Both|40 Years|80 Years|No|||April 2012|August 7, 2014|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251757||112447|
NCT01247857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 02-2008|Local Anesthetic Nebulization for Pain Control After Laparoscopic Cholecystectomy|Double Blind Randomized Phase III Controlled Trial Comparing the Effect of Preoperative and Postoperative Nebulization of Ropivacaine on Pain Control After Laparoscopic Cholecystectomy||San Gerardo Hospital|No|Completed|April 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|70 Years|No|||March 2008|November 23, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247857||112743|
NCT01248117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4929s|Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy|Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab (2.0mg) Prospectively|PEARL2|Retina Consultants of Hawaii||Recruiting|November 2010|February 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|25 Years|N/A|Accepts Healthy Volunteers|||November 2010|November 24, 2010|November 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01248117||112723|
NCT01248377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 002/10|Skin Testing and ELISPOT Assay in Patients With a History of Non-Immediate Reactions to Cephalosporins|The Results of Skin Testing and The Detection of Cytokine Secretion From Drug Specific Peripheral Blood Mononuclear Cells Using ELISPOT Assay in the Diagnosis of Nonimmediate Reactions to Cephalosporins||Chulalongkorn University|Yes|Completed|June 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|Samples Without DNA|PBMCs and serum will be collected for further analysis, if indicated|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with a history of non-immediate hypersensitivity reactions to        cephalosporins|October 2011|October 9, 2011|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248377||112703|
NCT01248143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPP and TEA IN DIABETES|Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases|Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases||Touro College|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248143||112721|
NCT01248715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETOS|Rapid Empiric Treatment With Oseltamivir Study (RETOS)|Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)|RETOS|University of Louisville|Yes|Enrolling by invitation|November 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1000|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248715||112678|
NCT01249599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0210/1|Stress-induced Vascular Dysfunction: Evaluation of Endothelial Function in a Cohort of Patients With Takotsubo Syndrome|Stress-induced Vascular Dysfunction: Evaluation of Endothelial Function in a Cohort of Patients With Takotsubo Syndrome||University of Zurich|Yes|Completed|November 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|44|||Both|18 Years|80 Years|No|Non-Probability Sample|male or female subjects, age 18-80 with a diagnosis of Takotsubo Syndrome according to        standard clinical criteria [Strony, J., et al., Analysis of shear stress and hemodynamic        factors in a model of coronary artery stenosis and thrombosis. Am J Physiol, 1993. 265 (5        Pt 2): p. H1787-96.] in the last 10 years.|December 2012|December 10, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01249599||112610|
NCT01257802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00043071|GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases|GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases|LUPRON|University of Michigan|Yes|Recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|75|||Female|18 Years|40 Years|No|||July 2013|July 1, 2013|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257802||111982|
NCT01257815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DGB14|Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment|Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema.|RELIGHT|Novartis||Completed|January 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257815||111981|
NCT01258088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-PSR-104|Safety Study of Ointment for the Treatment of Plaque-type Psoriasis|A Randomized, Double-Blind, Vehicle-Controlled, Multiple Cohort Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment B, 2% in Healthy Volunteers and Patients With Mild-to-Moderate Plaque-Type Psoriasis|AN2728-PSR-104|Anacor Pharmaceuticals, Inc.|Yes|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 9, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01258088||111960|
NCT01258647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0509|Acceptability of a Cereal for Complementary Feeding of Infants and Young Children Made From Caterpillars|Caterpillar Cereal: Maternal and Infant Acceptability|CAT01|University of North Carolina, Chapel Hill|No|Completed|October 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|8 Months|10 Months|Accepts Healthy Volunteers|||August 2011|August 26, 2011|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258647||111917|
NCT01258686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK SIL-C-301|Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy|A Double-blind Phase III Study With Silymarin in the Patients Infected With HCV Who Failed Conventional Antiviral Therapy||Bukwang Pharmaceutical|No|Completed|November 2010|August 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258686||111914|
NCT01259297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100G2301|A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People|A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People|APOLLO|Novartis||Terminated|January 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|2336|||Both|65 Years|N/A|No|||February 2014|February 27, 2014|December 10, 2010|Yes|Yes|Terminated early in agreement with Health Authorities for feasibility reasons|No|December 18, 2013|https://clinicaltrials.gov/show/NCT01259297||111867|Due to early termination, 1759 patients were randomized as against 11,000. Only 25 primary endpoints had accrued during median follow-up of 209 days as against planned 2000 in 5 years. These low numbers significantly limit interpretation of results.
NCT01259882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291001|A Single Dose Escalation Study In Healthy Volunteers To Determine The Pharmacokinetics, Safety And Tolerability Of PF-05089771 In Healthy Volunteers|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration, Pharmacokinetics And Exploratory Pharmacodynamics Of PF-05089771 In Healthy Volunteers||Pfizer|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|61|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 31, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01259882||111822|
NCT01259284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0591|Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer|A Double Blinded, Randomized Study Comparing the Effectiveness of Fish Oil Supplements, Oral Statins, and Placebo in Reducing the Incidence of Atrial Fibrillation Following a Lung Resection in Patients With Lung Cancer||M.D. Anderson Cancer Center|Yes|Terminated|January 2011|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|2|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|December 10, 2010|Yes|Yes|Terminated due to low accrual.|No|April 24, 2012|https://clinicaltrials.gov/show/NCT01259284||111868|
NCT01250418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00031783|SNAP VS BIS(OAA/S) Scale During a Sedation Regimen With and Without Ketamine|A Comparison Between the Correlation of the Bispectral Index Versus Snap Index With the Observer's Assessment of Alertness and Sedation (OAA/S) Scale During a Sedation Regimen With and Without Ketamine||Northwestern University|No|Terminated|August 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|25|||Female|18 Years|64 Years|No|||August 2014|August 18, 2014|August 3, 2010||No|Monitor manufacturer stopped marketing plan for the product.|No|July 23, 2014|https://clinicaltrials.gov/show/NCT01250418||112548|
NCT01250691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAP-OU-isolation|Effects of Isolated Rooms on the Prevalence of Hospital Acquired Pneumonia in a Respiratory ICU|Epidemiologic Study of Hospital Acquired Pneumonia in a Respiratory ICU||Eskisehir Osmangazi University|Yes|Completed|January 2004|August 2010|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|532|||Both|18 Years|N/A|No|Non-Probability Sample|All of the patients who had been admitted to the ICU during this period were included in        the study|January 2004|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250691||112528|
NCT01250665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CogImp01|Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis|Cohort Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Early and Remitting Relapsing Multiple Sclerosis||Cantonal Hospital of St. Gallen|No|Not yet recruiting|January 2011|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|65|||Both|18 Years|55 Years|No|Non-Probability Sample|MS-Patients will be recruited in the outpatient clinic of the neurology department of the        cantonal hospital of Saint Gallen, responsible for treatment of MS patients of Northeast        Switzerland.|November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250665||112530|
NCT01250652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67LH13102010|Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses|Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study|LevoHydroxy|Association Asthma, Bulgaria|Yes|Completed|March 2011|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||July 2013|July 15, 2013|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250652||112531|
NCT01250899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE Vitamin D|Vitamin D in HIV-Infected Patients on HAART|Vitamin D, Immune Activation, and Metabolic Abnormalities in HIV-Infected Patients on Antiretroviral Therapy||University of California, Los Angeles|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|90 Years|No|||November 2014|November 24, 2014|November 30, 2010||No||No|August 25, 2014|https://clinicaltrials.gov/show/NCT01250899||112512|This trial was prospective, but open label and not randomized. However, randomization to placebo would not have been clinically appropriate.
NCT01251185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR CHF-IL|Extracorporeal Shockwave Myocardial Revascularization (ESMR) Therapy For The Treatment of Chronic Heart Failure|Extracorporeal Shockwave Myocardial Revascularization(ESMR)Therapy For The Treatment of Chronic Heart Failure.||Medispec|No|Completed|January 2011|December 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||February 2013|February 17, 2013|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251185||112490|
NCT01251172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02555|RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant||National Cancer Institute (NCI)||Withdrawn|December 2010|||July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|November 30, 2010|Yes|Yes|Because of "No Participant Enrollment."|No||https://clinicaltrials.gov/show/NCT01251172||112491|
NCT01251510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-INK I|Bile Acid-induced GLP-secretion. A Study in Cholecystectomized Subjects|Bile Acid-induced GLP-secretion. A Study in Cholecystectomized Subjects||University Hospital, Gentofte, Copenhagen|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|N/A||2|Actual|20|Samples With DNA|blood samples|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects and cholcystectomised patients (chol)|January 2013|January 22, 2013|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251510||112466|
NCT01251471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OENB-13903|Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response|Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response||Medical University of Vienna|Yes|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|45 Years|No|||October 2014|October 1, 2014|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251471||112469|
NCT01251484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBF1120 GBM|BIBF 1120 in Recurrent Glioblastoma Multiforme|Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme||Rigshospitalet, Denmark|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251484||112468|
NCT01251497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|texn0043|¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos|¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos|Yo Puedo|Texas AgriLife Extension Service|No|Completed|September 2009|October 2010|Actual|October 2010|Actual|Phase 0|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|||||||Both|50 Years|N/A|No|||November 2010|December 1, 2010|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251497||112467|
NCT01252069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL09-027|PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)|A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding||PregLem SA|Yes|Completed|January 2011|January 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Female|18 Years|48 Years|No|||January 2016|January 12, 2016|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01252069||112423|
NCT01252056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260-09-805-01|A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy|A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy||Otsuka Beijing Research Institute|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|353|||Both|40 Years|75 Years|No|||May 2013|May 7, 2013|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01252056||112424|
NCT01247870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.0086|Metformin in Chronic Obstructive Pulmonary Disease|A Randomised, Double-blind, Placebo-controlled Trial of Metformin in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: a Pilot Study||St George's, University of London|No|Completed|January 2011|May 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|35 Years|N/A|No|||May 2015|May 6, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247870||112742|
NCT01248130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001593|Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders|Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders||Massachusetts General Hospital|No|Terminated|November 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|6 Years|17 Years|No|||September 2014|September 15, 2014|November 19, 2010|Yes|Yes|Due to a change in the research priorities of the principal investigator in combination with    low subject interest.|No|September 15, 2014|https://clinicaltrials.gov/show/NCT01248130||112722|This study was terminated early due to a change in the research priorities of the Principal Investigator in combination with low subject interest. Therefore, no data was analyzed.
NCT01248403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001RDE35T|A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy|A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen|AIO-STO-0111|Krankenhaus Nordwest|Yes|Active, not recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01248403||112701|
NCT01249339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/3/2|In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus|In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Four Brands of Swedish 'Snus' in Regular Snus Users|SMWS03|Contract Research Organization el AB|No|Completed|May 2004|April 2005|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 26, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249339||112630|
NCT01249612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(H-A-2008-063, nr. 24100|Knee Joint Icing and Knee-extension Strength|No Effect of Knee Joint Icing on Knee-extension Strength After Total Knee Arthroplasty. A Randomized Cross-over Study|IS|Hvidovre University Hospital|No|Terminated|April 2010|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01249612||112609|
NCT01249625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00031266|The Respiratory Protection Effectiveness Clinical Trial|Incidence of Respiratory Illness in Outpatient Healthcare Workers Who Wear Respirators or Medical Masks While Caring for Patients|ResPECT|Johns Hopkins University|Yes|Active, not recruiting|December 2010|December 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|18 Years|100 Years|No|||March 2016|March 17, 2016|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249625||112608|
NCT01249651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HL00001|To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole|An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole.||AstraZeneca||Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|20 Years|N/A|No|||June 2012|October 1, 2012|November 26, 2010||No||No|June 8, 2012|https://clinicaltrials.gov/show/NCT01249651||112606|
NCT01257828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-10-001|Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)|Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study|CSM-Protect|AOSpine North America Research Network|No|Recruiting|December 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|80 Years|No|||October 2015|October 28, 2015|October 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01257828||111980|
NCT01258335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-887|Omega-3-fatty Acids on Age-related Macular|Short Term Ocular Safety Assessment of High Dose Omega-3 Supplementation for Age-Related Macular Degeneration.|Omega 3|Mid Atlantic Retina|No|Completed|October 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|25|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||November 2011|November 21, 2011|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258335||111941|
NCT01258972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-0020|Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effectiveness of the Tryton Side Branch Stent Used With DES in Treatment of de Novo Bifurcation Lesions in the Main Branch & Side Branch in Native Coronaries|TRYTON PIVOTAL IDE Coronary Bifurcation Extended Access Study|TRYTON|Tryton Medical, Inc.|Yes|Active, not recruiting|December 2010|July 2016|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|133|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2015|November 11, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258972||111892|
NCT01260129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-SDS-401|Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH|Safety and Efficacy of 8mg Once-daily Versus 4mg Twice-daily Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH ; 12-week, Double-blind, Randomized, Comparison, Multi-center Study||JW Pharmaceutical|Yes|Completed|October 2010|October 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|424|||Male|50 Years|N/A|No|||March 2012|March 28, 2012|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01260129||111803|
NCT01259596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH083664|Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)|A Randomized Controlled Trial (RCT)of Cognitive Behavioral Therapy-Telephone (CBT-T) for Late-Life Generalized Anxiety Disorder (GAD)||Wake Forest Baptist Health|Yes|Completed|January 2011|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|60 Years|N/A|No|||June 2015|June 15, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01259596||111844|
NCT01250951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ARU01|This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.|1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.||Novartis||Completed|December 2009|September 2011|Actual|July 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|2 Years|N/A|No|||December 2011|December 1, 2011|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01250951||112508|
NCT01250678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CogNtz|Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab|Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab||Cantonal Hospital of St. Gallen|No|Not yet recruiting|January 2011|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|55 Years|No|Non-Probability Sample|MS-patients will be recruited in the outpatient clinic of the neurology department of the        cantonal hospital of Saint Gallen, responsible for treatment of MS patients of Northeast        Switzerland.|November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250678||112529|
NCT01250912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043324|Imaging With a Radio Tracer to Guide VT Ablations|Three Dimension Neuron Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Ventricular Tachycardia Ablations||University of Maryland|Yes|Recruiting|March 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|July 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250912||112511|
NCT01251198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stent For Life|Stent For Life Observatory|Stent For Life Observatory|SFL|French Cardiology Society|No|Completed|November 2010|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|460|||Both|18 Years|N/A|No|Non-Probability Sample|Patients affected are patients with acute coronary syndrome with ST segment elevation ST        (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance,        intensive care unit, cardiac catheterization lab).|June 2012|June 13, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251198||112489|
NCT01252082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86067|Non-surgical Periodontal Therapy Effects Metabolic Control in Diabetics|Evaluation of Effect of Nonsurgical Periodontal Therapy on Metabolic Control in Patients With Type II Diabetes||Mashhad University of Medical Sciences|Yes|Completed|June 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|70 Years|No|||April 2015|April 7, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252082||112422|
NCT01251770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE-15-2010|Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children|Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children|surgical-Na|Hospital General de Niños Pedro de Elizalde|Yes|Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|1 Month|16 Years|No|||October 2011|December 20, 2011|November 30, 2010||No||No|December 13, 2011|https://clinicaltrials.gov/show/NCT01251770||112446|
NCT01248169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0187|Impedance Cardiographic (ICG) Assessment of Pregnant Women With Severe Hypertension to Assess Impact of Standard Therapy|Impedance Cardiographic Assessment of Gravidas With Severe Hypertension (ICASH)to Assess Impact of Standard Therapy on Hemodynamic Parameters - A Pilot Study|ICASH|University of Mississippi Medical Center|No|Completed|December 2009|November 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|30|Samples Without DNA|One tube of blood|Female|18 Years|45 Years|No|Non-Probability Sample|Nulliparous or parous patients with severe hypertension, a singleton gestation,        gestational age greater than 20 weeks along who are admitted to the Wiser Hospital for        Women and Infants at the University of Mississippi Medical Center.|December 2013|December 11, 2013|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01248169||112719|
NCT01247883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1261005|A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers|A Two Period, 2 Sequence Crossover To Establish The Relative Bioavailability Of A Single Pf-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers||Pfizer|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 31, 2011|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247883||112741|
NCT01247896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3301001|Single Dose Escalation Study of PF-05190457 in Healthy Volunteers|A Phase 1 Placebo-controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of PF-05190457 Under Fasted and Fed Conditions in Healthy Adult Subjects||Pfizer|No|Completed|December 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247896||112740|
NCT01248156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101311|The Maintenance of Human Atrial Fibrillation|The Maintenance of Human Atrial Fibrillation||University of California, San Diego|Yes|Recruiting|December 2010|June 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|86|||Both|21 Years|N/A|No|Probability Sample|Subjects will be men and women of all races aged above 21 years undergoing clinically        indicated ablation of persistent and paroxysmal AF subjects.|December 2013|December 11, 2013|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248156||112720|
NCT01249001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000019462|Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents|Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents||The Hospital for Sick Children|No|Suspended|October 2010|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|12 Years|18 Years|No|||November 2015|November 17, 2015|November 23, 2010||No|lack of personnel resource and protocol amendment needed|No||https://clinicaltrials.gov/show/NCT01249001||112656|
NCT01249352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF024-201|A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer|A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer|NICE|Eurofarma Laboratorios S.A.|No|Completed|January 2009|November 2013|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249352||112629|
NCT01249365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113618|The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study||GlaxoSmithKline||Recruiting|January 2011|September 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|465|||Female|26 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 10, 2016|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01249365||112628|
NCT01249664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15170|VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)|A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia|Myrror|Bayer|Yes|Completed|December 2010|August 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|November 26, 2010|Yes|Yes||No|February 16, 2014|https://clinicaltrials.gov/show/NCT01249664||112605|
NCT01258361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/LM-03|Echocardiographic Assessment of Volume Variation Secondary to Preoperative Fasting|Echocardiographic Assessment of Volume Variation Secondary to Preoperative Fasting||Centre Hospitalier Universitaire de Nīmes|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients recruited during anesthesia consultations carried out before programmed        gynecological or visceral surgeries.|March 2015|March 25, 2015|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258361||111939|
NCT01258673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FHC-CT-301|A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy|A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)||Boryung Pharmaceutical Co., Ltd|Yes|Completed|November 2010|||December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|263|||Both|18 Years|N/A|No|||December 2010|January 2, 2012|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258673||111915|
NCT01259609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH_OT|Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy|||Seoul National University Hospital|No|Completed|September 2008|May 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|82|||Both|20 Years|70 Years|No|||December 2010|December 13, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01259609||111843|
NCT01260649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001672|N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression|||Massachusetts General Hospital|No|Recruiting|November 2010|||January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01260649||111763|
NCT01260389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2010/587|Pharmaceutical Care for Chronic Obstructive Pulmonary Disease (COPD) Study.|Pharmaceutical Care for COPD Study|PHARMACOP|University Hospital, Ghent|No|Completed|December 2010|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|734|||Both|50 Years|N/A|No|||May 2012|May 11, 2012|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260389||111783|
NCT01250964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0435|Endothelial Cell Loss and Induced Astigmatism After Wound-directed and Wound-assisted IOL Injection|Endothelial Cell Loss and Surgically Induced Astigmatism After 2.2 mm Wound Assisted vs 2.4 mm Wound-Directed Clear Corneal Incisions for Intraocular Lens Insertion During Cataract Surgery||University of North Carolina, Chapel Hill|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250964||112507|
NCT01251224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01AI083238|Mouse Allergen and Asthma Intervention Trial|Mouse Allergen and Asthma Intervention Trial|MAAIT|Johns Hopkins University|Yes|Active, not recruiting|November 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|6 Years|17 Years|No|||February 2016|February 26, 2016|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01251224||112487|
NCT01251237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL0706-01/2009 (VOM)|Study to Assess the Tolerability, Safety and Efficacy of an Adapted Gut Cleansing Solution in Routine Colon Cleansing Prior to Colonoscopies|Open Study to Assess the Tolerability, Safety and Efficacy of an Adapted 2 Litre Gut Cleansing Solution (NRL0706) in Routine Colon Cleansing Prior to Colonoscopies for Colon Tumour Screening.||Norgine|No|Completed|March 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251237||112486|
NCT01250925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04-029|Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface|Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study||Massachusetts Eye and Ear Infirmary|No|Active, not recruiting|August 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 10, 2012|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250925||112510|
NCT01250938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH07816502S1|Effectiveness of Early Intervention in an Underserved Population|2/2-Effects of Parent-Implemented Intervention for Toddlers With Autism Spectrum||University of Michigan|Yes|Recruiting|July 2009|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|24 Months|54 Months|No|||November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250938||112509|
NCT01251211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOTNEP|Botulinum Toxin in Peripheral Neuropathic Pain|Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain||Hospital Ambroise Paré Paris|No|Completed|October 2010|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|85 Years|No|||March 2016|March 10, 2016|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251211||112488|
NCT01252095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG545101|Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours|An Open-label, Single Centre Phase I Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours||Progen Pharmaceuticals|Yes|Terminated|January 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|November 30, 2010||No|Unexpected injection site reactions.|No|May 21, 2012|https://clinicaltrials.gov/show/NCT01252095||112421|Early termination due to unexpected injection site reactions leading to small numbers of subjects analyzed. An MTD could not be determined for this study.
NCT01247909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infaseme|Infant Severe Sepsis and Bacterial Meningitis in Malawi|An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi|Infaseme|University of Malawi College of Medicine|Yes|Active, not recruiting|April 2010|April 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|238|||Both|N/A|2 Months|No|||January 2014|January 15, 2014|January 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01247909||112739|
NCT01248182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0059|Bone to Skin Thickness Study: Obese Versus Normal Population|Bone to Skin Thickness Study: Obese Versus Normal Population||University of Mississippi Medical Center|No|Terminated|September 2010|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with pelvic ring injury or acetabular fracture|April 2012|April 5, 2012|November 23, 2010||No|Study was terminated by investigator|No||https://clinicaltrials.gov/show/NCT01248182||112718|
NCT01248416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180984|Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature|A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature|ThrasherAI|Nemours Children's Clinic|Yes|Active, not recruiting|November 2010|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|77|||Male|12 Years|18 Years|No|||May 2015|May 17, 2015|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248416||112700|
NCT01248429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKI-CPK 1003|Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases|National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)|TKI-CPK-1003|Centre Oscar Lambret|No|Completed|November 2010|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|154|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated for a solid tumor by thyrosin kinase inhibitors|June 2012|June 6, 2012|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248429||112699|
NCT01248728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-018|Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)|A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids in the Treatment of Young Children With Autism||Anagnostou, Evdokia, M.D.|No|Completed|November 2010|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|2 Years|5 Years|No|||June 2014|June 19, 2014|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01248728||112677|
NCT01249014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11102010-7189|Temperature Study in Cesarean Section|Study Using Fluid Warming and Forced Air Warming Immediately Prior to and During Elective Cesarean Section||Stanford University|No|Recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|45|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01249014||112655|
NCT01249027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-388|XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study|XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study|XV CHINA SAS|Abbott Vascular|No|Active, not recruiting|November 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2605|||Both|N/A|N/A|No|Non-Probability Sample|General Chinese interventional cardiology population|October 2015|October 11, 2015|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01249027||112654|
NCT01249378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.563/16|Metabolic Impact of Fat Digestion|Metabolic Impact of the Digestion of Fat in Emulsified vs Non-emulsified Form in Lean or Obese Volunteers|LIPINFLOX|Hospices Civils de Lyon|Yes|Recruiting|March 2010|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 26, 2010|July 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01249378||112627|
NCT01249638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22011|Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC|Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer||Ludwig-Maximilians - University of Munich|Yes|Recruiting|December 2010|December 2016|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|516|||Both|18 Years|N/A|No|||November 2010|March 11, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249638||112607|
NCT01258114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAATHERMES|Maâthermes: Spa Treatment for Overweight and Obesity|Maâthermes a Randomised Controlled Trial of Spa Treatment of Overweight and Obesity|MAATHERMES|Association Francaise pour la Recherche Thermale|No|Completed|March 2007|December 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|400|||Both|20 Years|70 Years|No|||December 2010|December 9, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01258114||111958|
NCT01259310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEPOD|Women With Epilepsy: Pregnancy Outcomes and Deliveries|Women With Epilepsy: Pregnancy Outcomes and Deliveries|WEPOD|New York University School of Medicine|No|Completed|November 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|199|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with epilepsy between 18 and 40 years of age, recruited from epilepsy clinics in New        York and Boston, and control women without epilepsy between 18 and 40 years of age,        recruited from Obstetrics and Gynaecology clinics, local academic institutions, and        referrals from epilepsy clinic employees or patients.|March 2016|March 4, 2016|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01259310||111866|
NCT01260402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/12|Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure.|Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure.|EPI-ENDO|University Hospital, Bordeaux|Yes|Recruiting|March 2011|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2014|August 20, 2014|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01260402||111782|
NCT01259908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1953-4|Laparoscopic Surgical Treatment of Abdominal Aortic Aneurysms and Aorto-iliac Occlusive Disease|Laparoscopic Aortic Surgery: Norwegian Experiance|LAS|Oslo University Hospital|No|Recruiting|September 2010|September 2020|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Patients with infra-renal abdominal aortic aneurysm (AAA) with a size 55mm or greater.        Patients with aorto-iliac occlusive disease (Type D lesion according to the Trans        Attlantic intersociety Consensus TASC II)|September 2010|April 24, 2015|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259908||111820|
NCT01260155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-A001-005|A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects|A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects||Eisai Inc.||Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|December 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01260155||111801|
NCT01250977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12910|Effect of Donepexil on Smoking|The Effect of Acetylcholinesterase Inhibitors on Smoking Behavior||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|October 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Masking: Double-Blind, Primary Purpose: Supportive Care|4||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|October 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250977||112506|
NCT01250990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811956|Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis|A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Effects Of Niacin On Reverse Cholesterol Transport As Measured Using 3H Particulate Cholesterol in Healthy Volunteers|ENTHRALL|University of Pennsylvania|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 21, 2011|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01250990||112505|
NCT01251250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 169009|Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia|Phase I Clinical Trial of Neem Leaf Extract for the Treatment of Chronic Lymphocytic Leukemia||Roswell Park Cancer Institute|Yes|Withdrawn|December 2010|||July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|November 30, 2010|No|Yes|lost sponsor support|No||https://clinicaltrials.gov/show/NCT01251250||112485|
NCT01251523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL09338601A2|Improving Asthma Outcomes Through Cultural Competence Training for Physicians|Improving Asthma Outcomes Through Cultural Competence Training for Physicians||University of Michigan|Yes|Recruiting|November 2010|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|1282|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251523||112465|
NCT01251783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metlin&MetlosChildren|A Prebiotic Agave Derivated Metlin & Metlos in Infant Formula|Double Blind, Randomized, Controlled Clinical Trial for Evaluate The Efficiency and Safety of a Fiber System From Agave, With Prebiotic Action, Metlin® and Metlos®, Incorporated to an Infant Formula for Term Newborn Babies||National Institute of Pediatrics, Mexico|Yes|Completed|February 2010|October 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|600|||Both|N/A|30 Days|Accepts Healthy Volunteers|||December 2010|December 1, 2010|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251783||112445|
NCT01252108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQ109-H001|Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers|Phase 2A Open-label Study to Evaluate Safety, Tolerability, and Antimicrobial Activity of Single, Daily Doses of SQ109 in Urea Breath Test Positive Volunteers||Sequella, Inc.|No|Withdrawn|March 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 30, 2010|No|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01252108||112420|
NCT01252121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-275|Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline|||Alcon Research|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|27|||Both|18 Years|N/A|No|||May 2012|October 26, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01252121||112419|
NCT01247922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-774-206|Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205|Open-label, Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205||Astellas Pharma Inc|Yes|Terminated|May 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|1 Year|21 Years|No|||December 2015|December 7, 2015|November 23, 2010|Yes|Yes|In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety    concerns. As a result, the companion trial, OSI-774-206 has been stopped|No|October 26, 2015|https://clinicaltrials.gov/show/NCT01247922||112738|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01248195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP7242114|Optimization of Treatment and Management of Schizophrenia in Europe|Optimization of Treatment and Management of Schizophrenia in Europe|OPTIMISE|UMC Utrecht|Yes|Recruiting|May 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|500|||Both|18 Years|40 Years|No|||July 2015|July 16, 2015|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01248195||112717|
NCT01248481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15316|GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin|Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress||Bayer|No|Completed|September 2010|July 2012|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|539|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with DM in korea|June 2013|June 19, 2013|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248481||112695|
NCT01248442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENM-EA-011|Immune and Metabolic Effects of Vitamin D Supplementation in Healthy Humans|Placebo Controlled Study to Assess the Effects of Vitamin D Supplementation on Parameters of the Immune, Endocrine and Metabolic System in Healthy Women and Men.||Medical University of Graz|Yes|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248442||112698|
NCT01248455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110024|A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma|A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM)||National Institutes of Health Clinical Center (CC)|Yes|Terminated|November 2010|September 2017|Anticipated|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|November 24, 2010|Yes|Yes|Lack of patients meeting the defined primary obj. (50% decline in M-protein).|No|April 29, 2015|https://clinicaltrials.gov/show/NCT01248455||112697|Study stopped after the first stage due to lack of patients meeting the defined primary objective (50% decline in M-protein). The study did not continue to the second stage of enrollment due to lack of efficacy as defined by our criteria.
NCT01248741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01987|CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse|High Dose Rate (HDR)Prostate Brachytherapy With Vitesse tm|Vitesse|British Columbia Cancer Agency|No|Completed|December 2010|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|45 Years|80 Years|No|||February 2013|February 8, 2013|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01248741||112676|
NCT01249040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU93-CM-13|The Study of Different Treatment Programs for Patients With Frozen Shoulder|The Study of Different Treatment Programs for Patients With Frozen Shoulder||China Medical University Hospital||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|||Anticipated|30|||Both|25 Years|N/A|No|||September 2004|November 26, 2010|November 24, 2010||||No||https://clinicaltrials.gov/show/NCT01249040||112653|
NCT01249677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08- BO-LSBE|Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes|Chronic Reduction of Fasting Gylcaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes||Ruhr University of Bochum|No|Completed|January 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||October 2008|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249677||112604|
NCT01258985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005521-01A1|Tai Chi and Physical Therapy for Knee Osteoarthritis|Tai Chi and Physical Therapy for Knee Osteoarthritis|TCPT|Tufts Medical Center|Yes|Active, not recruiting|March 2011|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|40 Years|N/A|No|||December 2013|December 9, 2013|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258985||111891|
NCT01260142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2083-A001-410|A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion|A Randomized, Open-Label, Single-Bolus, 2-Period, Multi-Dose Level, 3 Cohort Crossover Design, Pharmacokinetic/Pharmacodynamic Study of Lusedra (Fospropofol Disodium) Injection Compared With Propofol Injectable Emulsion||Eisai Inc.||Completed|November 2010|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|December 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01260142||111802|
NCT01259349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMLH-002-EYE|Effect of Minimising Ultrasound Power to 1% During Cataract Surgery on Corneal Endothelium.|Standard Coaxial Microincision Cataract Surgery Versus Coaxial Microincision Cataract Surgery Using 1% Ultrasound in Immature Senile Cataract :a Corneal Endothelium Study|OCTOPUS|Dr. Ram Manohar Lohia Hospital|Yes|Recruiting|November 2010|April 2012|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|40 Years|N/A|No|||November 2010|December 14, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01259349||111863|
NCT01259635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0510-10-TLV|Biofeedback to Ameliorate Freezing of Gait|Biofeedback-based Motor Learning to Ameliorate Freezing of Gait||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Anticipated|40|||Both|40 Years|85 Years|No|||December 2010|December 12, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01259635||111841|
NCT01260441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS-807120|An In-Hospital Family Member Cardiopulmonary Resuscitation (CPR) Education Program|CPR Education of Patient Family Members Using CPR Anytime Training Program||University of Pennsylvania|No|Completed|October 2007|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01260441||111779|
NCT01260688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02544|Cediranib Maleate With or Without Dasatinib in Patients With Hormone-Resistant Prostate Cancer Resistant to Treatment With Docetaxel|A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2010|||January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|N/A|No|||October 2013|October 7, 2013|December 14, 2010|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT01260688||111760|
NCT01251003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0061|Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury|Safety of Autologous Human Umbilical Cord Blood Treatment for Traumatic Brain in Children||The University of Texas Health Science Center, Houston|Yes|Withdrawn|January 2011|May 2015|Actual|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Months|17 Years|No|||December 2015|December 9, 2015|November 29, 2010|Yes|Yes|Unable to identify eligible subjects with traumatic brain injury who also have banked    umbilical cord blood at CBR.|No||https://clinicaltrials.gov/show/NCT01251003||112504|
NCT01251263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90304|Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.|Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.|Estradiol/MAM|Scott and White Hospital & Clinic|No|Recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251263||112484|
NCT01251536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51532|Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer|A Two Arm Phase II Study of FOLFIRI in Combination With Standard or Escalating Dose of Cetuximab as First Line Treatment of K-Ras Wild Type Metastatic Colorectal Cancer: Everest 2|Everest2|Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|December 2010|March 2019|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|375|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251536||112464|
NCT01251796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-005|A Study of ARQ 197 in Combination With Erlotinib|A Phase I Study of ARQ 197 in Combination With Erlotinib in CYP2C19 Poor Metabolizer Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer||Kyowa Hakko Kirin Company, Limited||Completed|December 2010|||April 2011|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||||||Both|20 Years|N/A|No|||March 2013|March 22, 2013|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01251796||112444|
NCT01252160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E05-CL-3001|Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage|A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain|STRIDE|Astellas Pharma Inc|No|Completed|October 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|306|||Both|18 Years|90 Years|No|||January 2016|January 7, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252160||112416|
NCT01247961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-002192|Early Treatment With Dexamethasone in Mild Acute Pancreatitis|Intravenous Dexamethasone for the Early Treatment of Mild Acute Pancreatitis: A Double-Blind, Randomized, Placebo Controlled Trial||Brigham and Women's Hospital|Yes|Recruiting|November 2010|July 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||November 2010|November 30, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01247961||112735|
NCT01247935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34115/14|Electroacupuncture and Trancutaneous Electrical Nervous Stimulation (TENS) for Colonoscopy Analgesia|Electroacupuncture and Trancutaneous Electrical Nervous Stimulation Analgesia for Colonoscopy: a Prospective, Randomized, Controlled Study||Azienda Per I Servizi Sanitari N. 2 Isontina|No|Completed|November 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|60|||Both|18 Years|80 Years|No|||June 2010|July 11, 2011|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01247935||112737|
NCT01247948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jst2010caos|Evaluating the Accuracy of Navigation Assisted Pedicle Screw Placement of Spine Surgery|A Multi-center Randomized Controlled Trial Evaluating the Accuracy of Navigation Assisted Pedicle Screw Placement of Spine Surgery|J0001I41|Beijing Jishuitan Hospital|Yes|Not yet recruiting|February 2011|February 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|656|||Both|18 Years|75 Years|No|||November 2010|December 9, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247948||112736|
NCT01248494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BRE 1055|PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer|A Phase Ib Trial of BKM120 (a PI3K Inhibitor) or BEZ235 (a PI3K/mTOR Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer||Vanderbilt-Ingram Cancer Center|Yes|Completed|November 2010|October 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248494||112694|
NCT01248468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176-P-401|Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine|A Multi-center, Randomized, Double-blind, Parallel-group Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine.||Novartis|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|752|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|November 23, 2010||No||No|March 22, 2012|https://clinicaltrials.gov/show/NCT01248468||112696|
NCT01248754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02888|Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study|A Phase II Study Using 18F-FDOPA Positron Emission Tomography Imaging for Neurosurgery and Assessment of Surgical Resection||British Columbia Cancer Agency|No|Recruiting|July 2011|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248754||112675|
NCT01248767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG/10/98|A Prospective Clinical Study of a Cohort of Pathological or "at Risk" Gamblers Seeking Treatment|A Prospective Clinical Study of a Cohort of Pathological or "at Risk" Gamblers Seeking Treatment in the University Hospital of Nantes||Nantes University Hospital|No|Recruiting|September 2008|||||N/A|Observational|Observational Model: Cohort||1|||||Both|18 Years|N/A||Non-Probability Sample|Pathological or "at risk" gambling|January 2014|January 7, 2014|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248767||112674|
NCT01249391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROHH051|Splinting to Treat Hand Osteoarthritis|Splinting to Treat Interphalangeal Joint Deformity in Hand Osteoarthritis(Splint OA Study)|SPLINTOA|Imperial College London|Yes|Completed|September 2010|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|90 Years|No|||July 2011|February 15, 2016|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249391||112626|
NCT01249404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-55-52120-140|Dysport® Adult Lower Limb Spasticity Study|A Phase III, Multicentre, Double-blind, Prospective, Randomized, Placebo-controlled Study, Assessing the Efficacy and Safety of Dysport® Used for the Treatment of Lower-limb Spasticity in Adult Subjects With Hemiparesis Due to Stroke or Traumatic Brain Injury||Ipsen|Yes|Completed|March 2011|May 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|348|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|November 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01249404||112625|
NCT01249690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCZH-2010-CT-001|Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma|Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes||Second Military Medical University|Yes|Recruiting|June 2010|June 2014|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2010|November 29, 2010|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249690||112603|
NCT01259895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPE18|Effects of Time of Sleep Restriction in Obesity|Effect os Sleep Restriction on Control of Food Intake and Metabolism of Obese Subjects||Federal University of São Paulo||Completed|February 2009|June 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|20|||Male|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic, community sample, residents of the city of Sao Paulo|August 2014|August 14, 2014|December 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01259895||111821|
NCT01259362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLRIBEIRO1|Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients|Efeitos da Estimulacao Magnetica Transcrania de Repeticao ( EMTr) no Tratamento da Dependencia ao Uso de Cocaina|TMSCOCDEPEND|University of Sao Paulo General Hospital|No|Recruiting|March 2010|July 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|40 Years|No|||September 2010|December 21, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01259362||111862|
NCT01260168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exact Sciences 2010-A|Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies|Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies||Exact Sciences Corporation|No|Completed|October 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|435|Samples With DNA|Residual specimens and histopathology tissue slides or blocks will be stored for up to 10      years in the Sponsor's on-site bio-repository or similar commercial bio-repository      contracted by the Sponsor.|Both|40 Years|90 Years|No|Non-Probability Sample|Patients who have had colorectal cancer or pre-malignancy confirmed by colonoscopic        biopsy-based diagnosis.|May 2015|May 12, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01260168||111800|
NCT01261039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|h-3-2009-145|Production of Vitamin D Metabolites by UV-radiation From Solar Bed|Production of Vitamin D Metabolites by UV-radiation From Solar Bed||Hvidovre University Hospital|No|Completed|April 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261039||111733|
NCT01256931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV-305|Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients.|Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients.||Sahlgrenska University Hospital, Sweden|No|Recruiting|December 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|110|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Transplant patients at the out-patient clinical ward and staff members of the Transplant        Institute, Sahlgrenska University Hospital|December 2010|December 8, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256931||112049|
NCT01251302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX 000011|Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern (IMPACT-CARD)|Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern|IMPACT-CARD|CardioDx|No|Completed|November 2010|June 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|171|Samples With DNA|PaxGene tube for RNA collected|Both|21 Years|N/A|No|Probability Sample|The study will enroll a patient population that present with chest pain or anginal        equivalent symptoms who are referred to a cardiologist for evaluation.|December 2014|December 3, 2014|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251302||112481|
NCT01251315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 - 04 - 2268 - 01|The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels|PILOT: The Effects of Short Term Administration of a Novel Glutathione Precursor (FT061452), on Serum and Intracellular Glutathione Levels||Charles Drew University of Medicine and Science|Yes|Completed|December 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|24|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|November 29, 2010|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT01251315||112480|
NCT01251276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rHB01C|Hepatitis B Challenge Dose in Adults|A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥50 Years Old) Vaccinated With a Primary Series of an Hepatitis B Vaccine||Sanofi Pasteur MSD|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|204|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 10, 2011|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01251276||112483|
NCT01251289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-072|The Prevalence of Group B Streptococcus Positive Pregnant Patients in an Inner City Tertiary Care Center|The Prevalence of Group B Streptococcus Positive Pregnant Patients in an Inner City Tertiary Care Center||St. Michael's Hospital, Toronto||Completed|December 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|628|||Female|N/A|N/A|No|Probability Sample|Group B streptococcus positive pregnant women|December 2009|June 8, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251289||112482|
NCT01251549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RW003 ver. 4|Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO)|Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO)||Argo Medical Technologies Ltd.|No|Recruiting|March 2009|August 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|55 Years|No|||January 2012|January 9, 2012|November 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01251549||112463|
NCT01251809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-PEGASP.1/adults|Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia|A Randomized, Multi-centre, Parallel-group, Open Label, Oncaspar® Controlled Dose Ranging Trial of Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia||medac GmbH|Yes|Terminated|January 2011|May 2013|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|56|||Both|18 Years|55 Years|No|||May 2013|May 17, 2013|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01251809||112443|
NCT01247974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-PR-1006|Evaluation Of New Onset Postoperative Atrial Fibrillation|Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM® for Pericardial Closure||CorMatrix Cardiovascular, Inc.|Yes|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|439|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|November 23, 2010|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT01247974||112734|
NCT01248208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|357349|FluMist in Egg Allergic Patients|Flu Vaccine in Egg-allergic Patients Minimizing Injections Safety Trial|FluEMIST|Walter Reed Army Medical Center|Yes|Recruiting|September 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|6 Months|N/A|No|||November 2010|November 24, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248208||112716|
NCT01248507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-401-ES|Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations|Comparative Evaluation of COPD Specific Quality of Life Assessment Questionnaires (the COPD Assessment Test, the Clinical COPD Questionnaire, the COPD Severity Score and the Airways Questionnaire 20 as Predictive Tools for Risk of Acute COPD Exacerbations||Takeda|No|Completed|January 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|634|||Both|40 Years|N/A|No|Non-Probability Sample|COPD patients|August 2013|August 16, 2013|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01248507||112693|
NCT01248780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015913|Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Centocor, Inc.|No|Completed|September 2010|July 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|November 24, 2010||No||No|October 5, 2012|https://clinicaltrials.gov/show/NCT01248780||112673|
NCT01249053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-062|Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma|||China Medical University Hospital|No|Recruiting|August 2010|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|25 Years|85 Years|No|Non-Probability Sample|Between January 2006 and December 2008, we will retrospectively enroll 100 consecutive        LADC patients who were admitted to the Department of Thoracic Surgery of China Medical        University Hospital.|November 2010|November 26, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01249053||112652|
NCT01249066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-096|Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma|Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma||China Medical University Hospital|No|Recruiting|September 2010|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|||Both|25 Years|85 Years|No|Non-Probability Sample|Lung cancer received lobectomy in CMUH|September 2010|November 26, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01249066||112651|
NCT01249079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-214|Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan|Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan||China Medical University Hospital||Recruiting|October 2010|||December 2013|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|600|||Both|16 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Schizophrenia patients and their biological parents|October 2010|November 30, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01249079||112650|
NCT01249417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-55-52120-141|Dysport® Pediatric Lower Limb Spasticity Study|A Phase III, Multicentre, Double Blind, Prospective, Randomised, Placebo Controlled Study Assessing the Efficacy and Safety of DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy||Ipsen|No|Completed|July 2011|June 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|241|||Both|2 Years|17 Years|No|||May 2015|May 26, 2015|November 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01249417||112624|
NCT01249430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02554|Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia|A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia.||National Cancer Institute (NCI)||Active, not recruiting|January 2011|||May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||October 2015|December 8, 2015|November 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01249430||112623|
NCT01249963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATEM2010|Enteral Nutrition Product in Mild Acute Pancreatitis|Evaluation of Oral Enteral Nutrition Supplement in Patients With Mild Acute Pancreatitis||Vegenat, S.A.|No|Recruiting|February 2011|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2011|June 21, 2012|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249963||112582|
NCT01251068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Measurement of Cerebral and Peripheric Tissue Oxygenation in Anemic Preterm Infants Who Underwent Blood Transfusion|Measurement of Cerebral and Peripheric Tissue Oxygenation in Anemic Preterm Infants Who Underwent Blood Transfusion:A Near Infrared Spectroscopy Study.||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|December 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|N/A|N/A|No|||November 2010|December 6, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251068||112499|
NCT01259011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1190|A Representational Intervention to Promote Preparation for End-of-life Decision Making|A Randomized Controlled Trial of SPIRIT: A Representational Intervention to Promote Preparation for End-of-Life Decision Making|SPIRIT|University of North Carolina, Chapel Hill|Yes|Completed|March 2010|April 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01259011||111889|
NCT01259921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANS2008-06|EEG Biofeedback in the Treatment of Chronic Treatment-Resistant PTSD|Application of Neurofeedback as a Mechanism of Affect Regulation Treatment of Adults With Complex Adaptation to Chronic Interpersonal Trauma Exposure||Justice Resource Institute|No|Active, not recruiting|December 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||June 2011|June 27, 2011|December 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01259921||111819|
NCT01260701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02619|Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer|A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer||National Cancer Institute (NCI)|No|Completed|January 2011|July 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||November 2015|December 14, 2015|December 14, 2010|Yes|Yes||No|July 7, 2014|https://clinicaltrials.gov/show/NCT01260701||111759|
NCT01256944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-99041|To Study Polycystic Ovary Syndrome in Taiwanese Women|To Study Polycystic Ovary Syndrome in Taiwanese Women||Taipei Medical University WanFang Hospital|No|Completed|August 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|290|Samples Without DNA|Blood sample|Female|15 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Polycystic Ovary Syndrome(PCOS)|December 2015|December 8, 2015|December 7, 2010||No||No|November 28, 2013|https://clinicaltrials.gov/show/NCT01256944||112048|
NCT01257178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12809|A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment|A Single Dose Pharmacokinetics Study of LY2624803 in Subjects With Hepatic Impairment||Eli Lilly and Company|No|Terminated|November 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 2, 2011|December 7, 2010|No|Yes|Trial was Terminated prior to subjects receiving study drug; no trial results|No||https://clinicaltrials.gov/show/NCT01257178||112030|
NCT01257464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02131|Sitagliptin in Cystic Fibrosis-Related Diabetes|The Effects of the DPPIV Inhibitor Sitagliptin in Cystic Fibrosis-related Diabetes||University of British Columbia|No|Terminated|September 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|19 Years|N/A|No|||March 2014|March 5, 2014|December 2, 2010|Yes|Yes|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01257464||112008|
NCT01257477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10LOT01|LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|Research Study to Evaluate LOTRONEX® in Severe IBS-D: Analysis of Current Clinical Practice Environment|RELIANCE|Prometheus Laboratories|No|Completed|November 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|65 Years|No|Non-Probability Sample|Women ≥ 18 years of age with severe diarrhea-predominant IBS, who have chronic IBS        symptoms lasting 6 months or longer and who have not responded adequately to other IBS        therapy will be eligible to enroll in the study.|April 2013|April 1, 2013|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01257477||112007|
NCT01251328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE DHM-AN-OR-2010/01|Near INfrared Spectroscopy in Aortic valvE ReplacemenT|Near Infrared Spectroscopy in Aortic Valve Replacement|INSERT|Deutsches Herzzentrum Muenchen|No|Completed|December 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01251328||112479|
NCT01251588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACI00809|Extension Study for Participants of Previous Study MACI00206 [NCT00719576] of MACI® Implant for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle|An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® Implant) for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea||Vericel Corporation|No|Completed|December 2010|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|55 Years|No|||August 2015|August 17, 2015|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251588||112460|
NCT01251575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2206.00|Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant|A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial||Fred Hutchinson Cancer Research Center|Yes|Recruiting|December 2010|||November 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||March 2016|March 9, 2016|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01251575||112461|
NCT01251562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTL0510|Safety Study of Sterile Compound c31510 for Injection to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound c31510 for Injection Administered Intravenously to Subjects With Solid Tumors||Berg, LLC||Suspended|January 2011|May 2014|Anticipated|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|November 30, 2010|No|Yes|Interim Analysis|No||https://clinicaltrials.gov/show/NCT01251562||112462|
NCT01251822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-01/2010 (PRUC)|Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation|Double-dummy, Double-blind, Randomised, Parallel Group, Controlled Comparative Study of Polyethylene Glycol (PEG)Plus Electrolytes Versus Prucalopride in Females With Chronic Constipation Who Failed Adequate Relief With Laxatives||Norgine|No|Completed|November 2010|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Female|18 Years|75 Years|No|||August 2012|August 30, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251822||112442|
NCT01251835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321060|Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan|A Phase 1, Open Label, Fixed Sequence Design, Multiple Dose Study To Assess The Effect Of Rifampin On The Pharmacokinetics Of Sitaxsentan In Healthy Subjects||Pfizer|No|Withdrawn|December 2010|January 2011|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2011|March 4, 2015|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01251835||112441|
NCT01252134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG10078 / SILVER|Evaluation of Silicone Hydrogel Lens Wettability With Marketed Lens Care Solutions|The Evaluation of Silicone Hydrogel Lens Wettability With Marketed Lens Care Solutions|SILVER|Alcon Research|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|6||Actual|22|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|December 1, 2010|Yes|Yes||No|May 8, 2012|https://clinicaltrials.gov/show/NCT01252134||112418|
NCT01252147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-066|Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment Scale for Assessment of Overall Eyelash Prominence|||Allergan|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|68|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Japanese adults|August 2012|August 24, 2012|December 1, 2010|Yes|Yes||No|November 30, 2011|https://clinicaltrials.gov/show/NCT01252147||112417|
NCT01247987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB 10-0018|Comparison of Transfers of Thawed Blastocysts Versus Blastocysts Derived From Thawed Bipronuclear Oocytes|Comparison of Transfers of Thawed Blastocysts Versus Blastocysts Derived From Thawed Bipronuclear Oocytes||Fertility Center of Las Vegas|No|Completed|December 2010|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247987||112733|
NCT01248247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0360|BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Recruiting|June 2011|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|450|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248247||112713|
NCT01248221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006643|Carbon-13 (13C)-Spirulina Platensis Gastric Emptying Breath Test (GEBT)|[13C]-Spirulina Platensis GEBT - Dual-Label Validation Study||Mayo Clinic|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|November 23, 2010|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01248221||112715|
NCT01248234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0097|Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone?|Does Administration of Etomidate and Propofol if the Anesthetic Induction of the Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngosacopy, When Compared to Propofol or Etomidate Alone?||University of Mississippi Medical Center|No|Withdrawn|July 2012|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|0|||Both|65 Years|90 Years|No|||July 2012|July 12, 2012|November 23, 2010||No|Did not begin|No||https://clinicaltrials.gov/show/NCT01248234||112714|
NCT01248520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09100504|Influenza and Text Messaging in Pregnancy|Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake||University of Pittsburgh|No|Completed|September 2010|April 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|216|||Female|14 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01248520||112692|
NCT01248533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/866|Screening for Abdominal Aortic Aneurysm in 65 Year Old Males in Oslo||AAAscreening|Oslo University Hospital|No|Enrolling by invitation|January 2011|December 2029|Anticipated|December 2029|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1500|||Male|65 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|65 year old males in Oslo|November 2009|November 24, 2010|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01248533||112691|
NCT01248793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015916|Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis||Centocor, Inc.|No|Completed|October 2010|March 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|November 24, 2010||No||No|May 25, 2012|https://clinicaltrials.gov/show/NCT01248793||112672|
NCT01249092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1003|Pentoxifylline for Primary Biliary Cirrhosis|A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis||The Cleveland Clinic|Yes|Completed|November 2010|March 2013|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|76 Years|No|||October 2013|October 16, 2013|November 24, 2010|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01249092||112649|Our study was a small open label pilot completed with no technical problems. The information generated will be useful in designing future larger studies. The main limitation is that PBC is a rare disease which resulted in prolonged enrollment phase.
NCT01249703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chunhua Deng|The Early Diagnosis and Warning Role of Erectile Dysfunction|The Early Diagnosis and Warning Role of Erectile Dysfunction:a Multi-institutional Clinical Study.||Sun Yat-sen University|Yes|Recruiting|January 2008|January 2020|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Case Control||1|Anticipated|150000|||Male|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|men with erectile dysfunction healthy men general male population|January 2008|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249703||112602|
NCT01249716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22|Follow-up Home Visits With Nutrition|Follow-up Home Visits With Nutrition (OHE)|OHE|University of Copenhagen|Yes|Completed|December 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|152|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 27, 2012|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249716||112601|
NCT01251081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHVHF|Effect of the Intensity of Continuous Renal Replacement Therapy|Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Sepsis and Acute Kidney Injury: Single-center Randomized Clinical Trial||Zhejiang University|No|Completed|January 2004|June 2010|Actual|August 2009|Actual|N/A|Interventional|Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|80 Years|No|||January 2004|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251081||112498|
NCT01259648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2009/AC-02|Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects|Randomized Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects||Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|65 Years|90 Years|No|||March 2015|March 18, 2016|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259648||111840|
NCT01260454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Qutenza White|The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain|The Qutenza® Patch for Disabling Treprostinil Infusion Site Pain||University of Rochester|No|Completed|November 2010|April 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|15 Years|80 Years|No|||January 2016|January 22, 2016|December 9, 2010|Yes|Yes||No|January 22, 2016|https://clinicaltrials.gov/show/NCT01260454||111778|
NCT01260467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB34285|Memantine for Recurrent Glioblastoma|A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma||University of Rochester|Yes|Terminated|November 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|December 10, 2010|No|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01260467||111777|
NCT01261052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.005|Real-time Adaptation to Changes in Insulin Sensitivity|Sensor-Controlled Insulin and Glucagon Delivery in Subjects With Type 1 Diabetes: Real-time Adaptation to Changes in Insulin Sensitivity||Legacy Health System|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|December 15, 2010|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT01261052||111732|
NCT01256957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|869329|Effect of HEPA Air Filters on Subclinical Markers of Cardiovascular Health|Assessing the Impact of Wood Stove Interventions on Air Quality|WEST|Simon Fraser University|No|Completed|November 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|56|||Both|19 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 8, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01256957||112047|
NCT01256970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-99075|The Study of Polycystic Ovary Syndrome (PCOS) and Questionnaire|The Study of Polycystic Ovary Syndrome (PCOS) and Questionnaire||Taipei Medical University WanFang Hospital|Yes|Completed|November 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|306|Samples Without DNA|whole blood|Female|15 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Polycystic Ovary Syndrome(PCOS)|September 2013|September 10, 2013|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256970||112046|
NCT01257191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT AADCRC-UCLA-02|A Study to Compare the Effects of Different Sized Particles on Cells in the Nose|Cellular Inflammation Characterization of Nasal Challenges With Fine and Ultrafine Particles||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|5||Actual|25|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01257191||112029|
NCT01248000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-LH|The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy|The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the "Real World": a Population Based Study From Northern Italy||Gruppo Italiano Studio Linfomi|No|Completed|May 2009|May 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|136|||Both|18 Years|N/A|No|Non-Probability Sample|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of        Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.|November 2010|November 24, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01248000||112732|
NCT01248013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0575|Irritable Bowel Syndrome Hypnotherapy|Outcome Effectiveness Predictors of Irritable Bowel Syndrome Hypnotherapy||Mind-Body Digestive Center|No|Completed|September 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|20 Years|N/A|No|||January 2011|January 5, 2011|November 22, 2010||No||No|November 24, 2010|https://clinicaltrials.gov/show/NCT01248013||112731|Subjects who dropped out did so for reasons of inconvenience of scheduling attendance.
NCT01251601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1691|The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters|The Effect of Pregnancy on the Pharmacokinetics of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters||University of North Carolina, Chapel Hill|No|Withdrawn|November 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Female|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited by their HIV clinic providers|January 2012|January 31, 2012|November 30, 2010|No|Yes|Withdrawn due to inability to recruit eligible participants|No||https://clinicaltrials.gov/show/NCT01251601||112459|
NCT01251614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M04-717|A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate|A Multicenter, Randomized, Double-dummy, Double-blind Study Evaluating Two Doses of Adalimumab Versus Methotrexate (MTX) in Pediatric Subjects With Chronic Plaque Psoriasis (Ps)||AbbVie|Yes|Completed|December 2010|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|114|||Both|4 Years|17 Years|No|||December 2014|December 19, 2014|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251614||112458|
NCT01248273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-184|Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission|Phase I Trial of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|19 Years|N/A|No|||March 2015|March 24, 2015|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01248273||112711|
NCT01251848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321061|Drug Interaction Between Ritonavir And Sitaxsentan|A Phase 1, Open Label, Randomized, Multiple Dose Study To Assess The Two-Way Drug Interaction Between Sitaxsentan And Low Dose Ritonavir In Healthy Subjects||Pfizer|No|Withdrawn|January 2011|February 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|0|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01251848||112440|
NCT01251861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02648|Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer|Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Male|18 Years|N/A|No|||December 2015|January 18, 2016|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251861||112439|
NCT01252173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120-05|Measurement Of Endotracheal Tube Cuff Pressure In Emergency Department Patients|MEASUREMENT OF ENDOTRACHEAL TUBE CUFF PRESSURE IN EMERGENCY DEPARTMENT PATIENTS||Beth Israel Medical Center||Withdrawn|October 2005|September 2006|Actual|September 2006|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|All emergency department patients, and all patients admitted from the ED|April 2015|April 20, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252173||112415|
NCT01249144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTHD-10-05|Visual and Refractive Outcomes After Implantation of Aspheric IOLs With Different Dioptric Increments and Manufacturing|A Randomized Fellow-eye Controlled Clinical Trial to Compare the Visual and Refractive Outcomes Between Two Aspheric IOLs With Different Dioptric Increments and Manufacturing Tolerances in Patients Undergoing Bilateral Cataract Surgery||Lenstec Incorporated|No|Terminated|October 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|21 Years|N/A|No|||March 2014|March 17, 2014|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01249144||112645|
NCT01248260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1KG14|Preventing Fetal Body and Brain Size Reduction in Low-income Smoking Mothers: A Randomized Clinical Trial|Preventing Fetal Body and Brain Size Reduction in Low-income Smoking Mothers: A Randomized Clinical Trial||University of South Florida|Yes|Active, not recruiting|February 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|450|||Female|18 Years|44 Years|No|||December 2015|December 3, 2015|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01248260||112712|
NCT01249976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K060210|Recent Techniques for Diagnosing Central Venous Catheter-related Bloodstream Infections in Children|Evaluation of Recent Techniques for Diagnosing Central Venous Catheter-related Bloodstream Infections in Critically Ill Children|Incat|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|148|||Both|N/A|18 Years|No|||July 2012|July 25, 2012|November 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01249976||112581|
NCT01248806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S39/100|Continuous Observation of Smoking Subject|Validation of Low-dose Spiral CT for Early Diagnosis of Lung Cancer in a High Risk Population|COSMOS|European Institute of Oncology|No|Active, not recruiting|October 2004|December 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|5203|Samples With DNA|whole blood, serum|Both|50 Years|N/A|No|Non-Probability Sample|community sample|December 2015|January 21, 2016|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248806||112671|
NCT01249105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-160|MK-2206 for Recurrent Malignant Glioma|A Phase II Study of MK-2206 for Recurrent Malignant Glioma||Dana-Farber Cancer Institute|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 24, 2010|Yes|Yes|Merck (supplier of study drug & funding) has undergone a large reprioritization, in which they    had to terminate many oncology trials, including this one.|No||https://clinicaltrials.gov/show/NCT01249105||112648|
NCT01249118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEK4952g|An Absolute Bioavailability Study in Healthy Subjects Comparing Oral to Intravenous Administration of GDC-0973|A Phase 1, Single Dose, Randomized, Cross-over Absolute Bioavailability Study in Healthy Subjects Comparing Oral to Intravenous Administration of GDC-0973||Genentech, Inc.||Completed|November 2010|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 16, 2013|November 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01249118||112647|
NCT01249131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEK4953g|A Study of Relative Bioavailability and Food Effect Study of GDC-0973 in Healthy Subjects|A Phase I, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of GDC-0973 in Healthy Subjects||Genentech, Inc.||Completed|November 2010|||||Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2011|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01249131||112646|
NCT01249443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-078|Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection|A Phase 1 Study of Vorinostat in Combination With Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection||AIDS Malignancy Consortium|No|Recruiting|November 2013|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||November 2015|February 2, 2016|November 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01249443||112622|
NCT01250782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlnHSD-001-09|Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.|Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.|GluTrac|Hospital Universitari Son Dureta|Yes|Recruiting|October 2010|October 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2010|November 30, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250782||112521|
NCT01250795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FhCMB HAI-05-001|Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults|A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years||Fraunhofer, Center for Molecular Biotechnology||Active, not recruiting|November 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|100|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2011|September 19, 2011|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250795||112520|
NCT01250548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-293|The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)|The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment||Baylor Research Institute|Yes|Completed|May 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|August 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01250548||112539|
NCT01250561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-06-001|Reduction of Postherpetic Neuralgia in Herpes Zoster|||Center for Clinical Studies, Texas|Yes|Completed|February 2002|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|133|||Both|50 Years|N/A|No|||November 2010|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250561||112538|
NCT01260181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25434|A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations|Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor.||Hoffmann-La Roche||Active, not recruiting|March 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01260181||111799|
NCT01260480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NST-CA007|An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation|A Prospective, Multicenter Study, to Evaluate the Efficacy and Safety of [18F]-ML-10, a Positron Emission Tomography (PET) Imaging Radiotracer, in Early Detection of Response of Non-Hematological Tumors to Concurrent Chemoradiotherapy||Aposense Ltd.|No|Recruiting|December 2010|||February 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2010|December 16, 2010|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01260480||111776|
NCT01260714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02559|Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia|A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥ 60 With Poor Prognosis Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)|Yes|Terminated|December 2010|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|60 Years|N/A|No|||June 2015|August 18, 2015|December 14, 2010|No|Yes|Inadequate accrual rate|No||https://clinicaltrials.gov/show/NCT01260714||111758|
NCT01260727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 262|Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults|A Phase I Study of the Safety and Immunogenicity of PENNVAX-G DNA (ENV & GAG) Administered by Intramuscular Biojector 2000 or CELLECTRA Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 ENV/CM240 GAG/POL) Boost in Healthy, HIV Uninfected Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|February 2010|June 2015|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|92|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|December 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01260727||111757|
NCT01261065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-CDA|Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure|Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure||Michael Debakey Veterans Affairs Medical Center|No|Completed|December 2001|October 2005|Actual|October 2005|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|55|||Both|18 Years|N/A|No|||December 2010|December 15, 2010|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261065||111731|
NCT01256983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SleepTx-1|Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation|Daily Light Intervention in Renal Transplant Recipients Having a Sleep-Wake Dysregulation|SleepTx-1|University of Basel|Yes|Completed|October 2010|July 2013|Actual|June 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|December 8, 2010||No||No|September 26, 2013|https://clinicaltrials.gov/show/NCT01256983||112045|The study was very long and burdensome for the participants, a full powered study should be shorter.
NCT01257204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-031|Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection|A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 Infection||Bristol-Myers Squibb|No|Completed|December 2010|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|196|||Both|18 Years|70 Years|No|||November 2015|November 10, 2015|December 1, 2010|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01257204||112028|
NCT01257217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M09-051|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2010|||||N/A|N/A|N/A||||||||||||||July 13, 2011|December 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257217||112027|
NCT01257230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.444|Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma|A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma.||Boehringer Ingelheim||Completed|December 2010|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|398|||Both|12 Years|17 Years|No|||August 2014|August 27, 2014|December 6, 2010||||No|June 12, 2014|https://clinicaltrials.gov/show/NCT01257230||112026|
NCT01257503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39489-D|Homeopathic Cold Remedy for Children Study|Randomized Controlled Trial of a Homeopathic Cold Remedy for Children||University of Washington|No|Completed|December 2010|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|263|||Both|2 Years|5 Years|No|||December 2014|December 31, 2014|December 8, 2010||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01257503||112005|
NCT01252212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00019|Adherence, Improvement Measure (AIM) System|Adherence, Improvement Measure (AIM) System; Challenge Topic: 10-MH-101|AIM|University of California, San Francisco|No|Completed|August 2010|December 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|99|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01252212||112412|
NCT01252225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lidocaine1|Lidocaine: Effect of Lidocaine in Chronic Cough|Effect of Lidocaine and Its Delivery in Patients With Chronic Cough||University Hospital of South Manchester NHS Foundation Trust|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||September 2011|September 15, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01252225||112411|
NCT01248546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/144 (REK)|Tomosynthesis in the Oslo Breast Cancer Screening Program|Digital Breast Tomosynthesis in the Oslo Mammography Screening Program|DBT|Oslo University Hospital|No|Active, not recruiting|November 2010|September 2015|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25000|||Female|50 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 50 to 69 years attending the national breast cancer screening program who sign        an informed consent regarding participation in the trial|February 2013|February 4, 2013|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248546||112690|
NCT01251874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02552|Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer|A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2010|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01251874||112438|
NCT01251887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110028|Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition|Dietary Linoleic Acid Regulation of Omega-3HUFA Metabolism: Satiety and Body Composition Among Overweight Female Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|November 2010|June 2020|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|180|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|February 11, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251887||112437|
NCT01252186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSE-HSP-203|A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women|A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-Day Extended Cycle Oral Contraceptive Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women.||Teva Pharmaceutical Industries|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|265|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 27, 2015|November 30, 2010|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01252186||112414|
NCT01248832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA104573-5|Smokers' Quitline for Asian Language Speakers|Smokers' Quitline for Asian Language Speakers||University of California, San Diego|No|Completed|August 2004|November 2008|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2277|||Both|18 Years|75 Years|No|||December 2013|December 10, 2013|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248832||112669|
NCT01249729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97015|3D Reconstructed Image Processin by Computer Proram From MRI Data|3D Reconstructed Image Processin by Computer Proram||China Medical University Hospital|Yes|Not yet recruiting|September 2008|September 2009|Anticipated|||N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|||Both|1 Year|1 Year|Accepts Healthy Volunteers|Non-Probability Sample|The study expect to seek 100 patients to use the magnetic resonance imaging of brain        before and after the acupoint electroacupuncture, measuring the response of all the brain        activities, and then implement the two-dimentional image into three-dimensional image by        Amira software.|August 2008|November 26, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249729||112600|
NCT01249469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003024M|Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011|Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011 on Solar Lentigines by Harmonic Generation Microscopy||National Taiwan University Hospital|No|Recruiting|June 2010|June 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||April 2010|November 25, 2010|November 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01249469||112620|
NCT01250288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C023699-16|Usage of Health Information Exchange (HIE) Technologies|Patient Adoption and Use of Health Information Exchange (HIE) Technologies||Weill Medical College of Cornell University|No|Completed|April 2011|October 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|7800|||Both|18 Years|N/A|No|Non-Probability Sample|Consumers (patients and their proxies) and their healthcare providers who are being        exposed to a novel interoperable personal health management system in the Brooklyn        community.|December 2012|December 20, 2012|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250288||112558|
NCT01250301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qmul200910|De-nicotinised Cigarettes Study|Complementing Current NHS Stop Smoking Service Treatments for Smokers With Behavioural Replacement: The Role of De-nicotinised Cigarettes|Denic|Queen Mary University of London|No|Completed|July 2011|July 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250301||112557|
NCT01250535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0576|Human Cytochrome P450 4F Enzymes and Drug Interactions|Human Cytochrome P450 4F Enzymes and Drug Interactions||University of North Carolina, Chapel Hill|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01250535||112540|
NCT01249989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL075451|Make Better Choices|Make Better Choices (MBC) - Multiple Behavior Change in Diet and Activity|MBC2|Northwestern University|Yes|Completed|November 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|212|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01249989||112580|
NCT01250314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070121|Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density|Radiological, Biological, Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density|OSTEHOM|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2008|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|79|||Male|40 Years|70 Years|No|||July 2012|July 1, 2012|November 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01250314||112556|
NCT01250587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDC-3111|Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea|A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PDC31 in Patients With Primary Dysmenorrhea||PDC Biotech GmbH|Yes|Completed|November 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 20, 2012|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250587||112536|
NCT01251705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CompCornea|Comparation of Different Devices to Measure Corneal Thickness|Comparation of Different Devices to Measure Corneal Thickness||Technische Universität Dresden|No|Recruiting|November 2010|February 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|volunteers without corneal disease|December 2010|December 1, 2010|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251705||112451|
NCT01260493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VårdkedjaVårdal|Continuum of Care for Frail Elderly People|Continuum of Care, From the Emergency Ward to Living at Home - Implementation and Evaluation of an Intervention for Frail Elderly People||Vardalinstitutet The Swedish Institute for Health Sciences|No|Completed|October 2008|October 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|181|||Both|65 Years|N/A|No|||June 2014|June 11, 2014|November 30, 2010||No||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01260493||111775|
NCT01260740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110055|The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans|The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|272|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|August 5, 2015|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260740||111756|
NCT01260753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPh/00071/10|Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge|Double Blind Randomised Placebo and Active Controlled, Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge to Allergic Patients Otherwise Healthy||Palau Pharma S.A.||Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260753||111755|
NCT01260766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP003|Acne Treatment With Active Oplon's Patches - 15-18 Years Old|Phase II- Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid||Oplon-Pure Science Ltd.|Yes|Not yet recruiting|January 2011|June 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|65 Years|No|||December 2010|December 16, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260766||111754|
NCT01261078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-2010-12-05|The Bupivacaine Dose Sparing Effect of Intrathecal Epinephrine|The Bupivacaine Dose Sparing Effect of Intrathecal Epinephrine for Spinal Anesthesia in Total Knee Replacement Arthroplasty||Seoul Medical Center|No|Completed|December 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|5||Anticipated|75|||Both|40 Years|80 Years|No|||December 2010|July 19, 2011|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261078||111730|
NCT01257243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGPGEMS0110|Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment|Multicentric, Randomized, Open-label Trial to Evaluate the Superiority of Fixed Dose Combination of Oxomemazine, Guaifenesin and Potassium Iodate to Guaifenesin Monotherapy in Acute Cough Treatment||EMS|No|Recruiting|February 2013|September 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||February 2013|February 26, 2013|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257243||112025|
NCT01257516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081216|An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers|An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of 660 Mg (2 X 330 Mg Tablets) Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 300 Mg Of The Immediate Release Formulation Administered Twice Daily||Pfizer|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 17, 2011|December 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01257516||112004|
NCT01257763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU38370|Tolerability Study of the Application of a 3M Microstructure Transdermal System|Tolerability Study of the Application of a 3M Microstructure Transdermal System by Finger Pressure to the Face in Healthy Subjects Stratified by Age and Fitzpatrick Skin Type||Northwestern University|Yes|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|54|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257763||111985|
NCT01252238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p001286|Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance|Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance||Brigham and Women's Hospital||Terminated|June 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|75 Years|No|||June 2013|June 24, 2013|December 1, 2010||No|Study sponsor terminated study due to AE's reported with valsartan and aliskiren|No|June 24, 2013|https://clinicaltrials.gov/show/NCT01252238||112410|No conclusions can be drawn from study due to very low sample size. The sponsor terminated the study after a separate study reported adverse events in a diabetic population who had taken both valsartan and aliskiren.
NCT01248026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2010-035|Impact of Buttermilk on Cholesterol Concentration and Homeostasis|Impact of Buttermilk on Cholesterol Concentration and Homeostasis|BMILK|Laval University|No|Completed|January 2011|December 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01248026||112730|
NCT01248572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTHD-10-03|Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL|Evaluation of Lens Effective Position, Stability and Prediction With a 12mm Uniplanar, Biaspheric Intraocular Lens||Lenstec Incorporated|No|Completed|October 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|40 Years|N/A|No|||March 2014|March 17, 2014|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248572||112689|
NCT01248819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 04-2008|Local Anesthetic Nebulization and Instillation for Pain Control After Laparoscopic Surgery|Double Blind Randomized Phase III Controlled Trial Comparing the Effect of Intraperitoneal Nebulization of Ropivacaine With Intraperitoneal Instillation of Ropivacaine on Pain Control After Laparoscopic Cholecystectomy||San Gerardo Hospital|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||March 2008|November 24, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248819||112670|
NCT01248845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMG_titr|Comparative Effects on Diaphragmatic Electrical Activity and Respiratory Pattern of Various Levels of Assistance|Comparative Effects on Diaphragmatic Electrical Activity and Respiratory Pattern of Various Levels of Assistance in Pressure Support and in Neurally Adjusted Ventilatory Assist||University of Lausanne Hospitals|No|Recruiting|August 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|90 Years|No|||June 2015|June 7, 2015|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01248845||112668|
NCT01249157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-189|Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast|Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast||Memorial Sloan Kettering Cancer Center||Terminated|November 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Female|21 Years|N/A|No|||November 2015|November 19, 2015|November 24, 2010||No|Lack of accrual|No|October 17, 2015|https://clinicaltrials.gov/show/NCT01249157||112644|The first 5 patients who consent to the study were used for training purposes only.
NCT01250067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC92-2314-B-039-016|Motor-related Cortical Potential in Patients With Essential Tremor|||China Medical University Hospital||Completed|August 2003|||||N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||||||Both|20 Years|75 Years|No|||September 2005|November 26, 2010|November 26, 2010||||No||https://clinicaltrials.gov/show/NCT01250067||112575|
NCT01250600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU99-NCTU-12|Effects of Intelligent Tele-Cardiopulmonary Exercise System on Rehabilitation for Patients With Myocardial Infarction|Application of Intelligent Wireless and Portable Tele-Cardiopulmonary Exercise System on Rehabilitation for Patients With Myocardial Infarction||China Medical University Hospital||Not yet recruiting|January 2011|April 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||November 2010|November 29, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01250600||112535|
NCT01250834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11551|LY2189265 and Atorvastatin Interaction Study|Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|November 29, 2010|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01250834||112517|
NCT01250002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00025240|Lidocaine and Outpatient Gynecologic Laparoscopy|The Effect of Perioperative Systemic Lidocaine on Quality of Recovery After Outpatient Gynecologic Laparoscopy||Northwestern University|No|Completed|November 2010|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|64 Years|No|||June 2014|June 25, 2014|November 27, 2010|Yes|Yes||No|March 5, 2012|https://clinicaltrials.gov/show/NCT01250002||112579|Quality of recovery (QOR-40) instrument validation was performed in the in-patient setting and formal validation for the outpatient setting is still lacking.
NCT01250015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Does Numerical And Pictorial Information On Risk And Benefit Affects The Uptake Of Colorectal Cancer Screening?|THE RESULTS OF A RANDOMISED CONTROLLED QUESTIONNAIRE-BASED TRIAL ON WHETHER PROVISION OF NUMERICAL AND PICTORIAL INFORMATION ON RISK AND BENEFIT AFFECTS THE UPTAKE OF COLORECTAL CANCER SCREENING?||County Durham and Darlington NHS Foundation Trust|Yes|Completed|September 2007|September 2008|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|400|||Both|60 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects attending GP and hospital outpatients|March 2008|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250015||112578|
NCT01250327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080205|Medico-economic Evaluation of a Non-chirurgical Pulmonary Valve Replacement (REVALV)|Medico-economic Evaluation of a Non-chirurgical Pulmonary Valve Replacement for the Treatment of Lesions of the Ventricular Outflow Tract.|REVALV|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Both|5 Years|70 Years|No|||November 2010|September 17, 2013|November 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01250327||112555|
NCT01250574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2356|Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections|||University Hospital, Akershus|No|Active, not recruiting|November 2010|December 2016|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|173|||Both|18 Years|N/A|No|Non-Probability Sample|Department of Gastroenterological surgery|December 2015|December 29, 2015|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250574||112537|
NCT01251965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0450|Phase l/II Study of Ruxolitinib for Acute Leukemia|A Phase I/II Study to Determine the Safety and Efficacy of Ruxolitinib, a JAK1/JAK2 Inhibitor, in Subjects With Relapsed or Refractory Acute Leukemia||M.D. Anderson Cancer Center|No|Completed|December 2010|||October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|14 Years|N/A|No|||October 2015|October 14, 2015|November 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251965||112431|
NCT01255787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004/CCT-002|Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder|A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder||Takeda|No|Completed|November 2010|April 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|600|||Both|20 Years|64 Years|No|||October 2013|October 25, 2013|December 6, 2010||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01255787||112137|
NCT01260506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-111-122|Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme|||Vascular Biogenics Ltd. operating as VBL Therapeutics|Yes|Active, not recruiting|December 2010|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|December 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01260506||111774|
NCT01260519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSCC-00001- HT|Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coronary Angiography|Efficacy of a Single Dose Intravenous Heparin During Diagnostic Angiography in Reducing Sheath-clot Formation: A Randomized Controlled Trial||Prince Sultan Cardiac Center, Adult Cardiology Department.|No|Completed|July 2008|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|304|||Both|18 Years|80 Years|No|||December 2010|December 14, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01260519||111773|
NCT01260779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-10-EA-02|Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors|Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration||Provectus Pharmaceuticals||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||February 2016|February 23, 2016|December 13, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01260779||111753|
NCT01256996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-329/2009|Therapy of Peri-implantitis: Scaling Versus Low Abrasive Powder|A Randomized Multicenter Study in the Therapy of Periimplantitis: Scaling Versus Low Abrasive Powder||Heidelberg University||Enrolling by invitation|January 2011|January 2012|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||October 2010|December 8, 2010|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256996||112044|
NCT01257256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU-DMR99-IRB-246|Investigating the Relationships Among Illness Cognition, Social Support, Stress, and Emotional Reactions of Infertile Patients|Health Service Administration China Medical University|HSA-246|China Medical University Hospital|Yes|Recruiting|December 2010|June 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|simple random sampling|December 2010|December 8, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257256||112024|
NCT01225172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA191-011|Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors|A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors||Bristol-Myers Squibb|No|Completed|December 2010|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Female|18 Years|N/A|No|||December 2014|December 5, 2014|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225172||114471|
NCT01249820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 10.01 / SC25|Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease|Pharmacokinetics of Anidulafungin Given Intravenously as Antifungal Prophylaxis to Recipients of an Allogeneic Haematopoietic Stem Cell Transplant Following Myeloablative Chemotherapy or Patients Receiving Intensive Chemotherapy for AML-MDS|ANIDULAPK|Radboud University|No|Completed|November 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|64 Years|No|||January 2013|January 31, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01249820||112593|
NCT01252251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-123|RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma|A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252251||112409|
NCT01252264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDCR #: 10-183-E|FaceBase Biorepository|FaceBase Biorepository||University of Iowa|Yes|Recruiting|November 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|5000|Samples With DNA|-  A biological sample will be obtained by a blood draw. In adults, we will obtain a blood           sample of 1-2 tablespoons (10-30 mL). For children, the amount will be smaller           depending on their weight: 1 mL per kg to a maximum of 30 mL.        -  If a blood draw is refused, DNA can be taken from a cheek swab, spit sample or           fingerstick.        -  If a participant is having surgery for a medical reason, we may request a tissue sample           (for example: skin, bone, or muscle). If there were to be extra tissue, amniotic fluid,           other biological samples available from a procedure performed for clinical indications,           we may request a sample.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with a craniofacial anomaly and their family members.|November 2011|November 2, 2011|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01252264||112408|
NCT01248039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-FSP2|Preoperative Pain, Function, and Activity for Total Hip and Knee Arthroplasty Patients|The Influence of Preoperative Pain, Function, and Activity on Time to Fulfill Discharge Criteria for Total Hip and Knee Arthroplasty Patients||Hvidovre University Hospital|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Concesutive hip and knee arthroplasty patients from a department of orthopaedic surgery|July 2012|July 18, 2012|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248039||112729|
NCT01248052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13844|A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY2979165 in Healthy Subjects||Eli Lilly and Company|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|25|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 24, 2011|November 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01248052||112728|
NCT01248286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-0924|Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes|Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes||Icahn School of Medicine at Mount Sinai|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01248286||112710|
NCT01248585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC23|Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases|A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases||Canadian Cancer Trials Group|Yes|Completed|November 2010|November 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01248585||112688|
NCT01248598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-10-RMB CTIL|The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis|||Rambam Health Care Campus|No|Recruiting|October 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Patient of the Department of Periodontology, School of Graduate Dentistry Rambam Health        care campus|October 2010|November 24, 2010|November 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01248598||112687|
NCT01249183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPV03C|Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old|An Open-label, Randomised, Multicentre Study to Evaluate the Immunogenicity and Safety of a Booster Dose of Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Adsorbed Vaccine (REPEVAX) Administered Concomitantly Versus Non-concomitantly With an Influenza Vaccine (VAXIGRIP) to Subjects of 60 Years of Age and Older||Sanofi Pasteur MSD|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|954|||Both|60 Years|99 Years|Accepts Healthy Volunteers|||October 2011|November 27, 2015|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01249183||112642|
NCT01249170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010B0299|Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows|Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows||Ohio State University|No|Completed|November 2010|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||November 2013|November 15, 2013|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01249170||112643|
NCT01249794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO/URC/ER/mm 183/DG|Non Invasive Ventilation After Cardiac Surgery|Effectiveness of Continuous Positive Airway Pressure Outside the Intensive Care Unit After Cardiac Surgery|CPAP-CCH|Università Vita-Salute San Raffaele||Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249794||112595|
NCT01249807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-185|Taiwanese People's Willingness to Participate in Cancer Screening: Colon, Oral Cavity, Breast, and Cervical Cancer Screening|||China Medical University Hospital|Yes|Active, not recruiting|October 2010|||October 2010|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients patients' families Community people|November 2010|November 29, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249807||112594|
NCT01249456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFEM345DKR04|Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients|An Observational, Multicenter Study on the Safety and Efficacy of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients Who Completed Adjuvant Tamoxifen or Toremifen Treatment||Novartis||Completed|May 2006|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|392|||Female|N/A|N/A|No|Probability Sample|Postmenopausal early breast cancer patients who have finished adjuvant treatment with        Tamoxifen or Toremifen for 5 years after curative surgery as "indications" described in        local product labeling|June 2015|June 24, 2015|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249456||112621|
NCT01249742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007.13.003|Sugarsquare. Focus on the Adolescent: Digital Treatment of Type 1 Diabetes Through the Internet|Sugarsquare. Focus on the Adolescent: Digital Treatment of Type 1 Diabetes Through the Internet||Radboud University|No|Completed|February 2009|November 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|65|||Both|12 Years|21 Years|No|||November 2010|November 26, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01249742||112599|
NCT01249755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110901|International Validation of a Delirium Prediction Model for ICU Patients|International Validation of a Delirium Prediction Model for ICU Patients (PRE-DELIRIC) in ICUs; a Multicentre Trial.||Radboud University|No|Completed|November 2011|August 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to the ICU|August 2012|August 9, 2012|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249755||112598|
NCT01250041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-153-SDR|Continuous Saphenous Block Versus Continuous Femoral Block for Total Knee Arthroplasty|Continuous Saphenous Block Vs. Continuous Femoral Block for Total Knee Arthroplasty: Prospective, Randomized, Double Blind Study.||McGill University Health Center|No|Not yet recruiting|January 2011|December 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01250041||112577|
NCT01251406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-01-210|Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure|A Randomized, Parallel, Placebo-controlled, Double-blind Phase IIa Study of Efficacy and Safety of Recombinant Human Neuregulin-1 (Neucardin) in Subjects With Stable Chronic Heart Failure|ZS-01-210|Zensun Sci. & Tech. Co., Ltd.|Yes|Completed|January 2012|March 2014|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251406||112473|
NCT01251692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BQ-1-10-ARVO|Phototherapeutic Keratectomy (PTK) on Recurrent Corneal Erosions|Ten-year Results of Phototherapeutic Keratectomy on Recurrent Corneal Erosions|PTK x CE|Instituto de Olhos de Goiania|Yes|Completed|January 1996|January 2010|Actual|January 2000|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||November 2010|December 1, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251692||112452|
NCT01255800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0109.cc|Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer|A Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer: a Rational Anti-Cancer Stem Cell Combination.||University of Colorado, Denver|Yes|Completed|April 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|December 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01255800||112136|
NCT01248091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0|The Effect of Nitroprusside on Intrauterine Device (IUD) Insertion|The Effect of Nitroprusside on the IUD Insertion Experience in Nulliparous Women: a Pilot Study||Oregon Health and Science University|Yes|Completed|December 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 12, 2012|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248091||112725|
NCT01261091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-060/2009|Early Tracheostomy in Ventilated Stroke Patients|Stroke-Related Early Tracheostomy vs. Prolonged Orotracheal Intubation in Neurocritical Care Trial|SETPOINT|Heidelberg University|No|Completed|September 2009|April 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261091||111729|
NCT01249222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-230-402|Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasmapheresis|Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasma Therapeutic Exchange||Tehran University of Medical Sciences|Yes|Recruiting|November 2008|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|27|||Both|16 Years|N/A|No|||November 2010|November 26, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01249222||112639|
NCT01225185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APSF|Assessing Cerebral Blood Flow Autoregulation During Surgery in the Head-up Position|Assessing Cerebral Blood Flow Autoregulation in the Head-up Versus Supine Position During General Anesthesia and Its Relationship With Postoperative Neurocognitive Changes and Serum Biomarkers of Brain Injury||Johns Hopkins University|No|Completed|July 2010|April 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|240|||Both|18 Years|N/A|No|Non-Probability Sample|120 patients undergoing shoulder surgery in the supine lateral position and 120 subjects        undergoing surgery in the beach chair position.|August 2015|August 31, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01225185||114470|
NCT01249482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201008001M|Symptom Assessment for GERD Patients Receiving H. Pylori Eradication|Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication||National Taiwan University Hospital|No|Recruiting|September 2010|August 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|70 Years|No|Non-Probability Sample|Consecutive reflux patients documented by validated questionnaires (GerdQ) and upper        endoscopy will be enrolled from the outpatient clinic.|November 2010|December 10, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249482||112619|
NCT01249495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/736-2|Treatment of Chronic Leg Ulcer in Outpatient's Department and i Primary Care - Wound Size and Inflammation|Treatment of Chronic Legg Ulcer in Outpatient's Department and i Primary Care - Wound Size and Inflammation||Oslo University Hospital|No|Recruiting|November 2010|November 2013|Anticipated|November 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2010|December 9, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249495||112618|
NCT01225783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10095KCTIL|The Validity and Reliability of Self Measurement of Upper Limb Volume|The Validity and Reliability of Self Measurement of Upper Limb Volume in Treating Lymphedema in Breast Cancer Patients||Meir Medical Center|No|Recruiting|November 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|20 Years|80 Years|No|||March 2012|March 16, 2012|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225783||114425|
NCT01248884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113948|Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)|Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination||GlaxoSmithKline||Completed|December 2010|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|721|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||May 2014|July 3, 2014|November 24, 2010|Yes|Yes||No|May 8, 2014|https://clinicaltrials.gov/show/NCT01248884||112665|
NCT01248897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114021|Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib|A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy|BioPATH|GlaxoSmithKline|No|Completed|August 2010|September 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|158|Samples With DNA|Tumor tissues|Female|N/A|N/A|No|Probability Sample|Asia Pacific erb2+/HER2 Breast Cancer Patients|March 2015|April 23, 2015|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248897||112664|
NCT01249196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART_AD_III_2009|A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease|||SK Chemicals Co.,Ltd.||Completed|May 2010|||August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|256|||Both|55 Years|85 Years|No|||November 2010|November 25, 2013|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01249196||112641|
NCT01248065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 001|Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma|Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma|VIDA|Milton S. Hershey Medical Center|Yes|Completed|April 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|408|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|November 24, 2010|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01248065||112727|
NCT01248312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-208|Incidence of Hypercapnea in Morbidly Obese Post-Surgical Bariatric Patients Using the Sen Tec Transcutaneous PCO2 Monitor|Estimation of the Incidence of Hypercapnea in Morbidly Obese Post-Surgical Patients Using the Sen Tec Transcutaneous PCO2 Monitor||William Beaumont Hospitals|Yes|Completed|October 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 morbidly obese post surgical laparoscopic bariatric patients and 10 thin subjects        undergoing laparoscopic procedures|August 2012|August 17, 2012|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01248312||112708|
NCT01248299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-DIS 2010-06|Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.|A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable Toxicity After a 6-weeks Chemotherapy Course .|E-DIS|Centre Oscar Lambret|Yes|Recruiting|January 2011|September 2016|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248299||112709|
NCT01248611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFCP1-2010|Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer|Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer An Open Label Prospective Phase I b Study|NFCP1-2010|St. Olavs Hospital|No|Completed|January 2011|September 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01248611||112686|
NCT01254448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5619-238-CLP-003|Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease|Two-Part, Sequential Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TC-5619-238 in Elderly Subjects With and Without Alzheimer's Disease||Targacept Inc.|No|Completed|September 2010|May 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|38|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254448||112240|
NCT01250860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW-08-AM|Short-term Effects of the Simultaneous Use of Two Physiotherapeutic Methods in the Treatment of Adolescent Idiopathic Scoliosis - Pilot Study|Short-term Effects of the Simultaneous Use of Two Physiotherapeutic Methods in the Treatment of Adolescent Idiopathic Scoliosis - Pilot Study||Medical University of Silesia|Yes|Completed|May 2009|April 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Female|10 Years|16 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250860||112515|
NCT01250054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-319-C-018|Comparison of Two Multifocal Contact Lenses|||Alcon Research|No|Completed|October 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|35 Years|N/A|No|||July 2011|June 26, 2012|November 29, 2010|Yes|Yes||No|July 19, 2011|https://clinicaltrials.gov/show/NCT01250054||112576|
NCT01254708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGM201000428|Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients|A Pilot Study to Determine the Safety and Clinical Efficacy of Once-Weekly Inhaled AmBisome for the Prevention of Aspergillus Colonization in Lung Transplant Recipients||University Health Network, Toronto||Suspended|January 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|November 22, 2010||No|Study has been placed on hold due to unavailability of funding.|No||https://clinicaltrials.gov/show/NCT01254708||112220|
NCT01249768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADDO|Parkinson's Disease, Diagnostic Observations (PADDO)|Observational Study Assessing the Diagnostic Contribution of 3-Tesla MRI, CSF Analysis and a Second Opinion in a Specialized Movement Disorder Centre, in Differentiating Between Parkinson's Disease and Atypical Parkinsonism|PADDO|Radboud University|No|Active, not recruiting|July 2010|July 2015|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Whole blood, cerebrospinal fluids|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with a hypokinetic-rigid syndrome with a disease duration of maximum 36        months and in whom a definitive diagnosis has not been established yet.|September 2010|November 26, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249768||112597|
NCT01249781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-99-IRB-191|The Related Factors With Resilience in Caregivers Whose Child With Leukemia|||China Medical University Hospital||Enrolling by invitation|September 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|18 Years|No|Non-Probability Sample|Families of children was diagnosed acute lymphoblastic leukemia|November 2010|November 26, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249781||112596|
NCT01251120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25346|A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis|A Pragmatic, Randomized, Parallel Group Study of the Effect on Disease Remission, Work Productivity and Tolerability of Tocilizumab in Combination With DMARDs and Individually Designed Best Practice DMARD Therapy in Patients With Early, Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Terminated|November 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|November 30, 2010|No|Yes|The study was stopped prematurely due to lack of enrollment.|No|November 3, 2014|https://clinicaltrials.gov/show/NCT01251120||112495|
NCT01255488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R02930-S2|Research Abstract Usefulness in Clinical Decision-making|Family Nurse Practitioner Perception of Journal Abstract Usefulness in Clinical Decision-making: a Randomized Controlled Trial||Uniformed Services University of the Health Sciences|No|Not yet recruiting|December 2010|June 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|50|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2010|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255488||112160|
NCT01255501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0701-01|First in Human Study of NI-0701 in Healthy Volunteers|A First in Man Randomized Placebo Controlled Study of Single Ascending Intravenous Doses of NI-0701 in Healthy Volunteers||NovImmune SA||Completed||||||Phase 1|Interventional|N/A|2||||||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|December 6, 2010||||No||https://clinicaltrials.gov/show/NCT01255501||112159|
NCT01248351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAC_2009|Reversibility of Dual Antiplatelet Therapy by Platelets|Reversibility of Dual Antiplatelet Therapy by Platelets.Phase II Study||Medical University of Graz|No|Completed|November 2010|March 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2011|April 27, 2011|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01248351||112705|
NCT01257009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Statin sympathetic|Atorvastatin and Sympathetic Activity in Chronic Kidney Disease|Atorvastatin Reduces Sympathetic Activity in Patients With Chronic Kidney Disease||UMC Utrecht|Yes|Completed|August 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||10|||Both|18 Years|85 Years|No|||November 2010|December 8, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257009||112043|
NCT01229436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1531002|Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)|Prospective Open-Label Investigation Of The Non-surgical Treatment With Collagenase Clostridium Histolyticum (Xiapex)|POINT X|Pfizer|No|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|254|||Both|18 Years|70 Years|No|||January 2014|January 29, 2014|October 26, 2010||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01229436||114146|Results were not reported for fifth injection as no finger received 5 injections.Results are reported for 'number of days of concomitant pain medication' as 'amount of pain medication' was interpreted as total number of days with pain medication use.
NCT01257269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031/06|Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)|Thrombotic Thrombocytopenic Purpura Registry - A Prospective Observational Study for Patients Suffering From Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)|TTP registry|University Hospital Inselspital, Berne|No|Recruiting|October 2006|October 2030|Anticipated|||N/A|Observational|Observational Model: Case-Only||2|Anticipated|180|Samples With DNA|Whole blood and plasma|Both|N/A|N/A|No|Non-Probability Sample|Patients with either confirmed or with suspected hereditary TTP and their family members        are eligible for enrollment|February 2016|February 23, 2016|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01257269||112023|
NCT01225497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FV526|Eccentric Exercise for Chronic Mid-portion Achilles Tendinopathy|Effects of Two Eccentric Exercise Protocols on Reported Pain Intensity, Function, and Treatment Satisfaction in Adults With Chronic Mid-portion Achilles Tendinopathies||Queen Margaret University|No|Not yet recruiting|November 2010|February 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|70 Years|No|||September 2010|October 20, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01225497||114446|
NCT01225510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1131003|A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma|A Phase 2 Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Binding CovX-body, In Patients With Recurrent Glioblastoma||Pfizer|No|Withdrawn|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225510||114445|
NCT01257776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeTMAd/ICPD/2008|Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients|Using Mesenchymal Stem Cells From Adipose Tissue (CeTMAd) as Cell Regeneration Therapy in Chronic Ischemic Syndrome of Lower Limbs in Diabetic Patients||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Completed|December 2010|July 2015|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|85 Years|No|||November 2014|August 4, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257776||111984|
NCT01258062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-GEL-NT/001|Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults|Phase 1, Double Blind, Randomized, Placebo Controlled Study to Assess Safety and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults.||Nanotherapeutics, Inc.|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|7|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2012|January 23, 2012|December 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258062||111962|
NCT01253330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090445|Usage, Usability & Effect on Adherence and Clinical Outcomes of Text Message Reminders for Adolescents With Asthma|Study of the Usage, Usability, Acceptability, and Effect on Adherence and Clinical Outcomes of a Web Based Text Messaging System for Adolescents With Asthma- Phase 2||Children's Hospital Medical Center, Cincinnati|No|Completed|November 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|61|||Both|12 Years|22 Years|No|||February 2016|February 11, 2016|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01253330||112326|
NCT01249209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI HF Kongsvinger|Outpatient Treatment of Patients With Morbid Obesity - a Two-year Follow up|Qualitative Retrospective Study Where the Intervention Consisted of Group Therapy and Individual Interviews Over a Two-year Period||Sykehuset Innlandet HF|No|Completed|May 2010|October 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|60 Years|No|||June 2010|November 26, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01249209||112640|
NCT01253616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-T-01|Proof-of-Concept Study Assessing VNS Paired With Tones for Tinnitus|A Proof-of-Concept Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus||MicroTransponder Inc.|No|Completed|December 2010|June 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||August 2012|August 14, 2012|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253616||112304|
NCT01248624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0525-CE|Randomized Controlled Trial of Early Palliative Care for Patients With Advanced Cancer|Early Specialized Palliative Care Team Intervention for Patients With Metastatic Cancer: A Cluster Randomized Trial||University Health Network, Toronto|Yes|Active, not recruiting|December 2006|June 2016|Anticipated|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|461|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01248624||112685|
NCT01248858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113794|Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.|A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.||GlaxoSmithKline|No|Terminated|December 2010|June 2015|Anticipated|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||April 2015|June 25, 2015|November 18, 2010|No|Yes|The reason for termination was lack of tolerability and efficacy of the combination treatment|No||https://clinicaltrials.gov/show/NCT01248858||112667|
NCT01248871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAPOR 001|"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail|"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail||University Medical Center Groningen|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|120|||Both|18 Years|80 Years|No|||December 2012|December 18, 2012|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248871||112666|
NCT01250873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12611|A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline|LY2216684 and Sertraline Pharmacokinetic Interaction Study in Healthy Subjects||Eli Lilly and Company|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01250873||112514|
NCT01251133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-VHCL004|Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study|A Phase III Study to Assess Immunogenicity and Safety of 4th LBVH0101 Vaccination Compared With 4th Hiberix™ Vaccination in Healthy Toddlers Who Completed Primary Vaccination in LG-VHCL002 Study||LG Life Sciences|Yes|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|122|||Both|12 Months|15 Months|No|||November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251133||112494|
NCT01254721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00086|A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study|A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative, Phase 4 Study|STAR|AstraZeneca|No|Terminated|December 2010|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|65 Years|No|||April 2014|April 9, 2014|December 3, 2010|Yes|Yes|Difficulty of recruitment.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT01254721||112219|
NCT01250847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMS-4001|Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)|Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)|ES-ARMS|Severance Hospital|Yes|Recruiting|November 2010|October 2012|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|83|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||November 2010|August 18, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250847||112516|
NCT01255241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-10CTIL|The Effect of Lower Limb Deformities (LLD) on Children's Gait and on Energy Expenditure|The Effect of Lower Limb Deformities (LLD) on Children's Gait and on Energy Expenditure|LLD|Rambam Health Care Campus|No|Recruiting|February 2011|August 2014|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|6 Years|18 Years|No|Non-Probability Sample|Thirty patients will be recuited from primary care clinic|July 2011|July 28, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255241||112179|
NCT01255254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB 0350-10 CTIL|The Effect of Oral Hygiene and Full Mouth Scaling on Metabolic Control in Patients With Type II Diabetes|||Rambam Health Care Campus|No|Recruiting|August 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|75 Years|No|||August 2010|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255254||112178|
NCT01252303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0639-F3R|The Effect of Nutrisystem Meal Provision on Weight|The Effect of a Behavioral Weight Loss Program With Nutrisystem Meal Provision on Change in Weight, Fasting Blood Glucose, Cholesterol, and Blood Pressure Over 12 Weeks.||University of Kentucky|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01252303||112405|
NCT01248962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-184|Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer|Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in theTreatment of Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|21 Years|N/A|No|||February 2016|February 18, 2016|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248962||112659|
NCT01229137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE-SENSE|Physiological Response to Exercise: Sensor Evaluation at Specified Exertions|Physiological Response to Exercise: Sensor Evaluation at Specified Exertions|PRE-SENSE|Boston Scientific Corporation|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|71|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients with an implanted CRT-D|September 2012|September 10, 2012|October 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01229137||114169|
NCT01257022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA025894-01|Familias Unidas: Preventing Drug Abuse and HIV in Hispanic First Offenders|Preventing Drug Abuse and HIV in Hispanic First Offenders||University of Miami|Yes|Completed|August 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|242|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257022||112042|
NCT01258075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEL-307|Colesevelam Pediatric Type 2 Diabetes Mellitus Study|Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects With Type 2 Diabetes Mellitus|WELKid DM|Daiichi Sankyo Inc.|Yes|Recruiting|November 2010|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|230|||Both|10 Years|17 Years|No|||November 2015|November 4, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258075||111961|
NCT01257529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081227|An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Evaluate The Effects Of A Low, Medium And High Fat Evening Meal On The Pharmacokinetics Of Pregabalin Controlled Release Formulation As Compared To The Immediate Release Formulation||Pfizer|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|December 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01257529||112003|
NCT01250106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotic-01|Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications|Phase I Study of Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications||German Diabetes Center|No|Recruiting|November 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01250106||112572|
NCT01249833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAI-001-10|Effect of Oseltamivir on Cognitive Function in Subjects With Influenza|Randomised, Open-label, Multi-Centre, Phase IV Study Assessing the Effect of Oseltamivir Treatment on Cognitive Function in Subjects With Confirmed Influenza Virus Infection|FOCUS|Trial Management Group Inc.|No|Completed|November 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|65 Years|No|||September 2012|April 18, 2013|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249833||112592|
NCT01253642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005688|Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel|A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy||OHSU Knight Cancer Institute|Yes|Recruiting|July 2010|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253642||112302|
NCT01253655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1961009|To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers|A Phase 1, Open-Label Study To Evaluate 5-HT6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]PF-04171252 Following Single Oral Dose Administration Of PF-05212365 (SAM-531) In Healthy Subjects|3193A1-1103|Pfizer|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 26, 2011|November 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253655||112301|
NCT01253629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2212|Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome||Novartis||Completed|November 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|175|||Both|18 Years|45 Years|No|||July 2014|July 8, 2014|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253629||112303|
NCT01253902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LUM-09-014|Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|164|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|December 2, 2010|Yes|Yes||No|October 8, 2012|https://clinicaltrials.gov/show/NCT01253902||112282|
NCT01254123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL28593.029.09|Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)|Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)|EXAMI|VU University Medical Center|No|Recruiting|November 2009|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2010|December 3, 2010|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254123||112265|
NCT01250886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|456/2553(EC2)|Acid-base Balance in Patients Undergoing Colonoscopy|Intravenous Fluid Administration in Patients Undergoing Colonoscopy: Double Blind, Randomised Clinical Trial of Underlying Acid-base Derangement||Mahidol University|Yes|Enrolling by invitation|December 2010|April 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250886||112513|
NCT01251146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200006-515|A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension|Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Patients With Essential Hypertension||Merck KGaA||Completed|November 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|177|||Both|25 Years|65 Years|No|||January 2014|January 20, 2014|November 30, 2010||No||No|November 1, 2012|https://clinicaltrials.gov/show/NCT01251146||112493|
NCT01251419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002|The Impact of Social Proximity on Conversion to Generic Prescription Medications|The Impact of Social Proximity on Conversion to Generic Prescription Medications||National Bureau of Economic Research, Inc.|No|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|10000|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251419||112472|
NCT01251432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09040437|Risk Factors and Potential Causes of Eustachian Tube Dysfunction in Adults|Risk Factors and Potential Causes of Eustachian Tube Dysfunction in Adults With Clinically Diagnosed Chronic Otitis Media With Effusion and/or Eustachian Tube Dysfunction||University of Pittsburgh|No|Active, not recruiting|June 2010|June 2018|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|75 Years|No|Non-Probability Sample|adults with tympanostomy tube(s) for chronic otitis media and/or eustachian tube        dysfunction|February 2016|February 26, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251432||112471|
NCT01254981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090103|SORT-OUT V - Randomised Clinical Comparative Study of the Nobori and the Cypher Stent.|Randomized Clinical Comparative Study of the Nobori and the Cypher Stents in Unselected Subjects With Ischemic Heart Disease|SORT-OUT V|Aarhus University Hospital Skejby|Yes|Completed|July 2009|December 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2504|||Both|N/A|N/A|No|||August 2013|August 28, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01254981||112199|
NCT01251718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART06T|Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease|Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease||Eisai Inc.||Active, not recruiting|October 2010|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Alzheimer's Disease|April 2015|April 20, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251718||112450|
NCT01251991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022822-34|Cholesterol Lowering Treatment With Psyllium Husks and Isolated Soy Protein in Hypercholesterolemia|Additive Cholesterol Lowering Effect by Concomitant Treatment With Psyllium Husks and Isolated Soy Protein in Addition to Heart-healthy Diet in Hypercholesterolemia|ProFi|Aalborg Universitetshospital|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|41|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2011|January 28, 2014|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251991||112429|
NCT01248104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100064|Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery|Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery||Loma Linda University|No|Active, not recruiting|March 2010|February 2015|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248104||112724|
NCT01248689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-IM-0553-CTIL|Effect of Sevoflurane Concentration on Intraocular Pressure in Surgical Children With Healthy Eyes|The Effect of Different Concentrations of Sevoflorane on Intraocular Pressure in Children Undergoing Ocular Surgery Under General Anesthesia||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2011|June 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Anticipated|21|||Both|N/A|18 Years|No|||November 2010|November 23, 2010|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248689||112680|
NCT01248702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01537|A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy|A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy|CAPTURE|University of British Columbia|No|Not yet recruiting|April 2012|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01248702||112679|
NCT01248975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114387|Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID||GlaxoSmithKline|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|145|||Female|18 Years|N/A|No|||April 2012|June 14, 2012|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248975||112658|
NCT01261117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STO5336205575|Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants|Oral Versus Intravenous Ibuprofen Treatment||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Completed|January 2009|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|7 Days|No|||November 2010|August 8, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01261117||111727|
NCT01261130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-10-01|Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults|Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With or Without GLA-AF in Brazilian Adults||Albert B. Sabin Vaccine Institute|Yes|Completed|November 2011|December 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|13||Actual|102|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|December 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01261130||111726|
NCT01257789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHM-GB learning study|Eliminating Learning Curve Related Morbidity in Fast Track Laparoscopic Roux-en-Y Gastric Bypass|Structured Bariatric Fellowship Programme Moelholm Private Hospital - Denmark. Learning Laparoscopic RY - Gastric Bypass One Way to do it||Private Hospital Moelholm|No|Completed|March 2009|February 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Female|18 Years|65 Years|No|Non-Probability Sample|300 consequtive patients already sceduled for laparoscopic gastric bypass surgery|February 2010|December 9, 2010|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257789||111983|
NCT01258322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neph-1000|Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients|Twelve Weeks of Pioglitazone Therapy Significantly Attenuates Dysmetabolism and Reduces Inflammation in Prevalent Peritoneal Dialysis Patients. A Randomized, Cross-over Trial.||Huashan Hospital|Yes|Completed|January 2008|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|N/A|N/A|No|||March 2007|December 9, 2010|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258322||111942|
NCT01258296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-04804|Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction|Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction|Fentanyl Patch|University of California, San Francisco|Yes|Completed|February 2003|August 2007|Actual|August 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||December 2010|December 9, 2010|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258296||111944|
NCT01258309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Olo-keto/2009|Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis|||Allergan|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258309||111943|
NCT01237405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018123|A Study of FolateScan in Patients With Knee Osteoarthritis|Study of 99mTc-EC20 Imaging (FolateScan) in Participants With Knee Osteoarthritis||Duke University|Yes|Completed|October 2010|October 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|25|Samples With DNA|whole blood, serum, urine, synovial fluid|Both|18 Years|N/A|No|Non-Probability Sample|Males and females over the age of 18 years with at least one symptomatic knee with        evidence of osteoarthritis on radiograph.|November 2012|November 26, 2012|October 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01237405||113538|
NCT01237678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immunogen 0007|A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer|A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer||ImmunoGen, Inc.|Yes|Completed|November 2010|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|145|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01237678||113517|
NCT01237691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPPN1110F01|An Evaluation of California's Experiment With HOPE|Phase 1 Study of California's HOPE Experiment||Pepperdine University|Yes|Active, not recruiting|November 2010|March 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|105|||Male|18 Years|N/A|No|||August 2011|August 9, 2011|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01237691||113516|
NCT01237652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESA 5971|Perioperative Myocardial Ischemia in Isolated Systolic Hypertension|Perioperative Myocardial Ischemia in Isolated Systolic Hypertension (PROMISE)|PROMISE|Ottawa Hospital Research Institute|No|Completed|November 2006|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|312|||Both|45 Years|N/A|No|Non-Probability Sample|Perioperative ISH and normotensive presenting for Non-cardiac surgery|November 2010|November 8, 2010|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01237652||113519|
NCT01237665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTT 09-02|IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer|A Phase II Trial of Neoadjuvant IXO Regimen (Irinotecan, Capecitabine [Xeloda], Oxaliplatin) Followed by Combined Modality Capecitabine and Radiation for Locally Resectable Advanced Rectal Cancer|IXOr|Ottawa Hospital Research Institute|Yes|Active, not recruiting|September 2010|December 2017|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||October 2012|October 12, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01237665||113518|
NCT01235182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADMB2010|Ultrasound in Acute Dyspnea in the Field|Combination of Lung Ultrasound(a Comet-tail Sign) and N-terminal Pro-brain Natriuretic Paptide in Differentiating Acute Dyspnea in Prehospital Emergency Setting||University Clinical Centre, Maribor|No|Completed|July 2007|August 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|248|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with acute dyspnea in the time o the investigation in the field-prehospital        settingInclusion criterion for the study was shortness of breath as the primary complaint        (defined as either the sudden onset of dyspnea without history of chronic dyspnea or an        increase in the severity of chronic dyspnea). Exclusion criteria were age <18 years,        history of renal insufficiency, trauma, severe coronary ischemia (unless patient's        predominant presentation was dyspnea), and other causes of dyspnea: pneumonia, pulmonary        embolism, carcinoma, pneumothorax, pleural effusion, intoxications (drugs), anaphylactic        reactions, upper airway obstruction, bronchial stenosis, and gastroesophageal reflux        disorder, according to the history, clinical status, and additional laboratory tests        available in prehospital setting (D-dimer, troponin, C-reactive protein)|July 2007|November 4, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235182||113708|
NCT01238276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 75,736|Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion|Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion|DAD|Sonescence, Inc.||Available|January 2014|||December 2015|Anticipated|Phase 1|Expanded Access|N/A|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 8, 2010|No|Yes||||https://clinicaltrials.gov/show/NCT01238276||113472|
NCT01234077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPC M1|Study Comparing In-laboratory Polysomnography Electrocardiogram (PSG ECG) to Simultaneously Recorded In-laboratory ECG on the CPC M1 Device|A Single Blind Randomized Study Comparing In-laboratory Polysomnography Electrocardiogram to Simultaneously Recorded In-laboratory Electrocardiogram on the CPC M1 Device and Compared to Home Recorded Electrocardiogram With the CPC M1 Device.||National Jewish Health|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|70 Years|No|||April 2015|April 14, 2015|October 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234077||113793|
NCT01234350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE200486 CS39|Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer|A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With Firmagon (Degarelix) on a GnRH Agonist||Ferring Pharmaceuticals|Yes|Active, not recruiting|January 2011|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1511|||Male|N/A|N/A|No|Non-Probability Sample|Patients with prostate cancer from primary care|October 2015|October 22, 2015|November 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01234350||113772|
NCT01234363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.590|Renal Allograft : Evaluation of Parenchymal Fibrosis by Elastography|Evaluation of the Potential of Elastography for Noninvasive Assessment of Fibrosis in Kidney Transplant|GREFE|Hospices Civils de Lyon|Yes|Recruiting|May 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01234363||113771|
NCT01234623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2008-005757-38|Cord Blood Serum in the Treatment of Ocular Surface Diseases|Pilot Phase. Cord Blood Serum in the Treatment of Ocular Surface Diseases||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Adult outpatients suffering from ocular surface discomfort and recurrent or permanent        corneal epithelial defects|April 2011|May 25, 2011|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01234623||113751|
NCT01234636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RINH_1000|Conjugated Linoleic Acid Supplementation Study|Effects of cis9,trans11 Conjugated Linoleic Acid on Platelet Function, Markers of Haemostasis and Inflammation on Humans|CLASS|University of Aberdeen|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|30 Years|74 Years|Accepts Healthy Volunteers|||November 2015|November 12, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234636||113750|
NCT01236105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12814|Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject|Evaluation of the Impact of Activated Charcoal and Time of Dose on the Absorption of LY2624803 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 17, 2011|November 4, 2010|No|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT01236105||113638|
NCT01236118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13625|A Study of LY2439821 in Rheumatoid Arthritis|An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate||Eli Lilly and Company|No|Completed|December 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Both|20 Years|N/A|No|||February 2013|February 12, 2013|November 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01236118||113637|
NCT01249898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luria004-HMO-CTIL|The Treatment and Intra-operative Imaging of Scaphoid Fracture Reduction and Fixation|||Hadassah Medical Organization||Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|85 Years|No|Probability Sample|Patients that suffer fron Scaphoid fractures(nonunion included).|February 2014|March 3, 2014|November 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01249898||112587|
NCT01249586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELBPS|E-learning: Teaching of Blindness Prevention|E-learning as a Complement to Traditional Teaching of Blindness Prevention|ELBPS|Clinica Oftamologica Zona Sul|No|Completed|February 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|N/A|1||||||Both|18 Years|40 Years||||November 2010|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249586||112611|
NCT01249885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112010hmo-ctil|Implications of Pacifier Use in Israeli Children|Observational Study - Pacifier Use in Israeli Children||Hadassah Medical Organization|No|Not yet recruiting|January 2011|January 2013|Anticipated|January 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|400|||Both|2 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|400 children|November 2010|November 29, 2010|November 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01249885||112588|
NCT01250444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREMVEN|Effects of Inspiratory Muscle Training on Cardiovascular Function in Hypertension.|Inspiratory Muscle Training: Effects on Blood Pressure, Heart Rate Variability and Functional Capacity in Hypertensive Patients.|TREMVEN|Federal University of Health Science of Porto Alegre|Yes|Active, not recruiting|March 2009|||July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|14|||Both|30 Years|70 Years|No|||October 2010|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250444||112546|
NCT01250717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P-001577|Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer|Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer||Dana-Farber Cancer Institute|Yes|Completed|January 2001|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|N/A|No|||August 2012|December 16, 2013|November 23, 2010|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT01250717||112526|Although this study has the longest median follow-up periods reported (80 months or 6.6 years), the overall number of participants is too few to make strong judgements about efficacy
NCT01236300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-2010-INSPECT|In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors|In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors|INSPECT|University of Chicago|Yes|Completed|July 2010|May 2012|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|November 5, 2010|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01236300||113623|
NCT01236313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005011039|Aortic Wall and Left Ventricular Mechanics: Echocardiographic and Hemodynamic Analysis|Aortic Wall and Left Ventricular Mechanics: Echocardiographic and Hemodynamic Analysis||Weill Medical College of Cornell University|No|Terminated|July 2010|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients undergoing bypass and/or valve surgery with general anesthesia|February 2016|February 16, 2016|November 4, 2010||No|Insufficient recruitment to complete study|No||https://clinicaltrials.gov/show/NCT01236313||113622|
NCT01236586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110017|RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia|A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia||National Institutes of Health Clinical Center (CC)||Withdrawn|October 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|21 Years|No|||April 2011|December 30, 2011|November 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01236586||113601|
NCT01236820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTCHANG001|A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients|L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients|L5|China Medical University Hospital|No|Recruiting|September 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|48|Samples Without DNA|Blood|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents in Taiwan, mostly in Taichung area|November 2010|November 8, 2010|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236820||113583|
NCT01237158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nov 2010|Genetic Association Study Between GAD1 and Reelin Polymorphisms and GABA/Glutamate MRS in Bipolar Disorder Type 1 and Healthy Controls: SPECGENE PROJECT|Genetic Association Study Between GAD1 and Reelin Polymorphisms and GABA/Glutamate MRS in Bipolar Disorder Type 1 and Healthy Controls: SPECGENE PROJECT|SPECGENE|University of Sao Paulo|Yes|Recruiting|October 2010|||October 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|140|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Bipolar Disorder Patients|October 2010|August 15, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237158||113557|
NCT01234662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CESAR|Influence of Surgical Regional Anesthesia on Postoperative Pain|Combined Spinal Epidural Anesthesia (CSE) vs Spinal Anesthesia for Elective Cesarean Sections. Influence of Surgical Regional Anesthesia on Postoperative Pain|CESAR|Charite University, Berlin, Germany|No|Active, not recruiting|November 2010|December 2012|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|171|||Female|18 Years|N/A|No|||May 2012|May 31, 2012|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234662||113748|
NCT01238003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-10-0087|Clinical Relevance of Anti-Neutrophil Cytoplasm Antibody (ANCA)in Hospitalized Patients|||Hillel Yaffe Medical Center||Not yet recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|380|||Both|N/A|N/A|No|Probability Sample|Patients hospitalized in internal medicine ward|November 2010|November 9, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238003||113492|
NCT01238016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01A03|Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - a Pilot Study|Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - a Pilot Study - A One Month Non-controlled Observational Study|Pilot|Hypo-Safe A/S|No|Suspended|November 2010|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|August 31, 2015|November 8, 2010||No|Replaced by new study|No||https://clinicaltrials.gov/show/NCT01238016||113491|
NCT01238029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907-002|Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer|Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab|CELAVIE|Sponsor GmbH|Yes|Terminated|October 2010|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||November 2014|November 20, 2014|November 2, 2010||No|new methods of treatment, no more patients appilicable for study|No||https://clinicaltrials.gov/show/NCT01238029||113490|
NCT01234948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|self funded|Oral Malodour and Periodontal Disease-related Parameters|Oral Malodour and Periodontal Disease-related Parameters. Clinical and Real-time PCR Findings||Aristotle University Of Thessaloniki|No|Completed|January 2008|September 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|78|Samples With DNA|The tongue coating was collected with repeated strokes under relative pressure, using a      sterile plastic microbiology loop of 10μl capacity from the terminal sulcus to the apex of      the tongue. Samples were stored on ice in 1.5ml sterile Eppendorf tubes containing 0.4ml      purified H2O. After vortex mixing for 30 seconds to evenly disperse the material the samples      were stored at -70oC until required. The laboratory analysis was performed blind. Once      thawed the tongue specimen was vortex mixed for 30 seconds and an aliquot was taken for      subsequent use in the real-time PCR analysis. Lysates of samples were prepared by boiling      the aliquot for 10 minutes after puncturing the cap with a fine sterile needle to prevent      pressure build up.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Systemically healthy non-smokers were screened for oral halitosis in the Department of        Periodontology, Aristotle University of Thessaloniki, Greece.|November 2010|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234948||113726|
NCT01234090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01628|Living With Aphasia: An International Study|Living With Aphasia: An International Study||New York University School of Medicine|Yes|Terminated|June 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Probability Sample|Inpatient/outpatient hospital population|December 2015|December 9, 2015|October 15, 2010||No|Funding stopped|No||https://clinicaltrials.gov/show/NCT01234090||113792|
NCT01234376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0003|Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis|Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis||University of Erlangen-Nürnberg Medical School|No|Recruiting|November 2010|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|45|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patients with eosinophilic esophagitis who underwent EGD for the evaluation of their        symptoms.        Control patients who underwent EGD because of other reasons.|January 2013|January 23, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234376||113770|
NCT01234649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP10-012|Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)|Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)||Woman's|Yes|Recruiting|August 2011|October 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234649||113749|
NCT01234922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98710|Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors|A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension||Comprehensive Cancer Center of Wake Forest University|No|Terminated|February 2011|April 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|November 3, 2010||No|slow accrual|No|December 9, 2014|https://clinicaltrials.gov/show/NCT01234922||113728|
NCT01235169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEIL02-HMO-CTIL|Evaluation of the Proximal Femoral Nail Antirotation With Cement Augmentation in Osteoporotic Femoral Neck Fractures|||Hadassah Medical Organization||Not yet recruiting||||March 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Both|60 Years|90 Years|No|||March 2013|March 21, 2013|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235169||113709|
NCT01235494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15080|Development of New MRI Pulse Sequences for Probing Lung Function in Volunteers With Hyperpolarised 3He Gas|Development of New MRI Pulse Sequences for Probing Lung Function in Volunteers With Hyperpolarised 3He Gas||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|July 2010|||April 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235494||113684|
NCT01236664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB1043|An Evaluation of the Memory at Work Program|An Evaluation of the Memory at Work Program||Baycrest|No|Withdrawn|January 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 11, 2011|November 8, 2010||No|The sponsor is no longer developing this program and therefore has withdrawn the funding.|No||https://clinicaltrials.gov/show/NCT01236664||113595|
NCT01249911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LreuteriMexico|Lactobacillus Reuteri DSM 17938 and Prevention of Respiratory and Gastrointestinal Infections in Mexican Infants|Efficacy & Cost-Effectiveness of Lactobacillus Reuteri DSM 17938 Administration to Prevent the Risk of Respiratory or Gastrointestinal Infections in Child Day Care Centers: A Randomized, Double Blind, Placebo Control Trial (RDDCT).||National Institute of Pediatrics, Mexico|Yes|Not yet recruiting|January 2011|June 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|269|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||November 2010|November 29, 2010|November 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01249911||112586|
NCT01250171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPJMR0092202|The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients|A Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Intravenous Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Syndrome||Novartis||Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|85 Years|No|||December 2012|December 4, 2012|November 29, 2010|Yes|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT01250171||112567|
NCT01250457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202688|Topical Timolol for the Treatment of Benign Vascular Periocular Lesions|Topical Timolol for the Treatment of Benign Vascular Periocular Lesions||Loyola University|No|Withdrawn|June 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|November 29, 2010|Yes|Yes|Unknown, PI has left the institution. There was no enrollment.|No||https://clinicaltrials.gov/show/NCT01250457||112545|
NCT01250730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081022|A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066|A Phase 1, Open Label, Dose Escalation, Single Oral Dose Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066||Pfizer|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|18|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|November 17, 2010|No|Yes||No|October 20, 2011|https://clinicaltrials.gov/show/NCT01250730||112525|
NCT01236326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009011249|Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation|A Randomized, Prospective, Parallel Group Study of Conventional Laparoscopic Donor Nephrectomy (LDN) Versus Laparoendoscopic Single Site Donor Nephrectomy (LESS-DN) in Living Donor Kidney Transplantation||Weill Medical College of Cornell University|No|Completed|November 2010|October 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|November 4, 2010||No||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01236326||113621|Inability to secure complete data on the donor questionnaires (25% of subjects did not return 2-month questionnaire); no validated tool available to assess donor recovery and satisfaction; clinical donor follow-up was suboptimal.
NCT01236599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMCT-01|Thermoregulation in the Preterm Infant|Comparison of Polyethylene Wrap With and Without Previous Drying in Preterm Infants: A Randomized Clinical Trial.||Instituto Mexicano del Seguro Social|Yes|Completed|August 2009|June 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|28 Weeks|37 Weeks|Accepts Healthy Volunteers|||November 2010|November 5, 2010|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236599||113600|
NCT01236612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHMI9|Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|EHMI9|Radboud University|Yes|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|25|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01236612||113599|
NCT01236833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-225-PED|Lactated Ringer's Solution in Neonates With Feeding Intolerance|Enteral Administration of Lactated Ringer's Solution in Neonates With Feeding Intolerance, a Randomized Controlled Trial|LR|McGill University Health Center|Yes|Active, not recruiting|November 2010|September 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||August 2011|August 2, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236833||113582|
NCT01237145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIRD01|Bronchoalveolar Immune Response Determination|Study to Determine the Immune Response From Broncho-alveolar Cells Against Pigeon Specific Antigens|BIRD|Bossink, A.W.J.|No|Not yet recruiting|September 2011|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|Samples Without DNA|Cells obtained from Broncho alveolar lavage and blood collection|Both|18 Years|N/A|No|Non-Probability Sample|Patients suspected to have pigeon induced extrinsic allergic alveolitis will be recruited        by advertisment in bird fanciers journals. Controls will be patients at the department of        pulmonology and tuberculosis needing examination for other reasons|June 2011|June 14, 2011|November 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01237145||113558|
NCT01237431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-MHH-Hep_Reflex-EK5413|Importance of Liver Innervation for the Osmopressor Response in Humans|Importance of Liver Innervation for the Osmopressor Response in Humans|HEP-Reflex|Hannover Medical School|No|Completed|November 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|60 Years|No|||August 2009|February 22, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237431||113536|
NCT01237444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH-10 GARDEL study|Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.|A Phase 3, Randomized, Open Label, Controlled Study of Lopinavir/Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.|GARDEL|The Huesped Foundation|Yes|Completed|December 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|417|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237444||113535|
NCT01234935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIO-TORI PA-01|Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery|A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma||Translational Oncology Research International|Yes|Active, not recruiting|January 2011|October 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234935||113727|
NCT01234961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS2005_ME|Outcome Study of the ReDO Intervention for Women With Stress-related Disorders|Outcomes of the Work Rehabilitation Method Redesigning Daily Occupations (ReDO) - a Quasi-experimental Study Among Women With Stress-related Disorders||Lund University|No|Completed|September 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|20 Years|64 Years|No|||November 2012|November 13, 2012|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234961||113725|
NCT01235221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218MS301|Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.|Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials||Biogen|No|Completed|December 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|70 Years|No|||July 2014|July 3, 2014|November 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01235221||113705|
NCT01235507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25303|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)|Actemra - Local Bosnian Open, Multicentric, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis After Inadequate Response to DMARDs||Hoffmann-La Roche||Completed|February 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|October 15, 2010|No|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT01235507||113683|
NCT01235832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE 106|The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors|The Effect of One Avocado Per Day on Established and Emerging Cardiovascular Disease (CVD) Risk Factors||Penn State University|No|Completed|November 2010|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|54|||Both|21 Years|70 Years|No|||April 2015|April 27, 2015|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01235832||113659|
NCT01236144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON 845-10|A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.|An NCRI Acute Myeloid Leukaemia Working Group Pilot Trial Under the Auspices of the Cardiff Experimental Cancer Medicine Centre to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.|AML18 Pilot|Cardiff University|Yes|Completed|April 2011|January 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|113|||Both|60 Years|N/A|No|||June 2014|June 10, 2014|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236144||113635|
NCT01236391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1104-CA|Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)|Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma|PCYC-1104-CA|Pharmacyclics|No|Completed|February 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|October 18, 2010|No|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01236391||113616|
NCT01236404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB1023-PT-CL-0001|Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus|Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)||PhaseBio Pharmaceuticals Inc.|Yes|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||May 2013|May 13, 2013|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236404||113615|
NCT01236417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 169310|Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia|Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia||Roswell Park Cancer Institute|Yes|Completed|March 2010|||March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|27|||Female|18 Years|N/A|No|||April 2012|April 12, 2012|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236417||113614|
NCT01236430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07551|A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)|A Study to Evaluate the Definitive Bioequivalence of SCH 900068 With Marketed Products (Protocol No. P07551)||Merck Sharp & Dohme Corp.|No|Completed|February 2011|February 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236430||113613|
NCT01249924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000|The Effectiveness of Perioperative CPAP to Reduce Obstructive Sleep Apnea Related Adverse Events|The Effectiveness of Perioperative CPAP to Reduce the Occurrence of Sleep Apnea Related Adverse Events in Surgical Patients With Obstructive Sleep Apnea||University Health Network, Toronto|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||July 2012|December 17, 2013|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249924||112585|
NCT01250184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GrupoRS0001|Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.|Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial.||Grupo Rehabilitacion en Salud|No|Completed|May 2009|September 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|127|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 4, 2014|November 27, 2010||No||No|September 27, 2014|https://clinicaltrials.gov/show/NCT01250184||112566|The therapists were not the same throughout the investigation, however all were standardized to interventions; especilaistas doctors who applied the injections were different. No specific measure of patient-centered operation is used.
NCT01250470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 171010|Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma|Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas||Roswell Park Cancer Institute|Yes|Active, not recruiting|September 2012|||May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250470||112544|
NCT01251016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 1011/09|Effect of Bariatric Surgery on Gut Hormones Production and Cure of Type 2 Diabetes Mellitus|Changes in Gene Expression of Intestinal Tissue From Type 2 Diabetes Patients Submitted to Roux-en-Y Gastric Bypass||University of Sao Paulo|Yes|Recruiting|July 2010|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|60 Years|No|Non-Probability Sample|Severe obese patients with T2DM candidates to Roux-en-Y gastric bypass surgery|December 2015|December 5, 2015|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251016||112503|
NCT01251029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197/10|Effect of N-acetylcysteine on Renal Functioning of Chronic Kidney Diseases(CKD) Patients After General Anesthesia|Ability of N-acetylcysteine to Prevent Deterioration in Renal Functioning in CKD Patients Undergoing Major Surgery Under General Anesthesia||Assaf-Harofeh Medical Center||Not yet recruiting|January 2011|January 2014|Anticipated|September 2013|Anticipated|Phase 1|Interventional|N/A|1||||||Both|18 Years|70 Years|No|||November 2010|November 30, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01251029||112502|
NCT01236339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTR 10-03|Early TIPS for Ascites Study|The GORE® VIATORR® TIPS Endoprosthesis Versus Large-Volume Paracentesis for the Treatment of Ascites in Patients With Portal Hypertension||W.L.Gore & Associates|Yes|Terminated|December 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|69 Years|No|||May 2014|May 1, 2014|November 4, 2010|Yes|Yes|Slow enrollment|No|January 31, 2014|https://clinicaltrials.gov/show/NCT01236339||113620|Early termination due to very low enrollment.No subjects completed 24 month follow-up,sample size too small for adequate statistical analysis.Collected Adverse Events limited to hospitalizations and Liver Disease Complications as defined in protocol.
NCT01236352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA215-001|Multiple Ascending Dose of BMS-911543|A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis||Bristol-Myers Squibb|No|Completed|April 2011|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|84|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236352||113619|
NCT01236625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU-RTB-0003|The Effect of Adhesiolysis During Elective Abdominal Surgery on Per- and Postoperative Complication, Quality of Life and Socioeconomic Costs|A Prospective Study on the Effect of Adhesiolysis During Elective Laparotomy or Laparoscopy on Per- and Postoperative Complication, Quality of Life and Socioeconomic Costs|LAPAD|Radboud University|No|Completed|June 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|752|||Both|18 Years|N/A|No|Probability Sample|patient undergoing elective laparotomy or laparoscopy in the department of surgery of the        Radboud University Nijmegen Medical Centre (tertiary referral center).|September 2010|November 1, 2012|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01236625||113598|
NCT01236846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-1236-RV|Vitamin D Receptor Polymorphisms and Efficacy of Vitamin D-Fortified Yogurt Drink in Patients With Type 2 Diabetes|Determination of VDR Single Nucleotide Polymorphisms (SNPs ) and Their Rols in Efficacy of Vitamin D-fortified Yogurt Drink on the Metabolic-, Inflammatory - and Oxidative Stress Parameters in Type 2 Diabetic Patients||National Nutrition and Food Technology Institute|Yes|Completed|October 2009|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Actual|180|||Both|30 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01236846||113581|
NCT01234389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0004|Immediate Detection of Helicobacter Infection With a New Electrochemical System.|Immediate Detection of Helicobacter Infection With a New Electrochemical System||University of Erlangen-Nürnberg Medical School|Yes|Recruiting|October 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234389||113769|
NCT01234103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-04-1-0159|Preventing Health Damaging Behaviors in Male and Female Army Recruits|Preventing Health Damaging Behaviors in Male and Female Army Recruits||United States Department of Defense|Yes|Recruiting|September 2010|September 2013|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234103||113791|
NCT01234402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13944|Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients|An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy||Eli Lilly and Company|No|Active, not recruiting|March 2011|December 2015|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|153|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234402||113768|
NCT01234675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-17|The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia|The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia||Cleveland Sleep Research Center|Yes|Completed|November 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|November 3, 2010|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01234675||113747|A well-established adaptation and re-adaptation to laboratory effects may have compromised our results. Other study biases include biases inherent in the crossover design, and a small sample size.
NCT01235546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F090323006|Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection|Cesarean Section Optimal Antibiotic Prophylaxis Trial|C/SOAP|University of Alabama at Birmingham|Yes|Completed|May 2011|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2013|||Female|14 Years|N/A|No|||May 2015|May 21, 2015|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235546||113680|
NCT01235559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN25305|A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)|Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.||Hoffmann-La Roche||Completed|December 2010|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|604|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235559||113679|
NCT01235195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501097|A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioequivalence Study Comparing Sertraline Hydrochloride 50 mg Film-Coated Tablets To Sertraline Hydrochloride 50 mg Hard Capsules Under Fasted Conditions||Pfizer|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|November 3, 2010||No||No|November 21, 2011|https://clinicaltrials.gov/show/NCT01235195||113707|
NCT01235208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDstudy|The Effect of the Treatment Program "Dr. Fedon Lindbergs Vektcoach" on Body Weight and Composition and Hormonal Profile|The Effect of a Low Carbohydrate Low Energy Ketogenic Diet Followed by Progressively Increased Intake of Low Glycemic Foods Over 7 Months on Weight and Body Composition and Hormonal Profile||Eurodiet Scandinavia AS|No|Completed|October 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|44|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235208||113706|
NCT01235520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN25307|A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)|Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.||Hoffmann-La Roche||Completed|January 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|595|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235520||113682|
NCT01235845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCCIK001|Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma|A Phase I/II Clinical Trial Evaluating DC Activated Cytokine-induced Killer Cell(DCIK) Combined With DC Treatment for Glioma||Qingdao University|No|Not yet recruiting|January 2011|September 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||November 2010|December 2, 2010|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01235845||113658|
NCT01236157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09365|Monitoring of Nontraumatic Chest Pain Borne by the "Department of Emergency Help Medicalized" (SAMU)|Monitoring of Nontraumatic Chest Pain Borne by the "Department of Emergency Help Medicalized" (SAMU)|DOLORES|French Cardiology Society|Yes|Completed|November 2009|May 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1816|||Both|15 Years|N/A|No|Non-Probability Sample|All patients that call to the SAMU-ACS because of chest pain|June 2012|June 13, 2012|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01236157||113634|
NCT01236443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 00-02|Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus|A Phase I/II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for the Treatment of High Grade Dysplasia, Carcinoma-in-situ and Early Adenocarcinoma in Barrett's Esophagus||Roswell Park Cancer Institute|Yes|Completed|August 2000|April 2013|Actual|May 2003|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|November 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01236443||113612|
NCT01250236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grueb Klin CT|Effect of Brimonidine on Corneal Thickness|Effect of Brimonidine on Corneal Thickness||Augenarztpraxis Breisach|No|Recruiting|December 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|consecutive|December 2010|December 2, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250236||112562|
NCT01250197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-12286-CS101|Formulation Comparison in Normal Volunteers|A Double-masked, Crossover Study Assessing the Ocular and Systemic Safety and Systemic Absorption of Two Formulations of 0.5% AR-12286 Ophthalmic Solution in Normal Volunteers||Aerie Pharmaceuticals|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 20, 2010|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250197||112565|
NCT01250210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL11|Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration|Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration||Agile Therapeutics|No|Completed|September 2007|October 2008|Actual|February 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|123|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 29, 2010|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01250210||112564|
NCT01250223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F2-study|Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)|F2-PROTOCOL: Prospective Collection of Data of Possible Prognostic Relevance in Patients With Follicular Lymphoma||Associazione Angela Serra per la ricerca sul cancro|No|Active, not recruiting|February 2003|December 2016|Anticipated|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1093|Samples Without DNA|Formalin-fixed tissue for central diagnostic pathology review|Both|18 Years|N/A|No|Non-Probability Sample|Previously-untreated patients with de novo diagnosis of Follicular Lymphoma according to        World Health Organization (WHO) classification (grade 1,2,3a,3b)|January 2016|January 5, 2016|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01250223||112563|
NCT01250743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRI-101|A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C|An Open-Label Pilot Study of the Safety, Tolerability and Anti-Viral Activity of High Dose Intravenous Ascorbic Acid in Patients Chronically Infected With Hepatitis C Virus Genotype 1, Who Have Failed Prior Therapy With Interferon-alpha and Ribavirin||Health Innovations, Frontier Research Institute|No|Terminated|January 2009|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||November 2010|February 17, 2011|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250743||112524|
NCT01251042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-DRA-0006|Comparison Between Return and Wastage of Your Own Blood, Collected During Spinal Surgery, for Verification of Safety When Returning Blood|A Prospective, Randomized, Controlled Study on Intra-operative Autologous Transfusion With the Sangvia® Blood Salvage System in Spinal Surgery||Wellspect HealthCare|No|Completed|October 2010|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|September 24, 2010||No||No|March 12, 2013|https://clinicaltrials.gov/show/NCT01251042||112501|
NCT01236365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 185500|Statins in Children With Type 1 Diabetes and Hypercholesterolemia|Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function||Nemours Children's Clinic|Yes|Completed|October 2010|November 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|10 Years|20 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|November 2, 2010|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01236365||113618|
NCT01236638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCL09101E|Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)|A Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability & Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis||Gilead Sciences|Yes|Completed|November 2010|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236638||113597|
NCT01236859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP180|Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus|Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus After Orthopedics Surgery||Prince of Songkla University|Yes|Completed|September 2009|November 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|180|||Both|15 Years|70 Years|No|||October 2013|October 8, 2013|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236859||113580|
NCT01236872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0703/91 Acute|The Acute Effect of Beetroot Juice in Normal and Hypertensive Subjects|The Acute Effect of Beetroot Juice on Circulating Nitrate and Nitrite Levels and Blood Pressure in Normotensives and Hypertensives||Queen Mary University of London|Yes|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|15|||Both|18 Years|85 Years|No|||July 2011|August 4, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236872||113579|
NCT01237171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cs131-Lung001|A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer|Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC||IsoRay Medical, Inc.|No|Recruiting|November 2010|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients with clinical stage I non-small cell lung cancer who are not candidates for full        lobectomy.|November 2010|November 8, 2010|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01237171||113556|
NCT01234116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP Study|Post-Exposure Prophylaxis in Health Care Workers|A Prospective, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Raltegravir + Truvada Versus Kaletra + Truvada, for Post-exposure Prophylaxis in Health Care Workers|PEP|Henry Ford Health System|No|Completed|February 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 26, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234116||113790|
NCT01234415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/16|Bone Substitute in the Multi Traumatized Nasal Septum Reconstruction|Multicentric Pilot, Clinical Study of a Bone Substitute Safety and Efficacy in the Multi Traumatized Nasal Septum Reconstruction|NASEPT|University Hospital, Bordeaux|Yes|Completed|September 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|60 Years|No|||March 2015|March 17, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234415||113767|
NCT01234428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOB-12-STS-AG|Esophageal Dysmotility and Dilatation After Laparoscopic Gastric Banding|Esophageal Dysmotility Disorders Following Laparoscopic Gastric Banding - An Underestimated Complication.||Spital STS AG|No|Completed|June 1998|March 2010|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|167|||Both|18 Years|65 Years|No|||November 2010|November 2, 2010|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234428||113766|
NCT01234688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Effects of Aerobic Training in End Stage Renal Disease Patients|Effects of Aerobic Training During Hemodialysis on Exercise Tolerance in End Stage Renal Disease Patients||Federal University of Juiz de Fora|Yes|Completed|June 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||July 2010|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234688||113746|
NCT01234701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI_Liver_Tumours_Evlauation|Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI)|Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI) in Non-Cirrhotic Patients - A Double Blind International Multicenter Study|MRevaluation|University of Zurich|Yes|Completed|October 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|108|||Both|18 Years|90 Years|No|Non-Probability Sample|Primary care clinics|May 2012|May 25, 2012|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234701||113745|
NCT01235572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2449.00|Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy|Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML||Fred Hutchinson Cancer Research Center|No|Completed|December 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|18 Years|75 Years|No|||February 2015|February 5, 2015|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235572||113678|
NCT01235234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-301KCS|Trial of CF101 to Treat Patients With Dry Eye Disease|A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease||Can-Fite BioPharma|No|Completed|July 2011|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|236|||Both|18 Years|N/A|No|||March 2014|March 10, 2015|November 3, 2010|Yes|Yes||No|February 22, 2015|https://clinicaltrials.gov/show/NCT01235234||113704|
NCT01235533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95004-62-161|Fish Oil Supplementation in Late-life Depression|The Assessment for the Effects of Health Products on Depression and Cognitive Function:Fish Oil in Patients With Late-life Depression||Taipei City Psychiatric Center, Taiwan|No|Completed|May 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|89|||Both|60 Years|N/A|No|||November 2010|November 4, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235533||113681|
NCT01235858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAS-2009|Aseptic Techniques During Epidural Analgesia in the Labor Floor|Responding to the ASRA (American Society of Regional Anesthesia) Challenge - Should Gowning be the Standard of Practice for Epidural Anesthesia: A Randomized Control Trial|EAS|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|Yes|Completed|November 2009|December 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|240|||Female|18 Years|N/A|No|||July 2011|April 3, 2012|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01235858||113657|
NCT01235871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB1578-2010-001|A Single and Multiple-Dose Study of SB1578|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB1578 When Administered Orally to Healthy Adult Subjects With One Single-Dose Group Crossing Over to Assess Food Effect||S*BIO|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|November 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01235871||113656|
NCT01236170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7148-I|Understanding Quality and Equity in Wheelchairs for Veterans|Understanding Quality and Equity in Wheelchairs for Veterans||VA Office of Research and Development|Yes|Completed|March 2011|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|497|||Both|18 Years|N/A|No|Probability Sample|Participants will be recruited from the following four VA Medical Centers: the        Philadelphia VA Medical Center in Philadelphia, PA; the Louis Stokes VA Medical Center in        Cleveland, OH; The Hunter Holmes McGuire VA Medical Center in Richmond, VA; and the James        J. Peters VA Medical Center in Bronx, NY. Recruitment will occur at SCI clinics, amputee        clinics, wheelchair clinics, and patient registries.|February 2015|February 5, 2015|November 4, 2010||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01236170||113633|
NCT01249937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARP2TWH|Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab|Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab|STAR|University Health Network, Toronto|No|Recruiting|January 2011|October 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2011|February 8, 2011|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249937||112584|
NCT01250249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCGV/034/08|A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.|A Randomized, Open Label, Single-period, Single-treatment, Controlled Multi Center Phase Iii Study of Comparing Safety and Reactogenecity of Lyophilized BCG Vaccine ip (0.1 mg in 0.1 ml) of Green Signal Bio Pharma Private Limited India With BCG Vaccine (0.1 mg in 0.1 ml) of Serum Institute of India Limited (SIIL),India in 120 Healthy Children.||Green Signal Biopharma Private Limited|Yes|Completed|November 2008|June 2009|Actual|June 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|N/A|14 Years|Accepts Healthy Volunteers|||November 2010|November 29, 2010|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01250249||112561|
NCT01250483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSA and alpha blockers|Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)|||Seoul National University Hospital|Yes|Completed|January 2001|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|174|||Male|40 Years|80 Years||Probability Sample|Men aged more than 40 years who presented with BPH/LUTS and performed transrectal prostate        biopsy during the period of AB medication between January 2001 and December 2009.|November 2010|November 27, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01250483||112543|
NCT01250756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1841007|A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.|A Phase 4, Randomized, Open-label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan.||Pfizer|No|Completed|November 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|321|||Both|3 Months|6 Months|Accepts Healthy Volunteers|||January 2013|January 22, 2013|November 29, 2010|Yes|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT01250756||112523|
NCT01251627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECI2009-AISSM06|Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia|A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia|DECI2009|Fondazione Italiana Sindromi Mielodisplastiche Onlus|No|Active, not recruiting|April 2010|May 2016|Anticipated|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|95 Years|No|||August 2015|February 2, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251627||112457|
NCT01252199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP_STX005/STX005EXT|Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2|A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (cαStx1) and 2 (cαStx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial)||Thallion Pharmaceuticals|Yes|Completed|November 2010|February 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|6 Months|18 Years|No|||April 2013|April 23, 2013|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252199||112413|
NCT01237704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRF 475210|Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy|Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy: a Randomised-controlled Trial||Chinese University of Hong Kong|Yes|Recruiting|January 2011|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2013|February 24, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01237704||113515|
NCT01238042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 02-18|Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus|A Pilot Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus||Roswell Park Cancer Institute|Yes|Completed|March 2003|November 2014|Actual|October 2004|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01238042||113489|
NCT01238055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-09-031|Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer|Randomized Phase II Trial of Sunitinib and Docetaxel in Advanced Gastric Cancer Patients Who Had Prior Chemotherapy With Fluoropyrimidine and Platinum||Samsung Medical Center|No|Completed|November 2008|October 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||January 2012|April 8, 2013|January 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01238055||113488|
NCT01238315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N03-NCL|Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis|A Phase Ib Study of the Safety and Preliminary Efficacy of Allogeneic Intracerebral Human Central Nervous System Stem Cell Transplantation in Subjects With Non-Refractory Infantile and Late Infantile Neuronal Ceroid Lipofuscinosis||StemCells, Inc.|Yes|Withdrawn|November 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Months|6 Years|No|||January 2015|January 13, 2015|November 5, 2010|No|Yes|Lack of timely patient accrual|No||https://clinicaltrials.gov/show/NCT01238315||113469|
NCT01238328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-0906|Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis|Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis||Tehran University of Medical Sciences|Yes|Recruiting|September 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|8 Years|No|||May 2012|May 31, 2012|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238328||113468|
NCT01234714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI_Steatosis_Outcomes|Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications|Liver Fat Quantification by Magnetic Resonance Imaging (MRI): A Novel Tool for Prediction of Postoperative Complications After Major Liver Resection?|MRsteatosis|University of Zurich|Yes|Completed|October 2010|July 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|84|||Both|18 Years|90 Years|No|Non-Probability Sample|Primary care clinics|February 2012|February 7, 2012|November 3, 2010||No||No|November 11, 2011|https://clinicaltrials.gov/show/NCT01234714||113744|
NCT01234727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-MKG-FSL-10008|Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes|Multicentre Performance Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes Randomised to Multiple Devices||Abbott Diabetes Care|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|501|||Both|18 Years|75 Years|No|Non-Probability Sample|Up to 480 subjects with type 1 or 2 diabetes mellitus|March 2011|July 4, 2011|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234727||113743|
NCT01234974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 09-095|IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus|Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma||Milton S. Hershey Medical Center|Yes|Withdrawn|December 2010|December 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|August 24, 2010|No|Yes|Study never undertaken|No||https://clinicaltrials.gov/show/NCT01234974||113724|
NCT01235247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0709-63|Decision Support AMPATH|Electronic Medical Records to Improve Patient & Public Health in Rural Kenya||Indiana University|No|Recruiting|February 2011|March 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Primary Purpose: Health Services Research|1||||||Both|N/A|N/A||||September 2007|July 28, 2011|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235247||113703|
NCT01235260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017497|Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes|A Study of Cancer Risk Associated With Becaplermin Use in Veteran Diabetes Patients Served by the U.S. Veterans Health Administration||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Active, not recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|N/A|N/A|No|Probability Sample|Patients with diabetic foot ulcers who are members of the U.S. Department of Veterans        Affairs Health Care System (VA)|February 2013|February 18, 2013|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235260||113702|
NCT01236209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182014/V50|Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback|Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback||Oslo University College|Yes|Completed|March 2009|January 2013|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|140|||Female|18 Years|N/A|No|||May 2013|May 8, 2013|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236209||113630|
NCT01236222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cycling|Health Effects of Commuter Cycling|Health Effects of Commuter Cycling||University of Southern Denmark||Completed|March 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|10 Years|13 Years|Accepts Healthy Volunteers|||August 2011|August 8, 2011|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01236222||113629|
NCT01235884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-RF-01/10|Prevention of the Minor Digestive Disorders by Lactobacillus Reuteri Supplementation|Prevention of the Minor Digestive Disorders by Lactobacillus Reuteri Supplementation.||University of Bari|Yes|Completed|September 2010|July 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|492|||Both|N/A|7 Days|Accepts Healthy Volunteers|||February 2013|February 4, 2013|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01235884||113655|
NCT01236183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si246/2553(E)|Evaluation of Learning Curve of Manual Skills in Anesthesia Residents|Evaluation of Learning Curve of Manual Skills in Anesthesia Residents||Mahidol University|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|N/A|No|Non-Probability Sample|new anesthesia residents|July 2011|July 21, 2011|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01236183||113632|
NCT01236456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65865|High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy|A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy||Stony Brook University||Withdrawn|October 2003|November 2006|Anticipated|||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|75 Years|No|||August 2011|August 11, 2011|November 5, 2010|||I am relocating to Johns Hopkins Medical Center|No||https://clinicaltrials.gov/show/NCT01236456||113611|
NCT01236703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HemoSIRS|Hematological Infection Score Compared to the Hospital Standard for Diagnosis of SIRS or Sepsis on ICU|Hematological Infection Profile (ICIS/ICPS) Compared to Actual Best Hospital Practice for Differentiation of SIRS and Sepsis and Management of Antiinfective Therapy in ICU Patients||Charite University, Berlin, Germany|No|Completed|March 2010|October 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|207|||Both|18 Years|N/A|No|Non-Probability Sample|All IC department patients (WAN 8i, WAN 14i and WNC S1i Charite Berlin) will be enrolled        in the study.|January 2012|January 3, 2012|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236703||113592|
NCT01236716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG1002|Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung|A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung|C-TONG1002|Chinese Society of Lung Cancer|Yes|Completed|November 2010|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|85 Years|No|||August 2014|August 4, 2014|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236716||113591|
NCT01249950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 157 02|Study on the Appropriateness of Bariatric Surgery in Adolescents|Study on the Appropriateness of Bariatric Surgery in Adolescents||University Hospital, Toulouse|No|Terminated|October 2009|October 2013|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|13 Years|18 Years|No|Probability Sample|adolescents|November 2013|November 8, 2013|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249950||112583|
NCT01250509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11640-29259-03A|Craving and Lifestyle Management Through Mindfulness Study|Effects of Stress Reduction on Eating, Fat Distribution, and Cell Aging Among Overweight Women|CALMM|University of California, San Francisco|No|Completed|November 2006|July 2008|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 16, 2013|November 23, 2010||No||No|May 29, 2012|https://clinicaltrials.gov/show/NCT01250509||112541|
NCT01250496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSUAGETrial|Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging|Attenuation of the Side Effect Profile of Regadenoson: A Randomized Double-Blind Placebo Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging.|ASSUAGE|Rush University Medical Center|Yes|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|248|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01250496||112542|
NCT01251055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-98-096|GlyT-1 Inhibitor Treatment for Refractory Schizophrenia|GlyT-1 Inhibitor Treatment for Refractory Schizophrenia and Its Effects on NMDA Modulation||China Medical University Hospital|No|Completed|April 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||October 2013|October 27, 2013|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01251055||112500|
NCT01237717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1-15|Relationship of Urine Sodium Excretion to Central Blood Pressure and Aortic Pulse Wave Velocity|Relationship of Urine Sodium Excretion to Central Blood Pressure and Aortic Pulse Wave Velocity||DongGuk University|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|200|Samples With DNA|Serum, Plasma, and DNA sample (whole blood)|Both|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with or without hypertension|January 2013|January 21, 2013|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237717||113514|
NCT01238068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMSC-10-OS-10-357-CTIL|Comparison of the Results of Treatment by Gamma Nail Versus Dynamic Hip Screw for Unstable Intertrochanteric Hip Fractures|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|November 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2010|November 9, 2010|October 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238068||113487|
NCT01238081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010CF004|The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults|The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults.||University Hospital of South Manchester NHS Foundation Trust|No|Completed|December 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Adults with cystic fibrosis attending the Manchester Adult Cystic Fibrosis Centre,        Manchester, UK|May 2012|May 31, 2012|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238081||113486|
NCT01238341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pancreatobiliary disorders|Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy|Prospective Evaluation of Clinical Utility of Endoscopic Retrograde Cholangiopancreatography (ERCP) With Overtube in Patients With Altered Gastric Anatomy||University of Florida|No|Completed|June 2007|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a medical indication for ERCP and have altered gastric anatomy and are        referred for the procedure as part of their standard medical care will be considered for        this study.|October 2015|October 2, 2015|November 8, 2010||No||No|September 2, 2015|https://clinicaltrials.gov/show/NCT01238341||113467|
NCT01238354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSSO-2010/2|Family & Friends - the Significance of a Significant Other in Treatment|Conservative Treatment of Obesity at Røros Rehabilitation Centre - A Randomised Trial||Norwegian University of Science and Technology|No|Completed|November 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|80|||Both|18 Years|50 Years|No|||April 2015|April 14, 2015|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238354||113466|
NCT01234454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS-USA-242|Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI|Risperidone Effects On Frontal And Temporal Cortical Function In Schizophrenia Patients Undergoing FMRI Cognitive Task Performance||University of North Carolina, Chapel Hill|Yes|Completed|January 2002|December 2007|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|34|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2010|April 1, 2015|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234454||113764|
NCT01234740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10134|Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases|BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors||City of Hope Medical Center|Yes|Completed|December 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|September 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01234740||113742|
NCT01234987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCHHSGCTIL|Diagnosis of Cancer Using Breath Samples|Diagnosis of Cancer Using Breath Samples||Technion, Israel Institute of Technology||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|||||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|People that undergo screening for breast, colon or lung cancers people diagnosed with        breast, colon or lung cancers|December 2010|October 27, 2011|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234987||113723|
NCT01235273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOSCAproject|Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.|Phase 2 Study of Growth Hormone Administration in Patients With Chronic Heart Failure and Low IGF-1 Levels|TOSCA2|Federico II University|No|Suspended|January 2011|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|80 Years|No|||February 2014|February 18, 2014|November 4, 2010||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01235273||113701|
NCT01236235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-401|Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting|A Non Comparative Observational Study to Describe the Duration and Outcome of Treatment in Therapy naïve HIV Positive Patients Initiated on Atazanavir (ATV)/ Ritonavir (RTV)-Based Highly Active Antiretroviral Therapy (HAART) Regimens|REMAIN|Bristol-Myers Squibb|No|Completed|January 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|525|||Both|18 Years|N/A|No|Non-Probability Sample|Patients attending HIV specialized management centers will be considered.|September 2013|September 4, 2013|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236235||113628|
NCT01235897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10998|MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies|A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab||University of California, San Francisco|Yes|Completed|March 2011|November 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|November 4, 2010|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01235897||113654|MTD was defined as a dose resulting in 3 or fewer DLTs in 11 patients, plus a cohort of 4 patients by a modified TPI dose escalation method. Based on interim toxicity data from other studies, study dose did not exceed 135mg weekly.
NCT01236196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7658-I|Telephone Cognitive Behavior Therapy for OEF Veterans With Pain|Telephone Cognitive Behavior Therapy for OEF Veterans With Pain||VA Office of Research and Development|Yes|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|50 Years|No|||December 2014|December 12, 2014|November 1, 2010||No||No|December 5, 2014|https://clinicaltrials.gov/show/NCT01236196||113631|The fact that this study was conducted in northern California may have posed some threat to external validity when applying these findings to the nationwise VA system.
NCT01236469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGA0903.000 - C(09/09)|CryoValve® SG Aortic Human Heart Valve Combination Study|CryoValve® SG Aortic Human Heart Valve Combination Retrospective/Prospective, Multi-Center, Cohort Study|SGAV|CryoLife, Inc.|No|Completed|June 2010|February 2012|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|6 Years|27 Years|No|Non-Probability Sample|Pediatric (21 years of age or younger) patients who received a CryoValve SG Aortic Valve        distributed during the 2000 to 2003 period as an aortic valve replacement.|August 2015|August 17, 2015|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01236469||113610|
NCT01236729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL122009|Disability and Self-rated Health Following Primary Knee Replacement|The Effects of Primary Knee Replacement for Osteoarthritis on Disability in Activities of Daily Living and Self-rated Health in Older People||Coxa, Hospital for Joint Replacement|No|Active, not recruiting|December 2009|June 2016|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|460|||Both|75 Years|N/A|No|Non-Probability Sample|Patients refererred to or operated on with primary knee replacement in a population-based        tertiary care hospital|August 2015|August 9, 2015|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01236729||113590|
NCT01237002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pringle 120 minutes|Pringle Time Exceeding 120 Min in Liver Resection|Safety of Intermittent Pringle Maneuver Cumulative Time Exceeding 120 Min in Liver Resection||University of Milan|No|Completed|January 2005|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|189|||Both|29 Years|85 Years|No|Probability Sample|Among 426 consecutive patients who underwent hepatectomy, we retrospectively selected 189        patients with clamping time exceeded 60 minutes: 117 having intermittent Pringle maneuver        less 120 minutes and 72 having clamping time exceeding 120 minutes were analysed.|October 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237002||113569|
NCT01250262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258-2010|Resistance Exercise Effects on Fear Avoidance and Physical Function in Obese Older Adults With Low Back Pain|Resistance Exercise Effects on Fear Avoidance Beliefs and Physical Function in Obese, Older Adults With Chronic Low Back Pain||University of Florida|No|Completed|November 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|60 Years|85 Years|No|||February 2014|February 12, 2014|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01250262||112560|
NCT01250275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2010:125|Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease|Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease (PAD)||University of Manitoba|No|Completed|September 2011|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|7||Actual|53|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 25, 2013|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250275||112559|
NCT01250769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRC-0703|Evaluating the Effect of Tooth Cleaning Devices on Oral Health|Evaluating the Effect of a Novel Interproximal Cleaning Device on Oral Health||Philips Oral Healthcare|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|170|||Both|18 Years|70 Years|No|||August 2012|August 21, 2012|May 5, 2010|Yes|Yes||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01250769||112522|
NCT01251653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.93|A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel|A Phase I Dose Escalation Trial of Once Daily Oral Treatment Using Afatinib (BIBW2992) Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors.||Boehringer Ingelheim||Completed|November 2010|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|94|Samples Without DNA|Pharmacokinetic samples|Both|18 Years|N/A|No|Non-Probability Sample|solid tumors|May 2015|May 10, 2015|December 1, 2010||||No||https://clinicaltrials.gov/show/NCT01251653||112455|
NCT01251666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01463-52|Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening|Comparison of Performances of Two Automated Immunochemical Faecal Occult Blood Tests in Colorectal Cancer Screening, in Reference to Usual Care Guaiac Test|HeMO|University Hospital, Caen|No|Completed|June 2008|August 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|1||Actual|19797|||Both|50 Years|74 Years|No|||August 2012|August 31, 2012|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01251666||112454|
NCT01251900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911035|BRCA Mutations in Latinas|BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects||National Institutes of Health Clinical Center (CC)||Recruiting|November 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|2000|||Female|18 Years|99 Years|No|||February 2016|February 18, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251900||112436|
NCT01251913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110036|A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes|A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes||National Institutes of Health Clinical Center (CC)||Terminated|November 2010|April 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|7|||Both|18 Years|100 Years|No|||April 2015|December 16, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251913||112435|
NCT01251926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110042|EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors|Pilot Study of Weekly EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|November 2010|April 2014|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2014|May 3, 2014|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01251926||112434|
NCT01237730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKU-HR99|Tailored Antibiotics Prophylaxis for Percutaneous Endoscopic Gastrostomy|Impact of Oropharyngeal Microorganism Colonization on the Peristomal Infection After Percutaneous Endoscopic Gastrostomy and the Effect of Tailored Antibiotics Prophylaxis|PEG|National Cheng Kung University|No|Recruiting|July 2010|August 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|80 Years|No|||July 2010|November 9, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237730||113513|
NCT01237743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr304-09|Microembolic Signals and Serum Markers of Neuronal Damage During Transcatheter Aortic Valve Implantation.|Transcranial Doppler Microembolic Signals and Serum Markers of Neuronal Damage During Transcatheter Aortic Valve Implantation||Sahlgrenska University Hospital, Sweden|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|Samples Without DNA|Serum levels of S-100β Determined by an electrochemoluminescence immunoassay using the      Modular system and the S100β reagent kit (Roche Diagnostics, Basel, Switzerland).|Both|N/A|N/A|No|Non-Probability Sample|Patients with aortic stenosis rejected for open-heart surgery due to unacceptable risks.|November 2010|March 14, 2011|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237743||113512|
NCT01238094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-017|Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer|Placebo-controlled, Double-blinded Phase III Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer||Samsung Medical Center|No|Recruiting|April 2010|May 2014|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|258|||Both|18 Years|N/A|No|||January 2012|June 13, 2013|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01238094||113485|
NCT01238367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3600|A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543|Multi-centre, Open-label, Non-randomised Single Dose Trial Investigating the Pharmacokinetics of N8 in Japanese Subjects With Haemophilia A||Novo Nordisk A/S|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|12 Years|66 Years|No|||June 2013|June 10, 2013|November 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238367||113465|
NCT01238380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 10/H0106/63|Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes|Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes|UNITED|NIHR Exeter Clinical Research Facility|Yes|Completed|December 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1916|Samples With DNA|Samples with DNA and plasma samples.|Both|N/A|50 Years|No|Non-Probability Sample|Patients currently under the age of 50 years, diagnosed under the age of 30years, from        South-West England and Tayside, Scotland, UK.|April 2014|April 2, 2014|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238380||113464|
NCT01235286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kraemer001|Cutaneous Remote Ischemic Preconditioning in Plastic Surgery|Effects of Remote Ischemic Preconditioning in Cutaneous Microcirculation of Anterolateral Thigh Flaps|RIPC|Hannover Medical School|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|27|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2010|November 4, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235286||113700|
NCT01235585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN25306|A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)|Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.||Hoffmann-La Roche||Completed|December 2010|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|597|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235585||113677|
NCT01235910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0746|Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation|Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation||University of Colorado, Denver|No|Terminated|May 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|21 Years|70 Years|No|||July 2015|July 21, 2015|November 3, 2010|Yes|Yes|Study was stopped early due to difficulty finding patients who met I/E criteria.|No|December 10, 2014|https://clinicaltrials.gov/show/NCT01235910||113653|The study was stopped due to difficulty finding patients who met the strict inclusion/exclusion criteria. Only one patient was started on study drug.
NCT01232257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2S-NAC|Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)|Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease||UMC Utrecht|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 25, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232257||113932|
NCT01232270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0409|The Optimal Effect Site Concentration of Propofol for Conscious Sedation in Elderly Male Patients Undergoing Urologic Surgery Under Spinal Anesthesia With or Without Intrathecal Fentanyl|The Optimal Effect Site Concentration of Propofol for Conscious Sedation in Elderly Male Patients Undergoing Urologic Surgery Under Spinal Anesthesia With or Without Intrathecal Fentanyl||Yonsei University|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|43|||Male|60 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01232270||113931|
NCT01236482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oxytocined50-HMO-CTIL|Oxytocin in Cesarean Delivery|Comparing Oxytocin and Oxytocin-ergometrine Combinations for Increasing Uterine Tone in Cesarean Delivery: a Pharmacokinetic-pharmacodynamic Study.||Hadassah Medical Organization|No|Not yet recruiting|November 2010|May 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|No|||September 2010|November 5, 2010|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01236482||113609|
NCT01236742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-ZG50-1|Discontinuation of Orthokeratology on Eyeball Elongation in Myopic Children|Discontinuation of Orthokeratology on Eyeball Elongation (DOEE) Study. (1) Discontinuation of Lens Wear in Existing Ortho-k Children|DOEE1|The Hong Kong Polytechnic University|No|Completed|July 2010|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236742||113589|
NCT01237015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-157|Effect of Nasal Continuous Positive Airway Pressure (CPAP) on Oral Feeding in Human Neonates|Effect of Nasal Continuous Positive Airway Pressure (CPAP) on Sucking, Swallowing and Coordination of Breathing and Swallowing During Oral Feeding in Human Neonates||Université de Sherbrooke|Yes|Recruiting|September 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2010|January 25, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237015||113568|
NCT01237275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-10-14|Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients|Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients||Samsung Medical Center|Yes|Active, not recruiting|October 1999|December 2016|Anticipated|December 2003|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|300|||Both|19 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01237275||113548|
NCT01237288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10010301|Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets|Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets||Zeria Pharmaceutical|No|Completed|September 2010|July 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|1 Year|14 Years|No|||September 2013|September 30, 2013|November 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01237288||113547|
NCT01250808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008ZX09312-026|Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy|||Peking University||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||November 2010|November 30, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250808||112519|
NCT01251341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AT004698|The Compassion and Attention Longitudinal Meditation Study|Mechanisms of Meditation|CALM|University of Arizona|Yes|Completed|September 2009|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|226|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251341||112478|
NCT01251640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14905|Combination With Gemcitabine in Advanced Pancreatic Cancer|A Multi-center, Phase I/II Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pancreatic Cancer|BAGPAC|Bayer|Yes|Completed|January 2011|August 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|November 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01251640||112456|
NCT01251679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIRD-5288|Household Influenza Transmission Study|Study to Assess Effectiveness of Nonpharmaceutical Interventions (Handwashing, Face Mask Use) to Prevent Influenza Transmission in Households|HITS|Centers for Disease Control and Prevention|No|Active, not recruiting|April 2008|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2920|||Both|1 Month|15 Years|No|||September 2012|September 10, 2012|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01251679||112453|
NCT01251939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|n7860088|Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious|Observational Study of Near Infrared Spectroscopy to Monitor Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious in Preterm Infants||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Completed|October 2011|August 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|N/A|N/A|No|Non-Probability Sample|All infants who born in Zekai Tahir Burak Maternity and Teaching Hospital between january        2011 and january 2012 and met the entry criteria first underwent echocardiography and        cranial ultrasonography.|August 2012|August 19, 2012|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01251939||112433|
NCT01238107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-102-2001|A Clinical Study With MT-102 in Subjects With Cancer Cachexia|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate Doses of MT-102 in Subjects With Cachexia Related to Stage III and IV Non-small Cell Lung Cancer and Colorectal Cancer||PsiOxus Therapeutics Ltd|Yes|Completed|April 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|87|||Both|25 Years|80 Years|No|||September 2014|September 9, 2014|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238107||113484|
NCT01238393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTH-092-10|Treatment of Epiretinal Membranes With Ranibizumab|A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study|LERM|Queen's University|Yes|Completed|November 2010|January 2012|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|November 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238393||113463|
NCT01238406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006000ctil|Overnight MD-Logic|Multicenter, Prospective, Open Label, Cross Over, Pilot Trial to Evaluate Blood Glucose Control Overnight Under Closed-loop Insulin Delivery With MD Logic Artificial Pancreas (MDLAP)System in Patients With Type 1 Diabetes||Rabin Medical Center|No|Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|263|||Both|10 Years|65 Years|No|||November 2015|November 26, 2015|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238406||113462|
NCT01238419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR010WS|Physiotulle vs Urgotul in the Treatment of Leg Ulcer|Clinical Assessment of Physiotulle Dressing Compared to Urgotul Dressing in the Treatment of Leg Ulcer||Coloplast A/S|No|Completed|November 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||October 2010|September 2, 2011|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01238419||113461|
NCT01234129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kitty1|Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma|Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma||Instituto Mexicano del Seguro Social|No|Completed|June 2002|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|320|||Both|18 Years|65 Years|No|Probability Sample|Patients with multiple myeloma previously untreated|December 2009|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234129||113789|
NCT01234142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051142|A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days|A Phase 1, Investigator And Subject Blind (Sponsor Open), Randomized, Placebo Controlled, Parallel Cohort, Escalating Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of A Varenicline Transdermal Delivery System In Adult Smokers||Pfizer|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 13, 2011|August 14, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01234142||113788|
NCT01234441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 DK084016-01|Intra Hemodialytic Oral Protein and Exercise (IHOPE)|Intradialytic Protein Supplementation & Exercise Training in Dialysis Patients.|IHOPE|University of Illinois at Urbana-Champaign|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|150|||Both|30 Years|80 Years|No|||December 2015|December 1, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234441||113765|
NCT01235299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kraemer002|Free Flap Microcirculatory Monitoring Correlates to Free Flap Temperature Assessment|Free Flap Microcirculatory Monitoring Correlates to Free Flap Temperature Assessment||Hannover Medical School|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|54|||Both|16 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients suffering from a soft tissue defect at any location of the body receiving free        flap soft-tissue defect coverage at the Department of Plastic, Hand and Reconstructive        Surgery, Medical School Hannover, Germany.|November 2010|November 4, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235299||113699|
NCT01235637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 10 10|Alfentanil Versus Sufentanil for Pain in Children During for Tracheal Suction|Efficacy of Alfentanyl Versus Sufentanyl in Children for Pain During Treatment by Tracheal Suction in an Intensive Care Unit.|DOLOREAPEDIA|University Hospital, Grenoble|Yes|Completed|June 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|1 Month|15 Years|No|||July 2012|July 3, 2012|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235637||113674|
NCT01235598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0028|Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)|A 16-week Double-blind, Placebo-controlled (for Initial 2 Weeks) Randomized Period, Followed by a 24-week Open-label Extension to Assess Magnetic Resonance Image (MRI) - Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)|MARVELOUS|UCB Pharma|No|Completed|December 2010|May 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|November 4, 2010|Yes|Yes||No|September 26, 2013|https://clinicaltrials.gov/show/NCT01235598||113676|
NCT01235923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-380|Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants|A Randomized, Masked Study of Weekly Erythropoietin Dosing in Preterm Infants||University of New Mexico|No|Completed|April 2006|December 2009|Actual|March 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|100 Days|No|||June 2012|June 19, 2013|November 4, 2010||No||No|November 29, 2012|https://clinicaltrials.gov/show/NCT01235923||113652|pilot study with only 20 infants evaluated
NCT01232283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-009|Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis|ESTEEM 2|Celgene|No|Active, not recruiting|November 2010|November 2016|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|413|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|October 29, 2010|Yes|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01232283||113930|
NCT01232296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2208|A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment|An Open-label, Randomized, Multi-center, Phase II Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib as First-line Treatment in Adult Patients With Advanced Hepatocellular Carcinoma||Novartis||Completed|July 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|September 30, 2010||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01232296||113929|
NCT01236495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si578/2010|Comparison for Pethidine Requirement in Patients Received Spinal Morphine 0.2 and 0.3 mg for Post Lobectomy Analgesia|Comparison for Pethidine Requirement in Patients Received Spinal Morphine 0.2 and 0.3 Milligram for Post Lobectomy (Lung) Analgesia|pain|Mahidol University|No|Completed|November 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||March 2012|March 11, 2012|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236495||113608|
NCT01236508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100606-01H|Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease|Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease||Ottawa Heart Institute Research Corporation|No|Active, not recruiting|November 2010|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|60 Years|N/A|No|||February 2016|February 23, 2016|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236508||113607|
NCT01236755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-ZG50-2|Discontinuation of Lens Wear in New Ortho-k Children (DOEE2)|Discontinuation of Orthokeratology on Eyeball Elongation (DOEE) Study. (2) Discontinuation of Lens Wear in New Ortho-k Children|DOEE2|The Hong Kong Polytechnic University|No|Completed|October 2010|December 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|90|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236755||113588|
NCT01237028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0439|Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers|Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers||Yonsei University|No|Recruiting|December 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|168|||Both|20 Years|70 Years|No|||June 2013|June 1, 2013|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237028||113567|
NCT01237041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110004|Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children|Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|May 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|91|||Both|7 Years|15 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|November 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01237041||113566|
NCT01233362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-WC-05|Study of Alternative Vaccination Schedule of Oral Cholera Vaccine|A Randomized Controlled Trial To Evaluate the Immunogenicity of Two Doses of the Modified Killed Whole-Cell Oral Cholera Vaccine Under Two Alternative Vaccination Schedules.||International Vaccine Institute|No|Completed|December 2010|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|386|||Both|1 Year|N/A|Accepts Healthy Volunteers|||August 2012|September 24, 2013|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01233362||113847|
NCT01233661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08060137|Short Atrioventricular Delay Pacing|Short Atrioventricular Delay Pacing|SAVD|University of Pittsburgh|No|Withdrawn|January 2011|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|2||Actual|0|||Both|N/A|N/A|No|||January 2016|January 4, 2016|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233661||113825|
NCT01250821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021459-16|Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility|Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility||Rigshospitalet, Denmark|Yes|Completed|December 2010|April 2013|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Female|18 Years|39 Years|No|||April 2013|April 18, 2013|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250821||112518|
NCT01251094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRM99-IRB-233|Dementia Registry for Parkinson's Disease|||China Medical University Hospital||Completed|November 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|50 Years|90 Years|No|Non-Probability Sample|Parkinson's Disease patients.|February 2012|February 13, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251094||112497|
NCT01251354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-52-58064-007|Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy|A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.||Ipsen||Terminated|November 2010|July 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|November 23, 2010|Yes|Yes|The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the    primary endpoint will not be reached.|No|August 6, 2015|https://clinicaltrials.gov/show/NCT01251354||112477|Study terminated due to poor enrollment
NCT01251367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-55-52120-142|Dysport® Adult Lower Limb Spasticity Follow-on Study|A Phase III, Prospective, Multicentre, Open Label, Extension Study, to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Lower Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury||Ipsen|No|Completed|June 2011|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|352|||Both|18 Years|80 Years|No|||April 2015|April 28, 2015|November 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251367||112476|
NCT01248325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZUR-LO-2009|A Study of Luffa Operculate Nasal Solution 5mg/mL Compared With Saline (NaCl 09%) for the Relief of Nasal Obstruction|Clinical Trial Unicenter, Phase III, Randomized, Double-blind, Comparative to Evaluate the Efficacy, Tolerability and Superiority of Luffa Operculate Nasal Solution 5mg/mL Compared With Saline Solution in the Relief of Nasal Obstruction.||Zurita Laboratorio Farmaceutico Ltda.|No|Not yet recruiting|January 2011|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|90 Years|No|||November 2010|November 23, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01248325||112707|
NCT01251952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU 2010-039|Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation|Phase I Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation.||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|November 2010|May 2013|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|70 Years|No|||October 2013|October 25, 2013|November 30, 2010|Yes|Yes|Drug unavailable|No|October 25, 2013|https://clinicaltrials.gov/show/NCT01251952||112432|Analysis was not completed due to the small number of patients accrued.
NCT01238120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31416|The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients|A Phase II Study of the Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients Undergoing Chemotherapy||University of Rochester|Yes|Recruiting|November 2010|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|116|||Both|18 Years|99 Years|No|||October 2015|October 6, 2015|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238120||113483|
NCT01238432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-103|The Genetics of Severe Asthma in Children|The Genetics of Severe Asthma in Children||Connecticut Children's Medical Center|No|Recruiting|October 2009|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|558|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children with asthma|January 2016|January 27, 2016|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238432||113460|
NCT01234155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-027|Exercise Training and Type 2 Diabetes|||Rigshospitalet, Denmark|No|Completed|August 2010|November 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01234155||113787|
NCT01234168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-52030-736|A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea|An International, Cross Sectional, Non-interventional, Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea|SYMNET|Ipsen|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|340|||Both|18 Years|N/A|No|Non-Probability Sample|Out-patients|January 2013|January 31, 2013|October 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01234168||113786|
NCT01231698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2048|Heart Rate Control With Esmolol in Septic Shock|Strict Heart Rate Control With Esmolol in Septic Shock: a Randomized, Controlled, Clinical Pilot Study||University of Roma La Sapienza|No|Completed|December 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||November 2011|January 23, 2013|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231698||113975|
NCT01235962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113387|A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)|A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy|PROTECT|Novartis|Yes|Active, not recruiting|November 2010|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235962||113649|
NCT01235975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113807|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years|Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older||GlaxoSmithKline||Completed|November 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|56 Years|N/A|Accepts Healthy Volunteers|||August 2011|July 23, 2012|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235975||113648|
NCT01231412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2448.00|Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant|A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2010|||September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|N/A|No|||December 2015|December 28, 2015|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231412||113997|
NCT01231685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN260|Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection|A Randomized Prospective Open Label Study of Switching to Raltegravir Based ART Compared to Maintaining Ritonavir Boosted PI-based ART on Liver Fibrosis Progression in HIV-HCV Coinfected Patients||McGill University Health Center|Yes|Completed|December 2011|March 2016|Actual|March 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01231685||113976|
NCT01237327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971-ONC-0028-094|Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer|Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study||Pfizer|No|Completed|November 2001|December 2009|Actual|December 2007|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|N/A|N/A|No|||May 2011|May 3, 2011|November 3, 2010|Yes|Yes||No|December 7, 2010|https://clinicaltrials.gov/show/NCT01237327||113544|At the time of study completion in 2007, via protocol amendment participants still on treatment were allowed to continue treatment, being monitored for Serious Adverse Events (SAE) only. The final participant discontinued in 2009.
NCT01237340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 701048-009|Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study|A Phase IIIb, Open-label, Single-arm, Multicenter Study to Assess the Immunogenicity of the Recombinant-Human Growth Hormone (r-hGH) Liquid Multidose Formulation (Saizen® Solution for Injection) When Administered to Male and Female Adults With Documented Growth Hormone Deficiency (GHD)||EMD Serono|No|Terminated|October 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|60 Years|No|||August 2013|August 4, 2013|November 5, 2010|Yes|Yes|The Sponsor voluntarily terminated this trial because compliance to strict Good Clinical    Practice (GCP) requirements was not ensured - No safety concerns|No|September 11, 2012|https://clinicaltrials.gov/show/NCT01237340||113543|
NCT01237587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14099|A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome|Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome||Eli Lilly and Company|No|Recruiting|March 2011|October 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|13 Years|17 Years|No|||October 2015|October 20, 2015|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01237587||113524|
NCT01232569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA25220|A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis||Hoffmann-La Roche||Completed|March 2011|November 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|656|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 1, 2010|Yes|Yes||No|April 18, 2013|https://clinicaltrials.gov/show/NCT01232569||113908|
NCT01232816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-202-SDR|Role of T Helper 17 and Regulatory T Cells in Delayed Graft Function|Can T Helper 17 and Regulatory T Cells Explain the Pathophysiology of Delayed Graft Function in Renal Transplant Recipients?||McGill University Health Center|No|Active, not recruiting|July 2010|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Urine Kidney biopsy Kidney preservation fluid|Both|18 Years|N/A|No|Non-Probability Sample|All kidney transplant recipients at our institution will be recruited prior to their        operative procedure.|April 2015|April 6, 2015|October 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01232816||113889|
NCT01233089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-368-C-107|Fitting Children With Contact Lenses|Quality of Life and Ease of Fit, Fitting Children With Contact Lenses|COPPER|Alcon Research|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|194|||Both|8 Years|16 Years|No|||September 2011|October 16, 2012|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233089||113868|
NCT01233349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/K/00310|Safety and Efficacy of Litramine in Overweight and Obese Subjects|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of LitramineTM in Reducing Body Weight in Overweight and Obese Subjects||InQpharm Group|No|Completed|July 2010|January 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233349||113848|
NCT01233375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-101-003|Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma|A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine- Refractory Patients With Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression||Clovis Oncology, Inc.|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|October 26, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233375||113846|
NCT01233388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD1619|Real-time Influenza Vaccine Surveillance|Real-time Influenza Vaccine Surveillance: FLUNET||Columbia University|No|Completed|November 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Pediatric, adult and OB patiente receiving an influenza vaccine|June 2012|June 8, 2012|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01233388||113845|
NCT01233401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005006837|Tdap Vaccination for Infant Caregivers|Tdap Vaccination for Infant Caregivers in the Pediatric Office||Yale University|No|Completed|June 2010|June 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|102|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|18-64 year old men and women who are mothers or other infant caregivers of 2 week old        infants|July 2011|July 26, 2011|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01233401||113844|
NCT01251978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4927s|Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)|Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma||New England Retina Associates|Yes|Completed|July 2010|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|50 Years|90 Years|No|||May 2013|May 1, 2013|November 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251978||112430|
NCT01252277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12349|Breast Cancer Risk Biomarkers in Premenopausal Women|Modulation of Breast Cancer Risk Biomarkers in Premenopausal Women by High Dose Omega-3 Fatty Acids||University of Kansas Medical Center|No|Completed|November 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Female|25 Years|54 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01252277||112407|
NCT01251107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41/99|Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma|Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL)||Fondazione Michelangelo|No|Completed|March 2000|November 2009|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|331|||Both|17 Years|60 Years|No|||February 2011|August 11, 2015|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01251107||112496|
NCT01251380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-55-52120-147|Dysport® Pediatric Lower Limb Spasticity Follow-on Study|A Phase III, Prospective, Multicentre, Open Label, Extension Study Assessing the Long Term Safety and Efficacy of Repeated Treatment With DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy||Ipsen|No|Completed|October 2011|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|216|||Both|2 Years|17 Years|No|||May 2015|May 26, 2015|November 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01251380||112475|
NCT01251393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACJC2010|Cocaine/Crack and Reduction of Compulsion With Biperiden|Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden||Federal University of São Paulo|Yes|Completed|May 2011|November 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|50 Years|No|||November 2012|November 23, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01251393||112474|
NCT01252771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-188|Phosphate Kinetic Modeling 2|Phosphate Kinetic Modeling 2|PKM2|Fresenius Medical Care North America|No|Completed|September 2010|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||June 2011|August 14, 2014|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252771||112369|
NCT01248637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIMO-PANC|Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole|A Clinical Trial of Intratumoral Hypoxia and Its Biologic Correlates in Patients Undergoing Surgical Resection of Localized Pancreatic Cancer, Using Pre-operative Administration of the Hypoxia Marker Pimonidazole.||University Health Network, Toronto|No|Recruiting|October 2010|||January 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|100|Samples With DNA|Pancreatic Tumor biopsy and blood samples.|Both|18 Years|N/A|No|Non-Probability Sample|Participating in ICGC Pancreatic Cancer Genome Project.|July 2015|July 10, 2015|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248637||112684|
NCT01248650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRK-820_HD_I_2008|Safety Study of TRK-820 for Patient With Hemodialysis|A Clinical Study to Investigate Pharmacokinetics and Safety of Single-Dose TRK-820 Soft Capsule in Patient With Hemodialysis|TRK-820|SK Chemicals Co.,Ltd.|No|Completed|December 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|N/A|No|||November 2009|November 24, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01248650||112683|
NCT01234467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1011|Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma|A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|November 2010|November 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|65 Years|N/A|No|||February 2016|February 11, 2016|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234467||113763|
NCT01234480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO-10-06084|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2010|||||N/A|N/A|N/A||||||||||||||February 13, 2015|October 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234480||113762|
NCT01234753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSKGUCH-1|Follow up of Adults With Congenitally Malformed Hearts With Focus on Computer-Based Education and Psychosocial Support|Follow up of Adults With Congenitally Malformed Hearts With Focus on Computer-Based Education and Psychosocial Support||University Hospital, Linkoeping|No|Completed|May 2006|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|1||Actual|114|||Both|18 Years|N/A|No|||January 2009|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234753||113741|
NCT01235000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 200903CVC-203708/99971a|TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost|TITRE IIB Follow-Up: TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost|TITRE IIB|British Columbia Centre for Disease Control|No|Enrolling by invitation|October 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|29 Months|51 Months|Accepts Healthy Volunteers|Non-Probability Sample|Participants of an earlier clinical trial (TITRE I); enrolled in winter 2008/09 as        previously unimmunized infants and toddlers (6-23 months of age) who later participated in        2009-10 study (TITRE II) to receive 2009-10 influenza vaccine|November 2010|November 4, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235000||113722|
NCT01235988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114013|Meta-analysis - Eltrombopag|Systematic Review of the Clinical and Cost Effectiveness of Treatments for Idiopathic (Immune) Thrombocytopenic Purpura (ITP): Direct Meta Analysis||GlaxoSmithKline|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1|||Both|18 Years|N/A|No|Probability Sample|Meta-analysis: A systematic review was conducted to obtain all relevant evidence relating        to eltrombopag and relevant studies were selected|November 2011|November 3, 2011|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235988||113647|
NCT01236534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC08-022LUB|Lubiprostone in Patients With Multiple Sclerosis Associated Constipation|Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation||University of Rochester|No|Completed|November 2010|April 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|November 4, 2010|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01236534||113605|
NCT01237067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110022|Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers|A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2010|December 2016|Anticipated|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|99 Years|No|||February 2016|March 8, 2016|November 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01237067||113564|
NCT01232582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ001|Safety and Efficacy of MRgFUS for the Treatment of Low Back Pain|Safety and Efficacy of ExAblate MR Guided Focused Ultrasound for the Treatment of Low Back Pain Related to Facet Joint Osteoarthritis||InSightec|No|Completed|October 2009|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2012|February 19, 2012|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01232582||113907|
NCT01232829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02537|Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer|A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer||National Cancer Institute (NCI)|Yes|Completed|October 2010|May 2014|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2014|November 19, 2014|October 30, 2010|Yes|Yes||No|November 19, 2014|https://clinicaltrials.gov/show/NCT01232829||113888|The study met criteria to accrue 32 subjects but only 18 were enrolled. It was decided to stop further enrollment after RO4929097 was discontinued by the sponsor and was no longer a development candidate.
NCT01233102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIBS-IHS-20101010|Mesenchymal Stem Cells Treat Liver Cirrhosis|Umbilical Cord Mesenchymal Stem Cell Transfusion in Patients With Severe Liver Cirrhosis||Chinese Academy of Sciences|Yes|Suspended|October 2009|December 2019|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||February 2016|February 19, 2016|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01233102||113867|
NCT01238510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009009|Comparison Between Provisional Versus Routine Kissing Balloon Technique After Main Vessel Crossover Stenting for Bifurcated Lesions.||PROTECT-SB|Saiseikai Yokohama City Eastern Hospital||Completed|March 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|85 Years|No|||April 2013|April 22, 2013|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238510||113454|
NCT01256086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-64428-3278|Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg|Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg in Patients With Stable Asthma Using Bronchoprovocation With Methacholine as a Bioassay Randomized, Double-blind, Four-period, Four-sequence Cross-over Trial||MEDA Pharma GmbH & Co. KG|No|Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|60 Years|No|||July 2012|August 13, 2012|December 7, 2010|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01256086||112114|
NCT01256398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02621|Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults ≥ 18 Years With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG||National Cancer Institute (NCI)||Active, not recruiting|December 2010|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||February 2016|March 14, 2016|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256398||112090|
NCT01252290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12350|Breast Cancer Risk Biomarkers in Postmenopausal Women|Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids||University of Kansas Medical Center|Yes|Completed|November 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Female|25 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01252290||112406|
NCT01256723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-LESSON2.0|Japan Unprotected Left Main Coronary Artery Disease Percutaneous Coronary Intervention (PCI) Strategy On New Generation Stents|Multicenter Prospective Registry of PCI With a New Generation Everolimus- Eluting Stent for Unprotected Left Main Coronary Artery Disease|J-LESSON|Associations for Establishment of Evidence in Interventions|Yes|Active, not recruiting|October 2010|May 2018|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|750|||Both|20 Years|N/A|No|Probability Sample|The left coronary artery superintendence part change to a morbid state is possessed, and        it is a patient for whom the PCI treatment is necessary.|October 2013|October 28, 2013|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01256723||112065|
NCT01248078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|226/2003|Antibiotic Prophylaxis Before Surgery Versus After Cord Clamping in Elective Cesarean Delivery - a Double-blind, Prospective, Randomized Placebo-controlled Trial|||Medical University of Vienna|No|Completed|March 2004|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1112|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|November 24, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248078||112726|
NCT01249235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-10-0538|Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery|Prospective Randomized Controlled Trial Comparing Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery||University Health Network, Toronto||Recruiting|October 2010|October 2011|Anticipated|October 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|No|||October 2010|November 24, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01249235||112638|
NCT01249248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0158|PD2i Analysis of Heart Rate Variability in Competitive Sports|PD2i Analysis of Heart Rate Variability in Competitive Sports|PACA|University of Mississippi Medical Center|Yes|Completed|October 2010|July 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Actual|90|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|College athletes on competitive teams.|April 2012|April 10, 2012|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01249248||112637|
NCT01253031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6928-P|Working Memory Changes With Aging and Hearing Loss|Effects of Aging and Hearing Loss During Rapid Sound Processing||VA Office of Research and Development|Yes|Completed|March 2011|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|63|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|All populations meeting the inclusion criteria|December 2015|December 21, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01253031||112349|
NCT01234493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE4rand1|Syndesmotic Injury and Fixation in Supination-External (SE) Ankle Fractures|Syndesmotic Injury and Fixation in SE Ankle Fractures: A Prospective Randomized Study||University of Oulu|Yes|Completed|June 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|140|||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2010|November 3, 2010|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234493||113761|
NCT01234766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1015|Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma|A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study)|Fol-BRITe|Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|October 2010|December 2020|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|October 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234766||113740|
NCT01235013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIS-MVC|Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3|Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3|DIS-MVC|Hospital Clinic of Barcelona|No|Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2010|November 18, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235013||113721|
NCT01236560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02616|Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma|A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas||National Cancer Institute (NCI)||Active, not recruiting|November 2010|||March 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|268|||Both|3 Years|21 Years|No|||December 2015|March 24, 2016|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236560||113603|
NCT01236573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110011|Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes|Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12||National Institutes of Health Clinical Center (CC)|Yes|Terminated|October 2010|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Actual|34|||Both|18 Years|66 Years|No|||October 2015|October 26, 2015|November 5, 2010|Yes|Yes|Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.|No|August 20, 2015|https://clinicaltrials.gov/show/NCT01236573||113602|Due to the unexpected toxicities, likely attributable to the tumor infiltrating lymphocytes (TIL) transduced with IL-12, and low percentage of durable responses, we decided to close this study.
NCT01231932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110014|Investigating Molecular-Genetic Correlates of Fatigue Experienced by Cancer Patients Receiving Treatment|Investigating Molecular-Genetic Correlates of Fatigue Experienced by Cancer Patients Receiving Treatment||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|90|||Both|18 Years|N/A|No|||May 2015|June 9, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231932||113957|
NCT01231945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911015|Low-Cost Molecular Cervical Cancer Screening Study|Low-Cost Molecular Cervical Cancer Screening Study||National Institutes of Health Clinical Center (CC)||Completed|October 2010|December 2010||||N/A|Observational|Time Perspective: Prospective|||Anticipated|7500|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 22, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01231945||113956|
NCT01231958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50HL105185|Boston Puerto Rican Health Study|The Boston Puerto Rican Health Study: Center for Population Health and Health Disparities|BPRHS|University of Massachusetts, Lowell|No|Active, not recruiting|June 2004|November 2015|Anticipated|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1499|Samples With DNA|blood, urine, saliva|Both|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Puerto Ricans older adults, aged 45-75 years, living in the Boston area.|May 2015|May 27, 2015|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01231958||113955|
NCT01236781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN PA 4006|Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates|Comparison of Full-Field Digital Mammography With Digital Breast Tomosynthesis Image Acquisition in Relation to Screening Call-Back Rate||American College of Radiology Imaging Network|Yes|Active, not recruiting|December 2010|||June 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|550|||Female|25 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236781||113586|
NCT01236794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20MD002316ELSC|Community-Based Participatory Research to Improve Health and Quality of Life of Latino Youth: Every Little Step Counts|Community-Based Participatory Research to Improve Health and Quality of Life of Latino Youth: Every Little Step Counts|ELSC|Arizona State University|Yes|Active, not recruiting|June 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|14 Years|85 Years|Accepts Healthy Volunteers|||November 2010|November 5, 2010|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01236794||113585|
NCT01237600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|447/2550(EC2)|Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction|Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction||Mahidol University|No|Completed|January 2008|November 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237600||113523|
NCT01237886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-569|Weaning And Variability Evaluation|Weaning And Variability Evaluation|WAVE|Ottawa Hospital Research Institute|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|660|||Both|18 Years|N/A|No|Non-Probability Sample|ICU patients|March 2014|March 17, 2014|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01237886||113501|
NCT01238185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INHANSE-ASPOD|Aspirin Mouthwash in Treating Patients With Oral Leukoplakia|Oral Topical Cyclooxygenase Inhibitor (Aspirin) Mouthwash for Treatment of Oral Dysplasia||National Cancer Institute (NCI)||Completed|February 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||November 2010|August 9, 2013|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238185||113478|
NCT01238211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02615|Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)||Active, not recruiting|December 2010|||July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 9, 2010|Yes|Yes||No|July 21, 2014|https://clinicaltrials.gov/show/NCT01238211||113477|
NCT01237912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPA0403|European Exposure Study|A European, Multi-centre Study to Determine the Exposure of Adult Smokers and Non-smokers to Cigarette Smoke Constituents||Philip Morris Products S.A.|No|Completed|April 2005|December 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|1667|Samples Without DNA|Urine|Both|21 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male or female 21 years of age or older with a stable health status as determined by the        Investigator and who were able to understand the subject information and to comply with        the study procedures and study schedule.|November 2010|November 9, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237912||113499|
NCT01248338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeES/05/Neb-EnD/001|Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function|Comparison the Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function and Large Artery Stiffness|NEMENDAS|Berlin-Chemie AG Menarini Group|No|Completed|March 2006|December 2009|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|30 Years|65 Years|No|||November 2010|November 24, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01248338||112706|
NCT01256736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-TCZ302|To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis|Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study||JW Pharmaceutical|Yes|Completed|March 2010|November 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|October 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01256736||112064|
NCT01252537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU 2010/14|Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia|Assessment of Immunosuppression in HIV-infected Patients With Tuberculosis With Access to Antiretroviral Therapy in Primary Health Care Centres in Ethiopia - Clinical and Immunological Markers and Associations With Treatment Outcome||Lund University|No|Completed|September 2010|January 2014|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1200|Samples Without DNA|Aliquoted plasma will be collected from consenting participants and stored at -80 C for      analysis of potential prognostic markers reflecting immune activation and inflammation      status.|Both|18 Years|N/A|No|Probability Sample|Patients initiating treatment for tuberculosis in primary health centres providing        integrated TB-HIV care in Oromia region, Ethiopia|April 2014|April 21, 2014|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01252537||112387|
NCT01249521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03501|Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer|Open Label Phase II Study Evaluating the Combination of Bevacizumab and AMG386 Without Chemotherapy as First Line Treatment of Advanced Colorectal Cancer|Vengeance|Austin Health|Yes|Recruiting|November 2010|November 2012|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||November 2010|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249521||112616|
NCT01249534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG10/144|Diagnostic Value of C-reactive Protein for Detection of Postoperative Inflammatory Complications After Gastroesophageal Cancer Surgery|||Cantonal Hospital of St. Gallen|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Given indication for gastroesophageal cancer surgery|November 2010|December 9, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249534||112615|
NCT01249508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2008/482|Nutrition Labeling Program to Promote Healthy Dietary Patterns|A University Canteen-based Labeling Program to Promote Healthy Dietary Patterns||University Ghent|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|474|||Both|17 Years|35 Years|Accepts Healthy Volunteers|||December 2010|December 21, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249508||112617|
NCT01234779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WN25333|A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia|A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia||Hoffmann-La Roche||Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|301|||Both|18 Years|65 Years|No|||February 2016|February 1, 2016|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234779||113739|
NCT01235026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fondecyt-1080519|Synbiotics and Low Grade Inflammation in Obese Subjects|Impact of the Administration of a Synbiotic on Low Grade Inflammation in Obese Subjects||University of Chile|Yes|Recruiting|November 2010|January 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|44|||Both|20 Years|50 Years|No|||October 2010|December 16, 2010|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01235026||113720|
NCT01235039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject -030J|A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus|A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus||Biodel|No|Completed|July 2009|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|43|||Both|19 Years|65 Years|No|||July 2015|July 28, 2015|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235039||113719|
NCT01235312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kraemer003|Microcirculatory Mapping of the Aging Hand and Foot|||Hannover Medical School||Completed|September 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Both healthy subjects and patients suffering from diabetes mellitus or manifested        peripheral arterial occlusive disease|June 2011|June 21, 2011|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235312||113698|
NCT01235624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8300|Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes|Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes||University Hospital, Montpellier|Yes|Completed|March 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1161|||Both|5 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235624||113675|
NCT01236274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01|The Risk of Myocardial Infarction in Users of Antipsychotic Agents|The Risk of Myocardial Infarction in Users of Antipsychotic Agents: a CALIBER Study||London School of Hygiene and Tropical Medicine|Yes|Active, not recruiting|November 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|90000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of patients registered at those GPRD practices that        agreed to linkage with the MINAP database, and whose practices are "up to standard"        according to the GPRD criteria.        Self-controlled Case Series:        Patients who experienced an MI and received an antipsychotic agent during up to standard        (UTS) follow-up in the GPRD, will be included and will act as their own control.        Case- control Study:        All cases of first recorded occurrence of an MI, identified by the recording of a Read        code in the GPRD within the UTS period until December 2009 will be identified. Five        controls for each case will be selected matched by age, gender, General Practitioner and        registration in the GPRD on the date of MI of the case.|November 2010|November 5, 2010|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01236274||113625|
NCT01236547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02614|Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer|A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer||National Cancer Institute (NCI)|Yes|Recruiting|October 2010|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|121|||Both|18 Years|N/A|No|||November 2015|March 14, 2016|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236547||113604|
NCT01236807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR INFORM-10|MR INFORM - MR Perfusion Imaging to Guide Management of Patients With Stable Coronary Artery Disease|MR INFORM - a Randomized Non-inferiority Multicenter Trial Comparing MR Perfusion Imaging and Fractional Flow Reserve (FFR) to Guide Management of Patients With Stable Coronary Artery Disease||King's College London|Yes|Recruiting|December 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|918|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236807||113584|
NCT01237080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-058|Intubation of Morbidly Obese Patients. A Clinical Trial, Comparing Glide Scope ® With Fastrach TM|Intubation of Morbidly Obese Patients. A Randomized Clinical Trial, Comparing GlideScope ® With Fastrach TM.||Glostrup University Hospital, Copenhagen|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||January 2013|January 17, 2013|November 8, 2010||No||No|October 29, 2012|https://clinicaltrials.gov/show/NCT01237080||113563|Acta Anaesthesiol Scand 2012; 56: 755–761
NCT01237314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04037-10-C|The Impact of Food on Blood Sugar in People With Type 2 Diabetes|Evaluation of the Glycemic Impact of Food in Patients With Type 2 Diabetes Taking Glargine and/or Exenatide|REACT2|HealthPartners Institute|No|Completed|November 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|46|||Both|18 Years|75 Years|No|Non-Probability Sample|Participants in Clinical Trials Study NCT01089569|April 2013|November 30, 2015|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01237314||113545|
NCT01237925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERE 185v2-10|Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Gel) in the Relief of Sunburn Related Symptoms|Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Gel) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Mild to Moderate Sunburn Related Symptoms||Mantecorp Industria Quimica e Farmaceutica Ltd.||Not yet recruiting||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|2 Years|60 Years|No|||November 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237925||113498|
NCT01237093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911018|Developing Biomarkers of Dietary Intake|Developing Biomarkers of Dietary Intake||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|August 5, 2015|November 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01237093||113562|
NCT01237353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GastricpH-6264|Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers|Pilot Study Evaluating Gastric Re-acidification Using Betaine Hydrochloride in Healthy Volunteers With Pharmacologically Induced Hypochlorhydria||University of California, San Francisco|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||May 2013|May 14, 2013|November 5, 2010|No|Yes||No|May 14, 2013|https://clinicaltrials.gov/show/NCT01237353||113542|
NCT01237366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03DA029423|Study Targeting Affect Regulation|A Pilot RCT of Expressive Writing With HIV-Positive Methamphetamine Users|STAR|University of California, San Francisco|Yes|Completed|September 2010|May 2014|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|56|||Male|18 Years|N/A|No|||October 2014|October 23, 2014|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01237366||113541|
NCT01237613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP027ext|Prospective Study on Artelon® Tissue Reinforcement in Repair of Chronic Ruptures and Re-ruptures of the Achilles Tendon|Prospective Study on Artelon® Tissue Reinforcement in Repair of Chronic Ruptures and Re-ruptures of the Achilles Tendon||Orthopedic Foot and Ankle Center, Ohio|No|Terminated|November 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|September 16, 2010|Yes|Yes|Sponsoring company declared bankrupty|No|May 8, 2015|https://clinicaltrials.gov/show/NCT01237613||113522|The sample size is small due to the study being terminated early because of sponsor bankrupty,
NCT01237899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14121|Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance|Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance After Multiple Oral Dosing of LY2623091 in Healthy Volunteers||Eli Lilly and Company|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|November 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01237899||113500|
NCT01234831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001336|A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients|A Novel Approach to MRSA Screening of Colonized Patients and Impact on Hospital Resource Allocation and Patient Care||Massachusetts General Hospital|No|Active, not recruiting|December 2010|March 2016|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|463|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 28, 2010|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT01234831||113735|This study was conducted at a single tertiary academic center and in the absence of any national guidelines, we implemented the local standard of care for discontinuation of CP, the components of which are found in variable combinations nationally.
NCT01234844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10157-2010CTIL|The Relationship Between Pet Therapy and "Well-being" in Geriatric Rehabilitation In-patients|The Relationship Between Pet Therapy and "Well Being" in Geriatric Rehabilitation In-patients||Meir Medical Center|No|Enrolling by invitation|November 2010|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|N/A|N/A|No|||August 2011|August 27, 2011|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234844||113734|
NCT01234857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-041|A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)|A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients||Merck Sharp & Dohme Corp.|Yes|Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|115|||Female|18 Years|N/A|No|||January 2015|January 19, 2015|September 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234857||113733|
NCT01248676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cindy Multi-Language Online|An Evaluation of the Usability and Usefulness of a Multi-language Online Patient Education Module|An Evaluation of the Usability and Usefulness of a Multi-language Online Patient Education Module: A Pilot Study||Sunnybrook Health Sciences Centre|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|N/A|N/A|No|||August 2011|August 15, 2011|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01248676||112681|
NCT01248663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-020|Reconstruction Method and Delayed Gastric Emptying After Pancreatic Surgery|Influence of the Reconstruction Method on the Incidence of Delayed Gastric Emptying After Pylorus Preserving Pancreaticoduodenectomy. A Prospective, Randomized Trial.||Medical University of Vienna|No|Completed|April 2007|August 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|90 Years|No|||April 2007|November 24, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248663||112682|
NCT01248910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASES|Health Benefits of Alpine Skiing for the Elderly|SASES: SAlzburg Skiing in the Elderly Study: Health Benefits of Alpine Skiing for the Elderly|SASES|University of Salzburg|No|Completed|December 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|N/A|2||||||Both|60 Years|75 Years||||October 2010|November 24, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01248910||112663|
NCT01249261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001079|Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover|A 1-year, Risedronate-free, Multicenter, Outpatient, Phase IIIb Extension Study to Assess Bone Turnover Recovery in Women With Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, and RVE1998080 (no NCT Study Numbers)||Warner Chilcott|No|Completed|October 2001|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|N/A|85 Years|No|||October 2011|October 27, 2011|November 24, 2010|No|Yes||No|July 14, 2011|https://clinicaltrials.gov/show/NCT01249261||112636|
NCT01250119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25279|A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.|Assess the Incidence of Mutations in the Tyrosine Kinase Domain of the Endothelial Growth Factor Receptor in UK Patients With Newly Diagnosed Metastatic or Recurrent Non-small Cell Lung Cancer and to Investigate the Quality of Life of These Patients Undergoing First-line Therapy With Erlotinib.||Hoffmann-La Roche||Completed|March 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|688|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|November 29, 2010|No|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01250119||112571|
NCT01249846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI/015P|The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis|The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis||Dexcel Pharma Technologies Ltd.|No|Completed|December 2010|||||Phase 3|Interventional|Primary Purpose: Treatment|2||||||Both|21 Years|N/A|No|||January 2013|January 16, 2013|November 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01249846||112591|
NCT01230892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027953|Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques|The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease||Emory University|Yes|Completed|February 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|21 Years|79 Years|No|||February 2015|February 12, 2015|September 10, 2010|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01230892||114036|
NCT01231178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B272|The Effect of an Alginate Based Beverage on Weight Loss|Alginate Fibers Effect on Body Weight and Risk Markers for Type 2 Diabetes and Cardiovascular Disease.|ALGOBES|University of Copenhagen|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||April 2010|October 29, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01231178||114015|
NCT01231425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE6-ACU-2010-01|Prospective Study of Clinical Utility of Acupuncture in Back Pain|Prospective Epidemiological Study To Evaluate The Clinical Utility Of Acupuncture In The Treatment Of Back Pain (Study PUCTURE-CV)|PUCTURE-CV|Group G-6|No|Active, not recruiting|July 2010|October 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|102|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is patients who go to the Acupuncture Office diagnosed of cervical,        thoracic or lumbar pain caused by musculoskeletal diseases, pretreated with        pharmacological treatment, they start treatment with acupuncture as adjunctive therapy for        symptoms of their disease.        Initially it was estimated that the optimal number of patients included to achieve the        objectives of the study is 102 patients|November 2011|November 7, 2011|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01231425||113996|
NCT01236287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904010380|Special Access for the Use of Voclosporin for Kidney Transplantation|Special Access for the Use of Voclosporin for Kidney Transplantation||Weill Medical College of Cornell University||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|65 Years||||July 2015|July 9, 2015|November 4, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01236287||113624|
NCT01237106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 0120100297|In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS)|In Vitro Maturation for Polycystic Ovary Syndrome (PCOS)- A Pilot Study||University Reproductive Associates|No|Completed|November 2010|November 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01237106||113561|
NCT01237626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2008610-01H|CIHR Team in Driving in Older Persons|The CIHR Team in Driving in Older Persons (Candrive II) Research Program|CANDRIVE|Ottawa Hospital Research Institute|Yes|Enrolling by invitation|October 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|932|||Both|70 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The cohort will be established in 7 cities in 4 provinces, including Ontario (Ottawa,        Thunder Bay, Toronto, Hamilton), Quebec (Montreal), Manitoba (Winnipeg) and British        Columbia (Victoria). Participants will be recruited through the media - newspapers        (community and city), radio, public presentations and newsletters to senior associations.        We have established collaboration with two senior organizations; Canada's Association for        the Fifty-plus (CARP) and the Federal Superannuates National Association (FSNA). These        senior organizations will be targeted through mail out letters and presentations at annual        meetings. Additionally, recruitment posters will be displayed at local community centres,        fitness centres, doctor's offices, hospitals and other clinic waiting rooms.|July 2015|July 24, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237626||113521|
NCT01238237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-712|Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA|Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma||Northwell Health|No|Active, not recruiting|December 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01238237||113475|
NCT01234012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMF001-PRT001|Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1|A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1||ImmunoFrontier, Inc.|No|Completed|May 2011|March 2014|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|October 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01234012||113798|
NCT01234025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 183750-CS3|Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)|A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer||Ionis Pharmaceuticals, Inc.|No|Active, not recruiting|November 2010|March 2015|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|112|||Male|18 Years|N/A|No|||November 2012|November 1, 2012|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234025||113797|
NCT01234285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0595|Safety of Heparin in Patients With Septic Shock|Safety of Heparin Anticoagulation for Prevention of Death in Patients With Septic Shock.||University of Colorado, Denver|Yes|Withdrawn|December 2010|October 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|90 Years|No|||May 2014|May 19, 2014|September 23, 2010|Yes|Yes|Sara Cheng, MD has left the Univ. of Colorado and the study has been closed.|No||https://clinicaltrials.gov/show/NCT01234285||113777|
NCT01234584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIL0227-10-RMB|Soft and Hard Tissue Changes Around the New Lance® Implants Using Traditional and Switch Platform Abutments|||Rambam Health Care Campus||Recruiting|September 2010|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|45|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2010|December 7, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234584||113754|
NCT01234597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_05146|Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day|A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day|SeLan|Sanofi||Completed|December 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|21 Years|N/A|No|||June 2015|June 17, 2015|November 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01234597||113753|
NCT01249287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IRB-031|FMRI in Monitoring Intracerebral Stem Cell Implantation for Chronic Stroke Patients|||China Medical University Hospital|Yes|Active, not recruiting|April 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|35 Years|70 Years|No|Non-Probability Sample|University hospital|November 2010|November 26, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249287||112634|
NCT01248923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-520-111|A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|||Array BioPharma||Active, not recruiting|December 2010|||March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248923||112662|
NCT01248936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25597|A Study of RO5185426 in Patients With Metastatic Melanoma|A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA||Hoffmann-La Roche||Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|374|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|November 24, 2010|Yes|Yes||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01248936||112661|
NCT01248949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI3617-1043|A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors|Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors||MedImmune LLC|No|Completed|October 2010|October 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|162|||Both|18 Years|99 Years|No|||December 2015|December 3, 2015|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01248949||112660|
NCT01249274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005006793|Progesterone for Postpartum Cocaine Relapse|Progesterone for Postpartum Cocaine Relapse||Yale University|Yes|Completed|August 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|50 Years|No|||August 2013|August 26, 2013|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01249274||112635|
NCT01249859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADCI 001|Prognosis of Signet Ring Cells in Upper Digestive Neoplasms|Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas?|ADCI001|University Hospital, Lille|Yes|Completed|March 2010|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|2500|||Both|18 Years|95 Years|No|Probability Sample|Intention to treat retrospective case control multicentric study, Patients will be divided        into two groups (ADCI or ADNCI) depending on the presence or not of signet ring cells on        definitive histologic analysis Another analysis based on chemo administration or not will        be provided A pairing on demographic criteria (age, sex, ASA score, center, TNM stage and        will be done to ensure comparability in case control study groups.|December 2014|December 8, 2014|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01249859||112590|
NCT01250132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.599|Ante-hypophyseal Dysfunctions in Children Following Moderate to Severe Traumatic Brain Injuries|Are Ante-hypophyseal Dysfunctions in the Acute Phase of Moderate to Severe Traumatic Brain Injury Predictive of Long-term Ante-hypophyseal Sequelae in Children?|Endoc-TC|Hospices Civils de Lyon|No|Recruiting|October 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|2 Months|16 Years|No|||September 2015|September 15, 2015|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01250132||112570|
NCT01230632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100510a|Metabolic Phenotyping of Individuals Born Following Assisted Reproduction Techniques|Metabolic Phenotyping of Individuals Born Following Assisted Reproduction|IMPART|University of Adelaide|Yes|Completed|September 2010|September 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|34|||Both|16 Years|26 Years|Accepts Healthy Volunteers|||December 2013|December 7, 2013|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01230632||114056|
NCT01230905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008341-01H|Study to Monitor the Effects of Androgen Suppression Treatment on the Heart|Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve?|AST|Ottawa Heart Institute Research Corporation|No|Completed|July 2008|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|181|||Male|40 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01230905||114035|
NCT01235351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMI 56|Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56|Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56|ELEVATE-TIMI56|The TIMI Study Group|Yes|Active, not recruiting|October 2010|||October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|275|||Both|18 Years|75 Years|No|||October 2011|October 4, 2011|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235351||113695|
NCT01235364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-nr 2009/ 218|Assessment of Pain With Insertion of the Foley Catheter for Induction of Labour|||Uppsala University Hospital|No|Completed|August 2009|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|N/A|No|||August 2009|August 10, 2011|November 4, 2010||||No||https://clinicaltrials.gov/show/NCT01235364||113694|
NCT01235650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00390|Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care|Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care||Nationwide Children's Hospital|No|Completed|September 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|160|||Both|N/A|N/A|No|Non-Probability Sample|Spinal fusion patients|January 2012|January 27, 2012|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235650||113673|
NCT01235663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breastfeeding-2650|Minimizing the Risk for Obesity During Infancy by Extensive Advisory Service|Does Advisory Support to Prolong the Breast-feeding Period Reduce the Risk for Obesity and Metabolic Dysfunction in Infants of Obese Mothers ?||Hvidovre University Hospital|No|Completed|September 2010|December 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|226|||Both|N/A|3 Days|Accepts Healthy Volunteers|||March 2015|March 17, 2015|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235663||113672|
NCT01235676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEXA-2650|Tissue Composition of Newborn Infants of Obese and Lean Mothers|Is it Possible to Reduce the Number of Macrosomic Infants With Abundant Fat Tissue by Lifestyle Intervention During Pregnancy ?||Hvidovre University Hospital|No|Completed|February 2010|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|270|||Both|N/A|3 Days|Accepts Healthy Volunteers|||March 2013|March 18, 2013|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235676||113671|
NCT01237639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120673|Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation|Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation: The TRIST Study|TRIST|Ottawa Hospital Research Institute|Yes|Recruiting|March 2011|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2015|February 8, 2015|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01237639||113520|
NCT01237379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McNamara NARSAD|Peroxisomal Defects and Familial Risk for Bipolar Disorder|Peroxisomal Defects and Familial Risk for Bipolar Disorder||University of Cincinnati|No|Completed|October 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||4|Actual|80|None Retained|Laboratory methods: The gas chromatography procedure used to determine red blood cell fatty      acid composition. Briefly, total fatty acid composition will be determined. Indices of      peroxisome function, including (1) plasma very long chain fatty acids concentrations, (2)      plasma bile acid C27 intermediate concentrations, (3) plasma pipecolic acid concentrations,      and (4) RBC plasmalogen concentrations, will be determined by liquid chromatography tandem      mass spectrometry and gas chromatography. Plasma cytokine and C-Reactive Protein      (CRP)concentrations will be determined. All blood analyses will be performed by a technician      blinded to diagnostic group identity.|Both|10 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Subjects: In order to accomplish this aim, 20 healthy controls, 20 high-risk, 20        ultra-high risk, and 20 first-episode manic youth (ages 10-18 years old) will be recruited        at a rate of 1 subject/group per month over the first 20 months. Subjects being recruited        from the following IRB approved NIMH-sponsored trials: MH077138 (UC-IRB #: 07-04-10-03,        BITREC Project 3; PI: DelBello), MH083924 (UC-IRB #: 04-09-15-03, CO-PIs        DelBello/McNamara), and MH080973 (UC-IRB #: 08-10-30-01, PI: DelBello).|December 2014|December 19, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01237379||113540|
NCT01237392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYSDH-Dbr-06-08|Ultrasonic Wound Debridement vs. Standard Sharp Debridement|Ultrasonic Surgical Wound Debridement vs. Standard Sharp Debridement In the Treatment of Chronic Wounds: A Single Center, Randomized, Parallel, Clinical Outcome Trial||Calvary Hospital, Bronx, NY|No|Completed|June 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|75|||Both|18 Years|90 Years|No|||July 2014|July 22, 2014|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237392||113539|
NCT01237990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-LC-2009-01|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures||Pathfinder Therapeutics|Yes|Completed|August 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject with liver cancer scheduled for a laparoscopic staging and open liver        resection procedure.|January 2012|January 19, 2012|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237990||113493|
NCT01237938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 71005|Effect of a Low Glycemic Index Diet on Breast Density|Pilot Study of the Effect of a Low Glycemic Index Diet on Breast Density (Diet and Breast Health Study )||Roswell Park Cancer Institute|Yes|Terminated|March 2006|||October 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|46|||Female|40 Years|60 Years|No|||April 2014|April 2, 2014|November 8, 2010||No|test|No||https://clinicaltrials.gov/show/NCT01237938||113497|
NCT01237951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0506|High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma|High-dose Gemcitabine, Busulfan and Melphalan With Autologous Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2010|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|70 Years|No|||May 2015|May 1, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237951||113496|
NCT01234038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 183750-CS4|Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel|A Phase 1b/2 Study of Carboplatin-Paclitaxel, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Stage IV Non-Small Cell Lung Cancer|NSCLC|Ionis Pharmaceuticals, Inc.|No|Active, not recruiting|November 2010|March 2015|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|112|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234038||113796|
NCT01234051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSWOG 2010-1|Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer|Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer||Korean South West Oncology Group|No|Recruiting|November 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||November 2010|December 9, 2011|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01234051||113795|
NCT01234298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-320|SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia|A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Low- and High-dose Range Groups of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia|NSS|Shire||Withdrawn|January 2012|February 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||September 2011|March 13, 2012|October 29, 2010|Yes|Yes|Study was discontinued due to non-safety related business prioritization decisions|No||https://clinicaltrials.gov/show/NCT01234298||113776|
NCT01234311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10TASQ10|A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer||Active Biotech AB|Yes|Completed|March 2011|August 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1245|||Male|18 Years|N/A|No|||October 2015|October 2, 2015|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234311||113775|
NCT01234883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPIVTUSA001|Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis|A Double-Blind, Randomized, Comparative Efficacy and Safety Trial of Intravenous Solutions for the Treatment of Moderate to Severe Dehydration in Children With Acute Gastroenteritis||Baxter Healthcare Corporation|No|Terminated|June 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|6 Months|10 Years|No|||December 2013|February 28, 2014|November 3, 2010|Yes|Yes|Insufficient enrollment|No|February 28, 2014|https://clinicaltrials.gov/show/NCT01234883||113731|Early termination of study due to low enrollment.
NCT01234896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1080|Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products|Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products. A Study in Healthy Smokers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|October 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|44|||Both|19 Years|50 Years|No|||July 2012|July 6, 2012|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234896||113730|
NCT01249300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-130|Comparison of Ultrasound and Videofluoroscopic Imaging Techniques in Diagnosing Dysphagia in Stroke Patients|Comparison of Ultrasound and Videofluoroscopic Imaging Techniques in Diagnosing Dysphagia in Stroke Patients||China Medical University Hospital||Not yet recruiting|December 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|20 Years|70 Years|No|Non-Probability Sample|The Stroke Center inpatients and outpatients with known or suspected dysphagia can be        included for study as well as patients who are admitted specifically for this protocol.        (Difficulty swallowing food or pills,changed swallowing ability,coughing or choking when        eating, shortness of breath during swallowing, food backing up into the mouth or nasal        passage, fever or voice changes after swallowing, pain when swallowing, unexplained loss        of weight.|November 2010|November 26, 2010|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249300||112633|
NCT01249313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-237|Risk Factor and Outcome of Candidemia|||China Medical University Hospital||Not yet recruiting|September 2011|December 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|90 Years|No|Non-Probability Sample|patient had candidemia from 2002-2010|June 2011|June 22, 2011|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01249313||112632|
NCT01249547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC022|Nasopharyngeal Carcinoma (NPC) Axitinib|Phase 2 Study of Axitinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma||Chinese University of Hong Kong|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249547||112614|
NCT01249872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|morbid obesity_post-op pain|Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens|Postoperative Thoracic Epidural Analgesia in Super Obese Patients (~BMI 60 kg m-2) Undergoing Open Weight Loss Surgery :Does the Addition of Morphine to 0.1% and 0.2% Levobupivacaine Affect Postoperative Pain Relief, Perioperative Lung Function, Return of Normal Gastrointestinal Mobility and Ambulation?||University of Patras|No|Completed|January 2010|September 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|96|||Both|18 Years|50 Years|No|||June 2013|June 18, 2013|November 22, 2010||No||No|March 31, 2013|https://clinicaltrials.gov/show/NCT01249872||112589|Patients in groups A and D did not receive epidural morphine intraoperatively.We excluded patients aged > 50 yr as increasing the age of morbidly obese patients, might have increased the risk of perioperative complications
NCT01250145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13764|A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women|A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women||Eli Lilly and Company|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|251|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 21, 2012|November 29, 2010|No|Yes||No|September 21, 2012|https://clinicaltrials.gov/show/NCT01250145||112569|
NCT01250431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-YOUNT-11/24/10|Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques)|Gene Expression Correlates of PTSD Symptom Change After EFT (Emotional Freedom Techniques): A Randomized Controlled Trial||Soul Medicine Institute|No|Recruiting|November 2010|November 2017|Anticipated|November 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01250431||112547|
NCT01235377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMS156|Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study|Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study||VA Pharmacy Benefits Management Strategic Healthcare Group|No|Completed|September 2011|February 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 4, 2010|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01235377||113693|
NCT01235390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917609-1|Effects of the Consumption of California Walnuts on Cardiovascular Health|Effects of California Walnuts on Vascular Function and Immune Health in Postmenopausal Women||University of California, Davis|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01235390||113692|
NCT01235689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-271|Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease|An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease|CALM|AbbVie|No|Active, not recruiting|February 2011|November 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|253|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235689||113670|
NCT01235702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-0724|Metro Atlanta Heart Disease Study - II (MAHDS II)|Multiple CVD Risk Reduction in Adult African-Americans: A Pilot Study||Morehouse School of Medicine|No|Completed|September 2002|October 2003|Actual|October 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|210|||Both|21 Years|65 Years|No|||March 2003|November 4, 2010|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235702||113669|
NCT01236001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1021|Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older|Multi-center, Observational, Drug-utilization Study in Belgium to Evaluate the Use of VIMPAT® in Clinical Practice as Adjunctive Treatment of Partial Onset Epilepsy in Subjects Aged 16 and Older.||UCB Pharma|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|192|||Both|16 Years|N/A|No|Non-Probability Sample|Routine clinical practice of neurologist / neuropsychiatrist / neurosurgeon /        neuropediatrician Sampling based upon request by the Belgian reimbursement authorities:        request to report on 100 patients|August 2013|August 6, 2013|November 5, 2010|No|Yes||No|May 13, 2013|https://clinicaltrials.gov/show/NCT01236001||113646|
NCT01236014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114014|Indirect Comparison Between Eltrombopag & Romiplostim|Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events||GlaxoSmithKline|No|Completed|August 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|1|||Both|18 Years|N/A|No|Probability Sample|Identified through a systematic review: TRA102537, Kuter 2008|November 2011|November 3, 2011|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01236014||113645|
NCT01236027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10080337|Specimen Collection Study for Development and Validation of Laboratory Procedures|Collection of Biological Specimens for Development and Validation of Laboratory Procedures to Support Future Clinical Research Studies||University of Pittsburgh|No|Recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-negative women|February 2016|February 10, 2016|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01236027||113644|
NCT01235416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20050107|A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors|A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors||Amgen||Completed|September 2005|February 2010|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|October 29, 2010||||No||https://clinicaltrials.gov/show/NCT01235416||113690|
NCT01235728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0873-022|A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)|A Double Blind, Active-Comparator-, and Vehicle-Controlled, Multiple-Dose Study to Evaluate the Efficacy and Pharmacokinetics of MK-0873 in Patients With Plaque Psoriasis||Merck Sharp & Dohme Corp.|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|24|||Both|18 Years|65 Years|No|||April 2015|April 23, 2015|November 4, 2010|Yes|Yes||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01235728||113667|
NCT01236040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114371|Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old|Immunogenicity and Safety Study of GSK Biologicals' Cell Culture Derived Pandemic Influenza Vaccines GSK2590066A and GSK2340273A Administered to Healthy Adults 18 - 49 Years Old||GlaxoSmithKline||Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|521|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2011|April 11, 2013|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01236040||113643|
NCT01237418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10240|French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010|French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010|FAST-MI 2010|French Cardiology Society|Yes|Active, not recruiting|October 2010|December 2022|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3700|Samples With DNA|When normal blood test done at the patient's admission into ISB, an additional quantity of      60 ml of blood will be drawn up for building a DNAthèque (15 ml) and a serum bank (45 ml) on      only markers related to atherosclerotic disease|Both|18 Years|N/A|No|Probability Sample|Patients will be recruited consecutively in the CIAU member during a period of 2 months,        including sub-populations of specific interest (diabetes and / or elderly patients, for        example). A list of eligible patients not included and must be completed by the        participating centers during the same period, with reasons for non inclusion.        A questionnaire will be sent to each center prior to recruitment, including type of        service and number of beds in the facility.        The study will be given to any medical facility, University Hospital, CHG, CHR, health        facility of the Army, including a clinic or intensive care unit entitled to receive        emergency ACS. In each center, a medical consultant will be appointed to collect        phenotypic data for the study case report forms in electronic patient.|February 2015|February 12, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237418||113537|
NCT01237964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7631-JH-CTIL|Injectable Collagenase For Burns' Associated Contracture|Phase 2 Of Injectable Collagenase (Xiaflex) For Burns' Associated Contracture||Sheba Medical Center|No|Not yet recruiting|March 2011|August 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||November 2010|November 9, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01237964||113495|
NCT01237977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-MDTX-GL-0901|Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines|Double-blind, Randomized, Active Drug Comparative, Parallel Designed, Multi-center,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of "Meditoxin® Versus Botox® in the Treatment of Glabellar Lines||Medy-Tox|No|Completed|November 2009|||September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|314|||Both|20 Years|65 Years|No|||April 2012|April 24, 2012|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01237977||113494|
NCT01238289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18DK070666-01A1|Randomized Trial of Peer Led Education-Project Dulce|Peer-Led Diabetes Education Programs in High Risk Mexican Americans Evaluates Glycemic Control Compared to Standard Approaches: A Project Dulce™ Promotora Randomized Trial||Scripps Whittier Diabetes Institute|Yes|Completed|September 2006|February 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|207|||Both|21 Years|75 Years|No|||November 2010|January 5, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238289||113471|
NCT01238302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM-10-03|Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma(PRP) in Large to Massive Tears|Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma(PRP) in Large to Massive Tears : A Randomized Controlled Trial||Seoul National University Hospital|No|Completed|July 2009|||October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|No|||March 2013|March 11, 2013|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238302||113470|
NCT01238250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0320|Online Study of Individuals With Genetic Changes and Features of Autism: Simons Variation in Individuals Project (Simons VIP)|Online Study of Individuals With Genetic Changes and Features of Autism: Simons Variation in Individuals Project (Simons VIP Phase 2)||Simons VIP Connect|No|Recruiting|October 2010|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||5|Anticipated|5000|Samples With DNA|Whole blood will be collected for the purposes of DNA analysis and for some participants to      establish a cell line that can be used for research-related purposes.|Both|N/A|N/A|No|Non-Probability Sample|The study continues to enroll and collect data from individuals with 16p11.2 and 1q21 CNVs        in addition to the genetic changes associated with autism, specified above. Data is also        collected from matched sibling control subjects and parents.        This study has already collected data on approximately 100 individuals with a 16p11.2        deletion, 100 individuals with a 16p11.2 duplication, 10 individuals with a 1q21.1        deletion, 10 individuals with a 1q21.1 duplication and approximately 220 matched sibling        control subjects and 440 parents.|November 2015|November 16, 2015|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238250||113474|
NCT01238263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yavuzyesilova|Autologous Serum Skin Testing in Patients With Atopic Dermatitis Autologous Serum Skin Testing in Patients With Atopic Dermatitis|||Yuzuncu Yıl University|Yes|Completed|April 2009|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|90|||Both|1 Year|45 Years|Accepts Healthy Volunteers|Probability Sample|90|May 2009|November 9, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238263||113473|
NCT01234064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS Pilot Substudy|Graduated Compression Stockings (GCS) Pilot Substudy|Graduated Compression Stockings (GCS) for Prevention of Venous Thromboembolism in Patients Who Have Major Surgery: Pilot Study Assessing Feasibility of Adding This Evaluation to the PeriOperative ISchemic Evaluation-2 Trial (POISE-2 Trial)||McMaster University|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|45 Years|N/A|No|||December 2011|January 16, 2012|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234064||113794|
NCT01234324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO/CAO-STO-0801|ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction|An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.|NEOPECX|AIO-Studien-gGmbH|Yes|Active, not recruiting|October 2010|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01234324||113774|
NCT01234337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12444|Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer|A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer||Bayer|Yes|Active, not recruiting|February 2011|June 2016|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|537|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 4, 2010|Yes|Yes||No|May 10, 2015|https://clinicaltrials.gov/show/NCT01234337||113773|Results of exploratory analysis of biomarkers are anticipated in the month of February, 2016.
NCT01234610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15455|Feasibility Study of Exercise Training for Abdominal Aortic Aneurysm Disease|Exercise Therapy for Abdominal Aortic Aneurysm Disease: a Feasibility Study||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Recruiting|January 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|No|||November 2010|November 4, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234610||113752|
NCT01234909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 10/129, GC 1141|Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis|The Atopic Dermatitis Clinic as an Entry Point for Community Outreach in Asthma, Missed Immunizations, and Vitamin D Deficiency||Medical College of Wisconsin|No|Terminated|November 2010|March 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|98|||Both|1 Year|18 Years|No|Non-Probability Sample|Children's Hospital of Wisconsin Pediatric Dermatology clinic|May 2015|May 28, 2015|November 3, 2010||No|Not meeting enrollment goals.|No||https://clinicaltrials.gov/show/NCT01234909||113729|
NCT01235819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM/CHCC/03/2010|Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus|Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus||Command Hospital, India|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|12 Years|30 Years|No|||November 2010|September 19, 2011|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01235819||113660|
NCT01249326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0084|Protein Need and Interest of " Quick Proteins " to the Obese Subject Operated by Bariatric Surgery (BIBOP)|Protein Need and Interest of " Quick Proteins " to the Obese Subject Operated by Bariatric Surgery (BIBOP)|BIBOP|University Hospital, Clermont-Ferrand||Recruiting|December 2010|June 2016|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|70|||Both|18 Years|60 Years|No|||July 2012|July 13, 2012|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01249326||112631|
NCT01249573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2010/580|The Effect of Fascia Therapy and Transcutaneous Fibrolysis on Acute Ankle Sprain|The Effect of Fascia Therapy and Transcutaneous Fibrolysis on Acute Ankle Sprain in Young Adults.||University Ghent|No|Completed|October 2010|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|35 Years|No|||June 2011|June 9, 2011|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01249573||112612|
NCT01249560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009 A/12|Impact of Raltegravir on the Viral Reservoirs|Impact of Raltegravir on the Viral Reservoirs||Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|January 2011|March 2011|Anticipated|January 2011|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|60 Years|No|Probability Sample|hiv +|December 2009|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01249560||112613|
NCT01250158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 000369|Liver-PILP First-in-Man|First In-vivo Trial of the Liver Percutaneous Isolated Localized Perfusion (PILP) Set for the Treatment of Liver Metastases|PILP FiM|Medical Device Works NV SA|Yes|Recruiting|September 2010|||January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01250158||112568|
NCT01250704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-190|Inherited Myokymia: A Clinical and Genetic Study of a Family|Inherited Myokymia: A Clinical and Genetic Study of a Family||China Medical University Hospital|Yes|Recruiting|April 2010|||March 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|18|Samples With DNA|Genomic DNA was extracted from each patient's peripheral blood leukocytes using Genomaker      DNA extraction kit (Blossom, Taipei, Taiwan). The complete KCNA1 coding region, including      the intron/exon boundaries, was amplified according to the procedure reported by Imbrici et      al|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We interview and examine the family members directly at our hospital and home visit or        indirectly by telephone visit.|November 2010|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250704||112527|
NCT01234818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG 2006|Management of Endometrial Hyperplasia With a LNG-IUS: Multicenter Study: KGOG2006|Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System:Single Arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2006)|KGOG2006|Korean Gynecologic Oncology Group|No|Recruiting|November 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|20 Years|N/A|No|||November 2012|November 8, 2012|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234818||113736|
NCT01235091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-0438|Prevention of HIV and STDs in Drug Using Women|Prevention of HIV and STDs in Drug Using Women|WTW|Washington University School of Medicine|Yes|Completed|August 2000|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Prevention|3||Actual|501|||Female|18 Years|N/A|No|||November 2010|November 4, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01235091||113715|
NCT01235104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0652/10|Impact of Total Nephrectomy on Patients With Kidney Stone|Impact of Total Nephrectomy on Patients With Kidney Stone||University of Sao Paulo General Hospital|No|Active, not recruiting|January 2001|October 2010|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with kidney stone submitted to total nephrectomy from january 2001 to october        2010 at University of Sao Paulo General Hospital|January 2001|November 4, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01235104||113714|
NCT01235403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1007|Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure|A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses|SELF|UCB Pharma|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|November 3, 2010|Yes|Yes||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01235403||113691|
NCT01235715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29054|The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery|The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery||Hospital for Special Surgery, New York|No|Completed|September 2010|September 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|20 Years|90 Years|No|||August 2013|August 22, 2013|October 8, 2010||No||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01235715||113668|
NCT01237119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE2013|Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis|48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes|LEAN|University of Birmingham|Yes|Completed|August 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|70 Years|No|||March 2016|March 22, 2016|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237119||113560|
NCT01237132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC EWE|East-West Hepatocellular Carcinoma Study Group|EAST-WEST HEPATOCELLULAR CARCINOMA STUDY GROUP||University of Milan|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|Patients affected by HCC|December 2009|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237132||113559|
NCT01243996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD63-1|High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant|High-dose Ibuprofen for Patent Ductus Arteriosus in Extremely Preterm Infants: a Randomized Controlled Study||University of Florence|No|Completed|June 2008|October 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|70|||Both|N/A|24 Hours|No|||July 2010|November 18, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243996||113037|
NCT01244308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T86|Effectiveness and Reliability of VectSelect™ Feature for Avoidance of Phrenic Nerve Stimulation in Cardiac Resynchronisation Therapy (CRT) Patients|Effectiveness and Reliability of VectSelect™ Feature for Avoidance of Phrenic Nerve Stimulation in CRT Patients|Efface|St. Jude Medical|No|Completed|March 2008|August 2011|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|132|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with indication for implantation of CRT-D device|July 2013|July 26, 2013|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01244308||113013|
NCT01278277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARSAF02|Saffron Supplementation in Stargardt's Disease|A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations|STARSAF02|Catholic University of the Sacred Heart|No|Active, not recruiting|February 2011|December 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|8 Years|60 Years|No|||July 2015|July 31, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278277||110408|
NCT01276340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008433|Prospective Evaluation of Keat Electrostimulator in the Auto-reeducation of Female Urinary Incontinence|Prospective Evaluation of Keat Electrostimulator in the Auto-reeducation||Centre Hospitalier Universitaire de Saint Etienne|Yes|Completed|September 2010|February 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Female|18 Years|N/A|No|Non-Probability Sample|women with stress, urge and mixed incontinence with an indication for perineal reeducation        follow in gynecology|May 2012|May 16, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276340||110557|
NCT01276353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-221|A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia|A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia||Eisai Inc.||Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|50 Years|N/A|No|||August 2014|August 5, 2014|January 12, 2011||No||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01276353||110556|
NCT01277224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI081297|Effectiveness of a Physical Activity Intervention on the Obesity of Schoolchildren|Effectiveness of a Leisure Time Physical Activity Intervention on the Overweight and the Obesity in Schoolchildren. The Cuenca's Study|Movi2|University of Castilla-La Mancha|Yes|Completed|September 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1200|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277224||110489|
NCT01277484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEC-KOR-9007|Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML|Single Arm, Open Label, Phase I Study for Dose and Schedule Finding of Decitabine in Patients With Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation|PODAC|Seoul St. Mary's Hospital|No|Active, not recruiting|January 2011|December 2015|Anticipated|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||November 2015|November 18, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277484||110469|
NCT01243294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP209OC|Study Evaluating a New Ostomy Appliance With Regard to Leakage, Handling and Comfort|Cross-over, Open Label Study Evaluating a New Ostomy Appliance With Regard to Leakage, Handling and Comfort||Coloplast A/S|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|56|||Both|18 Years|N/A|No|||October 2011|October 4, 2011|August 9, 2010||No||No|February 17, 2011|https://clinicaltrials.gov/show/NCT01243294||113091|
NCT01246843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO200904|Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib|Evaluation of Cognitive Function of Patients Treated With Sunitinib or Sorafenib||Radboud University|No|Completed|July 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with mRCC are asked by their own physician.|October 2011|November 1, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246843||112821|
NCT01243541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10CC03|Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel|Cold Therapy to Prevent Paclitaxel-Induced Peripheral Neuropathy and Cutaneous Toxicity||Northwestern University|Yes|Active, not recruiting|October 2010|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|66|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01243541||113072|
NCT01243554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETiP-Ob|Exercise Training in Pregnancy for Obese Mothers|Exercise Training in Pregnancy. Good for the Mother - Good for the Child?||Norwegian University of Science and Technology|No|Recruiting|September 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|No|||February 2016|February 4, 2016|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01243554||113071|
NCT01247636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03247|Home-Exercise vs General Physical Activity: Effect on Health-related Quality of Life|Effect of Progressive Home-Exercise on Health-related Quality of Life, Balance and Mobility in Older People Discharge From an Outpatient Geriatric Clinic.||Oslo University Hospital|No|Completed|January 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|110|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2005|November 23, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01247636||112760|
NCT01243307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT327-1002|A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers|A Phase I, Single-centre, Multiple-dose, Placebo-controlled Crossover Study to Investigate the Pharmacodynamic Effects of CT327 (0.1% Topical Cream) on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers||Creabilis SA|No|Completed|January 2011|May 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243307||113090|
NCT01236898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sialic acid-1|Pharmacokinetic Study on N-acetylneuraminic Acid|Pharmacokinetic Study on N-acetylneuraminic Acid in Patients With Distal Myopathy With Rimmed Vacuoles (DMRV) - Hereditary Inclusion Body Myopathy (hIBM)||Tohoku University|Yes|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|40 Years|No|||August 2011|September 7, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236898||113577|
NCT01236911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT071110|Prognosis Association of Hypocalcemia on Moderate-severe TBI, COHORTE STUDY|||Universidad Autonoma de San Luis Potosí|No|Recruiting|October 2010|November 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|16 Years|65 Years|No|Non-Probability Sample|Patients bettween 16 and 65 years old with moderate -severe TBI with less as 24 hours ,        without administration of steroids or statins|November 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236911||113576|
NCT01236378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1741018|Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients|An Open-Label, Non-Randomized Study To Evaluate The Steady-State Pharmacokinetics Of Sirolimus Tablets In Chinese Patients With Stable Renal Allografts||Pfizer|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2011|February 29, 2012|November 5, 2010|No|Yes||No|January 30, 2012|https://clinicaltrials.gov/show/NCT01236378||113617|
NCT01237184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003M78573|Initial Stability of Posterior Maxillary Implants With Bicortical Fixation|Comparison of Initial Implant Stability of Posterior Maxillary Implants With Bicortical Fixation to Implants Engaging Only the Alveolar Crest||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|September 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Eligible volunteers must be at least 18 years old, partially edentulous in maxillary        posterior region with 7-11 mm residual bone height under the sinus floor and be indicated        for CBCT scan for diagnosis and treatment planning, and of a medical risk of ASA I or II        classification to participate. Patients with bone pathology, sinus infection, and who are        pregnant will be excluded.        Implants requiring tapping, site of an implant replacement, and implant with dehiscence        and/or fenestration will be excluded.|December 2013|December 16, 2013|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01237184||113555|
NCT01237197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009M88952|Exenatide in Extreme Pediatric Obesity|Exenatide in Extreme Pediatric Obesity||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|October 2010|October 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|12 Years|19 Years|No|||September 2014|September 4, 2014|November 1, 2010|Yes|Yes||No|September 10, 2013|https://clinicaltrials.gov/show/NCT01237197||113554|
NCT01237470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nicolaus Copernicus University|The Desarda and Lichtenstein Techniques in Inguinal Hernia Treatment.|The Desarda and Lichtenstein Techniques in Primary Hernia Treatment in Adult Males: Randomised, Multicenter, Blinded Study.|DESLICH|Nicolaus Copernicus University|Yes|Terminated|January 2005|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2009|||Male|18 Years|N/A|No|||July 2010|November 8, 2010|November 8, 2010||No|protocol completed|No||https://clinicaltrials.gov/show/NCT01237470||113533|
NCT01246986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13665|A Study of LY2157299 in Participants With Hepatocellular Carcinoma|Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma||Eli Lilly and Company|No|Recruiting|March 2011|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|190|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246986||112810|
NCT01247246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-SCV-MUC-P2b-002|Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer|A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy||SciClone Pharmaceuticals|No|Active, not recruiting|December 2010|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|160|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|November 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01247246||112790|
NCT01247545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/0303|Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery|Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in Coronary Artery Bypass Graft Surgery|ERICCA|University College, London|Yes|Completed|November 2010|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1612|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247545||112767|
NCT01247805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481293|A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions|A Pivotal Randomised, Open-Label 3-Way Crossover Study To Demonstrate Bioequivalence Of The Sildenafil Citrate Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil Citrate 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions||Pfizer|No|Completed|January 2011|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|November 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247805||112747|
NCT01247818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-10-PS-23|Randomized Study of PH-10 for Psoriasis|A Phase 2 Dose-Randomized, Vehicle-Controlled Study of PH-10-Aqueous Hydrogel for the Treatment of Plaque Psoriasis||Provectus Pharmaceuticals|No|Completed|December 2010|March 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01247818||112746|
NCT01277809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-BEB 10-125|The Effects of a Walking Program on Balance, Falls and Well Being in Individuals Residing in Long-term Care|Community Alliance for Quality of Life in Long Term Care: The Effects of a Walking Program on Balance, Falls and Well Being in Individuals Residing in Long-term Care||University of Saskatchewan|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|179|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277809||110444|
NCT01247077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLL-159361|Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?|Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?||Karolinska Institutet|No|Completed|November 2008|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|44|||Both|18 Years|55 Years|No|||March 2015|March 30, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247077||112803|
NCT01247389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-183-SDR|Incisional Hernia After Midline Versus Transverse Extraction Incision in Laparoscopic Colectomy|Incisional Hernia After Midline Versus Transverse Extraction Incision in Laparoscopic Colectomy: A Pilot Randomized Trial||McGill University Health Center|No|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 26, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247389||112779|
NCT01277991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921135|A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550|Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2-period, Crossover, Bioequivalence Study Comparing Phase 2b 1 Mg And 5 Mg Tablet Formulations Of Cp-690,550 Under Fasted Conditions||Pfizer|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277991||110430|
NCT01247415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pcirn-clin-invest-aller-1011|Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine|Clinical Investigation of Anaphylaxis, Allergic-like Reactions and Oculo-Respiratory Syndrome (ORS) Following Administration of an Adjuvanted Vaccine Against H1N1 Pandemic Influenza||PHAC/CIHR Influenza Research Network|No|Active, not recruiting|January 2011|November 2012|Anticipated|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|138|Samples With DNA|whole blood,PBMC and serum|Both|10 Years|64 Years|No|Non-Probability Sample|During the 2009-2010 immunization campaign against pandemic H1N1, the Canada has immunized        most of its population with a dose-sparing adjuvanted vaccine produced by GlaxoSmithKline        (GSK). Following the vaccination, some people reported having allergic-like reactions        (anaphylaxis, oculo-respiratory syndrome and allergy). This study will compare three        groups of patients (cases): those who had allergic-like reactions, those who had        anaphylaxis and those who had ORS post vaccination to vaccinated individuals who had no        such adverse events (controls).|July 2012|July 3, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247415||112777|
NCT01247402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACUBA 1|Paclitaxel Balloon Versus Standard Balloon in In-stent Restenoses of the Superficial Femoral Artery (PACUBA I Trial)|A Monocenter Randomized Clinical Trial of PAClitaxel drUg-eluting BAlloon Versus Standard Percutaneous Transluminal Angioplasty to Reduce Restenosis in Patients With In-stent Stenoses in the Superficial Femoral and Proximal Popliteal Artery|PACUBA 1|Medical University of Vienna|Yes|Recruiting|November 2010|December 2012|Anticipated|November 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|90 Years|No|||October 2010|December 8, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247402||112778|
NCT01243580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL14|AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol|An Open-Label Study to Evaluate Pharmacokinetic Profile of Agile TCDS AG200-15 and to Compare Exposure to Ethinyl Estradiol to Oral Contraceptive (Orthocyclen®) in Healthy Female Volunteers||Agile Therapeutics|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|December 2, 2010|November 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243580||113069|
NCT01236677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xfcrb123456|The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing|The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing||Capital Medical University|Yes|Recruiting|August 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|Samples With DNA|sputum,serum,and throat swabs|Both|14 Years|90 Years|No|Probability Sample|Confirmed community acquired pneumonia|August 2010|December 13, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236677||113594|
NCT01236924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112.2010|Effectiveness of Global Postural Reeducation in Patients With Chronic Symptomatic Lumbar Disc Herniation|Effectiveness of Global Postural Reeducation in Patients With Chronic Symptomatic Lumbar Disc Herniation||Universidade Gama Filho|Yes|Active, not recruiting|January 2011|||||Phase 1|Interventional|Primary Purpose: Treatment|1||||||Male|25 Years|45 Years|No|||November 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236924||113575|
NCT01236937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gentofte CT guided biopsy|Respiration Gated Laser Guided CT Lung Nodule Biopsy|Respiration Gated Laser Guided CT Lung Nodule Biopsy|GENCTBIOPSY|University Hospital, Gentofte, Copenhagen|Yes|Recruiting|March 2010|July 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|N/A|N/A|No|||May 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236937||113574|
NCT01237210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7T|7T MRS in Parkinson's Disease|Magnetic Resonance Spectroscopy of Parkinson's Disease at 7 Tesla||University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|February 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|26|||Both|45 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parkinson's patients and healthy controls|December 2015|December 8, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237210||113553|
NCT01237483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2008-01|Reirradiation and Erbitux in the HNSCC|A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck||Groupe Oncologie Radiotherapie Tete et Cou|Yes|Recruiting|October 2010|February 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|75 Years|No|||August 2014|August 12, 2014|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237483||113532|
NCT01237496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18675|Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253|Longitudinal Analysis of HBV-specific T Cell Responses in Patients With HBeAg-negative Chronic Hepatitis B (CHB) Treated With Pegylated Interferon Alfa-2a (40 KD) (Pegasys - RO258310). Immunology Sub-study of ML18253||Hoffmann-La Roche||Completed|July 2005|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|November 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01237496||113531|
NCT01246999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC10-005/Dartmouth 22164|Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children|Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal (A/California/7/2009-like (2009 H1N1), A/Perth/16/2009-like (H3N2), and B/Brisbane/60/2008-like (B/Victoria Lineage) Influenza Vaccines in Children||University of Rochester|No|Active, not recruiting|October 2010|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|88|||Both|2 Years|9 Years|Accepts Healthy Volunteers|||November 2010|August 2, 2011|November 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246999||112809|
NCT01247285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-141|90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions|A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|May 2001|July 2001|Actual|July 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 24, 2011|November 22, 2010|No|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01247285||112787|
NCT01247259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLIT-POLYSENSITIZATION|Efficacy of Sublingual Immunotherapy in Polysensitized Allergic Rhinitis Patients|Efficacy of Sublingual Immunotherapy With House Dust Mite Extract in Poly-allergen-sensitized Allergic Rhinitis Patients||Seoul National University Hospital|No|Completed|November 2007|October 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|4 Years|53 Years|No|||November 2010|November 22, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01247259||112789|
NCT01276379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-1002|Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab|Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment|POSIBA|Grupo Espanol Multidisciplinario del Cancer Digestivo|Yes|Recruiting|January 2011|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|170|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276379||110554|
NCT01278017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG290361|The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis|The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis||Chang Gung Memorial Hospital|Yes|Recruiting|August 2010|July 2012|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Both|3 Months|18 Years|No|||November 2010|January 14, 2011|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01278017||110428|
NCT01243749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP124|Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Real-World Patient Population in China|RESOLUTE China Registry: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Real-World Patient Population in China|R-C Registry|Medtronic Vascular|Yes|Active, not recruiting|December 2010|July 2018|Anticipated|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients suitable for drug-eluting stent implantation according to the applicable        guidelines on percutaneous coronary interventions and the Instructions for Use of the        Resolute Zotarolimus-Eluting Coronary Stent System.        All consecutive patients eligible for drug-eluting stent implantation with the elective        use of the Resolute stent in one or more target lesions are candidates to be enrolled.|October 2015|October 8, 2015|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01243749||113056|
NCT01243762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-027|A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027)|Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.|No|Terminated|November 2010|March 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|48|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01243762||113055|
NCT01244685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139939|Trial With Deltex Cardio in Elective Bowel Resection Patients|Randomized Controlled Trial With Deltex CardioQ in Elective Bowel Resection Patients||Stony Brook University|No|Completed|March 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244685||112984|
NCT01245933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GI0881|Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in Patients With COPD|Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD|COSYCONET|Philipps University Marburg Medical Center|Yes|Active, not recruiting|November 2010|July 2021|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2741|Samples With DNA|blood urine sputum|Both|40 Years|N/A|No|Non-Probability Sample|Since the original recruitment strategy was not as successful as expected,the mode of        recruitment was extended to other physicians, patients' groups and organisations and        advertising to local media. The recruitment is supported by professional measures of        communication organized by the coordinating centre Marburg.|January 2016|January 26, 2016|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01245933||112891|
NCT01246219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc004981ctil|Short Stature Related Distress|The Influence of Growth Hormone (GH) Therapy on Short Stature Related Distress a Prospective Randomized Controlled Trial||Rabin Medical Center|No|Recruiting|October 2011|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Male|8 Years|13 Years|No|||November 2015|November 26, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01246219||112869|
NCT01247623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03700|Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma|Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma||Oslo University Hospital|No|Completed|January 2005|September 2012|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|N/A|||||||Both|18 Years|75 Years||||November 2014|November 4, 2014|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247623||112761|
NCT01247090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0454|Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease|Pilot Study of the Effect of Intradialytic Vasopressin Infusion on Chronic Blood Pressure Control in Hypertensive Patients With End Stage Renal Disease: A Program to Develop a Decisive, Randomized Controlled Trial||Columbia University|Yes|Recruiting|October 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 22, 2010|Yes|Yes||No|April 4, 2011|https://clinicaltrials.gov/show/NCT01247090||112802|
NCT01247103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3340C00002|Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects|A Phase 1, Single-centre Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Dose, Parallel-group Study to Determine the Safety, Tolerability, and Pharmacokinetics of AZD4316 in Healthy Volunteers||AstraZeneca||Withdrawn|December 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|128|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2010|November 30, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01247103||112801|
NCT01243606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH090053-01|Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders|Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders||Boston University|Yes|Active, not recruiting|December 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|January 14, 2016|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01243606||113067|
NCT01247649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006039ctil|Assessing Continuous Non- Invasive Blood Glucose Sensor- Physical Logic AG|Assessing Continuous Non- Invasive Blood Glucose Sensor- Physical Logic AG||Rabin Medical Center|No|Terminated|November 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|65 Years|No|||November 2012|November 18, 2012|November 21, 2010||No|sponsor decision|No||https://clinicaltrials.gov/show/NCT01247649||112759|
NCT01243593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000019942|Transversus Abdominis Plane Block in Children Undergoing Open Pyeloplasty Surgery|Transversus Abdominis Plane Block in Children Undergoing Open Pyeloplasty Surgery||The Hospital for Sick Children|No|Completed|November 2010|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|1 Month|6 Years|No|||May 2015|May 29, 2015|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243593||113068|
NCT01236690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLing|Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy|The Clinical Research of the Intermediate and Advanced Hepatoma Treated by Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy||Changhai Hospital|Yes|Recruiting|November 2010|November 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|284|||Both|18 Years|70 Years|No|||October 2010|June 27, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236690||113593|
NCT01236950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9/2006a|Study of an Essential Oil and a Delmopinol Mouthrinse Effect on Dental Plaque Accumulation Index, Gingivitis Index and on Streptococcus Mutans, Lactobacillus, Aerobic and Anaerobic Oral Bacteria Colony Counts.|Study of an Essential Oil and a Delmopinol Mouthrinse Effect on Dental Plaque Accumulation Index, Gingivitis Index and on Streptococcus Mutans, Lactobacillus, Aerobic and Anaerobic Oral Bacteria Colony Counts.||University of Lisbon|No|Completed|April 2007|September 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|90|||Both|15 Years|N/A|Accepts Healthy Volunteers|||July 2010|November 9, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236950||113573|
NCT01236963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9/2006b|Essential Oils Mouthrinse and Dental Floss, Comparison of Efficacy on Interproximal Gingivitis and Dental Plaque Accumulation|Comparison of Efficacy on Interproximal Gingivitis and Dental Plaque Accumulation of an Essential Oils Mouthrinse and Dental Floss.||University of Lisbon|No|Completed|September 2007|September 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|15 Years|N/A|Accepts Healthy Volunteers|||July 2010|November 9, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236963||113572|
NCT01237756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198/08|Electrical Impedance Tomography for Endotracheal Tube Placement|Electrical Impedance Tomography for Endotracheal Tube Placement in Pediatric Patients||University Hospital Freiburg|No|Completed|September 2008|May 2010|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Actual|18|||Both|N/A|10 Years|No|||June 2008|November 9, 2010|January 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01237756||113511|
NCT01247298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100708009|A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma|RAD 0902: A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma|RAD 0902|University of Alabama at Birmingham|Yes|Active, not recruiting|October 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|19 Years|N/A|No|||April 2015|April 15, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247298||112786|
NCT01247831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT/ORA/1|The Effect of Selective Laser Trabeculoplasty (SLT) on Ocular Rigidity|The Effect of Selective Laser Trabeculoplasty (SLT) on Ocular Rigidity|SLT/ORA|Technische Universität Dresden|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247831||112745|
NCT01247571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02658|Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus||National Cancer Institute (NCI)|Yes|Active, not recruiting|January 2011|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Female|18 Years|N/A|No|||January 2016|March 4, 2016|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01247571||112765|
NCT01278550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2NANC|Prevention of Recurrent Ulcer Bleeding in High-risk Users of Low-dose Aspirin|Prevention of Recurrent Ulcer Bleeding in High-risk Users of Low-dose Aspirin (NSAID#2NANC Study)||Chinese University of Hong Kong|No|Completed|January 1995|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|503|||Both|18 Years|N/A|No|Non-Probability Sample|High-risk patients were from our hospital while average-risk patients were from our        out-patient clinics|August 2015|August 10, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278550||110387|
NCT01244321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVADIS002|COVADIS Pilot Trial: COseal in Ventricular Assist DevIceS|A Controlled, Single-Center Clinical Pilot Study to Evaluate the Performance of CoSeal as a Barrier for Adhesion Prevention in Patients Submitted to Ventricular Assist Device VAD)|COVADIS|German Heart Institute|No|Recruiting|December 2010|February 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with end stage heart failure, awaiting heart transplantion, with need for VAD        (ventricular assist device)|January 2015|January 28, 2015|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244321||113012|
NCT01246531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0688/07|Metabolic Assessment of Aging Men With Urinary Lithiasis|Clinical Investigation of Aging Men With Renal Stones: The Role of Bone Demineralization (Metabolic and Hormonal Assessment)||University of Sao Paulo General Hospital|Yes|Completed|January 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|||Male|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from Urological Division of University of São Paulo General Hospital, in São        Paulo (Brazil). Towards data bank, we called patients above fifty years-old who had        urolithiasis diagnosis. Patients with benign prostate hyperplasia, above fifty years-old,        had called to the control group.|October 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246531||112845|
NCT01246570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adherence|Exercise Training Adherence After Cardiac Rehabilitation in Coronary Heart Disease Patients|Supported Home-based Exercise Training Versus Usual Care After Cardiac Rehabilitation. A Randomized Controlled Study||Norwegian University of Science and Technology|No|Completed|November 2010|January 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|35 Years|80 Years|No|||September 2014|September 24, 2014|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01246570||112842|
NCT01246583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921116|CP-690-550 Ointment For Chronic Plaque Psoriasis|A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis||Pfizer|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|71|||Both|18 Years|N/A|No|||April 2013|April 9, 2013|November 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246583||112841|
NCT01246856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201005|MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study|MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC)|TOXTAC|Radboud University||Recruiting|November 2010|||October 2011|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|150|||Female|18 Years|N/A|No|Probability Sample|patients who have been treated with TAC one year previously|September 2011|September 9, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246856||112820|
NCT01246544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patient Safety|Helsinki Declaration on Patient Safety|Helsinki Declaration on Patient Safety|Patient Safety|Charite University, Berlin, Germany|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|N/A|N/A|No|Probability Sample|Members of the innovation alliance Berlin-Brandenburg (INABBRA)|September 2011|September 7, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246544||112844|
NCT01246557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LENDEX-LLC-09|Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment|Open Label Multi-center Pilot Phase I/II Non-controlled Clinical Trial to Assess Safety and Efficieecy of the Lenalidomide and Dexamethasone Association in Patients With Chronic Relapse or Treatment Resistant Lymphatic Leukemia Following Treatment Containing Fludarabine.|LENDEX-LLC-09|Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|December 2009|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2011|April 3, 2014|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01246557||112843|
NCT01247662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201005041R|Psychometric Studies of the Chinese Versions of the SRS, CAST, and AQ|Psychometric Studies of the Chinese Versions of the Social Responsiveness Scale, the Childhood Asperger's Syndrome Test, and the Autism Spectrum Quotient||National Taiwan University Hospital|Yes|Completed|January 2011|December 2011|Actual|||N/A|Observational|N/A||3|Actual|2460|||Both|6 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants include (1) ASD group: 200 cases with DSM-IV ASD; (2) ADHD group: 200        cases with DSM-IV ADHD; (3) Normally developing control group: a school-based sample of        around 1200 grade 1 to grade 8 students.|April 2012|November 14, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247662||112758|
NCT01247675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-001 CT002|A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH) in Adults With Growth Hormone Deficiency|A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency||Ascendis Pharma A/S|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Both|20 Years|70 Years|No|||June 2013|June 2, 2013|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247675||112757|
NCT01243372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-SWOG-150506-80405-BRAF|Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer|Evaluating BRAF Mutations as Predictors of Efficacy in Cetuximab-Treated Colorectal Cancer Patients: A Retrospective Study of Tissues From CALGB / SWOG||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|November 2009|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1142|Samples With DNA|Tissue|Both|18 Years|N/A|No|Probability Sample|Patients previously enrolled on CALGB-C80405 who have KRAS WT or KRAS mut tumor and have        been randomized to treatment with either bevacizumab or cetuximab alone in a primary care        clinic setting.|July 2015|July 9, 2015|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243372||113085|
NCT01243333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI43948|Multi-Tracer PET in Early Phase Trials|Multi-Tracer PET (Positron Emission Tomography) Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents||University of Utah|Yes|Recruiting|February 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|This companion clinical study is designed to obtain pre-therapeutic imaging assessments        using positron emission tomography (PET) imaging in 50 evaluable patients (those patients        who had baseline and followup PET imaging) with various forms on malignancy and at        approximately 28 days (day 25 -32), after institution of the therapeutic drug from various        primary therapeutic clinical trials.|December 2015|December 8, 2015|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243333||113088|
NCT01243879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08.077|The Effect of Food Stimuli on the Calorie Restriction Response in Healthy Subjects|The Effect of Food Stimuli on the Calorie Restriction Response in Healthy Subjects||Leiden University Medical Center||Completed||||||N/A|Interventional|N/A|2||||||Male|18 Years|70 Years|Accepts Healthy Volunteers|||November 2010|November 18, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01243879||113046|
NCT01237223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A1301|Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension|An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension||Novartis|No|Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|1342|||Both|20 Years|N/A|No|||May 2012|May 11, 2012|October 29, 2010||No||No|May 11, 2012|https://clinicaltrials.gov/show/NCT01237223||113552|
NCT01237236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEE011X2101|A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.|A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma||Novartis|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01237236||113551|
NCT01238133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03813|Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer|A Phase 1 Study of Neoadjuvant Chemotherapy With the Gamma Secretase Inhibitor RO4929097 in Combination With Paclitaxel and Carboplatin in Patients With Clinical Stage II-III Triple Negative Breast Cancer||National Cancer Institute (NCI)|Yes|Terminated|December 2010|August 2015|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||May 2015|September 3, 2015|November 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238133||113482|
NCT01237509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Soevn01|EEG Changes of type1 Diabetes During Sleep -Insulin Induced Hypoglycemia|Registration of EEG Changes During Sleep Associated With Insulin Induced Hypoglycemia in Type 1 Diabetic|sleep|Hypo-Safe A/S|No|Completed|January 2009|June 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|70 Years|No|Non-Probability Sample|Type 1 diabetes|November 2010|March 19, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237509||113530|
NCT01237522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF- 377|A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers|A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers.||University of Southern Denmark|Yes|Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2010|December 28, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237522||113529|
NCT01237769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome|Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome||University of Ioannina|No|Recruiting|October 2010|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|75 Years|No|||November 2010|August 17, 2011|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237769||113510|
NCT01237782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORP-PT-002|Efficacy of a Propolis-based Denture Cleanser|Efficacy of a Propolis Solution for Cleaning Complete Dentures: a Randomized Crossover Trial||University of Sao Paulo|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|45 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 24, 2014|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237782||113509|
NCT01274988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACDBS|Deep Brain Stimulation of Nucleus Accumbens to Prevent Opiate Relapse|Deep Brain Stimulation of Nucleus Accumbens as a New Treatment to Prevent Relapse for Opiate Addicts||Tang-Du Hospital|Yes|Recruiting|February 2011|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|January 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274988||110661|
NCT01275261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00820|Pilot Study of Avoidance of Bladder Catheters in Stroke Patients to Avoid Urinary Tract Infections|Pilot Randomized Trial of a Nursing Protocol to Avoid Bladder Catheterization in Patients With Stroke||University of California, San Francisco|No|Terminated|January 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|January 7, 2011||No|Investigator no longer at institution-no data analyzed|No||https://clinicaltrials.gov/show/NCT01275261||110640|
NCT01275274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2007|Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens|Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens||University of North Carolina, Chapel Hill|No|Withdrawn|January 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|January 10, 2011|Yes|Yes|no subject enrolled in nearly 2 years|No||https://clinicaltrials.gov/show/NCT01275274||110639|
NCT01277510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070208|Pediatric Chronic Kidney Disease Safety and Efficacy|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis||Amgen|Yes|Terminated|June 2011|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|6 Years|17 Years|No|||May 2015|June 12, 2015|January 13, 2011|Yes|Yes|Study was suspended in agreement between sponsor and FDA due to concerns about the study    design after a fatality had occurred in the presence of hypocalcemia.|No|April 29, 2015|https://clinicaltrials.gov/show/NCT01277510||110467|The study was terminated early with a smaller sample size. However, the study was still sufficiently powered for the double-blind phase. The data collected in the open-label phase is very sparse.
NCT01245361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1200/001|A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit|"A Comparative Study Of A 6-Month Infliximab (Remicade®) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis (RA) : Clinical, Radiological (MRI) And Synovial Benefit P1200/001".|UA-IFX|Université Catholique de Louvain|No|Completed|November 2007|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||October 2013|October 30, 2013|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245361||112935|
NCT01245647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA018934-01|Will Having Alcohol Treatment Improve Functioning?|Pharmacotherapy for Hazardous Drinking in HIV Infected Women: Randomized Trial|WHAT-IF|University of Florida|No|Completed|November 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|January 10, 2014|November 19, 2010|Yes|Yes||No|August 27, 2013|https://clinicaltrials.gov/show/NCT01245647||112913|Sample size was very small, and 3 participants did not return for any follow-up visits; 15 completed through the Month 4 assessment, and 12 completed through Month 7. Therefore, our ability to draw conclusions based on this sample is limited.
NCT01245660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/04|A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy|Pilot Study of Lapatinib (Tyverb®) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy|LAPAINBLAD|University Hospital, Bordeaux|Yes|Terminated|January 2011|October 2011|Actual|October 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|November 18, 2010||No|The rythm of enrollment was not compatible with the objective of recruitement in the research.|No||https://clinicaltrials.gov/show/NCT01245660||112912|
NCT01245673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02710|Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma|Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol® (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|November 2010|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245673||112911|
NCT01246869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI44704|Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water|Assessment of Primary and Metastatic Brain Tumor Hypoxia With 18F-Fluoromisonidazole, [18F]Fluoro-2-deoxy-D-glucose (FDG) and [15O]Water (H215O)||University of Utah|Yes|Recruiting|August 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Study patients: Adult patients (18 years or older) with glial neoplasms or brain        metastasis. We expect that up to 40 total people may be enrolled in this study. This will        assure that 30 evaluable patients (patients who have complete imaging results and blood        data available for data analysis).|March 2016|March 15, 2016|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246869||112819|
NCT01247116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC-UOC-2009|First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension|First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study||University of Calgary|No|Recruiting|December 2009|||December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|85 Years|No|Non-Probability Sample|Consecutive patients with idiopathic pulmonary arterial hypertension (IPAH) or PAH        associated with connective tissue disease that are naive to PAH targeted therapies will be        enrolled.|November 2010|November 23, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247116||112800|
NCT01247428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS-FIH-2010-01|First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease|A First-In-Human Trial of a New Novel DES (MiStent System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in the Native Coronary Arteries|DESSOLVE-I|Micell Technologies|Yes|Active, not recruiting|November 2010|January 2016|Anticipated|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|85 Years|No|||September 2015|September 21, 2015|November 18, 2010||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01247428||112776|
NCT01247441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR02/11/10|Breast Cancer Registry - National University Health System, Singapore|||National University Hospital, Singapore|No|Recruiting||||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Female|21 Years|N/A|No|Probability Sample|Breast Cancer|January 2014|January 13, 2014|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01247441||112775|
NCT01243359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00764|Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies|Phase I Pharmacodynamic Trial of Sequential Sunitinib With Bevacizumab in Patients With Renal Cell Carcinoma and Other Advanced Solid Malignancies||National Cancer Institute (NCI)||Completed|October 2010|||February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||October 2013|April 1, 2014|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01243359||113086|
NCT01243905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCUPsychiatry003|Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders|Group Psychoeducational Program for Mothers of Preschool Children With High Functional Pervasive Developmental Disorders: a Randomized Controlled Trial||Nagoya City University|No|Recruiting|September 2010|March 2012|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Female|N/A|N/A|No|||January 2011|January 18, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01243905||113044|
NCT01244204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K99HL089710-01A1|Role of Vitamin D in Innate Immunity to Tuberculosis|Vitamin D Supplementations as Adjunct to Anti-tuberculosis Drugs in Mongolia||Harvard School of Public Health|No|Completed|November 2009|March 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01244204||113021|
NCT01243346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-BRE-002|Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene|Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions, Including the D842V Mutation, in the PDGFRA Gene||Arog Pharmaceuticals, Inc.|No|Completed|April 2011|||July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2014|November 4, 2014|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243346||113087|
NCT01243853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER001|Alpha-galactosidase Enzyme and Irritable Bowel Syndrome|Alpha-galactosidase Enzyme and Irritable Bowel Syndrome|ALFA|Verman Oy Ab|No|Recruiting|December 2010|February 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|65 Years|No|||January 2011|January 14, 2011|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01243853||113048|
NCT01236976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIPA Full-On|SCIPA Full-On :Intensive Exercise Program After Spinal Cord Injury|SCIPA Full-On :Intensive Exercise Program After Spinal Cord Injury|SCIPA Full-On|University of Melbourne|Yes|Recruiting|December 2010|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||August 2010|August 4, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236976||113571|
NCT01236989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR vs NAR|Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC|Anatomical Liver Resection by Means of Ultrasound-guided Vessel Compression Versus Non-anatomical Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial|ARversusNAR|University of Milan|Yes|Not yet recruiting|January 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||October 2010|November 8, 2010|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01236989||113570|
NCT01237795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORP-PT-003|Experimental Denture Pastes|A Randomized Trial of Experimental Dentifrices for Cleaning Dentures||University of Sao Paulo|No|Completed|February 2008|December 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|36|||Both|45 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 24, 2014|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237795||113508|
NCT01237808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 15-10|Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation|Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation||University of Ulm|Yes|Recruiting|March 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|61 Years|N/A|No|||October 2014|October 14, 2014|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237808||113507|
NCT01237834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB6698|Physiological Responses in Tobacco Chippers|Physiological Responses in Tobacco Chippers (Non Nicotine-dependent Light Smokers)||Oregon Health and Science University|No|Completed|November 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|178|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|General population|October 2014|October 28, 2014|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237834||113505|
NCT01238146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02536|Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)|Yes|Withdrawn|October 2010|||April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|November 9, 2010|No|Yes|No patients accrued.|No||https://clinicaltrials.gov/show/NCT01238146||113481|
NCT01238445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-095|Assessing Response to Albuterol in Bronchiolitis|Assessing Response to Albuterol in Bronchiolitis||Connecticut Children's Medical Center|No|Recruiting|November 2010|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|2 Years|No|Probability Sample|Children hospitalized in the intensive care unit with bronchiolitis|January 2016|January 27, 2016|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238445||113459|
NCT01234181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHZJU CT001|Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases|Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Intracoronary Transplantation in Myocardial Infarction and Other Heart Diseases.|CSHSBMMCTTHD|Second Affiliated Hospital, School of Medicine, Zhejiang University|Yes|Not yet recruiting|November 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||November 2010|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234181||113785|
NCT01275768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-GI-201101|Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice|A Double Blind, Randomized Controlled Prospective Trial of Endo-biliary Radio-frequency Ablation for Maintenance of Metal Stent Patency in Patients With Malignant Obstructive Jaundice||Asian Institute of Gastroenterology, India|Yes|Active, not recruiting|January 2011|September 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2011|January 13, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275768||110601|
NCT01276041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-142|Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer|Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276041||110580|
NCT01243515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLS STP-9000006|Comparison of a Non-Invasive Central Venous Pressure Device and Physical Examination in Patients With Chronic Kidney Disease|Clinical Validation of a Non-Invasive Central Venous Pressure Device in Comparison With Physical Examination in Patients With Chronic Kidney Disease and Healthy Volunteers||Mespere Lifesciences Inc.|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients with Chronic Kidney Disease (CKD)|February 2013|February 7, 2013|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243515||113074|
NCT01245686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2028|Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk|A Combined Lifestyle and Medication Intervention to Reduce CVD Risk||University of North Carolina, Chapel Hill|Yes|Completed|February 2011|November 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|489|||Both|35 Years|79 Years|Accepts Healthy Volunteers|||February 2013|February 5, 2013|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245686||112910|
NCT01245699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-037|MIHS Emergency Department CPR Quality Improvement Project|MIHS Emergency Department CPR Quality Improvement Project||Maricopa Integrated Health System|No|Recruiting|November 2010|June 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the ED who require chest compressions|November 2015|November 17, 2015|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245699||112909|
NCT01246232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1498|Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia|Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia|AMICUS|Imperial College London|Yes|Completed|September 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||September 2011|March 31, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246232||112868|
NCT01246245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|049-10 CTIL|Nursing Care Management of External Fixation in Hospitalization: Pin Site Infection Incidence|||Rambam Health Care Campus||Not yet recruiting|December 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients after external fixation insertion|July 2010|November 22, 2010|November 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01246245||112867|
NCT01247129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-2010|Delaying the Superficial Inferior Epigastric Artery (SIEA) Flap and Determining the Change in SIEA Diameter and Blood Flow|Delaying the Superficial Inferior Epigastric Artery (SIEA) Flap: A Solution to the Problem of the Small Caliber of the Donor Artery||University Medical Centre Ljubljana|No|Completed|September 2009|September 2010|Actual|May 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|80 Years|No|||November 2010|November 23, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247129||112799|
NCT01247142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52756|Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis|||Universitaire Ziekenhuizen Leuven|No|Completed|January 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|24|Samples Without DNA|exhaled breath condensate|Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Hospitalized adult patients of the department of Hematology or Intensive Care Unit,        University Hospital, Leuven, Belgium|July 2014|July 4, 2014|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247142||112798|
NCT01247454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0481|Medication Management and Culture of Safety|Risk Informed Intervention Development and Implementation of Safe Ambulatory Care|MM|University of Colorado, Denver|Yes|Completed|July 2009|September 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|7000|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01247454||112774|
NCT01247688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26336-UCALL|Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies|Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies (UCALL)|UCALL|Baylor College of Medicine|Yes|Withdrawn|November 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||December 2013|December 11, 2013|November 17, 2010|Yes|Yes|This study was withdrawn due to low accrual.|No||https://clinicaltrials.gov/show/NCT01247688||112756|
NCT01247701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26558-UCAML|Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies|Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML)|UCAML|Baylor College of Medicine|Yes|Recruiting|November 2010|November 2027|Anticipated|November 2024|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|17 Years|No|||December 2015|December 21, 2015|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247701||112755|
NCT01247714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGENAT-DIABET NP UGR|Clinical Evaluation of a Specific Enteral Diet for Diabetics|Clinical Evaluation of a Specific Enteral Diet for Diabetics.A Randomised Cross-Over Study||Vegenat, S.A.|No|Active, not recruiting|September 2009|May 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|43|||Both|55 Years|N/A|No|||November 2010|December 9, 2014|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247714||112754|
NCT01244867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-H5VLP-002|Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine|A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.||Medicago|Yes|Completed|November 2010|September 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|255|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01244867||112970|
NCT01245166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCD09013B|A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus|||Lotus Pharmaceutical|Yes|Recruiting|November 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|20 Years|80 Years|No|||November 2010|November 19, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245166||112948|
NCT01243866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD109|Effect of Dental Treatment on Children's Growth|Effect of Dental Treatment on Children's Growth||King Fahad Armed Forces Hospital|Yes|Completed|February 2007|January 2008|Actual|January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|72 Months|95 Months||||January 2008|November 18, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01243866||113047|
NCT01243619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-169|FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer|3'-Deoxy-3'(18) F-Fluorothymidine Positron Emission Tomography/Computed Tomography (PET/CT) for Initial Staging, Radiotherapy Target Definition, and Assessment of Response to Therapy in Patients With Esophageal Cancer: A Pilot Study||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2010|||March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|September 30, 2010|No|Yes||No|February 18, 2015|https://clinicaltrials.gov/show/NCT01243619||113066|
NCT01237535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005788ctil|Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates|Luteal Phase Support With Progesterone vs Estrogen and Progesterone on Pregnancy Rates in Ovarian Stimulation and Intrauterine Insemination Cycles: a Prospective Randomized Study||Rabin Medical Center|No|Not yet recruiting|November 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|400|||Both|20 Years|40 Years|No|||November 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237535||113528|
NCT01237548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Narghile Endotheil RMC 284|The Evaluation of the Acute Effect of Water-Pipe Smoking on the Endothelial Function and the Respiratory System|||Rambam Health Care Campus|Yes|Completed|January 2011|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal People who have smoked Water-pipe, at least once before.|June 2013|June 10, 2013|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01237548||113527|
NCT01237821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS1007033A|Comparing OTC Acne Treatment to Prescription Regimen|A MULTI-CENTER, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TWO ACNE CREAMS IN SUBJECTS WITH MILD TO MODERATE ACNE VULGARIS||Milton S. Hershey Medical Center|No|Completed|October 2010|October 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237821||113506|
NCT01238159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-06-019|Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma|Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by MIDLE (Methotrexate, Ifosfamide, Dexamethasone, L-asparaginase, Etoposide) Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma||Samsung Medical Center|Yes|Completed|August 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2015|March 1, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238159||113480|
NCT01238458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-1852A|Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers|Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers|[18F]AV-45|Chang Gung Memorial Hospital|Yes|Enrolling by invitation|November 2009|June 2013|Anticipated|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|150|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 27, 2012|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01238458||113458|
NCT01234194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVI_2010|Composite Variability Index and Propofol Remifentanil Anesthesia|Changes in the Composite Variability Index in Response to Different Remifentanil Concentrations and Standardized Painful Stimuli.||University Hospital, Bonn|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|24|||Both|18 Years|N/A|No|||September 2010|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234194||113784|
NCT01276665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|154/08|Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Perioperative Outcome in Patients Undergoing Radical Cystectomy|Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Blood Loss and Perioperative Outcome in Patients Undergoing Open Radical Cystectomy||University Hospital Inselspital, Berne|No|Completed|November 2009|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276665||110532|
NCT01276925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-Z-THAMBUS|Total Hip Arthroplasty: Multiple Blocks by UltraSound|The Effect of Ultrasound Guided Blockade of the Femoral Nerve, the Anterior Division of the Obturator Nerve, and the Lateral Femoral Cutaneous Nerve on Postoperative Pain, Morphine Consumption, and Mobilization After Total Hip Arthroplasty.|THAMBUS|Bispebjerg Hospital|Yes|Recruiting|August 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|81|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01276925||110512|
NCT01246596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-AOI-01|Chronic Presence of Epstein Barr Virus in Epithelial Cells From Gingiva is Associated With Periodontitis|||Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2011|January 2014|Anticipated|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2010|December 17, 2012|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01246596||112840|
NCT01246609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0322-10CTIL|The Effect of Irrigation Solution Volume on Electrolytes and Acid-Base Balance|The Effect of Irrigation Solution Volume on Electrolytes and Acid-Base Balance in Patients Undergoing Percutaneous Lithotripsy||Rambam Health Care Campus|No|Terminated|November 2014|September 2015|Actual|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|80 Years|No|Probability Sample|This is an observational prospective study of consequtive 200 adult patients undergoing        elective surgery of percoutanous lithotripsy in our operating rooms.|September 2015|September 7, 2015|November 22, 2010||No|the doctor who ran this study, left|No||https://clinicaltrials.gov/show/NCT01246609||112839|
NCT01246895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG-CIP04-P|Follow-Up Study Comparing BST-CarGel and Microfracture in Repair of Articular Cartilage Lesions in the Knee|FOLLOW-UP STUDY EVALUATING THE LONG-TERM SAFETY AND EFFICACY OF BST-CarGel® AND MICROFRACTURE IN REPAIR OF FOCAL ARTICULAR CARTILAGE LESIONS ON THE FEMORAL CONDYLE (Extension Study of Protocols CG-CIP01-P & CG-CIP02-P)||Piramal Healthcare Canada Ltd|No|Enrolling by invitation|December 2010|March 2014|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|55 Years|No|Probability Sample|Patients that have been treated under either protocol CG-CIP01 or CG-CIP02|September 2012|September 21, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246895||112817|
NCT01246908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX157-201|Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression|CX157-201|CeNeRx BioPharma Inc.|No|Completed|November 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|360|||Both|20 Years|65 Years|No|||July 2012|July 8, 2012|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246908||112816|
NCT01247155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9151|First Postoperative Day Review After Uneventful Phacoemulsification|||Veroia General Hospital||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|65 Years|90 Years||Probability Sample|291 consecutive patients who underwent uneventful phacoemulsification cataract surgery        were randomized into two groups: i) Next day review (NDR group, n=146) and ii) No next day        review (NNDR group, n=145).|April 2009|November 23, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247155||112797|
NCT01247168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3660C00001|An Open-Label, Dose-Escalation Study of AZD2461|An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors||AstraZeneca||Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01247168||112796|
NCT01247467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR04/21/10|Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot Study|||National University Hospital, Singapore|No|Active, not recruiting|August 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10|||Female|N/A|N/A|No|Non-Probability Sample|Archival tumor samples that dates back to the 1990s|January 2014|January 21, 2014|August 26, 2010||||No||https://clinicaltrials.gov/show/NCT01247467||112773|
NCT01247480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR05/22/10|Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer|||National University Hospital, Singapore|No|Active, not recruiting|September 2010|December 2014||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Female|N/A|N/A|No|Non-Probability Sample|800 breast cancer patients who fulfill the eligibility criteria will be selected from the        NUH breast cancer registry (400 for training, 400 for validation).|January 2014|January 21, 2014|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01247480||112772|
NCT01243658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX02|"The Effects of Oxytocin on Patients With Borderline Personality Disorder"|||University of Freiburg|Yes|Recruiting|January 2011|January 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Anticipated|150|||Both|18 Years|50 Years|No|||December 2014|December 8, 2014|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01243658||113063|
NCT01243892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L4917g|A Study of Growth in Patients Using the Nutropin AQ Nuspin|A Phase IV, Open Label, Multicenter, Case-controlled Study of Growth in Patients Using the Nutropin AQ Nuspin|NuSpin Go|Genentech, Inc.||Terminated|November 2010|||August 2014|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|15|||Both|2 Years|14 Years|No|Non-Probability Sample|prepubertal children with growth hormone deficiency or idiopathic short stature|January 2013|January 7, 2013|November 17, 2010|No|Yes|The study was closed due to the slow enrollment rate.|No||https://clinicaltrials.gov/show/NCT01243892||113045|
NCT01244594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164600|The Effects of Two Functional Electrical Stimulation Cycling Paradigms|The Effects of Two Functional Electrical Stimulation Cycling Paradigms||Thomas Jefferson University|No|Completed|July 2010|October 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||January 2014|January 7, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01244594||112991|
NCT01244607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0801-02|NI-0801 in Allergic Contact Dermatitis|A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis||NovImmune SA|No|Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study|2||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2010|November 18, 2010|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01244607||112990|
NCT01243632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86/12/02|Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment|A Phase II Trial of Low-dose Gemcitabine in Prolonged Infusion and Cisplatin in Treatment of Malignant Pleural Mesothelioma||Institute of Oncology Ljubljana||Completed|December 2002|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|18 Years|85 Years|No|||November 2010|November 17, 2010|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01243632||113065|
NCT01244217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY10717|Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)|An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Perennial Allergic Rhinitis||Sanofi|No|Completed|October 2010|August 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|6 Months|11 Years|No|||October 2013|October 12, 2013|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244217||113020|
NCT01237847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFA#2838|A Brief Intervention to Improve Adherence in Teens With Inflammatory Bowel Disease|A Brief Intervention to Improve Adherence in Teens With Inflammatory Bowel Disease|PHONE|Rosalind Franklin University of Medicine and Science|No|Active, not recruiting|July 2010|July 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|11 Years|18 Years|No|||November 2010|November 9, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01237847||113504|
NCT01229735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01353|Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures|A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures||UCB Pharma|No|Completed|November 2010|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|343|||Both|16 Years|80 Years|No|||January 2016|January 13, 2016|October 26, 2010|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT01229735||114123|
NCT01230021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13CD-3760|Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency|A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to Less Than 6 Years Old) Subjects With Congenital FXIII A-subunit Deficiency|mentor™4|Novo Nordisk A/S|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|1 Year|6 Years|No|||September 2014|September 3, 2014|October 27, 2010|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01230021||114101|
NCT01238471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0479-09CTIL|Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study|Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study.||Rambam Health Care Campus|Yes|Completed|May 2010|July 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|14 Weeks|No|||June 2014|June 12, 2014|November 8, 2010||No||No|May 12, 2014|https://clinicaltrials.gov/show/NCT01238471||113457|
NCT01234207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZV_PAL1|Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle|Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle|CZV_PAL1|University of California, Berkeley|No|Completed|February 2009|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|95|||Both|39 Years|80 Years|Accepts Healthy Volunteers|||November 2010|June 21, 2011|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234207||113783|
NCT01234220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPR-AVIS|Adrenal Vein Sampling International Study (AVIS Study)|Multicenter Study on Use and Interpretation of Adrenal Vein Sampling|AVIS|University Hospital Padova|Yes|Completed|May 2010|November 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2604|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with Primary Aldosteronism who underwent AVS during the last 5 years in 15        worldwide centers.|January 2013|January 14, 2013|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01234220||113782|
NCT01244763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-041|Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia|||FibroGen|Yes|Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|18 Years|75 Years|No|||January 2013|January 28, 2013|November 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244763||112978|
NCT01277263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2010-7789|Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging|Predicting Pathological Response Within the 1st Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured With Diffuse Optical Spectroscopic Imaging||University of California, Irvine|Yes|Recruiting|December 2010|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|37|Samples Without DNA|C-Protein serum|Female|21 Years|75 Years|No|Non-Probability Sample|Study population will be selected from an outpatient population of the Cancer Center        Clinic, Beckman Laser Medical Clinic of University of California, Irvine and UCI Pacific        Breast Care. Subjects with the requisite diagnosis of breast cancer will be candidates for        enrollment.|February 2016|February 5, 2016|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277263||110486|
NCT01245010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|755|Water Beverage Intervention Trial for Reducing Risk Factors of Metabolic Syndrome in Young Mexican Free Living Women|Randomized Controlled Trial of a Water Beverage Intervention Trial for Reducing Risk Factors of Metabolic Syndrome in Young Mexican Free Living Women||Mexican National Institute of Public Health|Yes|Completed|April 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|240|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01245010||112960|
NCT01245023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-Surg-007|Adhesiolysis in Chronic Abdominal Pain|Laparoscopic Adhesiolysis in Treatment of Chronic Abdominal Pain - a Prospective Randomized Trial||North Karelia Central Hospital|No|Withdrawn|January 2014|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||December 2012|December 31, 2012|November 19, 2010||No|lack of funding|No||https://clinicaltrials.gov/show/NCT01245023||112959|
NCT01245374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3826|Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents|Assessment of the Ease of Use of Norditropin NordiFlex® Relative to the One of the Device Previously Used by Patients or Parents||Novo Nordisk A/S|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|6 Years|18 Years|No|||October 2012|October 19, 2012|November 19, 2010|Yes|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT01245374||112934|
NCT01245946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-146|Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris|Efficacy Comparison Study of Topical Aminolaevulinic Acid-Photodynamic Therapy Versus Adapalene Gel 0.1% Plus Doxycycline for Treatment of Moderate Acne Vulgaris. Randomized, Simple Blind, Controlled Trial.||Pontificia Universidad Catolica de Chile|Yes|Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|30 Years|No|||November 2010|May 31, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245946||112890|
NCT01246258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROHH0046|Otolith Function in Patients With Primary Ciliary Dyskinesia|Otolith Function in Patients With Primary Ciliary Dyskinesia: a Pilot Study||Imperial College Healthcare NHS Trust|Yes|Recruiting|September 2010|||December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|16 Years|30 Years|No|Non-Probability Sample|Ten patients from the PCD clinic at the Royal Brompton Hospital, London.|August 2013|August 14, 2013|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246258||112866|
NCT01246882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000134|Stroke Inpatient Rehabilitation Reinforcement of ACTivity|Stroke Inpatient Rehabilitation Reinforcement of ACTivty: An International Multisite Clinical Trial|SIRRACT|University of California, Los Angeles|Yes|Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246882||112818|
NCT01246934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVUORT001|Segment Transport Versus Acute Shortening In The Treatment of Tibial Pseudarthroses With Bone Loss|||Bezmialem Vakif University|No|Completed|October 2009|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|13 Years|50 Years||||November 2010|November 23, 2010|November 23, 2010||||No||https://clinicaltrials.gov/show/NCT01246934||112814|
NCT01247181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMPS|Cameroon Mobile Phone SMS Trial|Improving Adherence to HAART Using Mobile Phone Text Messages|CAMPS|Yaounde Central Hospital|Yes|Completed|November 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|200|||Both|21 Years|65 Years|No|||September 2011|September 7, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247181||112795|
NCT01247194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-461-102|A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1|A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection||Presidio Pharmaceuticals, Inc.|No|Completed|October 2010|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|No|||February 2012|February 1, 2012|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247194||112794|
NCT01247493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0704-029-205|Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)|Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia)|m-FLAI|Seoul National University Hospital|No|Completed|June 2007|July 2010|Actual|June 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|60 Years|N/A|No|||November 2010|November 23, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01247493||112771|
NCT01247727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010075R|Heart Rate Variability in Extracorporeal Membrane Oxygenation (ECMO) Patients|Clinical Application of Multimodal Physiological Signal Analysis in Critical Ill Patients Depending on Extracorporeal Membrane Oxygenation||National Taiwan University Hospital|Yes|Not yet recruiting|July 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with the support of extracorporeal membrane oxygenation|March 2011|April 21, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247727||112753|
NCT01243385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 08/09|Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer|Metformin in Castration Resistant Prostate Cancer. A Multicenter Phase II Trial.||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|December 2010|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Male|18 Years|N/A|No|||January 2015|January 13, 2015|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243385||113084|
NCT01243645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO0110|MP-1 Biofeedback: Pattern Stimulus Versus Audio-feedback in AMD|MP-1 Biofeedback: Pattern Stimulus Versus Audio-feedback in Age Related Macular Degeneration (AMD)||University of Roma La Sapienza|No|Completed||||||N/A|Interventional|N/A|||||||Both|56 Years|89 Years||||September 2010|November 17, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243645||113064|
NCT01244568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1318|Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2|Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment- Study 2||University of North Carolina, Chapel Hill|No|Completed|December 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|218|||Male|45 Years|N/A|No|||August 2014|December 19, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01244568||112993|
NCT01244581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OYS_Tapiainen_001|Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry|Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry||University of Oulu|No|Completed|September 1999|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|N/A|16 Years|No|||June 2012|June 19, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244581||112992|
NCT01245244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020894-17|Morphine Modulation of The Brain's Pain Matrix|Morphine Modulation of The Brain's Pain Matrix|Mor2010|University of Aarhus|Yes|Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245244||112944|
NCT01245257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHNC-Alk-Hep|Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis|Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis||University of Aarhus|No|Recruiting|November 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum, plasma, urine|Both|18 Years|70 Years|No|Probability Sample|Patients with alcoholic hepatitis admitted to hospital for treatment.|December 2013|December 1, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01245257||112943|
NCT01245179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BUS43T|Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease|Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell Disease|LBH589|Georgia Regents University|Yes|Recruiting|November 2010|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||September 2015|February 11, 2016|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245179||112947|
NCT01245205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02550|Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer|A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-Expansion in Advanced HER2+ Breast Cancer||National Cancer Institute (NCI)||Completed|November 2010|||August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|November 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01245205||112946|
NCT01237249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM2010MAS65|Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone|A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (Rd).||PETHEMA Foundation|Yes|Active, not recruiting|March 2011|November 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|65 Years|N/A|No|||December 2015|December 11, 2015|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01237249||113550|
NCT01237262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELIDACE in PSO|Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy|Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy|ELIDACE|University of Padova|Yes|Not yet recruiting|November 2010|||November 2010|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|70 Years|No|||November 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237262||113549|
NCT01233947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-AFP-003|Study of AFP464 +/- Faslodex in ER + Breast Cancer|A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy||Tigris Pharmaceuticals|No|Terminated|May 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Female|18 Years|N/A|No|||January 2012|January 6, 2012|November 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233947||113803|
NCT01229722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44MH080655-02|ARemind: A Personalized System to Remind for Adherence|ARemind: A Personalized System to Remind for Adherence|ARemind|Dimagi Inc.|Yes|Completed|October 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|70|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|October 26, 2010||No||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01229722||114124|
NCT01229748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090623|Family Intervention for Teen Drinking in the ER|Family Intervention for Teen Drinking and Alcohol-Related Crises in the ER||University of Miami|No|Completed|November 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229748||114122|
NCT01229761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18677|Study to Improve Survival Among HIV-Exposed Infants in Botswana|A Randomized Study of Cotrimoxazole Prophylaxis and Longer Breastfeeding Duration to Improve Survival Among HIV-Exposed Infants in Botswana|Mpepu|Harvard School of Public Health|Yes|Active, not recruiting|May 2011|July 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|3724|||Female|18 Years|N/A|No|||June 2015|June 5, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01229761||114121|
NCT01230307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD3|Vitamin D Supplementation for Treatment of Heart Failure|D suppLementation In HearT FaiLure (DELIGHTFUL)|DELIGHTFUL|University of Michigan|No|Terminated|October 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|October 27, 2010|Yes|Yes|Unable to recruit sufficient number of patients.|No||https://clinicaltrials.gov/show/NCT01230307||114079|
NCT01230606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-1324|Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention|Ambulatory Closure Device Percutaneous Intervention: a Multi-Center Randomized Trial Evaluating Patient Satisfaction, Safety, and Cost Effectiveness of Ambulatory PCI in the Current Era|ABCD-PCI|Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|303|||Both|18 Years|75 Years|No|Probability Sample|The target population for this study will include patients undergoing an elective PCI.        Overall, 600 patient will be recurited from two sites in the United Sates. As this is a        feasiblity study, enrollment will be restricted to low-risk patients. For this reason, the        study will be limited to patients under 75 years of age. All patients must meet all of the        inclusion criteria and have none of the exclusion criteria to be enrolled into the study.|July 2011|July 26, 2011|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01230606||114058|
NCT01244776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEC 01|Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer|Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer||Shaanxi Aierfu Activtissue Engineering|Yes|Recruiting|April 2010|July 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||May 2011|May 5, 2011|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244776||112977|
NCT01244789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENGOT-EN2-DGCG/EORTC55102|Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer|A Phase III Trial of Postoperative Chemotherapy or no Further Treatment for Patients With Node-negative Stage I-II Intermediate or High Risk Endometrial Cancer||Danish Gynecological Cancer Group|Yes|Recruiting|December 2011|January 2018|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|678|||Female|18 Years|N/A|No|||August 2012|August 10, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244789||112976|
NCT01245036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sarc/Att/01|Efficacy of Antituberculous Therapy in Management of Sarcoidosis|Rifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled Trial||Postgraduate Institute of Medical Education and Research|Yes|Completed|January 2009|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|15 Years|75 Years|No|||May 2013|May 13, 2013|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01245036||112958|
NCT01245049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111763|Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children|Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 3 and 4-year-old Children||GlaxoSmithKline||Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|387|||Both|3 Years|4 Years|Accepts Healthy Volunteers|||August 2013|October 17, 2013|November 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245049||112957|
NCT01245387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5751021|Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration|Long-Term Non-Interventional Study (AB Study) To Investigate The Efficacy And Safety Of Macugen® In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice|MACULA|Pfizer|No|Completed|August 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1001|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with neovascular age-related macular degeneration|January 2011|January 12, 2011|September 29, 2010|No|Yes||No|December 21, 2010|https://clinicaltrials.gov/show/NCT01245387||112933|Time to first AE not estimated due to insufficient number of events. Visit numbers for NEI-VFQ-25 deviated from numbering used in other analyses; it represents the sequence number of questionaries administered (Visit 1=first assessment, etc.).
NCT01246284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02231|The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata|Efficacy and Safety of Different Concentrations of Intralesional Triamcinolone Acetonide in Alopecia Areata: A Prospective, Randomized, Double-blind, Placebo-controlled Study||University of British Columbia|No|Completed|December 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|5|||Both|19 Years|N/A|No|||June 2015|June 3, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01246284||112864|
NCT01246622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 179510|Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients||Roswell Park Cancer Institute|Yes|Active, not recruiting|February 2011|||May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|November 12, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01246622||112838|
NCT01246635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA-2005-02|Smith & Nephew's European Trufit Study|A Prospective, Multi-Center, Randomized, Single-Blind, Controlled Study Comparing the Trufit CB (Cartilage Bone) Implant to Microfracture for the Treatment of Patients With Single, Isolated Defects of the Knee||Smith & Nephew, Inc.|Yes|Completed|March 2008|December 2014|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|153|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|November 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01246635||112837|
NCT01246648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-13|Chronic Presence of Epstein Barr Virus in Sulcular and Junctional Epithelial Tissue From Gingiva is Associated With Severe Periodontitis|||Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2011|January 2013|Anticipated|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|6|||Male|12 Years|N/A|Accepts Healthy Volunteers|||November 2010|August 6, 2012|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01246648||112836|
NCT01246674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-FSP|Thigh Swelling, Hip-muscle Strength, and Functional Performance Following Total Hip Arthroplasty|Thigh Swelling, Hip-muscle Strength, and Functional Performance Following Total Hip Arthroplasty Monitored Pre-operatively, on the Day of Discharge, and One Week Post-surgery|THA|Hvidovre University Hospital|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|from a department of orthopedic surgery|July 2012|July 18, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246674||112834|
NCT01247740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0805|Comparison of Three-chamber-bag Versus Compounded Bag|A Prospective, Controlled, Randomized, Blinded, Parallel Group Multicentre Study on the Safety and Efficacy of a Convenience Three-chamber Bag for Parenteral Nutrition in Post-operative Patients After Abdominal Surgery Versus a Compounded Monobag||B. Braun Melsungen AG|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|85 Years|No|||January 2012|January 9, 2012|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247740||112752|
NCT01243671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-509|A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease|A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease||AbbVie|No|Completed|October 2010|June 2013|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|15 Years|N/A|No|||June 2014|June 27, 2014|November 17, 2010||No||No|March 26, 2013|https://clinicaltrials.gov/show/NCT01243671||113062|
NCT01243684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090404|A Magnetic Resonance Imaging Study of Patients With Cervical Spondylosis|Structural Spinal Cord Integrity in Patients With Cervical Spondylosis in Relation to Clinical Status|Tractocervical|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2010|January 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 18, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01243684||113061|
NCT01243918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/6-D|Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure|Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure|OPTI O2|Nantes University Hospital|No|Terminated|November 2010|June 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|N/A|No|||October 2013|October 4, 2013|November 18, 2010||No|Difficulty of recruitment|No||https://clinicaltrials.gov/show/NCT01243918||113043|
NCT01244230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFY10718|Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)|An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Atopic Dermatitis||Sanofi|No|Completed|November 2010|August 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|6 Months|11 Years|No|||October 2013|October 12, 2013|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244230||113019|
NCT01244243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2004-3852|Robot-Assisted Hand Motor Therapy for Subjects With Hemiparetic Stroke|Robot-Assisted Hand Motor Therapy for Subjects With Hemiparetic Stroke|Robot3|University of California, Irvine|No|Completed|January 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|November 3, 2010||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01244243||113018|
NCT01244256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCGGLE10407|Evaluation of Efficacy and Comparative Isolation of the Association Beclomethasone Clotrimzaol + + Gentamicin in Patients With Acne Contaminated|Isolation and Comparative Efficacy of the Combination of beclometasona0, 025% + Gentamicin 0.1% + Clotrimazole 1% Topical Dermatological Cream of GLENMARK PHARMACEUTICALS, in Patients Infected With Acne|acne|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Suspended|April 2007|September 2007|Anticipated|August 2007|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||April 2007|November 18, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01244256||113017|
NCT01245270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 10/S0801/54|A Single Supplement of a Standardised Bilberry Extract Modifies Glycaemic Response|A Single Supplement of a Standardised Bilberry Extract (36% (w/w) Anthocyanins) Modifies Glycaemic Response in Persons With Type 2 Diabetes Controlled by Diet and Lifestyle.||University of Aberdeen|Yes|Completed|September 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Male|40 Years|70 Years|No|||April 2015|April 30, 2015|November 16, 2010||No||No|August 23, 2013|https://clinicaltrials.gov/show/NCT01245270||112942|
NCT01245530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INM-176|An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia|Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study||Whanin Pharmaceutical Company|Yes|Completed|June 2008|March 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|280|||Both|50 Years|80 Years|No|||June 2011|June 9, 2011|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01245530||112922|
NCT01244880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8241014|Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects|Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 2-Way, 4-Period Crossover Study To Assess Effects Of PF-02545920 On Ketamine-Induced Aberrant Prefrontal Response To Associative Learning In Healthy Subjects||Pfizer|No|Terminated|April 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|4|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|November 5, 2010|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01244880||112969|
NCT01245504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31673 E/B|Assessment of Socket Shapes Made by Central Fabrication Facilities|Clinical Evaluation of an Algorithm to Assess Sockets Made by Central Fabrication Facilities||University of Washington|No|Completed|November 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|people with lower limb amputation that are ambulatory|April 2014|April 24, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01245504||112924|
NCT01237561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-19|Translating The GOLD COPD Guidelines Into Primary Care Practice|Translating The GOLD COPD Guidelines Into Primary Care Practice|LungAge|Memorial Hospital of Rhode Island|Yes|Active, not recruiting|October 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|3593|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01237561||113526|
NCT01233674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08120067|Examination of Left Atrial Fibrosis Using MRI|Examination of Left Atrial Fibrosis Using MRI||University of Pittsburgh||Withdrawn|March 2011|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|all patients referred for standard of care MRI|January 2016|January 4, 2016|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233674||113824|
NCT01233960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 611|Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease|A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease||Mesoblast, Ltd.|No|Active, not recruiting|September 2010|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|70 Years|No|||June 2014|May 19, 2015|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233960||113802|
NCT01234805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98410|Yoga Therapy in Treating Patients With Malignant Brain Tumors|Yoga and Brain Cancer: A Feasibility Study||Comprehensive Cancer Center of Wake Forest University|No|Terminated|December 2010|||September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Both|18 Years|N/A|No|||September 2012|July 27, 2015|November 3, 2010||No|Slow Accruals|No||https://clinicaltrials.gov/show/NCT01234805||113737|
NCT01230034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIPV001DIM2010|Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria|Randomized, Controlled, PROBE Trial, Evaluating the Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic Patients and Mild to Moderate Hypertension With Microalbuminuria||University of Pavia|Yes|Recruiting|October 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|70 Years|No|||October 2010|October 27, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230034||114100|
NCT01230320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORP-PT-001|Simplified vs. Conventional Methods for Complete Denture Fabrication|Simplified vs. Conventional Methods for the Fabrication of Complete Dentures in a Public Health Setting||University of Sao Paulo|No|Active, not recruiting|October 2010|December 2014|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|40|||Both|45 Years|N/A|No|||July 2014|July 24, 2014|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230320||114078|
NCT01230619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH002|Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis|A Two Day, Randomised, Single Blind, Parallel Group Trial of Repeat Doses of Intranasal RV568 in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)||Respivert Ltd|No|Completed|October 2010|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Male|18 Years|55 Years|No|||December 2010|December 3, 2010|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01230619||114057|
NCT01245075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-090|Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction|Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction|NASA|University of Cologne|Yes|Recruiting|January 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245075||112955|
NCT01245400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI-ZLig-01-10-01|Safety and Efficacy Study of the Z-Lig Medical Device Compared to Allograft|A Prospective, Randomized, Double-Blind, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the Z-Lig Medical Device Compared to Allograft for the Reconstruction of Ruptured Anterior Cruciate Ligaments|Z-Lig|Aperion Biologics, Inc.|No|Active, not recruiting|November 2010|April 2017|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||March 2014|March 11, 2014|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01245400||112932|
NCT01245712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0818|Partial Breast Proton Beam Irradiation|Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation||M.D. Anderson Cancer Center|No|Recruiting|November 2010|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245712||112908|
NCT01245725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10002|Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention|A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention|ATLAST-PCI|Medicure|No|Suspended||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1900|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|November 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245725||112907|
NCT01246297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROSM0090|Effect of Pulmonary Rehabilitation in Lung Cancer Survivors|A Pilot Study of Early Outpatient Pulmonary Rehabilitation Following Thoracic Surgery for Lung Cancer||Imperial College Healthcare NHS Trust|No|Recruiting|October 2010|November 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||November 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246297||112863|
NCT01246921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNIP_UVB|Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo|Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Recruiting|September 2009|||August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2009|November 23, 2010|November 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01246921||112815|
NCT01243697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101001|Assessment of Desogestrel in Ondine Syndrome|Assessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine Syndrome|RESPIRONDINE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2011|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|10 Years|60 Years|No|||October 2012|November 13, 2013|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243697||113060|
NCT01243931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00006612-PTK|Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy|Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy||Oregon Health and Science University|No|Recruiting|June 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01243931||113042|
NCT01244893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1636BI|Study of ACUVUE® ADVANCE® PLUS Contact Lenses.|||Johnson & Johnson Vision Care, Inc.||Completed|October 2010|||November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|39 Years|No|||May 2015|May 6, 2015|November 18, 2010|No|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01244893||112968|
NCT01245283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|614-2009|Resistance Exercise and Knee Osteoarthritis Pain, Functional Impairment and Cartilage Turnover|Comparative Resistance Exercise Effect on Knee Osteoarthritis Pain, Functional Impairment and Cartilage Turnover||University of Florida|No|Completed|November 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|60 Years|85 Years|No|||November 2014|November 19, 2014|November 5, 2010||No||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01245283||112941|
NCT01245517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99053|The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient|The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient||Taipei Medical University WanFang Hospital|Yes|Recruiting|September 2010|June 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|85 Years|No|||November 2010|November 18, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01245517||112923|
NCT01245543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC480IV-001|Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors|Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Withdrawn|November 2010|June 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|November 17, 2010|Yes|Yes|Clinical investigations have been discontinued and transfer to BMS 3/24/2015|No||https://clinicaltrials.gov/show/NCT01245543||112921|
NCT01233934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERP 185v3-10|Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites|||Mantecorp Industria Quimica e Farmaceutica Ltd.|Yes|Not yet recruiting|February 2011|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|2 Years|60 Years|No|||November 2010|November 2, 2010|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01233934||113804|
NCT01233687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-058|AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer|A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer||University of Pittsburgh|Yes|Recruiting|August 2011|January 2015|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01233687||113823|
NCT01234532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047658|0927GCC: Entinostat and Anastrozole in Treating Postmenopausal Women With Triple-Negative Breast Cancer That Can Be Removed by Surgery|A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response||University of Maryland||Terminated|October 2010|December 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|November 3, 2010|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01234532||113758|
NCT01234545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3850|Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors|A Prospective Observational Study on the Home Treatment of Haemarthrosis With rFVIIa (Activated Recombinant Factor VII) in Haemophilia A and B Patients With Inhibitors||Novo Nordisk A/S|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Male|2 Years|N/A|No|Non-Probability Sample|Patients with congenital haemophilia and inhibitors to Factor VIII or IX.|November 2014|November 13, 2014|November 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01234545||113757|
NCT01234272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0368|Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-|Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-||Yonsei University|No|Completed|August 2010|June 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|20 Years|N/A|No|||August 2011|August 15, 2011|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234272||113778|
NCT01234558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLYX13-C201|Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression|Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder||Naurex, Inc|No|Completed|May 2011|July 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|115|||Both|18 Years|65 Years|No|||September 2012|September 10, 2012|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01234558||113756|
NCT01235065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042451|GlideScope Versus Direct Laryngoscope for Emergency Intubation|GlideScope vs. Direct Laryngoscope for Emergency Intubation||University of Maryland|Yes|Active, not recruiting|July 2008|March 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|658|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01235065||113717|
NCT01235078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04|Observation of Intraosseous Vascular Access in the Emergency Department|An Observational Study of Intraosseous Vascular Access Compared to Central Venous Catheters in the Emergency Department||Vidacare Corporation|No|Completed|April 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|105|||Both|N/A|N/A|No|Non-Probability Sample|patients requiring urgent vascular access|June 2012|June 28, 2012|November 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01235078||113716|
NCT01244425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|550904|Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection|A Randomized, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fibrin Sealant VH S/D 500 S-apr (Tisseel) for Hemostasis in Subjects Undergoing Hepatic Resection||Baxter Healthcare Corporation|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|November 18, 2010||No||No|January 9, 2013|https://clinicaltrials.gov/show/NCT01244425||113004|
NCT01244438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP1039-002|Study of FP-1039 in Subjects With Endometrial Cancers|An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations||Five Prime Therapeutics, Inc.|Yes|Withdrawn|January 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||March 2012|March 8, 2012|November 17, 2010|Yes|Yes|Study FP1039-002 was not feasible. The original assumption was at least 5% of patients    screened would qualify, but after screening 70 patients, none qualified.|No||https://clinicaltrials.gov/show/NCT01244438||113003|
NCT01245413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP213OC|Controlled Randomized Study With Athena Base Plate Versus SenSura Base Plate on Perspiring Skin|Controlled Randomized Study With a New Base Plate Versus SenSura Base Plate on Perspiring Skin||Coloplast A/S|No|Completed|November 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Male|50 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|November 16, 2010||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT01245413||112931|
NCT01245738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-204|Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)|Dyslipidemia: REsidual and Mixed Abnormalities IN Spite of Statin Therapy: The Dyslipidemia REMAINS Study: A Multicenter, Prospective, Observational Study of Lipid Profiles and Treatment Patterns at Presentation and After 12 Weeks of Statin Therapy Among Indian Adults Presenting With First Coronary Event|REMAINS|Merck Sharp & Dohme Corp.|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|635|||Both|35 Years|N/A|No|Non-Probability Sample|Patients experiencing their first acute coronary event who are admitted to participating        tertiary cardiac care centers in India will potentially be eligible for the study.|August 2015|August 12, 2015|August 13, 2010|No|Yes||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01245738||112906|
NCT01246271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-234|Sub Urethral Sling With or With Out Anterior Repair|a Retrospective Cohort Recognize the Out Comes of SUS With or Without Anterior Vaginal Repair||Tabriz University|Yes|Completed|February 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|98|||Female|27 Years|78 Years|No|Probability Sample|woman with stress urinary incontinence|January 2008|November 22, 2010|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246271||112865|
NCT01245959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YP2010171|Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Active, not recruiting|January 2011|April 2018|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|476|||Both|18 Years|59 Years|No|||January 2014|February 12, 2014|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245959||112889|
NCT01245972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRPP-101001|Pilot Study of PDL to Treat BCC and SCCIS|A Pilot Study to Examine the Effectiveness of 595nM Pulsed Dye Lasers in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma in Situ|PDLNMSC|University of California, San Diego|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245972||112888|
NCT01245998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVETR2010|Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis|Prospective, Randomized, Double-blinded Trial of the Efficacy and Safety of Different Doses and Duration of Low Molecular Weight Heparin (Dalteparin) in Superficial Vein Thrombosis|REVETR|University Medical Centre Ljubljana|Yes|Active, not recruiting|September 2010|November 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|85 Years|No|||August 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245998||112886|
NCT01246336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB09-0196|Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath|Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.||Rambam Health Care Campus|No|Completed|August 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|41|Samples Without DNA|Exhaled breath|Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients diagnosed with Idiopathic Parkinson's disease and Parkinsonism will be included.|November 2015|November 4, 2015|November 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01246336||112860|
NCT01246661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4001-002|MilkScreen™ Home Test for Alcohol in Breast Milk Clinical Study|MilkScreen™ Home Test for Alcohol in Breast Milk Clinical Study||UpSpring Baby, Ltd.|Yes|Active, not recruiting|March 2010|November 2010|Anticipated|April 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female subjects 21 years and older will be recruited for this study.|November 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246661||112835|
NCT01247506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912020R|Different Genetic Features Associated With Hepatic Carcinogenesis|Identification of Survival-related microRNAs in Hepatocellular Carcinoma||National Taiwan University Hospital|No|Recruiting|February 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|160|Samples With DNA|HCC tissues and paired nontumor tissues|Both|45 Years|70 Years|No|Probability Sample|A total of 160 patients with histologically proven HCC were collected by Dr. Po-Huang        Lee's Lab (The Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan)|November 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247506||112770|
NCT01247766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-213|Safety Study of Abatacept to Treat Rheumatoid Arthritis|Post-marketing Observational Study Assessing the Long-term Safety of Abatacept Using a Population-based Cohort of Rheumatoid Arthritis Patients in the Province of British Columbia||Bristol-Myers Squibb|No|Active, not recruiting|December 2010|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|8000|||Both|18 Years|N/A|No|Non-Probability Sample|Residents of British Columbia who have received health care service for rheumatoid        arthritis|February 2016|February 1, 2016|November 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247766||112750|
NCT01243398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000689080|Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy|Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy||University of Oxford|Yes|Completed|March 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243398||113083|
NCT01243411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-802|A Study of AA4500 in Men With Peyronie's Disease|A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease||Endo Pharmaceuticals|No|Completed|November 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|348|||Male|18 Years|N/A|No|||March 2015|March 31, 2015|November 17, 2010|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01243411||113082|
NCT01243424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.74|CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes|A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.||Boehringer Ingelheim||Active, not recruiting|October 2010|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|6000|||Both|40 Years|85 Years|No|||January 2016|January 12, 2016|November 17, 2010||||No||https://clinicaltrials.gov/show/NCT01243424||113081|
NCT01243944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424B2301|Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)|Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)||Incyte Corporation||Active, not recruiting|October 2010|December 2018|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|November 17, 2010|Yes|Yes||No|December 22, 2014|https://clinicaltrials.gov/show/NCT01243944||113041|
NCT01243957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12597|A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.|LY2216684 and Fluoxetine Pharmacokinetic Interaction Study in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 20, 2011|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01243957||113040|
NCT01244620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321056|A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses|A Phase 1, Open Label, Randomized, Four Period, Crossover, Multiple Dose Study To Assess The Pharmacokinetic Interaction Between Sitaxsentan and Tadalafil and The Effect Of Sildenafil On Sitaxsentan PK In Healthy Subjects||Pfizer|No|Terminated|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 18, 2012|November 15, 2010|No|Yes|Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,    specifically new emerging evidence of hepatic injury.|No|January 18, 2012|https://clinicaltrials.gov/show/NCT01244620||112989|Study endpoints were not analyzed due to early termination.
NCT01244906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 911|Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant|A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation||Northside Hospital, Inc.|No|Completed|December 2010|December 2014|Actual|April 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|75 Years|No|||January 2015|April 9, 2015|November 18, 2010|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01244906||112967|
NCT01246141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101012|The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease|The Institute of Cardiovascular Surgery||Xijing Hospital|Yes|Completed|January 1998|April 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|68|||Both|21 Years|67 Years|No|Probability Sample|patients with aortic valve and mitral valve diseases and functional tricuspid valve        regurgitation underwent surgical operations from Nov., 1998 to Dec., 2009 in our        institute.|January 1998|November 22, 2010|November 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01246141||112875|
NCT01246154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC001|An Evaluation of Exercise Tolerance in Asthmatic Patients|||Physio Care|Yes|Not yet recruiting|November 2010|January 2011|Anticipated|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|15|||Both|40 Years|50 Years|No|Non-Probability Sample|KNOWN ASTHMATIC PATIENTS|November 2010|November 22, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01246154||112874|
NCT01245556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA206-005|Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma|A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma||Bristol-Myers Squibb|Yes|Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|November 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01245556||112920|
NCT01245569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0910-PR-0021|A Study in Patients With Chronic Obstructive Pulmonary Disease|A 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Seretide® 500/50 (Fluticasone 500 µg Plus Salmeterol 50 µg/Actuation), 1 Inhalation b.i.d., in Patients With Chronic Obstructive Pulmonary Disease|FUTURE|Chiesi Farmaceutici S.p.A.|No|Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|373|||Both|40 Years|N/A|No|||April 2012|April 2, 2012|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245569||112919|
NCT01234246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL32121.008.10|Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners.|Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners.||University of Tilburg|No|Recruiting|March 2010|March 2014|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1200|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with colorectal cancer and their partners|August 2010|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234246||113780|
NCT01234259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN-WR- 01|Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment|Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment - a Pilot Study||Venus Concept|No|Completed|December 2010|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 3, 2015|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234259||113779|
NCT01238523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH-001|Study of Tibial Shaft Fractures in Children|Early Weight-Bearing in the Closed Treatment of Tibial Shaft Fractures in Children||University of California, Los Angeles|Yes|Completed|May 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|4 Years|14 Years|No|||May 2010|November 9, 2010|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238523||113453|
NCT01238536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39023-A|Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)|Multicenter Randomized Controlled Trial of Epidural Steroid Injections for Spinal Stenosis in Persons 50 and Older|LESS|University of Washington|Yes|Completed|April 2011|September 2015|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|50 Years|N/A|No|||December 2015|December 3, 2015|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01238536||113452|
NCT01235741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA104|A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects|A Randomized, Double-Blind, Placebo-Controled, Multicenter Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects Following A Low‑Calorie Diet Lead-In||AstraZeneca|No|Terminated|January 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|November 2, 2010|Yes|Yes|Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in    invitro assay in 2 participants.|No|August 12, 2013|https://clinicaltrials.gov/show/NCT01235741||113666|
NCT01235754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESTW009|Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)|A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women||BioSante Pharmaceuticals|No|Completed|October 2010|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|626|||Female|30 Years|66 Years|No|||January 2013|January 4, 2013|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235754||113665|
NCT01234571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0273-10CTIL|Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension|||Rambam Health Care Campus|No|Not yet recruiting|November 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|N/A|No|Non-Probability Sample|The study population includes patients with PAH who receive chronic (more than 3 months)        Treprostenil treatment administered intravenously as a single agent therapy who maintain        chronic hemo-dialysis therapy. Patients must be in stable condition for at least one        month. Patients other than class I PAH will be not included in this study.|October 2010|November 3, 2010|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01234571||113755|
NCT01244802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002834|Immune Responses to Yellow Fever Vaccine|Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination||Emory University|No|Recruiting|November 2010|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults between the ages of 18 to 45 years or 55 or above who previously received        the yellow fever vaccine|February 2016|February 3, 2016|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244802||112975|
NCT01245062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114267|GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma|A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma||GlaxoSmithKline|Yes|Active, not recruiting|November 2010|July 2016|Anticipated|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|322|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|November 18, 2010|No|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01245062||112956|
NCT01245751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-029|Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)|Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX™ Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX™||Merck Sharp & Dohme Corp.|No|Completed|April 2011|May 2015|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|600|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|November 19, 2010|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT01245751||112905|
NCT01245777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITiRiP-1|Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy|Exploratory Study of the Efficacy, Practicability and Safety of Intravenous Iron Supplementation Therapy in Moderate to Severe Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy||University of Zurich|Yes|Completed|October 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|N/A|No|||December 2014|December 4, 2014|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245777||112903|
NCT01245985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPF-C-HIT|TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors|Induction Chemotherapy With TPF Followed by Radioimmunotherapy With Cetuximab and Intensity Modulated Radiotherapy (IMRT) Plus Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx: TPF-C-HIT|TPF-C-HIT|Heidelberg University|Yes|Terminated|November 2010|November 2013|Anticipated|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||April 2013|April 23, 2013|November 22, 2010||No|slow recruitment (only 8 patients recruited and treated until 12/2012)|No||https://clinicaltrials.gov/show/NCT01245985||112887|
NCT01246310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|agunco7/2010|Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients|Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients.||AGUNCO Obstetrics and Gynecology Centre|No|Recruiting|November 2010|||December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|No|||June 2011|June 23, 2011|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01246310||112862|
NCT01246323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBINED ANASTHESIA GYNECOLOGY|Combined Anesthesia for Laparoscopy Surgery in Gynecology|Combined General and Spinal Anesthesia vs. General Anesthesia for Pain Relief During Laparoscopy Gynecological Surgery||Rambam Health Care Campus|No|Recruiting|November 2010|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|70 Years|No|||November 2010|August 4, 2011|November 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01246323||112861|
NCT01247207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-016 DMD|Study of Ataluren for Previously Treated Patients With nmDBMD in the US|An Open-label, Safety Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy||PTC Therapeutics|No|Enrolling by invitation|November 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Male|N/A|N/A|No|||February 2014|February 3, 2014|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247207||112793|
NCT01243437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEZID-5859|A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans|A Randomized, Non-inferiority, Active Controlled Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin Versus Doxycycline in the Treatment of Plague in Humans||Centers for Disease Control and Prevention|Yes|Recruiting|December 2010|||June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|8 Years|N/A|No|||September 2012|September 10, 2012|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243437||113080|
NCT01243450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAM-04|Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo|Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo||Spear Pharmaceuticals|Yes|Completed|October 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|958|||Both|12 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|November 16, 2010|Yes|Yes||No|September 7, 2014|https://clinicaltrials.gov/show/NCT01243450||113079|
NCT01243970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/0182|Ephedrine vs Phenylephrine - ECG Changes|Randomised, Double-blind, Phase IV Study to Compare the Incidence of ECG Changes During Elective Caesarean Section Under Spinal Anaesthesia When Using Phenylephrine or Ephedrine Infusion to Maintain Baseline Systolic Blood Pressure||University College London Hospitals|Yes|Recruiting|April 2012|November 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 5, 2015|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01243970||113039|
NCT01243710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUNN1007|Taurolidine in Haemodialysis Catheter Related Bacteraemia|A Randomised Controlled Trial of Taurolidine With Heparin for Prevention of Recurrence of Catheter Related Bacteraemia in Haemodialysis Patients.||Imperial College Healthcare NHS Trust|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243710||113059|
NCT01244633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY301|Ecopipam Treatment of Tourette Syndrome|Ecopipam Treatment of Tourette Syndrome||Psyadon Pharma|Yes|Completed|October 2010|July 2013|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2015|August 27, 2015|November 17, 2010|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01244633||112988|This was an open label study with no placebo control
NCT01244646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CNL-DUM-2010/1|Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.|Perceived Hypoglycemia- and Weight-related Quality of Life of Patients With Sulfonylurea Derivate-treated Diabetes Mellitus Type 2, a Non-interventional Study.||AstraZeneca|No|Terminated|December 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|||Both|35 Years|N/A|No|Probability Sample|General practitioners, group practices in primary care, pharmacists|December 2012|December 5, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244646||112987|
NCT01244932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP-01|Minimum Effective Volume of Local Anesthetic Using Ultrasound for Brachial Plexus Block|Determination of the Minimum Effective Volume of Local Anesthetic Using Ultrasound Guidance for Interscalene Brachial Plexus Block||Federal University of São Paulo|No|Completed|September 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|33|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 8, 2012|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01244932||112966|
NCT01274975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Astrostem|Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.|Safety of Autologous Adipose Derived Mesenchymal Stem Cells in Patients With Spinal Cord Injury|MSC|Biostar||Completed|July 2009|February 2010|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|19 Years|60 Years|No|||March 2014|March 24, 2014|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01274975||110662|
NCT01245582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11719|Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients|A Randomized Phase III Study of Oxaliplatin (Eloxatin) and Capecitabine on Top of Sorafenib Versus Sorafenib Alone as First-line Palliative Treatment in Advanced Hepatocellular Carcinoma Patients|SECOX|Sanofi|Yes|Withdrawn|July 2011|August 2015|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||November 2011|November 8, 2011|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245582||112918|
NCT01238224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003921-25|Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes|The Effect of Selective PDE-5 Inhibition on Capillary Recruitment, Glucose Uptake and Endothelial Function Following a Mixed Meal in Patients With Type 2 Diabetes Patients.||Vastra Gotaland Region|No|Terminated|November 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|40 Years|65 Years|No|||June 2015|June 18, 2015|October 6, 2010||No|Durability of study medications could not be guaranteed after the expire date.|No||https://clinicaltrials.gov/show/NCT01238224||113476|
NCT01235429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILI ARRA Supplement|Partners in Care Diabetes Self-management Intervention|Specific Aim 3: Partners in Care Randomized Controlled Trial||University of Hawaii|Yes|Completed|October 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|November 12, 2013|November 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01235429||113689|
NCT01235767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-068|Animal Source Food Supplement and Pregnancy in Vietnam|Effect of Animal Source Food Supplement Prior to and During Pregnancy on Birth Weight and Prematurity in Rural Vietnam|VACVINA|Children's Hospital & Research Center Oakland|Yes|Recruiting|January 2011|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1044|||Female|18 Years|30 Years|No|||July 2013|July 31, 2013|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235767||113664|
NCT01235780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098060-3|Factors Affecting Corneal Hysteresis in Taiwanese|Factors Affecting Corneal Hysteresis in Taiwanese||Far Eastern Memorial Hospital|No|Completed|December 2009|July 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|83|||Both|33 Years|86 Years|No|Probability Sample|Normal population and patients receiving phacoemulsification|December 2009|November 5, 2010|August 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01235780||113663|
NCT01236053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114790|Cancer in Patients With Gabapentin (GPRD)|Risk of Cancer in Patients Exposed to Gabapentin in the GPRD||GlaxoSmithKline|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|2323608|||Both|N/A|N/A|No|Probability Sample|The study cohort from which cases and controls are drawn is all subjects in the UK GPRD        1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are registered        in GPRD before that time, and at the time of registration if later than Jan 1, 1993.        Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of        cancer prior to the cohort entry date. Follow-up ends Dec 31, 2008, or earlier if the        subject leaves the GPRD for any reason including death. There are several advantages to        the GPRD dataset for this study. It is a large dataset with detailed longitudinal        prescription data, and long term follow-up (mean 7 years) to allow for latency in        carcinogenicity. It provides good representation of the elderly who are disproportionately        affected by cancer, and routinely includes data recorded by general practitioners on        potential risk factors such as smoking, alcohol consumption and body mass index.|January 2012|February 2, 2012|October 14, 2010||No||No|July 1, 2011|https://clinicaltrials.gov/show/NCT01236053||113642|
NCT01245088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCDZ|Chondroitin Sulfate for Crohn's Disease|A Pilot Study of Chondroitin Sulfate (CS) for the Treatment of Mild to Moderate Crohn's Disease||University Hospital Case Medical Center|No|Withdrawn|January 2011|May 2012|Anticipated|March 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||August 2012|August 29, 2012|November 19, 2010|No|Yes|Sponsor withdrew support after no patients enrolled|No||https://clinicaltrials.gov/show/NCT01245088||112954|
NCT01245114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THAO|Tübingen High Altitude Ophthalmology Study|Tübingen High Altitude Ophthalmology Study (THAO)|THAO|University Hospital Tuebingen|No|Completed||December 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|healthy volunteers|July 2010|December 2, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245114||112952|
NCT01245439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25095|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis|Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD||Hoffmann-La Roche||Completed|September 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|November 17, 2010|No|Yes||No|October 5, 2015|https://clinicaltrials.gov/show/NCT01245439||112929|
NCT01245764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-046|GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)|Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa||Merck Sharp & Dohme Corp.|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|250|||Female|9 Years|26 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|November 19, 2010|Yes|Yes||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01245764||112904|
NCT01246349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000017625|Motivational Interviewing for Weight Loss|Motivational Interviewing as an Intervention to Increase Adolescent Self-Efficacy and Promote Weight Loss||The Hospital for Sick Children|No|Completed|September 2010|November 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|10 Years|18 Years|No|||March 2014|March 15, 2014|November 11, 2010||No||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01246349||112859|
NCT01246687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED2009-CM(SG)-004-QKF|Web-based Dietary Intervention for Diabetic Patients|Dietary Intervention Among Patients With Type 2 Diabetes Mellitus: An e-Approach|myDIDeA|Monash University||Active, not recruiting|March 2010|September 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|134|||Both|18 Years|N/A|No|||November 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246687||112833|
NCT01247753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 DK71552-1|Walking Exercise and Nutrition to Reduce Diabetes Risk for You (WENDY)|Stepping Up to Health - Walking Exercise and Nutrition to Reduce Diabetes Risk for You (WENDY)|WENDY|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Not yet recruiting|March 2011|September 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|N/A|No|||February 2011|February 1, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247753||112751|
NCT01243736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000198|Assessment of Combined Bowel Preparation for Capsule Endoscopy Study|Assessment of Combined Bowel Preparation for Capsule Endoscopy Study|CEPREP|Mayo Clinic|Yes|Completed|April 2010|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01243736||113057|
NCT01243983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX211-11|Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis|A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects With Active Noninfectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye||Lux Biosciences, Inc.|Yes|Completed|February 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243983||113038|
NCT01244269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPH.NMS.2011|The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.|Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease.||Laval University||Terminated|December 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|6|||Both|N/A|75 Years|No|||October 2012|October 19, 2012|November 18, 2010||No|Inadequate enrolment, protocol too challenging for participants, lack of observable benefit    after analysis of 6 patients.|No||https://clinicaltrials.gov/show/NCT01244269||113016|
NCT01244659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACEMS0410|A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment|An Open Randomized Non-inferiority Study to Compare Safety and Efficacy of Immunosuppressive Regiments Using Tacrolimus From EMS and Prograf® in Post Renal Transplanted Patients||EMS|Yes|Suspended|May 2014|December 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|November 18, 2010||No|Study suspended by decision strategically.|No||https://clinicaltrials.gov/show/NCT01244659||112986|
NCT01245595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18977|Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery|A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass|KIDPROAM|Stanford University|Yes|Completed|November 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|N/A|18 Years|No|||June 2015|June 3, 2015|November 19, 2010||No||No|March 31, 2015|https://clinicaltrials.gov/show/NCT01245595||112917|
NCT01245881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LK-13-2010|Fractional Photothermolysis for Treating Melasma|A Multicenter Study of Fractional Photothermolysis in the Treatment of Melasma||Laserklinik Karlsruhe||Completed|March 2008|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|N/A|N/A|No|||November 2010|November 22, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245881||112895|
NCT01246466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2009-1|Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study|Feasibility Trial of a Hybrid Approach for Treatment of Patients With Persistent or Longstanding Persistent Atrial Fibrillation With Radiofrequency Ablation|DEEP|AtriCure, Inc.|Yes|Completed|November 2010|November 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246466||112850|
NCT01246479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-324|Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study|Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study||Valneva Austria GmbH|No|Completed|October 2010|September 2014|Actual|October 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|9 Months|20 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|October 6, 2010|No|Yes||No|April 13, 2015|https://clinicaltrials.gov/show/NCT01246479||112849|
NCT01235117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000688119|Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia|A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML)||National Cancer Institute (NCI)||Completed|January 2010|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2010|August 23, 2013|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235117||113713|
NCT01235442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080470|Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis|A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis||Amgen|No|Completed|September 2010|December 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|592|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|October 28, 2010|Yes|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT01235442||113688|
NCT01235455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14235|Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors|Portuguese BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis (MS) After Conversion to Betaferon by Using Elements of the BetaPlus Program|POR-BetaPlus|Bayer|No|Completed|August 2007|May 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with RRMS or SPMS attending an hospital outpatient MS clinic|October 2012|October 30, 2012|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235455||113687|
NCT01235793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019873|The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma|A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma|DRBEAT|Cedars-Sinai Medical Center|Yes|Recruiting|September 2010|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||November 2014|June 3, 2015|November 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235793||113662|
NCT01236066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114910|Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia|A Study on the Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia||GlaxoSmithKline||Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|5 Years|No|Non-Probability Sample|Australian children aged < 5 years who have been vaccinated with RotaTeq (in Queensland)        and Rotarix (in New South Wales) from 2007 to 2009 as well as all children aged < 5 years        hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis,        before and after introduction of Rotarix vaccination in New South Wales, Australian        Capital Territory, Tasmania and Northern Territory, from 1998 to 2009.|December 2011|December 13, 2011|October 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01236066||113641|
NCT01245426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114749|A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)|A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to Determine the Efficacy and Dose Response of Repeat Inhaled Doses of GW870086X on FEV1 in Adults With Persistent Asthma||GlaxoSmithKline|No|Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|136|||Both|18 Years|65 Years|No|||March 2012|March 29, 2012|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245426||112930|
NCT01246011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001386|Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion|Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion||Massachusetts General Hospital|Yes|Terminated|November 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|9|||Both|18 Years|N/A|No|||February 2012|March 9, 2012|November 17, 2010|Yes|Yes|Enrollment was too slow.|No|January 3, 2012|https://clinicaltrials.gov/show/NCT01246011||112885|The study was ended early due to slow enrollment and results will not be analyzed. The 4 subjects who completed the study were all in the same arm of the study.
NCT01247220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101717|REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study|REVOLUTIONARY: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by Ultra Widefield angIOgraphy in combiNAtion With Ranibizumab Study Phase II|Revolution|Retina Associates of Florida, P.A.|Yes|Completed|November 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|90 Years|No|||October 2014|October 3, 2014|November 17, 2010|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01247220||112792|small study size
NCT01247519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912023R|The Effects of Post-hospitalization Telehealth Care in the Patients Who Admitted Via Emergency Department|The Effects of Post-hospitalization Telehealth Care in the Patients Who Admitted Via Emergency Department||National Taiwan University Hospital|No|Recruiting|December 2009|December 2011|Anticipated|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||October 2010|November 23, 2010|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01247519||112769|
NCT01247532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-01 Study 1003-02B|Pilot Study of Mindfulness-Based Stress Reduction for Patients With Persistent Cancer-Related Fatigue|Pilot Study of Mindfulness-Based Stress Reduction for Patients With Persistent Cancer-Related Fatigue||Indiana University|Yes|Completed|March 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247532||112768|
NCT01244672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106946|Trans-anal Hemorrhoidal Dearterialization (THD) vs. Hemorrhoidectomy|Trans-anal Hemorrhoidal Dearterialization (THD) vs. Hemorrhoidectomy for 3rd and 4th Degree Hemorrhoids in at Least Three Quadrants: A Prospective Randomized Control Pilot Study.|THD|Stony Brook University|No|Completed|December 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244672||112985|
NCT01244945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1026D|Lactobacillus Reuteri DSM 17938 in Functional Constipation|Effect of Lactobacillus Reuteri DSM 17938 on Gut Motility in Patients With Functional Constipation|LRFC|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|No|Completed|January 2011|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|19 Years|65 Years|No|||March 2014|March 26, 2014|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01244945||112965|
NCT01244282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08085|A Study of Two Methodologies for Measuring Blood Flow in the Brain in Response to Non-Drug Stimuli (P08085/MK-0000-180)|A Pilot Clinical Trial to Study Arterial Spin Labeling and USPIO-enhanced MRI Methodologies for Measuring Hemodynamic Responses to Non-Drug Stimuli in Healthy Subjects||Merck Sharp & Dohme Corp.|No|Completed|November 2010|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 30, 2014|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01244282||113015|
NCT01244295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5645|Study of Interpersonal Therapy and Complicated Grief Treatment in Adults 50 Years and Older|Complicated Grief Treatment in Older Adults|CGTOA|New York State Psychiatric Institute|Yes|Completed|March 2008|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|50 Years|95 Years|No|||January 2014|January 15, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244295||113014|
NCT01277770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00011652|Studies of Kidney Transplant Outcome|Studies of Kidney Transplant Outcome||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|May 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|7500|||Both|N/A|N/A|No|Non-Probability Sample|Kidney transplant recipients at the University of Minnesota|May 2015|May 26, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01277770||110447|
NCT01277783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSYNC|ALternate Site Cardiac ReSYNChronization (ALSYNC) Study|ALternate Site Cardiac ReSYNChronization Study|ALSYNC|Medtronic Cardiac Rhythm Disease Management|Yes|Enrolling by invitation|January 2011|December 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01277783||110446|
NCT01278511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52940|Prospective Pilot Study Validating the Canadian C-Spine Rule Pre-hospital|A Prospective Pilot Study Validating the Canadian C-Spine Rule in a Pre-hospital Setting||Katholieke Universiteit Leuven|No|Withdrawn|January 2011|||||N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|January 13, 2011||No|Not feasible|No||https://clinicaltrials.gov/show/NCT01278511||110390|
NCT01278524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPROVE-ICU|International Multicenter Study One Day Prevalence Observational Study for Delirium on ICU|International Multicenter Study One Day Prevalence Observational Study for Delirium on ICU|IMPROVE-ICU|Charite University, Berlin, Germany|No|Completed|January 2011|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1002|||Both|N/A|N/A|No|Probability Sample|ICU patients|August 2013|August 9, 2013|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278524||110389|
NCT01275235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC10016|Exposure to Type II Diabetes for Two Siblings With the Same Parents|Metabolic Traits of Adult Sib-pairs Discordant for Intrauterine Diabetes Exposure.|T2DM|Pennington Biomedical Research Center|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|10|Samples Without DNA|Whole blood, urine and muscle cell.|Both|20 Years|34 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community|August 2014|August 8, 2014|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275235||110642|
NCT01275248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OND-003|Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Who Have Not Adequately Responded To Treatment With A Serotonin Reuptake Inhibitor||Transcept Pharmaceuticals|Yes|Terminated|January 2011|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|130|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|January 10, 2011|Yes|Yes|lack of efficacy|No||https://clinicaltrials.gov/show/NCT01275248||110641|
NCT01275469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-209-4|Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.|A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80 mg) Orally Administered Once Daily for 35 Days in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. A Double Blind, Parallel Group, Placebo-controlled and Randomized Study.||Genfit|No|Completed|June 2009|January 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|75 Years|No|||January 2011|January 11, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275469||110624|
NCT01275755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2402-002|Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain||Cubist Pharmaceuticals LLC|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|January 11, 2011|Yes|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01275755||110602|
NCT01234870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR1_STU00006013|Comprehensive Evaluation of Ischemic Heart Disease Using MRI|Comprehensive Evaluation of Ischemic Heart Disease Using MRI||Northwestern University|Yes|Completed|June 2010|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|October 5, 2010|Yes|Yes||No|September 2, 2014|https://clinicaltrials.gov/show/NCT01234870||113732|The small number of subjects results in reduced statistical power; The cohort was selected from patients at a single medical center, potentially reducing generalizability; Variability in patient behavior during MR scans may affect analyses
NCT01235806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-CPR-01|Contribution of ESAOTE™ Low Field MRI for Diagnosis of Scaphoid Fractures|Contribution of ESAOTE™ Low Field MRI for Diagnosis of Scaphoid Fractures.||Centre Hospitalier Universitaire de Nice|No|Completed|March 2009|March 2012|Actual|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|36|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01235806||113661|
NCT01236079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL105231-01|Cessation Service Use and Effectiveness for Hospitalized Smokers|Inpatient Technology-Supported Assisted Referral|I-TSAR|Kaiser Permanente|Yes|Active, not recruiting|December 2011|May 2016|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|900|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01236079||113640|
NCT01245127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52762|Ilaris (Canakinumab) in the Schnitzler Syndrome|Ilaris (Canakinumab) in the Schnitzler Syndrome. A Case Series.||Universitaire Ziekenhuizen Leuven|No|Completed|May 2011|May 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|85 Years|No|||November 2010|June 14, 2012|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245127||112951|
NCT01246973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 10054|Oral Curcumin for Radiation Dermatitis|Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients||University of Rochester|Yes|Completed|February 2011|January 2015|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|686|||Female|21 Years|120 Years|No|||February 2016|February 8, 2016|November 22, 2010|Yes|Yes||No|January 5, 2016|https://clinicaltrials.gov/show/NCT01246973||112811|
NCT01247233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTS02-SHARE|Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI)for Breast Cancer|Phase III Multicentric Trial Comparing Accelerated Partial Breast Irradiation (APBI) Versus Standard or Hypofractionated Whole Breast Irradiation in Low Risk of Local Recurrence of Breast Cancer|SHARE|UNICANCER|Yes|Active, not recruiting|December 2010|October 2025|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1006|||Female|50 Years|N/A|No|||August 2015|August 4, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01247233||112791|
NCT01243723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021919-17|Study Assessing the Efficacy of Eductyl® for the Treatment of Patients With Dyschesia|Étude Comparative, randomisée, Double-insu, en Groupes parallèles évaluant l'efficacité d'Eductyl® Versus Placebo Chez Des Patients Souffrant d'Une dyschésie|EDUCDYS|Laboratoires Techni Pharma|Yes|Completed|November 2010|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|75 Years|No|||March 2014|March 18, 2014|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243723||113058|
NCT01244022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-P03112010|Cytokine Changes After Colorectal Cancer Resection|Postoperative Serum Cytokine Changes After Radical Resection of Colorectal Cancer||University Hospital Dubrava|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|Samples Without DNA|For each patient, serum samples will be stored at -80°C for later determining of serum      cytokine levels|Both|20 Years|90 Years|No|Non-Probability Sample|Patients with colorectal cancer treated in the University Hospital Dubrava|July 2013|July 15, 2013|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01244022||113035|
NCT01244035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8266-008|A Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008 AM1)(COMPLETED)|Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Different Dosing Regimens of MK-8266 or Placebo in Subjects With Hypertension||Merck Sharp & Dohme Corp.|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|12||Actual|31|||Male|21 Years|60 Years|No|||October 2015|October 30, 2015|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01244035||113034|
NCT01276015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1780|Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy|SPREAD AND EFFECTIVENESS OF BOTULINUM NEUROTOXIN A IN SPASTIC EQUINUS IN CEREBRAL PALSY:SHORT-TERM STUDY||Universita di Verona|Yes|Completed|December 2009|May 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|25 Months|9 Years|No|||November 2009|January 18, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01276015||110582|
NCT01276327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1264.14|Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin 5 mg / Pioglitazone 30 mg Compared With Its Mono-components in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Replicate Design Study With Two Treatments in Four Crossover Periods)||Boehringer Ingelheim||Completed|January 2011|||May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|June 3, 2014|January 12, 2011||||No|March 12, 2014|https://clinicaltrials.gov/show/NCT01276327||110558|
NCT01245296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATIBAR08|Early Versus Delayed Cord Clamping at Term: Outcomes in Swedish Infants|Early Versus Delayed Cord Clamping at Term: Outcomes in Swedish Infants||Uppsala University|No|Completed|April 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|392|||Both|37 Weeks|42 Weeks|Accepts Healthy Volunteers|||August 2014|August 19, 2014|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01245296||112940|
NCT01278238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-013025-42|Optimization of Hemodynamic Conditions During Caesarean Section Under Spinal Anaesthesia|Hemodynamic Effect of Prophylactic Phenylephrine Versus Lower Limb Compression in Women During Caesarean Section Under Spinal Anaesthesia||Anestesiavdelingen Baerum Sykehus|No|Completed|January 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 9, 2013|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278238||110411|
NCT01278251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-4556|Functional Review of Distal Biceps Re-Insertion|||West Penn Allegheny Health System||Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|||||Both|20 Years|80 Years||Non-Probability Sample|Patients who have received primary distal biceps repair by Dr. Schmidt.|January 2011|January 14, 2011|January 14, 2011||||No||https://clinicaltrials.gov/show/NCT01278251||110410|
NCT01274715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA ID 10G09.H|HOPE Pilot for Veterans With Complex Diabetes|Behavioral Health Coaching for Rural Veterans With Diabetes and Depression|HOPE|Michael Debakey Veterans Affairs Medical Center|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|January 10, 2011||No||No|October 25, 2012|https://clinicaltrials.gov/show/NCT01274715||110682|A very small sample was collected, and there was not a control group to compare to our intervention group.
NCT01276028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014892|Acupuncture in Menopause|Acupuncture for Vasomotor Symptoms|AIM|Wake Forest Baptist Health|Yes|Completed|April 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|45 Years|60 Years|No|||July 2014|July 29, 2014|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276028||110581|
NCT01276366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL30111.101.09|Amphia Premature Infant Pain Study|Amphia Premature Infant Pain Study; Breast Milk vs Sucrose|APIP|Amphia Hospital|No|Active, not recruiting|January 2010|||September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|N/A|2 Months|Accepts Healthy Volunteers|||December 2009|June 21, 2011|April 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01276366||110555|
NCT01276639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921078|A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis|Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|Yes|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|901|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|January 12, 2011|Yes|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01276639||110534|
NCT01235156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG0823SUL|Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions|A Single-dose, Open Labeled, Multicenter Phase IIa Clinical Study on the Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions||Jiangsu Furui Pharmaceuticals Co., Ltd|Yes|Recruiting|November 2010|||||Phase 2|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|36|||Both|18 Years|70 Years|No|Probability Sample|18-70 year-old patients with premature ventricular contractions or non-sustained        ventricular tachycardia (VT)|November 2010|November 4, 2010|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01235156||113710|
NCT01235130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT88068|Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation|Phase 3 A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Long-chain N-3 Polyunsaturated Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation|AFFORD|Montreal Heart Institute|Yes|Completed|March 2009|May 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|337|||Both|18 Years|N/A|No|||May 2013|May 21, 2013|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01235130||113712|
NCT01235143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSU 136|Emergence Agitation Between Sevoflurane and Desflurane in Pediatric|Comparison the Incidence of Emergence Agitation Between Sevoflurane and Desflurane After Pediatric Urologic Surgery||Prince of Songkla University|Yes|Completed|May 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|136|||Both|1 Year|9 Years|No|||October 2013|October 8, 2013|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235143||113711|
NCT01236651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dr hegab protocol|Meperidine Versus Drotaverine Regarding the Effect on the Duration of the First Stage of Labor in Full Term Primigravidae|Comparison Between Meperidine and Drotaverine Regarding the Effect on the Duration of the First Stage of Labor in Full Term Primigravidae||Ain Shams University|Yes|Not yet recruiting|November 2010|September 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|200|||Male|N/A|N/A|Accepts Healthy Volunteers|||November 2010|November 8, 2010|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01236651||113596|
NCT01236092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mwilson consulting, llc|Low Back Study to Compare Traditional Physical Therapy With Combined Therapy Protocol|Clinical Study Comparing Traditional Physical Therapy and Alternate Therapy in Patients With Lumbar Radiculitis and Radiculopathy Secondary to Neural Compression.||Michael Wilson & Associates Health Care Consulting, LLC|Yes|Terminated|April 2011|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|36|||Both|25 Years|65 Years|No|||July 2012|April 7, 2015|November 4, 2010||No|Inadequate patient enrollment|No||https://clinicaltrials.gov/show/NCT01236092||113639|
NCT01245790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00009|A Study of Fostamatinib in Subjects With Impaired Kidney Function|An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg||AstraZeneca|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 15, 2011|November 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01245790||112902|
NCT01246947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044723|Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation|A Prospective Randomized Trial of Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Mitral Operation||University of Maryland|Yes|Recruiting|November 2010|November 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2010|November 29, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246947||112813|
NCT01246960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14057|A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer|Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach||Eli Lilly and Company|No|Completed|April 2011|May 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|November 8, 2010|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01246960||112812|
NCT01247779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROBOGYN - 1004|Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy|Assessment of Perioperative Morbidity in Gyneco-oncology According to the Surgical Approach : Coelioscopy Versus Robot-assisted Coelioscopy|ROBO-GYN|Centre Oscar Lambret|Yes|Active, not recruiting|December 2010|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|386|||Female|18 Years|N/A|No|||February 2016|February 15, 2016|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01247779||112749|
NCT01243463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP09125|Bariatric Surgery and Obstructive Sleep Apnea|Effects of Bariatric Surgery on Obstructive Sleep Apnea|BAROSA|Summa Health System|No|Completed|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|20 Years|85 Years|No|Non-Probability Sample|Obese women, 20 - 85 years of age|July 2011|July 20, 2011|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01243463||113078|
NCT01243476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINTRA-REV|Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome|Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.|SINTRA-REV|Fundación General de la Universidad de Salamanca|No|Recruiting|January 2010|January 2020|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243476||113077|
NCT01243489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571ADE75T|Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation|CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy|Crescendo|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|No|Active, not recruiting|October 2010|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243489||113076|
NCT01244009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-4827-002|A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)|A Phase II Efficacy Study of MK-4827 in Patients With Mantle Cell Lymphoma||Merck Sharp & Dohme Corp.|No|Withdrawn|December 2010|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244009||113036|
NCT01275742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P20NR010679-04|Helping Others Toward Positive Emotions in People With Heart Failure|Testing a Brief Cognitive Therapy Intervention for Depressive Symptoms in Patients With Heart Failure|HOPE-HF|University of Kentucky|No|Active, not recruiting|January 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|21 Years|N/A|No|||June 2013|June 18, 2013|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275742||110603|
NCT01276626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nestle 09.25.NRC|Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome|Pilot Study of Probiotic Bifidobacterium Longum (B. Longum) on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome (IBS).||Nestlé|No|Completed|January 2011|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|65 Years|No|||August 2014|August 4, 2014|December 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01276626||110535|
NCT01276886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISDIC-1|Italian Study Group on Complicated Diverticulosis|Italian Study Group on Complicated Diverticulosis: The Natural History of Left-sided Acute Diverticulitis|GISDIC|Gruppo Italiano per lo Studio della Diverticolite Complicata|Yes|Completed|January 1996|December 1999|Actual|December 1999|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|All consecutive patients with left sided acute diverticulitis diagnosed clinically by the        presence of abdominal pain, associated with leukocytosis (>11x109) and/or fever >38°C,        confirmed by imaging (CT scan, ultrasonography, water soluble contrast enema) either alone        or in combination and/or by operative findings|December 2010|January 21, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276886||110515|
NCT01278784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-141010|Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers|Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers||Medical University of Vienna|Yes|Completed|March 2011|September 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 7, 2012|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01278784||110369|
NCT01276899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-CROC-03|Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients|Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients||Jewish General Hospital|No|Recruiting|September 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|Tumor samples from the primary breast tumor or metastatic lesions will be obtained by needle      core biopsy. In the neoadjuvant setting, samples will be also collected at the time of      surgery. To obtain sufficient material for tissue banking, four needle core biopsies will be      removed from the same neoplastic lesion. Two of the biospecimens will be snap frozen for      phosphoprotein preservation, one will be placed in RNAlater for nucleic acid preservation      and the other one will be placed in formalin for FFPE. Additionally, blood samples will be      collected at different time points during treatment.|Female|18 Years|N/A|No|Probability Sample|This study will be conducted in patients with a diagnosis of breast cancer and        pathologically identified as triple negative (not expressing estrogen receptor (ER),        progesterone receptor (PR) and HER2 protein, and not showing ERBB2 gene amplification) who        will be undergoing neoadjuvant treatment or chemotherapy for metastatic disease.|November 2012|November 28, 2012|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276899||110514|
NCT01276912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOP-GO-2010|Study TO Prevent Diabetes With Short-term Insulin Glargine Only|A Multicenter, Randomized, Controlled Trial to Prevent Diabetes With Short-term Insulin Glargine Treatment or Lifestyle Intervention|STOP-GO|Beijing Tongren Hospital|Yes|Recruiting|January 2011|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|2420|||Both|25 Years|65 Years|No|||January 2011|January 13, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01276912||110513|
NCT01236131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10080491|The Role of Novel Organisms in Acute Endometritis|Characterization of Novel Organisms in the Genital Tract of Women With PID and Determination of Their Association With Endometritis.||University of Pittsburgh|No|Enrolling by invitation|November 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|450|Samples With DNA|Endometrial biopsy specimens and isolates may be retained and stored in various registries      such as:        1. Human Microbiome Project        2. J Craig Venture Institute        3. PathoGene        4. American Type Culture Collection        5. CGS MindTouch Wiki hosted on Amazon's Elastic Compute Cloud           (http://www.amazon.com/gp/browse.html?node-3435361)52 and will utilize MindTouch's           Amazon Machine Image of their Wiki platform for rapid deployment|Female|15 Years|40 Years|No|Non-Probability Sample|Endometrial biopsy samples from women participating in University of Pittsburgh IRB        PRO10010112 and PRO10010159|March 2014|March 12, 2014|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01236131||113636|
NCT01235468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7959-AN-CTIL|Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)|Allogenic Transplantation of Ex-vivo Expanded CB Progenitors for Haematological Disorders||Sheba Medical Center|No|Withdrawn|June 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||December 2015|December 1, 2015|November 2, 2010||No|loss of support|No||https://clinicaltrials.gov/show/NCT01235468||113686|
NCT01235481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-159|Validation of an Exercise DVD for Maintenance After Pulmonary Rehabilitation.|Validation of an Exercise DVD for Maintenance After 12-week Outpatient Pulmonary Rehabilitation Program: a Randomized Clinical Trial.||Nova Scotia Health Authority|No|Completed|December 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01235481||113685|
NCT01236885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2425.00|Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant|Use of a Computer-Guided Glucose Management System for Patients Undergoing Blood and Marrow Transplants (BMT)||Fred Hutchinson Cancer Research Center||Completed|December 2012|||February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|19|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|November 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01236885||113578|
NCT01237457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|78,256|177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms|177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms||Excel Diagnostics and Nuclear Oncology Center|Yes|Active, not recruiting|October 2010|October 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01237457||113534|
NCT01246375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-SY-454-CTIL|Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids|Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|60 Years|90 Years|No|||November 2010|November 24, 2010|November 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01246375||112857|
NCT01246388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-TI-01|Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy|Evaluation of Fibrosis and Steatosis in Patients With Chronic Hepatopathy: Non-invasive Imaging and Serum Markers vs. Liver Biopsy||Tischendorf, Jens, M.D.|No|Active, not recruiting|May 2010|December 2014|Anticipated|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood Serum|Both|18 Years|N/A|No|Probability Sample|in- and outclinic patients of the RTWH University Hospital (Department of Medicine III)        with chronic hepatopathy and the necessity of undergoing liver biopsy for diagnostic work        up|March 2012|October 19, 2014|October 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01246388||112856|
NCT01246713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000135|Effect on Acetaminophen Metabolism by Liquid Formulations|Effect on Acetaminophen Metabolism by Liquid Formulations: Do Excipients in Liquid Formulation Prevent Production of Toxic Metabolites?||Beth Israel Deaconess Medical Center|No|Completed|December 2010|July 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 26, 2013|November 22, 2010||No||No|February 18, 2013|https://clinicaltrials.gov/show/NCT01246713||112831|
NCT01247558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-006|Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy|Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy||Pamlab, Inc.|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|500|||Both|25 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Diabetes and Peripheral Neuropathy or Peripheral Circulatory Disorder with        Lower Limb Ulceration Who Have Been Treated with Metanx® or Not Treated with Metanx®.        Patients selected for the study will be identified from a review of available medical and        pharmacy data during the period from 01/01/2003 to 06/30/2006. The date of the first        pharmacy claim of interest within the intake period will be defined as the index date.|July 2012|July 23, 2012|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247558||112766|
NCT01247792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIDECS|End-of-life Decision-making in Patients With Sepsis-related Organ Failure|A Time-series Intervention Analysis of End-of-life Decision-making in Patients With Sepsis-related Organ Failure|EIDECS|Center for Sepsis Control and Care, Germany|No|Active, not recruiting|August 2010|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|180|||Both|N/A|N/A|No|||January 2016|January 27, 2016|November 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01247792||112748|
NCT01243502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2114/06-CT327|A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers|A Multiple Dose, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Topically Administered CT327 in Healthy Male Volunteers||Creabilis SA|No|Completed|September 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||November 2010|November 17, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243502||113075|
NCT01250340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes and Oxidative Stress|Type 2 Diabetes Mellitus and Atherosclerosis|Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis||University of Roma La Sapienza|Yes|Recruiting|August 2010|December 2012|Anticipated|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||November 2012|November 27, 2012|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01250340||112554|
NCT01250353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12416/05|The Use of Natural Latex Biomembrane in Ocular Surface Reconstruction|The Use of Natural Latex Biomembrane in Ocular Surface Reconstruction and Pterygium||University of Sao Paulo|No|Completed|June 2006|July 2009|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|90 Years|No|||December 2009|November 29, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01250353||112553|
NCT01259505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBCCTA-001-STT|Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer|Phase I Study of Multiple-Vaccine Therapy Using Epitope Peptides Restricted to HLA-A*2402 in Treating Patients With Refractory Breast Cancer||Tokyo Medical University|Yes|Completed|December 2009|November 2014|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|85 Years|No|||November 2014|November 13, 2014|December 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01259505||111851|
NCT01260324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481282|Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|The Detection and Epidemiology of NAION in a Commercially Insured Population in the United States.||Pfizer|No|Completed|August 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|21283|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consisted of members of the Ingenix Normative Health Informatics        (NHI) Database during 01/01/2003 through 12/31/2007, who were 18 years of age or older        with at least 183 days of continuous enrollment in the database and without any doctor        visits associated with a diagnosis of ischemic optic neuropathy during the 183 days prior        to cohort entry.|August 2011|August 17, 2011|November 5, 2010|No|Yes||No|March 16, 2011|https://clinicaltrials.gov/show/NCT01260324||111788|
NCT01259492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124D2302|Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)|A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD||Novartis||Completed|November 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|725|||Both|18 Years|60 Years|No|||September 2014|September 29, 2014|December 11, 2010|Yes|Yes||No|August 6, 2013|https://clinicaltrials.gov/show/NCT01259492||111852|
NCT01259778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-522|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|ECOS KOR|Merck KGaA||Active, not recruiting|February 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|200|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259778||111830|
NCT01260038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOGA 1001|Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.|Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.|HERMES|University Hospital, Antwerp|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|107|None Retained|At diagnosis a tumor sample is collected for histological evaluation, this sample will be      used for the biomarker analysis.|Both|18 Years|N/A|No|Probability Sample|newly diagnosed patients with Non Small Cell Lung Cancer|January 2012|January 17, 2012|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260038||111810|
NCT01260051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uhcmc|Intrapartum Epidural Fentanyl/Bupivacaine Analgesia, Infant Feeding Behavior, & Breast-Feeding Outcomes|Intrapartum Epidural Fentanyl/Bupivacaine Analgesia, Infant Feeding Behavior, & Breast-Feeding Outcomes||University Hospital Case Medical Center|No|Completed|March 2010|November 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|310|||Female|18 Years|N/A||Non-Probability Sample|Parturients who delivered at UHCMC between August 2009 and January 2010|February 2010|December 16, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260051||111809|
NCT01260285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01703|The Safety of Vardenafil in Patients Undergoing Cardiac Surgery|The Safety of Vardenafil in Patients Undergoing Cardiac Surgery||McGuire Research Institute|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|90 Years|No|||November 2011|November 2, 2011|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01260285||111791|
NCT01260298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST2010-2|Protocol To Evaluate Patient Measurements After Ultrasonic Treatment|Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.||Sound Surgical Technologies, LLC.|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female between the ages of 20 and 50 years with BMI between 20 and 30 who are scheduled to        be treated using the MC1 device.|March 2011|March 9, 2011|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260298||111790|
NCT01261156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5555-A001-022|A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects|An Open-label, Single-Sequence Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects||Eisai Inc.|No|Completed|October 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|November 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01261156||111724|
NCT01260558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. S03310|Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography|Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term|PPS/PFS-OCT|Deutsches Herzzentrum Muenchen|No|Recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2012|May 7, 2012|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260558||111770|
NCT01257282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-07-001|Prevalence and Prognostic Value of Unrecognized Myocardial Injury in Stable Coronary Artery Disease (PUMI)|Prevalence and Prognostic Value of Unrecognised Myocardial Injury in Stable Coronary Artery Disease (PUMI)- a Multicenter, Observational Cohort Study.|PUMI|Uppsala University|No|Recruiting|September 2007|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|275|Samples With DNA|Plasma samples for biochemical markers. Whole blood samples for extraction of DNA for      genetic analysis.|Both|N/A|N/A|No|Non-Probability Sample|Patients with stable coronary artery disease without previously known myocardial        infarction or coronary intervention|December 2010|December 8, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01257282||112022|
NCT01227915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TODUNI0610|Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis|RANDOMIZED CLINICAL EVALUATION OF EFFECTIVENESS COMPARISON BETWEEN DRUGS OPHTHALMOLOGICAL TOBRACORT® (TOBRAMYCIN + DEXAMETHASONE - LAB. UNIÃO QUÍMICA)AND TOBRADEX® (TOBRAMYCIN + DEXAMETHASONE - LAB. ALCON) IN REDUCING THE SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|February 2011|||February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2010|October 22, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01227915||114263|
NCT01228721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNFL-Eyetracker-Foll|Reproducibility of Retinal Nerve Fiber Layer Thickness Measurements Using the Eye Tracker and Retest Function of Spectralis® SD-OCT in Glaucomatous Eyes and Healthy Controls|||University of Zurich||Terminated|January 2009|December 2010||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||||||Both|18 Years|N/A|No|||October 2010|October 25, 2010|October 25, 2010||||No||https://clinicaltrials.gov/show/NCT01228721||114201|
NCT01228734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR62202-057|A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients|An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status|TAILOR|Merck KGaA|Yes|Active, not recruiting|August 2010|January 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|503|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01228734||114200|
NCT01229007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-BIO-08-53|Study of Biostate® in Children With Hemophilia A|A Phase III, Open-Label, Multicentre Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Biostate® in Paediatric Subjects With Haemophilia A||CSL Behring|Yes|Completed|August 2010|July 2014|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|N/A|12 Years|No|||July 2014|July 8, 2014|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01229007||114179|
NCT01228773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-YoungHo|The Efficacy of Health Navigation® for Cancer-Related Fatigue in Cancer Survivors|The Efficacy of Web-based, Tailored Program(Health Navigation®) for the Management of Cancer-Related Fatigue in Cancer Survivors||National Cancer Center, Korea|Yes|Enrolling by invitation|July 2009|July 2010|Anticipated|July 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|266|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2009|October 26, 2010|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01228773||114197|
NCT01225094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16593|Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair|Curcumin to Prevent Perioperative Complications After Elective Abdominal Aortic Aneurysm Repair: a Randomized Controlled Trial||Lawson Health Research Institute|Yes|Active, not recruiting|November 2011|July 2015|Anticipated|March 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3500|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01225094||114477|
NCT01225445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE 498/6015|Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial|Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial||Chinese University of Hong Kong|No|Completed|April 2002|October 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|25 Years|No|||April 2002|October 20, 2010|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225445||114450|
NCT01250080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB709/06|Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.|||Hospital Universitari Son Dureta||Completed|January 2007|September 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Single Blind (Outcomes Assessor)|2||Actual|43|||Both|18 Years|75 Years|No|||September 2008|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250080||112574|
NCT01258257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARLYDRAIN|EARLYdrain - Outcome After Early Lumbar CSF-drainage in Aneurysmal SAH|EARLYdrain - Prospective Outcome Study of Early Lumbar Drainage in Aneurysmal Subarachnoid Hemorrhage|EARLYDRAIN|Charite University, Berlin, Germany|Yes|Active, not recruiting|January 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258257||111947|
NCT01258049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART004|Superiority of ArTiMist Versus Quinine in Children With Severe Malaria|A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.||Proto Pharma Ltd|Yes|Completed|December 2010|September 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|N/A|N/A|No|||January 2014|January 27, 2014|December 9, 2010||No||No|September 13, 2013|https://clinicaltrials.gov/show/NCT01258049||111963|
NCT01260077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP_UNCISAL_1010/2009|Steady State Vestibular Evoked Myogenic Potentials|Steady State Vestibular Evoked Myogenic Potentials||Universidade Estadual de Ciências da Saúde de Alagoas|Yes|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|||||Both|18 Years|35 Years||Probability Sample|Normal subjects.|February 2009|December 14, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260077||111807|
NCT01260337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12987|The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study|The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study||Temple University|No|Completed|March 2010|August 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|75 Years|No|||September 2010|June 28, 2013|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01260337||111787|
NCT01260064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Frumious|Open Appendectomy Versus Laparoscopic Appendectomy|The Outcomes of Various Appendectomy Techniques in a High-volume Center.||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|Yes|Completed|October 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|15 Years|N/A|No|||May 2011|May 25, 2011|December 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01260064||111808|
NCT01260311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221085|Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder|Post Marketing Surveillance To Assess The Safety And Efficacy Of Fesoterodine (Toviaz) On Filipino Patients Diagnosed With Over-Active Bladder||Pfizer|No|Completed|February 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|508|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with Over-active bladder|September 2014|September 4, 2014|November 22, 2010||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01260311||111789|The implementation of Protocol Amendment 1 led to removal of all primary efficacy outcome measures, therefore the efficacy outcome measures were not investigated or reported.
NCT01260571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAA 554-10/v6|Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)|Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)||Zurita Laboratorio Farmaceutico Ltda.|No|Not yet recruiting|January 2011|March 2011|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|62|||Both|12 Years|35 Years|No|||September 2010|December 14, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260571||111769|
NCT01260857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6821003|Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension|An Open Label, Observational, Post Marketing Surveillance Study To Assess The Safety And Efficacy Of The Spironolactone Plus Hydroflumethiazide (Aldazide) In The Treatment Of Filipino Patients With Stage 1 To 2 Hypertension||Pfizer|No|Withdrawn|March 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|65 Years|No|Non-Probability Sample|patients ages >/= 18 years old with Stage 1 or 2 hypertension|May 2013|May 13, 2013|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260857||111747|
NCT01260870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EURO CANAL|European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)|European Study of POBA Versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia||Bayer|Yes|Terminated|August 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|December 13, 2010|Yes|Yes|Bayer terminated the program and sold the IP to Medronic|No||https://clinicaltrials.gov/show/NCT01260870||111746|
NCT01261143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK-C-0701-301|Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy|Phase III Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy||Bukwang Pharmaceutical||Completed|August 2010|||April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|164|||Both|19 Years|N/A|No|||October 2011|April 24, 2012|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01261143||111725|
NCT01261169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ATW06T|Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study|Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study||Genovate Biotechnology Co., Ltd.,|No|Recruiting|January 2009|December 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|About 40 patients with uveitis|December 2010|December 14, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261169||111723|
NCT01257035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20100054|Predictive Value of 18F-FAZA in Rectum Cancer|The Predictive Value of 18F-FAZA-PET/CT in Neoadjuvant Radiation for Patients With Locally Advanced Rectum Cancer|FAZA|Vejle Hospital|No|Terminated|November 2010|August 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Probability Sample|Patients with locally advanced rectum cancer receiving preoperative radiation treatment        and concomitant chemotherapy at the Dept. of Oncology, Vejle Hospital.|June 2013|June 14, 2013|December 8, 2010||No|The logistics of this trial (incl. supply of tracer) in connection with the patients'    treatment course caused the inclusion rate to be very slow.|No||https://clinicaltrials.gov/show/NCT01257035||112041|
NCT01257568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68|Rejuvenate Modular Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Rejuvenate® Modular Hip System||Stryker Orthopaedics|No|Active, not recruiting|November 2010|May 2022|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257568||112000|
NCT01228786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHADADA-PGI|Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism|Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|October 2007|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|Parathyroid Adenoma and normal parathyroid gland|Both|N/A|N/A|No|Non-Probability Sample|Patients with Primery Hyperparathyroidism (PHPT)|July 2012|July 19, 2012|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01228786||114196|
NCT01228799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVC-1|Trabeculectomy Versus Canaloplasty|Longterm Comparison Between Trabeculectomy and Canaloplasty in Open-angle Glaucoma|TVC|University Eye Hospital, Würzburg|No|Completed|June 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||October 2010|August 16, 2013|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01228799||114195|
NCT01228214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-3 2007|Novel Treatment for Coronary Artery Disease|Randomized Double-Blind Placebo-Controlled Study of Pyrazinoylguanidine Hydrochloride (Amiloride) in Subjects With Coronary Artery Disease||University of Carabobo|No|Active, not recruiting|March 2011|September 2013|Anticipated|April 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|35 Years|75 Years|No|||March 2013|March 18, 2013|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228214||114240|
NCT01229371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADD-V-A001|Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers|Randomized, Parallel-group, Double-blind Multi-center Phase III Study to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers, in Elderly and Young Adults||Crucell Holland BV|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|440|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|October 22, 2010||No||No|October 23, 2012|https://clinicaltrials.gov/show/NCT01229371||114151|
NCT01225757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168-10-FB|Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC|Comparison of Traditional (Central Venous Pressure (CVP) and Urine Output Guided) Versus Echocardiography Guided Fluid Management in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC)||University of Nebraska|Yes|Withdrawn|November 2010|November 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 21, 2014|July 14, 2010||No|Logistical problems prior to the recruitment phase.|No||https://clinicaltrials.gov/show/NCT01225757||114427|
NCT01226628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017548|A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration|Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled, Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age-related Macular Degeneration||Janssen Research & Development, LLC|Yes|Active, not recruiting|September 2010|November 2019|Anticipated|March 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|24|||Both|50 Years|N/A|No|||January 2016|January 18, 2016|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226628||114361|
NCT01226082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-SB-411-CTIL|The Effect of Transcranial Direct Current Stimulation for Chronic Pain on Ophthalmologic Parameters|The Effect of Transcranial Direct Current Stimulation for Chronic Pain on Ophthalmologic Parameters|tDCS|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|90 Years|No|||October 2010|October 20, 2010|October 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01226082||114403|
NCT01226329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-IRB00329/07/08|The Right Question Project-Mental Health: An Intervention to Increase Engagement and Retention in Mental Health Care|The Right Question Project-Mental Health: An Intervention to Increase Engagement and Retention in Mental Health Care|RQP-MH|Cambridge Health Alliance|No|Completed|July 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|724|||Both|18 Years|70 Years|No|||June 2013|June 11, 2013|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01226329||114384|
NCT01226342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Golnik-COPD-TENS-1|Transcutaneous Electrical Muscle Stimulation In Chronic Obstructive Pulmonary Disease (COPD)|Transcutaneous Electrical Muscle Stimulation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)||The University Clinic of Pulmonary and Allergic Diseases Golnik|No|Completed|January 2009|October 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|35 Years|85 Years|No|||April 2013|April 10, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01226342||114383|
NCT01259206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.10.2008/127|Plantar Faciitis and Diabetes Mellitus|Increased Calcaneal Spur Incidence in Patients With Obesity and Type 2 Diabetes Mellitus|No acronym|Gulhane School of Medicine|Yes|Completed|February 2009|March 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|93|||Both|49 Years|69 Years|Accepts Healthy Volunteers|Probability Sample|93 paitents and 42 control group|October 2008|June 17, 2011|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259206||111874|
NCT01260090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7301P|Vagus Nerve Stimulation to Augment Recovery From Minimally Conscious or Persistently Vegetative States After Traumatic Brain Injury|Vagus Nerve Stimulation to Augment Recovery From Minimally Conscious or Persistently Vegetative States After Traumatic Brain Injury||VA New York Harbor Healthcare System||Recruiting|January 2011|October 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|60 Years|No|||January 2011|August 9, 2011|December 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01260090||111806|
NCT01256801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMPE|Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion|Gene Expression Profiling of Breast Cancer Cells in Pleural Effusion Prodict the Response of Malignant Pleural Effusion to Immunotherapy|GMPE|Beijing Cancer Hospital|Yes|Completed|November 2010|December 2013|Actual|January 2013|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|Samples Without DNA|The cancer cells are taken from the malignant pleural effusion of breast cancer patiets.|Female|18 Years|75 Years|No|Probability Sample|The breast cancer patiets present with pleural effusion and can receive chemotherapy.|July 2015|July 27, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01256801||112059|
NCT01256814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SystemCHANGE-HIV|Study of SystemCHANGE-HIV|SystemCHANGE-HIV: A Pilot Study Exploring the Effect of a Systems-based Intervention to Increase Physical Activity, Sleep Behavior, and Mental Wellness||Case Western Reserve University|No|Completed|January 2011|June 2011|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|43|||Both|21 Years|N/A|No|||August 2011|August 29, 2011|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01256814||112058|
NCT01260584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS747S-B-U4002|The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease|The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease||Daiichi Sankyo Inc.|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|74 Years|No|||November 2012|November 12, 2012|December 13, 2010|Yes|Yes||No|September 19, 2012|https://clinicaltrials.gov/show/NCT01260584||111768|
NCT01260883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 59883|Ketorolac in Postoperative Infants: Pharmacokinetics and Safety|Ketorolac in Postoperative Infants: Pharmacokinetics and Safety||Seattle Children's Hospital|Yes|Completed|May 2000|December 2010|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|77|||Both|2 Months|18 Months|No|||June 2013|June 4, 2013|December 9, 2010|Yes|Yes||No|July 20, 2011|https://clinicaltrials.gov/show/NCT01260883||111745|
NCT01260896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02204|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsule in Healthy Subjects Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|September 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 24, 2011|December 14, 2010|No|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01260896||111744|
NCT01256775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCX4016-X-208|Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)|A Multicenter, Double-blind, Randomized, Parallel Group Study to Assess the Effect of NCX4016 vs Placebo on Walking Distance in Patients With Peripheral Arterial Occlusive Disease at Leriche-Fontaine Stage II||NicOx Research Institute S.r.l.|Yes|Completed|September 2003|April 2005|Actual|April 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|442|||Both|40 Years|80 Years|No|||January 2011|January 18, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01256775||112061|
NCT01257048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6256M00046|Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler|An Open, Randomised, Parallel Group Multi-centre, Methodology Study, Evaluating the Sensitivity of Oxygen-Enhanced Magnetic Resonance Imaging (OE-MRI) in Detecting and Comparing Response to 8 Weeks Treatment With Budesonide/Formoterol Turbuhaler® (320/9 µg Bid) and Formoterol Turbuhaler® (9 µg Bid) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca||Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Both|40 Years|N/A|No|||August 2012|August 31, 2012|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01257048||112040|
NCT01257295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC-10/22|Properties of Dietary Fibre and Energy Intake|Properties of Dietary Fibre and Energy Intake: an Intervention to Study the Effect of Physicochemical Properties of Dietary Fibre on Energy Intake and Underlying Mechanisms|ProVe|Wageningen University|No|Completed|December 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|29|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2011|December 23, 2011|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257295||112021|
NCT01257581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDALS-001|Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)|SDALS-001|Massachusetts General Hospital|Yes|Completed|March 2011|February 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|December 8, 2010|Yes|Yes||No|March 10, 2014|https://clinicaltrials.gov/show/NCT01257581||111999|
NCT01227473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0563|We Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans|A Mindfulness-based Intervention to Reduce Diabetes Risk in Pre-diabetic African Americans||University of North Carolina, Chapel Hill|Yes|Completed|February 2010|May 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|74|||Both|25 Years|65 Years|No|||June 2012|June 13, 2012|April 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01227473||114297|
NCT01228227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMA II|ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading|High Loading ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis : Comparison With Atorvastatin High Dose Reloading.|ROMAIIReload|University of Roma La Sapienza|Yes|Completed|October 2010|August 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01228227||114239|
NCT01228474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX003|Single Embryo Transfer vs. Double Embryo Transfer in an Oocyte Donation Programme|A Prospective, Randomized, Controlled Trial Comparing SET vs DET in an Oocyte Donation Programme||Institut Universitari Dexeus||Terminated|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Female|18 Years|50 Years|No|||June 2015|June 30, 2015|October 25, 2010||No|Due to the high number of multiples pregnancies in the double embryo transfer group, we have    decided to stop the enrollment of patients at 07/31/2012|No||https://clinicaltrials.gov/show/NCT01228474||114220|
NCT01229397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A005|Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V|A Phase III Open, Randomized, Parallel, Multi-center Study in Children Aged 6 - 35 Months to Compare the Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V Administered According to a 0/4 Week Schedule||Crucell Holland BV|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|205|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||August 2013|January 7, 2014|October 22, 2010||No||No|October 23, 2012|https://clinicaltrials.gov/show/NCT01229397||114149|
NCT01226303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICC APL STUDY 01|Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia|Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia||Associazione Italiana Ematologia Oncologia Pediatrica|Yes|Recruiting|January 2009|January 2018|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|21 Years|No|||August 2015|September 14, 2015|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226303||114386|
NCT01258283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2008/VB-03|PET / CT With 18F-FDG: Does it Optimize the I 123-MIBG Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator?|PET / CT With 18F-FDG (18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography): Does it Optimize the I 123-MIBG (Iodine 123 Metaiodobenzylguanidine) Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator for Primary Prevention in Patients With Heart Failure of Ischemic Origin?||Centre Hospitalier Universitaire de Nīmes|No|Terminated|June 2011|April 2016|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Coronary patients that should benefit from ICD (Implanted Cardiac Defibrillator)        implantation for primary prevention according to current recommendations, that is to say        with LVEF (left ventricular ejection fraction) <30% in NYHA (New York Heart Association)        stage II or III and within one month of an myocardial infarction or within 3 months of a        complete revascularization.|October 2015|November 4, 2015|December 9, 2010||No|Inclusion rate too slow / infeasible.|No||https://clinicaltrials.gov/show/NCT01258283||111945|
NCT01258569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JOHN002914HE|Entereg Laparoscopic Colon Resection Study|Entereg Laparoscopic Colon Resection Study||Hartford Hospital|No|Completed|November 2010|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|85 Years|No|||August 2015|August 24, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258569||111923|
NCT01258894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010019R|Investigation of Human Alpha-fetoprotein Genes|Investigation of Human Alpha-fetoprotein Genes||National Taiwan University Hospital|No|Recruiting|December 2010|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples With DNA|10c.c Whole Blood|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The patients and their family with elevated AFP (>20 ng/mL) and normal AFP patients being        control groups.|December 2010|December 21, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01258894||111898|
NCT01258907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDL4758g|A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)|A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER - Goal of Oxidized Ldl and Activated Macrophage Inhibition by Exposure to a Recombinant Antibody)||Genentech, Inc.||Completed|March 2010|||July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|147|||Both|35 Years|80 Years|No|||February 2016|February 1, 2016|December 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258907||111897|
NCT01258920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017077|A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia|A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia||Janssen Pharmaceutical K.K.|No|Completed|October 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Both|20 Years|N/A|No|||June 2014|June 23, 2014|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258920||111896|
NCT01259544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-EX-110|BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency|||Exalenz Bioscience LTD.|Yes|Completed|January 2009|March 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 15, 2012|December 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01259544||111848|
NCT01259817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1300 001|Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)|Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2011|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|December 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259817||111827|
NCT01260935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 3722|Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures|A Prospective Randomized Single-Blinded Multi-Institutional Study Comparing the Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures||Swedish Medical Center|No|Completed|November 2002|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|75 Years|No|||January 2012|January 16, 2012|November 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01260935||111741|
NCT01260948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-1255|10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|April 2006|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 24, 2011|December 14, 2010|No|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01260948||111740|
NCT01256827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-72116|Seven Year Update of Macular Degeneration Patients|Seven Year Observational Update of Macular Degeneration Patients Post-MARINA/ANCHOR and HORIZON Trials (SEVEN UP Study)|SEVEN UP|University of California, San Francisco|No|Completed|December 2010|April 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|65|Samples With DNA|blood samples will be drawn|Both|55 Years|N/A|No|Non-Probability Sample|Exudative AMD patients who were previously participants in ranibizumab treatment arms of        the ANCHOR or MARINA studies, and who subsequently enrolled in the HORIZON extension study|November 2013|November 12, 2013|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256827||112057|
NCT01260597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002|Tobacco Quit Line Re-enrollments for the Underserved|Re-engagement in Evidence-based Quit Line Treatment for Low Income Smokers||Alere Wellbeing|No|Completed|September 2010|July 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2985|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260597||111767|
NCT01260909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0038|Real-Time MV/kV Image Guided Radiation Therapy|Real-Time MV/kV Image Guided Radiation Therapy||Stanford University|Yes|Not yet recruiting|January 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|48|||Male|18 Years|N/A|No|Probability Sample|prostate cancer patients at Stanford University|December 2013|December 12, 2013|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260909||111743|
NCT01260922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R05-1254|10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.|A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.||Teva Pharmaceuticals USA|No|Completed|April 2006|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 24, 2011|December 14, 2010|No|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01260922||111742|
NCT01256788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007133|Post-op Treatment With Hyaluronic Acid Injections|Prospective Randomized Study Evaluating Clinical Effectiveness of Post-op Treatment With Hyaluronic Acid Injections in Degenerative Joint Disease & Meniscal Tears||The Hawkins Foundation|Yes|Terminated|September 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|33|||Both|40 Years|N/A|No|||July 2015|July 23, 2015|December 6, 2010|Yes|Yes|Insurance now covers post-op HA injections, drastically decreasing enrollment.|No||https://clinicaltrials.gov/show/NCT01256788||112060|
NCT01257061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECEMS1010|Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment|Unicentric Comparing Effectiveness Superiority of to Clemastine Fumarate 1, 0 mg/g + Dexamethasone 0, 5 mg/g to Dexchlorpheniramine Maleate 10 mg/g in Eczema Treatment.||EMS|Yes|Recruiting|September 2012|August 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|50 Years|No|||March 2013|March 1, 2013|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01257061||112039|
NCT01257308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99047|Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients|Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|August 2010|August 2013|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|N/A|No|Probability Sample|Lung Cancer Patients|December 2010|December 8, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257308||112020|
NCT01257321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA-HMO-CTIL|Risk Stratification of Post Tonsillectomy Respiratory Complications in the Pediatric Population|||Hadassah Medical Organization||Not yet recruiting||||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|14 Years||Probability Sample|children, suffering of obstructive sleep apnea, having their tonsills removed|December 2010|December 8, 2010|December 8, 2010||||No||https://clinicaltrials.gov/show/NCT01257321||112019|
NCT01227993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110012|Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|CSC-Ext|National Institutes of Health Clinical Center (CC)|No|Completed|October 2010|June 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|October 22, 2010|Yes|Yes||No|July 2, 2013|https://clinicaltrials.gov/show/NCT01227993||114257|
NCT01228006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATEMS0310|Study for Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals (Natugerin®) in Improvement of Stress and Fatigue|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Not yet recruiting|September 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2010|October 22, 2010|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01228006||114256|
NCT01229059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFAIR|Free Fatty Acid Induced Insulin Resistance|Assessment of the Time Course of Lipid Induced Insulin Resistance|FFAIR|German Diabetes Center|No|Recruiting|March 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|muscle biopsies|Both|20 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Healthy, lean non-diabetic humans|October 2010|October 26, 2010|March 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01229059||114175|
NCT01225471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMU-H21-40-PⅠ/Ⅱ|Novel Peptide Vaccination for Patients With Advanced Prostate Cancer|Phase1/2 Study of Vaccination With CDCA1 Derived Epitope Peptide for HLA-A24-positive Patients With Advanced Prostate Cancer||Iwate Medical University|Yes|Active, not recruiting|June 2009|May 2012|Anticipated|May 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|20 Years|85 Years|No|||June 2009|June 22, 2011|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01225471||114448|
NCT01227486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|disb-01-10|Verification of Endotracheal Tube Placement by Ultrasound in the Obese Patient|||Bispebjerg Hospital|No|Completed|October 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|N/A|No|Probability Sample|Obese patients admitted for planned bariatric surgery on Glostrup Hospital, Denmark|November 2010|November 23, 2010|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01227486||114296|
NCT01227772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA04/26/10|Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer|A Phase I/IIa Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer||National University Hospital, Singapore|No|Active, not recruiting|November 2010|June 2016|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|23|||Both|21 Years|N/A|No|||June 2015|June 17, 2015|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227772||114274|
NCT01258582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 MH073445 (Phase II)|Two Approaches to Routine HIV Testing in a Hospital Emergency Department|Optimizing Strategies for Universal HIV Testing (The USHER Trial): Phase II|USHER|Massachusetts General Hospital|Yes|Completed|May 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1651|||Both|18 Years|N/A|No|||May 2012|June 10, 2012|December 10, 2010||No||No|May 3, 2012|https://clinicaltrials.gov/show/NCT01258582||111922|
NCT01258595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM09|A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age|Safety and Immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age||Sanofi|No|Completed|November 2010|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|50 Years|64 Years|Accepts Healthy Volunteers|||September 2011|September 19, 2011|December 10, 2010|Yes|Yes||No|September 19, 2011|https://clinicaltrials.gov/show/NCT01258595||111921|
NCT01258933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0266|Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy|Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258933||111895|
NCT01259219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifabutin (RBT)|Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra|Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra|RBT|Harriet Shezi Children's Clinic|Yes|Recruiting|November 2010|June 2012|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||December 2010|December 13, 2010|December 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259219||111873|
NCT01259232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH001|The Imaging Genetic Study of Schizophrenia and Family|||Kunming Medical University|Yes|Recruiting|September 2011|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||3|Anticipated|100|||Both|15 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|schizophrenia patients and their relatives|March 2014|March 19, 2014|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01259232||111872|
NCT01259245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSRF08091291|Effectiveness of Incorporating Tai Chi in Pulmonary Rehabilitation Program for Chronic Obstructive Pulmonary Disease Patients in Primary Health Care|Effectiveness of Incorporating Tai Chi in Pulmonary Rehabilitation Program for COPD Patients in Primary Health Care|COPD|Kwong Wah Hospital|Yes|Completed|March 2011|May 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|21 Years|N/A|No|||March 2013|March 2, 2013|December 3, 2010||No||No|October 2, 2012|https://clinicaltrials.gov/show/NCT01259245||111871|There was high attrition rate of 28% which further contributed to our small sample size with wide 95% confidence interval of several outcome variables results.
NCT01259518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIN2755-I-01|Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas|A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens||Trin Therapeutics GmbH|Yes|Recruiting|November 2009|January 2012|Anticipated|September 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01259518||111850|
NCT01259531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-SDS-403|Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)|A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia|STRONG|JW Pharmaceutical|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Male|50 Years|N/A|No|||March 2012|March 28, 2012|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01259531||111849|
NCT01259830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etoricoxib-fast-track|Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery|A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery||Charite University, Berlin, Germany|No|Terminated|March 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259830||111826|
NCT01260961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220080189|Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial|Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial||Rutgers, The State University of New Jersey|Yes|Active, not recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|5 Years|17 Years|No|||September 2014|September 23, 2014|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01260961||111739|
NCT01258140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120/08|Detection of Pulmonary Embolism With Low-dose CT Pulmonary Angiography|Detection of Pulmonary Embolism With CT Pulmonary Angiography Using Reduced Contrast Medium and Radiation Dose: Comparison of 100 kVp and 80 kVp Protocols|REDOPED|University Hospital Inselspital, Berne|No|Completed|September 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|504|||Both|18 Years|N/A|No|||January 2013|January 21, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01258140||111956|
NCT01257074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PENEMS1010|Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis|A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis.||EMS|No|Completed|February 2012|October 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01257074||112038|
NCT01257334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99050|Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea||Taipei Medical University WanFang Hospital|Yes|Enrolling by invitation|September 2010|July 2012|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1390|||Both|18 Years|N/A|No|||December 2010|December 8, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257334||112018|
NCT01257347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1720|Measuring Adherence to Control Hypertension|Electronically Measuring Medication Adherence to Improve the Management of Uncontrolled Hypertension|MATCH|Columbia University|Yes|Completed|January 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|80 Years|No|||February 2015|February 4, 2015|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257347||112017|
NCT01257594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ7500|EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas|Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation||Columbia University|Yes|Active, not recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|December 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257594||111998|
NCT01257607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIM-724|Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye|A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model||Mimetogen Pharmaceuticals USA, Inc.|Yes|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257607||111997|
NCT01257841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002P-000518SA1|Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects|Effects of Four-day Fast on Gut-derived Hormones and Inflammatory Markers in Healthy, Normal-weight Women.||Massachusetts General Hospital|Yes|Completed|November 2002|December 2003|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2010|December 9, 2010|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257841||111979|
NCT01258699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK-C-0701-101|A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects|A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects||Bukwang Pharmaceutical||Completed|August 2009|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2010|December 10, 2010|December 10, 2010||||No||https://clinicaltrials.gov/show/NCT01258699||111913|
NCT01258712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA230TW|Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients|Randomized, Placebo-controlled Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients||Chugai Pharma Taiwan|No|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|20 Years|75 Years|No|||December 2012|December 12, 2012|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01258712||111912|
NCT01227161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0723|New Formula for Selection of Proper Size of Endotracheal Tube (ETT) in Children: Ultrasonographic Examination|New Formula for Selection of Proper Size of ETT in Children: Ultrasonographic Examination||Yonsei University|No|Completed|February 2010|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|215|||Both|N/A|7 Years|Accepts Healthy Volunteers|Probability Sample|University Hospital (Severance Hospital, Seoul, S.Korea)|May 2011|May 12, 2011|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227161||114321|
NCT01228838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C204|Study of NGX-1998 for the Treatment of Postherpetic Neuralgia|A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects With Postherpetic Neuralgia (PHN)||NeurogesX|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|183|||Both|18 Years|90 Years|No|||May 2011|September 6, 2012|October 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01228838||114192|
NCT01237860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001 Rev 04|Evaluation of the Safety and Performance of the NESS L300 Plus System|Evaluation of the Safety and Performance of the NESS L300 Plus System|L300Plus|Bioness Inc|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|80 Years|No|||November 2011|November 14, 2011|November 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01237860||113503|
NCT01228279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA6951|Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis|Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis|SAPD|Ottawa Hospital Research Institute|Yes|Recruiting|July 2007|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01228279||114235|
NCT01228526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEI-003|A Multicenter, Prospective, Observational Study With PriMatrix for the Treatment of Neuropathic Diabetic Foot Ulcers|||Integra LifeSciences Corporation||Completed|August 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a diabetic foot ulcer and meet the inclusion/exclusion criteria|November 2012|November 7, 2012|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228526||114216|
NCT01226043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_05191|Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus|An Open Label Randomized Multicenter Study to Assess Patient Preference for and Evaluate Clinical Benefit of Insulin Glargine (Lantus®) SoloSTAR® Pen Versus Conventional Vial/Syringe Method of Insulin Glargine (Lantus®) Injection Therapy in Patients With Type 2 Diabetes Mellitus|Pen Preference|Sanofi||Completed|October 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|85 Years|No|||July 2013|July 30, 2013|October 19, 2010|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT01226043||114406|
NCT01234233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THER-JH|Effects of Preoperative Warming of Patients on Postoperative Hypothermia and Shivering|Effects of Preoperative Warming of Patients on Postoperative Hypothermia and Shivering.|THER4-1|University of Schleswig-Holstein|No|Completed|March 2010|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01234233||113781|
NCT01258946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491-764-10/1539|Epicardial Adipose Tissue Thickness in Polycystic Ovary Syndrome (PCOS)|The Relationship Between Epicardial Adipose Tissue Thickness, Insulin Resistance and Plasma Adiponectin Concentrations In Patients With Polycystic Ovary Syndrome||Gulhane School of Medicine|Yes|Completed|January 2009|August 2010|Actual|May 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|45|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|45 patients wit pcos and 45 control cases|August 2010|June 10, 2011|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258946||111894|
NCT01259258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|varicocele|Dye Assisted Lymphatic Sparing Subinguinal Varicocelectomy|Dye Assisted Lymphatic Sparing Varicocelectomy,Prospective Randomized Study|varicocele|Mansoura University|Yes|Completed|January 2008|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2010|December 13, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259258||111870|
NCT01259271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-FSB-1001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2010|||||N/A|N/A|N/A||||||||||||||March 16, 2011|December 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259271||111869|
NCT01259557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-PRT-BP02|Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm|Multi-center, Phase Ⅳ, Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® in Subjects With Essential Blepharospasm||Medy-Tox|No|Completed|August 2010|August 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01259557||111847|
NCT01259570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000007066|Bioavailability of Vitamin D Encapsulated in Casein Micelles, Compared to Its Bioavailability in the Milk-fat, or in a Synthetic Emulsifier Currently Used for Supplementation and Enrichment|||Rambam Health Care Campus|No|Not yet recruiting|January 2011|May 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 13, 2010|December 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01259570||111846|
NCT01260610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AIN05T|Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients|An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients||Institute of Liver and Biliary Sciences, India|No|Withdrawn|June 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||June 2011|June 15, 2015|December 14, 2010||No|lack of funds|No||https://clinicaltrials.gov/show/NCT01260610||111766|
NCT01257867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03015|Lithia Water Study: Effects of Lithia Water on BDNF and Oxidative Stress Markers in Healthy Male Participants|Lithia Water Study: Effects of Lithia Water on BDNF and Oxidative Stress Markers in Healthy Male Participants||University of British Columbia|No|Terminated|March 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|5|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|December 8, 2010||No|This study was terminated by the Principal Investigator|No||https://clinicaltrials.gov/show/NCT01257867||111977|
NCT01257087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUCOSURG1|Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery|Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery.|GLUCOSURG1|Imperial College London|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||April 2015|April 30, 2015|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257087||112037|
NCT01257360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISP_AG52|Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)|NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)|NEO-RIT|WiSP Wissenschaftlicher Service Pharma GmbH|Yes|Active, not recruiting|December 2010|July 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01257360||112016|
NCT01257620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Celiac|Clinical Trial on the Effects of Bifidobacterium Infantis in Active Celiac Disease|Exploratory, Randomized, Double-blind, Placebo-Controlled Study on the Effects of Bifidobacterium Infantis in Active Celiac Disease|Celiac|Bai, Julio M.D.|Yes|Completed|December 2010|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|75 Years|No|||February 2012|February 10, 2012|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257620||111996|
NCT01257854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-018105-41|Polymorphisms and Busulfan Pharmacokinetic Study|Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation||Swiss Pediatric Oncology Group|No|Recruiting|February 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|Samples With DNA|DNA from each patient are kept. Plasma from some centers are kept|Both|N/A|18 Years|No|Non-Probability Sample|primary care clinic of pediatric|November 2015|November 25, 2015|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257854||111978|
NCT01258127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCVC001|Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)|Adjuvant Chemotherapy of Pemetrexed/Carboplatin Compared With Vinorelbine/Carboplatin in Patients With Completely Resected NSCLC||Shanghai Nancy Medical Sci-Tech Co. Ltd|Yes|Recruiting|August 2010|August 2015|Anticipated|August 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|134|||Both|18 Years|80 Years|No|Probability Sample|Patients are eligible to be included in the study only if they meet all of the following        criteria.|December 2010|December 9, 2010|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258127||111957|
NCT01258374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RALDAR-HCB|Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.|Dual Therapy With Raltegravir 400 mg BID and Darunavir/Ritonavir 800/100 mg QD in HIV Infected Patients Failing to Nucleoside Reverse Transcriptase Inhibitors Based Regimens|RALDAR|Hospital Clinic of Barcelona|No|Completed|May 2010|December 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|65 Years|No|Probability Sample|A total of 20 HIV-infected patients failing NRTI based regimens will be included . At        least 12 of these patients will undergo a complete pharmacokinetic study.|August 2015|September 1, 2015|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258374||111938|
NCT01259622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJI-202|Effects of Intravenous K201 on the Restoration of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation|A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset|TUNDRA-AF|Sequel Pharmaceuticals, Inc|Yes|Terminated|February 2011|December 2011|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2011|May 13, 2011|December 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259622||111842|
NCT01227759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA-10-1-042|Tyrosur® Gel-Investigation on Wound Healing Efficacy|A Phase IIa, Single-center, Randomized, Observer-blind Trial With Intraindividual Comparison of Treated Versus Untreated to Assess the Wound Healing Efficacy of Topical Tyrosur® Gel||Engelhard Arzneimittel GmbH & Co.KG|Yes|Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2010|October 25, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227759||114275|
NCT01237873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPA100A1302|Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension|A Open-label, 52 Week, Extension to an 8-week, Double Blind, Multicenter, 6-arm, Placebo-controlled, Parallel Group Study to Evaluate the Long Term Safety of SPA100 (Aliskiren/Amlodipine)||Novartis||Completed|January 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|20 Years|N/A|No|||March 2012|March 22, 2012|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01237873||113502|
NCT01229085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALMOGLEN20906|Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis|CLINICAL ASSESSMENT OF THE EFFECTIVENESS OF ASSOCIATION MONETASONE FUROATE 0.1% SALICYLIC ACID AND 5% FOR SUBMISSION OF OINTMENT TOPICAL DERMATOLOGICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS.|Psoriasis|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|70 Years|No|||February 2008|October 26, 2010|February 8, 2008||No||No||https://clinicaltrials.gov/show/NCT01229085||114173|
NCT01229098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 80185-G24|Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris|A Phase 2 Maximal Use Systemic Exposure Study Evaluating the Safety and Efficacy of Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Gel Applied Once Daily in Subjects With Extensive Psoriasis Vulgaris on the Scalp and Non-scalp Regions of the Body (Trunk and/or Limbs)||LEO Pharma|No|Completed|October 2010|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229098||114172|
NCT01238484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010:004|Ankle Equinus Contracture Treated With Dynamic Splinting|Ankle Equinus Contracture Treated With Dynamic Splinting in a Randomized, Controlled Trial||Dynasplint Systems, Inc.|No|Terminated|August 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|90 Years|No|||July 2013|July 10, 2013|November 9, 2010||No|Centers could not meet enrollment goals|No||https://clinicaltrials.gov/show/NCT01238484||113456|
NCT01238497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-10|SOURCE XT REGISTRY|SAPIEN XT™ Aortic Bioprosthesis Multi-region Outcome Registry||Edwards Lifesciences|Yes|Active, not recruiting|September 2010|December 2018|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with symptomatic aortic stenosis|April 2014|April 1, 2014|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01238497||113455|
NCT01228578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD060333-01|Multi-vitamins, HAART and HIV/AIDS in Uganda|Multi-vitamins, HAART and HIV/AIDS in Uganda||Harvard School of Public Health|Yes|Completed|April 2010|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01228578||114212|
NCT01228591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-1636BB|Pilot Dispensing Evaluation of a Plus Power Lens|||Johnson & Johnson Vision Care, Inc.|No|Completed|October 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|45 Years|No|||May 2015|May 6, 2015|October 22, 2010|No|Yes||No|September 17, 2013|https://clinicaltrials.gov/show/NCT01228591||114211|
NCT01259583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO2-01|Carbon Dioxide Insufflation (CO2) and Warm Water Infusion (WWI) Versus Standard Air Insufflation (AI) for Unsedated Colonoscopy|||Valduce Hospital||Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|341|||Both|18 Years|80 Years|No|||March 2013|March 12, 2013|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259583||111845|
NCT01259843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07387|French National Observatory of Aortic Syndromes|French National Observatory of Aortic Syndromes|ONSAA|French Cardiology Society|No|Completed|August 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|280|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of        acute aortic syndrome whose diagnosis was subsequently confirmed in due course of        hospitalization by further investigations.|June 2012|June 13, 2012|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259843||111825|
NCT01260103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRI-BT-54|Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma|A Randomized Phase 3 Study of Antineoplastons A10 and AS2-1 vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma After Carboplatin or Cisplatin Therapy||Burzynski Research Institute|No|Withdrawn|December 2011|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|18 Years|No|||January 2016|January 12, 2016|December 13, 2010|Yes|Yes|Withdrawn: study halted prematurely, prior to enrollment of first participant|No||https://clinicaltrials.gov/show/NCT01260103||111805|
NCT01260350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7977-0523|Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3|A Multi-center, Open-Labeled Exploratory Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 400 mg and Ribavirin for 12 Weeks With and Without Pegylated Interferon in Treatment-Naïve Patients With Chronic HCV Infection Genotype 2 or Genotype 3||Gilead Sciences|No|Completed|December 2010|December 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|22||Actual|292|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|December 13, 2010|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01260350||111786|
NCT01260363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022500-50|Comparison of Infiltration Analgesia With Femoral Nerve Block After Hamstrings Anterior Cruciate Ligament Reconstruction|Pain Treatment After Anterior Cruciate Ligament Reconstruction||University of Aarhus|Yes|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01260363||111785|
NCT01260623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-406|Pilot Study of How Children With Asthma Exacerbations Metabolize Prednisone|In Vivo Prednisolone/Prednisone Pharmacokinetic Pilot Study in Children With Asthma Exacerbations||Lawson Health Research Institute|No|Recruiting|January 2010|March 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|2 Years|16 Years|No|Non-Probability Sample|children between the ages of 2 and 16 years who present to the tertiary care pediatric        emergency department in London, Ontario with an asthma exacerbation|December 2010|December 14, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260623||111765|
NCT01257399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03010302A|Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase|Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase||Tillotts Pharma AG|No|Completed|November 2010|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|64 Years|No|||April 2013|April 3, 2013|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257399||112013|
NCT01257412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1693C00002|Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone|A 24-week National Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Trial in India to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone.||AstraZeneca|No|Suspended|January 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|375|||Both|19 Years|N/A|No|||February 2012|February 29, 2012|December 8, 2010|Yes|Yes|FSI delayed until 15 January 2013|No||https://clinicaltrials.gov/show/NCT01257412||112012|
NCT01257373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-2010-01|Efficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in Diabetes|Efficacy and Safety of Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent in Treatment of Complex Coronary Lesions in Diabetes||Xijing Hospital|Yes|Recruiting|April 2010|April 2013|Anticipated|April 2011|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|||Both|18 Years|N/A|No|Non-Probability Sample|This registry study will be conducted in 56 centers in which Firebird 2 stent is        implemented. The data of 1300 patients, in which only Fireibrd2 stent is implanted, will        be collected. All inclusive patients should be definitely diagnosed type 2 DM, either        before or during the present hospitalization and with complex coronary lesions. The        diagnosis criteria is the World Health Organization(WHO) recommended criteria 1999        version. I.e., fasting blood glucose ≥7.0mmol/L，random blood glucose ≥11.1mmol/L，or OGTT        2h blood glucose ≥11.1mmol/L. Impaired fasting glucose (6.0mmol/L～7.0mmol/L) or Impaired        glucose tolerance (oral glucose tolerance test(OGTT) 2h blood glucose        7.8mmol/L～11.1mmol/L) can not be enrolled. The stress-induced hyperglycemia of acute        coronary syndrome is illegible.|November 2009|December 28, 2010|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257373||112015|
NCT01257386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03010301A|Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis|Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis||Tillotts Pharma AG|No|Completed|November 2010|March 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|64 Years|No|||April 2013|April 3, 2013|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257386||112014|
NCT01258387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101.1|Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure|A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure|GGF2-1101-1|Acorda Therapeutics|Yes|Completed|December 2010|March 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||June 2014|June 30, 2014|December 8, 2010|No|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01258387||111937|
NCT01258400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-012|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2010|||||N/A|N/A|N/A||||||||||||||November 15, 2011|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258400||111936|
NCT01258725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amnioinfusioncirculation|Alterations of the Uteroplacental and Fetal Pulmonary Circulation Following Amnioinfusion|Alterations of the Uteroplacental and Fetal Pulmonary Circulation in Patients With Severe Idiopathic Oligohydramnios Following Amnioinfusion Therapy in a Longitudinal Study||Szeged University|No|Not yet recruiting|January 2011|December 2012|Anticipated|September 2011|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Female|18 Years|49 Years|No|||December 2010|December 10, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01258725||111911|
NCT01258998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02890|Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma|Phase II Study of MK-2206 in Patients With Relapsed Lymphoma||National Cancer Institute (NCI)||Completed|December 2010|August 2015|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||August 2015|October 9, 2015|December 10, 2010|Yes|Yes||No|October 9, 2015|https://clinicaltrials.gov/show/NCT01258998||111890|
NCT01259323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-0914|Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Extrinsic Atopic Dermatitis||Regeneron Pharmaceuticals|Yes|Completed|December 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|December 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01259323||111865|
NCT01259336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Itracon asp|Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis|A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS|ITRACONASP|Postgraduate Institute of Medical Education and Research|Yes|Completed|July 2010|December 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|14 Years|80 Years|No|||November 2010|February 18, 2012|December 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259336||111864|
NCT01258738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801031|Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes|A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etanercept On A Background Nsaid In The Treatment Of Adult Subjects With Non Radiographic Axial Spondyloarthritis With A 92 Week Open Label Extension|EMBARK|Pfizer|No|Completed|February 2011|October 2014|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|49 Years|No|||September 2015|September 14, 2015|December 9, 2010|Yes|Yes||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01258738||111910|
NCT01259024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108256|The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead|Hepatic Arterial Embolization of Hepatocellular Carcinoma With a Doxorubicin Eluting Bead||Washington University School of Medicine|Yes|Completed|December 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259024||111888|
NCT01237574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/38|Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease|Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease|CALMET|University Hospital, Bordeaux|No|Recruiting|December 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|-  serum        -  plasma (DNA)|Both|18 Years|N/A|No|Non-Probability Sample|18 years old patient with chronic liver disease (liver biopsy with bridging fibrosis or        cirrhosis) or non-invasive markers of fibrosis (fibrotest > 0.58, FibroScan > 7.9 kPa), no        decompensated cirrhosis, chronic alcohol use and/or metabolic syndrome.|March 2015|March 4, 2015|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01237574||113525|
NCT01225120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2007.072t|Amputee Gait Training Using Virtual Reality and Real-Time Feedback|Amputee Gait Training Using Virtual Reality and Real-Time Feedback|VRGAIT|Brooke Army Medical Center|No|Enrolling by invitation|August 2007|||September 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|October 19, 2010|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01225120||114475|
NCT01225133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARAKA-1|Complex Āyurvedic Treatment in Osteoarthritis of the Knee Compared to Standard Care.|The CARAKA-Trial: Complex Āyurvedic Treatment in Osteoarthritis of the Knee Against Standard Care.A Multicentre, Randomized, Controlled Clinical Trial Based on Traditional Āyurveda-Diagnosis.|CARAKA|Charite University, Berlin, Germany|Yes|Completed|October 2010|March 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|40 Years|70 Years|No|||March 2015|March 30, 2015|October 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01225133||114474|
NCT01228318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00038739|Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)|Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)|BLIR-HIV|Emory University|Yes|Active, not recruiting|January 2011|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|30 Years|50 Years|No|||May 2015|May 26, 2015|October 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228318||114232|
NCT01228604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100021|Cost-Effectiveness Study Of The Treatment Of Attention Deficit/Hyperactivity Disorder In Brazil|COST-EFFECTIVENESS STUDY OF THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN BRAZIL||Hospital de Clinicas de Porto Alegre||Completed|December 2010|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Male|8 Years|10 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|October 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01228604||114210|
NCT01259856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1300-00002|Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)|Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2011|June 2024|Anticipated|June 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259856||111824|
NCT01259869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I204|A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression|A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression||Canadian Cancer Trials Group|No|Completed|January 2011|February 2015|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||February 2015|April 10, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01259869||111823|
NCT01260116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS897429|Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia|Efficacy and Safety of Ziprasidone in the Treatment of Depressive Symptoms in Patients With Schizophrenia：an 8-week Open-label Study||Wuhan University|Yes|Not yet recruiting|December 2010|March 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|65 Years|No|Probability Sample|First-episode or non-refractory recurrent male or female in-hospitalized subjects (aged 18        to 65 years) with a diagnosis of schizophrenia company with depressive symptoms|December 2010|December 14, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260116||111804|
NCT01260376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100221|Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise|Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise||University of Aarhus|No|Completed|April 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|9|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260376||111784|
NCT01257633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2010/BL-01|Surgical Treatment of Early Stage Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance|Observational Study on Surgical Treatment of Early Stage (T1-T2) Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance||Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2011|October 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|90 Years|No|Non-Probability Sample|This study is aimed at all patients with early stage (T1 or T2) glottic and / or        supraglottic squamous cell carcinoma of the larynx, whatever their status and cervical        lymph nodes without distant metastases (M0) and for whom endoscopic surgical treatment        with robotic assistance is indicated following a multidisciplinary meeting.|March 2015|March 26, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257633||111995|
NCT01257126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAT458CMX01|Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection|Efficacy of Diclofenac Potassium Versus Nimesulide in the Treatment of Fever and Pain in Children Aged 3 to 7 Years With Community Acquired, Non-complicated, Upper Respiratory Tract Infection||Novartis||Withdrawn|April 2011|||December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|3 Years|7 Years|No|||April 2012|April 25, 2012|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257126||112034|
NCT01258192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH-ESCC-01|Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients|Multicenter,Phase ⅡStudy of Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Squamous Cell Carcinoma Patients|nabPCESCC|Zhejiang Cancer Hospital|Yes|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|70 Years|No|||July 2014|July 28, 2014|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01258192||111952|
NCT01257659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2010/RdeT-01|STARR Trans-anal Resection Versus Vaginal Rectocele Repair Using Elevate: Effects on Defecatory Function|STARR Type Trans-anal Resection Versus Vaginal Rectocele Repair Using a Posterier Elevate Prothesis: a Randomized, Multicentric, Prospective Study on Defecatory Function|RectoVerso|Centre Hospitalier Universitaire de Nīmes|No|Terminated|September 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||October 2015|October 30, 2015|December 9, 2010||No|Unable to find enough patients who accept randomization of surgical procedures.|No||https://clinicaltrials.gov/show/NCT01257659||111993|
NCT01257646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2009/JF-01|Observation of the Gait Cycle in Patients With Hemiplegia in Order to Improve the Triggering of Functional Electrical Stimulation|Observation of the Gait Cycle in Patients With Hemiplegia in Order to Improve the Triggering of Functional Electrical Stimulation|MASEA|Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|20 Years|75 Years|No|Non-Probability Sample|Study patients are recuted from the patient pool that is either hospitalized or consulting        in the department of Neurological Reeducation and Readaptation at the Grau du Roi medical        center at the Nîmes University Hospital (Centre Hospitalier Universitaire de Nîmes).        Patients are stroke victims with gait problems.|March 2015|March 24, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257646||111994|
NCT01257880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4865S-09|Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)|Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)|CAMP|Swedish Medical Center|No|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|31|||Both|18 Years|55 Years|No|Non-Probability Sample|Otherwise healthy persons who have a diagnosis of MA, based on the International        Classification of Headache Disorders Diagnostic Criteria, will be recruited from headache        and neurology clinics. Potential subjects can self refer if they have a diagnosis of MA.|September 2011|September 21, 2011|December 8, 2010||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT01257880||111976|Subjects were recruited from a headache clinic and had a high degree of migraine burden; thus, the sample may not accurately represent the general migraine population. The number of men in the sample was insufficient to test sex differences.
NCT01257893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4959S-10|Aspirin Resistance in Women With Migraine|Aspirin Resistance in Women With Migraine|ARWM|Swedish Medical Center|No|Withdrawn|November 2010|August 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|0|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257893||111975|
NCT01258153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIC-03|Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic|Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Administration of Nepadutant in Infant Colic|no-cry|Menarini Group|No|Completed|November 2010|March 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|115|||Both|N/A|20 Weeks|No|||May 2015|May 26, 2015|December 9, 2010|Yes|Yes||No|May 4, 2015|https://clinicaltrials.gov/show/NCT01258153||111955|
NCT01258413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPGHC: 65/99|Laparoscopic vs Abdominal Radical Hysterectomy In Patients With Early Cervical Cancer|Laparoscopic vs Abdominal Radical Hysterectomy With Pelvic Lymphadenectomy in Patients With Early Cervical Cancer: A Randomized Clinical Trial||Hospital Nossa Senhora da Conceicao|No|Completed|November 1999|February 2009|Actual|February 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|No|||November 2010|December 22, 2010|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258413||111935|
NCT01258426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPP1(DM)|Human Selenoprotein P Concentration With Glucose Tolerance Status|Human Selenoprotein P Concentration With Glucose Tolerance Status||Korea University|No|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|||||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Total 180 patients Normal 60-IGT 60-T2DM 60|December 2010|December 10, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258426||111934|
NCT01259037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elastography1|A Study of Ultrasonography With Elastography in Skin Neoplasms|||Wayne State University||Recruiting|January 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Skin biopsies of lesions imaged with ultrasound are processed for routine histology and      retained.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General dermatologic population from suburban referral clinic.|December 2010|December 10, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01259037||111887|
NCT01259375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI45197|Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma|A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma|ARSARC-PI-0010|University of Utah|No|Completed|September 2011|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259375||111861|
NCT01227551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA-007|A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma|A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK(Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma||Viralytics|Yes|Completed|October 2011|||June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|October 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227551||114291|
NCT01227785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOTICE-HF 0410|Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study|Next Generation INCEPTA ICD and CRT-D Field Following Study: Respiratory Rate Trend Evaluation in Heart Failure (HF) Patients|NOTICE-HF|Guidant Corporation|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients should be selected from the investigator's general population and be indicated        for an ICD or CRT-D implantation.|April 2014|April 9, 2014|October 22, 2010||No||No|December 11, 2013|https://clinicaltrials.gov/show/NCT01227785||114273|
NCT01228058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0160|A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients|A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients|RapidTEG|The University of Texas Health Science Center, Houston|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1450|||Both|18 Years|N/A|No|Non-Probability Sample|The target population for this study is all major-trauma patients admitted to one of the        three participating ACS-verified academic Level 1 trauma centers.|December 2012|December 17, 2012|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01228058||114252|
NCT01238172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-70807|Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance|The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|January 2011|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|464|||Male|50 Years|80 Years|No|||August 2015|August 20, 2015|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01238172||113479|
NCT01228071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3350-302|Time to Eugonadal Range, Time to Steady State and Drying Time|Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application||Endo Pharmaceuticals|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Male|18 Years|65 Years|No|||June 2013|June 18, 2013|October 22, 2010|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01228071||114251|
NCT01228344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566A2424|Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria|Surveillance for the Effectiveness and Safety of Artemether-lumefantrine in Pediatric and Adult Patients With Malaria||Novartis||Recruiting|May 2010|||May 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|Any male or female infant, child or adult patient diagnosed with malaria who received        artemether-lumefantrine and was reported to the Centers for Disease Control, Atlanta GA.|November 2012|November 27, 2012|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01228344||114230|
NCT01228903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0625|Uric Acid and the Endothelium is CKD|Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?||University of Colorado, Denver|Yes|Active, not recruiting|October 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||October 2015|October 12, 2015|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228903||114187|
NCT01229202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2007-331|Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery|Use of Vascular Endothelial Growth Factor Inhibitor, Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery||Nova Scotia Health Authority|No|Recruiting|July 2008|June 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|30 Years|N/A|No|||June 2011|June 29, 2011|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01229202||114164|
NCT01260636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH-137|Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries|A Phase III, Comparative Multi-center Randomized Double-blind, Crossover Study of the Safety, Tolerability and Diagnostic Efficacy of Gadobenate Dimeglumine and Gadopentetate Dimeglumine in Magnetic Resonance Angiography of the Carotid, Renal/Abdominal and Peripheral Arteries|VALUE|Bracco Diagnostics, Inc|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|120|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260636||111764|
NCT01256840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-CHR-10-01323|Long-term Caloric Restriction and Cellular Aging Markers|Caloric Restriction With Optimal Nutrition and Aging Study|CRONA|University of California, San Francisco|No|Completed|December 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|75|Samples With DNA|Whole blood, serum.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample and Calorie Restriction Society|September 2011|September 20, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01256840||112056|
NCT01256853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC002|Modified Vaccinia Ankara (MVA) Vaccine Study|A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens||Chinese University of Hong Kong|No|Completed|September 2006|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01256853||112055|
NCT01256866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsd130947|Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine|Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine||Hospital Sao Domingos|Yes|Recruiting|November 2010|June 2012|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|75 Years|No|||November 2010|December 8, 2010|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01256866||112054|
NCT01257100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911040|Environmental and Genetic Determinants of NPC|Environmental and Genetic Determinants of NPC||National Institutes of Health Clinical Center (CC)||Recruiting|November 2010|||||N/A|Observational|N/A|||Anticipated|4000|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 30, 2015|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257100||112036|
NCT01256905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/6268|Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies|Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies|Armodafinil|New York University|No|Recruiting|December 2010|||April 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|50 Years|80 Years|No|||April 2010|December 8, 2010|December 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256905||112051|
NCT01257139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-008372-13|Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments||ESOGIA|Rennes University Hospital||Completed|January 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|490|||Both|70 Years|N/A|No|||April 2015|April 1, 2015|January 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01257139||112033|
NCT01258452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1013-PR-0052|Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects|Randomized, Balanced, Single Dose, Cross-Over Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects|CT03|CERESPIR|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|December 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258452||111932|
NCT01257906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acta/Clin-Tret/2009|Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo|A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING CLINDAMYCIN PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL (ACTAVIS MID-ATLANTIC LLC) TO ZIANA® (CLINDAMYCIN PHOSPHATE 1.2% AND TRETINOIN 0.025%) GEL (MEDICIS, THE DERMATOLOGY COMPANY®) AND BOTH ACTIVE TREATMENTS TO CLINDAMYCIN PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL PLACEBO (ACTAVIS MID-ATLANTIC LLC) IN THE TREATMENT OF MILD TO SEVERE ACNE VULGARIS||Actavis Mid-Atlantic LLC|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1225|||Both|12 Years|40 Years|No|||December 2010|December 9, 2010|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257906||111974|
NCT01257919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15386|Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea|Investigator-blinded, Randomized, Cross-over, Multiple Dose Phase I Study on Safety and Pharmacokinetics of Topically Applied Azelaic Acid Foam, 15% Compared to Azelaic Acid Gel, 15% in Subjects With Papulopustular Rosacea||Bayer|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|December 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01257919||111973|
NCT01258166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00023348|Traumatic Ulnar Translocation of the Carpus|Traumatic Ulnar Translocation of the Carpus: Early Diagnosis and Treatment||Northwestern University||Completed|January 2005|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|10|||Both|17 Years|80 Years|No|Non-Probability Sample|Patients who suffered traumatic ulnar translocation of the carpus|February 2012|February 2, 2012|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258166||111954|
NCT01258179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.2009|Peri-operative Expression Analysis of Pancreatic Stone Protein in a Surgical Study Population|Peri-operative Expression Analysis of Pancreatic Stone Protein and Pancreatitis-associated Protein in a Surgical Study Population||University of Zurich|Yes|Recruiting|February 2011|April 2015|Anticipated|December 2014|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|160|Samples With DNA|Venous blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing major abdominal surgery|February 2014|February 3, 2014|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01258179||111953|
NCT01258439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROaR+|Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.|Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART.|ROaR+|St Vincent's Hospital, Sydney|Yes|Completed|November 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2015|January 8, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258439||111933|
NCT01258751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2081007|This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers|A Phase 1, Open-Label Study To Evaluate 5-Ht6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11c]PF-04171252 Following Single Oral Dose Administration Of PF-05212377 (Sam-760) In Healthy Subjects||Pfizer|No|Completed|December 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|December 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258751||111909|
NCT01258764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STSI 10-5486|Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril|Series of Single Patient Trials Comparing the Efficacy Between the Most Commonly Prescribed Thiazide Diuretic in the US, Hydrochlorothiazide, and Lisinopril for the Treatment of Stage 1 Hypertension.|1HAT|Scripps Translational Science Institute|No|Completed|November 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258764||111908|
NCT01259934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nordic-IFN-melanoma trial|Nordic Adjuvant IFN Melanoma Trial|Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma||Karolinska Institutet|Yes|Completed|November 1996|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|855|||Both|18 Years|N/A|No|||December 2010|December 13, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01259934||111818|
NCT01227811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDBEQ_DFNLP/ELEA_011|Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.|Single Dose, Two-period, Crossover, Fed Bioequivalence Study of Darifenacin Extended Release Oral Formulation (Darisec(R) 15 mg) vs. Enablex(R) 15 mg in Healthy Volunteers.||Center for Clinical Pharmacology Research Bdbeq S.A.|No|Not yet recruiting|November 2010|March 2011|Anticipated|December 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2010|October 22, 2010|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01227811||114271|
NCT01227798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-H1N1|Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza|A Pilot Study to Evaluate the Safety and Efficacy of IFN-alfacon1 (INFERGEN) in the Treatment of Hospitalized Patients Presenting With Influenza-like Illnesses Due to the Pandemic 2009 Swine Origin Influenza A Virus (S-OIV) H1N1 and Other Circulating Influenza Viruses||University Health Network, Toronto|No|Not yet recruiting|November 2010|November 2011|Anticipated|November 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||August 2010|October 22, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227798||114272|
NCT01228084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6613|Sulforaphane in Treating Patients With Recurrent Prostate Cancer|The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer||OHSU Knight Cancer Institute|Yes|Completed|November 2010|May 2013|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||January 2014|January 14, 2014|October 19, 2010|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT01228084||114250|
NCT01228331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000686545|Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL|A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology||Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|October 2010|September 2021|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|660|||Both|1 Year|17 Years|No|||September 2015|September 7, 2015|October 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01228331||114231|
NCT01228643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANBER0607|Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs|STUDY OF EFFECTIVENESS OF THE USE OF PANCREATIC ENZYME: NORZYME® -(MADE IN THE LABORATORY PANCREALIPASE BERGAMO) INPATIENTS WITH PANCREATIC INSUFFICIENCY IN USE SUBSTITUTEENZYMATIC WHEN COMPARED TO PRODUCT CREON®||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Withdrawn|June 2007|December 2011|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|5|||Both|14 Years|65 Years|No|||February 2008|October 25, 2010|February 11, 2008||No||No||https://clinicaltrials.gov/show/NCT01228643||114207|
NCT01228916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA132950-01A2|Community-Partnered Dominican Republic Tobacco Control|Community-Partnered Tobacco Control in Underserved Dominican Republic Communities||University of Rochester|Yes|Recruiting|June 2010|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3656|||Both|1 Year|N/A|Accepts Healthy Volunteers|||October 2013|October 31, 2013|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228916||114186|
NCT01228929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32315|Non-invasive Ocular Surface Measurements Before and After Interventions|Non-invasive Ocular Surface Measurements Before and After Interventions||University of Rochester|No|Terminated|July 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|18|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|October 25, 2010||No|The study was terminated.|No|July 31, 2015|https://clinicaltrials.gov/show/NCT01228929||114185|
NCT01256879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00046139|Cimetidine Biowaivers|Evaluation of Excipient Effects on Biopharmaceuticals Classification System (BCS) Class 3 Drug Cimetidine||University of Maryland|Yes|Recruiting|March 2011|May 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01256879||112053|
NCT01257113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2591|Supervised Exercise Therapy vs Home Exercises for Patients With Subacromial Impingement|Is Supervised Exercise Therapy a Better Option Than Home Exercises for Patients With Subacromial Impingement When Looking at Pain and Function?||Norwegian University of Science and Technology|No|Completed|January 2011|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||June 2015|June 22, 2015|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257113||112035|
NCT01261013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOFV-1|Intrastromal Corneal Ring Segment Implantation in 219 Keratoconic Eyes at Different Stages|Intrastromal Corneal Ring Segment Implantation in 219 Keratoconic Eyes at Different Stages||Fernandez-Vega Ophthalmological Institute|Yes|Completed|January 2008|March 2010||||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|219|||Both|20 Years|60 Years|No|Non-Probability Sample|Patients with keratoconus (stage I; stage II and stage III,according to the        Amsler-Krumeich keratoconus classification) in whom KeraRing ICRS were implanted at the        Fernández-Vega Ophthalmological Institute, Oviedo, Spain.|November 2010|December 23, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261013||111735|
NCT01257932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2010-7812|Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging|Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging||University of California, Irvine|Yes|Completed|December 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Female|18 Years|N/A|No|Non-Probability Sample|primary care clinic and community sample|August 2015|August 4, 2015|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257932||111972|
NCT01257672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM8E53XM|Symptomatic Treatment of Acute Gastroenteritis|Oral Ondansetron vs Domperidone for Symptomatic Treatment of Vomiting During Acute Gastroenteritis in Children: Multicentre Randomized Controlled Trial||IRCCS Burlo Garofolo|Yes|Completed|July 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|356|||Both|1 Year|6 Years|No|||April 2014|April 17, 2014|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257672||111992|
NCT01257685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPP1(NAFLD)|Selenoprotein P and Non-alcoholic Fatty Liver Disease|Selenoprotein P and Non-alcoholic Fatty Liver Disease||Korea University|No|Completed|September 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|120|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers for visiting routine medical check in our clinic|December 2010|December 9, 2010|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257685||111991|
NCT01257698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAR-2|Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy|A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy||Mid Atlantic Retina|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|N/A|N/A|No|||February 2012|February 8, 2012|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257698||111990|
NCT01257945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-0750|Exercise for People With Parkinson's Disease|Exercise, Physical Function, and Parkinson's Disease||University of Colorado, Denver|Yes|Completed|April 2003|July 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|163|||Both|35 Years|N/A|No|||October 2012|October 1, 2012|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01257945||111971|
NCT01257958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC #97-676-311|Vitamin D Pilot Study in Patients With Multiple Sclerosis|Vitamin D Pilot Study in Patients With Multiple Sclerosis||University of Wisconsin, Madison|No|Completed|February 1998|June 2000|Actual|February 2000|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||||||Both|18 Years|45 Years|No|||December 2010|October 1, 2015|December 8, 2010||Yes||||https://clinicaltrials.gov/show/NCT01257958||111970|
NCT01258777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016345|A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects|A Phase I Study to Evaluate the Safety and Pharmacokinetics of CNTO 148 Following Single Subcutaneous Administration to Healthy Japanese and Caucasian Subjects||Centocor, Inc.|No|Completed|October 2010|April 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258777||111907|
NCT01258205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090519|Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease||Amgen|No|Completed|February 2011|April 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|December 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258205||111951|
NCT01259050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zinc-ALS|Safety Study of High Doses of Zinc in ALS Patients|Phase 1 Open Label Study of Zinc Therapy in ALS Patients||Phoenix Neurological Associates, LTD|Yes|Completed|October 2010|March 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||March 2012|March 9, 2012|December 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01259050||111886|
NCT01259063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-165|RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder|Phase I/II Study of RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259063||111885|
NCT01259388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA2-003-10S|A Pilot Study of Lithium in Progressive Multiple Sclerosis|A Pilot Trial of Lithium in Progressive Multiple Sclerosis||VA Office of Research and Development|No|Active, not recruiting|May 2011|December 2015|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|65 Years|No|||September 2015|September 2, 2015|December 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259388||111860|
NCT01259661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99070|Physical Activity and Metabolic Risk Factors in Postmenopausal Women|Physical Activity and Metabolic Risk Factors in Postmenopausal Women||Taipei Medical University WanFang Hospital|No|Recruiting|October 2010|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Female|35 Years|64 Years|No|||December 2010|December 12, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01259661||111839|
NCT01259960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-Senker|Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease. A Prospective Long-term Evaluation|Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease. A Prospective Long-term Evaluation.||General Hospital Amstetten|No|Recruiting|February 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|258|||Both|18 Years|N/A|No|Probability Sample|All patients who will undergo minimal access surgical technige for degenerative lumbar        disease fusion|March 2015|March 16, 2015|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01259960||111816|
NCT01260194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25477|A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer|An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer||Hoffmann-La Roche||Completed|June 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|December 13, 2010|No|Yes||No|February 15, 2016|https://clinicaltrials.gov/show/NCT01260194||111798|
NCT01227837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1388-2365|Effect of omega3 on Congestive Heart Failure|Effect of Omega 3 Supplementation on Brain Natriuretic Peptide (BNP) Serum Levels Functional Capacity and Systolic and Diastolic Function of Heart Failure Patients||Shiraz University of Medical Sciences|Yes|Completed|October 2008|March 2010||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|3 Months|73 Years||||September 2010|October 22, 2010|September 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01227837||114269|
NCT01228357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-08-07|Predict Antidepressant Responsiveness Using Pharmacogenomics|Predict Antidepressant Responsiveness Using Pharmacogenomics||Samsung Medical Center|Yes|Recruiting|February 2003|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|19 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|October 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01228357||114229|
NCT01228370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-SDS-402|Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder|A 12-week, Open-label, Multi-center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder||JW Pharmaceutical|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Both|20 Years|N/A|No|||October 2010|October 3, 2012|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228370||114228|
NCT01228617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431114-NICTDP1063|Single-dose Pharmacokinetics of Oral Nicotine Replacement Products|Single-dose Pharmacokinetics of Oral Nicotine Replacement Products - An Exploratory Study in Healthy Volunteers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|September 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|40|||Both|18 Years|50 Years|No|||October 2011|October 4, 2011|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228617||114209|
NCT01228630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOREMS0810|Comparative Effectiveness of Two Associations of Loratadine + Pseudoephedrine, Cloratadd-d ® (Coated Pill) Produced by the Laboratory Ems and Claritin-d ® (dräger), Produced by Schering-plough in Patients With Perennial Allergic Rhinitis|Evaluating the Effectiveness of Two Commercial Preparations of Loratadine + Pseudoephedrine Cloratadd-d ® (Coated Pill) Produced by the Laboratory EMS S / AE Claritin-d ® (dräger), Produced by Schering-plough SA, in Patients With Perennial Allergic Rhinitis||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|August 2011|May 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|12 Years|N/A|No|||February 2013|February 22, 2013|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01228630||114208|
NCT01228656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALMOGLEN10906|Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate|CLINICAL EVALUATION OF EFFECTIVENESS OF ASSOCIATION MOMETASONE FUROATE 0.1% AND SALICYLIC ACID 5% COMPARED WITH 0.1% MOMETASONE FUROATE INSULATED TOPICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS IN PLATE|Psoriasis|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Suspended|September 2006|October 2011|Anticipated|October 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2008|October 25, 2010|February 7, 2008||No||No||https://clinicaltrials.gov/show/NCT01228656||114206|
NCT01228942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15248|A Prospective Trial of COXEN Chemotherapy Prediction|A Prospective Trial of COXEN Chemotherapy Prediction in Persistent and Recurrent Ovarian, Fallopian Tube, and Peritoneal Carcinomas||University of Virginia|Yes|Withdrawn|October 2010|June 2013|Actual|October 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|0|||Female|18 Years|95 Years|No|||June 2014|June 5, 2014|October 20, 2010|No|Yes|Lack of funding/resources|No||https://clinicaltrials.gov/show/NCT01228942||114184|
NCT01260974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1768P|Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients|Pilot Study: Efficacy of Caspofungin for Antifungal Prophylaxis for Selected High Risk Liver Transplant Patients|CPHRLTX|Azienda Ospedaliera di Padova|Yes|Recruiting|May 2009|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|38|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01260974||111738|
NCT01260987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-044|Fractional CO2 Laser Assisted Photodynamic Therapy|Conventional Versus Fractional CO2 Laser Assisted Photodynamic Therapy for Basal Call Carcinomas and Actinic Keratoses||Bispebjerg Hospital|Yes|Completed|October 2010|August 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01260987||111737|
NCT01261000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23051|Tissue Biomarker for Pegvisomant Action|Tissue Biomarker for Pegvisomant Action||Cedars-Sinai Medical Center|No|Completed|November 2010|December 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||February 2015|February 2, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261000||111736|
NCT01260662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 10-3230|Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation|Randomized Blinded Three Arm Trial of Propofol, 1:1 Combination of Propofol and Ketamine, and 4:1 Combination of Propofol and Ketamine for Procedural Sedation in the Emergency Department||Minneapolis Medical Research Foundation|No|Completed|November 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|271|||Both|1 Year|N/A|No|||June 2015|June 15, 2015|December 13, 2010|Yes|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT01260662||111762|
NCT01260675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-BUP-NT/002|Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone|A Study to Assess the Pharmacokinetic Profile of an Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8mg/2mg Capsules Relative to the Pharmacokinetic Profile of Suboxone® (Buprenorphine HCl/Naloxone HCl 8mg/2mg Sublingual Tablets).||Nanotherapeutics, Inc.|No|Completed|December 2010|||January 2011|Actual|N/A|Observational|N/A||2|Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy normal volunteers|April 2015|April 13, 2015|December 13, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01260675||111761|
NCT01256892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244/2002|Insulin Dependent Gestational Diabetes Mellitus: Randomized Trial of Induction of Labour at 38 and 40 Weeks of Gestation|||Medical University of Vienna|No|Completed||||||N/A|Interventional|N/A|||||||Female|18 Years|N/A|No|||December 2010|December 9, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256892||112052|
NCT01257425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-94-52014-178|Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg|A Phase II, Multicentre, Open, Prospective, Randomised, Parallel-Group, Pharmacodynamic Equivalence Study on Intramuscular Versus Subcutaneous Applications of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Patients With Advanced Prostate Cancer|PAMIS|Ipsen|No|Completed|December 2010|May 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Male|18 Years|N/A|No|||April 2014|April 30, 2014|December 8, 2010|No|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01257425||112011|
NCT01258478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocole 09-263|Lung Cancer Rehabilitation Study|Short-Term Pre-operative Rehabilitation for Patients With Lung Cancer: A Randomized Trial.|LCRS|University Hospital, Geneva|No|Recruiting|December 2010|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||December 2010|December 10, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01258478||111930|
NCT01258504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K330|Influence of CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Bosentan|Influence of Cytochrome P450 3A4 (CYP3A4)-Induction by St. John's Wort (SJW) on the Steady State Pharmacokinetics of Bosentan||Heidelberg University|No|Completed|January 2011|June 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|May 2015|May 29, 2015|December 10, 2010||No||No|July 9, 2014|https://clinicaltrials.gov/show/NCT01258504||111928|Interindividual changes of the interaction were large suggesting that close monitoring of bosentan effects is advisable because in a sizeable fraction of volunteers the exposure to bosentan was reduced.
NCT01258517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS-018|The Effect of Surfactant Administration on Cerebral Oxygenation|The Effect of the Type and the Method of Surfactant Administration on Oxygenation in Preterm Infants: a Near Infrared Spectroscopy Study||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|November 2010|December 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|23 Weeks|32 Weeks|No|||November 2010|December 10, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01258517||111927|
NCT01258465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH39434|Research in Autism: Parent Intervention|Research in Autism: Parent Intervention||University of California, San Diego|Yes|Completed|January 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|24 Months|47 Months|No|||December 2010|December 10, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258465||111931|
NCT01259089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10L01|Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer|A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors||Northwestern University|Yes|Active, not recruiting|March 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|December 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259089||111883|
NCT01259076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10B01|Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer|Effect of Weight Loss on Breast Density Using Both Digital Mammography and Breast MRI||Northwestern University|Yes|Terminated|February 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|43|||Female|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pre-menopausal women between the ages of 30 and 50 who are eligible and undergoing        evaluation for gastric bypass surgery|April 2015|April 9, 2015|December 10, 2010||No|Study was closed early due to slow accrual.|No||https://clinicaltrials.gov/show/NCT01259076||111884|
NCT01259401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7037-R|Treating Sleep Problems in VA Adult Day Health Care|Treating Sleep Problems in VA Adult Day Health Care|HERO-ADHC|VA Office of Research and Development|No|Completed|November 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|60 Years|N/A|No|||January 2015|January 6, 2015|December 10, 2010||No||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01259401||111859|Small sample size; predominantly male study sample
NCT01259674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-Resp-09|Evaluation of the Efficacy and Tolerability of ABO/MEG-B-09 in Children With Acute Cough|Randomized, Single-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Tolerability of ABO/MEG-B-09 in Pediatric Cough|ABOMEG|Aboca Spa Societa' Agricola|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|3 Years|6 Years|No|||December 2014|December 1, 2014|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259674||111838|
NCT01259687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-09-0124-CTIL|Pulse Transit Time in Anesthetized Patients: Blood Pressure or Cardiac Output as Measured With NICOM Monitor|Pulse Transit Time in Anesthetized Ventilated Patients: Affect of Blood Pressure or Cardiac Output as Measured With NICOM Monitor|PuTT-NICOM|Carmel Medical Center|No|Completed|January 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing various types elective surgery which require continous invasive        monitoring of blod pressure|November 2013|November 23, 2013|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01259687||111837|
NCT01259947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LALBA201012|Lippia Alba for Migraine Prophylaxis and Treatment|Chemical Composition and Therapeutic Effects of Lippia Alba (Mill.) N. E. Brown Leaves Ethanolic Extract in Patients With Migraine||Casa Espirita Terra de Ismael|Yes|Completed|July 2006|October 2010|Actual|April 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01259947||111817|
NCT01260207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-391|Using IVR to Maintain ACS Patients on Best Practice Guidelines|Using Interactive Voice Response to Improve Disease Management and Compliance With Acute Coronary Syndrome Best Practice Guidelines|IVR-ACS BPG|Lawson Health Research Institute|No|Suspended|January 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|654|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|December 13, 2010||No|Recruitment has been suspended due to revised sample size and resource availability|No||https://clinicaltrials.gov/show/NCT01260207||111797|
NCT01227850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Refeedingindex0810|Leptin, IGF1 and the Refeeding Index|Leptin and IGF1; Diagnostic Markers of Refeeding Syndrome and Mortality||King's College Hospital NHS Trust|No|Completed||||||N/A|Observational|Observational Model: Case-Only||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to our department at King's College Hospital, for commencement of        parenteral nutrition (PN).These included all ages above 18 and both sexes. Consent to        commence PN was taken from the patients prior to starting it. Daily bloods were taken for        routine laboratory analysis as part of the usual patient care.|October 2010|October 22, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227850||114268|
NCT01228383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB-M-A008|Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults|A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects||Crucell Holland BV|Yes|Completed|December 2011|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|240|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 3, 2013|October 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228383||114227|
NCT01228955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091309|Yoga Intervention for Cancer Survivors|Yoga Intervention for Cancer Survivors||Vanderbilt University|Yes|Completed|February 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|||Both|18 Years|90 Years|No|Non-Probability Sample|Survivors of Adult or Pediatric Cancer|December 2013|December 17, 2013|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01228955||114183|
NCT01229241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-019393-32|Assessment of Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion|Prospective Randomized Double-blinded Study of Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion|LEVOROPI|IRCCS Policlinico S. Matteo|Yes|Completed|July 2005|July 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|90 Years|No|||January 2012|January 19, 2012|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01229241||114161|
NCT01229254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4448-006|Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation (Study MK-4448-006)|A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter||Merck Sharp & Dohme Corp.|No|Completed|September 2010|April 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|189|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|September 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229254||114160|
NCT01260415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH DDP - CRCLM1|A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases|A Phase II Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases||University Health Network, Toronto|Yes|Completed|August 2010|||June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260415||111781|
NCT01260428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-AGIR-2|Effects of Expiratory Pressure on Arterial Oxygenation During Hypoxia|Arterial Oxygenation During Hypoxia : Effects of an Added Expiratory Resistance|hypex|AGIR à Dom|No|Recruiting|February 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample with mounteneering experience|February 2012|February 27, 2012|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260428||111780|
NCT01256918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMLH-001-EYE|Study of Phacodepth Required for Safe and Effective Chop During Phacoemulsification for Cataract.|Evaluation of Phacodepth Required to Achieve Full Thickness Nuclear Crack in Various Grades of Cataract and to Determine the Correlation Between the Two.|CALIBCHOP|Dr. Ram Manohar Lohia Hospital|Yes|Completed|November 2010|February 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|200|||Both|40 Years|N/A|No|Non-Probability Sample|The study will be conducted at EYE DEPARTMENT, Post Graduate Institute of Medical        Education and Research(PGIMER) , Dr R.M.L Hospital.        A consecutive sample of all eyes with cataract reporting to the eye OPD of Dr.        R.M.L.Hospital and fulfilling the inclusion criteria, would be enrolled in the study        starting a date following ethics committee approval till March 2011 ,after a written        informed consent.|July 2012|July 7, 2012|December 7, 2010||No||No|February 24, 2011|https://clinicaltrials.gov/show/NCT01256918||112050|first time use of callibrated phacotip to measure phacotip penetration during vertical chop during phacoemulsification , hence no pre existing results to compare with.
NCT01257438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-08-002|FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis|Prospective, Multi-Center, Randomized, Concurrently-Controlled Study of the FLUENCY® PLUS Endovascular Stent Graft in the Treatment of In-stent Restenosis in the AV Access Venous Outflow Circuit (RESCUE)|RESCUE|C. R. Bard|Yes|Active, not recruiting|December 2010|October 2015|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|232|||Both|21 Years|N/A|No|||July 2013|November 5, 2013|December 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257438||112010|
NCT01257451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23150|Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents)||Novartis||Completed|December 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|431|||Both|70 Years|N/A|No|||December 2012|December 14, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01257451||112009|
NCT01258231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000P001639|Identification of Genomic Predictors of Adverse Events After Cardiac Surgery|Identification of Genomic Predictors of Adverse Events After Cardiac Surgery|CABGGenomics|Brigham and Women's Hospital|No|Recruiting|August 2000|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|DNA, buffy coat, plasma and serun|Both|20 Years|90 Years|No|Non-Probability Sample|Adult patients undergoing heart surgery|July 2015|July 14, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258231||111949|
NCT01258491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K115|Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects|Double-blind, Randomized, Placebo-controlled, Single-center, 2 Treatment, 3-way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects||Heidelberg University||Completed|May 2005|December 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2005|December 10, 2010|December 10, 2010||||No||https://clinicaltrials.gov/show/NCT01258491||111929|
NCT01258530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115096|A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers|A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers||GlaxoSmithKline|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 5, 2011|December 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258530||111926|
NCT01259167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|762/10|JOBA & Chronic LOw BAck Pain JOBA® & Chronic LOw BAck Pain JOBA® & Chronic LOw BAck Pain JOBA® & Chronic LOw BAck Pain|JOBA & Chronic LOw BAck Pain|JOBA-Loba|Catholic University of the Sacred Heart|Yes|Enrolling by invitation|January 2011|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control||3|Anticipated|50|||Both|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Subject attending the Physiatrist and Geriatric Outpatient Clinics of the Department of        Gerontology, Geriatric and Physiatrist Sciences of the University Hospital "Agostino        Gemelli" (Rome, Italy) with non-specific Low Back Pain, with or without sciatic        irradiation, from at least 3 months.|November 2010|December 13, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259167||111877|
NCT01258790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #: 2010-2689|Repetitive Transcranial Magnetic Stimulation to Reduce Tics|Using Transcranial Magnetic Stimulation to Reduce Tics||Children's Hospital Medical Center, Cincinnati|Yes|Completed|November 2010|March 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|10 Years|60 Years|No|||May 2014|May 30, 2014|December 10, 2010|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01258790||111906|
NCT01258803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06476|A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)|A Randomized, Evaluator-Blind, Crossover, Single Dose Study of the Bronchodilator Effect of Formoterol Fumarate in Combination With Mometasone Furoate Metered Dose Inhaler Delivered With and Without a Spacer Versus Placebo and Foradil® Aerolizer® in Children With Persistent Asthma (Protocol No. P06476)||Merck Sharp & Dohme Corp.|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|92|||Both|5 Years|11 Years|No|||October 2015|October 9, 2015|December 9, 2010|Yes|Yes||No|October 1, 2012|https://clinicaltrials.gov/show/NCT01258803||111905|
NCT01259102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1002|Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods|A Parallel Open-Label Study to Examine Plasma Concentrations of Buprenorphine Following Reapplication of 10-mg Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods in Healthy Subjects||Purdue Pharma LP|No|Completed|November 2000|March 2001|Actual|March 2001|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|December 10, 2010|Yes|Yes||No|January 13, 2011|https://clinicaltrials.gov/show/NCT01259102||111882|
NCT01259115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP1009|Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole|A Single Center, Randomized, Double-Blind, Crossover Study to Assess Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of BTDS and Ketoconazole, Used As a CYP3A4 Inhibitor, in Healthy Subjects||Purdue Pharma LP|No|Completed|October 2002|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|December 10, 2010|Yes|Yes||No|January 7, 2011|https://clinicaltrials.gov/show/NCT01259115||111881|
NCT01259128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC-SER120-ELD-2010-01|Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia|A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (≥ 75 Years Old) With Nocturia||Serenity Pharmaceuticals, Inc.|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|75 Years|95 Years|No|||April 2014|April 24, 2014|April 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259128||111880|
NCT01259414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC2011A|Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma|Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Active, not recruiting|February 2012|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|844|||Both|18 Years|70 Years|No|||November 2015|March 11, 2016|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259414||111858|
NCT01259700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025963|High Cardiovascular Risk Management and Salt Reduction in Rural Villages in China|China Rural Health Initiative: High Cardiovascular Risk Management and Salt Reduction in Rural Villages in China -- Two Parallel Large Cluster Randomized Controlled Trials||The George Institute for Global Health, China|Yes|Completed|December 2010|June 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|120|||Both|N/A|N/A|No|||February 2016|February 15, 2016|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259700||111836|
NCT01259713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-EU-131-0247|Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)|AmBiGuard|Gilead Sciences|Yes|Completed|April 2011|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|355|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|December 10, 2010|Yes|Yes||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01259713||111835|
NCT01259973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-065|Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers|Phase I Clinical Trial. Study of the Impact of Pharmacogenetic Markers in Predicting the Appearance of Extrapyramidal Symptomatology After the Treatment With Typical vs. Atypical Antipsychotics, in Healthy Volunteers|APSEP|Hospital Clinic of Barcelona|No|Enrolling by invitation|February 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2011|April 15, 2011|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259973||111815|
NCT01259986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB6452|Treatment of Vitiligo With Low-energy Visible Light Laser|Treatment of Recalcitrant Forms of Vitiligo With a Low-energy 635 nm Visible Light Laser||Henry Ford Health System|Yes|Terminated|October 2010|September 2012|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|December 14, 2010||No|3 patients enrolled, no meaningful repigmentation observed. Recruitment halted.|No||https://clinicaltrials.gov/show/NCT01259986||111814|
NCT01260220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-09-489|Randomized Trial of Segmental Versus Circumferential Antral Ablation in Paroxysmal Atrial Fibrillation|Randomized Trial of Segmental Versus Circumferential Antral Ablation in Paroxysmal Atrial Fibrillation|CABLE|Lawson Health Research Institute|Yes|Recruiting|November 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2010|December 13, 2010|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01260220||111796|
NCT01228097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK085615|Neural Response to Eating and Weight Status|Changes in Neural Response to Eating After Bariatric Surgery: MRI Results|NEWS|University of Pennsylvania|Yes|Completed|April 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|75|Samples With DNA|Whole blood will be drawn for safety labs. Blood plasma will be archived for analysis.|Female|18 Years|N/A|No|Non-Probability Sample|Women with extreme obesity (i.e., BMI 40 kg/m2) or moderate obesity (BMI 35.0-39.9 kg/m2)        plus significant weight-related comorbidities.|December 2011|March 9, 2015|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01228097||114249|
NCT01228110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06111972|Corticosteroids in Community Acquired Pneumonea|Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings||Cairo University|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||July 2009|October 25, 2010|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228110||114248|
NCT01228396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIMS04|AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis|A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis||Daval International Limited|Yes|Active, not recruiting|May 2009|March 2012|Anticipated|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2011|August 16, 2011|September 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01228396||114226|
NCT01228409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA 10-0093|Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?|An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability||Frankel, Amylynne, M.D.|Yes|Recruiting|October 2010|||December 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||June 2011|June 21, 2011|October 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228409||114225|
NCT01228669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7415-3813|Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-0000-2021 Administered Intravenously and Subcutaneously to Healthy Male Subjects and Haemophilia Subjects|Explorer 1|Novo Nordisk A/S|No|Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|52|||Male|18 Years|65 Years|No|||August 2014|August 25, 2014|October 25, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01228669||114205|
NCT01229267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-001|A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM4)|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)||Merck Sharp & Dohme Corp.|Yes|Completed|November 2010|December 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1257|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01229267||114159|
NCT01224977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarker sputum airway study4|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.|BioSput-Air|Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2011|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01224977||114486|
NCT01224990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s51240|Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Gastro-intestinal Tumors|Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Gastro-intestinal Tumors.|s51240|Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|November 2010|December 2015|Anticipated|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|N/A|N/A|No|||April 2015|April 9, 2015|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01224990||114485|
NCT01261026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEJ-060866|Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?|Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?|UNIFESP|Federal University of São Paulo||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Female|15 Years|40 Years||Non-Probability Sample|ectopic pregnancy abnormal intrauterine pregnancy normal intrauterine pregnancy|December 2007|December 15, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261026||111734|
NCT01258218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-10-027-EU-LV|Accent MRI Pacemaker and Tendril MRI Lead New Technology Assessment|Accent MRI Pacemaker and Tendril MRI Lead New Technology Assessment||St. Jude Medical|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with approved Class I or Class II indication per ESC guidelines for implantation        of a dual chamber pacemaker or single chamber pacemaker.|June 2012|June 5, 2012|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258218||111950|
NCT01258842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-SBUS-6-FON-02|Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults|Double-blind, Randomized, Placebo-controlled Trial of the Effects of Prophylactic Bifidobacterium Lactis HN019 Supplementation on the Incidence of Influenza Infection in Healthy Adults||Fonterra Research Centre|No|Recruiting|December 2010|May 2011|Anticipated|May 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|426|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2010|December 10, 2010|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258842||111902|
NCT01259154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU123|Combined RF Surgery of the Tongue Base and Uvulopalatopharyngoplasty (UPPP) for Obstructive Sleep Apnea|Combined Bipolar Radiofrequency Surgery of the Tongue Base and Uvulopalatopharyngoplasty for Obstructive Sleep Apnea||Charles University, Czech Republic|Yes|Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|||||Both|18 Years|80 Years||Probability Sample|Patients with obstructive sleep apnea not treated by CPAP|December 2010|December 13, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259154||111878|
NCT01259180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUIMS-pp-10|Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis|Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis : A Preliminary Study||East West Neo Medical Center|No|Not yet recruiting|December 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Female|16 Years|55 Years|No|||October 2010|December 13, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259180||111876|
NCT01258816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP4055-109|The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)|A Phase I Study of the Human Pharmacokinetics and Cardiac Safety of Elacytarabine||Clavis Pharma|No|Completed|October 2010|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|November 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258816||111904|
NCT01258829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0803/86|British Randomised Controlled Trial of Atrioventricular (AV) and Interventricular (VV) Optimisation (BRAVO)|British Randomised Controlled Trial of AV and VV Optimisation (BRAVO): Randomised Clinical Trial of the Effects of Non-invasive Haemodynamic Optimisation of Cardiac Resynchronisation Devices on Exercise Capacity|BRAVO|Imperial College London|Yes|Completed|December 2010|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||May 2014|June 29, 2015|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258829||111903|
NCT01259141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP201011|The Optimization of Mycoplasm Pneumonia Antibiotic Therapy|The Optimization of Mycoplasm Pneumonia Antibiotic Therapy: Multi-centre, Prospective, Randomized Controlled Study||Capital Medical University|Yes|Completed|October 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|60 Years|No|||July 2015|July 25, 2015|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259141||111879|
NCT01259427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-340|Reducing Internalized Stigma in People With Serious Mental Illness|Reducing Internalized Stigma In People With Serious Mental Illness|ESS|VA Office of Research and Development|No|Completed|October 2011|September 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|80 Years|No|||February 2016|February 5, 2016|December 10, 2010||No||No|October 28, 2015|https://clinicaltrials.gov/show/NCT01259427||111857|
NCT01259440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPO 10-101|Using Telemedicine to Improve Veteran Sleep Apnea Care|Using Telemedicine to Improve Veteran Sleep Apnea Care||VA Office of Research and Development|No|Completed|August 2011|May 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|23|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|December 10, 2010||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01259440||111856|
NCT01259726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP20621-200|Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI||Shire|Yes|Completed|May 2011|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|173|||Both|18 Years|N/A|No|||March 2014|February 11, 2015|December 9, 2010|Yes|Yes||No|January 20, 2015|https://clinicaltrials.gov/show/NCT01259726||111834|
NCT01259999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Huddinge Municipality and SLL|Energy Dense Formula to People Living in Old Peoples Home|Distribution of an Energy Rich Formula at Medication Rounds to Individuals Living in Old Peoples Home - Effects on Energy Intake Compared to Standard Nutritional Treatment||Karolinska University Hospital|No|Completed|April 2010|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|65 Years|N/A|No|||June 2011|June 30, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01259999||111813|
NCT01260792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-APN-02|Children and Parents With ADHD and Related Disorders|Validation and Norms for Attention Deficit/Hyperactivity Disorder Scales in Children and Adults. Description of Associated Factors.|ChiP-ARD|Centre Hospitalier Universitaire de Nice|No|Completed|February 2010|December 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|2600|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Two non-independant study groups: children aged 5 to 18, and at least one of their parents|September 2009|March 23, 2012|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260792||111752|
NCT01228422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT2ABLA0908|Pharmacokinetics and Pharmacodynamics of Interferon Alpha 2A|Study of Pharmacokinetics and Pharmacodynamics of Alpha Interferon-2A of Blausiegel Trade and Industry the Compared the Product Roferon A, of Laboratory of Roche|interferon|L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|No|Completed|March 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|March 2009|October 25, 2010|October 21, 2008||No||No||https://clinicaltrials.gov/show/NCT01228422||114224|
NCT01228682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-101|Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice|A Multi-Centre, Multi-National, Observational Post-Authorisation Safety Study to Document the Drug Utilisation of Samsca and to Collect Information on the Safety of Samsca When Used in Routine Medical Practice||Otsuka Frankfurt Research Institute GmbH|No|Active, not recruiting|October 2010|April 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are treated with Samsca|April 2013|April 30, 2013|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228682||114204|
NCT01228123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONVINT|Clinical Trial Comparing Continuous Versus Intermittent Hemodialysis in ICU Patients|Prospective Randomised Clinical Trial of the Effect of Continuous Versus Intermittent Renal Replacement Therapy on the Mortality and Outcome of Acute Renal Failure in ICU Patients|CONVINT|Charite University, Berlin, Germany|No|Completed|January 2002|January 2008|Actual|October 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|252|||Both|18 Years|N/A|No|||July 2010|May 23, 2011|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228123||114247|
NCT01228136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCMPA02|Tranexamic Acid and Pediatric Adenotonsillectomy|Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children||Irmandade Santa Casa de Misericórdia de Porto Alegre|No|Completed|January 2010|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|95|||Both|4 Years|12 Years|No|||October 2010|December 21, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01228136||114246|
NCT01228981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/SAU-OSM/103226/2008|Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy|Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy||Association for Innovation and Biomedical Research on Light and Image|No|Completed|March 2010|March 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Type-2 diabetic subjects in the early stages of non-proliferative retinopathy (level 30 to        35 ETDRS) included in the clinical trial "Validation of a predictive model to estimate the        risk of conversion to clinically significant macular edema and/or vision loss in mild        nonproliferative diabetic retinopathy in diabetes type 2" (Protocol number:        PTDC/SAU-OSM/72635/2006; ongoing at AIBILI Clinical Trial Center).|April 2014|April 4, 2014|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01228981||114181|
NCT01228708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Active Implementation-FEAA|Effects of an Active Implementation of a Guideline for Chronic Obstructive Pulmonary Disease|Effects of an Active Implementation of a Chronic Disease Management Programme for Patients With Chronic Obstructive Pulmonary Disease (COPD)||University of Aarhus|Yes|Completed|August 2009|November 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|3021|||Both|35 Years|N/A|No|||March 2012|March 27, 2012|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228708||114202|
NCT01228994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1632009|Baclofen for Smoking Cessation in a Non-Psychiatric Population|Testing the GABAergic Hypothesis of Nicotine Dependence: a Randomized Clinical Trial of Baclofen|Baclofen|Centre for Addiction and Mental Health|No|Terminated|October 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 11, 2013|October 25, 2010||No|The study was terminated because of difficulties recruiting subjects.|No||https://clinicaltrials.gov/show/NCT01228994||114180|
NCT01257711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B/08/333|A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer|A Prospective Randomised Study Comparing Billroth II With Roux-en-Y Reconstruction After Radical Distal Subtotal Gastrectomy for Gastric Cancer|SCAR|National Healthcare Group, Singapore|No|Recruiting|October 2008|December 2016|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|160|||Both|21 Years|80 Years|No|||April 2012|April 13, 2012|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257711||111989|
NCT01257724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS/FHS REB 10-268|Effects of an Evidence Service on Community-based AIDS Service Organizations' Use of Research Evidence|Effects of an Evidence Service on Community-based AIDS Service Organizations' Use of Research Evidence: A Protocol for a Randomized Controlled Trial||Ontario HIV Treatment Network|No|Active, not recruiting|March 2011|January 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Actual|58|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2011|December 14, 2011|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257724||111988|
NCT01257152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Screening MR for Recurred BrCa|Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy|Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy||Seoul National University Hospital|No|Active, not recruiting|December 2010|December 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|750|||Female|20 Years|50 Years|No|Non-Probability Sample|Breast cancer patients undergoing conservation surgery and radiation therapy|March 2013|March 11, 2013|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01257152||112032|
NCT01257165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60R020.05|Driving Simulator Performance After Intake of Zopiclone Sleeping Pills|Driving Simulator Performance Related to Serum Concentrations of the Benzodiazepine-like Hypnotic Zopiclone||St. Olavs Hospital|No|Withdrawn|August 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|0|||Male|25 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01257165||112031|
NCT01257984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14701|Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function|A Multicenter, Open-label, Randomized, Controlled, Two-arm Study to Assess Compliance With Daily Tablet Intake of Women on Treatment With the Oral Contraceptive SH T00186D/BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function Over 12 Months||Bayer|No|Completed|December 2010|September 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|508|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 27, 2014|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257984||111968|
NCT01257997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2010p001900|Quantification of Human Adipogenesis|Quantification of Human Adipogenesis||Brigham and Women's Hospital|No|Active, not recruiting|December 2010|February 2016|Anticipated|February 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Fat biopsy. Oral mucosal smear. White blood cells.|Both|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers. Aged 18-49 years. Free of significant chronic medical illness. Free of        illicit substance abuse.|June 2014|June 25, 2014|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01257997||111967|
NCT01258855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02498|Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study||National Cancer Institute (NCI)|No|Active, not recruiting|January 2011|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|105|||Both|17 Years|N/A|No|||February 2016|February 29, 2016|December 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01258855||111901|
NCT01258868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110041|Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas|Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas||National Institutes of Health Clinical Center (CC)||Suspended|December 2010|November 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|99 Years|No|||December 2015|January 1, 2016|December 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01258868||111900|
NCT01226641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InitiativePS-TELESAS|Usefulness of a Telemedicine System for OSA Patients Follow-up With High Cardiovascular Risk|Usefulness of a Telemedicine System for OSA Patients Follow-up With High Cardiovascular Risk|TELESAS|Initiative Pour la Sante|Yes|Terminated|July 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|85 Years|No|||January 2013|January 16, 2013|October 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01226641||114360|
NCT01259453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0005011791|Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules|Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules|HVS|Yale University|Yes|Completed|May 2003|August 2006|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|595|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 13, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01259453||111855|
NCT01259739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flavanols - Exercise|Cocoa Flavanols and Exercise Capacity|The Impact of Dietary Cocoa Flavanols on Cardio-pulmonary Exercise Capacity in Human.||Heinrich-Heine University, Duesseldorf|No|Completed|November 2010|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|13|||Male|20 Years|36 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259739||111833|
NCT01260012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/794-1|Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis|Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver.||Addis Ababa University|No|Recruiting|January 2010|December 2015|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|414|||Both|5 Years|60 Years|No|||September 2010|December 14, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260012||111812|
NCT01260233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-476|Effect of a Perioperative Smoking Cessation Program on Smoking Cessation/Reduction and Perioperative Complications|The Effect of a Perioperative Smoking Cessation Program on Rates of Smoking Cessation/Reduction and Perioperative Complications: a Randomized Clinical Trial.||Lawson Health Research Institute|No|Completed|October 2010|August 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260233||111795|
NCT01260532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98049|The Association of Costimulatory Molecules and PPAR-polymorphisms With Autoimmune Thyroid Disease in Taiwan|The Association of Costimulatory Molecules and PPAR-polymorphisms With Autoimmune Thyroid Disease in Taiwan||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|July 2009|June 2019|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|20 Years|N/A|No|Probability Sample|Autoimmune thyroid patients|December 2010|December 13, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260532||111772|
NCT01261104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOBCEP104/2010|Relationship Between Hearing Thresholds, Handicap and Time for Treatment-seeking|Relationship Between Hearing Thresholds, Handicap and Time for Treatment-seeking in a Public Hearing Healthcare Service||University of Sao Paulo|Yes|Completed|April 2010|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|18 Years|N/A||Non-Probability Sample|Hearing impaired adults and elderly attended at a public hearing healthcare service|December 2010|December 15, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261104||111728|
NCT01228565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2009-01|Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®|Placebo Controlled Randomized Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®|GORTEC 2009-01|Groupe Oncologie Radiotherapie Tete et Cou|No|Completed|August 2010|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|76|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228565||114213|
NCT01227876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREUNI0710|Clinical Efficacy of the Drug Ster® Compared With Predfort® in Control of Postoperative Inflammation in Cataract Surgery|Assessment of Clinical Efficacy of 1% Prednisolone Acetate (Ster ®), Produced by união química, Compared to 1% Prednisolone Acetate (Pred ® Fort), Produced by Allergan, in the Control of Postoperative Inflammation in Cataract Surgery.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|January 2011|||February 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||October 2010|October 22, 2010|October 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01227876||114266|
NCT01228149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35131; EUDRA CT 2010-019975-30|COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy|Investigation of the Efficacy and Safety of Preoperative IOP Reduction With Preservative-free COSOPT-S® (Dorzolamide/Timolol, MSD) Eye Drops Versus Oral Acetazolamide and Dexamethasone Eye Drops||Johannes Gutenberg University Mainz|Yes|Completed|August 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01228149||114245|
NCT01228435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-134|IPI-504 in NSCLC Patients With ALK Translocations|A Phase II Study of IPI-204, A Novel Hsp90 Inhibitor in NSCLC Patients With ALK Translocations||Massachusetts General Hospital|Yes|Terminated|October 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|October 25, 2010|Yes|Yes|slow accrual|No|May 28, 2013|https://clinicaltrials.gov/show/NCT01228435||114223|We were unable to accrue due to competing studies.
NCT01229293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF20050133-2|Gait Analysis and Neuromuscular Function After Primary Total Hip Replacement|The Effect of Implant Design on Postoperative Mechanical Muscle Function Recovery and Gait in Hip Replacement Patients: A Randomized Clinical Trail|RTHA and THA|University of Southern Denmark|Yes|Completed|February 2007|November 2011|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|40 Years|65 Years|No|||September 2012|September 21, 2012|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01229293||114157|
NCT01229306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-002|Repeat Ablation Procedure in Patients With Relapse of Atrial Fibrillation|Repeat Ablation Procedure in Patients With Relapse of Paroxysmal Atrial Fibrillation Using Reisolation of Pulmonary Vein Versus Reisolation of Pulmonary Vein With Additional Anterior Line||Deutsches Herzzentrum Muenchen|No|Recruiting|July 2010|January 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|80 Years|No|||May 2013|May 2, 2013|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229306||114156|
NCT01225029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 07-1069|Fluid Management in Transient Tachypnea of the Newborn|A Randomized Controlled Trial of Fluid Management in Transient Tachypnea of the Newborn||Icahn School of Medicine at Mount Sinai|Yes|Completed|June 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|N/A|24 Hours|No|||September 2013|September 24, 2013|October 18, 2010||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01225029||114482|As a small, single center study, our results may not be fully generalizable to the TTN patient population in all hospital types on a national level.
NCT01257490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA141663|Integrated Smoking Cessation Treatment for Low Income Community Corrections|Integrated Smoking Cessation Treatment for Low Income Community Corrections||University of Alabama at Birmingham|Yes|Completed|October 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|689|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|October 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257490||112006|
NCT01257971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CHR-CRE-2010/1|Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors|Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) Reductase Inhibitors in Croatia||AstraZeneca|No|Completed|January 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1868|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated by specialist|March 2012|March 19, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01257971||111969|
NCT01258244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-118|Arizona Prehospital CPR Quality Improvement Project|Arizona Prehospital CPR Quality Improvement Project||Maricopa Integrated Health System|No|Recruiting|May 2010|June 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|450|||Both|24 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Emergency medical services providers in 4 different Arizona cities|November 2015|November 17, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258244||111948|
NCT01250613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-037|Genomic Study of Congenital Malformation|Genomic Study of Congenital Malformation||China Medical University Hospital|Yes|Recruiting|June 2010|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Anticipated|900|||Both|N/A|N/A|No|Non-Probability Sample|Genomic aberrations in patients diagnosed as congenital malformation with unknown etiology|November 2010|November 29, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01250613||112534|
NCT01258881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201004066R|Retrospective Study of Ovarian Cancer Patients With Brain Metastasis|Retrospective Study of Ovarian Cancer Patients With Brain Metastasis||National Taiwan University Hospital|No|Recruiting|April 2010|December 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|70|||Female|25 Years|80 Years|No|Probability Sample|ovarian cancer patients with brain metastasis|December 2010|December 10, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258881||111899|
NCT01259466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001006181|Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers|Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers||Yale University|No|Completed|July 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||August 2015|August 27, 2015|November 11, 2010|Yes|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT01259466||111854|
NCT01259479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110047|Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors|A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 2010|May 2015|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|3 Years|25 Years|No|||May 2015|May 30, 2015|December 11, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01259479||111853|
NCT01259752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P080603|Compression Stockings in Ankle Sprain|Prospective Randomized Study of Compression Stockings in Ankle Sprain in Adults|CASED|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|55 Years|No|||June 2010|July 30, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01259752||111832|
NCT01259765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-009|Llama Antibody, Rotavirus Diarrhoea, Children|Safety and Tolerability of a Novel Llama-derived Anti-rotavirus VHH Fragment in Human Volunteers (Part-I), and Its Effect on Severity and Duration of Rotavirus Diarrhoea in Children (Part II). (This Registration Only Covers Part II)||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|January 2006|November 2009|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|176|||Male|6 Months|24 Months|No|||February 2006|August 8, 2011|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259765||111831|
NCT01260025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009L01132|Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor|Dose Escalation Study of Tolerability and Pharmacokinetics of PEDylated Recombinant Human Endostatin(M2ES)in the Treatment of Advanced Solid Tumor||Sun Yat-sen University|Yes|Completed|September 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||February 2012|February 14, 2012|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01260025||111811|
NCT01260246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-533|Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes|Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes.||Lawson Health Research Institute|No|Terminated|December 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|December 13, 2010||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01260246||111794|
NCT01260259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTR-3953179|Seattle Cardiorenal Remote Ischemic Preconditioning Trial|Effect of Remote Ischemic Preconditioning in Children Undergoing Cardiac Surgery|SCRIPT|Seattle Children's Hospital|Yes|Completed|December 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Both|N/A|18 Years|No|||September 2013|September 16, 2013|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01260259||111793|
NCT01260545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-PT015|Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies|Phase I Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies||XBiotech, Inc.||Completed|April 2011|September 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|December 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01260545||111771|
NCT01260805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3341001|A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.|A Phase I, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Bioequivalence Of Ethinylestradiol + Gestodene - Harmonet 0,02mg + 0,075mg (Laboratórios Pfizer Ltda.) In The Sugar Coated Tablets Form, Versus Femiane® 0,02mg + 0,075mg (Schering Do Brasil Química E Farmacêutica Ltda.), In The Sugar Coated Tablets Form, Under Fasted Conditions In Female And Healthy Volunteers.||Pfizer|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|32|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 18, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260805||111751|
NCT01260818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZTCM-201001|Topical Application of Tranexamic Acid Reduces Postoperative Blood Loss in Total Hip Arthroplasty|Prospective Randomized Trial Comparing Topical Tranexamic Acid Plus Standard Of Care Versus Standard Of Care For The Reduction Of Blood Loss Following Primary Total Hip Arthroplasty Surgery||The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine|Yes|Recruiting|December 2010|||December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||December 2010|November 30, 2011|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01260818||111750|
NCT01228864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 153209|Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag|Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag||Roswell Park Cancer Institute|Yes|Recruiting|September 2009|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228864||114190|
NCT01229124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B1|RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia|SCOR in Targeted Therapies for Infant Leukemias Project 4: MicroRNA Sequencing of Infant AML||Children's Oncology Group|No|Active, not recruiting|October 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|Tissue|Both|N/A|1 Year|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia.|May 2015|May 11, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229124||114170|
NCT01228201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTNU - project no 46028000|Physical Exercise and Coronary Artery Plaque Composition|Physical Exercise and Coronary Artery Plaque Composition||Trondheim University Hospital|No|Completed|November 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||April 2013|April 10, 2013|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01228201||114241|
NCT01228448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-241|In-Room PET in Proton Radiation Therapy|Pilot Study of In-Room PET in Proton Radiation Therapy||Massachusetts General Hospital|Yes|Recruiting|October 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01228448||114222|
NCT01228695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2421CTIL|Prospective Study of the Impact of Systemic Corticosteroid Use on Measures of Sleep Disordered Breathing|||Rambam Health Care Campus||Completed|January 2007|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1||20|||Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled for long-term treatment with oral prednisone (> 10 mg/d for 3 months or        more)|February 2010|October 25, 2010|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01228695||114203|
NCT01228968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRImethods060229|Toward an Automated Method of Abdominal Fat Segmentation of MR Images|Toward an Automated Method of Abdominal Fat Segmentation of MR Images||Washington University School of Medicine|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|9|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will have a wide range of body mass index and other physical characteristics.|May 2011|May 11, 2011|October 25, 2010||No||No|April 11, 2011|https://clinicaltrials.gov/show/NCT01228968||114182|
NCT01229020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB010|Distribution of Regional Lung Function by Vibration Response Imaging|Distribution of Regional Lung Function, as Determined by the Vibration Response Image Generated by the VRI-2000 System as Compared With Standard Radio-nuclear Method||Deep Breeze|No|Completed|February 2004|January 2006|Actual|January 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|85 Years|No|Probability Sample|Males and females who were diagnosed with moderate-to-severe COPD by lung function studies        and clinical evaluation|October 2010|October 26, 2010|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229020||114178|
NCT01228747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01159|A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)|A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged ≥16 Years, With Generalized Tonic-clonic (GTC) Seizures||UCB Pharma|No|Completed|October 2010|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|361|||Both|16 Years|N/A|No|||May 2015|May 29, 2015|October 22, 2010|No|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT01228747||114199|
NCT01228760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASG-5ME-10-1|A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer|A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)||Astellas Pharma Inc|No|Completed|October 2010|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Actual|46|||Male|18 Years|N/A|No|||June 2013|June 6, 2013|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01228760||114198|
NCT01229033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-EP-001|Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF|Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF - ATTAC CFAE Trial|ATTAC CFAE|Deutsches Herzzentrum Muenchen|No|Recruiting|January 2010|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|80 Years|No|||October 2010|October 26, 2010|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229033||114177|
NCT01229319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0933|Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses|An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms||Frankel, Amylynne, M.D.|Yes|Recruiting|October 2010|August 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229319||114155|
NCT01257750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-09-063|Treatment of Corneal Neovascularization With Topical Pazopanib|Safety and Efficacy of Topical Pazopanib in Treatment of Corneal Neovascularization||Massachusetts Eye and Ear Infirmary|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|November 22, 2010|Yes|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT01257750||111986|
NCT01257737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-011|To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)|Long Term Use of HPN-100 in Urea Cycle Disorders||Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Active, not recruiting|October 2010|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|1 Year|N/A|No|||December 2015|December 2, 2015|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01257737||111987|
NCT01258543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAK-OST-1|Osteopathic Evaluation on Patients With Non-specific Back Pain: An Inter-examiner Reliability Study|Osteopathic Evaluation on Patients With Non-specific Back Pain: An Observational Inter-examiner Reliability Study||Kirnan, Jaime|Yes|Completed|November 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|60 Years|No|Non-Probability Sample|Community Sample|June 2011|June 9, 2011|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258543||111925|
NCT01258270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-10-01A|Efficacy and Patient Satisfaction With AQUACEL® Ag Surgical Dressing Compared to Standard Surgical Dressing|Efficacy and Patient Satisfaction With AQUACEL® Ag Surgical Dressing Compared to Standard Surgical Dressing. A Prospective, Randomized Study in Primary Total Joint Arthroplasty.||OrthoCarolina Research Institute, Inc.|Yes|Completed|December 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|90 Years|No|||January 2012|June 6, 2013|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01258270||111946|
NCT01258556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|919|The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis|||Lawson Health Research Institute||Completed|June 2010|||July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|80 Years|No|||December 2010|December 10, 2010|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01258556||111924|
NCT01259791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-450|Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design|Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design||Lawson Health Research Institute|No|Completed|September 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259791||111829|
NCT01259804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOP-I|Study of Tolerance to Oral Peanut|Efficacy and Safety of High-dose Peanut Oral Immunotherapy With Factors Predicting Outcome|STOP|Cambridge University Hospitals NHS Foundation Trust|No|Completed|January 2008|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|7 Years|17 Years|No|||January 2015|January 13, 2015|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01259804||111828|
NCT01226901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-4827-005|A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)|A Phase I Study of MK-4827 in Patients With Solid Tumor||Merck Sharp & Dohme Corp.|Yes|Terminated|November 2010|November 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|October 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01226901||114340|
NCT01259193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRFB-021|Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC|Phase II Study of Sorafenib and Zoledronic Acid in Advanced HCC||Fudan University|No|Recruiting|October 2010|July 2012|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||October 2010|April 13, 2011|December 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01259193||111875|
NCT01227200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emc100061ctil|The Effect of Adding Pain Relievers to Local Anesthesia Before Preforming Drainage in Peritonsillar Abscess|The Efficiency of DYPIRON and TRAMADOL in Addition to Local Anesthesia Prior to Incision and Drainage Procedure in Peritonsillar Abscess|pta|HaEmek Medical Center, Israel|No|Not yet recruiting|November 2011|December 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|65 Years|No|||October 2010|October 22, 2010|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01227200||114318|
NCT01227499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|huashan001|Differential Diagnosis of STA-PSV in Thyrotoxicosis|Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease||Huashan Hospital|Yes|Completed|June 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|169|||Both|15 Years|85 Years|No|Probability Sample|primary care clinic|May 2014|May 2, 2014|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01227499||114295|
NCT01227512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08-275|Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia|Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia|SALACIA|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Terminated|October 2010|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|October 22, 2010|Yes|Yes|Recruitment challenges and results of interim futility analysis, which showed less than likely    to achieve primary endpoint goal-length of hospital stay.|No|May 29, 2014|https://clinicaltrials.gov/show/NCT01227512||114294|
NCT01228045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1/CDDP/Her|A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer|A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer.||National University Hospital, Singapore|Yes|Active, not recruiting|February 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||October 2014|October 13, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01228045||114253|
NCT01260272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects|A Randomized, Unblinded, Single Research Site, Comparator Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects||Louisville Metabolic and Atherosclerosis Research Center|No|Completed|December 2010|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|49|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 3, 2014|December 13, 2010||No||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01260272||111792|This was a single research site pilot study, which would benefit from a larger study, or at least, a similar confirmatory study.
NCT01228305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090497|Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass|Does Preoperative Acetaminophen Reduce Biochemical Markers of Oxidative Stress From Cardiopulmonary Bypass?||Vanderbilt University|Yes|Recruiting|July 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|N/A|17 Years|No|||April 2012|April 11, 2012|October 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228305||114233|
NCT01228552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79,629|The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine|A Randomized Double Blind, Placebo Controlled Phase III Trial to Determine the Efficacy and Safety of Topical Intra-oral Ketoprofen for the Treatment of Acute Migraine||Behar, Caren, M.D.|Yes|Not yet recruiting|December 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2010|June 4, 2011|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01228552||114214|
NCT01260831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000018562|Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)|Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH): a Cluster Randomized Trial of the Bedside Paediatric Early Warning System|EPOCH|The Hospital for Sick Children|Yes|Recruiting|January 2011|October 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100000|||Both|N/A|18 Years|No|||December 2013|December 23, 2013|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01260831||111749|
NCT01260844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-160|Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.|An Open-Label Study to Evaluate the Effect of a Single Dose of Briakinumab on the Pharmacokinetics of Single Doses of Caffeine, Tolbutamide, Omeprazole, Metroprolol, and Midazolam in Subjects With Moderate to Severe Psoriasis||Abbott|No|Withdrawn|April 2011|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|55 Years|No|||May 2011|October 19, 2011|December 14, 2010|Yes|Yes|Study stopped|No||https://clinicaltrials.gov/show/NCT01260844||111748|
NCT01227902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113905|Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures|An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures|IR|GlaxoSmithKline|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|203|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|July 16, 2010||No||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01227902||114264|
NCT01228188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW1127/10|Inverted ILM Repositioning as Treatment for Full Thickness Macular Holes|Surgical Inverted ILM Repositioning as Autologous Dressing for Idiopathic Full Thickness Macular Holes Treatment||Military Institute of Medicine, Poland|Yes|Recruiting|August 2010|August 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|85 Years|No|||September 2010|October 25, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01228188||114242|
NCT01228461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091550|Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients|||Vanderbilt University|No|Recruiting|February 2010|February 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|Samples Without DNA|Serum samples for IL-1ra and CRP|Both|15 Years|39 Years|No|Non-Probability Sample|Adolescents and young adult survivors of Hodgkin Lymphoma|October 2010|November 11, 2010|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01228461||114221|
NCT01229046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026692|Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants|Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants||Duke University|No|Withdrawn|September 2010|||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|N/A|90 Days|No|||November 2012|November 12, 2012|October 14, 2010|No|Yes|No enrollment occured. Subjects will be enrolled under a new protocol.|No||https://clinicaltrials.gov/show/NCT01229046||114176|
NCT01229345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32W3|Effect of Exercise With or Without Breakfast, on Metabolism, Appetite and Cognition|The Interactive Effect of Breakfast Consumption and Exercise on Metabolism, Appetite and Cognitive Function||Northumbria University||Completed|October 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01229345||114153|
NCT01229358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001149/1|Clinical Trial of a Silver Eluting Dressing System|Prospective, Randomized Clinical Trial of a Silver Eluting Dressing System for Prevention of Lower Extremity Revascularization Wound Complications|SILVER|Brigham and Women's Hospital|No|Completed|October 2010|December 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01229358||114152|
NCT01225068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00036897|Effect of Milnacipran in Chronic Neuropathic Low Back Pain|An Exploratory Randomized Placebo Controlled Trial of Milnacipran in Patients With Chronic Neuropathic Low Back Pain||Northwestern University|No|Completed|October 2010|April 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||December 2013|December 5, 2013|October 13, 2010|Yes|Yes||No|April 17, 2013|https://clinicaltrials.gov/show/NCT01225068||114479|
NCT01258036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-37|Mother Daughter Bone Microarchitecture|Rôle de la Microarchitecture Osseuse Dans le déterminisme héréditaire de la fragilité Osseuse|MODAM|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|March 2010|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1040|Samples With DNA|serum plasma urine whole blood for DNA extraction|Female|20 Years|N/A|No|Probability Sample|1. Fractured mothers and their daughters (case group)          2. Non-fractured mothers and their daughters (control group)|January 2012|September 27, 2012|March 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01258036||111964|
NCT01258010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JFH2011-001|Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery|Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|85 Years|No|||April 2014|April 30, 2014|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01258010||111966|
NCT01258023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022871-78|Seasonal Flu Vaccine in Adult Transplant Recipients|A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine Including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers|Fluad Tx|HepNet Study House, German Liverfoundation|Yes|Completed|November 2010|April 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|122|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01258023||111965|
NCT01267513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytone/Lifebeam Monitor|Ambulatory Measurements of Physiological Parameters|Noninvasive Ambulatory Measurements of Physiological Parameters Using a DLS-based Sensor|LIFEBEAM|Meir Medical Center|Yes|Recruiting|April 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal volunteers will be studied. Individuals undergoing routine cardiac stress testing        will be studied. Stable patients admitted to the pulmanary ward who are being monitored        routinely for oxygen saturation and pulse will be studied.|March 2012|March 16, 2012|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267513||111236|
NCT01272323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP005A|Cat-PAD Follow on Study|An Optional 1 Year Follow up Study to Evaluate the Continued Efficacy of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber||Circassia Limited|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|170|||Both|18 Years|65 Years|No|Non-Probability Sample|Subject previously randomised in study CP005 and completed all dosing visits and the PTC|May 2011|May 19, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272323||110866|
NCT01272557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SoraDox|Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial|Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial|SoraDox|Martin-Luther-Universität Halle-Wittenberg|Yes|Active, not recruiting|December 2010|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272557||110848|
NCT01268098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR-C10-007|Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)|A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism||Shire|No|Completed|January 2011|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|85 Years|No|||March 2015|November 10, 2015|December 28, 2010|Yes|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01268098||111191|
NCT01273116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nr. 60-61900-98-272, NPO|In Hospital Care and Welfare Standard|Towards an In Hospital CARE AND WELFARE STANDARD for Frail Elderly|CWSInHosp|Radboud University|No|Completed|January 2011|January 2013|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|404|||Both|70 Years|N/A|No|||January 2013|January 21, 2013|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01273116||110805|
NCT01268631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0368-10-TLV|Mechanism-based Choice of Therapy: Can Treatments Success in Fibromyalgia Patients be Coupled to Psychophysical Pain Modulation Profile?|Mechanism-based Choice of Therapy: Can Treatments Success in Fibromyalgia Patients be Coupled to Psychophysical Pain Modulation Profile?|MTF|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||December 2010|December 30, 2010|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268631||111150|
NCT01268891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13484A|Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in Korea||H. Lundbeck A/S|No|Completed|January 2011|||June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|30 Years|N/A|No|||October 2013|October 7, 2013|December 30, 2010||No||No|June 28, 2013|https://clinicaltrials.gov/show/NCT01268891||111130|
NCT01273909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFM001|Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment|Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment||The National Institute of Lymphology|No|Enrolling by invitation|July 2010|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects who are patients of the "Dr Marga" Practice or the Center for Restorative        Breast Surgery that consent to participate in this research study will be selected. There        is no age, ethnicity or gender requirement.|June 2014|June 4, 2014|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273909||110744|
NCT01274455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0401401|Gene Therapy of Pancreatic Ductal Adenocarcinoma|PILOT STUDY OF GENE THERAPY FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA WITH INTRATUMOURAL INJECTION OF JetPEI/DNA COMPLEXES WITH ANTITUMOURAL EFFECT AND CHEMOSENSITIZING ACTIVITY FOR GEMCITABINE|TherGAP|University Hospital, Toulouse|No|Completed|December 2010|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01274455||110702|
NCT01274468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14781|Tumor Markers in Lung Cancer|Tumor Markers in Lung Cancer||University of Oklahoma|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Lung biopsy|Both|45 Years|N/A|No|Non-Probability Sample|Ten patients with an expected age >45 years|August 2012|August 8, 2012|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01274468||110701|
NCT01274481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15123|Iloprost Effects on Gas Exchange and Pulmonary Mechanics|Effect of Iloprost on Gas Exchange and Pulmonary Mechanics in Patients With Pulmonary Hypertension and ARDS/ALI||University of Oklahoma|Yes|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274481||110700|
NCT01270815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081188|An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following Various Sized Lunches As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Pregabalin Controlled Release Formulation Administered At Lunch Following Various Caloric Intakes As Compared To The Immediate Release Formulation||Pfizer|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 12, 2011|January 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01270815||110982|
NCT01270828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081224|Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia|A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)||Pfizer|Yes|Completed|March 2011|November 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|806|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 4, 2011|Yes|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01270828||110981|
NCT01274702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vision Study|Visual Reconstitution Therapy After Optic Neuritis|Visual Reconstitution Therapy After Optic Neuritis|VISION|Charite University, Berlin, Germany|Yes|Completed|May 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||October 2013|May 20, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274702||110683|
NCT01267253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000690083|Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of Brivanib (BMS582664, IND #108417) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)||National Cancer Institute (NCI)||Suspended|April 2011|||February 2013|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|51|||Female|18 Years|N/A|No|||September 2012|September 6, 2012|December 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267253||111256|
NCT01267539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-970110-E|Suan Tsao Jen Tang for Treating Menopause With Sleep Problem: a Clinical Observation|||Taipei City Hospital|Yes|Completed|April 2008|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|67|||Female|40 Years|60 Years|No|Non-Probability Sample|The subjects enrolled in the study were climacteric women, ranging from 40-65 years of        age, with a Pittsburg Sleep Quality Index (PSQI) of greater than six. These women spent 45        minutes or more falling asleep, slept less than six hours, and had struggled with this        issue continuously for at least one month.|January 2008|December 27, 2010|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267539||111234|
NCT01271595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/214/07a|AUTO-ACUSAR - Effects of Acupuncture on the Autonomic Nervous System in Seasonal Allergic Rhinitis Patients|Acupuncture in Seasonal Allergic Rhinitis- Effects on the Autonomic Nervous System (AUTO-ACUSAR)- an Explorative Substudy of ACUSAR|AUTO-ACUSAR|Charite University, Berlin, Germany|Yes|Active, not recruiting|August 2009|May 2011|Anticipated|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|60|||Both|16 Years|45 Years|No|||December 2010|January 6, 2011|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01271595||110922|
NCT01271569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFDA2009L09746|A Study to Assess the Efficacy and Safety of Fospropofol Disodium|A Phase 1,Open, Dose-escalation Study to Assess the Efficacy and Safety of Fospropofol Disodium Injection in Healthy Volunteers||West China Hospital|Yes|Completed|March 2010|January 2011|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2010|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271569||110924|
NCT01267227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0225|Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress|Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress||University of Mississippi Medical Center|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|88 Years|No|||May 2013|May 2, 2013|December 17, 2010||No||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01267227||111258|
NCT01272076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-OCT-GA-2010-1-v2|Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)|Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)||Carl Zeiss Meditec, Inc.|Yes|Completed|January 2011|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|85|||Both|50 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|December 2013|December 17, 2013|January 5, 2011||No||No|June 24, 2013|https://clinicaltrials.gov/show/NCT01272076||110885|No adverse event were found or reported for this study.
NCT01273129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110051|Surgery as a Treatment for Medically Intractable Epilepsy|Surgery as a Treatment for Medically Intractable Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|8 Years|N/A|No|||June 2015|June 16, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273129||110804|
NCT01273402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-072-09 (NCI 5R01CA107088-04)|Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer|Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide||Immunomedics, Inc.|No|Terminated|February 2011|August 2018|Anticipated|February 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|January 5, 2011|Yes|Yes|A new study is being designed. No patients were enrolled.|No||https://clinicaltrials.gov/show/NCT01273402||110783|
NCT01272570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00036200|Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors|Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors: The Role of Aromatase Inhibitors||University of Michigan|No|Completed|September 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|58|Samples Without DNA|whole saliva|Female|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|29 postmenopausal women with a history of early stage BCa receiving adjuvant AI therapy        and 29 postmenopausal women without cancer|May 2015|May 26, 2015|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272570||110847|
NCT01272817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#13-6255|Nonmyeloablative Allogeneic Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation|Mini-allo|Scripps Health|No|Recruiting|October 2001|||January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|72 Years|No|||December 2013|December 5, 2013|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272817||110828|
NCT01273662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201008013M|Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma|Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma||National Taiwan University Hospital|No|Recruiting|April 2011|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01273662||110763|
NCT01273389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017551|An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis||Janssen Research & Development, LLC|No|Completed|August 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|70 Years|No|||February 2016|February 25, 2016|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273389||110784|
NCT01273649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007065R|Therapeutic Effects of Cryotherapy on Arthrogenic Muscle Inhibition in Patients With Cruciate Ligament Reconstruction|Therapeutic Effects of Cryotherapy and Transcutaneous Nerves Stimulation on Arthrogenic Muscle Inhibition in Patients With Anterior Cruciate Ligament Reconstruction||National Taiwan University Hospital|Yes|Recruiting|January 2011|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|20 Years|40 Years|No|||May 2014|May 27, 2014|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01273649||110764|
NCT01274208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZMC- 89/10|Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C|Enhanced HCV Nonstructural Protein 3 (NS3) -Specific T Cell Proliferation,Interferon γ (IFNγ) and Interleukin-10 (IL-10) Secreting Clones, and Peripheral Blood Natural Killers T Cells ( NKT Cells) in Patients With Type I Gaucher Disease Infected With HCV : An Advantage in Anti Hepatitis Immunity?||Shaare Zedek Medical Center|No|Recruiting|January 2011|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Gaucher Disease were recruited from the Sha'are Zedek Gaucher disease        clinic, a national referral center for the disease.|November 2014|November 18, 2014|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274208||110721|
NCT01274221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-321|Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 3b, Randomized, Double-blind, Multicenter, Placebo Controlled, Dose Optimization, Crossover, Analog Classroom, Safety and Efficacy Study of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD))||Shire|No|Withdrawn|February 2011|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|13 Years|17 Years|No|||January 2012|January 18, 2012|January 7, 2011|Yes|Yes|Cancellation was not safety related but a shift in study priorities for Shire.|No||https://clinicaltrials.gov/show/NCT01274221||110720|
NCT01270308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-699/08|Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions|Open Label, Randomized, Two-treatment, Three-period, Three-sequence, Partial Replicate Oral Bioequivalence Study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited, India Comparing With That of PREVACID® (Containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc. USA, in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|December 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2009|January 4, 2011|January 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270308||111021|
NCT01270568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002386|Mind-body Interventions in Cardiac Patients|||Massachusetts General Hospital|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||January 2011|January 20, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270568||111001|
NCT01270841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-203|Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism|A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism||Repros Therapeutics Inc.|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|83|||Male|21 Years|65 Years|No|||June 2014|June 27, 2014|January 4, 2011|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01270841||110980|
NCT01267305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SICUTEG-01|The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery|The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery||Shanghai Zhongshan Hospital|No|Completed|January 2011|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|362|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|December 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01267305||111252|
NCT01266993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113977|Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children|Persistence of Antibodies After Vaccination With a Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children and Safety and Immunogenicity of a Booster Dose at 68 Months Post-primary Vaccination||GlaxoSmithKline||Completed|January 2011|May 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|282|||Both|4 Years|16 Years|Accepts Healthy Volunteers|||November 2014|December 11, 2014|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266993||111276|
NCT01267266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02563|Saracatinib in Treating Patients With Prostate Cancer|A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer||National Cancer Institute (NCI)||Terminated|December 2010|November 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Male|N/A|N/A|No|||January 2013|March 18, 2015|December 24, 2010|Yes|Yes|Per protocol, study was terminated due to low rate of randomized patients.|No|January 30, 2015|https://clinicaltrials.gov/show/NCT01267266||111255|
NCT01267279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJRC-Reclast|Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty|Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty||Spokane Joint Replacement Center|No|Completed|January 2005|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|December 24, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01267279||111254|
NCT01267877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBGYN13730|Patient Perception of Mammogram Guidelines|Patient Perception of Mammogram Guidelines||University of Massachusetts, Worcester|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|247|||Female|39 Years|49 Years|Accepts Healthy Volunteers|||December 2010|December 28, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01267877||111208|
NCT01267890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU-DMR99-IRB-254|The Conflicts of Ethics and Law on Patient's Surrogate|Health Service Administration China Medical University (Chih-Jaan Tai)||China Medical University Hospital|Yes|Recruiting|December 2010|July 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|120 physicians in two hospitals|December 2010|December 28, 2010|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01267890||111207|
NCT01271322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT200811021017|Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)|Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric Junction During Neoadjuvant Treatment: HICON Trial|HICON|National Center for Tumor Diseases, Heidelberg|No|Terminated|October 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|75 Years|No|||April 2013|April 10, 2013|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01271322||110943|
NCT01271335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTO-1|Collagenase Total Occlusion-1 Trial|Collagenase Total Occlusion-1 Trial||Sunnybrook Health Sciences Centre|Yes|Completed|November 2009|February 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|35 Years|N/A|No|||March 2012|March 22, 2012|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271335||110942|
NCT01271348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPM-032|Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise|Multiple-dose, Randomized, Double Blinded, Placebo-controlled, Cross Over Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise||X-pert Med GmbH||Completed|January 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 31, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271348||110941|
NCT01272362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BFR01|To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol|Study of the Predictive Value of Airway Obstruction Reversibility on the Effectiveness of Indacaterol (Onbrez® Breezhaler ®) 150 Mcg Once Daily in Patients With Moderate to Severe COPD|REVERBREZ|Novartis||Completed|April 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|625|||Both|40 Years|N/A|No|||November 2012|November 29, 2012|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272362||110863|
NCT01272375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1691011|This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers||Pfizer|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Actual|48|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 11, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272375||110862|
NCT01272336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035986|Study Effects of Intermittent Hypoxia on Restoring Hand Function Following SCI|Intermittent Hypoxia Promotes Restoration of Hand Function Following SCI||Emory University|No|Completed|December 2010|October 2015|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 23, 2016|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01272336||110865|
NCT01271803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO25395|A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma|A Phase IB, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination With GDC-0973 When Administered in BRAFV600E Mutation-Positive Patients Previously Treated (But Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally- Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed After Treatment With Vemurafenib||Hoffmann-La Roche||Active, not recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01271803||110906|
NCT01272830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Summa-09136|Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements|A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties|Apatone-B|IC-MedTech Corporation|Yes|Active, not recruiting|October 2010|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272830||110827|
NCT01272596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sloan-Study|Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis|Evaluation of Low Contrast Sloan Visual Charts as Method for the Assessment of Disease Progression in Multiple Sclerosis||Charite University, Berlin, Germany|No|Completed|December 2009|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|65 Years|No|Probability Sample|Patients with Clinically Isolated Syndrome or Definite Multiple Sclerosis|November 2013|May 20, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01272596||110845|
NCT01273415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-12-049|Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer|Usefulness of Ki67 Proliferative Index to Predict Recurrence and Benefit From Adjuvant Chemotherapy in Hormone Receptor (HR)-Positive Breast Cancer||Samsung Medical Center|No|Active, not recruiting|August 2010|January 2011|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1070|||Female|20 Years|85 Years|No|Probability Sample|postoperative hormone receptor-positive breast cancer patients from 2004 to 2007 at        Samsung Medical Center|January 2011|January 7, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01273415||110782|
NCT01273428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-101-09-041|HP011-101, HP828-101, and Standard Care for Pressure Ulcers|Comparison of HP011-101, HP828-101, and Standard Care in the Management of Stage I-II Pressure Ulcers in Patients With Spinal Cord Injury||Healthpoint|No|Withdrawn||November 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|12 Years|N/A|No|||January 2011|September 10, 2012|December 3, 2010|Yes|Yes|The device test article is no longer available|No||https://clinicaltrials.gov/show/NCT01273428||110781|
NCT01273441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEQvsCONC (TRA-047)|Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice|Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice||Hospital Universitario de la Princesa|No|Recruiting|December 2010|July 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273441||110780|
NCT01273922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDV-3-001|Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida|Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults||NovaDigm Therapeutics, Inc.||Completed|January 2011|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273922||110743|
NCT01274195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-SCT -1001|Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML|Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML||Seoul National University Hospital|Yes|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|N/A|21 Years|No|||November 2013|November 17, 2013|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274195||110722|
NCT01270321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00041909|A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer|A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer||Emory University|Yes|Recruiting|November 2010|June 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270321||111020|
NCT01270334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cytoph|Effect of Vaginal PH on Treatment Effectiveness With Misoprostol for First Trimester Missed Abortions|Effect of Vaginal PH on Treatment Effectiveness With Misoprostol for First Trimester Missed Abortions||HaEmek Medical Center, Israel|Yes|Not yet recruiting|February 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|women dignosed with missed abortion in the first trimester|January 2011|January 4, 2011|January 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01270334||111019|
NCT01270581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0603|High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation|High Flow Nasal Cannula vs Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|N/A|24 Hours|No|||January 2012|January 11, 2012|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01270581||111000|
NCT01267318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-301|Evaluation of Gastric Juice Samples During Standard Gastroscopy Procedure|||Given Imaging Ltd.|No|Terminated|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|Samples With DNA|Gastric juices content suctioned from patients routinely during the course of Gastroscopy.|Both|18 Years|N/A|No|Non-Probability Sample|All gastric juice samples should contain blood. This will be determined by the treating        physician based on visual assessment in a region alongside the fresh biopsy site just        performed, and prior to any saline washing.|July 2012|July 4, 2012|December 26, 2010||No|Sponsor decided to terminate the entire project, and therefore there was no use for the    samples collected in the study.|No||https://clinicaltrials.gov/show/NCT01267318||111251|
NCT01267006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114922|Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old|A Randomized Cross-over Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Twice Daily Oral Administration of GSK1325756, Compared to Placebo, in Healthy Subjects; and the Pharmacokinetic Profile of Twice Daily Oral Administration of GSK1325756 in Healthy Fed and Fasted Elderly Subjects||GlaxoSmithKline|No|Completed|November 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||October 2011|August 23, 2012|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267006||111275|
NCT01267552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Drains Trial|Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer|Randomized Clinical Trial of Axillary Lymphadenectomy Without Drainage for Breast Cancer Treatment||Universidade Federal de Goias|No|Completed|July 2000|December 2007|Actual|September 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Female|N/A|N/A|No|||July 2010|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267552||111233|
NCT01267903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT003|A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children|A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|January 2011|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|100|||Both|5 Years|22 Years|No|||January 2011|June 9, 2011|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01267903||111206|
NCT01271842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-26|Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study|Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study|RESPIFLU|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|October 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|38|||Both|18 Years|65 Years|No|Non-Probability Sample|Two groups of survivors of severe acute respiratory distress syndrome due to influenza A        H1N1 infection will be recruited; the first required extracorporeal oxygenation at the        time of viral infection, and the second did not require extracorporeal oxygenation at the        time of viral infection. Patients will be recruited at least 9 months after ICU discharge.        Eighteen case patients matching inclusion and non-inclusion criteria were selected from        our national registry, and 32 controls (with inclusion and exclusion criteria) were        matched on age, sex, and body mass index.|December 2012|December 27, 2012|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01271842||110903|
NCT01272115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-785-048|Integrative Health Care Model for Climacteric Stage Women|Integrative Health Care Model for Climacteric Stage Women|IHCM|Coordinación de Investigación en Salud, Mexico|Yes|Completed|February 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|380|||Female|45 Years|59 Years|Accepts Healthy Volunteers|||May 2012|May 1, 2012|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01272115||110882|
NCT01272622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKSR 463|Prospective Study of Children and Adolescents With Craniopharyngioma|KRANIOPHARYNGEOM 2007 - Multicenter Prospective Study of Children and Adolescents With Craniopharyngioma||Klinikum Oldenburg gGmbH|Yes|Recruiting|October 2007|September 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|18 Years|No|||April 2015|April 16, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01272622||110843|
NCT01271829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100220|Incorporating Avocados in Meals|Incorporating Avocados in Meals: Effect on Glycemic Index, Insulin Response, Satiety and Satiety-related Gastrointestinal Peptides in Humans||Loma Linda University|Yes|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|3||Actual|30|||Both|23 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271829||110904|
NCT01272583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DARE_2010|Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery|Effects of 6 Weeks Treatment With a Dipeptidyl Peptidase 4 Inhibitor on Counterregulatory and Incretin Hormones During Acute Hypoglycaemia in Patients With Type 1 Diabetes: a Randomized Double Blind Placebo-controlled Cross-over Study|DARE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|March 2011|October 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|16|||Male|18 Years|55 Years|No|||February 2014|February 14, 2014|January 5, 2011||No||No|October 15, 2013|https://clinicaltrials.gov/show/NCT01272583||110846|
NCT01272349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00035986a|Intermittent Hypoxia Elicits Prolonged Restoration of Motor Function in Human SCI|Intermittent Hypoxia Elicits Prolonged Restoration of Motor Function in Human SCI||Emory University|Yes|Completed|December 2010|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 20, 2013|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01272349||110864|
NCT01272843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEACOG2011|Physiological Magnetic Resonance Imaging (MRI) to Improve Carotid Endarterectomy Outcomes|||Sunnybrook Health Sciences Centre|Yes|Not yet recruiting|February 2011|January 2015|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|30 Years|80 Years|No|Non-Probability Sample|Atherosclerosis is a major risk factor for ischemic cerebrovascular events such as stroke        (Bots, Hoes et al. 1997). Carotid endarterectomy (CEA) and carotid stenting (CAS) are        common surgical procedures aimed at reducing stroke risk. For individuals with symptomatic        stenosis > 70%, CEA has a higher event-free survival compared to medical therapy (Barnett,        Taylor et al. 1998) and is considered highly beneficial treatment (Rothwell, Eliasziw et        al. 2003). To date, however, few studies have attempted to relate effects of the surgery        to changes in brain physiology and function.|December 2010|January 7, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272843||110826|
NCT01272856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10063|Study on the Safety of Abatacept in Relapsing Polychondritis|An Open-Label, Single-Center, Phase I Study on the Safety of Abatacept in Relapsing Polychondritis||Benaroya Research Institute|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|80 Years|No|||August 2012|August 3, 2012|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01272856||110825|
NCT01273688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EpiFlex|Eccentric Training With or Without Elbow Brace for Epicondylitis|Eccentric Training With Our Without Elbow Brace for Epicondylitis - a Randomized Clinical Trial|EpiFlex|Hannover Medical School|No|Not yet recruiting|February 2011|November 2011|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||January 2011|January 7, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01273688||110761|
NCT01273675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201008056R|An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy|An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy||National Taiwan University Hospital|Yes|Active, not recruiting|September 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum and Urine|Both|30 Years|75 Years|No|Non-Probability Sample|Type II Diabetic diasese with hypertension ( systolic 140-160 mm/Hg, dystolic 80-100        mm/Hg) for 8 weeks.|September 2010|January 7, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01273675||110762|
NCT01273935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MevesASS01|Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke|Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke||Ruhr University of Bochum|No|Completed|January 2010|December 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the stroke unit|January 2010|January 10, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01273935||110742|
NCT01273948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1003|Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection|A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection||Peregrine Pharmaceuticals|No|Completed|January 2011|February 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|65 Years|No|||February 2012|February 2, 2012|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273948||110741|
NCT01266447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02659|Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2011|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|March 14, 2016|December 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266447||111318|
NCT01267032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLA-09-S09|Helping Veterans Quit Smoking by Improving Their Sleep|Improving Smoking Cessation Outcomes in PTSD With CBT for Insomnia|ISCWCBTI|VA Office of Research and Development|Yes|Terminated|October 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|December 23, 2010||No|Terminated after two years by CSRD|No||https://clinicaltrials.gov/show/NCT01267032||111273|
NCT01267045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-008-10S|Mindfulness-Based Stress Reduction for Gulf War Syndrome|A Randomized Controlled Trial of a Mindfulness Based Intervention for Gulf War Syndrome||VA Office of Research and Development|No|Completed|October 2010|April 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|December 23, 2010||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01267045||111272|
NCT01267292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-P50-09262-Project2.1|Psychopharmacology for Cocaine Dependence - Buspirone|Psychopharmacology of Novel Medications for Cocaine Dependence - Buspirone||The University of Texas Health Science Center, Houston|Yes|Completed|March 2011|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|60 Years|No|||June 2015|June 11, 2015|December 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01267292||111253|
NCT01267565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABoyer4|Tracheal Dosage of Amylase : a New Surrogate for Microaspirations in Ventilated ICU Patients|||Université Victor Segalen Bordeaux 2|No|Completed|September 2010|June 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267565||111232|
NCT01277822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954F-399|Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)|The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlodipine 5 mg Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|334|||Both|18 Years|80 Years|No|||March 2015|March 25, 2015|January 13, 2011|No|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01277822||110443|
NCT01272128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-AVO-01|Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study|A Multicenter, Prospective Non-interventional Study to Evaluate the Quality of Life in Belgian Patients With CIS or RRMS in Whom Interferon Beta-1a IM Treatment Has Been Initiated|AVAIL|Biogen|No|Completed|December 2012|September 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) or Clinically Isolated        Syndrome (CIS) who meet the criteria for prescription of Interferon Beta-1a IM at up to 20        Belgian institutions may participate into this study.|October 2015|October 16, 2015|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01272128||110881|
NCT01272141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00031112|A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer|Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer||Emory University|Yes|Terminated|December 2010|January 2014|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|N/A|No|||September 2014|September 11, 2014|January 6, 2011|Yes|Yes|Slow accrual, Funding stopped|No|September 3, 2014|https://clinicaltrials.gov/show/NCT01272141||110880|
NCT01268696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/202/10/KE|Genetic Assessment of the Patients With Metabolic Syndrome|Genetic Assessment of the Patients With Metabolic Syndrome in Polish Population|GENMetS|Medical Universtity of Lodz|Yes|Active, not recruiting|December 2010|January 2015|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|the blood samples taken into EDTA|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with metabolic syndrome|December 2010|July 20, 2011|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268696||111145|
NCT01268709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YRC-1246|Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome|||Qom University of Medical Sciences|Yes|Completed||||||Phase 2|Interventional|Primary Purpose: Treatment|3||||||Both|N/A|N/A||||December 2010|December 30, 2010|December 30, 2010||||No||https://clinicaltrials.gov/show/NCT01268709||111144|
NCT01272609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-11|Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel|Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel||Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2011|May 2012|Anticipated|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|6 Months|18 Years|No|||January 2011|March 23, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01272609||110844|
NCT01272102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-OCT-GCA-2010-1|Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma|Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma||Carl Zeiss Meditec, Inc.|Yes|Completed|November 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|119|||Both|40 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|June 2013|June 24, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272102||110883|
NCT01269229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0522|A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis|A Phase 2 Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis||Yonsei University|Yes|Recruiting|January 2010|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269229||111104|
NCT01269242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004SC08166|The Effects of Bindarit in Preventing Stent Restenosis|A Pilot Study to Evaluate the Efficacy and Safety of Different Bindarit Dosages in Preventing Stent Restenosis||Aziende Chimiche Riunite Angelini Francesco S.p.A|No|Completed|January 2009|April 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|148|||Both|19 Years|N/A|No|||June 2012|June 7, 2012|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269242||111103|
NCT01273142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zzly-37183|Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection|A Prospective, Open-label 96-week Observational Pilot Study to Compare the Safety of Efavirenz Versus Nevirapine (Each in Combination With Zidovudine and Lamivudine or Tenofovir and Lamivudine) in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection.||Henan Provincial Hospital|No|Not yet recruiting|January 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|60 Years|No|Probability Sample|Antiretroviral treatment naive patients with HIV-1 RNA level≥500 copies/ml and with AST or        ALT > 2x the upper limit of normal, and TBIL > 1.5x the upper limit of normal.|December 2010|January 7, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01273142||110803|
NCT01273155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110060|Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction|A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|March 2018|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|110 Years|No|||February 2016|February 18, 2016|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01273155||110802|
NCT01273168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110061|Endoxifen in Adults With Hormone Receptor Positive Solid Tumors|Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|October 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||April 2015|July 30, 2015|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01273168||110801|
NCT01273181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110062|MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes|Phase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)|Yes|Terminated|December 2010|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|9|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 7, 2011|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01273181||110800|
NCT01273454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016324|An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients|An Open-label, Multi-center, Non-interventional Study to Investigate Clinical Usefulness of Hydromorphone OROS in Korean Cancer Patients||Janssen Korea, Ltd., Korea||Completed|June 2009|December 2009|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|648|||Both|20 Years|N/A|No|Non-Probability Sample|Patients suffering from cancer pain who visit the study sites during study and eligible to        be treated with OROS hydromorphone at the discretion of the investigator.|September 2013|September 3, 2013|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273454||110779|
NCT01270100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA025385|Recovery Management Intervention in China|Reducing HIV/AIDS and Drug Abuse Among Heroin Addicts Released From Compulsory Rehabilitation in China||University of California, Los Angeles||Completed||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A||||December 2010|January 4, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270100||111037|
NCT01273961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0310-0003|Study of Radiofrequency Device for Use in Non-Invasive Cosmetic Procedures|Radiofrequency Magnetic Induction Device for Use in Non-Invasive Body Contouring||Rocky Mountain Biosystems, Inc.|No|Completed|December 2010|January 2012|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273961||110740|
NCT01274234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 10-342 (IRB HKU)|OCT Evaluation of Healing of COMBO Stent|Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study|EGO-COMBO|The University of Hong Kong|Yes|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|85 Years|No|||February 2013|February 27, 2013|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01274234||110719|
NCT01274247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-SD-0385-CTIL|Use of Topical Benzocaine for Analgesia in Lingual Frenotomy of the Newborn|Time of Cry After Lingual Frenotomy in Infants With Lingual Frenulum and Breastfeeding Difficulties, With or Without Use of Topical Benzocaine Analgesia||Tel-Aviv Sourasky Medical Center|No|Terminated|February 2011|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|N/A|7 Days|Accepts Healthy Volunteers|||August 2012|August 1, 2012|January 10, 2011||No|The study ethics committee recommended concluding the study for longer crying time with    benzocaine and very short crying time in all participants.|No||https://clinicaltrials.gov/show/NCT01274247||110718|
NCT01267344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1210|A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC|A Randomized Phase II Study of Gemcitabine Plus Oxaliplatin (GEMOX) With or Without Cetuximab in Locally Advanced and Metastatic Biliary Tract Cancer (BTC)|BTC|National Health Research Institutes, Taiwan|Yes|Recruiting|December 2010|December 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|N/A|No|||October 2013|October 28, 2013|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01267344||111249|
NCT01267357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230CTIL|P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer|Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance||Rambam Health Care Campus|No|Completed|July 2010|||November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|62|Samples With DNA|Existing paraffin pathology blocks in hospital's library were used. Remainder of material      was returned to the library.      No identifying features were retained or attached to specimens.|Female|18 Years|N/A|No|Non-Probability Sample|women diagnosed with endometrial cancer, having undergone surgery and having received        chemotherapy in our institution.|November 2010|December 26, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01267357||111248|
NCT01276938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|istgeiort|Exclusive Intraoperative Radiation Therapy for Breast Cancer|Tolerance Evaluation of Exclusive Intraoperative Radiation Therapy at Different Doses for Breast Cancer Conservative Treatment||National Institute for Cancer Research, Italy|Yes|Recruiting|April 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|45 Years|85 Years|No|||September 2010|January 13, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01276938||110511|
NCT01276951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cacao III|Controlled Clinical Trial to Determine the Effective Dose of Cocoa in Lowering Blood Pressure|Controlled Clinical Trial of the Effect of Cocoa Consumption in Lowering Blood Pressure and in the Modulation of Endothelial Inflammation in Hypertensive Patients Assigned to an Entity Health Promoting.||Universidad de Antioquia|Yes|Recruiting|December 2008|March 2011|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|65 Years|No|||May 2010|January 13, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01276951||110510|
NCT01277276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2008-6549|Study of Chemotherapy Side Effects in Cancer Patients: Non-invasive Optical Measurements of the Brain|Study of Chemotherapy Side Effects in Cancer Patients: Non-invasive Optical Measurements of the Brain||University of California, Irvine|No|Withdrawn|November 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|70 Years|No|Non-Probability Sample|primary care clinic, community sample|August 2015|August 5, 2015|January 12, 2011||No|no participant enrolled|No||https://clinicaltrials.gov/show/NCT01277276||110485|
NCT01277523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.456|Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma||Boehringer Ingelheim||Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|392|||Both|12 Years|17 Years|No|||October 2014|October 14, 2014|January 13, 2011||||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01277523||110466|
NCT01278303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060057a|Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta|Covered Cheatham Platinum Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta|COASTII|Johns Hopkins University|Yes|Completed|July 2010|December 2014|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|N/A|N/A|No|||February 2016|February 15, 2016|August 2, 2010|Yes|Yes||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01278303||110406|
NCT01268449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laser-tinnitus-202|Evaluation of Low Dose Laser in Treatment of Tinnitus|Phase 1 Evaluation of Low Dose Laser in Treatment of Tinnitus||Islamic Azad University of Mashhad|Yes|Completed|March 2008|September 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||August 2010|December 29, 2010|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268449||111164|
NCT01268462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31012010|Use of Heliox Associated With PEEP in Patients With Asthma|||Universidade Federal de Pernambuco|Yes|Completed|July 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|65 Years|No|||October 2010|December 29, 2010|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268462||111163|
NCT01268722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30357/2-12-2010|Balloon Angioplasty Versus Primary Stenting for the Treatment of Femoropopliteal Artery Chronic Total Occlusions|Balloon Angioplasty Versus Self-expanding Stent for Recanalization of Chronic Total Occlusions of the Femoral Artery|FACTORY|University of Patras|Yes|Recruiting|December 2010|December 2016|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|30 Years|N/A|No|||December 2010|April 5, 2012|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01268722||111143|
NCT01272882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC#30067|Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS|Electrical Impedance Tomography (EIT) Monitoring: A Pilot Comparison to Standard of Care Assessments in Adults With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)||Christiana Care Health Services|No|Completed|May 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|January 3, 2011||No||No|October 31, 2012|https://clinicaltrials.gov/show/NCT01272882||110823|
NCT01272869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP211OC|Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags|Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags||Coloplast A/S|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||November 2012|November 29, 2012|December 14, 2010||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT01272869||110824|
NCT01269593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-139|PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study|PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study||Memorial Sloan Kettering Cancer Center||Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|55|||Both|18 Years|90 Years|No|||November 2015|November 11, 2015|December 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01269593||111076|
NCT01269580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/2008_Cardiovascolare|Diabetic Foot and Vascular Progenitor Cells|The Diabetic Foot: Relevance of Vascular Progenitor Cells as a Prognostic Marker of Cardiovascular Mortality, Restenosis, and Atherosclerotic Disease Progression in Treated Limb.||IRCCS Multimedica|No|Active, not recruiting|February 2009|June 2015|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|122|||Both|18 Years|N/A|No|Probability Sample|Diabetic patients with peripheral ischemia|August 2013|August 7, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269580||111077|
NCT01269840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00008411|Comparison of Two Radial Head Implants|Comparison of Monopolar In-Growth and Loose Bipolar Radial Head Implants in the Treatment of Irreparable Radial Head Fractures||Northwestern University|Yes|Completed|March 2010|September 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|41|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients suffering radial head fractures, with or without other elbow injuries, requiring        radial head replacement|October 2014|October 5, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269840||111057|
NCT01265836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CTH-DUM-2010/1|Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes|Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes|DEMAND|AstraZeneca|No|Withdrawn|March 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1064|||Both|18 Years|N/A|No|Non-Probability Sample|1. Provision of subject informed consent          2. Female or male aged = 18 years          3. Patients eligible for treatment of dyslipidemia with statins, according to the             current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention.          4. Receiving lipid-lowering drug treatment for at least 15 days.|April 2011|April 11, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01265836||111365|
NCT01265810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esperanz-002|Caphosol in Oral Mucositis Due to Targeted Therapy|Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy|COMTT|Waterland Hospital|No|Recruiting|September 2011|April 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265810||111367|
NCT01265823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W11-050|Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis|Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis||AbbVie|No|Completed|October 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|75 Years|No|||February 2013|February 1, 2013|December 22, 2010||No||No|February 1, 2013|https://clinicaltrials.gov/show/NCT01265823||111366|
NCT01266161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3491001|Multiple Dose Dental Pain Study Of Ibuprofen Extended Release|A Multiple Dose Dental Pain Study Of An Ibuprofen 600 Mg Extended Release Caplet||Pfizer|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|16 Years|40 Years|No|||April 2012|April 19, 2012|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266161||111340|
NCT01266174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGI12004|Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults|Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia||Amarantus BioScience Holdings, Inc.|Yes|Completed|August 2011|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||April 2015|April 13, 2015|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266174||111339|
NCT01267968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114926|An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects|An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|25|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|March 1, 2012|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01267968||111201|
NCT01267383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-VIN-102|Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg in Fed Conditions|Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fed Conditions in Healthy Human Adult Subjects.||Dr. Reddy's Laboratories Limited|No|Completed|September 2006|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|December 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267383||111246|
NCT01266694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02|Cochicine Treatment for Post- Operative Pericardial Effusion|Cochicine Treatment for Post- Operative Pericardial Effusion: The POPE 2 Study A Multicenter, Double-blind, Randomized Trial|POPE2|French Cardiology Society|No|Completed|April 2011|January 2014|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|199|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266694||111299|
NCT01266707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|560|Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma|Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma||Fukushima Medical University|Yes|Recruiting|March 2007|March 2013|Anticipated|March 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|20 Years|80 Years|No|||December 2010|December 23, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266707||111298|
NCT01277289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crodex01|Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease|Multicenter, Randomized, Double-blind, Parallel-group Study of Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease|Crodex|Erydel|No|Terminated|April 2009|June 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|80 Years|No|||September 2012|September 18, 2012|January 5, 2011||No|due to the big difficulty to enrol suitable patients|No||https://clinicaltrials.gov/show/NCT01277289||110484|
NCT01277536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTIMATE|Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland|Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland (ESTIMATE): Evaluation of a Prediction Rule||University Hospital, Geneva|No|Completed|December 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1478|||Both|18 Years|N/A|No|Non-Probability Sample|Several public hospitals of Switzerland, genral internal medicine divisions|March 2014|March 17, 2014|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277536||110465|
NCT01277549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT10-03|Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors|Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors||Terumo BCT|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|71|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Community Volunteers|May 2013|May 2, 2013|January 13, 2011|Yes|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT01277549||110464|
NCT01277835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VATS-lidocaine|Intravenous Lidocaine Infusion During Video-assisted Thoracic Procedures for Improved Pain Control|Intravenous Lidocaine Infusion During VATS Procedures Reduces Postoperative Analgesic Requirements||University of Saskatchewan|No|Completed|February 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|75 Years|No|||February 2013|December 1, 2014|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01277835||110442|
NCT01268189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-09-008|Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds|Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds||United States Army Institute of Surgical Research|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|December 21, 2010|No|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01268189||111184|
NCT01268475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0671/10|Exercise Capacity in Bronchiectasis Resection|Impact of Pulmonary Resection on Exercise Capacity in Patients With Bronchiectasis||University of Sao Paulo|Yes|Recruiting|March 2009|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with clinical and radiological diagnosis of bronchiectasis recruited on Pulmonary        Suppurative Disease Clinic of Thoracic Surgery Department|November 2010|December 29, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01268475||111162|
NCT01269320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0172-10-HMO-CTIL|Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease|||Hadassah Medical Organization|Yes|Withdrawn|January 2012|||||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||August 2011|August 27, 2012|January 3, 2011||No|Sponsors decision|No||https://clinicaltrials.gov/show/NCT01269320||111097|
NCT01269632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-AO1219-48|Cohort of Young Adults Infected With HIV Since Birth or During Childhood|Long Term Evaluation of Young Adults Born to HIV-infected Mothers. A Cohort of Young Adults Infected With HIV Since Birth or During Childhood|CO19 COVERTE|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|June 2010|December 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01269632||111073|
NCT01268995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2009-012712-40|Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation|A Randomized, Prospective Trial to Evaluate the Effect of Conversion From Tacrolimus to Cyclosporine A After Early Initiation of Insulin Therapy in Patients With New-onset Diabetes Mellitus After Kidney Transplantation|ISINODAT|Medical University of Vienna|Yes|Terminated|September 2009|December 2010|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|80 Years|No|||January 2011|January 3, 2011|January 3, 2011|Yes|Yes|It was impossible to recruit the scheduled number of patients|No||https://clinicaltrials.gov/show/NCT01268995||111122|
NCT01273194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110063|Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents|Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents||National Institutes of Health Clinical Center (CC)||Completed|December 2010|September 2015||||N/A|Observational|N/A|||Actual|12|||Both|10 Years|99 Years|Accepts Healthy Volunteers|||September 2015|November 4, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273194||110799|
NCT01269619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG-001|Comparative Study of Static and Dynamic Back Supports for Lower Back Pain|Comparative Study of Static and Dynamic Back Supports for Lower Back Pain||Wolfson Medical Center|Yes|Not yet recruiting|February 2011|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||December 2010|January 2, 2011|January 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01269619||111074|
NCT01269866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1J-US-X059|Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus|Duloxetine (Cymbalta) in the Reduction of Pain Severity in Patient With Systemic Lupus Erythematosus: A Pilot Study||Brain Resource Center|No|Completed|December 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|January 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269866||111055|
NCT01269853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-353|Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA|Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.||Northwell Health|No|Recruiting|October 2010|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269853||111056|
NCT01270113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA025252|Improving Methadone Maintenance Treatment Compliance and Outcomes in China|Improving Methadone Maintenance Treatment Compliance and Outcomes in China||University of California, Los Angeles|No|Completed||||||N/A|Interventional|N/A|||||||Both|18 Years|N/A||||December 2010|January 4, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270113||111036|
NCT01266200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-027|Identification of Microcirculation and Inflammation After Posterior Stabilization of the Spine|Identification of Cutaneous and Muscular Microcirculation and Inflammatory Response After Posterior Stabilization of the Spine|MicroSpine|RWTH Aachen University|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01266200||111337|
NCT01266213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-001|Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women|Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman|FLAG|Samsung Medical Center|Yes|Recruiting|December 2010|December 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|147|||Female|N/A|55 Years|No|||July 2011|July 26, 2011|December 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01266213||111336|
NCT01266187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-005|Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study)|Perioperative Chemotherapy With FOLFOX Plus Cetuximab Versus Adjuvant FOLFOX Plus Cetuximab for Patients With Resectable Liver Metastases of Colorectal Carcinoma||RWTH Aachen University|No|Terminated|July 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|December 20, 2010||No|Recruitment difficulities|No||https://clinicaltrials.gov/show/NCT01266187||111338|
NCT01266460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0265|Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix||Gynecologic Oncology Group|Yes|Suspended|May 2011|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Female|18 Years|N/A|No|||February 2016|February 10, 2016|December 23, 2010|Yes|Yes|Unacceptable Toxicity|No||https://clinicaltrials.gov/show/NCT01266460||111317|
NCT01267058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263855/002|Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults|Single-blind, Clinical Study of the Immunogenicity and Reactogenicity of SB Biologicals' dTpa, pa Vaccines and a Td Vaccine, Given as a Booster Dose to Healthy Adults, From the Age of 18 Years Onwards||GlaxoSmithKline||Completed|September 1997|February 1998|Actual|February 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 23, 2010|December 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267058||111271|
NCT01267396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-VIN-103|Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions|Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.||Dr. Reddy's Laboratories Limited|No|Completed|September 2006|October 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|December 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267396||111245|
NCT01267695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJP-320.6700.09010|Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor|Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor||Peking University|Yes|Completed|May 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267695||111222|
NCT01267708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|431-10 CTIL|Platelet Function in Patients Undergoing PCI|||Rambam Health Care Campus|No|Recruiting|November 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|To examine PLT function in all patients undergoing PCI to our center|November 2010|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267708||111221|
NCT01267630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANE100806A11|The Validity of the Thai Version of the Confusion Assessment Method|The Validity and Reliability of Thai Version of the Confusion Assessment Method for the Intensive Care Unit (CAM -ICU)||Chiang Mai University|No|Enrolling by invitation|January 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|55 Years|N/A|No|Non-Probability Sample|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48        hours.|January 2011|June 22, 2011|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267630||111227|
NCT01267643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5Z10|Alefacept in Patients With Relapsed/Refractory Aplastic Anemia|A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia||The Cleveland Clinic|Yes|Suspended|May 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|December 20, 2010|Yes|Yes|Study drug not available at this time|No||https://clinicaltrials.gov/show/NCT01267643||111226|
NCT01267656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|684E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2010|||||N/A|N/A|N/A||||||||||||||August 10, 2012|December 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267656||111225|
NCT01277302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4967g|A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion|A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion||Genentech, Inc.||Completed|February 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|202|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|January 13, 2011|Yes|Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT01277302||110483|
NCT01277562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10005|Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer|Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer||City of Hope Medical Center|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|56|||Both|18 Years|N/A|No|Probability Sample|Adults with newly diagnosed osteopenia and osteoporosis with diagnosis of non-metastatic        breast or prostate cancer|June 2015|June 3, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277562||110463|
NCT01277848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#107849|PLAC1 in Reproduction|PLAC1 in Reproduction||University of South Florida|Yes|Recruiting|May 2009|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Female|14 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women at USF coming in for their first prenatal appointment|December 2014|December 1, 2014|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277848||110441|
NCT01269021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1005|An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)|Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.||Nanjing University School of Medicine|Yes|Completed|November 2010|April 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|60 Years|No|||March 2016|March 15, 2016|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01269021||111120|
NCT01269307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39736|Combination Ketamine and Propofol vs Propofol for Emergency Department Sedation: A Prospective Randomized Trial|Combination Ketamine and Propofol vs Propofol for Emergency Department Sedation: A Prospective Randomized Trial||University of Utah|Yes|Completed|June 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01269307||111098|
NCT01269333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0330-HMO-CTIL|Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel|Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel. a Randomized, Double-blind Placebo Controlled, Crossover Trial||Hadassah Medical Organization||Completed|January 2011|||July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269333||111096|
NCT01269346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-208|Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer|A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer||Eisai Inc.||Active, not recruiting|December 2010|June 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|December 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01269346||111095|
NCT01269359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARZ-003HMO-CTIL|Robotic Assisted Vertebral Body Augmentation - a Radiation Reduction Tool|||Hadassah Medical Organization|No|Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Non-Probability Sample|men and women that are candidates to vertebral body augmentation|March 2013|March 21, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269359||111094|
NCT01269372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-203|Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon|Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon||Given Imaging Ltd.|No|Completed|December 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator)|1||Actual|30|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2013|August 3, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01269372||111093|
NCT01269645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15820|Facts and Attitudes About Clinical Trials|Evaluating Educational Materials About Cancer Clinical Trials|FACT|H. Lee Moffitt Cancer Center and Research Institute|No|Completed|July 2009|July 2014|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|471|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01269645||111072|
NCT01269892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-9|Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea|Study of Nutritional Regime for Acute Diarrhea||Isfahan University of Medical Sciences|Yes|Completed|January 2009|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|74|||Both|3 Months|14 Months|Accepts Healthy Volunteers|||January 2009|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269892||111053|
NCT01269008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 -434|Closed Loop System With Pramlintide Versus Exenatide|CLOSED LOOP SYSTEM IN TYPE 1 DIABETES MANAGEMENT COMPARISON WITH PRAMLINTIDE Vs EXENATIDE|Closedloop|Albert Einstein College of Medicine of Yeshiva University|No|Completed|December 2010|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|30 Years|No|||January 2013|January 23, 2013|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269008||111121|
NCT01269281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0559019|Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions|Open Label, Randomized, Two Way Crossover, Comparative Evaluation of Relative Bioavailabilities of Two Formulations of Sumatriptan Succinate Tablets 100 mg (Dr. Reddy's Laboratories Limited, India)With the Reference Formulation Imitrex Tablets 100 mg (Glaxosmilthkine) in Healthy Adult Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|July 2005|July 2005|Actual|July 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2005|January 3, 2011|January 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269281||111100|
NCT01269255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0555|A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer|A Phase I Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer||Yonsei University|Yes|Completed|December 2009|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|20 Years|75 Years|No|||June 2013|June 1, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269255||111102|
NCT01269268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0213|Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis|Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis||Yonsei University|No|Recruiting|June 2010|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|260|Samples Without DNA|peripheral blood and serum will be retained|Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|active TB patients group : from the referred center TB care clinic healthy control : from        the community sample|February 2014|February 4, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269268||111101|
NCT01265862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM2011-001|Does the Use of the GlideRite® Endotracheal Tube in Combination With the I-gel® Improve Intubation Success Rate?|Comparison of LMA-Fastrach® and I-gel® for Tracheal Intubation: Does the Use of the GlideRite® Endotracheal Tube in Combination With the I-gel® Improve Success Rate?||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265862||111363|
NCT01270126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS_optnerve_SCT|Trial of Alternating Current Stimulation in Optic Neuropathy|Treatment of Patients With Optic Neuropathy Using Transorbital Alternating Current Stimulation - a Randomized Trial|SCT_optnerve|University of Magdeburg|No|Completed|November 2006|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||September 2013|September 4, 2013|January 3, 2011||No||No|June 19, 2013|https://clinicaltrials.gov/show/NCT01270126||111035|
NCT01265849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS001P3|Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity|Phase III Study of LI [Multikine®] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only|IT-MATTERS|CEL-SCI Corporation|Yes|Recruiting|December 2010|December 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|880|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|December 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01265849||111364|
NCT01267084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017539|A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies|An Open-Label, Multicenter Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies||Janssen Research & Development, LLC|Yes|Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|December 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01267084||111269|
NCT01267097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCWH01-2009|The PAC Study: Parents as Agents of Change in Pediatric Weight Management|The PAC Study: Parents as Agents of Change in Pediatric Weight Management|PAC|University of Alberta|No|Completed|September 2010|January 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||February 2014|February 19, 2014|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01267097||111268|
NCT01266473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/802|Study of Individualized Physiotherapy for Airway Clearance in Cystic Fibrosis.|Efficacy Study of Physiotherapy for Airway Clearance in Cystic Fibrosis. Randomized Controlled Trials in Single Subjects (N of 1 RCT`s).||Oslo University Hospital|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|September 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01266473||111316|
NCT01266720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|689|HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)|Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer||Fukushima Medical University|Yes|Active, not recruiting|April 2008|March 2012|Anticipated|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|80 Years|No|||December 2010|December 23, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266720||111297|
NCT01267071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114136|A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers|A Single Dose, Open Label, Nonrandomized, Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers||GlaxoSmithKline|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 26, 2011|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01267071||111270|
NCT01267682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR012242|Cognitive Intervention For Delirium in Dementia|Reserve For Delirium Superimposed On Dementia (DSD)||Penn State University|Yes|Active, not recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|256|||Both|65 Years|N/A|No|||September 2015|September 30, 2015|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267682||111223|
NCT01277315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-ALS01|Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis|Open Safety and Tolerability Trial to Evaluate a Subcutaneous Injection Solution of 100 mg of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis||Charite University, Berlin, Germany|No|Recruiting|February 2011|||June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2011|February 25, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277315||110482|
NCT01277328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25332|An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|Tocilizumab (RoActemra) poST Marketing Observational Study in DMARD-IR Patients to Assess Efficacy and Safety in routiNE Clinical Practice - STONE||Hoffmann-La Roche||Terminated|May 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|95|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis receiving RoActemra/Actemra|December 2015|December 1, 2015|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277328||110481|
NCT01277575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS-PP-2010-08-25-001|Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia|Multicenter Study of Non-invasive Repetitive Paraorbital Alternating Current Stimulation of the Brain: Therapy for Aphasy||University of Magdeburg|No|Terminated|December 2010|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|75 Years|No|||January 2011|December 18, 2013|January 14, 2011||No|recruitment efforts did not result in a sufficient number of patients|No||https://clinicaltrials.gov/show/NCT01277575||110462|
NCT01277861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092010-013|Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment|Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment||University of Texas Southwestern Medical Center|Yes|Completed|January 2011|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|64 Years|No|||March 2013|March 14, 2013|November 3, 2010||No||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01277861||110440|
NCT01269034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 -435|New Onset Type 1 Diabetes: Role of Exenatide|New Onset Type 1 Diabetes: Role of Exenatide||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|December 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269034||111119|
NCT01269398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARZ-004-HMO-CTIL|GO-LIF With Percutaneous Facet Fusion|Achieving Solide Fusion, Comibing the GO-LIF Procedure for Spinal Fixation and Stabilization With Percutaneous Posetrior Facets Fusion.||Hadassah Medical Organization||Not yet recruiting||||August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment|2||||||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269398||111091|
NCT01269411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02565|RO4929097 in Treating Patients With Recurrent Invasive Gliomas|Phase I Pharmacodynamic and "High Content" Study of the Gamma-Secretase Inhibitor RO4929097 in Patients With Recurrent Malignant Gliomas (MGs) Targeting p75NTR to Inhibit Brain Tumor Initiating Cells (BTICs) and Recurrent Invasive Gliomas||National Cancer Institute (NCI)||Terminated|July 2011|||February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|December 31, 2010|No|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT01269411||111090|
NCT01269658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08636|A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)|A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis||Merck Sharp & Dohme Corp.||Terminated|December 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|14 Years|70 Years|No|||October 2013|October 29, 2013|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269658||111071|
NCT01269671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 10/102|Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain|Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain|FAP|Medical College of Wisconsin|Yes|Withdrawn|January 2011|April 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|18 Years|No|||August 2015|August 21, 2015|January 3, 2011|Yes|Yes|PI has left institution|No||https://clinicaltrials.gov/show/NCT01269671||111070|
NCT01269879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIBES-2010|VIBration Training in EpicondylitiS|Vibration Training in Epicondylitis - a Randomized Trial|VIBES|Hannover Medical School|No|Not yet recruiting|January 2011|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||January 2011|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269879||111054|
NCT01269905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COAG-001|Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management|||Johann Wolfgang Goethe University Hospitals||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|||||Both|18 Years|90 Years|No|Non-Probability Sample|Patients received heart valve replacement and were retrospectively allocated in three        groups|January 2005|January 3, 2011|January 3, 2011||||No||https://clinicaltrials.gov/show/NCT01269905||111052|
NCT01269294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017491|TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers|A Double-blind, Double-dummy, Randomized, 4-period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of TMC435 on the QTc Interval in Healthy Subjects||Tibotec Pharmaceuticals, Ireland|Yes|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|December 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01269294||111099|
NCT01269606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-3877|Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes|A Trial Comparing the Pharmacokinetic Properties of Insulin Aspart With Fast-acting Insulin Human Following Intravenous Infusion or Intramuscular Injection in Japanese Subjects With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Both|20 Years|65 Years|No|||June 2014|June 13, 2014|January 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01269606||111075|
NCT01265888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol # GeNO-P-2010-002|Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.|A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl.|PHiano|Geno LLC|No|Recruiting|March 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|75|||Both|18 Years|80 Years|No|||October 2015|October 29, 2015|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265888||111361|
NCT01266226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP01|Effect of ACP on Surgical Repair of Rotator Cuff Tears|Effect of Autologous Plasma (ACP) on Surgical Repair of Rotator Cuff Tears||Schulthess Klinik|Yes|Completed|December 2010|February 2015|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266226||111335|
NCT01266733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006111057|Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment|Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment||Hospital Galdakao-Usansolo|Yes|Completed|February 2007|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|N/A|No|||December 2010|June 17, 2015|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266733||111296|
NCT01266746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye001|Optical Coherence Tomography in Gas-filled Eyes|Clinical Observation of Postoperative Status of Macular Hole in Gas-filled Eyes by Spectral Domain-optical Coherence Tomography||Kyorin University|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|37|||Both|35 Years|85 Years|No|Non-Probability Sample|The patients who had a vitreous surgery for macular hole, macular hole retinal detachment,        myopic traction maculopathy and examined spectral domain optical coherence tomography        preoperatively and postoperatively.|December 2012|December 31, 2012|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01266746||111295|
NCT01267370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FiberCCF-EPM1|Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial|Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial|SOYFIBER|Federal University of São Paulo|No|Completed|January 2002|October 2003|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|2 Years|12 Years|No|||October 2003|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267370||111247|
NCT01266759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-261z|Efficacy of Combined Contraceptive Vaginal Ring(NuvaRing)in Women With Idiopathic Menorrhagia|Combined Contraceptive Vaginal Ring or Norethisterone for Treatment of Idiopathic Menorrhagia||Mansoura University|Yes|Completed|July 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Female|20 Years|35 Years|No|||December 2010|December 23, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266759||111294|
NCT01267669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-PHT-01|A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding|A Double Blind Randomized Placebo-Controlled Trial of Somatostatin in Association With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding|AVB-EVL+S|Govind Ballabh Pant Hospital|No|Completed|November 2005|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|12 Years|75 Years|No|||December 2010|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267669||111224|
NCT01268241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW02/2010|The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease|International Observational Retrospective Case Review of Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Males and Females With Anderson-Fabry Disease|SWITCH|University of Rostock|Yes|Recruiting|December 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|Samples With DNA|Plasma and urine GB3 and lyso-GB3 and agalsidase antibodies will be analyzed in central      laboratories, there is consent for extra blood samples to be taken (at the time of the      switch and after 6, 12 and 24 months)|Both|18 Years|N/A|No|Probability Sample|Hemizygous male or heterozygous female patients at 18 years with genetically confirmed        diagnosis of Anderson-Fabry disease|February 2016|February 8, 2016|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268241||111180|
NCT01268254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-48200805|Red Wine and Ageing and Atherosclerosis|The Red Wine Project: a Study of Ageing Indexes and Prevalence of Atherosclerosis in Regular Red Wine Consumers Versus Abstainers||University of Sao Paulo|No|Recruiting|October 2009|April 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|total blood sample|Male|50 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|male subjects, between 50 years-old and 70 years-old, divided in 2 groups: usual red wine        consumers and red wine abstemious|September 2010|December 28, 2010|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268254||111179|
NCT01267994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DC011827-01|A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease|A Phase I/II Open-label Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease||Northwell Health|Yes|Completed|June 2011|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|13 Years|75 Years|No|||March 2015|March 23, 2015|December 28, 2010|No|Yes||No|September 16, 2014|https://clinicaltrials.gov/show/NCT01267994||111199|
NCT01277874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36738|Oscillatory Versus Non-Oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support|Oscillatory Versus Non-Oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support||University of Utah|No|Suspended|December 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|246|||Both|N/A|28 Days|No|||December 2015|December 23, 2015|January 13, 2011||No|PI has left Institution|No||https://clinicaltrials.gov/show/NCT01277874||110439|
NCT01278095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0555-CL-103|Oral Bioavailability of GLPG0555 in Different Solid Formulations|A Randomized, Open Label, 3-way Crossover Study to Compare the Oral Bioavailability of GLPG0555 After Single-dose Intake in Healthy Subjects as a Solid Dispersion Formulation, With and Without Food, Relative to a Nanosuspension Formulation||Galapagos NV|No|Completed|January 2011|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 23, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278095||110422|
NCT01278108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0778-CL-101|First-in-Human Single Ascending and Multiple Dose of GLPG0778|Double-blind, Placebo-controlled, Dose-ranging Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Oral Doses, and Multiple Oral Doses of GLPG0778 in Healthy Subjects.||Galapagos NV|No|Completed|December 2010|May 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278108||110421|
NCT01278342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMS995BIC03|Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients|An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventional Regimen|HOSCAR|Novartis||Completed|September 2006|November 2009|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|70|||Both|18 Years|N/A|No|||April 2011|April 20, 2011|January 14, 2011||No||No|January 22, 2011|https://clinicaltrials.gov/show/NCT01278342||110403|
NCT01278615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02558|Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma||National Cancer Institute (NCI)|Yes|Terminated|December 2010|May 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2014|January 4, 2016|January 15, 2011|Yes|Yes|Closed Prematurely.|No|September 4, 2015|https://clinicaltrials.gov/show/NCT01278615||110382|
NCT01278628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19200049sagasumco|SUMCO Metabolic Syndrome Project|||Fukuoka University|Yes|Recruiting|August 2009|||December 2011|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|80|||Both|40 Years|74 Years|Accepts Healthy Volunteers|||July 2009|June 23, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278628||110381|
NCT01269047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 -436|Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia|Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|December 2010|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|12 Years|21 Years|No|||January 2016|January 12, 2016|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269047||111118|
NCT01269385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS1084|Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia|Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial||Mayo Clinic|Yes|Active, not recruiting|January 2011|||June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|December 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269385||111092|
NCT01269931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-23051|Evaluation of Clinical Endobronchial Ultrasound Skills Following Clinical Versus Simulation Training.|Evaluation of Clinical Endobronchial Ultrasound Skills Following Clinical Versus Simulation Training.||University of Calgary|Yes|Completed|June 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|18 Years|N/A|No|Probability Sample|A prospective, comparative study of 2 groups of learners, performing EBUS-TBNA on        patients. Patients are randomly assigned to undergo bronchoscopy with a trainee from Group        1 or Group 2. Learners are pulmonary medicine trainees at the University of Calgary.        Patients are suspected lung cancer patients with mediastinal adenopathy seen by the        University of Calgary Interventional Pulmonary Medicine service.|December 2010|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269931||111050|
NCT01270191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB 201010013MB|The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients|The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients||Taipei Veterans General Hospital, Taiwan|No|Recruiting|November 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|30 Years|70 Years|No|||June 2013|June 26, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270191||111030|
NCT01265914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-01.1_CS_01|A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine|A Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of an Influenza A Vaccine (FP-01.1)||Immune Targeting Systems Ltd|Yes|Completed|August 2010|August 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265914||111359|
NCT01270152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0925-0586|Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter|Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter.||University of Sao Paulo|Yes|Completed|October 2008|July 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|21|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270152||111033|
NCT01270139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NANOM-FIM|Plasmonic Nanophotothermic Therapy of Atherosclerosis|Plasmonic Photothermal Therapy of Flow-Limiting Atherosclerotic Lesions With Silica-Gold Nanoparticles: a First-in-Man Study|NANOM-FIM|Ural Medical University|Yes|Completed|April 2007|June 2010|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|180|||Both|45 Years|65 Years|No|||October 2015|October 26, 2015|December 30, 2010|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01270139||111034|The study was launched as a PROBE trial. But randomization was broken because of the specific study design, where procedures differ significantly, and impossibility to calculate sample size due to absolute novelty of the technology.
NCT01270165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0168|Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B|Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months||Yonsei University|Yes|Recruiting|June 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|20 Years|70 Years|No|||January 2012|January 31, 2012|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270165||111032|
NCT01265901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA901-301|IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma|A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma||immatics Biotechnologies GmbH|Yes|Completed|December 2010|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265901||111360|
NCT01266239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-REVERSE|Comparison Between Everolimus-eluting Stent (EES) and Sirolimus-eluting Stent (SES) in the Bifurcation Lesion|Japanese Registry Study in Comparison Between Everolimus-eluting Stent and Sirolimus-eluting Stent for the Bifurcation Lesion|J-REVERSE|Shin Yukuhashi Hospital|Yes|Recruiting|July 2010|July 2015|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|300|||Both|20 Years|85 Years|No|||December 2010|December 23, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266239||111334|
NCT01266512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_05158|Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer|Phase II Study of Concurrent Chemoradiotherapy Using IMRT (With Single Photon Emission Computed Tomography/SPECT-CT to Define Functional Lung Volume and Positron Emission Tomography/PET to Define Gross Tumour Volume/GTV) and Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer (NSCLC)|C-CRISP|Sanofi||Completed|January 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|December 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01266512||111313|
NCT01266486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-TSC-647|Effect of Metformin on Breast Cancer Metabolism|A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy||Oxford University Hospitals NHS Trust|No|Completed|May 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|41|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266486||111315|
NCT01266499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPCCTIL|A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).|A Randomized Open Label Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).||Rambam Health Care Campus|No|Active, not recruiting|July 2009|January 2012|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|N/A|No|||July 2009|December 23, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266499||111314|
NCT01266772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/213/10/KE|Effect of Montelukast in Asthma in Children|The Effect of Montelukast on Anti-inflammatory Treatment and Asthma Exacerbation Prevention in Children Sensitive to Dust Mites.||Medical Universtity of Lodz|Yes|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|6 Years|14 Years|No|||February 2013|February 6, 2013|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266772||111293|
NCT01267110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12371|Engaging Diverse Underserved Communities to Bridge the Mammography Divide|Engaging Diverse Underserved Communities to Bridge the Mammography Divide||University of Kansas Medical Center|No|Completed|September 2010|August 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|261|||Female|40 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 15, 2015|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01267110||111267|
NCT01268826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00482-37|DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children|DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children.|DESHYDRAT|Rennes University Hospital|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Urine|Both|9 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|500 children aged 9-11|January 2011|January 21, 2011|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01268826||111135|
NCT01269099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-2010-01-24|Hypokalemia and Intravenous Patient Controlled Analgesia|Hypokalemia and Intravenous Patient Controlled Analgesia||Seoul Medical Center|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|80 Years|No|||December 2010|January 3, 2011|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01269099||111114|
NCT01268553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tyvaso Switch|Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication|Transition From Parenteral Prostanoids to Inhaled Treprostinil||Los Angeles Biomedical Research Institute|No|Active, not recruiting|August 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|80 Years|No|||March 2016|March 2, 2016|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268553||111156|
NCT01278121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.1122.3|Study of the Potential of a Macronutrient Balanced Normocaloric Diet to Treat Lifestyle Diseases|Food and Health; Testing of the Anti-Inflammatory Potential of a Macronutrient Balanced Normocaloric Diet||Norwegian University of Science and Technology|Yes|Completed|February 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|16 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 3, 2012|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01278121||110420|
NCT01278355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2010.041dt|Assessing the Feasibility of Integrating Ear Acupuncture Into the Aeromedical Evacuation System From RAB to AAFB|The Feasibility of Integrating Ear Acupuncture for Pain in Patients Being Transported Via the Aeromedical Evacuation System From Ramstein Air Base to Andrews AFB, Maryland USA: An Observational Study||Samueli Institute for Information Biology||Completed|January 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|Military beneficiaries undergoing aeromedical evacuation from Ramstein Air Base to Andrews        Air Force Base who are experiencing pain.|December 2012|December 2, 2013|January 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01278355||110402|
NCT01278368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOADJUVANT_MATCH|Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection|PREOPERATIVE CHEMOTHERAPY DOES NOT ADVERSELY AFFECT SHORT-TERM OUTCOME AFTER PANCREATIC RESECTION.||Università Vita-Salute San Raffaele|No|Completed|January 2003|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||December 2012|December 21, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278368||110401|
NCT01278641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082-07|Men With Fibromyalgia or Chronic Widespread Pain - Effect of Exercise on Symptoms and Body Functions|Men With Fibromyalgia or Chronic Widespread Pain - Effect of Exercise on Symptoms and Body Functions||Göteborg University|No|Completed|January 2008|November 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|44|||Male|18 Years|60 Years|No|||April 2008|January 18, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278641||110380|
NCT01274598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AT002952-01A2|Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects|Open Label Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects||Massachusetts General Hospital|Yes|Completed|December 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|January 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274598||110691|
NCT01269424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE6307|O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma|O6-Benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis||Case Comprehensive Cancer Center|Yes|Recruiting|December 2010|June 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|70 Years|No|||April 2015|July 27, 2015|December 31, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01269424||111089|
NCT01269437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM2010002|Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma|Open-label, Randomized, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Budesonide Novolizer Dry Powder Inhaler Compared With Budesonide Turbuhaler Dry Powder Inhaler in Chinese Mild to Moderate Asthma Patients||NovaMed Pharmaceuticals Inc.|Yes|Recruiting|December 2010|October 2011|Anticipated|October 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|332|||Both|12 Years|70 Years|No|||April 2011|August 22, 2011|December 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01269437||111088|
NCT01269684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ACH04|Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients|A 6-Month Open Pilot Study to Investigate the Safety and Tolerability of Immediate Conversion From Calcineurin Inhibitor Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients|HERMES|Novartis||Suspended|August 2008|||June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|October 5, 2010||No|No patient has never been included in the trial|No||https://clinicaltrials.gov/show/NCT01269684||111069|
NCT01269944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dGEMRIC HTO|Effects of Osteotomies Around the Knee on Cartilage Glycosaminoglycan Content Using dGEMRIC Non-invasive Imaging|Effects of Osteotomies Around the Knee on Cartilage Glycosaminoglycan Content Using dGEMRIC Non-invasive Imaging, a Pilot Study||UMC Utrecht|Yes|Active, not recruiting|July 2007|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|85 Years|No|Probability Sample|All patients above 18 years with osteoarthritis of the knee and a future planned osteotomy        of the tibia or femur are eligible for participation in this study.|January 2011|January 3, 2011|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01269944||111049|
NCT01269957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMB029/2009|Halitosis and Mouth Breathing in Children|Halitosis and Mouth Breathing in Children||University of Nove de Julho|Yes|Completed|November 2009|August 2010|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|55|||Both|3 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|All children registered at the clinic of the specialization course in pediatric dentistry        of the ABCD/SP in 2008 were included in the study.        The children were divided into two groups based on breathing pattern (nasal and mouth) for        the evaluation of halitosis. Breathing pattern was determined by a clinical evaluation and        specific tests (mirror test and water-in-mouth test) and confirmed by the evaluation of an        otolaryngologist.|August 2010|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269957||111048|
NCT01265953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Portland VA-09-0607|Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation|Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation||Portland VA Medical Center|Yes|Recruiting|July 2011|||April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Male|21 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 25, 2013|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265953||111356|
NCT01269918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1056|A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain|A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain|RemivsDex|Outcomes Research Consortium|Yes|Recruiting|February 2011|March 2013|Anticipated|February 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|80 Years|No|||February 2013|February 8, 2013|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01269918||111051|
NCT01265875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-01|Secretin Infusion for Pain Due to Chronic Pancreatitis|Secretin Infusion for Pain Due to Chronic Pancreatitis||ChiRhoClin, Inc.|Yes|Completed|December 2010|April 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|70 Years|No|||March 2016|March 8, 2016|December 22, 2010|Yes|Yes||No|July 29, 2013|https://clinicaltrials.gov/show/NCT01265875||111362|
NCT01266798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK S-07414b [1.2007.2076]|Effects of a Patient Directed Web-portal to Improve Health Literacy Skills|Effects of a Patient Directed Web-portal to Improve Health Literacy Skills|PREP|Oslo and Akershus University College of Applied Sciences||Completed|March 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 2, 2014|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266798||111291|
NCT01266811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017743|A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma||Centocor, Inc.|Yes|Withdrawn|July 2011|December 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|December 23, 2010|Yes|Yes|Study canceled based on results of different study with similar hypothesis, investigational    agent, & patient|No||https://clinicaltrials.gov/show/NCT01266811||111290|
NCT01266252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2010/786|Dexmedetomidine in Mechanically Ventilated Neonates With Single-Organ Respiratory Failure.|Dexmedetomidine Pharmacokinetics - Pharmacodynamics in Mechanically Ventilated Neonates With Single-organ Respiratory Failure (NEODEX).|NEODEX|University Hospital, Ghent|Yes|Recruiting|February 2011|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|1 Month|No|||May 2015|May 11, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266252||111333|
NCT01267422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAVCT-2|Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)|Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy|rAAV2-ND4|Huazhong University of Science and Technology|Yes|Completed|April 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|8 Years|60 Years|No|||May 2015|May 17, 2015|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267422||111243|
NCT01267435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-8|Evaluation of Tibial and Femoral Tunnel Position After Arthroscopic Reconstruction of the Anterior Cruciate Ligament|Study of Evaluation of Tibial and Femoral Tunnel Position After ACL Reconstruction||Isfahan University of Medical Sciences|Yes|Completed|October 2008|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267435||111242|
NCT01266785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6572|Infliximab, Regulatory T Cells, IL2 and Crohn's Disease|Analysis of Relationship Between Infliximab Treatment Response, Regulatory T Cells, and Interleukin-2 in Crohn's Disease||Oregon Health and Science University|Yes|Recruiting|December 2010|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2010|July 20, 2011|December 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266785||111292|
NCT01267123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1173017|The Value of the Trendelenburg Position During Routine Colonoscopy: A Pilot Study.|The Value of the Trendelenburg Position During Routine Colonoscopy: A Pilot Study.||University of Missouri-Columbia||Not yet recruiting|January 2011|||December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|40|||Both|18 Years|75 Years|No|||December 2010|December 23, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267123||111266|
NCT01267409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EmotionalPD-HMO-CTIL|Mapping and Manipulating the Emotional Territories of the Basal Ganglia in PD Patients|Mapping and Manipulating the Emotional Territories of the Subthalamic (STN) Area in Deep Brain Stimulation (DBS) Treated Parkinson Patients||Hadassah Medical Organization|No|Recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|40 Years|75 Years|No|||January 2012|January 12, 2012|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01267409||111244|
NCT01269112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-069(NAC 09-27)|Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy|Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial||University Hospital, Geneva|Yes|Recruiting|November 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||December 2010|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269112||111113|
NCT01269463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-BP-EF001|Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting|A Randomized, Double-Blind Study of the Time Course of Response to Biphentin Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting||Rhodes Pharmaceuticals, L.P.|No|Completed|December 2010|February 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|6 Years|12 Years|No|||January 2013|January 22, 2013|December 31, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269463||111086|
NCT01278134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP25213|A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)|INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment With a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir Boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) With or Without Copegus® in Interferon Naïve HCV Genotype 1 Infected Patients||Hoffmann-La Roche||Completed|February 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|170|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278134||110419|
NCT01278381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANCREATICODUODENECTOMY_SCORE|Prognostic Score To Predict Major Complications After Pancreaticoduodenectomy|A PROGNOSTIC SCORE TO PREDICT MAJOR COMPLICATIONS AFTER PANCREATICODUODENECTOMY.||Università Vita-Salute San Raffaele|No|Completed|January 2002|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|700|||Both|18 Years|85 Years|No|Non-Probability Sample|700 patients undergoing pancreaticoduodenectomy in our Institution from 2002 to 2010|November 2010|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278381||110400|
NCT01278394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-201 Cohort 3|Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail|An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail||Anacor Pharmaceuticals, Inc.|No|Completed|March 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|65 Years|No|||July 2014|July 25, 2014|January 14, 2011|Yes|Yes||No|July 25, 2014|https://clinicaltrials.gov/show/NCT01278394||110399|
NCT01278654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walkstation2|Lottery Incentives for Moving|||Harvard University|Yes|Completed|March 2011|August 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|212|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278654||110379|
NCT01269697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/31|Lutein Influence on Macula of Persons Issued From Amd Parents|Lutein Influence on Macula of Persons Issued From Amd Parents|LIMPIA|University Hospital, Bordeaux|Yes|Completed|January 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269697||111068|
NCT01266291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811542|Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients|Sabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability Study|STARS: TS|University of Pennsylvania|Yes|Recruiting|August 2010|December 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266291||111330|
NCT01266551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3204|Car Safety Seat and Gastroesophageal Reflux Disease|The Car Safety Seat; Cause of Increased Gastroesophageal Reflux Disease in Infants?||University Hospital, Antwerp|No|Terminated|October 2008|August 2010||August 2010||N/A|Interventional|Primary Purpose: Treatment|1||||||Both|N/A|6 Months|No|||October 2008|December 21, 2010|December 21, 2010||No|Intended number of patients reached|No||https://clinicaltrials.gov/show/NCT01266551||111310|
NCT01265927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0314|A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer|A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer||Indiana University|Yes|Completed|January 2011|October 2015|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|December 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01265927||111358|
NCT01265940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZITM1|Pazopanib and Vinflunine in Urothelial Cancer of the Bladder|Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment||Lukas-Krankenhaus GmbH|No|Completed|March 2011|August 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265940||111357|
NCT01266265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIN-PH-403|Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies|A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution|Aspire|United Therapeutics|No|Completed|December 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1333|||Both|N/A|N/A|No|Non-Probability Sample|community centers, academic institutions|January 2016|January 20, 2016|December 22, 2010|No|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT01266265||111332|
NCT01270178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110103|Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy|Prospective Trial of Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy||Taipei Veterans General Hospital, Taiwan|No|Not yet recruiting|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|420|||Both|20 Years|N/A|No|Non-Probability Sample|chronic hepatitis B patients received RFA therapy for HCC|January 2011|January 4, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270178||111031|
NCT01266824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812311|Proparacaine and Mydriatic Eye Drops|Randomized Control Trial of the Effects of Proparacaine on the Pain Response to Mydriatic Eye Drops||Children's Hospital of Philadelphia|Yes|Terminated|December 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|5|||Both|N/A|N/A|No|||February 2013|February 15, 2013|December 21, 2010||No|Recruitment for the study has been terminated due to poor enrollment|No|December 10, 2012|https://clinicaltrials.gov/show/NCT01266824||111289|Enrollment for the randomized controlled study above was poor and the study was terminated without patient analysis. An observational study of the pain response to mydriatic eye drops without use of Proparacaine was completed in place of this trial.
NCT01266837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001LDE36T|Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)|An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy|MARC-2|iOMEDICO AG|Yes|Active, not recruiting|March 2011|September 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266837||111288|
NCT01266850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0017|Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules|Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|March 2011|March 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|1384|||Both|6 Weeks|14 Weeks|Accepts Healthy Volunteers|||September 2014|October 23, 2014|December 23, 2010|Yes|Yes||No|October 9, 2014|https://clinicaltrials.gov/show/NCT01266850||111287|
NCT01267136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010-086|A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy|A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy||Children's Hospitals and Clinics of Minnesota|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|4 Years|15 Years|No|||March 2014|March 11, 2014|December 23, 2010||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01267136||111265|There was insufficient power to detect differences in safety.
NCT01267448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-10-182|Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia|A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia||John H. Stroger Hospital|Yes|Recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2010|April 15, 2011|December 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267448||111241|
NCT01267461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015-10-MMC|Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells|||Meir Medical Center||Available||||||N/A|Expanded Access|N/A|||||||Female|18 Years|90 Years||||August 2012|August 9, 2012|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267461||111240|
NCT01267721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-029|Macrophage Migration Inhibitory Factor (MIF)- Cardiac Surgery|Macrophage Migration Inhibitory Factor (MIF) as a Marker of Perioperative Inflammatory Reaction During Heart Surgery||RWTH Aachen University|No|Completed|January 2011|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|inflammatory markers (different)|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing open heart surgery and use of heart lung device|October 2014|October 7, 2014|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01267721||111220|
NCT01268007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-46|Heartbeat Sensitivity Calibration Using the ECG Accessory|This is an Observational, Un-blinded, Non-significant Risk, Non-interventional Study Designed to Collect ECG Data on at Least One Subject Out of a Pool of up to Three (3) Healthy Male Subjects at One Clinical Site (Clinical Trials of Texas).||Cyberonics, Inc.|Yes|Completed|December 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Male|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Normal Healthy male|December 2010|January 20, 2011|December 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01268007||111198|
NCT01268566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI-575-1042|A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme|A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme||MedImmune LLC|No|Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|95 Years|No|||March 2014|March 14, 2014|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268566||111155|
NCT01268813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METASC011|Personalized Medicine for Diabetes Prediction and Prevention of Complications|Personalized Medicine in Diabetes Using a Nanotechnology Platform||Rambam Health Care Campus|No|Not yet recruiting|February 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2010|December 30, 2010|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268813||111136|
NCT01269125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003/89 PGNI|GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.|Ultralong Administration of GnRH-a Before in Vitro Fertilization Improves Fertilization Rate But Not Pregnancy Rate in Women With Endometriosis. A Prospective, Randomized, Controlled Trial.||University of Ioannina|No|Completed|May 2004|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Female|29 Years|38 Years|No|||July 2013|July 23, 2013|January 3, 2011||No||No|June 29, 2012|https://clinicaltrials.gov/show/NCT01269125||111112|
NCT01269476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-001-PH1-09|Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers|Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers||SeneXta Therapeutics SA|No|Completed|December 2009|August 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 31, 2010|September 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01269476||111085|
NCT01269489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134/09/09|Health-related Quality of Life in General Slovenian Population|Health-related Quality of Life in General Slovenian Poplation Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire QLQ-C30||Institute of Oncology Ljubljana|No|Recruiting|December 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|sample from general Slovenian population|March 2012|March 23, 2012|January 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01269489||111084|
NCT01278407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-341|A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase||Eisai Inc.||Completed|February 2011|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|142|||Both|50 Years|N/A|No|||December 2015|December 30, 2015|January 14, 2011||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT01278407||110398|
NCT01278667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-10-BNZ|Methylphenidate and the Relations Between Emotional Processing and Social Functioning Among Children With ADHD|Difficulties in Emotional Processing, the Influence of Methylphenidate on This Processing and the Relations Between Emotional Processing and Social Functioning Among Children With ADHD||Bnai Zion Medical Center|No|Recruiting|January 2011|June 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|80|||Both|9 Years|12 Years|No|Non-Probability Sample|Children with ADHD are in high risk to develope social difficulties. The present study        will examine the emotional processing in those children. The main purpose is to        investigate the connection between memory and recognition of facial expressions, how those        abilities influence social functioning and if Methylphenidate influence the emotional        processing.        The study will include 80 children in ages 9-12 years, recruited from a community sample        include schools in Haifa. They will devided in 2 groups; children with ADHD treated with        Methylphenidate, and healthy children without ADHD. The children will do computerized        tasks that examine recognition and memory of facial expressions. Social function will be        examined by questionnaires filled by parents and teachers.|January 2011|January 23, 2011|January 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01278667||110378|
NCT01278680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walkstation3|Incentives for Moving|||Harvard University|Yes|Withdrawn|February 2011|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|January 18, 2011||No|Enrollment has not begun; study suspended indefinitely due to change in management at company    where we were going to conduct the study.|No||https://clinicaltrials.gov/show/NCT01278680||110377|
NCT01274624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REO 022|Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer|A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer||Oncolytics Biotech|No|Recruiting|December 2010|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01274624||110689|
NCT01265966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMC 32H10|Cortisol Response to Moderate and Deep Sedation in Children|Characterization of the Normal Cortisol Response to Moderate and Deep Sedation in Adrenally Sufficient Children||Tripler Army Medical Center|Yes|Completed|December 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|149|None Retained|This is an observational study measuring salivary cortisol levels. No interventions will      done based on these measurements during the study. Specimens will be disposed off at the end      of the study.|Both|3 Months|18 Years|No|Non-Probability Sample|Male and female military health care beneficiaries ages 3 months to 18 years of age        presenting to the Tripler Army Medical Center pediatric sedation uni twho do not have any        diagnosis consistent with or concerning for adrenal insufficiency, to include recent        tapering of exogenous steroids in the last 6 months.|March 2013|March 8, 2013|December 22, 2010||No||No|December 8, 2012|https://clinicaltrials.gov/show/NCT01265966||111355|There is concern that the presence of a cortisol response is merely a biochemical phenomena and not of clinical importance for minor surgeries/mild stress.
NCT01265979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52989|WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib|Whole Body Diffusion-weighted MRI (WB-DWI) for Early Prediction and Evaluation of Therapy Response in Patients With Advanced Metastatic Gastrointestinal Stromal Tumors (GIST) Treated With Regorafenib.||Universitaire Ziekenhuizen Leuven|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|5|||Both|N/A|N/A|No|Non-Probability Sample|patients with advanced, metastatic gastro-intestinal stromal tumors treated with        regorafenib or placebo|April 2015|April 9, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265979||111354|
NCT01266304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT006453 -1|The Healing Context in Complementary and Alternative Medicine (CAM): Instrument Development and Initial Validation|The Healing Context in CAM: Instrument Development and Initial Validation|HEAL|University of Pittsburgh|Yes|Completed|January 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample, conventional primary care clinic, and integrative medicine clinic.|November 2015|November 30, 2015|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01266304||111329|
NCT01266317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10110151|Combined PEX, Rituximab and Steroids in Acute IPF Exacerbations|Open-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations||University of Pittsburgh|Yes|Active, not recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2016|January 4, 2016|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266317||111328|
NCT01266564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25198|An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer|A Non-interventional Multicenter Study of First-line Avastin® (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer||Hoffmann-La Roche||Active, not recruiting|September 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|210|||Both|18 Years|N/A|No|Probability Sample|Colorectal cancer patients receiving Avastin in combination with chemotherapy|March 2016|March 1, 2016|December 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01266564||111309|
NCT01266278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2010/637|Analysis of Sport Specific Adaptations of the Shoulder in Adolescent Elite Handball Players and the Influence of the Preventive Use of Tape on These Outcome Measurements.|Analysis of Sport Specific Adaptations of the Shoulder in Adolescent Elite Handball Players and the Influence of the Preventive Use of Tape on Shoulder Strength, Mobility, the Position of the Scapula and the Size of the Subacromial Space.||University Ghent|No|Completed|November 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Female|15 Years|25 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01266278||111331|
NCT01266863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABoyer3|E Test Strips Applied to Bronchoalveolar Lavage for Suspicion of Hospital-acquired Pneumonia to Accelerate Antibiogram Analysis.|||Université Victor Segalen Bordeaux 2|No|Completed|September 2010|December 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266863||111286|
NCT01266525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRI10734|Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy||Sanofi|Yes|Completed|February 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|291|||Both|55 Years|N/A|No|||February 2016|February 12, 2016|December 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266525||111312|
NCT01267474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPQ:474135/2006-3|Reducing the Use of Sugar by School Lunch Cooks in Public Schools|Reducing the Use and the Consumption of Sugar by School Lunch Cooks in Public Schools: a Cluster Randomized Trial||Rio de Janeiro State University|No|Completed|March 2007|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|95|||Female|18 Years|65 Years|No|||November 2010|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267474||111239|
NCT01267149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-2010|A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines|Phase 4 Study - A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines||Goldman, Butterwick, Fitzpatrick and Groff|Yes|Recruiting|August 2010|||||N/A|Observational|N/A||1|Anticipated|13|||Both|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cosmetic Dermatology Practice Patients|December 2010|December 27, 2010|December 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267149||111264|
NCT01267162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-174-0156|Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients|Long-term Observational Study on Anti-HBV Effect of Tenofovir Disoproxil Fumarate (TDF) and Resistance Surveillance in Asian-American Adult Patients Formerly Participating Gilead 123 Studies||Medical Procare PLLC|Yes|Completed|September 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|75 Years|No|Probability Sample|adult infected with chronic hepatitis B|March 2016|March 14, 2016|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267162||111263|
NCT01267175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETP08-2625|United Kingdom User Evaluation, MiniMed Paradigm® X54 System|United Kingdom User Evaluation, MiniMed Paradigm® X54 System|X54User|Medtronic Diabetes|No|Completed|January 2009|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Both|18 Years|65 Years|No|||February 2011|February 16, 2011|December 23, 2010||No||No|January 21, 2011|https://clinicaltrials.gov/show/NCT01267175||111262|
NCT01268033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I08013|Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood|A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood|NEPHRUTIX|University Hospital, Limoges|No|Completed|December 2010|May 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|2 Years|18 Years|No|||March 2015|March 20, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01268033||111196|
NCT01267734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOST-ASSURE|Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen|Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease|HOST-ASSURE|Seoul National University Hospital|Yes|Recruiting|June 2010|June 2015|Anticipated|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|3750|||Both|18 Years|N/A|No|||December 2013|December 15, 2013|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267734||111219|
NCT01268020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMH3-01|Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC|An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate [18F]-FMH3 by Positron Emission Tomography (PET) for Quantization of the Receptor Histamine-3 in Human|FMH3|Institute for Neurodegenerative Disorders|No|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 8, 2013|December 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01268020||111197|
NCT01268267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2010-008-01|Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting|Clinical Trial Protocol for Ninja 2 System With TATSU Sensor||Ascensia Diabetes Care|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|94|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 28, 2010|Yes|Yes||No|April 27, 2012|https://clinicaltrials.gov/show/NCT01268267||111178|
NCT01268280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 4023|Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis|A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy||Cytokinetics|Yes|Terminated|December 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|80 Years|No|||October 2012|September 16, 2013|December 28, 2010|Yes|Yes|Closed after complete treatment of 32 patients after 21 months' recruitment.|No||https://clinicaltrials.gov/show/NCT01268280||111177|
NCT01268852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Insignia versus Damon Q|Effectiveness of Insignia ™ Versus Standard Orthodontic Treatment With Damon Q Brackets|Effectiveness of Insignia ™ Versus Standard Orthodontic Treatment With Damon Q Brackets||Radboud University|No|Completed|January 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|180|||Both|12 Years|30 Years|No|Probability Sample|Patients are recruited after their recall from the list of patients waiting for active        orthodontic therapy in the private office of orthodontist RP, situated in Zeeland and the        private office of orthodontist JG situated in Noord Brabant (The Netherlands).|January 2016|January 25, 2016|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268852||111133|
NCT01270022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI031216|Development, Implementation and Evaluation of the Impact of a Guideline in Clinical Practise for Cardiovascular Risk|Development, Implementation and Evaluation of the Impact of a Guideline in Clinical Practise for Cardiovascular Risk.||Gerencia De Atencion Primaria Area 2 De Madrid||Completed|January 2004|July 2010|Actual|April 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||||||Both|14 Years|N/A|No|||January 2011|January 4, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270022||111043|
NCT01269502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2009.60|Prevention of Secondary Foot Ulcers in Patients With Diabetes Using Systematic Measuring of Skin Temperature.|Prevention of Secondary Foot Ulcers in Patients With Diabetes. Will People With Diabetes Who Have Had a Foot Ulcer be Able to Prevent Secondary Ulcers by Systematically Measuring Their Skin Temperature?||Oslo University Hospital|No|Completed|June 2009|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Both|18 Years|80 Years|No|||September 2014|September 18, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269502||111083|
NCT01278420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMF vs Restor MF 3D|AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL|AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL||Innovative Medical|No|Recruiting|September 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|August 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01278420||110397|
NCT01278433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV34|A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China|Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study||Sanofi|No|Completed|December 2010|June 2012|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|5007|||Both|60 Days|89 Days|Accepts Healthy Volunteers|||March 2013|March 28, 2013|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278433||110396|
NCT01278693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-11|Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients|Study of Treatment of Dyslipidemia for Hemodialysis||Isfahan University of Medical Sciences|Yes|Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||August 2009|January 18, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278693||110376|
NCT01274637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010303-01H|PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot|Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism|PROSPER|Ottawa Hospital Research Institute|Yes|Completed|March 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|37|||Female|18 Years|N/A|No|||October 2014|October 6, 2014|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274637||110688|
NCT01278706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kmc110154CTIL|Endometrial Biopsy Protocol for In Vitro Fertilization (IVF)|Comparing Timing and Number of Endometrial Biopsies in IVF Treatment and Identifying Biochemical Markers to Predict Endometrial Receptivity||Kaplan Medical Center|Yes|Not yet recruiting|January 2011|||January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||December 2010|January 25, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278706||110375|
NCT01270230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH09089901-A1|A Randomized Controlled Trial of the Bruthas Project|A Randomized Controlled Trial of the Bruthas Project||University of California, San Francisco|No|Active, not recruiting|February 2011|August 2016|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01270230||111027|
NCT01266577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110045|Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle|Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|March 16, 2016|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266577||111308|
NCT01267214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGN-THA-08-01|The Efficacy and Safety of Intraarticular Sodium Hyaluronate (Hyalgan) After Proximal Tibial Osteotomy in Treatment of Knee Osteoarthritis Patients|||TRB Chemedica||Completed|February 2009|July 2011|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|35 Years|65 Years|No|||November 2012|November 20, 2012|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267214||111259|
NCT01266876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1003|Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of REGN727 in Patients With Heterozygous Familial Hypercholesterolemia||Regeneron Pharmaceuticals|Yes|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|77|||Both|18 Years|75 Years|No|||August 2015|August 20, 2015|December 23, 2010|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01266876||111285|
NCT01266889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Measurement of Cerebral Oxygenation Using NIRS Method in the Preterm Infants With Intracranial Haemorrhagia|||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|December 2010|May 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|3 Days|No|Non-Probability Sample|primer care clinic|December 2010|December 23, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01266889||111284|
NCT01266538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-ID-467-CTIL|Inflammatory Bowel Disease(IBD)Database|Epidemiologic, Clinical, Endoscopic and Histological Database of Patients With Inflammatory Bowel Disease (IBD)|IBD|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2011|December 2026|Anticipated|December 2026|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|2500|Samples Without DNA|blood serum, gastrointestinal biopsies, fecal samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|1. Cases: Patients diagnosed with Inflammatory Bowel Disease (IBD) attending the             departement of Gastroenterology (Tel Aviv Sourasky Medical Center) for a regular             follow up / treatment.          2. Controls:Family members of IBD patients, Patients with Irritable Bowel Syndrome             (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient             performing screening endoscopy|December 2010|December 23, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266538||111311|
NCT01267487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 4316/09|Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass|Phase 4 Study of Fixed-dose and Titration Schemes of Heparin and Protamine in Cardiopulmonary Bypass Cardiac Surgeries : Evaluation of Post-operatory Blood Loss and Transfusion Requirements||SANE-Society of Anesthesiology|Yes|Completed|July 2009|November 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|240|||Both|18 Years|75 Years|No|||December 2010|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267487||111238|
NCT01267747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPR-PAPPHY|Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation|Prospective Assessment of The Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation|PAPPHY|University Hospital Padova|Yes|Recruiting|March 2011|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Venous blood will be withdrawn to measure        -  levels of ions (sodium, potassium, magnesium), creatinine, proBNP, and TSH in the           serum, and        -  percent HbA1c levels, plasma aldosterone concentration (PAC), renin concentrations           (DRA) and renin activity (PRA) in the plasma.      A venous blood specimen will be used to separate buffy coat for downstream identification of      SNP associated with primary aldosteronism and development of atrial flutter or fibrillation.      Urine specimens will be collected to measure microalbuminuria.|Both|18 Years|75 Years|No|Probability Sample|Hypertensive patients presenting with atrial fibrillation or flutter AFF) at primary care        European clinics (Internal Medicine, Cardiology, Endocrinology).|March 2014|March 26, 2014|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267747||111218|
NCT01268046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-002311|Effects of Aging and Estrogen on Memory and Cognition|Effects of Aging and Estrogen on Cortical Function||Massachusetts General Hospital|Yes|Recruiting|November 2009|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268046||111195|
NCT01268059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI-575-1031|A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer|A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer||MedImmune LLC|No|Completed|December 2010|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|123|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268059||111194|
NCT01268293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-J081-105|A Study of E7080 in Subjects With Solid Tumor|A Phase 1 Study of E7080 in Subjects With Solid Tumor||Eisai Inc.||Completed|February 2011|April 2013|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||February 2014|February 21, 2015|December 28, 2010||No||No|February 21, 2015|https://clinicaltrials.gov/show/NCT01268293||111176|
NCT01268579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-218|Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma|A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|65 Years|No|||April 2015|April 29, 2015|December 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01268579||111154|
NCT01268839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016984|A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers|A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Subjects||Tibotec, Inc||Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 2, 2013|December 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01268839||111134|
NCT01268865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-240|Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis|Clinical Application of Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis in HBV and HCV-infected Patients|ARFI|China Medical University Hospital|Yes|Recruiting|December 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|HBV or HCV-infected patients about to undergo liver biopsy to assist in clinical decision        making|June 2011|June 2, 2011|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01268865||111132|
NCT01269788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-02-30-10638|Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial|Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial||Tehran University of Medical Sciences|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|144|||Both|18 Years|60 Years|No|||March 2012|March 5, 2012|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269788||111061|
NCT01270256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-660-B|NasoNeb Delivery of an Intranasal Steroid|Evaluation of NasoNeb™ Delivery of an Intranasal Steroid in the Treatment of Perennial Allergic Rhinitis||University of Chicago|Yes|Completed|January 2011|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|55 Years|No|||July 2014|July 17, 2014|January 3, 2011|Yes|Yes||No|June 16, 2014|https://clinicaltrials.gov/show/NCT01270256||111025|
NCT01270035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA80MTX|Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate|||Keio University||Recruiting|January 2011|||January 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||December 2010|June 23, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270035||111042|
NCT01278186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0909|Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions|Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)|BABILON|B.Braun Surgical SA||Active, not recruiting|June 2010|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|N/A|N/A|No|||July 2012|July 16, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278186||110415|
NCT01278446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.42.PED|Extensively Hydrolyzed Formula: Hypoallergenicity|Evaluation of Hypoallergenicity of a 100% Whey, Extensively Hydrolyzed Infant Formula||Nestlé|No|Completed|February 2011|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|2 Months|12 Years|No|||November 2013|November 1, 2013|January 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01278446||110395|
NCT01278459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005759-21|Can Atorvastatin Improve Vascular Function in Women With a History of Preeclampsia?|Can Atorvastatin Improve Vascular Function in Women With a History of Preeclampsia? A Randomised, Double-blinded, Placebo-controlled Crossover Trial of Atorvastatin in Women With a History of Preeclampsia.|PVS3|University of Oxford|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|11|||Female|18 Years|50 Years|No|||May 2015|May 29, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278459||110394|
NCT01278719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIMSPGS412|The Factors Associated With the Formation of Nasal polyp-a Case Control and Descriptive Study|'The Factors Associated With the Formation of Nasal Polyp'|ACAAGSONP|Karnataka Institute of Medical Sciences|Yes|Recruiting|January 2010|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|180|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with nasal polyps attending Otorhinolaryngology outpatient department at the        Karnataka institute of medical sciences, Hubli which is a tertiary care hospital situated        in the north of Karnataka state in India.The hospital caters to all socioeconomic strata        with vast diversities.|April 2012|April 20, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278719||110374|
NCT01266330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R011770040|Dairy Attenuation of Metabolic Disease|Dairy Attenuation of Oxidative and Inflammatory Stress in Metabolic Syndrome||University of Tennessee|No|Completed|June 2008|January 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|50 Years|No|||December 2010|December 22, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266330||111327|
NCT01266590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12600|A Study of LY2216684 and Digoxin in Healthy Subjects|Effect of LY2216684 on the Pharmacokinetics of Digoxin in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 15, 2011|December 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01266590||111307|
NCT01266603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0113|High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI|A Phase II Trial of High Dose Interleukin-2 (HDIL-2) With Recombinant MAGE-A3 Protein Combined With Adjuvant System AS15 (recMAGE-A3 + AS15) in Patients With Unresectable or Metastatic Melanoma||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2012|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266603||111306|
NCT01266980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113970|A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.|An Open-label, Non-randomized Pharmacokinetic and Safetystudy of Repeat Doses of Fluticasone Furoate and GW642444Mcombination in Healthy Subjects and in Subjects With Severe Renalimpairment.||GlaxoSmithKline|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266980||111277|
NCT01267240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02556|Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|19 Years|N/A|No|||February 2015|July 1, 2015|December 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267240||111257|
NCT01266902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017434|A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1|An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278||Janssen R&D Ireland|No|Active, not recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|483|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01266902||111283|
NCT01267188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1001|Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia|A Phase 2, Open-Label, Dose Titration Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder||Neurocrine Biosciences|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||April 2011|April 18, 2011|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01267188||111261|
NCT01268085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-10-330|Radiation Safety Alert|Radiation Safety Alert- A Randomized Controlled Trial||Montefiore Medical Center|Yes|Active, not recruiting|December 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|2200|||Both|N/A|N/A|No|||December 2010|December 28, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01268085||111192|
NCT01268319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0114|CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow|A Randomized Pilot Trial of the Use of a Distal Protection Device to Prevent Peri-procedural MI During Dilation of Coronary Stenoses Caused by Plaques With Large Lipid Cores|CANARY|InfraReDx|Yes|Terminated|March 2011|||September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|December 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268319||111174|
NCT01267760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mhd1|Clinical and Biochemical Effects of Multipass Hemodialysis|Clinical and Biochemical Effects of Multipass Hemodialysis|MHD|Herlev Hospital|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|90 Years|No|||July 2013|July 6, 2013|January 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01267760||111217|
NCT01267773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH086606|Treatment of Conduct Problems and Depression|Treatment of Youth Comorbid Conduct Problems and Depression||Rhode Island Hospital|Yes|Recruiting|August 2010|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|8 Years|14 Years||||March 2013|March 20, 2013|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01267773||111216|
NCT01268878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC 2010-01|Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol|Hematologic Toxicity Observation of the TPF Medical Protocol. Description of the Impact of Febrile Neutropenia in Patients Who Receive the Chemotherapy of the TPF Medical Protocol in Head and Neck Cell Carcinoma|OTOHTPF|Groupe Oncologie Radiotherapie Tete et Cou|No|Completed|June 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Non-Probability Sample|people who undergo first traitement by chemotherapy (docetaxel+cisplatin+-FU) for head and        neck cell carcinoma, whom age is over eighteen,|January 2014|January 2, 2014|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268878||111131|
NCT01268306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLC-01|Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses|A Single-site, Open-Label Prospective Evaluation of Biocompatibility and Corneal Staining Associated With Use of Bausch & Lomb (B+L) BioTrue Contact Lens Multi-purpose Solution (MPS) and B+L PureVision Contact Lenses.||Epstein, Arthur B., OD, FAAO|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 29, 2010|December 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268306||111175|
NCT01268592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-204A|Fertility Preservation in Female Cancer Patients|Vitrification of Oocytes From Female Cancer Patients to Preserve Their Fertility Potential||Northwell Health|No|Terminated|October 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Female|14 Years|42 Years|No|||April 2013|April 22, 2013|November 1, 2010||No|Study technique has been declared part of standard care|No||https://clinicaltrials.gov/show/NCT01268592||111153|
NCT01269762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001003M|Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules|Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules||National Taiwan University Hospital|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2011|January 2, 2012|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01269762||111063|
NCT01269775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10764|Comparison of Face to Face Lecture, Interactive Internet Based and Computer Based Teaching|Comparison of Face to Face Lecture Based, Interactive Internet Based and Computer Based Teaching Regarding Students' Knowledge Achievement and Satisfaction: A Randomized Controlled Trial||Tehran University of Medical Sciences|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3|||84|||Both|N/A|N/A||||January 2011|January 3, 2011|January 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01269775||111062|
NCT01274156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3060 RMB|Double Blind Placebo Controlled Study on the Effect of Extracorporal Shock Wave Therapy on Erectile Dysfunction|The Effect of Low Intensity Shock Wave Therapy on Erectile Dysfunction in Patients Responding to PDE5i's|LI-ESWT|Rambam Health Care Campus|No|Completed|August 2010|November 2010|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|80 Years|No|||January 2011|January 10, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01274156||110725|
NCT01274169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NANOCTIL|Measurment of GFR by Nasal Sensors|||Rambam Health Care Campus||Completed|March 2008|March 2010||||N/A|Observational|N/A||1|||||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|volunteers subjects with different stages of CKD|February 2008|January 10, 2011|January 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01274169||110724|
NCT01274182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP13-201|GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy|A Randomized, Double-blind, Controlled Study to Evaluate PK, PD, Safety and Efficacy of GP2013 and Rituximab in Patients With Rheumatoid Arthritis Refractory or Intolerant to Standard DMARDs and up to Three Anti-TNF Therapies.||Sandoz|Yes|Active, not recruiting|January 2011|||January 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|297|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274182||110723|
NCT01270048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B070057|The Effect of Bunsimgieum on the Chest Discomfort of Hwa-byung's Major Symptom|The Effect of Bunsimgi-eum(Fenxinqiyin) on the Chest Discomfort of Hwa-byung's Major Symptom : Randomized, Double-blinded, Placebo-control Trial||Korea Health Industry Development Institute|Yes|Completed|May 2008|August 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|144|||Both|20 Years|65 Years|No|||September 2009|January 4, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270048||111041|
NCT01270542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USC-HS-09-00068|Avastin for PDR (Proliferative Diabetic Retinopathy)|Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management|PDR|University of Southern California|No|Completed|June 2009|July 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270542||111003|
NCT01278732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK D-4-10|Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mass|Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mas||Klinikum Wels-Grieskirchen|No|Completed|January 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|March 2015|March 31, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278732||110373|
NCT01274663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731001|A Study Of PF-05175157 In Healthy Volunteers|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-05175157 After Administration Of Single Escalating Oral Doses Under Fasted And Fed Conditions In Healthy Volunteers||Pfizer|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|63|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|January 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01274663||110686|
NCT01274949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3060 radical|The Effect of Low Intensity Shockwave Therapy for ED in Post Radical Prostatectomy Patients Who Didn't Respond to PDE5i|The Effect of Low Intensity Shock Wave Therapy in Post Radical Prostatectomy Severe ED Patients Not Responding to Oral Medication|LI-ESWT|Rambam Health Care Campus|Yes|Completed|February 2010|August 2011|Actual|July 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|80 Years|No|||September 2011|September 13, 2011|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01274949||110664|
NCT01266616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5281|Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults|A Phase I Randomized, Partially Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a Cytokine Enhanced HIV-1 Multi-Antigen (HIV MAG) pDNA Vaccine Delivered Intramuscularly Followed by in Vivo Electroporation (IM/EP) or Intramuscularly in HIV-1 Infected Adults Receiving ART||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2011|April 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|62|||Both|18 Years|55 Years|No|||November 2015|November 24, 2015|December 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01266616||111305|
NCT01266642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0559|Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer|Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2011|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|288|||Female|40 Years|N/A|No|||February 2016|February 8, 2016|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266642||111303|
NCT01266967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113929|A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain|BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain|Break MB|GlaxoSmithKline|Yes|Completed|February 2011|November 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|N/A|No|||March 2014|April 24, 2014|December 2, 2010|Yes|Yes||No|June 24, 2013|https://clinicaltrials.gov/show/NCT01266967||111278|
NCT01272089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-013|A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis|A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis||Alcon Research|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|N/A|No|||September 2012|September 16, 2012|January 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01272089||110884|
NCT01266915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112008-008|Cutaneous Lupus Registry|Molecular Studies on Cutaneous Lupus||University of Texas Southwestern Medical Center|No|Recruiting|January 2009|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects diagnosed with Lupus Erythematosus|December 2014|December 1, 2014|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266915||111282|
NCT01266928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gungorduk10|Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study|||Erzincan Military Hospital|Yes|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|244|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266928||111281|
NCT01266941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111789|A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.|An Open-label, Non-randomized, Pharmacokinetic and Safety Study of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment||GlaxoSmithKline|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|35|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266941||111280|
NCT01266954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113124|An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer|An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer||GlaxoSmithKline||Completed|June 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Female|18 Years|85 Years|No|||January 2012|January 26, 2012|October 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266954||111279|
NCT01267500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R765/49/2010|Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia|Randomized Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia||Singapore National Eye Centre||Terminated|October 2010|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|3 Years|12 Years|Accepts Healthy Volunteers|||November 2014|November 23, 2015|December 27, 2010||No|Difficulty to keep children in randomly assigned groups.|No||https://clinicaltrials.gov/show/NCT01267500||111237|
NCT01267786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnesthSurg1|The Effect of Volatile Anesthetics Sevoflurane and Desflurane on Liver, Renal and Cardiovascular Systems During Liver Surgery|The Effect of Volatile Anesthetics Sevoflurane and Desflurane on Liver, Renal and Cardiovascular Systems During Liver Surgery||Aretaieio Hospital|Yes|Recruiting|December 2010|||December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|30 Years|80 Years|No|||December 2010|December 28, 2010|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01267786||111215|
NCT01267201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0121005|A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form|A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, Crossover Bioavailability Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/Ml to Methylprednisolone 32 Mg Tablet Under Fasted Conditions||Pfizer|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 24, 2012|December 13, 2010|No|Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT01267201||111260|
NCT01267799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|photocopiers|Health Status of Workers in Photocopier Units|Correlation Between Pulmonary Function and Selected Serum/Sputum Biomarkers of Pulmonary Damage Among Workers in Photocopier Units||Avinashilingam Deemed University|No|Recruiting|July 2011|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|exposure to photocopier emissions|July 2012|July 11, 2012|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01267799||111214|
NCT01268072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP221|A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease|A Prospective Observational Study to Evaluate Biomarkers in Acute Exacerbations in Chronic Obstructive Pulmonary Disease||MedImmune LLC|No|Terminated|February 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|61|Samples Without DNA|Symptom, physiological data, blood, and sputum.|Both|40 Years|N/A|No|Non-Probability Sample|The subjects in this study will be adult males or females, ≥40 years of age, at increased        risk for AECOPD (Cohort 1) or who present with severe AECOPD requiring hospitalization        (Cohort 2).|February 2013|February 18, 2013|December 28, 2010||No|Study was completed with 69 subjects enrolled due to difficult enrolment and adequate    biomarker data was avaible with 69 subjects in the study.|No||https://clinicaltrials.gov/show/NCT01268072||111193|
NCT01267812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10137|Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation|A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation||City of Hope Medical Center|Yes|Recruiting|August 2011|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|N/A|No|||December 2015|December 7, 2015|December 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267812||111213|
NCT01267825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low Back Radiculopathy: CT|CT Guided Injection for Low Back Radiculopathy: A Randomized Clinical Trial|A Randomized Trial of CT-guided Perineural Injection With a Corticosteroid Plus a Long Acting Local Anesthetic Versus Standard Medical Management in Patients With Acute Lumbar Radiculopathy and a Corresponding Disc Herniation||Montefiore Medical Center|No|Withdrawn|September 2010|August 2014|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|21 Years|50 Years|No|||July 2011|July 13, 2011|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01267825||111212|
NCT01268605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRL1013|Postoperative Hypersensitivity Randomized Comparative Effectiveness Research Trial|Resin Based Composite Occlusal Restoration Postoperative Hypersensitivity: Randomized Comparative Effectiveness Research Trial|POH RCERT|Pearl Network|Yes|Completed|September 2010|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|341|||Both|15 Years|60 Years|No|||September 2014|September 18, 2014|October 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01268605||111152|
NCT01268618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-SUS-05-NAT-01|Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia|A Double-blind, Randomized, Placebo-controlled, Dual-center Study on the Effect of Healthy Trinity (Retail Label)/Trenev Trio (Professional Label) on Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and Functional Dyspepsia||Sprim Advanced Life Sciences|No|Terminated|January 2011|August 2011|Anticipated|August 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 20, 2011|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268618||111151|
NCT01268332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Population Council #508|Safety and Adherence of a Non-medicated Intravaginal Ring (IVR)|Expanded Safety and Adherence Study of a Non-medicated Intravaginal Ring|MTN-005|Population Council|Yes|Completed|May 2011|||September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|195|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|December 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268332||111173|
NCT01269138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STERProtocol7.0|Treatment of Inherited Factor VII Deficiency|Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study|STER|University of L'Aquila|Yes|Completed|January 2007|November 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|223|Samples Without DNA|Plasma for Factor VII inhibitor assay is stored and sent to a Central Laboratory for the      inhibitor determination. Samples are discharged after the inhibitor determination|Both|N/A|90 Years|No|Non-Probability Sample|Number of patients affected by inherited Factor VII deficiency to be studied Planned        number of patients to be recruited: >200 Planned number of evaluable bleeding episodes        >100 Planned number of surgical procedures >50 It is planned to include patients to the        registry from all over the world|November 2012|November 26, 2012|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269138||111111|
NCT01269515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUSCOX2|Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients|Optional Immunomodulating Therapy and Improved Vaccination Responses by Adjuvant Administration of a Cyclooxygenase Type 2 Inhibitor in Antiretroviral naïve HIV-infected Patients|OUSCOX2|Oslo University Hospital|No|Completed|October 2010|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|No|||November 2014|November 10, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269515||111082|
NCT01269151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LucERG-001|Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD|A Prospective, Non-randomized, Mono-center, Cohort Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections on Retinal Function in Patients With Wet Age-related Macular Degeneration During Twelve Month|LucERG|University of Luebeck|Yes|Completed|October 2010|April 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|50 Years|N/A|No|||April 2015|April 7, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269151||111110|
NCT01269164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB6914|Face Transplantation Clinical Trial|Protocol for Composite Facial Allograft Transplant||The Cleveland Clinic|Yes|Recruiting|July 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|18 Years|60 Years|No|||January 2014|January 28, 2014|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01269164||111109|
NCT01270555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999-P-009198|Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults|Efficacy Of Bupropion SR For Attention Deficit Hyperactivity Disorder (ADHD) In Adults With Recent Past or Current Substance Use Disorders||Massachusetts General Hospital|No|Completed|May 1999|||July 2001|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|60 Years|No|||March 2013|March 4, 2013|January 3, 2011|Yes|Yes||No|January 7, 2011|https://clinicaltrials.gov/show/NCT01270555||111002|
NCT01270802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck 38258|Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients|A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism||Indiana University|Yes|Completed|April 2011|April 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2013|November 24, 2013|January 4, 2011||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT01270802||110983|The study was open-label. Correction for multiple testing was not performed, so apparently significant results may be falsely positive.
NCT01274689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT100111|External Lid Loading for the Temporary Treatment of the Paresis of the M. Orbicularis Oculi: a Clinical Note|External Lid Loading for the Temporary Treatment of the Paresis of the M. Orbicularis Oculi: a Clinical Note||Charite University, Berlin, Germany|No|Completed|May 1997|August 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|152|None Retained|n.a.|Both|N/A|N/A|No|Non-Probability Sample|patients with lagophthalmos due to surgery, central or peripheral paresis|June 2008|January 10, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274689||110684|
NCT01274962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIR 009|A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer|An Adaptative Randomized Phase II Study on the Timing of FOLFOX for Patients With Operable Stage III Rectal Cancer||Sir Mortimer B. Davis - Jewish General Hospital||Recruiting|November 2009|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274962||110663|
NCT01267526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-517|A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment|"Easypod™ Connect Registry": A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of SAIZEN® in Pediatric Subjects Using Easypod™ Auto-injector|ECOS CAN|Merck KGaA|No|Active, not recruiting|May 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|206|||Both|2 Years|18 Years|No|Non-Probability Sample|Pediatric subjects 18 and under who are prescribed SAIZEN® (Health Canada approved        indications) using the easypod™ auto-injector.|March 2015|March 3, 2015|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267526||111235|
NCT01271816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-532|Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Patients|Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic ARVC Patients|PREPARE|Lawson Health Research Institute|Yes|Terminated|December 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|2 Years|N/A|No|Probability Sample|ARVC gene carriers with minimal or no evidence of being clinically affected|January 2014|January 2, 2014|January 4, 2011||No|inadequate recruitment|No||https://clinicaltrials.gov/show/NCT01271816||110905|
NCT01255293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAR-3|Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments|A Prospective, Randomized Study Comparing 1000 Centistoke and 5000 Centistoke Silicone Oil Tamponade for Repair of Proliferative Vitreoretinopathy Retinal Detachments and Diabetic Tractional Retinal Detachments||Mid Atlantic Retina|No|Completed|November 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|N/A|N/A|No|||June 2013|June 13, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255293||112175|
NCT01255540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/326b|After Eighty Study|A Randomised Prospective Study of an Invasive Strategy Versus Medical Therapy in Patients Over 80 Years With Non ST-Elevation Myocardial Infarction (NSTEMI) or Unstable Angina Pectoris (UAP)||Oslo University Hospital|Yes|Active, not recruiting|December 2010|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|492|||Both|80 Years|N/A|No|Probability Sample|Multicenter study|October 2015|October 21, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255540||112156|
NCT01255553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-025-A|Partial Breast Irradiation in a Low-risk Population Screened With MRI|Image Guided Partial Breast Irradiation (PBL) In A Low-Risk Population Screened With Magnetic Resonance Imaging (MRI)||University of Chicago|No|Withdrawn|June 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|40 Years|N/A|No|||March 2014|March 3, 2014|November 22, 2010|Yes|Yes|No patients enrolled.|No||https://clinicaltrials.gov/show/NCT01255553||112155|
NCT01256554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0653|Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression|Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management of Patients With Inoperable, Previously Irradiated Metastatic Epidural Spinal Cord Compression (MESCC)||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2010|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01256554||112078|
NCT01256541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10068|Kristalose as Bowel Evacuant Prior to Colonoscopy|A Single Center, Open-Label, Pilot Study to Determine the Safety, Efficacy, and Patient Preference of Kristalose as a Bowel Evacuant Prior to Colonoscopy||Benaroya Research Institute|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2011|October 5, 2011|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01256541||112079|
NCT01252368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1744|Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)|Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)||University of Zurich||Completed|December 2009|May 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients attending the hospital for clarification of gastrointestinal symptoms by        gastroduodenoscopy or colonoscopy|November 2012|November 28, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01252368||112400|
NCT01252875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081244|Treat Stroke to Target|EVALUATION OF TWO SECONDARY CARE STRATEGIES AFTER STROKE OR TRANSIENT ISCHEMIC ATTACK (TIA): ACHEIVED TARGET LDL-C TO 100 mg/dL (+/- 10,mg/dL) OR LESS THAN 70 mg/dL.|TST|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2010|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3760|||Both|18 Years|N/A|No|||December 2013|February 24, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252875||112361|
NCT01252888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-018|Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents|A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents||Glaukos Corporation|No|Active, not recruiting|December 2010|||July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252888||112360|
NCT01252628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-866-003|Phase 1 and 2 Study of PX-866 and Cetuximab|Phase 1/2 Study of PX-866 and Cetuximab||Oncothyreon Inc.|Yes|Completed|December 2010|January 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|178|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252628||112380|
NCT01252836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-160|Study Evaluating AWBAT-D Versus the Standard of Care of Split-thickness Skin Graft Donor Sites|Randomized, Prospective, Pilot Study Evaluating a Temporary Skin Substitute (AWBAT-D) Versus the Standard of Care in the Postoperative Treatment of Split-thickness Skin Graft Donor Sites||Georgetown University|Yes|Terminated|September 2010|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 11, 2015|December 1, 2010||No|P.I decided to prematurely end this study.|No||https://clinicaltrials.gov/show/NCT01252836||112364|
NCT01252849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-016|Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects|A Prospective, Randomized, Controlled Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted With One, Two, or Three Trabecular Micro-Bypass Stents||Glaukos Corporation|No|Active, not recruiting|December 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252849||112363|
NCT01253434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2022-J081-001|E2022 Patch Formulation Single Dose Phase I Study|E2022 Patch Formulation Single Dose Phase I Study||Eisai Inc.||Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|80|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2011|May 13, 2013|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01253434||112318|
NCT01253135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-017|Study to Determine if Fibrin Affects the Ability of a Wound to Heal|An Open-label, Randomized, Evaluator-Blinded Study of the Effect of Polymerized Fibrin Applied Topically Once Per Week, on Healing of Induced Thermal Wounds, Versus Weekly Application of White Petrolatum||Healthpoint|No|Completed|January 2011|November 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|November 30, 2010|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT01253135||112341|
NCT01254630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-011|A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)|A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|June 2011|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|5264|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254630||112226|
NCT01267578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMU-03|Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)|Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens (STF-II) for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma||University of Yamanashi|Yes|Recruiting|April 2010|May 2012|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|80 Years|No|||December 2010|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267578||111231|
NCT01267591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZLeuven|Peripheral Artery Tonometry in Children With Type 1 Diabetes and Obese Children|Peripheral Artery Tonometry in Children With Type 1 Diabetes and Obese Children.||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|January 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|70|||Both|12 Years|19 Years|Accepts Healthy Volunteers|Probability Sample|children seen at consultation in University Hospital|January 2009|December 27, 2010|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267591||111230|
NCT01271621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 1013|Influence of Glidescope Assisted Endotracheal Intubation on Intraocular Presure|||King Khaled Eye Specialist Hospital|Yes|Recruiting|June 2010|August 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|60 Years|No|||May 2010|January 6, 2011|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01271621||110920|
NCT01267916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-2010-12-13|Intrinsic PEEP During Mechanical Ventilation of Patients With Obesity|Intrinsic PEEP During Mechanical Ventilation of Patients With Obesity. Influence of Low Respiratory Rate With Unchanged Minute Volume.||Seoul Medical Center|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|6||Actual|20|||Both|20 Years|80 Years|No|||January 2012|January 29, 2012|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01267916||111205|
NCT01268176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2660|The Effect of a Meal on Vitamin D Absorption|Meal Effects on the 25OHD3 Response to Supplemental Vitamin D3||Tufts University|No|Completed|December 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|62|||Both|50 Years|69 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268176||111185|
NCT01244347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM 6KWTCT|Folic Acid Dosage and Malformations Reduction|Randomized Clinical Trial to Evaluate the Efficacy of High Dose of Folic Acid to Prevent the Occurrence of Congenital Malformations||Azienda Ospedaliera Universitaria Integrata Verona|Yes|Active, not recruiting|July 2009|September 2016|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|5000|||Female|18 Years|44 Years|No|||January 2015|January 13, 2015|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01244347||113010|
NCT01244711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSQUET0483|Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines|An Open-label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines in Treatment-refractory Patients With Unipolar Depression or Generalized Anxiety Disorder and Chronic Benzodiazepine Use||Weill Medical College of Cornell University|No|Terminated|September 2008|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|November 18, 2010|Yes|Yes|Terminated: recruiting or enrolling participants has halted prematurely|No|December 18, 2014|https://clinicaltrials.gov/show/NCT01244711||112982|
NCT01244724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXP-MD-109|Lexapro for Major Depression in Patients With Epilepsy|Lexapro for Major Depression in Patients With Epilepsy||Weill Medical College of Cornell University|No|Terminated|October 2007|March 2012|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|November 18, 2010|Yes|Yes|Unable to recruit targeted #|No|December 24, 2014|https://clinicaltrials.gov/show/NCT01244724||112981|
NCT01244984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113989|A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma|A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects With Asthma||GlaxoSmithKline|No|Completed|July 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|N/A|No|||June 2013|August 15, 2013|November 18, 2010||No||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01244984||112962|
NCT01245920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-15770|Effects of Bone Graft Placement at Implant Installation on Buccal Plate Stability|Effects of Bone Graft Placement at Implant Installation on Buccal Plate Stability: A Randomized Controlled Clinical Trial||Creighton University|Yes|Withdrawn|November 2010|May 2012|Actual|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 28, 2012|November 19, 2010|Yes|Yes|Inadequate number of patients whou could meet inclusion criteria.|No||https://clinicaltrials.gov/show/NCT01245920||112892|
NCT01255007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN100405CE2010|Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases|Prospective Comparison of 3T Gd-EOB-DTPA-enhanced MRI, Diffusion Weighted MR Imaging and MDCT of Colorectal Liver Metastases for Preoperative Detection and Assessment of Treatment Response Following Chemotherapy Treatment||University Health Network, Toronto|No|Completed|September 2010|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01255007||112197|
NCT01255306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBSM-30-1/10|The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy|The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy||University Hospital "Sestre milosrdnice"|Yes|Completed|April 2010|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|80 Years|No|Probability Sample|tertiary care clinic|March 2012|March 22, 2012|December 6, 2010||No||No|December 18, 2011|https://clinicaltrials.gov/show/NCT01255306||112174|
NCT01255566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unfunded|Medical Therapy Versus Sinus Surgery for Chronic Rhinosinusitis: A Prospective, Multi-institutional Study|A Comparison of Medical Therapy to Medical Therapy Plus Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis||Oregon Health and Science University|No|Completed|August 2009|August 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|186|||Both|18 Years|N/A|No|Probability Sample|Adult subjects (> 18 years) were prospectively enrolled from four tertiary rhinology        practices including Oregon Health & Science University (OHSU); Northwestern University        (NWU); Medical University of South Carolina (MUSC); and the University of Pennsylvania        (UPenn). All patients were diagnosed with chronic rhinosinusitis (CRS) as defined by the        2007 Adult Sinusitis Guidelines.|April 2013|April 23, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255566||112154|
NCT01252381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH 77|Supplementary Intake of Vitamin D During 12 Weeks Strength Training in Younger and Older People|The Importance of Supplementary Intake of Vitamin D on the Efficacy of 12 Weeks of Strength Training in Both Vitamin D Sufficient Younger and Older People||Bispebjerg Hospital||Active, not recruiting|November 2010|||February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Male|20 Years|75 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252381||112399|
NCT01252394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ScO2 cardiac output|Correspondence of ScO2 and Cardiac Output in Hemodialysis|ScO2 and Cardiac Output - Correspondence Study in Hemodialysis Patients||Danish State Hospital|No|Recruiting|November 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|N/A||1|Anticipated|37|||Both|18 Years|N/A|No|Non-Probability Sample|Hemodialysis patients|October 2010|December 2, 2010|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252394||112398|
NCT01252615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36576-C|Patient and Partner Intervention After an Implantable Cardioverter Defibrillator (ICD)|Patient and Intimate Partner Intervention to Improve Outcomes After an ICD|P+P|University of Washington|No|Active, not recruiting|July 2009|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|301|||Both|21 Years|N/A|No|||November 2014|November 7, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01252615||112381|
NCT01252901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT1 Registry|Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases|Registry for Patients With WT1 Mutation Associated Diseases||Universitätsklinikum Hamburg-Eppendorf|No|Completed|October 2010|June 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|52|||Both|N/A|N/A|No|Probability Sample|Patients with WT1 mutation|May 2015|May 27, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252901||112359|
NCT01253109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/11|Continuous Intraocular Pressure (IOP) Monitoring in Pigmentary Dispersion Syndrome and Pigmentary Glaucoma Patients|Detection of Induced IOP Fluctuations by SENSIMED Triggerfish® in Pigmentary Syndrome and Glaucoma Patients||Sensimed AG|No|Terminated|September 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|60 Years|No|Probability Sample|Patients with confirmed diagnosis of pigmentary dispersion syndrome or pigmentary glaucoma        on both eyes|January 2012|January 23, 2012|December 2, 2010||No|Law agreement between Triggerfish signal and GAT IOP during both sessions. However, an    increase in the Triggerfish signal was observed during jogging phase.|No||https://clinicaltrials.gov/show/NCT01253109||112343|
NCT01253447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-02186|AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia||National Cancer Institute (NCI)|No|Completed|October 2010|April 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2013|December 23, 2014|December 1, 2010|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01253447||112317|
NCT01253798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTNU-ISM-KH-2010|Group Exercise After Hip Replacement Surgery|What Type of Group Exercise Should be Chosen for Osteoarthritis Patients in the Rehabilitation Phase Following Hip Replacement Surgery?||Norwegian University of Science and Technology|No|Terminated|November 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|N/A|N/A|No|||September 2012|September 19, 2012|December 2, 2010||No|recruitement unsuccessful|No||https://clinicaltrials.gov/show/NCT01253798||112290|
NCT01254916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Danish SNOT 22|The Sinonasal Outcome Test - 22, Validated for Danish Patients|The Sinonasal Outcome Test - 22, Validated for Danish Patients||Odense University Hospital||Completed|October 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|15 Years|75 Years|No|Non-Probability Sample|Patients with chronic rhinosinusitis diagnosed by a medical doctor|May 2012|May 6, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01254916||112204|
NCT01267331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006AA02A104|Cell Therapy in Patients With Chronic Ischemic Heart Disease Undergoing Cardiac Surgery|A Prospective,Randomized, Placebo-Controlled Study of Intramyocardial Injection of Autologous Bone-Marrow Mononuclear Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery||Chinese PLA General Hospital|Yes|Recruiting|December 2010|June 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2010|January 11, 2011|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267331||111250|
NCT01268488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2010-008-02|Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting|Clinical Trial Protocol for NINJA 2 System With CONTOUR Sensor||Ascensia Diabetes Care|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|98|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 29, 2010|No|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT01268488||111161|It was decided that this investigational BG monitoring system would not be part of a regulatory submission. It will not proceed to market.
NCT01267604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rFSH-INOPLUS|Ovarian Stimulation: Inositol and Melatonin|Improving Oocyte Retrieval Using a Combined Therapy of Recombinant Follicle Stimulating Hormone (rFSH) and Inositol and Melatonin||AGUNCO Obstetrics and Gynecology Centre|No|Recruiting|December 2010|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||December 2010|December 27, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267604||111229|
NCT01267617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-5046|Measuring Cardiovascular Stress in Patients on Hemodialysis|Measuring Cardiovascular Stress in Patients on Hemodialysis||West Penn Allegheny Health System|No|Enrolling by invitation|November 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients receiving hemodialysis at a single center|December 2010|December 27, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267617||111228|
NCT01267929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-P-1-71/51|Effects of Mirror Neurons Stimulation on Motor Skill Rehabilitation in Children With Cerebral Palsy|||Thammasat University|Yes|Completed|September 2009|October 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|2 Years|10 Years|No|||February 2014|February 15, 2014|December 28, 2010||No||No|March 5, 2012|https://clinicaltrials.gov/show/NCT01267929||111204|This Video Compact Disc (VCD) program was applicable for children with cerebral palsy with spastic diplegia who had high GMFCS level (1-3). Generalized the results to children with other types of cerebral palsy with different severity are limited.
NCT01245348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REST|Relative Effectiveness of Schizophrenia Therapy Study|Relative Effectiveness of Schizophrenia Therapy (REST) Study|REST|Medco Health Solutions, Inc.|No|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|N/A||2|Actual|1110|Samples With DNA|One milliliter of saliva will be self collected by study subjects for genetic testing.|Both|18 Years|N/A|No|Non-Probability Sample|Adults (≥18y/o) with either a schizophrenia or bipolar disorder diagnosis and were/are new        to therapy for olanzapine, risperidone, quetiapine or ziprasidone.|February 2013|February 22, 2013|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01245348||112936|
NCT01245634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25601|A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|Study Assessing 20 mg/kg Dose of the Recombinant Human Monoclonal Antibody Against P-selectin in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery||Hoffmann-La Roche||Completed|December 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|384|||Both|18 Years|85 Years|No|||March 2016|March 1, 2016|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245634||112914|
NCT01254747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-347-C-003v2s2v2|Clinical Evaluation of an Investigational Soft Contact Lens|||Alcon Research|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|130|||Both|N/A|N/A|No|||April 2012|June 26, 2012|December 3, 2010|Yes|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT01254747||112217|
NCT01254760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-416-C-001 Sub 04|Comparison of Two Multifocal Contact Lenses Worn on a Daily Disposable Basis|||Alcon Research|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|79|||Both|41 Years|68 Years|No|||January 2012|June 26, 2012|December 3, 2010|Yes|Yes||No|January 17, 2012|https://clinicaltrials.gov/show/NCT01254760||112216|
NCT01255020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAPDRRF|Renal Protective Effects of Restricted Protein Dietary With α-keto Acid in CAPD Patients|Safety and Efficacy Evaluation of Restricted Protein Dietary Supplemented With α-keto Acid on Protecting Residual Renal Function in CAPD Patients——A Prospective, Double Blind Randomized, Parallel Control, Multi-center Clinical Trial||Sun Yat-sen University|Yes|Completed|March 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|70 Years|No|||May 2015|May 20, 2015|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01255020||112196|
NCT01255579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tantucci_1|Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma|Effects on Small Airways Obstruction of Two Long-term Treatments With Extrafine Beclomethasone/Formoterol vs Fluticasone/Salmeterol in Asthma|FORTINO|Università degli Studi di Brescia|No|Completed|July 2007|||December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2008|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255579||112153|
NCT01255878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87284|Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism|The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial||Mashhad University of Medical Sciences||Completed|March 2010|November 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years||||December 2010|December 7, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01255878||112130|
NCT01256203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-PO-PHOTB05-01|Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light|Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light||Pinnacle Biologics Inc.|No|Withdrawn|May 2013|March 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|December 7, 2010|Yes|Yes|Sponsor cancelled the study|No||https://clinicaltrials.gov/show/NCT01256203||112105|
NCT01256216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121509|Signature Versus Computer Assisted Surgery Study|A Comparison of Signature Custom Cutting Guides and Computer Assisted Surgery Techniques With the Vanguard Knee System||Biomet, Inc.|No|Enrolling by invitation|September 2010|July 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|February 4, 2015|May 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256216||112104|
NCT01256567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14200|A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer|A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer||Eli Lilly and Company|Yes|Completed|December 2010|February 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|20 Years|N/A|No|||May 2014|May 16, 2014|December 7, 2010|No|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01256567||112077|
NCT01256580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-10-101|Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD|Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration|CNV|Massachusetts Eye and Ear Infirmary|No|Withdrawn|August 2010|September 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|October 29, 2010|Yes|Yes|Lack of eligible subjects.|No||https://clinicaltrials.gov/show/NCT01256580||112076|
NCT01256593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081261|Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Lyrica(Regulatory Post Marketing Commitment Plan)|RAINBOW|Pfizer|No|Active, not recruiting|February 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4000|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A0081261 prescribes the Lyrica capsule.|March 2016|March 7, 2016|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256593||112075|
NCT01252407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TensIC|Acute Effect of Transcutaneous Electrical Nerve Stimulation in Heart Failure|Acute Effect of Transcutaneous Electrical Nerve Stimulation on the Sympathetic and Parasympathetic Systems in Individuals With Heart Failure|TensIC|Federal University of Health Science of Porto Alegre|Yes|Active, not recruiting|November 2010|December 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||November 2010|August 1, 2012|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252407||112397|
NCT01253148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16236|Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma|Phase II Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres As First-Line Treatment For Cholangiocarcinoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|January 2011|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253148||112340|
NCT01252914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-019|A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent|A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent||Glaukos Corporation|No|Active, not recruiting|December 2010|December 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252914||112358|
NCT01253122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-037-002|Comparative Bioavailability in Healthy Elderly Volunteers|Comparative Bioavailability of TRx0037 and TRx0014 in Healthy Elderly Volunteers||TauRx Therapeutics Ltd|No|Completed|February 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 2, 2010|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253122||112342|
NCT01254292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13362|LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study|Multicenter, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 12 µg LNG/Day Initial in Vitro Release Rate (LCS12) in Comparison to a Combined Oral Contraceptive Containing 30 µg Ethinyl Estradiol and 3 mg Drospirenone (Yasmin®) in Young Women (18-29 Years) Over 18 Months of Use||Bayer|No|Completed|January 2011|May 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|567|||Female|18 Years|29 Years|No|||June 2015|June 29, 2015|November 22, 2010|Yes|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01254292||112252|
NCT01254305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-06|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder|A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder||Forest Laboratories|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|262|||Both|18 Years|65 Years|No|||August 2014|August 5, 2014|December 3, 2010|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01254305||112251|
NCT01255423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197-P-320|Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain||Novartis|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||September 2012|September 3, 2012|December 1, 2010|Yes|Yes||No|June 8, 2012|https://clinicaltrials.gov/show/NCT01255423||112165|
NCT01255696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV003-1021|Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease|A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac Disease||Alvine Pharmaceuticals Inc.|No|Completed|November 2010|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|75 Years|No|||July 2012|July 30, 2012|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255696||112144|
NCT01268501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-319-C-019|Clinical Assessment of a Multifocal Contact Lens for People Who Use Reading Glasses Only|Clinical Assessment of a New Multifocal Contact Lens With Emmetropic Presbyopes||Alcon Research|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|40 Years|48 Years|No|||February 2012|June 26, 2012|December 29, 2010|Yes|Yes||No|January 13, 2012|https://clinicaltrials.gov/show/NCT01268501||111160|
NCT01268735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPCOF Petricek|The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye|The Effect of Ocular Surface Lubricant Eyedrops on Lid Parallel Conjunctival Folds (LIPCOF) and Other Signs and Symptoms of Dysfunctional Tear Syndrome|LIPCOF|University of Zagreb|No|Completed|April 2009|February 2010|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|229|||Both|18 Years|N/A|No|||December 2010|December 30, 2010|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01268735||111142|
NCT01253941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBT-COPD2010_FORSTIII|Effects of Mud Bath Therapy in Chronic Obstructive Pulmonary Disease|Effects of Mud Bath Therapy in Chronic Obstructive Pulmonary Disease||Fondazione Salvatore Maugeri|Yes|Completed|June 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|45 Years|90 Years|No|||September 2013|September 11, 2013|December 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253941||112279|
NCT01254162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL10001|Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers|A 4-Week, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Potential of Topically Applied 0.75% (w/w) MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers||Mimetica Pty Limited|Yes|Completed|July 2010|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|135|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254162||112262|
NCT01254175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1096|Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children|Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2010|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|28|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||December 2014|December 2, 2014|December 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01254175||112261|
NCT01254474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/42|Evaluation of Depolarization and Repolarisation Activity During Cardiac Arrhythmia Using a Novel Monophasic Action Potential Catheter|Evaluation of Depolarization and Repolarisation Activity During Cardiac Arrhythmia Using a Novel Monophasic Action Potential Catheter|EvaMAP|University Hospital, Bordeaux|No|Suspended|January 2011|January 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01254474||112238|
NCT01254487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07EU01|e-BioMatrix PostMarket Surveillance Registry|A Postmarket Surveillance Registry of the BioMatrix Drug-eluting Stent||Biosensors Europe SA|Yes|Active, not recruiting|March 2008|April 2015|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1121|||Both|18 Years|N/A|No|Non-Probability Sample|"Real world, all comer" patients|September 2014|September 6, 2014|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254487||112237|
NCT01254773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAB-001-SC-ALZ-2003|Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease|SUMMIT AD|JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Yes|Completed|December 2010|March 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|146|||Both|50 Years|89 Years|No|||April 2014|April 21, 2014|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254773||112215|
NCT01255033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/09|Oxygen Peripheral Saturations and Lung Surgery|Evaluation of the Continuous Measurement of Tissular (StO2) and Cerebral (ScO2) Oxygenation During Lung Surgery and During the 6 First Postoperative Hours (Prospective Monocentric Study).||Hopital Foch|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients submitted for scheduled lung surgery requiring one-lung ventilation|June 2011|June 23, 2011|December 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01255033||112195|
NCT01255046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCD09009A|Study of STA-1 as an Add-on Treatment to Donepezil|A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease||Sinphar Pharmaceutical Co., Ltd|Yes|Not yet recruiting|December 2015|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|136|||Both|50 Years|N/A|No|||August 2014|August 19, 2014|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255046||112194|
NCT01255592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00014|Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis|A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis|STRATUS|AstraZeneca||Completed|February 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|80 Years|No|||September 2015|September 7, 2015|December 2, 2010|Yes|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01255592||112152|
NCT01255891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McG 0913|Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate|A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate||McGill University|No|Recruiting|January 2010|January 2015|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|46|||Male|18 Years|85 Years|No|||August 2009|December 7, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01255891||112129|
NCT01255904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27453|A Trial Of Oral Chloral Hydrate Versus Intranasal Dexmedetomidine For Sedated Abr Exams|A RANDOMIZED CONTROLLED TRIAL OF ORAL CHLORAL HYDRATE VERSUS INTRANASAL DEXMEDETOMIDINE FOR SEDATED ABR EXAMS.||Baylor College of Medicine|Yes|Completed|August 2011|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|90|||Both|6 Months|8 Years|No|||January 2016|January 25, 2016|November 18, 2010|Yes|Yes||No|January 25, 2016|https://clinicaltrials.gov/show/NCT01255904||112128|This study was not designed to detect small differences in rare adverse and the overall safety of either medication cannot be assessed based on these results alone.
NCT01256606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT001|Prenatal Test for Fetal Aneuploidy Detection|Investigational Study of a Prenatal Diagnostic Test for Fetal Aneuploidy||Ariosa Diagnostics, Inc|No|Completed|August 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|4000|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women planning to undergo chorionic villus sampling or amniocentesis for fetal        genetic evaluation|January 2013|January 8, 2013|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01256606||112074|
NCT01252420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDVTANZ|Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis|Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER)|TWISTER|Monash Medical Centre|No|Recruiting|November 2010|November 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|330|||Both|18 Years|N/A|No|||July 2010|December 3, 2010|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01252420||112396|
NCT01252641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-728-1002|Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects|A Phase 1/2, Open Label, Single Infusion Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases (SB-728-T) in HIV Infected Subjects||Sangamo Biosciences|No|Completed|November 2010|May 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252641||112379|
NCT01252927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009:073|Evaluation of a Gatekeeper Training Program|Evaluation of a Gatekeeper Training Program as Suicide Intervention Training for Medical Students||University of Manitoba|No|Active, not recruiting|October 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|110|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 23, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01252927||112357|
NCT01253811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F13CD-3835|Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency|A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency. Safety Extension Trial to F13CD-3760|mentor™5|Novo Nordisk A/S|No|Completed|January 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|1 Year|6 Years|No|||April 2015|April 7, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253811||112289|
NCT01253824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-01-4|Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers|Pharmacodynamics of NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol) and IKH-01( 1mg Norethisterone and 0.035mg Ethinyl Estradiol); Effect of NPC-01 and IKH-01 on Serum Concentrations of Estradiol, Progesterone, FSH and LH.||Nobelpharma|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|14|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|December 2, 2010||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01253824||112288|
NCT01253460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0516|Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)|A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH||M.D. Anderson Cancer Center|No|Recruiting|July 2011|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253460||112316|
NCT01254643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-008|A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).|A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls||Merck Sharp & Dohme Corp.|No|Completed|January 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Female|9 Years|15 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|December 3, 2010|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01254643||112225|
NCT01254656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271037|A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022|A Long Term Open-Label Extension Study Of Lersivirine For The Treatment Of HIV-1 Infection||Pfizer|No|Terminated|February 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|108|||Both|18 Years|N/A|No|||January 2014|May 27, 2014|December 3, 2010|Yes|Yes|See termination reason in detailed description.|No|January 21, 2014|https://clinicaltrials.gov/show/NCT01254656||112224|The study was terminated on 29 Jan 13 due to termination of lersivirine development program. All participants were enrolled from study A5271015 except one from A5271022. Above summarized outcome measures included participants enrolled from A5271015.
NCT01255709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-B3|Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS|CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers||Amphastar Pharmaceuticals, Inc.|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255709||112143|
NCT01268514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVPERH0108|ENHANCE: A Prospective EvaluatioN of Permacol™ in tHe Repair of Complex AbdomiNal Wall CasEs|ENHANCE: A Prospective Long-term EvaluatioN of the Use of Permacol™ Biological Implant in tHe Repair of Complex AbdomiNal Wall CasEs|ENHANCE|Medtronic - MITG|No|Active, not recruiting|February 2011|February 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|All subjects who will undergo planned surgical treatment for complex abdominal wall repair        with Permacol™ implantation and agree to 36 months of follow-up.|July 2015|July 14, 2015|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268514||111159|
NCT01268748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-064|Single Port Versus Four Ports Laparoscopic Cholecystectomy and Early Postoperative Pain|Efficacy of Transumbilical Versus Standard Laparoscopic Cholecystectomy on Postoperative Pain|UMBI-CHOL|Bispebjerg Hospital|No|Recruiting|September 2010|June 2012|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|75 Years|No|||September 2010|December 30, 2010|September 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01268748||111141|
NCT01253954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China|Epidemiology of Invasive Candida Infections in Critically Ill Patients: A Multicenter, Prospective, Observational Study in China|china-scan|Southeast University, China|No|Recruiting|November 2009|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|85 Years|No|Non-Probability Sample|Adult ICU patients above 18 with invasive candida infection|November 2009|December 3, 2010|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01253954||112278|
NCT01254188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107E2401|Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients|Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase|ENESTxtnd|Novartis||Completed|April 2011|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|421|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 2, 2010||No||No|November 2, 2015|https://clinicaltrials.gov/show/NCT01254188||112260|
NCT01254500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-100-108|To Investigate the Event Related Potentials (ERPs) of Patients With Brain Lesions|||China Medical University Hospital||Recruiting|September 2010|||September 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with brain lesions young normal controls old normal controls|December 2010|December 3, 2010|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254500||112236|
NCT01254513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERICO10/0910 (GetugP03)|Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients|Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), "Vulnerable" or "Frail" , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)|GERICO10|UNICANCER|No|Recruiting|November 2010|November 2016|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Male|75 Years|N/A|No|||January 2013|January 29, 2013|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01254513||112235|
NCT01254526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4880g|Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer||Genentech, Inc.||Completed|December 2010|April 2013|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01254526||112234|
NCT01254786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201013|Non-dependent HFPPV Versus CPAP for Video-assisted Thoracoscopy|Comparative Study of the Non-dependent Continuous Positive Pressure Ventilation and High Frequency Positive Pressure Ventilation During One-lung Ventilation for Thoracoscopy||King Faisal University|Yes|Completed|May 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||December 2010|December 6, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01254786||112214|
NCT01255319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allo-038|Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS)|Conditioning With Cyclophosphamide, Fludarabine and Antithymocyte Globulin for Allogeneic Hematopoietic Cell Transplantation in Lower Risk Myelodysplastic Syndrome|CyFluATG|Cooperative Study Group A for Hematology|No|Recruiting|November 2010|November 2014|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with lower risk MDS|December 2010|December 6, 2010|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01255319||112173|
NCT01255917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11033|Nerve Growth Factor in Chronic Pancreatitis|Nerve Growth Factor in Chronic Pancreatitis||Virginia Commonwealth University|No|Completed|February 2008|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|38|Samples Without DNA|Pancreatic fluid obtained by duodenal aspiration|Both|18 Years|70 Years|No|Non-Probability Sample|Test group: Subjects with CP in each morphological stage and matched for age, race,        gender, narcotic dependence and etiology of CP will be enrolled Controls: Subjects        undergoing upper gastrointestinal endoscopy (UGIE) for non-pancreatic causes.|March 2016|March 3, 2016|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255917||112127|
NCT01255930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99016|Evaluation of Placenta Maturity by the Sonographic Textures|Evaluation of Placenta Maturity by the Sonographic Textures||Taipei Medical University WanFang Hospital|No|Recruiting|January 2010|January 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Female|20 Years|N/A|No|Probability Sample|pregnant women|December 2010|December 7, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255930||112126|
NCT01252654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R683/33/2009|Comparison of Intralase and Visumax Femtosecond Laser for Laser In Situ Keratomileusis|||Singapore Eye Research Institute|Yes|Recruiting|January 2010|December 2010|Anticipated|August 2010|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|||Both|21 Years|60 Years|No|Non-Probability Sample|Myopic patients presenting to refractive service eligible for LASIK|May 2010|December 1, 2010|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01252654||112378|
NCT01252940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-264-0106|Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF|A Phase 3 Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients||Gilead Sciences|No|Completed|November 2010|October 2014|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|482|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|December 1, 2010|Yes|Yes||No|March 8, 2013|https://clinicaltrials.gov/show/NCT01252940||112356|
NCT01252953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSUREVEAL1|REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification|REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease|REVEAL|University of Oxford|Yes|Active, not recruiting|June 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30624|||Both|50 Years|N/A|No|||May 2015|May 29, 2015|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252953||112355|
NCT01253161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16438|Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)|Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|January 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|November 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253161||112339|
NCT01253174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91457|Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)|Open-label, Randomized, Three-fold Crossover Study to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.03 mg Ethinylestradiol (EE) and 3 mg Drospirenone (DRSP) Without [SH T470FA] and With [SH T04532A] 0.451 mg Metafolin®, and to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.451 mg Metafolin® Without [SH T04532C] and With 0.03 mg EE/ 3 mg DRSP [SH T04532A] in 42 Healthy Young Women||Bayer|No|Completed|August 2006|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|December 2, 2010||No||No|December 9, 2010|https://clinicaltrials.gov/show/NCT01253174||112338|
NCT01253473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYMB0012|Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)|COPDGene Ancillary Proposal: Symbicort Intervention in "Airway Predominant|SACOPD|National Jewish Health|Yes|Active, not recruiting|April 2012|December 2015|Anticipated|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|46|||Both|45 Years|80 Years|No|||October 2015|October 5, 2015|November 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253473||112315|
NCT01253837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19TNFα-02/07|L19TNFα in Patients With Advanced Solid Tumors|Phase I/II Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Patients With Advanced Solid Tumors||Philogen S.p.A.|No|Completed|September 2007|September 2011|Actual|May 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253837||112287|
NCT01254058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 06-056|Saccadic Eye Movements Are Impaired In Glaucoma|Novel Vision Testing Paradigms for Patients With Glaucoma||St. Michael's Hospital, Toronto|No|Enrolling by invitation|July 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|40 Years|80 Years|No|Non-Probability Sample|19 glaucoma patients and 21 age-matched controls will be identified and consented.|October 2015|October 13, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01254058||112270|
NCT01254045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11182010-7215|Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome|Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome||Stanford University|No|Completed|February 2007|January 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|10|||Male|13 Years|29 Years|No|||August 2014|August 28, 2014|December 2, 2010||No||No|August 3, 2011|https://clinicaltrials.gov/show/NCT01254045||112271|
NCT01255176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEMFRTALC2010|Rebalancing Thoraco Abdominal Heart Disease in Infants (RTAC)|Evaluation of the Effects of Physical Therapy Method of Restoring Cardiac Thoracic Abdominal Infants|RTAC|University of the State of Santa Catarina|Yes|Completed|January 2010|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|N/A|24 Months|No|||December 2010|June 18, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255176||112184|
NCT01255189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3498|Measurement of the Effect of Positional Changes on Cerebral Oxygenation in Preterm Infants|Measurement of the Effect of Positional Changes on Cerebral Oxygenation in Preterm Infants: A Near Infrared Spectroscopy Study||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|December 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|2 Months|No|||December 2010|August 5, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01255189||112183|
NCT01267942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P75/4/2008|Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.|Single Intraoperative Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Full Oral Course in Prevention of Post Adenotonsillectomy Morbidity:A Randomised Clinical Trial.||University of Nairobi|Yes|Completed|May 2008|October 2009|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|126|||Both|N/A|12 Years|No|||October 2009|December 28, 2010|December 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267942||111203|
NCT01267955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02564|Vismodegib in Treating Patients With Advanced Chondrosarcomas|A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267955||111202|
NCT01268228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICECG-12-2010|Intracoronary Electrocardiogram (ECG) and Myonecrosis After Bifurcation Stenting|COronary SIde Branch Residual IschemiA and COllateralization Assessment Study (COSIBRIA & Co Study)|COSIBRIA&CO|University National Heart Hospital|Yes|Completed|December 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|131|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Significant, >50% diameter stenosis artery scheduled for stent insertion at the main             vessel (Medina types: 1xx, x1x, 11x);          -  Side branch vessel at least 2.0mm|October 2013|October 14, 2013|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268228||111181|
NCT01268527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6201-E044-204|A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris|A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris||Eisai Inc.||Completed|March 2010|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||December 2012|June 26, 2014|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268527||111158|
NCT01268761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810-C-052-JG|GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome|Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 18, 2013|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01268761||111140|
NCT01268774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melisse study|Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.|Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide||LEO Pharma|Yes|Completed|February 2009|July 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|529|||Both|18 Years|N/A|No|Non-Probability Sample|patinets with multiple myeloma treated with thalidomide or lenalidomide|April 2013|April 17, 2013|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01268774||111139|
NCT01253967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110436|Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in Children < 5 Years of Age in Romania|Hospital-based Surveillance to Estimate the Disease Burden of Rotavirus Gastroenteritis in Children < 5 Years of Age in Romania||GlaxoSmithKline||Completed|February 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1234|Samples Without DNA|Stool samples|Both|N/A|5 Years|No|Non-Probability Sample|Children < 5 years of age treated at a hospital site (subjects hospitalised with community        acquired acute gastroenteritis, subjects who visited the emergency room for acute        gastroenteritis or subjects with medical care associated rotavirus infection).|April 2015|April 9, 2015|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01253967||112277|
NCT01254201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00013091|The Pathogenesis of Idiopathic Dry Eyes|||University of Michigan|No|Active, not recruiting|June 2008|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Females aged 18 yrs or older in the community or seen in Kellogg Eye Center will be        offered enrollment into the study.|January 2016|January 26, 2016|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254201||112259|
NCT01254539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Extension CMN/ELA|Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)|Phase I/II Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)||Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Yes|Active, not recruiting|October 2010|December 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|63|||Both|18 Years|70 Years|No|||December 2010|March 11, 2015|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254539||112233|
NCT01254799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOX-DMPA|Doxycycline in Treatment of Bleeding With Depot Medroxyprogesterone Acetate (DMPA)|Doxycycline in Treatment of Bleeding With DMPA: a Double Blinded Randomized Controlled Trial|DOX-DMPA|Assiut University|Yes|Completed|January 2008|January 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Female|20 Years|50 Years|No|||November 2011|November 25, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01254799||112213|
NCT01255059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-GWASLC-Epi-Tianjin|GWAS Research of Lung Cancer in Tianjin|GWAS Research of Lung Cancer by Department of Epidemiology and Biostatistics in Tianjin Medical University Cancer Institute and Hospital||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|June 2010|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|500|Samples With DNA|Peripheral blood sample (10 ml) was collected from each study subject. Buffy coats were      isolated and frozen for DNA extraction.|Female|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients were newly diagnosed and histologically confirmed primary non-small cell lung        cancer from Tianjin Medical University Cancer Hospital.The control subjects who underwent        health check-up in hospitals were frequency-matched to cases on gender and age. All the        subjects were genetically unrelated Chinese with Han ethnicity.|January 2012|December 21, 2015|December 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01255059||112193|
NCT01255332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-023|Helicobacter Pylori Immune Thrombocytopenic Purpura|Efficacy of Helicobacter Pylori Eradication for the 1st Line Treatment of Immune Thrombocytopenic Purpura (ITP) Patients With Moderate Thrombocytopenia|HpyloriITP|Cooperative Study Group A for Hematology|Yes|Recruiting|September 2010|August 2012|Anticipated|August 2011|Anticipated|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|26|||Both|20 Years|55 Years|No|Non-Probability Sample|immune thrombocytopenic purpura|November 2010|December 6, 2010|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01255332||112172|
NCT01256229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC010075|Outcomes In Children With Developmental Delay And Deafness|OUTCOMES IN CHILDREN WITH DEVELOPMENTAL DELAY AND DEAFNESS: A PROSPECTIVE, RANDOMIZED TRIAL||Stanford University||Recruiting|September 2009|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|252|||Both|N/A|5 Years|No|||December 2015|December 7, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01256229||112103|
NCT01256242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTI-2010-03|Pilot Study of Augment Rotator Cuff for Surgical Treatment of Full Thickness Rotator Cuff Tears|A Single Blinded, Multi-center, Randomized, Controlled, Pilot Study to Evaluate the Safety and Performance of Augment™ Rotator Cuff for Primary Surgical Treatment of Full Thickness Rotator Cuff Tears||BioMimetic Therapeutics|No|Active, not recruiting|November 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||May 2011|May 27, 2011|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01256242||112102|
NCT01252446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|219.04 REK|Children With ADHD Symptoms: Comorbid Conditions, Cognitive and Social Performance|Children With ADHD Symptoms: Comorbid Conditions, Cognitive and Social Performance|NF ADHD|University of Bergen|Yes|Recruiting|September 2008|December 2010|Anticipated|June 2010|Actual|Phase 1/Phase 2|Observational|Time Perspective: Retrospective||1|Anticipated|187|||Both|6 Years|17 Years|No|Non-Probability Sample|One hundred eihgty seven children and adolescent referred to a Child and Adolescent Mental        Health Clinic in Haugesund, Rogaland, Norway with the sympthoms of innattentivity,        hyperactivity and impulsivity. Ninety one of them has been diagnosed with ADHD by the ICD        10 Classification and Diagnostic system and ninety six has been diagnised with other        diagnosis accordning to ICD 10 classification .        All referred children has been evaluated in this study. The diagnosis was made by child        psychiatrist and relevant team and was based on the standard somatic and mental        examination, information from the parents and teachers and diagnostics        interviews.(Clinicians manual for assessment and parent training from Russell A. Barkley        and SDQ-nor questionnaire ).|January 2009|December 2, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01252446||112394|
NCT01252667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2430.00|Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant|A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML||Fred Hutchinson Cancer Research Center|Yes|Recruiting|January 2011|||January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|2 Years|N/A|No|||February 2016|February 23, 2016|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01252667||112377|
NCT01252966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812429|Cognitive Training for Nicotine Dependence|Cognitive Training for Nicotine Dependence||University of Pennsylvania|Yes|Completed|March 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|65 Years|No|||July 2015|October 2, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252966||112354|
NCT01253187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91460|Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)|Open-label, Randomized, Three-fold Crossover Study to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.02 mg Ethinylestradiol (EE) and 3 mg Drospirenone (DRSP) Without [SH T00186D] and With [SH T04532B] 0.451 mg L-mefolinate (Metafolin), and to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.451 mg L-mefolinate (Metafolin) Without [SH T04532C] and With 0.02 mg EE/ 3 mg DRSP [SH T04532B] in 42 Healthy Young Women||Bayer|No|Completed|October 2006|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|December 2, 2010||No||No|December 9, 2010|https://clinicaltrials.gov/show/NCT01253187||112337|
NCT01253200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLOCk-CTI|Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter|Clinical Evaluation of the Blazer® Open-Irrigated Radiofrequency Ablation Catheter for the Treatment of Type 1 Atrial Flutter|BLOCk-CTI|Boston Scientific Corporation|No|Completed|January 2011|January 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||February 2013|April 16, 2014|November 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253200||112336|
NCT01253213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR55-101|BR55 in Prostate Cancer: an Exploratory Clinical Trial|Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2||Bracco Diagnostics, Inc|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Male|40 Years|N/A|No|||April 2013|April 23, 2013|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253213||112335|
NCT01253486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMM 2010|Expressive Writing for Heart Healing|Use of Expressive Writing in the Cardiac Rehabilitation of Obese In-patients With Ischemic Heart Disease (IHD)|WrittenHeart|Istituto Auxologico Italiano|No|Completed|January 2010|May 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|100|||Both|N/A|70 Years|No|||September 2013|September 23, 2013|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253486||112314|
NCT01253499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-037-003|Multiple Dose Study of TRx0037|A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers||TauRx Therapeutics Ltd||Completed|March 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|31|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 16, 2010|December 2, 2010||No||||https://clinicaltrials.gov/show/NCT01253499||112313|
NCT01254669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H26306|An Intervention Study To Improve HPV Immunization in Haitian and African American Girls|A Randomized Clinical Trial To Improve HPV Immunization in Haitian and African American Girls||Boston Medical Center|No|Completed|January 2011|March 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|11 Years|15 Years|Accepts Healthy Volunteers|||October 2014|October 24, 2014|July 28, 2010||No||No|July 31, 2014|https://clinicaltrials.gov/show/NCT01254669||112223|Limitations:small sample,Enrolling only mothers, of daughters who are African-American and Haitians lead to longer recruitment time/non-generalizable data. Future studies should include heterogeneous ethnicities,fathers, sons, and any legal guardian.
NCT01254318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07501|Assessment of the Fungal Infection Incidence Across Canada for High Risk Subjects With Hematological Disease (Study P07501)|Temporal Realistic Assessment of the Fungal Infection Incidence Across Canada for High Risk Subjects With Hematological Disease (TRAFIC)|TRAFIC|Merck Sharp & Dohme Corp.|No|Completed|March 2013|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|130|||Both|N/A|N/A|No|Non-Probability Sample|Participants at high risk for IFI at medical institutions in Canada|April 2015|April 9, 2015|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01254318||112250|
NCT01254331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22642|An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment|Open Label, Multicenter, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs||Hoffmann-La Roche||Completed|February 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|December 3, 2010|No|Yes||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01254331||112249|
NCT01255436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCS IM 2010-002 (R-006TE)|Effectiveness of SMS Text Reminders to Improve Blood Pressure Among Patients With Hypertension|Effectiveness of SMS Text Reminders to Improve Blood Pressure Among Patients With Hypertension at a General Medicine Outpatient Clinic in a Tertiary Center in Manila, Philippines: A Randomized Controlled Trial||University of the Philippines|Yes|Completed|January 2011|July 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|700|||Both|19 Years|N/A|No|||October 2012|October 6, 2012|December 6, 2010||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01255436||112164|Strong conclusions cannot be made because of high attrition rate for the study. Also, several records had unevaluable data so these were not included in the analysis.
NCT01268787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QCR-10013|A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine|A Phase I, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine Administrated With Adjuvant AlPO4 in Health Volunteers||National Health Research Institutes, Taiwan|Yes|Completed|December 2010|September 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2013|April 15, 2015|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01268787||111138|
NCT01269060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-484|Efficacy of Single Incision (Embryonic NOTES) Laparoscopic Colorectal Surgery|Phase 2 Study of Efficacy of Single Incision (Embryonic NOTES) Laparoscopic Colorectal Surgery||National Cancer Center, Korea|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2012|August 2, 2012|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269060||111117|
NCT01254227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2214|Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload|Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Patients With Severe Cardiac Iron Overload Due to Chronic Blood Transfusion (HYPERION)|HYPERION|Novartis||Completed|January 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|10 Years|N/A|No|||November 2014|November 3, 2014|September 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01254227||112257|
NCT01254214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907S70361|Journeys to Wellness: A Transplant Candidate Study|Mindfulness for Symptom Reduction: A Transplant Candidate Study in Program Grant Studies of Organ Transplantation in Animals and Man 2P01 DK013083||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2010|August 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|66|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01254214||112258|
NCT01254812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-080|Does the Application of a Bilateral-dual Transverse Abdominal Plane (TAP)Block Have an Influence on Lung Function?|Changes on Pulmonary Function After Application of a Bilateral-dual TAP-block||Bispebjerg Hospital|Yes|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Young (18-45 yrs), healthy males with no history of lung diseases.|September 2011|September 22, 2011|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254812||112212|
NCT01255072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBellini - 0996/07|rTMS in Elderly Depressed:Neuronavegated Study|Repetitive Transcranial Magnetic Stimulation in Elderly Depressed: Neuronavegated Study||University of Sao Paulo General Hospital|No|Recruiting|August 2009|December 2011|Anticipated|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|75 Years|No|||May 2007|June 29, 2011|December 3, 2010||Yes||No||https://clinicaltrials.gov/show/NCT01255072||112192|
NCT01255605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIC/INSSA/UPB-01|Impact of IPT With Sulfadoxin Pyrimetamin on Pregnant Women and Their Babies Outcomes in Peri-urban Areas of Bobo-Dioulasso(Burkina Faso)|Impact of Intermittent Preventive Treatment (IPT) With Sulfadoxine-pyrimethamine (SP) on the Morbidities Associated With Malaria in Pregnant Women and Newborns in Peri-urban Areas of Bobo-Dioulasso, 5 Years After Its Adoption by the National Program for Fight Against Malaria in Burkina Faso.||Université Polytechnique de Bobo-Dioulasso|Yes|Completed|September 2010|June 2011|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|772|Samples With DNA|The investigators make thick and thin blood smear and collect a few drops of blood on the      3MM paper Whatmann Schleicher-Schuell.|Female|N/A|N/A|No|Probability Sample|Our study population is constitued by pregnant women coming for antenatal care or delivery        in two peripheral heath facilities of Bobo-Dioulasso(Lafiabougou and Secteur 24).|June 2012|June 15, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255605||112151|
NCT01255618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|The Measurement Of Cerebral Oxygenisation With NIRS Method İn Polycythaemic Infants Might Add A Criterion To Indicate PPET?|||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|November 2010|January 2011|Anticipated|December 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|None Retained|blood|Both|N/A|48 Hours|Accepts Healthy Volunteers|Probability Sample|Preterm infants who admitted to neonatal intensive care unit.|November 2010|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255618||112150|
NCT01256619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132/793|Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health|||Tehran University of Medical Sciences|No|Recruiting|September 2010|||September 2010|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2010|December 7, 2010|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256619||112073|
NCT01252433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoodED201|Children's Intake of Foods Reduced in Energy Density|Children's Intake of Foods Reduced in Energy Density||Penn State University|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|49|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252433||112395|
NCT01252979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0091|Ketones & Mitochondrial Heteroplasmy|Ketones & Mitochondrial Heteroplasmy||The University of Texas Health Science Center, Houston|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|N/A|No|||February 2012|February 3, 2012|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252979||112353|
NCT01253226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13060|A Study for Japanese Patients With Rheumatoid Arthritis|Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate||Eli Lilly and Company|No|Completed|September 2009|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|32|||Both|20 Years|75 Years|No|||September 2011|September 16, 2011|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253226||112334|
NCT01253512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-2010-01|Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)|Double Blind, Placebo Controlled, Escalating Single-dose, Pilot Study to Assess the Safety of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)||Thrombotech Ltd.|Yes|Not yet recruiting|March 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|22|||Both|18 Years|85 Years|No|||December 2010|December 2, 2010|November 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253512||112312|
NCT01253525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14204|Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas|A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas||Eli Lilly and Company|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||May 2014|May 16, 2014|December 2, 2010|No|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01253525||112311|Cycle 3 and beyond pharmacokinetic sampling was collected per the protocol-defined limited sampling schedule.
NCT01253538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1077FF (PROMISE)|Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Populations Using Formula Feeding (PROMISE)|Formula Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)|PROMISE|National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|April 2011|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|1000|||Both|N/A|N/A|No|||November 2015|November 2, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253538||112310|
NCT01254071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114694|A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.|An Open-label, Randomized, Single Dose, Two-Period Crossover Study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg Capsules and Tamsulosin Hydrochloride 0.2mg|ARI114694|GlaxoSmithKline|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2011|December 8, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01254071||112269|
NCT01254344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-056|Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Ceftriaxone Sodium/Metronidazole for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery in Chinese Adults||Merck Sharp & Dohme Corp.|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|599|||Both|18 Years|80 Years|No|||November 2015|November 2, 2015|December 3, 2010|Yes|Yes||No|October 16, 2012|https://clinicaltrials.gov/show/NCT01254344||112248|
NCT01254357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002459|Burn Outcomes in Young Adult Burn Survivors|Burn Outcomes in Young Adult Burn Survivors- A Multicenter Outcomes Study|YA|Massachusetts General Hospital|No|Completed|December 2011|July 2015|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|19 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Persons having suffered a burn injury and treated at participating study sites that are        between the ages of 19-30 years of age and speak English.|October 2015|October 5, 2015|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01254357||112247|
NCT01254682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSTWA-07-01|Intra-articular Hyaluronan Substitution in Arthroscopy of the Wrist|Intra-articular Hyaluronan Substitution in Arthroscopy of the Wrist||TRB Chemedica AG|No|Completed|January 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|80 Years|No|||September 2011|September 27, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01254682||112222|
NCT01254929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAG00065R|F-18 PET Bone Scans Versus Tc-99m Bone Scans for the Diagnosis of Bone Metastases|18F-Fluoride PET Bone Scans Versus Traditional 99mTc-MDP Gamma Camera Bone Scans for the Diagnosis of Bone Metastases: a Blinded, Prospective Trial||Seattle Nuclear Medicine|No|Active, not recruiting|December 2010|June 2016|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have cancer and have been referred for evaluation for bone metastases.|November 2015|November 17, 2015|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254929||112203|
NCT01254942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01291|Mobilizing Evidence Into Action to Improve Outcomes of Vulnerable Seniors|Mobilizing Evidence Into Action to Improve Outcomes of Vulnerable Seniors||University of British Columbia|No|Completed|December 2010|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|62|||Both|65 Years|N/A|No|||October 2014|October 2, 2014|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01254942||112202|
NCT01255449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOT-BOS-01|Respiratory Impedance and Obliterative Bronchiolitis|Predictive Value of Within-breath Respiratory Input Impedance in the Early Diagnosis of Obliterative Bronchiolitis After Allogeneic Hematopoietic Stem Cell Transplantation|FOT-BOS|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Yes|Completed|December 2010|June 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|70 Years|No|||December 2012|December 22, 2012|December 6, 2010||No||No|September 18, 2012|https://clinicaltrials.gov/show/NCT01255449||112163|
NCT01255462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFG316A2102|Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration|A Multicenter, Open Label, Single Ascending Dose Study to Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration||Novartis||Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|55 Years|90 Years|No|||April 2012|April 30, 2012|December 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255462||112162|
NCT01268202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 1383 - PRAVACUR|Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis|Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis|PRAVACUR|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|December 2010|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268202||111183|
NCT01268215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCIRB # 10-0250|Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.|The Effect of Endotracheal Instillation of Surfactant With and Without Budesonide on the Development of Bronchopulmonary Dysplasia in Ventilator-dependent, Extremely Low Birth Weight Infants: A Pilot Study||East Carolina University|Yes|Recruiting|July 2010|December 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|45|||Both|24 Weeks|28 Weeks|No|||July 2010|December 28, 2010|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268215||111182|
NCT01269073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005628|Comparison Of The Berlin Questionnaire To The Portland Sleep Quiz|Comparison Of The Berlin Questionnaire To The Portland Sleep Quiz In Identification Of Patients At Risk For Obstructive Sleep Apnea||Oregon Health and Science University|Yes|Enrolling by invitation|January 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Probability Sample|adults presenting to a sleep center|January 2011|January 27, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269073||111116|
NCT01269086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00001|Family Preventive Visits to Detect Risk Factors in the Family|Family Preventive Visits to Detect Risk Factors in the Family||Pontificia Universidad Catolica de Chile|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2010|May 26, 2011|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01269086||111115|
NCT01269450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0023-08-EMC|Progesterone and Second Trimester Bleeding|The Impact of Progesterone on the Risk of Preterm Birth Among Women With Second Trimester Bleeding. A Double Blind Placebo Controlled Trial||HaEmek Medical Center, Israel|Yes|Recruiting|December 2010|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|268|||Female|18 Years|N/A|No|||February 2016|February 20, 2016|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269450||111087|
NCT01254565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-4169-003|Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism|A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism||KAI Pharmaceuticals|Yes|Completed|March 2011|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254565||112231|
NCT01254578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02551|Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers|A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies||National Cancer Institute (NCI)||Active, not recruiting|November 2010|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|December 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01254578||112230|
NCT01254552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-44-011|Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis|Assessment With Cardiac Computed Tomography Angiography (CCTA) and Magnetic Resonance Imaging (MRI) in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis|ACCREDIT|Guerbet|Yes|Active, not recruiting|August 2010|December 2016|Anticipated|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|351|||Both|50 Years|75 Years|No|||February 2016|February 24, 2016|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01254552||112232|
NCT01254825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-ME-10|The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy|The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy||Glostrup University Hospital, Copenhagen|Yes|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2012|September 9, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01254825||112211|
NCT01255085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PureNet_22627|Yellow Pea Protein and Fibre and Short Term Food Intake|The Effect of Yellow Pea Protein and Fiber on Short Term Food Intake, Subjective Appetite and Glycemic Response in Healthy Young Males||University of Toronto||Completed|May 2008|June 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|20|||Male|20 Years|29 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01255085||112191|
NCT01255098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98085|A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood Culture|A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood Culture||Taipei Medical University WanFang Hospital|No|Completed|November 2009|November 2010|Actual|||N/A|Observational|Observational Model: Case Control||2|Actual|300|||Both|20 Years|N/A|No|Probability Sample|emergency cases|December 2010|December 3, 2010|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01255098||112190|
NCT01255345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-037|Female Chronic Pelvic Pain|Female Chronic Pelvic Pain: Prevalence, Risk Factors and Clinical Characteristics With Particular Reference to the Pelvic Musculature|Female CPP|Copenhagen University Hospital at Herlev|Yes|Recruiting|January 2011|December 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|2500|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|2500 adult women living in Copenhagen Country and Zealand Country (total population 2,4        million), Denmark|October 2010|June 23, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255345||112171|
NCT01255943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSA290200600013|Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices|Testing Spread and Implementation of Novel MRSA-Reducing Practices||Maine Medical Center Research Institute|Yes|Active, not recruiting|July 2010|October 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|175|||Both|N/A|N/A|No|Probability Sample|prevalent hemodialysis patients at two outpatient dialysis units|July 2010|December 7, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255943||112125|
NCT01256255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOA-FLU-2010-11|Influenza Virus - A Multicenter Registry|INFLUENZA VIRUS INFECTIONS IN TRANSPLANT RECIPIENTS: A MULTICENTER REGISTRY||University of Alberta|No|Active, not recruiting|November 2010|December 2015|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|serum and nasal swabs|Both|N/A|N/A|No|Non-Probability Sample|Solid organ transplant recipients on at least one immunosuppressive medication and        Hematopoietic stem cell transplant recipients (allogeneic or autologous) with the        diagnosis of influenza infection by standard laboratory technique|May 2015|May 26, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01256255||112101|
NCT01256632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4316s|Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy|Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy|PVD|Vision Research Foundation|No|Completed|October 2007|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|40|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 26, 2012|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256632||112072|
NCT01253876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Soy milk weight blood pressure|Effect of Soymilk Replacement on Anthropometric and Blood Pressure Value|||Isfahan University of Medical Sciences|Yes|Completed|March 2010|October 2010|Actual|August 2010|Actual|Phase 4|Interventional|N/A|2||||||Female|18 Years|28 Years|Accepts Healthy Volunteers|||March 2010|December 2, 2010|December 2, 2010||||No||https://clinicaltrials.gov/show/NCT01253876||112284|
NCT01254084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes II-Study3|Effect of Gynostemma Pentaphyllum Tea in Insulin Sensitivity in Type 2 Diabetic Patients|Gynostemma Pentaphyllum Tea Improves Insulin Sensitivity in Type 2 Diabetic Patients||Hanoi Medical University|Yes|Completed|February 2010|November 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|40 Years|70 Years|No|||February 2010|December 3, 2010|December 3, 2010||||No||https://clinicaltrials.gov/show/NCT01254084||112268|
NCT01254370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVG10E118|Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease|A Phase 2, Randomized Study Evaluating the Safety and Efficacy of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® in Subjects With Glaucoma or Ocular Hypertension and Ocular Surface Disease||Novagali Pharma||Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254370||112246|
NCT01254383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481289|Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.|An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of Sildenafil Following Fasted Administration Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered With Or Without Water Relative To Viagra® Oral Tablet With Water||Pfizer|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|36|||Male|45 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 7, 2011|November 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01254383||112245|
NCT01254396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481290|Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.|An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered Without Water Under Fed Compared To Fasted Conditions||Pfizer|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|45 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 7, 2012|November 19, 2010|No|Yes||No|January 7, 2012|https://clinicaltrials.gov/show/NCT01254396||112244|AUC (0-t) was the intended primary outcome measure.
NCT01254955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFGBG-141031|Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients|Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients||Sahlgrenska University Hospital, Sweden|No|Completed|October 2009|August 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Tranplant patients at the out-patient clinical ward and staff members at the Transplant        Institute, Sahlgrenska University Hospital.|January 2012|January 13, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01254955||112201|
NCT01255761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0064|A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects|Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia|PREDICT|UCB Pharma|No|Completed|November 2010|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|736|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|December 6, 2010|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT01255761||112139|
NCT01255202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|189/09|The Prediction of Preeclampsia/Toxemia in Twin Pregnancy|Prospective Longitudenal Study in the Prediction of Preeclampsia/Toxemia in Twin Pregnancy||Assaf-Harofeh Medical Center|No|Recruiting|September 2009|December 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|serum and urine|Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|women with twin preganacy undergoing nuchal scan in our department|December 2010|December 6, 2010|December 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01255202||112182|
NCT01256385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02596|Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy|A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy|MAESTRO HN|National Cancer Institute (NCI)||Completed|November 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256385||112091|
NCT01267981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 09.091|Efficacy of Small Bowel Preparation in Capsule Endoscopy|Impact of Small Bowel Preparation Using Polyethylene Glycol for Endoscopic Video-capsule (EVC)Exploration in Unexplained Gastrointestinal Bleedings|PREPINTEST|University Hospital, Brest|No|Completed|September 2010|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|858|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01267981||111200|
NCT01269710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1734|Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study|Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study|SATIETY|University of North Carolina, Chapel Hill|No|Completed|October 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|Samples Without DNA|fasting glucose, lipid profile, insulin, leptin, prolactin, AST, ALT, CRP, adiponectin,      ghrelin, cortisol, and relevant cytokines or peptide hormones (e.g., NP-Y, resistin,      TNF-alpha, IL-1b, IL-2, IL-6, IL-8, IL-12, IL-18), sex hormones (e.g., testosterone,      dehydroepiandrosterone, estrogen, luteinizing hormone, follicle stimulating hormone, and sex      hormone binding globulin), and SGAP level (not baseline), to assure compliance. TSH and CBC      will be measured at baseline only.      Each subject will be asked to provide an additional 16 ml blood sample (approximately 1      tablespoon) for DNA collection and genotyping.|Both|3 Years|19 Years|No|Non-Probability Sample|The investigators aim to recruit 200 individuals between the ages of 3 and 19, from a        diverse range of ethnic and racial backgrounds, who have a clinical diagnosis of psychotic        disorders, mood disorder or an autism spectrum disorder and are considered for treatment        with second generation antipsychotic (SGAP) medication by a physician.        Every effort will be made to recruit participants of all ethnicities, races and genders.        The investigators will specifically target recruitment efforts toward minorities by using        minority media and informational liaison with community organizations that serve minority        populations.|January 2013|January 18, 2013|January 3, 2011||No||No|November 8, 2012|https://clinicaltrials.gov/show/NCT01269710||111067|This study only enrolled 4 subjects, thus, sample size was a significant limitation. Further, since only a single subject completed to Week 52, it is difficult to determine treatment indication effectiveness with second generation antipsychotics.
NCT01270204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201018116|The Effect of Food Taste, Temperature, and Viscosity on Swallowing Efficiency|The Effect of Food Taste, Temperature, and Viscosity on Swallowing Efficiency||University of California, Davis|No|Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|1|||Both|55 Years|N/A|Accepts Healthy Volunteers|Probability Sample|40 dysphagic volunteers and 10 healthy volunteers|April 2013|April 22, 2013|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01270204||111029|
NCT01254591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000689973|Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer|Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation||National Cancer Institute (NCI)||Recruiting|November 2006|||August 2013|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|1||Anticipated|500|||Both|N/A|N/A|No|||December 2010|August 23, 2013|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254591||112229|
NCT01254838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMU-H20-30-P1|Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma|||Iwate Medical University|Yes|Completed|November 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|N/A|||||||Both|20 Years|80 Years||||November 2008|December 6, 2010|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01254838||112210|
NCT01254851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203031|Post Operative Walking Enhancements for Recovery (POWER) Trial|Post Operative Walking Enhancements for Recovery (POWER) Trial|POWER|Loyola University|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|146|||Female|18 Years|N/A|No|||June 2015|June 15, 2015|December 3, 2010||No||No|April 24, 2012|https://clinicaltrials.gov/show/NCT01254851||112209|Difficulty ensuring that encouragement was given, as we did not quantify the frequency of encouragement by the health care team. Loss of data due to loss of pedometers
NCT01255111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010AC1|Adaptation to Nocturnal Noninvasive Ventilation in Patients With Chronic Respiratory Failure (ROOMILA)|Adaptation to Nocturnal Noninvasive Ventilation in Patients With Chronic Respiratory Failure|ROOMILA|Groupe de Recherche sur le Handicap Respiratoire|No|Completed|October 2010|June 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic respiratory failure at stable state who are indicated to domiciliary        noninvasive ventilation|June 2011|June 22, 2011|December 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01255111||112189|
NCT01255358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEDAT 01|Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients|Evaluations of Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Ataxia Teleangiectasia Patients|IEDAT01|Erydel|No|Completed|February 2011|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|3 Years|N/A|No|||December 2011|December 27, 2011|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01255358||112170|
NCT01255631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE3803|Pulsed Electromagnetic Fields (PEMF) and Post-Axillary Surgery Morbidity|Use of Pulsed Electromagnetic Fields in Reducing Arm and Shoulder Complaints in Breast Cancer Patients After Lymph Node Dissection||Columbia University|Yes|Terminated|October 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Female|18 Years|N/A|No|||September 2015|September 15, 2015|December 1, 2010|Yes|Yes|Poor enrollment|No|February 5, 2015|https://clinicaltrials.gov/show/NCT01255631||112149|Early termination leading to small numbers of subjects analyzed
NCT01256268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16472|Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids|Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|June 2011|December 2016|Anticipated|February 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01256268||112100|
NCT01256281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0934|Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I|RESCUED: Phase I: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency|RESCUED|Icahn School of Medicine at Mount Sinai|Yes|Terminated|September 2010|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 7, 2010||No|lack of resources|No|December 2, 2013|https://clinicaltrials.gov/show/NCT01256281||112099|study was terminated due to lack of resources. no data analysis for this study.
NCT01256294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AUS90|Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients|A Prospective, Multi-center, Open-label, Randomized, Two Period, Two Sequence, Crossover Study to Compare the Steady State Pharmacokinetics of Generic Tacrolimus (Sandoz) to Prograf in Stable Renal Transplant Patients||Novartis||Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|November 1, 2010||No||No|May 21, 2012|https://clinicaltrials.gov/show/NCT01256294||112098|
NCT01252680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-HA-4014|Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines|A Randomized, Double-blind Clinical Trial of Two Inactivated Hepatitis A Vaccines in Healthy Children||Sinovac Biotech Co., Ltd|No|Completed|April 2010|May 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|303|||Both|18 Months|5 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01252680||112376|
NCT01254110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/142/HP|Amino Acid and Intestinal Protein Metabolism : Working Study|Physiological Study on Glutamine and Leucine Effects on Intestinal Protein Metabolism|Intesmetapro|University Hospital, Rouen|No|Completed|April 2009|February 2012|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|36|Samples Without DNA|whole blood duodenal tissue|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers|October 2013|October 15, 2013|March 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01254110||112266|
NCT01254422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD32|Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia|Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia||Sanofi|Yes|Completed|December 2010|January 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|250|||Both|2 Years|11 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254422||112242|
NCT01253850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAR Adherence HIV Youth:1|Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I|Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I||Fenway Community Health|Yes|Active, not recruiting|August 2010|December 2011|Anticipated|July 2011|Actual|Phase 1|Observational|Observational Model: Cohort||1|Anticipated|40|||Both|13 Years|24 Years|No|Non-Probability Sample|HIV-infected youth between the ages of 13 and 24|April 2011|July 22, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253850||112286|
NCT01253863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-7|Diagnostic Accuracy of the Preoperative Clinical Examination in Upper Limb Injuries|Study of Accuracy of Preoperative Examination in Penetrating Wound||Isfahan University of Medical Sciences|Yes|Completed|August 2006|September 2009|Actual|May 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|250|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2006|December 2, 2010|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253863||112285|
NCT01254409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRM151F-12GL|A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Masked, Sponsor-Unmasked, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRM-151 Administered Intravenously to Patients With Idiopathic Pulmonary Fibrosis|PRM151F-12GL|Promedior, Inc.|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|40 Years|80 Years|No|||October 2014|October 24, 2014|December 3, 2010|No|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT01254409||112243|
NCT01254695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Improving the Efficacy of Sacral Nerve Stimulation for Fecal Incontinence by Alteration of Stimulation Parameters|Improving the Efficacy of Sacral Nerve Stimulation for Fecal Incontinence by Alteration of Stimulation Parameters||University of Aarhus|Yes|Completed|July 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|15|||Both|18 Years|N/A|No|||November 2011|November 9, 2011|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254695||112221|
NCT01255774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYEE-07.14|Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy|Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter|FVF4193s|The New York Eye & Ear Infirmary|No|Recruiting|June 2007|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|51 Years|90 Years|No|||December 2011|December 2, 2011|December 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255774||112138|
NCT01246804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 10.02|The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)|The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)|GINGER|Radboud University|No|Completed|November 2010|May 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246804||112824|
NCT01255215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iNO RCT|Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial|Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial||University Health Network, Toronto|Yes|Completed|July 2011|January 2014|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|1 Year|10 Years|No|||December 2012|February 19, 2014|December 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01255215||112181|
NCT01247324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA21092|A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis|A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis||Hoffmann-La Roche||Active, not recruiting|August 2011|November 2019|Anticipated|November 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|821|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247324||112784|
NCT01268540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-T240|Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses|Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses|COAST|Hoya Surgical Optics, Inc.|No|Completed|December 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|235|||Both|50 Years|N/A|No|||February 2015|February 4, 2015|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268540||111157|
NCT01269723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1806|Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers|Effects of Sulforaphane (SFN)on Innate Immune Responses to Live Attenuated Influenza Virus in Smokers and Nonsmokers||University of North Carolina, Chapel Hill|No|Completed|December 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|51|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01269723||111066|
NCT01269736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0711003292|Implementation of Practice Standards for ECG Monitoring|Implementation of Practice Standards for ECG Monitoring|PULSE|Yale University|Yes|Recruiting|August 2008|March 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50000|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269736||111065|
NCT01270217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDIRB-201018332|Behavior and Driving Safety Study II|Behavior and Driving Safety Study II||University of California, Davis|No|Active, not recruiting|December 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2012|October 27, 2012|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270217||111028|
NCT01255124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT002|Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children|Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1297|Samples Without DNA|Umbilical cord blood serum and blood serum, Nasopharyngeal swabs, rectal swab|Both|2 Years|3 Years|No|Non-Probability Sample|The study population are the health infants born after September 2007 in 6 countries in        Jinagsu Province.|September 2011|September 12, 2011|December 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01255124||112188|
NCT01254864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0070|Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies|Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies||M.D. Anderson Cancer Center|Yes|Active, not recruiting|March 2011|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Male|18 Years|N/A|No|||September 2015|September 21, 2015|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254864||112208|
NCT01255644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT_2010-021786-78|Antiviral Treatment of Chronic Lymphocytic Leukemia|Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study|VGCV-CLL|Medical University of Vienna|Yes|Completed|December 2010|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255644||112148|
NCT01255956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Restenoza II 4.0|Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)|Efficacy Evaluation of In-bare Metal Stent Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter. Study With Intravascular Ultrasound and Optical Coherence Tomography|ISRII|Medical University of Warsaw|No|Recruiting|December 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2011|January 24, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255956||112124|
NCT01252459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG NUK/RT 2010-1|Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme|Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial|GLIAA|University Hospital Freiburg|Yes|Not yet recruiting|July 2011|July 2014|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2010|December 15, 2010|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252459||112393|
NCT01253551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017608|VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir|A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state||Tibotec BVBA||Completed|December 2010|April 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 13, 2012|December 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253551||112309|
NCT01245608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRI/90.22|Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.|Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.|PolyIran-L|Tehran University of Medical Sciences|Yes|Active, not recruiting|October 2011|March 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2400|||Both|50 Years|N/A|No|||April 2015|April 20, 2015|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245608||112916|
NCT01246180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.554|Microcirculation & ASICs|Study of the Cutaneous Microcirculation: ASIC Involvement.||Hospices Civils de Lyon|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 27, 2011|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246180||112872|
NCT01254097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotic-1|Probiotics in Primary Care|Feasibility Study of Probiotics in Primary Care||Milton S. Hershey Medical Center|No|Completed|March 2011|April 2014|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|51|||Both|18 Years|79 Years|No|||September 2015|September 23, 2015|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254097||112267|
NCT01255228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99055|Effect of Low Glycemic Index Diet on Body Composition and Mechanism of Obese Women|Effect of Low Glycemic Index Diet on Body Composition and Mechanism of Obese||Taipei Medical University WanFang Hospital|No|Active, not recruiting|May 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||December 2010|December 5, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01255228||112180|
NCT01255475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq 474992/2009-8|Blood Pressure Reduction in Heart Failure|Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial|REPIC|University of Sao Paulo|Yes|Completed|January 2011|January 2013|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255475||112161|
NCT01255748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REG001-09|Registry Study for Radiation Therapy Outcomes|Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Radiation Therapy||Proton Collaborative Group|No|Recruiting|June 2009|||June 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7000|||Both|N/A|N/A|No|Non-Probability Sample|Radiation Oncology patients|December 2015|December 7, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255748|10 Years|112140|
NCT01246817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO200903|Temsirolimus-RCC-imaging|Evaluation of the Activity of Temsirolimus With FDG-PET and FLT-PET in Patients With Renal Cell Cancer||Radboud University|Yes|Recruiting|August 2009|||August 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246817||112823|
NCT01247350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14089|A Study of LY3009104 for Healthy Subjects|A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects||Eli Lilly and Company|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|34|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 12, 2011|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247350||112782|
NCT01247363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14130|A Study of LY2608204 in Patients With Type 2 Diabetes|Safety and Tolerability of Multiple Ascending Doses of LY2608204 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|70 Years|No|||April 2011|April 1, 2011|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01247363||112781|
NCT01256060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001|Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)|Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)||Anagnostou, Evdokia, M.D.|Yes|Completed|November 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|10 Years|17 Years|No|||December 2015|December 29, 2015|November 22, 2010||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01256060||112116|The sample size is too small to view both safety and efficacy data. The design did not exceed the commonly used 24 IU / dose, so it is not clear that higher doses would not confer benefit. In the absence of placebo, adverse events may be inflated.
NCT01256073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH 2101-102|A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia|An Open-label, Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia||Innate Pharma|No|Completed|February 2007|September 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|60 Years|80 Years|No|||February 2014|February 27, 2014|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256073||112115|
NCT01256372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP214-CS007|An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery|An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery||Action Pharma A/S|Yes|Completed|October 2010|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|77|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|December 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256372||112092|
NCT01252784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allo-039|Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation|Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Followed by Prophylactic Dose-escalating Donor Lymphocyte Infusions in Higher Risk Myelodysplastic Syndrome|RICandDLI|Cooperative Study Group A for Hematology|No|Recruiting|November 2010|October 2014|Anticipated|October 2012|Anticipated|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|None Retained|This clinical trial will use busulfan, fludarabine, thymoglobulin and methylprednisolone for      conditioning therapy, and cyclosporine and methotrexate for prevention of GVHD. All drugs      had been previously accepted for administration to human in respective indication and there      is no need to further evaluate the efficacy and the safety of each drug separately.      Dose-escalating DLI is also widely accepted procedure after allogeneic HCT.|Both|16 Years|N/A|No|Non-Probability Sample|Patients with higher risk MDS|November 2010|December 1, 2010|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252784||112368|
NCT01268800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0588-10-rmb-CTIL|Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy|Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy, a Sensitive Method for Identifying Resistant AML Clones||Rambam Health Care Campus|No|Recruiting|February 2011|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood bone marrow and buccal smear|Both|18 Years|N/A|No|Non-Probability Sample|Adults (>18) AML patients|May 2014|May 5, 2014|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01268800||111137|
NCT01270009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PP-10|Role of BCL-B in Multiple Myeloma|Implication of the Antiapoptotic Protein BCL-B in the Pathogenesis of Multiple Myeloma||Centre Hospitalier Universitaire de Nice|No|Recruiting|November 2010|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients with Multiple Myeloma and MGUS newly diagnosed at the Service de Medecine        Interne-Cancerologie department of the Nice CHU|May 2012|May 15, 2012|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270009||111044|
NCT01269983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CdL_Ft_lombalgia_09|Effectiveness of Fascial Manipulation for Chronic Low Back Pain|Effectiveness of Fascial Manipulation for Chronic Low Back Pain. A Randomized Controlled Trial||University of Bologna|No|Recruiting|April 2009|December 2010|Anticipated|December 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|60 Years|No|||April 2009|January 4, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269983||111046|
NCT01269996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010.523|JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients|JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients|JUBILEE|Chinese University of Hong Kong|Yes|Completed|May 2011|February 2015|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|80 Years|No|||August 2015|August 21, 2015|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01269996||111045|
NCT01255137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100203|Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer|Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer||National Institutes of Health Clinical Center (CC)|Yes|Completed|September 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|80 Years|No|||April 2013|April 25, 2013|December 4, 2010|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01255137||112187|
NCT01255371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12221 ALISA|A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir|A Multicenter Phase III Trial of Second-line Antiretroviral Treatment Strategies in African Adults (Tanzania Ans South Africa) Using Atazanavir or Lopinavir/Ritonavir|ALISA|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Withdrawn|March 2012|December 2014|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|November 29, 2010||No|drug procurement issues|No||https://clinicaltrials.gov/show/NCT01255371||112169|
NCT01255657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-847|A Study of ABT-806 in Subjects With Advanced Solid Tumor Types|A Phase 1 Study of ABT-806 in Subjects With Advanced Solid Tumor Types Likely to Either Overexpress Wild-Type Epidermal Growth Factor Receptor (EGFR) or to Express Variant III Mutant EGFR||AbbVie|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|November 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01255657||112147|
NCT01255670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224/13/03/02/2009|Penicillin and Metronidazole in Treatment of Peritonsillar Abscess|Penicillin and Metronidazole in Treatment of Peritonsillar Abscess - Prospective, Double-blind, Randomized, Placebo-controlled Study||Helsinki University Central Hospital|No|Completed|February 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2010|April 8, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255670||112146|
NCT01255969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXCITE-001|EXerCise Introduction To Enhance Performance in Dialysis(EXCITE)|EXerCise Introduction To Enhance Performance in Dialysis: the EXCITE Study|EXCITE|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|Yes|Active, not recruiting|April 2010|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01255969||112123|
NCT01255982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-DUM-2010/1|Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up|Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up||AstraZeneca|No|Completed|March 2011|October 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|249|||Both|18 Years|55 Years|No|Probability Sample|Outpatients from Mental Health Centres or Psychiatric Offices, diagnosed with bipolar I or        II disorder experiencing an acute depressive episode.|October 2012|October 25, 2012|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01255982||112122|
NCT01253239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TECNIS-ReZoom-2010|Evaluation the TECNIS IOL in Both Eyes VS the ReZoom IOL in One and TECNIS IOL in the Opposite|A Retrospective Evaluation Comparing Post Operative Visual Outcomes in Patients Implanted With the TECNIS IOL in Both Eyes Versus the ReZoom IOL in One Eye and TECNIS IOL in the Opposite Eye||Bucci Laser Vision Institute|No|Recruiting|November 2010|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|120|||Both|42 Years|86 Years|Accepts Healthy Volunteers|Non-Probability Sample|Stable post operative cataract and clear lens extraction patients who have been implanted        with either the TECNIS multifocal IOLs in both eyes or TECNIS multifocal IOL in one eye        and the ReZoom in the opposite eye|January 2013|January 24, 2013|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01253239||112333|
NCT01253252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A01424-49|Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms (AAA) Metabolic Activity|Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms(AAA)Metabolic Activity|AAAendo|Central Hospital, Nancy, France|No|Completed|August 2009|||August 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|February 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01253252||112332|
NCT01253564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO25653|A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases|An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases||Hoffmann-La Roche||Completed|November 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|December 2, 2010||No||No|July 13, 2015|https://clinicaltrials.gov/show/NCT01253564||112308|
NCT01246193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HPS10C|CKD-828(80/2.5mg) Pharmacokinetic Study|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 80mg and S-Amlodipine 2.5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|65|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 17, 2011|November 17, 2010||||No||https://clinicaltrials.gov/show/NCT01246193||112871|
NCT01254994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Entecavir|The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure|A Prospective Open Label Control Study to Evaluate the Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure||Sun Yat-sen University|Yes|Completed|August 2007|December 2010|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||August 2007|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01254994||112198|
NCT01254435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH14709|Positioning During Colonoscopy|Does Patient Position During Extubation at Colonoscopy Influence the Quality of Mucosal Visualisation?||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|May 2009|September 2010|Actual|August 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|41|||Both|18 Years|N/A|No|||March 2009|December 3, 2010|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254435||112241|
NCT01254968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW-07-AM|Influence of Direction of Movement While Walking|Influence of Direction of Movement While Walking Upon the Blood Flow Rate Through Brain, Examined by Transcranial Doppler Sonography in Young Healthy Subjects.||Medical University of Silesia|Yes|Completed|December 2008|April 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1|||Both|20 Years|24 Years|Accepts Healthy Volunteers|Probability Sample|20 healthy subjects (11 men, 9 women, average age 23.94) participated in a study measuring        the speed of blood flow in middle cerebral arteries using transcranial Doppler        (transcranial Doppler Sonography) while walking on a treadmill.|November 2010|December 6, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01254968||112200|
NCT01246167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10127|Treatment of Proximal Humeral Fractures|An International, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Conservative, Plate Fixation and Prosthesis in Treatment of Displaced 2, 3, and 4 Part Fractures of Proximal Humerus of 60 Years and Older Patients|TPHF|Tampere University Hospital|Yes|Recruiting|January 2011|September 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|290|||Both|60 Years|N/A|No|||November 2015|November 18, 2015|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01246167||112873|
NCT01246492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34AK1|The Effect of Artificial Sweeteners on Blood Glucose Response|The Effect of Artificial Sweeteners on Blood Glucose Response||Northumbria University|No|Withdrawn|November 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246492||112848|
NCT01247051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE001AHK|Comparison of Two Different Heart-lung Machine Filling Methods: Precoating Versus Colloidal Fluids|||Johann Wolfgang Goethe University Hospitals|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|78 Years|95 Years|No|||August 2011|August 26, 2011|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247051||112805|
NCT01247376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/59-31/4|Temperature Sensitive Release of PGE2 and Diminished Energy Requirements in Synovial Tissue With Postoperative Cryotherapy - A Prospective Randomised Study After Knee Arthroscopy|Temperature Sensitive Release of PGE2 and Diminished Energy Requirements in Synovial Tissue With Postoperative Cryotherapy - A Prospective Randomised Study After Knee Arthroscopy||Karolinska Institutet|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|60 Years|No|||November 2010|November 23, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247376||112780|
NCT01256749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100294|A Comparative Study of Global 12 Lead Electroencephalogram to Frontal SedlineTM Electroencephalogram|A Comparative Study of Global 12 Lead Electroencephalogram to Frontal SedlineTM Electroencephalogram Monitoring for the Evaluation of Intraoperative Burst Suppression During Elective Craniotomy or Transphenoidal Pituitary Resection||Loma Linda University|No|Completed|December 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|90 Years|No|Non-Probability Sample|Adult patients scheduled for elective craniotomy or transphenoidal pituitary resection at        LLUMC University Hospital in which the surgeon has requested intraoperative burst        suppression therapy regardless of the inciting etiology will be eligible to participate in        this study.|September 2014|September 8, 2014|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01256749||112063|
NCT01247038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU33|A Multicentre Trial to Compare Two Articulating Bearing Surfaces as Used in Cementless Primary Hip Arthroplasty|A Multicentre Prospective Randomised Control Trial to Compare Two Articulating Bearing Surfaces, Ceramic on Metal and Metal on Metal Large Diameter Femoral Heads, as Used in Cementless Primary Hip Arthroplasty|MagnumCRCT|Biomet, Inc.|No|Active, not recruiting|January 2011|November 2022|Anticipated|November 2022|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|70 Years|No|||March 2014|June 22, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247038||112806|
NCT01252797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100528006|Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)|RAD 1002: Phase I Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases|RAD 1002|University of Alabama at Birmingham|Yes|Active, not recruiting|October 2010|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|19 Years|N/A|No|Probability Sample|patients who have brain metastases and will undergo both surgery and radiation therapy for        treatment.|March 2016|March 7, 2016|November 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252797||112367|
NCT01269970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G.0175.03|Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy|Early Metabolic Response Evaluation With 18-FDG PET-CT in Esophageal Cancer Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy||Universitaire Ziekenhuizen Leuven|Yes|Completed|January 2004|December 2009|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Probability Sample|locally advanced esophageal cancer (cT2-4 N0/+) of the esophagus (n=42) and GEJ (n=13)|January 2011|January 3, 2011|January 3, 2011||||No||https://clinicaltrials.gov/show/NCT01269970||111047|
NCT01269749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904005064|Radioactive Iodide Therapy for Pediatric Graves' Disease|Radioactive Iodide Therapy for Pediatric Graves' Disease||University of Florida|No|Recruiting|October 2010|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|N/A|18 Years|No|||November 2015|November 24, 2015|October 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269749||111064|
NCT01270243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-636-A|Bacterial Microbiota In The Tonsils Of Children|Bacterial Microbiota In The Tonsils Of Children Undergoing Adenotonsillectomy And Normal Controls||University of Chicago|Yes|Recruiting|December 2010|December 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|2 Years|12 Years|No|Probability Sample|Children undergoing adenotonsillectomies at the Comer Children's Hospital|January 2011|January 19, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270243||111026|
NCT01255683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unfunded2|Oral Steroid Treatment for Chronic Rhinosinusitis|Single-arm Clinical Evaluation of Oral Steroid Treatment for Chronic Rhinosinusitis||Oregon Health and Science University|No|Withdrawn|December 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Adult study population with a confirmed diagnosis of chronic sinusitis presenting to the        tertiary rhinology clinic at Oregon Health & Science University (OHSU).|December 2010|April 21, 2015|December 6, 2010||No|Lack of proposed funding.|No||https://clinicaltrials.gov/show/NCT01255683||112145|
NCT01255384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-DIABETES-HMO-CTIL|Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes|Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes: Molecular Studies of the Placenta and Cord Blood and Possible Correlation to Postnatal Development.||Hadassah Medical Organization|No|Not yet recruiting|December 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|Placental biopsy cord bloos Saliva|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Infants of diabetic mothers. The follow-up will start at the high risk pregnancy clinic.        The obstetrician will follow women with pre-gestational and gestational diabetes. The        neonates will be evaluated and followed for epigenetic changes and neurodevelopmental        outcome|December 2010|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255384||112168|
NCT01256307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8508|Effects of an Individualized Training Program on Severity Markers of Obstructives Sleep Apnea/Hypopnea Syndrome (OSAS)|Effects of an Individualized Training Program on Severity Markers of Obstructives Sleep Apnea/Hypopnea Syndrome (OSAS)|REEVASAS|University Hospital, Montpellier|No|Completed|November 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|30 Years|65 Years|No|||December 2014|December 3, 2014|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01256307||112097|
NCT01256645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT 2010|Transfusion Strategies in Weaning Patients|Liberal Versus Restrictive Transfusion Management in Patients Being Weaned From Prolonged Mechanical Ventilation|WTT|Krankenhaus Kloster Grafschaft|No|Recruiting|December 2010|February 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2010|December 7, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256645||112071|
NCT01253265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13061|A Study in Rheumatoid Arthritis|Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate Treatment||Eli Lilly and Company|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|32|||Both|20 Years|75 Years|No|||January 2012|January 11, 2012|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253265||112331|
NCT01253278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13183|A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Oral Doses of LY2393910 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|March 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|38|||Both|21 Years|70 Years|No|||June 2011|June 9, 2011|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253278||112330|
NCT01253889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02069|Sweetheart Study: Oral Glucose for Reducing Stress During Echocardiographic Assessment in Infants in the NICU|Glucose 25% and Facilitated Tucking for Reducing Procedural Stress During Neonatologist-performed Cardiac Echocardiography in Infants in the NICU||Children's & Women's Health Centre of British Columbia|No|Completed|December 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|104|||Both|N/A|6 Months|No|||July 2015|July 21, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253889||112283|
NCT01255267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-041|The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients|The Correlation Between Genetic Polymorphism, Platelet Activity, , Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients||China Medical University Hospital|Yes|Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|||||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Acute coronary syndrome and chronic coronary artery diseae patients|December 2010|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255267||112177|
NCT01245894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VF-20060|Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on the Coronary Microcirculation||Odense University Hospital|Yes|Completed|November 2007|June 2010|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|81 Years|No|||November 2007|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245894||112894|
NCT01246505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-0012|Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions|Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions|PFAST-CTOs|BridgePoint Medical|Yes|Completed|July 2011|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246505||112847|
NCT01246830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52731|The Use of 2D and 3D Imaging Modalities and Its Influence on Diagnosis and Treatment Planning in Orthodontics|The Use of 2D and 3D Imaging Modalities and Its Influence on Diagnosis and Treatment Planning in Orthodontics||Universitaire Ziekenhuizen Leuven|No|Completed|January 2012|September 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Both|12 Years|25 Years|No|Non-Probability Sample|Patients who are seeking orthodontic and maxillofacial surgery treatments at the        University Hospital Leuven with the need of conventional panoramic radiographs,        cephalometric radiographs and cone beam CT images.|September 2010|December 2, 2014|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246830||112822|
NCT01247064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 10-007460|Hypertonic Saline for Acute Bronchiolitis|Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department||Children's Hospital of Philadelphia|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|2 Months|23 Months|No|||July 2014|July 31, 2014|November 15, 2010||No||No|March 14, 2014|https://clinicaltrials.gov/show/NCT01247064||112804|
NCT01247337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI 1003|Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma|Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Gemcitabine and Capecitabine in Combination With Cetuximab in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma. A Phase II Trial.||Herlev Hospital|Yes|Active, not recruiting|November 2010|March 2015|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|March 20, 2014|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247337||112783|
NCT01256762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP14B014|Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer|A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer||Geron Corporation|No|Completed|November 2010|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256762||112062|
NCT01247610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003087R|Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder|Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder||National Taiwan University Hospital|Yes|Recruiting|January 2011|December 2015|Anticipated|||N/A|Observational|Observational Model: Cohort||2|Anticipated|390|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|17 Years|24 Years|No|Non-Probability Sample|The sample will consist of (1) 217 adolescents (180 males, 83%) who were diagnosed of ADHD        at childhood and followed up by Gau and consented to this follow-up study, and (2) 173        healthy controls (123, Males, 71%) without lifetime ADHD to late adolescence and        adulthood. This cohort was established from 2005 to 2008. We will invite them for complete        assessments 6 years after their assessments at adolescence according to the original        assessment schedules from 2005-2008. The estimated age ranges are 17-24 years old.|January 2012|November 14, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01247610||112762|
NCT01253070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02618|Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia||National Cancer Institute (NCI)||Active, not recruiting|April 2011|||October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|60 Years|N/A|No|||December 2015|January 13, 2016|December 2, 2010|Yes|Yes||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01253070||112346|
NCT01270269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101037|ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit|ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit|ACT-ICU|Vanderbilt University|No|Active, not recruiting|February 2011|December 2016|Anticipated|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01270269||111024|
NCT01265992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-270|Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis|Post Marketing Observational Study to Assess Patient Management Practices and Quality of Life With the Capsules Form of Paricalcitol in the Treatment of SHPT in Stage 3 - 5 Chronic Kidney Disease Patients Not Yet on Dialysis Under Conditions of Usual Clinical Care (CAPITOL)|CAPITOL|AbbVie|No|Completed|February 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitals with nephrology clinic.|January 2014|January 22, 2014|November 29, 2010||No||No|November 8, 2013|https://clinicaltrials.gov/show/NCT01265992||111353|
NCT01266005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-410|A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients|A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients||Bukwang Pharmaceutical||Terminated|August 2009|January 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|December 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01266005||111352|
NCT01266018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2009-007|Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer|Phase II Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer||Ludwig Institute for Cancer Research|No|Active, not recruiting|December 2010|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266018||111351|
NCT01266343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99018|Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma|Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma||Taipei Medical University WanFang Hospital|No|Completed|January 2007|December 2009|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|60|||Both|20 Years|N/A|No|Probability Sample|Glaucoma patients|December 2010|December 23, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266343||111326|
NCT01266356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99019|A TMU/NIH Integrated Research Project Translation of Basic Research to Clinical Diagnosis and Treatment of Mild Traumatic Brain Injury (mTBI)|A TMU/NIH Integrated Research Project Translation of Basic Research to Clinical Diagnosis and Treatment of Mild Traumatic Brain Injury (mTBI)||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|August 2009|August 2012|Anticipated|||N/A|Observational|Observational Model: Case Control||2|Anticipated|500|||Both|17 Years|N/A|No|Probability Sample|Brain Injury Patients|December 2010|December 22, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266356||111325|
NCT01256658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566B2401|A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)|A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemether-lumefantrine (Coartem® / Coartem® Dispersible)||Novartis|No|Completed|November 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14075|||Both|N/A|N/A|No|||November 2013|January 14, 2014|December 6, 2010||No||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01256658||112070|
NCT01255995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2PR2240936|Natural History of IOL in Pseudo Exfoliation Syndrome|The Natural History of Artificial Intraocular Lenses (IOL) in Eyes With Exfoliation Syndrome|PXF|Aurolab|Yes|Active, not recruiting|December 2010|May 2022|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|PXF subjects with or without glaucoma who require cataract surgery. Controls without PXF        who require cataract surgery|November 2012|November 15, 2012|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01255995||112121|
NCT01252693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-153-10-1|International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer|Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer||Spectrum Pharmaceuticals, Inc|No|Completed|November 2010|May 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Male|18 Years|N/A|No|||June 2015|June 2, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252693||112375|
NCT01252992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081253|Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis|Paradoxical Reactions During Anti-mycobacterial Treatment of Extrapulmonary Tuberculosis in Non Immuno-compromized Patients : Clinical, Radiological et Immunological|PARATB|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|Blood samples (immunologic test), DNA, RNA, Biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Extra-pulmonary tuberculosis|October 2015|October 13, 2015|November 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01252992||112352|
NCT01253577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P500-1009|A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis|A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis|ADVANCE II|Intersect ENT||Completed|December 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|December 2, 2010|Yes|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT01253577||112307|
NCT01244958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFM07-Rtx-Lef|Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis|Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis - a Multicenter Randomised Double-blind Clinical Trial||Johann Wolfgang Goethe University Hospitals|Yes|Completed|August 2010|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|75 Years|No|||March 2016|March 23, 2016|September 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01244958||112964|
NCT01245309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG1001|Endometrial Scratching Prior to Controlled Ovarian Stimulation (COH) in Women Undergoing In-vitro Fertilization With Previous IVF Failure|Endometrial Injury Prior to Controlled Ovarian Stimulation (COH) in Women Undergoing In-vitro Fertilization in Women With Previous IVF Failure.|ESICOHF|Mansoura University|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Female|N/A|40 Years|No|||January 2014|January 14, 2014|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245309||112939|
NCT01255826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dina Shinkar MD protocol|Ventilatory Management of the Preterm Neonate in the Delivery Room|Ventilatory Management of the Preterm Neonate in the Delivery Room.||Ain Shams University|Yes|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|112|||Both|27 Weeks|33 Weeks|No|||September 2014|September 12, 2014|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01255826||112134|
NCT01246518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOB015-I|Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis|An Open, Multi-centre Trial Comparing the Efficacy and Safety of Two Different Treatment Regimens of Topical MOB015 Treatment of Distal Subungual Onychomycosis (DSO)||Moberg Derma AB|No|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|70 Years|No|||September 2011|October 24, 2012|November 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01246518||112846|
NCT01255514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0510|Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma|Sequential High-dose Dexamethasone and Response Adopted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Multicenter Phase 2 Study||Yonsei University|Yes|Recruiting|October 2009|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|20 Years|65 Years|No|||March 2014|March 4, 2014|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255514||112158|
NCT01256099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1810-31/3|Internet-CBT for Insomnia|Guided Internet-treatment for Insomnia. Treatment Effects, Health Economics and Interaction With Depression|IpsyInsomni|Karolinska Institutet|No|Completed|January 2010|February 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|191|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01256099||112113|
NCT01256411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2219E1|A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension|An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension||Novartis||Completed|November 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|341|||Both|N/A|N/A|No|||September 2015|September 22, 2015|December 7, 2010||No||No|July 21, 2015|https://clinicaltrials.gov/show/NCT01256411||112089|
NCT01256424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC CE203/10|Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia|A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2)||Photocure|No|Completed|April 2011|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|262|||Female|18 Years|N/A|No|||August 2014|August 21, 2014|December 7, 2010|Yes|Yes||No|August 6, 2014|https://clinicaltrials.gov/show/NCT01256424||112088|
NCT01256437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6046|Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream Lotion, for EGFR'I Induced Acneiform Rash|Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream Lotion, for EGFR'I Induced Acneiform Rash|EGFR'I|Rabin Medical Center|No|Recruiting|January 2011|December 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|N/A|No|||October 2013|October 27, 2013|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256437||112087|
NCT01252550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU341|Effects of Activia in IBS|Association Between GI Microbiota, Low-grade Inflammation and Classical Pathophysiological Factors in Patients With Irritable Bowel Syndrome (IBS) and Effect of the Consumption of Activia on GI Symptoms Provoked by a Lactulose Challenge Test in IBS Patients|MOSAIC|Sahlgrenska University Hospital, Sweden|Yes|Completed|May 2010|August 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252550||112386|
NCT01253083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110037|Mobility Training to Improve Motor Behavior in Toddlers With or at Risk for Cerebral Palsy: A Pilot Study|Mobility Training to Improve Motor Behavior in Toddlers With or at Risk for Cerebral Palsy - A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|November 2010|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|12 Months|36 Months|No|||April 2015|May 15, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253083||112345|
NCT01253421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P001568|The Effects of Dopamine on Reward Processing|The Effects of Dopamine on Reward Processing||Mclean Hospital|No|Recruiting|February 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253421||112319|
NCT01270776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 - 0112 - E|Efficacy Study Comparing 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine|Comparison of 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine for Skin Antisepsis Prior to Venepuncture in Very Low Birth Weight Infants: A Planned Non-inferiority Trial||Mount Sinai Hospital, Canada|No|Recruiting|January 2011|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|462|||Both|N/A|28 Days|No|||May 2013|May 13, 2013|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270776||110985|
NCT01266031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTTC11-02|Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma|Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2011|||July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266031||111350|
NCT01266044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0584|Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia|Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2011|||April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|435|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266044||111349|
NCT01266057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0588|Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer|A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|April 2011|||April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|December 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01266057||111348|
NCT01266070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0650|TKI 258 in Von Hippel-Lindau Syndrome (VHL)|A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome||M.D. Anderson Cancer Center|No|Terminated|November 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 22, 2010|Yes|Yes|Trial met toxicity stopping rule|No||https://clinicaltrials.gov/show/NCT01266070||111347|
NCT01266369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB06013|Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation|A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open-label, 2-parallel Group, Phase IIa Study to Compare Efficacy and Safety of AB1010 at 3 or 6 mg/kg/Day in Treatment of Patients With Mastocytosis With Handicap and Bearing Activating Point Mutations in the Phosphotransferase Domain of c-Kit Such as the Main Mutation Asp-816-Val (D816V)||AB Science|No|Completed|February 2007|May 2010|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||December 2010|December 23, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266369||111324|
NCT01266382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|93/09|The Effect of AposTherapy on the Level of Pain, Function and Quality of Life in Patients With Neuro-muscular and Neurological Disorders|||Assaf-Harofeh Medical Center|No|Recruiting||||||N/A|Interventional|Primary Purpose: Treatment|||||||Both|18 Years|85 Years|Accepts Healthy Volunteers|||July 2009|December 23, 2010|December 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266382||111323|
NCT01266629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-147|The Clinical Utility of Fecal Caprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy|The Clinical Utility of Fecal Calprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy: A Prospective Study||Shaare Zedek Medical Center|No|Recruiting|December 2010|September 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|consecutive patients referred for capsule on an outpatient basis will include in the        study. Indications for EC will be suspicion of crohn's disease, unexplained anemia, and        bleeding, and abnormal findings in commuted tomography. All patients underwent non        diagnostic colonoscopy and gastroscopy prior to EC referral.|October 2010|January 10, 2011|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266629||111304|
NCT01256671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-230|DHEA Against Vaginal Atrophy - Safety Study of 12 Months|DHEA Against Vaginal Atrophy - Safety Study of 12 Months||EndoCeutics Inc.|Yes|Completed|December 2010|December 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|530|||Female|40 Years|75 Years|No|||February 2016|February 19, 2016|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256671||112069|
NCT01256684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-231|DHEA Against Vaginal Atrophy - 3-Month Efficacy Study|DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA)||EndoCeutics Inc.|Yes|Completed|December 2010|November 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|255|||Female|40 Years|75 Years|No|||February 2016|February 19, 2016|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01256684||112068|
NCT01252472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00039333|Flomax Study for Floppy Iris Syndrome|Diagnostic Imaging for Intraoperative Floppy Iris Syndrome||University of Michigan|No|Completed|June 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|36|||Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult male patients seen and scheduled for cataract surgery at the Kellogg eye Centers in        Ann Arbor, Livonia and Brighton campuses.|April 2015|April 24, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252472||112392|
NCT01252706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-AM-292-CTIL|Estimation of Alcohol, Substance and Cigarettes Exposure Among Pregnant Women in the Israeli Periphery and Center, and the Contribution of Brief Intervention|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2011|July 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10000|||Female|18 Years|50 Years|No|||November 2010|December 1, 2010|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252706||112374|
NCT01252719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-ORI-10-01|Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection|A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I)|SOLO I|The Medicines Company|Yes|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|960|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252719||112373|
NCT01253005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 320030_0-0197|The Effect of Physical Properties of Lipid Emulsions on Gastrointestinal Function|The Effect of Physical Properties of Lipid Emulsions on Gastrointestinal Motility and Transit, Hormonal Feedback, Visceral Sensation and Satiety in Healthy Volunteers||University of Zurich||Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|50 Years|No|||November 2012|November 13, 2012|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01253005||112351|
NCT01244971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR 03-539|Exercise and Acarbose in Type 2 Diabetes|Effect of Exercise Training - Alone or in Combination With Acarbose - on Clinical and Metabolic Factors, and Studies of Cellular and Moleculargenetic Factors, in Type 2 Diabetes.||Karolinska Institutet||Completed|January 2004|||June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|62|||Both|45 Years|60 Years||||December 2003|November 19, 2010|November 19, 2010||||No||https://clinicaltrials.gov/show/NCT01244971||112963|
NCT01245907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100528/CARIN|Climacteric Therapy With Applied Relaxation Using InterNet|Climacteric Therapy With Applied Relaxation Using InterNet - CARIN Study|CARIN|Ostergotland County Council, Sweden|No|Terminated|February 2011|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Female|45 Years|N/A|No|||April 2014|April 24, 2014|November 22, 2010||No|Unacceptable high drop-out rate.|No||https://clinicaltrials.gov/show/NCT01245907||112893|
NCT01255839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KA-01177-M|The Balloon Project for Birth Induction|A Prospective Multi-centre Randomised Comparison on Induction of Labour With Double-balloon Installation Device Versus Prostaglandin E2 Minprostin||Glostrup University Hospital, Copenhagen|No|Completed|December 2002|December 2010|Actual|September 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|825|||Female|N/A|N/A|No|||January 2002|December 7, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255839||112133|
NCT01255813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pathway CH-1 (CIP-001)|Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache|Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache||Autonomic Technologies, Inc.|Yes|Completed|December 2010|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255813||112135|
NCT01256112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R03 DK070627 (completed)|Parent Supported Weight Reduction in Down Syndrome|Parent Supported Weight Reduction in Down Syndrome||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|September 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|13 Years|26 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01256112||112112|
NCT01256450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP-301|Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain|A 12-Week, Placebo Controlled, Double Blind, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Buprenorphine HCl Buccal Film in Subjects With Moderate to Severe Chronic Low Back Pain||Endo Pharmaceuticals|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|334|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 7, 2010|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01256450||112086|
NCT01256463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-5540|HIV Prevention for PLHIV: Evaluation of an Intervention Toolkit for HIV Care & Treatment Settings|HIV Prevention for People Living With HIV/AIDS: Evaluation of an Intervention Toolkit for HIV Care and Treatment Settings||Centers for Disease Control and Prevention|No|Active, not recruiting|October 2009|January 2013|Anticipated|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3548|||Both|18 Years|N/A||||April 2012|April 4, 2012|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256463||112085|
NCT01252342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytocin|Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?|Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?||University of Saskatchewan||Withdrawn|August 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|January 9, 2012|November 30, 2010||No|Proposed doses were too large, bolus oxytocin may cause cases of arrythmias, and some even    advocate slowing down the infusion rates that are currently used.|No||https://clinicaltrials.gov/show/NCT01252342||112402|
NCT01252316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS-812096|Cardiopulmonary Resuscitation (CPR) Dissemination Study Using Nurses and Volunteers|An In-Hospital VSI CPR Dissemination Study Using Nurses and Volunteers||University of Pennsylvania|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01252316||112404|
NCT01252329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10030462|Comparison of Elective Lymph Node Treatment Versus Clinical Observation in the Absence of Palpable Lymph Nodes for High Risk Skin Squamous Cell Carcinoma (SCC)|High Risk Cutaneous Squamous Cell Carcinoma Treated With Mohs Surgery Randomized to Elective Management of the Draining Lymph Nodes vs. Periodic Clinical Nodal Observation||University of Pittsburgh|Yes|Terminated|April 2011|May 2022|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|November 30, 2010||No|insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01252329||112403|
NCT01252563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0531097|Amlodipine 10mg Drug Use Investigation|Enhanced Dose Norvasc Treatment For Essential Hypertension In Realworld (Norvasc®10mg Drug Use Investigation)|ENTER10|Pfizer|No|Completed|December 2010|November 2013|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14141|||Both|20 Years|N/A|No|Probability Sample|The subjects who have been treated with amlodipine 5mg at least 4 weeks and had not        achieved target BP.|January 2014|January 9, 2014|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01252563||112385|
NCT01252810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE 145-002|Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure|A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure||GE Healthcare|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|284|||Both|65 Years|N/A|No|||May 2014|May 1, 2014|December 1, 2010|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01252810||112366|
NCT01253759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NERA-2|Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma|10 Years Report of Combined Simultaneous Transpupillary Thermotherapy and ICG-based Photodynamic Therapy for Choroidal Melanoma||New England Retina Associates|No|Completed|January 2009|March 2009|Actual|January 2009|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|46|||Both|18 Years|95 Years|No|Non-Probability Sample|Subjects selected from retina specialist general patient population.|May 2013|May 1, 2013|March 25, 2009||No||No||https://clinicaltrials.gov/show/NCT01253759||112293|
NCT01253772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STER01P|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia in Neonates|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia in Neonates||SterilMed, Inc.|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4|||Both|N/A|6 Months|No|Non-Probability Sample|Neonatal children undergoing complex cardiac surgical procedures.|December 2010|December 2, 2010|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253772||112292|
NCT01270789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0230-A|LIraglutide and Beta-cell RepAir (LIBRA) Study|A Randomized Controlled Study Assessing the Effect of Liraglutide on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes Mellitus: The LIraglutide and Beta-cell RepAir (LIBRA) Study|LIBRA|Mount Sinai Hospital, Canada|No|Completed|January 2011|May 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|30 Years|75 Years|No|||September 2014|September 10, 2014|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270789||110984|
NCT01271101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASY-CHINA|The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome|The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome|EASY-CHINA|Fudan University|Yes|Recruiting|July 2010|August 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1800|||Both|21 Years|80 Years|No|Non-Probability Sample|Chinese patients with non-ST-elevated acute coronary syndrome|July 2010|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271101||110960|
NCT01271582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT_08_001|Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients|Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen||Asan Medical Center|No|Active, not recruiting|January 2009|July 2016|Anticipated|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01271582||110923|
NCT01256697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA -08-5086-YR-CTIL|The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa|The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella||Sheba Medical Center|No|Completed|August 2008|January 2011|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|N/A|No|||December 2013|December 19, 2013|February 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01256697||112067|
NCT01252485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG BiO|Registry Study on Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage - The AMLSG Biology and Outcome (BiO)-Project|Registry Study on Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage - The AMLSG Biology and Outcome (BiO)-Project|AMLSG BiO|University of Ulm|No|Recruiting|July 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|patients with newly diagnosed AML in all AMLSG participating centers (50-60 centers in        Germany and Austria)|July 2014|July 22, 2014|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252485||112391|
NCT01252732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-ORI-10-02|Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection|A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)|SOLO II|The Medicines Company|Yes|Completed|December 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1019|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252732||112372|
NCT01252745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-1-2010-01|Efficacy of an Intranasal Testosterone Product|An Open Label, Randomized, Balanced, Three Treatment, Parallel Design, Pharmacokinetic Study of Intranasal TBS-1 Administration to Hypogonadal Men||Trimel Biopharma SRL|No|Completed|August 2010|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|80 Years|No|||December 2010|December 1, 2010|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01252745||112371|
NCT01253291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13417|A Study of Japanese Rheumatoid Arthritis Patients|An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate||Eli Lilly and Company|No|Completed|May 2010|March 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|20 Years|75 Years|No|||April 2014|April 30, 2014|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01253291||112329|
NCT01253304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13765|A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment|A Single Dose Pharmacokinetic Study of LY2189265 in Subjects With Varying Degrees of Hepatic Impairment||Eli Lilly and Company|No|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|December 1, 2010|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01253304||112328|
NCT01245621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCC-BAKI: D0946|Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)|Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes|ENABLE III|Dartmouth-Hitchcock Medical Center|Yes|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|360|||Both|18 Years|N/A|No|||October 2013|January 2, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01245621||112915|
NCT01254734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09206|Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer|Outcomes in Transoral Robotic Microsurgery for Head and Neck Tumors||City of Hope Medical Center|Yes|Terminated|April 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|November 3, 2010|No|Yes|The study will be rewritten as a data registry study|No||https://clinicaltrials.gov/show/NCT01254734||112218|
NCT01255852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLH2|Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting|Phase 4 of Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting|APORIAS|Jinling Hospital, China|Yes|Completed|January 2011|July 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255852||112132|
NCT01255865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arizant 10-1026|Comparison Study of Core Temperature Thermometry Systems|Deep Tissue Thermometry 510(k) Premarket Notification Trial||Arizant Healthcare|No|Enrolling by invitation|December 2010|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Crossover||7|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|120 subjects of any racial, gender, or ethnic background in who simultaneous measurments        of deep tissue, oral, or rectal temperature can be made|June 2011|June 30, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255865||112131|
NCT01256125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-sen U 11-5-1|Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.|Therapeutic Effects of Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.||Sun Yat-sen University|Yes|Recruiting|October 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|60|||Both|15 Years|65 Years|No|Probability Sample|Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease,        autoimmune liver disease and so on.|October 2010|December 7, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256125||112111|
NCT01256138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunYat-sen U 11-5-2|Allogene MSCs Transplantation in Liver for Patients With Chronic Liver Diseases Through Portal Vein by Ultrasound Guiding|||Sun Yat-sen University|Yes|Recruiting|October 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|60|||Both|15 Years|65 Years|No|Probability Sample|Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease,        autoimmune liver disease and so on.|October 2010|December 7, 2010|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256138||112110|
NCT01256151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131024|Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet|Open-label, Randomized, Single-Dose, 2 Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet||Pfizer|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 24, 2011|December 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01256151||112109|
NCT01256476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.04US|Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia|A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA|PREVAIL-US|Kowa Research Institute, Inc.|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|80 Years|No|||May 2012|May 2, 2012|December 7, 2010|Yes|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT01256476||112084|
NCT01256489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02-010|Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)|Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis||Massachusetts Eye and Ear Infirmary|Yes|Withdrawn|December 2010|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2015|November 3, 2015|November 19, 2010|No|Yes|Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (~3 in    1 million). No eligible subjects have been identified.|No||https://clinicaltrials.gov/show/NCT01256489||112083|
NCT01256502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURE-001|The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery|||Allergan||Completed|October 2010|April 2014|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Female|18 Years|N/A|No|||December 2015|December 15, 2015|December 7, 2010|Yes|Yes||No|December 18, 2013|https://clinicaltrials.gov/show/NCT01256502||112082|None to report.
NCT01252355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC6058|Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta|A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta|TERACLES|Sanofi|Yes|Terminated|January 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|534|||Both|18 Years|55 Years|No|||May 2014|May 30, 2014|November 30, 2010|Yes|Yes|Sponsor decision to prematurely stop the study, not linked to any safety concern.|No|April 23, 2014|https://clinicaltrials.gov/show/NCT01252355||112401|The early termination of study with reduced sample size and participant follow-up impacts the power and interpretability, and limits the ability to assess the overall benefit/risk of adjunctive therapy. Termination was not due to any safety concerns.
NCT01252576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Villari|Linguistic and Cultural Validation in Italian of Female Sexual Function Index (FSFI) Questionnaire|Linguistic and Cultural Validation in Italian of Female Sexual Function Index Questionnaire (FSFI)||Club Italiano Femminile di Urologia|No|Active, not recruiting|December 2010|||June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|women from general population whit or without sexual dysfunction|June 2011|June 21, 2011|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252576||112384|
NCT01252823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/33|Implantable Loop Recorder in Hemodialysis Patients|Identification and Prevention of Sudden Cardiac Death Causes in Hemodialysis Patients|RYTHMODIAL|University Hospital, Bordeaux|No|Active, not recruiting|December 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|72|||Both|45 Years|80 Years|No|||August 2014|August 20, 2014|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01252823||112365|
NCT01253785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STER05|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia||SterilMed, Inc.|No|Completed|May 2010|July 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, consenting, non-smoking subjects, 18 years or older, both genders and a range of        skin tones.|December 2010|December 2, 2010|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253785||112291|
NCT01271127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL31278.058.10|Screening for Coronary Artery Disease After Mediastinal Irradiation|Screening for Coronary Artery Disease After Mediastinal Irradiation in Hodgkin Lymphoma Survivors|SCAR|Leiden University Medical Center|No|Completed|January 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|50|||Both|35 Years|60 Years|No|||June 2013|June 11, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271127||110958|
NCT01271361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T114E4|Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients|Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients: an Optical Frequency Domain Imaging (OFDI) Study|TROFI|Terumo Europe N.V.|Yes|Completed|November 2010|December 2012|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271361||110940|
NCT01271114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISCAM AN-2010/28|Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension|Hypertonic Saline and Terlipressin Linked To an Early Goal-Driven Protocol for Septic Shock or Sepsis-Associated Hypotension: A Pilot Trial (HYSATESS)|HYSATESS-p|Hospital General de Ciudad Real|Yes|Terminated|June 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|90 Years|No|||March 2014|March 7, 2014|January 4, 2011||No|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT01271114||110959|
NCT01271608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0203.0.028.000-08|Study to Evaluate the Need of Needle Change for Application of Intramuscular, Subcutaneous and Intradermal Injection.|Intramuscular and Subcutaneous Injections: is it Necessary to Have Needles Exchanged?||Hospital M'Boi Mirim|Yes|Completed|June 2009|November 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1240|||Both|18 Years|N/A|No|||June 2009|January 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01271608||110921|
NCT01252498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC1005|Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis|A Pilot Study to Evaluate the Role of Cyclooxygenase Pathway in Radiation Therapy and Chemoradiation Therapy Induced Mucositis in Head and Neck Cancer Patients||University of Vermont|No|Completed|December 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|None Retained|Saliva will be collected at 4 time points before, during, immediately after, and several      weeks after radiotherapy for head and neck cancer.|Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving radiotherapy or chemoradiotherapy for oral cancers. Consecutive        patients will be invited to participate.|February 2014|February 3, 2014|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252498||112390|
NCT01252511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-271|Determinants of Fat Malabsorption After Roux-en-Y Gastric Bypass|Surgical Treatment of Severe Obesity by Roux-en-Y Gastric Bypass: a Randomized Prospective Study on the Effect of Reciprocal Changes in Y-limb Lengths on Intestinal Absorption of Dietary Fat, Protein and Carbohydrate.||Baylor Research Institute|No|Active, not recruiting|January 2011|May 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252511||112389|
NCT01253603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039A2201|Efficacy, Safety, and Pharmacokinetics of QAW039|A Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Pharmacokinetics of QAW039 in Steroid-free Patients With Mild to Moderate Persistent Asthma||Novartis||Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|170|||Both|18 Years|65 Years|No|||August 2013|October 29, 2013|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253603||112305|
NCT01244997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4729|Evaluation of Implants Placed Immediately or Delayed Into Extraction Sites|Prospective Evaluation of Immediate Temporized Implants||Louisiana State University Health Sciences Center in New Orleans|No|Completed|November 2003|May 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|21 Months|65 Years|Accepts Healthy Volunteers|||November 2010|November 19, 2010|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01244997||112961|
NCT01244698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160583-3|Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction|Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction||Stony Brook University|No|Completed|November 2010|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244698||112983|
NCT01254461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00016|A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin|A Phase I, Open Label, Randomised, Parallel Group Study of Repeated Oral Doses of AZD1981 (100 mg Twice Daily and 400 mg Twice Daily Via Tablet) for Eight Days and Single Doses of Pravastatin (Pravachol® Tablet 40 mg) to Evaluate the Pharmacokinetic Interaction of AZD1981 and Pravastatin in Healthy Male Volunteers||AstraZeneca||Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 28, 2011|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01254461||112239|
NCT01255527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0482|Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study|A Phase 1/2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study||Yonsei University|Yes|Recruiting|October 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|53|||Both|20 Years|65 Years|No|||June 2013|June 1, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255527||112157|
NCT01256190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC-002 NL|A Study of Fibrocaps in Liver Surgery in the Netherlands|A Phase 2, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety and Study of Topical Fibrocaps™ and Gelatin Sponge in Surgical Hemostasis in the Netherlands||ProFibrix, Inc.|Yes|Completed|December 2010|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|December 6, 2010||No||No|April 11, 2013|https://clinicaltrials.gov/show/NCT01256190||112106|
NCT01256164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC-002|U.S. Study of Fibrocaps in Surgical Hemostasis|A U.S. Phase 2, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Fibrocaps™ and Gelatin Sponge (USP) in Surgical Hemostasis||ProFibrix, Inc.|No|Completed|December 2010|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|70|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|December 6, 2010|Yes|Yes||No|April 11, 2013|https://clinicaltrials.gov/show/NCT01256164||112108|
NCT01256177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D144CC00005|Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression|A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression||AstraZeneca|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|361|||Both|18 Years|65 Years|No|||December 2015|January 4, 2016|December 7, 2010||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01256177||112107|
NCT01256515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001437|Health Management Training to Enhance Influenza Vaccine Immunogenicity|Health Management Training to Enhance Influenza Vaccine Immunogenicity||Massachusetts General Hospital|No|Completed|November 2009|June 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 28, 2013|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256515||112081|
NCT01256528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0053|Delayed-Delayed Breast Reconstruction|A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients With Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy||M.D. Anderson Cancer Center|No|Completed|December 2010|||September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|N/A|No|||September 2015|September 14, 2015|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01256528||112080|
NCT01252602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024|Prenatal Depression and Failure to Breastfeed|Prospective Study of Maternal Prenatal Depression as a Risk Factor for Failure to Breastfeed||Oklahoma State University Center for Health Sciences|Yes|Withdrawn|December 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Female|18 Years|52 Years|Accepts Healthy Volunteers|Probability Sample|Women receiving prenatal care at the OSU Houston Parke obstetrics clinic in Tulsa,        Oklahoma, who are in their third trimester between 34 and 38 weeks gestation|October 2014|October 16, 2014|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252602||112382|
NCT01252862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-017|Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents|A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents||Glaukos Corporation|No|Active, not recruiting|December 2010|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01252862||112362|
NCT01252589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoL - CML0310|Patient Reported Outcomes in Chronic Myeloid Leukemia|Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|November 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|480|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (18 years of age or older) with confirmed diagnosis of Philadelphia        chromosome positive CML undergoing all possible treatments available.|July 2015|July 29, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01252589||112383|
NCT01253096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-L19IL2-03/09|Intratumoral Application of L19IL2 in Patients With Malignant Melanoma|A Phase II Study of Intratumoral Application of L19IL2 in Patients With Stage III/IV Melanoma.||Philogen S.p.A.|No|Completed|April 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253096||112344|
NCT01254032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114169|Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD|A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With Chronic Obstructive Pulmonary Disease|PACE|GlaxoSmithKline|No|Completed|August 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|70|||Both|40 Years|N/A|No|Probability Sample|Approximately 550 male and female outpatient subjects will be enrolled in order to have        approximately 300 exacerbation events. Approximately 15 centres in Korea, China,        Australia, and Taiwan will be required to recruit the subjects.        Country Planned Number of Subjects Korea 170 China 150 Taiwan 130 Australia 100|May 2012|June 12, 2013|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01254032||112272|
NCT01271140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-086-BMA|High Dose Insulin Therapy to Improve Liver Function|High Dose Insulin Therapy to Improve Liver Function in Patients With HCV Liver Cirrhosis||McGill University Health Center|Yes|Active, not recruiting|January 2011|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271140||110957|
NCT01271374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR-2010-001|Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome|Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan|AMORE|InVasc Therapeutics, Inc.|Yes|Active, not recruiting|April 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271374||110939|
NCT01271387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-1105|Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment|An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon With That in Matched Healthy Control Subjects||Vanda Pharmaceuticals|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|29|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|January 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01271387||110938|
NCT01271855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201720|Trial Assessing Maternal Post-Partum Pain|CRAMPS Trial: Controlled Randomized Trial Assessing Maternal Post-partum Pain With Suppositories|CRAMPS|Loyola University|No|Completed|May 2009|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|217|||Female|18 Years|N/A|No|||April 2013|April 25, 2013|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271855||110902|
NCT01253018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6935-R|Evaluation of Robot Assisted Neuro-Rehabilitation|Evaluation of Robot Assisted Neuro-rehabilitation|SRT3|VA Office of Research and Development|Yes|Completed|April 2011|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|21 Years|N/A|No|||February 2016|February 1, 2016|November 24, 2010||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01253018||112350|The amount of change on our primary outcome measure (FM) for this population of stroke survivors with moderated to severe upper extremity motor impairment was less than predicted (4 points vs. 8) resulting in the study groups being underpowered.
NCT01253317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-08-0403|Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)|PHARMACOLOGICAL TREATMENT OF RETT SYNDROME BY STIMULATION OF SYNAPTIC MATURATION WITH IGF-1||Children's Hospital Boston|Yes|Completed|December 2010|January 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Female|2 Years|12 Years|No|||January 2013|January 24, 2013|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253317||112327|
NCT01253590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-213|Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation|Feasibility of Remote Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation||Memorial Sloan Kettering Cancer Center||Terminated|December 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|22 Years|N/A|No|Non-Probability Sample|Two cardiology attending physicians, Dr. Michelle Johnson and Dr. Carol L. Chen, who are        members of this research team, will identify post-operative patients whose primary        attending has made a decision to discharge.|March 2015|March 4, 2015|December 2, 2010||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01253590||112306|
NCT01245322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAV-3-BV|Treatment of Bacterial Vaginosis Combined With Human Lactobacilli|Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses||Skaraborg Hospital|No|Completed|January 2007|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Female|18 Years|50 Years|No|||November 2014|November 6, 2014|November 19, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01245322||112938|
NCT01245335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI-2011-1|Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)|Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease||Harvest Technologies|Yes|Completed|May 2011|November 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245335||112937|
NCT01246206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU 2009-095|Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT|A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation||Barbara Ann Karmanos Cancer Institute|Yes|Completed|November 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|70 Years|No|||May 2014|May 15, 2014|November 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246206||112870|
NCT01255280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3293841|Behavioral Activation and HIV Risk Reduction for Men Who Have Sex With Men With Crystal Meth Abuse|Behavioral Activation and HIV Risk Reduction for MSM With Crystal Methamphetamine Abuse||Massachusetts General Hospital|Yes|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|No|||May 2012|May 31, 2012|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01255280||112176|
NCT01261689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREAT01|The Randomised Epidural Analgesia in Term Delivering Women Trial (TREAT)|The Randomised Epidural Analgesia in Term Delivering Women Trial|TREAT|Maastricht University Medical Center|Yes|Completed|September 2008|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|488|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 26, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01261689||111683|
NCT01261949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-rTMS-Tinnitus-02|Combined Low Frequency Frontal and Temporal rTMS Treatment in Chronic Tinnitus|Effectiveness of Low Frequency Combined Frontal and Temporal Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Chronic Tinnitus||University of Regensburg|No|Completed|April 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||January 2016|January 7, 2016|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01261949||111663|
NCT01292460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201050|Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies|A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those Given Individually in Patients With Open Angle Glaucoma or Ocular Hypertension||Santen Oy|No|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|600|||Both|18 Years|N/A|No|||March 2011|March 12, 2013|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292460||109323|
NCT01262521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protective dietary nitrate|Dietary Nitrate and Cardiovascular Health|Physiological Effects of Oral Nitrate on Vascular Function||Heinrich-Heine University, Duesseldorf|No|Completed|November 2010|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|21 Years|36 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262521||111619|
NCT01262534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017545|A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.|Observational Epidemiological Registry to Assess the Clinical Profile in Patients With Moderate to Severe Psoriasis in Spain||Janssen-Cilag, S.A.||Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|1042|||Both|18 Years|N/A|No|Probability Sample|Patients from hospital sites and out-patient dermatology clinics will participate under        the conditions of standard clinical practice|May 2013|May 3, 2013|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262534||111618|
NCT01292915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GVN-DUM-2010/1|Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients|Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients|NIS-PUB|AstraZeneca|No|Completed|October 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1044|||Both|18 Years|N/A|No|Non-Probability Sample|NVUGIB patients in 13 hospitals in Hanoi, HCMC, Danang|May 2014|May 15, 2014|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01292915||109288|
NCT01292928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G100291|SuperNOVA Clinical Stenting Trial|Stenting of the Superficial Femoral (SFA) and Proximal Popliteal Arteries (PPA) With the Boston Scientific INNOVA Self-Expanding Bare Metal Stent System||Boston Scientific Corporation|No|Active, not recruiting|April 2011|July 2016|Anticipated|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|299|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 9, 2011|Yes|Yes||No|August 14, 2015|https://clinicaltrials.gov/show/NCT01292928||109287|
NCT01293188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10185|Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement|Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement|ARVA|French Cardiology Society|No|Completed|January 2011|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|434|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with calcified aortic stenosis operated on for bioprosthetic aortic valve        replacement|March 2015|March 6, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293188||109267|
NCT01293825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer IIR-WS883414|Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)|Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder|Zip Ad|University Hospital Case Medical Center|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|February 10, 2011|Yes|Yes||No|December 28, 2013|https://clinicaltrials.gov/show/NCT01293825||109218|
NCT01295541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-2009-05a|Early Progressive Mobility in the CVICU: Assessing Current Status|Early Progressive Mobility in the CVICU: Assessing Current Status||Hill-Rom|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of patients admitted to the CV-Intensive Care Unit.|February 2011|February 11, 2011|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01295541||109086|
NCT01255150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110044|Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer|Frequency of Epidermal Growth Factor Receptor Mutations in Latinos/Hispanics With Non-Small Lung Cancer||National Institutes of Health Clinical Center (CC)||Completed|December 2010|April 2015||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|15|||Both|2 Years|N/A|No|||April 2015|April 30, 2015|December 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01255150||112186|
NCT01255163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100423|A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease|A Pilot Study of Exendin-4 in Alzheimer s Disease||National Institutes of Health Clinical Center (CC)||Recruiting|November 2010|December 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|100|||Both|60 Years|N/A|No|||August 2015|March 2, 2016|December 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01255163||112185|
NCT01265433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-134|Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy|Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265433||111396|
NCT01265186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|704/2010|Evaluation of Sedation in Newborns|Evaluation of Sedation in Newborns - a Prospective, Controlled, Observer Blinded Clinical Trial in 67 Patients||Medical University of Vienna|No|Recruiting|December 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|67|||Both|N/A|28 Days|Accepts Healthy Volunteers|Probability Sample|Ventilated term newborns with or without pharmacological sedation/analgesia|December 2010|December 22, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265186||111415|
NCT01265446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|075-A-301|Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.|A Randomized, Double-blind, Parallel Group, Single-dose Study of the Efficacy of Lidocaine 8 mg + Cetylpyridinium Chloride (CPC) 2 mg Fixed Combination Lozenges on Sore Throat Pain Intensity Compared to Lozenges Containing Lidocaine 1 mg and CPC 2 mg in Subjects With Sore Throat Due to Upper Respiratory Tract Infection.||Novartis|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|December 20, 2010||No||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01265446||111395|
NCT01265459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35GA1001|Different Volumes of Durolane in Knee OA|Double-Blind, Randomized Study of Three Different Volumes of Durolane in Subjects With Osteoarthritis of the Knee||Q-Med AB|No|Completed|January 2011|November 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|68|||Both|40 Years|85 Years|No|||March 2014|March 17, 2014|December 17, 2010||No||No|December 3, 2013|https://clinicaltrials.gov/show/NCT01265459||111394|
NCT01265472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB455-CTIL|Comparison of Translocator Protein Expression and Binding Activity in Normal Tissue Versus Non Melanotic Malignancy|Comparison of the Expression Level of Translocator Protein (TSPO) and Binding Activity in Normal Cutaneous Tissue Versus Non Melanotic Cutaneous Malignancy.||Rambam Health Care Campus|No|Not yet recruiting|January 2011|July 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Specimens of normal skin, squamous cell carcinoma or basal cell carcinoma|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Not an observational study.|December 2010|December 22, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265472||111393|
NCT01265732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0041012|A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers|An Open Label, Randomized 3-Way Crossover Single Dose Study To Compare The Pharmacokinetics And Relative Bioavailability Of PF-04191834 Using An Oral Wet-Milled Suspension Formulation Versus An Oral Single Dose Dispersion Formulation Under Fasted Conditions In Healthy Volunteers||Pfizer|No|Withdrawn|December 2010|January 2011|Anticipated|January 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|November 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01265732||111373|
NCT01261455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-09-0999A|Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia|Prospective Randomized Pilot Study Comparing the Surgical Times Between Inferior Versus Superior Conjunctival Autografts for Primary Pterygia||University Health Network, Toronto|Yes|Recruiting|October 2010|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||October 2010|December 14, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01261455||111701|
NCT01261468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS-24h|Treatment With Spinal Cord Stimulation: Effect on Sensory Parameters|Treatment With Spinal Cord Stimulation: Effect on Sensory Parameters||Danish Pain Research Center|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261468||111700|
NCT01261702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008/2552|Magnesium Infusion for Pain Relief After Thoracotomy. A Randomized Controlled Trial.|Intravenous Magnesium Infusion for Pain Relief After Thoracotomy. A Randomized Controlled Trial.||Mahidol University|No|Terminated|February 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||February 2013|February 14, 2013|December 15, 2010||No|not include patient anymore|No||https://clinicaltrials.gov/show/NCT01261702||111682|
NCT01294137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-AGIR-3|Sleep Apnea in Frail Elderly|Accuracy of Pulse Oximetry to Detect Sleep Apnea in Frail Hospitalized Patients|SAFE|AGIR à Dom|Yes|Completed|March 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|80|||Both|75 Years|N/A|No|||February 2011|May 7, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294137||109194|
NCT01294722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100769|A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti‐Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea|The Prevalence of Out-patients With Rheumatoid Arthritis Fulfilling the Indication for Anti-tumor Necrosis Factor(TNFa) Therapy in General Hospital Setting in Korea: a Multi-center, Non-interventional, Observational Study||Janssen Korea, Ltd., Korea|No|Completed|December 2011|August 2012|Actual|August 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1700|||Both|20 Years|N/A|No|Non-Probability Sample|Participants with diagnosis of RA visiting an internist as an outpatient|March 2013|March 18, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294722||109149|
NCT01262274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIBC1009|Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer|Randomized Phase II Trial of Anastrozole in Combination With/Without Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Primary Breast Cancer|Neo-ACET BC|Translational Research Informatics Center, Kobe, Hyogo, Japan|Yes|Terminated|December 2010|April 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Female|N/A|N/A|No|||May 2015|May 19, 2015|December 15, 2010||No|Due to an adverse event revelation.|No||https://clinicaltrials.gov/show/NCT01262274||111638|
NCT01292941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP065CC|Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers|Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers||Coloplast A/S|No|Withdrawn|March 2011|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Actual|0|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 6, 2015|February 9, 2011||No|Product development project closed prematurely|No||https://clinicaltrials.gov/show/NCT01292941||109286|
NCT01293201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105781-3|Trial of STAHIST in Seasonal Allergic Rhinitis|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of STAHIST in Adult and Adolescent Subjects With a History of Seasonal Allergic Rhinitis||Magna Pharmaceuticals, Inc.|No|Completed|March 2011|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|290|||Both|12 Years|60 Years|No|||April 2011|August 31, 2011|February 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01293201||109266|
NCT01293526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SonR Access|Acute Optimization of Cardiac Resynchronization Therapy (CRT)Using Echocardiography and SonR|Acute Optimization of Cardiac Resynchronization Therapy (CRT) Using Echocardiography and SonR|SonR Access|Piedmont Healthcare|No|Recruiting|February 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293526||109241|
NCT01294423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692C00006|Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus|A 24-week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise||AstraZeneca|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|261|||Both|20 Years|N/A|No|||July 2014|July 17, 2014|February 10, 2011|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01294423||109172|For participants who did not complete 24 weeks LOCF (last observation carried forward) was used. Only values prior to rescue medication were used for outcome measures except for total body weight which was evaluated regardless of rescue.
NCT01295008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-308|Androgenetic Alopecia in Fabry Disease|Androgenetic Alopecia in Fabry Disease||Baylor Research Institute|No|Completed|December 2010|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|107|||Male|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Selected from specialy clinic|January 2016|January 12, 2016|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01295008||109127|
NCT01256008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009BAI77B06-3|Intervention Study of Depression in Breast Cancer Patients|Early Identification and Early Warning of Psychological Problems in Breast Cancer Patients, and Intervention Study Using Cognitive Behavioral Therapy on Depression in Breast Cancer Patients||Wenzhou Medical University|Yes|Completed|December 2010|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|392|||Female|20 Years|65 Years|No|||April 2015|April 9, 2015|December 6, 2010|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01256008||112120|
NCT01254877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA018896|Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons|Ondansetron Pharmacotherapy for Hazardous Drinking in HIV+, African-American Women||Johns Hopkins University|Yes|Recruiting|December 2010|August 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254877||112207|
NCT01254890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0511|Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome|Phase I/II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227)||M.D. Anderson Cancer Center|No|Completed|January 2011|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254890||112206|
NCT01254903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0655|Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC)|Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC)||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2010|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|December 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01254903||112205|
NCT01264900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH086525|Cognitive Behavioral Aggression Treatment|Cognitive Behavioral Aggression Treatment: Effects on Brain and Behavior||Temple University|Yes|Completed|May 2010|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|55 Years|No|||March 2016|March 3, 2016|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264900||111437|
NCT01265199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT-406-CS-002|Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)|Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)||Ascenta Therapeutics|No|Terminated|February 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|74 Years|No|||January 2013|January 21, 2013|December 20, 2010|No|Yes|Study was terminated before a MTD was determined for administrative reasons|No||https://clinicaltrials.gov/show/NCT01265199||111414|
NCT01265485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 107|An Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects|An Open Label Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects||RDD Pharma Ltd|No|Completed|August 2011|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 21, 2011|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01265485||111392|
NCT01265745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036-10-01|Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects|A Phase I, Double-blind, Randomized, Placebo Controlled, Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) as a 120 Minute Infusion in Healthy, Normal Subjects||PharmAthene, Inc.|Yes|Completed|December 2010|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 6, 2013|December 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01265745||111372|
NCT01295775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRESS_Korea|Diabetic Retinopathy Sulodexide Study|A Multicentre, Double-Blind, Randomised, Placebo Controlled Study of the Activity of Sulodexide in Diabetic Patients With Mild to Moderate Non-Proliferative Retinopathy|DRESS|Ajou University School of Medicine|Yes|Completed|February 2009|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|N/A|No|||November 2012|November 5, 2012|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01295775||109068|
NCT01296009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYF-861234|Effect of Traditional Chinese Medicine (TCM) on Embryo Implantation in In-vitro Fertilization (IVF) Patients|Effect of Traditional Chinese Medicine (TCM) on Embryo Implantation in In-vitro Fertilization (IVF) Patients||Wuhan University|Yes|Recruiting|November 2010|May 2011|Anticipated|May 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|300|||Female|18 Years|35 Years|No|||November 2010|February 14, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296009||109052|
NCT01291940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Emollient Evaluation Study|The Effects of Emollient Therapy on the Skin Barrier|The Effects of Emollient Therapy on the Skin Barrier Function|EES|Oregon Health and Science University|Yes|Recruiting|January 2011|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|190|||Both|3 Months|N/A|Accepts Healthy Volunteers|||June 2013|June 19, 2013|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01291940||109363|
NCT01291953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0419-2010|Effectiveness of Early Detection of Atrial Fibrillation|Effectiveness of Early Detection of Atrial Fibrillation in People 65 Years or More bt Physicians and Nurse in Primary Care|FAMDAP|Hospital Universitario Reina Sofia|No|Completed|January 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|6990|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 17, 2015|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01291953||109362|
NCT01294735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4827-014|Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)|A Phase I Study of MK-4827 in Combination With Temozolomide in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.|No|Completed|February 2011|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294735||109148|
NCT01294748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS-CEM-2010-02|Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease|Clinical Investigation of a DES (MiStent™ System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in Native Coronary Arteries.|DESSOLVE-II|Micell Technologies|Yes|Active, not recruiting|February 2011|August 2016|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|85 Years|No|||April 2015|April 7, 2015|February 10, 2011||No||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01294748||109147|
NCT01292447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0084|A Trial of 2% Lidocaine Gel for Intrauterine Device (IUD) Insertion|A Randomized Controlled Trial of 2% Lidocaine Gel for IUD Insertion||Women and Infants Hospital of Rhode Island|No|Completed|February 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|150|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||December 2013|December 6, 2013|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01292447||109324|
NCT01293214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000073|Vascularized Composite Allotransplantation for Multiple Extremity Amputations|Vascularized Composite Allotransplantation for Multiple Extremity Amputations||Brigham and Women's Hospital|No|Recruiting|February 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||January 2015|January 26, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293214||109265|
NCT01293539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1071|Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma|Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|March 2011|August 2021|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|18 Years|No|||November 2015|November 17, 2015|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01293539||109240|
NCT01293552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-1207-101-ACNE|Clinical Trial To Evaluate ANT-1207 In Subjects With Acne|Clinical Trial To Evaluate Botulinum Neurotoxin Type A (ANT-1207) In Subjects With Acne||Anterios Inc.|Yes|Completed|January 2011|July 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|72|||Both|18 Years|70 Years|No|||June 2013|June 28, 2013|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01293552||109239|
NCT01295307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-BRIDGE-046|Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia|BRIDGE|Technische Universität Dresden||Completed|March 2011|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|40 Years|N/A|No|||October 2015|October 6, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01295307||109104|
NCT01295814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 10-0061|Efficacy Study of Adalimumab to Treat Interstitial Cystitis|An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC)||ICStudy, LLC|Yes|Completed|March 2011|July 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|No|||July 2015|July 12, 2015|February 14, 2011|Yes|Yes||No|July 20, 2013|https://clinicaltrials.gov/show/NCT01295814||109065|
NCT01292018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIN-DUM-2010/1|Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India|A Non Interventional, Cross Sectional, Epidemiological Study on the Management of Dyslipidemia in Type 2 DM Adult Patients in India|SOLID|AstraZeneca|No|Completed|February 2011|February 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|5400|Samples Without DNA|Lipid profile ( Low Density Lipoproteins(LDL), High Density Lipoprotein (HDL), Triglycerides      & Total cholesterol) Blood Glucose Measurements (Fasting Plasma Glucose)|Both|18 Years|N/A|No|Non-Probability Sample|Type 2 Diabetics with dyslipidemia on stable dose of Lipid Lowering Drugs(LLDs).|February 2013|February 20, 2013|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01292018||109357|
NCT01256021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT_PRT_CP02|The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy|Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy||Medy-Tox|No|Recruiting|August 2010|July 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|212|||Both|2 Years|18 Years|No|||August 2010|December 7, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01256021||112119|
NCT01255397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF-001|Proposed Research Protocol For Male Infertility|Proposed Research Protocol For Male Infertility||HaEmek Medical Center, Israel|No|Not yet recruiting|January 2011|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||December 2010|December 6, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255397||112167|
NCT01255410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 271|Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Metapneumovirus Vaccine, rHMPV-Pa Lot HMPV #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HMPV-Seropositive Children 12 to 59 Months of Age, and HMPV-Seronegative Infants and Children 6 to 59 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2011|January 2015|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|7||Actual|60|||Both|6 Months|49 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|December 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01255410||112166|
NCT01264913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-049-A|Cardiometabolic Risk of Shiftwork|Cardiometabolic Risk of ShiftWork: Sleep Loss vs.Circadian Disruption|SW|University of Chicago|Yes|Recruiting|August 2009|||June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will enroll 44-46 regular day workers (work hours between 7:00 a.m. and 7:00 p.m. on        all work days) and 44-46 shift workers on rotating schedules (changing shift at lease once        a week and having work hours between 7:00 p.m. and 7:00 a.m. on at least 10 days per        month). Both groups of subjects will work at least 30 hours per week at the University of        Chicago, University of Chicago Medical Center, or other Chicago area medical center and        have maintained their work schedule for at least 6 months.|January 2013|September 4, 2013|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01264913||111436|
NCT01264926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|saf004-CTIL-HMO|Evaluation of the Difference in the Acromion Humerus Gap at Sitting,Lying|||Hadassah Medical Organization|No|Active, not recruiting|February 2012|||March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|men and women with or without shoulder pain0|March 2013|March 21, 2013|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01264926||111435|
NCT01294930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOPC|Indicators of Operative and Postoperative Complications in Patients Operated for Hip Fracture|Indicators of Operative and Postoperative Complications in Patients Operated for Hip Fracture|IOPC|University Hospital, Linkoeping|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|None Retained|Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with hip fracture operated at the hospital in Norrkoeping|February 2013|February 20, 2013|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01294930||109133|
NCT01295229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194279|Calorie Reduction Or Surgery: Seeking Remission for Obesity And Diabetes|Feasibility, Efficacy, and Mechanisms of Surgical vs Medical Diabetes Treatment|CROSSROADS|University of Washington|Yes|Completed|May 2011|June 2015|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|25 Years|65 Years|No|||March 2016|March 22, 2016|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01295229||109110|
NCT01295242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39810-C|Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)|Natural History of HPV Infections in Mid-Adult Women|WHIM|University of Washington|No|Completed|February 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|409|Samples With DNA|Self-collected vaginal samples for HPV testing. Self-collected oral samples for HPV testing.      Serum samples for HPV antibody testing.|Female|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 to 50 year old women affilitated with Univeristy of Washington (student, staff,        faculty)|November 2013|November 15, 2013|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01295242||109109|
NCT01295476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL10B1|Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia|Biological Correlates With T-cell Acute Lymphoblastic Leukemia (T-ALL) Gene Expression and Clinical Outcome||Children's Oncology Group||Active, not recruiting|April 2011|||January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|135|Samples With DNA|Bone Marrow|Both|1 Year|30 Years|No|Non-Probability Sample|Newly diagnosed T-cell acute lymphoblastic leukemia|May 2015|May 1, 2015|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295476||109091|
NCT01296022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34725.018.10|A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy|Randomized Trial to Study the Efficacy and Adverse Effects of the Subcutaneous and Transvenous Implantable Cardioverter Defibrillator (ICD) in Patients With a Class I or IIa Indication for ICD Without an Indication for Pacing|PRAETORIAN|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|February 2011|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|850|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01296022||109051|
NCT01291966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0101/2008|Efficacy of a Intervention to Reduce Medication Errors and Improve Adherence|Efficacy of a Intervention to Reduce Medication Errors and Therapeutic Failure in Patients Over 65 Years Polypharmacy|ATEM-AP|Hospital Universitario Reina Sofia|No|Completed|January 2010|September 2010|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|154|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2010|February 8, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01291966||109361|
NCT01291979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAngUH1|The Effect of Intravenous Lidocaine on Pain After Tonsillectomy|Intravenous Lidocaine for Effective Pain Relief After Tonsillectomy: a Prospective, Randomized, Double-blind, Placebo-controlled Study||Chung-Ang University Hospital|No|Not yet recruiting|February 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|65 Years|No|||February 2011|February 8, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01291979||109360|
NCT01292239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017686|A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients|A Phase III, Randomized, Double-blind, Placebo-controlled Trial in Japan to Investigate the Efficacy and Safety of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naive, Genotype 1, Hepatitis C-infected Subjects||Janssen Pharmaceutical K.K.|No|Completed|February 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|183|||Both|20 Years|70 Years|No|||December 2013|December 16, 2013|February 1, 2011|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT01292239||109340|
NCT01295294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15105|Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)|International, Prospective, Double-blind, 3-arm Comparative, Randomized, Placebo-controlled Phase IV Study on the Effect of Counseling and Either Tranexamic Acid or Mefenamic Acid or Placebo, on the Management of Bleeding/Spotting in Women Using the Levonorgestrel-releasing Intrauterine System (MIRENA) for Contraception.||Bayer|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|187|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 2, 2014|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295294||109105|
NCT01294995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST Chinese liquor study|Effect of Short-term Chinese Tea-flavor Liquor Consumption|Phase 1 Study of Chinese Tea-flavor Liquor|ESTCTFLC|Zhejiang University|Yes|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|23 Years|28 Years|Accepts Healthy Volunteers|||October 2010|February 11, 2011|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294995||109128|
NCT01295528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transtek BPM TMB-986|Clinical Study of Blood Pressure Monitor in Conformance With the ANSI/AAMI SP10 Standard|Verify the functionS of BPM TMB-986 to Comply With ANSI/AAMI SP10|BPM|BTS International|No|Completed|May 2010|October 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The subject population included patients suffering from hypertension, labile hypertension,        normal, and hypotension. The 95 patients had a wide range in age, weight, height, heart        rate, systolic and diastolic blood pressures.        18~99 years old. Male or Female. Arm circumference in 22-42cm.|February 2011|February 11, 2011|January 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295528||109087|
NCT01292668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 175410|Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer|A Phase I Study for Superficial Basal Cell Carcinoma to Determine the Irradiance - Dependent Pain Threshold for Methylaminolevulinate (MAL)/PDT.||Roswell Park Cancer Institute|Yes|Completed|March 2011|September 2014|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|February 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01292668||109307|
NCT01292954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading-2-2011|Effect of Blueberries on Vascular Function in Healthy Men|Effects of Blueberries on Vascular Function and Blood Pressure in Healthy Men||University of Reading|Yes|Completed|October 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|10|||Male|19 Years|40 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01292954||109285|
NCT01292694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101618|Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure|Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure||Vanderbilt University|No|Recruiting|April 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|16|||Both|18 Years|85 Years|No|||March 2016|March 7, 2016|February 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01292694||109305|
NCT01293578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006952|Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication|Translating Information on Comparative Effectiveness Into Practice (TRICEP)|TRICEP|Mayo Clinic|No|Completed|January 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|550|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 18, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01293578||109237|
NCT01262378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASK # 1557|Harmonic vs HF Knife in Patients Requiring Abdominal Surgery|Clinical Outcome of the Seroma Amount Using the Harmonic vs the HF Knife for Surgery According to Lockwood and Abdominoplastic Surgery: A Prospective Controlled Study||Asklepios proresearch|No|Active, not recruiting|February 2009|February 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||December 2010|December 16, 2010|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262378||111630|
NCT01262651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA0958|A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex® in Relieving Persistent Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.||GW Pharmaceuticals Ltd.|Yes|Active, not recruiting|December 2010|July 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|380|||Both|18 Years|N/A|No|||January 2014|June 2, 2015|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01262651||111609|
NCT01262664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0369|Prohibitin Targeting Peptide 1 (Fat Zapper)|A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2012|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Male|18 Years|N/A|No|||July 2015|July 10, 2015|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01262664||111608|
NCT01292031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023310-31|Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)|Randomized, Open Label, Multicenter, Non-inferiority Trial to Compare Safety and Efficacy of Colistin vs. Meropenem in VAP Caused by CR-GNB|MagicBullet|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Yes|Completed|May 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01292031||109356|
NCT01256034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|furukawa2009|Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy|Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy|EPIPD|Chiba University|No|Completed|May 2009|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|December 7, 2010||No||No|September 24, 2012|https://clinicaltrials.gov/show/NCT01256034||112118|
NCT01256047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|furukawa2009-2|Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy|Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy||Chiba University|No|Recruiting|May 2009|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256047||112117|
NCT01256320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2009:081:110|Egg Study With Peripheral Arterial Disease|The Impact of Egg Consumption on Indices of Vascular Health in Individuals With Peripheral Arterial Disease||University of Manitoba|No|Completed|June 2010|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|3||Actual|60|||Both|40 Years|N/A|No|||June 2013|June 18, 2013|June 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01256320||112096|
NCT01294657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0161|Obesity: Cancer Risk Among African Americans|Obesity: Cancer Risk Among African Americans-Developing Interventions Through Community Collaboration||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2011|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|16 saliva samples to be collected for hormone testing.|Both|18 Years|65 Years|No|Probability Sample|African Americans will be recruited from Windsor Village United Methodist Church in        Houston, Texas.|September 2015|September 2, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294657||109154|
NCT01295255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1130|Interaction Effect of Asthma and Aeroallergen Category on the Psychological Status in Allergic Rhinitis Patients|||Beijing Tongren Hospital||Completed|February 2009|November 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|524|||Both|16 Years|60 Years|No|Probability Sample|524 affected individuals (311 males and 213 females) with AR were prospectively recruited        from the rhinology clinic of the Otolaryngology, Head and Neck Surgery Department of        Beijing Tongren Hospital from February 2009 to November 2009.|January 2011|February 11, 2011|February 11, 2011||||No||https://clinicaltrials.gov/show/NCT01295255||109108|
NCT01295268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-019|Study of Emu Oil vs. Placebo for Vulvar Pain in Women.|The Efficacy of Emu Oil vs. Placebo in Minimizing Vulvar Pain Levels in Women--A Randomized, Double Blinded, Placebo-Controlled Trial.||William Beaumont Hospitals|No|Terminated|February 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Female|18 Years|N/A|No|||May 2012|May 7, 2012|February 10, 2011||No|enrollment volume due to placebo arm of trial|No||https://clinicaltrials.gov/show/NCT01295268||109107|
NCT01295489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0271|Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma||Gynecologic Oncology Group||Active, not recruiting|March 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|39|||Female|18 Years|N/A|No|Non-Probability Sample|Patients with previously untreated invasive ovarian epithelial, fallopian tube, or primary        peritoneal cancer|March 2016|March 16, 2016|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295489||109090|
NCT01295788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEO 09/05E|Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial)|Simultaneous vs Delayed Initiation of REAL-Time Continuous Glucose Monitoring in Children and Adolescents With Type 1 Diabetes Starting Insulin Pump Therapy||Children's Hospital of Eastern Ontario|Yes|Active, not recruiting|June 2011|January 2015|Anticipated|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|5 Years|18 Years|No|||December 2014|December 5, 2014|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01295788||109067|
NCT01295827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07990|Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)|Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma||Merck Sharp & Dohme Corp.|No|Active, not recruiting|March 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|12||Anticipated|1260|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295827||109064|
NCT01291992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-259|Seizures After Cardiac Surgery -- A Study With Continuous EEG Monitoring|Seizures After Cardiac Surgery -- A Prospective Study With Continuous EEG Monitoring||Lawson Health Research Institute|No|Recruiting|September 2010|January 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the CSRU postoperatively who have given informed consent to have        immediate and continous EEG monitoring for the first 24 hours postoperatively|February 2011|February 8, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291992||109359|
NCT01292967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading-2010_03|Influence of Sugar on the Bioavailability of Cocoa Flavanols|The Influence of Maltitol on the Absorption and Metabolism of Flavanols From Chocolate||University of Reading|Yes|Completed|April 2008|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|15|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2010|February 9, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01292967||109284|
NCT01265316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007676|Measurement of the Quality of Pediatric CPR|Pediatric CPR Quality: Quantitative Measurement of Pediatric Cardiopulmonary Resuscitation (CPR) Quality During In-Hospital Cardiac Arrest|PediQ-CPR|Children's Hospital of Philadelphia|No|Completed|October 2010|June 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|||Both|1 Year|7 Years|No|Probability Sample|Cardiac arrests (chest compression events) occurring in the pediatric intensive care unit        having consented for enrollment in the study.|February 2014|February 5, 2014|December 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01265316||111405|
NCT01265602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 569 000 - 1004|Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis|Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis||Almirall, S.A.||Completed|November 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|889|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265602||111383|
NCT01291758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-229|Exercise in Gulf War Illness (GWI)|||Georgetown University|Yes|Completed|July 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|50|Samples With DNA|Plasma, serum, urine, cerebrospinal fluid (CSF), and buccal swab samples retained for      testing as described in protocol.|Both|38 Years|86 Years|Accepts Healthy Volunteers|Non-Probability Sample|All veterans who served in the Armed Forces between August 1990 and July 1991|February 2014|February 24, 2014|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291758||109377|
NCT01292005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006648|Pentoxifylline Treatment of Acute Pancreatitis|Pentoxifylline Treatment in Acute Pancreatitis; A Double-Blind Placebo-Controlled Randomized Trial||Mayo Clinic|Yes|Completed|April 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||October 2013|October 23, 2013|October 19, 2010|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01292005||109358|
NCT01293266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudickar2|Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation|Effect of Propofol and Sevoflurane on Base Excess, pH and Lactate in Pediatric Heart Catheterisation|PRISCATHLAB|University of Schleswig-Holstein|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|40|||Both|N/A|12 Years|No|||February 2011|March 10, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293266||109261|
NCT01294150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012CP|The Safety and Effectiveness of UroLift: LIFT Pivotal Study|Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms|LIFT|NeoTract, Inc.|Yes|Active, not recruiting|February 2011|February 2017|Anticipated|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|206|||Male|50 Years|N/A|No|||July 2015|July 15, 2015|February 7, 2011|No|Yes||No|April 1, 2014|https://clinicaltrials.gov/show/NCT01294150||109193|
NCT01294410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM129-005|Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis|A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)||Bristol-Myers Squibb|Yes|Completed|March 2011|December 2014|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|305|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294410||109173|
NCT01263860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAH115G6HCV|A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients|A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus||Third Affiliated Hospital, Sun Yat-Sen University|No|Completed|December 2010|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|242|||Both|18 Years|70 Years|No|||November 2014|November 14, 2014|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01263860||111517|
NCT01255722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-44-012|Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography|Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (X-ACT Study)|X-ACT|Guerbet|Yes|Completed|November 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|468|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|December 3, 2010||No||No|August 27, 2015|https://clinicaltrials.gov/show/NCT01255722||112142|The main limitation of the study is the absence of gold standard such as conventional angiography to confirm the readers’ assessments. Diagnostic accuracy could therefore not be compared.
NCT01255735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04-024|Randomized Controlled Trial of Voice on Children With Vocal Nodules|Randomized Controlled Trial of Voice on Children With Vocal Nodules||Massachusetts Eye and Ear Infirmary|Yes|Active, not recruiting|January 2011|June 2016|Anticipated|October 2015|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|114|||Both|6 Years|10 Years|Accepts Healthy Volunteers|Probability Sample|Children ages 6-10 who have hoarseness and vocal nodules|July 2015|January 11, 2016|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01255735||112141|
NCT01252524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0422|Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study|Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study||East Carolina University|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01252524||112388|
NCT01252758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-7-2010-01|Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma|A Phase II Study to Assess the Efficacy and Safety of a Single Inhaled Dose of Albuterol Sulfate Dry Powder Via the Trivair Deposition System Versus Albuterol Sulfate HFA pMDI in Patients With Intermittent or Persistent Mild Asthma||Trimel Biopharma SRL|No|Not yet recruiting|March 2011|||June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|24|||Both|18 Years|65 Years|No|||December 2010|December 1, 2010|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01252758||112370|
NCT01256333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00942-37|Optimization of Arterial Oxygen Transport by Positive End-expiratory Pressure Variation in Acute Respiratory Distress Syndrome|Optimization of Arterial Oxygen Transport by Positive End-expiratory Pressure Variation in Acute Respiratory Distress Syndrome|OPTIPEP|Rennes University Hospital||Completed|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute respiratory distress syndrome|July 2013|July 2, 2013|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01256333||112095|
NCT01294943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bauru School of Dentistry, USP|Evaluating the Effectiveness of the Tongue Cleaner in Critical Patients|Evaluating the Effectiveness of the Tongue Cleaner in Patients Wholly or Partially Dependent Care||University of Sao Paulo|Yes|Completed|January 2010|December 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|tongue biofilm|Both|15 Years|N/A|No|Probability Sample|Patients undergoing intubation in the intensive care unit|August 2012|August 14, 2012|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294943||109132|
NCT01294956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-043|A Clinical Evaluation of an Investigational Lubricant Eye Gel (FID 115958D)|||Alcon Research|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294956||109131|
NCT01292993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-103-DDI|A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects|A Phase 1, Randomized, Open-Label, 3-Period, 3-Treatment, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of LX4211 and Metformin in Healthy Subjects||Lexicon Pharmaceuticals|No|Completed|February 2011|||March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 29, 2011|February 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01292993||109282|
NCT01293006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-032|Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)|A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease||Merck Sharp & Dohme Corp.|No|Completed|March 2011|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|85 Years|No|||January 2016|January 22, 2016|February 8, 2011|No|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01293006||109281|
NCT01294163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-09-C3-026|Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery|Efficacy and Safety of Xenon Anaesthesia Compared to Sevoflurane Anaesthesia and Total Intravenous Anaesthesia for On-pump Coronary Artery Bypass Graft Surgery: a Randomised, Three-arm, Single-blind, International Study||Air Liquide Santé International|No|Completed|April 2011|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|509|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|February 9, 2011||No||No|November 6, 2015|https://clinicaltrials.gov/show/NCT01294163||109192|
NCT01295320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114825|Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects|Long Term Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Subjects||GlaxoSmithKline||Completed|February 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|129|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295320||109103|
NCT01295801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301PLAGH-20101027001|Vitamin B6 on Relieving Linezolid-associated Cytopenias|The Effects and Mechanism of Vitamin B6 on Relieving Linezolid-associated Cytopenias||Chinese PLA General Hospital|Yes|Recruiting|November 2010|September 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Use of linezolid|October 2010|February 14, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01295801||109066|
NCT01291745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-MDS-PROTOCOL|Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES|Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES|O-MDS-Protocol|Fondazione Amelia Scorza Onlus|No|Recruiting|September 2010|September 2015|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|bone marrow and buccal cell samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with MDS detected by current diagnostic techniques (i.e., peripheral        blood cytopenia, bone marrow morphology, cytogenetics andFISH analysis).|February 2011|February 7, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291745||109378|
NCT01292681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICC|Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer|Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer||Radboud University|No|Recruiting|August 2009|||January 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01292681||109306|
NCT01293565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-003|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia||Edimer Pharmaceuticals|No|Completed|February 2011|July 2011|Actual|May 2011|Actual|N/A|Observational|N/A||2|Actual|27|Samples With DNA|Whole blood, serum|Male|14 Years|29 Years|Accepts Healthy Volunteers|Non-Probability Sample|HED Affected Members of the UCSF Craniofacial Clinic, HED Affected Members of the National        Foundation for Ectodermal Dysplasia|June 2012|June 26, 2012|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293565||109238|
NCT01293838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMHR REB#2007036|Cipralex® for Anxiety Disorders in Adolescents|Cipralex® for Anxiety Disorders in Adolescents: Clinical and Physiological Changes Associated With Open Label, Flexible-dose Treatment|CAP-E|University of Ottawa|Yes|Recruiting|March 2008|January 2012|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|18 Years|No|||January 2011|February 10, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293838||109217|
NCT01261585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 08-01|Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT|Study of the Modification of the Fixation of FDG, F-Miso and FLT Measured in PET/CT at Patients Before and in the Course of Exclusive Radiotherapy or Concomitant Radiochemotherapy for Primitive Bronchial Cancer|RTEP4|Centre Henri Becquerel|Yes|Completed|December 2008|December 2009|Actual|November 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|5|||Both|18 Years|75 Years|No|Probability Sample|Diagnosed patients with non-small-cell lung carcinoma|January 2009|December 15, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261585||111691|
NCT01292265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0033|A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)|A Phase 3b, Open Label, Multicenter, Exploratory Study to Assess Changes in Joint Inflammation Using Ultrasonography in Subjects With Rheumatoid Arthritis Treated for 12 Weeks With Certolizumab Pegol|SWIFT|UCB Pharma|No|Terminated|February 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|February 7, 2011|Yes|Yes|Termination of study due to low enrollment. There were no safety issues.|No|October 26, 2012|https://clinicaltrials.gov/show/NCT01292265||109338|
NCT01292486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT10-02|Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure|Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Multiple Myeloma Patients||Terumo BCT|No|Completed|February 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|32|||Both|18 Years|N/A|No|||April 2013|April 24, 2013|February 2, 2011|Yes|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT01292486||109321|
NCT01293851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110065|Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage|Characterization of the Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Peripheral Neuropathy Progression||National Institutes of Health Clinical Center (CC)||Terminated|December 2010|November 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|3|||Both|18 Years|N/A|No|||November 2012|February 19, 2014|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01293851||109216|
NCT01295021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIN-DUM-2010/2|The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.|A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.|SORT|AstraZeneca|No|Completed|February 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1514|||Both|18 Years|N/A|No|Non-Probability Sample|Primary hypertensive patients|June 2013|June 7, 2013|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01295021||109126|
NCT01256710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-10-012-EU-TV|Trifecta Durability Study|Trifecta Durability Study||St. Jude Medical|No|Active, not recruiting|January 2011|June 2021|Anticipated|June 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|801|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that are candicate for implantation or have been implanted over the past 9 months        with a St. Jude Medical Trifecta heart valve.|November 2014|November 21, 2014|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01256710||112066|
NCT01243775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|m601NSC10B|BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC|Phase II Trial of First Line Docetaxel and Oxaliplatin in Stage IV or Relapsed Non-Small Cell Lung Cancer|BELOXAN|Chonnam National University Hospital|Yes|Completed|November 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|November 15, 2010||No||No|July 19, 2015|https://clinicaltrials.gov/show/NCT01243775||113054|
NCT01256346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUHSC IRB 15458|Electrocardiography Versus Pulse Oximetry for Newborn Heart Rate Determination|A Comparison of Electrocardiography Versus Pulse Oximetry for Determination of Initial Heart Rate in Preterm Newborns: A Pilot Study.||University of Oklahoma|No|Withdrawn|April 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|20 Minutes|No|Probability Sample|Thirty babies believed to be of 24-32 weeks gestational age who are to be born at the        University of Oklahoma Health Sciences Center.|December 2014|December 1, 2014|December 6, 2010||No|Study completed by another institution prior to enrollment of first subject.|No||https://clinicaltrials.gov/show/NCT01256346||112094|
NCT01256359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_015|Docetaxel With or Without AZD6244 in Melanoma|A Double Blind Randomised Phase 2 Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma|DOC-MEK|University of Oxford|No|Active, not recruiting|October 2010|October 2015|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|16 Years|N/A|No|||November 2013|April 8, 2015|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01256359||112093|
NCT01294982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100011031|Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency|Phase II, Randomized, Double-blind, Placebo-controlled Trial of the AOBO-001 for the Treatment of Overactive Bladder With Symptoms of Urge Urinary Incontinence and Frequency||American Oriental Bioengineering, Inc.|No|Completed|December 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|January 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294982||109129|
NCT01293877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP111BH|Laparoscopic Gastric Plication Compared With Laparoscopic Sleeve Gastrectomy|Laparoscopic Gastric Plication for Treatment of Morbid Obesity|LGP|Bikkur Holim Hospital|No|Not yet recruiting|March 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 10, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293877||109214|
NCT01291784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1450|Anti-TGF-beta Therapy in Patients With Myelofibrosis|Phase I Study of GC1008 in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera/Essential Thrombocythemia Related Myelofibrosis (Post-PV/ET MF)||Icahn School of Medicine at Mount Sinai|Yes|Terminated|February 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||November 2014|November 21, 2014|February 7, 2011|Yes|Yes|Early termination when the drug was no longer made available by the pharmaceutical company due    to unanticipated management and administrative decisions.|No|July 31, 2013|https://clinicaltrials.gov/show/NCT01291784||109375|Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.Limited patient data (2 evaluable patients), a dose accumulation ratio cannot be determined.
NCT01295554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/10-03 - AngioIRM-Native|Comparative Study of Non-enhanced Versus Contrast Enhanced MR Angiography in Peripheral Arterial Disease on a 3T MR Scanner.|Comparative Study of Non-enhanced Versus Contrast Enhanced MR Angiography in Peripheral Arterial Disease on a 3T MR Scanner.|AngioIRMNative|Rennes University Hospital|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Non-Probability Sample|patient known or clinically suspected to present a peripheral arterial disease|February 2012|February 10, 2012|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295554||109085|
NCT01295567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dipy-cabg|Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?|Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective CABG?||Radboud University|Yes|Completed|December 2009|September 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|95|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01295567||109084|
NCT01292473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4882g|A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)|A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)||Genentech, Inc.|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|323|||Both|12 Years|75 Years|No|||October 2013|October 9, 2013|February 7, 2011|Yes|Yes||No|June 17, 2013|https://clinicaltrials.gov/show/NCT01292473||109322|
NCT01293227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005213|WRx Distal Radius Wrist Fracture Study|The Effect of Intramedullary Locked Nail Versus Volar Locked Plating in the Treatment of Extra-articular and Minimally Displaced Intra-articular Distal Radius Fractures: A Prospective Randomized Trial.||Mayo Clinic|No|Terminated|February 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|85 Years|No|||January 2012|January 23, 2012|February 4, 2011||No|Funding was withdrawn due to inadequete enrollment.|No||https://clinicaltrials.gov/show/NCT01293227||109264|
NCT01293240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-368-C-400|Prospective Study of Lens Performance of a Monthly Replacement Lens at Two Weeks and Four Weeks|Prospective Study of Lens Performance of a Monthly Replacement Lens at Two Weeks and Four Weeks||Alcon Research|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|N/A|No|||May 2012|June 26, 2012|February 9, 2011|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT01293240||109263|
NCT01294397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101324|Effects of Denosumab on the Pharmacokinetics of Etanercept|The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis||Amgen||Terminated|March 2011|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Female|45 Years|80 Years|No|||March 2016|March 8, 2016|January 13, 2011|No|Yes|The study was stopped because only 38% of subjects had been enrolled after 5 years and    multiple protocol amendments aimed at improving enrollment.|No||https://clinicaltrials.gov/show/NCT01294397||109174|
NCT01265615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDCRS03|Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients|Phase 4 Study of Paricalcitol and Calcitriol for Reparative Management of Chronic Allograft Dysfunction and Renocardiac Syndrome in Vitamin D Insufficient Renal Transplant Recipients||Ural Medical University|Yes|Completed|October 2009|September 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|109|||Male|40 Years|75 Years|No|||May 2015|May 14, 2015|December 22, 2010|Yes|Yes||No|December 27, 2010|https://clinicaltrials.gov/show/NCT01265615||111382|
NCT01261247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0986|Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma||Mayo Clinic|Yes|Active, not recruiting|January 2011|||November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261247||111717|
NCT01292980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-2009-08|Air Fluidized Therapy (AFT) in Patients With Suspected Deep Tissue Injury (sDTI)|Air Fluidized Therapy Use in Patients Who Present With Suspected Deep Tissue Injury - a Case Series||Hill-Rom|No|Completed|August 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|N/A|N/A|No|Non-Probability Sample|Patients who present to the hospital with SDTI|February 2011|February 10, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292980||109283|
NCT01293253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA01|Effect of Daily Stair Walking on Cardiovascular Health|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|IRMA|National Research Centre for the Working Environment, Denmark|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||October 2011|October 28, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293253||109262|
NCT01261819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH Project #2142-4860|"Laparoscopic" Cystoscopy Versus Traditional Cystoscopy|"Laparoscopic" Cystoscopy Versus Traditional Cystoscopy in Patients Undergoing Minimally Invasive Hysterectomy: A Prospective Comparison Study||Florida Hospital|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|68|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2009|December 20, 2010|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01261819||111673|
NCT01262690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2291001|A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin|A Phase 1 Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05230901 Administered Subcutaneously To Healthy Subjects||Pfizer|No|Terminated|November 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 11, 2011|November 23, 2010|No|Yes|The study was terminated on 21-Sept-2011 due to the emergent safety concern of sensory    symptoms.|No||https://clinicaltrials.gov/show/NCT01262690||111606|
NCT01262066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lifeskills BP study|Effects of Lifeskills Workshop on BP in Hypertensive Employees|RCT of LifeSkills Workshop on BP in Hypertensive Employees|Lifeskills BP|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|September 2002|August 2006|Actual|August 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|75 Years|No|||November 2010|December 15, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262066||111654|
NCT01263015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114467|A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)|A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects||ViiV Healthcare|Yes|Active, not recruiting|February 2011|March 2015|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|844|||Both|18 Years|N/A|No|||May 2014|May 29, 2014|December 16, 2010|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01263015||111581|
NCT01263028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM2010001|Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose|Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose|EASY|Kaiser Permanente|No|Terminated|August 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|December 16, 2010||No|Strong enrollment efforts resulted in few eligible subjects and high screen failures due to    CKD patients with higher vitamin D levels than anticipated.|No|August 21, 2012|https://clinicaltrials.gov/show/NCT01263028||111580|Study terminated due to insufficient enrollment numbers.
NCT01247597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110034|DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study|DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study||National Institutes of Health Clinical Center (CC)||Recruiting|November 2010|||||N/A|Observational|N/A|||Anticipated|1500|||Both|N/A|100 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247597||112763|
NCT01243528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINI01|Observational Study at the Influence of Malnutrition on Infections|Prospective, Non-interventional Observational Study at the Influence of Malnutrition on Nosocomial Infections in Patients During Early Neurological Rehabilitation|Malnutrition|Schoen Clinic Bad Aibling|No|Completed|June 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|Patients in neurological rehabilitation facility|December 2014|December 12, 2014|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01243528||113073|
NCT01244360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU Smoliga Resveratrol|The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance|The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance|MUresv|Marywood University|No|Active, not recruiting|November 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|44|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01244360||113009|
NCT01244373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quatrix01|A Prospective Observational Case Series of a Four-ring-haptic Acrylic One-piece IOL|Observational Case Series of the Implantation of Intraocular Lens "QUATRIX® Aspheric Evolutive Pre-loaded".|Qu01|General Hospital Linz|No|Completed|May 2008|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|50 Years|90 Years|No|Non-Probability Sample|Patients with advanced age-related cataract and indication for phacoemuslification of the        lens with following implantation of an intraocular lens (posterior chamber)|November 2010|November 18, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244373||113008|
NCT01244048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H35_08|Intervention With n3 LC-PUFA-supplemented Yogurt|Intervention With n3 LC-PUFA-supplemented Yogurt: Effects on Cardiovascular Risk Factors and Inflammatory Biomarkers||University of Jena|Yes|Completed|February 2009|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|53|||Both|25 Years|75 Years|No|||March 2012|March 6, 2012|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01244048||113033|
NCT01244334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEMC 5/2009-011|Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.|A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal Edema.||Cincinnati Eye Institute Northern Kentucky|Yes|Completed|March 2009|November 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|21 Years|N/A|No|||August 2012|August 6, 2012|November 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244334||113011|
NCT01292707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTc TACT|A Cluster-randomised Trial of Interventions to Improve Antimalarial Prescribing With Malaria Tests|A Cluster-randomised Trial of Health Worker and Community Interventions to Improve Adherence to National Guidelines for the Use of ACTs in Tanzania|TACT|London School of Hygiene and Tropical Medicine|Yes|Completed|February 2011|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1152|||Both|N/A|N/A|No|||November 2014|November 18, 2014|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01292707||109304|
NCT01292720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITD-HI|Vitamin D Supplementation in Chronic Stable Heart Failure|Vitamin D Supplementation in Chronic Stable Heart Failure: a Randomized, Double-blind, Placebo-controlled Trial|VITD-HI|Medical University of Graz|No|Completed|April 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|45 Years|90 Years|No|||May 2014|May 23, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01292720||109303|
NCT01295034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-0679|Vitamin D Supplements for HIV-positive Patients on cART|Vitamin D Supplements for HIV-positive Patients on cART||Icahn School of Medicine at Mount Sinai|Yes|Completed|March 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||February 2016|February 11, 2016|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295034||109125|
NCT01295502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9926|Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer|A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes||Gynecologic Oncology Group||Active, not recruiting|April 2011|||December 2019|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|February 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295502||109089|
NCT01295515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110057|Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy|Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|January 2020|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||June 2015|September 24, 2015|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01295515||109088|
NCT01264406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10008|The Comparison of Energy in Take and Body Weight EXERCISE|Examination of Mechanisms (E-MECHANIC) of Exercise-induced Weight Compensation|E-MECHANIC|Pennington Biomedical Research Center|No|Completed|December 2010|December 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control||3|Actual|198|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The study population group will be 198 sedentary, overweight and obese(BMI levels > 25        kg/m2 and < 40 kg/m2) individuals. Based on previous studies, we expect to enroll 132        females and 66 males. Participants will be randomly assigned to an 8 kcal/kg/week, 20        kcal/kg/week, or control group. The exercise groups will be closely monitored during        exercise sessions for six months in our exercise-training laboratory.|February 2016|February 3, 2016|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264406||111475|
NCT01264419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM-2008-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2009|||||N/A|N/A|N/A||||||||||||||November 18, 2014|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264419||111474|
NCT01264705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062010-150|Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer|A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264705||111452|
NCT01264718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|082010-138|A Randomized Trial of Effects of Parent Mentors on Insuring Minority Children|A Randomized Trial of Effects of Parent Mentors on Insuring Minority Children||University of Texas Southwestern Medical Center|No|Active, not recruiting|December 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|300|||Both|N/A|18 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264718||111451|
NCT01265017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDRI 2009-06|Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes|Single-center, Double-masked, Placebo-controlled Parallel-group Study of Pregnancy-related Hormones Estradiol and Medroxyprogesterone, in Conjunction With Hydrocortisone and Growth Hormone to Stimulate C-peptide Secretion in Women With T1DM||William Sansum Diabetes Center|No|Recruiting|July 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|15|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01265017||111428|
NCT01261832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreaUGuroH SILOAM|Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients|Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent|SILOAM|Korea University Guro Hospital|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|951|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01261832||111672|
NCT01261845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13683|Ecology of Medical Care - Utilisation of Health Care in Austria|Ecology of Medical Care - Utilisation of Health Care in Austria|ECOHCARE|Medical University of Vienna|No|Completed|February 2010|March 2013|Actual|October 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|3500|||Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The Austrian population 15 years and older .|April 2015|April 17, 2015|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01261845||111671|
NCT01262092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-DA010017-pilot|Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals|Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals|Detox|University of Arkansas|Yes|Completed|October 2010|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||June 2013|June 19, 2013|December 15, 2010||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT01262092||111652|
NCT01262079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRC 700|Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.|Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|December 2010|August 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Anticipated|180|Samples With DNA|Serum Plasma PBMC Whole-blood|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy participants ages 6 years and older who are available for 3 clinic study visits        over approximately eight months. Participants must be willing and able to donate blood for        storage and research. Females must not be or become pregnant during the study. Multiple        subjects from the same household may not be enrolled into the same age group.|August 2011|August 11, 2011|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262079||111653|
NCT01261572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3550-CL-0009|Study to Find Maintenance Dose for Periodic Administration of ASP3550|Phase II Study of ASP3550 - A Maintenance-dose Finding Study for Periodic Dosage Regimen in Patients With Prostate Cancer -||Astellas Pharma Inc|Yes|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|155|||Male|20 Years|N/A|No|||July 2013|July 8, 2013|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01261572||111692|
NCT01263301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-06-024-ER|Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm|Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm||Mennonite Christian Hospital|No|Completed|August 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|16|||Both|N/A|N/A|No|||February 2013|February 3, 2013|December 16, 2010||No||No|July 9, 2011|https://clinicaltrials.gov/show/NCT01263301||111559|the number of the study is small, no standard technique for measurement of blood flow of vascular access
NCT01263314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8266-003|Safety, Tolerability and Pharmacokinetics of MK-8266 in Elderly Subjects With High Blood Pressure (MK-8266-003 AM1)|A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8266 in Elderly Subjects With Hypertension||Merck Sharp & Dohme Corp.|No|Completed|November 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|16|||Both|65 Years|80 Years|No|||October 2015|October 30, 2015|November 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263314||111558|
NCT01263574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-03-0132|Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome|||Children's Hospital Boston|Yes|Not yet recruiting|February 2011|September 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|48|||Both|3 Months|N/A|Accepts Healthy Volunteers|||December 2010|December 28, 2010|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263574||111538|
NCT01263587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082864|Hepatitis B Research Network Adult Cohort Study|Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study)|HBRN|University of Pittsburgh|Yes|Recruiting|December 2010|May 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|Samples With DNA|Liver biopsy tissue, blood (serum, plasma, and DNA)|Both|18 Years|N/A|No|Non-Probability Sample|The study population will be recruited from multi-site clinical centers in the United        States and Canada including primary care hospitals and community centers.|January 2016|January 6, 2016|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01263587||111537|
NCT01253668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 04810|Brivanib Metastatic Renal Cell Carcinoma|Brivanib (BMS-582664, Brivanib Alaninate) in Treatment of Refractory Metastatic Renal Cell Carcinoma - A Phase II Pharmacodynamic and Baseline Biomarker Study||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|November 2010|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253668||112300|
NCT01244737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 104365|FLT-PET Imaging of Brain Tumors in Children|Phase 2 Study of [18F]FLT for PET Imaging of Brain Tumors in Children||Children's Hospital Boston|No|Enrolling by invitation|October 2010|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|75|||Both|N/A|21 Years|No|||July 2015|July 7, 2015|October 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244737||112980|
NCT01293604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS34|The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease|||USDA Beltsville Human Nutrition Research Center|Yes|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|69|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 13, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01293604||109235|
NCT01293617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS36|Blackberry Intake and Biomarkers of Cancer Risk|Blackberry Intake and Biomarkers of Cancer Risk||USDA Beltsville Human Nutrition Research Center||Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|52|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 15, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01293617||109234|
NCT01293864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002154|Structural Analysis of Human Tissue|Structural Analysis of Human Tissue||Wake Forest School of Medicine|No|Terminated|April 2007|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|Samples Without DNA|Abdominal tissue|Both|18 Years|65 Years|No|Non-Probability Sample|Study population consists of patients who are being seen in the Plastic & Reconstructive        Surgery Clinic for surgical removal of excess abdominal skin (abdominoplasty).|December 2015|December 7, 2015|February 10, 2011||No|This is not a clinical trials study|No||https://clinicaltrials.gov/show/NCT01293864||109215|
NCT01294761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00005823-SPARE2011|Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir|Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function|SPARE|National Center for Global Health and Medicine, Japan|Yes|Completed|February 2011|December 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|20 Years|N/A|No|||March 2015|March 27, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294761||109146|
NCT01294774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKRP203A2202|Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus|A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus||Novartis||Terminated|February 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||April 2013|April 11, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294774||109145|
NCT01295281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOF-0018|Evaluation of a New Catheter Material for Intermittent Catheterization|A Prospective, Randomized, Cross-over Study - Evaluation of a New Catheter Material for Intermittent Catheterization||Wellspect HealthCare|No|Completed|March 2011|||May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Male|18 Years|N/A|No|||January 2014|January 15, 2014|January 21, 2011|Yes|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT01295281||109106|
NCT01292252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSFSpineForteo|Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion|Assessment of the Efficacy of Forteo (Teriparatide) in Patients Undergoing Posterolateral Lumbar Spinal Fusion||University of California, San Francisco|Yes|Recruiting|August 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|60 Years|90 Years|No|||December 2015|December 2, 2015|February 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01292252||109339|
NCT01264432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02913|Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer|A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-abdominal Disease||National Cancer Institute (NCI)||Active, not recruiting|January 2011|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|December 18, 2015|December 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01264432||111473|
NCT01264744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-UroF|Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)|Concordance Study for Detection of Chromosomal Aberrations Using FISH in Urine Samples Sections||Applied Spectral Imaging Ltd.|No|Completed|November 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|174|Samples Without DNA|Urine samples|Both|N/A|N/A|No|Probability Sample|patients with hematuria that are suspected in having bladder carcinoma, and in patients        previously diagnosed with bladder cancer.|December 2010|December 22, 2010|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01264744||111449|
NCT01265030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-491-B|A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis|A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis||Maine Medical Center|Yes|Recruiting|February 2014|March 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|29 Years|No|||September 2015|September 22, 2015|December 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01265030||111427|
NCT01265043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1159|A Randomized Clinical Trial of Oral Health Promotion Interventions Among Patients After Stroke|A Randomized Clinical Trial of Oral Health Promotion Interventions Among Patients Following Stroke||The University of Hong Kong|Yes|Completed|July 2008|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|50 Years|N/A|No|||June 2015|June 9, 2015|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01265043||111426|
NCT01265329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0810-C-051-MM|Methods for Objective Selection of Competent Sperm||MACS|Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|237|||Both|18 Years|37 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01265329||111404|
NCT01265342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM7RANLZ|Efficacy of Nebulised Beclometasone in Viral Wheezing Prophylaxis|Efficacy Of Nebulised Beclometasone Versus Placebo In Preventing Viral Wheezing In Pre-School Children|ENBe|Mario Negri Institute for Pharmacological Research|Yes|Completed|October 2010|October 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|576|||Both|12 Months|71 Months|No|||March 2014|March 10, 2014|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265342||111403|
NCT01265628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC GATE Strategie|Validation of the GATE Software|Validation of the GATE Software for Static Visual Field Examinations|ValGATE|University Hospital Tuebingen|No|Completed|November 2010|||August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Both|18 Years|N/A|No|Probability Sample|selected from the eye hospital's database|January 2012|January 25, 2012|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265628||111381|
NCT01262131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10242-01|Evaluation of Magnetic Fields to Treat Fibromyalgia|A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Fibromyalgia: Pilot Study Protocol||pico-tesla Magnetic Therapies, LLC|No|Completed|December 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|December 14, 2010|Yes|Yes||No|May 13, 2011|https://clinicaltrials.gov/show/NCT01262131||111649|
NCT01262144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|421CTIL|SUV Max as Predictor of Outcome in Cervical Cancer|A Study to Evaluate the Value of SUV-Max in PET-FDG in Predicting Outcome of Surgery Vis a Vis Need for Radiotherapy||Rambam Health Care Campus|No|Completed|August 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Female|18 Years|80 Years|No|Non-Probability Sample|Females age 18-80, diagnosed with cervical cancer|November 2010|December 15, 2010|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01262144||111648|
NCT01262105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-002|Device to Reduce Surgery Site Contamination - Spine|Reduction of Airborne Microbes in the Surgical Field During Spine Procedures Using Directed Local Airflow||Nimbic Systems, LLC||Completed|November 2009|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|23|||Both|N/A|N/A|No|||April 2012|April 9, 2012|December 15, 2010|No|Yes||No|March 14, 2012|https://clinicaltrials.gov/show/NCT01262105||111651|
NCT01262118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921130|Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis|An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis||Pfizer|No|Completed|May 2011|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|69|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 17, 2012|November 15, 2010|Yes|Yes||No|December 17, 2012|https://clinicaltrials.gov/show/NCT01262118||111650|
NCT01262391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-075|Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents|A Multicenter, Open-label, Single Ascending Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Patients Aged 5 to 17 Years (Inclusive) With Overactive Bladder (OAB)||Astellas Pharma Inc|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|42|||Both|5 Years|17 Years|No|||August 2011|August 31, 2011|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01262391||111629|
NCT01262703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT1000|Safety Study of a Bioresorbable Coronary Stent|Pilot Study of the ReZolve™ Sirolimus-Eluting Bioresorbable Coronary Stent|RESTORE|REVA Medical, Inc.|Yes|Active, not recruiting|December 2011|September 2018|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262703||111605|
NCT01263366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-4|Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients|Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy||ProCertus BioPharm, Inc|No|Terminated|January 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Female|18 Years|N/A|No|||April 2013|April 17, 2013|December 16, 2010|No|Yes|Enrollment issues|No||https://clinicaltrials.gov/show/NCT01263366||111554|
NCT01262742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02|Carbetocin at Elective Cesarean Delivery|Carbetocin at Elective Cesarean Delivery: A Dose Finding Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 2, 2011|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262742||111602|
NCT01263600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082864Pediatric|Hepatitis B Research Network Pediatric Cohort Study (HBRN)|Cohort Hepatitis B Virus (HBV) Pediatric Protocol||University of Pittsburgh|Yes|Recruiting|December 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Liver biopsy tissue, blood (serum, plasma, and DNA)|Both|6 Months|17 Years|No|Non-Probability Sample|Pediatric patients from Children's Hospitals and university medical centers in the United        States and Canada|October 2015|January 6, 2016|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01263600||111536|
NCT01247844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10214|Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment|Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment||FHI 360|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|50|||Male|18 Years|54 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01247844||112744|
NCT01244061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051139|A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider|A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline||Pfizer|Yes|Completed|December 2010|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|498|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|November 17, 2010|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01244061||113032|One SAE, exposure via semen, was not included under the Adverse Events since this event was considered to be experienced by a non-study participant, who was the study participant's partner. This event was coded as nonserious in the safety database.
NCT01253928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224/05|Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD|Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals||Centre Hospitalier Universitaire Vaudois||Recruiting|March 2007|||June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|20 Years|N/A|No|||February 2007|December 3, 2010|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01253928||112280|
NCT01254149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|577-10-FB|IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic|Intraocular Pressure Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic||University of Nebraska|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|43|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects 19 years of age and older with normal eyes and with ocular disease.|June 2012|June 13, 2012|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01254149||112263|
NCT01294436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1692C00012|Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus|A Long Term Open Label Study to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy or Combination Therapies With Anti-diabetic Drugs in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control||AstraZeneca||Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|728|||Both|20 Years|N/A|No|||November 2013|November 22, 2013|February 10, 2011|Yes|Yes||No|July 10, 2013|https://clinicaltrials.gov/show/NCT01294436||109171|In the efficacy analysis, for participants who did not complete 52-week treatment period LOCF (last observation carried forward) was used.
NCT01294449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MADIT-CRT PAR|Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry|Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry|MADIT-CRT PAR|Boston Scientific Corporation|No|Completed|March 2011|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|394|||Both|21 Years|N/A|No|Probability Sample|The registry involves only those patients that participated in the MADIT-CRT IDE study        within the United States.|March 2014|December 3, 2014|February 7, 2011||No||No|August 25, 2014|https://clinicaltrials.gov/show/NCT01294449||109170|
NCT01263847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Friesland|Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls|The Effect of Galactooligosaccharide (GOS) Supplementation on Calcium Absorption and Retention in Female Adolescent Girls|Friesland|Purdue University|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|31|||Female|10 Years|12 Years|Accepts Healthy Volunteers|||January 2011|January 12, 2011|March 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263847||111518|
NCT01264133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-411|A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B|An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B||Bukwang Pharmaceutical|No|Terminated|September 2009|December 2014|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|December 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01264133||111496|
NCT01264445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI B002|Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines|A Phase I Double-blinded, Placebo-controlled, Randomized Trial in HIV-uninfected, Healthy Adult Volunteers to Evaluate the Safety and Immunogenicity of an Adjuvanted GSK HIV Vaccine Administered With Ad35-GRIN Investigational Vaccine||International AIDS Vaccine Initiative|Yes|Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|147|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2013|February 8, 2013|December 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01264445||111472|
NCT01264731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15168|Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma|Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma|MEL53|University of Virginia|Yes|Suspended|January 2011|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|December 20, 2010|Yes|Yes|Study staff out on medical leave|No||https://clinicaltrials.gov/show/NCT01264731||111450|
NCT01261598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB06-02|Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival|Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival|RTEP2|Centre Henri Becquerel|Yes|Recruiting|November 2007|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01261598||111690|
NCT01261858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/10/600|Sternal Closure With Biologic Bone Cement in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|Reinforced Sternal Closure Using Osteoconductive Biologic Bone Cement (Kryptonite) in Patients Undergoing Coronary Artery Bypass Grafting||National University Heart Centre, Singapore|No|Not yet recruiting|February 2011|January 2013|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|50 Years|79 Years|No|||November 2010|December 22, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261858||111670|
NCT01261884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33905|Exercise in Pregnancy for Reduction of Blood Pressure in Obese Patients|Exercise Intervention in Pregnancy for Reduction of Blood Pressure in Obese Gravidas||Milton S. Hershey Medical Center|No|Completed|November 2010|January 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|66|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01261884||111668|
NCT01262716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9439|A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer|A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer||Rogers Sciences Inc.|Yes|Completed|December 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3|||Female|N/A|N/A|No|Non-Probability Sample|The study population will consist of 3 female patients. Eligible patients will be        recruited from cancer centers in North America specializing in breast cancer. Recruitment        has begun with the Hematology/Oncology, Dermatologic Oncology, and Radiation Oncology        programs at Tufts Medical Center, Rhode Island Hospital and the teaching hospitals        affiliated with Tufts and Brown Universities. All research related activity will only take        place at the Tufts Medical Center.|October 2011|October 24, 2011|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262716||111604|
NCT01262729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xenon-MTH-Study|Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation|Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation|10-015|RWTH Aachen University|No|Terminated|September 2011|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|December 16, 2010||No|Feasibility and Recruitment problems|No||https://clinicaltrials.gov/show/NCT01262729||111603|
NCT01262404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-Emory-01|Imaging Cerebral and Sub-cerebral Correlates of Meditative States|Imaging Cerebral and Sub-cerebral Correlates of Meditative States|calm|Boston University|Yes|Recruiting|January 2010|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|December 2010|December 16, 2010|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262404||111628|
NCT01263041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ghada a. saleh MD protocol|Effect of L-arginine and Glutamine on Preterm|Effect of Early Enteral Supplementation of L-arginine and Glutamine on Preterm Neonate|preterm|Ain Shams University|Yes|Completed|May 2011|March 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|75|||Both|N/A|N/A|No|||April 2014|April 14, 2014|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263041||111579|
NCT01263067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-10|Lifespan Integration for Posttraumatic Stress Disorder From an Auto Accident|Lifespan Integration Therapy for Posttraumatic Stress Disorder of Adults Involved in an Auto Accident||Argosy University|Yes|Completed|October 2010|January 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01263067||111577|
NCT01263054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-10-0001|Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain|A Prospective, Randomized, Multi-Center, Open-Label Clinical Trial Comparing Disc Biacuplasty With Medical Management for Discogenic Lumbar Back Pain|COLD|Halyard Health|No|Completed|December 2010|April 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|21 Years|N/A|No|||March 2015|February 11, 2016|November 29, 2010|Yes|Yes||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01263054||111578|
NCT01253343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0892|Pediatric Aggression and Violence|Salivary Hormones and Pediatric Aggression and Violence: A Feasibility Study||Children's Hospital Medical Center, Cincinnati|No|Completed|September 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|17|Samples Without DNA|Saliva specimens will be retained for future research use for particpants who have given      proper consent.|Male|7 Years|9 Years|No|Non-Probability Sample|A total of 24 male subjects (ages 7-11) will be recruited to two groups from inpatient        units at CCHMC:          1. Inpatient high aggression: Twelve inpatient males (6 African-American and 6             Caucasian) will be recruited based on completion of the BRACHA and the             Predatory-Affective Aggression Scale.          2. Inpatient low aggression: Twelve inpatient males (6 African-American and 6 Caucasian)             will be recruited based on completion of the BRACHA and the Predatory-Affective             Aggression Scales.|May 2013|May 23, 2013|November 1, 2010||No||No|November 19, 2012|https://clinicaltrials.gov/show/NCT01253343||112325|
NCT01253044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0159|Acceptance and Commitment Therapy (ACT) for OEF/OIF Veterans|Initial Randomized Controlled Trial of Acceptance and Commitment Therapy (ACT) for Distress and Impairment in OEF/OIF Veterans||Veterans Medical Research Foundation|Yes|Completed|November 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|December 1, 2010||No||No|June 30, 2015|https://clinicaltrials.gov/show/NCT01253044||112348|
NCT01253057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99061|A Research on the Hospital Pollution Control and Hygine Intervention of Chemotherapy Drugs Exposure|A Research on the Hospital Pollution Control and Hygine Intervention of Chemotherapy Drugs Exposure||Taipei Medical University WanFang Hospital|No|Active, not recruiting|October 2010|December 2011|Anticipated|||N/A|Observational|Observational Model: Case Control||2|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|cleaning staff|December 2010|December 1, 2010|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01253057||112347|
NCT01253356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-00002|ACTIONS - Aortic Counterpulsation to Improve Outcomes in Noncardiac Surgery|A Multicenter, Randomized, Controlled Pilot Study of Intra-Aortic Balloon Counterpulsation to Prevent Perioperative Cardiac Events in High-Risk Cardiac Patients Undergoing Noncardiac Surgery|ACTIONS|Datascope Corp.|Yes|Terminated|January 2011|February 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1|||Both|18 Years|N/A|No|||January 2012|January 5, 2012|December 2, 2010|No|Yes|Only 1 patient recruited and deemed ineligible.|No||https://clinicaltrials.gov/show/NCT01253356||112324|
NCT01253369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-125|Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer|A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)||Dana-Farber Cancer Institute|Yes|Completed|June 2010|December 2014|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|November 17, 2010|Yes|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT01253369||112323|
NCT01253681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090155|Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer|A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers||Amgen|No|Completed|November 2010|January 2015|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01253681||112299|
NCT01253694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DME-NERA|Ranibizumab as a Rescue Therapy for Diabetic Macular Edema|Ranibizumab in Residual Diabetic Macular Edema Following Previous Intravitreal Bevacizumab Therapy||New England Retina Associates|Yes|Withdrawn|March 2011|July 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||May 2013|May 1, 2013|November 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253694||112298|
NCT01253707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101132|A Study of AMG 337 in Subjects With Advanced Solid Tumors|A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors||Amgen||Active, not recruiting|December 2010|November 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 24, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253707||112297|
NCT01265056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200909736|The Effect of Neurontin on Pain Management in the Acutely Burned Patient|The Effect of Neurontin on Pain Management in the Acutely Burned Patient||University of Iowa|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||January 2013|November 30, 2015|December 20, 2010||No||No|January 22, 2013|https://clinicaltrials.gov/show/NCT01265056||111425|
NCT01263548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vyvanse-BD|To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder|||University Health Network, Toronto||Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|45|||Both|18 Years|55 Years|No|Probability Sample|Individuals who have a diagnosis of Bipolar Disorder and ADHD.|May 2012|May 31, 2012|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01263548||111540|
NCT01263561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0888-A|Prospective Randomized Study Comparing Ex-PRESS to Trabeculectomy|Prospective Randomized Study Comparing Ex-PRESS to Trabeculectomy||University of Toronto|No|Completed|April 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|85 Years|No|||December 2014|December 7, 2014|December 14, 2010||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01263561||111539|
NCT01265641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00011|To Investigate the Effects of AZD1981 on the QT Interval|A Single-centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four-period Crossover Study in Healthy Male Volunteers, to Assess the Effect on QT/QTc Interval of Single Oral Doses of AZD1981 (200 mg and 2000 mg) Using Moxifloxacin (Avelox®) as a Positive Control||AstraZeneca||Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|44|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01265641||111380|
NCT01265654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OCZ-FAS-2010/1|Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer|Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer|HOT ABC|AstraZeneca||Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|234|||Female|N/A|N/A|No|Probability Sample|Postmenopausal women with hormone sensitive advanced breast cancer that have been treated        with minimum two hormonal agents according to approved SmPC.|November 2011|November 22, 2011|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265654||111379|
NCT01261260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-002083-McLean|Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers|The Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers|Uridine-GABA|Mclean Hospital|No|Completed|November 2006|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|33|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2010|December 14, 2010|December 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01261260||111716|
NCT01261273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T113E2|e-NOBORI Observational Registry of Nobori DES|Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients|e-NOBORI|Terumo Europe N.V.|Yes|Active, not recruiting|August 2010|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||14|Anticipated|18000|||Both|18 Years|N/A|No|Probability Sample|Patients suitable for PCI intervention|May 2015|May 11, 2015|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261273||111715|
NCT01261611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-134|Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia|A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short Term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport® and Dysport RU®) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport RU® Following Repeated Treatments of Subjects With Cervical Dystonia||Ipsen|No|Completed|April 2011|May 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|333|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|December 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01261611||111689|
NCT01261624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/08/2357/36|Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis|A Multicenter, Open Label, Dose Finding Study to Evaluate Efficacy and Safety of Givinostat Administered in Two Different Doses in Patients With Poly JIA Not Adequately Responding to the Standard Treatment.||Italfarmaco|No|Terminated|October 2010|March 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|2 Years|17 Years|No|||March 2014|March 11, 2014|December 15, 2010||No|The primary reason for the decision to discontinue the study is lack of enrolment; this    decision is not related to any tolerability concerns with Givinostat|No|January 14, 2014|https://clinicaltrials.gov/show/NCT01261624||111688|
NCT01261871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2008.0045|Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning|Intraocular Pressure During Robotic Prostatectomy, Laparoscopic Surgery, and Open Exploratory Laparotomy||United States Naval Medical Center, San Diego|Yes|Completed|December 2008|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Male|18 Years|N/A|No|Non-Probability Sample|Patients who are undergoing primary radical prostatectomy for the diagnosis of prostate        cancer at Naval Medical Center San Diego.|December 2009|December 16, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261871||111669|
NCT01261637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-4518-2009|Abdominal Wall Local Anesthesia to Maximize Postoperative Pain Control After Cesarean Delivery|Ultrasound Guided 0.25% Ropivacaine Transversus Abdominis Plane Block in Addition to Intrathecal Morphine and Multimodal Analgesia for the Management of Postoperative Pain Among Women Undergoing Cesarean Delivery.||IWK Health Centre|Yes|Completed|July 2009|January 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 22, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261637||111687|
NCT01261897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-PJ-10|The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Total Knee Arthroplasty|The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Total Knee Arthroplasty||Rigshospitalet, Denmark|Yes|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|85 Years|No|||October 2011|October 3, 2011|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01261897||111667|
NCT01262157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|507-10 RMB|Low Intensity ShockWave Therapy for ED in Non Responders to PDE5i - a Double Blind Placebo Controlled Study|A Clinical Randomized Double Blind Placebo Controlled Study on the Effect of Low Intensity Shock Wave Therapy for Erectile Dysfunction in a Group of Patients Not Responding to Oral Therapy|LI-ESWT|Rambam Health Care Campus|Yes|Recruiting|April 2010|January 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|20 Years|85 Years|No|||May 2010|May 18, 2011|July 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01262157||111647|
NCT01262170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-002|A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers|A Randomized, Double-Blind, Active-Controlled, Crossover, Pilot Study to Evaluate the Safety and Efficacy of CigRx™ Lozenge, a Non-Nicotine Non-Tobacco Dietary Supplement, in Daily Smokers in Temporarily Reducing the Desire to Smoke||Rock Creek Pharmaceuticals, Inc.|No|Completed|April 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|23 Years|72 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262170||111646|
NCT01263353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230F2102|Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs|An Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study|COOPERATE-1|Novartis||Completed|November 2010|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263353||111555|
NCT01262443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESREFO01|Prospective Study to Evaluate the Efficacy of Transcatheter Ablation of Atrial Flutter With a Standard Irrigated Catheter With Flexible Tip. The FLEX STUDY|Prospective Study to Evaluate the Acute and 6-month Efficacy of Transcatheter Radiofrequency Ablation of Common Atrial Flutter With a Standard Irrigated Catheter With Flexible Tip.|FLEX|Ettore Sansavini Health Science Foundation|Yes|Completed|November 2010|February 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2014|May 18, 2014|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01262443||111625|
NCT01262417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPRAC2T|Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation|Evaluationof the Efficiency of a Resorbable Barrier Membrane for the Prevention of Abdominal and Peri-hepatic Adhesion in Patients With Colorectal Cancer Requiring Two-stage Surgery for the Resection of Hepatic Metastases|SEPRAC2T|Centre Leon Berard|Yes|Completed|July 2008|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||May 2010|December 16, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262417||111627|
NCT01262430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-296|Application of Radiostereometric Analysis (RSA) to Triathlon Knee Components Inserted Using the OtisMed Custom-fit Total Knee Replacement System|Randomized Control Trial Using RSA to Compare the OtisMed Customfit Total Knee Replacement Procedure With Computer Assisted Surgery||Dalhousie University|No|Active, not recruiting|April 2011|April 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|21 Years|80 Years|No|||August 2015|August 6, 2015|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01262430||111626|
NCT01263080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOVERY2|Evaluation of Mirtazapine and Folic Acid for Schizophrenia:|Multicentre Randomised Double-blind, Placebo-controlled 2x2 Factorial Trial Investigating the Effects of Adding Mirtazapine and Folic Acid to Existing Therapy for Patients With Schizophrenia|RECOVERY2|Capital Medical University|Yes|Recruiting|November 2010|November 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|330|||Both|18 Years|70 Years|No|||July 2015|July 27, 2015|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263080||111576|
NCT01263093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12593|A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel|Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of R-130964, the Active Metabolite of Clopidogrel, in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263093||111575|
NCT01263106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12594|A Study of LY2216684 and Theophylline in Healthy Subjects|Effect of LY2216684 on the Pharmacokinetics of Theophylline in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263106||111574|
NCT01263392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Speedi 10|Comparing Urinary Tract Infections in Children With Spina Bifida Using Two Types of Catheters for Catheterization|A Comparison of the Incidence of Symptomatic Urinary Tract Infections in Children With Spina Bifida Using Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters for Clean Intermittent Catheterization: a Randomized Cross Over Trial||University of Alberta|No|Completed|April 2007|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|3 Months|18 Years|Accepts Healthy Volunteers|||March 2013|June 19, 2013|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263392||111552|
NCT01253382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-88/26|Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema|A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema (HAE)||Dyax Corp.|Yes|Withdrawn|June 2012|||April 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|17 Years|No|||July 2012|July 16, 2012|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01253382||112322|
NCT01253395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-4167|Exercise for Fibromyalgia|Randomized Equivalency Trial of Strength Compared to Aerobic Exercise on Pain Severity in Adults With Fibromyalgia||Mayo Clinic|Yes|Completed|April 2006|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A||||December 2010|December 2, 2010|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01253395||112321|
NCT01253720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070731|PACE CALL: Weight Loss Study for Childhood Leukemia Survivors|PACE CALL: A Tailored Weight Management Program for Childhood ALL Survivors||Huang, Jeannie, M.D.||Completed|June 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|38|||Both|7 Years|18 Years|No|||March 2015|January 25, 2016|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01253720||112296|
NCT01264757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 29034|Steps Toward Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population|Steps Toward Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population|STEPS|Pennington Biomedical Research Center|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01264757||111448|
NCT01264770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00004|Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)|(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis|OSKIRA -4|AstraZeneca|Yes|Terminated|January 2011|August 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|644|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|December 17, 2010|Yes|Yes|AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to    Rigel Pharmaceuticals.|No|November 22, 2013|https://clinicaltrials.gov/show/NCT01264770||111447|
NCT01264783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.1.1.H1|Safety and Tolerability of RNS60 Given by IV to Healthy Subjects|Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects||Revalesio Corporation|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 30, 2011|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264783||111446|
NCT01265355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCLB001|Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement|Community Based Prophylaxis for Rotavirus Gastroenteritis in Children by an Anti-rotavirus Protein Based Food Supplement||Christian Medical College, Vellore, India|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|330|||Both|6 Months|12 Months|Accepts Healthy Volunteers|||February 2015|February 3, 2015|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265355||111402|
NCT01265368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGN1601-CT1|A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)|A Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination With a DNA-based Double Stem Loop Immunomodulator in Patients With Advanced Renal Cell Carcinoma (ASET Study)|ASET|Mologen AG|Yes|Active, not recruiting|December 2010|November 2017|Anticipated|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265368||111401|
NCT01265082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006012R|Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission|Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission||National Taiwan University Hospital|No|Active, not recruiting|December 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic,|December 2010|December 21, 2010|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265082||111423|
NCT01265095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011023RB|Establish Quantitative PCR to Measure Bacteria Load of the VRE Bacteremia|Establish Quantitative PCR to Measure Bacteria Load of the VRE Bacteremia||National Taiwan University Hospital|No|Recruiting|December 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|VRE bacteremia|August 2012|August 28, 2012|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01265095||111422|
NCT01265381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911049|Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study|Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|550|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|April 11, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265381||111400|
NCT01261286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER-2010|Drug-Disease Interaction in Crohn's Disease|Pharmacodynamics and Pharmacokinetics of Verapamil in Crohn's Disease Patients||University of Alberta|No|Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 14, 2010|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261286||111714|
NCT01261299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#200|Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer|A Phase 0 Clinical Trial of Microdosing Carboplatin and Molecular Profiling for Chemoresistance||University of California, Davis|Yes|Recruiting|December 2010|November 2016|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261299||111713|
NCT01261312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-110-01|SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)|A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)||Astex Pharmaceuticals|No|Active, not recruiting|December 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|November 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01261312||111712|
NCT01261325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01358|Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures|BRITE|UCB Pharma|No|Completed|December 2010|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|768|||Both|16 Years|80 Years|No|||August 2015|August 28, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261325||111711|
NCT01261910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMC-2009-53|Enhancing Education Regarding Living Donor Transplant Among Kidney Transplant Candidates|Enhancing Education Regarding Living Donor Transplant Among Kidney Transplant Candidates||St. Barnabas Medical Center|No|Completed|December 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|500|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261910||111666|
NCT01262183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO200905|Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus|A Randomised Phase II Study of Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus|PANORAMIC|Radboud University|Yes|Terminated|January 2011|October 2012|Anticipated|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|70 Years|No|||April 2012|May 10, 2012|December 15, 2010||No|low recruitment numbers|No||https://clinicaltrials.gov/show/NCT01262183||111645|
NCT01262456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS41|Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablets for the Treatment of Nocturia in Adult Males||Ferring Pharmaceuticals|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|395|||Male|18 Years|N/A|No|||September 2015|September 16, 2015|December 15, 2010|Yes|Yes||No|June 18, 2015|https://clinicaltrials.gov/show/NCT01262456||111624|
NCT01262755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K24DK083268|Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology|Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology|TRIAGE|Temple University|No|Completed|April 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|450|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|All adult individuals (age 18-80)residing in the 19140 zip code area will be eligible for        participation. We will interview 750 African American residents and 250 self-described        Caucasian residents.|April 2015|April 16, 2015|December 16, 2010||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01262755||111601|
NCT01263691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS.AVA.201 / DMID 10-0013|Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults|A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults||Emergent BioSolutions|Yes|Completed|December 2010|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|6||Actual|105|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 1, 2014|December 17, 2010|No|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01263691||111529|
NCT01263977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THEMIS|Thermodilution - Controlled Management of Volume Therapy in Septic Shock|A Randomized Mono-center Study Looking at the Effect of Thermodilution Controlled Therapy for Volume Optimization on the Duration of Septic Shock in Patients With Septic Shock|THEMIS|Charite University, Berlin, Germany|No|Completed|December 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01263977||111508|
NCT01263405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2010-7852|Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging|Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging||University of California, Irvine|Yes|Completed|December 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|3|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic and community sample|August 2015|August 5, 2015|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01263405||111551|
NCT01263418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1018|Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas|A Phase II Trial Of Ofatumumab In Older (≥70 Years) Patients With Previously Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas||UNC Lineberger Comprehensive Cancer Center|Yes|Withdrawn|June 2011|January 2018|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|70 Years|N/A|No|||October 2015|October 8, 2015|December 16, 2010|Yes|Yes|No patients enrolled and funding has been withdrawn.|No||https://clinicaltrials.gov/show/NCT01263418||111550|
NCT01253408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008314 Part A|Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)|Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome||Mayo Clinic|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|36|||Both|18 Years|75 Years|No|||March 2013|March 22, 2013|November 18, 2010|Yes|Yes||No|February 4, 2013|https://clinicaltrials.gov/show/NCT01253408||112320|This study included assessment of only four doses of dronabinol over 2 days.
NCT01253733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091146|MD2Me - Texting to Promote Chronic Disease Management|TAHLC - Texting to Promote Adolescent Health Liaisons and Chronic Disease Management||Huang, Jeannie, M.D.|Yes|Completed|October 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|81|||Both|14 Years|22 Years|No|||January 2016|January 25, 2016|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01253733||112295|
NCT01264471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09378|Mechanisms of Mitochondrial Defects in Gulf War Syndrome|Mechanisms of Mitochondrial Defects in Gulf War Syndrome||Medical Neurogenetics, LLC|Yes|Completed|May 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|26|Samples With DNA|whole blood and tissue|Both|18 Years|N/A|No|Non-Probability Sample|Gulf War Veterans who have been diagnosed with Gulf War Syndrome|April 2015|April 10, 2015|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01264471||111470|
NCT01264484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVANTAGE|ADVANTAGE® Prosthetic Heart Valve Long-term Follow-up Trial|ADVANTAGE Prosthetic Heart Valve Long Term Follow Up||Medtronic Cardiovascular|No|Terminated|December 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control||1|Actual|212|||Both|N/A|N/A|No|Non-Probability Sample|The subject population for this study includes all patients who were already enrolled in        the ADVANTAGE Prosthetic Heart Valve Study in two German Centers and are still available        for follow-up|October 2015|October 19, 2015|December 20, 2010||No|The primary objective was considered sufficient for follow-up.|No||https://clinicaltrials.gov/show/NCT01264484||111469|
NCT01264497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH9507/II/Diabetes/006|Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes|A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus||Theratechnologies|No|Completed|February 2002|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|55|||Both|50 Years|N/A|No|||December 2010|December 20, 2010|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264497||111468|
NCT01265069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201005064M|Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy|Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy||National Taiwan University Hospital|No|Recruiting|November 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01265069||111424|
NCT01265108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSRC-986|Effects of Iron on Exercise Capacity During Hypoxia|Effects of Intravenous Iron Supplementation on Exercise Capacity During Sustained Alveolar Hypoxia in Healthy Humans.||University of Oxford|No|Completed|November 2010|April 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265108||111421|
NCT01265121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2008/10045-3|Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.|Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.||University of Sao Paulo General Hospital|No|Active, not recruiting|September 2009|June 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|12|||Both|18 Years|80 Years|No|||November 2010|December 21, 2010|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01265121||111420|
NCT01265134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99063|Efficacy of Arch Insoles in the Dynamic Postural Control for the Elderly|Efficacy of Arch Insoles in the Dynamic Postural Control for the Elderly||Taipei Medical University WanFang Hospital|No|Active, not recruiting|October 2010|August 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Female|65 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|the elders|December 2010|December 31, 2010|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265134||111419|
NCT01265667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF101-202PS|Trial of CF101 to Treat Patients With Psoriasis|A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis||Can-Fite BioPharma|Yes|Completed|July 2011|May 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|188|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265667||111378|
NCT01265680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-05|Blood Sparing Strategies: Single Shot High Dose Erythropoietin Two Days Before Heart Surgery|Single High Dose Erythropoietin Obviates Transfusions: an Independent, Blinded, Prospective Randomized Study in Heart Surgery Population.|SHOT|Cardiochirurgia E.H.|Yes|Completed|February 2012|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|600|||Both|N/A|N/A|No|||April 2013|April 5, 2013|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265680||111377|
NCT01261650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBRO 1|Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome|Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome||Karl Landsteiner Institute of Remobilization and Functional Health|Yes|Terminated|December 2010|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A||||July 2014|July 2, 2014|December 14, 2010||No|There could not be enough patients recruited|No||https://clinicaltrials.gov/show/NCT01261650||111686|
NCT01261663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09017|Impact of the Time of Oral Nutritional Supplements (ONS) Consumption on Daily Alimentary Intakes of Malnourished Elderly|Impact of the Time of Oral Nutritional Supplements (ONS) Consumption on Daily Alimentary Intakes of Malnourished Elderly Subjects Hospitalized in Long Term Care Unit (LTCU)|ACTICLAN|University Hospital, Limoges|No|Completed|January 2011|June 2014||November 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|48|||Both|70 Years|N/A|No|Non-Probability Sample|Malnourished elderly (age >=70 y) hospitalised in long term care unit (LTCU)having a NOS        medical prescription|November 2013|November 4, 2013|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261663||111685|
NCT01262196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-205|Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients|A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of MP4OX Treatment, in Addition to Standard Treatment, in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock||Sangart|Yes|Completed|May 2011|November 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|348|||Both|N/A|N/A|No|||August 2013|August 20, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262196||111644|
NCT01262469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERICO 09/0907|Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.|PHASE II STUDY Evaluating the Toxicity and Activity of the Combination Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over With Metastatic Breast Cancer Over Expressing HER2|GERICO09|UNICANCER|No|Completed|December 2009|November 2013|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|70 Years|N/A|No|||December 2014|December 14, 2014|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262469||111623|
NCT01262768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00010835|Efficacy of Portion Size Measurement Aids|Exploring the Accuracy and Acceptability of Portion Size Measurement Aids in Parents of Overweight Children|PSMA|University of Alberta|No|Completed|April 2010|January 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 19, 2014|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262768||111600|
NCT01263990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VaSNex|Validation of Stroke Volume Measurement by a New Noninvasive Hemodynamic Monitoring System (NexFin)in Comparison to Different Invasive Procedures as Picco2, FloTrac and TEE|Prospective, Monocentric Pilot Study for the Validation of Stroke Volume by Use of NexFin in Comparison to Different Hemodynamic Monitoring Procedures (Picco2, FloTrac and TEE)|VaSNex|Charite University, Berlin, Germany|Yes|Completed|September 2010|June 2013|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01263990||111507|
NCT01264549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRAWINSKI|Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)|Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients|STRAWINSKI|Charite University, Berlin, Germany|Yes|Completed|December 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01264549||111464|
NCT01264016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2010-004-01|Performance of a New Glucose Meter System|Performance of the TATSU/Tradewind Blood Glucose Monitoring System||Ascensia Diabetes Care|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|96|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|December 18, 2010|Yes|Yes||No|April 4, 2012|https://clinicaltrials.gov/show/NCT01264016||111505|
NCT01253746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1072|Genetics of Neural Tube Defects|Genetics of Neural Tubes Defects|NTD|John P. Hussman Institute for Human Genomics|No|Recruiting|April 2009|||||N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|Blood sample|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any individual with a diagnosis of NTD and his/her selected family members can        participate, if willing|December 2010|December 2, 2010|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01253746||112294|
NCT01253980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095/2010|Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children|The Efficacy of Prophylactic Antibiotics in the Management of Pneumonitis Following Paraffin (Kerosene) Ingestion in Children||University of Cape Town|Yes|Completed|July 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|3 Months|13 Years|No|||October 2015|October 7, 2015|December 3, 2010||No||No|May 6, 2013|https://clinicaltrials.gov/show/NCT01253980||112276|Early termination leading to small number of participants. Some patients did not attend follow-up and were only contacted by phone, therefore clinical data not available for all participants at follow-up.
NCT01264185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 063|Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings|Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings|HPTN063|HIV Prevention Trials Network|No|Completed|April 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|751|Samples With DNA|Blood, genital fluids|Both|18 Years|N/A|No|Non-Probability Sample|Asia (Thailand) and South America (Brazil)          -  100 heterosexual men,          -  100 heterosexual women,          -  100 Men having sex with men (MSM), and          -  ~40 community members and stakeholders        Africa (Zambia)          -  100 heterosexual men,          -  100 heterosexual women,          -  ~40 community members and stakeholders|August 2014|August 18, 2014|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01264185||111492|
NCT01264198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-RO-330-CTIL|The Role of Resistance Training in Non Alcoholic Fatty Liver Disease|The Role of Resistance Training in Non Alcoholic Fatty Liver Disease||Tel-Aviv Sourasky Medical Center|No|Completed|December 2010|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|20 Years|60 Years|No|||December 2010|March 26, 2014|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01264198||111491|
NCT01264211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAR-THA-05-01|Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)|A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study||TRB Chemedica|Yes|Completed|October 2010|April 2014|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||November 2015|November 3, 2015|June 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01264211||111490|
NCT01264796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18DK083936-01|Community-Based Diabetes Care for Korean American Immigrants|Community-Based Diabetes Care for Korean American Immigrants||Johns Hopkins University|Yes|Recruiting|November 2009|June 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|30 Years|75 Years|No|||December 2010|December 21, 2010|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264796||111445|
NCT01264809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/B/07|Exercise Consultation for Type 2 Diabetes Patients in Real Life|Does Exercise Consultation Have a Realistic Chance of Increasing the Physical Activity Level of Type 2 Diabetes Patients in Real Life?|APDT 2|Centre Hospitalier Universitaire de Fort-de-France|Yes|Not yet recruiting|March 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|70 Years|No|||December 2010|December 21, 2010|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264809||111444|
NCT01264822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT10T|Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori|Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori||Eisai Inc.||Active, not recruiting|January 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Hospitals and Clinics in Japan|May 2015|May 13, 2015|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264822||111443|
NCT01265407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911050|Malaria Surveillance in Rakai, Uganda|Malaria Surveillance in Rakai, Uganda||National Institutes of Health Clinical Center (CC)||Completed|December 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1700|||Both|6 Months|N/A|No|||May 2015|September 24, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265407||111398|
NCT01265394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-067-015|Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects|A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40||GE Healthcare|No|Completed|December 2010|April 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|218|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|December 21, 2010|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01265394||111399|
NCT01261351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_16/0921|Study of Coagulation Activation Markers and Pre Eclampsia|Coagulation Activation Markers and Pre Eclampsia : Correlation With Complications|PRESTIGE|University Hospital, Lille|Yes|Completed|May 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|300|Samples With DNA|-  Maternal blood and urine        -  cord blood|Female|18 Years|50 Years|No|Non-Probability Sample|pregnant women from two University hospitals in France|December 2014|December 17, 2014|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01261351||111709|
NCT01262261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-811|Re-Treatment Study of Probuphine in Opioid Addiction|A Phase 3, Six-Month, Open-Label, Re-Treatment Study of Probuphine in Opioid Addiction||Titan Pharmaceuticals|Yes|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|65 Years|No|||October 2012|October 6, 2014|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262261||111639|
NCT01261923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT 2010-020212-11|Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease|Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients||University Hospital, Gentofte, Copenhagen|No|Completed|December 2010|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 26, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261923||111665|
NCT01262209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-481|Clinical Effectiveness of Low Vision Rehabilitation in Glaucoma Patients|Clinical Effectiveness of Low Vision Rehabilitation in Glaucoma Patients With Moderate or Severe Vision Loss|LOVIT|Lawson Health Research Institute|No|Recruiting|May 2011|September 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 3, 2011|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262209||111643|
NCT01262222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-206|Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events|Endothelial Dysfunction in Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood draw|Both|50 Years|N/A|No|Non-Probability Sample|All patients scheduled for major intrathoracic or intraabdominal surgery who meet        inclusion criteria and are seen either in preoperative cardiology consultation or by        another pre-surgical service such as general medicine will be eligible for screening.|September 2015|September 16, 2015|December 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01262222||111642|
NCT01262482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-0802|Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment|A Phase 2 Trial of Oxaliplatin and Sorafenib Combination in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Relapsed After a Cisplatin Based Treatment||Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Completed|October 2008|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||December 2010|November 8, 2012|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262482||111622|
NCT01262495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kabiri HMO-CTIL|Testicular Tissue Viability After Cryopreservation|||Hadassah Medical Organization|Yes|Not yet recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|5|||Male|15 Years|75 Years|No|||December 2010|December 16, 2010|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262495||111621|
NCT01263119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12595|A Study of LY2216684 and Warfarin in Healthy Subjects|Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263119||111573|
NCT01263431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Emorroidi grado 3|Comparison Between Excisional Hemorrhoidectomy and Haemorrhoidal Dearterialisation With Anopexy|Prospective Randomized Trial on Surgical Treatment of Grade 3 Hemorrhoids: Hemorrhoidectomy Versus Doppler-guided Transanal Haemorrhoidal Dearterialisation and Anopexy||Scientific Institute San Raffaele|Yes|Completed|July 2010|April 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||January 2015|January 21, 2015|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263431||111549|
NCT01263444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-246|Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy|Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy||Alcon Research|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||May 2014|May 18, 2014|December 17, 2010||No||No|April 23, 2014|https://clinicaltrials.gov/show/NCT01263444||111548|A single-arm, non-randomized study somewhat limits interpretation of efficacy results. A 3-month duration does not allow for long-term safety conclusions; however, data obtained at V2 and V3 did not vary much, indicating a steady state at Month 1.
NCT01263717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-000638|Effects of Growth Hormone Releasing Hormone in HIV|Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV Lipodystrophy||Massachusetts General Hospital|Yes|Completed|December 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||October 2014|October 10, 2014|December 16, 2010|Yes|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01263717||111527|
NCT01264003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEAH-1002-IHR|Antibiotic Prophylaxis in Mesh Repair of Inguinal Hernias|Single Dose Antibiotic Prophylaxis in Lihtenstein Repair for Primary Inguinal Hernias||Diskapi Teaching and Research Hospital|No|Completed|May 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|200|||Both|18 Years|80 Years|No|||May 2008|December 20, 2010|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264003||111506|
NCT01293799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 590-09|Prevention of Peritonitis in Peritoneal Dialysis|Prevention of Peritonitis in Patients With Peritoneal Dialysis - Effects of Regular Follow-up of Patients´ Theoretical Knowledge and Practical Skills With Focus on Infection Prophylaxis|PEPS|Sahlgrenska University Hospital, Sweden|Yes|Completed|January 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|750|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293799||109220|
NCT01253993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-271|Impaired Decision-making in Adolescents|Impaired Decision-making in Adolescents: A Vulnerability Factor for the Development of Substance Use and Abuse.||UMC Utrecht|Yes|Completed|April 2006|September 2007|Actual|June 2007|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|152|||Both|14 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|DBD adolescents were recruited from judicial and forensic institutions. Healthy controls        consisted of volunteers.|December 2010|December 3, 2010|March 2, 2007||No||No||https://clinicaltrials.gov/show/NCT01253993||112275|
NCT01254240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DER-USZ-AAN-005|Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases|Randomized Double-blind Phase 2 Study of Impact of Ultraviolet A (UVA) on Pruritus During Ultraviolet A/B (UVA/B) Phototherapy of Inflammatory Dermatoses|PRUVAB|University of Zurich|Yes|Recruiting|December 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01254240||112256|
NCT01263912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02028|EFA Nutrition 1-2 Yr-Olds|Essential Fatty Acid Nutrition in Infants 1 to 2 Years-of-Age||University of British Columbia|Yes|Active, not recruiting|December 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|200|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||April 2015|April 14, 2015|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263912||111513|
NCT01263925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0580|Prostaglandin E1 in Outpatients With Intermittent Claudication|Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication||UCB Pharma|Yes|Completed|April 2001|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|561|||Both|40 Years|N/A|No|||May 2012|October 17, 2014|December 17, 2010||No||No|April 17, 2012|https://clinicaltrials.gov/show/NCT01263925||111512|
NCT01264523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNAV-ROVI-001-2010|Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients|Short-term Effect of the Intake of Moderately High-protein, Low-glycemic Load Products on Anthropometrical, Glucose Metabolism and Lipid Metabolism Biomarkers, in Type-2 Diabetes Patients||Clinica Universidad de Navarra, Universidad de Navarra||Completed|September 2009|September 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|45 Years|75 Years|No|||September 2012|September 7, 2012|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264523||111466|
NCT01264510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/074|Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha)|The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness|Baha|University Hospital, Ghent|No|Active, not recruiting|March 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01264510||111467|
NCT01264835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10-0003|Assessment of a Slotted Anoscope That Facilitates Hemorrhoidectomy|||Ethicon Endo-Surgery|No|Terminated|December 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|December 17, 2010||No|Slow Enrollment|No|November 28, 2011|https://clinicaltrials.gov/show/NCT01264835||111442|No analyses are being reported for the primary outcome measure as this trial was terminated early. The procedure was only performed with the slotted anoscope in 1 subject. No assessment or analysis of primary or secondary objectives was performed.
NCT01265147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Daping H 001|Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma|Phase II Study to Evaluate Efficacy and Safety of Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Patients With Nasopharyngeal Carcinoma||Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|No|Not yet recruiting|January 2011|December 2017|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||November 2010|January 19, 2011|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01265147||111418|
NCT01265420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHtSC-Thumb 101|Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb|The Efficacy and Safety of Xiaflex Injections for the Treatment of Thumb Cords in Dupuytren's Contractures||Indiana Hand to Shoulder Center|No|Completed|December 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 8, 2015|December 21, 2010|No|Yes||No|March 28, 2015|https://clinicaltrials.gov/show/NCT01265420||111397|1 patient was seen at Day 10, but not at day 30. At Day 10, patient met the primary endpoint
NCT01265693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-10-0076-CTIL|The Effect of Antiviral Therapy With Pegylated Interferon-alpha on Auditory Disability|The Effect of Antiviral Therapy With Pegylated Interferon-alpha for Chronic Hepatitis C and B on Auditory Disability: A Prospective Study|HLIPT2010|Carmel Medical Center|No|Recruiting|January 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with chronic hepatitis C or B treated with pegylated interferon alpha|November 2013|February 5, 2015|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01265693||111376|
NCT01261338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10100801 1R21ES019206-01|Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama|Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama|PCBs|University of Cincinnati|No|Active, not recruiting|December 2010|October 2012|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|28|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261338||111710|
NCT01261377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P001753|Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)|Comparison of Effects of Bi-level Positive Airway Pressure Therapy and Nocturnal Oxygen Therapy on Right and Left Ventricular Hemodynamics in Overlap Syndrome (Co-existent Chronic Obstructive Airway Disease and Obstructive Sleep Apnea)||Brigham and Women's Hospital|Yes|Terminated|November 2010|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|175|||Both|18 Years|75 Years|No|||April 2013|April 30, 2013|December 15, 2010|Yes|Yes|the fellow interested in this project left the institution|No||https://clinicaltrials.gov/show/NCT01261377||111707|
NCT01261962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP:2010/08787-1|Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer|Modulation of Immune Response by Oral Zinc Supplementation in Adjuvant Chemotherapy for Colon Cancer: a Study of Global Gene Expression and Function of Humoral Immunity and Neutrophils||University of Sao Paulo|No|Not yet recruiting|February 2011|August 2013|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 16, 2010|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01261962||111662|
NCT01262781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFGH 6281|Is Fructose Linked to Adiposity in Babies?|Is Fructose Linked to Adiposity in Babies?|FLAB|University of California, San Francisco|No|Completed|January 2011|January 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women between 18 to 40 years of age are eligible for this study|April 2014|April 9, 2014|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262781||111599|
NCT01263132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200057-500|Neuropathic Pain Management|Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study|M-F0434|Merck KGaA|No|Completed|February 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|70 Years|No|||January 2014|January 20, 2014|December 14, 2010||No||No|September 19, 2011|https://clinicaltrials.gov/show/NCT01263132||111572|
NCT01263457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-516|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|ECOS UK|Merck KGaA||Active, not recruiting|November 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|202|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263457||111547|
NCT01263704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25464|A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia|A Phase II, Multicenter, Single Arm Study to Determine the Efficacy and Safety of Low Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab as Primary Therapy in Elderly Untreated Patients (>/=65 Years Old) With Chronic Lymphocytic Leukemia||Hoffmann-La Roche||Active, not recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|65 Years|N/A|No|||March 2016|March 1, 2016|December 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263704||111528|
NCT01293500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD060171-01A2|Goal-directed Resuscitative Interventions During Pediatric Inter-facility Transport (The GRIPIT Trial)|Goal-directed Resuscitative Interventions During Pediatric Inter-facility Transport (The GRIPIT Trial)|GRIPIT|Arkansas Children's Hospital Research Institute|Yes|Recruiting|October 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|1 Month|17 Years|No|||January 2012|January 18, 2012|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01293500||109243|
NCT01293513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-IY-0190-10-TLV-CTIL|Structured Treatment Interruption (STI) in Acute/Primary HIV|Structured Treatment Interruption (STI) in Acute/Primary HIV||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||February 2011|February 9, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01293513||109242|
NCT01294098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0331|Efficacy Study of Femoral Nerve Block in Children With a Femur Fracture|Examining the Efficacy of Femoral Nerve Block in Children With a Femoral Shaft Fracture||Washington University School of Medicine|Yes|Enrolling by invitation|February 2011|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|180|||Both|7 Years|14 Years|No|||June 2015|June 10, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01294098||109197|
NCT01294111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tai Chi for heart failure|Tai Chi Training for Elderly People With Chronic Heart Failure|||Umeå University||Active, not recruiting|November 2010|September 2015|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|90|||Both|70 Years|N/A|No|||December 2014|December 2, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01294111||109196|
NCT01254006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLA0110|Retinal Nerve Fibres Layers Thickness Study in Glaucomatous Patients|||University of Roma La Sapienza||Completed||||||N/A|Interventional|N/A|||||||Both|30 Years|80 Years||||August 2009|December 3, 2010|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01254006||112274|
NCT01254019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114044|A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|DMD114044|GlaxoSmithKline|Yes|Completed|December 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Male|5 Years|N/A|No|||October 2014|October 23, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01254019||112273|
NCT01254253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFFECT|Functional and Clinical Benefits of PCI in Patients With CTO|Multimodality Imaging Evaluation of Functional and Clinical Benefits of Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Lesion||Xijing Hospital|Yes|Recruiting|October 2008|November 2011|Anticipated|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|N/A|70 Years|No|||November 2011|November 21, 2011|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01254253||112255|
NCT01264224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-TRPV1-PI-01|PAC-14028 in Healthy Male Volunteers|A Dose-block Randomized, Double-blind, Placebo-controlled Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of PAC-14028 After Oral Administration in Healthy Male Volunteers.||Amorepacific Corporation|No|Completed|December 2010|||June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|60|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 19, 2014|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264224||111489|
NCT01264237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRK008b-2010|Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain|An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain||Analgesic Solutions|Yes|Recruiting|March 2011|April 2012|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2011|March 22, 2011|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264237||111488|
NCT01264536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIDISI 56909|Pilot Study: Lactoferrin for Prevention of Neonatal Sepsis|Pilot Study: Lactoferrin for Prevention of Neonatal Sepsis|NEOLACTO|Universidad Peruana Cayetano Heredia|Yes|Completed|December 2010|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|190|||Both|N/A|72 Hours|No|||September 2012|September 7, 2012|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264536||111465|
NCT01264848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7/2010|Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI)|Endovascular Correction of Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Evaluation of Influence of These Treatments on the Symptoms of Multiple Sclerosis||Euromedic Specialist Clinics, Poland|No|Completed|March 2010|December 2012|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|N/A|N/A|No|||February 2015|February 9, 2015|December 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01264848||111441|
NCT01264861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28849|A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging|Open-Label Escalating Dose Study Using [123/]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients||Newron|No|Terminated|December 2010|||January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|40 Years|80 Years|No|||February 2012|March 28, 2013|December 20, 2010|Yes|Yes|The Dopamine transporter brain imaging trial is terminated due to a company decision to return    all rights for Safinamide back to Newron Pharmaceuticals|No||https://clinicaltrials.gov/show/NCT01264861||111440|
NCT01265160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81929|Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)|Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)|JZF|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|November 2010|June 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|240|||Both|18 Years|65 Years|No|Probability Sample|Combined metabolic syndrome in patients with hyperlipidemia|September 2010|December 22, 2010|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265160||111417|
NCT01261936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEVA-3|Evaluation of Menses in Congenital Bleeding Disorders|Protocol for the Determination of Menstrual Blood Losses in Women Affected by Congenital Bleeding Disorders|MEVA-3|University of L'Aquila|No|Recruiting|February 2010|December 2011|Anticipated|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Vacuum sealed soiled pads and tampons, will be weighted and than opportunely discarghed|Female|18 Years|45 Years|No|Non-Probability Sample|Women affected by CBDs and candidated to receive, as commonly performed in clinical        practice a specific substitutive therapy or Desmopressine (rFVIII, rFVIIa, Desmopressine ,        FVIII concentrates rich in VWF, Activated Prothrombin Complex) will be followed for four        consecutive menseses .The number of women enrolled will be between 30 and 50, regardless        of parity.|December 2010|December 16, 2010|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01261936||111664|
NCT01265706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTV_LAMIS II|Livalo Acute Myocardial Infarction Study (LAMIS)|1-year, Prospective, Randomized, Open-label, Parallel Group Observational Study to Evaluate the Safety and Efficacy of 4mg/Day of Pitavastatin Versus 2mg/Day of Pitavastatin in Acute Myocardial Infarction(AMI)||JW Pharmaceutical|No|Completed|July 2010|December 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|AMI patients who are in need to be treated by statins|December 2014|December 12, 2014|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01265706||111375|
NCT01261364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10002|Pharmacogenetic-Directed Treatment for Major Depression|The Evaluation of the Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting:A Randomized Double Blind Pilot Study||Assurex Health Inc.|Yes|Completed|September 2009|September 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|80 Years|No|||December 2015|December 2, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261364||111708|
NCT01262508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Autonomics - Prediction|Development of Algorithms to Predict Hemodynamic Instability|Development of Algorithms to Detect and Predict Hemodynamic Instability in Patients at Risk||Heinrich-Heine University, Duesseldorf|No|Completed|September 2010|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patients being at risk of sudden cardiac death|February 2016|February 18, 2016|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262508||111620|
NCT01292213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112956|A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom|Identification and Characterisation of Bacteria Causing Chronic Cough Among Children in the United Kingdom||GlaxoSmithKline||Terminated|May 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|19|Samples With DNA|Cough swab, oropharyngeal swab, nasopharyngeal swabs, blood and bronchoscopy/      bronchoalveolar lavage samples.|Both|6 Months|72 Months|No|Non-Probability Sample|Children aged six to 72 months, residing in the United Kingdom. These children will be        classified as cases and controls.        Cases will be children who have had persistent cough for greater than eight weeks and are        undergoing general anaesthesia for clinically indicated bronchoscopy/ bronchoalveolar        lavage as part of the diagnostic process for chronic cough.        Controls will be children who are undergoing general anaesthesia with endotracheal        intubation for elective surgery or endoscopy for non-respiratory-related conditions and        had no acute or chronic respiratory symptoms during the four weeks prior to the visit.|September 2014|September 4, 2014|February 3, 2011||No|• Long delay due to challenges with sample analysis at local labs; • Low recruitment of case    and control subjects; • Constant staff turn-over in the sites.|No||https://clinicaltrials.gov/show/NCT01292213||109342|
NCT01292226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML19835|A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).|Relationships Between Pharmacokinetic and Pharmacodynamic Strategies for Assessment of the Risks for Acute Rejection and Side Effects of Mycophenolate Mofetil||Hoffmann-La Roche||Completed|December 2006|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|65 Years|No|||February 2015|February 23, 2015|February 3, 2011|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01292226||109341|
NCT01262794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0074|Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects|A Phase 1, Randomized, Double-blind, Placebo Controlled, Single-center, Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of CDP6038 Administered Subcutaneously to Healthy Japanese Males||UCB Pharma|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|20|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 26, 2011|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01262794||111598|
NCT01262807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2010:187|Reducing Range of Motion Deficits Post Radial Fracture|Reducing Range of Motion Deficits With In-cast Exercises: A Randomized Controlled Trial||University of Manitoba|No|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262807||111597|
NCT01262820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC0921|Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab|A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab|LCCC0921|UNC Lineberger Comprehensive Cancer Center|Yes|Completed|December 2010|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|December 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262820||111596|
NCT01263145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02562|MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer|Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2011|||October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||October 2015|January 11, 2016|December 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263145||111571|
NCT01263470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/CCT-001|Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan|A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|480|||Both|20 Years|N/A|No|||February 2012|February 1, 2012|December 17, 2010||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01263470||111546|
NCT01293812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sucrose#3236|Effect on Pain of Oral Sucrose Versus Placebo in Children 1 to 3 Months Old Needing Venipuncture|A Randomized Double-blind Trial Comparing the Effect on Pain of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Venipuncture||St. Justine's Hospital|No|Completed|February 2011|June 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|1 Month|3 Months|Accepts Healthy Volunteers|||December 2015|December 21, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293812||109219|
NCT01294085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1001|Case Series Study of Biliary Tract Cancer Patients in Japan|Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer||Kansai Hepatobiliary Oncology Group|Yes|Completed|November 2010|August 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|300|||Both|20 Years|N/A|No|Non-Probability Sample|300|November 2011|November 24, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01294085||109198|
NCT01294124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101920DM.INT|Investigating the Neurobiology of Tinnitus|Investigating The Neurobiology of Tinnitus||Washington University School of Medicine|Yes|Not yet recruiting|March 2015|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Active-duty or reserve United States military personnel between the ages of 18 and 30 of        either sex, all races and ethnicity, who are scheduled for initial deployment to theater        with a Military Occupational Specialty code (MOS) of 11B Infantryman, 11C Indirect Fire        Infantryman, 19D Calvary Scout, or 19K Armor Crewman.|December 2014|December 8, 2014|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01294124||109195|
NCT01254266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5833|The Efficacy of an Inpatient Program for Long-term Weight Maintenance in Children and Adolescents With Morbid Obesity|Morbid Obesity in Children and Adolescents : Does Inpatient Treatment in a Psychosomatic Unit Increases the Chance for a Long-term Weight Maintenance?||Rabin Medical Center|No|Recruiting|December 2010|September 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|10 Years|18 Years|No|||May 2010|July 24, 2011|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01254266||112254|
NCT01254279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAZ_C_05331|Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen|Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients||Sanofi||Completed|December 2010|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|984|||Male|18 Years|N/A|No|||January 2015|January 19, 2015|December 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01254279||112253|
NCT01254604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2452-002|Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)|A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or Ocular Hypertension in India||Merck Sharp & Dohme Corp.|No|Completed|December 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|80 Years|No|||March 2015|March 24, 2015|December 3, 2010|No|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT01254604||112228|
NCT01254617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02557|Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer|Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study|ADCC|National Cancer Institute (NCI)||Active, not recruiting|February 2011|||January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|December 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01254617||112227|
NCT01264250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4120C00001|A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers|A Phase I, Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Subjects||AstraZeneca|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 23, 2011|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01264250||111487|
NCT01264263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-DUM-2010/1|Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes|Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes|ALTO|AstraZeneca|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|181|Samples Without DNA|Whole blood and serum, urine|Both|20 Years|80 Years|No|Probability Sample|360 patients who has diabetic mellitus with dyslipidemia|March 2012|March 12, 2012|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01264263||111486|
NCT01265719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6111143|Long-Term Non-Interventional Latanoprost Study|A Prospective, Non-interventional, Longitudinal Cohort Study To Evaluate The Long-term Safety Of Latanoprost Treatment In Pediatric Populations|LYNX|Pfizer|No|Active, not recruiting|December 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|N/A|17 Years|No|Non-Probability Sample|Pediatric populations diagnosed with glaucoma or elevated intraocular pressure|March 2016|March 7, 2016|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265719||111374|
NCT01261390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002671|Sleep Apnea Intervention for Cardiovascular Disease Reduction|A Planning Study: Sleep Apnea Intervention for Cardiovascular Disease Reduction|BestAIR|Brigham and Women's Hospital|Yes|Active, not recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|45 Years|75 Years|No|||March 2014|March 4, 2014|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261390||111706|
NCT01264874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S480/209|MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients|Phase III, Randomized, Double Blind Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients|MelaViD|European Institute of Oncology|No|Recruiting|May 2010|February 2025|Anticipated|February 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|878|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01264874||111439|
NCT01261403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA001-RA-001|Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis|A Phase 2, Randomized, Double- Blind, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Active Rheumatoid Arthritis||Celgene|Yes|Terminated|December 2010|September 2013|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|75 Years|No|||July 2014|July 16, 2014|December 15, 2010|Yes|Yes|Enrollment terminated pending additional Phase 1 data|No||https://clinicaltrials.gov/show/NCT01261403||111705|
NCT01261416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101335-2|Pharmacokinetics of Levetiracetam (Keppra) in Neonates|Pharmacokinetics and Safety of IV Levetiracetam (Keppra) in Full Term and Preterm Neonates||Children's Hospital Medical Center, Cincinnati|No|Completed|October 2008|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|||Both|N/A|30 Days|No|Non-Probability Sample|Infants ≥ 32 weeks gestation and ≤ 30 days of age requiring treatment with levetiracetam        for clinical and/or electrographic seizures or seizure prophylaxis.|December 2010|December 15, 2010|December 15, 2010||Yes||No||https://clinicaltrials.gov/show/NCT01261416||111704|
NCT01261676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-4-047|Current Dutch Practice on Caesarean Sections: Identification of Barriers and Facilitators for Optimal Care|Current Dutch Practice on Caesarean Sections: Identification of Barriers and Facilitators for Optimal Care.|SIMPLE|Maastricht University Medical Center||Enrolling by invitation|December 2010|||October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|1000|||Female|N/A|N/A|No|Non-Probability Sample|1. Development of quality indicators: 12-15 obstetricians and midwives          2. Current care study: All women (1000) who underwent a CS in one of the 20             participating hospitals during the study period (3-4 months). All hospitals             participate in the Dutch consortium and consist of university teaching-,             non-university teaching- and non-university-non-teaching hospitals.          3. Barrier analysis: Qualitative: 15-20 professionals and 15-20 patients from the             hospitals in the upper and lower extremes of the 'adherence distribution'.             Quantitative: obstetricians in the Netherlands and 200 experienced patients.          4. CBA study: depending on the outcome of phase 2 and 3 of the study, the implementation             strategy will be designed for a target group with low guideline adherence and high             incidence.|October 2012|October 29, 2012|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261676||111684|
NCT01261429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVNS|Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)|Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)||Centre Leon Berard|Yes|Completed|December 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261429||111703|
NCT01261442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0435-BE|Can Ultrasound Detect Diabetic Peripheral Neuropathy?|Can Ultrasound Detect Diabetic Peripheral Neuropathy?||University Health Network, Toronto|Yes|Completed|January 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|80 Years|No|Non-Probability Sample|100 adult diabetic patients scheduled to undergo a nerve conduction study.|June 2010|April 25, 2012|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261442||111702|
NCT01262235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKM-PLK1-001|A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients|A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors||Arbutus Biopharma Corporation|Yes|Completed|December 2010|August 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262235||111641|
NCT01262248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ti-NBI|Computer-based Classification of Colorectal Polyps Using Narrow-band Imaging|Computer-based Classification of Small Colorectal Polyps||Tischendorf, Jens, M.D.|No|Completed|May 2010|March 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|434|||Both|18 Years|N/A|No|Probability Sample|patients who underwent colonoscopy and colorectal polyps with a size of 10mm or smaller        were detected|June 2011|June 15, 2011|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262248||111640|
NCT01276210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC RAD1060|Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases|A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|February 2011|June 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|January 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276210||110567|
NCT01275937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMUH-2011|A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy|A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding||Taipei Medical University|No|Recruiting|August 2011|January 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|65|||Both|N/A|N/A|No|||August 2011|August 11, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01275937||110588|
NCT01275950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|647|A Study to Evaluate the Impact of Direct and Surrogate Advertising and Compliance With the Bill With the Respect to Sale of Tobacco Products Around Educational Institutes|An Intervention Study To Evaluate The Impact Of Direct and Surrogate Advertising And Compliance With The Bill With The Respect To Sale Of Tobacco Products Around Educational Institutes||Tata Memorial Hospital|Yes|Recruiting|May 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|480|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|January 12, 2011|June 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01275950||110587|
NCT01275963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-401/2010|New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function|New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function|LAX|Heidelberg University|No|Recruiting|January 2011|December 2021|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||8|Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals and patients with various cardiac pathologies, who undergo routine        echocardiography at our department|July 2015|July 6, 2015|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01275963||110586|
NCT01276262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00012|Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects|A Single-blind, Placebo-controlled, 2-period, Fixed Sequence Study to Determine the Effects of Coadministration of Fostamatinib 100 mg Twice Daily on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects||AstraZeneca||Completed|March 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|22|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 17, 2012|January 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01276262||110563|
NCT01277458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EthMSM01|Ethnicity Data in HIV Positive Men Who Have Sex With Men|Accuracy of Ethnicity Recording in MSM Patients With HIV of Non-White Ethnicity in London||Public Health England|No|Not yet recruiting|June 2011|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Male|18 Years|N/A|No|Non-Probability Sample|400 Non-White HIV positive Men who have sex with men|December 2010|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277458||110471|
NCT01277757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02892|Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer|Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation||National Cancer Institute (NCI)|No|Active, not recruiting|March 2011|||August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|January 13, 2016|January 13, 2011|Yes|Yes||No|October 14, 2015|https://clinicaltrials.gov/show/NCT01277757||110448|
NCT01277978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARBOXY-005498-78-Graz|Haemodynamic Effects of Oxytocin and Carbetocin|Haemodynamic Assessment at Primary Caesarean Section After Administration of Carbetocin Versus Oxytocin: a Doubleblind Randomized Trail||Medical University of Graz|No|Completed|January 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|84|||Female|18 Years|40 Years|No|Probability Sample|Women undergoing elective caesarean section after regional anesthesia at an University        hospital providing intrapartum care.|January 2011|January 14, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277978||110431|
NCT01266122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21MH085314-02|Addressing Psychosocial Needs and HIV Risk in Indian MSM|Addressing Psychosocial Needs and HIV Risk in Indian MSM||Massachusetts General Hospital|Yes|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|96|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|November 24, 2010||No||No|August 4, 2014|https://clinicaltrials.gov/show/NCT01266122||111343|
NCT01266135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2203|Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPF||Novartis||Terminated|December 2010|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||April 2015|April 14, 2015|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266135||111342|
NCT01278498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMOTION|The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients|A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life|EMOTION|Asan Medical Center|Yes|Active, not recruiting|January 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|444|||Both|20 Years|N/A|No|||October 2014|October 8, 2014|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278498||110391|
NCT01278758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2109|A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function|A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function||Novartis||Terminated|March 2010|||November 2010|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|January 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01278758||110371|
NCT01278771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0496CTIL|Coronary Anomalies in Congenital Heart Disease|Coronary Anomalies in Congenital Heart Disease|CHD|Rambam Health Care Campus|No|Not yet recruiting|March 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1200|||Both|N/A|86 Years|No|Probability Sample|1200 patients with Congenital Heart Disease who underwent Cardiac catheterization with        angiography.|October 2010|January 19, 2011|January 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01278771||110370|
NCT01243320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40281|In Vivo Assessment of Silver Biomaterial Nano-Toxicity|In Vivo Assessment of Silver Biomaterial Nano-Toxicity||University of Utah|Yes|Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|November 16, 2010|No|Yes||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01243320||113089|
NCT01243567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF-AGN-OPH-GLA-010|Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated|||Allergan|No|Completed|June 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|85 Years|No|||January 2013|January 22, 2013|November 17, 2010|Yes|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT01243567||113070|
NCT01244074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO0210|Visual Rehabilitation of Patients With Myopic Maculopathy|||University of Roma La Sapienza||Completed||||||N/A|Interventional|N/A|1||||||Both|35 Years|57 Years||||February 2010|November 18, 2010|November 18, 2010||||No||https://clinicaltrials.gov/show/NCT01244074||113031|
NCT01244386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-CT-Crohn's|Low-dose CT Using Iterative Reconstruction in Patients With Inflammatory Bowel Disease|||University College Cork|No|Recruiting|June 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients under the care of the hospital gastrointestinal services including in-patients        and outpatients.|November 2010|November 18, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244386||113007|
NCT01244399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INO_ESP2010|Influence of "Espresso" on Adsorption of Myo-inositol|Influence of "Espresso" on Adsorption of Orally Administrated Myo-inositol in Humans||AGUNCO Obstetrics and Gynecology Centre||Completed|November 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|12|||Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers|June 2011|January 11, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244399||113006|
NCT01244087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBSR|Pilot Clinical Trial (Phase II) of Inquiry-based Stress Reduction (IBSR) Program for Survivors of Breast Cancer|Pilot Clinical Trial (Phase II) of Inquiry-based Stress Reduction (IBSR) Program for Survivors of Breast Cancer||Tel-Aviv Sourasky Medical Center|No|Completed|December 2010|May 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|90 Years|No|Probability Sample|Women aged 21 or older previously diagnosed with Stage 0-III BC who underwent surgery and        received adjuvant or neo-adjuvant chemotherapy and/or radiation will be recruited|June 2013|June 13, 2013|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01244087||113030|
NCT01244100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-ASA-003|Food-Effect Pharmacokinetic Study of PL2200|||PLx Pharma||Completed|October 2010|||December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 10, 2010|October 25, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244100||113029|
NCT01274611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU40780|Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)|Comparing the Efficacy Between Suction-Curettage and Botox Injections in the Treatment of Axillary Hyperhidrosis||Northwestern University|Yes|Completed|December 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|January 10, 2011|Yes|Yes||No|July 18, 2013|https://clinicaltrials.gov/show/NCT01274611||110690|There was a the lack of long-term assessment of comparative effectiveness. It is uncertain whether suction-curettage removes the eccrine sweat glands or mainly the apocrine glands.
NCT01274832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG200911|Prospective Study to Compare Results of STN-DBS Between Early Treated and Late-treated PD Patient|Prospective Study to Compare the Impact on Motor, Neuropsychological, Psychiatric Outcomes and Quality of Life of STN-DBS Between Early Treated and Late-treated PD Patients.|DeBraStE|A.O. Ospedale Papa Giovanni XXIII|No|Not yet recruiting|February 2011|September 2014|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|70 Years|No|Non-Probability Sample|This prospective clinical study will enroll 40 patients affected by PD. Patients enrolled        will be divided into two groups based on the duration of disease. The first group will be        composed by patients with PD duration of 5, while the second group will be composed by        patients with a duration of disease longer than 10 years.|October 2008|January 13, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274832||110673|
NCT01275404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-204|Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program|ACT-ED: Acceptance and Commitment Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program|ACT-ED|Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2010|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Male|21 Years|N/A|No|||October 2015|October 9, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275404||110629|
NCT01275352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNCKA-1|CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression|A Randomized, Double Blind Pilot Study Evaluating CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression in Caucasian Hypertensive Patients Treated With Eplerenone||Washington University School of Medicine|Yes|Withdrawn|December 2011|June 2015|Actual|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|40 Years|80 Years|No|||June 2015|June 1, 2015|January 10, 2011||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01275352||110633|
NCT01275677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02572|Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer|A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2011|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|3260|||Female|18 Years|N/A|No|||February 2016|March 24, 2016|January 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275677||110608|
NCT01275690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-179-B|Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing|Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing||University of Chicago|No|Recruiting|May 2010|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|We will enroll 100 consecutive patients referred to the Pulmonary Hypertension Center and        scheduled for cardiac catheterization with right heart catheterization and acute        vasodilator testing as part of their evaluation of PH.|September 2013|September 27, 2013|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275690||110607|
NCT01275703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-180-B|Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing|Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing||University of Chicago|No|Withdrawn|May 2010|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|We will enroll 200 consecutive patients referred to the Pulmonary Hypertension Center and        scheduled for exercise testing as part of their evaluation of PH.|December 2015|December 21, 2015|January 10, 2011||No|The PI left this institution, and the study was closed.|No||https://clinicaltrials.gov/show/NCT01275703||110606|
NCT01275976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34932|Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture|Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture|CAESAR|UMC Utrecht|Yes|Terminated|April 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|80 Years|No|||February 2015|February 3, 2015|January 12, 2011||No|Futility and limited feasibility|No||https://clinicaltrials.gov/show/NCT01275976||110585|
NCT01277185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Camp Calcium 11|Calcium Metabolism in Mexican American Adolescents|Calcium Metabolism in Mexican American Adolescents||Purdue University|No|Completed|April 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||January 2011|January 13, 2011|January 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277185||110492|
NCT01277471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142|Effect of Meal Frequency on Insulin Resistance in Subjects With Type 2 Diabetes|Effect of Meal Frequency on Insulin Resistance, Insulin Secretion, and Hepatic Fat Content in Subjects With Type 2 Diabetes|Frequency|Institute for Clinical and Experimental Medicine|Yes|Completed|December 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|30 Years|70 Years|No|||April 2012|April 4, 2012|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01277471||110470|
NCT01269801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUVE_BTX-09-01|Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds|A Phase IV Prospective, Open Label, Randomized, Crossover Study Evaluating BOTOX Cosmetic for Injection and JUVEDERM Injectable Gel for the Treatment of Moderate to Severe Facial Wrinkles and Folds|JUVE_BTX|AboutSkin Dermatology and DermSurgery, PC|Yes|Completed|January 2011|February 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|January 2, 2011||No||No|July 11, 2014|https://clinicaltrials.gov/show/NCT01269801||111060|
NCT01270061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-587|Project Wellness: Increasing HIV Testing Among West African Immigrants|Project Wellness: Increasing HIV Testing Among West African Immigrants||North Bronx Healthcare Network|No|Withdrawn|April 2012|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 7, 2015|January 3, 2011||No|We did not receive proper funding to complete this study|No||https://clinicaltrials.gov/show/NCT01270061||111040|
NCT01270282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-101-CL-10-02|Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus|Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus|TACTT1|Auris Medical, Inc.||Completed|February 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|65 Years|No|||January 2015|January 13, 2015|December 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270282||111023|
NCT01266434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si481/2010|The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma|The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma|Simvastatin|Mahidol University|No|Completed|January 2011|March 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||March 2016|March 15, 2016|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01266434||111319|
NCT01276392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-AHTSDKM|Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy|Platelet Function, Whole Blood Coagulation and Fibrinolysis During Continuous Renal Replacement Therapy - a Comparison of Citrate and Heparin Anticoagulation||Heinrich-Heine University, Duesseldorf|No|Withdrawn|January 2011|February 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Critical ill patients with acute renal failure and the need of continuous renal        replacement therapy.|August 2015|August 19, 2015|January 12, 2011||No|A main person involved left the site|No||https://clinicaltrials.gov/show/NCT01276392||110553|
NCT01266395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RES-DUM-2010/2|Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)|Impact of Morning Symptoms in Clinical Control of COPD|IMPAEPOC|AstraZeneca|No|Completed|January 2010|July 2011|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1268|||Both|40 Years|N/A|No|Probability Sample|General Practitioners and pneumologist|August 2011|August 8, 2011|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01266395||111322|
NCT01266408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2010_02|INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)|International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study||Center for Epidemiology and Health Research, Germany|Yes|Recruiting|October 2010|December 2025|Anticipated|November 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|80000|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women using oral contraceptives|January 2016|January 27, 2016|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266408||111321|
NCT01266655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BACLAD|Baclofen for the Treatment of Alcohol Dependence|Baclofen for the Treatment of Alcohol Dependence - BACLAD|BACLAD|Charite University, Berlin, Germany|No|Completed|February 2011|May 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|64 Years|No|||September 2014|September 4, 2014|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266655||111302|
NCT01243827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTIST|Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study|Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study||Jichi Medical University|Yes|Recruiting|November 2010|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|80 Years|No|||November 2010|July 18, 2012|November 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243827||113050|
NCT01243814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N08-429|A Double-blind RCT of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle|A Double-blind, Randomized, Placebo-controlled Study of the Relative Efficacy of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle||Henry DeGroot, M.D.|No|Completed|October 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||November 2010|March 19, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01243814||113051|
NCT01244113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0150|Optimal Dose of Propofol for Induction of Deep Sedation for Brain MRI Scanning in Children With Cerebral Palsy|Optimal Dose of Propofol for Induction of Deep Sedation for Brain MRI Scanning in Children With Cerebral Palsy||Yonsei University|Yes|Completed|July 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|6 Months|5 Years|No|||November 2010|November 18, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244113||113028|
NCT01244451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL0809|GIMEMA CLL0809 Study (BendOfa)|A Single-Arm Multi-Center Trial of Bendamustine Given With Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL). EudraCT Number 2009-017663-42. GIMEMA CLL0809 Protocol|BendOfa|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|December 2010|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||May 2014|January 29, 2015|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244451||113002|
NCT01274910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5961|Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial|Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial|EFOPaKR-01|Rabin Medical Center|Yes|Recruiting|January 2011|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|80 Years|No|||February 2013|November 21, 2013|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01274910||110667|
NCT01275131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-117-105|Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)|Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20)||Halozyme Therapeutics|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|January 10, 2011|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01275131||110650|
NCT01275079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resident_Permpoon|Change of Nasalance After Tonsillectomy in Thai Adult|Change of Nasalance After Tonsillectomy in Thai Adult||Chulalongkorn University|No|Recruiting|January 2011|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Rt. and Lt.tonsil|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Thai adults who were performed tonsillectomy|January 2011|January 11, 2011|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01275079||110654|
NCT01275092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CorPath PRECISE|Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)|CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)|PRECISE|Corindus Inc.|Yes|Completed|January 2011|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|164|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|January 7, 2011|Yes|Yes||No|August 9, 2012|https://clinicaltrials.gov/show/NCT01275092||110653|
NCT01274884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACLUX2010|Tightrope Fixation of Acromioclavicular Joint Dislocation - a Prospective Series|Prospective Series of Acute Acromioclavicular Dislocations Grade III+. Arthroscopic Fixation With Tightrope (R).||Sykehuset Asker og Baerum|No|Completed|March 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274884||110669|
NCT01275209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHCD122A2104|Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma|A Phase Ib, Multicenter, Open-label Study of HCD122 Administered Intravenously in Combination With Bendamustine in Patients With CD40+ Follicular Lymphoma Who Are Refractory to Rituximab|LIFT|Novartis||Completed|February 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275209||110644|
NCT01275417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMRR99-IRB-152|Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head|Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head|BCSM|China Medical University Hospital|Yes|Completed|September 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only||2|Actual|160|||Female|6 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|community sample: This experiment will recruit 100 volunteers age ranged 18-80 years old        and 60 children under 10 years old.|January 2011|September 23, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275417||110628|
NCT01275638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03/05|The Effect of Moderate-Dose Steroid Therapy in Sepsis|The Effect of Moderate-Dose Steroid Therapy in Sepsis: A Placebo-Controlled, Randomized Study||TC Erciyes University|Yes|Completed|April 2005|May 2009|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|55|||Both|17 Years|N/A|No|||April 2005|January 11, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275638||110611|
NCT01275651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-151004|Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole|Androgen Receptor (AR) Activity in Castration-Resistant Prostate Cancer (CRPC) and Response to Ketoconazole||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|December 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|48|Samples With DNA|Tissue, bone marrow, and blood|Male|N/A|N/A|No|Non-Probability Sample|Patients with prostate cancer registered to Cancer and Leukemia Group B (CALGB) 9583 and        CALGB 9663|July 2015|July 23, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275651||110610|
NCT01276587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2598|Study of Vitamin D in Children With Sickle Cell Disease|Pilot Study of Vitamin D Therapy to Prevent Respiratory Complications in Children With Sickle Cell Disease||Columbia University|Yes|Completed|January 2011|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|3 Years|20 Years|No|||February 2016|February 27, 2016|January 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276587||110538|
NCT01276860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112316|The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea|The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea|PVT|University of Arkansas|Yes|Active, not recruiting|May 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276860||110517|
NCT01277198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lapastone|Role of Flexible Cystoscopy in Laparoscopic Stone Surgery|The Role of Flexible Cystoscopy in Laparoscopic Stone Surgery: a Single Surgeon Experience||Seoul National University Hospital|Yes|Completed|January 2005|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|80|||Both|20 Years|60 Years|No|Non-Probability Sample|71 patients with complex renal stones and large or impacted ureter stones. All the        patients underwent laparoscopic pyelolithotomies with concomitant calyceal stone removal        or ureterolithotomy using a flexible cystoscopy or not.|January 2011|January 13, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277198||110491|
NCT01277211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06450|A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)|A Randomized, Open-Label, Controlled, Multi-Center Trial to Evaluate the Contraceptive Efficacy, Cycle Control, Safety and Acceptability of NuvaRing® (SCH 900702) in Chinese Women||Merck Sharp & Dohme Corp.|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|983|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 12, 2011|Yes|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01277211||110490|
NCT01270074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZI001|Prevention of Bronchiectasis in Infants With Cystic Fibrosis|A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis.|COMBATCF|Queensland Children's Medical Research Institute|Yes|Recruiting|April 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|130|||Both|6 Weeks|6 Months|No|||October 2014|October 22, 2014|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01270074||111039|
NCT01270295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0086|Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLiRAGE).|Soluble Forms and Ligands of the Receptor for Advanced Glycation End Products (RAGE) in the Pulmonary Edema Fluid and Plasma From ICU Patients With ALI/ARDS : an Observational Prospective Study.|SoLiRAGE|University Hospital, Clermont-Ferrand||Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|60|||Both|18 Years|95 Years|No|Probability Sample|Defined population|March 2013|March 12, 2013|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270295||111022|
NCT01276405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25174|An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)|The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)||Hoffmann-La Roche||Active, not recruiting|March 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|123|||Both|18 Years|N/A|No|Probability Sample|Patients with colon cancer stage III (Duke C) on Xeloda monotherapy|December 2015|December 1, 2015|January 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01276405||110552|
NCT01266421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2010_03|Visanne Post-approval Observational Study (VIPOS)|International Active Surveillance Study of Medication Used for the Treatment of Endometriosis: Visanne Post-approval Observational Study||Center for Epidemiology and Health Research, Germany|Yes|Recruiting|December 2010|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|25000|||Female|N/A|N/A|No|Non-Probability Sample|Women using medications for the treatment of endometriosis|January 2016|January 27, 2016|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266421||111320|
NCT01266668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chonbuk 011|The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)|Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma in Patients Treated With R-CHOP; Consortium for Improving Survival of Lymphoma (CISL) Study||Chonbuk National University Hospital|No|Completed|February 2010|June 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|||Both|20 Years|85 Years|No|Probability Sample|The primary breast DLBCL group was identified from the nation-wide surveys in the        university hospital, general hospital, and cancer institute of Korea. And, the nodal DLBCL        group, as a matching control group, was selected from the data registry of Korean Society        of Hematology Lymphoma Working Party.|November 2011|November 28, 2011|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01266668||111301|
NCT01243840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-CARP|Japan Central Aortic Pressure Prospective Study|Central Blood Pressure Follow-up Study in Japanese|J-CARP|Jichi Medical University|No|Recruiting|June 2010|June 2019|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ages eligible for Study: 20 Years to 90 Years Genders eligible for Study: Both Accepts        healthy volunteers: Yes|June 2010|January 23, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01243840||113049|
NCT01244126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21839|Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy|Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes||Baylor College of Medicine|No|Completed|May 2008|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|171|||Both|6 Months|6 Years|No|||February 2016|February 3, 2016|September 16, 2010||No||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01244126||113027|This study used an objective pain scale where the minimum clinically important difference in scores is unknown. The study did not use a group receiving no active treatment as this was unethical. We also did not measure blood levels of opioids.
NCT01244464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV29|A Study of the Safety of IMOVAX Polio™ in China|Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study||Sanofi|No|Completed|November 2010|December 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|800|||Both|60 Days|89 Days|Accepts Healthy Volunteers|||August 2012|August 2, 2012|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01244464||113001|
NCT01244815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06107|Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)|Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P06107)||Merck Sharp & Dohme Corp.|Yes|Completed|June 2011|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|404|||Both|10 Years|17 Years|No|||August 2015|August 25, 2015|November 18, 2010|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01244815||112974|
NCT01274923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0200-09-rmb europe|Double Blind Placebo Controlled Study on the Effect of Extracorporal Shock Wave Therapy on Erectile Dysfunction in PDE5i Responders|The Effect of Low Intensity Shock Wave Therapy on Erectile Dysfunction in Patients Responding to PDE5i's|LI-ESWT|Rambam Health Care Campus|No|Recruiting|August 2010|October 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|20 Years|80 Years|No|||January 2011|May 17, 2011|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01274923||110666|
NCT01275170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7655-005|A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005 AM1)|A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Subjects With Impaired Renal Function||Merck Sharp & Dohme Corp.|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|49|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275170||110647|
NCT01274897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_39|A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea|A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea||Novartis|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|450|||Both|11 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|January 9, 2011|Yes|Yes||No|March 13, 2012|https://clinicaltrials.gov/show/NCT01274897||110668|
NCT01275144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12596|A Study of the Effect of LY2216684 on Lorazepam|Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Lorazepam in Healthy Subjects||Eli Lilly and Company|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|January 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01275144||110649|
NCT01275157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13276|Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects|Disposition of [14C]-LY2452473 Following Oral Administration in Healthy Human Subjects||Eli Lilly and Company|No|Completed|January 2011|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275157||110648|
NCT01275365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG037547|Optimizing Protein Intake in Older Americans With Mobility Limitations|Optimizing Protein Intake in Older Americans With Mobility Limitations|OPTIMen|Brigham and Women's Hospital|Yes|Recruiting|May 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|152|||Male|65 Years|N/A|No|||December 2015|December 9, 2015|January 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275365||110632|
NCT01275989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|848/2009|Ear Acupuncture Effectiveness In Reducing The Signs And Symptoms Of Stress And Anxiety|EAR ACUPUNCTURE EFFECTIVENESS IN REDUCING THE SIGNS AND SYMPTOMS OF STRESS AND ANXIETY|EAEIRTSOSAA|University of Sao Paulo|No|Terminated|March 2010|November 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|56|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2010|January 12, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01275989||110584|
NCT01275664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0272|Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer|Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy||Gynecologic Oncology Group||Suspended|June 2011|||May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|January 11, 2011|No|Yes|Temporarily Closed to Accrual|No||https://clinicaltrials.gov/show/NCT01275664||110609|
NCT01276600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 066|Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers|Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers|HPTN066|HIV Prevention Trials Network|Yes|Completed|January 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|32|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||November 2011|November 29, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276600||110537|
NCT01276613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0371|Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas|Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas||M.D. Anderson Cancer Center|No|Recruiting|January 2011|||March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|January 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01276613||110536|
NCT01276873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1094/09|Clinical Variations and Pain Assessment in Newborns Submitted to Intratracheal Aspiration With Open and Closed System|Clinical Variations and Pain Assessment in Newborns Submitted to Intratracheal Aspiration With Open and Closed System.||Federal University of São Paulo|Yes|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|28 Days|No|||December 2010|January 12, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276873||110516|
NCT01269554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diar-GB-Finland 2011|Etiology of Diarrhea in Guinea-Bissau and in Finland|Etiology of Diarrhea in Guinea-Bissau and in Finland||Bandim Health Project|No|Active, not recruiting|November 2010|December 2014|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||8|Anticipated|800|Samples Without DNA|Faecea samples are collected for analysis of patogens|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|1. children and adults with diarrhea reporting to Bandim Health Centre          2. age and sex mached children and adults without diarrhea from Bandim          3. children and adults with a recent travel history and suffering from diarrhea             reporting to Postitalo Travel Clinic          4. children and adults without diarrhea and no recent travel history reporting to             Postitalo Travel Clinic|March 2014|March 10, 2014|November 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01269554||111079|
NCT01269528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Evaluation of Palivizumab|Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation|Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation||Rambam Health Care Campus|Yes|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|Samples Without DNA|Whole blood for complete blood count , IGE and cytokines.|Both|4 Years|7 Years|No|Non-Probability Sample|Premature babies 29-32 weeks of gestation born during 2007 and 2010|November 2015|November 8, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269528||111081|
NCT01269541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSA-2010|MESS-study MRSA Eradication Study Skåne|MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers|MESS|Region Skane|Yes|Recruiting|March 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|69|||Both|5 Years|N/A|No|||May 2015|May 25, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269541||111080|
NCT01265797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSC-13|Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches|Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches||University of Toledo Health Science Campus|No|Completed|December 2011|July 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|December 15, 2010|No|Yes||No|August 7, 2013|https://clinicaltrials.gov/show/NCT01265797||111368|Recall bias in completing survey instruments. Incomplete diary data with regards to headache symptoms, acute medication use and relief limited analysis for other proposed secondary outcomes.Higher than anticipated drop-out rate.
NCT01266148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ANO02|SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance|SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early CNI Avoidance|SCHEDULE|Novartis|No|Completed|November 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|70 Years|No|||May 2015|May 15, 2015|August 9, 2010|Yes|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT01266148||111341|
NCT01276691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsprinFire2011|Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting|Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting||University of Illinois at Urbana-Champaign|No|Completed|February 2011|December 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|24|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01276691||110530|
NCT01266681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACDC MainS|Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm|Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus|ACDC|Eastbourne General Hospital|Yes|Not yet recruiting|March 2011|||May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2010|December 23, 2010|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01266681||111300|
NCT01267019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBB-004-10S|Social Cognition Intervention|Augmenting Social Cognitive Intervention for Veterans With Schizophrenia|ASCI|VA Office of Research and Development|Yes|Active, not recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|60 Years|No|||November 2015|November 18, 2015|December 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01267019||111274|
NCT01244477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7760-P|Neuroimaging the Impact of Treatment on Neural Substrates of Trust in Post-Traumatic Stress Disorder (PTSD)|Neuroimaging the Impact of Treatment on Neural Substrates of Trust in PTSD||VA Office of Research and Development|No|Active, not recruiting|May 2011|December 2015|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|61|||Both|18 Years|50 Years|No|||October 2015|October 8, 2015|November 17, 2010||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT01244477||113000|This is a pilot study based on a small sample of Veterans with PTSD.
NCT01244503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH-BID-FIS-808|Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)|Prediction of Severity of Liver Disease in Patients With Suspected Nonalcoholic Fatty Liver Disease (NAFLD) by 13C Octanoate Breath Test (OBT)||Virginia Commonwealth University|No|Terminated|February 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|November 17, 2010|Yes|Yes|Budgetary Issues|No|August 7, 2014|https://clinicaltrials.gov/show/NCT01244503||112998|
NCT01244516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-201007|Multi-Center 2-Week Clinical Evaluation of Three Silicone Hydrogel Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2010|||November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|540|||Both|18 Years|39 Years|No|||May 2015|May 6, 2015|November 17, 2010|Yes|Yes||No|November 29, 2011|https://clinicaltrials.gov/show/NCT01244516||112997|
NCT01244828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06238|Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)|Long-term Study of Asenapine in Subjects With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (Protocol P06238)||Merck Sharp & Dohme Corp.|No|Completed|April 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Both|20 Years|N/A|No|||July 2015|July 30, 2015|November 18, 2010|No|Yes||No|July 30, 2015|https://clinicaltrials.gov/show/NCT01244828||112973|
NCT01245101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM 20100499|Addition of Raltegravir to Established Antiretroviral Suppressive Therapy|A Prospective, Open-Label, Double-Arm, Crossover, Single-Center Pilot Study to Evaluate the Addition of Raltegravir to Established Suppressive Antiretroviral Therapy While Monitoring Changes in Markers of Immune Activation Among HIV-1 Infected Individuals Without Adequate Immune Restoration||University of Miami|No|Active, not recruiting|November 2010|October 2015|Anticipated|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245101||112953|
NCT01274650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-040|Correlation Between Wound Volume and Depth of Decubitus Ulcers And Resting Energy Expenditure|Correlation Between Wound Volume and Depth of Decubitus Ulcers And Resting Energy Expenditure||Saint Elizabeth Regional Medical Center|No|Recruiting|September 2010|September 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|19 Years|N/A|No|||July 2011|July 19, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01274650||110687|
NCT01275222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001C2206|Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors|A Phase I-II, Open-label Study of RAD001 in Combination With Glivec®/Gleevec™ (Imatinib) in Patients With Glivec/Gleevec-refractory/Resistant Gastrointestinal Stromal Tumors.||Novartis||Completed|November 2002|September 2008|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||February 2013|February 9, 2013|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275222||110643|
NCT01275183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1012|Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck|A Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of the Head and Neck||New Mexico Cancer Care Alliance|Yes|Completed|December 2010|April 2015|Actual|April 2015|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01275183||110646|
NCT01275196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ECN02|Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients|ENESTChina: A Phase III Multi-center, Open-label, Randomized Study of Nilotinib Versus Imatinib in Chinese Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||Novartis||Completed|April 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|267|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|January 10, 2011|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT01275196||110645|
NCT01276002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKSH-122010|Evaluation of Pancreatic Duct Stenting in Patients With Pancreatic Pseudocysts.|Randomized Multicenter Study on Pancreatic Duct Stenting in Disrupted or Obstructed Ducts in Context With Endoscopic Treatment of Pancreatic Pseudocysts.|Disduct|University of Schleswig-Holstein|No|Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276002||110583|
NCT01268345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonMedical2|AST Clinical Investigation|||Andon Medical Co.,Ltd|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|63|||Both|21 Years|78 Years|Accepts Healthy Volunteers|||December 2010|December 29, 2010|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268345||111172|
NCT01275430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAS-3004|Assessment of the Precision of the Sherlock 3CG Tip Positioning System|A Study to Assess the Precision of the Sherlock 3CG Tip Positioning System as a Tool to Guide Peripherally Inserted Central Catheter Placement|STAT-PICC|C. R. Bard|No|Terminated|January 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|27|||Both|21 Years|N/A|No|||April 2012|April 20, 2012|January 11, 2011|Yes|Yes|Phase I completed. Phase II is being redesigned.|No||https://clinicaltrials.gov/show/NCT01275430||110627|
NCT01268917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fuwai Hospital 2010-259|The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass|||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|March 2010|||March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||March 2010|December 30, 2010|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268917||111128|
NCT01268930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hemostaticmatrix|Comparison of Hemostatic Matrix and Bipolar Coagulation in Surgical Treatment of Endometriomas|||Ankara University|Yes|Completed|September 2010|March 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|40 Years|No|||December 2010|June 21, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01268930||111127|
NCT01269177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPE.IT|Mortality and Risk Factors in Patients With Acute Cardiogenic Pulmonary Edema: a Multicentric, Observational, Prospective Study|Mortality and Risk Factors in Patients With Acute Cardiogenic Pulmonary Edema: a Multicentric, Observational, Prospective Study|ACPE|University of Milan||Recruiting|May 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to the Emergency Department with acute cardiogenic pulmonary edema|October 2010|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269177||111108|
NCT01269827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-1A-I-007|Pentoxifylline and Systemic Inflammation in Hemodialysis Patients|Randomized, Double-Blinded, Controlled Clinical Trial of the Effect Pentoxifylline vs Placebo on the Serum Concentrations of TNF-a, IL-6 and CRP of Patients in Hemodialysis||Coordinación de Investigación en Salud, Mexico|Yes|Completed|January 2006|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|No|||January 2011|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269827||111058|
NCT01269814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rockall-GIH|The Impact of Rockall Risk Scoring System on Management of Upper Gastrointestinal System Bleeding|The Impact of Rockall Risk Scoring System on Timing of Endoscopy, Length of Hospital Stay, Morbidity and Mortality in Patients With Upper Gastrointestinal System Bleeding||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|Yes|Recruiting|December 2010|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients older than 18 years with upper gastrointestinal hemorrhage.|October 2012|October 16, 2012|December 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01269814||111059|
NCT01275781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2690C00009|Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion|A Phase 1, Open-Label, Non-randomized, Single-Center Study to Assess Distribution, Metabolism and Excretion After [14C]-Labelled Intravenous Administration of AZD9742 as a 2-hour Infusion to Healthy Male Volunteers||AstraZeneca|No|Withdrawn|January 2011|February 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Male|55 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 28, 2013|January 11, 2011|No|Yes|Withdrawn due to the local Radiation Safety Committee refusing to approve it.|No||https://clinicaltrials.gov/show/NCT01275781||110600|
NCT01276054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-09-12|Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.|Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program||University of Southern California|Yes|Terminated|December 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|4|||Female|18 Years|N/A|No|||February 2014|July 1, 2014|January 11, 2011|Yes|Yes|P.I. left|No|July 1, 2014|https://clinicaltrials.gov/show/NCT01276054||110579|Study terminated early due to P.I. moving to another institution.
NCT01276704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12377|Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer|Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer||University of Kansas Medical Center|Yes|Recruiting|November 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|242|||Female|21 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01276704||110529|
NCT01276717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32833|Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma|Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas||University of Rochester|Yes|Completed|January 2011|January 2015|Actual|July 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276717||110528|
NCT01276457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIT02E1|Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients|An 18 Month Extension to the Multicenter, Randomized, Open-label Trial (NCT00170885) to Evaluate the Safety, Tolerability, and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de Novo Renal Transplant Recipients|EVEREST|Novartis||Completed|May 2006|February 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|65 Years|No|||May 2011|May 17, 2011|January 12, 2011||No||No|January 25, 2011|https://clinicaltrials.gov/show/NCT01276457||110548|
NCT01276678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1478|Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis|Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis (The MAGMA STUDY)|MAGMA|LifeBridge Health|No|Recruiting|June 2010|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1300|Samples With DNA|Biomarker Analysis by Multi-Analyte Profiling Genetic Testing-GWAS and CYP2C19 genotyping      Comprehensive Lipoprotein Cholesterol Profile Platelet aggregation and      Thrombelastography-Clot characteristics and antiplatelet response Urinary      11-dehydrothromboxane|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 1300 subject's ≥18 years undergoing coronary angiography (inpatient cohort)or        who have undergone coronary angiography within 5 years (outpatient cohort, not to exceed        50 subjects) will be enrolled. In addition, 300 healthy controls free from any        pharmacologic therapy will also be enrolled.|November 2013|November 5, 2013|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276678||110531|
NCT01244555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0085|Muscle Treatment for Management of Pain & Disability in Tension-type Headache|Muscle Treatment for Management of Pain & Disability in Tension-type Headache||University of Colorado, Denver|Yes|Completed|April 2010|December 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|69|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244555||112994|
NCT01244139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|215MS101|Safety Study of BIIB033 in Subjects With Multiple Sclerosis|A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis||Biogen|Yes|Completed|October 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|47|||Both|18 Years|60 Years|No|||November 2012|November 8, 2012|November 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01244139||113026|
NCT01244152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK074485-01A2|Self-Management in African Americans With Diabetes and Hypertension|Lifestyle Improvement Through Food and Exercise (LIFE): Self-Management in African Americans With Diabetes and Hypertension|LIFE|Rush University Medical Center|No|Completed|July 2008|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|59|||Both|18 Years|80 Years|No|||November 2010|November 18, 2010|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01244152||113025|
NCT01244165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WH-2004-01|Study of Cytrix Use in Pelvic Floor Prolapse Treatment|Clinical Investigation of Fetal Bovine Dermis Material (Cytrix) for Use in the Treatment of Pelvic Floor Prolapse||Boston Scientific Corporation|No|Completed|January 2002|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Female|30 Years|85 Years|Accepts Healthy Volunteers|||November 2010|November 18, 2010|November 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01244165||113024|
NCT01244490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-316|Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder||Shire|Yes|Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|338|||Both|6 Years|17 Years|No|||June 2014|February 4, 2015|November 16, 2010|Yes|Yes||No|May 9, 2014|https://clinicaltrials.gov/show/NCT01244490||112999|
NCT01244529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-201011|Comparison of Lens Fit and Lens Power of a New Contact Lens to Two Marketed Contact Lenses in a Population of Soft Contact Lens Wearers|||Johnson & Johnson Vision Care, Inc.|No|Completed|September 2010|||November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|41|||Both|18 Years|55 Years|No|||December 2015|December 21, 2015|November 17, 2010|Yes|Yes||No|December 19, 2011|https://clinicaltrials.gov/show/NCT01244529||112996|
NCT01244542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4706|Pain and Schizophrenia|Pain and Schizophrenia||University Hospital, Strasbourg, France|No|Recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|107|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Primary care and day clinic in Strasbourg, Erstein and Besançon          -  Healthy controls from or near Strasbourg, Erstein or Besançon.|June 2015|June 18, 2015|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01244542||112995|
NCT01245140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117221|Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis|Efficacy of Oral Alitretinoin Treatment in Patients With Palmo-plantar Pustulosis (PPP) Inadequately Responding to Standard Topical Treatment||GlaxoSmithKline|No|Completed|April 2011|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||September 2014|February 5, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01245140||112950|
NCT01244841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/807-4|Effects on Health Status in Patients Early Discharged After Primary Percutaneous Coronary Intervention (PCI)|The Effect on 30 Day Health Status After Early Discharge in Patient With ST Elevation Myocardial Infarction Treated With Primary PCI|INUT|Helse Stavanger HF|No|Completed|September 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|N/A|N/A|No|||May 2013|May 7, 2013|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01244841||112972|
NCT01274936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Qishe|Qishe Pill for Cervical Radiculopathy|Effectiveness of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy: a Randomized, Double-blind, Placebo-controlled, Multicentre Trial||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|March 2012|June 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||November 2014|November 11, 2014|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01274936||110665|
NCT01268358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-02|Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis|A Single Center, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.||Zymenex A/S|Yes|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|10|||Both|5 Years|20 Years|No|||May 2011|May 6, 2011|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01268358||111171|
NCT01268371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BESS|Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents|Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents|BESS|Ajou University School of Medicine|Yes|Active, not recruiting|December 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1462|||Both|20 Years|N/A|No|||February 2014|February 11, 2014|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268371||111170|
NCT01276275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130N00010|Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel|A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in National Swedish Registries||AstraZeneca|No|Completed|January 2014|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|7200|||Both|N/A|N/A|No|Non-Probability Sample|All patients aged 20 to 84 years before their first study drug dispension (start date)        will be included in the study. The study period will start the first month after        ticagrelor market introduction in Sweden (the first of June 2011),|April 2015|April 23, 2015|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276275||110562|
NCT01276288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.42|Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes|Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between 25 mg BI 10773 and 25 mg Hydrochlorothiazide or 5 mg Torasemide Under Steady State Conditions in Patients With Type 2 Diabetes Mellitus in an Open-label, Randomised, Cross-over Trial||Boehringer Ingelheim||Completed|January 2011|||June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|23|||Both|20 Years|65 Years|No|||August 2014|August 5, 2014|January 12, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01276288||110561|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information"
NCT01276301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.43|DDI Between BI Empagliflozin (10773) and Verapamil|Relative Bioavailability of BI 10773 Given Alone and Together With Verapamil - an Open-label, Randomised, Crossover Trial in Healthy Subjects||Boehringer Ingelheim||Completed|January 2011|||February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|January 12, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01276301||110560|
NCT01268943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-013|Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients|Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer||Chinese Academy of Medical Sciences|No|Completed|November 2010|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|71 Years|N/A|No|||March 2015|March 17, 2015|December 28, 2010||No||No|March 5, 2015|https://clinicaltrials.gov/show/NCT01268943||111126|
NCT01268956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101231001|Circulating Lymphatic Progenitor Cell and Lymph Node Metastasis|Correlation of Circulating Lymphatic Progenitor Cells With Lymph Node Metastasis in Ovarian Cancer Patients||Hospital Universitari de Bellvitge|No|Not yet recruiting|January 2011|September 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|blood serum|Female|15 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|ovarian cancer patients|December 2010|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01268956||111125|
NCT01269190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0613|Proflavine: A Feasibility Study for In Vivo Imaging of Oral Neoplasia|Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study||M.D. Anderson Cancer Center|No|Recruiting|December 2010|||December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|155|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|December 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01269190||111107|
NCT01269203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0457|Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients|A Phase II Randomized Study of the Efficacy of Curcumin for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients||M.D. Anderson Cancer Center|Yes|Withdrawn|October 2012|||October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|December 30, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01269203||111106|
NCT01275001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHBG-1360-MRI|Effects of Music Intervention on the Brain Development of Preschool Children|Effects of Music Intervention on the Brain Development of Preschool Children||Avera McKennan Hospital & University Health Center|Yes|Completed|December 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|34|||Both|3 Years|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in this research project will be involved with a different research project        (Avera Family Wellness Program) investigating the effects of a family-based wellness        approach to addressing emotional-behavioral needs of preschool-age children and their        families. The Avera Family Wellness Program (AFWP) consists of a group of children who        receive the family-based intervention and a group of control preschool-age children.|January 2011|October 4, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275001||110660|
NCT01270087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REUMAUMAS 2005-1|The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.|The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.||Skåne University Hospital|Yes|Completed|May 2005|February 2007|Actual|February 2007|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||January 2007|January 4, 2011|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270087||111038|
NCT01276067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10940307|Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions|A Study to Evaluate the Relative Bioavailability of Donepezil Hydrochloride 10 mg Tablets (OHM Laboratories, Inc., USA) Compared to ARICEPT® (Donepezil Hydrochloride) 10 mg Tablets (Eisai Inc.) in Healthy Volunteers Under Fasted Conditions.||Ranbaxy Inc.|No|Completed|October 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|July 19, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276067||110578|
NCT01276418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-SBUSUR-ACF-09-01|ENT FiberLase CO2 Study|ENT FiberLase CO2 Study||Lumenis Ltd.||Active, not recruiting|October 2010|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2012|January 15, 2012|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01276418||110551|
NCT01276431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP4504|Norspan Efficacy and Safety Among Elderly Subjects|||Mundipharma AB||Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|50 Years|75 Years|No|||February 2014|February 5, 2014|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01276431||110550|
NCT01276470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110072|Environmental Risk Factors for the Anti-synthetase Syndrome|Environmental Risk Factors for the Anti-Synthetase Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|||||N/A|Observational|N/A|||Anticipated|450|||Both|2 Years|120 Years|Accepts Healthy Volunteers|||November 2015|March 1, 2016|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276470||110547|
NCT01276483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-2010/2089|Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients|Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI||Oslo University Hospital|No|Recruiting|February 2011|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|GIST patients suitable for medical treatment with targeted therapies.|January 2016|January 22, 2016|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276483||110546|
NCT01276964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEVA-1/2007|Protocol for the Determination of Menstrual Losses in Healthy Women With Apparently Normal Cycles|Protocol for the Determination of Menstrual Losses Using a System for the Quantitative Determination of Menses (Quantitative Evaluation of Menses [QUEM] Method) and Its Application to Healthy Women With Apparently Normal Cycles|MEVA-1|University of L'Aquila|Yes|Recruiting|September 2007|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Soiled oads and tampons, vacuum sealed are retained till their evaluation, they will be      appropiately discharged after their analysis|Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|women in the fertile age with apparently normal cycles|July 2012|July 13, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276964||110509|
NCT01245465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-FSP-20|Profermin® in Active Ulcerative Colitis|Safety and Efficacy of Profermin® to Induce Remission in Patients With Ulcerative Colitis|CUPE-1|Nordisk Rebalance A/S|No|Completed|January 2009|November 2009|Actual|November 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|50 Years|No|||November 2010|November 22, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01245465||112927|
NCT01245803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6998|Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS|Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome|AVATAR|Beijing Anzhen Hospital||Recruiting|April 2010|May 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|75 Years|No|||July 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245803||112901|
NCT01245816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP FAP-301|A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)|A Randomized Phase III Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)||Cancer Prevention Pharmaceuticals, Inc.|Yes|Withdrawn|March 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||April 2015|April 23, 2015|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01245816||112900|
NCT01244178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003-GEN|Hyperinsulinemic Therapy in Sepsis|Hyperinsulinemic Therapy in Sepsis||McGill University Health Center|No|Active, not recruiting|November 2010|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244178||113023|
NCT01244191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-A-U302|ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)||Daiichi Sankyo Inc.|Yes|Active, not recruiting|November 2010|November 2015|Anticipated|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|988|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|November 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01244191||113022|
NCT01245153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHAB_201011|Rectal Balloon Training in Female Urinary Incontinence|Phase 2B Study of Rectal Ballooning Training in Female Urinary Incontinence||Chulalongkorn University|Yes|Completed|November 2010|October 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|25 Years|70 Years|No|||January 2016|January 31, 2016|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01245153||112949|
NCT01245452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1200/002|Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate|Comparative Study of the Clinical Response and Cardiorespiratory Endurance in Early Rheumatoid Arthritis Patients Treated With Tocilizumab or Methotrexate Addendum Protocol : Global Gene Expression Profiles in Synovial Biopsies|TOMERA|Université Catholique de Louvain|No|Completed|May 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|No|||October 2013|October 30, 2013|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245452||112928|
NCT01275443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 040|Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.|A Pharmacokinetic Evaluation of the Exposure and Distribution of TMC278LA for Use as Pre-exposure Prophylaxis, in Plasma and Genital Tract / Rectal Compartments, Following a Single Intramuscular Dose at Different Doses in HIV-negative Healthy Volunteers.||St Stephens Aids Trust|No|Completed|January 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 3, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275443||110626|
NCT01275456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/01 Valex1|Validation of an Environmental Exposure Chamber for Inhalation Studies With House Dust Mite Allergen in Patients With Allergic Rhinitis|Validation of an Environmental Exposure Chamber for Inhalation Studies With House Dust Mite Allergen in Patients With Allergic Rhinitis||Fraunhofer-Institute of Toxicology and Experimental Medicine|Yes|Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|18|||Both|18 Years|55 Years|No|||July 2011|July 4, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275456||110625|
NCT01275716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-623-A|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications. Is a Picture Really Worth a Thousand Words?|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications. Is a Picture Really Worth a Thousand Words?||University of Chicago|No|Recruiting|December 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275716||110605|
NCT01268384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APBCC_01|Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer|Phase II Study of Fixed Dose Rate Gemcitabine Plus Capecitabine in Locally Advanced Pancreatic Cancer||Asan Medical Center|No|Completed|April 2006|August 2011|Actual|July 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268384||111169|
NCT01276314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-1413A3|Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions|Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR)||Chang Gung Memorial Hospital|Yes|Recruiting|January 2009|December 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|N/A|No|||July 2009|January 11, 2011|July 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01276314||110559|
NCT01269216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0361|A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer|A Randomized Phase II Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer||Yonsei University|Yes|Completed|October 2008|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269216||111105|
NCT01274494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CME-ATA-2010/1|COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication|COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication||AstraZeneca|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1501|||Both|21 Years|N/A|No|Non-Probability Sample|multi-centre survey of patients|September 2013|September 10, 2013|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274494||110699|
NCT01269567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/24|Drainage After Rectal Excision for Rectal Cancer|Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer|GRECCAR 5|University Hospital, Bordeaux|Yes|Completed|January 2011|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|494|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01269567||111078|
NCT01275287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2218|Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab|Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis||University of North Carolina, Chapel Hill|No|Withdrawn|May 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|December 13, 2010|Yes|Yes|the study failed to enroll any patient and sponsor wished to stop.|No||https://clinicaltrials.gov/show/NCT01275287||110638|
NCT01276080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10940308|Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions|A Study to Evaluate A Study to Evaluate the Relative Bioavailability of Donepezil Hydrochloride 10 mg Tablets (OHM Laboratories, Inc., USA) Compared to ARICEPT® (Donepezil Hydrochloride)10 mg Tablets (Eisai Inc.) in Healthy Volunteers Under Non-Fasted Conditions||Ranbaxy Inc.|No|Completed|October 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|July 8, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276080||110577|
NCT01276444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCVO2-2008|Comparison of Goal-directed Algorithms of Hemodynamic Therapy After Combined Valve Repair|Comparison of Goal-directed Algorithms of Hemodynamic Therapy After Combined Valve Repair: a Randomized Clinical Trial||Northern State Medical University|No|Completed|January 2008|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|43|||Both|18 Years|N/A|No|||January 2011|January 12, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01276444||110549|
NCT01276977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRUSZOLM0028|Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine|Zolmitriptan Nasal Spray VS Eletriptan in the Acute Treatment of Migraine||California Medical Clinic for Headache|No|Completed|April 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|15 Years|70 Years|No|||January 2011|January 13, 2011|January 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276977||110508|
NCT01245231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B6|Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia|Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML-II||Children's Oncology Group|No|Active, not recruiting|November 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Both|N/A|30 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia (AML)|May 2015|May 5, 2015|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245231||112945|
NCT01244854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 10-226|Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness|Life Goals Behavioral Change to Improve Outcomes for Veterans With SMI||VA Office of Research and Development|No|Completed|October 2010|March 2015|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|55|||Both|18 Years|N/A|No|||May 2014|April 6, 2015|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01244854||112971|
NCT01246024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THS0001|Influence of Hypoxia on Electroretingraphy (ERG) Measurements|||University Hospital Tuebingen|No|Not yet recruiting|February 2011|April 2013|Anticipated|April 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246024||112884|
NCT01246362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACL-3|Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty|A Randomized Controlled Trial to Study the Efficacy of Pre-emptive Etoricoxib in Reducing Postoperative Pain and Improving Functional Outcome in Total Knee Arthroplasty||Singapore General Hospital|No|Completed|July 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|50 Years|80 Years|No|||August 2014|August 3, 2014|November 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01246362||112858|
NCT01246700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225510|Sensory Attention Focused Exercise in Parkinson's Disease|Sensory Attention Focused Exercise in Parkinson's Disease: A Randomized Double-Crossover Trial.||Sun Life Financial Movement Disorders Research and Rehabilitation Centre|No|Active, not recruiting|June 2008|December 2010|Anticipated|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|N/A|N/A|No|||September 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246700||112832|
NCT01267838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBK2 study|Randomised Comparison of T-stenting Versus Culotte Technique for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents|Randomised Comparison of T-stenting Versus Culotte Technique for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents.|BBK2|Heart Center Bad Krozingen|No|Recruiting|February 2010|June 2012|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2010|December 28, 2010|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01267838||111211|
NCT01275729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-503-B|The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury|The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury||University of Chicago|No|Recruiting|December 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275729||110604|
NCT01268670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005-052|The Addition of Oral Analgesics to LET During Laceration Repair|Adjunctive Oral Analgesia for Laceration Repair: Assessing Pain in a Pediatric Emergency Department||Children's Hospitals and Clinics of Minnesota||Suspended|July 2012|||July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|4 Years|10 Years|No|||July 2013|July 30, 2013|December 29, 2010|No|Yes|This study is currently suspended due to transition of the investigator.|No||https://clinicaltrials.gov/show/NCT01268670||111147|
NCT01268644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBA937|Effects of Metreleptin in Type 1 Diabetes Mellitus|Open Label Single Center Pilot Study to Study Teh Effects of Metreleptin Administration in Patients With Type 1 Diabetes Mellitus ( T1DM ).||University of Texas Southwestern Medical Center|Yes|Terminated|September 2010|August 2014|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|50 Years|No|||June 2015|June 22, 2015|December 29, 2010|No|Yes|Sponsor request|No||https://clinicaltrials.gov/show/NCT01268644||111149|
NCT01268904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0098-10-HYMC|Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures|||Hillel Yaffe Medical Center||Not yet recruiting|January 2011|August 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|6 Months|18 Years|No|Probability Sample|Pediatric inpatients and emergency patients|December 2010|December 30, 2010|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01268904||111129|
NCT01274507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017362|A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease|A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease||Janssen Research & Development, LLC|No|Completed|July 2010|July 2014|Actual|July 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|328|||Both|18 Years|70 Years|No|||September 2014|September 25, 2014|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01274507||110698|
NCT01274741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLA-CX000308-01 (VA CSRD)|Study of Treatment for Posttraumatic Stress Disorder and Substance Use|Pilot Study of an Integrated Exposure-Based Model for Posttraumatic Stress Disorder and Substance Use Disorder||VA Boston Healthcare System|Yes|Recruiting|January 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 24, 2013|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274741||110680|
NCT01275495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003-63|Telephone Assessment and Skill-Building Intervention for Stroke Caregivers|Telephone Assessment and Skill-Building Intervention for Stroke Caregivers|TASKII|Indiana University|No|Completed|May 2010|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|254|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275495||110622|
NCT01275508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FITC-ADA 01-2010|Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut|Prospective, Monocentric, Open-label, Clinical Phase 1 Study to Demonstrate the Safety and Tolerability of FITC-Adalimumab After Single Topical Administration to the Intestinal Mucosa During Endomicroscopy in Patients With Crohn's Disease|FA-Crohn|University of Erlangen-Nürnberg Medical School|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|70 Years|No|||September 2012|September 13, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01275508||110621|
NCT01275794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-ONG-2010/1|Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage|Screening Epidemiological Program on Compensation Evaluation of DM Type 2 Patients on OAD Monotherapy and Physicians Satisfaction of Their Usage||AstraZeneca|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1849|||Both|35 Years|N/A|No|Non-Probability Sample|Clinical practice|June 2012|June 1, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275794||110599|
NCT01275807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGR-2025/2008-Lesi|Effectiveness and Safety of Acupuncture for Climacteric Syndrome in Patients With Breast Cancer|Acupuncture as an Integrated Intervention for the Control of Symptoms of Climacteric Syndrome in Patients Affected by Breast Cancer|AcCliMaT|Azienda Usl di Bologna|No|Completed|March 2010|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Female|18 Years|65 Years|No|||September 2015|September 21, 2015|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01275807||110598|
NCT01275820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1330-Nutralin|A Study to Evaluate Glucose and Insulin Response to Nutralin|A Study to Evaluate Glucose and Insulin Response to Nutralin||Avera McKennan Hospital & University Health Center|Yes|Completed|June 2010|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals in and around the area of Sioux Falls, SD|January 2011|January 11, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275820||110597|
NCT01275846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA100602|Deployment of American Heart Association Heart Failure Protocols and Content Within the Intel® Health Guide System|Study for Deployment of American Heart Association Heart Failure Protocols and Educational Content Within the Intel® Health Guide System With a Congestive Heart Failure Cohort||American Heart Association|No|Active, not recruiting|June 2010|March 2011|Anticipated|January 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|26|||Both|N/A|N/A|No|||January 2011|January 12, 2011|January 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01275846||110595|
NCT01276093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-10-023-ND-AB|Pulmonary Vein Ablation Versus Amiodarone in the Elderly|Pulmonary Vein Ablation Versus Amiodarone in the Elderly|PAVANE|St. Jude Medical|Yes|Terminated|July 2011|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|65 Years|N/A|No|||December 2015|December 28, 2015|January 11, 2011||No|DSMB recommendation; enrollment too slow|No||https://clinicaltrials.gov/show/NCT01276093||110576|
NCT01276106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-201-DM-001|Study of AC-201 in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of AC-201 in Patients With Type 2 Diabetes Mellitus||TWi Biotechnology, Inc.|No|Completed|January 2011|March 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|259|||Both|20 Years|75 Years|No|||November 2014|November 17, 2014|January 11, 2011|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01276106||110575|
NCT01276119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0001|The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, Single-dose, Dose-escalating Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CDP6038 in Healthy Male Subjects||UCB Pharma|No|Completed|September 2008|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|14||Actual|67|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 21, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276119||110574|
NCT01276730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|464.05|Advanced Cervical Cancer Trial in India|A Pilot Phase II Two-Arm, Randomized Clinical Trial of Concomitant Immunotherapy (With Interferon-Alpha and Retinoic Acid) and Radiation Therapy for the Treatment of Advanced Cervical Cancer in India||James Graham Brown Cancer Center|Yes|Active, not recruiting|October 2007|||September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||April 2014|April 23, 2014|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01276730||110527|
NCT01277029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099022-E|Study of Psychiatric Aspects in Women With Lower Urinary Tract Symptoms|||Far Eastern Memorial Hospital||Recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|20 Years|99 Years|No|Probability Sample|Patients with low urinary tract symptoms|February 2016|February 22, 2016|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277029||110504|
NCT01277042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114590|Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)|Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects||GlaxoSmithKline||Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1212|||Female|26 Years|45 Years|Accepts Healthy Volunteers|||September 2013|October 4, 2013|January 13, 2011|Yes|Yes||No|September 6, 2012|https://clinicaltrials.gov/show/NCT01277042||110503|
NCT01276990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1277.2|Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.|Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 ZW (Powder in Bottle Formulation) at 12.5 mg q24h, 12.5 mg q12h, 12.5 mg q8h, 25 mg q12h, 25 mg q8h, 50 mg q12h, 37.5 mg q8h and 50 mg q8h Dose Levels for 10 Days in Healthy Male Volunteers (Randomized, Double-blind Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Withdrawn|January 2011|||September 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|9||Actual|0|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|January 13, 2011||||No||https://clinicaltrials.gov/show/NCT01276990||110507|
NCT01277003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0994266G|To Investigate the Therapeutic Effect of Aculife Magnetic Therapist on Carpal Tunnel Syndrome|To Investigate the Therapeutic Effect of Aculife Magnetic Therapist on Carpal Tunnel Syndrome||China Medical University Hospital|Yes|Recruiting|December 2010|||February 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||November 2010|January 18, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277003||110506|
NCT01277016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMN-03|A Trial for Systemic Light-chain (AL) Amyloidosis|A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis|EMN-03|European Myeloma Network|Yes|Recruiting|January 2011|August 2016|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01277016||110505|
NCT01245842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100286_1|The Hand Osteoarthritis Exercise Trial|Osteoarthritis Care in Primary Health: Hand Exercises and Telephone Counselling for Hand OA - a Randomized Controlled Trial||Diakonhjemmet Hospital||Completed|January 2011|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|130|||Both|40 Years|85 Years|No|||October 2013|October 27, 2013|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245842||112898|
NCT01246076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011810|Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents|Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents||Washington University School of Medicine|No|Completed|June 2011|August 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|November 15, 2010|Yes|Yes||No|August 26, 2015|https://clinicaltrials.gov/show/NCT01246076||112880|
NCT01246037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-262|Beta-blockers in i-PAH|Beta-blocker Therapy in Idiopathic Pulmonary Arterial Hypertension||VU University Medical Center|Yes|Active, not recruiting|February 2011|April 2014|Anticipated|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01246037||112883|
NCT01245829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cellomed001|A Randomized Trial Comparing Matt and Antimicrobial Cellomed Laminates|Bacterial Contamination of Critical Care Observation Charts: a Randomized Trial Comparing Matt and Antimicrobial Cellomed Laminates.||County Durham and Darlington NHS Foundation Trust|No|Not yet recruiting|February 2011|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|16 Years|N/A|No|||November 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245829||112899|
NCT01246050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 09-170|Developing a "Hub and Satellite" Heart Failure Provider's Network: A New Model of Community Based Outpatient Clinic (CBOC) Providers Study|Developing a Hub and Satellite Heart Failure Providers Network||VA Office of Research and Development|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||May 2011|February 6, 2014|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01246050||112882|
NCT01246063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102043|Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma||Washington University School of Medicine|Yes|Recruiting|May 2012|November 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|53|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|November 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246063||112881|
NCT01267851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM2010-06-02|Clinical Database and Biobank of Patients With Gynecologic Neoplasms|A Large Multicentre Clinical Database and Biobank of Patients With Gynecologic Neoplasms||Huazhong University of Science and Technology|Yes|Recruiting|January 1999|||||N/A|Observational|N/A||1|||||Female|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|gynecologic diseases, such as cervical cancer, ovarian cancer, endometrial cancer,        choriocarcinoma, uterine myoma, endometriosis, as well as part of population-based healthy        women|December 2010|February 14, 2011|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01267851||111210|
NCT01267864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine4|A Randomized Trial of Valproate Versus Ketorolac Versus Metoclopramide for Acute Migraine|IV Valproate for Acute Migraine. A Randomized Comparison Versus IV Metoclopramide and IV Ketorolac||Montefiore Medical Center|Yes|Recruiting|November 2010|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|21 Years|64 Years|No|||October 2012|October 27, 2012|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01267864||111209|
NCT01268111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTUHSC-VitD-RBP4|Effect of Vitamin D Replacement on Insulin Sensitivity|Effect of Vitamin D Supplementation on Insulin Sensitivity and Retinol-binding Protein 4 Levels in Subjects With Vitamin D Deficiency||Texas Tech University Health Sciences Center|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|December 28, 2010|No|Yes||No|January 4, 2013|https://clinicaltrials.gov/show/NCT01268111||111190|
NCT01268124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3253A1-1001-JA|Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HTC-867 Administered Orally to Healthy Japanese Male Subjects||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|56|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2010|December 28, 2010|January 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01268124||111189|
NCT01268683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPI 201|Glyburide Advantage in Malignant Edema and Stroke Pilot|A Multi-center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.|GAMES-PILOT|Remedy Pharmaceuticals, Inc.|Yes|Completed|May 2011|February 2013|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||May 2014|May 14, 2014|December 29, 2010|Yes|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT01268683||111146|The trial was a single arm; there is thus no placebo to compare RP-1127 to.
NCT01268657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23 MH 09244|Intervention for Anxiety After Falls|Intervention for Disabling Anxiety in Older Adults Injured by Falls||Weill Medical College of Cornell University|Yes|Active, not recruiting|January 2011|July 2016|Anticipated|October 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|65 Years|N/A|No|||June 2015|June 1, 2015|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268657||111148|
NCT01275014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCG_KCHIR_01|Corticosteroids as Additive in Temporomandibular Joint (TMJ) Arthrocentesis|Corticosteroids as Additive in Arthrocentesis of the Temporomandibular Joint: Double Blind, Randomised Controlled Trial of Effectiveness.||University Medical Center Groningen|Yes|Active, not recruiting|December 2008|December 2010|Anticipated|December 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||November 2010|January 11, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01275014||110659|
NCT01275521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/39|A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy|Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.|PROTOX|University Hospital, Bordeaux|No|Active, not recruiting|January 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Male|50 Years|85 Years|No|||May 2014|May 7, 2014|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275521||110620|
NCT01275833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESTORE AV|Restoration of Atrioventricular Synchrony Trial|Restoration of Atrioventricular Synchrony Trial|RESTORE-AV|Boston Scientific Corporation|No|Terminated|July 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|2|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|January 2, 2011|Yes|Yes|Difficult subject recruitment|No||https://clinicaltrials.gov/show/NCT01275833||110596|
NCT01275534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 264-10|Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation|Patient Reported Outcomes in View of Symptom Experience of Late Effects and Self-management After Haematopoietic Stem Cell Transplantation - A Mixed Methods Study|PROVIVO|University Hospital, Basel, Switzerland|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|375|||Both|18 Years|N/A|No|Non-Probability Sample|Long-term survivors after allogeneic stem cell transplantation|January 2013|January 16, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01275534||110619|
NCT01276496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00619|Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery|A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies||National Cancer Institute (NCI)||Completed|December 2010|||March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2015|March 14, 2016|January 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01276496||110545|
NCT01277354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810277|Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication|Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication||University of Pennsylvania|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Female|18 Years|49 Years|No|||December 2011|December 9, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01277354||110479|
NCT01277601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0149|Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (PEG) Versus TDF or PEG Monotherapy in Chronic Hepatitis B|A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)||Gilead Sciences|No|Completed|April 2011|July 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|751|||Both|18 Years|75 Years|No|||September 2015|September 9, 2015|January 13, 2011|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT01277601||110460|There were no limitations affecting the analysis or results.
NCT01277341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00082|Safety and Efficacy of Bepotastine in the Treatment of Seasonal Allergic Rhinitis|||Bausch & Lomb Incorporated|Yes|Completed|December 2010|May 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|600|||Both|12 Years|N/A|No|||December 2013|December 4, 2013|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277341||110480|
NCT01277588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAS2010/003|Evaluation of the Physicians and Patients Experience of Fetal Scalp Sampling|||Uppsala University Hospital|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|51|||Female|18 Years|N/A|No|Non-Probability Sample|Women who are subjected to fetal scalp sampling during labor Physicians performning fetal        scalp sampling|January 2012|January 16, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277588||110461|
NCT01245855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGEACS|Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention|Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention|PGEACS|First Affiliated Hospital, Sun Yat-Sen University|Yes|Not yet recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||October 2010|November 22, 2010|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01245855||112897|
NCT01245478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000105|DePuy Revision TKA Implant 5yr Survivorship|Clinical Outcome and 5-year Implant Survival Rate Among Adult Revision Total Knee Arthroplasty Patients With DePuy Implant Components||The New England Baptist Hospital|No|Withdrawn|November 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Any NEBH patients who received DePuy implant components during a Revision TKA procedure,        performed by either:          -  Dr. Geoffrey Van Flandern          -  Dr. David Mattingly          -  Dr. James Nairus          -  Dr. James Bono          -  Dr. Daniel Ward          -  Dr. Carl Talmo|April 2013|April 30, 2013|November 19, 2010||No|Retrospective record review only (no subject enrollment). Contract never executed between    Sponsor and Site.|No||https://clinicaltrials.gov/show/NCT01245478||112926|
NCT01245491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-2010/2021b|The Effects of Vibration on Hypoxia|The Effects of Vibration on Hypoxia||Institute of Aviation Medicine, Oslo, Norway|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|13|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|January 13, 2011|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01245491||112925|
NCT01246401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007007169|Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations|Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations|NewHope|Yale University|Yes|Active, not recruiting|March 2011|August 2016|Anticipated|February 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 7, 2016|November 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246401||112855|
NCT01246726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON/2009/3235|Multiple Oncological Serial Scans Study|The Tumour Bed as Target for Breast Irradiation Following Breast Conserving Surgery|MOSS|University Hospitals Bristol NHS Foundation Trust|No|Recruiting|November 2010|May 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Female|18 Years|80 Years|No|||October 2010|February 3, 2012|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01246726||112830|
NCT01268150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-206|A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer|A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer||Eisai Inc.||Completed|February 2011|August 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Female|18 Years|N/A|No|||April 2015|April 22, 2015|December 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01268150||111187|
NCT01268397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wilcke-02|Unstable Dorsally Displaced Fractures of the Distal Radius in the Elderly|Unstable Dorsally Displaced Fractures of the Distal Radius in the Elderly. A Randomized Comparison Between Operative Fixation and Plaster Cast Treatment.||Danderyd Hospital|No|Recruiting|December 2009|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|75 Years|N/A|No|||March 2016|March 8, 2016|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268397||111168|
NCT01268137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP-012004|DBS in Treatment Resistant Major Depression|DEEP BRAIN STIMULATION IN TREATMENT RESISTANT MAJOR DEPRESSION. Controlled and Crossed Study on Efficacy and Safety.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Active, not recruiting|January 2008|June 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|No|||December 2010|December 28, 2010|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01268137||111188|
NCT01274520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD6236|Hypothermic Machine Preservation-Phase 2|Hypothermic Machine Preservation of Extended Criteria Liver Allografts for Transplantation|HMP2|Columbia University|Yes|Completed|December 2009|July 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|90 Years|No|||July 2014|July 22, 2014|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274520||110697|
NCT01268969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMRO-1234|Comparison Between Two Different Technique in Treatment of Chronic Pilonidal Disease|A Prospective Randomized Trial-comparing Excision and Limberg Flap Closure Versus Karydakis Flap Reconstruction for Treatment of Sacrococcygeal Pilonidal Disease|PND|Mansoura University|Yes|Completed|February 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||February 2008|January 3, 2011|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268969||111124|
NCT01274780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATADAR|Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients|||Hospital Clinic of Barcelona|No|Completed|May 2011|January 2014|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274780||110677|
NCT01275300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806115 - FitzGerald, MD|Biosynthesis of PGD2 in Vivo|A Pilot Study to Measure Plasma and Urinary Prostaglandin D2 Metabolites Evoked by Niacin|Niacin|University of Pennsylvania|Yes|Completed|July 2007|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|May 14, 2013|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01275300||110637|
NCT01275040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-UP-61B/2010|The Efficacy of Specialist Collaboration and Mobile Screening for Improving the Management of Diabetes|The Efficacy of Primary and Tertiary Specialist Care Collaboration and Mobile Complications Screening for Improving the Management of Diabetes at Primary Health Care Level in Tshwane District - A Cluster Randomized Trial|CCMSD|University of Pretoria|Yes|Enrolling by invitation|June 2010|May 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01275040||110657|
NCT01275313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09120362|Trial on Wheeled Mobility for Preventing Pressure Ulcers|RCT on Wheeled Mobility for Preventing Pressure Ulcers|RCT-WC2|University of Pittsburgh|Yes|Completed|April 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|256|||Both|60 Years|N/A|No|||January 2016|January 25, 2016|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275313||110636|
NCT01276132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-291-A|Patient Satisfaction and Safety Outcomes After Enrollment in a Same-Day (SD) Percutaneous Coronary Intervention Program|Patient Satisfaction and Safety Outcomes After Enrollment in a Same-Day (SD) Percutaneous Coronary Intervention Program||University of Chicago|No|Recruiting|June 2010|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Every patient who presents to the Cardiac Catheterization Laboratory for coronary        angiography will be given the opportunity to participate in this program. The        determination on whether or not a patient is selected to undergo Same-Day PCI is based on        the clinical decision of the practicing physician according to conventionally accepted        inclusion and exclusion criteria. The decision on whether or not to participate in the        questionnaire study will not affect any treatment decisions. The only exclusion criteria        will be if the patient declines participation. The investigators would like to enroll 250        patients over a three year period.|December 2015|December 18, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01276132||110573|
NCT01277055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCB10071|MRI Perfusion Imaging at 3Tx Compared to Invasive FFR Measurements|MRI Perfusion Imaging at 3T With TX Parallel RF Technology to Identify Myocardial Ischemia Compared to Invasive FFR Measurements|Vision MRT|Heart Center Bogenhausen|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|90 Years|No|Non-Probability Sample|patients with intermediate lesion who underwent cardiac catheterization inluding        measurement of the myocardial fractional flow reserve|January 2011|January 13, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277055||110502|
NCT01277367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811570|Vitality Health Incentives for Physical Activity|A Prospective, Randomized Clinical Trial Comparing the Effectiveness of Different Types of Incentives in Increasing Physical Activity Behavior on the Vitality Health Promotion Programme||University of Pennsylvania|No|Active, not recruiting|May 2010|June 2012|Anticipated|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|9000|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277367||110478|
NCT01277614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMS-STA-08-01|Therapeutic Lifestyle Modifications to Reduce Burden of Chronic Disease|A Randomized Control Trial for the Implementation of Lifestyle Modifications to Reduce the Burden of Chronic Disease Among University Staff||The University of The West Indies|Yes|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|65 Years|No|||January 2011|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277614||110459|
NCT01277887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT009241|Smoking Cessation for Smokers With Sleep Problems|Smoking Cessation for Smokers With Sleep Problems||Yale University|Yes|Completed|December 2010|March 2012|Actual|March 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||June 2014|June 12, 2014|January 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277887||110438|
NCT01245868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRS-AN2009-03-09|Spinal Anaesthesia for Knee Arthroscopy: Does Lignocaine Shorten the Effect of Bupivacaine|Spinal Anaesthesia for Knee Arthroscopy: Does Lignocaine Shorten the Effect of Bupivacaine?||Frederikssunds Hospital, Denmark|Yes|Completed|November 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||May 2015|May 7, 2015|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01245868||112896|
NCT01246128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911463|Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics|PET Assay of Acetylcholine Beta2* Nicotinic Receptor Density in Smoking and Non-Smoking Schizophrenics||National Institutes of Health Clinical Center (CC)||Withdrawn|October 2010|July 2011||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|December 30, 2011|November 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01246128||112876|
NCT01246089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-09-2010-AR|Ranibizumab for Myopic Neovascularization|Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization||Instituto de Olhos de Goiania|Yes|Active, not recruiting|July 2009|November 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 31, 2013|November 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01246089||112879|
NCT01246414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 001/10|Inflammatory Markers in Exhaled Breath Condensates From Asthmatic Patients|Inflammatory Markers in Exhaled Breath Condensates From Asthmatic Patients||Chulalongkorn University|No|Completed|January 2010|May 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|38|Samples Without DNA|Exhaled breathe condensates|Both|15 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Asthmatic patients in Allergy clinic, King Chulalongkorn Memorial Hospital (10 allergic        and 10 non-allergic) and 10 non-asthmatic controls will be enrolled to this study to        collect exhaled breathe condensates (EBC) and measure levels of inflammatory cytokines in        EBC|November 2010|November 22, 2010|January 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01246414||112854|
NCT01246427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBC|Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer|Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy|HBC|Centre Leon Berard|No|Completed|January 2010|November 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Female|18 Years|90 Years|No|||March 2015|March 10, 2015|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01246427||112853|
NCT01246739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/297|Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome|Adrenalectomy Versus Follow-up in Patients With Mild Hypercortisolism: a Prospective Randomized Controlled Trial|AUSC|Region Skane|No|Recruiting|June 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01246739||112829|
NCT01246752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-ETAL-1-045|Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR|Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)|AML|University Hospital Carl Gustav Carus|Yes|Recruiting|November 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|356|||Both|18 Years|60 Years|No|||December 2014|December 2, 2014|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246752||112828|
NCT01268163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOE061|The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer|A Phase 1, Double-blinded, Randomised, Multi-centre, Three-period, Three-treatment, Crossover Study to Compare the Intravenous Pharmacokinetic and Safety Characteristics of European Taxotere® and American Taxotere® With Hospira Docetaxel Injection Administered at a Therapeutic Dose in Cancer Patients.||Hospira, Inc.|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|October 8, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01268163||111186|
NCT01268410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL2010/51|Epidemiology of Respiratory Insufficiency in Critical Care|Epidemiological Study of Patients With Acute Respiratory Failure Admitted to Brazilian Intensive Care Units|ERICC|Hospital Sirio-Libanes|Yes|Completed|June 2011|November 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|773|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to intensive care units in Brazil with acute respiratory failure|September 2012|September 19, 2012|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268410||111167|
NCT01268423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONIS SA10I20012|Early Percutaneous Tracheostomy and Swallowing Dysfunction|Impact of Early Percutaneous Tracheostomy on the Incidence of Swallowing Dysfunction in Critically Ill Patients on Mechanical Ventilation. A Randomized Clinical Trial||University of Chile|Yes|Recruiting|January 2011|June 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2010|January 4, 2011|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268423||111166|
NCT01274767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3NANC|Prevention of Recurrent Ulcer Bleeding in High-risk Aspirin Users Who Are Not Infected With Helicobacter Pylori|Prevention of Recurrent Ulcer Bleeding in High-risk Aspirin Users Who Are Not Infected With Helicobacter Pylori: A Prospective Cohort Study (NSAID#3NANC Study)|3NANC|Chinese University of Hong Kong|No|Completed|January 1995|September 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|467|||Both|18 Years|N/A|No|Non-Probability Sample|High-risk patients were from our hospital while average-risk patients were from our        out-patient clinics.|January 2011|August 10, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274767||110678|
NCT01268982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88724|Effect of Socket Preservation Procedure on Dimensional Changes of the Ridge, and Its Efficacy.|Dimensional Changes of the Alveolar Ridge Contour After Socket Preservation, Stability of Implants Placed, and Histological Evaluation of Newly Formed Bone at These Sites.||Mashhad University of Medical Sciences|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|32|||Both|19 Years|57 Years|Accepts Healthy Volunteers|||January 2010|January 3, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01268982||111123|
NCT01274754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRTE|Neuroprotection With Erythromycin in Cardiac Surgery|Perioperative Administration of Erythromycin and Brain Protection||AHEPA University Hospital|No|Completed|November 2008|September 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|Blood samples will be taken from all patients for the detection of tau protein, IL-1 and      IL-6,        1. preoperatively        2. 12 hours after surgery        3. the 6th day after surgery|Both|18 Years|80 Years|No|Non-Probability Sample|patients scheduled for elective cardiac surgey coronary artery bypass grafting|December 2014|December 1, 2014|March 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01274754||110679|
NCT01275326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99060|Indoor Air Quality and Infectious Aerosols in Health Care Facilities|Indoor Air Quality and Infectious Aerosols in Health Care Facilities||Taipei Medical University WanFang Hospital|No|Completed|April 2010|December 2010|Actual|||N/A|Observational|Observational Model: Case-Only||1|Actual|120|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|people who work in Health Care Facilities|January 2011|January 21, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275326||110635|
NCT01275547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB28/10|The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam|The Analgesic Effect of Combined Treatment With Intranasal S-Ketamine and Intranasal Midazolam Compared With Morphine Patient Controlled Analgesia in Spinal Surgery Patients|NASKEMI|University Hospital, Basel, Switzerland|No|Completed|January 2011|December 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275547||110618|
NCT01275560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/073/HP|Does the Negativation of the Glucose Hydrogen Breath Test Come Along With a Reduction of the Symptoms of Gaz Incontinence ?|||University Hospital, Rouen|Yes|Completed|January 2011|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275560||110617|
NCT01275859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0729|Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer|Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer|Neo-All-In|Asan Medical Center|No|Completed|September 2010|May 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|N/A|No|||July 2012|November 28, 2014|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01275859||110594|
NCT01275872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-GIPMR-85|Effect of Guided Imagery and Progressive Muscle Relaxation as a Means to Improve the Psychological Well-being and the Quality of Life for Patients With Breast and Prostate Cancer|A Randomized Clinical Trial on the Effect of Guided Imagery and Progressive Muscle Relaxation for the Management of Pain, Stress, Anxiety and Depression as a Means to Improve the Psychological Well-being and the Quality of Life for Patients With Breast and Prostate Cancer||Cyprus University of Technology|Yes|Completed|April 2010|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Both|18 Years|72 Years|No|||October 2011|October 31, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01275872||110593|
NCT01276509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7281006|Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease|A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)|OPERA|Pfizer|Yes|Completed|April 2011|October 2015|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|265|||Both|18 Years|75 Years|No|||December 2015|December 7, 2015|January 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276509||110544|
NCT01276743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01051979|Study of PTPN22 C1858T Polymorphism in Children and Adolescents of Greek Origin With T1DM|Study of Protein Tyrosine Phosphatase Non-receptor Type 22 (PTPN22) C1858T Polymorphism in Children and Adolescents of Greek Origin With Type 1 Diabetes Mellitus (T1DM)||Aristotle University Of Thessaloniki|Yes|Completed|February 2010|February 2013|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|200|Samples With DNA|whole blood|Both|3 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and adolescents of Greek origin who attended the Pediatric Diabetes Outpatient        Clinic of 4th Department of Pediatrics of Medical School of Aristotle University of        Thessaloniki for T1DM|February 2014|February 27, 2014|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276743||110526|
NCT01276756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAIL001|Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)|Randomized Study for the Assessment of Nitazoxanide in the Treatment of Chronic Hepatitis C Genotype 4||Cairo University|Yes|Completed|December 2010|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||March 2013|March 19, 2013|January 12, 2011|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01276756||110525|
NCT01277068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00844-35|Effects of Various Bariatric Surgical Procedures on Intestinal Triglyceride-rich-lipoprotein (TRL) Metabolism in Obese Patients|Effects of Various Bariatric Surgical Procedures on Intestinal Triglyceride-rich-lipoprotein (TRL) Metabolism in Obese Patients||Assistance Publique Hopitaux De Marseille|No|Completed|September 2010|||September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|36|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277068||110501|
NCT01277081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7100991|Effect of Paracetamol on the Common Cold|To Assess the Subjective Effect of Two Paracetamol Preparations on the Feeling of Breathing in Subjects With the Common Cold.||GlaxoSmithKline|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||June 2013|February 2, 2015|January 12, 2011||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01277081||110500|
NCT01277380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99029|Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR|Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|August 2010|August 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|20 Years|N/A|No|Probability Sample|H1N1 Influenza|January 2011|January 13, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277380||110477|
NCT01277393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99058|Care of Critically Ill Patients Enteral Nutrition Guidelines for the Implementation of the Effectiveness of the Intervention|Care of Critically Ill Patients Enteral Nutrition Guidelines for the Implementation of the Effectiveness of the Intervention||Taipei Medical University WanFang Hospital|No|Active, not recruiting|September 2010|March 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|ill patients|January 2011|January 12, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277393||110476|
NCT01277627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAP-NEV-2010-01|Influence of Nevirapine on HCV Viral Load|Influence of Nevirapine on HCV Viral Load Among HIV/HCV-coinfected Patients|HELICON|Valme University Hospital|No|Not yet recruiting|January 2011|||July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2010|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277627||110458|
NCT01277640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-012/IPM 010|Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures|Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures||International Partnership for Microbicides, Inc.|Yes|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|48|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|January 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277640||110457|
NCT01277900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADSMT-1|Efficacy and Safety Study of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) to Treat Type 2 Diabetes Mellitus|Efficacy and Safety Study of LRYGB to Treat Type 2 Diabetes Mellitus|ADSMT-1|Asia Metabolic Surgery Research Group|Yes|Not yet recruiting|January 2011|December 2013|Anticipated|January 2012|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Blood and urine|Both|30 Years|60 Years|No|Non-Probability Sample|500 type 2 diabetes mellitus patients with BMI between 25-35 kg/m2|January 2011|January 14, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01277900||110437|
NCT01246778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAR|Sunitinib and Atrial Trabeculae Contractility|The Influence of Sunitinib on Contractility of Human Atrial Trabeculae|SCAR|Radboud University|No|Completed|November 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only||2|Actual|20|None Retained|Atrial tissue|Both|18 Years|N/A|No|Non-Probability Sample|44 patients undergoing cardiac surgery with extracorporal circulation|April 2014|April 30, 2014|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246778||112826|
NCT01246791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-01-3|Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers|A Single Dose Pharmacokinetics Study of NPC-01 (1mg Norethisterone and 0.02mg Ethynyl Estradiol) in Healthy Female Volunteers||Nobelpharma|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|November 18, 2010||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01246791||112825|
NCT01246102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110029|AT13387 in Adults With Refractory Solid Tumors|Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|November 2010|April 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|120 Years|No|||March 2016|March 16, 2016|November 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01246102||112878|
NCT01246115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDMD-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld||||||N/A|N/A|N/A||||||||||||||November 22, 2010|November 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01246115||112877|
NCT01246440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICO-1001|Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission|A Phase II of Intraperitoneal Catumaxomab as a Consolidation Therapy in Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma in Second or Third Complete Clinical Disease Remission||Grupo Español de Investigación en Cáncer de Ovario|No|Recruiting|June 2010|September 2013|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|18 Years|N/A|No|||November 2010|November 24, 2010|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01246440||112852|
NCT01246765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-001861|National Pregnancy Registry for Atypical Antipsychotics|National Pregnancy Registry for Atypical Antipsychotics||Massachusetts General Hospital|No|Recruiting|November 2008|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|800|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women from across the United States will be enrolled in this registry.|October 2015|October 13, 2015|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01246765|15 Months|112827|
NCT01247012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILOVE-134698|Minimization of IntraLipid Versus Omegaven|A Randomized Controlled Trial of Minimization of Intralipid Versus Omegaven for the Treatment of Severe Cholestasis- A Pilot Trial|MILOve|Children's & Women's Health Centre of British Columbia|Yes|Recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|6 Months|No|||September 2011|September 6, 2011|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247012||112808|
NCT01247272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01-140|90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions|A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|May 2001|July 2001|Actual|July 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 24, 2011|November 22, 2010|No|Yes||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01247272||112788|
NCT01278030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 534|Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates|Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates (ENVISION)|ENVISION|St. Jude Medical|No|Completed|August 2010|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|N/A|N/A|No|||October 2013|October 21, 2013|January 12, 2011||No||No|June 4, 2013|https://clinicaltrials.gov/show/NCT01278030||110427|
NCT01268436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2709|Cohort Comparison of Dental Nerve Block With Other Forms of Analgesia in Alleviating the Pain of Toothache|Cohort Comparison of Dental Nerve Block With Other Forms of Analgesia in Alleviating the Pain of Toothache|Cohort Dental|Albany Medical College|No|Completed|January 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|64|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients identified by ED providers as having dental pain will be screened for        enrollment.|December 2010|March 20, 2014|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01268436||111165|
NCT01278290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNinosBuenosAires-Triptorelin|Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls|Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls.||Hospital de Niños R. Gutierrez de Buenos Aires|Yes|Active, not recruiting|July 2010|October 2011|Anticipated|April 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Female|3 Years|8 Years|No|||December 2010|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278290||110407|
NCT01278589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA_Biofood|Antioxidative Effect of Plantago Asiatica L. Extract|Acute Effect of Plantago Asiatica L. Extract on Antioxidative Biomarkers in Subjects With Mild Hyperlipidemia: A Pilot Study||Ewha Womans University|No|Completed|December 2010|September 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|40|||Both|30 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 27, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278589||110384|
NCT01275027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1340-Nutralin|A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin|A Phase II, Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin||Avera McKennan Hospital & University Health Center|Yes|Withdrawn|January 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|January 10, 2011||No|Sponsor recalled the study|No||https://clinicaltrials.gov/show/NCT01275027||110658|
NCT01275885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1040D0038|Vitamin D Intervention in Infants - Pilot|Vitamin D Intervention in Infants - Pilot|VIDI-P|Helsinki University Central Hospital||Completed|August 2010|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|113|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2011|July 15, 2011|January 12, 2011||||No||https://clinicaltrials.gov/show/NCT01275885||110592|
NCT01275898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS_001|Comparison of INVOS and FORE SIGHT Cerebral Oximeter|Assessing Cerebral Oxygenation During Different Surgical Procedures - Comparison of INVOS and ForeSight Cerebral Oximeter||Johannes Gutenberg University Mainz|No|Recruiting|April 2010|||||N/A|Observational|Observational Model: Cohort||4|Anticipated|35|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients scheduled for surgical intervention in beach chair position, prone position and        head down position|March 2010|August 4, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01275898||110591|
NCT01276145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-292-A|Prevalence Of Internal Pudendal Artery Disease In Patients With Erectile Dysfunction Undergoing Diagnostic Coronary Angiography|Prevalence Of Internal Pudendal Artery Disease In Patients With Erectile Dysfunction Undergoing Diagnostic Coronary Angiography||University of Chicago|No|Recruiting|September 2010|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Male|40 Years|85 Years|No|Non-Probability Sample|Only stable patients scheduled to undergo clinically indicated coronary angiography under        non-emergent conditions will be approached for participation in the study.|December 2015|December 18, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01276145||110572|
NCT01276158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200905711|Ultrasound-image Versus Doppler-guided Radial Artery Cannulation in Infants and Small Children|||University of Iowa|Yes|Active, not recruiting|May 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|N/A|48 Months|No|||January 2011|January 11, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276158||110571|
NCT01276522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-SS-Canakinumab|Efficacy and Safety of Canakinumab in Schnitzler Syndrome|Efficacy and Safety of Canakinumab in Schnitzler Syndrome||Radboud University|No|Completed|January 2011|December 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276522||110543|
NCT01276769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC2010A03|Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer|Phase IIb Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Epirubicin as Neoadjuvant Treatment in Locally Advanced Triple-negative Breast Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2008|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|70 Years|No|||November 2011|November 15, 2011|December 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276769||110524|
NCT01277094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25414|A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease|Multi-center, Double-blind, Randomized, Placebo-controlled Study of Selective 11 Beta-HSD1 Inhibition With RO5093151 for 12 Weeks to Investigate Efficacy, Safety and Pharmacokinetics of RO5093151 in Non-alcoholic Fatty Liver Disease and Its Metabolic Consequences.||Hoffmann-La Roche||Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|35 Years|65 Years|No|||March 2016|March 1, 2016|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277094||110499|
NCT01277107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN 09 006|A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia|Double Blind, Polysomnographic, Two-Way Crossover Study To Compere The Efficacy Of Gastric Retentive Zaleplon (Zaleplon AP) To Placebo In Subjects With Insomnia Characterized By Both Difficulty In Falling Asleep And Staying Asleep||Intec Pharma Ltd.|Yes|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|65 Years|No|||December 2014|December 18, 2014|January 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277107||110498|
NCT01277432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010-281|Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)|A Multicentre Study to Investigate the Prevalence and Factors Associated With Depression in Chinese Patients With Type 2 Diabetes|DD2|Chinese University of Hong Kong|Yes|Completed|July 2010|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|3218|||Both|25 Years|75 Years|No|Probability Sample|Tertiary Hospitals and community centre|August 2015|August 20, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277432||110473|
NCT01277679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114747|Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunteers and in Patients With Cardiac Failure|An Evaluation of MRI Measures of Lung Water Increases With Postural Changes in Healthy Subjects and in Patients With Cardiac Failure: A Methods Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure||GlaxoSmithKline|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01277679||110454|
NCT01278147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00147-46|Cancer Fatigue Education Program|Development and Implementation of a Cancer Fatigue Education Program||Institut de Cancérologie de la Loire|No|Completed|May 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|80 Years|No|||January 2011|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278147||110418|
NCT01276652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SleepICU111|Sleep and Circadian Rhythms in Mechanically Ventilated Patients|Sleep and Circadian Rhythms in Mechanically Ventilated Patients: a Feasibility and Mechanistic Study.||University of Chicago|Yes|Active, not recruiting|November 2001|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|25|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01276652||110533|
NCT01277237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Edin2008-008275-34|The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease|The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease||University of Edinburgh|No|Completed|September 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2010|January 22, 2014|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277237||110488|
NCT01246453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC07/90479|Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema|A Prospective, Randomized, Double Blind, Controlled Trial to Evaluate Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Pleural Empyema||Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|December 2003|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||July 2011|July 15, 2011|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01246453||112851|
NCT01247311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01689|Vitamin D and the Health of Blood Vessels in Kidney Disease|The Impact of Vitamin D Supplementation on Vascular Stiffness and Blood Pressure in Chronic Kidney Disease Patients||University of British Columbia|Yes|Completed|November 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|129|||Both|19 Years|N/A|No|||September 2014|September 23, 2014|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01247311||112785|
NCT01247584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B2|Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia|Telomere Length and Telomerase Mutations in Pediatric Acute Myeloid Leukemia||Children's Oncology Group|No|Active, not recruiting|November 2010|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|234|Samples With DNA|bone marrow|Both|N/A|21 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia.|May 2015|May 11, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01247584||112764|
NCT01274533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE5097|Lenalidomide in HTLV-1 Adult T-Cell Leukemia|A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma||Columbia University|Yes|Completed|December 2010|May 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||July 2013|June 22, 2015|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274533||110696|
NCT01274572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC 10-11|Blood for Immune Response to Provenge® in HRPC|Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients||Mary Crowley Medical Research Center|No|Withdrawn|January 2011|June 2011|Actual|January 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Subjects that will be included in this study will be receiving Provenge as standard of        care treatment for their prostate cancer and will be willing to consent to the additional        blood draws.|April 2015|April 6, 2015|January 10, 2011||No|Drug became available with insurance reimbursement|No||https://clinicaltrials.gov/show/NCT01274572||110693|
NCT01274793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CB505203|Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy|Multicentre Randomized Controlled Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy||Huazhong University of Science and Technology|Yes|Recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274793||110676|
NCT01274546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-705|Long Term Foundation Knee Study|A Long-term, Multicenter Follow Up Study of the Cruciate-retaining Foundation Knee System||Encore Medical, L.P.|No|Completed|August 2010|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|43|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will include only subjects who received the cruciate-retaining Foundation Knee        System during or before the year 2000 and who voluntarily consent to take part in this        study.|August 2012|August 6, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274546||110695|
NCT01274559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-133|Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia||Merck Sharp & Dohme Corp.|No|Terminated|March 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1173|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 25, 2010|Yes|Yes|In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a    significant increase in incidence of some types of non-fatal SAEs|No|January 30, 2014|https://clinicaltrials.gov/show/NCT01274559||110694|MK-0524A-133 was stopped prior to completion. Raw individual efficacy data were obtained but none of planned efficacy outcomes were summarized or analyzed. Only safety data were summarized.
NCT01275911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN#08-22|Non-opioid Analgesia for Fast-track Surgery|Fast-track Laparoscopic Surgery. The Effect of Anesthetic Technique||McGill University Health Center|Yes|Completed|January 2009|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||March 2013|March 25, 2013|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01275911||110590|
NCT01276171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201001776|Ultrasound-image Guided Versus Doppler Guided Versus Palpation Technique for Arterial Cannulation in Adults|Ultrasound-image Guided Versus Doppler Guided Versus Palpation Technique for Arterial Cannulation in Adults||University of Iowa|Yes|Completed|February 2010|April 2015|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|749|||Both|18 Years|99 Years|No|||November 2015|November 30, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276171||110570|
NCT01276535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECACNEP1|Study of the Use of Low Level Laser Therapy to Reduce Acne|A Pilot Study to Evaluate the Efficacy of Low-level Laser Therapy in Reducing Blemishes by Quantifying a Decrease in Signs of Blemishes, Both Non-inflammatory and Inflammatory||Erchonia Corporation|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 7, 2015|January 11, 2011|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT01276535||110542|
NCT01276782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00042993|Levothyroxine in Pregnant SLE Patients|Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease||Johns Hopkins University|Yes|Withdrawn|January 2011|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|0|||Female|18 Years|45 Years|No|||September 2015|September 9, 2015|January 12, 2011|Yes|Yes|Withdraw the study because further analysis showed that it would be futile.|No||https://clinicaltrials.gov/show/NCT01276782||110523|
NCT01276795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-053-SDR|Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients|Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients||McGill University Health Center|Yes|Completed|January 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|13|||Both|18 Years|90 Years|No|||July 2010|January 12, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276795||110522|
NCT01277406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4SC-201-3-2010|4SC-201 (Resminostat) in Advanced Colorectal Carcinoma|A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Resminostat (4SC-201) in Combination With a Second-line Treatment in Patients With K-ras Mutated Advanced Colorectal Carcinoma|SHORE|4SC AG|Yes|Completed|January 2011|February 2015|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01277406||110475|
NCT01277653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFP-PIVKA|Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma|Prospective, Randomized Study of PIVKA-II and AFP Measurement Every 3 Months Compared to AFP Every 6 Months in Surveillance Program for Early Detection of Hepatocellular Carcinoma||Yonsei University|Yes|Recruiting|June 2007|June 2011|Anticipated|June 2010|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|1000|||Both|20 Years|75 Years|No|Probability Sample|Liver cirrhosis|September 2009|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277653||110456|
NCT01277666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114151|A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease|A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease|SHIELD-1|GlaxoSmithKline|Yes|Completed|December 2010|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|608|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|January 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277666||110455|
NCT01277718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEK4954g|A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of GDC 0973 in Healthy Subjects|A Phase 1, Open-Label, 3-Period, Randomized, Crossover Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of GDC 0973 in Healthy Subjects||Genentech, Inc.||Completed|January 2011|||||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 23, 2011|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277718||110451|
NCT01277952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0264|Deep Brain Stimulation for Traumatic Brain Injury|Deep Brain Stimulation for Treatment of Severe Disability From Traumatic Brain Injury||Ohio State University|Yes|Active, not recruiting|January 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|20 Years|60 Years|No|||February 2016|February 19, 2016|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277952||110433|
NCT01277913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2011|The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1|The Effect of Supplementation With Two Different Doses of Vitamin D (500 IU vs 1000IU)on Bone Mineral Density, Serum 25 Hydroxyvitamin D and Hand Grip Strength in Children With Diabetes Mellitus Type 1 - a Randomized Controlled Trial.||Medical University of Warsaw|No|Completed|January 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|8 Years|11 Years|No|||January 2011|November 3, 2013|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277913||110436|
NCT01277926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OBR-DUM-2010/1|Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer|Patterns of Care in Hormone-Receptor Positive, Advanced Breast Cancer in Brazil: A Prospective, Observational Study||AstraZeneca|No|Terminated|April 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Female|18 Years|N/A|No|Probability Sample|Primary care clinic|December 2012|December 5, 2012|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277926||110435|
NCT01277692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114885|A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.|A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Subjects||GlaxoSmithKline|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|58|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|March 8, 2012|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277692||110453|
NCT01278160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3883|Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756|An Extension Trial of BIAsp-3756, Explorative Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens on the Effect of Glycaemic Control in Chinese Type 2 Diabetes Patients||Novo Nordisk A/S|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|20 Years|80 Years|No|||October 2014|October 16, 2014|January 14, 2011|Yes|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT01278160||110417|
NCT01278173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13098A|A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)|A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)||Lundbeck LLC|No|Completed|December 2010|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|65|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|January 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01278173||110416|
NCT01277250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01DA031515|Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient|Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient||University of Alabama at Birmingham|Yes|Completed|July 2011|November 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1548|||Both|19 Years|N/A|No|||June 2015|June 17, 2015|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277250||110487|
NCT01247025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jrings1|Prolonged Grief and Suicide Among Veterans|Examining Prolonged Grief Disorder and Its Relationship to Self-Directed Violence Among Veterans||VA Eastern Colorado Health Care System|No|Withdrawn|November 2010|August 2011|Anticipated|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participants in this observational study will be all individuals willing and eligible        among those seeking outpatient mental health services at the Eastern Colorado Healthcare        System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC). It is expected that 180        participants will be enrolled in an effort to obtain up to 150 completed protocols. Women        and minorities will be recruited as a routine part of the study. However, given the        participant population within the Eastern Colorado Healthcare System (ECHCS)/Denver        Veterans Affairs Medical Center (VAMC), it is expected the majority of participants will        be Caucasian men.|March 2014|March 21, 2014|November 22, 2010||No|Study should not have been listed on ClinicalTrials.gov|No||https://clinicaltrials.gov/show/NCT01247025||112807|
NCT01278264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANESAB001|Transversus Abdominis Plane Blocks With Abdominoplasty|Transversus Abdominis Plane Blocks in Patients Scheduled for an Abdominoplasty. A Prospective, Randomized, Double Blind, Comparison Between the Posterior Approach and Placebo.|TAPA|Clinique Saint-Jean, Bruxelles|No|Not yet recruiting|June 2011|August 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||February 2011|April 26, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278264||110409|
NCT01274728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wo 09.070|PAclitaxel-eluting Balloon in Primary PCI in Amsterdam; Pilot Study|Pilot Study on PAclitaxel-eluting Balloon in Primary PCI in Amsterdam. A Clinical Evaluation, to Study the Feasibility and Safety of a Paclitaxel-eluting Balloon in Primary Percutaneous Coronary Intervention for Acute ST-elevation Myocardial Infarction.|PAPPA-pilot|Onze Lieve Vrouwe Gasthuis|Yes|Recruiting|November 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Biochemistry, haematology|Both|18 Years|N/A|No|Probability Sample|Patients who are presented at the emergency room or in ambulance with STEMI|January 2011|January 10, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274728||110681|
NCT01278563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC467410|A Trial to Investigate the Impact of a Low Glycemic Index (GI) Diet on Body Mass Index and Obesity Related Cardiovascular and Hormonal Factors in Chinese Adolescents|A Randomized Controlled Trial to Investigate the Impact of a Low Glycemic Index (GI) Diet on Body Mass Index and Obesity Related Cardiovascular and Hormonal Factors in Chinese Adolescents||Chinese University of Hong Kong|No|Not yet recruiting|January 2011|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|280|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||January 2011|January 18, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278563||110386|
NCT01278576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCMC10AH07|Botulinum Toxin A Adult Gastrocnemius Muscle Study|An Efficacy Comparison of Botulinum Toxin A Injection Into Two Different Sites in Gastrocnemius Muscle for the Treatment of Spastic Patients, Randomized Controlled Trial|BTX-A|The Catholic University of Korea|Yes|Completed|January 2011|May 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|70 Years|No|||January 2011|May 14, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01278576||110385|
NCT01278316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27735|Rural Veterans With Post-traumatic Stress Disorder (PTSD) And Comorbid Mild Traumatic Brain Injury (TBI): A Feasibility Study|Remote Administration Of Cognitive Training Tasks In Rural Veterans With PTSD And Comorbid Mild TBI: A Feasibility Study||Michael Debakey Veterans Affairs Medical Center|No|Active, not recruiting|January 2011|May 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278316||110405|
NCT01274806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI0890418|Take-Care Program: Effectiveness of a Physical Therapy Program on Cancer Related Symptoms|TAKE-CARE: EFFECTIVENESS OF A PHYSICAL THERAPY COMBINING CORE STABILITY EXERCISE AND MASSAGE IN CANCER RELATED SYMPTOMS|TAKE-CARE|Instituto de Salud Carlos III|Yes|Completed|January 2009|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|78|||Female|18 Years|65 Years|No|||January 2009|January 11, 2011|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01274806||110675|
NCT01274819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLA 2011|Dynamic Light Application to Prevent ICU Acquired Delirium|Dynamic Light Application to Prevent ICU Acquired Delirium|DLA|Jeroen Bosch Ziekenhuis|No|Completed|July 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274819||110674|
NCT01275924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIGHTROPE-SS|Tightrope or Screw Fixation of Acute Tibiofibular Syndesmotic Injury|Tightrope or Screw Fixation of Acute Tibiofibular Syndesmotic Injury. Randomised Controlled Trial.|TIGHTROPE-SS|Sykehuset Asker og Baerum|No|Active, not recruiting|January 2011|March 2018|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||May 2015|May 20, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275924||110589|
NCT01276184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047046|Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil|A Randomized, Controlled Trial to Compare the Effectiveness of SMS Text Message Reminders Compared to Usual Care to Increase Adherence to the Gardasil Vaccine Dosing Schedule (GCC 1063GCC).||University of Maryland|No|Not yet recruiting|January 2011|January 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|200|||Female|18 Years|26 Years|Accepts Healthy Volunteers|||January 2011|January 12, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276184||110569|
NCT01276197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-132|DVDs About Blood Pressure|Using Stories to Address Disparities in Hypertension||VA Office of Research and Development|Yes|Completed|January 2013|January 2016|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|620|||Both|19 Years|N/A|No|||February 2016|February 17, 2016|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276197||110568|
NCT01277120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25178|An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)|The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With cOlorectal Cancer Treated With AvaStin Based First Line Regimens (CRONOS 1)||Hoffmann-La Roche||Active, not recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|174|||Both|18 Years|N/A|No|Probability Sample|First-line treatment with Avastin|March 2016|March 1, 2016|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277120||110497|
NCT01277133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25191|An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)|The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With Metastatic Breast Cancer Treated With First Line Regimens Based On AvaStin||Hoffmann-La Roche||Active, not recruiting|June 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|83|||Both|18 Years|N/A|No|Probability Sample|Female patients with metastatic HER2 negative breast cancer. First-line treatment with        Avastin|February 2016|February 1, 2016|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277133||110496|
NCT01277146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59R5-001|A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors||OncoMed Pharmaceuticals, Inc.|No|Active, not recruiting|December 2010|August 2015|Anticipated|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|90 Years|No|||February 2014|February 7, 2014|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01277146||110495|
NCT01277419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESPIC|German Spondyloarthritis Inception Cohort|German Spondyloarthritis Inception Cohort|GESPIC|Charite University, Berlin, Germany||Active, not recruiting|July 2000|||July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|803|||Both|N/A|N/A|No|Probability Sample|Patients included in GESPIC were required to have a definite clinical diagnosis of axial        SpA according to the treating rheumatologist.        In the Juvenile SpA group patients with juvenile disease onset (≤16 years) were included.|May 2015|May 6, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277419||110474|
NCT01276834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOCTX-2|Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation|Randomised Comparison of Two Different Immunosuppressive Regimens on Progression of Arteriosclerosis in Renal Transplant Patients.|NOCTX-2|Dianet Dialysis Centers|No|Terminated|September 2010|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|January 12, 2011||No|insufficient patients enrolled|No||https://clinicaltrials.gov/show/NCT01276834||110519|
NCT01277159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10105|Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine|Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine||Hospital for Special Surgery, New York|No|Completed|October 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|108|||Both|18 Years|75 Years|No|||July 2012|July 2, 2012|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277159||110494|
NCT01278212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.0584|Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer|A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients||James Graham Brown Cancer Center|Yes|Recruiting|January 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Female|21 Years|N/A|No|||May 2015|May 12, 2015|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01278212||110413|
NCT01277705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|711866/003|Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®|Assess Immunogenicity, Reactogenicity of GSK Biologicals'-dTpa-IPV Vaccine Versus dTpa & IPV Vaccines Administered Separately & Compared With Aventis Pasteur MSD's Td-IPV Vaccine When Administered to Healthy Adolescents & Adults||GlaxoSmithKline||Completed|January 2002|April 2002|Actual|April 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|806|||Both|15 Years|N/A|No|||January 2011|January 13, 2011|January 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277705||110452|
NCT01277939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDRI-612|CPT for Offenders With SUD|Computerized Psychosocial Treatment for Offenders With Substance Use Disorders|CPT|National Development and Research Institutes, Inc.|Yes|Completed|September 2009|August 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|376|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01277939||110434|
NCT01277796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032-08|Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis|Pilot Study of Thermotherapy Treatment for Cutaneous Leishmaniasis in Peru With the HECT-CL Device|HECT|Universidad Peruana Cayetano Heredia||Available||||||N/A|Expanded Access|N/A|||||||Both|8 Years|80 Years||||January 2011|January 14, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277796||110445|
NCT01277497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2902|Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4|A Randomized Study on the Effects of Sevelamer Carbonate Versus Calcium Acetate on Biomarkers of Vascular Calcification, Inflammation, and Endothelial Dysfunction in Chronic Kidney Disease Stages 3 and 4||Albany College of Pharmacy and Health Sciences|No|Terminated|January 2011|March 2016|Anticipated|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 6, 2011|Yes|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT01277497||110468|
NCT01278810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG0929ICR|Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients|A Phase I ,Single Center, Open-labeling, Single and Dose-escalating Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Novel ERa36 Modifier Icaritin in Advanced Breast Patients||Chinese Academy of Medical Sciences|No|Recruiting|November 2010|December 2011|Anticipated|November 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|65 Years|No|||November 2010|January 27, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278810||110367|
NCT01278069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-PETAML-043|PET-CT in AML for Detection of Extramedullary AML Manifestations|PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations|PETAML|Technische Universität Dresden|No|Completed|February 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|93|||Both|18 Years|80 Years|No|Probability Sample|Inpatients or Outpatients with newly diagnosed or relapsed AML AML|September 2013|September 16, 2013|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278069||110424|
NCT01278082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUC-63/COC|SOIBD Collagenous Colitis Maintenance Study|Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules Versus Placebo for Maintenance of Remission in Patients With Collagenous Colitis|SCCMS|Dr. Falk Pharma GmbH|Yes|Completed|April 2008|September 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278082||110423|
NCT01278602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 11-01|R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma|A Multi-center Phase II Study of R-ESHAP Followed by Autologous Transplantation as Salvage Treatment for Patients With Refractory or Relapsed Diffuse Large B-cell Lymphoma.||Fudan University|No|Recruiting|December 2010|February 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||March 2013|March 2, 2013|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278602||110383|
NCT01275053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002p000097|In Vivo Leptin Signaling in Humans After Acute Leptin Administration|In Vivo Leptin Signaling in Humans After Acute Leptin Administration||Beth Israel Deaconess Medical Center|No|Completed|July 2002|||December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|January 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01275053||110656|
NCT01275066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-004|A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)||BioMarin Pharmaceutical|Yes|Completed|February 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|177|||Both|5 Years|N/A|No|||June 2014|June 6, 2014|January 10, 2011|Yes|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT01275066||110655|
NCT01275573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 155 02|Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Pain Perception in Parkinson's Disease|High Frequency rTMS (Repetitive Transcranial Magnetic Stimulation) Effect Applied on Primary Cortical Motor, on Nociceptive Perception Thresholds in Parkinson's Disease Patients: a Physiopathology Study|rTMS|University Hospital, Toulouse|Yes|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01275573||110616|
NCT01275586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-06|Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|Pilot Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas||Indiana University|Yes|Active, not recruiting|January 2011|January 2017|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275586||110615|
NCT01276548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPMOC202|A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer|||Samyang Biopharmaceuticals Corporation||Recruiting||||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||Female|18 Years|N/A|No|||January 2011|January 12, 2011|January 12, 2011||||No||https://clinicaltrials.gov/show/NCT01276548||110541|
NCT01276808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WO nummer R-10.420|Magnetic Navigation for Contrast and Radiation Reduction|Reduction in Contrast Volume and Radiation With Magnetic Navigation: a Prospective Randomised Trial|MAGNA|Onze Lieve Vrouwe Gasthuis|No|Recruiting|October 2011|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01276808||110521|
NCT01276561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 09 196|Single Incision Versus Standard Laparoscopic Splenectomy|Single Incision Versus Standard Laparoscopic Splenectomy||Children's Mercy Hospital Kansas City|No|Active, not recruiting|October 2009|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|1 Year|18 Years|No|||January 2016|January 27, 2016|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276561||110540|
NCT01276821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSTUTHIOM|Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Bronchiolitis.|Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial.||Tribhuvan University Teaching Hospital, Institute Of Medicine.|Yes|Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|6 Weeks|2 Years|No|||April 2013|April 23, 2013|January 12, 2011|Yes|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT01276821||110520|
NCT01277172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-1908|TREatment of degeNerative and Neoplastic Diseases With Rituximab|Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients|TREND|Probiomed S.A. de C.V.|Yes|Recruiting|October 2010|October 2011|Anticipated|September 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|54|||Both|18 Years|80 Years|No|||January 2011|January 12, 2011|January 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01277172||110493|
NCT01277445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01B46-10-0156|Effects of Fructan Prebiotics on the Intestinal Microbiota|Evaluation of the Effects of Fructan Prebiotics on the Intestinal Microbiota in Humans: Human Clinical Feeding Trial.||Guelph Food Research Centre|No|Completed|January 2011|March 2013|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277445||110472|
NCT01278225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0675|Neurofeedback and Pain|Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2011|||March 2018|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Patients receiving chemotherapy at UT MD Anderson Cancer Center in Houston, Texas|February 2016|February 4, 2016|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278225||110412|
NCT01278199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K081202|Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance|A Multicentric Randomized Trial Comparing the Bronchial Artery Embolization Combined With Medical Measures and the Medical Measures Alone in the Treatment of Non-severe Acute Hemoptysis of Mild-to-moderate Abundance|ARTEMHYS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|210|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278199||110414|
NCT01278472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0321/4|Cosmesis and Body Image After Single Port or 4-Port Laparoscopic Cholecystectomy|Cosmesis and Body Image After Single Port Laparoscopic or Conventional Laparoscopic Cholecystectomy: A Double Blinded Randomised Controlled Trial||University of Zurich|Yes|Recruiting|January 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2011|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278472||110393|
NCT01278004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3116|Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study)|A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy|CINE-E|Royal Marsden NHS Foundation Trust|Yes|Recruiting|May 2010|||December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|44|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01278004||110429|
NCT01275482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deltoid|Effectiveness of Transverse Friction Massage in Latent Myofascial Trigger Points in Anterior Deltoid Muscle|Effectiveness of Transverse Friction Massage Causing or Not Local Twitch Response in Anterior Deltoid Muscle Latent Myofascial Trigger Points||University of Castilla-La Mancha|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 6, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275482||110623|
NCT01244412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM-001|Assessment of Prototype Hand-held Fundus Camera|Assessment of Prototype Hand-held Fundus Camera||University of Rochester|No|Terminated|December 2010|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|18 years or older|May 2015|May 15, 2015|November 17, 2010||No|The PI wanted to make additional changes to the hand held camera therefore he terminated the    study rather than continue with an outdated camera design.|No|June 5, 2013|https://clinicaltrials.gov/show/NCT01244412||113005|It was determined that the project should stop in order for more technical changes to be made on the prototype
NCT01274585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH2010-P-000239|Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence|Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence||Massachusetts General Hospital|Yes|Terminated|January 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 11, 2014|January 7, 2011|Yes|Yes|Study was terminated due to low recruitment rates|No|December 30, 2013|https://clinicaltrials.gov/show/NCT01274585||110692|
NCT01278043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-222-A|Antiplatelet Response, Interval Variability & Events in Percutaneous Coronary Intervention (ARIVE-PCI) Registry|Incidence, Predictors and Impact of Response Variability to Oral Dual Antiplatelet Therapy, as Measured by Point-of-care Platelet Aggregometry, Following Percutaneous Coronary Intervention|ARIVE-PCI|University of Chicago|No|Recruiting|May 2010|May 2013|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|100 consecutive patients undergoing PCI at a single medical center will be enrolled in        this prospective, open cohort study.|January 2011|January 19, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01278043||110426|
NCT01278056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670EDE08T|The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis|The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial|DEFINE|Crolll Gmbh|Yes|Completed|March 2010|July 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278056||110425|
NCT01275105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-100-0008|A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)|A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)||Eye Therapies, LLC|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|68|||Both|18 Years|N/A|No|||March 2012|March 2, 2012|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275105||110652|
NCT01275118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMF-09-002 Rev.5|Comparison of Postoperative Visual Acuity and Spectacle Independence Between the Tecnis Multifocal Intraoculer Lens (IOL) and the Crystalens Accommodating IOL|Comparative Study of Photopic and Mesopic Distance, Intermediate and Near Visual Acuity, and Spectacle Independence With Bilateral Implantation of the Tecnis Multifocal (TMF) Intraocular Lens or Crystalens AO (CAO) Intraocular Lens||Drs. Fine, Hoffman and Packer, LLC|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01275118||110651|
NCT01275599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX10-950-024|Drug-Drug Interaction Study Between Telaprevir and Buprenorphine|A Phase 1, Open-Label, Single-Sequence Study to Examine the Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy||Vertex Pharmaceuticals Incorporated|No|Completed|January 2011|||April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|64 Years|No|||June 2011|June 7, 2011|January 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01275599||110614|
NCT01276223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-078|Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients|A Multi-Center, Randomized, Double-Masked Evaluation of Anti-Inflammatory Treatment in Patients With Dry Eye||Alcon Research|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|722|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 8, 2013|January 11, 2011|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01276223||110566|
NCT01276236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02850|Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)|Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)||University of California, San Francisco|No|Enrolling by invitation|February 2011|April 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01276236||110565|
NCT01276249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD03335-01|The STAPLE International Post-Market Registry|The STAPLE-International Post-Market Registry||Aptus Endosystems|No|Active, not recruiting|August 2010|March 2018|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with a qualifying AAA suitable for elective endovascular repair.|July 2015|July 14, 2015|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01276249||110564|
NCT01276574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53/180/2009|Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT|Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Positron Emission Tomography/Computed Tomography)|Mupet|Turku University Hospital|No|Active, not recruiting|October 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|tumour samples, whole blood and serum samples|Female|18 Years|79 Years|No|Non-Probability Sample|Patients with clinical suspicion of advanced EOC referred to surgery to Turku University        hospital.|May 2015|May 20, 2015|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01276574||110539|
NCT01276847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-206|A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)|A Clinical Trial to Assess the Effects of Ustekinumab and Etanercept on Skin and Blood Biomarkers of Psoriasis in Patients With Moderate to Severe Disease||Merck Sharp & Dohme Corp.|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|19 Years|N/A|No|||January 2015|January 13, 2015|January 12, 2011|No|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT01276847||110518|
NCT01277731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gyeongsang-20100701|Methylprednisolone Replacement for Dexamethasone-induced Hiccup|Pilot Study of Methylprednisolone Replacement for Dexamethasone-induced Hiuup Patients||Gyeongsang National University Hospital|No|Withdrawn|July 2010|December 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|70 Years|No|||November 2012|November 18, 2012|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01277731||110450|
NCT01277744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0528|Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor|A Phase II Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor and Other Non-Carcinomas||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2011|||March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|1 Year|N/A|No|||January 2016|January 25, 2016|January 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01277744||110449|
NCT01277965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009 A01136 51|Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity|Use of a CMGS to Validate Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Treated With Subcutaneous Continuous Insulin Infusion and Practicing Physical Activity|DIABRASPORT|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|Yes|Completed|March 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|20|||Both|18 Years|N/A|No|||January 2012|April 19, 2013|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01277965||110432|
NCT01266083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-143|Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)|Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01266083||111346|
NCT01266096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-155|PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study|PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study||Memorial Sloan Kettering Cancer Center||Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|11|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|December 21, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01266096||111345|
NCT01266109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019892|Enhancing Juvenile Drug Court Outcomes With Evidence-Based Practices|Enhancing Juvenile Drug Court Outcomes With Evidence-Based Practices||Medical University of South Carolina|No|Completed|September 2007|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|12 Years|17 Years|No|||May 2013|June 17, 2013|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01266109||111344|
NCT01278485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-402|Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)|Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects|NEEDS|Merck Sharp & Dohme Corp.|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|726|||Both|30 Years|N/A|No|Non-Probability Sample|Adults with Type 2 diabetes mellitus ≥30 years of age who have been treated with        sulphonylurea (SU) monotherapy or SU+ merformin (MF) combination therapy for at least 6        months by a cardiologist, nephrologist, or family practice doctor.|July 2015|July 17, 2015|January 13, 2011||No||No|May 14, 2013|https://clinicaltrials.gov/show/NCT01278485||110392|
NCT01278745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-11|Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation|Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|September 2011|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|163|||Both|18 Years|75 Years|No|||February 2016|February 12, 2016|January 16, 2011|Yes|Yes|Due to inability to meet accrual goals within the funding period|No||https://clinicaltrials.gov/show/NCT01278745||110372|
NCT01274676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S111/508|Carotid Stenting in Patients With High Risk Carotid Stenosis ("Soft Plaque")|Randomized Trial of Proximal-versus Distal Cerebral Protection on Micro Embolization During Carotid Artery Stenting in Patients With High Risk Lipid Palque|MOMA|Centro Cardiologico Monzino|Yes|Completed|February 2009|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Both|18 Years|85 Years|No|||September 2009|January 10, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274676||110685|
NCT01243788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO113162|The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD|Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD.||Fudan University|Yes|Recruiting|July 2009|October 2011|Anticipated|February 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|40 Years|79 Years|No|||October 2008|November 18, 2010|November 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01243788||113053|
NCT01243801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTB-10|Prevention of Persistent Postsurgical Pain After Thoracotomy|Phase 4 Study of Prevention of Persistent Postsurgical Pain After Thoracotomy Using Ketamine||Hospital Clinic of Barcelona|No|Completed|September 2008|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|104|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01243801||113052|
NCT01278537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERATECS|Patient Empowerment and Risk-assessed Treatment to Improve Outcome in the Elderly After Onco-surgery|Patient Empowerment and Risk-assessed Treatment to Improve Outcome in the Elderly After Gastrointestinal, Thoracical or Urogenital Cancer Surgery.|PERATECS|Charite University, Berlin, Germany|No|Completed|February 2011|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|690|||Both|65 Years|N/A|No|||March 2014|March 13, 2014|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278537||110388|
NCT01278797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.41|Telmisartan and Amlodipine Versus Monocomponent Tablets|A Single-Dose, Comparative Bioavailability Study of Telmisartan/Amlodipine 80 mg/10 mg Tablets Versus Micardis 80 mg Tablets With Norvasc 10 mg Tablets Under Fasting Conditions||Boehringer Ingelheim||Completed|January 2011|||February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|January 17, 2011||||No|February 13, 2012|https://clinicaltrials.gov/show/NCT01278797||110368|
NCT01244750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-330|Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting|Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)|SIMPLICITY|Bristol-Myers Squibb|No|Active, not recruiting|December 2010|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort||4|Actual|1494|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited at oncology practices or oncology centers linked to a hospital        in the North Americas, Europe and potentially at additional sites in South America, and        Asia|March 2016|March 18, 2016|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01244750||112979|
NCT01274845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|503-02-02215338-22961-03550|Use of Heliox in the Management of Neonates With Meconium Aspiration Syndrome|Use of Heliox in the Management of Neonates With Meconium Aspiration Syndrome||Poznan University of Medical Sciences|No|Completed|December 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|1 Day|No|||January 2011|January 11, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274845||110672|
NCT01274858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-059/6|Sensory Mapping and Thermal Thresholds After Thoracic Surgery|Sensory Mapping and Thermal Thresholds After Thoracic Surgery||Rigshospitalet, Denmark|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|12|||Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients|February 2011|September 27, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274858||110671|
NCT01274871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2008-059/drain|Sensory Changes From Chest Drains|Late Sensory Changes From Chest Drain Insertion During Thoracotomy||Rigshospitalet, Denmark|No|Completed|December 2009|December 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Post thoracotomy patients after lung cancer in Denmark|January 2011|January 11, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01274871||110670|
NCT01278329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEXMUSIC|Maternal Music Exposure During Pregnancy Influences Neonatal Behaviour|Effect of Maternal Ante-natal Music Exposure on Neonatal Behavior Measured Using Brazelton Neonatal Behavioral Scale: A Randomized Open-label Study|PEXMUSIC|NSCB Medical College|Yes|Completed|January 2003|December 2005|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|339|||Female|19 Years|29 Years|No|||December 2010|January 14, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278329||110404|
NCT01275378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC17181|Comparative Effectiveness Research for Two Medical Home Models for Attention Deficit Hyperactivity Disorder|COMPARATIVE EFFECTIVENESS RESEARCH FOR TWO MEDICAL HOME MODELS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER||Boston Medical Center|No|Active, not recruiting|October 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|156|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|October 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01275378||110631|
NCT01275391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFADEcSBIRT|cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use|cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use||Children's Hospital Boston|No|Withdrawn|September 2011|September 2013|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|600|||Both|12 Years|21 Years|No|||October 2011|October 6, 2011|January 11, 2011||No|This project was not funded.|No||https://clinicaltrials.gov/show/NCT01275391||110630|
NCT01275339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1334b|Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study|Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study|ASPEN|Washington University School of Medicine|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|56|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01275339||110634|
NCT01275612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIS/MSC 08|Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers|Ex-Vivo Expanded Mesenchymal Stem Cells To Repair The Kidney And Improve Function In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers|CIS/MSC08|Mario Negri Institute for Pharmacological Research|No|Recruiting|November 2010|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01275612||110613|
NCT01275625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001101|Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia|A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia||ViiV Healthcare|No|Completed|June 2011|July 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|98|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|January 11, 2011|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01275625||110612|
NCT01284881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 10/42/284|Self-Reported Versus Objective Measured Compliance With Oral Appliance Therapy for Obstructive Sleep Apnea Hypopnea Syndrome|Self-Reported vs Objective Measured Compliance With Oral Appliance Therapy for Obstructive Sleep Apnea Hypopnea Syndrome||University Hospital, Antwerp|No|Completed|November 2010|December 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|OSAHS|January 2012|January 31, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284881||109902|
NCT01284894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.624/28|Esophageal High Resolution Manometry and Dysphagia|Diagnostic Yield of Esophageal High Resolution Manometry in Patients With Unexplained Dysphagia||Hospices Civils de Lyon|No|Completed|February 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|247|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284894||109901|
NCT01285427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR0000279|Clinical Protocol SeCore, uTYPE and 3500 Dx System|SeCore Sequencing Kit and 3500xl Dx Genetic Analyzer Clinical Performance Testing vs. SSP UniTray||Life Technologies Corporation|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|300|Samples With DNA|DNA isolated from whole blood samples|Both|N/A|N/A|No|Non-Probability Sample|A, B, C, DRB1, DRB3/4/5, DQB1, DPB1 loci|April 2014|April 15, 2014|January 12, 2011||No||No|May 8, 2013|https://clinicaltrials.gov/show/NCT01285427||109861|
NCT01285440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000748|Use of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions|Determination of the Sensitivity of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions|Lowdoseprebx|Mayo Clinic|Yes|Enrolling by invitation|March 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|95 Years|No|Non-Probability Sample|A total of 150 patients will be studied. Each patient will have a suspicious lesion on        mammogram, ultrasound or breast MRI for which biopsy is scheduled. The lesion size on        mammogram, ultrasound or breast MRI must be less than 2 cm in diameter and must be        considered "suspicious" or "highly suspicious" for malignancy|March 2016|March 18, 2016|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285440||109860|
NCT01285726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM-PD-02-INT|Initiative for Patient Outcomes in Dialysis - Peritoneal Dialysis (PD) (IPOD-PD Study)|Initiative for Patient Outcomes in Dialysis - PD (IPOD-PD Study)|IPOD-PD|Fresenius Medical Care Deutschland GmbH|No|Active, not recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1092|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with chronic kidney disease (CKD) starting renal replacement therapy on APD        or CAPD|August 2013|April 28, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285726||109838|
NCT01285466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235A2118|A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab|A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer||Novartis||Completed|January 2011|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|110|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285466||109858|
NCT01286480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-Chapter-01|Congenital Heart Adolescents: Program of Transition Evaluation Research|Evaluation of Novel Transition Interventions for Youth With Congenital Heart Disease|CHAPTER|University of Alberta|No|Completed|January 2011|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|17 Years|No|||June 2014|June 18, 2014|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286480||109780|
NCT01286493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC5303|Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination|Immune Response After Booster Vaccination in HIV - Infected Patients Who Ever Received Rabies Primary Vaccination||Queen Saovabha Memorial Institute|Yes|Completed|February 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|January 26, 2011||No||No|April 21, 2014|https://clinicaltrials.gov/show/NCT01286493||109779|Small sample size heterogeneous characteristics of participants Use only CD4+ T lymphocyte counts as the only immunologic surrogate marker
NCT01286506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16710A|Observational Study of Blood Pressure Measurements and Continuous Dialysis|Observational Study Evaluating the Hemodynamic Relationship Between Volume Removal and Pulse Pressure Variation During Renal Replacement Therapy||University of Chicago|No|Recruiting|February 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Adult ICU patients requiring CVVHD who have an indwelling arterial line.|March 2014|March 27, 2014|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286506||109778|
NCT01286519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0865|Pharmacokinetics of Off Label Pediatric Medications|Pharmacokinetics of Off Label Pediatric Medications||University of North Carolina, Chapel Hill|No|Recruiting|July 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|8 Years|No|Non-Probability Sample|children < 8 years of age currently receiving a therapeutic agent at a dose or for an        indication not currently included on the FDA label as part of standard of care|December 2015|December 18, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01286519||109777|
NCT01287403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.14 MET|Response of Alkylresorcinols to Different Cereals|Response of Alkylresorcinols and Other Biomarkers to Different Cereals||Nestlé|No|Completed|January 2011|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|January 30, 2011||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01287403||109709|
NCT01287156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110084|Evaluation and Diagnosis of Potential Research Subjects With Traumatic Brain Injury|Evaluation and Diagnosis of Potential Research Subjects With Traumatic Brain Injury (TBI)||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2500|||Both|18 Years|N/A|No|||July 2015|November 24, 2015|January 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01287156||109728|
NCT01287702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|early feeding after ligation|Early Feeding Following Ligation of Acute Bleeding Varices|The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices||E-DA Hospital|Yes|Recruiting|January 2011|October 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|20 Years|80 Years|No|||February 2011|February 28, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287702||109688|
NCT01283893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0637|Standardization of D2 Lymphadenectomy and Surgical Quality Control: KLASS-02-QC|Standardization of D2 Lymphadenectomy and Surgical Quality Control for KLASS-02 Trial: KLASS-02-QC||Yonsei University|Yes|Recruiting|December 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|160|||Both|20 Years|80 Years|No|Non-Probability Sample|Gastric cancer patients|June 2013|June 1, 2013|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283893||109978|
NCT01287988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-012|Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies|Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies.||ThromboGenics|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have previously participated in either of the ocriplasmin Phase III studies        (TG-MV-006 or TG-MV-007)|April 2014|April 4, 2014|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287988||109666|
NCT01295671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-06-0242|Beverages and Societal Health|Sugar Sweetened Beverages And Cardiovascular Disease Risk|BASH III|Children's Hospital Boston|No|Completed|February 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|203|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295671||109076|
NCT01283451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS-01|Ability of Near Infrared Spectroscopy to Isolate Compartments of the Extremity|Ability of Near Infrared Spectroscopy to Isolate Compartments of the Extremity||J&M Shuler|No|Active, not recruiting|January 2010|||December 2016|Anticipated|Phase 1|Observational|Time Perspective: Cross-Sectional||1|Anticipated|63|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study sample will consist of healthy volunteers recruited from the principle        investigator's private practice.|September 2015|September 4, 2015|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283451||110012|
NCT01283464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKM10-R-01|Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles|Double-blinded, Single-center, Parallel-arm Comparison Study of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage||Johns Hopkins University|Yes|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|35 Years|N/A|No|||January 2011|July 19, 2013|January 24, 2011|Yes|Yes||No|April 12, 2013|https://clinicaltrials.gov/show/NCT01283464||110011|
NCT01283828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7.2|Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age in the United States|Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age in the United States||Gynuity Health Projects|Yes|Completed|November 2010|April 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4977|Samples With DNA|Vaginal and rectal swabs|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 5,000 women aged 18 to 45 years in the United States will be enrolled in the        study. Women will be recruited from approximately 25 clinics and solo or group practices        providing maternity care (pre- and post-natal), abortion, STI prevention & treatment,        family planning, and student health services. All women will be recruited, excluding women        seeking emergency or oncological care.|October 2013|October 4, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283828||109983|
NCT01284400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-HOMECARE|Home-based Disease Management Program to Improve Clinical Outcomes in Patients With Heart Failure|The Japanese Heart Failure Outpatients Disease Management and Cardiac Evaluation (J-HOMECARE)||Japanese Heart Failure Outpatient Disease Management Evaluation Investigators|Yes|Completed|January 2007|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|156|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284400||109939|
NCT01284088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-01|Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Setting|A Prospective, Randomized, Open Label, Trial Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Settings||Ministry of Health, Rwanda|Yes|Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|217|||Male|21 Years|54 Years|Accepts Healthy Volunteers|||March 2012|March 14, 2012|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01284088||109963|
NCT01284101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-10-0632-B|Prospective Randomized Study Comparing Endothelial Cell Loss Using the Tan EndoGlide With Forceps for Insertion of the Donor Graft in DSAEK|Prospective Randomized Study Comparing Endothelial Cell Loss Using the Tan EndoGlide With Forceps for Insertion of the Donor Graft in DSAEK||University Health Network, Toronto||Recruiting|January 2011|||January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01284101||109962|
NCT01284374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP 38094|Parent-son-provider Decision-making About HPV Vaccination|An Investigation of Parent-son-provider Decision-making About HPV Vaccination||Indiana University|No|Completed|February 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|N/A||3|Actual|62|||Both|13 Years|17 Years|No|Non-Probability Sample|Parent-Adolescent pairs attending community-based adolescent health primary care clinics|December 2012|December 13, 2012|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01284374||109941|
NCT01284907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAMDHREC NO: 09/58|Vit D to Treat Asthma in Children: a Randomized, Double-blind, Placebo-controlled Trial|Vit D to Treat Asthma in Children: a Randomized, Double-blind, Placebo-controlled Trial||United Arab Emirates University|Yes|Withdrawn|March 2013|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|12 Years|No|||December 2014|December 16, 2014|January 24, 2011|Yes|Yes|No Participants|No||https://clinicaltrials.gov/show/NCT01284907||109900|
NCT01285167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-401-DE|Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)|Daxas for COPD Therapy (DACOTA)|DACOTA|Takeda|No|Completed|August 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3645|||Both|18 Years|N/A|No|Non-Probability Sample|patients diagnosed with severe COPD.|November 2012|November 7, 2012|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01285167||109881|
NCT01285180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-402-DE|Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD|Daxas in COPD Therapy|DINO|Takeda|No|Completed|August 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5472|||Both|18 Years|N/A|No|Non-Probability Sample|patients diagnosed with severe COPD.|November 2012|November 7, 2012|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01285180||109880|
NCT01285193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT10-HPP-001|Treating Hypertension With Breath Control|A Randomized Controlled Trial to Treat Hypertension by Regularising and Slowing Breathing||Penang Hospital, Malaysia|No|Not yet recruiting|June 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|84|||Both|19 Years|N/A|No|||January 2011|January 26, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285193||109879|
NCT01285453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A1102|Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors|A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors||Novartis||Completed|March 2009|||December 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||November 2012|November 26, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285453||109859|
NCT01285739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-12-2010|Tracheostomized COPD Patients and Non Invasive Mechanical Ventilation|Eight-year Follow up in Tracheostomized COPD Patients Undergoing Domiciliary Non Invasive Mechanical Ventilation.||Fondazione Salvatore Maugeri|Yes|Active, not recruiting|January 2002|December 2011|Anticipated|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|247|Samples Without DNA|whole blood, tracheobronchial aspirate (TBA)|Both|50 Years|85 Years|No|Non-Probability Sample|Cohort was selected from patients admitted to Weaning Center. Patients weaned from        invasive mechanical ventilation but who needed to keep endotracheal canula were enrolled        for the study. Patients with COPD, tracheostomized and in domiciliary invasive mechanical        ventilation was the control group.|December 2010|November 10, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285739||109837|
NCT01285999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2227|A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion|PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion|PLATINUM China|Boston Scientific Corporation|No|Active, not recruiting|January 2011|April 2014|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||January 2013|January 30, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01285999||109817|
NCT01286285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIV HOSP WUERZBURG 7106877|Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria|An Active, Epidemiological Surveillance Study on Influenza-related Hospitalizations to Intensive Care Units and Fatalities in Paediatric Hospitals in Bavaria Covering the Influenza Seasons 2010/2011 and 2011/2012||University Children's Hospital, Wuerzburg|No|Enrolling by invitation|October 2010|March 2012|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|1140|Samples With DNA|Naso-pharyngeal swab, if not available nasal wash or other respiratory secretion (only if      collected routinely by the hospital)|Both|1 Month|16 Years|No|Non-Probability Sample|Children ≤16 years of age, in hospitals with paediatric intensive care units or paediatric        intensive care beds in Bavaria, Germany|January 2011|January 27, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01286285||109795|
NCT01287169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911074|BPA Biomonitoring Study in Cashiers|BPA Biomonitoring Study in Cashiers||National Institutes of Health Clinical Center (CC)||Withdrawn|January 2011|December 2012||||Phase 1|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|100 Years|No|||December 2012|February 12, 2016|January 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01287169||109727|
NCT01291433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081239|Trial of Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy|Randomized Clinical Trial Evaluating Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy: the PENTOCLO Trial|PENTOCLO|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|March 2011|May 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|74 Years|No|||February 2016|February 5, 2016|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01291433||109402|
NCT01283295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006248|Immune Monitoring and Assay Development in Organ Transplant Recipients|Immune Monitoring and Assay Development in Organ Transplant Recipients|IMP|Emory University|No|Recruiting|November 2007|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|5000|Samples With DNA|PBMCs, serum, urine, kidney and liver biopsy samples, broncheolar lavage fluid|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pediatric or adult organ transplant recipients, candidates for organ transplant, donors        and normal volunteers of Emory University Hospital, the Emory Transplant Center or        Children's Healthcare of Atlanta (CHOA)|January 2016|January 20, 2016|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283295||110024|
NCT01288248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anestudea-001|Noninferiority Clinical Trial With Laryngeal Mask and Endotracheal Tube|The Risk of Laryngospasm in Children is Similar to the Use of the Laryngeal Mask and the Endotracheal Tube in Children 2 Years to 14 Years: Clinical Trial Randomized Noninferiority||Universidad de Antioquia|Yes|Active, not recruiting|January 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|338|||Both|2 Years|14 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288248||109647|
NCT01288508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Supra Fiber|Investigation of Supra Fiber in the Treatment of Adults With Constipation|Investigation of Supra Fiber in the Treatment of Adults With Constipation-A Double-blind Randomized Controlled Trial||Georgia Regents University||Completed|October 2010|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|75 Years|No|||September 2014|September 16, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01288508||109627|
NCT01288001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSTP-THA-10-01|Study of Evaluating the Duration of Efficacy of One Intra Articular Injection of Sodium Hyaluronate 2.0% in Patients With Painful Osteoarthritis of the Knee|A Pilot, Open, Randomised, Controlled, add-on Study Evaluating the Duration of Efficacy of One Intra Articular Injection of Sodium Hyaluronate 2.0% in Patients With Painful Osteoarthritis of the Knee||TRB Chemedica||Completed|March 2011|July 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|70 Years|No|||November 2012|November 20, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288001||109665|
NCT01288755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017773|TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir|A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC278 25 mg q.d. and Raltegravir 400 mg b.i.d.||Tibotec Pharmaceuticals, Ireland||Completed|February 2011|May 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288755||109608|
NCT01295710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-ATG-SCT-01|Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)|Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors||Neovii Biotech|Yes|Active, not recruiting|June 2011|February 2022|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|260|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01295710||109073|
NCT01283477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITM - LI 11|Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery|Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery||Letterkenny General Hospital|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|March 26, 2012|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283477||110010|
NCT01283490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100300|The Effect of Sonophoresis on Topical Anesthesia: A Pilot Study|The Effect of Sonophoresis on Topical Anesthesia: a Clinical Trial||Loma Linda University|Yes|Completed|February 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283490||110009|
NCT01284127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS001|Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis|Phase IV Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis||Johns Hopkins University|No|Active, not recruiting|March 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|38|||Both|18 Years|100 Years|No|Non-Probability Sample|All patients with MRI-confirmed superficial siderosis currently residing in the United        States.|February 2016|February 23, 2016|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01284127||109960|
NCT01284413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1002|Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer|Phase I/II Study of Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer||Kansai Hepatobiliary Oncology Group|Yes|Completed|December 2010|August 2013|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|20 Years|N/A|No|||June 2014|June 29, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01284413||109938|
NCT01284387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC-001-ALZ-2001|Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease|A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease|ACCTION|JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Yes|Completed|January 2011|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|126|||Both|50 Years|89 Years|No|||December 2014|December 11, 2014|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01284387||109940|
NCT01284686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00913-54|Pathophysiology of Neuronal Oscillations Within Subthalamo-cortical Loops in Parkinson's Disease|Pathophysiology of Neuronal Oscillations Within Subthalamo-cortical Loops in Parkinson's Disease||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|September 2010|||March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|20|||Both|N/A|N/A|No|||August 2014|August 28, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284686||109917|
NCT01284673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00076-33|Characterization of the Cord Blood Stem Cell in Situation of Neonatal Asphyxia|Characterization of the Cord Blood Stem Cell in Situation of Neonatal Asphyxia|NEOCORD|Assistance Publique Hopitaux De Marseille|No|Completed|April 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|N/A|20 Minutes|No|||September 2014|September 2, 2014|April 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01284673||109918|
NCT01284920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0111|A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients|A Phase I/II, Open-Label, Uncontrolled, Dose-Escalation Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer||Astellas Pharma Inc|Yes|Completed|November 2010|July 2014|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|47|||Male|20 Years|N/A|No|||January 2016|January 29, 2016|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01284920||109899|
NCT01285479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2404|Pregnancy Registry Trial|The Multi-National Pregnancy Fingolimod Exposure Registry in Multiple Sclerosis (Epidemiological Study Protocol FTY720D2404)||Novartis||Recruiting|October 2011|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|N/A|N/A|No|Non-Probability Sample|Women with MS who become pregnant and were exposed to at least one dose of Gilenya during        pregnancy (or up to 8 weeks before last menstrual period).|February 2016|February 2, 2016|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285479||109857|
NCT01285765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNH 2009-1B|Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+|Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+||The Lymphoma Academic Research Organisation|Yes|Recruiting|December 2010|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|80 Years|No|||October 2015|October 16, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01285765||109835|
NCT01285778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-0902|Vectibix for the Treatment of Anal Cancer|Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma|VITAL|Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Active, not recruiting|October 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||September 2013|March 10, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01285778||109834|
NCT01286012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-FP-01 PRIME|Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients|Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate: The PRIME Study|PRIME|Rockwell Medical Technologies, Inc.|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|January 18, 2011|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01286012||109816|
NCT01286025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M15700-101|Comparing the Effect of Video-cases and Text-cases on Medical Students' Learning in Tutorial|A Randomized Crossover Study to Compare the Critical Thinking of Medical Students When Using Video-based or Written Cases||Harvard University Faculty of Medicine|No|Completed|February 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286025||109815|
NCT01286831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106181|A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.|An Open-label, Single-arm Study to Determine the Excretion Balance and Metabolic Disposition of [14C]GW642444 Administered as a Single Dose of an Oral Solution to Healthy Male Volunteers||GlaxoSmithKline|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|May 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01286831||109753|
NCT01291173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-208|Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder|BED|Shire|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|271|||Both|18 Years|55 Years|No|||December 2014|December 22, 2014|February 4, 2011|Yes|Yes||No|October 26, 2012|https://clinicaltrials.gov/show/NCT01291173||109422|External investigation at a site was initiated for reasons unrelated to the study. Lacking information on the investigation, it was deemed prudent to exclude data from subjects enrolled at site (n=11) from the primary analyses of efficacy and safety.
NCT01291186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-2010-1-14|Effect of Body-mass Index (BMI) on Median Effective Dose of Intrathecal Hyperbaric Bupivacaine|The Effect of BMI on Median Effective Dose (ED50) of Intrathecal Hyperbaric Bupivacaine for Total Knee Replacement Arthroplasty||Seoul Medical Center|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|12||Actual|108|||Both|40 Years|80 Years|No|||January 2011|August 2, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291186||109421|
NCT01291719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBIS-1|Insulin Balanced Infusion System|Insulin Balanced Infusion System Control of Glucose||Admetsys Corporation|Yes|Active, not recruiting|November 2008|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|21 Years|85 Years|No|||January 2015|January 26, 2015|February 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01291719||109380|
NCT01291732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1283.5|Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (12.5 mg, 50 mg, 200 mg) of BI 135585 XX (Tablet) in Chinese and Japanese Healthy Male Volunteers (Randomised, Double-blind,Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|February 2011|||April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|February 7, 2011||||No||https://clinicaltrials.gov/show/NCT01291732||109379|
NCT01291706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 10 17|Transcranial Doppler on Admission of Patients With Mild to Moderate Traumatic Brain Injury|Prospective, Multicentre, Observational Study|TCD|University Hospital, Grenoble|No|Completed|February 2011|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|369|||Both|15 Years|N/A|No|Non-Probability Sample|Primary admission of patients following mild to moderate traumatic brain injury who need        exploration with brain CT scan.|April 2014|April 25, 2014|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291706||109381|
NCT01288261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0884-04|Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer|A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer||University of Arizona|Yes|Active, not recruiting|January 2011|||December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|January 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288261||109646|
NCT01288768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/6-31|Is a Knee Arthroscopy of Any Benefit for the Middleaged Patient With Meniscal Symptoms?|Is a Knee Arthroscopy of Any Benefit for the Middleaged Patient With Meniscal Symptoms?||University Hospital, Linkoeping|No|Completed|March 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|45 Years|64 Years|No|||May 2013|May 2, 2013|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01288768||109607|
NCT01289054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571A2403|A Global Imatinib and Nilotinib Pregnancy Exposure Registry|A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS)||Novartis||Completed|January 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4|||Female|N/A|N/A|No|Non-Probability Sample|Women exposed to any dose of Gleevec/Glivec or Tasigna during pregnancy or within 6 months        prior to conception|April 2015|April 14, 2015|January 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289054||109585|
NCT01291875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127/2009|Periodontal Treatment and Metabolic Control in Type 2 Diabetic Patients|||University of Sao Paulo|No|Recruiting|February 2011|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|732|||Both|30 Years|80 Years|No|||February 2014|February 10, 2014|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01291875||109368|
NCT01283841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291-07|Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Four-period, Two Sequence, Single Dose, Replicate, Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet of Dr. Reddy's Laboratories Limited Comparing With That of Cellcept 500 mg Tablet of Roche Laboratories in Healthy, Adult,Human, Male Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 25, 2011|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283841||109982|
NCT01284140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11162B|Improving the Sleep and Circadian Rhythms of Mechanically Ventilated Patients|Improving the Sleep and Circadian Rhythms of Mechanically Ventilated Patients||University of Iowa|Yes|Active, not recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01284140||109959|
NCT01284153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52869|Potential Benefits of Radiotherapy in Prone Position for Breast Cancer Patients: a Planning Study|A Comparison of Three Radiotherapy Techniques for Breast Cancer: a Planning Study||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Female|N/A|N/A|No|Non-Probability Sample|Patients who have an indication for radiotherapy of the breast and/or the lymph nodes.|February 2011|February 3, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01284153||109958|
NCT01284439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655/2553(EC4)|Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma|Effect of Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% in the Treatment of Ocular Surface Disease in Glaucoma Patients||Mahidol University|No|Recruiting|January 2011|February 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 26, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284439||109936|
NCT01284699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01227-50|Evaluation of the Safety and Efficacy of Bilateral Subthalamic Nucleus (SNT) Radiosurgery in Idiopathic Severe Parkinson's Disease Fulfilling Inclusion Criteria for STN Deep Brain Stimulation and Presenting With a Contraindication to Intracerebral Electrode Implantation.|Evaluation of the Safety and Efficacy of Bilateral Subthalamic Nucleus (SNT) Radiosurgery in Idiopathic Severe Parkinson's Disease Fulfilling Inclusion Criteria for STN Deep Brain Stimulation and Presenting With a Contraindication to Intracerebral Electrode Implantation.||Assistance Publique Hopitaux De Marseille|No|Recruiting|April 2010|||April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|70 Years|No|||August 2014|August 28, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284699||109916|
NCT01284946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEFD2010-01|Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda|A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload||Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2011|January 26, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284946||109897|
NCT01284933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD-CAPIAS-01|Carotid Plaque Imaging in Acute Stroke|Carotid Plaque Imaging in Acute Stroke|CAPIAS|Ludwig-Maximilians - University of Munich|No|Recruiting|February 2011|||December 2017||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|whole blood, serum, plasma, RNA|Both|50 Years|N/A|No|Probability Sample|Patients admitted to a specialized stroke service because of an acute stroke or TIA|March 2016|March 24, 2016|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01284933||109898|
NCT01285206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H1107/5|Carbon Polymer Blankets to Prevent Incidence Of Peri-Operative Hypothermia (IPH) in the DSU|A Study To Determine Whether Carbon Polymer Blankets Can Reduce The During And After Short, Day Operations||Brighton and Sussex University Hospitals NHS Trust|Yes|Recruiting|December 2010|March 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2010|January 26, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01285206||109878|
NCT01286038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16523|Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia|A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Who Progressed or Are Resistant to Hypomethylating Agents||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|March 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286038||109814|
NCT01286259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 10-02648|Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals|Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals||University of California, San Francisco|Yes|Completed|January 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286259||109797|
NCT01286272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02625|Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma|A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239) and Bendamustine in Patients With Untreated Follicular Lymphoma||National Cancer Institute (NCI)||Recruiting|April 2011|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||February 2016|March 24, 2016|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286272||109796|
NCT01290887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072/3085|Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma|An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma||Teva Pharmaceutical Industries|Yes|Terminated|June 2011|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1052|||Both|12 Years|75 Years|No|||October 2015|October 21, 2015|February 4, 2011|Yes|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT01290887||109444|
NCT01290900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00007|A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers||AstraZeneca|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 14, 2011|February 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290900||109443|
NCT01291459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/HD/01|Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients|Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus|NNNB|Association Pour la Recherche en Infectiologie|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01291459||109400|
NCT01288014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE1779|Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine|Relationship of Cytokine Production and Immune Responses to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine||Columbia University|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|26|Samples With DNA|Blood samples|Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Relatively healthy people over age 60 who have not had Zostavax previously.|January 2014|January 27, 2014|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288014||109664|
NCT01288781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F002686|Intracranial Pressure in Experimental Models of Headache|Intracranial Pressure in Experimental Models of Headache||Bangor University|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|February 6, 2012|January 27, 2011||No||No|November 24, 2011|https://clinicaltrials.gov/show/NCT01288781||109606|Acetazolamide did not reduce high altitude headache as expected. Nevertheless the relationship between optic nerve sheath diameter and headache could still be determined by completing other analyses.
NCT01288794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM6P824B|Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis|The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial|ANSWER|University of Bologna|Yes|Active, not recruiting|March 2011|May 2016|Anticipated|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288794||109605|
NCT01288807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100686|Effect of Milnacipran on Pain in Fibromyalgia|Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study|Forest|University of California, San Diego|Yes|Recruiting|February 2011|December 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||June 2013|June 24, 2013|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288807||109604|
NCT01295918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|128/13.01.2011|Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children|Efficacy of the Probiotic Lactobacillus Reuteri in Prevention of Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children and Adolescents|AADreuter|St Marina University Hospital, Varna, Bulgaria|Yes|Completed|February 2011|September 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|3 Years|18 Years|No|||September 2013|September 7, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01295918||109057|
NCT01283854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003302_Newnham|The Cycle Study: a Study of the Effectiveness of Cycling Exercise in Breaking the Cycle of Pregnancy Diabetes|Preventing Gestational Diabetes Mellitus Using a Home-based Supervised Exercise Program During Pregnancy||The University of Western Australia|Yes|Completed|June 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|172|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|February 27, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283854||109981|
NCT01284166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dorzo-Brimo-Timo/2010|Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|||Allergan|No|Withdrawn|July 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|January 25, 2011|Yes|Yes|Study was never initiated due to company decision. No study subjects were ever enrolled or    treated.|No||https://clinicaltrials.gov/show/NCT01284166||109957|
NCT01284426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|374/2551(EC3)|Natural History of Chronic Urticaria|The Natural History of Chronic Urticaria in Childhood: A Prospective Study|NHCU|Mahidol University|No|Completed|March 2003|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|||Both|4 Years|15 Years|No|Non-Probability Sample|Pediatric allergy clinic, Siriraj Hospital Mahidol University, Thailand, Children 4-15        years of age with chronic urticaria.|December 2015|December 30, 2015|January 20, 2011||No||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01284426||109937|This study did not perform basophil histamine releasing assay to identify the existence of functional autoantibodies, since there was no available laboratory to do this test.
NCT01289015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90200/3015/1|Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|NAFT-600|Merz Pharmaceuticals, LLC|No|Completed|February 2011|January 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|855|||Both|12 Years|N/A|No|||July 2013|July 26, 2013|January 28, 2011|Yes|Yes||No|July 26, 2013|https://clinicaltrials.gov/show/NCT01289015||109588|
NCT01284712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/16|Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)|||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|July 2009|||July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|27|||Both|18 Years|N/A|No|Probability Sample|VAQUEZ'S DISEASE|September 2015|September 29, 2015|August 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01284712||109915|
NCT01284959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBIRB1005-58|Different Safety Profile of Risperidone and Paliperidone Extended-release|Different Safety Profile of Risperidone and Paliperidone Extended-release: a Double-blind, Placebo-controlled Trial With Healthy Volunteers||Chonbuk National University Hospital|No|Completed|June 2010|December 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|34|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||September 2012|September 21, 2012|January 25, 2011||No||No|February 29, 2012|https://clinicaltrials.gov/show/NCT01284959||109896|The sample size was small, which presents higher risk of a type II error. The time of assessment after administering placebo or risperidone was noon to 2 PM, which may have contributed to the increased reports of sedation
NCT01284972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-02|HINTEGRA Total Ankle Prosthesis Follow-up|Short to Mid Term Follow-up of Patient Implanted With the HINTEGRA® Total Ankle Prosthesis||Integra LifeSciences Services|No|Completed|February 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|225|||Both|18 Years|N/A|No|Non-Probability Sample|Patient implanted with an Hintegra® Total Ankle Prosthesis (only prosthesis designed with        pegs) in primary ankle surgery since a minimum of 2 years|October 2012|October 9, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284972||109895|
NCT01285219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG3|A Study Comparing Pegylated Filgrastim and Filgrastim in Support for Chemotherapy|A Multicenter, Randomized, Cross-over Phase 3 Comparing Preventive Pegylated Filgrastim and Filgrastim in Cancer Patients Receiving Myelosuppressive Chemotherapy||Chinese Academy of Medical Sciences|Yes|Completed|January 2006|December 2008|Actual|May 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|337|||Both|18 Years|70 Years|No|||January 2011|January 26, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01285219||109877|
NCT01285492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A1301|Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of QVA149 (110 Mcg Indacaterol / 50 Mcg Glycopyrrolate o.d.) Using Tiotropium (18 Mcg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Novartis||Completed|January 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|40 Years|N/A|No|||December 2013|December 3, 2013|January 25, 2011||No||No|September 4, 2013|https://clinicaltrials.gov/show/NCT01285492||109856|
NCT01291212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIV-01|Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone|Efficacy of LH Activity in Low Responder Patients With Transdermal Testosterone: a Randomised Controlled Study.||Hospital Clinic of Barcelona|No|Active, not recruiting|January 2011|September 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|104|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||January 2011|February 7, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291212||109419|
NCT01291446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR(AG)32/2010|Effect of Diet on Intestinal Gas Production and Evacuation in Healthy Subjects and Flatulent Patients|Objective Markers Flatulence: Determination of Gas Production and Evacuation in Response to Dietary Manipulations||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|November 2010|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291446||109401|
NCT01287455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483 CTIL|The Effect of Vitamin D Replacement on Airway Reactivity, Allergy and Inflammatory Mediators in Exhaled Breath Condensate in Vitamin D Deficient Asthmatic Children|||Rambam Health Care Campus||Completed|February 2011|December 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|83|||Both|6 Years|18 Years|No|||June 2013|June 12, 2013|January 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01287455||109705|
NCT01288040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010292|Locomotor Training for Neurological Disease|Locomotor Training for Neurological Disease||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|January 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|2 Years|80 Years|No|||March 2015|March 31, 2015|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01288040||109662|
NCT01287754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25575|A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations|A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor||Hoffmann-La Roche||Completed|October 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||May 2015|June 1, 2015|January 24, 2011|No|Yes||No|May 6, 2015|https://clinicaltrials.gov/show/NCT01287754||109684|
NCT01287715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR 10-1-203|Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis|When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis|ABC-STOP|Erasmus Medical Center|No|Recruiting|January 2011|September 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|17 Years|No|||January 2011|January 31, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287715||109687|
NCT01287728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022182-10|The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy|The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2011|August 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|182|||Female|18 Years|N/A|No|||August 2014|August 27, 2014|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287728||109686|
NCT01288027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU07310|Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa|A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa||Sanofi|Yes|Completed|June 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|January 27, 2011|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01288027||109663|
NCT01288521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIowa0843|Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients|Utilizing Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients||University of Iowa|Yes|Enrolling by invitation|October 2008|September 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|65 Years|No|||January 2011|January 31, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01288521||109626|
NCT01295437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lichtenstein hernia repair|Comparison of Three Meshes in Lichtenstein Hernia Repair|A Single-surgeon Randomized Study Comparing Three Composite Meshes on Chronic Pain After Lichtenstein Hernia Repair in Local Anesthesia|Lichtenstein|Kuopio University Hospital|Yes|Completed|March 2003|January 2011|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|85 Years|No|||February 2011|February 11, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295437||109094|
NCT01295736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021135-13|Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY|Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study|SEDUCE|University Hospital, Lille|Yes|Completed|November 2010|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||July 2012|January 31, 2014|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295736||109071|
NCT01295931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0577|Nuclear and Near-Infrared (NIR) Imaging in Melanoma|Diagnostic Nodal Staging for Melanoma With Nuclear and Near-Infrared (NIR) Molecular Optical Imaging||M.D. Anderson Cancer Center|No|Completed|February 2011|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|February 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295931||109056|
NCT01295944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160009|Carboplatin and Bevacizumab for Recurrent Ependymoma|Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|July 2020|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|99 Years|No|||October 2015|November 14, 2015|February 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295944||109055|
NCT01283867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295-07|Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet of Dr. Reddy's Laboratories Limited Comparing With That of Cellcept 500 mg Tablet of Roche Laboratories in Healthy, Adult,Human, Male Subjects Under Non-fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|November 2007|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 25, 2011|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283867||109980|
NCT01283880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML6919|Renal Tubular Acidosis in Incident Renal Transplant Recipients|Renal Tubular Acidosis in Incident Renal Transplant Recipients||Universitaire Ziekenhuizen Leuven|No|Recruiting|May 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|renal transplant recipients|January 2011|May 29, 2012|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283880||109979|
NCT01288729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01272011-7439|Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter|Duration of Infusion Set Function: A Study Comparing the Quick-Set Teflon Catheter vs Sure-T Steel Infusion Set Catheter||Stanford University|Yes|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|N/A|N/A|No|||April 2015|April 8, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288729||109610|
NCT01289028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107DDE05|Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.|An Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.||Novartis||Completed|November 2008|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|January 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01289028||109587|
NCT01284725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022859-30|Weaning of Immunosuppression in Nephritis of Lupus|Weaning of Immunosuppression in Nephritis of Lupus|WIN-Lupus|Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2011|August 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2013|August 29, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01284725||109914|
NCT01284985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-05|Short Term Follow-up of Patient Implanted With the Metatarso-Phalangeal Prosthesis METIS®|Short Term Follow-up of Patient Implanted With the Metatarso-Phalangeal Prosthesis METIS®||Integra LifeSciences Services|No|Completed|February 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Subject who has an indication of:          -  Hallux Rigidus;          -  Hallux Limitus with degenerative joint disease;          -  Painful Hallux Valgus;          -  Osteoarthritis;          -  Rheumatoid arthritis;          -  Post-traumatic arthritis. For which surgeon has recommended that a METIS® prosthesis             be implanted|September 2014|September 10, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284985||109894|
NCT01285232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anakinra1|The Effect of Anakinra on Insulin Secretion|The Effect of Interleukin-1 Receptor Antagonist on Insulin Secretion in Subjects With Beta Cell Dysfunction||Radboud University|Yes|Active, not recruiting|January 2011|December 2012|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|16|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||September 2010|March 23, 2012|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01285232||109876|
NCT01285505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131020|Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation|Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To An Alprazolam Sublingual Tablet||Pfizer|No|Withdrawn|April 2011|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285505||109855|
NCT01285518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2901001|Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes||Pfizer|No|Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|84|||Both|30 Years|65 Years|No|||September 2011|September 16, 2011|January 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01285518||109854|
NCT01286051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08115|Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles|Efficacy of Single Dose Ganirelix in Gonadotropin Ovulation Induction Cycles||Houston Fertility Institute|No|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01286051||109813|
NCT01286298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 10-396|Diode Laser in Gingival Enlargement Related to Orthodontics|The Clinical Application of Diode Laser in Gingival Enlargement Related to Orthodontics||The University of Hong Kong|Yes|Recruiting|October 2010|June 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|10 Years|40 Years|Accepts Healthy Volunteers|||January 2011|January 27, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286298||109794|
NCT01286532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RRU-XXX-2010/1|Asthma in Children|A Six-month Non-interventional Prospective Study of Various Controller Therapies for Moderate Persistent and Severe Persistent Asthma in Children in Real Life Outpatient Clinical Practice||AstraZeneca|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|283|||Both|5 Years|11 Years|No|Non-Probability Sample|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination        therapy with ICS and LABA who have completed at least one valid CACT assessment after the        study entry|January 2013|January 31, 2013|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01286532||109776|
NCT01285791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|obesity17-HMO-CTIL|Sonographic Evaluation of Visceral Fat After Bariatric Surgery|Sonographic Evaluation of Visceral and Subcutaneous Fat in Morbidly Obese Patients Before and After 3 Different Types of Bariatric Surgery.||Hadassah Medical Organization|No|Completed|January 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|39|||Both|18 Years|70 Years|No|Non-Probability Sample|Morbid obese patients admitted electively to our surgery ward after receiving detailed        explanation about each type of surgery and after independently choosing to undergo either        a laparoscopic adjustable gastric banding, a sleeve gastrectomy or a gatsric bypass will        be offered to participate in the study.        The patients must meet criteria for being morbid obese as defined as a body mass index        greater than 40 kg/meter*meter or a body mass index greater than 35 with relevant        comorbidities. The patients must meet other inclusion and exclusion criteria as defined        below.        The patients will be offered to participate in the study regardless of their gender or        race.|February 2016|February 18, 2016|January 10, 2011||No||No|February 18, 2016|https://clinicaltrials.gov/show/NCT01285791||109833|
NCT01287468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99052|Academia Sinica Investigator Award 2010|Academia Sinica Investigator Award 2010||Taipei Medical University WanFang Hospital|No|Active, not recruiting|June 2010|December 2014|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|415|||Female|20 Years|N/A|No|Non-Probability Sample|Breast Cancer patients|January 2011|January 31, 2011|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287468||109704|
NCT01288066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epoca Hemi vs. Total 2011|Effectiveness of Hemi- Versus Total Shoulder Arthroplasty Using Implants of the "Epoca" System|A Randomized Multicenter Study Comparing the Effectiveness of Hemi- Versus Total Shoulder Arthroplasty in Patients With a Degenerative Joint Disease|Epoca H vs T|AO Clinical Investigation and Documentation|No|Recruiting|September 2011|February 2022|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288066||109660|
NCT01288274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bixby 001|Community Based Distribution of Injectable Contraceptives in Tigray, Ethiopia|Safety and Feasibility of Community Based DMPA Provision in Tigray, Ethiopia|CBDDMPA|University of California, Berkeley|No|Completed|June 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1062|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|January 31, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288274||109645|
NCT01288287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0042|Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients|A Prospective, Multicentre, Non-interventional, Observational, Cohort Study to Evaluate the Long Term Clinical, Patient Reported and Health Care Resource Utilization Effects of an Early Response to Certolizumab Pegol (Cimzia®) in Rheumatoid Arthritis Patients in Daily Clinical Practice in the United Kingdom and Eire.|RA-PROACTIVE|UCB Pharma|No|Completed|July 2011|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|152|||Both|18 Years|N/A|No|Non-Probability Sample|Patient presenting with Rheumatoid Arthritis (RA) and having prescribed certolizumab pegol        (CZP, Cimzia®) at the clinic|January 2015|January 27, 2015|January 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288287||109644|
NCT01288534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.064|Hypofractionated Stereotactic Body Radiation Therapy (SBRT)|A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion||University of Michigan Cancer Center|Yes|Active, not recruiting|January 2011|February 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288534||109625|
NCT01295749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC - 1014|Effects of Laryngeal Tube Ventilation on no Flow Time During Out of Hospital Cardiac Arrest|Reduction of no Flow Time During Out of Hospital Cardiac Arrest by Using Laryngeal Tube for Airway Management by Nurses.|FLOWERS|University Hospital, Grenoble|No|Completed|March 2011|June 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|84|||Both|18 Years|N/A|No|||July 2012|July 2, 2012|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295749||109070|
NCT01284465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081204AAH231 26|Type 2 Diabetes Self-management Intervention for Low-income Women|A Comprehensive Approach to Type 2 Diabetes Self-management for Low-income Women||Meharry Medical College|No|Completed|January 2011|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Female|21 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284465||109934|
NCT01284452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si630/2010|Efficacy of Hydrocortisone in Treatment of Severe Sepsis/Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Efficacy of Moderate Dose Hydrocortisone in Treatment of Severe Sepsis and Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome: A Randomized Controlled Trial||Mahidol University|No|Completed|December 2010|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|80 Years|No|||April 2015|April 17, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01284452||109935|
NCT01288742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017770|TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin|A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Transporter Substrates, Digoxin and Rosuvastatin||Tibotec Pharmaceuticals, Ireland||Completed|January 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288742||109609|
NCT01289821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11728|First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib|An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib||Bayer|Yes|Completed|February 2011|June 2014|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|February 3, 2011|No|Yes||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01289821||109526|
NCT01289301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Polyoma IFB 29|Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant|Polyomavirus BK Nephropathy After Renal Transplantation: Randomized Clinical Trial to Demonstrate That Switching to mTOR Inhibitor is More Effective Than a Reduction of Immunosuppressive Therapy|BKVIRUS|Hannover Medical School|Yes|Not yet recruiting|October 2011|October 2018|Anticipated|October 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||October 2010|February 2, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289301||109566|
NCT01289561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00036826|Combined Effects of Alcohol and Caffeine|Combined Effects of Alcohol and Caffeine||Johns Hopkins University|No|Completed|January 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289561||109546|
NCT01285531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPASS13373|Pediatric Lumbar Puncture Success Using the COMPASS|Institutional Review Board Application #13373, Entitled "A Randomized Clinical Trial of Pediatric Lumbar Puncture Success Using The Compass, a Compact Quantitative Pressure Transducer||Seattle Children's Hospital|No|Recruiting|January 2011|||January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|N/A|18 Years|No|||February 2011|February 15, 2011|December 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285531||109853|
NCT01285804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00487|Impact of Using a Cuffed Endotracheal Tube on Limiting the Risk of Airway Fire|||Nationwide Children's Hospital|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Both|N/A|N/A|No|||January 2012|January 27, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285804||109832|
NCT01290055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046406|Turnover of Antigen Specific Lymphocytes After Immunization With the Yellow Fever Vaccine|Turnover of Antigen Specific Lymphocytes After Immunization With the 17D Yellow Fever Vaccine||Emory University|No|Recruiting|February 2011|January 2020|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290055||109508|
NCT01290068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-269|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2011|||||N/A|N/A|N/A||||||||||||||October 26, 2012|February 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290068||109507|
NCT01290081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBIDU-1230|Enhanced Tuberculosis Case Detection Among Substitution Treatment Patients|Prevalence of Latent Tuberculosis and Enhanced Tuberculosis Case Detection Among Injecting Drug Users Receiving Methadone Substitution Treatment|TBIDU|National Institute for Health Development, Estonia||Completed|October 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|112|||Both|18 Years|N/A||||January 2008|February 3, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290081||109506|
NCT01290367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-DR001|Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain|A Prospective, Double Blind, Controlled Study Evaluating Safety and Preliminary Efficacy of a Single Injection of Adult Mesenchymal Precursor Cells (MPCs) Combined With Hyaluronan in Subjects With Chronic Discogenic Lumbar Back Pain||Mesoblast, Ltd.|Yes|Active, not recruiting|August 2011|July 2015|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||January 2014|November 6, 2014|February 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290367||109484|
NCT01286545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASIC 30505 registry|European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study|European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study|EASIC registry|Rheumazentrum Ruhrgebiet|No|Not yet recruiting|February 2011|October 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|95 Years|No|Non-Probability Sample|Patients with ankylosing spondylitis who have completed:          1. the trials ASSERT, EASIC and EASIC extension (overall 7 years)          2. the trial DIKAS (overall 10 years)        and who are still on infliximab or another anti-TNF agent wor who have terminated anti-TNF        treatment|January 2011|January 27, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286545||109775|
NCT01287741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21005|A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)|A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)||Hoffmann-La Roche||Active, not recruiting|July 2011|March 2018|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1418|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|January 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287741||109685|
NCT01287780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/18054|Local Gentamicin Application to Reduce Postoperative Infection Rate|Local Gentamicin Application to Reduce Postoperative Infection Rate in Hemiarthroplasty After Fracture of the Proximal Femur: a Randomized Controlled Trial||Oslo University Hospital|Yes|Completed|January 2011|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|800|||Both|N/A|N/A|No|||August 2013|August 15, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01287780||109682|
NCT01287793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1811062|Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects|Randomized, 4-Way, Crossover Single Dose, Placebo And Active Controlled Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects||Pfizer|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 23, 2011|January 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287793||109681|
NCT01288053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIADCDAllo2005|Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease|Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease||Northwestern University|No|Recruiting|January 2010|January 2019|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|45 Years|No|||March 2016|March 21, 2016|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288053||109661|
NCT01288547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07045V|Effects of Theobromine and Caffeine on Mood, Cognition and Blood Pressure|Temporal Change of Mood and Cognition in Healthy Subjects After Consumption of Theobromine and/ or Caffeine||Unilever R&D|No|Completed|May 2008|July 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|24|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 22, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288547||109624|
NCT01288833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALID PA19624|Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study|Real Time Colorectal Polyp Diagnosis in Colorectal Cancer Screening Using Close Focus High Definition Narrow Band Imaging Colonoscopy Compared to Conventional Histopathology Diagnosis - the VALID (Veterans Affairs Lesion Interpretation and Diagnosis) Colonoscopy Study|VALID|VA Palo Alto Health Care System|Yes|Active, not recruiting|March 2011|December 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|558|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 11, 2014|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288833||109602|
NCT01291927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBS-PSU-001|Pancreas-sparing Duodenectomy Versus Pancreatoduodenectomy for Early-stage Periampullary Carcinoma|Comparison of Pancreas-sparing Duodenectomy With Pancreatoduodenectomy for Early-stage Periampullary Carcinoma:A Prospective Non-Randomized Trial||Southwest Hospital, China|Yes|Recruiting|May 2005|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||January 2011|February 8, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01291927||109364|
NCT01285271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-017|A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon|The Safety and Feasibility of Delivering Xenon to Patients Before and After Coronary Artery Bypass Graft Implantation: a Pilot Study|CArDiAX|RWTH Aachen University|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|N/A|No|||October 2011|October 5, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01285271||109873|
NCT01288495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Long Term Fructose|Long Term Fructose|Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance: a Double-blind, Randomized Crossover Study||Georgia Regents University||Terminated|February 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|January 31, 2011||No|PI moved institutions and changed study protocol|No||https://clinicaltrials.gov/show/NCT01288495||109628|
NCT01289587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252/10|Promoting Physical Activity in Patients With Type 2 Diabetes (DIAfit)|Efficacy and Feasibility of a Program to Promote Physical Activity in Patients With Type 2 Diabetes (DIAfit)|DIAfit|University of Lausanne Hospitals|No|Active, not recruiting|February 2011|October 2015|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01289587||109544|
NCT01289600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARDS1|Mechanical Ventilation and Respiratory Muscle Work of Breathing in Acute Respiratory Distress Syndrome (ARDS) Patients|The Role of Diaphragm Electromyography (EMG) Guided Mechanical Ventilation on Respiratory Physiology in Mechanically Ventilated Patients With Acute Respiratory Distress Syndrome (ARDS)||University Medical Center Nijmegen|Yes|Completed|January 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01289600||109543|
NCT01289847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMX04|A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency|A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents||Bio Products Laboratory|No|Completed|March 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|2 Years|16 Years|No|||December 2014|December 15, 2014|January 27, 2011|Yes|Yes||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01289847||109524|
NCT01289314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAP-HYST-TRIAL|Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy|A Comparison of Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy.||Oslo University Hospital|No|Recruiting|February 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|62|||Female|N/A|N/A|No|||February 2011|February 9, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289314||109565|
NCT01289574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASC-J9-202|Topical ASC-J9 Cream for Acne|Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of 0.1% and 0.025% ASC-J9 Creams Applied Topically Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris||AndroScience Corp|No|Completed|February 2011|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|181|||Both|12 Years|N/A|No|||July 2014|July 29, 2014|February 2, 2011|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01289574||109545|
NCT01289795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF_NCRC_EPC01|Endothelial Function and Progenitor Cells in Acute Ischemic Stroke|Endothelial Function and Progenitor Cells in Acute Ischemic Stroke|EPCAS|Charite University, Berlin, Germany|No|Recruiting|July 2010|June 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|whole blood, serum, PBMC, plasma|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with first-ever ischemic stroke transferred to our stroke unit|January 2011|February 3, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01289795||109528|
NCT01290094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25399|A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis|Interventional, Single Arm, Open Label Study of the Efficacy, Safety and Compliance to the Treatment With Intravenous (IV) Ibandronate (Bonviva®) in the Postmenopausal Osteoporosis Treatment of Bisphosphonates naïve Patients in Daily Practice||Hoffmann-La Roche||Completed|April 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|50 Years|N/A|No|||June 2015|July 17, 2015|January 20, 2011|No|Yes||No|July 17, 2015|https://clinicaltrials.gov/show/NCT01290094||109505|
NCT01290380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2111|A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies|An Open-label, Multi-center Study to Evaluate the Effects of ASA404 Alone and in Combination With Taxane-based Chemotherapy on the Pharmacokinetics of Simvastatin, Caffeine, Omeprazole, and Diclofenac in Patients With Advanced Solid Tumor Malignancies||Novartis||Terminated|February 2010|||November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290380||109483|
NCT01290393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114176|Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada|Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada||GlaxoSmithKline||Terminated|September 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2|||Female|15 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women aged 15 to 25 years and residing in the United States or in Canada|April 2013|May 2, 2013|February 3, 2011|No|Yes|Low accrual of subjects primarily attributable to the low uptake of Cervarix in the US and    Canada in women aged 15 to 25 years of age.|No||https://clinicaltrials.gov/show/NCT01290393||109482|
NCT01290679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017380|An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys®) and Ribavirin (Copegus®) or Peginterferon α-2b (PegIntron®) and Ribavirin (Rebetol®) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects|QUEST-2|Janssen R&D Ireland|Yes|Completed|March 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|393|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|January 7, 2011|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01290679||109460|
NCT01290666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 157|Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair|Multicenter,Prospective, Observational Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair||W.L.Gore & Associates|No|Completed|March 2011|September 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|93|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290666||109461|
NCT01290913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB10090470|Xolair Enhances Oral Desensitization in Peanut Allergic Patients|Xolair Enhances Oral Desensitization in Peanut Allergic Patients||Children's Hospital Boston|Yes|Completed|February 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|7 Years|25 Years|No|||March 2015|March 18, 2015|February 4, 2011|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01290913||109442|
NCT01287494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCM in China|Depression Care Management for Depressed Elders in China Primary Care|Collaborative Care for Depressed Elders in China|DCM|Zhejiang University|Yes|Recruiting|August 2010|July 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|320|||Both|60 Years|N/A|No|||January 2011|January 28, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01287494||109702|
NCT01285388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB12066_001|Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers|A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects||KT&G Life Sciences Corp|Yes|Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|6||Actual|50|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 26, 2011|July 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01285388||109864|
NCT01288300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-526-A|Health and Faith (Salud y Fe): Community-Based Diabetes Pilot Intervention|Health and Faith (Salud y Fe): Community-Based Diabetes Pilot Intervention||University of Chicago|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01288300||109643|
NCT01288313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/35|Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Human Milk Composition of Lactating Women|Effect of N-3 Polyunsaturated Fatty Acids Supplementation on the Human Milk Composition of Lactating Women: Nutritional Intervention With Rapeseed Oil and n-3 Margarine Compared to Standard Olive Oil|Oméga 3|University Hospital, Bordeaux|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|82|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288313||109642|
NCT01288560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project I-A|IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF)|Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) Project I-A of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)|AIMI-HF|Ottawa Heart Institute Research Corporation|Yes|Recruiting|January 2011|September 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1511|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01288560||109623|
NCT01285011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-08|Short Term Follow-up of Patient Implanted With the Proximal Interphalangeal Implant|Short Term Follow-up of Patient Implanted With the Proximal Interphalangeal||Integra LifeSciences Services|No|Completed|April 2009|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|156|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient who needs a proximal interphalangeal joint arthrodesis for whose surgeon has        recommended that a proximal Interphalangeal Implant Ipp-On be implanted|September 2014|September 10, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285011||109892|
NCT01285037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13008|A Study of LY2801653 in Advanced Cancer|A Phase 1 Study of LY2801653 in Patients With Advanced Cancer||Eli Lilly and Company|No|Recruiting|November 2009|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|January 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01285037||109890|
NCT01289327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5634|Propofol Versus Midazolam+Alfentanil for Sedation During Bronchoscopy: Comparison by Cutaneous Carbon Dioxide Tension|Propofol Versus Midazolam Plus Alfentanil for Sedation During Flexible Bronchoscopy: Respiratory Depression Comparison Inspected by Cutaneous Carbon Dioxide Tension Level||Rabin Medical Center|Yes|Completed|April 2010|January 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||December 2010|February 2, 2011|January 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01289327||109564|
NCT01289340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6021rmc|Wound Healing and Pain Management in Partial Thickness Burns|Pain Management and Wound Healing in Partial Thickness Burn: Comparative, Post Marketing, Observational Trail Comparing Advanced Foam Dressings to Conventional Treatment.||Rabin Medical Center|Yes|Not yet recruiting|March 2011|March 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|40 Years|No|Non-Probability Sample|patients ages 18-40 with no co-morbidities nor pregnant.|January 2011|February 2, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289340||109563|
NCT01289613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USchleswig-Holstein|Clinically Relevant Asymmetry of Bispectral Index|Clinically Relevant Asymmetry of Bispectral Index During Anesthesia for ENT Surgery in Adults and Children||University of Schleswig-Holstein|No|Completed|June 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|88|||Both|N/A|N/A|No|Non-Probability Sample|Children and adults during anesthesia for ENT surgery|May 2014|May 21, 2014|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289613||109542|
NCT01289834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK20100112|A Migration and Bone Density Study Comparing Hi-Fatigue Bone Cement and Palacos Bone Cement|A Migration (RSA) and Bone Density (DEXA) Study Comparing Hi-Fatigue Bone Cement and Palacos Bone Cement in Fixation of a Smooth vs. a Fine-blasted Femoral Stem. A Prospective Randomized Study on Primary Total Hip Arthroplasty.||University of Aarhus|Yes|Active, not recruiting|August 2010|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|71 Years|N/A|No|||October 2014|October 21, 2014|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01289834||109525|
NCT01289860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading_2010_01|Investigating the Acute Effects of Flavonoids in Blueberries on Cognitive Function.|A Controlled, Cross-over, Acute Intervention Study Investigating the Cognitive and Neuronal Effects of Flavonoids in Blueberries.||University of Reading|Yes|Completed|May 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01289860||109523|
NCT01290107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B7|Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia|MLL Rearrangements in Acute Myeloid Leukemia: A Pilot Project to Expand and Study MLL-ENL in NOD SCID Gamma Mice||Children's Oncology Group|No|Active, not recruiting|February 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|9|Samples With DNA|Bone Marrow|Both|N/A|30 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia.|May 2015|May 11, 2015|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290107||109504|
NCT01290406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235C2201|BEZ235 Trial in Patients With Advanced Endometrial Carcinoma|A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma||Novartis||Withdrawn|March 2012|December 2017|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||June 2012|June 20, 2012|February 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290406||109481|
NCT01290419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX 757.101|Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine|A Phase 1 Randomized, Observer-Blinded,Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus F Protein Particle Vaccine in Healthy Adults||Novavax|Yes|Completed|December 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|150|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|February 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290419||109480|
NCT01290432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roseff-01|The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women|The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women||Palm Beach Center for Reproductive Medicine|Yes|Completed|February 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||May 2012|May 24, 2012|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290432||109479|
NCT01289808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAOR 005.CTIL|Reduced Infant Response To A Routine Care Procedure After Glucose 25% Analgesia|Reduced Infant Response To A Routine Care Procedure After Glucose 25% Analgesia||The Baruch Padeh Medical Center, Poriya|No|Terminated|February 2011|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|180|||Both|N/A|16 Days|Accepts Healthy Volunteers|||January 2012|January 6, 2012|January 27, 2011|Yes|Yes|changes were made to the which needed an entireley new submission|No||https://clinicaltrials.gov/show/NCT01289808||109527|
NCT01290939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-26101|Bevacizumab and Lomustine for Recurrent GBM|Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Active, not recruiting|October 2011|April 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|433|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290939||109440|
NCT01291225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00368|Safe Play Areas for Ross County Kids Project|Safe Play Areas for Ross County Kids Project|SPARK|Nationwide Children's Hospital|No|Not yet recruiting|February 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 7, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291225||109418|
NCT01290926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-023695-91|Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer|Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer|SoMore|Jules Bordet Institute|No|Completed|February 2011|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290926||109441|
NCT01291199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ro-002/05|Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome|Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome||University of Cologne|Yes|Completed|November 2006|April 2010|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|80 Years|No|||January 2011|February 7, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01291199||109420|
NCT01291472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3214|Disposition of Intravenous Ketorolac|Disposition of Intravenous Ketorolac After Cesarean Section||Universitaire Ziekenhuizen Leuven|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Female|18 Years|50 Years|No|||February 2011|December 12, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01291472||109399|
NCT01287767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI09|A Support Program for Carers of Persons With Dementia|A Support Program for Carers of Persons With Dementia - a 24 Months RCT|DIF2|Norwegian Centre for Ageing and Health|Yes|Completed|October 2009|January 2015|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|230|||Both|N/A|N/A|No|||October 2015|October 6, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01287767||109683|
NCT01285934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetes2008|Hematopoietic Stem Cell Support Versus Insulin in T1D|A Trial of High Dose Immunosuppression and Autologous Hematopoietic Stem Cell Support Versus Intensive Insulin Therapy in Adults With Early Onset Type I Diabetes Mellitus||Northwestern University|Yes|Withdrawn|January 2009|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|16 Years|35 Years|No|||March 2015|August 19, 2015|January 27, 2011|Yes|Yes|No participant enrolled|No||https://clinicaltrials.gov/show/NCT01285934||109822|
NCT01288079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4131C00001|A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy||AstraZeneca|No|Terminated|February 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|145|||Both|18 Years|65 Years|No|||November 2012|November 14, 2012|January 26, 2011|Yes|Yes||No|August 7, 2012|https://clinicaltrials.gov/show/NCT01288079||109659|The study was terminated early and thus only a fraction of the planned number of patients were randomized and many did not complete the study. As a consequence the possibility of interpreting efficacy over an 8 week period is considerably reduced.
NCT01288092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235B2201|BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer|A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer, With or Without PI3K Activated Pathway||Novartis||Withdrawn|March 2012|||September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|January 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288092||109658|
NCT01285921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100106|Functional Link Between Hippocampal and Vestibular Systems: a Pilot Study in Epilepsy Surgery|Functional Link Between Hippocampal and Vestibular Systems: a Pilot Study in Epilepsy Surgery Principal Investigator: Elizabeth VITTE|HIPPOCAMPE|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|February 2011|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|22|||Both|18 Years|N/A|No|||November 2015|December 8, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285921||109823|
NCT01286701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01362|Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions|Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2002|March 2002|Actual|February 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2012|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286701||109763|
NCT01284764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGI-2011-01|Efficacy Study of a Low Volume of Water Intake and Mosapride for Endoscopy in Patients With Subtotal Gastrectomy|Efficacy of a Low Volume of Water Intake and Mosapride for Endoscopy Preparation in Gastric Cancer Patients With Subtotal Gastrectomy: A Randomized Controlled Trial|SMW|Inje University|No|Completed|January 2011|September 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|144|||Both|18 Years|80 Years|No|||October 2011|October 4, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284764||109911|
NCT01285024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 10-916|A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty|A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty||The Cleveland Clinic|Yes|Completed|December 2010|December 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|85 Years|No|||July 2015|July 9, 2015|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285024||109891|
NCT01284777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00295-34|Nuclear Matrix and Cancer: Proteomic and Genomic Analyses Using Microarray in Cells Obtained Via Thoracocentesis|||Assistance Publique Hopitaux De Marseille|No|Completed|May 2010|||May 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Probability Sample|patients with metastatic disease|August 2014|August 28, 2014|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01284777||109910|
NCT01289353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10-01969|Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer|Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks)||New York University School of Medicine|Yes|Active, not recruiting|December 2010|December 2020|Anticipated|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||December 2015|December 15, 2015|January 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289353||109562|
NCT01289626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0127|Efficacy of Lanthanum Carbonate in Calciphylaxis|Evaluation of Efficacy of Lanthanum Carbonate (Fosrenol) in Patients With Calciphylaxis||University of Wisconsin, Madison|Yes|Completed|February 2011|May 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|February 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289626||109541|
NCT01290159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8150-CM-CTIL|The Development Of A Novel Biomarker For Early Identification Of The Individual's State Of Tolerance To Heat|Preliminary Study of Identifying the Tolerance to Heat by a Novel Biomarker of Oxidative Stress||Sheba Medical Center|No|Completed|May 2011|July 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|10|||Male|18 Years|28 Years|Accepts Healthy Volunteers|Non-Probability Sample|young (18-28 years old) post heat stroke subjects, and matched healthy controls|December 2013|December 18, 2013|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290159||109500|
NCT01290120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NILG 2009-012950-19|Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma|Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma||Northern Italy Leukemia Group|No|Completed|November 2002|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|182|||Both|15 Years|N/A|No|||September 2014|September 15, 2014|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01290120||109503|
NCT01290133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VNK114995|Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)|A Phase I, Randomized, Placebo-Controlled, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of the Captisol™ Formulation of Vestipitant (GW597599) in Healthy Adult Subjects||Accenture|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|55|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 11, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01290133||109502|
NCT01290445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051078|Varenicline Pregnancy Cohort Study|Varenicline Pregnancy Cohort Study Protocol Chantix (Registered)/Champix-(Registered) (Varenicline Tartrate)||Pfizer|No|Active, not recruiting|April 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|The study population will consist of all live born and stillborn infants in Denmark and        Sweden.|January 2016|January 21, 2016|January 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290445||109478|
NCT01290458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTH-2008|The Effect of Antioxidant Vitamin Supplementation on Muscle Performance and Redox Status After Eccentric Training|The Effect of Antioxidant Vitamin Supplementation on Muscle Performance and Redox Status After Eccentric Training||University of Thessaly|Yes|Completed|June 2009|June 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|28|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2011|February 4, 2011|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290458||109477|
NCT01290692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVI-AST-005|Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma|Phase 2 Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma||TVAX Biomedical|No|Active, not recruiting|June 2011|February 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|18 Years|N/A|No|||September 2012|September 16, 2012|February 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290692||109459|
NCT01290965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCY-635-104|Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients|A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Effect of Treatment With SCY 635 on Plasma HCV RNA Following 15 Days of Oral Administration in Adult Patients With Chronic Hepatitis C Infection||Scynexis, Inc.|No|Completed|April 2007|January 2009|Actual|December 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|57|||Both|18 Years|65 Years|No|||February 2011|November 5, 2014|February 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290965||109438|
NCT01291238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/772-32|School Intervention With Daily Physical Activity and Healthy Food for Students With an Intellectual Disability.|Lifestyle Related Health and Health Promoting Activities for Youths With Intellectual Disabilities||Karolinska Institutet|Yes|Completed|March 2004|June 2010|Actual|June 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|145|||Both|16 Years|22 Years|No|||February 2011|February 7, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291238||109417|
NCT01291498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU-PT-2010-01|High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma|High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma||Oxford University Hospitals NHS Trust|No|Terminated|April 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|February 7, 2011||No|The manufacturer is not currently supporting research in this indication.|No|June 27, 2013|https://clinicaltrials.gov/show/NCT01291498||109397|
NCT01291511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO522D2301|Relapse Prevention Study in Patients With Schizophrenia|A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension|REPRIEVE|Vanda Pharmaceuticals||Active, not recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|February 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01291511||109396|
NCT01291485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010022|Electronic Intervention for HIV Medication Adherence|Randomized Clinical Trial Examining the Efficacy of an Electronic Intervention for HIV Medication Adherence||Oklahoma State University Center for Health Sciences|Yes|Completed|January 2011|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|97|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01291485||109398|
NCT01287481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AR057808|Pain and Stress Management for Fibromyalgia|Emotional Exposure and Cognitive Behavioral Therapies for Fibromyalgia||Wayne State University|No|Completed|May 2011|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|230|||Both|18 Years|75 Years|No|||March 2016|March 15, 2016|November 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01287481||109703|
NCT01287533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112942|Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids|Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids||Seoul National University Hospital|Yes|Completed|April 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|167|||Female|18 Years|75 Years|No|||November 2014|November 18, 2014|January 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01287533||109699|
NCT01286181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008433|Device-guided Breathing for Shortness of Breath in COPD|Device-guided Slow Breathing in COPD Patients With Clinically Significant Dyspnea: Phase 2||Mayo Clinic|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|40 Years|N/A|No|||April 2013|April 1, 2013|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01286181||109803|
NCT01286194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-A001-315|A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms|A Multi-Center, Open-Label, All-Comers, Single Group Observational Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC )Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms||Eisai Inc.||Completed|April 2006|January 2007||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|community sample|January 2006|January 28, 2011|January 11, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01286194||109802|
NCT01285674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0035-10-ZIV|Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.|INTRATYMPANIC STEROID TREATMENT FOR THE PREVENTION OF INNER EAR TOXICITY ASSOCIATED WITH SYSTEMIC TREATMENT WITH CISPLATIN.||Ziv Hospital|Yes|Not yet recruiting|January 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|90 Years|No|||January 2011|January 27, 2011|January 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01285674||109842|
NCT01286714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01210-39|Assessment of Fistula Closure by OTSC Clip After Bariatric Surgery|Assessment of Fistula Closure by OTSC Clip After Bariatric Surgery||Assistance Publique Hopitaux De Marseille|No|Completed|January 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01286714||109762|
NCT01286389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0706/10 CAPPesq|Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition|Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition||University of Sao Paulo General Hospital|No|Completed|January 2011|October 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|60 Years|N/A|No|||November 2014|November 4, 2014|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286389||109787|
NCT01286675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-346|Effect of Eltrombopag Plus Granulocyte Colony-stimulating Factor (G-CSF) on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant (ASCT)|A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation||Dana-Farber Cancer Institute|Yes|Recruiting|March 2011|||December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|16|||Both|18 Years|70 Years|No|||August 2015|August 6, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286675||109765|
NCT01286688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01361|Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions|Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2002|March 2002|Actual|February 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2012|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286688||109764|
NCT01284504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL0001|Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer|The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial||Stanford University|Yes|Withdrawn|January 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||June 2013|June 23, 2013|January 25, 2011||No|low accrual rate; the only participant withdrew after signing consent|No||https://clinicaltrials.gov/show/NCT01284504||109931|
NCT01285869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-INT-2010-13|Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia|Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia: a Prospective Randomized Controlled Trial.|IMIEPAP|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|November 2010|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|314|||Both|65 Years|N/A|No|||February 2016|February 29, 2016|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285869||109827|
NCT01286116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA0444|A Multinational Trial To Evaluate The Parachute Implant System|A MULTINATIONAL TRIAL TO EVALUATE THE PARACHUTE IMPLANT SYSTEM: PARACHUTE PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE|PARACHUTE|CardioKinetix, Inc|No|Active, not recruiting|May 2011|June 2018|Anticipated|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|79 Years|No|||February 2015|February 2, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286116||109808|
NCT01289366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0006|Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Inflammatory Bowel Disease (IBD)|Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Patients With Inflammatory Bowel Disease||University of Erlangen-Nürnberg Medical School|Yes|Completed|May 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|85 Years|No|Probability Sample|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy.|August 2011|August 10, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289366||109561|
NCT01289379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bickel-HFJV|The Effect of High Frequency Jet Ventilation (HFJV)During Laparoscopic Operations|The Effect of High Frequency Jet Ventilation (HFJV)on Pneumoperitoneum Induced Cardiovascular Changes, During Laparoscopic Surgery.|HFJV|Western Galilee Hospital-Nahariya|No|Completed||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 2, 2011|October 19, 2010||||No||https://clinicaltrials.gov/show/NCT01289379||109560|
NCT01289873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP 37942|Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College Women|Prevalence, Persistence, and Risk Factors for Oral HPV Infections in College Women|HOP-IN|University of Florida|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1036|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|female college students|August 2013|September 9, 2013|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289873||109522|
NCT01289886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2290/2|Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects|BR-A-657, A Phase 1, Double-blind, Placebo-controlled, Ascending Single Oral Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects Incorporating a Comparison of Fed/Fasted Pharmacokinetics||Boryung Pharmaceutical Co., Ltd|Yes|Completed|September 2003|December 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|February 3, 2011|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01289886||109521|
NCT01289899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2290/9|Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects|BR-A-657, A Phase 1, Double-blind, Placebo-controlled, Ascending Multiple Oral Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects||Boryung Pharmaceutical Co., Ltd|Yes|Completed|January 2004|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 3, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01289899||109520|
NCT01290146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT code 2009-016958-41|ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE|Early Use of Levosimendan Compared to Usual Care in Advanced Chronic Heart Failure (ACHF)|ELEVATE|Niguarda Hospital|No|Suspended|February 2011|||June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|80 Years|No|||January 2016|January 16, 2016|February 3, 2011||No|Due to lack of enrollment|No||https://clinicaltrials.gov/show/NCT01290146||109501|
NCT01290471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U31565-A-U101|Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors|Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors||Daiichi Sankyo Inc.|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|February 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290471||109476|
NCT01290705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17790|Dosage-dependence of Graded Exercise Therapy in Patients With Patellofemoral Pain Syndrome.|Dosage-dependence of Graded Exercise Therapy in Patients With Patellofemoral Pain Syndrome. A Randomized Controlled Clinical Trial.||Norwegian University of Science and Technology|No|Completed|November 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|16 Years|50 Years|No|||February 2016|February 17, 2016|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290705||109458|
NCT01290952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030211|On Versus Off Pump Myocardial Revascularization Study|ON Pump vs OFF Pump Myocardial Revascularization in High Risk Patients: a Randomized Study|On-Off|Medtronic Italia|No|Active, not recruiting|September 2006|June 2011|Anticipated|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|630|||Both|18 Years|N/A|No|||February 2011|February 4, 2011|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290952||109439|
NCT01290978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-011219|Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin|Prospective, Randomized Comparison of Two Presurgical Skin Antiseptic Preparations and Resultant Surgical Incise Drape Adhesion to Skin||3M|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 16, 2013|February 4, 2011|No|Yes||No|January 29, 2013|https://clinicaltrials.gov/show/NCT01290978||109437|All 22 subjects enrolled completed the study
NCT01291251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VH-TBE-1|Compliance With Antibiotic Treatment in General Practice|Compliance With Antibiotic Treatment in General Practice||Norwegian Medical Association|No|Completed|February 2010|February 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|||Both|N/A|N/A|No|Probability Sample|Patients in two different primary care clinics.|April 2012|April 23, 2012|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291251||109416|
NCT01291524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081238|Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Evaluate The Effects Of Caloric Content And Time Of Dosing On The Pharmacokinetics Of Pregabalin Controlled Release Formulation As Compared To The Immediate Release Formulation||Pfizer|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 13, 2011|February 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01291524||109395|
NCT01291537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CECILE 2010-020769-25|Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients|||Poitiers University Hospital||Recruiting||||||Phase 2|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|80 Years|No|||February 2011|July 9, 2012|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291537||109394|
NCT01287520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11613|A Study of LY2090314 in Patients With Advanced or Metastatic Cancer|Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin||Eli Lilly and Company|No|Completed|November 2007|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|25 Years|N/A|No|||June 2011|June 19, 2011|January 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287520||109700|
NCT01285102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCCC IRB 10-002|Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer|Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease||Fox Chase Cancer Center|No|Terminated|October 2010|January 2013|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|January 26, 2011|Yes|Yes|This study was closed early by the DSMB due to increased toxicity.|No||https://clinicaltrials.gov/show/NCT01285102||109885|
NCT01285375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|236153|Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution|||Helsinki University Central Hospital|No|Recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|75 Years|No|||January 2011|January 26, 2011|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285375||109865|
NCT01286415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0116|Group Cognitive Processing Therapy for Combat-related Posttraumatic Stress Disorder (PTSD)|Group Cognitive Processing Therapy for Combat-related PTSD||VA Boston Healthcare System|Yes|Completed|September 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01286415||109785|
NCT01286168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008061|Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction|Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction||Mayo Clinic|Yes|Completed|May 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|January 26, 2011|Yes|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT01286168||109804|
NCT01287065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114624|A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function|A Randomised, Repeat-dose, Placebo-controlled, Double-blind Study to Evaluate and Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, When Administered Either in the Morning or in the Evening, in Male and Female Asthmaticsubjects||GlaxoSmithKline|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|70 Years|No|||June 2013|August 22, 2013|January 27, 2011||No||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01287065||109735|
NCT01287078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110068|Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans|Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|10 Years|80 Years|No|||October 2015|February 4, 2016|January 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287078||109734|
NCT01287052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101-006|Nitrous Oxide for Acute Migraine Pain in the Emergency Room (ED)|Nitrous Oxide for Acute Pediatric Migraine Pain Management in the Emergency Room||Children's Hospitals and Clinics of Minnesota|No|Completed|June 2011|January 2015|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|8 Years|18 Years|No|||April 2014|July 29, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287052||109736|
NCT01285622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofL IRB#10.0537|Plethysmography Variability Index as an Indicator of Adequacy of Preload|Cardiac Output Changes and Evaluation of Plethysmography Variability Index (PVI) as an Indicator of Adequacy of Preload in Women Undergoing Robotic Surgery||University of Louisville|No|Enrolling by invitation|January 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Female|18 Years|65 Years|No|Non-Probability Sample|40 female subjects scheduled for elective robotic gynecological surgery under general        anesthesia|November 2012|November 12, 2012|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01285622||109846|
NCT01286623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 041|The Pharmacology/Aging Clinic|Study Title: The Pharmacology/Aging Clinic: Clinical Routine Monitoring of HIV-infected Patients Over 50 Year of Age.|SSAT041|St Stephens Aids Trust|No|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|N/A|N/A|No|Non-Probability Sample|HIV-infected patients over 50 years of age|June 2012|June 6, 2012|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286623||109769|
NCT01289392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0352/09|Continuous Positive Airway Pressure (CPAP), Oral Appliance and Physical Exercise in the Obstructive Sleep Apnea|Effects of the Treatment With Continuous Positive Airway Pressure (CPAP) and Oral Appliance, Associated or Not Associated With Physical Exercise, in the Obstructive Sleep Apnea||Associação Fundo de Incentivo à Pesquisa|Yes|Completed|October 2010|||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|25|||Male|25 Years|65 Years|No|||March 2013|April 25, 2013|January 31, 2011||No||No|January 28, 2013|https://clinicaltrials.gov/show/NCT01289392||109559|
NCT01289418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pcirn-surveillancehcw-0910|Surveillance for Adverse Events Following Pandemic H1N1 Immunization|Short and Long-Term Electronic Surveillance of a Large Number of Healthcare Workers Following Administration of an Adjuvanted Ph1n1 Vaccine||PHAC/CIHR Influenza Research Network|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|6525|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The active surveillance was conducted in three Canadian hospitals participating in the        Public Health Agency of Canada/Canadian Institutes for Health Research- Influenza Research        Network (PCIRN): Quebec City, Toronto, and Halifax. Healthcare workers immunized in these        institutions were offered to participate in a web-based active surveillance of vaccine        safety.|August 2012|August 15, 2012|February 2, 2011||No||No|July 9, 2012|https://clinicaltrials.gov/show/NCT01289418||109557|Only 52% answered the 3 surveys. We don't know why 48% didn't complete the 3 surveys (were they too sick or not motivated).We didn't have a group of comparable unvaccinated individuals (to estimate the risks attributable to the vaccine).
NCT01289912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-06-0247|Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)|Randomized Double-Blind Phase 2 Trial Of RAD001 For Neurocognition In Individuals With Tuberous Sclerosis Complex|TSC|Children's Hospital Boston|Yes|Completed|January 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|6 Years|21 Years|No|||January 2016|January 27, 2016|February 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289912||109519|
NCT01290484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10202010-7129|A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations|An Investigational Pilot Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations||Stanford University|Yes|Completed|December 2010|December 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|6 Months|10 Years|No|||May 2015|May 22, 2015|February 3, 2011|Yes|Yes||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01290484||109475|Baseline MRI examinations were performed within 6 months prior to commencement of sildenafil; several subjects took sildenafil for more than 20 weeks due to MRI scheduling and personal accommodations
NCT01290731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017698|A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy|A Phase III, Open-label Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Genotype 1, Hepatitis C-infected Subjects Who Relapsed After Previous IFN-based Therapy||Janssen Pharmaceutical K.K.|No|Completed|January 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|20 Years|70 Years|No|||December 2013|December 16, 2013|February 3, 2011|Yes|Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT01290731||109456|
NCT01290718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21833|A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.|Study of Trastuzumab Combined With Capecitabine on HER2-positive Metastatic Breast Cancer Patients Pretreated With Trastuzumab and Taxanes or HER2- Positive Breast Cancer Patients Relapsed From (Neo)Adjuvant Therapy of Trastuzumab and Taxanes||Hoffmann-La Roche||Terminated|December 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|65 Years|No|||December 2014|December 15, 2014|February 3, 2011|No|Yes|Slow recruitment|No|December 3, 2014|https://clinicaltrials.gov/show/NCT01290718||109457|
NCT01290991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanish-2010-01|A Study to Evaluate the Safety of Augment™ Bone Graft|A Pilot Study to Augment™ Bone Graft Plus Evaluate the Safety of Allograft for Treatment of Osteochondral Defects (OCD) of the Knee||Nova Scotia Health Authority|No|Completed|July 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|40 Years|No|||August 2012|August 20, 2012|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01290991||109436|
NCT01291264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04134|Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]|Evaluation of Abbott RealTime CT/NG for the Detection of Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] From the Pharynx, Rectum & Urethra of Men Who Have Sex With Men [MSM]||University of California, San Francisco|No|Terminated|June 2012|May 2013|Actual|May 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|260|Samples With DNA|clinician-collected rectal and pharyngeal swabs along with FCUs|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men who have sex with men (MSM) voluntarily presenting at the City STD clinic.|January 2014|January 21, 2014|February 1, 2011||No|Abbott Molecular stopped funding of study|No|January 21, 2014|https://clinicaltrials.gov/show/NCT01291264||109415|Our limitations are small number of subjects enrolled due to early termination of the study and we had no pharyngeal CT infections.
NCT01291550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0196-09|Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples|||Rambam Health Care Campus|No|Recruiting|September 2010|||||N/A|Observational|Time Perspective: Prospective||3|Anticipated|300|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Out patient clinic patients diagnosed with neurodegenerative conditions healthy control        and subjects diagnosed with ADHD.|September 2010|February 7, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291550||109393|
NCT01287507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lactoferrin|Lactoferrin Prophylaxis in VLBW and Regulator T-cells|Oral Lactoferrin Prophylaxis to Prevent Sepsis and Necrotising Enterocolitis of Very Low Birth Weight Neonates in Neonatal Intensive Care Unit and Effect on T-regulatory Cells.||Ankara University|No|Completed|December 2009|December 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|60|||Both|N/A|1 Day|No|||August 2014|August 25, 2014|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287507||109701|
NCT01291563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017167|TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions|A Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group Trial to Evaluate the Effect of Single-dose TMC207 on the QT/QTc Interval in Healthy Subjects||Tibotec BVBA||Completed|February 2011|April 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 5, 2012|February 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01291563||109392|
NCT01285687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0076-09-ZIV|Acupuncture for Post-tonsillectomy Pain Control in Children|Acupuncture for Post-tonsillectomy Pain Control in Children: a Single-blinded, Randomized, Controlled Study||Ziv Hospital|Yes|Completed|January 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|3 Years|12 Years|No|||June 2015|June 30, 2015|January 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01285687||109841|
NCT01285700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-03|Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis|A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.||Zymenex A/S|No|Active, not recruiting|January 2011|November 2012|Anticipated|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|5 Years|21 Years|No|||September 2012|September 25, 2012|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01285700||109840|
NCT01286428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-LC-2010-02|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures||Pathfinder Therapeutics|Yes|Completed|January 2011|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject scheduled for a laparoscopic procedure where liver surface visualization and        surface swabbing is feasible with standard port placement.|March 2012|March 12, 2012|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286428||109784|
NCT01286402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0681|Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy|Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy||The University of Texas Health Science Center, Houston|Yes|Completed|April 2011|May 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|January 25, 2011|Yes|Yes||No|June 30, 2015|https://clinicaltrials.gov/show/NCT01286402||109786|
NCT01287091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4930g|A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet|An Open-Label, 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet||Genentech, Inc.||Completed|October 2010|||||Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|46|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 19, 2011|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287091||109733|
NCT01287104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110073|A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias|A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Hematologic Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|October 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|86|||Both|4 Years|35 Years|Accepts Healthy Volunteers|||December 2015|February 5, 2016|January 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287104||109732|
NCT01287338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP0 AC 01|A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.|A Randomized, Double-Masked, Placebo-Controlled, Proof of Concept Study to Evaluate the Short-term Safety and Efficacy of the QLT Proprietary Olopatadine Punctal Plug Delivery System in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.||Mati Therapeutics Inc.|No|Terminated|October 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|65 Years|No|||September 2013|September 16, 2013|January 27, 2011||No|Lack of definitive clinical results.|No||https://clinicaltrials.gov/show/NCT01287338||109714|
NCT01286363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|monegfg11|Facial Patterns and Masticatory Symmetries|Preferred Chewing Side, Symmetry of Bite Force and Occlusal Contact Area of Subjects With Different Craniofacial Vertical Dimensions||University of Campinas, Brazil|No|Completed|September 2006|December 2008|Actual|June 2007|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|86|||Both|18 Years|32 Years|Accepts Healthy Volunteers|Non-Probability Sample|Students and staff of Piracicaba Dental School, and individuals seeking for dental        treatment at the same institution|January 2011|January 28, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01286363||109789|
NCT01286636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANN02|Artificial Neural Network Directed Therapy of Severe Obstructive Sleep Apnea|Artificial Neural Network Directed Therapy of Severe Obstructive Sleep Apnea||State University of New York at Buffalo|No|Withdrawn|January 2011|June 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|75 Years|No|||January 2016|January 12, 2016|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286636||109768|
NCT01286649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS001-2009|Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia|Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia.||RepliCel Life Sciences, Inc.|No|Active, not recruiting|December 2010|October 2016|Anticipated|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|55 Years|No|||January 2016|January 5, 2016|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01286649||109767|
NCT01289431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|685|Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis|Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).||Bausch & Lomb Incorporated|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|251|||Both|12 Years|N/A|No|||November 2013|November 22, 2013|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289431||109556|
NCT01289639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA-2-044-08S-2|Insulin Resistance in Non-alcoholic Fatty Liver Disease|Insulin Resistance in Non-alcoholic Fatty Liver Disease (Protocol Drug Change From Project Career Development Award (CDA)-2-044-08S)||VA Office of Research and Development|No|Terminated|October 2005|August 2015|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|11|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|January 21, 2011||No|Low recruitment in intervention study. Baseline data published.|No|October 1, 2014|https://clinicaltrials.gov/show/NCT01289639||109540|Due to low enrollment, the study was stopped prematurely. Due to the low number of subjects enrolled, statistical analysis was not possible on the intervention study.
NCT01283152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072010-121|Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.|Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.|PSE|University of Texas Southwestern Medical Center|Yes|Completed|January 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||December 2014|December 9, 2014|January 24, 2011||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01283152||110035|
NCT01283165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZimWorm|Worm Infestation and Child Health in Zimbabwe|Analysis on the Burden of Helminths-plasmodium Polyparasitism, Impact on Anaemia and Effects of Integrated School Based Parasite Control and Health Education in Zimbabwe|Zimworms|University of Zimbabwe|Yes|Completed|April 2003|December 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1303|||Both|5 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary school going children living in rural and commercial farming areas|January 2003|November 9, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283165||110034|
NCT01290172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/689|Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.|A Single-center, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.||University Hospital, Ghent|No|Completed|December 2010|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|No|||November 2014|November 27, 2014|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290172||109499|
NCT01290497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM-ME3710/403|Efficacy and Safety of 3 Different Dosage Regimens of Hyaluronic Acid in Patients With Knee Osteoarthritis (OA)|Pilot, Unicentre, Randomized, Parallel, Controlled Study to Evaluate the Efficacy and Safety of Three Different Intraarticular Dosage Regimens of Adant® in Patients With Osteoarthritis of the Knee||Tedec-Meiji Farma, S.A.|No|Completed|November 2010|November 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|45 Years|N/A|No|||February 2014|February 28, 2014|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01290497||109474|
NCT01290510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHY106Tendon-2010-08|Hyaluronan in the Treatment of Painful Tendinopathy|Hyaluronan in the Treatment of Painful Tendinopathy||TRB Chemedica AG|No|Completed|February 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|75 Years|No|||September 2011|September 21, 2011|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01290510||109473|
NCT01283724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13788|Visanne Study to Assess Safety in Adolescents|A Multi-center, Open Label, Single-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of 2 mg Dienogest Tablets for the Treatment of Endometriosis in Adolescents Over a Treatment Period of 52 Weeks|VISADO|Bayer|No|Completed|March 2011|June 2014|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|111|||Female|12 Years|17 Years|No|||August 2015|August 12, 2015|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283724||109991|
NCT01291004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSG-OI-101|A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives|A Multicenter, Open-label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins||Teva Pharmaceutical Industries|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|206|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|February 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01291004||109435|
NCT01290744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LWM-2010-ENL|Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy|Effect of Additional Clofazimine on ENL Reactions in Leprosy||Leonard Wood Memorial|No|Completed|August 2010|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|15 Years|70 Years|No|||June 2015|June 3, 2015|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01290744||109455|
NCT01291017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0332991|Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.|A Phase II Clinical Trail of the Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Previously Treated, Advanced NSCLC Patients With Wildtype Retinoblastoma Protein (RB) and Inactive Cyclin Dependent Kinase (CDK)N2a||University of Florida|Yes|Active, not recruiting|February 2011|March 2016|Anticipated|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 1, 2011|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01291017||109434|
NCT01291030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/416|The Impact of Magnesium Supplementation on Insulin Resistance and Secretion in Renal Transplant Recipients|The Impact of Magnesium Supplementation on Insulin Resistance and Secretion in Renal Transplant Recipients||University Hospital, Ghent|No|Recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|70|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01291030||109433|
NCT01291277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-08-00172|Time Interval for Endoscopic Variceal Ligation|Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices||University of Southern California|No|Completed|August 2008|December 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||December 2015|December 5, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01291277||109414|
NCT01291290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2009-002|START - Early Thrombocyte Administration to Patients With Ruptured Abdominal Aortic Aneurism|Thrombocyte Administration Versus no Thrombocytes to Patients With Ruptured Abdominal Aortic Aneurism Before Transport to Hospital With Vascular Surgical Department|rAAA|Rigshospitalet, Denmark|No|Recruiting|March 2010|March 2015|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Both|N/A|N/A|No|||March 2013|March 13, 2013|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291290||109413|
NCT01284842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Philipps-University Marburg|Call- Associated Acute Fatigue in Surgical Residency|Call-associated Acute Fatigue in Surgical Residency- Subjective Perception or Objective Fact?|CAFIS|Philipps University Marburg Medical Center|No|Completed|October 2007|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|38|||Both|28 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  38 surgeons (20 male, 18 female)          -  4 senior registrars, 15 junior registrars, 19 interns          -  age 24-48 years; mean 30 years|June 2008|January 26, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284842||109905|
NCT01285947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 40788|Comparing the Pain Experience Between Patients Who Have and Who Have Not Undergone Dermatologic Procedures|A Pilot Study of 20 Subjects: Pain Experience in Naive vs. Non-naive Subjects Undergoing Energy-based Dermatologic Procedures||Northwestern University|Yes|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|January 27, 2011|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT01285947||109821|
NCT01286441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIR001|A Phase 2 Trial of East Indian Sandalwood Oil in the Treatment of Common Warts (Verruca Vulgaris)|A Randomized, Double-blind, Parallel-group, Multicenter, Placebo-controlled Phase 2 Dose-ranging Trial of the Efficacy and Safety of a New Botanical Drug Product Containing East Indian Sandalwood Oil in the Treatment of Common Warts (Verruca Vulgaris)||ViroXis Corporation|No|Completed|November 2012|June 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|176|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286441||109783|
NCT01286454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221068|This Is A Study Of Bioavailability And Food Effect For Fesoterodine.|An Open-Label, Single-Dose, Randomized, Cross-Over Study To Estimate The Bioavailability And Food Effect Of 4 Mg Fesoterodine Extended Release Beads-In-Capsule Formulations Compared To Commercial Tablet Formulation In Healthy Volunteers||Pfizer|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|December 3, 2010|No|Yes||No|December 1, 2011|https://clinicaltrials.gov/show/NCT01286454||109782|
NCT01286467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371002|A Study Of PF-04449913 Administered Alone In Select Solid Tumors|A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors||Pfizer|No|Completed|May 2011|December 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|January 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01286467||109781|
NCT01286727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-09|Study to Improve Renal Function After Kidney Transplantation|Multicenter Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation and at Risk for Dialysis||Angion Biomedica Corp|Yes|Active, not recruiting|February 2010|February 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|May 4, 2015|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286727||109761|
NCT01286740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-264-0111|Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR|A Phase 2B Open Label Pilot Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV 1 Infected Subjects||Gilead Sciences|No|Completed|January 2011|March 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|January 27, 2011|Yes|Yes||No|March 8, 2013|https://clinicaltrials.gov/show/NCT01286740||109760|
NCT01287364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-301|Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis|Psychometric Evaluation of a Novel Questionnaire Designed to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids Administered Via HFA Aerosol or Aqueous Suspension Used for the Treatment of Allergic Rhinitis||Sunovion|Yes|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|185|||Both|12 Years|N/A|No|||October 2012|October 31, 2012|January 26, 2011|Yes|Yes||No|May 1, 2012|https://clinicaltrials.gov/show/NCT01287364||109712|
NCT01287351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002/10|Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study|Retrospective, Real-life Observational Evaluation of the Effectiveness and Cost-effectiveness of Extra-fine Hydrofluoroalkane (HFA) Beclometasone (BDP) Compared With Fluticasone Propionate (FP) in the Management of Asthma in a Representative Population in the United States (US)|USQvarAsthma|Research in Real-Life Ltd|No|Completed|January 2004|October 2010|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|82903|||Both|5 Years|80 Years|No|Non-Probability Sample|Asthma patients who either:        (i) Initiate ICS therapy as one of:          -  HFA-BDP pMDI          -  FP pMDI        OR        (ii) Step up ICS therapy as one of:          -  HFA-BDP pMDI          -  FP pMDI|August 2013|August 2, 2013|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287351||109713|
NCT01286376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSI|Evaluating the Effectiveness of LACTOFOS in Constipated Patients|Randomized, Double Blind, Comparative LACTOFOS With Placebo in Constipation Patients.|COSI|University of Sao Paulo|Yes|Recruiting|August 2010|August 2011|Anticipated|March 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|75 Years|No|||December 2010|January 28, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01286376||109788|
NCT01295047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPONCU101|Comparison of Medical Therapies in Marfan Syndrome.|Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial||Cardiff University|Yes|Completed|July 2006|December 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|16 Years|60 Years|No|||January 2006|February 11, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295047||109124|
NCT01295060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3332-301|Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly|PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY||Endo Pharmaceuticals|No|Terminated|February 2011|June 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|February 10, 2011|Yes|Yes|Program was terminated for business reasons|No||https://clinicaltrials.gov/show/NCT01295060||109123|
NCT01287026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110091|Real-time MRI Right Heart Catheterization Using Passive Catheters|Real-Time MRI Right Heart Catheterization Using Passive Catheters||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|January 2017|Anticipated|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|150|||Both|2 Years|N/A|No|||September 2015|October 6, 2015|January 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287026||109738|
NCT01289652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBE-C V 2.3, 03 June 20|The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals|PRospective OBservational Evaluation of the Natural History and Treatment of Acute HCV in HIV-positive Individuals: The PROBE-C Study|PROBE-C|Istituto Superiore di Sanità|Yes|Recruiting|May 2011|April 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|For phylogenetic analysis HCV RNA detection will be performed.|Both|18 Years|75 Years|No|Non-Probability Sample|600 acute HCV infections with/without HIV infection|April 2014|April 22, 2014|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01289652||109539|
NCT01284075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS051|The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery|The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|April 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|10|||Female|19 Years|N/A|No|||August 2014|August 21, 2014|January 25, 2011||No|Low accrual|No||https://clinicaltrials.gov/show/NCT01284075||109964|
NCT01290185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luyet Coiled Catheters|Coiled Catheters for Regional Anesthesia|Improving the Success Rate of Continuous Peripheral Nerve Blocks Using a Novel Coiled Catheter||Sunnybrook Health Sciences Centre|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01290185||109498|
NCT01283737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-BIO-T-XX-001-01|Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD)|A Randomized, Subject-blind, Controlled Pilot Trial to Evaluate the Effectiveness and Safety of the Use of Demineralized Bone Matrix (DBX®) Versus Mosaicplasty in the Treatment of Late-Stage Osteochondritis Dissecans (OCD) of the Knee in Patients With a Mature Skeleton||Synthes GmbH|No|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||June 2012|June 25, 2012|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01283737||109990|
NCT01283750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90032824|Maximizing Independence at Home (MIND at Home)|Maximizing Independence at Home (MIND at Home): Dementia Care at Home Study||Johns Hopkins University||Completed|July 2008|December 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|303|||Both|70 Years|N/A|No|||June 2014|June 11, 2014|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283750||109989|
NCT01290757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.117|Bioequivalence of Two Different Capsule Types of Dabigatran|Bioequivalence of Two Different Capsule Types of 150 mg Dabigatran Etexilate Made From Two Different Drug Product Batches, Following Oral Administration in Healthy Male and Female Volunteers (Open-label, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)||Boehringer Ingelheim||Completed|January 2011|||April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2013|May 8, 2014|February 2, 2011||||No|April 18, 2012|https://clinicaltrials.gov/show/NCT01290757||109454|
NCT01284296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00524B|Comparison of Three Methods of Hemoglobin Monitoring|Comparison of Three Methods of Hemoglobin Monitoring in Patients Undergoing Spine or Hip Surgery||University of California, San Francisco|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|January 19, 2011||No||No|April 3, 2012|https://clinicaltrials.gov/show/NCT01284296||109947|
NCT01284309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-081|A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects|A Phase 1b, Randomized, Double-Masked, Parallel Group, Placebo Controlled Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects||Astellas Pharma Inc|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|321|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|December 10, 2013|January 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01284309||109946|
NCT01284621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.45|Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers|Relative Bioavailability of Multiple Oral Doses of BI 10773 (25 mg) and Ramipril (5 mg) Administered Together Compared to Multiple Oral Doses of BI 10773 (25 mg) Alone and Ramipril (5 mg) Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Three Way Crossover, Clinical Phase I Study)||Boehringer Ingelheim||Completed|January 2011|||March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|January 20, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01284621||109922|
NCT01284595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00007|Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931|[14C] AZD8931 - A Phase I, Open Label Study of the Absorption, Metabolism, Excretion, and Pharmacokinetics Following a Single Oral Dose to Healthy Male Subjects||AstraZeneca|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Male|50 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 12, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284595||109924|
NCT01284608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OES-DUM-2010/1|Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)|Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)|UROCOR|AstraZeneca|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|||Male|18 Years|N/A|No|Non-Probability Sample|Prostate cancer patients in androgen-ablaction treatment in urological departments|December 2012|December 21, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284608||109923|
NCT01285401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200136-532|Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment|A Three Arm, Randomized, Double Blind, Placebo Controlled, Multicenter, Phase II Study to Evaluate the Efficacy of Vigantol® Oil as Add on Therapy in Subjects With Relapsing Remitting Multiple Sclerosis Receiving Treatment With 44mg Tiw of Rebif®|SOLAR|Merck KGaA|Yes|Completed|March 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|232|||Both|18 Years|55 Years|No|||June 2015|June 3, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285401||109863|
NCT01285713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007632|IV Glucose for Dehydration Treatment|Effects of Glucose Containing Fluid in the Treatment of Acute Dehydration||Children's Hospital of Philadelphia|No|Completed|September 2010|March 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|2 Months|12 Years|Accepts Healthy Volunteers|||March 2013|April 1, 2013|January 27, 2011||No||No|December 14, 2012|https://clinicaltrials.gov/show/NCT01285713||109839|Single center study Small sample size Enrollment available 16 hours/day Evaluated one dextrose load of 500mg/kg
NCT01286220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012010-059|Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis|A Randomized, Controlled, Evaluator-blinded Study to Evaluate the Efficacy of Dilute Bleach Baths on Skin Disease Control in Pediatric Patients With Atopic Dermatitis||University of Texas Southwestern Medical Center|No|Recruiting|December 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Years|17 Years|No|||January 2011|January 28, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01286220||109800|
NCT01285986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAMICOS|Scandinavian Miller Collar Study|Scandinavian Miller Collar Study|SCAMICOS|University Hospital, Linkoeping|Yes|Completed|January 1995|June 1998|Actual|June 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|352|||Both|20 Years|N/A|No|||January 2011|January 27, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285986||109818|
NCT01286753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO25530|A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation|An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine||Hoffmann-La Roche||Active, not recruiting|June 2011|October 2015|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286753||109759|
NCT01287377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100683|Smoking Cessation With the Nicotine Patch: A Pilot Study of Patch Messaging|Smoking Cessation With the Nicotine Patch: A Pilot Study of Patch Messaging||University of California, San Diego|No|Completed|November 2010|November 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|243|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287377||109711|
NCT01283243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0027|Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients|Prospective Study for Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients Without Abnormal Liver Function and Chronic Liver Disease||Yonsei University|Yes|Recruiting|October 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|80 Years|No|Probability Sample|HIV patients without abnormal liver function and chronic liver disease|February 2012|February 1, 2012|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283243||110028|
NCT01294787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2305|Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.|BRIGHT|Novartis||Completed|February 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Both|40 Years|N/A|No|||March 2013|March 19, 2013|February 10, 2011|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT01294787||109144|
NCT01294800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06402|A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)|A Phase 2, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Preladenant in Japanese Subjects With Moderate to Severe Parkinson's Disease. (Phase 2; Protocol No. P06402)||Merck Sharp & Dohme Corp.|Yes|Completed|February 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|450|||Both|30 Years|85 Years|No|||September 2015|September 3, 2015|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294800||109143|
NCT01295619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS I-020805/01|A Study to Assess Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy|A Prospective, Open, Multi-center, Single-arm Study of the Performance and Safety of I-020805 in the Prevention of Cerebrospinal Fluid Leakage Following Elective Cranial Surgery||Kuros Biosurgery AG|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|41|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01295619||109080|
NCT01295632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-049|Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)|Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer||Merck Sharp & Dohme Corp.|No|Completed|February 2011|August 2015|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|65|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|February 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295632||109079|
NCT01283425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G080106/B|Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions|An Open-label, Randomized, Two-period Crossover Study to Evaluate the Safety Use of the InsuPatch Device in Daily Life Conditions.|Daily Life|Insuline Medical Ltd.|No|Completed|February 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|65 Years|No|||April 2012|September 3, 2014|January 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283425||110014|
NCT01287286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XMRPG890251|Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy|Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy— a Double Blinded, Randomized, Placebo-controlled Trial||Chang Gung Memorial Hospital|No|Recruiting|June 2010|May 2012|Anticipated|April 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|80 Years|No|||January 2011|February 6, 2011|January 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01287286||109718|
NCT01283763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITIC2|Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia|ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial|ITIC2|Medical University of Vienna|Yes|Recruiting|May 2013|January 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|N/A|No|||July 2013|July 15, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283763||109988|
NCT01284361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4875-I|Comparison of Two Intermittent Urinary Catheters|User Preference Study to Compare a 40cm Intermittent Catheter to a 30cm Intermittent Catheter||Hollister Incorporated|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|91|||Male|18 Years|N/A|No|||July 2012|October 17, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01284361||109942|
NCT01283412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIHMZK02004|Dexmedetomidine on Postoperative Delirium and Quality of Recovery in Geriatric Patients|Intraoperative Application of Dexmedetomidine on the Incidence of Postoperative Delirium and Quality of Recovery in Geriatric Patients Undergoing Major Surgery||Huazhong University of Science and Technology|Yes|Recruiting|June 2013|||June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|60 Years|N/A|No|||November 2013|November 19, 2013|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283412||110015|
NCT01284062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2421003|Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients|A Phase 2a, Randomized, Double-blind, Sponsor Unblinded, Placebo-controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Subjects With Active Ulcerative Colitis||Pfizer|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|65 Years|No|||November 2014|November 10, 2014|January 25, 2011|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01284062||109965|
NCT01284049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081231|Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease|Study in Adults on HPN Who Have Developed PNALD Comparing Equivalent Doses of Two Lipid Emulsions: OMEGAVEN 10%®, Enriched in n-3 EFA, and a Standard Lipid Emulsion, Intralipid 20%® Not Enriched in n-3 EFA + Vitamin E Supplement|MEGANORM|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2011|July 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||November 2015|December 8, 2015|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284049||109966|
NCT01284634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMD09112|Study to Assess the Effect of Cannabidiol on Liver Fat Levels in Subjects With Fatty Liver Disease.|A Randomised, Partially-blind, Placebo-controlled, Pilot, Dose-ranging Study to Assess the Effect of Cannabidiol on Liver Fat Levels in Subjects With Fatty Liver Disease||GW Research Ltd|No|Completed|February 2011|September 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|January 26, 2011||No||No|December 3, 2013|https://clinicaltrials.gov/show/NCT01284634||109921|
NCT01284855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 08-192|Comparison of Two Dose Regimens of Snake Antivenom for the Treatment of Snake Bites Envenoming in Nepal|A Randomized, Double-blind, Clinical Trial of Two Dose Regimens of VINS Polyvalent Antivenom (ATC J06AA03) for the Treatment of Snake Bites With Neurotoxic Envenoming in Nepal||University Hospital, Geneva|Yes|Active, not recruiting|April 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|5 Years|N/A|No|||December 2012|December 12, 2012|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284855||109904|
NCT01284868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-053|A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.|An Exploratory Study Into the Mechanism of Mirabegron-induced Cardiovascular Effects in Healthy Male Subjects.||Astellas Pharma Inc|No|Completed|July 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2011|July 1, 2013|January 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01284868||109903|
NCT01285115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B082005|The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form|Phase 3 The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form : A Randomized, Double Blind, Parallel-controlled Trial||Korea Health Industry Development Institute|Yes|Completed|December 2008|July 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|147|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2010|January 26, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285115||109884|
NCT01285960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF031|ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids|A Clinical Study to Evaluate Safety of the ExAblate Model 2100 Type 1.1 System (ExAblate 2100/2000 UF V2 System) in the Treatment of Symptomatic Uterine Fibroids||InSightec|No|Active, not recruiting|May 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|106|||Female|18 Years|64 Years|No|||March 2016|March 2, 2016|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285960||109820|
NCT01286207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462 Pooled 022/025/029|Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)|Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029)||Merck Sharp & Dohme Corp.|No|Completed|March 1995|May 1997|Actual|May 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|1959|||Both|18 Years|65 Years|No|||February 2015|February 13, 2015|January 27, 2011|Yes|Yes|||May 20, 2011|https://clinicaltrials.gov/show/NCT01286207||109801|
NCT01286766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0332|Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma|A Randomized Phase II Trial of Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma||Yonsei University|Yes|Completed|September 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|70 Years|No|||March 2014|March 4, 2014|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286766||109758|
NCT01286779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251001|BAX 326 (rFIX) Continuation Study|BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study||Baxalta US Inc.|Yes|Recruiting|April 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|65 Years|No|||February 2016|February 18, 2016|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286779||109757|
NCT01286792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2010|||||N/A|N/A|N/A||||||||||||||March 17, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286792||109756|
NCT01287117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4881g|A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)||Genentech, Inc.||Completed|February 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|319|||Both|12 Years|75 Years|No|||November 2013|November 4, 2013|January 27, 2011|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01287117||109731|
NCT01287130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110075|AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer|A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|January 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|99 Years|No|||February 2016|February 6, 2016|January 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287130||109730|
NCT01287390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/012|Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck|Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck: a Multicenter, Two-arm, Randomized Phase II Trial.||University Hospital, Ghent|No|Completed|October 2011|May 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01287390||109710|
NCT01283256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIL/ZONE/CT01/2010|A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.|Evaluation of Safety and Efficacy of Zonisamide in Adult Patients With Partial, Generalized and Combined Seizures: An Open Labeled, Non-comparative, Observational Study||Eisai Inc.||Completed|January 2011|May 2013|Actual|January 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|655|||Both|18 Years|75 Years|No|Non-Probability Sample|Single Cohort Study involving community patients with epilepsy|January 2014|January 23, 2014|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283256||110027|
NCT01283269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00034934|A Rehabilitation Intervention for Amnestic Mild Cognitive Impairment|A Multicenter Rehabilitation Intervention for Amnestic Mild Cognitive Impairment||Emory University|No|Completed|October 2010|July 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|128|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01283269||110026|
NCT01295346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-04b|Biomarkers of Mild and Moderate Traumatic Brain Injury|Biomarkers of Mild and Moderate Traumatic Brain Injury||Banyan Biomarkers, Inc|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|290|Samples Without DNA|Whole blood, serum, plasma|Both|18 Years|80 Years|No|Non-Probability Sample|Subjects who present to the health care facility with Traumatic Brain Injury (GCS 9-15)        within 4 hours of injury.|March 2013|March 11, 2013|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01295346||109101|
NCT01295606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52907|Cefazolin Pharmacokinetics: Elimination Clearance in Neonates|Cefazolin Pharmacokinetics: Elimination Clearance in Neonates||Universitaire Ziekenhuizen Leuven|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|N/A|28 Days|No|||December 2010|December 12, 2011|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01295606||109081|
NCT01283178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC 13222|Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC|A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)||Virginia Commonwealth University|Yes|Terminated|July 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|19 Years|N/A|No|||March 2016|March 22, 2016|January 24, 2011|No|Yes|Closed by PRMS for Slow accrual|No||https://clinicaltrials.gov/show/NCT01283178||110033|
NCT01283438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUBARD-CP-001|A Prospective, Randomized, Multicenter Study to Demonstrate the Superiority of the Barricaid to Discectomy for Primary Lumbar Disc Herniation|A Prospective, Randomized, Multicenter Study to Demonstrate the Superiority of the Barricaid to Discectomy for Primary Lumbar Disc Herniation||Intrinsic Therapeutics|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|21 Years|75 Years|No|||January 2016|January 28, 2016|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01283438||110013|
NCT01283776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1430|Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation|A Phase II Study to Investigate the Efficacy of Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation|OCTET-CY|University of Cologne|No|Completed|March 2011|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|N/A|No|||June 2014|June 8, 2014|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283776||109987|
NCT01283789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12418|Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer|Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer||University of Kansas Medical Center|Yes|Recruiting|February 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Female|18 Years|N/A|No|||March 2016|March 23, 2016|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283789||109986|
NCT01283802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOCUS|Intraoperative Cholangio-Ultrasound in Resective Liver Surgery|More Than 400 Hepatectomies Without Intraoperative Cholangiography: Prospective Validation of the Role of Ultrasound|IOCUS|University of Milan|No|Completed|June 2004|June 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|448|||Both|N/A|N/A|No|Probability Sample|Patients undergoing resective liver surgery for hepatobiliary tumors|June 2010|January 25, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283802||109985|
NCT01284348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-011-NSCL-001|Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer|An Open-Label Randomized, Phase 2A, Dose-ranging Study (Part 1) of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens Followed by a Phase 2B/3, Double-blind, Randomized, Placebo-controlled Study (Part 2) of Sotatercept (Ace-011) for Chemotherapy-Induced Anemia in Subjects With Metastatic Non-small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapeutic Regimens||Celgene|Yes|Terminated|January 2011|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|25|||Both|18 Years|N/A|No|||August 2014|August 27, 2014|December 17, 2010|Yes|Yes|Persistent low enrollment made study continuation no longer feasible|No||https://clinicaltrials.gov/show/NCT01284348||109943|
NCT01284660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00009-11 HYMC|Docosahexaenoic Acid (DHA) Effects on Cognitive Function, Craving and Psychosocial Factors in Heavy Cigarette Smokers|||Hillel Yaffe Medical Center|Yes|Completed|November 2011|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|51|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01284660||109919|
NCT01284647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-081|A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis|A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis||Changhai Hospital|Yes|Completed|February 2011|June 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|65 Years|No|||January 2014|January 13, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284647||109920|
NCT01284322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H30142|Fresolimumab In Systemic Sclerosis|OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL||Boston University|Yes|Completed|January 2011|March 2014|Actual|June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01284322||109945|
NCT01284335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12267|A Safety Study in Patients With Advanced Solid Tumors|A Phase 1 Multicenter, Dose-escalation Study of LY573636-Sodium in Combination With 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Active, not recruiting|July 2008|February 2016|Anticipated|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|230|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|January 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01284335||109944|
NCT01285141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022740-20|Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine|Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Three Cervico-vaginal Topical Immunisations With a Fixed Dose of HIV CN54gp140 Glycoprotein-hsp70 Conjugate Vaccine|TL01|St George's, University of London|No|Completed|July 2011|December 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285141||109883|
NCT01285154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012045RC|Modified Triple Osteotomy for Acetabular Dysplasia|Modified Triple Osteotomy for Acetabular Dysplasia - A Modified Technique for Better Femoral Head Medialization and Coverage||National Taiwan University Hospital|Yes|Recruiting|February 2011|June 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|2|||Both|6 Years|N/A|No|Probability Sample|Young adults and adolescents underwent triple innominate osteotomy for symptomatic        acetabular dysplasia in our institution|January 2011|April 21, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285154||109882|
NCT01285414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-6827-021|Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase 2 Study of Verubulin With Radiation Therapy and Temozolomide in Subjects Newly Diagnosed With Glioblastoma Multiforme||Myrexis Inc.|Yes|Completed|December 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|69 Years|No|||April 2012|April 10, 2012|January 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285414||109862|
NCT01285752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK106 II-02|A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)|||Asahi Kasei Pharma Corporation||Completed|February 2011|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|65 Years|No|||April 2012|April 6, 2012|January 27, 2011||||No||https://clinicaltrials.gov/show/NCT01285752||109836|
NCT01285973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-10|Evaluation of Integra® Artificial Dermis for the Treatment of Leg Ulcers|||Integra LifeSciences Services|No|Completed|April 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|90 Years|No|Probability Sample|The study population will be patients with "difficult" lower limb ulcers, whose wounds        have not responded to directed healing for more than 6 months or who have a wound > 10        cm².|August 2015|August 11, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285973||109819|
NCT01286233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP MA.32.F|Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32|Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer||NSABP Foundation Inc|No|Active, not recruiting|July 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|394|Samples With DNA|Blood sample|Female|18 Years|74 Years|No|Non-Probability Sample|Patients with breast cancer who have been diagnosed and have undergone definitive surgical        treatment for invasive breast cancer within the previous 12 months and who are eligible        for randomization to NCIC MA.32.|September 2015|September 8, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286233||109799|
NCT01286246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21492|Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor|Pilot Randomized Controlled Trial of Vaginal Progesterone to Prevent Preterm Birth in Women With Threatened Preterm Labor|PROTO|University of Calgary|No|Terminated|January 2011|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Female|18 Years|50 Years|No|||January 2015|January 7, 2015|January 27, 2011||No|Trial investigators were unable to recruit the estimated sample|No||https://clinicaltrials.gov/show/NCT01286246||109798|
NCT01286805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10038|Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial|Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial|LPB Hip Scope|Hospital for Special Surgery, New York|Yes|Completed|May 2010|May 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|65 Years|No|||May 2013|May 1, 2013|January 28, 2011||No||No|July 23, 2012|https://clinicaltrials.gov/show/NCT01286805||109755|
NCT01286818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14223|A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)|A Phase 1b Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine||Eli Lilly and Company|Yes|Completed|February 2011|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||October 2014|October 3, 2014|January 25, 2011|No|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01286818||109754|
NCT01287143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110083|Quantifying and Understanding the Signs and Symptoms of Fever|Beyond Intuition: Quantifying and Understanding the Signs and Symptoms of Fever||National Institutes of Health Clinical Center (CC)||Completed|January 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|99|||Both|18 Years|100 Years|No|||May 2015|September 24, 2015|January 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01287143||109729|
NCT01283581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RX-3341-202|A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections|A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid||Melinta Therapeutics, Inc.|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|256|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|January 24, 2011|Yes|Yes||No|August 23, 2013|https://clinicaltrials.gov/show/NCT01283581||110002|
NCT01283594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN115-CL02|Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off|A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off||Biotie Therapies Inc.|No|Completed|March 2011|||October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|420|||Both|30 Years|80 Years|No|||May 2014|January 12, 2016|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283594||110001|
NCT01283607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Digicoach|E-health Cognitive Behavioral Therapy in Women Treated by in Vitro Fertilization (IVF)|Treatment of Depression and Anxiety by an E-health Cognitive Behavioral Therapy (Digicoach) in Women Treated by in Vitro Fertilization (IVF)||University Medical Center Nijmegen|Yes|Completed|February 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|120|||Female|18 Years|42 Years|No|||November 2013|November 14, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283607||110000|
NCT01283282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00005145|Investigation of the Athero-Protective Effects of Clopidogrel|Phase 4 Study of Clopidogrel in Patients With Stable Coronary Artery Disease to Determine Effects on Vascular Function, Biomarkers and Endothelial Progrenitor Cells|APECS|Emory University|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|48|||Both|21 Years|80 Years|No|||April 2015|April 15, 2015|January 24, 2011||No||No|March 6, 2015|https://clinicaltrials.gov/show/NCT01283282||110025|Limited sample size
NCT01291823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH10|Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer|A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal||Zhejiang Cancer Hospital|Yes|Recruiting|December 2010|December 2014|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|70 Years|85 Years|No|||February 2011|February 7, 2011|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01291823||109372|
NCT01283191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD301598 1R36DA030619-01|Behavioral Incentives to Increase Exercise in Cocaine Dependent Women|Using Behavioral Incentives to Promote Exercise Compliance in Cocaine Dependent Women||Virginia Commonwealth University|Yes|Completed|May 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Female|18 Years|N/A|No|||December 2014|December 16, 2014|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283191||110032|
NCT01283204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0596|Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer|Randomized Phase II Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer||Yonsei University|No|Active, not recruiting|February 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|228|||Both|20 Years|N/A|No|||March 2016|March 3, 2016|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283204||110031|
NCT01283815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUSOper193|Laparoscopic Management of Periappendicular Abscess|Laparoscopic Management of Periappendicular Abscess - Randomized Controlled Trial||Helsinki University Central Hospital|No|Completed|January 2011|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||September 2014|September 21, 2014|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01283815||109984|
NCT01284114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMU-N1|Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients|Effects of Aliskiren on Blood Pressure, Heart and Kidney in Elderly Hypertensive Chronic Kidney Disease Patients||Jichi Medical University|No|Completed|February 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|65 Years|N/A|No|||July 2012|September 19, 2012|January 25, 2011||No||No|July 5, 2012|https://clinicaltrials.gov/show/NCT01284114||109961|
NCT01262547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-001784|A New Micrografting Technique for Vitiligo|A Randomized Controlled Pilot Study to Examine the Use of Micrografting, Using a Novel Grafting Technique for the Repigmentation of Vitiligo||Massachusetts General Hospital|No|Terminated|September 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|80 Years|No|||October 2014|October 30, 2014|December 16, 2010||No|The study sponsor was acquired by a company that focuses on chronic wounds.|No|June 18, 2014|https://clinicaltrials.gov/show/NCT01262547||111617|Early termination of study leading to small number of subjects analyzed.
NCT01272063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-OCT-DR-2010-1|Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography|Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography||Carl Zeiss Meditec, Inc.|Yes|Completed|November 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|91|||Both|50 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|June 2013|June 24, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272063||110886|
NCT01263158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L586-97|Labour Augmentation by Means of Oxytocin - Obstetric Outcome and Women's Experiences|||Göteborg University|No|Completed|October 1998|December 2003|Actual|||N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2072|||Female|18 Years|48 Years|No|||August 2015|August 10, 2015|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263158||111570|
NCT01263483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/CCT-003|Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|230|||Both|33 Years|85 Years|No|||February 2012|February 1, 2012|December 17, 2010||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01263483||111545|
NCT01264029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110030|Efficacy of Mindful Tai Chi on Obese or Overweight Adults: A Randomized Controlled Clinical Trial|Efficacy of Mindful Tai Chi Intervention on Obese and Overweight Adults: A Randomized Controlled Clinical Trial||National Institutes of Health Clinical Center (CC)||Terminated|December 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|4||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|September 24, 2015|December 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01264029||111504|
NCT01264328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTCC-2009-03|Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer|"Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer"|VECTITAX|Grupo Español de Tratamiento de Tumores de Cabeza y Cuello|No|Not yet recruiting|December 2010|October 2012|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2010|December 20, 2010|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01264328||111481|
NCT01264302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10640610|Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions|A Randomized, Single-dose, Two-treatment, Two-way, Crossover Bioequivalence Study of Finasteride 5 mg Tablets (Dr. Reddy's Laboratories Limited) With the Reference Formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.) Under Fed Conditions in Healthy Adult Male Subjects.||Dr. Reddy's Laboratories Limited|No|Completed|November 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2006|December 20, 2010|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264302||111483|
NCT01265277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4453|Changes in Sleep Patterns and Stress in Infants Entering Child Care|Changes in Sleep Patterns and Stress in Infants Entering Child Care: Implications for SIDS Risk||Children's Research Institute|No|Terminated|July 2009|March 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|Samples Without DNA|urine samples from both mom and baby|Both|N/A|3 Months|Accepts Healthy Volunteers|Non-Probability Sample|infants from 0 to 3 months in the United States|January 2016|January 4, 2016|December 20, 2010||No|PI changed institutions|No||https://clinicaltrials.gov/show/NCT01265277||111408|
NCT01265550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|573|A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors|CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors||VA Office of Research and Development|Yes|Active, not recruiting|August 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|393|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265550||111387|
NCT01265563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-004-10S|Glutathione in Diabetic Nephropathy|Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy|CGDN|VA Office of Research and Development|Yes|Active, not recruiting|January 2011|March 2016|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|110|||Both|18 Years|76 Years|No|||March 2015|March 30, 2015|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01265563||111386|
NCT01265251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-088M|Computerized Neuropsychology in Idiopathic Normal Pressure Hydrocephalus (INPH)|Evaluation of a Computerised Neuropsychological Test Battery for Idiopathic Normal Pressure Hydrocephalus (INPH)||Umeå University|No|Completed|August 2007|April 2010|Actual|April 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|97|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Reliability: Healthy elderly Validity: Various diseases Feasibility: Possible        INPH-patients|December 2010|December 22, 2010|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265251||111410|
NCT01261507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHF-183-0531A|Reader Study of DeltaView™ Chest Radiograph Software|Reader Study to Demonstrate That Use of DeltaView™ is Superior to the Use Standard Prior and Current Antero/Posterior (AP/PA) X-ray Image Pair||Georgetown University|No|Completed|November 2010|December 2012|Actual|December 2011|Actual|N/A|Observational|N/A||1|Actual|15|||Both|35 Years|100 Years|No|Non-Probability Sample|Radiologists in community practice of radiology chest radiographs of individuals with or        without a lung nodule|November 2015|November 4, 2015|December 14, 2010|Yes|Yes||No|April 5, 2013|https://clinicaltrials.gov/show/NCT01261507||111697|The main limitation is that the experimental format for this study is similar to, but not identical to the clinical pattern of practice in that more data is recorded during the study than would normally be gathered in clinical practice
NCT01261520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU 2005-167|Chinese Women and Mammography Screening|Promoting Adherence to Mammography Use in Chinese Women||Georgetown University|No|Completed|July 2005|||August 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|671|||Female|40 Years|N/A|No|||April 2012|April 23, 2012|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261520||111696|
NCT01288235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-206|Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation|A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes||Massachusetts General Hospital|Yes|Recruiting|January 2011|||January 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|1 Year|25 Years|No|||February 2016|February 25, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288235||109648|
NCT01274117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/20-4-10|Trial Comparing One-stage With Two-stage Basilic Vein Transposition|Randomized Trial Comparing Transposition of the Basilic Vein, for Vascular Access, Performed in One-stage Versus Two-stages||University of Patras|No|Terminated|December 2010|||May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|90 Years|No|||June 2015|June 1, 2015|January 10, 2011||No|PRIMARY EFFICACY OUTCOME MEASURE (MATURATION) WAS SIGNIFICANT, IN FAVOR OF THE TW0-STAGE    PROCEDURE|No||https://clinicaltrials.gov/show/NCT01274117||110728|
NCT01270516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diaphragm EPA HMB|Effect of EPA and HMB on Strength in ICU Patients|Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients||University of Kentucky|Yes|Recruiting|January 2014|May 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270516||111005|
NCT01271296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.2007.2620 (REK)|Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease|Use of Liquorice and Grapefruit in Patients With Addison's Disease||Haukeland University Hospital|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|17|||Both|18 Years|80 Years|No|||December 2010|January 13, 2011|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01271296||110945|
NCT01271309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/2007_Ferrara|Stem Cell Migratory Activity: Prognostic Marker in Myocardial Ischemia|Migratory and Angiogenic Dysfunction of Circulating CD133 Stem Cells: a New Prognostic Marker in Myocardial Ischemia.||IRCCS Multimedica|No|Completed|July 2007|July 2013|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|170|||Both|18 Years|N/A|No|Probability Sample|Patients will be recruited sequentially at the Operative Unit of Ferrara having the        following characteristics: Thoracic pain lasting at least 20 min and ST changes or left B        block, not present in previous ECG. MI will be confirmed by elevation of troponin I and        CK-MB. Patients will be treated according to international guidelines. With regard to        medical treatment, this will include all available drugs except for statins, which will be        inserted only 14 days post-MI, to avoid the confounding effect of these drugs on stem cell        biology.        Patients reporting thoracic pain 24 hours prior to hospitalization will be excluded.        Similarly, those with HF symptoms resistant to therapy will be excluded. By contrast,        patients with Killip II e III LV dysfunction will be included.|August 2013|August 7, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271309||110944|
NCT01271556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALM101012008|Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients|Salmeterol Improves Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients|SALM1|University of Milan|No|Completed|December 2008|July 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|20|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||December 2008|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271556||110925|
NCT01263496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/OCT-001|Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan|A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan.||Takeda|No|Completed|May 2007|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|438|||Both|29 Years|87 Years|No|||February 2012|February 1, 2012|December 17, 2010||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01263496||111544|
NCT01262833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811936|Pudendal Assessment in Erectile Dysfunction|A Cohort Study of the Functional Significance of Internal Pudendal Artery Stenoses in Patients With Erectile Dysfunction|INDEED|University of Pennsylvania|Yes|Terminated|September 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10|||Male|18 Years|N/A|No|Non-Probability Sample|sexually active men, scheduled for cardiac catheterization or peripheral artery        catheterization, who have at least one risk factor for ED|January 2012|March 13, 2014|November 12, 2010||No|data suggesting pudendal artery stenosis rarely being cause of ED|No||https://clinicaltrials.gov/show/NCT01262833||111595|
NCT01262846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn FLU 02|Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals|Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals||University of Pennsylvania|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|232|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262846||111594|
NCT01264042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTBI_pw|Iron Supplementation During Pregnancy and Non-Transferrin-Bound Iron (NTBI)|Iron Supplementation During Pregnancy and Non-Transferrin-Bound Iron (NTBI)|NTBI_pw|Swiss Federal Institute of Technology|Yes|Completed|January 2011|September 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264042||111503|
NCT01264315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-GITMO-413|Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant|Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant||Fondazione Neoplasie Sangue Onlus|Yes|Recruiting|September 2008|December 2017|Anticipated|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|65 Years|No|||February 2016|February 5, 2016|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264315||111482|
NCT01264341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 21/10|Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma|Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer||Hellenic Cooperative Oncology Group|No|Terminated|December 2010|April 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||October 2015|February 11, 2016|December 20, 2010||No|Based on the developments in the treatment of recurrent metastatic renal cancer, the study    treatment is no longer considered to be the best treatment option|No||https://clinicaltrials.gov/show/NCT01264341||111480|
NCT01264354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-412|An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B|An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B||Bukwang Pharmaceutical|No|Completed|March 2010|February 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|December 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01264354||111479|
NCT01264614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB#00663|Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults|Neuropsychological and Neuroimaging Effects of Strengthening Exercise for Early Dementia and Normative Older Adults||Union College, New York|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 9, 2015|December 21, 2010||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01264614||111459|
NCT01261208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-990152|The Study of the Prevalence of Helicobacter Pylori Infection Among HIV/AIDS Cohort|The Study of the Prevalence of Helicobacter Pylori Infection Among HIV/AIDS Cohort||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|May 2010|May 2011|Anticipated|May 2010|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|HIV/AIDS group|September 2010|December 14, 2010|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01261208||111720|
NCT01261221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-990168|Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans|||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|137|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Tibetan colony of India|July 2011|May 21, 2012|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261221||111719|
NCT01261533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISBOR-61165995002|Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment|The Multi-center Exploratory Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment||GuangZhou WeiShiBo Biotechnology Co., ltd|Yes|Recruiting|September 2010|June 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|122|||Both|18 Years|65 Years|No|||May 2013|May 22, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261533||111695|
NCT01261182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB-7135830|Targeting School Feeding Programs at Vulnerable Sub-Groups|Study of School Feeding Programs' Impact on Anemia Status in Pre-adolescent Girls and Other Vulnerable Household Members in a Cluster-Randomized Trial in Uganda||International Food Policy Research Institute|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2083|||Both|6 Years|13 Years||||December 2010|December 14, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261182||111722|
NCT01261195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-990030|Establishment of Vascular Permeability Model for Research Purpose by Human Umbilical Vascular Endothelial Cells|Establishment of Vascular Permeability Model for Research Purpose by Human||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|March 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|60|Samples With DNA|the umbilical cord|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy pregnant women|June 2011|August 16, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261195||111721|
NCT01262040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-180|Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive|Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive||Memorial Sloan Kettering Cancer Center||Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|154|||Both|19 Years|N/A|No|||December 2015|December 9, 2015|December 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01262040||111656|
NCT01289041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120C2201|BKM120 as Second-line Therapy for Advanced Endometrial Cancer|A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma||Novartis||Completed|February 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Female|18 Years|N/A|No|||March 2015|March 30, 2015|January 26, 2011|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01289041||109586|
NCT01270529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03869|Pedometers to Assess and Increase Physical Activity Among Children With Chronic Kidney Disease|Pedometers to Assess and Increase Physical Activity Among Children With Chronic Kidney Disease||University of California, San Francisco||Active, not recruiting|July 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|6 Years|20 Years|No|Probability Sample|All potential subjects will be selected from the Pediatric Nephrology or Transplant        Outpatient Clinic or the Pediatric Hemodialysis Unit at UCSF.|January 2015|January 5, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270529||111004|
NCT01274416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016058|Acceptance-Based Separated Family Treatment for Adolescent Anorexia Nervosa|Acceptance-Based Separated Family Treatment for Adolescent Anorexia Nervosa|ASFT|Duke University|Yes|Completed|May 2009|May 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|12 Years|18 Years|No|||August 2013|August 12, 2013|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01274416||110705|
NCT01271075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCUM 2010|Bilastine Updosing - Characterization of Underlying Mechanisms|Double-blind, Triple Cross-over, Placebo-controlled Study to Assess the Efficacy, Mechanisms, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Cold Contact Urticaria (CCU)|BUCUM|Charite University, Berlin, Germany|Yes|Completed|September 2010|December 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||May 2012|May 30, 2012|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01271075||110962|
NCT01271088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUTF 2010/32|Protective Effect of N-acetylcysteine Against From Ototoxicity|Phase 3 Study of Protective Effect of N-acetylcysteine Against From Ototoxicity||TC Erciyes University|Yes|Completed|June 2010|November 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|No|||November 2011|November 15, 2011|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271088||110961|
NCT01270737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHKGRF465810|Whole Soy and Daidzein on Reduction of Blood Pressure in Postmenopausal Chinese Women|A Double-blind Randomized Controlled Trial on Whole Soy and Daidzein Supplementation on Reduction of Blood Pressure in Prehypertensive Postmenopausal Chinese Women||Chinese University of Hong Kong|Yes|Not yet recruiting|March 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|270|||Female|48 Years|70 Years|Accepts Healthy Volunteers|||July 2010|January 4, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270737||110988|
NCT01271049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-00-02|An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths|A Double-blind, Randomized, Controlled Evaluation of the Tolerability of a Proprietary Oil Blend in Adults Residing in Areas Endemic for Helminth Infections.||Mondelēz International, Inc.|No|Terminated|January 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|January 3, 2011||No|Due to a business decision to stop the project, the study was terminated early.|No||https://clinicaltrials.gov/show/NCT01271049||110964|
NCT01262872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114174|Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants|Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Years in The Gambia||GlaxoSmithKline||Completed|February 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|8||Actual|1320|||Both|56 Days|4 Years|Accepts Healthy Volunteers|||September 2015|September 14, 2015|December 2, 2010|Yes|Yes||No|March 13, 2014|https://clinicaltrials.gov/show/NCT01262872||111592|
NCT01263171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000691166|Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery|A Stratified Phase II Study of Neoadjuvant Chemotherapy Given Before SCPRT as Treatment for Patients With MRI-Staged Operable Rectal Cancer at High Risk of Metastatic Relapse|COPERNICUS|Wales Cancer Trials Unit|Yes|Recruiting|April 2012|||July 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263171||111569|
NCT01263184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5442 - Az 070402/0911|Symptoms of Degeneration in Shoulder of Wheelchair-users|Längsschnittstudie Zur Belastungsinduzierten Anpassung, Schädigung Oder Degeneration Der Schulter Bei Rollstuhlathleten/-Innen|Sodisow|Hannover Medical School||Recruiting|November 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|wheelchair users, sportiv people|November 2010|December 28, 2010|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263184||111568|
NCT01263197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12598|A Study of LY2216684 in Healthy Subjects Receiving Albuterol or Propanolol|Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol||Eli Lilly and Company|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 15, 2011|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263197||111567|
NCT01263210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU62601|Pneumococcal Vaccination of Otitis-prone Children|Conjugate Pneumococcal Vaccination - a Randomized Study in Young Otitis-prone Children||Lund University Hospital|Yes|Completed|March 2003|June 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|109|||Both|N/A|6 Months|No|||December 2010|December 17, 2010|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263210||111566|
NCT01263223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12607|A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors|Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors||Eli Lilly and Company|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||April 2011|April 1, 2011|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263223||111565|
NCT01263509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/OCT-003|Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan|A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|June 2007|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|33 Years|85 Years|No|||February 2012|February 1, 2012|December 17, 2010||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01263509||111543|
NCT01263730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000262|Tai Chi Training for Treating Depressed Chinese Americans|Tai Chi Training for Treating Depressed Chinese Americans||Massachusetts General Hospital|No|Completed|February 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01263730||111526|
NCT01263743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002244|Relaxation Response Training to Treat Hypertension|Relaxation Response Training to Treat Hypertension: Effects on Blood Pressure, Biomarkers, and Endothelial Function||Massachusetts General Hospital|No|Completed|April 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|58|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01263743||111525|
NCT01264055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110046|Cross-sectional Characterization of Idiopathic Bronchiectasis|Cross-Sectional Characterization of Idiopathic Bronchiectasis||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|270|||Both|18 Years|N/A|No|||July 2015|October 27, 2015|December 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01264055||111502|
NCT01264367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-403|A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)|A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)||Bukwang Pharmaceutical|No|Completed|December 2008|May 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||July 2012|December 17, 2014|December 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01264367||111478|
NCT01264627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005820|A New Translational Tool for Studying the Role of Breathing in Meditation|Project Inspire: A New Translational Tool for Studying the Role of Breathing in Meditation||University of California, San Francisco|No|Active, not recruiting|February 2011|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|128|||Female|50 Years|N/A|No|||December 2015|December 1, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01264627||111458|
NCT01264978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV2009111087|Evaluation of Utility Quadriceps Magnetic Stimulation in COPD (Chronic Obstructive Pulmonary Disease) Patients After Hospital Exacerbation|Evaluation of Utility Quadriceps Magnetic Stimulation in COPD (Chronic Obstructive Pulmonary Disease) Patients After Hospital Exacerbation|COPD|Hospital de Cruces|Yes|Not yet recruiting|January 2011|July 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|32|||Both|30 Years|N/A|No|||December 2010|December 21, 2010|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01264978||111431|
NCT01265264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4208-203|Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol|A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy||BioCryst Pharmaceuticals|Yes|Completed|December 2010|February 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|279|||Both|18 Years|69 Years|No|||October 2013|October 28, 2013|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265264||111409|
NCT01261559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39071-B|Breast Displacement and CT Radiation Dose|Effect of Displacement During Computed Tomography on Breast Radiation Dose and Image Quality|Chrysalis|University of Washington|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|72|||Female|18 Years|60 Years|No|||August 2013|August 30, 2013|December 8, 2010||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01261559||111693|
NCT01261546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hospital Infanta Sofia|Clinical Trial Corticoids For Empyema And Pleural Effusion In Children|MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN|CORTEEC|Hospital Infanta Sofia|Yes|Completed|December 2010|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|1 Month|14 Years|No|||May 2015|May 29, 2015|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261546||111694|
NCT01261780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS10328|MC-5A for Chemotherapy Induced Peripheral Neuropathy|Treatment of Painful Chemotherapy -Induced Peripheral Neuropathy With the MC-5A Pain Therapy Medical Device, a Randomized, Double-Blind, Sham-Controlled Clinical Trial||University of Wisconsin, Madison|Yes|Completed|April 2011|November 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||October 2012|May 29, 2015|December 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01261780||111676|
NCT01261793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0010|Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease|EMBODY 2|UCB Pharma|Yes|Completed|December 2010|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|792|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261793||111675|
NCT01262053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05-156E|Investigating Wrong-Patient Computerized Physician Order Entry (CPOE) Errors|Investigating Wrong-Patient CPOE Errors||Montefiore Medical Center|Yes|Active, not recruiting|December 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|3||Anticipated|5000|||Both|N/A|N/A|No|||December 2010|December 24, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262053||111655|
NCT01289067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1222|Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca|Predicting Response to Platinum Chemotherapy in Metastatic Castration Resistant Prostate Ca(mCRPC)Using a Genomic Signature for "BRCAness": A Phase II Prospective Open Label Clinical Trial of Satraplatin in Men With mCRPC Who Have Progressed on Docetaxel||Icahn School of Medicine at Mount Sinai|Yes|Completed|December 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||January 2015|January 13, 2015|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289067||109584|
NCT01289080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-09-226|Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects|A Single-dose, Open-label, Parallel-group, Matched Trial Evaluating the Pharmacokinetics of Oral OPC-34712 Tablets in Subjects With Normal Renal Function and Renally Impaired Subjects||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|January 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|February 1, 2011|No|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01289080||109583|
NCT01261481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1865|Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact|Comparison of the Relative Oral Bioavailability of Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact||University of North Carolina, Chapel Hill|Yes|Completed|January 2011|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|December 14, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01261481||111699|
NCT01270750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHC2/29/22-09-2008|Bosentan for Severe Mitral Valve Dysfunction|Pilot Trial of Bosentan for Secondary Pulmonary Hypertension Due to Severe Mitral Valve Dysfunction|BOSMIVAR|General Hospital of Chalkida|No|Recruiting|December 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|60 Years|85 Years|No|||January 2011|January 27, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270750||110987|
NCT01270763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GxB in Look AHEAD|Gene x Behavior Interaction in the Look AHEAD Study|Gene x Behavior Interaction in the Look AHEAD Study||The Miriam Hospital|Yes|Completed|July 2009|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4108|Samples With DNA|DNA obtained as part of the parent study|Both|45 Years|74 Years|No|Non-Probability Sample|5,145 individuals who are overweight or obese, have type 2 diabetes and are enrolled in        the Look AHEAD Study|March 2015|March 17, 2015|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01270763||110986|
NCT01261975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|607|Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System|Co-Axial Micro-incision Cataract Surgery(C-MICS) Versus Standard Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System||Bausch & Lomb Incorporated|No|Completed|August 2009|July 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Both|50 Years|N/A|No|||January 2012|January 24, 2012|December 15, 2010|Yes|Yes||No|September 21, 2011|https://clinicaltrials.gov/show/NCT01261975||111661|
NCT01262287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-036-2|Dutasteride for the Reduction of Alcohol Use in Male Drinkers|Placebo Controlled Pilot Study of Dutasteride for the Reduction of Alcohol Use in Male Drinkers||University of Connecticut Health Center|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Male|18 Years|65 Years|No|||December 2012|December 24, 2012|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262287||111637|
NCT01262560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1012|Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer|Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer||Radiation Therapy Oncology Group|Yes|Completed|February 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|163|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262560||111616|
NCT01262859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-039|Pilot Study for Locally Advanced Head and Neck Cancer|Pilot Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer||University of Pittsburgh|Yes|Withdrawn|December 2010|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|December 16, 2010|Yes|Yes|PI relocated to another institution. No subjects went on treatment.|No||https://clinicaltrials.gov/show/NCT01262859||111593|
NCT01262573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001586|Barbed Suture vs Smooth Suture for Vaginal Cuff Closure|Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial||Brigham and Women's Hospital|No|Completed|December 2010|November 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Female|18 Years|N/A|No|||April 2015|April 27, 2015|December 15, 2010||No||No|April 27, 2015|https://clinicaltrials.gov/show/NCT01262573||111615|
NCT01262586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23151|Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.|Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device||Novartis||Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||May 2012|May 3, 2012|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262586||111614|
NCT01262885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114470|A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects|A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects||GlaxoSmithKline|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Actual|84|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262885||111591|
NCT01262898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114479|Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis|A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis||GlaxoSmithKline|No|Completed|May 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|79|||Both|18 Years|80 Years|No|||April 2015|April 27, 2015|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262898||111590|
NCT01264068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCHIRB-970208-E|The Influence of Chinese Medicine on Metabolomics in Menopausal or Postpartum Women|||Taipei City Hospital||Recruiting|August 2008|December 2009|Anticipated|April 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||March 2008|December 20, 2010|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264068||111501|
NCT01264081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110048|Lapatinib in Stage IV Melanoma With ERBB4 Mutations|A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations||National Institutes of Health Clinical Center (CC)|No|Terminated|December 2010|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|December 18, 2010|Yes|Yes|Protocol would not be able to reach stated accrual.|No|March 10, 2015|https://clinicaltrials.gov/show/NCT01264081||111500|
NCT01264380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25396|A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma|A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients||Hoffmann-La Roche||Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|December 20, 2010|Yes|Yes||No|July 29, 2015|https://clinicaltrials.gov/show/NCT01264380||111477|Results for OS was not reported due to change in planned analysis.
NCT01263756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000173|Autism Spectrum Disorders (ASD) Driving Study|A Study of the Driving Performance of Individuals With Autism Spectrum Disorders||Massachusetts General Hospital|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|||Both|16 Years|50 Years|No|Non-Probability Sample|Adolescents and adults, ages 16-50, with Autism Spectrum Disorders.|December 2011|December 6, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01263756||111524|
NCT01263769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0072|Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)|A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2011|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263769||111523|
NCT01263782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0097|BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer|BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting||M.D. Anderson Cancer Center|Yes|Active, not recruiting|May 2011|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|225|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263782||111522|
NCT01264991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-183|The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients|The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients - A Double-Blinded Randomized Placebo (Sham) Controlled Multi-Centre Trial|SLAMSHAM|Slagelse Hospital|No|Recruiting|December 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|150|||Both|35 Years|55 Years|No|||July 2015|July 27, 2015|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01264991||111430|
NCT01265290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDAPOIG.01.03.01-00-068/09-00C|Optimizing Diagnostics Of Syncope Events Using Intelligent Telemetric Solutions.|Optimizing Diagnostics And Therapy Of Arrhythmia And Syncope Events Using Intelligent Telemetric Solutions. Diagnostics Of Syncope In Children.|TELEMARC3|Institute of Cardiology, Warsaw, Poland|No|Recruiting|February 2011|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|640|||Both|N/A|18 Years|No|||December 2011|December 2, 2011|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265290||111407|
NCT01265576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT1-CAX-200|Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)|A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia||Vicus Therapeutics|Yes|Active, not recruiting|December 2010|April 2016|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265576||111385|
NCT01271634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xzheng-hfs-1|Observe Abnormal Potential From the Offending Vessel to the Facial Muscles of HFS Patients|Observation of the Abnormal Potential From the Offending Vessel to the Facial Muscles of Hemifacial Spasm Patients||Shanghai Jiao Tong University School of Medicine|No|Enrolling by invitation|January 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|This study will enroll 20 cases of hemifacial spasm patients who want to undergo        microvascular decompression.|July 2011|July 22, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271634||110919|
NCT01261806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01 MH052135|Mental Health Services for Toddlers in Foster Care|Mental Health Services for Toddlers in Foster Care||University of Delaware|Yes|Active, not recruiting|April 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Both|2 Years|3 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01261806||111674|
NCT01272154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-01|Cerebellum and Cortical Plasticity: the Case of Dystonia|Cerebellum and Cortical Plasticity: the Case of Dystonia|CERDYS|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|January 2011|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 27, 2012|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272154||110879|
NCT01289093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Quality of Life After Laparoscopic Inguinal- Incisional and Umbilical Herniotomy.|Quality of Life After Laparoscopic Inguinal- Incisional- and Umbilical Herniotomy.|life-in|Koege Sygehus|Yes|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|140|||Both|18 Years|80 Years|No|Non-Probability Sample|Primary care|May 2012|May 25, 2012|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289093||109582|
NCT01261494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-210-5|Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus|A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 12 Weeks in Patients With Type 2 Diabetes Mellitus. A Multicentre, Randomised, Double Blind, Placebo-Controlled Study.||Genfit|No|Completed|December 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|75 Years|No|||July 2011|July 12, 2011|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01261494||111698|
NCT01262001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-3019-049|Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis|A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis|FGCL-3019-049|FibroGen|No|Active, not recruiting|March 2011|June 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|35 Years|80 Years|No|||January 2014|January 15, 2014|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262001||111659|
NCT01261715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|155-2010|Staples Versus Dermabond for Closure of the Skin After Cesarean Section|Staples Versus Dermabond for Closure of the Skin After Cesarean Section||Meir Medical Center|No|Enrolling by invitation|January 2011|||February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|N/A|No|||October 2010|December 15, 2010|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01261715||111681|
NCT01261728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-208|Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma|Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261728||111680|
NCT01261741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90001-2267 / 1|Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems|Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of 10mg Memantine in the Treatment of Memory, Concentration or Attention Problems in the Absence of Dementia||Merz Pharmaceuticals GmbH|No|Completed|November 2010|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|299|||Both|50 Years|80 Years|No|||November 2013|November 26, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261741||111679|
NCT01261988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-0512-10-A723|Assess the Safety and Adhesive Performance of the VIPER System When Compared to Esteem™|A Single Center, Feasibility Study Using Healthy Volunteers to Assess the Safety and Adhesive Performance of the VIPER System When Compared to the Esteem™ Cut to Fit One Piece Closed End Pouch||ConvaTec Inc.|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2010|December 16, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01261988||111660|
NCT01262300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0189|Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents|Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Nursing Home Residents||University of Colorado, Denver|No|Active, not recruiting|November 2010|June 2016|Anticipated|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|60 Years|N/A|No|||November 2015|November 30, 2015|December 15, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01262300||111636|
NCT01263249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Volunteer Anterior Posterior|Effects of Catheter Tip Location Relative to the Femoral Nerve on Sensory and Motor Function|Continuous Femoral Nerve Blocks: Effects of Catheter Tip Location Relative to the Femoral Nerve on Sensory and Motor Function||University of California, San Diego|No|Completed|January 2010|June 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 13, 2011|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263249||111563|
NCT01263522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAusE2011|Optimization of Preventive Effects of Physical Training|Optimization of Preventive Effects of Physical Training "Saarländische Ausdauer-Etappe (SAusE)"|SAusE|Saarland University||Recruiting|December 2010|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|200|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||December 2010|December 17, 2010|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263522||111542|
NCT01263808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2339|Cardiac Safety of Indacaterol|A Randomized, Multiple-dose, Placebo- and Positive-controlled Parallel Group Study to Evaluate the Effects of Indacaterol on Cardiac Safety in Healthy Subjects||Novartis||Completed|April 2008|||August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|404|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2010|December 20, 2010|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263808||111521|
NCT01264393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2054-10|State-wide Health Approach to Increase Reach and Effectiveness: Study 1|Using a State-Wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies|SHARE|The Miriam Hospital|Yes|Completed|January 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|500|||Both|18 Years|70 Years|No|||April 2013|April 23, 2013|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01264393||111476|
NCT01264679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMAG-FER-CKD-253|A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease|An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease||AMAG Pharmaceuticals, Inc.|Yes|Active, not recruiting|May 2011|April 2019|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|245|||Both|6 Months|17 Years|No|||September 2014|September 15, 2014|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264679||111454|
NCT01264692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-067A201|Essential Hypertension|A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension|REDUCE-1|Actelion|No|Completed|February 2011|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|196|||Both|18 Years|75 Years|No|||June 2012|June 12, 2012|December 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01264692||111453|
NCT01264640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LO-0005|Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma|The Impact of Aspirin and Clopidogrel on Brain-derived Neurotrophic Factor (BDNF) Concentrations in Human Serum and Plasma||University of Rostock|No|Active, not recruiting|July 2010|March 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2010|December 21, 2010|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01264640||111457|
NCT01264653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wenzhou Medical College|Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery|Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery||Wenzhou Medical University|Yes|Completed|December 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|60|||Both|40 Years|80 Years|No|||July 2012|July 4, 2012|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264653||111456|
NCT01264666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute Chinese liquor study|Postprandial Effect of Chinese Tea Flavor Liquor on Selected CVD Risk Factors|Phase I Study of Chinese Tea Flavor Liquor on Human Health|TFL|Zhejiang University|Yes|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|16|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||May 2010|December 21, 2010|December 21, 2010||Yes||No||https://clinicaltrials.gov/show/NCT01264666||111455|
NCT01265303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDAPOIG.01.03.01-00-068/09-00D|Telemetric Arrhythmia and Syncope Diagnosis - Evaluation of Arrhythmia Treatment Efficacy|OPTIMIZING DIAGNOSTICS AND THERAPY OF ARRHYTHMIA AND SYNCOPE EVENTS USING INTELLIGENT TELEMETRIC SOLUTIONS - Evaluation of Arrhythmia Treatment Efficacy|TELEMARC 4|Institute of Cardiology, Warsaw, Poland|No|Recruiting|February 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|360|||Both|18 Years|80 Years|No|||May 2013|May 6, 2013|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265303||111406|
NCT01265589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011001|Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome|Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome|RDS|Third Military Medical University|Yes|Not yet recruiting|January 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|28 Days|No|||November 2010|July 25, 2011|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265589||111384|
NCT01261234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIBRAIN1010|Carotid Artery Stenting With Cilostazol Addition for Restenosis|Effect of Cilostazol on In-stent Restenosis After Carotid Artery Stenting; Multi-center, Prospective, Randomized, Open-label Blind-endpoint Trial|CAS-CARE|Kobe City General Hospital|Yes|Enrolling by invitation|December 2010|March 2016|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|45 Years|80 Years|No|||October 2012|October 14, 2012|December 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01261234||111718|
NCT01271166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BAU14|Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer|||Novartis||Terminated|October 2007|||August 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2011|January 5, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01271166||110955|
NCT01271413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00042772|Cognitive Stimulation|Effects of Cognitive Training in Methadone Maintenance Patients||Johns Hopkins University|No|Completed|December 2010|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|January 5, 2011||No||No|November 23, 2013|https://clinicaltrials.gov/show/NCT01271413||110936|
NCT01271426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NihonU-1|Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs|Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab||Nihon University||Completed|April 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|74|Samples With DNA|white blood cell|Both|50 Years|N/A|No|Probability Sample|outpatients in hospital|January 2011|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271426||110935|
NCT01271868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB1001-02|Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B|Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B||Cangene Corporation|Yes|Active, not recruiting|November 2010|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|N/A|12 Years|No|||June 2013|June 14, 2013|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271868||110901|
NCT01288820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1102|Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria|Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup|ACTPQ|University of Oxford|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|331|||Both|1 Year|N/A|No|||August 2013|August 28, 2013|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288820||109603|
NCT01289106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-10-10-21A-13|Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects|Open-Label, Randomized Controlled Trial Comparing Three Strategies of Hepatitis B Vaccination in HIV-1-Infected Patients With CD4 Cell Counts Above 200 permm3 and Suppressed Viral Load||Chiang Mai University|No|Recruiting|January 2011|April 2012|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|132|||Both|18 Years|60 Years|No|||January 2011|February 2, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289106||109581|
NCT01262014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICO-1002|Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer|Phase II, Multicenter, Prospective, Single Arm, Open Labeled Clinical Trial Investigating Pazopanib, a Multi-targeted Tyrosine Kinase Inhibitor (TKI) of VEGFR-1, -2, -3, PDGFR-α and -β and c-Kit in Patients With Platinum-resistant Advanced Ovarian Cancer.||Grupo Español de Investigación en Cáncer de Ovario|No|Active, not recruiting|December 2010|December 2015|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||March 2012|March 19, 2012|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262014||111658|
NCT01262027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0296|TKI258 for Metastatic Inflammatory Breast Cancer Patients|A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse||M.D. Anderson Cancer Center|No|Completed|January 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262027||111657|
NCT01261754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TcTx-P101|A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers|A Phase I Study of the PK, Tissue Distribution and Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen, 99mTc-MIP-1404 and 99mTc-MIP-1405, in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers||Molecular Insight Pharmaceuticals, Inc.|No|Completed|December 2010|||February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|16|||Male|21 Years|N/A|No|||November 2015|November 23, 2015|November 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01261754||111678|
NCT01262599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE8848|Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery|Effect of Pulsed Electromagnetic Fields on Postoperative Recovery After TRAM Flap Breast Reconstruction||Columbia University|Yes|Completed|February 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|85 Years|No|||August 2015|August 4, 2015|December 1, 2010||No||No|May 12, 2015|https://clinicaltrials.gov/show/NCT01262599||111613|
NCT01262911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115083|Effect of SRT2379 on Endotoxin-Induced Inflammation|A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects||GlaxoSmithKline|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|17|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2011|July 26, 2011|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01262911||111589|
NCT01262924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263855/003|Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine|A Phase III, Blinded, Randomised, Monocentre, Comparative Clinical Study of the Immunogenicity, Reactogenicity and Safety of a Single Booster Dose of SB Biologicals' Candidate dTpa and pa Vaccines and SB Biologicals' Licensed Td Vaccine in Healthy Adults Aged ≥18 Years||GlaxoSmithKline||Completed|October 1997|December 1998|Actual|December 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|December 16, 2010|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262924||111588|
NCT01262937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0706002810|A Study to Examine the Human Gastrointestinal Tract Using the Confocal Endomicroscope|A Pilot Study to Examine the Human Gastrointestinal Tract Using the Confocal Endomicroscope||Yale University|No|Recruiting|July 2009|||December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2010|December 17, 2010|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01262937||111587|
NCT01263236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14095|A Study of LY2940094 in Major Depressive Disorder|A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of LY2940094 in Healthy Male Subjects||Eli Lilly and Company|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 11, 2011|December 16, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263236||111564|
NCT01263821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S09-0069|Image Guided Therapy in the Treatment of Gliomas|Image Guided Adaptive Multi-modality Therapy in the Treatment of Gliomas||New York University School of Medicine|Yes|Terminated|August 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|7 Years|N/A|No|||January 2016|January 21, 2016|December 16, 2010||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01263821||111520|
NCT01264094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-408|A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period|A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period||Bukwang Pharmaceutical|No|Terminated|November 2009|June 2015|Actual|November 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|December 19, 2010||No|Enrollment|No||https://clinicaltrials.gov/show/NCT01264094||111499|
NCT01274260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Steroids in Pediatic ALI/ARDS|Trial of Steroids in Pediatric Acute Lung Injury/ARDS|Steroids in Pediatric Acute Lung Injury/ARDS Trial: A Blinded, Placebo-controlled, Randomized Clinical Trial|SPALIT|University of Tennessee|No|Active, not recruiting|October 2010|December 2014|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Month|18 Years|No|||May 2014|May 23, 2014|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01274260||110717|
NCT01270347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mpex-209|Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients|Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients|TIS|Forest Laboratories|Yes|Completed|January 2011|June 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|267|||Both|12 Years|N/A|No|||July 2013|July 11, 2013|January 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01270347||111018|
NCT01265004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-26|Identification of Microcirculation After Surgical Treatment of Rupture of the Achilles Tendon|Evaluation of Microcirculation in Skin and Tendon After Surgical Treatment of Acute Rupture of the Achilles Tendon With Stitches or Fibrin-glue|MicroASR|RWTH Aachen University|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute traumatic rupture of the achilles tendon|November 2012|November 26, 2012|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01265004||111429|
NCT01270854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDIRB-200917793|Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients|Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients||University of California, Davis|No|Completed|February 2011|April 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270854||110979|
NCT01271153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100610|Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients|Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients.||Pontificia Universidad Catolica de Chile|Yes|Completed|August 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271153||110956|
NCT01271400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1|LANDA Embryo Freezing Technique.|Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates|Freezing|West Coast Fertility Centers|Yes|Active, not recruiting|December 2010|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|20|||Female|21 Years|37 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infertility patients|September 2011|September 6, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271400||110937|
NCT01272180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_03|Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults|Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations||Novartis||Completed|August 2011|September 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|484|||Both|10 Years|25 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|January 6, 2011|Yes|Yes||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01272180||110877|
NCT01272414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0261-A|Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction|||University of Toronto||Withdrawn|January 2011|February 2012|Actual|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||December 2010|June 2, 2015|January 6, 2011|Yes|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01272414||110859|
NCT01271647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHCTOP2011|Classic Yin and Yang Tonic Formula for Osteopenia|Randomized Controlled Trial of Classic Yin and Yang Tonic Formula in Osteopenia|CYYTO|Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|February 2011|July 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|55 Years|75 Years|No|||January 2011|July 26, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01271647||110918|
NCT01289119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322_02|Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes|An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes||Takeda|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|506|||Both|18 Years|75 Years|No|||February 2013|February 17, 2013|February 1, 2011||No||No|February 17, 2013|https://clinicaltrials.gov/show/NCT01289119||109580|
NCT01289405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 2002/08|Phonoaudiologic Therapy Adjunct to Treatment on Patients With Obstructive Sleep Apnea|Phonoaudiologic Therapy as an Adjunct to the Continuous Positive Airway Pressure Treatment on Patients With Obstructive Sleep Apnea Syndrome||Associação Fundo de Incentivo à Pesquisa|Yes|Completed|October 2010|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Male|25 Years|65 Years|No|||February 2014|February 5, 2014|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289405||109558|
NCT01262612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201001|Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion|A Phase II Study of Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion||Radboud University|Yes|Terminated|April 2010|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262612||111612|
NCT01262313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC019|Healthy Creations: Community Based Lifestyle Intervention Validation|Healthy Creations: Community Based Lifestyle Intervention Validation||USDA Grand Forks Human Nutrition Research Center|No|Completed|December 2010|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|46|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2013|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262313||111635|
NCT01262326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012005-053|Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production|||University of Texas Southwestern Medical Center||Enrolling by invitation|January 2005|||December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2010|December 16, 2010|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01262326||111634|
NCT01263262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004643|A Comparison of Infection Rates Between Two Surgical Sites|A Comparative Assessment Between Two Surgical Sites of the Rate of Corneal Toxicity and Ototoxicity With the Use of Povidone-iodine Versus Chlorhexidine-alcohol for Facial Lesions Treated With Mohs Micrographic Surgery||Mayo Clinic|No|Completed|January 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients 18 years of age or older undergoing Mohs micrographic surgery for a        skin neoplasm(s) on the face at the Dermatology Surgery Center at the Mayo Clinic in        Rochester, Minnesota, and at the University of Toronto in Toronto, Ontario, Canada, will        be included. Exclusion criteria will include: those undergoing MMS for a lesion on the        eyelid margin, patients with a history of ongoing eye pain, history of a pre-existing        corneal ulcer within 12 months prior to surgery, history of a perforated tympanic        membrane, and patients with an active infection at the operative site at the time of        surgery. If post-operative follow-up is not completed, the study subject will be excluded        from the study.|September 2013|October 23, 2013|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01263262||111562|
NCT01263535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/06|Use of an Ocular Telemetry Sensor in Tafluprost Treated Patients|Circadian Continuous Intraocular Pressure Monitoring With SENSIMED Triggerfish® Ocular Telemetry Sensor in Patients on Tafluprost Treatment||Sensimed AG|No|Terminated|September 2010|May 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01263535||111541|
NCT01273701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011014RB|Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence|Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence||National Taiwan University Hospital|No|Not yet recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||December 2010|January 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01273701||110760|
NCT01273974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-5905|The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients|The Comparison of Serum Antibody Response to Standard Intramuscular and Half Dose Intradermal Influenza Vaccine in Hemodialysis Patients in Shiraz City in 1388.||Shiraz University of Medical Sciences|Yes|Completed|October 2009|February 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|80 Years|No|||August 2010|January 10, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01273974||110739|
NCT01273987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neobladder-01|Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study|||Southwest Hospital, China|No|Enrolling by invitation|December 2010|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Female|40 Years|70 Years|No|||December 2010|January 10, 2011|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273987||110738|
NCT01273714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN/501/ZKL/87/L|Subtotal Versus Total Thyroidectomy for Benign Goiter|Subtotal Versus Total Thyroidectomy for Benign Thyroid Disease - a Prospective Case-control Surgical Outcome Study.||Jagiellonian University|Yes|Completed|January 1999|December 2009|Actual|December 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8006|||Both|18 Years|65 Years|No|||January 2011|January 7, 2011|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273714||110759|
NCT01274000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-701|A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients|Phase II Study of YM060 - Double-blind, Parallel-group Comparative Study in Patients (Female) With Diarrhea-predominant Irritable Bowel Syndrome||Astellas Pharma Inc|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|409|||Female|20 Years|64 Years|No|||October 2015|October 9, 2015|January 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01274000||110737|
NCT01274273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DARENCA-1|Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer|A Randomized Phase II Trial of IL-2/IFN-α Plus Bevacizumab Versus IL-2/IFN-α in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1||University of Aarhus|Yes|Active, not recruiting|October 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||August 2012|December 1, 2014|June 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01274273||110716|
NCT01270594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2010-1187|A Pilot Study to Evaluate a Telepharmacy Intervention to Improve Inhaler Adherence in Veterans With COPD|A Pilot Study to Evaluate a Telepharmacy Intervention to Improve Inhaler Adherence in Veterans With COPD||University of Wisconsin, Madison|No|Completed|January 2011|April 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|97|||Both|60 Years|N/A|No|||May 2015|May 26, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270594||110999|
NCT01270360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 09268|Validation of an Alternative Biological Test to Increase the Detection Sensitivity of a Colon Tumour|Validation of a Non Invasive methylateDNA Test for te Diagnosis of Colorectal Tumour in Asymptomatic Individuals|VATNIMAD|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|502|Samples With DNA|Blood, Serum Urine, Stools Tissues|Both|50 Years|75 Years|No|Non-Probability Sample|population of asymptomatic subjects selected by a positive faecal occult blood test (FOBT)        to undergo colonoscopy|June 2015|June 12, 2015|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01270360||111017|
NCT01270607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04132010-5662|Acupuncture and Pain Processing|Acupuncture and Pain Processing||Stanford University||Completed|April 2010|August 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01270607||110998|
NCT01270867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DQR0038|Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke|Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2)|TREVO2|Stryker Neurovascular|Yes|Completed|February 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|85 Years|No|||July 2015|July 13, 2015|January 4, 2011|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01270867||110978|
NCT01271920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2109|Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab|A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen||Novartis||Completed|September 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271920||110897|
NCT01272427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoodIntakeKids_21595|Glucose, Whey Protein and Time to the Next Meal on Mealtime Food Intake in Children|The Effect of Glucose, Whey Protein and Time to the Next Meal on Food Intake and Subjective Appetite in Normal Weight and Overweight/Obese Children||University of Toronto|No|Completed|January 2010|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|36|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272427||110858|
NCT01272193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3896|Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™: JAPAN)|BOOST™|Novo Nordisk A/S|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|296|||Both|20 Years|N/A|No|||October 2015|October 21, 2015|January 6, 2011|Yes|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT01272193||110876|
NCT01288846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBKF-03-UiO|Medication List in and Out of Hospital|Communication About Medication Through the Medication List Coming Into the Hospital With the Patient, Being Changed in the Hospital and Then Returning With the Patient to the Community.||University of Oslo|Yes|Not yet recruiting|March 2011|December 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Acutely hospitalized patients into medical ward|January 2011|February 3, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01288846||109601|
NCT01289132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-536/CCT-001|Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension||Takeda|No|Completed|July 2007|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|926|||Both|20 Years|N/A|No|||February 2011|February 1, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289132||109579|
NCT01262625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN 4701: RESCUE|Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations|ACRIN 4701 RESCUE: Randomized Evaluation of Patients With Stable Angina Comparing Utilization of Diagnostic Examinations|RESCUE|American College of Radiology Imaging Network|Yes|Terminated|January 2011|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1050|||Both|40 Years|N/A|No|||October 2014|October 27, 2014|December 15, 2010||No|Funding timeline completed|No||https://clinicaltrials.gov/show/NCT01262625||111611|
NCT01262638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETC-1002-003|A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.||Esperion Therapeutics|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|177|||Both|18 Years|80 Years|No|||November 2011|August 27, 2015|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262638||111610|
NCT01262950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099089-E|Development of a Fall Prevention and Fall Detection System for Ambulatory Rehabilitation of Parkinson's Patients|||Far Eastern Memorial Hospital||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||October 2010|December 17, 2010|December 16, 2010||||No||https://clinicaltrials.gov/show/NCT01262950||111586|
NCT01262963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113463|An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors|An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects With BRAF Mutant Solid Tumors||GlaxoSmithKline|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|December 2, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01262963||111585|
NCT01263275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10368|Trial of Transcranial Direct Current Stimulation (tDCS) for Depression|Open Pilot Trial of Transcranial Direct Current Stimulation (tDCS) for Depression.||The University of New South Wales|No|Completed|December 2010|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|90 Years|No|||September 2015|September 15, 2015|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01263275||111561|
NCT01263834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 53-296-02-1-2|Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome|The Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome: A Randomized Controlled Trial|Bevacizumab|Prince of Songkla University|Yes|Completed|December 2010|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|80 Years|No|||January 2014|January 30, 2014|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263834||111519|
NCT01264107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-409|An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine|An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine||Bukwang Pharmaceutical|No|Completed|April 2009|April 2012|Actual|January 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|37|||Both|N/A|N/A|No|Probability Sample|An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses        With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine|July 2012|July 24, 2012|December 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01264107||111498|
NCT01264120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0909-20178 NIHR|The Impact of a Bariatric Rehabilitation Service on Patient Outcomes|The Impact of a Bariatric Rehabilitation Service on Weight Loss and Psychological Adjustment.||University of Surrey|No|Enrolling by invitation|September 2011|March 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|290|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 23, 2014|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01264120||111497|
NCT01274312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090113 - 1|Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Colorectal Transport|Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Colorectal Transport||University of Aarhus|Yes|Completed|September 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2012|May 9, 2014|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01274312||110713|
NCT01270620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12062010-7277|Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement|Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement: A Pilot Assessment of Short-term and Long-term Differences in Outcome||Stanford University|No|Completed|December 2010|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|65 Years|N/A|No|||October 2015|October 1, 2015|December 14, 2010||No||No|July 18, 2015|https://clinicaltrials.gov/show/NCT01270620||110997|
NCT01270386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HENGRUI 20101219|A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer|A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Study of Apatinib as Third Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer||Jiangsu HengRui Medicine Co., Ltd.|Yes|Completed|March 2010|September 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Both|18 Years|70 Years|No|||February 2012|February 9, 2012|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01270386||111015|
NCT01270880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-070|Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Phase II Trial of STA-9090 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Based Chemotherapy||Barbara Ann Karmanos Cancer Institute|Yes|Completed|January 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|18 Years|N/A|No|||April 2015|April 1, 2015|January 4, 2011|Yes|Yes||No|April 1, 2015|https://clinicaltrials.gov/show/NCT01270880||110977|Small sample size.
NCT01270893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0722|Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)|A Two-Arm Study of Preoperative Nilotinib for Patients With Resectable or Potentially Resectable Gastrointestinal Stromal Tumor (GIST)||M.D. Anderson Cancer Center|No|Withdrawn|January 2011|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|January 4, 2011|Yes|Yes|No particapnt recruitment.|No||https://clinicaltrials.gov/show/NCT01270893||110976|
NCT01274286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99069|Evaluation of the Effectiveness of the New Hospital Accreditation|Evaluation of the Effectiveness of the New Hospital Accreditation||Taipei Medical University WanFang Hospital|No|Completed|January 2010|December 2010|Actual|||N/A|Observational|N/A||1|Actual|0|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients Doctors|January 2011|January 9, 2011|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01274286||110715|
NCT01271439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPLACE|Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma|A Phase II Study of Neoadjuvant Chemotherapy + IMRT Combined With Cetuximab in Advanced T Stage of Nasopharyngeal Carcinoma|REPLACE|Sun Yat-sen University|Yes|Completed|September 2010|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||November 2011|August 10, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271439||110934|
NCT01271452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/Facial/011|Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines|||Allergan|No|Completed|September 2010|April 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|65 Years|No|||December 2011|December 9, 2011|January 5, 2011|Yes|Yes||No|December 9, 2011|https://clinicaltrials.gov/show/NCT01271452||110933|
NCT01271660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2010-132|A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis|A Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy and Safety of 6-week Treatment of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis||Seoul National University Boramae Hospital|No|Recruiting|July 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|N/A|75 Years|No|||December 2015|December 1, 2015|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01271660||110917|
NCT01271894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-ENCORE1-PK|The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)|The Intensive Pharmacokinetics Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks||Kirby Institute|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|40|||Both|16 Years|N/A|No|||November 2012|May 10, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271894||110899|
NCT01271907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110052|Drosophila-generated CTL|Phase II Study of Metastatic Melanoma Using a Nonmyeloablative Lymphodepleting Regimen Followed by Melanoma-Reactive T-Cells Sensitized in Vitro With Peptide-Pulsed Drosophila Cells||National Institutes of Health Clinical Center (CC)|No|Terminated|December 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|January 6, 2011|Yes|Yes|Study was terminated due to poor accrual.|No|November 7, 2012|https://clinicaltrials.gov/show/NCT01271907||110898|
NCT01272453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-209|Computed Tomography Dose Reduction Using Sequential or Fast Pitch Sprial Technique|Computed Tomography Dose Reduction Using Sequential or Fast Pitch Sprial Technique Employed in Cardiothoracic Imaging|CTDOSE|William Beaumont Hospitals|No|Completed|January 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2640|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing clinically indicated cardiothoracic computed tomography (CT),        including pulmonary or aortic angiography and coronary CT angiography (CCTA)at 10 sites.        Patient selection will be based on a site consecutive CT scan log.|May 2014|May 29, 2014|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272453||110856|
NCT01272206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7128-3729|Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects|A Single-centre, Randomised, Double-blind, Single Dose, Cross-over Trial Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021, Following Intravenous Administration in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|49 Years|No|||August 2014|August 19, 2014|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01272206||110875|
NCT01272700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0201|The Effect of Pressure Controlled Ventilation on the Pulmonary Mechanics in Prone Position Using the Wilson Frame: A Comparison With Volume Controlled Ventilation|The Effect of Pressure Controlled Ventilation on the Pulmonary Mechanics in Prone Position Using the Wilson Frame: A Comparison With Volume Controlled Ventilation||Yonsei University|Yes|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|40|||Both|20 Years|65 Years|No|||February 2012|February 2, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01272700||110837|
NCT01286142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25182|Oseltamivir Infant Influenza Safety Study|A Prospective, Observational Safety Study in Children <= 24 Months of Age Receiving Oseltamivir for the Treatment or Prophylaxis of Influenza Infection||Charite University, Berlin, Germany|No|Completed|December 2009|September 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|900|||Both|N/A|24 Months|No|Non-Probability Sample|The study will be conducted in multiple sites in multiple countries within the European        Union. Initially, five countries (United Kingdom, Austria, Finland, Poland, Germany) are        selected for inclusion, but additional countries in Europe, are likely to be added. It is        estimated that 3-12 sites per country will be enrolled, with a target of at least 900        patients. If additional countries are added, the number of sites/patients recruited per        country will be adjusted accordingly.|October 2011|October 13, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01286142||109806|
NCT01286662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriemliH|A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome|In Modern Era, Recurrent Desmoids Determine Outcome in Patients With Gardner Syndrome: A Cohort Study of Three Generations of an Adenomatous Polyposis Coli (APC-) Mutation-Positive Family Across 30 Years||Triemli Hospital|No|Completed|January 1978|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|105|||Both|N/A|N/A|No|Non-Probability Sample|Since 1978, we have been following a family of 105 descendants with Gardner syndrom. APC        (adenomatous polyposis coli) mutation carriers were screened by endoscopy, and colorectal        resection was performed upon pending malignancy. Desmoid tumors were treated by excision        or radiotherapy and brachytherapy.|January 2011|January 27, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01286662||109766|
NCT01262976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113935|Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults|Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a Tuberculosis Endemic Region||GlaxoSmithKline||Completed|January 2011|June 2015|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|240|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262976||111584|
NCT01262989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114071|SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin|Randomized, Two-period, Cross-over, Bioequivalence Study on Tamsulosin Hydrochloride 0,4 mg Prolonged Release Hard Gelatin Capsule Versus SECOTEX® (Tamsulosin Hydrochloride) 0,4 mg Prolonged Release Hard Gelatin Capsule (Boehringer Ingelheim) in Healthy Male Volunteers Under Fasting Conditions.||GlaxoSmithKline|No|Completed|January 2010|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|September 3, 2010||No||No|March 3, 2011|https://clinicaltrials.gov/show/NCT01262989||111583|
NCT01272895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 10-256 (IRB HKU)|OCT Evaluation of Early Healing of EPC Capturing (GENOUS) Stent (EGO Study)|Evaluation of Endothelial Progenitor Cell (EPC) Capturing (GENOUS) Stent After Coronary Stenting Utilizing Optical Coherence Tomography (OCT): the EGO Study|EGO|The University of Hong Kong|Yes|Completed|June 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|85 Years|No|||February 2013|February 27, 2013|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01272895||110822|
NCT01272908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML20381|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)|Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)||Hoffmann-La Roche||Completed||August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|80 Years|No|||July 2014|July 8, 2014|January 7, 2011|No|Yes||No|May 12, 2014|https://clinicaltrials.gov/show/NCT01272908||110821|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT01273207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110064|Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans|Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans||National Institutes of Health Clinical Center (CC)||Recruiting|December 2010|June 2025|Anticipated|June 2025|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|10 Years|80 Years|No|||October 2015|November 3, 2015|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273207||110798|
NCT01273220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911056|National Epidemiologic Survey on Alcohol and Related Conditions-III|National Epidemiologic Survey on Alcohol and Related Conditions -III||National Institutes of Health Clinical Center (CC)||Completed|December 2010|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|65100|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273220||110797|
NCT01273233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV71-1001-Ia|Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults|A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults||Sinovac Biotech Co., Ltd|Yes|Completed|December 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|36|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273233||110796|
NCT01274026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183590-1|Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders|Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression in PKU "Nonresponders" to Kuvan® (Sapropterin Dihydrochloride)|IST|Tulane University School of Medicine|No|Recruiting|January 2011|January 2012|Anticipated|August 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|21 Years|Accepts Healthy Volunteers|||January 2011|January 10, 2011|January 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01274026||110735|
NCT01274351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107ETR02|Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|A Phase II Multi-center, Open-label, Non-randomized Study of Nilotinib as First Line Treatment in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||Novartis||Active, not recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01274351||110710|
NCT01273467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016510|A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)|A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction||Janssen Research & Development, LLC|Yes|Completed|December 2010|July 2013|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|80 Years|No|||March 2014|March 16, 2014|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01273467||110778|
NCT01273480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017536|A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies|An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies||Janssen Research & Development, LLC|Yes|Completed|December 2010|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|December 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01273480||110777|
NCT01270399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10160-2010CTIL|Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer|Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer||Meir Medical Center|No|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|lung tissue with primary malignant neoplasm|March 2012|October 29, 2012|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270399||111014|
NCT01270633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEI-004|A Study With Primatrix Dermal Repair Scaffold For The Treatment Of Diabetic Foot Ulcers|A Multi-Center, Prospective, Randomized Study With Primatrix Dermal Repair Scaffold For The Treatment Of Diabetic Foot Ulcers||Integra LifeSciences Corporation|No|Suspended|December 2010|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|January 4, 2011|Yes|Yes|Site selection|No||https://clinicaltrials.gov/show/NCT01270633||110996|
NCT01270906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2101 (CHIR-258-001)|Safety of CHIR-258 (TKI258) in Advanced Solid Tumors|A Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyniamics of CHIR-258 in Subjects With Advanced Solid Tumor Malignancies||Novartis||Terminated|December 2003|||October 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||January 2011|January 4, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01270906||110975|
NCT01271179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPH04618|Study of Sequential Perfusion of Liver Grafts to Prevent Nonanastomotic Biliary Strictures After Liver Transplantation|Study of Sequential Perfusion of Liver Grafts With Low-viscosity and High-viscosity Preservation Solutions to Decrease the Incidence of Nonanastomotic Biliary Strictures After Liver Transplantation||Shanghai Jiao Tong University School of Medicine|Yes|Completed|July 2004|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|141|||Both|18 Years|65 Years|No|||December 2010|January 5, 2011|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01271179||110954|
NCT01271192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIHSYSU02|Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer|A Randomized Multicenter Clinical Trial of Direct Surgical Resection Compared to Neoadjuvant Followed by Surgical Resection in Treating Patients With Operable Local Recurrent Carcinoma Of The Rectum|NARC|Sun Yat-sen University|Yes|Recruiting|December 2010|December 2020|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|80 Years|No|||December 2010|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271192||110953|
NCT01271465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004010988|Analysis of Donor Biopsy Tissue Samples at the Time of Kidney Transplant|mRNA and microRNA Profiles in Renal Transplant at the Time of Organ Reperfusion||Weill Medical College of Cornell University||Recruiting|September 2010|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Both|18 Years|80 Years|No|||January 2011|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271465||110932|
NCT01271673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|827|Cohort Study to Assess the Level of Compliance in Undertaking Breast Self Examination Among Women Attending Preventive Oncology Clinic|A Short Duration Pilot Cohort Study to Assess the Level of Compliance in Undertaking Breast Self Examination (BSE) Among Women Attending Preventive Oncology Clinic||Tata Memorial Hospital||Recruiting|November 2010|April 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women attending Preventive Oncology Clinic in the month of November-December 2010.|November 2010|January 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01271673||110916|
NCT01273025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPK-10-003|Lime Powder Regimen in Healthy Volunteers|Medicinal Effect of Lime Powder Regimen in HK-2 Cell Exposed to Lithogenic Crystals and Its Citraturic and Antioxidative Responses in Healthy Volunteers|LimePKphase1|Chulalongkorn University|Yes|Enrolling by invitation|December 2010|March 2011|Anticipated|March 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 7, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01273025||110812|
NCT01273038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP210OC|Clinical Investigation for New Filter to Ostomy Bags|Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags||Coloplast A/S|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||November 2012|February 22, 2013|December 14, 2010||No||No|January 9, 2012|https://clinicaltrials.gov/show/NCT01273038||110811|
NCT01273298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-MPOC-UL|Effects of Cardioselective β-blockers on Dynamic Hyperinflation in COPD|Effects of Cardioselective Beta-blockers on Dynamic Hyperinflation in Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)||Laval University|No|Completed|June 2008|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|50 Years|N/A|No|||November 2010|June 22, 2011|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01273298||110791|
NCT01286155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-002718|Epidemiology of Barrett's Esophagus: A Population Based Study|Epidemiology of Barrett's Esophagus: A Population Based Study||Mayo Clinic|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|534|Samples With DNA|Blood|Both|18 Years|95 Years|No|Non-Probability Sample|Olmsted county resident|May 2013|May 3, 2013|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01286155||109805|
NCT01287299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2500-080|Glycemic Load, Metabolism & Obesity in Pregnancy|Dietary Glycemic Load & Metabolism in Obese Pregnant Women|PANS|Children's Hospital & Research Center Oakland|No|Completed|July 2005|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|64|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2011|January 30, 2011|January 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01287299||109717|
NCT01272388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1334a|Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study|Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study|ASPEN-AVR|Washington University School of Medicine|Yes|Terminated|January 2011|April 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|January 6, 2011|Yes|Yes|We designed a different pilot trial based on data obtained after this study started - the 2    studies were too overlapping to continue both.|No||https://clinicaltrials.gov/show/NCT01272388||110861|
NCT01272648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20090142|Rehabilitation After Radiotherapy for Prostate Cancer|Rehabilitation and Coping of Effects After Curative Radiotherapy for Prostate|RePCa|Odense University Hospital|No|Completed|February 2010|January 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|161|||Male|18 Years|N/A|No|||January 2011|January 28, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272648||110841|
NCT01272635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 002|Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.|Azithromycin for Preventing the Development of Upper Respiratory Tract Illness Into Lower Respiratory Tract Symptoms in Children and Oral Corticosteroids for Treating Episodes of Significant Lower Respiratory Tract Symptoms in Children|APRIL - OCELOT|Milton S. Hershey Medical Center|Yes|Completed|March 2011|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|607|||Both|12 Months|71 Months|No|||January 2015|January 9, 2015|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272635||110842|
NCT01273727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3433-001|Ozurdex for Macular Edema Post Membrane Peeling|Ozurdex in Treatment of Macular Edema Post Membrane Peeling||Retina Specialists, PC|Yes|Completed|June 2010|April 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|21 Years|N/A|No|||May 2015|May 12, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273727||110758|
NCT01274013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1280-HEPC|Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers|A Pilot Study on Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers||Avera McKennan Hospital & University Health Center|Yes|Active, not recruiting|October 2009|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|Serum|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is a comparison study between two different populations: a study group and a control        group. The study group will consist of fifty individuals with a diagnosis of chronic        Hepatitis C. The control group will consist of fifty individuals who are considered to be        generally healthy.|July 2015|July 20, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01274013||110736|
NCT01274299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067-10-ZIV|Measurements of Facial Dimensions in Infants and Toddlers 0-4 Years of Age|Facial Dimensions in Infants and Toddlers||Ziv Hospital|No|Recruiting|November 2010|November 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|N/A|4 Years|Accepts Healthy Volunteers|Probability Sample|Healthy infants|January 2011|January 9, 2011|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01274299||110714|
NCT01270412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10196-2010CTIL|Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis|Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis - A Randomized-Double-Blind Trial|PRP|Meir Medical Center|No|Not yet recruiting|September 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|75 Years|No|||July 2011|July 16, 2011|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01270412||111013|
NCT01270373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neo2010|NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?|Randomized Phase II Trial of the Sequences of Anthracyline and Taxane in Locally Advanced Breast Cancer|NeoSAMBA|Instituto Nacional de Cancer, Brazil|No|Active, not recruiting|August 2010|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Female|N/A|N/A|No|||March 2013|March 18, 2013|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270373||111016|
NCT01270945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-PT017|Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.|Phase II Open Label,Randomized Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody(CV-18C3)in Reducing Restenosis in Patients Undergoing Percutaneous Femoro-popliteal Revascularization.||XBiotech, Inc.|No|Completed|June 2011|April 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270945||110972|
NCT01270958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112185|A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis|A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis (PAR)|AVY-REG00108VN|GlaxoSmithKline|No|Completed|August 2009|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|August 31, 2010||No||No|October 28, 2010|https://clinicaltrials.gov/show/NCT01270958||110971|
NCT01271205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|580CTIL|Red Cell Distribution Width and Mortality in Adult Pneumonia Patients|||Rambam Health Care Campus||Not yet recruiting|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with pneumonia|December 2010|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271205||110952|
NCT01270919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73|A Prospective, Post-market, Multi-center Feasibility Study of the BioDuct® Meniscal Repair Device|This Study Will be a Prospective, Non-randomized Evaluation of the Change Between Preoperative and Postoperative Outcomes for Those Who Receive the BioDuct® Device Meniscal Repair Device.||Stryker Orthopaedics|No|Terminated|November 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|45 Years|No|||May 2014|May 22, 2014|January 4, 2011|Yes|Yes||No|May 22, 2014|https://clinicaltrials.gov/show/NCT01270919||110974|
NCT01270932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-0505|Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients|An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal Failure||University Health Network, Toronto|Yes|Recruiting|November 2010|April 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01270932||110973|
NCT01271686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 101705 bimatoprost|24-hour IOP-lowering Effect of 0.01% Bimatoprost|24-hour IOP-lowering Effect of 0.01% Bimatoprost||University of California, San Diego|Yes|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|40 Years|80 Years|No|||May 2014|May 19, 2014|January 6, 2011|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01271686||110915|
NCT01271933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081245|Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients|A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Fibromyalgia (Protocol A0081245)||Pfizer|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|777|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271933||110896|
NCT01271946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-03133|A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access System|A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access System|RECITAL|Arstasis, Inc.|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|351|||Both|18 Years|85 Years|No|||January 2013|January 23, 2013|January 5, 2011|Yes|Yes||No|October 26, 2012|https://clinicaltrials.gov/show/NCT01271946||110895|
NCT01271959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-207|A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study|A Multicenter, Post-Market Follow-up Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study||Precision Therapeutics|No|Terminated|November 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|167|Samples With DNA|DNA, RNA, and proteomic research will be conducted on excess tissue cells.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with solid tumor malignancies|October 2012|October 4, 2012|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271959||110894|
NCT01272219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-1839|Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes|Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation||Novo Nordisk A/S|No|Completed|June 2011|March 2015|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|3731|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|January 6, 2011|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01272219||110874|
NCT01272726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1260-ADHD|Influence of Education on Acceptance of Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Among Women|Influence of Education on Acceptance of Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Among Women||Avera McKennan Hospital & University Health Center|Yes|Completed|March 2009|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|Samples With DNA|saliva|Female|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women in and around the Sioux Falls area.|May 2012|May 31, 2012|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272726||110835|
NCT01273051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO 2010_121|Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer|CHEMORADIOTHERAPY FOR RECTAL CANCER IN THE DISTAL RECTUM FOLLOWED BY ORGANSPARING TRANSANAL ENDOSCOPIC MICROSURGERY: CARTS Study CApecitabine, Radiotherapy and Tem Surgery. A PHASE II, FEASIBILITY TRIAL|CARTS|Radboud University|Yes|Recruiting|November 2010|||July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01273051||110810|
NCT01287039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072/3082|A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma|A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma||Teva Pharmaceutical Industries||Completed|April 2011|March 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|489|||Both|12 Years|75 Years|No|||September 2015|September 23, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287039||109737|
NCT01287312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shlomoco-HMO-CTIL|Trichloroacetic Acid for Endoscopic Tracho-esophageal Fistula Repair|Trichloroacetic Acid for Endoscopic Tracho-esophageal Fistula Repair||Hadassah Medical Organization|No|Recruiting|January 2011|January 2013|Anticipated|January 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Month|20 Years|No|||January 2011|January 31, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01287312||109716|
NCT01272401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC_IRB_10085|Quality of Life in Breast Cancer Patients and Survivors|Determinants and Correlates of Physical Activity in Breast Cancer Survivors||University of Illinois at Urbana-Champaign|No|Completed|June 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|500|||Female|18 Years|N/A|No|Non-Probability Sample|Community dwelling breast cancer patients and survivors|June 2012|June 13, 2012|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01272401||110860|
NCT01272921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00035380|The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block|A Dose Response Study for Duration of Analgesia Using Bupivacaine and Ropivacaine for Infragluteal Parabiceps Sciatic Block||Northwestern University|No|Completed|November 2010|||August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|142|||Both|18 Years|75 Years|No|||September 2014|September 12, 2014|January 7, 2011||No||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01272921||110820|We used 5-mL increments of local anesthetic w/epinephrine between 5-30 mL which may have prevented from identifying more precisely the volume at which onset/duration were similar.
NCT01272934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-P-318|Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain||Novartis||Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|January 7, 2011|Yes|Yes||No|August 7, 2012|https://clinicaltrials.gov/show/NCT01272934||110819|
NCT01273246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV71-1001-Ib|Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children|A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children.||Sinovac Biotech Co., Ltd|Yes|Completed|January 2011|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|10||Actual|132|||Both|6 Months|11 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273246||110795|
NCT01273753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heung-BIA1|Effects of Intradialytic Exercise as Assessed by Bioimpedance Analysis and Blood Volume Monitoring|Using Bioimpedance Analysis and Blood Volume Monitoring to Assess the Impact of Intradialytic Exercise||University of Michigan|No|Completed|January 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01273753||110756|
NCT01270659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1774|Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury|Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial|FAIRTOP II|University of Oklahoma|Yes|Completed|May 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|60|||Both|18 Years|60 Years|No|||December 2014|December 2, 2014|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270659||110994|
NCT01274325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si446/2010|Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma|Comparison of Anti-inflammatory Effects of Seroflo 125 Inhaler With Seretide Evohaler(25/125) in Patients With Asthma||Mahidol University|Yes|Completed|February 2011|July 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|80 Years|No|||September 2013|September 9, 2013|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01274325||110712|
NCT01274338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02649|Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery|A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma||National Cancer Institute (NCI)|Yes|Recruiting|May 2011|||May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|1545|||Both|12 Years|N/A|No|||October 2015|March 17, 2016|January 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274338||110711|
NCT01271491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-097|The Genetics of Respiratory Failure in Bronchiolitis|The Genetics of Respiratory Failure in Bronchiolitis||Connecticut Children's Medical Center|No|Recruiting|November 2010|October 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|146|||Both|N/A|2 Years|No|Probability Sample|Children hospitalized with bronchiolitis|January 2016|January 27, 2016|November 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01271491||110930|
NCT01271699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS01/2011|Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis|Multiple Sclerosis and Fabry Disease: Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis - an Epidemiological Study||University of Rostock|Yes|Recruiting|January 2011|March 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|Samples With DNA|Fabry diagnostic will be done centrally: blood samples will be stored for analysis of      a-galactosidase in blood, Gb3 as well as lyso-Gb3. In all cases direct analysis of the gene      will be done, especially in females where due to the Lyonisation effect a-galactosidase      activity might be normal in blood although the patient might suffer from Fabry disease.|Both|18 Years|50 Years|No|Probability Sample|Adult Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis        according to the McDonald diagnostic criteria for Multiple Sclerosis|October 2015|October 6, 2015|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01271699||110914|
NCT01271478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS/IMSS/PROT/G09/739|Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients|Effect of Telmisartan and Captopril on Systemic Inflammation of Patients on Hemodialysis||Coordinación de Investigación en Salud, Mexico|No|Completed|August 2009|||December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|70 Years|No|||February 2013|February 12, 2013|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01271478||110931|
NCT01272232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-1922|Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes|Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period||Novo Nordisk A/S|No|Completed|June 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|846|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 6, 2011|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01272232||110873|
NCT01272466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-003619-29|Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma|Vaccination With Peptides Derived From Anti-apoptotic Proteins From the Bcl-2 Family, Administered in Combination With Montanide ISA-51 in Relation to Treatment With Proteasome Inhibitors in Patients With Relapsed Multiple Myeloma||Herlev Hospital|No|Recruiting|February 2010|||February 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||May 2009|January 6, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01272466||110855|
NCT01272713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/10/ALFRED/52|Air Verses Oxygen In myocarDial Infarction Study|A Randomised Controlled Trial of Oxygen Therapy in Acute Myocardial Infarction (AVOID - Air Verses Oxygen In myocarDial Infarction Study)|AVOID|Bayside Health|Yes|Active, not recruiting|October 2011|August 2014|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|638|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01272713||110836|
NCT01273064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-1027-05|Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders||Conatus Pharmaceuticals Inc.|Yes|Terminated|January 2011|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|114|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|December 21, 2010|Yes|Yes|Risk-benefit ratio|No|March 29, 2012|https://clinicaltrials.gov/show/NCT01273064||110809|This study was terminated early after 3 reports of hyperbilirubinemia occurred(2 on 60mg bid and 1 on 30mg bid of CTS 1027). Two incidents were reported as part of an SAE. The risk/benefit ratio did not warrant further continuation of the study.
NCT01273571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017815|A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers|An Open-Label, Fixed Sequence Study to Investigate the Potential for Pharmacokinetic and Pharmacodynamic Interaction Between Single-Dose Metformin and Multiple-Dose Canagliflozin in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2010|February 2011|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|December 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01273571||110770|
NCT01273584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCH/2008/001|Metformin in Obese Non-diabetic Pregnant Women|Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?|MOP|Epsom and St Helier University Hospitals NHS Trust|Yes|Completed|October 2010|September 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|450|||Female|19 Years|50 Years|No|||January 2016|January 21, 2016|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273584||110769|
NCT01287325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNK333C2201|Efficacy of DNK333 in Patients With COPD and Cough|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Clinical Efficacy, Tolerability and Safety of Two Weeks Treatment With DNK333 100 mg Bid in Patients With COPD and Cough.||Novartis||Completed|September 2003|||April 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|35 Years|80 Years|No|||January 2011|January 28, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01287325||109715|
NCT01283217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0708|Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer|A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0)||Yonsei University|Yes|Recruiting|March 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|20 Years|N/A|No|||June 2013|June 1, 2013|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283217||110030|
NCT01272947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOSG-P-319|Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects With Acute Blunt Soft Tissue Injuries/Contusions of the Limbs||Novartis|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|January 7, 2011|Yes|Yes||No|July 17, 2012|https://clinicaltrials.gov/show/NCT01272947||110818|
NCT01272960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP4-13|Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial|Randomized, Open-label, Controlled Trial of Immediate Postpartum Versus Interval Insertion of Mirena to Increase the Usage at 6 Months After Delivery|MISTIC|Washington University School of Medicine|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|53|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272960||110817|
NCT01273259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2003/04|Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults|Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults. Phase 2 Trial||University Hospital, Bordeaux|No|Not yet recruiting|January 2011|||March 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|75 Years|No|||January 2011|January 7, 2011|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273259||110794|
NCT01273272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-130034/1a|Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers|Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial|CBTAC|University of Zurich|No|Recruiting|February 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|95 Years|No|||July 2015|July 25, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01273272||110793|
NCT01273493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017542|A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction|An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction||Janssen Research & Development, LLC|Yes|Completed|December 2010|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|December 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01273493||110776|
NCT01273506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017599|A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 25-mg Extended-Release Tamper-Resistant Formulation (TRF) Tablets Relative to One 50-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2010|February 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01273506||110775|
NCT01273740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWEXSUS|Swedish External Support Study|Swedish External Support Study is Randomized Trial of the Effect of External Support of PTFE-grafts for Bypass to Below Knee Arteries.|SWEXSUS|University Hospital, Linkoeping|No|Completed|January 1995|June 1998|Actual|June 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|334|||Both|20 Years|N/A|No|||January 2011|January 7, 2011|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273740||110757|
NCT01273766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97710|Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies|Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|January 2011|December 2014|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|16|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|January 7, 2011||No||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01273766||110755|adverse events were only tracked on Arm I
NCT01274039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcetazolamideTrialCologne|Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide|Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide. A Possible Pretreatment for Trabeculectomy Surgery.||University of Cologne|No|Completed|February 2009|February 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|All patients of the university hospital with a planed trabeculectomy in 3 to 4 weeks.|April 2013|April 12, 2013|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274039||110734|
NCT01270997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE-III-10|Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients|A Multicenter Randomized Double-blind Active-controlled Parallel Group Phase Ⅲ Trial to Evaluate the Equivalence in Efficacy and Safety of HD203 and Enbrel in Combination With Methotrexate in Patients With Rheumatoid Arthritis||Hanwha Chemical|No|Completed|December 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|294|||Both|20 Years|N/A|No|||July 2014|July 13, 2014|January 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01270997||110968|
NCT01270646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/29|Impact of Intraventricular Electrical Activation in Resynchronization Therapy|Study of the Role of Intraventricular Electrical Activation in the Treatment of Congestive Heart Failure by Cardiac Resynchronization Therapy: Invasive Evaluation and Validation of Non-Invasive Strategy Using CardioInsight ®|CARTO-CRT|University Hospital, Bordeaux|No|Completed|January 2011|November 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270646||110995|
NCT01271504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-701|E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma||Eisai Inc.|No|Active, not recruiting|April 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|99 Years|No|||November 2015|November 16, 2015|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271504||110929|
NCT01271972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R910-ST-1010|Study of Nesvacumab (REGN910/ SAR307746)|A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies||Regeneron Pharmaceuticals|Yes|Completed|January 2011|May 2015|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|53|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|January 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01271972||110893|
NCT01271985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRC.89.17|Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill|Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians|PolyIran|Tehran University of Medical Sciences|Yes|Active, not recruiting|February 2011|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|7000|||Both|50 Years|79 Years|No|||May 2014|May 6, 2014|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01271985||110892|
NCT01272245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0736|Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2011|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|60 Years|N/A|No|||January 2016|January 14, 2016|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272245||110872|
NCT01272479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1692|Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C|Comparison of Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With and Without Chronic Hepatitis C||Istanbul University|Yes|Completed|August 2008|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients on chronic hemodialysis|November 2009|January 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272479||110854|
NCT01273597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-644|Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands|Post-marketing Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Paricalcitol i.v. in the Treatment of Chronic Kidney Disease (CKD) 5 Stage Patients With (Severe) Secondary Hyperparathyroidism in Hungary||AbbVie|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Stage 5 chronic kidney disease patients treated in haemodialysis centers in Hungary|January 2013|January 11, 2013|November 22, 2010||No||No|November 21, 2012|https://clinicaltrials.gov/show/NCT01273597||110768|
NCT01283230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0015|Evaluation of Liver Fibrosis Staging With Acoustic Radiation Force Impulse Elastography|Prospective Cohort Study for Evaluation of Liver Fibrosis Staging With Acoustic Radiation Force Impulse Elastography in Patients With Chronic Liver Disease and Healthy Liver/Kidney Donors||Yonsei University|Yes|Completed|July 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|150|||Both|20 Years|80 Years|No|Probability Sample|Patients with chronic liver disease, Healthy liver and kidney donors|February 2012|February 1, 2012|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283230||110029|
NCT01272687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD02/2011|Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation|Epidemiological Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation|PadGau|University of Rostock|Yes|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|18 Years|N/A|No|Probability Sample|adult patients with a confirmed diagnosis of Parkinson's disease|January 2014|January 6, 2014|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01272687||110838|
NCT01272973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-3692|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|96|||Male|18 Years|60 Years|No|||February 2015|February 20, 2015|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01272973||110816|
NCT01272986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP512011|Trial of Screening for ALOA-IgG AtheroAbzyme Test|Trial of Screening for ALOA-IgG AtheroAbzyme Test Comparing Healthy,Asymptomatic Myocardial Ischemic and Acute Coronary Syndrome Patients|OP512011|Omicron Pharmaceuticals|Yes|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|March 6, 2011|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272986||110815|
NCT01273779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-0802|Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis|OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis|OASIS|Agennix|Yes|Suspended|June 2011|December 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1280|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|January 7, 2011|Yes|Yes|Data Safety Monitoring Board recommendation|No||https://clinicaltrials.gov/show/NCT01273779||110754|
NCT01274052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-060015|Study of Postprandial Incretin Response in Women With Gestational Diabetes|Reduced Postprandial GLP-1 Response in Gestational Diabetes Mellitus: a Fully Reversible Phenomenon||University Hospital, Gentofte, Copenhagen|No|Completed|March 2007|July 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|19|Samples Without DNA|Blood Plasma|Female|N/A|N/A|No|Probability Sample|Healthy pregnant woman were examined with a 75 g oral glucose tolerance test. Subjects        with plasma glucose (PG) values at 120 min >9.0 mmol/l were diagnosed with gestational        diabetes and subjects with PG <9.0 mmol/l were enrolled as healthy controls.|January 2011|January 10, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274052||110733|
NCT01273519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-585|Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab|Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab||AbbVie|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic and medical practice specialized in rheumatology|February 2014|February 25, 2014|January 7, 2011||No||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01273519||110774|
NCT01270425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11175-10CTIL|Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis|Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis||Meir Medical Center|No|Completed|January 2011|November 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with SSc according to the current international classification|March 2012|February 27, 2013|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270425||111012|
NCT01270685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 10-046|2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies|2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies||VA Office of Research and Development|No|Withdrawn|July 2010|August 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|0|||Both|18 Years|89 Years|No|Non-Probability Sample|Veterans with spinal cord injury        Comparison group of Veterans without SCI/D        Health care providers in the SCI/D System of Care        Infection control chiefs at VA facilities|June 2015|June 25, 2015|June 3, 2010||No|Not a Clinical Trial requirement per VA HSR&D|No||https://clinicaltrials.gov/show/NCT01270685||110992|
NCT01270698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-IMMU-130-01|Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer|A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Colorectal Cancer.||Immunomedics, Inc.|No|Completed|May 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|January 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270698||110991|
NCT01270971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-301|Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail|A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults||Anacor Pharmaceuticals, Inc.|No|Completed|December 2010|||November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|594|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|January 3, 2011|Yes|Yes||No|July 25, 2014|https://clinicaltrials.gov/show/NCT01270971||110970|
NCT01270984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131HPS10D|Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects|Imatinib|Chong Kun Dang Pharmaceutical|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270984||110969|
NCT01271218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curves-OA-06|Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program|Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program: a Randomized Placebo Controlled Clinical Trial||Texas A&M University|No|Completed|November 2005|December 2006|Actual|December 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Female|18 Years|70 Years|No|||January 2011|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271218||110951|
NCT01271231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020-2009|Study on Periodontal Treatment in Diabetic Patients|Effects of Periodontal Treatment on Clinical Parameters and Glucose Metabolism in Diabetic Patients||Universidad de Antioquia||Completed|April 2010|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271231||110950|
NCT01271725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.98|LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures|LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting||Boehringer Ingelheim||Active, not recruiting|May 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|74|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|January 6, 2011||||No||https://clinicaltrials.gov/show/NCT01271725||110912|
NCT01271712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14874|Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)|A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib|GRID|Bayer|Yes|Active, not recruiting|January 2011|June 2016|Anticipated|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|199|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 17, 2010|Yes|Yes||No|May 24, 2013|https://clinicaltrials.gov/show/NCT01271712||110913|Overall survival results are confounded by the fact that 85% of the participants initially randomized to placebo switched to open-label regorafenib.
NCT01272258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 140 2102|A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Observed Systemic, Long-Acting, Anti-HIV Treatment With a Monoclonal Anti CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-Infected Injection Drug Users With Viral Rebound and Documented Poor Adherence to the Previous Antiretroviral Regimen||CytoDyn, Inc.|No|Recruiting|December 2013|February 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|79|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272258||110871|
NCT01272271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0273|Safety of Overnight Corneal Reshaping Lenses|Postmarket Study of the Safety of Overnight Corneal Reshaping Lenses||Ohio State University|No|Completed|February 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1317|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Randomized sample of optometry and ophthalmology patients seen by 200 practitioners in        various practice settings, stratified on manufacturer, practitioner volume.|January 2011|January 6, 2011|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272271||110870|
NCT01272492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00035707|Infant Nutrition: Evaluation of an Educational Touchscreen Computer Program|Infant Nutrition: Evaluation of an Educational Touchscreen Computer Program for Use in a Spanish-speaking Population of Caregivers of Young Children (APA Phase II)||Johns Hopkins University|No|Completed|March 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Prevention|2||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|January 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272492||110853|
NCT01272505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSSILSVSCSILS|Conventional SILS vs Harmonic Scalpel SILS||SILS|Mansoura University||Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|137|||Both|14 Years|80 Years|No|||April 2010|January 6, 2011|January 6, 2011||||No||https://clinicaltrials.gov/show/NCT01272505||110852|
NCT01272739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1300-IHBG10|Randomized Study to Evaluate the Effect of an Investigational Product on Weight Loss and Body Composition|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of IHBG-10 on Weight Loss and Body Composition||Avera McKennan Hospital & University Health Center|Yes|Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|October 4, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272739||110834|
NCT01273350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Physician IDE G # 040160|A Prospective, Non-Randomized, Evaluation of Low-Risk Patients Undergoing Carotid Stenting With ANgiomax (Bivalirudin)|Physician I.D.E. G#040160; Low Risk Carotid Stenting Study Using Bivalirudin at PinnacleHealth Hospitals and Holy Spirit Hospital||SPSI d.b.a Capital Cardiovascular Associates|Yes|Recruiting|October 2004|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|154|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273350||110787|
NCT01273324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2012-079|Radiostereometric Analysis (RSA) and DEXA to Evaluate Fixation and Wear of the Restoration ADM Acetabular System|Prospective Clinical Study Using Radiostereometric Analysis (RSA) and DEXA to Evaluate Fixation and Wear of the Restoration ADM Acetabular System||Dalhousie University|No|Active, not recruiting|November 2011|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|21 Years|80 Years|No|Non-Probability Sample|Osteoarthritis of the hip|August 2015|August 6, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273324||110789|
NCT01273337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IS-001|Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects|A Phase 2 Randomized, Controlled Study With a Phase 1 Safety Cohort Testing ALD-401 Derived From Autologous Bone Marrow Delivered Via Intracarotid Infusion in Subjects With Ischemic Stroke With Blinded Assessments||Aldagen|Yes|Active, not recruiting|March 2011|January 2015|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|30 Years|83 Years|No|||January 2014|January 14, 2014|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273337||110788|
NCT01273870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDA-02|Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers|Post Marketing Surveillance Investigating Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers||Praxisverbund Dialyse und Apherese|No|Completed|December 2010|February 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|80 Years|No|Non-Probability Sample|8 patients will undergo 1 treatment each with the 4 high-flux dialyzer types using a        bloodflow of 300 ml/min, dialysate flow 500 ml/min and the dialysis machine Fresenius 5008|November 2010|February 1, 2011|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01273870||110747|
NCT01283503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120X1101|A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors|A Phase I Study of BKM120, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors||Novartis|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||January 2015|January 7, 2015|January 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283503||110008|
NCT01283516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378X2101|A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase|A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)||Novartis|No|Active, not recruiting|January 2011|March 2016|Anticipated|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|304|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 24, 2011|No|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01283516||110007|
NCT01273285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNFL-Repro|Reproducibility of Nerve Fiber Layer Thickness Measurements in Patients With Glaucoma and Healthy Controls Using Spectral-Domain and Time-Domain OCT|||University of Zurich||Terminated|April 2009|||March 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|50|||Both|18 Years|N/A|No|||January 2011|January 7, 2011|January 7, 2011||||No||https://clinicaltrials.gov/show/NCT01273285||110792|
NCT01273532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017602|A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 50-mg Extended-Release, Tamper-Resistant Formulation (TRF) Tablets Relative to One 100-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|December 2010|March 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01273532||110773|
NCT01274065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1290-Pharm|Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Outcomes|Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Subject Outcomes||Avera McKennan Hospital & University Health Center|Yes|Completed|September 2009|November 2014|Actual|November 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|Samples With DNA|saliva|Both|13 Years|N/A|No|Non-Probability Sample|The study participants will all reside at the South Dakota Developmental Center (SDDC),        which serves a unique population of people with developmental diabilities and co-occuring        psychiatric disorders.|January 2015|January 13, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01274065||110732|
NCT01274078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHN_exc_blueberries|Effects of Exercise With or Without Blueberries on Cardiovascular Risk Markers|Effects of Exercise With or Without Blueberries on Cardiovascular Risk Markers||University Hospital, Linkoeping|No|Completed|July 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274078||110731|
NCT01274377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00013947|Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT|A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation||Duke University|Yes|Recruiting|February 2011|February 2018|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|January 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01274377||110708|
NCT01274364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010-112|Establishing a Diabetes Registry Using the JADE-DIAMOND Electronic Portal (CN001)|China-JD Program: A Multi-centre Demonstration Project to Evaluate the Effectiveness and Acceptability of the Joint Asia Diabetes Evaluation (JADE) and DIAbetes MONitoring Database (DIAMOND) Programs in Asian Type 2 Diabetic Patients|China-JD|Asia Diabetes Foundation|Yes|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3586|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01274364||110709|
NCT01270672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 218/10|Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)|Effects of Carvedilol on the Cardiovascular and Subjective Response to MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy")||University Hospital, Basel, Switzerland|Yes|Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270672||110993|
NCT01271283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02568|Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia|Lenalidomide for the Treatment of CLL Patients With High-Risk Disease||National Cancer Institute (NCI)||Withdrawn|December 2010|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2011|June 3, 2015|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271283||110946|
NCT01271010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25136|A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status|Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status||Hoffmann-La Roche||Active, not recruiting|June 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|70 Years|No|||February 2016|February 1, 2016|January 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01271010||110967|
NCT01271257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUBH R990011|Pharmacokinetics of Misoprostol With Titrated Oral Administration|Phase 1 Study of Titrated Oral Misoprostol||China Medical University Hospital|Yes|Completed|January 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271257||110948|
NCT01271270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110066|Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration|A Phase I Unmasked Study to Investigate the Safety and Tolerability of Subconjunctival Injections of Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Completed|December 2010|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2012|February 19, 2014|January 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01271270||110947|
NCT01271244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAM 6-7-2008|Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder|Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF)||VA Nebraska Western Iowa Health Care System|No|Completed|June 2008|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|19 Years|55 Years|No|||August 2011|October 2, 2014|January 5, 2011|Yes|Yes||No|October 2, 2014|https://clinicaltrials.gov/show/NCT01271244||110949|Due to small number of subjects recruited in major depression groupwe are unable to compare to the PTSD group.
NCT01271517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract-number 2005-001726-80|Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis|Effects of New Longacting Insulin Analogs on Metabolic Control, Endogenous Insulin Production, GH/IGF-I Axis and Quality of Life - Comparison of NPH, Glargine Och Detemir Insulin From the Debut of Type 1 Diabetes Mellitus in Adolescents|BAS|Karolinska Institutet|No|Active, not recruiting|September 2005|||March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|7 Years|17 Years|No|||January 2011|January 5, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271517||110928|
NCT01272284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP006SU|The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study|The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study||Coloplast A/S|No|Completed|December 2010|January 2014|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Female|18 Years|N/A|No|||June 2014|June 19, 2014|January 5, 2011|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01272284||110869|
NCT01271998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-119|Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg|Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg TR-701 Free Acid in Healthy Volunteers||Trius Therapeutics LLC|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|September 15, 2011|December 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01271998||110891|
NCT01272011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7182-W|Effects of Breathing and Walking Treatments on Recovery Post-Spinal Cord Injury|Intermittent Hypoxia and Locomotor Training: Effects Following SCI||VA Office of Research and Development|No|Completed|May 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272011||110890|
NCT01272752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1310-IHBG10|Anti-psychotic Medication (New Use) Weight Loss Study|Surveillance Study of Weight Response and Body Composition in Subjects Who Are First-Time Users (Less Than 3 Months) of the Following Medications: Risperdal, Seroquel, and/or Zyprexa, in Combination With 500 mg IHBG-10 TID||Avera McKennan Hospital & University Health Center|Yes|Withdrawn|April 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|January 6, 2011||No|Study did not get started.|No||https://clinicaltrials.gov/show/NCT01272752||110833|
NCT01273077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS1001|Evaluation of Universal Rotavirus Vaccination Program|Evaluation of Universal Rotavirus Vaccination Program||Dalhousie University|No|Recruiting|December 2010|March 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|10000|||Both|6 Weeks|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All infants in Nova Scotia DHA 9 and PEI born after October 1, 2010 until September 31,        2012 will be eligible for Rotarix immunization. Infants must be 6 weeks to 6 months of age        at time of vaccination.        All confirmed hospitalized Rotavirus cases from 2008-2010 and 2010-2012 will be entered in        a database.        All Intussusception cases after program start.        Small sample size of outpatient confirmed rotavirus cases during rotavirus peak season        2011 and 2012 will be studied.        Parents of infants eligible to receive Rotarix during the program will be invited to        complete a KAB survey during the program as well as all healthcare providers eligible to        administer Rotarix vaccine. Program organizers will be invited to take part in key        informant interviews at the end of the program.|January 2011|January 7, 2011|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273077||110808|
NCT01273363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RRU-DUM-2010/1|Non-interventional Retrospective Multicenter Study of Patients With Bronchial Asthma During a Routine Visit to Out of Patients' Clinics|Non-interventional Retrospective Multicenter Study of Patients With Bronchial Asthma During a Routine Visit to Out of Patients' Clinics|NIKA|AstraZeneca|No|Completed|December 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical practice|February 2012|February 27, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273363||110786|
NCT01273636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712018R|Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia|Concurrent Endometrial Cancer With Endometrial Hyperplasia or Endometrial Intraepithelial Neoplasia - Focus on Risk Factors Analysis||National Taiwan University Hospital|No|Recruiting|January 2005|June 2011|Anticipated|January 2006|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Female|30 Years|70 Years|No|Non-Probability Sample|We retrospectively reviewed the cases of seventy-seven patients who had hysterectomies for        endometrial hyperplasia between January 1996 and September 2006 at the Department of        Obstetrics and Gynecology, National Taiwan University Hospital. A preoperative pathologic        diagnosis of endometrial hyperplasia was obtained in all patients.|December 2010|January 6, 2011|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT01273636||110765|
NCT01273610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10112|Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer|Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer||City of Hope Medical Center|Yes|Recruiting|April 2011|||March 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|60 Years|N/A|No|||March 2016|March 11, 2016|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273610||110767|
NCT01273623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1139|The Jetstream G3™ Calcium Study|A Prospective, Single-Arm Study to Evaluate the Effects of the Jetstream G3 System on Calcified Peripheral Vascular Lesions||Boston Scientific Corporation|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|100 Years|No|||October 2015|October 19, 2015|December 20, 2010||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01273623||110766|
NCT01274143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00017894|Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)|Impact of Remote Familial Colorectal Cancer Assessment and Counseling|Family CARE|University of Utah|Yes|Completed|May 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|496|||Both|30 Years|74 Years|No|||May 2015|May 26, 2015|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01274143||110726|
NCT01283529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/27693|Reference Values for Pulse Induced Continuous Cardiac Output (PiCCO) Variables in Children|Reference Values for Cardiac Output and Blood Volume Variables in Children With Normal Cardiac Function Measured Under General Anesthesia.||Oslo University Hospital|No|Active, not recruiting|January 2011|September 2015|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|15 Years|No|Non-Probability Sample|40 children age 0 - 15 years undergoing major neurosurgery under general anesthesia|April 2015|April 21, 2015|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01283529||110006|
NCT01283542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230D2401|Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.|An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma|Passion I|Novartis||Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01283542||110005|
NCT01273792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarkers Susac Syndrome|Investigation of Biomarkers in Susac Syndrome|Investigation of Relevant Biomarkers in Patients With Susac Syndrome||Charite University, Berlin, Germany|No|Recruiting|May 2010|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Blood samples (serum, Blood cells)|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients with Susac syndrome (male/female; healthy control subjects|February 2013|February 11, 2013|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01273792||110753|
NCT01273805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-310|Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer|Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|December 2010|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273805||110752|
NCT01273818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC-001|Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair|Is Topical Antibiotic Prophylaxis Effective in Lichtenstein Hernia Repair: a Comparison Study||Diskapi Teaching and Research Hospital|Yes|Completed|January 2011|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|276|||Both|16 Years|80 Years|No|||September 2014|December 17, 2014|January 10, 2011||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT01273818||110751|
NCT01273831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-10|Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia|Study of Effects of Cisatracurium and Atracurium on Intraocular Pressure||Isfahan University of Medical Sciences|Yes|Completed|July 2009|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|90|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2009|January 10, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01273831||110750|
NCT01274091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28//2010|Gene - Diet Interactions|Gene-diet Interactions|Genediet|University of Eastern Finland|No|Completed|August 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274091||110730|
NCT01270438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02571|Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer|A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)||National Cancer Institute (NCI)||Withdrawn|December 2010|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270438||111011|
NCT01270451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/302d, 2008/6365 (REK)|Guidance in Diet and Physical Activity for Prevention of Weight Gain After Gastric Bypass Surgery|Guidance in Diet and Physical Activity for Prevention of Weight Gain After Gastric Bypass Surgery.||Oslo University Hospital|No|Completed|September 2008|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|165|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01270451||111010|
NCT01271738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00013658|Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer|Measuring the Effect of Additional Tumor Cavity Margins Excision at the Time of Breast Conserving Surgery for Stage 0, I, II, and III Breast Cancer Patients on Re-excision Rate, Cosmetic Results and Total Costs||Emory University|Yes|Completed|September 2009|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Female|18 Years|N/A|No|||August 2015|August 13, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01271738||110911|
NCT01272024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909005722|An Intervention to Improve Outcomes in Patients With Advanced Cancer|An Intervention to Improve Outcomes in Patients With Advanced Cancer|TEAMS|Yale University|No|Recruiting|September 2009|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Both|21 Years|N/A|No|||January 2011|January 6, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272024||110889|
NCT01272037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02623|Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer|A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer||National Cancer Institute (NCI)|Yes|Recruiting|January 2011|||February 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|5000|||Female|18 Years|N/A|No|||March 2016|March 24, 2016|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272037||110888|
NCT01272297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shock wave III|The Effect of Low Intensity Shock Wave Therapy for ED in PDE5i Non Responders|The Effect of Low Intensity Shock Wave Therapy in Severe ED Patients Not Responding to Oral Medication|LI-ESWT|Rambam Health Care Campus|Yes|Completed|January 2010|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|18 Years|80 Years|No|||December 2012|December 18, 2012|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01272297||110868|
NCT01272518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|459/2010|Assessment of Cardiac Autonomic Behavior in Patients With Mood Disorders|Assessment of Cardiac Autonomic Behavior in Patients With Mood Disorders With a Focus on the Chaos Theory||Sao Jose do Rio Preto University|Yes|Recruiting|January 2011|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Probability Sample|Acutely hospitalized patient and in ambulatorial attendance with Bipolar Disorder or Major        Depressive Disorder.|October 2015|October 6, 2015|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272518||110851|
NCT01272531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 1 U01 MH92758-01|Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)|Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)||University of California, San Diego|Yes|Recruiting|January 2011|January 2016|Anticipated|January 2013|Anticipated|Phase 4|Observational|Time Perspective: Prospective||2|Anticipated|880|Samples With DNA|DNA from patients with bipolar disorder|Both|18 Years|N/A|No|Probability Sample|Inpatient and outpatients with bipolar affective disorder|April 2012|April 9, 2012|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01272531||110850|
NCT01272765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1320-IHBG10|Anti-psychotic Medication (Stable Dose) Weight Loss Study|Surveillance Study of Weight Response and Body Composition in Subjects Taking a Stable Dose of Risperdal, Seroquel, and/or Zyprexa for Greater Than 3 Months in Combination With 500 mg IHBG-10 TID||Avera McKennan Hospital & University Health Center|Yes|Withdrawn|March 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|January 6, 2011||No|Study did not get started.|No||https://clinicaltrials.gov/show/NCT01272765||110832|
NCT01273090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1112|Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma|A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas||Children's Oncology Group||Completed|May 2011|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|1 Year|21 Years|No|||January 2014|January 29, 2014|January 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01273090||110807|
NCT01273883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008292|A Trial of Magnesium Dependent Tinnitus|A Phase III Trial of Magnesium Dependent Tinnitus||Mayo Clinic|No|Completed|July 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|38|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 7, 2011||No||No|January 7, 2015|https://clinicaltrials.gov/show/NCT01273883||110746|
NCT01264601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 00038826|Safe Administration of Flu Vaccine to Egg Allergic Children|Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg|SAFE|University of Michigan|Yes|Completed|October 2010|August 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|6 Months|24 Years|No|||June 2013|June 6, 2013|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01264601||111460|
NCT01273896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-145|Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer|A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|January 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 6, 2011|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01273896||110745|
NCT01264952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-Z 16/KSOPKR-6|Treatment of Liver Metastases With Electrochemotherapy|Treatment of Liver Metastases With Electrochemotherapy|ECTJ|Institute of Oncology Ljubljana|Yes|Completed|November 2008|November 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|December 15, 2010||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01264952||111433|
NCT01265212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP ID: 37392|Prevalence of Human Papillomavirus in Men Living in the Northern Plains|Prevalence of Human Papillomavirus in Men Living in the Northern Plains||Sanford Health|No|Completed|September 2010|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|110|Samples With DNA|Epithelial skin swabs collected for the purpose of HPV DNA detection. DNA extraction and HPV      testing will be performed.|Male|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Male residents of South Dakota.|April 2014|April 22, 2014|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265212||111413|
NCT01265498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH-FLINT (IND)|The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)|The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial|FLINT|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|March 2011|September 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|December 21, 2010|Yes|Yes||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01265498||111391|
NCT01265511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCY-635-201|Study of SCY-635, Pegasys and Copegus in Hepatitis C|A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection||Scynexis, Inc.|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||May 2012|May 29, 2012|November 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01265511||111390|
NCT01283555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATH HS-522|Comparative Safety Study of Two Vaginal Applicators With Tenofovir|Comparative Safety Study of Pre-Filled Plastic and User-Filled Paper Vaginal Applicators With Candidate Microbicide, Tenofovir||PATH|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|July 10, 2012|January 24, 2011|Yes|Yes||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01283555||110004|Due to an error in the interpretation of the user instructions and resulting depth of plunger insertion into the barrel by the participants, the dose delivery data for the prefilled applicator were not valid.
NCT01283568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAMALINEHIPERICIN|Safety and Efficacy Study of Gamaline+Hipericin in PMS|Phase IV Study of Combined GAMALINE and HIPERICIN for Treating Pre-Menstrual Syndrome and Vasomotor Symptoms|GH|Phytopharm Consulting Brazil|Yes|Recruiting|January 2011|February 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|240|||Female|25 Years|55 Years|No|Probability Sample|Only women from 25 to 55 years old with PMS symptoms|November 2011|November 25, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283568||110003|
NCT01273558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017719|A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus|An Open-Label Study to Compare Two Methods for Determining the Renal Threshold for Glucose in Subjects With Type 2 Diabetes Mellitus||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|January 2011|July 2011|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||April 2013|April 19, 2013|December 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01273558||110771|
NCT01274403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM03|A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma|||Gruppo Italiano Studio Linfomi|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label|2||Actual|130|||Both|65 Years|N/A|No|||December 2010|January 10, 2011|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01274403||110706|
NCT01270464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072/3081|A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma|A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma||Teva Pharmaceutical Industries|Yes|Completed|December 2010|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|315|||Both|12 Years|75 Years|No|||May 2014|May 23, 2014|December 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270464||111009|
NCT01270503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA71|Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines|Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines||Sanofi|No|Completed|December 2010|July 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|538|||Both|2 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|January 4, 2011|No|Yes||No|October 31, 2014|https://clinicaltrials.gov/show/NCT01270503||111006|
NCT01270477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FROST|Hyperbaric Oxygen Treatment as Adjuvant Treatment for Frost Injury|Study of the Possible Improvement in Level of Sequela and Amputation/Amputation Level After Frost Injury by the Adjuvant Treatment of Hyperbaric Oxygen.|FROST|Oslo University Hospital|No|Recruiting|January 2011|October 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||April 2011|April 18, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01270477||111008|
NCT01270490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interferon-gamma 001|Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia|A Multicentre, Prospective, Randomized Open-label Pilot Study to Assess the Feasibility and Preliminary Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia||Radboud University|Yes|Recruiting|January 2011|||January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2012|February 13, 2012|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270490||111007|
NCT01274390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021198|Impact of Blood Storage Duration on Physiologic Measures|Impact of Blood Storage Duration on Physiologic Measures: RECESS Ancillary Physiologic Study (RECAP)|RECAP|Duke University|Yes|Completed|January 2011|January 2014|Actual|January 2014|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|390|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac surgery patients enrolled in the RECESS study (NCT00991341) at selected hospitals|July 2014|July 1, 2014|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01274390||110707|
NCT01271023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTR|Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System|Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System|CTR|Juvenile Diabetes Research Foundation Artificial Pancreas Project Consortium|Yes|Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|12 Years|65 Years|No|||April 2014|April 21, 2014|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271023||110966|
NCT01271530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoyalCSI DMurray|Arm Cycling to Improve Fitness in Polio Survivors|The Impact of an Arm Ergometry Training Programme on Cardiovascular Fitness, Energy Cost of Walking and Fatigue in Prior Polio Patients||Royal College of Surgeons, Ireland|No|Completed|July 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|75 Years|No|||September 2013|September 18, 2013|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01271530||110927|
NCT01271751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-208-3|Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity|A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 28 Days in Atherogenic Dyslipidaemic Patients With Abdominal Obesity. A Double Blind, Placebo-controlled and Randomized Study.||Genfit|No|Completed|January 2009|November 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|75 Years|No|||January 2011|January 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01271751||110910|
NCT01271764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099095-E|The Association of G9a Protein and Outcome of Patients With Endometrial Cancer|||Far Eastern Memorial Hospital||Completed|January 2011|September 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|97|||Female|20 Years|N/A|No|||September 2012|September 25, 2012|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271764||110909|
NCT01271777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-210-6|Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity|A Pilot Study to Evaluate the Efficacy of GFT505 (80mg) Orally Administered Once Daily for 8 Weeks on Insulin Sensitivity Using a Glucose Clamp Technique and Safety in Male Patients With Insulin Resistance and Abdominal Obesity. A Multicentre, Randomised, Single Blind, Placebo-Controlled, Cross Over Study.||Genfit|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|75 Years|No|||September 2012|September 21, 2012|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01271777||110908|
NCT01272050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 09/10|Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery|Dose Intensified Salvage Radiotherapy in Biochemically Relapsed Prostate Cancer Without Macroscopic Disease. A Randomized Phase III Trial.||Swiss Group for Clinical Cancer Research|No|Active, not recruiting|January 2011|December 2025|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Male|18 Years|75 Years|No|||April 2015|April 9, 2015|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272050||110887|
NCT01272310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8033-YM-CTIL|Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.|A Phase I/II, Open Clinical Trial to Assess the Safety, Tolerability and Efficacy of a Fixed Dose Combination Therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN Alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infected Subjects Who Failed to Respond Following a Course of Peg-IFN and RBV Therapy (SoC).||Sheba Medical Center|No|Not yet recruiting|January 2011|July 2013|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|70 Years|No|||January 2011|January 6, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01272310||110867|
NCT01272544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mouraiso|Oral Health of Individuals Who Attended a Mother-child Dental Care Program - Longitudinal Study|Oral Health of Individuals Who Attended a Mother-child Dental Care Program - Longitudinal Study||Universidade Federal do Piauí|No|Completed|September 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|278|||Both|9 Years|13 Years|No|Non-Probability Sample|Letters were sent to 343 of the examined children, inviting the guardians to take their        children for an oral health assessment at the children's dental clinic at UFPI. The number        of children that returned for an examination was 139, and these individuals comprised the        experimental group.        Control Group After assessing the characteristics of the experimental group, the control        group was determined and consisted of 139 individuals (93 females and 46 males) who were        paired to the experimental group according to their socio-demographic characteristics and        age but who had not attended the PPPWB.        The study hypothesis is that individuals who attended the PPPWB have better oral health        than those who did not attend it.|September 2009|January 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01272544||110849|
NCT01272778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADE-LDR 10-02|Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)|Acute Effect of Four Doses of Lorazepam on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction™ Test||Orasi Medical, Inc.|No|Recruiting|October 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|5||Anticipated|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2011|January 7, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272778||110831|
NCT01272791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1002|Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer|A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer||Peregrine Pharmaceuticals|No|Completed|January 2011|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|January 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01272791||110830|
NCT01272804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621003|Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-04937319 In Adult Patients With Type 2 Diabetes Mellitus (T2DM)||Pfizer|No|Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|70 Years|No|||January 2012|January 25, 2012|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01272804||110829|
NCT01273103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113393|A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects|An Open Label, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 200 mg, Administered as an Oral Suspension to Healthy Adult Subjects||ViiV Healthcare|No|Withdrawn|January 2011|February 2011|Anticipated|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 15, 2014|January 6, 2011|No|Yes|GSK2248761 development program is on clinical hold.|No||https://clinicaltrials.gov/show/NCT01273103||110806|
NCT01273376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010MDD01|Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study of RX-10100 in Subjects With Major Depressive Disorder.|MDD|Rexahn Pharmaceuticals, Inc.|Yes|Completed|December 2010|October 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|314|||Both|18 Years|65 Years|No|||November 2013|November 18, 2013|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01273376||110785|
NCT01264939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q4883g|A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists||Genentech, Inc.||Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|336|||Both|12 Years|75 Years|No|||September 2013|September 23, 2013|December 20, 2010|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01264939||111434|
NCT01264965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-238-B|Non-cancer Pain and Cognitive Impairment: A Disabling Relationship|Opioids Versus Extra Strength Acetaminophen for the Management of Moderate Persistent Non-cancer Pain||University of Chicago|No|Terminated|January 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|65 Years|N/A|No|||November 2014|November 12, 2014|December 20, 2010|Yes|Yes|recruitment problems|No||https://clinicaltrials.gov/show/NCT01264965||111432|
NCT01265225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.CTIL|Prognostic Value of Stem Cell Related Markers|Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II||The Baruch Padeh Medical Center, Poriya|Yes|Withdrawn|February 2011|April 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Actual|0|||Female|18 Years|N/A|No|Non-Probability Sample|100 tumor specimens from women with grade 0-11 ductal breast cancer|December 2013|December 22, 2013|December 21, 2010||No|no finance|No||https://clinicaltrials.gov/show/NCT01265225||111412|
NCT01265238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-SEF-ICF-1|Neuro-orthopaedic Surgery in the Treatment of the Spastic Equinovarus Foot|Study of the Efficacy and Safety of the Neuro-orthopaedic Surgery in the Treatment of the Spastic Equinovarus Foot With ICF Assessment||University Hospital of Mont-Godinne|No|Completed|December 2009|December 2014|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with central neurological disease (stroke, traumatic brain injury, spinal cord        injury, multiple sclerosis) suffering from a spastic equinovarus foot referred to an        interdisciplinary spasticity group in a University Hospital|December 2014|December 31, 2014|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01265238||111411|
NCT01265524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTST-21|Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease|A Phase 2, Randomized, Double-Blind, Multi-center Study Comparing CLP Versus Placebo in Heart Failure Patients With Chronic Kidney Disease||Sorbent Therapeutics|No|Completed|April 2011|||November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|113|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|December 20, 2010|Yes|Yes||No|January 3, 2013|https://clinicaltrials.gov/show/NCT01265524||111389|
NCT01265537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03047|A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf|A Prospective, Open Label, Pilot Study Comparing the Use of Low-target Advagraf With Rabbit Antithymocyte Globulin Induction Versus Conventional Target Advagraf With Basiliximab Induction in a Steroid-avoidance Immunosuppressive Protocol for de Novo Renal Transplant Recipients|Astellas|University of British Columbia|No|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|N/A|No|||December 2015|December 2, 2015|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265537||111388|
NCT01284179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0772|Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study|Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study||University of North Carolina, Chapel Hill|Yes|Terminated|February 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|January 25, 2011||No|Unable to enroll|No||https://clinicaltrials.gov/show/NCT01284179||109956|
NCT01274104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1350-Myalgia|A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia|A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia||Avera McKennan Hospital & University Health Center|Yes|Withdrawn|October 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|88 Years|No|||April 2015|April 21, 2015|January 6, 2011||No|PI resigned.|No||https://clinicaltrials.gov/show/NCT01274104||110729|
NCT01270724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GemPOx|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors||Children's Hospital Los Angeles|Yes|Recruiting|August 2010|||December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|N/A|N/A|No|||February 2012|February 16, 2012|January 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01270724||110989|
NCT01271036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOYNAP0010|Safety Study of a Sensitive Sensual Touch and Personal Lubricant|A Single-Center, Medically Supervised, Safety Evaluation Study of a Sensitive Sensual Touch and Personal Lubricant Product in Couples||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|January 30, 2014|January 4, 2011|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT01271036||110965|
NCT01270711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7231030|Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)|Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)|SUCRE|Pfizer|No|Completed|November 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|22014|||Both|N/A|N/A|No|Non-Probability Sample|Cohort of patients, who are treated with cabergoline during the study period. This cohort        will be divided in new users and prevalent users based on when cabergoline was started.        New (incident) users will be all persons who have a first prescription for cabergoline        after the date that the change in SPC was made. Prevalent users will be all cohort members        who received a cabergoline prescription during the study period but who had also been        using cabergoline prior to the change in SPC.|February 2014|April 14, 2014|December 9, 2010||No||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01270711||110990|Results not reported for Year 2012 (Year 7) since several databases did not contribute data for Year 7 and amount of person-time of follow-up dropped in all databases. Designation of primary and secondary endpoints was based on study team's input.
NCT01271062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG 09/061/2B|Restoration of Beta Cell Function and Cardiovascular Parameters in Relation to Adipoinsular and Enteroinsular Axes After Gastric Bypass Surgery|Restoration of Beta Cell Function and Cardiovascular Parameters in Relation to Adipoinsular and Enteroinsular Axes After Gastric Bypass Surgery in Severely Obese Patients With Type 2 Diabetes||Cantonal Hospital of St. Gallen|Yes|Completed|October 2009|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|55|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01271062||110963|
NCT01271543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 35113|Comparing Hemodynamic Changes for Intubation With Shikani Intubating Stylet and Macintosh Laryngoscope|||Penn State University|No|Completed|February 2011|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||November 2013|November 12, 2013|January 5, 2011||No||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01271543||110926|NO adverse events
NCT01271790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-196-0140|A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140||Gilead Sciences|Yes|Completed|October 2010|September 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|245|||Both|18 Years|70 Years|No|||January 2014|January 8, 2014|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01271790||110907|
NCT01281176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02575|High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors|Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2011|||April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|20|||Both|19 Years|N/A|No|||November 2015|December 14, 2015|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281176||110186|
NCT01281397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project code: 198-1980976-097|Bleeding Prediction in Patients Following Cardiac Surgery Using Whole Blood Aggregometry and Thromboelastometry|Bleeding Prediction in Patients Undergoing Cardiac Surgery Using Whole Blood Impedance Aggregometry and Rotational Thromboelastometry||University of Zagreb|Yes|Terminated|August 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing elective cardiac surgery with cardiopulmonary bypass are enrolled        in study.|December 2014|December 1, 2014|January 19, 2011||No|After 148 patients enrolled, interim analysis revealed positive results in regard to primary    hypothesis.|No||https://clinicaltrials.gov/show/NCT01281397||110169|
NCT01281631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP001-10-002|A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)||Neuraltus Pharmaceuticals, Inc.|Yes|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|136|||Both|21 Years|80 Years|No|||November 2012|November 20, 2012|January 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281631||110152|
NCT01279200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00041349|Use of High Cost Monitoring During Letrozole Ovulation Induction|Use of High Cost Monitoring During Letrozole Ovulation Induction and Effect on Pregnancy Rates - A Pilot Study||University of Michigan|No|Completed|January 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Female|21 Years|39 Years|Accepts Healthy Volunteers|||January 2015|January 5, 2015|January 18, 2011|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01279200||110337|The original intent was to study 400 women, but due to recruiting and time restraints, final enrollment was only 21. Therefore, statistical analyses of the results were eliminated, as well as some additional outcome measures originally planned for.
NCT01278953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-002 527|TOCCASTAR - TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation|A Prospective, Randomized, Multicenter, Interventional Study to Evaluate the Safety and Effectiveness of the TactiCath Percutaneous Ablation Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Using Contact Force Assisted Radiofrequency Ablation|TOCCASTAR|St. Jude Medical|Yes|Completed|January 2011|September 2015|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|295|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|January 17, 2011|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01278953||110356|
NCT01279187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00042770|The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone|The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone||University of Michigan|No|Terminated|February 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|30 Years|85 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279187||110338|
NCT01280110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPC1|The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients|The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients||University of Campinas, Brazil|No|Completed|March 2011|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|January 18, 2011||No||No|June 7, 2012|https://clinicaltrials.gov/show/NCT01280110||110267|
NCT01280422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99009|Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database|Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database||Taipei Medical University WanFang Hospital|No|Completed|February 2010|August 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|67128927|||Both|20 Years|N/A|No|Non-Probability Sample|patients|January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280422||110243|
NCT01281488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10155|Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors|A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors||City of Hope Medical Center|Yes|Active, not recruiting|October 2011|||September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|January 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281488||110163|
NCT01261767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8226-1848|First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects|A Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Trial of Anti-IL-20 (109-0012) 100 mg/Vial in Psoriatic Subjects, Followed by an Expansion Phase||Novo Nordisk A/S|No|Terminated|April 2008|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|75 Years|No|||February 2016|February 3, 2016|December 14, 2010|Yes|Yes|Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns    were present|No||https://clinicaltrials.gov/show/NCT01261767||111677|
NCT01311115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-1269|Using Group Commitment for Smoking Cessation|Using Group Commitment for Smoking Cessation||University of California, Berkeley|No|Recruiting|November 2010|August 2011|Anticipated|February 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||February 2011|March 8, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311115||107900|
NCT01311401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067-08|Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel|Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel||Ziv Hospital|No|Recruiting|October 2009|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|670|||Both|35 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Circassians in Israel|February 2013|February 19, 2013|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01311401||107878|
NCT01309542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3151A1-303|Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder|A 10 Month Open-Label Evaluation Of The Long-Term Safety Of DVS-233 SR In Outpatients With Major Depressive Disorder.||Pfizer|No|Completed|August 2003|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1403|||Both|18 Years|75 Years|No|||April 2011|April 22, 2011|February 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309542||108020|
NCT01309750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-008|Small Bowel Transit Time in Clostridium Difficile Colitis|Small Bowel Transit Time in Clostridium Difficile Colitis||William Beaumont Hospitals|Yes|Terminated|April 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with clostridium difficile colitis.|September 2012|September 17, 2012|March 3, 2011||No|logistics|No||https://clinicaltrials.gov/show/NCT01309750||108004|
NCT01309763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF005A|Safety and Tolerability of AFFITOPE AD03|A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess the Tolerability and Safety of Repeated Administrations of a Single-dose of AFFITOPE AD03 to Alzheimer's Disease Patients|MimoVax|Affiris AG|Yes|Completed|October 2010|November 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|28|||Both|50 Years|80 Years|No|||December 2011|December 19, 2011|September 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01309763||108003|
NCT01309776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-11-029|Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder|Comparison of Tianeptine Versus Escitalopram for the Treatment of Depression and Cognitive Impairment in Patients With Major Depressive Disorder: A Randomized, Multicenter, Open-label Study|CAMPION|Samsung Medical Center|No|Completed|March 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|40 Years|N/A|No|||January 2013|January 24, 2013|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01309776||108002|
NCT01311362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K331|Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan|Influence of CYP3A4-induction by St. John's Wort (SJW) on the Steady State Pharmacokinetics of Ambrisentan||Heidelberg University|No|Completed|March 2011|December 2012|Actual|April 2012|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|May 2015|May 29, 2015|March 8, 2011||No||No|July 9, 2014|https://clinicaltrials.gov/show/NCT01311362||107881|The extent of this interaction was small and thus likely without clinical relevance.
NCT01280357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHL101801|Accuracy and Reliability of Fetal Heart Rate and Uterine Contraction Monitoring Method|Study to Determine Substantial Equivalence of Electrohysterography (EHG) Monitoring to Tocodynanometer Monitoring||Monica Healthcare Ltd|No|Completed|February 2010|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|60|||Female|15 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 20, 2013|January 19, 2011|Yes|Yes||No|August 11, 2011|https://clinicaltrials.gov/show/NCT01280357||110248|
NCT01281189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223AS302|Phase 3 Study of Dexpramipexole in ALS|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis|EMPOWER|Knopp Biosciences|Yes|Completed|March 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|943|||Both|18 Years|80 Years|No|||November 2014|November 24, 2014|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281189||110185|
NCT01281904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA151445|Acupressure for Persistent Cancer Related Fatigue|Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors|AcuCrft|University of Michigan|No|Completed|April 2011|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|288|||Female|18 Years|N/A|No|||August 2015|August 5, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281904||110131|
NCT01281917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO10407|Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma||University of Wisconsin, Madison|No|Completed|February 2011|June 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281917||110130|
NCT01282177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114142|Influenza Vaccine Safety and Effectiveness in Healthcare Providers|Monitoring Seasonal and Pandemic Vaccine Safety and Effectiveness in Healthcare Providers:A Prospective Cohort Study||Dalhousie University|No|Suspended|October 2009|June 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|||Both|18 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|A cohort of adult HCP will be offered the opportunity to participate in this surveillance        study at Influenza vaccination clinics in their health care facility|January 2011|January 21, 2011|January 7, 2011||No|Unable to measure vaccine effectivness in season following the Pandemic.|No||https://clinicaltrials.gov/show/NCT01282177||110110|
NCT01279226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0310-0002A|Investigation of Radiofrequency Device for Treatment of Wrinkles and Rhytides|Radiofrequency Magnetic Induction Device for Use in Dermatologic Procedures for the Non-Invasive Treatment of Wrinkles and Rhytides||Rocky Mountain Biosystems, Inc.|Yes|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||October 2012|November 30, 2012|January 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01279226||110335|
NCT01279551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-003|Topical Application of GTN 0.4% in the Treatment of Anismus Following Stapled Haemorrhoidopexy|Topical Application of GTN 0.4% in the Treatment of Anismus Following Stapled Haemorrhoidopexy|TAGASH|University of Roma La Sapienza||Completed|January 2004|December 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||January 2011|January 24, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279551||110310|
NCT01279512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-011|Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)|Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial||Royan Institute|Yes|Completed|December 2006|December 2008|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|40 Years|No|||August 2006|January 5, 2012|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279512||110313|
NCT01279525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279/03|Intervention to Reduce Falls Incidence|EFFECTIVENESS OF A MULTIFACTORIAL INTERVENTION PROGRAM TO REDUCE FALLS INCIDENCE AMONG COMMUNITY-LIVING ELDERLY PEOPLE|EPICA|Andalusian Regional Ministry of Health|No|Completed|January 2005|January 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|404|||Both|70 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 18, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279525||110312|
NCT01279538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7163-CL-0103|A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation|A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety, and Tolerability Study of ASKP1240 in de Novo Kidney Transplantation||Astellas Pharma Inc|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|46|||Both|18 Years|65 Years|No|||February 2012|February 8, 2012|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01279538||110311|
NCT01279837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSG-06-103-01(CCE)|Pharyngocise Dose Response Study|Muscle Preservation and Swallow Function Following Radiotherapy: A Dose Response Study||University of Florida|No|Completed|June 2006|December 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|130|||Both|21 Years|90 Years|No|||January 2011|January 4, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01279837||110288|
NCT01279824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD054752|Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing|A Randomized Controlled Trial of NMES vs. Traditional Dysphagia Therapy After Stroke|ANSRS|University of Florida|Yes|Completed|April 2008|April 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|53|||Both|21 Years|90 Years|No|||January 2011|January 4, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01279824||110289|
NCT01280123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS-ZONE|Pioglitazone in Early Parkinson's Disease|A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease||University of Rochester|Yes|Completed|March 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|210|||Both|30 Years|N/A|No|||September 2013|September 15, 2015|December 3, 2010|Yes|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01280123||110266|
NCT01280435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99046|Islide-Establishing a Clinical Dermatopathology Online Discourse System|Islide-Establishing a Clinical Dermatopathology Online Discourse System||Taipei Medical University WanFang Hospital|No|Completed|August 2010|December 2010|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Both|20 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|interns|January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280435||110242|
NCT01280760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPMC|Impact of Neurally Adjusted Ventilator Assist (NAVA) Mode on Patient Ventilator Asynchrony Using Non-invasive Ventilation (NAVA-NIV)|Impact of Neurally Adjusted Ventilator Assist (NAVA) Mode on Patient Ventilator Asynchrony Using Non-invasive Ventilation (NAVA-NIV)|NAVA-NIV|Pierre and Marie Curie University|No|Completed|January 2011|May 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|90 Years|No|Probability Sample|NIV required on post extubation period|December 2013|December 18, 2013|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280760||110217|
NCT01280773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437129518|Effect of NAVA on Duration of Weaning in Difficult to Wean Patients|Department of Critical Care Medicine, Nanjing Zhong-Da Hospital, Southeast University School of Medicine, China; Department of Critical Care Medicine St. Michaels's Hospital, University of Toronto, Canada||Southeast University, China|Yes|Recruiting|January 2014|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||May 2014|May 27, 2014|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01280773||110216|
NCT01312077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-SMOH|The Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic for Total Hip Replacement|Postoperative Analgesia in Total Hip Replacement: a Comparison of the Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic With Intrathecal Morphine.||Cork University Hospital|No|Recruiting|October 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312077||107828|
NCT01262339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0193|BTX-A Treatment for Palmar Hyperhidrosis|Randomized, Single-blind Comparison of Botulinum Toxin Treatment for Palmar Hyperhidrosis Via Iontophoresis Versus Intradermal Injection||University of Wisconsin, Madison|Yes|Terminated|November 2010|November 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|2|||Both|16 Years|N/A|No|||January 2015|January 13, 2015|December 15, 2010|Yes|Yes|low enrollment; principal investigator left sponsoring institution|No|December 4, 2014|https://clinicaltrials.gov/show/NCT01262339||111633|
NCT01311960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB No. 227/53|Topical Bevacizumab for Preventing Recurrent Pterygium|Topical Bevacizumab 0.05% Eye Drops for Preventing Recurrent Pterygium, A Randomized, Double-masked, Controlled Trial||Chulalongkorn University|Yes|Completed|December 2010|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|30 Years|N/A|Accepts Healthy Volunteers|||March 2011|April 6, 2013|December 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01311960||107837|
NCT01312233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R18HP15126-02|Collaborative Care for Older Adults With Back Pain (COCOA)|Co-Management of Older Adults With Low Back Pain by Medical Physicians and Doctors of Chiropractic|COCOA|Palmer College of Chiropractic|Yes|Completed|March 2011|March 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|131|||Both|65 Years|N/A|No|||November 2015|November 4, 2015|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01312233||107816|
NCT01312246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0878|EnSeal Efficacy and Bursting Pressure in Human Vessels|EnSeal Efficacy and Bursting Pressure in Human Vessels||University of Illinois at Chicago|No|Not yet recruiting|April 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|21 Years|90 Years|No|||January 2011|March 9, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312246||107815|
NCT01309984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2083-A001-405|A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure|An Open-label, Single Initial-dose, Multi-center Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure||Eisai Inc.||Completed|November 2010|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|45 Years|No|||November 2015|November 2, 2015|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309984||107986|
NCT01309997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2343.00|Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease|A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation||Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|March 2011|||December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|2 Years|N/A|No|||August 2015|August 10, 2015|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309997||107985|
NCT01310244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1014-Bel|Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)|The Maximum Tolerated Dose and to Evaluate Safety and Efficacy of Belinostat (PXD-101) in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)||Spectrum Pharmaceuticals, Inc|No|Completed|December 2010|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|February 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01310244||107966|
NCT01280370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231/09|Prospective Evaluation of Laparoscopic and Open Incisional Hernia Repair: a Multicenter Cohort Study|Prospective Evaluation of Laparoscopic and Open Hernia Repair: a Multicenter Cohort Study|IHR_SALTC|University Hospital Inselspital, Berne|No|Recruiting|September 2010|October 2018|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1600|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing incisional hernia repair|December 2015|December 10, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280370||110247|
NCT01281410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 462|Inspiratory Muscle Training in Patients Receiving Allogenic Stem Cell Transplantation|Effectiveness of an Inspiratory Muscle Training in Patients Receiving Allogenic Stem Cell Transplantation||Elisabethinen Hospital|Yes|Recruiting|January 2011|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|17 Years|80 Years|No|||November 2010|June 30, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01281410||110168|
NCT01281644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA111810|Treatment of Keratosis Pilaris With 810 nm Diode Laser|Treatment of Keratosis Pilaris With 810 nm Diode Laser|KP|Northwestern University|Yes|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||October 2014|October 15, 2014|January 20, 2011||No||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01281644||110151|
NCT01282437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVALT11|Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC|Prophylactic Cranial Irradiation (PCI) Versus Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer; A Phase III Randomized Study.|NVALT11|Maastricht Radiation Oncology|No|Completed|January 2009|March 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282437||110090|
NCT01282658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJCC-001|Pharmacogenomics Study of CPT-11 as the First-line Chemotherapy for mCRC|Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC|PSIFL|Huazhong University of Science and Technology|No|Recruiting|November 2010|May 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|whole blood|Both|18 Years|75 Years|No|Non-Probability Sample|primary care clinic|November 2010|February 16, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282658||110073|
NCT01279239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|META-LAB-10-07-003C-02|Metabonomics Fingerprinting of Multiple Trauma|Establishing 1H Nuclear Magnetic Resonance (NMR) Based Metabonomics Fingerprinting Profile for Severe Poly Trauma Patients||Sichuan Academy of Medical Sciences|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|Samples Without DNA|Plasma from peripheral blood.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who are suffering from poly trauma.|July 2011|July 26, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01279239||110334|
NCT01279564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|181-09CTIL|Comparison Between Etview Tracheoscopic Ventilation Tube - TVT to Standard Endotracheal Intubation|Comparison Between Etview Tracheoscopic Ventilation Tube - TVT to Standard Endotracheal Intubation During Regular and Difficult Intubation||Rambam Health Care Campus||Completed|February 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|72|||Both|18 Years|80 Years|No|||February 2011|November 4, 2014|January 17, 2011||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01279564||110309|
NCT01279850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081262|Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Long Term Use Of Lyrica(Regulatory Post Marketing Commitment Plan)|RAINBOW-L|Pfizer|No|Active, not recruiting|August 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involving A0081262 prescribes the Lyrica capsule.        And the patients who are administered Lyrica for over 52 weeks (MAX 104 weeks).|March 2016|March 7, 2016|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279850||110287|
NCT01280149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB-IND 4458|Reduction of IgE Antibody in Human Allergic Subjects|Reduction of IgE Antibody in Human Allergic Subjects||Northwestern University|No|Enrolling by invitation|January 2011|||January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|60|||Both|18 Years|65 Years|No|||October 2015|October 2, 2015|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01280149||110264|
NCT01280136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH085594|Web-Based Middle School HIV Prevention Curricula: Aspiring for Reach and Impact|Web-Based Middle School HIV Prevention Curricula: Aspiring for Reach and Impact||The University of Texas Health Science Center, Houston|No|Completed|December 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1700|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01280136||110265|
NCT01280448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99054|The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism|The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism||Taipei Medical University WanFang Hospital|No|Active, not recruiting|September 2010|September 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|genes|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Lung Cancer patients|January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280448||110241|
NCT01280461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99067|An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia|An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia||Taipei Medical University WanFang Hospital|Yes|Enrolling by invitation|July 2010|December 2011|Anticipated|||N/A|Observational|Observational Model: Cohort||2|Anticipated|142|||Both|18 Years|N/A|No|Probability Sample|Patients with nosocomial bacterial pneumonia or healthcare-associated pneumonia(HCAP)|January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280461||110240|
NCT01280786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Synta 4783-14|Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia||Synta Pharmaceuticals Corp.|No|Active, not recruiting|January 2011|August 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|January 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01280786||110215|
NCT01313325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/14/2006|Hippotherapy to Improve the Balance of Children With Movement Disorders|Hippotherapy to Improve Balance Deficits in a Cohort of Children With Movement Disorders: A Pilot Study|HPOT|Central Michigan University|No|Completed|September 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|16|||Both|5 Years|17 Years|No|||March 2011|March 10, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01313325||107736|
NCT01313338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114/2552(EC3)|Experience in Predicting Decision Making for Receiving Treatment in Acute Coronary Syndrome Patients|Cognitive Representation, Emotional Responses and Hospitalization Experience in Predicting Decision Making for Receiving Treatment Among Patients With Acute Coronary Syndrome||Mahidol University|No|Completed|April 2009|September 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|132|||Both|18 Years|N/A|No|Non-Probability Sample|Acute coronary syndrome patients|March 2011|March 10, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313338||107735|
NCT01262352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX10-770-106|Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of VX-770 on Lung Clearance Index in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 >90% Predicted||Vertex Pharmaceuticals Incorporated|Yes|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|6 Years|N/A|No|||February 2013|February 4, 2013|December 15, 2010|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT01262352||111632|
NCT01262365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0009|Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease|EMBODY 1|UCB Pharma|Yes|Completed|December 2010|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|793|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262365||111631|
NCT01312805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICA_Asthma_Study|Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting|Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting||Indiana University|No|Completed|July 2005|July 2008|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|2098|||Both|3 Years|11 Years|Accepts Healthy Volunteers|||March 2011|March 10, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312805||107773|
NCT01313130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT090444|Advanced MRI In Acute Military TBI|ADVANCED MRI IN ACUTE MILITARY TBI||Washington University School of Medicine|No|Enrolling by invitation|October 2010|August 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|400|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|active duty United States military personnel|December 2014|December 8, 2014|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01313130||107751|
NCT01313494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-301-RD|A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:|A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial|ACROSS|Takeda||Completed|March 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|626|||Both|40 Years|80 Years|No|||July 2013|July 31, 2013|March 3, 2011||No||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01313494||107723|
NCT01280383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE KEK 123/10|Non-invasive Neurally Adjusted Ventilatory Assist|Non-invasive Neurally Adjusted Ventilatory Assist (niNAVA) After Extubation: Proposal for a Crossover-randomized Feasibility Trial||University Hospital Inselspital, Berne|No|Withdrawn|November 2010|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|85 Years|No|||July 2015|July 22, 2015|January 10, 2011||No|Study does not meet the new legal requirements set forth in the Human Research Act|No||https://clinicaltrials.gov/show/NCT01280383||110246|
NCT01311089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0055|A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy|A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction||Yonsei University|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|169|||Both|20 Years|N/A|No|Non-Probability Sample|120 patients with papillary thyroid carcinoma who underwent thyroidectomy at Yonsei        University Health System were enrolled. 60patients were conventional open thyroidectomy        group and 60 patients were robotic thyroidectomy group. All of these patients was over 20        years old.|January 2015|January 26, 2015|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311089||107902|
NCT01280929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DPT04T|Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy|Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy||Association for Innovation and Biomedical Research on Light and Image|No|Completed|September 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01280929||110204|
NCT01282190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0100/2008|Effectiveness of Motivational Interview in Patients With Dyslipidemia|Effectiveness of Motivational Interview in Patients With Dyslipidemia Treated in Primary Care Consultations (Dislip-EM Study)|Dislip-EM|Hospital Universitario Reina Sofia|Yes|Completed|June 2010|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|207|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282190||110109|
NCT01282424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-09|Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma|A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents|DELTA|Gilead Sciences|No|Active, not recruiting|May 2011|March 2016|Anticipated|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|January 21, 2011|Yes|Yes||No|August 22, 2014|https://clinicaltrials.gov/show/NCT01282424||110091|
NCT01282957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812211|Way to Health, Healthy Measures|Financial Incentives for Home-based Health Management: A Pilot Randomized Trial||University of Pennsylvania|No|Enrolling by invitation|February 2011|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|60|||Both|18 Years|80 Years|No|||June 2011|June 21, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01282957||110050|
NCT01282970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1283.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (5 to 100 mg q.d. for 14 Days) of BI 135585 XX in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|February 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|72|||Both|20 Years|70 Years|No|||November 2014|November 18, 2014|January 24, 2011||||No||https://clinicaltrials.gov/show/NCT01282970||110049|
NCT01278966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-09180a (REK)|Modified Atkins Diet in Children and Adolescents With Drug-resistant Epilepsy|Modified Atkins Diet in Children and Adolescents With Drug-resistant Epilepsy - a Prospective Pilot Trial||Oslo University Hospital|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|2 Years|18 Years|No|||December 2010|January 17, 2011|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01278966||110355|
NCT01280162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR # 1737|Malaria Active Epidemiology and Treatment Study|An Active Malaria Epidemiology Cohort Study With Evaluation of a 2 Day Versus 3 Day Treatment Regimen of DHA-Piperaquine for Patients With Uncomplicated Malaria||Armed Forces Research Institute of Medical Sciences, Thailand|No|Completed|September 2010|December 2012|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 18, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280162||110263|
NCT01280175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FB/PS/14/163/06|Foster With or Without Charcoal Block or Aerochamber Plus|Pharmacokinetics and Lung Bioavailability of BDP/Formoterol HFA Fixed Combination After Single Administration in 12 Healthy Volunteers Using the Standard Actuator With or Without Charcoal Block or the Aerochamber Spacer.||Chiesi Farmaceutici S.p.A.|No|Completed|December 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 19, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01280175||110262|
NCT01279577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSU-2/CDA|Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease|Double-blind, Randomised, Placebo-controlled, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Three Different Dosages of Oral Trichuris Suis Ova (TSO) Suspension in Active Crohn's Disease|TRUST-2|Dr. Falk Pharma GmbH|Yes|Completed|November 2010|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|254|||Both|18 Years|75 Years|No|||February 2015|February 9, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279577||110308|
NCT01310894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1001 PCM301|Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.|A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance|PCM301|Steba Biotech S.A.|Yes|Completed|February 2011|August 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|413|||Male|18 Years|N/A|No|||November 2015|November 6, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01310894||107916|
NCT01310907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-315|Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia|||China Medical University Hospital||Recruiting|February 2011|||||N/A|Observational|N/A||3|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The case group include 200 patients and the control group include 200 patients.|March 2011|March 6, 2011|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01310907||107915|
NCT01280474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99071|Effects of Maternal Depressive Symptomatology on Pregnancy Outcomes and Newborn Development --- How is Paternal Psychopathology Involved?|Effects of Maternal Depressive Symptomatology on Pregnancy Outcomes and Newborn Development --- How is Paternal Psychopathology Involved?||Taipei Medical University WanFang Hospital|No|Active, not recruiting|August 2010|August 2013|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women and their spouses|January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280474||110239|
NCT01280487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSTK474-101|A Safety Study of Oral ZSTK474 in Patients With Cancer|A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies||Zenyaku Kogyo Co., Ltd.|Yes|Completed|January 2011|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01280487||110238|
NCT01281020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS50/01/08|Adherence With Fixed Versus Unfixed Glaucoma Therapy|A 3-month, Observational Study Investigating With Electronic Monitoring the Level of Adherence and Treatment Satisfaction With Latanoprost/Timolol Fixed Combination Versus Unfixed Therapy in Open-angle Glaucoma||Aristotle University Of Thessaloniki|No|Completed|May 2009|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|132|||Both|18 Years|80 Years|No|Probability Sample|All patients who use latanoprost/timolol fixed combination therapy with once-a-day dosing        in the evening        All patients already treated with timolol twice daily and latanoprost once in the evening|May 2014|May 9, 2014|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281020||110197|
NCT01281267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P000550|Face Transplantation for Treatment of Severe Facial Deformity|Transplantation of Allograft Face or Facial Subunit for Treatment of Severe Facial Deformation||Brigham and Women's Hospital|Yes|Recruiting|September 2009|September 2018|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||January 2015|January 26, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281267||110179|
NCT01272167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0085|Effects of a Long-term Grapefruit Juice Consumption on Vascular Protection and Bone Metabolism|Effects of a Long-term and Regular Grapefruit Juice Consumption on Vascular Protection and Bone Metabolism : a Cross-over Designed Study to Determine the Specific Role of Naringin||University Hospital, Clermont-Ferrand||Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|52|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01272167||110878|
NCT01279772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG33|This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas|A Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas Treated With R-CHOP With or Without Radiotherapy|IELSG33|International Extranodal Lymphoma Study Group (IELSG)|No|Terminated|October 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Previously untreated patients with localized DLBCL of the breast.|July 2012|July 6, 2012|January 18, 2011||No|due to slow accrual (only 1 patient entered)|No||https://clinicaltrials.gov/show/NCT01279772||110293|
NCT01313767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-PRT-ST01|MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity|A Randomized, Double Blind, Multi-center, Active Drug Controlled Clinical Trial to Compare the Efficacy and Safety of MEDITOXIN® Versus BOTOX® in Treatment of Post Stroke Upper Limb Spasticity||Medy-Tox|No|Completed|March 2011|February 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|20 Years|N/A|No|||April 2012|April 24, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313767||107702|
NCT01313780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN10-KR-002|A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients|A 4-week Multicentre, Randomized, Open Label, Parallel Group, Active Control Phase IV Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone in Comparison With Oxycontin in Korean Patients With Cancer Pain(TOP)|TOP|Mundipharma Korea Ltd|No|Completed|May 2011|June 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|20 Years|N/A|No|||July 2015|July 7, 2015|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01313780||107701|
NCT01280708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/11-E|Protocol DIVAT-Uro|Establishment of a National Thematic Network in Urology for the Extension of the Cohort DIVAT (Données Informatisées et Validées en Transplantation) in Surgical Parameters of Renal and Pancreatic Transplant Patients : An Innovative Tool for the Promotion of Epidemiological Studies, Identification of Risk Factors and Good Practices in the Domain of Transplant Surgery||Nantes University Hospital|Yes|Recruiting|January 2010|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney        transplant.|September 2011|September 6, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280708||110221|
NCT01280682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-SR-021|Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes|Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes||Nanjing Medical University|Yes|Recruiting|July 2010|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|8 Years|45 Years|No|||April 2010|January 19, 2011|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01280682||110223|
NCT01281202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-01005/CS# 1030 TRANSFERRED|Vigabatrin for the Treatment of Cocaine Dependency|Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2011|December 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|January 20, 2011|No|Yes||No|February 2, 2016|https://clinicaltrials.gov/show/NCT01281202||110184|
NCT01282671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multic-PEP 2007-160|Effects of Deep Breathing Exercises Two Months After Cardiac Surgery|Effects of Deep Breathing Exercises Two Months After Cardiac Surgery||Uppsala University|No|Completed|September 2007|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01282671||110072|
NCT01282684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX115-01|Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers|A Phase 1 First in Human Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers||Plexxikon|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 26, 2015|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01282684||110071|
NCT01282983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKEA2010|Study of Digestive Tolerance of Orange Juice With Fibers|Study of Digestive Tolerance of Orange Juice With Fibers||University of Sao Paulo|Yes|Recruiting|October 2010|September 2011|Anticipated|February 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2010|January 24, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01282983||110048|
NCT01278979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ann2010|Diagnosing Perineal Tears, Does Different Assessment Methods Affect the Midwife's Clinical Judgement of Perineal Tears?|Diagnosing Perineal Tears. Consistency in Midwifes Clinical Judgement When Assessing Perineal Tears Using Two Different Assessment Methods.||Ostfold Hospital Trust|Yes|Completed|January 2011|February 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|400|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01278979||110354|
NCT01279213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109|Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia|Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study||Universidad Nacional de Rosario|No|Completed|January 2009|December 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2009|January 18, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01279213||110336|
NCT01311258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20123|Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome|A Program for Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia or High Grade Myelodysplastic Syndrome|MRD|University of Rochester|No|Recruiting|August 2007|August 2025|Anticipated|August 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|peripheral blood and bone marrow aspirate|Both|18 Years|N/A|No|Non-Probability Sample|Hematology/oncology clinic|December 2015|December 17, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311258||107889|
NCT01310972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2071-027|Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX|Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX||King Faisal Specialist Hospital & Research Center|Yes|Completed|September 2007|September 2007|Actual|September 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|14 Years|85 Years|No|Non-Probability Sample|Colon Cancer Registry|December 2011|February 24, 2016|March 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310972||107910|
NCT01310647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-018009-26|Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders|Prospective Randomized Controlled Trial of Antral Follicle Priming Prior to IVF-ICSI in Previously Diagnosed Low Responders.|FOLLPRIM|Instituto de Investigacion Sanitaria La Fe|Yes|Completed|June 2011|February 2014|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|66|||Female|18 Years|41 Years|No|||February 2014|February 27, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310647||107935|
NCT01311856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0504|Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors|Telephone Counseling-Mailed Materials Versus Internet Weight Management Interventions in Overweight Cancer Survivors||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2011|||March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Participants recruited from UT MD Anderson Cancer Center clinics in Houston, Texas|November 2015|November 3, 2015|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01311856||107845|
NCT01311245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM5-IESO03|Testing Alcohol Interventions Among Job-seekers|Testing Stage Tailored vs. Non-stage Tailored Interventions Among Job-seekers With Risky Drinking|TOPAS|University Medicine Greifswald|No|Completed|July 2008|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|1243|||Both|18 Years|64 Years|No|||December 2015|December 1, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311245||107890|
NCT01311531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIK 2009/318|Volar Locking Plate vs Fragment Specific Fixation in Wrist Fractures|Treatment of Distal Radial Fractures With Volar Locking Plates Versus Fragment-specific Fixation (TriMed Classic). A Randomized Trial||Region Skane|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||January 2014|January 23, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01311531||107869|
NCT01311817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-0002296|Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine|Transcutaneous Immunization With actA/plcB-Deleted Listeria Monocytogenes Expressing Influenza A Nucleoprotein (BMB72) and Cholera Toxin Adjuvant||Massachusetts General Hospital|Yes|Completed|January 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311817||107847|
NCT01311830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-005379|Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons|Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons||Mayo Clinic|No|Completed|September 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|534|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 22, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311830||107846|
NCT01312961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT11457|Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma|Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy||Sanofi||Completed|March 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|65 Years|No|||January 2013|January 13, 2014|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312961||107762|
NCT01271881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORE-01|Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins|Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins||American Access Care|Yes|Recruiting|October 2010|||October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|70 Years|No|||January 2011|January 6, 2011|December 1, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01271881||110900|
NCT01279785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TX-P104|A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy|A Phase 1 Pilot Study of 123I-MIP-1072 Single Photon Emission Computed Tomography (SPECT)/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy||Molecular Insight Pharmaceuticals, Inc.|No|Withdrawn|March 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Male|18 Years|N/A|No|Probability Sample|Up to twenty adult men with biopsy confirmed prostate cancer scheduled for prostatectomy        at the NIH Clinical Center will undergo 123I-MIP-1072 SPECT/CT and optional CGCP imaging        prior to prostatectomy. These patients will also have undergone/will undergo        multi-parametric 3T MR imaging at NIH which is considered standard of care at NIH clinical        center.|November 2015|November 23, 2015|January 18, 2011|Yes|Yes|Similar study to be completd once kit for new formulation becomes available.|No||https://clinicaltrials.gov/show/NCT01279785||110292|
NCT01279798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR001-04|Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)|Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.||NovaRx Corporation||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2011|February 25, 2011|October 29, 2010|Yes|Yes||||https://clinicaltrials.gov/show/NCT01279798||110291|
NCT01280071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-10-TLV|Adenosine Activity in Producing Venoarteriolar Reflexes|||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting||||||N/A|Interventional|Primary Purpose: Basic Science|1||||||Male|18 Years|50 Years||||January 2011|January 19, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01280071||110270|
NCT01280084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02900|Labour Analgesia and Movement in Babies|The Effect of Labour Analgesia on Babies' Movements After Birth: An Actigraphic Study|LAMB|University of British Columbia|Yes|Completed|February 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|40|||Female|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy women who have vaginal deliveries at BC Women's Hospital|February 2012|February 10, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01280084||110269|
NCT01280058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02567|Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer|A 2-Arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin®) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2010|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01280058||110271|
NCT01281423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA598-505|Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV Infection|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection||Hoffmann-La Roche|No|Active, not recruiting|December 2010|May 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|274|||Both|18 Years|65 Years|No|||November 2012|November 20, 2012|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281423||110167|
NCT01280942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0514|Early Warning System for Clinical Deterioration on General Hospital Wards|Early Warning System for Clinical Deterioration on General Hospital Wards.||Washington University School of Medicine|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20031|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280942||110203|
NCT01281657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2399E1|Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program|A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program||Novartis||Completed|February 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with relapsing forms of MS who have participated in previous fingolimod trials        and now taking commercially available fingolimod as part of routine medical care|September 2012|September 5, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01281657||110150|
NCT01281683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010059R|Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy|Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy||National Taiwan University Hospital|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for TACE or RFA with newly-diagnosed unresectable HCC or tumor        recurrence after operation|January 2011|January 20, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281683||110148|
NCT01281930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0719|Abscess Packing Versus Wick Placement After Incision and Drainage|Abscess Packing Versus Wick Placement After Incision and Drainage||Washington University School of Medicine||Recruiting|June 2009|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|6 Months|18 Years|No|||January 2011|January 20, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281930||110129|
NCT01281956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110039|PRX-00023 Therapy in Localization-Related Epilepsy|A Phase II Clinical Trial of PRX-00023 Therapy in Localization-Related Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|May 2018|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||April 2015|March 5, 2016|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281956||110127|
NCT01282996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0087|Intraoperative Protective Ventilation in Abdominal Surgery (IMPROVE Study)|Intraoperative Lung Protective Ventilation in Abdominal Surgery: A Randomized Controlled Study||University Hospital, Clermont-Ferrand||Completed|January 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|400|||Both|40 Years|90 Years|No|||October 2012|October 4, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01282996||110047|
NCT01283009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|574|Extended Steroid in CAP(e)|CSP #574 - Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans With Severe Community-Acquired Pneumonia|ESCAPe|VA Office of Research and Development|Yes|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1450|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01283009||110046|
NCT01278992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006C002P|Rhodiola Rosea for Mental and Physical Fatigue|A Randomized Trial of Rhodiola Rosea for Mental and Physical Fatigue in Nurses||Government of Alberta|Yes|Enrolling by invitation|January 2011|April 2011|Anticipated|April 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|90|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 14, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01278992||110353|
NCT01310985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2071-051|A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer|A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer||King Faisal Specialist Hospital & Research Center|Yes|Completed|March 2008|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|15|||Both|14 Years|85 Years|No|Non-Probability Sample|Patients with Localized (Non-Metastatic) Rectal Cancer|December 2011|February 24, 2016|March 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310985||107909|
NCT01311583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-010|Evaluating Teach Back as a Method for Improving Self-Care Behaviours in Heart Failure Patients|Evaluating Teach Back as a Method for Improving Self-Care Behaviours in Heart Failure Patients||St. Michael's Hospital, Toronto|No|Completed|October 2011|February 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01311583||107865|
NCT01311544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01158-31|Evaluation of 4D Magnetic Resonance Angiography (K-t Blast) of Supraortic Vessels in Acute Ischemic Stroke Patients|Evaluation of 4D Magnetic Resonance Angiography (K-t Blast) of Supraortic Vessels in Acute Ischemic Stroke Patients||Rennes University Hospital||Completed|March 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke|May 2012|May 15, 2012|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311544||107868|
NCT01311557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td519|Study of Adacel® Vaccine Administered to Persons 10 Years of Age|Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age||Sanofi|No|Completed|March 2011|January 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1302|||Both|10 Years|11 Years|Accepts Healthy Volunteers|||April 2012|April 27, 2012|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311557||107867|
NCT01311570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B080910|Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients|A Single Center, Open Label, Dose-titration, add-on Study Assessing the Feasibility, Safety and Therapeutic Effect of Buprenorphine in Adult Patients With Diagnosis of Major Depression.||Shalvata Mental Health Center|Yes|Not yet recruiting|October 2012|||February 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|68 Years|No|||September 2012|September 23, 2012|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01311570||107866|
NCT01312090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09RUSRAS|Chronic Intermittent Cold Exposure on Weight Loss|Chronic Intermittent Cold Exposure on Weight Loss|CICE|Helsinki University Central Hospital|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|50 Years|No|||September 2012|September 5, 2012|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312090||107827|
NCT01312662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VisComp01|Towards Worldwide Comparability of Visual Acuity Assessment|Towards Worldwide Comparability of Visual Acuity Assessment A Pilot Study Comparing ETDRS Visual Acuity Charts, Projected Landolt Charts and the Freiburg Visual Acuity Test (FrACT) With a View to Developing a Mathematical Transformation Routine Between the Results From These Three Tests|VisComp|University Hospital Tuebingen|No|Recruiting|March 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||7|Anticipated|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|University eye Hospital Tuebingen|March 2011|March 8, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312662||107783|
NCT01312987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANI I, Shoulder to Shoulder|Improving Nutrition and Health Outcomes in Intibuca, Honduras (MANI I)|Improving Nutrition and Health Outcomes in Intibuca, Honduras|MANI I|Shoulder to Shoulder|Yes|Completed|March 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|5 Months|18 Months|Accepts Healthy Volunteers|||July 2011|July 31, 2011|March 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01312987||107761|
NCT01313026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LARS 001|Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation|Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation. A Randomized Cross Over Study.||University of Aarhus|Yes|Recruiting|January 2011|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01313026||107758|
NCT01272661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFS-1|Breast for Success: A Family-Centered Intervention in Support of Breastfeeding Among High-risk Low-income Mothers|Breast for Success: A Family-Centered Intervention in Support of Breastfeeding Among High-risk Low-income Mothers in Cleveland|BFS|University Hospital Case Medical Center|Yes|Completed|June 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|1296|||Female|14 Years|N/A|No|||December 2014|December 11, 2014|December 27, 2010||No||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01272661||110840|
NCT01280409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0426|Metformin Postpartum for GDM RCT for Reduced Weight Retention|The Effects of Metformin on Retained Postpartum Weight in Women With Gestational Diabetes: A Randomized, Placebo-Controlled Trial||The University of Texas Health Science Center, Houston|No|Completed|January 2011|August 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Female|18 Years|49 Years|No|||December 2015|December 3, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280409||110244|
NCT01280721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-10-003|A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]|A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]||Otsuka Pharmaceutical Co., Ltd.|No|Completed|November 2010|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|23 Years|53 Years|No|||October 2015|October 16, 2015|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01280721||110220|
NCT01280734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neurim-PIS1|Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects|Randomised, Double-blind, 3-way Crossover, Single Dose, Placebo-controlled Study Investigating the Effect on Postural Instability of Melatonin and Zolpidem in Healthy Adult Subjects Aged of 55 to 64 Years.||Neurim Pharmaceuticals Ltd.|Yes|Completed|January 2011|May 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|26|||Both|55 Years|64 Years|Accepts Healthy Volunteers|||December 2011|December 11, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280734||110219|
NCT01280396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1205|Metabolic Side-effects for Second-generation Antipsychotics|Metabolic Side-effects in Patients Receiving Clozapine and Second-generation Antipsychotics in an Outpatient Clinic||The University of Hong Kong||Recruiting|November 2010|||July 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|372|||Both|18 Years|N/A|No|Non-Probability Sample|Out-patients in a public psychiatric out-patient centre|January 2011|January 28, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280396||110245|
NCT01280695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSDC-0602-C002|A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients|A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients||Metabolic Solutions Development Company|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|129|||Both|18 Years|75 Years|No|||March 2014|March 17, 2014|January 20, 2011|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01280695||110222|
NCT01281436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ|Health Information Technology to Support Clinical Decision Making in Obesity Care|Health Information Technology to Support Clinical Decision Making in Obesity Care||Arizona State University|Yes|Recruiting|October 2010|September 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|January 20, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01281436||110166|
NCT01281670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201009070R|The Effects of Combining Whole Body Vibration Training With Plyometric Jumping on the Neuromuscular Adaptations of Human Triceps Surae Muscles|The Effects of Combining Whole Body Vibration Training With Plyometric Jumping on the Neuromuscular Adaptations of Human Triceps Surae Muscles||National Taiwan University Hospital|Yes|Recruiting|January 2011|December 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Anticipated|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||January 2011|January 20, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281670||110149|
NCT01281696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010077M|Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis|A Phase II Study of Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis||National Taiwan University Hospital|Yes|Completed|January 2011|October 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|75 Years|No|||October 2013|October 15, 2013|December 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01281696||110147|
NCT01281943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104170|Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer|Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer||Washington University School of Medicine|No|Withdrawn|June 2011|May 2014|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|January 20, 2011|Yes|Yes|Doxil Shortage|No||https://clinicaltrials.gov/show/NCT01281943||110128|
NCT01282203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-638|Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevorane in Adult Patients Required General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on Cardiovascular System in Common Clinical Practice|Evaluation of VIMA With SEVOrane in Adult Patients Required General Anesthesia fOr Surgery in TErms of Quality of Anesthesia and Its Influence on Cardiovascular sysTem In commON Clinical Practice (SEVOPROTECTION)|SEVOPROTECTION|AbbVie||Completed|July 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1122|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing planned or urgent surgery|January 2013|January 28, 2013|January 21, 2011||No||No|November 30, 2012|https://clinicaltrials.gov/show/NCT01282203||110108|Troponin T and CK-MB values were not collected in the study, therefore no conclusions can be made regarding the influence of volatile induction and maintenance anesthesia with Sevorane on myocardial ischemia markers.
NCT01282450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oligometa's|Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)|Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC).||Maastricht Radiation Oncology|No|Completed|May 2006|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01282450||110089|
NCT01282463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13943|Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma|An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy||Eli Lilly and Company|No|Completed|April 2011|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|148|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282463||110088|
NCT01282697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4791|Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors|Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors|RAPIRI|University Hospital, Strasbourg, France|Yes|Not yet recruiting|February 2011|August 2014|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|1 Year|21 Years|No|||January 2011|January 24, 2011|November 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01282697||110070|
NCT01279603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO-2C-001|Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas|A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GO-203-2c Given Intravenously Daily X21 Repeated Every 28 Days in Patients With Advanced Solid Tumors Including Lymphomas||Genus Oncology, LLC||Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|January 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279603||110306|
NCT01310660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0806/87|Evaluation of Levator Injuries Using Transvaginal Endosonography|Evaluation of Levator Injuries Using Transvaginal Endosonography|ELITE|Croydon University Hospital|No|Completed|January 2011|||July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|269|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nulliparous|January 2016|January 29, 2016|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310660||107934|
NCT01279863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5500-DB048|VRI in Children With Acute Respiratory Symptoms.|Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms.|VRI|Rabin Medical Center|No|Not yet recruiting|February 2011|February 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|||Both|3 Years|18 Years|No|Probability Sample|Children, 3-18 years old|May 2010|August 11, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279863||110286|
NCT01310933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099086-E|Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy|Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy||Far Eastern Memorial Hospital|No|Recruiting|December 2010|February 2012|Anticipated|||N/A|Observational|Time Perspective: Retrospective||2|Anticipated|40|||Both|3 Years|80 Years|No|Non-Probability Sample|From November 2007 to September 20010, sonograms of eleven cases notes with pathological        diagnoses of Kikuchi's disease and ten patients with malignant lymphoma were studied.|January 2012|January 31, 2012|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01310933||107913|
NCT01311908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201005058R|Incidence of Reflux Esophagitis After Pancreaticoduodenectomy|Effect of a Roux-en-Y Reconstruction on Reflux Esophagitis After Pancreaticoduodenectomy||National Taiwan University Hospital|Yes|Recruiting|March 2011|December 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|esophageal mucosal biopsy for Real-Time PCR for COX-2 activity|Both|18 Years|N/A|No|Probability Sample|tudy the effect of a Roux-en-Y reconstruction on GERD and marginal ulcer after        pancreaticoduodenectomy|March 2011|March 22, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311908||107841|
NCT01311271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1011-056-003|Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation(rTMS) on the Recovery After Stroke|Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation on the Recovery of Upper Motor Function After Stroke: a Randomized Controlled Trial||Seoul National University Bundang Hospital|Yes|Terminated|January 2011|||February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2|||Both|20 Years|90 Years|No|||May 2015|May 18, 2015|March 4, 2011||No|Only two subjects have been recruited from start of the study. We decided to start the study    in this topic, after revising the study protocol.|No||https://clinicaltrials.gov/show/NCT01311271||107888|
NCT01311284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR-AR-2010-A1|Comparison Airway Devices in Nasotracheal Intubation in Manikin|Comparison of Airtraq Nasotracheal Mcgrath and Macintosh Laryngoscope in Nasotracheal Intubation: A Manikin Study|MGR-AR2010A1|Complexo Hospitalario Universitario de A Coruña|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|63|||Both|23 Years|65 Years|No|||January 2012|January 3, 2012|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311284||107887|
NCT01312142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012007RC|Changes of Weaning Parameter in Weaning Failure Patient After Tracheostomy as a Predictor of Subsequent Weaning|Changes of Weaning Parameter in Weaning Failure Patient After Tracheostomy as a Predictor of Subsequent Weaning||National Taiwan University Hospital|No|Recruiting|March 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with difficult weaning and received subsequent tracheostomy|December 2011|December 19, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312142||107823|
NCT01312155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-338|Assisted Intubation|||McGill University Health Center|No|Completed|March 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|90 Years|No|Probability Sample|Patients undergoing general anesthesia with endotracheal intubation|October 2013|October 24, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312155||107822|
NCT01311869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Green Tea Study|Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids|Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids||Meharry Medical College|Yes|Terminated|December 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|2||Actual|43|||Female|18 Years|N/A|No|||October 2013|October 23, 2013|March 7, 2011|Yes|Yes|IRB Decision|No||https://clinicaltrials.gov/show/NCT01311869||107844|
NCT01312103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH085641|Internet-Based Intervention to Improve Mental Health Outcomes for Abused Women|Internet-Based Intervention to Improve Mental Health Outcomes for Abused Women||Johns Hopkins University|Yes|Active, not recruiting|March 2011|March 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|720|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312103||107826|
NCT01312116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2007-0756|Psychodynamic Internet Treatment Versus Cognitive Behavioral Therapy (CBT) for Generalized Anxiety Disorder|Psychodynamic Versus Cognitive Behavioral Internet-Delivered Guided Self-help for Generalized Anxiety Disorder: A Randomized Controlled Trial||Linkoeping University|No|Completed|January 2009|December 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01312116||107825|
NCT01312129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20-381|Effects of Sulfasalazine on BOLD Response to Alcohol Cues|Effects of Sulfasalazine on BOLD Response to Alcohol Cues||The Mind Research Network|No|Completed|March 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|21 Years|55 Years|No|||September 2014|September 18, 2014|March 9, 2011|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01312129||107824|
NCT01313689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114242|Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia|An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL)||GlaxoSmithKline|No|Active, not recruiting|April 2011|June 2018|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 10, 2011|No|Yes||No|November 6, 2014|https://clinicaltrials.gov/show/NCT01313689||107708|
NCT01313702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEP001/2011|Single Pill to Avert Cardiovascular Events|Effect of Polipill on Patients at High Cardiovascular Risk : a Randomized Controlled Trial|SPACE|Hospital do Coracao|No|Not yet recruiting|October 2012|July 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313702||107707|
NCT01272440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTH-1|A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia|PEG-asparaginase Treatment in the NOPHO ALL-2008 Protocol: Antibody Formation, Pharmacokinetics, Pharmacodynamics and Side Effects.||Aarhus University Hospital|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood, Cerebrospinal fluid|Both|1 Year|18 Years|No|Non-Probability Sample|Children aged between 1 and 18 years old, diagnosed ALL and treated according to the        NOPHO-ALL 2008 protocol|November 2013|November 12, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01272440||110857|
NCT01272674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|adipo2008|Adiponectin and Circulating Progenitor Cells (CPC) Function|Adiponectin Promotes the Migration of Circulating Progenitor Cells Through p38-mediated Induction of the CXCR4 Receptor||University of Leipzig|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01272674||110839|
NCT01281241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33244.018.10|Study on Mechanical and Electrical Alternans|The Connection Between Mechanical Alternans Measured by Pressure-Volume (PV) Loop Catheter in Patients With Ischemic Heart Failure and the Occurrence of Microvolt T Wave Alternans (MTWA)||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Active, not recruiting|September 2010|June 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients admitted to the hospital with a left ventricular ejection fraction (LVEF) under        35%, due to coronary artery disease with an indication for electrophysiological        investigation.|October 2010|January 20, 2011|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281241||110181|
NCT01281215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR - 381298|Education Interventions Model for Rational Drug Use (RDU)|Education Interventions Model for Rational Drug Use||University of Sao Paulo|No|Completed|March 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|N/A|No|||October 2012|October 31, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01281215||110183|
NCT01281969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110058|Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)|A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2011|December 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Both|4 Years|13 Years|No|||February 2016|March 9, 2016|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281969||110126|
NCT01281982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110081|(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas|(11C)N-Desmethyl-Loperamide as a Marker of P-Glycoprotein Function in Patients With Gliomas||National Institutes of Health Clinical Center (CC)||Terminated|January 2011|September 2012||||N/A|Observational|Time Perspective: Prospective|||Actual|2|||Both|18 Years|99 Years|No|||September 2012|December 16, 2015|January 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281982||110125|
NCT01282216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J10140|Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide|Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant (BMT) With High-dose Post Transplantation Cyclophosphamide.||Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|April 2011|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 30, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01282216||110107|
NCT01282476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-441|Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma|Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma||Massachusetts General Hospital|Yes|Active, not recruiting|June 2011|August 2015|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282476||110087|
NCT01282710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRT-09-01|Comparison of SureCALL® EMG Labor Monitor® and Tocodynamometer to Intrauterine Pressure Catheter Measurement (IUPC) Measurement in Pregnant Women|Comparison of SureCALL® EMG Labor Monitor® and Tocodynamometer to Intrauterine Pressure Catheter Measurement in Pregnant Women||Reproductive Research Technologies, LP||Completed|August 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Female|15 Years|40 Years|No|Non-Probability Sample|Women in labor with uncomplicated singleton pregnancies and IUPC indicated with membranes        ruptured and sufficient cervical dilation.|February 2011|February 16, 2011|January 21, 2011||No||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01282710||110069|
NCT01310920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-316|The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome|||China Medical University Hospital||Recruiting|February 2011|||||N/A|Observational|Observational Model: Case Control||2|Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The case group includes 200 patients and the control group includes 200 patients.|March 2011|March 8, 2011|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01310920||107914|
NCT01310452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prof gao xin|Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin|A Multi-centre, Open-labeled, Randomized, Parallel Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After 26 Weeks Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily||Fudan University|No|Active, not recruiting|January 2011|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|70 Years|No|||June 2010|March 7, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310452||107950|
NCT01310946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2021-051|Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology|Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|June 2003|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|203|||Both|14 Years|85 Years|No|Non-Probability Sample|Acute Lymphocytic Leukemia Database|December 2011|December 11, 2011|March 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310946||107912|
NCT01310673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS #16820|Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout|Therapy for Acute Gout: Does Initial Use of Allopurinol Effect Duration and/or Recurrence Rate of Acute Attacks||White River Junction VAMC|No|Completed|January 1998|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Male|18 Years|N/A|No|||March 2011|March 7, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310673||107933|
NCT01311882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-035|A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)|A Multiple Dose Study to Evaluate Next Day Effects of MK-4305 on Driving Performance in Healthy Non-Elderly Subjects||Merck Sharp & Dohme Corp.|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|28|||Both|21 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311882||107843|
NCT01311895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 10-07-201|Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone|Randomized Clinical Trial Comparing Two Protocols Using IV Hydromorphone||Montefiore Medical Center|No|Recruiting|January 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|21 Years|65 Years|No|||March 2011|September 15, 2011|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311895||107842|
NCT01312701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zeta-im-1|Study of Blood Immune Cells in Cancer Patients Compared to Controls|Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls||Hadassah Medical Organization|No|Recruiting|March 2011|December 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|The investigators will collect peripheral blood for facts analysis of intracellular levels      of proteins.      Some of these cells may be frozen for longer periods of time for comparison with other new      samples.|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|controls - patients who were deemed eligible for blood donation cancer patients - patients        with solid tumors who agreed to participate in the study|March 2011|March 9, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01312701||107780|
NCT01312714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-TL-2011|Vitamin D3 Supplementation in Dialysis Patients|A Randomized, Placebo-Controlled, Double Blind Study Evaluating the Effect of Cholecalciferol on Vasoactive Hormones, Heart Function, Arterial Stiffness, and Blood Pressure in Dialysis Patients.||Regional Hospital Holstebro|Yes|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312714||107779|
NCT01312428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64|Pelvic Alignment Level (PAL) Instrument Evaluation|A Prospective Clinical Evaluation of Acetabular Cup Placement in Total Hip Replacements Utilizing a Pelvic Alignment Level (PAL) Instrument|PAL|Stryker Orthopaedics|No|Terminated|February 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|March 8, 2011|Yes|Yes|Lagging enrollment|No|August 15, 2014|https://clinicaltrials.gov/show/NCT01312428||107801|
NCT01312688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0034-11-HMO-CTIL|Early Goal-directed Therapy and Myocardial Dysfunction|The Effect Early Goal-directed Therapy on Myocardial Dysfunction and Survival in ICU Patients With Severe Sepsis and Septic Shock: A Prospective Randomized Controlled Trial|SEPT-MD|Hadassah Medical Organization|Yes|Not yet recruiting|July 2011|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2011|March 9, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01312688||107781|
NCT01313377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000696193|Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery|Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts||National Cancer Institute (NCI)||Recruiting|July 2009|||July 2016|Anticipated|Phase 3|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Both|18 Years|N/A|No|||March 2011|March 10, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313377||107732|
NCT01309451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OA002|Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema|A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema||Maturi, Raj K., M.D., P.C.|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|March 3, 2011|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT01309451||108026|
NCT01309477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGNS-002|The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)|||Sun Yat-sen University|Yes|Completed|January 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|14 Years|60 Years|No|||October 2011|November 1, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01309477||108025|
NCT01309490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ribavirin-004|Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients|An Open-label, Dose Escalation Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Expressing Elevated eIF4E||Jewish General Hospital|No|Recruiting|March 2011|June 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2011|March 4, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309490||108024|
NCT01272999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-4024|Impact of Prevnar 13 on Ear Infections in Children|Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children||Pfizer|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|391|None Retained|Microbiology samples (middle ear fluid) taken by treating physicians in standard course of      care for ear infections.|Both|6 Weeks|18 Years|No|Non-Probability Sample|Children aged 6 weeks to 18 years|September 2014|September 10, 2014|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01272999||110814|
NCT01273012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P001h/53|Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital|Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital|infloran|Phramongkutklao College of Medicine and Hospital|No|Recruiting|April 2010|December 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|128|||Both|3 Months|6 Years|No|||July 2011|July 28, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01273012||110813|
NCT01281254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060517|AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)|A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Amgen|Yes|Active, not recruiting|March 2011|November 2018|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|223|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281254||110180|
NCT01280955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024433|Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant|A Phase I/II Study: Enhancing Donor Hematopoietic Cell Engraftment With Plerixafor in Myeloablative Allogeneic Hematopoietic Cell Transplantation||Duke University|Yes|Active, not recruiting|December 2011|February 2018|Anticipated|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|January 20, 2011|Yes|Yes||No|September 27, 2015|https://clinicaltrials.gov/show/NCT01280955||110202|Study was limited to recipients of matched adult donor grafts
NCT01280968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019787|Improving the Efficacy of Anti-Nicotine Immunotherapy|Improving the Efficacy of Anti-Nicotine Immunotherapy|PETNic002|Duke University|Yes|Completed|December 2010|April 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|52|||Both|18 Years|55 Years|No|||January 2014|January 29, 2014|November 16, 2010|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01280968||110201|
NCT01281228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2010Exbrain001|The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes|The Effect of GLP-1 Receptor Activation on Central Reward and Satiety Circuits in Response to Food Stimuli in Obesity and Diabetes|Braini-Ex|VU University Medical Center|No|Completed|September 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281228||110182|
NCT01281995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110092|Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers|Effects of Systemically Administered Hydrocortisone on the Human Immunome in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|January 2011|||||Phase 1|Observational|Time Perspective: Prospective|||Actual|22|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01281995||110124|
NCT01282008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911067|Message Testing for Tobacco-Related Corrective Statements|Message Testing for Tobacco-Related Corrective Statements||National Institutes of Health Clinical Center (CC)||Completed|January 2011|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|627|||Both|14 Years|17 Years|No|||January 2016|January 29, 2016|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282008||110123|
NCT01282229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT MC 06-001|Study to Compare Laser Assisted New Attachment Procedure (LANAP) to Traditional Treatments of Chronic Periodontitis|A Multi-Center Single Blind Study of the Laser Assisted New Attachment Procedure Compared to Scaling and Root Planing Alone, Modified Widman Flap Surgery, and Coronal Debridement Alone in the Treatment of Chronic Periodontitis|LANAP|Institute for Advanced Laser Dentistry|No|Completed|October 2010|October 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|59|||Both|25 Years|75 Years|No|||September 2015|September 15, 2015|January 13, 2011||No||No|June 18, 2015|https://clinicaltrials.gov/show/NCT01282229||110106|
NCT01279005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0425-10CTIL|Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV|Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV - Focus Groups, Observational Study|MSM HIV|Rambam Health Care Campus|No|Not yet recruiting|February 2011|July 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Male|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|40-50 years old MSM|January 2011|January 18, 2011|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01279005||110352|
NCT01279018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-028|Persistent Pain After Breast Cancer Treatment With Docetaxel|Persistent Pain After Breast Cancer Treatment With Docetaxel||Rigshospitalet, Denmark|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2490|||Female|18 Years|80 Years||Non-Probability Sample|Patients treated for breast cancer in Denmark 2007 and 2008|June 2010|January 18, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01279018||110351|
NCT01279252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEAR|CLL Empirical Antibiotic Regimen|A Phase II Trial of Broad Spectrum Antibiotic Therapy for Early Stage, Non-progressive Chronic Lymphocytic Leukaemia Without Adverse Prognostic Factors|CLEAR|King's College Hospital NHS Trust|No|Active, not recruiting|July 2011|December 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279252||110333|
NCT01279590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPD10558-010|Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)|A Double-blind, Randomized, Placebo-controlled and Active-comparator-controlled Phase 2b Study to Evaluate Statin-associated Myalgia Incidence, Lipid Profile Effect, and Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients With Primary Hypercholesterolemia, Fredrickson IIa or IIb, Who Have Discontinued Two or More Prior Statin Therapies Due to Statin-associated Myalgia||Furiex Pharmaceuticals, Inc|No|Completed|March 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|282|||Both|40 Years|N/A|No|||December 2011|December 19, 2011|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279590||110307|
NCT01311011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2081-026|Study of the Clinical Efficacy of Autologous SCT in Patients With Critical Limb Ischemia|Phase II Prospective Study of the Clinical Efficacy of Autologous SCT in Patients With Critical Limb Ischemia||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|November 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|26|||Both|14 Years|85 Years|No|Non-Probability Sample|Patients with Critical Limb Ischemia|December 2011|December 11, 2011|March 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311011||107907|
NCT01311310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0907-028-286|Effect of Remote Ischemic Preconditioning on Children Undergoing Cardiac Surgery|Effect of Remote Ischemic Preconditioning on Children Undergoing Cardiac Surgery: Implication of Preoperative Cyanosis||Seoul National University Hospital|Yes|Completed|October 2009|December 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|60|||Both|1 Month|10 Years|No|||March 2011|April 30, 2012|September 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01311310||107885|
NCT01310959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2021-084|Establishing a Data Base for Aplastic Anemia and Other Marrow Failure Syndrome|Establishing a Data Base for Aplastic Anemia and Other Marrow Failure Syndrome||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|January 2003|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|88|||Both|14 Years|85 Years|No|Non-Probability Sample|Aplastic Anemia and Other Marrow Failure Syndrome Database|December 2011|December 11, 2011|March 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310959||107911|
NCT01311297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POPEYE|Clinical Monitoring of Endothelial Dysfunction for Pregnant Women and in the Perioperative Course|Clinical Monitoring of Endothelial Dysfunction for Pregnant Women and in the Perioperative Course - a Pilot Study||Charite University, Berlin, Germany|No|Recruiting|March 2011|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|Samples Without DNA|Whole blood, serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Female patients being treated in the Department of Gynecology and Obstetrics, Campus        Virchow Klinikum, Charité - Universitaetsmedizin Berlin|January 2016|January 25, 2016|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311297||107886|
NCT01312168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012085RB|Endothelial Dysfunction, Monocyte Activation, and Vasculopathy in Patients With Obstructive Sleep Apnea (OSA) and Effect of 6-month CPAP Treatment|Endothelial Dysfunction, Monocyte Activation, and Vasculopathy in Patients With Obstructive Sleep Apnea and Effect of Six-month CPAP Treatment: A Large-scale, Double-blind, Randomized, Placebo-controlled Trial||National Taiwan University Hospital|Yes|Recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312168||107821|
NCT01312441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00741|Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D|Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D||Albany College of Pharmacy and Health Sciences|No|Terminated|January 2011|August 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|March 9, 2011|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT01312441||107800|
NCT01313403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110097|Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder|Imaging Serotonin 5-HT1A Receptors in the High Affinity State in Brains of Patients With Major Depressive Disorder||National Institutes of Health Clinical Center (CC)||Withdrawn|February 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|55 Years|No|||April 2012|May 10, 2012|March 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01313403||107730|
NCT01313039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIAMI-20100252|Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer|Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer||University of Miami Sylvester Comprehensive Cancer Center|Yes|Completed|February 2011|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||May 2014|July 25, 2014|March 9, 2011|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01313039||107757|Only 4 patients were enrolled and of these 4 only 1 patient had evaluable study data.
NCT01313390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000696702|Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer|DORA: A Phase I and Randomized Phase II Study of Docetaxel and RAD001 (Everolimus) in Advanced/Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|DORA|University College, London|Yes|Terminated|June 2009|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2011|December 9, 2011|March 10, 2011||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01313390||107731|
NCT01310036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25637|A Study of Tarceva (Erlotinib) as First Line Therapy in Patients With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations|An Open-label Multi-center Study of Erlotinib (Tarceva®) as First Line Therapy Until and Beyond Disease Progression in NSCLC Patients Who Harbour EGFR Mutations||Hoffmann-La Roche||Active, not recruiting|April 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|208|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01310036||107982|
NCT01310049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0058-S01|LEO 32731 - A Study in Healthy Male Subjects|LEO 32731 - A Phase I, Single-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects||LEO Pharma|No|Completed|March 2011|November 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|5||Actual|111|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2011|November 4, 2013|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01310049||107981|
NCT01273545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017668|PRILIGY Usage Patterns in Selected Populations|PRILIGY Usage Patterns in Selected Populations||Janssen Research & Development, LLC|No|Completed|January 2010|December 2012|Actual|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3000|||Male|N/A|N/A|No|Non-Probability Sample|Male patients prescribed PRILIGY by physicians who contributed data to the CSD electronic        health services databases for German urologists, German general practitioners, or Italian        general practitioners.|April 2014|April 7, 2014|December 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01273545||110772|
NCT01281748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORTICOSTEROIDS AND ACUTE COPD|Evaluation Of The Efficacy Of Corticosteroids In Patients With An Acute Exacerbation Of Chronic Obstructive Pulmonary Disease Receiving Ventilator Support|||Hospital Universitario Getafe||Terminated|July 2005|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||May 2005|January 21, 2011|January 20, 2011||No|Low rate of enrollment|No||https://clinicaltrials.gov/show/NCT01281748||110143|
NCT01281462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-MD-02|Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections|A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection||Forest Laboratories|No|Completed|December 2010|July 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|217|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|January 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281462||110165|
NCT01281709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011019RC|Primary Care Physician's Wishes and Influencing Factors Toward Provision of Integrated Health Care|Primary Care Physician's Wishes and Influencing Factors Toward Provision of Integrated Health Care||National Taiwan University Hospital|Yes|Enrolling by invitation|January 2011|April 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The primary care physicians who serve in the excecutive centers of their community medical        groups|January 2011|January 20, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281709||110146|
NCT01281722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012044RB|Role of SLURP-1 in Melanoma and Melanoma Stem Cells|||National Taiwan University Hospital|No|Recruiting|January 2011|July 2019|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|serum, DNA, tissue|Both|20 Years|95 Years|Accepts Healthy Volunteers|Probability Sample|case and control study of melanoma disease|January 2011|January 21, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281722||110145|
NCT01282489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11142-2010CTIL|Evaluation of Methods to Asses Visual Prosthesis Systems Using Sighted Volunteers and Visual Reality Simulator|Evaluation of Methods to Asses Visual Prosthesis Systems Using Sighted Volunteers and Visual Reality Simulator||Meir Medical Center||Recruiting|August 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers with normal or corrected to normal sight|June 2014|May 19, 2015|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282489||110086|
NCT01313299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-145|Dysport® Adult Upper Limb Spasticity|A Phase III, Multicentre, Prospective, Double Blind, Randomised, Placebo Controlled Study, Assessing the Efficacy and Safety of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury||Ipsen||Completed|August 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|243|||Both|18 Years|80 Years|No|||September 2015|September 23, 2015|March 10, 2011|Yes|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01313299||107738|
NCT01282723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRT-10-01|Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring Patients by Practicing Clinicians|Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring Patients by Practicing Clinicians||Reproductive Research Technologies, LP||Completed|August 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Female|15 Years|40 Years|No|Non-Probability Sample|Women in labor with uncomplicated singleton pregnancies and IUPC indicated with membranes        ruptured and sufficient cervical dilation.|February 2011|February 16, 2011|January 21, 2011||No||No|January 24, 2011|https://clinicaltrials.gov/show/NCT01282723||110068|
NCT01283022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Miso-Obs-205|Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)|A Multicenter, Open-Label, Phase II Study of the 200 mcg Misoprostol Vaginal Insert (MVI 200) to Obtain Pharmacokinetics in Women at Term Gestation (The MVI-PK Study)||Ferring Pharmaceuticals|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Female|18 Years|N/A|No|||March 2014|March 10, 2014|January 20, 2011|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01283022||110045|
NCT01309880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|686E|Evaluation of a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens||Bausch & Lomb Incorporated|No|Completed|December 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 13, 2015|March 4, 2011|Yes|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01309880||107994|
NCT01309893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|687E|A Study to Evaluate a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens||Bausch & Lomb Incorporated|No|Completed|December 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 20, 2014|March 4, 2011|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01309893||107993|
NCT01309906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|688E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2010|||||N/A|N/A|N/A||||||||||||||August 10, 2012|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309906||107992|
NCT01310426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnaSphRF-HMO-CTIL|Risk Factors for Anal Sphincter Damage During Vaginal Delivery|Risk Factors for Anal Sphincter Damage During Vaginal Delivery|AnaSphRF|Hadassah Medical Organization|No|Completed|March 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|33|||Female|17 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population are women between ages 17 and 40 after their first delivery at the        Hadassa Mount Scopus hospital in Jerusalem, Israel.|July 2015|July 26, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01310426||107952|
NCT01310439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH126115|Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants|A Placebo-controlled Trial of Brain Activity Changes Following Psychostimulant Medication in Adolescent Combined-subtype ADHD||Hartford Hospital|No|Completed|May 2004|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|38|Samples With DNA|Saliva samples for genotyping|Both|13 Years|50 Years|No|Non-Probability Sample|Participants will be recruited from the community and referred from psychiatric outpatient        clinics.|March 2011|March 7, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310439||107951|
NCT01311323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHP-1|Revascularization in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) With Multivessel and/or Unprotected Left Main Coronary Disease|Revascularization Strategy (PCI With DES Implantation vs CABG) in Patients With Non ST Elevation Acute Coronary Syndrome With Multivessel and/or Unprotected Left Main Coronary Disease|MILESTONE|American Heart of Poland|Yes|Not yet recruiting|June 2011|January 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|21 Years|N/A|No|||July 2010|March 8, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311323||107884|
NCT01311596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101201|Show Me to Help Me|Show Me to Help Me||Akron Children's Hospital|No|Completed|February 2011|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|83|||Both|4 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children who are established patients, 4-18 years old, and present to the        NeuroDevelopmental Science Center for a follow-up office visit during the study period,        since a diagnosis will be available at the time of the study (patients in the lab study        may be new patients if they have a diagnosis at the time their lab work is prescribed).        The NeuroDevelopmental Science Center at Akron Children's Hospital provides nearly 25,000        visits annually to children and youth affected by neurological, developmental, and        behavioral disorders. This includes children with autism, intellectual disabilities,        physical disabilities, learning disabilities, epilepsy and other neurological conditions.|June 2014|June 23, 2014|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311596||107864|
NCT01313429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110111|Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum|Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum||National Institutes of Health Clinical Center (CC)||Completed|February 2011|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||April 2015|May 13, 2015|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01313429||107728|
NCT01312181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA024606|HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics|HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care||Research Foundation for Mental Hygiene, Inc.|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|390|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312181||107820|
NCT01312454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-038|Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C|A Proof of Concept Study to Assess the Safety and IOP-Lowering Effect of AL-59412C Injected Intravitreally||Alcon Research|No|Terminated|June 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|4|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|March 4, 2011|Yes|Yes|Management decision|No||https://clinicaltrials.gov/show/NCT01312454||107799|
NCT01312467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01744|A Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index|A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index||National Cancer Institute (NCI)|Yes|Completed|March 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|45|||Both|35 Years|80 Years|No|||June 2014|June 3, 2015|March 7, 2011|Yes|Yes||No|May 11, 2015|https://clinicaltrials.gov/show/NCT01312467||107798|
NCT01311661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.29|A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma|Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the Respimat® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma||Boehringer Ingelheim||Completed|March 2011|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|70 Years|No|||March 2014|March 28, 2014|March 4, 2011||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01311661||107859|
NCT01311674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-012|Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)|Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)||Cangene Corporation|No|Active, not recruiting|September 2009|December 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1000|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 8, 2011|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311674||107858|
NCT01313416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-C-0100|Gemcitabine and CT-011 for Resected Pancreatic Cancer|A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer||Georgia Regents University|Yes|Suspended|September 2012|February 2018|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||April 2015|July 15, 2015|March 10, 2011|Yes|Yes|Pidilizumab (CT-011) licensing transfer; Pending Medivation Inc. review.|No||https://clinicaltrials.gov/show/NCT01313416||107729|
NCT01312506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-067|Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls|Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Serum/Plasma From Patients With Metastatic Melanoma to the CNS and Respective Controls for Gene Expression and Proteomic Profiling||University of Pittsburgh|Yes|Withdrawn|July 2012|November 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|September 2015|September 2, 2015|March 8, 2011|No|Yes|Trial experienced funding issues, was never opened to accrual.|No||https://clinicaltrials.gov/show/NCT01312506||107795|
NCT01313715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT004|A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants|A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Actual|360|||Both|6 Months|60 Months|No|||March 2011|December 30, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313715||107706|
NCT01310530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110026|Partial Breast Proton Therapy for Early Stage Breast Cancer|Phase 2 Trial of Partial Breast Proton Therapy for Early Stage Breast Cancer With Low and Intermediate Risk Factors.||Loma Linda University|Yes|Active, not recruiting|May 2011|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|40 Years|80 Years|No|||August 2015|August 31, 2015|March 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01310530||107944|
NCT01311687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-003|A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study|A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multipe Myeloma|NIMBUS|Celgene|Yes|Active, not recruiting|March 2011|September 2017|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|455|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|March 8, 2011|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01311687||107857|
NCT01273311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911071|CARDIA Brain MRI Substudy|Contribution of Diabetes and Its Causes to Signs of Brain Aging in a Young-to-Middle Age Cohort||National Institutes of Health Clinical Center (CC)||Completed|December 2010|February 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|725|||Both|35 Years|55 Years|Accepts Healthy Volunteers|||February 2014|October 23, 2014|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01273311||110790|
NCT01312389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 29810|A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|29|||Female|18 Years|N/A|No|||June 2015|June 15, 2015|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312389||107804|
NCT01281475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-12-0610|A Trial of Levodopa in Angelman Syndrome|A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome||Children's Hospital Boston|Yes|Completed|January 2011|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|4 Years|12 Years|No|||July 2015|July 17, 2015|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281475||110164|
NCT01281735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIC09-33|Pediatric Chronic Myeloid Leukemia Registry|INTERNATIONAL STUDY of Chronic Myeloid Leukaemia (CML) Treatment and Outcomes in Children and Adolescents|PCMLR|Poitiers University Hospital|Yes|Recruiting|January 2011|January 2016|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|N/A|18 Years|No|Non-Probability Sample|All patients less than 18 years of age with newly diagnosed Philadelphia positive and/or        bcr-abl positive CML are eligible whatever the phase of the disease, the type of treatment        and the enrollment or not in a clinical study.|February 2011|February 7, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01281735||110144|
NCT01282242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR WITNESS|MR WITNESS: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients|MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients|MR WITNESS|Massachusetts General Hospital|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|85 Years|No|||March 2016|March 21, 2016|January 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282242||110105|
NCT01313312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-148|Dysport® Adult Upper Limb Spasticity Extension Study|A Phase III, Multicentre, Prospective, Open Label Extension Study to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury||Ipsen||Completed|November 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|258|||Both|18 Years|80 Years|No|||May 2015|May 7, 2015|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313312||107737|
NCT01313624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-219-0101|Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection|AIR-BX1|Gilead Sciences|Yes|Completed|April 2011|June 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|March 10, 2011|Yes|Yes||No|March 7, 2014|https://clinicaltrials.gov/show/NCT01313624||107713|
NCT01313962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIT02-11-01|Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of Flufirvitide-3 Nasal Spray in Healthy Subjects||Autoimmune Technologies, LLC|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313962||107687|
NCT01310465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FudanU-0457034|The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion|The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion||Fudan University|Yes|Recruiting|January 2011|April 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|70 Years|No|||January 2011|March 7, 2011|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310465||107949|
NCT01311921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChinaMUH|Children's Susceptibility to Enterovirus 71 in Different Areas of Taiwan|The Specific Aims Are to Find Factors Associated With Different Severe/Fatal Incidences in Different Areas of Taiwan. We Will do 1. Comparison of Gene Variants in EV71 Cases With Different Severity and Normal Children in Different Areas of Taiwan to Find Susceptible Genes and Genetic Polymorphism Related to the Clinical Outcomes 2. Social, Behavioral and Environmental Factors Related to EV71 Infections in Different Areas of Taiwan|DMR100-IRB-010|China Medical University Hospital|Yes|Enrolling by invitation|February 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|DNA,swab,blood|Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Symptoms very like Enterovirus type 71 of hand, foot, and mouth disease or Herpangina,|March 2011|March 8, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311921||107840|
NCT01313442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110112|Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer|Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|February 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|99 Years|No|||September 2015|October 17, 2015|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313442||107727|
NCT01313455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110119|Adrenal Hyperplasia Among Young People With PCOS|Adrenal Hyperplasia Among Young Patients With Polycystic Ovarian Syndrome||National Institutes of Health Clinical Center (CC)||Completed|March 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|96|||Female|16 Years|29 Years|No|||September 2015|September 17, 2015|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313455||107726|
NCT01309737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921079|A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis||Pfizer|Yes|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|960|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|March 4, 2011|Yes|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01309737||108005|
NCT01310010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DASA-TRAS|Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia|Multicenter, Non-randomized Phase II Pilot Study to Assess the Efficacy and Safety of Dasatinib After Allogeneic Stem Cell Transplantation in Patients With de Novo Philadelphia Positive (Bcr-abl +) Acute Lymphoblastic Leukemia|DASA-TRAS|Grupo Espanol de trasplantes hematopoyeticos y terapia celular|No|Active, not recruiting|April 2010|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01310010||107984|
NCT01310023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD052102 - PH100|Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women|Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women|SMARTT|Harvard School of Public Health|No|Recruiting|March 2007|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|3400|Samples With DNA|Serum, cell pellets, meconium, saliva|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 0 - < 12 years born of HIV-infected mothers recruited from a clinical        setting.|January 2016|January 14, 2016|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01310023||107983|
NCT01310738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVBrasil_2007|Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil|Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil|LVBrasil|University of Brasilia|Yes|Terminated|February 2011|February 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|380|||Both|6 Months|50 Years|No|||January 2016|January 20, 2016|March 7, 2011||No|DSMB recommendation based on programmed interim analysis.|No||https://clinicaltrials.gov/show/NCT01310738||107928|
NCT01312207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101020RC|Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy|Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy||National Taiwan University Hospital|No|Recruiting|February 2011|February 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|32|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases with macular tractional retinoschisis with or without combined traction detachment        (TRD) in proliferative diabetic retinopathy confirmed by optical coherence tomography|January 2011|March 8, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312207||107818|
NCT01312220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101061RC|Growth Factors and Hepatic Progenitor Cells in Acute Liver Failure|Relationship of Serological Growth Factors and Hepatic Progenitor Cells in Acute Liver Failure||National Taiwan University Hospital||Recruiting|February 2011|February 2013|Anticipated|||N/A|Observational|Observational Model: Cohort||1|Anticipated|10|Samples With DNA|Serum Liver piece|Both|18 Years|75 Years|No|Non-Probability Sample|acute liver failure who received liver transplantation|February 2011|March 8, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312220||107817|
NCT01312519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-04|Powered Bone Marrow Aspiration and Core Biopsy System Compared to Manual Devices|A Trial of the Vidacare Powered Bone Marrow Aspiration and Core Biopsy Systems (OnControl by Vidacare) Compared to Traditional Manual Devices||Vidacare Corporation|No|Completed|January 2010|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|November 3, 2010|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT01312519||107794|
NCT01313078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100028|Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer|Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer||National Institutes of Health Clinical Center (CC)|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||August 2012|October 8, 2015|March 9, 2011|Yes|Yes||No|August 13, 2012|https://clinicaltrials.gov/show/NCT01313078||107754|
NCT01313468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1541|Interval Training and Resting Metabolism|Effect of Aerobic Interval Training on NEAT in Sedentary Men|NEAT|Norwegian University of Science and Technology|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 9, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313468||107725|
NCT01313481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2008.1352|Effect of the Otago Programme Delivered as Home Exercise or Group Exercise|A Randomized Controlled Trial of the Effect of Otago Exercise Delivered as Home Exercise or Group Exercise in Fall-prone Older Persons|FALLFOR|Norwegian University of Science and Technology|No|Completed|October 2008|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|65 Years|N/A|No|||October 2011|October 18, 2011|March 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01313481||107724|
NCT01279421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00013931|High Risk Crack Use Settings and HIV in El Salvador|High Risk Crack Use Settings and HIV in El Salvador|Encuentro|Medical College of Wisconsin|Yes|Recruiting|November 2010|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1870|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 10, 2016|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279421||110320|
NCT01273844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1006|Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)|Study of the Combination of Bortezomib and Dexamethasone Followed by HSCT in AL||Nanjing University School of Medicine|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||November 2015|November 1, 2015|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01273844||110749|
NCT01313637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113361|A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease|DB2113361|GlaxoSmithKline|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1493|||Both|40 Years|N/A|No|||February 2014|February 20, 2014|March 10, 2011|No|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01313637||107712|
NCT01313000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST2001-1|Study To Evaluate Upper Arm Autologous Fat Transfer|Pilot Study To Evaluate Upper Arm Autologous Fat Transfer||Sound Surgical Technologies, LLC.|No|Completed|March 2011|March 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male patients undergoing abdominal liposuction who wish autologous fat transfer to the        upper arms|March 2012|March 23, 2012|March 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01313000||107760|
NCT01282021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911086|Molecular Immunohematology in Ethiopian Sub-Populations|Molecular Immunohematology in Ethiopian Sub-Populations||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282021||110122|
NCT01312636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3862|Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Congenital FVII Deficiency - Registry for All Treated Patients||Novo Nordisk A/S|No|Completed|March 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|36|||Both|N/A|N/A|No|Probability Sample|All subjects with a FVII deficiency to whom activated recombinant human factor VII        (NovoSeven®) is administered|October 2014|October 17, 2014|March 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01312636||107785|
NCT01312948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA13122010|Study of the Usability and Efficacy of a New Pediatric CPAP Mask|Pediatric Nasal Mask (Pixi) Usability Study||ResMed|No|Completed|January 2011|August 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|7 Years|No|||August 2011|April 9, 2012|February 6, 2011||No||No|October 31, 2011|https://clinicaltrials.gov/show/NCT01312948||107763|
NCT01309919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH10-190|Bleeding Patterns and Complications After Postpartum IUD Placement: a Pilot Study|Bleeding Patterns and Complications After Postpartum Intrauterine Device (IUD) Placement: a Pilot Study||Baystate Medical Center|No|Completed|January 2011|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Female|18 Years|55 Years|No|||January 2015|January 22, 2015|March 4, 2011||No||No|November 27, 2013|https://clinicaltrials.gov/show/NCT01309919||107991|Low rate of bleeding diary return limited our assessment of the primary outcome of bleeding/spotting days after delivery.
NCT01310478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-85|Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer|PhaseⅠClinical Study of Recombinant Human Endostatin in Combination With mFOLFOX6 as Initial Therapy for Patients With Metastatic Colorectal Cancer||Fudan University|No|Recruiting|August 2010|||May 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|17 Years|70 Years|No|||June 2010|March 7, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310478||107948|
NCT01310699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIND FLAT PA19624|Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study|Full Inspection With Narrow Band Imaging (NBI) for Detection of Flat Lesions And Tumors During Colonoscopy- The FIND FLAT Colonoscopy Study|NBI|VA Palo Alto Health Care System|Yes|Recruiting|January 2013|December 2020|Anticipated|June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 11, 2014|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310699||107931|
NCT01310179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNP-001|Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors|Phase I, Open-label Study Evaluating the Safety of Escalating Doses of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally With Co-administration of Fludarabine Phosphate Intravenously) in Subjects With Advanced Solid Tumors||PNP Therapeutics, Inc.|Yes|Completed|February 2011|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|19 Years|N/A|No|||May 2015|May 26, 2015|March 3, 2011|No|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01310179||107971|
NCT01312727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081258|Hereditary Tubulointerstitial Nephritis|Phenotypical and Genetic Characterization of Adult Hereditary Chronic Tubulointerstitial Renal Diseases|NTIH|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2010|March 2016|Anticipated|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|225|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01312727||107778|
NCT01309503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/743a (REK )|Speech Intelligibility in Noise Using the Hearing in Noise Test (HINT)|Speech Intelligibility in Noise and Estimation of Binaural Benefits Using the Hearing in Noise Test (HINT). Studies on Normal Hearing Children and Adults, Groups of Hearing Aid Users and Cochlea Implant Users.||Oslo University Hospital|No|Recruiting|March 2011|March 2015|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|600|||Both|5 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients at the ENT department, Oslo University hospital, Rikshospitalet. Normal hearing        group recruited from different schools and kindergartens.|March 2011|March 28, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309503||108023|
NCT01309516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pill110409|Randomised Control Trial of a Complex Intervention for Postnatal Depression|Efficacy of Learning Through Play Plus Intervention to Reduce Maternal Depression for Women With Under-nourished Children: A Randomized Controlled Trial From Pakistan||Pakistan Institute of Learning and Living|No|Completed|May 2009|May 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Female|18 Years|N/A|No|||September 2015|September 19, 2015|January 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01309516||108022|
NCT01310517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLVG2011|Hand Injected Ventriculography vs. Power Injected Left Ventriculography|Comparison of Very Low Contrast Volume Hand Injected Ventriculography to Standard Contrast Volume Power Injected Left Ventriculography From the Radial Artery Approach for Estimation of Left Ventricular Ejection Fraction.||Loma Linda University|No|Terminated|August 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|The subjects enrolled in this study will be adults referred for radial coronary        angiography with left ventriculography for clinical indications.|October 2014|October 1, 2014|March 7, 2011||No|Study was stopped due to low enrollment.|No||https://clinicaltrials.gov/show/NCT01310517||107945|
NCT01311102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13531-01|The Impact of Pain Scores on Intrauterine Lidocaine Versus Normal Saline Infusion at the Time of IUD Placement|Double Blind, Randomized, Prospective Trial of Impact of Pain Scores on Intrauterine Lidocaine vs Normal Saline Infusion Before IUD Placement.||Women's Health Care Clinic, Torrance, California|No|Completed|July 2008|December 2012|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|June 21, 2010||No||No|October 14, 2013|https://clinicaltrials.gov/show/NCT01311102||107901|This was a small pilot study, so may have missed small differences in pain score. Based on the results obtained, a sample size of 418 subjects would be needed to detect a statistically significant difference in the pain scores.
NCT01311375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-03-85-7538|Omega 3 in Intervention Spinal Cord Injured People|Evaluation of Omega 3 Supplementation on Neurological Recovery , Lipid Profile and Antioxidant Enzymes and Hormones After Chronic Spinal Cord Injury.||Tehran University of Medical Sciences|Yes|Completed|November 2010|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 13, 2012|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01311375||107880|
NCT01312740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB: 2007-A00329-44|Effects of Two Hypocaloric Diets on Weight Loss|Effects of Two Hypocaloric Diets on Weight Loss and Inflammatory Markers||Ceprodi S.A. Kot||Completed|May 2007|July 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|||Actual|13|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||March 2011|March 10, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312740||107777|
NCT01312766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10EU/hMG02|Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients|Safety and Efficacy Study Comparing a New hMG Formulation (hMG-IBSA) to a Reference Product (Menopur®) in Patients Undergoing Ovarian Stimulation for in Vitro Fertilisation (IVF)||IBSA Institut Biochimique SA|No|Completed|February 2011|December 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|270|||Female|18 Years|40 Years|No|||July 2015|July 23, 2015|March 7, 2011||No||No|February 28, 2014|https://clinicaltrials.gov/show/NCT01312766||107776|
NCT01312779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-07|Magna Mitral - 23mm|Clinical Evaluation of the Size 23mm Carpentier-Edwards PERIMOUNT Magna Mitral Bioprosthesis, Model 7000TFX||Edwards Lifesciences|Yes|Recruiting|March 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|13 Years|N/A|No|||January 2016|January 20, 2016|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312779||107775|
NCT01313104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10G02|Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer|Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia||Northwestern University|Yes|Withdrawn||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|0|||Female|18 Years|N/A|No|||June 2012|June 8, 2012|March 9, 2011|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01313104||107753|
NCT01313117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUALA-01|Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy|Dose Finding and Tolerability Study of Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Peripheral Neuropathy||Northwestern University|Yes|Completed|February 2012|January 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||September 2014|September 26, 2014|March 9, 2011|Yes|Yes||No|September 20, 2014|https://clinicaltrials.gov/show/NCT01313117||107752|The small number of enrolled patients precluded any meaningful ALA dose finding or neuropathy prevention efficacy statements. A formal statistical analysis of the data was not able to be performed.
NCT01309529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11.03.01|Day Zero Urinary Catheter Removal in Gen Thoracic Surgery Patients|Day Zero Urinary Catheter Removal in General Thoracic Surgery Patients Receiving Thoracic Epidural Analgesia: Recatheterization Rates and Urinary Tract Infection Occurrences||Memorial Health System|No|Recruiting|March 2011|October 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General thoracic surgery patients with a thoracic epidural that meet the eligibility        criteria admitted to a specific tertiary care facility starting March 1, 2011 and ending        August 1, 2011.|March 2011|March 4, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309529||108021|
NCT01310270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04615|The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation|The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation|OMEGA-PAD|University of California, San Francisco|No|Completed|April 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|50 Years|N/A|No|||November 2013|November 6, 2013|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310270||107964|
NCT01279434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS/DHPT/CT/006|Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial|Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial||Institute of Liver and Biliary Sciences, India|No|Withdrawn|January 2012|June 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||November 2011|May 27, 2015|December 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01279434||110319|
NCT01279447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00026632|Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control|Infrapatellar Nerve Block for Post-operative Analgesia for Knee Arthroscopy||Northwestern University|No|Completed|January 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|April 14, 2014|January 17, 2011|Yes|Yes||No|December 5, 2013|https://clinicaltrials.gov/show/NCT01279447||110318|outpatient nature and self reporting of outcome measures
NCT01273857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHLW10103228|Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology|Phase I Study of Cardiac Progenitor Cell Therapy in Patients With Single Ventricle Physiology|TICAP|Okayama University|Yes|Completed|January 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|N/A|6 Years|No|||May 2015|June 12, 2015|January 10, 2011||No||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01273857||110748|
NCT01313013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prompt1|A Question Prompt Sheet for Depressive Outpatients|||Technische Universität München|No|Completed|July 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2011|March 9, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01313013||107759|
NCT01313351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100310|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2010|||||N/A|N/A|N/A||||||||||||||August 24, 2012|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313351||107734|
NCT01313663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113758|A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population|A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin + Pemetrexed or Cisplatin + Pemetrexed||GlaxoSmithKline|No|Terminated|February 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||October 2013|October 16, 2014|January 27, 2011|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01313663||107710|
NCT01312649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4880|Feeling of Being in Control of One's Own Action|Feeling of Being in Control of One's Own Action: Which Mechanisms in Healthy Volunteers and in Mental Diseases||University Hospital, Strasbourg, France|No|Recruiting|April 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|370|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01312649||107784|
NCT01309412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017737|A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma|A Phase 1 Study of CNTO 328 (Siltuximab) in Combination With Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma||Janssen Pharmaceutical K.K.|Yes|Terminated|January 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|N/A|No|||May 2014|May 16, 2014|March 3, 2011|No|Yes|Protocol was stopped due to the safety issue in Global|No||https://clinicaltrials.gov/show/NCT01309412||108029|
NCT01309659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028687|Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia|A Randomized, Open-Label, Wait-list Control Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia and a Serum Ferritin Between 20 and 200 ng/mL||Duke University|Yes|Terminated|May 2011|September 2014|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|65 Years|N/A|No|||January 2016|January 7, 2016|February 17, 2011|Yes|Yes|Lack of Enrollment|No|July 30, 2014|https://clinicaltrials.gov/show/NCT01309659||108011|Small sample size.
NCT01309672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000696565|S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy|Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II||Southwest Oncology Group|Yes|Active, not recruiting|September 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Male|18 Years|120 Years|No|||December 2015|December 8, 2015|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309672||108010|
NCT01309932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-008|Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin|A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects|D-LITE|Bristol-Myers Squibb|No|Completed|March 2011|September 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|165|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309932||107990|
NCT01310192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2004-040|Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography|Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography||Queen's Medical Centre|No|Completed|June 2004|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Male|18 Years|N/A|No|||October 2015|October 1, 2015|June 24, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01310192||107970|
NCT01311336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 1012|Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain|Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim||University of Vermont|Yes|Recruiting|May 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|55|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311336||107883|
NCT01310686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4990s|Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy|Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy||West Coast Retina Medical Group, Inc.|No|Active, not recruiting|April 2011|June 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with Wet Age-Related Macular Degeneration|February 2012|February 24, 2012|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310686||107932|
NCT01310998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2898-3|Acute Psychological Effects of High Intensity Exercise With Schizophrenia|Acute Psychological Effects of High Intensity Exercise in Patients With Schizophrenia||Norwegian University of Science and Technology|No|Completed|December 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 1, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01310998||107908|
NCT01310257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10052|Measures of Pain Relevant to Knee Osteoarthritis|Evaluation of Questionnaire Measures for Patients With Osteoarthritis of the Knee||University of Nottingham|No|Completed|December 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|448|||Both|18 Years|N/A|No|Non-Probability Sample|We aim to recruit a cross section of participants covering a broad spectrum of people with        OA of the knee. Community participants will be identified from a cohort of patients who        have already agreed to be contacted about future research studies. Additional participants        will be identified from clinics at Nottingham University Hospitals and Sherwood Forest        Hospitals NHS Foundation Trust, GP surgeries in the local area and patients on a knee OA        pathway from Nottingham Healthcare partnership. These sources of recruitment will include        those attended rheumatology and orthopaedic specialist clinics for knee OA and        rheumatology outpatients at the Queens Medical Centre (QMC)|January 2014|January 16, 2014|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01310257||107965|
NCT01281865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02577|Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma|A Phase 1b/2 Study of Imatinib in Combination With Everolimus in Synovial Sarcoma||National Cancer Institute (NCI)||Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2013|October 3, 2014|January 21, 2011|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01281865||110134|
NCT01281878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1251|Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate|PILOTSTUDIE ZUR PYRIDOXALPHOSPHATTHERAPIE BEI PATIENTEN MIT PRIMÄRER HYPEROXALURIE TYP I (PHOX-B6-PILOT) Pilot Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate|PHOX-B6-Pilot|University of Cologne|No|Completed|December 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|5 Years|60 Years|No|||October 2012|October 26, 2012|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281878||110133|
NCT01311947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-313|Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B|Relation of Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B||China Medical University Hospital|Yes|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|103|Samples With DNA|Serum specimens|Both|18 Years|65 Years|No|Non-Probability Sample|HBeAg-positive chronic hepatitis B|July 2013|July 29, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311947||107838|
NCT01282385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-SIM-2010-04|Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension|Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension|SIMBETA|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Not yet recruiting|April 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2011|January 24, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282385||110094|
NCT01313741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anchor Peg Study|This is a 2 Year Follow up Clinical and Radiographic Analysis of a Novel All Polyethelene Glenoid Component in Standard Total Shoulder Arthroplasty.|||Knoxville Orthopedic Clinic||Not yet recruiting|April 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||March 2011|March 10, 2011|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313741||107704|
NCT01313754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWSS-01|Comparison of Skin Incision Closure Material for the Transobturator Suburethral Sling Procedure|||Loma Linda University|Yes|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|N/A|No|||January 2013|January 29, 2013|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313754||107703|
NCT01310283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A106017|Caries Management by Risk Assessment in Children|Caries Management by Risk Assessment in Children||University of California, San Francisco|No|Completed|April 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|120|||Both|5 Years|9 Years|Accepts Healthy Volunteers|||November 2012|November 9, 2012|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01310283||107963|
NCT01279811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01091|The Canadian Multicentre CSF Monitoring and Biomarker Study|The Canadian Multicentre CSF Monitoring and Biomarker Study|CAMPER|University of British Columbia|Yes|Recruiting|January 2011|March 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|17 Years|N/A|No|||January 2016|January 27, 2016|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279811||110290|
NCT01280097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02079|Study of Sleep and Delirium in the Intensive Care Unit (ICU)|Sleep Disruption and ICU Delirium: Delirium Assessment and Monitoring Combined With the Evaluation of Sleep Using the Sedline Brain Function Monitor.|SID|University of California, San Francisco|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|Samples With DNA|Blood will be collected as part of the study. It will be used to measure circadian markers      that will include core body temperature, cortisol and melatonin rhythms. If subjects agree,      some will be stored in a bank for future research.|Both|45 Years|N/A|No|Non-Probability Sample|The study population will include elderly patients admitted to the intensive care unit at        UCSF.|July 2015|July 13, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01280097||110268|
NCT01274130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0417|Investigatory Study of Metformin's Pharmacokinetics, Pharmacodynamics and Drug Drug Interactions Classifying the Group by MATE1 Genotype in Healthy Volunteers|Investigatory Study of Metformin's Pharmacokinetics, Pharmacodynamics and Drug Drug Interactions Classifying the Group by MATE1 Genotype in Healthy Volunteers||Yonsei University|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274130||110727|
NCT01274429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2314|Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults|Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|December 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|January 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01274429||110704|
NCT01313676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113782|Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease|A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease||GlaxoSmithKline|Yes|Completed|January 2011|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16599|||Both|40 Years|80 Years|No|||February 2016|March 3, 2016|February 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313676||107709|
NCT01309958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018592|DPBRN Development of a Patient Based Provider Intervention for Early Caries Management|Development of a Patient Based Provider Intervention for Early Caries||Dental Practice-Based Research Network|No|Completed|June 2008|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|334|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ghg@uab.edu|August 2015|August 5, 2015|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309958||107988|
NCT01313975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203/10|Electrolyte and Fluid Disturbances in Subarachnoid Hemorrhage and Traumatic Brain Injury|Disturbances of the Sodium and Fluid Balance in Patients With Severe Traumatic Brain Injury and Non-traumatic Subarachnoid Hemorrhage. A Systematic Observational Study||University Hospital Inselspital, Berne|No|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|85|Samples With DNA|serum and urine samples|Both|18 Years|N/A|No|Probability Sample|Intenisve Care Medicine patients with non-traumatic subarachnoid hemorrhage or severe        traumatic brain injury|April 2013|April 16, 2013|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01313975||107686|
NCT01309698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A1103|Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes|An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes||Novartis||Completed|February 2011|||April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|24|||Both|20 Years|64 Years|No|||October 2011|October 10, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309698||108008|
NCT01309685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911465|Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment|Effect of Varenicline on a Laboratory Model of Tobacco Addiction and on Withdrawal-Induced Cognitive Impairment||National Institutes of Health Clinical Center (CC)||Withdrawn|February 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind|1||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|February 19, 2014|March 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01309685||108009|
NCT01310205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-SCV-HCV-P2-001-Extension|Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV|An Extension of Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Pegylated Interferon and Ribavirin After Completing Treatment in a Phase 2 Study and Have Relapsed After at Least 44 Weeks Tx With Peg-IFN and RBV.||SciClone Pharmaceuticals|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|N/A||2|Actual|12|||Both|18 Years|N/A|No|Non-Probability Sample|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to        participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001        and are eligible for retreatment with peg-IFN and RBV|March 2011|March 7, 2012|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310205||107969|
NCT01310725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mdr001|Evaluation of Graft Material in Coronary Artery Bypass Grafting (CABG)|Mid-term Patency of Radial Artery and No Touch Saphenous Vein as Grafts in CABG; A Randomised Controlled Trial.||University Hospital Orebro|No|Completed|January 2004|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|108|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||September 2010|March 7, 2011|March 7, 2011||||No||https://clinicaltrials.gov/show/NCT01310725||107929|
NCT01311024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL/1843/6.02.01/2010|Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage|Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study|FinIPcarr|National Institute for Health and Welfare, Finland|No|Active, not recruiting|April 2011|December 2018|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|2341|Samples Without DNA|Nasopharyngeal and oropharyngeal swabs obtained.|Both|3 Years|7 Years|Accepts Healthy Volunteers|Non-Probability Sample|Non-PCV-vaccinated 3 to 7 year-old siblings living in the same household with a younger        child vaccinated in the cluster-randomized Finnish Invasive pneumococcal Disease Trial        (ClinicalTrials.gov Identifier:NCT00861380)|August 2015|August 10, 2015|March 7, 2011||No||No|April 2, 2014|https://clinicaltrials.gov/show/NCT01311024||107906|
NCT01311037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2081-064|The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer|The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer A Prospective Trial||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|January 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2|||Female|45 Years|85 Years|No|Non-Probability Sample|Receptor Positive Premenopausal Women with Advanced Breast Cancer.|December 2011|December 11, 2011|March 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311037||107905|
NCT01313052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH078003-03|Forensic Assertive Community Treatment: An Emerging Model of Service Delivery|Forensic Assertive Community Treatment: An Emerging Model of Service Delivery|FACT|University of Rochester|Yes|Completed|May 2008|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01313052||107756|
NCT01313065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX15/2503-01 v.9|Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors|A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors||Vaccinex Inc.|No|Completed|January 2011|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|March 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01313065||107755|
NCT01281618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004899|Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus|Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus|CR20|Mayo Clinic|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|48|Samples With DNA|Tissue specimens from Barrett's esophagus|Both|18 Years|90 Years|No|Non-Probability Sample|Those diagnosed with barrett's esophagus confirmed by pathology with no dysplasia or low        grade dysplasia|May 2013|May 3, 2013|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281618||110153|
NCT01282164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-810|The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis|The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis|GST|The Cleveland Clinic|No|Active, not recruiting|January 2011|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01282164||110111|
NCT01282151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_L_05478|TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer|A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer|TRAIL|Chonnam National University Hospital|Yes|Terminated|July 2011|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|January 21, 2011||No|Difficulty in recruitment due to approval of maintenance pemetrexed treatment|No||https://clinicaltrials.gov/show/NCT01282151||110112|
NCT01282918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORDIC -1.1|NORDIC ICD (Cardioverter Defibrillator Implantation) Trial|NO Regular Defibrillation Testing In Cardioverter Defibrillator Implantation (NORDIC ICD) Trial||Biotronik SE & Co. KG|Yes|Completed|February 2011|May 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1077|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01282918||110053|
NCT01282606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6603/1121|Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation|An Open Label, Non-randomized Dose-escalation Study to Assess Safety and Tolerability of SI-6603 in Patients With Lumbar Disc Herniation (Phase II Study)||Seikagaku Corporation|Yes|Completed|December 2007|||August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|30 Years|70 Years|No|||September 2013|September 5, 2013|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282606||110077|
NCT01282905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML3999|Hydrogen Sulfide Detoxification and Butyrate Metabolism in Ulcerative Colitis|Impact of the Mucosal Detoxification Mechanism of Hydrogen Sulphide on the Oxidation Pathway of Butyrate in Ulcerative Colitis||Katholieke Universiteit Leuven|No|Completed|October 2008|December 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|106|Samples With DNA|colon tissue|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|IBD patients clinic (Universitaire Ziekenhuizen Leuven)|January 2011|January 25, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282905||110054|
NCT01278914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC Prostate|Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer|Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer||Oslo University Hospital|No|Completed||||||Phase 1/Phase 2|Interventional|N/A|||||||Male|45 Years|N/A|No|||July 2011|July 21, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01278914||110359|
NCT01279148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 MCT V7|Electromagnetic Tracking of Devices During Interventional Procedures|Electromagnetic Tracking of Devices During Interventional Procedures||Philips Healthcare|No|Not yet recruiting|April 2014|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|Liver Biopsy analyzed as per standard of care|Both|18 Years|N/A|No|Probability Sample|Hospitals and Out-patient Clinics|November 2013|November 28, 2013|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279148||110341|
NCT01280747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081247|Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study|Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study||Pfizer|No|Terminated|January 2011|April 2012|Actual|April 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|42|||Both|18 Years|N/A|No|Probability Sample|There are six practice types that are expected to be able to provide patients to this        study. Of these, four (internal medicine, family/general practitioners, neurologists, and        anesthesia/pain physicians) will be expected to enroll patients into both pDPN and FM        disease groups. The fifth group, rheumatology physicians, will be expected to enroll        patients into the FM cohort only and the sixth group, endocrinologists, will be expected        to enroll patients into the pDPN cohort only.|June 2012|June 6, 2012|January 19, 2011||No|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01280747||110218|
NCT01280981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP12B-MR-304|A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding|A Multi-center, Open Label Extension Study to Evaluate the Safety of an Oral Dose of Tranexamic Acid (XP12B) Administered Three Times Daily During Menstruation for the Treatment of Menorrhagia||Ferring Pharmaceuticals|Yes|Completed|April 2007|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|288|||Female|18 Years|49 Years|No|||June 2011|June 28, 2011|January 19, 2011|Yes|Yes||No|May 3, 2011|https://clinicaltrials.gov/show/NCT01280981||110200|
NCT01274442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/771|Impact of Genetic Polymorphisms on Dental Implant Loss|A Case-control Study on the Impact of Genetic Polymorphisms on Dental Implant Loss.|Polymorphism|University Hospital, Ghent|No|Recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|68|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01274442||110703|
NCT01309971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122012|DPBRN Longitudinal Study of Questionable Occlusal Caries Lesions|Longitudinal Study of Questionable Occlusal Caries Lesions||Dental Practice-Based Research Network|No|Completed|August 2008|December 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2624|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The participants directly involved in this study were the patients who have sought dental        treatment in the DPBRN practitioner-investigators' practices.|February 2014|February 14, 2014|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309971||107987|
NCT01313650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113373|A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease|DB2113373|GlaxoSmithKline|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1538|||Both|40 Years|N/A|No|||October 2012|January 16, 2014|March 10, 2011|No|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT01313650||107711|
NCT01310491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renewing Health WP WP 13 Fin|RENEWING HEALTH - RegioNs of Europe WorkINg Together for HEALTH|RENEWING HEALTH Large-scale Real-life Study in Finland||South Karelia, Social and Health Care District|No|Completed|February 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|595|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310491||107947|
NCT01309945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN162-006|Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression|A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients With Treatment Resistant Major Depression||Bristol-Myers Squibb|Yes|Completed|April 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|889|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|February 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309945||107989|
NCT01311076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-329_102|TAK-329 Glucose Clamp Study|A Phase 1, Randomized, Placebo- and Active-Controlled, 4-Period Crossover, Proof of Concept Glucose Clamp Study to Compare the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single Doses of TAK-329 With a Single Dose of a Subcutaneously-Injected Rapid-Acting Insulin Analog in Subjects With Type 1 Diabetes Mellitus.||Takeda|No|Completed|March 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|37|||Both|18 Years|50 Years|No|||February 2012|February 9, 2012|March 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01311076||107903|
NCT01311635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9830C00020|A Bioavailability Study Comparing 3 Different AZD1981 Tablets|A Phase I, Open Label, Randomised, 4-way Crossover Study to Investigate the Relative Bioavailability of Single Dose AZD1981 Via 3 Different Tablets in Healthy Men and Healthy Women of Non-childbearing Potential||AstraZeneca||Completed|April 2011|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 6, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01311635||107861|
NCT01311648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13400|BAY81-8973 Pediatric Safety and Efficacy Trial|A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy||Bayer|Yes|Recruiting|June 2011|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Male|N/A|12 Years|No|||March 2016|March 4, 2016|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01311648||107860|
NCT01311609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-005|A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients|Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients||Alcon Research|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311609||107863|
NCT01311622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00013|Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects|An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Co-Administered With Fostamatinib in Healthy Subjects||AstraZeneca||Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|February 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311622||107862|
NCT01313728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-7966|A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products|An Investigator-Blind, Phase 4 Study Assessing Mitigation of Facial Irritation When Comparing the Use of Two Acne Treatment Products (Retin-A Micro® 0.1 % Pump and Aczone®) With One Treatment Product (Retin-A Micro® 0.1 % Pump) Using a Split-Face Model||Valeant Pharmaceuticals International, Inc.|No|Completed|December 2010|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|March 10, 2011|Yes|Yes||No|October 14, 2011|https://clinicaltrials.gov/show/NCT01313728||107705|
NCT01281891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA001|Postoperative Pain Relief Following Total Hip Arthroplasty. A Comparison Between Intrathecal Morphine (IM) and Local Infiltration Analgesia (LIA)|Postoperative Pain Relief Following Total Hip Arthroplasty. A Comparison Between Intrathecal Morphine (IM) and Local Infiltration Analgesia (LIA)|HÖFTPLASTIK|University Hospital Orebro|Yes|Recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|85 Years|No|||September 2012|September 11, 2012|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281891||110132|
NCT01282619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LY200901-04|Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease|A Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Study to Evaluate the Safety and Efficacy of Huperzine A Sustained-Release Tablets in Patients With Mild to Moderate Alzheimer's Disease||Shandong Luye Pharmaceutical Co., Ltd.|Yes|Recruiting|May 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|390|||Both|50 Years|85 Years|No|||January 2011|January 24, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282619||110076|
NCT01282931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOS-10-002|Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer|Development and Implementation of a Patient-reported Outcome Questionnaire to Assess the Value of Progression-free Survival for Women With Metastatic Breast Cancer.||Health Outcomes Solutions|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Female 18 and older U.S. resident Clinical diagnosis of metastatic breast cancer|October 2011|October 9, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282931||110052|
NCT01278940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC malignant melanoma|Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma|Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma||Oslo University Hospital|No|Completed|March 2002|August 2004|Actual|August 2004|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2013|June 26, 2013|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01278940||110357|
NCT01278927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0902|Exercise and Stress Management Post Autologous and Allogeneic Transplant (BMT CTN 0902)|A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients (BMT CTN #0902)||Medical College of Wisconsin|Yes|Completed|January 2011|November 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|711|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 17, 2011||No||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01278927||110358|
NCT01279161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTO DIAB|The Role of FTO Gene Polymorphism and Insulin Preparation in Obesity in Children With Type 1 Diabetes Mellitus|The Role of FTO Gene Polymorphism and Insulin Preparation in Overweight/Obesity in Children With Type 1 Diabetes Mellitus|FTO_T1DM|University of Bialystok|Yes|Completed|December 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|2000|Samples With DNA|Small amount of peripheral blood for isolation of DNA for assessment of FTO polymorphism.|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be        patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of        Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from all        over Poland (Białystok, Warszawa, Gdańsk, Katowice, Wrocław). Reference group will be made        of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes        was excluded. In these children diagnostics procedures will be conducted for reasons other        than body weigh related diseases (excluding simple obesity). The children will not receive        any treatment that might influence their body weight.|December 2014|December 1, 2014|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279161||110340|
NCT01279460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Munich-CKD-PWA|Aortic Stiffness in Chronic Kidney Disease Stage 2 to 4|Evaluation of Aortic Stiffness in CKD II to IV||Technische Universität München|No|Completed|October 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|167|||Both|18 Years|N/A|No|Non-Probability Sample|Patients were enrolled in a prospective study of vascular stiffness and CV risk in        patients with CKD stages 2 to 4. They were predominantly recruited from outpatients        attending nephrology clinics at the Klinikum rechts der Isar der Technischen Universität        München and at a private nephrological clinic in Weissenburg October 2007 to December        2008.|January 2011|January 17, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279460||110317|
NCT01280994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025110|Hyperpolarized 129Xe MRI for Imaging Pulmonary Function|Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease||Duke University|No|Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|January 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01280994||110199|
NCT01265758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDAPOIG.01.03.01-00-068/09-00A|Telemetric Arrhythmia Diagnosis in Adults|OPTIMIZING DIAGNOSTICS AND THERAPY OF ARRHYTHMIA AND SYNCOPE EVENTS USING INTELLIGENT TELEMETRIC SOLUTIONS - Evaluation of Arrhythmia Diagnostics in Adults|TELEMARC1|Institute of Cardiology, Warsaw, Poland|No|Recruiting|February 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|360|||Both|18 Years|80 Years|No|||February 2013|February 18, 2013|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01265758||111371|
NCT01309711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARBLE|Magnetic Resonance Biomarkers in Neonatal Encephalopathy|A Multicentre Prospective Study on Magnetic Resonance Biomarkers in Neonatal Encephalopathy|MARBLE|Thayyil, Sudhin|No|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|Blood and urine|Both|N/A|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy control infants, Infants with Neonatal encephalopathy, Healthy adult volunteers|November 2015|November 2, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309711||108007|
NCT01309425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017782|A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers|A Single-Dose, Open-Label, Randomized, Four-Way Crossover Study to Assess the Dose-Proportionality of the Pharmacokinetics of Tapentadol, Given as Tamper-Resistant Tablets, in Healthy Japanese and Korean Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|February 2011|May 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|52|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2012|January 30, 2014|March 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01309425||108028|
NCT01312532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-17|Comparing Fixed-bearing Versus Mobile-bearing Prosthesis in Total Knee Arthroplasty: A Prospective Randomized Trial|Study of Prosthesis in Total Knee Arthroplasty||Isfahan University of Medical Sciences|Yes|Completed|June 2004|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2004|March 9, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312532||107793|
NCT01312792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10025|Operational Research Management for Children With Severe Pneumonia|Operational Research on Management at First Level Facilities for Children With Severe Pneumonia|OR-pneumonia|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|August 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|300|||Both|2 Months|5 Years|No|||March 2011|July 9, 2014|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312792||107774|
NCT01310296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1003/ 02749MZ|Lofexidine ADME & Mass Balance in Volunteers|A Single-Center, Open-Label, Two-Period, Two-Treatment, Randomized Sequence Study to Determine the Mass Balance and Absolute Bioavailability of a Single Oral Dose of 14C-Labeled Lofexidine Compared to a Single Intravenous Dose of Lofexidine||US WorldMeds LLC|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2011|August 29, 2011|March 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01310296||107962|
NCT01310712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Sao Paulo|Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study|Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study.||University of Sao Paulo|No|Completed|December 2010|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2011|September 21, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310712||107930|
NCT01311050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2081-068|A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer|A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|January 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|46|||Both|14 Years|85 Years|No|Non-Probability Sample|Metastatic Colorectal Cancer|December 2011|December 11, 2011|March 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311050||107904|
NCT01310062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-317-3991|The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer|Strategic Alliance for The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer||Ministry of Health, Malaysia|No|Recruiting|August 2010|August 2012|Anticipated|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1600|Samples With DNA|Red blood cell and white blood cell|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Selected hospitals for study|March 2011|March 4, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01310062||107980|
NCT01310075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0324|Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction|Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction: A Blinded, Prospective, Randomized, Controlled Trial||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2011|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|398|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01310075||107979|
NCT01312194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08176567-9|Periapical Healing After One or Two-visits to Endodontic Treatment in Adolescents Patients|Periapical Healing After One or Two-visits to Endodontic Treatment in Adolescents Patients|PHAP|Universidade Federal do Rio de Janeiro|Yes|Completed|May 2004|August 2008|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312194||107819|
NCT01312480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-1R01CA140576-01A2|Adolescent Smoking Cessation in Pediatric Primary Care|Adolescent Smoking Cessation in Pediatric Primary Care|Smokebusters|American Academy of Pediatrics|Yes|Active, not recruiting|May 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|8160|||Both|14 Years|25 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312480||107797|
NCT01311934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-001|Visceral Stiffness Measurement Using Acoustic Radiation Force Impulse|Clinical Application of the Spectrum of Visceral Stiffness Measurement Using Acoustic Radiation Force Impulse Technology|ARFI|China Medical University Hospital|No|Recruiting|March 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with chronic liver diseases|May 2011|May 24, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311934||107839|
NCT01281384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project I-B|Routine vs Selective Cardiac Magnetic Resonance in Non-Ischemic Heart Failure|Routine vs Selective Cardiac Magnetic Resonance in Non-Ischemic Heart Failure (OUTSMART-HF) Project I-B of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)|OUTSMART|Ottawa Heart Institute Research Corporation|Yes|Recruiting|January 2011|September 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|504|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281384||110170|
NCT01282944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812090|Encouraging Walking in Older Adults|Encouraging Walking in Older Adults||University of Pennsylvania|No|Completed|March 2011|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|92|||Both|65 Years|N/A|No|||February 2014|March 4, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282944||110051|
NCT01282398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-SIM-2010-06|Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis|Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial|SIMPRO|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Not yet recruiting|April 2011|April 2015|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|80 Years|No|||January 2011|January 24, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282398||110093|
NCT01282411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.006|Anatomic Outcomes Following Ozurdex Injections|Anatomic Outcomes Following Ozurdex Injection||Barnes Retina Institute|Yes|Recruiting|February 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|N/A|No|Non-Probability Sample|Branch retinal vein occlusion (BRVO) Central retinal Vein occlusion (CRVO)|January 2011|January 21, 2011|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282411||110092|
NCT01282632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ro123|Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression|A Double Blind Pilot Trial to Evaluate Efficacy Trends and Safety of Risperidone and Olanzapine as add-on Therapy to Serotonin Type Antidepressants in Subjects With Treatment Resistant Depression (TRD)||Sunnybrook Health Sciences Centre|Yes|Completed|August 2002|March 2004|Actual|March 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||September 2010|January 24, 2011|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282632||110075|
NCT01282645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-CMF-C-16-204-01|Case Series to Evaluate Patient Specific Implants (PSI) in Polyether Ether Ketone (PEEK) Performance After 2 Years|A Retrospective Case Series to Evaluate the Long Term Outcome of the Use of Synthes Patient Specific Implants (PSI®) Made of Polyether Ether Ketone (PEEK) for the Treatment of Cranial Defects in Patients With a Mature Skeleton||Synthes GmbH|No|Withdrawn|July 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|In 30 clinics worldwide, all patients who received a PSI in PEEK at least 2 years ago, who        fullfil the in-and exclusion criteria, will be asked to participate|March 2013|March 21, 2013|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282645||110074|
NCT01279499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sevoflurane-propofol-obesity|Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients|Propofol Versus Sevoflurane as Sole Anesthetic Agent in Gastric By-Pass Surgery for Morbid Obesity: A Prospective Randomized Clinical Trial||University of Patras||Recruiting|April 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|50 Years|No|||March 2010|January 19, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01279499||110314|
NCT01279174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ortho-Koeln-1-2011|Galileo-Hip Whole Body Vibration /Conventional Physiotherapy /Coxarthrosis|Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Coxarthrosis: a Randomized, Controlled Study||University of Cologne|No|Completed|June 2012|October 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|80 Years|No|||December 2015|December 8, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279174||110339|
NCT01279473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A1101E1|Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)|A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ALL (Philadelphia Positive Acute Lymphocytic Leukemia)(Extension Study)||Novartis||Completed|August 2005|||December 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|N/A|No|||August 2011|August 22, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01279473||110316|
NCT01279486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0187|Clearblue Home Pregnancy Test Consumer Study|Clearblue Home Pregnancy Test Consumer Study||SPD Development Company Limited|No|Completed|December 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Urine samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers requesting a pregnancy test|September 2011|September 27, 2011|December 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01279486||110315|
NCT01281007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F125EMS1010|Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes|A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes||EMS|Yes|Completed|July 2012|March 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|January 20, 2011||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01281007||110198|
NCT01265771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDAPOIG.01.03.01-00-068/09-00B|Optimizing Diagnostics Of Arrhythmia Events In Children Using Intelligent Telemetric Solutions|Optimizing Diagnostics And Therapy Of Arrhythmia And Syncope Events Using Intelligent Telemetric Solutions. Diagnostics Of Arrhythmia In Children|TELEMARC2|Institute of Cardiology, Warsaw, Poland|No|Recruiting|February 2011|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|400|||Both|N/A|18 Years|No|||December 2011|December 2, 2011|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265771||111370|
NCT01265784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-434-P2-cIAI-1|Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections|A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety, and PK of 2 Dose Regimens of TP-434 Compared With Ertapenem in Adult Community-Acquired Complicated Intra-abdominal Infections||Tetraphase Pharmaceuticals, Inc.|Yes|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|143|||Both|18 Years|75 Years|No|||August 2015|August 4, 2015|December 21, 2010|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01265784||111369|
NCT01309724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1074|Hemodynamic Optimization By Non-Invasive Determination Of Cardiac Output In Critically Ill Patients|HEMODYNAMIC OPTIMIZATION BY NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT IN CRITICALLY ILL PATIENTS: A RANDOMIZED, CONTROLLED TRIAL||Washington University School of Medicine|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01309724||108006|
NCT01310218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHC 09-158-1|Length of Post Operative Dressing After Carpal Tunnel Release|Length of Postoperative Dressing After Mini-open Carpal Tunnel Release: A Randomized Prospective Comparison||University of Connecticut Health Center|No|Completed|May 2009|November 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||March 2011|March 4, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01310218||107968|
NCT01310231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-027|A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer|A Randomized Phase II, Double Blind Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Receiving First, Second, Third or Fourth Line Chemotherapy With Anthracycline, Taxane, Platinum, Capecitabine or Vinorelbine Based Regimens||Ozmosis Research Inc.|Yes|Recruiting|March 2011|September 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Female|18 Years|75 Years|No|||November 2015|November 9, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01310231||107967|
NCT01311388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99049|Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center|Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center||Taipei Medical University WanFang Hospital|No|Active, not recruiting|August 2010|December 2013|Anticipated|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1500|||Both|20 Years|N/A|No|Probability Sample|cancer patients|March 2011|March 8, 2011|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01311388||107879|
NCT01310309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-380 Registry|EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease|EXecutive Registry: XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.|EXecutive|Abbott Vascular|No|Completed|September 2007|June 2011|Actual|October 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Multi-Vessel Coronary Artery Disease (MVD) treated with the XIENCE V®        Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).|December 2012|December 20, 2012|March 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01310309||107961|
NCT01310504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME 10 0050|The Use of the FAST (Focused Abdominal Scan for Trauma) Scan by Paramedics in Mass Casualty Incidents|The Use of the FAST Scan by Paramedics in Mass Casualty Incidents||Genesys Regional Medical Center|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310504||107946|
NCT01311349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074A1-102056|Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics|Evaluation of the Antimicrobial Activity In Vitro of Tigecycline in Comparison to Other Broad Spectrum Antibiotics in Isolates Collected From Patients||Wyeth is now a wholly owned subsidiary of Pfizer|No|Completed|December 2005|September 2006|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|1575|||Both|N/A|N/A|No|Probability Sample|Hospitalized patients and outpatients|August 2009|March 7, 2011|August 10, 2009||No||No||https://clinicaltrials.gov/show/NCT01311349||107882|
NCT01280669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00046190|Intravitreal Sirolimus as Therapeutic Approach to Uveitis|Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis|SAVE-2|Johns Hopkins University|No|Not yet recruiting|March 2011|March 2013|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|N/A|No|||January 2011|January 20, 2011|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01280669||110224|
NCT01280916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33795-C|Mindful Awareness in Body-Oriented Therapy for Women's Substance Abuse Treatment|Mindful Awareness in Body-Oriented Therapy for Women's Substance Abuse Treatment||University of Washington|No|Completed|October 2008|March 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Female|18 Years|N/A|No|||September 2012|September 12, 2012|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01280916||110205|
NCT01312493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1017|Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab|Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab||UNC Lineberger Comprehensive Cancer Center|Yes|Withdrawn|December 2011|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|March 8, 2011|Yes|Yes|Funding source was terminated before enrollment of first subject|No||https://clinicaltrials.gov/show/NCT01312493||107796|
NCT01281150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02490|Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|January 2011|||April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281150||110188|
NCT01281163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02574|Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer|A Phase 1b Dose-Escalation Study of the AKT Inhibitor MK-2206 (NSC# 749607) Plus Lapatinib (NSC# 727989) Administered in Patients With HER2 Positive Metastatic Breast Cancer||National Cancer Institute (NCI)||Terminated|January 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||April 2015|August 26, 2015|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281163||110187|
NCT01284023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS-02|Use of Near Infrared Spectroscopy to Detect Muscle Perfusion in the Lower Extremity of Uninjured Subjects|Use of Near Infrared Spectroscopy to Detect Muscle Perfusion in the Lower Extremity of Uninjured Subjects||J&M Shuler|No|Active, not recruiting|January 2011|December 2016|Anticipated|August 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Uninjured volunteers will be recruited from a pool of uninjured individuals at the        principle investigator's practice. Participation will be completely volutnary|September 2015|September 4, 2015|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284023||109968|
NCT01284036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2331001|A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects|Ascending Single Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of PF-05230905 Administered Subcutaneously Or Intravenously To Healthy Subjects|FIH|Ablynx|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|63|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|September 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01284036||109967|
NCT01292746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_FA001|Study of the Effect of Low Level Laser Light on Hair Growth on the Female Human Scalp|An Evaluation of the Effect of the Erchonia ML Scanner (MLS) on the Treatment of Androgenic Alopecia in Females||Erchonia Corporation|No|Terminated|February 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|60 Years|No|||November 2015|November 7, 2015|February 8, 2011|Yes|Yes|Recruitment and subject study compliance was difficult|No|July 9, 2015|https://clinicaltrials.gov/show/NCT01292746||109301|
NCT01293045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROU_COLHYD09|Biological Bone Markers and Hydrolyzed Collagen Supplement in Menopausal Healthy Women|Study of Change in Biological Markers of Bone Metabolism Following Consumption of Hydrolyzed Collagen for 3 Months in Healthy, Non-osteoporotic, Menopausal Women.||Nealth Sarl|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|44|||Female|55 Years|65 Years|Accepts Healthy Volunteers|||February 2011|April 8, 2014|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01293045||109278|
NCT01293929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A102065-1011-1070100|Association of Circulating Chemerin Levels and Arterial Stiffness|||Korea University|Yes|Recruiting|February 2011|March 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese and age, gender matched non-obese group who underwent a medical health check in the        Korea University Guro hospital|January 2011|March 3, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293929||109210|
NCT01294215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14024|High Dose BAYA1040_Nifedipine: a Long Term Combination Study|A Multicenter, Open Label, Long Term Study of Oral BAYA1040_CR 80 mg (40 mg Bid) in Combination With Other Antihypertensives for 52 Weeks in Patients With Essential Hypertension||Bayer|No|Completed|February 2011|June 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|20 Years|N/A|No|||June 2014|June 20, 2014|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294215||109188|
NCT01294228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0409|Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU|Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU|REAL-ICU|Biosite|No|Completed|March 2011|December 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1001|Samples Without DNA|Plasma Urine|Both|21 Years|N/A|No|Non-Probability Sample|All comers ordered to be admitted to the ICU.|January 2015|January 28, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294228||109187|
NCT01294501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0786|Decreasing Medication Errors by Caregivers Using a Health Literacy Intervention|Decreasing Medication Errors by Caregivers Using a Health Literacy Intervention||Columbia University|No|Terminated|February 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|132|||Both|2 Months|8 Years|No|||April 2015|April 23, 2015|February 4, 2011||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT01294501||109166|
NCT01294852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ankara University-01|Comparison of Two Strategies for Surfactant Prophylaxis in Premature Infants|A Randomized Trial: Comparison of Two Strategies for Surfactant Prophylaxis in Premature Infants||Ankara University|No|Recruiting|January 2010|June 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|N/A|2 Years|No|||December 2009|June 21, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01294852||109139|
NCT01294865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ankara University-02|Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis|The Plasma Levels of suPAR in Late-onset Neonatal Sepsis|suPAR|Ankara University|No|Active, not recruiting|January 2010|June 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Serum|Both|N/A|1 Month|Accepts Healthy Volunteers|Non-Probability Sample|Infants in Ankara University neonatal intensive care unit|December 2009|February 11, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01294865||109138|
NCT01295125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-10-23|Comparative Study of Biologic Mesh Versus Repair With Component Separation.|Randomized Control Trial of Biologic Mesh (XenMATRIXTM) vs. Component Separation Alone in Contaminated Ventral Hernia Repair:a Pilot Study|Davol|University Hospital Case Medical Center|Yes|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 25, 2012|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01295125||109118|
NCT01295086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Her-TEX|Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer|Dose Determination of Taxotere®, Eloxatin® and Xeloda® (TEX)in Combination With Herceptin® as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV)||Odense University Hospital|No|Recruiting|March 2011|January 2018|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|85 Years|No|||January 2015|January 20, 2015|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295086||109121|
NCT01295099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS001|Keloid Scarring: Treatment and Pathophysiology|Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease||Queen Mary University of London|Yes|Active, not recruiting|February 2011|January 2015|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|85 Years|No|||February 2011|February 11, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295099||109120|
NCT01295372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13639A|Safety and Efficacy of Zicronapine in Patients With Schizophrenia|A 6-month, Randomised, Double-blind, Parallel-group, Risperidone-controlled, Fixed-dose Study Evaluating the Safety and Efficacy of Zicronapine in Patients With Schizophrenia||H. Lundbeck A/S|No|Completed|April 2011|||October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|65 Years|No|||October 2012|October 30, 2012|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01295372||109099|
NCT01294384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10078X-001|Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease|||Allergan|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|305|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|February 10, 2011|Yes|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01294384||109175|
NCT01294696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-140|Survey of Osteoarthritis Real World Therapies (MK-0663-140)|Survey of Osteoarthritis Real World Therapies (SORT)|SORT|Merck Sharp & Dohme Corp.|No|Completed|October 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1261|||Both|50 Years|N/A|No|Non-Probability Sample|Participants who are presently receiving prescribed oral or topical analgesics which        commenced at least two weeks prior to enrollment|September 2015|September 2, 2015|December 22, 2010|No|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01294696||109151|
NCT01294670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-096|Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors|A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|4 Years|21 Years|No|||March 2016|March 1, 2016|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294670||109153|
NCT01294683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524B-118|A Study to Evaluate Efficacy and Safety of Extended-Release Niacin (+) Laropiprant (+) Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)|A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia||Merck Sharp & Dohme Corp.|No|Terminated|February 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|977|||Both|18 Years|85 Years|No|||October 2014|October 27, 2014|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294683||109152|
NCT01286350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-2856 (UNC IRB)|FL3X Study: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes (FL3X)|FL3X: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes|FL3X|University of North Carolina, Chapel Hill|Yes|Recruiting|May 2014|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|13 Years|16 Years|No|||December 2015|December 1, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01286350||109790|
NCT01286610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFO192/2-P3-Vibro-01|Applicability and Safety of Vibration Therapy in Intensive Care Unit (ICU) Patients|Application of Vibration Therapy as a Measure of Muscle Activation in ICU Patients and Its Effect on Hemodynamics, Intracranial Pressure as Well as Energy Metabolism|VTICU|Charite University, Berlin, Germany|Yes|Completed|February 2011|May 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01286610||109770|
NCT01295840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 10-046-SP-HF|Quartet Lead and Resynchronization Therapy Options|QUARTET LEAD AND RESYNCHRONIZATION THERAPY OPTIONS To Investigate the Stimulatory Possibilities Offered by the Different Configurations Available for the Quartet Lead and Their Effect on Haemodynamic and Clinical Response.|QUARTO|St. Jude Medical|No|Completed|January 2011|September 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|51|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|February 3, 2011||No||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01295840||109063|
NCT01291797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSSM 10-0568|Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease|Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease||Icahn School of Medicine at Mount Sinai|No|Terminated|July 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4|||Both|N/A|2 Months|No|Probability Sample|Anticipated, 65 newborns with congenital heart disease and 20 newborns without congenital        heart disease|August 2011|August 17, 2011|February 3, 2011||No|due to inability to recruit sufficient sample size in reasonable time frame.|No||https://clinicaltrials.gov/show/NCT01291797||109374|
NCT01292057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH P50 AA010761|Aripiprazole Effects on Alcohol Drinking and Craving|Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication||Medical University of South Carolina|Yes|Completed|February 2011|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|21 Years|40 Years|No|||March 2016|March 17, 2016|February 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01292057||109354|
NCT01292291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-PR11|MRI in Diagnosing Prostate Cancer|PROMIS - Prostate MRI Imaging Study - Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterization of Prostate Cancer||National Cancer Institute (NCI)||Not yet recruiting|April 2011|||April 2013|Anticipated|N/A|Interventional|Primary Purpose: Diagnostic|1||Anticipated|714|||Male|N/A|N/A|No|||September 2011|August 6, 2013|February 8, 2011||||No||https://clinicaltrials.gov/show/NCT01292291||109336|
NCT01293682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25741|Effects of High Dose Calcitriol in Breast Cancer Patients|A Pilot Study of the Effects of High-Dose Oral Calcitriol in Breast Cancer Patients Prior to Surgery||University of Rochester|Yes|Completed|November 2010|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Female|18 Years|88 Years|No|||June 2015|June 3, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293682||109229|
NCT01293916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4109553136|Spica Casting in Pediatric Femur Fractures: Study of Single Leg Versus Double Leg Spica Casts|Spica Casting in Pediatric Femur Fractures: A Prospective Randomized Controlled Study of Single Leg vs Double Leg Spica Casts||Johns Hopkins University|Yes|Completed|June 2006|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||April 2013|April 3, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293916||109211|
NCT01294202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT13387/0002|A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST|An Open-Label, Randomised, Multi-Centre, Phase II Study to Investigate the Safety and Efficacy of AT13387, Either as Monotherapy or in Combination With Imatinib, in Patients With Unresectable and/or Metastatic Malignant GIST Whose Tumour Has Progressed Following Treatment With a Maximum of Three Tyrosine Kinase Inhibitors||Astex Pharmaceuticals|No|Completed|March 2011|July 2014|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294202||109189|
NCT01294241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEB-10|Case Series Documentation of Patients With Epidermolysis Bullosa|Open, Prospective, Controlled Case Series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare® Versus Non-adhesive Wound Dressing Alone in Accelerating the Epithelialization of Skin Lesions of Patients With Epidermolysis Bullosa Hereditaria||Birken AG|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|1 Year|95 Years|No|||July 2012|July 29, 2012|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01294241||109186|
NCT01294514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0132|Novel Non-Invasive Monitoring Parameter in Healthy Volunteers|Novel Cardio-Respiratory Parameter in Healthy Volunteers||Medtronic - MITG|No|Completed|February 2011|March 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|August 2014|August 5, 2014|February 10, 2011|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT01294514||109165|
NCT01294540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-001|Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Doses of E2609 in Healthy Subjects and an Elderly Cohort||Eisai Inc.|No|Completed|December 2010|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|30 Years|85 Years|Accepts Healthy Volunteers|||August 2013|August 28, 2013|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294540||109163|
NCT01295151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR10/9589|SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.|Randomised-controlled Trial of Switching to Alternative Tumour-necrosis Factor (TNF)-Blocking Drugs or Abatacept or Rituximab in Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug|SWITCH|University of Leeds|Yes|Active, not recruiting|August 2011|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|477|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295151||109116|
NCT01295411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01421-38|Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia|Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|January 2011|September 2015|Anticipated|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|40 Years|No|||April 2015|April 27, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01295411||109096|
NCT01295424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH 5070212|Epidemiology and Cost-effectiveness of Out-Of-Hospital Cardiac Arrest in Finland|FinnResusci: Epidemiology and Cost-effectiveness of Out-Of-Hospital Cardiac Arrest in Finland|FINNRESUSCI|Kuopio University Hospital|No|Completed|March 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2600|Samples Without DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Out-of-hospital cardiac arrest patients|January 2015|January 30, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01295424||109095|
NCT01295385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00233-36|Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy|Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy||Assistance Publique Hopitaux De Marseille|No|Recruiting|February 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01295385||109098|
NCT01295684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-085|Cranberry Juice and Cardiovascular Disease|The Influence Of Cranberry Juice On Risk Factors For Cardiovascular Disease||USDA Beltsville Human Nutrition Research Center|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Anticipated|60|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 11, 2011|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01295684||109075|
NCT01295697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-2208-05|Study of EZN-2208 Pediatric Patients With Solid Tumors|A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors||Enzon Pharmaceuticals, Inc.|No|Active, not recruiting|February 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|1 Year|21 Years|No|||March 2012|March 7, 2012|December 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01295697||109074|
NCT01291771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.611|Myocardial Microvascular Disease in ESRD|Detection and Outcomes of Myocardial Microvascular Disease in Patients With End Stage Renal Disease|MICROCARD|Hospices Civils de Lyon|Yes|Terminated|January 2011|January 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291771||109376|
NCT01294709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-014|A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)|A Double-Blind, Randomized, Placebo-Controlled, 2-Period Crossover Study to Assess the Safety, Tolerability, and Effects of MK-0974 on Exercise Tolerance in Patients With Stable Angina||Merck Sharp & Dohme Corp.|No|Completed|February 2008|March 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|85 Years|No|||December 2015|December 16, 2015|February 10, 2011|No|Yes||No|September 3, 2014|https://clinicaltrials.gov/show/NCT01294709||109150|
NCT01294969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-10-15|Patient Perception Study for AL-4943A|||Alcon Research|No|Completed|September 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|12 Years|N/A|No|||October 2011|December 14, 2012|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294969||109130|
NCT01286961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGI 2011-02|The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy|The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy|TOSP|Inje University|Yes|Completed|January 2011|September 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|360|||Both|18 Years|85 Years|No|Non-Probability Sample|Adult outpatients who undergo colonoscopy|October 2011|October 4, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01286961||109743|
NCT01286974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-966|A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.|Disposition of [14C]ABT-869 in Patients With Solid Tumors Following a Single Oral Dose Administration||Abbott|No|Terminated|August 2011|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|3|||Male|18 Years|N/A|No|||September 2012|September 19, 2012|January 28, 2011|No|Yes|Terminated early, Sponsor Decision|No||https://clinicaltrials.gov/show/NCT01286974||109742|
NCT01286987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-001|Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors|A Phase 1, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib in Patients With Advanced or Recurrent Solid Tumors||Medivation, Inc.||Active, not recruiting|December 2010|December 2016|Anticipated|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|January 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01286987||109741|
NCT01287260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13176|High Dose BAYA1040_Nifedipine: a Dose-comparative Study|A Multicenter, Double-blind, Parallel-group Comparative Study Between Oral BAYA1040_CR 80 mg and 40 mg for 8 Weeks in Patients With Essential Hypertension for Whom Oral BAYA1040_CR 40 mg is Insufficient||Bayer|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|352|||Both|20 Years|N/A|No|||January 2014|January 28, 2014|January 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01287260||109720|
NCT01283126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS #: 2010-09|Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery|Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery||Joslin Diabetes Center|No|Recruiting|January 2011|October 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 20, 2014|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283126||110037|
NCT01292317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN and NGAL 1.0|Neutrophil Gelatinase-associated Lipocalin (NGAL) and Contrast Media Induced Nephropathy|Early Detection and Intervention of Acute Contrast Media Induced Nephropathy Using Neutrophil Gelatinase-associated Lipocalin (NGAL) May Improve Renal Outcome: A Study in Patients Undergoing Intra-arterial Angiography.||Medical University of Graz|No|Completed|January 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|819|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292317||109334|
NCT01292759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.194.10 (7203)|Non-invasive Assessment of Arterial Blood Pressure and Functional Hemodynamic Parameters|An Evaluation of a New, Non-invasive Monitoring Device in Major Abdominal Surgery Patients||Johannes Gutenberg University Mainz|No|Recruiting|July 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for elective abdominal surgery|July 2010|February 14, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01292759||109300|
NCT01293058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-16|Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose|Study of Routs of Naloxone Administration for Opioid Overdosed Patients||Isfahan University of Medical Sciences|Yes|Completed|March 2007|June 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|15 Years|50 Years|Accepts Healthy Volunteers|||March 2007|February 9, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293058||109277|
NCT01293071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU_SATURNWP2|Effect of Antibiotic Rotation in the ICU on the Prevalence of Antibiotic Resistant Gram-negative Colonisation|The SATURN Consortium, "Impact of Specific Antibiotic Therapies on the Prevalence of hUman Host ResistaNt Bacteria". Workpackage 2: The SATURN ICU-trial.|SATURN|UMC Utrecht|Yes|Completed|January 2011|January 2014|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10000|||Both|10 Years|N/A|No|||November 2015|November 30, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293071||109276|
NCT01292304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-IST-10-06|Tolvaptan for Ascites in Cirrhotic Patients|Single Center, Open Labeled Pilot Study Evaluating the Safety and Efficacy of Tolvaptan in Patients With Cirrhotic Ascites||University of Florida|No|Completed|March 2012|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||June 2015|June 30, 2015|February 7, 2011|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01292304||109335|
NCT01292538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-GREEN001|Study of the Effectiveness of Green Diode Laser Light on Body Shaping|A Double-blind, Placebo-controlled Randomized Evaluation of the Effect of the Erchonia Scanner Device (GLS) Green Diode on Body Contouring of the Waist, Hips and Thighs||Erchonia Corporation|No|Completed|February 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|February 8, 2011|Yes|Yes||No|April 1, 2014|https://clinicaltrials.gov/show/NCT01292538||109317|
NCT01293383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCB 0902|A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects|A Phase 1 Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects. A Single Centre, Prospective, Randomised, Double-blinded, Vehicle-controlled Clinical Study||LEO Pharma|No|Completed|March 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293383||109252|
NCT01293942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTT 10-01|IXO+A in mCRC With Liver-only Metastases|A Single-arm Phase II Downsizing Study of Irinotecan, Capecitabine and Oxaliplatin (IXO) and Bevacizumab as First-line Treatment to Assess Conversion to Resectability of Liver-only Metastases in Colorectal Cancer Patients With Initially Unresectable Metastases||Ottawa Hospital Research Institute|Yes|Withdrawn|March 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01293942||109209|
NCT01294254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSH-10|Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites|Open, Prospective, Controlled, Randomised, Multicenter Phase II Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites|OleoSplit|Birken AG|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|95 Years|No|||April 2015|April 2, 2015|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01294254||109185|
NCT01294527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBR-00980|Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy|Multicenter, Prospective Evaluation of Performance, Safety, and Surveillance of the WiCS-LV System in Patients Indicated for Cardiac Resynchronization Therapy|WiSE-CRT|EBR Systems, Inc.|Yes|Active, not recruiting|February 2011|October 2016|Anticipated|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|November 18, 2015|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01294527||109164|
NCT01295164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 214 03|Measurement of High Order Aberrations in Late Stages Keratoconus|Feasibility of Measurement of High Order Aberrations in Late Stages Keratoconus by Using an Adaptive Optics Visual Simulator AOVIS-I|VOPTICA|University Hospital, Toulouse|No|Recruiting|October 2011|October 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|500|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01295164||109115|
NCT01295138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIFEANAES1|Pilot Study of the Effect of Lactulose on Post Caesarean Section Constipation|Pilot Study of the Effect of Lactulose on Post Caesarean Section Constipation||NHS Fife|No|Not yet recruiting|February 2011|July 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|16 Years|50 Years|No|||December 2010|February 22, 2011|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01295138||109117|
NCT01295398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01237-32|Influence of the Nebulizer on the Clinical Efficacy of Hypertonic Saline 3% in Children Aged Less Than 18 Months and Hospitalized With Acute Viral Bronchiolitis|Influence of the Nebulizer on the Clinical Efficacy of Hypertonic Saline 3% in Children Aged Less Than 18 Months and Hospitalized With Acute Viral Bronchiolitis||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|December 2010|November 2014|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|168|||Both|N/A|18 Months|No|||March 2011|August 28, 2014|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01295398||109097|
NCT01292278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSF 06/179|Constitution of Cerebrospinal Fluid and Blood Database/Specimen in Acute Stage of Subarachnoid Hemorrhage (aSAH) Patients|The Possible Role of Neuropeptide Y After Spontaneous Subarachnoid Hemorrhage||University of Regensburg|Yes|Recruiting|January 2006|December 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90|Samples Without DNA|cerebrospinal fluid / serum|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|consecutive pts. with subarachnoid hemorrhage|December 2014|December 4, 2014|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292278||109337|
NCT01293279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCgenos|HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China|HCV Viral Genotyping Distribution and Genetic Variation in IL28B Distributions Among the Han Ethnic Chinese in China|HCV|Peking University People's Hospital|Yes|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|997|Samples With DNA|By having the approvals from the EC and China National Human Genetic Resource Management      Office (under China Ministry of Health) and having the patient informed consent, blood      samples of all recruited patients will be retained under the proper conditions in Peking      University People's Hospital, Beijing, China|Both|18 Years|N/A|No|Probability Sample|1000 Han ethnic Chinese in China|June 2011|October 6, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293279||109260|
NCT01292499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIMAT‐De|Italian Network for the Improvement of Compliance in Depression|Italian Network for the Improvement of Compliance in Depression||Ospedale Amedeo di Savoia|Yes|Recruiting|March 2009|July 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|1264|||Both|18 Years|N/A|No|||December 2010|February 8, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01292499||109320|
NCT01287000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911076|Gulf Long-Term Follow-Up Study|Gulf Long-Term Follow-Up Study||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|55000|||Both|21 Years|N/A|No|||July 2015|March 22, 2016|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01287000||109740|
NCT01287013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110082|Comparing Navigation With Xperguide vs. Electromagnetic Tracking vs. Conventional Methods During Percutaneous Image Guided Procedures|Prospective Randomized Trial Comparing Navigation With Xperguide vs. Conventional Methods During Percutaneous Image Guided Procedures||National Institutes of Health Clinical Center (CC)||Completed|January 2011|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|87|||Both|18 Years|N/A|No|||April 2015|August 6, 2015|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287013||109739|
NCT01287273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-10-0010-CTIL|The Impact of Early Embryos Incubation on Pregnancy Rate in IVF|The Impact of Early Embryos Incubation on Pregnancy Rate in IVF|IVF-2010|Carmel Medical Center|No|Recruiting|April 2011|||February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|660|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|660 IVF patients. patients who are candidates for embryo cryopreservation cycle will be        offered to participate in the present prospective randomized study.        After detailed verbal and written explanation on the study protocol they will sign an        informed consent and then randomized to 2 groups.|December 2013|December 5, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01287273||109719|
NCT01292772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 12110|The Effects of Radiation in Reconstructed Breasts|The Effects of Radiation Therapy on the Reconstructed Breast: An Evaluation Using MR Imaging||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2010|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|90 Years|No|Probability Sample|The target population will consist of patients with a diagnosis of unilateral breast        cancer who elect to undero bilateral mastectomy with immediate free flap reconstruction.        Patients will be treated by members of the Division of Plastic and Reconstructive Surgery        and will receive postoperative radiation therapy to the affected breast.|January 2016|January 22, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01292772||109299|
NCT01292798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4978s|Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab|Open Label, Phase I/II, Residual Edema Evaluation With 0.5mg and 2.0mg Ranibizumab Formulations (REEF)|REEF|California Retina Consultants|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|February 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01292798||109297|
NCT01293084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFF Account #LAUBE06A0|Hypertonic Saline and Mucociliary Clearance in Children|Acute Inhalation of Hypertonic Saline Does Not Improve Mucociliary Clearance in All Children With Cystic Fibrosis||Johns Hopkins University|No|Completed|July 2007|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|7 Years|12 Years|No|||September 2015|September 10, 2015|February 9, 2011|Yes|Yes||No|September 10, 2015|https://clinicaltrials.gov/show/NCT01293084||109275|
NCT01293344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALIMED-2007-180 A3 R-2|Effects of the Mediterranean Diet on Cardiovascular Risk Profile in Men and Women|Gender Differences in Response to the Mediterranean Diet|ALIMED|Laval University|No|Completed|October 2007|October 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|70|||Both|25 Years|50 Years|No|||October 2011|October 5, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293344||109255|
NCT01293955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joins_Carp_IV_2009|Assessment of Protective Effect of JOINS on Cartilage in Knee Osteoarthritis|A Randomized, Double Blinded, Parallel Group, Placebo-controlled Clinical Trial to Assess the Protective Effect of JOINS on Cartilage in Knee Osteoarthritis|Joins_Carp_Ⅳ|SK Chemicals Co.,Ltd.|No|Completed|August 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|45 Years|79 Years|No|||April 2015|April 23, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01293955||109208|
NCT01293968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qums353|Therapeutic Effects of "Ibuprofen, Diphenhydramine and Aluminium MgS" on Recurrent Aphthous Stomatitis|Therapeutic Effects of "Ibuprofen, Diphenhydramine and Aluminium MgS" on Recurrent Aphthous Stomatitis||Qazvin University Of Medical Sciences|Yes|Completed|November 2010|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|37|||Both|10 Years|N/A|No|||May 2012|May 16, 2012|February 10, 2011||No||No|May 5, 2011|https://clinicaltrials.gov/show/NCT01293968||109207|Small number of population. Studying just one concentration of Ibuprofen. Lack of a placebo.
NCT01293981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-000058|Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)|Radiographic and Clinical Outcomes of PureGen Osteoprogenitor Cell Allograft in Posterior Lumbar and Transforaminal Interbody Fusion Procedures||Alphatec Spine, Inc.||Terminated|February 2011|||January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with symptomatic lumbar degenerative disc disease (DDD) at 1 or 2        contiguous levels between L1 and S1.|January 2016|January 15, 2016|February 9, 2011||No|Product no longer on the market|No||https://clinicaltrials.gov/show/NCT01293981||109206|
NCT01294267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1423|Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation|PERcutaneous heModynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation|PERMIT1|Icahn School of Medicine at Mount Sinai|Yes|Completed|September 2010|January 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|90 Years|No|||March 2013|March 23, 2013|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294267||109184|
NCT01294904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKD and infertility|Mechanisms of Infertility and Hormonal Changes in Patients With Chronic Kidney Disease|Studies of Infertility in Patients With Chronic Kidney Disease||Lund University|No|Enrolling by invitation|January 2011|August 2016|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|100|Samples Without DNA|Samples are stored at SUS, Malmö, Sweden|Both|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|outpatient cohorts|January 2011|February 11, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01294904||109135|
NCT01294878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|omalizumab-ic|Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome|Explorative Study on the Use of Omalizumab in Patients Suffering From Interstitial Cystitis/Painful Bladder Syndrome|IComaliz|IRCCS Policlinico S. Matteo|Yes|Completed|March 2009|October 2010|Actual|September 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|N/A|No|||December 2010|February 11, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01294878||109137|
NCT01294891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006948|Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease|Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease||Oregon Health and Science University|Yes|Completed|February 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|6|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with SCD or PNH who are seen in the OHSU Hematology clinic and are asked to        participate|October 2014|October 27, 2014|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01294891||109136|
NCT01295723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003 Mobetron|Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)|Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)||St. Joseph Hospital of Orange|Yes|Recruiting|January 2011|December 2021|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|40 Years|N/A|No|||September 2012|September 17, 2012|February 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01295723||109072|
NCT01295905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-347-C-004|Prospective Study of an Investigational Daily Disposable Contact Lens|||Alcon Research||Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Both|N/A|N/A|No|||May 2012|June 26, 2012|February 11, 2011|Yes|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT01295905||109058|
NCT01293591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Garlic Study 2010|Garlic Intake And Biomarkers Of Cancer Risk|GARLIC INTAKE AND BIOMARKERS OF CANCER RISK||USDA Beltsville Human Nutrition Research Center|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|1||Actual|18|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||February 2011|February 9, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01293591||109236|
NCT01295853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMRO2345|T3 Versus T4 Sympathicotomy for Treatment of Primary Palmar Hyperhidrosis|T3 Versus T4 Sympathicotomy for Treatment of Primary Palmar Hyperhidrosis: a Prospective Randomized Study||Mansoura University|Yes|Completed|February 2008|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|136|||Both|15 Years|38 Years|No|||February 2008|February 14, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01295853||109062|
NCT01295333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023608-28|Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance|Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance||Assistance Publique Hopitaux De Marseille|No|Completed|May 2011|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01295333||109102|
NCT01295580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1018DLN|Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis|Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis||Bioventus LLC|No|Completed|January 2011|February 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|40 Years|80 Years|No|||July 2013|July 22, 2013|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295580||109083|
NCT01295593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPA-CdA|Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)|Phase I-II Study of Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia (CLL) Patients||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|December 2010|April 2013|Anticipated|April 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01295593||109082|
NCT01292551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEMPO study|Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.|Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test|TEMPO|Rigshospitalet, Denmark|Yes|Completed|February 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|15 Years|N/A|No|||April 2013|April 18, 2013|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292551||109316|
NCT01292564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-MRI001|Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist|An Evaluation of the Effect of the Erchonia ML Scanner (MLS) as Applied to Body Contouring of the Waist and Hips on Fat Emulsification Pilot Study.||Erchonia Corporation|No|Withdrawn|February 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|February 8, 2011|Yes|Yes|Insufficient resources at test site for recruitment.|No||https://clinicaltrials.gov/show/NCT01292564||109315|
NCT01292577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118404|Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia|Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia||University of Pittsburgh|Yes|Completed|September 2010|September 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|55 Years|No|||February 2011|December 1, 2014|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01292577||109314|
NCT01293097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCAP|Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI|Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI)|ISCAP|Peking University First Hospital|Yes|Completed|June 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2884|||Both|20 Years|75 Years|No|||April 2013|April 28, 2013|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293097||109274|
NCT01293396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENM-DA-008|Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids|Comparison of the Impact of Biphasic Insulin Aspart 30(BiAsp30), Biphasic Insulin Aspart 70 (BiAsp 70) and Insulin Aspart on Postprandial Glucose and Lipid Metabolism During Two Consecutive Meals in Type 2 Diabetics.|HUCKEPACK2|Medical University of Graz|No|Completed|June 2010|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|35 Years|75 Years|No|||September 2011|September 22, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293396||109251|
NCT01293357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCB 0901|A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects|A Phase 1 Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects A Single Centre, Randomised, Controlled, Investigator Blinded Study With Intra-individual Comparison of the Active Formulation and Its Components||LEO Pharma|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293357||109254|
NCT01293370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|refKSH2910|Important Factors in Integration of Vocational Rehabilitation in Mental Health|Important Factors in Integration of Vocational Rehabilitation in Mental Health|IVRMH|University Hospital of North Norway|Yes|Completed|February 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|||Both|16 Years|50 Years|No|Non-Probability Sample|Admitted or discharged hospital patient, who also receives vocational rehabilitation|July 2013|July 1, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01293370||109253|
NCT01293695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194610|Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial|Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial||Baylor University|Yes|Completed|September 2007|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|187|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|February 10, 2011||No||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01293695||109228|limitations: results may not generalize to all women with hot flashessome hot flashes occur at other times than during the climactericself-selection bias (predispositions to mind-body therapy)population was largely caucasian
NCT01293708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R80|Realities, Expectations and Attitudes to Life Support Technologies in Intensive Care for Octogenarians:|Realities, Expectations and Attitudes to Life Support Technologies in Intensive Care for Octogenarians:|Realistic 80|Clinical Evaluation Research Unit at Kingston General Hospital|No|Completed|September 2009|February 2013|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|610|||Both|80 Years|N/A|No|Non-Probability Sample|80+ year old admitted to ICU|February 2013|February 19, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293708||109227|
NCT01293721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-KSWH|Study of Low-Magnitude, High-Frequency Vibration Treatment on Osteoporotic Hip Fracture Healing|Prospective Randomized Controlled Trial of the Efficacy of Low-Magnitude, High-Frequency Vibration Treatment on Osteoporotic Hip Fracture Healing||Chinese University of Hong Kong|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|65 Years|85 Years|No|||May 2012|May 22, 2012|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293721||109226|
NCT01293734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sygzwu|Research on Traditional Chinese Medicine (TCM) Clinical Treatment of the Acute Episode of Bronchial Asthma.|||Liaoning University of Traditional Chinese Medicine|Yes|Completed|December 2008|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|360|||Both|18 Years|65 Years|No|||January 2011|February 10, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293734||109225|
NCT01294280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150802|Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy|Participation in the Lung Adjuvant Cisplatin Evaluation Biological Program (LACE-BIO). A Study of Prognostic and Predictive Markers in Early Stage Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Recruiting|July 2008|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1606|Samples With DNA|Tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients registered to Cancer and Leukemia Group B (CALGB) 9633|July 2015|July 23, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294280||109183|
NCT01294553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105709|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of Avandamet® Administered in Korean Diabetic Patients According to the Prescribing Information|AVANDAMETPMS|GlaxoSmithKline|No|Completed|June 2004|January 2010|Actual|January 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|717|||Both|N/A|N/A|No|Probability Sample|Type II diabets mellitus patients prescribed rosiglitazone/metformin in general hospital|February 2011|July 15, 2011|February 10, 2011||No||No|February 17, 2011|https://clinicaltrials.gov/show/NCT01294553||109162|
NCT01295463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-FERTI|Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer|Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center||National Cancer Institute (NCI)||Recruiting|December 2010|||June 2012|Anticipated|N/A|Observational|N/A|||Anticipated|96|||Both|18 Years|45 Years|No|||February 2011|August 9, 2013|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295463||109092|
NCT01295190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudickar3|Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass|Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass: Effect on Metabolic Acidosis and Clinical Outcome|PRISKIKO|University of Schleswig-Holstein|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|N/A||2|Actual|200|||Both|N/A|16 Years|No|Non-Probability Sample|Children scheduled for heart surgery including cardiopulmonary bypass.|May 2014|May 21, 2014|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295190||109113|
NCT01295177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSULIN22|Topic Insulin Accelerates Wound Healing in Diabetes|Topic Insulin Accelerates Wound in Diabetes|insulin|University of Campinas, Brazil|Yes|Completed|January 2004|September 2007|Actual|August 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|80 Years|No|||February 2011|February 10, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01295177||109114|
NCT01262677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081194|Once-A-Day Pregabalin For Partial Seizures|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures - Protocol A0081194||Pfizer|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|334|||Both|18 Years|N/A|No|||September 2013|September 13, 2013|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01262677||111607|
NCT01263002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLV-413|A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC|An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B Associated Hepatocellular Carcinoma||Bukwang Pharmaceutical||Completed|June 2010|September 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263002||111582|
NCT01263288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1982|Effect of Vitamin D Supplementation on Muscular Strength, Musculoskeletal Pain and Headache|Effect of Vitamin D Supplementation on Muscular Strength, Musculoskeletal Pain and Headache in Immigrants Living in Norway. Randomized, Double Blinded, Placebo Controlled Study||University of Oslo|Yes|Completed|January 2011|January 2013|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|251|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263288||111560|
NCT01292083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-09-15|Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery|A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression in Triple Negative Invasive Breast Cancer||University of Southern California|Yes|Withdrawn|January 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2014|February 5, 2014|February 2, 2011|Yes|Yes|No accrual last 2 years|No||https://clinicaltrials.gov/show/NCT01292083||109352|
NCT01292330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-Liver surgery -Nutrition|A Clinical Study to Evaluate the Clinical Outcomes of Hepatectomy With Nutritional Risk After Preoperative Nutritional Support|A Clinical Study to Evaluate the Clinical Outcomes of Hepatectomy With Nutritional Risk After Preoperative Nutritional Support||Peking Union Medical College Hospital|No|Recruiting|January 2010|November 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|90 Years|No|||February 2011|February 8, 2011|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01292330||109333|
NCT01291810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNF-K-005|Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety and Immunogenicity of Neovacs' TNFα-Kinoid in Adult Subjects With Crohn's Disease||Neovacs|Yes|Completed|February 2011|May 2014|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||September 2014|September 17, 2014|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01291810||109373|
NCT01292070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN048AD|Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy|A Dose-Escalating Phase 0 Study to Evaluate the Safety and Local Cutaneous Reactivity of Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD) in Cat-allergic Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|March 2011|April 2011|Actual|April 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||January 2014|January 6, 2014|February 7, 2011|No|Yes|Futility|No|January 6, 2014|https://clinicaltrials.gov/show/NCT01292070||109353|The experimental protein (human Fcgamma1-Fel d1 fusion protein) & control protein (standardized cat hair allergenic extract) elicited comparable reactivity in the first four participants dosed and consequently the trial was discontinued for futility
NCT01292590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000140/1; BIDMC|Effect of Dietary Fat on Glycemic Control in Type 1 Diabetes|Use of Closed Loop Control to Examine the Effect of Changes in Dietary Fat Intake on Insulin Requirements and Glucose Control||Joslin Diabetes Center|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||September 2012|September 18, 2012|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01292590||109313|
NCT01292785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P23021FWF|Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity|Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity: A Longitudinal Study Using 7 Tesla Ultrahigh-field Magnetic Resonance Imaging||Medical University of Vienna|Yes|Completed|January 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Transsexuals urging sex reassignment in a clinical setting will be enrolled at the Unit        for Gender Identity Disorder at the General Hospital in Vienna. 20 female-to-male (FtM)        and 20 male-to-female (MtF) transsexuals will be asked to undergo this fMRI, MRI, DTI and        resting-state functional connectivity study. Transsexual subjects are aged between 18 and        50 years old and free from hormone-treatment at baseline.        40 healthy control subjects, matched for age, sex and sexual orientation to transsexual        subjects will be recruited.|April 2015|April 8, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01292785||109298|
NCT01292603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25341|A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia|An Adaptive, Comparative, Randomized, Parallel-group, Multi Center, Phase Ib Study of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With Chemotherapy (Fludarabine and Cyclophosphamide), in Patients With Previously Untreated CLL||Hoffmann-La Roche||Active, not recruiting|April 2011|November 2017|Anticipated|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|240|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|February 8, 2011|No|Yes||No|September 23, 2015|https://clinicaltrials.gov/show/NCT01292603||109312|
NCT01292811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-048|Restoration of Upper Limb Function in Individuals With Sub-Acute Spinal Cord Injury|Restoration of Upper Limb Function in Individuals With Sub-Acute Spinal Cord Injury|MCRCT|Toronto Rehabilitation Institute|No|Recruiting|January 2011|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01292811||109296|
NCT01293110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2010-0207/0|Lower Urinary Tract Dysfunction Database|Database of Patients With Lower Urinary Tract Dysfunction Treated at the University of Zürich||Balgrist University Hospital|No|Recruiting|January 2010|January 2030|Anticipated|January 2030|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|7000|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ages Eligibility: minimum 18 years Genders Eligibility: female and male|January 2016|January 28, 2016|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293110||109273|
NCT01293422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifa-2|Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis|PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon|Rifa-2|University of Oulu|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 7, 2012|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293422||109249|
NCT01293409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI (FWA00000190) 11/2008b|Bright Light Therapy in Seasonal Affective Disorder (SAD)|Transcranial Brain-Targeted Bright Light Treatment Via Ear Canals in Seasonal Affective Disorder (SAD) - a Randomized Placebo Controlled Dose Finding Study||University of Oulu|Yes|Completed|November 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 30, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01293409||109250|
NCT01293994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11222010-7229|A Study of Genetic Variation Influencing Pain and Response to Opioid Medications in Patients With Chronic Pain|A Study of Genetic Variation Influencing Pain and Response to Opioid Medications in Patients With Chronic Pain||Stanford University||Enrolling by invitation|February 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Saliva biospecimen collection will be performed via mail or in person. The Principal      Investigator will send participants a letter informing them of the opportunity to      participate in a study of genetic variation influencing pain and opioid responsiveness      phenotypes. If participants agree to provide a saliva biospecimen and to participate in the      study of genetic variation influencing pain and opioid responsiveness phenotypes ("the      study"), an informed consent letter to participate in the study and an Oragene™ DNA      Self-Collection Kit, in disk format OG-250 (DNA Genotek, Inc., Ottowa, Ontario, Canada) will      be sent to the participant by the Principal Investigator. According to the manufacturer      instructions, participants will provide a 2 ml saliva sample, which will be preserved using      the reagents provided within the Oragene kit. Saliva samples are considered stable at room      temperature for 5 years by Oragene.|Both|18 Years|71 Years|No|Non-Probability Sample|Any gender, ages 18-70, of any ethnic background|February 2012|February 13, 2012|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293994||109205|
NCT01294007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-000061|Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)|A Radiographic Analysis Using PureGen Osteoprogenitor Cell Allograft Versus Autologous Bone in Posterolateral Fusion in a Side-by-Side Comparison in the Same Patient (PLF)||Alphatec Spine, Inc.||Terminated|February 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|50 Years|N/A|No|||January 2016|January 15, 2016|February 9, 2011||No|Product no longer on the market|No||https://clinicaltrials.gov/show/NCT01294007||109204|
NCT01294293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9925|TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Gynecologic Oncology Group||Completed|March 2011|||July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||December 2014|December 23, 2014|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294293||109182|
NCT01294566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114422|FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers|A Randomized, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Asian Adult Subjects||GlaxoSmithKline|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294566||109161|
NCT01294579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114612|Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)|A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed After Rituximab or a Rituximab Containing Therapy||Novartis|No|Recruiting|May 2011|August 2021|Anticipated|August 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294579||109160|
NCT01283906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC-10U1101|A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients|A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck|MuGard|Access Pharmaceuticals, Inc.|No|Completed|January 2011|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283906||109977|
NCT01283919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN/23/87/04-05|Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition|A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed Release Tablets (Wyeth Laboratories, USA) in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|October 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 25, 2011|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283919||109976|
NCT01295762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMMUNEURO|Immunomonitoring of Children With Neuroblastoma|Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies|Immuneuro|Centre Leon Berard|No|Recruiting|May 2011|July 2019|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|N/A|21 Years|No|||July 2015|July 1, 2015|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295762||109069|
NCT01295450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDC-APEVINAT-01/10|Study to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex|A Clinical Multicenter, Phase III, Randomized, Double-blind, Prospectively to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex in Stimulating the Appetite||MDCPharma Produtos Farmaceuticos LTDA|Yes|Not yet recruiting|April 2011|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|7 Years|14 Years|No|||February 2011|February 11, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01295450||109093|
NCT01264146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-025|Hyperbaric Oxygen Therapy in Calcaneal Intraarticular Fractures: Can it Decrease the Soft-tissue Complication Rate?|Hyperbaric Oxygen Therapy in Calcaneal Intraarticular Fractures: Can it Decrease the Soft-tissue Complication Rate?|HOCIF|RWTH Aachen University|No|Completed|April 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 26, 2012|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01264146||111495|
NCT01264458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001889|Microvesicle Production After Acute Trauma and Its Clinical Impact on Venothromboembolism|Microvesicle Production After Acute Trauma and Its Clinical Impact on Venothromboembolism||Mayo Clinic|No|Active, not recruiting|January 2011|||January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2720|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Trauma patients arriving to Saint Mary's Emergency Department and control patients.|May 2015|May 5, 2015|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264458||111471|
NCT01264159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0090-10-HYMC|Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients|||Hillel Yaffe Medical Center||Terminated|January 2011|July 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|N/A|N/A|No|||May 2012|May 31, 2012|December 20, 2010||No|The principle investigator decided to change the protocol|No||https://clinicaltrials.gov/show/NCT01264159||111494|
NCT01291836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDDP-09EE-081|Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)|Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)|AKINESIS|Alere San Diego|Yes|Active, not recruiting|December 2010|October 2014|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples Without DNA|Urine Samples, Plasma Samples|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be enrolled primarily from hospital emergency rooms located at various        academic centers located throughout the USA and Europe.|June 2014|June 30, 2014|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291836||109371|
NCT01292343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UREDC3rd|Triclosan Toothpaste and Third Molar Surgery|Effect of a Triclosan Containing Dentifrice on Oral Bacteria and Postoperative Complications Following Third Molar Surgery||University of Rochester|No|Completed|February 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|141|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01292343||109332|
NCT01292356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUTACETUX 2010-0198378-85|Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response|||Poitiers University Hospital||Recruiting|December 2010|||December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2011|July 9, 2012|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01292356||109331|
NCT01292369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0566.CTIL|Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study|Observational Study Aimed to Characterize a System for Breast and Colon Cancer Diagnosis by Breath Testing - NaNose Study||Rambam Health Care Campus|No|Recruiting|February 2011|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|560|Samples Without DNA|Breath samples|Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women coming for medical tests:          1. Women coming for a breast biopsy following a suspicious breast imaging result.          2. Men and women coming for a colonoscopy, reffered by their family physician, due to             complaints indicating the possibility of colon cancer.|August 2011|August 17, 2011|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01292369||109330|
NCT01292616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05-10|Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement|||University of Zurich||Recruiting|October 2011|October 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with rheumatoid arthritis (RA) that have cervical involvement documented        with MRI showing pannus in the atlanto-axial joint.|February 2012|February 23, 2012|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292616||109311|
NCT01292824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_10-104|Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients|Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection|ITX5061|University of Birmingham|No|Completed|February 2011|May 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01292824||109295|
NCT01293435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-IEU-DUM-2010/1|Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections|Observational Study to Assess Clinical Management Patterns in Patients With Hospitalised Community-Acquired Pneumonia (CAP) or Complicated Skin and Skin Structure Infections (cSSSI)|REACH|AstraZeneca|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|4035|||Both|18 Years|N/A|No|Probability Sample|Patients over 18, diagnosed with community acquired pneumonia or complicated skin and skin        structure infection hospitalised between 2010-12-01 and 2011-01-31.|September 2012|September 6, 2012|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01293435||109248|
NCT01293448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0001.A|Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium|Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium||C2 Therapeutics, Inc.|No|Completed|December 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|80 Years|No|||April 2015|April 24, 2015|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01293448||109247|
NCT01293747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903/I/PRO|Pharmacokinetics of Injectable Estradiol and Progesterone Microspheres Suspension|Multiple-dose Pharmacokinetic Study of Two Aqueous Suspensions of Estradiol and Progesterone Microspheres (1 mg/20 mg & 0.5 mg/15 mg) for Intramuscular Administration, in Postmenopausal Volunteers.||Productos Científicos S. A. de C. V.|No|Completed|February 2011|October 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293747||109224|
NCT01294020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1206|Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®|A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up||Astellas Pharma Inc|Yes|Recruiting|May 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|80|||Both|5 Years|16 Years|No|||February 2016|February 16, 2016|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294020||109203|
NCT01294306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02578|MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy|Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy||National Cancer Institute (NCI)|Yes|Completed|February 2011|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||May 2015|September 28, 2015|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294306||109181|
NCT01294592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114615|Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement|Comparative Efficacy of Dutasteride Plus Tamulsoin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement.|CONDUCT|GlaxoSmithKline||Completed|December 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|742|||Male|50 Years|N/A|No|||June 2014|July 17, 2014|February 10, 2011||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT01294592||109159|
NCT01294605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263855/034|Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)|Double-blind, Randomized, Phase III Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of Three Consecutive Doses of dTpa, or of dTpa-IPV Followed by Two Doses of Td Vaccine , and Compared to Three Consecutive Doses of Td Vaccine Administered to Healthy Adults in a 0,1,6-month Schedule||GlaxoSmithKline||Completed|April 2003|September 2004|Actual|September 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|460|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 17, 2011|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294605||109158|
NCT01283932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN/23/88/04-05|Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition|A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed Release Tablets (Wyeth Laboratories, USA) in Healthy, Adult, Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|October 2004|December 2004|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 25, 2011|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283932||109975|
NCT01283945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-3810-I-01|Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors|An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours||Servier|No|Active, not recruiting|July 2010|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283945||109974|
NCT01283958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|no sponsor|The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome|Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome||Gachon University Gil Medical Center||Completed|September 2007|May 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|12 patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization|May 2010|January 25, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283958||109973|
NCT01284192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3026-CL-0101|Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)|A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects With Advanced Malignancies||Astellas Pharma Inc|No|Active, not recruiting|December 2010|March 2016|Anticipated|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|January 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01284192||109955|
NCT01284478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCRVA-2011-Ozurdex-16-1|Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery|Phase 2 Study of Ozurdex for Combined Pseudophakic Cystoid Macula Edema and Diabetic Macula Edema After Cataract Surgery||Northern California Retina Vitreous Associates|No|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 3, 2012|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01284478||109933|
NCT01295957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI851|Alzheimer's Disease Reminiscence Quality of Life|Phase 4 Study of a Reminiscence Program to Improve Quality of Life of Alzheimer's Disease Long Term Care Residents Using a Randomized Controlled Trial||Universidad Nacional de Rosario|No|Completed|January 2010|November 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|135|||Both|65 Years|87 Years|Accepts Healthy Volunteers|||February 2010|February 14, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01295957||109054|
NCT01295970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 10-0486-C|Surgery Versus Radiosurgery for the Treatment of Single Brain Metastases|Feasibility of a Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Single Brain Metastases||University Health Network, Toronto|Yes|Withdrawn|April 2011|September 2018|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|N/A|No|||June 2013|June 11, 2013|February 11, 2011||No|Recruitment challenges|No||https://clinicaltrials.gov/show/NCT01295970||109053|
NCT01263327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-PRO-001|Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine|An Open-Label, Single-dose, Non-Randomized, Safety and Tolerability Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 55 Years||Xiamen University|No|Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263327||111557|
NCT01263340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCO115217|Characterisation of People With COPD|Observational, Multi-centre, Retrospective Cohort Study to Evaluate Prevalence, Incidence, Severity, Co-morbidities and Burden of Disease in Patients With a Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) by Close Scrutiny of the Patient Journey|CoCO|National Services for Health Improvement Ltd|Yes|Completed|December 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|People with a Read code diagnosis of COPD|December 2013|December 4, 2013|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01263340||111556|
NCT01264172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-28|Identification of Microcirculation and Inflammation After Minimal-invasive Osteosynthesis of the Proximal Femur|Identification of the Cutaneous and Muscular Microcirculation and Inflammatory Response After Minimal-invasive Osteosynthesis of the Proximal Femur|MicroProxFem|RWTH Aachen University|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|60 Years|N/A|No|||November 2012|November 26, 2012|December 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01264172||111493|
NCT01292096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-649|Intervening With and Improving Care for Patients at Risk for Frequent Hospital Admissions|Intervening With and Improving Care for Patients at Risk for Frequent Hospital Admissions||New York University School of Medicine|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|19|||Both|18 Years|64 Years|No|||February 2016|February 29, 2016|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01292096||109351|
NCT01292122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-GDS-001-VCT|Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds|A Single-Center, Prospective, Randomized Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds||Organogenesis|No|Terminated|June 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|55 Years|No|||December 2012|December 19, 2012|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01292122||109349|
NCT01292135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1108-CA|Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)|A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Pharmacyclics|No|Completed|February 2011|May 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|February 2, 2011|No|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT01292135||109348|
NCT01292382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMSCogOld|Effects of rTMS on the Cognition of Elderly With Mild Memory Complaints|Effects of rTMS on the Cognition of Elderly With Cognitive Impairment no Dementia ( CIND )|TMSMemOld|University of Sao Paulo General Hospital|Yes|Recruiting|November 2010|July 2012|Anticipated|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|60 Years|74 Years|No|||August 2010|April 20, 2011|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01292382||109329|
NCT01292863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2359|The Impact of Delflex on Mesothelial Cell Viability and Peritoneal Transport|The Impact of a Biocompatible Peritoneal Dialysis Solution (Delflex Neutral pH) on Mesothelial Cell Viability and Peritoneal Transport|Delflex|University of North Carolina, Chapel Hill|No|Withdrawn|March 2011|May 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|February 8, 2011|Yes|Yes|Study was modified to in vitro design and no longer involves participants|No||https://clinicaltrials.gov/show/NCT01292863||109292|
NCT01292876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10010500|Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)|Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury|MTURR|University of Pittsburgh|Yes|Completed|December 2010|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||December 2015|December 31, 2015|February 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01292876||109291|
NCT01293461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBX129801-PK-101|Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes|A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus||Cebix Incorporated|No|Completed|April 2011|October 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||February 2013|February 25, 2013|February 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01293461||109246|
NCT01293760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p001355|Immediate Post-placental Insertion of the Copper T 380A After Cesarean Delivery Versus 6 Week Post-cesarean Insertion|Immediate Post-placental Insertion of the Copper T 380A After Cesarean Delivery Versus 6 Week Post-cesarean Insertion: A Pilot Randomized Controlled Trial||Planned Parenthood League of Massachusetts|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|68|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 8, 2012|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293760||109223|
NCT01294033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000142/01|Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease|Effect of Therapeutic Hyperoxia on Maximal Oxygen Consumption and Perioperative Risk Stratification in Patients With Chronic Obstructive Pulmonary Disease||Beth Israel Deaconess Medical Center|No|Completed|August 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 10, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01294033||109202|
NCT01294046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE Number : G100007|Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches|Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches||The Cleveland Clinic|Yes|Completed|March 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|February 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294046||109201|
NCT01294917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBR-305-9608|Comparison of a New Abbott Medical Optics (AMO) Multi-Purpose Solution (MPS) to Existing Contact Lens Regimens|Comparison of a New AMO MPS to Existing Contact Lens Regimens||Abbott Medical Optics|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|3||Actual|40|||Both|17 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|February 10, 2011||No||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01294917||109134|
NCT01295203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPH 1957|Internet-based Physical Activity Intervention|Internet-based Physical Activity Intervention||University of Southern Denmark|No|Completed|May 2008|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12287|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2008|February 11, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295203||109112|
NCT01295216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN268200900028C|Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings|Mobile Health to Prevent Progression of Pre-hypertension in Latin American Urban Settings||Institute of Nutrition of Central America and Panama|No|Terminated|September 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|637|||Both|30 Years|60 Years|No|||August 2015|August 24, 2015|February 11, 2011||No|No significant change for the primary objective at 12 months|No||https://clinicaltrials.gov/show/NCT01295216||109111|
NCT01283646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRPEMS0910|Efficacy and Tolerability of Apevitin BC Comparing to Vitamin Complex in Stimulating the Appetite|Multicenter Clinical Study, Phase III, Randomized, Double-blind, of Prospectively Evaluate the Effectiveness and Tolerability of Apevitin BC Comparing to Vitamin Complex in Appetite Stimulation|Inappetence|EMS|Yes|Completed|October 2011|October 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|5 Years|15 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283646||109997|
NCT01284205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3348-302|First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC|Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression||Bioniche Life Sciences Inc.|Yes|Withdrawn|January 2010|February 2017|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|January 25, 2011|Yes|Yes|This indication is not being pursued at this point in time.|Yes||https://clinicaltrials.gov/show/NCT01284205||109954|
NCT01284751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVH-04|The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients|The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients||Herlev Hospital|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|21|||Female|30 Years|70 Years|No|Non-Probability Sample|Department of Breast Surgery|May 2011|May 11, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01284751||109912|
NCT01263379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10202010-7130|Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa|A Phase 1 Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)||Stanford University|Yes|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|13 Years|N/A|No|||March 2016|March 17, 2016|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263379||111553|
NCT01263613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS10103|Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer|Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer||University of Wisconsin, Madison|Yes|Completed|December 2010|June 2013|Actual|June 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Female|18 Years|N/A|No|||April 2014|April 4, 2014|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263613||111535|
NCT01295879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3346|Vitamin D Repletion in Stone Formers With Hypercalciuria|Effect of Ergocalciferol Repletion on Urine Calcium Among Stone Formers With Vitamin D Deficiency and Hypercalciuria||New York Presbyterian Hospital|No|Completed|September 2010|June 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|February 14, 2011||No||No|September 10, 2012|https://clinicaltrials.gov/show/NCT01295879||109060|
NCT01291849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0578|The Effect-site Concentration of Remifentanil for Preventing Cough During Emergence From Balanced Anesthesia for Nasal Surgery|||Yonsei University|No|Completed|March 2010|May 2010|Actual|||Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|60 Years|No|||January 2011|February 8, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01291849||109370|
NCT01292109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999169 CS03|A Study of PICOPREP in Patients Needed to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery.|Compliance and Efficacy in the Use of PICOPREP for Bowel Cleansing||Ferring Pharmaceuticals|No|Completed|December 2010|February 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|252|||Both|N/A|N/A|No|Non-Probability Sample|Patients about to undergo X-ray examination, endoscopy or surgery.|February 2012|February 8, 2012|February 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01292109||109350|
NCT01292148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT-TH|Measurement of Core Temperatures During Therapeutic Hypothermia|Core Temperature Measurement in Therapeutic Hypothermia: Tympanic Membrane, Bladder and Rectal Versus Pulmonary Artery Methods|TH|Seoul National University Hospital|No|Completed|February 2011|May 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|No|Probability Sample|Post cardiac arrest care with therapeutic hypothermia|July 2015|July 17, 2015|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01292148||109347|
NCT01292161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-15|Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C|Study of Silymarin for Improving Hepatitis C||Isfahan University of Medical Sciences|Yes|Completed|March 2006|September 2006|Actual|September 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|55|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2006|February 8, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292161||109346|
NCT01292837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01363|A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures|An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Levetiracetam in Japanese Patients (≥4 to <16 Years) With Uncontrolled Generalized Tonic-clonic (GTC) Seizures Despite Treatment With 1 or 2 Antiepileptic Drug(s)||UCB Pharma|No|Completed|February 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|4 Years|15 Years|No|||April 2015|April 27, 2015|February 8, 2011|Yes|Yes||No|June 3, 2014|https://clinicaltrials.gov/show/NCT01292837||109294|
NCT01292850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120080090|Skin Sterility After Ethyl-Chloride Spray|Skin Sterility After Ethyl-Chloride Spray||Rutgers, The State University of New Jersey|No|Completed|February 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healty adult (18-85) volunteers|February 2011|February 9, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292850||109293|
NCT01292902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27012011|Regional Distribution of Ventilation in Patients With Chronic Heart Failure|||Universidade Federal de Pernambuco|Yes|Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|31|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2011|February 9, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01292902||109289|
NCT01293175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSA-FF-002|Whole Grain Polyphenol Bioavailability and Effects on Health|Whole Grain Polyphenol Bioavailability and Effects on Inflammatory, Oxidative and Hormonal Status||Federico II University|Yes|Completed|February 2011|August 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293175||109268|
NCT01293123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0067|Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals|Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals||University of California, San Diego|Yes|Terminated|December 2011|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|February 9, 2011|Yes|Yes|Did not meet enrollment goals|No||https://clinicaltrials.gov/show/NCT01293123||109272|
NCT01293136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00073|Retrospective Femoral Nerve Block Study|||Nationwide Children's Hospital|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|400|||Both|N/A|N/A|No|Non-Probability Sample|Patients that had reconstructive knee surgery|January 2012|January 27, 2012|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293136||109271|
NCT01293786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-02-2011|Serum Magnesium and Vascular Calcification|Comparison of Vascular Calcification Between Kidney Transplant Recipients and Predialysis Chronic Kidney Disease and Its Association With Serum Magnesium||Ramathibodi Hospital|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|400|Samples Without DNA|serum|Both|18 Years|N/A|No|Probability Sample|Kidney transplant recipients and predialysis chronic kidney disease patients from        outpatient nephrology clinic of Ramathibodi hospital, Mahidol University|May 2011|May 25, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293786||109221|
NCT01294059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-06|Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients|Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients||University of Florida|No|Completed|November 2009|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|51|||Both|30 Years|65 Years|No|||July 2014|July 29, 2014|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294059||109200|
NCT01293773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007/CE-RMB|Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus|Outcome of seCond Generation Drug-ELuting Stents in Patients With Diabetes Mellitus: cOmparison of Three differenT Drug Regimens|OCELOT|Policlinico Casilino ASL RMB|Yes|Withdrawn|October 2010|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||August 2011|November 6, 2014|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01293773||109222|
NCT01294631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017851|A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers|An Open-Label, Two-Period, Fixed-Sequence Study to Explore the Effects of Multiple Doses of Hydrochlorothiazide on the Pharmacodynamics, Pharmacokinetics, and Safety of Multiple Doses of Canagliflozin in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 13, 2012|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294631||109156|
NCT01287416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2010:192|Circle of Life. Improving Capacity of Swampy Cree Community Members to Recognize People at Risk for Suicide|Circle of Life.Improving Capacity of Swampy Cree Community Members to Recognize People at Risk for Suicide: A Randomized Controlled Pilot Study||University of Manitoba|No|Completed|July 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|55|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 9, 2014|January 10, 2011||No||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01287416||109708|
NCT01283620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-277|Atlantic Canada Modified Constraint Induced Movement Therapy Trial|Atlantic Canada Modified Constraint Induced Movement Therapy Trial||Nova Scotia Health Authority|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283620||109999|
NCT01284517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050292|Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression|A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.|PREVAIL3|Sunovion|Yes|Completed|November 2010|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|75 Years|No|||October 2013|October 31, 2013|January 25, 2011|Yes|Yes||No|August 7, 2013|https://clinicaltrials.gov/show/NCT01284517||109930|
NCT01284530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|538P107|Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy|Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy||Supernus Pharmaceuticals, Inc.||Completed|January 2011|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|4 Years|17 Years|No|||June 2013|June 4, 2013|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01284530||109929|
NCT01283971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA25522|A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor|A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor||Hoffmann-La Roche||Terminated|May 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|January 25, 2011|Yes|Yes|The study was closed due to the slow enrollment rate.|No|October 7, 2013|https://clinicaltrials.gov/show/NCT01283971||109972|Data interpretation was limited by the very small sample size (enrollment 1/7 of planned sample size; not powered for formal statistical analysis) and the open-label observation (study un-blinded following protocol amendment to terminate enrollment).
NCT01284491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAK VP-00070|A Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0|A Prospective, Randomized, Controlled Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0|PRECISE|Medtronic Surgical Technologies|No|Terminated|January 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Female|18 Years|70 Years|No|||January 2013|January 3, 2013|January 25, 2011|Yes|Yes|Termination due to acquisition of PEAK Surgical by Medtronic|No|November 29, 2012|https://clinicaltrials.gov/show/NCT01284491||109932|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.
NCT01263639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patient Satisfaction|Improving Patient Satisfaction Improving Patient Satisfaction|Improving Patient Satisfaction in the Orthopaedic Trauma Population||Vanderbilt University|Yes|Completed|January 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|228|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|December 16, 2010||No||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01263639||111533|No adverse events. Limitations included poor patient follow-up due to poor patient participation with telephone call surveys.
NCT01263873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-10-05|Examining the Ease of Intubation Using the Parker Flex-Tip® or a Standard Endotracheal Tube|Examining the Ease of Intubation Using the Parker Flex-Tip® or a Standard Mallinckrodt® Endotracheal When Using the Glidescope®|ETT|University Hospital Case Medical Center|Yes|Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|December 17, 2010||No||No|May 26, 2011|https://clinicaltrials.gov/show/NCT01263873||111516|Limitations of this study included an un-blinded use of ETTs
NCT01263886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10259|Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer|A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer|DISRUPT|Sanofi|No|Completed|February 2011|October 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|December 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263886||111515|
NCT01263899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB1518-2010-005|A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies|A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies||S*BIO|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263899||111514|
NCT01295892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pkvw6k|Chronic Effects of Estrogen in Microcirculation|Chronic Effects of Estrogen in Microcirculation and Insulin Resistance in Postmenopausal Obese Women||Rio de Janeiro State University|No|Completed|December 2011|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Female|48 Years|55 Years|No|||April 2013|April 17, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01295892||109059|
NCT01291862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0008|Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion|Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion||Yonsei University|No|Recruiting|June 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|20 Years|70 Years|No|||January 2012|January 31, 2012|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01291862||109369|
NCT01292629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-N251|Comparison of the Hoya Surgical Optics (HSO) iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.|Comparison of the HSO iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.||Hoya Surgical Optics, Inc.|No|Completed|February 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|50 Years|N/A|No|||March 2015|March 18, 2015|February 4, 2011|Yes|Yes||No|February 11, 2015|https://clinicaltrials.gov/show/NCT01292629||109310|
NCT01292642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000927|Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence|Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence|CBT-MJ-NIC|Mclean Hospital|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||August 2013|August 13, 2013|February 8, 2011|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT01292642||109309|slightly more than one‐third of participants did not complete treatment. The small sample size and relatively high proportion of treatment non‐completers may limit our interpretation of the results.
NCT01285817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-12|A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.|A Phase II Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing Solid Tumours.|SFCE METRO 01|Assistance Publique Hopitaux De Marseille|No|Recruiting|November 2010|March 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|4 Years|21 Years|No|||October 2015|October 22, 2015|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01285817||109831|
NCT01293149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00075|Clonidine in Femoral Nerve Block Surgery in Children|The Effects of Clonidine on Postoperative Analgesia After Single Shot Femoral Nerve Block Following Arthroscopic Knee Surgery in Children||Nationwide Children's Hospital|No|Withdrawn|April 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|21 Years|No|||May 2015|May 6, 2015|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01293149||109270|
NCT01293162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMOPREV-2011|The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk|Study on the Role of a Combination of Nutraceuticals (Armolipid Prev) With an Effect on Blood Pressure and Lipids in the Control of Cardiovascular Risk|ARMOPREVCVR|Federico II University|Yes|Completed|September 2010|October 2014|Actual|October 2014|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Metabolic syndrome|February 2016|February 2, 2016|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293162||109269|
NCT01286311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reducing CV Risk|Tailored Communication to Reduce Cardiovascular Risk|Tailored Communication to Reduce Cardiovascular Risk||Northwestern University|Yes|Completed|January 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|464|||Both|40 Years|79 Years|No|||January 2015|January 27, 2015|January 27, 2011||No||No|May 13, 2013|https://clinicaltrials.gov/show/NCT01286311||109793|
NCT01294319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110078|Evaluation of Cortisol Resistance in Young Endurance-trained and Elderly Men|Evaluation of Cortisol Resistance in Young Endurance-Trained and Elderly Men||National Institutes of Health Clinical Center (CC)||Suspended|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|51|||Male|18 Years|80 Years|No|||July 2015|January 22, 2016|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294319||109180|
NCT01294332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110088|Effect of Aerobic Exercise Training on Cardiorespiratory Function in Patients With Traumatic Brain Injury|Effect of Aerobic Exercise Training on Cardiorespiratory Function in Patients With Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Completed|January 2011|February 2014|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|21 Years|45 Years|No|||June 2015|July 22, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294332||109179|
NCT01294618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-560|Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia|"Phase II Multicenter Study Evaluating the Efficacy and the Safety of a Combination of Nilotinib Plus Pegylated Interferon Alpha 2a for de Novo Chronic Phase Chronic Myelogenous Leukemia Patients"|NILOPEG|Hospices Civils de Lyon|Yes|Completed|March 2011|September 2013|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2011|August 25, 2014|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01294618||109157|
NCT01287195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001448|Oral OKT3 for the Treatment of Active Ulcerative Colitis|Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis||Brigham and Women's Hospital|Yes|Active, not recruiting|February 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|65 Years|No|||May 2013|May 9, 2013|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287195||109725|
NCT01283633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robotics-Neuromod-Mendez|Investigation of the Use of Remote Presence Robots in Delivery of Neuromodulation|Investigation of the Use of Remote Presence Robots in the Administration of Neuromodulation Treatment||Nova Scotia Health Authority|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||March 2012|March 9, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01283633||109998|
NCT01285635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2010.031|A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck|A Phase II of AT-101 in Combination With Docetaxel in Patients With Recurrent, Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||University of Michigan Cancer Center|Yes|Terminated|June 2010|January 2016|Anticipated|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|January 20, 2011|Yes|Yes|drug is no longer manufactured|No|January 20, 2015|https://clinicaltrials.gov/show/NCT01285635||109845|
NCT01285648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROCETO130682|Study of CPAP as Intervention After Lung Resection|APPLICATION OF CONTINUOUS POSITIVE AIRWAY PRESSURE IN POSTOPERATIVE OF LUNG RESECTION|CPAP|University of Campinas, Brazil|Yes|Completed|November 2007|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|75 Years|No|||January 2011|January 26, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01285648||109844|
NCT01284790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00439-30|Pitch and Loudness Perception by Cochlear Implant Listeners: Psychophysics and Objective Measures|Pitch and Loudness Perception by Cochlear Implant Listeners: Psychophysics and Objective Measures||Assistance Publique Hopitaux De Marseille|No|Terminated|January 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01284790||109909|
NCT01284803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00648-31|Feasibility and Acceptability of an Educational Intervention to Improve the Management of Depression in Primary Care.|Feasibility and Acceptability of an Educational Intervention to Improve the Management of Depression in Primary Care||Assistance Publique Hopitaux De Marseille|No|Completed|November 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|18 Years|65 Years|No|||April 2015|April 20, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284803||109908|
NCT01284218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-609|Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)|Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||5|Actual|23514|||Both|18 Years|N/A|No|Non-Probability Sample|Commercial health plan members|November 2013|November 7, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284218||109953|
NCT01284231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP216|A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas|A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas||MedImmune LLC|No|Completed|December 2010|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|78|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01284231||109952|
NCT01263652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpinePainIMPO|Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients|The Relationship Between Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients||Western Galilee Hospital-Nahariya|No|Not yet recruiting|December 2010|December 2013|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|15 Years|N/A|No|||November 2010|December 16, 2010|October 6, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01263652||111532|
NCT01263665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBL 10-04|Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis|Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface to Treat de Novo and/or Restenotic Lesions of the Superficial Femoral Artery (SFA)||W.L.Gore & Associates|No|Completed|December 2010|November 2015|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|21 Years|N/A|No|||November 2015|November 18, 2015|December 8, 2010|Yes|Yes||No|January 13, 2014|https://clinicaltrials.gov/show/NCT01263665||111531|
NCT01263678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22508|Helping Patients With Spinal Stenosis Make a Treatment Decision: A Randomized Study Assessing The Benefits of Health Coaching||SST HCoach RCT|Dartmouth-Hitchcock Medical Center|No|Completed|November 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|199|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01263678||111530|
NCT01263626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCD 1-2|Cough Monitoring Study|Monitoring Cough Device - Step 1 and 2||Vanderbilt University|No|Completed|November 2010|December 2014|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who present to the ENT or GI clinics at Vanderbilt Medical Center with a chief        complaint of chronic cough will be eligible for participation in this study. Patients who        meet eligibility requirements will be able to participate regardless of sex, social        status, or ethnicity.|June 2015|June 5, 2015|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01263626||111534|
NCT01292174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMB-108|Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers|A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Ibalizumab in HIV-Negative, At-Risk Volunteers|TMB-108|TaiMed Biologics Inc.|Yes|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|February 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01292174||109345|
NCT01292395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03|Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency|The Musculoskeletal Response to Energy Deficit: Defining Optimal Protein Intake||United States Army Research Institute of Environmental Medicine|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01292395||109328|
NCT01292408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201004|Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients|Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients:a Pilot Study||Radboud University|Yes|Recruiting|January 2011|||January 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||January 2012|January 19, 2012|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01292408||109327|
NCT01292421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 124207|Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination|Pilot Study Testing the Immunogenic Efficacy of an Edible Vaccine for Hepatitis B in Healthy Volunteers||Roswell Park Cancer Institute|Yes|Withdrawn|February 2013|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|February 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01292421||109326|
NCT01292655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA216-001|Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors|Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors||Bristol-Myers Squibb|No|Active, not recruiting|March 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|110|||Both|18 Years|N/A|No|||December 2015|February 25, 2016|January 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01292655||109308|
NCT01292889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seasonality605|Study of Genes in Relation to Seasonal Affective Disorder and Major Depressive Disorder|Gene Polymorphisms in Mood Disorders|Season605|University of Pittsburgh|No|Completed|October 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|30|Samples With DNA|Saliva samples for DNA collection|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|community sample|January 2016|January 5, 2016|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292889||109290|
NCT01293474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDI-OCT|Choroidal Thickness in Glaucoma Patients and Healthy Controls|||University of Zurich||Enrolling by invitation|February 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients and controls are selected out of our primary care clinic|December 2014|January 5, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293474||109245|
NCT01293487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1151001|Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.|A Phase I Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of RN564 In Women With Osteopenia And In Healthy Men||Pfizer|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|68|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01293487||109244|
NCT01287429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-UTurin-001|Lung Ultrasound for Acute Dyspnea in Emergency Department|Lung Ultrasound for Acute Dyspnea in Emergency Department - Prospective Multicenter Study on Accuracy, Reproducibility, and Diagnostic Impact of Lung Ultrasound in the Evaluation of Patients With Dyspnea in the Emergency Department||University of Turin, Italy|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1005|||Both|18 Years|N/A|No|Probability Sample|Hospital Emergency Departments sample|October 2010|November 19, 2012|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287429||109707|
NCT01286844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112361|GSK2190915 Pediatric Study|An Open Label, Dose Escalation Study to Examine the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of Single and Repeat Oral Doses of GSK2190915 in Children Aged From 1 to 11 Years With Asthma||GlaxoSmithKline|No|Withdrawn|November 2010|May 2011|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|11 Years|No|||April 2015|April 15, 2015|October 7, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286844||109752|
NCT01287182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP2912011|Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis|Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis||Omicron Pharmaceuticals|Yes|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 18, 2013|January 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287182||109726|
NCT01287221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003108|Study of Rifampicin in Multiple System Atrophy|Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy|MSA|Mayo Clinic|Yes|Terminated|March 2011|January 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|30 Years|80 Years|No|||February 2014|February 11, 2014|January 28, 2011|Yes|Yes|DSMB recommended stopping the study after an interim analysis of the primary endpoint revealed    that futility criteria were met.|No|July 2, 2013|https://clinicaltrials.gov/show/NCT01287221||109723|The study was terminated early; the Data Safety and Monitoring Board recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met.
NCT01283308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00016503|A Randomized Trial of Diabetes Prevention Through Lifestyle Change in India|The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India|D-CLIP|Emory University|No|Active, not recruiting|May 2009|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|599|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283308||110023|
NCT01283321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00036062|RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery|RiaSTAP vs. Conventional Transfusion for Patients Undergoing Valve Replacement Surgery: RiaCT|RiaCT|Emory University|Yes|Terminated|January 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|85 Years|No|||January 2015|February 2, 2015|January 24, 2011|Yes|Yes|Insufficient funding to complete total projected enrollment|No|January 20, 2015|https://clinicaltrials.gov/show/NCT01283321||110022|Early termination leading to small number of subjects analyzed
NCT01283334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00040298|A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer|A Phase I/IIB Study of Combination Weekly Carboplatin, Cetuximab and Dose Escalation of RAD001 in Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Emory University|Yes|Completed|January 2011|November 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|January 24, 2011|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01283334||110021|Limitations of this analysis include the small sample size in this phase 1b study, a patient population with mixed primary sites of disease, and variable doses of everolimus.
NCT01283984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3060C00001|AZD2115 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD2115 After Single Ascending Doses in Healthy Male Subjects||AstraZeneca||Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|96|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 17, 2011|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283984||109971|
NCT01283997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0022|Prevention of Treatment Induced Neuropathy in Multiple Myeloma|A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2011|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283997||109970|
NCT01285882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG/10/89|Representations of Transplantation in Patients and in Health Care Professionals|Representations of Transplantation in Patients With Mucoviscidosis, in Their Assistants and in Their Medical Persons||Nantes University Hospital|No|Completed|June 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients for whom a lung transplant indication is established|April 2015|April 14, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285882||109826|
NCT01285063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mc01162010ctil|Intervention Study for Overweight and Obese Kindergarten Children|Combined Physical Activity and Diet Intervention for the Treatment of Overweight and Obesity in Kindergarten Children||Meir Medical Center|No|Withdrawn|January 2013|February 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|4 Years|6 Years|No|||February 2013|February 20, 2013|December 7, 2010||No|We were not successful in raising money for this project|No||https://clinicaltrials.gov/show/NCT01285063||109888|
NCT01285336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IRB-309-1|The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis|The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis.||China Medical University Hospital||Completed|August 2010|||||N/A|Interventional|Primary Purpose: Health Services Research|1||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 27, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285336||109868|
NCT01264887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF5503/52|Tapentadol in Chronic Malignant Tumour Related Pain|Open-label, Single-arm, Flexible Dosing, Phase III Trial, With Oral Tapentadol Prolonged Release (PR) in Subjects With Chronic Malignant Tumor-related Pain Who Have Completed the Maintenance Period of the KF5503/15 Trial.||Grünenthal GmbH|No|Terminated|March 2011|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|December 16, 2010||No|Administrative reasons|No|April 30, 2015|https://clinicaltrials.gov/show/NCT01264887||111438|The trial was stopped for administrative reasons. Three years after trial initiation 2 participants were in the trial and to permit analysis and reporting the sponsor decided to terminate the trial.
NCT01263938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol #: 812196|Modulation of Monocyte Activation by Atorvastatin in HIV Infection|Pilot Study to Evaluate Effects of Atorvastatin on Monocyte Activation in HAART-treated HIV Infected Individuals||University of Pennsylvania|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|December 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263938||111511|
NCT01263951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 19309|Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone|A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|November 2010|||November 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|89 Years|No|||December 2015|December 14, 2015|November 29, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01263951||111510|
NCT01291888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00034784|Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease|Efficacy and Tolerability of Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease: A Single-center Randomized Trial.||University of Michigan|No|Completed|March 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|A total of 30 ml blood (CBC with differential and platelets-3ml, comprehensive panel-5-7ml,      biomarkers-20ml) will be drawn by venipuncture typically from the antecubital vein at      baseline visit (30ml), and week 6-study midpoint (30ml) and end of study (30ml). At the      screening visit only 10ml blood will be required (CBC and Comprehensive Panel).|Both|18 Years|85 Years|No|Probability Sample|A total of 50 patients with CKD meeting the inclusion and exclusion criteria listed below        will after informed consent be randomized to either nebivolol or sustained release        metoprolol succinate and followed for 3 months or early termination of the study.|August 2015|August 4, 2015|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01291888||109367|
NCT01292187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-01-201|A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis|A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture||Tarsa Therapeutics, Inc.|No|Completed|January 2011|July 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|129|||Female|45 Years|N/A|No|||September 2014|September 5, 2014|February 7, 2011|Yes|Yes||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01292187||109344|
NCT01292434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LitB-UT-01|Lunch is in the Bag: Helping Parents Increase Fruit, Vegetables, and Whole Grains in Preschool Sack Lunches|Lunch in the Bag: Packing More Fruit, Vegetables, Grain in Preschool Sack Lunches|LIITB|The University of Texas Health Science Center, Houston|Yes|Completed|June 2008|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1266|||Both|3 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01292434||109325|
NCT01286558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.37|Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg Plus Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination in Patients With Hypertension||Boehringer Ingelheim||Completed|January 2011|||September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|225|||Both|20 Years|N/A||||January 2014|June 17, 2014|January 28, 2011||||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01286558||109774|
NCT01286571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1283.3|Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food|Bioavailability and Pharmacokinetics of 50 mg BI 135585 XX Administered as Tablet With and Without Food to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)||Boehringer Ingelheim||Completed|January 2011|||March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|January 28, 2011||||No||https://clinicaltrials.gov/show/NCT01286571||109773|
NCT01286857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMP 01|An Investigation to Evaluate the Function of a New Silicon Cover Film and an On-top Suction Device to be Used in a NPWT System in the Treatment of Acute and Chronic Wounds|A Prospective, Open, Non-controlled Proof-of-concept Investigation to Evaluate the Function of a New Silicon Cover Film and an On-top Suction Device to be Used in a NPWT System in the Treatment of Acute and Chronic Wounds||Molnlycke Health Care AB|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2011|July 15, 2011|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01286857||109751|
NCT01286064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-D178768|Colorectal Cancer Detection by Means of Optical Fluoroscopy|Role of Natural Fluorescence of Human Blood Plasma in Patients With Colorectal Cancer.||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Recruiting|October 2010|April 2011|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Anticipated|200|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2010|January 28, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01286064||109812|
NCT01286584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144/2010-02|Varenicline in Drug Treatment|Smoking Cessation in a Drug Treatment Program: A Randomized Trial of Varenicline Versus Placebo.|ViRT|Centre for Addiction and Mental Health|No|Completed|June 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||February 2015|February 3, 2015|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01286584||109772|
NCT01287442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TE-WBCS-IOP|Evaluation of Filtering Blebs Using the "Wuerzburg Bleb Classification Score" Compared to Other Clinical Findings, e.g. the Intraocular Pressure (IOP)|||University of Zurich||Completed|January 2009|December 2010||||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Diagnosis of glaucoma, status post trabeculectomy|November 2011|November 3, 2011|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287442||109706|
NCT01283347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-2160A|18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging|Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging|8F-DTBZ|Chang Gung Memorial Hospital|Yes|Completed|May 2010|December 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||December 2012|December 25, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01283347||110020|
NCT01283074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22016|An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)|Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)||Hoffmann-La Roche||Completed|May 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis B on treatment with Pegasys|March 2016|March 1, 2016|January 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01283074||110041|
NCT01283087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400229|Spinal Anesthesia Using Lidocaine and Sufentanil and (Transient Neurological Symptoms) TNS|Spinal Anesthesia Using Lidocaine and Sufentanil and TNS (=Transient Neurological Symptoms)||Vestre Viken Ringerike Sykehus|No|Recruiting|January 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|19 Years|N/A|No|Probability Sample|Patients who are submitted for surgery at a local hospital and where spinal anesthesia is        indicated.|July 2015|July 3, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283087||110040|
NCT01284244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100131A|A Randomized Controlled Trial of the Uresta Continence Pessary|A Randomized Controlled Trial of the Uresta Continence Pessary; Short-term Uresta Efficacy Study (SURE Study)|SURE|Mount Sinai Hospital, Canada|No|Recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|N/A|No|||August 2011|August 2, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284244||109951|
NCT01285349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA6653|HIV/STI Prevention for Drug-Involved Couples|HIV/STI Prevention for Drug-Involved Couples|Connect II|Columbia University|No|Completed|November 2005|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|564|||Both|18 Years|40 Years|No|||January 2011|January 26, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01285349||109867|
NCT01285362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF0695|Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study|Fish Oil for the Treatment of Nonalcoholic Fatty Liver Disease in Children||Columbia University|No|Completed|March 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|12 Years|18 Years|No|||March 2015|March 5, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285362||109866|
NCT01285661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001P|Optimal Duration of Anticoagulation in Deep Venous Thrombosis|Identification of the Optimal Duration of Anticoagulation in Patients With Deep Venous Thrombosis of the Lower Extremities With the Use of Residual Vein Thrombosis in Combination With D-Dimer|MORGAGNI|University of Padova|Yes|Recruiting|March 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1250|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01285661||109843|
NCT01286129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP-2005-3|Nasal Allergen Challenge in Rhinitic Subjects|Comparative Responses to Nasal Allergen Challenge in Allergic Rhinitic Subjects With or Without Asthma||Laval University|No|Completed|November 2005|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|45 Years|No|||May 2013|May 24, 2013|January 13, 2011||No||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01286129||109807|
NCT01263964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/118/10|Troponin Elevation in Acute Ischemic Stroke (TRELAS)|Troponin Elevation in Acute Ischemic Stroke (TRELAS) - a Prospective Study on the Frequency and Correlation to Coronary Artery Disease and to Stroke Localisation|TRELAS|Charite University, Berlin, Germany|No|Completed|February 2011|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|Samples Without DNA|Biomarkers indicating myocardial or neuronal damage|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted because acute ischemic stroke and additional troponin-elevation(cases)        or non-stemi (controlls)|July 2014|July 18, 2014|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01263964||111509|
NCT01291901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP2/P2/10/2|NP2 Enkephalin For Treatment of Intractable Cancer Pain|A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy||Diamyd Inc|No|Completed|January 2011|November 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|February 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01291901||109366|
NCT01291914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX005-2010-001|Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized,Placebo-Controlled, Two-Phase Study (a Single Ascending Dose Phase Followed by a Proof of Concept Phase) to Assess the Safety, Efficacy and Pharmacokinetics of FX005 for the Treatment of Pain in Osteoarthritis of the Knee||Flexion Therapeutics, Inc.|Yes|Completed|December 2010|March 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|140|||Both|40 Years|N/A|No|||February 2013|February 22, 2013|February 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01291914||109365|
NCT01292200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-185|Breast Health in Chinese American Women|A RCT to Promote Mammography Adherence Among Chinese Immigrant Women||Georgetown University|No|Active, not recruiting|July 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|954|||Female|42 Years|N/A|No|||March 2015|March 25, 2015|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01292200||109343|
NCT01286077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016270|Velcade Consolidation Bone Study|A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease||Janssen-Cilag International NV|No|Completed|September 2009|April 2014|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|January 27, 2011|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01286077||109811|
NCT01285245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34377.091.10|Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus|Effect of Interleukin-1 Receptor Antagonist on Insulin Sensitivity in Type 1 Diabetes Mellitus.||Radboud University|No|Recruiting|April 2011|December 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|65 Years|No|||November 2010|April 13, 2011|November 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01285245||109875|
NCT01285258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-13|Emergency Peripartum Hysterectomy: A Prospective Study in Iran|Study of Peripartum Hysterectomy for Maternal Hemorrhage||Isfahan University of Medical Sciences|Yes|Completed|March 2004|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|41|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2004|January 26, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285258||109874|
NCT01285544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipinon Study|The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia|Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial||Seoul National University Hospital|Yes|Completed|September 2008|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|289|||Both|20 Years|79 Years|No|||December 2013|December 15, 2013|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01285544||109852|
NCT01286103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017824|A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers|An Open-Label, Multiple-Dose Study to Assess the Steady-State Pharmacokinetics, Pharmacodynamics and Safety of Once-Daily Versus Twice-Daily Dosing With Canagliflozin in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2011|May 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|January 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01286103||109809|
NCT01286337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ligasure|Axillary Lymphadenectomy. A Randomized Trial Comparing Bipolar Vessel Sealing To Conventional Technique|Axillary Lymphadenectomy. A Randomized Trial Comparing Bipolar Vessel Sealing To Conventional Technique||University of Milano Bicocca|No|Completed|April 2009|January 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Female|18 Years|80 Years|No|||August 2010|January 28, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01286337||109791|
NCT01286870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222CA-1208-01|Becker Continued Access Study|Continued Access Study of the Mentor Becker Expander/Breast Implant||Mentor Worldwide, LLC|No|Terminated|June 2009|November 2020|Anticipated|November 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||October 2015|October 26, 2015|January 27, 2011|No|Yes|Sponsor terminated|No||https://clinicaltrials.gov/show/NCT01286870||109750|
NCT01287208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001271|Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents|Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents||Massachusetts General Hospital|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|104|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 31, 2012|January 28, 2011||No||No|October 31, 2012|https://clinicaltrials.gov/show/NCT01287208||109724|One limitation is that wearing the activity monitor, even a blinded monitor, may have prompted residents to increase their steps. This may have decreased the ability to see a large difference between the intervention and control groups.
NCT01286909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP912011|Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)|Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)|LaFlavon|Omicron Pharmaceuticals|Yes|Recruiting|January 2011|June 2011|Anticipated|June 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|45 Years|75 Years|No|||February 2011|February 9, 2011|January 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286909||109747|
NCT01286922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC29018|The Insulin Sensitivity Using Aerobic Interval Conditioning|The Insulin Sensitivity Using Aerobic Interval Conditioning|ISAIC|Pennington Biomedical Research Center|Yes|Completed|July 2009|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01286922||109746|
NCT01286883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 10-066|Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells|Prevalence of Stem Cell and Prognostic Markers in Circulating Tumor Cells of Patients With Metastatic Colorectal Cancer Undergoing Chemotherapy||Milton S. Hershey Medical Center|Yes|Recruiting|February 2011|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood will be drawn at 7 different time intervals to analyze CSC and other prognostic      markers on circulating tumor cells.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic colorectal cancer|January 2014|January 3, 2014|January 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01286883||109749|
NCT01286896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10PKS|Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors|Use of Individual PK-guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors||The Netherlands Cancer Institute|No|Recruiting|March 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01286896||109748|
NCT01284543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-10-0631-B|Study Comparing Tan EndoGlide With the Busin Glide for Insertion of the Donor Graft in DSAEK|Randomized Prospective Study Comparing Tan EndoGlide With the Busin Glide for Insertion of the Donor Graft in Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)||University Health Network, Toronto||Recruiting|January 2011|||January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||January 2011|January 25, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01284543||109928|
NCT01284556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGG-901|Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures|An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Phenobarbital as Adjunctive Therapy in Participants (> or = 17 to 70 Years Old) With Partial Onset Seizures||West-Ward Pharmaceutical|Yes|Active, not recruiting|November 2010|October 2014|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|345|||Both|17 Years|70 Years|No|||May 2014|May 27, 2014|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01284556||109927|
NCT01283659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project I-C|IMAGE-HF Project I-C: Computed Tomographic Coronary Angiography for Heart Failure Patients|Computed Tomographic Coronary Angiography for Heart Failure Patients (CTA -HF) Project I-C of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)|CTA-HF|Ottawa Heart Institute Research Corporation|Yes|Recruiting|February 2011|June 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01283659||109996|
NCT01283672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS33|Acute Heart Health Benefits of Whole Grain Barley and Oats in Healthy Men and Women|||USDA Beltsville Human Nutrition Research Center|Yes|Completed|January 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|||Anticipated|18|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||July 2011|July 15, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01283672||109995|
NCT01285076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-401|Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)|Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects (NEEDS Study)|NEEDS|Merck Sharp & Dohme Corp.|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|834|||Both|30 Years|N/A|No|Non-Probability Sample|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU +        MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist,        or family practice doctor.|January 2015|January 29, 2015|January 26, 2011||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01285076||109887|
NCT01293890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201110500|Adherence to Medication and Its Impact on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: The AMICE Prospective Study|Adherence to Medication and Its Impact on COPD Exacerbations: The AMICE Prospective Study|AMICE|Katholieke Universiteit Leuven|No|Recruiting|March 2011|||September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood urine|Both|40 Years|N/A|No|Non-Probability Sample|patients that are admitted to the Pneumology of Geriatry Service of UZ Leuven after        entering the emercency ward with a COPD exacerbation|July 2013|July 29, 2013|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01293890||109213|
NCT01294189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOLD|Advance Directives and End-of-life Decision Making in Intensive Care Medicine in Germany|The Impact of Instituting a Law for Advance Directives on End-of-life Decision Making in Intensive Care Medicine in Germany||Charite University, Berlin, Germany||Completed|August 2008|February 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|224|||Both|N/A|N/A|No|Probability Sample|All intensive care department patients (MAN101i and MAN103i Charité Berlin) will be        enrolled in the study|January 2011|February 10, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294189||109190|
NCT01294176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00005634|Lipoic Acid as a Treatment for Acute Optic Neuritis|Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study||Oregon Health and Science University|Yes|Recruiting|January 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|August 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01294176||109191|
NCT01285895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG/10/90|Needs in Education for Pulmonary or Cardiopulmonary Transplanted Cystic Fibrosis Patients|Assessing of the Educational Needs of Patients Who Received a Lung Transplantation or a Simultaneous Heart-lung Transplantation for Mucoviscidosis||Nantes University Hospital|No|Completed|September 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who received a lung transplantation or a simultaeous heart-lung transplantation        for mucoviscidosis|April 2015|April 14, 2015|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285895||109825|
NCT01285908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110085|Intravenous Norepinephrine for Orthostatic Hypotension|Safety and Efficacy of Intravenous Norepinephrine for Orthostatic Hypotension||National Institutes of Health Clinical Center (CC)|Yes|Completed|January 2011|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|January 25, 2011||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01285908||109824|
NCT01264276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007554|Telemedicine Approaches to Evaluating Acute-phase ROP|Telemedicine Approaches to Evaluating Acute-phase ROP|e-ROP|Children's Hospital of Philadelphia|Yes|Completed|July 2011|January 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|269|||Both|32 Weeks|40 Weeks|No|Probability Sample|Babies with birth weighs of <1251g at selected large clinical centers in the US|February 2015|February 3, 2015|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264276||111485|
NCT01265173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCCSBP|Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis|Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis||Korea University|Yes|Recruiting|April 2007|April 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|261|||Both|16 Years|70 Years|No|||April 2014|April 8, 2014|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01265173||111416|
NCT01284738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00198-31|Beta-thalassemia and Microparticles|Beta-thalassemia and Microparticles||Assistance Publique Hopitaux De Marseille|No|Completed|March 2010|||February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|33|||Both|15 Years|N/A|No|||August 2014|August 28, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284738||109913|
NCT01284998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-07|Short Term Follow-up of Patent Implanted With the B-BOP Lock Plate|Short Term Follow-up of Patent Implanted With the B-BOP Lock Plate||Integra LifeSciences Services|No|Completed|June 2009|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|85|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who need a fixation of osteotomy of the basis of the first metatarsal.|September 2014|September 10, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284998||109893|
NCT01285843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01.004.14|Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component|Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component.||Medacta International SA||Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||July 2011|September 9, 2014|January 26, 2011||No||No|August 27, 2014|https://clinicaltrials.gov/show/NCT01285843||109829|
NCT01285609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-104|Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin|Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)||Bristol-Myers Squibb|No|Active, not recruiting|January 2011|December 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|920|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285609||109847|
NCT01286090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003946|An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus|Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|July 2003|October 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|70 Years|No|||January 2011|January 27, 2011|January 13, 2011|Yes|Yes|Sponsor request|No||https://clinicaltrials.gov/show/NCT01286090||109810|
NCT01283113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS # 2010-01|Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method|Evaluation of Intra-Abdominal Fat Contents in Patients With Type 2 Diabetes Using a Novel Non-Invasive Method of Bioelectric Impedance||Joslin Diabetes Center|No|Enrolling by invitation|August 2010|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Both|18 Years|80 Years|No|Non-Probability Sample|The investigators will identify and recruit 500 patients. Participants for this study (men        and women) will be recruited for the diabetes outpatient clinic of the Joslin Diabetes        Center. Subjects from minority and various ethnic/racial groups will be invited to        participate in the study at the same proportional to Massachusetts's population, which is        86.5% white, 6.9 Black, 0.3% American Indian and Alaska, 4.9 Asian, 0.1% Native Hawaiian        and Other Pacific Islander and 8.2% of Hispanic or Latino origin. The investigators will        monitor our recruitment by gender and race/ethnicity and modify our recruitment procedures        if necessary to ensure that there is no selection bias due to these factors.|February 2016|February 22, 2016|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01283113||110038|
NCT01284010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-21001|Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia|Genome-Wide Analysis of Genetic Alterations in Adult Acute Lymphoblastic Leukemia||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|February 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|16 Years|N/A|No|Non-Probability Sample|Acute lymphoblastic leukemia (ALL) patients treated on protocols CALGB 9511, 19802, 10001,        10102, and 10403, and who have been registered on the companion study CALGB 9665 (The        CALGB Leukemia Tissue Bank)|July 2015|July 23, 2015|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284010||109969|
NCT01287234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SonR Pilot|Atrio-Ventricular (AV) Delay Optimization Using Echocardiography Versus the SonR Signal|Atrio-Ventricular Delay Optimization in Patients Implanted With a Cardiac Resynchronization Device Using Echocardiography Versus the SonR Signal: A Pilot Study|SonR Pilot|Piedmont Healthcare|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287234||109722|
NCT01283100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114122|A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.|A Phase 1, Open Label, Single Sequence, Two-Way Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1379572 Pharmacokinetics in Healthy Adult Subjects||ViiV Healthcare|No|Withdrawn|March 2011|June 2011|Anticipated|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 22, 2014|January 6, 2011|No|Yes|In a Phase II study in HIV-infected patients there were a number of seizures, although exact    causality could not be assessed phase 1 activity was terminated.|No||https://clinicaltrials.gov/show/NCT01283100||110039|
NCT01284829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00705-34|Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Diagnosis of Indeterminate Adrenal Tumors on Conventional Imaging: A French Prospective Multicentric Study|Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Diagnosis of Indeterminate Adrenal Tumors on Conventional Imaging: A French Prospective Multicentric Study||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|February 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|165|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01284829||109906|
NCT01284816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00696-33|Impact of Bariatric Surgery on Epicardial Adipose Tissue and on Myocardial Function|Impact of Bariatric Surgery on Epicardial Adipose Tissue and on Myocardial Function||Assistance Publique Hopitaux De Marseille|No|Completed|September 2010|||July 2015|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|44|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01284816||109907|
NCT01285089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3856|Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia|Prospective French Study on ACQUIred Haemophilia Treatment With Recombinant Factor VIIa (NovoSeven®) A Prospective Observational Study on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for the Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia|ACQUI-7|Novo Nordisk A/S|No|Completed|December 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|N/A|N/A|No|Non-Probability Sample|Any patient diagnosed with acquired haemophilia and treated with at least one injection of        activated recombinant human factor VII can be included in the study. The treatment will be        performed according the local practice.|January 2014|January 29, 2014|January 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01285089||109886|
NCT01293630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11270|A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors|An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Paclitaxel and Carboplatin Every 3 Weeks in Patients With Advanced Solid Tumors||Sanofi|No|Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|75 Years|No|||October 2015|October 29, 2015|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01293630||109233|
NCT01293643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08077|A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)|A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated||Merck Sharp & Dohme Corp.|No|Completed|May 2010|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Female|18 Years|45 Years|No|||August 2015|August 7, 2015|February 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01293643||109232|
NCT01294488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-5085|Using Technology to Augment the Implementation and Effectiveness of PCIT|Using Technology to Augment the Implementation and Effectiveness of PCIT||Centers for Disease Control and Prevention|Yes|Completed|January 2007|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|317|||Both|20 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 7, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294488||109167|
NCT01294813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bronchoscopy- EIT|Bronchoscopy and Electric Impedance Tomography (EIT) Pilot Study|Bronchoscopy and Electric Impedance Tomography to Investigate the Influence of Bronchoscopy on Pulmonary Regional Ventilation Measurements by Electric Impedance Tomography (EIT)|Broncho-EIT|RWTH Aachen University|No|Recruiting|January 2011|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2011|February 15, 2011|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294813||109142|
NCT01294462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00027|Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)|A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned||AstraZeneca|No|Completed|February 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|801|||Both|20 Years|N/A|No|||May 2014|June 18, 2014|February 10, 2011|Yes|Yes||No|July 10, 2013|https://clinicaltrials.gov/show/NCT01294462||109169|
NCT01294475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-5054|Preventing Child Maltreatment Through A Cellular-Phone Technology-Based Parenting Program|Preventing Child Maltreatment Through A Cellular-Phone Technology-Based Parenting Program||Centers for Disease Control and Prevention|Yes|Completed|May 2007|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|371|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 7, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294475||109168|
NCT01264289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10640609|Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions|A Randomized, Single-dose, Two-treatment, Two-way, Crossover Bioequivalence Study of Finasteride 5 mg Tablets (Dr. Reddy's Laboratories Limited) With the Reference Formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.) Under Fasting Conditions in Healthy Adult Male Subjects.||Dr. Reddy's Laboratories Limited|No|Completed|November 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||December 2006|December 20, 2010|December 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01264289||111484|
NCT01264562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKH 109132|Cognition in Breast Cancer Patients: The Impact of Cancer-related Stress|Cognition in Breast Cancer Patients: The Impact of Cancer-related Stress|Cognicares|Ludwig-Maximilians - University of Munich|No|Completed|January 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|254|Samples Without DNA|Saliva|Female|18 Years|65 Years|No|Probability Sample|Patients of the Ludwig Maximilian University of Munich Breast Cancer Center; Klinikum        Landshut Department of Obstetrics and Gynecology and Breast Cancer Services; Kreisklinik        Ebersberg Department of Gynecology and Obstetrics; Klinikum Dritter Orden Department of        Gynecology and Obstetrics; Rotkreuzklinikum Muenchen Department of Gynecology and        Obstetrics, Helios Amper Hospital Dachau, Department of Gynecology and Obstetrics|April 2015|April 18, 2015|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264562||111463|
NCT01285557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-S1303|Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial|An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy|DIGEST|Taiho Oncology, Inc.|Yes|Active, not recruiting|February 2011|May 2016|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285557||109851|
NCT01285830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGB 99/02|Primary Prevention of Allergic Disease in Early Child by Lactobacillus Reuteri|Primary Prevention of Allergic Disease in Early Child by Lactobacillus Reuteri||Linkoeping University|No|Completed|February 2001|May 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|232|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|March 19, 2014|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01285830||109830|
NCT01285570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-101-CL-P007|Ulimorelin Study of Efficacy and Safety (ULISES 007)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection|ULISES|Tranzyme, Inc.||Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|332|||Both|18 Years|80 Years|No|||July 2012|July 25, 2012|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285570||109850|
NCT01286935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW-1015/018/III/2006|18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD|A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic||Newron|Yes|Completed|August 2007|August 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|544|||Both|30 Years|80 Years|No|||January 2011|January 28, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01286935||109745|
NCT01286948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol # 441|Prevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG|A Randomized, Cross-over, Clinical Trial to Assess the Prevention of Ovulation Achieved by Single Intra-vaginal Administration of 0.75 mg Levonorgestrel (LNG) Gel (Levogel) as Compared to 1.5 mg Oral LNG||Population Council|Yes|Completed|January 2011|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|20|||Female|21 Years|39 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01286948||109744|
NCT01285856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00256-33|Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications|Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications||Assistance Publique Hopitaux De Marseille|No|Recruiting|August 2010|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|220|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|July 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01285856||109828|
NCT01286324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101,749|Chamomile for Chronic Primary Insomnia|A Pilot Grant to Examine the Feasibility, Efficacy and Tolerability of a Standardized Chamomile Extract in Treating Chronic Primary Insomnia||University of Michigan|No|Completed|July 2008|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|64 Years|No|||June 2013|June 24, 2013|January 24, 2011|No|Yes||No|January 21, 2013|https://clinicaltrials.gov/show/NCT01286324||109792|Used subjective sleep measures. We did not assess the characteristics of participants' sleep difficulties and these sleep issues may be important considering the age-range of individuals included in the study
NCT01284270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hawaii|Lipid Rich Necrotic Core Lesion Detected by Cardiac Magnetic Resonance Imaging (CMR)|High Amount of Lipid Rich Necrotic Core Lesion Identified by Pre-interventional Intravascular Ultrasound (IVUS) is Associated With High Rate of Delayed Hyper-enhancement as Detected by Contrast-enhanced Cardiac Magnetic Resonance Imaging|Hawaii|Piedmont Healthcare|No|Withdrawn|January 2011|||January 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|No|||June 2011|September 4, 2013|January 21, 2011||No|Study not to be initiated|No||https://clinicaltrials.gov/show/NCT01284270||109949|
NCT01284283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR 2 Year|2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use|2-Year Post-Approval Study to Investigate the STAR Ankle Under Actual Conditions of Use|STAR|Stryker Trauma GmbH|No|Recruiting|November 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|98|||Both|18 Years|85 Years|No|||July 2015|July 10, 2015|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01284283||109948|
NCT01284569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-0061-1.1/10|Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients|A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA||Ablynx|Yes|Completed|March 2011|||October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|80 Years|No|||December 2012|February 26, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01284569||109926|
NCT01284257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AUS40|Observational Registry Study of Renal Transplant Patients|A Phase IV, Non-interventional, Multi-center, Open-label, Prospective, Observational Study of the Safety, Effectiveness, Tolerability and Compliance of Immunosuppressive Regimens Using Mycophenolic Acid to Treat de Novo Renal Transplant Patients in Routine Clinical Practice|MORE registry|Novartis|No|Suspended|June 2007|||May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|947|||Both|18 Years|N/A|No|Probability Sample|This study will enroll approximately 1,200 de novo (newly transplanted within 2 weeks)        renal transplant patients from approximately 30-60 transplant centers across the United        States. Patients should be consented prior to the first dose of MPA, +/- 14 days from the        date of the transplant and be enrolled as soon as feasible after transplantation but not        later than 2 weeks post-transplantation. Enrollment targets will be capped globally at 800        patients being treated with myfortic® and 400 patients being treated with CellCept®.|January 2011|January 26, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284257||109950|
NCT01284582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF007|Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)|Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP), in Healthy Male Subjects With High Density Lipoprotein Cholesterol (HDLc) Blood Concentrations Equal or Below 80 mg/dl||Affiris AG|Yes|Completed|May 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 4, 2012|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01284582||109925|
NCT01293019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 080701|Osteopathic Treatment in Adult Patients With Cystic Fibrosis|Impact of an Osteopathic Manipulative Treatment on Pain of Adult Patients With Cystic Fibrosis - a Pilot Study|MUCOSTEO|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2009|December 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293019||109280|
NCT01293032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13311|Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer|Choosing Neoadjuvant Chemotherapy Versus Hormonal Therapy for Breast Cancer Based on Gene Expression Profile||Virginia Commonwealth University|Yes|Active, not recruiting|April 2011|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|64|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|February 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01293032||109279|
NCT01293292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15466|Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action|Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action. A Two-year Open-label Single-arm Study of Teriparatide in Secondary Care|Forsteo|Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|January 2011|July 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|N/A|84 Years|No|||December 2012|December 14, 2012|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01293292||109259|
NCT01293305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGSGEO1010|Study With Chondroitin Sulfate and Glucosamine Sulfate (in Dosage Capsule and Sachet) in Treating Osteoarthritis|Randomized Evaluation Of Not Less Medical Association Chondroitin Sulfate Plus Glucosamine Sulfate (In Powder Dosage Forms And Oral Capsule), Manufactured By The Geolab Pharmaceutical Industry Ltd, Compared To The Drug Condroflex® (Powder And Oral Capsule), Manufactured In The Laboratory Zodiac, The Treatment Of Osteoarthritis.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Not yet recruiting|November 2011|December 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|320|||Both|40 Years|N/A|No|||January 2011|February 9, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01293305||109258|
NCT01293903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLQX-DCM-01|Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy|A Multi-center, Randomized, Double, Placebo-controlled, Parallel Group Study of Improving Heart Function and Immunoregulation Effects of Qiliqiangxin Capsule in Patients With Dilated Cardiomyopathy|QLQX-DCM|Huazhong University of Science and Technology|Yes|Recruiting|January 2012|June 2015|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|14 Years|70 Years|No|||September 2012|September 4, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01293903||109212|
NCT01294826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922AUS06T|Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer|Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer||Swedish Medical Center|No|Completed|February 2011|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|February 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01294826||109141|
NCT01295359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPOCexacaminhada|Impact of a Hospital Physical Therapy Program on Chronic Obstructive Pulmonary Disease (COPD) Patients|Impact of a Hospital Physical Therapy Program on Exacerbated Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial||Universidade Federal de Sao Carlos|No|Recruiting|March 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|85 Years|No|||February 2011|March 18, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295359||109100|
NCT01295645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0518|Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis|A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant||M.D. Anderson Cancer Center|Yes|Recruiting|March 2011|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|N/A|No|||December 2015|December 29, 2015|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01295645||109078|
NCT01295658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSC-MAP-0102|Cancer Experience Registry: An Online Initiative to Change the Future of Cancer Care|Cancer Experience Registry: An Online Initiative to Change the Future of Cancer Care||Cancer Support Community, Research and Training Institute, Philadelphia|No|Recruiting|March 2013|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any individual who has received a cancer diagnosis.|December 2014|December 23, 2014|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295658||109077|
NCT01295073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00165|Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus|Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus||University of British Columbia|No|Not yet recruiting|June 2014|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|19 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 28, 2014|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01295073||109122|
NCT01294072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-GI-10 Curcumin|Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue|Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue||James Graham Brown Cancer Center|Yes|Recruiting|January 2011|December 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|35|||Both|20 Years|N/A|No|||May 2014|May 28, 2014|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01294072||109199|
NCT01264575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC-2010-12-18|ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty|ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty||Seoul Medical Center|No|Completed|December 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|12||Actual|162|||Both|40 Years|80 Years|No|||January 2012|January 29, 2012|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264575||111462|
NCT01264588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPCGP-2008|The Effects of Topical Calcium Glycerophosphate on Surgical Wound Healing and Residual Scarring|A Randomized, Single Blind, Comparative, Controlled Study On The Effects Of Topical Calcium Glycerophosphate On Surgical Wound Healing And Residual Scarring In Bilateral Total Knee Arthroplasty Patients|TOPCGP-2008|AkPharma Inc.|Yes|Completed|April 2008|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|20|||Both|45 Years|75 Years|No|||December 2010|December 20, 2010|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01264588||111461|
NCT01285284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-237|Effect of Music Over the Tolerance to Colonoscopy.|The Effect of Music Over the Tolerance to Colonoscopy ¿Does it Reduce the Discomfort, the Anxiety and the Need of Sedation? Multicentric Randomized Controlled Trial.|EMOC|Pontificia Universidad Catolica de Chile|Yes|Recruiting|March 2011|October 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2011|August 8, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285284||109872|
NCT01285583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO19622 CL E Q 1425-1|Safety Extension Study of TRO19622 in ALS|An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole||Trophos|Yes|Completed|October 2010|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|271|||Both|N/A|N/A|No|||March 2013|March 29, 2013|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01285583||109849|
NCT01285596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-072|A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex|An Open-label, Randomized, 2-way Crossover Study to Evaluate the Pharmacokinetics of Mirabegron and Its Metabolites in Healthy Young and Elderly Male and Female Subjects||Astellas Pharma Inc|No|Completed|March 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 1, 2013|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01285596||109848|
NCT01285297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHX 09-003|Safety Study of Transmyocardial Revascularization (TMR) With Bone Marrow Aspirate (BMAC) for Angina Reduction|A Prospective, Multicenter, Single Arm Study of Transmyocardial Revascularization (TMR) Plus Bone Marrow Aspirate Concentrated (BMAC) Using the Cardiogenesis PHOENIX Combination Handpiece Delivery System|PHOENIX|Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.|Yes|Terminated|October 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01285297||109871|
NCT01283386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25137|A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status|Prospective Randomized Study to Compare Efficacy and Safety of RFC-lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-line Therapy in Patients With B-cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status||Hoffmann-La Roche||Active, not recruiting|April 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|60 Years|N/A|No|||February 2016|February 1, 2016|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01283386||110017|
NCT01287247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-4066-5|Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States|Prospective, Observational Trial Evaluating Xeomin®(incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States|XCiDaBLE|Merz Pharmaceuticals, LLC|No|Completed|February 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|688|||Both|18 Years|N/A|No|Probability Sample|Subjects 18 years of age or older. The physician must have chosen to treat the patient        with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study.|April 2015|April 9, 2015|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287247||109721|
NCT01283685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSI-10q2109|Breathing Helium-Hyperoxia During Exercise in Patients With Chronic Obstructive Pulmonary Disease|Does Breathing Helium-Hyperoxia Increase the Tolerance of One-Legged Exercise in Ventilatory Limited Patients With Chronic Obstructive Pulmonary Disease||West Park Healthcare Centre|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||July 2012|July 10, 2012|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01283685||109994|
NCT01283698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H553000-1005|Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis|An Investigator-blind, Controlled Study to Assess the Efficacy of Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test||Almirall, S.A.|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Anticipated|20|||Both|18 Years|75 Years|No|||May 2015|May 28, 2015|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01283698||109993|
NCT01286597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120100047|The Effects of Lactose Intolerance on Gastrointestinal Function and Symptoms in a Chinese Population|The Effects of Lactose Intolerance on Gastrointestinal Function and Symptoms in a Chinese Population||Sir Run Run Shaw Hospital|Yes|Recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Anticipated|3000|||Both|16 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 7, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01286597||109771|
NCT01292512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bereavement Management.|Bereavement Management - Description, Assessment and Care|Bereavement Management. Description, Assessment and Care. A Randomized Controlled Study.||University of Aarhus|Yes|Completed|June 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|402|||Both|18 Years|N/A|No|||March 2012|March 9, 2012|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292512||109319|
NCT01292525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/7-D|Protocol Calcineurin Inhibitor (CNI) Weaning|Prospective, Multicenter, Randomized, Double-blind, Controlled Parallel Group Study Designed to Assess the Risk-benefit Balance of the Gradual Withdrawal of a Calcineurin Inhibitor (Tacrolimus) in Renal Transplant Patients Over 4 Years and Clinically Selected||Nantes University Hospital|Yes|Terminated|May 2011|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|No|||May 2015|March 22, 2016|February 8, 2011||No|Difficulties of recruitment|No||https://clinicaltrials.gov/show/NCT01292525||109318|
NCT01292733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 4707|Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer|Ovarian Cancer Early Detection Screening Program|OCEDP|Swedish Medical Center|No|Terminated|August 2009|December 2015|Actual|December 2015|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|534|||Female|30 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 15, 2016|November 30, 2010|Yes|Yes|Closed per local IRB due to advancements in standard ovarian cancer screening.|No||https://clinicaltrials.gov/show/NCT01292733||109302|
NCT01293318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281/10|Study of Copeptin as a Diagnostic Marker for Acute Pancreatitis|Copeptin Pancreatitis Trial|COPA|University Hospital, Basel, Switzerland|No|Active, not recruiting|March 2011|April 2016|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Patients presenting to the emergency departement or in-hospital patients with acute        pancreatitis|December 2015|December 15, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293318||109257|
NCT01293331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD35|Study of Febrile Illness for Dengue-Endemic Areas in Latin America|Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Latin America||Sanofi|No|Completed|August 2010|April 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3000|||Both|9 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|Participants aged 9 to 16 years in 4 countries in Latin America: Brazil, Mexico, Colombia        and Puerto Rico|June 2015|June 16, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293331||109256|
NCT01293656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08166|Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)|Cross-sectional Study of Inflammatory Bowel Disease Severity and Treatment Patterns in Eastern Europe, Middle East, and North Africa. (P08166)||Merck Sharp & Dohme Corp.|No|Withdrawn|August 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with CD or UC who visit the study sites in Eastern Europe, Middle East, and        North Africa during the study period will be asked to participate.|June 2015|June 1, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01293656||109231|
NCT01293669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-6987-23-CRD-002|Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus|Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus||Targacept Inc.|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|September 3, 2013|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01293669||109230|
NCT01294839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-10-016-AP-LV|Right Ventricular Outflow Tract Study|Right Ventricular Outflow Tract Septal Pacing for Cardiac Dysfunction Prevention Evaluation|RVOTCARE|St. Jude Medical|Yes|Active, not recruiting|March 2011|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|380|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294839||109140|
NCT01295112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-OZAB-11-001|Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion|Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion||Texas Retina Associates|No|Recruiting|May 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 20, 2015|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01295112||109119|
NCT01295866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1129|Evaluation Effects of Nasal Nitric Oxide Measurements Are Associated With Atopy Status in Chronic Nasal Inflammation|||Beijing Tongren Hospital|Yes|Completed|January 2010|November 2010|Actual|October 2010|Actual|Phase 1|Observational|Observational Model: Cohort||1|Actual|131|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients were prospectively recruited from the Rhinology Clinics of the Otolaryngology,        Head and Neck Surgery Department of Beijing TongRen Hospital from January 2010 to November        2010. After application of the exclusion criteria, the study was discussed with 410        consecutive patients with a primary diagnosis of chronic nonallergic nasal inflammation.        Of these, 214 agreed to take part in, of which 83 were excluded (57 diagnosed as other        nasal diseases such as fungal sinusitis, inverted papilloma and so on, 20 with obviously        medicine history in the latest two weeks, and 6 refused to continue). Thus, 131 patients        were randomized for inclusion and 20 normal adults were recruited as well in our study.|January 2011|February 14, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01295866||109061|
NCT01294371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-762|Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin)|Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot.||AbbVie|No|Completed|February 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|391|||Female|18 Years|50 Years|No|Non-Probability Sample|Primary care clinic|May 2013|May 10, 2013|February 10, 2011||No||No|May 10, 2013|https://clinicaltrials.gov/show/NCT01294371||109176|
NCT01294345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110093|Personalized Genomic Research|Personalized Genomic Research||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1000|||Both|N/A|N/A|No|||August 2015|August 7, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01294345||109178|
NCT01294358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110099|Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial|Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial||National Institutes of Health Clinical Center (CC)||Completed|January 2011|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01294358||109177|
NCT01294644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-10-17|Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat|Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Completed|January 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|360|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|February 10, 2011||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01294644||109155|
NCT01285050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00040361|Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds|Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy||Johns Hopkins University|No|Completed|January 2011|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|99 Years|No|||February 2016|February 22, 2016|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285050||109889|
NCT01285310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-RA-002|Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate||Celgene|Yes|Terminated|December 2010|September 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|237|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|November 19, 2010|Yes|Yes|Study is terminated due to lack of efficacy|No|April 22, 2014|https://clinicaltrials.gov/show/NCT01285310||109870|The study was terminated before the 2–year time point was reached due to lack of clinical efficacy.
NCT01285323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072/3083|A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma|A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma||Teva Pharmaceutical Industries|Yes|Completed|March 2011|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|464|||Both|12 Years|75 Years|No|||September 2015|September 24, 2015|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01285323||109869|
NCT01283139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-MEDI-545-1067|A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults|A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus||MedImmune LLC|Yes|Completed|March 2011|April 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|835|||Both|18 Years|75 Years|No|||October 2014|October 14, 2014|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283139||110036|
NCT01283399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25270|An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis|A Non-interventional Multicenter Study of MabThera® (Rituximab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis||Hoffmann-La Roche||Active, not recruiting|August 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|||Both|21 Years|N/A|No|Probability Sample|All participants with active refractory RA who were eligible to receive treatment with        methotrexate and rituximab in the Investigators' opinion as per the routine clinical        practice following inadequate response to a single cycle of anti-TNF therapy.|March 2016|March 1, 2016|January 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01283399||110016|
NCT01283711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC210114_A|Evaluation of Safety and Efficacy of the Apollo™ System for Treatment of Wrinkles and Rhytides|Evaluation of Safety and Efficacy of the Apollo™ System for Treatment of Wrinkles and Rhytides||Pollogen|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||November 2011|May 16, 2013|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283711||109992|
NCT01292044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2010/VT-02|The Role of Elastography in the Diagnosis of Thyroid Nodules|The Role of Elastography in the Diagnosis of Thyroid Nodules||Centre Hospitalier Universitaire de Nīmes|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|188|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01292044||109355|
NCT01283360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009001|Microbicide Safety and Acceptability in Young Men|Microbicide Safety and Acceptability in Young Men|Project Gel|CONRAD|Yes|Completed|October 2010|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|249|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283360||110019|
NCT01283373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DST4964g|A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer||Genentech, Inc.||Recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|87|||Male|18 Years|N/A|No|||May 2015|May 28, 2015|January 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01283373||110018|
NCT01303679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arobase (GINECO-BR107)|1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer|Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.||ARCAGY/ GINECO GROUP|Yes|Terminated|June 2010|May 2018|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|February 23, 2011||No|Not reveal any significant difference between the 2 treatment arms|No||https://clinicaltrials.gov/show/NCT01303679||108469|
NCT01303692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OKR-CAS-2010/1|Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent|Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent||AstraZeneca|No|Completed|April 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|312|||Male|50 Years|N/A|No|Probability Sample|Prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent|January 2015|January 13, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303692||108468|
NCT01303991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC B251/03|Hexvix Photodynamic Therapy in Patients With Bladder Cancer|A Phase I Feasibility Study of Hexvix Photodynamic Therapy in Patients With Intermediate or High-risk Bladder Cancer||Photocure|No|Completed|March 2005|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01303991||108445|
NCT01304498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDS01C|Immunogenicity and Tolerability of V503 Versus GARDASIL|A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus (HPV) Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-old)||Sanofi Pasteur MSD|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|600|||Female|9 Years|15 Years|Accepts Healthy Volunteers|||December 2011|December 22, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304498||108406|
NCT01304511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08198|Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®|Post-Marketing Surveillance Orgalutran (Ganirelix)®||Merck Sharp & Dohme Corp.|No|Completed|February 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|711|||Female|N/A|N/A||Non-Probability Sample|Women undergoing COH for ART|April 2015|April 28, 2015|February 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01304511||108405|
NCT01304758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET001|ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Essential Tremor||InSightec|No|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||August 2013|August 22, 2013|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304758||108386|
NCT01304771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001923|Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly|A Phase I Trial of the Safety and Efficacy of Adjuvant AKSB (Agri-King Synbiotic) Synbiotic in Patients 65 Years of Age and Older Receiving the Influenza Vaccine||Mayo Clinic|Yes|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|22|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 19, 2012|December 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01304771||108385|
NCT01304784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-111-01-01-03|A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer|A Phase 1 and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors||Merrimack Pharmaceuticals|No|Completed|January 2011|June 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01304784||108384|
NCT01305070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAIR 3.0|Standard Balloon Angioplasty Versus Angioplasty With a Paclitaxel-eluting Balloon for Femoral Artery In-stent Restenosis|Femoral Artery In-Stent Restenosis (FAIR) Trial|FAIR|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|No|Completed|January 2010|June 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|21 Years|N/A|No|||April 2013|February 5, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305070||108362|
NCT01301196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC 91409|Reducing Sedentary Behaviour in Young Adults at Risk of Diabetes|An Intervention to Decrease Sedentary Behaviour in Young Adults at Risk of type2 Diabetes Mellitus - Project STAND|STAND|Loughborough University|Yes|Recruiting|October 2010|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|189|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||October 2010|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301196||108657|
NCT01301469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0801|Comparison of HES 130 in Balanced and in Unbalanced Solution|Prospective, Randomized, Double-blind, Controlled, Multicenter Study on the Efficacy and Safety of HES 130/0. 42 in a Balanced Electrolyte Solution vs a HES 130/0.4 in a Sodium Chloride Solution in Elective Surgery Patients||B. Braun Melsungen AG|No|Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|70 Years|No|||January 2012|January 2, 2012|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01301469||108636|
NCT01305902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-040-2|Substance Use and Fitness|Substance Use and Fitness: A Pilot Study of Contingency Management in Older Adults||University of Connecticut Health Center|Yes|Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|55 Years|75 Years|No|||June 2012|June 14, 2012|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305902||108298|
NCT01301703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0068-09|Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis|The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|March 2011|February 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2010|February 22, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301703||108619|
NCT01302028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0064|Renal Impairment Study With ASP1941|An Open-label, Parallel Group Study to Assess the Effect of Different Grades of Renal Impairment in Patients With Type 2 Diabetes Mellitus on the Pharmacokinetics, Pharmacodynamics and Safety & Tolerability of ASP1941 Relative to Type 2 Diabetes Mellitus With Normal Renal Function and Healthy Volunteers||Astellas Pharma Inc|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|40|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|February 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302028||108594|
NCT01290848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000020942|A Health Promotion Campaign Targeting Caregivers of Young Children|Take TIME for Your Child's Health: A Health Promotion Campaign Targeting Caregivers of Young Children|TIME|The Hospital for Sick Children|No|Completed|September 2010|April 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1374|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 25, 2013|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290848||109447|
NCT01307059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-524|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Sweden|Easypod Connect: A Swedish, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|ECOS SWE|Merck KGaA|No|Active, not recruiting|June 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|159|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the Easypod™ electromechanical device.|March 2015|March 3, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307059||108209|
NCT01306747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACKLE2011|Stanford Chronic Pain Self-Management Programme in Danish Chronic Pain Patients|A Randomized Controlled Trial of the Stanford Chronic Pain Self-Management Programme in Danish Chronic Pain Patients||University of Aarhus|Yes|Active, not recruiting|February 2011|December 2015|Anticipated|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||April 2013|January 19, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01306747||108233|
NCT01307033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-351|A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)|A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]||Merck Sharp & Dohme Corp.|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|278|||Both|20 Years|80 Years|No|||January 2015|January 21, 2015|March 1, 2011|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT01307033||108211|
NCT01307514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0417-08-HMO|Effects of Heating Massaging Vibrating Vicinity of the Insulin Delivery Site|Protocol for Evaluation of the Effects of Heating Massaging Vibrating or Application of Topical Agent on the Vicinity of the Insulin Delivery Site||Hadassah Medical Organization||Not yet recruiting|November 2008|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|65 Years|No|Non-Probability Sample|The participants will be patients with insulin dependent diabetes using standard insulin        injections or continuous insulin infusion pumps.|September 2008|March 1, 2011|October 2, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307514||108174|
NCT01307774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP38250|Survey of Predictors of Human Papillomavirus (HPV) Vaccination Among Parents of Rural Adolescent Girls in Mysore, India|Survey of Predictors of HPV Vaccination Among Parents of Rural Adolescent Girls in Mysore, India||Public Health Research Institute, India|No|Recruiting|June 2014|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|800|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will survey attitudes of parents of adolescent girls attending 10 schools in        rural Mysore Taluk in Mysore District.|October 2014|October 28, 2014|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307774||108154|
NCT01307501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUC10-LNG06|Safety and Efficacy of Cryoablation for Metastatic Lung Tumors|Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients - Safety and Efficacy|ECLIPSE|Galil Medical|Yes|Active, not recruiting|August 2011|May 2017|Anticipated|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307501||108175|
NCT01308021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTT-gpASIT005|Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis|Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis||BioTech Tools S.A.|No|Completed|December 2010|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|202|||Both|18 Years|50 Years|No|||May 2014|May 23, 2014|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01308021||108135|
NCT01307748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#00006890|Effects of Stress-reducing Aromatherapy|Physiologic and Expectancy Effects of Stress-reducing Aroma in Older Adults||Oregon Health and Science University|Yes|Completed|December 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|92|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307748||108156|
NCT01307761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099144-E|An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules|An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules||Far Eastern Memorial Hospital|No|Recruiting|December 2010|August 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|500|||Both|18 Years|90 Years|No|Non-Probability Sample|The investigators want to retrospectively review the medical records of nodules which        underwent head and neck ultrasound(US) examination and US-FNA cytology from 2007 July to        2010 Dec at Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan.        No patient included in this series had a previous diagnosis of thyroid malignancy.|September 2011|September 16, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01307761||108155|
NCT01303419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-CEDM-001|Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer|A Multicenter, Open-Label, Crossover Trial to Assess Non-Inferiority of Dual Energy Contrast-Enhanced Digital Mammography (DE-CEDM) Compared to Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) for Identifying a Change in Patient Management in Women With Newly Diagnosed Breast Cancer||GE Healthcare|No|Terminated|April 2010|||October 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|350|||Female|21 Years|N/A|No|||January 2012|October 31, 2012|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01303419||108489|
NCT01308255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR05/7092|Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)|A Multi-centre Randomised Double Blind Placebo Controlled Study Comparing Two Regimens of Combination Therapy in Early DMARD Naive Rheumatoid Arthritis.|IDEA|University of Leeds|No|Completed|September 2006|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|80 Years|No|||March 2010|March 3, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308255||108117|
NCT01308606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015940|TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study|A Phase I, Open-label, Randomized, Single-dose, 2-panel, Crossover Trial in Healthy Subjects to Assess the Relative Bioavailability of TMC435 HPMC Capsule Compared to the TMC435 Gelatin Capsule and to Assess the Effect of Different Meal Types on the Bioavailability of Both Formulations||Tibotec Pharmaceuticals, Ireland||Completed|March 2011|June 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|March 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01308606||108091|
NCT01308619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10150|Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo|A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules||Galderma Laboratories, L.P.|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|70 Years|No|||July 2014|July 8, 2014|March 2, 2011||No||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01308619||108090|
NCT01304238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108745|Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II|Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht||GlaxoSmithKline|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|195|||Both|18 Years|N/A|No|Probability Sample|Hospitalized patients with HIT|January 2011|March 10, 2011|January 27, 2011||No||No|January 27, 2011|https://clinicaltrials.gov/show/NCT01304238||108426|Due to the retrospective nature of the data collection in this study, it is impossible to be precise about dose and frequency of dosing.
NCT01304524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-003|A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3|Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With Cellectra-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.|HPV-003|Inovio Pharmaceuticals|Yes|Completed|April 2011|January 2016|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|167|||Female|18 Years|55 Years|No|||February 2016|February 22, 2016|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304524||108404|
NCT01304537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kamada-AAT (IV) - 008|Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus|Open Label, Proof of Concept, Phase I/II Study of the Safety, Tolerability and Efficacy of Intravenous Alpha-1 Antitrypsin (AAT) [Trade Name Glassia™] in Type 1 Diabetes Mellitus||Kamada, Ltd.|No|Completed|June 2011|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|10 Years|25 Years|No|||February 2013|February 18, 2013|February 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304537||108403|
NCT01309386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017326|A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants|A Randomized, Open-Label, Parallel-Arm, Optimal Dose-Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended-Release (ER) in Japanese Subjects Treated With Around-the-Clock Opioid Analgesics for Their Moderate to Severe Chronic Malignant Tumor- Related Cancer Pain||Janssen Pharmaceutical K.K.|No|Completed|August 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|N/A|No|||February 2013|February 8, 2013|February 17, 2011|Yes|Yes||No|February 8, 2013|https://clinicaltrials.gov/show/NCT01309386||108031|
NCT01305369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prina01|The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma|The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma: a Pilot Randomised Controlled Trial (PRINA Study)|PRINA|University of Milan|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|74 Years|No|||March 2012|March 5, 2012|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305369||108339|
NCT01305668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-01-2011|Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Emphysema|Effectiveness of Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Emphysema Phenotype||Villa Pineta Hospital|No|Completed|August 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|40 Years|90 Years|No|Non-Probability Sample|COPD patients with or without Emphysema phenotype|December 2014|December 9, 2014|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305668||108316|
NCT01305915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0271-CE|Getting Back on Track: An Educational Group for Women With Breast Cancer|Getting Back on Track: A Single-session Psychoeducational Group Intervention for Women With Breast Cancer Completing Adjuvant Treatment|GBOT|University Health Network, Toronto|Yes|Completed|November 2007|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|444|||Female|18 Years|N/A|No|||February 2011|February 25, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305915||108297|
NCT01306227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC IR07 - Dr TOURNEUX|L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia|L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial||Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|February 2011|February 2015|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|5 Years|No|||September 2011|September 26, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306227||108273|
NCT01306513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL28562.000.09|Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema|Effect of Autologous Bone Marrow Derived Mesenchymal Stromal Cells Prior to Lung Volume Reduction Surgery for Severe Pulmonary Emphysema- a Phase I Safety and Feasibility Study||Leiden University Medical Center|No|Completed|October 2010|November 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|40 Years|65 Years|No|||November 2012|November 16, 2012|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306513||108251|
NCT01291680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033-10-TLV|Assessment of Central Pain in the Peripartum Period|Assessment of Central Pain in the Peripartum Period||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|March 2011|September 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted as an open label, observational research. The setting of the        study is the Obstetric ER of the Lis Maternity Hospital, Tel Aviv sourasky medical center.        Participants in the study will be pregnant women attending the obstetric ER for routine        term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The        current study will focus on women attending a regular followup, not considered to be at        high risk.        All participants will be requested to sign written informed consent on recruitment.|February 2011|February 7, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01291680||109383|
NCT01307540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT3687|Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients|Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients||Hadassah Medical Organization||Completed|February 2007|||December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A||||June 2010|March 1, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307540||108172|
NCT01307046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-352|MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)|A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium||Merck Sharp & Dohme Corp.|No|Completed|March 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|336|||Both|20 Years|80 Years|No|||October 2015|October 8, 2015|March 1, 2011|No|Yes||No|January 2, 2013|https://clinicaltrials.gov/show/NCT01307046||108210|
NCT01307293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02172011-7504|Prevention of Postpartum Traumatic Stress (PTSD) in Mothers With Preterm Infants.|Randomized Controlled Trial of a Brief Cognitive Behavioral Intervention Designed to Prevent and Reduce Symptoms of Posttraumatic Stress in Mothers of Preterm Infants.||Stanford University|No|Completed|April 2011|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|N/A|No|||November 2014|November 18, 2014|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307293||108191|
NCT01307787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210.076|Effects of a Rehabilitation Program on Physical Performance and Disease Self-management in Rheumatoid Arthritis.|Effects of a Group-based Exercise and Educational Program on Physical Performance and Disease Self-management in Rheumatoid Arthritis: a Randomized Controlled Study||University Medical Center Groningen|No|Completed|April 2005|May 2007|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|34|||Both|18 Years|66 Years|No|||January 2011|May 11, 2011|March 2, 2011||No||No|March 15, 2011|https://clinicaltrials.gov/show/NCT01307787||108153|An important limitation in our study was the low number of participants included in both groups which may have induced a lack of power.
NCT01307800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12430|A Study of LY2140023 in Patients With Schizophrenia|A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia||Eli Lilly and Company|Yes|Terminated|March 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|1100|||Both|18 Years|65 Years|No|||October 2012|January 11, 2013|March 1, 2011|Yes|Yes|The decision to stop the trial was based on efficacy results in the overall schizophrenia    participant population.|No||https://clinicaltrials.gov/show/NCT01307800||108152|
NCT01308034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT - SUTENT|Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy|Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy||Centre Leon Berard|Yes|Recruiting|March 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01308034||108134|
NCT01308268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIET-05|Management of Soil-transmitted Helminthiasis and Strongyloidiasis|Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area||Universidad Nacional de Salta|No|Recruiting|December 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|1 Year|N/A|Accepts Healthy Volunteers|||February 2011|March 3, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308268||108116|
NCT01308281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0025|Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)|Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)||Yonsei University|Yes|Recruiting|October 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|20 Years|79 Years|No|||March 2014|July 13, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308281||108115|
NCT01308294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P009-2010DR1082|Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients|Vaccination of Melanoma Patients (Stage II-IV) With ImmuFact IMP321, Tumor Antigenic Peptides and Montanide|LAG-3/IMP321|Centre Hospitalier Universitaire Vaudois|No|Terminated|June 2010|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|March 3, 2011||No|Low enrollment rate|No||https://clinicaltrials.gov/show/NCT01308294||108114|
NCT01308008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7547-R|Home Exercise for Older Diabetics|Home Program to Enhance Mobility in Older Veteran Diabetics||VA Office of Research and Development|No|Active, not recruiting|November 2011|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|60 Years|N/A|No|||February 2016|February 4, 2016|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01308008||108136|
NCT01308879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070342|Effects of Routine Feedback to Clinicians on Youth Mental Health Outcomes: A Randomized Cluster Design|Effects of Routine Feedback to Clinicians on Youth Mental Health Outcomes: A Randomized Cluster Design||Vanderbilt University|No|Completed|May 2004|June 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|356|||Both|11 Years|18 Years|No|||March 2011|March 3, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308879||108070|
NCT01308892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33506.081.10|Cardiovascular Health Effects of Flavanol Rich Chocolate|Cardiovascular Health Effects of Flavanol Rich Chocolate|CHOC|Wageningen University|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|44|||Male|45 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01308892||108069|
NCT01309126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-CL-PGG-CRC1031|Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer|A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer|PRIMUS|Biothera|Yes|Active, not recruiting|April 2011|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|795|||Both|18 Years|N/A|No|||July 2015|December 8, 2015|February 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309126||108051|
NCT01308866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLEGATS|Effectiveness of a Shared Decision Aid Tool for Cardiovascular Risk Prevention in Hypercholesterolemic Patients|Effectiveness of a Shared Decision Aid Tool for Cardiovascular Risk Prevention in Hypercholesterolemic Patients|PLEGATS|Jordi Gol i Gurina Foundation|Yes|Completed|July 2007|March 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|298|||Both|14 Years|75 Years|No|||March 2011|March 2, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308866||108071|
NCT01309113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-AG-E-3|Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome|Double-blind Comparison of VAC BNO 1095 Film Coated Tablets With Placebo to Identify Dose Dependent Effects in Patients Suffering From Cyclic Mastodynia and Premenstrual Syndrome||Bionorica SE||Completed|March 2011|November 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|191|||Female|18 Years|45 Years|No|||July 2013|July 8, 2013|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01309113||108052|
NCT01305681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00458|Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization|||Nationwide Children's Hospital||Recruiting|February 2011|||December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|35 Years|No|||November 2011|November 2, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305681||108315|
NCT01305694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-2010-16|Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.|PhaseⅠ/ⅡTrial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia.|MSC|Guangzhou General Hospital of Guangzhou Military Command|Yes|Recruiting|February 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|16 Years|N/A|No|||February 2011|February 28, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305694||108314|
NCT01305928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12345|Hospitalized Smokers|Increasing Post-Discharged Follow-Up Among Hospitalized Smokers||University of Kansas Medical Center|No|Active, not recruiting|February 2011|January 2016|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1054|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01305928||108296|
NCT01306240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC IR09 - Dr TOURNEUX|Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation|Surfactant Treatment Compared to Nasal Continuous Positive Airway Pressure for the Management of Respiratory Distress Syndrome in the Newborn Between 35 and 41 Weeks of Gestation|ASPEN|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|March 2011|November 2013|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|152|||Both|N/A|1 Month|No|||September 2011|September 26, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306240||108272|
NCT01306526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB: C/10/341|Relationship Between Obstructive Sleep Apnea and Coronary Atherosclerosis|Intravascular Ultrasound Diagnostic Evaluation of Atherosclerosis in Singapore- Obstructive Sleep Apnea (IDEAS-OSA) Study|IDEAS-OSA|National University, Singapore|No|Completed|February 2011|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|118|||Both|21 Years|80 Years|No|Non-Probability Sample|Patients aged 21 to 80 years who are scheduled to undergo either an elective, urgent or        emergent diagnostic coronary angiography are eligible|January 2014|January 7, 2014|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306526||108250|
NCT01291147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010JTW01|Local Anaesthetic Infusion For Laparoscopic Hysterectomy|Local Anaesthetic Infusion For Laparoscopic Hysterectomy: A Randomised Controlled Trial||Ashford and St. Peter's Hospitals NHS Trust|No|Completed|February 2011|February 2013|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|N/A|No|||November 2013|November 12, 2013|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01291147||109424|
NCT01291160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPF-409|Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers|A Prospective, Randomized Blinded Multicenter, Parallel Study Comparing Transdermal, Continuous Oxygen Delivery to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers||Ogenix Corporation|Yes|Completed|October 2009|February 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|20 Years|90 Years|No|||April 2014|April 11, 2014|February 4, 2011|No|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT01291160||109423|
NCT01308346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-390|ABSORB PHYSIOLOGY Clinical Investigation|ABSORB PHYSIOLOGY Clinical Investigation: Clinical Evaluation of the Short and Long-Term Effects of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold on Coronary Artery Blood Flow and Physiological Responsiveness||Abbott Vascular|No|Terminated|November 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|1|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|March 2, 2011|No|Yes|Due to a challenging protocol inclusion/ exclusion criteria, only one subject was enrolled    since the trial was initiated in June 2011.|No||https://clinicaltrials.gov/show/NCT01308346||108110|
NCT01308359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-am-0512-CTIL|Use of Glucose and Saline for Fetal Movement Perception|Impact of Glucose Administration on Perception of Fetal Movements||Tel-Aviv Sourasky Medical Center|No|Recruiting|January 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 3, 2011|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01308359||108109|
NCT01307306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ins_met_jeschke|Glucose Control in Severely Burned Patients|Glucose Control in Severely Burned Patients: Mechanisms and Therapeutic Potential||Sunnybrook Health Sciences Centre|No|Recruiting|March 2011|September 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|90 Years|No|||July 2015|July 28, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01307306||108190|
NCT01307527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTL-CXL-HMO-CTIL|Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI|||Hadassah Medical Organization||Enrolling by invitation||||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1|||Both|18 Years|N/A|No|||February 2011|March 2, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307527||108173|
NCT01308060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.40131|A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)|A MULTI-CENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF CD07743 FOR THE IMPROVEMENT OF LATERAL CANTHAL LINES (CROW'S FEET)||Galderma R&D|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|335|||Both|18 Years|65 Years|No|||August 2012|August 6, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308060||108132|
NCT01308333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED11|Investigation of Chronic Inflammatory Processes in Male Individuals With Hypohidrotic Ectodermal Dysplasia|Investigation of Chronic Inflammatory Processes in the Respiratory Tract and the Eyes of Male Individuals With X-linked Hypohidrotic Ectodermal Dysplasia||University Hospital Erlangen||Completed|April 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|38|Samples Without DNA|tear fluid|Male|6 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED) and healthy controls|January 2014|January 7, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308333||108111|
NCT01308671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCTC-001-WS704502|Influence of Varenicline on the Antiplatelet Action of Clopidogrel|Influence of Varenicline on the Antiplatelet Action of Clopidogrel : the Randomized, Open-label VACL (Varenicline Clopidogrel) Study|VACL|General Hospital of Chinese Armed Police Forces|Yes|Recruiting|October 2010|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|79 Years|No|||April 2015|June 23, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01308671||108086|
NCT01308047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIST016|Comparing Heavy Levobupivacaine With Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine.|Comparative Study of Non-inferiority Between Heavy Levobupivacaine With Enantiomeric Excess of 50% (Bupivacaine S75: R25) and Heavy Racemic Bupivacaine (Bupivacaine S50: R50) in Spinal Anesthesia for Orthopedic Procedures in the Lower Limbs.||Cristália Produtos Químicos Farmacêuticos Ltda.|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|February 23, 2011||No|The Sponsor has no interest in continuing the study.|No||https://clinicaltrials.gov/show/NCT01308047||108133|
NCT01308918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ-20420|The New GlideRite DLT Stylet®: An Observational Study|The New GlideRite DLT Stylet®: An Observational Study||Laval University|No|Completed|May 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|50 patients having an elective thoracic surgery (non cardiac) via either thoracopscopy or        thoracostomy. Patients were all 18 years old or over, and have read, understood and signed        an informed consent at the preoperative evaluation or on surgery morning.|February 2012|February 21, 2012|March 1, 2011||No||No|June 22, 2011|https://clinicaltrials.gov/show/NCT01308918||108067|
NCT01308307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8821|Is Non-cycloplegic Photorefraction Applicable for Screening Refractive Risk Factors of Amblyopia?|Is Non-cycloplegic Photorefraction Applicable for Screening Refractive Risk Factors of Amblyopia?||hahid Beheshti University of Medical Sciences||Completed|October 2009|August 2010|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|185|||Both|1 Year|14 Years|No|||October 2009|March 7, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308307||108113|
NCT01308320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0111|Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia|Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia||Yonsei University|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|42|||Female|20 Years|59 Years|No|||March 2011|March 3, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308320||108112|
NCT01308632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENOM-007|Metronomic Temozolamide in Patients With Recurrent Glioblastoma|PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA||Grupo Español de Investigación en Neurooncología|No|Active, not recruiting|November 2007|June 2012|Anticipated|June 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2011|March 2, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01308632||108089|
NCT01308905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU 2009-031|Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)|Pilot Study to Determine the Utility of [18F] 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography in Monitoring Patient Response to Chemotherapy in Neuroblastoma||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|21 Years|No|||March 2016|March 20, 2016|February 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01308905||108068|
NCT01309139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1298.2|Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers|An Open Label, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Via Respimat® B Versus the Combination of the Monoproducts of Tiotropium Via Respimat® A and BI 54903 Via Respimat® B in Healthy Volunteers||Boehringer Ingelheim||Completed|March 2011|||June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|March 1, 2011||||No||https://clinicaltrials.gov/show/NCT01309139||108050|
NCT01309399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-09|Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur|Early Effects of PTH on the Proximal Femur||Health Research, Inc.|Yes|Active, not recruiting|August 2010|March 2016|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|60|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309399||108030|
NCT01305122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUMEURS GLIALES|Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma|Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study||Centre Leon Berard|No|Recruiting|February 2011|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|183|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305122||108358|
NCT01305382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0808M43361|Noninvasive Evaluation of Cardiac Allograft Vasculopathy|Noninvasive Evaluation of Cardiac Allograft Vasculopathy in Heart Transplant Recipients II|CAVII|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|October 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Heart Transplant subjects within 10 years of heart transplantation Subjects with advanced        heart failure Healthy Volunteers|March 2013|March 13, 2013|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305382||108338|
NCT01305707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TECHUB2007|Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression|Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial||Hospital Universitari de Bellvitge|No|Terminated|July 2009|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|February 28, 2011||No|Difficulties in recruiting|No||https://clinicaltrials.gov/show/NCT01305707||108313|
NCT01305941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1025|A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases|A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|September 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|21 Years|N/A|No|||February 2016|February 19, 2016|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305941||108295|
NCT01306253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A003|A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2009/2010-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations||Crucell Holland BV|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|February 28, 2011||No||No|December 14, 2011|https://clinicaltrials.gov/show/NCT01306253||108271|
NCT01306266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAMC 211004|Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops|A Randomized, Double-blind, Placebo-controlled, Crossover Trial of Rizatriptan 10 mg Oral Disintegrating Tablet for Treatment of Acute Attacks of Chronic, Blast-induced, Post-traumatic Headache in U.S. Military Troops|Maxalt|Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Withdrawn|February 2011|August 2011|Anticipated|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|49 Years|No|||August 2015|August 17, 2015|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306266||108270|
NCT01306539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-07-4849|Neuropsychiatric Effects of Deep Brain Stimulation in Patients With Parkinson's Disease|Neuropsychiatric Effects of Deep Brain Stimulation in Patients With Parkinson's Disease||University of California, San Diego|No|Enrolling by invitation|July 2008|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2013|March 26, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306539||108249|
NCT01307072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye003|Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy|Compliance to Ophthalmic Follow-up Examinations Affect Outcome of Vitrectomy for Proliferative Diabetic Retinopathy||Kyorin University|No|Completed|September 2008|April 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|94|||Both|N/A|N/A|No|Probability Sample|The patients that underwent their first vitreous surgery for proliferaftive diabetic        retinopathy|July 2012|July 31, 2012|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307072||108208|
NCT01282255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8226-3875|Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis|A Randomised, Double Blind, Placebo-controlled, Multiple Dose Trial of Anti-IL-20 (109-0012) in Subjects With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|75 Years|No|||May 2012|May 10, 2012|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282255||110104|
NCT01307813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-10-31|Apollo Overstitch, a Treat and Resect Model|Evaluation of a Novel Endoscopic Suturing Device in a Treat and Resect Model|Overstitch|University Hospital Case Medical Center|Yes|Completed|February 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 12, 2014|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307813||108151|
NCT01308073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMIC2_2011_02_03|Stability of Middle Molecule Clearance|Long-time Stability of Middle Molecule Clearance During CI-Ca CVVHD|EMIC2|Heinrich-Heine University, Duesseldorf|No|Completed|March 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of surgical intensive care unit|December 2014|December 18, 2014|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01308073||108131|
NCT01309165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR 230433|Exploring the Efficacy of Combined Task-Specific and Cognitive Strategy Training in Subacute Stroke|Exploring the Efficacy of Combined Task-Specific and Cognitive Strategy Training in Subacute Stroke: A Phase II Clinical Trial.||St. John's Rehab Hospital|No|Completed|April 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309165||108048|
NCT01309152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICK R-10.29A/MICK|Cefazolin Subcutaneous Microdialysis in Morbidly Obese Patients|Peri-and Postoperative Subcutaneous Adipose Tissue Cefazolin Determination Using Microdialysis in Morbidly Obese and Non-obese Patients|MICK|St. Antonius Hospital|No|Completed|January 2011|August 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|16|Samples With DNA|serum and microdialysis filtrate of subcutenous tissue|Both|21 Years|60 Years|No|Non-Probability Sample|8 morbidly obese patients undergoing weight reducing surgery And 8 non-obese patients        undergoing surgery which will require an arterial line, nadroparin and cefazolin        administration perioperatively and postoperative stay at the Post-Anesthesia Care Unit.|January 2013|January 2, 2013|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309152||108049|
NCT01305174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE 3.0|Iliac, Common and External (ICE) Artery Stent Trial|Balloon Expandable vs. Selfexpandable Stents to Treat Stenosis or Occlusions of Common and External Iliac Artery Disease||Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|No|Recruiting|October 2010|July 2014|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|21 Years|N/A|No|||April 2013|April 24, 2013|February 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01305174||108354|
NCT01305148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG-0109|Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)|Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)|WARFARIN|Iverson Genetic Diagnostics, Inc.|Yes|Suspended|August 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|3800|||Both|65 Years|N/A|No|||August 2015|August 27, 2015|February 25, 2011|Yes|Yes|Sponsor is raising funds for the remainder of the study|No||https://clinicaltrials.gov/show/NCT01305148||108356|
NCT01305161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09010|Flow Cytometry Applied to the Diagnosis of Peri-anaesthesic Reactions|Diagnostic Accuracy of Flow Cytometry Applied to the Diagnosis of Peri-anaesthesic Reactions Induced by Neuromuscular Blockers|CYPREANE|University Hospital, Limoges|No|Recruiting|April 2011|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|212|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01305161||108355|
NCT01308645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB Injection HCC|Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)|PhaseⅡ, Open Label, Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma|HCC|SBPharmaceutical IND, Co., LTD|Yes|Recruiting|December 2010|March 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2011|June 8, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308645||108088|
NCT01308658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017776|TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions|A Phase I, Open-label, Randomized, 2-panel, 2-way Crossover Pivotal Bioequivalence Trial Between the Commercially Available 400-mg Tablet Formulation (F030) and the 800-mg Tablet Formulation of Darunavir (G002), in the Presence of Low-dose Ritonavir Under Fasted and Fed Conditions||Tibotec Pharmaceuticals, Ireland||Completed|January 2011|May 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308658||108087|
NCT01305954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1027|Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients|LCCC 1027: Expression Of P16INK4a As A Predictor Of Myelosuppression In Patients With Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|December 2010|December 2015|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients at UNC North Carolina Cancer Hospital and other participating        sights.|February 2014|February 26, 2014|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01305954||108294|
NCT01306279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H0713/7|The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective|The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective||Imperial College London|No|Completed|February 2011|||August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Sputum|Both|16 Years|N/A|No|Non-Probability Sample|Adult patients with Cystic Fibrosis attending to commence intravenous antibiotics for a        pulmonary exacerbation of CF|March 2013|March 17, 2016|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306279||108269|
NCT01305135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-AZA-IDA-09|Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes|A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes||Groupe Francophone des Myelodysplasies|Yes|Active, not recruiting|December 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|41|||Both|18 Years|N/A|No|||April 2015|October 28, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305135||108357|
NCT01305395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007M85473|Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients|Early Vs Late Sirolimus-Initiation Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients|STOPCAV|University of Minnesota - Clinical and Translational Science Institute|Yes|Terminated|November 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|60|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|February 25, 2011|Yes|Yes|Due in part, to reduced transplant volume and enrollment has been difficult.|No||https://clinicaltrials.gov/show/NCT01305395||108337|
NCT01306799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810599|To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use|Effect of Chronic Proton Pump Inhibitor Therapy on Bone Mineral Density and Bone Structure in Mid to Late Adulthood|BE-CAST|University of Pennsylvania|No|Completed|January 2010|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|||Both|40 Years|75 Years|No|Probability Sample|-  Patients who either are starting or have been receiving long-term continuous PPI             therapy for erosive esophagitis or Barrett's esophagus diagnosed within the past             three years.          -  Patients who are starting PPI therapy for gastroesophageal reflux disease (GERD) and             have shown a subjective improvement in symptoms within 4 weeks of starting therapy.             This improvement will be assessed either through documentation in their medical             record or through telephone interview with permission from their physician.          -  Patients who are starting PPI therapy for ulcer prophylaxis in a setting of chronic             aspirin use.          -  Patients who are starting PPI therapy for extraesophageal manifestations of GERD.|May 2015|October 7, 2015|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01306799||108229|
NCT01307085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIP1126|Effect of Remote Ischemic Preconditioning on Lung Injury After Pulmonary Resection|Effect of Remote Ischemic Preconditioning on Lung Injury in Patients Undergoing Pulmonary Resection:a Randomised Controlled Trial||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|February 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Both|18 Years|65 Years|No|||December 2013|December 11, 2013|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307085||108207|
NCT01307332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02482|Advanced MRI Measures of Repair in Alemtuzumab Treated Patients|Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients|iCAMMS-IST|University of British Columbia|Yes|Active, not recruiting|March 2011|December 2018|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|50 Years|No|||April 2015|April 10, 2015|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307332||108188|
NCT01307553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleeve III|Over and Under/Aneugraft Pericardium Covered Stent Long Term Follow up Registry|OVER AND UNDER/ANEUGRAFT PERICARDIUM COVERED STENT Long Term Follow Up Registry|Sleeve III|ITGI Medical|No|Recruiting|September 2010|April 2015|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting for PCI.|March 2011|March 1, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307553||108171|
NCT01307319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-305|Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies|Study of Two Doses of an Investigational Nasal Aerosol Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies||Teva Pharmaceutical Industries|No|Completed|March 2011|August 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|715|||Both|6 Years|11 Years|No|||February 2015|February 3, 2015|February 28, 2011|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01307319||108189|
NCT01308086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/09.12|Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer|A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer||Hellenic Oncology Research Group|No|Recruiting|October 2010|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01308086||108130|
NCT01308099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091332|Assessment of Vascular Endothelial Function in Postural Tachycardia Syndrome|Assessment of Vascular Endothelial Function in Postural Tachycardia Syndrome (POTS)||Vanderbilt University|No|Recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|57|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Postural Tachycardia Syndrome        Controls will be age & sex matched to the patients with POTS|June 2015|June 22, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01308099||108129|
NCT01308684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25389|A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma|Open-label, Combined Dose-finding (Phase I) and Efficacy-finding (Phase II) Study of RO5323441 in Combination With Bevacizumab for Patients With Recurrent Glioblastoma||Hoffmann-La Roche||Completed|May 2011|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01308684||108085|
NCT01308372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CFR-XXX-2011/1|Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week|Cardiovascular Risk in General Practice in France||AstraZeneca|No|Completed|October 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|9246|||Both|50 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care|November 2011|November 4, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01308372||108108|
NCT01308931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-012|The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels|The Effect of Tubal Ligation, Essure Placement, AND Levonorgestrel Intrauterine Device on Serum Anti-Mullerian Hormone Rates Over Time||Maricopa Integrated Health System|No|Withdrawn|January 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|0|||Female|25 Years|40 Years|No|Non-Probability Sample|Women seeking contraceptive methods seen at Maricopa Integrated Health System, Fertility        Centers of Arizona, or St Joseph's Hospital & Medical Center|August 2014|August 4, 2014|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308931||108066|
NCT01308944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0447 / 201104047|Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients|Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients||Washington University School of Medicine|No|Completed|August 2010|August 2015|Actual|August 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||August 2015|August 14, 2015|February 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01308944||108065|
NCT01309178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APA-IIb|Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo|Anti-inflammatory Pulmonal Therapy of CF Patients With Amitriptyline and Placebo - a Randomised, Double-blind, Placebo-controlled, Multicenter, Cohort - Study|APA-IIb|University Children’s Hospital Tuebingen|Yes|Recruiting|May 2009|May 2011|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|14 Years|65 Years|No|||March 2009|March 4, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309178||108047|
NCT01305187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90028_4007_0|Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3|Monocentric, Randomized, Subject and Rater Blinded Clinical Investigation to Prove the Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3 Containing Lidocaine - After Single Injection for Correction of Nasolabial Folds (NLF)||Merz Pharmaceuticals GmbH|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 17, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305187||108353|
NCT01305434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLE-DM2|Mulberry Leaf Extract and Blood Glucose Control in Diabetics|Randomized Double Blind Cross Over Trial to Examine the Effect of Mulberry Leaf Extract on Post Prandial Glucose in Type 2 Diabetics||Craig, Nancy, M.D.|No|Completed|September 2011|December 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01305434||108334|
NCT01305408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/3073|Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder||Teva Pharmaceutical Industries|Yes|Completed|March 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|399|||Both|18 Years|65 Years|No|||January 2015|January 15, 2015|February 25, 2011|Yes|Yes||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01305408||108336|
NCT01305421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|griptest92|Grip Test in Ventilated ICU Patients|The Role of the Grip Test in the Evaluation of Extubation Success in ICU Patients.|griptest92|Centre Hospitalier Universitaire Brugmann|No|Recruiting|January 2011|April 2011|Anticipated|March 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2011|February 25, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305421||108335|
NCT01305720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|734|The Effect of Mydriatic Eye Drops on Cerebral and Mesenteric Oxygenation in Preterm Infants|The Effect of Mydriatic Eye Drops on Cerebral and Mesenteric Oxygenation in Preterm Infants||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Not yet recruiting|March 2011|December 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|90 Days|No|||February 2011|February 28, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305720||108312|
NCT01305967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB Injection|Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer|Phase Ⅱa,Open Label,Multicenter Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer||SBPharmaceutical IND, Co., LTD|No|Recruiting|January 2003|June 2011|Anticipated|May 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||February 2011|February 27, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01305967||108293|
NCT01306292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR1-133|Safety of SonoVue on Pulmonary Hemodynamics|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Crossover, Safety Study of the Effect of Intravenous Bolus Injections of SonoVue on Pulmonary Hemodynamics in Subjects With and Without Pulmonary Hypertension||Bracco Diagnostics, Inc|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|36|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|February 23, 2011|Yes|Yes||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01306292||108268|
NCT01306318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-10|A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)|A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions||Eisai Inc.||Completed|February 2011|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01306318||108266|
NCT01306552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/133/10|Evaluation of a Combined Parent-student Programme for Smoking Prevention in Berlin Schools|BEST Prevention Study. "Berlin Evaluates School Tabacco Prevention" Study Evaluation of a Combined Parent-student Programme for Smoking Prevention in Berlin Schools|BEST|Charite University, Berlin, Germany|No|Recruiting|October 2010|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3400|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||January 2011|March 1, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306552||108248|
NCT01306825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4683|Clinical Evaluation of Daptomycin Bone Penetration|Clinical Evaluation of Daptomycin Bone Penetration|DAPTO-HUS|University Hospital, Strasbourg, France|No|Recruiting|May 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patient under treatment with daptomycin and undergoing imperative surgery with bone        withdrawal|March 2015|June 17, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01306825||108227|
NCT01307579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL0933|Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy|A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)||Children's Oncology Group|Yes|Recruiting|April 2011|||October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|575|||Both|3 Months|30 Years|No|||February 2016|February 22, 2016|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307579||108169|
NCT01306812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALVe|Survey of Adolescent Living in Vestmanland|Risk Factors for Alcohol Abuse and Deviant Behaviour - Biochemical and Molecular Studies in Adolescents From Swedish County|SALVe|Uppsala University|No|Completed|January 1998|||||N/A|Observational|Time Perspective: Prospective||1|||||Both|16 Years|19 Years|Accepts Healthy Volunteers|Probability Sample|16 and 19-year-olds school students in county of Vestmanland.|March 2011|August 19, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306812||108228|
NCT01307345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-058-1|Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence|Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence||University of Connecticut Health Center|Yes|Completed|February 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|30|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307345||108187|
NCT01307566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM2-CPAP|Evolution With CPAP Treatment of a Cohort of Type 2 Diabetic Patients With Apnea-hypopnea Syndrome|Evolution With CPAP Treatment of a Cohort of Type 2 Diabetic Patients With Moderate to Severe Apnea-hypopnea Syndrome and Poor Glycemic Control|DM2-CPAP|Hospital de Granollers|No|Completed|March 2011|January 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|69 Years|No|||January 2015|January 5, 2015|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01307566||108170|
NCT01307852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0427|In Vivo Dosimetry During Prostate Cancer Radiotherapy|Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2011|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|18 Years|N/A|No|||April 2015|April 2, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307852||108148|
NCT01307826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27022011KASS|Massage in Treating Painful Shoulder|Comparison of the Effectiveness of Massage Based on the Tensegrity Rule and Classical Massage in Treating Painful Shoulder||University School of Physical Education in Wroclaw|No|Completed|January 2008|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||September 2010|March 2, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307826||108150|
NCT01307839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110014|Lidocaine Patch for Relief of Pain During Epidural Placement in Laboring Patients|A Randomized, Controlled Trial of the Lidocaine Patch for Relief of Pain During Epidural Needle Insertion in Laboring Patients||Loma Linda University|No|Withdrawn|December 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|45 Years|No|||April 2012|April 11, 2012|March 1, 2011||No|Study was stopped due to non-availability of the lidocaine placebo patches.|No||https://clinicaltrials.gov/show/NCT01307839||108149|
NCT01309191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10-24|Microarray Analysis of Scalp Biopsies After Minoxidil Treatment|Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil||University Hospital Case Medical Center|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 25, 2014|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309191||108046|
NCT01309217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL105218-01|Dissemination of Tobacco Tactics for Hospitalized Smokers|Dissemination of Tobacco Tactics Versus 1-800-QUIT-NOW for Hospitalized Smokers||University of Michigan|Yes|Completed|July 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1528|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309217||108044|
NCT01308385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRPEX-2|Prediction and Characterization of Acute and Chronic Postoperative Pain|Prediction and Characterization of Acute and Chronic Postoperative Pain - a Longitudinal Observational Study of the Relationship Between Experimental Pain Modulation and Clinical Postoperative Pain in Patients Undergoing Minimally Invasive Repair of Pectus Excavatum||University of Aarhus|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|15 Years|N/A|No|Probability Sample|Elective consequtive patients admitted for surgical correction of pectus excavatum|August 2014|August 7, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308385||108107|
NCT01309204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-041|Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension|Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|May 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1184|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|March 3, 2011|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01309204||108045|
NCT01308697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03410|Flail Chest: A Randomized Controlled Study|Operative Versus Non Operative Management of Flail Chest: A Randomized Controlled Feasibility Study||University of British Columbia|No|Completed|April 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01308697||108084|
NCT01305473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE007|A Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite|A Single Arm, Single-Center, Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite|Sepramesh|C. R. Bard|No|Completed|August 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have been treated with Sepramesh at least 12 months before starting in this        study.|July 2012|July 31, 2012|February 25, 2011||No||No|June 12, 2012|https://clinicaltrials.gov/show/NCT01305473||108331|Study was designed to use existing data. Limitations include: limited data generalizability given the retrospective, single center study design; incomplete documentation did not permit evaluation of recovery time as pre-specified secondary endpoint.
NCT01305772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00023859|Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN|Identification of a Gene Expression Signature Profile for Panitumumab Sensitivity in Untreated Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)|TOP0901|Duke University|Yes|Terminated|January 2011|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|February 14, 2011|Yes|Yes|This study was terminated for low accrual.|No|September 10, 2013|https://clinicaltrials.gov/show/NCT01305772||108308|Early termination leading to small numbers of subjects analyzed.
NCT01305200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL1031|Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant|A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation||Children's Oncology Group|Yes|Active, not recruiting|March 2011|||June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|226|||Both|4 Years|21 Years|No|||March 2016|March 21, 2016|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305200||108352|
NCT01305447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prapavessis NCIC RCT|Getting Physical on Cigarettes - Smoking Cessation & Relapse Prevention|Getting Physical on Cigarettes: Exercise and Smoking Cessation - Preventing Relapse||University of Western Ontario, Canada|No|Completed|October 2009|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|413|||Female|18 Years|65 Years|No|||June 2012|December 15, 2014|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305447||108333|
NCT01305460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-AZA intensif|Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)|A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients||Groupe Francophone des Myelodysplasies|No|Active, not recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|81|||Both|18 Years|75 Years|No|||April 2015|October 28, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305460||108332|
NCT01305733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coxa - LIA|Local Infiltration Analgesia During Total Knee Arthroplasty|Local Infiltration Analgesia During Total Knee Arthroplasty - Reduced Opiate Consumption and Faster Mobilisation Postoperatively - Randomized Controlled Trial|LIA|Coxa, Hospital for Joint Replacement|Yes|Active, not recruiting|March 2011|December 2012|Anticipated|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||May 2012|May 8, 2012|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305733||108311|
NCT01305993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB injection-G002|Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer|Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Gastirc Cancer||SBPharmaceutical IND, Co., LTD|No|Not yet recruiting|May 2011|||December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||February 2011|February 27, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305993||108291|
NCT01306305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A004|A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations||Crucell Holland BV|No|Completed|June 2010|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|February 28, 2011||No||No|March 1, 2012|https://clinicaltrials.gov/show/NCT01306305||108267|
NCT01306591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bevacizumab for nAMD|Bevacizumab for Neovascular Age-related Macular Degeneration|Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration||Peking University People's Hospital|Yes|Completed|January 2008|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|210|||Both|50 Years|90 Years|No|||December 2010|March 1, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306591||108245|
NCT01306565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atorvastatin and CRP level|High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)|Comparison Between Effect of High Dose and Low Dose of Atorvastatin in Reduction Level of CRP in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)||Hormozgan University of Medical Sciences|No|Completed|January 2009|January 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||November 2008|March 1, 2011|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306565||108247|
NCT01306578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUCH-GBS|Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)|Comparison of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Mechanically Ventilated Children With Guillain Barre Syndrome. A Randomized Study.||Mansoura University Children Hospital|Yes|Completed|January 2007|February 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|1 Month|18 Months|No|||February 2011|March 1, 2011|March 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01306578||108246|
NCT01307592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000695874|Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma|Pilot Study of GC. (Gemcitabine-Rituximab-Oxaliplatin Combination) Given Every 14 Days With Maintenance Lenalidomide for the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma||National Cancer Institute (NCI)||Recruiting|February 2011|||February 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||February 2011|January 9, 2014|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307592||108168|
NCT01307098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CL01|Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Lysosomal Acid Lipase Deficiency|An Open Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency||Alexion Pharmaceuticals|Yes|Completed|May 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|65 Years|No|||June 2014|June 2, 2014|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307098||108206|
NCT01308112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHTM-5664|Prenatal Iron and Malaria Study|A Randomised Trial to Assess the Safety and Efficacy or Iron Supplementation in Kenyan Pregnant Women|PIMAL|London School of Hygiene and Tropical Medicine|Yes|Completed|October 2011|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|470|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|March 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01308112||108128|
NCT01308411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10010|Predicting Steroid Response Using Exhaled Nitric Oxide|Using Exhaled Nitric Oxide to Step Down Inhaled Corticosteroid Therapy in Asthma|PCR|University of Nottingham|No|Completed|November 2010|September 2013|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|191|||Both|18 Years|75 Years|No|||January 2014|January 31, 2014|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01308411||108106|
NCT01308710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R56NR004909|The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia|Endothelial Assessment of Risk From Lipids in Youth: Mediterranean Diet|EARLYMedit|University of California, San Francisco|Yes|Completed|January 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|10|||Both|8 Years|17 Years|No|||January 2014|January 23, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308710||108083|
NCT01308957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012999|Fish Oil and Muscle Function|Omega-3 Fatty Acids, Muscle Mass and Muscle Function||Washington University School of Medicine|Yes|Completed|June 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01308957||108064|
NCT01305226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIL/STA/05/2007|A Trial Using Double-Bolus THR-100 Versus Streptokinase|A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction|THR-100|Bharat Biotech International Limited|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|30 Years|75 Years|No|||February 2012|February 2, 2012|December 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305226||108350|
NCT01305486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVL-HE008|A Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation|A Prospective, Multi-Center Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation|XenMatrix|C. R. Bard|No|Terminated|September 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are diagnosed with a ventral or incisional hernia that require a component        separation repair with the use of a biological graft.|January 2013|January 14, 2013|December 22, 2010||No|Sponsor decision, not safety related.|No||https://clinicaltrials.gov/show/NCT01305486||108330|
NCT01306045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110096|Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies|Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|700|||Both|18 Years|100 Years|No|||July 2015|November 4, 2015|February 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306045||108287|
NCT01305213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02666|Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|March 2011|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305213||108351|
NCT01306058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110102|Sorafenib and TRC105 in Hepatocellular Cancer|A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)||National Institutes of Health Clinical Center (CC)||Recruiting|February 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|99 Years|No|||September 2015|October 6, 2015|February 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306058||108286|
NCT01306617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-746|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Completed|February 2011|October 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|65 Years|No|||December 2014|December 29, 2014|February 28, 2011|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01306617||108243|
NCT01306006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV-EPI|The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age|The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age|MVEPI|Bandim Health Project||Recruiting|February 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3500|||Both|9 Months|35 Months|Accepts Healthy Volunteers|||August 2014|August 6, 2014|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01306006||108290|
NCT01306019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110007|Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)|Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency||National Institutes of Health Clinical Center (CC)||Recruiting|October 2010|December 2025|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|30 Years|No|||March 2016|March 18, 2016|February 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306019||108289|
NCT01306032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110080|ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin s Lymphoma|Ph II Randomized Trial of the Combination of ABT-888 With Metronomic Oral Cyclophosphamide in Refractory BRCA-Pos Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Neg Breast Cancer, and Low-Grade NHL||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2011|May 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|N/A|No|||July 2014|January 23, 2015|February 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306032||108288|
NCT01306331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP001|Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel|A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel||Evofem Inc.|Yes|Completed|April 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3389|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|February 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306331||108265|
NCT01305746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-SLE3322|A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321|An Open-Label Long-term Safety Extension Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC)||Anthera Pharmaceuticals|Yes|Completed|April 2011|October 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|382|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305746||108310|
NCT01305759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD-JK-01|Psychological, Sexually and Social Consequences of Osteoarthritis Treatment With THA or TKA and Joint Preserving Surgery|Psychological, Sexually and Social Consequences of Osteoarthritis Treatment With Total Hip or Total Knee Arthroplasties and Joint Preserving Surgery||Hvidovre University Hospital|No|Active, not recruiting|April 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|250|||Both|16 Years|60 Years|No|Non-Probability Sample|Young adults undergoing TKA/THA/PAO with now other major health complications.|September 2011|September 19, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305759||108309|
NCT01305980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB injection-C002|Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer|Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Colorectal Cancer||SBPharmaceutical IND, Co., LTD|No|Recruiting|December 2010|March 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 3, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305980||108292|
NCT01307618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02580|Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma|A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma||National Cancer Institute (NCI)||Active, not recruiting|February 2011|||January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||October 2014|February 3, 2015|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307618||108166|
NCT01307631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00521|Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer|A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer||National Cancer Institute (NCI)||Active, not recruiting|March 2011|||January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Female|18 Years|N/A|No|||November 2015|January 4, 2016|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307631||108165|
NCT01307111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC #09-426|Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in IUD Insertion for Nulliparous Women||University of New Mexico|Yes|Completed|February 2011|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307111||108205|
NCT01307358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRC-0742|A Study Comparing the Interproximal Plaque and Gingivitis Effects of Three Interdental Cleaning Modalities|A Randomized Parallel Study Comparing the Interproximal Plaque and Gingivitis Effects of Three Interdental Cleaning Modalities|PAU|University of North Carolina, Chapel Hill|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307358||108186|
NCT01307371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIABETES-STEMI|Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)|Effects and Mechanism of Autologous Bone Marrow Mononuclear Cells (BMMNC)Transplantation in Diabetic Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Who Have Undergone Percutaneous Coronary Intervention (PCI)||Xijing Hospital|Yes|Recruiting|March 2007|December 2011|Anticipated|March 2008|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|110|Samples With DNA|Serum, Plasma|Both|25 Years|60 Years|No|Non-Probability Sample|Patients of STEMI with the culprit lesion of left anterior decending (LAD)coronary artery        were enrolled in this study.|February 2011|February 28, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01307371||108185|
NCT01307865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFW-001-SA|Volume Restoration of the Aging Midface With Sculptra Aesthetic|Volume Restoration of the Aging Midface With Sculptra Aesthetic||Williams Center Plastic Surgery Specialists||Completed|January 2011|June 2013|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 13, 2013|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307865||108147|
NCT01307878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110101|New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction|Study of New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction||Fudan University|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||December 2013|December 10, 2013|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307878||108146|
NCT01308125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 2009-03 PREPARE PICSO|Safety And Feasibility Study Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention|PREPARE PICSO A Study To Evaluate The Safety And Feasibility Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention|PICSO|Miracor Medical Systems|No|Completed|October 2010|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308125||108127|
NCT01308138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMRIPC|Myocardial Physiology And Microanatomy In Individuals Undergoing Heart Surgery|Study of Gaining Further Understanding of the Underlying Mechanisms of Myocardial Function|TRIMRIPC|Norwegian University of Science and Technology|No|Completed|January 2011|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|60|||Both|N/A|N/A|No|||August 2015|August 19, 2015|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308138||108126|
NCT01308424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-03-0112|Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection|A Randomized, Double-blind, Parallel, Placebo-controlled Study for the Assessment of the Safety and Efficacy of BTL-TML-HSV for the Treatment of Recurrent Symptomatic Oral Herpes Virus Infection||Beech Tree Labs, Inc.|No|Completed|January 2011|November 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|March 2, 2011|Yes|Yes||No|May 22, 2013|https://clinicaltrials.gov/show/NCT01308424||108105|
NCT01308437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3-WOS-IMS-01|Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics|An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.||Wockhardt|No|Terminated|March 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|55 Years|No|||August 2013|August 21, 2013|February 9, 2011|Yes|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT01308437||108104|
NCT01308723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25497|A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma|Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination With Sorafenib (Nexavar®), in Patients With Advanced or Metastatic and/or Unresectable Hepatocellular Carcinoma||Hoffmann-La Roche||Completed|March 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|21 Years|N/A|No|||March 2016|March 1, 2016|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308723||108082|
NCT01308970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002785|Quantification of Outcome Measures for Mind-body Interventions|Quantification of Outcome Measures for Mind-body Interventions||Massachusetts General Hospital|No|Completed|March 2011|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Actual|455|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01308970||108063|
NCT01308983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000|Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension||SAPHA|Georgia Regents University|Yes|Recruiting|September 2010|||December 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308983||108062|
NCT01305785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIS Plus|AMIS Plus - National Registry of Acute Myocardial Infarction in Switzerland|National Registry of Acute Myocardial Infarction in Switzerland|AMIS Plus|Luzerner Kantonsspital|No|Recruiting|January 1997|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60000|||Both|N/A|N/A|No|Probability Sample|Acute myocardial infarction definition:          1. Characteristic ischemic symptoms          2. ECG changes indicating new ischemia (ST-T changes or new left bundle branch block) or             developing pathological Q-waves          3. A dynamic increase or decrease in biomarker or troponin (I or T) levels above the             individual hospital cut-off for MI. The internationally accepted guidelines for             troponin levels are set at least one value above the 99th percentile of the upper             reference limit (URL). Cut-off levels for either total creatine kinase (CK) or             creatine kinase MB fraction (CK-MB) at least twice the upper limit of normal.|April 2013|April 16, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305785||108307|
NCT01306071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110108|Observational Study of Persons With Hepatitis B Virus Infection in North America|Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study)||National Institutes of Health Clinical Center (CC)||Recruiting|February 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|February 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01306071||108285|
NCT01306344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2607(REK)|Qualitative Descriptive Study of the Meaning of the Ward Round|Qualitative Descriptive Study of the Meaning of the Ward Round||Oslo University Hospital|No|Not yet recruiting|February 2011|December 2011|Anticipated|March 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|12|||Both|18 Years|N/A||Probability Sample|Inpatients at a hospital ward. Nurses and physicians working at the same hospital ward.        Heterogeneous groups.|February 2011|February 28, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306344||108264|
NCT01306357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RZO 01|Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device|Evaluation De L'Observance Globale Et De La Duree De Traitement Par Zomacton® Avec Le Stylo Transjecteur Zomajet® Etude Pharmaco-Epidemiologique Observationnelle Longitudinale Prospective|ZOMAJET|Ferring Pharmaceuticals|No|Completed|September 2007|November 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|87|||Both|N/A|N/A|No|Non-Probability Sample|All patients who meet the criteria of the Treatment Information Sheet (growth hormone        deficiency or Turner's syndrome) for which treatment is initiated with Zomacton® 4 mg        using the Zomajet® 2 Vision needle-free device or with Zomacton® 10 mg using the Zomajet®        Vision X.|February 2012|February 6, 2012|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306357||108263|
NCT01306630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-10-114|A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors|A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors||AVEO Pharmaceuticals, Inc.|No|Completed|November 2010|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|November 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306630||108242|
NCT01306890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-3|A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer|A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer|PROCEED|Dendreon|No|Active, not recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Male|18 Years|N/A|No|Non-Probability Sample|Men at least 18 years of age that have advanced prostate cancer that is treated with        sipuleucel-T|February 2016|February 29, 2016|February 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01306890||108222|
NCT01306877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVHEPH0109|Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids|Prospective Single Blinded Randomized Controlled Trial Comparing The Covidien EEA™ Hemorrhoid and Prolapse Stapling Set With DST Series™ Technology Vs. Ethicon PPH03 In A Hemorrhoidopexy Procedure (HEMOSTASIS)|HEMOSTASIS|Medtronic - MITG|No|Completed|January 2011|January 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|85 Years|No|||October 2014|October 24, 2014|January 28, 2011||No||No|February 20, 2014|https://clinicaltrials.gov/show/NCT01306877||108223|
NCT01306903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mini-ECC001AHK|Minimal Extracorporeal Circuits (MECC) in Cardiac Surgery Procedures|Minimal Extracorporeal Circuits (MECC) in Cardiac Surgery Procedures|MECC|Johann Wolfgang Goethe University Hospitals||Completed|March 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306903||108221|
NCT01307150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK09409-HMO-CTIL|Climatotherapy At The Dead Sea For Atopic Dermatitis|Evaluation of the Efficacy of Dead Sea Climatotherapy on Atopic Dermatitis Patients.||Hadassah Medical Organization|No|Not yet recruiting|June 2009|December 2009|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Atopic Dermatitis patient.|July 2009|March 1, 2011|July 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01307150||108202|
NCT01307163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ran19-HMO-CTIL|Systemic Variables in the Saliva of Children Undergoing Liver Transplantation|Systemic Variables in the Saliva of Children Undergoing Liver Transplantation||Hadassah Medical Organization|No|Not yet recruiting|January 2008|December 2008|Anticipated|December 2008|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|60|Samples Without DNA|saliva|Both|2 Years|16 Years|No|Non-Probability Sample|In this prospective study 60 subjects will be examined. Children and adolescents from        Schnaidder's hospital for children after a successful liver transplantation will be        characterized as the study group. As a control group, 32 healthy examinees in the same age        group will be selected from the dental pediatric department at Hadassah hospital, Ein        karem, Jerusalem|December 2007|March 1, 2011|January 10, 2008||No||No||https://clinicaltrials.gov/show/NCT01307163||108201|
NCT01306604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN04/2011|Biomarker for Niemann Pick Type C Disease|Biomarker for Niemann Pick Type C Disease an International, Multicenter, Epidemiological Study|BioNPC|University of Rostock|Yes|Recruiting|March 2011|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 20ml EDTA      and a dry blood spot filter card. To proof the correct NPC nosis in those patients where up      to the enrollment in the study no genetic testing has been done, sequencing of NPC1 and/or      NPC2 will be done. The analyses are done in the Albrecht-Kossel-Institute for      Neuroregeneration (AKos) Gehlsheimerstr.20, 18055 Rostock (Germany)|Both|N/A|N/A|No|Probability Sample|Patients with a diagnosis of Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion        for Niemann Pick Type C syndrome NPC1/NPC2 disease|November 2015|November 10, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306604||108244|
NCT01308164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc005814ctil|MD Logic Pump Advisor -Pediatric Study|Evaluation of Automated-Insulin Pump Setting Using the MD-Logic Pump Advisor -Minors Sub Study||Rabin Medical Center|No|Recruiting|March 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|10 Years|18 Years|No|||February 2016|February 28, 2016|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01308164||108124|
NCT01306838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFIRB00011501|Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy|Early Supplementation of Enteral Lipid With Combination of Microlipid and Fish Oil in Infants With Enterostomy|EMLFO|Wake Forest School of Medicine|No|Active, not recruiting|October 2009|October 2014|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|N/A|60 Days|No|||May 2013|May 24, 2013|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306838||108226|
NCT01306851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTTISUCOL-001|Prevention of Anastomotic Leak in Gastrointestinal (GI) Anastomosis With the Application of Tisseal in the Anastomotic Line|Multicenter, Randomized, Controlled, Single Blinded, Phase IV Study Comparing 2 Parallel Groups in the Evaluation of the Prevention of Anastomotic Leaks in GI High Risk Anastomosis, With or Without the Application of Fibrin Glue in the Anastomotic Line||Hospital General Universitario Gregorio Marañon|No|Recruiting|June 2007|June 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|200|||Both|N/A|N/A|No|||May 2007|March 1, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306851||108225|
NCT01306864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-017|Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding|Clinical Evaluation of Hemospray: Hemostasis of Active GI Luminal Tract Bleeding|HALT|Cook||Recruiting|December 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01306864||108224|
NCT01307124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 152|Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)|A Multicenter Randomized Study to Compare the Safety and Efficacy of Low-dose Versus Standard Dose Lopinavir/Ritonavir Containing HAART Regimen in Virological Suppressed HIV-infected Thai Children||The HIV Netherlands Australia Thailand Research Collaboration|Yes|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|199|||Both|N/A|18 Years|No|||March 2015|March 23, 2015|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01307124||108204|
NCT01307137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00915|Peer-led and Telehealth Comparative Effectiveness Research (CER) Adoption for Diabetes Prevention and Management|Peer-lead and Telemedicine Activated Care (PACT) in Diabetes Prevention and Management||South Florida Veterans Affairs Foundation for Research and Education||Not yet recruiting|June 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|85|||Both|60 Years|N/A|No|||January 2011|March 1, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307137||108203|
NCT01308450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBD0111|Adult Normative Performance of the Quotient ADHD System|Adult Normative Performance on Quotient ADHD System - Adolescent and Adult Version (Ages 15-55 Years Old)|ADHD|BioBehavioral Diagnostics Company|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|300|||Both|15 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Well-screened, Healthy Non-ADHD Controls, Ages 15-55 from a single private practice        clinic.|November 2013|November 4, 2013|March 2, 2011||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT01308450||108103|
NCT01307605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 35/10|Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma|Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.||Swiss Group for Clinical Cancer Research|Yes|Active, not recruiting|February 2011|December 2015|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307605||108167|
NCT01309230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL 105|Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer|Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer|FANG Ovarian|Gradalis, Inc.|Yes|Active, not recruiting|February 2011|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|18 Years|N/A|No|||November 2015|November 10, 2015|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309230||108043|
NCT01305239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA5990024|A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients|A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients|ETAPE|Pfizer|No|Terminated|October 2008|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|398|||Female|45 Years|N/A|No|Non-Probability Sample|Postmenopausal patients, hormone receptor positive, who have had surgical treatment for        histologically confirmed early breast cancer that was nonmetastatic at the time of the        initial diagnosis, treated by Aromasin as adjuvant endocrine therapy.|November 2011|March 8, 2012|February 24, 2011|No|Yes|See termination reason in detailed description.|No|March 8, 2012|https://clinicaltrials.gov/show/NCT01305239||108349|Study recruitment was stopped due to difficulty enrolling the target number of participants. There were no safety concerns in the decision to terminate this study.
NCT01305499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2914|A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)|A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination With 5-Azacytidine (5AC, NSC 102816) in Elderly Patients With Acute Myeloid Leukemia (AML)||Case Comprehensive Cancer Center|Yes|Recruiting|July 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|60 Years|N/A|No|||March 2016|March 7, 2016|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305499||108329|
NCT01305811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW080059(W81XWH-09-2-0064)|Acupuncture in the Treatment of Gulf War Illness|Acupuncture in the Treatment of Gulf War Illness||New England School of Acupuncture|Yes|Completed|July 2009|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|39 Years|N/A|No|||May 2015|May 20, 2015|February 24, 2011||No||No|September 29, 2014|https://clinicaltrials.gov/show/NCT01305811||108305|
NCT01305798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003|The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening Participation|The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening Participation||National Bureau of Economic Research, Inc.|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|11000|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01305798||108306|
NCT01306370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017804-95|Fibrin Glue or Tranexamic Acid for Total Knee Arthroplasty|Prevention of Postoperative Blood Loss: Randomised Unicentric Parallel Clinical Trial That Assess the Efficacy of Fibrin Glue and Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.|ATRHEMOS|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|June 2010|November 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|172|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306370||108262|
NCT01306643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-10|Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma|Single-agent CAL-101 for Previously Teated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events||Gilead Sciences|No|Completed|February 2011|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306643||108241|
NCT01306916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-20018|Coexisting Thyroid Disease and Hyperparathyroidism|Coexisting Thyroid Disease and Hyperparathyroidism||Walter Reed Army Medical Center|No|Completed|September 2004|July 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|200 military health care beneficiaries over the age of 18 years with primary and secondary        hyperparathyroidism scheduled to undergo parathyroid resection.|July 2012|July 2, 2012|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01306916||108220|
NCT01307176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00008601|Exercise Training Program for Cerebellar Ataxia|Exercise Training Program for Cerebellar Ataxia||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|February 2011|February 2015|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|95 Years|No|||March 2015|March 31, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01307176||108200|
NCT01307397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO25515|A Study of RO5185426 in Patients With Metastatic Melanoma|An Open-label, Multicenter Study to Assess the Safety of RO5185426 in Patients With Metastatic Melanoma||Hoffmann-La Roche||Active, not recruiting|March 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3286|||Both|16 Years|N/A|No|||December 2015|December 31, 2015|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01307397||108183|
NCT01307384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU2010-02H|Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) Study|Prospective Post Market Clinical Follow-Up Study of the Continuum Metal on Polyethylene Acetabular System||Zimmer, Inc.|No|Recruiting|March 2011|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood drawn for metal ion testing|Both|18 Years|75 Years|No|Non-Probability Sample|Patients from surgeons medical practice who are candidates for primary hip arthroplasty|October 2014|October 16, 2014|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01307384||108184|
NCT01307891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F101004001 (UAB1028)|Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer|An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer||University of Alabama at Birmingham|Yes|Active, not recruiting|March 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307891||108145|
NCT01308151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILL-UoM Self Harm 250410|Culturally Adapted Cognitive Behavioral Therapy for Prevention of Self Harm|Culturally Adapted Manual Assisted Cognitive Behavioral Therapy for Prevention of Self Harm: A Randomized Control Trial||Pakistan Institute of Learning and Living|No|Completed|March 2010|October 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|16 Years|64 Years|No|||December 2013|December 15, 2013|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308151||108125|
NCT01309009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIC-05 (NOCRY-a)|Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment|Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Efficacy and Safety of Oral Administration of Nepadutant in Infant Colic Babies Not Responder to Conventional Treatments|nocry-a|Menarini Group|No|Withdrawn|February 2011|January 2013|Anticipated|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|6 Weeks|4 Months|No|||November 2012|November 5, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01309009||108060|
NCT01308736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS777117|Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit|Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit||Rutgers, The State University of New Jersey|Yes|Completed|January 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2015|July 22, 2015|January 28, 2011|Yes|Yes||No|May 18, 2015|https://clinicaltrials.gov/show/NCT01308736||108081|
NCT01308996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G100313|Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation|A Prospective, Open Label, Randomized, Multicenter, Controlled Clinical Study of INFUSE® Bone Graft Used as an Alternative to Autogenous Bone Graft for Vertical Alveolar Ridge Augmentation||Medtronic Spinal and Biologics|Yes|Withdrawn|April 2012|September 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|75 Years|No|||August 2012|March 12, 2015|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01308996||108061|
NCT01309256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0659|Multi-institutional Study on the Assessment of Robotic Surgery for Gastric Cancer|||Yonsei University|Yes|Completed|March 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|1650|||Both|20 Years|N/A|No|Non-Probability Sample|Gastric cancer patients|June 2013|June 1, 2013|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309256||108041|
NCT01305252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07152010-6565|A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil), 2 FDA Approved Pulmonary Hypertension Medications|CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil||Stanford University|Yes|Active, not recruiting|July 2010|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|69 Years|No|||May 2014|May 21, 2014|November 2, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305252||108348|
NCT01305265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|weottp|Post-operative Sore Throat as Determined by Endotracheal Tube Inflation Technique|Post-operative Sore Throat as Determines by Endotracheal Tube Inflation Technique||University of California, San Francisco|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|141|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 6, 2014|February 24, 2011||No||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01305265||108347|
NCT01305512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_10_28|Pharmacokinetic, Safety and Tolerability Study of SPARC1028|||Sun Pharma Advanced Research Company Limited|No|Active, not recruiting|May 2012|April 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01305512||108328|
NCT01305525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-01|A Prospective Clinical Outcomes Registry|Partnership for Advancement In Neuromodulation (PAIN): A Prospective Clinical Outcomes Registry|PAIN Registry|St. Jude Medical|No|Completed|June 2009|April 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|614|||Both|18 Years|N/A|No|Probability Sample|Patients implanted with a neuromodulation system|April 2014|July 24, 2015|February 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01305525||108327|
NCT01305538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN169-002|Crossover Post-herpetic Neuralgia (PHN)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Cross-over Study of the Efficacy and Safety of BMS-954561 in Patients With Post-herpetic Neuralgia (PHN)||Bristol-Myers Squibb|No|Completed|March 2011|June 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|85 Years|No|||November 2015|November 6, 2015|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305538||108326|
NCT01305824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-201-201|A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease|Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease||Proteon Therapeutics|Yes|Completed|March 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305824||108304|
NCT01306097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zinc supplementation|Zinc Supplementation and Severe and Recurrent Diarrhea|Evaluating the Impact of 3 Months Daily Zinc Supplementation on Incidence of Severe and Recurrent Diarrhea in 6 to 36 Months Age Children||Hormozgan University of Medical Sciences|No|Completed|January 2009|May 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|100|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||January 2009|February 28, 2011|February 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306097||108283|
NCT01306084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110109|Viral Infections in Healthy and Immunocompromised Hosts|Viral Infections in Healthy and Immunocompromised Hosts||National Institutes of Health Clinical Center (CC)||Recruiting|February 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|N/A|N/A|No|||August 2015|September 24, 2015|February 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01306084||108284|
NCT01306396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03105084 (IB)|Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight Children|Investigation on the Preventive Effect of Reduced Fructose Consumption on the Development of Non-alcoholic Fatty Liver Disease in Children in a Long Term Study||University of Hohenheim|No|Recruiting|April 2009|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||February 2011|February 28, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01306396||108260|
NCT01306929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACR16C015|Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease|A Multi-center, North American, Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease (Open-Hart)|OPEN-HART|Teva Pharmaceutical Industries|Yes|Active, not recruiting|March 2011|May 2021|Anticipated|April 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|235|||Both|N/A|N/A|No|||March 2016|March 1, 2016|February 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306929||108219|
NCT01306942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2010-04|Dasatinib In Combination With Trastuzumab And Paclitaxel In The First Line Treatment Of Her2-Positive Metastatic Breast Cancer (MBC) Patients|A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (Mbc) Patients||Spanish Breast Cancer Research Group|No|Active, not recruiting|July 2011|December 2016|Anticipated|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Female|18 Years|N/A|No|||December 2015|December 9, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01306942||108218|
NCT01301625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol #M10-001|MitraClip System in Australia and New Zealand|A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand|MitraClipANZ|Evalve|Yes|Terminated|November 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients eligible to receive the MitraClip implant at the designated        investigational sites in Australia and New Zealand.|November 2015|November 2, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01301625||108625|
NCT01307189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER1199|Effects of Tiotropium on Walking Capacity in Patients With COPD|Effects of Tiotropium on Walking Capacity in Patients With COPD||Laval University|No|Completed|April 2005|August 2010|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|50 Years|85 Years|No|||August 2010|February 28, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307189||108199|
NCT01301898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1111_P1/2|To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients|Randomized, Single-blind, Active-controlled, Phase 1/2 Study to Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome (Mucopolysaccharidosis II) Patients||Green Cross Corporation|Yes|Completed|May 2010|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|31|||Male|6 Years|35 Years|No|||February 2012|February 12, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301898||108604|
NCT01307410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMR-303-3B Extension|A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China|A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China - 3B Extension A Study of China Cardiometabolic Registries (CCMR)|CCMR-3B Ext|China Cardiometabolic Registries|No|Active, not recruiting|March 2011|December 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|||Both|40 Years|N/A|No|Probability Sample|Patients with type 2 diabetes who previously participated in the 3B study from either        community (tier 1), regional (tier 2), or teriary (tier 3) hospitals|February 2011|February 13, 2013|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307410||108182|
NCT01307904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAEU Dates GI Study|The Glycemic Indices of Five Common Varieties of Dates in the Tested Among Healthy and Diabetic Subjects|The Glycemic Indices of Five Common Varieties of Dates in the Tested Among Healthy and Diabetic Subjects|Dates|United Arab Emirates University|No|Completed|March 2010|July 2010|Actual|March 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|23|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2010|March 2, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307904||108144|
NCT01307644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237-10-FB|Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness|Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women||University of Nebraska|Yes|Active, not recruiting|May 2011|June 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|301|||Female|40 Years|69 Years|No|||June 2015|June 29, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307644||108164|
NCT01307657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|568-10-FB|Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects|Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects||University of Nebraska|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307657||108163|
NCT01308463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.EX002|Discovery Elbow Long-Term Survivorship|Discovery Elbow Long-Term Survivorship Study||Biomet, Inc.|No|Enrolling by invitation|January 2011|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|The Study population shall be participanting in the Discovery Elbow Multi-center Study who        provide consent for the Discovey Elbow Long-term Survivoship Study|December 2015|January 11, 2016|July 23, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01308463||108102|
NCT01308476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.474|SMS Reminder to Assess Adherence|Assessment if a Daily SMS (Short Message System) Reminder Improves the Adherence of COPD Patients to Therapy With Spiriva® 18 Microgram||Boehringer Ingelheim||Completed|March 2011|||November 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|95|||Both|18 Years|N/A|No|Non-Probability Sample|Patients|January 2013|January 17, 2013|March 1, 2011||||No|November 20, 2012|https://clinicaltrials.gov/show/NCT01308476||108101|
NCT01308749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0493|A Study of Oxytocin in Children and Adolescents With Autistic Disorder|A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder|Oxytocin|University of North Carolina, Chapel Hill|No|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|3 Years|17 Years|No|||September 2013|September 10, 2013|February 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01308749||108080|
NCT01308762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM-101-001|A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients|An Intra-patient Placebo-controlled, Phase I Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 (Heat-killed Mycobacterium Obuense) in Adult Melanoma Cancer Patients||Immodulon Therapeutics Ltd|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|19|||Both|18 Years|N/A|No|||September 2012|November 8, 2012|February 16, 2011|No|Yes||No|March 30, 2011|https://clinicaltrials.gov/show/NCT01308762||108079|
NCT01308775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC077515|Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer|A Pilot Study Comparing a Patient-Centered Symptom Reporting Follow Up Program (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer|CC077515|University of California, San Francisco|No|Completed|January 2011|March 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|102|||Female|18 Years|N/A|No|||March 2015|March 6, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01308775||108078|
NCT01309243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-264-0110|Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults||Gilead Sciences|No|Completed|February 2011|February 2014|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|799|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|March 3, 2011|Yes|Yes||No|September 25, 2013|https://clinicaltrials.gov/show/NCT01309243||108042|
NCT01309269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22911|Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine|Non-interventional Study to Investigate the Long Term Effects of MIRCERA in Clinical Routine||Hoffmann-La Roche||Completed|September 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1083|||Both|18 Years|N/A|No|Probability Sample|Chronic kidney disease patients treated with Mircera for renal anemia|February 2016|February 1, 2016|March 3, 2011||No||No|September 2, 2015|https://clinicaltrials.gov/show/NCT01309269||108040|
NCT01309282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22935|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Reponders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)|Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor||Hoffmann-La Roche||Completed|July 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|N/A|No|Probability Sample|Patients with sero-positive rheumatoid arthritis starting treatment with MabThera/Rituxan        following lack of response or intolerance to single TNF-inhibitor|November 2015|November 2, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309282||108039|
NCT01305278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN-TGH-NO-0004|The Efficacy of Balance Gaming as an Adjunct to Vestibular Rehabilitation Therapy|The Efficacy of Balance Gaming as an Adjunct to Vestibular Rehabilitation Therapy||University Health Network, Toronto|No|Recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01305278||108346|
NCT01305291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADM FB2-1 Hendrich|Fibersol-2 Clinical Trials Related to Appetite|Fibersol-2 Clinical Trials Related to Appetite||Iowa State University|No|Completed|November 2008|November 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|20|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||February 2011|February 25, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305291||108345|
NCT01305551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-146|BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin Hydrochloride (HCl) XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States||AstraZeneca|No|Withdrawn|March 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 4, 2014|February 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01305551||108325|
NCT01304680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI/IOP 03/11|Evaluation of Fluid Resuscitation in Children With Cancer With Severe Sepsis / Septic Shock|||Grupo de Apoio ao Adolescente e a Crianca com Cancer|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|pediatric patients admitted to intensive care unit with septic chock|November 2012|November 28, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304680||108392|
NCT01300832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-589-A|The Incidence of Perioperative Deep Venous Thromboses of the Lower Extremities|The Incidence of Perioperative Deep Venous Thromboses of the Lower Extremities||University of Chicago|Yes|Recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|1000|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300832||108685|
NCT01300845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI 2010-02|Trial Aiming at Assessing the Effect of Humidification on the Comfort of the Patient Receiving an Oxygen Therapy|Prospective, Randomized, Multi-center Trial Aiming at Assessing the Effect of Humidification on the Comfort of the Patient Receiving an Oxygen Therapy.|OXYREA|University Hospital, Angers|No|Completed|March 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|356|||Both|18 Years|N/A|No|||February 2014|November 19, 2014|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300845||108684|
NCT01306110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS02-062007|Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study|Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study|DIABSCAN|Association HGE CHU Bordeaux Sud|No|Completed|June 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|277|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diabetes|January 2016|January 7, 2016|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306110||108282|
NCT01306383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SODISWATER EU 031650|Solar Disinfection (SODIS) of Drinking Water for Use in Developing Countries or in Emergency Situations|Assessment of the Health Benefits Associated With Consumption of Solar Disinfection of Drinking Water by Children Under Age 5 Years, With Particular Emphasis on Dysentery and Childhood Diarrhoea|SODISWATER|Royal College of Surgeons, Ireland|No|Completed|June 2008|May 2010|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2400|||Both|12 Months|5 Years|Accepts Healthy Volunteers|||February 2011|November 9, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306383||108261|
NCT01301638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099150-E|Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections|||Far Eastern Memorial Hospital|No|Not yet recruiting|February 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Before Daptomycin (Cubicin ®) approved by the U.S. FDA in 2003, There were large-scale        clinical trials conducted that include more than 1,000 subjects and than Daptomycin got        complicated skin and soft tissue infections (CSSSI) indication. After 2004, Daptomycin got        new indications about bacteremia and endocarditis due to success outcomes in the clinical        trial which included infected in blood flow and endocardial infected patients.        All subjects in Daptomycin clinical trials are European and American race. It is necessary        that collecting safety and efficacy data of Daptomycin in Taiwan race. I will intent to        evaluate the safety and efficacy of Daptomycin which were used in patients with serious        gram-positive infections retrospectively. And the outcome could be a reference for        Daptomycin future using|February 2011|February 22, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301638||108624|
NCT01301924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StdvsaltCL|Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis|Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis||Oswaldo Cruz Foundation|Yes|Active, not recruiting|October 2008|July 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|264|||Both|13 Years|N/A|No|||June 2015|June 17, 2015|February 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01301924||108602|
NCT01301937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|low dosage ML|Low Antimonial Dosage in American Mucosal Leishmaniasis|Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes||Oswaldo Cruz Foundation|Yes|Recruiting|October 2008|December 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|13 Years|N/A|No|||June 2015|June 17, 2015|February 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01301937||108601|
NCT01302275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIOXC|Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain|Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain: Predictors of Response - a Randomised, Double-blind, Placebo-controlled Clinical Trial|IMIOXC|Odense University Hospital|Yes|Completed|February 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||May 2014|May 2, 2014|February 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302275||108575|
NCT01302288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEG1056|Endolumenal Partial Myotomy for the Treatment of Esophageal Achalasia|Endoscopic Submucosal Tunnel Dissection for Endolumenal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia||The Oregon Clinic|Yes|Recruiting|October 2010|||October 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||October 2010|February 25, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302288||108574|
NCT01301911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPTN-Ia-1.0|Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer|A Phase I Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer||Jiangsu HengRui Medicine Co., Ltd.|Yes|Terminated|January 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 20, 2012|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01301911||108603|
NCT01302262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143/2010|Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans|Does the Insula Control Smoking-induced Dopamine Release? A TMS/[11C]-PHNO Study in Humans. Part I: Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans.||Centre for Addiction and Mental Health|No|Completed|February 2011|March 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|Samples With DNA|Whole blood (15mL)|Both|21 Years|45 Years|No|Non-Probability Sample|Healthy smokers|March 2013|March 4, 2013|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302262||108576|
NCT01302535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/728|The Impact of Yoga on Blood Pressure and Quality of Life in Patients With Hypertension|The Impact of Yoga on Blood Pressure and Quality of Life in Patients With Hypertension - a Randomised Controlled Trial in Primary Health Care|YHIP|Region Skane|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|83|||Both|N/A|80 Years|No|||February 2012|February 22, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302535||108555|
NCT01302808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCC-12508|Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase I/II Study of Erlotinib and Romidepsin in Advanced Non-Small Cell Lung Cancer||University of Texas Southwestern Medical Center||Completed|September 2009|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|February 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302808||108536|
NCT01308177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-10-044|Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection|Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial||Samsung Medical Center||Enrolling by invitation|March 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||March 2011|March 2, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308177||108123|
NCT01308489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10115|Minimally Invasive Surgery in Treating Patients With Spinal Tumors|Comparison of Minimally Invasive Approaches of Spine Tumor Surgery||City of Hope Medical Center|Yes|Terminated|May 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|March 1, 2011|No|Yes|Lack of subject response|No||https://clinicaltrials.gov/show/NCT01308489||108100|
NCT01308502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007341|A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux|A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux||Children's Hospital of Philadelphia|No|Withdrawn|January 2010|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|1 Month|17 Years|No|||March 2012|March 29, 2012|March 2, 2011|No|Yes|Difficulty recruiting patients due to logistics|No||https://clinicaltrials.gov/show/NCT01308502||108099|
NCT01303601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWang|Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression|Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression: a Randomized, Double-blind, Placebo Controlled Study||China Medical University, China|Yes|Completed|January 2009|October 2010|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|60 Years|No|||December 2008|February 24, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303601||108475|
NCT01303614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hysterosalpingography-2010|Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysterosalpingography Practice|Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysterosalpingography Practice: a Prospective Randomized Double Blind, Placebo-controlled Clinical Trial|HSG-2010|Consorci Sanitari de Terrassa|No|Not yet recruiting|April 2011|September 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|80 Years|No|||September 2010|February 24, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303614||108474|
NCT01309022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN040CT|Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)|Immunosuppressive Medications for Previous Participants in Clinical Trial NIS01 (ITN005CT, NCT00014911)||National Institute of Allergy and Infectious Diseases (NIAID)||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||February 2016|February 5, 2016|March 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01309022||108059|
NCT01304160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 09.153|Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer|Phase I/II Study to Investigate the Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|September 2010|July 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01304160||108432|
NCT01304407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27088|Calcium Absorption in Patients With Rothmund-Thomson Syndrome|Evaluation of Calcium Absorption in Patients With Rothmund-Thomson Syndrome||Baylor College of Medicine|No|Enrolling by invitation|March 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|4 Years|N/A|No|Non-Probability Sample|Patients with Rothmund-Thomson Syndrome (RTS)|March 2015|March 25, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01304407||108413|
NCT01304420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10439|Ultrasonography in Juvenile Idiopathic Arthritis|Changes in Joint-Cartilage as a Measure of Outcome in Juvenile Idiopathic Arthritis - Assessed by Ultrasonography and Biomarkers||University of Aarhus|No|Completed|October 2009|November 2011|Actual|November 2011|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|95|Samples Without DNA|Serum specimens taken for rutine markers of inflammation.|Both|5 Years|15 Years|No|Non-Probability Sample|Children diagnosed with Juvenile Idiopathic Arthritis, followed in dept of pediatric        rheumatology, Aarhus University Hospital, Skejby|March 2012|March 21, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01304420||108412|
NCT01304966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qnischent01|Human Papillomatosis Genotyping of Children in Thailand|Human Papillomatosis Genotyping and Severity in Patients With Recurrent Respiratory Papillomatosis of Children in Thailand||Queen Sirikit National Institute of Child Health|No|Completed|March 2011|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|Samples With DNA|Papillomatous tissue samples taken from endoscopic biopsies will be collected by the ENT      specialists.Samples collected from the subjects will be analyzed for HPV genotype at the      Unit of virology and molecular, Department of pathology, Faculty of medicine Ramathibodi      hospital.|Both|N/A|18 Years|No|Probability Sample|Target enrollment will be all children who are diagnosed with RRP.|October 2013|January 1, 2014|February 25, 2011|Yes|Yes||No|April 13, 2013|https://clinicaltrials.gov/show/NCT01304966||108370|The number of patients participating in this study was low , so additional studies should be conducted to make the research more effective.
NCT01301404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|763/2553(EC2)|10% Carbohydrate Drink for Preventing Post-operative Nausea and Vomiting (PONV) After Spinal Morphine|Oral Rehydration Therapy With 10% Carbohydrate Drink for Preventing Postoperative Nausea and Vomiting (PONV) After Low Dose of Spinal Morphine in Patients Undergoing Total Knee Replacement||Mahidol University|No|Completed|February 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|50 Years|85 Years|No|||June 2012|July 18, 2013|February 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01301404||108641|
NCT01301092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13989|A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.|A Study to Evaluate the Safety, Tolerability, and Absolute Bioavailability of Subcutaneous LY2189265||Eli Lilly and Company|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 3, 2014|February 18, 2011|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01301092||108665|
NCT01301105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT002114-01|The Effects of Mindfulness Training on Pain Regulation, Negative Affect, Attention, and Social Stress|The Effects of Mindfulness Training on Pain Regulation, Negative Affect, Attention, and Social Stress.||University of Wisconsin, Madison|No|Completed|October 2005|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|October 1, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301105||108664|
NCT01301391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDKO-125a-007|Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy|Phase II Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy||Tiziana Life Sciences, PLC|No|Recruiting|January 2011|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||September 2015|November 3, 2015|February 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301391||108642|
NCT01302314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSØ-2011041|Cognitive Rehabilitation in Patients With Spina Bifida|Cognitive Rehabilitation in Patients With Spina Bifida: Effects on Executive Functions, Psychological and Health Related Factors||Sunnaas Rehabilitation Hospital|No|Completed|January 2011|December 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|20 Years|46 Years|No|||January 2014|January 21, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302314||108572|
NCT01302561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|355-2010|Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season|Protocol 2: Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season|GOS|University of Florida|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|84|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 1, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302561||108553|
NCT01302574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 69/04.02|Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides|The Role of Sweet Taste Receptor Blockade on Intragastric Liquid Meal-stimulated Secretion of Satiation Peptides in Healthy Humans||University Hospital, Basel, Switzerland|No|Completed|January 2010|June 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2011|February 23, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302574||108552|
NCT01302847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1093|Safety of and Immune Response to Dolutegravir (GSK1349572) in HIV-1 Infected Infants, Children, and Adolescents|Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|March 2011|||May 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|160|||Both|N/A|17 Years|No|||March 2016|March 14, 2016|February 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302847||108533|
NCT01302860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2307|Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease|A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)||Novartis|Yes|Completed|November 2010|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|1 Month|60 Months|No|||July 2015|July 22, 2015|February 22, 2011|Yes|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01302860||108532|
NCT01302873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2210|Study of BGG492 in Patients With Chronic Subjective Tinnitus|A Multicenter, Randomized, Double-blind, Placebo- Controlled, Cross-over, Proof of Concept Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 2 Weeks of BGG492 in Patients With Chronic Subjective Tinnitus||Novartis||Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|75 Years|No|||April 2012|April 24, 2012|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01302873||108531|
NCT01302548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101227|The Effect Of Wound Irrigation With Irrisept™ Delivery System On Abscess Healing In Patients Presenting To The Emergency Department|THE EFFECT OF WOUND IRRIGATION WITH IRRISEPT™ Delivery System ON ABSCESS HEALING IN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT||University of Florida|Yes|Terminated|February 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|12 Years|N/A|No|||February 2014|February 28, 2014|September 29, 2010|Yes|Yes|Study did not accrue the required number of study subjects.|No|September 9, 2013|https://clinicaltrials.gov/show/NCT01302548||108554|
NCT01302821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 8701|C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer|NCI 8701: A Pilot Study Utilizing C11 Alpha Methyl Tryptophan (AMT) PET Functional Imaging in Patients With Metastatic Invasive Breast Cancer Treated With 1 Methyl D Tryptophan Plus the Ad p53 DC Vaccine||H. Lee Moffitt Cancer Center and Research Institute|No|Withdrawn||December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302821||108535|
NCT01302834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-1016|Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer|Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|June 2011|||June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|706|||Both|18 Years|120 Years|No|||November 2015|November 14, 2015|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302834||108534|
NCT01303133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09080266|Natural History of Amyloid Deposition in Adults With Down Syndrome|Natural History of Amyloid Deposition in Adults With Down Syndrome||University of Pittsburgh|Yes|Recruiting|August 2009|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|64|Samples With DNA|Trisomy 21 ApoE|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Non-Demented Adults with Down Syndrome, ages 30 and above|January 2016|January 8, 2016|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01303133||108511|
NCT01303367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99076|Medication Management and Care of Demented Patients With Behavioral and Psychological Symptoms of Dementia in Taiwan: A Retrospective Pilot Study|Medication Management and Care of Demented Patients With Behavioral and Psychological Symptoms of Dementia in Taiwan: A Retrospective Pilot Study||Taipei Medical University WanFang Hospital|No|Completed|January 2002|December 2010|Actual|||N/A|Observational|Time Perspective: Retrospective||2|Actual|200|||Both|20 Years|N/A|No|Non-Probability Sample|dementia patients|February 2011|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01303367||108493|
NCT01303107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIST019|Comparative Mixture of Non-racemic and Racemic Enantiomers of Bupivacaine in Cesarean|A Non-Inferiority Phase 3 Comparative Study Between a Heavy Levobupivacaine in 50% Enantiomeric Excess (Bupivacaine S75:R25) and Heavy Racemic Bupivacaine for Cesarean Operation||Cristália Produtos Químicos Farmacêuticos Ltda.|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2011|March 25, 2014|February 23, 2011||No|The Sponsor has no interest in continuing the study.|No||https://clinicaltrials.gov/show/NCT01303107||108513|
NCT01303120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0021-11-HYMC|Does a Single Shot Femoral Nerve Block Alone Produce Appropriate Pain Relief?|Does a Single Shot Femoral Nerve Block Alone Produce Appropriate Pain Relief After Total Knee Arthroplasty or Should an Addition of Sciatic, Obturator and Lateral Femoral Cutaneous Nerve Blocks be Recommended?||Hillel Yaffe Medical Center|Yes|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|107|||Both|30 Years|85 Years|No|||February 2011|January 20, 2015|February 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01303120||108512|
NCT01303354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB 080582|Lumbar Transforaminal Epidural Dexamethasone|Lumbar Transforaminal Epidural Dexamethasone: A Prospective, Randomized, Double-Blind Clinical Trial||Ahadian, Farshad M., M.D.|No|Completed|April 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01303354||108494|
NCT01304173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3329-401|Retrospective Chart Review of Valstar|A Retrospective Analysis to Evaluate the Effectiveness, Safety and Tolerability of Intravesical Valrubicin for the Treatment of Bladder Carcinoma in Situ in Clinical Practice||Endo Pharmaceuticals|No|Completed|March 2011|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|113|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have been treated with valrubicin in a clinical practice setting.|February 2014|February 14, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01304173||108431|
NCT01304433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-O-H-0811|Safety Profile of Hydroxyethyl Starch|Evaluation on the Safety Profile of Hydroxyethyl Starch (HES) 130/0.42||B. Braun Melsungen AG|No|Completed|January 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|adult patients|October 2011|October 27, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01304433||108411|
NCT01304706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-11-008|Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study|||Alimera Sciences|No|Completed|April 2011|||November 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|N/A|N/A|No|||April 2015|April 17, 2015|February 24, 2011|Yes|Yes||No|April 17, 2015|https://clinicaltrials.gov/show/NCT01304706||108390|
NCT01303887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN99217456|A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients|Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC|PACIFICO|University of Liverpool|Yes|Recruiting|October 2009|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|680|||Both|60 Years|N/A|No|||October 2010|May 4, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303887||108453|
NCT01304446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1463|Enteral Nutrition in Cancer Patients|Enteral Nutrition Support in Children and Adolescents With Cancer: a Non-randomized Controlled Clinical Trial||Grupo de Apoio ao Adolescente e a Crianca com Cancer|Yes|Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|1 Year|N/A|No|||February 2011|February 24, 2011|October 23, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01304446||108410|
NCT01304693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-083|ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients|Safety and Efficacy Study of ESBA1008 Versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration||Alcon Research|No|Completed|October 2010|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|376|||Both|50 Years|N/A|No|||July 2014|July 7, 2014|February 24, 2011|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01304693||108391|
NCT01304979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035-10|'Acupuncture Therapy' for Pain and Function Recovery in Spine Surgery Patients|'Acupuncture Therapy' for Pain and Function Recovery in Spine Surgery Patients|Acuspine|Beth Israel Medical Center|Yes|Completed|September 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|114|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 29, 2014|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01304979||108369|
NCT01300858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGEN-001-301|A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients|A Phase I/II Study of the Safety and Biological Activity of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients Who Had Previously Received Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Therapy||EGEN, Inc.|Yes|Terminated|June 2011|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|80 Years|No|||June 2015|June 15, 2015|February 18, 2011|Yes|Yes|Sites could not enroll patients.|No||https://clinicaltrials.gov/show/NCT01300858||108683|
NCT01301430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ParvOryx01|Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.|Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.|ParvOryx01|Oryx GmbH & Co. KG|Yes|Completed|September 2011|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2015|December 3, 2015|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301430||108639|
NCT01301950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08004|Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty|Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty Using TruMatch® Personalized Solutions Compared to Conventional Total Knee Arthroplasty||DePuy Orthopaedics|No|Completed|May 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Males and females who are appropriate candidates for primary knee replacement between the        ages of 18 and 80 years, inclusive, with non-inflammatory degenerative joint disease will        be considered for this investigation.|August 2014|August 26, 2014|December 2, 2010|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT01301950||108600|A statistically powered sample size was not obtained; Two secondary objectives (compare costs & compare differences in OR efficiency as a function of institution type & geographic location) could not be assessed as originally intended by the protocol
NCT01302301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROV10-117A|Endolumenal Partial Myotomy for Esophageal Motility Disorders|Endoscopic Submucosal Tunnel Dissection for Endolumenal Partial Myotomy of the Lower Esophageal Sphincter for Atypical Primary Motility Disorders Such as Achalasia and Esophageal Spasm||The Oregon Clinic|Yes|Recruiting|January 2011|||November 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||November 2010|February 25, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302301||108573|
NCT01301963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3A10|Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide|Comparison of Plerixafor and G-CSF Versus G-CSF Alone for Stem Cell Mobilization in Patients With Multiple Myeloma Previously Treated With Lenalidomide||Case Comprehensive Cancer Center|Yes|Terminated|July 2011|||June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|19 Years|N/A|No|||July 2014|July 7, 2014|February 22, 2011|Yes|Yes|Slow Accrual|No|July 7, 2014|https://clinicaltrials.gov/show/NCT01301963||108599|
NCT01302327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wolfram-HMO-CTIL|GLP Analogs for Diabetes in Wolfram Syndrome Patients|||Hadassah Medical Organization|No|Not yet recruiting|March 2011|||March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302327||108571|
NCT01302587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABM-AS-307|A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)|A Prospective, Open Label, Assessment of [an Albuterol] Hydrofluoroalkane (HFA) Metered Dose Inhaler MDI Integrated Dose Counter||Teva Pharmaceutical Industries|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|306|||Both|4 Years|N/A|No|Non-Probability Sample|People diagnosed with asthma or Chronic Obstructive Pulmonary Disease (also known as COPD,        emphysema or chronic bronchitis)|June 2012|June 21, 2012|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302587||108551|
NCT01303146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070805|Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation|and Safety of METAZYM (Recombinant Human Arylsulfatase A or rhASA) for the Treatment of Patients With Late Infantile MLD Who Had Previously Hematopoietic Stem Cell Transplantation|Azylis|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2008|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|6 Months|N/A|No|||February 2011|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303146||108510|
NCT01303380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2402|Canakinumab in Patients With Active Hyper-IgD Syndrome|An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS)||Novartis||Completed|March 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|24 Months|N/A|No|||October 2015|October 13, 2015|February 23, 2011||No||No|July 15, 2015|https://clinicaltrials.gov/show/NCT01303380||108492|
NCT01303640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C494|NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial|NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial|NEXT|Kyoto University, Graduate School of Medicine|Yes|Completed|May 2011|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3235|||Both|N/A|N/A|No|||December 2015|December 9, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303640||108472|
NCT01303913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP03-2010|Predicting Oxygen Desaturation in Chronic Obstructive Pulmonary Disease (COPD) Patients|Composite Analysis on Factors That Predict Oxygen Desaturation During Walking in COPD||Villa Pineta Hospital|No|Completed|June 2010|February 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|40 Years|80 Years|No|Non-Probability Sample|COPD patients|February 2011|February 25, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303913||108451|
NCT01303926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goim 2903|Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer|Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM|ERACLE|Gruppo Oncologico Italia Meridionale|Yes|Active, not recruiting|January 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|70 Years|No|||April 2012|April 9, 2012|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01303926||108450|
NCT01303627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiskapiTRH|Safety of Remifentanil Infusion|The Effects of Maintenance a Remifentanil Infusion on the Hemodynamic Variables and Recovery Quality||Diskapi Teaching and Research Hospital|No|Completed|February 2011|April 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|60 Years|No|||June 2012|June 15, 2012|February 24, 2011|No|Yes||No|January 30, 2012|https://clinicaltrials.gov/show/NCT01303627||108473|The limitation of our study is age and ASA status of the included patients’. The relatively older or ASA status III,IV population may interfere the effect-site concentration TCI of remifentanil
NCT01303900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVD study 1|Cardiovascular Disease (CVD) in Haemophilia|Cardiovascular Disease in Adult Haemophilia Patients||UMC Utrecht|No|Enrolling by invitation|January 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Male|30 Years|N/A|No|Non-Probability Sample|All male haemophilia patients aged 30 years or older who are treated at one of the        participating haemophilia treatment centers (Utrecht and Groningen, The Netherlands, and        Sheffield, london, Cardiff and Glasgow, UK).        Patients are recruited during regular clinic visits.|February 2011|February 24, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303900||108452|
NCT01304459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI/IOP 01/11|Vancomycin Serum Concentrations in Pediatric Oncology Patients Under Intensive Care|Vancomycin Serum Concentrations in Pediatric Oncology Patients Under Intensive Care||Grupo de Apoio ao Adolescente e a Crianca com Cancer|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric oncology patients on intensive care unit for treatment of infections.|March 2012|March 21, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304459||108409|
NCT01304719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092506B3F|A Computer-based Intervention to Augment Home Visitation Services: The E-Parenting Project|A Computer-based Intervention to Augment Home Visitation Services: The E-Parenting Project||Centers for Disease Control and Prevention|Yes|Completed|October 2007|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|413|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 13, 2013|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01304719||108389|
NCT01304992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H48-11|Cholesterol-lowering Effects of Lupin Protein|Effects of Lupin Protein on Lipid and Protein Metabolism in Moderate Hypercholesterolemic Subjects||University of Jena|Yes|Completed|February 2011|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|66|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304992||108368|
NCT01305005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC2011BNZYJ|Effect of Phacoemulsification on Ocular Blood Flow in Human|To Investigate Ocular Haemodynamics After Phacoemulsification Surgery||Wenzhou Medical University|No|Completed|March 2011|May 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|58|||Both|60 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients who underwent phacoemulsification surgery in Eye Hospital of Wenzhou Medical        College|July 2012|July 16, 2012|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305005||108367|
NCT01300871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alopecia|Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer|Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer||University Health Network, Toronto|No|Terminated|January 2011|January 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients that attend Medical Oncology Breast Clinics at Princess Margaret Hospital.|February 2011|September 25, 2014|February 18, 2011||No|Poor patient accrual|No||https://clinicaltrials.gov/show/NCT01300871||108682|
NCT01301131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajCEU 54-002|Probiotics for Prevention of Ventilator-Associated Pneumonia (VAP)|Randomized Controlled Trial of Fermented Dairy Product Containing L. Casei Shirota for Prevention of Ventilator-Associated Pneumonia|VAP|Mahidol University|No|Recruiting|December 2011|October 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||December 2011|December 29, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301131||108662|
NCT01301144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911106|Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis|Sensitivity and Specificity of Oral Urea Breath Testing for Presumptive Diagnosis and Treatment Response in Pulmonary Tuberculosis in Bamako, Mali||National Institutes of Health Clinical Center (CC)||Completed|February 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301144||108661|
NCT01289470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP1881|Clinical Assessment of Nonin 7600 Near Infrared Spectroscopy (NIRS) Tissue Oximetry During Cardiovascular Surgery|Clinical Assessment of Nonin 7600 Near Infrared Spectroscopy (NIRS) Tissue Oximetry During Cardiovascular Surgery||Nonin Medical, Inc|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing Coronary Artery Bypass Graft (CABG) and valvular surgery with        cardiopulmonary bypass|May 2012|May 18, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01289470||109553|
NCT01302002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA113/10|The Use of Metformin in Early Breast Cancer Patients Pre-Surgery|The Use of Metformin in Early Breast Cancer Patients Pre-Surgery: A Phase 0 Study Regarding The Biological Effect||Instituto Nacional de Cancer, Brazil|Yes|Withdrawn|January 2011|February 2016|Actual|February 2016|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01302002||108596|
NCT01302015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vascostem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease||Biostar|No|Completed|December 2007|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|80 Years|No|||March 2014|March 24, 2014|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01302015||108595|
NCT01301976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-49|Nutritional State and Intake Nutrients Assessment in Ulcerative Colitis|Nutritional State in Ulcerative Colitis Patients||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2009|February 2011|Actual|March 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|59|Samples Without DNA|Serum|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with Ulcerative Colitis in remission|February 2011|February 22, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301976||108598|
NCT01301989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE4951|Reducing Sleep Disparities in Minority Children|Reducing Sleep Disparities in Urban, Minority School-Aged Children||Columbia University|Yes|Completed|July 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|60 Months|87 Months|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301989||108597|
NCT01302600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO19622 CL E Q 1275-1|Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.|Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients.||Trophos|Yes|Completed|November 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|3 Years|25 Years|No|||October 2013|October 18, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01302600||108550|
NCT01302899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2260|To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy|A Single-blind, Double Dummy, Randomized, Multi-dose, Two Sequence, Crossover, Study to Investigate the Effects of Renin Inhibitor (Aliskiren 300 mg) on Albuminuria in Non-diabetic Nephropathy Patients Treated With Ramipril 10 mg and Volume Intervention (ARIA)|ARIA|Novartis||Terminated|January 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||December 2012|December 21, 2012|February 9, 2011||No|In consequence of termination of ALTITUDE. A number of studies were continued in consultation    with the Altitude Data Monitoring Committee.|No|December 21, 2012|https://clinicaltrials.gov/show/NCT01302899||108529|
NCT01303172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM-101-002|A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer|A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer||Immodulon Therapeutics Ltd|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01303172||108508|
NCT01302886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBHQ880A2204|Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma|A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma||Novartis||Completed|May 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||October 2014|October 7, 2014|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302886||108530|
NCT01303159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14865|Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer|Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer||Weill Medical College of Cornell University|No|Terminated|March 2010|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|February 18, 2011|Yes|Yes|EndoHPB probe is FDA approved and considered standard of care|No||https://clinicaltrials.gov/show/NCT01303159||108509|
NCT01303393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etics review Dnr 558/2006|Information Needs After Surgery for Colorectal Cancer|Information Needs After Surgery for Colorectal Cancer - From the Perspective of the Patient and Next of Kin||Region Skane|No|Completed|January 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Inclusion criteria are patients over 18 years of age that have had a surgery for        colorectal cancer without having a stoma, and their next of kin with whom they live. They        should be able to speak and read Swedish.|February 2011|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303393||108491|
NCT01303653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEG 1280|Endoscopic Treatment of Intestinal Fistulas and Perforations|Endoscopic Treatment of Intestinal Fistulas and Perforations||The Oregon Clinic|Yes|Recruiting|October 2010|||October 2010|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|85 Years|No|||July 2010|February 25, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303653||108471|
NCT01304212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATR-2011|Effectiveness of Analgesia in Total Knee Arthroplasty|Comparison of the Analgesic Effect of Femoral Nerve Block, Intraarticular Infiltration or a Combination of Both in the Control of Pain in Total Knee Arthroplasty|ATR-2011|Consorci Sanitari de Terrassa|No|Completed|April 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|137|||Both|66 Years|N/A|No|||August 2014|August 27, 2014|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304212||108428|
NCT01304186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH086491|An Automated, Tailored Information Application for Medication Health Literacy|An Automated, Tailored Information Application for Medication Health Literacy||Nova Southeastern University|No|Completed|June 2010|June 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|124|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01304186||108430|
NCT01304472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-3|Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment|Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment||University of Patras|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|85 Years|No|||August 2011|August 21, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304472||108408|
NCT01304485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIC-AC-001|PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma|Phase 2 Study: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse||Phoenix Molecular Imaging|No|Recruiting|April 2011|April 2017|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Male|18 Years|N/A|No|||March 2015|March 6, 2015|February 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304485||108407|
NCT01304732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI/IOP 04/11|Totally Implantable Catheters in Pediatric Hematology-oncology: a Study on Infectious Complications|||Grupo de Apoio ao Adolescente e a Crianca com Cancer|No|Completed|January 2011|January 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|158|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric oncology patients with diagnosis of catheter infection|March 2012|March 13, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304732||108388|
NCT01304745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/896|Rehabilitation of Women Following Treatment for Gynaecological Cancer; a Randomized, Controlled Study|Rehabilitation of Women Following Treatment for Gynaecological Cancer; a Randomized, Controlled Study||Haukeland University Hospital|Yes|Not yet recruiting|October 2009|June 2014|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|130|||Female|18 Years|N/A|No|||July 2013|July 7, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304745||108387|
NCT01305018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071287|Branched-chain Amino Acids Supplementation and Resistance Exercise-induced Muscle Damage and Inflammation|Effects of Leucine and Branched-chain Amino Acids (BCAA) Supplementation on Resistance Exercise-induced Muscle Damage and Inflammation: a Randomized, Double-blind, and Placebo-controlled Study||University of Sao Paulo|Yes|Suspended|August 2011|August 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2011|May 4, 2011|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305018||108366|
NCT01305031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2011-225, YKK10038|Resuscitation of Late-preterm Infants by Using Room Air or 100% Oxygen|Resuscitation of Late-preterm Infants by Using Room Air or 100% Oxygen||Nanjing Medical University|Yes|Completed|February 2011|December 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|34 Weeks|37 Weeks|No|||October 2014|October 25, 2014|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305031||108365|
NCT01300884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200705716|Sierra High Definition Ano-Rectal Manometry|||University of Iowa||Recruiting|February 2008|||December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit 20 healthy volunteers, 20 patients with fecal incontinence, 20 patients        with constipation. Because anorectal disorders are more common in women, we will recruit        approximately 8 men and 12 women in each group. Because it is possible subjects may sign        consent but not participate in the study, or drop out of the study before completion, we        will recruit a total of 80 subjects.|March 2011|March 7, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01300884||108681|
NCT01289483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-808|Fospropofol for Sedation During Elective Awake Intubation|||Outcomes Research Consortium|No|Terminated|February 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|0|||Both|18 Years|64 Years|No|||April 2011|April 27, 2011|January 31, 2011||No|sponsor has decided not to support this study.|No||https://clinicaltrials.gov/show/NCT01289483||109552|
NCT01306487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye002|Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery|Correlation Between Visual Acuity and Recovery of Foveal Cone Microstructures After Macular Hole Surgery||Kyorin University|No|Completed|March 2008|August 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|58|||Both|N/A|N/A|No|Probability Sample|Consecutive patients with surgically-closed MHs after successful vitrectomy|July 2012|July 31, 2012|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306487||108253|
NCT01306734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPO-SKS-2011|Hypothermia and Circulatory Arrest During Surgery on the Ascending Aorta: A Comparison Between Two Cooling Methods|Hypothermia and Circulatory Arrest During Surgery on the Ascending Aorta: A Comparison Between Two Cooling Methods||University of Aarhus|No|Recruiting|March 2011|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|Bloodsamples serum plasma|Both|18 Years|80 Years|No|Probability Sample|Tertiary care clinic. Patients eligible for planned ascending aorta aneurism repair under        deep hypothermic circulatory arrest.|March 2012|March 20, 2012|January 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01306734||108234|
NCT01301651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712039R|Effects of Virtual Reality Training in Patients With Parkinson's Disease|Effects of Virtual Reality Augmented Balance Training for Postural Control in Patients With Parkinson's Disease|Parkinson|National Taiwan University Hospital|No|Completed|November 2007|December 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|42|||Both|50 Years|80 Years|No|||February 2011|October 13, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301651||108623|
NCT01302613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 082010-335|Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma|A Pilot and Phase II Study of Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma||University of Texas Southwestern Medical Center|Yes|Terminated|March 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2012|May 29, 2015|February 21, 2011||No|Drug shortage|No||https://clinicaltrials.gov/show/NCT01302613||108549|
NCT01302912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-OALs-Register|Lymphoma in the Orbit|||University of Zurich||Enrolling by invitation|February 2011|May 2012|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patient, who underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at        the University Hospital Zurich, Division of Ophthalmology|November 2011|November 3, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302912||108528|
NCT01303185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99074|Pulsed Dye Laser for the Psoriatic Nail|Pulsed Dye Laser for the Psoriatic Nail||Taipei Medical University WanFang Hospital|No|Completed|January 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|||Both|16 Years|N/A|No|Non-Probability Sample|Psoriatic nail patients|December 2014|December 11, 2014|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01303185||108507|
NCT01303198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kaiserswertherdiakonie|Autoset T Versus CPAP Therapy, a Comparison of Titration and Therapy|Autoset T Versus CPAP- Ein Titrations- Und Therapievergleich||Kaiserswerther Diakonie|Yes|Recruiting|June 2001|April 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2011|February 23, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01303198||108506|
NCT01303406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-III-004|Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)|A Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study of Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone|PROTI|Santhera Pharmaceuticals|Yes|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|10 Years|N/A|No|||February 2016|February 10, 2016|February 22, 2011||No||No|December 11, 2015|https://clinicaltrials.gov/show/NCT01303406||108490|
NCT01303666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEO118|Tidal Irrigation Versus Intra-articular Steroid Injection in the Treatment of Knee Osteoarthritis|Tidal Irrigation Versus Intra-articular Steroid Injection in the Treatment of Knee Osteoarthritis||Portsmouth Hospitals NHS Trust|No|Completed|November 2000|December 2004|Actual|July 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|150|||Both|40 Years|90 Years|No|||November 2000|February 24, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01303666||108470|
NCT01303965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012-24; IUCRO-0307|Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)|Phase I/II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy With Lenalidomide and Sirolimus in Patients With High-Risk Multiple Myeloma||Indiana University|Yes|Active, not recruiting|February 2011|July 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01303965||108447|
NCT01303978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DN10007|Phase II Proof-of-concept Study of APD421|Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting||Acacia Pharma Ltd|No|Completed|February 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|51|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303978||108446|
NCT01304225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASCAL-001|Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser|Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser - an Anatomic and Functional Evaluation of Different Treatment Strategies||Federal University of São Paulo|Yes|Recruiting|September 2010|March 2013|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304225||108427|
NCT01303939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-009|Does Glaucoma Cause Loss of Brain Function?|Neuroimaging Brain Changes in Glaucoma||Wills Eye|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|37|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Glaucoma Service, Wills Eye Institute|June 2015|June 9, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303939||108449|
NCT01303952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD01|Therapy of Chronic Cold Agglutinin Disease With Eculizumab|Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab|DECADE|University Hospital, Essen|Yes|Completed|February 2011|June 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303952||108448|
NCT01304199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEC/NP-252/2010|Cancer Survivorship Issues: A Survey of Patients in India.AIIMS Study (CANSURVIVE)|Cancer Survivorship Issues: A Survey of Patients in India.AIIMS Study (CANSURVIVE)|CANSURVIVE|All India Institute of Medical Sciences, New Delhi|No|Recruiting|January 2011|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|75 Years|No|Non-Probability Sample|This study will evaluate the cancer patients visiting Dr BRAIRCH,AIIMS,New Delhi,India        after a cancer diagnosis and the cancer treatments have been completed.        The patients will be entered into this study(survey) during the follow up visits to the        clinic.        Patients will be evaluated and assessed for their cancer survivorship issues on the basis        of a questionnaire (CSQ) developed by the investigators after the literature review. The        mental status of the survivors is assessed by a MINI- international neuro-psychiatric        interview, suitably modified to incorporate the CSQ in this survey.|July 2012|July 11, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304199||108429|
NCT01305044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34851|The HEALS Project - Health Education and Active Living for Surviving Seniors|Biobehavioral Effects of Tai Chi Chih Among Elderly Female Cancer Survivors|HEALS|University of Utah|Yes|Completed|December 2009|November 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|63|||Female|55 Years|90 Years|No|||November 2015|November 9, 2015|February 18, 2011||No||No|March 13, 2013|https://clinicaltrials.gov/show/NCT01305044||108364|
NCT01305057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cosmos1|Efficacy Test on Skin Hydration and Skin Barrier Function|Human Use Test on Skin Hydration and Skin Barrier Function||Cosmos Technical Center|Yes|Completed|February 2009|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|1||Actual|20|||Both|33 Years|62 Years|Accepts Healthy Volunteers|||February 2011|February 25, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01305057||108363|
NCT01300897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DK057100-2|Investigation of Cortico-Rectal Pathways in Healthy Subjects|Investigation of Cortico-Rectal Pathways in Healthy Subjects|Aim 2|Georgia Regents University|No|Active, not recruiting|August 2005|June 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|40 Healthy volunteers.|January 2014|January 8, 2014|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01300897||108680|
NCT01305083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI2010-01|Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.|A Randomized, Double Blind, Placebo Controlled, Multicentric Study to Assess the Efficacy and Safety of Udenafil Tablets in Patients Suffering From Erectile Dysfunction.||Abdi Ibrahim Ilac San. ve Tic A.S.|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Male|18 Years|60 Years|No|||May 2012|May 11, 2012|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305083||108361|
NCT01301183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002768|Effects of Anorexia Nervosa on Peak Bone Mass|Effects of Anorexia Nervosa on Peak Bone Mass||Massachusetts General Hospital|Yes|Recruiting|February 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Female|14 Years|22 Years|Accepts Healthy Volunteers|||June 2015|June 30, 2015|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301183||108658|
NCT01301443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS1/001/10|Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)|A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration|GEM|Oxford BioMedica|Yes|Active, not recruiting|February 2011|May 2015|Anticipated|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|50 Years|N/A|No|||April 2015|April 20, 2015|February 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01301443||108638|
NCT01301456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1111002|Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females|A Phase 1, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Completed|March 2011|April 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|13||Actual|84|||Female|18 Years|70 Years|No|||May 2012|May 15, 2012|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301456||108637|
NCT01289977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G183ZU|Immune Responses After Human Subject Challenge With Sand Fly Bites|Immune Responses After Human Subject Challenge With Sand Fly Bites: Exploratory Study for Selection of Potential Leishmania Vaccine Antigen Candidates||Uniformed Services University of the Health Sciences|Yes|Active, not recruiting|October 2010|April 2016|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|68|Samples With DNA|Plasma and white blood cells will be retained.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female military health care beneficiaries in good health, age 18-50|May 2015|May 29, 2015|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01289977||109514|
NCT01289990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.31|Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes|A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23||Boehringer Ingelheim||Completed|February 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|13||Actual|2705|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|January 31, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01289990||109513|
NCT01306760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSO ETM/6|The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy|The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy (ECT) for Depression: Does it Improve Treatment Outcome?|KANECT|University of Aberdeen|No|Completed|March 2011|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||November 2015|November 4, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306760||108232|
NCT01301664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97022|Cartilage Tissue Engineering|||Far Eastern Memorial Hospital||Available||||||N/A|Expanded Access|N/A|||||||Both|30 Years|70 Years||||March 2013|March 6, 2013|October 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01301664||108622|
NCT01302340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER001-02-01|Delta-THC in Behavioral Disturbances in Dementia|Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia||Radboud University|Yes|Completed|September 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01302340||108570|
NCT01302353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITEI|Phase I Trial of Emulsified Isoflurane|Phase I Trial of Emulsified Isoflurane in Adult Healthy Volunteers||Sichuan University|Yes|Completed|May 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|16||Actual|78|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2010|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302353||108569|
NCT01307280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0209792|Weight Management Demonstration Project: HEALTH|Weight Management Demonstration Project: Healthy Eating and Active Living in TRICARE Households|HEALTH|RTI International|No|Completed|August 2006|December 2009|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2395|||Both|18 Years|64 Years|No|||January 2012|January 25, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01307280||108192|
NCT01288716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209AS208|Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders||Seaside Therapeutics, Inc.|Yes|Completed|May 2011|September 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|5 Years|21 Years|No|||July 2013|July 30, 2013|January 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288716||109611|
NCT01280188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE992026 CS43|A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).|Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients||Ferring Pharmaceuticals|No|Completed|January 2011|August 2012|Actual|August 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|6 Years|75 Years|No|||August 2012|August 10, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280188||110261|
NCT01280201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETNE-1002|Pazopanib as Single Agent in Advanced NETs|A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers||Grupo Espanol de Tumores Neuroendocrinos|No|Active, not recruiting|December 2010|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||July 2013|April 1, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280201||110260|
NCT01280838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA029008|Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico|Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico||University of California, San Diego|Yes|Completed|January 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280838||110211|
NCT01281085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAGEX-24519|Validation of a Score for Shoulder Function Evaluation Based on Movement Analysis|Validation of a Kinematic Functional Shoulder Score Including Only Essential Movements: a Pilot Study||Haute Ecole Cantonale Vaudoise de Santé|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with a shoudler condition, as stated during the medical examination        performed at the specialized shoulder consultation of the hospital|April 2011|April 13, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281085||110193|
NCT01282099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100603|A Critical Appraisal of the Role of Near Infrared Spectroscopy (NIRS) in the Pediatric Intensive Care Unit (PICU)|Is There a Canary in the PICU? A Critical Appraisal of the Role of Near Infrared Spectroscopy (NIRS) in the Pediatric Intensive Care Unit (PICU)||Akron Children's Hospital|No|Completed|September 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|22|||Both|N/A|15 Years|Accepts Healthy Volunteers|Probability Sample|neonates to 16 years of age requiring stay in the PICU postoperative congenital heart        disease patients non-cardiac patients|June 2014|June 24, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282099||110116|
NCT01282333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02576|Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer|Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Terminated|January 2011|||February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|January 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01282333||110098|
NCT01281319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR510010CTIL|Evaluation of a Serology Diagnostic Kit for the Detection of Genital Mycoplasma in Pregnancy|Evaluation of a Diagnostic Kit for the Detection of Serum Antibodies Anti Genital Mycoplasma in High Risk Pregnant Women||Promyco Diagnostics|No|Recruiting|January 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|Cervix swab, amniotic fluid and serum samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal and high risk pregnant women|January 2011|January 20, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281319||110175|
NCT01281553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003952|A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease|Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of R051619 (Cisapride Oral Suspension 0.2 mg/kg q.i.d.) for the Treatment of Symptomatic Gastro-Oesophageal Reflux Disease (GORD) in Infants and Children||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|September 2003|October 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|1 Month|18 Months|No|||January 2011|January 20, 2011|January 20, 2011|Yes|Yes|Sponsor request|No||https://clinicaltrials.gov/show/NCT01281553||110158|
NCT01281800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22k/06/08|Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma|Cisplatin With Either Alimta or Gemcitabine in Long Infusion for Mesothelioma: A Randomised Phase II Trial (AGILI Trial)|AGILI|Institute of Oncology Ljubljana||Recruiting|August 2008|||August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01281800||110139|
NCT01282840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099049-F|Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.|||Far Eastern Memorial Hospital||Recruiting|July 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|20 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|January 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01282840||110059|
NCT01282853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-99-C-029|Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Peptic Ulcer Bleeding|The Influence of Biopsy Number and Site on the Sensitivity of Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Bleeding Gastroduodenal Ulcer||Far Eastern Memorial Hospital|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|116|||Both|18 Years|N/A|No|||January 2011|August 28, 2015|January 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01282853||110058|
NCT01282866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM- ABU-LSDuet-08-001|Hair Count Reduction Verification Study With the LightSheer Duet HS Handpiece|Hair Count Reduction Verification Study With the LightSheer Duet HS Handpiece||Lumenis Ltd.||Completed|June 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|February 20, 2014|January 9, 2011|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01282866||110057|
NCT01282554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01149-30|Evaluation of Electrostimulation Program During Dialysis Sessions in Chronic Renal Failure Patients|Evaluation of Electrostimulation Program During Dialysis Sessions in Chronic Renal Failure Patients|EMS-Dialyse|Rennes University Hospital|No|Completed|January 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01282554||110081|
NCT01282814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30024|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study|Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as the Content of 1 x 150 mg Extended-Release Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.||Teva Pharmaceuticals USA||Completed|February 2003|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 11, 2011|January 24, 2011||Yes||No|February 11, 2011|https://clinicaltrials.gov/show/NCT01282814||110061|
NCT01328834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGLN-003|Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis|||Sun Yat-sen University|Yes|Completed|January 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|14 Years|65 Years|No|||October 2011|November 1, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328834||106554|
NCT01328860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIND14281|Autologous Stem Cells for Spinal Cord Injury (SCI) in Children|Safety of Autologous Stem Cell Treatment for Spinal Cord Injury in Children||Memorial Hermann Health System|Yes|Terminated|April 2011|June 2016|Anticipated|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|15 Years|No|||June 2014|June 6, 2014|April 1, 2011|Yes|Yes|Principal Investigator relocated to Orlando, Florida.|No||https://clinicaltrials.gov/show/NCT01328860||106553|
NCT01291121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0623|Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion|Intravitreal Administration of Ranibizumab Combined With Intravitreous Injection of Expansile Gas and Induction of Posterior Vitreous Detachment in Treatment of Exudative AMD With Posterior VMA: a Pilot, Open Label, Comparative Study||Yonsei University|Yes|Completed|February 2011|June 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|50 Years|N/A|No|||January 2015|January 21, 2015|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291121||109426|
NCT01291394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-515|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|ECOS FRA|Merck KGaA|No|Active, not recruiting|January 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|224|||Both|2 Years|18 Years|No|Non-Probability Sample|Subjects who are taking SAIZEN® for a pediatric registered indications using the Easypod™        electromechanical device.|March 2015|March 3, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01291394||109405|
NCT01291407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-012|A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer|A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer||Chinese Academy of Medical Sciences|Yes|Completed|November 2010|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|75 Years|No|||September 2013|September 17, 2013|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291407||109404|
NCT01291420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG 11-001|Dendritic Cell Vaccination for Patients With Solid Tumors|Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study||University Hospital, Antwerp|No|Enrolling by invitation|February 2011|||February 2014|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2013|July 11, 2013|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291420||109403|
NCT01282736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01122011-7362|Guided Self-Help for Binge Eating Disorder|Comparison of Integrative Response Therapy and Cognitive Behavioral Therapy Guided Self-Help for Binge Eating Disorder||Stanford University|Yes|Active, not recruiting|June 2010|May 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2013|May 13, 2013|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01282736||110067|
NCT01283035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00549|A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase II Study of MK-2206 in the Treatment of Recurrent High-Grade Serous Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||National Cancer Institute (NCI)||Completed|April 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||July 2014|April 29, 2015|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283035||110044|
NCT01288469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI11566|Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose/Dose Regimen, Multicenter Study Evaluating the Efficacy and Safety of SAR236553 When Co-administered With 80 mg of Atorvastatin Over 8 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL (≥2.59 mmol/L) on Atorvastatin 10 mg||Sanofi|Yes|Completed|January 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|75 Years|No|||January 2015|August 21, 2015|February 1, 2011|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01288469||109630|
NCT01288690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU082810B3F|Stress Reduction in Middle Eastern Refugees|Stress Reduction in Middle Eastern Refugees||Wayne State University|No|Completed|December 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01288690||109613|
NCT01288703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0050|Computerized-Adaptive Testing: Feasibility In Women With Pelvic Floor Disorders (CAT)|Computerized-Adaptive Testing: Feasibility In Women With Pelvic Floor Disorders|CAT|Women and Infants Hospital of Rhode Island|No|Completed|August 2010|February 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|60 women seeking care for PFDs will be eligible. Women will be excluded if they are unable        to read English or have cognitive limitations precluding the completion of PROMIS        questionnaires.|May 2014|May 27, 2014|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01288703||109612|
NCT01288989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14247|A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors|Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available||Eli Lilly and Company|No|Completed|March 2011|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|January 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288989||109590|
NCT01289002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07EU02|e-BioMatrix PostMarket Registry|A Postmarket Registry of the BioMatrix™ and BioMatrix Flex™ Drug Eluting Stents.|eBMX-PMR|Biosensors Europe SA|Yes|Active, not recruiting|April 2008|April 2015|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Non-Probability Sample|"Real world, all comer" patients|September 2014|September 6, 2014|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289002||109589|
NCT01288482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000019446|AeroEclipse II Agreement|Use of the AeroEclipse II Breath Actuated Nebulizer for the Delivery of Methacholine Chloride Bronchoprovocation Agent: A Pilot Study.||The Hospital for Sick Children|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|10 Years|65 Years|No|||May 2014|May 12, 2014|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01288482||109629|
NCT01280526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ro-CHOP|A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas|A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas|Ro-CHOP|The Lymphoma Academic Research Organisation|Yes|Completed|January 2011|March 2014|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|80 Years|No|||May 2014|May 21, 2014|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01280526||110235|
NCT01280539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECU2012-002|The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis|||Hasselt University|Yes|Completed|January 2011|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|68 Years|No|||September 2012|September 4, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280539||110234|
NCT01281332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBGY-208-10|Mechanical Device for the Relief of Hot Flashes|Evaluation of a Novel Mechanical Device for Relief of Menopausal Vasomotor Symptoms.||Queen's University|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01281332||110174|
NCT01281566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003955|A Study of Cisapride in Premature Infants With Feeding Problems|Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of R051619 (Cisapride Oral Suspension 0.2mg/kg q.i.d) for the Treatment of Feeding Intolerance in Premature Infants||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|March 2003|July 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|36 Weeks|99 Weeks|No|||January 2011|January 20, 2011|January 20, 2011|Yes|Yes|Sponsor request|No||https://clinicaltrials.gov/show/NCT01281566||110157|
NCT01282359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PRO-2010-16|Efficacy of a Minimal Intervention Educational Program in the Asthma Control and Exacerbations Prevention|Efficacy of a Minimal Intervention Educational Program in the Asthma Control and Exacerbations Prevention|PROMETEO|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|October 2011|September 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|70 Years|No|||September 2015|September 15, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01282359||110096|
NCT01282086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-637|Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevorane in Adult Patients Requiring General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on the Cardiovascular System in Common Clinical Practice|Evaluation of VIMA With Sevorane in Adult Patients Required General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on Cardiovascular System in Common Clinical Practice (SEVOPROTECTION)|SEVOPROTECTION|AbbVie||Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1365|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing planned or urgent surgery|January 2013|January 4, 2013|January 21, 2011||No||No|December 7, 2012|https://clinicaltrials.gov/show/NCT01282086||110117|The data on troponin T values were not collected in the study and CK-MB was detected in a small number of patients, therefore no conclusions can be made regarding the influence of VIMA with Sevorane on myocardial ischemia markers.
NCT01282320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2009/1429|WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women|WHAT - Effectiveness of Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women. A Randomized Controlled Pragmatic Pilot Study|WHAT|University Hospital of North Norway|No|Active, not recruiting|January 2011|December 2013|Anticipated|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2013|July 1, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282320||110099|
NCT01278875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-208-BMA|Function of High Density Lipoproteins in Acute Coronary Syndromes|High Density Lipoprotein Function in Acute Coronary Syndromes|HDL_ACS|McGill University Health Center|No|Recruiting|January 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|65|Samples Without DNA|Serum Plasma HDL isolated by ultracentrifugation|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to hospital with an acute coronary syndrome, within 72 hours|June 2014|June 20, 2014|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278875||110362|
NCT01278862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3M ESPE CR-10-004|Clinical Evaluation of Lava Digital Veneer System (DVS) Crowns|Clinical Evaluation of Lava Digital Veneer System (DVS) Crowns||3M|No|Terminated|November 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|19 Years|N/A|No|||July 2013|January 22, 2015|January 14, 2011||No|product no longer on market|No||https://clinicaltrials.gov/show/NCT01278862||110363|
NCT01329133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/43|Deep Brain Stimulation and Obsessive-compulsive Disorder|Treatment of Severe and Resistant Obsessive-compulsive Disorder by High-frequency Stimulation of the Ventral Striatum and the Subthalamic Nucleus|STOC2|University Hospital, Bordeaux|Yes|Recruiting|April 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|60 Years|No|||August 2014|August 19, 2014|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329133||106532|
NCT01287663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01406-33|Effectiveness of Permethrin Impregnated Underwear in Preventing Louse Proliferation in Infected Homeless|Effectiveness of Permethrin Impregnated Underwear in Preventing Louse Proliferation in Infected Homeless|ERPOUPER|Assistance Publique Hopitaux De Marseille|No|Terminated|January 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287663||109690|
NCT01282749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O02-07-003-E|Effectiveness of SisterTalk Hartford for Weight Loss Among African-American Women|The Hospitals-Churches Partnership for Health Project: SisterTalk Hartford||University of Connecticut Health Center|No|Completed|October 2002|August 2006|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|322|||Female|18 Years|N/A|No|||May 2014|May 27, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282749||110066|
NCT01279291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2866-US-001|Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer|Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer||Kyowa Hakko Kirin Pharma, Inc.|No|Terminated|January 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|22|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|January 11, 2011|No|Yes|The study was stopped due to the inability to determine an acceptable dose with the potential    for further study|No||https://clinicaltrials.gov/show/NCT01279291||110330|
NCT01279642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1967/06|Placement of Peripherally Inserted Central Venous Catheters (PICC) in Children Guided by Ultrasound|The Use of Doppler Vascular Ultrasound by Nurses During the Placement of Peripherally Inserted Central Venous Catheters in Children: Clinical, Randomized and Controlled Trial.||Federal University of São Paulo|Yes|Completed|August 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|1 Month|18 Years|Accepts Healthy Volunteers|||July 2010|January 18, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279642||110303|
NCT01287689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIGNS|Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study|An Open, Uncontrolled, Non-interventional Observational Cohort Outcome Study of Immunoglobulins in 3 Indications: Primary and Secondary Immunodeficiencies and Neurological Auto-immune Diseases|SIGNS|Technische Universität Dresden|No|Recruiting|July 2010|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|704|||Both|N/A|N/A|No|Non-Probability Sample|Ambulatory or hospital-based patients (no age restriction)|January 2015|January 6, 2015|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01287689|2 Years|109689|
NCT01287975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERC Grant No: 092 148 0066|Brain Computer Interface (BCI) Technology for Stroke Hand Rehabilitation|ARTS-BCI: Advanced Brain Computer Interface (BCI) Technology for Wrist and Hand Rehabilitation After Stroke|ARTS-BCI|Tan Tock Seng Hospital|No|Completed|January 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|21|||Both|21 Years|80 Years|No|||March 2014|March 11, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01287975||109667|
NCT01288222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010LSUC043|Selecting a Favorable KIR Donor in Unrelated HCT for AML|KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor||Masonic Cancer Center, University of Minnesota|No|Recruiting|June 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288222||109649|
NCT01279629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED 865-10v3|Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis|Open Clinical Study, Comparing Non-inferiority for Efficacy of the Drug Tazarotene 0.1% Versus the Comparator Drug Calcipotriol 0.005% in the Treatment of Chronic Plaque Psoriasis|MED|Glenmark Farmacêutica Ltda|Yes|Suspended|February 2011|||||N/A|Observational|N/A||2|Anticipated|50|||Both|18 Years|65 Years|No|Probability Sample|50 patients will be selected from both sexes, healthy, between 18 and 65 years with a        clinical diagnosis of chronic plaque psoriasis with PASI <20%, according to the criteria        of inclusion and exclusion.|January 2011|June 17, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279629||110304|
NCT01280227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05288|Supporting Patient Provider Communication in Paediatric Care|Supporting Patient Provider Communication for Children With Cancer and Congenital Heart Disease|SiSom|Oslo University Hospital|No|Active, not recruiting|January 2005|July 2016|Anticipated|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|144|||Both|7 Years|12 Years|No|||November 2015|November 30, 2015|September 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01280227||110258|
NCT01280240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-PK-CIA-06|Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).|PK-CIA-06|Pharmacosmos A/S|Yes|Completed|March 2012|November 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|January 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01280240||110257|
NCT01280565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB08026|A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit|A Prospective, Multicenter, Randomized, Open-label, Activecontrolled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit||AB Science|Yes|Recruiting|January 2011|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|August 6, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01280565||110232|
NCT01281345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIHAM_02|SIHAM Candidemia Network:An Observational Study|A Multicenter Observational Study of Candidemia Among ICU Patients in India||Society of Indian Human & Animal Mycologist|No|Completed|April 2011|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1400|Samples With DNA|Candida isolates|Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients with candidemia diagnosed in ICUs > 48 h after admission during the        study period will be included in each site|January 2011|November 18, 2014|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281345||110173|
NCT01281579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017695|A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers|An Open-Label, Randomized, Parallel-Group, Single-Center Study to Evaluate the Single and Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 29, 2012|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281579||110156|
NCT01281826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-99-093|Dual-energy CT in Detecting Bone Marrow Edema of Vertebral Compression Fractures|Use of Dual-energy CT in Detecting Bone Marrow Edema of Vertebral Compression Fractures||National Cheng-Kung University Hospital|Yes|Recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients are recruited from Department of Orthopedics between january 2011 and december        2011.|January 2011|February 9, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281826||110137|
NCT01282125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAS og nasalstenose|Nasal Obstruction in Sleep Apnea Patients Compared to the General Population|A Comparative Study of Nasal Obstruction in a Sleep Apnea Population Compared to the General Population||Norwegian University of Science and Technology|No|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients: St Olavs Hospital, Trondheim, Norway Controls: Community sample, residents of        Trøndelag, Norway|February 2016|February 8, 2016|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01282125||110114|
NCT01282138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-278|Assessment of Alcon's Ocular Image Quantification System|A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC)||Alcon Research|No|Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|13|||Both|18 Years|65 Years|No|||July 2012|December 16, 2012|January 20, 2011|Yes|Yes||No|June 20, 2012|https://clinicaltrials.gov/show/NCT01282138||110113|This was a pilot study with a small number of subjects not adequately powered to detect treatment differences.
NCT01282346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLX84|SOLX Gold Shunt for Refractory Glaucoma|Clinical Evaluation of the SOLX Gold Shunt for the Reduction of Intraocular Pressure (IOP) in Refractory Glaucoma||SOLX, Inc.||Active, not recruiting|January 2011|||December 2015|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|No|||December 2014|December 12, 2014|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282346||110097|
NCT01282567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01455-34|Study for the Artificial Pancreas Project : Determination of a Tuning Strategy of Metabolic Profiles|Preliminary Study for the Artificial Pancreas Project : Determination of a Tuning Strategy of Metabolic Profiles||Rennes University Hospital||Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|70 Years|No|||February 2012|February 2, 2012|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01282567||110080|
NCT01282892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0052-08|Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis|Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis||Ziv Hospital|No|Active, not recruiting|February 2009|December 2010|Anticipated|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|50 patients (age 53±7) with excess of visceral fat visceral, 30 patients with NAFLD and 30        sex, age matched individuals without NAFLD will be recruited|January 2011|January 24, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01282892||110055|
NCT01279109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101552|Starting Pediatric Obesity Prevention in Pregnancy|Starting Pediatric Obesity Prevention in Pregnancy||Vanderbilt University|Yes|Completed|January 2011|April 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|153|||Female|16 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279109||110344|
NCT01278888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s-20080085|Minimally Invasive or Open Surgery for Lung Cancer: Pain, Quality of Life and Economy.|Minimally Invasive or Open Surgery for Lung Cancer: Pain, Quality of Life and Economy.|PLEACE|Odense University Hospital|Yes|Recruiting|September 2008|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01278888||110361|
NCT01329367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUGENOI-UN|Nutrigenomics And Children Obesity: A Moderate Weight Loss Intervention Study|Efecto de Una Intervención Dietética Sobre La Expresión De Genes De La Inflamación Y El Estrés Oxidativo En Niños Obesos|NUGENOI|Clinica Universidad de Navarra, Universidad de Navarra|No|Active, not recruiting|January 2010|December 2012|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|42|||Both|7 Years|15 Years|No|||October 2011|October 5, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01329367||106514|
NCT01282502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-457|Midostaurin (PKC412) for Locally Advanced Rectal Cancer|Phase I Study of Chemoradiation With Midostaurin (PKC412) For Locally Advanced Rectal Cancer||Massachusetts General Hospital|Yes|Recruiting|August 2011|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|January 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01282502||110085|
NCT01279304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04-10/02|Radiotherapy After Primary Chemotherapy for Breastcancer|Radiotherapy After Primary CHEMotherapy for cT1-2cN1M0 Breast Cancer.: a Multicentre Prospective Registration Study.|RAPCHEM|Maastricht Radiation Oncology|No|Recruiting|January 2011|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|710|||Female|N/A|N/A|No|Probability Sample|patients with cT1-2cN0-1(cytology/histology and/or positive SN, excluding patients with >        3 pathologic axillary nodes on imaging) breast cancer, treated with at least three cycles        of chemotherapy followed by breast surgery are eligible for the study.|February 2014|February 27, 2014|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279304||110329|
NCT01279343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-135|Cervical Foley Plus Vaginal Misoprostol for Labor Induction|Cervical Foley Plus Vaginal Misoprostol Versus Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial||Washington University School of Medicine|Yes|Recruiting|January 2011|March 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|January 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279343||110326|
NCT01279031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abbott2010-Whitestar|Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial|Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial||Innovative Medical|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|21 Years|N/A|No|||January 2012|January 13, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01279031||110350|
NCT01279265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0048|Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic|Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Crying, Intestinal Microbiota, and Intestinal Inflammation in Infants With Colic|LGG|The University of Texas Health Science Center, Houston|Yes|Completed|September 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|N/A|3 Months|Accepts Healthy Volunteers|||October 2015|October 7, 2015|January 12, 2011||No||No|June 11, 2015|https://clinicaltrials.gov/show/NCT01279265||110332|75% of eligible babies either declined to enter the study or dropped out.
NCT01279278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAGEDOCC1|Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?|Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? A Cluster Randomised Controlled Study.|Pagedocc1|University of Paris 5 - Rene Descartes|Yes|Recruiting|September 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2700|||Both|50 Years|74 Years|No|||September 2010|January 18, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279278||110331|
NCT01279616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-00383|A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease|A Pilot Study of an Immunosuppressive and Myeloablative Preparative Regimen for Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Severe Sickle Cell Disease||Nationwide Children's Hospital|Yes|Suspended|September 2010|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|21 Years|No|||June 2015|June 5, 2015|January 18, 2011||No|PI moving to a different institution.|No||https://clinicaltrials.gov/show/NCT01279616||110305|
NCT01279876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8153-54-04-87|Melatonin in Relapsing-Remitting Multiple Sclerosis Patients|Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients||Tehran University of Medical Sciences|Yes|Completed|October 2010|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|45 Years|No|||August 2015|August 12, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279876||110285|
NCT01280825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-487-A|The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing|The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing||University of Chicago|No|Recruiting|January 2011|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples With DNA|Whole blood and DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults receiving ongoing routine medical care and regularly using at least 1 (but no more        than 6) prescription medications at the time of enrollment.|January 2016|January 6, 2016|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280825||110212|
NCT01281098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-02-2009|Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.|Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).||Association for Innovation and Biomedical Research on Light and Image|No|Completed|March 2010|February 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||April 2013|March 18, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281098||110192|
NCT01281839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017371|An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects Who Relapsed After Previous Interferon-based Therapy|PROMISE|Janssen R&D Ireland|Yes|Completed|February 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|394|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|January 7, 2011|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01281839||110136|
NCT01282112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101014|Sedation for Brainstem Evoked Auditory Response (BEAR) Testing Using Intravenous Pentobarbital|Sedation for Brainstem Evoked Auditory Response (BEAR) Testing Using Intravenous Pentobarbital - A Retrospective Study||Akron Children's Hospital|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|416|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children from 0 to 18 years of age undergoing BEAR testing using midazolam and        pentobarbital protocol for moderate sedation.|June 2014|June 25, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282112||110115|
NCT01288105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-106|Use of Optical Coherence Tomography to Determine the Optimal Management of Patients With Drug-eluting Stents Who Need Non-cardiac Surgery|Use of Optical Coherence Tomography to Determine the Optimal Management of Patients With Drug-eluting Stents Who Need Non-cardiac Surgery||North Texas Veterans Healthcare System|No|Terminated|January 2011|February 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|107|||Both|18 Years|N/A|No|||December 2010|December 27, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01288105||109657|
NCT01282580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10024|Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention|Omega 3 Fatty Acids and Breast Cancer Prevention: Protective Benefits of Increased Fish Consumption||Ohio State University Comprehensive Cancer Center|Yes|Completed|July 2010|August 2014|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 24, 2015|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282580||110079|
NCT01282879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-099|Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients|Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation|ITRAG|Samsung Medical Center|Yes|Terminated|December 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Both|19 Years|N/A|No|||January 2011|January 24, 2011|January 23, 2011||No|In interim analysis, this study met the primary hypothesis.|No||https://clinicaltrials.gov/show/NCT01282879||110056|
NCT01288872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0049|Praziquantel-Pharmacokinetic Study|Praziquantel Pharmacokinetics in Pregnancy and During Lactation||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|N/A|No|||September 2013|September 26, 2013|January 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288872||109599|
NCT01288885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0001|First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects|A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food-effect of Single Oral Doses of ASP1941 in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|November 2006|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|76|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 1, 2011|February 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288885||109598|
NCT01278901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100300|The Effect of PPI Therapy on the Result of Helicobacter Pylori Diagnostic Tests|||Rabin Medical Center|No|Not yet recruiting|February 2011|||February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Cohort of helicobacter pylori positive patients undergoing EGD for different indications        and not treated with PPI|January 2011|January 18, 2011|January 16, 2011||||No||https://clinicaltrials.gov/show/NCT01278901||110360|
NCT01331083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I205|A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer|A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer||Canadian Cancer Trials Group|No|Completed|May 2011|November 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Male|18 Years|N/A|No|||November 2015|November 27, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331083||106386|
NCT01331096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Teleanesthesia3054|Tele-Anesthesia - Trans-Continental Anesthesia Compared to Standard Practice|Tele-Anesthesia - Trans-Continental Anesthesia Compared to Standard Practice||Azienda Ospedaliero, Universitaria Pisana|Yes|Recruiting|March 2011|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients undergoing elective thyroid gland surgery|March 2011|April 6, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331096||106385|
NCT01283048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-405|Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma|A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283048||110043|
NCT01283061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0759156|Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioavailability Study Of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of 'ACCOLATE' Tablets 20 mg of Astrazeneca Pharmaceuticals, USA In Healthy Adult Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|December 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|January 25, 2011|January 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01283061||110042|
NCT01279083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29-001|Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension|A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension||Santen Inc.|No|Completed|January 2011|February 2012|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|147|||Both|18 Years|N/A|No|||December 2012|December 14, 2012|January 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279083||110346|
NCT01279044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UR6PS000684-01|Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)|Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM): Adaptation of the Personalized Cognitive Counseling (PCC) Intervention||San Francisco Department of Public Health|No|Completed|September 2007|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|385|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 30, 2014|January 18, 2011||No||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01279044||110349|Self-report data subject to recall bias Sample is San Francisco SUMSM; may not be generalizable to other locations 42% screened as substance-dependent per SDS Inclusion of dependent MSM reduced ability to detect significant intervention effects
NCT01279889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03231|Predicting Hypotension Related to Spinal Anesthesia|Predicting Hypotension Resistant to Phenylephrine (PE) Infusion in Elective Cesarean Delivery (CD)||University of British Columbia|Yes|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Female|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy women who are admitted to the hospital for a scheduled elective cesarean delivery|February 2012|February 10, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279889||110284|
NCT01279330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAGEDOCC2|Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?|Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? A Cluster Randomised Controlled Study.|Pagedocc2|University of Paris 5 - Rene Descartes|No|Recruiting|September 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1569|||Both|50 Years|74 Years|No|||September 2010|January 18, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279330||110327|
NCT01280253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USILAN-2|Preoperative Biochemical Predictors of Outcome in Patients With Hip Fracture|Can Biochemical Tests Predict Outcome in Patients With Hip Fracture?||Region Skane|Yes|Completed|January 2011|||August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1012|Samples Without DNA|Litium-heparin plasma EDTA plasma|Both|18 Years|N/A|No|Non-Probability Sample|patients presenting with hip fracture at University Hospital Lund Sweden|April 2015|April 8, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01280253||110256|
NCT01280266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RaynaudSNUH|Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon|Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial||Seoul National University Hospital||Completed|January 2011|June 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||December 2012|December 7, 2012|January 14, 2011||No||No|July 4, 2012|https://clinicaltrials.gov/show/NCT01280266||110255|
NCT01280552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-107-201|A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)|A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation||ImmunoCellular Therapeutics, Ltd.|Yes|Completed|January 2011|December 2015|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|80 Years|No|||October 2014|February 2, 2016|January 19, 2011|Yes|Yes||No|October 2, 2014|https://clinicaltrials.gov/show/NCT01280552||110233|
NCT01280279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nocturiaact|Necessity for Repetitive Education of Behavioral Modification|Short-term Effects of Systematized Behavioral Modification Program (SBMP) for Nocturia: A Prospective Study||Seoul National University Hospital|Yes|Completed|May 2009|January 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients who had the urine volume at nighttime more than one third of total daily urine        volume (NPU) and voided more than two times at nighttime (nocturia)|January 2011|January 19, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01280279||110254|
NCT01281111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV106|Alternate Dosing Regimens of BG00012 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of BG00012 Administered With and Without 325 mg Aspirin in Healthy Adult Volunteers|109HV106|Biogen|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 17, 2011|January 20, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01281111||110191|
NCT01281605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10M MHIS112|Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes|Comparison of Two Titration Programs of Adding Insulin Detemir to Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes Patients||Mackay Memorial Hospital|Yes|Recruiting|January 2011|May 2016|Anticipated|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||March 2016|March 15, 2016|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281605||110154|
NCT01281852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02661|Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix||National Cancer Institute (NCI)||Active, not recruiting|April 2011|||March 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Female|18 Years|N/A|No|||December 2015|March 4, 2016|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281852||110135|
NCT01288131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/01_Medicine|Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment|Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone||Chulalongkorn University|No|Terminated|January 2009|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|60 Years|No|||January 2014|January 27, 2014|February 1, 2011||No|We observed >90 % efficacy in cyclophosphamide and Prednisolone group for treatment of    anti-i-HuEpo associated PRCA|No||https://clinicaltrials.gov/show/NCT01288131||109656|
NCT01288352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET 4 EAST|Early Treatment of Atrial Fibrillation for Stroke Prevention Trial|Early Therapy of Atrial Fibrillation for Stroke Prevention Trial (EAST).|EAST|German Atrial Fibrillation Network|Yes|Recruiting|February 2011|November 2019|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2745|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288352||109639|
NCT01282372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-179|Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab|A 2-year HRQL Observational Study Evaluating the Effect of Treatment With Adalimumab on Work Productivity and Sleep in Patients With Rheumatic Diseases in Greece||AbbVie|No|Completed|March 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|18 Years|99 Years|No|Non-Probability Sample|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received        adalimumab in accordance with approved label, as prescribed by the physicians under normal        clinical practice.|October 2015|October 8, 2015|January 21, 2011||No||No|July 28, 2015|https://clinicaltrials.gov/show/NCT01282372||110095|
NCT01288326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3876|Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes Mellitus|ROOTS|Novo Nordisk A/S|No|Completed|February 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|254|||Both|18 Years|N/A|No|Probability Sample|Subjects with type 2 diabetes mellitus for whom physicians determine that liraglutide is        an appropriate new treatment.|August 2014|August 25, 2014|January 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288326||109641|
NCT01282593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/10-05|Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).|Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).|LAL TEL/ALM1|Rennes University Hospital|No|Recruiting|November 2010|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|1 Year|18 Years|No|||December 2015|December 17, 2015|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282593||110078|
NCT01288898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0002|Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941|A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of ASP1941 and to Explore the Effect of ASP1941 on Urine and Blood Glucose Levels in Healthy Subjects||Astellas Pharma Inc|No|Completed|May 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 1, 2011|February 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288898||109597|
NCT01289184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR QUALITY IN PHOTOCOPY UNITS|Air Quality Monitoring and Health Surveillance of Workers in the Photocopier Units|Air Quality Monitoring and Health Surveillance of Workers in the Photocopier Units||Avinashilingam Deemed University|No|Recruiting|January 2011|December 2013|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Anticipated|200|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|At least two years of working experience in photocopier units|January 2011|February 2, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289184||109575|
NCT01289197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD057893-02|Health Promotion in Early Adolescence: Sleep, Activity, and Emotion Regulation|Health Promotion in Early Adolescence: Sleep, Activity, and Emotion Regulation||University of Pittsburgh|Yes|Completed|April 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|324|||Both|10 Years|13 Years|No|||January 2016|January 8, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289197||109574|
NCT01289145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEP-2011-PK|Stage-based Exercise Promotion Study|Stage-based Exercise Promotion Study|STEPS|Freie Universität Berlin|Yes|Completed|February 2011|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|November 13, 2012|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289145||109578|
NCT01282762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV2-HBV-19|Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease|An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV™ Compared With Engerix-B® in Adults With Chronic Kidney Disease Who Have Previously Received At Least One Hepatitis B Vaccine Series||Dynavax Technologies Corporation|No|Completed|December 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|147|Samples Without DNA|Serum retained during study duration for additional testing if indicated|Both|18 Years|75 Years|No|Non-Probability Sample|Subjects with Chronic Kidney Disease previously enrolled in the Dynavax clinical studies        DV2-HBV-17 and DV2-HBV-18|August 2015|February 26, 2016|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01282762||110065|
NCT01278823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK089547|Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes|Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes|Stampede II|The Cleveland Clinic|Yes|Active, not recruiting|January 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||July 2014|July 30, 2014|January 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01278823||110366|
NCT01279993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8659|Orthoptic Changes Following Photorefractive Keratectomy|Orthoptic Changes Following Photorefractive Keratectomy||hahid Beheshti University of Medical Sciences|Yes|Completed|April 2008|April 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care|1||||||Both|18 Years|59 Years|Accepts Healthy Volunteers|||April 2008|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01279993||110276|
NCT01279057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71047201|A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Fluticasone Furoate Nasal Spray (Lek Pharmaceuticals) With Veramyst® Nasal Spray (GlaxoSmithKline) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis||Sandoz Inc.||Completed|December 2010|||February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|962|||Both|12 Years|N/A|No|||December 2012|December 14, 2012|January 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279057||110348|
NCT01279317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-035|Vinegar Co-ingestion in Type 2 Diabetes|The Effect of Vinegar Co-ingestion on Postprandial Glucose Control in Type 2 Diabetes Patients||Maastricht University Medical Center|No|Completed|September 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|12|||Male|40 Years|70 Years|No|||August 2011|August 25, 2011|January 17, 2011||No||No|July 20, 2011|https://clinicaltrials.gov/show/NCT01279317||110328|
NCT01279655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MECU2012-001|Motor Training and White Matter in Multiple Sclerosis (MS)|The Influence of a tDCS Combined Long-term Motor Training Program on Structural White Matter Changes in the Brain, Functionality and Psychological Outcome Measures in Multiple Sclerosis.||Hasselt University|Yes|Terminated|January 2011|May 2013|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279655||110302|
NCT01279928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNEHREC 09/04/15/5.10|Detection of Vascular Injury in Diabetes Through Eye and Nailfold Data (DIVIDEND) - A Pilot Study|Detection of Vascular Injury in Diabetes Through Eye and Nailfold Data (DIVIDEND) - A Pilot Study|DIVIDEND|John Hunter Hospital|No|Completed|March 2010|October 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|26|||Both|8 Years|18 Years|No|Non-Probability Sample|Participants were recruited from the John Hunter Children's Hospital paediatric diabetes        clinic. They were between the ages of 8-18 years old.|January 2011|January 24, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01279928||110281|
NCT01279668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC_001|Montelukast for Persistent Cough in Young People and Adults|A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care|MAC|University of Oxford|Yes|Active, not recruiting|May 2011|November 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|276|||Both|16 Years|49 Years|No|||October 2012|October 8, 2012|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279668||110301|
NCT01279902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_NHL01|Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL|Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised Stage I or II CD20+ Diffuse Large B-cell Lymphoma||Asan Medical Center|No|Active, not recruiting|August 2010|January 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|80 Years|No|||February 2016|February 20, 2016|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01279902||110283|
NCT01279915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0456-CL-0011|A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects|Phase I Study of ASP0456 - A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Non-elderly Healthy Male Subjects||Astellas Pharma Inc|No|Completed|October 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|32|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||January 2011|January 18, 2011|January 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01279915||110282|
NCT01280591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14837|Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain|A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep|Morpheus II|Bayer|No|Completed|October 2010|February 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|712|||Both|12 Years|45 Years|No|||May 2015|May 13, 2015|January 20, 2011|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01280591||110230|
NCT01280851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN10-0202-A|Living Renal Donor MRI Study|Comprehensive Morphological and Functional Assessment of Living Renal Donor With Magnetic Resonance Imaging With Comparison to Computed Tomographic Angiography and Renal Scintigraphy||University Health Network, Toronto|No|Withdrawn|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|0|||Both|18 Years|65 Years|No|||January 2012|January 13, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280851||110210|
NCT01281592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|253-SOL1-01|A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours|Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours||Aptose Biosciences Inc.||Completed|January 2011|January 2014|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281592||110155|
NCT01281371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K344|Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan|Clinical Devolution of a Medication Change at Patients With Mono- or Combination Therapy With Sitaxentan to a Regime Without Sitaxentan.||Heidelberg University|No|Completed|January 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples With DNA|only remaining blood of the security laboratory for analysis of plasma concentrations of      drugs|Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with Sitaxentan|December 2010|June 26, 2013|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281371||110171|
NCT01287546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13298|A Study of LY2875358 in Participants With Advanced Cancer|A Phase 1 Study of LY2875358 in Patients With Advanced Cancer||Eli Lilly and Company|No|Active, not recruiting|April 2010|April 2016|Anticipated|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|117|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287546||109698|
NCT01287806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uilis-china|Ulinastatin in Inhalation Lung Injury|Multicenter,Randomized,Parallel Assignment,Blank Control Study of Ulinastatin in Inhalation Lung Injury||Chinese PLA General Hospital|No|Not yet recruiting|February 2011|January 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||January 2011|January 31, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01287806||109680|
NCT01287819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-12-10-04|Apolipoprotein E Gene and Functional MRI|Polymorphisms of Apolipoprotein E Gene and the Presentation of Resting-state Functional MRI|fMRI|Taipei Medical University Shuang Ho Hospital|No|Recruiting|May 2012|June 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|DNA|Both|45 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|people aged 45-65 years taking health examination in TMU SHH no cognitive impairment by        MMSE and AD8 screening|October 2012|October 17, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287819||109679|
NCT01287832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ1210-01|Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)|||St. John Health System, Michigan|Yes|Terminated|June 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|January 31, 2011|Yes|Yes|Low patient enrollment|No|December 2, 2013|https://clinicaltrials.gov/show/NCT01287832||109678|
NCT01288365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc K015/2011|The Impact of Exercise Training on Functional Capacity in Heart Failure|Impact of Exercise Training on Functional Capacity in Heart Failure Patients With Preserved Ejection Fraction.||Meir Medical Center|No|Recruiting|March 2011|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|80 Years|No|||March 2012|March 16, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01288365||109638|
NCT01288378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-65091-06093|Empirical Versus Preemptive Antifungal Therapy|Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Active, not recruiting|March 2012|July 2016|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|556|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288378||109637|
NCT01288573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI12860|A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone|A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants.||Sanofi|Yes|Active, not recruiting|March 2014|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|46|||Both|1 Year|18 Years|No|||October 2015|October 6, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288573||109622|
NCT01288586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR 8 Year|Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients|Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of Scandinavian Total Ankle Replacement (STAR) Ankle Among Continued Access Study Patients|STAR 8|Stryker Trauma GmbH|No|Enrolling by invitation|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|N/A|No|Probability Sample|The study population consists of all living subjects who participated in the continued        access study.|December 2015|December 2, 2015|November 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288586||109621|
NCT01288859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSA-FF-01|Physiological Effects of New Polyphenol-enriched Foods in Humans|Physiological Effects of New Polyphenol-enriched Foods in Healthy Humans||Federico II University|Yes|Completed|December 2010|July 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|January 27, 2011||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT01288859||109600|
NCT01289158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-131-PED|Combined Malonic and Methylmalonic Aciduria (CMAMMA): Gene Identification and Outcome Study|||McGill University Health Center|No|Recruiting|February 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|6|Samples With DNA|1. A 5 cc sample of blood from a vein in EDTA tube for DNA testing        2. A 5 cc sample of urine sample to measure the levels of MA and MMA        3. An additional 5 cc (1 tsp) of blood sample will be collected from the parents for DNA           testing|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Biochemical Genetics clinics patients with non-classical CMAMMA|October 2010|February 7, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289158||109577|
NCT01296828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP PUC/SP 302/2008|Lips and Tongue of Mouth Breathing Children|Posture, Tone and Mobility of Lips and Tongue of Mouth Breathing Children||Pontificia Universidade Catolica de Sao Paulo|Yes|Enrolling by invitation|October 2009|May 2011|Anticipated|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|40|||Both|7 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|40 mouth breathing children, 26 (65%) male and 14 (35%) female, aging between 7 and 10        years old, were involved in this research realized in Instituto CEFAC, São Paulo, SP,        Brazil.|November 2010|February 15, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01296828||108989|
NCT01282775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0509|Interventions to Control Obesity in Community Colleges (CDC WAY to Health)|Interventions to Control Obesity in Community Colleges||University of North Carolina, Chapel Hill|Yes|Completed|September 2005|March 2007|Actual|November 2006|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1029|||Both|18 Years|N/A|No|||January 2011|January 21, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01282775||110064|
NCT01278836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-12|Fasciocutaneous Flaps for Leg Defects|Study of Fasciocutaneous Flaps for Treatment of Leg Defects||Isfahan University of Medical Sciences|Yes|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|23|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2009|January 26, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01278836||110365|
NCT01279070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REPYFLEC Clinical Trial|Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia|Efficacy of Repyflec Cognitive Remediation Group Training in Cognition, Functional Outcomes and Psychiatric Symptoms of Outpatients With Schizophrenia.||Fundació Sant Joan de Déu|No|Completed|September 2006|March 2011|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|60 Years|No|||May 2013|August 14, 2013|January 14, 2011||No||No|November 16, 2011|https://clinicaltrials.gov/show/NCT01279070||110347|It would be useful to widen the assessment of cognitive measures and negative symptoms. Metacognition has not been appropriately studied.
NCT01279733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC8036|Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis|Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis|Microarray|Columbia University|No|Completed|October 2008|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4450|Samples With DNA|-  Additional 15 ml of amniotic fluid (minimum 10 ml) for amniocentesis        -  Blood sample (10 ml) from each parent will be obtained in case of a need to test for           suspected familial copy number variants (CNVs) or discrepant results, and also to           evaluate for maternal cell contamination (patient's blood sample).        -  10 ml of amniotic fluid with suspended cells, (minimum 7 ml)        -  5 mg of villi (minimum of 2mg)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 4,400 prenatal diagnostic samples will be obtained from patients undergoing        prenatal testing for standard indications. Patients will be recruited at participating        prenatal diagnostic centers by designated study personnel; recruitment of patients will be        initiated as a pilot study. These patients will not contribute to the final planned sample        size of 4400 patients. Two sub-studies will then be initiated consisting of 250 (or more)        patients enrolled with sufficient amniotic fluid sample and 250 (or more) patients with        sufficient villus sample.|August 2012|August 21, 2012|July 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01279733||110296|
NCT01279681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N0949|Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer|Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|January 2011|||September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|380|||Both|70 Years|N/A|No|||July 2015|July 23, 2015|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279681||110300|
NCT01279694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/3-D|Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)|Phase I/II Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma.|CARMYSAP|Nantes University Hospital||Completed|October 2010|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|65 Years|N/A|No|||September 2013|March 16, 2016|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279694||110299|
NCT01279707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6125|Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)|Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL)|MARALL|Queen Mary University of London|Yes|Active, not recruiting|January 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Both|16 Years|N/A|No|||July 2014|July 11, 2014|April 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279707||110298|
NCT01279941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e6309|Safety & Health Improvement: Enhancing Law Enforcement Departments|Safety & Health Improvement: Enhancing Law Enforcement Departments|SHIELD|Oregon Health and Science University|Yes|Completed|August 2010|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|489|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 28, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01279941||110280|
NCT01279720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03MI14|Gene Therapy ADA Deficiency|Phase I Gene Therapy Protocol for Adenosine Deaminase Deficiency||Great Ormond Street Hospital for Children NHS Foundation Trust||Completed|October 2003|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|18 Years|No|||September 2015|September 11, 2015|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01279720||110297|
NCT01280292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8213-RP-CTIL|Central Hypothyroidism, a Novel Laboratory Measurement|Central Hypothyroidism,a New Laboratory Approach for Hormone Measurement||Sheba Medical Center|No|Enrolling by invitation|February 2011|July 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|90 Years|No|||February 2011|February 2, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280292||110253|
NCT01280578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPONDER|The Coherex FlatStent™ EF PFO Migraine Registry|The Coherex PFO Migraine Registry||Coherex Medical|Yes|Not yet recruiting|February 2011|||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280578||110231|
NCT01280604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPGA-10KMani-01|Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy|Effects of Fenofibrate 160mg to 54mg Conversion on Triglyceride Levels in Patients on Statin Therapy||Kaiser Permanente|Yes|Completed|October 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|January 19, 2011||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01280604||110229|
NCT01280864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806750|MAPP Investigation of Pelvic Floor-Brain Neurobiologic Axis in IC/IBS and IBS|Investigation of Pelvic Floor-Brain Neurobiologic Axis in IC/IBS and IBS||University of Iowa||Terminated|March 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects: Sixty six consecutive adult, out-patients, over 18 years with IC alone and 66        adult patients with IBS alone and 30 healthy controls will be recruited for this 5 year        study and to fulfill all 4 aims of this study. All study aims will recruit under a unified        strategy. For most of the funding cycle, we will recruit simultaneously for several study        aims. To prevent confusion about concordant studies, similar standardized forms and        diagnostic tests will be used for each aim, with supplemental tools as needed.|April 2012|April 18, 2012|January 19, 2011||No|the study PI left the university of iowa|No||https://clinicaltrials.gov/show/NCT01280864||110209|
NCT01291576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/069/HP|Functional Outcomes of Surgical Management of Deep Endometriosis Infiltrating the Rectum|Randomized Trial Comparing Digestive and Urinary Dysfunction Secondary to 2 Surgical Techniques Used in the Management of Deep Endometriosis Infiltrating the Rectum: Colorectal Resection and Rectal Nodules Excision (ENDORE)|ENDORE|University Hospital, Rouen|No|Active, not recruiting|March 2011|September 2023|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|45 Years|No|||January 2016|January 22, 2016|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01291576||109391|
NCT01287559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-005|Monitoring Necrotizing Enterocolitis in Premature Infants|Monitoring Necrotizing Enterocolitis in Premature Infants Using Depth-Resolved Broad Spectrum NIRS||Spectros Corporation|Yes|Not yet recruiting|March 2011|||December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|6 Weeks|No|Non-Probability Sample|Infants hospitalized for prematurity in a Neonatal ICU|January 2011|January 31, 2011|January 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01287559||109697|
NCT01287858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC430-001|Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects|A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects||Daiichi Sankyo Inc.|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|January 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287858||109676|
NCT01287845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15117|PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers|Open-label, Multi Center PET/CT Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 18F Labeled PET Tracer BAY1075553 Following a Single Intravenous Administration of 300 MBq in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers.||Piramal Imaging SA|No|Completed|February 2011|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|14|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 18, 2013|January 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287845||109677|
NCT01288144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p000842|Clinical Decision Support for Women With a History of Gestational Diabetes|Clinical Decision Support for Women With a History of Gestational Diabetes||Brigham and Women's Hospital|No|Completed|July 2007|||November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1000|||Female|N/A|N/A|No|||February 2012|February 3, 2012|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01288144||109655|
NCT01289210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRXP-A104|VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas|A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas||VentiRx Pharmaceuticals Inc.|Yes|Terminated|July 2011|October 2012|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|February 1, 2011|No|Yes|The study was stopped due to slow rate of recruitment.|No|May 28, 2014|https://clinicaltrials.gov/show/NCT01289210||109573|Due to slow enrollment, the study was closed by the sponsor. 2 participants were enrolled. 1 participant was analyzed for the primary outcome measure (tumor response) and 2 participants were analyzed for safety and toxicity.
NCT01289223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDM3502|A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.|A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab|ROBIN|Mundipharma Research Limited|Yes|Recruiting|February 2011|July 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289223||109572|
NCT01288339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-0903|Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer|An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy|PULSE|Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Active, not recruiting|November 2010|September 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||November 2012|March 10, 2015|December 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01288339||109640|
NCT01288599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laparoscopy SSK|Single Versus Conventional Laparoscopy for Benign Adnexal Disease|Single Port Laparoscopy Versus Conventional Laparoscopy for Benign Adnexal Disease - A Randomized Controlled Trial.||Sorlandet Hospital HF|Yes|Completed|January 2011|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|June 29, 2012|November 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01288599||109620|
NCT01289704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUP09013|Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A)|A Multicenter Study to Evaluate the Effects on Charcot−Marie−Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program.|TreSPE|University of Genova|No|Not yet recruiting|February 2011|January 2012|Anticipated|October 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2010|February 3, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01289704||109535|
NCT01296841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TELEMED PA|Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care|A Randomized Controlled Pilot: Use of Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care||VA Palo Alto Health Care System|Yes|Completed|October 2009|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|34|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|February 15, 2011||No||No|January 15, 2012|https://clinicaltrials.gov/show/NCT01296841||108988|
NCT01297140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.508|The PACO Study ("Personnalité Alzheimer COmportement")|The Role of Personality in the Occurrence of Behavioural Disorders in Patients Suffering From Alzheimer Disease|PACO|Hospices Civils de Lyon|No|Recruiting|January 2009|November 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|252|||Both|50 Years|N/A|No|||October 2014|October 2, 2014|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01297140||108965|
NCT01282788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2071|Efficacy of Caterpillar Cereal for Complementary Feeding in the Democratic Republic of Congo|A Novel Sustainable Complementary Feeding Product for Infants and Young Children in the Democratic Republic of Congo: Caterpillar Cereal|CAT02|University of North Carolina, Chapel Hill|Yes|Completed|January 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|222|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||December 2013|December 5, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282788||110063|
NCT01282801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02205|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsules in Healthy Subjects Under Fed Conditions.||Teva Pharmaceuticals USA||Completed|September 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 11, 2011|January 24, 2011||Yes||No|February 11, 2011|https://clinicaltrials.gov/show/NCT01282801||110062|
NCT01278849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2105|An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function|A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of ASA404 in Adult Cancer Patients With Impaired Hepatic Function and With Normal Hepatic Function||Novartis||Terminated|January 2010|||November 2010|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2012|November 26, 2012|January 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01278849||110364|
NCT01279746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0003-10-EMC|The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia|The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia||HaEmek Medical Center, Israel|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients with saturation under 94% room air|June 2015|June 21, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01279746||110295|
NCT01279356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-088|Volatile Organic Compounds (VOCs) and Liver Diseases|Analysis of Volatile Organic Compounds in Exhaled Air as a Non-invasive Biomarker for Liver Diseases||Maastricht University Medical Center|No|Not yet recruiting|February 2011|August 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|The following biospecimens will be collected: exhaled air and plasma/serum|Both|18 Years|85 Years|No|Non-Probability Sample|The study population will include patients with various liver diseases visiting the        outpatient clinic.|January 2011|January 27, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279356||110325|
NCT01279954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e7035|Abatacept in the Treatment of Uveitis|An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis.||Oregon Health and Science University||Recruiting|January 2012|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|6 Years|N/A|No|||January 2015|January 8, 2015|January 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279954||110279|
NCT01279967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6837|A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma|A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma|ADAM|Barts & The London NHS Trust|No|Active, not recruiting|January 2011|March 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||May 2012|November 19, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01279967||110278|
NCT01280617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-065|Low Dose Thymoglobin in Renal Transplant Patients|Low Dose Thymoglobulin As Induction Agent on Prednisone-Free Regimens of Renal Transplant Recipients||Lahey Clinic|No|Completed|October 2010|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|80 Years|No|||May 2014|May 28, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280617||110228|
NCT01279980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H1308/63|Clinical Trial Comparing Epidurals and Local Anaesthetic Wound Catheters in Patients Having Bowel Surgery|Continuous Wound Infiltration With Local Anaesthetic vs. Epidurals in an Enhanced Recovery Protocol: A Randomised Controlled Trial||Scarborough General Hospital|Yes|Recruiting|February 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2011|February 17, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01279980||110277|
NCT01280305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8287-MW-SHEBA|Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder|A Randomized Trial Administering Raloxifene vs Placebo as add-on to Antipsychotics in Post Menopausal Patients With Schizophrenia or Schizoaffective Disorder|RAL-S-01|Sheba Medical Center|No|Not yet recruiting|March 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|45 Years|65 Years|No|||January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280305||110252|
NCT01281124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02570|Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer|Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC||National Cancer Institute (NCI)||Active, not recruiting|January 2011|||April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 20, 2011|Yes|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT01281124||110190|Due to low enrollment of this trial all outcomes were not assessed.
NCT01281358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10027|Helping Our Premature Infants ON to Better Motor Skills (HOP-ON)|Development and Evaluation of a Parenting Intervention to Promote Development in Infants Born Very Premature|HOP-ON|University of Nottingham|No|Completed|March 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|160|||Both|N/A|N/A|No|||December 2015|December 1, 2015|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01281358||110172|
NCT01291589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P30AI060354-07|HIV Prevention in Very High Risk Men Who Have Sex With Men|HIV Prevention in Very High Risk Men Who Have Sex With Men|ENGAGE|Fenway Community Health|Yes|Active, not recruiting|September 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Male|18 Years|N/A|No|||May 2012|May 7, 2012|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01291589||109390|
NCT01287871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09136|Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer|Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer||City of Hope Medical Center|Yes|Completed|January 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|332|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|200 participant recruited from the Inland Empire, Trinidad and Tobago|October 2012|October 12, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287871||109675|
NCT01288924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-10-11-19A-12|Can Parecoxib Reduce Post-operative Ipsilateral Shoulder Pain?|Can Preemptive Analgesia With Parecoxib Reduce Post-operative Ipsilateral Shoulder Pain? A Double-blinded, Randomized, Placebo-controlled Trial.||Chiang Mai University|No|Recruiting|February 2011|July 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288924||109595|
NCT01288937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3404|A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain|A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain||Columbia University|No|Active, not recruiting|November 2010|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|80 Years|No|||December 2013|December 13, 2013|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01288937||109594|
NCT01288612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007787|Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus|Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus|challenge|Mayo Clinic|No|Completed|February 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|459|||Both|50 Years|95 Years|Accepts Healthy Volunteers|||December 2014|December 23, 2014|January 28, 2011|No|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01288612||109619|
NCT01288625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-2011-DP|Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine|Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine||Sun Pharmaceutical Industries Limited|No|Suspended|March 2011|||December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|18 Years|70 Years|No|||October 2012|October 12, 2012|February 1, 2011||No|There were IP availability issues due to which the study could not be started.|No||https://clinicaltrials.gov/show/NCT01288625||109618|
NCT01288911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0222|A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer|A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer||Astellas Pharma Inc|Yes|Active, not recruiting|March 2011|June 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|375|||Male|18 Years|N/A|No|||February 2016|February 10, 2016|February 1, 2011|Yes|Yes||No|October 15, 2015|https://clinicaltrials.gov/show/NCT01288911||109596|
NCT01289171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30AI045008|Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients|Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients: Prospective Treatment Trial With Topical Glycolic Acid and HPV Genotype Characterization||University of Pennsylvania|No|Completed|January 2009|October 2010|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|7 Years|N/A|Accepts Healthy Volunteers|||January 2011|February 1, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01289171||109576|
NCT01289717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-08|Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients|Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients - Transplant Proteogenomics|PROGENI-KI|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|307|Samples With DNA|Samples of blood, urine, and tissue|Both|18 Years|N/A|No|Probability Sample|Adults undergoing kidney transplantation.|August 2015|August 21, 2015|February 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01289717||109534|
NCT01296880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-011|Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy|Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy||State University of New York - Downstate Medical Center|No|Completed|June 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|17 Years|N/A|No|Non-Probability Sample|Patients being treated at epilepsy clinics at SUNY Downstate Medical Center|June 2012|December 23, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01296880||108985|
NCT01282827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS-optnerv-BCT|Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve)|Paraorbital-occipital Alternating Electric Current Stimulation in Patients With Optic Neuropathy||University of Magdeburg|No|Completed|November 2006|March 2010|Actual|March 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||January 2011|January 25, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282827||110060|
NCT01279369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117104-4|The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta|The Use of Fetal Fibronectin (fFN) in Predicting Preterm Delivery Due to Abruptio Placenta in Patients With Minor Maternal Trauma.||Winthrop University Hospital|Yes|Terminated|October 2009|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples Without DNA|Fetal fibronectin|Female|18 Years|N/A|No|Non-Probability Sample|Patients eligible for inclusion in the study are women aged 18 or over with singleton        intrauterine pregnancy ≥20 weeks gestational age and ≤35 weeks gestational age presenting        to the Winthrop University Hospital Labor & Delivery triage unit with a chief complaint of        maternal trauma.|January 2015|January 9, 2015|January 14, 2011||No|Study no longer feasible as quantitative assessment of fFN can only be performed at one    laboratory.|No||https://clinicaltrials.gov/show/NCT01279369||110324|
NCT01279382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P113/99|Effect of Hypnotherapy in Irritable Bowel Syndrome (IBS)|Effectiviteit Van Hypnotherapie Bij Prikkelbare Darmsyndroom (Effectiveness of Hypnotherapy in Irritable Bowel Syndrome)||Maastricht University Medical Center|Yes|Completed|January 2002|January 2006||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|112|||Both|18 Years|N/A|No|||January 2011|January 18, 2011|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279382||110323|
NCT01279759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01339|Follow up of Patients Operated With Anterior Cruciate Ligament Reconstruction|Pre- and Post Operative Predictive Factors for Function 6 Months After Anterior Cruciate Ligament Reconstruction||Haraldsplass Deaconess Hospital|No|Recruiting|October 2010|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|35|||Both|N/A|N/A|No|Non-Probability Sample|Patients planned for reconstruction of the anterioir crucuate ligament with hamstrings        graft.|January 2013|January 17, 2013|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01279759||110294|
NCT01280032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-Kypho-IORT-01|Kypho-IORT: Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases|Kypho-IORT: Phase II Study for Dose Escalation of Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases|Kypho-IORT|Universitätsmedizin Mannheim|No|Completed|January 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|50 Years|N/A|No|||November 2013|November 12, 2013|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280032||110273|
NCT01280318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 2008-03|Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery|Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery|HNSCC|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|January 2009|September 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280318||110251|
NCT01280331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q8003-022|Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients|A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Effects of Q8003 to the Morphine-Equivalent Doses of Oxycodone and of Morphine on the Opioid-Related Adverse Events of Moderate to Severe Nausea, Emesis, and Dizziness in Subjects With Acute Moderate-to-Severe Postoperative Pain Following Bunionectomy Surgery||QRxPharma Inc.|No|Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|375|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01280331||110250|
NCT01280630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIN-XXX-2010/1|Multicentre Retrospective Study to Understand Anti-thrombotic Treatment Patterns and Outcomes of Acute Coronary Syndrome (ACS) Patients|A Multicentre Retrospective Study to Understand Anti-thrombotic Treatment Patterns and Outcomes of Acute Coronary Syndrome (ACS) Patients in India|TRACE|AstraZeneca|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|ACS patients admitted in tertiary care hospitals|January 2012|January 31, 2012|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01280630||110227|
NCT01280877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS-PP-2010-08-10-001|Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)|Multicenter Study of Paraorbital-Occipital Alternating Current Stimulation Therapy in Patients With Optic Neuropathy||University of Magdeburg|No|Completed|December 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||January 2011|March 29, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280877||110208|
NCT01280890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCCNor|Person- Centred Care Among Nursing Home Patients With Dementia|Person-centred Care and Dementia Care Mapping Among Nursing Home Patients - a 10 Months Randomised Controlled Intervention Study||Norwegian Centre for Ageing and Health|Yes|Completed|February 2011|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|624|||Both|N/A|N/A|No|||June 2012|June 11, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01280890||110207|
NCT01280903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR010904-01A1|Staying Active With Arthritis|Promoting Physical Activity in Older Adults With Comorbidity|STAR|University of Pittsburgh|Yes|Completed|January 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|182|||Both|50 Years|N/A|No|||January 2016|January 13, 2016|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01280903||110206|
NCT01281137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000692740|Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07|SOLE Estrogen Substudy (SOLE-EST) - Investigating Changes in Estrogen Levels and Grip Strength for Patients Participating in the SOLE Trial|SOLE-EST|International Breast Cancer Study Group|Yes|Active, not recruiting|October 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|Samples With DNA|Serum, whole blood,|Female|18 Years|N/A|No|Non-Probability Sample|Patients randomized to the SOLE trial (IBCSG 35-07) and participate in the Quality of Life        substudy.|March 2015|March 13, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281137||110189|
NCT01287572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-YS-319-CTIL|Efficiency of Ventilation During Conscious Sedation in the Pediatric Intensive Care Unit|Efficiency of Ventilation During Conscious Sedation of Pediatric Patients Undergoing Minor Procedures in the Pediatric Intensive Care Unit||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2011|August 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|18 Years|No|Non-Probability Sample|pediatric patirnts 0- 18 years admitted to the pediatric intensive care unit and        undergoing minor procedures|January 2011|January 31, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01287572||109696|
NCT01287585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2009-001|Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy|A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy|ADI-PEG 20|Polaris Group|Yes|Active, not recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|636|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01287585||109695|
NCT01288638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pulse-PCOS|Lifestyle Intervention for Polycystic Ovary Syndrome: Pulse-Based Diet and Exercise|A Lifestyle Intervention for Women With Polycystic Ovary Syndrome: The Role of a Pulse-Based Diet and Aerobic Exercise on Infertility Measures and Metabolic Syndrome Risk||University of Saskatchewan|Yes|Recruiting|January 2011|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|166|||Female|18 Years|35 Years|No|||September 2014|May 27, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01288638||109617|
NCT01288651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-247|Iron Deficiency In Pulmonary Hypertension|Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension||VU University Medical Center|No|Recruiting|January 2011|January 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2011|February 1, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288651||109616|
NCT01289522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORTEC2008-03TPex|Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Study of Cetuximab, Docetaxel and Cisplatin as First-line Treatment in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinomas - GORTEC2008-03 TPEx||Groupe Oncologie Radiotherapie Tete et Cou|No|Active, not recruiting|September 2009|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|70 Years|No|||January 2014|January 2, 2014|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289522||109549|
NCT01289730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enbrel_uSpA-2|Etanercept (Enbrel) in Undifferentiated Spondyloarthritis|An Open-label Study of Etanercept (Enbrel) Efficacy in Undifferentiated Spondyloarthritis|Enbrel_uSpA-2|Charite University, Berlin, Germany|Yes|Active, not recruiting|February 2002|May 2012|Anticipated|September 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||February 2002|February 3, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289730||109533|
NCT01289496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25553|Ribavirin Dose Optimization for the Treatment of Hepatitis C|Ribavirin Dose Optimization for the Treatment of Hepatitis C: A Pilot Study||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Completed|February 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2012|February 24, 2014|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01289496||109551|
NCT01289236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-02|"MILNACIPRAN" in Subjects With Chronic Shoulder Pain|An Exploratory, Randomized, Single Blinded, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of "MILNACIPRAN" in Subjects With Chronic Shoulder Pain||Delray Research Associates|No|Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|40|||Both|25 Years|N/A|No|||August 2012|August 7, 2012|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289236||109571|
NCT01289509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-A001-007|A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects|A Randomized, Open-Label, 4-Way Crossover Replicate Design Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects||Eisai Inc.||Completed|December 2010|May 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|January 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01289509||109550|
NCT01290315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT08022|Intravenous Ferric Carboxymaltose (FCM) Versus IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women|A Randomized, Controlled Study to Investigate the Safety and Oxidative Stress Potential of Intravenous Ferric Carboxymaltose (FCM) vs. IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women||Luitpold Pharmaceuticals|No|Recruiting|August 2009|||March 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Female|18 Years|50 Years|No|||February 2011|February 3, 2011|November 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290315||109488|
NCT01290627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10035/IIS-000126|In Vivo Determination of 3D Patellofemoral Mechanics|In Vivo Determination of 3D Patellofemoral Mechanics|Patella|The University of Tennessee Knoxville|No|Completed|February 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|30|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects recruited from patients chosen from practice of Dr.'s Dennis and Haas at Colorado        Joint Replacement for implanted knee, having either one of the two kinds of implants        specified.|January 2014|January 21, 2014|February 3, 2011||No||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01290627||109464|No adverse effects, events or unexpected risks occurred The sample size per group was small Age of the TKA groups were matched, the age of the normal subjects were not Cartilage thickness for normals had to be assumed as MRIs could not be obtained
NCT01328743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA-P01-AA019072-1|Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting|Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting||Brown University|No|Active, not recruiting|May 2011|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Male|18 Years|N/A|No|||January 2016|January 25, 2016|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328743||106561|
NCT01279096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-010826-20|Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia|A Phase I Dose Escalation Study of Clofarabine Given in Combination With Multi-agent Therapy for Remission Induction in Pediatric Patients With Acute Lymphoblastic Leukemia in First Relapse or Refractory to First Line Therapy -|Vandevol|University Hospital, Lille|Yes|Completed|January 2010|June 2013|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|1 Year|23 Years|No|||December 2014|December 8, 2014|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279096||110345|
NCT01279395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151973-1|Anti-inflammatory Agents and Cholesterol Metabolism|Impact of Anti-inflammatory Agents on Cholesterol Metabolism and Atherogenic Potency of Patient Plasma||Winthrop University Hospital|No|Recruiting|November 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|40 Years|70 Years|No|Probability Sample|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis        are considered|December 2014|December 8, 2014|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01279395||110322|
NCT01279408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 10-0484-CE|Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)|Prospective Observational Study Of Patients With Asymptomatic Centrally Located Advanced NSCLC Who Are Not Suitable For Curative Treatment||University Health Network, Toronto|No|Recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Patients with Centrally Located Advanced NSCLC who are Asymptomatic and who are not        Suitable for Curative Treatment|February 2016|February 8, 2016|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01279408||110321|
NCT01289925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00002109|Effect of Selenium Intervention on Inflammation in Older Adults|Antioxidant Nutrient Inflammation Interventions in Older Adults||Johns Hopkins University|Yes|Recruiting|February 2006|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|1200|||Both|70 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 3, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01289925||109518|
NCT01280006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-MMHAP-COX-IH-2010001|Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans|Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans||University of Calgary|Yes|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 2, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01280006||110275|
NCT01280019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRC-ARF|FRC Guided Therapy in Acute Respiratory Failure|Functional Residual Capacity Guided Alveolar Recruitment Strategy in Patients With Acute Respiratory Failure After Cardiac Surgery||University of Luebeck|No|Recruiting|October 2010|May 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2011|January 19, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280019||110274|
NCT01280344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-IPAM-202|Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function|Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis||Helsinn Therapeutics (U.S.), Inc|No|Completed|March 2011|||June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|320|||Both|18 Years|85 Years|No|||August 2013|August 30, 2013|January 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01280344||110249|
NCT01280643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-033|Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression||Fox Chase Cancer Center|Yes|Completed|March 2010|||December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01280643||110226|
NCT01280656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22995|A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)|Retrospective Study to Access the Impact Caused by the Use of Interferon (Pegylated or Not) for the Treatment of Chronic Hepatitis C Patients in Brazil (DECISION)||Hoffmann-La Roche||Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|660|||Both|18 Years|70 Years|No|Probability Sample|Hepatitis C patients that received interferon (pegylated or conventional) during the        period stipulated (from 01-Sep-2007 to 31-Aug-2008)|October 2015|October 1, 2015|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01280656||110225|
NCT01291043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297/09|Efficacy of Shiatsu in Individuals With Fibromyalgia: a Randomized Clinical Trial|Efficacy of Shiatsu in Pain, Flexibility, Sleep, Anxiety and Quality of Life in Individuals With Fibromyalgia: a Randomized Clinical Trial||University of Sao Paulo General Hospital|No|Completed|July 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|30 Years|60 Years|No|||November 2012|November 14, 2012|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01291043||109432|
NCT01291303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMV01AECB|Optimization of Ventilator Setting for Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Optimization of Ventilator Setting by Flow and Pressure Curves Analysis During Noninvasive Ventilation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease|NIMV01AECB|University of Milan|No|Completed|October 2009|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|40 Years|N/A|No|||October 2010|February 7, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291303||109412|
NCT01288404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055217|Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium|A Pilot Study of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium||Ramathibodi Hospital|No|Completed|January 2008|November 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|February 1, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288404||109635|
NCT01288417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 10.05|Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir|Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir|OPAL|Radboud University|No|Completed|August 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 23, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01288417||109634|
NCT01289262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kartal2|Long Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure|Long Term Comparison of Double Layer Continuously Locked Closure of Uterine Incision in Cesarean Section Versus Double Layer Purse String Closure (Turan Technique): A Prospective Randomized Study||Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi|Yes|Completed|January 2011|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|40 Years|No|||January 2016|January 20, 2016|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289262||109569|
NCT01289769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-10-11-19B-11|The Effect of Dexmedetomidine on Hemodynamic Response During Double Lumen Endotracheal Intubation|The Effect of Prophylactic Dexmedetomidine on Hemodynamic Disturbances During Double Lumen Endotracheal Intubation. A Double-blinded, Randomized, Placebo-Controlled Trial.||Chiang Mai University|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|No|||December 2011|December 14, 2011|February 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289769||109530|
NCT01289249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3023-1|Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet|Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet||Oslo University Hospital|No|Completed|January 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Two blood samples are taken from each included patient. (Each 2 ml heparin full blood).|Both|3 Months|18 Years|No|Non-Probability Sample|Patients at the Pediatric medical ward.|November 2014|November 5, 2014|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01289249||109570|
NCT01289743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enbrel _AS-2|Etanercept (Enbrel) in Ankylosing Spondylitis|An Open-label Study of Etanercept (Enbrel) Efficacy in Ankylosing Spondylitis|Enbrel_AS-2|Charite University, Berlin, Germany|Yes|Active, not recruiting|February 2002|May 2012|Anticipated|September 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|No|||February 2002|February 3, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289743||109532|
NCT01289756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKP237|Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene|Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene||Robert Bosch Gesellschaft für Medizinische Forschung mbH|No|Completed|December 2009|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289756||109531|
NCT01290003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/054/Ab-Pro-M|Role of Antibiotics in Preventing Infection in Babies Born Through Meconium Stained Liquor|Role of Prophylactic Antibiotics in Preventing Neonatal Sepsis in Neonates Born Through Meconium Stained Amniotic Fluid - A Randomized Controlled Trial|AbProM|Lady Hardinge Medical College|Yes|Completed|June 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|250|||Both|N/A|2 Hours|No|||September 2015|September 26, 2015|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290003||109512|
NCT01290302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1AZA10001|Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia|Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia||Luitpold Pharmaceuticals|No|Completed|October 2010|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|January 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290302||109489|
NCT01291134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-000053|PureGen: A Radiographic Analysis of Rate and Quality of Fusion in Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF)|PureGen Osteoprogenitor Cell Allograft: A Radiographic Analysis of Rate and Quality of Fusion in Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF)||Alphatec Spine, Inc.||Terminated|February 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects suffering from symptoms of cervical degenerative disc disease (DDD) in one to        four contiguous levels between C3 and T1.|December 2013|December 31, 2013|February 4, 2011||No|PureGen was taken off of the market|No||https://clinicaltrials.gov/show/NCT01291134||109425|
NCT01279122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STARR2010-NF-IOL|Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses|Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses||Innovative Medical|No|Recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 16, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01279122||110343|
NCT01279135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project 803|Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix|Phase III Randomized Trial of Image Guided Intensity Modulated Radiotherapy (IG-IMRT) and Conventional Radiotherapy for Late Toxicity Reduction After Postoperative Radiotherapy in Ca Cervix.|PARCER|Tata Memorial Hospital|Yes|Recruiting|January 2011|February 2018|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|N/A|No|||January 2011|January 18, 2011|January 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01279135||110342|
NCT01289665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2644-7780|The Effect of Lubricating Gel on Patient Comfort During Speculum Insertion.|The Effect of Lubricating Gel on Patient Comfort During Speculum Insertion.||Florida Hospital|No|Completed|February 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|July 19, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289665||109538|
NCT01289678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJCC 06-05|Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia|Phase II Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia||Leo W. Jenkins Cancer Center|Yes|Recruiting|July 2006|June 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289678||109537|
NCT01290224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC10C8|MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy|Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Evaluation of a Sham Procedure and Phase II Trial||Mayo Clinic|Yes|Completed|February 2011|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|February 1, 2011|Yes|Yes||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01290224||109495|
NCT01280045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRPUSP-UROGIN-001|Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy|Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns||University of Sao Paulo|No|Recruiting|January 2011|January 2015|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 29, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01280045||110272|
NCT01290523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-SIRT-HCC|Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma|Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Hepatocellular Carcinoma: A Pilot Study||University of California, San Francisco|Yes|Terminated|May 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|February 1, 2011||No|Off study clinical use of Y90 glass microspheres (TheraSphere)|No|July 28, 2015|https://clinicaltrials.gov/show/NCT01290523||109472|
NCT01290536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-SIRT-Metastases|Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases|Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Metastatic Liver Disease From Primary Colorectal, Neuroendocrine, Cholangiocarcinoma, Melanoma, and Breast Cancers Refractory to Chemotherapy: A Pilot Study||University of California, San Francisco|Yes|Completed|June 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|February 1, 2011|Yes|Yes||No|May 10, 2014|https://clinicaltrials.gov/show/NCT01290536||109471|
NCT01290770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008178|Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina|Search a Correlation Between Lipoprotein(a) Rate and TFPI(Tissue Factor Pathway Inhibitor)Activity in Obese Patients With Chest Pain Like Angina||Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|February 2011|April 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|whole blood and serum|Male|18 Years|N/A|No|Non-Probability Sample|obese men with chest pain like stable angina|September 2014|September 26, 2014|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290770||109453|
NCT01291056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00038807|Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation|Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation: A Double-blind, Placebo-controlled, Crossover Study||University of Utah|Yes|Completed|January 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|November 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01291056||109431|
NCT01291316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GABA-SPUM|GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation|||University Hospital, Geneva|No|Completed|April 2010|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|25|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 13, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291316||109411|
NCT01288170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM/NEB-02/09|Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®|Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®||Erempharma|No|Recruiting|February 2010|||July 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|6 Years|N/A|No|||February 2011|February 1, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288170||109653|
NCT01288950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR-0138|Vitamin D Supplementation Enhances Immune Response to Bacille-Calmette-Guerin (BCG) Vaccination in Infants|Vitamin D Supplementation Enhances Immune Response to BCG Vaccination in Infants|BCG-25-D|University of California, San Diego|No|Completed|February 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|49|||Both|N/A|3 Days|Accepts Healthy Volunteers|||August 2012|August 20, 2012|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288950||109593|
NCT01289535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.621|Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years|Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years|Expand IDWP21|Hospices Civils de Lyon|No|Recruiting|November 2010|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|750|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 29, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289535||109548|
NCT01290640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Komistek AG 08-19-20|Comparison of Kinematics for Subjects Implanted With a PFC Sigma Rotating Platform or Fixed Bearing TC3 Prosthesis|In Vivo Comparison of Kinematics for Subjects Implanted With a Press Fit Condylar Sigma Rotating Platform or Fixed Bearing Total Condylar III Prothesis|PFC & TC3|The University of Tennessee Knoxville|No|Completed|February 2011|February 2013|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|22|||Both|40 Years|85 Years|No|Non-Probability Sample|Subjects requiring total knee arthroplasty|January 2014|January 21, 2014|February 3, 2011||No||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01290640||109463|No limitations were encountered.
NCT01290861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAB Beta|Cognitive Assessment Battery (CAB) Beta Study|Cognitive Assessment Battery (CAB)Beta Study|CAB|CHDI Foundation, Inc.|No|Completed|February 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|255|||Both|25 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will be pre-HD, early stage HD and control subjects. The cognitive        tests will be given to all participants. (only varied by order of administration) in order        to determine what measures will be best at detecting cognitive changes associated with HD.|August 2012|August 2, 2012|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290861||109446|
NCT01290874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p001898|Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)|Blacks and Exacerbations on LABA vs. Tiotropium (BELT)|BELT|Brigham and Women's Hospital|Yes|Completed|January 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1071|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|December 28, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290874||109445|
NCT01329029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-404-RD|Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)|Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial|REACT|Takeda|No|Completed|May 2011|May 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1945|||Both|40 Years|N/A|No|||September 2015|September 25, 2015|March 30, 2011||No||No|March 10, 2015|https://clinicaltrials.gov/show/NCT01329029||106540|
NCT01289444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR012711-01|Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle|Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle|FACE|Children's Research Institute|Yes|Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|216|||Both|14 Years|21 Years|No|||January 2016|January 27, 2016|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01289444||109555|
NCT01289457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0788|Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome|Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome||M.D. Anderson Cancer Center|No|Recruiting|February 2011|||February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|292|||Both|18 Years|60 Years|No|||November 2015|November 23, 2015|February 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01289457||109554|
NCT01289938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKP231|Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine|Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine|MalD|University Hospital Tuebingen|No|Active, not recruiting|July 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289938||109517|
NCT01290211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001103|Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Open-Label, Fixed-Sequence Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects||ViiV Healthcare|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290211||109496|
NCT01290809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093074|Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients|Cognitive Sequelae of Prophylactic Cranial Irradiation in Non-small Cell Lung Cancer Patients||Maastricht Radiation Oncology|Yes|Completed|January 2011|October 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|170|||Both|18 Years|N/A|No|Probability Sample|Patients will be recruited from 5 hospitals participating in the phase III trial:        Prophylactic Cranial Irradiation (PCI) versus observation in radically treated patients        with stage III non-small lung cancer: a phase III randomized study ((NVALT 11/DLCRG-02).|October 2015|October 13, 2015|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01290809||109450|
NCT01290198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 10 01|Role of Epoxy-eicosatrienoic Acids in Post-occlusive Hyperemia and Thermal Hyperemia|Role of Epoxy-eicosatrienoic Acids in Post-occlusive Hyperemia and Thermal Hyperemia|EETY|University Hospital, Grenoble|Yes|Completed|February 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290198||109497|
NCT01290549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCS4968g|A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma|An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics Of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma||Genentech, Inc.||Completed|March 2011|November 2014|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290549||109470|
NCT01290783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACO-002|Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC|Randomized Double-blind Phase III Trial of FOLF(HA)Iri vs FOLFIRI for Second or Third Line Therapy in Irinotecan-naïve Patients With Metastatic Colorectal Cancer|FOLF(HA)iri|Alchemia Oncology|Yes|Active, not recruiting|December 2011|December 2015|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||August 2014|April 28, 2015|January 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290783||109452|
NCT01291329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006AA02Z469|Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)|Phase 2 Study of Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With ST-segment Elevation Acute Myocardial Infarction (AMI)|WJ-MSC-AMI|Navy General Hospital, Beijing|Yes|Completed|February 2011|July 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01291329||109410|
NCT01291602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00010|A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects||AstraZeneca|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|15|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|February 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01291602||109389|
NCT01288430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS2248-A-U101|A Study of DS-2248, in Subjects With Advanced Solid Tumors|A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Terminated|March 2011|March 2015|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|February 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288430||109633|
NCT01288664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-PRGLN-002|Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis|||Sun Yat-sen University|Yes|Withdrawn|January 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|14 Years|65 Years|No|||December 2013|February 10, 2014|February 1, 2011||No|sponsor withdraw from this study|No||https://clinicaltrials.gov/show/NCT01288664||109615|
NCT01289275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CA159533-01|Smoking Cessation in Hospitalized Smokers|Smoking Cessation in Hospitalized Smokers||University of California, San Diego|Yes|Completed|August 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1270|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01289275||109568|
NCT01280513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML5174|Effect of Increased Protein Intake on Colonic Metabolism|Influence of a Protein Diet on the Colonic Metabolism and Phosphorus Housekeeping in Healthy Volunteers.||Katholieke Universiteit Leuven|No|Completed|October 2009|||June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280513||110236|
NCT01280799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH08597|Family Treatment for Adolescents With Anorexia Nervosa|Acceptance Based Separated Family Treatment for Adolescents With Anorexia Nervosa||Towson University|Yes|Completed|May 2009|||May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|12 Years|18 Years|No|||May 2014|May 16, 2014|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280799||110214|
NCT01290328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0843|Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation|Epoetin Alfa in the Treatment of Post-Transplant Anemia: A Randomized Controlled Trial||Mehrotra, Anita, M.D.|Yes|Terminated|February 2011|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2012|February 26, 2014|February 3, 2011|Yes|Yes|low enrollment, termination of funding|No||https://clinicaltrials.gov/show/NCT01290328||109487|
NCT01290653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU UCH 203|Dry Needling Versus Strain-counterstrain on the Upper Trapezius|Dry Needling Versus Strain Counterstrain Technique: Pilot Study Comparing Effects Over the Upper Trapezius Myofascial Trigger Point|DNJ|Cardenal Herrera University|Yes|Completed|February 2011|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 13, 2014|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290653||109462|
NCT01282034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORT-12|Study for the Treatment of Knee Chondral and Osteochondral Lesions|Multicenter Randomized Controlled Trial for the Treatment of Knee Chondral and Osteochondral Lesions: Marrow Stimulation Techniques vs MaioRegen||Fin-Ceramica Faenza Spa|No|Active, not recruiting|January 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|No|||June 2014|June 20, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282034||110121|
NCT01329042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU01/47|Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis|||Ouiheng International Healthcare Co., Ltd|No|Completed|May 2005|February 2008|Actual|October 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 4, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329042||106539|
NCT01289691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHSC2010AAPL|Atelectasis After Pulmonary Lobectomy: The Effect Of Air During One-Lung Ventilation (OLV) On Postoperative Atelectasis|Atelectasis After Pulmonary Lobectomy: The Effect Of Air During One-Lung Ventilation (OLV) On Postoperative Atelectasis.||London Health Sciences Centre|No|Recruiting|July 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2011|February 2, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289691||109536|
NCT01290575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB122-004|Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes Treated With Metformin Monotherapy.||Bristol-Myers Squibb|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|67|||Both|18 Years|70 Years|No|||March 2012|March 26, 2012|February 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290575||109468|
NCT01290588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364-09-FB|Aqueous Humor Dynamics and Biometric Parameters in Eyes of Children|Aqueous Humor Dynamics and Biometric Parameters in Eyes of Children||University of Nebraska|No|Not yet recruiting|December 2012|July 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort||4|Anticipated|144|||Both|15 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Children          -  Adults          -  Caucasian or African American|June 2012|June 13, 2012|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290588||109467|
NCT01290601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TQ study 058|Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults|A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults||U.S. Army Medical Research and Materiel Command|Yes|Completed|September 2003|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|70|||Both|20 Years|60 Years|No|||April 2015|April 23, 2015|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290601||109466|
NCT01290562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 10-0540-C|Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases (Spine SBRT)|A University of Toronto Phase II Study to Determine Efficacy of Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases||University Health Network, Toronto|Yes|Active, not recruiting|June 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|19 Years|N/A|No|||January 2016|January 26, 2016|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01290562||109469|
NCT01290796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMD-2112|Clinical Evaluation of Ajust™ in Stress Urinary Incontinence|Clinical Evaluation of Ajust™ in Stress Urinary Incontinence (CEASe)|CEASe|C. R. Bard|No|Completed|January 2011|October 2015|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Female|18 Years|N/A|No|||November 2015|November 23, 2015|February 4, 2011||No||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01290796||109451|
NCT01291069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00050085|Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients|Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients||University of Utah|Yes|Recruiting|September 2011|||February 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|8 Years|35 Years|No|||June 2012|June 6, 2012|February 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01291069||109430|
NCT01287884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|600824|Correlation of Arterial Blood Gas (ABG) and Venous Blood Gas (VBG) in the Undifferentiated Critically Ill Patient|Correlation of Arterial Blood Gas (ABG) and Venous Blood Gas (VBG) in the Undifferentiated Critically Ill Patient||Christiana Care Health Services|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|156|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287884||109674|
NCT01287897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0151003|A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy|A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Crohn's Disease Who Are Anti-tnf Inadequate Responders (Andante)|ANDANTE|Pfizer|Yes|Completed|February 2011|February 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|January 31, 2011|Yes|Yes||No|September 14, 2015|https://clinicaltrials.gov/show/NCT01287897||109673|Enrollment into the 200 mg arm was halted on 14 August 2013 before reaching the planned sample size due to safety findings in NCT01405196. Hence the 200 mg vs placebo comparisons were excluded from the primary analyses and reported separately.
NCT01288157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016273|A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects|A Randomized, Open-label Study to Evaluate the Pharmacokinetics of a Single Subcutaneous Administration of 50 mg or 100 mg Golimumab in a Pre-filled Syringe Formulation to Healthy Male Chinese Subjects||Centocor, Inc.||Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 26, 2014|November 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01288157||109654|
NCT01288391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7128-3840|Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients|An Open Non-randomised Dose Escalation Trial Investigating the Safety and Pharmacokinetics of Single Intravenous Administrations of NNC128-0000-2011 in Patients With Haemophilia A or B||Novo Nordisk A/S|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|N/A|No|||June 2012|July 4, 2012|February 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288391||109636|
NCT01288963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-333|IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma|The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|February 2010|February 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|153|Samples With DNA|tumor tissue, blood|Both|18 Years|N/A|No|Non-Probability Sample|Subjects enrolled on DF/HCC Protocol 06-149|September 2015|September 1, 2015|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01288963||109592|
NCT01288976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-0901|ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe|ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe|ACCESS-EU|Evalve|No|Completed|October 2008|August 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|567|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Mitral Regurgitation|March 2014|March 6, 2014|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01288976||109591|
NCT01281293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epilepsy (E)-103|Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated|A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.|V-COMPAS|Cyberonics, Inc.|No|Recruiting|January 2011|October 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|7 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with a diagnosis of refractory seizures that        are treated with adjunctive VNS Therapy.|February 2016|February 4, 2016|January 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281293||110177|
NCT01281306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2223|An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension||Novartis||Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|910|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|January 20, 2011|Yes|Yes||No|July 21, 2015|https://clinicaltrials.gov/show/NCT01281306||110176|
NCT01290016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-10-03|Youth Lifestyle Intervention With Food and Exercise|MY LIFE Study - McGill Youth Lifestyle Intervention With Food and Exercise Study|MYLIFE|McGill University|No|Completed|December 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|132|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01290016||109511|
NCT01290029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090005|Study to Evaluate Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease|An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis||Amgen|No|Completed|November 2010|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|2190 Days|No|||November 2015|November 5, 2015|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290029||109510|
NCT01290341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 90200/3016/1|Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|NAFT-600|Merz Pharmaceuticals, LLC|No|Completed|February 2011|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|860|||Both|12 Years|N/A|No|||July 2013|July 26, 2013|January 28, 2011|Yes|Yes||No|July 26, 2013|https://clinicaltrials.gov/show/NCT01290341||109486|
NCT01290354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112867|Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer|An Open-label Positron Emission Tomography Study to Investigate and Quantify Brain and Tumour Penetration of [11C]Lapatinib in Subjects With HER2-overexpressing Breast Cancer.||GlaxoSmithKline|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Female|18 Years|N/A|No|||July 2013|August 1, 2013|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01290354||109485|
NCT01281761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2010-08-006|Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)|Phase II Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer Patients Who Have Failed Irinotecan and Oxaliplatin-based Chemotherapy||Samsung Medical Center|No|Completed|November 2010|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01281761||110142|
NCT01282528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMICADEART4011|Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis|Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis|ULTRA|Peking Union Medical College Hospital|Yes|Recruiting|September 2010|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|65 Years|No|||January 2011|January 24, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282528||110083|
NCT01328782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1190|The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures|The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures||University of Colorado, Denver|No|Completed|June 2008|June 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|124|||Both|4 Years|12 Years|No|||June 2012|May 26, 2015|September 22, 2010|Yes|Yes||No|February 27, 2012|https://clinicaltrials.gov/show/NCT01328782||106558|
NCT01290237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-11-0561|Use of a Loading Dose of Vancomycin in Pediatric Dosing|The Use of a Loading Dose of Intravenous Vancomycin Will Achieve Therapeutic Concentration Earlier Than Conventional Pediatric Dosing: A Randomized Controlled Trial||Children's Hospital Boston|No|Terminated|February 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|59|||Both|2 Years|18 Years|No|||March 2012|March 8, 2012|January 28, 2011||No|PI leaving institution, slow enrollment|No||https://clinicaltrials.gov/show/NCT01290237||109494|
NCT01290250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIONAOS-ORANGE|Evaluation of a New Orange-Based Beverage Enriched With Polyphenols in Adult Humans|Evaluation of a New Orange-Based Beverage Enriched With Polyphenols (Whole Press) on Features of Metabolic Syndrome and Cardiovascular Risk Factors Related to Inflammation and Antioxidant Defense System in Adult Humans|BIONAOS|The Coca-Cola Company|Yes|Completed|February 2010|July 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|210|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01290250||109493|
NCT01290263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-185|Amgen 386 for Recurrent Glioblastoma|Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|December 2010|December 2016|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|January 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01290263||109492|
NCT01290835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMDC10101|Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer|Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer|CKPBI|Essentia Health|No|Active, not recruiting|June 2010|August 2020|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|60 Years|60 Years|No|||September 2015|September 30, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290835||109448|
NCT01291082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53057|Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo)|Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)|METAMARBO|Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2011|August 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|20 Years|80 Years|No|Probability Sample|Breast cancer patients|January 2013|January 26, 2013|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01291082||109429|
NCT01291342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1702|Detection and Identification of Preeclampsia Via Volatile Biomarkers|Detection and Identification of Preeclampsia Via Volatile Biomarkers|DIP|The Nazareth Hospital, Israel|Yes|Completed|September 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples Without DNA|Breath Serum|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|women treated in the Nazareth Hospital and Emek Medical Center|August 2012|February 5, 2013|February 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01291342||109409|
NCT01291615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1003|Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer|Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer||Kansai Hepatobiliary Oncology Group|Yes|Completed|December 2010|May 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|20 Years|N/A|No|||October 2014|October 21, 2014|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01291615||109388|
NCT01287598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12434|BAY73-4506 Probe Substrate Study|A Phase I, Non-randomized Open-label Study to Evaluate the Effect of BAY73-4506 (Regorafenib) on Probe Substrates of CYP 2C9 (Warfarin), 2C19 (Omeprazole) and 3A4 (Midazolam) in a Cocktail Approach (Group A) and on a Probe Substrate of CYP 2C8 (Rosiglitazone, Group B) in Patients With Advanced Solid Tumors||Bayer|No|Active, not recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|118 Years|No|||January 2016|January 20, 2016|January 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287598||109694|
NCT01287611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kartal1|Short Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure|Short Term Comparison of Double Layer Continuously Locked Closure of Uterine Incision in Cesarean Section Versus Double Layer Purse String Closure (Turan Technique): A Prospective Randomized Study||Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi|Yes|Completed|January 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|168|||Female|18 Years|40 Years|No|||April 2015|April 8, 2015|January 26, 2011||No||No|July 7, 2014|https://clinicaltrials.gov/show/NCT01287611||109693|The present trial is a single-center study. The similar results should be supported in a multicenter study. Another limitation of this study is the more than 25% overall rate of loss to follow-up.
NCT01287910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amsterdam|Transmyocardial Laser Revascularization and Cardiovascular Magnetic Resonance Imaging|Effect of Transmyocardial Laser Revascularization on Myocardial Perfusion and Left Ventricular Structure by Cardiovascular Magnetic Resonance Imaging and Dynamic Volumetric Computed Tomography|Amsterdam|Piedmont Healthcare|No|Terminated|January 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|18 Years|N/A|No|||August 2013|September 4, 2013|January 31, 2011||No|Lack of patient population|No||https://clinicaltrials.gov/show/NCT01287910||109672|
NCT01287923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00812-37|Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans|Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans|BMS-LyTrans|Rennes University Hospital|No|Recruiting|February 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort||4|Anticipated|400|Samples With DNA|For this study, 4 newly included cohorts are necesseray :        -  100 new DLBCL patients are necessary. The blood will be taken at the diagnosis for           DLBCL patients included 075-GOELAMS trial or 075-like patient.        -  100 healthy blood donors. This cohort of matched for sex & gender will be constituted           at the EFS (French Blood Bank) of Rennes.        -  100 septic patients included at the Rennes University Hospital.        -  100 075-like DLBCL patients in completed remission.      This project will also used already available blood collections: 2) Mantle cell lymphoma, 3)      localized DLBCL and septic shock. Paraffin blocks of patient 075-trial DLBCLs are in the      GOELAMSthèque bank localized in the Pathology Department Hôtel Dieu, Paris supervised by Pr      Diane Damotte. Tissue Microarrays and complete paraffin blocks as well as some -80° tumors      are already available.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|DLBCL or Healthy blood donors or septic patient or GOELAMS 075 patients in completed        remission|December 2015|December 17, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287923||109671|
NCT01289782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017386|An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinfected Subjects|QUEST-1|Janssen R&D Ireland|Yes|Completed|February 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|395|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|January 7, 2011|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01289782||109529|
NCT01290042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101261|Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.|A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.||Amgen||Completed|February 2011|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|January 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290042||109509|
NCT01281501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|619/2010|Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole|A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain||Chulalongkorn University|No|Completed|January 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|15 Years|50 Years|No|||September 2013|September 9, 2013|January 17, 2011|Yes|Yes||No|April 8, 2012|https://clinicaltrials.gov/show/NCT01281501||110162|1. This was a small, single-centered study. 2. Exaggerated self-evaluation of the patients' pain score and the physician’s expectation of a “good outcome” may also have biased the report. 3. The short-term recurrence of the pain was not studied.
NCT01281514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 10-019|Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE||Fox Chase Cancer Center|Yes|Recruiting|December 2010|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281514||110161|
NCT01281527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017215|Paliperidone Palmitate Flexible Dosing in Schizophrenia|A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics|PALMFlexS|Janssen-Cilag International NV|No|Completed|November 2010|November 2013|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1044|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|January 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01281527||110160|
NCT01281280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epilepsy (E)-101|PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1|A Post-Market, Open Observational Long-term Effectiveness Follow-up Study of Participants With Drug-resistant Epilepsy With Partial-onset Seizures Previously Enrolled in a Randomized Controlled Trial (E-100: PuLsE) Comparing Best Medical Practice With or w/o Adjunctive Vagus Nerve Stimulation Therapy|PuLsE 2|Cyberonics, Inc.|No|Completed|March 2011|April 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|81|||Both|16 Years|N/A|No|Probability Sample|The study population will consist of participants previously enrolled in the original        PuLsE study diagnosed with drug-resistant epilepsy with partial-onset seizures. All        patients will be analyzed according to the treatment that they have actually received and        followed in this new study regardless of what treatment groups they were randomized in the        previous study.|October 2014|October 14, 2014|January 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01281280||110178|
NCT01282268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209FX301|Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome|Harbor-A|Seaside Therapeutics, Inc.|Yes|Completed|May 2011|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|12 Years|50 Years|No|||July 2013|July 30, 2013|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282268||110103|
NCT01282515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALH ELP 2/10|Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT|A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP)||Oslo University Hospital|No|Active, not recruiting|August 2011|||April 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|N/A|No|||August 2012|August 23, 2012|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01282515||110084|
NCT01282541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00025405|Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora|Determination of the Optimum Delivery Route for the Intraglandular Administration of Botulinum Toxin A in Patients With Refractory Epiphora||Merbs, Shannath, M.D., Ph.D.|Yes|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282541||110082|
NCT01328795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGM@ACS|Cardiogoniometry (CGM) for Early Diagnosis of Acute Coronary Syndromes (ACS)|Cardiogoniometry Zur Früherkennung Akuter Myokardischämien Bei ACS-Symptomatik|CGM@ACS|Stiftung Institut fuer Herzinfarktforschung|No|Completed|June 2009|May 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|249|||Both|18 Years|N/A|No|||April 2011|April 1, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01328795||106557|
NCT01290614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10088-H41|A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)|A Chronic Care Model Based QI Program to Improve the Care of Patients With CKD||University of Minnesota - Clinical and Translational Science Institute|No|Completed|February 2011|June 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|2199|||Both|18 Years|85 Years|No|||June 2015|June 16, 2015|February 4, 2011||No||No|May 19, 2015|https://clinicaltrials.gov/show/NCT01290614||109465|
NCT01291667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPES|Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE|A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab( Cipterbin®) Plus vinorelbinE Simultaneously or Sequencely|HOPES|Shanghai CP Guojian Pharmaceutical Co.,Ltd.|Yes|Completed|May 2009|||||Phase 3|Observational|Time Perspective: Prospective||1|Anticipated|330|||Both|18 Years|70 Years|No|Probability Sample|HER2-positive metastatic breast cancer patients|February 2011|February 7, 2011|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01291667||109384|
NCT01290822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC1492|Optimized Biventricular Pacing Allograft Recipients|Optimized Biventricular Pacing in Allograft Recipients|BiBET|Columbia University|No|Terminated|January 2007|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|66|||Both|N/A|N/A|No|||October 2013|October 11, 2013|February 2, 2011|Yes|Yes|Slow accrual and anticipated loss of funding|No||https://clinicaltrials.gov/show/NCT01290822||109449|
NCT01291095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTOFAFRTVSCRTINHNSCCAIIMS|Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma|Phase II Randomized Controlled Trial of Accelerated Fractionation Radiotherapy (6 Fractions Per Week) Versus Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|February 2011|December 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|60 Years|No|||March 2011|March 3, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291095||109428|
NCT01291355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER10-042|Maternal Positioning and Occipitoposterior Fetal Position|Maternal Positioning to Correct Occipitoposterior Fetal Position in Labor: A Randomized Controlled Trial||University Hospital, Geneva|Yes|Completed|February 2011|October 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|438|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291355||109408|
NCT01291628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Socks|Prevention of Capecitabine Induced Hand and Foot Syndrome|A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome||Rabin Medical Center|Yes|Not yet recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01291628||109387|
NCT01291641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT-01|Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy|Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy (IMPACT on IMT): A Randomized, Multicenter, Multinational Study|IMPACT on IMT|Seoul National University Hospital|Yes|Active, not recruiting|March 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|342|||Both|20 Years|N/A|No|||May 2015|May 19, 2015|January 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01291641||109386|
NCT01287936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-STR01|A Study of Modified Stem Cells in Stable Ischemic Stroke|A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke||SanBio, Inc.|Yes|Active, not recruiting|January 2011|June 2016|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||November 2015|November 16, 2015|January 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01287936||109670|
NCT01288183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00180-39|Anodal Transcranial Direct Current Stimulation (tDCS) in the Treatment of Tobacco Addiction|Behavioral Impact of Prefrontal Anodal Transcranial Direct Current Stimulation on Smokers||Hôpital le Vinatier|No|Completed|January 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01288183||109652|
NCT01280214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC119710ctil|Local Triamcinolone Injection in Active Thyroid Orbitopathy|Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy||HaEmek Medical Center, Israel|Yes|Not yet recruiting|February 2011|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2011|January 19, 2011|January 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01280214||110259|
NCT01280500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS10-014|Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN|Accelerating Implementation of Comparative Effectiveness Findings on Clinical and Delivery Systems by Leveraging AHRQ Networks||Carolinas Healthcare System|Yes|Enrolling by invitation|March 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|1040|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01280500||110237|
NCT01281540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR003949|An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options|Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Terminated|May 2003|November 2003|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||January 2011|January 20, 2011|January 20, 2011|Yes|Yes|Sponsor request|No||https://clinicaltrials.gov/show/NCT01281540||110159|
NCT01281787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S365/407|PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer|Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer|PRESAGE|European Institute of Oncology|No|Completed|April 2008|October 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|320|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01281787||110140|
NCT01281774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-HDL-10-68|A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers|An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers||CSL Limited|Yes|Completed|January 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01281774||110141|
NCT01282047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022898-33|Lenalidomide in Kaposi Disease Associated With HIV Infection|Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Lenalidomide in Kaposi Disease Associated With HIV Infection (ANRS 154/LENAKAP)|LENAKAP|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Terminated|October 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|19 Years|75 Years|No|||July 2014|July 31, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282047||110120|
NCT01282281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS688773|Prospective Metabolic Monitoring of Youth and Adults With Bipolar Disorder|Prospective Metabolic Monitoring of Youth and Adults With Bipolar Disorder.||Sunnybrook Health Sciences Centre|Yes|Completed|January 2011|September 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|13|||Both|14 Years|65 Years|No|Non-Probability Sample|Thirty adolescent participants with BD (type I, II, or not otherwise specified), and 30        adult participants with BD will be enrolled. Participants with BD will be recruited from        the Youth and Adult Mood Disorder Clinics. Psychiatry Division staff will identify        patients who meet the study criteria during weekly treatment team meetings. New referrals        will also be screened to identify potential participants.|January 2014|January 16, 2014|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01282281||110102|
NCT01282294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-BIO-T-XX-190-02|Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures|Prospective Open Label Post Market Clinical Follow-up to Evaluate the Clinical Usefulness of the Operative Stabilization of Closed and Open Fractures of the Tibia Using Gentamicin - Coated Titanium Nails||Synthes GmbH|No|Completed|February 2011|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the ER with a tibia fracture|February 2015|February 25, 2015|January 21, 2011||No||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01282294||110101|
NCT01282307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20070070|Improving Insight in Patients Diagnosed With Schizophrenia|Meaningful Change With the Method Guided Self-Determination - a Randomised Controlled Study for Patients Diagnosed With Schizophrenia.|GEBRCT|University of Aarhus|Yes|Completed|February 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|70 Years|No|||August 2012|August 13, 2012|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01282307||110100|
NCT01329094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lene Nyboe Jacobsen 2|Physical Activity in Patients With Severe Mental Illness|Physical Activity in Patients With Severe Mental Illness||University of Aarhus|No|Completed|March 2009|August 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Psychiatric in- and outpatients admitted to Aarhus University Hospital, Risskov, Denmark|April 2011|April 4, 2011|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01329094||106535|
NCT01289951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVERAL|Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis|Phase I, Open Label, Unicentric Study of Multiple-dose Pharmacokinetics of Raltegravir in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus With and Without Advanced (Child-Pugh C) Hepatic Cirrhosis.|LIVERAL|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Completed|December 2010|October 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01289951||109516|
NCT01289964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DryCupping2009|The Effect of 5 Times Dry Cupping in the Treatment of Chronic Neck Pain|Randomised Controlled Pilot Study: the Effect of Dry Cupping on Pain and Sensory Thresholds in the Treatment of Chronic Non Specific Neck Pain|TS|Universität Duisburg-Essen|No|Completed|July 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||July 2009|August 18, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01289964||109515|
NCT01291381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-BIO-01|Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children|Regulatory T Cells in the Response to SIT in Allergic Rhinitis.||Beijing Tongren Hospital|Yes|Completed|February 2009|October 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|9 Years|14 Years|No|||January 2009|February 7, 2011|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01291381||109406|
NCT01287962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HENGRUI 20110301|Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer|Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer:a Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study||Sun Yat-sen University|Yes|Active, not recruiting|April 2011|March 2014|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|70 Years|No|||January 2012|December 5, 2013|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287962||109668|
NCT01288209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017689|A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy|A Phase III, Randomized, Open-label, Two-arm Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Hepatitis C, Genotype 1-Infected Subjects Who Failed to Respond to Previous IFN-based Therapy||Janssen Pharmaceutical K.K.|No|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|20 Years|70 Years|No|||December 2013|December 18, 2013|February 1, 2011|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT01288209||109650|
NCT01291108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210669-013|Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|125|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|February 4, 2011|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01291108||109427|
NCT01291368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-16-02-50-09|Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care|Does Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care?||University of Aarhus|Yes|Completed|September 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|248|||Both|18 Years|N/A|No|Probability Sample|All adult patients at the ICUs ITA and 600 at Århus Sygehus, Denmark from September 2009        and at Hillerød Intensive, Denmark from 15th October 2010 to 1st October 2011.|October 2012|October 19, 2012|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01291368||109407|
NCT01291654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZMC-Hammerman-Acamol-2011|Paracetamol and Patent Ductus Arteriosus (PDA)|Paracetamol in the Treatment of Patent Ductus Arteriosus in the Premature Neonate||Shaare Zedek Medical Center|No|Recruiting|April 2012|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|2 Weeks|No|||December 2012|December 18, 2012|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01291654||109385|
NCT01287624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2010-04|Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)|A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer|TNBC|Fudan University|No|Completed|January 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Female|18 Years|70 Years|No|||March 2015|March 19, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287624||109692|
NCT01288443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFI11565|Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of Five Doses and Two Dose Regimens of SAR236553 Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL (≥ 2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy||Sanofi|Yes|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|183|||Both|18 Years|75 Years|No|||August 2015|August 21, 2015|February 1, 2011|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01288443||109632|
NCT01288456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-1000-0005|Study to Evaluate Novel Gastric Space Occupying Device|A Single Centre 30-day Observational Non-randomised Study to Evaluate Preliminary Safety and Efficacy of a Novel Gastric Space Occupying Device as an Aid for Weight Loss||Obalon Therapeutics, Inc.|No|Completed|January 2011|March 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|21 Years|64 Years|No|Non-Probability Sample|Patients will be selected from a community sample that satisfy the inclusion/exclusion        criteria.|May 2012|May 25, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01288456||109631|
NCT01288677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017272|TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers|Phase I, First In-human, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability, and Blood and Plasma Pharmacokinetics of Increasing Single Oral Doses of TMC649128||Tibotec Pharmaceuticals, Ireland||Completed|January 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01288677||109614|
NCT01280812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0031274|Applying Mobile Persuasive Technologies to Increase Physical Activity in Women|Applying Mobile Persuasive Technologies to Increase Physical Activity in Women||University of California, San Francisco|Yes|Completed|February 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|210|||Female|25 Years|69 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01280812||110213|
NCT01281033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-PCI|CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial|CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial|SMART|Careggi Hospital|Yes|Completed|December 2010|March 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01281033||110196|
NCT01281059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0429-10-HMO-CTIL|Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test|||Hadassah Medical Organization|Yes|Active, not recruiting|January 2011|||||N/A|Interventional|N/A|||||||Both|18 Years|N/A|No|||August 2011|August 27, 2012|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01281059||110195|
NCT01281072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911-DIAPEP277|Study To Evaluate Long Term Treatment Effect Of Diapep277® In Patients Who Have Completed Study 901 And Study 910** (Extension To 901)|||Hadassah Medical Organization|No|Not yet recruiting||||||Phase 3|Interventional|Intervention Model: Single Group Assignment|||||||Both|20 Years|50 Years||||January 2011|January 20, 2011|January 20, 2011||||No||https://clinicaltrials.gov/show/NCT01281072||110194|
NCT01281813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017230|TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV|Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1-Infected Adults (Roll Over Patients From C211, C214 & C229)||Janssen R&D Ireland|No|Active, not recruiting|August 2011|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|133|||Both|18 Years|99 Years|No|||February 2016|February 26, 2016|December 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01281813||110138|
NCT01282060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO0662-1|Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients 70 Years Old and Over : a Cohort Study.|Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients .||Association Pour la Recherche en Diabetologie et en Geriatrie|Yes|Active, not recruiting|March 2009|||July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|986|||Both|70 Years|N/A|No|Probability Sample|-  Patients suffering from type 2 diabetes and aged 70 and over.          -  Having received medicinal or non-medicinal therapy (in the case of diabetics treated             with insulin, the lengh of time between diagnosis of diabtees and the introduction of             insulin therapy is at least 6 months).          -  Suffering from type 2 diabetes at least one year.          -  With autonomy defined by a score greater than or equal to 3/6 on the ADL scale and             able of being followed-up during hospital or private consultations over the next 5             years.          -  Patients who did not refuse to participate in the study after receiving information             on the study (Patient Information Leaflet).        The patient are monitored in the hospital or private sector throughout Metropolitan        France.|January 2011|January 21, 2011|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01282060||110119|
NCT01282073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMFPRIMER|Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy|A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy|MMFPRIMER|Kyungpook National University|Yes|Recruiting|March 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01282073||110118|
NCT01328821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP505.1001 CTP-499|Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499|A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose, Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability Study of CTP-499 in Healthy Adults||Concert Pharmaceuticals|No|Completed|March 2011|June 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|October 25, 2011|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01328821||106555|
NCT01290276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024378|Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation|Phase Ia/Ib Study of Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation||Duke University|No|Completed|December 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|January 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01290276||109491|
NCT01290289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6111972|Analgesia in Labor, a Prospective Parallel Study to Compare Regional Analgesia and Intravenous (IV) Pethidine Analgesia|Analgesia in Labor, a Prospective Parallel Single Blind Study to Compare Regional Analgesia (Combined Spinal Epidural Analgesia (CSE), Epidural Analgesia (E)) and Intravenous (IV) Pethidine Analgesia||Cairo University|No|Completed|July 2009|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|60|||Female|18 Years|45 Years|No|||July 2009|February 4, 2011|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01290289||109490|
NCT01291693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108376|Testing Delivery Channels of Brief Motivational Alcohol Intervention|Testing Delivery Channels of Brief Motivational Alcohol Intervention Among General Hospital Inpatients With Risky Drinking: Personal Counseling Versus Computer-generated Feedback Letters|PECO|University Medicine Greifswald|No|Completed|February 2011|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|975|||Both|18 Years|64 Years|No|||December 2015|December 1, 2015|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01291693||109382|
NCT01287637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKD03|Early Closure of Temporary Ileostomy|Early Closure of Temporary Ileostomy- a Randomized Clinical Trial|EASY|Herlev Hospital|No|Completed|February 2011|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01287637||109691|
NCT01287949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPV04C|Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older|An Open-label, Multicentre Study to Evaluate the Immunogenicity and Safety of One Dose of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older Without a Previous Diphtheria- and Tetanus-containing Booster Within the Last 20 Years||Sanofi Pasteur MSD|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|342|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 6, 2012|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01287949||109669|
NCT01288196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017752|A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CNTO 6785 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects||Janssen-Cilag International NV||Completed|February 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|February 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01288196||109651|
NCT01289288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-297|A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese|A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese|CRC|Georgetown University|Yes|Completed|July 2007|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|480|||Both|50 Years|74 Years|No|||May 2013|May 20, 2013|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01289288||109567|
NCT01289548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK201001|Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation|Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation||Huazhong University of Science and Technology|No|Completed|May 2010|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|120|||Both|N/A|N/A|No|||September 2012|July 8, 2013|February 2, 2011||No||No|September 5, 2012|https://clinicaltrials.gov/show/NCT01289548||109547|The trial was conducted only in our hospital and had a relatively small sample size because of the scarcity of relative living donor renal transplantation compared to other surgeries.
NCT01299207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0022189|PITT PCI Xience Registry|PITT PCI Xience Registry: A Prospective Evaluation of Dual Antiplatelet Therapy Compliance and Outcomes After Treatment With the Xience Stent||University of Pittsburgh|No|Completed|August 2011|December 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2506|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of all consecutive patients who undergo coronary        stenting with the Xience drug-eluting stent in any of the 4 University of Pittsburgh        Medical Center's Hospitals (UPMC Presbyterian, UPMC Shadyside, UPMC Mercy, and UPMC        Passavant).|January 2016|January 5, 2016|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01299207||108809|
NCT01299805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_124|Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults|A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Effects of Oral Administration of Lu AA21004 20 mg on the Concentrations of Selected Neurotransmitters in Healthy Male Subjects||Takeda|No|Completed|March 2011|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|17|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 24, 2013|February 17, 2011|No|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT01299805||108763|
NCT01299818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104-10-TLV|Assessment of Central Pain in Patients Who Undergo Spinal Surgery and Influence in Surgery Outcome|Assessment of Central Pain in Patients Who Undergo Spinal Surgery and Influence in Surgery Outcome||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|March 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|patients sufferring of cervicalgia and/or low back pain and/or radiculopathy that are        candidates to spinal surgery|February 2011|February 17, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299818||108762|
NCT01300351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997L00021|Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women|A Randomised, Double-Blind, Parallel-Group, Multicentre Study Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With ER+ Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy||AstraZeneca|No|Completed|March 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|249|||Female|18 Years|N/A|No|||April 2015|April 23, 2015|February 17, 2011|Yes|Yes||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01300351||108721|China CONFIRM Study was planned as a bridge study to the CONFIRM Study and therefore was not formally powered to detect a statistically significant difference between two treatment groups.
NCT01300624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7695-R|Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia|Effect Of Verb Network Strengthening Treatment on Lexical Retrieval in Aphasia|VNeST|VA Office of Research and Development|No|Completed|March 2011|July 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|January 21, 2011||No||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01300624||108701|
NCT01300637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96064|Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients|Prevalence of Metabolic Syndrome and Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients||Taipei Medical University WanFang Hospital|No|Recruiting|November 2008|July 2011|Anticipated|April 2009|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||February 2011|February 18, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300637||108700|
NCT01300611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2010-001|TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation|Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation|USBTXA127CBT|US Biotest, Inc.||Active, not recruiting|January 2011|May 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|60 Years|No|||December 2013|December 18, 2013|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300611||108702|
NCT01296269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXTandAVP-HMO-CTIL|Effects of Intranasal Oxytocin and Vasopressin on Social Behavior|Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls||Hadassah Medical Organization|No|Recruiting|April 2011|||May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Anticipated|150|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01296269||109032|
NCT01296282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0094-10-HYMC|Comparison Between Internal and External Chest Impedance Measurement|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2011|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|Patients with heart failure with CRT pacemaker|February 2011|February 13, 2011|February 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01296282||109031|
NCT01296594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-080-3|Improving Antihypertensive Medication Adherence|Improving Antihypertensive Medication Adherence||University of Connecticut Health Center|Yes|Completed|February 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296594||109007|
NCT01328470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIANO-CKD2|Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease|Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel|CKD|Kyunghee University Medical Center|Yes|Completed|September 2009|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|85|||Both|20 Years|80 Years|No|||July 2009|April 1, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01328470||106582|
NCT01322152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XELIRIcrc|Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer|Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients||Fudan University|Yes|Completed|March 2011|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|70 Years|No|||June 2013|June 10, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322152||107063|
NCT01322438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15524|Effect of Rifampin on the Pharmacokinetics of BAY73-4506|A Phase 1, Non-Randomized, Open Label Study to Determine the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers||Bayer|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01322438||107041|
NCT01322451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0259-CL-104|Oral Bioavailability of Two Solid Formulations of GLPG0259.|A Randomized, Open Label, 2-way Crossover Study to Compare the Oral Bioavailability of 2 Solid Dose Formulations of GLPG0259 After Single-dose Intake in Healthy Subjects||Galapagos NV|No|Completed|November 2010|January 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|March 23, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01322451||107040|
NCT01322464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP0601|Study to Assess Food Effect on Sativex Bioavailability|A Phase I Study to Assess the Effect of Food on the Single-Dose Bioavailability of Sativex, and to Compare the Single and Multiple Dose Pharmacokinetics of Sativex at Three Dose Levels||GW Pharmaceuticals Ltd.|No|Completed|January 2008|February 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|25|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322464||107039|
NCT01329120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRPEX-1|Short and Long-term Effects of Surgical Repair of Pectus Deformities|Short and Long-term Effects of Surgical Repair of Pectus Excavatum and Pectus Carinatum - A Questionnaire Study of Persistent Post-surgical Pain, Health-related Quality of Life, Patient Satisfaction, and Aesthetic Outcome||University of Aarhus|No|Not yet recruiting|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|1000|||Both|7 Years|N/A|No|Probability Sample|All consecutive patients referred to the Department of Cardiothoracic and Vascular        Surgery, Aarhus University Hospital, Skejby for the purpose of pectus deformity repair        from January 1, 2001 to December 31, 2010 are invited to participate in the study.|June 2012|May 31, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329120||106533|
NCT01329341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8094-I|Service Dogs for Veterans With PTSD|Service Dogs for Veterans With PTSD: A Randomized Clinical Trial||VA Office of Research and Development|Yes|Active, not recruiting|July 2011|October 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|62|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01329341||106516|
NCT01329705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dyna-2011|Dynamic Splinting for Plantarflexion in Spastic Hemiplegia|Dynamic Splinting for Excessive Plantarflexion in Patients With Spastic Hemiplegia: A Randomized, Controlled Study of Gait Analysis||Dynasplint Systems, Inc.|No|Withdrawn|May 2011|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||August 2013|August 8, 2013|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329705||106488|
NCT01329965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE LPSpilot|Safety and Feasibility of an Endotoxemia Model|Safety and Feasibility of an Endotoxemia Model: Pilot Study||Penn State University|Yes|Completed|April 2011|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|6|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|April 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01329965||106468|
NCT01329978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7977-0724|Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6|The ATOMIC Study: A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic HCV Infection Genotype 1,4, 5, or 6|ATOMIC|Gilead Sciences|No|Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|332|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|March 30, 2011|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01329978||106467|
NCT01331057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI07023|Bilingualism: Validation Of "Avicenne's Elal"|Validation of "AVICENNE's ELAL": Instrument of Mother Tongue Assessment and Impact of Familial and Transcultural Factors on Early Bilingualism in Migrants' Children Born in France|BILINGUISME|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|450|||Both|5 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children are five to six years old, in the third class of nursery school and if their        first language is unique, and, one of the three languages that we defines for the first        step of validation: tamil, soninké, Arabic|June 2014|February 2, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331057||106388|
NCT01327976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D01088|ReCharge Clinical Trial|ReCharge Clinical Trial|ReCharge|EnteroMedics|Yes|Active, not recruiting|May 2011|December 2016|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|234|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327976||106618|
NCT01327989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ev3-02-2010|Solitaire FR Thrombectomy for Acute Revascularisation|STAR: Solitaire FR Thrombectomy for Acute Revascularisation|STAR|ev3|Yes|Active, not recruiting|October 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|210|||Both|18 Years|85 Years|No|Probability Sample|Patients presenting acute ischemic stroke with mechanical thrombectomy treatment deemed        appropriate. Consecutive evaluation.|August 2012|August 27, 2012|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01327989||106617|
NCT01298908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0 - Sep 6th, 2006|Comparison of Treatments in Venous Insufficiency|The Utility of Novel Ambulatory Treatment Techniques in Venous Insufficiency||Helsinki University Central Hospital|No|Completed|October 2007|December 2015|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|231|||Both|20 Years|70 Years|No|||January 2016|January 6, 2016|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298908||108832|
NCT01299844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-351|Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic, and Health Outcomes Among Latinos|Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic, and Health Outcomes Among Latinos|DIALBEST|University of Connecticut|No|Completed|December 2006|September 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|22 Years|N/A|No|||February 2011|February 17, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01299844||108760|
NCT01299519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012904|Progressive Weight Loss and Metabolic Health|Progressive Weight Loss and Metabolic Health|PWL|Washington University School of Medicine|No|Active, not recruiting|February 2011|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|59|||Both|21 Years|65 Years|No|||March 2016|March 1, 2016|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01299519||108785|
NCT01299532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GB0801|Macrolane VRF30 for Enhancement of Shape and Fullness of Female Breast|An Open, Multi-center Study Evaluating Efficacy and Safety of Macrolane VRF30 for Enhancement of the Shape and Fullness of the Female Breast|COBRA|Q-Med AB|No|Completed|November 2008|October 2013|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|71|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||February 2011|November 8, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01299532||108784|
NCT01300130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45-95|Investigations on Improving Docosahexaenoic and Arachidonic Acid Content in Preterm Infant Formula|Investigations on Improving Docosahexaenoic and Arachidonic Acid Content in Preterm Infant Formula||Ludwig-Maximilians - University of Munich|No|Completed|June 1995|March 1998|Actual|March 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|66|||Both|N/A|14 Days|No|||February 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300130||108738|
NCT01331447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXEM-03|Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions|A Pilot Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|May 2004|May 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|12|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331447||106358|
NCT01300364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC07/90093|Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia|Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia||Fundació Sant Joan de Déu|Yes|Recruiting|November 2008|||December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|249|||Both|18 Years|65 Years|No|||November 2008|February 18, 2011|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01300364||108720|
NCT01296295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10/40.|Effectiveness of Regular Reporting of Spirometric Results on Smoking Quit Rate.|Effectiveness of Regular Reporting of Spirometric Results Combined With a Smoking Cessation Advice by a Primary Care Physician on Smoking Quit Rate in Adult Smokers: a Randomized Controlled Trial.|ESPIROTAB|Jordi Gol i Gurina Foundation|No|Active, not recruiting|January 2005|March 2011|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|466|||Both|18 Years|N/A|No|||February 2011|February 13, 2011|July 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01296295||109030|
NCT01296542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-BV-C|A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery|A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification||Bucci Laser Vision Institute|Yes|Recruiting|May 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects with scheduled cataract surgery, men and women, 18 years of age and older.|July 2011|July 11, 2011|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01296542||109011|
NCT01296555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMT4979g|A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer|An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer||Genentech, Inc.||Recruiting|March 2011|September 2019|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|724|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01296555||109010|
NCT01296568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13525|C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors|Disposition of [14C]LY2603618 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumors||Eli Lilly and Company|No|Completed|February 2011|February 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|February 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01296568||109009|
NCT01296854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/NM-02|The Effect of Spa Treatment on Chronic Obstructive Pulmonary Disease|The Effect of Spa Treatment on Chronic Obstructive Pulmonary Disease|BPCeaux|Centre Hospitalier Universitaire de Nīmes|Yes|Terminated|May 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|40 Years|80 Years|No|||March 2015|March 24, 2015|February 15, 2011||No|The feasability of inclusions has proven very low.|No||https://clinicaltrials.gov/show/NCT01296854||108987|
NCT01328496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCBT01|Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen|Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen||St. Jude Children's Research Hospital|No|Recruiting|June 2011|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|43|||Both|N/A|21 Years|No|||October 2015|October 6, 2015|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328496||106580|
NCT01322503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR033018|Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus|Evaluation of the Susceptibility of Human Volunteers With Different Histo-Blood Group Antigens to Norovirus||Children's Hospital Medical Center, Cincinnati|No|Completed|October 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|40|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2012|February 9, 2012|October 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01322503||107036|
NCT01329354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFNK|Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy|Phase II Clinical Trial of Immunotherapy With Rituximab and Autologous Effector Lymphocytes in Patients With Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy||Clinica Universidad de Navarra, Universidad de Navarra|No|Active, not recruiting|March 2011|November 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|75 Years|No|||May 2015|July 16, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01329354||106515|
NCT01329627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 50/2010 - TAME|Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer|Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer|TAME-01|Instituto do Cancer do Estado de São Paulo|No|Terminated|August 2010|August 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|November 8, 2010||No|Toxicity|No||https://clinicaltrials.gov/show/NCT01329627||106494|
NCT01329926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGN-9001|Molecular Analysis of Human Neural Stem Cells|Molecular Analysis of Adult Human-derived Neural Stem Cells||NeuroGeneration|No|Enrolling by invitation|June 2011|||October 2016|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Brain tissue obtained during neurosurgical procedures yields undifferentiated neural stem      cells that are subsequently expanded.|Both|35 Years|85 Years|No|Non-Probability Sample|Patients with Parkinson's disease or parkinsonism|October 2015|October 15, 2015|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01329926||106471|
NCT01330251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laihdutusleikkaustutkimus|The Effect of Gastric Bypass Surgery on Diabetes|Laihdutusleikkauksen Vaikutus Diabetekseen||University of Oulu|No|Recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|Samples With DNA|Serum, plasma, feces, intestinal tissue|Both|18 Years|65 Years|No|Non-Probability Sample|All patients are recruited from Oulu University Hospital|July 2015|July 15, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01330251||106449|
NCT01331603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPI1CTIL|Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis|Assessment of Labile Plasma Iron (LPI) as an Alternative Parameter for Iron Overload in MDS and Primary Myelofibrosis Patients With Iron Overload and Its Correlations With the Classical Iron Overload Parameters.||Wolfson Medical Center|No|Not yet recruiting|March 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|low and high risk MDS patients and primary myelofibrosis patients.The risk stratification        of these patients will be calculated according to the WPSS (WHO adapted Prognostic Scoring        System)|March 2011|April 7, 2011|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01331603||106346|
NCT01298895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0192/09.01.2009.|Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome|Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome||General Hospital Sveti Duh|No|Completed|January 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|224|||Both|40 Years|N/A|No|Probability Sample|A prospective cohort study of 224 eyes of patients planned for cataract surgery was        conducted at the University Eye Clinic, General hospital Sveti Duh, Zagreb, Croatia. The        inclusion criteria was age of patients over 40 years. Sex and refractive eye state were        randomly chosen out of all cataract patients operated at the Clinic from January 2009        until July 2009.|January 2009|February 17, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298895||108833|
NCT01298609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_545|Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia|A Randomized Controlled Pilot Study to Examine the Efficacy of Greater Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia||St. Jude Medical|No|Completed|June 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01298609||108855|
NCT01299545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01046-33|Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy|Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy|PRINT|TcLand Expression S.A.|No|Terminated|February 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|123|Samples With DNA|Whole blood sampling in Paxgene tubes (DNA, RNA) Whole blood sampling in EDTA tubes|Both|18 Years|N/A|No|Non-Probability Sample|Patients suffering from RA eligible to a first biologic therapy for whom the treating        rheumatologist envisages infliximab therapy will be included in this study.|January 2013|January 31, 2013|February 16, 2011||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01299545||108783|
NCT01299558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102934|Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects|An Open-label, Non-randomised, Three-way Crossover, Single Dose Study to Determine the Absolute Bioavailability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder, in Healthy Subjects||GlaxoSmithKline|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|16|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||May 2011|May 12, 2011|June 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01299558||108782|
NCT01299571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105194|AVODART(Dutasteride) Post-marketing Surveillance(PMS)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVODART(Dutasteride) Administered in Korean BPH(Benign Prostatic Hyperplasia) Patients According to the Prescribing Information|AVO PMS|GlaxoSmithKline|No|Completed|December 2004|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3977|||Male|N/A|N/A|No|Probability Sample|The Korean BPH Patients administrated dutasteride|May 2011|May 19, 2011|February 17, 2011||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT01299571||108781|
NCT01300104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC Grant agreement 242244|Feasibility Study on a Nordic Lifestyle Intervention Trial Among Men With Prostate Cancer|Feasibility Study on a Nordic Lifestyle Intervention Trial Investigating the Effect of Vigorous Activity and Intake of Whole Grain Rye on Cancer Progression, Insulin Sensitivity and Inflammation Among Men With Early Stage Prostate Cancer.||Danish Cancer Society|No|Completed|February 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|55 Years|70 Years|No|||February 2015|February 18, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300104||108740|
NCT01331460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA029880|HIV and Drug Use in Georgian Women|HIV and Drug Use in Georgian Women|IMEDI|University of North Carolina, Chapel Hill|No|Active, not recruiting|April 2011|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|128|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|December 1, 2015|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01331460||106357|
NCT01331473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROVENON01|PROximal Protection VErsus NON-Protection in Carotid Artery Stenting|PROximal Protection VErsus NON-Protection in Carotid Artery Stenting (PROVENON Study) A Randomized Prospective MRI-based Trial.|PROVENON|Saarland University|Yes|Recruiting|May 2011|June 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||March 2011|December 2, 2011|March 30, 2011||||No||https://clinicaltrials.gov/show/NCT01331473||106356|
NCT01331707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUTCH PEERS|DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population|DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2)|DUTCH PEERS|Cardio Research Enschede BV|Yes|Completed|November 2010|December 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1811|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01331707||106338|
NCT01327781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-00847|Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer|Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer||National Cancer Institute (NCI)|No|Active, not recruiting|March 2011|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Female|18 Years|N/A|No|||February 2016|February 29, 2016|March 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01327781||106633|
NCT01300650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR-HF Pilot Study|Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure|Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure||Virginia Commonwealth University|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|February 17, 2011|Yes|Yes||No|December 2, 2011|https://clinicaltrials.gov/show/NCT01300650||108699|
NCT01296308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-4517|Complementary and Integrative Therapy for Diabetic Neuropathy|Effectiveness of a Complementary and Integrative Therapy in Diabetic Neuropathy Patients.|CIT-DN|Universität Duisburg-Essen|Yes|Completed|March 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|July 2012|July 16, 2012|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296308||109029|
NCT01296321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-FAS-2008-1145|Tailored Internet-administrated Treatment of Panic Symptoms - A Randomised Controlled Trial|Tailored Internet-administrated Treatment of Panic Symptoms - A Randomised Controlled Trial|NOVA III|Linkoeping University||Active, not recruiting|February 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|45 Years|No|||February 2011|February 15, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296321||109028|
NCT01328509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/AL/0137|Zinc and Inflammation in Sepsis|Zinc and Inflammation in Sepsis||University of Aberdeen|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|39|Samples Without DNA|Peripheral whole blood will be sampled from an indwelling arterial line and plasma will be      separated. Peripheral blood mononuclear cells will be separated using single density      gradient centrifugation and RNA extracted. Nuclear extracts of MNC will also be prepared.|Both|16 Years|N/A|No|Non-Probability Sample|Successive patients admitted to the Intensive Care Unit at Aberdeen Royal Infirmary who        fulfil the following criteria for sepsis, given below, within a 24h time window.        • .|July 2013|July 4, 2013|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328509||106579|
NCT01318499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-003|Nepafenac 0.3% Two Study|Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% Compared to Nepafenac Ophthalmic Suspension 0.1% and Vehicle for Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery||Alcon Research|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1342|||Both|18 Years|N/A|No|||December 2012|December 14, 2012|March 15, 2011|Yes|Yes||No|November 1, 2012|https://clinicaltrials.gov/show/NCT01318499||107343|Study excluded patients who were under the age of 18, had uncontrolled glaucoma, were at risk of developing macular edema (diabetic retinopathy), and women of childbearing potential. Therefore, results may not be generalizable to these populations.
NCT01318512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25317|An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis|The Dosage of MIRCERA in the Treatment of Renal Anaemia in Patients With Chronic Renal Disease Who do Not Undergo Haemodialysis in Clinical Practice||Hoffmann-La Roche||Completed|July 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|340|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic kidney disease receiving Mircera treatment|January 2016|January 14, 2016|March 17, 2011|No|Yes||No|October 29, 2015|https://clinicaltrials.gov/show/NCT01318512||107342|
NCT01322711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATORVASA|Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes|Effects on Oxidative Stress, Coagulation, Platelet Activation and Inflammatory Indexes of Atorvastatin and/or Aspirin Treatment in Patients at High Risk of Vascular Events||University of Roma La Sapienza|No|Active, not recruiting|March 2011|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2015|May 27, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322711||107020|
NCT01331330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-09-035-EU-DB|European Deep Brain Stimulation (DBS) Depression Study|A Clinical Evaluation of Different Device Parameters for the Management of Patients With Treatment Resistant Major Depressive Disorder, Single or Recurrent Episode, With Deep Brain Stimulation||St. Jude Medical||Completed|May 2011|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|21 Years|70 Years|No|||May 2015|May 18, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331330||106367|
NCT01328028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111050|Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand|Hospital-based Epidemiological Study on the Distribution of Human Papillomavirus (HPV) Types in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) in New Zealand||GlaxoSmithKline||Completed|April 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|244|Samples With DNA|Cervical specimen|Female|18 Years|N/A|No|Non-Probability Sample|Women aged >= 18 years at the time that the cervical specimen was taken, and diagnosed        with invasive cervical cancer stage IB or greater|June 2011|August 23, 2012|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328028||106614|
NCT01328379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DER-401|Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis|Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis||Acorda Therapeutics|Yes|Completed|March 2011|July 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|430|||Both|18 Years|70 Years|No|||September 2013|September 3, 2013|March 29, 2011|Yes|Yes||No|April 16, 2013|https://clinicaltrials.gov/show/NCT01328379||106589|
NCT01330771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-GON-2004-01|Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP|Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP Within a Protocol of Controlled Ovarian Hyperstimulation in IVF in Normoresponders Women Undergoing Downregulation With GnRH Antagonist||Ferring Pharmaceuticals|No|Completed|October 2006|September 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Female|18 Years|38 Years|No|Non-Probability Sample|Females affected by sterility able to undergo IVF|April 2011|April 6, 2011|April 6, 2011||||No||https://clinicaltrials.gov/show/NCT01330771||106409|
NCT01298271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC99-2314-13-010-049-MY3|Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker|A Randomized Trial of GVS Alone vs. Nadolol||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|April 2010|October 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||June 2011|June 14, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01298271||108879|
NCT01298596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35995-J|Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women|Impact of Cryotherapy Versus Loop Electrosurgical Excision Procedure (LEEP) on Recurrence of Cervical Intraepithelial Neoplasia and HIV-1 Cervical Shedding Among HIV-positive Women|PHE-LEEP|University of Washington|Yes|Active, not recruiting|June 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||June 2015|June 30, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298596||108856|
NCT01298622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD001|The Imaging Genetic Study of the Core Family of Obsessive-compulsive Disorder (OCD) Patient|The Study of Structural and Functional Brain Abnormalities and the Association With the Genetic Polymorphism in the Core Family of OCD Patient||Kunming Medical University|Yes|Recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|100|Samples With DNA|perapheral blood DNA of all participants|Both|15 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|OCD patients and their parents|March 2014|March 19, 2014|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298622||108854|
NCT01298635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GJ-PACG-phacotrab/trab|Comparison of Phacotrabeculectomy and Trabeculectomy in the Treatment of Primary Angle-closure Glaucoma (PACG)|Comparison of Combined Phacotrabeculectomy and Trabeculectomy Only in the Treatment of Primary Angle-closure Glaucoma||Sun Yat-sen University|Yes|Completed|January 2005|May 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|40 Years|82 Years|No|||November 2004|February 17, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298635||108853|
NCT01330888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7800-P|Exploring Deployment Stress and Reintegration in Army National Guard Chaplains|Exploring Deployment Stress and Reintegration in Army National Guard Chaplains||VA Office of Research and Development|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|102|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|ARNG Chaplains who have ever/never been deployed to OEF/OIF combat theaters|February 2015|February 18, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330888||106401|
NCT01299857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/141/HP|Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab|EVALUATION CLINIQUE ET BIOLOGIQUE A LONG TERME DES PATIENTS ATTEINTS DE FORMES SEVERES DE PEMPHIGUS TRAITES PAR LE RITUXIMAB|Suiviritux|University Hospital, Rouen|No|Completed|June 2011|June 2012|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299857||108759|
NCT01300117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP-KC|Influence of Extracorporeal Circulation During Cardiac Surgery on the Development of Postoperative Thrombotic Thrombocytopenic Purpura (TTP)|Influence of Extracorporeal Circulation During Cardiac Surgery on the Development of Postoperative TTP||Johann Wolfgang Goethe University Hospitals|No|Recruiting|October 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery at the University Hospital|December 2011|December 28, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300117||108739|
NCT01328145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022123-29|Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease|Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Trial|ASA-COPD|Medical University of Vienna|Yes|Recruiting|April 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|75 Years|No|||December 2012|December 24, 2012|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01328145||106605|
NCT01328158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-760|Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection|Drug Use Investigation of Kaletra Tablets (Quaque Die, QD) on Patients With HIV-infection||AbbVie||Completed|June 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|236|||Both|N/A|N/A|No|Non-Probability Sample|All participants who receive Kaletra for the treatment of Human Immunodeficiency Virus        infection per approved label|December 2014|December 12, 2014|April 1, 2011||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01328158||106604|
NCT01327794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000698059|Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer|The Relationship of Serum 25-Hydroxyvitamin D to Overall Survival in Advanced Pancreatic Cancer||Alliance for Clinical Trials in Oncology||Withdrawn|June 2011|||December 2012|Anticipated|N/A|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||May 2012|June 27, 2013|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01327794||106632|
NCT01328119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34908.068.10|Uremic Toxin Removal and Hemodynamics in Long-hour Hemodialysis and Hemodiafiltration|Uremic Toxin Removal and Hemodynamics in Long-hour Hemodialysis and Hemodiafiltration; a Randomized Cross-over Study||Maastricht University Medical Center||Completed|October 2011|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||June 2013|June 12, 2013|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01328119||106607|
NCT01328132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-287-BMA|Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant|||McGill University Health Center|No|Not yet recruiting|March 2011|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||January 2011|March 31, 2011|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328132||106606|
NCT01328808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4839 - APAP|Metabolism and Toxicity of Acetaminophen|Metabolism and Toxicity of Acetaminophen in Preterm Infants||Children's Research Institute|No|Recruiting|October 2011|December 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|22 Weeks|37 Weeks|No|||January 2016|January 11, 2016|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328808||106556|
NCT01318525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALF-5755_P2_ALF|Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure|A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure||Alfact Innovation|Yes|Recruiting|October 2010|September 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||April 2011|April 4, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318525||107341|
NCT01318538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA - 5R01DA015434-05|Recovery Group for Women With Substance Use Disorders|Recovery Group for Women With Substance Use Disorders||Mclean Hospital|No|Active, not recruiting|August 2008|June 2012|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|135|||Both|18 Years|N/A|No|||May 2011|May 11, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01318538||107340|
NCT01322724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00007299|Comparing Warm Versus Cool Temperature Water During Colonoscopy|Comparing Warm Versus Cool Temperature Water During Colonoscopy||OHSU Knight Cancer Institute|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|175|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 24, 2012|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322724||107019|
NCT01327677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00029336|Safety Study of Analgesia After Craniotomy Surgery With End Tidal CO2 Monitoring|Post Craniotomy Analgesia Safety Monitoring With ET CO2||Johns Hopkins University|Yes|Recruiting|May 2010|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||April 2015|April 23, 2015|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01327677||106640|
NCT01327690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-GROUP-12/10/10|Mental Health in Veterans and Families After Group Therapies|Mental Health in Veterans and Families After Group Therapies||Soul Medicine Institute|Yes|Recruiting|December 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|3||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01327690||106639|
NCT01329185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV-777|Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients|Double Blinded Placebo Controlled Study to Assess Clinical and Antiviral Activity of Valganciclovir (VAL) in Solid Organ Transplant Donors to Reduce Viral Transmission From Donor to Recipient||University of Minnesota - Clinical and Translational Science Institute|No|Completed|June 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|17|||Both|6 Months|N/A|No|||May 2015|May 26, 2015|April 1, 2011||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01329185||106528|Study was unblinded 2 months following the enrollment of the final donor, when a recipient developed post-transplant lymphoproliferative disorder with evidence of EBV infection at the single cell level by detection of EBV encoded small nuclear RNA.
NCT01330498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-002-TY|Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical|Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical Sample Collection With MRI and Relapse Analysis of a Tysabri Patient Cohort||Rocky Mountain MS Research Group, LLC|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|229|Samples Without DNA|Serum for PK/PD, SVCAM back-up samples will be kept.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with relapsing forms of MS. Conducted at one site in the US. Subjects currently        enrolled in TOUCH Prescribing Program, and participated in Foley 001-001-TY eligible.        Subset of approx. 40 patients to participate in Part B. 11 high risk bivalent patients 11        low risk monovalent patients 9 patients who participated in 2009 PK/PD study (Biogen Idec,        101MS406) 9 patients with infusion cycle of 38 days plus or minus 2 days        Part C "Intracellular energetic in Tysabri therapy":        Patients whose iATP fell into the bottom 20th percentile will be asked to participate in a        sub-study that includes Part A with the addition of collecting iATP. This number is        approximately 50 participants.        Part D patients from 001-001-TY with low or normal IgG4 levels will be asked to        participate in sub-study for an additional IgG4 assay collected at 3-5 days post-infusion.        This number is approximately 30 participants.|January 2012|January 4, 2012|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01330498||106430|
NCT01297725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fascia Study|Sharp Versus Blunt Fascial Incision at Caesarean Section|Sharp Versus Blunt Fascial Incision at Caesarean Section: A Prospective Randomized Double-blinded Case-Control Study With the Case as it's Own Control.||Holbaek Sygehus|No|Completed|January 2011|October 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|30|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 18, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297725||108921|
NCT01298284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V99C1-026|A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol|Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|October 2009|December 2011|Anticipated|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||June 2011|June 14, 2011|October 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01298284||108878|
NCT01298297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUMS-THESIS 88|Efficacy of Buprenorphine for Treatment of Acute Pain|Comparison of Sublingual Buprenorphine With Intravenous Morphine Sulfate in Treatment of Acute Pain Due to Long Bone Fracture||Tehran University of Medical Sciences|No|Completed|February 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|16 Years|N/A|No|||December 2012|December 6, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298297||108877|
NCT01298310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285M00032|A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)|A Randomised, Double-blind, Placebo-controlled, Three-way Cross-over Single Center Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)||AstraZeneca|No|Completed|February 2011|May 2012|Actual|May 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|27|||Both|18 Years|80 Years|No|||May 2012|May 21, 2012|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298310||108876|
NCT01298921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0205|A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache|A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache||Geisinger Clinic|No|Recruiting|January 2011|November 2012|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|65 Years|No|||March 2012|March 15, 2012|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298921||108831|
NCT01299220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10020317|Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)|Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash||University of Pittsburgh|Yes|Withdrawn|November 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|February 15, 2011|Yes|Yes|Unable to enroll subjects by sponsor deadline|No||https://clinicaltrials.gov/show/NCT01299220||108808|
NCT01299233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-OCT|Reproducibility of RNFL Circle Scans With ART-Function of Heidelberg Spectralis SD-OCT Software Version 5.3|Reproducibility of RNFL Circle Scans With ART-Function of Heidelberg Spectralis SD-OCT Software Version 5.3||University of Zurich|No|Enrolling by invitation|February 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients and controls are selected out of our primary care clinic|December 2014|January 5, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01299233||108807|
NCT01299246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-2224-B|The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region|The Effectiveness of Improving Self-care and Health Status After Promoting Counseling for the Diabetics Mellitus Patients With DM Foots Around Yunlin and Chiayi Region||Chang Gung Memorial Hospital|Yes|Active, not recruiting|November 2009|July 2013|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|1||Actual|386|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2009|February 17, 2011|January 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01299246||108806|
NCT01331720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-MEN-2006-03|Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation|Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation Protocols Which Are the Most Common in Clinical Practice Using High Purified Gonadotrophins (u-FSH-HP y u-hMG-HP) in IVF/ICSI|DESCARTES|Ferring Pharmaceuticals|No|Completed|November 2007|July 2010|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|279|||Female|N/A|N/A|No|Non-Probability Sample|Females affected by sterility able to undergo IVF/ICSI|April 2011|April 7, 2011|April 6, 2011||||No||https://clinicaltrials.gov/show/NCT01331720||106337|
NCT01331499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL-SP-10-001|Salient Aquamantys Spine Trial|A Post-Market, Prospective, Multicenter, Randomized Trial Comparing the Use of Standard of Care Blood Sparing Techniques With and Without the Aquamantys System to Facilitate Hemostasis in Subjects Undergoing Multi-level Spinal Fusions||Salient Surgical Technologies|No|Terminated|April 2011|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12|||Both|18 Years|70 Years|No|||June 2012|June 6, 2012|April 6, 2011||No|Study terminated due to Medtronic acquisition|No||https://clinicaltrials.gov/show/NCT01331499||106354|
NCT01331174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403/06|Pulsed Short Wave in Females With Knee Osteoarthritis|Pulsed Short Wave in Females With Knee Osteoarthritis: A Multicenter, Randomized, Placebo-controlled Clinical Trial|PSW|Irmandade da Santa Casa de Misericordia de Sao Paulo|No|Completed|August 2006|December 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|121|||Female|40 Years|N/A|No|||November 2012|November 26, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331174||106379|
NCT01331967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAISE II|The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT)|||Korea University Anam Hospital||Completed|February 2011|August 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|94|||Both|18 Years|80 Years|No|||March 2014|March 1, 2014|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331967||106318|
NCT01327807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCIR100913|Cure Cystinosis International Registry|Cure Cystinosis International Registry|CCIR|Cystinosis Research Foundation|No|Recruiting|August 2010|December 2022|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|750|||Both|N/A|N/A|No|Non-Probability Sample|International cystinosis community|March 2014|March 10, 2014|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327807||106631|
NCT01327820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/R/AN/01|Study of Post-operative Oxygen Consumption Following Vascular Surgery|Study of Post-operative Oxygen Consumption Following Vascular Surgery||NHS Lothian|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|27|||Both|N/A|N/A|No|Non-Probability Sample|Patients presenting for major vascular surgery at the Royal Infirmary of Edinburgh|March 2011|March 23, 2016|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01327820||106630|
NCT01328483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/21/2008/MSAF-OPS|Effect Of Intrapartum Oropharyngeal (IP-OP) Suction on Meconium Aspiration Syndrome|Role of Intrapartum Oropharyngeal (IP-OP) Suction in Neonates Born Through Meconium Stained Amniotic Fluid on Meconium Aspiration Syndrome|MSAF-OPS|Lady Hardinge Medical College|Yes|Completed|May 2008|April 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|540|||Both|N/A|10 Minutes|No|||September 2015|September 26, 2015|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328483||106581|
NCT01328756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-404|Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 4, Open-Label, Multicentre, Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)||Shire||Completed|July 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|314|||Both|6 Years|17 Years|No|||October 2014|July 9, 2015|March 29, 2011|No|Yes||No|May 15, 2015|https://clinicaltrials.gov/show/NCT01328756||106560|Since this study is an open-label trial, results should be interpreted with caution.
NCT01328769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42916|Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)|Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)||University of Utah|Yes|Completed|March 2011|January 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|49|||Both|18 Years|60 Years|No|||July 2015|August 13, 2015|March 29, 2011|Yes|Yes||No|July 7, 2015|https://clinicaltrials.gov/show/NCT01328769||106559|
NCT01328171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO KRK 0109|FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)|An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type|VOLFI|AIO-Studien-gGmbH|Yes|Recruiting|April 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|93|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01328171||106603|
NCT01328535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1076|Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|Individualized (Timed) Temozolomide Administration as a Means of Immune Reconstitution in Patients With Metastatic Melanoma||Mayo Clinic|Yes|Suspended|January 2011|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328535||106577|
NCT01319123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-019|Evaluate the Impact of Drawtex in Venous Leg Ulcers|Clinical Study to Comparatively Evaluate the Impact of Drawtex Wound Dressing Against Wound Bioburden in Moderately to Highly Exuding Venous Leg Ulcers||Southwest Regional Wound Care Center|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01319123||107296|
NCT01331863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091203|Airway and/or Pulmonary Vessels Transplantation|Replacement of the Airways and/or the Pulmonary Vessels Using a Cryopreserved Arterial Allograft|TRACHBRONCAR|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|May 2011|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 13, 2014|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01331863||106326|
NCT01328665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUIRB03282011-1|Evaluating an Expressive Writing Intervention About Communicatively-Restricted Organizational Stressors|Evaluating an Expressive Writing Intervention About Communicatively-Restricted Organizational Stressors: A Six-Week Randomized, Controlled Trial||Santa Clara University|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01328665||106567|
NCT01329640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP 17/2010 TraQ-Me 01|Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)|Phase II Feasibility Study of Weekly Paclitaxel Plus Weekly Trastuzumab Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide Plus Weekly Trastuzumab for Locally Advanced HER2-Positive Breast Cancer||Instituto do Cancer do Estado de São Paulo|No|Terminated|September 2010|September 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||May 2014|May 20, 2014|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01329640||106493|
NCT01329653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6219/#7161R|Exercise, Age-Related Memory Decline, And Hippocampal Function|Exercise, Age-Related Memory Decline, And Hippocampal Function||New York State Psychiatric Institute|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|182|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||August 2015|October 5, 2015|July 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01329653||106492|
NCT01297998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHBO1004|A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy|A Phase I Study of Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin in Patients With Biliary Tract Cancer Undergoing Curative Resection Without Major Hepatectomy||Kansai Hepatobiliary Oncology Group|Yes|Completed|January 2011|June 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|20 Years|N/A|No|||June 2014|June 29, 2014|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01297998||108900|
NCT01298011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRT 10-001|Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer|A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer||Pancreatic Cancer Research Team|No|Completed|May 2011|May 2015|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298011||108899|
NCT01297985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B050003b|A Randomized Controlled Trial of Mental Health Peer-Led Education|Efficacy of Peer-Led Education in Improving Mental Health Recovery Outcomes in Tennessee|BRIDGES|University of Illinois at Chicago|No|Completed|January 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|428|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 16, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297985||108901|
NCT01298648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-706|Special Investigation in Patients With Crohn's Disease (All Patients Investigation)|Special Investigation (All Cases Investigation in Patients With Crohn's Disease)||AbbVie||Completed|November 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1716|||Both|16 Years|N/A|No|Non-Probability Sample|All patients who receive Humira for the treatment of Crohn's Disease|March 2014|March 19, 2014|January 26, 2011||No||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01298648||108852|
NCT01298934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-0572|LBH589 (Panobinostat) for the Treatment of Myelofibrosis|A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|September 2009|July 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298934||108830|
NCT01298947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHOTOPAC|Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions|Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions|PHOTOPAC|Herz-Zentrums Bad Krozingen|Yes|Enrolling by invitation|April 2011|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2011|February 18, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298947||108829|
NCT01330355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|646|Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis|Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age||Bausch & Lomb Incorporated|No|Terminated|May 2011|October 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|N/A|31 Days|No|||August 2014|September 2, 2014|April 5, 2011|Yes|Yes|Lack of enrollment|No|August 21, 2014|https://clinicaltrials.gov/show/NCT01330355||106441|
NCT01330602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-C/10/005|Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis|Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis: The IMPRESS Study- A Multi-centre, Randomised Controlled Trial|IMPRESS|National University Hospital, Singapore|Yes|Recruiting|May 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|1310|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 8, 2013|May 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01330602||106422|
NCT01331733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-MEN-2006-01|Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist|Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist Following Two Protocols of Ovulation Induction for Intrauterine Insemination|PROMENIA|Ferring Pharmaceuticals|No|Completed|November 2006|March 2009|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|131|||Female|18 Years|36 Years|No|Non-Probability Sample|Females affected by sterility able to undergo intrauterine insemination|April 2011|April 7, 2011|April 6, 2011||||No||https://clinicaltrials.gov/show/NCT01331733||106336|
NCT01331746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX10008|Proof-of-concept (PoC) Study of APD515|Randomised, Double-blind, Placebo-controlled Phase II Proof-of-concept Study of APD515 Solution for Oromucosal and Oral Administration for Relief of Xerostomia in Patients With Cancer||Acacia Pharma Ltd|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01331746||106335|
NCT01331512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903320|The InChianti Follow-Up Study|The InChianti Follow-Up Study||National Institutes of Health Clinical Center (CC)||Completed|January 2003|January 2015||||N/A|Observational|N/A|||Anticipated|1200|||Both|65 Years|N/A|No|||January 2015|January 3, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331512||106353|
NCT01331759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF1-2010|Neuropattern™ for Workplace Health Promotion|Neuropattern™ Stress Diagnostics in Workplace Health Promotion||Daacro|Yes|Completed|January 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|79|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01331759||106334|
NCT01327495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39738-A|PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate|Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2)|PROS-2|University of Washington|Yes|Completed|October 2011|December 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|62|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327495||106654|
NCT01327833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDPC-CODE|CODE Registry - Cardiac Arrest Outcomes Data Evaluation|Cardiac Arrest Outcomes Data Evaluation|CODE|Instituto Dante Pazzanese de Cardiologia||Completed||||||N/A|Observational|Time Perspective: Cross-Sectional||1|||||Both|18 Years|N/A||Probability Sample|Patients in cardiac arrest in-hospital in 17 hospitals and institutes of public and        private Brazilian specialties.|March 2011|April 1, 2011|March 31, 2011||||No||https://clinicaltrials.gov/show/NCT01327833||106629|
NCT01328184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.41|Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon|An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers||Boehringer Ingelheim||Completed|April 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|April 1, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01328184||106602|
NCT01328197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-0006-10|Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms|A Phase I Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms||Bolton Medical|Yes|Active, not recruiting|June 2011|January 2017|Anticipated|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||February 2016|February 11, 2016|March 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01328197||106601|
NCT01328548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-450|Zoster Vaccine Response in the Frail Elderly|Immune and Genetic Correlates of Response to Zoster Vaccine in the Frail Elderly: a Pilot Study||McMaster University|No|Active, not recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|250|Samples With DNA|Retained specimens include DNA and blood cells.|Both|80 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Elderly, non-ambulatory residents of nursing homes.|November 2015|November 12, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01328548||106576|
NCT01319136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 08-130M|Improved Analysis Methods for Infusion Tests|Novel Infusion Method for Describing CSF Dynamics||Umeå University|No|Completed|March 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|48|||Both|N/A|N/A|No|Non-Probability Sample|Patients that had a preoperative investigation because of communicating hydrocephalus. MRI        revealed ventriculomegaly (Evans ratio > 0.3), no obstruction to CSF flow at visual        inspection. Most, but not all, fulfilled the criteria of "probable" or "possible" INPH.|March 2009|March 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319136||107295|
NCT01319149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-020|A Study of the Effects of Molecular Diagnostic Directed Wound Gels on Wound Care Outcomes|A Retrospective Study Of the Effects of Molecular Diagnostic Directed Wound Gels on Wound Care Outcomes||Southwest Regional Wound Care Center|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|400|||Both|18 Years|N/A|No|Probability Sample|Patients with wounds who have been treated at Southwest Regional Wound Care Center.|September 2012|September 11, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01319149||107294|
NCT01328392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Takeda IISR|Evaluating Treatment Response in Laryngo-Pharyngeal Reflux|Evaluating Treatment Response in Laryngo-Pharyngeal Reflux||University of Washington||Not yet recruiting|May 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2011|March 31, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01328392||106588|
NCT01296802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUK_Study_72|Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging|Investigation of Serotonin Neurotransmission in "Ecstasy" Users Employing Combined Dexfenfluramine Challenge and Positron Emission Tomography: a Functional Probe to Assess MDMA Neurotoxicity|DEXFEN_PET|University of Zurich|No|Completed|April 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01296802||108991|
NCT01328951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25460|A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy|A Randomized, Double-Blind, Placebo-Controlled Phase III Study of First-Line Maintenance Tarceva Versus Tarceva at the Time of Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-Based Chemotherapy||Hoffmann-La Roche||Completed|September 2011|January 2016|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|643|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 4, 2011|Yes|Yes||No|January 29, 2016|https://clinicaltrials.gov/show/NCT01328951||106546|
NCT01297400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEBO-BPII-001 v1.2|A Clinical Study of the Efficacy and Safety of MEBO® Wound Ointment in Subjects With Partial Thickness Burns|A Phase II, Randomized, Controlled, Single-Center Pilot Study of the Efficacy and Safety of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Partial Thickness Burns||Skingenix, Inc.||Not yet recruiting|January 2016|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|65 Years|No|||May 2015|May 18, 2015|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01297400||108945|
NCT01298349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-10|Perception Processing in Schizophrenia Patients and Normal Population|Perception Processing in Schizophrenia Patients and Normal Population.||HaEmek Medical Center, Israel|Yes|Not yet recruiting|February 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients diagnosed with schizophrenia or schizo-affective disorder according to DSM4 and        normal population with no psychiatric history|February 2011|February 16, 2011|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01298349||108873|
NCT01298323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00088|Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment|A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib|88|AstraZeneca||Active, not recruiting|February 2011|March 2016|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|130 Years|No|||February 2016|February 3, 2016|February 16, 2011|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01298323||108875|
NCT01298336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRCN10-DR-ANDREJAK-MELLE|Treatment of Mycobacterium Xenopi Pulmonary Infection|Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi|CAMOMY|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298336||108874|
NCT01330056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-001|Functional Organ Preservation Surgery|A Prospective Randomized Controlled Trial of Functional Organ Preservation Surgery vs. Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma|FOPS|Asan Medical Center|Yes|Recruiting|September 2010|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||January 2015|January 13, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330056||106461|
NCT01330901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPAS|Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis|UsTekinumab for the Treatment Of Patients With Active Ankylosing Spondylitis (TOPAS) - a 28-week, Prospective, Open-label, Proof-of-concept Study|TOPAS|Charite University, Berlin, Germany|No|Completed|October 2011|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330901||106400|
NCT01331187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH-2011-1|Influence of Routinely Adding Ultrasound Screening in Medical Department|Influence on Diagnostics and Inpatient Workflow of Routinely Adding Ultrasound Screening by Pocket-size Ultrasound in a Medical Department||Levanger Hospital|Yes|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|600|||Both|16 Years|N/A|No|||April 2011|May 31, 2012|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01331187||106378|
NCT01331486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2279|Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract|Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract||University of North Carolina, Chapel Hill|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|24|||Both|18 Years|N/A|No|||December 2011|February 6, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331486||106355|
NCT01331213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000485|Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome|Effect of Pregabalin on Colonic Motor and Sensory Function in Adults With Irritable Bowel Syndrome With Predominant Constipation||Mayo Clinic|No|Completed|April 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|18|||Both|18 Years|65 Years|No|||January 2014|January 17, 2014|April 6, 2011|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01331213||106376|
NCT01331525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM CAN0739|The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer|A Phase II Trial of the Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (ICE)|ICE|University Hospital Southampton NHS Foundation Trust.|Yes|Active, not recruiting|June 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331525||106352|
NCT01331772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASAPAS|Impact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy|Randomized Controlled Study Assessing the Feasibility and the Medico-economic Impact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy|PASAPAS|Centre Leon Berard|No|Completed|July 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Female|18 Years|75 Years|No|||October 2014|October 29, 2014|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331772||106333|
NCT01327521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0030|Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma|International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma||Stanford University|Yes|Withdrawn|February 2011|||February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|March 30, 2011||No|Accrual below target levels|No||https://clinicaltrials.gov/show/NCT01327521||106652|
NCT01327547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001098|A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B|A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus||ViiV Healthcare|Yes|Completed|May 2011|March 2015|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|March 22, 2011|Yes|Yes||No|April 9, 2014|https://clinicaltrials.gov/show/NCT01327547||106650|Results of the population pharmacokinetic analysis and exposure-response relationship between maraviroc pharmacokinetics and liver fibrosis biomarkers at 48 weeks, will be included when the Basic Results are finalized off the Last Subject Last Visit.
NCT01327508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-TRI-01|TRIGEN SURESHOT™ Distal Targeting System Study|A Prospective, Multi-center, Randomized, Comparison Study of the TRIGEN SURESHOT™ Distal Targeting vs. Standard Targeting Instrumentation|Sureshot|Smith & Nephew, Inc.|No|Terminated|April 2011|June 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|March 30, 2011||No|Primary endpoint voided. Dosimeters did not capture radiation dose as expected.|No|June 6, 2014|https://clinicaltrials.gov/show/NCT01327508||106653|
NCT01327846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885M2301|Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)|A Randomized, Double-blind, Placebo-controlled, Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients With Elevated hsCRP Including Substudies to Evaluate the Effect of Canakinumab on Carotid Atherosclerosis, and on Glucose Control Following OGTT in T2DM|CANTOS|Novartis||Active, not recruiting|April 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|10120|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|March 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327846||106628|
NCT01327859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-E044-318|Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia|A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia||Eisai Inc.||Completed|March 2003|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|357|||Both|40 Years|N/A|No|||November 2015|November 2, 2015|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327859||106627|
NCT01328522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKM12058|Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients|||Sanofi|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||October 2011|October 21, 2011|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328522||106578|
NCT01328873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 909|Fiberoptic Bronchoscopy (FOB) in Hematopoietic Stem Cell Transplant (HSCT) and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates|A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction With Fiberoptic Bronchoscopy (FOB) in Hematopoietic Stem Cell Transplant (HSCT) and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates||Northside Hospital, Inc.|No|Active, not recruiting|March 2011|December 2016|Anticipated|October 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 29, 2016|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328873||106552|
NCT01319513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Darwin 1a - Bolus versus Pulse|Post-exercise Dietary Protein Strategies|The Effect of the Pattern Post-exercise Aminoacidemia on Myofibrillar Protein Synthesis||McMaster University|No|Completed|July 2009|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2011|March 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319513||107266|
NCT01296815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41-10|Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity|Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity||Centro de Investigación en. Enfermedades Infecciosas, Mexico|No|Completed|September 2010|December 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|60 Years|No|||July 2015|July 22, 2015|February 15, 2011||No||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01296815||108990|
NCT01297101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25268(C-TONG1101)|Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy|A National, Multi Center, Randomized, Open-label, Phase II Trial of Tarceva Versus Combination of Gemcitabine Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N1,N2 NSCLC With Activating EGFR Mutation in Exon 19 or 21||Shanghai Chest Hospital||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2011|February 15, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297101||108968|
NCT01297738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISAB|Diet, Insulin Sensitivity And the Brain|The Effect of Dietary Patterns and Diet Composition on Insulin Sensitivity and Cerebral Dopamine- and Serotonin Transporters|DISAB|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|February 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|39|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297738||108920|
NCT01297751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFS02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2011|||||N/A|N/A|N/A||||||||||||||January 23, 2012|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01297751||108919|
NCT01329237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPARE-II-Imaging|COMPARE-II- Vasomotion and Imaging Substudy|Comparison of the Everolimus Eluting (XIENCE-V® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study The COMPARE II Trial Imaging and Vasomotion Substudy|COMPARE-IT|University of Freiburg|No|Recruiting|March 2011|||March 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|80 Years|No|||January 2011|April 4, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01329237||106524|
NCT01298661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD6reprod|Reliability, Sensitivity and Validity of the 6 Minute Step Test in Chronic Obstructive Pulmonary Disease (COPD) Patients|Evaluation of Reliability, Sensitivity and Validity of the Six Minute Step Test in Patients With Chronic Obstructive Pulmonary Disease and Its Relation With Predictors Markers of Risk of Death||Universidade Federal de Sao Carlos|No|Completed|February 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|91|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|October 31, 2013|February 17, 2011||No||No|April 16, 2013|https://clinicaltrials.gov/show/NCT01298661||108851|The enrolled patient's and subject's numbers were smaller than the estimated for healthy elders and different COPD groups, because of the low acceptance of a three days evaluation protocol. So COPD patients were analyzed in a single group.
NCT01330381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD555-303|Prucalopride in Pediatric Subjects With Functional Constipation|Trial Consisting of an 8-week Double-blind Placebo-controlled Part to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of Prucalopride in Paediatric Subjects With Functional Constipation, Aged ≥6 Months to <18 Years, Followed by a 16-week Open-label Comparator (PEG) Controlled Part, to Document Safety and Tolerability up to 24 Weeks|FC|Shire|Yes|Completed|April 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|215|||Both|6 Months|17 Years|No|||January 2014|April 13, 2015|April 4, 2011||No||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01330381||106439|
NCT01330615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB-E/09/612|Efficacy Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA) for Analgesia Prior to Cryotherapy of Verrucae Plantaris|A Double-Blind, Randomized, Placebo-Controlled Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA) for Analgesia Prior to Cryotherapy of Verrucae Plantaris in Adults||National University Hospital, Singapore|No|Recruiting|February 2010|December 2010|Anticipated|December 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|64|||Both|21 Years|N/A|No|||April 2011|April 6, 2011|May 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01330615||106421|
NCT01330628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D013474|Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis|EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis|EXCITE ISR|Spectranetics Corporation|No|Completed|June 2011|May 2015|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|85 Years|No|||May 2015|May 18, 2015|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330628||106420|
NCT01330914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDB-007-10F|Effects of Gastric Bypass Surgery and Calcium Metabolism and the Skeleton|Effects of Gastric Bypass Surgery on Calcium Metabolism and the Skeleton||VA Office of Research and Development|No|Completed|July 2011|January 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|serum, urine|Both|25 Years|70 Years|No|Non-Probability Sample|Men and women 25 to 70 years old scheduled to undergo gastric bypass surgery|December 2015|December 2, 2015|April 5, 2011||No||No|December 2, 2015|https://clinicaltrials.gov/show/NCT01330914||106399|
NCT01331200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007822|Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-Tissue Plasminogen Activator (IV-tPA)|Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-tPA Infusion.|EMISTPA|Mayo Clinic|Yes|Completed|January 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients experiencing acute ischemic stroke who receive intravenous tissue plasminogen        activator (IV-tPA) infusion, survive to discharge from the hospital, are hemodynamically        stable, and are mobilized by physical and/or occupational therapy within 24 hours post-tPA        infusion.|February 2013|February 25, 2013|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331200||106377|
NCT01331538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82622/08|Temporomandibular Dysfunction and Cervical Posture|Correlation Between Temporomandibular Dysfunction and Cervical Posture in Different Occlusal Angle Classes in Adolescents||University of Nove de Julho|No|Completed|February 2009|March 2010|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|296|||Both|10 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|adolescents aged between 10 and 20 years. As criteria for inclusion, age group and the        presence of first permanent molar|February 2009|April 7, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331538||106351|
NCT01327534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAMI|ETAMI-Study: Early Thienopyridine Treatment to Improve Primary Percutaneous Coronary Intervention (PCI) in Patients With Acute Myocardial Infarction|ETAMI-Study: Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute Myocardial Infarction|ETAMI|Stiftung Institut fuer Herzinfarktforschung|Yes|Active, not recruiting|May 2011|June 2013|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|74 Years|No|||April 2013|April 11, 2013|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327534||106651|
NCT01331785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACG‐CR‐026‐2010|Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis|Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis||The Cleveland Clinic|Yes|Withdrawn|April 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||April 2011|July 29, 2013|April 7, 2011|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01331785||106332|
NCT01327872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-010|Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects|A Randomized, Open-Label, 4-Group, 2-Period Replicate Design Study to Evaluate Within- and Between-Subject Variability in Exposure of Two Lots of E5501 20 mg Tablets, Administered as Single Doses of 40 mg, in the Fasted and Fed Conditions to Healthy Subjects||Eisai Inc.|No|Completed|February 2011|June 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01327872||106626|
NCT01328210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2006-AV|Effects of Blood Letting in Metabolic Syndrome|Effects of Blood Letting on Insulin Sensitivity and Blood Pressure in Patients With Metabolic Syndrome: A Randomized Controlled Trial||Charite University, Berlin, Germany|No|Completed|July 2008|May 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|25 Years|70 Years|No|||November 2011|November 5, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01328210||106600|
NCT01328223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Radiotherapy-Sorafenib|Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma|Phase II Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma||China Medical University Hospital|Yes|Recruiting|September 2010|December 2012|Anticipated|June 2012|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|20 Years|69 Years|No|Non-Probability Sample|Paitents with unresectable hepatoma with transarterial chemoembolization (TACE) failure or        who are not suitable for TACE.|March 2011|April 1, 2011|March 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01328223||106599|
NCT01328236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138CAN2026|Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia|Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia|Bortezomib|Clinical Service, China|Yes|Recruiting|September 2010|September 2015|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2011|September 21, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01328236||106598|
NCT01328249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-210|Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer|A Phase II, Single-Arm, Feasibility Study of Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer||Eisai Inc.|No|Active, not recruiting|March 2011|November 2017|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|100 Years|No|||February 2016|February 24, 2016|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328249||106597|
NCT01329146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00302-53|Pulse Pressure Variations as Index of Preload Dependency During Thoracic Surgery|Pulse Pressure Variations as Index of Preload Dependency During Thoracic Surgery||University Hospital, Lille|Yes|Completed|October 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing a thoracic surgery (lobectomy or pneumonectomy)and requiring        hemodynamic monitoring (artery catheter, oesophageal doppler)in the thoracic surgery unit        of the university hospital of Lille.|October 2008|April 4, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329146||106531|
NCT01328964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112608|Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population|Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population||GlaxoSmithKline|No|Completed|June 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|9906|||Both|4 Years|11 Years|No|Non-Probability Sample|Claims related to pediatric patients age 4-12 in the database with one or more outpatient        pharmacy claims for fluticasone propionate 44 micrograms (FP44) or budesonide (BUD) or        montelukast (MON) between January 1, 2000 and June 30, 2008.|August 2011|September 8, 2011|March 4, 2010||No||No|April 8, 2011|https://clinicaltrials.gov/show/NCT01328964||106545|
NCT01328977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00029824|Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy|Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy||Johns Hopkins University|No|Completed|March 2010|October 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|45|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|April 1, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328977||106544|
NCT01297114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB0596|Imaging of Cognition, Learning, and Memory in Aging|Imaging of Cognition, Learning, and Memory in Aging||Columbia University|No|Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|550|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited from ads placed in local newspapers and notices posted in the        vicinity of Columbia University, the Columbia Presbyterian Medical Center, and in local        senior centers that provide written consent for notice placement. We will also utilize a        market mailing approach. Letters will be sent to appropriately aged potential subjects        randomly selected from commercial lists. Additional elderly subjects will be recruited        from the Sergievsky Joint Database. Informed consent will be elicited from all subjects.|February 2016|February 25, 2016|February 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01297114||108967|
NCT01297413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEM 101-M|A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke|A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke||Stemedica Cell Technologies, Inc.|Yes|Active, not recruiting|February 2011|December 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|February 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01297413||108944|
NCT01297426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDA-013-10F|Leptin Signaling in Lean and Obese Humans|Leptin Signaling in Humans|Leptin signali|VA Office of Research and Development|No|Withdrawn|April 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|diabetic or nondiabetic lean and obese subjects|December 2015|December 23, 2015|February 14, 2011||No|funding expired|No||https://clinicaltrials.gov/show/NCT01297426||108943|
NCT01298024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/173|A Pilot Study on Exercise After Achilles Tendon Rupture|NEMEX-ATR: A Randomized Pilot Study on Early Neuromuscular Exercise in Non-surgically Treated Achilles Tendon Rupture|NEMEX-ATR|Region Skane|Yes|Completed|March 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|No|||August 2012|April 5, 2013|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01298024||108898|
NCT01329016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|820|Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)|Glyburide and Metformin for Gestational Diabetes Mellitus|GDM|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Active, not recruiting|July 2011|June 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|360|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01329016||106541|
NCT01329497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phosphorus|The Effect of Systemic Dietary Instruction on Management of Plasma Phosphorus Levels in Peritoneal Dialysis (PD) Patients|||Shanghai Jiao Tong University School of Medicine|No|Recruiting|January 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||November 2010|April 15, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329497||106504|
NCT01329510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/05|Sleep and Nocturnal Melatonin in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|The Effects of Methylphenidate on Sleep Patterns in Adults With ADHD: An Open Label Polysomnographic Study|ADHD|Assaf-Harofeh Medical Center|No|Completed|August 2005|May 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|18 Years|60 Years|No|||August 2005|April 5, 2011|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01329510||106503|
NCT01330641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816140|Accuracy of Needle Placement Into The Subacromial Space of The Shoulder|Accuracy of Needle Placement Into The Subacromial Space of The Shoulder||University of California, Davis|Yes|Completed|September 2008|March 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||April 2011|April 6, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330641||106419|
NCT01330654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010030|Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers|Using Heart Rate Variability to Analyze the Effect of Beta Blockers on Intermediate Risk Patients Undergoing Laparoscopic Surgical Procedures||University of California, San Francisco|Yes|Withdrawn|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|0|||Both|40 Years|75 Years|No|||June 2012|June 25, 2012|April 5, 2011|Yes|Yes|no patients were enrolled. Study was closed prior to study start.|No||https://clinicaltrials.gov/show/NCT01330654||106418|
NCT01330927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-008|Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)|A Randomised, Double-blind, Placebo-controlled, Five-way Cross-over Dose Response Study to Determine the Effect of VA106483 on Nocturnal Urine Volume in Elderly Male Subjects With Nocturia and Benign Prostatic Hypertrophy (BPH)||Vantia Ltd|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|30|||Male|65 Years|N/A|No|||August 2011|August 1, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01330927||106398|
NCT01331551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01ES17285-2|Mesalamine and Reproductive Health Study|Crossover Study on Human Exposure to Phthalates and Male Fertility|MARS|Harvard School of Public Health|No|Recruiting|May 2010|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|Blood for hormones, urine for phthalates, semen for DNA and RNA|Male|18 Years|55 Years|No|Non-Probability Sample|Men between the ages of 18-55 who have inflammatory bowel disease.|March 2016|March 8, 2016|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331551||106350|
NCT01331798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-100-0002|Evaluation of Cohera TissuGlu in the Management of Wound Drainage Following Abdominoplasty|Clinical Evaluation of the Cohera TissuGlu Device in the Management of Wound Drainage Following Abdominoplasty||Cohera Medical, Inc.|Yes|Completed|December 2009|May 2010|Actual|May 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 7, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331798||106331|
NCT01327560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100003|Sleep Quality and Related Factors in Hemodialysis Patients|Sleep Quality and Related Factors in Hemodialysis Patients||Taipei Medical University WanFang Hospital|No|Enrolling by invitation|February 2011|December 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|20 Years|N/A|No|Non-Probability Sample|Hemodialysis Patients|March 2011|March 31, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327560||106649|
NCT01327885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-309|Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma|A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma||Eisai Inc.|Yes|Active, not recruiting|March 2011|February 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|452|||Both|18 Years|N/A|No|||December 2015|January 26, 2016|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327885||106625|
NCT01327898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA024579|Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM)|||Nova Southeastern University|Yes|Completed|November 2008|July 2014|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|515|||Male|18 Years|55 Years|No|||July 2014|July 24, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327898||106624|
NCT01328262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/476|A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching|A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching||Haukeland University Hospital|No|Suspended|November 2010|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|16 Years|N/A|No|||May 2012|March 27, 2015|February 24, 2011||No|Few patients, time consuming to find suiting blood bags with the "right" weight.|No||https://clinicaltrials.gov/show/NCT01328262||106596|
NCT01328561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110104|Oxytocin and Arginine Vasopressin in Pain Relief|The Role of Oxytocin and Arginine Vasopressin in Human Placebo Analgesia||National Institutes of Health Clinical Center (CC)||Terminated|March 2011|March 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|167|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|April 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01328561||106575|
NCT01328574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110130|TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma|A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma||National Institutes of Health Clinical Center (CC)|No|Completed|March 2011|November 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|April 1, 2011|Yes|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT01328574||106574|
NCT01329952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-NMGH|Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment|Reinfection Rates and Long Term Outcomes in Currently Injecting Drug Users Following Successful Treatment for Hepatitis C||Pennine Acute Hospitals NHS Trust|No|Not yet recruiting|May 2011|June 2014|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|90|Samples Without DNA|Blood will be taken for Hepatitis C RNA, plus Hepatitis C genotype if positive. Blood will      also be taken for liver function tests and a full blood count.|Both|18 Years|N/A|No|Non-Probability Sample|This will focus specifically on long term outcomes for patients who are current and past        injecting drug users at the time of their treatment. Injecting drug users who have already        completed therapy and achieved SVR will be asked to return for assessment. During this        study, the investigators will also enquire about any drug use prior to, during and after        completing therapy. The investigators will compare this group with past injectors, (last        injected at least 6 months prior to starting treatment) a group that most centres would        consider appropriate for treatment).|March 2011|April 5, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329952||106469|
NCT01330524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8749|Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo|Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy||hahid Beheshti University of Medical Sciences||Recruiting|January 2010|November 2011|Anticipated|November 2010|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|N/A|N/A|No|||November 2009|April 5, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01330524||106428|
NCT01329744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23DK080644-01A1|Effects of IGF-I in HIV Metabolic Disease|Effects of Recombinant IGF-I in HIV Associated Metabolic Disease||University of Texas Southwestern Medical Center|Yes|Terminated|June 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|60 Years|No|||March 2016|March 22, 2016|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01329744||106485|
NCT01297439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091109|New Prophylactic Maneuver: the "Pushing" Maneuver, Aiming to Reduce the Risk for Shoulder Dystocia|CONTRADYS : A Randomized Controlled Trial of a New Prophylactic Maneuver, the "Pushing" Maneuver, Aiming to Reduce the Risk for Shoulder Dystocia|CONTRADYS|Assistance Publique - Hôpitaux de Paris|No|Terminated|March 2011|March 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1538|||Female|18 Years|45 Years|No|||April 2015|April 29, 2015|February 9, 2011||No|the study stopped due to the lack of inclusion.|No||https://clinicaltrials.gov/show/NCT01297439||108942|
NCT01297452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-192|BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors|A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|February 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01297452||108941|
NCT01297465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200061-504|PERgoveriS In Stratified Treatment for Assisted Reproductive Technique|A Phase IIIB, Multicentre, Multinational, Randomized, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® Day 1 to Day 5 Followed by Pergoveris® Starting Day 6 to Pergoveris® Starting Day 1 in Women Between 36 and 40 Years of Age Undergoing Assisted Reproductive Technique (ART)|PERSIST|Merck KGaA||Completed|May 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Female|36 Years|40 Years|No|||January 2014|January 10, 2014|February 15, 2011||No||No|October 23, 2013|https://clinicaltrials.gov/show/NCT01297465||108940|
NCT01297764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002074 - QUAD RV-0549|A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|QUAD|Hackensack University Medical Center|Yes|Recruiting|April 2011|August 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01297764||108918|
NCT01297491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120D2201|Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer|An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway|BASALT-1|Novartis|No|Completed|May 2011|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 11, 2011|No|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01297491||108939|
NCT01329783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001104|EuroSIDA As An External Comparator To MOTIVATE Trials|Incidence And Risk Factors For Acquired Immune Deficiency Syndrome (AIDS) Defining And Non-AIDS Defining Malignancies, And Other AIDS Defining Illnesses In The EuroSIDA Study||ViiV Healthcare|No|Completed|April 2007|March 2011|Actual|March 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1181|||Both|16 Years|N/A|No|Non-Probability Sample|-  Patient aged over 16 at baseline.          -  Viral Load (VL) > 5000 copies/ml at baseline (and measured in 6 months prior to             baseline).          -  No changes in antiretroviral (ARV) regimens in the month period prior to baseline, or             on no ARVs in the month prior to baseline.          -  > 3 months exposure (sequential or cumulative) to at least 3 of the following;          -  Any nucleoside or nucleotide reverse transcriptase inhibitor (NRTI)          -  Non-nucleoside reverse transcriptase inhibitor (NNNRTI)          -  Protease Inhibitor (PI )          -  Enfuvirtide|May 2011|May 13, 2011|March 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01329783||106482|
NCT01329770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017837-23|Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome|Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome|SXF-TRA152|The Mediterranean Institute for the Advance of Biotechnology and Health Research|Yes|Completed|December 2010|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|6 Years|18 Years|No|||April 2015|April 13, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01329770||106483|
NCT01330082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09123209916|Adjunctive Photodynamic Therapy in the Treatment of Chronic Periodontitis|Efficacy of Adjunctive Photodynamic Therapy Using Light-emitting Diode in the Treatment of Chronic Periodontitis||Tehran University of Medical Sciences|Yes|Active, not recruiting|April 2010|May 2011|Anticipated|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|N/A|No|||April 2011|April 5, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330082||106460|
NCT01330095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1016|Early Administration of Bifidobacterium to Very Low Birth Weight Infants|Early Administration of Bifidobacterium Bifidum to Very Low Birth Weight Infants: A Pilot Study||Tokyo Women's Medical University|No|Completed|March 2007|December 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Both|N/A|7 Days|No|||December 2008|April 5, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01330095||106459|
NCT01330368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007747|Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children|Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children||Children's Hospital of Philadelphia|No|Active, not recruiting|October 2010|June 2016|Anticipated|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|32|Samples Without DNA|urine|Both|5 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|200 control patients (124 controls participated in unique protocol ID: 2007-10-5528 data        will be used for this study, we will be trying to recruit about 76 control patients for        this study) and 30 study patients with SLE|February 2016|February 29, 2016|December 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01330368||106440|
NCT01330407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01247-50|Comparative Assessment of Adjuvant Effect of Cultured Epidermal Autografts Versus Skin Allografts on Wound Healing of Burns Treated With Widely Expanded Skin Autograft Using Meek Micrografting Technique MEEKADEAU|Comparative Assessment of Adjuvant Effect of Cultured Epidermal Autografts Versus Skin Allografts on Wound Healing of Burns Treated With Widely Expanded Skin Autograft Using Meek Micrografting Technique MEEKADEAU|MEEKADEAU|Assistance Publique Hopitaux De Marseille|Yes|Recruiting|April 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|60 Years|No|||November 2015|November 18, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330407||106437|
NCT01330667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELF for Hyperbilirubinemia|Effect of Early Limited Formula on Total Serum Bilirubin Among Newborns With Hyperbilirubinemia|Effect of Early Limited Formula on Total Serum Bilirubin Among Newborns With Hyperbilirubinemia||University of California, San Francisco|No|Not yet recruiting|July 2015|June 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|N/A|96 Hours|Accepts Healthy Volunteers|||December 2014|December 15, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01330667||106417|
NCT01330979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-12286-CS204|24-hour Efficacy of AR-12286|A Phase 2 Open Label Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Open-angle Glaucoma or Ocular Hypertension||Aerie Pharmaceuticals|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|40 Years|80 Years|No|||March 2014|March 25, 2014|April 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330979||106394|
NCT01330940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100|Effect of Diet Orange Soda on Urinary Lithogenicity|Effect of Diet Orange Soda on Urinary Lithogenicity||VA New York Harbor Healthcare System|No|Completed|November 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330940||106397|
NCT01330953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14151|A First Human Study of a Ferroportin Antibody|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Healthy Subjects||Eli Lilly and Company|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Anticipated|48|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 26, 2011|March 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01330953||106396|
NCT01330966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAPSMCS1002|Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma|A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma||Vector Oncology|No|Active, not recruiting|April 2011|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|April 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330966||106395|
NCT01331226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001796|Support Person Intervention to Promote a Smoking Helpline|Support Person Effectiveness Study to Promote Smoker Utilization of the QUITPLAN Helpline|ClearWay #4|Mayo Clinic|No|Completed|July 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1020|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331226||106375|
NCT01331239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCI699C2201|Safety and Efficacy of LCI699 in Cushing's Disease Patients.|A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease||Novartis|No|Active, not recruiting|March 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|75 Years|No|||November 2015|November 20, 2015|April 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01331239||106374|
NCT01331564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL096760|eMOMS of Rochester|Electronically-Mediated Weight Interventions for Pregnant and Postpartum Women|eMOMS|University of Rochester|Yes|Completed|May 2011|December 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1641|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01331564||106349|
NCT01327586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA12952 from VACHS account|Abstinence-Linked Money Management Multisite|Abstinence-Linked Money Management Multisite||Yale University|Yes|Completed|December 2009|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01327586||106647|
NCT01327599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-272|Efficacy of Changing to DUOTRAV® From Prior Therapy|Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed)||Alcon Research|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|March 30, 2011|No|Yes||No|November 22, 2013|https://clinicaltrials.gov/show/NCT01327599||106646|
NCT01327612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101116|Open Label Extension Study of Conatumumab and AMG 479|A Phase 2 Open Label Extension Study of Conatumumab and AMG 479||Amgen|No|Active, not recruiting|March 2011|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327612||106645|
NCT01327573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI-EC-0017|Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation|Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation: A Randomized, Open-Label, Pilot Intervention Trial||Yale University|No|Active, not recruiting|March 2011|February 2015|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||March 2014|March 27, 2014|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01327573||106648|
NCT01327911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTMT-01|Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)|A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)||Neurotech Pharmaceuticals|Yes|Active, not recruiting|May 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|21 Years|N/A|No|||February 2015|February 20, 2015|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327911||106623|
NCT01328587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110134|Eltrombopag for Moderate Aplastic Anemia|A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|March 2011|March 2025|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328587||106573|
NCT01328886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025B1301E1|Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children|An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment||Novartis||Completed|March 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|6 Years|15 Years|No|||August 2014|August 29, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328886||106551|
NCT01329458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepFocUS|Contrast Enhanced Ultrasound For The Evaluation Of Focal Liver Lesions|Contrast Enhanced Ultrasound for the Evaluation of Focal Liver Lesions - a Multi-center Study on the Usefulness in the Clinical Practice|HepFocUS|Societatea Romana de Ultrasonografie in Medicina si Biologie|No|Recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|The patients included in the study will be patients discovered with FLL at standard        ultrasound. The focal lesions will be characterized by CEUS and the diagnosis established        will be compared with the final diagnosis of the patient.        The final diagnosis will be established based on all available imaging and clinical data:        computer tomography, MRI, biopsy, follow up information.|April 2011|April 5, 2011|April 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01329458||106507|
NCT01330342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 042|Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma|Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma|SSAT042|St Stephens Aids Trust|No|Recruiting|May 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|40|||Both|N/A|N/A|No|Probability Sample|HIV seropositive individuals with and without lymphoma.|June 2012|June 8, 2012|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01330342||106442|
NCT01297153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|icircAP|Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery|Aphakia vs Pseudophakia - Randomized Clinical Trial in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery||Iladevi Cataract and IOL Research Center|Yes|Completed|May 2003|May 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|24 Months|No|||June 2011|June 30, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01297153||108964|
NCT01297166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLQ-006|A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris|A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris.||LEO Pharma|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01297166||108963|
NCT01297504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-129|A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America|A One-Year Observational Study of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America||AbbVie|No|Completed|February 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|464|||Both|N/A|2 Years|No|Non-Probability Sample|The study was conducted at primary care clinics in Latin America.|September 2014|September 19, 2014|February 15, 2011||No||No|August 22, 2014|https://clinicaltrials.gov/show/NCT01297504||108938|
NCT01329549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.117|Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)|An Open-label, Dose Escalation Phase I Study of the Safety and Tolerability of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Japanese Patients With a First, Second or Third Platinum-sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer.||Boehringer Ingelheim||Terminated|April 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Female|20 Years|N/A|No|||November 2014|November 26, 2014|April 1, 2011||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01329549||106500|The trial was prematurely terminated because of worldwide disruption of pegylated liposomal doxorubicin (PLD) supplies.
NCT01330108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCOBA-PH|Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension|Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension|SCOBA-PH|University of Alabama at Birmingham|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|19 Years|N/A|No|||June 2014|July 17, 2014|April 4, 2011|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01330108||106458|There is bias in the study due to the fact that subjects have been proven to tolerate the initial drug in the study (bosentan) and adequate time was not allowed for subjects to be able to tolerate ambisentan
NCT01330121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #10-165|Bridging the Gap by Transitional Care|Pharmacist Discharge Counseling: Bridging the Gap by Transitional Care||John H. Stroger Hospital|Yes|Completed|September 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|130|||Both|18 Years|85 Years|No|||April 2011|April 5, 2011|April 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330121||106457|
NCT01330394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPES45397090/09|Transcranial Direct Current Stimulation Over Dorsolateral Prefrontal Cortex in Alcoholism|Alcoholism Treatment by Cognitive Neuromodulation Produced by Repeated Transcranial Direct Current Stimulation Over the Left Dorsolateral Prefrontal Cortex||Federal University of Espirito Santo|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||September 2013|November 26, 2013|April 5, 2011||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01330394||106438|
NCT01330420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P001633|Behavioral Medicine Intervention With Depressed Patients in a Community Health Center Setting|Outcomes and Cost-Effectiveness of a Behavioral Medicine Intervention With Depressed Patients in a Community Health Center Setting||Massachusetts General Hospital|No|Completed|September 2007|August 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|28|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 31, 2013|March 11, 2011||No||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01330420||106436|4/28 didn't complete both pre/post assessments & thus didn't contribute data for this study & were excluded. It's possible that the 24 completers had a higher degree of motivation & commitment, which enhanced the effectiveness of the intervention.
NCT01330992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-RC2-HL101340|Human Circadian Sensitivity to Very Short Light Pulses|Human Circadian Sensitivity to Very Short Light Pulses||Brigham and Women's Hospital|No|Completed|December 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|400|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2011|August 19, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01330992||106393|
NCT01331005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCR.net Protocol R|NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)|A Phase II Evaluation of Topical Non-steroidal Anti-inflammatories in Eyes With Non Central Involved Diabetic Macular Edema||Diabetic Retinopathy Clinical Research Network|Yes|Completed|May 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||December 2014|January 9, 2015|April 6, 2011|Yes|Yes||No|December 30, 2014|https://clinicaltrials.gov/show/NCT01331005||106392|
NCT01331018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2097.00|Gene Therapy for Fanconi Anemia|Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)||Fred Hutchinson Cancer Research Center|Yes|Recruiting|February 2012|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|4 Years|N/A|No|||February 2016|February 16, 2016|March 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01331018||106391|
NCT01331252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP|Pneumonia in Tetanus Study|Can the Incidence of Nosocomial Pneumonia in Severe Tetanus be Reduced by Nursing Patients Semi-recumbent? A Randomised Comparison of Supine or Semi-recumbent Body Position|BP|Oxford University Clinical Research Unit, Vietnam|No|Completed|August 2000|March 2002|Actual|March 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|200|||Both|1 Year|90 Years|No|||September 2011|September 14, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331252||106373|
NCT01331811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS12229 PAANTHER 01|Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)|Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam) and Africa (Burkina Faso, Cameroon) ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research)||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|April 2011|May 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|441|||Both|N/A|13 Years|No|||August 2015|August 4, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331811||106330|
NCT01327963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D01079|Retrospective Transoral Incisionless Fundoplication (TIF) Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study|Long-term Outcomes After Transoral Incisionless Fundoplication (TIF) Performed in Routine Clinical Practice: The Retro TIF Study|RetroTIF|EndoGastric Solutions|No|Terminated|September 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|85 Years|No|||February 2014|August 31, 2015|March 30, 2011|Yes|Yes|The sponsor is focusing on prospective randomized studies|No||https://clinicaltrials.gov/show/NCT01327963||106619|
NCT01327924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3870|Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone|Ease of Use and Tolerability of Norditropin NordiFlex® in Growth Hormone naïve Children: Impact on Daily Life||Novo Nordisk A/S|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|77|||Both|N/A|16 Years|No|Non-Probability Sample|Growth hormone treatment naïve children for whom a prescription of Norditropin NordiFlex®        is initiated according to the SPC (Summary of Product Characteristics)|June 2014|June 23, 2014|March 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01327924||106622|
NCT01327937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-MOA-002-AG|A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers|A Prospective, Randomized, Controlled, Single-Site Post Marketing Study to Identify & Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers||Organogenesis|No|Completed|March 2011|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327937||106621|
NCT01327950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC SFA Brazil - ISROTH10003|Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions|EPIC SFA - Physician Initiated Trial Investigating the Efficacy of the EPICTM Nitinol Vascular Stent System (Boston Scientific) in Superficial Femoral Lesions: A Prospective, Multi-center Non- Randomized Study - Endoconsul 003|EPIC SFA BR|Endovascular Consultoria Limitada|Yes|Completed|October 2010|November 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions|January 2014|January 29, 2014|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01327950||106620|
NCT01328275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 153|Progress Adult Study|The Thai HIV Disease Progression: An Observational Database||The HIV Netherlands Australia Thailand Research Collaboration|No|Active, not recruiting|December 2007|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5600|Samples With DNA|serum|Both|18 Years|N/A|No|Probability Sample|HIV-infected patients currently receiving ART at Bamrasnaradura Institute, Sanpatong        Hospital or HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok.|March 2015|March 27, 2015|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01328275||106595|
NCT01328288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 154|Progress Pediatric Study|The Thai Pediatric HIV Disease Progression: An Observational Database||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|January 2009|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|840|Samples With DNA|serum|Both|N/A|18 Years|No|Probability Sample|long-term follow-up of HIV-infected children from: 1. Bamrasnaradura infectious disease        institute, 2. Faculty of Medicine Siriraj Hospital, Mahidol University, 3. Chiangrai        Prachanukroh Hospital, Chiang Rai, 4. Sanpatong Hospital, Chiang Mai, and 5. HIV-NAT, Thai        Red Cross AIDS Research Center, Bangkok|February 2016|February 19, 2016|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01328288||106594|
NCT01329172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_47/0928|Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients|Impact of Polyunsaturated Fatty Acids n-3 on Nasal Mucins Expression in Cystic Fibrosis Patients|NOSTRIL|University Hospital, Lille|No|Recruiting|September 2010|May 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|30 Years|No|||December 2015|December 3, 2015|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01329172||106529|
NCT01330043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09272010-6949|Extended Treatment for Smoking Cessation|Extended Treatment for Smoking Cessation||Stanford University|No|Active, not recruiting|March 2010|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|October 7, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01330043||106462|
NCT01322087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-125|Does the Access to Small Delicious Dishes, Have a Positive Effect on Nutritional Intake in Patients at Nutritional Risk?|Does the Access to Small Delicious Dishes, 24 Hours a Day, Have a Positive Effect on Nutritional Intake in Patients at Nutritional Risk?|SGG|Copenhagen University Hospital at Herlev|Yes|Completed|January 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01322087||107068|
NCT01322347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMTI-SFP-5|Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)|A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study||Rockwell Medical Technologies, Inc.|Yes|Completed|April 2011|February 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|294|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|March 22, 2011|Yes|Yes||No|March 20, 2015|https://clinicaltrials.gov/show/NCT01322347||107048|
NCT01329250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFX468|Pharmacokinetics and Safety of Moxifloxacin|Pharmacokinetics and Safety of Moxifloxacin; a Dose Escalation in Patients With Tuberculosis|MFX468|University Medical Center Groningen|Yes|Terminated|May 2011|August 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|March 8, 2011||No|slow enrolment of patients and new insights|No||https://clinicaltrials.gov/show/NCT01329250||106523|
NCT01329523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHBG-1370-IGF|A Study to Compare Genetic Variations of IGF-I and IGF-II|A Non-Randomized Controlled Cross-Sectional Study to Compare Genetic Variations of IGF-I and IGF-II in Patients With Moderate to Severe Dementia and Younger Family Members, in Relation to Age-Matched Unaffected Controls||Avera McKennan Hospital & University Health Center|Yes|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|50|Samples With DNA|saliva and blood|Both|50 Years|81 Years|Accepts Healthy Volunteers|Non-Probability Sample|There are three groups of participants for this research study: one group will consist of        individuals diagnosed with dementia; another group will consist of younger biological        family members of the patients with dementia; and the third group will consist of        individuals without dementia who are matched in age to the patients with dementia.|January 2011|October 4, 2011|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01329523||106502|
NCT01329562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114680|CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet|Evaluation of CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Saliva of Menstrual Migraine Patients Before and After Treatment With Treximet™||Cady, Roger, M.D.|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Female|18 Years|45 Years|No|||March 2014|March 11, 2014|March 17, 2011|Yes|Yes||No|October 8, 2013|https://clinicaltrials.gov/show/NCT01329562||106499|
NCT01329575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 11.005|Predicting Malignancy Using Endoluminal Ultrasound Characteristics in Mediastinal Lymph Nodes|Predicting Malignancy Using Endoluminal Ultrasound Characteristics in Mediastinal Lymph Nodes|CT0024|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2011|July 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|February 2016|February 26, 2016|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329575||106498|
NCT01329796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISI-06-01|Pertubation With Lignocaine in Endometriosis|Pertubation With Lignocaine in Endometriosis Associated Symptoms Effect Study|PLEASE|Isifer AB|Yes|Completed|March 2007|March 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|21 Years|N/A|No|||April 2011|April 5, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329796||106481|
NCT01330134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-621A|Comparison of Two Lidocaine Administration Techniques|Comparison of Two Lidocaine Administration Techniques||University of Chicago|No|Completed|February 2011|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|490|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330134||106456|
NCT01330680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C041003|Genetic Determinants of Cardiovascular Response to Coffee Drinking|Genetic Determinants of Cardiovascular Response to Coffee Drinking||G. d'Annunzio University|Yes|Completed|September 2004|September 2010|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|110|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2011|April 6, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01330680||106416|
NCT01330693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH081854-01A2|Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy|Cortical Excitability: Phenotype and Biomarker in ADHD Therapy||University of Cincinnati|Yes|Active, not recruiting|September 2009|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|7 Years|12 Years|No|||August 2015|August 17, 2015|April 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330693||106415|
NCT01330706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCM 2011|Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery|Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery|ribebeva|Universidad Complutense de Madrid|Yes|Completed|February 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|80 Years|No|||February 2009|April 6, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01330706||106414|
NCT01331278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0509-0060|A Comparative Study of Knee Systems|A Comparative Study of Knee Systems Employing Personalized Computer Generated Cutting Guides for Total Knee Arthroplasty|Bake-Off|Foundation for Southwest Orthopedic Research|Yes|Completed|September 2009|March 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2011|April 7, 2011|April 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01331278||106371|
NCT01331577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKSIT_2011|Comparison of the Efficacy of an Integrative-kinesiological to a Cognitive-behavioural Intervention|Psychoneuroendocrinological Efficacy Study of an Integrative-kinesiological to a Cognitive-behavioural Intervention With Healthy Individuals|IKSIT|University of Zurich||Completed|December 2013|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|November 4, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331577||106348|
NCT01327625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ALLO-041|Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans|A Pilot Study Evaluating the Efficacy of Azithromycin, N-acetylcystein and Inhaled Corticosteroid Combination Therapy for Bronchiolitis Obliterans After Allogeneic Hematopoietic Cell Transpantation||Asan Medical Center|No|Terminated|March 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|15 Years|75 Years|No|||July 2014|July 8, 2014|March 31, 2011||No|Preliminary reports of this study was too bad.|No||https://clinicaltrials.gov/show/NCT01327625||106644|
NCT01331070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100136|Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging|Central Control of Breathing in Patients With Chronic Obstructive Pulmonary Disease: Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging|CHAOSBOLD|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2011|March 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 13, 2013|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01331070||106387|
NCT01328301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mak0001|Effect of Speed-dependent Treadmill Training in Patients With Subacute Stroke|Speed-dependent Treadmill Training is Effective to Improve Gait and Balance Performance in Patients With Sub-acute Stroke||The Hong Kong Polytechnic University|Yes|Completed|December 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||March 2015|March 18, 2015|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328301||106593|
NCT01328600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906259|Marinobufagenin as a Target for DIGIBIND in Preeclampsia|Marinobufagenin as a Target for DIGIBIND in Preeclampsia||National Institutes of Health Clinical Center (CC)||Completed|August 2006|July 2014||||N/A|Observational|N/A|||Anticipated|170|||Female|18 Years|50 Years|No|||July 2014|October 23, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328600||106572|
NCT01329692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025927|Early Intervention for Morbidly Obese Patients After Roux-en-Y Gastric Bypass (RYGB) Surgery|Early Intervention in Patients With Predicted Poor Long-term Outcome Following Laparoscopic Roux-en-Y Gastric Bypass: a Prospective Randomized Study|Back on Track|Duke University|No|Terminated|December 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|8|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|April 4, 2011||No|The PI has left Duke-the primary study site and the sponsor retreat the support|No||https://clinicaltrials.gov/show/NCT01329692||106489|
NCT01321814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-LJ-HYP1|Cognitive Behavioral Therapy for Hyperacusis|||Linkoeping University|No|Completed|June 2004|December 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|No|||May 2014|May 24, 2014|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01321814||107089|
NCT01322100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJ 1020|Electrochemotherapy as a Palliative Treatment for Brain Metastases|Electrochemotherapy as a Palliative Treatment for Brain Metastases||Copenhagen University Hospital at Herlev|Yes|Terminated|April 2011|July 2013|Actual|July 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|March 23, 2011||No|Due to slow patient recruitment|No||https://clinicaltrials.gov/show/NCT01322100||107067|
NCT01329263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812369|Smoking Topography and Harm Exposure in Menthol Cigarettes|Smoking Topography and Harm Exposure in Menthol Cigarettes|MQAT|University of Pennsylvania|Yes|Completed|September 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|87|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|April 1, 2011||No||No|January 24, 2013|https://clinicaltrials.gov/show/NCT01329263||106522|Attrition rate over 35 day protocol of brand switching cigarette.
NCT01329536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHBG-1380-Agitation|The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease|The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease Compared to Age- and Gender-Matched, Non-Agitated In-Patients With Late-Onset Alzheimer's Disease||Avera McKennan Hospital & University Health Center|Yes|Completed|December 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples With DNA|saliva and blood|Both|65 Years|N/A|No|Non-Probability Sample|Patients with a diagnosis of probable Alzheimer's Disease (late-onset)|February 2011|October 4, 2011|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01329536||106501|
NCT01329276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_0905_/_ISSSYMB0020|Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.|A Randomized, Double-blind, Placebo-controlled, Two Way Cross-over Study to Assess the Particle Deposition and Acute Effects of Formoterol and Budesonide Combination Therapy (Symbicort® Forte Turbohaler®) on the Upper Airway Dimensions in COPD Patients.||University Hospital, Antwerp|Yes|Completed|June 2010|January 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|40 Years|N/A|No|||March 2011|April 1, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01329276||106521|
NCT01329848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15EY021021|Accommodation Disorders|Using Accommodative Lag to Diagnose Accommodation Disorders|AD|Western University of Health Sciences|No|Completed|December 2010|August 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|83|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Graduate students from Western University of Health Sciences|December 2014|December 23, 2014|April 4, 2011||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01329848||106477|
NCT01329809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-HEP012|Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors|A Phase IIa Study of Neoadjuvant JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion or Intratumoral Injection Followed by Surgical Resection in Patients With Metastatic Colorectal Tumors Within the Liver||Jennerex Biotherapeutics|Yes|Terminated|October 2011|March 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||July 2011|April 9, 2013|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01329809||106480|
NCT01329822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-201104|Effects of Caloric Restriction on Fetuin-A and Cardiovascular Risk Factors|The Effects of Caloric Restriction on Fetuin-A and Cardiovascular Risk Factors in Rats and Humans: A Randomized Controlled Trial||Korea University|Yes|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||April 2011|April 5, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329822||106479|
NCT01329835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWG32011|Effect of Psycho-education on Gestational Weight Gain and Anxiety/Depression in Obese Pregnant Women|Effect of Psycho-education on Gestational Weight Gain and Anxiety/Depression in Obese Pregnant Women||Limburg Catholic University College|No|Recruiting|March 2008|December 2013|Anticipated|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|180|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||July 2008|December 5, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01329835||106478|
NCT01330147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG12-208|HPV Prevalence in the Mouth and Oropharynx of the Tonsillectomy Population|HPV Prevalence in the Mouth and Oropharynx of the Tonsillectomy Population|Oromouth|University of Birmingham|No|Recruiting|March 2013|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|925|Samples With DNA|Oral rinse, Oral Mucosal Trasudate, Urine, Whole Blood, Nail brushings, Mouth brush biopsies      (scrapes) and Tonsillectomy specimens|Both|N/A|65 Years|No|Non-Probability Sample|Patients undergoing a tonsillectomy operation for non-cancerous reasons at the hospital        will be recruited for this study.|July 2015|July 9, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01330147||106455|
NCT01330459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU FAMPLAN 6734|Hydrocodone For Pain Control in First Trimester Surgical Abortion|An Evaluation of Hydrocodone/Acetaminophen for Pain Control in First Trimester Surgical Abortion||Oregon Health and Science University|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|122|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 20, 2012|April 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330459||106433|
NCT01331031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013/2008|Parafunctional Habits and Temporomandibular Disorder in Adolescents|Association Between Parafunctional Habits and Signs and Symptoms Temporomandibular Disorder in Adolescents||University of Nove de Julho|Yes|Completed|February 2008|January 2011|Actual|May 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|244|||Both|10 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|244 adolescents between 10 and 20 years of age and enrolled in a municipal school system.|October 2010|April 6, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331031||106390|
NCT01331265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22651|Perceived Lactose Intolerance|Understanding Perceived Lactose Intolerance in White, Black, and Hispanic Adults||Baylor College of Medicine|No|Completed|January 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|3815|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|white, black, and Hispanic adults; 18-50 years of age|April 2009|April 7, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331265||106372|
NCT01331590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104323|Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia|A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia||Washington University School of Medicine|No|Active, not recruiting|July 2011|August 2016|Anticipated|October 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01331590||106347|
NCT01331824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1341|Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma|Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma||Icahn School of Medicine at Mount Sinai|Yes|Terminated|February 2011|July 2015|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||November 2015|November 21, 2015|April 6, 2011|Yes|Yes|due to a development decision by the funder|No|October 15, 2015|https://clinicaltrials.gov/show/NCT01331824||106329|The trial was terminated prematurely due to the results of a phase 3 study seeking registration for amrubicin in small cell lung cancer in the United States, leading the industry funder to discontinue further clinical development of amrubicin.
NCT01330264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016075|Study of Intracranial Pressure (ICP) Monitoring in Critically Ill|Study of ICP Monitoring in Critically Ill|SIM City|Duke University|No|Completed|July 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the ICU that are receiving Intracranial Pressure (ICP) monitoring.|December 2012|December 10, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330264||106448|
NCT01330784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-GON-2004-02|Assessment of the Therapeutic Utility of hMG-HP|Assessment of the Therapeutic Utility of hMG-HP Within a Protocol of Controlled Ovarian Hyperstimulation in IVF in Normoresponders Women Undergoing Downregulation With GnRH Antagonist||Ferring Pharmaceuticals|No|Completed|October 2006|September 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Female|18 Years|38 Years|No|Non-Probability Sample|Females affected by sterility able to undergo IVF|April 2011|April 6, 2011|April 6, 2011||||No||https://clinicaltrials.gov/show/NCT01330784||106408|
NCT01331616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-5148|Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab|A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab||West Penn Allegheny Health System|Yes|Recruiting|March 2011|July 2012|Anticipated|March 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||April 2011|April 21, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01331616||106345|
NCT01331629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-THERAPIE|Impact of Art Therapy on Fatigue and Quality of Life of Patients Treated With Adjuvant Radiotherapy for Breast Cancer|Impact of Art Therapy on Fatigue and Quality of Life of Patients Treated With Adjuvant Radiotherapy for Breast Cancer|ART-THERAPIE|Centre Francois Baclesse|No|Recruiting|July 2010|December 2015|Anticipated|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|320|||Female|18 Years|N/A|No|||February 2012|May 5, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331629||106344|
NCT01331850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV21913|A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C|A Randomized Open-label Study to Evaluate the Sustained Virologic Response of Danoprevir/Ritonavir and Copegus in Combination With RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed Previous Standard Therapy||Hoffmann-La Roche||Completed|May 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|381|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01331850||106327|
NCT01328366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-627|Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab|A Real World Observational Study to Evaluate the Impact of Adalimumab Therapy on Quality of Life and Psychological Factors Associated With Severe Psoriasis|Body Image|AbbVie|No|Completed|May 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|153|||Both|18 Years|N/A|No|Non-Probability Sample|Secondary Care Outpatients|June 2015|June 11, 2015|April 1, 2011||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01328366||106590|
NCT01331642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG05/2011|Biomarker for Gaucher Disease|Biomarker for Gaucher Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioGaucher|University of Rostock|Yes|Recruiting|April 2011|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 5ml EDTA      blood and a dry blood spot filter card are taken. To proof the correct Gaucher diagnosis in      those patients where up to the enrollment in the study no genetic testing has been done,      sequencing of Gaucher will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|N/A|N/A|No|Probability Sample|Patients with Gaucher Disease based on biochemical and/or genetic criteria or high-grade        suspicion for Gaucher disease.|October 2015|October 6, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331642||106343|
NCT01321827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGCST|Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis||MIPA|Postgraduate Institute of Medical Education and Research|Yes|Active, not recruiting|April 2011|December 2015|Anticipated|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Years|70 Years|No|||October 2015|October 20, 2015|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01321827||107088|
NCT01322386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4751|Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin|The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin.|PSC|Stanford University|Yes|Completed|May 2007|January 2012|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|1 Month|20 Years|No|||February 2016|February 5, 2016|February 10, 2011|Yes|Yes||No|May 22, 2015|https://clinicaltrials.gov/show/NCT01322386||107045|
NCT01322399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000014; SRH|Structural Integration for Chronic Low Back Pain|Structural Integration for Chronic Low Back Pain||Spaulding Rehabilitation Hospital|Yes|Completed|December 2010|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||December 2013|December 9, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322399||107044|
NCT01329055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-119|Events Before Death|International Comparison of Evolution of Clinical and Laboratory Parameters in Chronic Hemodialysis Patients||Renal Research Institute|Yes|Completed|January 2000|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50000|||Both|18 Years|88 Years|No|Non-Probability Sample|Hemodialysis patients|April 2011|April 4, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329055||106538|
NCT01329068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201006|Patient Empowerment by Group Medical Consultations|Patient Empowerment by Group Medical Consultations in the Follow-up of Breast Cancer Survivors and Surveillance of Women With a BRCA Mutation|GMC|Radboud University|No|Recruiting|April 2011|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|320|||Female|18 Years|N/A|No|||October 2011|January 19, 2012|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01329068||106537|
NCT01329289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-078|SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma|Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma||University of Pittsburgh|Yes|Withdrawn|December 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 29, 2011|Yes|Yes|Clinical trial being transferred to Columbia University with the Investigator.|No||https://clinicaltrials.gov/show/NCT01329289||106520|
NCT01329601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Int_HRO_1|Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI|Effect of the Stage Specific Cognitive Intervention Program on Functional Cortical Activation in Alzheimer's Disease|ECIF|University of Rostock|No|Recruiting|January 2011|December 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|55 Years|N/A|No|||January 2011|April 5, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01329601||106496|
NCT01329861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smarta2011|Internet-based Cognitive Behavioural Treatment for Chronic Back Pain|Guided Internet-based Cognitive Behavioural Treatment for Chronic Back Pain Reduces Catastrophizing:a Randomized Controlled Trial||Linkoeping University|No|Completed|June 2004|August 2005|Actual|May 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||April 2011|April 5, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329861||106476|
NCT01330160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_42/0907|Study of Factors Influencing Post-stroke Dementia|Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of Dementia or Cognitive Disorders After Stroke|strokdem|University Hospital, Lille|No|Recruiting|February 2010|December 2020|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|Samples With DNA|standard biological parameters (ionogram, blood count, glycemia, lipids, renal function,      vitamin B12, thyroid hormones, homocysteinemia), specialized biology (inflammation,      oxidative, vascular biomarkers ; amyloid and tau markers), genotype (apolipoprotein E,      apolipoprotein C, kinesin, Angiotensin Converting Enzyme...).|Both|40 Years|95 Years|No|Non-Probability Sample|Patients without dementia displaying an hemispheric ischemic or hemorrhagic stroke        hospitalized during the 72h following the beginning of stroke|December 2015|December 1, 2015|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01330160||106454|
NCT01330433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110074|Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery|Effects of CoSeal in Reducing Perioperative Bleeding & Adhesions in Pediatric Heart Surgery||Loma Linda University|No|Completed|August 2011|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|17 Years|No|||March 2016|March 23, 2016|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330433||106435|
NCT01330446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0557|Single Agent Armodafinil for Patient-Reported Fatigue|Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study||M.D. Anderson Cancer Center|Yes|Active, not recruiting|May 2011|||May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330446||106434|
NCT01330719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB2001400349|Mechanisms and Treatment Response of Aggressive Periodontitis in Children|Mechanisms and Treatment Response of Aggressive Periodontitis in Children: Aberrant Immunological Phenotypes/Functions in the Progression of AgP||University of Florida|No|Recruiting|December 2006|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|960|||Both|5 Years|90 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330719||106413|
NCT01330732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/08|Kyphosis Evaluation Using SPINESCAN®|The Correlation Between Radiological Evaluation of Kyphosis and Evaluation Using SPINESCAN®||Assaf-Harofeh Medical Center|No|Not yet recruiting|December 2008|November 2009|Anticipated|November 2009|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine        X-rays.        Age: 7 and above.|August 2008|April 6, 2011|March 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01330732||106412|
NCT01331291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-190|Bosutinib in Adult Patients With Recurrent Glioblastoma|An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)||Massachusetts General Hospital|Yes|Completed|April 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|March 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01331291||106370|
NCT01327651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 067 (ADAPT)|The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)|The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)|ADAPT|National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|622|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327651||106642|
NCT01328613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999908320|A Prospective Study of Postpartum Depression in Women With Major Depression|A Prospective Study of Postpartum Depression in Women With Major Depression||National Institutes of Health Clinical Center (CC)||Terminated|November 2007|September 2014||||N/A|Observational|N/A|||Anticipated|120|||Female|18 Years|N/A|No|||September 2014|September 30, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328613||106571|
NCT01328626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-175|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma||AbbVie|No|Active, not recruiting|June 2011|September 2016|Anticipated|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|211|||Both|18 Years|99 Years|No|||January 2016|January 23, 2016|April 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328626||106570|
NCT01329380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-764|Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)|Special Investigation (All Cases Investigation in Patients With Ankylosing Spondylitis)||AbbVie||Active, not recruiting|November 2010|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|16 Years|N/A|No|Non-Probability Sample|All patients who receive Humira for the treatment of Ankylosing Spondylitis|March 2016|March 15, 2016|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01329380||106513|
NCT01329393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH083894|Benefits Management for People With Psychiatric Disabilities|Benefits Management for People With Psychiatric Disabilities||Yale University|No|Completed|August 2010|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01329393||106512|
NCT01331317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011255-44|Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy|The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy||Steno Diabetes Center|Yes|Completed|April 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||April 2012|April 12, 2012|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01331317||106368|
NCT01327664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457C2399|Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis|A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis|SUPPORT|Novartis||Withdrawn|March 2011|||May 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|February 24, 2011|Yes|Yes|Study will not be initiated as planned.|No||https://clinicaltrials.gov/show/NCT01327664||106641|
NCT01328002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-14|Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia|A Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia|MyFi|Forest Laboratories|Yes|Terminated|April 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|13 Years|17 Years|No|||August 2012|August 23, 2012|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328002||106616|
NCT01328015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxybutynin and Hyperhidrosis|A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis|The Use of Oxybutynin in Women After Thoracoscopic Sympathectomy and the Effect on Plantar Hyperhidrosis||Federal University of São Paulo|Yes|Completed|March 2010|June 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|40 Years|No|||November 2010|April 1, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01328015||106615|
NCT01328639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Achord 1101-10|TeamCare PCN: Collaborative Care for Diabetes and Depression|TeamCare PCN: Collaborative Care for Patients With Diabetes and Depression in Primary Care Networks|TeamCare-PCN|The Alliance for Canadian Health Outcomes Research in Diabetes|No|Completed|November 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|157|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01328639||106569|
NCT01328925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM02-3022|Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children|Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children||Romark Laboratories L.C.|No|Completed|December 2005|June 2006|Actual|June 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|5 Years|No|||April 2011|April 1, 2011|March 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328925||106548|
NCT01328938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCPGC P2/3|GCPGC in Chemotherapy-induced Neutropenia|A Randomized,Multi-center,Parallel-group, Phase II(Single-blind)/Phase III(Double- Blind)Study to Determine the Optimal Dose and to Evaluate the Efficacy and Safety of GCPGC on Chemotherapy-induced Neutropenia Compared to Neulasta(Pegfilgrastim)||Green Cross Corporation|No|Completed|October 2010|May 2013|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|177|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01328938||106547|
NCT01296516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10041|Postpartum Weight Loss and Exercise (PRIDE)|Early Postpartum Treatment of Gestational Diabetes With Weight Loss and Exercise|PRIDE|Pennington Biomedical Research Center|No|Recruiting|February 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|50|||Female|18 Years|45 Years|No|||March 2016|March 24, 2016|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296516||109013|
NCT01322113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA/K PUMP-MANIA-HMO-CTIL|Involvement of the Sodium Pump and Endogenous Digitalis-like Compounds in Bipolar Disorder|Involvement of the Sodium Pump and Endogenous Digitalis-like Compounds in Bipolar Disorder|NA\K-MANIA|Hadassah Medical Organization|No|Completed|May 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|30 cc of pperipheral blood will be taken every 4 months to determine circulating DLC levels      in patients|Both|18 Years|80 Years|No|Non-Probability Sample|ALL BIPOLAR PATIENTS IN THE HADASSAH MEDICAL ORGANIZATION PSYCHIATRIC OUTPATIENTS CLINIC|March 2011|September 25, 2013|March 23, 2011||||No||https://clinicaltrials.gov/show/NCT01322113||107066|
NCT01318408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEPPRA|Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia|A Prospective, Phase 4, Open-Label, Twelve-Week Study to Examine the Cognitive Impact and Tolerability of Levetiracetam (Keppra) in Elderly Patients With Seizures of Partial Onset||Drexel University|Yes|Completed|November 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|60 Years|90 Years|No|||June 2015|June 22, 2015|March 16, 2011||No||No|February 17, 2014|https://clinicaltrials.gov/show/NCT01318408||107350|
NCT01329081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL24621|Rehabilitation After Fast-track Total Knee Arthroplasty|Rehabilitation After Fast-track Total Knee Arthroplasty|HOLEST|University of Aarhus|Yes|Recruiting|April 2010|July 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2011|April 4, 2011|April 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01329081||106536|
NCT01329302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00589-30|Benefit of Follicular Flushing During Oocyte Retrieval for Poor Responder Patient in an Assisted Reproductive Technology Program|Follicular Flushing for Poor Responder Patient in an Assisted Reproductive Technology Program: Flush Study||University Hospital, Strasbourg, France|No|Recruiting|March 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|260|||Female|18 Years|43 Years|No|||September 2015|September 29, 2015|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01329302||106519|
NCT01329614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6001|Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving|Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving||New York State Psychiatric Institute|Yes|Completed|October 2009|July 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|40|||Both|21 Years|60 Years|No|||July 2013|July 24, 2013|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01329614||106495|
NCT01329887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 736|The Effect of Ketanserin on the Microcirculation in Sepsis|Evaluation of the Effect of Ketanserine on Sublingual Microcirculation by SDF Imaging in Septic Patients on the Intensive Care||Medical Centre Leeuwarden|No|Completed|March 2011|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329887||106474|
NCT01329874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89549|Anesthetic Efficacy of Gow-Gates Versus Conventional Inferior Alveolar Nerve Block Techniques|Comparison of the Anesthetic Efficacy in Mandibular Molars With Acute Irreversible Pulpitis With Either Conventional Inferior Alveolar or Gow-gates Nerve Block Techniques Plus Buccal or Lingual Infiltration||Mashhad University of Medical Sciences|Yes|Recruiting|March 2011|September 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|80|||Both|12 Years|50 Years|Accepts Healthy Volunteers|||January 2011|April 5, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329874||106475|
NCT01330173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02914|Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma|A Phase 1b Study of GDC-0449 Following Autologous Transplantation in Patients With High Risk First Remission or Relapsed Multiple Myeloma||National Cancer Institute (NCI)||Completed|December 2010|November 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||September 2014|December 19, 2014|April 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01330173||106453|
NCT01331044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09023|Ready to Use Therapeutic Food (RUTF) in Severe Malnourished Children|Efficacy and Acceptability of Ready to Use Therapeutic Food (RUTF) in Children Aged 6-24 Months With Severe Acute Malnutrition in Bangladesh|RUTF|International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|October 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|224|||Both|6 Months|24 Months|Accepts Healthy Volunteers|||June 2015|July 26, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331044||106389|
NCT01328340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1043138|High-speed Power Training in Older Adults With Knee Osteoarthritis (OA)|The Effect of High-speed Power Training on Muscle Performance, Function and Pain in Older Adults With Knee OA||University of Missouri-Columbia|No|Completed|June 2005|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2011|April 1, 2011|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328340||106592|
NCT01328353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TeleFamilies|Telehealth Nursing Intervention for Children With Complex Health Care Needs (CCHCN)|Telehealth Nursing Intervention for Children With Complex Health Care Needs||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2009|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|163|||Both|2 Years|15 Years|No|||September 2014|September 3, 2014|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01328353||106591|
NCT01329159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA indoor/pollution|Cardio-Respiratory Health and Indoor Pollution|Cardio-Respiratory Health in High Altitude Residents Exposed to Indoor Pollution||Università degli Studi di Ferrara|No|Not yet recruiting|April 2011|July 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|14 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|residents in the Kumbu Valley (Nepal)|March 2011|April 4, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01329159||106530|
NCT01329939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-029B|The Effect of Montelukast on Asthma Control in Obese Asthmatic Children and Adolescents|The Effect of Montelukast on Asthma Control in Overweight/Obese Early-Onset Asthmatics||Northwell Health|No|Completed|April 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Both|7 Years|17 Years|No|||April 2015|April 15, 2015|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01329939||106470|
NCT01300052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-PSR-204|AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis|A Multicenter, Randomized, Double-Blind, 12-Week Study of the Safety and Efficacy of AN2728 Versus AN2728 Vehicle in the Treatment of Patients With Mild-to-Moderate Plaque-Type Psoriasis||Anacor Pharmaceuticals, Inc.|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300052||108744|
NCT01300065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|642|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2011|||||N/A|N/A|N/A||||||||||||||August 10, 2012|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300065||108743|
NCT01299831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2010082|The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity|THE RELATIONSHIP BETWEEN BODY COMPOSITION AND GROWTH HORMONE, SIRT SIGNALING, PROTEIN TURNOVER AND INSULIN SENSITIVITY. Studies of Signaling Pathways in Fat and Muscle, and Turnover of Protein, Sugar and Fat After Stimulation With Growth Hormone and During Fasting in Lean and Obese Subjects||University of Aarhus|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|19|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01299831||108761|
NCT01300325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENHS|Effectiveness of Nebulized Hypertonic Saline and Epinephrine in Hospitalized Infants With Bronchiolitis|Effectiveness of Nebulized Hypertonic Saline and Epinephrine in Hospitalized Infants With Bronchiolitis||Federico II University|Yes|Completed|November 2008|December 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|136|||Both|N/A|2 Years|No|||January 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300325||108723|
NCT01328652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004 10/10|Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy|A Randomized, Double-blind, Placebo-controlled Study of Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy||Advanced Center for Specialty Care|No|Not yet recruiting|June 2011|January 2013|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|59 Years|No|||April 2011|April 4, 2011|April 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01328652||106568|
NCT01329406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRX001-2010|Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis|A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis||Analgesic Solutions||Recruiting|July 2011|September 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|75 Years|No|||August 2011|August 16, 2011|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01329406||106511|
NCT01296529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100517002|Study on Immunopathogenesis in HIV and Hepatitis C Coinfection|A Pilot Study on Immunopathogenesis in HIV and Hepatitis C Coinfection||Rush University Medical Center|No|Completed|July 2011|July 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|59|Samples Without DNA|serum and plasma|Both|18 Years|N/A|No|Non-Probability Sample|a) HIV monoinfected; b) hepatitis C monoinfected; c) HIV/HCV coinfected untreated for        hepatitis C; and d) HIV/HCV coinfected with clearance of HCV virus. Subjects will be all        matched by age and estimated duration of hepatitis C infection where applicable. In        addition, subjects in strata a and c will be matched by length of ARV therapy and CD4        count first established in strata d observed immediately before the initiation of        successful hepatitis C therapy or documentation of negative HCV RNA in subjects with        spontaneous clearance. Subjects in strata b will be matched in the same manner to strata        d, except length of ARV therapy and CD4 count variables will not be considered. All        subjects with HIV infection will be on HAART with undetectable viral loads.|December 2012|December 11, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01296529||109012|
NCT01329315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA020075|Project Chill: Tailored Youth Drug Intervention In Primary Care|Tailored Youth Drug Intervention In Primary Care||University of Michigan|Yes|Completed|September 2005|November 2012|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1141|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01329315||106518|
NCT01329588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-002-947|Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers|Periodical Presumptive Treatment of Gonorrhoea in Female Sex Workers: Impact on Prevalence of the Disease in Sex Workers and Their Clients||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|March 2001|April 2002|Actual|April 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|636|||Female|18 Years|N/A|No|||February 2013|February 12, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01329588||106497|
NCT01329900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0796|Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas|Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2011|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||March 2016|March 14, 2016|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01329900||106473|
NCT01329913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6325-003|Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-6325 in Hepatitis C Infected Male and Female Patients||Merck Sharp & Dohme Corp.|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|65 Years|No|||February 2015|February 4, 2015|April 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01329913||106472|
NCT01330186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI 1026|Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy|18F-FMISO-PET, 18F-FDG-PET/CT, DWI-MRI and DCE-MRI Scans as Predictors of Response to Radiotherapy +/- Chemotherapy in Patients With Anal Cancer.||Copenhagen University Hospital at Herlev|No|Recruiting|February 2011|May 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients with anal canal or perianal cancer|April 2011|April 11, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330186||106452|
NCT01330199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1393|Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions|A Phase I Investigation of Single-Dose Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions||University of North Carolina, Chapel Hill|Yes|Completed|February 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|49|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|August 17, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01330199||106451|
NCT01330472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131025|An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study Of Xanax XR Tablet 3 mg (Sourced From Caguas) Versus Xanax XR Tablet 3 mg (Sourced From Barceloneta) In Healthy Subjects||Pfizer|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|April 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01330472||106432|
NCT01330485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE4510/3-1|Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder|Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder||Philipps University Marburg Medical Center|No|Recruiting|November 2010|September 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330485||106431|
NCT01331304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS019371-01|Comparative Effectiveness Study for Bipolar Disorder|Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder||Massachusetts General Hospital|Yes|Completed|September 2010|September 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|482|||Both|18 Years|68 Years|No|||May 2014|May 23, 2014|April 6, 2011|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT01331304||106369|
NCT01331837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA25204|A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors|A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)||Hoffmann-La Roche||Active, not recruiting|August 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3080|||Both|50 Years|N/A|No|||September 2015|September 18, 2015|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01331837||106328|
NCT01328899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0011|Feasibility Study of PneumRx's Lung Volume Reduction Coil (LVRC)|Feasibility Study of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema||PneumRx, Inc.|No|Completed|December 2009|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|35 Years|N/A|No|||March 2012|March 11, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328899||106550|
NCT01328912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6576|Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients|Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients: A Randomized Controlled Trial||Queen's University|Yes|Completed|February 2012|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|429|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328912||106549|
NCT01329666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF1846|Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D|Early Effect of Vitamin D in Primary Hyperparathyroidism||Columbia University|Yes|Withdrawn|May 2010|January 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|45 Years|N/A|No|||March 2015|March 4, 2015|April 4, 2011||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01329666||106491|
NCT01329679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110111H|Impact of Energy Drinks on Cardiovascular Endpoints|Evaluation of 5-Hour ENERGY® Drink on the Blood Pressure and Electrocardiographic Parameters on Young Healthy Volunteers: A Randomized, Double Blind, Crossover, Placebo-controlled Trial||David Grant U.S. Air Force Medical Center|No|Terminated|April 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|April 4, 2011||No|Unable to recruit enough subjects|No||https://clinicaltrials.gov/show/NCT01329679||106490|
NCT01330511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10020402|Simplified Diagnostic Algorithm for Evaluation of Neonates With Prenatally Detected Hydronephrosis|Simplified Diagnostic Algorithm for Evaluation of Neonates With Prenatally Detected Hydronephrosis||Rush University Medical Center|No|Completed|January 2005|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|76|||Both|N/A|2 Years|No|Non-Probability Sample|Infants with prenatally diagnosed hydronephrosis by ultrasound who have consulted        pediatric nephrology|April 2011|April 5, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01330511||106429|
NCT01300078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF101-008|A Clinical Trial Assessing Safety of MF101 for Hot Flushes|A Phase 1 Open Label, Randomized Clinical Trial Assessing Safety of MF101 for Hot Flushes and Menopausal Symptoms in Postmenopausal Women||Bionovo|Yes|Active, not recruiting|March 2011|June 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300078||108742|
NCT01300091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B07103-3|Burden of Shoulder Disorders in Primary Health Care|Burden and Management of Shoulder Disorders in Primary Health Care||Central Finland Hospital District|Yes|Active, not recruiting|October 2007|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|128|||Both|N/A|N/A|No|Probability Sample|All patients consulting a general practitioner due to shoulder disorder during the        recruitment period are included. The study population consists of two public health        centres with a population of 120 000 individuals and two occupational medicine clinics        with a population of 15 000 individuals. The population of health centres and occupational        health clinics overlap partially.|February 2012|February 9, 2012|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300091||108741|
NCT01300338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003562|Blood Pressure Telemonitoring and Goal Blood Pressure in Diabetes|Does Home Telemonitoring Increase the Number of Diabetic Patients at Goal Blood Pressure in a Primary Care Practice?||Mayo Clinic|No|Completed|March 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|75 Years|No|||March 2014|March 24, 2014|February 17, 2011|No|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01300338||108722|
NCT01300598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jointstem|Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Degenerative Arthritis|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Degenerative Arthritis||Biostar||Completed|December 2008|March 2012|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|75 Years|No|||March 2014|March 24, 2014|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300598||108703|
NCT01296243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP205|Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer|A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer||Genta Incorporated|No|Recruiting|February 2011|February 2015|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Male|18 Years|N/A|No|||July 2012|July 20, 2012|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01296243||109034|
NCT01296256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Benda-EAM2010-01|Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).|Bendamustine, Cytarabine, Etoposide and Melphalan as Conditioning for Autologous Stem Cell Transplant in Patients With Aggressive Non Hodgkin's Lymphoma.|BeEAM2010-01|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Completed|May 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|February 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01296256||109033|
NCT01296867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-value|Corneal Asphericity Adjustment (Q Adjustment) in Myopic and Hyperopic Patients Undergoing Refractive Correction With Excimer Laser|||Democritus University of Thrace|No|Completed|March 2006|May 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Forty eight myopic (24 patients) and 24 hyperopic eyes (12 patients)|February 2011|February 15, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01296867||108986|
NCT01297127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25398|Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection|Prospective Multicentre Noninterventional Observational Study on Predictors of Treatment Response in a Cohort of Treatment naïve HIV-infected Patients Treated With Saquinavir (PROSPECTOR)||Hoffmann-La Roche||Completed|August 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|151|||Both|18 Years|N/A|No|Probability Sample|Treatment-naïve HIV-infected patients initiated on treatment with Invirase|March 2016|March 1, 2016|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297127||108966|
NCT01296581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X82-CLI-101|Safety Study of X-82 in Patients With Advanced Solid Tumors|Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors||Tyrogenex|No|Active, not recruiting|February 2011|January 2017|Anticipated|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01296581||109008|
NCT01322672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#100885|Peri-Anesthetic Imaging of Cognitive Dysfunction|Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study|PAICOD|Vanderbilt University|No|Recruiting|March 2011|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|65 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be non‐rheumatoid, non‐immune‐compromised, males and females, 65+ years old,        scheduled for open abdominal surgery under general anesthesia of 3+ hour's duration.|January 2014|January 29, 2014|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322672||107023|
NCT01322685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99042|Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens|Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens||Taipei Medical University WanFang Hospital|No|Active, not recruiting|July 2010|June 2011|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|17 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Health people Tuberculosis or lung cancer|March 2011|March 23, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322685||107022|
NCT01322412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10 009 / SAPA|Adapted Physical Activity Effect and Fatigue in Patients With Breast Cancer|Adapted Physical Activity Effect on Aerobic Function and Fatigue in Patients With Breast Cancer Treated in Adjuvant Phase|SAPA|University Hospital, Limoges|No|Completed|May 2011|July 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|44|||Female|18 Years|75 Years|No|Probability Sample|adjuvant breast cancer|March 2011|January 10, 2014|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322412||107043|
NCT01322425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007M85352|Effect of Temperature on Pain and Brown Adipose Activity in Fibromyalgia|Urocortins and Musculoskeletal Hyperalgesia||University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|24|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy or patients with fibromylgia|August 2014|August 19, 2014|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01322425||107042|
NCT01329107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M20100122|Multimodal Rehabilitation Program to Bladder Cancer Patients|Efficacy of a Multimodal Rehabilitation Program to Bladder Cancer Patients|MRPBC|University of Aarhus|Yes|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|129|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01329107||106534|
NCT01329328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIBROB|Effect of Whole-body Vibration With or Without Localized Radiofrequency on Body Composition of Obese Female Subjects|Vibrazione Corporea Totale Con o Senza Radiofrequenza Localizzata su Composizione Corporea, Adipe Sottocutaneo e Parametri Ormonali in Donne Obese||Universita di Verona|No|Completed|July 2010|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01329328||106517|
NCT01329419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105711|HEPSERA Post Marketing Surveillance|A Post-marketing Surveillance to Monitor the Safety of HEPSERA(Adefovir Dipivoxil 10mg) Adminstered in Korean Subjects According to the Prescribing Information|HEPSERA PMS|GlaxoSmithKline|No|Completed|August 2004|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4393|||Both|18 Years|N/A|No|Probability Sample|Patients administrated adefovir dipivoxil at the site|March 2011|March 10, 2011|March 10, 2011||No||No|March 10, 2011|https://clinicaltrials.gov/show/NCT01329419||106510|
NCT01329432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-019|Surfactant Administration During Spontaneous Breathing|Early Administration of Surfactant in Spontaneous Breathing (TAKE CARE) Versus InSurE (Intubation, Surfactant, Extubation) : A Pilot Study|TAKE CARE|Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|December 2010|December 2011|Anticipated|January 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|23 Weeks|35 Weeks|No|||December 2010|April 5, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01329432||106509|
NCT01330238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2008-005351-14|The Efficacy of Zoledronic Acid in Modic Changes-related Low Back Pain (LBP)|Phase 2 Study of the Efficacy of Zoledronic Acid in Low Back Pain Related to Vertebral Endplate Signal Changes, the So-called Modic Changes||University of Oulu|No|Completed|December 2008|March 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||January 2014|January 14, 2014|February 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01330238||106450|
NCT01330745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/121/HP|Microcirculation in Cardiac Surgery|Mesenteric Microcirculatory Function Study Through Sublingual Evaluation During Cardiopulmonary Bypass|MICROCARD|University Hospital, Rouen|No|Completed|September 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|90 Years|No|||September 2014|September 5, 2014|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330745||106411|
NCT01330758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00005|A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females|A Phase I, Randomised, Open-label, Cross-over, Single-centre Study in Healthy Male and Non-fertile Female Volunteers to Determine the Relative Bioavailability of the Phase II Wet Granulation Tablet Formulation Compared to the Phase II/III Roller Compacted Tablet Formulation of AZD8931||AstraZeneca|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01330758||106410|
NCT01327638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-159|Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)|Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients||Merck Sharp & Dohme Corp.|No|Active, not recruiting|February 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|16671|||Both|16 Years|N/A|No|Probability Sample|Out-patients in Sweden with SpA/AS who took etoricoxib, other COX-2 inhibitors, or        nsNSAIDs from 2001-2010.|March 2016|March 11, 2016|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01327638||106643|
NCT01299181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022040-20|A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis|A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis||University of Edinburgh|No|Completed|November 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||August 2013|August 27, 2013|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01299181||108811|
NCT01299194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022042-24|Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa|A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in Patients With Pseudomonas Aeruginosa||University of Edinburgh|No|Active, not recruiting|November 2010|August 2016|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01299194||108810|
NCT01299506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-D-010-10|Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide|An Observational, Multicenter, Open-label Study of the Management of Patients With Advanced Soft Tissue Sarcoma After Failure of Anthracyclines and/or Ifosfamide or Patients Unsuited to Receive These Drugs||PharmaMar|No|Recruiting|December 2010|December 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|The study population will include patients with advanced soft tissue sarcoma after failure        of anthracyclines and/or ifosfamide or patients unsuited to receive these drugs. To be        enrolled in this study, the patients must meet all inclusion criteria and none of the        exclusion criteria.|February 2012|February 28, 2012|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01299506||108786|
NCT01302483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 2-01|Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia|A Phase II, Single-Center, Randomized, Double-Blind, Active-Treatment-Controlled, Parallel-Group Study of the Efficacy of Kovacaine Nasal Spray for Anesthetizing Maxillary Teeth in Healthy Dental Patients||St. Renatus, LLC||Completed|December 2008|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|February 18, 2011|Yes|Yes||No|March 2, 2011|https://clinicaltrials.gov/show/NCT01302483||108559|The VAS was misadministered such that even subjects with enough pain to require rescue reported essentially no pain on the global VAS. As this would exaggerate the efficacy of the study drug, these measures were not used to calculate its efficacy.
NCT01302496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZB-VUB-10-001|Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma|A Two-stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma|TriMix-Ipi|Universitair Ziekenhuis Brussel|No|Active, not recruiting|February 2011|||October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302496||108558|
NCT01302470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-052|Comparison of Epicardial Versus Conventional Lead Placement in Cardiac Resynchronization Therapy|Randomized Study of Endovascular Versus Epicardial Lead Placement for Resynchronization Therapy|REVERT|St. Luke's-Roosevelt Hospital Center||Completed|February 2005|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|85 Years|No|||February 2015|February 18, 2015|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302470||108560|
NCT01303094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-DIS-1001|Continuing vs Intermittent Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the 6th Cycle|Phase II Randomized Trial to Evaluate Two Strategies: Continuing Versus Intermittent (Drug-holiday) Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the Sixth Cycle|T-DIS|Centre Oscar Lambret|Yes|Not yet recruiting|February 2011|February 2017|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2012|March 6, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303094||108514|
NCT01311973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 003|Salivary Phosphorus and Level of Kidney Function|Assessment of the Relationship Between Salivary Phosphorus and Level of Kidney Function||Denver Nephrologists, P.C.|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|105|Samples Without DNA|Blood, urine, and saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy population an individuals with chronic kidney disease not on dialysis|March 2011|July 21, 2011|March 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01311973||107836|
NCT01312272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCC 2011-020223|Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?|Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?||VA Greater Los Angeles Healthcare System|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|No|||March 2014|March 31, 2014|March 9, 2011|No|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT01312272||107813|
NCT01312558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01312558|The Effect of the Mediterranean Diet on Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Randomised Trial||MEDOSAHS|University of Crete|Yes|Completed|November 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||February 2014|February 26, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01312558||107791|
NCT01313546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sunnybrook_Women's|A Comparison of Sartorius Vs. Quadriceps Evoked Motor Response for Femoral Nerve to Prevent Secondary Catheter Failure|A Comparison of Sartorius Vs. Quadriceps Evoked Motor Response for Femoral Nerve to Prevent Secondary Catheter Failure||Sunnybrook Health Sciences Centre|No|Not yet recruiting|May 2011|September 2012|Anticipated|May 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2011|March 10, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313546||107719|
NCT01313832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1012-120-345|The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension|||Seoul National University Hospital|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|60|||Both|N/A|1 Year|No|||February 2012|February 1, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313832||107697|
NCT01310361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iaum|Once-daily Therapy for Streptococcal Pharyngitis|Once-daily Therapy for Streptococcal Pharyngitis||Azad University of Medical Sciences|Yes|Completed|January 2004|March 2006||||Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||||||Both|6 Years|15 Years||||January 2005|March 7, 2011|March 7, 2011||||No||https://clinicaltrials.gov/show/NCT01310361||107957|
NCT01301677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPM-033|Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone|Double-blind, Randomised, Active (Hydrocortisone) Controlled Study of the Effect of 10% w/v Strontium Chloride Hexahydrate on Ultraviolet B Radiation (UVR) Induced Signs of Inflammation (Erythema and Pain) in Healthy Volunteers||X-pert Med GmbH|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 28, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01301677||108621|
NCT01301690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH No.:98041-3|Development of a Novel Methodology Using BMVC Staining as an Assistance to Cancer Cytological Diagnosis|||Far Eastern Memorial Hospital||Recruiting|January 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|We propose to collect consecutive patients (age range from 18 to 90 years old) with neck        lumps, receiving sonographic examination and FNA cytologic study.|September 2011|September 16, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301690||108620|
NCT01304069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119/180/2010|Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol|||Turku University Hospital||Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 8, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304069||108439|
NCT01303484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clasado2011|The Effect of Prebiotic B-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People|A Randomised, Double-blind, Placebo Controlled Cross- Over Study to Determine the Effect of prebioticB-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People|PRIMES|Clasado|Yes|Completed|May 2011|July 2014|Actual|November 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303484||108484|
NCT01304056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08175|How to Study Ventilatory Physiology With the Help of Surface Electromyography (EMG) Recordings|||Tampere University Hospital|No|Withdrawn|August 2009|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult population > 18 years of age|October 2013|October 8, 2013|February 24, 2011||No|Administrative reasons|No||https://clinicaltrials.gov/show/NCT01304056||108440|
NCT01304316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 2-02|Safety and Pharmacokinetics of Kovacaine Nasal Spray|Cardiovascular Changes and Tetracaine Pharmacokinetics Following Intranasal Administration of Standard and High Doses of Kovacaine Mist (Tetracaine Hydrochloride With Oxymetazoline Hydrochloride) in Healthy Volunteers||St. Renatus, LLC|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 15, 2015|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304316||108420|
NCT01301027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00028427|Adipokines in Hemodialysis Patients|Adipokines in Hemodialysis Patients||University of Utah|Yes|Enrolling by invitation|May 2008|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301027||108670|
NCT01301339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110007H|A1c FIT TEST: An Epidemiological Study Correlating Hemoglobin A1c With Results of the Air Force Physical FITness TEST.|A1c FIT TEST: An Epidemiological Study Correlating Hemoglobin A1c With Results of the Air Force Physical FITness TEST.||Mike O'Callaghan Federal Hospital|No|Completed|July 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|535|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Active duty Air Force personnel will be recruited from all male and female patients 18        years or older at the Mike O'Callaghan Federal Hospital. A total of 1040 subjects will be        recruited (520 subjects who have failed their Air Force physical fitness test and 520        volunteers who have passed their physical fitness test both within the last 6 months from        recruitment into this study).|November 2013|November 21, 2013|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01301339||108646|
NCT01301001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBrown Vulvodynia|A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response|A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response||University of Tennessee|Yes|Active, not recruiting|August 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301001||108672|
NCT01300715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBRF|An Alternative Technique for Lumbar Medial Branch Radiofrequency: Comparison With the Empirical Technique||MBRF LBP|Seoul National University Bundang Hospital|Yes|Recruiting|November 2010|||May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|80 Years|No|||October 2010|February 22, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01300715||108694|
NCT01300728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIG-KILE-032010|Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment|A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment|MCI|Sutter Health|Yes|Active, not recruiting|January 2011|November 2017|Anticipated|November 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|50 Years|84 Years|No|||August 2014|August 21, 2014|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300728||108693|
NCT01302522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT003842-01|Mental Practice Impact on Gait and Cortical Organization in Spinal Cord Injury (SCI)|Mental Practice Impact on Gait and Cortical Organization in SCI||University of Cincinnati|Yes|Completed|September 2008|December 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|||||||Both|18 Years|N/A||||February 2011|February 23, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302522||108556|
NCT01302782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110021H|The Effects of Normobaric Hypoxia on Blood Glucose Levels.|The Effects of Normobaric Hypoxia on Blood Glucose Levels.||Mike O'Callaghan Federal Hospital|No|Withdrawn|December 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We are recruiting male and female patients (MOFH personnel and DoD beneficiaries) whom are        at least 18 years of age from the Nellis Air Force Base population.|November 2013|November 21, 2013|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01302782||108538|
NCT01303068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC, 12-521|Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF|Detection of Pseudomonas. Aeruginosa in the Airways of Patients With Cystic Fibrosis Using of Aerosolized 13C-urea||University of New Mexico|No|Completed|August 2013|October 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01303068||108516|
NCT01311986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006030R|Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis|Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis||National Taiwan University Hospital|Yes|Active, not recruiting|November 2010|March 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|120|Samples Without DNA|Patient serum, and epidermal keratinocytes for mRNA retrieval|Both|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|patients with atopic dermatitis        patients with nummular eczema without atopy|March 2011|April 21, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311986||107835|
NCT01312844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002288|A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)|A Pilot Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)||Massachusetts General Hospital|No|Recruiting|April 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|50 Years|No|||July 2014|July 24, 2014|May 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01312844||107770|
NCT01312857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-137|Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer|A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|March 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312857||107769|
NCT01312870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNSICP-71421|Study of Postoperative Nutritional Support in Cardiac Surgery.|Prospective Randomized Study of Postoperative Nutritional Support in Cardiac Surgery.||Meshalkin Research Institute of Pathology of Circulation|Yes|Terminated|March 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|70 Years|No|||March 2015|March 23, 2015|March 2, 2011||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01312870||107768|
NCT01313182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11318|Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin|||3M|No|Completed|March 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1784|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|February 11, 2011|Yes|Yes||No|February 21, 2014|https://clinicaltrials.gov/show/NCT01313182||107747|Study failed to achieve target enrollment. The small sample size precluded a multivariate analysis. Nasal culture alone was used as a screen for S. aureus colonization, which has a sensitivity of only 48% to 66%.
NCT01313195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-028|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2011|||||N/A|N/A|N/A||||||||||||||November 16, 2011|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313195||107746|
NCT01313208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070561|Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy||Amgen|No|Completed|March 2011|May 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|March 10, 2011|Yes|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT01313208||107745|
NCT01309594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00005823-AMBi2011|HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation|A Safety and Efficacy Study of Autologous Bone Marrow Cell Infusion Therapy in HIV Infected Patients With Advanced Liver Cirrhosis|HIV-ABMi|National Center for Global Health and Medicine, Japan|Yes|Enrolling by invitation|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|70 Years|No|||September 2014|September 24, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309594||108016|
NCT01309828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491CLD_309|Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease|A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal Impairment||Takeda|No|Completed|March 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|N/A|No|||September 2013|September 28, 2013|March 4, 2011|Yes|Yes||No|September 28, 2013|https://clinicaltrials.gov/show/NCT01309828||107998|
NCT01302041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0321|A Study to Test if MDV3100 is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy|A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of MDV3100 in Patients With Hormone-naïve Prostate Cancer||Astellas Pharma Inc|No|Active, not recruiting|April 2011|December 2015|Anticipated|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Male|18 Years|N/A|No|||October 2015|October 26, 2015|February 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302041||108593|
NCT01303783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14725|Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension|A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients With Essential Hypertension|DISTINCT|Bayer|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|16||Actual|1381|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|February 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01303783||108461|
NCT01304082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000533|Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.|A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.||Massachusetts General Hospital|Yes|Recruiting|January 2011|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Anticipated|60|||Both|19 Years|N/A|No|||December 2013|December 16, 2013|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304082||108438|
NCT01303757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04-0156|A Novel Diet-Phenotype Interaction Affecting Body Weight|A Novel Diet-Phenotype Interaction Affecting Body Weight|FRESH Start|Children's Hospital Boston|No|Completed|February 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01303757||108463|
NCT01304043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMRO|French Observatory of Rare Malignant Tumors of the Ovary|Observatoire Francophone Des Tumeurs Malignes Rares de l'Ovaire : Protocole de Prise en Charge Chez l'Adulte (Tumeurs Germinales et Des Cordons Sexuels)||ARCAGY/ GINECO GROUP|No|Completed|January 2002|June 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|204|||Female|18 Years|N/A|No|Non-Probability Sample|female with rare ovarian cancer|April 2012|April 19, 2012|September 9, 2005||No||No||https://clinicaltrials.gov/show/NCT01304043||108441|
NCT01304602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12480|A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer|A Phase I Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer||University of Kansas Medical Center|Yes|Active, not recruiting|February 2011|January 2016|Anticipated|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304602||108398|
NCT01301040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJB 11-01|Early Cardiac Toxicity of Adjuvant CT in Elderly BC.|Early Detection of Chemotherapy Induced Cardiac Damage in Elderly Patients With Early Breast Cancer: a Randomized Phase II Trial Comparing (Neo) Adjuvant Epirubicin-cyclophosphamide (EC) Versus Docetaxel (Taxotere)-Cyclophosphamide (TC.)||Jules Bordet Institute|No|Terminated|March 2011|March 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2|||Female|65 Years|N/A|No|||February 2011|August 29, 2013|February 18, 2011||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01301040||108669|
NCT01301586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11022006|A Novel Combination Oral Agent to Treat Acne Vulgaris|A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF A NOVEL ORAL ACNE TREATMENT FOR THE TREATMENT OF ACNE VULGARIS||Nexgen Dermatologics, Inc.|No|Recruiting|November 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|13 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 18, 2011|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301586||108628|
NCT01301313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEVOPED1|Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children|Phase II Study to Evaluate the Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children||Hospital Universitario Ramon y Cajal|Yes|Terminated|February 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|116|||Both|N/A|18 Years|No|||January 2013|January 30, 2013|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301313||108648|
NCT01301326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAM-SUB|Subthreshold Laser Treatment Versus Threshold Laser Treatment for Symptomatic Retinal Arterial Macroaneurysm|Pilot Randomized Clinical Trial Comparing Subthreshold Laser Treatment Versus Threshold Laser Treatment for Retinal Arterial Macroaneurysm|RAM-SUB|IRCCS San Raffaele|No|Completed|April 2010|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|35 Years|90 Years|No|||January 2011|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301326||108647|
NCT01301820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMSA-maintenance Rev-5Aza|Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)|Phase II Multicentric Trial Maintenance Therapy With 6 Monthly Revlimid® Cycles Alternated With 6 Monthly Vidaza® Cycles in First CR After Induction LIA Chemotherapy for Elderly Fit Patients With Poor Prognosis Acute Myeloid Leukemia.||French Innovative Leukemia Organisation|Yes|Completed|January 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|60 Years|75 Years|No|||March 2016|March 15, 2016|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01301820||108610|
NCT01301833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000-A14|Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes|Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|462|||Both|20 Years|N/A|No|||October 2015|October 15, 2015|February 14, 2011||No||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01301833||108609|
NCT01311414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudickar6|Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation|Effect of Cafedrine/Theodrenaline and Urapidil During Carotid Endarterectomy on Cerebral Oxygenation Measured by Near Infrared Spectroscopy|NIRSMED|University of Schleswig-Holstein|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|March 7, 2011||No|The study was suspended due to organizational problems|No||https://clinicaltrials.gov/show/NCT01311414||107877|
NCT01302795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DER-USZ-AAN-008|Canakinumab for Pyoderma Gangrenosum|A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum||University of Zurich|Yes|Recruiting|February 2011|November 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01302795||108537|
NCT01312285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10276-01|Low Level Magnetic Fields for the Treatment of Osteoarthritis of the Hip|A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Osteoarthritis of the Hip: Pilot Study Protocol||pico-tesla Magnetic Therapies, LLC|Yes|Withdrawn|September 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||May 2011|May 27, 2011|January 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01312285||107812|
NCT01312571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-185-31 M|Treatment of Social Phobia Over the Internet|Functional Magnetic Resonance Imaging (fMRI) and Treatment of Social Phobia Over the Internet: Cognitive Behavioural Therapy (CBT) Versus Computerized Attention Training and the Possible Effect of Genetic Variation. (SOFIE-8)|SOFIE-8|Umeå University|Yes|Active, not recruiting|August 2010|December 2012|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01312571||107790|
NCT01313559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.78|Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer|An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients||Thomas Jefferson University|Yes|Terminated|June 2011|June 2018|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Male|18 Years|N/A|No|||July 2015|July 14, 2015|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313559||107718|
NCT01313845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB11F001|Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease|Randomized Double-blind Placebo-controlled Trial of Intravenous Amantadine on Gait Freezing in Patients With Parkinson's Disease||Seoul National University Hospital|Yes|Completed|February 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|30 Years|79 Years|No|||August 2012|August 8, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313845||107696|
NCT01309841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00004|Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)||AstraZeneca|No|Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|652|||Both|18 Years|84 Years|No|||May 2015|May 29, 2015|March 4, 2011|Yes|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT01309841||107997|
NCT01310387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAIN_LCA_2011|Prospective Study of Active Pain Management in Lung Cancer Outpatients (APM)|A Randomized Prospective Controlled Study of Active Pain Management in Lung Cancer Outpatients (APM)|APM|Chonnam National University Hospital|No|Completed|January 2011|June 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|79|||Both|20 Years|80 Years|No|||February 2016|February 4, 2016|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01310387||107955|
NCT01310400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG0826INF|Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children|Observer-blind, Randomized, Controlled Study to Determine the Immunogenicity and Safety of a Two-dose Regimen of Virosomal Subunit Influenza Vaccine Inflexal V in Healthy Young Children (≥6 Months to ≤35 Months) in Comparison With the Subunit Influenza Vaccine Agrippal||Crucell Holland BV|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|1356|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||August 2013|January 7, 2014|March 7, 2011||No||No|October 23, 2012|https://clinicaltrials.gov/show/NCT01310400||107954|
NCT01310413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114464|Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age|Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age||GlaxoSmithKline||Completed|March 2011|January 2014|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|7||Actual|842|||Both|6 Months|17 Years|Accepts Healthy Volunteers|||October 2015|January 14, 2016|February 24, 2011|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01310413||107953|
NCT01310140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002723|Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features|Comparative Risks for Insulin Resistance and Metabolic Syndrome (MS) Among Hospitalized Patients With Major Depressive Disorder With (MDpsy) or Without (MDD) Psychotic Features||Massachusetts General Hospital|No|Terminated|January 2011|September 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|85 Years|No|Non-Probability Sample|Eligible subjects are people who are inpatient in the medical-psychiatric unit at        Massachusetts General Hospital. Included subjects have working diagnosis of major        depressive disorder (MDD) or major depressive disorder with psychotic features (MDpsy).|November 2012|November 2, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01310140||107974|
NCT01310153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-09-409|Effect of Supine or Prone Position After Caesarean Birth|Effect of Supine or Prone Position at Delivery on Respiratory Outcomes in Full-Term Infants Following Elective Caesarean Birth||Montefiore Medical Center||Completed|September 2006|February 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Prevention|||||||Female|N/A|N/A||||March 2011|March 7, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01310153||107973|
NCT01306500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/035/2010/GLAM|Effect of Gastric Lavage in Preventing Feeding Problems in Babies Born With Meconium Stained Amniotic Fluid|Effect of Gastric Lavage in Preventing Feeding Problems in Late Preterm and Term Neonates Born With Meconium Stained Amniotic Fluid : A Randomized Controlled Trial|GLAM|Lady Hardinge Medical College|Yes|Completed|March 2010|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|538|||Both|N/A|1 Hour|No|||August 2014|August 7, 2014|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306500||108252|
NCT01304342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-17, M-18/21-12-2010|Sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) With or Without Opioids|The Effect of Intranasal Fentanyl Versus Remifentanil Infusion on Propofol Requirements During Elective Therapeutic ERCP, as Well on the Recovery, Pain, and Early Cognitive Function: A Randomized Control Trial||University of Athens|No|Completed|February 2011|July 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|50 Years|75 Years|No|||March 2012|August 2, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304342||108418|
NCT01304095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS-REMS-001|Ranolazine, Ethnicity and the Metabolic Syndrome|Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study|REMS|Atlanta Heart Specialists, LLC|No|Active, not recruiting|January 2011|November 2013|Anticipated|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01304095||108437|
NCT01304615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFH E01-1703-011|Foundations for Health|Foundations for Health: Combining Culinary Skills Training With a Lifestyle Intervention in Young Overweight Adults at Risk for Type 2 Diabetes|FFH|University of Tennessee|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 14, 2012|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01304615||108397|
NCT01301599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-024|Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)|Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia||Samsung Medical Center|Yes|Recruiting|January 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|315|||Male|45 Years|N/A|No|||January 2014|February 12, 2015|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301599||108627|
NCT01301846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-082|Participation of Manual Wheelchair Users in the Community|Participation of Manual Wheelchair Users in the Community: The Relationship to Wheelchair Skills Capacity||Nova Scotia Health Authority|No|Withdrawn|April 2011|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample of people who use manual wheelchairs|May 2015|May 5, 2015|February 22, 2011||No|Need to recruit research staff|No||https://clinicaltrials.gov/show/NCT01301846||108608|
NCT01301859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH087562-01A1|PERSONALIZED ANTIDEPRESSANT ADHERENCE STRATEGIES FOR DEPRESSED ELDERS|Treatment Initiation and Participation Program (TIP)|TIP|Weill Medical College of Cornell University|Yes|Active, not recruiting|January 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|260|||Both|65 Years|N/A|No|||December 2015|December 10, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301859||108607|
NCT01302236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JMU-N2|Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients|Effects of Eplerenone on Blood Pressure, Heart and Kidney in Elderly Hypertensive Early Stage Chronic Kidney Disease Patients||Jichi Medical University|No|Withdrawn|March 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||July 2012|July 4, 2012|February 23, 2011||No|We could not find patients who agreed to enrolled this clinical study.|No||https://clinicaltrials.gov/show/NCT01302236||108578|
NCT01311427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAMS 5R21 AR053506|Simplified Tai Chi for Reducing Fibromyalgia Pain|Simplified Tai Chi for Reducing Fibromyalgia Pain||Oregon Research Institute|Yes|Completed|August 2006|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|40 Years|N/A|No|||March 2011|March 7, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01311427||107876|
NCT01311700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METOCARD-CNIC|Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.|Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The ME"Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion" (METOCARD-CNIC): A Randomized, Controlled Parallel-group, Observer-blinded Clinical Trial of Early Pre-reperfusion Metoprolol Administration in ST-segment Elevation Myocardial infarctionTOCARD-CNIC Trial.|METOCARD-CNIC|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Yes|Active, not recruiting|November 2010|October 2013|Anticipated|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|80 Years|No|||February 2013|February 12, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311700||107856|
NCT01313221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090647|Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis|A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects With Moderate to Severe Plaque Psoriasis|REFINE|Amgen||Completed|April 2011|May 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|310|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|February 24, 2011||No||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01313221||107744|
NCT01313858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06554|A Study to Investigate the Use of Simponi® in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)|Non-Interventional Study Investigating the Use of Simponi® in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|GO-NICE|Merck Sharp & Dohme Corp.|No|Completed|April 2010|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1521|||Both|18 Years|N/A|No|Non-Probability Sample|Participants in a primary care clinic or office with rheumatoid arthritis, psoriatic        arthritis, or ankylosing spondylitis for whom the treatment with Simponi® by autoinjector        device is to be initiated for the first time|October 2015|October 25, 2015|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01313858||107695|
NCT01313871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08167|Assessment of the Disease Severity and Treatment Patterns of Rheumatoid Arthritis in Eastern Europe, Middle East and North African Countries (P08167)|Cross-sectional Study of Disease Severity and Treatment Patterns of Rheumatoid Arthritis, in Eastern Europe Middle East and North Africa||Merck Sharp & Dohme Corp.|No|Withdrawn|August 2011|November 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Adults with a confirmed diagnosis of rheumatoid arthritis|May 2015|May 29, 2015|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313871||107694|
NCT01313884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARCOMA0007|Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma|A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma||Stanford University|Yes|Terminated|May 2011|January 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|13 Years|N/A|No|||June 2014|June 18, 2014|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313884||107693|
NCT01309607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR07/29/10|Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer|Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer||National University Hospital, Singapore|Yes|Active, not recruiting|April 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Female|18 Years|N/A|No|||October 2014|October 13, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309607||108015|
NCT01310166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE01|Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|Biobank|Novartis||Completed|February 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|447|||Both|18 Years|65 Years|No|||January 2015|January 12, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01310166||107972|
NCT01302626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-4-120|Radiomics: a Study of Outcome in Lung Cancer|Radiomics: a Prospective Study of Outcome in Lung Cancer|Radiomics|Maastricht Radiation Oncology|No|Recruiting|March 2010|March 2014|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|216|Samples With DNA|-  Lung tumor tissue        -  Lung normal tissue|Both|18 Years|N/A|No|Probability Sample|Patients with lung cancer|July 2012|July 17, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302626||108548|
NCT01310634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-FY2011-236|Epidemiology and Prevention of Anxiety and Depression in Parents of Hospitalized Neonates|Epidemiology and Prevention of Anxiety and Depression in Parents of Hospitalized Neonates||Nanjing Medical University|Yes|Completed|January 2011|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310634||107936|
NCT01306773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-CP1|Convalescent Plasma Treatment in Severe 2009 H1N1 Infection|Convalescent Plasma Treatment in Patients With Severe 2009 H1N1 Infection: a Prospective Cohort Study||The University of Hong Kong|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2011|March 1, 2011|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01306773||108231|
NCT01306786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-HP1|Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication|Five Days Quadruple and Clarithromycin Containing Triple Therapy as Empirical First and Second-Line Treatment for Helicobacter Pylori Eradication: a Randomized Crossover Trial||The University of Hong Kong|Yes|Completed|November 2008|February 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|800|||Both|21 Years|N/A|No|||May 2015|May 26, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01306786||108230|
NCT01304355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC024-GC/ANMS|An Assessment of Cognitive Function in Irritable Bowel Syndrome|Kynurenine Pathway Metabolites as Novel Translational Biological Markers of Irritable Bowel Syndrome: Relationship to Gastrointestinal Function, Cognition and Co-morbid Depression||University College Cork|Yes|Recruiting|January 2011|January 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|85|Samples With DNA|Plasma Serum Saliva|Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|IBS Patients will be recruited from a university database of IBS patients, comprising        people who have previously either attended gastroenterology clinics at Cork University        Hospital or responded to direct advertisement regarding participation in IBS research.        Healthy Controls will be recruited from responders to a direct advertisement regarding        participation in IBS research|February 2011|February 24, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304355||108417|
NCT01304628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-3994-501|Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma|A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma||Palatin Technologies|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||December 2014|December 15, 2014|February 22, 2011|Yes|Yes|Sponsor terminated study prior to initiation.|No||https://clinicaltrials.gov/show/NCT01304628||108396|
NCT01304901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.10.0.İEG-0.15-00-01/5181|Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.|Phase 4 Study of Single Dose of Oral Montelukast When Adding to Standard Treatment in Acute Moderate to Severe Wheezing in Preschool Children.||Kecioren Education and Training Hospital|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|6 Months|5 Years|No|||December 2011|December 17, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304901||108375|
NCT01300754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNRosario|Effectiveness of Dextrose Injection for Osgood-Schlatter Disease|Phase 2 Study of Dextrose Injection for Sport-Limiting Osgood Schlatter Disease in Adolescents.||Universidad Nacional de Rosario|Yes|Completed|January 2006|September 2010|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|9 Years|17 Years|No|||January 2011|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01300754||108691|
NCT01301014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProneLachman1|Reliability and Diagnostic Accuracy of an Alternate Lachman's Test Performed in a Prone Position|Reliability and Diagnostic Accuracy of an Alternate Lachman's Test Performed in a Prone Position||University of Texas Southwestern Medical Center|No|Completed|September 2010|December 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|15 Years|60 Years||Non-Probability Sample|31 men and 21 women ranging in age from 16-57 years old with complaint of knee pain|February 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301014||108671|
NCT01301352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-192-PED|Feeding Children Nasogastrically Versus Nasojejunally While Receiving Noninvasive Positive Pressure Ventilation|The Efficacy and Safety of Gastric Feeding in Critically Ill Pediatric Patients Receiving Non-invasive Positive Pressure Ventilation: A Pilot Study|FeedNIV|McGill University Health Center|Yes|Completed|February 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|N/A|17 Years|No|||July 2014|July 14, 2014|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301352||108645|
NCT01301365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178/10|Autonomic Response During Cystodistension in Patients Suspected of Having Interstitial Cystitis|Autonomic Response During Cystodistension in Patients Suspected of Having Interstitial Cystitis||Assaf-Harofeh Medical Center|Yes|Enrolling by invitation|November 2010|June 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All patients having cystodistension suspected of painful bladder syndrome|November 2010|February 20, 2011|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01301365||108644|
NCT01301612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 110|Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)|A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma||Eurofarma Laboratorios S.A.|No|Withdrawn|January 2011|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||January 2012|July 10, 2014|February 21, 2011||No|Regulatory requirement. A phase III study is being designed.|No||https://clinicaltrials.gov/show/NCT01301612||108626|
NCT01301872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012005RB|Effect of Mechanical Ventilation Strategy on Lung Injury in Patients With Less Severe Acute Respiratory Distress Syndrome: Targeted on RAGE|Effect of Mechanical Ventilation Strategy on Lung Injury in Patients With Less Severe Acute Respiratory Distress Syndrome: Targeted on RAGE||National Taiwan University Hospital|No|Not yet recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|December 26, 2012|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301872||108606|
NCT01301885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOMET-231/2004|ENDOMET - Novel Diagnostic Tools and Treatments for Endometriosis|Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications|ENDOMET|Turku University Hospital|No|Active, not recruiting|October 2005|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|230|Samples With DNA|serum, peritoneal fluid, endometrium tissue, healthy peritoneum, tissue of endometriosis      (peritoneal, ovarian, deep infiltrating.      Extracted DNA, RNA, cDNA and protein from the above samples.|Female|19 Years|48 Years|Accepts Healthy Volunteers|Non-Probability Sample|Endometriosis: Finnish Caucasian women surgically treated for endometriosis; age 19-48, no        significant other disease or medication for other diseases        Healthy controls: symptomless Finnish Caucasian women going through laparoscopy for tubal        ligation; age 32-48, no significant other disease or medication|June 2012|June 1, 2012|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301885||108605|
NCT01302249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-12286-CS203|AR-12286 in Combination With Latanoprost|A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost||Aerie Pharmaceuticals|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302249||108577|
NCT01302509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1968|Enteral Nutrition in Cancer Patient|Enteral Nutrition Support in Children and Adolescents With Cancer: a Non-randomized Controlled Clinical Trial.||Grupo de Apoio ao Adolescente e a Crianca com Cancer|Yes|Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|1 Year|N/A|No|||February 2011|February 22, 2011|October 30, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01302509||108557|
NCT01311752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00703-50|Study of Human Papillomavirus Related Genital Pathology Among HIV Positive Women|Study of Human Papillomavirus Related Genital Pathology Among HIV Positive|ANRS CO17|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|November 2007|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|676|||Female|18 Years|65 Years|No|Non-Probability Sample||December 2012|December 26, 2012|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01311752||107852|
NCT01311713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C9722/2051|Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors|An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors||Teva Pharmaceutical Industries|No|Terminated|May 2011|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311713||107855|
NCT01311726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-7228|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2008|||||N/A|N/A|N/A||||||||||||||March 8, 2011|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311726||107854|
NCT01311739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMIS 112-C-01|Oral Cyanocobalamin (Eligen B12) Bioavailability Study|An Open-label, Single-Dose, Parallel-Group, Randomized Study of Comparative Bioavailability of B12 After Oral Administration of B2 Formulated With an Absorption Promoter (SNAC), Oral B12 Alone and IV B12 in Healthy Male Subjects||Emisphere Technologies, Inc.|No|Completed|May 2008|June 2008|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 8, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311739||107853|
NCT01313572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX-III-AP-002|Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI|The ASPECT2 Trial: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)|ASPECT2|Forest Laboratories|No|Terminated|August 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|197|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313572||107717|
NCT01309620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB A/08/045|Zinc Supplementation in Type 2 Diabetics|Does Zinc Supplementation Reduce the Extent of Oxidative Stress Damage in Diabetics? A Randomised Placebo-controlled Study.||National University Hospital, Singapore|No|Completed|January 2009|March 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||March 2011|March 3, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01309620||108014|
NCT01309633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP01/27/10|Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)|Phase II Open-label Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Systemic Therapy for Locally Advanced or Metastatic Nasopharyngeal Carcinoma||National University Hospital, Singapore|No|Recruiting|September 2011|February 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|No|||June 2015|June 17, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309633||108013|
NCT01309854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00014|Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects|An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily||AstraZeneca||Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 6, 2011|February 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309854||107996|
NCT01309867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|680|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2010|||||N/A|N/A|N/A||||||||||||||August 10, 2012|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309867||107995|
NCT01302366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU# 10-02181|A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma|A Phase II Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma||New York University School of Medicine|Yes|Terminated|February 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|February 14, 2011|Yes|Yes|due to lack of funding|No|January 26, 2015|https://clinicaltrials.gov/show/NCT01302366||108568|
NCT01302639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-03-032.7|Dietary Polyphenols and Lipid Oxidation|Dietary Polyphenols as Modulators of Lipid Oxidation and Mitochondrial Function in Overweight Volunteers||Maastricht University Medical Center|No|Completed|February 2011|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 8, 2014|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302639||108547|
NCT01302925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-01|PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects|PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate 0.05% and 0.015% Gel Followed by Hand Washing in Healthy Subjects.||Peplin|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|September 11, 2015|February 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302925||108527|
NCT01312402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101109|Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome|Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome||Akron Children's Hospital|No|Completed|January 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|12 Years|N/A|No|||June 2014|June 24, 2014|January 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312402||107803|
NCT01312415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKR-SMOH|The Analgesic Efficacy of Local Anaesthetic Wound Infiltration Versus Intrathecal Morphine for Total Knee Replacement|A Comparison of the Analgesic Efficacy of Local Anaesthetic Wound Infiltration Versus Intrathecal Morphine for Total Knee Replacement||Cork University Hospital|No|Recruiting|August 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312415||107802|
NCT01312675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA-I-H-0903|S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT|Randomized, Multi-Centre, Controlled Clinical Study on Effect of the Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) Therapy on Disease Severity and Inflammation in Mechanically-Ventilated Subjects Due to Severe Sepsis|SAFEbt|B. Braun Medical Inc.|Yes|Suspended|April 2011|June 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|March 8, 2011|Yes|Yes|Suspended to conduct interval analysis.|No||https://clinicaltrials.gov/show/NCT01312675||107782|
NCT01304641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2581188|Cardiovascular Events Based On Statin Initiation In The Elderly|Comparison Of Cardiovascular Event Rates In Elderly Patients With Newly Initiated Atorvastatin Or Simvastatin||Pfizer|No|Completed|November 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|31603|||Both|65 Years|N/A|No|Non-Probability Sample|This study included commercial health plan members and Medicare Advantage Part D enrollees        ages 65 years and older with a prescription for atorvastatin or simvastatin filled between        01 July 2006 and 30 November 2008 (subject identification period). The first observed        atorvastatin or simvastatin fill during the subject identification period was defined as        the index drug and the fill date was defined as the index date. A 12-month period prior to        the index date (defined as the pre-index period) was used for identification of comorbid        exclusionary conditions. The 12-month period prior to index date was also used for        assessment of pre-index patient characteristics. Patients were observed for a minimum of 3        months (following index date) until the earlier of either 1) disenrollment from the health        plan or 2) 28 February 2009 (post-index period). The pre- and post-index periods in        combination were defined as the analytic period.|March 2012|March 8, 2012|February 24, 2011|No|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01304641||108395|
NCT01304914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC10/QRCH16|Observational Research in Childhood Infectious Diseases Study|Prospective, Community-based, Longitudinal Dynamic Birth Cohort Study of Respiratory and Gastrointestinal Pathogen Identification in Brisbane Infants.|ORChID|Queensland Children's Medical Research Institute|No|Active, not recruiting|August 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|138|Samples With DNA|Parent-collected anterior-nasal swabs Nappy swabs|Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, term-delivered babies|April 2013|April 22, 2013|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304914||108374|
NCT01304927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010124801|Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial|Vitamin D Supplementation and Male Infertility: The Copenhagen Bone-Gonadal Study a Double Blinded Randomized Clinical Trial||Rigshospitalet, Denmark|Yes|Active, not recruiting|February 2011|April 2016|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Male|18 Years|N/A|No|||February 2016|February 3, 2016|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304927||108373|
NCT01300767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-336-C-019|Four Week Performance Comparison Between Two Commercially Available Silicone Hydrogel Lenses|4 Week Performance Comparison Between 2 Commercially Available Silicone Hydrogel Lenses||Alcon Research|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|N/A|N/A|No|||April 2012|June 26, 2012|February 18, 2011|Yes|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT01300767||108690|
NCT01301066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.05US|A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects|A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study||Kowa Research Institute, Inc.|No|Completed|December 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|252|||Both|18 Years|70 Years|No|||March 2014|March 27, 2014|February 18, 2011|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01301066||108667|
NCT01301378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-956 KeraSys|Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube|Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt||Wills Eye|Yes|Terminated|August 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|19 Years|N/A|No|||December 2012|December 20, 2012|February 22, 2011||No|kerasys had more erosions than tutoplast|No||https://clinicaltrials.gov/show/NCT01301378||108643|
NCT01310543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTRCT|Trial of the Teens and Toddlers Intervention|RCT of the Teens and Toddlers Intervention||London School of Hygiene and Tropical Medicine|Yes|Recruiting|December 2009|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|360|||Female|13 Years|14 Years|Accepts Healthy Volunteers|||April 2011|April 11, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01310543||107943|
NCT01310764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|971|Trabeculectomy With Subconjunctival Bevacizumab Injection|Efficacy and Safety of Trabeculectomy With Subconjunctival Bevacizumab Versus Trabeculectomy With Mitomycin C.||Rassoul Akram Hospital|Yes|Completed|April 2009|July 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||April 2009|March 28, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310764||107926|
NCT01311128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6980|Determination of the Accuracy of a Non-Invasive Continuous Blood Pressure Device|Determination of the Accuracy of a Non-Invasive Continuous Blood Pressure Device||Oregon Health and Science University|Yes|Recruiting|March 2011|||September 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2011|May 27, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311128||107899|
NCT01311141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020778-41|Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers Dori_MD_1|Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers - a Pilot Study||Medical University of Vienna||Completed|August 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2010|March 31, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311141||107898|
NCT01312584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading-2010-01|The Effects of Alkalised Cocoa on Human Vascular Function|The Effect of Alkalisation on the Absorption, Metabolism and Vascular Reactivity of Cocoa Flavanols||University of Reading|Yes|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|10|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||November 2010|March 9, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312584||107789|
NCT01311999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201009057R|Surveillance and Follow-up for Latent Tuberculosis Infection and Risk of Developing Active Tuberculosis in Patients Receiving Long-term Dialysis|Surveillance and Follow-up for Latent Tuberculosis Infection and Risk of Developing Active Tuberculosis in Patients Receiving Long-term Dialysis||National Taiwan University Hospital|No|Completed|February 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|234|||Both|18 Years|N/A|No|Probability Sample|The patients receiving long-term dialysis|December 2013|December 3, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01311999||107834|
NCT01313897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114344|UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma|UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma|NK2010-35|University of Arkansas|Yes|Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313897||107692|
NCT01313910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225193 (201118675)|CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements|CCRC: A Pilot Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements||University of California, Davis|No|Active, not recruiting|March 2011|February 2013|Anticipated|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313910||107691|
NCT01313949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2009-087|PLATINUM Program: A Feasibility Study on a Train-the-trainer Course on Peer Support for People With Type 2 Diabetes|Peer Leaders Accelerated Training Initiative to Unleash Potential of Mentorship (PLATINUM) Program: A Feasibility Study on a Train-the-trainer Course on Peer Support for People With Type 2 Diabetes|PLATINUM|Asia Diabetes Foundation|Yes|Completed|February 2009|August 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|75|||Both|18 Years|75 Years|No|||July 2014|July 21, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01313949||107688|
NCT01309646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114260|Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine|Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix™-IPV+Hib) Vaccine in Healthy Korean Infants||GlaxoSmithKline||Completed|March 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|454|||Both|42 Days|69 Days|Accepts Healthy Volunteers|||February 2013|April 18, 2013|February 24, 2011|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01309646||108012|
NCT01302054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221094|A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.|A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).||Pfizer|Yes|Completed|May 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|990|||Both|18 Years|N/A|No|||March 2013|March 22, 2013|February 18, 2011|Yes|Yes||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01302054||108592|
NCT01302067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221095|A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine|A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.||Pfizer|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|2012|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|February 18, 2011|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01302067||108591|
NCT01302379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54 CA155435-01 Project 3|Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors|Obesity-related Mechanisms and Mortality in Breast Cancer Survivors||University of California, San Diego|Yes|Active, not recruiting|August 2011|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|333|||Female|N/A|N/A|No|||December 2015|December 8, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302379||108567|
NCT01302392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-171-011|A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma|A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma|FOCUS|Onyx Pharmaceuticals|Yes|Completed|September 2010|September 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|315|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|February 10, 2011||No||No|July 6, 2015|https://clinicaltrials.gov/show/NCT01302392||108566|
NCT01302405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-724-101|Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors|A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors||Prism Pharma Co., Ltd.|Yes|Terminated|February 2011|June 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|February 18, 2011|No|Yes|closing due to low enrollment, no safety issues|No||https://clinicaltrials.gov/show/NCT01302405||108565|
NCT01302652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002188|Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment|Effects of Physiologic Growth Hormone Administration on Echocardiographic Parameters in Subjects With Growth Hormone Deficiency Following Cure of Acromegaly||Massachusetts General Hospital|No|Completed|February 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|Samples Without DNA|serum and plasma|Both|18 Years|75 Years|No|Non-Probability Sample|Men and women between age 18-75 who have developed growth hormone deficiency after history        of acromegaly with biochemical cure.|March 2015|March 17, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01302652||108546|
NCT01302938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121195|Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder|Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Center, Web-Based Phase IV Pilot Methodology Trial To Evaluate The Efficacy And Safety Of Tolterodine ER In Subjects With Overactive Bladder|REMOTE|Pfizer|No|Terminated|March 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Female|21 Years|N/A|No|||July 2013|July 22, 2013|February 22, 2011|Yes|Yes|Stop date for randomization: 31/5/2012. Recruitment terminated due to lack of recruitment. No    new safety issues were identified.|No|July 22, 2013|https://clinicaltrials.gov/show/NCT01302938||108526|The study was terminated prematurely due to low participant enrollment and due to relatively small sample size; results should be interpreted with caution. Early termination of the study was not related to any safety concern.
NCT01302951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24/06|Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.|Study on Pharmacokinetics of Moxifloxacin in Serum and Liver Tissue of Patients Undergoing Liver Resection Due to Primary or Secondary Tumor of the Liver|MOXI|University Hospital, Saarland|No|Completed|July 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|80 Years|No|||February 2011|February 23, 2011|January 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302951||108525|
NCT01313364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108HV104|A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle|A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle||Biogen|No|Terminated|March 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 11, 2011|March 10, 2011||No|The objective of the study has been achieved with fewer subjects than planned.|No||https://clinicaltrials.gov/show/NCT01313364||107733|
NCT01300780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17838/2010|Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching.|Effect of Preoperative Use of an Anti-inflammatory on Tooth Sensitivity Caused by In-office Bleaching: a Randomized, Double-blind Clinical Trial.||Universidade Estadual de Ponta Grossa|Yes|Enrolling by invitation|April 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||November 2011|November 12, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01300780||108689|
NCT01300793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06253|Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide|(RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL|V-RICE|University of California, San Francisco|Yes|Terminated|May 2007|April 2012|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|September 24, 2009|Yes|Yes|closed for low accrual and no data is available.|No||https://clinicaltrials.gov/show/NCT01300793||108688|
NCT01301053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15144|Pilot Study of Intensive Care Unit Continuous Glucose Monitoring|Pilot Study of Intensive Care Unit Continuous Glucose Monitoring||University of Virginia|Yes|Enrolling by invitation|February 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||January 2013|January 30, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301053||108668|
NCT01301079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anaana|Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia|Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Using Filaments, an Algometer, and Interleukins: a Double-blind, Randomized Study||Federal University of São Paulo|Yes|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|78 Years|No|||October 2014|November 6, 2014|February 22, 2011||No||No|November 10, 2013|https://clinicaltrials.gov/show/NCT01301079||108666|
NCT01310088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORTA-SJ-166|Blood Pressure and Central Vascular Stiffness in Obese Children. Relationship to Metabolic Disturbances and Subclinical Cardiovascular Damage. Effect of Weight Reduction|Blood Pressure and Central Vascular Stiffness in Obese Children. Relationship to Metabolic Disturbances and Subclinical Cardiovascular Damage. Effect of Weight Reduction|AORTA|Roskilde County Hospital|No|Recruiting|March 2011|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||March 2011|March 10, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01310088||107978|
NCT01310322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2340C00008|A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways|An Open, Partly Randomised, Four-way Cross-over Study in Healthy Subjects and in Patients With Mild Allergic Asthma to Investigate the Bioavailability and Basic Pharmacokinetics of a Single Dose of AZD5423 When Administered Intravenously, Orally, Inhaled Via SPIRA Nebuliser or Inhaled Via I-neb® AAD Systems||AstraZeneca||Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|February 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01310322||107960|
NCT01310556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.05.2009-131-1068|Unknown Glucose Metabolism Disorders In Patients With Coronary Artery Disease|The Relationship Between Previously Unknown Glucose Metabolism Disorders and Coronary Artery Disease in Patients Suffering From Coronary Artery Disease||Gulhane School of Medicine|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|230|||Both|30 Years|70 Years|No|Probability Sample|patients with coronary artery disease and who had no glucose metabolism disorders.|June 2009|June 17, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310556||107942|
NCT01310569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27.04.2010/1491-764-10|Subcutaneous Adipose Tissue in Cases With Polycystic Ovarian Syndrome|Relationship of Subcutaneous Adipose Tissue With HOMA-IR and Plasma Adiponectin Levels in Cases With Polycystic Ovarian Syndrome||Gulhane School of Medicine|No|Completed|January 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|52|||Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with PCOS witout any other metabolik diseases|August 2010|March 7, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310569||107941|
NCT01310777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-040|Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension|Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|May 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|771|||Both|18 Years|N/A|No|||December 2013|January 24, 2014|March 7, 2011|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01310777||107925|
NCT01310790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSN-6091-DaweiLiu|Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock|Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis||Chinese Septic Shock Network|Yes|Completed|October 2006|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|420|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01310790||107924|
NCT01311154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-0425-10-TLV|Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria|Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria - WP5|SATURN|Tel-Aviv Sourasky Medical Center|Yes|Recruiting|February 2011|July 2015|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|known carriers of resistant Enterobacteriaceae|March 2011|March 7, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311154||107897|
NCT01312909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051073|Smoking Cessation Study In Healthy Adolescent Smokers|A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers||Pfizer|Yes|Recruiting|April 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|12 Years|19 Years|No|||March 2016|March 23, 2016|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312909||107766|
NCT01313234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFR20100046019|Educational Intervention Targeting Nurses Attitudes and Knowledge About Cancer-related Pain Management|A Theory Based Educational Intervention Targeting Nurses Attitudes and Knowledge Concerning Cancer-related Pain Management: A Study Protocol of a Quasi-experimental Study Design||Blekinge Institute of Technology|No|Completed|April 2011|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 5, 2013|March 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01313234||107743|
NCT01312883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P60MD000270-06|Mothers Avoiding Depression Through Empowerment Intervention Trial|Center for Achieving and Sustaining Improved Health in Harlem: Patient Education to Reduce Postpartum Depressive Symptoms Among Minority Women|MADE IT|Icahn School of Medicine at Mount Sinai|Yes|Completed|September 2007|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|540|||Female|18 Years|N/A|No|||March 2011|March 9, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312883||107767|
NCT01313611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIEF|BRIEF Bendamustine and Rituximab In Elderly Follicular|BRIEF: Bendamustine and Rituximab In Elderly Follicular: A Multicentric Phase II Study Evaluating the Benefit of a Short Induction Treatment by Bendamustine and Rituximab Followed by Maintenance Therapy With Rituximab In Elderly (≥ 60 Years Old) Patients With Untreated Follicular Lymphoma Patients, With an Intermediate or High FLIPI Score|BRIEF|The Lymphoma Academic Research Organisation|Yes|Terminated|February 2011|June 2017|Anticipated|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|60 Years|N/A|No|||April 2015|April 7, 2015|February 21, 2011||No|Treament with rituximab during maintenance phase was stoped, according to DSMC    recommendations, since 3 cases of deaths occured.|No||https://clinicaltrials.gov/show/NCT01313611||107714|
NCT01313923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-7844|Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus|Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus||University of California, Irvine|No|Terminated|February 2011|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2016|February 24, 2016|March 10, 2011||No|Lack of funding|No|December 17, 2014|https://clinicaltrials.gov/show/NCT01313923||107690|No results as study has been terminated early by the investigator.
NCT01313936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIBG Irino|High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma|Pilot Study of High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed High-Risk Neuroblastoma||University of California, San Francisco|Yes|Completed|March 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|1 Year|30 Years|No|||July 2015|July 14, 2015|March 10, 2011|Yes|Yes||No|July 14, 2015|https://clinicaltrials.gov/show/NCT01313936||107689|
NCT01301716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4946g|A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors||Genentech, Inc.||Completed|September 2011|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01301716||108618|
NCT01302080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501093|Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)|Sprites: Sertraline Pediatric Registry For The Evaluation Of Safety|SPRITES|Pfizer|No|Recruiting|April 2012|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|900|||Both|6 Years|16 Years|No|Non-Probability Sample|The accessible population is children meeting inclusion/exclusion criteria from US centers        in various clinical settings, including the Child and Adolescent Psychiatry Trials Network        (CAPTN). From these, the study-eligible population (all children age 6 to 16 (inclusive)        with an anxiety, depressive, or obsessive-compulsive disorder, who are exposed to        sertraline under real-world conditions) will comprise an inception cohort of enrolled        subjects beginning treatment for one of the study-qualifying disorders with sertraline or        psychotherapy.|March 2016|March 16, 2016|February 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302080||108590|
NCT01302093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RACDIR1001|Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Racecadotril 100 mg FCT Versus Tiorfast® 100 mg Capsules, in Normal, Healthy, Non-Smoking Male and Female Subjects||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2011|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302093||108589|
NCT01302106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO2009AISSM05|Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes|Phase II Study of Clofarabine in Combination With Low Dose Cytarabine for Untreated Patients With Poor Risk Myelodysplastic Syndromes|CLO2009AISSM05|Fondazione Italiana Sindromi Mielodisplastiche Onlus|No|Withdrawn||||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|55 Years|80 Years|No|||September 2013|September 30, 2013|December 22, 2010||No|For increased induction mortality in older patients due to specific combinations of drugs,    other clinical factors such as patient age and comorbidities.|No||https://clinicaltrials.gov/show/NCT01302106||108588|
NCT01302691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954E-357|MK-0954E Study in Participants With Hypertension (MK-0954E-357)|A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration||Merck Sharp & Dohme Corp.|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|327|||Both|20 Years|80 Years|No|||April 2015|April 20, 2015|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302691||108545|
NCT01302964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P00009|Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders|Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders||Massachusetts General Hospital|Yes|Recruiting|August 2010|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|17 Years|No|||March 2016|March 13, 2016|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01302964||108524|
NCT01309438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017968|A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function|An Open-Label Study to Estimate the Effect of Multiple Doses of Erythromycin on the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With Renal Impairment and Normal Renal Function||Janssen Research & Development, LLC||Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 7, 2014|February 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01309438||108027|
NCT01304953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJHMZK11001|Tropisetron on Postoperative Pain|Tropisetron on Postoperative Pain in Women After Gynaecological Laparoscopy||Huazhong University of Science and Technology|Yes|Completed|January 2010|December 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|296|||Female|18 Years|50 Years|No|||February 2011|February 25, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304953||108371|
NCT01300806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09035355|Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting|Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting|SBIRT|University of California, San Francisco|Yes|Completed|July 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|210|||Both|18 Years|N/A|No|Probability Sample|primary care clinic patients|May 2013|May 20, 2013|February 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01300806||108687|
NCT01300819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0976|Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms|Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease||UCB Pharma|No|Completed|February 2011|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|349|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|February 18, 2011|Yes|Yes||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01300819||108686|
NCT01310335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-1|Effect of Whole-Body Vibration on Plasma Sclerostin Level|Effect of Whole-Body Vibration on Plasma Sclerostin Level in Healthy Young Adult Women|WBV-SCL|Bagcilar Training and Research Hospital|No|Completed|April 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310335||107959|
NCT01310582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19326|Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females|Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females||Hahnemann University Hospital|No|Completed|May 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|57|||Female|60 Years|85 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|March 7, 2011||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01310582||107940|
NCT01310803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3329-301|Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder|A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER||Endo Pharmaceuticals||Terminated|May 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|March 4, 2011|Yes|Yes||No|October 16, 2014|https://clinicaltrials.gov/show/NCT01310803||107923|This study was terminated early. Only one subject was enrolled. No study results were generated.
NCT01310816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-926-04|A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma|A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma||Infinity Pharmaceuticals, Inc.|Yes|Completed|February 2011|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310816||107922|
NCT01310829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0456|Virtual Reality Intervention in Cancer Genetics|Developing Providers' Communication and Counseling Skills in Cancer Genetics Using Virtual Reality||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2011|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Genetic counselors and genetic counseling students|April 2015|April 6, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310829||107921|
NCT01311167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexa_Cirr_2011|Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone|Prospective Randomized Double Blind Placebo Controlled Intervention Study of the Effect of Dexamethasone on the Sodium Retention in Patients With Liver Cirrhosis||University Hospital Inselspital, Berne|Yes|Terminated|February 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||April 2013|April 17, 2013|March 7, 2011||No|Recruitment problems (not enough patients were found who met eligibility criteria)|No||https://clinicaltrials.gov/show/NCT01311167||107896|
NCT01311180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Natreon-GAD-02-001|A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder|A Phase II Double-Blind, Parallel Group, Randomized, Placebo Controlled Clinical Trial of Sensoril® for Patients With Generalized Anxiety Disorder.||Natreon, Inc.||Completed|March 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||April 2015|April 20, 2015|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01311180||107895|
NCT01312012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010078M, 201507025RINC|The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test|The Effectiveness and Feasibility of Using Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test and Follow-up Study||National Taiwan University Hospital|No|Recruiting|January 2011|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|20 Years|40 Years|No|||October 2015|October 25, 2015|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01312012||107833|
NCT01311440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2326 (REK)|Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy|Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy - a Controlled, Randomized Trial||Oslo University Hospital|No|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|16 Years|N/A|No|||April 2015|April 21, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311440||107875|
NCT01313260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-21|Structural and Functional Connectivity in Partial Epilepsies Studied With MRI and MEG|Structural and Functional Connectivity in Partial Epilepsies Studied With MRI and MEG||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|February 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Refractory partial epilepsy patients|January 2012|September 27, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01313260||107741|
NCT01312935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMX56-203|Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)|A Phase 2 Proof of Concept Study of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)||PolyMedix, Inc.|No|Terminated|April 2011|August 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||May 2012|May 16, 2012|March 8, 2011|Yes|Yes|PolyMedix decided to stop enrollment in both clinical trials due to observations of reductions    in blood pressure.|No||https://clinicaltrials.gov/show/NCT01312935||107764|
NCT01313247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Par 06-0045|Paracetamol for Cancer Pain|Optimizing Medication for Cancer Pain. The Effect of Paracetamol. A Clinical and Pharmacological Trial to Research Whether Paracetamol Gives an Additional Effect on Pain Relief When the Patient is Treated With High Doses of Opioids||Haraldsplass Deaconess Hospital|No|Not yet recruiting|April 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2011|March 10, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313247||107742|
NCT01301482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110009H|Ear Acupuncture for Acute Sore Throat in Patients Unable to Take Non-steroidal Anti-inflammatory Agents (NSAIDs)|Ear Acupuncture for Acute Sore Throat in Patients Unable to Take Non-steroidal Anti-inflammatory Agents (NSAIDs)||Mike O'Callaghan Federal Hospital|No|Completed|October 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301482||108635|
NCT01301248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEEK2008RCT2|Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck|Phase II Safety and Toxicity Study of Cisplatin With or Without Cetuximab and Concomitant Radiotherapy for Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)||Theagenio Cancer Hospital|Yes|Active, not recruiting|March 2008|June 2011|Anticipated|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2011|May 16, 2011|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301248||108653|
NCT01301495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14989|Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus|Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus||Weill Medical College of Cornell University|No|Withdrawn|November 2010|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|February 17, 2011|Yes|Yes|No participants enrolled for more than 1 year.|No||https://clinicaltrials.gov/show/NCT01301495||108634|
NCT01301729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25288|A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment|A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer||Hoffmann-La Roche||Completed|March 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|February 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01301729||108617|
NCT01302418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-INFLUENZA-001|Collection and Testing of Respiratory Samples|Testing of Respiratory Specimens for the Validation of the QIAGEN ResPlex II Advanced Panel Test and the Artus Influenza A/B RT-PCR Test||QIAGEN Gaithersburg, Inc|No|Completed|February 2011|November 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|272|Samples With DNA|Extracted nucleic acid, Residual Universal Transport Medium|Both|N/A|N/A|No|Non-Probability Sample|The study population includes individuals having the signs and symptoms of an acute        respiratory tract infection suspected of being caused by a respiratory virus.|May 2012|May 22, 2012|February 18, 2011||No||No|March 23, 2012|https://clinicaltrials.gov/show/NCT01302418||108564|
NCT01303510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A002|A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2008/2009-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations||Crucell Holland BV|No|Completed|July 2008|July 2008|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|February 23, 2011||No||No|October 10, 2011|https://clinicaltrials.gov/show/NCT01303510||108482|
NCT01302977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 1087/07|Fetal Tracheal Occlusion in Severe Diaphragmatic Hernia: a Randomized Trial|Tracheal Occlusion Guided by Percutaneous Fetoscopy in Fetuses With Severe Isolated Congenital Diaphragmatic Hernia|BRAFETO|University of Sao Paulo General Hospital|Yes|Recruiting|May 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|N/A|N/A|No|||February 2011|February 23, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01302977||108523|
NCT01302990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-H1VLP-003|Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults|Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults||Medicago|Yes|Completed|February 2011|November 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|100|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2013|August 15, 2013|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302990||108522|
NCT01310751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJTUMS-200903|Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery|Randomized Double-blind Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension (PH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Disease (CHD)||Shanghai Jiao Tong University School of Medicine|Yes|Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|N/A|12 Years|No|||November 2015|November 22, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310751||107927|
NCT01309555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-521|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Australia|Easypod Connect: An Australian Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|ECOS AUS|Merck KGaA|No|Active, not recruiting|April 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|32|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the Easypod™ electromechanical device.|March 2015|March 3, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309555||108019|
NCT01309789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-011|A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms|A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma||Seattle Genetics, Inc.|No|Active, not recruiting|February 2011|June 2017|Anticipated|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|February 25, 2011|No|Yes||Yes||https://clinicaltrials.gov/show/NCT01309789||108001|
NCT01310595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HongKong PU|Manual Therapy on Head-repositioning Accuracy and Static Postural Balance in Neck Pain Patients|To Investigate the Effectiveness of Manual Therapy on Head-repositioning Accuracy and Static Postural Balance in Patients With Non-traumatic Chronic Mechanical Neck Pain.||The Hong Kong Polytechnic University|No|Completed|January 2010|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|65 Years|No|||August 2013|August 26, 2013|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310595||107939|
NCT01310842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0950|Social Determinants and Smoking Cessation|Social Determinants and Smoking Cessation||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2012|||July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|320|Samples Without DNA|Saliva samples at Baseline, week 12, and week 26 visits collected for cotinine tests.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Current smoker, age 18 years or above, with a history of at least 5 cigarettes/day for the        last year and resides in Houston, Texas.|December 2015|December 31, 2015|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01310842||107920|
NCT01311193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Velux-425|Circadian Sleep-wake Cycles and Light Therapy in Borderline Personality Disorder|Circadian Sleep-wake Cycles, Well-being and Light Therapy in Borderline Personality Disorder||University Hospital, Basel, Switzerland||Completed||||||N/A|Interventional|N/A|1||||||Female|20 Years|45 Years||||March 2011|March 7, 2011|March 3, 2011||||No||https://clinicaltrials.gov/show/NCT01311193||107894|
NCT01311466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-06408|Liver Transplantation and Uveal Malignant Melanoma|||Oslo University Hospital||Completed|January 2011|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years||||October 2015|October 14, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311466||107874|
NCT01311765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081248|Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU|Comparison of Two Durations of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in Intensive Care Unit: a Randomised Multicentre Study|DURAPOP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2011|November 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|N/A|No|||July 2015|December 8, 2015|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01311765||107851|
NCT01312025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIE123AR|Conventional Versus Modified Laparoscopic Cholecystectomy|Randomized Controlled Trial Comparing Between The Conventional Technique of Laparoscopic Cholecystectomy and A Proposed Modified Technique||Mansoura University||Completed||||||N/A|Interventional|N/A|2||||||Both|10 Years|90 Years||||August 2009|March 9, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312025||107832|
NCT01312311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-07-005|Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer|Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer||Samsung Medical Center|No|Recruiting|July 2006|||May 2011|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01312311||107810|
NCT01312324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01-040|Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer|A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors||Samsung Medical Center|No|Recruiting|February 2007|March 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01312324||107809|
NCT01312298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OpHas2011/3|General vs. Intrathecal Anesthesia for Total Knee Arthroplasty|General vs. Intrathecal Anesthesia Fort Total Knee Arthroplasty; a Randomized Clinical Trial||Region Skane|Yes|Completed|August 2011|January 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|45 Years|85 Years|No|||January 2013|March 6, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312298||107811|
NCT01313273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-93-52030-738|Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients|Randomised, Phase III Multicenter, Open Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Presenting Elevated Chromogranin A Levels|POSEIDON|Ipsen|No|Terminated|June 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Male|18 Years|N/A|No|||August 2015|August 28, 2015|March 10, 2011||No|Poor enrolment|No|April 28, 2015|https://clinicaltrials.gov/show/NCT01313273||107740|Study terminated due to poor enrollment
NCT01313585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/10|Device Mixing in Asthma, a General Practice Research Database Study|Retrospective, Real-life Observational Evaluation of the Effectiveness of Mixed Maintenance and Reliever Inhaler Types in Patients in the Management of Asthma in a Representative UK Primary Care Population|EBsalbutamol|Research in Real-Life Ltd|Yes|Completed|January 1991|March 2010|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|815377|||Both|4 Years|80 Years|No|Non-Probability Sample|Asthma patients on SABA therapy (any available) monotherapy who, at the index date,        either:        (i) IPDI: initiate ICS therapy as BDP EB at the index date and also receive reliever        therapy as either*:          -  Salbutamol EB, or          -  Salbutamol MDI, OR, who (ii) IPDA: receive a recorded increase in ICS therapy as BDP             EB at the index date and also receive reliever therapy as either*:          -  Salbutamol EB, or          -  Salbutamol MDI.|March 2011|March 11, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313585||107716|
NCT01313286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14233|A Study to Compare Two Forms of LY2608204 in Healthy People|The Relative Bioavailability of a Proposed Phase 2 LY2608204 Test Formulation Compared With the Current Phase 1 LY2608204 Reference Formulation After Administration of a Single Oral 80-mg Dose in Healthy Subjects||Eli Lilly and Company|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 5, 2011|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01313286||107739|
NCT01301508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2898-AD-202|Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis|A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study of the Safety and Efficacy of Topically Applied AN2898 and AN2728 in the Treatment of Patients With Mild-to-Moderate Atopic Dermatitis||Anacor Pharmaceuticals, Inc.|No|Completed|May 2011|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|75 Years|No|||April 2012|April 30, 2012|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301508||108633|
NCT01301742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.58|Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers|Relative Bioavailability of Single Dose BI 10773 Co-administered With Multiple Doses of 600 mg Gemfibrozil Bid Compared to Single Dose Treatment of BI 10773 Alone in Healthy Volunteers - a Phase I, Open-label, Randomised, 2-way Crossover Trial||Boehringer Ingelheim||Completed|February 2011|||May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|February 22, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01301742||108616|
NCT01301755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002035R|Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration|Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration||National Taiwan University Hospital|No|Recruiting|March 2010|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|immunocompromised patients|February 2011|February 18, 2011|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01301755||108615|
NCT01302119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2690-ONYC-302|Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail|A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults||Anacor Pharmaceuticals, Inc.|No|Completed|February 2011|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|604|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|February 21, 2011|Yes|Yes||No|July 25, 2014|https://clinicaltrials.gov/show/NCT01302119||108587|
NCT01302132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0055|Mass Balance Study of ASP1941|An Open Label Study to Evaluate the Pharmacokinetics of ASP1941 After a Single Oral Dose of 14C-labeled ASP1941 in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|May 2008|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 21, 2011|February 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302132||108586|
NCT01303276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRVO-blood flow study|Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)|Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion||University of Toronto|No|Not yet recruiting|June 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with central retinal vein occlusion will be recruited from the Retina Clinics of        Toronto Western Hospital|February 2011|February 22, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01303276||108500|
NCT01303289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEGENAT-TDP STD UGR|Clinical Evaluation of a Normoproteic Diet|Clinical Evaluation of a Normoproteic Diet With Ultra High Temperature Treatment|STDUGR|Vegenat, S.A.|No|Completed|February 2006|December 2007|Actual|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|60|||Both|65 Years|N/A|No|||February 2011|February 22, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01303289||108499|
NCT01303770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSCogRehab|Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis|Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis||Tel Aviv University||Active, not recruiting|February 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2013|December 24, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303770||108462|
NCT01309568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0138-01-A|"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"|"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"||Quidel Corporation|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2500|Samples Without DNA|Leftover nasal mucus placed in viral transport media will be retained after culture for      possible RT-PCR.|Both|N/A|N/A|No|Probability Sample|Subjects current exhibiting influenza like illness.|May 2011|May 10, 2011|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309568||108018|
NCT01309802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-SIUSOM-11-001|A Two-Part Study of BOTOX® Therapy for Ischemic Digits|A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits||Southern Illinois University|Yes|Active, not recruiting|May 2011|May 2018|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||August 2015|August 26, 2015|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01309802||108000|
NCT01310101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O-DEX-1, OFA 113815|Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia|Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia||Brno University Hospital|Yes|Completed|April 2011|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||February 2015|February 1, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310101||107977|
NCT01311479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMT-09|Osteopathic Manipulation for Female Interstitial Cystitis Patients With Sacroiliac Joint Dysfunction|Osteopathic Manipulation as a Therapeutic Intervention for Female Interstitial Cystitis Patients With Sacroiliac Joint Dysfunction||Pelvic and Sexual Health Institute|No|Recruiting|November 2009|October 2018|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||April 2014|April 11, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311479||107873|
NCT01311778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA027781|Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse|Cannabidiol as Treatment Intervention for Opioid Relapse||Hurd,Yasmin, Ph.D.|Yes|Completed|February 2010|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 20, 2013|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311778||107850|
NCT01312038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO011010385|Effect of Simethicone on Eustachian Tube Dysfunction|A Pilot Study of the Effect of Simethicone in Adult Subjects With a Common Cold on Eustachian Tube Dysfunction||University of Pittsburgh|No|Active, not recruiting|March 2011|July 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||December 2015|December 4, 2015|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312038||107831|
NCT01312610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading_2010_OJOC|Orange Juice Consumption and Cognitive Function|Effect of Chronic Orange Juice Consumption on Cognitive Function in Healthy Older Adults|OJOC|University of Reading|Yes|Completed|September 2010|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|40|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312610||107787|
NCT01312597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading-2011-01|Effects of Flavonoids on Cognitive Performance in Healthy Young Adults|Effects of Flavonoids on Cognitive Performance in Healthy Young Adults||University of Reading|Yes|Completed|October 2010|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312597||107788|
NCT01313598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0187-CL-102|GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors|An Open-label, Dose Escalating Phase Ib Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of GLPG0187 in Subjects With Solid Tumors||Galapagos NV|Yes|Completed|March 2011|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||June 2013|June 9, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01313598||107715|
NCT01301209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078/2006|Recto-Anal-Repair in the Treatment of Advanced Haemorrhoidal Disease|Prospective Observational Study of Recto-Anal-Repair in the Treatment Haemorrhoidal Disease Stage III/IV||Medical University of Vienna|No|Completed|January 2007|December 2007|Actual|December 2007|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with haemorrhoids stage III/IV|June 2006|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301209||108656|
NCT01302431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLTSI|Nurse-Led Manualized Telephone Support Intervention|An Exploratory Randomized Controlled Trial of a Manualized, Nurse-led, Telephone Intervention Support Service for Support Persons of People With Multiple Sclerosis||University of Dublin, Trinity College|Yes|Completed|April 2011|March 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|71|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302431||108563|
NCT01302171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-013112-12|Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy|Randomised Controlled Trial to Compare the Effects of G-CSF (Granocyte™) and Autologous Bone Marrow Progenitor Cells on Quality of Life and Left Ventricular Function in Patients With Idiopathic Dilated Cardiomyopathy|REGEN-DCM|Barts & The London NHS Trust|Yes|Completed|August 2010|July 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||November 2013|November 14, 2013|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01302171||108583|
NCT01302704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110003H|The Influence of Proton Pump Inhibitors (PPI's) on Blood Levels of 25-Hydroxyvitamin D.|The Influence of Proton Pump Inhibitors (PPI's) on Blood Levels of 25-Hydroxyvitamin D.||Mike O'Callaghan Federal Hospital|No|Withdrawn|April 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We are recruiting healthy volunteers (DoD beneficiaries) whom are at least 18 years of age        from the Nellis Air Force Base population. Subjects will not have any concomitant medical        conditions, been diagnosed with any chronic illness that requires regular monitoring by a        health care provider, have been living in Las Vegas for at least 3 months, and not be on        any medications. Some subjects may be the PI or AI's patients. No special populations will        be recruited.|November 2013|November 21, 2013|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302704||108544|
NCT01303003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-00560|Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block|Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block: Does it Enhance the Quality and Duration of Analgesia?||Steward St. Elizabeth's Medical Center of Boston, Inc.|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|85 Years|No|||April 2015|April 9, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303003||108521|
NCT01303016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MANI II, Shoulder to Shoulder|Improving Nutrition and Health Outcomes in Intibuca, Honduras|Improving Nutrition and Health Outcomes in Intibuca, Honduras|MANI II|Shoulder to Shoulder|Yes|Active, not recruiting|May 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|639|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||March 2011|March 5, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303016||108520|
NCT01303029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-10-01|Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer|A Phase IIb Randomized Study to Evaluate the Efficacy of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer|GECA|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Completed|February 2011|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01303029||108519|
NCT01304108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006359|Improving Venous Thromboembolism Prophylaxis|Spreading and Improving DVT Prophylaxis at Mayo Clinic (DVT-P-Spread)||Mayo Clinic|No|Completed|January 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|3000|||Both|17 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 24, 2011|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01304108||108436|
NCT01303523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC|Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort|Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort.|M2M-Thrombose|Floralis|Yes|Completed|December 2010|July 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1627|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients with a lower limb trauma, in winter sports resorts|March 2015|March 5, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303523||108481|
NCT01303536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OND2|Ondansetron Augmentation in Treatment-resistant OCD|Ondansetron Augmentation in Treatment-resistant OCD||Institute of Neuroscience, Florence, Italy|Yes|Completed|December 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|60 Years|No|||February 2011|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303536||108480|
NCT01309815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Haug, SKH|Existential Issues in Elderly People With Cancer|Existential Issues in Elderly People With Cancer in an Early Palliative Phase- a Phenomenological Hermeneutic Approach||Sykehuset Innlandet HF|Yes|Completed|February 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|21|||Both|70 Years|N/A|No|Non-Probability Sample|Cancer patients from 70 years and older, receiving palliative treatment and care in        Innlandet Hospital Trust|January 2013|January 25, 2013|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309815||107999|
NCT01310114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA001-SK-001|Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke|A Phase 2A, Prospective, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults Following Ischemic Stroke||Celgene|Yes|Terminated|March 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|80 Years|No|||July 2014|July 16, 2014|February 25, 2011|Yes|Yes|Study terminated by sponsor|No||https://clinicaltrials.gov/show/NCT01310114||107976|
NCT01310127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-02-11|Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%|Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery||Discover Vision Centers|No|Completed|November 2010|May 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|March 1, 2011||No||No|April 25, 2013|https://clinicaltrials.gov/show/NCT01310127||107975|The major limitation in the study is that it was a small pilot study so that the direct correlations of the study variable could not be evaluated. There were ethnic differences in the groups that could also influence the data.
NCT01310348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-2|Effect of Bone on Vibration-Induced Muscle Strength Gain|Effect of Bone Mineral Density on Vibration-Induced Muscle Strength Gain at The Lower Limbs|EBVIMSG|Bagcilar Training and Research Hospital|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 12, 2012|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310348||107958|
NCT01311791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSH-10-001|A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure|A Randomized, Controlled Study to Evaluate the Safety and Cardiovascular Effects of Algisyl-LVR™ as a Method of Left Ventricular Augmentation in Patients With Dilated Cardiomyopathy (AUGMENT-HF)|AUGMENT-HF|LoneStar Heart, Inc.|Yes|Active, not recruiting|August 2012|April 2016|Anticipated|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|79 Years|No|||June 2015|June 24, 2015|March 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01311791||107849|
NCT01312051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD027503|Childhood Metabolic Markers of Adult Morbidity in Blacks|||Children's Hospital of Pittsburgh|No|Recruiting|July 2004|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|200|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy black and white volunteers who are 8 to 17 years of age|January 2011|March 9, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01312051||107830|
NCT01312337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-07-252|Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)|A Phase II Trial of Gefitinib Monotherapy in Pretreated Patients With Advanced Non-small Cell Lung Cancer Not Harboring Active EGFR Mutations||Samsung Medical Center|No|Recruiting|September 2010|||August 2012|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||March 2011|March 8, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01312337||107808|
NCT01312350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-10-028|Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)|Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study||Samsung Medical Center|No|Recruiting|November 2010|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01312350||107807|
NCT01312363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-MEN|Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients|A Six-month, Open Labeled, Multi-centered, Observational Study for the Tolerability of Exelon Patch (Rivastigmine) for Patients With Alzheimer's Disease|X-MEN|Seoul National University Hospital|Yes|Recruiting|June 2009|July 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|51 Years|85 Years|No|Non-Probability Sample|Patients with Alzheimer's disease|March 2011|March 8, 2011|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01312363||107806|
NCT01312376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 26810, R01 FD 003520|Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer|A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vaccine||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|March 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|12|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312376||107805|
NCT01312922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNB01-C301|Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)|Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks||PharmaNeuroBoost N.V.|No|Completed|September 2011|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|555|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01312922||107765|
NCT01300910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10220|Comparison of the Shang Ring With Conventional Surgical Methods|Comparison of the Shang Ring With Conventional Surgical Methods: A Randomized Controlled Trial||FHI 360|Yes|Completed|February 2011|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|54 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01300910||108679|
NCT01300923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003-26|Acamprosate in Youth With Fragile X Syndrome|Pilot Study of Acamprosate in Youth With Fragile X Syndrome||Indiana University|Yes|Completed|August 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|5 Years|17 Years|No|||May 2015|May 14, 2015|August 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01300923||108678|
NCT01301222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVSMHEC|Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas|Randomized Controlled Trial on Role of Octreotide in Preventing Pancreatic Fistula and Complications After Pancreaticoduodenectomy in Patients With Soft Pancreas|PD|PVS Memorial Hospital|No|Completed|September 2010|February 2015|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|25 Years|75 Years|No|||February 2015|February 21, 2015|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301222||108655|
NCT01300936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0876-P6H|Trunk Strength Study|Abdominal Wall Hernias and Abdominal Wall Function: A Quantitative Study of Trunk Strength.||University of Kentucky|No|Completed|March 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients who will undergo laparoscopic ventral hernia repair or open repair. People        between the ages of 18 to 65 in relative good health.|March 2011|March 10, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300936||108677|
NCT01302184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROLEP|Robotic Locomotor Experience Applied to Parkinson's Disease|Robotic Locomotor Experience Applied to Parkinson's Disease (ROLEP)|ROLEP|Azienda Ospedaliero Universitaria Maggiore della Carita|No|Active, not recruiting|October 2010|October 2011|Anticipated|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|75 Years|No|||September 2011|September 26, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302184||108582|
NCT01302444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2 Trial|Treprostinil Combined With Tadalafil for Pulmonary Hypertension|Randomized Placebo Controlled Trial of Treprostinil Infusion Combined With Oral Tadalafil or Placebo in Pulmonary Arterial Hypertension|T2|Rhode Island Hospital|Yes|Terminated|March 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|80 Years|No|||April 2012|July 18, 2013|February 16, 2011||No|One subject enrolled and completed this study. The study was stopped due to poor recruitment.|No|June 7, 2013|https://clinicaltrials.gov/show/NCT01302444||108562|
NCT01302717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVPACE|Left Ventricular Pacing to Avoid Cardiac Enlargement Study|Impact of Left Ventricular Pacing on Left Ventricular Systolic Function in High-risk Bradycardia Patients|LVPACE|Seoul National University Hospital|No|Recruiting|April 2010|December 2019|Anticipated|December 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|N/A|80 Years|No|||November 2014|November 17, 2014|February 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01302717||108543|
NCT01302730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STANIRB-20278|Ankylosing Spondylitis and Spondyloarthritis Evaluation Tool Study|A Self-Administered Questionnaire for Early Detection of Axial Spondyloarthritis||Stanford University|No|Completed|April 2011|November 2013|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|490|||Both|18 Years|N/A|No|Non-Probability Sample|All patients referred to rheumatologist office will be potentially eligible.|November 2013|November 6, 2013|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01302730||108542|
NCT01303796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC682-12|A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia|SEAMLESS|Cyclacel Pharmaceuticals, Inc.|Yes|Active, not recruiting|January 2011|November 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|485|||Both|70 Years|N/A|No|||September 2012|August 17, 2015|February 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01303796||108460|
NCT01304121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSSHP#2701/2007|Bioactive Glass Granules in Filling of Bone Defects|Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects||Turku University Hospital|No|Completed|October 2006|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||June 2011|June 15, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01304121||108435|
NCT01304368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3953|Effects of Thermotherapy on Chronic Neck Pain|Randomized Controlled Pilot Study: Effects of a Heat Pad Application in Patients With Chronic Neck Pain||Universität Duisburg-Essen|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2011|February 24, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304368||108416|
NCT01304940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 2107|Women's Post Traumatic Stress Disorder (PTSD) Research Study|The Psychophysiology and Neurobiology of PTSD Across the Menstrual Cycle||VA Boston Healthcare System|Yes|Recruiting|December 2008|June 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples Without DNA|Urine, blood and saliva samples are taken. Only blood and saliva samples are retained and      used to measure stress hormone levels.|Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women, ages 18-55.|February 2011|February 25, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304940||108372|
NCT01310608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-View 3|Effect Study of Modified Transoesophageal Echocardiography on Cerebral Embolization After Cardiothoracic Surgery|Effect of Preoperative Imaging of the Ascending Aorta With Modified Transoesophageal Echocardiography on New Dw-MRI Lesions After Cardiac Surgery||Isala|Yes|Completed|March 2011|June 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01310608||107938|
NCT01310855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000696313|Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma|Multi-Center, Randomized, Double-Blind Phase II Study Comparing Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo in Subjects With Recurrent/Progressive Glioblastoma (DORIC Trial)||University College, London|Yes|Terminated|May 2011|January 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||July 2014|July 3, 2014|March 5, 2011||No|closed to recruitment early due to AstraZeneca not developing cediranib further|No||https://clinicaltrials.gov/show/NCT01310855||107919|
NCT01311206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101711|Low Intensity Resistance Training With Partial Blood Flow Restriction for Quadriceps Strengthening|Determining Efficacy of a Tolerable Means of Strengthening for Older Adults With Knee Osteoarthritis: Partial Blood Flow Restriction Low Intensity Resistance Training|PBFR|University of Iowa|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|50|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01311206||107893|
NCT01311518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-MI-201|A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction|A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery||RegeneRx Biopharmaceuticals, Inc.|No|Suspended|March 2016|August 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|75 Years|No|||November 2012|March 19, 2015|March 7, 2011|Yes|Yes|Trial suspended due to drug product manufacturer not GMP compliant|No||https://clinicaltrials.gov/show/NCT01311518||107870|
NCT01311804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2010|An Efficacy and Safety Study of Periarticular Parecoxib Sodium for Pain Management in Total Knee Arthroplasty|An Open Label,Multicentre, Randomized Trial to Determine the Efficacy of Periarticular Parecoxib Sodium In A Multimodal Cocktail vs Intravenous Parecoxib Sodium for Pain Management in Total Knee Arthroplasty||Ministry of Health, Malaysia|No|Not yet recruiting|April 2011|October 2011|Anticipated|April 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|50 Years|85 Years|No|||March 2011|March 8, 2011|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01311804||107848|
NCT01312064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011050MB|De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction|Clinical Outcome of de Novo Everolimus-based Immunosuppressive Therapy for Renal Transplantation Using Rituximab Induction||National Taiwan University Hospital|No|Terminated|April 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Both|15 Years|65 Years|No|||November 2012|December 26, 2012|January 26, 2011||No|Difficulty collecting|No||https://clinicaltrials.gov/show/NCT01312064||107829|
NCT01305096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/248-31/1|Effects of Yoga on Objective and Self-reported Health Indicators Among Female and Male Individuals|Effects of Yoga on Objective and Self-reported Health Indicators Among Female and Male Individuals||Karolinska Institutet|No|Completed|March 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305096||108360|
NCT01312623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudickar5|Organ Protection by Remote Ischemic Preconditioning for Surgical Treatment of Pediatric Congenital Heart Disease|Organ Protection by Remote Ischemic Preconditioning for Surgical Treatment of Pediatric Congenital Heart Disease|RIPHeart|University of Schleswig-Holstein|No|Terminated|March 2010|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|N/A|16 Years|No|||May 2014|May 21, 2014|March 8, 2011||No|The study was terminated, because it was not possible to recruit enough participants to    complete the study until the primary completion date.|No||https://clinicaltrials.gov/show/NCT01312623||107786|
NCT01305109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBIL/ROTA/021|A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E|A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants|ROTAVAC|Bharat Biotech International Limited|Yes|Active, not recruiting|March 2011|April 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|6800|||Both|6 Weeks|7 Weeks|Accepts Healthy Volunteers|||June 2012|June 9, 2012|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01305109||108359|
NCT01301235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002441|Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy|Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics of the Vastus Lateralis After Sub-maximal Exercise in Patients With Mitochondrial Myopathy||Massachusetts General Hospital|No|Completed|February 2011|April 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with mitochondrial disease|April 2012|April 27, 2012|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301235||108654|
NCT01301261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Σ-150/03-08-10|Sugammadex: Effect on the Awareness Monitoring and Hemodynamics|The Effect of Sugammadex on Hemodynamics, Oxygenation, End-tidal CO2, Entropy and Bispectral Index Intraoperatively Without Steroid Neuromuscular Blocker||University of Athens|No|Recruiting|December 2010|||February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|80 Years|No|||June 2012|June 18, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301261||108652|
NCT01303042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGU-247|Efficacy of Insulin Lispro Mix 50/50 Therapy|Multicenter Trial on Clinical Utility of Insulin Lispro Mix 50/50 T.I.D. Therapy in Patients With Type 2 Diabetes Mellitus||Aichi Gakuin University|Yes|Recruiting|February 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|20 Years|75 Years|No|||February 2011|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303042||108518|
NCT01303302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC CP TAN2007-032|The TANTALUS® II for the Treatment of Type 2 Diabetes|The TANTALUS® II for the Treatment of Type 2 Diabetes: A Single-Blind Cross-Over Study|Crossover|MetaCure (USA), Inc.|Yes|Active, not recruiting|April 2008|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||May 2014|May 27, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303302||108498|
NCT01303549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESITRA 0110|Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients|Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients|AVALTRA|Fundacion SEIMC-GESIDA|Yes|Completed|November 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||September 2013|May 29, 2014|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01303549||108479|
NCT01303809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BariatricFastTrack|Enhanced Recovery After Laparoscopic Sleeve Gastrectomy - a Randomised Controlled Trial|Enhanced Recovery After Laparoscopic Sleeve Gastrectomy - a Randomised Controlled Trial||University of Auckland, New Zealand|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|20 Years|60 Years|No|||May 2012|May 24, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303809||108459|
NCT01303822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-4600|Mindfulness-based Stress Reduction in Cancer Treatment|Mindfulness-based Stress Reduction in Supportive Cancer Treatment: Effects of a Day-care Clinic Group Program on Psychometric Parameters in Cancer Patients (Stressbewältigung Durch Achtsamkeit in Der Supportiven Onkologischen Therapie (SASO): Auswirkung Eines Tagesklinischen Gruppenprogramms Auf Psychometrische Parameter Bei Krebspatienten)|SASO|Universität Duisburg-Essen|No|Completed|March 2011|June 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303822||108458|
NCT01304381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPE001|Integrated Cardiac Care and Palliative Homecare for Patients With Severe Heart Failure|Integrated Cardiac Care and Palliative Homecare for Patients With Severe Heart Failure||Umeå University|Yes|Completed|January 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|72|||Both|N/A|N/A|No|||June 2013|June 16, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304381||108415|
NCT01304654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTI/IOP 02/11|ALI/ARDS in Oncologic Pediatric Patients|Practice of Mechanical Ventilation in Pediatric Oncologic Patients Diagnosed With Acute Lung Injury / Acute Respiratory Distress Syndrome||Grupo de Apoio ao Adolescente e a Crianca com Cancer|No|Active, not recruiting|January 2011|||March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|N/A|17 Years|No|Non-Probability Sample|Pediatric oncologic patients|March 2013|March 13, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304654||108394|
NCT01304667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-VOP.1 / CARE|Chemo- and Radiotherapy in Epithelial Vulvar Cancer|Chemo- and Radiotherapy in Epithelial Vulvar Cancer|CARE|AGO Study Group|No|Completed|February 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1618|||Female|18 Years|N/A|No|Non-Probability Sample|This retrospective, multicenter study is designed to collect tumor characteristics as well        as treatment data from patients diagnosed with primary or recurrent squamous cell cancer        of the vulva with emphasis on indication and application of radio- and chemotherapy|December 2015|December 22, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304667||108393|
NCT01310374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCWJ201101|Immune Response Study of Influenza Vaccine|Humoral and Cellular Immune Response Study of Influenza Vaccine||Centers for Disease Control and Prevention, China|Yes|Completed|March 2011|December 2012|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|207|Samples With DNA|blood|Both|12 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|July 2013|July 9, 2013|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310374||107956|
NCT01310621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC/2011/Sur-Lu-Lav|Comparison Of Surfactant Lung Lavage With Standard Care In The Treatment Of Meconium Aspiration Syndrome|Surfactant Lung Lavage Versus Standard Care In The Treatment Of Meconium Aspiration Syndrome- A Randomized Controlled Study|Sur-Lu-Lav|Lady Hardinge Medical College|Yes|Completed|January 2011|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|2 Hours|No|||July 2014|July 14, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01310621||107937|
NCT01311219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109438-1|Study Comparing Intramedullary Nailing, Plate Fixation, and Non-operative Treatment of Clavicle Fractures|Comparison of Intramedullary Nailing, Plate Fixation, and Non-operative Treatment of Acute, Displaced, Midshaft Clavicle Fractures: a Prospective Randomized Trial||University of Missouri-Columbia|No|Withdrawn|May 2009|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|480|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||March 2011|March 7, 2011|March 1, 2011||No|duplicate study|No||https://clinicaltrials.gov/show/NCT01311219||107892|
NCT01311492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC10035|Exercise Trial for Alzheimer's Disease|Exercise Trial for Alzheimer's Disease (EXTRA)|EXTRA|Pennington Biomedical Research Center|Yes|Completed|March 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|65 Years|N/A|No|||May 2013|May 23, 2013|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01311492||107872|
NCT01311505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3801001|Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)|An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin© 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane®, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects||Pfizer|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|February 15, 2011||No||No|March 23, 2012|https://clinicaltrials.gov/show/NCT01311505||107871|
NCT01304251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10.247|Effects of Short-term Fasting on Tolerance to Chemotherapy|Effects of Short-term Fasting on Tolerance to Adjuvant Chemotherapy in Breast Cancer Patients||Leiden University Medical Center|No|Completed|March 2011|January 2015|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Female|18 Years|N/A|No|||January 2016|January 9, 2016|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304251||108425|
NCT01304550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917394|Evaluation of the Accuracy of the Masimo Pulse-Hemoglobin-Meter Monitor in Surgical Patients|Evaluation of the Accuracy of the Masimo Pulse-Hemoglobin-Meter Monitor in Surgical Patients||University of California, Davis|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|48|||Both|N/A|N/A|No|Non-Probability Sample|Patience undergoing elect cardiac surgery.|September 2012|September 13, 2012|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01304550||108402|
NCT01304797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-302-02-01-01|Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer||Merrimack Pharmaceuticals|No|Active, not recruiting|March 2011|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|75|||Both|18 Years|N/A|No|||April 2015|March 14, 2016|February 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01304797||108383|
NCT01304563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-2010-149|2010/2011 Trivalent Influenza Vaccination|Safety and Efficacy of Dose Sparing Intradermal 2010/2011 Trivalent Influenza Vaccination With the Novel Microneedle Delivery Device||The University of Hong Kong|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|240|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01304563||108401|
NCT01304810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-4522|A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation|A Phase 3, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX™ as an Aid to Smoking Cessation||Nabi Biopharmaceuticals|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|300|Samples Without DNA|serum samples|Both|18 Years|65 Years|No|Non-Probability Sample|Subjects will be invited into this study following their participation in Nabi-4514 or        Nabi-4515.|May 2012|May 10, 2012|February 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304810||108382|
NCT01300702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4-2010-118#1|Neuropathic in the Acute Post Operative Phase|Identification of Neuropathic Pain in the Acute Post Operative Phase Following Thoracotomy||Rigshospitalet, Denmark|No|Terminated|February 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients undergoing thoracotomy|September 2011|September 28, 2011|February 22, 2011||No|recruitment problems|No||https://clinicaltrials.gov/show/NCT01300702||108695|
NCT01300949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-998|Spaeth/Richman Contrast Sensitivity Test|Validation and Reproducibility of Spaeth/Richman Contrast Sensitivity Test|SPARCS|Wills Eye|No|Completed|January 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|315|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Glaucoma Service, Wills Eye Institute Cataract and Primary Care Service, Wills Eye        Institute Retina Service, Wills Eye Institute|January 2015|January 29, 2015|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01300949||108676|
NCT01302145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0056|Drug to Drug Interaction Study With ASP1941 and Metformin|A Double-blind, Randomized, Placebo-controlled, Parallel Design Study, in Patients With Type 2 Diabetes Mellitus, to Investigate the Safety, Pharmacokinetics and Pharmacodynamics Interactions of Multiple Oral Doses of ASP1941 and Metformin||Astellas Pharma Inc|No|Completed|February 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|75 Years|No|||June 2015|June 5, 2015|February 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302145||108585|
NCT01302158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0059|Drug-drug Interaction Study With ASP1941 and Glimepiride|An Open-label, Randomized Crossover Study to Evaluate the Effect of ASP1941 on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa||Astellas Pharma Inc|No|Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 21, 2011|February 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01302158||108584|
NCT01303055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGU-248|Effects of Alogliptin on Pancreatic Beta Cell Function|Multicenter Trial on Effects of Alogliptin on Pancreatic Beta Cell Function||Aichi Gakuin University|Yes|Recruiting|February 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|75 Years|No|||February 2011|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303055||108517|
NCT01303315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC CPTAN2010-017|TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy|TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy||MetaCure (USA), Inc.|Yes|Terminated|January 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|21 Years|70 Years|No|||June 2011|June 21, 2011|February 23, 2011||No|Company strategic decision|No||https://clinicaltrials.gov/show/NCT01303315||108497|
NCT01303562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 9571|Clinical Assessment of Barley and Oat Phytochemicals|Clinical Assessment of Barley and Oat Phytochemicals: Acute Bioavailability, Pharmacokinetics, and Bioactivity||Tufts University||Completed|September 2010|February 2013|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|13|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01303562||108478|
NCT01304134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYI09-CN-302|Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment|A Prospective, Randomized, Blind, Multicentre, Parallel Group Study to Investigate the Efficacy and Safety of Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment||Mundipharma (China) Pharmaceutical Co. Ltd|Yes|Completed|March 2010|August 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|65 Years|No|||August 2015|August 10, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01304134||108434|
NCT01304394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ped3CB/P01/06/Mu.B|Safety During Use of Paediatric Triple Chamber Bag Formulas|Safety During Use of Paediatric Triple Chamber Bag Formulas, Administered IV at a Weight Dependant Dose During 5 Consecutive Days, in Paediatric Patients up to 18 Years Requiring Parenteral Nutrition.||Baxter Healthcare Corporation|No|Completed|February 2008|June 2009|Actual|December 2008|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|N/A|18 Years|No|||February 2011|February 24, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01304394||108414|
NCT01313806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 1123661|Study of Magnetic Fields to Treat Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy of the Application of Magnetic Fields Using the Resonator for the Treatment of Alzheimer‟s Disease in Addition to Standard of Care||pico-tesla Magnetic Therapies, LLC|Yes|Withdrawn|September 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|55 Years|N/A|No|||May 2011|May 27, 2011|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313806||107699|
NCT01313819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1012-044-344|The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy|A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy||Seoul National University Hospital|No|Recruiting|April 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|80 Years|No|||November 2011|November 9, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313819||107698|
NCT01303211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VES_5840|A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger|A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger|VES|London School of Hygiene and Tropical Medicine|Yes|Withdrawn|February 2012|November 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|0|Samples Without DNA|Sera samples will be separated from 5 ml blood sample obtained from cases and controls.|Both|1 Year|29 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cases: Patients with serogroup A meningococcal meningitis        Hospital controls: Patients admitted to the same hospital/health facility as the case with        an acute illness other than meningitis or septicemia.        Community controls:Healthy individuals recruited from the same community as the case|February 2013|February 18, 2013|February 8, 2011||No|No cases on NmA meningitis were recorded following vaccination with MenAfriVac|No||https://clinicaltrials.gov/show/NCT01303211||108505|
NCT01311232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-11-035|Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab|Hepatitis B Virus Reactivation in Asian Patients Treated With Rituximab-containing Treatment||Samsung Medical Center|Yes|Active, not recruiting|November 2010|December 2013|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|600|||Both|15 Years|90 Years|No|Non-Probability Sample|Patients with hepatitis B virus positivity and treated with rituximab-containing        chemotherapy to treat their disease, diffuse large B-cell lymphoma or follicular lymphoma|January 2013|January 12, 2013|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01311232||107891|
NCT01304030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001599|Improving Empathy and Relational Skills|Improving Empathy and Relational Skills in Resident Physicians: A Randomized Controlled Trial||Massachusetts General Hospital|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|99|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||February 2011|February 23, 2011|February 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01304030||108442|
NCT01304264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37552|Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients|Comparison of Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations During the Addition of Dorzolamid vs Timolol in Glaucoma Subjects Treated With Prostaglandin Analogue Monotherapy||Lithuanian University of Health Sciences|No|Completed|March 2011|November 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|35||No biospecimens will be retained|Both|18 Years|N/A|No|Probability Sample|Regular visitors of Eye Clinic of Lithuania University of Health Science hospital|January 2012|January 11, 2012|February 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304264||108424|
NCT01304277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-REP-082|This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.|A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease||Shire|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Male|18 Years|65 Years|No|||March 2014|March 25, 2014|February 15, 2011||No||No|December 30, 2013|https://clinicaltrials.gov/show/NCT01304277||108423|
NCT01304823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 69/04.03|Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY|The Role of Sweet Taste Receptor Blockade on Intraduodenal Glucose- and Liquid Meal-stimulated Secretion of Satiation Peptides in Healthy Humans||University Hospital, Basel, Switzerland|No|Completed|June 2010|January 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01304823||108381|
NCT01304836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1211|A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids|Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids - A Multicenter, Two Arm, Randomized, Open Label Clinical Study|ADVANCE|Astellas Pharma Inc|Yes|Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1166|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|February 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01304836||108380|
NCT01301521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110035H|Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics|Cinnamon Trial—Assessment of the effeCt of lIfestyle iNtervention Plus Water-soluble ciNnAMon Extract On loweriNg Blood Glucose in Pre-diabetics: A Randomized, Double-blind, Multicenter, Placebo Controlled TRIAL.|Cinnamon|Mike O'Callaghan Federal Hospital|No|Recruiting|November 2010|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|557|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301521||108632|
NCT01301768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI071265|Group Education to Improve the Iodine Nutrition in Pregnancy: Cluster Randomized Trial|Nutritional Status of Iodine in the Pregnant Population of Catalonia: a Study of Dietary Habits and Urinary Iodine||Jordi Gol i Gurina Foundation|Yes|Recruiting|November 2008|December 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|898|||Female|18 Years|55 Years|No|||February 2011|February 22, 2011|May 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01301768||108614|
NCT01301781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI801-201|BLI801 Laxative in Constipated Adults|A Pilot Efficacy Evaluation of BLI801 Laxative in Constipated Adults||Braintree Laboratories|No|Completed|January 2011|||May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301781||108613|
NCT01301794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWHp001640|Lovaza Mechanisms of Action|Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects||Brigham and Women's Hospital|No|Recruiting|August 2012|August 2014|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301794||108612|
NCT01301807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0733|Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)|Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma||M.D. Anderson Cancer Center|Yes|Recruiting|July 2011|||August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01301807||108611|
NCT01303328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CI-C02|Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)|A Randomized, Double-blind, Multi-centre, Placebo Controlled Phase II Clinical Study to Evaluate the Efficacy, Tolerance and Safety of an Aqueous Gel Containing an Antiviral, Directly Applied on the Cervix Exhibiting High Grade Intraepithelial Lesion.|Colvir-PhaseII|Mithra Pharmaceuticals|No|Completed|March 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|50 Years|No|||August 2012|February 15, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01303328||108496|
NCT01303575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U48DP001949|Internet-Based Sexual Health Education for Middle School Native American Youth|It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations|IYG-AI/AN|The University of Texas Health Science Center, Houston|No|Completed|September 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|574|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||November 2013|June 22, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01303575||108477|
NCT01303835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027661|Low Dose Naltrexone for Glioma Patients|Effects of Low Dose Naltrexone on Quality of Life in High Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial||Duke University|No|Completed|May 2011|May 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|February 23, 2011|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01303835||108457|
NCT01303848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKH2011Sport1|Circadian Rhythm of Blood Lactate|Circadian Rhythm of Blood Lactate, Lipid Transferproteins and Genetic Markers (PPARs, CLOCK, Bmal1)||Martin-Luther-Universität Halle-Wittenberg|No|Completed|February 2011|May 2012|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 healthy probands|May 2012|May 1, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303848||108456|
NCT01304147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0492|Intranasal Ketamine in Treatment-Resistant Depression|Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|21 Years|65 Years|No|||November 2014|November 17, 2014|February 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01304147||108433|
NCT01313507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGAM-05|High Infusion Speed Study|CLINICAL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF IMMUNOGLOBULIN INTRAVENOUS (HUMAN) 10% (NEWGAM) ADMINISTERED AT HIGH INFUSION RATES TO PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (EXTENSION OF STUDY NGAM 01)|NGAM-05|Octapharma|Yes|Completed|March 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|2 Years|75 Years|No|||October 2012|October 9, 2012|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313507||107722|
NCT01313520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08136|A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)|A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)||Merck Sharp & Dohme Corp.|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|February 25, 2011|No|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT01313520||107721|
NCT01313793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471022|A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804|A Phase 1 Open-Label Study Of Pf-00299804 In Healthy Volunteers To Demonstrate The Bioequivalence Of The Proposed Commercializable Formulation Administered As One 45-Mg Tablet Relative To Three 15-Mg Clinical Formulation Tablets||Pfizer|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01313793||107700|
NCT01301118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Graft take in burns|Graft Take and Microbiology in Burns|Split Thickness Skin Graft Take and Microbiology Evaluation in Burned Patients||Federal University of São Paulo|Yes|Suspended|October 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|ACUTE BURNED PATIENTS|January 2012|January 7, 2012|February 22, 2011||No|Technical problems with protocol.|No||https://clinicaltrials.gov/show/NCT01301118||108663|
NCT01303224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAK-04|Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)|Double-blind, Randomised, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Effect of Oral Ibodutant in Irritable Bowel Syndrome With Diarrhoea (IBS-D).|IRIS-2|Menarini Group|No|Completed|October 2010|July 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|565|||Both|18 Years|70 Years|No|||September 2015|September 22, 2015|February 23, 2011||No||No|January 10, 2013|https://clinicaltrials.gov/show/NCT01303224||108504|
NCT01303458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R00HD056160-02|Addressing Low-Income Families' Basic Social Needs at Pediatric Visits|Addressing Low-Income Families' Basic Social Needs at Pediatric Visits: the WE CARE Project||Boston Medical Center|No|Completed|January 2011|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|336|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303458||108486|
NCT01310868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000696316|Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma|An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) With Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma (GALA-5 Trial)||University College, London|Yes|Active, not recruiting|May 2011|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|March 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01310868||107918|
NCT01310881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2010-2|Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189|A Phase 1, Randomized, Subject Single Blinded, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of NSI-189 Phosphate in Healthy Subjects||Neuralstem Inc.|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|November 17, 2011|February 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01310881||107917|
NCT01303705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH&S IRB 10-088|Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer|Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy||Providence Health & Services|No|Recruiting|October 2010|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|37|||Male|18 Years|N/A|No|||September 2015|September 25, 2015|November 9, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01303705||108467|
NCT01303718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-05-026|INcrease Of VAgal TonE in CHF|INcrease Of VAgal TonE in CHF (INOVATE-HF) - A Randomized Study to Establish the Safety and Efficacy of CardioFit® for the Treatment of Subjects With Heart Failure and Left Ventricular Dysfunction|INOVATE-HF|BioControl Medical|Yes|Terminated|February 2011|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|730|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|February 18, 2011|Yes|Yes|Futility of Primary Efficacy Endpoint|No||https://clinicaltrials.gov/show/NCT01303718||108466|
NCT01304329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.63|Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin|Relative Bioavailability of BI 10773 and Simvastatin After Single and Combined Administration - an Open-label, Randomised, Crossover Trial in Healthy Subjects||Boehringer Ingelheim||Completed|February 2011|||April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 2, 2014|February 21, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01304329||108419|
NCT01304589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSBrown SAV-MD-18|Savella in Treatment for Provoked Vestibulodynia|An Open Label Trial of Milnacipran in the Treatment of Women With Provoked Vestibulodynia||University of Tennessee|No|Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|18 Years|54 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|February 24, 2011|Yes|Yes||No|December 29, 2013|https://clinicaltrials.gov/show/NCT01304589||108399|
NCT01304004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2010-154|Effect of a Drinkable Yogurt Enriched in Proteins and Fibers on Satiety|Effect of a Drinkable Yogurt Enriched in Proteins and Fibers on Satiety|JIVAGO|Laval University|No|Completed|October 2010|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01304004||108444|
NCT01304017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8401-HW-CTIL|Virtual Reality Intervention for Stroke Rehabilitation|Virtual Reality Intervention for Stroke Rehabilitation||Sheba Medical Center|No|Completed|September 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|80 Years|No|||June 2015|June 21, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01304017||108443|
NCT01304576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/126/HP|Orientation Agnosia: Clinical and Anatomical Study|Orientation Agnosia: Neuropsychological Evaluation, Associated Symptoms, Clinical and Anatomical Correlations|AGNORIENT|University Hospital, Rouen|Yes|Completed|September 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|34|||Both|18 Years|80 Years|No|||September 2014|September 1, 2014|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01304576||108400|
NCT01301274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE-20-2011|0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children|Randomized, Controlled, Double Blinded, Clinical Trial: 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children|NaCrICh|Hospital General de Niños Pedro de Elizalde|Yes|Completed|February 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|1 Month|18 Years|No|||March 2012|March 6, 2012|February 18, 2011||No||No|November 16, 2011|https://clinicaltrials.gov/show/NCT01301274||108651|Limitations: Antidiuretic hormone were not measured.
NCT01301300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH10-125|Evaluating Central Line Hub Contamination Using a Novel Capping Device|Demonstration of Central Line Hub Contamination Reduction Using a Novel Capping Device||NorthShore University HealthSystem Research Institute|No|Recruiting|April 2010|December 2011|Anticipated|September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|18 Years|N/A|No|||February 2011|February 22, 2011|February 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301300||108649|
NCT01301534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110041H|Comparison of Methods to Improve Abdominal Aortic Aneurysm (AAA) Screening Rates in the Primary Care Setting.|Comparison of Methods to Improve Abdominal Aortic Aneurysm (AAA) Screening Rates in the Primary Care Setting.||Mike O'Callaghan Federal Hospital|No|Completed|December 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Actual|1700|||Male|65 Years|75 Years|No|Non-Probability Sample|We will recruit approximately 1700 males (DoD beneficiaries) between the ages of 65-75        from their existing medical diagnostic records. There will be no special populations        included. Some respondents may be patients of the PI however; the data sets received by        the PI will be anonymous and will not be linked directly to the subjects.|November 2013|November 21, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01301534||108631|
NCT01302743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110004H|Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.|Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin as Initial Treatment for Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.||Mike O'Callaghan Federal Hospital|No|Recruiting|November 2010|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|309|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01302743||108541|
NCT01302756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110006H|The Effect of High Dose Folic Acid Versus Placebo on the Rate of Gestational Diabetes or Gestational Hypertension in Pregnant Women|The Effect of High Dose Folic Acid Versus Placebo on the Rate of Gestational Diabetes or Gestational Hypertension in Pregnant Women: a Randomized Controlled Trial.||Mike O'Callaghan Federal Hospital|No|Withdrawn|April 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|0|||Female|18 Years|N/A|No|||November 2013|November 21, 2013|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01302756||108540|
NCT01303341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02597|Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma|A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma||National Cancer Institute (NCI)|No|Recruiting|February 2011|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2015|March 23, 2016|February 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01303341||108495|
NCT01303588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YQ-LBP|Yoga and Qigong for Elderly Patients With Chronic Low Back Pain|Yoga and Qigong for Elderly Patients With Chronic Low Back Pain|YQ-LBP|Charite University, Berlin, Germany|No|Completed|May 2011|December 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|176|||Both|65 Years|N/A|No|||January 2013|January 18, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303588||108476|
NCT01303861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027351|Concurrent Bupropion / Varenicline for Smoking Cessation|Concurrent Bupropion / Varenicline for Smoking Cessation|ConNic4|Duke University|Yes|Completed|March 2011|July 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|702|||Both|18 Years|65 Years|No|||May 2014|August 4, 2014|February 23, 2011|Yes|Yes||No|July 5, 2014|https://clinicaltrials.gov/show/NCT01303861||108455|
NCT01303874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR05/7150|Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)|A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis|EMPIRE|University of Leeds|No|Active, not recruiting|September 2006|March 2011|Anticipated|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|80 Years|No|||February 2011|February 24, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01303874||108454|
NCT01312818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008LS113|Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|A Therapeutic Trial of Bortezomib (Velcade), Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)||Masonic Cancer Center, University of Minnesota|Yes|Terminated|June 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|2 Years|30 Years|No|||January 2013|April 29, 2015|March 9, 2011|Yes|Yes|Slow accrual|No|April 22, 2015|https://clinicaltrials.gov/show/NCT01312818||107772|
NCT01313143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPA368-10|A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol|A Prospective, Randomized, Double Blinded, Crossover, Two-treatment, Two-sequence, Short Term Pharmacokinetic, Pharmacodynamic and Tolerability, Single Centre Study to Compare AOP200704 vs. Esmolol in Healthy Subjects.||AOP Orphan Pharmaceuticals AG|No|Completed|March 2011|January 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 18, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313143||107750|
NCT01313533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R9-LRS-CS-01|Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes|Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes||St. Luke's Hospital, Chesterfield, Missouri|Yes|Not yet recruiting|January 2015|November 2020|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Both|25 Years|95 Years|No|||November 2014|November 6, 2014|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01313533||107720|
NCT01301417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETROPRESS|Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis|a RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing ™|RETROPRESS|novoGI|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|171|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Patients who underwent a laparoscopic or open colorectal resection with the creation        of an anastomosis using the ColonRing™ in routine clinical practice.|June 2013|June 4, 2013|February 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01301417||108640|
NCT01303237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR062202-539|A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)|PMS LAD SCCHN|Merck KGaA|No|Terminated|February 2011|March 2018|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|||Both|N/A|N/A|No|Non-Probability Sample|Unresectable Locally Advanced (Stage III/ IV A or IV B) SCCHN patients found eligible to        receive Cetuximab + RT|November 2014|November 7, 2014|February 23, 2011||No|The study was discontinued due to slow recruitment and subjects not completing follow up    period.|No||https://clinicaltrials.gov/show/NCT01303237||108503|
NCT01303250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM09_0031|Perioperative Colloid vs Crystalloid in Patients Undergoing Colorectal Surgery|Balanced 6 % HES 130/0.4 vs. Balanced Crystalloid-based Infusion in Patients Undergoing Colorectal Surgery|KoKris|University Hospital Muenster|No|Terminated|April 2011|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 22, 2011||No|The final decision of the review of HES-containing solution shall be awaited.|No||https://clinicaltrials.gov/show/NCT01303250||108502|
NCT01303432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTNS 001_03_2010|Effect of Yogurts Supplemented With Mobilee on Joint Function in Healthy Individuals With Joint Discomfort|Double-blind, Placebo-controlled Nutrition Intervention Trial, to Study Efficacy and Safety of Yogurts Supplemented With Mobilee on Joint Function, Joint Structure and Quality of Life of Adults With Low Intensity Gonalgia||Bioiberica|No|Completed|September 2010|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|80|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01303432||108488|
NCT01303445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9.197|Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers|Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox® Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study)||Boehringer Ingelheim||Completed|March 2011|||April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|November 27, 2013|February 23, 2011||||No|April 24, 2012|https://clinicaltrials.gov/show/NCT01303445||108487|
NCT01303731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0123-10-BZ|Comparison of Standard and Minidose Spinal Anesthesia for Cesarean Section Operation Using Marcaine Spinal 0.5% Heavy|Phase IV, Randomized, Parallel Designed, Single Blinded Study, Comparing the Standard and Minidose Spinal Anesthesia Using Marcaine Spinal 0.5% Heavy With Addition of Fentanyl During Cesarean Section||Bnai Zion Medical Center||Not yet recruiting|February 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2011|February 23, 2011|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01303731||108465|
NCT01304862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2RR024990|Electronic Self-management Resource Training for Mental Health|Electronic Self-management Resource Training for Mental Health|eSMART-MH|Case Western Reserve University||Not yet recruiting|February 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2011|February 25, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304862||108378|
NCT01304875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMC17883|Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease|Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease||Cedars-Sinai Medical Center|No|Recruiting|April 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Male|8 Years|18 Years|No|Non-Probability Sample|Boys between ages 8 and 18 years of age with Fabry disease not receiving enzyme        replacement therapy or an experimental therapy.|June 2013|June 25, 2013|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304875||108377|
NCT01304290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR-09-054|Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors|Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors||McGill University Health Center|Yes|Recruiting|October 2010|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|75 Years|No|||October 2013|October 24, 2013|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01304290||108422|
NCT01304303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_10_23|Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination|||Sun Pharma Advanced Research Company Limited|No|Recruiting|October 2011|July 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01304303||108421|
NCT01300962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1024|Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer|LCCC 1024: A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|August 2011|December 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|84|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300962||108675|
NCT01300975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABF-BO-2010-101|Intralesional Antimony for Bolivian Cutaneous Leishmaniasis|Short Course of Intralesional Antimony for Bolivian Cutaneous Leishmaniasis||Fundacion Nacional de Dermatologia|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|12 Years|N/A|No|||July 2012|July 3, 2012|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300975||108674|
NCT01300988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|75558-2|Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose|A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals||University of Pennsylvania|Yes|Completed|December 2010|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|December 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300988||108673|
NCT01301287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTH-96-2-028|The Effect of Chlorella on Glycemic Control of Diabetes|||Cardinal Tien Hospital||Recruiting|January 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2011|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301287||108650|
NCT01302197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00042905|Muscle Atrophy, Physical Performance and Glucose Tolerance Post Stroke|Muscle Atrophy, Physical Performance and Glucose Tolerance Post Stroke||Baltimore VA Medical Center|Yes|Recruiting|September 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Blood samples will be analyzed for metabolic biomarkers. Muscle tissue is collected for      measurements of muscle phenotype. A urine pregnancy test is performed in women of child      bearing age before CT imaging to exclude pregnant women due to the risk to an unborn fetus.|Both|21 Years|N/A|No|Non-Probability Sample|Acute Stroke|July 2015|July 21, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302197||108581|
NCT01302457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609-036|Oral Care Study on Burn Patients|Oral Care Study on Burn Patients||Saint Elizabeth Regional Medical Center|No|Recruiting|September 2007|September 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|PATIENT SELECTION CRITERIA          1. Patients age must be 19 and older.          2. Patients must be on a ventilator in the burn or intensive care unit.          3. The control group will be 19 years or older and be randomly picked from volunteer             staff at Saint Elizabeth Regional Medical Center.|February 2011|February 18, 2011|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01302457||108561|
NCT01302769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110008H|Ear Acupuncture for Acute Sore Throat.|Ear Acupuncture for Acute Sore Throat. A Randomized Controlled Trial.||Mike O'Callaghan Federal Hospital|No|Completed|October 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01302769||108539|
NCT01303081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812287|Pilot Randomized Control Trial of Financial Incentives for Smoking Cessation|Financial Incentive Structures for Smoking Cessation: A Pilot Randomized Trial||University of Pennsylvania|Yes|Completed|June 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 1, 2012|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01303081||108515|
NCT01312259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19522|Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome|Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome||Pelvic and Sexual Health Institute|No|Recruiting|April 2011|April 2018|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|70 Years|No|||April 2014|April 28, 2014|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01312259||107814|
NCT01312545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC1/2011|Comparison of Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand|Comparison of Exposure Rate Between Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand: A Randomized, Equivalence Controlled Trial and Multicenter Study||Mettapracharak Hospital|Yes|Recruiting|March 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01312545||107792|
NCT01312831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMIS-112-C-02|Efficacy and Safety Study of Oral Eligen® B12 in Subjects With Low Serum Cobalamin|A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing||Emisphere Technologies, Inc.|No|Completed|February 2009|December 2010|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||March 2011|March 9, 2011|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01312831||107771|
NCT01313156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKS#1833|LUPS-Lipids and Glucose Under Prospective Surveillance|Lipids and Glucose Under Prospective Surveillance|LUPS|Asklepios proresearch|No|Active, not recruiting|November 2008|||May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1962|||Both|25 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|so-called "Healthy-Workers", aged 25-60years, of Lufthansa-Technik, Hamburg, Germany, who        voluntarily aggreed to participate in the study.|March 2011|March 10, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313156||107749|
NCT01313169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000108/2;BIDMC|Electronic Medical Record Reminders and Panel Management to Improve Primary Care of Elderly Patients|Electronic Medical Record Reminders and Panel Management to Improve Primary Care of Elderly Patients||Beth Israel Deaconess Medical Center|No|Completed|May 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|54|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|March 10, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01313169||107748|
NCT01309581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-2251|Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression|Ketamine Anesthesia to Enhance Efficacy and Tolerability of Electroconvulsive Therapy in Patients With Unipolar or Bipolar Depression||Icahn School of Medicine at Mount Sinai|Yes|Terminated|April 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|65 Years|No|||July 2013|July 29, 2013|March 2, 2011||No|limited enrollment|No|November 7, 2012|https://clinicaltrials.gov/show/NCT01309581||108017|Early termination, limited enrollment, data analysis not done due to technical problems with measurement leading to unreliable and uninterpretable data.
NCT01301157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M518101-US01|Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients|||Maruho Co., Ltd.||Completed|February 2011|||January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|294|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01301157||108660|
NCT01301170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR-0922-129|Study Evaluating the Benefit of Dry Needling for Patients With Neck Pain|The Effectiveness of Dry Needling for Patients With Neck Pain: A Randomized Clinical Trial||Integrated Therapy Practice PC|No|Recruiting|February 2011|March 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|65 Years|No|||February 2011|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01301170||108659|
NCT01303263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001758/1; BWH|A Brief Intervention to Improve Cost-effective Resource Use Among Medicine Housestaff|A Brief Intervention to Improve Cost-effective Resource Use Among Medicine Housestaff||Brigham and Women's Hospital|No|Completed|September 2009|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized|2||Actual|96|||Both|N/A|N/A||||February 2011|June 21, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303263||108501|
NCT01303497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGIO-TAX-PLUS-0906|Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas|Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, in Association or Not With Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment.|ANGIO-TAX-PLUS|Centre Oscar Lambret|Yes|Active, not recruiting|September 2010|September 2018|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2012|March 6, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01303497||108483|
NCT01303471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008032|Pain Assessment During General Anesthesia|Pain Assessment During General Anesthesia : DOLANS (DOULeur ANeSthesie) Study|DOLANS|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|1||Actual|75|||Both|18 Years|55 Years|No|||May 2012|May 16, 2012|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01303471||108485|
NCT01303744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1014-PR-0053|Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074|A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment|CT04|CERESPIR|Yes|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|96|||Both|18 Years|79 Years|No|||December 2015|December 2, 2015|February 23, 2011|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01303744||108464|
NCT01304888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSP01|Evaluating the Impact of the Food Support Program (Programa de Apoyo Alimentaria)|Evaluating the Impact of the Programa de Apoyo Alimentaria||Instituto Nacional de Salud Publica, Mexico|No|Completed|October 2003|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|6687|||Both|N/A|N/A|No|||February 2011|July 25, 2012|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304888||108376|
NCT01300741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-336-C-018|One Month Performance Comparison Between Two Commercially Available Silicone Hydrogel Lenses|One Month Performance Comparison Between 2 Commercially Available Silicone Hydrogel Lenses||Alcon Research|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Both|N/A|N/A|No|||April 2012|June 26, 2012|February 18, 2011|Yes|Yes||No|April 11, 2012|https://clinicaltrials.gov/show/NCT01300741||108692|
NCT01304849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIA-HL-1|Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes|Phase II Study of Interim PET-CT Scan-guided Response Adapted Therapy in Hodgkin's Lymphoma||Cancer Institute WIA|No|Completed|January 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|12 Years|65 Years|No|||February 2015|February 2, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01304849||108379|
NCT01301560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-05-024|Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis|Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC)||Samsung Medical Center|No|Recruiting|June 2008|||May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||February 2011|February 22, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01301560||108630|
NCT01301573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAD-LTFU|Long Term Follow-Up Study for rAAV-GAD Treated Subjects|||Neurologix, Inc.||Terminated|January 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|30 Years|90 Years|No|Non-Probability Sample|Parkinson's disease patients who participated in a clinical trial in which they received        AAV-GAD gene transfer.|February 2012|February 20, 2012|February 18, 2011||Yes|Due to financial reasons|No||https://clinicaltrials.gov/show/NCT01301573||108629|
NCT01302210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHRQ 1R18HSO19968-01|Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities|Detection, Education, Research and Decolonization Without Isolation in Long-term Care to Control(DERAIL)MRSA|DERAIL MRSA|NorthShore University HealthSystem Research Institute|No|Active, not recruiting|October 2010|September 2014|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4200|||Both|18 Years|N/A|No|||February 2011|February 23, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302210||108580|
NCT01302223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGF and Cytokines in Burns|Keratinocyte Growth Factor and Cytokines in Burns.|Keratinocyte Growth Factor, Interleukin 1 Beta, 6, 8, 10, 12 and Tumor Necrosis Factor Alpha in Burned Patients.||Federal University of São Paulo|Yes|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|8|Samples With DNA|Normal skin will be collected at first burned patient debridment and send to Cell Culture      Laboratory to start fibroblast and queratinocyte culture.|Both|18 Years|50 Years|No|Non-Probability Sample|ACUTE BURNED PATIENTS|December 2012|December 5, 2012|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01302223||108579|
NCT01324791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zell02|Laparoscopic Antireflux Surgery Versus Endoscopic Full-thickness Gastroplication for Gastroesophageal Reflux Disease (GERD)|||General Public Hospital Zell am See||Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||March 2011|March 28, 2011|March 26, 2011||||No||https://clinicaltrials.gov/show/NCT01324791||106861|
NCT01325116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-DS-03-2011|Delayed Educational Reminders in Acute Myocardial Infarction (MI)|Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI): Cluster-randomized Controlled Trial|DERLA-STEMI|McMaster University|No|Completed|September 2011|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|852|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325116||106836|
NCT01325350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-058|Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss|||Allergan|No|Completed|June 2011|September 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|306|||Female|18 Years|59 Years|No|||March 2014|March 3, 2014|March 28, 2011|Yes|Yes||No|March 3, 2014|https://clinicaltrials.gov/show/NCT01325350||106818|
NCT01325363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-11-0006|Magnetoencephalographic (MEG) Evidence for Novel Metaphor Processing Among Schizophrenic Patients|Novel Metaphor Processing Among Schizophrenic Patients - Magnetoencephalographic (MEG) Evidence||Shalvata Mental Health Center|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|March 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01325363||106817|
NCT01325597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 4546/10|Effects of Functional Electrical Stimulation and Inspiratory Muscle Training in Heart Failure Patients|Effects of Functional Electrical Stimulation and Inspiratory Muscle Training in Heart Failure Patients: Randomized Clinical Trial||Instituto de Cardiologia do Rio Grande do Sul|No|Recruiting|March 2010|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|30 Years|70 Years|No|||March 2015|March 10, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01325597||106799|
NCT01325649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ocumstudy 19.08.2009|Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma|Optimal Surgery With Total Mesorectal Excision and MRI Based Multimodal Therapy of Rectal Carcinoma|OCUM|Johannes Gutenberg University Mainz|No|Recruiting|February 2009|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|782|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low        rectal carcinoma, and with cT4 tumors|March 2016|March 3, 2016|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325649||106795|
NCT01326871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-801-01-10|A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer|A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer||Altor Bioscience Corporation|Yes|Active, not recruiting|June 2011|October 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326871||106701|
NCT01326884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004|Zenith Low Profile AAA Endovascular Graft (ZLP) Clinical Study|ZLP Clinical Study|ZLP|Cook||Completed|February 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|20 Years|N/A|No|||March 2013|March 11, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01326884||106700|
NCT01327170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDMCCSC-FM|Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy|Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography||Federal University of São Paulo|No|Completed|November 2008|June 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||March 2011|March 30, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327170||106679|
NCT01326559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-1001 trial|Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)|Phase II Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil Followed by Weekly Docetaxel and Cetuximab in Concurrence With Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma (NPC)||Hong Kong Nasopharyngeal Cancer Study Group Limited|Yes|Recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|18 Years|70 Years|No|||March 2015|March 20, 2015|March 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01326559||106725|
NCT01296776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMS-Bone-2011|Effect of Electromyostimulation on Bone|Effects of Whole-Body Electromyostimulation on Osteoporosis and Sarcopenia in Independently Living, Frail Elderly Females||University of Erlangen-Nürnberg Medical School|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Female|70 Years|99 Years|Accepts Healthy Volunteers|||August 2012|December 1, 2015|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296776||108993|
NCT01297088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15146|PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.|Open-label, Single Center Study of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 18 µg Mass Dose) for Evaluation of Biodistribution in Pathological Tissue in Patients With Cancer or Inflammation||Piramal Imaging SA|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|30 Years|80 Years|No|||January 2013|January 18, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01297088||108969|
NCT01306656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF1797|Vitamin D Repletion in Primary Hyperparathyroidism|Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism||Columbia University|Yes|Recruiting|October 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01306656||108240|
NCT01306669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maternal_flu_HIVneg_101106|Influenza Vaccine Trial in HIV Uninfected Pregnant Women|Vaccination of HIV-uninfected Pregnant Women With Trivalent Influenza Vaccine in the Prevention of Influenza Illness During Early Infancy and in Mothers: Randomized Controlled Phase III Trial Evaluating Safety, Immunogenicity and Efficacy|MatfluHIVneg|University of Witwatersrand, South Africa|Yes|Completed|March 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2116|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306669||108239|
NCT01306682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maternal_flu_HIVpos_101107|Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity|Trivalent Influenza Vaccine in HIV-infected Pregnant Women and Kinetics of Transplacental Anti-influenza Antibody Transfer and Persistence in Young Infants: A Randomized Controlled Phase II Trial Evaluating Safety and Immunogenicity|MatfluHIVpos|University of Witwatersrand, South Africa|Yes|Completed|March 2011|July 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|194|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||February 2013|February 6, 2013|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306682||108238|
NCT01327430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H44-10|Phospholipid Absorption of a Milk Phospholipid|Effect of a Milk Phospholipid Supplementation on the Lipid Metabolism in Healthy Volunteers||University of Jena|Yes|Completed|May 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 31, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327430||106659|
NCT01323088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DK083654-01A1|Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes|Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes||University of Pittsburgh|Yes|Completed|August 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||April 2013|April 12, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01323088||106991|
NCT01323049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/JL-03|Comparison of Spontaneous Ventilation Time in Air Without Desaturation After Positive Pressure Extubation Versus Aspiration Extubation When Awakening From General Anesthesia|Comparison of Spontaneous Ventilation Time in Air Without Desaturation After Positive Pressure Extubation Versus Aspiration Extubation When Awakening From General Anesthesia||Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|68|||Both|18 Years|65 Years|No|||March 2015|March 25, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323049||106994|
NCT01323283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPP-8 OM3|Study of Omega-3 Fatty Acids Regarding Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects in 8 Year Old Children|Intervention Study of the Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects of Omega-3 Fatty Acids in 8 Year Old Children|STOPP-8 OM3|Karolinska Institutet|No|Not yet recruiting|September 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|480|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||March 2011|May 12, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323283||106976|
NCT01323621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112352|Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|512|||Both|40 Years|N/A|No|||March 2014|March 27, 2014|March 17, 2011|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01323621||106950|
NCT01323634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113109|Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease|A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|521|||Both|40 Years|N/A|No|||June 2014|June 16, 2014|March 17, 2011|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01323634||106949|
NCT01323881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHIRB98-05-05|Intermittent Theta Burst Stimulation After Acute Stroke|Theta Burst Stimulation on the Motor Cortex in Acute Stroke: a Randomized Controlled Trial||Taipei Veterans General Hospital, Taiwan|Yes|Completed|May 2009|||December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||May 2009|May 23, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323881||106930|
NCT01321177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN271200900019C|An Integrated Program for the Treatment of First Episode of Psychosis|Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program|RAISE ETP|Northwell Health|Yes|Active, not recruiting|July 2010|July 2017|Anticipated|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|15 Years|40 Years|No|||February 2016|February 12, 2016|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01321177||107138|
NCT01324206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080238|Development of 3T Magnetic Resonance Research Methods for NIA Studies|Development of 3T Magnetic Resonance Research Methods for NIA Studies||National Institutes of Health Clinical Center (CC)||Recruiting|August 2008|||||N/A|Observational|N/A|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|September 23, 2015|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324206||106906|
NCT01324765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09009-2|Women Overcoming and Managing Adversity Now (WOMAN) Study|Women Overcoming and Managing Adversity Now (WOMAN) Study|WOMAN|University of Connecticut Health Center|No|Completed|January 2009|November 2010|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Female|18 Years|N/A|No|||March 2011|March 28, 2011|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01324765||106863|
NCT01325415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00014|A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects|A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label, Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects||AstraZeneca|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|45|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|March 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01325415||106813|
NCT01322022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09070340|Treatment of Sleep Disturbances in Young Children With Autism|Treatment of Sleep Disturbances in Young Children With Autism||University of Pittsburgh|Yes|Completed|December 2009|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|24 Months|72 Months|No|||January 2015|August 11, 2015|March 22, 2011||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01322022||107073|
NCT01325090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09006 / APTODON|Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy|Early Administration of Botulinum Toxin Type A (Botox®) in Neuropathic Pain Due to Thoracoscopy or Thoracotomy: a Randomized, Double Blind, Placebo Controlled Study|APTODON|University Hospital, Limoges|No|Not yet recruiting|May 2011|November 2014|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|44|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325090||106838|
NCT01325103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-001|Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury|Phase 1 Study of Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury||Hospital Sao Rafael|Yes|Completed|July 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|50 Years|No|||May 2014|May 27, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325103||106837|
NCT01325376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKTA iWell 21|PH iWell Study to Compare an Online Interactive Technology to Self-directed Care in Overweight or Obese Individuals|SKTA iWell21 Clinical Trial Protocol. This is a Randomized Control Trial of 500 Adult Participants Randomized to Two Arms: Control Arm: Self Directed Program (SDP), Intervention Arm: Dynamic On-line Interactive Technology (DOIT)||SK Telecom Americas, Inc.|No|Active, not recruiting|October 2010|October 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|500|||Both|18 Years|70 Years|No|||April 2011|April 17, 2011|October 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01325376||106816|
NCT01326572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUNG007|Lung HIV Disease in a Large Cohort-Pitt|Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-Pitt|MACS|University of Pittsburgh|Yes|Active, not recruiting|January 2009|August 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|blood, sputum, oral wash, bronchial washes|Male|18 Years|72 Years|No|Probability Sample|primary clinic for Pittsburghs Mens Aids Clinic Study(MACS)|December 2015|December 2, 2015|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01326572||106724|
NCT01318642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080261|Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of AMG 479 or Placebo in Combination With Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas||Amgen|No|Terminated|May 2012|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|March 17, 2011|Yes|Yes|NCT01318642: Planned independent DMC Interim review: ended for futility w/no safety concerns|No||https://clinicaltrials.gov/show/NCT01318642||107333|
NCT01318889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMU1360|Dexpanthenol Mouthwash to Treat Oral Mucositis|Effects of Topical Dexpanthenol on Chemotherapy and Radiotherapy Induced Oral Mucositis||hahid Beheshti University of Medical Sciences|Yes|Recruiting|September 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||June 2010|July 5, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01318889||107314|
NCT01318902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16007|Study of Oral IXAZOMIB in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis|An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of IXAZOMIB (MLN9708) Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain Amyloidosis Who Require Further Treatment||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|May 2011|June 2015|Anticipated|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|March 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318902||107313|
NCT01327443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1142777|Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease|Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease||University of Missouri-Columbia|No|Recruiting|October 2010|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|60 Years|No|||March 2011|March 31, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01327443||106658|
NCT01297387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/2007_Cardiovascolare|Feasibility of Peripheral Angioplasty in Type D TASCII Lesions|An Observational, Prospective Study Evaluating Feasibility of Peripheral Angioplasty in Diabetic Patients With Critical Limb Ischemia in C and D Obstructions of Transatlantic Inter-Society Consensus (TASC II).||IRCCS Multimedica|No|Completed|January 2009|December 2009|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|344|||Both|18 Years|N/A|No|Probability Sample|Diabetic patients with critical limb ischemia|February 2011|February 18, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297387||108946|
NCT01306695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0022|Northern Manhattan Caregiver Intervention Project|Comparative Effectiveness of the NYU Caregiver Intervention in Latinos in Northern Manhattan|NOCIP|Columbia University|Yes|Completed|March 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|139|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306695||108237|
NCT01307228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS/FHS REB 10-267|Effects of an Evidence Service on Health System Policymakers' Use of Research Evidence|Effects of an Evidence Service on Health System Policymakers' Use of Research Evidence||McMaster University|No|Enrolling by invitation|January 2011|April 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Anticipated|100|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2010|March 1, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307228||108196|
NCT01323296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/S1103/50 (REC REF)|Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction|Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction||University of Edinburgh|No|Completed|November 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|80 Years|No|||October 2010|December 3, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323296||106975|
NCT01323647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114306|Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers|Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (PoliorixTM) in Healthy Chinese Toddlers||GlaxoSmithKline||Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|957|||Both|18 Months|24 Months|Accepts Healthy Volunteers|||July 2012|June 25, 2015|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323647||106948|
NCT01323660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114418|An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B|An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study B|COPD|GlaxoSmithKline|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|307|||Male|40 Years|N/A|No|||December 2013|March 13, 2014|March 24, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01323660||106947|
NCT01323907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2546|Compassionate Use of Omegaven IV Fat Emulsion|Compassionate Use of Omegaven IV Fat Emulsion in Infants With Life Threatening Parenteral Nutrition-associated Liver Disease (PNALD).||Columbia University|Yes|Enrolling by invitation|January 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Months|12 Months|No|||February 2015|February 3, 2015|March 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323907||106928|
NCT01321411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03356|Clinical Respiratory Evaluation Using Spectroscopy Trial|Clinical Respiratory Evaluation Using Spectroscopy Trial|CREST|University of British Columbia|No|Withdrawn|February 2012|September 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Critically Ill and Health Volunteers|March 2014|March 5, 2014|March 21, 2011||No|Not started and now discontinued|No||https://clinicaltrials.gov/show/NCT01321411||107120|
NCT01321424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALRGN01|Diurnal Variation in Tear Osmolarity|Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology||Ophthalmic Consultants of Long Island|No|Recruiting|March 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care facility|March 2011|November 16, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321424||107119|
NCT01324219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12146|Changing Talk to Reduce Resistiveness to Care|Changing Talk to Reduce Resistiveness to Care||University of Iowa|Yes|Active, not recruiting|March 2011|June 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01324219||106905|
NCT01324518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098006|Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease|Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease|ALPO|Orion Corporation, Orion Pharma|Yes|Completed|April 2011|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|55 Years|90 Years|No|||October 2014|October 20, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324518||106882|
NCT01322035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.0027|Erythrocyte and Adipocyte G6PD Activity Levels in Obesity|Erythrocyte and Adipocyte G6PD Activity Levels Correlate With Differing Degrees of Dyslipidemia, Insulin Resistance and Obesity||University of South Alabama|No|Completed|December 2009|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|Samples With DNA|Blood and tissue samples(adipose, omentum and liver biopsies)|Both|19 Years|70 Years|No|Probability Sample|All patients will be morbidly obese and undergo Roux-en-Y Gastric bypass surgery. Both        Type 2 diabetic and non-diabetic patients will be accepted into the study.|January 2013|February 1, 2016|June 23, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01322035||107072|
NCT01322282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CETALY1006|To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy|A Randomized, Open-Label, Single-Dose, Three-Period Crossover Bioequivalence Study to Compare an Orodispersible Tablet (ODT) Formulation of Cetirizine HCl 10 mg Taken With and Without Water Compared With a Standard Marketed 10 mg Tablet Taken With Water||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322282||107053|
NCT01325129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE814167313|Elastic Stable Intramedullary Nailing of Dislocated Clavicle Fractures in Children|Elastic Stable Intramedullary Nailing of Dislocated Clavicle Fractures in Children and Adolescents: Lessons Learned From the First 20 Patients|ESIN clavicle|University of Luebeck|Yes|Completed|April 2011|December 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|N/A|17 Years|No|Non-Probability Sample|Last 24 Patients we Treated with ESIN|February 2014|February 13, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325129||106835|
NCT01325389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myo+MEL_peri_women|Myo-inositol Plus Melatonin in Perimenopausal Women|Effects of Myo-inositol Plus Melatonin in Perimenopausal Women||AGUNCO Obstetrics and Gynecology Centre|No|Recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||||||Female|42 Years|48 Years|Accepts Healthy Volunteers|||March 2011|March 28, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325389||106815|
NCT01325402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2750C00002|An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease|Open-Label Positron Emission Tomography Study With Selective Beta Amyloid Radioligand (18Fluor)AZD4694 to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease||AstraZeneca|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|16|||Male|50 Years|85 Years|Accepts Healthy Volunteers|||December 2012|December 7, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01325402||106814|
NCT01325636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090801|Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus|Injection of CD4 and CD8 + T Cells Anti-CMV or Anti-adenovirus for the Treatment of Viral Infections Occurring After Allogenic Hematopoietic Stem Cell Transplantation (HSCT)|CTLantiCMV|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2010|May 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||June 2014|April 9, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325636||106796|
NCT01322854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMRT-MC2|Adjuvant Whole Breast Radiotherapy (RT) With Intensity Modulated Radiotherapy (IMRT) and a Simultaneous Integrated Boost Versus Conventional RT and a Sequential Boost|Randomized Phase III Trial Comparing Intensity Modulated Radiotherapy With Integrated Boost to Conventional Radiotherapy With Consecutive Boost in Patients With Breast Cancer After Breast Conserving Surgery|IMRT-MC2|Heidelberg University|Yes|Recruiting|March 2011|March 2018|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|502|||Female|18 Years|N/A|No|||February 2011|April 6, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322854||107009|
NCT01318928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UiO/IKO/PERIO-1|The Treatment of Periodontal Diseases|The Treatment of Periodontal Diseases. A Randomized, Blinded, Five Years Follow-up, Four-arm, Placebo Controlled Clinical Intervention Trial||University of Oslo|Yes|Active, not recruiting|January 2008|October 2016|Anticipated|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|184|||Both|35 Years|75 Years|No|||November 2013|November 19, 2013|January 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318928||107311|
NCT01319201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD009|Subclinical Atherosclerosis Using Dual-source CT Coronary Angiography in Chinese Adults With Different Glycaemic Status|Assessment of Subclinical Atherosclerosis Using Dual-source Computed Tomography Coronary Angiography in Chinese Adults With Different Glycaemic Status||Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|April 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|600|Samples With DNA|Blood and urine samples were collected and retained for biomarker analysis|Both|40 Years|70 Years|No|Probability Sample|200 adults with normal glucose regulation (NGR), 200 with impaired glucose regulation        (IGR) and 200 with type 2 diabetes were recruited from an urban community of Shanghai|March 2011|March 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319201||107290|
NCT01319175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-062|Hip-Flexion Strength Training: Can Elastic Bands Induce a Relevant Effect?|||Amager Hospital|Yes|Completed||||||N/A|Interventional|Allocation: Randomized, Masking: Single Blind (Outcomes Assessor)|1||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2010|March 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319175||107292|
NCT01319188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RATE01|Ranibizumab and the Risk of Arterial Thromboembolic Events|Ranibizumab for Age-Related Macular Degeneration and the Risk of Arterial Thromboembolic Events (RATE)|RATE|Ural Medical University|Yes|Terminated|June 2010|April 2015|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|3||Actual|380|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 17, 2015|March 18, 2011|Yes|Yes|The study was terminated under the political pressure of the Federal Security Service of the    Russian Federation (FSB) and the Russian Society of Cardiology|No||https://clinicaltrials.gov/show/NCT01319188||107291|
NCT01306708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.023.4.01.III|Amitriptyline Regarding Nimesulide in Acute Idiopathic Adhesive Capsulitis|Comparative Study Between Amitriptyline Regarding Nimesulide Associated to Nervous Blockade in the Acute Treatment of Idiopathic Adhesive Capsulitis||Universidade do Sul de Santa Catarina|No|Completed|February 2011|December 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||September 2011|January 27, 2012|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306708||108236|
NCT01307254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAFLA|Association Between Non-alcoholic Fatty Liver Disease and Iron Status|(BAFLA- Barzilai Fatty Liver and Iron Metabolism Study)|BAFLA|Barzilai Medical Center|No|Recruiting|January 2011|July 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Patients that will pass a CT scan at our institution. The scan must include the abdomen,        with or without any contrast material.|September 2012|September 19, 2012|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01307254||108194|
NCT01307267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1641001|A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab|A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)||Pfizer|No|Recruiting|June 2011|December 2018|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01307267||108193|
NCT01323348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCR.net-Protocol M|Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control|Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control||Diabetic Retinopathy Clinical Research Network|Yes|Completed|October 2011|January 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1875|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323348||106971|
NCT01323361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3264-1 (REK)|CA125 Levels and Other Inflammatory Markers in Laparoscopic Ventral Hernia Repair|Multi-centre Observational Pilot-study for Evaluation of Variation in CA-125 and Other Inflammatory Markers in the Perioperative Period of Laparoscopic Ventral Hernia Repair||Oslo University Hospital|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323361||106970|
NCT01323374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa FMS201|Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia|FMS201|Chelsea Therapeutics|Yes|Completed|January 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|120|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323374||106969|
NCT01323075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/PC-02|Pharmacodynamic Comparison of Truncal Blocks in Patients With or Without Metabolic Disease (Kidney Failure, Diabetes)|Pharmacodynamic Comparison of Truncal Blocks in Patients With or Without Metabolic Disease (Kidney Failure, Diabetes)||Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2011|December 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|120|||Both|18 Years|80 Years|No|Non-Probability Sample|Three patient populations schelduled for surgery on the hand or wrist. The three groups        include (1) patients with no metabolic or neurologic disease history, (2) patients with        renal insufficiency but not diabetes and (3) patients with diabetes but not renal        insufficiency.|March 2015|March 25, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323075||106992|
NCT01323309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-021|Trial of Individual Psychosocial Interventions for Cancer Patients|A Randomized Controlled Trial of Individual Psychosocial Interventions for Cancer Patients||Memorial Sloan Kettering Cancer Center||Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|414|||Both|21 Years|N/A|No|Probability Sample|Potential candidates for the study who meet the eligibility criteria of cancer diagnosis        and stage will be identified by the research staff and/or participating oncology staff or        co-investigators. Study investigators in the Pain & Palliative Care Service the Breast        Cancer Medicine Service, the Head & Neck Oncology Service, the Thoracic Medicine Service,        the Gastrointestinal Oncology Service, and the Genito-Urinary Oncology Service will serve        as liaisons to the Research Staff and help screen and identify potential subjects for the        study.|September 2015|September 25, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323309||106974|
NCT01323322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909248|Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)|Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|June 2009|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|4000|||Both|30 Years|64 Years|No|||February 2016|March 9, 2016|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323322||106973|
NCT01323335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909322|The Relationship Between Uric Acid and Inflammatory Markers|The Relationship Between Uric Acid and Inflammatory Markers||National Institutes of Health Clinical Center (CC)||Completed|March 2009|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|160|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||January 2014|October 23, 2014|March 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01323335||106972|
NCT01323673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115054|Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.|Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.||GlaxoSmithKline|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|12 Years|N/A|No|||February 2012|February 23, 2012|March 24, 2011|Yes|Yes||No|November 17, 2011|https://clinicaltrials.gov/show/NCT01323673||106946|
NCT01322061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.GK.06|Vitamin C Efficacy in Reducing Post Operative Pain|The Role of a Single Oral Dose (2g) of Vitamin C in Reducing Intensity of Pain and Opioids Consumption in Patients Undergoing Laparoscopic Cholecystectomy. A Randomized, Double-blinded, Placebo-controlled Study||American University of Beirut Medical Center|Yes|Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||January 2012|January 6, 2012|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01322061||107070|
NCT01322074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9991999|Systemic Inflammation Versus Acute Pain in Total Knee Arthroplasty (TKA)|The Relation Between Systemic Inflammatory Markers and Acute Pain in TKA||Hvidovre University Hospital|No|Completed|August 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|Blood samples for C reactive protein and interleukin 6 analysis.|Both|18 Years|N/A|No|Probability Sample|Patients operated with total knee arthroplasty|October 2011|October 14, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322074||107069|
NCT01324804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.1 - 19.11.2009|Antibiotic Concentration in Internal Mammary Graft Preparation|Target Tissue Concentration of Standard Antibiotic Treatment in Coronary Artery Bypass Grafting Using Left Internal Mammary Artery||Medical University of Vienna|No|Recruiting|November 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|N/A|No|Probability Sample|Patients referred for coronary artery bypass grafting to the Department of Cardiothoracic        Surgery with planned unilateral left internal mammary artery preparation and a high risk        profile for deep sternal wound infections will be asked to participate in this trial.|December 2009|March 28, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01324804||106860|
NCT01324531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMP 01|Arthroscopic Bankart Repair With and Without Remplissage in Anterior Shoulder Instability|Arthroscopic Bankart Repair With and Without Arthroscopic Infraspinatus Remplissage in Anterior Shoulder Instability With a Hill-Sachs Defect: A Randomized Controlled Trial||Panam Clinic|No|Recruiting|March 2011|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|14 Years|N/A|No|||December 2015|December 15, 2015|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01324531||106881|
NCT01322308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-487|Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus|Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial||National Heart Institute, Mexico|No|Completed|March 2007|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|55 Years|No|||September 2014|September 30, 2014|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322308||107051|
NCT01325662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-211|A Study to Evaluate the Use of an Indwelling Catheter to Obtain Cerebrospinal Fluid (CSF) by Low-rate Continuous Sampling (MK-0000-211)|A Clinical Study to Evaluate a Modified Serial CSF Sampling Method by Indwelling Lumbar Catheter in Healthy Volunteers||Merck Sharp & Dohme Corp.|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|11|Samples Without DNA|Cerebrospinal fluid (CSF)|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers from general population|July 2015|July 22, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325662||106794|
NCT01325987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F101109002|African American Children, Glycemic Control, and Type 2 Diabetes|Vitamin D on Glycemic Control in African American Children With Type 2 Diabetes|ACT|University of Alabama at Birmingham|Yes|Completed|March 2011|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|12 Years|18 Years|No|||January 2014|January 16, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325987||106769|
NCT01318655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00020|Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of NKTR-118 Following Single and Multiple Ascending Oral Dose Administration in Healthy Young and Elderly Japanese Subjects, and an Open Randomized, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics After Single Oral Doses of NKTR-118 in Healthy Male Japanese Subjects|Japan SMAD|AstraZeneca|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2011|August 24, 2011|March 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318655||107332|
NCT01318915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN039ST|Research Study of ATG and Rituximab in Renal Transplantation|Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenilate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients|RESTARRT|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|June 2011|June 2020|Anticipated|December 2018|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|March 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318915||107312|
NCT01319578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 005|PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum|A Single Blind Pharmacodynamic Study to Assess the Phosphate Binding Characteristics of K2CG Chewing Gum||Denver Nephrologists, P.C.|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|36|||Both|18 Years|N/A|No|||November 2011|November 11, 2011|March 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01319578||107261|
NCT01319851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00039680|Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation|Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation for Children With Non-Malignant Diseases Who Have Been Multiply Transfused: a Pilot Study||Emory University|Yes|Suspended|September 2010|||September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|21 Years|No|||February 2015|February 25, 2015|September 15, 2010|Yes|Yes|drug company is no longer making the drug|No|February 25, 2015|https://clinicaltrials.gov/show/NCT01319851||107240|Production of alefacept was halted in 2011.
NCT01319552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD3737|Fresh Versus Old Red Blood Cells for Transfusion|Immunomodulatory Properties of Fresh Versus Stored Packed Red Blood Cells for Transfusion||Columbia University|Yes|Completed|December 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|March 18, 2011|Yes|Yes||No|March 10, 2014|https://clinicaltrials.gov/show/NCT01319552||107263|
NCT01319565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110123|Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI|Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2011|June 2020|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|66 Years|No|||July 2015|August 12, 2015|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319565||107262|
NCT01307020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-TRA 02|Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain|Double-blind, Randomised, Placebo and Active Controlled, Parallel Group Study to Evaluate the Analgesic Effect of a Single Oral Administration of Four Different Combination Doses of DKP.TRIS With TRAM.HCL in Comparison With the Single Agents, on Moderate to Severe Pain Following Impacted Third Mandibular Molar Tooth Extraction|DEX-TRA 02|Menarini Group|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|10||Actual|745|||Both|18 Years|70 Years|No|||July 2013|July 31, 2013|February 28, 2011||No||No|October 11, 2012|https://clinicaltrials.gov/show/NCT01307020||108212|
NCT01298037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082864 HBRN Immunology|HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B|HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B||University of Pittsburgh|Yes|Recruiting|February 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be recruited from multi-site clinical centers in the United        States and Canada including primary care hospitals and community centers that have        enrolled into the HBRN cohort study (NCT01263587).|October 2015|January 6, 2016|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298037||108897|
NCT01299298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPO3700710|A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects||Sanofi|Yes|Completed|January 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|February 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01299298||108802|
NCT01320124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010930-01H|Creating a Tissue Bank of Knee Capsules|Knee Joint Contractures: Reversibility and Molecular Pathways||Ottawa Hospital Research Institute|No|Withdrawn|March 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|0|Samples With DNA|A blood sample will be drawn from each subject and stored with the capsule tissue.|Both|18 Years|N/A|No|Probability Sample|All patients booked for a total knee arthroplasty at the Ottawa Hospital, with a primary        diagnosis of osteoarthritis.|April 2015|April 22, 2015|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320124||107219|
NCT01323686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sksCRT|Empiric Versus Imaging Guided Left Ventricular Lead Placement in Cardiac Resynchronization Therapy|Empiric Versus Imaging Guided Left Ventricular Lead Placement in Cardiac Resynchronization Therapy|ImagingCRT|University of Aarhus|No|Completed|April 2011|September 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|182|||Both|40 Years|N/A|No|||August 2013|September 4, 2014|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01323686||106945|
NCT01323933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0024-101|First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Advanced Solid Tumors||Gilead Sciences|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|March 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01323933||106926|
NCT01324232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AVR-130|Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis|A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis|PRIME|Avanir Pharmaceuticals|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|85 Years|No|||April 2014|April 15, 2014|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324232||106904|
NCT01320891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-I-H-0909|Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators|Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators||Università degli Studi di Ferrara|Yes|Recruiting|February 2010|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||March 2011|March 22, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01320891||107160|
NCT01326650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Vitamin D and Mortality in Heart Failure|Effect of Vitamin D on All-cause Mortality in Heart Failure Patients|EVITA|Heart and Diabetes Center North-Rhine Westfalia|Yes|Active, not recruiting|November 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|79 Years|No|||September 2015|September 22, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326650||106718|
NCT01327209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-0000145|Blood Glucose Monitoring System Clinical Study|Blood Glucose Monitoring System Clinical Study|BGMS|Intuity Medical, Inc|No|Completed|December 2010|April 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|202|||Both|12 Years|70 Years|No|Non-Probability Sample|People who have been diagnosed with diabetes and are testing their blood glucose level at        least once per day.|June 2011|June 8, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327209||106676|
NCT01321398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02087|Transpulmonary Pressure Gradients in High Frequency Oscillation|Transpulmonary Pressure Gradients in High Frequency Oscillation Study|TPG in HFO|University of British Columbia|No|Completed|October 2010|March 2013|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Both|19 Years|N/A|No|Non-Probability Sample|Critically Ill|March 2014|March 14, 2014|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321398||107121|
NCT01325142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00040101|Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer|Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer||University of Michigan|No|Completed|August 2010|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|271|Samples With DNA|paraffin embedded tissue block and/or WBC|Both|21 Years|N/A|No|Non-Probability Sample|Academic medical center(s)|December 2014|December 1, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325142||106834|
NCT01322893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version2. 2011-03-03|Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer|Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer|CTC-MBC|Lund University Hospital|No|Recruiting|March 2011|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|N/A|No|Probability Sample|Women with metastatic breast cancer|February 2016|February 16, 2016|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322893||107006|
NCT01322906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABMS-LF|Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV)|Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by HBV||Sun Yat-sen University|Yes|Active, not recruiting|March 2011|July 2012|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|16 Years|65 Years|No|||October 2010|April 8, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322906||107005|
NCT01322295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1649a|Human Bronchial Microdialysis in Open Aortic Aneurysm Repair|Human Bronchial Microdialysis in Open Aortic Aneurysm Repair||Norwegian University of Science and Technology|No|Completed|March 2011|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|N/A|N/A|No|Non-Probability Sample|Patients assigned for elective open aortic surgery are enrolled by invitation|August 2012|August 8, 2012|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322295||107052|
NCT01322594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-MEDI2338-1033|A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease|A Phase 1, Single Ascending Dose Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease||MedImmune LLC|No|Completed|March 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|31|||Both|40 Years|N/A|No|||October 2013|October 9, 2013|March 23, 2011||No||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01322594||107029|
NCT01319214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-039-PSY|Reducing Drug Craving Memories|Reconsolidation as a Treatment Target for Cocaine Addiction||McGill University Health Center|No|Not yet recruiting|March 2011|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|50 Years|No|||January 2011|May 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319214||107289|
NCT01324882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-246-1|Colonoscope Insertion Trial Protocol|Study to Examine Insertion of 2 Colonoscopes Trial||University of Connecticut Health Center|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|57|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|March 24, 2011|Yes|Yes||No|May 8, 2013|https://clinicaltrials.gov/show/NCT01324882||106854|
NCT01325194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG-LBC-05|CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis|Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI≥ 2) Diffuse Large B-Cell Lymphoma|CHIC|Nordic Lymphoma Group|No|Recruiting|March 2011|December 2017|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|64 Years|No|||September 2014|September 27, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01325194||106830|
NCT01325207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10C03|Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer|Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer||Northwestern University|Yes|Recruiting|April 2011|March 2017|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|March 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01325207||106829|
NCT01306422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07044V|Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)|A Two Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of Twice-Daily Repeat Intake of 1110 mg of Hoodia Gordonii Purified Extract (PYM50717)||Unilever R&D|No|Completed|March 2008|October 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|64|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2011|February 28, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01306422||108258|
NCT01297777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-019189-94|Imatinib in KIT-negative Systemic Mastocytosis|Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations||Hospital Virgen de la Salud|No|Active, not recruiting|January 2011|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297777||108917|
NCT01320397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PST 2238-DM-10-001|Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations|Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile||RostaQuo S.p.A.|Yes|Not yet recruiting|May 2011|December 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|25 Years|60 Years|No|||March 2011|March 22, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01320397||107198|
NCT01320683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09053|Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer|A Phase II Trial of Radioimmunotherapy (Y-90 M5A) Following Hepatic Resection and FOLFIRI or FOLFOX Chemotherapy [+/-BEVACIZUMAB], or Xelox for Metastatic Colorectal Carcinoma to the Liver||City of Hope Medical Center|Yes|Terminated|March 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|March 18, 2011|Yes|Yes|This study will not be written up.|No||https://clinicaltrials.gov/show/NCT01320683||107176|
NCT01323699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28002|Behavioral Treatments for Anxiety and Depression in Veterans With Parkinson's Disease|Increasing Access and Implementation of Behavioral Treatments for Anxiety and Depression in Rural Veterans With Parkinson's Disease|BehTA-D|Michael Debakey Veterans Affairs Medical Center|No|Completed|November 2011|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01323699||106944|
NCT01323946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109825|Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children|Safety and Immunogenicity of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (GSK1562902A) in Children Aged 6 to 35 Months||GlaxoSmithKline||Completed|April 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|113|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||December 2013|December 19, 2013|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323946||106925|
NCT01320644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-06-005|A Study of Robotic Assisted Laparoscopic Sacral Colpopexy Using Alyte Mesh||ALYTE|Atlantic Health System|No|Completed|August 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|150|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be woman who underwent robotic assisted laparoscopic sacral        colpopexy at Morristown Memorial Hospital for the correction of pelvic organ prolapse        using synthetic polypropylene mesh|August 2012|August 2, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320644||107179|
NCT01320657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|A Clinical Trial of Three Fixed Orthodontic Appliances|A Randomised Clinical Trial of Orthodontic Treatment With 3 Fixed Appliance Systems Assessed Using Digital Models||Barts & The London NHS Trust|Yes|Active, not recruiting|August 2009|May 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 12, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320657||107178|
NCT01321190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40324-EA|Pain Quality Study|Pain Quality in Individuals With Low Back Pain, Headache, and Fibromyalgia||University of Washington|No|Completed|June 2011|April 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|307|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals who have a formal diagnosis of one of the three conditions studied and have        received services at either or both the Harborview Medical Center and the University of        Washington Medical Center.|January 2016|January 10, 2016|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321190||107137|
NCT01321450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2908|Economisation of Whipple Resection Using an Ultrasonic Dissection Device|Economisation of Preparation by Using an Ultrasonic Dissection Device in Partial Pancreatoduodenectomy||Universitätsklinikum Hamburg-Eppendorf|No|Completed|March 2009|October 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients planned for partial pancreatoduodenectomy for pancreatic head carcinoma,        periampullary carcinoma, chronic pancreatitis and other benign lesions.|November 2011|November 5, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01321450||107117|
NCT01321788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-CS TRIAL|Venous Thromboembolism Prophylaxis Post Cesarean Section|Venous Thromboembolism Prophylaxis Post Cesarean Section(PRO-CS-Trial)|PROCS|King Saud University|No|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Female|18 Years|35 Years|No|Non-Probability Sample|Consecutive adult patients (aged over 18 years) that had been delivered by emergency or        elective cesarean section with no previous history of VTE are eligible for the study.|February 2012|February 3, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321788||107091|
NCT01321762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0806/9|Prolapse and Pregnancy Assessment|Effect of Pregnancy and Childbirth on the Pelvic Floor|PAPA|Croydon University Hospital|Yes|Completed|April 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|403|||Female|18 Years|50 Years|No|Non-Probability Sample|Pregnant women with uncomplicated singleton pregnancy attending the ultrasound scan clinic        in the second trimester were invited to participate|April 2012|April 18, 2012|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01321762||107093|
NCT01321775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVANTHER|Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer|Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer||Hospital Universitario Madrid Sanchinarro|No|Recruiting|August 2009|November 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Female|18 Years|N/A|No|||June 2010|March 23, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01321775||107092|
NCT01322607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O7194-W|Task-oriented Training for Stroke: Impact on Function Mobility|Task-oriented Training for Stroke: Impact on Function Mobility|TOTS|VA Office of Research and Development|Yes|Active, not recruiting|July 2011|January 2015|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|40 Years|85 Years|No|||September 2014|September 17, 2014|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01322607||107028|
NCT01322867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6131023|A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets|A Phase IV, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine Relative Bioavailability of Alprazolam 0,75mg/ml (laboratórios Pfizer Ltda) in the Oral Solution-drops Form, Versus Frontal® 0,25mg (laboratórios Pfizer Ltda), in the Tablets Form, Under Fasted Conditions in Healthy Volunteers.||Pfizer|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01322867||107008|
NCT01322880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HF15660-101|Domestic Violence Discussion Session|Microfinance-Discussion Session Intervention in Post-Conflict Central African States||London School of Economics and Political Science|No|Completed|January 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|598|||Both|15 Years|65 Years|No|||February 2009|March 24, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322880||107007|
NCT01324336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6-MP pharmacokinetic 1|Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets|Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets||Children's Mercy Hospital Kansas City|No|Recruiting|July 2011|||December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|whole blood, plasma|Both|4 Years|17 Years|No|Non-Probability Sample|Patients ages 4-17 years of age who are receiving maintenance chemotherapy treatment for        ALL with 6-MP will be included|May 2013|May 31, 2013|March 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324336||106896|
NCT01324349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVEULV0032|Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery|A Prospective, Multi-Center, Randomized, Single-Blind Study to Compare the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery||Medtronic - MITG|Yes|Completed|February 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|March 24, 2011||No||No|June 20, 2012|https://clinicaltrials.gov/show/NCT01324349||106895|
NCT01325766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13424|Study of Yoga as a Therapy for Cystic Fibrosis (CF) Patients|Yoga as a Therapy for Adolescents and Young Adults With Cystic Fibrosis: A Pilot Study||Seattle Children's Hospital|No|Recruiting|February 2011|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|12 Years|25 Years|No|||March 2011|March 28, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01325766||106786|
NCT01306435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|077508|Low Power Laser and Exercise in Osteoarthritis of the Knee: a Randomized Clinical Trial|Effects of Low Power Laser Associated With Exercises in Osteoartite Knee: Randomized Clinical Trial, Double-blind, Controlled||University of Sao Paulo General Hospital|Yes|Completed|November 2009|February 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|75 Years|No|||February 2011|February 28, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01306435||108257|
NCT01298973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alcon2011-VIS-001|Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions|Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions||Innovative Medical|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|21 Years|N/A|No|||January 2012|January 13, 2012|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01298973||108827|
NCT01299285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14010|Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects|Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects||Eli Lilly and Company|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|February 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01299285||108803|
NCT01324869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902002|Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)|An Open-label, Randomized, Uncontrolled, Preliminary Clinical Study to Evaluate the Safety and Efficacy of KH902 Following Multiple Intravitreal Injection in Patients With Diabetic Macular Edema|Frontier-1|Chengdu Kanghong Biotech Co.,Ltd.|No|Completed|April 2010|October 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||February 2013|February 28, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01324869||106855|
NCT01325181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOV001|Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy|Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy||Seoul National University Hospital|Yes|Completed|July 2009|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|March 25, 2011||No||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01325181||106831|
NCT01320384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLORALI|Clinical Effect of the Association of Noninvasive Ventilation and High Flow Nasal Oxygen Therapy in Resuscitation of Patients With Acute Lung Injury (FLORALI Study)|Clinical Effect of the Association of Noninvasive Ventilation and High Flow Nasal Oxygen Therapy in Resuscitation of Patients With Acute Lung Injury. A Randomised Study (FLORALI Study)|FLORALI|Poitiers University Hospital|Yes|Completed|March 2011|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|314|||Both|18 Years|90 Years|No|||May 2014|May 12, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01320384||107199|
NCT01320670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-258|Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy|Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy||Nova Scotia Health Authority|No|Recruiting|June 2011|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|17 Years|N/A|No|Non-Probability Sample|Patients with first seizure or new-onset epilepsy aged > 17 years|January 2013|January 17, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320670||107177|
NCT01320904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBD 275767|Exercise and Muscle Stimulation in Patients With Knee Osteoarthritis|Neuromuscular Electrical Stimulation (NMES) on Knee Osteoarthritis(OA): an Equivalence Randomized Clinical Trial||Universidade Luterana do Brasil|Yes|Completed|August 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01320904||107159|
NCT01321801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHL25872/ 08/17/09|Pregabalin and Analgesia After Laparoscopic Cholecystectomy|Preoperative Use of Pregabalin and Analgesia Levels After Laparoscopic Cholecystectomy||Larissa University Hospital|Yes|Completed|November 2009|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01321801||107090|
NCT01326949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PVT-TIPS|Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis|Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined Anticoagulation and Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial||Fourth Military Medical University|No|Completed|May 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||March 2015|March 23, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326949||106695|
NCT01326962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22726|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF|Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF||Hoffmann-La Roche||Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|March 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01326962||106694|
NCT01322321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885I2208|ACZ885 in Type 1 Diabetes Mellitus|A Randomized, Double-blind, Multiple-dose, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ACZ885 in Patients With Newly Diagnosed Type-1 Diabetes Mellitus (T1DM)||Novartis||Withdrawn|March 2011|||June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|35 Years|No|||September 2012|September 4, 2012|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01322321||107050|
NCT01322334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hil2003/SE|Singing Exercises to Improve Symptoms of Snoring and Sleep Apnea|A Single Blinded Prospective Randomized Controlled Trial to Investigate Whether Singing Exercises Can Improve Symptoms of Snoring and Sleep Apnea||Royal Devon and Exeter NHS Foundation Trust|No|Completed|November 2005|November 2007|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|127|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322334||107049|
NCT01322048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110429|DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury|DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Severe Traumatic Brain Injury, A Pilot Randomized Clinical Trial Using Propranolol and Clonidine||Vanderbilt University|Yes|Active, not recruiting|August 2011|March 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|64 Years|No|||September 2015|September 29, 2015|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01322048||107071|
NCT01327482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38681-D|Levels of Raltegravir in the Female Genital Tissue|Modeling Intracellular and Extracellular Raltegravir (RAL) Pharmacokinetics in the Female Genital Tract and Blood After a Twice Daily 400mg Dose Over the Course of a Menstrual Cycle||University of Washington|No|Completed|October 2011|||December 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|March 30, 2011|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01327482||106655|
NCT01323140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TM1103|Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems|An Open Label, Dose-Proportionality, Bioavailability and Dose- Titration Investigation of the Pharmacokinetics, Metabolism, Efficacy and Safety of Two Testosterone Matrix Transdermal Systems (28 cm2 and 48 cm2) in Hypogonadal Men||Watson Pharmaceuticals|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|65 Years|No|||November 2012|November 30, 2012|March 21, 2011|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT01323140||106987|
NCT01323153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC25501|A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)|A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)||Hoffmann-La Roche||Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|45 Years|N/A|No|||March 2016|March 1, 2016|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323153||106986|
NCT01318668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMO31915|A Fmri Study on the Effects of a Conjugate Vaccine and Placebo on CNS Activation and Behavior Following a Nicotine Challenge|An fMRI-study on the Effects of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein a Conjugate Vaccine (NicVAX®) and Placebo on Central Nervous System Activation and Behaviour Following a Nicotine Challenge|EPU057|Maastricht University Medical Center|Yes|Completed|February 2011|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|38|||Male|25 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|March 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318668||107331|
NCT01323452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIRGIL|Entecavir for Chronic Hepatitis B|The Antiviral Efficacy of Entecavir in Chronic Hepatitis B Within the European Network of Excellence (VIRGIL)||Foundation for Liver Research|No|Completed|November 2010|March 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|418|||Both|18 Years|N/A|No|Probability Sample|all consecutive adult CHB patients treated with ETV monotherapy in 10 large European        referral centers|March 2011|March 24, 2011|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01323452||106963|
NCT01318941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2406|Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting|LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes|LUMINOUS|Novartis||Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|Outpatient ophthalmology Clinics|March 2016|March 3, 2016|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318941||107310|
NCT01318954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R07-2592B|The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis|The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis||Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|No|Completed|January 2008|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with allergic asthma and allergic rhinitis undergoing allergen immunotherapy|October 2015|October 28, 2015|September 28, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318954||107309|
NCT01324362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAM40065|GSK BHR Study (Sont - Second Study)|A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUSTM BID or Fluticasone Propionate DISK ...||GlaxoSmithKline||Completed|January 2003|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|446|||Both|12 Years|N/A|No|||October 2011|October 13, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01324362||106894|
NCT01324375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-052, part 2|Prediction of Pain in Total Hip Arthroplasty|Is Preoperative Pain Response Upon Tonic Heat Stimulation Predictive for Pain After Total Hip Arthroplasty?||Hvidovre University Hospital|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples With DNA|Blood samples|Both|18 Years|N/A|No|Probability Sample|Patients undergoing total hip arthroplasty (THA)|September 2012|September 25, 2012|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324375||106893|
NCT01324622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2442|Comparison of Cervical Laminectomy to Laminoplasty|Comparison of Cervical Laminectomy to Cervical Laminoplasty* in Patients With Cervical Myelopathy or Myeloradiculopathy Due to Multiple Level Cervical Spinal Canal Stenosis * ARCH™ Fixation System by SYNTHES||Synthes USA HQ, Inc.|No|Terminated|January 2006|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|March 23, 2011|No|Yes|terminated due to failure to meet enrolment goals|No||https://clinicaltrials.gov/show/NCT01324622||106874|
NCT01324635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.100|Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors|Phase I, Dose Finding Trial of the Combination of Panobinostat and Stereotactic Radiation in the Treatment of Brain Tumors||Thomas Jefferson University|Yes|Active, not recruiting|May 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324635||106873|
NCT01306721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11243|Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis|A Randomized, Double Blind, Parallel Group Study for Assessing the Efficacy and Safety of a Twice-daily Fexofenadine HCl 60 mg - Pseudoephedrine HCl 60 mg Combination or Fexofenadine HCl 60 mg - Pseudoephedrine HCl 120 mg Combination Versus Allegra® 60 mg in Patients With Seasonal Allergic Rhinitis||Sanofi|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|520|||Both|12 Years|N/A|No|||October 2013|October 12, 2013|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01306721||108235|
NCT01299623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HSO19339-01|Breast Cancer Prevention Education|Disseminating Breast Cancer Prevention to African American Women||University of Pennsylvania|No|Recruiting|August 2010|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|200|||Female|35 Years|70 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299623||108777|
NCT01326052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-004|Improvement of Anorectal Function While Preserving of Inferior Mesenteric Artery Performing Left Hemicolectomy for Diverticulosis|Effect of Inferior Mesenteric Artery Preservation Performing Left Hemicolectomy for Diverticulosis in the Anorectal Function|IPIMAL|University of Roma La Sapienza|No|Completed|January 2004|December 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||June 2012|June 12, 2012|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01326052||106764|
NCT01326325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081242|Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment|Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease|KEPAL|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2011|June 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01326325||106743|
NCT01320917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIR-01|Levonorgestrel-releasing Intrauterine Device on Obese Women: Effects on Hemostatic and Arterial Function|Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women||University of Sao Paulo|No|Active, not recruiting|February 2009|September 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2009|April 1, 2011|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320917||107158|
NCT01321203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-GI2010-02|Outcome of Carbon Dioxide Versus Air Insufflations During Endoscopic Retrograde Cholangiopancreatography (ERCP)|A Double-blind, Randomized, Controlled Trial of Air Insufflation Versus Carbon Dioxide Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP).||Asian Institute of Gastroenterology, India|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population age group 18yrs and above|July 2011|July 16, 2011|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321203||107136|
NCT01321437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCI 10-55|Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma|Phase 2 Study of the Anti-Angiogenesis Agent Axitinib (AG-013736) in Patients With Stage III Malignant Melanoma||University of California, Irvine|Yes|Recruiting|December 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321437||107118|
NCT01326312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200705|Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer|Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist|GTx758|GTx|Yes|Terminated|June 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|156|||Male|45 Years|80 Years|No|||April 2014|April 23, 2014|March 25, 2011|Yes|Yes|FDA Clinical Hold|No||https://clinicaltrials.gov/show/NCT01326312||106744|
NCT01326637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0447|Human Factors Intervention to Reduce Risk in Primary Care of the Elderly|A Human Factors Intervention to Reduce Risk in Primary Care of the Elderly|SAFE-C|University of Wisconsin, Madison|No|Active, not recruiting|May 2011|July 2016|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|2304|||Both|65 Years|N/A|No|||October 2015|October 1, 2015|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01326637||106719|
NCT01322945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10BN172|Barrow Nasal Inventory Survey|Observational Study of Nasal Outcomes Following Endonasal Surgery for Anterior Skull Base Lesions|BNI|St. Joseph's Hospital and Medical Center, Phoenix|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|||Both|18 Years|80 Years|No|Non-Probability Sample|Neurosurgery and endocrinology clinic|December 2013|December 9, 2013|March 23, 2011||No||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01322945||107002|
NCT01322958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVE'EM|Sonographic Assessment and Visualization of Ectopics in Emergency Medicine|Sonographic Assessment and Visualization of Ectopics in Emergency Medicine (SAVE'EM)|SAVE'EM|University of California, San Francisco|No|Completed|February 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|Samples Without DNA|Blood|Female|12 Years|55 Years|No|Non-Probability Sample|women at risk of ectopic pregnancy in emergency department|January 2014|January 14, 2014|April 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01322958||107001|
NCT01327222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOW-VISION|Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)|Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration|LOW-VISION|IRCCS San Raffaele|No|Completed|February 2011|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|55 Years|90 Years|No|||January 2011|March 31, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327222||106675|
NCT01327235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-90|Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites|A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|March 2011|July 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|336|||Both|18 Years|75 Years|No|||July 2014|July 31, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01327235||106674|
NCT01322620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3911|Survey Evaluating the Psychosocial Effects of Living With Haemophilia|Haemophilia, Experiences, Results and Opportunities (HERO): A Community-based Evaluation of the Psychosocial Effects of Haemophilia on Patients and Their Carers|HERO|Novo Nordisk A/S|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1236|||Male|18 Years|N/A|No|Non-Probability Sample|Adult males with haemophilia and parents/carers of children with haemophilia.|November 2014|November 13, 2014|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01322620||107027|
NCT01322633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001A1-100034|Risk of Cancer Among Pantoprazole Users|Long-Term Prospective Observational Study of the Risk of Cancer Among Pantoprazole Users||Pfizer|No|Completed|July 2004|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|61864|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with long-term exposure to pantoprazole and other proton pump inhibitors enrolled        in the Northern California Kaiser Permanente health maintenance organization.|January 2014|January 7, 2014|March 23, 2011|No|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01322633||107026|
NCT01323478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13267B|Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults|A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 (15 and 20 mg/Day) in Patients With Major Depressive Disorder||H. Lundbeck A/S|No|Completed|April 2011|October 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|75 Years|No|||December 2013|December 23, 2013|March 24, 2011||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01323478||106961|
NCT01323491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EER Nicorette - 01|"EASY EFFECTIVE SMOKELESS" With NICORETTE®|Nicht-interventionelle Studie (NIS) Zur Strukturierten Raucherentwöhnung Nach Dem Konzept "EINFACH ERFOLGREICH RAUCHFREI" unterstützt Durch NICROETTE®-Produkte||Johnson & Johnson GmbH|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|184|||Both|18 Years|N/A|No|Non-Probability Sample|general practitioners|May 2013|May 15, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01323491||106960|
NCT01323465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP0602|Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex|A Phase I, Open-label, Randomised, Crossover Study in 3 Parallel Groups to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex in Healthy Volunteers||GW Pharmaceuticals Ltd.|No|Completed|February 2008|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01323465||106962|
NCT01323751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACY-100|Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma|A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma|ACY-1215|Acetylon Pharmaceuticals Incorporated|Yes|Active, not recruiting|July 2011|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|February 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01323751||106940|
NCT01324024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812470|Attention & Memory Impairments in Menopausal Women|Attention & Memory Impairments in Menopausal Women: A Possible Role for Vyvanse?||University of Pennsylvania|No|Completed|May 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 2, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324024||106919|
NCT01325233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP018|The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke|The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke||PhytoHealth Corporation|No|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|80 Years|No|||December 2012|November 3, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325233||106827|
NCT01325506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-155|Effectiveness of Open and Robotic Prostatectomy|Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study|PROSTQA-RP2|Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2010|February 2020|Anticipated|February 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Male|18 Years|N/A|No|Non-Probability Sample|Subjects with localized prostate cancer who have elected to undergo a robot assisted        laparoscopic prostatectomy or an open prostatectomy from participating clinical sites|July 2015|July 6, 2015|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01325506||106806|
NCT01325519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002794|A Prospective Randomized Trial Using Video Images in Advance Care Planning in Seriously Ill Hospitalized Patients|||Massachusetts General Hospital|No|Recruiting|March 2011|||March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|60 Years|N/A|No|||January 2012|January 26, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325519||106805|
NCT01326078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIST011|Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures.|Comparison Between Propofol Nanoemulsion and Propofol Lipid Emulsion on Children Undergoing Ambulatory Invasive Procedures.||Cristália Produtos Químicos Farmacêuticos Ltda.|No|Withdrawn|June 2011|December 2011|Anticipated|July 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|6 Years|12 Years|No|||March 2014|March 25, 2014|March 28, 2011||No|The Sponsor has no interest in continuing the study.|No||https://clinicaltrials.gov/show/NCT01326078||106762|
NCT01297517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-033|Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%|Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension||Alcon Research|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1001|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|February 15, 2011|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01297517||108937|
NCT01325714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-351|Preventing Aggression in Veterans With Dementia|Preventing Aggression in Veterans With Dementia|PAVeD|VA Office of Research and Development|No|Completed|May 2011|September 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|203|||Both|60 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325714||106790|
NCT01325727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13510|Brief Computerized Feedback for Smokers in Recovery|Brief Computerized Feedback for Smokers in Recovery||Virginia Commonwealth University|No|Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 13, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325727||106789|
NCT01326039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH_2010_IIH|Ultrasound-guided Ilioinguinal-iliohypogastric Block for Inguinal Hernia Repair|Does Ultrasound-guided Ilioinguinal-iliohypogastric Block Improve Postoperative Pain Outcome After Unilateral Inguinal Hernia Repair?||Bispebjerg Hospital|Yes|Recruiting|May 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|19 Years|N/A|No|||April 2010|March 29, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326039||106765|
NCT01325740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107FX201|A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of STX107 in Adults With Fragile X Syndrome||Seaside Therapeutics, Inc.|Yes|Suspended|May 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|16|||Male|18 Years|50 Years|No|||December 2012|December 19, 2012|March 28, 2011|Yes|Yes|pending further evaluation|No||https://clinicaltrials.gov/show/NCT01325740||106788|
NCT01325753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 62210|Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body|A Pilot Study of Cryoablation for Patients With Oligometastatic Cancer Involving the Lung||Comprehensive Cancer Center of Wake Forest University|Yes|Withdrawn|March 2011|March 2017|Anticipated|March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|March 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325753||106787|
NCT01325467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin_05_01|Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry|Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry|HyperQ|BSP Biological Signal Processing Ltd.|No|Recruiting|May 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients referred for an exercise ECG treadmill test with nuclear myocardial        perfusion imaging (MPI).|March 2012|March 28, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325467||106809|
NCT01326338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM02-3019|Nitazoxanide for the Treatment of Prolonged Diarrhea in Children|Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Prolonged Diarrhea in Children||Romark Laboratories L.C.|No|Completed|March 2005|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|12 Months|11 Years|No|||March 2011|March 29, 2011|March 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326338||106742|
NCT01326026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3846|Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Insulin Degludec Once Daily in Insulin naïve Subjects With Type 2 Diabetes Mellitus When Titrated Using Two Different Titration Algorithms (BEGIN™: ONCE SIMPLE USE)|BEGIN™|Novo Nordisk A/S|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|March 29, 2011|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01326026||106766|
NCT01327248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA-BO|Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans|Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans|Frabo|Johann Wolfgang Goethe University Hospitals|No|Completed|May 2011|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|Samples With DNA|whole blood, serum, and Sputum|Both|6 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study is carried out in children and young adults (6 to 25 years). Both the patients        (20) and the healthy subjects (20) are recruited from the outpatient clinic of the        departement of Pediatric Allergy and Pulmonology, University Clinic, JW Goethe University,        Frankfurt/M, Germany.|June 2012|June 26, 2012|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327248||106673|
NCT01323504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09022 / musicthérapy|Pain and Music Therapy in Patients Suffering Arteritis|Pain and Music Therapy During the Wound Healing in Patient Suffering Arteritis of Stage 5 or 6.|Musicthérapy|University Hospital, Limoges|No|Not yet recruiting|April 2011|December 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|58|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01323504||106959|
NCT01323517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-101|Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity|A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity||Memorial Sloan Kettering Cancer Center||Recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323517||106958|
NCT01323166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoL after APR at SU|Quality of Life After Abdominoperineal Resection for Rectal Cancer, Comparing Two Surgical Techniques|Retrospective Study of APR Results Regarding Patients' Self Reported Quality of Life|APR|Sahlgrenska University Hospital, Sweden|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|75|||Both|N/A|N/A|No|Non-Probability Sample|colorectal section of one university hospital|September 2015|September 3, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323166||106985|
NCT01323179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11123111|Preopioid Versus Nonopioid in Total Knee Arthroplasty (TKA)|Acute Pain After Fast-track Total Knee Arthroplasty: Preoperative Opioid Versus Non-opioid||Hvidovre University Hospital|No|Completed|March 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|140|||Both|18 Years|N/A|No|Probability Sample|Patients operated with elective, primary, unilateral total knee artroplasty (TKA).|June 2013|June 4, 2013|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323179||106984|
NCT01324050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-DEP2011-PDT|Internet-delivered Psychodynamic Therapy for Depression|Internet-delivered Psychodynamic Therapy for Depression: a Randomized Controlled Trial||Linkoeping University|Yes|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|80 Years|No|||January 2011|August 1, 2011|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324050||106917|
NCT01324063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-06864|A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)|A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)||European Organisation for Research and Treatment of Cancer - EORTC||Completed|November 1986|||June 1994|Actual|Phase 3|Interventional|Allocation: Randomized, Primary Purpose: Treatment|||Anticipated|160|||Both|45 Years|60 Years|No|||July 2012|July 13, 2012|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324063||106916|
NCT01323764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDxDev-SCMP-2012|ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients|A Double- Blinded Comparison of the Accuracy of ShuntCheck, a Non-Invasive Device, to Radionuclide Shunt Patency Test in Evaluating Shunt Function in Patients With Adult Hydrocephalus With Possible Shunt Obstruction|SCNPH|NeuroDx Development|No|Completed|June 2011|July 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|35 Years|N/A|No|||October 2015|October 19, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01323764||106939|
NCT01323777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-10-050|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2011|||||N/A|N/A|N/A||||||||||||||March 15, 2013|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323777||106938|
NCT01324037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL29834.018.09|Diagnostic Algorithm in Suspected Upper Extremity Deep Vein Thrombosis|Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-dimer Test and Ultrasonography in Suspected Upper Extremity Deep Vein Thrombosis: a Prospective Management Study|Armour|University Medical Center Groningen|No|Completed|March 2010|April 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|406|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324037||106918|
NCT01325259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN08-VC / FAIR AD|FluoroAv45 Imaging Research-in Alzheimer's Disease|Molecular Imaging of Cerebral Amyloid Plaques Using PET With Fluoro Tracker for Early Diagnosis of Alzheimer's Disease|FAIR-AD|University Hospital, Tours|Yes|Completed|April 2009|December 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|54|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 5, 2016|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01325259||106825|
NCT01325532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 P000461|Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)|Efficacy and Safety of Cranial Electrical Stimulation (CES) for the Treatment of Major Depressive Disorder (MDD): A Pilot Study||Massachusetts General Hospital|Yes|Active, not recruiting|November 2010|November 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325532||106804|
NCT01325779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 2010-113|Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients|Prevention of Lower Extremity Deep Venous Thrombosis in the Surgical Intensive Care Unit: a Randomized Trial Comparing Subcutaneous Heparin and Subcutaneous Enoxaparin||William Beaumont Hospitals|Yes|Withdrawn|March 2011|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 17, 2013|March 28, 2011|Yes|Yes|poor enrollment|No||https://clinicaltrials.gov/show/NCT01325779||106785|
NCT01325792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS155|Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement|Prospective, Multicenter, Observational Study Evaluate Single-Staged Open Complex Ventral Incisional Hernia Repair Using a Biosynthetic Material for Midline Fascial Closure Reinforcement|COBRA|W.L.Gore & Associates|No|Completed|February 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|general and teaching hospitals|November 2015|November 18, 2015|March 28, 2011|No|Yes||No|April 10, 2015|https://clinicaltrials.gov/show/NCT01325792||106784|
NCT01298700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-054|Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|||Allergan|No|Active, not recruiting|April 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|807|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298700||108848|
NCT01298713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMRAD|Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer|Phase 2 Study Assessing the Tolerance and Efficacy of Tamoxifen Alone Versus the Association Tamoxifen-RAD001 (Everolimus) in Patients With Anti-aromatase Resistant Breast Metastatic Cancer||ARCAGY/ GINECO GROUP|No|Active, not recruiting|March 2008|||June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|111|||Female|18 Years|N/A|No|||November 2015|November 17, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298713||108847|
NCT01299311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-2-057|NEAT and Insulin Sensitivity|The Effect of Activity on Insulin Sensitivity and Lipid Metabolism in Sedentary, Overweight People.||Maastricht University Medical Center|Yes|Completed|December 2010|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|18|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299311||108801|
NCT01299324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHF2011-1|Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure|Feasibility Study of Retrograde Delivery of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Patients Diagnosed With Congestive Heart Failure (CHF)||Harvest Technologies|Yes|Completed|February 2011|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|January 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01299324||108800|
NCT01299662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-0718|Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers|An Open Label Study to Evaluate Innate Immune Responses Induced by a Pattern Recognition Receptor Agonist, Poly-ICLC (Hiltonol), in Healthy Volunteers||Rockefeller University|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|February 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01299662||108774|
NCT01325493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4735|Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia|Modulation of μ Opioid Receptor Mediated Analgesia, Tolerance and Hyperalgesia in Children and Adolescents|KPSF|Children's Research Institute|Yes|Completed|January 2010|September 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|10 Years|18 Years|No|||December 2015|December 14, 2015|February 25, 2011|Yes|Yes||No|June 17, 2015|https://clinicaltrials.gov/show/NCT01325493||106807|Patient sex and ethnicity could have led to analytical bias.
NCT01326975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254-2010|Effect of Continuous Positive Airway Pressure Delivered by Two Different Modalities on Breathing Pattern in Preterm Infants|Effects of Continuous Positive Airway Pressure (CPAP) Delivered by High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure on the Diaphragm Electrical Activity in Very Low Birth Weight Preterm Infants||Sunnybrook Health Sciences Centre|Yes|Completed|May 2011|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|10|||Both|N/A|12 Months|No|Non-Probability Sample|clinically stable preterm infants with birth weight less than 1.5 kilograms and        gestational age less than 32 weeks admitted to the neonatal intensive care unit at        Sunnybrook Health Sciences centre on nasal continuos positive airway pressure(CPAP) of 5-6        cmH2O support for at least 48 hours, treated with Methylxanthines for apnea of prematurity        and in less than 35% oxygen.|June 2015|June 16, 2015|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01326975||106693|
NCT01326663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075168|Divalproex Sodium for Mood Swings and Alcohol Use Following Head Injury.|A Double Blind Trial Of Divalproex Sodium For Affective Lability And Alcohol Use Following Traumatic Brain Injury||Denver Research Institute|No|Recruiting|October 2009|December 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||September 2012|September 6, 2012|March 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326663||106717|
NCT01326065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUH424503|Implementation of Laparoscopy-assisted Surgery for Colon Cancer|Implementation of Laparoscopy-assisted Surgery for Colon Cancer. A Prospective Population-based Study||Helse Stavanger HF|No|Terminated|February 2011|February 2017|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|All patients submitted for curative resection of colon cancer to the Dept. of Surgery,        Stavanger University Hospital. Catchment area of the hospital consists of a population of        300.000 inhabitants, with Stavanger UH as the only institution with surgical service|November 2014|November 17, 2014|February 27, 2011||No|Study had to be terminated due to lack of funding|No||https://clinicaltrials.gov/show/NCT01326065||106763|
NCT01326676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1656 (Sub-study of 241849 )|Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial|PESCA - A Randomised Controlled Trial of a Cardiovascular Polypill Treatment Strategy Compared With Usual Care on Carotid Intima-media Thickness in Individuals at High Risk of Cardiovascular Disease|PESCA|Imperial College London|Yes|Completed|February 2011|September 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|665|||Both|18 Years|N/A|No|||January 2013|May 28, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326676||106716|
NCT01326364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANC0009|Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection|Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection||Stanford University|Yes|Active, not recruiting|March 2010|September 2015|Anticipated|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|pancreatic adenocarcinoma|April 2013|April 23, 2013|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01326364||106740|
NCT01323556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH 11.2009|Mechanisms of Panic Disorders Treatment|Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure||University Medicine Greifswald|Yes|Recruiting|March 2010|May 2012|Anticipated|October 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||March 2011|April 8, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01323556||106955|
NCT01323192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017755|An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder|A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day||Janssen Pharmaceutical K.K.|No|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|284|||Both|18 Years|64 Years|No|||June 2013|June 27, 2013|March 10, 2011||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01323192||106983|
NCT01323530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-E044-203|A Phase 1b/2, Multicenter, Randomized, Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine|A Phase 1b/2, Multicenter,Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine||Eisai Inc.|Yes|Active, not recruiting|February 2010|May 2014|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323530||106957|
NCT01323543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10k002 PMCS 01|Safety and Performance of the Elaspine System in the Treatment of the Lumbar Spine|"Elaspine™ Implant System Post Marketing Clinical Study: A Prospective, Multicentre Study to Evaluate the Safety and Performance of the Elaspine™ System in the Surgical Treatment of Degenerative Lumbar Spine"||Spinelab AG|No|Completed|August 2010|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|21 Years|80 Years|No|||November 2015|November 16, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323543||106956|
NCT01323803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CoFAR5|Eosinophilic Esophagitis Databank|Eosinophilic Esophagitis (EoE) Databank (CoFAR 5)|CoFAR5|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|April 2011|August 2016|Anticipated|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|709|Samples With DNA|blood and saliva|Both|6 Months|65 Years|No|Probability Sample|Participants with biopsy proven Eosinophilic Esophagitis|March 2016|March 3, 2016|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323803||106936|
NCT01323790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00005|Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)||AstraZeneca|No|Completed|March 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|700|||Both|18 Years|84 Years|No|||May 2015|June 1, 2015|March 24, 2011|Yes|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT01323790||106937|
NCT01324674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-50|Relationship Between Treatment With Bach´s Flower Remedy and Spiritual Well-Being of People With Common Mental Disorder|Relationship Between Treatment With Bach´s Flower Remedy and Spiritual Well-Being of People With Common Mental Disorder||UPECLIN HC FM Botucatu Unesp|Yes|Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||March 2011|January 16, 2012|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01324674||106870|
NCT01324388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11552|A Study of the Effect of LY2189265 on Two Blood Pressure Drugs|Pharmacokinetic and Pharmacodynamic Effect of LY2189265 on Lisinopril in Subjects With Hypertension and Metoprolol in Healthy Subjects||Eli Lilly and Company|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 3, 2014|March 25, 2011|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01324388||106892|
NCT01324648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02847|Evaluation of the Bounce Back Program|A Randomized Controlled Trial Evaluation of Brief, Telephone Supported CBT Self-help in Primary Care Patients With Mild to Moderate Depression||University of British Columbia|Yes|Recruiting|March 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|213|||Both|19 Years|N/A|No|||September 2014|September 8, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01324648||106872|
NCT01324661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3857|The Protective Effect of Friendship on Peer Rejection in Overweight and Normal Weight Youth|The Protective Effect of Friendship on Peer Rejection in Overweight and Normal Weight Youth||University at Buffalo|No|Completed|December 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|104|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||September 2011|September 28, 2011|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01324661||106871|
NCT01324908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC BMT 1063|Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis|T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|July 2011|December 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|203|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324908||106852|
NCT01326143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESMED Narval ORM 001|Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH)|ORM Narval Mandibular Repositioning Device in the Second-line Treatment of Severe OSAH|ORCADES|ResMed|No|Active, not recruiting|May 2011|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|360|||Both|18 Years|N/A|No|Non-Probability Sample|Severe Obstructive Sleep Apnea Hypopnea|October 2015|December 8, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326143||106757|
NCT01326416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/066/HP|Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome|Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome. OBEFITT Study.|OBEFITT|University Hospital, Rouen|Yes|Completed|March 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|79|||Both|18 Years|55 Years|No|||January 2016|January 22, 2016|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326416||106736|
NCT01326767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-III-002|Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring|An Open-Label, Randomized, Parallel Group Study of Patients Treated With Paclitaxel With Standard Dosing Versus Pharmacokinetic Guided Dose Adjustment in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)|CEPAC-TDM|Central European Society for Anticancer Drug Research|No|Completed|March 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|366|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326767||106709|
NCT01325805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03212011-7603|Pregnancy Outcomes in Overweight Women With Prior Miscarriages Following a Structured Weight Loss Program Versus Weight-Loss Counseling|Pregnancy Outcomes in Overweight and Obese Women With a History of Recurrent Pregnancy Loss Randomized to a Structured Weight Loss Program Versus Routine Weight-Loss Counseling: A Pilot Study||Stanford University||Recruiting|December 2010|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||June 2011|June 13, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01325805||106783|
NCT01325818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCUMC20110324|The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris|The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris||Yokohama City University Medical Center|Yes|Recruiting|March 2011|February 2016|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|20 Years|N/A|No|||March 2011|March 31, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325818||106782|
NCT01298726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0040.0.238.000-09|Pharmaceutical Care in Type 2 Diabetes|Pharmaceutical Care Program for Users of Brazilian Public Health Care System With Type 2 Diabetes Mellitus: Randomized Controlled Clinical Trial||Universidade Federal de Ouro Preto|No|Completed|January 2010|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||January 2011|February 17, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298726||108846|
NCT01298739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RHU-XXX-2011/1|Asthma Control Study 2011|Asthma Control Study 2011||AstraZeneca|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1524|||Both|18 Years|N/A|No|Non-Probability Sample|Asthmatic patients above 18 y|October 2011|October 24, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298739||108845|
NCT01299675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SureScan PAS|SureScan Post-Approval Study|||Medtronic|No|Active, not recruiting|February 2011|November 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1810|||Both|N/A|N/A|No|Non-Probability Sample|Patients indicated for or implanted with a Medtronic SureScan Pacing System. All subjects        must meet Inclusion criteria and none of the Exclusion criteria.|February 2016|February 9, 2016|February 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01299675||108773|
NCT01299688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-12-008|HER2 Circulating Tumor Cells in Gastric Cancer|HER2 Circulating Tumor Cells in Gastric Cancer||Samsung Medical Center|No|Active, not recruiting|March 2010|September 2013|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood, circulating tumor cell|Both|18 Years|N/A|No|Non-Probability Sample|metastatic gastric cancer|June 2013|June 12, 2013|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299688||108772|
NCT01326741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002042|Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis|Detection of Clonal Mast Cell Disorders Among Patients With Exercise-induced Anaphylaxis||Brigham and Women's Hospital|No|Recruiting|March 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10|||Both|21 Years|N/A|No|Non-Probability Sample|Ten adults of either sex|March 2011|March 30, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326741||106711|
NCT01326988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Real-time Spinal Ultrasound|Real-time Ultrasound-guided Spinal Anesthesia:A Feasibility Study|Feasibility Study of the Use of Real-time Ultrasound Guidance to Administer Spinal Anesthesia||Sunnybrook Health Sciences Centre|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting for elective lower limb orthopaedic surgery to a specialist        orthopaedic hospital.|February 2012|February 3, 2012|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01326988||106692|
NCT01326351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|prolo-2011|Prolotherapy for the Treatment of Plantar Fasciitis|Plantar Fasciitis: Pain Relief and Improvement of Foot Function With Prolotherapy||Réseau de Santé Vitalité Health Network|No|Not yet recruiting|May 2011|February 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|90 Years|No|||April 2011|April 18, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326351||106741|
NCT01326689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2246-004|A Comparative Study of KW-2246|Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)|2246-004|Kyowa Hakko Kirin Company, Limited||Completed|March 2011|||June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||||||Both|20 Years|N/A|No|||November 2012|November 6, 2012|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01326689||106715|
NCT01323829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTXA EMG|EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction|A Pilot Study: Botulinum Toxin Type A Injections Into Pelvic Muscles for Patients With Refractory High Tone Pelvic Floor Dysfunction|BTXA EMG|Pelvic and Sexual Health Institute|No|Completed|November 2010|December 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|79 Years|No|||May 2014|May 2, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323829||106934|
NCT01323816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0145|Differences in Care Provided in Intensive Care Units (ICUs) With Physician Versus Nurse Practitioner First Responders|Process and Outcome Differences in Care Provided in Intensive Care Units (ICUs) With Physician Versus Nurse Practitioner First Responders||Ohio State University|No|Completed|March 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|3659|||Both|18 Years|N/A|No|Probability Sample|Any patients being seen at designated ICU during the time period being investigated.|June 2014|June 25, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323816||106935|
NCT01324115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000697500|NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of NG-Nitro-L-Arginine (L-NNA), a Nitric Oxide Synthase Inhibitor, Given as a Single Intravenous Infusion Over 10 Minutes in Patients With Advanced Solid Tumors||Cancer Research UK||Terminated|April 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Actual|6|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|March 25, 2011||No|Sponsor Decision|No||https://clinicaltrials.gov/show/NCT01324115||106912|
NCT01324102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7629-P|Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors|Yoga Cancer Rehabilitation Study|YogaCares|VA Office of Research and Development|No|Completed|May 2011|December 2015|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|90 Years|No|||December 2015|December 3, 2015|March 4, 2011||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01324102||106913|The goals of this study were modest. A small pilot pre-post randomized trial was completed with a Yoga therapy intervention and a Wait list intervention. Additional studies in larger samples are needed.
NCT01324076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000697324|Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer||National Cancer Institute (NCI)||Recruiting|November 2010|||November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|412|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324076||106915|
NCT01324089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO 10308|Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol|A Randomized, Double-Blind Pilot Trial of Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol||University of Wisconsin, Madison|Yes|Completed|March 2011|March 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 31, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01324089||106914|
NCT01324921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK40|Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics|Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics||Abbott Nutrition|Yes|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|75 Years|No|||March 2011|March 29, 2011|March 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01324921||106851|
NCT01324934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-AS-24-ES|Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids|Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression|IBERICA|Neovii Biotech|Yes|Terminated|October 2006|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||April 2015|April 30, 2015|March 21, 2011||No|Recruitment became very slow.|No||https://clinicaltrials.gov/show/NCT01324934||106850|
NCT01325246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH-1|Reoperation Rate Versus Clinical Recurrence After Ventral Hernia Repair|Correlation Between Reoperation and Clinical Palpable Recurrence 3 Years After Ventral Hernia Repair||University Hospital Koge|No|Completed|September 2010|June 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|945|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1200 patients who had a ventral hernia repair in 2007|December 2013|December 3, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01325246||106826|
NCT01324960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFM-Aza-ceplene|Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes|A Phase I and Phase II Study of the Efficacy and Safety of Maintenance Treatment With Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Who Achieved Hematological Response to Azacitidine||Groupe Francophone des Myelodysplasies|Yes|Withdrawn|March 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2011|March 19, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01324960||106848|
NCT01326156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56789|Study of Knee Replacements for Patellofemoral Osteoarthritis|Patellofemoral Arthroplasty (PFA) Versus Total Knee Replacement (TKR) for Isolated Patellofemoral Osteoarthritis|PFA/TKR|University of Aarhus|No|Active, not recruiting|June 2007|November 2025|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2015|August 3, 2015|May 19, 2009||No||No||https://clinicaltrials.gov/show/NCT01326156||106756|
NCT01326429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 019/11|Frequency and Origin of Dysnatremias in the Emergency Department|Frequency and Origin of Dysnatremias in the Emergency Department||University Hospital Inselspital, Berne|No|Withdrawn|October 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|0|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to the emergency department of a large tertiary university hospital        with a serum sodium below 135 mmol/L (hyponatremia) or exceeding 145 mmol/L.|July 2015|July 22, 2015|March 29, 2011||No|Job change of responsible investigators|No||https://clinicaltrials.gov/show/NCT01326429||106735|
NCT01326442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011MeckVitD|Vitamin D and Omega-3 Inhibit Metabolic Syndrome|Phase 3 Study of Vitamin D and Omega-3 Supplementation to Reduce Risk of Metabolic Syndrome||University of Guelph|Yes|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||June 2013|June 12, 2013|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326442||106734|
NCT01326169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA017895|ReDIAL: A Telephone Brief Intervention for Injured Emergency Department Patients|ReDIAL: A Telephone Brief Intervention for Injured Emergency Department Patients|ReDIAL|Rhode Island Hospital||Completed|March 2010|May 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|730|||Both|18 Years|N/A|No|||September 2014|September 10, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326169||106755|
NCT01327040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000346|Light Sensitization Study|Sensitization of Human Circadian Responses to Light||Brigham and Women's Hospital|No|Active, not recruiting|October 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|40|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||May 2015|May 1, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327040||106688|
NCT01299337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-004759|Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)|Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)|T3ECT|Mayo Clinic|Yes|Completed|June 2008|April 2012|Actual|April 2012|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|29|Samples With DNA|Thyroid measures at time of sustained response will include free T3, free T4, and TSH. All      draws will be done before ECT treatment. An additional free T3 will be obtained at the      second visit that confirms sustained response. The mean free T3 will be used as the outcome      measure. If a suppressed TSH is found, a TSH be repeated 1 week later. At the beginning of      the study 30 mL of blood will be drawn and a portion of the collected blood sample will      undergo DNA extraction. The extracted DNA will undergo genetic analysis. The remainder owill      be immortalized and stored for future study. Blood will be drawn into 1 10-mL EDTA tube and      2 10-mL Heparin tubes . Samples will be stored at Mayo Clinic BAP Lab for subsequent DNA      extraction, analysis, and storage.|Both|18 Years|64 Years|No|Probability Sample|Consultants at the Department of Psychiatry and Psychology will evaluate patients with a        diagnosis of depression (unipolar) for ECT. When a patient matches the study's diagnostic        criteria, and does not meet any of the exclusion criteria, he/she will be asked to        participate in the study.        Patient will be contacted prior to first ECT Treatment by study personnel|May 2012|May 10, 2012|June 10, 2008||No||No||https://clinicaltrials.gov/show/NCT01299337||108799|
NCT01300221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-16888|Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease|Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease|3DE-CHD|Drexel University|No|Withdrawn|February 2011|March 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|0|||Both|N/A|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1. (n=300) Subjects who are healthy normal children. Group 2. (n=300) Subjects who        have congenital heart disease. Group 3. (n=100) Subjects who have sickle cell disease.        Group 4. (n=50) Subjects who have Duchenne muscular dystrophy. Group 5. (n=50) Subjects        who have Marfan syndrome and aortic disease.|September 2013|September 4, 2013|February 17, 2011||No|Study did not receive IRB approval.|No||https://clinicaltrials.gov/show/NCT01300221||108731|
NCT01300468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDKO-125a-001|Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors|A Phase I Study of Oral PHA-848125AC Given Daily For 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days A Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients With Advanced/Metastatic Solid Tumors||Nerviano Medical Sciences|No|Completed|April 2006|December 2009|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||February 2011|February 18, 2011|February 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01300468||108712|
NCT01326754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-6029|Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malawi|Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Malawi||Centers for Disease Control and Prevention|Yes|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|498|||Both|6 Months|59 Months|No|||February 2013|February 21, 2013|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01326754||106710|
NCT01327001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RCZ-SYM-2010/1|Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients|Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients in Real Life Condition in Czech Republic (UFO)|UFO|AstraZeneca|No|Completed|April 2011|June 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|2815|||Both|6 Years|N/A|No|Probability Sample|Primary care clinic (specialists in allergology and pulmology)|July 2011|July 22, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01327001||106691|
NCT01327261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phoenix-Evoser (PHOE 1-0903)|Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers|Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers: A Single- Dose Randomized- Sequence, Open -Label Crossover Study|PHOE10903|University of Buenos Aires|Yes|Completed|August 2009|December 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||March 2011|August 3, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01327261||106672|
NCT01327274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD003341-03-06|Multicenter Trial of Magnetic Mini-Mover for Pectus Excavatum|Phase 3 Multicenter Study of Magnetic Mini-Mover for Pectus Excavatum|3MP|University of California, San Francisco|Yes|Active, not recruiting|December 2011|November 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327274||106671|
NCT01322971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03212011-7604|Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population|Pregnancy Outcomes Following Preconception Treatment of Asymptomatic Bacterial Vaginosis in an Infertility Population: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.||Stanford University|No|Terminated|February 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|November 16, 2015|March 23, 2011||No|Disease prevalence lower than expected in population.|No||https://clinicaltrials.gov/show/NCT01322971||107000|
NCT01322984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/238|Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder|Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder||University of Tromso|No|Not yet recruiting|March 2011|||January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01322984||106999|
NCT01323842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydro II|Emergency Department Ultrasound in Renal Colic|Hydro II: Emergency Department Ultrasound in Renal Colic||Queen's University|No|Completed|March 2011|December 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|414|||Both|16 Years|65 Years|No|Non-Probability Sample|ED patients with suspected renal colic being imaged while in the ED|November 2015|November 24, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323842||106933|
NCT01324180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16601|Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)|A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination With Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin With Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD)||H. Lee Moffitt Cancer Center and Research Institute|Yes|Recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|1 Year|30 Years|No|||October 2015|October 9, 2015|March 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324180||106908|
NCT01324128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-CL-05A|A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients|An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia||Vifor Inc.|Yes|Completed|March 2011|October 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1059|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|March 24, 2011|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT01324128||106911|
NCT01324141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110129|Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer|A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal||National Institutes of Health Clinical Center (CC)||Terminated|March 2011|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|90 Years|No|||April 2015|April 16, 2015|March 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324141||106910|
NCT01324427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-022|Telemedicine Evaluation for Stem Cell Transplant Patients|Pilot Trial of Telemedicine Evaluation for Stem Cell Transplant Patients||Memorial Sloan Kettering Cancer Center||Completed|March 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|43|||Both|18 Years|74 Years|No|||July 2014|July 16, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324427||106889|
NCT01324440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V710-002|Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)|A Randomized, Multicenter, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With Merck Aluminum Adjuvant or Without Merck Aluminum Adjuvant in Healthy Adults 18 to 70 Years of Age||Merck Sharp & Dohme Corp.|No|Completed|September 2006|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|64|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|February 24, 2011|No|Yes||No|September 9, 2011|https://clinicaltrials.gov/show/NCT01324440||106888|
NCT01324700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072010-235|Antidepressant Treatment at an Inner City Asthma Clinic|Antidepressant Treatment at an Inner City Asthma Clinic||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|July 2010|October 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|222|||Both|18 Years|70 Years|No|||May 2014|April 28, 2015|October 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324700||106868|
NCT01325012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Subgluteal vs Popliteal|Ultrasound-Guided Continuous Sciatic Nerve Blocks: Popliteal Versus Subgluteal Catheters|Ultrasound-Guided Continuous Sciatic Nerve Blocks: Popliteal Versus Subgluteal Catheters||University of California, San Diego|No|Terminated|March 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||March 2013|March 27, 2013|March 28, 2011|Yes|Yes|Surgeon doing procedures amenable to this study left institution.|No||https://clinicaltrials.gov/show/NCT01325012||106844|
NCT01324401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000609|Oral Peanut Immunotherapy|Oral Peanut Immunotherapy|PNOIT|Massachusetts General Hospital|No|Active, not recruiting|March 2011|July 2017|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|7 Years|21 Years|No|||January 2016|January 11, 2016|August 12, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324401||106891|
NCT01324414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002215|Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis|Predictive Value of Inflammation and Fibrosis in Skeletal Muscle for Liver Histopathology in Patients With Non Alcoholic Fatty Liver Disease: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis|NASHCR20|Mayo Clinic|No|Completed|December 2010|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with NAFLD|January 2016|January 7, 2016|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324414||106890|
NCT01324687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31563|Study Of Telemedicine Consultation at Home For Older Adults|Study Of Telemedicine Consultation at Home For Older Adults||University of Rochester|No|Completed|October 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1537|||Both|N/A|N/A|No|Non-Probability Sample|Adults residing in senior living communities.|February 2016|February 20, 2016|November 19, 2010||No||No|February 20, 2016|https://clinicaltrials.gov/show/NCT01324687||106869|
NCT01324947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-003/C|Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma|Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003||Celgene|No|Completed|May 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|March 27, 2011|Yes|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT01324947||106849|
NCT01325272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-53|Interrelations Between Spontaneous Otoacoustic Emissions and Transient Evoked Emissions|Interrelations Between Spontaneous Otoacoustic Emissions and Transient Evoked Emissions: Indication of Cochlear Damage in Newborn.||UPECLIN HC FM Botucatu Unesp|Yes|Completed|March 2009|September 2009||||N/A|Observational|Time Perspective: Retrospective||2|||||Both|N/A|5 Months|Accepts Healthy Volunteers|Probability Sample|Children born in this institution|May 2011|May 31, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325272||106824|
NCT01325831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0525|Changes of Functional Connectivity After rTMS in Depression|Change of Dopamine Pathway After rTMS Treatment in Major Depressive Disorder||Yonsei University|Yes|Completed|May 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|19 Years|70 Years|No|||January 2012|January 31, 2012|July 7, 2009||No||No||https://clinicaltrials.gov/show/NCT01325831||106781|
NCT01325844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0537|The Effects of Epidural Anesthesia on the Bioavailability of Nitric Oxide and Renal Function in Patients Undergoing Laparoscopic Surgery|The Effects of Epidural Anesthesia on the Bioavailability of Nitric Oxide and Renal Function in Patients Undergoing Laparoscopic Surgery||Yonsei University|Yes|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Male|20 Years|N/A|No|||February 2012|February 2, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325844||106780|
NCT01325883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/WMW01/15|The Effect of Chemotherapy and Surgery for Cancer on Exercise Capacity|The Effect of Neoadjuvant Chemotherapy on Exercise Capacity and Outcome Following Upper Gastrointestinal Cancer Surgery.||Aintree University Hospitals NHS Foundation Trust|No|Active, not recruiting|April 2011|January 2016|Anticipated|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|253|||Both|18 Years|N/A|No|Probability Sample|This is a multicentre study the recruitment will be from all the 3 centres included in the        study proposal|January 2016|January 4, 2016|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01325883||106777|
NCT01326182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4040-09|Intervention for Depressed Latina Mothers of Children With Asthma|Intervention for Depressed Latina Mothers of Children With Asthma|MAADRE|Rhode Island Hospital|Yes|Recruiting|August 2009|September 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|N/A|No|||July 2010|March 29, 2011|July 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01326182||106754|
NCT01326195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH086328|Dating Violence and HIV Prevention in Girls: Adapting Mental Health Interventions|Dating Violence and HIV Prevention in Girls: Adapting Mental Health Interventions||Rhode Island Hospital|Yes|Recruiting|May 2009|February 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|15 Years|17 Years|Accepts Healthy Volunteers|||March 2011|March 29, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326195||106753|
NCT01326780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-P-8023|A Study of a New Drug Treatment for Acne|A Multi-Center, Double-Blind, Vehicle Controlled, Phase II Study of JNJ 10229570-AAA for the Treatment of Acne Vulgaris||Valeant Pharmaceuticals International, Inc.|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|431|||Both|12 Years|N/A|No|||December 2012|December 21, 2012|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326780||106708|
NCT01299935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1HL048107|A Randomized Controlled Trial of Stress Reduction on Cardiovascular Morbidity and Mortality in African Americans|Stress Reduction and Cardiovascular Disease Morbidity and Mortality||Maharishi University of Management|Yes|Completed|January 1998|July 2007|Actual|June 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|201|||Both|N/A|N/A|No|||February 2011|February 23, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01299935||108753|
NCT01296100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT09-258|DEMOJUAN- DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia|DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia|DEMOJUAN|Centro de Investigacion Sanitaria|No|Active, not recruiting|February 2011|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|600|||Both|34 Years|69 Years|No|||April 2013|April 3, 2013|February 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01296100||109045|
NCT01323023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-0484|A Study to Examine Health Behavior Change Strategies for Primary Care|Common Measures, Better Outcomes (COMBO)||University of Colorado, Denver||Completed|June 2005|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|4463|||Both|2 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults, adolescents, and children in primary care practices.|September 2015|September 30, 2015|April 13, 2006|No|Yes||No||https://clinicaltrials.gov/show/NCT01323023||106996|
NCT01327014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WPU-201|Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia||Beijing Peking University WBL Biotech Co., Ltd.|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|116|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327014||106690|
NCT01327027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105,108|Vasopressin Effects on Human Social Communication|Phase 2 Study of Vasopressin Effects on Human Social Communication|AVP|Bowdoin College|Yes|Recruiting|September 2011|July 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|300|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327027||106689|
NCT01327287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9025-35075-01|Early Aggressive Pain Management is Associated With Improved Outcomes in Blunt Thoracic Trauma|Early Aggressive Pain Management is Associated With Improved Outcomes in Blunt Thoracic Trauma|Thoracic|University of California, San Francisco|No|Terminated|February 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|43|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult patients > 18 years of age admitted to San Francisco General Hospital Trauma service        with blunt thoracic trauma requiring IV opioids for pain relief|April 2015|April 16, 2015|March 29, 2011||No|inability to recruit participants despite numerous attempts|No||https://clinicaltrials.gov/show/NCT01327287||106670|
NCT01322997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03HD062545-01|Robotic Brace Incorporating Electromyography (EMG) for Moderate Affected Arm Impairment After Stroke|Robotic Brace Incorporating EMG for Moderate Affected Arm Impairment After Stroke||University of Cincinnati|No|Recruiting|September 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|35 Years|85 Years|No|||March 2011|March 23, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01322997||106998|
NCT01323205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018340|Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia|First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia||Janssen Research & Development, LLC|No|Completed|May 2011|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|65 Years|No|||May 2014|May 22, 2014|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323205||106982|
NCT01323868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03232011-7621|Endogenous Endophthalmitis in the Inpatient Setting|Endogenous Endophthalmitis Rates, Clinical Course, and Outcomes||Stanford University||Completed|July 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|||Both|N/A|N/A|No|Non-Probability Sample|Inpatients at Stanford Hospital with positive blood cultures who receive an Ophthalmology        consultation and eye examination.|November 2014|November 17, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323868||106931|
NCT01323894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|﻿DMR-99-IRB-122|﻿Ostoegenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling|﻿Ostoegenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons Between Non-viral and Viral Administration in Tissue Engineered Bone Regeneration||China Medical University Hospital|Yes|Not yet recruiting|March 2011|August 2013|Anticipated|August 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|3|||Both|10 Years|80 Years|No|Non-Probability Sample|The patients require surgery ner iliac or abdomen areas|March 2011|March 25, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323894||106929|
NCT01324167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99037|Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia|Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia||Taipei Medical University WanFang Hospital|No|Recruiting|May 2010|April 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|65 Years|No|Non-Probability Sample|schizophrenia or schizoaffective disorder patients|March 2011|March 25, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324167||106909|
NCT01324713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2010-1075|Does Gender Play a Role in Bone-mineral Density Measurement Precision?|Does Gender Play a Role in Bone-mineral Density Measurement Precision?||University of Wisconsin, Madison|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|180|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of 90 men and 90 women volunteers who are aged 65 years        and older, able and willing to provide informed consent.|March 2011|October 1, 2015|September 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01324713||106867|
NCT01324999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2326|Tadalafil for Sarcoidosis Associated Pulmonary Hypertension|Tadalafil for Sarcoidosis Associated Pulmonary Hypertension|SAPH|University of North Carolina, Chapel Hill|Yes|Completed|March 2011|October 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|March 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324999||106845|
NCT01324726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.ZK.05|Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms|Sites of Colonization in Hospitalized Patients With Infections Caused by Extended-Spectrum Beta-Lactamase Producing Escherichia Coli and Klebsiella Pneumoniae||American University of Beirut Medical Center|No|Completed|July 2012|April 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Cultures of urine, nasopharynx, rectum, skin, and wounds|Both|18 Years|N/A|No|Probability Sample|Cultures from clinical specimens growing ESBL-EC and ESBL-KP will be identified through        the Clinical Microbiology Laboratory at AUBMC. Patients will be selected for enrollment        according to the inclusion and exclusion criteria previously set. Permission from the        patient's primary physician will be sought at the time of identification before        approaching the patient.|June 2015|June 22, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01324726||106866|
NCT01324973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH090207|Web-Based Weight Management for Individuals With Mental Illness|Web-Based Weight Management for Individuals With Mental Illness|eWellness|University of California, Los Angeles|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01324973||106847|
NCT01324986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zell 03|A Study on the Effectiveness of Laparoscopic Fundoplication on Extraesophageal Manifestations of Gastroesophageal Reflux Disease (GERD)|||General Public Hospital Zell am See||Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||March 2011|April 8, 2011|March 27, 2011||||No||https://clinicaltrials.gov/show/NCT01324986||106846|
NCT01325545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-003788|Detection of Occult Paroxysmal Atrial Fibrillation After Stroke Using Prolonged Ambulatory Cardiac Monitoring|Detection of Occult Paroxysmal Atrial Fibrillation in Patients With Cryptogenic Stroke or TIA Using 21-Day Mobile Cardiac Outpatient Telemetry||Mayo Clinic|No|Completed|April 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|132|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stroke or TIA confirmed by a vascular neurologist within previous 3 months        with complete evaluation for stroke causes according to current standards.|December 2011|December 21, 2011|March 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01325545||106803|
NCT01325857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0668|Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach|Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach||Yonsei University|No|Completed|January 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|97|||Both|20 Years|N/A|No|||February 2012|February 26, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325857||106779|
NCT01325870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43-0566-000|Hemodynamic Effects of Standard Cardiopulmonary Resuscitation (CPR), Active Compression Decompression CPR With an Inspiratory Impedance Device, and Standard CPR With an Intrathoracic Pressure Regulator During Out-of-hospital Cardiac Arrest|Comparison of Standard Cardiopulmonary Resuscitation Alone Versus Active Compression Decompression Cardiopulmonary Resuscitation Plus an Impedance Threshold Device Versus Standard Cardiopulmonary Resuscitation Plus an Intrathoracic Pressure Regulator on Arterial Blood Pressures During Out-of-Hospital Cardiac Arrest||Advanced Circulatory Systems|Yes|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|March 28, 2011|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01325870||106778|
NCT01325571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0611|A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis|A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy||Astellas Pharma Inc|No|Completed|March 2011|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|70 Years|No|||March 2016|March 8, 2016|March 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01325571||106801|
NCT01325896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-MM-01|Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)|Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)||Hospital Universitario de la Princesa|No|Active, not recruiting|September 2002|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|65 Years|No|||March 2011|March 30, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01325896||106776|
NCT01325909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H1002/12|Exercise Training in Colorectal Cancer Patients|Does Short-term Exercise Intervention Improve Pre-operative Physical Fitness Following Neoadjuvant Chemoradiotherapy in Colorectal Cancer Patients?||Aintree University Hospitals NHS Foundation Trust|No|Completed|March 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01325909||106775|
NCT01326208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIT-PEEP-2010|Strategies to Optimize Positive End-expiratory Pressure (PEEP) in Patients With Acute Lung Injury|Influence of Different Strategies to Optimize Positive End-expiratory Pressure on Pulmonary Gas Exchange, Perfusion/Ventilation Matching and Homogeneity of Ventilation in Patients With Acute Lung Injury|EIT-PEEP|University Hospital, Bonn|No|Recruiting|March 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||March 2011|March 29, 2011|July 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01326208||106752|
NCT01326520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H49-11|Effect of Dietary Phospholipids on Atopic Dermatitis|Effect of Dietary Milk Phospholipids on Subjects With Atopic Dermatitis||University of Jena|Yes|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|60 Years|No|||June 2012|June 19, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326520||106728|
NCT01326455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00005016|Caring for the Radial Artery Post-angiogram|Caring for the Radial Artery Post-angiogram: A Pilot Study on a Comparison of Three Methods of Compression||University of Alberta|No|Completed|May 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 29, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326455||106733|
NCT01326468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10D.133|Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer|A Pilot Study of Chemoradiotherapy Plus Temsirolimus (Torisel) for Advanced Head and Neck Cancer||Thomas Jefferson University|Yes|Withdrawn|January 2011|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|March 29, 2011||No|funding|No||https://clinicaltrials.gov/show/NCT01326468||106732|
NCT01326481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105BC102|Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer|An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer|TRC105|Tracon Pharmaceuticals Inc.|Yes|Active, not recruiting|June 2011|December 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2014|August 27, 2014|March 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326481||106731|
NCT01300507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESTIGE 5.0 26.01.11|PRESTIGE: PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort|PREvention of Stent Thrombosis by an Interdisciplinary Global|PRESTIGE|Universitaire Ziekenhuizen Leuven|No|Recruiting|June 2011|March 2018|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Biospecimen: 1, thrombusaspiration from coronary arteries, storage and analysis at the      German Heart Center Munich; 2, DNA-samples: storage at German Heart Center Munich, Antonius      Hospital Nieuwegein, The Netherlands, University Hospitals Leuven Belgium and University      Hospital Leicester, UK|Both|N/A|N/A|No|Non-Probability Sample|Cases: all patients presenting with definite ST. Expected number of patients to be        included: 2000        Controls: patients undergoing PCI will be matched based on the following criteria:        Expected number of patients to be matched: 2000          1. who underwent a PCI for the same indication          2. who underwent a PCI on the same date (±5 days)          3. who underwent a PCI in the same interventional centre|January 2013|January 17, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300507||108710|
NCT01300520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-1|The Development of a Surgical Localizing Aid Medical Device|The Development of a Surgical Localizing Aid Medical Device and the Determination and Analysis of Significant Variables||Aeos Biomedical Inc.|Yes|Not yet recruiting|March 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300520||108709|
NCT01300533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIND-014-001|A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer|A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer||BIND Therapeutics|Yes|Completed|January 2011|February 2016|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|February 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01300533||108708|
NCT01296438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3872|A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1|A Randomised Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||February 2015|February 20, 2015|February 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01296438||109019|
NCT01296451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV003|Study of a New MVA Vaccine for Hepatitis C Virus|A Phase I Study to Assess the Safety and Immunogenicity of AdCh3NSmut and MVA-NSmut in Healthy Volunteers and Patients With Hepatitis C Virus Infection||ReiThera Srl|Yes|Recruiting|December 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|48|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01296451||109018|
NCT01296711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0057|Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056|A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056||UCB Pharma|No|Completed|March 2011|August 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|18 Years|N/A|No|||December 2013|August 26, 2014|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01296711||108998|
NCT01327352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-DN-P1b-01|Evaluation of the Influence of Food Regimen on Oshadi D Absorption|A Single Center, Non-randomized, Placebo Controlled Study for the Evaluation of the Influence of Food Regimen on Oshadi D Absorption||Oshadi Drug Administration|No|Completed|April 2011|October 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 20, 2012|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327352||106665|
NCT01327365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sheathless-TRI|Trans-Radial Coronary Interventions Using A Sheathless Guiding Catheter|Trans-Radial Percutaneous Coronary Interventions Using a Sheathless Guiding Catheter-Based Approach|Sheathless-TRI|University Hospital, Geneva|No|Recruiting|August 2010|||September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01327365||106664|
NCT01323218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0091|Sleep Apnea Syndrome and Vitamin D|Effect of the Correction of Vitamin D Deficiency in Patients With Obstructive Sleep Apnea-hypopopnea Syndrome (OSAHS)||University Hospital, Clermont-Ferrand||Recruiting|March 2011|June 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Both|30 Years|75 Years|No|||March 2011|March 24, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323218||106981|
NCT01323569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP0605|Abuse Potential of Sativex|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Abuse Potential of Sativex in Subjects With a History of Recreational Marijuana Use||GW Pharmaceuticals Ltd.|No|Completed|February 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|58|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01323569||106954|
NCT01324479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2102|Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors|A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors||Novartis|No|Recruiting|February 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|122|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|March 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324479||106885|
NCT01324193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10041|Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in CKD Patients|Effects of Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in Chronic Kidney Disease Patients||University of Illinois at Urbana-Champaign|Yes|Completed|January 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|33|||Both|30 Years|N/A|No|||December 2013|December 13, 2013|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01324193||106907|
NCT01324739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OeNB 13583|B-type Natriuretic Peptide and Glucose Metabolism|B-type Natriuretic Peptide Affects the Initial Response to Intravenous Glucose in a Placebo-controlled Cross-over Study in Healthy Volunteers||Medical University of Vienna|Yes|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||October 2010|March 28, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01324739||106865|
NCT01324752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-DDI-001|A Drug-Drug Interaction Study of Losartan and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults||Vifor Inc.|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|36|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|March 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324752||106864|
NCT01325285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0655|The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia|The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia||University of Toronto|No|Not yet recruiting|August 2011|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|14|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young individuals (age 18-30)|November 2010|August 17, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01325285||106823|
NCT01325558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-836-02-10|A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors|A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors||Altor Bioscience Corporation|Yes|Active, not recruiting|May 2011|February 2016|Anticipated|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325558||106802|
NCT01325298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 109752|UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia|UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia||Mercy Center for Corrective Eye Surgery|Yes|Recruiting|March 2011|May 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|14 Years|55 Years|Accepts Healthy Volunteers|||March 2011|March 28, 2011|March 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325298||106822|
NCT01325584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRMC 10-06|Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury|Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury||Midwestern Regional Medical Center|No|Recruiting|October 2012|December 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||October 2015|October 11, 2015|March 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325584||106800|
NCT01326221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0410|Single Dose Truvada in HIV-negative Men and Women|Extracellular and Intracellular TFV/FTC Residues After a Single Dose in HIV-Negative Men and Women: Implications for Pre-exposure HIV Prophylaxis Dosing of Truvada®|TAIL|University of North Carolina, Chapel Hill|No|Completed|October 2008|May 2009|Actual|May 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Twelve adult (18 years or older) healthy volunteers will be recruited to participate in        the study. A total of 6 men and 6 women will be enrolled. Subjects of all races and        ethnicities may participate, provided they meet study inclusion/exclusion criteria.|October 2012|October 9, 2012|March 2, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01326221||106751|
NCT01326234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15312|Computer-Based Program to Facilitate Readiness and Motivation for Smoking Cessation|Further Development and Testing of an Interactive Computer-Based Program to Facilitate Readiness and Motivation for Smoking Cessation||University of Oklahoma|Yes|Not yet recruiting|April 2012|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01326234||106750|
NCT01326533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082878|Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes|Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes||University of Pittsburgh|Yes|Completed|March 2011|December 2014|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|85 Years|No|||January 2016|January 28, 2016|March 29, 2011|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT01326533||106727|
NCT01326494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00184|Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia|Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia||University of British Columbia|No|Active, not recruiting|April 2011|December 2015|Anticipated|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Both|12 Months|18 Years|No|||April 2015|April 10, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326494||106730|
NCT01326507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0900303|Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism|Performances de l'h-FABP Pour Identifier dès Les Urgences Les Embolies Pulmonaires d'évolution défavorable||University Hospital, Toulouse|No|Completed|September 2009|December 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|165|||Both|18 Years|N/A|No|||December 2011|December 13, 2011|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01326507||106729|
NCT01296113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1001|Chemotherapy for Lung Cancer in HIV-positive Patients|Phase II Trial Evaluating the Efficacy and Safety of Carboplatin Plus Pemetrexed in Human Immunodeficiency Virus Positive (HIV+) Patients With Stage III (Not Amenable to Radiation or Inoperable) or Stage IV Nonsquamous Non Small Cell Lung Cancer|CHIVA|Intergroupe Francophone de Cancerologie Thoracique|No|Active, not recruiting|May 2011|December 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01296113||109044|
NCT01296126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110090|Structural and Functional Neuroimaging Studies of Combat Veterans|Structural and Functional Neuroimaging Studies of Combat Veterans||National Institutes of Health Clinical Center (CC)||Completed|January 2011|February 2014||||N/A|Observational|N/A|||Actual|81|||Both|18 Years|65 Years|No|||February 2014|March 4, 2016|February 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01296126||109043|
NCT01296139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110098|Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer|Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer||National Institutes of Health Clinical Center (CC)||Completed|January 2011|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Male|18 Years|100 Years|No|||March 2015|November 18, 2015|February 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01296139||109042|
NCT01297335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1461 Clonidine|Effect of Intrathecal Clonidine in Hypertensive Subjects With Poorly Controlled Blood Pressure|Hemodynamic Effect of Intrathecal Clonidine in Hypertensive Subjects: A Pilot Study to Assess Its Effectiveness in Hypertensive Subjects With Poor Blood Pressure Control (Phase II)||The Center for Clinical Research, Winston-Salem, NC|Yes|Completed|February 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 14, 2011|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01297335||108950|This study was limited by small sample size, and lack of control group.
NCT01327378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2009-007|The Incretin Effect in Patients With Kidney Impairment|The Incretin Effect in Non-diabetic Patients With Severe Renal Impairment Depending on Chronic Dialysis Treatment|UREMINC|University Hospital, Gentofte, Copenhagen|No|Completed|March 2009|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|30|Samples Without DNA|Plasma (10 ml per participant)|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|3 groups          1. Chronic hemodialysis treatment. Normal glucose tolerance (NGT). N=10          2. Chronic hemodialysis treatment. Impaired glucose tolerance (IGT). N=10          3. Healthy control subjects. Normal glucose tolerance. N=10        Glucose tolerance is evaluated at the screeningday. A 75 gram oral glucose tolerance test        (OGTT) is performed and the 120 minute value sets the glucose tolerance. NGT: < 7.8        mmol/L, IGT: > 7.7 mmol/L and < 11.1 mmol/L (according to WHO guidelines).|June 2010|March 31, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327378||106663|
NCT01323010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hidalba|Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes|Efficacy and Safety of Increasing Doses of Inhaled Albuterol Administered by Metered Dose Inhalers in Children With Acute Wheezing Episodes||University of Sao Paulo|No|Completed|September 2011|April 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Both|2 Years|18 Years|No|||February 2016|February 15, 2016|March 24, 2011||No||No|September 14, 2015|https://clinicaltrials.gov/show/NCT01323010||106997|The inclusion of a larger number of patients in this study may have uncovered differences in the efficacy outcomes studied between the groups.
NCT01323231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB -2010-05-0092|XY-Zone Program Evaluation: A School-Based Dropout Prevention Program for At-Risk Youth|XY-Zone Phase 1 Program Evaluation: A School-Based Dropout Prevention Program for At-Risk Male Youth||University of Texas at Austin|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|91|||Male|13 Years|20 Years|No|||July 2013|July 8, 2013|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323231||106980|
NCT01323582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|645-2008|Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis|Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis|AZI|University of Florida|No|Terminated|February 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|March 24, 2011|Yes|Yes|Original investigator left this institution, replacement investigator retired.|No|May 9, 2014|https://clinicaltrials.gov/show/NCT01323582||106953|
NCT01323920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007|Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors|Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study||Dana-Farber Cancer Institute|Yes|Completed|May 2011|November 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|60 Years|No|||February 2014|February 14, 2014|March 24, 2011|Yes|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT01323920||106927|
NCT01324492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001KCN01|Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor|A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor|\MACS1304|Novartis||Completed|December 2010|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|80 Years|No|||December 2014|December 26, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324492||106884|
NCT01324505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9535-3819|Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes|An Open-label, One-sequence Cross-over, Single Centre Trial Investigating the Influence of Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug After Multiple Dose Administration of Semaglutide in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||November 2012|November 6, 2012|March 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324505||106883|
NCT01324453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|opt004|Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)|Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in STEMI||Minneapolis Heart Institute Foundation|Yes|Recruiting|March 2011|March 2015|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|80 Years|No|||December 2013|December 3, 2013|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324453||106887|
NCT01325064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRS 498/A/10|Blood Pressure and Subclinical Organ Damage|Central and Peripheral Blood Pressure and Its Relation With Vascular Target Organ Damage in Carotid, Retinal and Arterial Stiffness. Developed and Validation of a Tool|Vasorisk|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Recruiting|June 2010|December 2014|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|34 Years|75 Years|No|Non-Probability Sample|The study population will be diabetic type 2 patients with a control group without        diabetes mellitus. We will include by consecutive sampling 300 patients between 34 and 75        and without previous cardiovascular disease, half of each group.|April 2011|March 4, 2014|March 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01325064||106840|
NCT01325077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 603/2010|Efficacy of a Nurse-based, Anesthesiologist-supervised Acute Pain Service for Pediatric Patients|Efficacy of a Nurse-based, Anesthesiologist-supervised Acute Pain Service for Pediatric Patients|Nurse-APS|Mahidol University|No|Recruiting|March 2011|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|103|||Both|31 Days|15 Years|No|||March 2011|March 27, 2011|March 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01325077||106839|
NCT01325025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071232|Imaging Study of the White Matter Lesions in Children With Metachromatic Leucodystrophy|Study of the Natural History of Cerebral White Matter Involvement in Metachromatic Leukodystrophy, Using High-field MRI and Diffusion Tensor Imaging|HCIT-MLD|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2010|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|29|||Both|1 Year|6 Years|No|||December 2015|December 15, 2015|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01325025||106843|
NCT01325038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beach08|Effects of Increased Muscle Mass on Resting Metabolic Rate|||University Hospital, Linkoeping|No|Completed|January 2008|August 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 28, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325038||106842|
NCT01325311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00451|Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer|Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy||National Cancer Institute (NCI)|Yes|Completed|December 2011|||July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|N/A|No|||August 2014|August 26, 2015|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325311||106821|
NCT01325324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|portable-Tono-Study|Comparison of Different Portable Tonometers (Icare Pro, TONO-Pen AVIA, Perkins Tonometer, PASCAL Hand Held Dynamic Contour Tonometer)|||University of Zurich|No|Enrolling by invitation|March 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2014|January 5, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01325324||106820|
NCT01325922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 274|50/50% Tilt and Tuned Defibrillation Waveform|50/50% Tilt and Tune Defibrillation Waveforms Utilizing High Voltage Lead Integrity Check Impedance||St. Jude Medical|No|Completed|January 2005|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|1||||||Both|18 Years|N/A||||March 2011|March 30, 2011|May 16, 2007||No||No||https://clinicaltrials.gov/show/NCT01325922||106774|
NCT01325935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPERA 1.0 - AEEI|Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients|Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA)|OPERA|Associations for Establishment of Evidence in Interventions|Yes|Completed|April 2011|December 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1187|||Both|20 Years|85 Years|No|||January 2016|January 5, 2016|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01325935||106773|
NCT01325948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RTR-XXX-2011/1|Cross-sectional Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life Activities|Cross-sectional Observational Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life Activities|COPD LIFE|AstraZeneca|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|497|||Both|45 Years|N/A|No|Non-Probability Sample|Outpatients from health institutions where the patients with COPD are treated|July 2011|July 20, 2011|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01325948||106772|
NCT01325961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/12-O|Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers|Medico-economic Evaluation Comparing Conformal Radiotherapy With Intensity Modulation (IMRT) Performed by, Helical Tomotherapy (Hi Art) and Dynamic Arc Therapy (RapidArc, VMAT) in Cancers With Pelvic Lymph Node Irradiation (Prostate, Cervix, Anal Canal)||Centre René Gauducheau|No|Recruiting|March 2011|||March 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label||||120|||Both|18 Years|N/A|No|||January 2011|March 29, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325961||106771|
NCT01326247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|studioterme|Effectiveness Of Therapy With A Thermal Water Nasal Aerosol In Children With Seasonal Allergic Rhinitis|EFFECTIVENESS OF THERAPY WITH A THERMAL WATER NASAL AEROSOL IN CHILDREN WITH SEASONAL ALLERGIC RHINITIS||Federico II University|Yes|Completed|April 2009|September 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|6 Years|14 Years|No|||December 2009|March 31, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326247||106749|
NCT01326832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.UK4A|10 Year Clinical Evaluation of Primoris Hip Component|Prospective Study for Evaluation of Proximally Anchored (Metaphysis) Cementless Femoral Component for Total Hip Arthroplasty. 10 Year Clinical Evaluation,DXA and RSA Follow-up of Primoris® Femoral Component.|Primoris|Biomet, Inc.|No|Recruiting|September 2011|December 2024|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|18 Years|65 Years|No|Probability Sample|younger patients with coxarthrosis|October 2015|October 2, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01326832||106704|
NCT01297036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121HPS07D_03|Pharmacokinetic Comparisons of Two Donepezil Formulations|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Donepezil Between Two Donepezil Products, Aricept® Tablet and Neuropezil ODT, in Healthy Subjects||Korea University Anam Hospital|No|Completed|January 2008|May 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|22|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2008|February 15, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297036||108973|
NCT01297348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0858A2-4406|Study Of Lybrel In Relation To Venous Thromboembolism|Postmarketing Study Of Lybrel In Relation To Venous Thromboembolism||Pfizer|No|Completed|July 2007|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|598682|||Female|15 Years|49 Years|No|Non-Probability Sample|The base population for each year of the study will comprise all 15 - 49 year old women        who have any recorded prescriptions for either continuous use ethinyl estradiol        20ug/levonorgestrel 90ug or a cyclic oral contraceptive that contains 20 µg ethinyl        estradiol. The women are identified from PharMetrics and MarketScan databases.        Additionally, women are enrolled if the index prescription is a new one; this is defined        as a prescription dispensed following a 4-month window in which no combined hormonal        contraception prescriptions were filled.|June 2013|June 27, 2013|February 14, 2011|No|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01297348||108949|Data for DVT, PE and CVST were not reported separately as the 3 were components of the primary endpoint VTE and not separate endpoints.
NCT01323062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1030|Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects|A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|May 2011|May 2016|Anticipated|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|March 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01323062||106993|
NCT01323244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017983|A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study|A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study.||Janssen R&D Ireland|No|Completed|December 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|142|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323244||106979|
NCT01323595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010011319|Effectiveness of Celecoxib After Surgical Sperm Retrieval|The Use of Celecoxib (Celebrex (c)) in Post-operative Pain Control After Microdissection Testicular Sperm Extraction||Weill Medical College of Cornell University|No|Terminated|January 2011|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|78|||Male|18 Years|65 Years|No|||June 2014|June 10, 2014|March 24, 2011|Yes|Yes|Interim analysis demonstrated significant benefit in intervention arm|No|October 29, 2013|https://clinicaltrials.gov/show/NCT01323595||106952|
NCT01323855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06512|A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)|A Study to Assess Pharmacokinetics of Preladenant in Subjects With Chronic Renal Impairment||Merck Sharp & Dohme Corp.|No|Completed|March 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|46|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|March 24, 2011|No|Yes||No|February 11, 2016|https://clinicaltrials.gov/show/NCT01323855||106932|
NCT01324544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3030|Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain|A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Aged From Birth to 6 Years of Age (Inclusive) Who Require Opioid Analgesia for Acute Moderate to Severe Pain||Purdue Pharma LP|No|Withdrawn|November 2011|August 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|6 Years|No|||February 2016|February 3, 2016|March 24, 2011|Yes|Yes|Due to change in development plan.|No||https://clinicaltrials.gov/show/NCT01324544||106880|
NCT01324466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-001-005|A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis|SHaRCS|NanoBio Corporation|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|847|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 15, 2013|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324466||106886|
NCT01324778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OTX-0001|Multi Centre Study Comparing OsseoSpeed TX With OsseoSpeed|An Open, Randomized, Prospective Multi Centre Study Comparing OsseoSpeedTM TX With OsseoSpeedTM in the Partially and Totally Edentulous Maxillae||Dentsply Implants||Active, not recruiting|March 2011|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324778||106862|
NCT01325051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 1020; IRB 10-2321|Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers|A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers||University of North Carolina, Chapel Hill|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||January 2012|January 3, 2012|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01325051||106841|
NCT01325337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-057|Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia|||Allergan|No|Completed|June 2011|September 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|307|||Male|18 Years|49 Years|No|||April 2014|April 8, 2014|March 28, 2011|Yes|Yes||No|March 3, 2014|https://clinicaltrials.gov/show/NCT01325337||106819|
NCT01325610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#10-15975|Vitamin D Effect on Calcium Absorption on Persons on Hemodialysis|The Effect of Oral Cholecalciferol (Vitamin D3) on Calcium Absorption in Persons on Long-term Hemodialysis|NEPH-Cal-D|Creighton University|No|Completed|April 2011|February 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|19 Years|N/A|No|||April 2012|April 3, 2012|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01325610||106798|
NCT01325623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epilepsy (E)-36|Seizure Detection and Automatic Magnet Mode Performance Study|Seizure Detection and Automatic Magnet Mode Performance Study|E-36|Cyberonics, Inc.|Yes|Completed|March 2011|July 2015|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|March 23, 2011|Yes|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT01325623||106797|
NCT01325974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/Mba/2011/TTBN-RDTmal|Time to Become Negative of Three Rapid Diagnostic Tests for Malaria|Time to Become Negative of Three Rapid Diagnostic Tests for Malaria in Children Under 5 Years of Age. Evaluation in Two Different Malaria Epidemiological Settings in Greater Mbarara District, South Western Uganda||Epicentre|No|Completed|September 2011|May 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|424|Samples Without DNA|Blood smears for microcopy|Both|N/A|5 Years|No|Non-Probability Sample|The study population will be patients under 5 years of age who attend the consultation        service of one health centre of Mbarara municipality (low transmission setting) and one        health centre in Kazo sub-county (high transmission setting).|November 2015|November 26, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01325974||106770|
NCT01326260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR 10-02652|Early Aggressive Correction of Severe Acidosis With Tris-hydroxymethylaminomethane (THAM)|Early Aggressive Correction of Severe Acidosis With Tris-hydroxymethylaminomethane (THAM) in Patients With Severe Traumatic Injury: A Retrospective Cohort Study|THAM|University of California, San Francisco|No|Recruiting|July 2010|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Both|1 Year|90 Years|No|Probability Sample|All patients admitted to San Francisco General Hospital from 2005 through 2009 with severe        traumatic injury requiring emergent surgery who develop severe acidosis|October 2014|October 28, 2014|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326260||106748|
NCT01326546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|71006.04|Therapeutic Hepatitis B Vaccine (Synthesized Peptide εPA-44) Joint Entecavir in Treating Chronic Hepatitis B Patients|A Randomized, Double-blind, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Synthesized Peptide) Joint Entecavir in Treating HBeAg Positive Chronic Hepatitis B Patients|THBVJEITCHBP|Chongqing Jiachen Biotechnology Ltd.|Yes|Active, not recruiting|June 2010|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|378|||Both|18 Years|65 Years|No|||June 2012|June 12, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326546||106726|
NCT01296750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH Co_LEAP|Late Compared to Early Physiotherapy Following Knee Dislocation|A Randomized Clinical Trial Comparing Late Versus Early Physiotherapy Start Times Following Multi Ligament Reconstruction for Knee Dislocation (Co-LEAP)|Co_Leap|St. Michael's Hospital, Toronto|No|Recruiting|June 2011|September 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2011|July 21, 2014|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296750||108995|
NCT01296763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1070|Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer|A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|January 2011|February 2016|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|January 21, 2011|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01296763||108994|The P.I. and Astrazeneca decided not to move forward with the Phase II part of the study. Therefore the arms of Irinotecan, Cisplatin, Mitomycin C with Olaparib versus Irinotecan, Cisplatin, Mitomycin C without Olaparib will not be compared.
NCT01327417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0613|Late-Life Depression|Cortical/Subcortical Circuits in Late-Life Depression||University of Illinois at Chicago|Yes|Recruiting|September 2009|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|-  Geriatric Medicine and Psychiatry clinics within the UIC Medical Center. Patients             with mood and other psychiatric disturbances are frequently referred by physicians             from both geriatric medicine and family medicine for a consultation and sometimes for             ongoing psychiatric care.          -  Community outreach efforts and recruitment through advertising in newsletters, local             newspapers|March 2011|March 31, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327417||106660|
NCT01323036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:014|Krill Oil Study Compared to Fish Oil|Assessment of Bioavailability of Krill Oil Compared to Fish Oil in Healthy Volunteers|Krill|University of Manitoba|Yes|Completed|May 2011|November 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01323036||106995|
NCT01323257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018010|TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)|A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r)||Tibotec Pharmaceuticals, Ireland|No|Completed|March 2011|August 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01323257||106978|
NCT01323270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971010|A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.|A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Repevax(Registered) And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged >/= 11 To <19 Years||Pfizer|Yes|Completed|March 2011|February 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|753|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|February 17, 2011||No||No|November 21, 2014|https://clinicaltrials.gov/show/NCT01323270||106977|
NCT01323608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102011521|The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study|The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study||Weill Medical College of Cornell University|No|Not yet recruiting|June 2011|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|40|||Both|6 Years|60 Years|No|||April 2011|April 18, 2011|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323608||106951|
NCT01309061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSC-Facial-Stem|The Effect of Human Adipose Tissue-derived MSCs in Romberg's Disease|Preliminary Investigation of the Effect of Human Adipose Tissue-derived Mesenchymal Stem Cell in Progressive Hemifacial Atrophy(Romberg's Disease)||Biostar|No|Completed|March 2008|February 2010|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|75 Years|No|||March 2014|March 24, 2014|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01309061||108056|
NCT01305356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTI-2010-01|Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions|A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions||BioMimetic Therapeutics|No|Active, not recruiting|March 2011|April 2014|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|201|||Both|21 Years|N/A|No|||October 2012|October 18, 2012|February 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305356||108340|
NCT01305330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM|The Natural History of Small Renal Masses|Role of Active Surveillance and Identification of Prognostic Factors for Progression in Early Stage Renal Cell Carcinoma||University Health Network, Toronto|No|Recruiting|August 2004|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|170|Samples With DNA|Biopsy cores, nephrectomy tissue, and blood and urine will be collected|Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|March 2016|March 4, 2016|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01305330||108342|
NCT01305863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGI-001-01-2008|Feasibility Study of the TGI Adipose-derived Stromal Cell (ASC)-Coated ePTFE Vascular Graft|A Randomized, Controlled, Parallel Group, Blinded, Feasibility Study of the TGI Adipose-derived Stromal Cell (ASC)-Coated ePTFE Vascular Graft for Femoral-tibial Bypass Grafting.|TGI-PVG-IDE|Tissue Genesis, Inc.|Yes|Active, not recruiting|February 2011|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 1, 2015|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305863||108301|
NCT01305850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|162/53|The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients|The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients||Chulalongkorn University|Yes|Recruiting|July 2010|October 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|100|||Both|20 Years|80 Years|No|||February 2011|March 8, 2011|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01305850||108302|
NCT01306461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201051|Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations|A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those of Tafluprost and Timolol Eye Drops Given Concomitantly in Patients With Open Angle Glaucoma or Ocular Hypertension||Santen Oy|No|Completed|March 2011|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306461||108255|
NCT01306474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xjyy090706|Observation on the Treg in the Uveitis Patients|Clinical Study on the Regulatory T Cells in the Uveitis Patients Treated by Methotrexate|OTUP|Xijing Hospital|Yes|Completed|July 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Actual|30|Samples Without DNA|Experimental:A Drug: prednisone profess to convinced 1-1.5mg/Kg.d Experimental:B Drug:      methotrexate profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced      0.5-1mg/Kg.d|Both|18 Years|60 Years|No|Non-Probability Sample|Ages eligible for Study:18 Years to 60 Years. Study Population had two eye attacks in a        year.|March 2011|March 2, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306474||108254|
NCT01347944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPMS- Celgene-MDS-ITA-002|MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry|Observational, Non-interventional, Multicenter Study Aimed at Collecting Retrospective/Prospective 648/96 Italian Registry Data Related to Lenalidomide (Revlimid®) Prescription to Patients With Myelodysplastic Syndromes|MORE|Celgene Corporation|Yes|Completed|January 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|149|||Both|18 Years|N/A|No|Non-Probability Sample|Patients affected by intermediate-1 and low risk MDS associated by deletion 5q who were        prescribed Revlimid from 31October 2008 to present.|March 2016|March 23, 2016|October 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01347944||105107|
NCT01348165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1306.1|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers (A Randomised, Single-blind, Placebo-controlled Phase I Study)||Boehringer Ingelheim||Terminated|May 2011|||August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|40|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||May 2014|June 18, 2014|May 3, 2011||||No|March 12, 2014|https://clinicaltrials.gov/show/NCT01348165||105090|The trial was put on hold due to a serious adverse event (post-treatment period) which was evaluated to be not drug related and the trial was subsequently terminated.
NCT01348776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-2|The Efficiency of the Hair2Go Device: A Prospective, Open, Label Study With Before-After Design|The Efficiency of the Hair2Go Device: A Prospective, Open, Label Study With Before-After Design||Syneron Medical|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 2, 2013|May 2, 2011|Yes|Yes||No|December 27, 2012|https://clinicaltrials.gov/show/NCT01348776||105043|
NCT01348789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-3|Safety for Frequent Use Conditions of Hair Removal Device|Safety of Hair2Go Device in Frequent Use Conditions: A Prospective, Open Label Study With Before-After Design|OHR-3|Syneron Medical|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|May 4, 2011|Yes|Yes||No|December 4, 2012|https://clinicaltrials.gov/show/NCT01348789||105042|
NCT01349023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoodED301|Energy Content and Energy Density of Pre-portioned Entrees|Effects of Energy Density and Energy Content of Pre-portioned entrées on Energy Intake|EDEN|Penn State University|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|73|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01349023||105025|
NCT01349036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-04|A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma|A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma||Plexxikon|No|Completed|August 2011|January 2015|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349036||105024|
NCT01306955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11192|The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease|The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study||Tehran University of Medical Sciences|Yes|Recruiting|February 2010|August 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|10 Years|70 Years|No|||March 2011|March 1, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01306955||108217|
NCT01306968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-10-09|Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI)|A Pilot Phase II Study of Hyperbaric Oxygen for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (HOPPS)|HOPPS|U.S. Army Medical Research and Materiel Command|No|Completed|February 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|79|||Both|18 Years|65 Years|No|||August 2014|August 25, 2014|February 24, 2011|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT01306968||108216|
NCT01307241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010/020/ICI|RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML|Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.||National Institute of Cancerología|No|Active, not recruiting|December 2010|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood samples.|Both|15 Years|N/A|No|Non-Probability Sample|Patients with acute lymphoblastic leukemia|November 2013|November 14, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307241||108195|
NCT01307722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS11-CT3-02|Left Atrial Distensibility Guiding Management in Advanced Chronic Heart Failure|Left Atrial Distensibility Guiding Management in Advanced Chronic Heart Failure||Kaohsiung Veterans General Hospital.|Yes|Not yet recruiting|August 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2011|March 2, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307722||108158|
NCT01307449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047973|Systems Biology of PNEUMOVAX®23 and PREVNAR 13®|Systems Biology of 23 Valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)||Emory University|No|Active, not recruiting|April 2014|January 2018|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|88|||Both|25 Years|89 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307449||108179|
NCT01307683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL097973|Maternal, Adiposity, Metabolism, and Stress Study|Maternal, Adiposity, Metabolism, and Stress Study (MAMAS)|MAMAS|University of California, San Francisco|Yes|Active, not recruiting|September 2009|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|202|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 3, 2015|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01307683||108161|
NCT01307943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSR1|Mindfulness-based Stress Reduction for Pediatric Mental Health|Mindfulness-based Stress Reduction for Pediatric Mental Health|MBSR|University of Alberta|Yes|Completed|January 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|12 Years|18 Years|No|||December 2013|December 9, 2013|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01307943||108141|
NCT01308827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP-036|Costa Rica Epidemiological Study on S. Pneumoniae|Continuation of the Costa Rican Epidemiologic Surveillance for Invasive Pneumococcal Disease After Introduction of the Seven Valent Vaccine Into the Universal Vaccination Program||Instituto de Atención Pediátrica|No|Suspended|March 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000||Bacterial isolates|Both|N/A|36 Months|No|Probability Sample|Costa Rican children aged 28 days to 36 months of age with suspected pneumococcal invasive        disease|March 2014|March 24, 2014|February 25, 2011||No|Study recruitment was suspended due to lack of funding|No||https://clinicaltrials.gov/show/NCT01308827||108074|
NCT01309074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA0082BY|Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline|Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline||Rush University Medical Center|No|Terminated|November 2009|December 2012|Actual|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|80 Years|No|||December 2012|December 6, 2012|March 2, 2011|Yes|Yes|Only two subjects were enrolled and completed the trial and enrollment of additional subjects    was too slow. Accordingly, it was decided to terminate the study.|No||https://clinicaltrials.gov/show/NCT01309074||108055|
NCT01309087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADx-0001: AEGIS CLIA|Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA|Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA|AEGIS|Allegro Diagnostics, Corp.|No|Completed|January 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|756|Samples With DNA|Cells, Blood|Both|21 Years|N/A|No|Non-Probability Sample|Patients who are undergoing clinically indicated bronchoscopy for rule out lung cancre and        have a history of cigarette smoking|March 2014|March 24, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309087||108054|
NCT01309360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2009 24|Ultrasound-guided Axillary Plexus Block - Dose Reduction of Prilocaine|Ultrasound-guided Block of the Brachial Plexus Using Prilocaine: Effects of Local-anesthetic Dose Reduction on Parameters of Block Quality and Adverse Effects in Outpatients||Helios Research Center|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|75 Years|No|||June 2011|July 6, 2011|March 4, 2011||No||No|May 4, 2011|https://clinicaltrials.gov/show/NCT01309360||108033|
NCT01296334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-115|Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine|Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine Following an Experimental Inflammatory Injury in Volunteers.|PASORII|University of Copenhagen|Yes|Completed|February 2011|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|34|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296334||109027|
NCT01305629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA029567-01|Intervention Targeting Substance Using Older Adults With HIV|Intervention Targeting Substance Using Older Adults With HIV||Hunter College|Yes|Active, not recruiting|June 2011|June 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|50 Years|N/A|No|||February 2016|February 17, 2016|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305629||108319|
NCT01305642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101IFOPILOT|Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study|Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study|IFO Pilot|McMaster Children's Hospital|No|Completed|February 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|32 Weeks|No|||May 2012|May 30, 2012|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305642||108318|
NCT01305876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8756|Yoga in an Urban School for Children With Emotional Behavioral Disorders|||Tufts Medical Center||Completed|December 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|41|||Both|7 Years|12 Years|No|||February 2011|February 25, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01305876||108300|
NCT01305889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02704|The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders|The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor in Depressed Elders||University of California, San Francisco|No|Recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|65 Years|N/A|No|||May 2015|May 15, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305889||108299|
NCT01297179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-068|A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill|A Double-blind Two-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics (PK) of an Ethinyl Estradiol and Levonorgestrel Containing Combined Oral Contraceptive (COC)||Astellas Pharma Inc|No|Completed|October 2008|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|July 1, 2013|February 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01297179||108962|
NCT01306188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMPHOS1|Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer Patients|Study of Prognostic Value of T Cell Receptor Diversity and CD4 Lymphopenia in First Relapse Breast or Lung Cancer Patients|LYMPHOS1|Centre Leon Berard|No|Completed|July 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|179|Samples With DNA|Whole blood, plasma, PBMC|Both|18 Years|N/A|No|Probability Sample|2 cohorts of patients (breast and lung cancer), with locally advanced or metastatic cancer|July 2015|July 1, 2015|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306188||108276|
NCT01306201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0131|Novel Non-Invasive Monitoring Parameter in a Hospital Setting|A Novel Cardio-Respiratory Parameter in a Hospital Setting||Medtronic - MITG|No|Completed|February 2011|March 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|General Care Floor Patients|August 2014|August 5, 2014|February 10, 2011|Yes|Yes||No|May 2, 2012|https://clinicaltrials.gov/show/NCT01306201||108275|
NCT01298375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35178.068.11|Metabolic Phenotyping in Humans|Metabolic Characterization of Type 2 Diabetic, Obese, Lean Sedentary and Endurance Trained Individuals in Vivo, ex Vivo and in Vitro|MetPhe|Maastricht University Medical Center|Yes|Recruiting|March 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|132|Samples With DNA|DNA, RNA, tissue, primary myoblasts, mitochondria|Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Human volunteers from the surrounding area|July 2012|July 18, 2012|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298375||108871|
NCT01347697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEAPE-2010-335-31M|Collagen Implant Compared to Gluteus Maximus Flap for Reconstruction of Pelvic Floor After ELAPE/EAPE in Rectal Cancer|Nordic Extended Abdominoperineal Excision (NEAPE) Study, a Randomized Clinical Trial Comparing a Collagen Implant With a Gluteus Maximus Flap for Reconstruction of Pelvic Floor After Extended Abdominoperineal Excision of Rectum in Rectal Cancer|NEAPE|Umeå University|Yes|Recruiting|May 2011|May 2018|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347697||105126|
NCT01345721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59P22E1|Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine|A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine||Novartis||Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|205|||Both|22 Months|45 Months|No|||August 2013|August 13, 2013|April 29, 2011|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01345721||105277|
NCT01349049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-05|Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)||Plexxikon|No|Active, not recruiting|November 2011|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349049||105023|
NCT01349309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 07-0462|The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients|The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients||Icahn School of Medicine at Mount Sinai|No|Completed|June 2007|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01349309||105003|
NCT01307462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2367.00|Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant|Targeted Therapy of Bronchiolitis Obliterans Syndrome|FAM for BOS|Fred Hutchinson Cancer Research Center|Yes|Completed|June 2011|||September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|6 Years|99 Years|No|||January 2016|January 21, 2016|March 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01307462||108178|
NCT01307956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221-09|Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer|A Phase II Study of Neo-Adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction||University of Nebraska|Yes|Recruiting|February 2011|||October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|19 Years|N/A|No|||July 2011|July 12, 2011|March 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01307956||108140|
NCT01308216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RyC-10|Transcranial Laser Therapy in the Rehabilitation of Hemiplegic Patients From Ischemic Stroke|Efficacy of Transcranial Laser Therapy for Improving Upper Extremity Functional Recovery in Hemiplegic Patients From Ischemic Stroke|REHELA|Hospital Universitario Ramon y Cajal|Yes|Terminated|November 2010|December 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|85 Years|No|||November 2011|April 2, 2012|March 3, 2011||No|Based in the negative of patients to shave de hair.|No||https://clinicaltrials.gov/show/NCT01308216||108120|
NCT01308567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11784|Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer|Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy|FIRSTANA|Sanofi||Active, not recruiting|May 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1170|||Male|18 Years|N/A|No|||December 2015|December 11, 2015|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01308567||108094|
NCT01308580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11785|Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer|Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen|PROSELICA|Sanofi|Yes|Completed|April 2011|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1201|||Male|18 Years|N/A|No|||September 2015|September 8, 2015|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01308580||108093|
NCT01308593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brow Study 25856/1|Brow Enhancement Study|Investigation Into Brow Aesthetics Using Botox in Conjunction With Juvederm Ultra XC as Evaluated by Patient Satisfaction||Skin Care and Laser Physicians of Beverly Hills|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308593||108092|
NCT01308840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGIH09067|Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer|Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer|UGIH09067|University of Rochester|Yes|Completed|December 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|August 9, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01308840||108073|
NCT01308853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GB0607|NASHA BE for Enhancement of the Shape and Fullness of the Female Breast|An Open, Multi-center Study Evaluating Treatment Procedure, Efficacy and Safety of NASHA BE for Enhancement of the Shape and Fullness of Teh Female Breast|COBRA|Q-Med AB|No|Completed|March 2007|May 2010|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Female|25 Years|50 Years|Accepts Healthy Volunteers|||February 2011|May 31, 2012|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01308853||108072|
NCT01309100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|672E|Product Feasibility of a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens||Bausch & Lomb Incorporated|No|Completed|November 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|144|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 27, 2014|March 3, 2011|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01309100||108053|
NCT01309373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016684|An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia|Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (REINTEGRA Study)||Janssen-Cilag, S.A.|No|Completed|November 2010|August 2011|Actual|||Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1809|||Both|18 Years|65 Years|No|Probability Sample|Patients seen in Spanish outpatient mental health facilities, with schizophrenia or        schizoaffective disorder|February 2012|February 13, 2012|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309373||108032|
NCT01305655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO2008CPG2|Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated Wih High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)|Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)|NOPHOCPG2|Nordic Society for Pediatric Hematology and Oncology|Yes|Recruiting|January 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|1 Year|18 Years|No|||January 2011|February 28, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305655||108317|
NCT01297192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-069|A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously|An Open-label, One-sequence, Two-arm Study to Evaluate the Effect of Steady State Concentrations of Mirabegron on the Pharmacokinetics of Solifenacin and to Evaluate the Effect of Steady State Concentrations of Solifenacin on the Pharmacokinetics of Mirabegron in Healthy Young Male and Female Subjects||Astellas Pharma Inc|No|Completed|March 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|41|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|February 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01297192||108961|
NCT01297530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15044|Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY87-2243 Given Once Daily in Subjects With Advanced Malignancies||Bayer|No|Terminated|April 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2013|July 28, 2013|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297530||108936|
NCT01306214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.49|Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus|A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on MDI Insulin Regimen Alone or With Metformin||Boehringer Ingelheim||Completed|February 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|566|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|February 28, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01306214||108274|
NCT01298050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOSG-TICCH-01-2011|Refractory IHCA and OHCA Treated With ECMO|Refractory In and Out of Hospital Cardiac Arrest Treated With Extracorporeal Membrane Oxygenation. Observational, Single Centre, Prospective Study.|SEAC|University of Milano Bicocca|No|Recruiting|July 2011|July 2013|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Adults 18-75 years old, community sample|July 2011|August 3, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298050||108896|
NCT01298388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000695273|Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998|Assessment of the Long Term Outcome of Childhood ALL Patients Enrolled in EORTC Children's Leukemia Group Trials Between 1971 and 1998||National Cancer Institute (NCI)||Not yet recruiting|July 2011|||March 2013|Anticipated|N/A|Observational|N/A|||Anticipated|3138|||Both|N/A|17 Years|No|||September 2011|September 15, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298388||108870|
NCT01348477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2010-1005-10|Comparison Between Elliptical Domed Mesh Technique and Lichtenstein Technique in Inguinal Hernia|Comparison Between Elliptical Domed Mesh Technique and Lichtenstein Technique, to Reduce Postoperative Pain in Open Inguinal Hernia Repair||Instituto Mexicano del Seguro Social|Yes|Recruiting|October 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||September 2010|May 4, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01348477||105066|
NCT01345929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625A-005|Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis|A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis||Cubist Pharmaceuticals LLC|No|Completed|June 2011|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|558|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 28, 2011|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT01345929||105261|Two identical P3 protocols were initiated (NCT01345929 and NCT01345955) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.
NCT01345734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3932|Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes|Liraglutide Effectiveness and Safety Data From Routine Clinical Practice in Philippines Study. A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes Mellitus in Philippines|Lead-Ph|Novo Nordisk A/S|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1056|||Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects with type 2 diabetes, including newly-diagnosed subjects or those already        receiving other anti-diabetic medications including GLP-1 analogues other than        liraglutide.|November 2015|November 11, 2015|April 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01345734||105276|
NCT01307475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000082|Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions|Freeman-Sheldon Syndrome Quality of Life Study (FSS-QLS): Cross-sectional, Cohort Study of Concomitant Disorder-Specific Contributors to Quality of Life and Clinical Outcome|FSS-QLS|Freeman-Sheldon Research Group, Inc.|No|Recruiting|February 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|20|None Retained|Blood samples will be taken but no retention is expected.|Both|N/A|N/A|No|Non-Probability Sample|Patients, family, and others affected world-wide are welcome, so long as they currently or        previously have had significant and meaningful contact with a person who has a qualifying        diagnosis.|October 2014|October 21, 2014|February 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01307475||108177|
NCT01307488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESIDA 7011|Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy|Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial|SALT|Fundacion SEIMC-GESIDA|Yes|Completed|September 2011|March 2015|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|286|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01307488||108176|
NCT01307969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164/2006|Formulations of Liposomal Local Anesthetics|Formulations of Liposomal Local Anesthetics for Dental Anesthesia||University of Campinas, Brazil|Yes|Completed|February 2007|June 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|40|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||February 2011|March 2, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01307969||108139|
NCT01307982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00043616|Comparative Anti-Reflux Procedures in Neurologically Impaired Children|Comparative Anti-Reflux Procedures in Neurologically Impaired Children|CARPNIC|University of Utah|Yes|Completed|January 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|6 Months|18 Years|No|||October 2013|October 17, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01307982||108138|
NCT01308229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIN0803|Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent|Assessment of the Safety and Efficacy of the Nile PAX® Drug Eluting Coronary Bifurcation Stent System for the Treatment of Single de Novo Bifurcation Lesions in Native Coronary Arteries|BIPAX|MINVASYS|Yes|Completed|December 2008|March 2015|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||November 2013|April 7, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308229||108119|
NCT01308242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33139CS|Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease|Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease||Penn State University|No|Recruiting|March 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|55|||Both|18 Years|80 Years|No|||February 2011|March 3, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308242||108118|
NCT01299584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105936|ULTIVA Post Marketing Surveillance|A Post Marketing Surveillance to Monitor the Safety of ULTIVA (Remifentanil) Adminstered in Korean Subjects According to the Prescribing Information||GlaxoSmithKline|No|Completed|September 2005|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|775|||Both|N/A|N/A|No|Probability Sample|The subjects are patients prescribed for Remifentanil by the investigators at the sites        based on prescription information in normal clinical practices.|February 2011|March 24, 2011|February 17, 2011||||No|March 24, 2011|https://clinicaltrials.gov/show/NCT01299584||108780|
NCT01300143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/6-M|Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma|Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma|TACERTE|Nantes University Hospital|Yes|Recruiting|June 2011|June 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|174|||Both|18 Years|N/A|No|||April 2014|December 16, 2015|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300143||108737|
NCT01300377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008-197|A Trial Assessing The Association Between Type Of Local Anesthesia Treatment And Postoperative Pain In Patients In Having Undergone Arrhythmia Surgery|A DOUBLE-BLIND RANDOMIZED TRIAL ASSESSING THE ASSOCIATION BETWEEN TYPE OF LOCAL ANESTHESIA TREATMENT AND POSTOPERATIVE PAIN IN PATIENTS IN HAVING UNDERGONE ARRHYTHMIA SURGERY||Baylor Research Institute|No|Active, not recruiting|November 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300377||108719|
NCT01300663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|412-09|A New Patient Reported Outcome Instrument to Assess Symptom Experience in Women With Vulvar Neoplasms (WOMAN-PRO)|Creating and Validating a Patient-reported Outcome Instrument to Assess Symptom Experience Related to Surgical Wounds in Women With Vulvar Neoplasms - A Mixed Methods Study|WOMAN-PRO|University of Basel|No|Recruiting|January 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|N/A||1|Anticipated|150|||Female|18 Years|N/A|No|Probability Sample|women with vulvar intraephitelial neoplasia or vulvar cancer following vulvar surgery|February 2011|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01300663||108698|
NCT01297569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DNO02|Ranibizumab "Treat and Extend" in Diabetic Macular Edma|An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema|OPTIMAL|Novartis||Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|18 Years|No|||January 2014|January 17, 2014|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297569||108933|
NCT01296893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02774|Can Exercise Improve Cancer Associated Cognitive Dysfunction?|Can Exercise Improve Cancer Associated Cognitive Dysfunction?|chemobrain|University of British Columbia|No|Active, not recruiting|January 2011|June 2015|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Female|40 Years|75 Years|No|||September 2014|September 26, 2014|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01296893||108984|
NCT01297543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLT008-02|Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia|A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia||Cellerant Therapeutics|No|Completed|March 2011|January 2015|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|10||Actual|45|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01297543||108935|
NCT01296607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SV.Protocol 4|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers - Protocol 4|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers||University of Edinburgh|No|Completed|February 2011|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 31, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296607||109006|
NCT01296620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-101-CL-P008|Ulimorelin Study of Efficacy and Safety (ULISES 008)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection||Tranzyme, Inc.||Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|330|||Both|18 Years|80 Years|No|||July 2012|July 25, 2012|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01296620||109005|
NCT01298063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.86|Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib|Pharmacokinetics, Safety and Tolerability of Different Oral Doses of Afatinib, in Subjects With Mild to Moderate Hepatic Impairment Compared to Healthy Subjects - a Phase I, Single-dose, Open-label, Dose-escalation Study in a Matched Group Design||Boehringer Ingelheim||Completed|February 2011|||January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2013|December 5, 2013|February 15, 2011||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01298063||108895|
NCT01298089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carriazo Pendular|A Study of Flap Thickness Results Using the Carriazo Pendular Microkeratome - 130 Micrometers Head.|LASIK Flap Thickness Predictability With the Carriazo Pendular Microkeratome||Democritus University of Thrace||Completed|February 2006|February 2009|Actual|February 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|131|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients submitted to LASER refractive correction at the Eye Institute of Thrace,        Democritus University|February 2011|February 17, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298089||108893|
NCT01348490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB18424-258|Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis|An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L||Incyte Corporation|Yes|Recruiting|June 2011|September 2020|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01348490||105065|
NCT01348503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004-05; IUCRO-0298|Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma|A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma||Indiana University|Yes|Terminated|May 2011|March 2014|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|May 4, 2011||No|Treatment was ineffective|No||https://clinicaltrials.gov/show/NCT01348503||105064|
NCT01348516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMCP-023-101|Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of KM-023 After Oral Administration in Healthy Subjects||Kainos Medicine Inc.||Completed|May 2011|||March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01348516||105063|
NCT01345448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|White Rabbit 2010-0001|Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy|Study of Safety and IOP Lowering Efficacy of Transdermal Brimonidine Therapy||Nanduri, Padma, M.D., FACS|No|Recruiting|April 2011|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|22|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 28, 2011|April 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345448||105298|
NCT01345461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25428|Fatigability of the Quadriceps Muscle in Non-cooperating Subjects|Fatigability of the Quadriceps Muscle in Non-cooperating Subjects||Rigshospitalet, Denmark|Yes|Recruiting|January 2010|June 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|healthy adult volunteers|April 2011|April 28, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01345461||105297|
NCT01345474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-SIU-11-002|Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)|Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)|NIHL|Southern Illinois University|Yes|Recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|April 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345474||105296|
NCT01345747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-Laparo|The Laryngeal Tube Suction Versus Endotracheal Tube for Ventilation in Gynecological Laparoscopic Surgery|The Laryngeal Tube Suction vs Endotracheal Tube for Ventilation in Gynecological Laparoscopic Surgery||Prince of Songkla University|Yes|Completed|June 2008|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|120|||Female|20 Years|65 Years|No|||April 2011|April 29, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01345747||105275|
NCT01306981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAIJ1006|Ranibizumab in Diabetic Vitrectomy|A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study|RaDiVit|Moorfields Eye Hospital NHS Foundation Trust|Yes|Active, not recruiting|May 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||May 2011|February 19, 2013|March 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01306981||108215|
NCT01306994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000079|Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions|Freeman-Sheldon Syndrome Evaluation and Diagnosis in Clinical Settings (FSS-EDICT) I: a Case-Control, Cross-Sectional Study of Baseline and Stress Physiology Parameters|FSS-EDICT I|Freeman-Sheldon Research Group, Inc.|No|Recruiting|February 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|None Retained|Blood samples will be taken but no retention is expected.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients world-wide are welcome, so-long as they have a qualifying diagnosis. Healthy        controls are welcome world-wide, as well.|October 2014|October 14, 2014|February 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01306994||108214|
NCT01307007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT08023|Hypophosphatemia With Intravenous Ferric Carboxymaltose Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding|A Randomized, Controlled Study to Investigate the Safety and Explore the Mechanism of Hypophosphatemia With Intravenous Ferric Carboxymaltose (FCM) Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding||Luitpold Pharmaceuticals|No|Active, not recruiting|August 2010|||May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||July 2013|July 1, 2013|October 4, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307007||108213|
NCT01298687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-081|Divided Dose of TRAVATAN®|||Alcon Research|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|67|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298687||108849|
NCT01307735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232447|International Myocarditis Registry|Prospective Assessment of the Clinical Utility of Cardiovascular Magnetic Resonance in Patients With Suspected Acute Myocarditis - A Pilot Study for Establishing an International Registry|mmr|Libin Cardiovascular Institute of Alberta|Yes|Enrolling by invitation|January 2010|July 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|78|Samples With DNA|Biopsy samples with viral or bacterial DNA|Both|18 Years|N/A|No|Probability Sample|Patients referred for a CMR study at the Stephenson Cardiovascular MR Centre for suspected        myocarditis will be screened. Patients with CMR-derived evidence for myocarditis (i.e. at        least two positive Lake Louise Criteria in at least one CMR scan during the clinically        acute phase of the disease) will be considered "myocarditis-positive".        As a control group, patients referred for suspected myocarditis but not fulfilling the        diagnostic CMR criteria for myocarditis and with normal systolic LV function. Both groups        will receive the same standard protocol as per the Consensus Group recommendations.|February 2011|March 2, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307735||108157|
NCT01307995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM-INK|The Incretin Effect in Patients With Gestational Diabetes Mellitus|Observational Study to Evaluate the Reduced Incretin Effect Observed in Patients With GDM in Relation to Reversibility After a Delivery.||Medical Universtity of Lodz|No|Completed|April 2007|May 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Crossover||2|Actual|20|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women above the age of 18 years with GDM) (Controls: pregnant women above the age        of 18 years with NGT)|January 2011|March 2, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307995||108137|
NCT01299597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109652|A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.|A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.||GlaxoSmithKline|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2011|February 24, 2011|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01299597||108779|
NCT01300676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(USMKK/PPP/JEPeM (198.3(11))|The Effects of Tualang Honey on Postmenopausal Women|The Effect of Tualang Honey and Hormonal Replacement Therapy (HRT) on Safety Profiles Among Postmenopausal Women||University of Science Malaysia|Yes|Completed|March 2009|June 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|79|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||November 2007|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01300676||108697|
NCT01296347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chumbley1|Low Dose Peri-operative IV Ketamine for Chronic Post-surgery Pain Prevention|A Double-blind, Randomised Placebo-controlled Trial to Determine Whether Low-dose Intravenous Ketamine Peri-operatively Can Prevent Chronic Post-surgical Pain, in Patients Undergoing Thoracotomy or Video Assisted Thoracic Surgery (VATS)||Imperial College Healthcare NHS Trust|Yes|Completed|April 2011|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|104|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01296347||109026|
NCT01296360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-325|Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country|Long-Term Immunity and Safety With or Without a Booster Dose Following Primary Vaccination With the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population in a JEV-Endemic Country. Open-Label, Randomized, Phase 3 Study||Valneva Austria GmbH|No|Completed|December 2010|October 2013|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|9 Months|18 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|December 28, 2010|No|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01296360||109025|
NCT01296633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR011300-01A1|Medtable: An Electronic Medical Record (EMR) Strategy to Promote Patient Medication Understanding and Use|Medtable: An Electronic Medical Record (EMR) Strategy to Promote Patient Medication Understanding and Use||University of Illinois at Urbana-Champaign|Yes|Active, not recruiting|February 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1042|||Both|40 Years|N/A|No|||May 2014|May 19, 2014|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01296633||109004|
NCT01297582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-6950POU001|Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Single-Dose Escalation and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd|No|Completed|January 2011|||June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|February 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01297582||108932|
NCT01297595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081019|Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule|A Phase 1, Open-Label, Single Dose, Randomized, Cross-Over Relative Bioavailability Study Comparing An Oral Liquid Formulation To A Formulated Capsule Of Crizotinib (PF 02341066) In Healthy Volunteers||Pfizer|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|February 15, 2011|No|Yes||No|January 5, 2012|https://clinicaltrials.gov/show/NCT01297595||108931|
NCT01297803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8772|Comparison of Two Method Antimetabolites Application on Corneal Function in Trabeculectomy Surgery|Corneal Endothelial Cell Loss Following Trabeculectomy With mitomycin_c Application Before Versus After Sclera Flap Dissection||hahid Beheshti University of Medical Sciences|Yes|Recruiting|November 2010|December 2011|Anticipated|June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|15 Years|80 Years|No|||November 2010|February 16, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01297803||108915|
NCT01297816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89122|Evaluation of Neuroprotective Effect of Minocycline|Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery|minocyclin &RD|hahid Beheshti University of Medical Sciences|Yes|Recruiting|December 2010|April 2011|Anticipated|December 2010|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||||||Both|8 Years|N/A|No|||December 2010|February 16, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01297816||108914|
NCT01297556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGI-IKA-IBS-2011|Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.|Examining Patient Attributes To Determine Optimal Treatment Outcome in Irritable Bowel Syndrome.|IBS|Michigan Gastroenterology Institute|Yes|Not yet recruiting|April 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2011|February 15, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297556||108934|
NCT01298102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etude 2009/INT044|Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients|Safety and Efficacy of Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Transplant and Dialyzed Patients: a Prospective Cohort Study.||Erasme University Hospital|Yes|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|185|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2010|February 16, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298102||108892|
NCT01297790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAS Protocol 2|Cough Responses to Tussive Agents in Health and Disease|Cough Responses to Tussive Agents in Health and Disease||University Hospital of South Manchester NHS Foundation Trust|No|Completed|November 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|102|Samples Without DNA|Sputum.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults aged 18 and over who are healthy non smokers, or are current smokers with no        respiratory conditions and normal spirometry, or have a diagnosis of asthma, chronic cough        or COPD.|September 2011|September 15, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297790||108916|
NCT01298076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHMRC project 632667|Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema|A Multicentre Randomised Clinical Trial of Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema||University of Sydney|No|Completed|October 2010|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01298076||108894|
NCT01298765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP-305|Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain|A 52-Week, Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain||Endo Pharmaceuticals|No|Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|434|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|February 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01298765||108843|
NCT01298986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.126 Hybrid AF|Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management|Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management|AF|Inova Health Care Services|No|Withdrawn|May 2011|September 2014|Actual|September 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|February 16, 2011||No|No subjects were ever enrolled.|No||https://clinicaltrials.gov/show/NCT01298986||108826|
NCT01349348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08-805-01|Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites|A Randomized, Double-blinded, Multicenter, Placebo Controlled, Parallel Designed Study, to Evaluate the Efficacy and Safety of Tolvaptan Tablet in Treatment of Patients With Cirrhosis Ascites, Using Diuretics as Initial Treatment||Otsuka Beijing Research Institute|No|Completed|October 2010|July 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|535|||Both|18 Years|75 Years|No|||October 2012|October 10, 2012|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01349348||105000|
NCT01345487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B275|Effect of Protein From Animal and Vegetable Sources on Appetite|Effect of Protein From Animal and Vegetable Sources on Appetite|PAVA|University of Copenhagen|No|Completed|April 2011|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01345487||105295|
NCT01299610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113434|A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo|A Randomised, Double-blind, Placebo-controlled Study of Topical GW870086X Formulation in Subjects With Moderate or Severe Atopic Dermatitis||GlaxoSmithKline|No|Completed|December 2010|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|65 Years|No|||July 2011|February 16, 2012|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299610||108778|
NCT01298362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCHARBI - 2010/02|Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer|Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer in Real World Clinical Settings in Greece|POCHARBI|Hellenic Breast Surgeons Society|Yes|Completed|March 2011|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|290|||Female|40 Years|90 Years|No|Non-Probability Sample|Post-menopausal female patients with ER-positive early breast cancer, who receive therapy        with a third generation AI either as first line hormonal treatment or as maintenance        therapy after first-line anthracycline- and/or taxane-based chemotherapy for a period no        longer than 1 month (4 weeks) prior to inclusion in the study|July 2014|July 19, 2014|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298362||108872|
NCT01298674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-01-2009|Epidemiological Study of the Prevalence of Age-Related Macular Degeneration in Portugal|Epidemiological Study of the Prevalence of Age-Related Macular Degeneration in Portugal||Association for Innovation and Biomedical Research on Light and Image|No|Completed|August 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|6023|||Both|55 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants with 55 or more years-old|October 2015|October 7, 2015|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298674||108850|
NCT01300169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUA-001|Operation Worth Living Project With Suicidal Soldiers at Ft. Stewart|A Randomized Clinical Trial of the Collaborative Assessment and Management of Suicidality Versus Enhanced Care as Usual for Suicidal Soldiers|OWL|The Catholic University of America|Yes|Active, not recruiting|March 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|No|||February 2015|February 3, 2015|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300169||108735|
NCT01298960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUNDEX001|Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients|Phase II Randomized Study of Cotreatment With Growth Hormone in a Long GnRH Agonist Protocol in Women With Previous Poor Ovarian Response|FUNDEX001|Institut Universitari Dexeus|No|Suspended|February 2011|June 2013||June 2013||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Female|18 Years|39 Years|No|||June 2015|June 30, 2015|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298960||108828|
NCT01299259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007744|Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease|Improving Primary Care Follow-up for Adolescents With PID: A Randomized Controlled Trial Using Text Message Reminders||Children's Hospital of Philadelphia|Yes|Completed|February 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|95|||Female|15 Years|N/A|No|||October 2014|October 27, 2014|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01299259||108805|
NCT01299272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11317|A Study in Prevention of Re-emergence of Depression Symptoms|LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder||Eli Lilly and Company|No|Completed|May 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2045|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299272||108804|
NCT01300689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV and MSM in China|Human Papillomavirus Infection and Knowledge and Attitudes About HPV Vaccines Among Men Who Have Sex With Men (MSM)|||Chinese Academy of Medical Sciences|No|Not yet recruiting|July 2011|||||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|3000|||Male|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A total of 3,000 eligible men who have sex with men (MSM) with 300 from each city will be        enrolled from ten cities (BeiJing, ShangHai, TianJin, ChongQing, GuangZhou, ZhengZhou,        Harbin, ShenYang, ChengDu, and KunMing) by the local CDCs and non-government MSM        organizations|February 2011|February 22, 2011|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01300689||108696|
NCT01296906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0823|Population Versus Practice-based Interventions to Increase Immunizations|Population Versus Practice-based Interventions to Increase Immunizations||University of Colorado, Denver|No|Completed|May 2010|September 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|31567|||Both|19 Months|N/A|No|||June 2013|June 19, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296906||108983|
NCT01296919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AssutaHS10-2010037|The Clinical Significance of the Uncinate Process Histopathology in Chronic Rhinosinusitis|New Insights on the Clinical Significance of the Uncinate Process Histopathology in Patients With Chronic Rhinosinusitis||Assuta Hospital Systems|Yes|Recruiting|March 2010|December 2011|Anticipated|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Pathologic uncinate process tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic rhinosinusitis whose uncinate process had to be removed to enable        surgical access to the sinuses.|February 2011|September 11, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296919||108982|
NCT01296932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1270.1|BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)|A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia||Boehringer Ingelheim||Recruiting|February 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 15, 2011||||No||https://clinicaltrials.gov/show/NCT01296932||108981|
NCT01297829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-11-15|Does Preoperative Caldolor Decrease the Requirement for Postoperative Narcotics|Does Preoperative Caldolor Decrease the Requirement for Postoperative Narcotics in Patients Undergoing Laparoscopic or Open Inguinal and/or Umbilical Hernia Repair? A Randomized, Double-Blind, Prospective Trial||St. Barnabas Medical Center|No|Active, not recruiting|February 2011|March 2015|Anticipated|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|51|||Both|18 Years|80 Years|No|||December 2014|December 12, 2014|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01297829||108913|
NCT01297855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajCEU51-001|Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii|Randomized Controlled Trial of Colistin Versus Colistin Plus Rifampicin in MDR P.Aeruginosa and A.Baumanii||Mahidol University|No|Recruiting|June 2010|August 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||December 2011|December 29, 2011|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01297855||108911|
NCT01297842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajCEU 54-001|Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections|An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections||Mahidol University|No|Recruiting|May 2011|August 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2011|December 29, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01297842||108912|
NCT01298128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFRH- 001|NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment|A Randomized Controlled Trial of NuvaRing® Versus Combined Oral Contraceptive Pills for Pre-treatment in In-Vitro Fertilization (IVF) Cycles||University of Toronto|No|Terminated|February 2006|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|38 Years|No|||October 2012|October 1, 2012|February 15, 2011||No||No|August 17, 2011|https://clinicaltrials.gov/show/NCT01298128||108890|early termination due to poor recruitment
NCT01298401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1102|Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas|A Phase I Study of Induction AMG 479 and Gemcitabine, Followed by AMG 479, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer||Radiation Therapy Oncology Group|Yes|Completed|February 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|8|||Both|18 Years|N/A|No|||November 2015|November 14, 2015|February 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01298401||108869|
NCT01298752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|664|Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery|The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery||Bausch & Lomb Incorporated|No|Terminated|February 2011|November 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||August 2013|November 22, 2013|February 16, 2011|Yes|Yes|Recruiting or enrolling participants has halted prematurely and will not resume; participants    are no longer being examined or treated.|No||https://clinicaltrials.gov/show/NCT01298752||108844|
NCT01299350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Valencia|Nt-proBNP Versus Clinical Guided Discharge in Acute Heart Failure|Randomized Comparison Between Nt-proBNP or Clinical Guided Discharges in Patients Hospitalized With Acute Heart Failure||University of Valencia|No|Completed|November 2010|March 2013|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|125|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299350||108798|
NCT01298999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE9648|Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus|Randomized Placebo-Controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus||Columbia University|Yes|Recruiting|November 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|22|||Both|18 Years|90 Years|No|||October 2015|October 15, 2015|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298999||108825|
NCT01349387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01389-30|Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing|Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing Whose Maturation Depends on the Protein HuR, Including Gene Encoding Insulin Receptor|METFORGENE|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|May 2011|January 2012|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|N/A|No|||May 2011|February 8, 2012|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01349387||104997|
NCT01345760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Sand|Expression Levels of RISC and Microprocessor Complex Components in Epithelial Skin Cancer|Expression Levels of RNA-induced Silencing Complex (RISC) Components TARBP1, TARBP2, Argonaute-1, Argonaute-2, PACT and Microprocessor Complex Component DGCR8 in Epithelial Skin Cancer||Ruhr University of Bochum|Yes|Completed|July 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||4|Actual|44|Samples With DNA|human skin|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with epithelial skin cancer and pre-malignant stages|October 2012|October 15, 2012|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01345760||105274|
NCT01345981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|propofol-pain|A Comparison of Pain Severity on Injection of MCT/LCT Propofol Between Lidocaine 20 mg, 40 mg, and Without Lidocaine.|A Comparison of Pain Severity on Injection of MCT/LCT Propofol Between Lidocaine 20 mg, 40 mg, and Without Lidocaine.||Prince of Songkla University|Yes|Completed|October 2008|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|210|||Both|18 Years|75 Years|No|||April 2011|April 29, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01345981||105258|
NCT01345994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT004714|Brain Plasticity in Carpal Tunnel Syndrome and Its Response to Acupuncture|||Martinos Center for Biomedical Imaging|Yes|Recruiting|May 2009|May 2013|Anticipated|May 2013|Anticipated|Phase 0|Interventional|N/A|2||||||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2011|April 29, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01345994||105257|
NCT01299896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02936|Connect to Quit for Smoking|Connect to Quit: Coordinated Care for Smoking Cessation Among Low Income Veterans|CTQ|University of Pittsburgh|No|Completed|March 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|633|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 27, 2011||No||No|January 21, 2016|https://clinicaltrials.gov/show/NCT01299896||108756|
NCT01300416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080AMY02|Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms|Open, Multi-centre, Non-interventional, Observational Study to Characterize the Impact That GI Complaints Have on Patient-reported Outcomes in Patients Who Have Had a Renal Transplant. Patients Will be Evaluated at Visit 1 and Then Again After 4 (+2) Weeks (Visit 2)|PROGIS|Novartis|No|Completed|July 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|101|||Both|18 Years|N/A|No|Probability Sample|Kidney transplanted Patients currently on MMF who have GI symptoms and will be converted        to EC-MPS treatment and patients currently on MMF without GI symptoms who will continue        with MMF therapy.|March 2016|March 23, 2016|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300416||108716|
NCT01299870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12416|Catamenial Epilepsy Treatment|Keishibukuryogan (Japanese Herbal Supplement) for the Adjunctive Treatment of Catamenial Epilepsy in Adult: Safety Study||University of Kansas Medical Center|Yes|Recruiting|February 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|17|||Female|21 Years|45 Years|No|||February 2012|February 13, 2012|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299870||108758|
NCT01299883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R24MDOO1594-06|West Philadelphia Consortium Randomized Control Trial|West Philadelphia Consortium to Address Disparities||University of Pennsylvania|No|Recruiting|August 2008|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|850|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2011|February 17, 2011|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01299883||108757|
NCT01300156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-524|Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)|A Multicenter Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Patients With Refractory or Relapsed Hodgkin's Lymphoma (HL)||National Cancer Center, Korea|No|Recruiting|February 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|75 Years|No|||February 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300156||108736|
NCT01300390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008776|Assessment of Endothelial Function, Apolipoproteins and Adiponectin|Assessment of Endothelial Function, Apolipoproteins, and Adiponectin Levels as Markers of Cardiovascular Before and After Liver Transplantation|Endo-PAT|Mayo Clinic|No|Active, not recruiting|June 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|Samples Without DNA|Serum samples will be retained for future liver transplant research.|Both|21 Years|N/A|No|Non-Probability Sample|Cirrhotic end-stage liver disease awaiting transplant|January 2016|January 13, 2016|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300390||108718|
NCT01300403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2009|Physiological Effects of Expiration With the Glottis Open in Lateral Posture (ELTGOL) and Flutter Valve in Patients With Bronchiectasis|Acute Physiological Effects of Expiration With the Glottis Open in Lateral Posture (ELTGOL) and Flutter Valve in Dynamic and Static Pulmonary Volumes of Patients With Bronchiectasis||Universidade Federal do Rio de Janeiro|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|60 Years|No|||September 2010|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300403||108717|
NCT01296386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC84-101|An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84|An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects||Valneva Austria GmbH|Yes|Completed|December 2010|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|82|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 24, 2014|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01296386||109023|
NCT01296659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDD 10-09|Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma|Phase Ib Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Patients With Advanced Unresectable Soft Tissue Sarcoma||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|February 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|February 3, 2011|No|Yes|Principal Investigator left institution.|No||https://clinicaltrials.gov/show/NCT01296659||109002|
NCT01297244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-10-202|A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma|A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma||AVEO Pharmaceuticals, Inc.|No|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||November 2013|November 4, 2013|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01297244||108957|
NCT01297257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP992|DELIVER Study: DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER Stenting||DELIVER|Medtronic Vascular|No|Completed|February 2011|April 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7845|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with symptomatic ischemic heart disease due        to stenotic lesions in coronary arteries or bypass graft that are amenable to percutaneous        treatment.|January 2014|January 21, 2014|December 20, 2010||No||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01297257||108956|
NCT01297205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-006|Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia|Open Label, Single-Center, Phase 1 Clinical Study to Evaluate the Safety and the Efficacy of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia||Medipost Co Ltd.|Yes|Completed|December 2010|December 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|N/A|14 Days|No|||April 2014|April 3, 2014|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01297205||108960|
NCT01297218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-007|The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease|Open-Label, Single-Center, Phase 1 Clinical Trial to Evaluate the Safety and the Efficacy of NEUROTSTEM®-AD in Patients With Dementia of the Alzheimer's Type||Medipost Co Ltd.|Yes|Completed|February 2011|December 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|50 Years|75 Years|No|||April 2012|April 19, 2012|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01297218||108959|
NCT01297868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVAAug-1|Impact of Exercise on Retinal Microvascular Regulation Measured by Dynamic Vessel Analysis in Healthy Individuals|||University Medicine Greifswald|No|Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|40 Years||Non-Probability Sample|healthy middle-aged subjects, unselected volunteers|February 2011|February 16, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297868||108910|
NCT01298141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-REP-081|A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease|A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease||Shire|Yes|Recruiting|May 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|N/A|No|||November 2015|November 20, 2015|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298141||108889|
NCT01298115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-1/09|Patient INformation About Options for Treatment - PINOT|Patient Information About Options for Treatment of Stage 5 Chronic Kidney Disease|PINOT|University of Sydney|No|Completed|July 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|721|||Both|N/A|N/A|No|Probability Sample|Adults and children with chronic kidney disease attending renal treatment centres in        Australian public hospitals and private practices.|February 2011|February 15, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298115||108891|
NCT01298414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B9|Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia|Pediatric Myeloid Leukemia-Specific miRNA Expression Profiles Induced by the Leukemic Stem Cell Niche||Children's Oncology Group|No|Active, not recruiting|February 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|Bone Marrow|Both|N/A|30 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia|May 2015|May 8, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298414||108868|
NCT01298440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AvastinRFI|Bevacizumab Effect on Blood Velocity|The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization||Optical Imaging, Ltd.|Yes|Completed|January 2008|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|Patients with choroidal neovascularization (CNV)|February 2011|February 16, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298440||108867|
NCT01299948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProCort1|Progression of HIV-Disease Under Low Dose Corticosteroids|A Phase II Clinical Trial to Assess Risk and Benefit of Oral Low Dose Prednisolone for HIV Infected People Prior to the Commencement of Antiretroviral Treatment|ProCort1|Medical Mission Institute, Germany|Yes|Completed|June 2007|May 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|326|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01299948||108752|
NCT01299012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1954|Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus|Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus, a Retrospective Chart Review||Kaleida Health|No|Active, not recruiting|October 2010|June 2013|Anticipated|February 2013|Anticipated|Phase 4|Observational|Time Perspective: Retrospective||1|Anticipated|10|||Both|18 Years|65 Years|No|Probability Sample|Type 1 Diabetes Mellitus|June 2012|June 5, 2012|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01299012||108824|
NCT01345773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-VTE-01|Incidence of Venous Thromboembolism Following Surgery in Patients With Gastric Cancer|Incidence of Venous Thromboembolism Following Surgery in Patients With Gastric Cancer; a Prospective Study||Seoul National University Bundang Hospital|No|Completed|May 2010|||September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|375|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with gastric cancer receiving curative or palliative gastric cancer surgery|November 2011|November 16, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01345773||105273|
NCT01346254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCPD|Glucose Control in Pre-Diabetic Renal Transplant Patients|Glucose Control in Pre-Diabetic Renal Transplant Patients: Efficacy and Safety of Vildagliptin and Pioglitazone|GCPD|Medical University of Vienna|No|Completed|December 2009|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|81 Years|No|||December 2011|December 2, 2011|April 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346254||105237|
NCT01299636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM60184-A-002-10|Study of PM060184 in Patients With Advanced Solid Tumors|Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors||PharmaMar|No|Completed|January 2011|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|February 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01299636||108776|
NCT01299649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMP 115-418|Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®|A Retrospective Observational Database Study To Compare In-Hospital All-Cause Mortality in Critically Ill Patients Undergoing Echocardiography With or Without DEFINITY®|DEF-418|Lantheus Medical Imaging|No|Completed|June 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|4300000|||Both|18 Years|N/A|No|Non-Probability Sample|All that received an echocardiogram|February 2011|February 17, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01299649||108775|
NCT01299909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2011-0087|Study Two on the Effectiveness of Mindfulness Training for Smokers|Study Two for Development of Novel Behavioral Intervention Mindfulness Training for Smokers|MTS2|University of Wisconsin, Madison|Yes|Recruiting|March 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299909||108755|
NCT01300195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4-2010-118#0|Prediction of Persistent Postsurgical Pain After Video-assisted Thoracic Surgery (VATS)|Factors Predicting Persistent Post-surgical Pain After Video-assisted Thoracic Surgery (VATS)||Rigshospitalet, Denmark|No|Recruiting|February 2011|April 2013|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|whole blood used to detect genetic polymorphism|Both|18 Years|N/A|No|Non-Probability Sample|Lung cancer patients|September 2011|September 27, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300195||108733|
NCT01296035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIH 20050782|Panitumumab and Gemcitabine in Relapsed Ovarian Cancer|A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.|PanGem|Women and Infants Hospital of Rhode Island|Yes|Terminated|February 2011|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||July 2015|July 28, 2015|February 9, 2011|Yes|Yes|Newer technologies available; poor accrual to study.|No|August 19, 2014|https://clinicaltrials.gov/show/NCT01296035||109050|This study was terminated prematurely due to poor accrual. The outcome measures could not be analyzed due to the small number or participants.
NCT01296048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transtek GBA|Clinical Test for Transtek Glass Body Analyzer|Verify the Functions and Efficiency of Transtek Glass Body Analyzer, GBF-830, GBF-835, GBF-950, SA-15|GBA|BTS International|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|74|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The subject population included patients whose age is above 18 years old. Male or Female.|December 2011|December 22, 2011|February 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01296048||109049|
NCT01296373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVNAT 136|A Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection|An Observational Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection Commencing Combination Antiretroviral Therapy (HIVNAT 136 RESTORE Study:Thailand)|RESTORE|Kirby Institute|No|Completed|September 2010|September 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|Samples With DNA|serum, plasma, PBMC and DNA will be stored for 10 years total.|Both|18 Years|N/A|No|Non-Probability Sample|HIV-1-infected adults aged 18 years or older with untreated HIV-1-infection and CD4+ of        350 cells/uL or less who are about to start or recommence combination antiretroviral        therapy which is expected to result in a 1 log or greater decline in plasma HIV RNA|December 2013|December 17, 2013|February 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01296373||109024|
NCT01296646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0939|Sweet Preference and Alcohol Craving|Sweet Preference and Alcohol Craving Predict Naltrexone Response in Alcoholism|SweetNal|University of North Carolina, Chapel Hill|Yes|Completed|January 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|65 Years|No|||October 2013|October 29, 2013|February 14, 2011|Yes|Yes||No|August 12, 2013|https://clinicaltrials.gov/show/NCT01296646||109003|
NCT01296945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00045360|Nutrition Knowledge for Spanish-speaking Parents|Nutrition Knowledge for Spanish-speaking Parents: Evaluation of Paper Handouts, Computer Modules and Web Modules||Johns Hopkins University|No|Completed|February 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Health Services Research|4||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 28, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01296945||108980|
NCT01296958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NS069275-01|Targeted Screening for Taenia Solium Tapeworms|Targeted Screening for Taenia Solium Tapeworms||Oregon Health and Science University|No|Completed|May 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1811|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 22, 2014|February 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01296958||108979|
NCT01297881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52460|Belgian Pulmonary Function Study|Belgian Pulmonary Function Study : the Belgian Thoracic Society|BPFS|Katholieke Universiteit Leuven|No|Completed|June 2011|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Caucasian outpatients with respiratory symptoms but without diagnosis|March 2013|March 4, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297881||108909|
NCT01297894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siriraj CEU53-001|Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii|Colistin Plus Fosfomycin in Multi-Drug Resistant Acinetobacter Baumannii||Mahidol University|No|Recruiting|June 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||December 2011|December 24, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297894||108908|
NCT01297231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-217|Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI|Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI in Early Stage Breast Cancer Patients on Tamoxifen||Memorial Sloan Kettering Cancer Center||Withdrawn|February 2011|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|blood or saliva|Female|21 Years|N/A|No|Non-Probability Sample|Eligible premenopausal patients with stage 0-3 breast cancer for whom MRI staging is        planned will be enrolled.|November 2012|November 12, 2012|February 14, 2011|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01297231||108958|
NCT01298492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7281007|A Study To Monitor Long-Term Treatment With PF-00547659|A Multicenter Open-label Extension Study To Assess Long-term Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera Ii)|OPERA II|Pfizer|Yes|Active, not recruiting|July 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|210|||Both|18 Years|75 Years|No|||March 2016|March 2, 2016|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298492||108864|
NCT01298791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34423|The Impact Of Physician Communication On Family Inpatient Experience|The Impact Of Physician Communication On Family Inpatient Experience||Boston Medical Center|No|Recruiting|February 2011|August 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|N/A|17 Years|No|||February 2011|February 17, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298791||108841|
NCT01298466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081256|Primary Care Identification Of Patients With Chronic Neuropathic Low Back Pain Study|Open-Labeled European Study To Support The Early Identification Of Patients With Chronic Neuropathic Low Back Pain In Primary Care And To Assess The Effectiveness And Tolerability Of Pregabalin In This Population|PINPOINT|Pfizer|No|Withdrawn|February 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 17, 2012|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298466||108866|
NCT01298479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6791034|Sayana-Uniject Volumetric Delivery|Quantitative Determination of the Volume of Suspension Delivered Via the Uniject Delivery System Following Simulated Subcutaneous Injection by Healthcare Professionals Into a Synthetic Subcutaneous Injection Training Device||Pfizer|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|Phase 0|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|nurses|February 2011|February 16, 2011|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01298479||108865|
NCT01298778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00012376|High Pain Intervention in Cesarean Sections|Improving Pain Relief For Those Who Need It Most After Cesarean Delivery||Wake Forest School of Medicine|Yes|Completed|August 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|45 Years|No|||December 2013|December 5, 2013|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298778||108842|
NCT01299025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ö28-10|Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit|Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit||Örebro County Council|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|February 17, 2011||No||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01299025||108823|
NCT01299961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA Rheumatology RA 001|Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis|Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis||University of California, Los Angeles|No|Completed|March 2011|February 2015|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|February 18, 2011|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01299961||108751|This is a very small open-label study of 25 patients on a FDA approved drug, where efficacy (by standard validated measures) and safety were not the primary end points.
NCT01296165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38027|International Travel and the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli|The Importance of International Travel in the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli||University of Calgary|Yes|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|173|Samples With DNA|Stool specimens|Both|18 Years|N/A|No|Non-Probability Sample|Travelers older than 18 years old that will visit India for longer than 5 days.|December 2014|December 1, 2014|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296165||109040|
NCT01299701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2108|A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors|An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Excretion (ADME) of ASA404 After a Single Intravenous Infusion of 3000 mg [14C]ASA404 in Patients With Advanced Solid Tumor Malignancies||Novartis||Completed|December 2008|||July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|February 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299701||108771|
NCT01346267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 1202|Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy|Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy|SCUSF1202|University of South Florida|Yes|Recruiting|May 2011|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|240|||Both|4 Years|18 Years|No|||March 2016|March 4, 2016|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346267||105236|
NCT01346280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911145|Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs|Quality of Care: The Impact of Multidisciplinary Care on Processes and Outcomes of Cancer Care||National Institutes of Health Clinical Center (CC)||Completed|April 2011|October 2015||||N/A|Observational|N/A|||Anticipated|1695|||Both|18 Years|99 Years|No|||October 2015|October 6, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346280||105235|
NCT01346475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30520-D - Phase 2|Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2|A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults||University of Washington|No|Active, not recruiting|November 2008|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||April 2011|April 29, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346475||105220|
NCT01346488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-772|Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)|Special Investigation (Working Productivity and Activity Impairment / WPAI in Japanese Patients With Rheumatoid Arthritis / RA)||AbbVie||Completed|June 2011|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2085|||Both|16 Years|99 Years|No|Non-Probability Sample|Single-arm, Multi-center, Prospective Cohort|January 2016|January 25, 2016|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346488||105219|
NCT01299922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Csa-LES|Clinical Trial Treatment in Lupus Nephritis|Phase III, Open, Randomized, Parallel-group Clinical Trial, to Evaluate the Efficacy and Safety of Treatment With Prednisone, Cyclosporine, Mycophenolic Acid Versus Prednisone and Mycophenolic Acid in Lupus Nephritis Type III-IV-V.|Csa-LES|Hospital Universitario Fundación Alcorcón|Yes|Withdrawn|February 2011|October 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2011|February 26, 2015|February 18, 2011||No|IT was impossible to find patients|No||https://clinicaltrials.gov/show/NCT01299922||108754|
NCT01300208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-11050-CLE-002|To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus|A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus||Celgene|Yes|Completed|October 2010|March 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|October 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300208||108732|
NCT01300182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wbvtrct|The Effect of Early WBVT on Neuromuscular Control After ACLR|The Effect of Early Whole-Body Vibration Therapy on Neuromuscular Control After Anterior Cruciate Ligament Reconstruction|WBVT|Chinese University of Hong Kong|Yes|Completed|November 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|N/A|N/A|No|||February 2013|February 12, 2013|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300182||108734|
NCT01300429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-014|Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus|Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Tissue|Both|18 Years|N/A|No|Non-Probability Sample|All patients seen by the Thoracic Oncology Service who have been diagnosed with an ALK        mutant NSCLC and treated with an ALK kinase inhibitor who have experienced objective        regression by RECIST, WHO, or clinical criteria and who then progress will be screened for        this protocol.|February 2016|February 2, 2016|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300429||108715|
NCT01296061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR FRN MOP-102732|Kidney Transplant Failure|Effect of Immunosuppressive Medication Use on Patient Outcomes Following Kidney Transplantation Failure||Ottawa Hospital Research Institute|No|Terminated|August 2011|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|Samples Without DNA|Class I and II HLA antibodies|Both|18 Years|N/A|No|Non-Probability Sample|Patients ≥ 18 years, who initiate chronic dialysis treatment after failure of a first        kidney transplant|February 2016|February 2, 2016|February 8, 2011||No|Funding ended.|No||https://clinicaltrials.gov/show/NCT01296061||109048|
NCT01297283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leadless ECG Evaluation Study|Leadless Electrocardiogram (ECG) Evaluation Study|Leadless ECG Evaluation Study|LECG|Medtronic Bakken Research Center|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|195|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|February 3, 2011||No||No|December 23, 2013|https://clinicaltrials.gov/show/NCT01297283||108954|
NCT01297621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mestre 1|Physical Activity and Sexuality After Reduction Mammaplasty|Satisfaction, Physical Activity and Sexuality Outcomes in Breast Reduction Patients||Federal University of São Paulo|No|Completed|May 2010|June 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Female|18 Years|45 Years|No|||July 2013|July 5, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297621||108929|
NCT01298167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101007845|Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery|Fast Absorbing Gut Suture Versus Cyanoacrylate Tissue Adhesive in the Epidermal Closure of Linear Repairs Following Mohs Micrographic Surgery||Yale University|Yes|Completed|February 2011|August 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|February 15, 2011||No||No|September 10, 2012|https://clinicaltrials.gov/show/NCT01298167||108887|
NCT01297608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 106|A Double Blinded Study to Examine the Effect of Coated Suppositories on Fecal Incontinence in Patients With Spinal Cord Injury|||RDD Pharma Ltd|No|Withdrawn|April 2011|September 2011|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||December 2013|December 11, 2013|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297608||108930|
NCT01298804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH091871|Preventing Maternal Depression In Head Start|Preventing Maternal Depression In Head Start||Boston Medical Center|Yes|Recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|230|||Female|15 Years|64 Years|No|||March 2014|March 6, 2014|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298804||108840|
NCT01299051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00010727|Steps to Health: Targeting Obesity in the Health Care Workplace|Steps to Health: Targeting Obesity in the Health Care Workplace||Duke University|Yes|Completed|January 2011|March 2016|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|550|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01299051||108821|
NCT01299064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15AT005342-01A1|Transcultural Mindfulness Assessment: A Mixed Methods Analysis|Transcultural Mindfulness Assessment: A Mixed Methods Analysis||Pacific University|No|Completed|August 2010|July 2014|Actual|July 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|Buddhist clergy and laypersons|October 2014|October 28, 2014|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299064||108820|
NCT01299038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-287|Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer|A Multi-dose Phase II Trial of Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2010|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299038||108822|
NCT01299363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-229|Dilators for Dyspareunia Prevention|Vaginal Dilators for Prevention of De Novo Dyspareunia After Prolapse Surgery: A Randomized Controlled Trial|DDS|Medstar Research Institute|No|Completed|September 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|N/A|No|||April 2015|April 7, 2015|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01299363||108797|
NCT01299714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10096|Community Awareness, Resources and Education (CARE II): Project 3|Community Awareness, Resources and Education (CARE II): Project 3||Ohio State University Comprehensive Cancer Center|Yes|Completed|February 2011|April 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|191|Samples With DNA|serum, Pap specimen, cervical specimen for HPV analysis, oral rinse specimen, saliva      specimen|Female|18 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be female, aged 18 - 26 years, residing in an Appalachian region, with        no history of HPV vaccination.|April 2015|April 27, 2015|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01299714||108770|
NCT01296464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2939136|Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens|Duration of Motor Response After Administration of Experimental Levodopa/Carbidopa/Entacapone Treatment Regimens Compared to Standard Treatment (Stalevo®);a Randomised,Double-blind,Crossover,Multicentre,Single Dose Study in Patients With Parkinson?s Disease and Wearing-off Symptoms|PARTEST|Orion Corporation, Orion Pharma|No|Completed|February 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|27|||Both|30 Years|N/A|No|||September 2011|September 9, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296464||109017|
NCT01300234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114648|Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)|A Multi-centre, Double Blind, Double Dummy, Randomised, Controlled Study to Evaluate the Efficacy and Safety of TDF 300mg Once Daily (QD) Versus Adefovir Dipivoxil (ADV) 10mg QD in Chinese Subjects With CHB|TDF in CHB|GlaxoSmithKline|No|Active, not recruiting|March 2011|August 2016|Anticipated|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|512|||Both|18 Years|69 Years|No|||July 2015|November 12, 2015|February 3, 2011||No||No|June 13, 2013|https://clinicaltrials.gov/show/NCT01300234||108730|
NCT01348698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110149|Evaluation of Molecular Markers in Adrenal Tumors|Evaluation of Diagnostic and Prognostic Molecular Markers in Adrenal Neoplasm||National Institutes of Health Clinical Center (CC)||Recruiting|April 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|90 Years|No|||September 2015|October 6, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348698||105049|
NCT01346501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-707|Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069|An Extended Observational Study (P12-707: HOPEFUL III Study) of Follow-up Survey (P12-069: HOPEFUL II Study) of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)||AbbVie||Completed|April 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|172|||Both|20 Years|99 Years|No|Non-Probability Sample|Participants with Rheumatoid Arthritis (RA) who continued the one year observational        period of study P12-069 and provided informed consent to participate in study P12-707.|February 2016|February 15, 2016|April 29, 2011||No||No|November 25, 2015|https://clinicaltrials.gov/show/NCT01346501||105218|
NCT01300494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOVAS 2 08.02.2011|BOVAS: Bifurcation Optimal Viewing Angle Selection Study|Bifurcation Optimal Viewing Angle Selection Study|BOVAS|University Hospital, Gasthuisberg|No|Not yet recruiting|March 2011|June 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|In patients undergoing coronary angiography, those with an angiographically significant        bifurcation lesion will be identified. A total of 50 patients will be selected. After        diagnostic angiography, optimal viewing angles for the bifurcation lesion will be        calculated using the dedicated Medis (Leiden, the Netherlands) software.|February 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300494||108711|
NCT01296087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-6987-23-CRD-001|TC-6987 for the Treatment of Mild to Moderate Asthma|A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma||Targacept Inc.|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|September 3, 2013|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01296087||109046|
NCT01296698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431112|Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week Trial to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers in a Naturalistic Environment||Johnson & Johnson Consumer and Personal Products Worldwide|No|Terminated|March 2011|June 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|February 14, 2011|Yes|Yes|Study terminated due to a technical issue (randomization error).|No|March 29, 2012|https://clinicaltrials.gov/show/NCT01296698||108999|Summary tabulations are not available for the primary and some secondary outcome measures because the study was terminated early due to a technical issue (randomization error).
NCT01300442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC1901-PNPD|Effects of Transcutaneous Electrical Diaphragmatic Stimulation on Respiratory Variables in COPD Patients|Fundamentation of TEDS Protocol in Healthy Subjects and Its Application in COPD Patients|COPD|Universidade Federal de Sao Carlos|Yes|Recruiting|February 2011|May 2011|Anticipated|April 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||January 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300442||108714|
NCT01300455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4305-036|Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)|A Study to Evaluate the Effects of MK-4305 in Patients With Obstructive Sleep Apnea||Merck Sharp & Dohme Corp.|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|February 17, 2011|No|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01300455||108713|
NCT01296074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81070203|Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response|The Perioperative Effect of Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response||Capital Medical University|Yes|Not yet recruiting|March 2011|August 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|65 Years|No|||January 2011|February 14, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296074||109047|
NCT01296672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROI10-352|3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer|Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test||The University of Texas Health Science Center at San Antonio|No|Recruiting|February 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Anticipated|500|||Male|55 Years|N/A|No|||September 2015|September 28, 2015|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01296672||109001|
NCT01297907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Crohn's|Bronchial Hyperreactivity in Children With Crohn Disease|||Rambam Health Care Campus|Yes|Completed|May 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|47|||Both|6 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Twenty-three children with Crohn disease in the age of 11 to 22 yr|October 2007|February 16, 2011|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01297907||108907|
NCT01298180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811601|Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?|Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?||University Hospital, Toulouse|No|Completed|January 2009|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|111|||Both|1 Year|5 Years|No|||May 2015|May 26, 2015|November 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01298180||108886|
NCT01298531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801132|A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis|A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis|SPARSE|Pfizer|No|Completed|May 2011|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|February 16, 2011|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01298531||108861|
NCT01298544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1841009|A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers|A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518||Pfizer|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|335|||Both|4 Years|5 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|November 29, 2010||No||No|February 13, 2012|https://clinicaltrials.gov/show/NCT01298544||108860|
NCT01298154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PureNet_23878|Effects of Intact and Hydrolyzed Pea Protein on Food Intake, Glycemic Response and Subjective Appetite|The Effects of Intact and Hydrolyzed Yellow Pea Protein on Food Intake, Glycemic Response, and Subjective Appetite in Healthy Young Men.||University of Toronto|No|Completed|July 2009|February 2011|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|26|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||February 2011|May 4, 2011|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01298154||108888|
NCT01299077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EISAI-MBL-2010-1|Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China|A Retrospective Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar Disc Degenerative Disease in China||Eisai Inc.|No|Completed|June 2010|November 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|478|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients visited to the clinics with lumbar disc degenerative disease|May 2011|December 21, 2011|February 16, 2011||No||No|August 16, 2011|https://clinicaltrials.gov/show/NCT01299077||108819|
NCT01299090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEL-09-02|Prospective Pellevé™ Neck Wrinkle Study|Prospective Pellevé™ Neck Wrinkle Study||Ellman International|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|February 4, 2011|No|Yes||No|November 9, 2014|https://clinicaltrials.gov/show/NCT01299090||108818|
NCT01299103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEL-10-02|Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial Wrinkles|A Prospective, Randomized, Open-Label, 3-Arm Parallel Study Comparing the Safety and Efficacy of Single Therapy Versus Double and Triple Therapy Using the Surgitron® Dual RF™ S5 With the Pellevé™ Wrinkle Treatment Handpiece and Pellevé™ Treatment Gel for the Treatment of Moderate Facial Wrinkles in Fitzpatrick Skin Types I - IV||Ellman International|No|Completed|April 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|February 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01299103||108817|
NCT01299389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017026|An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia||Janssen Pharmaceutical K.K.|No|Completed|October 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|20 Years|N/A|No|||June 2013|June 13, 2013|January 27, 2011|Yes|Yes||No|March 4, 2013|https://clinicaltrials.gov/show/NCT01299389||108795|
NCT01299402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adaptogen Study 002|A Study on the Effects of Soulera Herbal Blend Intake on Chronic Stress in Healthy Adults|A Pilot Double-Blind Crossover Study on the Effects of Soulera Herbal Blend Intake on Chronic Stress and Its Biomarkers in Healthy Adults||NEMA Research, Inc.|No|Terminated|August 2011|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 30, 2012|February 15, 2011||No|Financial Reasons|No||https://clinicaltrials.gov/show/NCT01299402||108794|
NCT01299415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA404A2113|Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor|A Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effects of Fluvoxamine on the Pharmacokinetics of ASA404 in Adult Patients With Solid Tumor Malignancies||Novartis||Terminated|August 2009|||September 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299415||108793|
NCT01299376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954E-356|MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)|A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] and an Open-label, Long-term Clinical Trial to Study the Safety of MK-0954E||Merck Sharp & Dohme Corp.|No|Completed|January 2011|September 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|268|||Both|20 Years|80 Years|No|||March 2015|March 11, 2015|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299376||108796|
NCT01299740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR513611CTIL|Skills Group for Children With Emotional Dysregulation and Their Parents|Dialectical Behavioral Therapy (DBT) Based Skills Group for Children With Emotional Dysregulation and Their Parents||Soroka University Medical Center|No|Recruiting|February 2011|July 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|9 Years|12 Years|No|||February 2011|March 27, 2011|February 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01299740||108768|
NCT01299727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-SAN-067|Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)|An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)||Shire|No|Active, not recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|3 Years|N/A|No|||December 2014|December 19, 2014|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299727||108769|
NCT01296191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-BV-A|Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification|Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification||Bucci Laser Vision Institute|No|Recruiting|May 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 11, 2011|February 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01296191||109038|
NCT01296204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/1B|Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131|Phase I of Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131|BB4|Centre René Gauducheau|No|Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1|||33|||Both|18 Years|N/A|No|||February 2011|March 21, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01296204||109037|
NCT01300247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAO4779g|A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)|An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia||Genentech, Inc.||Completed|June 2011|December 2015|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300247||108729|
NCT01300260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11371|Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose|The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion||Eli Lilly and Company|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|February 3, 2011||No||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01300260||108728|
NCT01300546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114933|Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine|TreximetTM in the Prevention and Modification of Disease Progression in Migraine||Cady, Roger, M.D.|No|Completed|December 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|65 Years|No|||May 2013|May 17, 2013|January 12, 2011|Yes|Yes||No|February 1, 2013|https://clinicaltrials.gov/show/NCT01300546||108707|
NCT01345604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCL block|Intraoperative Posterior Cruciate Ligament (Transcruciate) Injection After Total Knee Arthroplasty (TKA)|Reducing Posterior Knee Pain Following Total Knee Arthroplasty Using an Intraoperative Posterior Cruciate Ligament (Transcruciate) Injection||University of Saskatchewan|No|Completed|May 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|16 Years|N/A|No|||June 2012|December 1, 2014|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345604||105286|
NCT01348945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPACL-CS|Proprioceptive Function, Postural Stability & Clinical Outcome After Stump Preserving Anterior Cruciate Ligament Reconstruction Surgery|Proprioceptive Function, Postural Stability & Clinical Outcome After Stump Preserving Anterior Cruciate Ligament Reconstruction Surgery - A Comparative Study||Chinese University of Hong Kong|No|Active, not recruiting|May 2011|February 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|48|||Both|18 Years|N/A|No|||December 2010|May 5, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348945||105031|
NCT01296425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-523|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Austria|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Austria|ECOS AUT|Merck KGaA||Active, not recruiting|July 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|51|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the Easypod™ electromechanical device.|March 2015|March 3, 2015|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296425||109020|
NCT01297010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231/10|Dexamethasone Compared to Ondansetron and Dexamethasone for Prophylaxis of Postoperative Vomiting in Children|Dexamethasone Compared to Ondansetron and Dexamethasone for Prophylaxis of Postoperative Vomiting in Children Undergoing Ambulatory Surgery: Clinical Trial Randomized, Double Blind, Placebo-controlled|vomiting|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|134|||Both|1 Year|10 Years|No|||July 2011|August 2, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297010||108975|
NCT01297023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H47-11|Human Intervention Study With Calcium Phosphate and Vitamin D|The Effect of Vitamin D3 Alone and in Combination With Calcium Phosphate on Bone Metabolism in Healthy Adults||University of Jena|Yes|Completed|January 2011|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|60|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297023||108974|
NCT01296685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S 52937|Clinical Evaluation of Air Handling in Baby fx Oxygenator With Integrated Arterial Filter Versus Baby rx Oxygenator With Non Integrated Arterial Line Filter|Clinical Evaluation of Air Handling in Baby fx Oxygenator With Integrated Arterial Filter Versus Baby rx Oxygenator With Non Integrated Arterial Line Filter||Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|March 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|All children with body surface area between 0.25 and 0.5 m² who need cardiac surgery with        cardiopulmonary bypass. Urgent and norwood procedures are excluded.|February 2011|May 31, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296685||109000|
NCT01297296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD1051|A Multinational Trial to Evaluate the Longterm Safety of the Parachute Implant System|PARACHUTE III: A Multinational Trial to Evaluate the Longterm Safety of the Parachute System|PARACHUTEIII|CardioKinetix, Inc|No|Active, not recruiting|July 2011|June 2018|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|54|||Both|18 Years|79 Years|No|Non-Probability Sample|The study population will be open to all individuals who meet the inclusion/exclusion        criteria. This is a prospective, multi-center, non-randomized trial.|August 2015|August 6, 2015|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297296||108953|
NCT01296971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25246|A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)|Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon Alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER Study)||Hoffmann-La Roche||Withdrawn|December 2009|December 2009|Anticipated|December 2009|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 21, 2010|No|Yes|study was not started due to an administrative reason on the part of the local Health    Authority|No||https://clinicaltrials.gov/show/NCT01296971||108978|
NCT01297270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.47|Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)|A Phase III, Randomized, Double Blind and Placebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis C Infection.||Boehringer Ingelheim||Completed|April 2011|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|658|||Both|18 Years|70 Years|No|||August 2015|August 18, 2015|February 15, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01297270||108955|
NCT01298193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2009-02|Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients|A Prospective, Open Label, Non-comparative Trial to Determine the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients||Spanish Breast Cancer Research Group|No|Completed|May 2011|April 2014|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|212|||Female|18 Years|N/A|No|||June 2013|May 18, 2015|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01298193||108885|
NCT01299441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007600|Endotracheal Cardiac Output Monitor (ECOM) for Patients Undergoing Liver Transplantation|Noninvasive ECOM Monitoring of Hemodynamic Parameters During Liver Transplantation||Mayo Clinic||Active, not recruiting|February 2011|December 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|99 Years|No|Probability Sample|Patients undergoing liver transplantation|October 2015|October 29, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01299441||108791|
NCT01299766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG035025|Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment|Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment||Thomas Jefferson University|No|Active, not recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||February 2015|February 6, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01299766||108766|
NCT01298505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0711006|A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects|A Phase 1 Double-Blind (3rd Party Open), Randomized, Placebo-Controlled Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects.||Pfizer|No|Terminated|June 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|0|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2011|February 16, 2011|February 2, 2011|No|Yes|This study was stopped due to lack of evidence for clinical efficacy.|No||https://clinicaltrials.gov/show/NCT01298505||108863|
NCT01298518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0961007|A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients|A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Efficacy And Safety Of 4-Week Administration Of Multiple Oral Doses Of PF-04620110 In Type 2 Diabetes Mellitus Subjects With Insufficient Glycemic Control On Metformin||Pfizer|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|No|||October 2012|October 5, 2012|January 28, 2011|No|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT01298518||108862|
NCT01299779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#10C.29|Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS|The Incidence of Hyponatremia With Two Commonly Prescribed Purgatives for Colonoscopy-Polyethylene Glycol 3350 With a Sports Drink (PEG-SD) Compared to Polyethylene Glycol 3350 With Electrolyte Solution (PEG-ELS)||Thomas Jefferson University|No|Completed|June 2010|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|460|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|July 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01299779||108765|
NCT01299753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propran_Jeschke|Catecholamine Blockade Post-burn|Clinical and Molecular Effects of Catecholamine Blockade Post-burn||Sunnybrook Health Sciences Centre|No|Recruiting|February 2011|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||July 2015|July 28, 2015|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01299753||108767|
NCT01300286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024305|Open Label Use Of RiaStap During Aortic Reconstruction|Open Label Use Of RiaStap During Aortic Reconstruction||Duke University|Yes|Completed|December 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2014|December 5, 2014|January 9, 2011|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT01300286||108726|
NCT01299974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1621|Project PARIS: Parents and Residents in Session|Project PARIS: Parents and Residents in Session|PARIS|Icahn School of Medicine at Mount Sinai|No|Completed|February 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|83|||Both|N/A|N/A|No|||December 2015|December 22, 2015|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01299974||108750|
NCT01296152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5283|Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women|An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/Ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women||AIDS Clinical Trials Group|Yes|Completed|May 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|13 Years|N/A|No|||November 2015|November 18, 2015|February 14, 2011|Yes|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT01296152||109041|
NCT01296217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 07/11-M|Sentinel Lymph Node Detection in Prostate Surgery by Laparoscopy|"Evaluation of the Sentinel Lymph Node Technic of the Prostate by Laparoscopy"||Centre René Gauducheau|No|Completed||||||N/A|Interventional|Intervention Model: Single Group Assignment|1||Anticipated|24|||Male|18 Years|N/A|No|||February 2011|March 3, 2011|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01296217||109036|
NCT01296503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBRAM0001|Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma|Thalidomide Plus Dexamethasone as Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: a Multicenter Phase 3 Randomized Trial||Grupo de Estudos Multicentricos em Onco-Hematologia|Yes|Completed|October 2003|December 2010|Actual|July 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|70 Years|No|||February 2011|February 14, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01296503||109014|
NCT01296737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-027|Validation of Quantitative Ventricular Function Imaging Single Photon Emission Tomography (Spect)Using the D-SPECT Cardiac Camera|Validation of Quantitative Ventricular Function Imaging||Spectrum Dynamics|Yes|Completed|July 2010|May 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients who have been reffered by their physicians to the nuclear medicinew department        for the preformance of quantitative SPECT venricular function study and will voluntarily        participate in the study|February 2011|August 7, 2011|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01296737||108996|
NCT01296477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-115|To Evaluate the Use of ASTHMA IQ in a Primary Care Setting|Examination of ASTHMA IQ to Improve Patient Outcomes in a Primary Care Setting|AIQ|American Academy of Family Physicians||Completed|December 2010|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|375|||Both|12 Years|65 Years|No|Non-Probability Sample|The study will recruit approximately 400 patients with chronic persistent asthma. The        required sample size to identify a clinically significant difference in ACT scores from        baseline and between groups requires about 200 patients per group.|January 2016|January 4, 2016|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296477||109016|
NCT01346085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECIT-1|Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation|A Multi-step Trial Towards Single Donor Islet Transplantation in Type 1 Diabetic Patients, Using Calcineurin Inhibitor-free Immunosuppression|ECIT-1|Ospedale San Raffaele|Yes|Completed|October 2006|June 2012|Actual|June 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||April 2014|April 9, 2014|April 29, 2011||No||No|April 9, 2014|https://clinicaltrials.gov/show/NCT01346085||105250|
NCT01346332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005021|Healthy Volunteer Study|Performance of the Iontophoresis System With Headset in Healthy Volunteers|IPSHS|Acclarent|No|Completed|April 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|106|||Both|2 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 14, 2014|April 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01346332||105231|
NCT01346566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICIRCcionni|Prospective Study of Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses|Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses: A Prospective Case Series||Iladevi Cataract and IOL Research Center|Yes|Completed|January 2003|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|N/A|N/A|No|||May 2011|May 18, 2011|April 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01346566||105213|
NCT01296724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01346-33|PREMAPIV : Intravesical Pressure Variation at Different Bladder Instillation Volumes in Newborn Children|PREMAPIV : Intravesical Pressure Variation at Different Bladder Instillation Volumes in Newborn Children||Rennes University Hospital||Completed|February 2011|||July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|54|||Both|N/A|3 Months|No|||November 2013|November 25, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01296724||108997|
NCT01297673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2010-0207/02|Reflux in Spinal Cord Injury Patients With Neurogenic Lower Urinary Tract Dysfunction|Vesico-ureteral Reflux in a Contemporary Series of Spinal Cord Injury Patients With Neurogenic Lower Urinary Tract Dysfunction||Balgrist University Hospital|No|Completed|January 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|90 Years|No|Non-Probability Sample|Ages Eligibility: minimum 18 years Genders Eligibility: female and male|January 2013|January 7, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297673||108925|
NCT01297933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007681|Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease|Intravenous Omega-3 Fatty Acid (Omegaven) for Pediatric Patients With Total Parenteral Nutrition Associated Liver Dysfunction|Omegaven|Children's Hospital of Philadelphia||Available|January 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Expanded Access|N/A|||||||Both|N/A|21 Years|No|||March 2016|March 1, 2016|February 15, 2011|No|Yes||||https://clinicaltrials.gov/show/NCT01297933||108905|
NCT01296399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02511CTIL|In-stent Restenosis in Patients With Patent Previous Bare Metal Stent|The Rate of In-stent Restenosis Within Bare Metal Stents as Compared to Drug Eluting Stents in Patients With Patent Previously Deployed Bare Metal Stent||Rambam Health Care Campus|No|Completed|January 2000|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|300|||Both|N/A|N/A|No|Non-Probability Sample|all patients who underwent percutaneous coronary intervention in Rambam Medical Center        between 2000 -2010.|February 2011|February 14, 2011|February 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01296399||109022|
NCT01296412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-403|Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)|A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|March 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|653|||Both|18 Years|79 Years|No|||February 2015|February 23, 2015|February 14, 2011|Yes|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT01296412||109021|
NCT01297309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR-C10-008|A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)|A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)||Shire|No|Active, not recruiting|April 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|85 Years|No|||March 2016|March 16, 2016|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01297309||108952|
NCT01297660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2010-0207/01|Neuro-urological Outcome After Spinal Cord Injury|||Balgrist University Hospital|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|55|||Both|18 Years|90 Years|No|Non-Probability Sample|Ages Eligibility: minimum 18 years old Genders Eligibility: female and male|January 2013|January 7, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297660||108926|
NCT01297634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622|Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle|Phase IV Study of Radial Diffusion of the Botulinum Toxin Type A: Electromyographic Evaluation of the Frontal Muscle.||Ivo Pitanguy Institute|Yes|Completed|May 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297634||108928|
NCT01299454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-09-225|A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects|A Single-dose, Open-label, Parallel Group, Matched Study Evaluating the Pharmacokinetics of Oral OPC-34712 Tablet in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects||Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|December 2010|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 29, 2015|February 16, 2011|No|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01299454||108790|
NCT01299129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070/2009|Functional and Morphologic Aspects of Intravitreal Triamcinolone for Uveitis-associated Cystoid Macular Edema|Functional and Morphologic Aspects of Intravitreal Triamcinolone for Uveitis-associated Cystoid Macular Edema||Medical University of Vienna||Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|uveitis ambulance patients of the department of ophthalmology, medical university vienna|December 2011|December 24, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299129||108815|
NCT01299142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGI-101-CP002|Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)|Phase I Study of Human Monoclonal Antibody (FGI-101-1A6) in Normal Healthy Volunteers||Functional Genetics Inc.|Yes|Recruiting|January 2011|October 2011|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2011|February 16, 2011|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299142||108814|
NCT01298817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pepper Grant|Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat|Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat and Associated Cardio-metabolic Risk in Obese, Older Adults: A Feasibility Study|SILVER|Wake Forest School of Medicine|Yes|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|24|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01298817||108839|
NCT01298830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM GLP-1/01|GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage|GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage||CellMed AG, a subsidiary of BTG plc.|Yes|Terminated|October 2008|June 2011|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|N/A|No|||March 2013|March 25, 2013|February 15, 2011||No|Need for improvement of study medication. Safety data collected sufficient. No further gain in    knowledge expected.|No||https://clinicaltrials.gov/show/NCT01298830||108838|
NCT01300026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101262|AMG 319 Lymphoid Malignancy FIH|A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies||Amgen||Active, not recruiting|April 2011|February 2017|Anticipated|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01300026||108746|
NCT01300039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|573|Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter Formigenes|Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter Formigenes||VA New York Harbor Healthcare System|No|Completed|January 2003|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing upper endoscopy for any indication and who would have determination of        presence or absence of H. pylori. Stool samples then positive for colonization with        Oxalobacter formigenes.|February 2011|February 18, 2011|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01300039||108745|
NCT01300273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETO-011-IP4|Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy|Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy||Shanghai Jiao Tong University School of Medicine|No|Active, not recruiting|February 2011|July 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||September 2011|September 6, 2011|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300273||108727|
NCT01300000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK65|Effects of Early Nutrition on Growth|Effects of Early Nutrient Intake on Growth and Body Composition||Abbott Nutrition|Yes|Active, not recruiting|March 2010|September 2016|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|649|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||September 2015|September 29, 2015|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01300000||108748|
NCT01300299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-LUN-10-STEREO|STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)|STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)|STEREO|James Graham Brown Cancer Center|Yes|Terminated|February 2011|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|February 17, 2011|Yes|Yes|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01300299||108725|
NCT01305564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-09-007|A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System|A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter||C. R. Bard|Yes|Completed|June 2011|July 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|21 Years|N/A|No|||November 2015|November 3, 2015|January 31, 2011|Yes|Yes||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01305564||108324|
NCT01305577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-10-16|Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat|Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Completed|December 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|363|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 17, 2015|February 10, 2011||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01305577||108323|
NCT01305590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0004|Understanding Medication Adherence Among HIV Patients|Understanding Medication Adherence Among HIV Patients||National Bureau of Economic Research, Inc.|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2011|September 15, 2011|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01305590||108322|
NCT01296490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wingate 05|Physical Fitness Effect on the Different Oxidative Stress Measurements|Assessing Physical Fitness Effect on the Different Oxidative Stress Measurements, at Rest and After Acute Exercise||Wingate Institute|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 31, 2013|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01296490||109015|
NCT01316406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATH008-CLN02|Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine|A Phase II Placebo Controlled, Multicenter Study to Investigate the Safety and Efficacy of ATH008 Cream in Patients With Palmar-Plantar Erythrodysesthesia Syndrome (PPES) Secondary to Capecitabine Therapy.||Advancell - Advanced In Vitro Cell Technologies, S.A.|No|Completed|February 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|122|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316406||107502|
NCT01346579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-151101|Biomarkers in Tissue Samples From Older Women With Breast Cancer|PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer||Alliance for Clinical Trials in Oncology|No|Terminated|April 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|505|Samples With DNA|Tissue|Female|70 Years|N/A|No|Non-Probability Sample|Patients with breast cancer enrolled on Cancer and Leukemia Group B 9343|June 2015|June 12, 2015|April 30, 2011||No|Study closed prematurely.|No||https://clinicaltrials.gov/show/NCT01346579||105212|
NCT01346852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112607|Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients|Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients||GlaxoSmithKline|No|Completed|July 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|101437|||Both|4 Years|N/A|No|Probability Sample|The study intends to identify subjects at least 4 years of age with asthma and using        asthma medications|September 2011|September 15, 2011|April 15, 2011||No||No|May 5, 2011|https://clinicaltrials.gov/show/NCT01346852||105191|
NCT01297686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03368|Exercise Versus Corticosteroid Randomized Clinical Trial for Plantar Fasciitis|A Clinical Trial of a Multi-Element Exercise Program for Plantar Fasciopathy in Workers Required to Stand for Prolonged Periods of Time||University of British Columbia|No|Completed|May 2011|April 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|19 Years|60 Years|No|||March 2013|March 20, 2013|February 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01297686||108924|
NCT01297946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-01|Closed-loop Control of Glucose Levels in the Context of Exercise in Adults With Type-1 Diabetes|An Open-label, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Dual-hormone Closed-loop Strategy as Compared to Conventional CSII Therapy in Regulating Glucose Levels in Adults With Type-1 Diabetes in the Context of Exercise|CLASS-01|Institut de Recherches Cliniques de Montreal|No|Completed||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|65 Years|No|||January 2012|April 20, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297946||108904|
NCT01296984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSORG APER|Oncological and Functional Result of AbdominoPerineal Extra Levator Resection for Distal Rectal Cancer|A Registry Based Study of Clinical Results and of Health and Wellbeing in Patients After Abdominoperineal Resection for Rectal Cancer|APER|Sahlgrenska University Hospital, Sweden|No|Completed|February 2011|June 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1319|||Both|18 Years|N/A|No|Non-Probability Sample|All swedish patients registerd in the swedish rectalcancer registry undergoing APR        2007-2009|November 2014|November 17, 2014|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01296984||108977|
NCT01296997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H45-10|Calcium Phosphate and Incretins|Influence of a Calcium Phosphate Supplementation on the Secretion of Incretins in Humans.||University of Jena|Yes|Completed|July 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01296997||108976|
NCT01298843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-21|Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital|Pharmacokinetics of a Single Dose of Ceftaroline Fosamil in Children Ages Birth to Younger Than 12 Years With Suspected or Confirmed Infection||Forest Laboratories|Yes|Completed|April 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|53|||Both|N/A|11 Years|No|||May 2014|May 13, 2014|February 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01298843||108837|
NCT01298856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|014/52|The Effect of Hydrotherapy and Land-based Rehabilitation Program Combined With Ankle Taping in Athletes With Chronic Ankle Instability|The Effect of Hydrotherapy and Land-based Rehabilitation Program Combined With Ankle Taping on Ankle Functional Ability and Re-injury Rate in Athletes With Chronic Ankle Instability|CAI|Chulalongkorn University|No|Completed|June 2009|January 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|35 Years|No|||January 2011|February 16, 2011|January 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01298856||108836|
NCT01297920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-039|Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%|A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension||Alcon Research|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1062|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|February 15, 2011|Yes|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01297920||108906|
NCT01298869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/02_Medicine|The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients|The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in CKD Patients||Chulalongkorn University|No|Recruiting|February 2011|December 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|26 Years|No|Non-Probability Sample|Chronic kidney disease stage IV and V population|January 2014|January 27, 2014|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01298869||108835|
NCT01299168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATAGC-001|Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation|Multi-centric Observational Study to Analyse the Diagnostic Molecular Features in the Clinical Setting of Kidney Allograft Biopsies||University of Alberta|No|Recruiting|May 2011|December 2019|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Needle kidney biopsy core as per local standard of care|Both|18 Years|N/A|No|Probability Sample|The study population includes patients with a functioning kidney transplant undergoing a        biopsy for clinicalindications as standard of care to determine the cause of their graft        dysfunction (deterioration in graft function, delayed graft function, proteinuria).|March 2016|March 2, 2016|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01299168||108812|
NCT01299987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARGIT-E|Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer|TARGIT-E(Elderly) Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer|TARGIT-E|Universitätsmedizin Mannheim|Yes|Active, not recruiting|January 2011|November 2025|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|265|||Female|70 Years|N/A|No|||January 2016|January 18, 2016|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01299987||108749|
NCT01308515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090809|Vanguard Knee Anterior Stabilized Versus Posterior Stabilized Bearing Study|A Comparative Clinical Evaluation of the Vanguard Knee System's Anterior Stabilized & Posterior Stabilized Tibial Bearings|VGASPS|Biomet, Inc.|No|Withdrawn|September 2010|September 2010|Anticipated|September 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2011|December 5, 2011|June 2, 2010|Yes|Yes|Could not find interested researchers/clinicians to complete study protocol.|No||https://clinicaltrials.gov/show/NCT01308515||108098|
NCT01308528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT062|Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery|A Non-Inferiority Study of Enoxaparin Cristalia in Relation With Enoxaparin Sanofi-Aventis for Prophylaxis Against Venous Thromboembolism in Patients With High-Risk to Develop Thromboembolic Disease Undergoing Geral Abdominal Surgery||Cristália Produtos Químicos Farmacêuticos Ltda.|No|Recruiting|February 2015|January 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01308528||108097|
NCT01300013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100754|Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure||Amgen|Yes|Completed|April 2011|September 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|614|||Both|18 Years|85 Years|No|||March 2014|March 24, 2014|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01300013||108747|
NCT01300585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breast MRI|MRI Evaluation of the Breast Areolar Margin and Paryenchyma|MRI Evaluation to Assess the Relationship Between the Areolar Margin and Underlying Breast Paryenchyma Attachments to the Dermis|Breast MRI|Piedmont Healthcare|No|Terminated|February 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|68|||Female|18 Years|N/A|No|||May 2014|May 2, 2014|February 17, 2011||No|Lack of patient population|No||https://clinicaltrials.gov/show/NCT01300585||108704|
NCT01300559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016175|TissueLink Study During Multi-Level Spine Surgery|Efficacy of the TissueLink Coagulation System in Reducing Hemoglobin Loss During Multi-Level Spine Surgery||Duke University|Yes|Completed|April 2006|August 2012|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 3, 2013|February 3, 2011|Yes|Yes||No|October 31, 2012|https://clinicaltrials.gov/show/NCT01300559||108706|None encountered.
NCT01296178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETHEMA-LMA10|PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years|PROTOCOL FOR First Line TREATMENT ADAPTED TO RISK of Acute Myeloblastic Leukemia in Patients LESS THAN OR EQUAL TO 65 YEARS||PETHEMA Foundation|Yes|Recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|N/A|65 Years|No|||October 2015|October 13, 2015|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01296178||109039|
NCT01296789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101/10|Comparison of a Tissue Perfusion Guided Hemodynamic Protocol With a Standard Hemodynamic Protocol in Septic Shock Patients|Comparison of a Tissue Perfusion Guided Hemodynamic Protocol With a Conventional Hemodynamic Protocol in Septic Shock Patients: a Prospective, Randomised, Controlled Study||University Hospital Inselspital, Berne|No|Terminated|February 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 14, 2011||No|Problems implementing the trial|No||https://clinicaltrials.gov/show/NCT01296789||108992|
NCT01347398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ApneaLink|Validity of a Supersimplified Device for Diagnosis of Patients With Suspected Obstructive Sleep Apnoea-hypopnoea (OSAH)|Validity of a Supersimplified Device for Diagnosis of Patients With Suspected Obstructive Sleep Apnoea-hypopnoea (OSAH).||Basque Health Service|No|Active, not recruiting|March 2009|April 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|815|||Both|18 Years|75 Years|No|||February 2013|February 6, 2013|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01347398||105149|
NCT01348178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAO|Retrospective Follow-up Study After Periacetabular Osteotomy in Adults|Retrospective Follow-up Study After Periacetabular Osteotomy in Adults||University of Aarhus|Yes|Completed|March 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|401|||Both|N/A|N/A|No|Probability Sample|Patients who underwent PAO from 1999-2007|January 2012|January 6, 2012|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348178||105089|
NCT01316705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-MA-11-2009-02|Comparison Between Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) And Intra Cytoplasmic Sperm Injection (ICSI) Techniques With Eggs Donated|COMPARISON BETWEEN IMSI AND ICSI TECHNIQUES WITH DONATED EGGS||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|||||Both|18 Years|35 Years|No|Probability Sample|- Egg donation cycles|March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316705||107480|
NCT01316718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10085|Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)|Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).|MIBS|University of Nottingham|Yes|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|75 Years|No|||January 2014|January 16, 2014|September 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01316718||107479|
NCT01297361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K.Hassan|The Association Between Religious Origin and Age, and Vitamin B12 and Folic Acid Plasma Levels in Non Jewish Population in Western Galilee|||Meir Medical Center|No|Completed|February 2011|August 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|April 22, 2013|January 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01297361||108948|
NCT01297374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA100011|Effect of Three Non-drug Intervention in Treatment of Children With Overweight|EFFECT OF THREE NON-DRUG INTERVENTION IN TREATMENT OF CHILDREN WITH OVERWEIGHT|AMO|Hospital de Clinicas de Porto Alegre||Active, not recruiting|April 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|8 Years|15 Years|No|||February 2011|February 15, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297374||108947|
NCT01297322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL 0243|RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)|A Multi-Center, Prospective, Randomized, Controlled, Trial to Evaluate the Safety and Efficacy of the Cardiva VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures|RESPECT|Cardiva Medical, Inc.|Yes|Completed|September 2011|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|80 Years|No|||September 2014|September 30, 2014|February 10, 2011|Yes|Yes||No|September 30, 2014|https://clinicaltrials.gov/show/NCT01297322||108951|
NCT01297647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2010-0191/0|Incidence of Urinary Tract Infection After Urodynamic Investigation|Incidence of Urinary Tract Infection and Germ Identification After Urodynamic Investigation in Patients With Spinal Cord Injury||Balgrist University Hospital|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|317|||Both|18 Years|90 Years|No|||January 2013|January 7, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297647||108927|
NCT01299116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10250|Long-Acting Reversible Contraception|Long-Acting Reversible Contraception: New Research to Reduce Unintended Pregnancy|LARC|FHI 360|No|Active, not recruiting|December 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|900|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01299116||108816|
NCT01299428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5|Evaluation of the Cerebral Oxygenation With Near Infrared Spectrophotometry (NIRS) at the Hypernatremic Dehydration in Newborn|||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|February 2011|August 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|2|||Both|N/A|1 Month|No|||February 2011|February 17, 2011|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01299428||108792|
NCT01298882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIADM2-001|Diacerein on Insulin Secretion in Diabetes|Effect of Diacerein on Insulin Secretion in Patients With Type 2 Diabetes Mellitus and Overweight or Obesity||Coordinación de Investigación en Salud, Mexico|No|Completed||||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Both|40 Years|60 Years|No|||January 2011|February 16, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01298882||108834|
NCT01299155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-070|A Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses|A Randomized, Pilot Study, Subject Masked Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses (IOLs)||Alcon Research|No|Completed|March 2011|||September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|21 Years|N/A|No|||October 2011|October 22, 2012|February 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01299155||108813|
NCT01299467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9291006|A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge|A Randomized, Double-Blind, Third Party Open, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Duration Of Action Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects||Pfizer|No|Withdrawn|February 2011|February 2012|Anticipated|February 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|6||Actual|0|||Both|18 Years|60 Years|No|||November 2011|November 30, 2011|January 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01299467||108789|
NCT01299480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971012|A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years|A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged ≥11 To <19 Years||Pfizer|Yes|Completed|March 2011|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|1714|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|February 15, 2011|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT01299480||108788|
NCT01309321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10036|Perinatal Handwashing Intervention in Bangladesh|Development and Evaluation of Perinatal Handwashing Promotion for Improved Maternal Handwashing Behavior||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|October 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Female|N/A|N/A|No|||October 2010|March 12, 2014|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01309321||108036|
NCT01309334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIC/10/03|Imaging Young Myeloma (IMAgerie JEune Myélome)|Pharmacoeconomic and Clinical Prospective Comparison of PET-scan and MRI in Patients With de Novo Multiple Myeloma Less Than 65 Years of Age Treated According to IFM/DFCI 2009 Clinical Trial.|IMAJEM|Nantes University Hospital|No|Completed|February 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|152|||Both|18 Years|65 Years|No|||August 2014|August 22, 2014|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01309334||108035|
NCT01300312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIL/EPD/CT/01/2010|A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain|Evaluation of Efficacy and Tolerability of a Fixed Dose Combination of Eperisone Hydrochloride and Diclofenac Sodium in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain: An Observer Blind, Prospective, Randomized, Controlled Study||Eisai Inc.||Completed|February 2011|September 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|60 Years|No|||January 2013|January 4, 2013|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01300312||108724|
NCT01309035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-001-AE|Total Knee Arthroplasty - Accelerated Recovery Without Tourniquet|Total Knee Arthroplasty - Accelerated Recovery Without Tourniquet||Northern Orthopaedic Division, Denmark|Yes|Completed|March 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|50 Years|85 Years|No|||January 2015|January 29, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01309035||108058|
NCT01309295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25465|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis|A Prospective Study Evaluating the Efficacy and Safety of Mircera in Patients With CKD in Predialysis and Dialysis.||Hoffmann-La Roche||Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|N/A|No|Probability Sample|Chronic kidney disease patients initiated on Mircera treatment|March 2016|March 1, 2016|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309295||108038|
NCT01300572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2468.00|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome|A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)||Fred Hutchinson Cancer Research Center|Yes|Recruiting|January 2012|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01300572||108705|
NCT01305837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-370|Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis|Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis|COMTiMS|Rigshospitalet, Denmark|Yes|Completed|April 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||July 2013|July 10, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305837||108303|
NCT01306149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWO01-03-21|Natural History of Mineral Metabolism Parameters and Protein-bound Toxins in Incident Peritoneal Dialysis Patients|Natural History of Biochemical Parameters of Mineral Metabolism and Protein-bound Uremic Retention Molecules in Incident Peritoneal Dialysis Patients: a Longitudinal Observational Study||Universitaire Ziekenhuizen Leuven|No|Recruiting|July 2002|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|whole blood, serum, urine and dialysate|Both|18 Years|N/A|No|Non-Probability Sample|Incident peritoneal dialysis patients|December 2014|December 2, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01306149||108279|
NCT01306123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSB09/17|Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration|An Open, Randomized, Single-dose, Two-way Crossover Study to Characterize the Pharmacokinetic Properties of Cyanocobalamin When Administered as an Intranasal Spray and an Intramuscular Injection to Healthy Volunteers||Swedish Orphan Biovitrum|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|February 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01306123||108281|
NCT01306409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|362/09|Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)|Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents||University Hospital, Basel, Switzerland|Yes|Completed|January 2011|October 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01306409||108259|
NCT01348425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003|Zilver PTX Drug-Eluting Peripheral Stent Study|Evaluation of the Zilver PTX Drug-Eluting Peripheral Stent||Cook||Completed|May 2011|September 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||March 2014|December 29, 2015|April 29, 2011|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01348425||105070|
NCT01348438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENG CIP-001|Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial|Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial||Medtronic Cardiovascular|Yes|Active, not recruiting|August 2011|August 2018|Anticipated|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348438||105069|
NCT01347658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECHI-ETRA|Drug Interactions Between Echinacea Purpurea and Etravirine|DRUG INTERACTIONS BETWEEN ECHINACEA PURPUREA AND ETRAVIRINE||Fundacio Lluita Contra la SIDA|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01347658||105129|
NCT01297049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/427b|I-care: Stimulating Self-management in Patients With Type 2-diabetes|I-care: Stimulating Self-management in Patients With Type 2-diabetes Through Web-based Situational Feedback. A Pilot Study.|I-care|Oslo and Akershus University College of Applied Sciences|Yes|Active, not recruiting|April 2010|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Both|18 Years|70 Years|No|||December 2014|December 2, 2014|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297049||108972|
NCT01297062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB112|A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects|A Randomized, Phase 1, Three-Period, Placebo- and Positive-Controlled, Double-Blind, Crossover Study to Assess the Electrophysiological Effects of Exenatide at Therapeutic and Supratherapeutic Concentrations on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects||AstraZeneca|No|Completed|February 2011|May 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|94|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|February 9, 2011|No|Yes||No|April 27, 2012|https://clinicaltrials.gov/show/NCT01297062||108971|
NCT01297075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP00990002|Outreach Visits to Optimize Chronic Care Management in General Practice: A Cluster Randomized Trial|Outreach Visits to Optimize Chronic Care Management in General Practice: A Cluster Randomized Trial|Output|Research Unit Of General Practice, Copenhagen|No|Completed|March 2011|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|189|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||February 2011|May 22, 2014|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01297075||108970|
NCT01297972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP 16119|Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia|Bone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic Anemia||University of Sao Paulo|Yes|Completed|February 2011|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|No|||February 2014|February 2, 2014|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297972||108902|
NCT01298258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99NSC-REVAC|Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure|Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor||Taipei Veterans General Hospital, Taiwan|No|Recruiting|July 2010|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2010|February 16, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298258||108880|
NCT01298557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dana-REAC|MEG and DTI of Neural Function and Connectivity in Traumatic Brain Injury|Magnetoencephalography and High-Field Diffusion Tensor Magnetic Resonance Imaging of Neural Function and Connectivity in Traumatic Brain Injury|Dana-REAC|University of California, San Francisco|Yes|Completed|February 2007|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|69|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited through the neurosurgery clinic at San Francisco General        Hospital or referred to us by colleagues.|April 2013|April 29, 2013|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01298557||108859|
NCT01298206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD10-150 PANFLU|Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon|Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon||St. Jude Children's Research Hospital|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|129|Samples With DNA|Specimens collected from cases(ie positive for pandemic influenza by RT PCR) will be      processed in order to isolate and characterize the viruses causing infection.|Both|2 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cases will be selected from the outpatient clinics and inpatient units at American        Univeristy of Beirut thus the study team expect that selection bias would be minimal.        Confirmed cases attending other healthcare facilities for whom contact information is        available, will be contacted and invited to participate in this study. Controls will be        selected from the outpatient clinics and inpatient units of the Internal Medicine, Family        Medicine, and Pediatric and Adolescent Medicine Departments at AUBMC. Cases and controls        attending the hospital will be from the same catchment area, thus coming from the same        geographical areas, have similar socioeconomic status, and have similar chances of        exposure to influenza viruses. Other influenza case control studies have matched on sex        and enrolled hospital-based controls.|November 2013|November 20, 2013|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298206||108884|
NCT01298219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBD1033|Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)|A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction||Sucampo Pharma Americas, LLC|No|Completed|December 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|January 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298219||108883|
NCT01298232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-01-001C|One-year Outcomes of Electromechanical Activation Time (EMAT)-Guided vs. Symptom-guided Heart Failure Therapy in Acute Heart Failure Syndrome (AHFS) Patients|||Taipei Veterans General Hospital, Taiwan|No|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2011|February 16, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298232||108882|
NCT01298570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1029|Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer|Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|February 2011|February 2021|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|February 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01298570||108858|
NCT01308203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1608|Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease|Lipid Efficacy and Effects on HDL-C Metabolism of the Extended Release Niacin/Laropiprant Combination Added to Usual Therapy in Patients With Cardiovascular Disease and Low HDL-C That Did Not Achieve the Optional Very Low LDL-C Goal||Hospital Italiano de Buenos Aires|No|Terminated|October 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|75 Years|No|||August 2015|August 17, 2015|March 3, 2011||No|Merck has decided to discontinue all studies with extended-release niacin/laropiprant.because    the HPS2-THRIVE did not meet its primary endpoint|No||https://clinicaltrials.gov/show/NCT01308203||108121|
NCT01307917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A09-3502|Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes|Endothelial Dysfunction and the Role of Flavonoids in the Prevention of Nephropathy Among Pediatric Patients With Diabetes|flavonoid|Texas Tech University Health Sciences Center|No|Withdrawn|July 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|0|||Both|12 Years|21 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|November 15, 2010||No|No funding ever received|No||https://clinicaltrials.gov/show/NCT01307917||108143|
NCT01307930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-3616|Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations|Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers||Texas Tech University Health Sciences Center|No|Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307930||108142|
NCT01299493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1131 (201110005)|Systems Intervention to Promote Colorectal Cancer (CRC) Screening|Systems Intervention to Promote Colorectal Cancer Screening/ Program for the Elimination of Cancer Disparities||Washington University School of Medicine|No|Recruiting|June 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|18|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01299493||108787|
NCT01299792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP-001|Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction|Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Due to Spinal Cord Injury||Swiss Paraplegic Centre Nottwil|No|Completed|August 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|individuals with neurogenic bladder dysfunction due to spinal cord injury|November 2015|November 16, 2015|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01299792||108764|
NCT01309347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-1288 Study I|Evaluation of the Development of an Advanced, Conformable Prosthetic Socket, Study I|||Infoscitex Corporation|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|6|||Both|N/A|N/A|No|Non-Probability Sample|Study will be conducted at one prosthetic fabrication facility.|March 2012|March 1, 2012|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01309347||108034|
NCT01308788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGPS-prost-OAG|Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow|Examination of the Effect of Aqueous Suppressant Versus Aqueous Outflow Enhancing Glaucoma Medications on Ocular Perfusion Pressure and Blood Flow: A Mechanistic Study||Indiana University|No|Completed|March 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|35|||Both|30 Years|N/A|No|Non-Probability Sample|120 glacuoma patients|January 2014|January 23, 2014|March 2, 2011||No||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01308788||108077|Small number of subjects at final endpoint, participation number various by analysis and date
NCT01305603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH-USG-PNB-1|Ultrasound-guided Dual TAP Block: Magnetic Resonance (MR) Evaluation of the Distribution of Local Anesthetic|Dual TAP Block Characteristics - Evaluation of Local Anesthetic Distribution by MR Scanning||Bispebjerg Hospital|Yes|Completed|February 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 10, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01305603||108321|
NCT01296230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-067|Varicocelectomy: Can Sex-hormones Predict Improvements in Semen Quality?|Varicocelectomy: Can Sex-hormones Predict Improvements in Semen Quality?||Copenhagen University Hospital at Herlev|No|Terminated|February 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Male|18 Years|N/A|No|||February 2012|May 23, 2013|February 14, 2011||No|Failure to recruit participants|No||https://clinicaltrials.gov/show/NCT01296230||109035|
NCT01309308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 09/248|Sweeping the Membranes, Cervical Length and Duration of Labor|The Impact of Sweeping the Membranes on Cervical Length and Labor: A Randomized Clinical Trial||Baskent University|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||October 2011|October 3, 2011|March 4, 2011||No||No|March 18, 2011|https://clinicaltrials.gov/show/NCT01309308||108037|Patients who did not attend the second examination, patients who did not deliver in our clinic are excluded
NCT01306162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.112|Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects|Relative Bioavailability of a Single Dose of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Dronedarone Tablet) or in Combination With 400 mg Bid Dronedarone (Tablet) at Steady State in Healthy Male and Female Volunteers (an Open Label, Randomised, Four-sequence, Two Period Cross-over, Phase I Study)||Boehringer Ingelheim||Completed|February 2011|||May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|June 3, 2014|February 28, 2011||||No|May 23, 2012|https://clinicaltrials.gov/show/NCT01306162||108278|
NCT01306175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.40|Drug Interaction Study of Digoxin and BI 10773|Relative Bioavailability of a Single Oral Dose of Digoxin (0.5 mg) When Administered Alone or in Combination With Multiple Oral Doses of BI 10773 (25 mg qd) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two-way Crossover Study)||Boehringer Ingelheim||Completed|February 2011|||April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|February 28, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01306175||108277|
NCT01306136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300209|Pilot Study of Exposure Therapy for Posttraumatic Stress Disorder|Pilot Study of Exposure Therapy for the Treatment of Puerto Ricans With Posttraumatic Stress Disorder||University of Puerto Rico|No|Completed|November 2008|October 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||February 2011|February 28, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01306136||108280|
NCT01347164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5UR6PS001099|Evaluation of a New HIV Prevention Intervention for Black Bisexually-active Men|Development and Testing of HIV Prevention Interventions Targeting Black MSM/W|RISE|Public Health Management Corporation|No|Completed|December 2010|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|169|||Male|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 28, 2013|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347164||105167|
NCT01347957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IRB-231|Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia|||China Medical University Hospital|Yes|Recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347957||105106|
NCT01348451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2008-1|Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis|A Phase l, Open-label, First in Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis|ALS|Neuralstem Inc.|Yes|Active, not recruiting|January 2009|December 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|April 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01348451||105068|
NCT01348737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4080C00001|Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential||AstraZeneca||Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 5, 2012|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348737||105046|
NCT01307215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3436|TAP Block: Does Volume Make a Difference?|Lumbar Transversus Abdominal Plane (TAP) Block: Does Volume Make a Difference?||McMaster University|No|Completed|April 2011|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|31|||Female|18 Years|70 Years|No|||May 2011|April 23, 2013|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307215||108197|
NCT01297959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-101:PH3:2012:004|Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery|Phase 3 Study of the Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections Among Colorectal Surgery Patients (Triple IN Study-INhibition of INcisional INfections)|Triple IN|Excited States, LLC|Yes|Active, not recruiting|August 2012|June 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1350|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01297959||108903|
NCT01298245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201008023GB|Genetic Association of Diabetic Retinopathy-1|Genetic Association Studies of Diabetic Retinopathy (1): Vanguard Phase|DMR-1|Taipei Veterans General Hospital, Taiwan|No|Recruiting|February 2011|December 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples With DNA|The participants will receive fasting blood sampling for the measurements of glucose, HbA1c,      lipid profile, and biochemistry. An additional 10 ml blood sample will be taken for DNA      extraction from buffy coat. Early morning urine samples will also be collected for      evaluation of overt proteinuria by a dipstick method.|Both|20 Years|75 Years|No|Non-Probability Sample|Patients with DM who have received ophthalmic fundus examination within 6 months before        the study, either with or without diabetic retinopathy|December 2011|December 5, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01298245||108881|
NCT01298583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ankle tracking training|Ankle Tracking Training in Stroke|Ankle Tracking Training in Stroke||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|January 2007|December 2010|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|85 Years|No|||January 2012|January 9, 2012|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01298583||108857|
NCT01308801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00865-34|Repetitive Transcranial Magnetic Stimulation in Fibromyalgia|Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia|STIMALGI|University Hospital, Grenoble|No|Completed|April 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01308801||108076|
NCT01308190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAU-TEM-2009-01|Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer|Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer||Corporacion Parc Tauli|No|Recruiting|August 2010|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|173|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01308190||108122|
NCT01305343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scoli-Risk-1|Neurologic Complications in Spinal Deformity Surgery|Evaluation of Neurologic Complications Associated With Surgical Correction of Adult Spinal Deformity: A Prospective, Observational, Multi-center Study||AOSpine International|Yes|Completed|August 2011|March 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|273|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients receiving care at the investigative sites will be pre-screened as potential        subjects for this observational study study.|December 2015|December 23, 2015|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305343||108341|
NCT01305317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|statins and Immunoglobulins|Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients|Study of Statins' Effect on Serum IgG, IgA Ang IgM Level in Chronic Hemodialysis Patients||Hormozgan University of Medical Sciences|No|Completed|January 2007|January 2010|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|74|||Both|N/A|N/A|No|||January 2006|February 28, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01305317||108343|
NCT01305616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|975|Effect of Yellow-Tinted Intraocular Lens on Standard Automated Perimetry (SAP) and Short-wavelength Automated Perimetry (SWAP) in Patients With and Without Glaucoma|||Rassoul Akram Hospital|Yes|Completed|May 2008|January 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|34|||Both|40 Years|80 Years|No|||March 2008|March 25, 2011|February 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01305616||108320|
NCT01305304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 005/010 B|Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology|Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology||University Hospital Inselspital, Berne|No|Completed|January 2011|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|30|Samples Without DNA|serum, plasma|Male|40 Years|65 Years|No|Non-Probability Sample|residents of Switzerland, either with history of national competitive endurance running        (cases) or without history of endurance running (controls)|May 2013|May 14, 2013|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01305304||108344|
NCT01306448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vibrant-09-MS-CTIL|Safety Evaluation of the Vibrating Capsule|Safety Evaluation of the Vibrating Capsule in Aiding Reliving Constipated Individuals|Vibrant|Vibrant Ltd.|No|Completed|March 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01306448||108256|
NCT01347177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100298307|Clinical Trial of Zirconia and Metal Adhesive Bridges|A Single-centre Randomised Controlled Clinical Trial of Zirconia-based Versus Metal-based Adhesive Bridges for Replacing 2 Missing Teeth or Less in Adults.||Queen Mary University of London|No|Not yet recruiting|April 2012|April 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|176|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2011|February 8, 2012|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01347177||105166|
NCT01348763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRV_DRV_PK|The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study|A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects||Imperial College London|No|Completed|October 2011|May 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|65 Years|No|||December 2011|May 20, 2014|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01348763||105044|
NCT01348191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36261.060.11|Detection of Thyrotrophin Receptor in Human Myometrium|Detection of Thyrotrophin Receptor in Human Myometrium||Catharina Ziekenhuis Eindhoven|Yes|Completed|November 2011|January 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Biopsy of human myometrium|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women (n=10) with a term ( > 37 weeks) baby, who are scheduled for elective        caesarean section.|May 2013|May 23, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348191||105088|
NCT01297699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC-TCL-2010-01|Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)|Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.|GRC|Hospital Clinico Universitario de Santiago|No|Completed|March 2012|December 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01297699||108923|
NCT01297712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iScan study-1|Endoscopic Assessment of Polyp Histology|On-Site Endoscopic Prediction of Polyp Histology During Screening Colonoscopy||Universitätsklinikum Hamburg-Eppendorf|No|Terminated|September 2009|April 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1069|||Both|55 Years|N/A|No|||June 2015|June 1, 2015|February 14, 2011||No|enrollment terminated, analysis ongoing|No||https://clinicaltrials.gov/show/NCT01297712||108922|
NCT01307696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM|Self-Expanding Multi-Layered Partially Resorbable Lightweight Polypropylene Mesh Device (Proceed Ventral Patch® Or Pvp®) For The Treatment of Small and Medium Umbilical Ventral Hernias|Multicenter Prospective Clinical Registry To Evaluate The Safety And Efficacy Of A Self-Expanding Multi-Layered Partially Resorbable Absorbable Lightweight Polypropylene Mesh Device (Proceed Ventral Patch® Or Pvp®) For The Treatment Of Small And Medium Umbilical Ventral Hernias||Algemeen Ziekenhuis Maria Middelares|No|Completed|August 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients that were treated at the participating centres with a PVP™ for the repair of        an umbilical hernia or another abdominal wall hernia before February 2011, are eligible        for the trial.|April 2014|April 25, 2014|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01307696||108160|
NCT01307709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0032|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2011|||||N/A|N/A|N/A||||||||||||||April 25, 2012|March 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01307709||108159|
NCT01307202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-215-TKR|Morphine Consumption in Joint Replacement Patients, With or Without Gabapentin Treatment|Multiple Doses of Gabapentin and Postoperative Morphine Consumption in Total Knee Arthroplasty||McMaster University|No|Completed|October 2007|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|19 Years|90 Years|No|||November 2014|November 19, 2014|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307202||108198|
NCT01307423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSA-005|Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs|PALACE4|Celgene|No|Active, not recruiting|December 2010|June 2017|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|529|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|November 29, 2010|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01307423||108181|
NCT01307436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA 004 FU|Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines|A Phase III Randomised, Open, Controlled Study to Assess the Safety and Immunogenicity of Concomitant Administration of Virosomal Hepatitis A Vaccine (Epaxal®) With DTPaHibIPV, OPV and MMR Vaccines vs. Non-concomitant Administration in 12-15 Month Old Children. Follow-up: Serological Long-term Follow-up of Subjects for up to 42 Months, 5.5 and 7.5 Years After the Second Dose.||Crucell Holland BV|No|Completed|March 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|327|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||August 2013|July 28, 2014|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01307436||108180|
NCT01307670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109438|Comparison of Nailing, Plate Fixation and Non-operative Treatment of Midshaft Clavicle Fractures|Comparison of Intramedullary Nailing, Plate Fixation and Non-operative Treatment of Acute, Displaced, Midshaft Clavicle Fractures: a Prospective Randomized Trial||University of Missouri-Columbia|No|Withdrawn|April 2008|March 2010|Anticipated|March 2010|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|16 Years|80 Years|No|||May 2015|May 27, 2015|December 2, 2008||No|duplicate entry|No||https://clinicaltrials.gov/show/NCT01307670||108162|
NCT01308541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2083-A001-006|A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion|A Randomized, Open-label, 3 Period Crossover Study to Characterize the Pharmacokinetics and Pharmacodynamics of LUSEDRA (Fospropofol Disodium) Injection Administered Either by Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion||Eisai Inc.||Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01308541||108096|
NCT01308554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP1|Pain Relieving Efficacy of TAP Block in Patients After Laparoscopic Gastric Bypass.|Analgesic Efficacy of Ultrasound-guided Single Shot Subcostal Transversus Abdominis Plane (TAP) Block After Laparoscopic Gastric Bypass.||Funch-Jensen, Peter, M.D., D.M.Sc.|No|Completed|February 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|65 Years|No|||March 2014|March 25, 2014|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01308554||108095|
NCT01308814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0542|Perimenopausal Estrogen Replacement Therapy Study|Depression, Estrogen Replacement, and Cardiovascular Health in the Perimenopause|PERT|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|October 2010|February 2016|Anticipated|February 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|382|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||March 2015|August 31, 2015|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01308814||108075|
NCT01309048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02082011|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - A Pilot Study||Philips Healthcare|No|Completed|January 2011|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01309048||108057|
NCT01349140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPAREL Dose-Response|EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks|EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks: A Pharmacodynamics Investigation in Healthy Volunteers||University of California, San Diego|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 7, 2012|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349140||105016|
NCT01348594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0288-E|The Impact of Vitamin D Status on in Vitro Fertilization (IVF) Outcomes|The Impact of Vitamin D on Implantation and Clinical Pregnancy Rates Following in Vitro Fertilization||University of Toronto|No|Completed|April 2011|June 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|182|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing IVF at Mount Sinai Hospital|June 2012|June 18, 2012|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348594||105057|
NCT01348854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTO-103-ISAK|Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser System|A Multi-Center Prospective Study to Evaluate the Safety and Effectiveness of Arcuate Incisions Performed With the IntraLase iFS Femtosecond Laser System||Abbott Medical Optics|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 6, 2014|May 4, 2011||No||No|January 31, 2014|https://clinicaltrials.gov/show/NCT01348854||105038|BSCVA determination in eyes with progressing cataracts was sometimes unevaluable, although data are shown as reported.The number of eyes in "Post Cataract Surgery with Astigmatism" Arm was small, limiting data analysis.
NCT01349426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008067|Ligasure II: Standard Stapling Versus Ligasure|Standard Stapling Technique Versus Bipolar Fusion (With The Ligasure Impact and Force Triad Generator) To Complete The Fissure During Major Lung Resection: A Prospective Randomized Controlled Trial||Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|September 2010|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|172|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|May 4, 2011||No|diffculty to include patients|No||https://clinicaltrials.gov/show/NCT01349426||104994|
NCT01349127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cork Vitamin D 06/RD/C/533|Trial to Assess Vitamin D Requirements in Lactating Women|Randomised Placebo-controlled Supplementation Study With Vitamin D and Calcium in Breastfeeding Mothers|DMUMs|University College Cork|Yes|Completed|August 2008|December 2009|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|136|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|May 5, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01349127||105017|
NCT01345526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-VITA|Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream|A Double Blind Placebo Controlled Randomized Phase II Study Evaluating the Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream in First Line mCRC Patients Treated With Erbitux and FOLFIRI.||Universitätsmedizin Mannheim|No|Recruiting|April 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||April 2011|April 28, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01345526||105292|
NCT01345799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170CDT01|A Study of TRK-170 for the Treatment of Crohn's Disease|A Two Part, Multi-Centre, Randomized, Placebo-Controlled, Double-Blind Study of TRK-170 for the Treatment of Crohn's Disease||Toray Industries, Inc|No|Completed|April 2011|April 2014|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|123|||Both|18 Years|50 Years|No|||June 2014|June 11, 2014|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345799||105271|
NCT01346007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKU 7049687|Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome|Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome||National and Kapodistrian University of Athens|No|Active, not recruiting|January 2009|June 2011|Anticipated|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|2 Years|20 Years|Accepts Healthy Volunteers|||January 2009|April 29, 2011|April 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346007||105256|
NCT01346228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28199|Using Smart Phone Technology To Rural Veterans|USING SMART PHONE TECHNOLOGY AS A PLATFORM FOR DELIVERING MENTAL HEALTH CARE TO RURAL VETERANS||Michael Debakey Veterans Affairs Medical Center|No|Not yet recruiting|April 2011|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2011|April 29, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346228||105239|
NCT01346241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28272|Improving Access To Services to Community Based Outpatient Clinics (CBOC's)|Improving Access To Services With An Intensive Two-Day Treatment For Panic||Michael Debakey Veterans Affairs Medical Center|No|Recruiting|April 2011|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 29, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346241||105238|
NCT01338090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091104|89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors|89Zr-bevacizumab PET Imaging as Predictive Biomarker for Everolimus Efficacy in Patients With Neuroendocrine Tumors|NETPET|University Medical Center Groningen|Yes|Completed|April 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|80 Years|No|Probability Sample|Patients with metastatic neuroendocrine tumors.|August 2011|April 2, 2012|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01338090||105852|
NCT01342835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCK-55|Postoperative Analgesia in Children After Propofol Anesthesia|Postoperative Analgesia in Children After Propofol Anesthesia|propan|University Clinical Centre of Kosova|Yes|Recruiting|September 2010|July 2011|Anticipated|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||September 2010|April 26, 2011|April 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01342835||105497|
NCT01343173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/25|Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib|Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib|STIM 2|University Hospital, Bordeaux|Yes|Active, not recruiting|April 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01343173||105471|
NCT01349322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1005|Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery|A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|May 2011|||August 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2312|||Female|18 Years|N/A|No|||November 2015|November 14, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349322||105002|
NCT01345435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smartcare-DM|Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care|A Multi-center, Randomized, Parallel, Interventional, Open Label Trial to Compare Hemoglobin A1C-lowering Effect of Conventional Treatment and Smart Care Service in Patients With Type 2 Diabetes|Smart-DM|LG Electronics Inc.|Yes|Completed|January 2011|December 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|417|||Both|20 Years|60 Years|No|||May 2015|May 12, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345435||105299|
NCT01345708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT 2008-006713-25|A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia|A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Completed|January 2009|January 2011|Actual|January 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2011|April 29, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345708||105278|
NCT01345916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1009-PR-0050|Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients|A Phase 3,8-week Clinical Trial to Test the Efficacy of CHF1535 Via NEXT DPI® Versus Same Dose of CHF1535 pMDI and Beclomethasone DPI 100µg on PEF in Adult Asthmatic Patients After 1 Month of Treatment With FOSTER®|Neptune|Chiesi Farmaceutici S.p.A.|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|932|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01345916||105262|
NCT01346722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008046|Zinc Absorption From Zinc Biofortified Rice|Absorption of Zinc From Mixed Diets Containing Conventional Bangladeshi Rice, Zinc-biofortified Bangladeshi Rice, or Conventional Bangladeshi Rice With Added Zinc Among Young Children in a Peri-urban Community.||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|October 2009|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|42|||Both|36 Months|59 Months|Accepts Healthy Volunteers|||May 2011|May 2, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01346722||105201|
NCT01346735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCCM1|Multi-center Observational Study to Evaluate Epidemiology and Resistance Patterns of Common ICU-Infections (MOSER)|Multi-center Observational Study to Evaluate Epidemiology and Resistance Patterns of Common ICU-Infections (MOSER)|MOSER|Indian Society of Critical Care Medicine|Yes|Not yet recruiting|June 2011|December 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|70 Years|No|Non-Probability Sample|Adult ICU patients|May 2011|May 2, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346735||105200|
NCT01347242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTG002.07|Gene Therapy for Wiskott-Aldrich Syndrome (WAS)|Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome||Genethon|Yes|Recruiting|March 2011|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Male|N/A|N/A|No|||November 2014|November 24, 2014|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347242||105161|
NCT01347255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 90100-01|A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris|A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris||LEO Pharma|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|4||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 3, 2011||No||No|November 13, 2015|https://clinicaltrials.gov/show/NCT01347255||105160|
NCT01347801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS:H-3-2009-108|Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1|Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1||Rigshospitalet, Denmark|No|Completed|March 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|9||Actual|40|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347801||105118|
NCT01348880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15345|Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study|A Double-Blind Study to Evaluate the Pharmacodynamic Interaction Between 10 mg Vardenafil ODT (Orally Disintegrating Tablet) and Procardia XL® (Nifedipine GITS) in Elderly Male Patients With Both Hypertension and Erectile Dysfunction||Bayer|Yes|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|42|||Male|65 Years|80 Years|No|||May 2014|May 16, 2014|May 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01348880||105036|
NCT01348893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P002600A|Evaluation of a Yoga Program in Schools|Evaluation of Yoga During School as a Behavioral Prevention Program for Adolescent Health||Brigham and Women's Hospital|No|Active, not recruiting|August 2008|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1800|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|April 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01348893||105035|
NCT01349413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD|BRAVO Study for Functional Dyspepsia|Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia|BD|Chinese University of Hong Kong||Recruiting|August 2011|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|130|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349413||104995|
NCT01349439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-44|Reducing Reconsolidation of Trauma Memories With Propranolol|Reduction of the Reconsolidation of the Trauma Memory With Propranolol||Douglas Mental Health University Institute|No|Recruiting|March 2011|||January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|76|||Both|18 Years|65 Years|No|||June 2014|June 23, 2014|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01349439||104993|
NCT01349452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAN2011|Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis|Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis||Federal University of São Paulo|No|Completed|August 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||April 2011|May 5, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01349452||104992|
NCT01345786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06328|Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)|A 2-part, Cross-over Trial of NOMAC-E2 to Assess Bioequivalence Between the Phase 3 Pivotal Clinical Batches and a Batch Prepared Using the Commercial Drug Manufacturing Process||Merck Sharp & Dohme Corp.|Yes|Completed|November 2009|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|158|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 26, 2015|April 29, 2011|No|Yes||No|July 28, 2011|https://clinicaltrials.gov/show/NCT01345786||105272|
NCT01345539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-027|Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation|Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation (UPCI #10-027)||University of Pittsburgh|Yes|Recruiting|June 2011|February 2024|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|February 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345539||105291|
NCT01345812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090169|Time-lapse Evaluation of Embryo Development After Stimulation With One of Two Different Gonadotrophins.|Time-lapse Assessed Evaluation of Embryo Development After Stimulation With Either Recombinant Follicle Stimulating Hormone (FSH) or Urine-derived Follicle Stimulating Hormone (FSH).||University of Aarhus|No|Terminated|April 2011|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|291|||Both|21 Years|45 Years|No|||September 2012|September 13, 2012|April 29, 2011||No|Lack of patients for recruitment|No||https://clinicaltrials.gov/show/NCT01345812||105270|
NCT01346020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53270|Genomic Analysis of Patients With Chronic Lymphocytic Leukemia|Genomic Analysis of Patients With Chronic Lymphocytic Leukemia||Universitaire Ziekenhuizen Leuven||Active, not recruiting|April 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|53|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic lymphocytic leukemia|April 2011|April 29, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01346020||105255|
NCT01346033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2714|Evaluation of SCOUT DS in Subjects With Type 2 Diabetes|An Evaluation of a Non-invasive Diabetes Screening Device in Subjects With Type 2 Diabetes|TCOYD|VeraLight, Inc.|No|Completed|October 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|270|||Both|18 Years|N/A|No|Non-Probability Sample|Attendees of the Taking Control of Your Diabetes Health Fair, San Diego CA Convention        Center|December 2012|December 3, 2012|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346033||105254|
NCT01337856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHG DSRB B/07/310|Efficacy of Alcohol Hand-rubbing Covering All Hand Surfaces in Reducing Bacterial Hand Contamination of Healthcare Staff|Efficacy of Alcohol Hand-rubbing Covering All Hand Surfaces in Reducing Bacterial Hand Contamination of Healthcare Staff|B/07/310|Tan Tock Seng Hospital|Yes|Completed|October 2007|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2011|April 18, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01337856||105869|
NCT01338103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5474|Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex|Treatment of Moderate to Severe Patients With Pemphigus With the Monoclonal Anti CD20 Antibody Rituximab at a Protocol of 1000mgX2 and Assessment of Their Immune Status Via the Cylex Test||Rabin Medical Center|Yes|Recruiting|January 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||March 2011|April 29, 2011|April 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01338103||105851|
NCT01338116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6036|Optimal Antibiotic Treatment of Moderate to Severe Bacterial Infections|Optimal Antibiotic Treatment of Moderate to Severe Bacterial Infections: Integration of PCR Technology and Medical Informatics/Artificial Intelligence|CDSS|Rabin Medical Center|Yes|Not yet recruiting|January 2015|January 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01338116||105850|
NCT01339338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taizhou200935|Warming Contrast Media for Hysterosalpingography|Comparison of the Warm and Cold Contrast Media for Hysterosalpingography: a Prospective, Randomized Study||Taizhou Hospital|Yes|Recruiting|January 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|300|||Female|16 Years|40 Years|No|||April 2011|April 19, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01339338||105766|
NCT01339624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASAL FENTANYL-01|Nasal Fentanyl And Renal Colic|||Valduce Hospital||Completed|January 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|65 Years|No|||September 2009|April 19, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01339624||105744|
NCT01339637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2718|Evaluation of Low Source of Signal in SCOUT DS|Evaluation of Low Source of Signal in SCOUT DS|LSS|VeraLight, Inc.|No|Completed|April 2011|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|196|||Both|18 Years|N/A|No|Non-Probability Sample|Community sample|December 2012|December 3, 2012|April 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339637||105743|
NCT01346176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810894|The Influence of Default Options in Advance Directives|The Influence of Default Options in Advance Directives for Older Patients: A Pilot Study||University of Pennsylvania|Yes|Completed|April 2010|August 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|132|||Both|50 Years|N/A|No|||January 2016|January 4, 2016|April 29, 2011||No||No|December 21, 2012|https://clinicaltrials.gov/show/NCT01346176||105243|This is a small sample from a single health systemLimited to patients with serious thoracic diseasesWe did not randomly assign the ordering of options within the standard advance directive
NCT01346423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150160|Interdisciplinary Intervention Versus Brief Intervention for Patients With Musculoskeletal Pain|Is Interdisciplinary Intervention for Patients Sicklisted With Musculoskeletal Pain More Effective in Helping Patients Back to Work Than Than The Less Resource Demanding Brief Intervention Method?||Sykehuset Innlandet HF|Yes|Active, not recruiting|March 2011|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|60 Years|No|||March 2011|October 23, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01346423||105224|
NCT01346709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERISCOPE|Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe|Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe: Predicting Postoperative Pulmonary Complications in Europe: a 7-day Data Collection, Prospective, Observational Study|PERISCOPE|European Society of Anaesthesiology|No|Completed|May 2011|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5183|||Both|18 Years|N/A|No|Probability Sample|In-patient adult non-obstetric surgery|March 2014|March 4, 2014|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01346709||105202|
NCT01347281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-23/03-intern-6470|PET With [18F]HX4 in Head and Neck Cancer|Non Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET) in Head and Neck Cancer.||Maastricht Radiation Oncology|Yes|Completed|December 2011|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|100 Years|No|||October 2015|October 21, 2015|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347281||105158|
NCT01346982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILIDAR|Drug Interactions Between Silimarine and Darunavir/Ritonavir|Drug Interactions Between Silimarine And Darunavir/Ritonavir||Fundacio Lluita Contra la SIDA|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01346982||105181|
NCT01346995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072.07|The Effect of Experimental Knee Pain During Strengthening Exercises on Muscle Strength Gain|The Effect of Experimental Knee Pain During Strengthening Exercises on Muscle Strength Gain||Frederiksberg University Hospital|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||February 2010|May 3, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346995||105180|
NCT01348607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0803|Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy|A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy||University of South Florida|Yes|Terminated|July 2010|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|1|||Both|8 Years|18 Years|No|||January 2014|January 23, 2014|May 4, 2011|Yes|Yes|Study only randomized 1 subject and was determined not feasible by DSMB|No|July 5, 2013|https://clinicaltrials.gov/show/NCT01348607||105056|This study was closed prior to completion due to a lack of feasibility and low accrual by the Data Monitoring and Safety Board (DSMB).
NCT01348620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNT-2011|Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy: Impact on Postoperative Pain|||Sacro Cuore Don Calabria General Hospital|Yes|Recruiting|March 2011|||January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|75 Years|No|||May 2011|May 4, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01348620||105055|
NCT01348633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORF1|Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye|Phase 1. Validation and Calibration Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye||University of Toronto|No|Recruiting|March 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|275|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Flyers advertising the study will be posted on noticeboards within Toronto Western        Hospital. The cohorts will be selected from the respondents to the flyer. Clincians in the        Ophthalomology department in the Toronto Western Hopital will also offer the study to        patients whom they consider to be potential participants.|January 2013|January 16, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348633||105054|
NCT01348646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08017|Adult Follow-up of Preventive Study With Brief Smoking Intervention for Adolescents||TuNAMI|Tampere University Hospital||Completed|May 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2582|||Both|12 Years|29 Years|No|||May 2011|May 31, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348646||105053|
NCT01348659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09246M|Effects of Hypertonic Saline-HES Solution on Extracellular Water in Cardiac Surgery Patients|Effects of Hypertonic Saline-hydroxyethyl Starch Solution on Extracellular Water in Cardiac Surgery Patients||Tampere University Hospital|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|N/A|No|||May 2012|May 4, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01348659||105052|
NCT01349153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2150|Facebook-based Physical Activity Intervention for Young Adult Cancer Survivors: the FITNET Randomized Pilot Study|Facebook-based Physical Activity Intervention for Young Adult Cancer Survivors: the FITNET Randomized Pilot Study|FITNET|University of North Carolina, Chapel Hill|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|97|||Both|21 Years|39 Years|No|||December 2011|December 12, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01349153||105015|
NCT01345552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-028|Radiosurgery for Patients Recurrent Oligometastatic Disease|Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease (UPCI# 10-028)||University of Pittsburgh|Yes|Recruiting|June 2011|February 2024|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|February 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345552||105290|
NCT01345565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09020051|Hepatocyte Transplantation for Acute Decompensated Liver Failure|Hepatocyte Transplantation for Acute Decompensated Liver Failure||University of Pittsburgh|Yes|Recruiting|March 2011|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|21 Years|No|||September 2014|September 24, 2014|April 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01345565||105289|
NCT01345825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100185|Early Progressive Strength Training to Patients With Unicompartmental Knee Replacement|A Randomized Controlled Trial: The Effectiveness of 8-weeks Progressive Strength Training to Patients With Unicompartmental Knee Replacement, Initiated Within the First Postoperative Week||University of Aarhus|Yes|Completed|March 2011|July 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01345825||105269|
NCT01346046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2717|Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2|An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at the TCOYD Diabetes Conference|TCOYD2|VeraLight, Inc.|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|264|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Attendees of the Taking Control of Your Diabetes Health Fair, Albuquerque Convention        Center|December 2012|December 3, 2012|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346046||105253|
NCT01342562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0513|The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly|||Yonsei University|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|54|||Male|65 Years|85 Years|No|||March 2013|March 4, 2013|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01342562||105518|
NCT01342575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-11-02|Improvement of Trans-operatory X-ray Visualization During Anterior Cervical Surgery|Improvement of Trans-operatory X-ray Visualization During Anterior Cervical Surgery. Comparison of the Podalic Compression and Shoulder Traction Maneuvers||American British Cowdray Medical Center|No|Recruiting|December 2010|August 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|18 Years|70 Years|No|||March 2012|March 16, 2012|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01342575||105517|
NCT01342822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSI-01|Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization|A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization in a Population of Unrestricted Patients|PLATINUM+|European Cardiovascular Research Center|Yes|Active, not recruiting|October 2010|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|2980|||Both|18 Years|N/A|No|Non-Probability Sample|All comers, in the indications reimbursed in the participating countries|March 2012|March 12, 2012|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342822||105498|
NCT01340274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling|Evaluating the Benefits of the Community Reinforcement and Family Training(CRAFT) Approach to Concerned Significant Others(CSO) of Individuals Engaged in Problem Gambling (IPGs)||Colchester East Hants Health Authority|No|Not yet recruiting|April 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 21, 2011|February 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01340274||105694|
NCT01340287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU281|Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols|Effects of the Consumption of a Plant Sterols-enriched Dairy Fermented Product on Hypercholesterolemia Management in Hypercholesterolemic Adults||Danone Research|No|Completed|July 2008|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Basic Science|2||||||Both|21 Years|75 Years|Accepts Healthy Volunteers|||April 2011|April 21, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340287||105693|
NCT01345942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP25583|A Study on the Effect of Food on the Pharmacokinetics of RO5428029 in Healthy Volunteers|A Randomized, Open Label, Single Dose, Two Period, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of RO5428029 Following Oral Administration in Healthy Subjects||Hoffmann-La Roche||Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345942||105260|
NCT01346189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812701|A Trial of Behavioral Economic Interventions to Reduce Cardiovascular Disease (CVD) Risk|A Randomized Trial of Behavioral Economic Interventions to Reduce CVD Risk||University of Pennsylvania|Yes|Completed|September 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1503|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 8, 2014|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01346189||105242|
NCT01346436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-11-047|Value of Robotic Rectopexy for the Treatment of Complex Pelvic Floor Dysfunction|Randomized Double Blind Controlled Trial of the Value of Robotic Rectopexy for the Treatment of Complex Pelvic Floor Dysfunction||University Hospital, Geneva|No|Recruiting|April 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346436||105223|
NCT01346449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812950|Making Calories Count: Information Format and Food Choice|Making Calories Count: Information Format and Food Choice||University of Pennsylvania|No|Recruiting|January 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2012|October 16, 2012|January 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01346449||105222|
NCT01347541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40069-C|Piloting Acute Care to Primary Care Linkage of Safety Net Patients|Piloting Acute Care to Primary Care Linkage of Safety Net Patients|TSOS III|University of Washington|No|Active, not recruiting|May 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|April 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347541||105138|
NCT01347814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DompGastEmpt|Effect of 10mg Domperidone on Gastric Emptying of a High-fat Meal and Appetite Sensations in Healthy Adults|Does Domperidone, a D2-antagonist Alter Gastric Emptying Rates and Appetite Sensations in Healthy Adults?||University of Limerick|No|Completed|February 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|13|||Both|10 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 3, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347814||105117|
NCT01347528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVT MP 002|Improving MEDication Adherence in Chronic Heart Failure Using a TELEmedicine Device (TELEMED-HF)|A Randomized, Controlled Trial Using a TELEmedicine Solution to Improve MEDication Adherence in Chronic Heart Failure (TELEMED-HF)|TELEMED-HF|University of Tilburg|Yes|Withdrawn|October 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|50 Years|N/A|No|||December 2015|December 1, 2015|April 29, 2011||No|logistic and financial accounting reasons|No||https://clinicaltrials.gov/show/NCT01347528||105139|
NCT01348308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022293-14|Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients|Optimized Phase III Trial of Immuno-stimulation With Maraviroc, a CCR5 (Chemokine Receptor 5) Antagonist, Combined With Anti Retroviral Therapy in Advanced, Late Diagnosed HIV-1 Infected Patients With an AIDS-defining Event and/or CD4 (Cluster of Differentiation 4) Counts Below 200 Cells/mm³. ANRS 146 OPTIMAL|OPTIMAL|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|September 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|407|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01348308||105079|
NCT01348321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acne and levamisole|Comparison of Efficacy of Azithromycin and Levamisole Versus of Azithromycin in in the Treatment of Acne|Superior Efficacy of Azithromycin and Levamisole Versus of Azithromycin Alone in the Treatment of Inflammatory Acne Vulgaris: An Investigator Blind Randomized Clinical Trial on 169 Patients||Ahvaz Jundishapur University of Medical Sciences|Yes|Completed|November 2008|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2008|May 4, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01348321||105078|
NCT01348100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO522E2101|Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients|An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days||Novartis||Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|81|||Both|18 Years|65 Years|No|||December 2013|December 17, 2013|April 28, 2011|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01348100||105095|
NCT01348360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2010-02|Evaluation of Effectiveness and Safety of NOBORI Stent|Evaluation of Effectiveness and Safety of NOBORI Stent in Routine Clinical Practice; A Multicenter, Prospective, Observational Study|IRIS-NOBORI|CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|May 2010|April 2020|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with coronary artery disease requiring drug eluting stents|November 2015|November 10, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348360||105075|
NCT01348906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCPB|Intermittent Normoxia Reduces Myocardial Reperfusion Injury|Effect of Intermittent Normoxic Cardiopulmonary Bypass on Myocardial Reperfusion Injury in Adult Valve Replacement|INCPB|Central South University|Yes|Recruiting|May 2011|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Both|25 Years|65 Years|No|||May 2011|May 5, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348906||105034|
NCT01345591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09060101|A Study to Evaluate the Results of Facial Soft Tissue Reconstruction in Patients Who Have Suffered Traumatic Injury|Structural Fat Grafting for Craniofacial Trauma|BTI|University of Pittsburgh|Yes|Completed|September 2009|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01345591||105287|
NCT01345578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09040497|Hepatocyte Transplantation for Liver Based Metabolic Disorders|Hepatocyte Transplantation for Liver Based Metabolic Disorders||University of Pittsburgh|Yes|Recruiting|March 2011|February 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|21 Years|No|||December 2015|December 1, 2015|April 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01345578||105288|
NCT01347632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11115|Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue|Prospective Evaluation of the Impact of Bacterial Vaginosis and Its Treatment on Mucosal Susceptibility to HIV-1 Infection and Endpoints of Cervico-Vaginal Safety|CONRADBV|CONRAD|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|April 15, 2011||No||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01347632||105131|There were no serious adverse events related to product or procedures.
NCT01348386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC08/00011|Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum|Efficacy and Tolerance of the Topical Application of Potassium Hydroxide (10% and 15%) in the Treatment of Molluscum Contagiosum|EKOH-MOL 2008|Jordi Gol i Gurina Foundation||Completed|March 2010|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|53|||Both|2 Years|6 Years|No|||May 2011|September 30, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348386||105073|
NCT01339078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/255|Trial Comparing Kaffes Stent With Plastic Prosthesis in the Treatment of Anastomotic Biliary Strictures Post Orthotopic Liver Transplantation|Randomized Controlled Trial Comparing Kaffes Stent With Plastic Prosthesis in the Treatment of Anastomotic Biliary Strictures Post Orthotopic Liver Transplantation||University Hospital, Ghent|No|Recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01339078||105786|
NCT01339091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUR001-301|Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections||Durata Therapeutics Inc., an affiliate of Allergan plc|No|Completed|March 2011|November 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|573|||Both|18 Years|85 Years|No|||December 2013|December 26, 2013|April 18, 2011|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01339091||105785|
NCT01336517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E59007|Evaluation of the Effect of an Ankle Foot Orthoses for Ambulatory Function|Comprehensive Evaluations of the Effect of an Ankle Foot Orthoses for Ambulatory Function in Adults With Hemiplegia||Kessler Foundation|No|Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|75 Years|No|Non-Probability Sample|Participants with a history of hemiplegia secondary to stroke, between the ages of 18 and        75, who are greater than 6 months post and have been prescribed a custom molded AFO for        assistance with gait deviations|April 2011|April 14, 2011|October 2, 2009||No||No||https://clinicaltrials.gov/show/NCT01336517||105971|
NCT01339897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N6022-1H1-03|A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of N6022 in Healthy Subjects||Nivalis Therapeutics, Inc.|Yes|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|April 19, 2011|Yes|Yes||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01339897||105723|
NCT01339910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0901|Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)|A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)||Medical College of Wisconsin|Yes|Terminated|May 2011|November 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|272|||Both|18 Years|65 Years|No|||January 2016|January 7, 2016|April 20, 2011|Yes|Yes|Accrual terminated as recommended by the data and safety monitoring board.|No||https://clinicaltrials.gov/show/NCT01339910||105722|
NCT01345968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM10_0027|Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery|Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients With Orthopedic Surgery and High Risk of Blood Loss|PRIVIRON|University Hospital Muenster|No|Terminated|June 2011|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2013|August 7, 2013|April 21, 2011||No|Less patients than expected for inclusion, therefore recruitment is too low|No||https://clinicaltrials.gov/show/NCT01345968||105259|
NCT01346202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-BR-28/10-1|Effects of Multimodal Pain Therapy in Patients With Mixed Chronic Pain Syndromes|Influence of a Multimodal Day-unit Pain Therapy on Pain Experience, Pain-related Disability and Depression in Patients With Chronic Pain Syndromes|IMPERApain|Klinikum St. Georg gGmbH|No|Completed|January 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|260|||Both|18 Years|65 Years|No|Probability Sample|260 consecutive patients with chronic pain syndromes|July 2013|July 12, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01346202||105241|
NCT01346462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 813426|IMPaCT (Individualized Management Towards Patient-Centered Targets)|A Randomized Controlled Trial of a Novel Community Health Worker Care Transitions Intervention.|PaCT|University of Pennsylvania|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|513|||Both|18 Years|65 Years|No|||April 2014|April 30, 2014|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346462||105221|
NCT01346748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1268/09|The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage|The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage||University of Sao Paulo General Hospital|Yes|Recruiting|April 2011|February 2013|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|80|||Both|18 Years|65 Years|No|||April 2011|May 2, 2011|April 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346748||105199|
NCT01347008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2011/00012-3|Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis|Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial||Federal University of São Paulo|No|Recruiting|April 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||April 2011|May 3, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347008||105179|
NCT01347827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TO-CABG|Tissue Oxygenation During Heart Surgery|Comparison of Cerebral Tissue Oxygen Desaturation in Patients Undergoing On-pump or Off-pump Coronary Artery Bypass Grafting||University Medical Center Groningen|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|60 consecutive adult patients scheduled for elective CABG surgery will be randomized to        have the surgery performed either on-pump (n=30) or off-pump CABG (n=30).|January 2013|January 9, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01347827||105116|
NCT01347840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10-0004|Metabolic Factors of Outcomes From Gastric Bypass Surgery|Metabolic Factors of Outcomes From Gastric Bypass Surgery|Cassini|Ethicon Endo-Surgery|No|Terminated|April 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects having gastric bypass (GB) surgery within 4 months of screening visit.|April 2012|April 19, 2012|May 3, 2011||No|Study was terminated for business reasons.|No|April 19, 2012|https://clinicaltrials.gov/show/NCT01347840||105115|Trial termination due to business needs. One subject enrolled and withdrew consent. Zero subjects completed study. No subject data analyzed.
NCT01348048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DanPaCT2011|A Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction|Danish Palliative Care Trial (DanPaCT): A Randomised Clinical Multi-centre Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction in Patients With Cancer Reporting Palliative Needs|DanPaCT|Bispebjerg Hospital|No|Completed|May 2011|October 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|306|||Both|18 Years|N/A|No|||February 2015|March 2, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01348048||105099|
NCT01348295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN2010|Pediatric Ventilatory Care in Finland 2010|Pediatric Ventilatory Care in Finland 2010||University of Oulu|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|210|||Both|N/A|16 Years|No|Non-Probability Sample|All children under 16 years needing mechanical ventilation in Finland from 13th of        September 2010 to 19th of December 2010.|May 2011|May 4, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348295||105080|
NCT01348074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGH20090520|Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist|Phase II Study of Double Versus Single Reinitiation Dose of Warfarin After Interruption for Surgery|DOSIDO|McMaster University|No|Completed|April 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|N/A|N/A|No|||January 2014|January 14, 2014|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348074||105097|
NCT01347359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-2011|Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentoring Program|Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentoring Program|P2P EIA RCT|Sunnybrook Health Sciences Centre|No|Recruiting|May 2011|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347359||105152|
NCT01347593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ceftizoxime cesarean|Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery|Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery in Soba Hospital Sudan||University of Khartoum|Yes|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|220|||Female|14 Years|45 Years|No|||January 2013|January 16, 2013|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347593||105134|
NCT01348932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-008|The Relationship Between Single Nucleotide Polymorphisms of Chitinase 3-like 1 Gene,YKL-40 Serum Levels and Adult Asthma|The Relationship Between Single Nucleotide Polymorphisms of Chitinase 3-like 1 Gene,YKL-40 Serum Levels and Adult Asthma|CHI3L1|China Medical University Hospital|Yes|Recruiting|May 2011|December 2013|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1|Samples With DNA|The objective of this study was to investigate the relationship between single nucleotide      polymorphism of chitinase 3-like 1 and human asthma. The association between CHI3L1 SNPs and      the continuous outcomes were examined by real time PCR and gene sequencing analysis.|Both|20 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Taiwan|May 2011|May 5, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348932||105032|
NCT01349192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-too-10K0|Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)|Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)|STAR-Too|University of North Carolina, Chapel Hill|Yes|Completed|April 2011|December 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|4 Years|45 Years|No|||February 2016|February 10, 2016|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349192||105012|
NCT01346306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11036|Trial of Transcranial Direct Current Stimulation (tDCS)|Investigating Direct Current Stimulation as a Treatment for Depression: A Controlled Clinical Trial||The University of New South Wales|Yes|Recruiting|April 2011|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|90 Years|No|||May 2015|May 27, 2015|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01346306||105233|
NCT01346072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOLCOPEP11|Pilot Study of Using Copeptin to Predict Response to Tolvaptan|Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure||University of North Carolina, Chapel Hill|No|Completed|April 2011|December 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|April 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01346072||105251|
NCT01346839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24978|Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care|Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care||Baylor College of Medicine|No|Completed|February 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|1256|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|February 23, 2011||No||No|August 24, 2015|https://clinicaltrials.gov/show/NCT01346839||105192|
NCT01347112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008559|Varenicline Treatment for Active Alcoholic Smokers|Varenicline Treatment for Active Alcoholic Smokers||Mayo Clinic|No|Completed|June 2011|March 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 1, 2014|May 2, 2011|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01347112||105171|
NCT01348113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2009-A00591-56|Efficacy of a Brief Alcohol Intervention for Non Dependant Alcohol-misusing Patients Undergoing a Scheduled Surgery|Efficacy of a Brief Alcohol Intervention for Non Dependant Alcohol-misusing Patients Undergoing a Scheduled Surgery: a Randomized Controlled Trial|ITBCHIR|Rennes University Hospital|No|Terminated|July 2010|November 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|3|||Both|30 Years|75 Years|No|||April 2014|April 30, 2014|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01348113||105094|
NCT01339351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-62|Teleconference Group: Breast Cancer in African Americans (STORY)|Teleconference Group: Breast Cancer in African Americans|STORY|University of South Carolina|No|Completed|June 2005|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|185|||Female|21 Years|N/A|No|||April 2011|March 10, 2015|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01339351||105765|
NCT01339650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-976|Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||AbbVie|No|Active, not recruiting|May 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01339650||105742|
NCT01339936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9965-005 ID 10-12|Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers|||Optometric Technology Group Ltd|No|Completed|March 2011|May 2012|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|April 19, 2011||No||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01339936||105720|
NCT01336530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-03030-3277|Tepilta® Versus Oxetacaine, Antacids and Placebo|Clinical Trial to Assess the Efficacy of Fixed Combination Product Tepilta® in the Treatment of Radiation-induced Oesophagitis Compared to Its Active Ingredients Oxetacaine and Antacids, and to Placebo||MEDA Pharma GmbH & Co. KG|Yes|Recruiting|April 2011|November 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|810|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01336530||105970|
NCT01336543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-071|Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)|A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer||Louisiana State University Health Sciences Center Shreveport|Yes|Withdrawn|March 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|April 12, 2011||No|Low accrual, small patient population at center.|No||https://clinicaltrials.gov/show/NCT01336543||105969|
NCT01346215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPBER0211|Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure|Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure||Laboratório Químico Farmacêutico Bergamo Ltda.|Yes|Not yet recruiting|October 2011|February 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|132|||Both|18 Years|N/A|No|||April 2011|April 29, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01346215||105240|
NCT01346761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23146|Risk Education and Assessment for Cancer Heredity|Bridging Geographic Barriers: Remote Cancer Genetic Counseling for Rural Women|REACH|University of Utah|Yes|Active, not recruiting|August 2009|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1021|||Female|25 Years|74 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346761||105198|
NCT01347021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unifespcep0833/05|Compare Sacrospinous Fixation Versus High Uterosacral Ligament Fixation for Uterus Vaginal Prolapse III/IV|Sacrospinous Colpopexy Versus High Uterosacral Colpopexy in the Treatment of Genital Prolapse Grade III/IV in Women With Uterus||Federal University of São Paulo|Yes|Enrolling by invitation|May 2006|May 2011|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Female|50 Years|85 Years|Accepts Healthy Volunteers|||May 2006|May 3, 2011|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347021||105178|
NCT01347034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16441|Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)|A Phase II Study Evaluating Neoadjuvant Administration of High Dose Radiation Therapy and Intratumoral Autologous Dendritic Cells in Patients With High-risk Soft Tissue Sarcomas||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|January 2011|April 2016|Anticipated|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|May 2, 2011|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01347034||105177|Investigators planned to accrue 21 patients in each arm for a total of 42 participants.
NCT01347294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1331TMF|Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations|Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations||Oslo University Hospital|No|Not yet recruiting|August 2011|July 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|126|||Both|12 Years|80 Years|No|||April 2011|May 3, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01347294||105157|
NCT01347307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-044|Stereotactic Body Radiotherapy for Spine Tumors|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors||St. John's Mercy Research Institute, St. Louis|No|Active, not recruiting|September 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|May 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01347307||105156|
NCT01347853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2003-01|Safety and Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain|A Phase 3, Double-blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain||Luitpold Pharmaceuticals|No|Completed|June 2003|June 2007|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||May 2011|May 3, 2011|May 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347853||105114|
NCT01348061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN167001|Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls|Experimental Medicine Study to Evaluate the Kinetics of Cerebrospinal Fluid Biomarkers in Subjects With Alzheimer's Disease and Progressive Supranuclear Palsy Compared to Healthy Subjects Using a Heavy Water Labeling Method||KineMed|No|Completed|July 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|16|Samples With DNA|Whole blood|Both|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|AD, PSP and EHV subjects will be recruited via Contract Research Organizations (CROs).        Recruitment efforts will target the general population residing in communities in        proximity to the CROs.|October 2014|October 22, 2014|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348061||105098|
NCT01346527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-12828|Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes|Maternal Lipid Metabolism and Neonatal Heart Function in Diabetes||Washington University School of Medicine|Yes|Recruiting|April 2011|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples Without DNA|Maternal and umbilical cord serum|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants: All women who seek pre-natal care at the Women's Health Clinic Barnes Jewish        Hospital in St. Louis, Missouri are screened by history at the first visit for a        pre-existing diagnosis of diabetes mellitus (DM) (B or C type DM). Patients with a        diagnosis of pre-gestational diabetes are transferred to a specialty clinic dedicated        specifically to pre-natal care for women with diabetes. All patients with on-going        pregnancies and diabetes will be approached for enrollment. Non-DM subjects have a routine        screen for gestational diabetes at 24 wk gestation. After a normal result, these subjects        will be approached for enrollment as controls.|December 2013|December 18, 2013|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346527||105216|
NCT01347892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2010-21B|DeNovo NT Ankle LDC Study|Post Market, Longitudinal Data Collection Study of Articular Cartilage Lesions in the Ankle Treated With DeNovo(R) NT Natural Tissue Graft||Zimmer Orthobiologics, Inc.|No|Active, not recruiting|March 2011|September 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|205|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have received or who are scheduled to receive a DeNovo NT graft for repair of        a cartilage lesion in the ankle.|June 2015|June 3, 2015|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347892||105111|
NCT01349478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8422-GZ-CTIL|The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI)|Electrical Stimulation Induced Lower Limb Exercise Capacity, Cardiorespiratory Response, Cardiovascular Risk Factors and Muscle Activity Patterns in Response to Robotic Assisted Treadmill Gait Training in Individuals With Complete Motor Spinal Cord Injury||Sheba Medical Center|No|Not yet recruiting|May 2011|March 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|55 Years|No|||May 2011|May 5, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349478||104990|
NCT01346319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-778|Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.|A Randomized Double-Blind, Placebo-controlled Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Testosterone Undecanoate (ABT-SLV361) in Hypogonadal Males||Abbott|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|80 Years|No|||September 2011|November 1, 2011|April 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346319||105232|
NCT01346540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.82|A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.|LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology||Boehringer Ingelheim||Active, not recruiting|April 2011|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 19, 2011||||No||https://clinicaltrials.gov/show/NCT01346540||105215|
NCT01346553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESVV - PS-01|Safety and Efficacy of the External Synchronized Vein Valve (ESVV) in Treatment of Chronic Venous Insufficiency (CVI)|Safety and Primary Efficacy of the External Synchronized Vein Valve (ESVV) in Treatment of Chronic Venous Insufficiency (CVI) Sequel - A Pilot Study||GB-Veintech|No|Not yet recruiting|June 2011|January 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||April 2011|May 2, 2011|April 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01346553||105214|
NCT01347372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|095-2011|Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentor Training|Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentor Training|P2P EIA RCT|Sunnybrook Health Sciences Centre|No|Recruiting|May 2011|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2012|August 29, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347372||105151|
NCT01349205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-09-0457|Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study|Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study||The University of Texas Health Science Center, Houston|Yes|Terminated|March 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|2 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|May 3, 2011|Yes|Yes|The study medication in not available in the market|No||https://clinicaltrials.gov/show/NCT01349205||105011|
NCT01339663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2481.00|Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma|Phase I Study To Evaluate The Use Of Autologous T- Antigen-Presenting Cells (T-APC) To Enhance The Persistence Of Adoptively Transferred CD8+ Antigen-Specific T Cells (CTL) Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma||Fred Hutchinson Cancer Research Center|Yes|Completed|March 2012|||December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|April 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339663||105741|
NCT01339676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001958-99|Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)|Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS||University of Turku|No|Active, not recruiting|March 2008|June 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|55 Years|No|||April 2011|May 18, 2011|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339676||105740|
NCT01339949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLH005|Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)|A Double-masked, Sham Controlled, Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Wet AMD Patients With Recurrent Leakage Secondary to CNV||Oraya Therapeutics, Inc.|Yes|Withdrawn|June 2011|October 2014|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||December 2011|December 28, 2011|April 20, 2011||No|Sponsor decision to withdraw study to pursue others.|No||https://clinicaltrials.gov/show/NCT01339949||105719|
NCT01336231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COG-ANGIO|Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer|Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer : a Pilot Study|COG-ANGIO|Centre Francois Baclesse|No|Terminated|October 2008|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic|April 2011|October 5, 2012|April 12, 2011||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01336231||105991|
NCT01337154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMI-P2-NSCLC-01|First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer|A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer||CytRx|Yes|Terminated|April 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|April 15, 2011|Yes|Yes|Interim analysis showed that the primary endpoint would not be met.|No||https://clinicaltrials.gov/show/NCT01337154||105922|
NCT01346774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DK085290|Preventing Urinary Tract Infection Post-Surgery|Phase II Efficacy of Cranberry Powder in Preventing Catheter-associated Urinary Tract Infection Post Elective Gynecological Surgery|PUPS|University of Michigan|Yes|Completed|June 2011|October 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|N/A|No|||May 2015|May 26, 2015|April 29, 2011|Yes|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01346774||105197|
NCT01346787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-CAR-506|Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients|A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS|CCD|Stichting Hemato-Oncologie voor Volwassenen Nederland|Yes|Active, not recruiting|July 2011|October 2016|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|65 Years|N/A|No|||March 2015|March 24, 2015|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01346787||105196|
NCT01347047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1675|Institutional Registry of Amyloidosis|Institutional Registry of Amyloidosis||Hospital Italiano de Buenos Aires|No|Recruiting|April 2011|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Adults over 18 years old with diagnosis or suspected amyloidosis of Italiano Hospital of        Buenos Aires|December 2015|December 16, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347047||105176|
NCT01347320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsloUH|Preoperative Magnetic Resonance (MR) Imaging of Prostate Cancer|Clinical Impact of MR Imaging in Patients With Prostate Cancer||Oslo University Hospital|Yes|Completed|November 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Male|18 Years|N/A|No|||December 2013|December 27, 2013|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01347320||105155|
NCT01347554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVZT_2.0|Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction|Comparison of the Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Stent for Coronary Lesions in Acute Myocardial Infarction|EVERZOTA|Yonsei University|Yes|Completed|January 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|461|||Both|18 Years|N/A|No|||September 2014|September 23, 2014|April 27, 2011||No||No|September 23, 2014|https://clinicaltrials.gov/show/NCT01347554||105137|Relatively small number of sample size. Therefore, our result may be underpowerd. The incidence of clinical events were low. And we did not record the compliance of dual antiplatelet therapy for at least 1 year.
NCT01348919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18770/2049|CEP-18770 in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma|An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Teva Pharmaceutical Industries||Terminated|August 2011|May 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01348919||105033|
NCT01347866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1271002|Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer|A Multi-Arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer||Pfizer|No|Terminated|October 2011|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|105|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 2, 2011|No|Yes|Refer to Detailed Description for documentaion of Termination Statement.|No||https://clinicaltrials.gov/show/NCT01347866||105113|
NCT01349465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017365|3-year Follow-up Study in Patients Previously Treated With a TMC435 for the Treatment of Hepatitis C Virus (HCV) Infection|A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) Infection||Janssen R&D Ireland|No|Completed|July 2011|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|N/A|1||Actual|249|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349465||104991|
NCT01347086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.8|Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400mg, 800mg, 1200mg) of BI 207127 NA in Healthy Male Asian Volunteers and Single Oral Dose (1200 mg) of BI 207127 NA in Healthy Male Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Group)||Boehringer Ingelheim||Completed|May 2011|||June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|60|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|May 3, 2011||||No||https://clinicaltrials.gov/show/NCT01347086||105173|
NCT01347099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD-S|Internet-based Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)|Internet-based Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Randomized Controlled Trial||Karolinska Institutet|No|Active, not recruiting|February 2011|||June 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||May 2011|May 3, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347099||105172|
NCT01348373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2010-05|Evaluation of Effectiveness and Safety of the GENOUS STENT (IRIS-GENOUS STEMI)|Evaluation of Effectiveness and Safety of the GENOUS STENT in ST-Segment Elevation Myocardial Infarction||CardioVascular Research Foundation, Korea|Yes|Completed|May 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|464|||Both|N/A|N/A|No|Non-Probability Sample|STEMI Patients requiring primary PCI.|November 2015|November 10, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348373||105074|
NCT01348685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Solid and liquid 1|Comparing Liquid Versus Solid Forms of Sugars and Whey Protein|Effect of Drinking Liquid Compared to Eating Solid Treatment of Sugars or Whey Protein on Short-term Appetite and Food Intake||University of Toronto|Yes|Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Actual|43|||Male|19 Years|28 Years|Accepts Healthy Volunteers|||February 2011|May 4, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348685||105050|
NCT01314976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSR-01|Treatment Study of Metronidazole to Treat Dientamoebiasis in Children|Metronidazole for the Treatment of Dientamoebiasis in Children in Denmark - A Randomized, Placebo-controlled, Double-blinded Clinical Trial|DFPT|Statens Serum Institut|Yes|Completed|July 2011|June 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|12 Years|No|||June 2013|June 25, 2013|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01314976||107611|
NCT01315223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010-11-HYMC|Outpatient Lung Impedance-Guided Preventive Therapy in Patients With Chronic Heart Failure (CHF)|||Hillel Yaffe Medical Center|Yes|Recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|March 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01315223||107592|
NCT01315236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-112|Arikayce for Nontuberculous Mycobacteria|A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease||Insmed Incorporated|Yes|Completed|May 2012|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|85 Years|No|||December 2015|December 8, 2015|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315236||107591|
NCT01314989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cypro-24|Cyproheptadine as an Appetite Stimulant|Effect of Cyproheptadine on Weight Gain and Feeding Behavior in 2 to 4 Years Old Children With Failure to Thrive||St. Justine's Hospital|No|Recruiting|December 2010|January 2012|Anticipated|March 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|2 Years|4 Years|No|||March 2011|March 14, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01314989||107610|
NCT01347125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD 0201|ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study|ImCardia for DHF - Safety and Functionality|ImCardia|CorAssist Cadiovascular Ltd.|Yes|Terminated|April 2008|May 2012|Anticipated|April 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|50 Years|N/A|No|||May 2011|May 3, 2011|April 28, 2011||No|CorAssist believes that certain improvements are needed to the device|No||https://clinicaltrials.gov/show/NCT01347125||105170|
NCT01347905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iron absorption and obesity|Changes in Iron Absorption and Availability Before and After Weight Loss in Obese Pre-menopausal Women and Men.|Changes in Iron Absorption and Availability Before and After Weight Loss in Obese Pre-menopausal Women and Men.||Wageningen University|Yes|Completed|February 2011|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples With DNA|whole blood and serum|Both|18 Years|50 Years|No|Non-Probability Sample|Obese, premenopausal women and men aged 18 to 50 years after having undergone restrictive        bariatric surgery.|June 2015|June 5, 2015|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347905||105110|
NCT01315808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|whmc1|Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM|Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM: Comparing the Concept of dx/dt With QD Diabetes Prediction Model. D.E.R.M.S Initiative (Doctor Enabled Risk Management System)||Wyckoff Heights Medical Center|Yes|Terminated|March 2011|September 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Actual|542|||Both|18 Years|65 Years|No|Non-Probability Sample|We will recruit 1000 non-diabetes people those having at least one diabetes prone risk        factor.|March 2012|March 18, 2012|March 14, 2011||No|Due to lack of funds to continue this study.|No||https://clinicaltrials.gov/show/NCT01315808||107548|
NCT01316133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGLN-10-01-KOR|A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients|A Multicenter, Non-comparative, Open-labeled, Prospective Study to Evaluate the Efficacy and Safety of Tacrolimus (Prograf®) With Steroid in Korean Lupus Nephritis Patients Who Are Non-responders to Steroid Monotherapy|APPLE|Astellas Pharma Inc|No|Recruiting|February 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|20 Years|N/A|No|||October 2015|October 27, 2015|March 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316133||107523|
NCT01340573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04896|Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)|Non-Interventional Study Evaluating The Safety and Efficacy In Patients Receiving New PegIntron Pen for Hepatitis C||Merck Sharp & Dohme Corp.||Terminated|March 2007|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3|Samples With DNA|Efficacy measurements for sustained viral response HCV RNA were collected at week 24 of      study treatment and at week 24 of follow-up in Non-genotype-1 participants. Efficacy      measurements for Genotype-1 participants for sustained viral response HCV RNA were collected      at week 24 and at week 48 of study treatment, and at week 24 of follow-up.|Both|18 Years|N/A|No|Non-Probability Sample|Indonesian participants ≥18 years of age with confirmed chronic hepatitis C with HCV RNA        positive in plasma.|January 2015|January 20, 2015|November 18, 2010|No|Yes|Terminated early due to low enrollment.|No|October 4, 2011|https://clinicaltrials.gov/show/NCT01340573||105671|
NCT01336244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0778-CL-102|GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0778 in Healthy Male Subjects||Galapagos NV|No|Completed|April 2011|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|45|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336244||105990|
NCT01337167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V419-005|Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)|A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq™||Merck Sharp & Dohme Corp.|No|Completed|April 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1473|||Both|46 Days|89 Days|Accepts Healthy Volunteers|||February 2016|February 18, 2016|April 15, 2011|Yes|Yes||No|February 18, 2016|https://clinicaltrials.gov/show/NCT01337167||105921|
NCT01346800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICRO-PRASU-RITONAVIR|Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers|||University Hospital, Geneva|No|Completed|February 2011|September 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||April 2011|October 5, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01346800||105195|
NCT01347060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112605|Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy|Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy||GlaxoSmithKline|No|Completed|July 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|17448|||Both|65 Years|N/A|No|Non-Probability Sample|Medicare-eligible subjects age 65 years and older with a diagnosis of asthma being treated        with an inhaled corticosteroid|June 2011|July 28, 2011|June 10, 2010||No||No|May 5, 2011|https://clinicaltrials.gov/show/NCT01347060||105175|
NCT01347333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-045|Stereotactic Body Radiotherapy for Liver Tumors|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors||St. John's Mercy Research Institute, St. Louis|No|Active, not recruiting|September 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|May 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01347333||105154|
NCT01347567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-0135|Heart Failure (HF) Outpatient Monitoring Evaluation (HOME) Study|HF Outpatient Monitoring Evaluation (HOME) Study|HOME|Alere San Diego|No|Completed|April 2011|January 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|145|||Both|18 Years|75 Years|No|||February 2014|February 4, 2014|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347567||105136|
NCT01345838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAO and labrum|Acetabular Labral Tear in Dysplastic Hips|||University of Aarhus|Yes|Active, not recruiting|February 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|||Both|N/A|N/A|No|Probability Sample|Consecutive patients with developmental dysplasia of hip and who is scheduled for PAO|August 2013|August 15, 2013|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01345838||105268|
NCT01346293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M5I02|Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age|Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age||Sanofi|No|Completed|April 2011|September 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|3372|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|April 29, 2011|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01346293||105234|
NCT01347606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-Aysan|Secured Thyroidectomy With Intraoperative Methylene Blue Using|Prospective Randomized Technical Study|bluethyroid|SB Istanbul Education and Research Hospital|No|Recruiting|January 2010|July 2011|Anticipated|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|thyroid tissue|Both|18 Years|70 Years|No|Probability Sample|thyroidectomy indicated patients|January 2010|May 3, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347606||105133|
NCT01347619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13902|iADAPT: Off Label Use of Antipsychotics in the Nursing Home|iADAPT: Off Label Use of Antipsychotics in the Nursing Home||University of Massachusetts, Worcester|Yes|Completed|November 2010|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 28, 2014|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347619||105132|
NCT01314742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00013036|Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates|A Randomized Controlled Clinical Trial of Two Different Oral Care Regimens Combined With Ventilator-Associated Pneumonia (VAP) Bundle Strategy for Reduction of Duration of Mechanical Ventilation in a Neonatal Population||Wake Forest School of Medicine|No|Completed|May 2010|July 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|41|||Both|N/A|N/A|No|||February 2016|February 11, 2016|March 9, 2011||No||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01314742||107628|
NCT01314755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC.73.03|A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer|A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer|IMPACTHN|Aintree University Hospitals NHS Foundation Trust|No|Completed|November 2003|July 2008|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||March 2008|March 14, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01314755||107627|
NCT01315002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICSZ001|Nicotine Effects on Endophenotypes of Schizophrenia|Nicotine Effects on Endophenotypes of Schizophrenia||University Hospital, Bonn|Yes|Completed|July 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|121|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|March 14, 2011||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01315002||107609|
NCT01315548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEH-EUS-001|Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) in Focal Pancreatic Masses|Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) Used in the Differentiation of Focal Pancreatic Masses||University of Medicine and Pharmacy Craiova|Yes|Completed|March 2011|December 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|210|Samples With DNA|Pathology samples obtained from duodeno-pancreatectomies or caudal pancreatectomies done      with curative intent, as well as microhistological fragments obtained through EUS-FNA biopsy      processed by paraffin embedding|Both|18 Years|90 Years|No|Non-Probability Sample|The diagnosis of chronic pancreatitis will be based on the clinical information (history        of alcohol abuse, previous diagnosis of chronic pancreatitis or diabetes mellitus), as        well as a combination of imaging methods (ultrasound, CT and EUS). At least four criteria        of chronic pancreatitis during EUS will be considered for the positive diagnosis.        A positive cytological diagnosis will be taken as a final proof of malignancy of the        pancreas mass. The diagnoses obtained by EUS-FNA will be further verified either by        surgery or during a clinical follow-up of at least 6 months.|April 2014|May 13, 2015|March 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01315548||107567|
NCT01346592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_29|Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age|A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to < 72 Months of Age||Novartis||Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|6104|||Both|6 Months|72 Months|Accepts Healthy Volunteers|||March 2015|March 4, 2015|April 30, 2011|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01346592||105211|
NCT01347190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002_1004|Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis|A Double Blind, Randomized, Placebo Controlled, Single Dose, Phase I Study of the Safety and Tolerability of Alpha1 Proteinase Inhibitor (Human) Inhalation Solution (CR002) in Subjects With Cystic Fibrosis||CSL Behring||Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||April 2012|April 3, 2012|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347190||105165|
NCT01346865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2010-10|Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)|A Randomized, Placebo Controlled, Double-blind, Phase 4 Study to Evaluate Efficacy and Safety of Triple Anti-platelet Therapy Compared With Dual Antiplatelet Therapy in Patients Treated With Drug Eluting Stent for Coronary Artery Disease||CardioVascular Research Foundation, Korea|Yes|Terminated|May 2011|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|402|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|April 22, 2011|No|Yes|Low Recruitment|No||https://clinicaltrials.gov/show/NCT01346865||105190|
NCT01340586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV185-087|Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis|Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects on Hemodialysis||Bristol-Myers Squibb|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|November 29, 2011|April 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01340586||105670|
NCT01336257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIBA00019|Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer|Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer||Hospital Italiano de Buenos Aires|No|Recruiting|November 2009|June 2012|Anticipated|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|2200|||Female|50 Years|69 Years|No|||April 2012|April 13, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336257||105989|
NCT01337375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22936|A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy|Pharmacokinetics and Pharmacodynamics of Intravenous Administration of Pegylated Interferon-2a in Patients With Chronic Hepatitis C and Previous Non-response to Standard Combination Therapy With Pegylated Interferon and Ribavirin (Intervention Study)||Hoffmann-La Roche||Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|March 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337375||105906|
NCT01337388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25492|An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis|An Observational Study of the Efficacy of RoActemra in Smoking vs Non-smoking Patients With Rheumatoid Arthritis.||Hoffmann-La Roche||Completed|August 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients on treatment with RoActemra/Actemra|March 2016|March 1, 2016|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337388||105905|
NCT01347385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS-1|Barbed Suture Versus Traditional Suture Material for Laparoscopic Myomectomy|Barbed Suture Versus Traditional Suture Material for Laparoscopic Myomectomy: A Randomized Controlled Trial||Sunnybrook Health Sciences Centre|No|Not yet recruiting|January 2012|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|N/A|N/A|No|||April 2011|May 2, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01347385||105150|
NCT01347918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-MRI|1H-19F Gastrointestinal MRI in Health and IBS|Small Intestinal Transit and Motor Function in Health and IBS Patients Studied by Combined 1H and 19F Magnetic Resonance Imaging||University of Zurich|No|Suspended|July 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The healthy controls will be selected from among students and volunteers that have        responded to advertisments in local notice boards of the Zurich University Hospital and        the University of Zurich, as well as in an email newsletter ("Mediflash") of the Medical        Student Organisation.        The IBS patients are selected from the patient population seen in the Klinik and Polyklink        für Innere Medizin at the University Hopsital Zurich.|April 2015|April 8, 2015|May 3, 2011||No|Technical problems|No||https://clinicaltrials.gov/show/NCT01347918||105109|
NCT01347580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00006|A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)|A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.|ATLANTIC|AstraZeneca|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1875|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|April 19, 2011|Yes|Yes||No|November 13, 2014|https://clinicaltrials.gov/show/NCT01347580||105135|This urgent setting study included 8.6% of patients with symptoms of MI in ambulance but having finally not a STEMI diagnosis in cathlab.No prespecified hypothesis and procedure for adjustment was made on secondary endpoints.
NCT01349166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0088|Effects of 3 Months of Supervised Exercise Training|Effects of 3 Months of Supervised Exercise Training on Cardiometabolic and Inflammatory Biomarkers According to Glucose Tolerance (Normal, Intolerance and Type 2 Diabetes): Measures in Unstimulated and Stimulated Conditions||University Hospital, Clermont-Ferrand||Active, not recruiting|February 2008|February 2012|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|45|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 5, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01349166||105014|
NCT01349179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-089|Scan Hip Evaluation|Scan Evaluation at 9 Years of the Bone Acetabular Supporting Cups Without Cement (Couple Metal/Metal in Diameter 28 mm)|ETOSA|University Hospital, Clermont-Ferrand||Completed|December 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|N/A|N/A|No|||July 2014|July 4, 2014|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01349179||105013|
NCT01346826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0181|Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)|Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial||Asan Medical Center|Yes|Active, not recruiting|May 2011|May 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|156|||Both|16 Years|80 Years|No|||June 2015|June 22, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346826||105193|
NCT01314443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-212|Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function|Cardioprotective Synergy of Smoking Cessation and γ-Tocopherol in Restoring Vascular Endothelial Function||University of Connecticut|No|Completed|January 2011|December 2014|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|67|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|March 10, 2011||No||No|December 12, 2012|https://clinicaltrials.gov/show/NCT01314443||107651|Very few women were enrolled thereby precluding any assessment of potential gender differences for our outcome variables.
NCT01314456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaviGo- 01|3D Recording of a Trans-rectal Prostate Biopsy|3D Recording of a Trans-rectal Prostate Biopsy||HaEmek Medical Center, Israel|No|Not yet recruiting|March 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Male|18 Years|N/A|No|||March 2011|March 14, 2011|March 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01314456||107650|
NCT01314469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-559-f-S|Quality of Life in Patients With Intermediate Uveitis|Influence of Macular Edema on Quality of Life in Patients With Non-infectious Intermediate Uveitis||St. Franziskus Hospital||Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with intermediate uveitis|March 2011|July 19, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314469||107649|
NCT01314482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1119-6985|Minocycline for the Prevention of Post-operative Intercostal Neuralgia|The Efficacy of Prophylactic Administration of Minocycline in Reducing Chronic Intercostal Neuralgia Post-thoracotomy||University of Adelaide|No|Recruiting|November 2010|February 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|116|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314482||107648|
NCT01345864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1661006|Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults|A Randomized, Double-Blind, Sponsor Unblinded, Placebo- And Positive- Controlled Study To Evaluate The Effects Of Single Oral Administrations Of PF-04995274, Alone Or In Combination With Donepezil, On Scopolamine-Induced Deficits In Psychomotor And Cognitive Function In Healthy Adults||Pfizer|No|Terminated|May 2011|August 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 16, 2011|April 28, 2011|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01345864||105266|
NCT01346098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-IT|Islet Autotransplantation in Patients at Very High-risk Pancreatic Anastomosis|Total Pancreatectomy With Islet Autotransplantation as a Superior Alternative to Pancreatoduodenectomy in Patients at Very High-risk of Complications of the Pancreatic Anastomosis: a Single-center Prospective Randomised Clinical Trial|PAN-IT|Ospedale San Raffaele|Yes|Recruiting|July 2010|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2012|March 4, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346098||105249|
NCT01315249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2313|QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|ILLUMINATE|Novartis|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|523|||Both|40 Years|N/A|No|||July 2013|July 9, 2013|March 11, 2011|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT01315249||107590|
NCT01315262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR Urology|On Demand Versus Daily Sildenafil for Patients Undergoing Radical Prostatectomy|On Demand Versus Daily Sildenafil for Patients Undergoing Bilateral Nerve Sparing Radical Prostatectomy: a Randomized, Open Label, Parallel Group Trial|URO2010|Università Vita-Salute San Raffaele|Yes|Recruiting|January 2011|December 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Male|18 Years|65 Years|No|||February 2011|March 28, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315262||107589|
NCT01347411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIDAS|Effectiveness of the Treatment With Continuous Positive Airway Pressure(CPAP)in Stable Heart Failure With Ejection Fraction More Than 45% and Sleep Disordered Breathing|Effectiveness of the Treatment With CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) in Stable Heart Failure With Ejection Fraction More Than 45% and Sleep Disordered Breathing||Basque Health Service|No|Completed|September 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|420|||Both|18 Years|80 Years|No|||April 2011|May 3, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01347411||105148|
NCT01347671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|430409|Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy|A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.||Grünenthal GmbH|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|189|||Both|18 Years|75 Years|No|||June 2012|June 5, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347671||105128|
NCT01347684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103M96812|Assessing the Effectiveness of Two Treatment Strategies for Tension-type Headache|Assessing the Effectiveness of Two Treatment Strategies for Tension-type Headache||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||May 2015|May 29, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01347684||105127|
NCT01336556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0352/09T|Titration of Continuous Positive Airway Pressure Could Predict Success of Oral Appliance to Treat Sleep Apnea|Optimal Titration of Continuous Positive Airway Pressure Could Predict Success of Oral Appliance to Treat Obstructive Sleep Apnea Syndrome||Associacao Fundo de Incentivo a Psicofarmcologia|Yes|Recruiting|October 2010|||November 2011|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Male|25 Years|65 Years|No|||October 2011|October 25, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336556||105968|
NCT01336855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8211-04743-22|Collection of Blood for Multiple Collaborative Studies|Collection and Preservation of Blood and Serum Specimens From HIV Positive or HIV Negative Patients for Multiple Collaborative Studies||University of California, San Francisco|No|Recruiting|January 1988|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|Samples With DNA|Plasma, PBMCs, buffy coat, serum, saliva, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be selected based on positive or negative HIV antibody, depending on the        study for which blood is being collected. Patients will be chosen from the Positive Health        Practice populations at SFGH and UCSF, the General Medicine Clinic at the San Francisco        Veterans Affairs Medical Center. HIV uninfected healthy volunteers with comparable risk        factors to the HIV positive subjects will be recruited from the community.|April 2015|April 16, 2015|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336855||105945|
NCT01336868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52-00022-000|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2011|||||N/A|N/A|N/A||||||||||||||April 15, 2011|April 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336868||105944|
NCT01337739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00027663|Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery|Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery||Northwestern University|No|Terminated|October 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Female|18 Years|64 Years|No|||May 2013|May 23, 2013|April 19, 2010|Yes|Yes|The study drug delayed time of discharge which is clinically impracticable.|No|May 23, 2013|https://clinicaltrials.gov/show/NCT01337739||105878|Early termination of the study due to increased discharge time from the post anesthesia care unit with subjects receiving dexmedetomidine. The delay was consistent among the group.
NCT01345851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001342|Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer||Jonsson Comprehensive Cancer Center|Yes|Recruiting|March 2011|||May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|April 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01345851||105267|
NCT01348126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-08|Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer|A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer|GALAXY|Synta Pharmaceuticals Corp.|No|Terminated|May 2011|October 2015|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|385|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|May 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01348126||105093|
NCT01347645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7820-702|Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer||Eisai Inc.|No|Active, not recruiting|October 2011|September 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347645||105130|
NCT01347346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTG003.08|Gene Therapy for WAS|Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome||Genethon|Yes|Recruiting|May 2011|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Male|N/A|N/A|No|||November 2014|November 24, 2014|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347346||105153|
NCT01348672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORF2|Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye|Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye||University of Toronto|No|Recruiting|March 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|381|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The cohorts will be selected from the clinics of retinal and glaucoma specialists at the        Toronto Western Hospital and will be identified from their charts. Clinicians will ask        eligible patients whether they would be interested in participating.        Also flyers advertising the study will be posted at Toronto Western Hospital and anyone        interested can contact the principal investigator.|January 2013|January 16, 2013|February 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01348672||105051|
NCT01346059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-195|Intracolonic Vancomycin Therapy in Severe C. Diff Colitis|Intracolonic Vancomycin Therapy in Severe C. Diff Colitis: A Double Blinded Randomized Prospective Trial||William Beaumont Hospitals|Yes|Terminated|April 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||April 2011|September 15, 2012|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346059||105252|
NCT01314157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Prado|Evaluation of Isostretching Effects in Patients With Mechanical and Postural Chronic Low Back Pain|Evaluation of Isostretching Effects in Patients With Mechanical and Postural||Federal University of São Paulo|Yes|Not yet recruiting|March 2011|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Anticipated|54|||Both|18 Years|65 Years|No|||February 2011|March 11, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314157||107672|
NCT01314170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E01-ADA-VSUS-01-10|Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.|Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.||Adapt Produtos Oftalmológicos Ltda.|Yes|Not yet recruiting|May 2011|October 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 9, 2011|August 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01314170||107671|
NCT01314183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS019624-01|Enhancing the Effectiveness of Physical Therapy for People With Knee Osteoarthritis|Enhancing the Effectiveness of Physical Therapy for People With Knee||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|April 2011|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|300|||Both|40 Years|N/A|No|||June 2015|June 22, 2015|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01314183||107670|
NCT01345630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001095|Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1|A Multicenter, Randomized, Double‑Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral‑Naive Hiv‑Infected Patients With Ccr5‑Tropic Hiv‑1|MODERN|ViiV Healthcare|Yes|Terminated|September 2011|January 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|813|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|April 27, 2011|Yes|Yes|See termination reason in detailed description.|No|August 14, 2014|https://clinicaltrials.gov/show/NCT01345630||105284|The study was terminated following a preliminary review of the 48- week primary clinical efficacy data by the study’s external independent Data Monitoring Committee’s recommendation based on inferior efficacy of the investigational MVC+DRV/r arm.
NCT01346618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/11|The Validity of Bone Age Assessment by an Ultrasound Apparatus (SonicBone)|A Comparison of Bone Age Assessment by an Ultrasound Apparatus (SonicBone) and the X-ray Based Grulich and Pyle Method||Assaf-Harofeh Medical Center|No|Recruiting|May 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|4 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants are children and youth ages 4-17 years (inclusive) who performed or will        perform a X-ray of the left hand for bone age assessment as part of any clinical work up,        within 2 months of enrollment in this study.        Participants will be recruited according to advertising the study amongst pediatricians,        pediatric endocrinologists and from the pediatric population who visits the pediatric        endocrine clinic, endocrine testing room, adolescent medicine clinic, or being        hospitalized at the pediatric division, Assaf Haroffeh Medical Center.|November 2011|November 3, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01346618||105209|
NCT01347437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFAR Adherence HIV Youth:2|Improving Antiretroviral Medication Adherence Among HIV-infected Youth|Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase II||Fenway Community Health|No|Recruiting|July 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|13 Years|24 Years|No|||April 2011|July 22, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01347437||105146|
NCT01346605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECRUIT Study|Registry for CARDIAC PERFUSION CT|Registry for CARDIAC PERFUSION CT|RECRUIT|MDDX LLC|Yes|Withdrawn|May 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|35 Years|80 Years|No|Probability Sample|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac        catheterization laboratory for an invasive coronary angiogram or patients presenting with        chest pain and clinical indication of Coronary CT Angiography and an initial calcium score        above 300|December 2012|December 8, 2012|April 30, 2011||No|No funding|No||https://clinicaltrials.gov/show/NCT01346605||105210|
NCT01347203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPOC-001|A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting|A Randomized, Open-label, 4-period Crossover Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD) and the PK/PD Relationship of DPOC-4088 After Single Oral Dosing of 100 and 200 mg in 2 Prolonged Release Formulations (16 and 20 hr) in 12 Healthy Young Male Subjects||Diakron Pharmaceuticals|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 6, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347203||105164|
NCT01347424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XIANSHENG|Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography|||Sun Yat-sen University|Yes|Active, not recruiting|January 2011|October 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||November 2010|December 5, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01347424||105147|
NCT01336569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-26|Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol|Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%)||Alcon Research|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|April 14, 2011|No|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01336569||105967|
NCT01336881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEP11B1|Biomarkers in Tissue Samples From Young Patients With Liver Cancer|Genetics and Biology of Liver Tumorigenesis in Children||Children's Oncology Group|No|Active, not recruiting|April 2011|||July 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|99|Samples With DNA|Archived tumor tissue samples|Both|N/A|16 Years|No|Non-Probability Sample|Young patients with liver cancer|May 2015|May 5, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01336881||105943|
NCT01336894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z4099|Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer|A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) Versus Stereotactic Body Radiation Therapy in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)||Alliance for Clinical Trials in Oncology|Yes|Terminated|May 2011|||May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|April 15, 2011||No|recruiting or enrolling participants has halted prematurely and will not resume; participants    are no longer being examined or treated|No||https://clinicaltrials.gov/show/NCT01336894||105942|
NCT01338012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-1|Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)|An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)||Dendreon||Completed|November 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|N/A|No|||February 2016|February 29, 2016|March 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338012||105857|
NCT01347138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A102065|Health Care Management for the Elderly in Community Through Screening|||National Clinical Research Coordination Center, Seoul, Korea||Completed|May 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|57|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01347138||105169|
NCT01347151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glide VS Pentax|A Comparison of Cervical Spine Movement During Tracheal Intubation Using the Pentax or the Glidescope|||Prince of Songkla University|Yes|Active, not recruiting|May 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|75 Years|No|||May 2011|May 3, 2011|May 2, 2011||||No||https://clinicaltrials.gov/show/NCT01347151||105168|
NCT01347073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPN-100-012|Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)|A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)||Horizon Pharma Ireland, Ltd., Dublin Ireland|Yes|Completed|July 2011|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|6 Years|No|||June 2015|June 8, 2015|April 29, 2011|Yes|Yes||No|April 3, 2015|https://clinicaltrials.gov/show/NCT01347073||105174|The protocol was designed to capture information important for evaluating safety, pharmacokinetics, and efficacy while recognizing sampling limitations in young children and current standard of care.
NCT01347879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCTA206/11|A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris|PCTA206/11 A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi Center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris.||Photocure|No|Completed|May 2011|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|153|||Both|12 Years|35 Years|No|||December 2013|December 2, 2013|May 3, 2011|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01347879||105112|
NCT01348334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ataturk TRH-01|Synthetic Mesh Materials In Sling Surgery|Use Of Three Types Of Synthetic Mesh Materials In Sling Surgery: A Prospective Randomized Clinical Trial Evaluating Effectiveness And Complications||Ataturk Training and Research Hospital|No|Completed|July 2004|November 2010|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|144|||Female|31 Years|75 Years|Accepts Healthy Volunteers|||July 2004|May 4, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01348334||105077|
NCT01348347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.15|BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours|An Open-label Phase I Study of Once Every Three Weeks Intravenous Treatment With BI 6727 in Japanese Patients With Advanced Solid Tumours||Boehringer Ingelheim||Completed|April 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||August 2014|August 6, 2014|April 29, 2011||||No||https://clinicaltrials.gov/show/NCT01348347||105076|
NCT01318109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/CCT-006|Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Metformin in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|August 2008|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|288|||Both|26 Years|64 Years|No|||February 2012|February 1, 2012|March 16, 2011||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01318109||107373|
NCT01318317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09174|Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma|Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma||City of Hope Medical Center|Yes|Active, not recruiting|September 2011|||August 2022|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318317||107357|
NCT01318330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Homeo-GH|Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD)|Five-Week, Multi-center, Phase I Clinical Trial to Evaluate Safety of Homeo-GH After Intra Venus Administration for the Treatment of Graft Versus Host Disease Patients|Homeo-GH|HomeoTherapy Co., Ltd|No|Completed|November 2010|June 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2011|July 18, 2012|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01318330||107356|
NCT01349517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSchest2011001|Health-related Quality of Life of Patients With Esophageal Cancer After Surgery|Health-related Quality of Life of Patients With Esophageal Cancer After Surgery in China: A Prospective Cohort Study From Multi-center||Fudan University|Yes|Not yet recruiting|May 2011|December 2016|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|400|||Both|35 Years|70 Years|No|||January 2011|November 10, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01349517||104987|
NCT01349530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K080905|Evaluating of CREATIF an Anti-coagulation Clinic|Evaluating of the Benefit to the Patient by Managing of His Anticoagulation Treatment by an Anti-coagulation Clinic|CREATIF|Assistance Publique - Hôpitaux de Paris|No|Recruiting|May 2011|December 2013|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|170|||Both|18 Years|N/A|No|||November 2012|January 23, 2013|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349530||104986|
NCT01346345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB® Protocol #20101573|Aesthetic Evaluation of Two Piece 3mm Implants for Single Tooth Replacement of Maxillary Laterals and Mandibular Incisors|Aesthetic Evaluation of Two Piece 3mm Implants for Single Tooth Replacement of Maxillary Laterals and Mandibular Incisors||Dr.Suzanne Caudry Implant Dentistry and Periodontics|Yes|Enrolling by invitation|May 2011|May 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects for this study will be recruited from the practices of the six study centers (Dr.        Caudry + 5 centers from the North American PEERS group) within a period of eighteen months        from commencement of the study. A total of sixty subjects (ten per center) of any gender        and race aged 18 and older will be accepted provided they meet the inclusion and exclusion        criteria (see page 6). Dental implants for permanent tooth replacement are not indicated        for use in those under the age of 18. Vulnerable subjects will not be included.|April 2011|May 2, 2011|April 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346345||105230|
NCT01346904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POAG3243|a 3.0T Magnetic Resonance Imaging Study|The Central Nerve System Injury in Patients With Primary Open Angle Glaucoma||Huazhong University of Science and Technology|Yes|Not yet recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects recruited from the Department of Ophthalmology, Tongji Hospital, Tongji        Medical College, Huazhong University of Science and Technology. Clinical ophthalmic        assessments including measurement of visual acuities, intraocular pressure, slit-lamp        microscopes and funduscopes examinations, cup-to-dick ratio (CDR) evaluation, visual field        test [Octopus 101 Automated Perimeter, Haag-streit, Switzerland. Program G2], optical        coherence tomography for retinal nerve fiber layer thickness(RNFLT) around the optic        disk[Stratus OCT，Carl Zeiss Meditec, Dublin, CA .Scan Type :Fast RNFLT 3.4, Scan Length:        10.87mm].|May 2011|May 2, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346904||105187|
NCT01347450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20114|Protective Effects of Cocoa Ingestion Over Healthy Males Plasma Lipids Subjected to Peroxidative Conditions|Protective Effects of Cocoa Ingestion Over Healthy Males Plasma Lipids Subjected to Peroxidative Conditions||Fundación Santa Fe de Bogota|Yes|Completed|October 2007|August 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|136|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||September 2004|May 3, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01347450||105145|
NCT01346878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIUS-2|Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment|Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment||Fundacio Lluita Contra la SIDA|No|Completed|July 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|143|Samples With DNA|Plasma samples|Both|18 Years|65 Years|No|Non-Probability Sample|-  PI GROUP: prior virologic failure of a Highly active antiretroviral therapy (HAART)             regimen including a Protease inhibitor (PI) (ritonavir boosted or not), and a second             consecutive start HAART regimen including a PI boosted with ritonavir + 2 Nucleoside             Reverse Transcriptase Inhibitor (NRTI). The 6 months prior to the start of the second             HAART regimen, are considered as a baseline.          -  NNRTI GROUP: Virologic failure after a HAART regimen that includes 1 Non Nucleoside             Reverse Transcriptase Inhibitor (NNRTI) and 2 NRTIs, and beginning, consecutive or             not, a rescue HAART regimen with etravirine, in combination with any other drug. The             6 months before starting rescue HAART regimen with etravirine, are considered as a             baseline.          -  II GROUP: Virologic failure to any prior HAART and initiation of rescue HAART             including raltegravir, in combination with any other drug. The 6 months before             starting rescue HAART with raltegravir are considered as a baseline.|October 2012|October 24, 2012|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01346878||105189|
NCT01347970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11018|Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial|Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial||City of Hope Medical Center|Yes|Recruiting|May 2012|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|250|||Both|16 Years|N/A|No|||February 2016|February 10, 2016|May 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347970||105105|
NCT01348204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100107002|Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators|Nasal Potential Studies Utilizing CFTR Modulators (UAB Center for Clinical and Translational Science)||University of Alabama at Birmingham|Yes|Completed|March 2010|November 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|8 Years|65 Years|No|||January 2012|January 27, 2012|June 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01348204||105087|
NCT01336582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCXN101|Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer|Phase I Trial to Compare Pharmacokinetics and Safety of SYP-0704A With Taxotere in Subjects With Advanced Solid Tumor||Samyang Biopharmaceuticals Corporation|No|Completed|August 2009|August 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||December 2012|December 19, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01336582||105966|
NCT01336907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMP-DTR-01|Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)|Comparison Between Home Macular Perimeter and OCT Visual Field Defects in Patients With CNV||Notal Vision Ltd|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|55 Years|N/A|No|Non-Probability Sample|CNV subjects|April 2015|April 13, 2015|April 13, 2011||No|never started|No||https://clinicaltrials.gov/show/NCT01336907||105941|
NCT01337180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5690.14|Airway Inflammation Among Workers in the Silicon Carbide Processing Industry|Exposure to Aerosols and Airway Inflammation Among Workers in the Silicon Carbide Processing Industry||Sykehuset Telemark|Yes|Withdrawn|March 2011|December 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Induced sputum, serum, citrate- plasma, EDTA-plasma, whole blood and a PaxGene sample for      DNA isolation. Cell isolation, RNA isolation and gene expression analysis. Fluid phase      analyses.|Both|18 Years|N/A|No|Non-Probability Sample|Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both        administrative/office workers in the production and maintenance departments will be        invited to participate. Non- smokers and smokers and male and female workers will be        included in the main study group. Only non- smokers will be included in the sputum part of        the study.|June 2013|November 19, 2015|April 15, 2011||No|The industry plant from which we should recruit was closed down.|No||https://clinicaltrials.gov/show/NCT01337180||105920|
NCT01337765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2103|Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors||Array BioPharma||Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|April 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337765||105876|
NCT01346514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 11-231|Addiction Housing Case Management for Homeless Veterans|Addiction Housing Case Management for Homeless Veterans Enrolled in Addictions Treatment|AHCM|VA Office of Research and Development|Yes|Active, not recruiting|October 2011|May 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346514||105217|
NCT01346813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIPPAIN2_IDF|Epidemiology of Painful Procedures in Neonates|Epidémiologie Des Gestes Douloureux ou Stressants Chez Les Nouveau-nés Pris en Charge Dans Les unités de réanimation néonatale et pédiatrique et Par Les équipes de SMUR de la région d'Ile de France|EPIPPAIN|Hôpital Armand Trousseau|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|45 Weeks|No|Non-Probability Sample|Two settings: neonatal or pediatric intensive care units and regional pediatric transport        system (SMUR).        In intensive care units, during the first 14 days of admission prospective data will be        collected on all neonatal procedures causing pain, stress, or discomfort with the        corresponding analgesic therapy and pain assessment. A detailed record of conditions of        endotracheal intubations will also be carried out.        In the SMUR, neonates transported during the 2-months study period by all of 5 SMUR will        have all their procedures recorded in a specific data collection form. A real-time        assessment of pain induced by each procedure will be carried out by staff using the DAN        scale. A detailed record of conditions and neonate tolerance of endotracheal intubations        will also be carried out.|October 2011|October 24, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346813||105194|
NCT01348087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056B2279|Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome|An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome||Novartis||Completed|August 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|May 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01348087||105096|
NCT01317303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNSW10106|Comparison of Measures of Plasticity|Comparison of Measures of Plasticity||The University of New South Wales|No|Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317303||107435|
NCT01317862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCB_PG_01|A Comparison of Transcervical Foley Catheter and Prostaglandins for Induction of Labor at Term|||Seoul National University Hospital|No|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Female|N/A|N/A|No|||December 2013|December 8, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317862||107392|
NCT01317875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2201|Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)|||Incyte Corporation|Yes|Recruiting|March 2011|September 2020|Anticipated|September 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317875||107391|
NCT01317888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18508|Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas|An Access Protocol for Continued Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFr-425) Monoclonal Antibody Radiolabeled With 1-125 for High Grade Gliomas||Drexel University||Active, not recruiting|January 2010|||January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|18 Years|N/A|No|||January 2011|March 16, 2011|March 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317888||107390|
NCT01317901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16011|A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma|A Phase 1b/2 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma||Emergent Product Development Seattle LLC|Yes|Completed|May 2011|June 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||November 2012|August 1, 2013|March 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317901||107389|
NCT01318122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/OCT-004|Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan|A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|May 2008|August 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|336|||Both|33 Years|88 Years|No|||February 2012|February 1, 2012|March 16, 2011||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01318122||107372|331 participants were randomized in the core phase 2/3 thiazolidine (CCT-004) study and included in the Full Analysis Set in this study. 5 participants from CCT-004 study did not enter this study.
NCT01349231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901004660|Ketamine Infusion for Obsessive-Compulsive Disorder|Ketamine Infusion for Obsessive-Compulsive Disorder||Yale University|No|Completed|February 2009|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||May 2014|May 8, 2014|April 9, 2011||No||No|March 4, 2014|https://clinicaltrials.gov/show/NCT01349231||105009|
NCT01346384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-N2O|Time - Related Cuff Pressure and Volume of the Laryngeal Tube With the Use of Nitrous Oxide|Time - Related Cuff Pressure and Volume of the Laryngeal Tube With the Use of Nitrous Oxide||Prince of Songkla University|Yes|Completed|May 2008|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|15 Years|75 Years|No|Non-Probability Sample|patients with general anesthesia|April 2011|May 3, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01346384||105227|
NCT01346358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14311|A Study of IMC-CS4 in Subjects With Advanced Solid Tumors|Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available||Eli Lilly and Company|No|Recruiting|June 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01346358||105229|
NCT01346371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-01-11|The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer|The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer||Minnesota Eye Consultants, P.A.|Yes|Active, not recruiting|May 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 7, 2012|April 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01346371||105228|
NCT01347996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC2008-02|Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia|Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission||MEDA Pharma GmbH & Co. KG|No|Completed|July 2009|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347996||105103|
NCT01348230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1179277|Glycoproteomic Analysis of Urine in Women Undergoing Spontaneous Preterm Delivery|Glycoproteomic Analysis of Urine in Women Undergoing Spontaneous Preterm Delivery||University of Missouri-Columbia|Yes|Not yet recruiting|May 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Urine|Female|18 Years|50 Years|No|Probability Sample|Women with a history of preterm delivery who are currently pregnant and receiving care at        affiliates of the University of Missouri, including Missouri Ob/Gyn Associates, University        of Missouri Women's and Children's Hospital, and University of Missouri Center for        Maternal-Fetal-Medicine and Ultrasound Clinic.|May 2011|May 4, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348230||105085|
NCT01346891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1579|Polymorphisms of the Thiazide's Receptor Gene SLC12A3 and Development of Hyponatremia|Polymorphisms of the Thiazide's Receptor Gene SLC12A3 and Development of Hyponatremia||Hospital Italiano de Buenos Aires|No|Completed|July 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|40|||Both|21 Years|N/A|No|Probability Sample|Patients over 21 years old that require treatment with thiazide diuretics|July 2010|July 5, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346891||105188|
NCT01347983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRA230TW EX|Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients|Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients||Chugai Pharma Taiwan|No|Completed|May 2011|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|20 Years|75 Years|No|||April 2013|April 3, 2013|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347983||105104|
NCT01348217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0291-1crgi09|Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus|Prodige 26: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus|CONCORDE|Centre Georges Francois Leclerc|Yes|Recruiting|March 2011|||October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|252|||Both|18 Years|75 Years|No|||September 2014|March 20, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01348217||105086|
NCT01337193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUI 16333|Effect of Exercise and Biofeedback on Symptoms of Incontinence in Women With Stress Urinary Incontinence|Effect of Rehabilitative Ultrasound Imaging Biofeedback on Urinary Incontinence, Pelvic Floor Muscle Contractions and Quality of Life in Women With Stress Urinary Incontinence||Texas Woman's University|No|Terminated|February 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Female|20 Years|N/A|No|||November 2014|November 13, 2014|April 1, 2011||No|Principal investigator has decided not to continue her PhD studies.|No||https://clinicaltrials.gov/show/NCT01337193||105919|
NCT01337401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2010/10027|A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)|A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)|CASPS|Institute of Cancer Research, United Kingdom|Yes|Recruiting|May 2011|July 2018|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|16 Years|N/A|No|||November 2014|November 12, 2014|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01337401||105904|
NCT01337414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44EY018990-02|Tools to Optimize Patient Presentation After Onset of Exudative Age-Related Macular Degeneration (AMD)|Tools to Optimize Patient Presentation After Onset of Exudative AMD (Using the VMS Interactive Education and Early Detection Multi-Test)||Johns Hopkins University|Yes|Recruiting|May 2010|||May 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1000|||Both|N/A|N/A|No|||April 2011|April 15, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337414||105903|
NCT01338441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022000-41|Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples|Selections of Subjects With Dramatic Changes in Their Cardiac Repolarization Parameters After a Pharmacologic Stimulus Aiming to Collect Their Skin Biopsy and Blood Cells|iQTEST|Ectycell SASU|Yes|Completed|March 2011|August 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|130|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 14, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01338441||105835|
NCT01316991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUM 2010-066|A Study of Chewing Gum, Snacking and Appetite|Understanding the Role of Chewing Gum in Satiation, Satiety and Hunger Management|GUM|Institute for Food Safety and Health, United States|No|Active, not recruiting|December 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|56|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316991||107458|
NCT01317316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Serinken 003|Causes and Characteristics of Occupational Eye Injuries in Western Turkey|Causes and Characteristics of Occupational Eye Injuries in Western Turkey||Pamukkale University|No|Completed|January 2007|January 2011|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|816|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with WREI admitted to the center in the four-year period were enrolled in this        prospective study. Institutional Review Board approval was obtained before commencement of        the study. A special data recording system was developed for the study. The study sample        comprised only the casualties occurred at workplace and while working de facto.|November 2006|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317316||107434|
NCT01317563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALASE08140ALOA|Antioxidant Therapy in Lean and Obese Asthmatics|Phase 2 Study of Antioxidant Therapy in Lean and Obese Asthmatics|ALOA|Nemours Children's Clinic|No|Completed|July 2008|March 2016|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|12 Years|25 Years|No|||March 2016|March 21, 2016|March 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317563||107415|
NCT01317576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-3-002|Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!|Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!||Maastricht University Medical Center||Completed|March 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|81|||Male|40 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317576||107414|
NCT01348724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00001|Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118|A Phase I, Open-Label, Single-Centre Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After [14C]-Labelled Oral Administration of NKTR-118 to Healthy Male Volunteers||AstraZeneca||Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|35 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|April 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01348724||105047|
NCT01345656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14563|BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease|A Randomized, Double-blind, Multi-center Study to Assess Safety and Tolerability of Different Oral Doses of BAY94-8862 in Subjects With Stable Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease Versus Placebo (Part A) or Versus Placebo and Spironolactone (Part B)|ARTS|Bayer|Yes|Completed|May 2011|July 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|458|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01345656||105282|
NCT01348971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI-101|Coronary Artery Bypass and Nitrate Oral Supplementation|Effects of Oral Nitrate During Coronary Artery Bypass Surgery|CABANOS|Karolinska Institutet|No|Completed|March 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|80 Years|No|||September 2013|September 24, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348971||105029|
NCT01346111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1385|Multicenter Study of Generation Comorbidity Score|Multicenter Study for the Generation of a Score of Comorbidities||Hospital Italiano de Buenos Aires|No|Completed|April 2009|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2640|||Both|17 Years|N/A|No|Probability Sample|Adults, who were admitted to hospital for a non programme admission, medical or surgical        admission|March 2015|March 19, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346111||105248|
NCT01346670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F950802|Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects|An Open-randomized, Balanced, Crossover Relative Bioavailability Study of Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects||Taipei Medical University WanFang Hospital|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 1, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01346670||105205|
NCT01346917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHO10-1|Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery|Prospective Randomized Controlled Study for the Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery in Patients With Colorectal Cancer||Kangbuk Samsung Hospital|Yes|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|77|||Both|18 Years|N/A|No|||October 2012|October 15, 2012|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346917||105186|
NCT01346631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0130-10-EMC|The Paleolithic Diet and Male Factor Infertility|The Impact of a Paleolithic Diet on Sperm Parameters for Men Suffering From Male Infertility||HaEmek Medical Center, Israel||Withdrawn|May 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Months|N/A|No|||June 2015|June 21, 2015|May 1, 2011||No|We didn't start the study|No||https://clinicaltrials.gov/show/NCT01346631||105208|
NCT01346644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P024|Safety of Lactobacillus Fermentum in Newborn Infants|Study of Tolerance of an Infant Formula Supplemented With Lactobacillus Fermentum CECT5716||Puleva Biotech||Completed|February 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|137|||Both|N/A|30 Days||||May 2013|May 15, 2013|May 1, 2011||||No||https://clinicaltrials.gov/show/NCT01346644||105207|
NCT01347216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMPERA|COMPERA / COMPERA-KIDS|Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension|COMPERA|Technische Universität Dresden|Yes|Recruiting|June 2007|April 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with any manifestation of pulmonary hypertension|August 2015|August 24, 2015|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347216||105163|
NCT01348555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00162 PI 101 1A|Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162|||Pierre Fabre Medicament|Yes|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|June 3, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01348555||105060|
NCT01347710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS747158-301|A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.|A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)||Lantheus Medical Imaging|Yes|Completed|June 2011|September 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|795|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347710||105125|
NCT01347723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC10CC|Scrambler Therapy in Treating Pain and Peripheral Neuropathy in Patients Previously Treated With Chemotherapy|Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Open Access Trial||Mayo Clinic|Yes|Completed|March 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|194|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01347723||105124|
NCT01348802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-228972|A Randomized Trial Comparing "Push" Versus "Pull" Technology for Mobilizing Pain Evidence Into Practice Across Different Health Professions|A Randomized Trial Comparing "Push" Versus "Pull" Technology for Mobilizing Pain Evidence Into Practice Across Different Health Professions||McMaster University|No|Completed|August 2011|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|675|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348802||105041|
NCT01349062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00276991|Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS|Phase III Clinical Studies on Traditional CAM Therapy in the Treatment of HIV/AIDS||Traditional Alternative Medicine Research, India|Yes|Recruiting|March 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|8 Years|45 Years|No|||February 2016|February 19, 2016|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01349062||105022|
NCT01349335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-08-804-01|Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites|A Phase 2 Randomized, Double-blinded, Multicenter and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Different Doses of Tolvaptan Tablet in Patients With Cirrhotic Ascites||Otsuka Beijing Research Institute|No|Completed|April 2009|April 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|75 Years|No|||May 2011|October 10, 2012|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01349335||105001|
NCT01337206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-024|SX ELLA Esophageal Degradable BD Stent System|Evaluation of the Effectiveness of the SX ELLA Esophageal Degradable BD (BD Stent) Stent System|DESTINY|Cook||Completed|January 2012|January 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01337206||105918|
NCT01337427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00028117|Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis|Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis||Johns Hopkins University||Withdrawn|August 2010|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||September 2014|September 12, 2014|April 7, 2011|Yes|Yes|The study was not feasible to conduct in the US and abroad.|No||https://clinicaltrials.gov/show/NCT01337427||105902|
NCT01337752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBHQ880A2203|Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency|A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency||Novartis||Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|55 Years|N/A|No|||February 2014|February 18, 2014|April 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337752||105877|
NCT01338701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT000820212|An Exploratory Study to Evaluate Two Acupuncture Methods for the Treatment of Headaches Associated With Traumatic Brain Injury|A Randomized Exploratory Study to Evaluate Two Acupuncture Methods for the Treatment of Headaches Associated With Traumatic Brain Injury||Samueli Institute for Information Biology|No|Terminated|February 2011|April 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01338701||105815|
NCT01347931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0034|In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency|In-home Evaluation of the Breathe Technologies Noninvasive Open Ventilation (NIOV™) System in Patients With Severe Respiratory Insufficiency||Breathe Technologies, Inc.|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|21 Years|80 Years|No|||April 2012|April 20, 2012|May 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347931||105108|
NCT01348139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0570C00011|Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered Via Single Inhalation Device Compared to AZD3199 Administered Via Turbuhaler™ Inhaler in Patients With Asthma||AstraZeneca||Completed|May 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|39|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|May 3, 2011|Yes|Yes||No|January 28, 2013|https://clinicaltrials.gov/show/NCT01348139||105092|
NCT01348152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100CPT3|Effect of TU-100 in Patients With Functional Constipation|A Randomized, Double-Blinded, Placebo-Controlled Exploratory Study of Daikenchuto (TU-100) in Patients With Functional Constipation||Tsumura USA|Yes|Completed|September 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|80 Years|No|||September 2013|September 9, 2013|May 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01348152||105091|
NCT01348412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0329-1ghfr09|Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure|Phase II Randomized Study Comparing the Association of Intraarterial Perfusion of Raltitrexed and Oxaliplatin Versus Standard Chemotherapy Using Intravenous Perfusion for Colorectal Cancer Patient With Metastases Localized to Liver After Failure of Conventional Treatments.|HEARTO|Centre Georges Francois Leclerc|Yes|Recruiting|December 2010|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||June 2015|June 23, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01348412||105071|
NCT01349257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1015-PR-0055|Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI|Study Title: A Single-dose, Open-label, Randomised, 2-way Crossover, Clinical Pharmacology Study of Four Inhalations of CHF 1535 100/6 NEXT DPI® (Fixed Combination of Beclomethasone Diproponate 100 µg Plus Formoterol Fumarate 6 µg) Versus the Same Dose of CHF 1535 100/6 pMDI Both Administered With Charcoal Block.||Chiesi Farmaceutici S.p.A.|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||April 2012|April 6, 2012|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01349257||105007|
NCT01349270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201084|Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg|Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up|PRNC|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2004|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||September 2014|September 25, 2014|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349270||105006|
NCT01345396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B07620096465|Influence of an Asthma Education Programme on Asthma Control During Pregnancy|Assessment of an Educational Programme for Pregnant Asthmatic Women on the Level of Asthma Control and Unscheduled Doctor Visits During the Pregnancy||Centre Hospitalier Universitaire Saint Pierre|No|Suspended|February 2010|December 2013|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|18 Years|40 Years|No|||October 2013|October 11, 2013|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345396||105302|
NCT01345877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-132|Pain Sensitivity in Acute Inflammatory Pain|Pain Sensitivity in Acute Inflammatory Pain - Gender Differences and Validity of Sensory Tests|PASORI|University of Copenhagen|Yes|Completed|February 2010|February 2011|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|100|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345877||105265|
NCT01346124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-133|High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull|Phase II Study of High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull||Massachusetts General Hospital|Yes|Recruiting|December 2012|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01346124||105247|
NCT01347229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/06|SENSIMED Triggerfish® in Sitting and Supine Position|Assessment of Sitting and Supine Position IOP Using SENSIMED Triggerfish® and Standard Tonometers||Sensimed AG|No|Completed|April 2011|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 16, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01347229||105162|
NCT01347463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJV-cath-nipple|Validation of the Ipsilateral Nipple as the Directional Guide for Internal Jugular Vein (IJV) Catheterization|||Seoul National University Hospital|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|80 Years|No|||May 2013|May 20, 2013|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01347463||105144|
NCT01347476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|old age prostate|Aggressive Prostate Cancers in Elderly Patients|Patients Aged More Than 70 Had More Aggressive Prostate Cancers and Higher Risk of Biochemical Recurrence in Korea||Seoul National University Hospital|Yes|Completed|January 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1333|||Male|40 Years|80 Years|No|Non-Probability Sample|Men who underwent radical prostatectomy for the treatment of clinically localized prostate        cancer|May 2011|May 18, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01347476||105143|
NCT01347489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-Aysan|Cronic Pressure Wounds and Relation With Gender|Cronic Pressure Wounds and Relation With Gender|preswound|SB Istanbul Education and Research Hospital|No|Recruiting|November 2010|December 2012|Anticipated|June 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2|||Both|17 Years|90 Years|No|Non-Probability Sample|Cronic pressure wound patients|November 2010|May 4, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347489||105142|
NCT01347762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000096|Nabilone for Cannabis Dependence: A Pilot Study|Nabilone for Cannabis Dependence: A Pilot Study|NAB CAN|Mclean Hospital|No|Recruiting|June 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|45 Years|No|||December 2015|December 21, 2015|April 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01347762||105121|
NCT01348269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZOL446HDE38T|Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome|A Prospective, Bi-centric,Randomized, Primary Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome|ZoMARS|Wuerzburg University Hospital|No|Recruiting|May 2011|December 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||September 2011|September 22, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01348269||105082|
NCT01348568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-191|Low Glycemic Index Diet (With Canola Oil) for Type 2 Diabetics|Effect of Low Glycemic Index Diets (With Canola Oil) on Glucose Control in Non-Insulin Dependent Diabetics||University of Toronto|Yes|Completed|March 2011|March 2015|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|21 Years|N/A|No|||December 2015|December 7, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348568||105059|
NCT01347736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC10CE|Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection|Scrambler Therapy for the Treatment of Chronic Zoster Pain||Mayo Clinic|Yes|Active, not recruiting|March 2011|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01347736||105123|
NCT01347749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0208|Mindfulness and Present Centered Therapies for PTSD: Efficacy and Mechanisms|Mindfulness and Self-Compassion Meditation for Combat Posttraumatic Stress Disorder: Randomized Controlled Trial and Mechanistic Study||University of Michigan|No|Completed|March 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Male|21 Years|50 Years|No|||November 2014|November 14, 2014|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01347749||105122|
NCT01349075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07D.366|TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma|A Humanitarian Device Exemption Treatment Protocol of Therasphere for the Treatment of Unresectable Hepatocellular Carcinoma||Thomas Jefferson University|No|Recruiting|October 2007|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01349075||105021|
NCT01349361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024517-31|Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight|Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight||Bispebjerg Hospital||Recruiting|March 2011|||January 2013||Phase 2|Interventional|N/A|1||||||Both|18 Years|N/A||||March 2011|May 5, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349361||104999|
NCT01349374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01127-32|Skin Samples of Diabetic Patients and Healthy Volunteers Collection|Study Aiming to Collect Skin Samples of Diabetic Patients and Healthy Volunteers for Cellular Reprogramming, Within the Framework of New Therapeutic Strategies in Diabetes Treatment||Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Terminated|January 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|July 11, 2012|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01349374||104998|
NCT01337219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM/NEB-03-10|Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis|Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.|RM/NEB-03-10|Erempharma|No|Recruiting|April 2011|||September 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|16 Years|N/A|No|||February 2011|April 15, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01337219||105917|
NCT01337440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KanazawaU-1|Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases|The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases||Kanazawa University|Yes|Recruiting|April 2010|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||April 2011|April 15, 2011|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01337440||105901|
NCT01338714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100001-62-010|The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function|The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function: a Randomized Controlled Trial||Taipei City Hospital|Yes|Completed|May 2011|September 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|65 Years|No|||May 2014|May 6, 2014|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338714||105814|
NCT01338727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-009|Breastfeeding Education and Support Trial for Obese Women (BESTOW)|Breastfeeding Education and Support Trial for Obese Women (BESTOW)|BESTOW|University of Connecticut|No|Completed|September 2006|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|206|||Female|18 Years|N/A|No|||April 2011|April 18, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01338727||105813|
NCT01348984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFP TKA|Study of Transdermal Fentanyl Patch to Treat Postoperative Pain in Total Knee Arthroplasty|Transdermal Fentanyl Patch for Postoperative Analgesia in Total Knee Arthroplasty|TFP|Khon Kaen University|No|Completed|April 2010|December 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||February 2010|May 5, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348984||105028|
NCT01348997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU Lurie 10CC01|E-health Intervention for Cancer Survivors 2.0|E-Health Intervention for Cancer Survivors 2.0||Northwestern University|No|Withdrawn|May 2011|November 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 6, 2014|May 4, 2011||No|Study ended prior to completion of planning stage. No participants enrolled.|No||https://clinicaltrials.gov/show/NCT01348997||105027|
NCT01349244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 1006006943|Hydronephrosis on Ultrasound With CT Finding in Patients With Renal Colic|Correlation of Hydronephrosis on Point of Care Ultrasound With CT Finding in Patients With Expected Renal Colic||Yale University|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|N/A|No|Non-Probability Sample|This will be a prospective observational study involving a convenience sample of all ED        patients scheduled for NCT at some point during their emergency department visit.|July 2014|July 8, 2014|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01349244||105008|
NCT01345643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCPTS110419|Clinical Trial of West-China Perioperative Transfusion Score (WCPTS）for Massive Hemorrhagic Surgery|A Randomized Controlled Clinical Trial of Transfusion Under the Guidance of West-China Perioperative Transfusion Score(WCPTS）for Massive Hemorrhagic Surgery|WCPTS|West China Hospital|Yes|Recruiting|February 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|15 Years|70 Years|No|||April 2013|April 5, 2013|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01345643||105283|
NCT01345903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09202|Robotic-Assisted Surgery in Treating Patients With Spine Tumors|A Pilot Feasibility and Safety Study Using Robotic Assisted Surgery in Patients With Spine Tumors||City of Hope Medical Center|Yes|Withdrawn|December 2012|||June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|April 28, 2011|No|Yes|The protocol needs to be re-designed.|No||https://clinicaltrials.gov/show/NCT01345903||105263|
NCT01345669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.131|LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy|A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma||Boehringer Ingelheim||Recruiting|October 2011|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|669|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 28, 2011||||No||https://clinicaltrials.gov/show/NCT01345669||105281|
NCT01345890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/008/HP|Cortical Neuromodulation in Post Stroke Dysphagia|Neuromodulation in Post Stroke Dysphagia||University Hospital, Rouen|No|Completed|January 2007|June 2010|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|80 Years|No|||June 2013|June 17, 2013|February 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01345890||105264|
NCT01346397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCS-Campath-06|Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation|Prospective Randomized Trial Comparing CsA Versus Tacro After Campath Induction In Kidney Transplant Recipients|RSCS-Campath|Russian Academy of Medical Sciences|No|Recruiting|September 2010|September 2014|Anticipated|September 2013|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|blood and urine, taken at the time of protocol or case biopsies will be deeply freeze and      stocked for future examination for NAT or other molecules - candidates for diagnostic      markers.|Both|6 Months|60 Years|No|Probability Sample|Recipients of kidney allograft who underwent previous Campath induction and do receive        calcineurine inhibitor (CNI)|December 2012|December 6, 2012|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01346397|100 Years|105226|
NCT01346657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98030|The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects|The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects||Taipei Medical University WanFang Hospital|No|Completed|July 2009|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 1, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01346657||105206|
NCT01347775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMTRF-06001|Inspiratory Muscle Training in Patients With End Stage Renal Failure|Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial||The University of Queensland|Yes|Active, not recruiting|December 2007|February 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||May 2011|May 3, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01347775||105120|
NCT01348009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPK105|Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer|A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer||Genta Incorporated|Yes|Recruiting|May 2011|January 2014|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|20 Years|N/A|No|||March 2012|March 11, 2012|April 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01348009||105102|
NCT01348243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/9900/004/10|Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis|MULTICENTRE, RANDOMIZED, OPEN-LABEL, TWO-ARM PARALLEL GROUPS, ACTIVE CONTROLLED STUDY DESIGN TO DEMONSTRATE EFFICACY AND TOLERABILITY OF CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK VS CLODRONATE 100 MG/3,3ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK IN A 1-YEAR TREATMENT PERIOD OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS||Chiesi Farmaceutici S.p.A.|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|260|||Female|50 Years|N/A|No|||June 2013|June 21, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348243||105084|
NCT01348867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2009-394|Effectiveness of a Treat-to-target Clinic Led by a Nurse Consultants|A Randomised Study to Evaluate the Effectiveness of a Treat-to-target Clinic Led by a Nurse Consultant in Managing Patients With Type 2 Diabetes in Hong Kong||Asia Diabetes Foundation|Yes|Completed|March 2009|December 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|242|||Both|18 Years|75 Years|No|||May 2011|June 23, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348867||105037|
NCT01349114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110124007|Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects|Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects||University of Alabama at Birmingham|No|Terminated|June 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|21|||Both|19 Years|80 Years|No|||July 2014|July 15, 2014|May 4, 2011||No|Sponsor requested termination.|No|July 11, 2013|https://clinicaltrials.gov/show/NCT01349114||105018|Early termination leading to smaller number of subjects analyzed then anticipated, no adverse effects within the aliskiren group
NCT01348529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCDP1|Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)|Internet-based Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Pilot Study||Karolinska Institutet|No|Active, not recruiting|September 2010|||May 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2010|May 4, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01348529||105062|
NCT01348542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35933|Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia|Efficacy of Trazodone vs. Cognitive Behavioral Therapy in Patients With Chronic Insomnia Associated With Objective Short Sleep Duration||Milton S. Hershey Medical Center|No|Recruiting|April 2011|||April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|30 Years|60 Years|No|||April 2015|April 13, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01348542||105061|
NCT01348841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25973|Wound Interdisciplinary Teams (WIT): A Community- Based Pragmatic Randomized Controlled Trial|Wound Interdisciplinary Teams (WIT): A Community- Based Pragmatic Randomized Controlled Trial|WIT|University of Toronto|No|Completed|May 2011|October 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|451|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348841||105039|
NCT01349088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10G.30|Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer|Phase I/II Trial of Motesanib in Combination With Ixabepilone and Capecitabine in Women With Locally Recurrent or Metastatic Breast Cancer||Thomas Jefferson University|Yes|Withdrawn|December 2013|September 2018|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||January 2014|January 29, 2014|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349088||105020|
NCT01349101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.51|A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors|Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies||Thomas Jefferson University|Yes|Recruiting|February 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|April 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349101||105019|
NCT01337778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD062821-01A1|Dil Mil (Hearts Together)|Empowering Daughters and Mother-in-laws to Mitigate Gender-based Violence and Promote Women's Health in India||RTI International|Yes|Completed|August 2010|October 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|539|||Female|18 Years|85 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337778||105875|
NCT01338454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gungorduk12|Can we Use Intravenous Injection of Tranexamic Acid in Routine Practice With Active Management of the Third Stage of Labor?|||Erzincan Military Hospital||Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|450|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 16, 2011|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338454||105834|
NCT01338064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-YS-619-CTIL|Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)|Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|150|Samples Without DNA|1. Induced sputum (IS)        2. Exhaled Breath Condensate|Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|At least six months of occupational exposure to Caesar stone|April 2011|April 16, 2011|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01338064||105854|
NCT01338740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/566|Switching From Adalimumab to Infliximab|Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab|ADA-IFX|University Hospital, Ghent|No|Recruiting|April 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|At regular intervals, the results of interim blood tests will be documented (3x).      After 10, 26 and 52 weeks, additional serum samples will be taken for determination of      antibodies against Adalimumab and Infliximab. The serum levels of Adalimumab (week 0) and      Infliximab (week 10, 26 and 52) will be determined.|Both|18 Years|75 Years|No|Probability Sample|Patients with moderately to severely active Crohn's disease with primary non-response or        loss of response to Adalimumab, switch to Infliximab.|December 2014|December 4, 2014|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338740||105812|
NCT01338753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22197/2009-01|Study to Evaluate Markers of Response in Locally Advanced Breast Cancer|A Multicenter Phase II Study, to Evaluate the Predictive Markers of Response in Locally Advanced Breast Cancer, Treated With Bevacizumab Combined With Neoadjuvant Chemotherapy|IMAGING|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Completed|October 2009|May 2011|Actual|October 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|74|||Female|18 Years|70 Years|No|||September 2013|September 9, 2013|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01338753||105811|
NCT01348464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|girba2339|A Trial on Laparoscopic Appendectomy Versus Single Port Appendectomy|Transumbilical Single Port Laparoscopic Appendectomy Versus Conventional Laparoscopic Appendectomy in Adult Patients: A Prospective Randomized Control Study||Gachon University Gil Medical Center|No|Completed|March 2010|December 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|5 Years|85 Years|No|Probability Sample|The cohorts will be the residents of Incheon, Korea|April 2012|April 2, 2012|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01348464||105067|
NCT01348750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSD_HSC07_4684|Healing Touch & Guided Imagery for Posttraumatic Stress Disorder Symptoms|Healing Touch and Guided Imagery Intervention in Post-deployment Military Personnel With Posttraumatic Stress Disorder Symptoms||Scripps Center for Integrative Medicine|No|Completed|July 2008|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||May 2011|May 4, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348750||105045|
NCT01349010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-10-802-01|Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia|A Randomized, Double Blind, Placebo Control, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Imported Probucol in Hyperlipidemia Patients||Otsuka Beijing Research Institute|No|Completed|April 2011|February 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|20 Years|N/A|No|||June 2013|June 4, 2013|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01349010||105026|
NCT01346150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RDCRN PIDTC-6902|Patients Treated for SCID (1968-2010)|A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID (1968-2010) (RDCRN PIDTC-6902)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|May 2011|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|1146|Samples With DNA|Biospecimens may include blood, other tissues (e.g., buccal swab or brushing, hair      follicles), and/or bone marrow.|Both|N/A|N/A|No|Non-Probability Sample|Patients with diagnosis of SCID or SCID variants treated at Consortium Centers from        1968-2010|March 2016|March 17, 2016|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01346150||105245|
NCT01346163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809087|Add On Treatment for Cognitive Deficits in Schizophrenia|A Phase1B Study: A Placebo Controlled Study of PF-03654746 Given as Add-On Treatment of Cognitive Deficits in Schizophrenia||University of Pennsylvania|No|Completed|April 2009|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|40 Years|No|||April 2011|April 29, 2011|May 20, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01346163||105244|
NCT01346137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIG-10-131|Study of a COX-2 Inhibitor for Prevention of Ovulation|An Exploratory Study of a COX-2 Inhibitor(Meloxicam) for Prevention of Ovulation||Instituto Chileno de Medicina Reproductiva|Yes|Recruiting|January 2011|September 2011|Anticipated|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|56|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2011|May 2, 2011|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346137||105246|
NCT01346930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055B202|Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis|Long Term, Single-arm, Open-label Extension Study of the MUSIC Study to Assess the Safety and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis|MUSIC OL|Actelion|No|Withdrawn|July 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|May 2, 2011|No|Yes|Due to Protocol AC-055B201 (MUSIC) not meeting it's primary end point|No||https://clinicaltrials.gov/show/NCT01346930||105185|
NCT01346943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTURA-FIM-1|The Altura Abdominal Aortic Aneurysm (AAA) Endograft Safety and Feasibility Study|The Altura AAA Endograft Safety and Feasibility Study For Exclusion of Abdominal Aortic Aneurysms||Altura Medical Inc.|No|Active, not recruiting|April 2011|May 2019|Anticipated|May 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346943||105184|
NCT01347515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URoviraiVirgili|Bioactivity of Olive Oils Enriched With Their Own Phenolic Compounds (VOHF1)|Bioavailability and Bioactivity of Olive Oils Enriched With Their Own Phenolic Compounds in a Dose-response Study (VOHF1)|VOHF1|University Rovira i Virgili|Yes|Recruiting|April 2011|September 2011|Anticipated|June 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|12|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2011|May 27, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01347515||105140|
NCT01347788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005|Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer|Dose-Finding Pilot Study of XL184 in Men With Castrate-Resistant Prostate Cancer and Bone Metastases||Massachusetts General Hospital|Yes|Completed|April 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|34|||Male|18 Years|N/A|No|||October 2015|October 16, 2015|April 11, 2011|Yes|Yes||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01347788||105119|
NCT01348022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0361|Evaluation of Outcomes of EES Implantation for Unprotected Left Main Coronary Artery Stenosis (PRE-COMBAT 2)|Prospective Evaluation of Outcomes of Everolimus-Eluting Stent (XIENCE V) Implantation for Unprotected Left Main Coronary Artery Stenosis: Multicenter Trial||CardioVascular Research Foundation, Korea|Yes|Completed|August 2009|September 2015|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|397|||Both|18 Years|N/A|No|Non-Probability Sample|Coronary artery disease requiring drug eluting stents|November 2015|November 18, 2015|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01348022||105101|
NCT01348256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2009-01|Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma|Randomized Phase II Study With Dendritic Cell Immunotherapy in Patients With Resected Hepatic Metastasis of Colorectal Carcinoma||Clinica Universidad de Navarra, Universidad de Navarra|No|Recruiting|November 2010|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||November 2012|May 6, 2013|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348256||105083|
NCT01345513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGWS-001|Feasibility Clinical Study of Targeted and Genome-Wide Sequencing|Feasibility Clinical Study of Targeted and Genome-Wide Sequencing||University Health Network, Toronto|No|Suspended|March 2011|December 2015|Anticipated|April 2015|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Archival tumor tissue, fresh tumor biopsy, blood sample, pleural effusion (if available)or      ascites (if available)|Both|18 Years|N/A|No|Probability Sample|Patients from the Princess Margaret Hospital or other Ontario Institution|July 2015|July 14, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01345513||105293|
NCT01348828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0003|Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System|Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms||Endologix|Yes|Active, not recruiting|November 2011|May 2017|Anticipated|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|May 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01348828||105040|
NCT01348581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KERECIS-10-106-S1|Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing|Chronic Wound Treatment With Extracellular Matrix (ECM) Scaffold Made From Fish Proteins||Kerecis Ltd.|Yes|Recruiting|November 2010|||October 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2011|May 4, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348581||105058|
NCT01349400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS6-233|Watchful Waiting Versus Repair of Oligosymptomatic Incisional Hernias|Watchful Waiting vs. Repair of Oligosymptomatic Incisional Hernias|AWARE|Charite University, Berlin, Germany|Yes|Recruiting|November 2011|May 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|636|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349400||104996|
NCT01345500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110463|UCSD Take Charge Study|Randomized Clinical Trial of a Weight Loss Program in Type 2 Diabetes||University of California, San Diego|Yes|Completed|February 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|227|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 13, 2013|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345500||105294|
NCT01338467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYEMUST|Glaucoma Treatment by Circular Cyclocoagulation Using High Intensity Focused Ultrasound With the EYEOP Medical Device|Glaucoma Treatment by Circular Cyclocoagulation Using High Intensity Focused Ultrasound (HIFU). A Prospective, Multicenter, Open-label, Safety and Efficacy Study of the Treatment With the EYEOP Medical Device in Patients With Refractory Glaucoma||EyeTechCare|Yes|Completed|April 2011|November 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||March 2013|June 15, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01338467||105833|
NCT01338480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980361|Improving Informed Consent Process for Trauma Patients in the Emergency Department|Improving Informed Consent Process for Trauma Patients in the Emergency Department||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Recruiting|April 2010|||August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|240|||Both|18 Years|N/A|No|||April 2010|August 1, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338480||105832|
NCT01338493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maverick Global Registry|Maverick Total Disc Replacement in a 'Real World' Patient Population|Maverick Total Disc Replacement in a 'Real World' Patient Population - A Prospective, Multicenter, Observational Study|Maverick|Medtronic Spinal and Biologics|No|Completed|February 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|139|||Both|N/A|N/A|No|Non-Probability Sample|Patient eligibility is determined according to labeling|January 2016|January 26, 2016|February 17, 2011||No||No|August 6, 2014|https://clinicaltrials.gov/show/NCT01338493||105831|Seriousness of AEs was not assessed when the data were collected so it is not possible to separate SAEs and Other (Non-serious) AEs for the Maverick Registry. All events are here-reported as SAEs.
NCT01338129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC116131CTIL|The Effect of Vitamin c on Preventing Complex Regional Pain Syndrome (CRPS Type I) Following Ankle Fracture|The Effect of Vitamin c on Preventing Complex Regional Pain Syndrome (CRPS Type I) Following Ankle Fracture, Prospective Double Blind Study|CRPS|Rabin Medical Center|Yes|Not yet recruiting|April 2011|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|April 18, 2011|March 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338129||105849|
NCT01338506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA030143-01|Integrated Treatment of OEF/OIF Veterans With PTSD & Substance Use Disorders|Integrated Treatment of Operation Enduring Freedom/Operation Iraqi Freedom Veterans With Post-traumatic Stress Disorder and Substance Use Disorders|COPE|Medical University of South Carolina|Yes|Completed|April 2011|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||March 2016|March 14, 2016|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01338506||105830|
NCT01349283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVG-V-A002|Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns|A Prospective, Randomized, Double-blind, Parallel-group, Controlled Study of the Immunogenicity and Safety of the Recombinant Hepatitis B Vaccine (Hepavax-Gene TF) and a Comparator Univalent Hepatitis B Vaccine in Neonates||Crucell Holland BV|No|Completed|May 2011|November 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|1738|||Both|N/A|1 Day|Accepts Healthy Volunteers|||January 2013|March 3, 2014|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349283||105005|
NCT01349296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARIS|BIBF 1120 and RAD001 in Solid Tumors - Phase I|BARIS - BIBF1120 and RAD001 in Solid Tumors. A Phase I Trial to Evaluate the Safety and Tolerability of Combined BIBF 1120 and RAD001 in Solid Tumors and to Determine the Maximum Tolerated Dose (MTD) of the Combination|BARIS|University of Cologne|Yes|Recruiting|July 2012|March 2015|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349296||105004|
NCT01345409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005896-01|Acupuncture and Chiropractic Care for Chronic Pain in an Integrated Health Plan|Acupuncture and Chiropractic Care for Chronic Pain in an Integrated Health Plan|Relief|Kaiser Permanente|No|Active, not recruiting|December 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1242|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic musculoskeletal pain (CMP)|December 2015|December 21, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345409||105301|
NCT01345422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNS1|Wii Balance Board in Dizziness|A Pilot Study to Assess the Usefulness of the Wii Balance Board for Dizziness||Kaiser Permanente|No|Withdrawn||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 28, 2011||No|The study never started since it did not receive IRB approval|No||https://clinicaltrials.gov/show/NCT01345422||105300|
NCT01345682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.43|LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy|A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy||Boehringer Ingelheim||Active, not recruiting|January 2012|January 2016|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|483|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|April 28, 2011||||No|March 13, 2015|https://clinicaltrials.gov/show/NCT01345682||105280|
NCT01345695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027527|Bihar Evaluation of Social Franchising and Telemedicine|Bihar Evaluation of Social Franchising and Telemedicine in India|BEST|Duke University|No|Completed|May 2011|October 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|106380|||Both|N/A|N/A|No|Probability Sample|Randomly selected residents of 12 districts in Bihar State, India.|December 2015|December 14, 2015|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01345695||105279|
NCT01346956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02AMCRAVSAND07|Acute Cardiovascular Effects of Cigarette Smoking|Acute Cardiovascular Effects of Cigarette Smoking||Andhra Medical College|No|Completed|July 2002|August 2002|Actual|August 2002|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Twenty healthy male smokers|January 2003|May 3, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01346956||105183|
NCT01346969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXC 001-204|Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery|A Phase 2, Randomized, Double-blind, Within-subject Controlled Study to Evaluate Efficacy and Safety of Various Doses and Regimens of EXC 001 for the Amelioration of Scarring Following Revision of Scars From Prior Breast Surgery in Adult Subjects||Pfizer|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|68|||Both|18 Years|65 Years|No|||January 2013|May 30, 2013|May 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346969||105182|
NCT01346410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-060|Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Unresectable Pancreatic Cancer||St. John's Mercy Research Institute, St. Louis|No|Completed|September 2008|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|April 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01346410||105225|
NCT01346683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-0002|Study on OsseoSpeed™ TX Implants in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate the OsseoSpeed™ TX Implant With an Early Loading Protocol in Patients With Tooth Loss in the Posterior Mandible. A 3-years Follow-up Study.||Dentsply Implants||Active, not recruiting|February 2011|||May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|75 Years|No|||March 2016|March 23, 2016|May 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346683||105204|
NCT01346696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-0005|Study on OsseoSpeed™ TX Short Implants in a Chinese Population|An Open, Prospective, Multi-center Study Assessing the OsseoSpeed™ TX Length 6 mm in in the Posterior Maxilla and Mandible. A 3-years Follow-up Study.||Dentsply Implants||Completed|February 2011|||March 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|75 Years|No|||March 2016|March 21, 2016|May 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01346696||105203|
NCT01347502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smartphone_SNU|Prevalence of Bacterial Contamination on Smart Cell Phone vs. Non-smart Phone|Bacterial Contamination of Smart Phones of Health Care Workers||Seoul National University Hospital|No|Completed|April 2011|August 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|203|||Both|19 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthcare providers of MICU in Seoul national university hospital and Seoul national        university Bundang hospital who have cellular phones|July 2012|July 5, 2012|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01347502||105141|
NCT01347268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKH-8302-100-DR-08|Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist|A Prospective Randomized Study Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Administration in Patients at Risk for Severe OHSS||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Recruiting|January 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||January 2011|May 2, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01347268||105159|
NCT01348035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KYR-003-PKD|Efficacy Study of Water Drinking on PKD Progression.|Efficacy Study of Long-term Water Intake on the Progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).|ESWP|Kyorin University|No|Completed|April 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Urine|Both|20 Years|65 Years|No|Non-Probability Sample|The patients who visit Kyorin University Hospital.|May 2012|December 21, 2013|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01348035||105100|
NCT01348282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIANT-TE|Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study|Exploratory Controlled Prospective Randomized Trial to Compare the Efficacy and Safety of Two Different Pharmacology Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study||Fundacio Lluita Contra la SIDA|No|Completed|May 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|65 Years|No|||March 2014|March 31, 2014|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01348282||105081|
NCT01320241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320924197612177170-BS|Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture|An Unicentric RCT About Novel Radiation Stent Versus Nitinol SEMS for Palliative Treatment of Malignant Biliary Stricture||Southeast University, China|Yes|Completed|November 2008|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||March 2011|March 30, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320241||107210|
NCT01320254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT-Nr.: 2010-018850-11|PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)|Panitumumab in Combination With Cisplatin/Gemcitabine Chemotherapy in Patients With Cholangiocarcinomas - a Randomized Clinical Phase II Study|PiCCA|Hannover Medical School|Yes|Recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320254||107209|
NCT01320488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08/117|Breast Cancer in Young Women: Is it Different?|Breast Cancer in Young Women: Is it Different?|YoungWomen|National Guard Health Affairs|No|Recruiting|October 2009|October 2019|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|tumor and blood specimens to characterize the pathology and biology of the tumors, and      establish tumor bank for future studies|Female|40 Years|N/A|No|Non-Probability Sample|The proposed project is a prospective longitudinal cohort study of young women with breast        cancer. Over a 3-year period, we aim to identify a total of 600 women with newly diagnosed        breast cancer, of those 300 women age 40 and younger and 300 older women from academic and        community health care institutions across the Riyadh area. It is anticipated that at least        400 of these women (from study and control group) will agree to participate in the study.|January 2014|January 15, 2014|March 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01320488||107191|
NCT01320501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08/29|Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer|Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME)|REALME|National Guard Health Affairs|No|Recruiting|October 2009|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|March 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01320501||107190|
NCT01321255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOCUS|Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.|Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug|FOCUS|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Yes|Completed|January 2012|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2118|||Both|40 Years|N/A|No|||July 2014|July 14, 2014|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321255||107132|
NCT01321268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-03-CEL|Safety and Efficacy of a Dietary Supplement in Females With Cellulite|Safety and Efficacy of an Antioxidant Based Dietary Supplement With PUFAs in Healthy Female Volunteers With Cellulite (Orange Peel Skin)||DSM Nutritional Products, Inc.|No|Terminated|May 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|June 4, 2015|March 10, 2011||No|sponsor stopped study due to recruitment problems|No||https://clinicaltrials.gov/show/NCT01321268||107131|
NCT01320774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treatment with Daivobet® Gel|Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris|Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris||LEO Pharma|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|588|||Both|18 Years|N/A|No|Non-Probability Sample|Patients visiting their attending dermatologist in the primary care clinic|February 2012|February 9, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320774||107169|
NCT01321034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-022258-17|Effect of Niacin in the Lipoprotein (a) Concentration|Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration.||Instituto Aragones de Ciencias de la Salud|Yes|Completed|October 2011|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321034||107149|
NCT01322191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10920|Morphine PK Subgroup Analysis|A Randomized Controlled Comparison of Ketorolac Tromethamine and Morphine for Postoperative Analgesia in Critically-ill, 3-18 Year-old Children: A Subgroup Analysis of Developmental Changes in Morphine Kinetics and Efficacy||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|April 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|48|||Both|3 Years|18 Years|No|||March 2008|October 26, 2012|March 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01322191||107060|
NCT01321944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001137|Direct to Smoker Outreach in a Health Care Setting|A POPULATION-BASED DIRECT-TO-SMOKER OUTREACH OFFERING TOBACCO TREATMENT IN A HEALTH CARE SETTING: A RANDOMIZED CONTROLLED TRIAL|DTS|Massachusetts General Hospital|No|Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|590|||Both|18 Years|N/A|No|||March 2011|March 22, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321944||107079|
NCT01322750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|354344|Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma|Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma||Walter Reed Army Medical Center|No|Recruiting|December 2010|January 2023|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3125|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All adults (> 18 years of age) presenting for evaluation at breast center - who        subsequently undergo a diagnostic or therapeutic procedure and who do not have a prior        history of invasive carcinoma or clinically-apparent metastatic disease, will be eligible        for enrollment.|March 2011|March 24, 2011|March 24, 2011||||No||https://clinicaltrials.gov/show/NCT01322750||107017|
NCT01326819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QATP1962|Comparison of Normal Readings and Repeatability Across Skin Colors|Comparison Study of Three Regional Oxygen Saturation (rSO2) Systems Across a Wide Range of Skin Colors||Nonin Medical, Inc|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|231|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|November 2012|May 9, 2013|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01326819||106705|
NCT01327105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16974|Essure Transvaginal Ultrasound (TVU) Study|Use of Transvaginal Ultrasound to Confirm Essure® Micro-insert Placement in Women: Demonstration of Effectiveness||Bayer|Yes|Active, not recruiting|May 2011|July 2023|Anticipated|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|547|||Female|21 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01327105||106683|
NCT01327391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 7753|Tolerance of "on Line" Hemodiafiltration in Chronic Renal Failure Patients|Tolerance of "on Line" Hemodiafiltration and Impact on Morbidity and Cardiovascular Risk Factors in Chronic Renal Failure Patients|on-line-HDF|University Hospital, Montpellier|Yes|Completed|May 2005|May 2014|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|415|||Both|65 Years|90 Years|No|||March 2011|December 5, 2014|January 14, 2008||No||No||https://clinicaltrials.gov/show/NCT01327391||106662|
NCT01327404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0473|Depression in Type 2 Diabetes|Myelin, Glia and Depression in Type 2 Diabetes||University of Illinois at Chicago|Yes|Recruiting|October 2009|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|400|||Both|30 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients of all subject types will be recruited through the general medical, psychiatric,        and endocrinology clinics associated with the UIC Medical Center. Patients will be first        cleared for participation in the study by their primary physicians. The patient and family        will be approached by the PI or another investigator who will explain the research and its        goals. We also plan to recruit subjects through flyers and advertisements.|March 2011|March 31, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327404||106661|
NCT01318733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18142|Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea||Galderma|No|Completed|March 2011|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|449|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|March 9, 2011|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01318733||107326|
NCT01319032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013-11-HYMC|Genetic Polymorphism and Israeli Top-level Swimmers' Performance and Expertise|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Whole blood|Both|13 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Swimmers training at the Wingate Institute|March 2011|March 17, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01319032||107303|
NCT01319305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1743-001|BREATHE Long-Term Follow-Up Study|BREATHE Long-Term Follow-Up Study||Entellus Medical, Inc.|No|Completed|April 2010|||June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Participants who were treated with FinESS Sinus Treatment in the BREATHE I Study|June 2011|June 27, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01319305||107282|
NCT01319318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-OZU-10-017|Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy|||Allergan|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who plan on undergoing a pars plana vitrectomy|April 2013|April 15, 2013|March 18, 2011|Yes|Yes||No|April 15, 2013|https://clinicaltrials.gov/show/NCT01319318||107281|
NCT01319630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007|The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients|The Effect of Three Different Fluids(Albumin 5%, Normal Saline, HES 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients Using Sidestream Dark Field (SDF) Microscopy and Near-Infrared Spectroscopy (NIRS) Analysis||St. John's Mercy Research Institute, St. Louis|No|Not yet recruiting|April 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|N/A|No|Probability Sample|patients admitted to the Intensive Care Unit with diagnosis of sepsis.|June 2012|June 5, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319630||107257|
NCT01318746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4408|The Circadian Rhythm of Potassium and Cystatin C|The Circadian Rhythm of Potassium and Cystatin c and the Day-to-day Variability|Potassium|University of Erlangen-Nürnberg Medical School|No|Completed|April 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy persons compared to patients with renal failure|April 2013|April 16, 2013|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318746||107325|
NCT01319643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYGEN-TIPO-1.0-30-09-2009|Normal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU)|Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial|OXYGEN-ICU|University of Modena and Reggio Emilia|No|Recruiting|December 2009|November 2011|Anticipated|November 2010|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|N/A|No|||August 2010|March 21, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01319643||107256|
NCT01319955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09054|Flu Vaccine Against Childhood Pneumonia, Bangladesh|Influenza Vaccine Efficacy Against Childhood Pneumonia in an Urban Tropical Setting||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|August 2010|April 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3408|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||April 2010|August 27, 2015|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01319955||107232|
NCT01319968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11030-2011kCTIL|Postpartum Dyspareunia Resulting From Vaginal Atrophy|Postpartum Dyspareunia Resulting From Vaginal Atrophy: Prevalence, Characteristics and Risk Factors||Meir Medical Center|No|Completed|March 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|117|Samples Without DNA|Vaginal smears for cytology and pH measurment.|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|100 postpartum women attending the clinic for their postpartum visit|April 2012|April 7, 2015|March 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01319968||107231|
NCT01320228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B274|Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor|Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor|ORLIFAT|University of Copenhagen|No|Completed|April 2011|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|69|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 1, 2014|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320228||107211|
NCT01320475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/04|Epidural Levobupivacaine-sufentanil Versus Epidural Levobupivacaine and Intravenous Ketamine|Thoracic Epidural Analgesia: Epidural Levobupivacaine and Sufentanil Versus Epidural Levobupivacaine and Intravenous Ketamine||Hopital Foch|No|Terminated|September 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||July 2011|July 18, 2011|March 19, 2011||No|Difficulty of Recruitment|No||https://clinicaltrials.gov/show/NCT01320475||107192|
NCT01320748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS 11-001|fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults|fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults||Inova Health Care Services|No|Completed|February 2011|January 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01320748||107171|
NCT01320761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-10-19|A Study to Assess Injection Comfort of Two Formulations of ATX-101|A Study to Assess Injection Comfort of Two Formulations of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Administration in the Submental Area||Kythera Biopharmaceuticals|No|Completed||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 21, 2011|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320761||107170|
NCT01320800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH81881|CBT for Social Anxiety Disorder Delivered by School Counselors|CBT for Social Anxiety Disorder Delivered by School Counselors||New York University School of Medicine|Yes|Completed|October 2010|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|126|||Both|14 Years|17 Years|No|||January 2016|January 28, 2016|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01320800||107167|
NCT01321047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-2011-18|Balanced Propofol Sedation Versus Propofol Alone Sedation in Therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP)|Phase 4 Study of Balanced Propofol Sedation Versus Propofol Alone Sedation|ERCP|Soon Chun Hyang University|Yes|Enrolling by invitation|April 2011|October 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||March 2011|March 22, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321047||107148|
NCT01320787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0157|18-F-Fluoroacetate as PET Imaging Agent|A Phase I Study of 18-F-Fluoroacetate Sodium as a PET Imaging Agent for Tumor Detection||M.D. Anderson Cancer Center|No|Withdrawn|October 2014|||October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|March 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01320787||107168|
NCT01321294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zell01|Laparoscopic Nissen Versus Toupet Fundoplication: Objective and Subjective Results of a Prospective Randomized Trial|||General Public Hospital Zell am See||Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||March 2011|March 22, 2011|March 21, 2011||||No||https://clinicaltrials.gov/show/NCT01321294||107129|
NCT01321307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91-2010-HYMC|Aphtostomatitis and Mucositis Treatment by Natural Herbal Formula (Sorend®)|Aphtostomatitis and Mucositis Treatment by Natural Herbal Formula (Sorend®)||Hillel Yaffe Medical Center|No|Not yet recruiting|April 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|70 Years|No|Non-Probability Sample|Community population care|March 2011|March 22, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321307||107128|
NCT01321632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acne-002|Efficacy of Zingiber Officinalis (Homoeopathic Medicine) in Treatment of Acne Vulgaris|Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Zingiber Officinalis||Miglani, Anjali|Yes|Completed|March 2011|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|12 Years|25 Years|No|||October 2012|October 21, 2012|March 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01321632||107103|
NCT01321320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1439|Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP)|Investigation of the Role of FHL-1 and Myostatin in the Development of Intensive Care Unit Acquired Paresis (ICUAP) and the Effect of Increased Muscle Activity on These Pathways.||Imperial College London|No|Completed|April 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321320||107127|
NCT01321970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2009/VB-01|Validation/Evaluation of Multimodal Imaging Combining 3D Ultrasound and Stress Myocardial Scintigraphy in the Diagnosis of Coronary Artery Disease|Validation and Evaluation of Multimodal Imaging Combining Three-dimensional Ultrasound and Stress Myocardial Scintigraphy in the Diagnosis of Coronary Artery Disease||Centre Hospitalier Universitaire de Nīmes|No|Withdrawn|June 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|N/A|N/A|No|||March 2015|March 24, 2015|March 23, 2011||No|Impossible to start to the study.|No||https://clinicaltrials.gov/show/NCT01321970||107077|
NCT01322516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114231|Outcomes of Pandemic Influenza in Pregnancy|Outcomes of Pandemic Influenza in Pregnancy: an Observational Cohort Study||Dalhousie University|No|Active, not recruiting|September 2009|September 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|Nasopharyngeal swabs and serum|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|800 pregnant women followed through pregnancy during second and third waves of the 2009        influenza pandemic, and 2009/10 influenza season. Forty percent are high risk pregnancies:        either for maternal influenza complications (eg. underlying asthma, gestational diabetes        mellitus in prior pregnancies) or high risk for obstetrical complications (eg. prior        premature birth, multiple pregnancies). Recruitment from Halifax, Quebec City, Toronto,        Hamilton, Calgary, Edmonton, and Vancouver. Plan to enroll all women before the beginning        of the second wave; however, enrolment of women <20 weeks pregnant will continue at each        site until the second wave has peaked locally.|June 2011|June 14, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322516||107035|
NCT01322763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI755|Prevalence of Sleep Apnea/Hypopnea Syndrome in Obese Children|Prevalence of Sleep Apnea/Hypopnea Syndrome in Obese Children. The Significance of Hormonal Factors|NANOS|Sociedad Española de Neumología y Cirugía Torácica||Recruiting|March 2008|January 2012|Anticipated|May 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|3 Years|14 Years|No|Probability Sample|The population of study will be make for children of both sex, between 3 and 14 years old        and with body mass index (BMI) ≥ 95 percentile and with informed consent.|March 2011|March 24, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322763||107016|
NCT01322776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vel-FC-4003|Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma|Phase 1 and 2 Study of Combination Treatment of Bortezomib, Fludarabine and Cyclophosphamide in Patients With Recurrent Mantle Cell Lymphoma||Sun Yat-sen University|Yes|Recruiting|March 2011|October 2013|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2011|March 24, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322776||107015|
NCT01327118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC-PGF2-2010|Prostaglandin F2alpha in a Human Headache Model|Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of Prostaglandin F2alpha||Danish Headache Center|Yes|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2010|April 13, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327118||106682|
NCT01326845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2417|Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study|A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.|MACS1574|Novartis||Terminated|December 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|March 30, 2011||No|The trial was terminated due to insufficient enrollment.|No|September 11, 2013|https://clinicaltrials.gov/show/NCT01326845||106703|
NCT01327144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F500EMS1010|Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster|A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 500 mg Comparing To Aciclovir 400mg in Patients With Herpes Zoster||EMS|Yes|Recruiting|June 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||July 2015|July 30, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327144||106681|
NCT01322698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2009/BL-01|Staging Candidiasis in ICU Patients|Staging Candidiasis in ICU Patients||Centre Hospitalier Universitaire de Nīmes|No|Completed|October 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|422|Samples With DNA|Serum sample|Both|18 Years|N/A|No|Non-Probability Sample|The target population includes patients in ICUs at the Nîmes and Montpellier University        hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils >        500/mm3) at risk of developing invasive candidiasis.|March 2015|March 26, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322698||107021|
NCT01318421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND002-MS153|A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis|An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis||Elan Pharmaceuticals|No|Terminated|December 2010|||December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|March 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318421||107349|
NCT01318434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-1010-301|A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)|A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) (Triple Reuptake Inhibitor Anti-Depressant Effects - TRIADE Study)||Euthymics BioScience, Inc.|No|Completed|February 2011|February 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|342|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318434||107348|
NCT01318447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC-HM-001|CyberKnife® for Hepatic Metastases From Colorectal Cancer|International, Phase II Study of CyberKnife® for Hepatic Metastases From Colorectal Cancer||Accuray Incorporated|Yes|Terminated|January 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|March 16, 2011||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01318447||107347|
NCT01318759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0047-11-tav|(MIGA) Mini Geriatric Assessment To Replace the Comprehensive Geriatric Assessment|(MIGA) Mini Geriatric Assessment as Compared to the Current CGA|MIGA|Tel-Aviv Sourasky Medical Center|No|Recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|65 Years|N/A|No|Probability Sample|people aged over 65|March 2011|March 17, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318759||107324|
NCT01319045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iloprost ACHD|Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease|||University of California, Los Angeles|No|Terminated|June 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|March 18, 2011|No|Yes|enrollment was too slow|No|December 3, 2014|https://clinicaltrials.gov/show/NCT01319045||107302|Enrollment was too slow. The trial was discontinued.
NCT01319344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSyn-2010|Effect of Eplerenone on Endothelial Function in Metabolic Syndrome|Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome|MetSyn|University of Erlangen-Nürnberg Medical School|Yes|Completed|September 2010|April 2013|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Male|18 Years|N/A|No|||April 2013|April 16, 2013|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01319344||107279|
NCT01319656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRSQ-24423|Integration of Chronic Disease Rehabilitation Services Into Primary Care|Adaptation, Implementation and Evaluation of an Intervention Involving the Integration of Chronic Disease Rehabilitation Services Into Primary Care|PR1MaC|Université de Sherbrooke|No|Completed|February 2011|November 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|326|||Both|18 Years|75 Years|No|||December 2013|December 9, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01319656||107255|
NCT01319981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0598|Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia|Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia||M.D. Anderson Cancer Center|No|Recruiting|March 2013|||March 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319981||107230|
NCT01320527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-1350|A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease|A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease||University of Massachusetts, Worcester|Yes|Completed|August 2008|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|135|||Both|40 Years|N/A|No|||March 2016|March 2, 2016|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320527||107188|
NCT01320813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2010/BL-01|Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy|Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy||Centre Hospitalier Universitaire de Nīmes|Yes|Terminated|September 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|85 Years|No|||March 2015|March 24, 2015|March 22, 2011||No|Unable to find enough patients who accept randomization of surgical procedures.|No||https://clinicaltrials.gov/show/NCT01320813||107166|
NCT01321619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VID-VAR-01/11|Efficacy and Tolerability of the Use of Varicell Compared With Daflon|Study Clinical, Multicenter,Phase III,Prospective,Randomized,Comparative Double Blind/Double-dummy to Assess the Efficacy and Tolerability of the Use of Varicell in Reducing the Symptoms Caused by Chronic Venous Insufficiency and Hemorrhoidal Syndrome When Compared With Daflon||Vidfarma Indústria de Medicamentos Ltda.|Yes|Not yet recruiting|July 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|65 Years|No|||June 2011|June 13, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01321619||107104|
NCT01321060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIGS|Fluid Collections Management in Severe Acute Pancreatitis|Management of Sterile Fluid Collections in Patients With Severe Acute Pancreatitis:a Randomized Controlled Trial|FCMSAP|Nanjing University School of Medicine|No|Recruiting|January 2011|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|87|||Both|18 Years|70 Years|No|||January 2011|June 16, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321060||107147|
NCT01321073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAH-D|DelIVery for Pulmonary Arterial Hypertension (PAH)|DelIVery for Pulmonary Arterial Hypertension (PAH) Clinical Study|DelIVery|Medtronic Cardiac Rhythm Disease Management|Yes|Active, not recruiting|June 2011|January 2016|Anticipated|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321073||107146|
NCT01321645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acne-003|Efficacy of Azadirachta Indica (Homoeopathic Medicine) in Treatment of Acne Vulgaris|Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Azadirachta Indica||Miglani, Anjali|Yes|Completed|March 2011|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|12 Years|25 Years|No|||October 2012|October 21, 2012|March 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01321645||107102|
NCT01321957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-0209|Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer|FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study|CHARTA|Martin-Luther-Universität Halle-Wittenberg|Yes|Recruiting|May 2011|January 2017|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01321957||107078|
NCT01322529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-nuMoM2b-001|Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be|Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk|nuMoM2b|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Completed|September 2010|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10038|Samples With DNA|Blood serum, blood plasma, maternal deoxyribonucleic acid (DNA), urine supernatant, urine      cell pellet, cervico-vaginal fluid, bacterial vaginosis (BV) slide, cord blood (fetal DNA),      cord blood serum, placenta, fetal membranes, umbilical cord segment, placenta and umbilical      cord, chorionic villi and maternal decidua from clinical chorionic villus sampling (CVS),      amniotic fluid supernatant and cell pellet from clinical amniocentesis.|Female|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of a racially/ethnically/geographically diverse population        of 10,038 nulliparous pregnant women with singleton gestations recruited through 8        participating clinical sites and their subsites.|January 2016|January 11, 2016|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01322529||107034|
NCT01322204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10922|Codeine in Mechanically Ventilated Neonates|Absorption and Metabolism of Oral Codeine in Mechanically Ventilated Neonates||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|August 2008|||July 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|N/A|30 Days|No|||February 2012|February 7, 2012|March 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01322204||107059|
NCT01318564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0242|Diabetic Treatment Adherence|Treatment Adherence With Compliance Prompting Packaging||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2011|||March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|A fasting blood sample of 10 ml will be collected 2 days after randomization if the      physician considers the test as a standard of care.|Both|18 Years|N/A|No|Probability Sample|General Internal Medicine/Ambulatory Clinics at UT MD Anderson Cancer Center in Houston,        Texas Kelsey-Seybold Outpatient Clinics in Houston, Texas|January 2016|January 25, 2016|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01318564||107338|
NCT01318577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|682|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2010|||||N/A|N/A|N/A||||||||||||||August 10, 2012|March 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318577||107337|
NCT01318837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OABSSVSK-002|A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment|Reproducibility Study of OABSS and Its Response to Solifenacin Treatment (RESORT) and Validity in Korean Populations; Part 2: Responsiveness and Validity|RESORT-2|Astellas Pharma Inc|No|Completed|April 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|March 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318837||107318|
NCT01326858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-127|Safety and Comfort of AL-4943A Ophthalmic Solution|A Randomized, Double-Masked, Crossover Study to Evaluate the Safety and Comfort of AL-4943A Ophthalmic Solution, 0.7%||Alcon Research|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 27, 2015|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01326858||106702|
NCT01327157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0323/08|Study of a New Technique to Improve the Symptoms of Orofacial Discomfort in Patients With Peripheral Facial Paralysis|Neuro Occlusal Rehabilitation in Patient With Peripheral Facial Paralysis - a Randomized Clinical Trial||Federal University of São Paulo|Yes|Completed|March 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|60 Years|No|||March 2011|March 31, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327157||106680|
NCT01318460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEPA_CTS-03|Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery|Prophylactic Administration of Levosimendan in Patients With Impaired Left Ventricular Function Undergoing Coronary Surgery||AHEPA University Hospital|No|Completed|March 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|80 Years|No|||March 2014|March 11, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318460||107346|
NCT01318772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH-001|Clinical Image Evaluation for the DREX-KL80 Imaging System|Clinical Image Evaluation for the KALARE (DREX-KL80) With New Digital Camera and Image Processor||Toshiba America Medical Systems, Inc.|Yes|Completed|December 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patient 18 years and older|March 2011|March 17, 2011|March 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318772||107323|
NCT01319058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor495810ctil|Outcome of Laser or Debrider Tonsillotomy Versus Tonsillectomy in Obstructive Sleep Apnea|Laser or Debrider Tonsillotomy Versus Monopolar Tonsillectomy in Obstructive Sleep Apnea; Inflammation as a Determinate of Outcome|TVLOD|Soroka University Medical Center|No|Recruiting|August 2010|January 2012|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|75|||Both|2 Years|16 Years|No|||March 2011|March 18, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01319058||107301|
NCT01319357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAXA24011980GLIPTIN|Effects of Saxagliptin on Endothelial Function|Effects of Saxagliptin on Endothelial Function in Patients With Type 2 Diabetes|ESENDI|University of Erlangen-Nürnberg Medical School|Yes|Completed|October 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||February 2014|February 11, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01319357||107278|
NCT01319383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 0807|The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART|A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy||University of North Carolina, Chapel Hill|Yes|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319383||107276|
NCT01319669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG1001|Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy|Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy With GC/GP Regimens for Non-small-cell Lung Carcinoma Using Recombinant Human Thrombopoietin (rhTPO)||Chinese Society of Lung Cancer|No|Recruiting|February 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||February 2016|February 14, 2016|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01319669||107254|
NCT01319994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1102/82|Prevention of Metabolic Complications of Glucocorticoid Excess|Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study||Barts & The London NHS Trust|Yes|Recruiting|September 2010|January 2015|Anticipated|January 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||July 2012|July 24, 2012|February 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319994||107229|
NCT01320267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00969|Single Port Laparoscopic Colectomy|Single Incision Laparoscopic Right Hemi-colectomy Pilot Study|SILS|University of British Columbia|No|Withdrawn|December 2011|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|March 1, 2011||No|Industry Funding Withdrawn|No||https://clinicaltrials.gov/show/NCT01320267||107208|
NCT01320514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endoscopic Browlift|Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift|A Randomized, Controlled Study to Evaluate Safety and Efficacy of Fibrin Sealant VH S/D 4 S-APR (Artiss) for Tissue Adherence and Hemostasis and To Improve Wound Healing in Subjects Undergoing Endoscopic Browlift||Nguyen, Davis B., M.D.|Yes|Recruiting|December 2010|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Subjects planned for endoscopic browlift; healthy female or male; age 18-75|March 2011|March 19, 2011|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01320514||107189|
NCT01321086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7R01HL098909-03|Motivational Interviewing (MI) for African Americans With Peripheral Arterial Disease (PAD)|Promoting Walking in African Americans With Peripheral Arterial Disease||University of Kansas Medical Center|No|Active, not recruiting|June 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|174|||Both|N/A|N/A|No|||December 2015|December 11, 2015|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01321086||107145|
NCT01321099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFF_Fe_Study|Iron Absorption From Complementary Food Fortificants (CFFs) and Acceptability of CFFs by Beninese Children|||Swiss Federal Institute of Technology||Completed|May 2011|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|60|||Both|12 Months|36 Months|Accepts Healthy Volunteers|||November 2012|November 7, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321099||107144|
NCT01321333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N02-SC|Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury|A Phase I/II Study of the Safety and Preliminary Efficacy of Intramedullary Spinal Cord Transplantation of Human Central Nervous System (CNS) Stem Cells (HuCNS-SC®) in Subjects With Thoracic (T2-T11) Spinal Cord Trauma||StemCells, Inc.|Yes|Completed|March 2011|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|60 Years|No|||June 2015|June 16, 2015|March 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01321333||107126|
NCT01321671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081228|Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers|The Pharmacokinetics Of Pregabalin Controlled Release Formulation In Fed State Compared To The Controlled Release And Immediate Release Formulations In The Fasted State||Pfizer|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|March 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01321671||107100|
NCT01321684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1006-100-322|The Effect of Spinal Flexion in the Lateral Decubitus Position on the Unilaterality During Spinal Anesthesia|||Seoul National University Hospital|Yes|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|32|||Male|20 Years|45 Years|No|||May 2012|May 26, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01321684||107099|
NCT01321697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110583|A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer|||University of Arkansas|No|Terminated|March 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Female|18 Years|N/A|No|Probability Sample|Gynecology Oncology Clinic|August 2013|August 23, 2013|March 22, 2011||No|Principal Investigator Request|No|June 10, 2013|https://clinicaltrials.gov/show/NCT01321697||107098|Early termination of the study due to investigator decision. No subjects were analyzed.
NCT01322542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110114|YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome|A Pilot Trial of YF476, A Gastrin Antagonist, in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|March 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 16, 2016|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01322542||107033|
NCT01322555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110118|A Study of the Association Between Autism and Immune Changes in the Brain|Neuroimmune Activation in Austism: Imaging Translocator Protein Using Positron Emission Tomography (PET)||National Institutes of Health Clinical Center (CC)||Recruiting|March 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|45 Years|No|||August 2015|September 9, 2015|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01322555||107032|
NCT01322789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCFMRPUSP 2|Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients|Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients||University of Sao Paulo|Yes|Recruiting|September 2008|December 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|35 Years|Accepts Healthy Volunteers|||November 2010|March 24, 2011|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01322789||107014|
NCT01318551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15557|Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects|Investigation of Pharmacokinetics, Safety, Tolerability, and Pharmacodynamic Effects of BAY85-3934 in Male and Female Subjects With Renal Impairment and in Age- and Weight-matched Healthy Subjects Following a Single Oral Dose of 20 mg and 40 mg (Optional) BAY 85-3934 Administered as Tablets in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification||Bayer|No|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|56|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01318551||107339|
NCT01318850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI070258|Effects of Cognitive Remediation Therapy on Schizophrenia Patients Through Functional Magnetic Resonance Imaging|Analysis of the Effects of Cognitive Remediation Therapy on Schizophrenia Patients Through fMRI Techniques||Hospital Clinic of Barcelona|Yes|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2011|February 19, 2016|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318850||107317|
NCT01323101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-08-00017|Doxycycline Effects on Inflammation in Cystic Fibrosis|Effect of Doxycycline on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Patients With Cystic Fibrosis.||University of Southern California|Yes|Completed|April 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01323101||106990|
NCT01319825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-26|Preventive Treatment of Episodic and Chronic Migraine|Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine.||California Medical Clinic for Headache|No|Not yet recruiting|April 2011|July 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Both|18 Years|70 Years|No|||March 2011|March 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319825||107242|
NCT01318473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASNG-LFNA-102-IL|The Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided With Lesions Smaller Than 15 mm|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy With Lesions Smaller Than 15 mm|ActiSight|ActiViews Ltd.|Yes|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318473||107345|
NCT01318785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multicentrestudy "BF09-PH-01"|Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications|Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications (Therapeutische Bewertung Von Armkompressionsstrümpfen für Lymphatische Indikationen BF09-PH-01)|BF09-PH-01|University Medicine Greifswald|Yes|Recruiting|September 2011|November 2011|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||September 2011|September 5, 2011|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01318785||107322|
NCT01319071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015-11-HYMC|Genetic Polymorphism and Israeli Top-level Athletes|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Whole blood|Both|14 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Athletes training at the Wingate Institute|March 2011|March 17, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01319071||107300|
NCT01319370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-AGA02|Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia|Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks||Charite University, Berlin, Germany|Yes|Completed|November 2010|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|70 Years|No|||November 2013|November 6, 2013|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319370||107277|
NCT01319682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAngUH2|The Effect of Intravenous Lidocaine on Pain After Lumbar Spinal Fusion|Intravenous Lidocaine for Effective Pain Relief After Posterior Lumbar Spinal Fusion: a Prospective, Randomized, Double-blind, Placebo-controlled Study||Chung-Ang University Hospital|No|Completed|March 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|85 Years|No|||March 2011|August 1, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01319682||107253|
NCT01319396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM07_8DTS|Performance Validation of a Non-contact Breathing Frequency Monitor (Model BM07)|Performance Validation of a Non-contact Breathing Frequency Monitor (Model BM07)||ResMed|No|Completed|October 2010|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|24|||Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|twenty two plus volunteer subjects, distributed on the follwoing parameters: gender        balance: 1/3:2/3 or better. age range: aged 10 years through to senior citizens BMI range:        19 to 40+, or wider|March 2011|July 18, 2011|March 16, 2011||No||No|July 18, 2011|https://clinicaltrials.gov/show/NCT01319396||107275|
NCT01319409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09020493|Single- vs. Double-Bundle ACL Reconstruction|Single- vs. Double-Bundle ACL Reconstruction: A Prospective Randomized Trial||University of Pittsburgh|Yes|Completed|March 2011|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|14 Years|50 Years|No|||January 2016|January 4, 2016|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01319409||107274|
NCT01319695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234560|Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation|||National and Kapodistrian University of Athens||Recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319695||107252|
NCT01319708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234561|Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing In Vitro Fertilisation|Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing In Vitro Fertilisation||National and Kapodistrian University of Athens|Yes|Completed|March 2011|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Female|25 Years|45 Years|No|||November 2015|November 7, 2015|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319708||107251|
NCT01320007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLT006957|Lung Impedance Monitoring In Treatment of Chronic Heart Failure|Lung Impedance Monitoring In Treatment of Chronic Heart Failure|LIMIT-CHF|Barts & The London NHS Trust|No|Completed|September 2010|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2015|July 8, 2015|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320007||107228|
NCT01320280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.138|BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer|Single-arm, Open-label, Single-center Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer After Failure of Treatment With Docetaxel or Ineligible for Treatment With Docetaxel||Universitätsklinikum Hamburg-Eppendorf|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Male|18 Years|N/A|No|||April 2013|April 7, 2013|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01320280||107207|
NCT01320293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABBO-0001|Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.|Effect of Immunomodulatory Therapy With Adalimumab on Endothelial Function in Patients With Moderate to Severe Psoriasis||University of North Carolina, Chapel Hill|No|Completed|March 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|55 Years|No|||April 2015|April 17, 2015|March 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01320293||107206|
NCT01320826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-APCEndo-MK|The Alberta Primary Care Endoscopy (APC-Endo) Study|Prospective Study of the Quality of Colonoscopies Performed by Primary Care Endoscopists in Alberta, Canada|APC-Endo|University of Alberta|No|Completed|March 2010|October 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|577|||Both|18 Years|N/A|No|Non-Probability Sample|Physician colonoscopists: All Albertan family physicians and general internists who        perform colonoscopies will be invited to voluntarily participate in anonymized data        collection pertaining to the quality of colonoscopies they perform over a two month        period.        All patients having a colonoscopy done by an APC-Endo physician endoscopist during the        study period will be approached at the time of their endoscopy to consent to the post        procedure telephone survey.|August 2012|August 14, 2012|March 3, 2011||No||No|March 17, 2012|https://clinicaltrials.gov/show/NCT01320826||107165|
NCT01321112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-071|Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil|Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil Monotherapy|TBCP|Pontificia Universidad Catolica de Chile|Yes|Recruiting|February 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321112||107143|
NCT01321346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2009-012|A Study Of Panobinostat In Children With Refractory Hematologic Malignancies|A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Completed|March 2011|||October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|8 Years|21 Years|No|||November 2015|November 20, 2015|March 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01321346||107125|
NCT01322568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999903319|Research on Aging Project in Iceland: Second Stage|Age, Gene/Environment Susceptibility (AGES) Study||National Institutes of Health Clinical Center (CC)||Completed|January 2003|February 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|9500|||Both|32 Years|60 Years|No|||February 2014|October 23, 2014|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322568||107031|
NCT01322802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7396|Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer|A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer||University of Washington|No|Active, not recruiting|March 2012|||January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Female|18 Years|N/A|No|||April 2015|April 17, 2015|March 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01322802||107013|
NCT01322815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-4000-05|A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI|A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLOFOX or FOLFIRI in Patients With Newly Diagnosed Ras Mutant Positive Metastatic Colorectal Cancer or Patients With Ras Mutant Positive Colorectal Cancer Who Have Just Completed a First Line Therapy With an Oxaliplatin or Irinotecan Plus Fluoropyrimidine and Bevacizumab Containing Regimen||Georgetown University|Yes|Terminated|October 2010|December 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||September 2014|March 12, 2015|March 23, 2011|Yes|Yes|Poor accrual rate|No||https://clinicaltrials.gov/show/NCT01322815||107012|
NCT01318590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10 160|Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis|Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|March 2011|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318590||107336|
NCT01318616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-119|The Effect of Strength Training on the Hip Adduction Strength Measured With Hand-held Dynamometry|||Amager Hospital|Yes|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|34|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 20, 2012|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318616||107335|
NCT01319162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prevalence-PCOS-Obesity|Prevalence of Polycystic Ovary Syndrome (PCOS) in Obese Premenopausal Women|To Estimate the Prevalence of PCOS in Obese Premenopausal Women and Elucidate How They Respond to a Weight Reduction Treatment Program||Göteborg University|No|Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|All obese women between 18 and 50 years referred to a weight reduction treatment program        at the Sahlgrenska Obesity Center at Sahlgrenska University hospital will, after oral and        written informed consent, be screened for the diagnosis of PCOS according to NIH or        Rotterdam diagnostic criteria depending on the availability of ultrasonography.|January 2016|January 7, 2016|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319162||107293|
NCT01319526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-079|Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy|Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)||AIDS Malignancy Consortium|No|Terminated|June 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|Samples With DNA|PBMC|Both|18 Years|N/A|No|Non-Probability Sample|Clinical trial participants (subjects who are participating in parent protocol S0816 and        provide informed consent for participation in this substudy).|October 2015|October 1, 2015|December 18, 2010||No|Parent protocol (SWOG S0816 / AMC-073) discontinued|No||https://clinicaltrials.gov/show/NCT01319526||107265|
NCT01319539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02513|MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer|Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer||National Cancer Institute (NCI)||Terminated|April 2011|May 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|N/A|No|||July 2014|March 16, 2015|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319539||107264|
NCT01322737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-10-21|Feasibility Trial to Evaluate the Ability of the SuMO Tissue Access and Resection System|Evaluation of a Novel Endoscopic Polypectomy Device in Excised Human Colon and Gastric Tissue.|SUMO|University Hospital Case Medical Center|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 12, 2014|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01322737||107018|
NCT01318486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1483|HepZero:Heparin Free Dialysis With Evodial|HepZero:Heparin Free Dialysis With Evodial: A Prospective Multicenter, Open, Randomized, Controlled Clinical Study With Parallel Groups||Gambro Lundia AB|Yes|Completed|March 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01318486||107344|
NCT01318798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StV 33-2009|Development and Validation of an Enhanced Prediction Score for Postoperative Acute Renal Failure After Liver Resection|Development and Validation of an Enhanced Prediction Score for Post-operative Acute Renal Failure Following Liver Resection||University of Zurich|No|Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|549|||Both|18 Years|95 Years|No|Probability Sample|We included consecutively patients undergoing any type of hepatic surgery for benign as        well as malignant diseases between July first, 2002 and October 31, 2007 in a single        tertiary care center (Swiss Hepato-Pancreato-Biliary (HPB) Centre, University Hospital of        Zurich, Switzerland.|February 2015|February 9, 2015|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01318798||107321|
NCT01319084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0062|Development of a Versatile Intra-operative On-screen Audiovisual Mentoring System Using TileproTM Program for Robotic Gastrectomy|Development of a Versatile Intra-operative On-screen Audiovisual Mentoring System Using TileproTM Program for Robotic Gastrectomy||Yonsei University|Yes|Recruiting|March 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|20 Years|80 Years|No|Probability Sample|Outpatient clinic in severance hospital|January 2012|January 31, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319084||107299|
NCT01319422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC 1011007607|Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma|Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma||Yale University|No|Completed|June 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||June 2014|July 14, 2015|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319422||107273|
NCT01320020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-CAT-ST-01|A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients|A Phase I, Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients||Neovii Biotech|Yes|Terminated|February 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2013|July 1, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320020||107227|
NCT01320306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2292-2|Intracranial Aneurysms and Cognitive Function|Intracranial Aneurysms and Cognitive Function||University Hospital of North Norway|Yes|Enrolling by invitation|March 2011|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||4|Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with un-ruptured aneurysms in the anterior communicating artery and the middle        cerebral artery.A subgroup of patients suffering aneurismal subarachnoid hemorrhage.        University Hospital of North Norway|May 2012|May 11, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320306||107205|
NCT01320540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00041300|4R for Guideline Indicated BRCA Testing of Breast Center Patients|4R (Right Information and Right Care to the Right Patient at the Right Time) for Guideline Indicated BRCA Genetic Assessment of Breast Center Patients|4R|Northwestern University|Yes|Recruiting|March 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|202|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women newly diagnosed with breast cancer|April 2015|April 28, 2015|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320540||107187|
NCT01320553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_02_11|Effect of Different Concentrations of 1334H on Allergic Conjunctivitis|A Multi-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the of 1334H 0.15%, 0.3%, and 0.45% Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis||Sun Pharma Advanced Research Company Limited|No|Completed|June 2011|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|122|||Both|10 Years|N/A|No|||June 2012|June 6, 2012|March 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01320553||107186|
NCT01320839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2011-004|Effects of an Ankle-Foot Orthosis on Gait While Performing an Attention Demanding Task|Effects of an Ankle-Foot Orthosis on Gait While Performing an Attention Demanding Task in People With Poststroke Hemiplegia||Nova Scotia Health Authority|No|Completed|March 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|People who have had a hemiplegic stroke and have an ankle-foot orthosis.|March 2014|March 6, 2014|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01320839||107164|
NCT01321983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|141299/2009-6|Effects of Preoperative Inspiratory Muscle Training (IMT) in Obese Women Undergoing Open Bariatric Surgery|Effects of Preoperative Inspiratory Muscle Training (IMT) in Obese Women Undergoing Open Bariatric Surgery: Respiratory Muscle Strength, Lung Volumes and Diaphragmatic Excursion||Universidade Federal de Sao Carlos|No|Completed||||||N/A|Interventional|N/A|||||||Female|18 Years|65 Years||||March 2011|March 23, 2011|March 23, 2011||||No||https://clinicaltrials.gov/show/NCT01321983||107076|
NCT01322217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 106|Managerial Database II|Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III||Westat|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|513|||Both|12 Years|24 Years|No|Non-Probability Sample|All HIV-infected adolescents and young adults engaged in care at sites newly participating        in ATN III and their affiliates who are between 12 and 24 years of age, inclusive, are        aware of their HIV status and understand written and/or verbal English will be eligible        for inclusion in the study. In addition, new patients who have their initial clinic visit        within the enrollment period will also be eligible for participation|March 2016|March 1, 2016|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01322217||107058|
NCT01322581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911126|A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali|A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|3 Months|40 Years|Accepts Healthy Volunteers|||January 2016|February 23, 2016|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322581||107030|
NCT01322828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULCbicep|Trial Comparing Single Versus Double Incision to Repair Distal Bicep Tendon Ruptures|Randomized Control Trial Comparing Single Incision Versus Double Incision Surgery to Repair Distal Bicep Tendon Ruptures|BRT|Hand and Upper Limb Clinic, Canada|No|Completed|March 2004|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322828||107011|
NCT01322841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICA_Screening|Universal Screening for Tuberculosis and Anemia With the CHICA System|Universal Screening for Tuberculosis and Anemia With the CHICA System||Indiana University|No|Completed|October 2007|September 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|2239|||Both|3 Years|11 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|March 23, 2011||No||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01322841||107010|
NCT01318629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart Quest|Angina in Non Coronary Artery Disease|Invasive Findings in Patients With Angina Equivalent Symptoms But No Coronary Artery Disease; Results From the Heart Quest Cohort Study|HeartQuest|Luzerner Kantonsspital|No|Active, not recruiting|July 1996|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|718|||Both|N/A|N/A|No|Probability Sample|All consecutive patients who had coronary angiography at the Luzerner Kantonsspital        between July 1st 1996 and July 31st 2008 and who had no significant coronary stenoses (no        coronary stenoses ≥ 50%) were recruited for this study.|April 2013|April 16, 2013|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318629||107334|
NCT01318863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AST-015|A Normal Donor Sample Collection Study in Healthy Adults|A Normal Donor Sample Collection Study in Healthy Adults||Astute Medical, Inc.|No|Completed|April 2011|||September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Adults|September 2011|November 3, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318863||107316|
NCT01318876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pcirn-surveillancehcw-1011|Surveillance for Adverse Events Following Influenza Immunization|Active Surveillance of Adverse Events Following Immunization Among Healthcare Workers Immunized With the Influenza Vaccine||PHAC/CIHR Influenza Research Network|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|7645|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The active surveillance was conducted in five Canadian hospitals participating in the        Public Health Agency of Canada/Canadian Institutes for Health Research-Influenza Research        Network (PCIRN): Quebec City, Toronto, Halifax, Vancouver (2 sites), Ottawa and        Sherbrooke. Healthcare workers immunized in these institutions were offered to participate        in a web-based active surveillance of vaccine safety.|August 2012|August 15, 2012|March 18, 2011||No||No|July 9, 2012|https://clinicaltrials.gov/show/NCT01318876||107315|Only 70% answered the 2 surveys. We don't know why 30% didn't complete the 2 surveys (were they too sick or not motivated).We didn't have a group of comparable unvaccinated individuals (to estimate the risks attributable to the vaccine).
NCT01328678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1270-Alopecia|A Study of Vitamin D in Subjects With Alopecia Areata|A Pilot Study of Vitamin D in Subjects With Alopecia Areata||Avera McKennan Hospital & University Health Center|Yes|Completed|August 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women in and around the Sioux Falls area|July 2011|July 6, 2011|January 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01328678||106566|
NCT01328691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCho5|Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus|Prognostic Factors for Korean Patients With Renal Cell Carcinoma and Venous Tumor Thrombus Extension: Application of the New 2009 TNM Staging System||Seoul National University Hospital||Completed|March 2011|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|118|||Both|18 Years|N/A|No|Non-Probability Sample|From Feburary 1988 to April 2009, a total of 118 patients with RCC and venous tumor        thrombus who underwent radical nephrectomy and thrombectomy at our tertiary referal center|May 2011|May 9, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328691||106565|
NCT01320150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS735224|Risk Factors and Mechanisms for Persistent Postsurgical Pain After Total Knee Replacement|Risk Factors and Mechanisms for Persistent Postsurgical Pain After Total Knee Replacement|PPP-TKA|Rush University Medical Center|No|Recruiting|March 2011|March 2016|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|DNA, RNA|Both|18 Years|85 Years|No|Probability Sample|Osteoarthritis patients at the RUSH university medical center undergoing primary,        unilateral TKR|August 2014|August 26, 2014|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320150||107217|
NCT01318811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VU 110162|A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation|A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU||Vanderbilt University|No|Recruiting|March 2011|September 2020|Anticipated|June 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318811||107320|
NCT01319097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-RW-017|Study to Evaluate the Effect of Sorbion Sachet S Wound Dressing|Clinical Study of Evaluate the Effect of Sorbion Sachet S Wound Dressing on Soft Tissue Edema and Wound Bioburden in Moderately to Highly Exuding Pressure Ulcers||Southwest Regional Wound Care Center|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01319097||107298|
NCT01319435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LWH0852|TINN Pharmacokinetics (PK) Study Treat Infections iN Neonates|Phase I, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Ciprofloxacin in Neonates With Suspected or Proven Gram Negative Infection|TINN-PK|Liverpool Women's NHS Foundation Trust|Yes|Completed|January 2011|November 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|63|||Both|24 Weeks|52 Weeks|No|||October 2015|October 9, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01319435||107272|
NCT01319721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101215|Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane|Limbal Conjunctival Autograft Versus Amniotic Membrane Graft When Combined With Mitomycin C for Recurrent Pterygium: A Randomized Trial||Sun Yat-sen University|Yes|Completed|December 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|80 Years|No|||March 2015|March 5, 2015|March 21, 2011||No||No|March 4, 2015|https://clinicaltrials.gov/show/NCT01319721||107250|
NCT01320033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18195|Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris|A Multi Center, Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group Study Comparing the Efficacy and Safety of CD2475/101 40 mg Tablets Versus Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjects With Acne Vulgaris||Galderma|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|662|||Both|12 Years|N/A|No|||March 2013|March 6, 2013|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320033||107226|
NCT01320319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11005|Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients|Effect of EPA Nutritional Supplementation on Markers of Aerobic Performance, Lean Muscle Mass and Quality of Life on Patients Undergoing Curative Resection of Colorectal Cancer|EPA-colo|University of Nottingham|No|Recruiting|March 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|18 Years|85 Years|No|||December 2012|December 3, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01320319||107204|
NCT01320566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C10-003PLV|A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema|A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema||Aeris Therapeutics|Yes|Terminated|March 2011|November 2013|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|40 Years|N/A|No|||November 2013|November 13, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01320566||107185|
NCT01320579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL09002|Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis|Phase II Study to Investigate the Properties of Topical Twice Daily Doses of 2.5% and 5% Cis-urocanic Acid in Comparison to Active Comparator 0.1% Protopic® for up to 28 Days in Patients With Moderate or Severe Atopic Dermatitis||BioCis Pharma Ltd|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|159|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320579||107184|
NCT01321359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-001-004|A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis|SHaRCS|NanoBio Corporation|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|907|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 15, 2013|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321359||107124|
NCT01321710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMS Sleep|Sleep Disruption in New Mothers: An Intervention Trial|Sleep Disruption in New Parents: An Intervention Trial|MOMS|University of California, San Francisco|Yes|Completed|December 2004|May 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|152|||Female|18 Years|N/A|No|||January 2012|January 27, 2012|March 22, 2011||No||No|August 22, 2011|https://clinicaltrials.gov/show/NCT01321710||107097|
NCT01321723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGL-OR1001|Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women|A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo® in Postmenopausal Women With Osteoporosis||Unigene Laboratories Inc.|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|97|||Female|45 Years|80 Years|No|||January 2013|February 21, 2013|March 16, 2011||No||No|December 12, 2012|https://clinicaltrials.gov/show/NCT01321723||107096|
NCT01321996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE119/2008/0/Sper|68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis|Employment of 68Ga-DOTA-NOC in Patients With Idiopathic Pulmonary Fibrosis||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Terminated|February 2009|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|29|||Both|18 Years|75 Years|No|||January 2015|January 26, 2015|March 23, 2011||No|enrollment failure (only 29 patients were enrolled during the study period)|No||https://clinicaltrials.gov/show/NCT01321996||107075|
NCT01322230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1LM009538-R01|Trial of Educational Outcomes of WISE-MD|Randomized Trial of Educational Outcomes of WISE-MD|WISE|New York University School of Medicine|Yes|Completed|October 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|4||Actual|1363|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01322230||107057|
NCT01322243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKE-0724|Effect of Metabolic State on Anxiety in Human Subjects|Effect of Metabolic State on Anxiety in Human Subjects||Rockefeller University|No|Terminated|March 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 16, 2013|March 22, 2011||No|Due to mechanical issue with device|No||https://clinicaltrials.gov/show/NCT01322243||107056|
NCT01327703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-PA25CF10-01|Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT® 25,000 to KREON® 25,000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)||Forest Laboratories|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|7 Years|N/A|No|||March 2014|March 5, 2014|March 28, 2011||No||No|March 5, 2014|https://clinicaltrials.gov/show/NCT01327703||106638|
NCT01327729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHT00234|Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C|Clinical Trial of the Efficacy, Dosing, Safety and Tolerability of Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C||BioGeneric Pharma|Yes|Recruiting|November 2010|May 2013|Anticipated|April 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|65 Years|No|||March 2011|April 1, 2011|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01327729||106637|
NCT01328041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112574|A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.|A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.|VIKING-3|ViiV Healthcare|Yes|Completed|May 2011|May 2015|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|183|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|March 31, 2011|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01328041||106613|
NCT01328405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0012|Air-Q Intubating Laryngeal Airway Versus the Laryngeal Mask Airway (LMA)-Proseal|The Air-Q Intubating Laryngeal Airway Versus the LMA-Proseal: A Prospective, Randomized Trial of Airway Seal Pressure||University of Wisconsin, Madison|Yes|Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||July 2012|October 1, 2015|March 29, 2011|Yes|Yes||No|July 2, 2012|https://clinicaltrials.gov/show/NCT01328405||106587|
NCT01328418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akondroplazi - Bilen|Simultaneous Lengthening of Bilateral Femora and Tibiae in Achondroplastic Patients|Simultaneous Lengthening of Bilateral Femora and Tibiae in Achondroplastic Patients||Bilen, Fikri Erkal, M.D.||Completed|April 2002|March 2011|Actual|March 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|3 Years|11 Years|No|||April 2011|April 1, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328418||106586|
NCT01329211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|693-2009|Needs Assessment Evaluating Quality of Life Issues for Gastroparesis Patients and Caregivers|Needs Assessment Evaluating Quality of Life Issues for Gastroparesis Patients and Caregivers||University of Florida|No|Terminated|January 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|68|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The research plan involves reviewing patient records to identify potential subjects.        Questionnaires will be distributed to gastroparesis patients and their caregivers during        their visit to the GI clinic at the day of enrollment and at six-month intervals for a        two-year follow-up period, after informed consent has been obtained. Patients and        caregivers will also be recruited by telephone. Gastroparesis patients, who have an        established patient-physician relationship with Dr. Sultan, will be contacted by telephone        in order to inquire about their interest in participating in the study. The details of the        study, including the questionnaires, risks, and potential benefits will be discussed over        the phone. Then, if patients and/or their caregivers are willing to participate in the        study, the informed consent forms and the questionnaires will be mailed to them with a        posted envelope to be returned to Dr. Sultan by mail.|May 2013|May 17, 2013|March 24, 2011||No|PI left institution,replacement PI not able to do study.|No||https://clinicaltrials.gov/show/NCT01329211||106526|
NCT01324596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMCAN0749|A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib|A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib|REMoDL-B|University Hospital Southampton NHS Foundation Trust.|Yes|Recruiting|April 2011|April 2020|Anticipated|April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1132|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324596||106876|
NCT01324609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03242011-7564|Detection of Choroidal Nevus Cells in Vitrectomy Fluid|Detection of Choroidal Nevus Cells in Vitrectomy Fluid||Stanford University||Terminated|June 2010|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a choroidal nevus who are undergoing routine vitrectomy surgery for another        indication.|March 2012|March 22, 2012|March 25, 2011||No|Could not recruit enough patients|No||https://clinicaltrials.gov/show/NCT01324609||106875|
NCT01318824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011002|A Study of Bi-Level Positive Airway Pressure (BIPAP) Versus Non Invasive Positive Pressure Ventilation (NIPPV) for Neonatal Respiratory Failure|A Study of Bi-Level Positive Airway Pressure (BIPAP) Versus Non Invasive Positive Pressure Ventilation (NIPPV) for Neonatal Respiratory Failure|BIPAP|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Yes|Active, not recruiting|December 2010|February 2013|Anticipated|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|28 Days|No|||January 2011|March 22, 2011|February 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318824||107319|
NCT01319110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000362|Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation|Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation||Beth Israel Deaconess Medical Center|Yes|Recruiting|February 2011|March 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2011|March 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319110||107297|
NCT01319448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5856|Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease|Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia.||London School of Hygiene and Tropical Medicine|Yes|Completed|September 2011|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|270|||Both|6 Months|45 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01319448||107271|
NCT01319461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH-HYA-01-04|Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee|Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee: a Randomized, Masked Observed, Double Blind, Placebo Controlled, Multicenter Clinical Trial.||Med Pharma Co., Ltd.|Yes|Completed|May 2001|June 2002|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|200|||Both|50 Years|80 Years|No|||March 2011|March 23, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319461||107270|
NCT01319734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22|Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus|Phase 1 Study of Randomized Clinical Trial Comparing Vitamin C Supplementation Plus Oral Hypoglycemic Drugs Versus Hypoglycemic Drugs Alone on Serum Selenium, Zinc, Copper and Malondialdehyde Levels in Type 2 Diabetes Mellitus and Its Microvascular Complications|Vit C|Al-Neelain University|No|Recruiting|February 2011|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|20 Years|70 Years|No|||September 2013|September 17, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01319734||107249|
NCT01319747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL32865.044.10|Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial|Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial|VATCAT|Medisch Spectrum Twente|No|Recruiting|September 2010|February 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01319747||107248|
NCT01320046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11029-2011kCTIL|Vulvar Contact Dermatitis Resulting From Urine Incontinence|Vulvar Contact Dermatitis Resulting From Urine Incontinence: Prevalence, Characteristics and Risk Factors||Meir Medical Center|No|Withdrawn|March 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|0|Samples Without DNA|Vaginal smears taken for evaluation of vaginal estrogen status (identifying parabasal cells,      vaginal flora, vaginal pH)|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The prevalence of UI induced VCD will be evaluated in 3 groups:          1. Patients attending the urogynecological clinic for urinary incontinence-100 patients.             In this group we will recruit patients with UI, and will assess co-existence of VCD          2. Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100             patients). In this group we will recruit patients with VCD, and will assess             co-existence of UI.          3. Patients attending the general clinic for annual checkup, which will be matched for             age with the two other groups (200 patients).        These patients will be evaluated for symptoms of UI and VCD|April 2012|April 7, 2015|March 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01320046||107225|
NCT01320059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0832|Study of 18F-Fluoro-PEG6-IPQA|A Phase I Study of 18F-Fluoro-PEG6-IPQA as a PET Imaging Agent for Active/Mutant EGFR Expression in Tumors||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2012|||February 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|March 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01320059||107224|
NCT01320072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01-002|Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease|Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease Using a Safe, Low Dose Aspirin Challenge|ASAS|Montefiore Medical Center|Yes|Recruiting|May 2010|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|26|||Both|18 Years|90 Years|No|Probability Sample|Allergy/Immunology clinic population in Bronx, NY|September 2015|September 22, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01320072||107223|
NCT01320332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3291-CL-0003|A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis|A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Ulcerative Colitis||Telsar Pharma Inc.|No|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|16|||Both|18 Years|65 Years|No|||July 2012|July 23, 2012|March 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01320332||107203|
NCT01320592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02111|PD0332991/Paclitaxel in Advanced Breast Cancer|A Phase 1 Trial of PD0332991 and Paclitaxel in Patients With Rb-Expressing Advanced Breast Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|March 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|March 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320592||107183|
NCT01320852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMD-09-209|PET Scan as a Screening Tool for Liver Transplant in Patients With Hepatocellular Carcinoma (HCC)|PET Scan as a Screening Tool for Liver Transplant in Patients With HCC||McGill University Health Center||Completed|December 2010|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|100|||Both|18 Years|75 Years|No|||October 2013|October 24, 2013|December 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01320852||107163|
NCT01321125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011UGTO372|Chlorhexidine Against Sodium Hypochlorite as Skin Antiseptics|Comparative Study of 2% Chlorhexidine Gluconate in 70% Isopropyl Alcohol Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers||Universidad de Guanajuato|No|Completed|April 2011|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2011|June 20, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321125||107142|
NCT01321372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-VOR|An Observational Analysis of Voriconazole Therapeutic Drug Concentration Monitoring, Pharmacogenomics and Clinical Outcome Correlations in High-risk Hematology Patients|A Prospective, Observational Analysis of Voriconazole (VOR) Therapeutic Drug Concentration Monitoring, Pharmacogenomics and Clinical Outcome Correlations in High-risk Hematology Patients at Princess Margaret Hospital||University Health Network, Toronto|No|Completed|June 2007|June 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|N/A|N/A|No|Probability Sample|Acute leukemia (including myelogenous and lymphocytic) patients for remission induction        chemotherapy, reinduction chemotherapy and consolidation chemotherapy whose antifungal        treatment includes voriconazole.|March 2013|March 18, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321372||107123|
NCT01321736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103M96878|Gut Health Response to Dietary Fiber|Gut Health Response to a New Fiber Blend||University of Minnesota - Clinical and Translational Science Institute|No|Completed|April 2011|December 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321736||107095|
NCT01322009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS069247|Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury|Overcoming Membrane Transporters to Improve CNS Drug Delivery|Pro-NAC|University of Pittsburgh|Yes|Recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|2 Years|18 Years|No|||March 2011|March 23, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01322009||107074|
NCT01322256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2009/SJ-01|PET/CT Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot|Positron Emission Tomography - Computed Tomography (PET/CT) Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot|ISEOD|Centre Hospitalier Universitaire de Nīmes|No|Terminated|October 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|March 23, 2011||No|The study has proven to be infeasible.|No||https://clinicaltrials.gov/show/NCT01322256||107055|
NCT01322269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQP 1001-SCD-006|A Study of HQK-1001 in Patients With Sickle Cell Disease|A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease||HemaQuest Pharmaceuticals Inc.|Yes|Completed|April 2011|||March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|52|||Both|12 Years|60 Years|No|||June 2013|June 11, 2013|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01322269||107054|
NCT01328431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907005437|Treating Low-Income Smokers in the Hospital Emergency Department|Treating Low-Income Smokers in the Hospital Emergency Department||Yale University|No|Completed|October 2010|January 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|780|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|March 30, 2011||No||No|July 8, 2014|https://clinicaltrials.gov/show/NCT01328431||106585|
NCT01328444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114417|An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A|An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A|COPD|GlaxoSmithKline|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|349|||Both|40 Years|N/A|No|||March 2014|July 31, 2014|April 1, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01328444||106584|
NCT01328704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI-1390-Triathletes|Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period|Observational Study to Evaluate Changes in Iron, Vit-D, and CRP During a Twelve to Twenty-Four Week Supervised Triathlon Training Program||Avera McKennan Hospital & University Health Center|Yes|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood samples will be obtained three times throughout the course of the subject's      involvement in the study: baseline, 3 months, and 6 months.|Both|30 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and pre-menopausal women between the ages of 30 and 50 who are participating in the        Triathlon Training Program through the Avera Sports Institute|August 2014|August 22, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01328704||106564|
NCT01328717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D-2010-2011.09|Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial|Clinical Trial Protocol for Contour Link System With Contour Sensor||Ascensia Diabetes Care|No|Completed|December 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|78|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 1, 2011|Yes|Yes||No|April 27, 2012|https://clinicaltrials.gov/show/NCT01328717||106563|
NCT01328990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IZ5856|Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine for Intermittent Preventive Treatment in Children (IPTc)|Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine When Used for Malaria Intermittent Preventive Treatment in Children||London School of Hygiene and Tropical Medicine|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Both|3 Months|59 Months|Accepts Healthy Volunteers|||September 2011|September 16, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01328990||106543|
NCT01319838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047148|Aflac ST1001 Prolonged Isotretinoin|Prolonged Isotretinoin Therapy in Patients With High Risk Neuroblastoma|Aflac ST1001|Emory University|Yes|Withdrawn|March 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|30 Years|No|||December 2013|December 9, 2013|March 18, 2011|Yes|Yes|no patient enrollment|No||https://clinicaltrials.gov/show/NCT01319838||107241|
NCT01320137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115315|Study in Allergic Adults to Support the Development of Immunological Assays|A Study in Adult Subjects With Allergy to Support the Development of Immunological Assays||GlaxoSmithKline||Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|September 1, 2011|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320137||107218|
NCT01325220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209FX302|Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome|Harbor-C|Seaside Therapeutics, Inc.|Yes|Completed|June 2011|||June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|172|||Both|5 Years|11 Years|No|||July 2013|July 30, 2013|March 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325220||106828|
NCT01319474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|950359|Whole-leg Ultrasound in Pregnant Patients|Use of Whole-leg Ultrasound for Diagnosis of Deep Vein Thrombosis in Pregnant Patients|CLOT-3|Intermountain Health Care, Inc.|No|Recruiting|February 2011|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|268|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01319474||107269|
NCT01319487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOV2304/CLIN/201/P|Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy|A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy||Fovea Pharmaceuticals SA|Yes|Completed|May 2011|June 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|267|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319487||107268|
NCT01319760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MINI-AMI G100286|MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction|MINI-AMI: Minimizing INfarct Size With IMPELLA® 2.5 System Following PCI for Acute Myocardial Infarction|MINI-AMI|Abiomed Inc.|Yes|Terminated|April 2011|August 2013|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||May 2013|May 1, 2013|March 18, 2011|Yes|Yes|Change in business priority|No||https://clinicaltrials.gov/show/NCT01319760||107247|
NCT01319773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192371-021|Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye|||Allergan|No|Completed|November 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 25, 2015|March 18, 2011|Yes|Yes||No|January 31, 2012|https://clinicaltrials.gov/show/NCT01319773||107246|
NCT01320085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2201|A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma|A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations||Array BioPharma||Active, not recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|183|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320085||107222|
NCT01320345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAME0001|A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume|The Fenofibrate And Microvascular Event Eye (FAME 1 EYE) Trial: A Randomised Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Daily Oral Fenofibrate Compared With Placebo on Macular Thickness and Volume|FAME 1 EYE|University of Sydney|No|Not yet recruiting|September 2011|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2011|January 15, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320345||107202|
NCT01320605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E001|Trial of Compassionate Use of hp802-247 to Treat Venous Leg Ulcers in Subjects Who Have Failed Multiple Other Healing Technologies|TRIAL OF COMPASSIONATE USE OF HP802-247 TO TREAT VENOUS LEG ULCERS IN SUBJECTS WHO HAVE FAILED MULTIPLE OTHER HEALING TECHNOLOGIES||Atlantic Health System|No|Recruiting|March 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||March 2011|March 21, 2011|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320605||107182|
NCT01320865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis AMN-107|Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib|||The Cleveland Clinic|No|Withdrawn|August 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with PAH that are enrolled in the Nilotinib clinical trial.        http://clinicaltrials.gov/ct2/show/NCT01179737?term=tasigna+and+pulmonary+hypertension&rank=1|February 2014|February 3, 2014|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320865||107162|
NCT01321138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-75-10|Femoral Neuropathy After Anterior Cruciate Ligament Reconstruction: Femoral Nerve Block vs Patient-controlled Analgesia (PCA)|Comparison of Incidence of Femoral Neuropathy After Anterior Cruciate Ligament Reconstruction With Femoral Nerve Block Versus Patient-controlled Analgesia (PCA)||Centre Hospitalier Universitaire Vaudois|No|Completed|April 2011|November 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|74|||Both|16 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321138||107141|
NCT01321385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B8|Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia|Validation of a Classifier for Induction Response Prediction Using Single Cell Network Profiling (SCNP) Assays for Childhood AML||Children's Oncology Group|No|Active, not recruiting|March 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|97|Samples With DNA|bone marrow|Both|N/A|21 Years|No|Non-Probability Sample|Diagnosis of acute myeloid leukemia.|May 2015|May 8, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321385||107122|
NCT01331109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLN-MD-29|Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia|A Multicenter, Open-label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia|MyFi|Forest Laboratories|Yes|Terminated|April 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|13 Years|17 Years|No|||July 2013|July 31, 2013|March 31, 2011|No|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01331109||106384|This study was terminated early, resulting in a small number of patients analyzed. Only descriptive statistics were presented.
NCT01321749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC2011|The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease|||Capital Medical University|Yes|Completed|January 2008|||December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|196|||Both|18 Years|80 Years|No|||March 2012|March 30, 2012|March 23, 2011||No||No|January 11, 2012|https://clinicaltrials.gov/show/NCT01321749||107094|
NCT01331655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14700|Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America|A Multicenter, Open-label, 3-arm, Active-controlled, Parallel-group, 1-year Study to Investigate the Efficacy and Safety of a Flexible Regimen of the Combined Oral Contraceptive, With and Without 0.451 mg Levomefolate Calcium (BAY98-7071 and BAY86-5300, Respectively) Versus the Standard 24 + 4 Regimen With Levomefolate (BAY98-7071 + BAY86-7660) and to Assess Compliance With a Device (CADDY) in Healthy Women Who Desire Contraception||Bayer|No|Withdrawn|April 2013|November 2014|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01331655||106342|
NCT01331668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA-UZL-BIOBANK-001|BIOBANK Renal Transplantation University Hospitals Leuven|Biobank Renal Transplantation University Hospitals Leuven||Universitaire Ziekenhuizen Leuven|No|Recruiting|March 2004|December 2099|Anticipated|December 2099|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Biopsy material (tissue, RNA, DNA) Peripheral blood samples (serum, plasma, RNA, DNA) Urine      samples|Both|N/A|N/A|No|Probability Sample|All donors and recipients of a kidney transplant at the University Hospitals Leuven|June 2015|June 1, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331668||106341|
NCT01331876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-02|Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy|Evaluation and Comparison of Cerebral Activities Modifications Associated With Two Different Cognitive and Behavioral Therapies for Obsessive Compulsive Disorder Patients|TOC TOC|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|October 2009|July 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|March 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01331876||106325|
NCT01329224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242/10A|The Antiaggregation Monitoring (TAM) Registry|Acetylsalicylic Acid in Outpatient Practice - Results From The Antiaggregation Monitoring (TAM) Registry|TAM|University Hospital Freiburg|No|Recruiting|November 2010|April 2011|Anticipated|April 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients under chronic ASA treatment seen at our outpatient clinic|November 2010|April 14, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01329224||106525|
NCT01329471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-16-2011|Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2011|April 2013|Anticipated|April 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|75|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Female hospital patients|April 2011|April 5, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01329471||106506|
NCT01329484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-AD-TD-CTIL|Computerized Personal Interventions for Alzheimer's Patients|Computerized Personal Interventions for Alzheimer's Patients||Shaare Zedek Medical Center|No|Enrolling by invitation|March 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|159|||Both|60 Years|N/A|No|||February 2011|April 3, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01329484||106505|
NCT01329757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHNP-CT001|Efficacy and Safety of Growth Hormone Treatment in Spinal Cord Injury|Efficacy and Safety of Growth Hormone (GH) Treatment in Spinal Cord Injury(SCI): A Triple-blinded, Randomised, Placebo-controlled Trial|GHSCI|Hospital Nacional de Parapléjicos de Toledo|Yes|Active, not recruiting|April 2011|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|75 Years|No|||January 2015|January 9, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329757||106484|
NCT01324297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS_2011-215|The Topical Niacin Skin Flush Test in First Episode Psychosis|The Topical Niacin Skin Flush Test: A Means for Longitudinal Monitoring of Two Different Biological Subgroups of Patients With First Episode Psychosis||Nova Scotia Health Authority|No|Recruiting|December 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|19 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young adults|July 2015|July 29, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324297||106899|
NCT01324310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMI-ADVM-001|Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer|A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Ketoconazole on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer||Celgene|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|No|||May 2013|September 5, 2013|March 25, 2011|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT01324310||106898|
NCT01324323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMI-ADVM-002|Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer|A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Rifampin on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer||Celgene|No|Completed|April 2011|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|March 25, 2011|Yes|Yes||No|March 26, 2013|https://clinicaltrials.gov/show/NCT01324323||106897|
NCT01326702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02583|Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors|A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors||National Cancer Institute (NCI)||Completed|July 2011|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2015|October 14, 2015|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326702||106714|
NCT01319500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG 2009_02|Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia|Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia||Center for Epidemiology and Health Research, Germany|Yes|Completed|February 2009|||||N/A|Observational|Time Perspective: Retrospective||2|Actual|3776|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Overall, a representative sample of 100 gynecologists and 31 dermatologists are asked to        contribute OC prescribing data to this study.|October 2012|October 17, 2012|March 18, 2011||No||No|August 15, 2012|https://clinicaltrials.gov/show/NCT01319500||107267|
NCT01319786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QueensUBelfast|Effect of a Polyphenol Rich Diet on Vascular and Platelet Function|Effect of a Polyphenol Rich Diet on Vascular and Platelet Function- a Randomised Control Trial|PPhIT|Queen's University, Belfast|No|Completed|January 2011|August 2015|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|40 Years|65 Years|No|||October 2015|October 26, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01319786||107245|
NCT01320098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH074556-04|Parent Training for Attention Deficit Hyperactivity Disorder (ADHD) Preschoolers|Home-Based Parent Training in ADHD Preschoolers||New York University School of Medicine|No|Completed|January 2007|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|187|||Both|3 Years|4 Years|No|||December 2014|December 5, 2014|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01320098||107221|
NCT01320358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPRO400A2201|Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients|A 3-month, Exploratory, Non-randomized, Multi-center, Open Label Study to Evaluate the Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients||Novartis||Completed|April 2011|||November 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2011|September 20, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320358||107201|
NCT01320618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09-06-003|Prospective Cohort Study of Robotic Assisted Laparoscopic Sacrocolpopexy Using MPATHY Restorelle Mesh||MPATHY|Atlantic Health System|No|Completed|May 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|120|||Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Our study population will be woman who underwent Robotic assisted laparoscopic sacral        colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapseusing        synthetic polypropelene mesh.|March 2011|August 2, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320618||107181|
NCT01320631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09-08-008|Male Sexual Experience and Its Impact on Quality of Life Before and After Their Sexual Partners Undergo Polypropylene Mesh Augmented Pelvic Floor Reconstruction||SEXQ|Atlantic Health System|No|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Male sexual partners of women who are sexually active and are scheduled to undergo a mesh        augmented repair for pelvic organ prolapse referred to the Division of Urogynecology and        Reconstructive Pelvic Surgery|July 2012|August 2, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320631||107180|
NCT01320878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJTUMS-10-16|Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease|A Randomized Controlled Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease||Shanghai Jiao Tong University School of Medicine|Yes|Completed|October 2007|December 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Both|4 Years|12 Years|No|||June 2012|June 15, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01320878||107161|
NCT01321151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092010-188|Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers|Use of Resveratrol to Decrease Secondary Brain Injury Following Sports-Related Concussions: a Double-Blind, Placebo-Controlled Study|REPAIR|University of Texas Southwestern Medical Center|Yes|Completed|March 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 7, 2012|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321151||107140|
NCT01321164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPUVB 005|Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis|Fumaric Acid Esters Versus Fumaric Acid Esters Plus Narrow Band Type B Ultraviolet (UVB) in Patients With Severe Plaque Psoriasis||Medical University of Vienna|Yes|Completed|April 2011|April 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||May 2014|May 8, 2014|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321164||107139|
NCT01331122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa FOG201|Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease|A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease||Chelsea Therapeutics||Withdrawn|April 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|N/A|No|||March 2013|March 27, 2013|October 13, 2010|No|Yes|Never initiated. Withdrawn by sponsor.|No||https://clinicaltrials.gov/show/NCT01331122||106383|
NCT01331343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU007_022004|Effectiveness Study of the Guardian RT in Type 1 Diabetics|The Guard Control Trial - Randomized, Controlled, Muti-centric, Clinical Study to Assess Whether Type 1 Diabetic Patients in Poor Glycemic Control Can Improve Using the Real-time Values of the Guardian RT Versus Conventional Self-Monitoring Blood Glucose||Medtronic Diabetes|No|Completed|June 2004|June 2005|Actual|June 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|156|||Both|8 Years|59 Years|No|||April 2011|April 15, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331343||106366|
NCT01331902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1101-069-348|Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement|||Seoul National University Hospital|Yes|Recruiting|March 2011|September 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|N/A|No|||April 2011|April 7, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01331902||106323|
NCT01327742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP-0004-06 rev I|Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft|Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies||Bolton Medical||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||November 2012|November 16, 2012|March 31, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01327742||106636|
NCT01328054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114271|A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval|A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer||GlaxoSmithKline|No|Completed|December 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01328054||106612|
NCT01328067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF034|Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids|A Randomized Study to Evaluate the Safety and Effectiveness of MRgFUS Procedure Compared With Myomectomy for the Treatment of Uterine Fibroids||InSightec|No|Terminated|June 2011|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Female|18 Years|50 Years|No|||April 2012|April 26, 2012|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01328067||106611|
NCT01320943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-EU-174-0160|Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB|FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B|FINITE CHB|Gilead Sciences|Yes|Active, not recruiting|April 2011|August 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320943||107156|
NCT01321216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED.GD.06|Rotavirus Burden and Genotypes in a Sentinel Hospital Surveillance System in Lebanon|ESTIMATION OF THE DISEASE BURDEN AND PREVALENT GENOTYPES OF ROTAVIRUS (RV) CAUSING GASTROENTERITIS (GE) IN CHILDREN <5 YEARS OF AGE IN LEBANON BASED ON A SENTINEL HOSPITAL-BASED SURVEILLANCE PROGRAM.||American University of Beirut Medical Center|No|Recruiting|January 2011|June 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1600|Samples With DNA|Stool samples with rotavirus RNA|Both|N/A|5 Years|No|Non-Probability Sample|Children under 5 years of age admitted because of gastroenteritis to 6 major hospitals in        Lebanon|January 2013|January 31, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321216||107135|
NCT01321463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631029|Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Salmeterol Xinafoate/ Fluticasone Propionate Combination||Pfizer|Yes|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|377|||Both|40 Years|80 Years|No|||July 2012|July 8, 2013|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321463||107116|
NCT01325480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HISTORY - 1209|High Septal Pacing for Cardiac Resynchronization Therapy|High Septal Pacing for Cardiac Resynchronization Therapy Acute Research Study|HISTORY|Boston Scientific Corporation|Yes|Terminated|August 2011|May 2012|Actual|April 2012|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|15|||Both|50 Years|N/A|No|Non-Probability Sample|Heart failure patients with wide QRS and undergoing a CRT procedure|June 2012|June 20, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01325480||106808|
NCT01326390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0035|Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma|Impact of C-arm CT in Patients With Decreased Renal Function Undergoing Transhepatic Arterial Chemoembolization (TACE) for the Treatment of Hepato-Cellular Carcinoma||Stanford University|Yes|Active, not recruiting|May 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All patients we are seeking will already have been scheduled to undergo liver Transhepatic        arterial chemoembolizationWorld Health Organization treatment using C-arm CT as the        imaging guidance (with limited Digital Subtraction angiography as needed).|February 2012|February 2, 2012|July 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01326390||106738|
NCT01326715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110116|Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis|Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis||National Institutes of Health Clinical Center (CC)||Suspended|March 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|70 Years|No|||June 2015|July 15, 2015|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01326715||106713|
NCT01326728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110125|Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation|Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History||National Institutes of Health Clinical Center (CC)||Recruiting|March 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||September 2015|October 6, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01326728||106712|
NCT01319799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr112-09|Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve Replacement|Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve||Sahlgrenska University Hospital, Sweden|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|Cerebrospinal fluid levels of S100B, NSE , Tau and albumin detected by      elctrochemoluminescence immunoassay.|Both|N/A|N/A|No|Non-Probability Sample|Elective surgical aortic valve replacement|November 2010|July 19, 2011|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01319799||107244|
NCT01319812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOFLEX-I|Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents|The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents|BIOFLEX-I|Biotronik, Inc.|No|Active, not recruiting|July 2011|June 2018|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|456|||Both|18 Years|N/A|No|||October 2015|February 1, 2016|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319812||107243|
NCT01320111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMIHO-008/2008|Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment|Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer|PASO|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|Yes|Active, not recruiting|July 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||July 2014|July 14, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01320111||107220|
NCT01320371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44725|Analysis of Standard Versus Barbed Sutures in Primary Total Knee Arthroplasty.|Clinical Outcomes and Cost Analysis of Standard Versus Barbed Sutures for Closure in Primary Total Knee Arthroplasty: A Single Blinded Multicenter Prospective Randomized Trial.||University of Utah|Yes|Completed|January 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|363|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study and control groups will be made up of consecutive patients undergoing a median        parapatellar approach primary total knee arthroplasty at the University of Utah Hospital        and Clinics. The control group will undergo two-layer closure utilizing a standard        interrupted, knotted suture technique. The closures will be performed by 2 members of the        team (attending surgeon, resident, fellow, or PA) in ALL closures so as to limit the        possible confounder of closure time variation due to different numbers of people closing        the incision. This will specifically consist of arthrotomy closure using interrupted #1        Ethibond™ in figure of eight fashion and sudermal closure using 2-0 Monocryl™ in        interrupted buried fashion.|February 2014|February 3, 2014|March 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01320371||107200|
NCT01330537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-019|Exploring the Visual Sensitivity for Topological Properties in Newborn Infants|Exploring the Visual Sensitivity for Topological Properties in Newborn Infants||China Medical University Hospital||Recruiting|April 2011|March 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|N/A|14 Days|Accepts Healthy Volunteers|Probability Sample|full-term and healthy newborns|March 2012|March 12, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330537||106427|
NCT01330550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-209|Effect of High Fiber and Sugar Free Biscuits in Prediabetics Population|Effect of High Fiber and Sugar Free Biscuits in Diabetics Population||China Medical University Hospital|Yes|Recruiting|March 2011|December 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|1||Anticipated|60|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01330550||106426|
NCT01330563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19HPS11G|Drug-drug Interaction Study (CKD-501, Ketoconazole)|Drug-Drug Interaction Study to Investigate the Effect of Ketoconazole on the Pharmacokinetic Properties of CKD-501 in Healthy Male Volunteer: Open, Randomised, 2-way Crossover, Clinical Trial||Chong Kun Dang Pharmaceutical|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330563||106425|
NCT01331356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/4-T|Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia|Prospective Multicenter Pilot Study Evaluating the Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia According to the Criteria of Rome III|Impartox|Nantes University Hospital|Yes|Completed|October 2010|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||October 2013|October 4, 2013|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01331356||106365|
NCT01331681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91745|Intravitreal Aflibercept Injection in Vision Impairment Due to DME|A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema|VIVID-DME|Bayer|Yes|Completed|May 2011|March 2015|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|406|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|April 7, 2011|Yes|Yes||No|August 29, 2014|https://clinicaltrials.gov/show/NCT01331681||106340|
NCT01331889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMS_potassium|Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients|Potassium Change in the Fluid Management System (FMS) Reservoir and Its Effect on the Plasma Potassium Concentration During Liver Transplantation Surgery||Seoul National University Hospital|No|Recruiting|October 2011|||March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|19 Years|80 Years|No|Non-Probability Sample|adult liver transplantation recipients|May 2015|May 27, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331889||106324|
NCT01328457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLPMIM402|An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh|An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh||PATH|Yes|Completed|January 2011|June 2012|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|5 Years|55 Years|No|||August 2012|April 2, 2014|January 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01328457||106583|
NCT01328730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20110331|The Real-world Firebird 2 Versus Cypher Sirolimus-eluting Stent in Treating Patients With Coronary Artery Disease|Post-marketing Study Comparing the Efficacy and Safety of Firebird 2 Versus Cypher Sirolimus-eluting Stents in Treating Patients With Coronary Artery Disease in China|REFIRE|Shanghai Jiao Tong University School of Medicine|Yes|Withdrawn|April 2011|June 2013|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|N/A|No|||March 2011|June 13, 2011|April 1, 2011||No|the Cypher SES is now withdrawing in China market|No||https://clinicaltrials.gov/show/NCT01328730||106562|
NCT01329003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-YS-620-CTIL|DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)|DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|blood 20 ml(cc)|Male|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|At least six months of occupational exposure to Caesar stone|March 2011|April 1, 2011|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01329003||106542|
NCT01320956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100112|Study of the Effects of Hypnosis Before Undergoing Surgery, on Anxiety in Children Aged 10 to 18 Years|Impact of Pre Operative Hypnosis on Anxiety in Children Aged 10 to 18 Years|HYPOPANX|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|120|||Both|10 Years|215 Months|No|||September 2013|November 3, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320956||107155|
NCT01321229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC0902|The Influence of the Sleep Apnea on the Neurological and Functional Recovery|Influence of the Sleep Apnea Syndrome on the Functional Recovery After Stroke in a Rehabilitation Unit|SAS-AVC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2009|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|45|||Both|18 Years|N/A|No|Probability Sample|Patients with stroke history in the past 6 months (ischemic or hemorrhagic) and        Hospitalisation in PRM department and participation to a rehabilitation program during        study|February 2011|March 22, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321229||107134|
NCT01321476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carotid|Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis|Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis|Carotid|Piedmont Healthcare|No|Withdrawn||||||N/A|Observational|Time Perspective: Prospective||1|Actual|0|Samples With DNA|Carotid artery tissue Liver biopsy tissue Intestinal biopsy tissue Cell cultures|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing a carotid, liver, and/or intestinal biopsy|July 2011|September 4, 2013|March 14, 2011||No|Study was never initiated and internal decision to discontinue initiation process|No||https://clinicaltrials.gov/show/NCT01321476||107115|
NCT01321489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEU-SIL-05/09|A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies|A Clinical Phase III, Comparative, Open, Multicenter, Prospectively, to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet, Compared to Viagra ® 50mg Tablet Coated, in the Treatment of Erectile Dysfunction of Different Etiologies||Laboratório Teuto Brasileiro S/A|Yes|Not yet recruiting|September 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Male|18 Years|N/A|No|||March 2011|March 22, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01321489||107114|
NCT01324895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|406-2010|Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing|Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing|SIBO|University of Florida|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|944|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have had 14 C-D-Xylose Breath test performed in GI Motility Laboratory at the        University of Florida to help define the cause of their symptoms and for diagnosis of        SIBO, between January 2000 up until the date of IRB approval.|March 2012|March 23, 2012|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324895||106853|
NCT01326403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-ES-0129-CTIL|Tranexamic Acid in Hip Fracture Patients|Tranexamic Acid in Hip Fracture Patients||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|June 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01326403||106737|
NCT01329198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|414-2008|Brain Stimulation for the Treatment of Tourette Syndrome|Scheduled and Responsive Brain Stimulation for the Treatment of Tourette Syndrome||University of Florida|Yes|Active, not recruiting|September 2009|November 2017|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|25 Years|N/A|No|||November 2015|November 9, 2015|March 25, 2011|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01329198||106527|
NCT01329445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2010-22B|DeNovo NT Longitudinal Data Collection (LDC) Knee Study|Post Market, Longitudinal Data Collection Study of DeNovo NT for Articular Cartilage Defects of the Knee||Zimmer Orthobiologics, Inc.|No|Recruiting|February 2011|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients being recommended for arthroscopic or surgical intervention for articular        cartilage lesionis of the knee|July 2015|July 21, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01329445||106508|
NCT01329718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epigenomics_SPR0012|Specimens for Septin 9 Performance|Specimen Collection Protocol for the Performance Evaluation of the Septin 9 Assay|SPR0012|Epigenomics, Inc|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|562|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 1, 2014|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01329718||106487|
NCT01329731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASAS-1002X|Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients|White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months||Gaba International AG|Yes|Completed|March 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|11 Years|N/A|No|||May 2011|December 10, 2013|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01329731||106486|
NCT01330277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH03/2011|Biomarker for Hunter Disease|Biomarker for Hunter Disease an International, Multicenter, Epidemiological Protocol|BioHunt|University of Rostock|Yes|Recruiting|March 2011|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|After inclusion into the study, blood samples will be drawn to identify a deficiency or      absence of the enzyme iduronate-2-sulfatase (I2S).      The laboratory examinations of the blood samples will be done exclusively at the Laboratory      of the Albrecht-Kossel-Institute, University of Rostock. This laboratory offers an existing      infrastructure, a highly standardized quality of the workflow, a short examination time of      the samples and a long period of experiences in the assessment of the biological impact of      mutations and polymorphism.|Both|N/A|N/A|No|Probability Sample|Patients with Hunter Disease based upon biochemical and/or genetic criteria or patients        who are profoundly suspicious for Hunter disease|November 2015|November 10, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330277||106447|
NCT01330290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0939|Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support|A Multi-site, Non-interventional, Cross-sectional Evaluation of the Caregivers' and the Physicians' Preferred Route of Administration and the Physicians' Rationale for the Choice of Neupro® in Patients With Parkinson Requiring Caregiver Support|CARE-ACT|UCB Pharma|No|Completed|March 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|Idiopathic Parkinson's Disease (iPD) patients treated with a combination of L-dopa or        other oral iPD drug and Neupro® for at least one month and requiring caregiver support        documented as per medical records        Every consecutive, eligible patient to be treated with Neupro® as per physician's decision|November 2013|November 7, 2013|March 18, 2011|No|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01330290||106446|
NCT01330303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114073|SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin|Randomized, Two-period, Cross-over, Bioequivalence Study on Tamsulosin Hydrochloride 0,4 mg Prolonged Release Hard Gelatin Capsule Versus SECOTEX® (Tamsulosin Hydrochloride) 0,4 mg Prolonged Release Hard Gelatin Capsule Healthy Male Volunteers Under Fed Conditions||GlaxoSmithKline|No|Completed|December 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|37|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 19, 2011|August 30, 2010||No||No|March 10, 2011|https://clinicaltrials.gov/show/NCT01330303||106445|
NCT01330316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.48|A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients|A Phase III, Open-label Study of Once Daily BI 201335 240 mg for 24 Weeks in Combination With Pegylated interferon-a (PegIFN) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN / RBV Treatment||Boehringer Ingelheim||Completed|July 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|18 Years|70 Years|No|||July 2015|July 3, 2015|April 5, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01330316||106444|
NCT01331369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FURB 2010/01|Intensification of Care to Improve Adherence to Anti-hypertensives|Intensification of Care to Improve Adherence to Anti-hypertensives in Primary Care: a Pragmatic Clinical Trial.|HyperCare|Universidade de Blumenau|No|Recruiting|November 2010|April 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|396|||Both|18 Years|N/A|No|||November 2010|April 7, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01331369||106364|
NCT01331382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22AB2|Cerebral Blood Flow Effects of Resveratrol and Piperine in Humans|Effects of Resveratrol Alone or in Combination With Piperine on Cerebral Blood Flow Parameters and Cognitive Performance in Humans||Northumbria University|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|23|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331382||106363|
NCT01330797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOZ-1|The Effect of Ranibizumab on Eye Lens Opacity in Cases With Age-Related Macular Degeneration|The Effect of Ranibizumab on Eye Lens Opacity in Cases With Age-Related Macular Degeneration||Uludag University|Yes|Completed|January 2009|January 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|13|||Both|55 Years|85 Years|No|Non-Probability Sample|Neovascular age-related macular degeneration cases undergoing ranibizumab treatment|January 2011|April 6, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330797||106407|
NCT01330810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2243|Curcumin Pharmacokinetics|Crossover, Multiple Dose Pharmacokinetics of Two Curcumin Formulations in Healthy Volunteers||University of North Carolina, Chapel Hill|No|Completed|March 2011|April 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|February 6, 2013|April 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01330810||106406|
NCT01327755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-32122010|Rwanda Selenium Supplementation Clinical Trial|Effect of Selenium Supplementation on CD4 + Cell Recovery, Viral Suppression, Morbidity and Quality of Life of HIV Infected Patients in Rwanda: a Prospective, Double-Blinded, Placebo-Controlled Trial|RSST|The Canadian College of Naturopathic Medicine|No|Completed|February 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|21 Years|N/A|No|||February 2013|October 28, 2013|January 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327755||106635|
NCT01328080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00035842|Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy|Improving Acne Keloidalis Nuchae by Inducing Matrix Metalloproteinases in Vivo Using Targeted Ultraviolet-B Irradiation||Johns Hopkins University|No|Completed|February 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|11|||Male|18 Years|N/A|No|||May 2014|May 19, 2014|March 31, 2011||No||No|April 21, 2014|https://clinicaltrials.gov/show/NCT01328080||106610|
NCT01328093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14211|A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients|A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023||Eli Lilly and Company|Yes|Terminated|April 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|670|||Both|18 Years|65 Years|No|||November 2012|January 11, 2013|March 31, 2011|Yes|Yes|The decision to stop the trial was based on efficacy results in the overall schizophrenia    participant population.|No||https://clinicaltrials.gov/show/NCT01328093||106609|
NCT01328106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114091|Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma|A Single-Arm, Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in Subjects With Metastatic Uveal Melanoma or With Mutation-Positive GNAQ or GNA11 Metastatic Melanoma||GlaxoSmithKline|No|Withdrawn|November 2010|May 2012|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|March 18, 2010|Yes|Yes|The study was cancelled by the sponsor prior to initiation of study enrollment. No subjects    were accrued.|No||https://clinicaltrials.gov/show/NCT01328106||106608|
NCT01320163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1001-019-306|Clinical Acceptability of I-GEL® in Pediatric Patients: Comparison of Clinical Performance With Classic-LMA™|||Seoul National University Hospital|No|Completed|February 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|108|||Both|1 Year|9 Years|No|||May 2012|May 26, 2012|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01320163||107216|
NCT01320176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV1-F4-CT1|Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine|An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.||Institut Pasteur||Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|27 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|March 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01320176||107215|
NCT01320410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROV-RISP-2009-01|Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM®|Clinical Trial to Evaluate the Pharmacokinetics, Safety, and Tolerance of Single Dose Administration of a New Injectable Prolonged Release Formulation of Risperidone Using ISM® Technology in Healthy Volunteers||Rovi Pharmaceuticals Laboratories||Completed||||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Single Blind, Primary Purpose: Treatment|||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|April 30, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01320410||107197|
NCT01320696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|831001|Reverse Genetic H9N2 Influenza Vaccine Study in Adults|A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years||Nanotherapeutics, Inc.|Yes|Completed|March 2011|May 2012|Actual|June 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|275|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01320696||107175|
NCT01320930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TORKOL1|Rehabilitation in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD)|Early Detection and Rehabilitation of Subjects With COPD - Rehabilitation in Moderate COPD||Bispebjerg Hospital|No|Completed|January 2007|March 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|65 Years|N/A|No|||January 2011|March 22, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01320930||107157|
NCT01320969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002025|Could Meditation Modulate the Neurobiology of Learning Not to Fear?|Effects of Mindfulness Practice on the Neural Circuitry of Conditioned Fear Extinction in Healthy Participants||Massachusetts General Hospital|No|Completed|December 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|85|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01320969||107154|
NCT01321242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-ATC-2011/1|Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension|Observational Non-interventional Study - Epidemiological Survey "AchievemenT of Goal Resting HEart Rate on Beta-blockers in Patients With Stable angiNA and Hypertension in Routine Practice"|Athena|AstraZeneca|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical practice|May 2012|May 31, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321242||107133|
NCT01321502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMC-T500-PVFD-1|Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|July 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321502||107113|
NCT01321515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMC-T500-PVFS-1|Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|July 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 22, 2011|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321515||107112|
NCT01321840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jena-Endo-01|Cortical Plasticity in a Complex Intervention for Endometriosis|Investigation of Cortical Plasticity in a Complex Intervention for Endometriosis||University of Jena|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Female|18 Years|N/A|No|||May 2013|May 19, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01321840||107087|
NCT01326377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMDS0020|ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS)|A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once Every 2 Weeks in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk||Stanford University|Yes|Completed|May 2009|February 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|March 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326377||106739|
NCT01330030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07232007-459|Selegiline Patch for Treatment of Nicotine Dependence|Selegiline Patch for Treatment of Nicotine Dependence||Stanford University|Yes|Completed|July 2005|July 2011|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|230|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01330030||106463|
NCT01330329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0209-10|Comparison of Weight Loss Programs for Individuals With Severe Obesity|Comparison of a Traditional Behavioral Weight Loss Program Versus a Technology - Based Weight Loss Program in Severely Obese Individuals||The Miriam Hospital|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|21 Years|55 Years|No|||April 2012|April 18, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330329||106443|
NCT01330576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06SG14|Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis|Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis|CoolNEC|Great Ormond Street Hospital for Children NHS Foundation Trust|No|Recruiting|August 2010|||August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|N/A|N/A|No|||March 2012|March 1, 2012|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01330576||106424|
NCT01330849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52891|Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized Controlled Trial of a Behavior Modification Toolkit in Primary School Children With ADHD Behaviors||Universitaire Ziekenhuizen Leuven|No|Recruiting|December 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|5 Years|13 Years|Accepts Healthy Volunteers|||April 2011|April 6, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330849||106404|
NCT01329991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX115-02|Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate|A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interaction of PLX5622 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate||Plexxikon|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|26|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|April 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01329991||106466|
NCT01330004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080-11|Blood Pressure Change and Outcome|The Relationship of Systolic and Diastolic Blood Pressure Changes Over Time to Patient Outcomes in Incident Hemodialysis Patients|BP|Renal Research Institute|No|Completed|January 1999|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|12695|||Both|18 Years|88 Years|No|Non-Probability Sample|Renal Research Institute hemodialysis patients|May 2015|May 4, 2015|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01330004||106465|
NCT01330017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18123|Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)|A Randomized, Dose-ranging, Placebo-controlled Trial to Evaluate the Effects of Phenylephrine HCl Immediate Release Tablets on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis||Bayer|No|Completed|March 2011|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|539|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|April 4, 2011|Yes|Yes||No|May 24, 2012|https://clinicaltrials.gov/show/NCT01330017||106464|
NCT01331395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.097-1 (Esch)|Effect of Traditional Chinese Medicine on In Vitro Fertilization (IVF) Success Rates|A Randomized, Controlled Clinical Trial of the Effect of Traditional Chinese Medicine on IVF Success Rates|TCM-P002|Pacific Fertility Center|No|Terminated|June 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|8|||Female|21 Years|42 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|April 4, 2011||No|Enrollment rate slower than anticipated.|No||https://clinicaltrials.gov/show/NCT01331395||106362|
NCT01330823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARPAN-01|L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)|L-Carnitine in the Palliative Treatment of Advanced Pancreatic Cancer (CARPAN): a Prospective, Randomised, Placebo Controlled, Double Blinded, Multicentre Trial|CARPAN|University Medicine Greifswald|Yes|Suspended|June 2006|July 2010|Anticipated|October 2009|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|N/A|N/A|No|||April 2011|April 6, 2011|April 5, 2011||No|after interims analysis standard errors for inflammatory and nutritional markers varied    widely, that the power calculation required unattainable goals|No||https://clinicaltrials.gov/show/NCT01330823||106405|
NCT01327768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN1U00-1|Implantation of Olfactory Ensheathing Cells (OECs)|Evaluation of Safety, Feasibility and Treatment Potential for Old Stroke Patients Using Intracerebral Implantation of Olfactory Ensheathing Cells|OECs|China Medical University Hospital|Yes|Recruiting|January 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|6|||Both|35 Years|70 Years|No|||September 2011|September 29, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01327768||106634|
NCT01319864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047475|POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients|A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients||Emory University|Yes|Active, not recruiting|March 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|3 Years|29 Years|No|||July 2014|July 28, 2014|March 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01319864||107239|
NCT01320423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99073|Surgical Trial in Lobar Intracerebral Haemorrhage|Surgical Trial in Lobar Intracerebral Haemorrhage||Taipei Medical University WanFang Hospital|No|Active, not recruiting|August 2010|August 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|20 Years|N/A|No|||March 2011|March 18, 2011|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320423||107196|
NCT01320709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14835|Effect of Piroxicam on Ovulation|Single-center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Whether a Single-dose of Either 20 mg Piroxicam, 40 mg Piroxicam or 80 mg Piroxicam Shows an Effect on Ovulation After the Onset of LH Surge Compared to Placebo in Healthy Young Women||Bayer|No|Completed|March 2011|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|72|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|July 9, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320709||107174|
NCT01321866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2010/EP-01|Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients|Randomized Trial Comparing a Cutting Balloon to a Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients|PREST|Centre Hospitalier Universitaire de Nīmes|Yes|Terminated|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||October 2015|November 3, 2015|March 23, 2011||No|Inclusion curve too slow.|No||https://clinicaltrials.gov/show/NCT01321866||107085|
NCT01321879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0454|Safety and Efficacy of Telavancin|Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2011|||March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321879||107084|
NCT01322126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00710-HMO-CTIL|Comparison of Safety And Efficacy of Neuraxial Anesthesia, Palpation Versus Ultrasound|Comparison of Safety And Efficacy of Neyraxial Anesthesia,Palpation Versus Ultrasound||Hadassah Medical Organization|Yes|Not yet recruiting|April 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Both|18 Years|N/A|No|||March 2011|April 7, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01322126||107065|
NCT01322139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCP0607|Sativex Thorough QT/QTc Study|A Multiple-Dose, Randomized, Double-Blind, Placebo- and Active-Controlled, Four-Arm, Parallel Group Thorough QT/QTc Study to Evaluate the Electrophysiologic Effects of Sativex.||GW Pharmaceuticals Ltd.|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|258|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322139||107064|
NCT01326091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028159|Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction|Operative Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction||Duke University|Yes|Terminated|March 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||May 2015|June 22, 2015|March 29, 2011||No|Insufficient study support|No||https://clinicaltrials.gov/show/NCT01326091||106761|
NCT01326104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Re-MATCH|Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor|Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation|Re-MATCH|University of Florida|Yes|Recruiting|April 2010|March 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|30 Years|No|||January 2016|January 12, 2016|July 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326104||106760|
NCT01327300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106-2010|Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)|Randomized, Double-blind, Cross-over Study of the Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)|IBS|University of Florida|No|Completed|March 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||January 2014|January 15, 2014|March 24, 2011||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01327300||106669|The recruitment for this study ended on 3/2012 when Dr. Moshiree became adjunct faculty only at the University Florida. This study was limited with over 6 months of follow-up and the need for three endoscopies.
NCT01327313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200017-007|A Study of EMD525797 in Solid Tumor Patients in Japan|A Phase I, Open-label Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of EMD525797 After Single Dose and Repeated Dosing at Different Dose Levels in Japanese Patients With Advanced or Metastatic Solid Tumors and Progressive Diseases Following Prior Chemotherapy||Merck KGaA|No|Completed|January 2011|October 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|30|||Both|20 Years|N/A|No|||June 2014|June 13, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327313||106668|
NCT01327326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APS2011|Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain|Opioid Modulation of Two Models of Pain Inhibition in Healthy Controls and Patients With Temporomandibular Disorder (TMD)||University of Florida|No|Withdrawn|December 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 11, 2012|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327326||106667|
NCT01330589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-56-LGH|Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort|The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel|INDUCE-it|Lancaster General Hospital|No|Terminated|April 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 28, 2011|Yes|Yes|Inability to enroll subjects and changes in standard of care for PCI|No||https://clinicaltrials.gov/show/NCT01330589||106423|
NCT01330862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-MENA-SA-IRS-2010/01|Epidemiological Study to Describe Non-small-cell Lung Carcinoma (NSCLC) Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA|Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA|EPICLIN|AstraZeneca|Yes|Active, not recruiting|April 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|54|||Both|18 Years|N/A|No|Non-Probability Sample|All NSCLC patients attending the responsible department of treating this type of patients        (e.g. Oncology Department) for the first time (regardless of whether the patient is        diagnosed with locally, advanced or metastatic disease) at the participating sites from        the first of April 2011 to the end of September 2011|December 2012|December 11, 2012|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01330862||106403|
NCT01330875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LINFRUZ01|Lumbar Infiltration With Steroids - Effects on Pain Reduction|Lumbar Infiltration With Steroids - Effects on Pain Reduction||University of Zurich|Yes|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who got a lumbar infiltration in our clinic. The patients will have to answer        questions concerning their pain (the lumbar infiltration itself is not part of this        study).|May 2015|June 2, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01330875||106402|
NCT01331161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00050285|Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly|Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly||Emory University|No|Completed|July 2011|October 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|77|||Both|25 Years|79 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|April 6, 2011|Yes|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT01331161||106380|
NCT01331408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GC0609|A Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks|An Open, Post-marketing, Multi-center Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks||Q-Med AB|No|Completed|September 2008|May 2011|Actual|October 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|61|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2011|May 31, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01331408||106361|
NCT01331421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXEM-01|Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|July 2004|August 2004|Actual|July 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|48|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331421||106360|
NCT01331434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXEM-02|Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|October 2004|October 2004|Actual|October 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|47|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 7, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01331434||106359|
NCT01331135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047016|Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors|Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study|Aflac ST0901|Emory University|Yes|Active, not recruiting|April 2011|April 2021|Anticipated|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|N/A|30 Years|No|||March 2016|March 9, 2016|April 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01331135||106382|
NCT01331148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD Vitamin D|Vitamin D for Sickle Cell|Pilot Study of Vitamin D to Ameliorate Chronic Pain in Sickle Cell Disease|SCD Vitamin D|Emory University|Yes|Active, not recruiting|February 2009|December 2013|Anticipated|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|7 Years|21 Years|No|||March 2012|March 28, 2012|April 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01331148||106381|
NCT01331694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112646|Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|July 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|76130|||Both|40 Years|N/A|No|Non-Probability Sample|All population i.e. U>U40 years: Each initial maintenance treatment (IMT) cohort (FSC        250/50mcg dose only, IP, and TIO) includes patients aged 40 years and older with at least        9 months of continuous enrollment (6 months pre-index and at least three months        post-index) with a primary or secondary diagnosis of COPD [International Classification of        Disease, 9th revision, Clinical Modification (ICD-9-CM) codes 491.xx, 492.xx or 496.xx].        Patients are observed such that everyone provides minimum 6 months of pre index baseline        data and minimum 3 months post index (risk analysis) and minimum 12 months post index for        cost analysis. Patients must receive either a 30-day supply of FSC or IP or TIO as the        initial IMT medication, indicating "intent to treat." Patients may not also have a        prescription filled for the other IMT medication within 60 days of the index date, or for        the combination therapy budesonide/ formoterol (BFC), an inhaled corticosteroid (ICS) or a        long acting beta agonist (LABA).|August 2011|September 15, 2011|March 10, 2011||No||No|March 10, 2011|https://clinicaltrials.gov/show/NCT01331694||106339|
NCT01331915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUC 09-003|Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients|Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.|THERAVAC|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||Recruiting|September 2010|||October 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01331915||106322|
NCT01331928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH99-TD-C-111-007|Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer|A Phase II Study of Sequential Capecitabine Plus Oxaliplatin (XELOX) Followed by Docetaxel Plus Capecitabine (TX) in Patients With Unresectable Gastric||Taipei Veterans General Hospital, Taiwan|No|Recruiting|January 2011|||January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|20 Years|N/A|No|||January 2011|April 7, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01331928||106321|
NCT01331941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090277|A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function|An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function||Amgen||Completed|September 2011|November 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|March 24, 2011||||No||https://clinicaltrials.gov/show/NCT01331941||106320|
NCT01319877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25391|An Observational Study of Avastin (Bevacizumab) in Combination With 5-FU-Based Chemotherapy as First-Line Treatment in Chinese Patients With Metastatic Colorectal Cancer|Observational Study of Avastin Plus 5-FU Based Chemotherapy as First Line Treatment for Chinese Patients With Metastatic Colorectal Cancer.||Hoffmann-La Roche||Completed|March 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|609|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic colorectal cancer receiving first-line therapy with Avastin in        combination with 5-FU-based chemotherapy|March 2016|March 1, 2016|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319877||107238|
NCT01319890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Silverman1|The 'SILVERMAN1' Trial Single Incision Laparoscopic Versus Existing Resection (Minimal Access) for Neoplasia|The 'SILVERMAN1' Trial Single Incision Laparoscopic Versus Existing Resection (Minimal Access) for Neoplasia|SILVERMAN 1|Irish Clinical Outcomes in Research and Education|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|85 Years|No|Probability Sample|Patients with histologically proven right colon tumors, benign and malignant, aged 18-85        years will be included.|March 2012|March 31, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01319890||107237|
NCT01320189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36167|Dietary Protein Requirements on Unbalanced Diets|Dietary Protein Requirements and Caloric Over-consumption on Unbalanced Diets||Maastricht University Medical Center|No|Completed|May 2011|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01320189||107214|
NCT01320436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8356-AL-CTIL|Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis|Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients|5ASA|Sheba Medical Center|No|Completed|July 2011|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||February 2016|February 11, 2016|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320436||107195|
NCT01320722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002049|Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function|Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)|MODERATE|Brigham and Women's Hospital|No|Completed|March 2011|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|225|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320722||107173|
NCT01321281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC026-Marigot|A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects|Randomised, Placebo Controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects||University College Cork|Yes|Completed|March 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|36|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321281||107130|
NCT01321892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 09-0945|Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium|Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium||Icahn School of Medicine at Mount Sinai|No|Completed|June 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|64|Samples Without DNA|Retained specimens are punch biopsy specimens from the primary tumor resection.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with new head and neck cancer, who reside in the tri-state area.|June 2012|June 20, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321892||107083|
NCT01321580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-43|Hemoglobin MASIMO (Pronto 7) and Laboratory Measurement|Comparison of the Hemoglobin Results Obtained With the Masimo Pronto 7 and the Clinical Laboratory Measurement Study||Hopital Foch|No|Completed|January 2011|February 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||June 2011|June 4, 2011|March 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01321580||107107|
NCT01321905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1723-31/1|Prospective Intervention Study on Vitamin D in Patients With Cystic Fibrosis|5-month Pilot Intervention Study on Vitamin D in Patients With Cystic Fibrosis|D-vitamin|Karolinska Institutet|No|Recruiting|April 2010|||September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|6 Years|N/A|No|||March 2011|March 23, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01321905||107082|
NCT01321918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/6-A|Register and DNA Bank of Adult Extra-hospital Sudden Death (Protocol FASTER)|Register and DNA Bank of Adult Extra-hospital Sudden Death||Nantes University Hospital|No|Terminated|June 2007|November 2010|Actual|November 2010|Actual|N/A|Interventional|Masking: Open Label|2||Anticipated|2000|||Both|18 Years|N/A|No|||March 2011|March 23, 2011|March 23, 2011||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01321918||107081|
NCT01326117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027389|Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis|Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis||Duke University|Yes|Withdrawn|April 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||July 2014|July 25, 2014|March 29, 2011|Yes|Yes|lack of patients who meet inclusion criteria; there was one screen failure|No||https://clinicaltrials.gov/show/NCT01326117||106759|
NCT01326130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RisqueCardioMetabolique|Implementation of an Integrated Primary Care Network for Prevention and Management of Cardiometabolic Risks|Implementation of an Integrated Primary Care Network for Prevention and Management of Cardiometabolic Risks (RCM)|RCM|Public Health Department, Montreal|No|Not yet recruiting|April 2011|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|3000|||Both|18 Years|N/A|No|||March 2011|March 29, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326130||106758|
NCT01327339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106207|REQUIP RLS Post Marketing Surveillance|An Open-label, Multi-centre, Observational, Post-marketing Surveillance to Monitor the Safety of REQUIP(Ropinirole) Administered in Korean Restless Leg Syndrome Patients According to the Prescribing Information|REQUIP RLS PMS|GlaxoSmithKline|No|Completed|April 2006|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Probability Sample|The subjects are patients prescribed for ropinirole by the investigators at the sites        based on prescription information in normal clinical practices.|March 2011|March 3, 2011|March 3, 2011||No||No|March 3, 2011|https://clinicaltrials.gov/show/NCT01327339||106666|
NCT01322360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORP-OS+T-(2-17)-SPK-1|Safety and Pharmacokinetic Study of Oral Morphine Sulfate in Pediatric Subjects|A Multicenter, Open Label, Safety and Pharmacokinetic Study of Oral Morphine Sulfate Administration in Pediatric Subjects 2 Years Old Through 17 Years Old With Postoperative Pain||Roxane Laboratories|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|2 Years|17 Years|No|||January 2016|January 5, 2016|March 21, 2011|Yes|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01322360||107047|
NCT01322646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD058588|A Randomized Trial of Interventions for Teenage Drivers With Attention Deficit Hyperactivity Disorder (ADHD)|||State University of New York at Buffalo|No|Active, not recruiting|July 2010|March 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|172|||Both|16 Years|18 Years|No|||December 2015|December 11, 2015|August 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01322646||107025|
NCT01322919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001|Safety and Efficacy Study to Evaluate the Treatment of Both Near and Distance Vision in a Simultaneous Laser Procedure|A Prospective Study to Evaluate the Safety and Effectiveness of the Presbyopic LASIK Algorithm|Supracor|Technolas Perfect Vision GmbH|No|Completed|April 2010|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322919||107004|
NCT01318681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPU-055|Rhinitis, Cognition and Driving Performance|Effects of Treated and Untreated Allergic Rhinitis on Mood, Cognitive Functions and Actual Driving Performance||Maastricht University Medical Center|No|Completed|January 2011|October 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|22|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||March 2011|November 7, 2013|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318681||107330|
NCT01318694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2301|Efficacy and Safety Study of DEB025/Alisporivir Combined to Peg-IFN and Ribavirin in Chronic Hepatitis C Genotype 1 Treatment-naïve Patients|A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFN and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve||Novartis|Yes|Completed|March 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1073|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318694||107329|
NCT01318967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0537GCRC|Measurement of Kidney Blood Flow and Oxygen Levels by MRI|MRI for the Non-invasive Determination of Renal Blood Flow and Renal Oxygenation||Wake Forest School of Medicine|No|Completed|October 2010|June 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|March 18, 2011||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01318967||107308|
NCT01318980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114604|A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A|A Single Dose, Crossover Study in Healthy Female Subjects to Assess the Regional Absorption and Bioavailability of 100 mg GSK2190915A||GlaxoSmithKline|No|Completed|September 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|14|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 31, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318980||107307|
NCT01319227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeriBRUSBRAC|Periprosthetic Bone Remodeling Around Uncemented Components in Total Hip Arthroplasty|Periprosthetic Bone Remodeling Around Two Different Types of Uncemented Femoral Stems and Two Uncemented Acetabular Components in Total Hip Arthroplasty|PeriBRUSBRAC|Danderyd Hospital|No|Active, not recruiting|October 2009|December 2020|Anticipated|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|40 Years|70 Years|No|||April 2015|April 20, 2015|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319227||107288|
NCT01319240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-3871|Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects|A Trial to Investigate Pharmacokinetics, Safety and Tolerability of Insulin Degludec/Liraglutide (A3) Compared With Insulin Degludec and Liraglutide in Healthy Subjects||Novo Nordisk A/S|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|55 Years|No|||October 2015|October 1, 2015|March 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01319240||107287|
NCT01331954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/BG/FA/Jan2011|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU): a Feasibility Study||Theraclion||Active, not recruiting|March 2011|||April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2015|February 11, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01331954||106319|
NCT01319591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-043|Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate|Comparison of Creatinine Clearance Calculation Methods for Estimation of Glomerular Filtration Rate in Patients Receiving High-Dose Methotrexate||Dana-Farber Cancer Institute|Yes|Active, not recruiting|March 2011|September 2016|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving high-dose methotrexate therapy at Dana-Farber Cancer Institute/Brigham        and Women's Hospital|February 2016|February 12, 2016|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319591||107260|
NCT01319903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFX-1-P1.1|Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29|A Single Ascending, Placebo-controlled, Double-blind Study in Healthy Male Subjects to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the New Humanized Monoclonal Antibody CaCP29||InflaRx GmbH|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|26|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319903||107236|
NCT01320449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110035|Identification of New Serum Markers for Detection of Abuse With Erythropoietin|Identification of New Serum Markers for Detection of Abuse With Erythropoietin||University of Aarhus|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|35|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01320449||107194|
NCT01320202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMTI-SFP-4|Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients|A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study|CRUISE 1|Rockwell Medical Technologies, Inc.|Yes|Completed|March 2011|November 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|305|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|March 20, 2011|Yes|Yes||No|March 20, 2015|https://clinicaltrials.gov/show/NCT01320202||107213|
NCT01320982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-8273-10-MW-CTIL|Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder|A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder|MAP-S-01|Sheba Medical Center|No|Not yet recruiting|March 2011|July 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|400|||Both|18 Years|65 Years|No|||March 2011|March 22, 2011|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01320982||107153|
NCT01320995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2010/VL-02|Perineal Echography in the Delivery Room for the Detection of Anal Lesions|Perineal Echography in the Delivery Room for the Detection of Anal Lesions Among Primiparous Mothers: a Randomized Study|OASIS 1|Centre Hospitalier Universitaire de Nīmes|No|Terminated|September 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|111|||Female|18 Years|N/A|No|||March 2015|March 24, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01320995||107152|
NCT01321008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0035|Stage I/II Nasal NK Cell Lymphoma|Radiation Therapy Followed by Chemotherapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma||M.D. Anderson Cancer Center|No|Terminated|May 2011|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2014|January 21, 2015|March 21, 2011|Yes|Yes|Slow Accrual|No|May 20, 2014|https://clinicaltrials.gov/show/NCT01321008||107151|Early termination with too small number of subjects to perform analysis.
NCT01321528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC 11 YL 0037 CTIL|Trial of Inquiry-based Stress Reduction (IBSR) Program for Health Care Professionals|Pilot Clinical Trial of Inquiry-based Stress Reduction (IBSR) Program for Health Care Professionals||Tel-Aviv Sourasky Medical Center|No|Recruiting|March 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|67 Years|Accepts Healthy Volunteers|Non-Probability Sample|30 participants nurses in the geriatric departments in TASMC|March 2011|March 24, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01321528||107111|
NCT01321853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|144PG09|Home Care Medication Management Program for the Frail Elderly|Home Care Medication Management Program for the Frail Elderly||Arizona State University|Yes|Completed|May 2006|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|414|||Both|60 Years|N/A|No|||January 2012|January 4, 2012|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01321853||107086|
NCT01321931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP1081|Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products|Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2011|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|50|||Both|19 Years|50 Years|No|||July 2012|July 6, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321931||107080|
NCT01321593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/28|Hemoglobin Orsense and Laboratory Measurement|Comparison of the Hemoglobin Results Obtained With the Orsense Device and the Clinical Laboratory||Hopital Foch|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|emergency unit patients requiring an hemoglobin determination|June 2011|June 4, 2011|March 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01321593||107106|
NCT01321606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-010-10S|Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study|IMpact of PRObiotics for Reducing Infections in VEterans: The IMPROVE Study||VA Office of Research and Development|Yes|Completed|October 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|114|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01321606||107105|
NCT01322477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0022-11-HMO|Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency||HCC|Hadassah Medical Organization||Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||25|||Both|18 Years|80 Years||Non-Probability Sample|Advanced HCC|January 2011|March 23, 2011|February 14, 2011||||No||https://clinicaltrials.gov/show/NCT01322477||107038|
NCT01327053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225A2201|A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|BOLT|Novartis|Yes|Active, not recruiting|June 2011|July 2016|Anticipated|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 30, 2011|Yes|Yes||No|August 24, 2015|https://clinicaltrials.gov/show/NCT01327053||106687|230 patients evaluated in the study in the Full Analysis Set: 79 randomized to LDE225 (Sonidegib) 200mg group and 151 randomized to LDE225 800mg group. 1 patient randomized to the 800mg group did not receive study treatment.
NCT01327066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa QTc102|Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose|A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough ECG Trial||Chelsea Therapeutics|No|Completed|March 2011|June 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|52|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|March 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01327066||106686|
NCT01327079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4781|The Use of Methadone in Newborn Infants|Optimizing the Use of Methadone in Newborn Infants|Methadone|Children's Research Institute|Yes|Active, not recruiting|December 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|22 Weeks|43 Weeks|No|||January 2016|January 11, 2016|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327079||106685|
NCT01322373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADG 11-01|A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test|Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test: A Follow-up Study||Orasi Medical, Inc.|No|Enrolling by invitation|March 2011|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Both|20 Years|92 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who enrolled and completed Orasi Protocol ADG 08-01 will be contacted and invited        to participate in this follow-up study.|March 2011|March 23, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01322373||107046|
NCT01322659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1926P|Weaning Using Noninvasive Positive Pressure Ventilation by Means of Helmet in Patients With Acute Respiratory Failure|Weaning Using Noninvasive Positive Pressure Ventilation by Means of Helmet in Patients With Acute Respiratory Failure||University of Padova|Yes|Completed|March 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||March 2011|January 30, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01322659||107024|
NCT01322932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151/10|Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey|HIV-positive Patients Under Tenofovir, Emtricitabine and Efavirenz Therapy Switching From a Two-pill Regimen to a Single Pill Regimen: Patients'Opinion Survey||Policlinique Médicale Universitaire|No|Completed|July 2010|February 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|95|||Both|18 Years|N/A|No|Non-Probability Sample|Patients under TDF-FTC-EFV followed up at the Service of Infectious Disease of the        University Hospital of Lausanne and enrolled in the Swiss HIV Cohort Study (SHCS)        Adherence subgroup: patients enrolled in the HIV adherence program at the pharmacy of the        Department of Ambulatory Care & Community Medicine in Lausanne.|December 2015|December 21, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01322932||107003|
NCT01318707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BiomarkersHemA|Biomarkers Serum Collection Methodology Pilot Study|Biomarkers Serum Collection Methodology Pilot Study||Georgetown University|No|Completed|December 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Severe Hemophilia A|July 2012|July 23, 2012|December 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01318707||107328|
NCT01318993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114644|Open-Label Extension Study of GSK1605786A|An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease|SHIELD-3|GlaxoSmithKline|Yes|Terminated|April 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|400|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|March 3, 2011|Yes|Yes|This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based    on the results of Study CCX114151.|No||https://clinicaltrials.gov/show/NCT01318993||107306|
NCT01319253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOWEN-ANDER-001|A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies|Comparator Trial Evaluating Microbiological Resistance and Clinical Efficacy in Patients Using Alternation Therapy of Inhaled Antibiotics||Indiana University|No|Completed|March 2011|October 2015|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|27|||Both|6 Years|N/A|No|Non-Probability Sample|Primary care clinic|November 2015|November 5, 2015|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319253||107286|
NCT01319266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/1088|A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics of the Hydrocodone Bitartrate Extended-Release Tablet (45 mg) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment||Teva Pharmaceutical Industries|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 20, 2012|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319266||107285|
NCT01319604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/01|SENSIMED Triggerfish|Randomized Clinical Investigation to Assess the Efficacy of SENSIMED Triggerfish Continuous IOP Monitoring||Sensimed AG|No|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|9||Actual|59|||Both|18 Years|85 Years|No|||August 2012|August 7, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01319604||107259|
NCT01320462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS836526|Smoking Cessation Program in the Preadmission Clinic|Smoking Cessation Program in the Preadmission Clinic:The Combination of Counseling, Pharmacotherapy and Quit Line||University Health Network, Toronto|No|Active, not recruiting|December 2010|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|296|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320462||107193|
NCT01320735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-763|Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia|Prospective, Multi-Center, Observational Program to Assess Routine Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in the Russian Federation||AbbVie|No|Completed|February 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Male|18 Years|75 Years|No|Non-Probability Sample|Participants with advanced PCa|June 2015|June 11, 2015|February 14, 2011||No||No|May 19, 2015|https://clinicaltrials.gov/show/NCT01320735||107172|
NCT01321541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIX306 (PIX-R Trial)|Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant|A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant|PIX-R|CTI BioPharma|Yes|Recruiting|April 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|March 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321541||107110|
NCT01321554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-G000-303|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer||Eisai Inc.|Yes|Active, not recruiting|March 2011|March 2015|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|392|||Both|18 Years|N/A|No|||November 2014|December 18, 2014|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01321554||107109|
NCT01321567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT11T|Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis|Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis||Eisai Inc.||Completed|January 2011|August 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2157|||Both|N/A|N/A|No|Non-Probability Sample|Hospitals and Clinics in Japan|May 2015|May 13, 2015|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01321567||107108|
NCT01321658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1634|Geriatric Intervention in Frail Elderly Patients With Colorectal Cancer|Geriatric Intervention in Elderly Surgical Patients With Colorectal Cancer - a Randomized, Controlled Trial.||Oslo University Hospital|No|Completed|February 2011|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|65 Years|N/A|No|||October 2015|October 20, 2015|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01321658||107101|
NCT01322165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1438|National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions|National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions|GenTAC|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Active, not recruiting|November 2007|September 2016|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3800|Samples With DNA|If a blood specimen is obtained, it is separated and stored as plasma, viable cells, and      extracted DNA. If a saliva specimen is obtained, it is stored for DNA.|Both|N/A|N/A|No|Non-Probability Sample|The cohort consists of patients with conditions related to genetically-induced thoracic        aortic aneurysms.|December 2015|December 8, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01322165||107062|
NCT01322178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62202-203|Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients|Open-label, Uncontrolled, Multi-center, Phase II Study of Cetuximab in Combination With mFOLFOX-6 as First-line Treatment in Patients With KRAS Wild-type, Unresectable LIver Metastases of colorEctal Cancer|CLIME|Fudan University|Yes|Recruiting|December 2010|December 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|75 Years|No|||August 2011|August 11, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01322178||107061|
NCT01322490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNIT-PRV-301|A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer|A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer|Prospect|Bavarian Nordic, Inc.|Yes|Active, not recruiting|December 2011|August 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1298|||Male|18 Years|N/A|No|||September 2015|September 3, 2015|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01322490||107037|
NCT01326793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001438|Internet-Based Depression Screening for College Students|Internet-Based Depression Screening for College Students||Massachusetts General Hospital|No|Completed|September 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|1900|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 24, 2015|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01326793||106707|
NCT01326806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH_066159|A Parent-Based Intervention to Reduce Sexual Risk Behavior in Adolescents|Reducing Teen Sexual Behavior: A Clinic-Based Approach||New York University|Yes|Recruiting|November 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|900|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326806||106706|
NCT01327092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD066115-01A1|Cincinnati Home Injury Prevention Study|Injury Prevention in a Home Visitation Population|CHIP|Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|September 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|650|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 10, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327092||106684|
NCT01318382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08194|Residual Curarization and Its Incidence at Tracheal Extubation (P08194)|Residual Curarization and Its Incidence at Tracheal Extubation|RECITE|Merck Sharp & Dohme Corp.|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|302|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|March 17, 2011||No||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01318382||107352|
NCT01318395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100ADE07T|Aliskiren on Retinal Vasculature Treatment Study|Randomized, Double Blind, Active-controlled, Parallel Study to Analyse Effects of the Combination of Aliskiren and Valsartan on the Vascular Structure and Function of Retinal Vessels|ARTS|University of Erlangen-Nürnberg Medical School|Yes|Completed|May 2010|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Male|18 Years|75 Years|No|||June 2014|June 3, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318395||107351|
NCT01318720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCPT1|Short-Term Effects of Combined Manual Therapy to the Cervical and Thoracic Spine|Short-Term Combined Effects of Thoracic Spine Thrust Manipulation and Cervical Spine Non-Thrust Manipulation in Patients With Mechanical Neck Pain: A RCT||Masefield and Cavallaro Physical Therapy|No|Completed|November 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|60 Years|No|||April 2015|April 6, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318720||107327|
NCT01319006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114703|Relative Bioavailability Study for GSK1278863A|A Randomized, Open-label, 3-period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of Single Oral 100mg Doses of GSK1278863A||GlaxoSmithKline|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|September 13, 2012|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319006||107305|
NCT01319019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115032|A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|437|||Both|40 Years|N/A|No|||July 2014|July 16, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01319019||107304|
NCT01319279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/1089|A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics of the Hydrocodone Bitartrate Extended-Release Tablet (15 mg) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment||Teva Pharmaceutical Industries|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 20, 2012|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319279||107284|
NCT01319331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0667|The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes|The Effects of Open Label Alpha-1 Antitrypsin on the Progression of Type 1 Diabetes in Subjects With Detectable C-peptide||University of Colorado, Denver|Yes|Active, not recruiting|October 2010|December 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|6 Years|45 Years|No|||October 2015|October 14, 2015|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319331||107280|
NCT01319292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP38877|To Investigate the Prevalence of Children Asthma in China|To Investigate the Prevalence of Children Asthma in China and Compare With That of the Last 20 Years||Capital Institute of Pediatrics, China||Completed|April 2011|April 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|20000|||Both|N/A|14 Years|No|Probability Sample|children age from 0 to 14 years in big cities in China|August 2014|August 1, 2014|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319292||107283|
NCT01319617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/05|SENSIMED Triggerfish Safety and Tolerability|Evaluation of SENSIMED Triggerfish Safety and Tolerability in Glaucoma Patients and Glaucoma Suspects||Sensimed AG|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|41|||Both|18 Years|80 Years|No|||September 2013|September 4, 2013|March 18, 2011|No|Yes||No|June 4, 2013|https://clinicaltrials.gov/show/NCT01319617||107258|
NCT01319916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-10-18|Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue|Open-Label Study to Evaluate the Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 (Sodium Deoxycholate Injection) Into Abdominal Fat Tissue||Kythera Biopharmaceuticals|No|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 18, 2011|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319916||107235|
NCT01319929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14165|A Study of LY2828360 in Patients With Osteoarthritic Knee Pain|A Proof of Concept Study of the Effects of LY2828360 in the Treatment of Patients With Osteoarthritic Knee Pain.||Eli Lilly and Company|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|39|||Both|40 Years|75 Years|No|||May 2012|May 23, 2012|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01319929||107234|
NCT01319942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-sorafenib|Combined Radiotherapy and Sorafenib in Patients With Hepatoma|Combined Radiotherapy and Sorafenib in Patients With Hepatoma||China Medical University Hospital|Yes|Recruiting|June 2010|June 2013|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|20 Years|69 Years|No|Probability Sample|45 patients withunresectable hepatoma|March 2011|March 21, 2011|July 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01319942||107233|
NCT01320215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2010/SD-01|Complications Associated With Promontofixation for Pelvic Organ Prolapse: Comparing Robot Assisted Laparoscopic and Non-robot Assisted Laparoscopic Surgical Procedures|Complications Associated With Promontofixation for Pelvic Organ Prolapse: a Randomized Trial Comparing Robot Assisted Laparoscopic and Non-robot Assisted Laparoscopic Surgical Procedures|RoboLaps|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|June 2011|December 2021|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|364|||Female|18 Years|N/A|No|||August 2015|September 4, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01320215||107212|
NCT01321021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011DR2032|Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects|Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects|LoDi-Basel|University of Basel|Yes|Completed|March 2011|August 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|80|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01321021||107150|
NCT01341483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00110-229|Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study|Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study|IMPASSE|Medtronic Endovascular|No|Terminated|April 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|||Male|35 Years|70 Years|No|Non-Probability Sample|The study population will consist of male subjects 35 - 70 years of age undergoing        coronary or peripheral angiography and/or intervention for suspected or known coronary or        peripheral atherosclerotic disease (CAD or PAD).|January 2016|January 28, 2016|April 20, 2011||No|Sufficient information gathered|No||https://clinicaltrials.gov/show/NCT01341483||105601|
NCT01341496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110148|Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal|Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum||National Institutes of Health Clinical Center (CC)||Suspended|April 2011|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|99 Years|No|||July 2015|November 20, 2015|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01341496||105600|
NCT01341769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-08857 version 01|Blood Glucose and Insulin Responses to Snack Food Products|A Study to Determine the Effects of Added Ingredients on Glycaemic and Insulinemic Responses to a Snack Food||Mondelēz International, Inc.|No|Withdrawn|April 2011|July 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|April 22, 2011||No|Test ingredient production did not meet specification|No||https://clinicaltrials.gov/show/NCT01341769||105579|
NCT01342029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0124 - RWISE|Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia|Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia|RWISE|Cedars-Sinai Medical Center|Yes|Recruiting|May 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|147|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01342029||105559|
NCT01341509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW100|A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon|Insertional Achilles Tendinopathy: A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon||OAD Orthopaedics|No|Recruiting|April 2011|||April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 10, 2013|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341509||105599|
NCT01342380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#10-10-25|Pioglitazone and Quetiapine XR Pharmacogenetic Study|Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders||University Hospital Case Medical Center|Yes|Completed|February 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|42|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 310 subjects between the ages of 18 and 70 will be targeted for enrollment. We        anticipate a low enrollment rate of 200 from the targeted 310 participants. Eligible        participants will be diagnosed with DSM-IV bipolar disorder (type I, II, or not otherwise        specified) or DSM-IV major depressive disorder, as determined by extensive clinical        interview and the Mini-International Neuropsychiatric Interview-Plus (MINI-Plus).        Participants will be approached for enrollment if they are currently enrolled in one of        four studies: IRB protocol numbers 10-06-19, 12-07-29, 07-07-20, and 07-08-24. Please see        these protocols for additional study specific information.|July 2015|July 8, 2015|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342380||105532|
NCT01342042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPC/PRO-rE4/IIa-04|The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus|The Safety, Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese T2DM|SPPS|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|Yes|Recruiting|March 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|75 Years|No|||April 2011|April 25, 2011|April 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01342042||105558|
NCT01342055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-ESCL002|Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers|Phase I Study of Apetrol ES and Megace® in Healthy Male Volunteers||LG Life Sciences|No|Completed|March 2011|August 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|38|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 8, 2012|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342055||105557|
NCT01314196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNCISAL/1019|Progressive Resistance Training of the Biceps in Subacromial Impingement Syndrome|The Influence of Resistance Training Biceps as an Adjunct to Rehabilitation of the Shoulder in Subacromial Impingement Syndrome (SIS)|PRTB|Federal University of São Paulo|Yes|Completed|December 2008|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||December 2010|March 11, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01314196||107669|
NCT01314222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN169-001|Diabetic Peripheral Neuropathic Pain (DPNP)|A Randomized, Multicenter, Double-blind, Placebo and Active-controlled, Cross-over Study of the Efficacy and Safety of BMS-954561 in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)||Bristol-Myers Squibb|No|Completed|March 2011|July 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|178|||Both|18 Years|85 Years|No|||November 2015|November 6, 2015|February 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01314222||107667|
NCT01315054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-6014|A Methadone Maintenance Treatment Outcome Study in Three Provinces in China|A Methadone Maintenance Treatment Outcome Study in Three Provinces in China: Comparative Evaluation of the Impact of an Intensive Health Care Provider Training Program Combined With Expanded Services on Treatment Retention, Heroin Use, Methadone Dosing and HIV Risk Practices||Centers for Disease Control and Prevention|Yes|Active, not recruiting|May 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|7700|||Both|18 Years|N/A|No|||April 2012|March 13, 2014|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315054||107605|
NCT01315340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8068|Ocular Rigidity and Outflow Facility in Glaucomatous and Normal Eyes|Measurement of Ocular Rigidity, Outflow Facility and Ocular Blood Flow in Glaucomatous and Normal Eyes||Larissa University Hospital||Recruiting|March 2011|July 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||March 2011|March 16, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01315340||107583|
NCT01314781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOL-OAB-01-08|Therapy of the Overactive Bladder Syndrome|Comparison of Solifenacin Combined With Pelvic Floor Muscle and Whole Body Vibration Training With Solifenacin Alone in Patients With Overactive Bladder Syndrome. - A Prospective Randomized Parallel Group Trial|TOBS|Cantonal Hospital, Frauenfeld|Yes|Recruiting|January 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Female|18 Years|N/A|No|||August 2013|August 9, 2013|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01314781||107625|
NCT01315041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pi2011|"Pi" and Hot Flushes|Effects of Homeopathic Medicine "Pi" on Hot Flushes of Women With Menopausal Symptoms||Casa Espirita Terra de Ismael|No|Completed|December 2014|January 2016|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315041||107606|
NCT01315652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100113|Interest of a Standardized Monitoring of Rheumatoid Arthritis: The COMEDRA Trial|Evaluation of the Usefulness of a Center Specialized in the Standardized Management of Rheumatoid Arthritis: The COMEDRA Trial|COMEDRA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|March 2011|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|970|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01315652||107560|
NCT01344577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPA-2011-units|Buccal Plate Augmentation With Different Hydroxyapatite Based Material|Buccal Plate Augmentation Associated With Different Hydroxyapatite-based Biomaterials. A Multicenter Randomized Controlled Clinical Trial||University of Trieste|Yes|Recruiting|May 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|96|||Both|18 Years|80 Years|No|Probability Sample|primary care clinic|September 2012|September 16, 2012|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344577||105364|
NCT01344564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVA002|Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide|Initiation of Androgen Deprivation Therapy for the Treatment of Prostate Cancer Using Degarelix Acetate Followed by Leuprolide Acetate||Urology of Virginia|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|18 Years|N/A|No|||March 2013|March 15, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344564||105365|
NCT01344876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266-10-001|Phase I Study of OPB-51602 in Patients With Hematologic Malignancies|A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1)||Otsuka Pharmaceutical Co., Ltd.|No|Completed|April 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|20 Years|75 Years|No|||May 2015|May 20, 2015|April 26, 2011||No||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01344876||105342|
NCT01344252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1686|Topical Jelly and Intracameral Anesthesia Versus Subtenon Anesthesia, in Cataract Surgery|Topical Jelly and Intracameral Anesthesia Versus Subtenon Anesthesia, in Cataract Surgery: Preference and Surgical Conditions||Hospital Italiano de Buenos Aires||Withdrawn|April 2011|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01344252||105389|
NCT01344538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ginger-01HR|Ginger for Colorectal Cancer Prevention|Phase II Study of the Effects of Ginger Root Extract on Eicosanoids in Colon Mucosa in People at Normal and Increased Risk for Colorectal Cancer||University of Michigan|Yes|Completed|April 2007|December 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 21, 2013|April 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01344538||105367|
NCT01340885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANUC - Lou|Cognitive Decline in Non-demented PD|Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study||Oregon Health and Science University|No|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01340885||105647|
NCT01340898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114858|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK 134612) When Co-administered With Routine Vaccines in Healthy Infants and Toddlers||GlaxoSmithKline||Completed|January 2012|October 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|753|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340898||105646|
NCT01344863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25532|A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe|A Randomized, Open-label, 2-arm, Parallel Group, Single Dose, Multi-center Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of Trastuzumab Administered Subcutaneously as the Trastuzumab/rHuPH20 Formulation Using a Handheld Syringe or Using the Proprietary Single-use Injection Device (SID)||Hoffmann-La Roche||Completed|April 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01344863||105343|
NCT01341223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102009RC|Using Amniotic Membrane as the Carrier for ex Vivo Cell Culture for Cell Therapy in Ocular Surface Reconstruction|Using Amniotic Membrane as the Carrier for ex Vivo Cell Culture for Cell Therapy in Ocular Surface Reconstruction||National Taiwan University Hospital|Yes|Recruiting|March 2011|||March 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|50|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|age:Pregnant women from 18 to 50 years take cesarean section.|March 2012|March 4, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341223||105621|
NCT01345162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011856-23|Assessment and Prevention of Acute Post-herniotomy Pain|Randomized, Prospective Study of the Assessment, Prevention and Management of Acute Post-herniotomy Pain|PTSM04APHP|IRCCS Policlinico S. Matteo|Yes|Completed|March 2010|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|80 Years|No|||May 2014|May 21, 2014|April 19, 2011||No||No|March 17, 2014|https://clinicaltrials.gov/show/NCT01345162||105320|
NCT01340859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G172JF|Inpatient Post Admission Cognitive Therapy (PACT) for the Prevention of Suicide Attempts|Inpatient Post Admission Cognitive Therapy (PACT) for the Prevention of Suicide Attempts: A Pilot Study||Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Active, not recruiting|April 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340859||105649|
NCT01345136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD001|Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma|A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma||Jonsson Comprehensive Cancer Center|Yes|Recruiting|December 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|16 Years|65 Years|No|||February 2016|February 22, 2016|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345136||105322|
NCT01345149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-119|Effect of Intervention With Diet and Physical Activity in Obese Pregnant Women|Effect of Lifestyleintervention With Diet and Physical Activity in Obese Pregnant Women||Hvidovre University Hospital|Yes|Completed|April 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|420|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 5, 2012|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01345149||105321|
NCT01340833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113479|Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors|Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors||GlaxoSmithKline|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|April 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340833||105651|
NCT01340846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113771|A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors|A Four-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin and the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on the Repeat Dose Pharmacokinetics of GSK2118436, and the Repeat Dose Pharmacokinetics of GSK2118436 in Subjects With BRAF Mutant Solid Tumors||GlaxoSmithKline|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||August 2013|August 27, 2015|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01340846||105650|
NCT01341197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101016RC|Fecal Screening Assay for Taiwanese Population|A Pan-detecting Assay Based on Stool Samples for Taiwanese Population||National Taiwan University Hospital|No|Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3172|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Probability Sample|Our study will enroll consecutive subjects participating in the health check-up at        National Taiwan University Hospital (Health Management Center), who will undergo a        standard protocol, including I-FOBT, G-FOBT, HpSA, face-to-face interviews, blood        chemistries, colonoscopy and EGD. Prior to the examination, a self-administered        questionnaire will be used to collect information on participants' demographics, social        habits, clinical symptoms, and medical/medication histories. To ensure that our study        population was asymptomatic and the bleeders were occult, we excluded those who had overt        GI symptoms and overt GI bleeding from analyses. During the same period, patients with        screening detected GI tract cancers from other screening sites, such as throat cancer,        esophageal cancer, gastric cancer, and colorectal cancers, will also be invited to        participated in the study. This enrollment was based on insufficient GI cancer case number        in the interim analyses based on a single screening site.|November 2012|November 30, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341197||105623|
NCT01342068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOS-Dx and Tx|The Effectiveness of Diagnosis and Treatment of Thoracic Outlet Syndrome|The Effectiveness of Diagnosis and Treatment of Thoracic Outlet Syndrome||Nova Southeastern University|No|Completed|June 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|31|||Both|21 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from a variety of settings:          1. First and second year medical students from Nova Southeastern University College of             Osteopathic Medicine with symptoms of Thoracic outlet syndrome.          2. Patients from the Sanford Ziff Osteopathic Manipulation Clinic that exhibit symptoms             of Thoracic outlet syndrome          3. Patients from the Nova Southeastern University Sports Medicine Clinic that exhibit             symptoms of Thoracic outlest syndrome.|February 2013|April 24, 2013|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342068||105556|
NCT01342939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODY-INK|Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)|Postprandial Secretion of of Incretin Hormones and Incretin Effect in Patients With Maturity-onset Diabetes of the Young (MODY)||University Hospital, Gentofte, Copenhagen|No|Completed|January 2011|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|31|Samples With DNA|Buffy coat|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Genetically well-charaterized MODY2 and MODY3 patients at Hagedorn Research        Institute/Steno Diabetes Center|January 2013|January 14, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01342939||105489|
NCT01342952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114588|Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529|An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired||GlaxoSmithKline|Yes|Recruiting|June 2011|December 2024|Anticipated|December 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|8 Years|18 Years|No|||December 2015|February 4, 2016|April 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01342952||105488|
NCT01342653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011162-29|Clinical Trial at Neoadjuvant Peritoneal and Systemic Chemotherapy Plus HIPEC in Gastric Carcinomatosis|Phase II Multicentric Exploratory Single Cohort Clinical Trial to Assess Efficacy and Safety on a New Treatment Scheme by Systemic and Peritoneal Chemotherapy Plus Citoreduction and HIPEC Plus Adjuvant Treatment in Patients With Peritoneal Carcinomatosis From Gastric Cancer|HIPEC|Hospital General Universitario Gregorio Marañon|No|Recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|64 Years|No|||April 2011|November 12, 2012|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01342653||105511|
NCT01314508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-03-018|Increlex Treatment of Children With Chronic Liver Disease and Short Stature|Increlex Treatment of Children With Chronic Liver Disease and Short Stature||University of California, Los Angeles|No|Not yet recruiting|June 2011|||June 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|4 Years|18 Years|No|||February 2011|March 23, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01314508||107646|
NCT01315353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5282|HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women|A Randomized Trial To Compare An HPV Test-And-Treat Strategy To A Cytology-Based Strategy For Prevention Of CIN 2+ In HIV-Infected Women||AIDS Clinical Trials Group|Yes|Active, not recruiting|March 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|450|||Female|18 Years|N/A|No|||December 2015|December 18, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315353||107582|
NCT01315639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081205|New Biomarker for Alzheimer's Disease Diagnostic|Plasma Abeta Peptides and the Risk of Alzheimer's Disease. Diagnostic Performance and Predictive and Prognostic Values of Measurements of Plasma Amyloid Peptides Concentrations for the Diagnosis of Alzheimer's Disease|BALTAZAR|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|August 2010|February 2019|Anticipated|September 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1067|||Both|45 Years|N/A|No|||May 2015|May 12, 2015|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315639||107561|
NCT01315366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUBMC-GE-HF-1|Hypovitaminosis D : A Link Between Bone/Mineral and Fat/Fuel Metabolism|Phase III Study on the Effect of Vitamin D Supplementation on Indices of Mineral and Musculoskeletal Metabolism and on Parameters of Glucose and Fuel Metabolism in Elderly Subjects|GEHF-VitD|American University of Beirut Medical Center|Yes|Completed|January 2011|July 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|257|||Both|65 Years|95 Years|Accepts Healthy Volunteers|||March 2015|November 19, 2015|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01315366||107581|
NCT01315938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-015957-20|Abatacept Treatment in Polymyositis and Dermatomyositis|Abatacept Treatment in Polymyositis and Dermatomyositis|ARTEMIS|Karolinska Institutet|No|Recruiting|January 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||February 2010|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01315938||107538|
NCT01344590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15397|Ethanol Lock for Prevention of Central Line-Associated Blood Stream Infections|Ethanol Lock for Prevention of Central Line-Associated Blood Stream Infections||University of Virginia|No|Recruiting|February 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|50|||Both|N/A|N/A|No|||April 2011|April 27, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344590||105363|
NCT01344889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV22255|An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)|Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin||Hoffmann-La Roche||Completed|October 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4459|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C receiving a long-acting interferon plus ribavirin|March 2016|March 1, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344889||105341|
NCT01344902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC CO201/08|An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon|||Photocure|No|Terminated|February 2009|||October 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Both|18 Years|80 Years|No|||October 2013|October 22, 2013|January 14, 2010||No|The study was stopped due to inadequate efficacy after 13 patients were evaluated.|No||https://clinicaltrials.gov/show/NCT01344902||105340|
NCT01345175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-045|Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer|Randomized Control Trial Comparing Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|N/A|No|||March 2015|March 24, 2015|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345175||105319|
NCT01340911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115444|A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases|A Randomized, Placebo-Controlled, Single-Blind, Dose-Escalation, First-Time-in-Human Study to Assess the Safety and Pharmacokinetics of Single and Repeat Doses of SRT3025 in Normal Healthy Volunteers||GlaxoSmithKline|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|78|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340911||105645|
NCT01341236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Feeding VLBW|Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants|Evaluation of Splanchnic Oximetry,Doppler Flow Velocimetry in the Superior Mesenteric Artery and Feeding Tolerance in VERY LOW BIRTH WEIGHT IUGR and NON-IUGR Infants Receiving Bolus Versus Continuous Enteral Nutrition||San Gerardo Hospital|No|Completed|September 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|N/A|N/A|No|||March 2013|March 21, 2013|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01341236||105620|
NCT01341249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT11_DW224aa|A Study to Compare the Pharmacokinetic Profiles of DW224aa and DW224a|Clinical Trial to Compare the Pharmacokinetic Profiles of DW224aa (Aspartate) Tablet and DW224a (Hydrochloride) Capsule After a Single Oral Administration in Healthy Male Volunteers||Seoul National University Hospital|No|Completed|April 2011|||May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 15, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01341249||105619|
NCT01341535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/567|A Study Comparing Adaptive Biological Imaging - Voxel Intensity - Based Radiotherapy (Adaptive Dose Escalation) Versus Standard Radiotherapy for Head and Neck Cancer|A Two-arm Phase II Randomized Study, Comparing Adaptive Biological Imaging - Voxel Intensity - Based Radiotherapy (Adaptive Dose Escalation) Versus Standard Radiotherapy for Head and Neck Cancer.||University Hospital, Ghent|No|Recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01341535||105597|
NCT01340872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST10-01-301|Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)|A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1)|AEGIS-1|Iron Therapeutics|No|Active, not recruiting|August 2011|September 2014|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340872||105648|
NCT01341210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101071RC|Observational Study of the Decision Making Towards Clinical Trials in Cancer Patients|The Study of the Knowledge, Attitudes, and Decision Making Towards Clinical Trials in Cancer Patients||National Taiwan University Hospital|No|Recruiting|February 2011|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|116|||Both|20 Years|90 Years|No|Non-Probability Sample|Adult, cancer patients who have experience in contact with clinical trials|August 2013|August 23, 2013|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341210||105622|
NCT01341522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBMR01 - REPLY MRI STUDY|Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System|Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System||LivaNova|Yes|Withdrawn|January 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01341522||105598|
NCT01341795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM01|Genetic Variation in the Transporters and Hypoglycemic Agents|Effect of Genetic Variation in the Transporters on Glycemic Response and Pharmacokinetics of Sitagliptin and Metformin||Ajou University School of Medicine|No|Recruiting|July 2011|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|100|Samples With DNA|Blood|Both|20 Years|80 Years|No|Non-Probability Sample|Newly Diagnosed Type 2 Diabetes Patients|March 2014|March 25, 2014|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341795||105577|
NCT01341808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0047|Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients|Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease||Asan Medical Center|No|Completed|April 2011|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|493|||Both|18 Years|40 Years|No|||March 2013|March 16, 2013|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01341808||105576|
NCT01342666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF2039|Tomato Consumption and High Density Lipoprotein-cholesterol|Effect of Tomato Consumption on Serum High Density Lipoprotein-cholesterol Levels. A Randomized, Open-label, Single Blind, Clinical Trial||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|March 2009|December 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||February 2013|February 23, 2013|April 26, 2011||No||No|January 10, 2013|https://clinicaltrials.gov/show/NCT01342666||105510|
NCT01342965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO25121|A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations|A Multicenter, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors||Hoffmann-La Roche||Completed|March 2011|April 2014|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|April 26, 2011|No|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01342965||105487|
NCT01343277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018004|A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma|A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma||Janssen Research & Development, LLC|Yes|Active, not recruiting|June 2011|April 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|579|||Both|15 Years|N/A|No|||February 2016|February 19, 2016|April 26, 2011|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT01343277||105464|
NCT01314521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKAD|Suicidal Ideation and Behavior in Korean Adolescents With Depression|Suicidal Ideation and Behavior in Korean Adolescents With Depression||Hallym University Medical Center|Yes|Recruiting|January 2011|March 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|13 Years|18 Years|No|Probability Sample|outpatients of university hospitals. 50 from Hallym University Sacred Heart Hospital, 50        from Bundang CHA Hospital, 50 from Myongji Hospital.|March 2011|October 4, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01314521||107645|
NCT01314807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Rainbow study|Systemic Consequences and Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Action!|Systemic Consequences and Comorbidities in Mild/Moderate COPD, Time for Action!||Katholieke Universiteit Leuven|No|Active, not recruiting|June 2009|January 2018|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|Samples Without DNA|whole blood, cholesterol, LDL, HDL, creatinine, fibrinogen, glucose, insuline, NTproBNP,      CRP, Hba1C|Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Population-based sample from the general population: random selected patients from the        environment of Leuven (Nelson Study), and co-workers from the University Hospital of        Leuven|January 2014|January 28, 2014|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01314807||107624|
NCT01314820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC09OISI0161|Effects of Joint Effusion on Quadriceps Muscle|Effects of Joint Effusion on Quadriceps Muscle in Patients With Knee Osteoarthritis||The Catholic University of Korea|Yes|Completed|June 2009|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|40|||Female|50 Years|75 Years|No|||January 2010|March 14, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01314820||107623|
NCT01315067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-GW4/6-1|Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry|Non-invasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometry of Urine Samples - a Multicentre Diagnostic Phase III Trial||Hannover Medical School|Yes|Active, not recruiting|October 2011|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|600|Samples Without DNA|Urine samples, kidney allograft biopsies|Both|18 Years|N/A|No|Probability Sample|Patients with a kidney or combined kidney/pancreas transplantation from several German        transplant centres with an acute unexplained allograft dysfunction within the first year        of transplantation who require a clinically indicated allograft biopsy|February 2016|February 18, 2016|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315067||107604|
NCT01315951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME 10 0054|Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation|Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation||Genesys Regional Medical Center|No|Recruiting|March 2011|March 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|75 Years|No|||March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01315951||107537|
NCT01344941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD09-022 HIVBLD|Human Immune Responses Toward HIV-1 Envelope Antigens|Human Immune Responses Toward HIV-1 Envelope Antigens|HIVBLD|St. Jude Children's Research Hospital|No|Completed|March 2010|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|8|Samples Without DNA|Maximally, there will be up to 30 draws per study participant with no more than 120 ml of      blood collected at any one time and no more than 2.5 L collected for the entire study.      Samples will be used for continued B-cell and T-cell studies supportive of the 2 study      objectives. The volume of blood drawn will be closely monitored and will remain below the      defined criteria for minimal risk research.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: Previous St. Jude HIV-1 vaccine study participants will be contacted by phone by        study investigators or their designees to assess interest in participation in this        protocol.        Group 2: Participants will be recruited from those receiving care for their HIV infection        in the Translational Trials Unit at St. Jude.        Group 3: Participants will be recruited from the Memphis community. Recruitment will occur        on College and University campuses, from community groups, through word-of-mouth, and        through the use of a study brochure.|November 2015|November 4, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344941||105337|
NCT01344915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRCTFIN|Restricted vs. Free Knee Range Of Motion For Primary Traumatic Patellar Dislocation|RESTRICTED VS. FREE KNEE RANGE OF MOTION FOR PRIMARY TRAUMATIC PATELLAR DISLOCATION: A PROSPECTIVE RANDOMIZED STUDY||Tampere University Hospital|No|Active, not recruiting|December 2005|June 2011|Anticipated|January 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|50 Years|No|||January 2005|April 29, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344915||105339|
NCT01344928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95/180/2010|The Effects of Short-time High-intensity Interval Training on Tissue Glucose and Fat Metabolism in Healthy Subjects and Patients With Type 2 Diabetes||HITPET|Turku University Hospital|No|Recruiting||||||N/A|Interventional|N/A|2||||||Male|40 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 28, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344928||105338|
NCT01345188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-D032|Ranolazine in Ischemic Cardiomyopathy|Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study||Midwest Cardiovascular Research Foundation|Yes|Completed|April 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345188||105318|
NCT01345201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18R5-001|A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors||OncoMed Pharmaceuticals, Inc.|No|Active, not recruiting|May 2011|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|90 Years|No|||May 2014|May 7, 2014|April 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345201||105317|
NCT01340924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM|Relationship Between Gestational Diabetes and Type 2 Diabetes|Key Determinants of Type 2 Diabetes Prevention Among Women With a History of Gestational Diabetes Mellitus|GDM|Laval University|No|Active, not recruiting|September 2009|December 2014|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|whole blood; serum; white cell.|Female|18 Years|N/A|No|Non-Probability Sample|In order to avoid selection biases, we plan to recruit 450 women with a history of GDM        through administrative data from the Régie de l'assurance maladie du Québec (RAMQ).|July 2013|July 17, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01340924||105644|
NCT01341301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10D.06|Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One HLA Partially-Matched Related Donor||Thomas Jefferson University|Yes|Completed|May 2010|January 2014|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341301||105615|
NCT01341262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-BO2002|THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)|Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation for Patients Less Than 65 Years of Age With Newly Diagnosed Multiple Myeloma||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Completed|March 2002|January 2009|Actual|October 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|378|||Both|18 Years|65 Years|No|||March 2011|April 22, 2011|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01341262||105618|
NCT01341548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WL-1001-02-06|Civamide Nasal Solution for Cluster Headache|A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period|ECH|Winston Laboratories|No|Not yet recruiting|August 2016|July 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341548||105596|
NCT01341561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TnT hs 4|Relevance of Biomarkers in the Process of Weaning|The Relevance of Biochemical Markers in the Process of Weaning||Heidelberg University|No|Recruiting|April 2011|April 2013|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|routine blood parameters|Both|18 Years|N/A|No|Probability Sample|consecutively all patients on our intensive care unit who are artificially ventilated|March 2011|April 22, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01341561||105595|
NCT01341821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99023|Influences of Leadership Style on Team Climate for Quality|Influences of Leadership Style on Team Climate for Quality||Taipei Medical University WanFang Hospital|No|Completed|May 2010|March 2011|Actual|||N/A|Observational|Time Perspective: Retrospective||1|Actual|500|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|employees in the hospitals|April 2011|April 27, 2011|April 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01341821||105575|
NCT01342081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01111004|DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%|A Double-masked Study of DE-111 Ophthalmic Solution Versus Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension -Phase 3, Confirmatory Study-||Santen Pharmaceutical Co., Ltd.||Completed|May 2011|||September 2012|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|489|||Both|20 Years|N/A||||May 2015|May 19, 2015|April 25, 2011||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01342081||105555|
NCT01342094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01111005|DE-111 Against Timolol Ophthalmic Solution 0.5%|A Double-masked Study of DE-111 Ophthalmic Solution Versus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension - Phase 3, Confirmatory Study -||Santen Pharmaceutical Co., Ltd.||Completed|May 2011|||September 2012|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|20 Years|N/A||||June 2015|June 14, 2015|April 24, 2011||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01342094||105554|
NCT01342393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131-11|Proof of Concept Study for First-Sight Refractive Error Correction: Direct Comparison to Manifest Refraction and Autorefraction Results|Proof of Concept Study for First-Sight Refractive Error Correction:Direct Comparison to Manifest Refraction and Autorefraction Results||University of Nebraska|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|N/A||1|Actual|41|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population with refractive error between -4.50 to +4.50 diopter spherical error and        astigmatism up to -1.50 diopters|January 2012|January 9, 2012|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342393||105531|
NCT01342406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-10|Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics|Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics||University of Nebraska|No|Completed|September 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|31|||Both|40 Years|N/A|No|Non-Probability Sample|Subjects with open angle glaucoma|February 2014|February 14, 2014|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342406||105530|
NCT01342679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-02|A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib|A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib|CMR-CML|Kanto CML Study Group|Yes|Completed|April 2011|September 2014|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|N/A|No|||April 2011|September 14, 2015|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342679||105509|
NCT01343303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018292|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis|A Double-Blind, Randomized, Placebo-and Active-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Subjects With Osteoarthritis||Janssen Research & Development, LLC|No|Completed|March 2011|December 2011|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|43|||Both|18 Years|65 Years|No|||August 2012|August 8, 2012|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01343303||105462|
NCT01343290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018016|The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers|A Single-Dose, Open-Label, Randomized, 2-Period, 2-Sequence, Crossover Study to Determine the Effect of Food Coadministration on the Pharmacokinetics of 300 mg Canagliflozin in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 29, 2012|April 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01343290||105463|
NCT01314534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 07-090 / P070130|French Kabuki Syndrome Network. Epidemiology, Management of Patients and Research by Array-CGH|French Kabuki Syndrome Network. Epidemiology, Management of Patients and Research by Array-CGH|Kabuki|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2008|September 2015|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|N/A|N/A|No|Non-Probability Sample|Cross-sectional multicenter exploratory and observational study|February 2011|September 21, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314534||107644|
NCT01314547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM02020|Impact of Environmental Factors on Disease Activity in Spondyloarthritis (SPA): Results of the Prospective Co-Env Cohort|Impact of Environmental Factors on Disease Activity in Spondyloarthritis (SPA): Results of the Prospective Co-Env Cohort|CoEnv|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|patients with SPA disease|November 2010|October 12, 2012|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314547||107643|
NCT01315379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6166|Psychological Treatment for Children Suffering From Post Traumatic Stress Symptoms and Mild Traumatic Brain Injury|Prolonged Exposure Therapy (PE) for Post-traumatic Stress Symptoms and Mild TBI Symptoms in Children Following Motor Vehicle Accident.|TBI|Rabin Medical Center|No|Recruiting|April 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|6 Years|18 Years|No|Non-Probability Sample|Sixty children age 6 to 18 attending the Anxiety clinic in Schneider Children's Medical        Center of Israel, following MVA, will be included.|November 2014|November 13, 2014|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01315379||107580|
NCT01315678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-108|Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections|Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa||Insmed Incorporated|Yes|Completed|March 2012|August 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|6 Years|N/A|No|||March 2015|March 30, 2015|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315678||107558|
NCT01315964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3352|Effects of Plant Stanol Esters on Blood Flow|Effects of Dietary Plant Stanol Esters of Blood Flow Among Healthy Adult Human Subject. The BLOOD FLOW -Study|BLOOD FLOW|Helsinki University|No|Completed|February 2011|August 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01315964||107536|
NCT01316263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14244|A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors|A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)||ImClone LLC|No|Completed|August 2011|November 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316263||107513|
NCT01345253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113750|GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia|GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia||GlaxoSmithKline|No|Active, not recruiting|May 2011|March 2019|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|709|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345253||105313|
NCT01345227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT1|Bone Marrow as an Alternative Site for Islet Transplantation|Pilot Study to Assess Feasibility and Safety of Bone Marrow as Alternative Site in Islet Transplant Patients||Ospedale San Raffaele|Yes|Completed|August 2009|October 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2012|March 4, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345227||105315|
NCT01345240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113681|Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)|Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)||GlaxoSmithKline||Active, not recruiting|November 2011|December 2016|Anticipated|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|11||Actual|705|||Both|8 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2015|January 11, 2016|April 28, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01345240||105314|
NCT01345214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-7746POU003|A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia|An Open-label, Multiple-Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia||Ono Pharmaceutical Co. Ltd|No|Terminated|May 2011|||February 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|April 21, 2011|No|Yes|The study was terminated due to slow accrual of subjects.|No||https://clinicaltrials.gov/show/NCT01345214||105316|
NCT01341314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArthFndtn|Finding Early Rheumatoid Arthritis|Proof of Concept of an Internet-based Series Design Case-finding System for Very Early Rheumatoid Arthritis.||Brigham and Women's Hospital|No|Active, not recruiting|January 2010|July 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Frozen serum for future assay development|Both|18 Years|N/A|No|Non-Probability Sample|persons with joint pain or swelling for less than 3 months|May 2012|May 23, 2012|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341314||105614|
NCT01341275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26257|Adolescents' Response to Hepatitis B Vaccine Booster Dose|Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood|REACH|Baylor College of Medicine|No|Recruiting|April 2010|November 2011|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|400|||Both|16 Years|19 Years|No|||April 2011|April 22, 2011|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341275||105617|
NCT01341288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08F.298|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2008|||||N/A|N/A|N/A||||||||||||||February 10, 2016|March 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341288||105616|
NCT01341574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/161|Early Versus Delayed Treatment of Unilateral Neglect After Stroke|Influence of Prism Adaptation on Spatial Neglect in the Early Versus Delayed Phase After Stroke: a Randomized, Placebo-controlled Trial||University Ghent|No|Recruiting|August 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01341574||105594|
NCT01341847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-63|The Water Method Colonoscopy in Routine Unsedated Colonoscopy Examinations|The Water Method Colonoscopy in Routine Unsedated Colonoscopy Examinations : A Randomized Controlled Trial(RCT) in Diagnostic Cases in Indonesian Patients||Gadjah Mada University||Completed|April 2011|June 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|110|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01341847||105573|
NCT01341834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01-ST_ECRU|Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors|A Safety and Tolerability Study of RAD001 (mTOR Inhibitor) in Combination With Two Dosing Schedules of LBH589B (Histone Deacetylase Inhibitor) in Solid Tumors/ Lymphomas With Enrichment for EBV-Driven Tumors||National Cancer Centre, Singapore|No|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|21 Years|N/A|No|||August 2015|August 18, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341834||105574|
NCT01342107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-024|Effect of FID 114675A on Lens Wettability|The Effect of Alcon Multi-Purpose Disinfecting Solution (MPDS) on Lens Wettability||Alcon Research|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|66|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|January 7, 2011|Yes|Yes||No|March 21, 2012|https://clinicaltrials.gov/show/NCT01342107||105553|
NCT01342419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22010|Circadian Rhythms of Aqueous Humor Dynamics When Using Brimonidine in Humans With Ocular Hypertension|Circadian Rhythms of Aqueous Humor Dynamics When Using Brimonidine in Humans With Ocular Hypertension||University of Nebraska|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Crossover||1|Actual|35|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with intraocular pressure between 21 - 35 mmHg|June 2012|June 13, 2012|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342419||105529|
NCT01342978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOTSPOT|Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time|Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time|HOTSPOT|Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|October 2009|May 2017|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1200|Samples With DNA|Serum, oral rinse/saliva and some tumor samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|cohort of cancer patients with matched enrollment of spouses and non-cancer controls|March 2015|March 30, 2015|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01342978||105486|
NCT01343316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00041559|Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients|Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients||Johns Hopkins University|No|Terminated|November 2010|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|21|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients in the ICU setting|September 2013|September 17, 2013|April 26, 2011||No|lack of funding|No||https://clinicaltrials.gov/show/NCT01343316||105461|
NCT01343537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5981|Continuous Neurophysiological Monitoring Detection of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage Subjects|Real Time Continuous Neurophysiological Monitoring for Early Detection of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage Subjects||State University of New York - Upstate Medical University|No|Terminated|December 2010|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|89 Years|No|||April 2011|December 30, 2015|April 26, 2011||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01343537||105444|
NCT01343550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS6019|Creativity Group for Borderline Personality Disorder|Creativity Group for Borderline Personality Disorder||State University of New York - Upstate Medical University|Yes|Recruiting|February 2011|August 2011|Anticipated|August 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2011|April 27, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343550||105443|
NCT01343524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5891|Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis|Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis||State University of New York - Upstate Medical University|No|Completed|March 2010|January 2012|Actual|December 2010|Actual|N/A|Observational|N/A||1|Actual|14|||Both|4 Years|21 Years|No|Non-Probability Sample|The study population will include CF patients enrolled in studies that require PFTs using        study-provided spirometers. Any patient less than 22 years old, capable of performing PFTs        for research studies, will be offered this study as well.|January 2012|January 4, 2012|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01343524||105445|
NCT01315080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISTULA001|Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula|Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula||Hospital Universitario Virgen de la Arrixaca|Yes|Recruiting|March 2011|September 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with mammillary fistula|March 2011|March 14, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315080||107603|
NCT01315093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation|||National and Kapodistrian University of Athens||Recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Female|25 Years|43 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315093||107602|
NCT01315106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0013|High Resolution 3D Diffusion-weighted Breast MRI|High Resolution 3D Diffusion-weighted Breast MRI||Stanford University|Yes|Recruiting|March 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Stanford Radiology Department MRI facilities|February 2015|February 2, 2015|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315106||107601|
NCT01315392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTAOREF2000MJB|A Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures|A Randomized Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures: A Pilot Study||Carolinas Healthcare System|Yes|Completed|July 2000|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Actual|451|||Both|15 Years|N/A|No|||March 2011|March 14, 2011|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01315392||107579|
NCT01315691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-109|Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa|Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa||Insmed Incorporated|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|N/A|No|||January 2015|January 9, 2015|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315691||107557|
NCT01344954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB-402-006|Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery|Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery: A Phase 2b, Multicentre, Randomised, Active-Controlled, Double Blind, Double Dummy, Parallel Group Study||ThromboGenics|Yes|Completed|April 2011|May 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|632|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|March 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01344954||105336|
NCT01345266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113817|Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry|Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry||GlaxoSmithKline|No|Completed|February 2010|September 2010|Actual|June 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|106|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||October 2011|December 13, 2012|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01345266||105312|
NCT01345279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114016|Indirect Comparison Topotecan Cervical Carcinoma|Indirect Comparison of the Efficacy Between Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix||GlaxoSmithKline|No|Completed|June 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|1|||Female|21 Years|N/A|No|Probability Sample|The search was designed to identify all clinical data published since the Cancer Care        Ontario systematic review in 2006. The Cancer Care Ontario systematic review searched        MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Library        (Cochrane Database of Systematic Reviews (2006 Issue 1), and Cochrane Controlled Trials        Register (2006 Issue 1)), the Canadian Medical Association Infobase, and the National        Guidelines Clearinghouse. The conference proceedings of the American Society of Clinical        Oncology (1995-2005) and the European Society of Medical Oncology (2002-2005) were also        searched. The search was completed on 18 December 2008|April 2011|April 28, 2011|July 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01345279||105311|
NCT01340963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012345/96|The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort|Prognostic Value of the Spectral Turbulence Analysis of the Signal-averaged Electrocardiogram in Chagas Heart Disease|SEARCH-Rio|Universidade Gama Filho|Yes|Completed|June 1995|December 2012|Actual|March 2001|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|100|||Both|18 Years|75 Years|No|Non-Probability Sample|One hundred clinically stable subjects with at least 10 years of regular outpatients        follow-up and positive epidemiological history and serological confirmation of Chagas        disease with ate least two immunological tests.|December 2013|December 9, 2013|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340963||105641|
NCT01340976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13131|A Phase 1 Study of LY2787106 in Cancer and Anemia|A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia||Eli Lilly and Company|No|Completed|January 2010|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|19|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|January 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01340976||105640|
NCT01340937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V419-006|A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006 AM2)|A Phase III Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq ™||Merck Sharp & Dohme Corp.|No|Completed|May 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2808|||Both|46 Days|89 Days|Accepts Healthy Volunteers|||October 2014|October 21, 2014|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340937||105643|
NCT01340950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH092225|Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China|Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China||University of California, San Diego|Yes|Active, not recruiting|July 2010|March 2015|Anticipated|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|70 Years|No|||September 2014|September 24, 2014|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340950||105642|
NCT01341600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00044487|Clopidogrel PGX Bench to Bedside|Clopidogrel Pharmacogenetics Bench to Bedside - A Practical Application|PGXB2B|University of Maryland|Yes|Completed|July 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01341600||105592|
NCT01341587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045527|Smart Glucose Meter Project|Comparison of a Cellular-embedded Glucose Meter With Two-way Personalized Communication Between Patients and Care Managers With a Glucose Meter in Standard Practice in the Care of Diabetic Patients.||University of Maryland|Yes|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01341587||105593|
NCT01341873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10235|Nursing Intervention in Supporting Family Caregivers of Patients Undergoing Stem Cell Transplant|Nursing Intervention for Family Caregivers of HCT Patients||City of Hope Medical Center|Yes|Withdrawn|May 2012|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Supportive Care|2||Actual|0|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 20, 2012|April 21, 2011||No|The protocol was not funded by the NCI|No||https://clinicaltrials.gov/show/NCT01341873||105571|
NCT01341860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHU-110421|Investigation of Genetic Marker Associated With Obesity in Koreans|Investigation of Genetic Marker Associated With Obesity in Koreans, A Single-nucleotide Polymorphism(SNP) Analysis for Korean Obese|IGM-OK|Kyunghee University Medical Center|No|Terminated|January 2000|December 2011|Anticipated|December 2003|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|260|Samples With DNA|blood|Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|obese patients with BMI 25~30 kg/m2 who visited Kyung Hee University Hospital, Seoul,        Korea|April 2011|April 25, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01341860||105572|
NCT01342120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00085|PHARMO Institute Seroquel Safety Study|Seroquel Safety Study|PHARMO II|AstraZeneca|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|18325|||Both|18 Years|N/A|No|Non-Probability Sample|Population based sample of about 2.5 millions residents in the Netherlands|August 2011|August 31, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342120||105552|
NCT01342133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-005|Sweat Duct Imaging in Mother/Newborn Dyads|Sweat Duct Imaging in Mother/Newborn Dyads||Edimer Pharmaceuticals|No|Completed|April 2011|July 2011|Actual|April 2011|Actual|N/A|Observational|N/A||2|Actual|28|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will enroll up to twenty healthy term newborns and their mothers in the        Assessment Nursery at Barnes-Jewish Hospital.|June 2012|June 26, 2012|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01342133||105551|
NCT01342432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/069241|Impact of a Balance Reeducation Protocol on Pain, Function and Postural Control of Low Back Pain Patients|Comparison of Balance Reeducation Plus General Exercises Versus General Exercises Only: Impact on Pain, Function and Postural Control of Low Back Pain Patients||Centro Universitari Fieo|Yes|Completed|January 2009|October 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|40 Years|69 Years|No|||December 2009|April 26, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01342432||105528|
NCT01342692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081225|Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes|Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes|AZA-PLUS|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342692||105508|
NCT01342991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H1305/59|Trial of Open Milligan-Morgan Haemorrhoidectomy Versus Laser Closed Haemorrhoidectomy|Randomised Controlled Trial of Open Milligan-Morgan Haemorrhoidectomy Versus Laser Closed Haemorrhoidectomy||Northern Lincolnshire and Goole Hospitals NHS Foundation Trust|Yes|Completed|December 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2011|November 27, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01342991||105485|
NCT01343004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA058-05-003|Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women|A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture|ACTIVE|Radius Health, Inc.|Yes|Completed|April 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2463|||Female|50 Years|85 Years|No|||January 2015|January 26, 2015|April 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01343004||105484|
NCT01343563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000480|Trigeminal Nerve Stimulation for Depression: Dose Finding|Trigeminal Nerve Stimulation for Depression: Dose Finding||University of California, Los Angeles|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||February 2013|February 4, 2013|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01343563||105442|
NCT01343810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025227|Stress Reduction Training to Improve Sleep Quality, Stress Physiology & Cardiovascular Disease (CVD) Risk Markers|The Effect of Mindfulness-Based Stress Reduction on Sleep Quality, Stress Physiology & CVD Risk||Duke University|Yes|Completed|September 2010|October 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|87|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01343810||105423|
NCT01344083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1210-PII-04/10|Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis|||Laboratoires Thea||Completed|April 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||April 2011|April 11, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01344083||105402|
NCT01314846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-MN-10-2011-03|Co-culture and Advanced Maternal Age in PGS Program|Co-culture Versus Sequential Culture System in Advanced Maternal Age.|CC-PGS|IVI Madrid||Terminated|February 2009|December 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|346|||Female|40 Years|47 Years|No|Probability Sample|Women over 39 years old undergoing a PGS cycle|March 2011|February 26, 2016|March 10, 2011||No|difficulty to include patients|No||https://clinicaltrials.gov/show/NCT01314846||107621|
NCT01314859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-NIF-2010-01|Nifedipine Treatment in Preterm Labor|ADMINISTRATION OF NIFIDEPINE VERSUS ATOSIBAN IN PREGNANT WOMEN WITH A THREAT OF PREMATURE LABOR||Hospital Clinico Universitario de Santiago||Withdrawn|July 2011|July 2013|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|N/A|N/A|No|||February 2011|July 28, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01314859||107620|
NCT01315977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1243|Dietary Antioxidants, Redox Tone and Health Promotion: an Orthomolecular Study of Interactions|Orthomolecular Mechanisms of Health Effects of Antioxidant Rich Diets, With Focus on Green Tea (Camellia Sinensis), DNA Protection and Key Biochemical Products/Effects of the Antioxidant Response Element||The Hong Kong Polytechnic University|Yes|Recruiting|February 2011|April 2012|Anticipated|February 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Anticipated|60|||Both|N/A|70 Years|No|||February 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01315977||107535|
NCT01316289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilon|Pilon Fracture Reduction and Functional Outcome|Quality of Fracture Reduction and Its Influence on Functional Outcome in Patients With Pilon Fractures - a Prospective Multicenter Case Series||AO Clinical Investigation and Documentation|Yes|Active, not recruiting|November 2011|March 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|117|||Both|18 Years|N/A|No|Probability Sample|Patients with pilon fractures that fulfill the following inclusion and exclusion criteria|February 2016|February 12, 2016|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316289||107511|
NCT01344967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN-080520C|Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect||SuBDuE|University Health Network, Toronto||Completed|February 2009|December 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|21|||Female|18 Years|N/A|No|||June 2015|June 22, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344967||105335|
NCT01344980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2010:119|The Effects of a Stainless Steel Suture MGH Flexor Tendon Repair Coupled With Early Aggressive Range of Motion Rehabilitation: a Randomized Controlled Trial|A Pilot Study of a Randomized Controlled Trial Comparing Stainless Steel Suture Repair Coupled With Aggressive Post-Operative Rehabilitation to Polypropylene Suture Paired With Active Range of Motion Rehabilitation||University of Manitoba|No|Not yet recruiting|June 2011|June 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2011|April 28, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344980||105334|
NCT01341028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RYGBPFR001|Gut Hormones After Roux-en-Y Gastric Bypass (RYGBP) Plus Gastric Fundus Resection|Effects of the Resection of the Gastric Fundus on the Secretion of Ghrelin, Peptide-YY, Glucagon-like Peptide-1 and Insulin Secretion in Morbidly Obese Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass||University of Patras|Yes|Completed|May 2007|June 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|No|||February 2007|April 21, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01341028||105636|
NCT01340989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s52645|CO2 Absorption During Laparoscopy|Evaluation of Adding 4% of Oxygen and 10% of Nitrous Oxide to the CO2 Pneumoperitoneum Upon CO2 Resorption.||University Hospital, Gasthuisberg|No|Completed|August 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|60|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2011|October 25, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340989||105639|
NCT01341353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPA001|Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China|Atrial Fibrillation Therapy: A Multi-Center Clinical Study||Wuhan University|Yes|Recruiting|April 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1800|||Both|18 Years|75 Years|No|||April 2011|April 21, 2011|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341353||105611|
NCT01341327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2010-08|Observational Study for Left Main Disease Treatment|A GLOBAL, MULTICENTER, PROSPECTIVE, REAL WORLD OBSERVATIONAL STUDY FOR LEFT MAIN DISEASE TREATMENT|IRIS-MAIN|CardioVascular Research Foundation, Korea|Yes|Recruiting|July 2007|July 2019|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients with unprotected LMCA diseases at participating centers will be        evaluated for the entry into the study.|December 2015|December 14, 2015|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341327||105613|
NCT01341340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-112|The ABSORB BTK (Below The Knee) Clinical Investigation|A Clinical Evaluation of the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) for the Treatment of Subjects With Critical Limb Ischemia (CLI) From Occlusive Vascular Disease of the Tibial Arteries||Abbott Vascular|Yes|Terminated|August 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|80 Years|No|||December 2013|December 13, 2013|April 15, 2011||No|Discontinued due to poor enrollment. Insufficient number of patients enrolled to permit a    statistically rigorous assessment of safety and efficacy.|No||https://clinicaltrials.gov/show/NCT01341340||105612|
NCT01342185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a4xr2dv8|Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B|A Randomized, Controlled, Open-label, Multicenter Clinical Study of Treatment of Chronic Hepatitis B With TY—CZ—9999 Ozone Therapy System|EMOTCHB|Nanfang Hospital of Southern Medical University|Yes|Enrolling by invitation|March 2010|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|189|||Both|16 Years|N/A|No|||October 2012|October 17, 2012|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01342185||105547|
NCT01342497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBR-012CS01|Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study|A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diabetic Patients With Complicated Skin Ulceration on the Foot (Diabetic Foot Ulcer)|BBR-012|Bridge BioResearch Ltd.|Yes|Recruiting|July 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01342497||105523|
NCT01341886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METTC|Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer|||Mashhad University of Medical Sciences|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|N/A|80 Years|No|||April 2011|April 25, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01341886||105570|
NCT01342159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVBITA|Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema|Comparative Treatment of Intravitreal Bevacizumab and Triamcinolone Acetonide on Diabetic Macular Edema||Hallym University Medical Center|Yes|Completed|March 2009|December 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|20 Years|N/A|No|||March 2009|April 26, 2011|April 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01342159||105549|
NCT01342172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1339|Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma|Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma||Icahn School of Medicine at Mount Sinai|Yes|Terminated|March 2011|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|April 21, 2011|Yes|Yes|low accrual|No|November 20, 2014|https://clinicaltrials.gov/show/NCT01342172||105548|The trial was terminated because the regimen was deemed poorly tolerated for chronic administration because of the need for repeated dose delays and reductions coupled with slow accrual.There are no results for this study.
NCT01342146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci-004 CT|Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children|Efficiency and Safety of Pegylated Somatropin(PEG-somatropin) in the Treatment of Children With Growth Hormone Deficiency: a Multicenter, Randomized, Open-label, Controlled Phase 2 Study|PD|GeneScience Pharmaceuticals Co., Ltd.|Yes|Completed|May 2006|February 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|N/A|N/A|No|||May 2011|May 9, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342146||105550|
NCT01342445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shire-80000311112|Effects of LDX on Functioning of College Students With ADHD|Effects of Vyvanse on the Behavioral, Academic, and Psychosocial Functioning of College Students With ADHD||University of Rhode Island|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|28 Years|No|||March 2014|April 7, 2014|April 21, 2011||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT01342445||105527|No notable limitations or caveats are noted.
NCT01342705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091107|Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis|Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial|CIRROX|Assistance Publique - Hôpitaux de Paris|No|Terminated|May 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|N/A|No|||November 2012|April 20, 2015|April 14, 2011||No|delayed recruitment as compared to that expected|No||https://clinicaltrials.gov/show/NCT01342705||105507|
NCT01343329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00043058|Controlling Hyperadrenergic Activity in Neurologic Injury|Controlling Hyperadrenergic Activity in Neurologic Injury|CHAIN|Johns Hopkins University|Yes|Not yet recruiting|July 2011|||June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|N/A|No|||April 2011|April 27, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343329||105460|
NCT01344408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090189|Effectiveness of Computer Assisted Training for Older People With Vestibular Dysfunction|Effectiveness of Computer Assisted Training in Vestibular Rehabilitation for Older Patients With Vestibular Dysfunction||University of Aarhus|No|Active, not recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|63|||Both|65 Years|N/A|No|||October 2015|November 2, 2015|March 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01344408||105377|
NCT01343823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-88/27|Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema|Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema||Dyax Corp.|Yes|Terminated|June 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|April 27, 2011|Yes|Yes|Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was    substantially higher than described in medical literature.|No|September 4, 2013|https://clinicaltrials.gov/show/NCT01343823||105422|The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.
NCT01315704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-15|Alzheimer's Disease and Related Disorders|Maladie d'Alzheimer et Maladies apparentées : Caractérisation Des Anomalies Cognitivo-motrices, et Des Effets Des médicaments Anti-démence et de la Vitamine D à Partir de la Mise en Place d'Une Base de données au CMRR du CHU d'Angers|MERE|University Hospital, Angers|No|Recruiting|November 2009|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All patients of the University Memory Center of Angers University Hospital with respect to        the eligibility criteria|March 2011|March 14, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315704||107556|
NCT01316900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113360|24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease|A Multicenter Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GW642444 and With Tiotropium Over 24 Weeks in Subjects With COPD||GlaxoSmithKline|No|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|846|||Both|40 Years|N/A|No|||December 2013|July 16, 2015|March 15, 2011|No|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01316900||107465|
NCT01316913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113374|24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease|A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD||GlaxoSmithKline|No|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|872|||Both|40 Years|N/A|No|||August 2015|November 19, 2015|March 15, 2011|No|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01316913||107464|
NCT01317173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPH001|Factors Related to the Progression of Chronic Kidney Disease|The Impact of FGF23 and Klotho on Progression of Chronic Kidney Disease||Ankara Education and Research Hospital|No|Active, not recruiting|March 2008|June 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients diagnosed with non-diabetic chronic kidney disease between the ages of 18 and 65        years old.|January 2011|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317173||107445|
NCT01317186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPH002|The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease|||Ankara Education and Research Hospital|No|Recruiting|March 2011|||||N/A|Observational|Observational Model: Cohort||3|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|Stage 2-4 Non-diabetic Chronic Kidney Disease patients|March 2011|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317186||107444|
NCT01317199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1161|Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer|Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer||Johns Hopkins University|Yes|Active, not recruiting|July 2011|November 2016|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|139|||Male|18 Years|N/A|No|||February 2016|February 22, 2016|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317199||107443|
NCT01341652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO08801|Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer|Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer||University of Wisconsin, Madison|Yes|Recruiting|April 2011|March 2020|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Male|18 Years|N/A|No|||February 2016|February 18, 2016|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341652||105588|
NCT01341392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19HPS11H|Drug-drug Interaction Study(CKD-501, Amlodipine)|A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Amlodipine After Oral Administration in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 11, 2011|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341392||105608|
NCT01341405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG100649-2-02|Study of CG100649 Versus Celecoxib in Osteoarthritis Patients|A Double-blind, Randomized, Multicenter, Noninferiority, Phase II Repeat Dose Study of CG100649 Versus Celecoxib in Osteoarthritis Patients||CrystalGenomics, Inc.|Yes|Completed|April 2011|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|125|||Both|20 Years|N/A|No|||October 2012|October 9, 2012|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341405||105607|
NCT01341613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-0110|Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation|Efficacy of a Supplement Capsule Containing L. Reuteri Cardioviva™ on Managing Cholesterol Levels in Hypercholesterolemic Humans||Micropharma Limited|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|20 Years|75 Years|No|||November 2011|November 1, 2011|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341613||105591|
NCT01341626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA024672|Juvenile Justice Girls Randomized Control Trial: Young Adult Follow-up|Juvenile Justice Girls: Pathways to Adjustment and System Use in Young Adulthood||Oregon Social Learning Center|No|Active, not recruiting|January 1997|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|166|||Female|13 Years|18 Years|No|||October 2015|October 31, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01341626||105590|
NCT01341639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V419-007|Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)|A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months (V419-007-03)||Sanofi Pasteur MSD|No|Completed|May 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1250|||Both|46 Days|74 Days|Accepts Healthy Volunteers|||April 2013|April 9, 2013|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01341639||105589|
NCT01341925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0033|Omega-3 and Therapy Study for Depression|Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Depression|OATS|Ohio State University|Yes|Completed|September 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|73|||Both|7 Years|14 Years|No|||March 2016|March 4, 2016|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01341925||105567|
NCT01342471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTennessee|Physical Activity and Leisure-time Study (PALS)|TV Commercial Stepping: Can America's Top Sedentary Activity be Made More Active|PALS|University of Tennessee|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|58|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|April 21, 2011||No||No|September 5, 2012|https://clinicaltrials.gov/show/NCT01342471||105525|Small sample size, disproportionate female gender participation, and limited ethnic diversity. No follow up after 6 months. No control group, that received no intervention.
NCT01343056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10090392|Program Reinforcement Impacts Self Management (PRISM)|Program Reinforcement Impacts Self Management|PRISM|University of Pittsburgh|No|Recruiting|April 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|120|||Both|N/A|N/A|No|||June 2012|June 13, 2012|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01343056||105480|
NCT01343069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|check4outcome2|Safety Improvement and Checklist Application|Safety Analysis in Regard to the Introduction of Surgical Checklists in the Operation Rooms in a Tertiary Care Center|SICA|Regional Hospital of Bolzano|Yes|Withdrawn|June 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|N/A|N/A|No|||May 2015|May 4, 2015|April 26, 2011||No|insufficient quality of data|No||https://clinicaltrials.gov/show/NCT01343069||105479|
NCT01343082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01111006|DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension|A Long-term Open-label Study of DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension -Phase 3-||Santen Pharmaceutical Co., Ltd.||Completed|May 2011|||March 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Both|20 Years|N/A||||May 2015|May 19, 2015|April 24, 2011||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01343082||105478|
NCT01342458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LABIMPH_OA2|Effect of Footwear on the Clinical, Functional, and Biomechanical Aspects in Elderly Women With Knee Osteoarthritis (OA)|Therapeutic Effect of Inexpensive, Flexible and Non-heeled Footwear on the Clinical, Functional and Gait Biomechanics in Elderly Women With Knee Osteoarthritis: a Randomized Clinical Trial|OA|University of Sao Paulo General Hospital|No|Completed|March 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|56|||Female|60 Years|80 Years|No|||January 2015|January 11, 2015|April 20, 2011||No||No|November 6, 2014|https://clinicaltrials.gov/show/NCT01342458||105526|
NCT01342718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2010-011|Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea|Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea||Kyunghee University Medical Center|Yes|Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|75 Years|No|||June 2012|June 1, 2012|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342718||105506|
NCT01343017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2009/533|Impact of Increased Tidal Volumes on Oxygenation and Cardiac Output|Increased Tidal Volume During Anaesthesia Compared to PEEP. Impact on Arterial Concentration of Sevoflurane, Oxygenation and Cardiac Output in a Randomised Clinical Study of Overweight Patients.||Region Skane|No|Completed|September 2010|April 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||April 2011|April 26, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343017||105483|
NCT01343030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G10-0068|Prospective Radiologic Evaluation of Changes Following Fat Grafting|Prospective Radiologic Evaluation of Changes That Might Affect Breast Cancer Diagnosis Following Fat Grafting and Silicone Breast Implants||University of Minnesota - Clinical and Translational Science Institute|Yes|Enrolling by invitation|September 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|35|||Female|18 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will select patients from Clinique Spontini Paris France and from patients at the        University of Minnesota USA who have undergone placement of silicone breast implants with        fat grafting.|June 2014|June 9, 2014|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01343030||105482|
NCT01343043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP 04511|A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma|A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma|NY-ESO-1|Adaptimmune|Yes|Recruiting|March 2011|March 2028|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|4 Years|N/A|No|||March 2016|March 11, 2016|April 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01343043||105481|
NCT01344122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJDATS2-001|Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE)|Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE)|MATICCE|Rhode Island Hospital||Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 28, 2014|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01344122||105399|
NCT01344135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-3-004|Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy|Cost Effectiveness Analysis and Clinical Outcome of Nutritional Rehabilitation on Physical Functioning and Cardiometabolic Risk Profile in COPD Patients With Muscle Atrophy|NUTRAIN|Maastricht University Medical Center|Yes|Recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||September 2011|September 12, 2011|April 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01344135||105398|
NCT01343888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.30|Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)|A Phase III, Randomised, Double-blind and Placebo-controlled Study of Once Daily BI 201335 120 mg for 12 or 24 Weeks or BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Patients With Genotype 1 Chronic Hepatitis C Infection||Boehringer Ingelheim||Completed|April 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|656|||Both|18 Years|70 Years|No|||August 2015|August 18, 2015|April 20, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01343888||105417|
NCT01344681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0794|Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases|A Randomized Phase II, Multi-center, Non-inferiority Clinical Trial for Efficacy and Safety of Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases||Yonsei University|No|Completed|June 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01344681||105356|
NCT01316575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES-3|Prophylactic nCPAP Following Bowel Surgery (Bio-REB File 11-27)|Prophylactic Nasal Continuous Positive Airway Pressure (nCPAP) Following Bowel Surgery||University of Saskatchewan|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|March 7, 2011||No||No|July 20, 2012|https://clinicaltrials.gov/show/NCT01316575||107489|We made an assumption for FiO2, the respiratory quotient and barometric pressure in the alveolar air equation.We did not standardize the time between extubation and application of nCPAP.
NCT01316926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113939|Paxil CR Bioequivalence Study Brazil|Relative Bioavailability Study Between the Formulations: Paroxetine 25 mg Tablet With Controlled Release Manufactured by GSK Mississauga and Paroxetine 25 mg Tablets With Controlled Release Manufactured by SmithKline Beecham (Cidra), Fasted Administration in Healthy Volunteers for Both Genders.||GlaxoSmithKline|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2011|April 28, 2011|August 30, 2010||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT01316926||107463|The number of adverse events per intervention is not available in the final report.
NCT01317212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2467|Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme|A Phase I Trial of Carboplatin Administered by Convection-Enhanced Delivery to Patients With Recurrent/Progressive Glioblastoma Multiforme||North Bristol NHS Trust|Yes|Withdrawn|May 2015|May 2018|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|March 16, 2011||No|Sufficient funding could not be secured for the study|No||https://clinicaltrials.gov/show/NCT01317212||107442|
NCT01317225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2011-01|Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone|Use of 17α Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor During Current Pregnancy. Double Blind, Randomized, Controlled Trial.||Saint Thomas Hospital, Panama|No|Recruiting|June 2011|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Female|N/A|N/A|No|||January 2015|January 3, 2015|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317225||107441|
NCT01317823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS_CL_02|Bishop Score and Transvaginal Ultrasound for Preinduction Cervical Assessment in Multiparas|||Seoul National University Hospital|No|Completed|December 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|154|||Female|N/A|N/A|No|||October 2012|October 21, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317823||107395|
NCT01341418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-2676-3103|Suprapatellar Versus Infrapatellar Nailing in Tibial Fractures: A Pilot Study|Randomized Clinical Trial of Suprapatellar Versus Infrapatellar Tibial Nailing: A Pilot Study|SP-Pilot|Florida Orthopaedic Institute|No|Completed|April 2011|January 2016|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01341418||105606|
NCT01341899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKX07012|Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes|Prospective Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Recruiting|June 2006|December 2015|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|8 Years|35 Years|No|||July 2011|July 25, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341899||105569|
NCT01341912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENA-11|Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)|Clinical Study to Investigate the Long-Term Efficacy, Safety and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Haemophilia A - Extension Study to GENA-01||Octapharma|Yes|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|12 Years|65 Years|No|||December 2013|December 16, 2013|April 22, 2011|Yes|Yes||No|October 11, 2013|https://clinicaltrials.gov/show/NCT01341912||105568|Only 3 patients participated in the study and all 3 patients withdrew consent prematurely. Therefore the results are summarized descriptively only.
NCT01342198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081197|An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet|A Phase 1, Open-Label, Randomized, Cross-Over Study to Evaluate the Effects of Multiple Doses of Erythromycin on the Pharmacokinetics of a Single Dose of Pregabalin Controlled Release in Healthy Subjects||Pfizer|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 27, 2011|April 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01342198||105546|
NCT01342211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481005|A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins|A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety, And Tolerability Of PF-04950615 (RN316)Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin||Pfizer|Yes|Completed|July 2011|July 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|93|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01342211||105545|
NCT01342484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.56|Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Completed|April 2011|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|40|||Both|10 Years|17 Years|No|||February 2016|February 16, 2016|April 26, 2011||||No||https://clinicaltrials.gov/show/NCT01342484||105524|
NCT01342237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-SCT-1102|Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors|||Seoul National University Hospital|Yes|Recruiting|March 2011|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|N/A|N/A|No|||November 2013|November 17, 2013|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01342237||105543|
NCT01342224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHS 10-141B|Radiation Therapy, Tadalafil, Sargramostim, Gemcitabine, and Telomerase Vaccine (GV1001) in Patients With Pancreatic Cancer|Exploratory Trial of Immunochemoradiotherapy for Locally Advanced Pancreatic Adenocarcinoma||Providence Health & Services|No|Active, not recruiting|January 2011|April 2015|Anticipated|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01342224||105544|
NCT01343342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS|Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors|Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors|FAS|Laval University|No|Active, not recruiting|October 2009|March 2017|Anticipated|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01343342||105459|
NCT01343576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2009-052 (Adel)|Effect of Dairy Fat on Plasma Phytanic Acid in Human|Effect of Dairy Fat on Plasma Phytanic Acid in Healthy Volunteers - A Randomized Controlled Study||University of Copenhagen|No|Completed|August 2009|December 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2009|April 26, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01343576||105441|
NCT01343589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2009-052 (B del)|Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk|Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk||University of Copenhagen|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|38|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||June 2010|April 27, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01343589||105440|
NCT01343836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC10-102|Autologous Tenocyte Implantation in Patients With Chronic Achilles Tendinopathy|The Value of Autologous Tenocyte Implantation in Patients With Chronic Achilles Tendinopathy: a Double-blind Randomised Clinical Trial|ATI|Erasmus Medical Center|Yes|Completed|April 2011|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|55 Years|No|||February 2015|February 12, 2015|April 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01343836||105421|
NCT01343849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EventusDx_breast_2011ver2|Blood Test for Breast Cancer Associated Auto Antibodies|Blood Test for Breast Cancer Associated Auto Antibodies||Eventus Diagnostics Ltd|No|Recruiting|September 2011|September 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|serum plasma|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population includes all women that are scheduled for a pathological or        cytological confirmation either by any kind of biopsy or cytology, prior to any        anti-cancer treatment. The clinical suspicion includes one of the following: positive        mammography/US/MRI, and suspected physical check. Final verification ("true positive" or        "true negative") will be done in relation to pathology/cytology only.|November 2011|November 20, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343849||105420|
NCT01344148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008ZX10001-008|Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.|AIDS and Tuberculosis Co-infection Treatment Strategies Study of China.[ Eleven Fifth Key Research Grant From the Ministry of Science and Technology, the People's Republic of China]||Shanghai Public Health Clinical Center|Yes|Recruiting|February 2009|June 2013|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|65 Years|No|||August 2008|April 27, 2011|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01344148||105397|
NCT01344421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100206|Movement Pattern in Patients With Hip Dysplasia|Movement Pattern in Patients With Hip Dysplasia Operated With Minimally Invasive Approach in Peri-acetabular Osteotomy (PAO)||University of Aarhus|Yes|Completed|March 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|55|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with hip dysplasia and waiting for surgery.|April 2013|April 4, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344421||105376|
NCT01316588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/46|Recolonization Following Preoperative Disinfection Plastic Adhesive Drapes|Recolonization of the Skin Following Pre-operative Disinfection and Impact of the Use of Plastic Adhesive Drapes||Örebro University, Sweden|Yes|Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||July 2015|July 5, 2015|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01316588||107488|
NCT01316601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis CQAX576|A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease|||University of Zurich||Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|3|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316601||107487|
NCT01317498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000334 VMVN|The VMVN Study: Virological Monitoring in Viet Nam|Effect of Routine Viral Load Monitoring on Clinical and Immunological Outcomes and Antiretroviral Drug Resistance on Patients Taking First-line Antiretroviral Drugs in Vietnam|VMVN|Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|April 2011|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|650|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01317498||107420|
NCT01317264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M196|β-Glucans and the Metabolic Syndrome - a Human Intervention Study Under BEST|β-Glucans and the Metabolic Syndrome - a Human Intervention Study Under BEST||University of Copenhagen|No|Completed|November 2009|March 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2009|March 16, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01317264||107438|
NCT01345292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOXDHY0005|A Study of the Relief of Tooth Sensitivity of an Experimental Mouthrinse Device|Assessment of a Potassium Oxalate-Containing Formulation for the Relief of Dentinal Hypersensitivity||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|226|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|April 28, 2011|Yes|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT01345292||105310|
NCT01341015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0094-10|Bedside Ultrasound in the Diagnosis of Ankle Fractures in Children|Bedside Ultrasound in the Diagnosis of Ankle Fractures in Children||Rhode Island Hospital|No|Completed|June 2010|December 2011|Actual|September 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|2 Years|18 Years|No|||April 2011|December 3, 2012|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01341015||105637|
NCT01341041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0334-03|Chlorine Dioxide Versus Saline for Wound Irrigation|Wound Irrigation: Comparison of Normal Saline With Chlorous Acid Chlorine Dioxide Solution||Rhode Island Hospital||Completed|August 2004|June 2009|Actual|December 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||April 2011|April 21, 2011|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341041||105635|
NCT01341964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-090|Clopidogrel and Aspirin Interaction Study-2|Randomized Controlled Trial to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent|Interaction2|Population Health Research Institute|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341964||105564|
NCT01341379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007806|Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate|Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate||Children's Hospital of Philadelphia|Yes|Withdrawn|December 2010|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|3 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|April 22, 2011|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01341379||105609|
NCT01341665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/08|Subclassification of the Syndrome of Inappropriate ADH Secretion|Subclassification of the Syndrome of Inappropriate Antidiuresis Via Copeptin - What is the Genesis of ADH-independent SIADH?||University of Wuerzburg|No|Completed|March 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with chronic hyponatremia (> 3 days) due to SIADH in university hospital in        wuerzburg        healthy control subjects with normonatremia|April 2011|April 25, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341665||105587|
NCT01341678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 004|Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease|Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease (CKD)||Denver Nephrologists, P.C.|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|February 10, 2014|April 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01341678||105586|
NCT01342250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKCR-LD-1.0(2010)|Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis|Phase Ι/Π Study of Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis||Shenzhen Beike Bio-Technology Co., Ltd.|Yes|Completed|October 2010|October 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|70 Years|No|||October 2011|October 13, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342250||105542|
NCT01342263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|711174|Trial of an Internet-based Platform for Managing Chronic Diseases at a Distance|Utilization of an Interactive Internet-based Platform for Managing Chronic Diseases at a Distance|iCDM|Simon Fraser University|No|Active, not recruiting|May 2011|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|318|||Both|19 Years|N/A|No|||May 2015|May 18, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342263||105541|
NCT01342523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0007|Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources|Evaluation of NCI Smoking Intervention Resources|NCI|University of Wisconsin, Madison|Yes|Completed|October 2011|October 2013|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|32||Actual|1034|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|March 8, 2011||No||No|December 12, 2013|https://clinicaltrials.gov/show/NCT01342523||105521|
NCT01342536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0109|African American Depression Intervention Trial (AADI)|A Culturally Adapted Depression Intervention for African American Adults|AADI|University of Wisconsin, Madison|Yes|Recruiting|August 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|30 Years|60 Years|No|||October 2015|October 6, 2015|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342536||105520|
NCT01342731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU 003-11|Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii|Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii||Mahidol University|No|Recruiting|July 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342731||105505|
NCT01342744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si091/2011|Metformin in Postmenopausal Women With Metabolic Syndrome|Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome||Mahidol University|Yes|Recruiting|April 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 14, 2011|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01342744||105504|
NCT01343095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00013140|Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones|A Randomized Controlled Trial of Direct Noise Reduction in the ICU Using Overnight Application of In-ear Earplugs or In-ear Earplugs Plus Noise-Canceling Headphones to Reduce the Incidence and Duration of ICU Delirium||Wake Forest School of Medicine|No|Terminated|May 2011|June 2015|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|12|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|April 13, 2011||No|Loss of study staff|No||https://clinicaltrials.gov/show/NCT01343095||105477|
NCT01343355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM80H-01|Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)|Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)||St. Marianna University School of Medicine|No|Active, not recruiting|January 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|30 Years|75 Years|No|||July 2011|July 21, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01343355||105458|
NCT01343602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF-01-GX-1003|Enhancing Participation of Chronic Stroke Patients by Constraint Induced Movement Therapy (HOMECIMT)|Enhancing Participation of Chronic Stroke Patients in Primary Care by Modified Constraint Induced Movement Therapy (HOMECIMT)|HOMECIMT|Universitätsklinikum Hamburg-Eppendorf|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||December 2014|December 14, 2014|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343602||105439|
NCT01343615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MES2011|Study of Blood Flow Changes and Microemboli During Carotid Surgery|Hemodynamic Alterations in Middle Cerebral Artery and Intraoperative Microemboli During Carotid Endarterectomy and Angioplasty||University of Campinas, Brazil|No|Recruiting|September 2010|July 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||April 2011|April 28, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01343615||105438|
NCT01343862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0046-10-HMO|The Effect of Single Dose D-Cycloserine on Cognitive Outcome in Moderate Traumatic Brain Injury (TBI) Patients|The Effect of Single Dose D-Cycloserine on Cognitive Outcome in Moderate TBI Patients|DCS|Hadassah Medical Organization|Yes|Not yet recruiting|August 2011|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|55 Years|No|||April 2011|April 27, 2011|April 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01343862||105419|
NCT01343875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beyth03-HMO-CTIL|Evaluation the Operative Procedure Among Patients That Suffer From Tear of the Distal Tendon of the Biceps|||Hadassah Medical Organization|No|Not yet recruiting||||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|||||Both|18 Years|65 Years|No|Non-Probability Sample|men and women that went to surgery due to tear of the distal tendon in the biceps muscle.|December 2011|December 25, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343875||105418|
NCT01344161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCT138809092709N2|Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women|Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women||Tehran University of Medical Sciences|Yes|Completed|October 2009|March 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|85|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|April 18, 2011||No||No|July 25, 2011|https://clinicaltrials.gov/show/NCT01344161||105396|
NCT01344434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100270|ACToR-study : Angiographic CT of Renal Transplantation Candidate - Study|Angiographic CT of Renal Transplantation Candidate - Study|ACToR|University of Aarhus|No|Completed|February 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|167|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic kidney disease (CKD) who are renal transplantation candidates. Aged        > 18|February 2014|April 9, 2014|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01344434||105375|
NCT01317238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_SPX_303|Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers|An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers||Seoul National University Hospital|Yes|Completed|October 2010|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|145|||Both|32 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317238||107440|
NCT01317251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B281|Effect of Milk and Cheese on Fecal Fat Excretion and Blood Lipid|Effect of Milk and Cheese on Fecal Fat Excretion and Blood Lipid|MOFF|University of Copenhagen|No|Completed|March 2011|September 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|15|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2011|September 4, 2014|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01317251||107439|
NCT01317849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing-003|China Stroke Secondary Prevention Trial|Folic Acid and B Vitamins for Secondary Prevention of Stroke : A Double-blinded Randomized Controlled Trial|CSSPT|Xijing Hospital|Yes|Withdrawn|July 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|35 Years|75 Years|No|||August 2014|August 18, 2014|March 15, 2011||No|financial assistance financial assistance financial assistance financial assistance financial    assistance without financial assistance|No||https://clinicaltrials.gov/show/NCT01317849||107393|
NCT01341054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uspchamomilla01|Use of Chamomilla Recutita in Mucositis|Chamomilla Recutita Use of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation||University of Sao Paulo|Yes|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01341054||105634|
NCT01341067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMDC-001|Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes|Continuous Glucose Monitoring in Subjects With Type 2 Diabetes|DexlonT2|Rocky Mountain Diabetes and Osteoporosis Center||Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects of all adult ages (18 and older) with type 2 diabetes.|April 2014|April 1, 2014|April 21, 2011||No||No|March 22, 2013|https://clinicaltrials.gov/show/NCT01341067||105633|
NCT01341691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD 006|Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease (CKD)|A 2 Week Single Blind Study to Evaluate Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease||Denver Nephrologists, P.C.|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|6||Actual|12|||Both|18 Years|N/A|No|||April 2011|April 25, 2011|April 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01341691||105585|
NCT01341938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA142952|Nicotine Lozenges and Assisted Self-help for Smokeless Tobacco Cessation|Nicotine Lozenges and Assisted Self-help for Smokeless Tobacco Cessation|LASH|Oregon Research Institute|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1067|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 23, 2015|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01341938||105566|
NCT01333631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR513511CTIL|Valproic Acid With Chemoradiotherapy for Pancreatic Cancer|Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Gemcitabine for Unresectable Locally Advanced Pancreatic Cancer||Soroka University Medical Center||Not yet recruiting|June 2011|July 2015|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||March 2011|April 10, 2011|March 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01333631||106190|
NCT01342549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7201-I|Treatment Strategy for Alcohol Use Disorders in Veterans With TBI|Treatment Strategy for Alcohol Use Disorders in Veterans With TBI|AUD|VA Office of Research and Development|Yes|Completed|September 2011|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Male|18 Years|60 Years|No|||August 2015|August 20, 2015|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342549||105519|
NCT01342510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0139|Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol|The Evaluation of the Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol.||University of Wisconsin, Madison|Yes|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|October 1, 2015|April 25, 2011|Yes|Yes||No|April 20, 2012|https://clinicaltrials.gov/show/NCT01342510||105522|Problems with designation of ASA score differing from that given by anesthesiologist, insertion of a 20 gauge angiocatheter into the dorsum of the hand and anesthesia plan changing (general to monitored) prior to going to the operating room.
NCT01342757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02569|Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma|Using Proton Magnetic Resonance Spectroscopy (MRS) to Predict Response of Vorinostat Treatment in Glioblastoma||National Cancer Institute (NCI)|Yes|Completed|December 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||June 2014|April 14, 2015|April 26, 2011|Yes|Yes||No|May 3, 2013|https://clinicaltrials.gov/show/NCT01342757||105503|In five of the twelve cases spectroscopic indices could not be calculated because the tumor volume was outside of reliably measured voxels. These were primarily accounted for by tumor closeness to the skull or the small size of residual tumor.
NCT01343134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Marie Pierre 01|Anatomical and Functional Macular Changes in Retinal Detachment|||Centre Hospitalier Universitaire Dijon||Completed|January 2010|December 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with successful repair of rhegmatogenous retinal detachment after macula off and        minimum 6 month follow-up after surgery|January 2011|May 12, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343134||105474|
NCT01343108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100001|The Impact of Nurses' Emotional Labor on Job Satisfaction and Burnout|The Impact of Nurses' Emotional Labor on Job Satisfaction and Burnout||Taipei Medical University WanFang Hospital|No|Active, not recruiting|March 2011|December 2011|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|157|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|nurses|April 2011|April 27, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343108||105476|
NCT01343121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10_DOG04_124|Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy|Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy|Gemtrans|Christie Hospital NHS Foundation Trust|No|Active, not recruiting|January 2012|January 2018|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01343121||105475|
NCT01343368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010LS053|Preservation of Ovarian Function After Hematopoietic Cell Transplant|A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT)||Masonic Cancer Center, University of Minnesota|No|Active, not recruiting|July 2011|December 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|47|||Female|50 Years|N/A|No|||February 2016|February 23, 2016|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01343368||105457|
NCT01343901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22999|An Observational Study on Avastin (Bevacizumab) as First-Line Treatment in Colorectal Cancer Patients With Potentially Resectable Liver Metastases (PICASSO)|PICASSO Study: a Cohort Study of Patients With Metastatic Colorectal Cancer Treated With Avastin as First-line Therapy for Hepatic Metastases Considered as Potentially Resectable||Hoffmann-La Roche||Completed|September 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|221|||Both|18 Years|N/A|No|Probability Sample|Patients with colorectal cancer and hepatic or hepatic and pulmonary metastases only|March 2016|March 1, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343901||105416|
NCT01343914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25494|An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy|Retrospective Study to Determinate the Clinical Phenotype of Patients With Non Squamous NSCLC Treated With First Line Bevacizumab-based Therapy That Reached a Long PFS||Hoffmann-La Roche||Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|118|||Both|18 Years|N/A|No|Probability Sample|Non squamous NSCLC patients treated with bevacizumab-based first line therapy and PFS >/=        9 months|March 2016|March 1, 2016|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01343914||105415|
NCT01343927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005956-02A1|Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations|Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations||Boston Medical Center|Yes|Completed|June 2012|December 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|320|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01343927||105414|
NCT01344473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010DE11|A Trial of Tooth Mousse to Remineralise Post-orthodontic Treatment White Spot Lesions|A Randomised Controlled Trial of Tooth Mousse to Remineralise Post-orthodontic Treatment White Spot Lesions||University of Dundee|Yes|Completed|March 2011|November 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|10 Years|N/A|No|||January 2014|January 10, 2014|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01344473||105372|
NCT01344447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14607|Gadobutrol Enhanced MRA of the Supra-aortic Vessels|Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels|GEMSAV|Bayer|Yes|Completed|May 2011|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|479|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|April 5, 2011|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01344447||105374|
NCT01344460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91759|Gadobutrol Enhanced MRA of the Renal Arteries|Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease|GRAMS|Bayer|No|Completed|May 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|317|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|April 5, 2011|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01344460||105373|
NCT01317277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA031058-01A1|Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users|Personalized Text Messages to Improve ART Adherence in HIV+ Methamphetamine Users|iTAB|University of California, San Diego|Yes|Completed|April 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|75|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317277||107437|
NCT01316679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Urinary Biomarkers 101423|An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423|||Vanderbilt University|No|Not yet recruiting|March 2011|April 2014|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|75|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from Vanderbilt internal medicine, hepatology, hepatobiliary        surgery, and general surgery clinics.|March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316679||107482|
NCT01316939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114157|GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease|A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease|SHIELD-2|GlaxoSmithKline|Yes|Terminated|May 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|229|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|March 3, 2011|Yes|Yes|This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based    on the results of Study CCX114151.|No||https://clinicaltrials.gov/show/NCT01316939||107462|
NCT01317524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-089|The Effects of Homogenized and Unhomogenized Milk on Postprandial Metabolism in Healthy Overweight Men|The Effects of Homogenized and Unhomogenized Milk on Postprandial Metabolism in Healthy Overweight Men||Maastricht University Medical Center|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|18|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317524||107418|
NCT01317290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H50-11-KK|Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans|Accumulation of n-3 Long-chain (LC)-PUFA by Supplementation of ALA-rich Oil in Humans Depending on Age, Gender and Physiological Stage.|ALA_KK|University of Jena|Yes|Completed|February 2012|May 2013|Actual|September 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|78|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317290||107436|
NCT01341717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDC/SITA/021/2011|Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin|Open-labelled, Randomized, Active-controlled, Parallel-arm, Single-center Study on Effect of Sitagliptin on T2DM Patients on Treatment With Metformin and Insulin||Jothydev's Diabetes and Research Centre|Yes|Completed|February 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|440|||Both|25 Years|60 Years|No|||May 2014|May 29, 2014|April 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341717||105583|
NCT01343394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JB IND14312|Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children|Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children||Memorial Hermann Health System|Yes|Suspended|April 2011|April 2016|Anticipated|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Weeks|18 Months|No|||January 2014|January 21, 2014|April 25, 2011|No|Yes|UT-IRB insists on protocol design change -Not rel to any pt. safety/non-compliance-Recruiting    halted at UT/MHHS but may resume at FLHosp for Children-OrlandoFL|No||https://clinicaltrials.gov/show/NCT01343394||105455|
NCT01343407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1029-003|A Two-part Study of the Effects of MK-1029 in Allergen-challenged Asthmatics (MK-1029-003 AM1)|A Two-Part, Multicenter, Randomized, Clinical Trial to Study the Effects of Multiple Doses of MK-1029 on the Late Asthmatic Response to Lung Allergen Challenge in Asthmatics||Merck Sharp & Dohme Corp.|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|55 Years|No|||February 2016|February 24, 2016|April 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01343407||105454|
NCT01343654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15475|Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users|RCT of a Text Messaging Adherence Assessment & Intervention Tool for Rural HIV+ Drug Users|TEXTR34|University of Virginia|Yes|Completed|May 2011|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343654||105435|
NCT01341704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMVDU-013|Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa|Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali|MSP3-POC|Vac4All|Yes|Completed|May 2011|March 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|800|||Both|12 Months|48 Months|Accepts Healthy Volunteers|||August 2015|August 27, 2015|April 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01341704||105584|
NCT01341951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIMERIndia|Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis|G-CSF in Acute Liver Failure and Alcoholic Hepatitis - A Pilot Study|G-CSF|Postgraduate Institute of Medical Education and Research|No|Recruiting|June 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2011|April 25, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01341951||105565|
NCT01344486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52424|Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions|Peritoneal Cavity Conditioning During Laparoscopic Surgery Decreases Postoperative Pain, Inflammatory Reaction and Postoperative Adhesions||University Hospital, Gasthuisberg|No|Terminated|September 2010|December 2013|Actual|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 11, 2013|April 21, 2011||No|Investigator no longer works fulltime at investigational site: no inclusions possible|No||https://clinicaltrials.gov/show/NCT01344486||105371|
NCT01333891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-151010|Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure|Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure||Medical University of Vienna|Yes|Terminated|December 2012|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|1|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01333891||106170|
NCT01342770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03826|Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer|Pioglitazone as a Candidate Chemoprevention Agent for Lung Cancer: A Pilot Trial Using a Pre-surgical Model in Early Stage NSCLC||National Cancer Institute (NCI)|Yes|Terminated|April 2011|February 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2013|December 21, 2015|April 23, 2011|Yes|Yes||No|September 4, 2015|https://clinicaltrials.gov/show/NCT01342770||105502|
NCT01342783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST11B2|Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma|Next Generation Sequencing of Childhood Soft Tissue Sarcomas to Identify Drivers of Primary and Metastatic Disease||Children's Oncology Group|No|Active, not recruiting|May 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|18 Years|No|Non-Probability Sample|COG-D9902 soft tissue sarcoma biology and banking study participants.|May 2015|May 8, 2015|April 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01342783||105501|
NCT01343147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|533/10|Deep Versus Superficial Heating in Patients With Knee Osteoarthritis|Deep Versus Superficial Heating in Patients With Knee Osteoarthritis: a Double-blind Randomized Clinical Trial||Catholic University of the Sacred Heart|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343147||105473|
NCT01343381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANNeCTIN|Comparison of Heparin Types; Efficacy and Safety|Anticoagulant Effect and Reversal of Hepalean Compared With PPC Heparin in Patients Undergoing Cardiopulmonary Bypass: a Pilot Randomized Trial||McMaster University|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343381||105456|
NCT01343641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13684|Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects|A Phase 2, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Determine Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Subjects With Stage 4 and Stage 5 Kidney Disease||University of Virginia|Yes|Withdrawn|March 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|85 Years|No|||April 2012|April 25, 2012|July 29, 2010|Yes|Yes|Could not obtain drug supply from manufacturer|No||https://clinicaltrials.gov/show/NCT01343641||105436|
NCT01343628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13464|A Gene by Medication Interaction to the Acute Effects of Alcohol|A Gene by Medication Interaction to the Acute Effects of Alcohol|ATX|University of Virginia|Yes|Terminated|January 2008|April 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|43|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|April 26, 2011|No|Yes|Terminated due to lack of funding|No||https://clinicaltrials.gov/show/NCT01343628||105437|
NCT01344174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|preACLF2011|A Study Evaluating the Efficacy of Glucocorticoids in Patients With Pre-ACLF-HBV|A Randomized, Open Label Study Evaluating the Efficacy and Safety of Glucocorticoids in Patients With Pre-ACLF-HBV|preACLF|Third Military Medical University|Yes|Recruiting|May 2011|November 2013|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|65 Years|No|||June 2011|June 2, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01344174||105395|
NCT01344187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KXL-001|Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus||Avedro, Inc.|No|Active, not recruiting|July 2012|July 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|226|||Both|12 Years|N/A|No|||December 2015|December 23, 2015|April 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01344187||105394|
NCT01335412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-401|Safety Surveillance After Immunization With IXIARO|Active Surveillance for Adverse Events After Immunization With IXIARO(R) Among U.S. Military Service Personnel||Valneva Austria GmbH|Yes|Completed|March 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|20000|||Both|17 Years|N/A|No|Probability Sample|Active duty military personnel (Army, Navy, Air Force, and Marines) who are ≥17 years of        age and received at least one dose of Japanese encephalitis vaccine.|March 2015|March 9, 2015|April 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01335412||106054|
NCT01341730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUKCVC|The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)|Evaluation of the Effect of Atorvastatin and Pioglitazone in Carotid Atherosclerosis With the Use of 18Fluoride-Fludeoxyglucose(FDG) Positron Emission Tomography-computed Tomography (PET-CT)Imaging|PIONEER|The Catholic University of Korea|Yes|Completed|June 2011|August 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2012|November 23, 2012|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01341730||105582|
NCT01344759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHMC 2009-0514|Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea|Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea||Children's Hospital Medical Center, Cincinnati|Yes|Completed|June 2009|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|12 Months|25 Years|No|||January 2016|January 26, 2016|April 21, 2011|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01344759||105350|Failure to standardize mouth opening, due to stimulation of the subject during manipulation of the mouth No baseline measurements were obtained while awake Many patients had Downs syndrome so the results may not apply across all patients with OSA
NCT01316692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC MEL 1036|Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma|A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease||Vanderbilt-Ingram Cancer Center|Yes|Terminated|October 2011|March 2016|Anticipated|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|March 15, 2011|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01316692||107481|
NCT01327183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25619|A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention|A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF 2 DOSES OF RO4905417 (R1512) ADMINISTERED TO PATIENTS WITH NON ST-ELEVATION MYOCARDIAL INFARCTION (NON-STEMI) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)||Hoffmann-La Roche||Completed|May 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|532|||Both|19 Years|74 Years|No|||March 2016|March 1, 2016|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01327183||106678|
NCT01316965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.577|Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly|CONFUCIUS Study : Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly|CONFUCIUS|Hospices Civils de Lyon|No|Recruiting|April 2011|August 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|75 Years|N/A|No|||December 2015|December 14, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316965||107460|
NCT01316978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBUPAI1001|A Study to Test Bioequivalence Between One Test Formulation of Ibuprofen and Two Reference Treatments|A Single-Dose, Randomised, Crossover Bioequivalence Study to Compare the Rate and Extent of Absorption of a Test Formulation of Ibuprofen Fast Melt Orodispersible Tablet Versus Two Reference Formulations in Healthy Volunteers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316978||107459|
NCT01323114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDE-199979-1|The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study|The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study||McKenzie Health System|Yes|Recruiting|April 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|20 Years|65 Years|No|||March 2011|April 12, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323114||106989|
NCT01332474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114324|JCP Study of Investigation of Patient Background Characteristics|BOTOX®(BOTOX is a Registered Trade Mark of Allergan, Inc) Injection 50 and 100 Treatment of Equinus Foot Due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older: Investigation of Patient Background Characteristics||GlaxoSmithKline|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|||||Both|2 Years|N/A|No|Probability Sample|patients aged 2-year or older|April 2011|April 7, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332474||106279|
NCT01343420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK-Abelló Dog Allergen|Dog Hair Extract Study|Dog Hair Evaluation Potency by Prick Skin Testing||National Jewish Health|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|15|||Both|18 Years|60 Years|No|||April 2015|April 14, 2015|April 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01343420||105453|
NCT01342276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|711207|Trial of an Internet-based Platform for Monitoring Heart Failure Patients|Using the Internet for Self-management and Monitoring Patients With Heart Failure at a Distance|vHFC|Simon Fraser University|No|Terminated|April 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|19 Years|N/A|No|||November 2014|November 17, 2014|April 25, 2011||No|Due to futility of recruitment.|No||https://clinicaltrials.gov/show/NCT01342276||105540|
NCT01333345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-036 Addendum|Post-Implant Performance of the EC-3 IOL|Post-Implant Performance of the EC-3 IOL ADDENDUM TO THE PROTOCOL: Clinical Evaluation of the EC-3 Hydrophobic Acrylic Posterior Chamber Aphakic Intraocular Lens||Aaren Scientific Inc.|No|Enrolling by invitation|April 2011|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients who were enrolled in the EC-3 study and implanted with the EC-3 IOL.|April 2011|April 11, 2011|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333345||106212|
NCT01333358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 111746|Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients|Phase III A Prospective, Longitudinal, Rater-blinded Single-arm Study to Evaluate Alemtuzumab as an Effective Treatment in Stabilizing Overall Neurocognitive Function in RRMS Subjects at Specified Timepoints|CAMA-2|Central Texas Neurology Consultants||Not yet recruiting|May 2011|March 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||April 2011|April 22, 2011|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333358||106211|
NCT01344213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anesTKA08|Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine|Comparison of Analgesic Efficacy Among Pregabalin, Celecoxib, Pregabalin With Celecoxib and Placebo After Total Knee Arthroplasty Under Intrathecal Morphine|PCTKA|Chulalongkorn University|Yes|Completed|July 2008|October 2010|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|100|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2011|August 2, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01344213||105392|
NCT01344772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19902010|Total Hip Arthroplasty Compared to Internal Fixation for Displaced Intracapsular Fractures of the Femoral Neck|Total Hip Arthroplasty Compared to Internal Fixation for Displaced Intracapsular Fractures of the Femoral Neck. A Randomized, Controlled Trial With a Seventeen Year Follow-up||Danderyd Hospital|No|Completed|February 1990|June 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|65 Years|N/A|No|||November 2012|November 23, 2012|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344772||105349|
NCT01344785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAIN-1|The Effect of Loss of Offset After Pertrochanteric Fracture Treated With a Intramedullary Nail|The Effect of Loss of Offset After Pertrochanteric Fracture Treated With a Intramedullary Nail|PLAIN|Danderyd Hospital|No|Completed|April 2010|November 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|100|||Both|55 Years|N/A|No|Non-Probability Sample|100 consecutive patients with an intertrochanteric fracture presenting at the Orthopaedic        depertment of Danderyd Hospital, Sweden|October 2013|October 21, 2013|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344785||105348|
NCT01342796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_34|Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects|A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of MF59C.1-adjuvanted Subunit Influenza Vaccine or Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Aged 6 to <36 Months||Novartis||Completed|April 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|84|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||August 2012|August 23, 2012|April 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01342796||105500|
NCT01342809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08708b|Follow up by General Practitioner After Self-poisoning|Follow up After Self-poisoning by General Practitioner- a Randomised Clinical Trial||Oslo University Hospital|No|Completed|November 2009|May 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|75 Years|No|||May 2014|May 6, 2014|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01342809||105499|
NCT01343160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VBR CS 156|Multicenter Study of Removable GORE VIABIL® Biliary Endoprosthesis for Treatment of Benign Biliary Strictures|Multicenter Study of Removable GORE VIABIL® Biliary Endoprosthesis for Treatment of Benign Biliary Strictures||W.L.Gore & Associates|No|Completed|January 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01343160||105472|
NCT01334593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H1002/12b|Assessment of Fitness After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients|The Effect of Neoadjuvant Chemoradiotherapy on Exercise Capacity in Colrectal Cancer Patients||Aintree University Hospitals NHS Foundation Trust|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|Colorectal cancer is the third commonest cause of cancer related death (after breast and        lung cancer) in the United Kingdom and the second commonest in non smokers. Around 100 new        cases of colorectal cancer are diagnosed each day in the UK. In 2002 there were 34,889 new        cases of colorectal cancer diagnosed in the United Kingdom, and approximately 17,000        deaths (CRUK 2006). Almost three quarters of bowel cancer cases occur in people aged 65        and over. Within England, mortality rates are generally higher in the north of the        country.|December 2012|December 29, 2012|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334593||106116|
NCT01343940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29958|Strengthening Families and Reducing Risk Thru Developmental and Legal Collaboration|Project Dulce: Developmental Understanding and Legal Collaboration for Everyone|dulce|Boston Medical Center|Yes|Recruiting|February 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|480|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2011|April 27, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01343940||105413|
NCT01335126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9965-007|Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artificial Tears|Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artificial Tears||Hom, Milton M., OD, FAAO|No|Enrolling by invitation|March 2011|November 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 13, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335126||106076|
NCT01335139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN043AD|Long-Term Effects of Sublingual Grass Therapy|A Randomized, Double-blind, Single-center, Placebo Controlled Study of Sublingual Immunotherapy and Subcutaneous Immunotherapy in Adults With Seasonal Allergic Rhinitis (ITN043AD)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2011|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|108|||Both|18 Years|65 Years|No|||April 2015|April 15, 2015|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335139||106075|
NCT01341743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-04|Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy|A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy||Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|December 2010|December 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|360|||Both|18 Years|65 Years|No|||September 2013|October 28, 2013|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01341743||105581|
NCT01342601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL-041|Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents|Evaluation of the Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents: a Multicenter, Double-blind, Randomised, Placebo Controlled, Parallel Group Clinical Investigation||Bitop AG|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|5 Years|17 Years|No|||October 2011|October 12, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342601||105515|
NCT01335659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bif_3|Main Branch Versus Side Branch Ostial Lesion|Relationship Between Fractional Flow Reserve and Coronary Angiography/Intravascular Ultrasound Parameters in Ostial Lesions: Major Coronary Ostial Lesions Versus Side Branch Ostial Lesions||Seoul National University Hospital|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|77|||Both|21 Years|85 Years|No|Non-Probability Sample|from september 2009 to january 2011 patient who are undergone coronary angiography,IVUS        and FFR for the evaluation of coronary artery disease at SNUH|July 2011|July 20, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01335659||106035|
NCT01327456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1771|The Effects of a Self-management Intervention on Low Literacy Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized Controlled Trial of a Literacy-sensitive Self-management Intervention for Chronic Obstructive Pulmonary Disease Patients||University of North Carolina, Chapel Hill|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||March 2011|March 31, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01327456||106657|
NCT01323127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/AD-03|Preliminary Study of the Sagittal Alignment of the Lumbo-pelvic Complex in a Sitting Position|Preliminary Study of the Sagittal Alignment of the Lumbo-pelvic Complex in a Sitting Position||Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Two populations are compared: one with chronic back pain, and the other a group of        hospitalized patients with no lombo-peliven complications.|March 2015|March 25, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323127||106988|
NCT01327469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/517|The Efficacy of Five Anthelmintic Regimes Against Trichuris Trichiura Infections in Schoolchildren in Jimma, Ethiopia|The Efficacy of 5 Anthelmintic Regimes Against T. Trichiura Infections in Schoolchildren in Jimma, Ethiopia||University Ghent|No|Completed|December 2010|March 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|2250|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||March 2011|March 31, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327469||106656|
NCT01323439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMERICA|Axium™ MicroFX™ for Endovascular Repair of IntraCranial Aneurysm-A Multicenter Study||AMERICA|ev3||Recruiting|March 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|All patients presenting with an intracranial aneurysm will be evaluated by the neuro        interventional team, in accordance with institutional practice, to establish an        appropriate treatment plan based on the patient's medical condition and available        diagnostic screening prior to recruitment|June 2011|March 8, 2012|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323439||106964|
NCT01323725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StPaulKorea|Team-based Financial Incentives for Smoking Cessation|The Effectiveness of Team-based Financial Incentives for Increasing Long-term Smoking Cessation|StPaulKorea|St.Paul's Hospital, Korea|No|Recruiting|January 2011|July 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|N/A|No|||March 2011|March 25, 2011|March 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323725||106942|
NCT01323738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKonstanzMOdenwald2009-1|Effect of Psychoeducation on Motivation to Change in Traumatized Alcoholics|Effect of Psychoeducation on Motivation to Change in Traumatized Alcoholics||University of Konstanz|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|70 Years|No|||March 2011|March 30, 2011|December 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01323738||106941|
NCT01343186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1012IFN|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects|A Single-centre, Randomised, Positive-controlled, Single-dose, Dose-escalation Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ypeginterferon Alfa-2a in Healthy Subjects||Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|January 2011|November 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|January 30, 2012|April 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01343186||105470|
NCT01343212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-055|Stiffness Measurement of Liver Tumors and Visceral Parenchyma|Clinical Applications of Acoustic Radiation Force Impulse Technology in Stiffness Measurement of Liver Tumors and Visceral Parenchyma||China Medical University Hospital|No|Recruiting|March 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|subjects with hepatocellular carcinoma(HCC)|May 2011|May 17, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343212||105469|
NCT01344824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0825|Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers|A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|November 2010|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01344824||105345|
NCT01343667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRS 09-05|GORE Flow Reversal System and GORE Embolic Filter Extension Study|The Gore FREEDOM Study: GORE Flow Reversal System and GORE Embolic Filter Extension Study for the Ongoing Collection of Patient Outcomes|FREEDOM|W.L.Gore & Associates|No|Completed|April 2011|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1397|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 25, 2011|Yes|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT01343667||105434|
NCT01343953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090201|Cord Blood Transplantation in Severe Aplastic Anemia|A Prospective Phase II Study to Evaluate Cord Blood Transplantation in Inherited or Acquired Severe Aplastic Anemia Refractory or in Relapse After Immunosuppressive Therapy|APCORD|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2011|May 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|3 Years|55 Years|No|||December 2015|December 21, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343953||105412|
NCT01344200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/09E|The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children|The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children||Children's Hospital of Eastern Ontario|Yes|Not yet recruiting|April 2016|January 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|2 Years|19 Years|No|||January 2016|January 28, 2016|April 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01344200||105393|
NCT01344499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52808|Clearance Rate of Peritoneal Fluid After Full Conditioning Pneumoperitoneum|Clearance Rate of Peritoneal Fluid Assessed by Post-operative Ultrasound Decreases After Full Conditioning Pneumoperitoneum||University Hospital, Gasthuisberg|No|Completed|August 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 3, 2013|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01344499||105370|
NCT01344798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTG001.06|Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C|Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C||Genethon|Yes|Completed|November 2006|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|15 Years|N/A|No|||April 2011|April 28, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01344798||105347|
NCT01334125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13938|Adjunctive Metformin Therapy in Double Diabetes|Glycemic Control in Children and Adolescents With Double Diabetes: Trial of Optimized Insulin-Metformin Regimen|AMTIDD|University of Massachusetts, Worcester|Yes|Completed|February 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|10 Years|20 Years|No|||March 2016|March 3, 2016|March 21, 2011||No||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01334125||106152|The trial was stopped before reaching enrollment target because most youth were reluctant to commit to this long-term study.
NCT01334359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD055352-01A2|Exercise Effects on Cognition in School-Aged Children|ERPs to Academics: Exercise Effects on Cognition in School-Aged Children|FITKids|University of Illinois at Urbana-Champaign|Yes|Completed|July 2008|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|252|||Both|8 Years|9 Years|Accepts Healthy Volunteers|||July 2014|July 23, 2014|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01334359||106134|
NCT01334853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-CP223|A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma|A Prospective Observational Study to Assess the Role of Selected Biomarkers in Subjects Requiring Daily Medium- to High-dose Inhaled Corticosteroids for Persistent Asthma||MedImmune LLC|No|Completed|January 2011|September 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|97|Samples Without DNA|Blood and Sputum|Both|18 Years|75 Years|No|Non-Probability Sample|Adults with asthma on stable medium- to high-dose inhaled corticosteroids.|October 2012|October 10, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01334853||106096|
NCT01341444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS.2012.Prevena.Cooper.01|The Use of the Prevena Incision Management System (PIMS) on Closed Incisions in Renal Transplant Subjects|The Use of the Prevena Incision Management System on Closed Recipient Site Incisions in Renal Transplant Subjects|PIMS|KCI USA, Inc.|No|Active, not recruiting|August 2013|||July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01341444||105604|
NCT01341457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13574|A Study of LY2603618 in Combination With Gemcitabine in Patients With Solid Tumors|A Phase 1 Dose-Escalation Study of LY2603618 in Combination With Gemcitabine in Japanese Patients With Solid Tumors||Eli Lilly and Company|No|Active, not recruiting|May 2011|June 2016|Anticipated|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|20 Years|N/A|No|||September 2015|September 8, 2015|April 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01341457||105603|
NCT01341470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14270|A Study of LY2495655 in Healthy Subjects|A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2495655 in Japanese Subjects||Eli Lilly and Company|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|44|||Both|24 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|April 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01341470||105602|
NCT01342614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET140|The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension|The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension||China-Japan Friendship Hospital|Yes|Completed|May 2006|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|20 Years|65 Years|No|||November 2005|May 11, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01342614||105514|
NCT01341977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-026|Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution|Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution (MPDS)||Alcon Research|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|573|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 8, 2011|December 9, 2009|Yes|Yes||No|September 8, 2011|https://clinicaltrials.gov/show/NCT01341977||105563|
NCT01341990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-031|Effect of an Investigational Multi-Purpose Solution on Lens Moisture|Effect of SiH MPDS FID 114675A vs. a Marketed Multi-Purpose Solution on Lens Moisture||Alcon Research|No|Completed|November 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|68|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|December 9, 2009|Yes|Yes||No|March 21, 2012|https://clinicaltrials.gov/show/NCT01341990||105562|
NCT01323426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-079 and H-1-2011-032|Treatment of Stress Urinary Incontinence by Injection of Autologous Muscle Fibers Into the Urethral Sphincter.|Autologous Muscle Fiber Transplantation for Repair of the Urethral Sphincter in Patients With Stress Urinary Incontinence||Copenhagen University Hospital at Herlev|No|Active, not recruiting|May 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||January 2013|January 23, 2013|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01323426||106965|
NCT01314768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIMOH|Brief Intervention for Medication Overuse Headache|RCT of Structured Brief Intervention for Medication Overuse Headache Versus Business as Usual|BIMOH|University Hospital, Akershus|No|Completed|March 2011|December 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|123|||Both|18 Years|50 Years|No|||December 2015|December 29, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01314768||107626|
NCT01315015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU DENSE|Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial|Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial||UMC Utrecht|Yes|Enrolling by invitation|November 2011|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|36185|||Female|49 Years|75 Years|No|||September 2014|September 5, 2014|March 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01315015||107608|
NCT01344512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/36|Population Pharmacokinetics of Anti-infectious Drugs in Children|Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (< 12 Years Old)|PHARMA-A|University Hospital, Bordeaux|No|Completed|June 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|214|||Both|N/A|6 Years|No|||March 2015|March 17, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344512||105369|
NCT01343693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-059|MaxAn Post Market Surveillance Validation|A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate|MaxAn|Biomet, Inc.|No|Active, not recruiting|June 2011|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|This post market surveillance study will enroll two hundred (200) subjects across 10        clinical centers within the United States with subjects followed for 24 months        post-surgery. All subjects enrolled in the study will be recruited from the pool of        subjects presenting to each investigational site for an anterior cervical fusion        procedure. The 10 surgeons chosen to participate in this study will be thoroughly        knowledgeable in the medical, surgical and mechanical aspects of the MaxAn® Anterior        Cervical Plate System. The following inclusion and exclusion criteria must be met for a        patient to be considered eligible for participation in this study.|September 2015|February 26, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343693||105432|
NCT01343680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH23736|Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients|A Randomized Controlled Crossover Trial of Two Different Central Venous Catheter Flushing Schemes in Pediatric Hematology and Oncology Patients in Alberta, Canada||Alberta Children's Hospital|No|Terminated|April 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Both|N/A|17 Years|No|||May 2012|May 29, 2012|April 27, 2011||No|Poor patient accrual|No||https://clinicaltrials.gov/show/NCT01343680||105433|
NCT01343966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABE4869g|A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)|A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)||Genentech, Inc.||Completed|April 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|448|||Both|50 Years|80 Years|No|||March 2016|March 1, 2016|April 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01343966||105411|
NCT01340807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8497.01|A Comparison of External Mechanical Work Between Different Prosthetic Feet|A Comparison of External Mechanical Work Between Bionic and Conventional Prosthetic Feet in Transtibial Amputees During Functional Activities|SEW|Miami VA Healthcare System|Yes|Completed|March 2008|January 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2011|April 22, 2011|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01340807||105653|
NCT01340820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-007-422|Study of AERAS 422 in Healthy Adults|A Phase 1, Randomized, Controlled, Double-blind, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of AERAS-422 in Healthy Adults||Aeras|Yes|Completed|December 2010|May 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 15, 2012|February 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01340820||105652|
NCT01341158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5021000|NAM-Trial: Multiferon in Malignant Melanoma|Neoadjuvant Treatment of Locoregional Metastases in Malignant Melanoma (AJCC Stage IIIB/C) With Multiferon: a Phase IIa DeCOG Trial||University Hospital Tuebingen|Yes|Completed|April 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01341158||105626|
NCT01341171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0805|The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins|Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins||University of Vermont|No|Active, not recruiting|August 2009|September 2012|Anticipated|October 2010|Actual|N/A|Observational|N/A||1|Anticipated|60|Samples Without DNA|serum, plasma, platelet activated samples|Female|18 Years|N/A|No|Non-Probability Sample|Women using tamoxifen or aromatase inhibitor therapy for greater than 6 months|April 2011|April 21, 2011|July 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01341171||105625|
NCT01341184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0043|TMC207 +/- Rifabutin/Rifampin|A Phase I Open-Label Trial To Investigate the Pharmacokinetic Interaction Between Rifabutin Or Rifampin And A Single Dose Of TMC207 In Healthy Subjects||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|April 25, 2013|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01341184||105624|
NCT01345071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ErasmusMC-MEC-2011-032|Preconceptional Counselling in Active Rheumatoid Arthritis|Preconception Counselling for Women With a Pregnancy Wish and High Disease Activity of Rheumatoid Arthritis (RA) With a Prospective Observational Study Addressing Health Issues of Mother and Child.|PreCARA|Erasmus Medical Center|No|Recruiting|August 2011|||September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|blood of mother before, during and after pregnancy cordblood of newborn blood of newborn|Female|18 Years|45 Years|No|Non-Probability Sample|Women with high disease activity of RA and a pregnancy wish.|November 2011|November 3, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01345071||105327|
NCT01345084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 118|Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab|A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck|NICAP|Eurofarma Laboratorios S.A.|No|Withdrawn|November 2013|November 2017|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||August 2013|July 24, 2015|April 28, 2011||No|change company strategy|No||https://clinicaltrials.gov/show/NCT01345084||105326|
NCT01345370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOM-Glioblastome|Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients|Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas.|ECOM|Center Eugene Marquis|No|Completed|March 2009|June 2015|Actual|April 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|Samples With DNA|Freezed or/and parffine embedded tumor samples.|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with glioblastoma, eligible to resection and to a treatment according to the        Stupp schedule.|January 2016|January 28, 2016|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01345370||105304|
NCT01345383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/10-05-3898/38|Impact of Current Smoking in the Tolerance of Bronchoscopy|Impact of Current Smoking in the Tolerance of Bronchoscopy||Centre Hospitalier Universitaire Saint Pierre|No|Terminated|June 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Current and regular smokers needing a bronchoscopy as determined by their own physician|March 2015|March 9, 2015|April 28, 2011||No|the physician responsable for this protocol left our hospital|No||https://clinicaltrials.gov/show/NCT01345383||105303|
NCT01345331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008p001019|Ear Electro-stimulation for Chronic Pelvic Pain|Ear Electro-stimulation for Chronic Pelvic Pain|RAVANS|Brigham and Women's Hospital|No|Completed|May 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|18|||Female|21 Years|64 Years|No|||April 2011|April 28, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01345331||105307|
NCT01345344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p001021|Neuroimaging Effects of Cognitive Behavioral Therapy in Fibromyalgia|Neuroimaging Effects of Cognitive Behavioral Therapy in Fibromyalgia||Brigham and Women's Hospital|Yes|Recruiting|May 2014|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|3||Anticipated|200|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01345344||105306|
NCT01345357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C9722/1092|Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma|A Dose-Escalation Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP 1 and PARP 2 Inhibitor) in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma||Teva Pharmaceutical Industries|Yes|Completed|May 2011|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|April 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01345357||105305|
NCT01341106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 11-018|Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection|Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection|INFIRE|RWTH Aachen University|No|Terminated|April 2011|April 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Both|18 Years|75 Years|No|||September 2015|September 22, 2015|April 20, 2011||No|insufficient patient numbers have been recruited|No||https://clinicaltrials.gov/show/NCT01341106||105630|
NCT01341119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-11-047|Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma|Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma||Samsung Medical Center||Completed|November 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|N/A||Non-Probability Sample|tertiary hospital|August 2012|August 6, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341119||105629|
NCT01341132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03278|Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents|Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents||San Francisco Veterans Administration Medical Center|No|Enrolling by invitation|May 2011|||June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|75 patients of the San Francisco VA Medical Center with suspected HCC identified on        contrast-enhanced multi-detector CT, or on ultrasound and referred to contrast-enhanced        multi-detector CT.|April 2011|April 21, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341132||105628|
NCT01342003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b|HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b|genotype|Azienda Ospedaliera San Camillo Forlanini|No|Completed|February 2007|October 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|388|Samples With DNA|HCVRNA determination was performed quantitatively before the treatment (TaqMan Roche      Diagnostics). The TaqMan value utilized to determine the response was 15 IU/ml. TaqMan      method was a standardized method utilized from December 2007 in all the center of the CLEO      group. HCVRNA value was expressed as log10 IU/ml.|Both|18 Years|75 Years|No|Probability Sample|Three hundred and eighty-eight patients were included in the study. One hundred and        sixty-five were HCV genotype 1 subtype 1a (42.5%) while two hundred twenty-three were of        subtype 1b (57.5%).|October 2010|April 25, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01342003||105561|
NCT01342861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAPEN|INAPEN Protocol for Impact of Breakfast Improvement|INAPEN Protocol for Impact of Breakfast Improvement on the Nutritional Status of Hospitalized Patients (INcidence de l'Amélioration du Petit-déjeuner Sur l'Etat Nutritinonel Des Patients hospitalisés)|INAPEN|Centre Hospitalier de Meaux|Yes|Recruiting|October 2009|||June 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|800|||Both|18 Years|N/A|No|||April 2011|April 26, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01342861||105495|
NCT01342874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOS001|Improved Outcomes Associated With Inositol Dietary Supplementation in Women With Gestational Diabetes Mellitus|Improved Maternal and Fetal Outcomes Associated With Inositol Dietary Supplementation in Women With Early Gestational Diabetes Mellitus|inositol|G. d'Annunzio University|Yes|Completed|August 2010|August 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Female|18 Years|45 Years|No|Probability Sample|pregnant women presenting random fasting glucose during the first half of pregnancy above        92 mg%|April 2011|February 8, 2012|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01342874||105494|
NCT01314495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1530|Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis|A Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis||Columbia University|Yes|Withdrawn|September 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||November 2012|November 12, 2012|March 11, 2011|No|Yes|Halt in funding|No||https://clinicaltrials.gov/show/NCT01314495||107647|
NCT01315314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEDI MCS|Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction|Effects of Neutral pH and Low Glucose Degradation Product-containing Peritoneal Dialysis Fluid on Systemic Markers of Inflammation and Endothelial Dysfunction: a Randomized, Controlled 1-year Follow-up Study||Kyungpook National University|No|Completed|October 2005|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|75 Years|No|||April 2007|March 16, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315314||107585|
NCT01315587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23456|Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia|A Double-blind Placebo Controlled Trial the Comparison of Effectiveness of Repetitive TMS and iTBS on Negative Symptoms and Cognition in Patients With Schizophrenia||University of Tehran|Yes|Recruiting|January 2011|January 2017|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|50 Years|No|||August 2015|August 30, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315587||107564|
NCT01343719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1296.1|Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to a) Assess Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of 2 mg to 350 mg of BI 661051 Administered as Oral Drinking Solution (Powder in Bottle) in Healthy Male Volunteers, b) to Explore the Relative Oral Bioavailability of a Tablet Formulation and c) to Assess the Impact of a High Fat Meal on the Oral Bioavailability of the Oral Drinking Solution (Powder in Bottle)||Boehringer Ingelheim||Completed|April 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|11||Actual|64|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|April 19, 2011||||No||https://clinicaltrials.gov/show/NCT01343719||105430|
NCT01343732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD-DTMS-1|Tolerability, Safety and Efficacy of the HAC-Coil Deep Transcranial Magnetic Stimulation in Medication Resistance Obsessive Compulsive Disorder (OCD) Subjects|||Brainsway||Recruiting|June 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|40|||Both|18 Years|65 Years|No|||April 2011|January 26, 2015|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01343732||105429|
NCT01343745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FB/PS/14/169/07|Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)|Dose Response Evaluation of CHF 1535 HFA pMDI in Asthmatic Patients Using Lung Function, Adenosine Monophosphate Bronchial Challenge and Fractional Exhaled Nitric Oxide (FENO)||Chiesi Farmaceutici S.p.A.|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|50 Years|No|||March 2015|March 18, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01343745||105428|
NCT01343706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.1|Safety Tolerability and Pharmacokinetic of BI 409306|A Randomized, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses 0.5 mg to 500 mg of BI 409306 Administered Orally in Healthy Male Volunteers||Boehringer Ingelheim||Completed|April 2011|||August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|8||Actual|80|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|April 6, 2011||||No||https://clinicaltrials.gov/show/NCT01343706||105431|
NCT01345110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|A Longitudinal Multidimensional Population Study on Brain Aging|A Longitudinal Population Study on Brain Aging and Mental Performances for the 1935-1939 Born People Living in Abbiategrasso (a Small Town Near Milan)|InveCeAb|Fondazione Golgi Cenci|Yes|Completed|November 2009|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1321|Samples With DNA|whole blood and serum|Both|70 Years|75 Years|No|Non-Probability Sample|All the 1773 residents of Abbiategrasso, a town of 30.000 inhabitants near Milan,        Lombardy, Italy, born from 1935 to 1939 : 1724 subjects meets the inclusion criteria|December 2015|December 10, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01345110||105324|
NCT01345123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDMBKH-HD012011|Supporting Decision Making for Musculoskeletal Preference-Sensitive Care|A Prospective, Randomized Trial to Assess the Impact of Decision Aids and Health Coaching on Health Care Costs, Surgery Rates, and Decision Quality for Individuals At Risk for Musculoskeletal Preference-Sensitive Surgical Decisions||Health Dialog|No|Completed|January 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|9925|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 26, 2013|April 28, 2011||No||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01345123||105323|
NCT01344239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRIP701126|Limb Remote Ischemic Preconditioning Reduces Heart and Lung Injury After Abdominal Aortic Aneurysm Repair|Limb Remote Ischemic Preconditioning Reduces Heart and Lung Injury After Abdominal Aortic Aneurysm Repair:A Randomized Controlled Trial||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|January 2008|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|62|||Both|20 Years|80 Years|No|||May 2013|May 11, 2013|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01344239||105390|
NCT01344525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGIT-FKZ01GI0843|Pilot Project on Interdisciplinary Therapy of Obesity|Pilot Project on Interdisciplinary Therapy of Obesity and Its Consequences on Body Weight, Quality of Life and Gastrointestinal Parameters||University of Hohenheim||Active, not recruiting|May 2009|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|480|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344525||105368|
NCT01344837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8023|Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer|The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma||Gynecologic Oncology Group||Not yet recruiting|January 2100|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|360|||Female|N/A|N/A|No|Non-Probability Sample|Patients with uterine cancer|May 2015|May 27, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344837||105344|
NCT01344811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmartCare-OB|Effects of Telemonitoring Service for Obesity Care|A Randomized, Open, Parallel, Multi-center Trial to Evaluate Weight Loss Efficacy of Smart Care Service in Obese Patients With Metabolic Syndrome.|Smart-OB|LG Electronics Inc.|Yes|Completed|January 2011|June 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|661|||Both|20 Years|70 Years|No|||May 2015|May 12, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344811||105346|
NCT01345097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THRProxima|A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients|A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients||Ewha Womans University|No|Completed|May 2004|March 2011|Actual|March 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|20 Years|95 Years|No|||March 2011|April 28, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01345097||105325|
NCT01341145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-0106|Physical Fitness, Cardiovascular and Brain Health|Physical Fitness, Cardiovascular and Brain Health||University of Texas at Austin|No|Completed|March 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 10, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01341145||105627|
NCT01341756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B/09/134|Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial|Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial||National University Hospital, Singapore|Yes|Recruiting|July 2009|July 2012|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|21 Years|N/A|No|||April 2011|May 6, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01341756||105580|
NCT01342016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0911|A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients|A Randomized, Double-blind Double Dummy, Parallel Control and Multi-center Clinical Trial to Compare the Efficacy and Safety of Tacrolimus Capsules in Treatment of Lupus Nephritis With Leflunomide Tablets||Astellas Pharma Inc|No|Terminated|April 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|65 Years|No|||October 2014|October 15, 2014|April 25, 2011|No|Yes|Due to safety concern of active control drug|No||https://clinicaltrials.gov/show/NCT01342016||105560|
NCT01341782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-517|Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism|Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism||AbbVie|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|255|||Both|20 Years|N/A|No|||April 2013|April 17, 2013|April 25, 2011||No||No|April 17, 2013|https://clinicaltrials.gov/show/NCT01341782||105578|
NCT01342328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03906|Providing "Good Sleep" for ICU Sedation|Providing "Good Sleep" for ICU Sedation|ASRV|University of California, San Francisco|Yes|Active, not recruiting|May 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01342328||105536|
NCT01342341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chlorzoxazone|Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake|Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake||University of California, San Francisco|Yes|Completed|April 2011|December 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|April 19, 2011|Yes|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01342341||105535|
NCT01327196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO39/SA04/10|Cognitive Impairment and Cardiovascular Risk in Older|Detection of Mild Cognitive Impairment in People Older Than 65 Years of Age and Its Relationship to Cardiovascular Risk Factors (DECRIVAM)|DECRIVAM|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|No|Completed|June 2010|December 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|327|||Both|65 Years|N/A|No|Probability Sample|It will depart from a reference population of 420 people older than 65 years living in the        municipality of Salamanca|September 2014|September 4, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01327196||106677|
NCT01315028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN09CP546|Bipolar Intervention Study: Cognitive Interpersonal Therapy|A Pilot Randomised Controlled Trial of Cognitive Behaviour Therapy for Early Bipolar Disorder|BISCIT|NHS Greater Glasgow and Clyde|Yes|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|16 Years|N/A|No|||April 2014|July 29, 2014|March 7, 2011||No||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01315028||107607|A definitive clinical trial should incorporate an appropriate sample size, incorporate more than one therapist, assess fidelity and competence in therapy delivery and also include measurements of health economic dimensions of outcome.
NCT01315327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSA Omega-3|Omega-3 Fatty Acids in Tourette's Disorder|A Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acids in Children and Adolescents With Tourette's Disorder||New York University School of Medicine|Yes|Completed|May 2003|May 2012|Actual|February 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|6 Years|18 Years|No|||June 2014|June 30, 2014|March 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01315327||107584|
NCT01344265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zh_zhang1984|The Correlation Between B-type Natriuretic Peptide (BNP) and Global End Diastolic Volume|The Correlation Between BNP and Global End Diastolic Volume||Jinhua Central Hospital||Completed|June 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|80 Years|No|Probability Sample|critically ill patients who required hemodynamic monitoring using PiCCO|September 2012|April 1, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344265||105388|
NCT01344278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS019367-01|Diabetes Prevention Strategies in Women With Gestational Diabetes Mellitus (GDM)|Comparative Effectiveness of Diabetes Prevention Strategies in Women With GDM||Kaiser Permanente|Yes|Active, not recruiting|April 2011|December 2015|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|2480|||Female|18 Years|N/A|No|||August 2015|August 3, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344278||105387|
NCT01344005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000699222|Standard Medical Care or Urgent Chest X-ray in Diagnosing Lung Cancer in Smokers With Chest Symptoms Who Are Older Than 60 Years|A Pilot Clinical Trial Looking at the Effect on Lung Cancer Diagnosis of Giving a CXR to Smokers Aged Over 60 With Chest Symptoms||National Cancer Institute (NCI)||Not yet recruiting|June 2011|||June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Diagnostic|||Anticipated|386|||Both|60 Years|N/A|No|||April 2011|August 23, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344005||105408|
NCT01343992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0912-C-065-SA|Bed Rest or no Bed Rest?|Evaluation of the Influence of Bed Rest After Embryo Transfer in Outcome of IVF Treatment With Ovum Donation.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|May 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|240|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343992||105409|
NCT01344551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UReading-2011-02|Effects of Cocoa Flavanols on Human Cognitive Function|||University of Reading|Yes|Completed|February 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|63|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344551||105366|
NCT01314625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS 2009-50|A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients|A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma||University of Arkansas|No|Recruiting|March 2011|August 2012|Anticipated|June 2012|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|No|Probability Sample|To determine whether the orthostatic hypotension reported among subjects during        bortezomib-containing regimen is caused by a dysfunction of the autonomic nervous system        (ANS).|May 2012|May 15, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01314625||107637|
NCT01315444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT 101|Gastric Acid Rebound Secretion Measured by Alkaline Tide|Gradual Cessation of Proton Pump Inhibitor (PPI) Treatment May Prevent Rebound Acid Secretion in Dyspeptic and Reflux Patients, Measured by the Alkaline Tide Method.||Rabin Medical Center|No|Not yet recruiting|December 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|80 Years|No|||April 2014|April 28, 2014|March 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01315444||107575|
NCT01315457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-03-006|Infections Associated With the Use of Alemtuzumab|Asian Multinational Retrospective Analysis for Infectious Complications in Patients Treated With Alemtuzumab||Samsung Medical Center|No|Completed|April 2009|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|182|||Both|15 Years|90 Years|No|Probability Sample|Patients received alemtuzumab as a treatment for hematologic malignancy|May 2012|May 22, 2012|March 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01315457||107574|
NCT01316068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sulodexide20110311|Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients|Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients|Soften|Sun Yat-sen University|Yes|Enrolling by invitation|March 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||August 2010|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316068||107528|
NCT01316081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aox_obesity_SM|A 4-month Intervention of Antioxidant Supplementation in Overweight Children|A 4-month, Randomized, Placebo-controlled, Double-blind Intervention of Antioxidant Supplementation in Overweight Children Enrolled in an Outpatient Weight-loss Program: Effects on Oxidative and Inflammatory Markers, Hepcidin, Iron Status, and Components of the Metabolic Syndrome||Swiss Federal Institute of Technology|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|45|||Both|10 Years|18 Years|No|||June 2012|June 18, 2012|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316081||107527|
NCT01316003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KyorinEye004|Distinction of Cone Outer Segment Tips by Spectral-Domain Optical Coherence Tomography in Normal Eyes|Distinction of Cone Outer Segment Tips by Spectral-Domain Optical Coherence Tomography in Normal Eyes||Kyorin University|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|37|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Thirty-seven eyes of 37 individuals without eye diseases|July 2012|July 31, 2012|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316003||107533|
NCT01316016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUAFC002|Antidiabetic Properties of Rose Hip|Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons||Lund University|No|Completed|April 2009|January 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||February 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316016||107532|
NCT01316315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N6022-2A1-02|Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma|A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma||Nivalis Therapeutics, Inc.|No|Completed|March 2011|December 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|60 Years|No|||April 2014|April 17, 2014|March 7, 2011|No|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01316315||107509|
NCT01366599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115777|CV Events in Emetogenic Chemotherapy|Cardiovascular Events in Cancer Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy||GlaxoSmithKline|No|Completed|May 2009|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|12058|||Both|N/A|N/A|No|Non-Probability Sample|IHCIS, 2005-2007. The Impact National Managed Care Benchmark Database™ (formally known as        Integrated Healthcare Information Services - IHCIS - prior to its purchase by Ingenix, Inc        and referred to as IHCIS within GSK) is a comprehensive, de-identified U.S. healthcare        claims database that is representative of the non-elderly, insurance-carrying population        in the U.S. The database contains inpatient/outpatient and pharmacy claims, lab results        and enrollment information on over 82 million lives from 1997 to 2007. Over 75 percent of        all patients in the database have both medical and pharmacy benefits and, on average, 23.4        months of enrollment/claims information; the annual attrition rate is roughly 15-25        percent. The data are collected from over 45 different healthcare plans serving members        across nine census regions. The database is HIPAA compliant and features encrypted member        and provider IDs.|June 2011|June 2, 2011|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366599||103682|
NCT01366911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168-11-FB|Stem Cells Predicting Orthopedic Outcomes|Can Stem Cells Predict Orthopaedic Outcomes? The Correlation of Bone Density Findings Post Total Hip Arthoplasty With Stem Cell Assays Obtaned at Time of Surgery||University of Nebraska|No|Enrolling by invitation|April 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Orthopaedic surgical patients at specific clinic|June 2011|June 3, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01366911||103659|
NCT01366625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA-Denerv1|Renal Denervation in Patients With Resistant Hypertension and Obstructive Sleep Apnea|Effects of Renal Denervation on Blood Pressure and Clinical Course of Obstructive Sleep Apnea in Patients With Resistant Hypertension||Institute of Cardiology, Warsaw, Poland|No|Active, not recruiting|July 2011|December 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2014|November 27, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366625||103680|
NCT01357499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-reinthaler|Lower Leg Remote Ischemic Preconditioning in Elective Percutaneous Coronary Intervention (PCI)|Effects of Lower Leg Remote Ischemic Preconditioning in Combination With Electric Muscle Stimulation in Elective Coronary Artery Revascularisation|REMOTE|University Medicine Greifswald|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|venous blood samples (10 ml) will be taken from the femoral vein of the preconditioned leg      immediately before and after the preconditioning cycles.      Also arterial blood samples (10 ml)will be taken immediately before and after the      preconditioning cycle.|Both|18 Years|N/A|No|Probability Sample|Patients undergoing elective PCI fulfilling the inclusion and exclusion criteria.|June 2014|June 29, 2014|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01357499||104377|
NCT01354236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFR-CESP-20100403|Mental Health Related to School Dropout in Luxembourg|Psychosocial Risk- and Protective Factors of Secondary School Dropout in Luxembourg: an Exploratory Case-control Study||Public Research Centre Health, Luxembourg|Yes|Enrolling by invitation|January 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|16 Years|25 Years|No|Non-Probability Sample|Cases: The ministry for education retrieves a monthly record of students classified as        "school dropouts", who will be individually invited to participate in the study.        Controls: Normally enrolled students who are matched for age, gender, school and        educational grade. Their recruitment will be subsequent to the participation of cases.|May 2011|May 13, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01354236||104626|
NCT01315886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OX20-005|Conversion From Fast Acting Oral Opioids to Abstral®|Conversion From Fast Acting Oral Opioids to Abstral® (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain||Orexo AB|No|Suspended|February 2011|||December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|March 14, 2011||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01315886||107542|
NCT01315899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3098009|Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon|Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis|REINO|Orion Corporation, Orion Pharma|Yes|Terminated|March 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|15|||Both|18 Years|75 Years|No|||June 2014|June 26, 2014|March 14, 2011||No|Recommendation by study DSMC to the sponsor following interim analysis of 8 subjects.|No||https://clinicaltrials.gov/show/NCT01315899||107541|
NCT01315912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bpums|Dosage Optimization for Letrozole Treatment|Dosage Optimization for Letrozole Treatment in Clomiphene Resistant Patients With Polycystic Ovary Syndrome: A Prospective Interventional Study||Bushehr University of Medical Science|Yes|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||January 2008|March 25, 2011|March 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315912||107540|
NCT01315925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|751/2009|Pre-hospital Risk Factors for Invasive Fungal Infection|SEIFEM 2010: Epidemiological Survey on Possible Pre-Hospital Risk Factors for Developing Invasive Fungal Infections in Patients Affected by Acute Myeloid Leukemia|SEIFEM 2010|Catholic University of the Sacred Heart||Recruiting|January 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible        and not eligible for intensive chemotherapy.|March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01315925||107539|
NCT01316861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSAGL0110|Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus|A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus||EMS|Yes|Completed|September 2012|May 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316861||107468|
NCT01316874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9301/A9302|Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)|Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)|Bladder Cancer|Endo Pharmaceuticals|No|Completed|November 1993|April 1997|Actual|April 1997|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|March 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316874||107467|
NCT01317758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0017|H5N1 Mix and Match With AS03|A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered at Different Dose Levels Given With and Without AS03 Adjuvant||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|245|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|March 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01317758||107400|
NCT01317771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-5202|Analysis of the Fixation of the Proximal Biceps Tendon|Analysis of the Fixation of the Proximal Long Head of the Biceps Tendon||West Penn Allegheny Health System||Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10|||Both|18 Years|65 Years|No|Probability Sample|This research study will collect the MRI and questionnaire data from 10 subjects that have        undergone a subpectoral proximal biceps tendon tenodesis using the EndoButton.|March 2011|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317771||107399|
NCT01317433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-450|Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer|Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI.|SKINUX|ICO Paul Papin|Yes|Recruiting|December 2010|November 2015|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||February 2012|February 28, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317433||107425|
NCT01317719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC-5159|Prospective Biceps Study|Prospective Biceps Study||West Penn Allegheny Health System||Enrolling by invitation||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|80 Years|No|Non-Probability Sample|Patients who have received primary distal biceps repair by Dr. Schmidt|January 2011|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317719||107403|
NCT01318252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-080|AL-54478 Proof of Concept Study|||Alcon Research|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|March 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318252||107362|
NCT01314053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99084|Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections|Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections||Taipei Medical University WanFang Hospital|No|Active, not recruiting|February 2011|April 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|60|||Both|20 Years|N/A|No|Non-Probability Sample|Hospitalized patients who are prescribed daptomycin as part of required medical care for        gram positive infections as deemed necessary by his/her treating physician.|March 2011|March 10, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01314053||107680|
NCT01315158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1133|Propofol vs Propofol + Benzo/Opiates in High Risk Group|Incidence of Sedation Related Complications With Propofol Alone Versus Propofol With Benzodiazepines and Opiates in a High Risk Group Undergoing Advanced Endoscopic Procedures: A Randomized Controlled Trial||Washington University School of Medicine|Yes|Terminated|January 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|March 11, 2011|Yes|Yes|- The research team is not able to obtain the necessary support to continue the study.|No||https://clinicaltrials.gov/show/NCT01315158||107597|
NCT01315470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSF-HMO-CTIL|Use of Granulocyte Colony-stimulating Factor for the Treatment of Recurrent Implantation Failure in IVF Patients|Phase 1 Study of the Use of Granulocyte Colony-stimulating Factor for the Treatment of Repeated Implantation Failure in IVF Patients||Hadassah Medical Organization|No|Not yet recruiting|June 2011|March 2013|Anticipated|January 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||March 2011|March 23, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315470||107573|
NCT01315756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renewing Health Norway|Self-management in Type 2 Diabetes Patients Using the Few Touch Application|The Norwegian Study in Renewing Health: Stimulating Self-management in Patients With Type 2 Diabetes Mellitus Through Telecare With the Few Touch Application and Health Counseling - a Randomized Controlled Trial||University Hospital of North Norway|No|Completed|March 2011|October 2013|Actual|October 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|151|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315756||107552|
NCT01316367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCIII-0106|Effectiveness of PRECEDE Model for Health Education on Changes and Level of Control in Patients With Type 2 Diabetes Mellitus|Effectiveness of PRECEDE Model for Health Education on Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus||Hospital Carlos III, Madrid|No|Completed|February 2003|March 2005|Actual|February 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|600|||Both|31 Years|N/A|No|||March 2003|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316367||107505|
NCT01316328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFO-84/10|Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery|Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery|HYPOPRONE|Regina Elena Cancer Institute||Completed|May 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Female|48 Years|90 Years|No|Non-Probability Sample|breast cancer (BC) patients following single shot partial breast irradiation(SSPBI) after        breast conservative surgery|December 2010|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316328||107508|
NCT01316341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.44|Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus|Pharmacokinetics and Pharmacodynamics of BI 10773 After Single and Multiple Oral Dose of 10 mg and 25 mg BI 10773 in Chinese Male and Female Type 2 Diabetic Patients||Boehringer Ingelheim||Completed|March 2011|||January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|24|||Both|21 Years|70 Years|No|||May 2014|May 16, 2014|March 15, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01316341||107507|
NCT01316614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105404|EUS-guided Fine Needle Aspiration (FNA) With and Without the Use of a Stylet|Randomized Controlled Trial of Endoscopic Ultrasound Guided Fine Needle Aspiration of Solid Lesions With and Without a Stylet||Washington University School of Medicine|Yes|Completed|July 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|137|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|March 14, 2011|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01316614||107486|
NCT01316627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#G06-05-061-04|Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions|Crooked Mirror Externalization Therapy for Body Dysmorphic Disorder|BDD|Westwood Institute for Anxiety Disorders, Inc|Yes|Recruiting|April 2007|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2011|March 14, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01316627||107485|
NCT01366612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO#1278: Flu-Bu-TBI|PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation|PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant|FLUBUTBI|Hackensack University Medical Center|Yes|Recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|70 Years|No|||August 2015|August 21, 2015|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366612||103681|
NCT01356342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU10T11B|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old|||Adimmune Corporation||Completed|July 2010|May 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|181|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||December 2012|December 27, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356342||104466|
NCT01356355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE/HMP-02|Study of Herbmed Plus in Ureteral Stent Discomfort|Double Blind Exploratory Three Arm Randomized Trial to Evaluate the Safety and Efficacy of Herbal Preparation 'Herbmed Plus' in Ureteral Stent Discomfort||Amai Charitable Trust|No|Completed|April 2012|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|140|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356355||104465|
NCT01355133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myoblast/ISD/EKS01|Safety and Efficacy Study of Intrasphincteric Autologous Myoblast Injection to Treat Stress Urinary Incontinence|Transurethral Ultrasound-directed Injection of Autologous Myoblasts in Combination With Functional Electrical Stimulation in Patients With Intrinsic Urinary Sphincter Deficiency||University Medical Centre Ljubljana|No|Completed|August 2009|February 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|18 Years|75 Years|No|||May 2011|May 16, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01355133||104557|
NCT01355458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18140|Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea||Galderma|No|Completed|May 2011|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|May 16, 2011|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01355458||104533|
NCT01354561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP10|Respiratory Physical Therapy on the Cardiac Autonomic Modulation Paediatric Patients|Effect of Airway Clearance Therapy on the Cardiac Autonomic Modulation in Hospitalized Paediatric Patients||University of Sao Paulo|Yes|Completed|February 2007|May 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|2 Months|11 Months|No|||May 2011|May 13, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01354561||104601|
NCT01354834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-MEN-2003-01|Assessment of the Effectiveness of Menopur in Intrauterine Insemination|Assessment of the Clinical Efficacy of Menopur® in Intrauterine Artificial Insemination (From Partner or From Donor)||Ferring Pharmaceuticals|No|Completed|March 2004|April 2006|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|207|||Female|N/A|N/A|No|Non-Probability Sample|Females affected by infertility able to undergo intrauterine insemination|May 2011|May 16, 2011|May 16, 2011||||No||https://clinicaltrials.gov/show/NCT01354834||104580|
NCT01315665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHCMC-CFRC-2011-01|Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation|Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects||University Hospital Case Medical Center|No|Completed|April 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315665||107559|
NCT01316536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H9025-35126-01|Music Therapy is Associated With Decreased Pain and Agitation in Intubated ICU Patients|Music Therapy is Associated With Decreased Pain and Agitation in Intubated ICU Patients||University of California, San Francisco|No|Terminated|April 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|5|||Both|18 Years|70 Years|No|||April 2015|April 16, 2015|March 14, 2011||No|inability to recruit participants despite numerous attempts|No||https://clinicaltrials.gov/show/NCT01316536||107492|
NCT01316848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-10-115|A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects|A Phase 1, Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects||AVEO Pharmaceuticals, Inc.|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|March 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316848||107469|
NCT01317147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07120162|The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors|The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors||University of Pittsburgh|No|Completed|August 2007|August 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|70 Years|No|Non-Probability Sample|Bariatric surgery clinic- Morbidly obese patients seeking RYGB who met criteria for        bariatric surgery (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with severe obesity-related comorbidities)        and were received maintenance treatment with an SRI for primary mood or anxiety disorder.|March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317147||107447|
NCT01318005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-00455|Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation|The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?|OCP2|University of Southern California|No|Recruiting|January 2011|December 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|85|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|March 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318005||107381|
NCT01314638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01148-49|Study of Adherence and Effects of Balance Exercices (SIEL BLEU Associatio)|Etude de l'adhérence et Des Effets Des Ateliers "équilibre Siel Bleu" Sur la Marche, la Cognition, l'Autonomie et l'indépendance Des Sujets Atteints d'Une Maladie d'Alzheimer, et Sur le Fardeau de l'Aidant Principal|SIELBLEU|University Hospital, Angers|Yes|Recruiting|May 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients of Angers University Memory Center, with respect to the eligibility criteria|March 2011|March 11, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314638||107636|
NCT01314313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-12|The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves|The PARTNER II Trial "Placement of AoRTic TraNscathetER" Valves Trial" (US) [Edwards Study 2010-12]|PARTNER II|Edwards Lifesciences|Yes|Active, not recruiting|March 2011|September 2020|Anticipated|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|5650|||Both|N/A|N/A|No|||February 2016|February 1, 2016|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01314313||107660|
NCT01315483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA125243|Diet Composition, Weight Control, and Breast Carcinogenesis|Diet Composition, Weight Control, and Breast Carcinogenesis|CHOICE|Colorado State University|No|Completed|September 2008|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|259|||Female|21 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315483||107572|
NCT01315496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCIV_P3|GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock|A Placebo-controlled, Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Administration of 'IV-Globulin S Inj.' in Adult Subjects With Community-Acquired Severe Sepsis or Septic Shock||Green Cross Corporation|No|Terminated|October 2009|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|214|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315496||107571|
NCT01315509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMIDENTIST-HMO-CTIL|Dental Status of Patients With Severe Mental Illness||SMI-DENTAL|Hadassah Medical Organization||Completed|April 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|80 Years|No|Non-Probability Sample|THE SEVERE MENTAL ILL IN THE PSYCHIATRIC POPULATION OF THE HADASSAH MEDICAL ORGINIZATION        -PSYCHIATRIC OUTPATIENT CLINIC|March 2011|March 21, 2013|March 14, 2011||||No||https://clinicaltrials.gov/show/NCT01315509||107570|
NCT01315769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-51|Pelvic Floor Muscle Function in Nulliparous and Primiparous.|COMPARATIVE STUDY OF PELVIC FLOOR MUSCLE EVALUATION IN NULIPAROUS AND PRIMIPAROUS WOMEN. A Prospective Study||UPECLIN HC FM Botucatu Unesp|No|Completed|March 2006|September 2006|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Female|20 Years|30 Years|No|Probability Sample|The sample size was established considering a significance level of 5%, the test power of        80%, and the estimated error of 10%. According to these results and considering the range        between percentages of answers as the casual error, each group was established with        approximately 50 participants.|March 2011|March 14, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315769||107551|
NCT01315795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024604-10|Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease|An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders|LOCKCYST|Universitaire Ziekenhuizen Leuven|No|Completed|March 2011|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315795||107549|
NCT01316354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-BioFunCarb|Effect of Dietary Fibre and Whole Grain on the Metabolic Syndrome|Effect of Arabinoxylan and Beta-glucan Compared With Whole Grain and Whole Meal Bread in Subjects With the Metabolic Syndrome||Aarhus University Hospital|Yes|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316354||107506|
NCT01316653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100591|Growing Right Onto Wellness (GROW): Changing Early Childhood Body Mass Index (BMI) Trajectories|Growing Right Onto Wellness (GROW): Changing Early Childhood Body Mass Index (BMI) Trajectories|GROW|Vanderbilt University|Yes|Active, not recruiting|June 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|610|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01316653||107484|
NCT01366326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1109|Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects|A Multiple-Dose, Open-Label Study to Evaluate the Pharmacokinetics of MNTX in Healthy Adult Subjects||Valeant Pharmaceuticals International, Inc.|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366326||103703|
NCT01366339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1201|Tolerance and Pharmacokinetics Study of MNTX Tablets|A Replicate Design, Double-Blind, Randomized, Placebo-Controlled Tolerance and Pharmacokinetics Study of N-Methylnaltrexone Tablets in Normal, Healthy Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|October 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366339||103702|
NCT01357200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.02.US.CLI|Feeding Trial in the Obese Critical Care Population|Enteral Formula Tolerance in the Obese Critical Care Population||Nestlé|No|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|serum|Both|18 Years|N/A|No|Probability Sample|critically ill obese adults|January 2014|January 29, 2014|May 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01357200||104400|
NCT01357213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0091|Phase 1 PK Study of XOMA 3AB|A Phase I, Blinded, Placebo-controlled, Dose-escalation Study of the Safety and Pharmacokinetics of XOMA 3AB Administered Intravenously in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2011|May 2013|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|December 4, 2014|May 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357213||104399|
NCT01358513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RING OF FIRE|Role of Active Valvular Calcification and Inflammation in Patients With Aortic Stenosis|An Observational PET/CT Study Examining the Role of Active Valvular Calcification and Inflammation in Patients With Aortic Stenosis||University of Edinburgh|Yes|Active, not recruiting|July 2010|July 2015|Anticipated|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|168|Samples With DNA|In patients undergoing aortic valve replacement during the course of the trial we will      retain samples of their aortic valve for histological studies.|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The investigators will recruit 168 patients: 24 control patients, 24 mild, 48 moderate and        48 severe aortic stenosis|January 2015|January 9, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358513||104299|
NCT01366638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017935|A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection|A Phase III, Open-Label Study in Japan to Assess the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2b and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects||Janssen Pharmaceutical K.K.|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|79|||Both|20 Years|70 Years|No|||April 2014|April 10, 2014|June 2, 2011|Yes|Yes||No|October 17, 2013|https://clinicaltrials.gov/show/NCT01366638||103679|All outcome measures reported in this study are "Exploratory;" not "Primary" as indicated. "Primary" was chosen for each outcome measure because "Exploratory" is not available as an outcome measure type on this form.
NCT01316250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.AB.17|Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia|Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia||American University of Beirut Medical Center|Yes|Recruiting|August 2010|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|75 Years|No|||January 2015|January 14, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01316250||107514|
NCT01316549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0037192|Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation|Population Pharmacokinetics of Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation|HCT|University of California, San Francisco|No|Recruiting|September 2010|||June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|whole blood, DNA|Both|N/A|17 Years|No|Non-Probability Sample|The target population for the proposed study includes children 0-17 years of age        undergoing alloHCT for the treatment of malignant and nonmalignant disorders.        Patients receiving fludarabine over 3 to 5 days are eligible to participate.        All patients enrolled in this study will undergo PK sampling on the inpatient pediatric        BMT unit at UCSF Benioff Children's Hospital. The proposed research will not study any        patients receiving fludarabine in a clinic or any other out-patient setting.|December 2014|December 16, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316549||107491|
NCT01317459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1325|Guided Self-determination - Promoting Self-management in Type 1 Diabetes|Using Guided Self-determination (GSD) to Promote Improved Self-management in Adults With Type 1 Diabetes - an Intervention Study.|GSD|Haukeland University Hospital|No|Active, not recruiting|March 2011|December 2021|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|216|||Both|18 Years|55 Years|No|||September 2015|September 9, 2015|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01317459||107423|
NCT01314066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol #0907010498|Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)|Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)|VEGF-ARDS|Weill Medical College of Cornell University|Yes|Withdrawn|July 2010|February 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|75|||Both|18 Years|N/A|No|||March 2011|March 10, 2011|July 28, 2010|Yes|Yes|No funding|No||https://clinicaltrials.gov/show/NCT01314066||107679|
NCT01314079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTG-ASC-203|Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula|Follow-up Study to Evaluate the Sustained Efficacy and Safety for the Patients With Adipoplus Injected in Phase II Clinical Trials(ANTG-ASC-202)|ANTG-ASC-203|Anterogen Co., Ltd.|No|Active, not recruiting|April 2010|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|The patients who have participated in phase II clinical trial (ANTG-ASC-202) and injected        with Adipoplus at least once.|March 2012|March 14, 2012|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01314079||107678|
NCT01314352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50486|Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|December 2005|March 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 7, 2011|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01314352||107657|
NCT01318018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTB|Investigation on the Value of Bilateral Index (BIS) Monitoring for Magnetic Seizure Versus Electroconvulsive Therapy|||University Hospital, Bonn|No|Completed|February 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients suffering from depression|April 2012|April 15, 2012|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318018||107380|
NCT01318031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471021|Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects|Phase 1 Single Dose Open Label Study To Investigate The Potential DDI Between PF-00299804 And Paroxetine In Healthy Subjects||Pfizer|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318031||107379|
NCT01314924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOC-70|Effects of Acute Ingestion of Dark Chocolate on Endothelial Function in Hypertensive Patients|Featuring Treated Hypertensive Patients Who Improve Endothelial Function After Dark Chocolate||Hospital Universitario Pedro Ernesto|Yes|Completed|January 2011|September 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|21|||Both|40 Years|70 Years|No|||January 2012|January 10, 2012|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01314924||107615|
NCT01314911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC 004|Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults|A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|April 2011|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|64 Years|No|||December 2014|December 15, 2014|March 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01314911||107616|
NCT01315782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0555|Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis|Alveolar Dead Space as Predictor of Multi-organ Failure and Mortality in Medical Intensive Care Patients With Sepsis Requiring Mechanical Ventilation||The University of Texas Health Science Center, Houston|No|Recruiting|November 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to medical intensive care unit with severe sepsis or septic shock        requiring mechanical ventilation.|May 2015|May 31, 2015|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01315782||107550|
NCT01316094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0072|A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment|Long-term Study of ASP1941 - Study to Assess the Efficacy and Safety of ASP1941 in Patients With Type 2 Diabetes Mellitus Who Have Renal Impairment||Astellas Pharma Inc|No|Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|20 Years|74 Years|No|||January 2016|January 18, 2016|March 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316094||107526|
NCT01316666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101311|Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension|Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension|6103|Vanderbilt University|No|Active, not recruiting|March 2011|March 2018|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|participants with neurogenic orthostatic hypotension, which is a drop in systolic blood        pressure of at least 30 mmHg within 5 minutes of standing with associated impaired        autonomic reflexes.|December 2015|December 10, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316666||107483|
NCT01316952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114522|Coreg and HSRs-Updated Analysis|A Nested Case-control Study of the Association Between Coreg IR and Coreg CR and Hypersensitivity Reactions: Anaphylactic Reaction/Angioedema-Updated Analysis||GlaxoSmithKline|No|Completed|June 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|Derived from the LabRx database from Oct. 1st 2004 to Sep. 30th 2009. The LabRx Database        (referred to in publications as the "i3 InVision Data Mart") is provided by Ingenix        Pharmaceutical Services, Inc. It is a comprehensive, de-identified U.S. healthcare claims        database that contains the aggregated health claims experience of the covered lives        managed by United Healthcare. It contains only those covered lives for which there exists        a combined benefit structure including medical and prescription coverage. Overall, it is        representative of the non-elderly, insurance-carrying population in the U.S., but it also        contains information on several hundred thousand Managed Medicaid and Medicare Advantage        members. It contains inpatient, outpatient and pharmacy claims, lab results and enrolment        information on over 30.5 million lives from October 2004 through September 2009.|April 2015|April 14, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316952||107461|
NCT01316380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.442|Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 ug and 5 ug Once Daily) Compared to Placebo Over 12 Weeks in Mild Persistent Asthma||Boehringer Ingelheim||Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|465|||Both|18 Years|75 Years|No|||March 2015|March 25, 2015|March 15, 2011||||No|April 19, 2013|https://clinicaltrials.gov/show/NCT01316380||107504|
NCT01366079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dynamic study|Dynamic Position Change in Colonic Adenoma Detection|Dynamic Position Change in Colonic Adenoma Detection: a Prospective, Randomized, Multicenter Study||The Catholic University of Korea||Completed|July 2011|March 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1072|||Both|45 Years|N/A|No|||March 2015|March 30, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01366079||103722|
NCT01366352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1202|Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets|Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets: A Double-Blind, Single Dose, Crossover, Phase 1 Study in Normal Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|February 2004|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366352||103701|
NCT01357980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-155|Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis|A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.||Ipsen|No|Completed|May 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|47|||Both|18 Years|70 Years|No|||August 2014|August 21, 2014|May 17, 2011||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01357980||104340|
NCT01366365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1303|Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide|A Phase 1 Randomized, Double-Blind, Placebo Controlled Parallel Group Study of the Pharmacokinetics, Safety and Tolerability of Methylnaltrexone Bromide Administered as Single and Multiple Intravenous Doses to Healthy Adults and Elderly Male and Female Subjects||Valeant Pharmaceuticals International, Inc.|No|Completed|October 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366365||103700|
NCT01365897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2010|Effectiveness of Modafinil in Improving Cognitive Performance of University Students|Effectiveness of Modafinil in Improving Mnesic Performance and Executive Functions of University Students From Careers of High Academic Performance||Universidad de Valparaiso|No|Completed|September 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2010|June 2, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365897||103736|
NCT01363115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-P-000414|Calcium Supplementation for a Healthy Weight (CaSHeW)|Calcium Supplementation for a Healthy Weight (CaSHeW)|CaSHeW|Massachusetts General Hospital|No|Completed|July 2005|December 2006|Actual|October 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 27, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01363115||103947|
NCT01363128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0708|Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)|Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia||M.D. Anderson Cancer Center|No|Recruiting|July 2011|||August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||March 2016|March 9, 2016|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363128||103946|
NCT01316276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR02-110|Extension Study of Arikayce in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa Infection|Long Term Safety and Tolerability of Open-Label Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa||Insmed Incorporated|Yes|Completed|October 2012|||July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|206|||Both|6 Years|N/A|No|||December 2015|December 8, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316276||107512|
NCT01317160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC-Achilles|Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture|Intermittent Pneumatic Compression Effects on Venous Thromboembolism Incidence and Healing of Achilles Tendon Rupture||Karolinska University Hospital|No|Active, not recruiting|March 2011|September 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|18 Years|75 Years|No|||February 2016|February 15, 2016|March 16, 2011|Yes|Yes||No|January 18, 2016|https://clinicaltrials.gov/show/NCT01317160||107446|
NCT01314092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTG-ASC-210|Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula|Phase II Study to Evaluate Efficacy and Safety of ANTG-ASC (Autologous Cultured Adipose-derived Stem Cells) on the Complex Fistula Patients|ANTG-ASC-210|Anterogen Co., Ltd.|Yes|Recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2011|March 28, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01314092||107677|
NCT01314105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.119|BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer|Phase I Dose Escalation Trial to Determine the Maximum Tolerated Dose of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Patients With a First, Second or Third Platinum Sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer||Boehringer Ingelheim||Active, not recruiting|March 2011|March 2016|Anticipated|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Female|18 Years|N/A|No|||February 2016|February 22, 2016|March 8, 2011||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01314105||107676|
NCT01314365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-TL-52120-156|DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia|DYSPORT™ for Injection AbobotulinumtoxinA Neurotoxin Clinical & Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD)|ANCHOR-CD|Ipsen|No|Completed|April 2011|March 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with Cervical Dystonia treated with Dysport|April 2014|April 29, 2014|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01314365||107656|
NCT01314378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBTP|Effects of Intensive Behavioral Training Program on Impulsivity and Inhibitory Control in Smokers|Effects of Intensive Behavioral Training Program on Impulsivity and Inhibitory Control in Smokers|IBTP|Massachusetts General Hospital|No|Active, not recruiting|January 2011|October 2012|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 1, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01314378||107655|
NCT01314326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00006611 - AIGS|Advanced Imaging for Glaucoma Study|Advanced Imaging for Glaucoma Study|AIGS|Oregon Health and Science University|Yes|Active, not recruiting|September 2003|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|1000|||Both|40 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will enroll both males and females and include all ethnic and racial groups        through clinical practices in the centers. The study will enroll subjects in the older        adult age range commonly affected by glaucoma - 40 years or older. The study will exclude        people with life-threatening or debilitating illness that would make 5-year participation        unlikely or cooperation with tests difficult. For similar reasons those older than 79        years are excluded. The study also excludes those with any disease that might confound the        diagnosis of glaucoma. Otherwise people with any health status are eligible for        enrollment. Three groups of participants are recruited in the AIG study: normal (N),        glaucoma suspects & preperimetric glaucoma (GSPPG) and perimetric glaucoma (PG).|December 2013|December 5, 2013|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314326||107659|
NCT01314339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50485|Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|December 2005|February 2006|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2005|February 17, 2012|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01314339||107658|
NCT01314937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-242-PED|The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas|Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care||McGill University Health Center|Yes|Completed|September 2011|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1760|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||August 2014|August 25, 2014|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314937||107614|
NCT01315171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1009007394|Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.|The Effect of a Long-term Medium Chain Supplemented Diet on Cognitive Function and Brain Activation During Hypoglycemia in Type 1 Diabetes.||Yale University|No|Completed|January 2012|||August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|No|||February 2016|February 5, 2016|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315171||107596|
NCT01326000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25438|A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer|A Randomized, Multicenter, Open-label Phase II Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With KRAS Wild-type or Mutant Metastatic Colorectal Cancer||Hoffmann-La Roche||Completed|April 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|169|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|March 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326000||106768|
NCT01326273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROHH0202|Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation|Adoptive Transfer of Autologous CMV Specific CD8+ T Cells After Allogeneic Stem Cell Transplantationas Treatment for CMV Reactivation: A Phase I/II Clinical Trial.||Imperial College London|No|Withdrawn|April 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|June 3, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01326273||106747|
NCT01316107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0111|A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients|A Phase 3, Open-Label, Non-comparative Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Combination With Nateglinide in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With Nateglinide Alone||Astellas Pharma Inc|No|Completed|February 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|20 Years|N/A|No|||January 2016|January 19, 2016|March 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316107||107525|
NCT01316120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPVDry|Randomized Comparison of Vaginal Self Sampling for Human Papillomavirus (HPV) Testing by Standard Versus Dry Vaginal Swabs|Randomized Comparison of Vaginal Self Sampling for Human Papillomavirus (HPV) Testing by Standard Versus Dry Vaginal Swabs|HPVDry|University Hospital, Geneva|No|Enrolling by invitation|November 2010|December 2011|Anticipated|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Female|20 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 22, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316120||107524|
NCT01316393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-404|Effects of Mucoprotective Product on Xerostomia|Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients||Camurus AB|Yes|Completed|February 2011|June 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|20|||Both|18 Years|90 Years|No|||November 2011|November 8, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316393||107503|
NCT01326897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048222|Healthy Homes/Healthy Families|Healthy Homes/Healthy Families|HHHF|Emory University|No|Completed|February 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|510|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 8, 2016|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01326897||106699|
NCT01355991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01327|Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI|Acute and Chronic Effects of an Anticholinergic Agent or a Long-Acting Beta 2 Agonist on Levels of Exhaled Nitric Oxide and Pulmonary Function in Persons With Tetraplegia||James J. Peters Veterans Affairs Medical Center|No|Active, not recruiting|August 2011|August 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||October 2015|October 22, 2015|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355991||104493|
NCT01356004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CairoU|Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis|Live Attenuated Varicella Vaccine: A New Effective Adjuvant Weapon in the Battlefield Against Severe Resistant Psoriasis, a Randomized Controlled Trial||Cairo University|Yes|Completed|January 2010|November 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2011|May 18, 2011|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356004||104492|
NCT01356017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HPS11C|CKD-828 Drug Interaction Study (Telmisartan)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Telmisartan Between Free Combination of Telmisartan and S-amlodipine and Telmisartan Monotherapy in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 4, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356017||104491|
NCT01358253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ-2010-56|Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia|Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia||Ruijin Hospital|Yes|Completed|December 2010|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||May 2011|May 19, 2014|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358253||104319|
NCT01365351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOM/011207/03|Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON|Non-interventional Study With ZOMACTON in Children With Growth Hormone Deficiency||Ferring Pharmaceuticals|No|Enrolling by invitation|November 2007|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|873|||Both|N/A|N/A|No|Non-Probability Sample|Clinics and private practices|October 2015|October 20, 2015|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01365351||103778|
NCT01365910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC GI 1058|Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer|An Investigator Initiated, Phase II Study of Linifanib in Patients With Advanced, Refractory Colorectal Cancer Expressing Mutated kRas||Vanderbilt-Ingram Cancer Center|Yes|Terminated|June 2011|June 2013|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 24, 2014|June 1, 2011|Yes|Yes|Interim analysis determined the study did not meet criteria to proceed|No|June 13, 2014|https://clinicaltrials.gov/show/NCT01365910||103735|
NCT01366131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEF4984g|Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease||Genentech, Inc.||Completed|June 2011|||February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366131||103718|
NCT01316562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-025B|Predictive Value of Cognitive Tests Performed for the Diagnosis of Alzheimer's Disease and Related Disorders|Valeur prédictive d'Une évaluation Cognitive standardisée en Centre d'Examens de Santé Pour le Diagnostic de la Maladie d'Alzheimer ou Des Maladies apparentées en Population générale Chez Les Plus de 65 Ans Avec Plainte mnésique|EVATEM|University Hospital, Angers|Yes|Recruiting|July 2009|July 2012|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|500|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects with memory complaint recruited during a free medical examination in Health        examination centres of Lyon, Saint-Etienne and Angers, France|March 2011|March 8, 2012|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01316562||107490|
NCT01316887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113359|A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease|COPD nDPI|GlaxoSmithKline|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|563|||Both|40 Years|N/A|No|||May 2014|May 8, 2014|March 15, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01316887||107466|
NCT01318044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCK-30|Thiopental Versus Propofol During Magnetic Resonance Imagining in Children: Something Old, Something New|Thiopental Versus Propofol During Magnetic Resonance Imagining in Children||University Clinical Centre of Kosova|No|Recruiting|January 2011|May 2011|Anticipated|April 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Months|12 Years|Accepts Healthy Volunteers|||January 2011|March 17, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01318044||107378|
NCT01318265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12435|Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics|A Phase I, Non-Randomized, Open Label Study to Determine the Effetc of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of Regorafenib (BAY73-4506) in Healthy Volunteers||Bayer|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01318265||107361|
NCT01314118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017932|IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen|A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease||Janssen Biotech, Inc.|No|Active, not recruiting|May 2011|July 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Male|18 Years|99 Years|No|||January 2016|January 18, 2016|March 4, 2011|Yes|Yes||No|December 24, 2014|https://clinicaltrials.gov/show/NCT01314118||107675|These results are up to clinical cutoff 31 December 2013 when all enrolled subjects either completed 6 cycles of treatment or withdrew from study prior to end of cycle 6. Primary endpoint results are complete.
NCT01314391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN11B1|Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor|Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD||Children's Oncology Group|No|Active, not recruiting|August 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|Blood and Tumor tissue|Both|N/A|15 Years|No|Non-Probability Sample|Diagnosis of Wilms Tumor|May 2015|May 8, 2015|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314391||107654|
NCT01314131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMEP-01|Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home|Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home||Association Recherche Méthodologie Evaluation Psychiatrique|Yes|Recruiting|March 2011|June 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|48|||Both|60 Years|N/A|No|||January 2011|April 28, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314131||107674|
NCT01314651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMO-0002|Efficacy of Behavioral Insomnia Treatment for Chronic Migraine|Efficacy of Behavioral Insomnia Treatment for Chronic Migraine: A Randomized Controlled Pilot Study||University of Mississippi, Oxford|No|Completed|March 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||April 2014|April 22, 2014|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314651||107635|
NCT01314664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3329-402|A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)|A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)||Endo Pharmaceuticals|No|Terminated|May 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|subjects who will be receiving intravesical valrubicin treatment for NMIBC|June 2015|June 10, 2015|March 11, 2011||No|Business decision, not safety related|No||https://clinicaltrials.gov/show/NCT01314664||107634|
NCT01314690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2008-A00406-49|Human Intestinal Microbiota in Obesity and Nutritional Transition|Human Intestinal Microbiota in Obesity and Nutritional Transition|Micro-Obes|Ceprodi S.A. Kot||Completed|September 2008|March 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Primary Purpose: Health Services Research|1||Actual|49|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||March 2011|March 11, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01314690||107632|
NCT01314703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|371.1.02.15.11|Topical Antimicrobial Effectiveness Testing|Test for Preoperative Skin Preparations||CareFusion|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 30, 2012|March 10, 2011||No||No|February 8, 2012|https://clinicaltrials.gov/show/NCT01314703||107631|
NCT01315184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01DA022398|Study of Computer-Based Treatment for Drug Dependence|Pilot Trial of a Therapeutic Interactive Voice Response System for Buprenorphine Maintenance: The Recovery Line Support System|RLSS|Yale University|Yes|Completed|July 2010|July 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01315184||107595|
NCT01325688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP005-037|PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities|A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities||Peplin|No|Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|March 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325688||106792|
NCT01325701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1106-CA|Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)||Pharmacyclics|No|Active, not recruiting|May 2011|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|February 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01325701||106791|
NCT01315522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERBD2SEMS|Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents|Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent||Seoul National University Hospital|No|Completed|June 2010|April 2015|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Both|20 Years|N/A|No|||April 2015|April 20, 2015|June 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01315522||107569|
NCT01315535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP0301/10|Fast Titration of Oral Appliance at Obstructive Sleep Apnea Syndrome (OSAS) Treatment|Evaluation of the Efficacy and Side Effects of Fast Mandibular Advancement With Oral Appliance in the Treatment of Obstructive Sleep Apnea Syndrome||Associacao Fundo de Incentivo a Psicofarmcologia|No|Recruiting|March 2011|December 2013|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|120|||Both|19 Years|65 Years|No|Probability Sample|Subjects diagnosed with mild to moderate osas, according to the aasm criteria (2005) from        the respiratory disorders clinic (UNIFESP) referred to oral appliance treatment.|March 2011|June 21, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315535||107568|
NCT01326286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110299|Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer|Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer|CEASAR|Vanderbilt University|No|Active, not recruiting|March 2011|September 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|3265|||Male|18 Years|79 Years|No|Probability Sample|Population-based sample of men diagnosed with localized prostate cancer in the states of        Louisiana and New Jersey and the metropolitan areas of Atlanta and Los Angeles, augmented        with a convenience sample of men enrolled in the CaPSURE database, a national        observational disease registry.|December 2015|December 7, 2015|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01326286||106746|
NCT01326585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911-A|Study Trial of Dexamethasone Use for Alleviation of Symptoms After Scleral Buckle Eye Surgery|Effect of Dexamethasone on Postoperative Symptoms of Scleral Buckling Surgery Patients: a Randomized Control Trial||University of Toronto||Withdrawn|April 2011|April 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|79 Years|No|||January 2011|June 2, 2015|March 28, 2011|No|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01326585||106723|
NCT01326598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V4006|Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting|Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE)|SIMPLE|Valeritas, Inc.|No|Completed|January 2012|May 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|270|||Both|21 Years|80 Years|No|Non-Probability Sample|Type 2 Diabetes Mellitus|June 2015|June 1, 2015|March 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326598||106722|
NCT01326910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COOADM3002|Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema|A Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of an Over-the-Counter Cream in the Management of Mild to Moderate Atopic Dermatitis in Children||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|March 2011|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|6 Months|18 Years|No|||June 2012|June 27, 2012|March 30, 2011|Yes|Yes||No|June 27, 2012|https://clinicaltrials.gov/show/NCT01326910||106698|
NCT01326923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-109|Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer|Phase II Trial of Induction Chemotherapy (ICT) Followed by Concurrent Chemoraditherapy (CR) With Monoclonal Antibody Cetuximab in Locally Advanced Head and Nec Squamous Cell Cancer||Louisiana State University Health Sciences Center Shreveport|Yes|Terminated|June 2010|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 24, 2011||No|Principle Investigator left the institution.|No||https://clinicaltrials.gov/show/NCT01326923||106697|
NCT01356888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1004|Study of the Orsiro Drug Eluting Stent System|BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With Single de Novo Coronary Artery Lesions - II|BIOFLOW-II|Biotronik AG|Yes|Active, not recruiting|May 2011|April 2017|Anticipated|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|80 Years|No|||February 2015|February 1, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01356888||104424|
NCT01356901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-232|Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients|Persistence, Adherence and Clinical Effectiveness in Patients With Chronic Hepatitis B Viral Infection Treated With Entecavir in Real Life||Bristol-Myers Squibb|No|Completed|January 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|230|||Both|18 Years|N/A|No|Probability Sample|CHB Patients treated by Gastroenterologists/Hepatologists|June 2015|July 3, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01356901||104423|
NCT01365663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC4955-901|Multiple Ascending Dose Study of SPC4955 in Healthy Subjects|A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC4955 Administered to Healthy Subjects||Santaris Pharma A/S|No|Completed|May 2011|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01365663||103754|
NCT01366716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA021621|Contingency Management for Cocaine Dependence: Cash Versus Vouchers|Contingency Management for Cocaine Dependence: Cash Versus Vouchers||Treatment Research Institute|Yes|Completed|April 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|352|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01366716||103673|
NCT01317472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA-NC-DEX-115|The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux|A Double-Blinded, Placebo-Controlled Trial to Investigate Dexlansoprazole for the Treatment of Laryngopharyngeal Reflux||Indiana University|Yes|Terminated|March 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|November 14, 2013|March 16, 2011||No|Principal investigator left institution|No||https://clinicaltrials.gov/show/NCT01317472||107422|
NCT01317784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07373710|Behavioral Science Aspects of Rapid Test Acceptance|Behavioral Science Aspects of Rapid Test Acceptance|BSARTA|California State University, Long Beach|Yes|Completed|May 2011|August 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Screening|4||Actual|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317784||107398|
NCT01318057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1SC2HL110393-01A2|Pharmacogenetics of Warfarin in Puerto Ricans.|Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach.||University of Puerto Rico|Yes|Completed|February 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|350|Samples With DNA|Whole fresh blood and Genomic DNA samples fom enrolled patients|Both|18 Years|90 Years|No|Non-Probability Sample|Hispanic Puerto Rican patients from all geographic regions of the Island of Puerto Rico        who are currently receiving a standard stable dose of warfarin at the anticoagulation        clinic of the Veteran Affair Caribbean Healthcare System (VACHS)|January 2015|January 19, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318057||107377|
NCT01318291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38844|Effect of Psychological Intervention on Drop-out Rates in IVF|An Assessment of the Effect of a Brief Psychological Intervention on Decreasing Drop-Out Rates in IVF Patients||Boston IVF|No|Completed|April 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|166|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01318291||107359|
NCT01314417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110107|Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate|Treatment of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate|MEXX|National Institutes of Health Clinical Center (CC)|No|Terminated|February 2011|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|March 11, 2011|Yes|Yes|This study was terminated due to lack of recruitment.|No|July 18, 2013|https://clinicaltrials.gov/show/NCT01314417||107652|
NCT01314729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8901372055shirazUMS|Comparison of the Effect of Two Types of Fixed Retainers on the Health of the Gums|Clinical and Radiographic Comparison and Evaluation of Two Types of Lingual Fixed Retainers on the Health of Periodontium||Shiraz University of Medical Sciences|Yes|Recruiting|May 2010|May 2011|Anticipated|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|48|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||February 2011|March 14, 2011|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01314729||107629|
NCT01324817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-00006|Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitors for Use With Neonates|Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitors for Use With Neonates||Kai Medical, Inc.|No|Recruiting|January 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|N/A|2 Months|Accepts Healthy Volunteers|Non-Probability Sample|Neonates hospitalized at the Kapiolani Medical Center for Women and Children located in        Honolulu, HI|December 2011|December 12, 2011|March 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324817||106859|
NCT01314677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012|Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation|Open Label Randomized Trial of Early Assessment of Therapy Response Using 18FDG-PET/CT in Patients With Marginally Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer (NSCLC) Treated With Induction Concurrent Chemoradiation Followed by Resection and Adjuvant Chemotherapy||City of Hope Medical Center|Yes|Withdrawn|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|0|||Both|N/A|N/A|No|||June 2012|June 27, 2012|March 11, 2011|No|Yes|No subjects have been accrued to this trial. The PI will no longer be at COH and requests a    study withdrawal/closure.|No||https://clinicaltrials.gov/show/NCT01314677||107633|
NCT01315197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Talita Pavarini Borges|Massage for Low Back Pain in Nursing Staff|Application of Massage for Low Back Pain in Nursing Staff|Massage|University of Sao Paulo|Yes|Completed|October 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|58 Years|Accepts Healthy Volunteers|||October 2010|March 14, 2011|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315197||107594|
NCT01317589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 11-2-007|Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?|Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective Than Fentanyl?|310111-4|Maastricht University Medical Center|No|Completed|May 2011|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|February 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01317589||107413|
NCT01326013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDP-736-189|A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel|A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel (xTAG GPP) in Patients With Signs and Symptoms of Infectious Colitis and Gastroenteritis||Luminex Molecular Diagnostics|No|Completed|June 2011|March 2012|Actual|February 2012|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|1534|Samples With DNA|Stool|Both|N/A|N/A|No|Probability Sample|Clinical specimens collected from patients with signs and symptoms of infectious colitis        or gastroenteritis who are either hospitalized, admitted to emergency departments or        visiting outpatient clinics.|August 2012|August 22, 2012|March 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01326013||106767|
NCT01317914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000178|Prospective Study of Undiagnosed Celiac Disease|Epidemiology of Celiac Disease: A Prospective Study of Undiagnosed Celiac Disease in the Community||Mayo Clinic|No|Completed|July 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|60 Years|N/A|No|||May 2012|May 25, 2012|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01317914||107388|
NCT01326299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK92|Post Prandial Glucose Control Proof-of-Principle|Post Prandial Glucose Control Proof-of-Principle||Abbott Nutrition|Yes|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|50|||Both|21 Years|75 Years|No|||March 2011|March 29, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01326299||106745|
NCT01326611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rö05053781128|Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants|||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Completed|May 2008|December 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|273|||Both|N/A|2 Days|No|||May 2008|March 29, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326611||106721|
NCT01326624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90D0112|Study of the Wearable Defibrillator in Heart-Failure Patients|Study of the Wearable Defibrillator In Heart-Failure Patients|SWIFT|Zoll Medical Corporation|No|Active, not recruiting|March 2011|March 2016|Anticipated|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|patients with left ventricular dysfunction or advanced heart failure symptoms (New York        Heart Association functional Class III/IV), who have a high-risk for sudden cardiac death,        but are not eligible for an implantable defibrillator or are not able to receive one due        to their condition.|December 2014|May 27, 2015|March 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01326624||106720|
NCT01318343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSSC Zeltiq eZ App 8|Analysis of CoolSculpting by Zeltiq for Non-Invasive Cooling of Abdominal Fat Using the eZ App Large Applicator|Analysis of CoolSculpting by Zeltiq for Non-Invasive Cooling of Subcutaneous Fat of the Abdomen Using the eZ App Large Applicator||Laser and Skin Surgery Center of New York|Yes|Completed|March 2011|February 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The study population will consist of 20 subjects, ages 18-65 years, who have clearly        visible fat in the lower abdomen and are appropriate candidates as per the Study Doctor's        physical examination.|March 2015|March 30, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318343||107355|
NCT01326936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44DA026218|Online Primary Care Physician (PCP) Training in Screening, Brief Intervention, Referral, and Treatment|Fast Track SBIR Study Online PCP Training in Screening, Brief Intervention, Referral, and Treatment||Medical Directions, Inc|No|Completed|August 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 23, 2012|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01326936||106696|
NCT01357746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOPO8|Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)|Detection, Estimation and Characterization of Pulmonary Blood Pressure by Transthoracic Parametric Doppler (TPD)||Echosense Ltd.|No|Terminated|July 2011|||June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|N/A|No|||May 2011|August 17, 2013|May 17, 2011|Yes|Yes|Low recruitment|No||https://clinicaltrials.gov/show/NCT01357746||104358|
NCT01366443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROM Plus Clinical Study|Analysis of ROM Plus to Detect Rupture of Membranes|Analysis of ROM Plus to Detect Rupture of Membranes||Clinical Innovations, LLC|Yes|Completed|September 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|288|||Female|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy pregnant women between 15 or greater weeks gestation reporting with signs or        symptoms of rupture of membranes.|July 2012|July 30, 2012|June 2, 2011||No||No|April 26, 2012|https://clinicaltrials.gov/show/NCT01366443||103694|
NCT01366456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMCOH-IM01|Clinical Trials for Comparison of Two Kinds of Moxibustion|Clinical Trials for Comparison Between Shingigu and Charcoal Moxa on CV-12||Semyung University|Yes|Recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2010|June 8, 2011|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366456||103693|
NCT01366729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTvS_13DPD6_134993_BFHBZG|Gait Rehabilitation Post Stroke:the Long Term Effect of Two Walking Aids -Canes and TheraTogs|How to Improve Walking, Balance and Social Participation Following Stroke: a Comparison of Cane Walking to an Orthosis TheraTogs in Early Post-stroke Gait Rehabilitation. A Multi-centred, Single Blind,Randomized Control Trial.||Technical University of Bern|No|Terminated|November 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 2, 2011|Yes|Yes|Unable to recruite enough subjects to reach statistical power|No||https://clinicaltrials.gov/show/NCT01366729||103672|
NCT01366742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-05580|Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women|Natural History of Human Papillomavirus From Infection to Neoplasia in Adolescents and Young Women - Effect of Tobacco on Cervical Neoplasia in Young Women||University of California, San Francisco|No|Active, not recruiting|December 1987|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|900|Samples With DNA|Rbc, WBC vaginal lavages ,cytology,saliva ,anal samples|Female|13 Years|22 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community|December 2014|December 2, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366742||103671|
NCT01317485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTR2037|Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis|Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis: a Nationwide Multicenter Randomised Trial|Ladies|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|April 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|283|||Both|18 Years|85 Years|No|||March 2014|March 20, 2014|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317485||107421|
NCT01317797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M1-1188-002-EM|A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis|A Phase Ib Double-blind, Placebo-controlled, Randomized, Dose-escalating Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Subcutaneous Injections of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis on Treatment With Methotrexate|PRIORA|Takeda|No|Completed|March 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|February 18, 2011||No||No|July 24, 2015|https://clinicaltrials.gov/show/NCT01317797||107397|
NCT01317810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-060|A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication|A Phase 4, Observational, Non-interventional Study Measuring and Tracking Changes in Overactive Bladder Medication and/or Overactive Bladder Medication Dose in Subjects With Overactive Bladder||Astellas Pharma Inc|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with overactive bladder (OAB)|August 2015|August 31, 2015|March 16, 2011|No|Yes|Corporate decision not to initiate the trial|No||https://clinicaltrials.gov/show/NCT01317810||107396|
NCT01314716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-219-0104|Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)|AIR-BX2|Gilead Sciences|Yes|Completed|April 2011|July 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|March 11, 2011|Yes|Yes||No|March 7, 2014|https://clinicaltrials.gov/show/NCT01314716||107630|
NCT01324830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1287.1|Monotherapy Dose Finding With BI 847325 in Solid Tumours|An Open Label Phase Ia/Ib Study of Two Dosing Schedules of BI 847325, Orally Administered Once a Day in Patients With Advanced Solid Tumours, With Repeated Cyclic Administration in Patients With Clinical Benefit||Boehringer Ingelheim||Completed|April 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|March 23, 2011||||No||https://clinicaltrials.gov/show/NCT01324830||106858|
NCT01324843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909249|Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects|Safety and Tolerability of the Derma Vax Clinical Intradermal Electroporation System in Healthy Subjects||National Institutes of Health Clinical Center (CC)||Completed|June 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 23, 2011|March 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01324843||106857|
NCT01324570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP3031|Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children|An Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Buprenorphine Transdermal System (BTDS) in Children From 7 to 16 Years of Age, Inclusive, Who Require Continuous Opioid Analgesia for Moderate to Severe Pain||Purdue Pharma LP|Yes|Active, not recruiting|July 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|7 Years|16 Years|No|||November 2015|November 9, 2015|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324570||106878|
NCT01314404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV Study|KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)|KAP/WTP and HPV Prevalence Studies in Preparation for a Phase IV Trial of the Gardasil HPV Vaccine in a Developing World Setting (Bamako, Mali)|HPV|Global Alliance to Immunize Against AIDS Vaccine Foundation|No|Recruiting|March 2011|September 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|460|Samples With DNA|Two cervical scrapes and 2 blood samples will be collected from each of the 160 selected      patients.|Both|12 Years|N/A|Accepts Healthy Volunteers|Probability Sample|(i) The KAP/WTP study will take place in Mékin-Sikoro, a peri-urban neighborhood of Bamako        with a population of around 40,000. The study will comprise the six sectors of the        district, enrolling a total of 300 participants. The participants will range in age from        12 to 50 and will be selected randomly. The study population will be representative of the        following categories: men, women, adolescent boys, and adolescent girls.        (ii) The Prevalence study subjects will be recruited among women diagnosed with cervical        cancer who are attending a previously arranged appointment (i.e. not linked to the study)        to have either a curative biopsy or a more extensive surgical procedure with the        department of gynecology at Hôpital Gabriel Touré.|July 2011|July 15, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314404||107653|
NCT01314950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG034946-01A1|Alzheimer's Disease Multiple Intervention Trial|Alzheimer's Disease Multiple Intervention Trial|ADMIT|Indiana University|Yes|Completed|July 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|45 Years|N/A|No|||March 2016|March 7, 2016|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01314950||107613|
NCT01314963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03092011-7560|Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy|Efficacy of a Novel, High-Sensitivity, Portable, Hand-Held Gamma Camera Used Intraoperatively for Identification of Sentinel Lymph Nodes With Lymphoscintigraphy||Stanford University|Yes|Active, not recruiting|June 2008|April 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2011|March 11, 2011|March 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01314963||107612|
NCT01315210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOE 02C 010|D-Ribose for Fatigue in Subjects With Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of D-Ribose in Subjects With Fibromyalgia||RiboCor, Inc.|No|Completed|May 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|70 Years|No|||September 2013|September 11, 2013|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315210||107593|
NCT01317602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HellenicCardiovascularRS|Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study|Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study|MANAGE-AF|Hellenic Cardiovascular Research Society|No|Completed|March 2011|||September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|603|||Both|18 Years|N/A|No|Probability Sample|The MANAGE-AF study will enroll 600 consecutive patients from the emergency cardiology        departments and outpatient clinics in about 35 Greek hospitals. Their selection will be        made in an effort to recruit a representative sample of patients from different geographic        areas and stratums of the country.|April 2015|April 15, 2015|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317602||107412|
NCT01317615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001KDE37|RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation|A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC)||Novartis||Completed|April 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317615||107411|
NCT01317927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXD101-CLN-20|A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies|A Phase I Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies||Spectrum Pharmaceuticals, Inc|No|Completed|December 2010|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317927||107387|
NCT01318135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/OCT-005|Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan|A Long-term, Open-label Extension Study to Investigate the Long-term Safety of Alogliptin When Used in Combination With Sulfonylurea or Metformin in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|January 2009|April 2010|Actual|January 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|576|||Both|20 Years|64 Years|No|||July 2012|July 7, 2012|March 16, 2011|No|Yes||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01318135||107371|
NCT01318356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205520003-20110307|The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment|The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment|Qure|Radboud University|Yes|Completed|April 2011|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|156|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|March 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318356||107354|
NCT01318369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEEL-2011-01|Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain|The Safety, Tolerability, and Analgesic Efficacy of Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain|Delta-pain|Radboud University|No|Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01318369||107353|
NCT01365923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0019|Comparison of Dexmedetomidin and Remifentanil for the Effect on Airway Reflex and Hemodynamic Response During Emergence in Patients Undergoing Craniotomy|Comparison of Dexmedetomidin and Remifentanil for the Effect on Airway Reflex and Hemodynamic Response During Emergence in Patients Undergoing Craniotomy||Yonsei University|Yes|Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|74|||Both|20 Years|70 Years|No|||November 2013|June 29, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365923||103734|
NCT01365026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/01461|PVS: Innovative Programs For Healthy Lifestyle Promotion in Primary Care: 'Prescribe Healthy Life'|Feasibility and Potential Effectiveness of Innovative Programs for Health Promotion in Primary Care: The 'Prescribe Healthy Life' Project (PVS)|PVS|Basque Health Service|No|Recruiting|June 2011|December 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1366|||Both|10 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365026||103802|
NCT01365338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701003|A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects|Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, Parallel Group Study To Assess Effects Of PF-04958242 On Bold Functional MRI During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects||Pfizer|No|Completed|June 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|112|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 21, 2012|May 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01365338||103779|
NCT01366469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046469|Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting|Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting|CABG BALF|Emory University|Yes|Completed|April 2011|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples With DNA|BAL fluid, Serum|Both|18 Years|89 Years|No|Probability Sample|patients from Cardiothoracic surgery service|February 2014|February 18, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366469||103692|
NCT01366482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-4941|Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease|Directional AthErectomy Followed by a PaclItaxel-Coated BallooN to InhibiT RestenosIs and Maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment|DEFINITIVE AR|Medtronic Endovascular|Yes|Completed|July 2011|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366482||103691|
NCT01366768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003|Gut Hormones After Oral Versus Intravenous Amino Acids|Release of Gut Hormones After Oral Versus Intravenous Amino Acids||Lund University|Yes|Completed|May 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366768||103670|
NCT01366781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Gut Hormones After Meal Ingestion in Males Versus Females|Effects of Varying Meal Size on Gut Hormone and Islet Hormone Secretion in Males Versus Females||Lund University|Yes|Completed|May 2011|June 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Actual|24|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366781||103669|
NCT01318070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/CCT-004|Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|November 2007|October 2008|Actual|October 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|339|||Both|33 Years|88 Years|No|||February 2012|February 1, 2012|March 16, 2011||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01318070||107376|
NCT01317836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANCYST|PET-CT in Diagnosis of Pancreatic Cystic Neoplasms|PET-CT in Diagnosis of Pancreatic Cystic Neoplasms||Turku University Hospital|No|Completed|March 2011|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|The study subjects will be recruited from gastroenterological surgery department of Turku        University Hospital with clinical suspicion of pancreatic cystic neoplasm.|February 2014|February 14, 2014|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317836||107394|
NCT01318278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27661|Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants|Dopamine Versus Vasopressin for Cardiovascular Support in Extremely Low Birth Weight Infants: A Randomized, Blinded Pilot Study||Baylor College of Medicine|Yes|Completed|March 2011|September 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|70|||Both|N/A|24 Hours|No|||February 2015|February 24, 2015|March 16, 2011||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01318278||107360|
NCT01324557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InsulinPump|Insulin Pump Therapy and Continuous Glucose Monitoring in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients|||Guangdong General Hospital|Yes|Recruiting|March 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||March 2011|March 28, 2011|March 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324557||106879|
NCT01324583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11576|Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer|An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase I Study With Cabazitaxel Administered as a 1-hour Intravenous Infusion Every 3 Weeks in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer||Sanofi|No|Completed|January 2011|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|20 Years|73 Years|No|||January 2015|January 6, 2015|March 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01324583||106877|
NCT01325155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0043-11CTIL|Effect of Air Pollution in the Haifa Bay Area on Cardiovascular Morbidity and Mortality|Effect of Air Pollution in the Haifa Bay Area on Cardiovascular Morbidity and Mortality||Rambam Health Care Campus|Yes|Not yet recruiting|April 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|All Patients visiting the ER between Jan 2009 and Dec 2010 at the Rambam Medical Center in        Haifa Israel. Electronic medical record databases will be queried for ICD-9 codes of        related cardiac (acute coronary syndrome, heart failure, dysrhythmia/conduction        disturbance) diagnoses.|March 2011|March 28, 2011|March 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01325155||106833|
NCT01325428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.89|Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2) -Overexpressing Inflammatory Breast Cancer|An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer||Boehringer Ingelheim||Completed|August 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|18 Years|N/A|No|||January 2016|January 13, 2016|March 28, 2011||||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01325428||106812|Boehringer Ingelheim (BI) decided to stop further inclusion of patients and stop further treatment with the combination of Afatinib and Vinorelbine as of 03-May-2013. Recruitment into the trial was stopped by amendment in Jul 2013.
NCT01325441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBI608-201|A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies|A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies||Boston Biomedical, Inc|Yes|Recruiting|April 2011|||April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|390|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|March 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01325441||106811|
NCT01325675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3345-1(REK)|Aerobic Interval Training in Patients With Atrial Fibrillation|Aerobic Interval Training in Patients With Paroxysmal or Persistent Atrial Fibrillation||Norwegian University of Science and Technology|No|Completed|April 2011|February 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|51|||Both|18 Years|90 Years|No|||January 2016|January 7, 2016|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01325675||106793|
NCT01317940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-10-00273|Nutrition and Body Composition in Acute Lymphoblastic Leukemia|Nutrition and Body Composition in Acute Lymphoblastic Leukemia (Environment and Microenvironment in ALL #2)||Children's Hospital Los Angeles|Yes|Completed|March 2011|January 2016|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Actual|77|||Both|10 Years|29 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01317940||107386|
NCT01318161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/415-31|Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery|Epidural or Patient-controlled Analgesia for Colorectal Cancer Surgery. Long-term Outcomes.|EPICOL|Örebro University, Sweden|Yes|Recruiting|March 2011|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|80 Years|No|||February 2016|February 14, 2016|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318161||107369|
NCT01318174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LE-KE|Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease|Prevalence of Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease||Sykehuset Innlandet HF|No|Completed|April 2011|April 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with known or suspected COPD admitted with an exacerbation of unknown aetiology|July 2014|July 7, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318174||107368|
NCT01318187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|serinken 001|Intravenous Paracetamol or Morphine for the Treatment of Acute Flank Pain|Intravenous Paracetamol or Morphine for the Treatment of Acute Flank Pain : a Randomized, Double Blind, Controlled Clinical Trial||Pamukkale University|Yes|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|73|||Both|16 Years|55 Years|No|||January 2011|March 31, 2011|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318187||107367|
NCT01318148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKW-Inf-001|Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis|Prospective Trial to Evaluate Pharmacokinetic, Safety and Efficacy of Intermittent Application of Increased Doses of Caspofungin for Antifungal Prophylaxis in High Risk Patients|CASPHYLAX|Wuerzburg University Hospital|Yes|Completed|April 2011|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|March 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318148||107370|
NCT01314209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11102010|Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)|Dexmedetomidine Pharmacokinetics During Continuous Venovenous Hemodialysis in Critically Ill Patients||Helsinki University Central Hospital|No|Recruiting|March 2011|||March 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2011|October 23, 2012|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01314209||107668|
NCT01365936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTBIVF1|hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF|Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|20 Years|38 Years|No|||March 2012|March 28, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365936||103733|
NCT01365949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS11B1|Biomarker in Tissue Samples From Patients With Ewing Sarcoma|INI-1 Deletions in Ewing Sarcoma||Children's Oncology Group|No|Active, not recruiting|May 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|Samples With DNA|Tissue|Both|N/A|120 Years|No|Non-Probability Sample|Diagnosis of Ewing sarcoma.|May 2015|September 30, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365949||103732|
NCT01365715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-024|Preoperative Embolization in Surgical Treatment of Spinal Metastases.|Preoperative Embolization in Surgical Treatment of Spinal Metastases. A Randomized Controlled Trial.||Rigshospitalet, Denmark|No|Completed|May 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01365715||103750|
NCT01366144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02500|Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction|An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors||National Cancer Institute (NCI)|Yes|Recruiting|June 2011|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|276|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|June 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01366144||103717|
NCT01366183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0273|Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer|Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer||Gynecologic Oncology Group|No|Active, not recruiting|August 2011|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|290|||Both|75 Years|N/A|No|Non-Probability Sample|older patients with ovarian, primary peritoneal or fallopian tube cancer|February 2016|February 9, 2016|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366183||103714|
NCT01366495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA030771-01|A Randomized Controlled Trial of HIV Testing and Linkage to Care at Community Corrections|A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care Corrections||Friends Research Institute, Inc.|No|Active, not recruiting|April 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|6240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 6, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01366495||103690|
NCT01367041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-3|Effect of Bone on Vibration-Induced Muscle Electrical Activity|Effect of Hip Bone Mineral Density / Content on Vibration-Induced Hip Adductors Muscle Electrical Activity in Postmenopausal Women|PMO-WBV-sEMG|Bagcilar Training and Research Hospital|Yes|Completed|April 2011|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01367041||103649|
NCT01317511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-078.3|Protein Supply in Elderly|Overnight Protein Supply as a Dietary Strategy to Improve Muscle Mass in Elderly.||Maastricht University Medical Center|No|Completed|June 2010|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Male|65 Years|80 Years|Accepts Healthy Volunteers|||March 2011|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317511||107419|
NCT01318304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29331|Vaginal Innate Immunity in Normal and HIV-Infected Women|Vaginal Innate Immunity in Normal and HIV-Infected Women||Boston Medical Center|No|Recruiting|October 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|96|Samples Without DNA|Vaginal lavage samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women, 18 to 40 years old, with spontaneous menstrual cycles or with normal        ongoing pregnancy with gestational age between weeks 13 - 30 and able to provide informed        consent|December 2011|December 28, 2011|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01318304||107358|
NCT01318083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/CCT-005|Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Sulfonylurea in Subjects With Type 2 Diabetes in Japan||Takeda|No|Completed|August 2008|April 2009|Actual|April 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|312|||Both|20 Years|64 Years|No|||February 2012|February 1, 2012|March 16, 2011||No||No|June 8, 2011|https://clinicaltrials.gov/show/NCT01318083||107375|
NCT01324258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114784|Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors|A Phase I Trial of GSK1120212 and GSK1120212 in Combination With Gemcitabine in Japanese Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|January 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|N/A|No|||February 2014|February 13, 2014|January 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01324258||106902|
NCT01324271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005016|inVENT-In-Office Study|A Clinical Study Of The Acclarent Tympanostomy Tube (Tula™) Delivery System In-Office|inVENT-IO|Acclarent|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|6 Months|N/A|No|||December 2014|December 8, 2014|March 23, 2011|Yes|Yes||No|June 1, 2014|https://clinicaltrials.gov/show/NCT01324271||106901|
NCT01316419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.42|Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension|An Observational Study to Evaluate the Effects of Twynsta Tablets (Telmisartan and Amlodipine FDC, q.d.) With Life Style Modifications on Blood Pressure, Quality of Life, and Other Risk Factors in Korean Patients With Hypertension||Boehringer Ingelheim||Completed|March 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2089|||Both|19 Years|N/A|No|Probability Sample|Korean|September 2015|September 8, 2015|March 15, 2011||||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01316419||107501|
NCT01316432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIL-CDNP-CT006|PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients|A Study Assessing The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Subcutaneous Bolus And Subcutaneous Infusion Of Cenderitide In Patients With Chronic Heart Failure With Volume Overload (HF)||Nile Therapeutics|No|Completed|May 2011|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|3||Actual|58|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|March 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316432||107500|
NCT01324856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D672|Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic Duodenopancreatectomy|Results of Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic Duodenopancreatectomy in Patients With Soft Pancreas and Small Pancreatic Duct|PanAm|University of Belgrade|Yes|Not yet recruiting|April 2011|September 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2011|April 8, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01324856||106856|
NCT01325168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0085-11CTIL|The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With Post Traumatic Stress Disorder (PTSD)|The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With PTSD||Rambam Health Care Campus|No|Completed|August 2011|April 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|March 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01325168||106832|
NCT01325454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMUH-PARAPNEUMONIC STUDY|Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions|Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions||Taipei Medical University Hospital|Yes|Recruiting|January 2008|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Pleural effusions|Both|18 Years|90 Years|No|Probability Sample|Patients with pleural effusions of unknown causes admitted to Taipei Medical University        Hospital were included.|March 2011|March 28, 2011|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01325454||106810|
NCT01317953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTESCLC2011|Oral Green Tea Extract for Small Cell Lung Cancer|Phase ⅠStudy of Oral Green Tea Extract as Maintenance Therapy for Extensive-stage Small Cell Lung Cancer||Shandong Cancer Hospital and Institute|No|Recruiting|May 2011|August 2020|Anticipated|May 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||August 2015|December 8, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01317953||107385|
NCT01314014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36191|Imexon for Relapsed Follicular and Aggressive Lymphomas|A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults|ULYM11011|University of Rochester|Yes|Completed|May 2011|August 2014|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 10, 2011|Yes|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01314014||107683|
NCT01313988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10018V|Efficacy Study on the Lipid-lowering Effect of Plant Sterols and Fish Oil|Efficacy Study on the Lipid-lowering Effect of a Spread Enriched With the Recommended Dose of Plant Sterols and 3 Different Doses of Fatty Acids From Fish Oil||Unilever R&D|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|332|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||January 2012|February 5, 2012|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01313988||107685|
NCT01314235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clonidinstudy|Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel|The Influence of Clonidine on the Thrombozytes of Patients Under Double Anticagulation With ASS and Clopidogrel - an in Vitro Study||Goethe University||Recruiting|October 2010|||||N/A|Observational|Time Perspective: Prospective||1|||||Both|18 Years|N/A||Non-Probability Sample|patients going under vascular surgery with anticagulation with both ASS and clopidogrel|March 2011|March 11, 2011|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01314235||107666|
NCT01365962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST11B4|Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma|A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue||Children's Oncology Group|No|Active, not recruiting|June 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Diagnosis of rhabdomyosarcoma.|May 2015|May 8, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365962||103731|
NCT01366196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #27092|Pregabalin for the Treatment of Pain After Posterior Spinal Fusions|Pregabalin for the Treatment of Pain After Posterior Spinal Fusions.||Hospital for Special Surgery, New York|No|Completed|October 2008|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|21 Years|80 Years|No|||June 2011|July 23, 2012|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366196||103713|
NCT01366157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD11B1|Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma|Investigation to Evaluate the Levels of Human Germinal-center-Associated Lymphoma (HGAL) Protein in Pediatric Hodgkin Lymphoma and Correlate With Early Response||Children's Oncology Group|No|Active, not recruiting|May 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|23|Samples With DNA|Tissue|Both|N/A|21 Years|No|Non-Probability Sample|Diagnosed with low-risk classical Hodgkin lymphoma|May 2015|May 5, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366157||103716|
NCT01365975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911165|Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study|Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study||National Institutes of Health Clinical Center (CC)||Completed|May 2011|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1500|||Both|15 Years|60 Years|No|||January 2016|February 13, 2016|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365975||103730|
NCT01366794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|Macronutrients and Gut Hormone Secretion|Effects of Macronutrients on Gut Hormone and Islet Hormone Secretion in Healthy Volunteers and Type 2 Diabetes||Lund University|Yes|Completed|September 2011|September 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|36|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366794||103668|
NCT01366807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCR2011|Screening of Nutritional Status in Cardiac Surgery|Screening of Nutritional Status and Predictors of Adverse Outcome in Cardiac Surgery||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|January 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|894|Samples Without DNA|Serum, white cells|Both|18 Years|N/A|No|Probability Sample|Patients, who live in Russia, mostly in Siberia whom scheduled to cardiac surgery in one        institution.|March 2015|March 23, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366807||103667|
NCT01366820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-TBI-002|Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC|A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)|INTREPID2566|Neuren Pharmaceuticals Limited|Yes|Completed|February 2013|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|261|||Both|16 Years|75 Years|No|||March 2016|March 21, 2016|May 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366820||103666|
NCT01366833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MalignantDysphagia|Optimal Management of Malignant Dysphagia|Management of Malignant Dysphagia: Stent vs. Stent Plus Endoluminal Brachytherapy for the Palliation of Dysphagia in Metastatic Esophageal Cancer||McGill University Health Center|Yes|Not yet recruiting|June 2011|December 2013|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|72|||Both|18 Years|N/A|No|||June 2011|June 3, 2011|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366833||103665|
NCT01318096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-38154|Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients|A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients||Yunnan AIDS Care Center|No|Not yet recruiting|March 2011|September 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2011|March 17, 2011|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318096||107374|
NCT01323959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113060|Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults|Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination||GlaxoSmithKline||Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|212|||Both|25 Years|N/A|Accepts Healthy Volunteers|||November 2013|September 3, 2015|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01323959||106924|
NCT01323972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113398|Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children|Consistency of Immunogenicity and Non Inferiority of Three Production Lots of GSK Biologicals' Candidate Malaria Vaccine in Children||GlaxoSmithKline||Completed|May 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|327|||Both|5 Months|17 Months|Accepts Healthy Volunteers|||May 2012|May 24, 2012|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323972||106923|
NCT01314144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-CUH|Use of Continuous Wound Infusion of Bupivacaine for Analgesia Following Axillary Clearance Surgery|Does Continuous Wound Infusion of 0.2% Bupivacaine Provide Superior Analgesia Compared to Standard Opioid-based Therapy in Patients Following Axillary Clearance Surgery?||Cork University Hospital|No|Recruiting|August 2010|October 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||March 2011|March 11, 2011|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01314144||107673|
NCT01315821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1234|Effect of Saccharomyces Boulardii on Necrotizing Enterocolitis in Very Low Birth Weight Infants|Role Of Saccharomyces Boulardii in Preventin Necrotizing Enterocolitis in Very Low Birth Weight Infants||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|February 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Both|N/A|2 Months|No|||February 2011|August 4, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01315821||107547|
NCT01315834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC10psycho-cardioCTIL|Couples Coping With Coronary Heart Disease|The Contribution of Personality Traits to Marital Satisfaction, Well Being and Physical Health in Couples Coping With Coronary Heart Disease Versus a Control Group|psychocardio|Meir Medical Center|No|Recruiting|April 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Paitents hospitalized Meir Medical Center Cardiac Care Unite|March 2012|March 16, 2012|January 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315834||107546|
NCT01316731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33968.081.10|MyoGene: Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle|Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle||Wageningen University|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 20, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01316731||107478|
NCT01317004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DIT02|Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change|A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)|EPOC|Novartis||Completed|May 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||June 2015|June 18, 2015|March 15, 2011||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01317004||107457|
NCT01317329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL094760|"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"|"Reversibility of Cardiovascular Injury With Continuous Positive Airway Pressure (CPAP) Use: Mechanisms Involved"||University of Wisconsin, Madison|Yes|Completed|March 2011|December 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|21 Years|50 Years|No|||September 2015|September 29, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01317329||107433|
NCT01318200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCH001.0|Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)|International Randomized Study of Transarterial Chemoembolization Versus CyberKnife® for Recurrent Hepatocellular Carcinoma||Accuray Incorporated|Yes|Withdrawn|February 2011|February 2016|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01318200||107366|
NCT01314027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOPAC|Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer|Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)||University of Zurich|Yes|Recruiting|September 2009|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|18 Years|N/A|No|||March 2011|March 10, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01314027||107682|
NCT01314001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811722|Pharmacogenetics of Nicotine Addiction Treatment|Pharmacogenetics of Nicotine Addiction Treatment (PNAT)||University of Pennsylvania|Yes|Completed|December 2010|September 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|1246|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|March 10, 2011|Yes|Yes||No|January 4, 2016|https://clinicaltrials.gov/show/NCT01314001||107684|A limitation is that few Hispanics or Asians were included.
NCT01314248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|laryngeal mask airway & air Q|The Laryngeal Mask Airway (LMA) Unique and the Air-Q Intubating Laryngeal Airway (ILA) in Pediatric Patients|A Randomized Crossover Comparison Between the Air-Q Intubating Laryngeal Airway the Laryngeal Mask Airway-Unique in Children||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|50|||Both|6 Months|36 Months|Accepts Healthy Volunteers|Probability Sample|Healthy children undergoing general anesthesia for their scheduled elective outpatient        surgeries using a supraglottic airway device for airway maintenance.|July 2013|July 29, 2013|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01314248||107665|
NCT01366209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPF-016|Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)|ASCEND|Genentech, Inc.|Yes|Completed|June 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|555|||Both|40 Years|80 Years|No|||May 2015|May 7, 2015|June 2, 2011|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01366209||103712|
NCT01366170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANHL11B1|Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma|Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)||Children's Oncology Group|No|Active, not recruiting|May 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7|||Both|N/A|20 Years|No|Non-Probability Sample|Diagnosis of anaplastic large cell lymphoma.|May 2015|May 8, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366170||103715|
NCT01366508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112336|A Study to Characterize Event Related Potential Markers of Attentional Bias Towards Words and Images of Food|An Experimental Medicine Study to Characterize Event Related Potential Markers of Attentional Bias Towards Words and Images of Food in Healthy Volunteers||GlaxoSmithKline|No|Terminated|October 2009|October 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|5|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|April 14, 2011||No|Results of the study would unfortunately no longer be of any scientific interest to the    sponsor and would not be used to inform future studies.|No||https://clinicaltrials.gov/show/NCT01366508||103689|
NCT01366534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114460|Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults|Safety, Immunogenicity and Efficacy Against Malaria in the Sporozoite Challenge Model of One Dose of Ad35.CS.01 Malaria Vaccine Followed by Two Doses of Malaria 257049 Vaccine in Healthy Malaria-naïve Adults||GlaxoSmithKline||Completed|August 2011|July 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|68|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|September 3, 2015|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366534||103687|
NCT01366547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114581|Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets|A Randomized, Open-Label, Single‑Dose, 3‑Period, Crossover Evaluation of the Relative Bioavailability of Two Experimental Fixed-Dose Combination Tablet Formulations of Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared to Co‑Administered Dolutegravir 50 mg and EPZICOM™ (Abacavir 600 mg/Lamivudine 300 mg) Tablets in Healthy Adult Subjects||ViiV Healthcare|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|May 26, 2011|No|Yes||||https://clinicaltrials.gov/show/NCT01366547||103686|
NCT01366846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN049AD|Persistence of Oral Tolerance to Peanut|The Persistence of Oral Tolerance Induction to Peanut and Its Immunological Basis (ITN049AD)|LEAP-On|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|558|||Both|5 Years|5 Years|No|||March 2016|March 8, 2016|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366846||103664|
NCT01317537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS017234|Using an Electronic Personal Health Record to Empower Patients With Hypertension|Using an Electronic Personal Health Record to Empower Patients With Hypertension||Georgia Regents University|Yes|Completed|September 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator)|2||Actual|445|||Both|21 Years|80 Years|No|||March 2011|March 16, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01317537||107417|
NCT01317550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0872|A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil|A Pilot Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Completed|July 2011|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01317550||107416|
NCT01323712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHF PG/10/71/28462|Vitamin D Supplementation and Cardiac Hypertrophy in Chronic Kidney Disease (CKD)|Impact of Vitamin D Supplementation on Cardiac Hypertrophy and Function in Chronic Kidney Disease Patients - a Randomised Controlled Trial|5C|St George's, University of London|Yes|Active, not recruiting|March 2011|May 2014|Anticipated|March 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||December 2013|December 6, 2013|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01323712||106943|
NCT01324245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003-142|Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet|Paracrine Regulation of Renal Function by Dopamine in Normotensive Humans|Salt|Georgetown University|Yes|Completed|November 2002|May 2006|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|1||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2003|March 25, 2011|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01324245||106903|
NCT01323985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113776|SAP Depleter Dose Escalation Study in Healthy Volunteers|A Phase 1 Dose Escalation Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Intravenous Doses of GSK2315698A in Healthy Volunteers||GlaxoSmithKline|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 26, 2011|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323985||106922|
NCT01316146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC-1544-ATL|Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)|Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CART CD30)||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|December 2011|December 2032|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|N/A|No|||February 2016|February 10, 2016|March 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316146||107522|
NCT01316159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDICTION|Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology|Prediction of Progression of Coronary Artery Disease and Clinical Outcome Using Vascular Profiling of Shear Stress and Wall Morphology|PREDICTION|Brigham and Women's Hospital|Yes|Active, not recruiting|April 2007|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|506|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with coronary artery disease who present with an acute coronary syndrome and        require cardiac catheterization and percutaneous coronary intervention|March 2011|March 15, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316159||107521|
NCT01316172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Consult 1|Consultation in the Emergency Department|A Prospective, Randomized Controlled Study Demonstrating a Novel, Effective Model of Communication Among Physicians: The 5 Cs of Consultation|5 Cs|University of Illinois at Chicago|No|Completed|May 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|43|||Both|N/A|N/A||||March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316172||107520|
NCT01316744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000696704|Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain|A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients||National Cancer Institute (NCI)||Recruiting|April 2009|||October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care|1||Anticipated|214|||Both|18 Years|N/A|No|||March 2011|May 12, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316744||107477|
NCT01317030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROC2-10-110|Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers|Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers Using a Schirmer Strip for Tear Collection||Bausch & Lomb Incorporated|No|Completed|February 2011|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 15, 2013|March 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01317030||107455|
NCT01317017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLO-0717|Cell Responses to IFN-gamma|Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients||Rockefeller University|No|Terminated|July 2010|May 2011|Actual|May 2011|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 4, 2013|March 10, 2011||No|Unable to isolate sufficient cells from the skin biopsy to perform study experiments.|No||https://clinicaltrials.gov/show/NCT01317017||107456|
NCT01317342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0079|Hypothermic Oxygenated Perfusion (HOPE) of Human Liver Grafts|A Double Blinded Randomized Study on the Effects of Hypothermic Oxygenated Perfusion (HOPE) on Human Liver Grafts Before Transplantation||University of Zurich|Yes|Recruiting|September 2011|September 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|90 Years|No|||September 2011|September 23, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01317342||107432|
NCT01317979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSIRB2011003|Asian Diabetes Surgery Study (ADSS): Clinical Predictor for the Success of Metabolic Surgery|Asian Diabetes Surgery Study:A Multi-institutes Prospective Study Clinical Predictor for the Successful Treatment of Type 2 Diabetes After Metabolic Surgery|ADSS|Min-Sheng General Hospital|Yes|Recruiting|January 2011|December 2013|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Serum stored at a -85 ℃ refrigerator|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|1. Age between 18 to 65.          2. Type 2 DM > 6 months, HbA1C>7.0% under treatment          3. Body mass index >25 kg/m2          4. could follow up|March 2011|March 17, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01317979||107383|
NCT01314040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1003/ WP-B1|Study to Identify Biomarkers for Protein Intake|Study to Identify Biomarkers for Protein Intake; a Randomized, Fully Controlled Feeding Study|Biomarker|Wageningen University|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 30, 2011|February 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01314040||107681|
NCT01314261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-114|Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects|A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection||AbbVie|No|Completed|March 2011|February 2013|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|37|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|March 11, 2011|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01314261||107664|
NCT01314560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071008|Study of the Pathophysiological Mechanisms Involved in Bleeding Events|Study of the Pathophysiological Mechanisms Involved in Bleeding Events Observed in Patients With Lowe Syndrome|LOWE|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2009|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Male|6 Years|45 Years|Accepts Healthy Volunteers|||March 2011|September 16, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314560||107642|
NCT01366521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114092|Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils|A Multicenter, Open-label, Dose Ranging Study to Determine the Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Intravenously or Subcutaneously to Adult Asthmatic Subjects With Elevated Blood Eosinophil Levels||GlaxoSmithKline|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|70|||Both|18 Years|65 Years|No|||November 2015|January 14, 2016|May 12, 2011|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT01366521||103688|
NCT01366560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114639|Effect of GSK962040 on Oesophageal Function|A Double Blind Randomised Placebo Controlled Two Way Cross Over Study to Determine the Effect of GSK962040 on Oesophageal Function and Gastric Emptying in Healthy Male Volunteers.||GlaxoSmithKline|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|||Actual|14|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|February 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01366560||103685|
NCT01363024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFG4991g|Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors|An Open-Label, Multicenter, Phase I Dose-Escalation Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors||Genentech, Inc.||Completed|August 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363024||103954|
NCT01363037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-013/IPM 026|Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring|Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring||International Partnership for Microbicides, Inc.|Yes|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|48|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363037||103953|
NCT01363050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2005-03|Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers|A Phase 1, Open Label, Multiple Dose Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers||Luitpold Pharmaceuticals|No|Completed|January 2006|September 2006|Actual|February 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|May 27, 2011|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01363050||103952|
NCT01323387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1255|Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer|Lumbar Degenerative Disc Disease Treated With|ATB|Synthes USA HQ, Inc.|No|Completed|April 2004|February 2011|Actual|May 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 1, 2011|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01323387||106968|
NCT01323400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAZOGIST|Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)|A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib|PAZOGIST|Centre Leon Berard|No|Completed|March 2011|February 2016|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|90 Years|No|||February 2016|February 24, 2016|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01323400||106967|
NCT01323413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0080-11CTIL|Determinants of Penumbra in Acute Ischemic Stroke Patients|Determinants of Penumbra in Acute Ischemic Stroke Patients||Rambam Health Care Campus|No|Recruiting|April 2011|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|neurological ward|May 2014|May 1, 2014|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01323413||106966|
NCT01324284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-GI2011-01|Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy|Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation to Enhance the Colonoscopy Preparation Quality in an Indian Tertiary Care Center.|Lubiprostone|Asian Institute of Gastroenterology, India|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|442|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|March 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01324284||106900|
NCT01315275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DFR08|A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema|An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice|LUDIC|Novartis||Completed|February 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|394|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315275||107588|
NCT01315288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACSCDM-1|A Randomized Trial of Clinical Decision Making in Asymptomatic Carotid Stenosis|A Randomized Trial of Clinical Decision Making in Asymptomatic Carotid Stenosis||Henry Ford Health System|No|Completed|October 2008|August 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|409|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2011|March 14, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315288||107587|
NCT01323998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114462|Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan|Evaluating the Treatment Patterns in Men With Benign Prostatic Hypertrophy (Marketscan Database Study)||GlaxoSmithKline|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|35032|||Male|50 Years|N/A|No|Non-Probability Sample|Male patients aged 50 years or older with a diagnostic claim for BPH and at least one        prescription claim for a 5ARI or AB in the enrollment period|August 2011|February 16, 2012|March 24, 2011||No||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01323998||106921|
NCT01316445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3704|Pharmacodynamics of Nasal and Buccal Midazolam Using EEG|Comparing the Pharmacodynamics of Nasal and Buccal Midazolam Using EEG|nMDZ-EEG|Columbia University|No|Terminated|July 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|March 15, 2011|No|Yes|Funding agency no longer provide support.|No||https://clinicaltrials.gov/show/NCT01316445||107499|
NCT01316458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BDE15|Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy|An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy||Novartis||Completed|June 2003|||July 2010|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Male|18 Years|N/A|No|||March 2011|November 13, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316458||107498|
NCT01316757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-HN-027|Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer|Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.||Fox Chase Cancer Center|Yes|Active, not recruiting|February 2011|||March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316757||107476|
NCT01316770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110094|Dexamethasone Irrigation of the Parotid Glands in Primary Sj(SqrRoot)(Delta)Gren s Syndrome Subjects|A Randomized Within-Subject, Double-Blind, Placebo-Controlled Study of Dexamethasone Irrigation of the Parotid Glands in Primary Sj(SqrRoot)(Delta)Gren's Syndrome Subjects||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|14|||Female|18 Years|N/A|No|||May 2015|June 24, 2015|March 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316770||107475|
NCT01317043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0622|A Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy|A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy|0622|Sentara Norfolk General Hospital|Yes|Recruiting|July 2007|||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|76|||Male|18 Years|89 Years|Accepts Healthy Volunteers|||March 2011|March 16, 2011|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317043||107454|
NCT01317082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDL20-11|Use of the Pressure Right Device After Laparoscopic Surgery|||Therapeutics: 101 Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|80 Years||||February 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317082||107452|
NCT01317355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProKID|Multiple Symptoms in Cancer Patients a Cross Sectional Multi Center Study|Prevalence of Multiple Symptoms in Cancer Patients a Cross Sectional Prospective Multi Center Study|ProKID|Martin-Luther-Universität Halle-Wittenberg|No|Completed|June 2010|June 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|697|||Both|18 Years|80 Years|No|Probability Sample|in and out cancer patients of 5 German university hospitals currently undergoing cancer        treatment|September 2012|September 26, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317355||107431|
NCT01317628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201009040R|Effects of Tobacco Smoke Exposure on Epigenetic Signatures and Immunotoxicological Reactions|Effects of Tobacco Smoke Exposure on Epigenetic Signatures and Immunotoxicological Reactions||National Taiwan University Hospital|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01317628||107410|
NCT01314872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4618-008|A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM3 EXT1[AM2])|A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder||Merck Sharp & Dohme Corp.|Yes|Completed|March 2011|October 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|1307|||Both|18 Years|75 Years|No|||August 2015|August 4, 2015|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01314872||107619|
NCT01314885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9111003|Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers|Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Effects Of Single Inhaled Doses Of PF-03715455 (20 Mg) And PH-797804 (30 Mg) On Induced Sputum Neutrophils Following Inhaled Lipopolysaccharide (LPS) Challenge In Healthy Volunteers||Pfizer|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|39|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 1, 2012|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01314885||107618|
NCT01314274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bevacizumab HHT|Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia||Medical University of Vienna||Completed|March 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|No|||August 2013|August 8, 2013|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01314274||107663|
NCT01314573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOSCI-10-007|The Impact of High Intensity Exercise Upon EPC Number and Function in Young Women|The Impact of High Intensity Exercise Upon EPC Number and Function in Young Women||University of Leeds|Yes|Not yet recruiting|March 2011|November 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|12|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||March 2011|March 11, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314573||107641|
NCT01314833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BC Adjuvant CT1|Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients|A Randomized Prospective Open Multicentric Phase III Clinical Trial Compared TC, FEC100 Followed by Docetaxel and EC90 Followed by Paclitaxel as Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients||Fudan University|Yes|Active, not recruiting|June 2010|December 2018|Anticipated|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|3200|||Female|40 Years|65 Years|No|||July 2010|March 14, 2011|March 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01314833||107622|
NCT01365988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911468|Neutral Correlates of Risk-taking in Adolescents Exposed to Drugs Prenatally|Neural Correlates of Risk-Taking in Urban Adolescents||National Institutes of Health Clinical Center (CC)||Completed|May 2011|February 2013||||N/A|Observational|N/A|||Anticipated|70|||Both|14 Years|20 Years|Accepts Healthy Volunteers|||February 2013|August 20, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365988||103729|
NCT01366001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33BUP-101|ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine|A Phase 1, Multiple-dose, Parallel Group Study to Evaluate the Safety and Pharmacodynamic Effects of RDC-0313-buprenorphine (ALKS 33-BUP) Administered Alone and Co-administered With Cocaine to Opioid-experienced Cocaine Abusers||Alkermes, Inc.|Yes|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|33|||Both|21 Years|50 Years|No|||March 2012|March 8, 2012|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366001||103728|
NCT01366222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS-IRB02- 07022|Food Concentrates Supplementation to Alleviate Asthma in Children|Food Concentrates Supplementation to Alleviate Asthma in Children|FSAC|Academia Sinica, Taiwan|No|Completed|November 2007|February 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|10 Years|12 Years|No|||June 2011|June 2, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01366222||103711|
NCT01367093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10029|French and EuRopean Outcome Registry in Intensive Care Unit|French and EuRopean Outcome Registry in Intensive Care Unit|FROG-ICU|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2137|Samples Without DNA|Plasma and urine at admission and ICU discharge|Both|18 Years|N/A|No|Probability Sample|ICU patients admitted for severe illness those who are at risk of death in the year        following the discharge from ICU.|May 2015|June 1, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01367093||103645|
NCT01367106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081209|Effects of "in UTERO" Exposure to Glucocorticoids|Study of the Effects in Carbohydrate Metabolism and Renal Function of "in UTERO" Exposure to Glucocorticoids in Adult Offsprings (GLUCODEX)|GLUCODEX|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|46|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01367106||103644|
NCT01366885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-AS-11-1-11|Vitamin D to Prevent Autism in Newborn Siblings|Study of Vitamin D to Prevent Autism in Newborn Siblings||Oregon Health and Science University|Yes|Not yet recruiting|December 2011|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Female|20 Years|44 Years|No|||May 2011|June 2, 2015|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366885||103661|
NCT01324011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1449|Family PALS (PArtners in Lifestyle Support)|Family Diabetes Study (Family PALS (PArtners in Lifestyle Support)|PALS|University of North Carolina, Chapel Hill|Yes|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01324011||106920|
NCT01315574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007H|Effects of Anti-Glaucoma Medications on the Ocular Surface|In Vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells, Epithelium, and Nerves of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study|BAK|Massachusetts Eye and Ear Infirmary|No|Recruiting|February 2011|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315574||107565|
NCT01315561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSR-2011-01|Motion Style Acupuncture Treatment for Low Back Pain With Severe Disability|Motion Style Acupuncture Treatment for Low Back Pain With Severe Disability: a Randomised, Controlled, Trial Protocol|MSAT|Jaseng Hospital of Korean Medicine|Yes|Completed|April 2011|April 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|20 Years|60 Years|No|||October 2012|October 3, 2012|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315561||107566|
NCT01316471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD062538-01A1|Internet Intervention for Adolescents With Chronic Pain|Web-MAP 2: Internet Intervention for Adolescents With Chronic Pain||Seattle Children's Hospital|Yes|Completed|May 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|11 Years|17 Years|No|||May 2015|November 30, 2015|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01316471||107497|
NCT01317069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sinofuan201101|A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer|A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer||Simcere Pharmaceutical Co., Ltd|No|Recruiting|June 2010|April 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317069||107453|
NCT01317095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sternal Closure|A Study of Sternal Closure After Open Heart Surgery: Rigid Versus Wire Closure|A Prospective Randomized Study of Two Types of Sternal Closure After Open Heart Surgery: Rigid Sternal Fixation vs. Sternal Wire Closure||Thomas Jefferson University|Yes|Recruiting|March 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|79 Years|No|||December 2015|December 1, 2015|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01317095||107451|
NCT01317368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-AS-2010|The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Following Radical Prostatectomy|The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Versus Wound Infiltration Versus Placebo Following Open Radical Prostatectomy, a Double Blinded, Randomized Clinical Trial||Rigshospitalet, Denmark|Yes|Completed|March 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|75|||Male|18 Years|80 Years|No|||June 2012|June 19, 2012|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01317368||107430|
NCT01317641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3104001|Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer|Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component||Orion Corporation, Orion Pharma|Yes|Completed|March 2011|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|136|||Male|18 Years|N/A|No|||October 2014|October 20, 2014|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01317641||107409|
NCT01317654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES|Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone|Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone|ES|Oxford University Clinical Research Unit, Vietnam|No|Completed|April 2006|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|340|||Both|1 Year|90 Years|No|Non-Probability Sample|Survivors of TBM trial 2001-2005|September 2011|September 14, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317654||107408|
NCT01318213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARHQ ACTION TO #5|Benefits of Universal Glove and Gowning|Effect of the Use of Universal Glove and Gowning on Healthcare Associated Infection Rates and Antibiotic Resistant Bacteria|BUGG|Yale New Haven Health System Center for Healthcare Solutions|Yes|Active, not recruiting|December 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|2|Samples Without DNA|Nasal and peri-rectal culture samples will be banked in the research laboratory of Dr. J.      Kristie Johnson at the University of Maryland, School of Medicine. The samples will be      labeled with a participant ID without any personal identifiers. The entire sample will not      be used for this study. The remaining samples will be used for future research to answer any      infection control questions that arise about infection control in intensive care units that      may be answered with these samples. The remaining samples will be frozen and stored      indefinitely. The freezing method that will allow the study of other bacteria has been      validated. Depending upon the results, there may be some rationale for thawing the samples      and processing them for other antibiotic-resistant bacteria|Both|18 Years|N/A|No|Probability Sample|Adult patients in medical, surgical or combined medical/surgical ICUs.|January 2012|January 3, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01318213||107365|
NCT01318226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-1001|Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Multicenter, Parallel Group Study to Evaluate the Safety and Analgesic Activity of ATx08-001 When Administered to Subjects With Postherpetic Neuralgia||Aestus Therapeutics|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|85 Years|No|||August 2011|August 19, 2011|March 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01318226||107364|
NCT01315145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MiDAS III|MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS III|Vertos Medical, Inc.|Yes|Completed|March 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|50 Years|N/A|No|||August 2015|August 19, 2015|March 11, 2011|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01315145||107598|
NCT01315418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU201|Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation|Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation||Danone Research|No|Terminated|December 2006|||||N/A|Interventional|Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Basic Science|2||||||Both|18 Years|29 Years|Accepts Healthy Volunteers|||May 2011|May 3, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315418||107577|
NCT01315431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOST107|A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors|A Phase I Study of Tesetaxel Administered in Combination With Capecitabine to Subjects With Solid Tumors||Genta Incorporated|No|Active, not recruiting|March 2011|October 2012|Anticipated|August 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|March 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01315431||107576|
NCT01314287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN10/9556|Effect of Coughing on Oxygenation in the Post Anaesthetic Care Unit|Observational Study of the Effect of Coughing on Emergence From Anaesthesia on Oxygenation in the Postanaesthetic Care Unit||NHS Research and Development|Yes|Completed|January 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study subjects will be adult patients undergoing routine operations which are expected        to last longer than 45 minutes.|April 2014|April 10, 2014|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314287||107662|
NCT01314586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADM Beneflax ISU-1|Flax Lignans and Heart Health|Iowa State Study on Flax Lignans and Heart Health|ISULignan|Iowa State University|No|Completed|December 2007|November 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|93|||Both|40 Years|65 Years|No|||March 2011|March 11, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01314586||107640|
NCT01314599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-002-10|Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome|Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.||PharmaMar|No|Completed|May 2011|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|18 Years|N/A|No|||July 2015|November 4, 2015|March 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01314599||107639|
NCT01366014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-797-223|A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee|||Array BioPharma|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|157|||Both|40 Years|85 Years|No|||June 2013|June 6, 2013|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366014||103727|
NCT01366235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0214|Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug|Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug||Asan Medical Center||Completed|May 2011|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||May 2011|January 23, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366235||103710|
NCT01366872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAM-LP-2010|Agility LP Ankle Arthroplasty Outcomes|Agility LP Ankle Arthroplasty: Clinical and Radiographic Outcomes||Orthopaedic Associates of Michigan, PC|No|Completed|December 2010|September 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female and male subjects over the age of 18 at the time of procedure who have undergone        ankle joint replacement using the DePuy Agility LP Device.|November 2012|November 20, 2012|June 2, 2011||No||No|October 16, 2012|https://clinicaltrials.gov/show/NCT01366872||103662|
NCT01366586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SDU-QILU-G02|Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag|Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7 Antigen||Shandong University|Yes|Completed|May 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|5|Samples With DNA|Taken biopsies during endoscopy|Both|18 Years|80 Years|No|Non-Probability Sample|patients with endoscopically diagnosed gastric cancer|December 2011|December 27, 2011|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366586||103683|
NCT01367132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedStar 2010-450|Assessment of the Number of Umbilical Cord Vessels at the Time of Nuchal Translucency Screening|Assessment of the Number of Umbilical Cord Vessels at the Time of Nuchal Translucency Screening||Medstar Research Institute|No|Completed|February 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|123|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing nuchal transluscency screening during 11-13+6 weeks gestation,        followed by anatomy scan at 18-24 weeks gestation.|February 2013|February 20, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01367132||103642|
NCT01363076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2006-02|The Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years|A Study of the Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years||Luitpold Pharmaceuticals||Completed|June 2007|May 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|17 Years|No|||August 2012|August 20, 2012|May 27, 2011|Yes|Yes||No|March 8, 2012|https://clinicaltrials.gov/show/NCT01363076||103950|
NCT01315301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWE-2007-270|Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis|Randomized Clinical Trial to Determine the Most Appropriate Time to Start HIV Treatment in HIV & TB Coinfected Adults Being Treated for Tuberculosis.|TB-HAART|Karolinska Institutet|Yes|Recruiting|August 2008|March 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|450|||Both|18 Years|65 Years|No|||March 2011|March 14, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315301||107586|
NCT01316185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-HDV 01-921-01|Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)|An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)||Eiger BioPharmaceuticals|No|Recruiting|January 2011|May 2011|Anticipated|April 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|18 Years|N/A|No|||March 2011|March 14, 2011|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316185||107519|
NCT01316198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioPlant-LZ-AMD2011|Effects of Xanthophylls on Optical Density|Alteration of Optical Density and Plasma Xanthophylls After Short Term Supplementation With Macular Carotenoids in Patients With AMD||University of Jena|Yes|Completed|June 2010|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|N/A|N/A|No|||July 2012|July 26, 2012|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316198||107518|
NCT01315847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-067|Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)|A Three-Part Positron Emission Tomography Study of Brain CGRP Receptor Occupancy Levels Following Administration of MK-0974, Using [11C]MK-4232 as an Imaging Agent||Merck Sharp & Dohme Corp.|No|Completed|January 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|February 22, 2011|No|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01315847||107545|
NCT01316211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06k004|Clinical Trial Comparing Decompression With and Without Coflex™ Interlaminar Technology Treating Lumbar Spinal Stenosis|Comparative Evaluation of Clinical Outcome in the Treatment of Degenerative Spinal Stenosis With Concomitant Low Back Pain by Decompression With and Without Additional Stabilization Using the Coflex™ Interlaminar Technology||Paradigm Spine|No|Active, not recruiting|January 2008|March 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|N/A|N/A|No|||October 2014|October 29, 2014|March 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316211||107517|
NCT01316523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#224|Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma|Phase II Study of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non Hodgkin's Lymphoma||University of California, Davis|Yes|Recruiting|December 2010|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|February 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316523||107493|
NCT01317108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChemoN0|Prognostic and Predictive Impact of uPA/PAI-1|Adjuvant Chemotherapy in Node-negative Breast Cancer: Chemo N0|Chemo N0|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|June 1993|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|689|||Female|18 Years|65 Years|No|||March 2011|March 15, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01317108||107450|
NCT01317121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroSFB-PV3632|Multi-site Communication Deficits in Schizophrenia|Multi-site Communication Deficits Underlying Cognitive Dysfunction in the Prodromal Phase and First Episode of Schizophrenia||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|July 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|144|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Three groups of subjects will be included: patients with a first episode of schizophrenia,        subjects at increased risk for schizophrenia, and healthy control subjects.|June 2015|June 2, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317121||107449|
NCT01317381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.0. 08.12.2|ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill|ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill|(Greenpep)|University of Zurich||Recruiting|May 2010|May 2011||||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Admitted ICU Patients|August 2010|March 15, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01317381||107429|
NCT01317394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99078|Study and Analysis of Micafungin for Non-albican Candidemia: Efficacy, Risk Factor and Clinical Manifestation|Retrospective Study and Analysis of Micafungin for Non-albican Candidemia: Efficacy, Risk Factor and Clinical Manifestation||Taipei Medical University WanFang Hospital|No|Completed|December 2010|February 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|60|||Both|20 Years|N/A|No|Non-Probability Sample|non-albicans candidemia patients|March 2011|March 16, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317394||107428|
NCT01317667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-10-0002, FY09-03, A-16390|Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)|Phase 1 Escalating, Multiple-Dose Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Healthy Adults||U.S. Army Medical Research and Materiel Command|No|Completed|March 2011|December 2014|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|March 9, 2011|No|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT01317667||107407|
NCT01317680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0037-11-RMB|Low Intensity Shock Wave Therapy (LI-ESWT) for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors (LI-ESWT)|Low Intensity Shock Wave Therapy for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors- a Double Blind Placebo Controlled Study (LI-ESWT)|LI-ESWT|Rambam Health Care Campus|No|Recruiting|March 2011|December 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|80 Years|No|||May 2012|May 23, 2012|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01317680||107406|
NCT01317966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-001|Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia|A Multicentre Investigation of Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)|Incritop|Shandong University|No|Recruiting|March 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|199|||Both|16 Years|75 Years|No|Non-Probability Sample|100|November 2011|November 1, 2011|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01317966||107384|
NCT01314612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28115|Initial Study of Insomnia/Nightmare Group Treatment for Posttraumatic Stress Disorder (PTSD)|An Investigation Of The Effectiveness of a Cognitive Behavioral Group Treatment Addressing Insomnia and Nightmares In Veterans With PTSD||Michael Debakey Veterans Affairs Medical Center|Yes|Enrolling by invitation|March 2011|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2011|March 16, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01314612||107638|
NCT01315730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMO-0001|The Effects of Tactile Speech Feedback on Stuttering Frequency|The Effects of Tactile Speech Feedback on Stuttering Frequency||University of Mississippi, Oxford|No|Withdrawn|March 2011|||||Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 9, 2014|March 11, 2011|No|Yes|Patent being pursued prior to trial initiation|No||https://clinicaltrials.gov/show/NCT01315730||107554|
NCT01315743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jjj|Team COOL Pilot Study|Team COOL Pilot Study|Team COOL|University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 2007|March 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|50|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315743||107553|
NCT01315119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRS0005|SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants|The Role of SPY Intra-Operative Angiography in Determining Adequate Skin Perfusion in Immediate Breast Reconstruction With Implants||Stanford University|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|No|Non-Probability Sample|The patient population includes women with unilateral or bilateral breast cancer        undergoing immediate or delayed breast reconstruction.|December 2014|December 18, 2014|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315119||107600|
NCT01315405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0090|Facial Expression Recognition and Mirror Neurons in Parkinson's Disease|Do Facial Expression Recognition Disorder and Mirror Neurons Subtend Apathy in Parkinson's Disease?||University Hospital, Clermont-Ferrand||Recruiting|July 2010|July 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2011|March 15, 2011|February 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01315405||107578|
NCT01366573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115256|GSK1521498 Alcohol Interaction Study|A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects||GlaxoSmithKline|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|1|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01366573||103684|
NCT01366859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01291001F|Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior|Nutritional Intervention Using Supplementation With Cysteine-Rich Whey Protein Isolate (Immunocal®) in Children With Autism: Effects in Core Areas of Behavior- A Randomized Double-Blind Study||Nova Southeastern University|No|Recruiting|May 2011|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|60|||Both|3 Years|5 Years|No|||March 2016|March 21, 2016|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366859||103663|
NCT01366261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endo-0001|Rigid Versus Semirigid Thoracoscopy in Diagnosing Pleural Diseases: a Randomized Study|Rigid Versus Semirigid Thoracoscopy in Diagnosing Pleural Diseases: a Randomized Study||The University Clinic of Pulmonary and Allergic Diseases Golnik|Yes|Completed|January 2008|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|84|||Both|18 Years|N/A|No|||November 2011|November 9, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366261||103708|
NCT01366274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH1|Protective Manual Hyperinflation in Acute Mechanically Ventilated Trauma Patients|Comparison of Protective Manual Hyperinflation With Current Methods in Ventilated Acute Trauma Patients: a Randomized Controlled Trial||The University of Queensland|No|Active, not recruiting|September 2007|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2010|June 3, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366274||103707|
NCT01367145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMACOR II - 2011|OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease|OMEGA-3-POLYUNSATURATED FATTY-ACIDS (n3-PUFA) IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: EFFECTS ON ENDOTHELIAL FUNCTION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL||Medical University of Vienna|Yes|Completed|January 2011|March 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|71|||Both|18 Years|N/A|No|||August 2014|August 24, 2014|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01367145||103641|
NCT01367158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V102_02E1|Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines|Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY in Adolescents Who Previously Received the Same Study Vaccines||Novartis|No|Completed|July 2011|July 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|11||Actual|440|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|June 3, 2011||No||No|February 11, 2014|https://clinicaltrials.gov/show/NCT01367158||103640|
NCT01367171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102901|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2010|||||N/A|N/A|N/A||||||||||||||October 29, 2015|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367171||103639|
NCT01363089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2006-03|Study to Assess the Pharmacokinetics of Ketorolac Tromethamine and to Assess the Effects of a Oxymetazoline Hydrochloride on the Pharmacokinetics of Ketorolac Tromethamine|Open Label, Two-Way Crossover Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride on the Pharmacokinetics of Intranasal Ketorolac Tromethamine in Healthy Male Subjects||Luitpold Pharmaceuticals||Completed|January 2007|February 2008|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|62 Years|Accepts Healthy Volunteers|||May 2011|May 27, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363089||103949|
NCT01363323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1106|Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization|A Randomized, Double-Blind, Placebo/Positive Controlled, Evaluation of the Effects of MNTX on ECG Parameters and Cardiac Repolarization in Normal Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|November 2004|February 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|546|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363323||103932|
NCT01315860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01111110Exp.|Association of Biomechanical Changes and Weight Gain Throughout Pregnancy|Association of Biomechanical Changes and Weight Gain Throughout Pregnancy||Nova Southeastern University|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant females in their second or third trimester.|June 2012|June 17, 2012|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01315860||107544|
NCT01315873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU# 10-02009|Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma|Phase II Trial of Bortezomib and Bendamustine in the Treatment of Relapsed/Refractory Myeloma||New York University School of Medicine|Yes|Completed|September 2011|September 2015|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01315873||107543|
NCT01316484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-QM-001|Patient Understanding (Cognitive Debriefing) of a Daily Diary of Gastroparesis Symptoms|Protocol for the Patient Understanding (Cognitive Debriefing) of a Modified Gastroparesis Cardinal Symptom Index (GCSI) Daily Diary||Tranzyme, Inc.|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|70 Years|No|Non-Probability Sample|Hospital/Clinic Database|May 2011|May 23, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316484||107496|
NCT01316497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080052|Acute Kidney Injury in Children Operated for Congenital Heart Disease|Acute Kidney Injury in Children Operated for Congenital Heart Disease||University of Aarhus|No|Completed|July 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|N/A|15 Years|No|||September 2012|September 13, 2012|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01316497||107495|
NCT01317134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNEU-PV3334/2009/UKE|Endothelial Function in Patients With Pulmonary Arterial Hypertension|Serological and Non-invasive Evaluation of Endothelial Function in Patients With Pulmonary Arterial Hypertension||Universitätsklinikum Hamburg-Eppendorf|No|Active, not recruiting|July 2010|July 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01317134||107448|
NCT01316783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110110|Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations|Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|March 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|201|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316783||107474|
NCT01316796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110121|Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders|A Phase I Study of the Use of Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Hemolytic Disorders||National Institutes of Health Clinical Center (CC)||Completed|March 2011|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|99 Years|No|||November 2015|November 17, 2015|March 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316796||107473|
NCT01316809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110122|AZD8055 for Adults With Recurrent Gliomas|Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults With Recurrent Gliomas||National Institutes of Health Clinical Center (CC)||Completed|March 2011|April 2014|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|99 Years|No|||June 2015|December 16, 2015|March 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01316809||107472|
NCT01316822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-382-101|A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers|||Array BioPharma||Completed|March 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|December 1, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01316822||107471|
NCT01317732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.617|MOTIONPOD (TM) Validation and Calibration Study|Calibration and Validation of MOTIONPOD(TM) for Physical Activity Evaluation in Free-living Adults|MOTIONPOD(TM)|Hospices Civils de Lyon|No|Completed|October 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|128|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317732||107402|
NCT01317407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKKarlsruhe-VIPSafe|Automated Visual Monitoring for Improving Patient Safety (VIPSafe)|Automatisierte Optische Überwachung Mittels Videosensorik Zur Verbesserung Der Patientensicherheit Auf Intensivstation (Automated Visual Monitoring for Improving Patient Safety (VIPSafe))|VIPSafe|Staedtisches Klinikum Karlsruhe|No|Not yet recruiting|April 2011|||December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with a planned or not-planned stay at the intensive care unit after an operation|March 2011|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317407||107427|
NCT01317420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1280.2|Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types|A Phase I Dose Escalation Trial of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours During Escalation and Weekly in Selected Tumour Types During Expansion, With Repeated Administrations in Patients Showing Clinical Benefit.||Boehringer Ingelheim||Completed|April 2011|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|March 15, 2011||||No||https://clinicaltrials.gov/show/NCT01317420||107426|
NCT01317693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0571-10-RMB|Extracorporeal Shock Wave Therapy With a Wide Focus Probe for the Treatment of Erectile Dysfunction|Extracorporeal Shock Wave Therapy With a Wide Focus Probe for the Treatment of Erectile Dysfunction||Rambam Health Care Campus|Yes|Recruiting|March 2011|December 2013|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Male|18 Years|80 Years|No|||December 2012|December 18, 2012|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01317693||107405|
NCT01317706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS_CL_01|Comparison Between Ultrasonographic Cervical Length and Bishop Score in Preinduction Cervical Assessment|||Seoul National University Hospital|No|Completed|November 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|154|||Female|N/A|N/A|No|||March 2011|March 16, 2011|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317706||107404|
NCT01314898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0171007|A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers|A Phase 1, Double-Blind (Sponsor-Open), Placebo- And Active-Controlled, Single Dose, Crossover Study To Assess Antimineralocorticoid Activity Of Oral Pf-03882845 In Healthy Subjects.||Pfizer|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|March 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01314898||107617|
NCT01315132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08D.85|A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies|A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies||Thomas Jefferson University|Yes|Recruiting|April 2008|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01315132||107599|
NCT01316029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHS-001|Safety/Effectiveness Study of a Single Session of Laying-on-of-hands in Various Settings in Japan|A Large Cross-sectional Study of Laying-on-of-hands in Japan: Who Responds to it and What Facilitates the Response?|SELH|MOA Health Science Foundation|No|Completed|February 2007|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|44587|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any Japanese people who were interested in receiving laying-on-of-hands|January 2007|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316029||107531|
NCT01316042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35865|Metformin for the Treatment of Premature Pubarche in Girls|A Double Blind Randomized Controlled 12 Month Trial of Metformin for the Treatment of Premature Pubarche in Girls||Milton S. Hershey Medical Center|Yes|Terminated|May 2011|April 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Female|4 Years|10 Years|No|||September 2014|September 15, 2014|March 15, 2011|Yes|Yes|poor recruitment at collaborating sites|No||https://clinicaltrials.gov/show/NCT01316042||107530|
NCT01316055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD7.5D-ER012010|Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment|A Parallel, Three Arm, Open-label, Multi-dose Pharmacokinetic Study of Dalfampridine-ER 7.5 mg Twice Daily in Both Healthy Volunteers and Those With Mild and Moderate Renal Impairment||Acorda Therapeutics|No|Completed|January 2011|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|March 14, 2011|Yes|Yes||No|August 24, 2012|https://clinicaltrials.gov/show/NCT01316055||107529|
NCT01315717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00533-54|Gait and Alzheimer Interaction Tracking (GAIT) Study|Maladie d'Alzheimer et Troubles Locomoteurs : Caracterisation Des Anomalies Temporelles de la Marche et Etude Des Correlats Anatomo-cognitifs|GAIT|University Hospital, Angers|Yes|Recruiting|November 2009|November 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Anticipated|600|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients of the University Memory Center of Angers Hospital with respect to the        eligibility criteria.|March 2011|March 14, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01315717||107555|
NCT01315990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DERMATUX|FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema|Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema|DERMATUX|Johannes Gutenberg University Mainz|No|Active, not recruiting|January 2011|March 2018|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315990||107534|
NCT01316302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF2010SAD|12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder|A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder||The Medical Research Network|No|Completed|April 2011|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||October 2014|October 6, 2014|March 14, 2011|Yes|Yes||No|September 30, 2014|https://clinicaltrials.gov/show/NCT01316302||107510|
NCT01366040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-CAN-11-08|Avonex PEN Satisfaction and Patients Experience Clinical Trial|An Open-Label, Survey-Based, Multicenter Study to Determine Patient Satisfaction With Single-Use Prefilled Avonex® PEN Autoinjector in Multiple Sclerosis Patients|ASPECT|Biogen|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|89|||Both|18 Years|65 Years|No|Non-Probability Sample|Multiple Sclerosis (MS) subjects between the ages of 18 and 65, inclusive, who have been        treated with AVONEX® PS for at least 12 weeks prior to study entry.|May 2012|September 12, 2013|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366040||103725|
NCT01366898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-07OLD|Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)|PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years)||PETHEMA Foundation|Yes|Recruiting|May 2010|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|55 Years|N/A|No|||September 2015|September 16, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366898||103660|
NCT01366924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H06-04|Essential Amino Acids Supplementation and Muscle Protein Synthesis|The Effect of Amino Acid Supplementation on Skeletal Muscle Protein Turnover Following Endurance Exercise||United States Army Research Institute of Environmental Medicine|No|Completed|May 2007|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|23|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2011|June 2, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01366924||103658|
NCT01367184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR-IVC-01|National Inferior Vena Cava (IVC) Filter Registry|IVC Filter Study to Monitor and Measure Patients Outcomes Through Standardized Collection and Analysis of Clinical Information||American Venous Forum|Yes|Terminated|May 2011|May 2014|Anticipated|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20000|||Both|18 Years|80 Years|No|Non-Probability Sample|No specific criteria. Data from anyone who underwent IVC Filter Placement/Retrieval will        be eligible|June 2013|June 20, 2013|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367184||103638|
NCT01315613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-ST2|Role of ST2 in Acute Pancreatitis|Study of ST2-IL-33 Pathway in Acute Pancreatitis||Erasme University Hospital||Completed|January 2005|September 2008||September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients of Erasme University Hospital|September 2008|March 14, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01315613||107563|
NCT01315626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-2010-04|Bronchiectasis: Evaluation of an Educational Intervention|Identification of Patients With a Diagnosis of Bronchiectasis: Evaluation of an Educational Intervention||Hill-Rom|No|Withdrawn|January 2011|February 2011|Anticipated|February 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who present, or who have been seen in the above time periods, to the        participating primary care physician with the following inclusion / exclusion criteria        will be enrolled.|March 2011|March 17, 2015|December 20, 2010||No|Sponsor did not move forward with study|No||https://clinicaltrials.gov/show/NCT01315626||107562|
NCT01316224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-598|Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment|Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment|TOGETHER|AbbVie|No|Completed|April 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|Participants treated with adalimumab, per approved label, with moderate or severe plaque        psoriasis|April 2015|April 27, 2015|February 14, 2011||No||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01316224||107516|
NCT01316237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-119-0101|A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection|A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection||Gilead Sciences||Completed|January 2011|January 2012|Actual|October 2011|Actual|Phase 1|Interventional|N/A|9||Anticipated|90|||Both|18 Years|60 Years|No|||March 2012|March 22, 2012|February 3, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01316237||107515|
NCT01316510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201018539|Probiotics in Infants With Gastroschisis|Probiotics in Infants With Gastroschisis||University of California, Davis|No|Recruiting|March 2011|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|24|||Both|N/A|2 Weeks|No|||January 2015|January 22, 2015|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01316510||107494|
NCT01317446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASAS-1007X|Effect of Mouthrinsing on Inflammation of the Gums.|Effect of an Amine Fluoride/Stannous Fluoride Containing Mouthrinse on Gingival Inflammation,Plaque Development, Discoloration and Bacterial Plaque Composition Over Six Months.||Technische Universität Dresden|No|Completed|November 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01317446||107424|
NCT01317745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0016|H5N1 Mix and Match With MF59|A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered at Different Dose Levels Given With and Without MF59 Adjuvant||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|270|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2012|January 24, 2013|March 16, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01317745||107401|
NCT01316835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-2717B|Effectiveness of Sitagliptin in Glycemic Control in Real World|A Retrospective, Observational Study to Assess the Effectiveness of Glycemic Control of Diabetes in Real World After Sitagliptin Usage||Chang Gung Memorial Hospital|No|Recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1120|||Both|20 Years|N/A|No|Non-Probability Sample|Subjects with ICD-9 diagnostic codes of T2DM plus any prescription record of the        anti-glycemic drugs included in the hospital formulary during the study period will be        extracted from the hospital outpatient electronic database. Sitagliptin users who stayed        with Sitagliptin for at least 24 weeks will then further identified from this diabetes        cohort for efficacy analysis.|March 2011|March 15, 2011|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01316835||107470|
NCT01318239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0047|Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-anogenic Effect of Chemotherapeutic Regimens in Colorectal Liver Metastasis Patients|Study of Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-angiogenic Effect in Patients With Colorectal Liver Metastasis in Chemotherapeutic Regimens Including Avastin||Yonsei University|Yes|Completed|July 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|37|||Both|20 Years|N/A|No|||March 2014|March 4, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01318239||107363|
NCT01317992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1119-9613|Ibudilast in the Treatment of Medication Overuse Headache|Ibudilast in the Treatment of Medication Overuse Headache: A Double-blind, Randomised, Placebo-controlled Pilot Study||University of Adelaide|No|Recruiting|April 2011|August 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 4, 2013|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01317992||107382|
NCT01314300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERSATIS|Lidocaine 5% Plasters (Versatis® 5%) in Pediatric Neuropathic Pains and Vasoocclusive Sickle Cell Crisis Pains|VERSATIS - Efficacy and Safety of Lidocaine 5% Plasters (Versatis® 5%) in Child, Adolescents and Young Adults With Neuropathic Pains or Vasoocclusive Sickle Cell Crisis Pains||Centre Leon Berard|No|Completed|March 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|6 Years|21 Years|No|||October 2014|October 29, 2014|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01314300||107661|
NCT01364805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12505|New Treatment Option for Pancreatic Cancer|Translation of in Vitro and in Vivo Ascorbate Research Into a New Treatment Option for Pancreatic Cancer: Phase I/IIa Clinical Trial||University of Kansas Medical Center|Yes|Completed|April 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|N/A|No|||November 2015|November 5, 2015|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364805||103819|
NCT01365117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-167|Pharmacokinetic Study in Healthy Volunteers|Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Dose-proportionality Following Inhalation of Technosphere® Insulin Inhalation Powder (3 U and 4 U Insulin/mg) Using the Gen2 Inhaler||Mannkind Corporation|No|Completed|January 2011|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01365117||103795|
NCT01365429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSS-NA-001, XVO-NA-002|Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs|Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs||XVIVO Perfusion|Yes|Recruiting|May 2011|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|104|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01365429||103772|
NCT01365416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMMO|Personalised Medicine for Morbid Obesity|Genetic Analysis for Personalised Medicine for Morbid Obesity||Imperial College London|No|Recruiting|November 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|SALIVA BLOOD URINE AND FAECES TISSUE (Muscle, Liver, Subcutaneous fat, Visceral fat)|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|2000 obese patients|October 2012|June 3, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365416||103773|
NCT01365390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115356|To Evaluate the Incidence of Acute Otitis Media in Children in Five East European Countries|To Evaluate Incidence of Acute Otitis Media in Children Aged < 6 Years in Five East European Countries||GlaxoSmithKline||Completed|June 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|2258|||Both|N/A|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects aged < 6 years who are registered in primary care clinics of any of the        participating countries (Estonia, Lithuania, Poland, Romania and Slovenia) will be        enrolled in this study.|May 2014|July 24, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365390||103775|
NCT01365403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25263|A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers|A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE CARBAMAZEPINE ON SINGLE DOSE PHARMACOKINETICS OF RO4917838 IN HEALTHY MALE VOLUNTEERS||Hoffmann-La Roche||Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|16|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01365403||103774|
NCT01355289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-203|Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501|A Phase II, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, With an Open-Label Extension, to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects With Chronic Hepatitis C Virus Related Thrombocytopenia Who Are Potential Candidates for Antiviral Treatment||Eisai Inc.|Yes|Completed|November 2011|May 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|65|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355289||104546|
NCT01355601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6011|Effect of Carbohydrates From Nutritional Beverages in Children|Effect of Carbohydrates From Nutritional Beverages in Children||Mead Johnson Nutrition||Terminated|January 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind|2||Anticipated|88|||Both|33 Months|39 Months|Accepts Healthy Volunteers|||February 2014|February 26, 2014|May 16, 2011|||Terminated due to slow recruitment. 41 of 50 participants had enrolled at time of termination.|No||https://clinicaltrials.gov/show/NCT01355601||104522|
NCT01355939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-02112|Comparative Effectiveness Multicenter Trial for Adhesion Characteristics of Ventral Hernia Repair Mesh|A Prospective Multicenter Trial to Evaluate Adhesion Characteristics and Adhesiolysis-related Complications of Barrier-coated and Non-barrier-coated Intraperitoneal Mesh During Abdominal Re-exploration After Prior Ventral Hernia Repair||Washington University School of Medicine|Yes|Completed|May 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|173|||Both|18 Years|N/A|No|Non-Probability Sample|Investigators' patient population|February 2015|February 19, 2015|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01355939||104497|
NCT01356277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK092977-01|Intervention to Improve Adherence in Teen Kidney Transplant|TAKE-IT: Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial|TAKE-IT|McGill University Health Center|Yes|Active, not recruiting|February 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|170|||Both|11 Years|24 Years|No|||April 2015|April 6, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356277||104471|
NCT01356290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUV-MEMMAT-01|Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma|A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma|MEMMAT|Medical University of Vienna|Yes|Recruiting|April 2014|April 2022|Anticipated|April 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|19 Years|No|||March 2016|March 24, 2016|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356290||104470|
NCT01361464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02589|Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia|Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio||National Cancer Institute (NCI)||Completed|May 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|65 Years|N/A|No|||February 2015|March 19, 2015|May 24, 2011|Yes|Yes||No|November 15, 2013|https://clinicaltrials.gov/show/NCT01361464||104074|Due to trial not meeting primary endpoint of at least 3 CR/CRi after 2 cycles, accrual was suspended. 1 year survival was not calculated, not relevant in the setting of a median survival of 6.6 months and with study not meeting its primary endpoint.
NCT01361711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10H06|Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia|A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia||Northwestern University|Yes|Recruiting|June 2011|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01361711||104055|
NCT01361698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010B114|Illness Management and Recovery (IMR) in Danish Community Mental Health Centres|Illness Management and Recovery (IMR) in Danish Community Mental Health Centres: Protocol of a Randomized, Assessor-blinded Multi-centre Clinical Trial of a Recovery-oriented Program for People With Schizophrenia or Bipolar Disorder|IMR|Mental Health Centre Copenhagen|No|Completed|February 2011|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||February 2016|February 7, 2016|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361698||104056|
NCT01366937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200715660-2|Assessment of Vitamin B12 Bioavailability From Egg|Assessment of Vitamin B12 Bioavailability From Egg||USDA, Western Human Nutrition Research Center|No|Completed|August 2007|September 2009|Actual|September 2009|Actual|N/A|Observational|Observational Model: Case-Only||1|Anticipated|10|Samples With DNA|Plasma, serum, buffy coat, urine, stool|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults, 18 y or older|August 2011|August 3, 2011|January 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01366937||103657|
NCT01366950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110051|Work Place Health Promotion: a Change Project|Work Place Health Promotion as a Change Project|HEALTHCHANGE|University of Southern Denmark|No|Active, not recruiting|June 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366950||103656|
NCT01362920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT-001|Diagnostic and Prognostic Value of Serial Procalcitonin (PCT) Measurements in Critically Ill Patients|Diagnostic and Prognostic Value of Serial PCT Measurements in Critically Ill Patients|PCT|The Cleveland Clinic|No|Completed|April 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|||Both|N/A|N/A|No|Probability Sample|Prospective-observational study design in which a PCT measurement will be obtained on        admission to the Medical Intensive Care Unit (MICU) and then daily (as clinically        available)until discharge from the unit or death.|February 2013|February 15, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01362920||103962|
NCT01363414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVS20-THAI-05-01|Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes|Randomized Controlled Trial of the Effects of Sodium Hyaluronate on Wavefront Aberrations in Dry Eye Patients||Ramathibodi Hospital|No|Completed|January 2007|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||September 2010|May 31, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363414||103925|
NCT01363687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-03-047|The Effect of Remote Postconditioning on Graft Function in Patients Undergoing Living-related Kidney Transplantation|The Effect of Remote Postconditioning on Graft Function in Patients Undergoing Living-related Kidney Transplantation||Samsung Medical Center|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|70 Years|No|||December 2013|December 24, 2013|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01363687||103904|
NCT01363700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01141101|Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis|Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -||Santen Pharmaceutical Co., Ltd.||Completed||||June 2012|Actual|Phase 3|Interventional|N/A|3||Actual|87|||Both|20 Years|64 Years||||November 2014|November 5, 2014|May 30, 2011||No||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01363700||103903|
NCT01363674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104-520|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Greece|ECOS GRE|Merck KGaA|No|Active, not recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|171|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the Easypod™ electromechanical device.|March 2015|March 3, 2015|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01363674||103905|
NCT01363934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1113_P1|To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin|A Dose-Block Randomized, Double-blind Placebo Controlled, Open-label Active Controlled, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GC1113 After Single Intravenous/Subcutaneous Administration in Healthy Male Subjects||Green Cross Corporation|Yes|Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|100|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 17, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01363934||103885|
NCT01363947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNB4987g|Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer||Genentech, Inc.||Recruiting|June 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363947||103884|
NCT01363960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Retinopathy of prematurity|Retinopathy of Prematurity:Summary of a Decade|||Gulhane Military Medical Academy|Yes|Completed|March 1999|December 2010|Actual|December 2010|Actual|N/A|Observational|N/A||1|Actual|609|||Both|N/A|N/A|No|Probability Sample|neonates with Retinopathy of of prematurity|June 2009|May 31, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363960||103883|
NCT01364532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-5|Transradial Versus Transulnar Artery Approach for Coronary Interventions|A Randomized Study of Transradial Versus Transulnar Artery Approach for Coronary Interventions|AURA|University of Patras|No|Recruiting|April 2011|September 2011|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|572|||Both|19 Years|N/A|No|||April 2011|May 31, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01364532||103840|
NCT01364818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0962|Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment|Characterization of Potential Biomarkers to Assess Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment||University of North Carolina, Chapel Hill|No|Enrolling by invitation|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|3 Years|45 Years|No|Non-Probability Sample|Participants recruited for a clinical trial conducted by Dr. Sikich, or are private        patients of one of the study doctors.|December 2013|December 17, 2013|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01364818||103818|
NCT01365156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0952|Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix|A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2011|||September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|N/A|No|||March 2016|March 21, 2016|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365156||103792|
NCT01365169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0955|CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial|CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2011|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|MD Anderson Cancer Center patients from Head and Neck clinics, Colorectal clinics, and        Smoking Cessation groups.|February 2016|February 15, 2016|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365169||103791|
NCT01365741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTISUE|Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient|Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient||Rigshospitalet, Denmark|Yes|Active, not recruiting|February 2011|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||October 2013|October 23, 2013|December 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01365741||103748|
NCT01365728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05212011-7804|An Outcomes Study Comparing the Intralase FS 60 to the Intralase iFS When Performing LASIK Surgery for Nearsightedness|A Prospective Randomized Comparison of Fellow Eyes Undergoing LASIK With the Intralase FS 60 Versus the Intralase IFS||Stanford University|No|Active, not recruiting|April 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects age 21 and older with healthy eyes. Nearsightedness between -0.25 diopters and        -7.00 diopters with or without astigmatism of up to 3.00 diopters.|April 2015|April 2, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365728||103749|
NCT01355302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-703|E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer||Eisai Inc.|No|Terminated|November 2011|July 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||November 2013|November 14, 2013|May 16, 2011|Yes|Yes|Sites not recruiting|No||https://clinicaltrials.gov/show/NCT01355302||104545|
NCT01356849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-350|Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor|RADAR: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy|RADAR|AbbVie|Yes|Completed|April 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|149|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356849||104427|
NCT01356862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APREC-S-2010-01|Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer|Evaluation of the Effect of Pasireotide LAR Administration in the Lymphocele Prevention After Axillary Node Dissection for Breast Cancer|SOM 230|Alliance Pour La Recherche en Cancerologie|Yes|Recruiting|September 2010|July 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|90|||Female|18 Years|N/A|No|||May 2011|May 19, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01356862||104426|
NCT01357161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1775-004|A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)|A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer||Merck Sharp & Dohme Corp.|No|Active, not recruiting|July 2011|December 2016|Anticipated|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01357161||104403|
NCT01361724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4022|COPE-Co-morbidities, Parkinson's Disease and Exercise|COPE-Co-morbidities, Parkinson's Disease and Exercise|COPE|Oregon Health and Science University|Yes|Completed|March 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|58|||Both|40 Years|80 Years|No|||August 2012|October 1, 2014|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01361724||104054|
NCT01361737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOSERPE11|Serum Markers in Preeclamptic Women|||Oslo University Hospital|Yes|Completed|January 1999|May 2004|Actual|January 1999|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|||||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Norwegian pregnant women|May 2011|July 3, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361737||104053|
NCT01362660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4091055|A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth|A Protocol to Monitor the Neurological Development of Infants With Exposure In-utero From Birth to Aged 15 Months in Tanezumab Clinical Studies at Investigational Sites Overseen by Schulman and Associates Institutional Review Board||Pfizer|Yes|Completed|June 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|7|||Both|N/A|15 Months|No|Non-Probability Sample|Infants with potential exposure in utero through their parents partcipation in a tanezumab        clinical study|February 2013|February 5, 2013|May 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362660||103982|
NCT01362036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2010-003|Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia|Phase 1 Open-Label Dose-Escalating Study Evaluating the Safety and Preliminary Efficacy of TXA127 in Patients With Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia||US Biotest, Inc.|No|Terminated|April 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||May 2012|May 2, 2012|April 23, 2011|No|Yes|Enrollment feasibility issues, new study in design|No||https://clinicaltrials.gov/show/NCT01362036||104030|
NCT01355757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-142|Post-Operative Quality of Life Evaluation for Different Anesthesia Techniques for Arthroscopic Shoulder Surgery|Post-Operative Quality of Life Evaluation for Different Anesthesia Techniques for Arthroscopic Shoulder Surgery||St. Luke's-Roosevelt Hospital Center||Completed|June 2011|January 2013|Actual|January 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 16, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355757||104510|
NCT01363375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 97－2320－B－027－002－MY3|Effects of Different Foot Structures on Plantar Fasciitis and Therapeutic Footwear Intervention|The Investigation of Biomechanical Mechanism of Different Foot Structures on Plantar Fasciitis and the Evaluation of Efficacy on Therapeutic Footwear||Chang Gung Memorial Hospital|Yes|Recruiting|June 2009|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with normal foot structure or abnormal foot structure (flat foot or high arch        foot) will be invited to participant this study.|February 2008|May 31, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01363375||103928|
NCT01363193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBW Heparin study|Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients|Assessing Safety and Efficacy of Lean Body Weight-based Intravenous Heparin Dosing in Obese/Morbidly Obese Patients. A Pilot Study||Nazareth Hospital|No|Recruiting|July 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01363193||103941|
NCT01363726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor415005ctil|Surveillance of Rotavirus Gastroenteritis in Children <5 Years|Surveillance of Rotavirus Gastroenteritis Among Children <5 Years of Age Visiting the Pediatric Emergency Room in Southern Israel||Soroka University Medical Center|No|Recruiting|October 2005|||||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|5 Years|No|Probability Sample|Survieillance of Rotavirus Gastroenteritis Among Children Bedouin and Jewish < 5 years        with gastro enteritis visiting the ER in southern Israel|October 2005|May 31, 2011|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01363726||103901|
NCT01363986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25432|A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer|A Multicenter, Open Label Study to Assess the Effect of Trastuzumab + Whole Brain Radiotherapy (WBRT) on Brain Metastases From HER-2 Positive Breast Cancer. (bHERt-2)||Hoffmann-La Roche||Terminated|September 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|May 31, 2011|No|Yes|Study was prematurely terminated due to difficulties experienced in recruiting patients in a    reasonable timeframe.|No|May 7, 2014|https://clinicaltrials.gov/show/NCT01363986||103881|
NCT01363973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETI-01|Effect of Transcutaneous Electrical Stimulation on Post-stroke Dysphagic Patients|Pilot Study to Evaluate the Efficacy and Safety of Transcutaneous Electrical Stimulation on Swallowing in Patients With Oropharyngeal Dysphagia After Stroke|EETI-01|Hospital de Mataró|Yes|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363973||103882|
NCT01364272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05252011-7807|Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia|Investigation of Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia||Stanford University|Yes|Recruiting|September 2008|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All patients age 18 years and older with typical trigeminal neuralgia, as determined by        diagnostic criteria set by the International Headache Society, who was treated with SRS.|May 2011|June 1, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01364272||103860|
NCT01364844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS7423-A-U101|Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors|A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors||Daiichi Sankyo Inc.|No|Completed|July 2011|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364844||103816|
NCT01364558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIAZ.001.01|A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers|A Three-Period, Three-Treatment, Six-Sequence Randomized Crossover Study of the Bioavailability and Pharmacokinetics of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers",||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|May 20, 2011|Yes|Yes||No|July 20, 2012|https://clinicaltrials.gov/show/NCT01364558||103838|
NCT01365130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 243|Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen|A Phase II Study Of Cabazitaxel For Metastatic Gastroesophageal Adenocarcinomas That Have Relapsed After At Least One Line Of Chemotherapy||Brown University|Yes|Terminated|June 2011|August 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|May 11, 2011||No|As of 12/12/12 study closed to enrollment because study was determined to be ineffective.|No|February 20, 2014|https://clinicaltrials.gov/show/NCT01365130||103794|
NCT01365767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGRWLBKULT1|Contrast Ultrasound of the Small Intestine in Patients With Crohns Disease|Kontrast UltraLydsskanning af Tyndtarmen Hos Patienter Med Crohns Sygdom - et Pilotstudie. (Danish) Contrast Ultrasound of the Small Intestine in Patients With Crohns Disease - a Pilot Study (English)|KULT|Regionshospitalet Silkeborg|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated on Regional Hospital of Silkeborg.|July 2013|July 15, 2013|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01365767||103746|
NCT01365442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-WC-03|Pilot Introduction of Oral Cholera Vaccine in Orissa, India|Pilot Introduction of the Modified Bivalent Killed Whole Cell Oral Cholera Vaccine in Orissa||International Vaccine Institute|No|Completed|May 2011|September 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community||1|Actual|31552|||Both|12 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will be conducted in ~100 selected villages with approximate population of        50,000 in Satyabadi block of Puri district, Orissa|May 2013|May 21, 2013|March 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01365442||103771|
NCT01365754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYN-1009-MEY-0000-I|Dynamic Stabilization Versus Fusion|Posterior Dynamic Stabilization Versus Fusion in the Treatment of Lumbar Degenerative Disease|DYNORFUSE|Technische Universität München|Yes|Active, not recruiting|September 2011|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|440|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365754||103747|
NCT01355666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermaTherapy|Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting|Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting||Precision Fabrics Group, Inc.|No|Recruiting|September 2010|June 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|75|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2011|May 17, 2011|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01355666||104517|
NCT01360879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLOG1002|Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease|Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease|FIBROELAST|Japan Liver Oncology Group|Yes|Recruiting|September 2010|September 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|whole blood, serum, liver tissue|Both|20 Years|N/A|No|Probability Sample|Subjects with chronic hepatitis B or C, undergoing a liver biopsy as the standard of care        for their disease, will be eligible for the study. Subjects with other infectious viral        diseases or chronic liver disease are excluded for study enrollment.|August 2010|May 25, 2011|May 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01360879||104118|
NCT01361152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fixed- and Mobile TKA|Long-Term Comparison of Fixed- and Mobile-Bearing Total Knee Arthroplasties (TKAs) in Patients With OA ≤50 Years Old|Long-Term Comparison of Fixed- and Mobile-Bearing Total Knee Arthroplasties in Patients With Osteoarthritis Younger Than Fifty Years of Age||Ewha Womans University|No|Completed|April 1993|March 2011|Actual|March 1996|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|29 Years|50 Years|No|||October 2011|October 4, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01361152||104098|
NCT01361451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ111/N002|Myotrace: An Evaluation of a Novel Critical Illness Monitoring System|Myotrace: A Phase II Evaluation of a Novel Critical Illness Monitoring System||Guy's and St Thomas' NHS Foundation Trust|No|Completed|January 2011|January 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|It is envisaged that a subset of patients will have venous blood samples taken for future      analysis for inflammatory cytokines|Both|35 Years|N/A|No|Non-Probability Sample|Hospitalised patients with acute exacerbation of chronic obstructive pulmonary disease|November 2010|October 22, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361451||104075|
NCT01358526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONU3701|Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain|A Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Enriched Study Design to Assess the Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Pain Due to Chronic Low Back Pain Who Require Around-the-clock Opioid Therapy||Purdue Pharma LP|Yes|Completed|May 2011|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1095|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|May 20, 2011|Yes|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01358526||104298|
NCT01355809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-07-C2-017|Six-Minute Walk Test Comparing Helium/Oxygen to Nitrogen/Oxygen for COPD Rehabilitation|Single Centre, Exploratory, Phase II, Cross-over, Randomised Trial, Evaluating the Effect of Spontaneously Breathing He/O2 65%/35% to Either Spontaneously Breathing N2/O2 65%35% or Non-Invasive Ventilated N2/O2 65%/35% on a 6 Minute Walk Test in Severe COPD Patients|rehabilitate|Air Liquide SA|Yes|Terminated|December 2009|May 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|45 Years|75 Years|No|||August 2014|August 8, 2014|May 17, 2011||No|Due to low recruitment rate the sponsor decided to discontinue the study.|No||https://clinicaltrials.gov/show/NCT01355809||104507|
NCT01355783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7777-G000-301|A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma|A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma||Eisai Inc.||Withdrawn|March 2011|November 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||November 2013|November 14, 2013|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355783||104509|
NCT01365325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228/08|Handled Echocardiography and Chronic Heart Failure|Management of Chronic Heart Failure: Role of the Handled Echocardiography in Home Monitoring Care Programs||Federico II University|Yes|Completed|January 2009|December 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|118|||Both|70 Years|N/A|No|||December 2010|June 1, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01365325||103780|
NCT01363206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIPI|Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma|GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study|GIPI|Northern California Melanoma Center|No|Active, not recruiting|May 2011|May 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363206||103940|
NCT01363180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50AA010761-16|Stress-induced Drinking in Emerging Adults: the Role of Trauma History|Stress-induced Drinking in Emerging Adults: the Role of Trauma History|ARC5|Medical University of South Carolina|No|Recruiting|June 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|240|||Both|21 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|21-30 year olds|May 2011|November 15, 2012|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363180||103942|
NCT01363427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE 999907 (Pentasa)|Retrospective Data Analysis in Crohn's Disease|Retrospective Data Analysis of Newly Diagnosed Crohn's Disease Patients in Gastroenterological Surgeries|Crohn 2|Ferring Pharmaceuticals|No|Completed|March 2007|July 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|161|||Both|18 Years|N/A|No|Non-Probability Sample|Private practices|May 2011|May 31, 2011|May 30, 2011||||No||https://clinicaltrials.gov/show/NCT01363427||103924|
NCT01363466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNECO 02/0108|Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer|Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer||UNICANCER|No|Terminated|May 2003|November 2006|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Female|18 Years|70 Years|No|||May 2011|May 30, 2011|May 5, 2011||No|low recruitment|No||https://clinicaltrials.gov/show/NCT01363466||103921|
NCT01364012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO25404|A Study of Avastin (Bevacizumab) Versus Placebo in Combination With Carboplatin/Paclitaxel) in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy|A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase III Study Comparing Bevacizumab Plus Carboplatin/Paclitaxel Versus Placebo Plus Carboplatin / Paclitaxel in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy.||Hoffmann-La Roche||Active, not recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364012||103879|
NCT01363999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP25642|A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers|A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers||Hoffmann-La Roche||Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01363999||103880|
NCT01364285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05252011-7808|A Study of Patient Reported Outcomes After Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia|A Study of Patient Reported Outcomes After Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia||Stanford University||Recruiting|May 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|All of the patients since 2000 who have undergone stereotactic radiosurgical rhizotomy at        Stanford for treatment of trigeminal neuralgia.|May 2011|June 1, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01364285||103859|
NCT01364298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200054-603 CL028|Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management|Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain||Merck KGaA|Yes|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|353|||Both|18 Years|70 Years|No|||December 2013|December 18, 2013|May 31, 2011||No||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01364298||103858|
NCT01364571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3451001|Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years|Phase I/2 Placebo-Controlled, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years||Pfizer|Yes|Completed|August 2011|January 2013|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|456|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364571||103837|
NCT01364857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN09 - GL / CONAPE|French National Cohort of Children With Port Wine Stain|French National Prospective Cohort of Children With Port Wine Stain on a Limb = "Cohorte Nationale d'Enfants Avec Angiome Plan de Membre inférieur"|CONAPE|University Hospital, Tours|No|Active, not recruiting|November 2010|November 2020|Anticipated|November 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|150|||Both|2 Years|12 Years|No|||January 2016|January 4, 2016|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364857||103815|
NCT01365143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002288|Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy|||Mayo Clinic||Terminated|May 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|18 Years|N/A|No|||May 2014|May 30, 2014|May 26, 2011||No|Closing due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01365143||103793|
NCT01365195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024533|Effect of Ketamine on Postoperative Clinical Outcomes|Intraoperative Ketamine Administration in Colorectal Surgery: Effect on Postoperative Clinical Outcomes||Cedars-Sinai Medical Center|No|Enrolling by invitation|May 2011|October 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|102|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365195||103789|
NCT01366027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AVR-REG-001|PRISM Registry: Pseudobulbar Affect Registry Series|PRISM Registry: Pseudobulbar Affect Registry Series||Avanir Pharmaceuticals|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|N/A||1|Actual|5290|||Both|18 Years|N/A|No|Probability Sample|The population for this study will be 18 years and over|April 2014|April 15, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366027||103726|
NCT01366248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09E-1237-01|Integrative Oncology Outcomes Study in Breast Cancer|Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study|IO-OS-BC|Bastyr University|Yes|Active, not recruiting|August 2010|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|725|||Female|18 Years|N/A|No|Non-Probability Sample|Eligible participants for the study will include patients who are receiving care for their        cancer at participating Seattle area IO clinics. An average of two (up to four) matched        comparison controls will be recruited from the Washington State CSS.        All breast cancer patients seeking care at the participating IO clinics who meet        inclusion/exclusion criteria are eligible to participate in this study. Matched comparison        cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.|April 2014|May 1, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366248||103709|
NCT01355679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC 001|Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma|A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Refractory or Recurrent Neuroblastoma||Spectrum Health Hospitals|Yes|Active, not recruiting|May 2011|June 2015|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|14|||Both|1 Year|N/A|No|||March 2015|March 5, 2015|May 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01355679||104516|
NCT01356589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25289|A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)|Retrospective Study on Intrapatient VAriabiLity of the Hemoglobin Levels in Anemic CKD Patients in Predialysis (Stage 3-4) and Dialysis (Stage 5) Treated With MIRCERA® (RIVAL Study)||Hoffmann-La Roche||Completed|September 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1288|||Both|18 Years|N/A|No|Probability Sample|Chronic kidney disease patients with anemia treated with Mircera|November 2015|November 23, 2015|May 18, 2011||No||No|November 23, 2015|https://clinicaltrials.gov/show/NCT01356589||104447|
NCT01361165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906255|Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism|Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism||National Institutes of Health Clinical Center (CC)||Completed|September 2006|October 2008|Actual|||N/A|Observational|N/A|||Anticipated|10|||Both|N/A|N/A|No|||May 2011|May 24, 2011|May 24, 2011||||No||https://clinicaltrials.gov/show/NCT01361165||104097|
NCT01361178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09090483|Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement|Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement - Observational Arm||University of Pittsburgh|Yes|Completed|January 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|May 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01361178||104096|
NCT01361477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si227/2011|Data Registry of Intensive Care Unit (ICU) Siamitra and Intensive Care Unit (ICU) Salad-Samung|Data Registry of ICU Siamitra and ICU Salad-Samung||Mahidol University|No|Recruiting|May 2011|May 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|19 Years|N/A|No|Non-Probability Sample|Adult (> 18 years), admitting to ICU Siamitra and ICU Salad-Samung|May 2011|May 25, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361477||104073|
NCT01361490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSSO 2010/3|Rehabilitating Overweight People Back to Working Life|Rehabilitating Overweight People Back to Working Life|ARRO|Norwegian University of Science and Technology|No|Completed|November 2010|May 2014|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|405|||Both|19 Years|67 Years|No|Non-Probability Sample|Obese people where the obesity is the reason they are not actively taking part in working        life.|September 2014|September 4, 2014|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361490||104072|
NCT01356069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUMHS-2004|Efficacy of Time-limited Psychodynamic Psychotherapy and Informed Clinical Management in BPD High MHS Users|Sequential Brief Adlerian Psychodynamic Psychotherapy in Heavy Users of a Mental Health Service With Borderline Personality Disorder: a Two Years Follow-up Preliminary Randomized Study.|HUMSH|University of Turin, Italy|No|Completed|January 2004|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|35|||Both|20 Years|50 Years|No|||May 2011|May 18, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356069||104487|
NCT01366989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-SJA-001|INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation|INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation||Wright Medical Technology|Yes|Terminated|October 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who will be recruited for participation in this study received the TAA with        calcaneal stem between December 6, 2005 and November 13, 2007 at approximately 28 sites.|August 2012|August 30, 2012|June 2, 2011|Yes|Yes|The retrospective data review did not provide adequate information to continue the    investigation.|No||https://clinicaltrials.gov/show/NCT01366989||103653|
NCT01362933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version N°2.0 du 21/03/2011|National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients|National Evaluation of the Adherence to Recommendations of VTE Treatment in Cancer Patients|CARMEN|Floralis|No|Completed|May 2011|July 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|502|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with cancer present in the clinic, hospital, out patients diagnosed with a        VTE during the 6 previous months|March 2015|March 5, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01362933||103961|
NCT01363505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-021|Bladder Pressure Predicting Renal Failure in Critically Ill Patients as Compared to Hemodynamic Parameters|Is Intravesicular Pressure a Better Tool to Predict Renal Failure in Critically Ill Patients Compared With Routine Hemodynamic Parameters?||Northwell Health|Yes|Completed|May 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|The studied group will consist of patients admitted to the ICU (intensive care unit) or        CCU(coronary care ubnit) with evidence of ADHF. We aim in our study to find out if there        is a linear relationship between worsening of renal function , IAP ,hemodynamic (CVP) and        blood chemical measurements|January 2014|January 31, 2014|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01363505||103918|
NCT01363479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-10-01|An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting|Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy||Helsinn Healthcare SA|No|Completed|July 2011|||November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|743|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|May 30, 2011|Yes|Yes||No|November 6, 2014|https://clinicaltrials.gov/show/NCT01363479||103920|
NCT01363492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-REP-084|Safety Study of Replagal® Therapy in Children With Fabry Disease|An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy||Shire|No|Completed|May 2011|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|7 Years|17 Years|No|||April 2014|April 17, 2014|March 31, 2011|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01363492||103919|
NCT01363765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPPGH5254|Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil|Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial||Ataulpho de Paiva Foundation|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|34758|||Both|N/A|N/A|No|||March 2014|March 11, 2014|May 27, 2011|No|Yes||No|August 5, 2013|https://clinicaltrials.gov/show/NCT01363765||103898|The design has potential for bias, due to delayed treatment effects or to conditions that change over time. Both are unlikely: outcome (notification) was shortly after test and adjustment for time in multilevel mixed model confirmed primary analysis.
NCT01364311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-120111|Treatment of Dry Eye With Supplements|Treatment of Dry Eye With Supplements||Medical University of Vienna|Yes|Withdrawn|July 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|April 14, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01364311||103857|
NCT01364545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0606/74|Ketogenic Diets for Symptoms of Parkinson's Disease|Ketogenic Diets for Symptoms of Parkinson's Disease||University of Oxford|Yes|Recruiting|May 2011|||May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|42 Years|N/A|No|||May 2011|June 1, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01364545||103839|
NCT01364831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WingateHC1|Connection Between Sleep and Athletic Performance|Connection Between Sleep Quality and Duration and Performance in Young Athletes||Wingate Institute|No|Completed|June 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|19|||Both|13 Years|20 Years|Accepts Healthy Volunteers|||December 2013|December 31, 2013|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01364831||103817|
NCT01365182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE 14807|Improving Urinary Continence and Quality of Life in Prostate Cancer Patients|Improving Urinary Continence and Quality of Life in Prostate Cancer Patients||Case Western Reserve University|Yes|Completed|January 2009|June 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|279|||Male|21 Years|N/A|No|||February 2015|February 16, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01365182||103790|
NCT01365455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2302|Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|ERASURE|Novartis||Completed|June 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|738|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 1, 2011|Yes|Yes||No|February 16, 2015|https://clinicaltrials.gov/show/NCT01365455||103770|
NCT01365494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V49_25|Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules|A Phase IV, Multi-center, Randomized, Open-label Study of PCECV (Rabipur®) Comparing the Immunogenicity and Safety of Two Different Simulated Post Exposure Schedules (Zagreb 2-1-1 Versus Essen Regimen 1-1-1-1-1) in Healthy Indian Subjects||Novartis||Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 3, 2014|May 30, 2011||No||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01365494||103767|
NCT01365507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3844|Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily in Insulin-naïve Subjects With Type 2 Diabetes Mellitus When Using Two Different Titration Algorithms (BOOST™: SIMPLE USE)|BOOST™|Novo Nordisk A/S|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|276|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|May 31, 2011|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01365507||103766|
NCT01365468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001MIL04T|Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)|A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)||Novartis||Completed|April 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|10 Years|N/A|No|||June 2015|June 24, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01365468||103769|
NCT01365481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489K2305|Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age|A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease||Novartis|No|Completed|August 2011|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|6 Years|17 Years|No|||January 2016|January 12, 2016|May 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01365481||103768|
NCT01365780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-29|Hyperbaric Oxygen Therapy in Distal Radius Fractures: Can it Shorten Recovery Time and Increase Fracture Healing?|Identification of Microcirculation in Distal Radius Fractures After Surgical Treatment With and Without Hyperbaric Oxygen Therapy (HBOT)|HBOTRadius|RWTH Aachen University|No|Suspended|September 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|June 1, 2011||No|nump    acceptence by patient too low|No||https://clinicaltrials.gov/show/NCT01365780||103745|
NCT01360632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-227|Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPDC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Polaris Trial|Polaris|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|June 2011|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1539|||Both|18 Years|65 Years|No|||November 2015|November 30, 2015|May 24, 2011|Yes|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01360632||104137|
NCT01362049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS 10-045|Mechanisms of Specific Trunk Exercises in Low Back Pain|Mechanisms of Specific Trunk Exercises in Low Back Pain||University of Vermont|Yes|Active, not recruiting|March 2010|July 2013|Anticipated|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|93|||Both|21 Years|55 Years|No|||November 2011|November 7, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01362049||104029|
NCT01362361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICC-C (AIO-KRK-0111)|TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)|TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)|AIO-KRK-0111|Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|June 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|N/A|No|||April 2012|April 5, 2012|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01362361||104005|
NCT01362374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAM4983g|Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors|A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors||Genentech, Inc.||Active, not recruiting|July 2011|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|118|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|May 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362374||104004|
NCT01362647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B126201110617|Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit|A Non-interventional / Observational Study on Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit After Spontaneous Recovery or After Reversal of the Neuromuscular Block||Onze Lieve Vrouw Hospital|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|625|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will comprise about 600 surgical patients (the first 600 inpatients        and outpatients scheduled for anesthesia during the study period who meet the study        criteria).|October 2011|October 4, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01362647||103983|
NCT01366430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treatment of HC BPPV|Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo|Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo; Randomized Controlled Trial of Barbeque Rotation and Gufoni Maneuver|HC BPPV|Chonbuk National University|No|Completed|January 2009|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|170|||Both|11 Years|N/A|No|||January 2009|June 2, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366430||103695|
NCT01366690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00040431|The PeerCARE Study (Peer Community-based Assistant in REtention)|The PeerCARE Study (Peer Community-based Assistant in REtention): Effect of Peer Health Workers on People Living With HIV Not on Antiretroviral Therapy—A Randomized Trial|PeerCARE|Johns Hopkins University|No|Completed|June 2011|June 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366690||103675|
NCT01366703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pharao multicentre study|Optimized Heart Failure Therapy Through Continuous Monitoring|Optimized Heart Failure Therapy Through Continuous Monitoring. The PHARAO Multi-centre Study|pharao|Kennemer Gasthuis|Yes|Recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|50 patients with stable heart failure|May 2012|May 12, 2012|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366703||103674|
NCT01362946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH085796-01A2|Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits|Designing a Novel Behavioral Treatment Protocol for Children Characterized by Conduct Problems and Callous-unemotional Traits||Florida International University|Yes|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|7 Years|12 Years|No|||December 2015|December 10, 2015|January 7, 2011||No||No|March 3, 2015|https://clinicaltrials.gov/show/NCT01362946||103960|
NCT01363245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHART NYU|Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients|Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.||New York University School of Medicine|Yes|Completed|July 2011|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1618|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01363245||103938|
NCT01363713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01141102|A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis|A Long-term Open-label Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3 -||Santen Pharmaceutical Co., Ltd.||Completed||||September 2012|Actual|Phase 3|Interventional|N/A|1||Actual|130|||Both|12 Years|N/A||||September 2014|September 25, 2014|May 30, 2011||No||No|September 16, 2014|https://clinicaltrials.gov/show/NCT01363713||103902|
NCT01363739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3108|Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab|Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients|PROVETTA|Azienda Ospedaliero, Universitaria Pisana|No|Recruiting|April 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|265|||Both|N/A|N/A|No|Probability Sample|Metastatic colorectal cancer patients receiving FOLFIRI plu Bevacizumab as first-line        treatment|May 2011|May 31, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01363739||103900|
NCT01364051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02906|Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies|Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies||National Cancer Institute (NCI)|No|Active, not recruiting|May 2011|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|87|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|May 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364051||103877|
NCT01364064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC#2081-018|Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma|Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma||King Faisal Specialist Hospital & Research Center|Yes|Completed|January 2007|June 2008|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1153|||Both|N/A|N/A|No|||September 2013|February 24, 2016|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364064||103876|
NCT01364025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULS|Prophylactic Uterosacral Ligament Suspension at the Time of Hysterectomy for Prevention of Vaginal Vault Prolapse|Prophylactic Uterosacral Ligament Suspension at the Time of Hysterectomy for Prevention of Vaginal Vault Prolapse (PULS)||Kaiser Permanente|No|Active, not recruiting|August 2011|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|800|||Female|21 Years|N/A|No|||May 2015|May 19, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364025||103878|
NCT01364324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-493|Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients|Absorption of Anti-tuberculosis Drugs and Its Effect to Treatment Response in Gastrectomized Patients||National Cancer Center, Korea|Yes|Recruiting|September 2010|June 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|80 Years|No|Probability Sample|Among patients with pulmonary TB diagnosed in our hospital and treated with 4 first line        anti-TB drug(isoniazid/rifampicin/ethambutol/pyrazinamide= HREZ), we recruit patients who        underwent gastrectomy to Gastrectomy group. And then, we recruit age-sex matched patients        who did not underwent gastrectomy to Non-gastrectomy group.(age ±3 years)|March 2016|March 21, 2016|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01364324||103856|
NCT01364896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38458|Anal Human Papillomavirus in Inflammatory Bowel Disease Study|Characterization of Anal Human Papillomavirus (HPV) Infection in the University of Pittsburgh Inflammatory Bowel Disease (IBD) Cohort Study|AnalHPV&IBD|University of Pittsburgh|No|Completed|June 2011|December 2015|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|Samples Without DNA|Venous blood, anal swabs, vaginal swabs, high resolution anoscopy (HRA), anal biopsy samples|Both|18 Years|65 Years|No|Non-Probability Sample|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or        Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid        immunosuppressive agent|February 2016|February 10, 2016|May 26, 2011||No||No|December 3, 2015|https://clinicaltrials.gov/show/NCT01364896||103812|
NCT01365546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wil-24|Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery|Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures|WONDERS|Octapharma|Yes|Completed|June 2011|April 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|6 Years|N/A|No|||March 2015|March 5, 2015|May 27, 2011|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01365546||103763|
NCT01365559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-CAR-516|Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments|A Phase I/II Study of Carfilzomib as a Replacement for Multiple Myeloma Patients Failing Bortezomib-containing Regimens||Oncotherapeutics|No|Active, not recruiting|April 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01365559||103762|
NCT01365572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN09049-004|New Generation Drug Eluting Stent for In-stent Restenosis of Drug Eluting Stent( RESTENT-ISR Trial )|Prospective, Single-blinded, Randomized Comparison of the Clinical and Angiographic Results With Intravascular Analysis of EverolimuS-Eluting Versus ZoTarolimus-Eluting steNTs for In-Stent Restenosis(ISR) Lesions: Volumetric Analysis With Intravascular Ultrasound(IVUS) : Phase IV Multicenter Trial ( RESTENT-ISR Trial )|Restenosis|Korea University Anam Hospital|Yes|Recruiting|January 2010|March 2012|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|292|||Both|18 Years|80 Years|No|||March 2011|June 2, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365572||103761|
NCT01365793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917444-1|Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis|Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis||University of California, Davis|Yes|Recruiting|November 2010|November 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1510|||Both|N/A|17 Years|No|||June 2015|June 1, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365793||103744|
NCT01366287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0171006|A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption|A Randomized, Open-Label, Single Dose, Crossover Study To Estimate The Relative Oral Bioavailability And Food Effect Of PF-03882845 In Healthy Adult Volunteers||Pfizer|No|Completed|January 2011|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 2, 2011|January 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01366287||103706|
NCT01366300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPBIS-UC-2010|Effect of Intravenous Lidocaine on BIS-guided Propofol Requirements During General Anesthesia|Estimation of the Effect of Intravenous Lidocaine on BIS-guided Propofol Requirements During General Anesthesia||Pontificia Universidad Catolica de Chile|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2011|June 3, 2011|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366300||103705|
NCT01360892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLOG1003|Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography|Prediction of Incidence of Liver Cancer or PorTal Hypertension in Patients With Viral Hepatitis by Use of Real-time Tissue Elastography|PICTURE|Japan Liver Oncology Group|Yes|Recruiting|September 2010|September 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Probability Sample|Subjects with chronic hepatitis B or C will be eligible for the study. Subjects with other        infectious viral diseases or chronic liver disease are excluded for study enrollment.        Real-time Tissue Elastography®, serum maker and gastrointestinal endoscopy are performed.        If in the hopsital they can perform FibroScan®, FobroScan® also be performed.        The time between the Real-time Tissue Elastography®, blood sampling, FiroScan® must not        exceed four weeks.|August 2010|May 24, 2011|May 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01360892||104117|
NCT01361750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-OES-001|The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy|The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy: A Randomized Control Trial and Physiological Study||Peking University|Yes|Recruiting|May 2011|May 2013|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|30 Years|75 Years|No|||March 2011|May 26, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361750||104052|
NCT01355471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18141|Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea||Galderma|No|Completed|May 2011|January 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|293|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|May 16, 2011|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01355471||104532|
NCT01355796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UO1 HL102288|Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis|Randomized Cross Over Study of Inhaled Hypertonic Xylitol Versus Hypertonic Saline in Stable Subjects With Cystic Fibrosis||University of Iowa|Yes|Active, not recruiting|May 2011|December 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|16 Years|N/A|No|||June 2015|June 4, 2015|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355796||104508|
NCT01356394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|273/2006|Weight Loss Improves Renal Hemodynamics|Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome||Nucleus of Education Interdisciplinary Research and Treatment in Nephrology|No|Completed|January 2010|February 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|58|||Both|20 Years|65 Years|No|||January 2010|May 18, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01356394||104462|
NCT01356407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999169 CS02|Investigation of PICOPREP and PEG-ELS for Bowel Preparation for Colonoscopy|A Multi-center, Randomized, Single-blind Clinical Study of the Efficacy and Safety of PICOPREP and Polyethylene Glycol-electrolyte 4000 Powder for Oral Solution (PEG-ELS) for the Bowel Preparation Prior Colonoscopy||Ferring Pharmaceuticals|No|Completed|January 2011|July 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|70 Years|No|||December 2012|December 17, 2012|May 18, 2011||No||No|September 19, 2012|https://clinicaltrials.gov/show/NCT01356407||104461|
NCT01356680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD17|HD17 for Intermediate Stage Hodgkin Lymphoma|HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma||University of Cologne|Yes|Recruiting|December 2011|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|60 Years|No|||October 2015|October 30, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01356680||104440|
NCT01367002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012007786|Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer|Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma||Yale University|No|Recruiting|June 2011|July 2019|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|N/A|N/A|No|||August 2015|August 20, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01367002||103652|
NCT01362959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NicGoWell1.0|Nicotine Replacement Therapy in the Intensive Care Unit|Nicotine Replacement Therapy in the Intensive Care Unit: a Randomized, Controlled Pilot Study|NicGoWell|Gelderse Vallei Hospital|Yes|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362959||103959|
NCT01363258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR012737|Reducing Care-Resistant Behaviors During Oral Hygiene in Persons With Dementia|Reducing Care-Resistant Behaviors During Oral Hygiene in Persons With Dementia||Penn State University|Yes|Completed|April 2011|November 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|55 Years|N/A|No|||December 2015|December 9, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363258||103937|
NCT01363271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951160|Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients|Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients||Pfizer|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|7260|||Both|18 Years|64 Years|No|Non-Probability Sample|The study population will consist of patients with a hospitalization for complicated skin        and skin structure infections (cSSSI) or pneumonia. We will identify cases from January 1,        2007, to September 30, 2009, with additional 6 months pre-period and up to 6 months of        post-index follow-up period.|May 2012|May 21, 2012|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01363271||103936|
NCT01363752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1212|A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.|A Multicenter, Two Arm, Randomized, Open Label Clinical Study Investigating Renal Function in an Advagraf® Based Immunosuppressive Regimen With or Without Sirolimus in Kidney Transplant Patients|ADHERE|Astellas Pharma Inc|Yes|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|853|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01363752||103899|
NCT01363518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16589|Operative Versus Nonoperative Treatment of Humeral Shaft Fractures: A Prospective Cohort Comparison Study|Operative Versus Nonoperative Treatment of Humeral Shaft Fractures: A Prospective Cohort Comparison Study||St. Louis University|Yes|Enrolling by invitation|May 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|164|||Both|18 Years|65 Years|No|Probability Sample|Patients aged 18 to 65 years with a humeral shaft fracture.|March 2016|March 14, 2016|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363518||103917|
NCT01364077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-DIAL.01|Ivabradine in Hemodialysed Patients With Increased Heart Rate|Efficacy and Safety of Ivabradine in Hemodialysed Patients With Increased Heart Rate||Second University of Naples|Yes|Active, not recruiting|January 2010|||January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||June 2012|June 20, 2012|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01364077||103875|
NCT01363804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-11-117|A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects|A Phase 1, Open-label, Two-period, Single-sequence Study to Evaluate the Effect of Rifampin on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Tivozanib in Healthy Subjects||AVEO Pharmaceuticals, Inc.|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01363804||103895|
NCT01364337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC0990602-E|Blood Pressure and Glucose Lowering Diet for Taiwanese|Design and Testing Efficacy of Blood Pressure and Glucose Lowering Diet for Taiwanese Pre-/1st Staged Hypertension Patients and/or Pre-diabetes Patients|Taiwan_DASH|National Health Research Institutes, Taiwan|No|Active, not recruiting|November 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|65 Years|No|||May 2011|June 1, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364337||103855|
NCT01364870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR009844|Effect of TENS for Pain and Function After Total Knee Replacement|Effect of TENS on Hyperalgesia, Pain With Movement, and Function After TKR|TANK|University of Iowa|Yes|Completed|May 2008|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|317|||Both|30 Years|N/A|No|||May 2014|May 19, 2014|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364870||103814|
NCT01364883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC043|Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP|A Phase I Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP||University of Oxford|Yes|Completed|July 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|39|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364883||103813|
NCT01364584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0438|Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes|Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes|Exenatide|University of Colorado, Denver|No|Active, not recruiting|October 2010|June 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|46|||Both|45 Years|70 Years|No|||March 2016|March 4, 2016|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364584||103836|
NCT01364597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01266|Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy|Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy||UCB Pharma|No|Enrolling by invitation|July 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|N/A|17 Years|No|||March 2016|March 4, 2016|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364597||103835|
NCT01365208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC023|New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer|Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma||Chinese University of Hong Kong|No|Recruiting|July 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|68|Samples With DNA|EBV DNA|Both|18 Years|N/A|No|Probability Sample|paitent with advanced nasopharyngeal carcinoma|January 2016|January 28, 2016|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01365208||103788|
NCT01365221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWITCH 600/60|The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel|SWITCH 600/60: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel|SWITCH 600/60|Medstar Research Institute|No|Active, not recruiting|December 2010|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|75 Years|No|||October 2013|October 31, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01365221||103787|
NCT01365260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-002|Safety and Efficacy of an Injectable Medical Device to Treat Knee Osteoarthritis|A Double-Blind, Randomized, Feasibility Controlled Study to Assess the Safety and Efficacy of MM-II, an Injectable Intraarticular Medical Device, Intended to the Treatment of Symptomatic Knee Osteoarthritis||Moebius Medical Ltd.|No|Completed|October 2011|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|45 Years|N/A|No|||December 2012|December 4, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365260||103784|
NCT01358240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079-2951-303|Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis|A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis||AmDerma|No|Completed|June 2011|August 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|336|||Both|12 Years|N/A|No|||September 2012|September 27, 2012|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358240||104320|
NCT01366313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRH 02|The Median Effective Dose (ED50) of Paracetamol and Morphine : A Study of Interaction Study|The Median Effective Dose (ED50) of Paracetamol and Morphine for Postoperative Patients: A Study of Interaction.||Procare Riaya Hospital|Yes|Completed|September 2007|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||January 2011|December 7, 2012|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366313||103704|
NCT01355146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shire/CS02|Home Therapy With Replagal in Fabry Disease|Non Interventional Study of Replagal® Home Therapy in Patients With Fabry Disease||Shire|No|Recruiting|May 2011|May 2020|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|4 Years|N/A|No|Probability Sample|Patients with proven Fabry's Disease foreseen for home treatment with Agalsidase alfa at        German Fabry centers|February 2015|February 12, 2015|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355146||104556|
NCT01354873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 002315|Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging|Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging||Mayo Clinic|No|Completed|January 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|556|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and Women(not pregnant) presenting to the GI lab for colonoscopy. Child bearing        potential not excluded.|January 2014|January 8, 2014|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354873||104577|
NCT01355159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-107|High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention|Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia-Folic Acid Clinical Trial (FACT)|FACT|Ottawa Hospital Research Institute|Yes|Active, not recruiting|April 2011|July 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3656|||Female|18 Years|N/A|No|||November 2015|November 22, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01355159||104555|
NCT01355172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU10T11C|Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old|Clinical Study Protocol Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011， in Infants Aged Between 6-12months Old||Adimmune Corporation|Yes|Completed|November 2010|||September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|59|||Both|6 Months|1 Year|Accepts Healthy Volunteers|||July 2012|July 12, 2012|May 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01355172||104554|
NCT01355484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G300504|Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy||GTx|Yes|Completed|July 2011|June 2014|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|321|||Both|30 Years|N/A|No|||February 2016|February 4, 2016|May 12, 2011|Yes|Yes||No|February 4, 2016|https://clinicaltrials.gov/show/NCT01355484||104531|
NCT01355497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G300505|Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum|Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy||GTx|Yes|Completed|July 2011|June 2014|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|330|||Both|30 Years|N/A|No|||March 2015|March 18, 2015|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355497||104530|
NCT01356121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5289617|Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics|Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics||Govind Ballabh Pant Hospital|Yes|Recruiting|November 2010|July 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|70 Years|No|||March 2011|May 17, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356121||104483|
NCT01367015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-20/ April 2006|Early Versus Late Initiation of Feeding in Premature Growth Restricted Newborns With Absent or Reversed End Diastolic Flow On Umbilical Artery Doppler (AREDF)|A Randomized Clinical Trial on Comparison of Early Versus Late Initiation of Feeding in Preterm Small for Gestation Infants Below 35 Weeks Gestation With Prenatal Absent or Reversal of End Diastolic Flow (AREDF) in Umbilical Artery|AREDF|All India Institute of Medical Sciences, New Delhi|Yes|Completed|April 2006|March 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|N/A|72 Hours|No|||April 2006|June 3, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01367015||103651|
NCT01363232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2101|Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors||Array BioPharma||Active, not recruiting|August 2011|||March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01363232||103939|
NCT01363778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-11-116|A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects|A Phase 1, Open-label Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Tivozanib in Healthy Subjects||AVEO Pharmaceuticals, Inc.|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01363778||103897|
NCT01363817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA216-002|Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma||Bristol-Myers Squibb|No|Active, not recruiting|September 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||January 2016|February 10, 2016|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01363817||103894|
NCT01364636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYNDERELA-HF|Accuracy of Urinary NGAL in Predicting CardioRenal Syndrome in Acute Heart Failure at Emergency - CYNDERELA-HF Study|Accuracy of Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Cardio-renal Syndrome in Acute Decompensated Heart Failure at Emergency - CYNDERELA-HF Study|CYNDERELA-HF|Pro-Cardiaco Hospital|Yes|Recruiting|February 2011|September 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples Without DNA|Urine plasma serum|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to the Emergency rooms of Hospital PróCardíaco and Hospital        Universitário Antonio Pedro, presenting with acute heart failure according to the        Framingham's criteria. The subjects must sign the informed consent term.|April 2011|June 6, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01364636||103832|
NCT01364350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK61230-T2P1|TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study|TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study of the TODAY Clinical Trial Cohort|T2P1|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|March 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|550|Samples Without DNA|Blood and urine are collected on an annual basis and sent to the Central Biospecimen      Laboratory for analysis and storage.      Analyses performed on an annual basis are: HbA1c, insulin sensitivity and secreation      (fasting glucose, insulin, C-peptide, and proinsulin), 2-hour OGTT, pancreatic autoimmunity,      serum creatinine, liver function tests, lipids (LDL, triglycerides, free fatty acids,      lipoprotein subclass levels, average LDL particle density, and total apoB levels),      cardiovascular risk factors (fibrinogen, c-reactive protein, homocysteine vitamin B-12,      plasminogran activator inhibitor-1, interleukin-6), microalbumin.      HbA1c is also analyzed quarterly.|Both|12 Years|24 Years|No|Non-Probability Sample|participants in the TODAY clinical trial|September 2014|September 26, 2014|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01364350||103854|
NCT01364363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB#13-6190|Unrelated Donor Stem Cell Transplantation|Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors||Scripps Health|No|Recruiting|March 2005|January 2023|Anticipated|January 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|50|||Both|18 Years|69 Years|No|||December 2013|December 5, 2013|April 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364363||103853|
NCT01364610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bravo|An Assessment of pH Testing Methods|A Prospective Assessment of pH Testing Methods in Alberta||University of Calgary|No|Completed|July 2008|August 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|86|||Both|18 Years|75 Years|No|||June 2015|June 19, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364610||103834|
NCT01364623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-2-2011-01|PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women|An Open-label, Single and Multiple Application of Intranasal Testosterone Gel (TBS-2) in Healthy Premenopausal Female Subjects at Three Dose Levels||Trimel Biopharma SRL|Yes|Completed|September 2011|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 4, 2012|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364623||103833|
NCT01364909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XSEP1|Exercise in Critically Ill Patients With Sepsis|Early Intervention With Exercise in Critically Ill Patients With Sepsis: a Randomized Controlled Trial||The University of Queensland|No|Active, not recruiting|June 2007|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2008|June 2, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01364909||103811|
NCT01365806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NR012003-01A1|Home Electrocardiogram (ECG) Monitoring After Heart Transplantation|Home ECG Monitoring to Detect Allograft Rejection Following Heart Transplantation|NEW HEART|University of California, Los Angeles|Yes|Active, not recruiting|August 2011|January 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|adult heart transplant recipients from recruitment sites (Columbia University-New York        Presbyterian Medical Center; University of California, Los Angeles; and Cedars-Sinai        Medical Center|November 2015|November 30, 2015|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01365806||103743|
NCT01358500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEN001|An Assessment of Fentanyl Dose Requirements in Opioid-maintained Individuals|An Assessment of Fentanyl Dose Requirements in Opioid-maintained Individuals|FEN001|University of Adelaide|No|Recruiting|February 2012|May 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||February 2013|February 4, 2013|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01358500||104300|
NCT01366053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMX-DELAY2010|Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists|Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists: A Prospective, Observational, Phase IV Study (DELAY)|DELAY|CMX Research|No|Recruiting|March 2011|January 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with prostate cancer failing androgen deprivation therapy can be investigated in        this trial.|February 2012|February 2, 2012|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01366053||103724|
NCT01366066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-109|Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Stress Incontinence and Urge Incontinence||Copenhagen University Hospital at Herlev|No|Terminated|May 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|4|||Female|18 Years|N/A|No|||May 2013|May 23, 2013|May 30, 2011|Yes|Yes|Failure to recruit participants|No||https://clinicaltrials.gov/show/NCT01366066||103723|
NCT01354886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXGP240101|Single Dose FSH-GEX™ in Healthy Volunteers|A Phase I, Monocenter, Randomized, Placebo and Comparator Controlled, Single Blind, Rising Dose, Clinical Study to Determine Single Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Four Doses of FSH-GEX™ According to Adaptive Design (25, 75, 150 and 300 IU) Administered Subcutaneously in Healthy Pituitary-suppressed Female Volunteers||Glycotope GmbH|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|||Anticipated|18|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 25, 2011|May 11, 2011||||No||https://clinicaltrials.gov/show/NCT01354886||104576|
NCT01355822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETN_ESTG|Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies|Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies: a Prospective Randomized Pilot Study||University of Jena|No|Completed|April 2002|||January 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|111|||Female|18 Years|50 Years|No|||May 2011|May 26, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355822||104506|
NCT01356108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-11|Pulmonic Valve REplacement Multi-discIpline EMEA Registry|Implantation of the SAPIEN™ Transcatheter Heart Valve (THV) in the Pulmonic Position|PREMIER|Edwards Lifesciences|No|Active, not recruiting|January 2011|April 2017|Anticipated|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|All symptomatic patients with a regurgitant or stenotic pulmonary valved conduit treated        by implantation of the Edwards SAPIEN™ THV.|January 2014|May 21, 2014|May 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01356108||104484|
NCT01355835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF 259-0-0|Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease|Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease: Design of a Two-armed Double-blind Cross-over Study|STN/SNr|University Hospital Tuebingen|Yes|Completed|February 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|80 Years|No|||August 2012|August 7, 2012|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01355835||104505|
NCT01356433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|d2a3scvr|Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients|Effect of Oral Vitamin C on The Inflammatory Biomarkers in Hemodialysis||Peking University First Hospital|Yes|Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2012|September 19, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356433||104459|
NCT01367028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG 32|A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer|Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Breast Cancer|ABCSG 32|Austrian Breast & Colorectal Cancer Study Group|Yes|Completed|June 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01367028||103650|
NCT01362985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ19310|Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor|Monitoring of Plerixafor Off-Label Use in the European Group for Blood and Bone Marrow Transplantation (EBMT) Registry||Sanofi|No|Completed|July 2009|July 2014|Actual|July 2014|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|201|||Both|N/A|18 Years|No|Non-Probability Sample|Patients treated off-label with plerixafor.|August 2015|August 12, 2015|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362985||103957|
NCT01363531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDA study|Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies|Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies in the Non-complicated Acute Respiratory Tract Infections in General Practice|PDA|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|December 2009|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|405|||Both|18 Years|N/A|No|||March 2015|August 26, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01363531||103916|
NCT01363544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw 157003012|Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD)|Train Your Brain? Exercise and Neurofeedback Intervention for ADHD||VU University of Amsterdam|No|Completed|June 2010|January 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|112|||Both|7 Years|13 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01363544||103915|
NCT01363297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1931010|Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia|An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia||Pfizer|No|Active, not recruiting|August 2011|February 2016|Anticipated|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|May 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363297||103934|
NCT01363791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-KS-2009-205030|Meta-analyses of Fructose and Cardiometabolic Risk|Effect of Fructose on Metabolic Control in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development||University of Toronto|No|Active, not recruiting|May 2009|March 2016|Anticipated|March 2014|Actual|N/A|Observational|N/A||1|Anticipated|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Varied.|May 2015|May 26, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01363791||103896|
NCT01364649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_318|Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction|A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction||Takeda|No|Completed|June 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|55 Years|No|||October 2014|October 6, 2014|May 31, 2011|Yes|Yes||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01364649||103831|
NCT01364090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHCRP1007|A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3|A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b and Self Administered Ribavirin for Patients With Chronic HCV Genotype 2 or 3 and Injection Drug Use|ACTIVATE|Kirby Institute|Yes|Active, not recruiting|June 2012|September 2015|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364090||103874|
NCT01365234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Model 20066|Model 20066 Left Ventricular (LV) Lead Study|Model 20066 Left Ventricular (LV) Lead Study||Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|July 2011|August 2013|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01365234||103786|
NCT01365520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3893|A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A|Multi-Centre, Open-Label, Randomised Trial Investigating the Pharmacokinetics of a Single Dose of NNC 0155-0000-0004 (N8) in Patients With Haemophilia A||Novo Nordisk A/S|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|12 Years|56 Years|No|||July 2015|July 7, 2015|May 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01365520||103765|
NCT01365533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BY217/M2-034|A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma||Nycomed||Completed|December 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|No|||May 2012|May 4, 2012|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01365533||103764|
NCT01365247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA023187-01A1|Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)|A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence||The City College of New York|Yes|Completed|September 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|65 Years|No|||May 2015|May 13, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365247||103785|
NCT01354548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORSS-88571|Prevention of Trismus During Radiotherapy and Quality of Life in Head and Neck Cancer Patients|Prophylactic Training for the Prevention of Radiotherapy-induced Trismus - a Randomised Study. Health-related Quality of Life up to One Year After Radiotherapy in Patients With Head and Neck Cancer||University Hospital, Linkoeping|Yes|Active, not recruiting|February 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01354548||104602|
NCT01365819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shoptaw_varen2011|Varenicline for Methamphetamine Dependence|Varenicline for Methamphetamine Dependence: Phase II Clinical Trial||University of California, Los Angeles|Yes|Completed|February 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01365819||103742|
NCT01365832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSACRP-02|Change in C-reactive Protein (CRP) in Men and Women With Sleep Apnea After Continuous Positive Airway Pressure (CPAP)|CRP Evolution Pattern in CPAP Treated Obstructive Sleep Apnea Patients. Does Gender Play a Role?||University of Crete|No|Completed|January 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|436|||Both|18 Years|65 Years|No|||April 2011|June 3, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01365832||103741|
NCT01355523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVH-03|The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients|The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients|MELODY|Herlev Hospital|No|Terminated|July 2011|January 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Female|30 Years|75 Years|No|||April 2014|April 4, 2014|May 13, 2011||No|Inclusion rate not as expected. Not financially possible to involve other centres.|No|August 14, 2013|https://clinicaltrials.gov/show/NCT01355523||104528|Premature termination (54/260). Only included about 8% (54/703) of the patients assessed for eligibility.
NCT01356134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61/3527|Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)|Vascular Fundus Changes in Patients With High Probability of CCSVI (Chronic Cerebrospinal Venous Insufficiency)||Genetic Disease Investigators|Yes|Completed|May 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Aged-matched normals are patients at Total Eye Care. Multiple sclerosis and/or        Ehlers-Danlos patients will be accepted from any area, and will not be excluded based on        location of residence. They need not be patients of Total Eye Care.|April 2015|April 2, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01356134||104482|
NCT01356459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.261|Pressure Ulcer Prevention in Intensive Care Unit (ICU)|A Prospective Randomised Controlled Trial of the Effectiveness of Absorbent Silicone Self Adherent Dressings in the Prevention of Sacral and Heel Pressure Ulcers in Trauma and Critically Ill ED/ICU Patients||Melbourne Health|Yes|Completed|June 2011|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|440|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356459||104457|
NCT01362972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ18009|Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor|Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor||Sanofi|No|Active, not recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|9500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with data reported to the EBMT who have lymphoma or multiple myeloma (MM) and who        have undergone autologous haematopoietic stem cell (HSC) transplantation during the years        2008 up to and including 2012.|August 2015|August 12, 2015|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362972||103958|
NCT01362998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|goodman-2|Epidural Morphine Versus Epidural Fentanyl Infusion Following Cesarean Section|A Comparison of Single Dose Preservative Free Morphine With Fentanyl Infusion for Post-Cesarean Section Analgesia||Goodman, Evan, M.D.|Yes|Recruiting|March 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||May 2011|May 31, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01362998||103956|
NCT01363011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0118|Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment|A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment||Gilead Sciences|No|Completed|May 2011|February 2015|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|May 11, 2011|Yes|Yes||No|October 27, 2014|https://clinicaltrials.gov/show/NCT01363011||103955|
NCT01364103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1012-118-345|Study About Predicting Fluid Responsiveness in Children Undergoing Neurosurgery|||Seoul National University Hospital||Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|33|||Both|N/A|8 Years|No|||January 2012|January 31, 2012|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01364103||103873|
NCT01364116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1012-127-346|The Accuracy of Noninvasive and Continuous Hemoglobin Measurement by Pulse CO-Oximetry™ in Children Undergoing Volume Expansion|||Seoul National University Hospital|No|Completed|February 2011|December 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Both|1 Month|10 Years|No|Probability Sample|Children under 10 years old who were planned to take elective surgery which may cause        patients' hemodynamic unstability.        Patients who require intraoperative invasive arterial blood pressure monitoring.|June 2012|June 5, 2012|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01364116||103872|
NCT01363557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100601|Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis|Randomized to Assess the Efficacy of Whole Brain Radiation Therapy (WBRT) With Concomitant Gefitinib Followed by Maintenance Gefitinib, and Gefitinib Alone, in Lung Cancer Patients With Brain Metastasis|ARPEGE|Assistance Publique - Hôpitaux de Paris|No|Terminated|March 2012|May 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|May 25, 2011||No|Decision of Sponsor|No||https://clinicaltrials.gov/show/NCT01363557||103914|
NCT01364142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_bronchial blocker|A Blind Maneuver to Position an Endobronchial Blocker|A Blind Maneuver to Position an Endobronchial||Seoul National University Hospital|No|Completed|June 2011|February 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|80 Years|No|Probability Sample|patients undergoing thoracic surgery|June 2012|June 20, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364142||103870|
NCT01364922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-807|Phase 2 Chronic Low Back Pain Study|A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects With Chronic Low Back Pain||AbbVie|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|168|||Both|18 Years|75 Years|No|||December 2013|December 23, 2013|June 1, 2011|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01364922||103810|
NCT01364662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810P202|A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)||Supernus Pharmaceuticals, Inc.|No|Completed|June 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|121|||Both|6 Years|12 Years|No|||November 2015|November 16, 2015|May 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364662||103830|
NCT01364935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092165|Comparison of DuoFertility, LadyComp/BabyComp and Clearblue Monitors|Pilot Study Comparing Fertility Monitors: DuoFertility Monitor, LadyComp/Babycomp Monitor and Clearblue Ovulation Tests in Support of FDA Application||Cambridge University Hospitals NHS Foundation Trust|No|Completed|March 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female participants trying to conceive, with regular menstrual cycles.|June 2014|June 24, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364935||103809|
NCT01364961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-054|Resveratrol and Serum Apo A-I|The Effects of Resveratrol on Serum Apolipoprotein A-I Concentrations in Men and Women With Low HDL-cholesterol Concentrations||Maastricht University Medical Center|No|Completed|January 2011|August 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01364961||103807|
NCT01357174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-046|ROTATEQ™ Post-Marketing Surveillance in the Philippines|Protocol for ROTATEQ™ Post-Marketing Surveillance||Merck Sharp & Dohme Corp.|No|Terminated|October 2007|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|915|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Infants in the Philippines who received ROTATEQ.™ Information will be provided by the        physicians who administered the vaccine.|October 2015|October 29, 2015|May 18, 2011|No|Yes|Merck Sharp & Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing    surveillance (PMS) study|No||https://clinicaltrials.gov/show/NCT01357174||104402|
NCT01355107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC1|Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease|Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease - a Pilot Trial||University Hospital Freiburg|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|32|Samples Without DNA|whole blood|Male|18 Years|80 Years|No|Non-Probability Sample|Whole blood samples are taken from inpatients and outpatients of our primary care clinic|December 2011|December 13, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01355107||104559|
NCT01365585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481297|Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension|Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension||Pfizer|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|227|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at least 18 years of age diagnosed with pulmonary arterial hypertension (PAH; per        Dana Point classification) and treated with sildenafil citrate for their PAH|January 2013|January 8, 2013|June 1, 2011|Yes|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT01365585||103760|
NCT01355731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XMP10-163 ETBABN|Evaluating Therapeutic Boundaries Among Bedside Nurses At A Pediatric Hematology/Oncology Research Hospital|Evaluating Therapeutic Boundaries Among Bedside Nurses At A Pediatric Hematology/Oncology Research Hospital|EBABN|St. Jude Children's Research Hospital|No|Completed|May 2011|June 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is quality improvement study that is descriptive and is utilizing a convenience        sample of direct care registered nurses employed full-time for at least one year at St.        Jude Children's Research Hospital|September 2011|September 14, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355731||104512|
NCT01355744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSSB|Swiss Study on Spider Bites|Swiss Study on Spider Bites|SSSB|University of Zurich|No|Completed|June 2011|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|None Retained|Species of biting spider will be assessed if specimen is sent to us.|Both|N/A|N/A|No|Non-Probability Sample|Every person with a suspected spider and treated by a Swiss Physician.|October 2013|October 1, 2013|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01355744||104511|
NCT01355510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-MHH-CVRX-ReSy-EK5753|Effects of Electrical Baroreflex Stimulation on Sympathetic Activity, Renal Hemodynamics, and Insulin Sensitivity|Electrical Baroreflex Stimulation - Sympathetic Activity|CVRX-ReSy|Hannover Medical School|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with implanted devices for electrical baroreflex stimulation are recruited        according to inclusion and exclusion criteria until good quality recordings have been        obtained in 20 patients during both stimulator settings (ON and OFF) in the corresponding        study arm. After obtaining written informed consent patients will be investigated in the        laboratory.|September 2013|September 18, 2013|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355510||104529|
NCT01355848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39417-C|Improving Care Provided to Patients Treated in a Level 1 Trauma Center Post-suicide Attempt|Improving Care Provided to Patients Treated in a Level 1 Trauma Center Post-suicide Attempt||University of Washington|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|N/A|No|||March 2015|March 6, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01355848||104504|
NCT01356147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z4962s|Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)|Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit|PVAIN|Georgetown University|No|Active, not recruiting|May 2011|December 2015|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|4 Months|No|||August 2015|August 5, 2015|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01356147||104481|
NCT01356446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|check4outcome3|Checklist Application and Mortality|Impact of the Surgical Checklist on 30-day and 90-day Mortality in Elective Non-cardiac Surgery||Regional Hospital of Bolzano|Yes|Withdrawn|June 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|N/A|N/A|No|||May 2015|May 4, 2015|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356446||104458|
NCT01356160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-256-0148|GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy With GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection||Gilead Sciences||Completed|July 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|70 Years|No|||January 2014|January 2, 2014|May 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356160||104480|
NCT01356173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKI4956g|Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma|An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma||Genentech, Inc.||Completed|June 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356173||104479|
NCT01367054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2008|Adverse Events in Pharmaceutical Bioequivalence Study of Two Formulations of Metformine Hydrochloride 500 mg|Adverse Events in Pharmaceutical Bioequivalence Study of Two Formulations of Metformine Hydrochloride 500 mg||Biocinese|No|Active, not recruiting|June 2008|December 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2011|June 3, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01367054||103648|
NCT01363063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2006-01|Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers|A Phase 1, Double-Blind, Study of the Tolerability of Formulations of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers||Luitpold Pharmaceuticals||Completed|December 2006|June 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 27, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363063||103951|
NCT01364376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYYY-GC1105|S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma|S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma: a Multi-center, Open-labeled, Randomized Controlled Trial|Focus|Zhejiang University||Recruiting|June 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|583|||Both|18 Years|80 Years|No|||May 2011|July 29, 2014|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01364376||103852|
NCT01364155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIM-0705-CL-2001|Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR|A Randomized, Single-Blind, Placebo-Controlled Phase 2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR||Limerick BioPharma|No|Recruiting|May 2011|August 2011|Anticipated|August 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||May 2011|May 31, 2011|May 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364155||103869|
NCT01364389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPJMR0012201|A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica|A 2-week Single-blind, Randomized, 3-arm Proof of Concept Study of the Effects of AIN457 (Anti-IL17 Antibody), ACZ885 (Canakinumab, Anti-IL1b Antibody), or Corticosteroids in Patients With Polymyalgia Rheumatica, Followed by an Open Label Phase to Assess Safety and Long Term Efficacy||Novartis||Terminated|February 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|50 Years|85 Years|No|||March 2015|March 10, 2015|March 10, 2011||No|Data did not show that the two biologic treatments impacted PMR disease activity to the same    degree as steroid treatment within a 2-week treatment period.|No|February 17, 2015|https://clinicaltrials.gov/show/NCT01364389||103851|
NCT01364675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12011|Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects|Primary Prevention of Cardiovascular Disease in Pre-diabetic & Pre-hypertensive Subjects Using Multiple Risks Reduction Strategy: A Multi-center, Double-blind, Randomized Controlled Trial|PPCVD|Ramathibodi Hospital|Yes|Not yet recruiting|January 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|8900|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2011|June 1, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364675||103829|
NCT01355432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00236|Heart Rate Changes With Propofol|Changes in Heart Rate Following Administration of Propofol After Inhalational Induction||Nationwide Children's Hospital|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|1 Year|N/A|No|Non-Probability Sample|Surgery patients at Nationwide Children's Hospital.|May 2012|May 1, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01355432||104535|
NCT01364948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-28/Dec 2005|Effect of Coconut Oil Application in Reducing Water Loss From Skin of Premature Babies in First Week of Life (TEWL)|Effect of Topical Oil Application on Trans-epidermal Water Loss (TEWL) in Preterm Very Low Birth Weight (VLBW) Infants - A Randomized Clinical Trial|TopOilTewl|All India Institute of Medical Sciences, New Delhi|Yes|Completed|January 2006|December 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|74|||Both|N/A|168 Hours|No|||December 2005|June 1, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01364948||103808|
NCT01357187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFPIR001|An Evaluation of the Effect of the AmnioFix Amniotic Membrane Allograft in Patients Undergoing Posterior Instrumentation Removal|An Evaluation of the Effect of the AmnioFix™ Amniotic Membrane Allograft on Scar Tissue and Adhesions in Patients Undergoing Posterior Instrumentation Removal||MiMedx Group, Inc.||Completed|September 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||June 2014|March 16, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357187||104401|
NCT01364467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13538|The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study|The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study||Virginia Commonwealth University|No|Recruiting|May 2011|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|7 Years|18 Years|No|||November 2015|November 3, 2015|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364467||103845|
NCT01354821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090209|Medical & Economical Evaluation of Fenestrated & Branched Stent-grafts to Treat Complex Thoracal Abdominal Aneurysms|Medical & Economical Evaluation of Endovascular Therapy of Complex Thoracal Abdominal Aneurysms (Type 1-3 Thoracal Abdominal Aneurysms) by Fenestrated & Branched Stent-grafts|Windows2|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|November 2009|December 2015|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01354821||104581|
NCT01354587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hizentra|Evaluation of Efficacy and Tolerability of Hizentra®|Evaluation of Efficacy and Tolerability of Hizentra® in Subjects Transitioning From Vivaglobin® (16% SCIG Product) to Hizentra® (20% SCIG Product)||University of South Florida|Yes|Recruiting|October 2010|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|1 Year|75 Years|No|||July 2012|July 16, 2012|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354587||104599|
NCT01355211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC3NS070658|Putting Electroencephalography (EEG) in the Emergency Department|Diagnostic Utility of Emergency Electroencephalography in Identifying Non-convulsive Seizure and Subclinical Status Epilepticus in Patients With Altered Mental Status||Bio-Signal Group Corp.|Yes|Completed|April 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|261|||Both|13 Years|N/A|No|Non-Probability Sample|A total of 260 patients will be recruited for the study. Adult and pediatric patients ≥ 13        year-old with AMS on arrival to ED|February 2012|February 29, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355211||104551|
NCT01355536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46011600-57|Metabolic and Endocrine Status in Women With Prior Preterm Birth|Metabolic and Endocrine Status in Women With Prior Preterm Birth. A Cross Sectional, Case- Control Study||Namsos Hospital|No|Completed|October 2006|||April 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|262|Samples With DNA|Whole blood, serum,endometrial biopsy|Female|N/A|N/A|No|Non-Probability Sample|All women in municipalities having Namsos Hospital as their local Hospital and with        preterm births from January 1999 to Descember 2006 were identifed by searching birth        protocols. These women were invited to participate in the preterm birth study group. As        controls we identified the first term birth occuring in time after each preterm birth.        These women were invited to participate in the term birth study group.|May 2011|May 17, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01355536||104527|
NCT01355861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7508-W|Resistance Exercise for the Prevention of Age-related Sarcopenia|Negative Work Exercise as a Novel Treatment for Sarcopenia in Older Men|REPAiRS|VA Office of Research and Development|No|Withdrawn|June 2011|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|60 Years|79 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|March 14, 2011||No|Project has been withdrawn from funding consideration|No||https://clinicaltrials.gov/show/NCT01355861||104503|
NCT01355874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN 309-Hem-SE3-001|Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Intra-Anal Application of Iferanserin (10 mg) as a 0.5% Ointment in Subjects With Symptomatic Internal Hemorrhoids|VEN309|Ventrus Biosciences, Inc|No|Terminated|July 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|403|||Both|18 Years|75 Years|No|||July 2012|January 26, 2014|May 16, 2011|Yes|Yes|The primary endpoint was not met on the double blind data|No||https://clinicaltrials.gov/show/NCT01355874||104502|
NCT01356186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-1072|Pilot Trial of Inpatient Cognitive Therapy for the Prevention of Suicide in Military Personnel|Pilot Trial of Inpatient Cognitive Therapy for the Prevention of Suicide in Military Personnel With Acute Stress Disorder of Post Traumatic Stress Disorder|CDMRP|Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Active, not recruiting|July 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356186||104478|
NCT01356485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD-105|Safety Study of MP4CO in Adult Sickle Cell Patients|A Multi-center, Randomized, Double Blind, Dose Escalation Safety Study of MP4CO in Clinically Stable Adult Sickle Cell Patients||Sangart|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|32|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356485||104455|
NCT01356498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0407|Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout|Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout||Savient Pharmaceuticals|No|Completed|December 2006|January 2010|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|October 27, 2008|Yes|Yes||No|August 5, 2011|https://clinicaltrials.gov/show/NCT01356498||104454|
NCT01367067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/020/08/E|Prediction of Claustrophobia During MR Imaging|Prediction of Claustrophobia During MR Imaging: An Observational 18-Months Single Center Study|CLAUSTRO II|Charite University, Berlin, Germany|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8000|||Both|18 Years|N/A|No|Probability Sample|Adult inpatients and outpatients with a clinical indication of any part of the body who        are referred to Charité for MR imaging|May 2011|July 1, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01367067||103647|
NCT01367080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWETR-I-1|A Study to Compare the Pharmacokinetic Profiles of Etravil® Tablet 10mg and Etravil® Tablet 25mg|Clinical Trials to Compare the Pharmacokinetics Profile of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline Hydrochloride) Tablet 25mg After a Single Oral Administration in Healthy Male Volunteers|DWETR|Dong Wha Pharmaceutical Co. Ltd.|Yes|Completed|July 2011|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 6, 2014|June 2, 2011||No||No|February 20, 2013|https://clinicaltrials.gov/show/NCT01367080||103646|When collecting blood samples, few subjects were drawn blood later than that stated in protocol for about 1 ~ 2 minutes where results may not be effected.One of the subjects came in late for Post-study visit for about 4~6 days.
NCT01363830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P001125|Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy|Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study||Brigham and Women's Hospital|No|Recruiting|August 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01363830||103893|
NCT01363570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMDgene12011|Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes|Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes||McMaster University|No|Completed|January 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|99 Years|No|||March 2016|March 15, 2016|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01363570||103913|
NCT01363583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151:633=01|Study on the Effect of Prostacyclin Compared to Placebo in Traumatic Brain Injury|Prostacyclin Treatment in Severe Traumatic Brain Injury: a Microdialysis and Outcome Study||Umeå University|No|Completed|January 2002|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|15 Years|70 Years|No|||September 2001|May 27, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363583||103912|
NCT01363843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 224|Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)|Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)||Brown University|Yes|Completed|May 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|May 26, 2011|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT01363843||103892|
NCT01364129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPAIHB O5-P-O5|The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy|The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy||Legacy Health System|No|Completed|August 2006|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|567|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01364129||103871|
NCT01366092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-149|Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease||Dana-Farber Cancer Institute|Yes|Active, not recruiting|July 2011|||October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||June 2015|June 29, 2015|June 2, 2011|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01366092||103721|
NCT01364402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO1|Prevention of Contrast Induced Nephropathy by Erythropoietin|Prevention of Contrast Induced Nephropathy by Erythropoietin in Patients With Diabetes Mellitus and eGFR<60 ml/Min/1.73m2 Undergoing Percutaneous Coronary Intervention||Western Galilee Hospital-Nahariya|Yes|Recruiting|August 2011|December 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|142|||Both|18 Years|N/A|No|||September 2011|October 9, 2012|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01364402||103850|
NCT01355965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17510|Autologous Redirected RNA Meso-CIR T Cells|Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients With Progressive Malignant Pleural Mesothelioma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|May 2011|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355965||104495|
NCT01355978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0031|Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)|Acceptability, Comfort, and Exercise Tolerance Using a Non-invasive Ventilation System in Patients With Moderate-to-Severe COPD (PRIDE)|PRIDE|Breathe Technologies, Inc.|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|21 Years|80 Years|No|||February 2013|February 4, 2013|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355978||104494|
NCT01356329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08/118|Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients|A Randomized, Controlled, Open Label Study of the Efficacy and Safety of the Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin) Versus HeparinTM (Unfractionated Heparin) for Prevention of Venous Thromboembolism (VTE) in Gynecologic Oncology Patients|Lovenox|National Guard Health Affairs|No|Recruiting|October 2009|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|No|||January 2014|January 15, 2014|March 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01356329||104467|
NCT01357967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Seroquel ISS D1443C00053|The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope|The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope||Inje University|No|Recruiting|May 2011|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||October 2012|October 31, 2012|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01357967||104341|
NCT01358227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR104-1002|A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors|A Phase I, Multi-center, Open-label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given Weekly in Subjects With Solid Tumors||Proacta, Incorporated|No|Completed|December 2006|January 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||May 2011|May 23, 2011|May 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358227||104321|
NCT01365039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|690|Safety and Efficacy of a Contact Lens for Daily Disposable Use|A Study to Evaluate the Safety and Efficacy of a Novel Contact Lens for Daily Disposable Use||Bausch & Lomb Incorporated|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|173|||Both|18 Years|40 Years|No|||November 2013|November 20, 2013|June 1, 2011|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01365039||103801|
NCT01365052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15560|Safety Trial of Naproxen Sodium/ Diphenhydramine|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Safety and Tolerability Trial of Naproxen Sodium/ Diphenhydramine Combination in an OTC Population|MUST|Bayer|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|326|||Both|12 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|May 17, 2011|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01365052||103800|
NCT01365065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1121-9077|Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy|A Pilot Study to Assess the Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy||Bayside Health|Yes|Active, not recruiting|May 2011|February 2013|Anticipated|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||December 2012|December 3, 2012|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365065||103799|
NCT01355445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIT-0910|Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma : International Randomized Trial|International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma|VIT-0910|Centre Oscar Lambret|Yes|Active, not recruiting|January 2012|June 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Months|50 Years|No|||June 2014|June 20, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355445||104534|
NCT01355185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25750|Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences|Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences||AHS Cancer Control Alberta|No|Recruiting|August 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients seen at an academic institution (tertiary centre ...Cross Cancer Institute) for        consideration of prostate brachytherapy|October 2014|October 1, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355185||104553|
NCT01355224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-R21|Communicating Risk Information for Obesity|Communicating Genetic Information for Obesity||Boston University|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|798|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 17, 2014|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01355224||104550|
NCT01355549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-677-10|Platelet-Rich Plasma Therapy for Shoulder Pain in Persons With Spinal Cord Injury|A Pilot Study to Evaluate the Feasibility of Platelet-Rich Plasma Therapy as a Treatment for Chronic Shoulder Pain in Persons With Spinal Cord Injury||Kessler Foundation|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|60 Years|No|||January 2013|January 14, 2013|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355549||104526|
NCT01355562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLU1101|Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer|Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer||Loma Linda University|No|Withdrawn|March 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 3, 2012|April 28, 2011||No|Primary Investigator is no longer employed at LLU as of 02/29/12.|No||https://clinicaltrials.gov/show/NCT01355562||104525|
NCT01356199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00319-32|Effect of Artronat on the Quality of Life of Patient With Osteoarthritis|Effet du complément Alimentaire ARTRONAT(R) Sur la réduction de la Gonalgie Chez Des Sujets Arthrosiques||Lescuyer Laboratory|No|Completed|October 2011|December 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|7|||Both|40 Years|75 Years|No|||March 2014|March 17, 2014|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356199||104477|
NCT01356212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2002-02|Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device|Scintigraphic Assessment of Nasal Deposition and Clearance of 99mTc DTPA Ketorolac Solution Administered Using the Valois Nasal Spray Device||Luitpold Pharmaceuticals||Completed|September 2002|December 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 17, 2011|May 16, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01356212||104476|
NCT01356225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2003-05|A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery|A Randomized, Double-blind, Placebo-controlled, Parallel, Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery||Luitpold Pharmaceuticals|No|Completed|February 2004|||March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2011|May 18, 2011|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356225||104475|
NCT01356511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-002|High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial||Shandong University|Yes|Recruiting|September 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|80 Years|No|||September 2010|May 19, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356511||104453|
NCT01363284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diabetic_Duloxetine09CTIL|Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients|Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients Based on Assessment of Endogenous Analgesia Capabilities||Rambam Health Care Campus|No|Recruiting|June 2010|January 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|85 Years|No|||December 2009|May 29, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01363284||103935|
NCT01363349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020-CLIN-201|Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia|A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia|CLARITY|BioLineRx, Ltd.|No|Terminated|May 2011|April 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|50 Years|No|||September 2014|September 17, 2014|May 30, 2011||No|pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the    trial would not meet the pre-specified primary efficacy endpoint.|No|April 22, 2014|https://clinicaltrials.gov/show/NCT01363349||103930|
NCT01363362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT/OBF_EK 398122010|Selective Lasertrabeculoplasty and Ocular Hemodynamics in Glaucoma|Effect of Selective Lasertrabeculoplasty (SLT) on Ocular Hemodynamics in Glaucoma|SLT/OBF|Technische Universität Dresden|No|Completed|December 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||December 2012|December 17, 2012|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363362||103929|
NCT01363596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14070|International NaProTechnology Evaluation and Surveillance of Treatment for Infertility and Miscarriage (iNEST)|International Natural Procreative Technology Evaluation and Surveillance of Treatment for Infertility and Miscarriage (iNEST)|iNEST|University of Utah|No|Enrolling by invitation|January 2006|December 2026|Anticipated|December 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|N/A|No|Non-Probability Sample|Couples eligible for this study will be all couples who are considering NPT treatment to        help them conceive or maintain a pregnancy and who present to participating physicians or        providers during the time of their participation in the study.|August 2014|August 25, 2014|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363596||103911|
NCT01363856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSB_PROSCIS_01|Center for Stroke Research Berlin (CSB) Prospective Stroke Cohort|Center for Stroke Research Berlin (CSB) Prospective Stroke Cohort|CSB_PROSCIS|Charite University, Berlin, Germany|No|Recruiting|February 2010|June 2015|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|Samples With DNA|Samples with DNA whole blood, serum, RNA|Both|18 Years|N/A|No|Probability Sample|Patients admitted to a specialized stroke service because of an acute stroke|May 2011|June 1, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01363856||103891|
NCT01366651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016189|A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age|An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age||Janssen Research & Development, LLC|No|Terminated|March 2012|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Both|N/A|1 Year|No|||December 2013|December 4, 2013|April 14, 2011||No|Trial terminated early per business decision.|No||https://clinicaltrials.gov/show/NCT01366651||103678|
NCT01367210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023316-13|Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)|Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial|GUSTA|Catholic University of the Sacred Heart|No|Terminated|June 2011|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|June 3, 2011||No|Because a higher rate of virological failures in study versus control arm.|No||https://clinicaltrials.gov/show/NCT01367210||103636|
NCT01356602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2361|Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients|A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients||Novartis||Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|397|||Both|18 Years|85 Years|No|||December 2013|December 10, 2013|May 16, 2011|Yes|Yes||No|September 6, 2013|https://clinicaltrials.gov/show/NCT01356602||104446|
NCT01356875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMD-TXAGO|Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy|Phase II Clinical Trial for Treatment of Myelodysplastic Syndromes Comparing Hydralazine / Ac.Valproico and Supportive Care in Patients Not Candidates, Refractory and / or Intolerant to Intensive Chemotherapy||Basque Health Service|No|Not yet recruiting|September 2011|January 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||April 2011|May 19, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01356875||104425|
NCT01354223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC100239|Clinical Evaluation of Stenfilcon A Soft Contact Lens When Compared to Ocufilcon B Soft Contact Lens|Evaluation of the CooperVision Stenfilcon A Soft Contact Lens for Daily Wear When Compared to the CooperVision Ocufilcon B Soft Contact Lens||Coopervision, Inc.|Yes|Completed|October 2010|April 2011|Actual|March 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||January 2014|February 4, 2014|January 10, 2011|Yes|Yes||No|October 23, 2013|https://clinicaltrials.gov/show/NCT01354223||104627|
NCT01363908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-202|Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload|A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload||Shire|Yes|Terminated|August 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|6 Years|17 Years|No|||August 2014|May 27, 2015|May 30, 2011|Yes|Yes|This study was terminated due to treatment stop resulting in an inability to draw conclusions    from the data. Evaluation of nonclinical rat findings is ongoing.|No|May 6, 2015|https://clinicaltrials.gov/show/NCT01363908||103887|This study was terminated early because of non-clinical safety results. As such, not all subjects completed the study. The available efficacy data were summarized and analyzed as specified in the SAP; however, no efficacy conclusions could be drawn.
NCT01365377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMILLE-JJR-2|Impact of Information Strategy Based on Booklet on Anxiety in Family in ICU|Impact of the Deliverance and Use of a Written Detailed Information Brochure on Anxiety Felt by the Family Members of Patients Admitted in Intensive Care Unit|FAMILLE|Groupe Hospitalier Pitie-Salpetriere|No|Recruiting|April 2011|April 2013|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|16 Years|N/A|No|||April 2011|June 2, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365377||103776|
NCT01356615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814|Low Molecular Weight Heparin for Hemodialysis Anticoagulation|Low Molecular Weight Heparin (Enoxaparin Sodium) and Standard Unfractionated Heparin for Hemodialysis Anticoagulation||Tehran University of Medical Sciences|Yes|Completed|March 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|27|||Both|25 Years|76 Years|No|||May 2011|May 18, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01356615||104445|
NCT01356628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.14|A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer|A Phase II Study of PD-0332991 in Adult Patients With Advanced Hepatocellular Carcinoma||Thomas Jefferson University|Yes|Active, not recruiting|June 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356628||104444|
NCT01355198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV and glutathione|Role of HIV on Glutathione Synthesis and Oxidative Stress|Role of HIV on Glutathione Synthesis and Oxidative Stress||Baylor College of Medicine|No|Completed|August 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|21 Years|70 Years|No|||February 2013|February 5, 2013|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01355198||104552|
NCT01355575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021515-17|Rifaximin in Fatty Liver Disease|RiFL:Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?|RiFL|Imperial College London|No|Terminated|May 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|70 Years|No|||October 2012|October 16, 2012|May 17, 2011|Yes|Yes|Review of primary endpoint data by study Investigators concluded no further patients required.|No||https://clinicaltrials.gov/show/NCT01355575||104524|
NCT01355588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2005-02|Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers|A Phase 1, Double-blind, 4-way Crossover Study of the Tolerability, Safety and Pharmacokinetics of 4 Formulations of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers||Luitpold Pharmaceuticals|No|Completed|August 2005|March 2006|Actual|September 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|May 16, 2011|Yes|Yes||No|November 16, 2012|https://clinicaltrials.gov/show/NCT01355588||104523|
NCT01355887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHENXP003|A Trial to Compare Pringle Maneuver With Either Infrahepatic Inferior Vena Cava Clamping or Low Central Venous Pressure|A Prospective Randomized Comparative Trial to Compare Pringle Maneuver With Either Infrahepatic Inferior Vena Cava Clamping or Low Central Venous Pressure in Complex Liver Resections||Huazhong University of Science and Technology|Yes|Recruiting|January 2008|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|192||No biospecimens|Both|N/A|N/A|No|Probability Sample|During the study period, all patients who received liver resections were considered to be        included into this study.|January 2008|May 17, 2011|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355887||104501|
NCT01356238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-1|Application of Two Different Synthetic Sequential Media for the Human IVF-Embryo Transfer (IVF-ET) Program|Application of Two Different Synthetic Sequential Media for the Human IVF-ET Program||Maria Fertility Hospital|Yes|Completed|November 2009|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|360|||Female|20 Years|39 Years|Accepts Healthy Volunteers|||October 2009|May 18, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356238||104474|
NCT01356251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-066|Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma|Mesothelioma From a Patient Perspective: A Survey of Psychosocial Needs and Exploration of Online Support for Patients||Memorial Sloan Kettering Cancer Center||Completed|May 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|107|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356251||104473|
NCT01356524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYH-28-11|Relationship Between Mid-luteal Serum Progesterone Levels to Pregnancy Rates in Assisted Reproductive Techniques (ART)|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 18, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01356524||104452|
NCT01356537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shire/CS03|Home Therapy With VPRIV in Gaucher's Disease|Non Interventional Study of VPRIV® (Velaglucerase Alfa) Home Therapy in Patients With Gaucher's Disease||Shire|No|Recruiting|April 2011|June 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|2 Years|N/A|No|Probability Sample|Patients with proven Gaucher's Disease foreseen for home treatment with VPRIV        (Velaglucerase alfa) at German Gaucher centers|February 2015|February 12, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356537||104451|
NCT01367119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001430|Ketamine Anesthesia in Electroconvulsive Therapy|A Randomized Comparison of Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy (ECT) in Depression||Mayo Clinic|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|June 1, 2011|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01367119||103643|
NCT01367197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22300240|Study of the Effect of Exercise Training on Patients in Atrial Fibrillation|Randomised Study of the Effect of Exercise Training on Patients in Atrial Fibrillation||Copenhagen University Hospital, Hvidovre|No|Completed|January 2009|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||June 2011|June 3, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01367197||103637|
NCT01363869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED-11-02-07-13-X|Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals|Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals||Chiang Mai University|Yes|Completed|June 2011|March 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 23, 2013|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01363869||103890|
NCT01364688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-05-2011|Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease|Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease||Ramathibodi Hospital|No|Recruiting|May 2011|December 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2011|May 31, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01364688||103828|
NCT01364974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-HV02|A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP015K in Healthy, Non-Elderly Male and Female Adult Volunteers||Astellas Pharma Inc|No|Completed|January 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2011|June 1, 2011|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364974||103806|
NCT01363141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 03-0116-3|Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome|Effects of Glycooxidative Stress on Human Aging- Study #3||Icahn School of Medicine at Mount Sinai|Yes|Completed|December 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|383|||Both|50 Years|N/A|No|||May 2015|May 6, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363141||103945|
NCT01355406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-0003|Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System|Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System Study|OPEN|Cordis Corporation|Yes|Active, not recruiting|September 2011|January 2018|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|257|||Both|35 Years|N/A|No|||January 2015|January 22, 2015|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355406||104537|
NCT01355419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/10-07-45/3912|Sleep Schedules Modifications in Sleep Apnea Patients Treated by nCPAP|Evaluation of Sleep Schedules Modifications in Moderate to Severe Sleep Apnea Patients Treated by nCPAP||Centre Hospitalier Universitaire Saint Pierre|No|Completed|August 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Moderate to severe OSA|April 2015|April 27, 2015|May 6, 2011||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01355419||104536|
NCT01366976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110423|Inhibition of Lipid Peroxidation During Cardiac Surgery|Inhibition of Lipid Peroxidation During Cardiopulmonary Bypass||Vanderbilt University|No|Completed|July 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|80 Years|No|||January 2015|January 14, 2015|June 2, 2011|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01366976||103654|The exploratory analysis of acute kidney injury (AKI) was limited by the low incidence of postoperative AKI in the current study, so we were underpowered to detect small differences in creatinine or NGAL concentrations.
NCT01357486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/22|Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis|Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis|PRODIGE 21|University Hospital, Bordeaux|Yes|Recruiting|November 2011|February 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01357486||104378|
NCT01357733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC11EISI0293|Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients|Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma||The Catholic University of Korea|Yes|Recruiting|March 2012|March 2016|Anticipated|March 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|19 Years|N/A|No|||April 2012|April 9, 2012|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01357733||104359|
NCT01364233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-NU-2011-01|Safety Study of MotifMESH (cPTFE) in Abdominal Surgery|A Prospective Outcome Study of Condensed Fenestrated PTFE Mesh (MotifMESH) in Non-sterile Abdominal Wall Defects||Medline Industries|No|Completed|May 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01364233||103863|
NCT01364753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06302009-2940|Age-related Longitudinal Changes in Aviator Performance|Age-related Longitudinal Changes in Aviator Performance||Stanford University|No|Recruiting|January 2002|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|saliva|Both|45 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy older pilots holding active airplane license|December 2013|December 2, 2013|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364753||103823|
NCT01364766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08122010-6709|Continuous Glucose Monitor Use in School|The Impact of Continuous Glucose Monitor Use in the Classroom/School Environment||Stanford University||Active, not recruiting|August 2010|August 2020|Anticipated|August 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|1 Year|25 Years|No|Non-Probability Sample|Anyone with diabetes mellitus who is wearing a continous glucose sensor and is in school.|September 2012|September 18, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364766||103822|
NCT01354938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-822|Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis|Outcome Study to Evaluate the Role of Klaricid XL (Clarithromycin Modified Release) in the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Its Impact on Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ)||Abbott|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|220|||Both|35 Years|N/A|No|Non-Probability Sample|Primary care|February 2013|February 1, 2013|May 16, 2011||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT01354938||104572|
NCT01355614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAX576A2209|A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients|A Multi-center, Randomized, Double-blind, Active Controlled Study to Assess Efficacy, Safety and Tolerability of the Anti-IL13 Monoclonal Antibody QAX576 in the Treatment of Perianal Fistulas in Patients Suffering From Crohn's Disease||Novartis||Completed|June 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355614||104521|
NCT01355627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-2402-038-SP|TASALL - TachoSil® Against Liquor Leak|TachoSil® Versus Current Practice in Dura Sealing Techniques for the Prevention of Post-operative Cerebrospinal Fluid (CSF) Leaks in Patients Undergoing Skull Base Surgery: An Open Label, Randomised, Controlled, Multi-centre, Parallel Group Efficacy and Safety Trial.||Takeda|Yes|Completed|April 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|726|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|May 11, 2011||No||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01355627||104520|
NCT01355900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP-001|Comparison of Three Tourniquet Application Methods in Primary Total Knee Arthroplasty Surgery|Influence of the Intraoperative Tourniquet Application Method on the Perioperative Blood Loss, Frequency of Transfusion and Close Postoperative Outcomes in Primary Total Knee Arthroplasty Patients||Vilnius University|No|Completed|January 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|50 Years|80 Years|No|||March 2014|March 2, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355900||104500|
NCT01356823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPV-PRO-002|Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine|A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 25 Years||Xiamen University|No|Completed|March 2011|October 2013|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1600|||Female|18 Years|25 Years|Accepts Healthy Volunteers|||February 2014|January 3, 2016|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01356823||104429|
NCT01357122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEBO-2009-1|Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)|A Randomized, Observer-masked, Clinical Trial Comparing the Neusidl Corneal Inserter Corneal Transplant Technique to the Standard Forceps Insertion Technique for Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)||Legacy Health System|Yes|Active, not recruiting|July 2009|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|N/A|No|||May 2011|May 19, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01357122||104406|
NCT01357135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-201|An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)|Observational Study of the Treatment and Follow-up of Patients With Type II Diabetes Receiving Bitherapy With or Without Sitagliptin (Januvia®/Xelevia®).||Merck Sharp & Dohme Corp.|No|Completed|July 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|3453|||Both|19 Years|N/A|No|Non-Probability Sample|Participants with type II diabetes mellitus receiving a de novo prescription (for the        first time or within less than 8 weeks) for dual therapy with or without Januvia®/Xelevia®        or any other treatment regimen including Januvia®/Xelevia® by general practitioners in        private practice under real life conditions without any additional treatment or monitoring        procedures.|December 2015|December 11, 2015|May 18, 2011|No|Yes||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01357135||104405|The adverse events in this study were not systematically collected or assessed and therefore no direct comparison can be made between adverse events in the 3 study groups/arms.
NCT01363310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00037|The Quietude Study: Quetiapine Use for Agitated Depression|A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major Depressive Disorder||Physicians Research And Education Network||Terminated|October 2010|February 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||January 2014|January 7, 2014|May 20, 2011||No|Termination of sponsorship|No||https://clinicaltrials.gov/show/NCT01363310||103933|
NCT01363336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15190|Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease|Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease||Bayer|No|Completed|November 2009|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1882|||Both|N/A|N/A|No|Non-Probability Sample|The target population of this study is patient who have been administered with Adalat CR        for hypertension with diabetes and/or chronic kidney disease. The study is expected to        collect data of 2,000 pateints in Japan.|April 2015|April 3, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01363336||103931|
NCT01363609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2011LiBrain001|Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes|Central Effects of Endogenous Glucagon Like Peptide-1 (GLP-1) and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes|LIBRA|VU University Medical Center|No|Completed|October 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|May 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363609||103910|
NCT01363622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB061|Vaspin Levels Compared With Serum Insulin and Blood Glucose Levels in Neonates|Zekai Tahir Burak Maternity Teaching Hospital||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|May 2010|July 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|82|||Both|N/A|5 Days|Accepts Healthy Volunteers|Probability Sample|SGA infant LGA infant AGA infant|March 2011|June 1, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01363622||103909|
NCT01364415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230D2101|Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)|A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs)||Novartis||Active, not recruiting|August 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|May 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364415||103849|
NCT01364428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3923|Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Subjects With Type 2 Diabetes Mellitus (BEGIN™: COMPARE)|BEGIN™|Novo Nordisk A/S|No|Completed|June 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|373|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|May 31, 2011|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01364428||103848|
NCT01365845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1016-BR01|Proton Therapy for Lymph Nodes in Breast Cancer|Proton Therapy for Peripheral Lymph Nodes in Breast Cancer|BR01|University of Florida|Yes|Active, not recruiting|April 2012|January 2019|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|May 19, 2011|Yes|Yes||No|September 11, 2014|https://clinicaltrials.gov/show/NCT01365845||103740|
NCT01366378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1304|Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX|A Phase 1, Open-Label, Study of the Effect of Cimetidine, a Known Inhibitor of Active Renal Secretion, on the Single-Dose Pharmacokinetics of Intravenously-Administered Methylnaltrexone in Healthy Adults||Valeant Pharmaceuticals International, Inc.|No|Completed|January 2007|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01366378||103699|
NCT01366404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2010-09|Study of the Natural History of FFR Guided Percutaneous Coronary Intervention|A Multicenter, Prospective Cohort to Evaluate the Natural History of FFR Guided Percutaneous Coronary Intervention|IRIS FFR|CardioVascular Research Foundation, Korea|Yes|Recruiting|June 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|35 Years|N/A|No|Non-Probability Sample|Patients who had FFR measurement|February 2016|February 5, 2016|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366404||103697|
NCT01366417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|371.1.04.19.11|Topical Antimicrobial Effectiveness Testing|Test for Preinjection Skin Preparation||CareFusion|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|August 31, 2012|June 2, 2011||No||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01366417||103696|
NCT01355718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-3905|Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea|A 26-week, Multicentre, Open-labelled, Non-randomised, Non-interventional, Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea||Novo Nordisk A/S|No|Completed|August 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are currently treated with NovoNorm® alone or in combination with metformin        or TZD (thiazolidinedione) and will be additionally prescribed with insulin analogue at        the discretion of the physicians will be eligible for this study.|August 2014|August 8, 2014|May 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01355718||104513|
NCT01364246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKCR-MS-1.0(2010)|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica|Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica||Shenzhen Beike Bio-Technology Co., Ltd.|Yes|Recruiting|January 2010|December 2014|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||November 2012|November 26, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364246||103862|
NCT01363167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR# 17217|Identifying Vitamin D Deficiency in Very Low Birth Weight Infant (VLBW) Infants Part 2|Identifying Vit D Deficiency in VLBW Infants Part 2||Medical University of South Carolina|Yes|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|N/A|3 Days|No|||November 2014|November 21, 2014|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01363167||103943|
NCT01363401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYNR_CS_ALS201|Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis|An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis||Corestem, Inc.|Yes|Completed|February 2011|August 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|25 Years|75 Years|No|||August 2013|August 15, 2013|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01363401||103926|
NCT01364779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-025|Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients|Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients||Northwell Health|Yes|Completed|April 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|15|Samples Without DNA|Blood draw|Both|18 Years|N/A|No|Probability Sample|Patients presenting to the nephrology clinic at SIUH and the nephrology clinic at Staten        Island rehab and the admitted patients who give consent.|May 2013|May 14, 2013|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01364779||103821|
NCT01365078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-3-029|Stearidonic Acid and Lipid Metabolism|Effects of Stearidonic Acid on Serum Triacylglycerol Concentrations in Overweight and Obese Subjects||Maastricht University Medical Center|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365078||103798|
NCT01365364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP0546/08|Dopamine Transporter Density Profiles in Patients With Periodic Limb Movements|Dopamine Transporter Density Profiles Assessed by Tc-TRODAT and SPECT in Patients With Periodic Limb Movements|DOPATRANSPLM|Federal University of São Paulo|Yes|Completed|March 2009|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|16|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||May 2011|June 2, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01365364||103777|
NCT01365676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAM+HIP|GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms|Phase 3 Study Efficacy and Tolerance: The Use of 2 Phytomedicines in Association GAMALINE® 900mg + HIPERICIN® 300mg for the Treatment of Pre-Menstrual Syndrome (PMS) and Vasomotor Symptoms|657/10UFCSPA|Phytopharm Consulting Brazil|Yes|Not yet recruiting|March 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|240|||Female|25 Years|55 Years|No|||December 2011|December 5, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01365676||103753|
NCT01365689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR01588|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2011|||||N/A|N/A|N/A||||||||||||||February 14, 2012|June 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01365689||103752|
NCT01354964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-225|Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation|Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|March 2009|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||May 2011|May 16, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01354964||104570|
NCT01355640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2006471|Two Methods of Analgesia for Chinese Term Infants Receiving Heel Lance|A Randomized Controlled Trial of Breast-feeding and/or Non-nutritive Sucking as Analgesia for Chinese Term Infants Receiving Heel Lance||Peking Union Medical College|Yes|Completed|April 2008|May 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|90|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2012|January 26, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355640||104519|
NCT01355653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3571002|Heat Wrap Device Safety With Age and Body Fat|An Open Label Study To Compare The Effects Of Age And Body Fat On The Safety Of Two Heat Wrap Devices In Healthy Subjects||Pfizer|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|57|||Both|18 Years|84 Years|Accepts Healthy Volunteers|||August 2011|August 26, 2011|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355653||104518|
NCT01355913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diagnostik-Studie|Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells|Screening and Genetic Monitoring of Patients With MDS Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Active, not recruiting|October 2008|October 2019|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|20 ml of peripheral blood (pb) of a MDS patient are enriched by immunomagnetic cell        sorting (by MACS® system). A FISH analysis is performed on these CD34+ cells according to        product protocols using the FISH probe panels described above. The percentage of aberrant        interphase nuclei (IN) is measured related to all (at least 200) IN counted. FISH analyses        are performed every 2 months in the 1st and every 3 months in the 2nd and 3rd year of        follow-up by the same method using the standard panel and, if necessary, an informative        probe of the super panel. Pb counts are documented once a month, and full blood counts        with peripheral blasts are recommended at the time point of each FISH analysis. Bone        marrow (bm) biopsies are not part of the study, but they are recommended to be performed        every 6 to 12 months. If a bm biopsy is performed, conventional chromosome banding        analyses on bm metaphases and FISH analyses of enriched CD34+ and non-enriched bm cells        are performed.|August 2014|August 7, 2014|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01355913||104499|
NCT01356563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLH-100-05|Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients|Effects of Pharmacist on Medication-related Problems in Hemodialysis Patients: a Randomized,Controlled, Double-blind Study||Sin-Lau Hospital|Yes|Recruiting|May 2011|May 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|20 Years|90 Years|No|||May 2011|May 18, 2011|May 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01356563||104449|
NCT01356836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Monocyte subsets|The Association Between Different Monocyte Subsets and Coronary Collateral Development|||Yuksek Ihtisas Hospital|Yes|Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|105|||Both|18 Years|80 Years|No|Non-Probability Sample|Consecutive patients who were found to have >95% stenosis of at least one major coronary        artery in their first coronary angiogram were included in this study.|March 2011|May 19, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356836||104428|
NCT01363102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11112010|Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients|Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients|mSOMS|Massachusetts General Hospital|Yes|Active, not recruiting|June 2011|December 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||March 2016|March 16, 2016|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01363102||103948|
NCT01364168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD-PROSCIS-01|Prospective Cohort With Incident Stroke|Prospective Cohort With Incident Stroke|PROSCIS|Ludwig-Maximilians - University of Munich|No|Recruiting|February 2011|December 2021|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|850|Samples With DNA|whole blood, serum, RNA|Both|18 Years|N/A|No|Probability Sample|Patients admitted to a specialized stroke service because of an acute stroke|September 2015|September 2, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364168||103868|
NCT01365598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQPF912|Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda|Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda||London School of Hygiene and Tropical Medicine|Yes|Completed|December 2011|May 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|468|||Both|1 Year|10 Years|No|||June 2013|June 11, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365598||103759|
NCT01366118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62 202-878|Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients|Prospective Pilot Study of Therapeutic Targets (TT) Tailored Chemotherapy (Ch) and Intensity Modulated Radiotherapy (IMRT) as Neoadjuvant Treatment in Patients With Rectal Carcinoma|TT|Grupo Hospital de Madrid|No|Completed|October 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||October 2009|June 2, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01366118||103719|
NCT01366677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00039032|Yoga for Persons With Severe Visual Impairment|Development of a Yoga Intervention for Symptoms Related to Severe Visual Impairment|RPY|Johns Hopkins University|No|Completed|August 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366677||103676|
NCT01364259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05252011-7806|A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia|A Randomized, Placebo-controlled Trial of Amifostine for Prevention of Facial Numbness in Patients Receiving Stereotactic Radiosurgery for Trigeminal Neuralgia||Stanford University|Yes|Recruiting|September 2008|January 2015|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|N/A|No|||May 2011|June 1, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01364259||103861|
NCT01364480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10080021|Microelectrode Brain-Machine Interface for Individuals With Tetraplegia|Microelectrode Brain-Machine Interface for Individuals With Tetraplegia||University of Pittsburgh|Yes|Recruiting|May 2011|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|May 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364480||103844|
NCT01364792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valaciclovir-1|To Rescue Cognition With Valaciclovir|A Double Blind Placebo Controlled Study of Valaciclovir in Treatment of Psychosis in Patients With Schizophrenia||University Medical Center Groningen|No|Recruiting|April 2011|January 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364792||103820|
NCT01365104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23AG030967-01|Modulation of Cerebral Blood Flow Using Iron Chelators|Hypoxia-Inducible Transcription Factor 1 (HIF-1)in Vascular Aging|DFO|Brigham and Women's Hospital|Yes|Completed|March 2008|December 2014|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|97|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365104||103796|
NCT01365091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-162|Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil|Bioequivalence Study of Fixed Dose Combinations of Saxagliptin/Metformin Extended Release (XR) Relative to Co-administration of the Individual Components in Healthy Subjects in the Fasted and Fed States||AstraZeneca|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|112|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|May 16, 2011|No|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01365091||103797|
NCT01365702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_TLD and spiriva|Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung|Clinical Efficacy of Tiotripium in Patients With Airflow Obstruction Due to TB Destroyed Lung||Seoul National University Bundang Hospital|No|Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|Patients with TB destroyed lung visiting Seoul National University Bundang Hospital        Respiratory center for chronic respiratory symptoms will be screened for study        participants. Among the patients, those with definite pulmonary TB histor with airflow        obstruction on their PFT were entrolled.|June 2011|June 6, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365702||103751|
NCT01355237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005065-01A1-2|Observational Cohort Study of Chronic Low Back Pain|Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study II - Observational Cohort Study of Chronic Low Back Pain||Brigham and Women's Hospital|Yes|Completed|February 2012|December 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|309|||Both|21 Years|N/A|No|Non-Probability Sample|The CLBP patients will be identified from two different sources at Brigham and Women's        Hospital (BWH): those coming to be treated at the OCC, and those coming to non-OCC        physician providers at BWH (comparison group).|January 2016|January 11, 2016|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01355237||104549|
NCT01355263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090221|Effect of Vitamin A Supplementation on Iron Metabolic Homeostasis of Preschool Children in Sichuan,China|Effect of Vitamin A Supplementation on Iron Metabolic Homeostasis of Preschool Children in Sichuan,China||Chengdu Maternal and Children's Health Care Hospital|Yes|Completed|July 2011|August 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|450|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||February 2013|February 18, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01355263||104548|
NCT01355926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-034|A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery|Flexible Fiber-based CO2 Laser Versus Monopolar Cautery for Resection of Benign, Pre-malignant And Malignant Oral Cavity Lesions: A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery||Memorial Sloan Kettering Cancer Center||Recruiting|May 2011|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355926||104498|
NCT01356264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN# 11-004|Multimodal Prehabilitation for Colorectal Surgery|Multimodal Prehabilitation to Enhance Functional Recovery After Colorectal Surgery: a Randomized Controlled Trial||McGill University Health Center|No|Completed|July 2011|December 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|100 Years|No|||September 2015|September 26, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356264||104472|
NCT01356550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25260|A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838|||Hoffmann-La Roche||Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|35|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01356550||104450|
NCT01357473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|239|Stop Menstruation and Pregnancy Rates in Antagonist Protocol|Is Hormonal Exposure of Endometrium on the First Day After Menstruation Associated With the Probability of Pregnancy in Patients Treated With Rec-FSH/ GnRH Antagonist? A Prospective Trial||Universitair Ziekenhuis Brussel|No|Completed|November 2009|May 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Female|18 Years|37 Years|No|Non-Probability Sample|Infertility women treated with rec FSH/antagonist protocol|May 2011|May 19, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01357473||104379|
NCT01357720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QVX-V-A001|Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination|A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age||Crucell Holland BV|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|400|||Both|42 Days|64 Days|Accepts Healthy Volunteers|||August 2013|August 29, 2013|May 19, 2011||No||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01357720||104360|
NCT01354847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEAECC|Influence of Extracorporeal Circulation on Platelet Function of Patients Undergoing Cardiac Surgery|Influence of Extracorporeal Circulation on Platelet Function of Patients Undergoing Cardiac Surgery - a Prospective Observational Study||Goethe University|No|Completed|June 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Probability Sample|Cardiac surgery patients undergoing complex cardiac surgery (double valve, aortic surgery,        combined - or redo procedures)|October 2013|October 25, 2013|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01354847||104579|
NCT01355120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DeCOG -MM-PAL11|THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease|THE IPI - Multibasket Trial in Advanced Melanoma: Prospective Clinical Phase II Multibasket Study in Melanoma Patients With Advanced Disease (DeCOG MM-PAL11)|DeCOG|University Hospital, Essen|Yes|Completed|October 2011|September 2013|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|171|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01355120||104558|
NCT01365650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2007-03|Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis|Open Label, Three-Way Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride and Multiple Doses of Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis||Luitpold Pharmaceuticals|No|Completed|December 2007|June 2008|Actual|February 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|No|||June 2015|June 24, 2015|June 1, 2011|Yes|Yes||No|August 6, 2012|https://clinicaltrials.gov/show/NCT01365650||103755|
NCT01365871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOI-CREMS|CREMS Prostate Biopsy Pain Relief Study|Pain Relief With Local Anesthetic at Time of Prostate Biopsy: Comparing Apical and Basal Injection Versus Basal Injection Alone||University Health Network, Toronto|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Male|30 Years|N/A|No|||January 2012|January 17, 2012|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01365871||103738|
NCT01365884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-11-FB|First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age|Proof of Concept Study for First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age||University of Nebraska|No|Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|7 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population with refractive error between -4.50 to +4.50 diopter spherical error and        astigmatism up to -1.50 diopters.|June 2012|June 13, 2012|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365884||103737|
NCT01363440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-1009|Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema|A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema|VISTA DME|Regeneron Pharmaceuticals|Yes|Completed|May 2011|November 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|466|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|May 27, 2011|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT01363440||103923|
NCT01363453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999907|User Surveillance in Ulcerative Colitis|Acute and Remission Therapy of Ulcerative Colitis With Oral Mesalazine|CARE|Ferring Pharmaceuticals|No|Completed|October 2007|July 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Private practices|May 2011|May 31, 2011|May 30, 2011||||No||https://clinicaltrials.gov/show/NCT01363453||103922|
NCT01363648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLITTER-DW400|The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia|A Randomized, Double-blind, Placebo-controlled Phase IV Trial for an Evaluation of the Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia|GLITTER|Seoul National University Hospital|Yes|Completed|November 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|222|||Both|25 Years|84 Years|No|||October 2013|October 11, 2013|May 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01363648||103907|
NCT01363661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDCOR 2011|Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris|Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention|MEDCOR|Therabel Pharma SA/NV|Yes|Completed|June 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|April 1, 2011||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01363661||103906|Too limited sample size. Huge variability in all measurements. High drop-out rate. Add-on treatment was a challenge to demonstrate a difference between Coruno and placebo.
NCT01363921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HicoCARD 1481|Effect of HCO1100 on Cardiovascular Function|Effect of High Cut-off Membranes on Cardiovascular Function in Patients With End-stage Renal Disease (HICOCARD)|HicoCARD|Gambro Dialysatoren GmbH|No|Terminated|April 2011|December 2013|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|May 26, 2011||No|insufficient patient recruiting|No||https://clinicaltrials.gov/show/NCT01363921||103886|
NCT01364506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-54|The Effects of Aerobic Water Exercise on Pregnancy|Randomized Clinical Study of the Effects of Aerobic Water Exercise on Maternal Cardiovascular Adaptation to Pregnancy||UPECLIN HC FM Botucatu Unesp|No|Completed|January 2000|April 2001|Actual|April 2001|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|41|||Female|15 Years|26 Years|Accepts Healthy Volunteers|||May 2011|June 1, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364506||103842|
NCT01364519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9011082|A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers|A Randomized, Double-Blind (3rd Party Open), Placebo-Controlled, 2-Way Crossover Study To Determine The Effects Of A Single Inhaled Dose Of 500 MCG Fluticasone Propionate On Induced Sputum Neutrophils Following Inhaled Lipopolysaccharide (LPS) Challenge In Healthy Volunteers||Pfizer|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364519||103841|
NCT01364493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG1001|A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer|An Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) as a First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer||Peking University|No|Recruiting|May 2011|December 2015|Anticipated|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364493||103843|
NCT01339143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN10016-002|Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes|An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy||Korea University Anam Hospital|Yes|Recruiting|April 2010|May 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||April 2010|May 5, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01339143||105781|
NCT01339156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3914/48/10|Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain|Randomized, Double-blind, Placebo-controlled Phase I-Ib Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain||Piramal Enterprises Limited|No|Terminated|June 2011|June 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01339156||105780|
NCT01338545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25264|An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)|A Multi-centre Observational Study to Describe Usage and Dosification Patterns of RoActemra (Tocilizumab) Treatment in Rheumatoid Arthritis (RA) Patients in the Routine Clinical Practice. ACT-LIFE Study||Hoffmann-La Roche||Completed|July 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra after at        least one previous DMARD or TNF-inhibitor treatment|March 2016|March 1, 2016|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338545||105827|
NCT01339377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2-IPP-001-AO|Safety and Effectiveness Study of the AO-1000 Device to Treat Contained Herniated Discs|A Pilot Study to Evaluate the Safety and Effectiveness of Ozone Generated and Injected by the AO-1000 Device in the Treatment of Contained Herniated Discs||ActiveO Inc.|No|Active, not recruiting|August 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||June 2015|June 2, 2015|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339377||105763|
NCT01339702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-NINDS-R01NS071049|The EPIC Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines|Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines|EPIC|University of Arizona|No|Recruiting|September 2011|February 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|20000|||Both|N/A|N/A|No|Probability Sample|Adults and children of all ages with acute, moderate or severe TBI cared for in the        participating EMS systems of Arizona who are taken to a Level 1 Trauma Center (either        directly by EMS or transfered by EMS). This will include approximately 4 years of        retrospective cases and 4.5 years of prospective cases.|January 2013|February 15, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01339702||105738|
NCT01339975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/45|Chemokines and Renal Cancer|Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma.|ChemoRenCan|University Hospital, Bordeaux|No|Active, not recruiting|June 2011|May 2019|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|310|Samples With DNA|whole blood, urine and tissues|Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with localized, locally advanced or metastatic Renal Cell Carcinoma|August 2014|August 19, 2014|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01339975||105717|
NCT01340313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0775|Ultrasonographic Evaluation of Drug Spread in Epidural Space During Caudal Block in Children|||Yonsei University|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|72|||Both|3 Months|5 Years|No|Non-Probability Sample|3 months old ~ 5 years old children undergoing minor infra-umbilical urological surgery|March 2013|March 4, 2013|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01340313||105691|
NCT01342640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25300|A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia|A Single Arm, Open Label, Multicenter Phase IIIb/IV Clinical Trial to Assess the Efficacy, Safety and Tolerability of Monthly Administration of C.E.R.A. for the Treatment of Not on Dialysis Chronic Renal Anemia Not Currently Treated With ESA||Hoffmann-La Roche||Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|April 20, 2011|No|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT01342640||105512|
NCT01342900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOTO-001|Intraoperative Optimisation of Tissue Oxygenation|Intraoperative Monitoring and Optimisation of Tissue Oxygenation In High-Risk Surgical Patients for Reduction of Postoperative Complications: a Pilot Study||University Medical Center Groningen|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|48|||Both|65 Years|N/A|No|||February 2013|February 20, 2013|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342900||105492|
NCT01342913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113107|A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))|A 12-week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared With Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|531|||Both|40 Years|N/A|No|||May 2013|August 21, 2014|April 14, 2011|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01342913||105491|
NCT01343251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeRO-1|HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis|Prospective Analysis of Hemodialysis Reliable Outflow (HeRO) Vascular Access Graft vs. Cuffed Catheter Access in Hemodialysis||Hemosphere, Inc.|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with ESRD requiring permanent cuffed catheters were targeted. Participants        who had not exhausted peripheral venous access sites suitable for fistulas and grafts were        excluded.|February 2016|February 16, 2016|April 20, 2011|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01343251||105466|Target sample size (statistical power) was not achieved. Catheter reduction and fistula first policies limited recruitment. Additionally, study patients were not blind to exposure and this knowledge may have had an impact on QoL measurement.
NCT01344018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-62092-22092|Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma|A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS)|STRASS|European Organisation for Research and Treatment of Cancer - EORTC||Recruiting|January 2012|January 2020|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|N/A|No|||June 2013|August 7, 2014|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344018||105407|
NCT01340248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125HPS11F|A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2011|December 20, 2011|April 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340248||105696|
NCT01340261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-099|Pediatric Pain Rehabilitation Program|Registry: Pediatric Pain Rehabilitation Program||The Cleveland Clinic|No|Recruiting|March 2007|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|All participants admitted to the Cleveland Clinic Children's Hospital's Pain        Rehabilitation Program are eligible for enrollment in the registry.|April 2011|April 21, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340261||105695|
NCT01339065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUK CHS|The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital|The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital: A Randomized Clinical Trial||Makerere University|Yes|Recruiting|April 2011|June 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2011|April 19, 2011|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339065||105787|
NCT01340781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cephalon-01736|Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patients|Evaluation of Screening Tools for OSA in Hospitalized Medical Patients: A Validation Study|STOMP|MetroHealth Medical Center|Yes|Completed|February 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|65 Years|No|Non-Probability Sample|Hospitalized medical patients|July 2013|July 18, 2013|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340781||105655|
NCT01340794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02588|Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma|A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma||National Cancer Institute (NCI)|Yes|Terminated|May 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2014|May 22, 2015|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340794||105654|
NCT01348958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-2011-GES-0001-000|Evaluation of Orthopedic Knee Measurement Using Lunar iDXA|Evaluation of Orthopedic Knee Measurement Using Lunar iDXA||GE Healthcare|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|36|||Both|30 Years|N/A|No|||July 2014|July 14, 2014|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01348958||105030|
NCT01337323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112602|Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting|Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting||GlaxoSmithKline|No|Terminated|September 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients filling a new fluticasone furorate nasal spray (FFNS) prescription will be        recruited across 50 branches of a retail pharmacy chain with co-located convenient care        clinic located throughout the United States. Approximately 350 patients who have active        seasonal rhinitis and have used an intra-nasal steroid (INS) other than FFNS and another        prescription or over-the-counter allergy medication in the previous allergy season will be        enrolled in the study.|February 2013|February 15, 2013|April 15, 2011||No|Insufficient number of patient records met inclusion criteria|No||https://clinicaltrials.gov/show/NCT01337323||105910|
NCT01338558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25686|A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab|||Hoffmann-La Roche||Withdrawn|June 2011|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338558||105826|
NCT01349491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gilead-001|Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion|Ranolazine for the Prevention of Recurrent Persistent Atrial Fibrillation After Electrical Cardioversion: a Pilot Study||University of Oklahoma|Yes|Recruiting|March 2012|March 2014|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|N/A|No|||August 2012|August 8, 2012|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349491||104989|
NCT01349504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000067/1|Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease|Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease||Beth Israel Deaconess Medical Center|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|106|Samples Without DNA|Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients taking mesalamine for maintenance of remission of ulcerative colitis|August 2013|August 16, 2013|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01349504||104988|
NCT01339169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-008|YF476 and Type I Gastric Carcinoids|A Single Centre, Pilot Trial of YF476 in Patients With Chronic Atrophic Gastritis, Hypergastrinaemia and Type I Gastric Carcinoids||Trio Medicines Ltd.|No|Active, not recruiting|January 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339169||105779|
NCT01339390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-327|MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in VHA|MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in VHA|MOVE OUT|VA Office of Research and Development|No|Active, not recruiting|April 2012|August 2015|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2300|||Both|21 Years|75 Years|No|||May 2015|May 18, 2015|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339390||105762|
NCT01339403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001105|Kaiser Permanente HIV Cohort Study|Hiv Infection, Antiretroviral Therapy Use And Other Predictors Of Selected Clinical Events In Kaiser Permanente||ViiV Healthcare|No|Completed|February 2009|October 2013|Actual|October 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|282368|||Both|18 Years|N/A|No|Non-Probability Sample|HIV infected patients in the HIV Registry of Kasier Permanente Northern and Southern        California and a matched cohort of non-HIV infected patients in Kaiser Permanente|April 2015|April 2, 2015|March 16, 2011|No|Yes||No|October 27, 2014|https://clinicaltrials.gov/show/NCT01339403||105761|Designation of endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.
NCT01340326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donga 419|The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling||VALID|Dong-A University|No|Completed|November 2007|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|800|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340326||105690|
NCT01340599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE13805|Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery|Phase II, Randomized, Double Blind, Placebo Controlled Pilot Study of Polyphenon E in Men With Localized Prostate Cancer Scheduled to Undergo Radical Prostatectomy||Case Comprehensive Cancer Center|Yes|Terminated|October 2006|April 2007|Actual|April 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|5|||Male|45 Years|75 Years|No|||March 2012|March 14, 2012|April 20, 2011|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01340599||105669|
NCT01336270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090405|Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients|Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients: Impact on Immunity Versus Immunosuppression|IMMUMELA|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2011|March 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort||4|Actual|217|Samples With DNA|A bank of biological samples (human plasma and cells) will be done|Both|18 Years|N/A|No|Non-Probability Sample|Part 1: patients with a melanoma larger than 10mm or with cutaneous metastasis Part 2:        stage III melanoma patients who shall undergo a regional lymph node dissection Part 3:        retrospective study of patients who underwent a sentinel node procedure Part 4: stage IV        Patient achieves of inoperable melanomas the stage(stadium) III or IV that must receive in        treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the        inhibitor of B-raf) and carrier of at least two cutaneous metastases|August 2014|August 25, 2014|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336270||105988|
NCT01342926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114341|Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration|A Phase 2, Multi-centre, Randomised, Double-masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)||GlaxoSmithKline|Yes|Active, not recruiting|June 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|184|||Both|55 Years|N/A|No|||February 2016|March 17, 2016|April 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01342926||105490|
NCT01343264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP2002-01|Trimodality Therapy for Malignant Pleural Mesothelioma|Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy||HSK Wiesbaden|No|Recruiting|November 2002|||December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with malignant pleural mesothelioma prsentint at the Deparment of Thoracic        Surgery, HSK Wiesbaden|April 2011|April 26, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01343264||105465|
NCT01343485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPFA-Merck-38068|Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series|Staying on Track: Increasing Completion of the HPV Vaccine Series With the Use of an Innovative Patient and Provider Information and Tracking Tool||Planned Parenthood Federation of America|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|365|||Female|19 Years|26 Years|Accepts Healthy Volunteers|||September 2013|September 30, 2013|April 26, 2011||No||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01343485||105448|
NCT01343758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-11-153|Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children|A Double-blind Randomized Controlled Clinical Trial Investigating the Use of Intravenous Dextrose for Dehydration and Ketosis in Children With Gastroenteritis and Dehydration.||Children's Hospital Boston|No|Completed|January 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|188|||Both|6 Months|6 Years|Accepts Healthy Volunteers|||February 2012|February 22, 2012|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343758||105427|
NCT01344304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENRI|Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial|Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy||Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group|No|Recruiting|April 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|20 Years|N/A|No|||October 2012|October 22, 2012|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344304||105385|
NCT01336478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROHH0203|CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation|Safety and Toxicity of Escalating Doses of Adoptively Infused ex Vivo Selected CD56+CD3- NK Cells on Day 7 Following Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.||Imperial College London|No|Withdrawn|April 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|June 3, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01336478||105972|
NCT01348399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2011-01|Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)|Evaluation of Effectiveness and Safety of XIENCE PRIME™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study||CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|April 2011|December 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|N/A|N/A|No|Non-Probability Sample|Patients receiving XIENCE PRIME stents.|November 2015|November 16, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01348399||105072|
NCT01336465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS4986g|Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis|Phase II Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis||Genentech, Inc.||Completed|September 2011|June 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|April 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336465||105973|
NCT01336452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0566|Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers|Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers||Yonsei University|No|Recruiting|April 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|20 Years|N/A|No|||June 2013|June 1, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336452||105974|
NCT01337921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065-11-FB|A Multi-strain Synbiotic Versus a Multi-strain Probiotic in Premature Infants|A Randomized Controlled Trial on a Multi-strain Synbiotic vs. a Multi-strain Probiotic on Fecal Colonization in the Very Low Birth Weight Infant||University of Nebraska|No|Withdrawn|June 2011|June 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|N/A|N/A|No|||June 2011|June 24, 2011|March 16, 2011||No|Pending further safety information regarding polysaccharides and premature infants|No||https://clinicaltrials.gov/show/NCT01337921||105864|
NCT01338311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC 10-226|Salbutamol Tolerance Onset|Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset||University of Saskatchewan|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|65 Years|No|||July 2012|July 19, 2012|April 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338311||105845|
NCT01338571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 28012|Horton & Maizy Pilot Study for Resistant to Starch|The Effect of Resistant Starch on the Stool Microflora of Children: A Pilot Study||Pennington Biomedical Research Center|No|Completed|February 2008|July 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|4|None Retained|collect 3 daily stool samples are retained at baseline and after 4 weeks|Both|5 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|Children between ages 5 and 15|December 2015|December 17, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01338571||105825|
NCT01338584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-046|Trial Study of the Efficacy of Intensive Preoperative Pelvic Floor Muscle Training to Decrease Post-prostatectomy Urinary Incontinence|A Randomized Controlled Trial Study of the Efficacy of Intensive Preoperative Pelvic Floor Muscle Training to Decrease Post-prostatectomy Urinary Incontinence||Queen Mary Hospital, Hong Kong|No|Recruiting|February 2011|October 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|84|||Male|N/A|N/A|No|||November 2014|November 1, 2014|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01338584||105824|
NCT01338597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMMU-2011-ET-1|Impact of Dissection Area on the Clinical Outcome of Endoscopic Thyroidectomy|Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy|ET|Second Military Medical University|No|Not yet recruiting|April 2011|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||April 2011|April 18, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01338597||105823|
NCT01337310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPK106|Study of Tesetaxel in Japanese Patients With Solid Tumors|A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects With Advanced Solid Tumors||Genta Incorporated|Yes|Recruiting|April 2011|September 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|N/A|No|||March 2012|March 11, 2012|April 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337310||105911|
NCT01337557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-03-11|Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses|Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses||Hom, Milton M., OD, FAAO|No|Enrolling by invitation|May 2011|November 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 18, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01337557||105892|
NCT01337570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 009A|A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Safety and Efficacy Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women||International Partnership for Microbicides, Inc.||Withdrawn|July 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 8, 2012|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337570||105891|
NCT01339715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-032|The Difference Between Acupuncture and Far-infrared Ray Illumination at CV12 Acupoint|From the Changes of Ryodoraku Value at 12 Source Acupoints, and Heart Rate Viability to Explain the Difference Between Acupuncture and Far-infrared Ray Illumination at CV12（Zhongwan）Acupoint||China Medical University Hospital|Yes|Completed|April 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|25|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 20, 2012|April 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339715||105737|
NCT01339988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-MB-442-CTIL|Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)|Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2011|June 2019|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|N/A|21 Years|No|||April 2011|April 20, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01339988||105716|
NCT01340339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FernandoFigueiraIMI|Reverse Phototherapy With Super Light-emitting Diode(Super-LED) for Hyperbilirubinemia in Term and Late Preterm Infants|Efficacy of Reverse Phototherapy With Super Light-emitting Diode(Super-led) in Term and Late Preterm Infants:Randomized and Controlled Clinical Trial||Professor Fernando Figueira Integral Medicine Institute|No|Recruiting|October 2010|January 2012|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|35 Weeks|41 Weeks|No|||April 2011|April 21, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340339||105689|
NCT01340612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE10.111|Stenting in the Treatment of Aneurysm Trial|Stenting in the Treatment of Large, Wide-necked or Recurring Intracranial Aneurysms|STAT|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|April 2011|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340612||105668|
NCT01340625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-1188|Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions|A Relative Bioavailability Study of 0.4 mg/35 Mcg Norethindrone and Ethinyl Estradiol Chewable Tablets Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|December 2006|January 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2011|April 27, 2011|April 20, 2011|No|Yes||No|April 27, 2011|https://clinicaltrials.gov/show/NCT01340625||105667|
NCT01336283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/0529|Effectiveness of Different Exercise Training Programs to the Profile of COPD Patients|Effectiveness of Different Exercise Training Programs to the Profile of COPD Patients||Hospitales Universitarios Virgen del Rocío|No|Completed|March 2003|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|45 Years|80 Years|No|||March 2003|April 14, 2011|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01336283||105987|
NCT01336296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myfortic Preload|Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients|A 12-month, Prospective, Randomized, Dual Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic® (Mycophenolic Acid) Loading Regimens in Combination With Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)] or Simulect® (Basiliximab) Induction and Prograf® (Tacrolimus) in Early Corticosteroid Withdrawal||University of Cincinnati|No|Completed|September 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|75 Years|No|||May 2014|May 29, 2014|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01336296||105986|
NCT01340638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAntioquia SEAL- 001|Seal Pressure With Classical Laryngeal Mask and Cookgas Mask in Adult Patients|EFFECTIVENESS OF SEAL PRESSURE IN AIRWAY OF THE CLASSIC LARYNGEAL MASK AND THE COOKGAS LARYNGEAL MASK IN ADULT PATIENTS UNDERGOING SURGERY IN AMBULATORY SETTINGS||Universidad de Antioquia|No|Not yet recruiting|June 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|106|||Both|18 Years|N/A|No|||April 2011|April 20, 2011|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01340638||105666|
NCT01343498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI REFMAL 233|Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors|A Phase I PK/PD Study of the PI3 Kinase/mTOR Inhibitor BEZ235 Given Twice Daily for the Treatment of Patients With Advanced Solid Tumors||SCRI Development Innovations, LLC|No|Completed|April 2011|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01343498||105447|
NCT01343771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01-0634|Hormonal Therapy for Teens With Anorexia Nervosa|Effect of Adrenal and Gonadal Hormones on Bone Marrow and Appendicular BMD||Children's Hospital Boston|Yes|Active, not recruiting|June 2011|January 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|11 Years|18 Years|No|||June 2015|June 4, 2015|April 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01343771||105426|
NCT01344031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02586|MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase 1 Trial of MK-2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|31|||Female|18 Years|N/A|No|||January 2016|January 8, 2016|April 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01344031||105406|
NCT01344291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Turmeric-01|Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients|||Mashhad University of Medical Sciences|Yes|Recruiting|July 2011|August 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|45 Years|No|||October 2011|October 29, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01344291||105386|
NCT01344317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nationalbankprojekt Nr.13660|The Effect of Stimulating Substances on Brain Activity of Preterm Infants|The Effect of Stimulating Substances on Brain Activity Measured by Amplitude-integrated EEG and Long-term Neurodevelopmental Outcome of Preterm Infants Born Below 30 Weeks of Gestation||Medical University of Vienna|No|Active, not recruiting|June 2009|June 2016|Anticipated|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|23 Weeks|30 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Preterm infants born below a gestational age of 30 weeks|October 2015|October 30, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344317||105384|
NCT01344603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR epi CCH 38|Epidural and Cardiac Surgery|Epidural Analgesia in Cardiac Surgery||Università Vita-Salute San Raffaele||Completed||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|||||Both|18 Years|N/A|No|Probability Sample|patients undergoing cardiac surgery|April 2011|April 28, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344603||105362|
NCT01337128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/819|Carotid Endarterectomy Versus Carotid Artery Stenting? A Prospective Comparison of Neuropsychological Outcome in Patients With Carotid Stenosis.|Carotid Endarterectomy Versus Carotid Artery Stenting? A Prospective Comparison of Neuropsychological Outcome in Patients With Carotid Stenosis.||University Ghent|No|Recruiting|April 2011|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337128||105924|
NCT01340521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214-91|Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women|FSH and LH Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women||Milton S. Hershey Medical Center|No|Completed|March 1991|March 1994|Actual|March 1994|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01340521||105675|
NCT01337115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA 007/11(004-DEFI/007-CES)|Effect of a Sciatic Block (SNB) Combined With a Continuous Femoral Block (CFNB) on Pain Scores After Knee Arthroplasty|Effect of a Single Shot Sciatic Nerve Block (SNB) Combined With a Continuous Femoral Block (CFNB) on Pain Scores After Knee Arthroplasty. A Randomized Controlled Trial||Centro Hospitalar do Porto|No|Completed|April 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|N/A|No|||May 2012|May 17, 2012|April 15, 2011||No||No|March 21, 2012|https://clinicaltrials.gov/show/NCT01337115||105925|Difficulties in contacting patients by phone and getting reliable answers limit the value of the patient satisfaction parameter.No analysis was made on the effect of nerve blocks on rehabilitation
NCT01336803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSBONE0006|Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI|Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI||Stanford University|Yes|Recruiting|August 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|1 Year|40 Years|No|||September 2015|September 8, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01336803||105949|
NCT01337102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0349-CE|Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)|Randomized Trial to Investigate the Impact of a Computer-Generated Quality of Life Assessment Program on Treatment Patterns for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)|LUNL2|University Health Network, Toronto|Yes|Completed|November 2004|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|103|||Both|18 Years|N/A|No|||December 2011|December 13, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01337102||105926|
NCT01338324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-1229|Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease|Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease|Cyp|All India Institute of Medical Sciences, New Delhi|Yes|Completed|April 2010|September 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|41|||Both|18 Years|75 Years|No|||December 2011|December 12, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01338324||105844|
NCT01339182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1010GH|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers|A Randomized, Open-label, Single-dose, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated-Somatropin in Healthy Volunteers|Somatropin|Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2010|January 31, 2013|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01339182||105778|
NCT01339416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001106|HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University|Clinical Adverse Events In HIV-Infected Patients||ViiV Healthcare|No|Completed|March 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|8202|||Both|N/A|N/A|No|Non-Probability Sample|HIV infected patients seeking treatment at Johns Hopkins University, Vanderbilt University        and University of North Carolina at Chapel Hill|March 2014|March 14, 2014|March 16, 2011|No|Yes||No|March 14, 2014|https://clinicaltrials.gov/show/NCT01339416||105760|Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.
NCT01337895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11MR010|DAWL (Dairy and Weight Loss) Study|Diet and Weight Loss Study - a Weight Loss Trial to Determine Whether Dairy Products Augment Weight Loss for Adults Following an Energy-restricted Weight Loss Study|DAWL|University of Guelph|No|Withdrawn|May 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2011|November 10, 2011|April 15, 2011||No|Grant not funded, study will not launch|No||https://clinicaltrials.gov/show/NCT01337895||105866|
NCT01337908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G070020|A Study of Mood and Stress After Spinal Cord Injury|A Survey of Vulnerability Factors, Current Stress and Depression Risk in Spinal Cord Injury||University of Michigan|No|Completed|February 2009|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|377|Samples With DNA|Saliva samples collected with Oragene kit.|Both|19 Years|N/A|No|Probability Sample|Men and women with a traumatic spinal cord injury who are 18 years of age and older|March 2012|March 19, 2012|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337908||105865|
NCT01339728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-176-1|Far-infrared Ray Effect on CV12 Acupoint|Far-infrared Ray Illuminates Area of CV12 Acupoint to Investigate the Correlation of Skin Temperature and Skin Blood Flow Between CV12 Acupoint and Palm Central Part of Right Hand||China Medical University Hospital|Yes|Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|22|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||April 2011|April 20, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01339728||105736|
NCT01340001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/049/HP|Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies|Effects of Nucleus Basalis of Meynert Area Electrical Stimulation on Cognitive Behavioral Disorders in Dementia With Lewy Bodies : A Pilot Phase 1 Study|DEMENSTIM|University Hospital, Rouen|Yes|Recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|75 Years|No|||July 2015|July 29, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01340001||105715|
NCT01340014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-251|Patient Preference Comparison of AZARGA Versus COSOPT|Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|April 20, 2011|No|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT01340014||105714|
NCT01340027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-100|A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder|A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.|Symphony|Astellas Pharma Inc|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|12||Actual|1307|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|April 20, 2011|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT01340027||105713|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01340040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5621C00006|Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects|A Phase 1, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Japanese Subjects With Advanced Solid Tumours Refractory to Standard Therapy or for Which No Standard Therapy Exists||AstraZeneca|No|Completed|July 2011|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01340040||105712|
NCT01340352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0137-10-EMC|Is It Possible to Predict Pre Term Labor by Measuring Cervical Length in the Non-pregnant Uterus?|Is It Possible to Predict Pre Term Labor by Measuring Cervical Length in the Non-pregnant Uterus?||HaEmek Medical Center, Israel|Yes|Completed|May 2011|January 2015|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|62|||Female|18 Years|40 Years|No|Non-Probability Sample|HaEmek Medical Center delivery room.|June 2015|June 14, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340352||105688|
NCT01336309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # H10-226|Development of a Translational Tool to Study Yoga Therapy|Development of a Translational Tool to Study Yoga Therapy||University of Connecticut|Yes|Recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|750|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Yoga teachers, students, and researchers.|January 2016|January 22, 2016|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336309||105985|
NCT01343511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKCR-AUTISM-1.0(2009)|Safety and Efficacy of Stem Cell Therapy in Patients With Autism|Phase Ι/Π Study of Stem Cell Therapy in Patients With Autism||Shenzhen Beike Bio-Technology Co., Ltd.|Yes|Completed|March 2009|May 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|3 Years|12 Years|No|||October 2011|October 13, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343511||105446|
NCT01343784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 11-082|Assessment of Voiding After Sling|Assessment of Voiding After Sling (AVAS): A Randomized Trial of Two Methods of Post-operative Catheter Management After Midurethral Sling for Female Stress Urinary Incontinence|AVAS|The Cleveland Clinic|No|Completed|April 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|105|||Female|18 Years|81 Years|No|||February 2014|February 18, 2014|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343784||105425|
NCT01344044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Domain A/09/395|Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)|A Randomised Controlled Trial of a Brain-Computer Interface Based Intervention for the Treatment of ADHD||National Healthcare Group, Singapore|Yes|Active, not recruiting|January 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|6 Years|12 Years|No|||March 2016|March 22, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344044||105405|
NCT01344616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44HD047031-02A2|Reducing Preterm Births in Underserved Pregnant Women|Reducing Preterm Births in Underserved Pregnant Women||PHCC LP|No|Completed|August 2010|October 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|482|||Female|16 Years|48 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|July 27, 2010||No||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01344616||105361|
NCT01337141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIBERDEM-TELEMED-DIABETES|A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients|Multicentric Intervention Study Evaluating the Efficiency of the Implementation in the Spanish Health System of a Telematic System Applied to Metabolic Control Optimization for Type 1 Diabetes Mellitus (DM1) Patients||Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders|Yes|Completed|May 2011|November 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|50 Years|No|||January 2015|January 28, 2015|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01337141||105923|
NCT01340534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2011-02|Supplemental Perioperative Oxygen to Reduce the Incidence of Post-cesarean Wound Infection|Supplemental Perioperative Oxygen at 80% FIO2 to Reduce the Incidence of Post-cesarean Wound Infection. A Randomised, Clinical Trial||Saint Thomas Hospital, Panama|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|370|||Female|N/A|N/A|No|||January 2015|January 1, 2015|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01340534||105674|
NCT01340547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM1005|Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors|A Phase I Multicenter, Open-label Study of the Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors||Ziopharm|No|Active, not recruiting|June 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2013|July 17, 2013|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340547||105673|
NCT01337635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 10/146, GC 1169|Vitamin D Deficiency and Atopic Dermatitis|Treatment Of Vitamin D Deficiency And Effect On Atopic Dermatitis Severity||Medical College of Wisconsin|No|Terminated|November 2010|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|1 Year|18 Years|No|||September 2014|April 6, 2015|November 3, 2010||No|Not meeting enrollment goals.|No|September 16, 2014|https://clinicaltrials.gov/show/NCT01337635||105886|
NCT01337648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RadBio-10/191|Radiation Biodosimetry in Children Undergoing Total Body Irradiation|Radiation Biodosimetry in Children Undergoing Total Body Irradiation||Medical College of Wisconsin|No|Completed|November 2010|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|Samples With DNA|Stool|Both|2 Years|21 Years|No|Non-Probability Sample|Patients undergoing Total Body Irradiation (TBI) preceding hematopoietic stem cell        transplantation.|September 2015|September 2, 2015|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01337648||105885|
NCT01338610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-079|ESBA105 in Patients With Severe Dry Eye|Evaluation of ESBA105 in the Persistent Relief of Ocular Discomfort in Patients With Severe Dry Eye||Alcon Research|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|334|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|April 18, 2011|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT01338610||105822|
NCT01339195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10-PR-GODEFROY|Post-stroke Cognitive Impairment and Dementia|Post-stroke Cognitive Impairment and Dementia: Frequency and Anatomical Correlates With the French Version of the National Institute of Neurological Disorders and Stroke (NINDS)-Canadian Stroke Network Battery|GRECogVASC|Centre Hospitalier Universitaire, Amiens|No|Recruiting|August 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1208|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|February 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01339195||105777|
NCT01338844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI_vs_DCI_Oo_q|Role of Myo-inositol and D-chiro-inositol on Oocyte Quality|A Prospective, Randomized, Double Blind, Study on the Clinical Efficacy Myo-inositol Versus D-chiro-inositol in Women Undergoing in Vitro Fertilization Embryo Transfer.||AGUNCO Obstetrics and Gynecology Centre|No|Completed||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||||||Female|25 Years|45 Years|No|||April 2011|May 31, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01338844||105804|
NCT01339468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-08-04-KOR_Main|A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation|A Phase IV, Randomized, Open-label, Comparative, Single-center Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf® (Modified Release Tacrolimus) and Prograf® (Tacrolimus) in de Novo Living Donor Liver Transplant Recipients|MAIN|Astellas Pharma Inc|No|Completed|March 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|N/A|No|||October 2015|October 27, 2015|April 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339468||105756|
NCT01339741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsoriasisVitaminD|Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency|The Efficacy of Vitamin D3 for the Treatment of Chronic Plaque Type Psoriatic Patients With Vitamin D Deficiency and Insufficiency: a Randomized Controlled Trial||Chulalongkorn University||Recruiting|March 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||April 2011|April 20, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01339741||105735|
NCT01336322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITA-previousGDM|Metformin and Sitagliptin in Women With Previous Gestational Diabetes|Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Women With Previous Gestational Diabetes||University of Pisa|Yes|Not yet recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|45|||Female|18 Years|45 Years|No|||April 2011|April 19, 2011|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336322||105984|
NCT01336335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sympathetic activity and OSA|The Effects of Continuous Positive Airway Pressure (CPAP) on Sympathetic Activity in Different Sites of Activation|The Effects of Continuous Positive Airway Pressure (CPAP) on Sympathetic Activity in Different Sites of Activation||University of Sao Paulo|No|Active, not recruiting|July 2010|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|30 Years|60 Years|No|||July 2010|April 13, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336335||105983|
NCT01336595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKRzirconium|Comparison of Total Knee Arthroplasties With Oxidized Zirconium and Cobalt Chromium Femoral Components|Comparison of Total Knee Arthroplasties With Oxidized Zirconium and Cobalt Chromium Femoral Components in the Same Patients: A Prospective, Double Blinded, and Randomized Controlled Study||Ewha Womans University|No|Completed|January 2003|April 2011|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|331|||Both|30 Years|90 Years|No|||October 2011|October 4, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336595||105965|
NCT01336608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113108|A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD|A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).||GlaxoSmithKline||Completed|March 2011|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|446|||Both|40 Years|N/A|No|||April 2015|June 15, 2015|March 31, 2011|Yes|Yes||No|June 15, 2015|https://clinicaltrials.gov/show/NCT01336608||105964|
NCT01336920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|518-10|Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma|Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma||University of Nebraska|Yes|Active, not recruiting|June 2011|April 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|N/A|No|||August 2015|August 11, 2015|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336920||105940|
NCT01336933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|569-10|Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma|A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma||University of Nebraska|Yes|Active, not recruiting|July 2011|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||January 2013|January 20, 2013|March 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336933||105939|
NCT01343797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGNUT PEC10513|Glycemic and Insulinemic Index Determination of Two Products: Fructilight® and A Fruit Fructo-Oligosaccharides in Sweet Matrix|Glycemic and Insulinemic Index Determination of 2 Products: Fructilight® and A Fruit Fructo-Oligosaccharides in Sweet Matrix|IGNUT|CRITT Bio-Industries||Active, not recruiting|February 2011|May 2011|Anticipated|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 27, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01343797||105424|
NCT01344057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_32S|Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2011-2012, When Administered to Elderly Subjects||Novartis||Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|April 21, 2011||No||No|December 21, 2015|https://clinicaltrials.gov/show/NCT01344057||105404|
NCT01344070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC 2101100|Generic Formulations of Commonly-used Oral Drugs in Saudi Arabia:Interchangeability & Post-marketing Quality|Generic Formulations of Commonly-Used, Immediate-Release, Solid, Oral, Drugs in Saudi Arabia: Interchangeability & Post-Marketing Quality||King Faisal Specialist Hospital & Research Center|No|Completed|April 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|500|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|April 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01344070||105403|
NCT01344369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10816221|Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions|A Study to Evaluate the Relative Bioavailability of Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva Pharmaceuticals, USA) Compared to FEMCON® Fe (Norethindrone/Ethinyl Estradiol) 0.4 mg/0.035 mg Chewable Tablets (Warner Chilcott) in Healthy Female Volunteers Under Non-Fasted Conditions||Teva Pharmaceuticals USA|No|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 4, 2011|April 27, 2011|No|Yes||No|May 4, 2011|https://clinicaltrials.gov/show/NCT01344369||105380|
NCT01344330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01CA090890|Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients|Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients||Texas A&M University|Yes|Recruiting|January 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients scheduled for screening colonoscopy|August 2015|August 12, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344330||105383|
NCT01344343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPATTACK -6.0, 2012-09-24|HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial|HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial - Feasibility Pilot|HIPATTACK|Population Health Research Institute|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|60|||Both|45 Years|N/A|No|||November 2012|November 5, 2012|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344343||105382|
NCT01339923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_28|A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years|A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years||Novartis|No|Completed|April 2011|December 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|1409|||Both|71 Days|10 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|April 13, 2011|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01339923||105721|
NCT01340560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ref.no:2008-274|Endometrial Injury Increases Implantation and Pregnancy Rates|The Effect of Local Injury to the Endometrium for Implantation and Pregnancy Rates in ICSI -ET Cycles With Recurrent Implantation Failure: a Randomised Controlled Study||Selcuk University|No|Completed|September 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Female|25 Years|36 Years|Accepts Healthy Volunteers|||April 2011|April 20, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01340560||105672|
NCT01336816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI-042|A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge|A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, Containing Tobacco and Silver Salt - in Healthy Smokers||Star Scientific, Inc|No|Completed|July 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|43|||Both|23 Years|72 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336816||105948|
NCT01337336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113902|Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population|Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population||GlaxoSmithKline|No|Completed|October 2010|March 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|40 Years|N/A|No|Non-Probability Sample|The study population included patients with both COPD and depression/anxiety. They were        identified as follows: Patients who had at least one pharmacy claim for a maintenance        medication used to treat COPD were identified. Of these, patients were considered to have        comorbid depression/anxiety if they had at least one prescription claim for a medication        used to treat depression/anxiety and a diagnosis code for depression/anxiety during 1 year        pre-index or within 60 days after the index date.|June 2011|June 16, 2011|April 15, 2011||No||No|April 21, 2011|https://clinicaltrials.gov/show/NCT01337336||105909|
NCT01337661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-INDP-1048|A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations|An Exploratory Study of the Cellular Inflammatory Mechanisms Associated With Chronic Obstructive Pulmonary Disease Exacerbations||MedImmune LLC|No|Completed|April 2011|February 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|Blood, Endobronchial tissues and Bronchoalveolar (BAL) samples|Both|40 Years|85 Years|No|Non-Probability Sample|Subjects referred to the hospital clinic with AECOPD|August 2012|August 27, 2012|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01337661||105884|
NCT01337934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360/10|Lactated Ringer Versus Albumin in Early Sepsis Therapy|Ringer Versus Albumin In Septic Patients: a Randomized Controlled Clinical Trial|RASP|University of Sao Paulo|Yes|Recruiting|October 2013|July 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||October 2013|October 16, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01337934||105863|
NCT01338337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABRAZA|Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia|Multicentre, Open-label, Randomized Phase II Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 International Prognostic Scoring System(IPSS )) Without the 5q Deletion and Transfusion Dependent Anaemia|ABRAZA|Asociación Andaluza de Hematología y Hemoterapia|No|Completed|November 2010|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01338337||105843|
NCT01338896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1066|Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations|A Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease||UCB Pharma|No|Completed|April 2011|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2011|August 26, 2011|April 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338896||105800|
NCT01338909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-4|Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)|Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)and Presenting With High Platelet Reactivity, as Assessed With a Point of Care Assay, After 600mg Clopidogrel Loading Dose|PRO-GR-4|University of Patras|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|90 Years|No|||September 2011|September 29, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01338909||105799|
NCT01338857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00561|Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas|Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas||New York University School of Medicine|Yes|Terminated|April 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|2 Years|N/A|No|||January 2016|January 25, 2016|April 18, 2011|Yes|Yes|Sorafenib ineffective for tx of recurrent or progressive PLGA|No|June 24, 2013|https://clinicaltrials.gov/show/NCT01338857||105803|
NCT01338870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611003|Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes|A 12-week, Phase 2, Randomized, Double-blind, Placebo Controlled, Dose-ranging, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf-04991532 and Once Daily Sitagliptin in Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin||Pfizer|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|301|||Both|18 Years|70 Years|No|||March 2013|March 11, 2013|April 13, 2011|Yes|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT01338870||105802|
NCT01340053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDX5791-201|A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)||Ardelyx|No|Completed|May 2011|February 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|186|||Both|18 Years|75 Years|No|||February 2012|February 29, 2012|April 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340053||105711|
NCT01340066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2006-0081|Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence|A Randomized, Double-blind, Parallel, Placebo-controlled Study for the Assessment of the Safety and Efficacy of UISH001 for the Symptomatic Improvement of Urinary Incontinence||Beech Tree Labs, Inc.|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|94|||Female|18 Years|N/A|No|||March 2013|March 22, 2013|April 18, 2011|Yes|Yes||No|February 18, 2013|https://clinicaltrials.gov/show/NCT01340066||105710|
NCT01340651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18424-260|Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients|An Open-label Assessment of Once-daily Dosing of a Sustained Release (SR) Formulation of INCB018424 in Patients With Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, and Post-polycythemia Vera Myelofibrosis||Incyte Corporation|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||December 2013|February 5, 2014|April 21, 2011|Yes|Yes||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01340651||105665|
NCT01336348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAB-PRO-I|Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse|Comparison of Multiple Oral and/or Intravenous Anti-platelet Strategies in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary PCI|FABOLUS PRO|Università degli Studi di Ferrara|No|Completed|April 2010|June 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2012|October 9, 2012|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336348||105982|
NCT01336621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113413|Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS).|A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partial-Onset Seizures (Extension of Study RGB113905)|IR|GlaxoSmithKline|No|Active, not recruiting|February 2011|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|March 10, 2016|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01336621||105963|
NCT01336634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113928|Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.|A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer||GlaxoSmithKline|Yes|Recruiting|June 2011|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336634||105962|
NCT01336647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha02-003|An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation|An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation||Hatchtech Pty Ltd|Yes|Completed|April 2011|March 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|142|||Both|2 Years|N/A|No|||January 2015|January 13, 2015|April 14, 2011|Yes|Yes||No|December 4, 2013|https://clinicaltrials.gov/show/NCT01336647||105961|
NCT01336946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2010/607|HEalth Promotion Intervention in MEntal Health Care|Effectiveness and Cost-effectiveness of a Health Promotion Intervention Targeting Physical Activity and Eating Habits in Persons With Mental Disorders|HEPIMEC|University Ghent|No|Completed|January 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|742|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336946||105938|
NCT01336959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCT197A2202|Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery|A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)||Novartis|Yes|Terminated|September 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|83|||Both|18 Years|85 Years|No|||October 2014|May 20, 2015|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336959||105937|
NCT01344096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC6088|Thrombocytopathy in Gaucher Disease Patients|A 3 Years Prospective, Longitudinal Single Centre Study Designed to Delineate the Cause of the Thrombocytopathy in Gaucher Disease Patients||Rabin Medical Center|No|Recruiting|October 2010|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Blood Samples|Both|N/A|N/A|No|Non-Probability Sample|Gaucher disease patients treated and untreated wih Imiglucerase|July 2010|April 27, 2011|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01344096||105401|
NCT01344356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-046|Stereotactic Body Radiotherapy for Head and Neck Tumors|Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors||St. John's Mercy Research Institute, St. Louis|No|Active, not recruiting|July 2008|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|April 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01344356||105381|
NCT01344629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.28|Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use|Bioequivalence of Telmisartan Administrated in Two Different Ways: Both in Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Telmisartan 80 mg Tablet and Amlodipine 5mg Tablet in Concomitant Use in Healthy Male Volunteers. (an Open-label, Randomized, Single-dose, Four-period Replicated Crossover Study)||Boehringer Ingelheim||Completed|April 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|64|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|April 26, 2011||||No|July 10, 2012|https://clinicaltrials.gov/show/NCT01344629||105360|
NCT01344382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P50DA027841-02|Family Training Program for Parents of Substance Using Adolescents|CRAFT: Helping Parents Initiate and Support Their Adolescent's Treatment|FTP|Treatment Research Institute|Yes|Active, not recruiting|January 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344382||105379|
NCT01344642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007614-01H|Qualitative and Quantitative HIV RNA Detection in Saliva Using the Oragene RNA Kit|Qualitative and Quantitative HIV RNA Detection in Saliva Using the Oragene RNA Kit||Ottawa Hospital Research Institute|No|Completed|October 2007|December 2010|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV monoinfected HIV-HCV co-infected HIV and HCV uninfected control|October 2008|April 28, 2011|April 21, 2008||No||No||https://clinicaltrials.gov/show/NCT01344642||105359|
NCT01336218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00015|Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.|An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin||AstraZeneca||Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336218||105992|
NCT01337349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2192010|Effects of Pentoxiphylline on Left Ventricular (LV) Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure (CHF)|Effects of Pentoxiphylline on Left Ventricular Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure.|PENT-CHF|Henry Ford Health System|No|Recruiting|July 2010|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337349||105908|
NCT01337687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD Award|Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders|Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders|INOT|Montefiore Medical Center|No|Completed|October 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|55 Years|No|||May 2014|May 27, 2014|December 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337687||105882|
NCT01337674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4618-010|Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)|A Study to Evaluate the Co-Administration of MK-4618 With Antihypertensive Agents||Merck Sharp & Dohme Corp.|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|80 Years|No|||December 2015|December 22, 2015|April 15, 2011|No|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01337674||105883|
NCT01337947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB- HSR #15312|The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes|The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes||University of Virginia|No|Completed|April 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|DM1 and healthy controls|April 2011|September 26, 2014|April 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337947||105862|
NCT01338363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612N00016|Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists|Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists||AstraZeneca||Completed|May 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|23470|||Both|N/A|N/A|No|Non-Probability Sample|The study population will include all children aged 0 to 18 years receiving a first        dispension of acid suppressing drugs recorded in the PHARMO RLS database between September        2008 and October 2011. Subjects will be followed-up for at least 18 month. First review of        study outcomes including chart reviews is estimated to start in August 2011.|August 2015|August 27, 2015|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338363||105841|
NCT01338922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMPKIN|Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 DM|Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 DM - a Randomised Controlled Trial|PUMPKIN|University of Schleswig-Holstein|Yes|Recruiting|April 2011|||June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|272|||Both|6 Years|16 Years|No|||March 2011|June 21, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01338922||105798|
NCT01338883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBR-652-2-202|Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus|A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR 652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV 1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus||Tobira Therapeutics, Inc.|Yes|Completed|June 2011|June 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|143|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|April 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338883||105801|
NCT01339494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-24783|Nitric Oxide Production in MELAS Syndrome|ARGININE FLUX AND NITRIC OXIDE PRODUCTION IN PATIENTS WITH MELAS SYNDROME AND THE EFFECT OF ARGININE AND CITRULLINE SUPPLEMENTATION||Baylor College of Medicine|Yes|Recruiting|July 2009|||June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|3 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 19, 2011|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339494||105754|
NCT01339429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002279/1|Simplified Negative Pressure Wound Therapy|Evaluation of the Performance and Safety of a Simplified Negative Pressure Wound Therapy Device||Brigham and Women's Hospital|No|Completed|March 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|14 Years|90 Years|No|||May 2015|May 19, 2015|March 28, 2011||No||No|February 12, 2014|https://clinicaltrials.gov/show/NCT01339429||105759|
NCT01339442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105445|BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer|A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer||Washington University School of Medicine|Yes|Active, not recruiting|November 2011|December 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|31|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|April 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339442||105758|
NCT01340664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017914|An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin||Janssen Research & Development, LLC|Yes|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|279|||Both|18 Years|80 Years|No|||September 2014|September 5, 2014|April 21, 2011|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT01340664||105664|
NCT01336361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMT IRB 52-11|Emerging Physical Therapy Practice in Palliative Care: A Survey of Perceptions of Physical Therapists|Emerging Practice in Palliative Care: A Survey of the Perceptions of Physical Therapists Regarding the Role, Utilization, Goals, and Cultural Issues of Physical Therapy Intervention in the Palliative Care of Functionally Dependent Elderly.||University of Montana|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|228|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Physical Therapists who are members of the APTA and live in the United States.|September 2014|September 15, 2014|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336361||105981|
NCT01336660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM-10/02|A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco|Phase 2/3 Study for Scorpion North Africa Middle East Envenomation With a Immune F(ab')2 (Equine) Antivenom Alacramyn NAMO. A Randomized, Double-Blind, Placebo-controlled, Prospective and Multicenter Study||Instituto Bioclon S.A. de C.V.|Yes|Not yet recruiting|July 2012|January 2013|Anticipated|October 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Months|15 Years|No|||May 2012|May 14, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336660||105960|
NCT01336972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-284|Short-Term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|A Phase 2a, Single-Center Study Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/ Pharmacodynamics of Oral Tolvaptan in Subjects With ADPKD at Various Stages of Renal Function||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|October 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|70 Years|No|||December 2012|December 5, 2012|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336972||105936|
NCT01336985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110131|Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads|Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases||National Institutes of Health Clinical Center (CC)||Terminated|March 2011|March 2011|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|84 Years|No|||November 2014|November 4, 2014|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336985||105935|
NCT01344109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECU 003|A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy|A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy||Leo W. Jenkins Cancer Center|No|Withdrawn|February 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Serum will be centrifuged to plasma which will be transferred to alliquots, and frozen prior      to shipping. Exosomes will be extracted from the frozen plasma with half of the sample used      for antibody testing and the remaining sample will be used for RNA analysis.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Newly diagnosed breast cancer patients prior to neoadjuvant chemotherapy treatment and        healthy volunteers|August 2013|August 26, 2013|April 27, 2011||No|Lab company that was to do testing was sold|No||https://clinicaltrials.gov/show/NCT01344109||105400|
NCT01344395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016445-25|Use of Local Infiltration Analgesia Following Total Hip Arthroplasty|Local Infiltration Analgesia in Total Hip Arthroplasty - Efficacy of Multiple Bolus Injections With Ropivacaine and Ketorolac||University of Aarhus|Yes|Completed|March 2010|September 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2013|January 21, 2013|April 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01344395||105378|
NCT01344655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0901-PR-0012|Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients|A Single-centre, Double-blind, Double-dummy, Randomised, Crossover Study to Investigate the Effect of Formoterol HFA-pMDI Versus Salmeterol HFA-pMDI on Small Airways Physiological Parameters in COPD Patients|Imperial|Chiesi Farmaceutici S.p.A.|No|Completed|April 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|16|||Both|40 Years|N/A|No|||July 2013|July 29, 2013|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01344655||105358|
NCT01344668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101523|The Public Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care|The Public Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care|PRIDE|Vanderbilt University|Yes|Active, not recruiting|May 2011|May 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|411|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2015|June 19, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344668||105357|
NCT01336829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017989|TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.|A Phase I, Open Label, Randomized, 2-Panel, 2-Way Crossover Trial to Investigate the Pharmacokinetic Interaction Between Etravirine or TMC278 and Telaprevir at Steady-State in Healthy Subjects.||Tibotec Pharmaceuticals, Ireland||Completed|March 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01336829||105947|
NCT01337700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-21|Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism|Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism||Montefiore Medical Center|Yes|Completed|February 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|50 Years|No|||November 2014|November 19, 2014|December 27, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337700||105881|
NCT01338350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2340C00003|Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 After Administration of Single and Multiple Ascending Doses in Healthy Male Japanese Subjects||AstraZeneca||Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|96|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01338350||105842|
NCT01338623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P03/11|Bioequivalence Study of Tansulosine 0,4 mg Capsule in Health Subjects -Fed State|Bioequivalence Study of Tansulosine 0,4 mg Capsule in Health Subjects -Fed State|BET04cap|Biocinese|No|Recruiting|April 2011|May 2011|Anticipated|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|May 2, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338623||105821|
NCT01338935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005011060|Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002|A Phase I, Single-Site, Tri-Institutional, Open-Label, Three-Part, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of CW002 in Healthy Adult Anesthetized Volunteers|CW002|Weill Medical College of Cornell University|Yes|Terminated|May 2011|November 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|136|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 3, 2014|April 18, 2011|No|Yes|Pharmacokinetic stopping criteria for the study were met.|No||https://clinicaltrials.gov/show/NCT01338935||105797|
NCT01338636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EiPAH|An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Patients With Exercise Induced Pulmonary Arterial Hypertension|An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Patients With Exercise Induced Pulmonary Arterial Hypertension||Brigham and Women's Hospital|No|Recruiting|September 2008|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338636||105820|
NCT01340079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1LM010412-01|Virtual World Health Behavior Counseling for Patients With Diabetes|Virtual World Health Behavior Counseling for Patients With Diabetes||Boston Medical Center|Yes|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|89|||Female|18 Years|N/A|No|||May 2012|September 20, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01340079||105709|
NCT01339455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHREB ID# 23282|Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica|Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica|SCT-NMO|University of Calgary|No|Active, not recruiting|March 2011|December 2020|Anticipated|March 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01339455||105757|
NCT01339208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10100547|TREAT (Telemedicine for Reach, Education, Access, and Treatment)|TREAT (Telemedicine for Reach, Education, Access, and Treatment)|TREAT|University of Pittsburgh|Yes|Completed|June 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|35|||Both|18 Years|N/A|No|||April 2011|May 26, 2015|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01339208||105776|
NCT01340365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000279|Tai Chi, Physiologic Complexity, and Healthy Aging|Tai Chi, Physiologic Complexity, and Healthy Aging||Harvard University Faculty of Medicine|Yes|Completed|March 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340365||105687|
NCT01340378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00034496|A Pilot Study of Thrombin Generation Changes in Neonates Undergoing Placement of a Blalock-Taussig Shunt|A Pilot Study of Thrombin Generation Changes in Neonates Undergoing Placement of a Blalock-Taussig Shunt||Emory University|Yes|Completed|January 2010|December 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Serum samples only|Both|N/A|30 Days|No|Non-Probability Sample|1. Full-term neonates (37-42 weeks gestational age)          2. Apgar score of 7 or more at 5 minutes after delivery          3. Surgical placement of BT shunt or repair of an aortic coarctation          4. Parent or legal guardian willing to participate, and able to understand and sign the             provided informed consent|December 2014|December 10, 2014|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01340378||105686|
NCT01340677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018277|A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers|An Open-Label, Single-Dose, Randomized, 3-Period, Crossover Study to Evaluate the Pharmacokinetic Dose Proportionality of Canagliflozin of 50, 100, and 300 mg Under Fasted Conditions in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340677||105663|
NCT01336998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALEXANDRA 9159|Administration of Arginine Supplementation in Preterm Infants|Administration of Arginine Supplementation in Preterm Infants and Measurement of Fecal Calprotectin as an Inflammatory Marker of the Intestine||Alexandra Hospital, Athens, Greece|Yes|Active, not recruiting|June 2009|||June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|80|||Both|N/A|3 Days|No|||April 2011|April 15, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01336998||105934|
NCT01337011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1884|Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells|Pilot Study Comparing the Effect of Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells for Improving Left Ventricular Function in Chronic Ischemic Cardiomyopathy|AlsterMACS|Asklepios proresearch|No|Recruiting|July 2011|July 2017|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|80 Years|No|||August 2012|August 10, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01337011||105933|
NCT01337232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15DC011165-01|Building Complex Language|Building Complex Language: Effect of Treatment and Dosage||Governors State University|No|Completed|April 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|10 Years|14 Years|No|||November 2013|November 21, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01337232||105916|
NCT01337479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-049|A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials|Long-Term Assessment of Treatment Outcomes With Entecavir and Lamivudine for Chronic Hepatitis B Infection in Patients Who Have Enrolled in Phase III Entecavir Trials||Bristol-Myers Squibb|No|Completed|February 2003|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1097|||Both|N/A|N/A|No|Non-Probability Sample|Only subjects who participated in Entecavir Phase III studies AI463022, AI463023,        AI463026, and AI463027.|April 2011|April 18, 2011|April 15, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01337479||105898|
NCT01337453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27678|Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy|Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy||Baylor College of Medicine|No|Completed|April 2011|July 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|247|||Both|18 Years|N/A|No|Probability Sample|1. The investigators plan to study 300 consecutive patients treated with BoNT at the             Parkinson Disease center and Movement Disorders Clinic (PDCMDC) of Baylor College of             Medicine.          2. The investigators will invite patients to participate in the study during an             eight-month period that includes two cycles of BoNT injections. All patients within             this period will be invited to take part in the clinical study. This will include             patients who have never been injected in our clinic and are considered as "new"             patients; and patients who are followed on a regular basis in our clinic and are             considered as "established" patients.|August 2012|August 23, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01337453||105900|
NCT01344993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT MA09-hRPE AMD-001|Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration|A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry AMD|Dry AMD|Ocata Therapeutics|Yes|Active, not recruiting|April 2011|December 2015|Anticipated|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|55 Years|N/A|No|||October 2015|October 21, 2015|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01344993||105333|
NCT01341002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01247-48|Red Blood Cells (RBC) Transfusion Related to Central Venous O2 Saturation (ScvO2) Measurement|Red Blood Cells (RBC) Transfusion Related to Central Venous O2 Saturation||University Hospital, Lille|Yes|Completed|November 2009|May 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01341002||105638|
NCT01341366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.552-T|Fast-track Perioperative Program for Laparoscopic Colorectal Surgery|The Impact of Fast-track Perioperative Program on the Clinical and Immunological Outcomes After Laparoscopic Colorectal Surgery in Hong Kong Chinese Patients: A Prospective Randomized Trial||Chinese University of Hong Kong|No|Completed|November 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|75 Years|No|||April 2013|April 29, 2013|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01341366||105610|
NCT01336842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#220|Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors|Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer||University of California, Davis|Yes|Active, not recruiting|April 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|April 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336842||105946|
NCT01337986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ampyra Vision 2011 RTN|Ampyra for Optic Neuritis in MS|Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis||Washington University School of Medicine|No|Completed|May 2011|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|55 Years|No|||February 2014|February 14, 2014|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337986||105859|
NCT01338376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scilin20110124|Organization Program of DiabEtes INsulIN ManaGement|Organization Program of DiabEtes INsulIN ManaGement: An Open, Multi-center, Prospective, Randomized, 16-week, Controlled Clinical Study|OPENING|Chinese Diabetes Society|Yes|Recruiting|March 2011|May 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|18 Years|N/A|No|||April 2011|October 10, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01338376||105840|
NCT01339507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-05-11|A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft|A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft in Patients With a History of Allergic Conjunctivitis||Cunningham, Derek N., O.D., P.A.|Yes|Completed|April 2011|June 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who are diagnosed with allergic conjunctivitis and who meet all other        inclusion/exclusion criteria will be eligible to enter the study.|January 2016|January 26, 2016|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339507||105753|
NCT01339520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiabetesScorecardStudy|Diabetes Scorecard Educational Intervention Study|Use of a Card to Improve Risk Factor Control in Patients With Type II Diabetes||George Washington University|No|Completed|November 2008|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|104|||Both|40 Years|N/A|No|||November 2009|April 19, 2011|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339520||105752|
NCT01339221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112560|Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium|Epidemiological, Observational, Post Marketing Study of the Genetic Stability of GSK Biologicals' Rotavirus Vaccine (Rotarix™) in Children <5 Years of Age Diagnosed With Severe Gastroenteritis, in Belgium||GlaxoSmithKline||Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only||2|Actual|26|Samples Without DNA|Stool samples|Both|14 Weeks|5 Years|No|Non-Probability Sample|Children confirmed with G1 and/or P[8] cases from the RotaBel study, children between 14        weeks and <5 years of age, hospitalized for severe gastroenteritis in the study hospitals        and who are tested positive for rotavirus|October 2012|September 24, 2015|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339221||105775|
NCT01339481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2408-CL-0103|A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept|A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept||Astellas Pharma Inc|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|whole blood, serum|Both|18 Years|N/A|No|Probability Sample|Subjects with Rheumatoid Arthritis|November 2011|November 28, 2011|April 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339481||105755|
NCT01339780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113/180/2010|Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques|||Turku University Hospital||Completed|February 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|53|||Both|40 Years|80 Years|No|||February 2014|February 26, 2014|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01339780||105732|
NCT01339754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000698981|Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy|Salvage Therapy With Trabectedin in Metastatic Pancreatic Adenocarcinoma: A Single-Arm Phase II Trial|PACT-18|IRCCS San Raffaele|No|Completed|February 2011|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||August 2014|August 8, 2014|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01339754||105734|
NCT01340404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071247|Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy|A Multicenter Study Comparing the Results of Allogeneic Stem Cell Genoidentical in Children With Sickle Cell Anemia and Cerebral Vascular Disease Detected by Transcranial Doppler|DREPAGREFFE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|December 2010|October 2015|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|N/A|15 Years|No|||November 2015|November 30, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340404||105684|
NCT01336673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200039-503|Glucophage XR® Observational Study|An Observational Study on the Use of Glucophage XR® Therapy in the Management of Patients With Type 2 Diabetes||Merck KGaA|No|Terminated|June 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|518|||Both|18 Years|70 Years|No|Non-Probability Sample|Patient aged > 18 and diagnosed with type 2 diabetes and considered by physician as        suitable for treatment Glucophage XR®|June 2014|June 18, 2014|April 14, 2011||No|The study was scheduled for completion February 2013. Because of difficulties encountered in    completing the trial the study was terminated by sponsor June 2013.|No||https://clinicaltrials.gov/show/NCT01336673||105959|
NCT01336686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M102-21122|Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout|A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout||CymaBay Therapeutics, Inc.|No|Completed|May 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|18 Years|75 Years|No|||March 2015|March 30, 2015|April 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336686||105958|
NCT01337245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-02/08|Emergency Treatment of Coral Snake Envenomation With Antivenom|Emergency Treatment of Coral Snake Envenomation With Antivenom||University of Arizona|Yes|Recruiting|May 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|N/A|N/A|No|||March 2016|March 7, 2016|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337245||105915|
NCT01337466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVD001|Biodistribution and Dosimetry Evaluation of [124I]FIAU|Biodistribution and Dosimetry of [124i]FIAU in Patients With Prosthetic Joint Infection of The Knee or Hip and Healthy Subjects Using PET-CT Scanning||BioMed Valley Discoveries, Inc|No|Completed|December 2010|March 2013|Actual|December 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337466||105899|
NCT01337791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H200804IRB|Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels|||Southeast University, China|Yes|Completed|August 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Female|20 Years|40 Years|No|||April 2011|April 18, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337791||105874|
NCT01337804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18136|A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)|A Single Dose, Comparative, Open-label, Randomized, Crossover Bioequivalence Study of Omeprazole Administered as Zegerid® Powder for Oral Suspension 20 mg and Prilosec 40 mg Capsule in Healthy Subjects||Bayer|No|Completed|January 2011|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|April 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337804||105873|
NCT01338077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYALG1001|Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease|A Multi-center, Double-blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Sodium Alginate Oral Suspension (50 mg/ml) in Comparison to Omeprazole (20 mg/Cap) to Treat Non-erosive Gastro-esophageal Reflux Disease (NERD)||Chang Gung Memorial Hospital|Yes|Completed|October 2010|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|195|||Both|20 Years|75 Years|No|||February 2012|February 9, 2012|January 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01338077||105853|
NCT01344694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020-11|Epicardial Fat, Visceral Fat and Coronary Atherosclerosis|Association Between Epicardial Fat, Visceral Fat Accumulation & Cardiovascular Atherosclerosis||Ziv Hospital|Yes|Not yet recruiting|July 2011|March 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|110|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|50 patients (age 40-70) with excess of visceral fat (obese), 30 patient with liver fat and        30 sexes, age matched individuals will be recruited.|April 2011|May 13, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344694||105355|
NCT01344707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4SC-202-1-2010|Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)|Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor||4SC AG|No|Completed|March 2011|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2014|March 31, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01344707||105354|
NCT01345006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT SMD 01 MA09-hRPE|Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy|A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)||Ocata Therapeutics|Yes|Active, not recruiting|April 2011|December 2015|Anticipated|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|16|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|April 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01345006||105332|
NCT01345019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090482|Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma||Amgen|Yes|Recruiting|May 2012|January 2019|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1700|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345019||105331|
NCT01345305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00043846|Biomarker Development in Sturge-Weber Syndrome|Establishing Reliability for Quantitative EEG, Transcranial Doppler, Behavioral Outcomes and Optical Coherence Tomography in SWS: The Next Step Toward Biomarker Development|Pilot|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|July 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|6 Months|21 Years|No|Non-Probability Sample|1. Individuals with SWS and brain involvement (Aims 1-3): for the purposes of this study             SWS brain involvement is defined as having shown on MRI imaging evidence of the             typical vascular malformation which includes the following: leptomeningeal angioma,             choroid plexus glomus, and associated venous angioma/malformation.          2. Individuals with SWS and eye involvement (Aim 4): for the purposes of this study SWS             eye involvement is defined as individuals with a portwine birthmark in the V1             dermatomal distribution          3. Able (or parents able) to provide informed consent          4. Able to cooperate with tests          5. Age 6 months to 21 years (Aims 1-3 only)|July 2013|July 31, 2013|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345305||105309|
NCT01337362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-024|Recurrent Hypoglycaemia in Type 1 Diabetes|Recurrent Hypoglycaemia in Type 1 Diabetes: Effects on Cognitive Function, Cerebral Electrical Activity, and Skin Temperature|HypoNeuro|Hillerod Hospital, Denmark|No|Completed|May 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|23|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01337362||105907|
NCT01338389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-04|Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy|Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy||Centre Hospitalier Universitaire de Nice|No|Recruiting|December 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338389||105839|
NCT01338662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1009-057-332|Comparison of the Incidence of Dyskinesia in Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist|A 10-year Observational Study of the Incidence of Dyskinesia in Patients With Early Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist||Seoul National University Hospital|No|Recruiting|May 2011|April 2022|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|500|||Both|30 Years|60 Years|No|Probability Sample|outpatient clinic in SNUH|January 2012|January 25, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01338662||105818|
NCT01338948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0291|Image-guided Minimally Invasive Robotic Surgery Using Preoperative CT Scan for Gastric Cancer Patients|A Feasibility Study on Image-guided Minimally Invasive Robotic Surgery Using Preoperative CT Scan for Gastric Cancer Patients||Yonsei University|No|Completed|August 2009|December 2009|Actual|October 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||March 2011|April 19, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01338948||105796|
NCT01337960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7461-P|Ankle Robotics Training After Stroke|Ankle Robotics Training After Stroke: Effects on Gait and Balance||VA Office of Research and Development|Yes|Completed|July 2011|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|41|||Both|18 Years|80 Years|No|||May 2015|May 27, 2015|April 15, 2011||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01337960||105861|The control group was limited in both numbers and the fact that they were not available for retention testing. The technical challenges for reliable collection of anticipatory postural adjustments meant loss of those data for analysis.
NCT01337973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 09-333|Preventing Violence Among Veterans in Substance Use Disorder Treatment|Impact of Interventions to Reduce Violence and Substance Abuse Among VA Patients||VA Office of Research and Development|No|Active, not recruiting|June 2012|September 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|December 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01337973||105860|
NCT01339767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110144|Study of Toddlers With Language Delay|Markers of Autism Spectrum Disorders in At-Risk Toddlers: A Pilot Study||National Institutes of Health Clinical Center (CC)||Recruiting|April 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|159|||Both|9 Months|21 Months|Accepts Healthy Volunteers|||July 2015|August 11, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01339767||105733|
NCT01340105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT11005|Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation|Microwave Versus Radiofrequency Ablation for Hepatocellular Carcinoma: a Prospective Randomized Control Trial||Chinese University of Hong Kong||Recruiting|April 2011|April 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340105||105707|
NCT01340417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091108|Melatonin Levels in Preterm and Term Newborn Infants|Melatonin Levels in Preterm and Term Newborn Infants|MELIP|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2011|June 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|380|||Both|24 Weeks|41 Weeks|No|||September 2013|September 17, 2013|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01340417||105683|
NCT01340092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29964|Use of a Family Navigator in Families With Children Newly Diagnosed With Autism Spectrum Disorder|Use of a Family Navigator in Families With Children Newly Diagnosed With Autism Spectrum Disorder||Boston Medical Center|No|Active, not recruiting|April 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|192|||Both|15 Years|64 Years|No|||March 2014|March 19, 2014|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340092||105708|
NCT01340391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCS|Safety Study on a Wood-plastic Composite Cast|A Wood-plastic Composite Cast - a New Ecological Splinting Method||Helsinki University Central Hospital|Yes|Enrolling by invitation|August 2009|June 2011|Anticipated|April 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2011|April 21, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01340391||105685|
NCT01336374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813112|Vacant Lot Greening and Violence-Related Outcomes|A Pilot Randomized Controlled Trial of Vacant Lot Greening and Violence-related Outcomes||University of Pennsylvania|No|Completed|April 2011|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|29|||Both|18 Years|65 Years|No|Probability Sample|Residents living around two seperate sites (one site where vacant lots are greened and a        control site where vacant lots are not greened).|December 2011|December 2, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336374||105980|
NCT01337024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK09/2008|Heart Rate Variability (HRV) in Patients With Neurogenic Detrusor Overactivity (NDO) Before and After Botulinum Neurotoxin Type A (BoNT/A) Intradetrusor Injections|Heart Rate Variability in Patients With Neurogenic Detrusor Overactivity Before and After Botulinum Neurotoxin Type A Intradetrusor Injections|HRV/Botox|Balgrist University Hospital|No|Completed|March 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|36|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups, one control group without treatment, one group with NDO and treated with        BoNT/A, both measured with ECG|January 2013|January 7, 2013|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337024||105932|
NCT01337258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113979|Economic Analyses of the REDUCE Trial|Economic Analyses Alongside the REDUCE Clinical Trial||GlaxoSmithKline|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Male|50 Years|75 Years|No|Probability Sample|Men at increase risk for prostate cancer ages 50-75 who were enrolled in the REDUCE study|April 2011|April 14, 2011|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01337258||105914|
NCT01337492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2209|Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)|Pilot Study: Safety and Feasibility of Using Sorafenib as Neoadjuvant Treatment Prior to Orthotopic Liver Transplantation (OLT) in Patients With Hepatocellular Carcinoma||Case Comprehensive Cancer Center|Yes|Terminated|September 2010|January 2012|Actual|May 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|January 19, 2011|No|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT01337492||105897|
NCT01337817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI-043|A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers|A Randomized, Double-Blinded, Active-Controlled, Crossover, Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, Containing Tobacco and Silver Salt - in Healthy Smokers||Star Scientific, Inc|No|Completed|September 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|37|||Both|23 Years|72 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337817||105872|
NCT01337830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSI-044|Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen in Reducing Cigarette Craving in Smokers|A Randomized, Double-Blind, Crossover, Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, in Reducing Craving for a Cigarette in Daily Smokers||Star Scientific, Inc|No|Completed|October 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|111|||Both|23 Years|72 Years|Accepts Healthy Volunteers|||October 2014|October 23, 2014|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337830||105871|
NCT01344720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASL 4 Teramo|Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain|Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain||Azienda Sanitaria Locale 4, Teramo|No|Not yet recruiting|May 2011|June 2011|Anticipated|May 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2011|April 28, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01344720||105353|
NCT01344733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NIT-DUM-2010/1|A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)|A Non - Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient Diagnosed as With Treatment Resistant Major Depressive Disorder (MDD)|Improve|AstraZeneca|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|660|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with treatment resistant major depressive disorder will be evaluated in order to        assess the presence of hypomanic symptoms as cause of resistance.|March 2012|March 22, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01344733||105352|
NCT01345032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23012011|The Effect of Nutrition Follow up After Hospital Discharge in Undernourished Elderly|The Effect of Follow up on Nutrition Intervention After Discharge in Undernourished Geriatric Patients||Aarhus University Hospital|No|Completed|June 2011|December 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|208|||Both|75 Years|N/A|No|||December 2015|December 30, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345032||105330|
NCT01345318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0151005|B0151005 Open-Label Extension Study|A Multicenter Open-label Extension Study For Subjects Who Participated In Study B0151003 (Andante Ii)|ANDANTE II|Pfizer|Yes|Active, not recruiting|June 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345318||105308|
NCT01337713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052054|Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)|Efficacy of Massage and Light Touch Therapy for the Treatment of Generalized Anxiety Disorder|GAD|Emory University|Yes|Completed|September 2010|July 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||November 2014|November 10, 2014|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337713||105880|
NCT01337726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH086482|Combined Illness Management and Psychotherapy in Treating Depressed Elders|Combined Illness Management and Psychotherapy in Treating Depressed Elders|COPE|University of Iowa|Yes|Active, not recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|55 Years|N/A|No|||September 2013|October 9, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01337726||105879|
NCT01338675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-SCT -1002|Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)|||Seoul National University Hospital|Yes|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||November 2013|November 17, 2013|March 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01338675||105817|
NCT01338974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9031-S9333-S0112-S0301-A|S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia|Proteomic Signature Associated With Clinical Response to Cytarabine Based Induction Therapy in Patients With AML 56 Years and Older||Southwest Oncology Group|No|Completed|March 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|290|||Both|56 Years|N/A|No|Non-Probability Sample|Patients enrolled on S9031, S9333, S0112 or S0301 consenting to use of specimens for        future research|March 2015|March 5, 2015|April 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01338974||105794|
NCT01338987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110136|Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation|Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation||National Institutes of Health Clinical Center (CC)||Recruiting|March 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|9 Years|40 Years|No|||September 2015|January 29, 2016|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338987||105793|
NCT01339000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110146|Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy|A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects Following Chemotherapy||National Institutes of Health Clinical Center (CC)||Recruiting|April 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|60 Years|100 Years|No|||September 2015|November 7, 2015|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339000||105792|
NCT01338649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Light Therapy in PD|Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence|Effects of Bright Light Treatment on Daytime Sleepiness and Nocturnal Sleep in Patients With Parkinson's Disease||Northwestern University|Yes|Completed|November 2007|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|N/A|N/A|No|||September 2014|September 3, 2014|April 18, 2011||No||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01338649||105819|
NCT01339234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hicks -MS treadmill|Supported Treadmill Training for Progressive Multiple Sclerosis|Body-weight Supported Treadmill Training in Primary Progressive Multiple Sclerosis: A Pilot Trial||Hicks, Audrey, Ph.D.|No|Completed|April 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|60 Years|No|||April 2011|April 19, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01339234||105774|
NCT01339533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRV1015758|Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation|Airway Pressure Release Ventilation (APRV) vs. Conventional Volume Control Mechanical Ventilation for Patients With Respiratory Failure Requiring Invasive Mechanical Ventilator Support||Intermountain Health Care, Inc.|Yes|Recruiting|October 2011|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|246|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|April 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339533||105751|
NCT01340430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOHER-021|Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer|Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.||National Institute for Cancer Research, Italy|No|Active, not recruiting|March 2011|May 2025|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Female|18 Years|N/A|No|||February 2016|February 23, 2016|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01340430||105682|
NCT01340443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25435|An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma|A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL||Hoffmann-La Roche||Active, not recruiting|January 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|314|||Both|18 Years|N/A|No|Probability Sample|Previously untreated diffuse large B-cell lymphoma or follicular lymphoma patients|March 2016|March 1, 2016|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340443||105681|
NCT01336712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 922|Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases|A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies||Northside Hospital, Inc.|No|Completed|April 2011|July 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||December 2015|December 10, 2015|April 14, 2011|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01336712||105956|
NCT01336725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-08662c 2008/17575 (REK)|Learning and Coping With Chronic Illness|Learning and Coping With Chronic Illness||Oslo University Hospital|No|Completed|January 2009|December 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Learning and mastery centre|April 2011|April 15, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01336725||105955|
NCT01337037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHTD2010|Modified Video-assisted Thoracoscopic Surgery (VATS) Lobectomy for Early-stage Non-small Cell Lung Cancer (NSCLC)|||Peking University People's Hospital|Yes|Recruiting|April 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|in hospital patients|January 2015|January 24, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01337037|5 Years|105931|
NCT01337050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8471004|Asian Phase I Study Of PF-03446962|A Phase I Pharmacokinetic And Pharmacodynamic Study Of Pf-03446962 In Asian Patient With Advanced Solid Tumors||Pfizer|No|Completed|July 2011|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|April 6, 2011|No|Yes||No|July 16, 2015|https://clinicaltrials.gov/show/NCT01337050||105930|Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.
NCT01337271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-345|Performance of Neurally Adjusted Ventilatory Assist (NAVA) During Spontaneous Breathing Trial|Performance of Neurally Adjusted Ventilatory Assist (NAVA) During an Spontaneous Breathing Trial||University of Sao Paulo General Hospital|No|Completed|May 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|2||Actual|20|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01337271||105913|
NCT01337505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-206-P1-MTD-01|Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors|An Open-Label Phase 1 Study to Investigate the Safety and Maximum Tolerated Dose of INNO-206 (Doxorubicin-6-Maleimidocaproyl Hydrazone; DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors||CytRx|No|Completed|April 2011|December 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||February 2013|February 11, 2013|April 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337505||105896|
NCT01337518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EZN-4176-01|A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer|A Phase 1a/1b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients With Castration-Resistant Prostate Cancer||Enzon Pharmaceuticals, Inc.|No|Suspended|March 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Male|18 Years|N/A|No|||September 2012|December 17, 2012|April 15, 2011|No|Yes|Reassessment of strategic direction|No||https://clinicaltrials.gov/show/NCT01337518||105895|
NCT01337843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR052569|Online Cognitive Behavioral Therapy (CBT) Workbook|Wellness Workbook: Efficacy of an Online CBT Workbook for Chronic Low Back Pain|WW|Talaria, Inc|Yes|Completed|April 2011|July 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|198|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337843||105870|
NCT01337531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rFSH.- HP-FSH.PCOS|Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)|Recombinant FSH Versus Highly Purified FSH in PCOS Patients Undergoing Control Ovarian Stimulation and IVF: a Prospective Randomized Study||Genesis Center for Fertility & Human Pre-Implantation Genetics|Yes|Enrolling by invitation|May 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2011|April 18, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01337531||105894|
NCT01344746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP 38608|Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing|Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing||Beijing Children's Hospital|Yes|Enrolling by invitation|December 2010|April 2012|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|225|Samples With DNA|blood and adenotonsillar tissue|Both|2 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive children referred to the sleep center for PSG due to symptoms of SDB from        December 2009 to June 2010 were enrolled in the study. Normal age-, sex-, and        weight-matched children without a history of snoring participated as control subjects, who        were recruited from a community-based physical check-up activity.|August 2010|April 28, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01344746||105351|
NCT01345045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-891|A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects With Diabetic Neuropathic Pain||AbbVie|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|193|||Both|18 Years|75 Years|No|||January 2013|January 3, 2013|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01345045||105329|
NCT01341431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090102|Bee Venom for the Treatment of Parkinson Disease|Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease|MIREILLE|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|N/A|No|||June 2013|June 13, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01341431||105605|
NCT01337999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0127|Human Epididymis Protein 4 in Normal Menstruating Women|Human Epididymis Protein 4 in Normal Menstruating Women||Women and Infants Hospital of Rhode Island|Yes|Active, not recruiting|March 2011|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Serum|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ovulating women recruited from local college campuses, doctor's offices and hospitals.|December 2013|December 16, 2013|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337999||105858|
NCT01338402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-368-C-108|Evaluation of the Performance of AIR OPTIX® COLORS|||Alcon Research|No|Completed|April 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|47|||Both|17 Years|N/A|No|||February 2014|February 19, 2014|April 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01338402||105838|
NCT01338415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-374|FUTURE 3 Study Extension|A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension|FUTURE 3 Ext|Actelion||Completed|July 2011|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|3 Months|12 Years|No|||February 2016|February 17, 2016|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338415||105837|
NCT01338428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-110976|Sexual Assault Resistance Education for University Women|Sexual Assault Resistance Education for University Women: A Trial in Three Canadian Universities||University of Windsor|No|Completed|September 2011|November 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|916|||Female|17 Years|24 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01338428||105836|
NCT01338688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td-TIG|The Change of the Tetanus Antibody Titer After Single Injection of Td and Simultaneous Injection of TIG With Td|the Change of the Tetanus Antibody Titer After Single Injection of Tetanus Vaccine and Simultaneous Injection of Tetanus Immunoglobulin With Tetanus Vaccine?||Seoul National University Hospital|No|Completed|October 2008|October 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|250|Samples Without DNA|serum|Both|20 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy adult over twenty|April 2011|April 18, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01338688||105816|
NCT01339013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110322|Rebreathing of Carbon Dioxide With a Device Used for Giving Inhalational Anaesthesia|Dead Space Effect of an Anaesthesia Gas Reflector (AnaConDa)||Region Skane|No|Completed|April 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|April 13, 2011||No||No|March 14, 2014|https://clinicaltrials.gov/show/NCT01339013||105791|
NCT01338961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPO-2010|Normothermia Versus Hypothermia for Valvular Surgery Patients|Normothermia Versus Hypothermia for Patients With Valvular Heart Disease Operated Under Cardiopulmonary Bypass.||Meshalkin Research Institute of Pathology of Circulation|No|Completed|April 2011|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|140|||Both|20 Years|80 Years|No|||October 2013|October 30, 2013|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338961||105795|
NCT01339546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-4018|National Trends in Otitis Media in Children Under 5 Years of Age|National Trends In Ambulatory Care Visits For Otitis Media In Children Under The Age Of Five In The United States||Pfizer|No|Active, not recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|1|||Both|2 Months|5 Years|No|Probability Sample|National Ambulalatory Medical Care Survey (NAMCS)-national sample of visits to non        federally employed office based physicians who are primarily engaged in direct patient        care, and National Hospital Ambulatory Medical Care Survey (NHAMCS)- national sample of        visits to emergency and outpatient departments and to ambulatory surgery facilities in        noninstitutional general and short stay hospitals, exclusive of Federal, military, and        Veterans Administration hospitals, located in the 50 States and the District of Columbia|December 2015|December 14, 2015|December 22, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01339546||105750|
NCT01339793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99080|Exploring the Relationships Among Hospital's Corporate Social Responsibility, Job Attitudes and Job Performance|Exploring the Relationships Among Hospital's Corporate Social Responsibility, Job Attitudes and Job Performance||Taipei Medical University WanFang Hospital|No|Completed|January 2011|February 2011|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|employees in the hospitals|April 2011|April 27, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01339793||105731|
NCT01340690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD-EA-10-01-067|Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder|PAD-study: Nutritional Efficacy of Polyunsaturated Fatty Acids (Omega-3 and Omega-6) in Combination With Zinc and Magnesium Versus Placebo in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder (ADHD)|PAD|Johannes Gutenberg University Mainz|Yes|Recruiting|March 2011|April 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|438|||Both|6 Years|17 Years|No|||April 2015|April 7, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01340690||105662|
NCT01340703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KyorinEye005|Vitrectomy for Optic Disc Pit Maculopathy|Vitrectomy Without Laser or Gas Tamponade for Optic Disc Pit Maculopathy||Kyorin University|No|Completed|January 2005|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||January 2011|April 21, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340703||105661|
NCT01336387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2013-00468|Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers|A Randomized, Double-Blind, Single-dose and Multi-dose Study of the Novel Retinoid, 9cUAB30, to Determine Pharmacokinetics and Safety||National Cancer Institute (NCI)||Terminated|October 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|October 7, 2014|March 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336387||105979|
NCT01336699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0009|Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3|Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|January 2013|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|October 1, 2015|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336699||105957|
NCT01336738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611002|Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus|A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Pfizer|Yes|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|266|||Both|18 Years|70 Years|No|||June 2013|June 5, 2013|April 13, 2011|Yes|Yes||No|June 5, 2013|https://clinicaltrials.gov/show/NCT01336738||105954|
NCT01336751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOE901_4021|Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment|Lantus® (Insulin Glargine[rDNA Origin] Injection) vs Humalog® Mix 75/25 (75% Insulin Lispro Protamine Suspension and 25% Insulin Lispro Injection) as add-on Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and Glucophage (Metformin) Combination Treatment: a Randomized, Open, Parallel Study||Sanofi||Completed|July 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|79 Years|No|||April 2011|April 15, 2011|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336751||105953|
NCT01337063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001814|Multi-Center Medication Reconciliation Quality Improvement Study|Multi-Center Medication Reconciliation Quality Improvement Study|MARQUIS|Brigham and Women's Hospital|No|Completed|March 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1836|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337063||105929|
NCT01337076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM-EXP-A2010-01|Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy|Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy||Cochlear|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 18, 2014|April 14, 2011|Yes|Yes||No|September 18, 2014|https://clinicaltrials.gov/show/NCT01337076||105928|
NCT01337297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-UFES 296/10|Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction|Treatment of Crack-cocaine Addiction Through Cognitive Neuromodulation of the Prefrontal Cortex Produced by Transcranial Direct Current Stimulation.||Federal University of Espirito Santo|No|Completed|June 2011|May 2013|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||December 2013|December 23, 2013|April 14, 2011||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01337297||105912|Crack-cocaine is highly addictive, extremely difficult to treat and with high dropouts. 7 subjects started with anodal DLPFC tDCS showing high relapses (not shown). The remaining 13 subjects tested with bilateral DLPFC tDCS or sham were considered.
NCT01342289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1151|Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide|Shortened-duration Tacrolimus Following Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|July 2011|June 2022|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|6 Months|75 Years|No|||June 2015|June 30, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01342289||105539|
NCT01345058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001630|Add on Lacosamide Versus High Dose Monotherapy|Open Label Trial of Add on Lacosamide Versus High Dose Monotherapy in Patients With a Seizure Disorder||Brigham and Women's Hospital|Yes|Active, not recruiting|March 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2014|July 20, 2014|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345058||105328|
NCT01341080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS813511|Varenicline for Gait and Balance Impairment in Parkinson Disease|Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease|Chantix-PD|Rush University Medical Center|Yes|Recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|90 Years|No|||July 2014|July 15, 2014|April 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01341080||105632|
NCT01341093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/19761-3|Education Program for Cardiac Patients|Educational Program With Telephone Follow-up for Patients After Percutaneous Coronary Intervention: Randomized Controlled Trial||University of Sao Paulo|Yes|Completed|August 2011|October 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||May 2014|May 14, 2014|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01341093||105631|
NCT01332188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-100-0004|Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model||AC-170|Aciex Therapeutics, Inc.|No|Completed|April 2011|||June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|10 Years|N/A|No|||July 2012|July 10, 2012|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332188||106301|
NCT01338025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1094|Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy|Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation.|P1094|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Terminated|March 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|8 Years|24 Years|No|||October 2015|October 14, 2015|April 16, 2011|Yes|Yes|Study was halted for lack of accrual|No|April 24, 2014|https://clinicaltrials.gov/show/NCT01338025||105856|
NCT01338051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERCAPS I|The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru|The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru (PERCAPS)|PERCAPS|Preventive Oncology International, Inc.|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|642|||Female|30 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 16, 2014|April 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01338051||105855|
NCT01339559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01379|Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy|An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy|BRITE™|UCB Pharma|No|Active, not recruiting|April 2011|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|767|||Both|16 Years|N/A|No|||February 2016|February 12, 2016|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339559||105749|
NCT01339806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2010.199|The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury|Phase IV Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury|SCORE|Brooke Army Medical Center|Yes|Completed|June 2011|August 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|143|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01339806||105730|
NCT01339247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114035|Paxil CR Bioequivalence Study Brazil - Fed Administration|Relative Bioavailability Study Between the Formulations: Paroxetine 25 mg Tablets With Controlled Release Manufactured by GSK Mississauga and Paroxetine 25 mg Tablets With Controlled Release Manufactured by SmithKline Beecham (Cidra), Fed Administration in Healthy Volunteers of Both Genders||GlaxoSmithKline|No|Completed|October 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 5, 2011|August 31, 2010||No||No|March 24, 2011|https://clinicaltrials.gov/show/NCT01339247||105773|
NCT01340456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001-01|Cholesterol Metabolites as Markers for CYP3A Induction|Induction of Drug Metabolism by Rifampicin to Compare the Endogenous Biomarker 4beta-OHcholesterol With the Probe Drug Midazolam as Quantitative Markers for Cytochrome P450 3A4 Induction||Karolinska University Hospital|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|July 8, 2011|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340456||105680|
NCT01340144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000112|Evaluation of Patellar Crepitus Following Total Knee Arthroplasty|Evaluation of Patellar Crepitus Following PFC Sigma vs. PFC Sigma HP Total Knee Arthroplasty: Does Femoral Component Design Make a Difference?||Colorado Joint Replacement|No|Completed|April 2011|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1250|||Both|N/A|N/A|No|Probability Sample|Colorado Joint replacement clinic|March 2015|March 4, 2015|April 20, 2011|Yes|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01340144||105704|
NCT01340157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiFEX002|Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions|Randomized, Open Study to Assess the Impact of Two Different Types of Food on the Relative Bioavailability of Fexinidazole Tablets After Single Oral Dose in Healthy Male Volunteers||Drugs for Neglected Diseases|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2011|April 27, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01340157||105703|
NCT01340170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YA-OTX-0002|A Study Evaluating OsseoSpeed TX Using Different Drilling Protocols With Immediate Loading|An Open, Non-randomized, Prospective Multi-centre Study Evaluating a Soft Bone Drilling Protocol for Single Tooth Restoration in the Posterior Area With Immediate Loading||Dentsply Implants||Active, not recruiting|April 2011|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340170||105702|
NCT01340716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG 100531|Effects of Tai Chi Chuan in Patients After Recent Acute Myocardial Infarction|Effects of Tai Chi Chuan on Blood Pressure, Respiratory Muscle Strength and Functional Capacity in Patients After Recent Acute Myocardial Infarction: a Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Enrolling by invitation|March 2011|December 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 3, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340716||105660|
NCT01340742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-132|Remote Ischemic Preconditioning Before Abdominal Surgery|Remote Ischemic Preconditioning Before Abdominal Surgery and the Prevalence of Perioperative Complications||Lawson Health Research Institute|No|Recruiting|June 2010|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|440|||Both|18 Years|80 Years|No|||June 2011|June 29, 2011|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01340742||105658|
NCT01336400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT-TBM-090878|Genome-wide Single Cell Haplotyping as a Generic Method for Preimplantation Genetic Diagnosis|Genome-wide Single Cell Haplotyping as a Generic Method for Preimplantation Genetic Diagnosis||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Genomic DNA, single blastomere DNA|Both|N/A|N/A|No|Probability Sample|We aim to collect spare embryos of 30 couples that opt for preimplantation genetic        diagnosis (see Eligibility Criteria).|April 2010|April 14, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336400||105978|
NCT01336413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4603-I|Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans|Neuroactive Steroids and TBI in OEF/OIF Veterans||VA Office of Research and Development|Yes|Recruiting|October 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|21 Years|55 Years|No|||December 2015|December 10, 2015|April 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01336413||105977|
NCT01336764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18680|Enhancing Emotion Regulation During Driving in OEF/OIF Veterans|Enhancing Emotion Regulation During Driving in OEF/OIF Veterans||Stanford University|No|Recruiting|April 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01336764||105952|
NCT01336777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK080436|Regional Fat Depots and Insulin Resistance|Heterogeneity of Fat Depots||Stanford University|Yes|Active, not recruiting|August 2009|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|adipose tissue samples will be frozen for gene expression analysis.|Both|39 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, nondiabetic volunteers will be recruited from Stanford's General Surgery        Preoperative Clinic, Stanford's Bariatric Surgery Clinic, and nonsurgical volunteers who        respond to local newspaper advertisements.|December 2013|December 2, 2013|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01336777||105951|
NCT01337869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNEAH-2010GC1|Bascom Cleft Lift Versus Limberg Flap for Sacrococcygeal Pilonidal Sinus|Comparison of Bascom Cleft Lift Technique Versus Limberg Flap Closure for Treatment of Sacrococcygeal Pilonidal Disease: A Prospective Randomized Controlled Trial Evaluating for Patient Satisfaction and Early Recurrence||Trabzon Numune Training and Research Hospital|Yes|Recruiting|January 2011|December 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2011|April 18, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337869||105868|
NCT01338142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-NV-571-CTIL|Amorphous Calcium Carbonate (Acc) Versus Crystalline Calcium Carbonate (Ccc) Using Stable Calcium Isotopes In Postmenopausal Women|A Randomised, Double-Blind, Crossover Bioavailability Study Comparing Amorphous Calcium Carbonate (Acc) Versus Crystalline Calcium Carbonate (Ccc) Using Stable Calcium Isotopes In Postmenopausal Women||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2011|July 2012|Anticipated|May 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||March 2011|April 17, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01338142||105848|
NCT01338519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSDatabaseOdense|Database Study on Patients With PCOS|||Odense University Hospital|No|Recruiting|January 1997|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Female|15 Years|50 Years|No|Probability Sample|Premenopausal women referred with hirsutism or PCOS to Odense University hospital|January 1997|April 18, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338519||105829|
NCT01338792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-05-7|Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer|A Phase II Trial of Oxaliplatin and Pemetrexed in Hormone Refractory Prostate Cancer||University of Southern California|Yes|Completed|June 2006|December 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Male|18 Years|N/A|No|||February 2014|February 5, 2014|April 15, 2011|Yes|Yes||No|October 16, 2013|https://clinicaltrials.gov/show/NCT01338792||105808|
NCT01338779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN507ST|Study of Tolerant Kidney Transplant Recipients|Identification and Mechanistic Investigations of Tolerant Transplant Recipients|FACTOR|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|May 2004|August 2016|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||11|Actual|151|Samples With DNA|blood, urine and tissue samples|Both|18 Years|N/A|No|Probability Sample|-  primary care clinic          -  major kidney (renal) transplant programs|March 2016|March 3, 2016|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338779||105809|
NCT01335919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007757|Neonatal Non-Invasive Hemoglobin Determination|Non-invasive Continuous Hemoglobin in Pediatric Medicine: a Comparison Between Standard of Care CBC Hemoglobin (ADVIA 2120®) and the New Masimo® SpHb® Neonatal Sensor||Children's Hospital of Philadelphia|No|Withdrawn|September 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|1 Year|No|Probability Sample|Neonates admitted for a surgical procedure or admitted to the PICU or NICU where        hemoglobin determinations are expected.|January 2013|January 7, 2013|February 2, 2011||No|Company is redesigning measuring tool.|No||https://clinicaltrials.gov/show/NCT01335919||106015|
NCT01336192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHPH-11ZL113|Maintenance Gemcitabine in the Chinese Advanced Lung Cancer|Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin|MAGICAL|Tongji University|No|Recruiting|April 2011|April 2013|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||April 2011|April 13, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01336192||105994|
NCT01342848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021835-15|Effectiveness of Thrombus Aspiration in Plaque Reduction for Patients With Acute Coronary Syndromes|REduction of Myocardial Necrosis Achieved With Nose-dive Manual Thrombus Aspiration|REMNANT|G. d'Annunzio University|Yes|Completed|March 2011|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|76|Samples Without DNA|Histopathology assessment of aspirated material during manual TA. Quantitative analysis:      size and weight. Qualitative evaluation: a) thrombus containing only platelets, b) a      thrombus with an erythrocyte component c) any fragment of vessel wall, cholesterol crystals,      inflammatory cells or collagen tissue|Both|18 Years|75 Years|No|Probability Sample|45 patients with at least one "culprit" lesion, identified as a high-grade (>90%) lesion        in the territory of jeopardized myocardium, at coronary angiography performed for a recent        (<15 days, but after 24 hours) STEMI or a non-ST elevation (NSTE)-ACS within 72 hours of        symptoms.|June 2015|June 4, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01342848||105496|
NCT01339260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETU-08-18|An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting|A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy||Helsinn Healthcare SA|Yes|Completed|April 2011|||November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1455|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|April 19, 2011|Yes|Yes||No|November 6, 2014|https://clinicaltrials.gov/show/NCT01339260||105772|
NCT01339273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sponsorship review number:113|Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection|Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection- a Double Blind Randomised Controlled Trial||Oxford University Hospitals NHS Trust|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01339273||105771|
NCT01339286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC30800302|Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)|Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment||Peking University|Yes|Recruiting|March 2011|||December 2011|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|6 Years|16 Years|No|||April 2011|April 19, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01339286||105770|
NCT01340118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC asthma treatment based FeNO|Improvement of FeNO and FEF25-75 After Inhaled Corticosteroid Treatment of Asthma|Concurrent Improvement of Exhaled Nitric Oxide and FEF25-75 After Treatment With Inhaled Corticosteroid in Children With Controlled Asthma||Chungbuk National University|No|Completed|May 2010|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|8 Years|16 Years|No|||April 2011|April 20, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01340118||105706|
NCT01340131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HPS10G|CKD-828 (40/5mg) Pharmacokinetic Study|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 40mg and S-Amlodipine 5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|January 2011|April 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2011|April 27, 2011|March 30, 2011||||No||https://clinicaltrials.gov/show/NCT01340131||105705|
NCT01339819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01611|Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Dabi-ADP-1|Deutsches Herzzentrum Muenchen|No|Completed|April 2011|September 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01339819||105729|
NCT01339832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21875|An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer|Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: A Survival Analysis.||Hoffmann-La Roche||Completed|August 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Colorectal cancer patients having taken part in study ML18280|December 2015|December 29, 2015|April 20, 2011||No||No|December 29, 2015|https://clinicaltrials.gov/show/NCT01339832||105728|
NCT01340196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.50|Drug Drug Interaction of BI 201335 and Tenofovir|Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers||Boehringer Ingelheim||Completed|April 2011|||June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|April 20, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01340196||105700|
NCT01340482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN23-INT-001|A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia|A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|April 2011|October 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340482||105678|
NCT01340469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|076/2003|Effect of Oral Probiotic Supplementation on The Rate of Hospital Acquired Infection and Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants|Nosocomial Infections and Necrotizing Enterocolitis in Preterm Neonates Treated With Lactobacillus Acidophilus and Bifidobacterium Infantis in An Intensive Care Unit : A Randomized Controlled Study||King Chulalongkorn Memorial Hospital|No|Completed|January 2005|June 2008|Actual|March 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|N/A|28 Days|No|||March 2011|April 20, 2011|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340469||105679|
NCT01340729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0839|Open-Label Study of TPI 287 for Patients With Metastatic Melanoma|A Phase I/II Open-Label Study of TPI 287 for Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Withdrawn|September 2013|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|15 Years|N/A|No|||April 2013|April 4, 2013|April 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01340729||105659|
NCT01336426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAD-001|Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease|Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease|PAD-001|Vermillion, Inc.|Yes|Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1033|Samples Without DNA|Serum, Plasma and Frozen Red Blood Cells|Both|50 Years|N/A|No|Probability Sample|Subjects that meet the inclusion/exclusion criteria from 10 primary care sites.|December 2013|December 16, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01336426||105976|
NCT01336439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-2010-0017|Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism|Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism by Different Injection Sites Evaluated by Polysomnography|BBP|Yonsei University|No|Recruiting|March 2011|December 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|20 Years|65 Years|No|||March 2011|April 18, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01336439||105975|
NCT01338285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906178|Association of Formaldehyde Exposure to Myeloid Leukemia in Workers in Guangdong, China|Studies of Myeloid Progenitor Cells in Workers Exposed to Formaldehyde, a Putative Leukemogen||National Institutes of Health Clinical Center (CC)||Completed|June 2006|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|94|||Both|18 Years|50 Years|No|||October 2015|November 5, 2015|April 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01338285||105847|
NCT01338532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03c-2011-NAR|Time to Total Hip Replacement After Supervised Exercise and Patient Education|Time to Total Hip Replacement in Patients With Hip Osteoarthritis Going Through Both Supervised Exercise and Patient Education Compared to Those Going Through Patient Education Only. A 3.5-6 Year Follow-up of a Randomized, Controlled, Clinical Trial.||Oslo University Hospital||Active, not recruiting|March 2005|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|40 Years|80 Years|No|||August 2012|August 17, 2012|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01338532||105828|
NCT01338805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2212|Phase II BGG492 Capsule Extension for Partial Epilepsy|A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211||Novartis||Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|66 Years|No|||December 2012|December 6, 2012|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338805||105807|
NCT01339104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14814|Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity|An Open-label, Non-randomized Phase I Study of Regorafenib (BAY73-4506) to Evaluate Cardiovascular Safety Parameters, Tolerability, Pharmacokinetics, and Anti-tumor Activity in Patients With Advanced Solid Tumors||Bayer|No|Completed|April 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|April 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339104||105784|
NCT01339117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28050|Delivered Dietary Intervention for Children With Irritable Bowel Syndrome|Delivered Dietary Intervention for Children With Irritable Bowel Syndrome||Baylor College of Medicine|No|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|7 Years|17 Years|No|||May 2013|May 11, 2013|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01339117||105783|
NCT01342302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-2008|An Online Psychoeducational Intervention for Young Women With Breast Cancer and Their Partners|An Online Psychoeducational Intervention for Young Women With Breast Cancer and Their Partners|OPIC|Sunnybrook Health Sciences Centre|No|Completed|September 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2011|April 9, 2013|October 15, 2009||No||No||https://clinicaltrials.gov/show/NCT01342302||105538|
NCT01342315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-1000-01|Topical Antifungal Treatment for Tinea Cruris|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris||Medicis Global Service Corporation|No|Completed|May 2011|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|483|||Both|12 Years|N/A|No|||August 2013|August 20, 2013|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01342315||105537|
NCT01342588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-11-03|Accuracy of Lumbar Pedicle Screw Placement Assisted With Continuous Pulse-train Stimulation|Accuracy of Lumbar Pedicle Screw Placement Assisted With Continuous Pulse-train Stimulation During Track Creation and Screw Insertion||American British Cowdray Medical Center|No|Recruiting|January 2011|May 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|70 Years|No|||April 2011|April 26, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01342588||105516|
NCT01344226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-2011A|Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery|Clinical Outcomes and Evaluation of Lotemax (Loteprednol Ophthalmic Solution ) 0.5% QID for Treatment of Ocular Inflammation Associated With Cataract Surgery||Discover Vision Centers|Yes|Active, not recruiting|April 2011|June 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Male or Female 18 years of age scheduled for unilateral cataract surgery with intraocular        implant.|May 2013|May 13, 2013|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01344226||105391|
NCT01339052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-033|Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma|A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2011|March 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339052||105788|
NCT01339026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020219-35|Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention|Evaluating the Benefit of Additional Platelet Inhibition in Acute Coronary Syndrome Patients With High Platelet Reactivity Undergoing PCI|APACS-HPR|Royal Brompton & Harefield NHS Foundation Trust|No|Terminated|February 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|75 Years|No|||September 2014|September 17, 2014|April 19, 2011||No|Change in guidelines favouring newer antiplatelet drugs in ACS|No||https://clinicaltrials.gov/show/NCT01339026||105790|
NCT01339598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 11065|Remediation of Cognitive Dysfunction in Euthymic Bipolar Disorder Patients Using Transcranial Direct Current Stimulation (tDCS)|||The University of New South Wales|Yes|Completed|September 2011|October 2015|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|15|||Both|18 Years|65 Years|No|||July 2015|November 2, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01339598||105746|
NCT01339845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10061|Introduction of Cholera Vaccine in Bangladesh|Introduction of Cholera Vaccine in Bangladesh: " Impact Evaluation of Cholera Vaccine and Behaviour Change Interventions in Urban Dhaka"|ICVB|International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|September 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|240000|||Both|1 Year|N/A|Accepts Healthy Volunteers|||June 2015|July 26, 2015|April 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339845||105727|
NCT01339572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plerixafor-UF01|Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation|Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation||University of Florida|No|Active, not recruiting|April 2011|July 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339572||105748|
NCT01339585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 11064|The Effect of Timing of Transcranial Direct Current Stimulation (tDCS) for Enhancing Learning During Cognitive Training|The Effect of Timing of Transcranial Direct Current Stimulation (tDCS) for Enhancing Learning During Cognitive Training||The University of New South Wales|Yes|Completed|May 2011|||May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01339585||105747|
NCT01340209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.464|Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo Over 52 Weeks in Patients With Moderate to Severe Persistent Asthma||Boehringer Ingelheim||Completed|April 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|285|||Both|18 Years|75 Years|No|||June 2014|June 4, 2014|April 13, 2011||||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01340209||105699|
NCT01339884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10358B|A Study of Resveratrol as Treatment for Friedreich Ataxia|An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia||Murdoch Childrens Research Institute|Yes|Completed|April 2011|December 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01339884||105724|
NCT01340222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAGOT PHRC IR 2010|Monocyte Chemotactic Protein-1 (MCP-1) Expressing Monocytes to Predict Preterm Delivery: PhenoMAP Study|Evaluation of the Prognostic Value of Monocytes and Lymphocyte Phenotyping, Along With Intracellular MCP-1 Expression, to Predict Preterm Delivery for Women Hospitalized for Threat of Preterm Labor Between 24 and 34 Weeks of Amenorrhea: PhenoMAP Study|PHENOMAP|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|March 2011|||March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Female|18 Years|N/A|No|||January 2013|January 4, 2013|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01340222||105698|
NCT01340755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-409|Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer|A Pilot Study of Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|March 2011|May 2017|Anticipated|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01340755||105657|
NCT01340768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-262|Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)|An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting||Merck Sharp & Dohme Corp.|No|Completed|June 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|870|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|March 24, 2011|No|Yes||No|September 7, 2012|https://clinicaltrials.gov/show/NCT01340768||105656|
NCT01337544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNJ-NK-01/2009|Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours|Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours|NK|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|No|Terminated|January 2011|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|6 Months|22 Years|No|||November 2013|November 8, 2013|March 25, 2011||No|The parents of two patients enrolled who died, presented a claim against the hospital and the    study was halted.|No||https://clinicaltrials.gov/show/NCT01337544||105893|
NCT01338818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIT124D2302E1|Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder|A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD||Novartis||Completed|April 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|299|||Both|18 Years|60 Years|No|||November 2014|November 4, 2014|April 15, 2011|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT01338818||105806|
NCT01338831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFA102X2102|Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer|A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer||Novartis||Completed|September 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|73|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01338831||105805|
NCT01339130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09-PR-GODEFROY|Assessment of Social-emotional Functioning in Neurological Diseases|Assessment of Social-emotional Functioning in Stroke, Frontotemporal Dementia, Alzheimer and Parkinson Diseases|Emotion|Centre Hospitalier Universitaire, Amiens|No|Completed|June 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|177|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01339130||105782|
NCT01339364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240/4402|Impact of Three Continuing Education Meetings for Community Pharmacists on Weight Management|Evaluation of Three 1-day Educational Intervention to Promote Knowledge and Attitude of Community Pharmacists About Evidence-based Weight Management||Tehran University of Medical Sciences|No|Completed|January 2011|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Anticipated|180|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 25, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01339364||105764|
NCT01343225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP # 38879|Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection|Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection||East Carolina University|No|Not yet recruiting|May 2011|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|50 Years|No|||April 2011|April 27, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343225||105468|
NCT01343433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-3101-4|Influence of Light Therapy on Confusion in Patients at the Intensive Care Unit|Influence of Bright Light Therapy on Delirium in Patients at the Intensive Care Unit: a Pilot-study||Onze Lieve Vrouwe Gasthuis|No|Recruiting|March 2011|May 2011|Anticipated|May 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|All patients of 18 years and older who will be admitted to the Intensive Care Unit of the        Onze Lieve Vrouwe Gasthuis, Amsterdam can be included in the study. This is a medical        surgical level three ICU with 24 beds. There are over 90 specialised ICU nurses laborious        in this ICU. An average of 1500 patients a year is admitted, of which 750 from the        cardiothoracic surgical department.|April 2011|April 26, 2011|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01343433||105452|
NCT01343979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-049|Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome.|Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome. Development of a Clinical Score for Suspected H1N1 Infection.||Medical University of Graz|Yes|Completed|October 2010|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|800|||Both|N/A|N/A|No|Probability Sample|All patients tested for influenza illness by PCR of respiratory tract specimens at the        Institute of Hygiene, Karl-Franzens-University Graz, and at the Institute for Hospital        Hygiene and Microbiology, KAGES Graz.|April 2015|April 2, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01343979||105410|
NCT01343459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIORT - 01|Intra-Operative Electron Boost and Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment (BCT)|Hypofractionated Whole-Breast Irradiation Preceded by Intra-Operative Radiotherapy With Electrons as Anticipated Boost HIOB A New Option in Breast-Conserving Treatment for Operated Breast Cancer Stages I and II|HIOB|Paracelsus Medical University|Yes|Recruiting|January 2011|May 2021|Anticipated|March 2021|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Female|35 Years|N/A|No|||October 2015|October 19, 2015|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343459||105450|
NCT01338766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1967|Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression|Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression (STRiDE)|STRiDE|Baxano Surgical, Inc.|No|Active, not recruiting|April 2011|||December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|April 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01338766||105810|
NCT01339039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-329|Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma|Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma||Dana-Farber Cancer Institute|Yes|Terminated|December 2011|March 2016|Anticipated|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|April 6, 2011|No|Yes|Low accrual rate|No||https://clinicaltrials.gov/show/NCT01339039||105789|
NCT01339299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700642-603|Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)|The Endocrine Efficacy of Either Recombinant Luteinizing Hormone (r-LH) or Low Dose Recombinant Human Chorionic Gonadotropin (r-hCG) Supplementation for Recombinant Follicle Stimulating Hormone (r-FSH) Stimulation in Normogonadotrophic Women Undergoing in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Therapy Following a Long-term Gonadotropin Releasing Hormone (GnRH) Agonist Down Regulation Protocol||Regionshospitalet Viborg, Skive|No|Completed|October 2009|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Female|18 Years|35 Years|No|||April 2011|September 25, 2013|April 19, 2011||No||No|September 25, 2013|https://clinicaltrials.gov/show/NCT01339299||105769|
NCT01339325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGAddolorataH-MLirici-14-93|Laparo-endoscopic Single Site (LESS) Cholecystectomy Versus Standard LAP-CHOLE|Laparo-endoscopic Single Site Cholecystectomy Versus Standard Laparoscopic Cholecystectomy|LESSCHO|San Giovanni Addolorata Hospital|No|Not yet recruiting|May 2011|December 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|75 Years|No|||March 2011|April 19, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01339325||105767|
NCT01339858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-12|The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia||Breier-Stanley|Indiana University|Yes|Active, not recruiting|May 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339858||105726|
NCT01339871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0051|Phase I Study of Pazopanib and Vorinostat|A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2011|||April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|174|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|April 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339871||105725|
NCT01340183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0910C00015|Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics in Intravenous AZD5099 After Single Ascending Doses in Healthy Male and Female Subjects||AstraZeneca||Suspended|May 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|April 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01340183||105701|
NCT01349218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0180|Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns|In Infants and Newborns, is There a Relation Between the Potassium Level in Blood Samples Drawn From a Vein and Those Drawn From a Heel Stick?|PS|The University of Texas Health Science Center, Houston|Yes|Completed|March 2014|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|N/A|6 Months|Accepts Healthy Volunteers|||December 2015|December 11, 2015|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01349218||105010|
NCT01337089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA0999|Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain|A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain||GW Pharmaceuticals Ltd.|Yes|Active, not recruiting|January 2011|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|760|||Both|18 Years|N/A|No|||March 2015|May 19, 2015|April 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337089||105927|
NCT01340495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-205|Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy|Pilot Study of Proton Radiation Therapy for Invasive Breast Carcinoma Following Mastectomy||Massachusetts General Hospital|Yes|Recruiting|June 2011|||June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01340495||105677|
NCT01340508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B/09/377|Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal Cancer|A Phase II Trial of Preoperative Concurrent Chemotherapy and (IMRT) in Locally Advanced Rectal Cancer||National University Hospital, Singapore|Yes|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|21 Years|90 Years|No|||April 2011|April 20, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01340508||105676|
NCT01345617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0291|A Study of Sweat Testing Using a Quantitative Patch|A Study of Sweat Testing Using a Quantitative Patch||Polychrome Medical, Inc.|No|Completed|January 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|170|||Both|N/A|N/A|No|Non-Probability Sample|pediatric pulmonology clinic|November 2013|November 14, 2013|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01345617||105285|
NCT01337583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 009B|A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Safety and Efficacy Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women||International Partnership for Microbicides, Inc.||Withdrawn|July 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 8, 2012|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01337583||105890|
NCT01337596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14248|A Study of LY2951742 in Healthy Volunteers|A Safety, Tolerability, and Pharmacokinetic Study of Single, Escalating Subcutaneous Doses of LY2951742 in Healthy Volunteers||Eli Lilly and Company|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|9||Anticipated|61|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 18, 2012|April 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01337596||105889|
NCT01337882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAVER|Biodiesel Exhaust, Acute Vascular and Endothelial Responses|Inhalation of Dilute Biodiesel Exhaust: Acute Vascular and Endothelial Responses|BEAVER|University of Edinburgh|No|Completed|April 2011|November 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337882||105867|
NCT01339689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-0700|Ganaxolone in Posttraumatic Stress Disorder (PTSD)|A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder||Marinus Pharmaceuticals|Yes|Completed|April 2011|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|55 Years|No|||October 2015|October 1, 2015|April 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01339689||105739|
NCT01339962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181203|Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.|Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.||Pfizer|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1073|||Both|18 Years|N/A|No|Non-Probability Sample|All Danish patients diagnosed with metastatic renal cell carcinoma referred to the        involved centers.|August 2014|August 15, 2014|April 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01339962||105718|
NCT01340300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-009|Exercise and Metformin in Colorectal and Breast Cancer Survivors|Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2011|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|139|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01340300||105692|
NCT01342627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-019726-14|Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma|Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib|SERCC|Centro di Riferimento Oncologico - Aviano|No|Terminated|October 2010|September 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|65 Years|N/A|No|||October 2015|October 5, 2015|November 29, 2010||No|low enrollment rate|No||https://clinicaltrials.gov/show/NCT01342627||105513|
NCT01342354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16866B|Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer|A Phase I Study of Stereotactic Body Radiation Therapy in Patients With Unresected Carcinoma of the Pancreas or Ampulla||University of Chicago|No|Recruiting|April 2009|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01342354||105534|
NCT01342367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-625-A|Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer|A Feasibility Study of Oral Hormonal Therapy and Radiation for Non-metastatic, Intermediate or High Risk Prostate Cancer in Men 70 and Older or With Medical Comorbidities||University of Chicago|No|Recruiting|December 2010|April 2019|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||January 2016|January 6, 2016|April 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01342367||105533|
NCT01342887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2409.00|Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study||Fred Hutchinson Cancer Research Center|No|Terminated|April 2011|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01342887||105493|
NCT01343238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2009-70X-21091-01-3|Short- and Longterm Effects of Physical Activity and Dietary Restriction Postpartum|Short- and Longterm Effects of Physical Activity and Dietary Restriction Postpartum on Women's Weight and Body Composition: a Randomized Study|LEVA|Göteborg University|No|Completed|May 2007|June 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|76|||Female|N/A|N/A|No|||August 2012|August 29, 2012|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343238||105467|
NCT01343446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cer-Met-A2|Sleep Impairment and Coping Style in Diabetes|Sleep Impairment Can Influence The Coping Style Of Patients With Diabetes|Diabetesleep|Istanbul University|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|105|||Both|18 Years|65 Years|No|Non-Probability Sample|Followed-up in Cerrahpasa Clinics of Diabetes Patients with diabetes Patients with/without        diabetic complication Patients suffer from sleep impairment|April 2011|April 27, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343446||105451|
NCT01343472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP0311F08|Evaluation of the Washington Intensive Supervision Program|Evaluation of the Washington Intensive Supervision Program||Pepperdine University|No|Recruiting|January 2011|June 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Male|18 Years|N/A|No|||April 2011|April 27, 2011|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01343472||105449|
NCT01340235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-19|Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin|Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin||Centre Hospitalier Universitaire de Nice|No|Recruiting|June 2011|June 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|6 Months|8 Years|No|||October 2011|October 13, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01340235||105697|
NCT01339312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRV08|Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine|Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China||Sanofi|No|Completed|April 2011|September 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|816|||Both|10 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 27, 2014|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01339312||105768|
NCT01348711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI/06/FP-BIODOP-T1|Early Placental Insufficiency Screening|Placental Insufficiency Screening During First Trimester by a Combination of Uterine Artery Dopppler, Maternal PlGF and sFLT-1 in Hight Risk Population|BIODOP-T1|University Hospital, Tours|Yes|Completed|May 2007|May 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|SERUM|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant between 12 and 14 weeks|May 2011|May 4, 2011|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01348711||105048|
NCT01339611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OATeducation|Education Program for Patients Receiving Oral Anticoagulation|||University of Sao Paulo||Recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||March 2010|June 17, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01339611||105745|
NCT01336790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04052011-7662|National Lymphatic Disease and Lymphedema Registry|National Lymphatic Disease and Lymphedema Registry||Stanford University|No|Recruiting|March 2009|December 2025|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|Participants (national and international participants) with the presence of lymphatic        disease.|December 2015|December 16, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01336790||105950|
NCT01337609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002387|Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder|A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD)||Massachusetts General Hospital|No|Terminated|June 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|65 Years|No|||August 2013|August 7, 2013|April 15, 2011||No|Because the study sponsor chose to discontinue funding for this protocol following a change in    leadership, the study was terminated early.|No|May 29, 2013|https://clinicaltrials.gov/show/NCT01337609||105888|Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and data were not analyzed.
NCT01337622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101GRIP|Gastric Residuals in Preterm Infants|Gastric Residuals in Preterm Infants (GRIP)||McMaster Children's Hospital|No|Completed|March 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|N/A|48 Hours|No|||March 2015|March 26, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01337622||105887|
NCT01338298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047496, HP-00055154|Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia|Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia|DAAMSEL|University of Maryland|Yes|Recruiting|January 2011|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|50 Years|No|||December 2015|December 3, 2015|April 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01338298||105846|
NCT01360918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35192.044.11|Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery|Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery|CONTROL-AF|Medisch Spectrum Twente|No|Recruiting|May 2011|May 2013|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||April 2012|April 20, 2012|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01360918||104115|
NCT01360931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU_UW_11_085|The Roles of Neutrophil Elastase in Lung Cancer|The Roles of Neutrophil Elastase in Lung Cancer||The University of Hong Kong|No|Recruiting|January 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Small bronchial biopsy alongside with the corresponding Bronchoalveolar lavage and bronchial      aspirate will be collected in the same one bronchoscopy session|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects undergoing diagnostic bronchoscopy|May 2011|May 27, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01360931||104114|
NCT01351545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-CBA|A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)|A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications||Center for International Blood and Marrow Transplant Research|Yes|Recruiting|October 2011|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|99999|||Both|N/A|N/A|No|Non-Probability Sample|Recipients of unlicensed cryopreserved cord blood units who are being treated as U.S.        transplant centers.|March 2016|March 22, 2016|May 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01351545||104831|
NCT01360944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H553000-1006|Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test|An Investigator-blind, Controlled Exploratory Study to Assess the Efficacy and Safety of Different Concentrations of Active Ingredients in the Project LAS 41004 Compared to a Bland Ointment and to Active Control in a Psoriasis- Plaque- Test||Almirall, S.A.|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|22|||Both|18 Years|75 Years|No|||June 2015|June 4, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360944||104113|
NCT01361217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39288-A|The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity|The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity|FLUOXETINE|University of Washington|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01361217||104093|
NCT01361230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOC0676170|IMPROVE Critical Care Study (Pilot)|PILOT STUDY: A Randomized Controlled Trial of Intensive Care Management of Sedation Using Patient Responsiveness in Critical Care IMPROVE Critical Care Study Pilot||GE Healthcare|No|Completed|December 2009|May 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|74|||Both|16 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 25, 2011|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01361230||104092|
NCT01361542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/ASTNF/TB/2011|Effect Of Anti TNF Alpha Therapy And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population|Effect Of Anti TNF Alpha Therapy On Disease Activity And Bone Health, And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population||All India Institute of Medical Sciences, New Delhi|No|Completed|February 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|24|||Both|18 Years|55 Years|No|||January 2012|January 25, 2012|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361542||104068|
NCT01332227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-402|Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients|An Open-Label, Randomized Study Evaluating a Switch From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen Plus Any Third Agent to Either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on Their Present Treatment Regimen.|SPARTAN|Bristol-Myers Squibb|Yes|Completed|October 2011|February 2014|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|April 7, 2011|Yes|Yes||No|September 19, 2014|https://clinicaltrials.gov/show/NCT01332227||106298|
NCT01332253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-014|Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Trial of the Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy||Cumberland Pharmaceuticals|Yes|Completed|July 2011|August 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|6 Years|17 Years|No|||February 2014|February 3, 2014|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332253||106296|
NCT01333189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1185|Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback|Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback|RELOAD|University of Colorado, Denver|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Both|50 Years|85 Years|No|||August 2015|August 7, 2015|April 8, 2011||No||No|August 7, 2015|https://clinicaltrials.gov/show/NCT01333189||106224|
NCT01334021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0007|Genomic Testing for Primary Breast Cancer|Feasibility, Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity of HER2 Negative Primary Invasive Breast Cancer (Clinical Stage I to III)||M.D. Anderson Cancer Center|No|Recruiting|May 2011|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|Samples With DNA|Tumor biopsy performed before receiving any drugs to treat breast cancer.|Female|18 Years|N/A|No|Probability Sample|Breast cancer patients from UT MD Anderson Cancer Center in Houston, Texas|January 2016|January 29, 2016|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01334021||106160|
NCT01334489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECEP_LASER Trial|The Trial of Pessary After Laser for TTTS|Arabin Cervical Pessary for Prevention of Preterm Birth in Cases of Twin-to-twin Transfusion Syndrome Treated by Fetoscopic Laser Coagulation: The PECEP Laser Trial|PECEPLASER|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|December 2012|June 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|352|||Female|18 Years|N/A|No|||September 2015|September 1, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334489||106124|
NCT01359657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA212-002|Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma|A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma||Bristol-Myers Squibb|No|Completed|September 2011|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||July 2015|March 15, 2016|May 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359657||104211|
NCT01359644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-040|Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care|Parallel, Open-Label, Randomized Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PSI-7977 in Combination With BMS-790052 With or Without Ribavirin in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotypes 1, 2, or 3||Bristol-Myers Squibb|No|Completed|June 2011|October 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|350|||Both|18 Years|70 Years|No|||September 2015|September 23, 2015|May 23, 2011|Yes|Yes||No|August 21, 2015|https://clinicaltrials.gov/show/NCT01359644||104212|
NCT01359917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC06/MRE00/39|Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome|Psychological Morbidity and Facial Volume in HIV Lipodystrophy:||NHS Lothian|Yes|Completed|August 2006|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|50|||Both|18 Years|70 Years|No|Non-Probability Sample|50 patients with HIV facial lipoatrophy|March 2006|June 9, 2011|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359917||104191|
NCT01359930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaltrexoneBupropion-Ph1A-met|Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study|Phase 1 Study of Interactions Between Oral Naltrexone and Bupropion and Intravenous Methamphetamine in Methamphetamine Experienced Volunteers||National Institute on Drug Abuse (NIDA)||Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|16|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01359930||104190|
NCT01360749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD-LAM-2010-01|Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal|Multicentre, Double-Blind Trial to Evaluate the Efficacy and Safety of Lambdalina vs Placebo as an Anesthetic for Laser Hair Removal||ISDIN|No|Completed|May 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360749||104128|
NCT01361022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|263.511|To Assess the Bioequivalence of Brotizolam Tablets 250 Mcg vs. Lendormin Tablets 250 Mcg Administered to Healthy Adult Volunteers|A Randomized, Single-dose, Two-way Cross-over Study to Assess the Bioequivalence of Lendormin Tablets 0.25 mg (Delpharm Reims) vs. Lendormin Tablets 0.25 mg (Synmosa Biopharma Co. Ltd.) Administered to Healthy Adult Volunteers||Boehringer Ingelheim||Completed|August 2011|||November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|May 25, 2011||||No||https://clinicaltrials.gov/show/NCT01361022||104108|
NCT01360437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-6|Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention|Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI||University of Patras|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|80 Years|No|||June 2012|June 21, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360437||104151|
NCT01361035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJF-63523|Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients|Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients||Tulane University School of Medicine|No|Completed|June 2008|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|168|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361035||104107|
NCT01360723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-080|DNA Methylation and Arsenic-associated Urothelial Carcinoma|Comparison of DNA Methylation Between Urothelial Carcinoma and Healthy Controls||China Medical University Hospital|No|Recruiting|May 2011|||May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|600|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a hosital-based case-control study. Patients with urothelial carcinoma are        recruited by pathological verification of UC was done by routine urological practice        including endoscopic biopsy or surgical resection of urinary tract tumors followed by        histopathological examination by board-certified pathologists. Healthy controls without        evidence of UC or any other malignancy were recurited including those receiving adult        health examinations at China Medical University Hospital.|May 2011|May 26, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360723||104130|
NCT01360697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2011-095-T|An Evaluation of the Effectiveness and Acceptability of Delivering Structured Care in Chinese Type 2 Diabetic Patients|A Multi-Centre Demonstration Project to Evaluate the Effectiveness and Acceptability of the Joint Asia Diabetes Evaluation (JADE) in Chinese Type 2 Diabetic Patients in Jiangsu and Anhui (JA), China|JADE-JA|Asia Diabetes Foundation|Yes|Active, not recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4800|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360697||104132|
NCT01360957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23911|Effect of Consumption of Black Cumin (Nigella Sativa L.) Water Extract on Weight Loss in Overweight Women|||hahid Beheshti University of Medical Sciences|No|Withdrawn||June 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Female|16 Years|60 Years|Accepts Healthy Volunteers|||February 2011|November 17, 2015|May 24, 2011||No|Mahnaz Kazemipoor has not handed over human subject review board approval letter to her    colleague.|No||https://clinicaltrials.gov/show/NCT01360957||104112|
NCT01361815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0002-00|Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)|A Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI) for Subjects With MDD Who Complete/ Discontinued the CTP-0001-00 Protocol||Brainsway|Yes|Completed|July 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|22 Years|68 Years|No|||February 2015|February 1, 2015|May 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01361815||104047|
NCT01331980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113442|Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls|Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls||University of Arkansas|Yes|Completed|January 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|39|Samples Without DNA|Serum samples will be frozen and assayed together.|Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants for the cystic fibrosis (CF) group will be recruited from the pulmonary        clinic at Arkansas Children's Hospital. Healthy controls will be recruited from Arkansas        Children's Hospital outpatient clinics and the community.|July 2015|July 2, 2015|March 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01331980||106317|
NCT01332240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVITA001|External ValidatIon Trial of ASTER Trial|External ValidatIon Trial of Aster: the Need for Surgical Staging After Echo-endoscopic Mediastinal Staging in Clinical N2/3 Lung Cancer|EVITA|Universitaire Ziekenhuizen Leuven|No|Recruiting|April 2011|July 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|255|||Both|18 Years|95 Years|No|||April 2011|October 18, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01332240||106297|
NCT01332851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-103010-S|Supporting Parents Program|Training Social Work Providers: Intervention for Maltreating Families of Infants|SPP|University of Washington|No|Completed|January 2011|October 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332851||106250|
NCT01332864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV4OMTHA|Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache|Physiological and Behavioral Effects of Osteopathic Manipulative Treatment on Patients With Chronic Headache: A Randomized Clinical Trial|OMTHA|Western University of Health Sciences|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|N/A|N/A|No|||February 2013|February 11, 2013|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01332864||106249|
NCT01333202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-00-0980-02/2552|Fresh Lime Alone for Smoking Cessation|Efficacy of Fresh Lime Alone for Smoking Cessation|LIM|Thai Health Professional Alliance Against Tobacco|No|Completed|March 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2010|April 8, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01333202||106223|
NCT01333761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-0004|Cardiox Shunt Detection Technology Study|FDS-0004 Cardiox Shunt Detection Technology Study||Cardiox Corporation|No|Terminated|April 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|71|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|March 31, 2011|Yes|Yes|1)new FDS device design 2)improved Valsalva procedure 3)improved headbands and earpads.|No||https://clinicaltrials.gov/show/NCT01333761||106180|
NCT01334034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1953-3832|Safety of NNC 0123-0000-0338 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0123-0000-0338 in Healthy Subjects||Novo Nordisk A/S|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|70|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 28, 2011|April 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01334034||106159|
NCT01334775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36322.068.11|Comparison of Self-adhering Mesh and Conventional Mesh in Inguinal Hernia Repair.|Comparison of Cousin Biotech® Adhesix™ Versus Conventional Mesh in Open Anterior Inguinal Hernia Repair: a Multi-centre, Randomised, Double-blinded, Controlled Clinical Trial.||Maastricht University Medical Center|No|Not yet recruiting|June 2011|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Male|18 Years|N/A|No|||April 2011|April 12, 2011|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01334775||106102|
NCT01359969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1209|Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients|Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2 up to and Including 13 Years of Age||Pharming Technologies B.V.|No|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|13 Years|No|||November 2015|November 5, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01359969||104187|
NCT01359982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRx001-11-01|Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects|A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies|DINAMIC|EpicentRx, Inc.||Completed|September 2011|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359982||104186|
NCT01359943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2206|Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate|A Randomized, Double-blind, Placebo-controlled Study of Efficacy, Safety and Tolerability of Secukinumab at 12 Weeks Administered With an Intravenous (i.v.) or Subcutaneous (s.c.) Loading Regimen Compared to Placebo in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate||Novartis|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|221|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|May 19, 2011|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01359943||104189|
NCT01359956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SICOG 0109|Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma|Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study|SICOG 0109|National Cancer Institute, Naples|No|Completed|April 2002|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|269|||Both|18 Years|75 Years|No|||April 2014|April 1, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01359956||104188|
NCT01360229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0533|Acupuncture for Fatigue in Parkinson's Disease|Acupuncture as a Symptomatic Treatment for Fatigue in Parkinson's Disease||University of Colorado, Denver|No|Completed|August 2010|May 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|40 Years|N/A|No|||August 2015|August 10, 2015|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360229||104167|
NCT01360450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clonidine NICU-NAS|Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants|Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants:||Gauda, Estelle B., M.D.|Yes|Terminated|July 2011|December 2014|Anticipated|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|N/A|90 Days|No|||August 2014|August 11, 2014|October 13, 2010|Yes|Yes|The study was treminated because of low accural|No||https://clinicaltrials.gov/show/NCT01360450||104150|
NCT01361308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N30-003|Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)|A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause|N30-003|Noven Therapeutics|Yes|Completed|May 2011|February 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|614|||Female|40 Years|N/A|No|||October 2015|October 14, 2015|May 24, 2011|Yes|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01361308||104086|
NCT01361048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV-01|Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis|Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis||University of Alabama at Birmingham|No|Completed|December 2011|January 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Female|19 Years|N/A|No|||January 2014|January 6, 2014|May 24, 2011|Yes|Yes||No|November 18, 2013|https://clinicaltrials.gov/show/NCT01361048||104106|pilot study
NCT01360385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuRVO|Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab|Objective Measurement of Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With a Vascular Endothelial Growth Factor Inhibitor.|LuRVO|Glostrup University Hospital, Copenhagen|No|Completed|October 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed central retinal vein occlusion who have planned treatment        with intravitreal renibizumab|September 2012|September 11, 2012|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01360385||104155|
NCT01360398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114378|Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly|Contribution of Infectious Pathogens to Acute Respiratory Illness in Adults and Elderly||GlaxoSmithKline||Completed|June 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|152|||Both|40 Years|85 Years|No|||August 2014|August 7, 2014|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360398||104154|
NCT01361243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD066216-01A1|NOURISH+: Nourishing Our Understanding of Role Modeling to Improve Support and Health|NOURISHing Families to Promote Healthy Eating and Exercise in Overweight Children|NOURISH+|Virginia Commonwealth University|Yes|Recruiting|April 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361243||104091|
NCT01361555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN162-010|Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression|A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression||Bristol-Myers Squibb|Yes|Terminated|August 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|789|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|May 25, 2011|Yes|Yes|Failure to meet primary endpoint|No||https://clinicaltrials.gov/show/NCT01361555||104067|
NCT01361802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18.504|Ambroxol Spray Sore Throat Study|A Multi-centre, Randomised, Double-blind, Placebo Controlled Parallel Group, Dose Finding Study to Assess the Efficacy and Safety of Ambroxol Spray (2.5mg, 5mg or 10mg) Versus Placebo for the Temporary Relief of Sore Throat Pain in Patients With Acute Pharyngitis||Boehringer Ingelheim||Completed|May 2011|||August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|494|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|May 16, 2011||||No||https://clinicaltrials.gov/show/NCT01361802||104048|
NCT01362127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-nr 2006-001785-16|Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia|Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy|NeoRes|Karolinska University Hospital|Yes|Active, not recruiting|October 2006|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||August 2015|August 31, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362127||104023|
NCT01331993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00030|A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation|A Phase I, Open-label, Randomised, 3-way Crossover Study to Demonstrate Bioequivalence of a Single Oral Dose of Naproxen Administered as VIMOVO Manufactured at AstraZeneca AB Compared to That of VIMOVO Manufactured by Patheon Pharmaceuticals and a Marketed Enteric-coated Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers||AstraZeneca|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01331993||106316|
NCT01335997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524B-143|Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)|A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia||Merck Sharp & Dohme Corp.|No|Terminated|May 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1139|||Both|18 Years|85 Years|No|||October 2014|October 27, 2014|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335997||106009|
NCT01332006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBMCB - BS study|Intra-bone Cord Blood Transplantation|Intra-bone Cord Blood Transplantation for Hematological Malignancies Lacking a HLA Suitable Donor||Università degli Studi di Brescia|No|Recruiting|November 2009|June 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|65 Years|No|||December 2015|December 31, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01332006||106315|
NCT01332877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0029-11-WOMC|Breakfast Size and Weight Loss in Overweight/Obese Adults|The Effect of Breakfast Enriched With Protein and Carbohydrates on Weight Loss, Hunger, Satiety and Ghrelin in Overweight and Obese Adults||Wolfson Medical Center|Yes|Recruiting|April 2011|||November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||April 2011|April 8, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332877||106248|
NCT01333748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXSAL|Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer|Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer|EXSAL|Centre Francois Baclesse|Yes|Completed|April 2010|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|530|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 12, 2012|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01333748||106181|
NCT01334268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP 10009066DOC|Resolute Zotarolimus-Eluting Stent Versus the Taxus Liberte Paclitaxel-Eluting Stent for Percutaneous Coronary Intervention in China|A Randomized Controlled Trial of the Resolute Zotarolimus-Eluting Stent Versus the Taxus Liberte Paclitaxel-Eluting Stent for Percutaneous Coronary Intervention in a Real-World All-comer Patient Population in China|R-China RCT|Medtronic Vascular|Yes|Active, not recruiting|September 2011|December 2017|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334268||106141|
NCT01334515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL1021|Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma|Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma||Children's Oncology Group|Yes|Active, not recruiting|September 2011|||December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|1 Year|30 Years|No|||May 2015|May 1, 2015|April 12, 2011|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01334515||106122|
NCT01360762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMC0109|Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study|Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study||Institute of Tropical Medicine, Belgium|Yes|Completed|November 2011|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|72|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360762||104127|
NCT01360242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01345-34|Minimal Invasive Procedure for Myocardial Infarction|Patients Presenting With Acute STEMI Treated With Primary PCI : Comparison of the Impact of the MIMI Approach With a Conventional Strategy of Immediate Stenting|MIMI|Centre Hospitalier de la Région d'Annecy|No|Completed|June 2011|June 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01360242||104166|
NCT01360463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAKPRO|Efficacy of Drug and Risk Counseling Among Methadone Patients in Jakarta, Indonesia|Efficacy of Drug-HIV Counseling Among IDU at Methadone Clinics in Jakarta|JAKPRO|University of Pennsylvania|No|Recruiting|May 2009|May 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 24, 2011|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360463||104149|
NCT01361087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 2011-14507|Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome|Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With||Ann & Robert H Lurie Children's Hospital of Chicago|No|Withdrawn|April 2011|||December 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|6 Months|24 Years|No|||February 2016|February 4, 2016|May 25, 2011||No|No outside recruitment of subjects from Main Atenolol VS Losartan NIH study|No||https://clinicaltrials.gov/show/NCT01361087||104103|
NCT01360996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 11-003|Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism|Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism|BEYAZ-PCOS|Woman's|Yes|Completed|August 2011|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|53|||Female|16 Years|35 Years|No|||March 2016|March 8, 2016|May 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360996||104110|
NCT01361009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.682|a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients|Safety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing Surveillance||Boehringer Ingelheim||Completed|May 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|2017|||Both|30 Years|75 Years|No|Probability Sample|3000|June 2013|May 7, 2014|May 23, 2011||||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01361009||104109|
NCT01360970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU 2009-016055-22|Hepatitis A Vaccine in Patients With Immunomodulating Drugs|Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate||Sormland County Council, Sweden|Yes|Completed|September 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|68|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360970||104111|
NCT01361568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR845 CLIN2002|Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery|A Multi-Center, Double-Randomized, Double Blind, Placebo Controlled Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 Dosed Preoperatively and Postoperatively in Patients Undergoing a Laparoscopic Hysterectomy||Cara Therapeutics, Inc.|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|203|||Female|21 Years|65 Years|No|||May 2014|May 20, 2014|May 25, 2011|Yes|Yes||No|February 18, 2013|https://clinicaltrials.gov/show/NCT01361568||104066|
NCT01361828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beva-ERG-VEP|Optic Nerve and Retinal Functions With Bevacizumab|Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin).||Cairo University|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|24 Years|62 Years|No|Non-Probability Sample|Forty five eyes of 45 patients with choroidal neovascular membrane (CNV) who were prepared        for intravitreal injections of 1.25mg bevacizumab underwent baseline ERG and VEP in both        eyes before, and at 1 and 4 weeks after the intravitreal injections.Mean age was 50 years        ranging from 24-62 years with 25 females, with 28 AMD and 17 myopic patients.|January 2010|May 26, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01361828||104046|
NCT01362140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090160|Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects|A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)||Amgen|Yes|Active, not recruiting|December 2011|August 2017|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|147|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362140||104022|
NCT01362452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0835|Infusion of Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells|Donor-Derived, CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Umbilical Cord Blood Transplantation||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2012|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|1 Year|75 Years|No|||June 2015|June 23, 2015|May 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362452||103998|
NCT01332266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-702|E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck||Eisai Inc.|No|Active, not recruiting|May 2011|December 2014|Anticipated|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|95|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332266||106295|
NCT01332539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114872|An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy|An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy||GlaxoSmithKline|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|240|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatient with partial epilepsy|April 2013|May 23, 2013|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332539||106274|
NCT01333501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DIT01|Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms|A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy|Cognition|Novartis||Completed|May 2011|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|50 Years|No|||October 2015|October 12, 2015|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333501||106200|
NCT01333514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10040503|Carbohydrate Consumption as a Factor in Aspart Dosing|Carbohydrate Consumption as a Factor in Aspart Dosing Compared to the Regularly Used Standard of Care Basis of Dosing Aspart in the Inpatient Setting (CARB)|CARB|Rush University Medical Center|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333514||106199|
NCT01334086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-11-001|Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy|A Phase II Open Label Study of Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy||University Health Network, Toronto|Yes|Completed|September 2011|||August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|41|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01334086||106155|
NCT01334281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00027653 1682-05|An In-vitro Standardization of B Cell Elispot Assays|A Phase 1, Investigatory Initiated, In-vitro Standardization of B Cell Elispot Assays||Northwestern University|No|Terminated|February 2008|October 2012|Actual|April 2011|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|19|Samples Without DNA|Subjects will serve as a source of B-lineage cells, which will be tested for their ability      to produce IgG, tetanus antibodies, (as controls) and HLA specific antibodies that      coorespond to those detected by the flow PRA assay. They will be retained until they are      used up.|Both|18 Years|N/A|No|Non-Probability Sample|Any kidney, pancreas or heart transplant waitlisted subjects > or = to 18 years of age,        and of either gender. Subjects must be capable of understanding the study, informed        consent form, HIPPA process, and be willing to give informed consent.|April 2013|April 19, 2013|April 13, 2009||No|Technical difficulties perfecting laboratory test used on blood samples.|No||https://clinicaltrials.gov/show/NCT01334281||106140|
NCT01334294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT US 001.2|Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration|Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular AMD|CNV|Notal Vision Ltd|No|Completed|April 2011|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|55 Years|N/A|No|Probability Sample|Wet AMD|October 2014|October 2, 2014|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334294||106139|
NCT01334307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0008|Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)|Randomized Controlled Trial Of RePneu (LVRC) Endobronchial Coils For The Treatment Of Severe Emphysema With Hyperinflation (RESET Study)||PneumRx, Inc.|No|Completed|February 2010|September 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|35 Years|N/A|No|||May 2012|January 22, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01334307||106138|
NCT01361061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC3|AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver|AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver- am Multicenter HCC- Surveillance Study||University Hospital Freiburg|No|Recruiting|June 2010|September 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|measurement of tumor markers AFP, AFP-L3 and DCP in serum samples every 6 months|Both|18 Years|80 Years|No|Non-Probability Sample|All patients approved cirrhosis of the liver, but without a HCC - suspected lesion, are        included in this clinical trial|December 2011|December 14, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01361061||104105|
NCT01361295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-AF-002|Cerebral Embolism (CE) in Catheter Ablation of Atrial Fibrillation (AF)|The Occurrence of Cerebral Embolism (CE) in Catheter Ablation of Atrial Fibrillation (AF) Using Two Different Ablation Catheters|CE-AF|Leiden University Medical Center|Yes|Enrolling by invitation|March 2015|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 3, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01361295||104087|
NCT01361347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaassiltaM|Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children|Phase 4 Study: Milk Oral Immunotherapy for Cow's Milk Allergy in School-aged Children||Tampere University Hospital|Yes|Active, not recruiting|February 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|28|||Both|6 Years|16 Years|No|||May 2015|May 11, 2015|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361347||104083|
NCT01361360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thrasher|Permissive Hypercapnia and Brain Development in Premature Infants|||Arkansas Children's Hospital Research Institute||Active, not recruiting|May 2011|||May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|3 Months|5 Months|No|Probability Sample|Premature infants with birth weight 401-1000 g (gestational age < 30 weeks)|January 2015|January 13, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361360||104082|
NCT01361373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|-L- Dopa-Cerebral Palsy|Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study|||Shaare Zedek Medical Center||Recruiting|May 2010|August 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|4 Years|18 Years|No|||May 2011|May 26, 2011|June 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01361373||104081|
NCT01361594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048356|Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery|Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery|CABG|Emory University|Yes|Completed|June 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|338|||Both|18 Years|80 Years|No|||December 2014|December 18, 2014|February 3, 2011||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01361594||104064|
NCT01361607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA0962|Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer|A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy|SPRAY III|GW Pharmaceuticals Ltd.|Yes|Completed|May 2011|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|399|||Both|18 Years|N/A|No|||January 2014|December 17, 2014|May 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01361607||104063|
NCT01361282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEBO-2011-1|Using the Optovue OCT to Select IOL Power|Evaluation of Total Corneal Power Calculations for Intraocular Lens Selection Using the Optovue OCT in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Patients||Legacy Health System|No|Enrolling by invitation|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|54|||Both|18 Years|N/A|No|Non-Probability Sample|All study subjects will have received Descemet's Stripping Automated Endothelial        Keratoplasty (DSAEK) for Fuchs' Endothelial Dystrophy, together with concurrent cataract        surgery. Data collection will occur between 6 and 18 months following surgery.|May 2011|May 31, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361282||104088|
NCT01361256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA-NG-001|Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration|Pilot Study of WA-NG Telescope Prosthesis in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration||VisionCare Ophthalmic Technologies, Inc.|No|Withdrawn|May 2011|May 2016|Anticipated|April 2015|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||March 2015|March 16, 2015|May 24, 2011||No|No participants enrolled|No||https://clinicaltrials.gov/show/NCT01361256||104090|
NCT01361581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS/10014-4|Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy|Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy|Citrate|Charles University, Czech Republic|No|Recruiting|January 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|120|Samples Without DNA|frozen plasma|Both|16 Years|N/A|No|Non-Probability Sample|critically ill intensive care patients|May 2011|May 26, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361581||104065|
NCT01361841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUS-09-184|Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma|Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma||Centre Hospitalier Universitaire de Sherbrooke|Yes|Recruiting|January 2009|January 2013|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|141|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2010|May 26, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361841||104045|
NCT01358643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP 41-114|Operations Enduring Freedom and Iraqi Freedom (OEF/OIF)Veteran Preferences for Automated Physical Activity Interventions|Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) Veteran Preferences for and Feasibility of Automated Physical Activity Interventions: A Pilot Study||VA Ann Arbor Healthcare System|No|Enrolling by invitation|January 2011|May 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|30|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2011|June 1, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358643||104289|
NCT01332279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OER-HN-038|Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy|A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer||Fox Chase Cancer Center|No|Withdrawn|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 7, 2011|Yes|Yes|Pharmaceutical co. withdrew support. Study was never activated and did not accrue any    patients.|No||https://clinicaltrials.gov/show/NCT01332279||106294|
NCT01332552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115040|A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects|A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects||GlaxoSmithKline|No|Terminated|January 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|65 Years|No|||December 2011|December 1, 2011|April 7, 2011|No|Yes|Terminated due to unfavorable human pharmacokinetic properties|No||https://clinicaltrials.gov/show/NCT01332552||106273|
NCT01332565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115381|A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects|An Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects||ViiV Healthcare|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01332565||106272|
NCT01333228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC/CIRR|Evaluate Safety and Efficacy of Autologous Bone Marrow-derived Endothelial Progenitor Cells in Advanced Liver Cirrhosis|Pilot Clinical Trial (Phase I/II) to Evaluate Safety and Therapeutic Effects of the Administration of Autologous Bone Marrow-derived EPCs in Patients With Advanced Liver Cirrhosis||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|June 2012|March 2015|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||May 2015|May 25, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01333228||106221|
NCT01334047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-006|Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients|Phase I/II Trial of Vaccine Therapy in Recurrent Platinum Sensitive Epithelial Ovarian Cancer Patients Using Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and Survivin.||Oslo University Hospital|No|Terminated|April 2011|April 2022|Anticipated|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|75 Years|No|||August 2014|August 22, 2014|March 30, 2011||No|The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol    with an expected more efficient vaccine is currently being written.|No||https://clinicaltrials.gov/show/NCT01334047||106158|
NCT01334333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00446|Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients|Comparison of Medication Adherence Between Once Daily Tacrolimus (Advagraf®) and Twice Daily Tacrolimus (Prograf®) Administration in Stable Renal Transplant Recipients - a Randomized Study||University of British Columbia|No|Active, not recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|19 Years|N/A|No|||November 2015|November 19, 2015|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01334333||106136|
NCT01359670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPMD|Tadalafil and Sildenafil for Duchenne Muscular Dystrophy|Functional Muscle Ischemia and PDE5A Inhibition in Duchenne Muscular Dystrophy||Cedars-Sinai Medical Center|No|Completed|May 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|7 Years|15 Years|No|||August 2013|August 19, 2013|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359670||104210|
NCT01359683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17028|Heart Rate Variability Changes During Cardiac Surgery And The Incidence Of Post-Operative Cardiac Arrhythmias|Heart Rate Variability Changes During Cardiac Surgery And The Incidence Of Post-Operative Cardiac Arrhythmias||Drexel University|No|Withdrawn|September 2007|||September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||April 2008|June 12, 2013|April 7, 2008||No||No||https://clinicaltrials.gov/show/NCT01359683||104209|
NCT01360476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MD005849-01A1|Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients|Adjunct Vitamin D Therapy as a Means to Reduce the Disparity in Subclinical Target Organ Cardiac Damage Among Vulnerable Hypertensive Patients|AdDReaCH|Wayne State University|Yes|Completed|August 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|354|||Both|30 Years|74 Years|No|||December 2015|December 8, 2015|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360476||104148|
NCT01360502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2009-0021|Safety of Capsule Endoscopy in Patients With Implantable Cardiac Devices|Safety of Capsule Endoscopy Using Human Body Communication in Patients With Cardiac Pacemakers and Implantable Cardiac Defibrillators||Yonsei University|Yes|Completed|December 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6|||Both|20 Years|N/A|No|Non-Probability Sample|patients with implantable cardiac devices|September 2009|May 24, 2011|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360502||104147|
NCT01360775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09/90340|Nutritional Education for Dependant Patients|Intervention of Nutritional Education Addressed to Carers of Dependant Patients|atdom_nut|Jordi Gol i Gurina Foundation||Recruiting|January 2010|||June 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|65 Years|N/A|No|||October 2009|May 25, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360775||104126|
NCT01361074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UJaumeI01|In Vivo Versus Augmented Reality Exposure for Small Animal Phobia|In Vivo Versus Augmented Reality Exposure for Small Animal Phobia Treatment: A Randomized Controlled Trial|VARESAP|Universitat Jaume I|No|Completed|January 2011|January 2013|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||September 2013|December 3, 2015|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01361074||104104|
NCT01361958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-ESC/NOM-1-RD|Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol|Double-blind, Comparative, Randomized, Single Center, Between-subject, Dose-finding Clinical Trial to Compare 4 Doses of the Combination 17beta-estradiol/Nomegestrol Acetate Administered From Day 1 to Day 21 of the Menstrual Cycle on the Inhibition of Ovulation||Theramex|No|Completed|February 1997|September 1998|Actual|November 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|38|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2011|May 26, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361958||104036|
NCT01361971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAH100615|Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance|Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance|HOTAIR|University of Adelaide|No|Completed|April 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Male|45 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361971||104035|
NCT01361620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR2011|Genotypic and Phenotypic Correlates of Resistance to Aspirin|Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population|ARSENAL|George Washington University|No|Completed|December 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|190|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||January 2011|October 29, 2013|May 25, 2011||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01361620||104062|
NCT01361321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bondbone-HMO-CTIL|Bone Quality and Quantity Following Guided Bone Regeneration|Examining Bone Quantity and Quality Following Standard Guided Bone Regeneration Procedures||Hadassah Medical Organization|No|Recruiting|June 2011|October 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples Without DNA|Reisdual bone tissue formed while preparing alveolar bone for dental implant (by drilling      with a trephine bur)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healty over 18 years of age Patients who went through a GBR procedure previous to an        insertion of a dental implant which hasn't been insertd yet|September 2013|September 9, 2013|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01361321||104085|
NCT01361880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-095|Reduce African-American Infant Mortality|Randomized Messaging Trial to Reduce African-American Infant Mortality|SIDS|Children's Research Institute|No|Completed|June 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|1200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01361880||104042|
NCT01362166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-034|Frequency Response of the Foot-Yangming Stomach Channel: Zu-San-Li and Xian-Gu|With Different Frequency Electric Signals Study the Frequency Response of the Foot-Yangming Stomach Channel: Zu-San-Li and Xian-Gu|YCFR|China Medical University Hospital|Yes|Recruiting|May 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|community sample|May 2011|May 27, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362166||104020|
NCT01361269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FosClinChildren|Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria|Multicentre Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in African Children||Zentopharm GmbH|No|Not yet recruiting|June 2011|December 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|3 Years|10 Years|No|||May 2011|May 25, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361269||104089|
NCT01362153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015550|A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)|An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis||Centocor, Inc.|No|Completed|December 2007|February 2009|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|March 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362153||104021|
NCT01362777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF062007|Rehabilitation Program as an Alternative Therapy for Moderate to Severe Obstructive Sleep Apnea Syndrome|Effects of an In-Patient Individualized Rehabilitation Program on Severity and Symptoms of Obstructive Sleep Apnea Syndrome (OSAS):Results of a Randomized Controlled Pilot Study|Rehsolvas|5 Santé|No|Completed|November 2007|August 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|30 Years|70 Years|No|||September 2011|September 19, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362777||103973|
NCT01362790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110160|SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma|A Pilot/ Phase 2 Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma, Lung Cancer or Pancreatic Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|May 2011|April 2018|Anticipated|April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|75|||Both|18 Years|99 Years|No|||October 2015|November 17, 2015|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362790||103972|
NCT01358656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KR|Anterior Cruciate Ligament Reconstruction Using Single Bundle and Double Bundle Techniques|Comparison of the Anterior Cruciate Ligament Reconstruction Using Single Bundle and Double Bundle Techniques: Prospective Clinical Study|KR|Vita Care|Yes|Recruiting|January 2010|January 2012|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|45 Years|No|||May 2011|May 23, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358656||104288|
NCT01332890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCD192|Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects|A Randomized, Open-label, Multiple-dose, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects||Yuhan Corporation|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332890||106247|
NCT01333215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/24|Study of Cognitive Inhibition Disorders in Depressed Older Suicide Attempters|Etude Des Troubles de l'Inhibition Cognitive Chez le Sujet âgé déprimé Suicidant|ETIC|University Hospital, Angers|Yes|Recruiting|December 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients are recruited during their hospitalisation at Angers University Hospital with        respect to the eligibility criteria|December 2010|April 8, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01333215||106222|
NCT01332903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00013|Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069|A Phase I, Open-Label Study to Characterise the Absorption, Distribution, Metabolism and Excretion Following a Single Oral Dose of [14C]AZD5069 in Healthy Male Volunteers||AstraZeneca||Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Male|50 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|March 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01332903||106246|
NCT01332916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANMEM|Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging|Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging|CANMEM|Centre Francois Baclesse|No|Terminated|December 2010|April 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Female|45 Years|N/A|Accepts Healthy Volunteers|||May 2012|April 24, 2014|April 8, 2011||No|lack of patient|No||https://clinicaltrials.gov/show/NCT01332916||106245|
NCT01333774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13928|Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting|Compliance With Dietary Recommendations in Obese Diabetic Patients Undergoing Acarbose Therapy|CATERING|Bayer|No|Completed|May 2008|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|423|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic diabetic patients not treated with acarbose for approx. 3 mths.|May 2012|May 3, 2012|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01333774||106179|
NCT01334060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMCAN0700|WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation|WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation|WIN|University Hospital Southampton NHS Foundation Trust.|Yes|Suspended|February 2010|||April 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|184|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334060||106157|
NCT01334502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N1085|Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma|A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|March 2012|||February 2020|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|April 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01334502||106123|
NCT01334346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00931|Footwear Minimalism Study|An Investigation on Footwear Minimalism and Injury Risk in Runners||University of British Columbia||Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|91|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334346||106135|
NCT01334580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA024050-03|Cognitive-Behavioral Therapy for Pain and Opioid Dependence in Methadone Maintenance Treatment|Comparison of Cognitive-Behavioral Therapy and Methadone Drug Counseling for Methadone-Maintained Patients With Co-occurring Chronic Pain and Opioid Dependence||Yale University|No|Active, not recruiting|April 2011|July 2015|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334580||106117|
NCT01360255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC2|AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)|AFP - L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)||University Hospital Freiburg|No|Recruiting|May 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|measurement of tumor markers AFP, AFP-L3 and DCP in serum samples|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with confirmed hepatocellular carcinoma according to the AASLD criteria and who        are treated with transarterial chemoembolisation (TACE) are included in this clinical        trial. The patients are recruted in our primary care clinic in the department of        gastroenterology and hepatology.|December 2011|December 14, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01360255||104165|
NCT01360515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0020|A Study of Disposable Transnasal Esophagoscope|A Novel Disposable Transnasal Esophagoscope: a Prospective Pilot Trial of Feasibility, Safety and Tolerance||Yonsei University|Yes|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|50|February 2012|February 1, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360515||104146|
NCT01360528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ztb5326315185|Serum Folic Acid Levels in Preterm Infants|Zekai Tahir Burak Maternity and Teaching Hospital|FALIPI|Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|February 2011|October 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|100|||Both|24 Weeks|34 Weeks|No|Non-Probability Sample|Extremely low birth weight, Very low birth weight, Low birth weight|February 2011|February 15, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360528||104145|
NCT01360788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOLD-20378|GOLD Stage I Chronic Obstructive Pulmonary Disease (COPD)|GOLD Stage I COPD: Is it Really a Disease ? Exercise Tolerance, Muscle Function and Response to Bronchodilation in GOLD Stage I COPD Patients|GOLD|Laval University|Yes|Completed|February 2009|February 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|53|Samples Without DNA|Muscle biopsies Venous blood samples|Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants were recruted after a participation to a research protocol on i) prevalence        of COPD in Canada and ii) early detection of lung cancer. Finally, some participants were        recruited following medical consultation with a pneumologist.|May 2011|May 24, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01360788||104125|
NCT01362569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P23532|Endotoxin, Neutrophil Function and Albumin in Renal Insufficiency|Endotoxin, Neutrophil Function and Albumin in Renal Insufficiency|ENARI|Medical University of Graz|Yes|Active, not recruiting|July 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|195|Samples Without DNA|Serum, Plasma, Urine|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. 50 predialytic patients (a) 25 patients with an eGFR between 30 and 45 (KDIGO 3B) and             (b) 25 patients with an eGFR between 15 and 30 (KDIGO 4)          2. 50 patients undergoing hemodialysis or hemodiafiltration for ESRD (a) 25 patients             under therapy with sevelamer and (b) 25 patients without sevelamer          3. (a) 25 patients undergoing peritoneal dialysis for ESRD without signs of infection             and (b) 25 patients undergoing peritoneal dialysis for ESRD with peritonitis          4. 25 patients with acute renal failure          5. 45 patients after kidney transplantation (a) 15 patients with an eGFR > 45, (b) 15             patients with an eGFR between 30 and 45 and (c) 15 patients with an eGFR < 30          6. 25 age and sex-matched healthy controls|March 2016|March 14, 2016|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01362569||103989|
NCT01361334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM09_0018_PAZOPANIB_AML 2011|Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible|Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible|PAZOPANIB-AML|University Hospital Muenster|Yes|Active, not recruiting|June 2011|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2011|December 4, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01361334||104084|
NCT01361646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-GDCL001|Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189|||LG Life Sciences||Completed|June 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|129|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01361646||104060|
NCT01361893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3488|Factors Influencing the Racial Disparity in Sudden Infant Death Syndrome (SIDS)|Factors Influencing the Racial Disparity in Sudden Infant Death Syndrome (SIDS)|SIDS|Children's Research Institute|Yes|Completed|December 2004|September 2015|Actual|September 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|616|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01361893||104041|
NCT01361854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/11-05-42/4024|Comparison of 2 Different Hook-up Protocols to Perform Home-based Polysomnography|Comparison of 2 Different Hook-up Protocols to Perform Home-based Polysomnography||Centre Hospitalier Universitaire Saint Pierre|No|Completed|August 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|102|||Both|18 Years|90 Years|No|||May 2015|May 22, 2015|May 26, 2011||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01361854||104044|
NCT01361867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002030|Robotic Assessment of Lower Extremity Motor Learning|Robotic Assessment of Lower Extremity||Spaulding Rehabilitation Hospital|No|Active, not recruiting|February 2010|December 2015|Anticipated|September 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361867||104043|
NCT01362803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110161|AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors|A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)||National Institutes of Health Clinical Center (CC)||Recruiting|May 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|104|||Both|2 Years|18 Years|No|||September 2015|October 6, 2015|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362803||103971|
NCT01358669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15714|Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty|Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|30 Years|N/A|No|||December 2012|December 14, 2012|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01358669||104287|
NCT01358682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 SJA-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2011|||||N/A|N/A|N/A||||||||||||||September 9, 2013|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358682||104286|
NCT01332591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT11412|Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy.|Multivessel Coronary Disease Diagnosed at the Time of Primary PCI for STEMI: Complete Revascularization Versus Conservative Strategy. PRAGUE - 13 Trial|Prague-13|St. Anne's University Hospital Brno, Czech Republic|Yes|Completed|September 2008|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|No|||December 2014|December 31, 2014|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01332591||106270|
NCT01333527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0005824|Early Mobilization Following Arthroscopic Rotator Cuff Repair|Early Mobilization Following Arthroscopic Rotator Cuff Repair: a Randomized Controlled Trial||Shoulder & Upper Extremity Research Group of Edmonton|No|Active, not recruiting|April 2011|April 2017|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||May 2015|May 19, 2015|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333527||106198|
NCT01333787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FiberCCF - EPM2|Dietary Fiber Mixture in Constipated Pediatric Patients|A Controlled, Randomized, Double-blind Trial to Evaluate the Effect of a Dietary Fiber Mixture During Maintenance Treatment and on Colonic Transit Time in Constipated Pediatric Patients|MIXFIBER|Federal University of São Paulo|Yes|Completed|February 2008|December 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|4 Years|12 Years|No|||December 2010|April 11, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01333787||106178|
NCT01334073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/09|Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors|Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors|EVAX|University Hospital, Bordeaux|Yes|Completed|March 2011|January 2015|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01334073||106156|
NCT01332773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNR-7|The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer|The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer|Artery first|Heidelberg University|No|Recruiting|March 2010|July 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||December 2009|April 18, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332773||106256|
NCT01333085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000698330|Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery|Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|CAPRA|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|No|Completed|October 2009|May 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||March 2013|February 9, 2016|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333085||106232|
NCT01360294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SADQ|Development of Small Airway Disease Questionnaire|The Development of a Questionnaire to Assess Symptoms of Small Airways Disease in Patients With Asthma|SADQ|University Medical Center Groningen|No|Completed|September 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|65|||Both|18 Years|75 Years|No|Probability Sample|The study population will contain a total of 60 adult patients with asthma, 30 patients        with small airways disease and 30 patients without small airways disease.|June 2013|June 27, 2013|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01360294||104162|
NCT01360268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck (MISP) # 38846|The Metabolic Profile and Adipocytokine Alterations of Patients With HCV Infection Before and After HCV Therapy|The Metabolic Profile and Adipocytokine Alterations of Patients With HCV Infection Before and After HCV Therapy"||Chang Gung Memorial Hospital|No|Recruiting|January 2011|December 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects with chronic hepatitis C infections|February 2011|May 24, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360268||104164|
NCT01360281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE00780312000-10|Neuromuscular Electrical Stimulation and Strength Training in Patients With Knee Osteoarthritis|Neuromuscular Electrical Stimulation and Strength Training in Patients With Knee Osteoarthritis||Universidade Gama Filho|No|Recruiting|May 2011|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|34|||Both|38 Years|N/A|No|||May 2011|May 23, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01360281||104163|
NCT01360801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003234|High Definition White Light Endoscopy and Narrow Band Imaging for the Assessment of Barrett's Disease After Endoscopic Therapy|High Definition White Light Endoscopy and Narrow Band Imaging for the Assessment of Barrett's Disease After Endoscopic Therapy||Mayo Clinic|No|Terminated|February 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|88 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women (not pregnant) presenting to the GI Lab for Upper Endoscopy. Child-bearing        potential not excluded.|April 2014|April 8, 2014|May 18, 2011|Yes|Yes|enrollment moved very slowly which was not anticipated, and, funding issues|No||https://clinicaltrials.gov/show/NCT01360801||104124|
NCT01360814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC0491|Structured Multidisciplinary Intervention or Standard Medical Care in Improving Quality of Life in Patients Receiving Active Cancer Treatment|A Structured Multidisciplinary Intervention to Improve Quality of Life of Patients Receiving Active Oncological Treatment: A Randomized Trial||Mayo Clinic|Yes|Completed|January 2005|||March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|May 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01360814||104123|
NCT01361100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCORAL|Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract|Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract||Centre Leon Berard|No|Recruiting|December 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|485|||Both|40 Years|N/A|No|||October 2012|October 1, 2012|March 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01361100||104102|
NCT01362582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-2008-11-03-1018|Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer|Open-label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution Versus Best Supportive Nutritional Care in Patients With Pancreatic Cancer Receiving 2nd Line Chemotherapy|PANUSCO|National Center for Tumor Diseases, Heidelberg|Yes|Terminated|March 2010|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01362582||103988|
NCT01361919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLP 6534|Three Different Cardiopulmonary Resuscitation (CPR) Training Methods|The Benefits of a Simplified Method for CPR Training of Medical Professionals: A Randomized Controlled Study|BLS Pilot|St. Michael's Hospital, Toronto|No|Completed|September 2008|September 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|298|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01361919||104039|
NCT01361633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126177|The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly|The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly||Hartford Hospital|No|Completed|January 2008|February 2009|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 18, 2012|May 24, 2011|Yes|Yes||No|June 22, 2011|https://clinicaltrials.gov/show/NCT01361633||104061|DCS dosing was 1 hour prior to testing, rather than 4-8; the sample had homogenous cognitive capabilities; repeatedly administering DCS may have enhanced cognitive functioning; the measures may not have adequately tapped hippocampal-based learning.
NCT01362179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTDFU|National Marrow Donor Program Long-Term Donor Follow-Up|Incidence of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Normal Donors Undergoing Bone Marrow Harvest Versus Peripheral Blood Stem Cell Mobilization With Recombinant Human Granulocyte Colony-Stimulating Factor (rHuG-CSF)|LTDFU|Center for International Blood and Marrow Transplant Research|Yes|Active, not recruiting|October 2010|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|21932|||Both|18 Years|60 Years|No|Non-Probability Sample|10,000 unstimulated BM donors and 20,000 filgrastim-mobilized PBSC donors|October 2015|October 5, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362179||104019|
NCT01362478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99083|Gene Promoter DNA Methylations and Their Relationships With Endophenotypes in Patients With Schizophrenia|Gene Promoter DNA Methylations and Their Relationships With Endophenotypes in Patients With Schizophrenia||Taipei Medical University WanFang Hospital|No|Recruiting|August 2011|July 2014|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Gene promoter DNA methylations|Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|schizophrenia patients|June 2012|June 27, 2012|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362478||103996|
NCT01362491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH-11-16|Ibuprofen Sodium Tension Headache Study|Ibuprofen Sodium Tension Headache Study||Pfizer|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|226|||Both|18 Years|65 Years|No|||July 2014|July 29, 2014|May 19, 2011|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01362491||103995|
NCT01362816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2945-3|The European Palliative Care Cancer Symptom Study (EPCCS)|The European Palliative Care Cancer Symptom Study (EPCCS). A Prospective Data Collection|EPCCS|Norwegian University of Science and Technology|No|Completed|June 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1739|||Both|18 Years|N/A|No|Non-Probability Sample|The popuation consists of patients with incurable cancers who are enrolled in a palliative        care programme. They will be identified upon referral for non-curative cancer        treatment/palliative care to the centre, department, out-patient clinic, daycare centre,        hospice, or home-based care, depending on the palliaitve care organization model at the        participating centres. Patients will be followed every 4 weeks (3-5) for at least 6        months, or until death|September 2015|September 28, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01362816||103970|
NCT01362530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-208|A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Patients||Merck Sharp & Dohme Corp.|No|Completed|September 2011|August 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|307|||Both|6 Months|17 Years|No|||April 2015|April 17, 2015|May 26, 2011|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01362530||103992|
NCT01362829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907064R|Outcome Predictors in Patients With Severe Sepsis and Optimized Central Venous Oxygen Saturation|Outcome Predictors in Patients With Severe Sepsis and Optimized Central Venous Oxygen Saturation||National Taiwan University Hospital|No|Completed|August 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|Samples Without DNA|For each patient enrolled, 10mL blood is collected in EDTA-coated tube, which will be used      for plasma separation and for peripheral blood mononuclear cell collection.|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients who are admitted to medical intensive care units due to severe sepsis or        septic shock|May 2011|June 20, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01362829||103969|
NCT01333241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G090405102|Healthy Women Prepared for Life|Community-Based Lifestyle Promotion With Latino Women||University of California, Los Angeles|Yes|Active, not recruiting|August 2009|July 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|240|||Female|35 Years|64 Years|Accepts Healthy Volunteers|||April 2011|April 8, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01333241||106220|
NCT01333553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2010-7376|Monitoring the Response of Port Wine Stain Birthmarks to Laser Therapy With Wide-field Functional Imaging Technologies|Monitoring the Response of Port Wine Stain Birthmarks to Laser Therapy With Wide-field||University of California, Irvine|No|Recruiting|April 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Study population will be selected from an outpatient population with Port Wine Stain        birthmark at Beckman Laser Institute and Medical Clinic, University of California, Irvine.        Patients with Port Wine Stain birthmark will be candidates for participation.|February 2016|February 5, 2016|August 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01333553||106196|
NCT01333800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-AL-FE-001|Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma|Phase 4 Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma in a Hospital in Bogotá||Grünenthal Colombiana S.A.|Yes|Completed|July 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|6 Years|15 Years|No|||April 2011|April 11, 2011|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333800||106177|
NCT01333813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112688|Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children|Long-term Antibody Persistence of Hepatitis B Antibodies and Immune Response to a Hepatitis B Vaccine (Engerix-B Kinder) Challenge in Children Previously Vaccinated With Infanrix Hexa Vaccine||GlaxoSmithKline||Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|300|||Both|7 Years|8 Years|Accepts Healthy Volunteers|||July 2015|February 4, 2016|April 7, 2011|Yes|Yes||No|July 19, 2012|https://clinicaltrials.gov/show/NCT01333813||106176|
NCT01333826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP: RF-P109215-RESE-TF090932|Schooling, Income, and HIV Risk in Malawi|Does Schooling Protect Young Women From HIV?|SIHR|George Washington University|No|Active, not recruiting|September 2007|May 2019|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|3796|||Female|13 Years|22 Years|No|||March 2015|March 9, 2015|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01333826||106175|
NCT01333839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABG2011|Impact of Coronary Artery Bypass Graft (CABG) Surgery on Skeletal Muscle Mass and Insulin Sensitivity, Followed by Exercise Intervention|Impact of CABG Surgery and Subsequent Exercise Intervention on Insulin Sensitivity and Muscle Mass: a Cluster Randomized Trial||Hasselt University|No|Completed|February 2011|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|N/A|N/A|No|||March 2015|March 17, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01333839||106174|
NCT01333397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y-52-52120-146|Safety and Efficacy Study of Dysport RU and Glabellar Lines|A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines||Ipsen|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|176|||Female|30 Years|60 Years|No|||September 2015|September 29, 2015|April 8, 2011||No||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01333397||106208|
NCT01360827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200068-007|EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase Ib Trial of Multiple-ascending Doses of EMD 1201081 in Combination With 5-FU/Cisplatin and Cetuximab in First-line Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck||Merck KGaA|No|Terminated|August 2010|||April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|May 24, 2011||No|Study terminated due to potential safety concerns in combination with platinum-based therapies|No||https://clinicaltrials.gov/show/NCT01360827||104122|
NCT01360541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081240|Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia|Endoscopic Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia: a Randomised Controlled Trial vs Endoscopic Surveillance|RF-DBG|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|December 2010|December 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|80 Years|No|||April 2015|April 20, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360541||104144|
NCT01361399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11640|Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold|A 4-arm, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Single Dose, Parallel Group Study Comparing Efficacy and Safety of a Fixed Combination of 500 mg Acetylsalicylic Acid + 4 mg Lidocaine With 500 mg Acetylsalicylic Acid and 4 mg Lidocaine Monotherapy as Well as Placebo in Adult Patients With Sore Throat Associated With a Common Cold.||Bayer|No|Completed|November 2004|May 2005|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1088|||Both|18 Years|N/A|No|||May 2011|May 25, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361399||104079|
NCT01362257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112014|A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719|An Open-label, Two Period Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719, Administered as Single Dose of an Oral Solution and an Intravenous Infusion, to Healthy Male Adults||GlaxoSmithKline|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||August 2011|September 1, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362257||104013|
NCT01361659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2-008|Shockwave Treatment for Advanced Angina in Maastricht|Shockwave Treatment for Advanced Angina in Maastricht (SWAAM-study).|SWAAM|Maastricht University Medical Center|No|Recruiting|May 2007|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2011|July 11, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01361659||104059|
NCT01361945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922ZN11|AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer|A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer||Texas Tech University Health Sciences Center, El Paso|No|Withdrawn|July 2011|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||December 2015|December 8, 2015|May 24, 2011|Yes|Yes|Closed due to no enrollment|No||https://clinicaltrials.gov/show/NCT01361945||104037|
NCT01362595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-375B|A Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia|The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-dependent Diamond Blackfan Anemia|LeucineDBA|Northwell Health|Yes|Recruiting|June 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|N/A|No|||November 2015|November 19, 2015|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362595||103987|
NCT01362231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0024-201|A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis||Gilead Sciences|Yes|Completed|December 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|48|||Both|40 Years|85 Years|No|||July 2015|July 7, 2015|April 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362231||104015|
NCT01362244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111782|Mepolizumab in Nasal Polyposis|A Two-Part, Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis||GlaxoSmithKline|Yes|Completed|May 2009|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|70 Years|No|||November 2015|November 9, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362244||104014|
NCT01361932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFP-CA-01|Using Online Videos to Supplement Emergency Department Discharge Instructions|Speak Fast, Use Jargon, and Don't Repeat Yourself: Using Online Videos to Supplement Emergency Department Discharge Instructions||Sunnybrook Health Sciences Centre|No|Completed|November 2011|February 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|133|||Both|N/A|N/A|No|||March 2013|March 25, 2013|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361932||104038|
NCT01362218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-100820-01|Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol|Cardiovascular Fixed Combination Pill ASR: Pharmacodynamic Clinical Trial of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin, and Ramipril (Cardiovascular Polypill); LDL Cholesterol||Ferrer Internacional S.A.||Terminated|October 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|107|||Both|18 Years|75 Years|No|||April 2013|April 23, 2013|May 26, 2011||No|Per sponsor's decision|No||https://clinicaltrials.gov/show/NCT01362218||104016|
NCT01361906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHSAM/11|Effects of Sensomotoric Training on Neck/Scapular Pain in People With Visual Disability|Effects of Sensomotoric Training on Neck/Scapular Pain in People With Visual Disability||Centre for Rehabilitation Research, Örebro|No|Completed|September 2010|February 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|67 Years|No|||May 2014|May 28, 2014|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361906||104040|
NCT01362504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB0663|Pro-adrenomedullin as a Prognostic Marker in Neonatal Sepsis|Zekai Tahir Burak Maternity Teaching Hospital Neonatal Intensive Care Unit||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|May 2011|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|80|||Both|24 Weeks|42 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Preterm and term neonates with sepsis were enrolled in this study including 80 cases.|October 2011|October 7, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362504||103994|
NCT01362517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QVX-V-C001|Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B|Assessment of the Immunogenicity and Safety of Quinvaxem Vaccine (DTwP-HepB-Hib) Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by H. Influenzae Among Healthy Vietnamese Children||Crucell Holland BV|No|Completed|April 2010|April 2011|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|60 Days|120 Days|Accepts Healthy Volunteers|||August 2013|August 29, 2013|May 26, 2011||No||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01362517||103993|
NCT01362543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTF2|Traumatized Refugees -Stress Management Versus Cognitive Re-structuring|Treatment With Cognitive Behavioural Therapy in Traumatised Refugees - Stress Management Versus Cognitive Restructuring - a Randomised Clinical Trial||Mental Health Services in the Capital Region, Denmark|Yes|Completed|June 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01362543||103991|
NCT01358994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin02|Metformin Treatment, Renal Function and Lactic Acidosis|Metformin Treatment, Renal Function and Lactic Acidosis. A Population Based||Skane University Hospital|No|Completed|January 2011|April 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4500|||Both|18 Years|N/A|No|Probability Sample|All patients irrespective of age prescribed metformin according to a registry for the city        of Malmö|April 2011|May 20, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358994||104262|
NCT01359241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092232|Achieving Normal Glucose In Hospital Settings|An Open-label, Single-centre, Randomised, Two-period Crossover Study to Assess the Efficacy and Safety of 24-hour Closed-loop Glucose Control in Comparison With Conventional Treatment in Adults With Type 2 Diabetes on Non-insulin Glucose-lowering Agents|Angie01|University of Cambridge|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01359241||104243|
NCT01333254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-075|A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients|A Randomised Controlled Trial Comparing Different Methods for Short-Term Bladder Drainage in Patients With Hip Surgery||University Hospital Orebro|No|Completed|September 2009|June 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|170|||Both|50 Years|N/A|No|||December 2014|December 2, 2014|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01333254||106219|
NCT01333540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0074|A Study to Assess the Safety, Tolerability and Clinical Activity of TD−1211 in Patients With Opioid-Induced Constipation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD−1211 in Subjects With Opioid-Induced Constipation||Theravance Biopharma Antibiotics, Inc.|No|Completed|May 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||September 2014|September 3, 2014|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333540||106197|
NCT01333566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11889|Qigong Exercise May Benefit Patients With Fibromyalgia|Qigong Exercise May Benefit Patients With Fibromyalgia||University of Kansas Medical Center|No|Recruiting|July 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||June 2012|June 4, 2012|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333566||106195|
NCT01333579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT2006/55504-0|Low-frequency Transcranial Magnetic Stimulation To Enhance Motor Recovery In The Subacute Phase After Stroke|Low-frequency Transcranial Magnetic Stimulation To Enhance Motor Recovery In The Subacute Phase After Stroke||University of Sao Paulo General Hospital|No|Completed|February 2008|December 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|80 Years|No|||September 2013|September 16, 2013|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333579||106194|
NCT01334099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA3671RD IIR#1|Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients|Phase I Study of Local Radiation and CP-675,206 Administration in Patients With Inoperable Locally Recurrent or Metastatic Breast Cancer||University Health Network, Toronto|No|Terminated|July 2010|||March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|January 18, 2011||No|Contract with drug supplier expired and was not renewed.|No||https://clinicaltrials.gov/show/NCT01334099||106154|
NCT01333410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MahidolU|Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo|Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study||Mahidol University|Yes|Active, not recruiting|June 2009|December 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 7, 2012|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333410||106207|
NCT01361425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METILDOPA PE 1|Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)|Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial|METILDOPAPE|Professor Fernando Figueira Integral Medicine Institute|Yes|Recruiting|May 2011|February 2013|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2011|May 27, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361425||104077|
NCT01361672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4296 Chronic Performance|Model 4296 Left Ventricular (LV) Lead Chronic Performance Study|Attain Ability® Family Left Ventricular Lead Chronic Performance Study||Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|May 2011|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|1142|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with a 4296 LV Lead within 30 days. All subjects must meet Inclusion        criteria and none of the Exclusion criteria.|October 2014|October 1, 2014|May 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01361672||104058|
NCT01361113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1028|Neoadjuvant Pazopanib in Renal Cell Carcinoma|Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Establish Predictive Biomarkers of Drug Activity in Renal Cell Carcinoma||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|May 2011|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2016|January 17, 2016|May 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01361113||104101|
NCT01361386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CAP-XXX-2011/1|Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia|Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia|EPICOR ASIA|AstraZeneca|No|Completed|June 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13011|||Both|18 Years|N/A|No|Probability Sample|Asian patients hospitalized for ACS within 48 hours of symptom onset and who have a final        diagnosis of unstable angina (UA), STEMI or non-ST-segment elevation myocardial infarction        (NSTEMI).|June 2014|June 13, 2014|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01361386||104080|
NCT01362270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRF 811|Acupuncture for Sedation in the Intensive Care Unit (ICU)|Acupuncture for Sedation in the Intensive Care Unit||Oregon Health and Science University|Yes|Active, not recruiting|July 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|May 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362270||104012|
NCT01361997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011HRAEB001|Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination|Comparative Study of 70% Isopropyl Alcohol Against 2% Chlorhexidine- 70% Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination||Universidad de Guanajuato|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1117|||Both|18 Years|70 Years|No|||August 2012|July 13, 2013|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01361997||104033|
NCT01362283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114619|Epidemiologic Study to Evaluate the Proportion of Cardiovascular Disease Risk Factors in Korean Hypertensive Patients|A Nation-wide,Multi-center, Observational, Cross-sectional, Epidemiologic Study to Evaluate the Proportion of Cardiovascular Disease Risk Factors in Korean Hypertensive Patients|WONDeR|GlaxoSmithKline|No|Completed|August 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|700|||Both|18 Years|N/A|No|Probability Sample|Korea, Diagnosed hypertensive patient|July 2011|July 14, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01362283||104011|
NCT01362296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114653|An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer|A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared With Docetaxel in 2nd Line Subjects With Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC Stage IV)||GlaxoSmithKline||Completed|September 2011|September 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|May 19, 2011|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01362296||104010|
NCT01353989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hepatitis A vaccination|Hepatitis A Vaccination in the Elderly|Hepatitis A Vaccination in the Elderly||Rijnstate Hospital|No|Recruiting|July 2010|May 2012|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|5 times 7 ml of blood will be collected|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|80 >60 years, hepatitis A vaccination indicated 40 < 40 years, hepatitis A vaccination        indicated|June 2011|June 3, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01353989||104645|
NCT01349777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0483|Effectiveness of Clopidogrel Resinate in PCI(PRIDE)|Effectiveness of Clopidogrel Resinate(PRegrel®) in Patients Undergoing Percutaneous Coronary Intervention Compared With ClopiDogrEl Bisulfate(Plavix®)||CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1056|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01349777||104967|
NCT01362868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012|Water Drinking Test During Intraocular Pressure Fluctuation (IOP) Monitoring|Water Drinking Test (WDT) During Continuous Recording of Intraocular Pressure Fluctuation||Sensimed AG|No|Terminated|May 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 8, 2011|May 27, 2011||No|Too low effect on the output and low rate of responders|No||https://clinicaltrials.gov/show/NCT01362868||103966|
NCT01362855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCEPT Study|Advance Care Planning Evaluation in Hospitalized Elderly Patients|Advance Care Planning Evaluation in Hospitalized Elderly Patients: A Multicenter, Prospective Study|ACCEPT|Clinical Evaluation Research Unit at Kingston General Hospital|No|Recruiting|September 2011|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|900|||Both|55 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We will enroll patients who are at high risk of dying and/or their families (where        available).|February 2015|February 9, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01362855||103967|
NCT01362556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BABICA|Blood Gas Analysis and Buffering In Cardiac Arrest|Blood Gas Analysis and Buffering In Cardiac Arrest - A Multicenter, Prospective, Randomised, Double Blind Prehospital Trial to Evaluate the Impact of Early Blood-gas-analysis Targeted Buffer Therapy on ROSC After OOHCA|BABICA|Medical University of Graz|Yes|Completed|March 2011|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01362556||103990|
NCT01362842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTUH-201012108RC|Psychological and Physical Distress and Care Needs in Operable Lung Cancer Patients Receiving Surgery|Psychological and Physical Distress and Care Needs in Operable Lung Cancer Patients Receiving Surgery||National Taiwan University Hospital|Yes|Recruiting|January 2011|June 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|20 Years|N/A|No|Non-Probability Sample|Thoracic surgery outpatients|December 2010|May 27, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01362842||103968|
NCT01362192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-XLV01|Treatment of Lower Extremity Spider Veins With Excel V|A Clinical Evaluation of the Treatment of Lower Extremity Spider Veins Using a Dual Wavelength Laser Emitting 532 nm and 1064 nm Laser Energy||Cutera Inc.|No|Completed|May 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|May 25, 2011||No||No|June 17, 2013|https://clinicaltrials.gov/show/NCT01362192||104018|
NCT01362205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 09-0822|Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)||Denver Health and Hospital Authority|Yes|Terminated|March 2012|September 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|89 Years|No|||February 2016|February 6, 2016|May 24, 2010|Yes|Yes|DSMB recommendation for slow enrollment|No||https://clinicaltrials.gov/show/NCT01362205||104017|
NCT01359007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1977|FOLFIRINOX in Patients With Inoperable Pancreatic Cancer|A Phase II Study Evaluating the Rate of R0 Resection (Microscopically Negative Margins) After Induction Therapy With 5- Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan (FOLFIRINOX) in Patients With Borderline Resectable or Locally Advanced Inoperable Pancreatic Cancer.||University of Oklahoma|No|Terminated|May 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||May 2015|May 28, 2015|May 23, 2011|Yes|Yes|The principal investigator elected to terminate the study due to inactivity and low enrollment|No||https://clinicaltrials.gov/show/NCT01359007||104261|
NCT01359254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-020-B|Cord Blood Transplantation for Patients With Cancer|Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies||University of Chicago|No|Terminated|April 2010|June 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|May 20, 2011|No|Yes|did not accrue enough patients.|No|April 10, 2015|https://clinicaltrials.gov/show/NCT01359254||104242|
NCT01359488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRS-317 1a|VRS-317 in Adult Subjects With Growth Hormone Deficiency|A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults With Growth Hormone Deficiency||Versartis Inc.|No|Completed|March 2011|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|50|||Both|25 Years|65 Years|No|||July 2012|July 19, 2012|May 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359488||104224|
NCT01359787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15616|Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)|Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of Mapracorat Ointment in Three Concentrations Over Max. 4 Weeks in Subjects With Atopic Dermatitis (AD)||Bayer|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|197|||Both|18 Years|65 Years|No|||January 2015|January 19, 2015|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359787||104201|
NCT01333267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10060214|One Week Comparison Study of PTH and PTHrP Infusions|Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion||University of Pittsburgh|Yes|Withdrawn|January 2015|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|24 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|April 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01333267||106218|
NCT01333280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUALFOCUSAID|Efficacy of Dual Focus Mutual Aid for Persons With Co-occurring Disorders|Efficacy of Dual Focus Mutual Aid for Persons With Co-occurring Disorders||Western Michigan University|No|Completed|July 2008|April 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|352|||Both|18 Years|65 Years|No|||December 2014|December 9, 2014|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333280||106217|
NCT01333592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAD4301|Long-term Study of KAD-1229 in Type 2 Diabetes Patients|A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy||Kissei Pharmaceutical Co., Ltd.|No|Completed||November 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|136|||Both|20 Years|N/A|No|||November 2014|November 27, 2014|April 6, 2011||||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01333592||106193|
NCT01333852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METTAX200901|Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer|Randomized Phase II Study of Paclitaxel Plus Metformin or Placebo for the Treatment of Platinum-refractory, Recurrent or Metastatic Head and Neck Neoplasms|METTAX|Barretos Cancer Hospital|Yes|Terminated|February 2011|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|April 5, 2011||No|Low accrual|No||https://clinicaltrials.gov/show/NCT01333852||106173|
NCT01333865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000016|A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders|A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders||Massachusetts General Hospital|No|Completed|January 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|50 Years|No|||February 2016|February 26, 2016|November 19, 2010||No||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01333865||106172|
NCT01334112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS515376|Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma|A Phase II Trial of Axitinib (AG-013736) After Prior Antiangiogenic Therapy in Advanced Hepatocellular Carcinoma|AXITINIB|University Health Network, Toronto|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01334112||106153|
NCT01333150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090062|Effect of Propranolol on the Autonomic Nervous System and Muscle Pain|Effects of a Low-dose Propranolol on a Stress Induced Autonomic Response and on Muscle Pain||University of Aarhus|No|Recruiting|August 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|16|||Female|18 Years|60 Years|No|||March 2012|March 23, 2012|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01333150||106227|
NCT01333423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0013|Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)|A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Combination With Seliciclib for the Treatment of Patients With Metastatic Triple Negative Breast Cancer||M.D. Anderson Cancer Center|Yes|Withdrawn|September 2012|||September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|April 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01333423||106206|
NCT01361438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1509|De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients|A Multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. GIMEMA Protocol LAL1509, EudraCT Number 2010-019119-39|LAL1509|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|June 2011|October 2015|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|60 Years|No|||January 2015|January 27, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01361438||104076|
NCT01361984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sunovion IC-HRCT|Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography|Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent)||University of California, Los Angeles|No|Recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|N/A|No|||July 2012|July 18, 2012|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01361984||104034|
NCT01362010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX2010-03|Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients|Pilot, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Acne Vulgaris Patients||Foamix Ltd.|No|Completed|January 2012|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|12 Years|25 Years|No|||August 2013|August 14, 2013|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362010||104032|
NCT01353417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC SAN NIS 2011|Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection|A Single-site, Prospective Non-interventional-study With Adport Sandoz© Capsules for Prophylaxis of Graft Rejection in Patients With Stable Kidney Function After Renal Allograft.||Sandoz GmbH|Yes|Recruiting|April 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Retained types of biospecimen: whole blood, serum, urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients after renal transplantation who are treated in the general hospital of Vienna on        an outpatient basis|June 2014|June 6, 2014|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353417||104689|
NCT01353651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/6-Q|Endovascular Versus Open Repair of the Common Femoral Artery|Endovascular Versus Open Repair of the Common Femoral Artery: a Randomized Trial (TECCO)|TECCO|Nantes University Hospital|No|Completed|February 2011|September 2015|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|90 Years|No|||December 2015|December 22, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01353651||104671|
NCT01353664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMI-ADVM-004|A Rollover Study for Patients Who Participated in Other Romidepsin Protocols|An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols||Celgene|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|May 12, 2011|Yes|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01353664||104670|
NCT01350076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 511/2010|Liberal Versus Goal-directed Intraoperative Fluid Therapy in Pediatric Patients|Liberal VS Goal-directed Intraoperative Fluid Therapy in Pediatric Patients|GDT|Mahidol University|No|Not yet recruiting|October 2011|September 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|5 Years|No|||May 2011|May 6, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01350076||104944|
NCT01350310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOGA-DCM|Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy|Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy|NOGA-DCM|University Medical Centre Ljubljana|No|Completed|March 2011|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|65 Years|No|||April 2015|April 5, 2015|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350310||104926|
NCT01358747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Casasnovas PHRC N 2010|Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL|Randomized Phase III Study of a Treatment Driven by Early PET Response Compared to a Treatment Not Monitored by Early PET in Patients With Ann Arbor Stage III-IV or High Risk IIB Hodgkin Lymphoma|AHL 2011|Centre Hospitalier Universitaire Dijon|Yes|Completed|May 2011|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||||||Both|16 Years|60 Years|No|||January 2013|May 20, 2014|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01358747||104281|
NCT01358760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-234|Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy|||EndoCeutics Inc.|Yes|Completed|June 2011|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|450|||Female|40 Years|75 Years|No|||February 2016|February 19, 2016|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358760||104280|
NCT01358734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-AML-001|A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age|A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) Plus Lenalidomide (Revlimid®) Regimen Versus an Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia||Celgene|Yes|Active, not recruiting|August 2011|June 2018|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|88|||Both|65 Years|N/A|No|||December 2015|December 7, 2015|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358734||104282|
NCT01358721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-009|Phase I Biomarker Study (BMS-936558)|An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).||Bristol-Myers Squibb|No|Active, not recruiting|August 2011|November 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358721||104283|
NCT01358708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-LA-IBS09-01|Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg|Treatment of Diarrhea-predominant Irritable Bowel Syndrome With LACTEOL® 340 mg: A Pilot Study Evaluating Safety and Efficacy||Forest Laboratories|No|Terminated|June 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|May 16, 2010||No|Administrative reasons|No|June 20, 2013|https://clinicaltrials.gov/show/NCT01358708||104284|Because of early termination of this trial, the number of subjects analyzed was too small to perform statistical analyses and draw conclusions relative to the efficacy and safety of LACTEOL®.
NCT01359501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-259|Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients|Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients||China Medical University Hospital|Yes|Recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|No|||October 2012|October 21, 2012|May 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01359501||104223|
NCT01359800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS OBS T-004|Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients|A Multicentre, Observational, Cross-sectional Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients in Selected Areas of Gauteng and Eastern Cape|ISS OBS T-004|Istituto Superiore di Sanità|No|Completed|October 2010|July 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|531|Samples With DNA|Whole blood, cervical samples|Both|18 Years|45 Years|No|Non-Probability Sample|HIV positive, ARV-treated and treatment-naïve participants.|March 2016|March 3, 2016|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01359800||104200|
NCT01333007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22991|An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer|A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.||Hoffmann-La Roche||Completed|July 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|423|||Both|18 Years|N/A|No|Probability Sample|Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer|March 2016|March 1, 2016|April 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01333007||106238|
NCT01333020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR04/2010|Cross-linked Emulsion Study|A Pilot Study on the Effect of Protein Cross-linking on Gastric Layering and Emptying of a Food Emulsion||Institute of Food Research|Yes|Completed|November 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|4|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333020||106237|
NCT01333605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 11-02|IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma|Phase II Study of IGEV Followed by Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin Lymphoma.||Fudan University|No|Recruiting|April 2011|June 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|65 Years|No|||March 2013|March 2, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01333605||106192|
NCT01333878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS IM101-281|Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage|An Open-Label, Pilot Trial to Assess the Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage Determined by Low Field Extremity MRI (eMRI) and X-ray||Orrin M Troum, M.D. and Medical Associates|Yes|Completed|March 2011|January 2014|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333878||106171|
NCT01364714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-120-25298|Biomechanical Properties in Intensive Care Unit (ICU) Survivors 12-month After Discharge|Biomechanical Properties in ICU Survivors 12-month After Discharge||Rigshospitalet, Denmark||Recruiting|January 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|32|||Male|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|ICU survivors 12 months after discharge compared to age and gender matched controls|May 2011|June 1, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364714||103826|
NCT01364987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK01|Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers|A Phase 1, Open Label, Single Sequence, Drug Interaction Study of the Pharmacokinetics of ASP015K and Mycophenolate Mofetil (MMF) After Separate and Concomitant Administration to Healthy Adult Volunteers||Astellas Pharma Inc|No|Completed|May 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 1, 2011|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364987||103805|
NCT01365000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00025|Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects|A Phase I, Open-label, Randomized, Balanced, Single-dose, Two-Part Study to Assess the Relative Bioavailability of NKTR-118 in Three Formulations Under Fasted (3-Way Crossover) and Fed (2-Way Crossover) Conditions in Male and Non-fertile Female Subjects||AstraZeneca|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01365000||103804|
NCT01333176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02551|Point of Care HbA1c as a Screening Test for Type 2 Diabetes in First Nations|Community-based Screening for Diabetes Using a Validated Point-of-care HbA1c Assay in a British Columbia First Nations Community||University of British Columbia|No|Recruiting|April 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|320|||Both|14 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 24, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01333176||106225|
NCT01352871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-concentration|The Effects of Concentration/Meditation on the Innate Immune Response During Human Endotoxemia|The Effects of Concentration/Meditation on the Innate Immune Response During||Radboud University|Yes|Completed|March 2011|May 2011|Actual|April 2011|Actual|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1|||Male|45 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|One healthy male volunteer that masters the concentration/meditation technique.|February 2011|June 6, 2011|November 26, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01352871||104731|
NCT01352884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-224-01|Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer|||Amplimmune||Completed|March 2011|January 2014|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|May 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01352884||104730|
NCT01352897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSG-CRE-2011/1|Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In Hypercholesterolaemia|A Registry to Collect Data of Efficacy and Safety Between Rosuvastatin, and Atorvastatin and Simvastatin In Subjects With Type IIa and IIb Hypercholesterolaemia Under Real Clinical Settings||AstraZeneca|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from primary care and specialist clinics|May 2011|May 11, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01352897||104729|
NCT01361685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4396 Chronic Performance|Model 4396 Left Ventricular (LV) Lead Chronic Performance Study|Attain Ability® Family Left Ventricular Lead Chronic Performance Study||Medtronic Cardiac Rhythm Disease Management|No|Recruiting|May 2011|May 2021|Anticipated|February 2021|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1016|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with a 4396 LV Lead within 30 days. All subjects must meet Inclusion        criteria and none of the Exclusion criteria.|October 2014|October 1, 2014|May 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01361685||104057|
NCT01353144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS96-CT4-26|A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers|A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers||Kaohsiung Veterans General Hospital.|Yes|Completed|June 2007|May 2008|Actual|May 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|May 11, 2011||No||No|September 14, 2015|https://clinicaltrials.gov/show/NCT01353144||104710|The trial was performed in a single country
NCT01354002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBANK|Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility|Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility||St. Jude Children's Research Hospital|No|Recruiting|September 2009|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Samples With DNA as well as Samples Without DNA will be retained.      All samples that are collected and processed, including cryopreserved tumor cells, non-tumor      fractions isolated from tumor samples (plasma, serum); and non-tumor samples collected from      patients, controls and relatives; and cellular sub-fractions isolated from samples including      DNA, RNA and protein.      Any tumor or non-tumor sample, including blood, ascites, pleural effusion, bone marrow,      solid tumors, brain tumors, tissue uninvolved by tumor, cerebrospinal fluid, and urine      samples. These are kept sterile whenever possible, and tumor cells and tissues are      cryopreserved viable where possible. Specimens containing plasma are collected into syringes      containing preservative-free heparin to prevent clotting.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients, their relatives, and control populations treated at St. Jude Children's        Research Hospital (SJCRH), collaborating sites and affiliates.|September 2015|September 4, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01354002||104644|
NCT01354015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Fonseca|Diabetes Remote Care Management System|Diabetes Remote Care Management System|DRMS|Tulane University School of Medicine|No|Completed|May 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|May 6, 2011||No||No|December 30, 2014|https://clinicaltrials.gov/show/NCT01354015||104643|
NCT01349790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGAM-02|Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia|Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia||Octapharma|Yes|Completed|June 2011|February 2014|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349790||104966|
NCT01350336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02|Bronchial Thermoplasty in Severe Persistent Asthma|Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma|PAS2|Boston Scientific Corporation|Yes|Active, not recruiting|April 2011|December 2019|Anticipated|December 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|284|||Both|18 Years|65 Years|No|||May 2014|March 30, 2015|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350336||104924|
NCT01350349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH091045|Home-delivered Intervention for Depressed, Cognitively Impaired Elders|Home-delivered Intervention for Depressed, Cognitively Impaired Elders||Weill Medical College of Cornell University|Yes|Recruiting|April 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|65 Years|N/A|No|||December 2014|December 18, 2014|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350349||104923|
NCT01350050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a003c|Topical Pharyngeal Anesthesia With Articaine for Gastroscopy|Topical Pharyngeal Anaesthesia With Articaine for Gastroscopy. A Randomized Double-blind Study on Volunteers||Helsinki University Central Hospital|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 4, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350050||104946|
NCT01350063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10038|Health Impact of Treating and Safely Storing Shallow Tubewell Drinking Water|Health Impact of Treating and Safely Storing Shallow Tubewell Drinking Water||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|February 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1800|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||May 2011|January 1, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01350063||104945|
NCT01359046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007421|Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology|Randomized Control Trial of Silver-alloy Impregnated Suprapubic Catheters in Urogynecology Patients||Mayo Clinic|No|Recruiting|July 2011|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|444|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359046||104258|
NCT01359033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7-EIS-WP7-MINAP|MI Mortality Risk and Between-hospital Risk Variation in the United Kingdom and Sweden|Compare the Patient Risk and Between-hospital Variation in Myocardial Infarction Mortality in the United Kingdom and Sweden||University College, London|Yes|Active, not recruiting|March 2011|December 2020|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|370000|||Both|30 Years|N/A|No|Non-Probability Sample|For the UK, all patients with an admission recorded in the MINAP database during 1st        January 2004 and 31 December 2008 in 253 hospitals in England and Wales will be included        in the study. For Sweden, all patients with an admission recorded in the RIKS-HIA during        1st January 2004 and 31 December 2008 in 74 hospitals in Sweden will be included. Only        patients with acute myocardial infarction will be included as the study population.|February 2014|February 3, 2014|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359033||104259|
NCT01359020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALI/P/04-1|Ibuprofen, Acetaminophen and Dipyrone to Fever Control in Children|Randomized, Open Label, Comparative, Parallel, Multicenter Trial to Determinate the Efficacy Anf Tolerability of Ibuprofen, Acetaminophen and Dipyrone Drops to Fever Control in Children||Mantecorp Industria Quimica e Farmaceutica Ltd.|Yes|Completed|January 2007|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|396|||Both|6 Months|6 Years|No|||May 2011|May 23, 2011|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359020||104260|
NCT01359813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N/2008/51|Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis|Effects of Albumin Administration in Septic Cirrhotic Patients With Child > 8 Unrelated to Spontaneous Bacterial Peritonitis on Renal Function and Survival: A Multicenter Randomized Controlled Trial Comparing Use and Non-use of Human Albumin (Vialebex ®)|ALB-CIRINF|Centre Hospitalier Universitaire de Besancon|Yes|Terminated|December 2008|June 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|193|||Both|18 Years|80 Years|No|||July 2010|May 12, 2014|May 23, 2011||No|decision of independent monitoring committee:Risk of death at 3 months higher in Albumin group    than in control group, without reaching significance level.|No||https://clinicaltrials.gov/show/NCT01359813||104199|
NCT01350908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC2010-03|Study of Circulating Tumoral DNA in Ovarian Cancer|Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Ovarian Cancer||Institut Curie|No|Recruiting|April 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Female|18 Years|N/A|No|||March 2011|May 9, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350908||104880|
NCT01350921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00073|Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers|A Sequential, Open Label Study to Compare the Pharmacokinetics, Safety and Tolerability of Ticagrelor and Venlafaxine Given Concomitantly in Healthy Subjects Aged 18 to 45 Years||AstraZeneca|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|May 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01350921||104879|
NCT01333293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025ACH03T V1|The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients|The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Prospective Double-blind, Placebo-controlled, Multicentre Study, XOLMA-Study|XOLMA|University of Zurich||Completed|September 2011|January 2016|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|70 Years|No|||January 2016|January 15, 2016|July 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01333293||106216|
NCT01333618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXiao-01|Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter|Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter：A Randomized Double-Blind Comparison||China Medical University, China|Yes|Completed|September 2008|September 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|108|||Both|18 Years|80 Years|No|||August 2008|April 25, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01333618||106191|
NCT01364727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THOR0003|A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies|A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies||Stanford University|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|39|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364727||103825|
NCT01364740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04212009-2358|PMP-300E (Smart Watch): Portable Monitoring Device Study|PMP-300E: Validation of Portable Monitoring Device PMP-300E for Identification of Obstructive Sleep Apnea.|PMP-300E|Stanford University|No|Completed|April 2008|June 2009|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364740||103824|
NCT01365013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010111039|Evaluation of the Translation of the DE-PLAN Program for the Primary Prevention of Type 2 Diabetes in Routine Primary Care|Effectiveness of the Translation of a Type 2 Diabetes Primary Prevention Program in Routine Context of Primary Heath Care|DE-PLAN E|Basque Health Service|No|Recruiting|June 2011|June 2015|Anticipated|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2534|||Both|45 Years|70 Years|No|||September 2012|July 23, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365013||103803|
NCT01353430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VK2007-5832|Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)|Characterization of Familial Myopathy and Paget Disease of Bone||University of California, Irvine|No|Recruiting|January 2000|||December 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples With DNA|Whole blood, skin and muscle biopsy, urine sample, if available samples obtained from      previous diagnostic evaluations such as muscle biopsy.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with a personal or family history of VCP associated disease.|May 2011|May 12, 2011|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01353430||104688|
NCT01353157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE531033|Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery|Prediction for Systemic Inflammation With Clinical Scoring Systems and Inflammatory Cytokine Levels in Adult Cardiac and Major Abdominal Surgical Patients||Khon Kaen University|No|Completed|March 2010|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|whole blood taken from arterial line|Both|18 Years|N/A|No|Non-Probability Sample|adult patients who had undergone elective cardiac surgery with CPB|February 2010|May 11, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01353157||104709|
NCT01353677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-SQOL|Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database|Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database|09-SQOL|Center for International Blood and Marrow Transplant Research|Yes|Active, not recruiting|July 2011|||October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|390|||Both|2 Years|N/A|No|Probability Sample|Pediatric and adult allogeneic HCT recipients|July 2015|July 27, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353677||104669|
NCT01349803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003003|PT003 MDI Cardiovascular Safety Study|A Randomized, Double-blind, Parallel Group, 14-day, Multi-Center Study to Evaluate the Safety of PT003, PT005, PT001 and Foradil® Aerolizer® (12 µg, Open Label) as Evaluated by Holter Monitoring, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Pearl Therapeutics, Inc.|No|Completed|May 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|237|||Both|40 Years|80 Years|No|||May 2013|May 23, 2013|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349803||104965|
NCT01350089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED and alcohol intoxication|Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication|A Double Blind, Randomised, Placebo-controlled, Within-subject Crossover Study to Examine the Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication||Medical University of Vienna|No|Active, not recruiting|January 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|52|||Male|20 Years|26 Years|Accepts Healthy Volunteers|||May 2011|May 6, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01350089||104943|
NCT01350323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-O-1|Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization|Aqueous Humor Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Bevacizumab in Type 3 Versus Type 1 and 2 Neovascularization. A Prospective, Case-control Study.||University of Molise|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|33|||Both|55 Years|95 Years|No|||March 2009|May 6, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01350323||104925|
NCT01350609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14028|Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed|Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan and the Loose Combination of Both Components and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Subjects Under Fed Conditions in an Open Label, Randomized, 2-way-crossover Design||Bayer|No|Completed|April 2011|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01350609||104903|
NCT01350284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CinnGastEmpt|The Effect of Natural Food Flavourings on Gastrointestinal and Cardiovascular Physiological Responses.|Effect of Cinnamon on Gastric Emptying, Arterial Stiffness, Postprandial Lipaemia, Glycaemia, and Appetite Responses to High-fat Breakfast|CinnGastEmpt|University of Limerick|No|Completed|June 2009|March 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|9|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2011|May 6, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01350284||104928|
NCT01350297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/023/HP|Diaphragmatic Reinnervation of Tetraplegic Patients With Respiratory Insufficiency|Phrenic Reinnervation in Central Ventilatory Paralysis Due to Medullary Trauma With Phrenic Motoneuron Destruction|TETRADIA-UNI|University Hospital, Rouen|No|Completed|March 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||June 2013|June 17, 2013|February 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01350297||104927|
NCT01359293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912770|Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcomes and MRI Measures|Effects of Paliperidone Palmitate Versus Oral Antipsychotics on Clinical Outcome and sMR Measures in First Episode Patients: A Randomized Clinical Trial||University of Iowa|Yes|Recruiting|April 2011|December 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2011|May 23, 2011|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359293||104239|
NCT01359306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-Damage 1/2007|Right Ventricular Damage in Cardiovascular Magnetic Resonance|Right Ventricular Damage in ST-Elevation Myocardial Infarction. Risk Stratification by Visualization of Wall Motion, Edema and Delayed Enhancement Cardiovascular Magnetic Resonance||University of Leipzig|No|Completed|February 2006|May 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|524|Samples Without DNA|serum for assessment of creatine kinase myocardial band|Both|18 Years|N/A|No|Non-Probability Sample|524 consecutive patients with ST elevation myocardial infarction.|May 2011|May 23, 2011|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359306||104238|
NCT01359267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0032|Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer|A Pilot Feasibility Study of 99mTc EC DG SPECT/CT Imaging in the Treatment Response Evaluation in Patients With Locally Advanced Head and Neck Cancer||University of Chicago|No|Active, not recruiting|April 2011|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359267||104241|
NCT01359280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-332|Nurse Delivered Cell Phone Adherence Intervention (Pick It UP)|Nurse Delivered Cell Phone Adherence Intervention|PIU|University of Connecticut|No|Completed|July 2011|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|600|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359280||104240|
NCT01351233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMC|Evaluation of the Rotational Stability of The AcrySof Toric Intraocular Lens in the Capsular Bag in High Myopic Subjects|Evaluation of the Rotational Stability of The AcrySof Toric Intraocular Lens in the Capsular Bag in High Myopic Subjects||Wenzhou Medical University|Yes|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Both|30 Years|80 Years|No|||July 2012|July 4, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01351233||104855|
NCT01351506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10FEB010924|Effect of Body Weight Change to Surgical ICU Outcomes|Effect and Determinant Level of Admission Body Weight and Daily Weight Change and Prognoses of Critically and High Risk Surgical Patients||Chiang Mai University|Yes|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|465|||Both|18 Years|N/A|No|Non-Probability Sample|All admitted ICU patients which expected survive more than 24 hours.|November 2014|November 3, 2014|May 9, 2011||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT01351506||104834|
NCT01352052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDS-2011-099|Interdisciplinary Rehabilitation of Patients With Chronic Widespread Pain|Interdisciplinary Rehabilitation and Evaluation Programme for Patients With Chronic Widespread Pain: Randomized Controlled Trial, the IMPROvE Study|IMPROvE|Frederiksberg University Hospital|No|Enrolling by invitation|May 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Female|18 Years|N/A|No|||May 2011|May 10, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01352052||104792|
NCT01352364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I01|Analysis Of Equilibrium And Motor Coordination Of Deaf Children's Pre And Post Intervention Physiotherapeutic|Analysis Of Equilibrium And Motor Coordination Of Deaf Children's Pre And Post Intervention Physiotherapeutic||University of the Sinos Valley|No|Completed|July 2009|December 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|7 Years|10 Years|No|||July 2009|May 26, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352364||104770|
NCT01333306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10269|Enhancing Cognitive Training Using tDCS|||The University of New South Wales||Completed|September 2010|April 2013|Actual|||Phase 1|Interventional|Primary Purpose: Basic Science|1||||||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2010|April 23, 2013|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01333306||106215|
NCT01364181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Udenafil|The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients|The Impact of Udenafil on Exercise Capacity in Severe COPD Patients||Seoul National University Hospital|Yes|Completed|March 2010|May 2011|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|20 Years|80 Years|No|||May 2011|June 17, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364181||103867|
NCT01364441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2952POU001|Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Single-Dose Escalation and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd|No|Completed|May 2011|||August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|May 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01364441||103847|
NCT01364701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0449-10-RMB|Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment|A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment|PDE5i|Rambam Health Care Campus|No|Not yet recruiting|June 2011|July 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Female|35 Years|75 Years|No|||April 2011|June 17, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01364701||103827|
NCT01332786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-029|Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia|Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML||University Health Network, Toronto|Yes|Completed|March 2011|January 2015|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332786||106255|
NCT01332799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010787|Xanthine Oxidase Inhibition in Renal Transplant Recipients||XART|University of Iowa|No|Recruiting|February 2011|February 2016|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|85 Years|No|||April 2011|April 8, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332799||106254|
NCT01333098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011836|Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders|Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders|Mifepristone|Washington University School of Medicine|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 19, 2014|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333098||106231|
NCT01333449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Decitabine01|Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients|Prospective Phase II Study of Decitabine Induction Therapy to Reduce Pre-transplant Disease Burden Prior to Allogeneic Hematopoietic Cell Transplant in Patients With Newly Diagnosed Myelodysplastic Syndromes.||Singapore General Hospital|Yes|Terminated|July 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|21 Years|65 Years|No|||June 2014|June 16, 2014|November 30, 2010||No|Poor subject accrual|No||https://clinicaltrials.gov/show/NCT01333449||106204|
NCT01333462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-1008-001|Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008|A Phase 1 Randomized, Single-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 (Fluzone® + 60%W805EC) in Healthy Adult Volunteers||NanoBio Corporation||Completed|March 2009|September 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|12||Actual|199|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||April 2011|April 11, 2011|April 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333462||106203|
NCT01333475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110117|MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma|Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma||National Institutes of Health Clinical Center (CC)|No|Completed|March 2011|September 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||November 2014|September 29, 2015|April 9, 2011|Yes|Yes||No|November 19, 2014|https://clinicaltrials.gov/show/NCT01333475||106202|
NCT01358812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2934|FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer|Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer|TRIP|Gruppo Oncologico del Nord-Ovest|Yes|Completed|March 2010|||October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|75 Years|No|||March 2015|March 10, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358812||104276|
NCT01359085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-HF-0235-11-CTIL|Pain Relief Following Arthroscopic Rotator Cuff Repair: Perioperative Pregabalin Administration Versus Interscalene Brachial Plexus Block|Pain Relief Following Arthroscopic Rotator Cuff Repair: Perioperative Pregabalin Administration Versus Interscalene Brachial Plexus Block. a Prospective, Randomized, Double Blinded, Multicenter Trial||Tel-Aviv Sourasky Medical Center||Not yet recruiting|June 2011|||June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|56|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01359085||104255|
NCT01359878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017736-41|Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial|Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage - A Randomised Clinically Controlled Trial|FIB-PPH|Copenhagen University Hospital at Herlev|Yes|Completed|May 2011|July 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|249|||Female|18 Years|N/A|No|||September 2013|September 19, 2013|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359878||104194|
NCT01359852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017848|A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers|An Open-Label Study to Investigate the Dosimetry of the Positron Emission Tomography Ligand for the Metabotropic Glutamate Receptor-2 (mGlu2R), [11C]JNJ-42491293, and Displacement by the mGlu2R Positive Allosteric Modulator JNJ-40411813 in Healthy Male Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|May 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359852||104196|
NCT01359865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSHersheyMC|Comparison of Anesthetic Techniques on Total Hip Arthroplasty|The Influence of Anesthetic Technique on Post-operative Pain Scores and Range of Motion in Primary Total Hip Arthroplasty||Milton S. Hershey Medical Center|Yes|Terminated|July 2012|July 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|May 23, 2011||No|change in clinical practice- both surgeons have left the institution|No||https://clinicaltrials.gov/show/NCT01359865||104195|
NCT01350635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-BM32-001|Skin Test Study of BM32|Evaluation of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, by Skin Testing||Biomay AG|No|Completed|May 2011|September 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|60 Years|No|||December 2015|December 17, 2015|May 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01350635||104901|
NCT01350622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49065|Efficacy of PENNSAID® for Pain Management in the Emergency Department|Efficacy of PENNSAID® for Pain Management in the Emergency Department||University of Utah|No|Withdrawn|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01350622||104902|
NCT01350960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC5001-901|Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH|A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)||Santaris Pharma A/S||Terminated|May 2011|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 21, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01350960||104876|
NCT01350583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16047|Bicarbonate for Tumor Related Pain|A Pilot Study of Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|August 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|2|||Both|18 Years|N/A|No|||June 2013|August 7, 2013|May 6, 2011|Yes|Yes|PI Left Moffitt|No|June 5, 2013|https://clinicaltrials.gov/show/NCT01350583||104905|This Pilot Supportive Care study ended prematurely due to slow accrual and the initiating principal investigator leaving the institution. The outcome measures were based on 25 evaluable participants and there were only 2 participants enrolled.
NCT01350596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4371004|A Bioequivalence Study Of Ibuprofen 50mg/ml (laboratórios Pfizer Ltda) In The Oral Suspension Form.|An Open Label, Randomized, 2x2 Crossover, Single Dose, Phase 4 Study To Determine The Pharmaceutical Bioequivalence Of Ibuprofen 50mg/Ml (Laboratórios Pfizer Ltda) Oral Suspension Versus Alivium ® 50mg/Ml (Mantecorp Indústria Química E Farmacêutica Ltda.) Oral Suspension, In Healthy Fasting Volunteers.|B4371004|Pfizer|No|Completed|May 2011|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350596||104904|
NCT01359514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PostOperativePain05CTIL|Mechanism-based Choice of Therapy for Neuropathic Pain|Mechanism-based Choice of Therapy for Neuropathic Pain: Can Treatments Success in Neuropathic Post-operative Pain be Coupled to Psychophysical Pain Modulation Profile?||Rambam Health Care Campus|No|Active, not recruiting|April 2008|September 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||December 2007|May 23, 2011|July 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01359514||104222|
NCT01359527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJRC-DXA/Resurfacing|Dual Energy X-rayY Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)|A Dual Energy X-Ray Absorptiometry Comparison Of Periprosthetic Bone Loss Between Patients Undergoing Hip Resurfacing Surgery And Total Hip Arthroplasty||Spokane Joint Replacement Center|Yes|Recruiting|December 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|25|||Both|N/A|80 Years|Accepts Healthy Volunteers|Probability Sample|Adult patients undergoing hip replacement for osteoarthritis|December 2012|December 12, 2012|May 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359527||104221|
NCT01351779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0844-A|The Effect of Body Posture on Intraocular Pressure in Progressive Glaucoma|The Effect of Body Posture on Intraocular Pressure in Progressive Glaucoma||University of Toronto|Yes|Recruiting|May 2011|||May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|Glaucoma clinic patients|May 2011|May 9, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351779||104813|
NCT01364194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|516/2552(EC3)|Local Infiltration With Bupivacaine to Increase Quality of Post-operative Pain Control in Total Knee Replacement|Periarticular Injection With Bupivacaine For Post-Operative Pain Control In Total Knee Replacement: A Prospective Randomized Double-Blind Controlled Trial||Mahidol University|Yes|Completed|March 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|80 Years|No|||May 2011|June 1, 2011|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01364194||103866|
NCT01364207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-06-052|The Effects of Caffeinated Coffee on Intraocular Pressure|The Effects of Caffeinated Coffee on Intraocular Pressure||Massachusetts Eye and Ear Infirmary|No|Completed|November 2010|June 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|112|||Both|40 Years|89 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|November 5, 2010||No||No|June 8, 2012|https://clinicaltrials.gov/show/NCT01364207||103865|We gave subjects caffeinated coffee on one visit and decaffeinated coffee on the other visit. The changes in outcome parameters we observed (ie IOP changes) could be due to other non-caffeine components in the coffee.
NCT01364454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUERMG|General Practitioners (GP) Involvement in Colorectal Cancer (CRC) Screening|Effect of Eligible Patients Paper-based Reminder for General Practitioners on Colorectal Cancer Screening Participation||Paris 12 Val de Marne University|No|Active, not recruiting|June 2010|June 2011|Anticipated|June 2011|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|8140|||Both|50 Years|74 Years|No|||May 2011|June 1, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01364454||103846|
NCT01332812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maria J.C. Carmona|Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction|Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction in Elderly Patients Undergoing to General Anesthesia||University of Sao Paulo|Yes|Completed|January 2011|March 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|60 Years|90 Years|No|||September 2015|September 4, 2015|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332812||106253|
NCT01333111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7999-3747|Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients|A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC-0156-0000-0009 When Used for Treatment and Prophylaxis of Bleeding Episodes in Patients With Haemophilia B|paradigm™ 2|Novo Nordisk A/S|No|Completed|April 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|74|||Male|13 Years|70 Years|No|||April 2014|April 15, 2014|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333111||106230|
NCT01333124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-500|Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma|A Phase 2 Study of Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma||National Cancer Center, Korea|No|Recruiting|April 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|70 Years|No|||October 2015|October 5, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01333124||106229|
NCT01333735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COG AGE|Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon|Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon|COG AGE|Centre Francois Baclesse|No|Completed|December 2008|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|114|Samples Without DNA|NFS, uree, creatinin, ASAT, ALAT, PAL, GGT, Vit D, B12, Folates, Albumin, lipid, TSH,      testosteron, oestradiol, LH, FSH, TP, TCA, D-Dimeres, Homocystéine, plasmatic      biomarkers(protein S100, NSE, CRP, IL6)|Female|66 Years|N/A|No|Probability Sample|patients with chemotherapy group and patients without chemotherapy group (control group)|September 2015|September 3, 2015|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333735||106182|
NCT01333995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10001|Peer Conselling Infant Feeding Education Program|Peer Counselling to Improve Feeding Practices and Reduce Malnutrition in Children 0-2 Years in Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|June 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2050|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||February 2010|June 11, 2015|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01333995||106162|
NCT01359098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-003-000|Efficacy and Safety of Once-Daily Ciprodexa Otic Foam Compared to Twice-daily Ciprodex Ear Drops in Acute Otitis Externa|Safety and Efficacy of Once-Daily Dosing of Ciprodexa Otic Foam (Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Foam) Compared to Twice-Daily Dosing of Ciprodex (0.3% Ciprofloxacin and Dexamethasone 0.1% Otic Suspension) in Patients With Acute Otitis Externa|Ciprodexa Foam|Otic Pharma|No|Completed|July 2011|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|80 Years|No|||November 2011|November 1, 2011|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359098||104254|
NCT01349543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROSM0127|The Development of a Human Model of Respiratory Syncytial Virus Infection|The Development of a Human Model of Respiratory Syncytial Virus Infection||Imperial College London|Yes|Completed|May 2011|September 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 3, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349543||104985|
NCT01349556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00042104|Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream|Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin||Johns Hopkins University||Withdrawn|May 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|May 5, 2011||No|Study withdrawn due to volunteer disinterest in participating.|No||https://clinicaltrials.gov/show/NCT01349556||104984|
NCT01359332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081249|Evaluation of Therapeutic Hypothermia in Convulsive Status EPILEPTICUS in Adults in Intensive Care|Evaluation of the Interests of a Therapeutic Hypothermia Procedure in Convulsive Status EPILEPTICUS in Adults in Intensive Care - HYBERNATUS Study|HYBERNATUS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|December 2010|April 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359332||104236|
NCT01359345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GADOLLINUM|Nephrogenic Systemic Fibrosis With Gadollinum|The Prevalence and Severity of Nephrogenic Systemic Fibrosis in Patients Whom Underwent Imaging With Gadollinium(MRI/MRA) in University Hospital of Tehran Heart Center in 2003-2008|NSF|Imam Khomeini Hospital|Yes|Enrolling by invitation|July 2008|August 2012|Anticipated|May 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|200|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01359345||104235|
NCT01359605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-CVD2215|Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects|An Open-Label, Single-Dose, Study to Assess the Metabolism and Elimination of Varespladib After Oral Administration of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects||Anthera Pharmaceuticals|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 16, 2011|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359605||104215|
NCT01360203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS019311|Better Effectiveness After Transition - Heart Failure|Variations in Care: Comparing Heart Failure Care Transition Intervention Effects|BEAT-HF|University of California, Los Angeles|Yes|Completed|October 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1437|||Both|50 Years|N/A|No|||May 2014|May 7, 2014|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01360203||104169|
NCT01360190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-08-273-13|Neurophysiologic Monitoring of Antidepressant Treatment|Neurophysiologic Monitoring of Antidepressant Treatment|Lilly|University of California, Los Angeles|No|Completed|August 1994|August 1996|Actual|August 1996|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|No|||May 2011|May 24, 2011|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360190||104170|
NCT01360177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSMTS0012|Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers|Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers||Stanford University|Yes|Withdrawn|July 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01360177||104171|
NCT01350973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-085/CCT-002|Efficacy of TAK-085 in Participants With Hypertriglyceridemia|A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.||Takeda|No|Completed|November 2009|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|611|||Both|20 Years|74 Years|No|||February 2012|February 1, 2012|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350973||104875|
NCT01351246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD-TEAM-01|Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD): A Feasibility and Effectiveness Study||University of Cologne|No|Completed|May 2010|March 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|6 Years|12 Years|No|||April 2014|April 14, 2014|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01351246||104854|
NCT01350934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-264|A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)|A 6-Month, Randomized, Open-Label, Active-Comparator Controlled, Parallel-Group Study With a 6-Month Extension to Evaluate the Safety and Efficacy of Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination Tablets Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China||Merck Sharp & Dohme Corp.|No|Completed|June 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Female|56 Years|N/A|No|||June 2015|June 3, 2015|May 9, 2011|No|Yes||No|June 20, 2014|https://clinicaltrials.gov/show/NCT01350934||104878|
NCT01350947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI47081|A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia|A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML)||University of Utah|Yes|Completed|April 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|April 29, 2011|Yes|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT01350947||104877|
NCT01351766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA029445|Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation|Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation||University of Maryland|No|Recruiting|April 2010|April 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|21 Years|No|||June 2011|June 10, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351766||104814|
NCT01352390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813606|The Effect of a Coloring Prompt on Health Engagement|The Effect of a Coloring Prompt on Health Engagement||University of Pennsylvania|No|Not yet recruiting|May 2011|September 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|15000|||Both|18 Years|N/A|No|||May 2011|May 23, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01352390||104768|
NCT01364220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3560L00087|The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke|An Investigator-Sponsored,Double Blind,Placebo-controlled,Randomised,Multi-centre Study to Assess the Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke|EUREKA|Severance Hospital|Yes|Terminated|August 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|318|||Both|20 Years|N/A|No|||November 2014|November 19, 2014|May 26, 2011||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01364220||103864|
NCT01332487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114461|Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia|Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia||GlaxoSmithKline|No|Completed|August 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|4068|||Male|50 Years|N/A|No|Probability Sample|Male patients aged 50 years or older with a diagnostic claim for BPH; prescription claim        for an AB and a 5ARI in the observation period|September 2011|February 16, 2012|April 7, 2011||No||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01332487||106278|
NCT01332500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111208|Treximet ™ Pharmacy Budget Impact Model Database Validation Study|Treximet ™ Pharmacy Budget Impact Model Database Validation Study||GlaxoSmithKline||Completed|July 2009|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|61737|||Both|18 Years|65 Years|No|Probability Sample|Subject data from a claims database having at least one pharmacy claim for Treximet ™ or        an orally administered triptan during the study period.|April 2011|April 19, 2011|March 21, 2011||No||No|March 21, 2011|https://clinicaltrials.gov/show/NCT01332500||106277|
NCT01332825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39352-A|cAMP (Cyclic Adenosine Monophosphate) Levels in the Nose|cAMP Levels in the Nose||University of Washington|No|Completed|March 2011|December 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332825||106252|
NCT01333137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P276-00/52/10|A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin|An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin||Piramal Enterprises Limited|Yes|Terminated|August 2011|March 2014|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Female|18 Years|N/A|No|||September 2014|September 3, 2014|April 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01333137||106228|
NCT01332838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSSCA|A Comparison of Specialized Versus Standard Compression After Saphenous Ablation|A Comparison of Specialized Versus Standard Compression After Saphenous Ablation||University of Washington||Not yet recruiting|May 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|N/A|No|||April 2011|April 29, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01332838||106251|
NCT01334242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-104-NRM|A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects||Lexicon Pharmaceuticals|No|Completed|March 2011|||April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 18, 2011|April 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01334242||106143|
NCT01358838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 10/026|Ablative 10600 nm Fractional Laser Therapy for the Treatment of Scars|Ablative 10600 nm Fractional Laser Therapy for the Treatment of Scars; a Randomized Controlled Trial||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Completed|May 2010|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2010|February 6, 2013|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358838||104274|
NCT01358851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H 1005 6002 1007|LAS41005 in Hyperkeratotic Actinic Keratosis|A Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis||Almirall, S.A.||Completed|April 2011|August 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|85 Years|No|||May 2015|May 28, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01358851||104273|
NCT01359111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 563|Performance and Safety Evaluation of an Intradermal Delivery Device|Phase I Performance and Safety Evaluation of an Intradermal Delivery Device||PATH|No|Completed|May 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|May 2, 2011|No|Yes||No|April 16, 2012|https://clinicaltrials.gov/show/NCT01359111||104253|
NCT01359358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis IFSC-USP|Study of Methicillin-resistant Staphylococcus Aureus (MRSA) Isolated From Infected Patients in Brazil|Epidemiological Study of Methicillin-resistant Staphylococcus Aureus (MRSA) Isolated From Infected Patients During a Hospital Surveillance Period|MRSABrazil|University of Sao Paulo|Yes|Not yet recruiting|July 2011|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|20|||Both|1 Month|N/A|No|Non-Probability Sample|MRSA from infection or from colonization of a patient who was already infected by MRSA        during the time of the study|May 2011|May 23, 2011|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359358||104234|
NCT01359618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00009|Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart|A Single-centre, Randomised, Double-blind, Placebo Controlled Phase I Study in Two Parts: Part A to Assess a Safe and Tolerable Supratherapeutic Dose of TC-5214 After Single Ascending Oral Doses in Healthy Male Subjects, Followed by Part B: A Four-period Double-dummy Crossover Study to Investigate the Effect of 2 Single Doses (Therapeutic and Supratherapeutic) of TC-5214 on the QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Subjects||AstraZeneca|No|Terminated|June 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|16|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|April 28, 2011|No|Yes|Sponsor decision to terminate|No||https://clinicaltrials.gov/show/NCT01359618||104214|
NCT01360216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-5442|Cluster, Randomized Trial on Long Acting Reversible Contraception (LARC) Education and Training|Cluster, Randomized Trial on Provider LARC Education and Training|LARC|University of California, San Francisco|No|Completed|May 2011|August 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1500|||Female|18 Years|25 Years|No|||September 2013|September 25, 2013|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01360216||104168|
NCT01360411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17765|Tissue Characterisation by Endoscopic GI-elastography|Tissue Characterisation Using Ultrasound Based Strain Imaging(Elastography)Examining Lesions in the Gastrointestinal Wall, Adjacent Lymph Nodes and Pancreatic Lesions||Haukeland University Hospital|No|Completed|January 2007|July 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|137|Samples With DNA|Tissue samples are stored as pathological slides in the diognostic biobank of Dep. of      Pathology, Helse Bergen.|Both|18 Years|90 Years|No|Non-Probability Sample|Adult patients referred to EUS examination or relevant surgery at Haukeland University        Hospital, bergen, Norway within the inclusion period (2007- January 2011).|September 2012|September 4, 2012|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01360411||104153|
NCT01360424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS-LTO-PTH|Teriparatide Treatment in Patients With Inherited Osteoporosis|Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis||Helsinki University Central Hospital|No|Completed|May 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2015|September 27, 2015|May 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01360424||104152|
NCT01360710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Young obese hypertension|The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension|The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial||Baker IDI Heart and Diabetes Institute||Recruiting|January 2012|||January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|30 Years|No|||February 2012|February 1, 2012|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360710||104131|
NCT01360684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091932|Study of Axillary Skin Temperature as a Marker of Ovulation|Pilot Study of Measuring Axillary Skin Temperature, Using DuoFertility, as a Marker of Ovulation in 10 Women of Childbearing Age||Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|July 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infertile females of child bearing age with regular menstrual cycles trying to get        pregnant|May 2011|May 25, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360684||104133|
NCT01351259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A00598-49|Continuous Control of Polyurethane Tracheal-cuff Pressure: Efficiency of a Pneumatic Device|Continuous Control of Polyurethane Tracheal-cuff Pressure: Efficiency of a Pneumatic Device|Nosten|University Hospital, Lille|Yes|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|N/A|No|||August 2013|August 31, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351259||104853|
NCT01351272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W004PS0108_1|Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)|Genetic Modulation of Functional Brain Activity of Attention-deficit/Hyperactivity Disorder-related Working Memory Processes|BEAS|Wuerzburg University Hospital|Yes|Completed|May 2011|March 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|41|||Both|18 Years|50 Years|No|||December 2014|December 9, 2014|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01351272||104852|
NCT01351519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALA 11.07|A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain||MultiCare Health System Research Institute|Yes|Terminated|May 2011|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 7, 2011|Yes|Yes|Limited staff available for enrollment and limited availability of drug|No||https://clinicaltrials.gov/show/NCT01351519||104833|
NCT01351532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-063|Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention|Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention||China Medical University Hospital||Completed|April 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|67|||Female|N/A|N/A|No|||January 2012|January 30, 2012|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351532||104832|
NCT01361191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEL/TAMO-2006|Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma|Early Treatment Stratification Based on PET Scan Response to R-MEGACHOP Followed by R-MEGACHOP or R-IFE Plus Peripheral Autologous Stem Cell Transplant (PBSCT) in Patients With Poor Prognosis DLBCL|R-MEGACHOP|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Yes|Completed|June 2007|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|65 Years|No|||October 2013|October 29, 2013|April 14, 2008||No||No||https://clinicaltrials.gov/show/NCT01361191||104095|
NCT01361204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT2011001|Anti-stress Effect of Theanine on Students During Long-term Pharmacy Practices|Measurement of Stress Symptom in Students During Long-term Pharmacy Practices and Evaluation of Anti-stress Effect of Theanine Consumption on Students||University of Shizuoka|Yes|Completed|May 2011|April 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|20|||Both|22 Months|30 Years|Accepts Healthy Volunteers|||July 2013|July 14, 2013|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01361204||104094|
NCT01361516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021711-HMO-CTIL|Comparison of General Anaesthesia and Sedation on the Stone Fragmentation in Lithotripsy|Comparison of General Anaesthesia and Sedation on the Stone Fragmentation Efficacy of the Third Generation Lithotriptor||Hadassah Medical Organization|No|Not yet recruiting|July 2011|September 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|180|||Both|18 Years|N/A|No|||April 2011|May 25, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01361516||104070|
NCT01361529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACEA100108(FLP)|Safety Study of FLP Injection to Treat Tumor Patients|Phase 1 Study of FLP Injection on Tumor Patients||Acea Bio (Hangzhou) Co., Ltd.|No|Recruiting|June 2009|July 2011|Anticipated|June 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||May 2011|May 26, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361529||104069|
NCT01332201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1501|Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®|A Phase II, Open Label, Parallel Group, Multi-center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf® or Prograf® Based Immunosuppressive Regimen, Including a Long-term Follow-up||Astellas Pharma Inc|Yes|Completed|July 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|65 Years|No|||June 2015|June 12, 2015|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01332201||106300|
NCT01332214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3870C00001|To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses|A Randomised, Single-blind, Placebo-controlled Single-centre Phase I Study in Healthy Male Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses||AstraZeneca|No|Completed|May 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|90|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 18, 2011|April 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01332214||106299|
NCT01332513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114552|An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.|An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.||GlaxoSmithKline|No|Completed|February 2011|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|April 7, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01332513||106276|
NCT01332526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFT Bydgoszcz|FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).|The Oral Fructose Load Test and Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease With Comparison With Healthy Controls.||Collegium Medicum w Bydgoszczy||Not yet recruiting|May 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||7|Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Study I Patients with BMI> 30 and metabolic syndrome. Patient with BMI> 30 without        metabolic syndrome. Normal healthy controls. Study II Patients with CKD stage III and uric        acid < 7 mg/dl Patients with CKD stage III and uric acid > 7 mg/dl Patient with        asymptomatic hiperuricemia and eGFR > 90 ml/min/1.73 m2, , uric acid > 7 mg/dl        Hemodialysis patients|March 2011|April 15, 2011|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01332526||106275|
NCT01333163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEKRM 29414|GLP-1: Acute Effects on Kidney Function in Healthy Men|GLP-1: Acute Effects on Kidney Function in Healthy Men||University of Aarhus|Yes|Completed|May 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333163||106226|
NCT01333488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHS TBI Study|Mild Hypothermia and Supplemental Magnesium Sulfate Infusion in Severe Traumatic Brain Injury (TBI) Subjects|A Phase 2, Randomized, Controlled 2x3 Trial Comparing Clinical Outcomes in Patients With Severe Traumatic Brain Injury Using Mild Hypothermia and Concurrent and Supplemental Infusion of Magnesium Sulfate.||United States Department of Defense|Yes|Terminated|December 2011|June 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|April 8, 2011|Yes|Yes|Low accrual|No|August 4, 2015|https://clinicaltrials.gov/show/NCT01333488||106201|Low accrual leading to early termination and insufficient numbers for analysis.
NCT01334255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1009-Oph-002|iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)|A Phase 1b Multi-Center, Open-Label and Randomized Study of iSONEP (Sonepcizumab/LT1009) Administered as Intravitreous Injections to Subjects With PED Secondary to Exudative Age-Related Macular Degeneration or Polypoidal Choroidal Vasculopathy|PED|Lpath, Inc.|No|Terminated|March 2011|July 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|50 Years|N/A|No|||January 2012|April 22, 2013|April 8, 2011|Yes|Yes|Sponsor decision; not safety related|No||https://clinicaltrials.gov/show/NCT01334255||106142|
NCT01359384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU 84-11|Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment|||Johann Wolfgang Goethe University Hospitals||Not yet recruiting|May 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|whole blood, serum and sputum|Both|6 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study is carried out in children and young adults (6-60 years of age). Both the        patients (25) and the healthy subjects (25) are recruited from the outpatient clinic of        the departement of Pediatric Allergy and Pulmonology and the departement of Pediatric        Immune deficiency , University Clinic, JW Goethe University, Frankfurt/M, Germany|May 2011|May 23, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01359384||104232|
NCT01359124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#35938|Reaching Exercise Goals: Comparison of Exercise Means in Patients With Knee Osteoarthritis|Reaching Exercise Goals: Comparison of the Underwater Treadmill, Land Based Treadmill, and Exercise Cycle in Patients With Knee Osteoarthritis||Milton S. Hershey Medical Center|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|60|||Both|30 Years|60 Years|No|Probability Sample|Subjects for this study will be recruited from Penn State Milton S. Hershey Medical Center        and surrounding communities via internal and external advertisements.|February 2015|February 25, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359124||104252|
NCT01359371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 11-020|Evaluation of Peer Telephone Cessation Counseling for Smokers|Evaluation of Peer Telephone Cessation Counseling for Smokers||VA Office of Research and Development|No|Completed|June 2012|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|41|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatient veterans at the Ann Arbor VA|October 2014|April 6, 2015|May 20, 2011||No||No|October 28, 2014|https://clinicaltrials.gov/show/NCT01359371||104233|
NCT01359631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-001-A|Cephalic Vascular Recording Upon SPG Stimulation|Cephalic Vascular Recording Upon SPG Stimulation in CH Patients - Amendment to the Pathway CH-1 Trial||Autonomic Technologies, Inc.||Completed|June 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|65 Years|No|Non-Probability Sample|Community Sample|May 2012|May 13, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359631||104213|
NCT01359891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-469|Clinical Evaluation of Novel Biomarkers in Patients With Septicemia|Clinical Evaluation of Novel Biomarkers for Diagnosis, Therapy- Monitoring and Prognosis of Outcome in Patients With Septicemia|NOBIS|Medical University of Graz|Yes|Active, not recruiting|November 2010|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|750|Samples Without DNA|Left over EDTA-whole blood samples will be used for both, the Presage™ST2 assay and the      suPARnostic™ assay except for the additional EDTA-whole blood samples taken on day 1 and 2      of study enrollment being only tested for sST2.|Both|18 Years|N/A|No|Non-Probability Sample|Patients >18years with suspected / proven bacteremia/septicaemia admitted to the medical        university hospital Graz, Austria|August 2014|April 2, 2015|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359891||104193|
NCT01359904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-361 GEN|Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)|The Effect of Glucose Concentration in the Dialysate Bath on Glycemic Control Among Hemodialysis Patients With Type 2 Diabetes Mellitus||McGill University Health Center|No|Recruiting|May 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|95 Years|No|||October 2012|October 24, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359904||104192|
NCT01360736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-2-0129 Study 2|A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans - Study 2 (SAFEMIL)|A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans - Study 2|SAFEMIL|Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Active, not recruiting|September 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|89 Years|No|||March 2015|September 12, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01360736||104129|
NCT01332162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT-01-2011-HCPB|CArdiac Desynchronization In Obstructive HCM, CARDIO-HCM|CArdiac Desynchronization In Obstructive Hypertrophic CardioMyopathy|CARDIO-HCM|Hospital Clinic of Barcelona|No|Recruiting|June 2013|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01332162||106303|
NCT01332448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114237|Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials|Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials||GlaxoSmithKline|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|1|||Both|N/A|N/A|No|Probability Sample|All clinical trials found by search procedure:          1. In-house trial repositories at GSK and Roche          2. EMBASE (which includes MEDLINE) using the terms "orlistat", "Xenical" or "Alli", with             "placebo" and "clinical trial"          3. Recently published meta-analyses found by the search will also be searched for             relevant trials|April 2011|April 7, 2011|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01332448||106281|
NCT01333072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD062550-01A1|Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)|Biomarkers in Autism of Aripiprazole and Risperidone Treatment|BAART|Medical University of South Carolina|Yes|Completed|July 2011|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|82|||Both|6 Years|17 Years|No|||March 2016|March 14, 2016|September 20, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333072||106233|
NCT01363882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6753|Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)|Progression of Respiratory Dysfunction in Amyotrophic Lateral Sclerosis (ALS) Patients: A Comparison of Standard of Practice vs Polysomnography-Directed Nocturnal Non-Invasive Positive Pressure Ventilation||Columbia University|No|Active, not recruiting|February 2008|||January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||May 2011|May 31, 2011|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01363882||103889|
NCT01363895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP006|Interventional Strategies in Treatment of Atrial Fibrillation: Percutaneous Closure of the Left Atrial Appendage Versus Catheter Ablation|Interventional Strategies in Treatment of Atrial Fibrillation: Percutaneous Closure of the Left Atrial Appendage Versus Catheter Ablation|ISAR-AF|Deutsches Herzzentrum Muenchen|Yes|Recruiting|November 2010|November 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||November 2010|June 1, 2011|November 25, 2010||No||No||https://clinicaltrials.gov/show/NCT01363895||103888|
NCT01375738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0109|Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With Diabetes Mellitus|The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment||Yonsei University|No|Recruiting|July 2011|May 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|80 Years|No|||September 2012|September 12, 2012|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01375738||102987|
NCT01375998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15328|YAZ Post-marketing Surveillance in Japan|Drug Use Investigation of YAZ||Bayer|No|Active, not recruiting|June 2011|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3273|||Female|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who have received a prescription of YAZ on        the basis of the decision of the treating gynecologist. The study is expected to collect        data of 3,000 patients in about 300 gynecological practices in Japan.|March 2016|March 4, 2016|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01375998||102967|
NCT01376011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 K23AG030967-01A1-2|Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement|Hypoxia-inducible Transcription Factor 1 (HIF-1) in Vascular Aging|Quercetin|Brigham and Women's Hospital|Yes|Completed|June 2009|December 2014|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|106|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376011||102966|
NCT01376349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N10C1|Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms|Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|July 2011|||August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|464|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376349||102940|
NCT01372748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40404-B|Continuous Chest Compressions vs AHA Standard CPR of 30:2|Trial Of Continuous Compressions Versus Standard CPR In Patients With Out-Of-Hospital Cardiac Arrest|CCC|University of Washington|Yes|Completed|June 2011|November 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23711|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01372748||103211|
NCT01373905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Faculty of Medicine12.12.2006|Stepwise Positive End Expiratory Pressure Elevation For Lung Recruitment in Acute Respiratory Distress Syndrome (ARDS)|Stepwise PEEP Elevation With Determination of the Alveolar Collapsing Pressure Versus Sustained Lung Inflation as a Recruitment Maneuver in Patients With ARDS||Faculty of Medicine, University of Alexandria|No|Completed|January 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||February 2008|June 14, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01373905||103124|
NCT01374828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-452|Ketolorac Versus Saline at Laparoscopic Incision Sites|Prospective Randomized Double-blind Study of Incisional Local Anesthesia in Laparoscopic Surgery (Ketorolac Versus Normal Saline)||The Cleveland Clinic|No|Withdrawn|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|90 Years|No|||January 2013|January 9, 2013|June 15, 2011||No|lack of funding|No||https://clinicaltrials.gov/show/NCT01374828||103054|
NCT01374204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09004|Epilepsy-Associated Stigma|EPILEPSY-ASSOCIATED STIGMA AND ILLNESS EXPERIENCE IN PEOPLE WITH EPILEPSY|EPISTIGMA|University Hospital, Limoges|No|Active, not recruiting|July 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|This is a, descriptive and analytical study, based on a semi-directive interview among        people suffering from epilepsy.|August 2015|August 31, 2015|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374204||103101|
NCT01335048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6332011|Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity|Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity|ACHIDO|Ospedale Misericordia e Dolce|No|Completed|April 2011|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||January 2012|January 24, 2012|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01335048||106082|
NCT01334788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006780|Sleep Deprivation and Energy Balance|Sleep Deprivation and Energy Balance||Mayo Clinic|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 27, 2015|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01334788||106101|
NCT01335568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baermed 002|Hepatocyte Matrix Implant Study Indonesia|Intracorporeal Autologous Hepatocyte Matrix Implant: A New Tissue Engineering Procedure for Treatment of Hepatic Disease|HMIIndo|Baermed|Yes|Recruiting|April 2011|December 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 13, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01335568||106042|
NCT01335581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C69-10-M|Study of Laser Treatment of Melasma|A Study of the RevLite Q-Switched Nd:YAG Laser System With Smart Infinite (SI) Handpiece for the Treatment of Refractory Mixed Type Melasma||Cynosure, Inc.|No|Completed|April 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335581||106041|
NCT01335620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTG_60|The Raltegravir 60+ Study|An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age||Imperial College London|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|60 Years|N/A|No|||November 2011|May 20, 2014|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01335620||106038|
NCT01336179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTFD201127021|Comparative Effect of Chewing Sticks and Toothbrushing on Plaque Removal and Gingival Health|The Efficacy of the Miswak Chewing Sticks (Salvadora Persica)on Plaque Removal and Gingival Health: Randomised Clinical Trial||Taibah University|Yes|Completed|March 2011|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||April 2011|May 31, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01336179||105995|
NCT01332175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1600|The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal|The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal: a Randomised Controlled Trial.||University of Zurich|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|20 Years|75 Years|No|||August 2012|August 15, 2012|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01332175||106302|
NCT01336153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN89-01-117-7548|Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke|||Shahid Beheshti University|Yes|Completed|August 2009|December 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|30 Years|72 Years|No|||December 2010|April 29, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01336153||105997|
NCT01336166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIBP-2009|The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine|||Shanghai Institute Of Biological Products|Yes|Active, not recruiting|July 2009|||July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|480|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01336166||105996|
NCT01332747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD/SM/2008-11|Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation|Clinical Study on Hyperlipidemia and Comparative Evaluation of Efficacy of a Compound Unani Formulation (Safoof e Muhazzil) and Compressed Tablet of Safoof e Muhazzil in Its Management||Jamia Hamdard University|Yes|Completed|May 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 18, 2014|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01332747||106258|
NCT01332760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H5534-32614|Effect of Tool Design on Hand Pain in Dental Practitioners|Effect of Tool Design on Hand Pain in Dental Practitioners||University of California, San Francisco|Yes|Completed|April 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01332760||106257|
NCT01363635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si199/2011|Severe Sepsis/Septic Shock on Admission to the General Surgical ICU|Severe Sepsis/Septic Shock on Admission to the General Surgical ICU||Mahidol University|No|Not yet recruiting|June 2011|July 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|19 Years|90 Years|No|Non-Probability Sample|Adult surgical patient admiitiing to the general surgical ICU|June 2011|June 2, 2011|May 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01363635||103908|
NCT01335932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7217|Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure|A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study)|GRAIL|Fred Hutchinson Cancer Research Center|Yes|Recruiting|September 2011|March 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335932||106014|
NCT01336205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00008|Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation|An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain||AstraZeneca|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|844|||Both|18 Years|84 Years|No|||October 2014|October 13, 2014|April 14, 2011|Yes|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT01336205||105993|
NCT01371864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1772|Families and Pediatric Cardiac Surgery Multidisciplinary Teams: How Well Do We Communicate|Families and Pediatric Cardiac Surgery Multidisciplinary Teams: How Well Do We Communicate?||University of North Carolina, Chapel Hill|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|23|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be selected from a tertiary care academic children's hospital        including:          -  Inpatient population within the pediatric critical care unit, neonatal critical care             unit, and the cardiac intermediate care unit.          -  Outpatient population including the pediatric cardiothoracic surgery clinic patients.          -  Hospital personnel|March 2013|March 4, 2013|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371864||103279|
NCT01372176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002547-94|Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial|Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial|EAT-ICU|Rigshospitalet, Denmark|Yes|Recruiting|June 2013|February 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372176||103255|
NCT01373528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010249-01H|Impact of Topical Sinonasal Budesonide Irrigation on Hypothalamic-Pituitary-Adrenal Axis Function|Impact of Topical Sinonasal Budesonide Irrigation on Hypothalamic-Pituitary-Adrenal (HPA) Axis Function||Ottawa Hospital Research Institute|Yes|Terminated|December 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|June 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01373528||103152|
NCT01374841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S513/110|Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors|Nonmyeloablative Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies With Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression With Cyclophosphamide Administered Before and After Transplantation.||European Institute of Oncology|No|Recruiting|August 2010|December 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2015|January 21, 2016|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01374841||103053|
NCT01384461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25503|An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)|An Open-label, Multicenter Non-interventional Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|January 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|251|||Both|18 Years|N/A|No|Probability Sample|Patients with moderate to severe rheumatoid arthritis initiated on treatment with        RoActemra/Actemra in combination with methotrexate|March 2016|March 1, 2016|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384461||102320|
NCT01375166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-070111|Coupling of Neural Activity and Retinal Blood Flow in Diabetes|||Medical University of Vienna|Yes|Recruiting|March 2013|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|24 patients with early insulin dependent diabetes and no or mild non-proliferative        retinopathy, non-smokers 24 age and sex matched healthy controls, non-smokers|August 2015|August 24, 2015|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01375166||103029|
NCT01375452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032/08|Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) of Dr.Reddy's Laboratories Ltd and Femara 2.5 mg Tablets (Reference)of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2008|May 2008|Actual|May 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|40 Years|69 Years|Accepts Healthy Volunteers|||May 2011|June 23, 2011|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375452||103008|
NCT01375712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YAK_BSFS|Efficacy Evaluation of Probiotic Product on Bowel Habits in Healthy Subjects|Evaluation of the Impact of a Fermented Milk Containing Lactobacillus Casei Strain Shirota on Stool Consistency, Stool Frequency, Constipation-related Symptoms and Quality of Life in People Who Frequently Have Hard or Lumpy Stools||Yakult Honsha Co., LTD|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|238|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375712||102989|
NCT01334528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1483|Consistency of Automated Neuropsychological Assessment Metrics (ANAM) Performance in Those With Deployment Acquired Mild Traumatic Brain Injury (TBI)|Consistency of ANAM Performance in Those With Deployment Acquired Mild TBI|ANAM|VA Eastern Colorado Health Care System|Yes|Completed|February 2011|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans with a history of        mild traumatic brain injury (mTBI) with persistent self-reported symptoms.|January 2016|January 13, 2016|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334528||106121|
NCT01335074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRHCCTS2010|Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)|Temsirolimus for the Treatment of Advanced Hepatocellular Carcinoma in Patients With Intolerance to Sorafenib||Philipps University Marburg Medical Center|No|Recruiting|April 2011|||December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||April 2011|April 12, 2011|April 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335074||106080|
NCT01335061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1821010|Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B|A Multicenter, Open-label Study To Compare On-demand Treatment To A Prophylaxis Regimen Of Nonacog-alfa (Benefix) In Subjects With Moderately Severe To Severe Hemophilia B (Fix:c</=2%)||Pfizer|Yes|Completed|September 2011|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|12 Years|65 Years|No|||May 2015|May 12, 2015|March 30, 2011|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT01335061||106081|
NCT01335373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15511|Observational Program Neo-Penotran® Forte|Observational Program Neo-Penotran® Forte||Bayer|No|Completed|October 2010|April 2015|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13024|||Female|18 Years|90 Years|No|Non-Probability Sample|Patients in primary care setting.|April 2015|April 27, 2015|January 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01335373||106057|
NCT01335386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FECN2006KLY-01|Investigation of KLYX in Patients With Constipation|Efficacy and Safety of KLYX Versus Glycerine Enema in Chinese Patients With Constipation - a Randomised, Assessor-blind Pilot Study||Ferring Pharmaceuticals|No|Completed|April 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|65 Years|No|||February 2012|February 3, 2012|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335386||106056|
NCT01334606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBC-10-SQUIR04|Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units|Evaluation of Glycemic Control and User Acceptability of the BD Ultra-Fine Nano 4 mm x 32G Pen Needle for Injection of Long-acting or Basal Insulin Doses Above 40 Units||Becton, Dickinson and Company|No|Terminated|March 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|75 Years|No|||September 2013|September 11, 2013|April 8, 2011|Yes|Yes|This study was terminated due to unanticipated recruitment difficulties.|No|April 26, 2013|https://clinicaltrials.gov/show/NCT01334606||106115|
NCT01332461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112609|Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies|Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies||GlaxoSmithKline|No|Completed|November 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5677|||Both|40 Years|N/A|No|Non-Probability Sample|Managed care enrollees (aged >40 years) having at least one IP with primary or secondary        diagnosis of COPD (ICD code 491.xx, 492.xx and 496.xx) or at least one ER visit with        primary diagnosis of COPD (index event) during the study period was the target population|June 2011|August 4, 2011|March 18, 2011||No||No|March 18, 2011|https://clinicaltrials.gov/show/NCT01332461||106280|
NCT01363388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL002_168|A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment||ChemoCentryx|Yes|Completed|August 2011|January 2016|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|May 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01363388||103927|
NCT01335945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUC10-PAN09|Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer|Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer||Galil Medical|No|Terminated|August 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|April 13, 2011|No|Yes|Low enrollment & subjects didn't survive to study end due to cancer progression.|No||https://clinicaltrials.gov/show/NCT01335945||106013|
NCT01335958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGR4980g|Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer|A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer||Genentech, Inc.||Completed|April 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335958||106012|
NCT01383590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-003|Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis|Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis||Circassia Limited|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01383590||102387|
NCT01372462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0035|Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease|A Pilot Study of the Physiologic Effects of Using the Breathe Technologies Noninvasive Open Ventilation System During Constant Work Rate Exercise in Subjects With Chronic Obstructive Pulmonary Disease||Breathe Technologies, Inc.|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|10|||Male|40 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 5, 2012|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372462||103233|
NCT01372475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R29-09-02|Hymovis™ Versus Placebo in Knee Osteoarthritis|A Multi-Centre, Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Safety And Effectiveness Of A New Viscoelastic Hydrogel (Hymovis) In The Treatment Of Knee OA With An Open-Label Extension|Hymovis|Fidia Farmaceutici s.p.a.|No|Completed|March 2011|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|800|||Both|40 Years|N/A|No|||March 2014|March 11, 2014|June 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372475||103232|
NCT01384136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|036-2011 MMC|The Telomere System in Cord Blood and in the Placenta in High Risk Pregnancies|The Telomere System in Cord Blood and in the Placenta in High Risk Pregnancies||Meir Medical Center|Yes|Active, not recruiting|June 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|High risk pregnancies, third trimester, after the delivery/|June 2011|June 27, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384136||102345|
NCT01384149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|meirslt2011|EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA|A Pioneer Study: External Selective Laser Trabeculoplasty for Treating Uncontrolled Open Angle Glaucoma|ETSG|Meir Medical Center|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|40 Years|N/A|No|||August 2014|August 11, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01384149||102344|
NCT01384474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50737|Impact of Crew Resource Management Training to Improve the Effectiveness of Surgical Safety Checklist (IDILIC)|Impact of Crew Resource Management Training to Improve the Effectiveness of Surgical Safety Checklist|IDILIC|Hospices Civils de Lyon|No|Completed|September 2011|July 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|23056|||Both|18 Years|N/A|No|Non-Probability Sample|All patients needing a surgery who are hospitalized in one of the 31 departments.|July 2013|July 17, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01384474||102319|
NCT01384695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 09-0696 Project 1|A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1|A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia - Project 1||Anandasabapathy, Sharmila, M.D.|No|Terminated|June 2009|February 2014|Actual|February 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|67|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|June 28, 2011|Yes|Yes|Low/no enrollment. No subjects were enrolled over the past year.|No||https://clinicaltrials.gov/show/NCT01384695||102302|
NCT01384708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 10-0982|Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer|Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer||Anandasabapathy, Sharmila, M.D.|Yes|Completed|August 2010|October 2013|Actual|October 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|70|||Both|18 Years|N/A|No|||March 2014|January 7, 2016|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384708||102301|
NCT01384981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGL NIV|Effects of Non-invasive Ventilation on Rehabilitation Outcome in COPD-patients|Effects of Non-invasive Ventilation on Exercise Capacity and Quality of Life in COPD-patients GOLD III/IV||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Terminated|January 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||September 2015|September 3, 2015|June 27, 2011||No|major problems in recruiting patients due to very strict inclusion criteria|No||https://clinicaltrials.gov/show/NCT01384981||102280|
NCT01384994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARLIM|Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients|||Ludwig-Maximilians - University of Munich|No|Recruiting|August 2011|August 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|111|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01384994||102279|
NCT01385007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28155|Preventing Aggression In Veterans With Dementia (PAVED) - Telephone Sub-Study With Rural Veterans|Preventing Aggression In Veterans With Dementia (PAVED) - Telephone Sub-Study With Rural Veterans|PAVED-T|Michael Debakey Veterans Affairs Medical Center|No|Not yet recruiting|August 2011|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|65 Years|N/A|No|||June 2011|June 28, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01385007||102278|
NCT01334541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-2-0129-1|A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans- Study 1|A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans- Study 1|SAFE VET|VA Eastern Colorado Health Care System|No|Active, not recruiting|September 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|600|||Both|18 Years|89 Years|No|Non-Probability Sample|Veterans who were seen in a VA Emergency Department and were identified as being at risk        for suicide.|January 2016|January 22, 2016|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334541||106120|
NCT01335360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WesternU|Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight|Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight|NAWS|Western University of Health Sciences|No|Completed|May 2003|June 2003|Actual|May 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|21|None Retained|Levels were drawn prior to dosing, and at the following time intervals: 0.5hr, 1hr, 1.5hr,      2hr, 4hr, 6hr, 8hr, 12hr. ~10cc of blood were drawn with each sample, centrifuged, and      plasma separated into 2 cryovials. Samples were then frozen at -20oC. All samples (216)      weresent to Consolidated Laboratory Services for level determination by appropriate means.      All samples have now been destroyed.|Male|18 Years|50 Years|No|Probability Sample|HIV positive patients stable on a nevirapine containing regimen for at least 3 months|April 2011|April 12, 2011|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01335360||106058|
NCT01335906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-0315-2010|Evidence-informed Choice for Women Participating in Mammography Screening|A Randomized Trial of an Evidence-informed Choice Based on Appreciation of Risks and Benefits for Women Participating in Mammography Screening||Andaluz Health Service|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|332|||Female|45 Years|69 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01335906||106016|
NCT01334892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12011.201|L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients|A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients||Pari Pharma GmbH|Yes|Terminated|December 2009|December 2014|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 11, 2011||No|Interim analysis results revealed substantial increase of patient number, with unfeasible    study prolongation.|No||https://clinicaltrials.gov/show/NCT01334892||106093|
NCT01366963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101401|Cognitive Dysfunction in Postural Tachycardia Syndrome|Origins of Cognitive Dysfunction in Postural Tachycardia Syndrome (POTS)||Vanderbilt University|No|Completed|March 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Patients having been diagnosed with postural tachycardia syndrome and age & gender matched        normal controls|June 2015|June 22, 2015|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01366963||103655|
NCT01367223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCIHSJD5|Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation|Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation||Hospital Sant Joan de Deu|No|Completed|April 2010|May 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|1 Month|14 Years|No|||September 2013|September 5, 2013|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367223||103635|
NCT01363154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7683|Prevention of Photoparoxysmal Abnormalities by Mozart K448|Prevention of Photoparoxysmal Abnormalities Through Patterned Auditory Stimulation||Medical University of South Carolina|Yes|Terminated|November 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|10|||Both|5 Years|17 Years|No|||June 2013|June 2, 2013|May 27, 2011||No|terminated|No||https://clinicaltrials.gov/show/NCT01363154||103944|
NCT01335425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3-044|The Rolandic Epilepsy/ESES/Landau-Kleffner Syndrome and Correlation With Language Impairment Study||REL|Maastricht University Medical Center|No|Completed|October 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|47|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children aged 6 to 18 years seen in tertiary referral center for epilepsy Kempenhaeghe        with a proven diagnosis of Rolandic epilepsy and without intracerebral lesions (e.g.        tumour) on structural MRI or other pathology, which may influence cognition.        In addition, children with electrical status epilepticus of sleep (ESES), ESES-like, or        Landau-Klefner syndrome might be included.|September 2015|September 22, 2015|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335425||106053|
NCT01335672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-05|Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease|Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease||London School of Hygiene and Tropical Medicine|Yes|Completed|March 2011|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2100000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of patients registered at those GPRD practices that        agreed to the linkage with the MINAP database, and whose practices are "up to standard"        according to GPRD criteria. Practices taking part in the GPRD are chosen to be        representative of all UK practices, and 98% of people in the UK are registered with a GP.        Therefore the GPRD should be a representative sample of the UK population|April 2015|April 9, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335672||106034|
NCT01335685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16006|Study of Oral IXAZOMIB in Combination With Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of IXAZOMIB (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|June 2011|March 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|164|||Both|18 Years|N/A|No|||February 2015|February 23, 2015|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335685||106033|
NCT01384162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sNN0029-002|An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis|An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump||Newron Sweden AB|Yes|Terminated|June 2009|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|June 23, 2011||No|Issues with development and supply of infusion system for delivery of IMP. Lack of favorable    benefit risk ratio in sNN0029-003 study (review of interim data).|No||https://clinicaltrials.gov/show/NCT01384162||102343|
NCT01384175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPCAB-EA|Epidural Anesthesia and Postoperative Analgesia With Ropivacaine and Fentanyl|Epidural Anesthesia and Postoperative Analgesia With Ropivacaine and Fentanyl in Off-pump Coronary Artery Bypass Grafting||Northern State Medical University|No|Completed|January 2008|September 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01384175||102342|
NCT01384487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nidek RS3000-1|Nidek RS3000 Comparative Study|Comparative Study of the Nidek Optical Coherence Tomography RS-3000 and the RTVue OCT Predicate Device for the Measurements of Retinal and RNFL Thickness, Optic Disc Analysis, Pachymetry, Anterior Chamber Imaging and SLO Imaging.||Nidek Co. LTD.|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|89|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|February 2012|February 17, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384487||102318|
NCT01383850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heliox|NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS)|||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Completed|February 2008|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|28 Weeks|32 Weeks|No|||June 2011|June 27, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01383850||102367|
NCT01383863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-52014-187|A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer|A Prospective Observational Study Cohort to Assess the Rate of Castration Resistance, Disease Progression and Overall Survival Over a 3-year Period Post-androgen Deprivation Therapy Induction in Patients With Advanced Prostate Cancer Who Have Previously Participated in the Triptocare Study (Http://Clinicaltrials.Gov/ct2/Show/Study/NCT01020448)|TRIPTOCARE LT|Ipsen|No|Completed|October 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Male|18 Years|N/A|No|Non-Probability Sample|Patients with previously diagnosed advanced prostate cancer, and who have participated in        the Triptocare study and who have given written informed consent to participate in the        study. They have therefore been treated with triptorelin (22.5 mg, intamuscular) as an ADT        induction.|July 2014|July 29, 2014|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383863||102366|
NCT01384747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2011-03|Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)|A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease||CardioVascular Research Foundation, Korea|Yes|Recruiting|July 2011|May 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|354|||Both|19 Years|84 Years|No|||November 2015|November 16, 2015|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01384747||102298|
NCT01384721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRM-PRORECAD|Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease|Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease - CTCA-PRORECAD|PRORECAD|Azienda Ospedaliero-Universitaria di Parma|No|Recruiting|September 2010|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to CT Coronary angiography for suspected obstructive Coronary Artery        Disease based on high cardiovascular risk and/or symptoms and/or test abnormalities|December 2015|December 28, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384721||102300|
NCT01381042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2009-307|The Incidence and Factors of Brown Adipose Tissue in Chinese|Retrospective Study on the Incidence and Factors of Brown Adipose Tissue in Adult Chinese||Huashan Hospital|Yes|Active, not recruiting|February 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who underwent scanning for either cancer surveillance (CS) or medical check-up        (MC) from July 2006 to June 2010 in Huashan Hospital.|December 2009|June 23, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381042||102583|
NCT01335100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX-GPS|Does Botulinum Toxin Injections Improve Outdoor Activity in Children With Cerebral Palsy?- a Pilot Study|||Shaare Zedek Medical Center||Active, not recruiting|March 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|10|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|ambulatory children with CP following BTX injection to the lower limbs|May 2011|May 1, 2011|June 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01335100||106078|
NCT01335113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19891|A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity|A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity||Stanford University|No|Recruiting|October 2010|October 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Premature newborns who are screened for retinopathy of prematurity at Stanford|April 2011|April 12, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01335113||106077|
NCT01334801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-006757|Biomarkers in Aortic Stenosis - B.A.S.S.|Biomarkers in Aortic Stenosis, Hypertrophic Cardiomyopathy, Mitral Regurgitation, Aortic Regurgitation, Prosthetic Heart Valve Dysfunction, and Tricuspid Regurgitation From Pacemaker Leads Study|BASS|Mayo Clinic|No|Recruiting|July 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||11|Anticipated|400|Samples Without DNA|whole blood|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiology, referred for clinically-indicated echocardiograms|March 2015|March 24, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334801|2 Years|106100|
NCT01334814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1324-02|Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor|Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor||Mayo Clinic|No|Completed|January 2002|January 2010|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|8|||Both|50 Years|80 Years|No|||January 2012|January 4, 2012|March 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01334814||106099|
NCT01335087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/02763|Continuous Positive Airway Pressure (CPAP) in Patients With Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA)|Impact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome. Effect of Intervention With Continuous Positive Airway Pressure (CPAP). A Prospective Randomized Study. ISAACC Study|ISAACC|Sociedad Española de Neumología y Cirugía Torácica|Yes|Recruiting|April 2011|April 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1864|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01335087||106079|
NCT01366664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018607|A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin|A Randomized, Double-blind, Placebo-Controlled, Crossover Study Assessing the Pharmacodynamic Effects of Dapoxetine Concomitantly Administered in Subjects Taking Terazosin||Janssen Research & Development, LLC|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|N/A|No|||October 2014|October 3, 2014|June 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01366664||103677|
NCT01334905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-092|A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers|A Phase 1, Open-Label, Single Oral Dose Study to Assess the Safety, Pharmacokinetics and Effect of Food on the Pharmacokinetics of Mirabegron (YM178) in Healthy Volunteers||Astellas Pharma Inc|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||October 2011|June 10, 2013|April 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01334905||106092|
NCT01334866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D03782|Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery|Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery|MICS|Medtronic Cardiovascular|No|Completed|December 2009|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|80 Years|No|||November 2013|November 3, 2013|April 5, 2011||No||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01334866||106095|
NCT01335152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA106154|Online Stress Management and Coping Skills Training for Women With Breast Cancer|Coping With Breast Cancer and Treatment: An E-Learning Course for Skills and Strategies||Talaria, Inc|Yes|Completed|April 2010|August 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||May 2014|May 5, 2014|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335152||106074|
NCT01335698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-451|Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients|A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in Human Immunodeficiency Virus (HIV) Infected, Antiretroviral, Naive and Experienced Pediatric Subjects From 3 Months to Less Than 11 Years.(Pediatric Atazanavir International Clinical Evaluation: the PRINCE II Study)|PRINCE2|Bristol-Myers Squibb|Yes|Active, not recruiting|May 2011|July 2018|Anticipated|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|3 Months|11 Years|No|||October 2015|January 8, 2016|April 13, 2011|Yes|Yes||No|October 26, 2015|https://clinicaltrials.gov/show/NCT01335698||106032|
NCT01335711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVC-202|CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects|A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects||ChronTech Pharma AB|Yes|Recruiting|April 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|65 Years|No|||October 2011|October 11, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335711||106031|
NCT01335971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL105569|Broccoli Sprout Extracts Trial|Enhancing Nrf2 by Sulforaphane Treatment in COPD|BEST|Johns Hopkins University|Yes|Active, not recruiting|September 2010|June 2014|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|40 Years|N/A|No|||March 2014|March 19, 2014|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335971||106011|
NCT01383889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPREG 2011|Acute Maternal and Fetal Effects of Exercise in Pregnancy|Acute Effects on the Mother and Fetus in Two Modalities of Exercise in Pregnancy: a Randomized Controlled Trial.|EXPREG|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|December 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|120|||Female|20 Years|49 Years|Accepts Healthy Volunteers|||March 2013|March 4, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383889||102364|
NCT01383902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR03/2008|Chocolate Meal Study|The Effect of Meal Type on the Rate of Gastric Emptying||Institute of Food Research|Yes|Completed|May 2009|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|4|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383902||102363|
NCT01384188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5334POE010|A Study to Investigate the Effects of Food and Morning Versus Evening on Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women|A Two-part, Crossover Study to Investigate the Effects of Morning Versus Evening Dosing and Food Interaction on the Pharmacodynamics and Pharmacokinetics of Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women||Ono Pharmaceutical Co. Ltd|No|Completed|June 2011|December 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||July 2012|January 17, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384188||102341|
NCT01384201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/TCR/001/2007/CLE|Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia|Evaluation of the Use of Confocal Endomicroscopy in Conjunction With Chromoendoscopy in the Detection of Gastric Preneoplastic Neoplasia and Neoplasia in a High-Risk Population (R-CE-GCEP)|R-CE-GCEP|National University Hospital, Singapore|No|Completed|August 2007|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|100|None Retained|Biopsies from the stomach|Both|50 Years|N/A|No|Non-Probability Sample|Chinese, above 50 years old, at high risk of gastric cancer|June 2011|June 27, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384201||102340|
NCT01384734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI438-011|HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections|A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose||Bristol-Myers Squibb|Yes|Active, not recruiting|July 2011|July 2018|Anticipated|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|250|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384734||102299|
NCT01384760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Resp/Ng/2011|Lifestyle Modification Program to Treat Obstructive Sleep Apnea Patients|A Randomized Controlled Study to Examine the Effect of Lifestyle Modification Program in Obstructive Sleep Apnea Patients|OSA|Chinese University of Hong Kong|No|Completed|January 2011|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|185|||Both|30 Years|80 Years|No|||February 2015|February 3, 2015|June 10, 2011||No||No|August 4, 2014|https://clinicaltrials.gov/show/NCT01384760||102297|
NCT01385020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105057MC|Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects|Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects||National Taiwan University Hospital|No|Completed|July 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2011|October 13, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385020||102277|
NCT01385033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3328-002|[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)|A Clinical Trial to Characterize the Performance of [18F]MK-3328 in Subjects With Alzheimer's Disease or Mild Cognitive Impairment, and Healthy Young, and Healthy Elderly Subjects||Merck Sharp & Dohme Corp.|No|Terminated|August 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|June 8, 2011|No|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01385033||102276|
NCT01381055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCPX2011|Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis|Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis||Hospital Universitário Professor Edgard Santos|Yes|Active, not recruiting|January 2011|||January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|65 Years|No|||May 2013|December 26, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381055||102582|
NCT01334320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010018|Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma|Survival Benefit of Elective Neck Dissection for Patients With T1,2N0M0 Oral Squamous Cell Carcinoma—A Prospective Multicenter Randomized Controlled Study||Sun Yat-sen University|Yes|Recruiting|April 2011|December 2021|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|448|||Both|20 Years|70 Years|No|||April 2015|April 9, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01334320||106137|
NCT01365611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2006-04|Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects|Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Multiple Doses of Fluticasone Propionate in Healthy Subjects||Luitpold Pharmaceuticals|No|Completed|February 2007|March 2008|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|June 1, 2011|Yes|Yes||No|August 9, 2012|https://clinicaltrials.gov/show/NCT01365611||103758|
NCT01365624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2007-02|Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects|A Phase 1 Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects||Luitpold Pharmaceuticals|No|Completed|February 2008|July 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 3, 2013|June 1, 2011|Yes|Yes||No|August 2, 2012|https://clinicaltrials.gov/show/NCT01365624||103757|
NCT01365637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291002|The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Parallel Group Multiple Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of PF-05089771 In Healthy Subjects.||Pfizer|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01365637||103756|
NCT01335399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-006|Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma|A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma|ELOQUENT - 1|Bristol-Myers Squibb|Yes|Active, not recruiting|May 2011|July 2020|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|750|||Both|18 Years|N/A|No|||December 2015|March 11, 2016|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335399||106055|
NCT01335646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO16000|Surgery Versus Standardized Non-operative Care for the Treatment of Lumbar Disc Herniations: A Canadian Trial|||The London Spine Centre||Recruiting|February 2010|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||March 2016|March 2, 2016|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335646||106036|
NCT01334372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1058|Intensive Outpatient Treatment for Suicidal Veterans|Intensive Outpatient Treatment for Suicidal Veterans: A Randomized Clinical Trial and Feasibility Investigation|CAMS|VA Eastern Colorado Health Care System|No|Completed|February 2007|||December 2009|Actual|N/A|Interventional|N/A|2||Actual|48|||Both|18 Years|89 Years|No|||April 2011|April 12, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334372||106133|
NCT01334645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0092|Copeptin and Acute Coronary Syndrome Without ST-segment Elevation|Diagnostic Value of Copeptin Assay for Acute Coronary Syndrome Without ST-segment Elevation||University Hospital, Clermont-Ferrand||Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|134|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334645||106112|
NCT01335165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT30-PNH-002|Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)|A Phase 1, Single Ascending Dose Study of the Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)||Alexion Pharmaceuticals|No|Terminated|April 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||May 2014|May 21, 2014|April 12, 2011|No|Yes|Inability to reach enrollment as planned|No||https://clinicaltrials.gov/show/NCT01335165||106073|
NCT01335178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMRI-072086_YCSA|A Program to Protect Young Children From Tobacco Smoke Exposure|A Program to Protect Young Children From Tobacco Smoke Exposure||Tel Aviv University|No|Completed|January 2013|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Both|N/A|8 Years|Accepts Healthy Volunteers|||November 2015|December 8, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335178||106072|
NCT01335438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKRcementless|Total Knee Arthroplasty Comparing Cementless to Cemented Fixation|Total Knee Arthroplasty Comparing Cementless to Cemented Fixation, A Prospective Comparison of Long Term Outcomes Using and Identical Design of Prosthesis||Ewha Womans University|No|Completed|January 1997|March 2011|Actual|February 1998|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|30 Years|90 Years|No|||October 2011|October 4, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01335438||106052|
NCT01335464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.32|Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients|A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Boehringer Ingelheim||Completed|April 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|515|||Both|40 Years|N/A|No|||January 2015|January 29, 2015|April 13, 2011||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01335464||106050|
NCT01335477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.34|Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II|A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Boehringer Ingelheim||Completed|May 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|551|||Both|40 Years|N/A|No|||January 2015|January 29, 2015|April 13, 2011||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01335477||106049|
NCT01335724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|862-P-201|Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain|A Randomized, Double-blind, Placebo-controlled, Multi-center Parallel Group Phase IV Study to Evaluate the Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain||Novartis|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|April 13, 2011||No||No|May 11, 2012|https://clinicaltrials.gov/show/NCT01335724||106030|
NCT01335984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmartCare-HTN|Effects of Telemonitoring and Telemedicine Service for Hypertensive Care|A Multi-center, Randomized, Parallel, Interventional, Open Label Trial to Compare the Blood Pressure-lowering Effect of Conventional Treatment and Smart Care Service in Hypertensive Patients Receiving Any Conventional Treatment|Smart-HTN|LG Electronics Inc.|Yes|Completed|January 2011|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|440|||Both|20 Years|70 Years|No|||May 2015|May 12, 2015|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01335984||106010|
NCT01383642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00035747-70|Physiology of Vestibular Dysfunction and Clinical Implications|||Johns Hopkins University||Active, not recruiting|July 2010|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|70 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|community-dwelling adults age >70|March 2015|March 30, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01383642||102383|
NCT01383915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-123|Clinical Risk State for Bipolar Disorder in Adolescents|Characterizing the Clinical Risk State for Bipolar Disorder in Adolescents||Northwell Health|No|Recruiting|September 2009|May 2019|Anticipated|May 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|112|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Inpatients consecutively admitted to the adolescent inpatient unit of the Zucker Hillside        Hospital, NY|February 2016|February 16, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383915||102362|
NCT01383928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16008|Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of IXAZOMIB (MLN9708), Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment||Millennium Pharmaceuticals, Inc.|No|Completed|October 2011|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|June 27, 2011|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01383928||102361|
NCT01384500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098-2011|The Ornge Comparison of Tracheal Occlusion Pressures to Ensure Safety Trial|The Ornge Comparison of Tracheal Occlusion Pressures to Ensure Safety (OCTOPUS) Trial|OCTOPUS|Ornge Transport Medicine|Yes|Recruiting|July 2011|December 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|N/A|No|||July 2011|July 15, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01384500||102317|
NCT01384513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.247|A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies|A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies||Thomas Jefferson University|Yes|Recruiting|August 2011|July 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384513||102316|
NCT01381120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC-2010-03|Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms|Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms (LUTS) Post Ureteroscopy for Stone Management||Barrie Urology Associates|Yes|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|N/A|N/A|No|||August 2012|August 21, 2012|September 2, 2010|Yes|Yes||No|February 9, 2012|https://clinicaltrials.gov/show/NCT01381120||102577|
NCT01381432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112314|Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)|Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)||GlaxoSmithKline|No|Completed|December 2004|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|39|||Both|N/A|N/A|No|Probability Sample|The following subjects to whom azathioprine tablet is administered for "the suppression of        lung transplant rejection";          1. Subjects on whom lung transplantation is performed after approval and to whom             azathioprine tablet is administered from transplant surgery to May 2010.          2. Subjects on whom lung transplantation is performed before approval and who have             already completed the drug administeration as well as during the drug administration             at the time of the contract terminiation.|May 2013|May 9, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381432||102553|
NCT01385046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSU-123|Project Fit:a School- and Community-based Obesity Intervention|Project Fit:a School- and Community-based Intervention to Address Physical Activity and Healthy Eating Among Low-income Elementary School Children|FIT|Michigan State University|Yes|Completed|August 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|403|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01385046||102275|
NCT01381068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090780|Quantitative End Tidal CO2 Monitoring in the Delivery Room (DR)|Quantitative End Tidal CO2 Monitoring in the Delivery Room: Can we Prevent Hypo/Hypercapnia Upon Admission to the NICU?||University of California, San Diego|No|Active, not recruiting|October 2009|September 2011|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|N/A|15 Minutes|No|||June 2011|July 8, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01381068||102581|
NCT01381081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP2010|Platelet-rich Plasma Intra-articular Knee Injections for Knee Osteoarthritis|A Prospective, Randomized, Double-blinded, Clinical Trial, Comparing Platelet-rich Plasma Intra-articular Knee Injections Versus Corticosteroid Intra-articular Knee Injections for Knee Osteoarthritis||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|July 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|40 Years|80 Years|No|||February 2015|February 23, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381081||102580|
NCT01334554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100713|Study of Sildenafil Citrate on Insulin Resistance in African American|Effect of Sildenafil Citrate on Insulin Resistance and Endothelial Function in Obese African American Women||Vanderbilt University|Yes|Completed|April 2011|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|46|||Female|18 Years|60 Years|No|||May 2015|December 9, 2015|April 11, 2011|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01334554||106119|
NCT01334567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0141|Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan|A Rollover Protocol to Provide Subjects From Taiwan Continued Access to Tenofovir Disoproxil Fumarate After Completing Study GS-US-174-0108||Gilead Sciences|No|Completed|August 2010|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|69 Years|No|||February 2014|February 28, 2014|November 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01334567||106118|
NCT01333644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV FMD AGING|The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk|The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk||University of California, San Francisco|Yes|Completed|April 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|270|Samples With DNA|Serum, plasma, PBMCs|Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Treated and untreated HIV-infected individuals and HIV-uninfected individuals.|May 2015|May 29, 2015|March 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01333644||106189|
NCT01365858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2009/25|Virtual Action Planning in Stroke: a Control Rehabilitation Study|Effectiveness of Virtual Reality-based Cognitive Training in Daily Living in Stroke Patients Using Virtual Action Planning Supermarket (VAP-S)|VAPS REHAB|University Hospital, Bordeaux|Yes|Completed|May 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|29|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01365858||103739|
NCT01366105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-293|VAC NPWT KCI Dressing Study|Use of Negative Pressure Wound Therapy for At Risk Surgical Closures||Georgetown University|No|Withdrawn|August 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 1, 2013|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01366105||103720|
NCT01366391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0038.0 208.00-09|Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome|Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome||Biocinese|No|Recruiting|January 2011|October 2011|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|40 Years|No|||June 2011|June 3, 2011|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01366391||103698|
NCT01334619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSTMZ.2|Ropivacaine Volume for Ultrasound-guided Retrograde Infraclavicular Brachial Plexus Block|Ropivacaine Volume for Ultrasound-guided Retrograde Infraclavicular Brachial Plexus Block||Beijing Jishuitan Hospital|Yes|Completed|March 2010|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|30|||Both|18 Years|70 Years|No|||February 2010|April 12, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01334619||106114|
NCT01334879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4981S|High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy|High Dose (2.0mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy||The New York Eye Cancer Center|Yes|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|21 Years|N/A|No|||September 2014|September 30, 2014|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01334879||106094|
NCT01335217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000894|Trigeminal Nerve Stimulation for Post Traumatic Stress Disorder (PTSD) and Depression|Trigeminal Nerve Stimulation for PTSD and Depression||University of California, Los Angeles|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||February 2013|February 4, 2013|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01335217||106069|
NCT01335191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THYMON-11001|Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)|Clinical Study of TUTI-16 in Asymptomatic, HIV-1 Infected Subjects Effectively Controlled by Antiretroviral Therapy and the Effects on Viral Load During a Structured Treatment Interruption||Thymon, LLC|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|50 Years|No|||January 2013|January 14, 2013|April 12, 2011|Yes|Yes||No|December 7, 2012|https://clinicaltrials.gov/show/NCT01335191||106071|
NCT01334918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3606-CL-2001|A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)|A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)||Astellas Pharma Inc|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|124|||Both|45 Years|N/A|No|||July 2013|July 11, 2013|April 12, 2011|No|Yes||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01334918||106091|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01335451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3030C00004|Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Oral Administration of Single and Multiple Ascending Doses in Healthy Young and Elderly J||AstraZeneca|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|April 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01335451||106051|
NCT01336010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA015999-07|Treatment of Recently Acquired Hepatitis C Virus Infection|Treatment of Recently Acquired Hepatitis C Virus Infection|ATAHC-II|Kirby Institute|Yes|Completed|August 2011|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|82|||Both|16 Years|N/A|No|||August 2015|August 31, 2015|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336010||106008|
NCT01336023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-3697|Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes|A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension|DUAL™ I|Novo Nordisk A/S|No|Completed|May 2011|November 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1663|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336023||106007|
NCT01332019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105MS302|Long-Term Safety and Efficacy Study of Peginterferon Beta-1a|A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis|ATTAIN|Biogen|Yes|Completed|April 2011|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1077|||Both|18 Years|70 Years|No|||October 2015|October 23, 2015|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332019||106314|
NCT01332032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCM001|Promoting Breast Cancer Screening in Non-adherent Women|Promoting Breast Cancer Screening in Non-adherent Women||University of Massachusetts, Worcester|No|Completed|July 2009|May 2015|Actual|October 2014|Actual|Phase 4|Observational|Time Perspective: Prospective||3|Actual|36348|||Female|40 Years|84 Years|No|Non-Probability Sample|Women aged 40 to 84 who have life expectancy of five years, have at least one breast, and        who have been cared for by Fallon Community Health Plan and currently cared for by Reliant        Medical Group (formerly called Fallon Clinic) PCP. Interventions directed at women who are        at least 18 months from prior mammogram. Since July 2012, patients with a current Reliant        Medical Group PCP who have been enrolled in Blue Cross/Bluse Shield, Harvard Pilgrim or        Tufts health plans for 18 months may be eligible for enrollment.|May 2015|May 28, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332032||106313|
NCT01384773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF0594|Progressive Keratoconus or Ectasia Treatment Plan|Increasing CrossLinking of Corneal Collagen in Eyes With Progressive Keratoconus or Ectasia||Columbia University|No|Available|September 2010|April 2012|Anticipated|April 2012|Anticipated|N/A|Expanded Access|N/A|||||||Both|16 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 4, 2015|June 27, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01384773||102296|
NCT01384214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MedAff-BTX-0716|Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia|Pilot Study of the Effect of Botulinum Toxin Type A Treatment on Swallowing in Patients With Cervical Dystonia||Allergan|No|Completed|October 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|75 Years|No|||June 2011|June 28, 2011|June 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384214||102339|
NCT01384227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO # 08-1190|Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study|Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study||Anandasabapathy, Sharmila, M.D.|Yes|Completed|February 2009|||July 2011|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|June 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01384227||102338|
NCT01381692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02650|Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma|A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II)||National Cancer Institute (NCI)||Active, not recruiting|July 2011|||June 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||November 2015|December 18, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381692||102533|
NCT01385059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10151|Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer|A Randomized, Phase II Study Assessing Axitinib as Pre-Surgical Therapy in Patients With High Risk Prostate Cancer||City of Hope Medical Center|Yes|Active, not recruiting|October 2011|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|No|||December 2015|December 9, 2015|June 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385059||102274|
NCT01381094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKB-6548-CI-0005|42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia|Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4||Akebia Therapeutics|No|Completed|June 2011|March 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|93|||Both|18 Years|79 Years|No|||October 2012|October 3, 2012|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381094||102579|
NCT01381107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK33BUP-201|ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ALKS 33-BUP Administration in Subjects With Major Depressive Disorder (MDD)||Alkermes, Inc.|Yes|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|32|||Both|18 Years|65 Years|No|||August 2011|August 18, 2011|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381107||102578|
NCT01334827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11800|A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users|Rational Development of Combination Microbicide Therapies: A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users (Project MIST)|Project MIST|The Miriam Hospital|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|N/A||1|Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Individuals residing in the greater Providence RI metropolitan area|September 2012|September 27, 2012|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334827||106098|
NCT01334840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BW-09|Mechanism of Action of Vichy Catalan Water|Mechanism of Action of Vichy Catalan Water||National Research Council, Spain||Completed|November 2009|July 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|21|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2011|July 29, 2014|April 12, 2011||||No||https://clinicaltrials.gov/show/NCT01334840||106097|
NCT01333917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1524|Curcumin Biomarkers|Curcumin Chemoprevention of Colorectal Neoplasia||University of North Carolina, Chapel Hill|No|Completed|November 2010|January 2013|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|40 Years|80 Years|No|||January 2013|February 6, 2013|April 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01333917||106168|
NCT01333904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-0004|Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118|A Four-Part Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of PUR118 and Placebo in Normal Healthy Volunteers and Subjects With COPD||Pulmatrix Inc.|No|Completed|February 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01333904||106169|
NCT01334138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/233|Effect of Dietary Sodium Intake on Blood Pressure in Hypertensive Patients in Primary Care|Effect of Dietary Sodium Intake on Blood Pressure in Hypertensive Patients in Primary Care||University Ghent|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|50 Years|N/A|No|||April 2012|April 20, 2012|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334138||106151|
NCT01334632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-74-10|Incidence of Brachial Plexus Injury After Rotator Cuff Repair With Continuous Interscalene Block|Comparison of Incidence of Brachial Plexus Injury After Rotator Cuff Repair With Continuous Interscalene Block Versus Patient Controlled Analgesia Morphine||Centre Hospitalier Universitaire Vaudois|No|Withdrawn|April 2011|November 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|0|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||April 2011|March 19, 2014|April 11, 2011||No|Change of practice in the department (Nerve stimulation technique abandoned)|No||https://clinicaltrials.gov/show/NCT01334632||106113|
NCT01334957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-016|Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen|A Multi-Center, Open-Label, Surgical Surveillance Trial To Evaluate The Safety And Efficacy Of A Shortened Infusion Time of Intravenous Ibuprofen||Cumberland Pharmaceuticals|Yes|Completed|June 2011|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|April 12, 2011|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01334957||106088|
NCT01334983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007108|Rapid Easy Strength Training (REST) to Improve Function in Late Stage Cancer|Phase II Randomized Controlled Trial of Rapid and Easy Strength Training to Preserve Function in Late Stage Cancer|REST|Mayo Clinic|No|Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334983||106087|
NCT01334931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 4454/10|Use of Large Field of View During Image Acquisition for Coronary Angiography|Preferential Use of Large Field of View During Image Acquisition for Coronary Angiography With Flat Detector Technology: a Simple Step to Reduce Radiation Exposure|XRay Reduction|Instituto de Cardiologia do Rio Grande do Sul|No|Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|21 Years|N/A|No|||May 2012|May 7, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01334931||106090|
NCT01335204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSC 101637|Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer|Phase Ib/IIa Study of Cabazitaxel Plus Bavituximab for Patients With Castration-resistant Prostate Cancer Previously Treated With Chemotherapy||Medical University of South Carolina|Yes|Terminated|June 2011|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||March 2013|March 20, 2013|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335204||106070|
NCT01336036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03HN|Causes and Outcomes of Community Acquired Pneumonia|Etiology, Clinical Manifestations and Risk Factors for Community-acquired Pneumonia in Patients Admitted to Hospital|CAP|Oxford University Clinical Research Unit, Vietnam|No|Recruiting|February 2011|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Sputum Blood Urine Nasal and Throat swab|Both|18 Years|N/A|No|Non-Probability Sample|300 patients with community acquired pneumonia who meet the below inclusion/ exclusion        criteria will be recruited at two hospitals in Vietnam.|November 2013|November 22, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01336036||106006|
NCT01332292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102942|Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients|A Randomized, Double-blind, Placebo-controlled, Two-way Crossover 14-day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled Fluticasone Furoate 100ug (Micrograms) in Children Aged 5-11 Years With Persistent Asthma||GlaxoSmithKline|No|Completed|May 2010|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|27|||Both|5 Years|11 Years|No|||May 2014|May 29, 2014|October 28, 2010|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01332292||106293|
NCT01332578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7591227|A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies|A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies||GlaxoSmithKline|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|25|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|May 28, 2015|April 7, 2011||No||No|July 18, 2013|https://clinicaltrials.gov/show/NCT01332578||106271|
NCT01384526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|025950|Investigating the Impact of Tamoxifen Therapy on Ovarian Aging|Investigating the Impact of Tamoxifen Therapy on Ovarian Aging||University of California, San Francisco|Yes|Completed|June 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|266|Samples With DNA|Serum AMH, FSH, estradiol, and Inhibin B will be measured. Blood will be collected and      processed by the UCSF Center for Reproductive Health. Serum samples will be stored at -80oC      in a designated freezer with an alarm system. Biomarker assessments will be performed by      Quest Laboratories under standard quality control.|Female|25 Years|N/A|No|Non-Probability Sample|The UCSF Cancer Registry will be screened for female patients who were treated at the UCSF        Breast Care Center between 1985 and 2010 and who meet the eligibility criteria listed        below.|March 2015|March 6, 2015|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01384526||102315|
NCT01384539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0521|Vitamin D and Arterial Function in Patients With Chronic Kidney Disease|Vitamin D and Arterial Function in Patients With Chronic Kidney Disease||University of Colorado, Denver|Yes|Active, not recruiting|July 2011|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|June 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384539||102314|
NCT01384799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUDC-101-103|Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer|A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer||Curis, Inc.|No|Completed|November 2011|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|June 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01384799||102294|
NCT01385085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|922-2010-IDF-CTIL|Impact of Work Environment Absent of Natural Light on Vitamin D Levels|Impact of Work Environment Absent of Natural Light on Vitamin D Levels||Medical Corps, Israel Defense Force|No|Not yet recruiting|November 2011|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Anticipated|300|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|People employed in three types of natural sunlight exposure.|June 2011|June 28, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385085||102272|
NCT01385072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6188|Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies|Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies||Rabin Medical Center|No|Recruiting|August 2011|April 2015|Anticipated|August 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||June 2011|November 14, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385072||102273|
NCT01381406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111266|Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations|Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations||GlaxoSmithKline|No|Completed|July 2008|September 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3333|||Both|40 Years|N/A||Non-Probability Sample|Data for managed-care enrollees age 40 and older with a diagnosis of COPD and an index        event of at least one pharmacy claim for TIO during the study period (January 1, 2003        through April 30, 2008) were identified. Subjects were required to have ≥1 exacerbation in        the pre-index period (defined as a COPD-related emergency room visit or hospitalization),        ≥1 prescription claim for ipratropium or ipratropium/albuterol combination in the        pre-index period, ≥2 prescriptions for TIO (including the index prescription) during the        post-index period, no prescription for FSC during the pre-index period, and no        exacerbation or hospital/emergency room visit within 30 days after the index date.        ICD-9-CM code 490.xx, bronchitis not specified as chronic or acute, was included in an        attempt to enhance the validity of the analysis by capturing patients with chronic        bronchitis whose condition was coded incorrectly.|June 2011|September 15, 2011|June 23, 2011||No||No|September 15, 2011|https://clinicaltrials.gov/show/NCT01381406||102555|
NCT01381666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-701|Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)|||Merck Sharp & Dohme Corp.||Terminated|January 2003|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|22|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381666||102535|
NCT01381679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-205|Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)|Austrian Cholesterol Screening And Treatment II (ACT II)|ACT II|Merck Sharp & Dohme Corp.|No|Completed|May 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1682|||Both|N/A|N/A|No|Non-Probability Sample|Participants without adequate LDL-cholesterol reduction with a statin, representative        cross-section across all regions/parts of Austria (federal provinces, urban/rural areas,        office-based internists/general practitioners)|October 2015|October 12, 2015|June 23, 2011|No|Yes||No|November 23, 2011|https://clinicaltrials.gov/show/NCT01381679||102534|
NCT01333930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1251ao10ct|Placebo Controlled Study for Characterisation of Immunological Effects and Safety of Active O2|Characterisation of Immunological Effects and Safety of Active O2 After Strenuous Exercise in Comparison With Placebo: a Double-blind, Placebo Controlled, Balanced Cross-over Study in Healthy Subjects of Both Genders With Good Fitness Level||Adelholzener Alpenquellen GmbH|No|Completed|January 2012|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 11, 2012|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333930||106167|
NCT01333696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNTG 11-01|Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck|Phase II Study of Pemetrexed Monotherapy in Patients With Platinum-resistant Squamous Cell Carcinoma of Head and Neck||Fudan University|No|Recruiting|April 2011|June 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|75 Years|No|||March 2013|March 2, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01333696||106185|
NCT01334151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIAject 039J|Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes|A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration||Biodel|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|13|||Both|19 Years|70 Years|No|||July 2013|July 24, 2013|April 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01334151||106150|
NCT01334385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1080|Operation Enduring Freedom/Operation Iraqi Freedom Veterans' Experiences of Habituation to Pain, Perceived Burdensomeness, and Failed Belongingness|OEF/OIF Veterans' Experiences of Habituation to Painful Stimuli, Perceived Burdensomeness and Failed Belongingness||VA Eastern Colorado Health Care System|No|Completed|March 2007|November 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|35|||Both|18 Years|55 Years|No|Non-Probability Sample|Part I: Subjects were recruited from the population of over 250 OEF/OIF veterans with        active cases in MHS within the Eastern Colorado Health Care System (ECHCS).        Part II: Subjects were recruited from the population of over 250 OEF/OIF female veterans        being cared for within the ECHCS.|April 2011|April 12, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334385||106132|
NCT01334424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-IRB-98-2998B|Oxidative Stress in Robot-assisted Laparoscopic Radical Prostatectomy|Oxidative Stress in Robot-assisted Laparoscopic Radical Prostatectomy||Chang Gung Memorial Hospital|No|Recruiting|December 2009|April 2011|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|4||Anticipated|40|||Male|20 Years|80 Years|No|||April 2011|April 12, 2011|February 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01334424||106129|
NCT01335516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999908 CS04|Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices|Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices||Ferring Pharmaceuticals|No|Completed|November 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|70 Years|No|Non-Probability Sample|60 estimated eligible participants with an age of 18-70 years, suspected or diagnosed with        bleeding oesophageal varices. Patients have cirrhosis (from any cause, any Child class)        and upper gastrointestinal haemorrhage|October 2012|October 5, 2012|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01335516||106046|
NCT01335269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300.2|A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer|An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies||Boehringer Ingelheim||Completed|July 2011|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 7, 2011||||No||https://clinicaltrials.gov/show/NCT01335269||106065|
NCT01335490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3520|Intervening to Improve Infant Health in Ghana|Intervening to Improve Birth Weight and Infant Respiratory Health in Rural Ghana||Columbia University|Yes|Active, not recruiting|August 2013|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1415|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335490||106048|
NCT01335737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5948/6956R|Exercise and Inflammation|Exercise and Inflammation: Autonomic, Affective & Cellular Mechanisms||New York State Psychiatric Institute|Yes|Completed|January 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|241|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2014|May 1, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01335737||106029|
NCT01332045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-124|Continuous Saphenous Nerve Block for Total Knee Arthroplasty|Continuous Saphenous Nerve Block (Adductor Channel) and Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty||Frederiksberg University Hospital|Yes|Completed|April 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|75 Years|No|||January 2012|January 18, 2012|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332045||106312|
NCT01332305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111462|Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome|XP081|XenoPort, Inc.|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|217|||Both|18 Years|N/A|No|||May 2011|July 15, 2013|April 7, 2011|Yes|Yes||No|April 28, 2011|https://clinicaltrials.gov/show/NCT01332305||106292|
NCT01384552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8573 B|Do Weight Status and the Level of Dietary Restraint Moderate the Relationship Between Package Unit Size and Food Intake?|Do Weight Status and the Level of Dietary Restraint Moderate the Relationship Between Package Unit Size and Food Intake?||University of Tennessee|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|8||Actual|64|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|June 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01384552||102313|
NCT01384786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JCEM070948|The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter|The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter||Copenhagen University Hospital at Herlev|Yes|Completed|October 2004|July 2005|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4474|||Both|18 Years|N/A|No|Probability Sample|Radioiodine treated patients|June 2011|June 28, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384786||102295|
NCT01385111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-EUSEBUS|Combined Application of EBUS and EUS in Lung Cancer|Combined Application of EBUS-TBNA and EUS-B-FNA in Mediastinal Staging of Lung Cancer; EBUS-TBNA Centered Procedure vs. EUS-B-FNA Centered Procedure, a Randomized Study.||National Cancer Center, Korea|Yes|Completed|June 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|162|||Both|18 Years|N/A|No|||June 2011|October 17, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01385111||102270|
NCT01385098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0311-0034|Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients|Preoperative Vitamin D Status and Efficacy of Therapeutic Vitamin D Supplementation Postoperatively in Bariatric Surgery Patients||The Methodist Hospital System|No|Completed|July 2011|September 2015|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|September 24, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385098||102271|
NCT01381419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111321|First Time in Human Study (FTIH) With Positron Emission Tomography (PET)|A Single-blind, Randomised, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1144814 in Healthy Male and Female Subjects and an Open-label Positron Emission Tomography Study in Healthy Male Subjects to Evaluate the Neurokinin-1 (NK1) Receptor Occupancy of GSK1144814 in the Living Human Brain Using 11C GR205171.||GlaxoSmithKline|No|Completed|October 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01381419||102554|
NCT01381133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1022-0602|Adolescent Outpatient and Continuing Care Study|Adolescent Outpatient and Continuing Care Study|AOCCS|Chestnut Health Systems|Yes|Completed|September 2002|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|320|||Both|12 Years|18 Years|No|||August 2013|August 13, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381133||102576|
NCT01381146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014694-12|Victim Impact Modules for Jail Inmates|Phase 1-2 Study of Victim Impact Group Modules for Jail Inmates||George Mason University|Yes|Not yet recruiting|October 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 3, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01381146||102575|
NCT01381159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBMC002|Motivational Intervention for Asthma|Motivational Intervention for Asthma Control Trial|MI-ACT|Hopital du Sacre-Coeur de Montreal|No|Recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01381159||102574|
NCT01381952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH-PMS-01|Image Quality and Radiation Dose in Angiography|XRES4 Neuro Claim Study||Karolinska University Hospital|No|Completed|June 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|80 Years|No|||April 2014|April 23, 2014|June 20, 2011||No||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01381952||102513|
NCT01382212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-612|A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis|A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis||AbbVie|No|Completed|October 2011|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|10 Years|16 Years|No|||April 2015|April 28, 2015|June 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382212||102493|
NCT01382225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-045|Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome|A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome||Alcon Research|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1936|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|June 9, 2011|Yes|Yes||No|May 20, 2013|https://clinicaltrials.gov/show/NCT01382225||102492|
NCT01381705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000701978|Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma|Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods||National Cancer Institute (NCI)||Not yet recruiting|June 2011|||July 2011|Anticipated|N/A|Observational|N/A|||Anticipated|259|||Both|18 Years|N/A|No|||June 2011|June 28, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381705||102532|
NCT01365273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPTO 04|Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts|Open, Prospective, Randomised Investigation Evaluating Pain With the Use of Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts||Molnlycke Health Care AB|No|Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|70 Years|No|||August 2012|January 17, 2014|May 27, 2011||No||No|May 2, 2012|https://clinicaltrials.gov/show/NCT01365273||103783|
NCT01365286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ivabradine2009-2011|HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease|Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease||Medical Universtity of Lodz|Yes|Completed|May 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||May 2011|June 11, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01365286||103782|
NCT01365312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeonatalELT|Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature Neonates|A Prospective, Randomized, Blinded, Placebo-Controlled Trial of Periodic, Brief Ethanol Locks to Prevent Peripherally-Inserted Central Catheter (PICC) Infections in Preterm Infants in the Neonatal Intensive Care Unit||East Carolina University|Yes|Terminated|February 2010|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|N/A|32 Weeks|No|||October 2014|October 2, 2014|May 31, 2011|No|Yes|Primary investigator relocated|No||https://clinicaltrials.gov/show/NCT01365312||103781|
NCT01333956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11043|Effects of Pregabalin on Pain After Total Knee Arthroplasty|Effects of Pregabalin on Pain After Total Knee Arthroplasty: A Randomized, Controlled, Double-Blind Trial||Hospital for Special Surgery, New York||Completed|May 2011|June 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|80 Years|No|||March 2015|March 25, 2015|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333956||106165|
NCT01334164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1037-0905|Recovery Management Checkups for Women Offenders|Recovery Management Checkups for Women Offenders Experiment|RMC-WO|Chestnut Health Systems|Yes|Completed|July 2007|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|480|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334164||106149|
NCT01334398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-1146|A Health & Wellness Intervention for Individuals With Traumatic Brain Injury (TBI)|A Health & Wellness Intervention for Individuals With Traumatic Brain Injury||VA Eastern Colorado Health Care System|No|Completed|October 2008|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|74|||Both|18 Years|N/A|No|Probability Sample|Veterans and community members|November 2014|November 24, 2014|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334398||106131|
NCT01334411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTS-1-LS|Identifying Good and Poor Surgical Behaviour in the Danish Operating Room|||Herlev Hospital|No|Completed|September 2010|March 2011|Actual|||N/A|Observational|N/A||1|||||Both|N/A|N/A||Non-Probability Sample|The interview informants are health care personell in two Danish Hospitals as described in        the project description|April 2011|April 12, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01334411||106130|
NCT01334177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7406|TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck|Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)||University of Washington|No|Completed|June 2011|||June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|March 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01334177||106148|
NCT01334944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-015|Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen|A Multi-Center, Open-Label, Surveillance Trial To Evaluate The Safety and Efficacy of a Shortened Infusion Time of Intravenous Ibuprofen.||Cumberland Pharmaceuticals|Yes|Completed|June 2011|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|April 12, 2011|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01334944||106089|
NCT01335529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC27 BOCEPREVIH|Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin|Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With Peg-Interferon Alfa and Ribavirin, in Patients With HCV/HIV Co-infection Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin|BocepreVIH|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|May 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01335529||106045|
NCT01335230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 10110905|The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients|Exploring the Role of Gut-associated TH17 in Microbial Translocation in HIV and HCV/HIV Co-infected Patients||University of Cincinnati|No|Completed|April 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|40|Samples With DNA|Colon tissues|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators plan to enroll 40 human subjects including 10 HIV mono-infected, 10 HCV        mono-infected, 10 HIV/HCV co-infected patients, and 10 control subjects from the        outpatient clinic at the University of Cincinnati College of Medicine.|August 2015|August 27, 2015|April 12, 2011||No||No|June 24, 2013|https://clinicaltrials.gov/show/NCT01335230||106068|small number of subjects enrolled in the study (10 subjects in each group). It is cross-sectional study.
NCT01335503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-PEP-02|Effect of AN-PEP Enzyme on Gluten Digestion|Effect of AN-PEP Enzyme on Gastrointestinal Breakdown of Gluten||DSM Food Specialties|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335503||106047|
NCT01335750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-09-64, Sterling IRB 3576|A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand|A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand||Coopervision, Inc.|No|Completed|August 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 12, 2015|October 7, 2010|Yes|Yes||No|April 30, 2012|https://clinicaltrials.gov/show/NCT01335750||106028|
NCT01332058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL09890901 - Pilot|Motivational Interviewing (MI) for African Americans With Peripheral Arterial Disease (PAD) Pilot|Promoting Walking in African Americans With Peripheral Arterial Disease||University of Kansas Medical Center|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01332058||106311|
NCT01332929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REBECA|Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis|Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis||Centre Francois Baclesse|Yes|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|70 Years|No|||September 2013|September 11, 2013|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01332929||106244|
NCT01332942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14627|Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)|Randomized, Single-blind, Placebo-controlled, Combined Single / Multiple Dose Escalation, Group Comparison Study to Investigate Safety, Tolerability, Pharmacodynamic Effect and Pharmacokinetics of BAY 85-3934 in Patients With Renal Anemia Due to CKD (Stages 3 and 4)||Bayer|No|Completed|April 2011|December 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|6||Actual|44|||Both|18 Years|85 Years|No|||July 2015|July 12, 2015|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01332942||106243|
NCT01384812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DHC-PGE2-2011|Prostaglandin E2 in Migraine Suffers Without Aura.|Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of Prostaglandin E2 in Migraine Suffers Without Aura.||Danish Headache Center|Yes|Completed|September 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|12|||Both|18 Years|55 Years|No|||November 2011|November 8, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01384812||102293|
NCT01384825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISM 2010R1|Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases|Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases|COSMO|Fondazione Italiana Sclerosi Multipla|Yes|Active, not recruiting|December 2010|October 2012|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|2000|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of at least 1,200 adults with MS will be included in the study, as well as 400        healthy subjects and 400 subjects with other neurodegenerative diseases.|September 2012|September 14, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384825||102292|
NCT01384838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_BC_Sports|Exercise Training in Postmenopausal Patients With Breast Cancer|Randomized Trial of Exercise Training in Postmenopausal Patients With Hormone-receptor Positive Breast Cancer Undergoing Treatment With Aromatase Inhibitors||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Completed|June 2011|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Female|N/A|N/A|No|||June 2015|June 3, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384838||102291|
NCT01385124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6276|Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation|Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation||Rabin Medical Center|No|Recruiting|September 2012|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2012|June 18, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385124||102269|
NCT01385137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0927|S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I, II, or III Breast Cancer Receiving Hormone Therapy|S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III||Southwest Oncology Group|Yes|Completed|February 2012|March 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|262|||Female|18 Years|120 Years|No|||October 2015|October 15, 2015|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385137||102268|
NCT01381172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP OPT2009-009|Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C|Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C|FIX-HF-5C|Impulse Dynamics|Yes|Recruiting|January 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381172||102573|
NCT01381731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-201|A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)|||Merck Sharp & Dohme Corp.||Terminated|April 2005|June 2005|Actual|June 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|45 Years|No|||October 2015|October 29, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381731||102530|
NCT01381744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0066|Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers|A Phase I Safety and Immunogenicity Dose Escalation Trial of Plague Vaccine, Flagellin/F1/V, In Healthy Adult Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|January 28, 2016|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01381744||102529|
NCT01381445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113435|A Study Assessing GW870086X's Potential to Cause Skin Thinning|A Randomised, Double-blind (for GW870086X), Placebo-controlled Study of Topical GW870086X Formulation to Explore the Potential for Skin Thinning in Healthy Adult Volunteers||GlaxoSmithKline|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01381445||102552|
NCT01381718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCUSF 0901|Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor|A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor||University of South Florida|Yes|Recruiting|August 2011|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|143|||Both|6 Years|19 Years|No|||March 2016|March 4, 2016|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381718||102531|
NCT01333371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULC drf-Volar Plate|Assessing Volar Locking Plates in Patients Under 65 With a Distal Radius Fracture|Are Volar Locking Plates a Cost Effective Strategy for the Treatment of Distal Radius Fractures in Patients <65 Years of Age?|DRF|Hand and Upper Limb Clinic, Canada|No|Not yet recruiting|April 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|64 Years|No|||April 2011|April 11, 2011|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333371||106210|
NCT01333384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52030-739|Study in Polish Acromegalic Patients Treated With Somatuline Autogel|A Non-Interventional Retrospective (12 Months) and Prospective (at Least 24 Months) Resource Utilization Study, in the Population of Polish Acromegalic Patients Treated With Somatuline Autogel at Normal (4 Weeks) or Extended (6 or 8 Weeks) Dosing Interval||Ipsen|Yes|Completed|October 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|N/A||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Observation of 150 patients out of 500 routinely treated with somatostatin analogues in        Poland|August 2014|August 21, 2014|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333384||106209|
NCT01333969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSS10131|The Effect of Ischemic Preconditioning on Postoperative Pain After Total Knee Arthroplasty, a Randomized, Controlled Trial|The Effect of Ischemic Preconditioning on Postoperative Pain After Total Knee Arthroplasty, a Randomized, Controlled Trial||Hospital for Special Surgery, New York|Yes|Completed|April 2011|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01333969||106164|
NCT01333982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09056|Neonatal Sepsis, Evaluation, Bangladesh|Evaluation of a on Community-Based Management of Neonatal Sepsis||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|April 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|20000|||Both|N/A|2 Years|Accepts Healthy Volunteers|||April 2011|October 29, 2014|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01333982||106163|
NCT01333943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10146|Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty|Saphenous (Adductor Canal) Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty: A Novel Approach for Postoperative Analgesia||Hospital for Special Surgery, New York|Yes|Completed|March 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|90 Years|No|||November 2011|November 14, 2011|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333943||106166|
NCT01334437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EventusDx_ovary_2011ver2|Blood Test for Ovarian Cancer Associated Auto Antibodies|Blood Test for Ovarian Cancer Associated Auto Antibodies||Eventus Diagnostics Ltd|Yes|Recruiting|June 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|250|Samples With DNA|serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include women that have been diagnosed with suspected ovarian        cancer (OC), verified by pathology/cytology as patients, women with suspected ovarian        cancer but verified by pathology/cytology as non-cancers and a control set of blood        samples will be collected from age matched women with no history of cancer.|February 2014|February 19, 2014|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334437||106128|
NCT01334658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100|Study of Corneas Undergoing Balanced Salt Solution(BSS ®) Versus Glucose-bicarbonate-Ringer Lactate in Cataract Surgery|Study of Endothelial Cell Density of Corneas Undergoing Phacoemulsification Surgery Using Balanced Salt Solution (BSS ®) Versus Glucose-bicarbonate-Ringer Lactate as Irrigating Solution: a Randomized Clinical Trial.||Grupo de Estudos em Oftalmologia Clínica e Cirúrgica|No|Completed|August 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|50 Years|90 Years|No|||April 2011|April 12, 2011|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01334658||106111|
NCT01334671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W2-2009041|The Clinical Effect of Intensive Statin Therapy in STEMI Patients Before Emergency PCI|The Clinical Effect of Intensive Statin Therapy in STEMI(ST-elevated Myocardial Infarction) Patients Before Emergency PCI(Percutaneous Coronary Intervention)||General Hospital of Chinese Armed Police Forces|Yes|Recruiting|February 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||April 2011|April 12, 2011|March 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01334671||106110|
NCT01334684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GExpProMet|Gene Expression Profiles and Metformin Efficacy in Type 2 Diabetes|White Blood Cells Gene Expression Profiles as a Tool for Predicting Metformin Efficacy in Patients With Type 2 Diabetes Mellitus||Casa Sollievo della Sofferenza IRCCS|Yes|Not yet recruiting|May 2011|September 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|40 Years|70 Years|No|||February 2011|April 12, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334684||106109|
NCT01336088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX48621-201|ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease|Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease||Addex Pharma S.A.|Yes|Completed|April 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|30 Years|75 Years|No|||July 2012|July 13, 2012|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01336088||106002|
NCT01335763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_05128*|Pharmacist Intervention for Glycemic Control in The Community|Pharmacist Intervention for Glycemic Control in The Community (The RxING Study)|RxING|University of Alberta|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||August 2012|November 4, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335763||106027|
NCT01336049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N+TP-AEC3|Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer|Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial||Peking University|No|Recruiting|March 2011|||December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|75 Years|No|||March 2011|April 14, 2011|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01336049||106005|
NCT01336062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAB-PTX-GC|Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients|Phase Ib/IIa, Two-stage Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients||Peking University|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|75 Years|No|||May 2015|May 17, 2015|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01336062||106004|
NCT01332604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4945g|GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors|A Phase Ib, Open Label, Dose Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors||Genentech, Inc.||Completed|July 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332604||106269|
NCT01332617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-HEM-10-001|Phase II Study of Simvastatin for Relapsed/Refractory Myeloma|Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma||James Graham Brown Cancer Center|Yes|Withdrawn|April 2011|February 2019|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|April 7, 2011|No|Yes|Investigators no longer interested in activating study|No||https://clinicaltrials.gov/show/NCT01332617||106268|
NCT01332630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0198|TPI 287 in Breast Cancer Metastatic to the Brain|A Phase II Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2011|||August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332630||106267|
NCT01332955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023287-41|Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen|Pilot Study of PegInterferon-Ribavirin-Telaprevir Efficacy and Tolerability in HIV-HCV Coinfected Patients Who Had Previously Failed a PegInterferon-Ribavirin Regimen. (ANRS HC26 TelapreVIH)|TelapreVIH|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Completed|April 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01332955||106242|
NCT01332968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO21223|A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With MabThera/Rituxan (Rituximab) Plus Chemotherapy Followed by GA101 or MabThera/Rituxan Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)|A Multicentre, Phase III, Open Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) + Chemotherapy Compared to Rituximab + Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders.||Hoffmann-La Roche||Active, not recruiting|July 2011|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1401|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332968||106241|
NCT01384578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-NASH-02|Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis|A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis||Institute of Liver and Biliary Sciences, India|No|Withdrawn|July 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||July 2012|October 8, 2015|June 28, 2011||No|Lack of funds|No||https://clinicaltrials.gov/show/NCT01384578||102311|
NCT01381757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911175|Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali|Uitlity of MODS for the Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali||National Institutes of Health Clinical Center (CC)||Terminated|May 2011|March 2013||||N/A|Observational|Time Perspective: Prospective|||Anticipated|340|||Both|12 Years|N/A|No|||March 2013|September 24, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381757||102528|
NCT01382004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YAWS-AZ01|Single-dose Azithromycin for the Treatment of Yaws|Single-dose Azithromycin Versus Penicillin G Benzathine for the Treatment of Yaws in Children||Lihir Medical Centre|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Both|6 Months|15 Years|No|||April 2012|April 11, 2012|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382004||102509|
NCT01382017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCM-TMS-2010|Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study|||University of Kiel|Yes|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382017||102508|
NCT01381991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMCHSN03|The Efficacy of i-Scan for Detecting Reflux Esophagitis|A Prospective Randomized Controlled Trial of the Efficacy of i-Scan for Detecting Reflux Esophagitis||Konkuk University Hospital|No|Completed|July 2010|June 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 24, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01381991||102510|
NCT01382264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353757|Use of a Computer-Assisted Decision Support (CADS) System in Management of Patients With Type 2 Diabetes|The Use of a Computer-Assisted Decision Support (CADS) System to Improve Outcomes in Patients With Type 2 Diabetes|CADS|Walter Reed Army Medical Center|Yes|Not yet recruiting|July 2011|October 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|570|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382264||102489|
NCT01382251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009390-01H|Functional Recovery and Caregiver Burden Following Surgery in the Elderly|Functional Recovery and Caregiver Burden Following Surgery in the Elderly|FOCUS|Ottawa Hospital Research Institute|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|123|||Both|65 Years|N/A|No|Probability Sample|Patients undergoing ambulatory surgery and their primary caregivers|December 2013|December 17, 2013|June 23, 2011||No||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01382251||102490|Single center, relatively infrequent assessment, assessment of caregiver burden limited to primary caregiver, majority of caregivers were not employed outside the home.
NCT01333657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301PLAGH-20090923-001|The Application of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Relevant Acute Kidney Injuries|A Prospective Study on the Diagnosis, Severity and Prognosis of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Related Complications||Chinese PLA General Hospital|Yes|Completed|May 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|104|||Both|18 Years|N/A|No|Probability Sample|Between May 2010 and March 2011, inpatients were included who were in the intensive care        units (ICU) of the Department of Respiratory Disease, the Emergency Department, and the        Department of Surgery of the Chinese People's Liberation Army General Hospital.|March 2011|August 2, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01333657||106188|
NCT01334229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS#39262|Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Sitagliptin on the Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and Apolipoprotein B100 in Patients With Type 2 Diabetes|JANUB48|Laval University|Yes|Completed|April 2011|December 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|65 Years|No|||September 2014|September 3, 2014|April 11, 2011||No||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01334229||106144|
NCT01334697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT1-HEPT-01, 2010-022929-15|Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers|Phase I, Randomized, Multicenter, Double-blind, Single Dose, Dose-Escalation, Placebo-Controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous Administration of Cardiotrophin-1 (CT-1)in Healthy Volunteers||Digna Biotech S.L.|Yes|Active, not recruiting|November 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01334697||106108|
NCT01334190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10264|A Prospective Observational Study of the Performance of Zarin in Kenya|A Prospective Observational Study of the Performance of Zarin in Kenya||FHI 360|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|N/A||1|Actual|602|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy women aged 18-44|July 2013|July 1, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334190||106147|
NCT01334450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0316|Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients|Deep-TMS for the Treatment of Alzheimer Disease Patients||Hadassah Medical Organization|No|Not yet recruiting|June 2011|June 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|42|||Both|50 Years|80 Years|No|||April 2011|April 27, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334450||106127|
NCT01335243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/21|Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow|Multicentric, Prospective Study of Efficacy and Safety of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Marrow|MatriBone|University Hospital, Bordeaux|Yes|Active, not recruiting|May 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|65 Years|No|||January 2015|January 13, 2015|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01335243||106067|
NCT01335256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14856|Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies||Bayer|No|Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|N/A|No|||May 2013|May 1, 2013|January 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01335256||106066|
NCT01335802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-177|Relation Between Subclinical Hypothyroidism and Outcome of Pregnancy|Relation Between Thyroid Hormone Stimulated Mitochondrial Function and Spontaneous Abortion and Complications of Pregnancy in Subclinical Hypothyroidism|GravThyr|Naestved Hospital|No|Recruiting|October 2010|December 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Part 2: Fertile women from the General Suburban Population Study in Naestved (GeSuS),        Region Zealand, Denmark.        Part 3: Pregnant women (GA>27) who are consulting the department of obstetrics, Naestved        Hospital.|November 2012|November 19, 2012|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01335802||106024|
NCT01335776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT735639|A Comparison of MBSR and CBT for the Treatment of Insomnia in Cancer|An Objective Comparison of Cognitive Behavioral Therapy and Mindfulness-based Stress Reduction for the Treatment of Insomnia in Cancer Survivors Using Wrist Actigraphy: A Randomized Noninferiority Trial|I-CAN SLEEP|University of Calgary|No|Completed|September 2008|July 2012|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|111|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335776||106026|
NCT01336075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAST II|Atrial Fibrillation: Ablation or Surgical Treatment II: FAST II|Atrial Fibrillation: Ablation or Surgical Treatment II: FAST II A Randomized Study Comparing Non-pharmacologic Therapy in Patients With Drug-refractory Atrial Fibrillation Referred for a First Time Invasive Treatment.||Aalborg Universitetshospital|Yes|Terminated|April 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|75 Years|No|||January 2014|January 2, 2014|April 13, 2011||No|Too few participants|No||https://clinicaltrials.gov/show/NCT01336075||106003|
NCT01332643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reprogenetics-02|Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy|Comparison of Single Embryo Transfer With and Without Previous Analysis of All Chromosome Abnormalities Using Microarrays||Reprogenetics|Yes|Terminated|April 2011|September 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|30 Years|42 Years|No|||May 2012|May 25, 2012|April 7, 2011||No|Not enough patients enrolling|No||https://clinicaltrials.gov/show/NCT01332643||106266|
NCT01332656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC10260|Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel|A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel|OPSALIN|Sanofi|No|Completed|May 2011|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|154|||Female|18 Years|N/A|No|||November 2015|November 18, 2015|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332656||106265|
NCT01332981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22958|An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)|Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)||Hoffmann-La Roche||Completed|February 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|220|||Female|18 Years|N/A|No|Probability Sample|metastatic breast cancer patients treated by Herceptin® as 1st line therapy|January 2016|January 25, 2016|April 6, 2011|No|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT01332981||106240|
NCT01332994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22985|A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis|Efficacy and Safety Study of a Sequential Therapy of Tocilizumab (TCZ) and, if Initially Inadequately Responded to Tocilizumab (TCZ), Followed by Rituximab (RTX) in DMARD-IR Patients With Rheumatoid Arthritis (MIRAI)||Hoffmann-La Roche||Completed|March 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|519|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|March 18, 2011|No|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01332994||106239|
NCT01381471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113865|Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|August 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|11060|||Both|40 Years|N/A|No|Non-Probability Sample|Patients 40 years of age or older with at least one pharmacy claim for FSC during the        index date range (July 1, 2005 through June 30, 2006). An index date was designated as the        date of the first pharmacy claim for FSC. Patients were also required to have continuous        medical and pharmacy eligibility for the 12 month pre-Index year and the 12 month Index        year (referred to as the 24 month observation period), and the 3 month post-Index outcome        period (referred to as the outcome period). Eligible patients were further required to        have at least one medical claim with a diagnosis (either primary or secondary) of COPD        (ICD-9-CM code 490.xx, 491.xx, 492.xx, and 496), AND at least 1 pharmacy claim for an        anticholinergic medication, both occurring during the12 month pre-index period.|February 2012|March 15, 2012|June 23, 2011||||No|February 2, 2012|https://clinicaltrials.gov/show/NCT01381471||102550|
NCT01385215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024277|Strategies for Enhancing Mucosal Immunity to Influenza Vaccine|Strategies for Enhancing Mucosal Immunity to Influenza Vaccine||Duke University|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 5, 2012|April 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01385215||102262|
NCT01381458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113899|Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation|Differences in the Risk of Re-hospitalization and Other COPD-related (Chronic Obstructive Pulmonary Disease) Exacerbations and Costs for Patients Receiving Fluticasone Propionate-salmeterol Xinafoate Combination 250/50mcg (FSC) Versus Anticholinergics [i.e. Tiotropium (TIO) and Ipratropium or Combination Ipratropium-albuterol (IPR) Post-hospitalization or ED Visit for the Treatment of COPD.||GlaxoSmithKline|No|Completed|September 2010|March 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1936|||Both|40 Years|N/A||Non-Probability Sample|Managed care patients (aged >40 years) who were FSC naive in the 12 months pre-index        period. The index-date was the date of discharge of the index COPD-related        hospitalization/ED visit. Eligible patients were required to newly initiate or switch to        drug therapy with FSC or IPR/TIO during the identification period (01/01/2004 to        01/31/2008) to treat COPD. Patients who switched to another maintenance medication or had        an exacerbation in the treatment assessment period (30-days post-index date) were excluded        from the study. Follow-up period was 12 months post treatment assessment period.|June 2011|June 23, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381458||102551|
NCT01381770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|plt-msl001|Platelet-derived Factors for Treatment of Muscular Lesions|Platelet-derived Factors for Treatment of Muscular Lesions: a Phase II Trial||IRCCS Policlinico S. Matteo|No|Completed|September 2010|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381770||102527|
NCT01381783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|facectopica|Phacoemulsification Under Topical Anesthesia and Its Complications|||Instituto de Oftalmologia Ivo Correa-Meyer|Yes|Completed|January 2006|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|111|||Both|N/A|N/A|No|||March 2011|June 24, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01381783||102526|
NCT01382030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-002501-72|Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma|A Phase II Study Evaluating Neo-/Adjuvant EIA Chemotherapy, Surgical Resection and Radiotherapy in High-risk Soft Tissue Sarcoma|NeoWTS|Heidelberg University|Yes|Completed|June 2005|January 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|65 Years|No|||June 2011|June 23, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01382030||102507|
NCT01382290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI DIffusion Spine|Magnetic Resonance Imaging of the Spine|Magnetic Resonance Imaging of the Spine|MRIS|Children's Healthcare of Atlanta|No|Terminated|March 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|||Actual|0|||Both|N/A|18 Years|No|||May 2011|June 24, 2011|September 13, 2005||No|No patients were enrolled, due to logistic difficulties, no funding was acquired.|No||https://clinicaltrials.gov/show/NCT01382290||102487|
NCT01382277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDUCT|Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume|Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia|REDUCT|Peking University First Hospital|Yes|Recruiting|March 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|75 Years|No|||February 2011|June 23, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01382277||102488|
NCT01382472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICROS|Microcirculation In Acute Coronary Syndromes|MICROS-Pilot Study Microcirculation In Acute Coronary Syndromes; Effect of Pre-treatment of High Dose Rosuvastatin on Coronary Microcirculation in Primary PCI|MICROS|Helse Stavanger HF|No|Recruiting|September 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01382472||102473|
NCT01333670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AISLeC-001|Efficacy of Prontosan Solution on Chronic Ulcers|||Associazione Infermieristica per lo studio delle Lesioni Cutanee|Yes|Completed|April 2011|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|289|||Both|18 Years|N/A|No|||April 2011|January 14, 2014|April 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333670||106187|
NCT01333683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAS|Tinnitus and Arterial Hypertension|Tinnitus and Arterial Hypertension.is There Any Relationship?||Faculdade de Medicina de Valenca|No|Enrolling by invitation|April 2011|October 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|40 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients agedd between 40 and 50|March 2015|March 4, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01333683||106186|
NCT01334203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0108|A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)|A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus||Gilead Sciences|No|Withdrawn|May 2011|December 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|79 Years|No|||July 2012|July 27, 2012|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01334203||106146|
NCT01334216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICA_Smoking_Cessation_Study|Using Computers to Assist in Parental Smoking Cessation in a Pediatric Setting|Using Computers to Assist in Parental Smoking Cessation in a Pediatric Setting||Indiana University|Yes|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|362|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 12, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334216||106145|
NCT01334996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2506-04|Use of Tamoxifen in Systemic Mastocytosis|Treatment of Systemic Mastocytosis With Tamoxifen||Mayo Clinic|No|Recruiting|February 2005|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with systemic mastocytosis having up to 20% bone marrow involvement or clinical        symptoms not controlled on current medications.|August 2014|August 11, 2014|December 25, 2007||No||No||https://clinicaltrials.gov/show/NCT01334996||106086|
NCT01334736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-10-002|A Study of Novel Smoking Cessation Interventions in Current and Former Injection Drug Users|A Study of Novel Smoking Cessation Interventions in Current and Former Injection Drug Users||Johns Hopkins University|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 26, 2013|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334736||106105|
NCT01335009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-004-201MEL|Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma|A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects With Metastatic Melanoma||Morphotek|No|Active, not recruiting|May 2011|June 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||January 2016|February 15, 2016|March 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335009||106085|
NCT01332071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114040|Avandamet Bioequivalence Study Brazil - Fed Administration|Assessment of Relative Bioavailability of Avandamet 4 mg + 1000 mg (GSK) in the Form of Film Coated Tablets Versus Avandamet 2 mg + 500 mg (GSK) in the Form of Film Coated Tablets, in Healthy Volunteers After Feeding Standardized, Using Liquid Chromatography.||GlaxoSmithKline|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|April 14, 2011|August 31, 2010||No||No|March 17, 2011|https://clinicaltrials.gov/show/NCT01332071||106310|
NCT01332318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111463|Simulated Driving Study in Restless Legs Syndrome|A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome|XP083|XenoPort, Inc.|Yes|Completed|April 2007|November 2007|Actual|November 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|130|||Both|21 Years|65 Years|No|||June 2011|July 15, 2013|April 7, 2011|Yes|Yes||No|April 22, 2011|https://clinicaltrials.gov/show/NCT01332318||106291|
NCT01332331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112529|Efficacy and Safety of Ambrisentan in Children 8-18yrs|A Randomized, Open Label Study Comparing Safety and Efficacy Parameters for a High and a Low Dose of Ambrisentan (Adjusted for Body Weight) for the Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years||GlaxoSmithKline|Yes|Suspended|January 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|8 Years|18 Years|No|||December 2015|March 10, 2016|March 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01332331||106290|
NCT01332669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biocompatible-Korea|Drug-eluting Bead in Hepatocellular Carcinoma|Multicenter Registry of Chemoembolization Using Drug-eluting Bead in Patients With Unresectable Hepatocellular Carcinoma|REDEBUT|Seoul National University Hospital|Yes|Completed|April 2011|May 2015|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|20 Years|N/A|No|||May 2015|May 19, 2015|February 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01332669||106264|
NCT01332682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCCI-09-001-A|Resistance Training and Physical Functioning in Head and Neck Cancer Patients|Resistance Training and Physical Functioning in Head and Neck Cancer Patients||University of Alabama at Birmingham|No|Completed|March 2009|December 2012|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||May 2015|May 9, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332682||106263|
NCT01332695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST101-A002-203|A Pilot Efficacy and Safety Study of ST101 in Essential Tremor|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor||Sonexa Therapeutics, Inc.|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2012|January 4, 2012|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332695||106262|
NCT01385228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026577|Pazopanib, Docetaxel, Prednisone Prostate|Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors||Duke University|No|Active, not recruiting|June 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Male|18 Years|N/A|No|||March 2016|March 1, 2016|June 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01385228||102261|
NCT01381796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-15-NP101-013|Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults|A Phase I, Single Center, Open Label, Randomized, Single-Dose, Three-Way Crossover Study to Compare the Pharmacokinetics and Bioavailability of Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex in Healthy Volunteers and to Collect Resistance Data During Application of NP101||Teva Pharmaceutical Industries|No|Completed|December 2009|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01381796||102525|
NCT01381224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|629-2010|Do Lower Spine Injections Improve Outcomes for Lower Back Pain Patients|Do Lumbar Spine Injections Improve Short-Term Biomechanical Outcomes in Patients With Chronic Low Back Pain||University of Florida|No|Completed|January 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients receiving a lumbar epidural steroid injection for lumbar spine stenosis|April 2013|April 18, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01381224||102569|
NCT01373216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H8O-CY-O027|Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass|EXEnatide in Patients Undergoing Coronary Artery Bypass Grafting for Improved glUcose conTrol and hemodynamIc ValuEs|Executive|Charles University, Czech Republic|Yes|Completed|June 2011|December 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|85 Years|No|||January 2016|January 31, 2016|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01373216||103175|
NCT01373489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009204|Technology-assisted Case Management in Adults With Type 2 Diabetes|Effectiveness of Technology-Assisted Case Management in Low Income Adults With Type 2 Diabetes|TACM-DM|Medical University of South Carolina|Yes|Active, not recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|October 1, 2015|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373489||103155|
NCT01382485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIA2011|Reamer Irrigator Aspirator (RIA) vs Autogenous Iliac Crest Bone Graft (AICBG) for the Treatment of Non-unions|Reamer Irrigator Aspirator Versus Autogenous Iliac Crest Bone Graft for the Treatment of Non-Unions: A Multi-Centre Randomized Controlled Trial||St. Michael's Hospital, Toronto|No|Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01382485||102472|
NCT01382758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0527|Near Infrared Spectroscopy for the Detection of Acute Kidney Injury in Children Following Cardiac Surgery|Use of Near Infrared Spectroscopy (NIRS) for the Early Detection of Acute Kidney Injury in Children Post Cardiopulmonary Bypass||University of Colorado, Denver|Yes|Completed|July 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|107|Samples Without DNA|Serum, Urine|Both|N/A|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|All children undergoing cardiac surgery with the use of cardiopulmonary bypass at our        institution.|June 2012|January 17, 2013|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01382758||102451|
NCT01333436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-259|A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)|A Multicenter, Cross-sectional Study to Evaluate Plasma ApoB-48 Concentration Among Korean Diabetic Patients (With Normal to Moderately High LDL-C Levels)||Merck Sharp & Dohme Corp.|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|93|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 9, 2015|March 24, 2011|No|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT01333436||106205|
NCT01333709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRECCAR 4|Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma|A Randomized Multicenter Phase 2 Study: a Tailored Strategy for Locally Advanced Rectal Carcinoma|GRECCAR4|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Completed|May 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|150|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333709||106184|
NCT01334463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0502|Executive Dysfunction and Self-Harm Behavior: An Examination of Veterans With TBI, PTSD, or Both|Executive Dysfunction and Self-Harm Behavior: An Examination of Veterans With Traumatic Brain Injury, Post Traumatic Stress Disorder, or Both||VA Eastern Colorado Health Care System|No|Completed|July 2010|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|186|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants in this observational study will be recruited from the following        populations of OEF/OIF Veterans: 1.) those seeking mental health, rehabilitative,        psychological or other services within the Veterans Health Administration (VHA) Eastern        Colorado Healthcare System , 2.) those in existing clinical and research databases, and        3.) Veterans in the community not seeking care within the VHA.|January 2016|January 22, 2016|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334463||106126|
NCT01335022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00035483|African American Community Health Project on Cardiovascular Disease|African American Community Health Project on Cardiovascular Disease (AACP-CVD)|AACP-CVD|Northwestern University|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2011|April 12, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01335022||106084|
NCT01334710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047003|A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer|A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer||Emory University|Yes|Terminated|March 2011|December 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|April 6, 2011|Yes|Yes|safety issue observed on another hepatocellular study using OSI906|No|September 12, 2012|https://clinicaltrials.gov/show/NCT01334710||106107|A second trial evaluating OSI906 in Hepatocellular cancer was being run in parallel to this trial. There were safety signals in the second trial which led to stopping this trial.
NCT01335542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10002|Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade|Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade|PAI vs FNB|Hospital for Special Surgery, New York|Yes|Completed|March 2010|September 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|91|||Both|18 Years|85 Years|No|||July 2012|July 2, 2012|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01335542||106044|
NCT01335789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20274|Effect of Oxytocin on Stress in Marijuana Users|Effect of Oxytocin on Stress Response in Marijuana-dependent Individuals||Medical University of South Carolina|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|April 8, 2011|Yes|Yes||No|June 2, 2014|https://clinicaltrials.gov/show/NCT01335789||106025|Small sample size, non-treatment seeking sample, predominantly male sample
NCT01336101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prov 01 - 2011|Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent|Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent With Delivery System -The SUMMIT Registry|SUMMIT|Provascular GmbH|Yes|Completed|April 2011|November 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|85 Years|No|||April 2014|April 23, 2014|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01336101||106001|
NCT01336114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01263-36|A New 3D Geometrical Modelisation of Adolescent Idiopathic Scoliosis and Conception of a Personal Brace|A New 3D Geometrical Modelisation of Adolescent Idiopathic Scoliosis and Conception of a Personal Brace|MODEL MAKER|Rennes University Hospital||Completed|July 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Female|12 Years|15 Years|No|Non-Probability Sample|Patients with idiopathic scoliosis|November 2014|November 25, 2014|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01336114||106000|
NCT01332084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.19.INF|Use of Hypoallergenic (H.A.) Cereals in Children With Diagnosed Allergy to Wheat|Assessment of the Feasibility of a SOTI With Hypoallergenic (H.A.) Cereals in Children With Diagnosed IgE-mediated Allergy to Wheat||Nestlé|No|Completed|April 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|1 Year|12 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01332084||106309|
NCT01332344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112604|Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids|Comparison of Healthcare Utilization and Costs in Patients With Asthma Who Fluticasone/Salmeterol Inhalation Powder Versus Other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data.||GlaxoSmithKline|No|Completed|June 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5180|||Both|12 Years|65 Years|No|Probability Sample|The study intends to identify subjects with asthma treated with inhaled corticosteroids|August 2011|September 1, 2011|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01332344||106289|
NCT01332357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112606|Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit|Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit||GlaxoSmithKline||Completed|June 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|6139|||Both|12 Years|N/A|No|Probability Sample|The study intends to identify subjects with asthma discharged from an emergency department        that received fluticasone propionate/salmeterol from either an ED physician or from an        outpatient physician|October 2011|October 20, 2011|April 7, 2011||No||No|September 8, 2011|https://clinicaltrials.gov/show/NCT01332357||106288|
NCT01332396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113092|Drug Use Investigation for TYKERB Tablet (All Case Investigation)|Drug Use Investigation for TYKERB Tablet (All Case Investigation)||Novartis|No|Active, not recruiting|June 2009|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|3000|||Both|N/A|N/A|No|Probability Sample|All patients who have "HER2 overexpressing inoperable or recurrent breast cancer" and have        received TYKERB for the first time|March 2016|March 16, 2016|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332396||106285|
NCT01332409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113095|Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)|Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)||GlaxoSmithKline|No|Completed|August 2009|January 2013|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2000|||Both|N/A|N/A|No|Probability Sample|Patients who are diagnosed as having a chronic obstructive pulmonary disease (bronchitis        chronic / emphysema)|June 2013|June 6, 2013|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332409||106284|
NCT01333046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27471-TACTAL|Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL|Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma|TACTAL|Baylor College of Medicine|Yes|Recruiting|January 2012|January 2019|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|N/A|N/A|No|||February 2016|February 1, 2016|April 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01333046||106235|
NCT01372930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xjyy110504|Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction|The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction||Xijing Hospital|No|Recruiting|April 2010|||July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||March 2010|June 11, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372930||103197|
NCT01381237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2007-047|Effects of Game-based Balance Exercise for Older Adults With Fall History|Full Title Interactive Computer Game Exercise Regime, Effects on Balance Impairment in Frail Community-Dwelling Older Adults. A Randomized Controlled Trial||University of Manitoba|Yes|Completed|August 2007|August 2008|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|65 Years|85 Years|No|||March 2007|June 22, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01381237||102568|
NCT01373502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C20902|International Randomized Comparison Between DES Limus Carbostent and Taxus Drug Eluting Stents in the Treatment of De-novo Coronary Lesions||NEXT|CID - Carbostent & Implantable Devices|No|Active, not recruiting|October 2009|September 2015|Anticipated|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01373502||103154|
NCT01373515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCOne-1|Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia|Phase 1 Study of Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia||DCPrime BV|Yes|Completed|April 2011|May 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|12|||Both|18 Years|80 Years|No|||June 2013|June 3, 2013|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01373515||103153|
NCT01373879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC041|AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area|Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults and Children in a Malaria Endemic Area||University of Oxford|Yes|Completed|June 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|8||Actual|52|||Male|2 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01373879||103126|
NCT01373892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleevepet2|Prospective, Randomised Study: Metabolic and Functional Effects of Bariatric Surgery Accessed Using Positron Emission Tomography (PET) and MRI.|Prospective, Randomised Study: Metabolic and Functional Effects of Bariatric Surgery Accessed Using PET and MRI|Sleevepet2|Turku University Hospital|No|Recruiting|January 2011|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|August 13, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01373892||103125|
NCT01373853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103|A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery|A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery|1103|Technolas Perfect Vision GmbH|Yes|Completed|April 2011|December 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01373853||103128|
NCT01373866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_17/0927|Multimodal MRI-guided rTMS to Treat Refractory Hallucinations|Multimodal MRI-guided Repetitive Transcranial Magnetic Stimulation to Treat Drug-resistant Hallucinations: a Randomized Control Trial|MULTIMODHAL|University Hospital, Lille|Yes|Recruiting|November 2010|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|13 Years|60 Years|No|||December 2015|December 3, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373866||103127|
NCT01374178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14094|A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects|Relative Bioavailability of LY2963016 to LANTUS® After Single Dose Subcutaneous Administration to Healthy Subjects||Eli Lilly and Company|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|June 13, 2011||No||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01374178||103103|
NCT01333722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-169|Acute Pain Study Following Bunionectomy|A Randomized, Multicenter Study Comparing the Analgesic Efficacy and Safety of Hydrocodone / Acetaminophen Extended Release to Placebo in Subjects With Acute Pain Following Bunionectomy||AbbVie|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||March 2014|March 10, 2014|April 11, 2011|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01333722||106183|
NCT01334723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114482|Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia|Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia||GlaxoSmithKline||Completed|April 2010|June 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|35032|||Male|50 Years|N/A|No|Non-Probability Sample|Male patients aged 50 years or older with a diagnostic claim of BPH and prescription claim        for a 5ARI for at least 60 days during the observation period. Patients will be required        to be continuously eligible for 6 months prior to and at least 6 months after index date.|November 2011|December 8, 2011|April 7, 2011||No||No|April 14, 2011|https://clinicaltrials.gov/show/NCT01334723||106106|
NCT01335308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL085400|Brief Motivational Interviewing to Reduce Child Body Mass Index|Brief Motivational Interviewing to Reduce Child Body Mass Index|BMi2|University of Michigan|Yes|Recruiting|October 2009|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|650|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||March 2011|April 13, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335308||106062|
NCT01335815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TnT hs 3|High Sensitive Troponin T (hsTnT) and Copeptin as Prognostic Parameters in Patients With Elective Total Endoprosthesis|High Sensitive Troponin T (hsTnT) and Copeptin as Prognostic Parameters in Patients With Elective Knee and Hip Endoprosthesis||Heidelberg University|No|Recruiting|March 2011|March 2013|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|normal lab parameters|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|all patients with elective knee and hip endoprothesis|April 2011|April 13, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335815||106023|
NCT01335555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H1001/137|The Effect of Chemotherapy on Lactate Threshold in Cancer Patients|The Effect of Neoadjuvant Chemotherapy on Lactate Threshold in Patients With Surgically Resectable Upper Gastrointestinal Cancer.||Aintree University Hospitals NHS Foundation Trust|No|Completed|August 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|89|||Both|18 Years|N/A|No|Probability Sample|Upper gastrointestinal cancer patients receiving neoadjuvant chemotherapy|August 2007|April 18, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01335555||106043|
NCT01335841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC-10 25|Evaluation of an 3D Imaging Intensifier Coupled to a Navigation Station in the Surgery of the Spine and Pelvis|Evaluation of an 3D Imaging Intensifier Coupled to a Navigation Station in the Surgery of the Spine and Pelvis|FLUORONAV|University Hospital, Grenoble|Yes|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|150|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01335841||106021|
NCT01335854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812091|Promoting Continuous Positive Airway Pressure (CPAP) Adherence|Promoting CPAP Adherence and Treatment Outcomes in Patients With Obstructive Sleep Apnea||University of Pennsylvania|No|Completed|September 2011|August 2013|Actual|August 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|135|||Both|18 Years|N/A|No|||March 2012|May 20, 2014|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335854||106020|
NCT01332097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCT197A2201|Safety & Efficacy of BCT197A2201 in Chronic Obstructive Pulmonary Disease (COPD) Patients Presenting With an Exacerbation|An Exploratory, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of a Single and a Repeated Dose of Oral BCT197 in Patients With an Acute COPD Exacerbation||Novartis||Completed|March 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|183|||Both|40 Years|80 Years|No|||February 2014|February 19, 2014|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01332097||106308|
NCT01332110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23731|Treatment for Patellofemoral Pain Syndrome Using Footwear|Treatment for Patellofemoral Pain Syndrome Using Knee Abduction Moment-Reducing Footwear||University of Calgary||Completed|June 2011|August 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|50 Years|No|||February 2014|February 18, 2014|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332110||106307|
NCT01332370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112611|Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone|Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone||GlaxoSmithKline|No|Completed|December 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5391|||Both|18 Years|85 Years|No|Non-Probability Sample|Adults continuously enrolled in a large US health insurance plan with a diagnosis of        diabetes who are currently receiving Metformin|June 2011|June 23, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332370||106287|
NCT01332383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112925|Special Drug Use Investigation for AMERGE® Tablet (Long-term)|Special Drug Use Investigation for AMERGE Tablet (Long-term)||GlaxoSmithKline|No|Completed|May 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|N/A|N/A|No|Probability Sample|Patients with migraine headache who are naive to AMERGE|August 2015|August 10, 2015|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332383||106286|
NCT01332708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-SB-10-538-CTIL|Cholinergic Status and the Metabolic Syndrome|Cholinergic Status and the Metabolic Syndrome|Choliner stat|Tel-Aviv Sourasky Medical Center||Not yet recruiting|April 2011|September 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 8, 2011|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332708||106261|
NCT01333033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-80803|PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy|Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|July 2011|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333033||106236|
NCT01333059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sedation Cycling|Cycling of Sedative Infusions in Critically Ill Pediatric Patients|A Randomized, Double-blind, Controlled Trial of Cycling Continuous Sedative Infusions in Critically Ill Pediatric Patients Requiring Mechanical Ventilation||Cook Children's Health Care System|Yes|Terminated|September 2010|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|18 Years|No|||December 2012|December 6, 2012|April 6, 2011|Yes|Yes|Unable to adequately enroll over a reasonable enrollment period.|No||https://clinicaltrials.gov/show/NCT01333059||106234|
NCT01373242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2308|Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance|Peanut Sublingual Immunotherapy and Induction of Clinical Tolerance in Peanut Allergic Children (SLIT Tolerance TLC) {Sublingual Immunotherapy for Peanut Allergy}|SLIT-TLC|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|June 2011|December 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|11 Years|No|||June 2015|June 16, 2015|June 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373242||103173|
NCT01373229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026715|Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)|Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia||Duke University|No|Completed|January 2012|March 2015|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01373229||103174|
NCT01376362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110167|Topical Interferon Gamma for Macular Edema Secondary to Uveitis|The Treatment of Macular Edema Secondary to Uveitis Using Topical Interferon Gamma|JakStat2|National Institutes of Health Clinical Center (CC)|No|Completed|June 2011|March 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|June 17, 2011|Yes|Yes||No|August 3, 2012|https://clinicaltrials.gov/show/NCT01376362||102939|
NCT01374191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-SIUSOM-11-002|Botulinum Toxin Type A for Neuroma Pain|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial of Botulinum Toxin Type A for Neuroma Pain||Southern Illinois University|Yes|Withdrawn|January 2015|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374191||103102|
NCT01373593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-116|Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients|Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients||Rigshospitalet, Denmark|No|Terminated|January 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2011|June 19, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01373593||103147|
NCT01374555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-C103|Evaluation of the CardioSond Electronic Stethoscope in the Detection of Coronary Artery Disease|Validation of the CardioSond Sonospectrographic Digital Electronic Stethoscope in Diagnosing Coronary Artery Disease Versus CT Angiography||SonoMedica, Inc.|No|Suspended|August 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be sourced from patients presenting for cardiac CT angiography        who meet inclusion / exclusion criteria.|February 2013|February 20, 2013|June 14, 2011||No|Phase II cohort recruitment suspended until analysis of Phase I cohort completed|No||https://clinicaltrials.gov/show/NCT01374555||103075|
NCT01334008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2010-02|Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma|Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal Melanoma||Institut Curie|Yes|Recruiting|April 2011|||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2011|May 9, 2011|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01334008||106161|
NCT01334749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD-DEDEMAS-01|Observational Study on Determinants of Dementia After Stroke|Determinants of Dementia After Stroke|DEDEMAS|Ludwig-Maximilians - University of Munich|No|Recruiting|April 2011|April 2019|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|whole blood, serum, plasma, RNA, CSF|Both|18 Years|N/A|No|Probability Sample|Patients admitted to a specialized stroke service because of an acute stroke|March 2016|March 4, 2016|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01334749||106104|
NCT01334762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-157x|Efficacy of Letrozole and CC Alone in an IUI Program in Cases With Surgically Treated Minimal to Mild Endometriosis|Letrozole and CC Alone in an IUI Program in Women With Surgically Treated Minimal to Mild Endometriosis||Mansoura University|Yes|Completed|May 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Female|20 Years|36 Years|No|||April 2011|April 12, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334762||106103|
NCT01335282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW07-163|Traditional Chinese Medicine Syndrome Identification in Paediatric Neurology|Traditional Chinese Medicine Syndrome Identification in Paediatric Neurology||The University of Hong Kong|No|Recruiting|April 2007|December 2017|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|From Primary care clinic|April 2011|April 13, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335282||106064|
NCT01335828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 10 24|Elastography Interest in the Management of Thyroid Nodules|"ShearWave" Elastography Interest in the Management of Thyroid Nodules|SWETHY|University Hospital, Grenoble|Yes|Completed|November 2010|November 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|125|||Both|18 Years|N/A|No|||January 2013|January 24, 2013|November 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01335828||106022|
NCT01335607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355-006|A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)|A Phase I, Open-label Study to Evaluate the Relative Bioavailability of IDX184 and Food Effect in Healthy Male Subjects||Merck Sharp & Dohme Corp.|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|19 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|April 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01335607||106039|
NCT01335867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812864|Vigabatrin for Cocaine and Alcohol Dependence|A Phase II, Double-Blind, Placebo-Controlled, Pilot Trial of Vigabatrin for the Treatment of Cocaine and Alcohol Dependence|VGB|University of Pennsylvania|Yes|Terminated|April 2011|December 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|April 13, 2011|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01335867||106019|
NCT01336140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSUAGE-CKD|Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging|Attenuation of the Side Effect Profile Of Regadenoson: A Randomized Double-Blind Placebo-Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging and Have Severe Chronic Kidney Disease (ASSUAGE-CKD Trial)|ASSUAGE-CKD|Rush University Medical Center|Yes|Completed|June 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|April 11, 2011|Yes|Yes||No|December 2, 2012|https://clinicaltrials.gov/show/NCT01336140||105998|
NCT01336127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W.OR09-29|Effectiveness Study of Occupational Therapy in Parkinson's Disease|Effectiveness of Occupational Therapy in Parkinson's Disease: a Randomized Controlled Trial|OTiP|Radboud University|No|Completed|April 2011|June 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01336127||105999|
NCT01332123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWM-11.254|Biomechanical Assessment of Gait in Lower-Extremity-Amputees|Biomechanical Assessment of Gait in Lower-Extremity-Amputees||University of Wisconsin, Milwaukee|No|Completed|April 2011|August 2012|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01332123||106306|
NCT01332136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DC005805|Determinants of Medical and Surgical Treatment Outcomes in Chronic Sinusitis|Determinants of Medical and Surgical Treatment Outcomes in Chronic Sinusitis||Oregon Health and Science University|No|Enrolling by invitation|April 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|978|Samples Without DNA|Sinonasal mucosal tissue specimens|Both|18 Years|90 Years|No|Non-Probability Sample|Adult patients who have failed intial medical management for chronic sinusitis and have        presented to a tertiary care clinic for continued treatment.|October 2014|October 15, 2014|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332136||106305|
NCT01332721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105ST102|Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated|An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors||Tracon Pharmaceuticals Inc.|No|Completed|April 2011|December 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|April 7, 2011|No|Yes||No|February 12, 2014|https://clinicaltrials.gov/show/NCT01332721||106260|
NCT01332734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-03.03 nr BE-2-6|Microcirculatory Changes During Magnesium Sulphate Infusion in Sepsis|Microcirculatory Changes During Open Label Magnesium Sulphate Infusion in Severe Sepsis and Septic Shock||Medical Centre Leeuwarden|No|Completed|March 2010|January 2011|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|severe sepsis and septic shock after adequate fluid resuscitation according to pulmonary        artery catheter measurements|April 2011|April 4, 2011|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01332734||106259|
NCT01333319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KILT1|The Role of Biomarkers in the Early Detection of Acute Kidney Injury Induced by Liver Transplantation|The Role of Biomarkers in the Early Detection of Acute Kidney Injury Induced by Liver Transplantation : an Observational Analysis.|KILT|Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|December 2011|||June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Whole blood, urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients of the University Hospitals Leuven listed on the Eurotransplant waiting list for        liver transplantation and undergoing a liver transplantation|December 2015|February 10, 2016|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01333319||106214|
NCT01333332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15050|Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer|Phase II Trial of Accelerated Fraction Radiotherapy With Concomitant Capecitabine as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer||University of Virginia|Yes|Recruiting|August 2010|||August 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2011|April 8, 2011|March 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01333332||106213|
NCT01374880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIL number: 910198|Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease|Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|June 2009|January 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|3000|Samples Without DNA|Biomarkers assessment in plasma at different times according to the study cohort.|Both|18 Years|N/A|No|Probability Sample|Patients presenting with dyspnea secondary or not to heart failure. Patients with dyspnea,        edema, with heart failure, ambulatory or admitted for cardiac decompensation (even with        cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be        prospectively collected.        Patients with valvular disease or with chronic heart failure.|June 2013|August 13, 2013|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01374880||103050|
NCT01375205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Galderma Cetaphil Restoraderm|Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants|A Randomized Pilot Trial Comparing Cetaphil® Restoraderm® System and Standard Skin Care in Infants at Risk for Atopic Dermatitis||Oregon Health and Science University|No|Recruiting|June 2011|July 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|250|||Both|N/A|3 Weeks|No|||June 2011|June 20, 2011|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375205||103027|
NCT01373970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-217|The Clinical Significance of Acid Rebound in Functional Dyspepsia|The Clinical Significance of Acid Rebound: Symptoms of Reflux After PPI Treatment in Patients With Functional Dyspepsia|CLARIFY|University Hospital Koge|Yes|Terminated|May 2011|September 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373970||103119|
NCT01372995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049610|Vitamin D in Ventilated ICU Patients|High-Dose Vitamin D and Antimicrobial Peptide Expression in Lung Failure|R21 HL-110044|Emory University|Yes|Completed|July 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01372995||103192|
NCT01373307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK081324|An Intergenerational Community Based Participatory Research (CBPR) Intervention to Reduce Appalachian Health Disparities|An Intergenerational CBPR Intervention to Reduce Appalachian Health Disparities||University of Kentucky|No|Completed|March 2010|June 2014|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1250|||Both|8 Years|N/A|Accepts Healthy Volunteers|||December 2014|July 10, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01373307||103169|
NCT01373606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999908 CS01|A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1|An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1|HRS|Ferring Pharmaceuticals|No|Completed|November 2007|December 2009|Actual|March 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|20 Years|79 Years|No|||February 2012|February 13, 2012|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01373606||103146|
NCT01373619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFNEF-IVA-DIAL|Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine|Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine||Second University of Naples|Yes|Completed|January 2010|January 2012|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|85 Years|No|||January 2010|January 18, 2012|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01373619||103145|
NCT01375465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eur-002|The 001-DIOR Multicenter Registry|The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions)||Eurocor GmbH|No|Active, not recruiting|February 2011|||July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375465||103007|
NCT01334476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0554|VISN 19 MIRECC Research Database|VISN 19 MIRECC Research Database|Repository|VA Eastern Colorado Health Care System|No|Recruiting|June 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|N/A||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Receiving Medical Treatment at the Denver VA Medical Center 18 or older|January 2016|January 22, 2016|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01334476||106125|
NCT01335321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/11450-9|Evaluation of the Effect of Adding Corticosteroid to Viscosupplementation|Prospective And Randomized Study Evaluating Tthe Effect Of The Association Of Triamcinolone To The Viscosupplementation Of The Knee||University of Sao Paulo General Hospital|Yes|Completed|March 2011|July 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|108|||Both|45 Years|80 Years|No|||March 2011|December 22, 2014|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335321||106061|
NCT01335334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTHSCSPH100386|H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study|Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study.||The University of Texas Health Science Center, Houston|No|Recruiting|March 2011|August 2011|Anticipated|June 2011|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2011|April 13, 2011|April 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01335334||106060|
NCT01335035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AES04|Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload|Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload||Novartis||Completed|December 2008|||May 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01335035||106083|
NCT01335295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMD-2011|Safety Study of Flavocoxid in Duchenne Muscular Dystrophy|Open Pilot Trial to Test the Safety and Tolerability of Flavocoxid in Duchenne Muscular Dystrophy||University of Messina|No|Completed|March 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Male|4 Years|16 Years|No|||January 2014|January 31, 2014|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01335295||106063|
NCT01335347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXA01-001|Safety Study of an Oral Vaccine to Prevent Avian Influenza|A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults|H5N1|Vaxart|No|Completed|April 2011|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|54|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 2, 2013|April 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01335347||106059|
NCT01335594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAOS2011|Evaluation of Swallowing in Patients With Obstructive Sleep Apnea|Clinical, Endoscopical and Manometric Evaluation of Swallowing in Obstructive Sleep Apnea Syndrome||Hospital do Servidor Publico Estadual|No|Completed|February 2010|May 2011|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||April 2012|April 7, 2012|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01335594||106040|
NCT01335880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS10-385|Helping People to Exercise Regularly|Helping People to Exercise Regularly||University of Pennsylvania|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|117|||Both|55 Years|N/A|Accepts Healthy Volunteers|||July 2011|October 16, 2012|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335880||106018|
NCT01335633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|691-11 PVCE|Psychometric Validation of Cognitive Endpoints|Psychometric Validation of Cognitive Endpoints||Kessler Foundation|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|65 Years|No|Probability Sample|Individuals with Multiple Sclerosis|May 2012|May 1, 2012|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01335633||106037|
NCT01335893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC:11510|Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green|A Phase 1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subjects Undergoing Thoracic Surgery Presenting With Lung Nodules||University of Pennsylvania|No|Recruiting|May 2011|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01335893||106017|
NCT01332149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081265|Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy|An 11-week Randomized, Double-blind, Multi Center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (300 Mg/Day) Using A Fixed Dosing Schedule In The Treatment Of Subjects S With Pain Associated With Diabetic Peripheral Neuropathy.||Pfizer|Yes|Completed|July 2011|June 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|626|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 7, 2011|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01332149||106304|
NCT01332422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113405|Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)|Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)||GlaxoSmithKline|No|Completed|November 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|N/A|14 Years|No|Non-Probability Sample|Japanese pediatric patients (aged < 15 years) who diagnosed as having bronchial asthma for        which the indication of ADOAIR has been approved and who are using ADOAIR for the first        time and expected for a long-term use.|June 2014|July 3, 2014|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01332422||106283|
NCT01332435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113984|Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use|Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use||GlaxoSmithKline||Completed|November 2009|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|6896|||Male|50 Years|N/A|No|Probability Sample|This study aims to identify eligible patient data between July 1, 2000, and December 31,        2006, and allows for patient data to be followed for 6 months prior to and up to 1 year        following index prescription date.|August 2011|August 4, 2011|April 7, 2011||No||No|April 14, 2011|https://clinicaltrials.gov/show/NCT01332435||106282|
NCT01383954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p000667|The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis|The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis||Brigham and Women's Hospital|No|Completed|June 2011|December 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|20 Years|75 Years|No|||April 2013|April 26, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01383954||102359|
NCT01383967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13846|A Study of LY2979165 in Healthy Subjects|Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Multiple-Ascending Doses of LY2979165 in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|102|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|June 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01383967||102358|
NCT01384305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IRB-255-3|Establish a "Taiwan Rare Disorder Tissue Bank", to Collect and Repost Biological Samples and Disease Information From Patients With Rare Disorders|||China Medical University Hospital|No|Enrolling by invitation|December 2009|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Patients with rare disorders.|June 2011|June 28, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384305||102332|
NCT01374126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11019|Azithromycin Combination Therapy for the Treatment of Severe Malaria|Azithromycin Combination Therapy for the Treatment of Severe Malaria - A Pilot Safety and Efficacy Study in Uncomplicated Falciparum Malaria in Bangladesh||Medical University of Vienna||Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|8 Years|65 Years|No|||August 2013|August 22, 2013|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01374126||103107|
NCT01374139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1871035|Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects|A Phase 1, Open-Label, Randomized, Single-Dose, 2-Cohort, 2-Way Crossover Bioequivalence Study To Compare The Bosutinib Clinical Tablet And Clinical Capsule And To Investigate Food Effect On Bosutinib Commercial Formulation in Healthy Subjects||Pfizer|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|June 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01374139||103106|
NCT01374477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2011-05|Hypertensive Disorders of Pregnancy in Adolescence and Primipaternity|Hypertensive Disorders of Pregnancy in Adolescence and the Primipaternity Concept. Cases and Control Trial||Saint Thomas Hospital, Panama|No|Recruiting|June 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|110|||Female|N/A|19 Years|No|Probability Sample|Patients < 19 years old who delivered in our institution.|January 2015|January 1, 2015|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374477||103080|
NCT01374490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFHD3092|Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea|A Phase 3, Multicenter, Open-Label Evaluation of the Safety and Tolerability of Crofelemer in HIV-Positive Subjects With Diarrhea||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2011|||October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|251|||Both|18 Years|N/A|No|||July 2012|May 17, 2013|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374490||103079|
NCT01379001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AG031320|Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI|Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI||Hebrew Rehabilitation Center, Boston|No|Completed|July 2008|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379001||102739|
NCT01375088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|339888|Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers|Phase I Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers||Mashhad University of Medical Sciences|Yes|Completed|October 2010|May 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|15 Years|N/A|No|||November 2012|November 21, 2012|June 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375088||103035|
NCT01375387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1046|Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males|A Phase I, Randomized Double-blind, Placebo-controlled, Single-center, Single-dose, Three-way Cross-over Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Lacosamide Tablets in Healthy Male Chinese and Japanese Subjects||UCB Pharma|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|8||Actual|33|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|August 19, 2011|April 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375387||103013|
NCT01375660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-001-10S|D Vitamin Intervention in VA|Vitamin D Deficiency and Treatment in Male Veterans at Risk for Diabetes|DIVA|VA Office of Research and Development|Yes|Completed|May 2011|November 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|205|||Male|35 Years|85 Years|No|||February 2015|February 17, 2015|June 15, 2011||No||No|November 25, 2014|https://clinicaltrials.gov/show/NCT01375660||102993|
NCT01375673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 09-228|Effects of Exercise Training on Fluid Instability in Heart Failure Patients|Effects of Exercise Training on Fluid Instability in Heart Failure Patients||VA Office of Research and Development|No|Completed|November 2011|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||February 2015|April 6, 2015|October 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01375673||102992|
NCT01375907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rotavin01|Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults|A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam||National Institute of Hygiene and Epidemiology, Vietnam|Yes|Completed|August 2009|October 2009|Actual|October 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2011|June 16, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01375907||102974|
NCT01375920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EME-08/43/39|Antiglucocorticoid Augmentation of antiDepressants in Depression|Antiglucocorticoid Augmentation of antiDepressants in Depression|ADD|Northumberland, Tyne and Wear NHS Foundation Trust|Yes|Completed|February 2011|June 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01375920||102973|
NCT01381029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB080911|Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals|A Study to Examine Immunological Response in HIV-Infected Patients Receiving the Seasonal Influenza Vaccine||George Washington University|No|Completed|September 2009|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|N/A|No|Non-Probability Sample|HIV positive individuals receiving influenza vaccine as part of standard of care.|January 2016|February 8, 2016|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381029||102584|
NCT01381315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11737|Axillary Reverse Mapping|ARM: Axillary Reverse Mapping||University of Kansas Medical Center|Yes|Active, not recruiting|September 2009|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|211|||Female|18 Years|N/A|No|||June 2015|June 19, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01381315||102562|
NCT01381588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114777|The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women|The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women|TOP|GlaxoSmithKline|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1136|||Female|50 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Postmenopausal women|June 2011|June 30, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01381588||102541|
NCT01382121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeakVO2 PM RCT|Adolescent Fitness Assessment Program|Increasing Self-efficacy and VO2 Max Scores in Obese Adolescents: a Peer Modeling Intervention|AFAP|University of Western Ontario, Canada|No|Completed|September 2010|May 2012|Actual|April 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01382121||102500|
NCT01383174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15BB-1300|Nuevo Amanecer: Promoting the Psychosocial Health of Latinas|Nuevo Amanecer: Promoting the Psychosocial Health of Latinas||University of California, San Francisco|Yes|Completed|February 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|151|||Female|18 Years|N/A|No|||June 2015|June 12, 2015|June 3, 2011||No||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01383174||102419|
NCT01382368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCBH116278 CTIL|Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients|Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients||Rabin Medical Center|Yes|Enrolling by invitation|September 2011|September 2013|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|30 Years|90 Years|No|||November 2012|November 13, 2012|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01382368||102481|
NCT01382381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0081CTIL|Intravascular Stents Fracture Effects|Evaluation of Implanted Aortic Arch and Branch Pulmonary Artery Stents Durability and Function||Rambam Health Care Campus|No|Not yet recruiting|July 2011|July 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|80 Years|Accepts Healthy Volunteers|Probability Sample|Twenty patients who underwent stent implantation for coarctation of the aorta and for        branch pulmonary artery stenosis will be recruited for the study from our out-patients        follow-up clinic|February 2011|June 24, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382381||102480|
NCT01382615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1029|Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research|Evaluation of Immune Parameters and Function in Multiple Myeloma Patients and Healthy Individuals' Blood and Marrow Samples||Dartmouth-Hitchcock Medical Center|Yes|Terminated|August 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|Samples With DNA|15mL of peripheral blood 10mL of bone marrow aspirate|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center|September 2015|September 28, 2015|April 12, 2010||No|Unable to fill cohort|No||https://clinicaltrials.gov/show/NCT01382615||102462|
NCT01383421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-072|Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)|A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction With Adalimumab Treatment in Patients With Rheumatoid Arthritis (PASSION Study)|PASSION|AbbVie|No|Active, not recruiting|September 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|1000|||Both|18 Years|99 Years|No|Non-Probability Sample|Representative disease population selected from rheumatology clinics in the countries        selected.|January 2016|January 27, 2016|June 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01383421||102400|
NCT01383941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-19|Asthma Phenotypes in the Inner City|Asthma Phenotypes in the Inner City (ICAC-19)|APIC|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|717|Samples With DNA|Participants had the option of having blood, RNA, and DNA stored for use in future research      studies.|Both|6 Years|17 Years|No|Probability Sample|Inner-city Asthma Consortium (ICAC) children with mild to severe asthma|November 2015|November 5, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383941||102360|
NCT01384240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 09-1040|Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia|Evaluation of Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia||Anandasabapathy, Sharmila, M.D.|Yes|Terminated|April 2010|May 2014|Actual|July 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|183|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|June 27, 2011|No|Yes|Study is closed as the PI transferred to another institution.|No||https://clinicaltrials.gov/show/NCT01384240||102337|
NCT01384279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-099-03|The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity|The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity||Beitou Armed Forces Hospital, Taipei, Taiwan|Yes|Completed|May 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|25|||Both|20 Years|65 Years|No|||February 2012|February 23, 2012|June 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384279||102334|
NCT01384292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00006|Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients With Cancer-Related Pain||AstraZeneca||Terminated|June 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|June 28, 2011|Yes|Yes|The study was stopped early due to recruitment challenges|No|October 13, 2014|https://clinicaltrials.gov/show/NCT01384292||102333|Due to recruitment challenges, enrollment was stopped early. 14 patients were randomized (<5% of planned number), thus, there was insufficient data to perform the protocol-specified statistical analyses. Secondary outcome measures are not reported.
NCT01385150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000702952|Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia|Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)||Not yet recruiting|August 2011|||September 2011|Anticipated|N/A|Observational|N/A|||Anticipated|220|||Both|17 Years|60 Years|No|||June 2011|July 7, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385150||102267|
NCT01385163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU-AMHR-IRC-2010|Intervention Effectiveness in Improving Psychosocial and Economic Well-being of Sexual Violence Survivors in DRC|Study of Intervention Effectiveness in Improving Psychosocial and Economic Well-being of Sexual Violence Survivors in DRC||Johns Hopkins Bloomberg School of Public Health|No|Recruiting|October 2010|July 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1000|||Female|18 Years|90 Years|No|||June 2011|July 15, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01385163||102266|
NCT01374152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Perfetti|Perfetti Method in Upper Extremity of Stroke Patients|A Randomized Controlled Trial of Cognitive Sensory Motor Training Therapy on the Recovery of Upper Extremity Function in Acute Stroke Patients||Prasat Neurological Institute|No|Completed|July 2008|June 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||July 2012|July 15, 2012|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374152||103105|
NCT01374165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIL-SANG-001|Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients|A Phase I Open Label, Unblinded, Single Dose Study for Evaluating the Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients||Prolong Pharmaceuticals|Yes|Suspended||||||Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|15|Samples Without DNA|Whole blood and urine|Both|18 Years|65 Years|No|Probability Sample|Sickle Cell Disease (SCD) patients|January 2015|January 5, 2015|May 26, 2011||No|Study cancelled.|No||https://clinicaltrials.gov/show/NCT01374165||103104|
NCT01374503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-0651-1.1/11|First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4|A Phase I, Single-centre, Randomised, Single-blinded, Placebo-controlled Single Ascending Dose Study, Followed by an Open-label Extension, Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of ALX-0651, Administered Intravenously to Healthy Male Volunteers||Ablynx|Yes|Terminated|June 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|June 14, 2011||No|Proof of principle established with completed SAD part|No||https://clinicaltrials.gov/show/NCT01374503||103078|
NCT01374516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD15|Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America|Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America||Sanofi|Yes|Active, not recruiting|June 2011|April 2018|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20869|||Both|9 Years|16 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374516||103077|
NCT01379261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHILL-MI|Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction|Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention For the Treatment of Acute Myocardial Infarction|CHILL-MI|Region Skane|Yes|Completed|June 2011|November 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|79 Years|No|||November 2014|November 5, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379261||102719|
NCT01375101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88705|Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus|||Mashhad University of Medical Sciences||Recruiting|April 2010|September 2011|Anticipated|September 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|60 Years|No|||July 2011|July 25, 2011|June 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375101||103034|
NCT01375114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0854|The Effects of Ginseng on Cancer-Related Fatigue|The Effects of Ginseng on Cancer-Related Fatigue||M.D. Anderson Cancer Center|Yes|Recruiting|October 2011|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|158|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375114||103033|
NCT01375413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gossweiler Foundation|Dual Task Practice in Parkinson's Disease|Motor Learning in Parkinson's Disease: a Randomized Comparison of Integrated Versus Consecutive Dual Task Training|Duality-PD|Katholieke Universiteit Leuven|Yes|Completed|June 2011|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|121|||Both|40 Years|80 Years|No|||October 2015|October 30, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375413||103011|
NCT01375686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2715|Noninvasive Screening for Early Evidence of Diabetes With SCOUT DS|Noninvasive Screening for Early Evidence of Diabetes With SCOUT DS|NSEEDS|VeraLight, Inc.|No|Completed|June 2011|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|486|Samples Without DNA|Serum will be stored to later analyze lipids and insulin. This will be useful in      understanding metabolic disorders experienced by the patients measured. These measurements      can be used directly, or combined in a manner similar to the McAuley index to understand the      risk of insulin insensitivity.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|In the study, volunteers age 18 and above, of either sex and of any ethnic background,        will be recruited at up to 9 clinical sites. The number of sites may be decreased as the        sponsor has the right to close a site due to protocol compliance or enrollment issues        during the course of the study. All subjects will be at risk for diabetes based on the        American Diabetes Association Standard of Care Guidelines. Subjects in the 18-44 age range        must have a BMI > 25 plus an additional risk factor for type 2 diabetes.|December 2012|December 3, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375686||102991|
NCT01375933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-4516|A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers|A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Assess Comparability of a Single Phase 3 Lot and a Single Commercial Lot of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Healthy Adult Smokers||Nabi Biopharmaceuticals|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|June 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375933||102972|
NCT01376232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113634|Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)|Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)|DDI|GlaxoSmithKline|No|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|May 10, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376232||102949|
NCT01381328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gepheral|GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance|GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance||Università Vita-Salute San Raffaele|No|Recruiting|December 2011|September 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|February 2013|February 8, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381328||102561|
NCT01381341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-817|To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.|A Phase 1 Pharmacokinetic Study To Compare the Relative Bioavailability of Two Clinical Formulations of Linifanib in Subjects With Solid Tumors||Abbott|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|No|||January 2012|March 21, 2012|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381341||102560|
NCT01381601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114866|Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)|Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)||GlaxoSmithKline|No|Completed|March 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|18 Years|64 Years|No|Non-Probability Sample|Study subjects will be selected from a source population consisting of all persons in the        PharMetrics database with one or more days of eligibility for comprehensive health        benefits between January 1, 2000 and December 31, 2009.|May 2013|May 9, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381601||102540|
NCT01382147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-003103-12|Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)|A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia|AMLCG 2008|Ludwig-Maximilians - University of Munich|Yes|Active, not recruiting|July 2009|July 2016|Anticipated|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382147||102498|
NCT01382940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25641|A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis|A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis|RATE-RA|Hoffmann-La Roche||Completed|July 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|351|||Both|18 Years|N/A|No|||January 2014|March 3, 2014|June 24, 2011|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01382940||102437|
NCT01382628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-101|Determination of the Pathophysicologic Collagen Changes in the Diabetic Achilles Tendon|Determination of the Pathophysicologic Collagen Changes in the Diabetic Achilles Tendon.||Georgetown University|No|Suspended|May 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|50|Samples Without DNA|A tissue sample (20mg) of the Achilles tendon will be collected at this time. This tissue      will be preserved in a dry ice container and shipped to Midwestern University for processing      by the sub-investigator (CC). The specimens will be labeled numerically with a predetermined      subject number. No patient identifying information will be on these samples.|Both|18 Years|N/A|No|Non-Probability Sample|Patients at Georgetown University Hospital, Center for Wound Healing or patients admitted        to the Georgetown University Hospital (where the Limb service has been designated as a        consulting or primary service) will be recruited into the study. Patients scheduled for an        Achilles tendon lengthening procedure (as part of their SOC) will be recruited.|August 2015|August 10, 2015|June 21, 2011||No|We are currently trying to find someone to assay the collagen|No||https://clinicaltrials.gov/show/NCT01382628||102461|
NCT01382641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hoya AF-1|Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery|Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery||Innovative Medical|No|Active, not recruiting|September 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2011|October 5, 2011|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01382641||102460|
NCT01383694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS 22/09|Effect Of Piperine In Patients With Oropharyngeal Dysphagia|Effect of Natural Agonists of TRPV1 in the Treatment of Functional Oropharyngeal Dysphagia in Neurological Diseases and the Elderly: Piperine|FIS 2009_2|Hospital de Mataró||Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383694||102379|
NCT01383707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25625|A Study of Bevacizumab (Avastin) and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Colorectal Cancer|A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial)||Hoffmann-La Roche||Active, not recruiting|August 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01383707||102378|
NCT01383668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC102A|Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer|Combined PKCiota and mTOR Inhibition for Treatment of Advanced Squamous Lung Cancer||Mayo Clinic|Yes|Withdrawn|June 2011|||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|June 24, 2011|Yes|Yes|lack of access to study drug|No||https://clinicaltrials.gov/show/NCT01383668||102381|
NCT01383681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/NS/SPA/019|Retrospective Study of Patients With Spasticity in the Spanish Population|Observational Study To Establish The Methodology Used In The Evaluation, Treatment And Assessment Of Progression Of Spasticity In The Spanish Population||Allergan|No|Completed|February 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|235|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of spasticity are selected from rehabilitation departments within        the Spanish health system.|September 2013|September 9, 2013|June 27, 2011||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT01383681||102380|Not enough data was collected for analysis of Physician's Assessment of Spasticity outcome measures.
NCT01383993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501096|Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection|An Open-Label, Non-Controlled, Multicenter, Intravenous To Oral Switch, Phase 2 Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To Less Than 15 Years Who Are At High Risk For Systemic Fungal Infection||Pfizer|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Both|2 Years|15 Years|No|||April 2014|April 8, 2014|June 27, 2011|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01383993||102356|
NCT01378468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The Berlin 'Cream&Sugar' Study|Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke|The Berlin 'Cream&Sugar' Study: the Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke||Charite University, Berlin, Germany|Yes|Recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|573|||Both|18 Years|N/A|No|Non-Probability Sample|the study population consists of adults with first ischemic stroke within the last three        to seven days (at time of testing).|September 2015|September 7, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01378468||102780|
NCT01378728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGI Wound Imaging Trial|Clinical Validation of a 'Hand-held' Fluorescence Digital Imaging Device for Wound Care Applications|Clinical Validation Study of a 'Hand-held' Point-of-Care Fluorescence Digital Imaging Device for Real-time Detection and Diagnosis of Wound Infections and Longitudinal Monitoring of Wound Healing Status||University Health Network, Toronto|Yes|Recruiting|February 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|All patients previously diagnosed with chronic and/or acute wounds will be considered for        eligibility into this study.|March 2016|March 7, 2016|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378728||102760|
NCT01379222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012289|Endurant Stent Graft System Post Approval Study|Post Approval Study Evaluating the Long Term Safety and Effectiveness of the Endurant Stent Graft System (ENGAGE PAS)|ENGAGE PAS|Medtronic Endovascular|No|Active, not recruiting|August 2011|March 2018|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379222||102722|
NCT01379235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC105809KCTIL|Association Between Pilatis Exercise, Balance and Stability Measurements, and Quality of Life Among Elderly Population|Association Between Pilatis Exercise, Balance and Stability Measurements, and Quality of Life Among Elderly Population||Meir Medical Center|Yes|Completed|January 2012|July 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|65 Years|N/A|No|||June 2012|November 18, 2014|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01379235||102721|
NCT01379508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600A2409|Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept|OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept|Sebivo/Tyzeka|Novartis|No|Completed|March 2011|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|241|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379508||102700|
NCT01379521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001OHK02|Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC|A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor®) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study|TRACER|Novartis||Completed|June 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||January 2016|January 23, 2016|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01379521||102699|
NCT01379768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-373-C-102|Study of the Cell Response in the Tear Film After Overnight Contact Lens Wear|Polymorphonuclear Leukocyte Response During Overnight Lens Wear|CORNWALL|Alcon Research|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|65|||Both|17 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 6, 2013|June 9, 2011|Yes|Yes||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01379768||102680|
NCT01380067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8808|a New Way for Laparoscopic Inguinal Hernia Repair in Pediatric|Phase 3 Study of a New Way for Laparoscopic Inguinal Hernia Repair in Pediatric||The Second People's Hospital of GuangDong Province|Yes|Completed|January 2000|December 2010|Actual|December 2005|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|486|||Both|2 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|The sample size was calculated such that a 4% difference (α = 0.05) in recurrence rate at        5 years between the groups could be detected with a power of 0.9. This required a sample        size of 510 patients. Considering an estimated drop-out rate of 10%, we aimed to enroll        600 patients.|December 2010|June 22, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01380067||102658|
NCT01381614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114867|Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)|Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)||GlaxoSmithKline|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|18 Years|64 Years|No|Non-Probability Sample|Study subjects will be selected from a source population consisting of all persons in the        IHCIS database with one or more days of eligibility for comprehensive health benefits        between January 1, 2000 and December 31, 2009.|May 2013|May 9, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381614||102539|
NCT01381900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018541|A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea||Janssen Research & Development, LLC|Yes|Completed|August 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|678|||Both|18 Years|80 Years|No|||April 2014|April 23, 2014|June 23, 2011|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT01381900||102517|
NCT01382160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI10-DM/AFORA|Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)|Serum Concentration of Adalimumab (Humira) as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)|AFORA|University Hospital, Tours|Yes|Completed|January 2011|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|69|||Both|18 Years|N/A|No|||October 2013|October 1, 2013|December 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01382160||102497|
NCT01383200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101016|Tetracaine Versus Lidocaine Gel for Anesthetic Effect and Comfort in Patients Undergoing LASIK|Comparison of 0.5% Tetracaine Drops Versus 2% Lidocaine Gel for Anesthetic Efficacy and Comfort in Patients Undergoing LASIK||University of Miami|No|Terminated|June 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 16, 2015|June 13, 2011|Yes|Yes|eyes that received gel had slightly thinner than intended flaps|No|January 14, 2013|https://clinicaltrials.gov/show/NCT01383200||102417|
NCT01383408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSH-TCH-IIT-2011-1|Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection|Distinction Between Lung Cancer and Gynecological Cancers by Exhalation Analysis and Canine Scent Detection||Schillerhoehe Hospital|No|Terminated|March 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|752|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2013|May 5, 2013|June 24, 2011||No|Inconsistent training status of sniffer dogs|No||https://clinicaltrials.gov/show/NCT01383408||102401|
NCT01383447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-02202|Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|A Phase 1/2 Study of SNDX-275 in Combination With Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Terminated|October 2010|||April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2013|March 11, 2013|May 5, 2011|Yes|Yes|Administratively complete.|No||https://clinicaltrials.gov/show/NCT01383447||102398|
NCT01383720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP3659|REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve SystEm||REPRISE I|Boston Scientific Corporation|No|Active, not recruiting|April 2012|May 2017|Anticipated|May 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|70 Years|N/A|No|||April 2012|April 27, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383720||102377|
NCT01383980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00006259|Trial of Continuous Versus Interrupted Feeding for Intubated Intensive Care Unit Patients|A Randomized Trial of Continuous Versus Interrupted Enteral Feeding in Critically Ill Surgical Patients Requiring Mechanical Ventilation||Oregon Health and Science University|Yes|Not yet recruiting|July 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2011|June 27, 2011|June 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01383980||102357|
NCT01384851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9965-004|Efficacy of the Chronic Application of Tear Formulations|Therapeutic Efficacy of the Chronic Application of Tear Formulations for Dry Eye and Normal Subjects Under Conditions of Environmental Stress||Glasgow Caledonian University|Yes|Not yet recruiting|July 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|38|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2011|June 30, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01384851||102290|
NCT01381185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNO-KVO-1|REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction|Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction|REACT-MI|University Hospital Ostrava|Yes|Recruiting|May 2011|July 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|154|||Both|21 Years|90 Years|No|||February 2015|February 24, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01381185||102572|
NCT01381198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RecRan271/2006|Distal Rectus Femoris Transfer as a Part of Multilevel Surgery in Children With Spastic Diplegia|Distal Rectus Femoris Transfer as a Part of Multilevel Surgery in Children With Spastic Diplegia - a Randomized Clinical Trial|RectusTrans|Heidelberg University|No|Completed|June 2007|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|6 Years|16 Years|No|||January 2011|July 8, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01381198||102571|
NCT01378481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01139|High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma|High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma||National Cancer Institute (NCI)||Terminated|June 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||March 2014|December 22, 2014|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01378481||102779|
NCT01378741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN10-0771A|Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care|Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care||University Health Network, Toronto|No|Completed|April 2011|April 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|185|||Both|60 Years|N/A|No|||April 2015|April 17, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378741||102759|
NCT01379248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEMI-Late-Presenter|Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset|||University of Leipzig||Recruiting|June 2011|June 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|90 Years|No|||July 2012|July 27, 2012|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01379248||102720|
NCT01379014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/EE/0156|CORAL Study: Proof of Concept Trial|The CORAL Study of a Decision Aid Tool Regarding Disclosure of Mental Health Status to an Employer: Proof of Concept Randomised Control Trial|CORAL|Institute of Psychiatry, London|No|Recruiting|July 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|84|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01379014||102738|
NCT01379300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-216|A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)|A Randomized Clinical Trial to Validate Novel Biomarker Approaches After Single Doses of Anticoagulants in Healthy Young Male Subjects and in Healthy Elderly Subjects||Merck Sharp & Dohme Corp.|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01379300||102716|
NCT01379534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2211|A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer|A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer||Novartis||Completed|November 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|18 Years|N/A|No|||May 2015|May 2, 2015|June 6, 2011|Yes|Yes||No|March 18, 2015|https://clinicaltrials.gov/show/NCT01379534||102698|
NCT01379781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6285|Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression|Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression||New York State Psychiatric Institute|Yes|Completed|August 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2013|July 13, 2015|June 22, 2011||No||No|May 12, 2015|https://clinicaltrials.gov/show/NCT01379781||102679|
NCT01379794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECC-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2009|||||N/A|N/A|N/A||||||||||||||April 12, 2013|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379794||102678|
NCT01379807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGIO-2010-01|Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|SPIGA|Grupo Gallego de Investigaciones Oncologicas|No|Active, not recruiting|December 2010|December 2015|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||April 2011|March 10, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01379807||102677|
NCT01380080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5274|REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment|Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)|REMEMBER|AIDS Clinical Trials Group|Yes|Active, not recruiting|October 2011|April 2016|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|851|||Both|13 Years|N/A|No|||January 2016|January 26, 2016|June 22, 2011|Yes|Yes||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01380080||102657|
NCT01380418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H0605/9|Factors Associated With Chronic Respiratory Failure in Obesity|Factors Associated With Chronic Respiratory Failure in Obesity: A Cross-sectional Study||Oxford University Hospitals NHS Trust|No|Not yet recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|60|Samples With DNA|Blood, fat, muscle|Both|18 Years|85 Years|No|Non-Probability Sample|Obese (BMI > 30kg/m2) with or without OHS (18-85yrs)          1. Admitted for management of OHS          2. Attending the sleep and ventilation clinic          3. Being assessed for bariatric surgery|June 2011|July 7, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01380418||102631|
NCT01381627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11021|Safety Evaluation of Dexmedetomidine for EBUS-TBNA|Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration|EBUSed|Maisonneuve-Rosemont Hospital|Yes|Recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|75 Years|No|||June 2011|February 27, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01381627||102538|
NCT01381913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACRT-GC|Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer|Feasibility Trial of Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer Combined With Adjacent Tissue Invasion||Kagawa University|No|Completed|October 2005|May 2011|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|tissue|Both|20 Years|80 Years|No|Probability Sample|-  Histologically proven gastric adenocarcinoma          -  Tumor invasion of adjacent structures (T4) and/or tumors with bulky nodal metastases|October 2005|June 23, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01381913||102516|
NCT01382407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B427CTIL|Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab|Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab?||Rambam Health Care Campus|No|Active, not recruiting|July 2011|April 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|All patients above the age of 18 years, who have been diagnosed with confirmed KRAS-WT        mCRC, and are starting treatment with cetuximab, will be informed of the study.|May 2015|May 11, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382407||102478|
NCT01382654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033-102|Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis|||Merck Sharp & Dohme Corp.||Completed|September 2006|October 2006|Actual|October 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|131|||Both|18 Years|70 Years|No|||October 2015|October 8, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382654||102459|
NCT01382966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFM RENAL|Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients|The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients||RFM Renal Treatment Services|Yes|Not yet recruiting|July 2011|October 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Maintenance hemodialysis patients (minimum 6 months of duration) No infection, malignancy        and autoimmune disease Age> 18 years|June 2011|June 27, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01382966||102435|
NCT01383187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-OVZ-09-024|Autologous Platelets Concentrate and Autologous Thrombin for the Treatment of Deep Burn Trauma|An Open-label, Non Randomized, Single-Center Registry Study to Assess the Safety and Effects of Autologous Platelets Concentrate and Autologous Thrombin for the Treatment of Deep Burns Trauma||University Hospital Ostrava|Yes|Completed|November 2008|December 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|85 Years|No|||March 2013|March 21, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01383187||102418|
NCT01384006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXPAND|Extended Pancreas Donor Program - The EXPAND Study|EXTENDED PANCREAS DONOR PROGRAM - THE EXPAND STUDY|EXPAND|University of Regensburg|Yes|Recruiting|June 2011|June 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|110|||Both|18 Years|N/A|No|Probability Sample|Pancreas allograft recipients in Germany|June 2011|June 30, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384006||102355|
NCT01384318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00414|Accuracy of Using the CPAP Technique to Eliminate Air Leak and Prevent Excessive Endotracheal Tube Cuff Pressures|||Nationwide Children's Hospital|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|N/A|17 Years|No|Non-Probability Sample|Patients intubated with cuffed ETTs.|November 2012|November 29, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384318||102331|
NCT01383733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25448|A Study of RO5458640 in Patients With Advanced Solid Tumors|A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients With Advanced Solid Tumors||Hoffmann-La Roche||Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383733||102376|
NCT01384617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNOW study-1101|Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy|Roux-en-Y Anastomosis of the Pancreatic Stump Following Distal Pancreatectomy||Wakayama Medical University|Yes|Active, not recruiting|June 2011|June 2016|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|136|||Both|20 Years|N/A|No|||July 2014|July 4, 2014|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01384617||102308|
NCT01381211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/050|Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)|Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial (TRACE Trial)|TRACE|University Hospital, Ghent|No|Recruiting|September 2011|December 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01381211||102570|
NCT01378754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12588|Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia|A DOSE RANGING STUDY TO EVALUATE THE EFFECTIVENESS OF FOSPROPOFOL (LUSEDRA®) FOR INDUCTION OF ANESTHESIA FOR OUTPATIENT UROLOGIC HYDRODILATION THERAPY||University of Kansas Medical Center|Yes|Withdrawn|June 2011|June 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||October 2012|October 2, 2012|June 8, 2011|Yes|Yes|Loss of funding before enrollment.|No||https://clinicaltrials.gov/show/NCT01378754||102758|
NCT01379027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH087505|MoodHelper: Internet Cognitive Behavioral Therapy (CBT) for Depression|Internet CBT for Depression: Comparing Pure, Guided, and Stepped Care||Kaiser Permanente|Yes|Active, not recruiting|October 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1800|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01379027||102737|
NCT01379287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-202|Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors|A Phase I, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|June 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01379287||102717|
NCT01379560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPA/UIOS-AMD-1021|A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration|||Sucampo Pharma Americas, LLC||Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|50 Years|N/A|No|||March 2013|March 21, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379560||102696|
NCT01379274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS 2008-01|A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes|A Phase II Trial of Revlimid® (Lenalidomide) and Low Dose Vidaza® (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes||Rush University Medical Center|Yes|Terminated|January 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|90 Years|No|||November 2013|November 26, 2013|June 17, 2011|Yes|Yes|Loss of funding.|No||https://clinicaltrials.gov/show/NCT01379274||102718|
NCT01379547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101079RB|Procalcitonin to Shorten Antibiotics Duration in ICU Patients|Procalcitonin to Shorten Antibiotics Duration in ICU Patients- A China, Hong-Kong, Taiwan Multicenter Trial|ProShort|National Taiwan University Hospital|Yes|Recruiting|June 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1700|||Both|20 Years|N/A|No|||November 2012|November 26, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379547||102697|
NCT01379820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2008|Use of Orotracheal Continuous Positive Airway Pressure (CPAP) in Newborns With Respiratory Failure|Use of Orotracheal CPAP ( Gregory System) for Treatment of Respiratory Failure in Newborns||Hospital Angeles del Pedregal|Yes|Not yet recruiting|June 2011|June 2011|Anticipated|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||June 2011|June 22, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01379820||102676|
NCT01379833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT0120511|Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy|Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy||State University of New York at Buffalo|No|Recruiting|May 2011|May 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with severe CIDP.|June 2011|June 21, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01379833||102675|
NCT01381354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200911781|Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)|Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)||University of Iowa|Yes|Active, not recruiting|October 2010|May 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01381354||102559|
NCT01381640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4040689|A Study to Compare Two Paracetamol Tablets|A Single Dose Pharmacoscintigraphic Study Investigating the Differences in Gastrointestinal Behavior and Paracetamol Absorption Between Sustained Release Formula and Standard Release Formula||GlaxoSmithKline|No|Withdrawn|April 2010|May 2010|Anticipated|May 2010|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|June 20, 2013|June 23, 2011||No|Study was cancelled prior to enrolling any subjects.|No||https://clinicaltrials.gov/show/NCT01381640||102537|
NCT01381653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03DA031607|An Innovative HIV Prevention Intervention Using Social Networking Technology|An Innovative HIV Prevention Intervention Using Social Networking Technology||Hunter College|Yes|Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01381653||102536|
NCT01382173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOHAK-11|Monitoring of Acute Knee Injuries to Understand Osteoarthritis Development|The Acute Knee Injury Project||Lund University|No|Recruiting|March 2012|January 2019|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Joint fluid, Serum & Plasma|Both|12 Years|40 Years|No|Probability Sample|We will recruit approximately 150 patients annually over 3-4 years with the goal of        including at least:          -  200 knees with isolated or combined ACL injuries          -  50 isolated meniscus tears          -  50 primary patellar dislocations          -  50 contusions without ligamentous, cartilage or meniscus injury.        Patients will be recruited using two different strategies:          1. Those seeking medical care at the orthopedic emergency room (ER) at Helsingborg             hospital          2. Those referred to the orthopedic outpatient health care unit of Helsingborg hospital             due to an acute knee injury by their primary health care unit will be scheduled for a             clinical visit for baseline assessment (visit 1) within four weeks from their injury.             To facilitate recruitment, primary care units in the local area of Helsingborg will             be offered an opportunity to refer all patients with rotational knee trauma and             effusion directly to the orthopedic outpatient care unit.|September 2015|September 10, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382173||102496|
NCT01382420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-03-034|Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma|Long-term Effects of Adrenalectomy on Metabolic Syndrome, Glucose Metabolism, Lipid Metabolism, and Bone Metabolism in Subclinical Cushing's Syndrome of Adrenal Incidentaloma||Samsung Medical Center||Recruiting|May 2011|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|234|||Both|20 Years|70 Years|No|||November 2015|November 16, 2015|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01382420||102477|
NCT01383460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS ACLF 01|Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure|Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF)||Institute of Liver and Biliary Sciences, India|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|55|||Both|12 Years|75 Years|No|||July 2012|April 2, 2014|June 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01383460||102397|
NCT01383434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J10117|Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia|A Phase II Trial of Myeloablative Conditioning and Transplantation of HLA-matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated (MUD) Bone Marrow for Patients With Refractory Severe Aplastic Anemia||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|June 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|6 Months|70 Years|No|||October 2014|October 1, 2014|June 22, 2011||No|New revised SAA BMT study opened to take over this study|No||https://clinicaltrials.gov/show/NCT01383434||102399|
NCT01384877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00150|Subcutaneous Lidocaine For Cancer-Related Pain|A Randomized Double Blind Placebo Controlled Crossover Trial of the Use of Subcutaneous Lidocaine Infusion (SCLI) for Chronic Cancer-related Pain||British Columbia Cancer Agency|No|Recruiting|December 2011|||August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384877||102288|
NCT01385176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NECTAR-1109|Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)|Neural Cardiac Therapy for Heart Failure Study|NECTAR-HF|Boston Scientific Corporation|Yes|Active, not recruiting|June 2011|January 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385176||102265|
NCT01384591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-091|Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly|Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly||The University of Texas Medical Branch, Galveston|Yes|Completed|July 2011|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|6|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01384591||102310|
NCT01385189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVI-11-01|Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant|Phase I Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With Different Doses of the Novel Immunostimulant GLA-AF in Healthy Adults||Albert B. Sabin Vaccine Institute|Yes|Completed|May 2012|June 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|9||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|June 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01385189||102264|
NCT01372397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0613|Reversal of Obesity Cardiomyopathy|Reversal of Obesity Cardiomyopathy After Gastric Bypass||Washington University School of Medicine|Yes|Active, not recruiting|May 2010|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Blood Samples|Both|35 Years|65 Years|No|Probability Sample|Patients who are obese with heart failure and will undergo gastric bypass surgery or who        have already had gastric bypass surgery.|June 2015|June 4, 2015|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372397||103238|
NCT01384890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMAT, CBCT for H&N ca|Feasibility of VMAT and CBCT for Head and Neck Carcinomas|Feasibility of Volumetric Modulated Arc Therapy and Cone-Beam Computed Tomography for Head and Neck Carinomas: Analysis of Clinical Throughput and Patient Reported Outcomes.||British Columbia Cancer Agency|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Months|N/A|No|||February 2013|February 5, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384890||102287|
NCT01384903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3357-004|An Open-label Study of KW-3357|An Open-label Study of KW-3357 Compared to Plasma-derived Antithrombin for Disseminated Intravascular Coagulation (DIC) Associated With Infection|3357-004|Kyowa Hakko Kirin Company, Limited||Completed|June 2011|||May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|N/A|No|||June 2013|June 4, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384903||102286|
NCT01384916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR012005|Holistic Approaches to Depression|Holistic Approaches to Depression|HAD|Butler Hospital|Yes|Active, not recruiting|June 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384916||102285|
NCT01378767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110184|Health Benefits of a 21-day Daniel Fast|Biochemical, Hemodynamic, and Anthropometric Effects of a 21-day Daniel Fast in Men and Women||University of Memphis|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 20, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01378767||102757|
NCT01378780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS65675|Stroke Health and Risk Education (SHARE)|Stroke Health and Risk Education (SHARE)|SHARE|University of Michigan|No|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|760|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 27, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01378780||102756|
NCT01379313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-007|The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position|The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position||Samsung Medical Center|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|100|||Both|20 Years|65 Years|No|||September 2012|September 27, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379313||102715|
NCT01379573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00369|Preventive Approach to Congenital Heart Block With Hydroxychloroquine|Preventive Approach to Congenital Heart Block With Hydroxychloroquine|PATCH|New York University School of Medicine|Yes|Recruiting|January 2011|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|54|||Female|18 Years|45 Years|No|||March 2016|March 10, 2016|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01379573||102695|
NCT01379872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRP.11A|Assessment of New Radiation Oncology Technologies and Treatments|The Assessment of New Radiation Oncology Technologies and Treatments (ANROTAT) TROG Research Project TRP11.A|ANROTAT|Trans-Tasman Radiation Oncology Group (TROG)|No|Completed|June 2011|June 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Retrospective||4|Actual|138|||Both|18 Years|80 Years|No|Non-Probability Sample|Study Protocol A - IMRT Post Prostatectomy: Patients with prostate cancer (post        prostatectomy) Study Protocol B - IMRT Anal Cancer: Patients with anal cancer Study        Protocol C - IMRT Nasopharynx: Patients with nasopharynx cancer Study Protocol D - IGRT        Intact Prostate: Patients with prostate cancer|June 2011|February 12, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01379872||102673|
NCT01379846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-816/CCT-001|Study of TAK-816 in Healthy Infants|A Randomized, Double-Blind, Multicenter, Parallel-Group Comparative Phase III Study Evaluating the Efficacy and Safety of TAK-816 Compared With ActHIB in Healthy Infants||Takeda|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|416|||Both|3 Months|6 Months|Accepts Healthy Volunteers|||March 2013|March 4, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379846||102674|
NCT01380119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|imm02|Tuberculosis (TB) Immunotherapy Phase 2 Study|Phase 2 Study of Orally Formulated Heat-killed Mycobacterium Vaccae Study in TB Patients|imm02|Lisichansk Regional Tuberculosis Dispensary|No|Completed|August 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||October 2013|October 25, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01380119||102654|
NCT01380132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasha Dx Pilot study|Safety and Efficacy of Anorectal Application of Dx-gel for Treatment of Anal Incontinence|Safety and Efficacy of Anorectal Application of Dx-gel for Treatment of Anal Incontinence||Uppsala University Hospital|No|Completed|February 2004|May 2009|Actual|January 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|80 Years|No|||February 2010|June 27, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01380132||102653|
NCT01380457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11885|Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions|A Comparative Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|January 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|69|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380457||102628|
NCT01380470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brisa I|Prevalence of Undiagnosed Chronic Obstructive Pulmonary Disease Sufferers in the Region of Murcia|Prevalence of Undiagnosed Sufferers in Murcia :Cross-sectional Study||Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|No|Completed|February 2010|June 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2627|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Group of patients seen in consultation not previously diagnosed with COPD, both sexes,        aged between 40 and 70 years.|June 2011|June 23, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380470||102627|
NCT01381367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-97-C-037|PPSV23 Pneumococcal Vaccine in Chronic Obstructive Pulmonary Disease (COPD)|Phase 4 Study of PPSV23 Pneumococcal Vaccine in COPD Patients Using High Daily Dose of Inhaled Corticosteroid||Far Eastern Memorial Hospital|Yes|Completed|February 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|65 Years|No|||June 2011|June 24, 2011|February 16, 2009||No||No||https://clinicaltrials.gov/show/NCT01381367||102558|
NCT01382186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 11-397|Veterans Experiences Using Secure Messaging|Veterans' Experiences Using Secure Messaging on MyHealtheVet||VA Office of Research and Development|No|Completed|April 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|852|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Veterans in Tampa and Boston who have been Personally Authenticated for the SM feature on        MHV.|October 2014|April 6, 2015|June 15, 2011||No||No|October 28, 2014|https://clinicaltrials.gov/show/NCT01382186||102495|
NCT01382199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VB-Ven100-2011-01|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients|A Phase III Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients||Ventria Bioscience|Yes|Not yet recruiting|September 2011|March 2014|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Prevention|1||Anticipated|340|||Both|50 Years|N/A|No|||June 2011|June 23, 2011|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382199||102494|
NCT01382953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10131-01B|The Simple ECG Monitoring Trial (Comparison of a Novel Recording System With a Standard Holter Monitor)|The Simple ECG Monitoring Trial (Comparison of a Simple ECG Recording System With a Standard ECG Recording System for Holter Monitoring)||Seattle Institute for Cardiac Research|Yes|Completed|August 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic referral, Cardiology Clinic, Electrophysiology Clinic|January 2012|January 7, 2012|June 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382953||102436|
NCT01384331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R2011-01|New Treatments for Troublesome Bleeding in Implanon Users|Phase 4 Study Comparison of Two Combined Oral Contraceptive Regimens and an Intravaginal Hormonal Ring Against Placebo for Management of Bleeding Problems in Women Using Implanon, the Sub-dermal Contraceptive Implant||Family Planning Association New South Wales|No|Not yet recruiting|July 2011|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384331||102330|
NCT01383213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCAPOVERSO|Helmet Continuous Positive Airway Pressure (CPAP) Versus Oxygen Venturi in Severe Acute Respiratory Failure in Pneumonia|A Prospective, Randomized, Controlled Trial to Evaluate the Efficacy of CPAP Delivered by Helmet in Comparison With Oxygen Therapy by Venturi Mask in Severe Acute Respiratory Failure Caused by Pneumonia||University of Milan|Yes|Completed|February 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|June 13, 2011||No||No|December 31, 2013|https://clinicaltrials.gov/show/NCT01383213||102416|
NCT01384032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT085045MA|Study Into Genetic Influence on Cholesterol Response to Dietary Fat|Apolipoprotein E Genotype as a Determinant of LDL-cholesterol Response to Dietary Fat Manipulation|Satgene|University of Reading|Yes|Completed|January 2009|May 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|88|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01384032||102353|
NCT01385202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smart-AF|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation||Biosense Webster, Inc.||Completed|June 2011|May 2013|Actual|February 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|172|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|June 27, 2011|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01385202||102263|
NCT01384344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-03|Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy|Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Interest on Video Recognition and Actigraphy||Centre Hospitalier Universitaire de Nice|No|Completed|June 2011|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|82|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2011|December 17, 2012|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384344||102329|
NCT01372696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LST-SGM|Endoscopic Characteristics of Colonic Tumours|A Correlation of the Endoscopic Characteristics of Colonic LSTs With Their Somatic or Germline Mutations. A Prospective, Genome Wide Study|C-LST|Western Sydney Local Health District|No|Recruiting|November 2009|December 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|350|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01372696||103215|
NCT01372683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP 1103|Oat Breakfast Satiety Study|The Effect of Oat Based Breakfast Cereals on Satiety||PepsiCo Global R&D|No|Completed|May 2011|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|96|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 19, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372683||103216|
NCT01379040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF1|Volatile Organic Compounds in Cystic Fibrosis|Detection of Pulmonary Colonization in Cystic Fibrosis Patients|VOCCF|Landon Pediatric Foundation|No|Completed|August 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|24|||Both|1 Year|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be selected from Dr. Landon's primary care clinic.|August 2014|August 12, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379040||102736|
NCT01373983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-018920-21|Intrathecal Bolus Doses of Ziconotide|Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study|ZicBol|University Hospital, Linkoeping|Yes|Completed|August 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|18 Years|N/A|No|||December 2014|December 28, 2014|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01373983||103118|
NCT01380145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGS 2009-005|MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation|Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation||Ludwig Institute for Cancer Research|No|Active, not recruiting|June 2011|May 2018|Anticipated|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380145||102652|
NCT01380158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-225|Preventing Preterm Birth With a Pessary|Preventing Preterm Birth With a Pessary|PrePPy|Medstar Research Institute|No|Recruiting|January 2011|||October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|238|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|July 7, 2011|June 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380158||102651|
NCT01380483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99117|Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions|Randomized, 2-way Crossover, Comparative Bioequivalence Study of Par Pharmaceutical Inc. (USA) and Oclassen Pharmaceuticals Inc. (USA) (Monodox(R)) Doxycycline Monohydrate Equivalent to 100 mg Doxycycline Administered as a Single Dose of 100 mg In Healthy Adult Males Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|January 2000|April 2000|Actual|April 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01380483||102626|
NCT01380496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99118|Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions|Randomized, 3-Way Crossover, Comparative Bioequivalence Study of Par Pharmaceutical Inc. (USA) and Oclassen Pharmaceuticals Inc. (USA)(Monodox(R)) Doxycycline Monohydrate Equivalent to 100 mg Doxycycline Administered as a Single Dose of 100 mg In Healthy Adult Males Under Fasting and Fed Conditions||Par Pharmaceutical, Inc.|No|Completed|November 1999|November 1999|Actual|November 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01380496||102625|
NCT01380509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTL-P2-155|Bioavailability Study of Metronidazole Capsules Under Fasting Conditions|To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules( G.D. Searle, Inc) Under Fasting Conditions||Par Pharmaceutical, Inc.|No|Completed|August 2002|October 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380509||102624|
NCT01380522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTL-P2-156|Bioavailability Study of Metronidazole Capsules Under Fed Conditions|To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules/( G.D. Searle, Inc) Under Fed Conditions||Par Pharmaceutical, Inc.|No|Completed|August 2002|September 2002|Actual|September 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380522||102623|
NCT01380808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2011-05|Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)|A Phase II Study of Capecitabine and Pseudomonas Aeruginosa Combination in the Salvage Treatment of Metastatic Breast Cancer||Fudan University|Yes|Completed|May 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|18 Years|70 Years|No|||July 2013|July 25, 2013|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01380808||102601|
NCT01381380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276|Manual Therapy Treatment for Myofascial Pain|Effect of Manual Therapy After Trigger Point Injection for Myofascial Pain Syndrome||Federal University of São Paulo|Yes|Completed|November 2006|December 2009|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||November 2007|June 24, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381380||102557|
NCT01381393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110603|BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Administered in Korean Patients According to the Prescribing Information|BONPMS|GlaxoSmithKline|No|Completed|June 2007|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|659|||Female|N/A|N/A|No|Probability Sample|Patients administrated ibandronate with postmenopausal osteoporosis in Korea|November 2012|November 28, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381393||102556|
NCT01381926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F100929001|Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist|Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist (UAB Core Center for Basic Skeletal Research)|CMBD|University of Alabama at Birmingham|No|Recruiting|February 2011|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|30|||Female|45 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01381926||102515|
NCT01381939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6647416|Induction of Labor in Intrahepatic Cholestasis of Pregnancy|Induction of Labor in Intrahepatic Cholestasis of Pregnancy|ILICP|Karolinska Institutet|No|Completed|January 2000|April 2010|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|5000|||Female|N/A|N/A|No|Non-Probability Sample|Swedish women affected by ICP delivering at Danderyd Hospital between year 2000-2006.|March 2010|June 24, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381939||102514|
NCT01382706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-10-4|Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder|Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment||University of Southern California|Yes|Terminated|June 2011|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|June 23, 2011||No|Trial not progressing toward scientific goals|No||https://clinicaltrials.gov/show/NCT01382706||102455|
NCT01383746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100701|Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION|Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy|CHOLANGIOSIR|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|October 2011|October 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|June 27, 2011||No|Not enough inclusion|No||https://clinicaltrials.gov/show/NCT01383746||102375|
NCT01376583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK-H-3-2010-141|Exercise Controls Tumor Cell Growth Through AMPK Activation|Running From Cancer||Rigshospitalet, Denmark|No|Recruiting|March 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Bloodsamples wherefrom, serum is isolated and kept at -20 degrees celsius|Female|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Danish females in the age 18-30|November 2013|November 28, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376583||102922|
NCT01372111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRO11|Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer|Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial||Coastal Carolina Radiation Oncology|No|Active, not recruiting|March 2011|||March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01372111||103260|
NCT01373580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-0003|A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near Vision in Presbyopic Patients|A Prospective, Multinational Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc. PresbyLens Corneal Inlay for the Improvement of Near Vision in Presbyopic Subjects With MRSE From -0.50 to +1.00||ReVision Optics, Inc.|No|Active, not recruiting|April 2010|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|373|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||July 2015|January 28, 2016|June 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01373580||103148|
NCT01373944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-Spect Stress Only|Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI|Rapid-Acquisition Low-Dosimetry Tc-99m Stress-Only Myocardial Perfusion SPECT on the Spectrum Dynamics System: Comparison of Efficiency and Outcomes With Stress-Only Anger SPECT||Aspire Foundation|No|Completed|May 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|500|||Both|18 Years|90 Years|No|Non-Probability Sample|Consecutive patients referred for clinically-indicated myocardial perfusion SPECT|December 2013|December 20, 2013|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01373944||103121|
NCT01372943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED 1318-10|Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection|A Study Using "Synthetic Stool" or Pure Cultures of Probiotic Intestinal Bacteria From Healthy Donor Stool That Can be Used as an Enema to Replace the Use of Stool Transplant, for Treatment of Recurrent and Refractory CDI||Queen's University|No|Active, not recruiting|January 2010|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01372943||103196|
NCT01372956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CKR-XXX-2011/1|Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea|Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)|CRESENDO|AstraZeneca|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|4950|||Both|19 Years|N/A|No|Probability Sample|Primary Care|December 2011|December 21, 2011|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01372956||103195|
NCT01379586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4053POE001|A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers|A Phase 1, Single Centre, Three-part, Randomised, Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Multiple Ascending Doses of Oral ONO-4053 and the Effects of Food on This Profile in Healthy Male and Female Subjects||Ono Pharmaceutical Co. Ltd|No|Terminated|June 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379586||102694|
NCT01379599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00218400|Brief Intervention to Reduce STDs in ER Drug Users|Brief Intervention to Reduce STDs in ER Drug Users|SAFE|Boston Medical Center|Yes|Completed|November 2004|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|1030|||Both|18 Years|54 Years|No|||August 2014|August 20, 2014|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01379599||102693|
NCT01373658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20100910|Safety and Efficacy Registry of Yinyi Stent (SERY-II)|Safety and Efficacy Registry of Yinyi Polymer-free Paclitaxel-eluting Stent|SERY-II|Shanghai Jiao Tong University School of Medicine|No|Recruiting|May 2010|December 2011|Anticipated|October 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|80 Years|No|||March 2010|June 13, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01373658||103142|
NCT01373671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMS-SP09-01|Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging|Multi-center Case Collection Study to Create a Library of Images From Various Approved Full Field Digital Mammography (FFDM) Systems and 3D Images From Siemens Inspiration Digital Breast Tomosynthesis (DBT) System for Studies in Support of the Inspiration Digital Breast Tomosynthesis Approval|DBT|Siemens Medical Solutions USA - CSG|No|Completed|May 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|765|||Female|30 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 13, 2014|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373671||103141|
NCT01373684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV11-01|PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients|Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS)|PAS|Foundation for Liver Research|No|Recruiting|March 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373684||103140|
NCT01379885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCaliforniaSF|Reducing Immunization Distress (RID)|Childhood Immunization: Reducing Immunization Distress (RID) Using Multi-Modal Distraction|RID|University of California, San Francisco|No|Terminated|June 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|77|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|June 13, 2011||No|Estimated sample size not achieved due to decline in number of eligible patients and    difficulty recruiting and retaining research staff.|No||https://clinicaltrials.gov/show/NCT01379885||102672|
NCT01379898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESCRIPT2010.369|Phenoxybenzamine Versus Doxazosin in PCC Patients|Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment|PRESCRIPT|University Medical Center Groningen|No|Recruiting|December 2011|December 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379898||102671|
NCT01380171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-196|Primary Palatoplasty in Pediatric Patients - A Retrospective Review of Surgical Outcomes|Primary Palatoplasty in Pediatric Patients - A Retrospective Review of Surgical Outcomes||Children's Healthcare of Atlanta|Yes|Completed|February 2007|December 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1295|||Both|N/A|N/A|No|Non-Probability Sample|1295 patients with cleft lip/palate that have been treated since 1998 at the Center for        Craniofacial Disorders at Children's Healthcare of Atlanta on the Scottish Rite campus.|June 2011|June 24, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01380171||102650|
NCT01380184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-059|Pharmacokinetics of Ridaforolimus in Chinese Participants (MK-8669-059)|A Study to Assess the Pharmacokinetics of Ridaforolimus in Chinese Patients||Merck Sharp & Dohme Corp.|No|Completed|July 2011|April 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||February 2015|February 6, 2015|June 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380184||102649|
NCT01374269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLSejervsaine|Improvement in Pain,Function and HRQoL ( Health Related Quality of Life) in Subacute Low Back Pain: A Controlled Clinical Trial of Exercise vs NSAIDs (Nonsteroidal Antiinflammatory)|Improvement in Pain, Function and Quality of Life With a Protocolized Exercise Program Compared With Non-steroidal Anti-inflammatory Analgesics in Patients With Subacute Low Back Pain in Medellín, Colombia, 2009-2010|DLSEA|Grupo Rehabilitacion en Salud|Yes|Completed|June 2009|March 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|60 Years|No|||March 2014|March 18, 2014|June 14, 2011||No||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01374269||103096|The study population was associated with the university’s health service. Female subjects predominated. The 6-month follow-up prevents conclusions about the improvement duration. No subgroup classification was performed. No control group was planned.
NCT01374282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0172-001|Post Marketing Surveillance Study of Cuprimine|Post Marketing Surveillance Study of Cuprimine (MK-0172-001)||Merck Sharp & Dohme Corp.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A|No|||October 2015|October 21, 2015|June 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01374282||103095|
NCT01374594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL-INK II|Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients|||University Hospital, Gentofte, Copenhagen|No|Completed|June 2011|November 2012|Actual|June 2012|Actual|N/A|Observational|N/A||2|Actual|30||blood samples|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects and type 2 diabetes patients (T2DM)|January 2013|January 22, 2013|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374594||103072|
NCT01382433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010-11-SHA|Chronic Cannabis Users: A Model for Negative Symptoms in Schizophrenia|Clinical Assessment of Negative Symptoms Neurocognitive and Electrophysiological Characteristics in Chronic Cannabis Users||Shalvata Mental Health Center|Yes|Recruiting|July 2011|||July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|115|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 29, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382433||102476|
NCT01382238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114556|Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir|Relative Bioavailability Study of a Tablet Formulation vs. Pediatric Granule Formulation of Dolutegravir 50 mg and Effect of Different Types of Water Plus Infant Formula on the Pediatric Granule Formulation in Healthy Male and Female Volunteers||ViiV Healthcare|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 15, 2011|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01382238||102491|
NCT01382667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRLP06|Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy|Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis||Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|No|Completed|July 2011|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|Samples Without DNA|whole blood serum|Both|18 Years|70 Years|No|Non-Probability Sample|Twenty-five patients who had undergone surgical ablation of the primitive tumour (lung and        breast cancer) as definitive primary treatment and attending the Oncology Day Hospital of        our Institute,and the IRCCS Oncologico of Bari will be enrolled. They had to be scheduled        for adjuvant therapies associated with a standard dosage of antiserotoninergic drugs        according to ESMO recommendations|November 2012|November 8, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382667||102458|
NCT01382680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136/10|Comparison of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil and a Nitinol Guide Wire|Comparison of the Use of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil Guide Wire With a Nitinol Wire in Patients With Stenosis of the Bile Ducts in ERCP||Johann Wolfgang Goethe University Hospitals|No|Completed|October 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|222|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01382680||102457|
NCT01382693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36459 EP|Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia|Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia in Long-term Care: a Cluster-randomized Pilot Study||Milton S. Hershey Medical Center|No|Completed|June 2011|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|60 Years|N/A|No|||July 2012|July 3, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382693||102456|
NCT01383226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53313|Linear Endosonography for the Assessment of Sarcoidosis Stage O|CT Enlarged Mediastinal/Hilar Lymph Nodes Not Visible on Chest X-ray in the Non Cancer Patient : Diagnosis and Clinical Implications Using Endobronchial or Esophageal Ultrasound Controlled Needle Aspiration E(B)US-NA|LASSO|Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|June 2011|April 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2011|October 8, 2013|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383226||102415|
NCT01383473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHOOL1|Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients|Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients||St. Jude Children's Research Hospital|No|Completed|August 2011|July 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|14|||Both|6 Years|12 Years|No|Non-Probability Sample|Participants will consist of 6-12-year-old patients currently on therapy for a primary        diagnosis of a leukemia/lymphoma or solid tumor at St. Jude Children's Research Hospital        in Memphis, Tennessee. Potential participants will be recruited via a medical chart review        performed by the principal investigator in order to identify children who have been on        active therapy for a malignancy for 6 months (plus or minus 2 months) at the time of        enrollment on this protocol|August 2013|August 26, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383473||102396|
NCT01383486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15833|Self Selection Trial of Naproxen Sodium|A Pilot Self Selection Trial of an Extended-Release Over-the-Counter Analgesic|KEIFER SST|Bayer|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|253|||Both|12 Years|N/A|Accepts Healthy Volunteers|||June 2015|September 24, 2015|June 27, 2011|No|Yes||No|August 30, 2012|https://clinicaltrials.gov/show/NCT01383486||102395|
NCT01384604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 112010-097|Neurophysiological Studies in Schizophrenia and Psychiatric Disorders|Neurophysiological and Genetic Studies in Schizophrenia and Other Psychiatric Disorders|BSNIP|University of Texas Southwestern Medical Center|Yes|Recruiting|December 2007|||August 2012|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|1189|Samples With DNA|Blood, no more than 30cc; urine, small collection cup (about 30cc) to administer drug urine      screen and pregnancy tests for females; buccal swabs (at least 5 swabs from volunteers that      cannot donate blood); and, optional: 4mm punch of skin for dermal biopsy.|Both|15 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with schizophrenia, schizoaffective, or bipolar I disorder.|June 2012|June 21, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384604||102309|
NCT01384864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO# 09-0696 Project 3|Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia|Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia||Anandasabapathy, Sharmila, M.D.|Yes|Completed|August 2011|December 2015|Actual|December 2015|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384864||102289|
NCT01372124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXE36C201|A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36|A Phase I, Open Label, Parallel Group, Multi-center Single Dose Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36||NOXXON Pharma AG|No|Completed|June 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 18, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01372124||103259|
NCT01372410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115321|A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)|AC4115321|GlaxoSmithKline|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|163|||Both|40 Years|80 Years|No|||May 2012|December 19, 2013|June 9, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01372410||103237|
NCT01374256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISP 38889|Imipenem and Sulbactam in the Treatment of Imipenem-resistant Acinetobacter Baumannii Bacteremia|Effectiveness of Imipenem and Sulbactam in the Treatment of Bacteremic Patients Contracted With Imipenem-resistant Acinetobacter Baumannii||Taipei Veterans General Hospital, Taiwan|No|Not yet recruiting|July 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|Samples Without DNA|Acinetobacter baumannii isolates from the blood samples of patients|Both|18 Years|N/A|No|Non-Probability Sample|This retrospective study will be conducted at Taipei Veterans General Hospital, a 2900-bed        tertiary care medical center in Taiwan. Patients elder than 18 years old are included if        they have bloodstream infections due to A. baumannii regardless of primary infection        sites.|June 2011|June 14, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374256||103097|
NCT01374581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA-IHU-2010-01 version 1|Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria|A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains|QuinAct|Universiteit Antwerpen|Yes|Completed|May 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2117|||Both|12 Months|59 Months|No|||October 2014|October 21, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01374581||103073|
NCT01373632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110611|Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease|Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease|FESTA|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|June 2011|September 2013|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|570|||Both|18 Years|N/A|No|||June 2011|June 14, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373632||103144|
NCT01373645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20100909|Safety and Efficacy Registry of Yinyi Stent|Safety and Efficacy Registry of Yinyi Polymer-free Paclitaxel-eluting Stent|SERY-I|Shanghai Jiao Tong University School of Medicine||Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1045|||Both|18 Years|80 Years|No|||October 2008|July 27, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01373645||103143|
NCT01374347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0044-11 WOMC|Brain SPECT Following Cialis (Tadalafil ) Administration|Brain SPECT Perfusion Imaging Following Cialis (Tadalafil ) Administration in Patients With Vascular Risk Factors|CIALIS|Wolfson Medical Center|No|Completed|May 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|35 Years|80 Years|No|Non-Probability Sample|Male and female patients in the age range of 35-75 years.|February 2016|February 8, 2016|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374347||103090|
NCT01374360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-001|Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry|Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry||Alexion Pharmaceuticals|Yes|Recruiting|January 2007|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|N/A|N/A|No|Probability Sample|PNH Patients|April 2015|April 1, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01374360||103089|
NCT01374295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2981|Video Assisted Informed Consent for Lortab to Improve Patient Satisfaction and Knowledge|Video Assisted Informed Consent for Lortab to Improve Patient Satisfaction and Knowledge: A Randomized Control Study||Albany Medical College|Yes|Completed|March 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|120|||Both|18 Years|N/A|No|||June 2011|March 21, 2014|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01374295||103094|
NCT01374308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASVAC01|NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients|Phase IIII Study of a Therapeutic Vaccine Candidate Containing Hepatitis B Virus (HBV) Core Antigen (HBcAg) and HBV Surface Antigen (HBsAg) for Treatment of Patients With Chronic HBV Infection|NASVAC|Clinical Research Organization, Dhaka, Bangladesh|No|Active, not recruiting|June 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|60 Years|No|||December 2012|December 11, 2012|June 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01374308||103093|
NCT01374607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18/11|Comparison Between High-sensitivity Cardiac Troponin T and Standard Tnl Assays in Early Cardiac Ischemia Detection|Assessment of Highly Sensible T Troponin (Hs-TnT) Assay Compared to Standard Troponin Assay in the Early Detection of Cardiac Ischemia in Patients With Acute Coronary Syndrome||University of Lausanne Hospitals|No|Completed|July 2011|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the emergency with chest pain suspect of acute coronary syndrome|January 2016|January 24, 2016|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01374607||103071|
NCT01374620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-ANGI2|Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel|Phase I Study : Dose Escalation of Intravenous Weekly Paclitaxel in Association With Metronomic Administration of Cyclophosphamide|PAL-ANGI2|Centre Oscar Lambret|Yes|Active, not recruiting|June 2011|December 2014|Anticipated|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|65 Years|No|||August 2014|August 22, 2014|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374620||103070|
NCT01374919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ferumoxytol 1020|Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia|Total Dose Infusion of Ferumoxytol (1020mg) in 15 Minutes for Iron Defeciency Anemia||Auerbach Hematology Oncology Associates P C|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 13, 2014|June 14, 2011|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01374919||103047|
NCT01375231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10019|Anatomic Reconstruction of the Patellofemoral Joint|Anatomic Reconstruction of the Patellofemoral Joint: A Solution for Anterior Knee Pain||OrthoCarolina Research Institute, Inc.|Yes|Completed|June 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|N/A|N/A|No|||June 2014|June 26, 2014|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375231||103025|
NCT01381965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyorineye006|Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery|Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery||Kyorin University|No|Completed|March 2008|February 2011|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|72|||Both|20 Years|90 Years|No|||July 2012|July 31, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01381965||102512|
NCT01381978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIUC|Obesity Childhood in Cuenca-Ecuador: Prevalence and Risk Factors|Baseline Study. Obesity Childhood in Cuenca-Ecuador: Prevalence and Risk Factors||Universidad de Cuenca||Completed|October 2010|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|700|||Both|6 Years|9 Years|Accepts Healthy Volunteers|Probability Sample|Children (girls and boys) 6 to 9 years of age. Sample ramdomized of urban schools of        Cuenca Ecuador|May 2012|May 21, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381978||102511|
NCT01382732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2011-06|Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia|Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial||Saint Thomas Hospital, Panama|No|Recruiting|January 2012|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|636|||Female|N/A|N/A|No|||January 2015|January 1, 2015|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382732||102453|
NCT01382979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA016584|Evaluation of AlcoholEdu for College|Evaluation of AlcoholEdu: A Randomized Multi-Campus Trial||Pacific Institute for Research and Evaluation|No|Completed|July 2007|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|9571|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 24, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382979||102434|
NCT01382446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#09NU127|Chlorhexidine Gluconate Oral Care for Adults Experiencing Trauma|Evaluating Effectiveness of Chlorhexidine Gluconate Oral Care for Adults||St. Joseph's Hospital and Medical Center, Phoenix|No|Completed|July 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||December 2013|December 5, 2013|June 23, 2011||No||No|July 24, 2013|https://clinicaltrials.gov/show/NCT01382446||102475|Enrolling of trauma patients - consenting patients with unknown identification or next of kin status led to small number of subjects analyzed
NCT01382992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC001|A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples|||Peking Union Medical College Hospital||Active, not recruiting|June 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|150|Samples With DNA|Formalin-fixed, paraffin-embedded tissue slices and plasma samples are to be retained.|Both|18 Years|N/A|No|Non-Probability Sample|Non-small cell lung cancer patients who were diagnosed or treated in Peking Union Medical        College Hospital or Peking University People's Hospital|June 2011|June 24, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382992||102433|
NCT01384019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-001|Distal Protection Device in ST-elevation Myocardial Infarction (STEMI)|Distal Protection Device Did Not Improve Microvascular Obstruction Evaluated by Cardiac MR After Primary Percutaneous Intervention for ST-elevation Myocardial Infarction||Seoul National University Bundang Hospital|No|Completed|January 2004|August 2011|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|126|||Both|30 Years|80 Years|No|||February 2013|February 14, 2013|June 27, 2011||No||No|January 14, 2013|https://clinicaltrials.gov/show/NCT01384019||102354|
NCT01375946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL16|Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers|A Pharmacokinetic And Wearability Study of the Agile TCDS AG200-15 Following Weekly Application Under Various External Conditions in Healthy Female Volunteers||Agile Therapeutics|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 16, 2011|June 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375946||102971|
NCT01376284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114125|Drug Use Investigation for AVOLVE(BPH)|Drug Use Investigation for AVOLVE(BPH)||GlaxoSmithKline|No|Completed|December 2010|June 2014|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1000|||Male|15 Years|N/A|No|Probability Sample|Japanese male adult subjects with benign prostatic hyperplasia (BPH) who start the        treatment with dutasteride capsules|July 2014|July 24, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01376284||102945|
NCT01383772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICM1005|Retinal Laser by Multi-spot Photocoagulator and Driving Eligibility|A Prospective Clinical Study of the Effects of Panretinal Photocoagulation Delivered With a Multi-spot Photocoagulator on Retinal Sensitivity and Driving Eligibility in Patients With Diabetic Retinopathy||Moorfields Eye Hospital NHS Foundation Trust|Yes|Completed|June 2012|December 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|43|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01383772||102373|
NCT01376336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA308|Trial of Safe Water Storage Among People Living With HIV|Randomized Controlled Trial of Safe Water Storage Among People Living With HIV||London School of Hygiene and Tropical Medicine|No|Not yet recruiting|August 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1600|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2011|June 17, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01376336||102941|
NCT01372449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111576|A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)|A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism Targeting Memory and Motor Planning||Anagnostou, Evdokia, M.D.|Yes|Active, not recruiting|December 2011|March 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|12 Years|No|||February 2016|February 9, 2016|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372449||103234|
NCT01372722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSG-11-4712DBS|Deep Brain Stimulation (DBS) for Treatment Resistant Bipolar Disorder|Phase I Study of Bilateral DBS to the Nucleus Accumbens (NAcc-DBS) for Treatment Resistant Bipolar Disorder|DBS-BIPO|University Hospital, Bonn|No|Recruiting|May 2010|July 2015|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|20 Years|70 Years|No|||October 2013|October 28, 2013|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01372722||103213|
NCT01375491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090395|Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans|Blockade of Receptor Cleavage in Diabetes Mellitus With an MMP Inhibitor|DOXY|University of California, San Diego|No|Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|May 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375491||103005|
NCT01373034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUNG_SOY|The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome|The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome: Double-blind, Randomized, Placebo-controlled, Cross Over Clinical Trial||Seoul National University Hospital|No|Not yet recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|19 Years|75 Years|No|||June 2011|June 13, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373034||103189|
NCT01373333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102,384|Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome|Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome|34-DAP|The Cleveland Clinic||Available|September 1997|||September 2012|Anticipated|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||June 2014|June 16, 2014|June 13, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01373333||103167|
NCT01374373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOS-012010|Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia|A Phase 4 Study in the Treatment of Anemia With Weekly Epoetin Alfa Doses in Patients With Solid Tumors or Lymphoma Receiving Chemotherapy||Bio Sidus SA|No|Recruiting|June 2011|July 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01374373||103088|
NCT01373996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMW10|Clinical Investigation of Wireless Transmission of Invasive Blood Pressure Signal|Feasibility and Accuracy of Wireless Transmission of Invasive Blood Pressure Signal From Patient to Patient's Bedside Monitor||University Medical Centre Ljubljana|Yes|Completed|June 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|12|||Both|18 Years|80 Years|No|Probability Sample|Critically ill patients|April 2011|June 14, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01373996||103117|
NCT01374009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114141|H1N1 Vaccine in Pregnancy: a Registry for the Fall and Winter of 2009|H1N1 Vaccine in Pregnancy: a Registry for the Fall and Winter of 2009||Dalhousie University|No|Active, not recruiting|April 2010|December 2012|Anticipated|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|504|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women who recieved the H1N1 vaccine during pregnancy in 2009.|June 2011|June 14, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374009||103116|
NCT01374321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRO40303CLEQ1491-1|Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction|Phase II, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction||Trophos|Yes|Completed|October 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374321||103092|
NCT01374334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThresholdMarko|Lower Extremities Muscle Strength and Power Thresholds Required for Mobility Independence|Lower Extremities Muscle Strength and Power Thresholds Required for Mobility Independence in Older Adults||State University of New York - Upstate Medical University|No|Active, not recruiting|December 2008|October 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|53|||Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|fifty-three community dwelling male (21) and female (32) older adults (76.4±5.2 years)        were observed performing a chair rise, negotiating stairs, kneeling from a standing        position, and rising from supine to stand.|August 2010|July 6, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374334||103091|
NCT01374633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100206|Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients|Effect on Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients|SEPIA|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|December 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|June 8, 2011||No|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01374633||103069|
NCT01374932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The CPASMA trial|CPASMA: Is There an Improvement in Asthma in Patients With Both Asthma and OSAS Treated With CPAP?|The CPASMA Trial: Is There an Improvement in Asthma in Patients With Both Asthma and Obstructive Sleep Apnoea Syndrome (OSAS) Treated With Continuous Positive Airway Pressure (CPAP) After Six Months?|CPASMA|Cimera|No|Recruiting|July 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|70 Years|No|||June 2012|June 21, 2012|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01374932||103046|
NCT01374945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EasyGlide-CL-001|Clearpath Miniprep Colonoscopy Study|||EasyGlide|No|Withdrawn||||||N/A|Interventional|N/A|2||Actual|0|||Both|18 Years|70 Years||||February 2013|February 26, 2013|June 15, 2011|Yes|Yes|Withdrawn for business reasons|No||https://clinicaltrials.gov/show/NCT01374945||103045|
NCT01382459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor517111ctil|Constructed Intervention by Home and School Diabetes Nurse Visits on Diabetic Control of Children With Type I Diabetes|The Efficacy of Constructed Intervention by Home and School Visits by Diabetes Nurses on Diabetic Control of Children With Type I Diabetes||Soroka University Medical Center|Yes|Not yet recruiting|July 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|4 Years|18 Years|No|Probability Sample|type 1 DM children in the age of 4-18, living in Beer Sheva and the area, who are under        treatment in the pediatric diabetes unit in Soroka.|June 2011|June 24, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382459||102474|
NCT01382719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT-141-54|Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder|A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)||Palatin Technologies|Yes|Completed|June 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|612|||Female|21 Years|N/A|No|||December 2014|December 2, 2014|June 24, 2011|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT01382719||102454|
NCT01383239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#110556|Impact of Postoperative Management on Outcomes and Healing of Rotator Cuff Repairs|Impact of Postoperative Management on Outcomes and Healing of Rotator Cuff Repairs||Vanderbilt University|No|Active, not recruiting|September 2011|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|214|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383239||102414|
NCT01383759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-061|Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis|Pilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|June 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01383759||102374|
NCT01375699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13419|Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers|Randomized Open Label Study of Doxorubicin-based Chemotherapy Regimens, With and Without Sildenafil, With Exploratory Analysis of Intermediate Cardiac Markers||Virginia Commonwealth University|Yes|Active, not recruiting|August 2011|October 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375699||102990|
NCT01375959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-398|Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance|The Effect of Resveratrol in Older Adults With Impaired Glucose Tolerance: a Double-Blind Crossover Study|RSV|Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|April 2011|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|80 Years|No|||June 2011|June 16, 2011|May 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375959||102970|
NCT01376297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NETU-10-29|A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting|A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles.||Helsinn Healthcare SA|Yes|Completed|July 2011|||September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|413|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|June 16, 2011|Yes|Yes||No|November 6, 2014|https://clinicaltrials.gov/show/NCT01376297||102944|
NCT01374230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001922|Long-Term Multicenter Evaluation of the E1® Tibial Bearing|Long-Term Multicenter Evaluation of the E1® Tibial Bearing||Massachusetts General Hospital|No|Recruiting|September 2011|September 2021|Anticipated|September 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|20 Years|75 Years|No|||April 2015|April 14, 2015|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374230||103099|
NCT01374243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11244|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2011|||||N/A|N/A|N/A||||||||||||||November 5, 2012|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374243||103098|
NCT01376258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113907|Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database|Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database||GlaxoSmithKline|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|28903|||Male|65 Years|N/A|No|Non-Probability Sample|The study will include retrospective data from male patients aged 65 years and older with        continuous health plan enrollment from July 1, 2003 and June 30, 2009. Patient records        will be reviewed for data from the 6-months prior to and 1-year following the index date,        which represents the first prescription fill for a 5ARI|June 2011|June 16, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376258||102947|
NCT01372163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3301002|A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Doses Of PF-05190457 In Healthy And Type 2 Diabetic Adults||Pfizer|No|Terminated|July 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|7||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|June 10, 2011|No|Yes|B3301002 was discontinued on 18 April 2012 for strategic reasons.There were no safety concerns    leading to discontinuation of this study.|No||https://clinicaltrials.gov/show/NCT01372163||103256|
NCT01373294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16295|Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer|Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-muscle-invasive Transitional Cell Bladder Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|November 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373294||103170|
NCT01373567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TINEFCON/49/10|A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis|An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis||Piramal Enterprises Limited|No|Completed|December 2010|June 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|298|||Both|18 Years|N/A|No|||November 2012|November 21, 2012|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01373567||103149|
NCT01383343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02595|Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer|Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies||National Cancer Institute (NCI)|No|Active, not recruiting|August 2011|||January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||September 2015|March 23, 2016|June 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01383343||102406|
NCT01373697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEU-IBU- 01-10|Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel|Clinical Multicenter, Phase III, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ibuprofen 50mg/g Gel in the Treatment of Patients With Muscle Pain, Joint, or Pain Caused by Sprains, Contusions, Tendinitis, or Myofascial Compared to Profenid ® 25mg/g. Gel||Laboratório Teuto Brasileiro S/A|Yes|Not yet recruiting|June 2011|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|12 Years|65 Years|No|||June 2011|June 14, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01373697||103139|
NCT01374022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE - 0025.1.160.000-11|ART - Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial|Randomized Controlled Trial of Maximum Alveolar Recruitment Maneuver Plus Titrated PEEP Versus ARDSNet Strategy for ARDS|ART|Hospital do Coracao|Yes|Recruiting|June 2011|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1620|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01374022||103115|
NCT01374997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-PP-04|Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur|Screening Project for a Detection of Fabry Disease in Chronic Renal Failure Patients in Area PACA||Centre Hospitalier Universitaire de Nice||Active, not recruiting|June 2011|||March 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|380|||Male|18 Years|60 Years|No|||March 2011|July 7, 2011|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01374997||103042|
NCT01374646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JOIN2011 10-309|Community-based Program to Treat Childhood Obesity|Effects of a Community-based Program to Treat Childhood and Adolescent Obesity||UnitedHealth Group|No|Active, not recruiting|November 2010|January 2012|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|6 Years|17 Years|No|||January 2011|July 1, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374646||103068|
NCT01374971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATC2011|Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)|Open-Label Pre and Post Treatment Arthroscopic Synovial Biopsy Study for the Assessment of Certolizumab Pegol Immunomodulatory Synovial Effects on Select Biomarkers and Gene Expression||Arthritis Treatment Center, Maryland|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|June 14, 2011|Yes|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01374971||103044|Small sample size
NCT01375257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endocarditis-DK|Partial Oral Treatment of Endocarditis|Partial Oral Treatment of Endocarditis|POET|Rigshospitalet, Denmark|Yes|Recruiting|June 2011|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||June 2011|June 16, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01375257||103023|
NCT01375569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110181|TRC105 for Liver Cancer That Has Not Responded to Sorafenib|A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib||National Institutes of Health Clinical Center (CC)|No|Completed|June 2011|December 2015|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|80 Years|No|||February 2016|February 18, 2016|June 16, 2011|Yes|Yes||No|March 4, 2015|https://clinicaltrials.gov/show/NCT01375569||103000|
NCT01382745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-044|Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers|A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal Canal||Sir Mortimer B. Davis - Jewish General Hospital|Yes|Terminated|January 2012|January 2022|Anticipated|September 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|June 24, 2011||No|low recruitment|No||https://clinicaltrials.gov/show/NCT01382745||102452|
NCT01383252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VANCHCS-GI-005|Unsedated Colonoscopy for Colorectal Cancer Screening and Surveillance|Comparison of Study Method Versus Conventional Method for Performing Unsedated Colonoscopy for Colorectal Cancer Screening and Surveillance||VA Northern California Health Care System|Yes|Completed|February 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|10|||Both|50 Years|75 Years|No|||June 2013|June 13, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01383252||102413|
NCT01376271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114102|Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)|Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)||GlaxoSmithKline|No|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|N/A||1|Actual|600|||Both|N/A|N/A|No|Probability Sample|All subjects diagnosed as having social anxiety disorder (SAD) are to be given paroxetine        tablets according to the prescribing information|June 2014|June 30, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01376271||102946|
NCT01373281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD14|Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia|Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia||Sanofi|Yes|Active, not recruiting|June 2011|November 2017|Anticipated|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10275|||Both|2 Years|14 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|June 8, 2011|Yes|Yes||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01373281||103171|
NCT01374867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117/13/03/01/2010|CardShock Study and Registry|Pathophysiology and Prognostic Factors in Cardiogenic Shock - CardShock Study|CardShock|Helsinki University Central Hospital|No|Completed|October 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|220|Samples Without DNA|plasma, urine|Both|18 Years|N/A|No|Non-Probability Sample|Hospitals|January 2014|January 2, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01374867||103051|
NCT01375478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25580|An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis|Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION Study)||Hoffmann-La Roche||Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|197|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis|March 2016|March 1, 2016|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375478||103006|
NCT01376596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-273-PSY|Group Cognitive-behavioral Intervention for Social Anxiety in Schizophrenia|Manualized Group Cognitive-behavioral Intervention for Social Anxiety in Schizophrenia: An Efficacy Pilot Study.||McGill University|Yes|Completed|August 2011|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|50 Years|No|||April 2014|April 9, 2014|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376596||102921|
NCT01372735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOPANC|Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer|Clinical Phase I/II Trial to Investigate Neoadjuvant Intensity-Modulated Short Term Radiation Therapy (5x5 Gy) and Intraoperative Radiation Therapy (15 Gy) in Patients With Primarily Resectable Pancreatic Cancer - NEOPANC|NEOPANC|University Hospital Heidelberg|No|Not yet recruiting|August 2011|August 2017|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|50 Years|N/A|No|||June 2011|June 10, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01372735||103212|
NCT01373957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CRU-XXX-2011/1|Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Russia|Long-tErm Follow-uP of Antithrombotic Management Patterns In Acute CORonary Syndrome Patients in RUSsia|EPICOR-RUS|AstraZeneca|No|Completed|July 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical Practice|July 2014|July 10, 2014|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373957||103120|
NCT01383876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002931|Collar Immobilization Following a Posterior Cervical Laminectomy and Fusion|Collar Immobilization Following a Posterior Cervical Laminectomy and Fusion: A Randomized Controlled Trial||Brigham and Women's Hospital|No|Terminated|June 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|June 27, 2011||No|Enrollment too slow|No||https://clinicaltrials.gov/show/NCT01383876||102365|
NCT01373710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/501/M|Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis|Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis|HIT|Institut Curie|Yes|Recruiting|May 2011|May 2019|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01373710||103138|
NCT01374035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSD-24340|The Western Norway Mental Health Interface Study on Referral Letters|Interface Between Primary Care and Specialist Mental Health Care - the Referral Letters||Helse Fonna|No|Active, not recruiting|August 2010|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2011|March 17, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01374035||103114|
NCT01374048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-88|Intracranial Pressure Waves Via Lumbar Puncture|Are Intracranial Pressure Waves Measurable Through Lumbar Puncture?||Umeå University|No|Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|55 Years|78 Years|No|Non-Probability Sample|Patients with idiopathic normal pressure hydrocephalus|June 2011|June 13, 2011|June 13, 2011||||No||https://clinicaltrials.gov/show/NCT01374048||103113|
NCT01374685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911186|Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans|Family Communication of Hereditary Cancer Risk Among African Americans||National Institutes of Health Clinical Center (CC)||Terminated|June 2011|January 2016||||N/A|Observational|N/A|||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01374685||103065|
NCT01374659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korean AES007|Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma|Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients With Differentiated Thyroid Carcinoma Who Have Elevated Serum Thyroglobulin Levels But Are Tumor-negative on Conventional Imaging Studies||Korean Association of Endocrine Surgeons|Yes|Recruiting|July 2009|August 2012|Anticipated|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|15 Years|85 Years|No|Non-Probability Sample|Study patients who underwent total thyroidectomy with more than one of high dose        radioactive iodine treatment, showed elevated Tg levels, but who yielded no pathological        findings on conventional imaging during follow-up period.|January 2011|June 15, 2011|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01374659||103067|
NCT01374984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-005|VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection|Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection||Cangene Corporation|No|Enrolling by invitation|August 2007|February 2018|Anticipated|August 2017|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|A plasma sample for the determination of anti-vaccinia antibody level collected 5 days after      VIGIV administration and 5 days after VIGIV re-dosing as well (if applicable). Samples      collected Day 5 ±3 days will still provide valuable information for assessing anti-vaccinia      antibody levels in these subjects post-VIGIV administration. While plasma samples are      preferred, serum samples will also be accepted if available. Failure to obtain a Day 5      sample does not preclude retrospective enrollment into the VA-005 study to provide      observational data only.|Both|N/A|N/A|No|Probability Sample|Individuals who are administered VIGIV distributed from the US Strategic National        Stockpile for the treatment of complications due to vaccinia vaccination or vaccinia        infections.|April 2015|April 22, 2015|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374984||103043|
NCT01375270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-127|Glucolipotoxicity and Type 2 Diabetes|The Effects of Experimental Elevation of Plasma Glucose and Lipid on Pancreatic Beta-cell Function in Humans||Rigshospitalet, Denmark|No|Completed|April 2011|December 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01375270||103022|
NCT01375283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4-2010-118#2|Sensory Mapping Following Video-assisted Thoracic Surgery|Sensory Mapping Following Video-assisted Thoracic Surgery||Rigshospitalet, Denmark|No|Recruiting|June 2011|||August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|48|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing video-assisted thoracic surgery|January 2012|January 4, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375283||103021|
NCT01375582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35809|Objective Evaluation of Ocular Surface Lubricants in Two Environments|Objective Evaluation of Ocular Surface Lubricants||University of Rochester|Yes|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|20|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|June 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375582||102999|
NCT01376115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112279|Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg|Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg||Novartis|No|Active, not recruiting|January 2008|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|Subjects with the following diseases in Japanese adults and children          1. T-cell acute lymphocytic leukemia (T-ALL)          2. T-cell lymphoblastic lymphoma (T-LBL)|March 2016|March 11, 2016|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376115||102958|
NCT01374776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version number 2 fro|Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels|||University of Zurich||Recruiting|February 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|No|||December 2013|December 12, 2013|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01374776||103058|
NCT01383005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-752|Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)|Treatment Perception of QD Dosed Kaletra (Tablets) Based Treatment in HIV Infected Patients. Observational Cross-Sectional Study (QD-KAPITAL)|QD-Kapital|AbbVie|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|97|||Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected patients regularly visiting Spanish hospital/clinic physicians and treated        with lopinavir/ritonavir once-a-day regimens.|April 2013|April 30, 2013|May 31, 2011||No||No|December 28, 2012|https://clinicaltrials.gov/show/NCT01383005||102432|
NCT01383018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER1005|PROPPER Prospective Registry of Outcomes With Penile Prosthesis|Prospective Registry of Outcomes With Penile Prosthesis for Erectile Restoration (PROPPER)|PROPPER|American Medical Systems|No|Enrolling by invitation|June 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Male|N/A|N/A|No|Non-Probability Sample|Men with ED in the United States and Canada.|January 2016|January 25, 2016|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383018||102431|
NCT01375127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921053|Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients|An Observational Study To Collect Follow-up Clinical Data From Kidney Transplant Recipients Who Received Tofacitinib (CP-690,550) In Completed Phase 2 Studies||Pfizer|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|83|||Both|18 Years|70 Years|No|Probability Sample|Subjects who received treatment with tofacitinib in 2 completed Phase 2 studies who either        discontinued treatment prematurely or who did not elect to enroll in long-term extension        studies.|September 2013|September 25, 2013|June 13, 2011|Yes|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01375127||103032|
NCT01375426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDAMOXI|Efficacy Study for Standard Versus Double Dose of Amoxicillin in WHO Defined Non-severe Pneumonia|Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-centre Randomized Double Blind Controlled Trial in Pakistan||ARI Research Cell||Completed|September 2003|June 2004||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment||||900|||Both|2 Months|59 Months|No|||June 2011|June 16, 2011|June 16, 2011||||No||https://clinicaltrials.gov/show/NCT01375426||103010|
NCT01373918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001714|Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders|Low Dose Parenteral Fat for the Prevention of Parenteral Nutrition Associated Cholestasis in Neonates With Congenital/Acquired Gastrointestinal Disorders||University of California, Los Angeles|Yes|Completed|December 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|42|||Both|N/A|5 Days|No|||December 2014|December 1, 2014|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373918||103123|
NCT01373931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12615|A Study of LY2216684 in Healthy Females|Effect of LY2216684 on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects||Eli Lilly and Company|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|June 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01373931||103122|
NCT01374217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1167|Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma|Administration of an Oral PDE5 Inhibitor, Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|August 2011|February 2015|Anticipated|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2014|March 23, 2014|June 13, 2011||No|early stopping rule|No||https://clinicaltrials.gov/show/NCT01374217||103100|
NCT01375725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOB 0046|Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood|Mobius PT-INR Accuracy Clinical Study||Universal Biosensors Pty Ltd|No|Completed|September 2010|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects currently receiving coumadin (warfarin) treatment|June 2011|June 16, 2011|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375725||102988|
NCT01375179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKRP203A2201|Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients|A Multi-centre, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of KRP203 in Subjects With Moderately Active Refractory Ulcerative Colitis||Novartis||Terminated|December 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||May 2015|May 11, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01375179||103028|
NCT01382875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4013-PPR-09|The Comparison of Comprehensive Multi-disciplinary Program and Conventional Care Program on Fragility Fracture Elderly|Medico-social Impact of a Comprehensive Multi-disciplinary Program for the Care of Fragility Fracture of the Elderly -Implications for Healthcare Policy in Hong Kong||Chinese University of Hong Kong|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|160|||Both|65 Years|90 Years|No|||July 2015|July 27, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382875||102442|
NCT01383356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.19|Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet|A Single Dose Comparative Bioavailability Study of Linagliptin/Metformin hydrochloride2.5mg/500mg Combination Tablets Versus Linagliptin 2.5mg Tablets Administered With Glucophage 500mg Tablets Under Fasting Conditions||Boehringer Ingelheim||Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|June 27, 2011||||No|December 18, 2012|https://clinicaltrials.gov/show/NCT01383356||102405|
NCT01383083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIGER2011|Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease|Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease (Eisenmenger Physiology): Safety, Tolerability, Clinical, and Hemodynamic Effect.|EIGER|Maryknoll Medical Center|Yes|Active, not recruiting|November 2010|November 2012|Anticipated|June 2011|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|42|||Both|18 Years|80 Years|No|Probability Sample|Patients with PAH associated with congenital systemic-to-pulmonary shuntand treated with        iloprost for pulmonary hypertension        : patients with PAH associated with corrected and uncorrected congenital        systemic-to-pulmonary shunts and Eisenmenger's syndrome are included|November 2010|June 27, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01383083||102426|
NCT01383616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26033|Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures|Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures||Hospital for Special Surgery, New York|Yes|Completed|July 2006|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|50 Years|N/A|No|||April 2013|April 3, 2013|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01383616||102385|
NCT01383629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMERC004|The Effect of Preoperative Counseling on Patient Fear From Visual Experience During Vitrectomy Surgery Under Regional Anesthesia|The Effect of Preoperative Counseling on Patient Fear From Visual Experience During Vitrectomy Surgery Under Regional Anesthesia||University of Malaya|Yes|Completed|January 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|75 Years|No|||June 2011|June 27, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383629||102384|
NCT01374386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-10-2240-02|Impact of Exergaming on Adolescent Youth|RCMI Clinical Research Infrastructure Initiative: Exergaming||Charles Drew University of Medicine and Science|No|Recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|14 Years|Accepts Healthy Volunteers|||June 2011|June 15, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374386||103087|
NCT01374399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DJCLS R 10/42pf|Physical Exercise Therapy vs Relaxation in Allogeneic Stem Cell Transplantation (PETRA)|Effects of an One-year Physical Exercise Intervention on Prognosis, Side-effects and Complications After Allogeneic Stem Cell Transplantation|PETRA|German Cancer Research Center|No|Recruiting|February 2011|March 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|256|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01374399||103086|
NCT01374672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOST11B1|Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma|Observational - Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma||Children's Oncology Group|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|10 Years|20 Years|No|Non-Probability Sample|Diagnosed with high-grade osteoblastic osteosarcoma.|May 2015|May 8, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01374672||103066|
NCT01375036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-US-205-0128|Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients|A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates From Patients With Cystic Fibrosis in the United States [AIR-CF5]|AIR-CF5|Gilead Sciences|No|Active, not recruiting|August 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|510|Samples Without DNA|Pseudomonas aeruginosa isolates from sputum or throat swab specimens|Both|6 Years|N/A|No|Non-Probability Sample|A representative cross-section of individuals with mild (FEV1 75% to ≤ 90% predicted),        moderate (FEV1 40% to 74% predicted), or severe (FEV1 <40% predicted) lung disease and a        history of ≥ 2 lower respiratory tract cultures positive for PA (at any time) will be        enrolled. This will include approximately 100 individuals with pre-study exposure to        Cayston (defined as having received at least one prior 28-day course of Cayston at any        time before enrolling into the study). Enrollment will be monitored and potentially        modified to ensure that adequate numbers of participants in each disease severity category        are included. At the Investigator's discretion, participants enrolled in this study can be        allowed to participate in clinical trials with other investigational therapies as        appropriate.|September 2015|September 25, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375036||103039|
NCT01375296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH20100918|China Made Sirolimus Eluting Stent for Intermediate Lesion|China Made Sirolimus Eluting Stent for Treatment of Coronary Intermediate Lesion|SESIL|Shanghai Jiao Tong University School of Medicine||Recruiting|May 2009|November 2011|Anticipated|October 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||April 2009|June 16, 2011|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01375296||103020|
NCT01375309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1675|Bifidobacterium Supplementation for Very Low Birth Weight Infants|Effect of Bifidobacterium Bifidum Supplementation on Morbidity of Very Low Birth Weight Infants|Bifido(RCT)|Tokyo Women's Medical University|Yes|Completed|January 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|246|||Both|N/A|48 Hours|No|||March 2012|March 28, 2012|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01375309||103019|
NCT01375595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110182|Brain Areas Involved in Sound and Spoken Word Memory|The Role of the Inferior Frontal Gyrus in Long-Term Auditory Memory a rTMS Study||National Institutes of Health Clinical Center (CC)||Terminated|May 2011|October 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|45|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 31, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375595||102998|
NCT01375608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110184|Decitabine for High-Risk Sickle Cell Disease|An Extended Phase II Study of Decitabine in Subjects With High Risk Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|June 2011|February 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2015|February 6, 2016|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375608||102997|
NCT01375855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-000142-12|Late Incomplete Stent Apposition Evaluation II: Comparison Between Polimer-based and No-polimer Stent System. IVUS Based Study|Late Incomplete Stent Apposition Evaluation II: Vascular Effects Evaluation After Polimer and No-polimer Based Coronary Artery Drug Eluting Stent Ilmplantation. An IVUS Based Study|LISAII|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|October 2007|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|85 Years|No|||February 2007|June 16, 2011|December 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01375855||102978|
NCT01376128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112309|Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)|Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)||GlaxoSmithKline|No|Completed|March 2008|May 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|96|||Both|N/A|17 Years||Probability Sample|Male and female Japanese subjects whose age is under 18 with panic disorder, who are        considered appropriate to prescribe paroxetine tablet according to the prescribing        information|June 2011|June 16, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01376128||102957|
NCT01375140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0269|Ruxolitinib and Lenalidomide for Patients With Myelofibrosis|Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2011|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375140||103031|
NCT01375153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060/2009|Brain Natriuretic Peptide Effects on Appetite Regulating Hormones and Endothelial Derived Peptides|Effects of Brain Natriuretic Peptide on Appetite-regulating Hormones and Endothelial-derived Peptides|BNP/Appetite|Medical University of Vienna|No|Completed|November 2010|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|10|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01375153||103030|
NCT01375439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ddt1333|Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy|Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy and Submitted to Active Search of Genital Infection||UPECLIN HC FM Botucatu Unesp|No|Completed|August 2011|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|280|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2011|June 19, 2015|March 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01375439||103009|
NCT01374568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB F100317002|Changes in Bone Turnover With Increased Incretin Hormone Exposure|Changes in Bone Turnover With Increased Incretin Hormone Exposure (UAB Diabetes Research and Training Center Pilot and Feasibility Study)|DRTC|University of Alabama at Birmingham|No|Recruiting|July 2010|December 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|40|||Female|45 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 7, 2016|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01374568||103074|
NCT01374854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCMSC-T1DM|Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus|Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus: A Randomized Controlled Open-label Study||Fuzhou General Hospital|Yes|Active, not recruiting|January 2009|December 2014|Anticipated|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|40 Years|No|||November 2012|November 18, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01374854||103052|
NCT01375985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7100-us-101|Safety Study of Single Administration Intravenous Treatment for Influenza|A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects||Sarepta Therapeutics|Yes|Terminated|June 2011|November 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|June 16, 2011|No|Yes|The study was halted after enrollment of the first cohort because of lack of funding|No||https://clinicaltrials.gov/show/NCT01375985||102968|
NCT01371838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00002|A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia|A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia||AstraZeneca||Completed|December 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|848|||Both|18 Years|N/A|No|||November 2014|November 28, 2014|April 27, 2011|Yes|Yes||No|May 28, 2014|https://clinicaltrials.gov/show/NCT01371838||103281|
NCT01383096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_11_001|Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers|A Phase I Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers||Medicines for Malaria Venture|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|June 23, 2011||No||No|May 12, 2014|https://clinicaltrials.gov/show/NCT01383096||102425|
NCT01383109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-012-11|Human Mass Balance Study of Pyronaridine|A Human Mass Balance Study of Pyronaridine Using Accelerator Mass Spectrometry||Medicines for Malaria Venture|Yes|Completed|June 2011|December 2011|Actual|September 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|40 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01383109||102424|
NCT01383395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-070|Effect of Cilostazol on the Pharmacokinetics of Simvastatin|Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects||Samsung Medical Center|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|20 Years|48 Years|Accepts Healthy Volunteers|||May 2012|May 18, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383395||102402|
NCT01374074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0008|Racial Disparity in Barrett's Esophagus|Racial Disparity in Barrett's Esophagus||University of North Carolina, Chapel Hill|Yes|Completed|March 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|255|Samples With DNA|serum, plasma, buffy, esophageal biopsies|Both|18 Years|80 Years|No|Non-Probability Sample|The source of the study population will be patients aged 18-80 presenting at the        gastrointestinal (Gl) Endoscopy Clinic at UNC-Chapel Hill for elective upper endoscopy        with a primary or secondary indication of reflux symptoms. Any patient undergoing        endoscopy with classic reflux symptoms is eligible to participate in the study. These        symptoms include a substernal chest burning or warmth, a "waterbrash" sensation,        regurgitation, or any chest pain worst when supine or after meals.        Race will be self-identified race or ethnicity (SIRE) from a researcher-provided list.        According to the NIH Policy on Reporting Race and Ethnicity Data published in August 8,        2001 (NOT-OD-01-053), we will "use two separate questions with ethnicity information        collected first followed by the option to select more than one racial designation."        Patients in this study should be "Not Hispanic or Latino", and either "African American"        or "White".|September 2015|September 21, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01374074||103111|
NCT01374412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Transregio79B8|Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance Imaging|Examination of Bone Defects and Microcirculation Using Volume Computed Tomography and Dynamic Contrast-enhanced Magnetic Resonance Imaging||German Cancer Research Center|No|Recruiting|July 2010|July 2022|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients with benign osteoporosis|March 2016|March 21, 2016|April 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01374412||103085|
NCT01374425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25710|Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer|A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer||Genentech, Inc.||Completed|August 2011|July 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|376|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374425||103084|
NCT01374711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36068.091.11 BI|The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia|The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia. A Parallel Randomized Double-blind Placebo-controlled Study||Radboud University|Yes|Completed|May 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 26, 2013|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01374711||103063|
NCT01374724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20100149H-2|Preventing Relapse Following Involuntary Smoking Abstinence|Preventing Relapse Following Involuntary Smoking Abstinence|AFV|University of Tennessee|Yes|Active, not recruiting|May 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|23000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374724||103062|
NCT01375010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2194|Vitamin D HIV Study|The Effect of Vitamin D Repletion on Postmenopausal Women With HIV||Columbia University|Yes|Active, not recruiting|January 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|40 Years|70 Years|No|||November 2015|November 29, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375010||103041|
NCT01375023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S438/508|Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer|Allogenic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Refractory "Triple Negative" Breast Cancer||European Institute of Oncology|No|Terminated|June 2009|December 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||September 2012|June 19, 2015|June 15, 2011||No|Very low accrual rate|No||https://clinicaltrials.gov/show/NCT01375023||103040|
NCT01375322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTY-ABM-0601|ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria|Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria||TSH Biopharm Corporation Limited|No|Completed|June 2007|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|20 Years|80 Years|No|||June 2011|June 16, 2011|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375322||103018|
NCT01375621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911169|Livestock Contact and MRSA in Rural Areas|Epidemiology of Rural MRSA : Is Livestock Contact a Risk Factor?||National Institutes of Health Clinical Center (CC)||Completed|May 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3100|||Both|6 Months|100 Years|No|||June 2015|November 13, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375621||102996|
NCT01375868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHKT-RLP/2011|Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis|Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis||Institute of Hematology and Blood Transfusion, Czech Republic|Yes|Active, not recruiting|October 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375868||102977|
NCT01374542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/350/C|Respiratory Endoscopy: Diagnostic Yield, Technical Factors and Complications|Respiratory Endoscopy: Diagnostic Yield, Technical Factors and Complications||Singapore General Hospital|No|Recruiting|June 2011|May 2013|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|10 Years|N/A|No|Probability Sample|All patients undergoing respiratory endoscopy at Singapore General Hospital|June 2011|June 15, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374542||103076|
NCT01374789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WiSP_AG48|PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer|PURO - An Open-label, Randomised, Multicentre, Phase II Study to Evaluate the Efficacy of Chemotherapy With Gemcitabine and Cisplatin in Combination With the EGF Receptor Antibody Panitumumab (GemCisP) Versus GemCis in the First-line Therapy of Locally Advanced/Metastatic Urothelial Carcinoma in Patients With Wild-type HRAS|PURO|WiSP Wissenschaftlicher Service Pharma GmbH|Yes|Terminated|July 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|March 30, 2011||No|The study was terminated due to insufficient recruitment.|No||https://clinicaltrials.gov/show/NCT01374789||103057|
NCT01374802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.49|Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers|Effect of Multiple Dosing With 240 mg QD BI 201335 on the Steady-state Pharmacokinetics of 800 mg QD Darunavir Coadministered With 100 mg QD Ritonavir (DRV/r) in Healthy Male and Female Volunteers (an Open-label, Multiple-dose, Single Group, Single Fixed Sequence Phase I Study)||Boehringer Ingelheim||Completed|June 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|June 8, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01374802||103056|
NCT01374815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X10-07-335|The Online Advocate: Health Related Social Problems And Diet Quality Pilot Study|The Online Advocate: Health Related Social Problems And Diet Quality Pilot Study||Children's Hospital Boston|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 4, 2014|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01374815||103055|
NCT01376323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114728|A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin|A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin||GlaxoSmithKline|No|Completed|July 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|10||Actual|92|||Both|20 Years|70 Years|No|||May 2014|May 29, 2014|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376323||102942|
NCT01372423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-01-2011|Evaluation of Clinical Equivalence Between Two Lubiprostone Products|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Lubiprostone 24 Mcg Capsules (Anchen Pharmaceuticals, Inc.) With AMITIZA® (Lubiprostone) 24 Mcg Capsules (Sucampo Pharmaceuticals, Inc.) in the Treatment of Chronic Idiopathic Constipation||Anchen Pharmaceuticals, Inc|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|808|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|June 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372423||103236|
NCT01372436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARPSPBD2|Caries Risk Assessment in Children and Adolescents in the Alpes Maritimes (France)|Caries Risk Assessment in Children and Adolescents in the Alpes Maritimes (France)||Centre Hospitalier Universitaire de Nice|No|Recruiting|June 2007|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|678|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|Children in primary or high-schools|April 2008|January 23, 2013|April 22, 2008||No||No||https://clinicaltrials.gov/show/NCT01372436||103235|
NCT01372969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cx601-0101|Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.|Multicenter Phase I/IIa Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.||Cellerix|No|Completed|June 2009|September 2010|Actual|September 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||June 2011|June 13, 2011|August 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01372969||103194|
NCT01382355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDSAM 011|Prospective Donor Specific Antibody (DSA) Monitoring Protocol|Prospective Donor Specific Antibody (DSA) Monitoring Protocol To Detect Patient Characteristics and /or Changes In Immunosuppression on the Development of De Novo Antibodies||Providence Health & Services|No|Recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|1 ml aliquots of serum collected at specified time points|Both|18 Years|70 Years|No|Non-Probability Sample|Males and females aged 18-70 years old receiving a living donor or deceased donor kidney        or kidney/pancreas transplant|August 2011|August 2, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01382355||102482|
NCT01382589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV101|Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo|A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo|NSV|Clinuvel Pharmaceuticals Limited|No|Completed|September 2011|December 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||March 2013|March 21, 2013|June 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01382589||102464|
NCT01371851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-P50-DA018197-DoxMeth|Doxazosin for Psychostimulant Dependence|Clinical Efficacy of Doxazosin for Psychostimulant Dependence||University of Arkansas|Yes|Completed|June 2011|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|No|||July 2015|July 24, 2015|June 9, 2011|Yes|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01371851||103280|
NCT01382862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHANTOM-S|PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study|PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study|PHANTOM-S|Charite University, Berlin, Germany|Yes|Completed|May 2011|May 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|614|||Both|18 Years|N/A|No|||February 2013|September 14, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01382862||102443|
NCT01383122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01|The Efficacy of Pulsed Electromagnetic Field Therapy for Management of Post-operative Pain Following Cesarean Delivery|The Efficacy of Pulsed Electromagnetic Field Therapy for Management of Post-operative Pain Following Cesarean Delivery: a Randomised, Double-blind, Placebo-controlled Study||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Terminated|May 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|June 24, 2011||No|Planned interim analysis-no statistical significance for the primary outcome.|No||https://clinicaltrials.gov/show/NCT01383122||102423|
NCT01383135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0047|Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2|Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2||Stanford University|Yes|Suspended|October 2010|December 2015|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Stanford Clinic patients|November 2015|November 16, 2015|May 31, 2011|Yes|Yes|Converting from Exploratory IND to Full IND|No||https://clinicaltrials.gov/show/NCT01383135||102422|
NCT01383369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-FSP-2010-050|Postoperative Sleep Disturbances Role in Cognitive Test Results After Fast-track Hip and Knee Arthroplasty|Postoperative Sleep Disturbances Role in Cognitive Test Results After Fast-track Hip and Knee Arthroplasty||Rigshospitalet, Denmark|Yes|Completed|February 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|60 Years|N/A|No|Non-Probability Sample|Patients above 60 years undergoing hip/knee replacement surgery in a fest track set-up.|September 2011|September 27, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01383369||102404|
NCT01383603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-004|Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis|Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis||Circassia Limited|No|Completed|October 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01383603||102386|
NCT01384266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEC-001|A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery|A Randomized, Multicenter, Masked Evaluation of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate for the Treatment of Inflammation Following Cataract Surgery||Associated Eye Care, Minnesota|No|Recruiting|May 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Eye Clinic|June 2011|June 27, 2011|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01384266||102335|
NCT01374451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230I2201|Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET|A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study|COOPERATE-1|Novartis||Completed|June 2011|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||May 2015|May 16, 2015|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374451||103082|
NCT01374698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sapienza|Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.|Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study||University of Roma La Sapienza|No|Completed|January 2011|September 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|85 Years|No|||May 2013|May 13, 2013|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01374698||103064|
NCT01374737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHS_1|ED50 of Dexmedetomidine to Prevent Emergence Agitation in Children|ED50 of Dexmedetomidine for Reduction of Emergence Agitation Incidence Undergoing Tonsillectomy or Adenoidectomy in Desflurane Anesthesia Following Sevoflurane Induction in Children||Seoul National University Hospital|No|Recruiting|June 2011|February 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|25|||Both|2 Years|12 Years|No|||June 2011|June 15, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01374737||103061|
NCT01374750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWLee1004-052-316|Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)|A Randomized Phase Ⅱ, Trial With Sirolimus-containing Versus mTOR-inhibitor Free Immunosuppression in Patients Undergoing Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria|Sirolimus|Seoul National University Hospital|Yes|Active, not recruiting|May 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|80 Years|No|||September 2015|September 2, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01374750||103060|
NCT01375075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13049|A Study of LY2484595 in Japanese Subjects|A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects||Eli Lilly and Company|Yes|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|150|||Both|20 Years|N/A|No|||March 2012|May 24, 2012|June 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375075||103036|
NCT01375335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1818|The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement|The Effects of Dobutamine on Postoperative Systolic Deformation and Diastolic Function in Patients With Hypertrophic Cardiomyopathy Operated for Aortic Valve Stenosis||University of Aarhus|Yes|Suspended|June 2011|||August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|90 Years|No|||August 2013|August 6, 2013|June 14, 2011|Yes|Yes|Insufficient patient eligible for recruitment|No||https://clinicaltrials.gov/show/NCT01375335||103017|
NCT01375348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kogprem|Relationship Between Cognitive Function and Pain|Cognitive Function in Healthy Volunteers Exposed to Acute Pain Before and After Administration of Remifentanil||University of Aarhus|Yes|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|23|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375348||103016|
NCT01375634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS:M11-131-NIMED|Nasogastric Tube Insertion Using Midazolam in the Emergency Department|Nasogastric Tube Insertion Using Midazolam in the Emergency Department|NIMED|University of Vermont|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|49|||Both|18 Years|N/A|No|||July 2013|July 19, 2013|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01375634||102995|
NCT01375361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RandomizedAlbuterolCHF|Nebulized Albuterol for Congestive Heart Failure Exacerbation||ACHE|University of California, San Francisco|Yes|Withdrawn|April 2009|||July 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||October 2013|October 9, 2013|April 20, 2010|Yes|Yes|Low enrollment.|No||https://clinicaltrials.gov/show/NCT01375361||103015|
NCT01375881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017641|Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice|Post Authorization Non-interventional Study in HIV1-Infected Patients Starting or Already in Treatment With Darunavir||Janssen-Cilag S.p.A.||Completed|June 2009|December 2012|Actual|December 2012|Actual|Phase 4|Observational|Observational Model: Cohort||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|Patient using darunavir and ritonavir in clinical practice according to label in Italy.        Both naive and experienced patients are allowed to enter the study|May 2013|May 3, 2013|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01375881||102976|
NCT01376167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112582|Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse|A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.||GlaxoSmithKline|No|Recruiting|September 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Anticipated|924|||Both|16 Years|N/A|No|||February 2016|March 17, 2016|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376167||102954|
NCT01376180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112727|Drug Use Investigation for LAMICTAL|Drug Use Investigation for LAMICTAL||GlaxoSmithKline|No|Active, not recruiting|December 2008|August 2016|Anticipated|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Probability Sample|Subjects with epilepsy having the following seizure types.          -  partial seizures (including secondary generalized seizures)          -  tonic-clonic seizures          -  generalized seizures of Lennox-Gastaut syndrome|April 2015|April 16, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376180||102953|
NCT01375972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_0803|Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma|Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer||Asan Medical Center|No|Completed|March 2008|August 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375972||102969|
NCT01376310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114375|GSK1120212 Rollover Study|MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia||GlaxoSmithKline|No|Recruiting|March 2011|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|February 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376310||102943|
NCT01372137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXH94C001|First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94|First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94||NOXXON Pharma AG|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|January 22, 2016|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01372137||103258|
NCT01372150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061014|A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Fluoxetine-referenced, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder||Pfizer|Yes|Completed|November 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|340|||Both|7 Years|17 Years|No|||October 2015|October 19, 2015|June 9, 2011|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01372150||103257|
NCT01372982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033/08|Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) Of Dr.Reddy's Laboratories Ltd And Femara 2.5 mg Tablets (Reference) Of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|April 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Female|40 Years|69 Years|Accepts Healthy Volunteers|||June 2011|June 13, 2011|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372982||103193|
NCT01373255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0043-08-EMC|Balloon Catheters in Cases of Abnormal Placentation|Balloon Catheter for Occlusion of the Pelvic Vasculature as an Adjuvant Therapy in Cases of Placenta Accreta|Accreta|HaEmek Medical Center, Israel|Yes|Completed|January 2009|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Female|18 Years|45 Years|No|||June 2015|June 14, 2015|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01373255||103172|
NCT01381874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018286|A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy|Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy||Janssen Research & Development, LLC|Yes|Active, not recruiting|August 2011|September 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|299|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381874||102519|
NCT01381887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018373|A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Placebo-Controlled, Randomized, Crossover, Multicenter Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Subjects With Type 2 Diabetes Mellitus||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|37|||Both|25 Years|70 Years|No|||April 2013|April 19, 2013|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01381887||102518|
NCT01382134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-075|Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction|Effect of Aspirin, in Vitro Hemodilution and Desmopressin on Platelet Dysfunction Associated With Mild Hypothermia in Healthy Volunteers||The University of Hong Kong|Yes|Completed|July 2011|September 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382134||102499|
NCT01382602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-019|Autologous Muscle-derived Cells Female Stress Urinary Incontinence Clinical Study|A Double-blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Effectiveness of Cook MyoSite Incorporated AMDC in Female Patients With Stress Urinary Incontinence||Cook||Active, not recruiting|December 2011|January 2017|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|June 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382602||102463|
NCT01383382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL096624|Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool|Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool|PRISM|Saint Luke's Health System|No|Completed|September 2009|September 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1399|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac patients undergoing a non-emergent percutaneous coronary intervention (PCI)        procedure for their heart disease.|June 2011|September 7, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383382||102403|
NCT01384565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS DLD 01|G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease|A Prospective Randomized Double Blind Trial to Study the Efficacy of G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease||Institute of Liver and Biliary Sciences, India|No|Completed|July 2011|March 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|55|||Both|12 Years|75 Years|No|||July 2012|July 30, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384565||102312|
NCT01374100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-068|Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy|Effect of Qigong Therapy in Patients With Advanced NSCLC and GI Cancer Undergoing Chemotherapy||McGill University|Yes|Active, not recruiting|February 2009|December 2015|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01374100||103109|
NCT01374113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR701165_025|Safinamide Renal Impairment Trial|An Open-label, Parallel-group, Single Center, Single Oral Dose Trial to Investigate the Pharmacokinetics (PK) of 50 mg Safinamide in Subjects With Moderate and Severe Renal Impairment Compared to Matched Subjects With Normal Renal Function||Newron|No|Completed|June 2011|||October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2011|March 28, 2013|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374113||103108|
NCT01374464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/0934|Reducing Respiratory Side Effects of Interscalene Brachial Plexus Block|A Double Blind Randomised Control Trial Assessing Effects of Local Anaesthetic Concentration (0.5% vs 0.75%) and Volume (5mls vs 15mls) on the Respiratory Consequences of Ultrasound Guided Interscalene Brachial Plexus Nerve Block||Royal Surrey County Hospital|No|Not yet recruiting|August 2012|March 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|92|||Both|18 Years|80 Years|No|||June 2011|June 15, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01374464||103081|
NCT01374763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10133M|A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery|A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery||Tampere University Hospital|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01374763||103059|
NCT01375049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-205-0162|Aztreonam Lysine for Pseudomonas Infection Eradication Study|Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients With Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Culture Positive for Pseudomonas Aeruginosa (PA)|ALPINE|Gilead Sciences|Yes|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|3 Months|17 Years|No|||July 2014|July 7, 2014|June 15, 2011|Yes|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01375049||103038|
NCT01375062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902-057-F-CS|Obtaining Undifferentiated Cells From Testis Biopsy|Isolation, Culture and Characterization Stem Cells From Testis Biopsy||Igenomix|No|Completed|May 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|October 16, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01375062||103037|
NCT01375374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0978|Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide|Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Levetiracetam|VICTOR|UCB Pharma|No|Terminated|July 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Male|18 Years|45 Years|No|||November 2014|November 20, 2014|May 9, 2011|Yes|Yes|Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading    study center Investigators; decision thus made to terminate.|No|November 20, 2014|https://clinicaltrials.gov/show/NCT01375374||103014|The results of this study are limited due to the small sample size.
NCT01375400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aspirin|Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.|Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.|Aspirin|Central Hospital, Nancy, France|No|Recruiting|December 2010|||July 2011|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2011|June 20, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375400||103012|
NCT01375647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROVIDE|Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh|Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh|PROVIDE|University of Vermont|No|Completed|May 2011|November 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|700|||Both|N/A|7 Days|Accepts Healthy Volunteers|||April 2015|April 13, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01375647||102994|
NCT01375894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-07-11|Body Movement Imitation and Perspective Perception Among Psychiatric Patients|||Shalvata Mental Health Center|Yes|Not yet recruiting|March 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|20 Years|65 Years|No|||December 2011|December 29, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01375894||102975|
NCT01371825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CL03|Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease|An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency||Alexion Pharmaceuticals|Yes|Active, not recruiting|May 2011|December 2015|Anticipated|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|24 Months|No|||March 2015|March 6, 2015|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371825||103282|
NCT01372709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|771-0008|TriVascular Post-Market Registry|A Post-Market Study to Evaluate the Safety and Performance of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System||TriVascular, Inc.|Yes|Active, not recruiting|May 2011|January 2019|Anticipated|December 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|501|||Both|18 Years|N/A|No|Probability Sample|The Ovation™ or Ovation Prime™ Abdominal Stent Graft System study is a multicenter,        prospective, observational post-market study of subjects receiving the Ovation™ or Ovation        Prime™ Abdominal Stent Graft System for the treatment of abdominal aortic aneurysms (AAA).        The Ovation™ or Ovation Prime™ Abdominal Stent Graft System Post-Market Study intends to        expand the clinical evidence of the safety and performance of the Ovation™ or Ovation        Prime™ Abdominal Stent Graft System in an all comers ("real world") patient population.|April 2015|April 23, 2015|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372709||103214|
NCT01373541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InFat_003|Effect of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Infants in China|Effect of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Infants in China: a Double Blind, Multi-center, Randomized, Controlled Trial||Enzymotec|No|Completed|May 2011|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|171|||Both|N/A|14 Days|Accepts Healthy Volunteers|||January 2012|February 11, 2014|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373541||103151|
NCT01373554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-N01GI1|Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)|PMK-N01GI1|PharmaKing|Yes|Completed|May 2011|October 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||December 2013|December 8, 2013|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01373554||103150|
NCT01382394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0459-09-RMB|Impact of Clinical, Demographic and Laboratory Variables on Brain Natriuretic Peptide Levels|Impact of Clinical, Demographic and Laboratory Variables on Brain Natriuretic Peptide Levels||Rambam Health Care Campus|No|Withdrawn|July 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|The study will be performed at Rambam Medical Center, Israel. Patients admitted to the        department of internal medicine will be divided to two groups|August 2011|August 3, 2011|June 23, 2011||No|No Patients were recruited during the study period|No||https://clinicaltrials.gov/show/NCT01382394||102479|
NCT01382927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBVOBP|Impact of Spontaneous Breathing on Ventilation Distribution in Obese Patients|Impact of Spontaneous Breathing on Ventilation Distribution in Obese Patients||Technische Universität Dresden|No|Recruiting|April 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|16|||Both|18 Years|85 Years|No|Non-Probability Sample|Obese Patients aged 18-85, scheduled for elective hip arthroplasty|June 2011|June 24, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01382927||102438|
NCT01383655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVMg135/2010|Intravenous Magnesium in Wheezy Bronchitis|The Efficacy of Intravenous Magnesium in Acute Wheezy Bronchitis in Small Children - a Randomized, Controlled Study||University of Oulu|No|Completed|March 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|6 Months|4 Years|No|||January 2016|January 20, 2016|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01383655||102382|
NCT01382888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT/Heparin - 01/11|Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis|Efficacy and Local Tolerability of Topically Applied Heparin (Heparin 2,400 IU /ml Cutaneous Spray) on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis. A Multicentre, Randomized, Double-blind and Placebo-controlled Pilot Study||Cyathus Exquirere Pharmaforschungsgmbh|Yes|Terminated|July 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|June 24, 2011||No|The Sponsor decided to terminate the study due to the low patient recruitment.|No||https://clinicaltrials.gov/show/NCT01382888||102441|
NCT01382901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VIT05009|Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)|A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)||Luitpold Pharmaceuticals||Completed|March 2006|July 2007|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||July 2011|July 8, 2011|February 23, 2011|Yes|Yes||No|February 23, 2011|https://clinicaltrials.gov/show/NCT01382901||102440|
NCT01382914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR01-2011|Determination of a Threshold for Mouth Rinse Induced Discoloration of Teeth|Determination of a Threshold for Mouth Rinse Induced Discoloration of Teeth||Technische Universität Dresden|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2012|January 16, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382914||102439|
NCT01383148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG4010.14/TIME|Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer|A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)|TIME|Transgene|Yes|Active, not recruiting|April 2012|March 2019|Anticipated|January 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01383148||102421|
NCT01383161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001740|18-Month Study of Curcumin|18-Month Double-Blind, Placebo-Controlled Study of Curcumin|Curcumin|University of California, Los Angeles|Yes|Active, not recruiting|March 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|132|||Both|50 Years|90 Years|No|||December 2015|December 2, 2015|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01383161||102420|
NCT01384253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREVAMED01|Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy|Phase I Trial of Intraperitoneal ²¹²Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy||Areva Med LLC|Yes|Active, not recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|19 Years|N/A|No|||June 2015|June 22, 2015|June 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01384253||102336|
NCT01354028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130342|Effects of Massage Therapy to Induce Sleep in Preterm Infants|Effects of Massage Therapy to Induce Sleep in Preterm Infants||University of Arkansas|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|20 Weeks|No|||April 2013|April 25, 2013|May 12, 2011||No||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01354028||104642|The sample size was small. 30 infants were enrolled, but 7 infants were discharged or became ineligible and could not start the study.
NCT01354249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fperrone|Preoperative Feeding With a Whey Protein Plus Carbohydrate Drink on the Acute Phase Response and Insulin Resistance|Effects of Preoperative Feeding With a Whey Protein Plus Carbohydrate Drink on the Acute Phase Response and Insulin Resistance.||Federal University of Mato Grosso do Sul|Yes|Completed|July 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||May 2011|May 13, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01354249||104625|
NCT01354574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200210295|Thermic & Lipemic Properties of Dietary Carbohydrates|Thermic & Lipemic Properties of Dietary Carbohydrates|FL33|USDA, Western Human Nutrition Research Center|No|Completed|October 2002|June 2005|Actual|June 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|28|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||July 2011|July 12, 2011|August 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01354574||104600|
NCT01354860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI1002|Moxibustion for Knee Osteoarthritis|Moxibustion for Knee Osteoarthritis: a Randomized Pilot Clinical Trial||Korea Institute of Oriental Medicine|Yes|Completed|December 2010|May 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|70 Years|No|||September 2010|May 16, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01354860||104578|
NCT01352065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-ERA-2011|Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration|Phase 3 Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration|ERAATH|Center for Health, Exercise and Sport Sciences, Serbia|Yes|Completed|January 2011|May 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01352065||104791|
NCT01352078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041408|Wound Etiology and Healing Study|The Wound Etiology and Healing Study|WE-HEAL|George Washington University|No|Recruiting|May 2011|June 2021|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|1. Residual tissue left over after routine debridement surgery        2. Wound fluid that would otherwise be discarded        3. Residual blood/ serum samples left over after pre-surgery blood tests have been           performed.        4. Wound biofilm        5. Wound photographs|Both|18 Years|N/A|No|Non-Probability Sample|Non healing wounds|August 2015|August 25, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352078||104790|
NCT01352091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCSG002|Adjuvant AI Combined With Zoladex|A Randomized ,Open Label Study Comparing the Efficacy of Zoladex® Combined With Arimidex® for 3-2 Years After Selective Estrogen Receptor Modulators (SERMs) as an Adjuvant Therapy for 2-3 Years Versus Continuing Tamoxifen up to 5 Years for Premenopausal Early Breast Cancer Patients With Hormone Receptor Positive, Lymph Node Positive or Tumor≥ 4cm.||Fudan University|Yes|Recruiting|May 2008|April 2018|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|670|||Female|18 Years|N/A|No|||April 2008|May 10, 2011|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352091||104789|
NCT01362712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-18 100|Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects|An Exploratory, Phase I, Open Label, Multi-Center, Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects||Siemens Molecular Imaging|No|Terminated|May 2011|April 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|7|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|May 13, 2011|No|Yes|Unable to enroll breast cancer patients with current I/E criteria.|No||https://clinicaltrials.gov/show/NCT01362712||103978|
NCT01362673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9391012|PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions|A Phase 1, Randomized, Subject- And Investigator Blind, Sponsor Open, Placebo Controlled, Single- And Multiple-Dose Escalation Study Of PF-04171327 In Healthy Adult Japanese And Western Subjects In Fasting And Fed Conditions||Pfizer|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362673||103981|
NCT01362686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS019818-01|Comparative Research of Alzheimer's Disease Drugs|Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs|COMET-AD|Indiana University|Yes|Active, not recruiting|April 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|65 Years|N/A|No|||August 2015|August 27, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362686||103980|
NCT01358552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-003|Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)|Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)||Pamlab, Inc.|No|Terminated|January 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|53|||Female|18 Years|39 Years|Accepts Healthy Volunteers|Probability Sample|Pregnant women who have been prescribed Néevo®/ NéevoDHA®|April 2013|April 30, 2013|May 18, 2011||No|Insufficient number of participants|No||https://clinicaltrials.gov/show/NCT01358552||104296|
NCT01358565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX1A-105|Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction|Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction||Pfizer|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 21, 2011|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358565||104295|
NCT01358825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115375|Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™|Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™||GlaxoSmithKline||Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|58|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||March 2013|May 16, 2013|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358825||104275|
NCT01357954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVH-DJC-1-2011|The Efficacy of Targeted Training on the Postural Control and Gross Motor Function in Children With Cerebral Palsy|||Hvidovre University Hospital|No|Active, not recruiting|June 2010|June 2013|Anticipated|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|2 Years|15 Years|No|||March 2013|March 19, 2013|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01357954||104342|
NCT01362023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YES|Efficacy of an Educational School-based Intervention to Reduce Prevalence of Obesity in Childhood-EdAl-2|A Primary-school-based Study to Reduce Prevalence of Childhood Obesity in Terres de l'Ebre (Catalunya (Spain) - EDAL-Educació en Estils Saludables de Vida alimentació-2: Study Protocol for a Randomized Controlled Trial|EDAL2|University Rovira i Virgili|Yes|Enrolling by invitation|May 2011|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Both|7 Years|8 Years|Accepts Healthy Volunteers|||May 2011|June 9, 2011|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01362023||104031|
NCT01362894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-346-C-013|Clinical Comparison of Two Daily Disposable Toric Lenses|Clinical Comparison of Two Daily Disposable Toric Lenses||Alcon Research|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||July 2012|July 3, 2012|May 27, 2011|Yes|Yes||No|July 3, 2012|https://clinicaltrials.gov/show/NCT01362894||103964|
NCT01362907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-347-C-013|Clinical Comparison of Silicone Hydrogel and HEMA-based Daily Disposable Contact Lenses|||Alcon Research|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||June 2012|June 28, 2012|May 27, 2011|Yes|Yes||No|June 28, 2012|https://clinicaltrials.gov/show/NCT01362907||103963|
NCT01357759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAB022-001|Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis||Morphotek|No|Completed|May 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||November 2015|November 13, 2015|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01357759||104357|
NCT01359072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-327-PSY|Enhancing Coping Skills in Patients With Cancer|Enhancing Coping Skills in Patients With Cancer - a Randomized Controlled Study||McGill University Health Center|No|Terminated|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|May 20, 2011||No|This study is currently terminated due to low recruitment rate.|No||https://clinicaltrials.gov/show/NCT01359072||104256|
NCT01359592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000700624|S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma|A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)||Southwest Oncology Group|No|Recruiting|September 2011|||June 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|155|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|May 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01359592||104216|
NCT01358266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32-007|Study Assessing Double-masked Uveitis Treatment|A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis|SAKURA|Santen Inc.|Yes|Recruiting|May 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358266||104318|
NCT01357798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHUFBA001|Botulinum Toxin Type A in Treatment of Cranial Allodynia in Patients With Headache|Botulinum Toxin Type A Versus 0,9% Saline in Treatment of Cranial Allodynia in Patients With Headache||Federal University of Bahia|No|Completed|December 2010|||April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2011|May 20, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01357798||104354|
NCT01358006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017485|A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers|An Open Label Dose-Ranging Study in Healthy Male Subjects to Investigate the Binding Potential of JNJ-40411813 to Serotonin 2A Receptors in the Central Nervous System||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|13|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 8, 2013|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358006||104338|
NCT01358279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-4615-A|Transcranial Direct Current Stimulation for Migraine Attack|||Seoul National University Hospital||Completed|January 2009|March 2011|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|17 Years|70 Years|No|||June 2012|June 15, 2012|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01358279||104317|
NCT01354041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01831|Fear of Recurrence Pilot Intervention for Women With Breast Cancer|A Pilot Intervention to Address Fear of Recurrence in Breast Cancer Survivors|WiLLoW|University of California, San Francisco|Yes|Completed|March 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|N/A|No|||January 2014|January 23, 2014|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01354041||104641|
NCT01354262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRMC 10 0023|Effect of Vitamin D Supplementation on Hemoglobin A1c|Does Vitamin D Supplement Alter Serum Level of Glycosylated Hemoglobin in Adult Patients Between 34-74 Years With Type 2 Diabetes Mellitus and Vitamin D Deficiency?||Genesys Regional Medical Center|No|Completed|March 2011|June 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|34 Years|69 Years|No|||April 2015|April 22, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354262||104624|
NCT01354275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH532008|In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome|IVF/ICSI Outcomes of OCP Plus GnRH Agonist Protocol Versus OCP Plus GnRH Antagonist Fixed Protocol in Women With PCOS|PCOS and ivf|Baskent University|Yes|Terminated|March 2009|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|300|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 1, 2012|May 12, 2011||No|. The trial would be continued if there was a difference of ≥3 % between trial arms. However,    the difference between ongoing pregnancy rates was <1 %|No||https://clinicaltrials.gov/show/NCT01354275||104623|
NCT01362062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22835|An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biologic DMARD and/or Anti-TNF Therapy|A Study to Observe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti TNF Therapy.||Hoffmann-La Roche||Completed|October 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|117|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients with inadequate response to DMARD and/or anti-TNF therapy|December 2015|December 1, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362062||104028|
NCT01362075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTB-001|Pain Management After Shoulder Prosthesis: A Clinical Trial of Nerve Block and Local Infiltration|Pain Management After Shoulder Arthroplasty: A Randomised Clinical Trial of Interscalene Block and Local Infiltration Analgesia||Horsens Hospital|No|Terminated|July 2011|October 2014|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|90 Years|No|||August 2014|August 7, 2014|May 26, 2011||No|After 3 years of recruitment, the study was stopped due to time constraints.|No||https://clinicaltrials.gov/show/NCT01362075||104027|
NCT01358617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL11B3|Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma|Observational - Expression of Ubiquitin Carboxyl-Terminal Hydrolase 1 (UCHL1) in Neuroblastoma Cancer Stem Cells and Its Relationship to Patient Prognosis||Children's Oncology Group|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|90|Samples With DNA|Tumor Tissue|Both|N/A|N/A|No|Non-Probability Sample|Patients With Neuroblastoma|May 2015|May 11, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358617||104291|
NCT01362413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOR 65/10|Validation of Laboratory Test for Predicting Bone Tissue Regeneration|Validation of Laboratory Test for Predicting Bone Tissue Regeneration in Patient Affected by Aseptic Pseudarthrosis and Treated With Platelet Gel|Rebone-test|Istituto Ortopedico Rizzoli|No|Completed|January 2011|June 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|March 2015|March 27, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362413||104001|
NCT01362699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018802|Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults|A Single Center, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy of JNJ 31001074 on Cue Induced Craving for Alcohol in Adult Subjects With Alcohol DependenceH3 Alcoholism||Janssen Research & Development, LLC|Yes|Withdrawn|August 2011|August 2012|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|62 Years|No|||April 2012|April 27, 2012|May 19, 2011|Yes|Yes|Re-prioritization lead to study cancellation.|No||https://clinicaltrials.gov/show/NCT01362699||103979|
NCT01358578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2303|Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis|A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|FIXTURE|Novartis|Yes|Completed|June 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|1306|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|May 20, 2011|Yes|Yes||No|February 16, 2015|https://clinicaltrials.gov/show/NCT01358578||104294|
NCT01358591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32AN1|Effect of a High Calcium Breakfast on Exercise Metabolism and Appetite|||Northumbria University||Completed|May 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|9|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 2, 2012|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01358591||104293|
NCT01362335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nex-001|Nexfin®-Monitoring System|Electronic Registration of Noninvasively Acquired Hemodynamic Parameters Using Nexfin®-Monitoring System||University Medical Center Groningen|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients, that are having a routine surgical procedure.|January 2013|January 15, 2013|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01362335||104007|
NCT01362348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114987|12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)|An Open-label, Phase 2a Study to Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients With Neovascular Age-related Macular Degeneration||GlaxoSmithKline|No|Terminated|July 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|50 Years|N/A|No|||December 2012|January 4, 2013|May 19, 2011|Yes|Yes|Lack of efficacy identified during a preliminary analysis|No||https://clinicaltrials.gov/show/NCT01362348||104006|
NCT01356368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC09/095|Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer|A Pilot Study of Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer Based on Molecular Markers|Customizing|National Guard Health Affairs|No|Terminated|May 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|March 19, 2011||No|slow accrual rate|No||https://clinicaltrials.gov/show/NCT01356368||104464|
NCT01356381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A2389|Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes|A Single-center,Double-blind,Randomised,Placebo-controlled,Parallel-group Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin on Insulin Sensitivity and Its Underlying Mechanism in Patients With T2DM Treated With Metformin||Novartis|No|Completed|April 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|70 Years|No|||August 2013|August 29, 2013|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356381||104463|
NCT01357239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056B2214|Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AFQ056 in Adolescent Patients With Fragile X Syndrome||Novartis||Completed|May 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|139|||Both|12 Years|17 Years|No|||May 2015|May 10, 2015|May 18, 2011|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01357239||104397|
NCT01357512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIAMRI|Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer|Evaluation of Diagnostic Value of 3-T MRI in Suspected Prostate Cancer||University of Oulu|No|Active, not recruiting|April 2011|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|130|||Male|40 Years|72 Years|No|||December 2015|December 2, 2015|April 14, 2011|No|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01357512||104376|
NCT01356927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30255|Same-day Long-acting Reversible Contraception for Medication Abortion|Etonogestrel Implant or Depot Medroxyprogesterone Acetate for Medication Abortion|SaLMA|Boston University|No|Active, not recruiting|May 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|45 Years|No|||March 2014|March 18, 2014|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356927||104421|
NCT01357772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAL 01|Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia|Randomized Placebo-controlled Phase III Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia|TAM-01|Ente Ospedaliero Ospedali Galliera|Yes|Active, not recruiting|November 2008|December 2023|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1400|||Female|18 Years|75 Years|No|||August 2015|August 3, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01357772||104356|
NCT01357993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017758|A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder|An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day||Janssen Pharmaceutical K.K.|No|Completed|May 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|253|||Both|18 Years|65 Years|No|||March 2014|March 27, 2014|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357993||104339|
NCT01358292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11021-1|Efficacy Study of Surgical Technique in Intramedullary Tibia Nailing, Using Trigen META Tibia Nails|Semi-extended Position vs. 90 Degrees of Flexion for Intramedullary Nailing of the Tibia: a Randomized Clinical Trial|TrigenMETA|Smith & Nephew, Inc.|Yes|Completed|February 2011|October 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|70 Years|No|||November 2015|November 12, 2015|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01358292||104316|
NCT01354288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081254|Therapeutic Education in Very Young Children With Diabetes Mellitus|Therapeutic Education in Very Young Children With Diabetes Mellitus. Evaluation of the Impact of a Specific Tool for Parents on Glycemic Control and Prevention of Acute Events (Hypoglycemia and Ketosis)|DIAB-EDUC|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2011|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|24|||Both|12 Months|6 Years|No|||April 2015|April 20, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01354288||104622|
NCT01354600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2009-0001|Effects of Positive Energy Balance and Exercise on Appetite Hormones in Sedentary Men and Women|Short-term Positive Energy Balance and Exercise on 24-hour Plasma Levels of Hunger and Satiety Hormones in Sedentary Lean and Obese Men and Women||University of Wisconsin, Madison|No|Completed|May 2009|February 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01354600||104598|
NCT01354899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WINDOW 01|A Open Study to Evaluate the Performance of Dressing on Subject With High Risk of Skin Breakdown|A Multi-Centre, Post CE Mark, Open Study to Evaluate the Performance of Thin Self-adherent Dressing Coated With a Soft Silicone Layer on Subjects With a High Risk of Skin Breakdown||Molnlycke Health Care AB|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|Critically ill patients at ICU.|September 2011|September 13, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01354899||104575|
NCT01354912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001|The Incidence of Nontuberculous Mycobacterial Pulmonary Infection in Bilateral Bronchiectasis and Bronchiolitis|||Meir Medical Center|No|Recruiting|May 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|90 Years|No|Probability Sample|All patients with bronchiectasis or bronchiolitis|March 2012|March 10, 2013|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01354912||104574|
NCT01362101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-001316|Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol|Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol|physio|Massachusetts General Hospital|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01362101||104025|
NCT01362114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B080009|The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung|Phase 4 Study of The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung : A Randomized, Double Blind, Placebo-control Trial||Korea Health Industry Development Institute|Yes|Recruiting|July 2010|June 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|65 Years|No|||April 2012|April 16, 2012|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01362114||104024|
NCT01358630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/322b|Vascular and Periodontal Disease - Microbial, Genetic and Histological Causalities|Periodontal-, Cardiovascular- and Aneurysmal Diseases.||University of Oslo|Yes|Recruiting|October 2008|October 2015|Anticipated|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Whole blood, samples from vascular tissues (atherosclerotic plaques and aneurysmal wall),      saliva|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing vascular surgery at Oslo University Hospital, Aker, previously        randomly collected patients with periodontitis, and randomly selected blood donors at Oslo        University Hospital, Ullevål.|November 2010|May 23, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358630||104290|
NCT01358604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL11B2|Biomarkers in Samples From Young Patients With Neuroblastoma|ROR1 as a Novel Target for Neuroblastoma||Children's Oncology Group|No|Active, not recruiting|May 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|120 Years|No|Non-Probability Sample|Patients diagnosed with neuroblastoma.|May 2015|September 30, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01358604||104292|
NCT01358864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.7|Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)|A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment||Boehringer Ingelheim||Completed|June 2011|May 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|678|||Both|18 Years|70 Years|No|||September 2015|September 22, 2015|May 23, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01358864||104272|
NCT01359137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP0311F09|An Assessment of SAFE (Swift Accountable Fair Enforcement) in Cochise County|An Assessment of Arizona's SAFE (Swift Accountable Fair Enforcement) Program in Cochise County||Pepperdine University|No|Enrolling by invitation|January 2011|August 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|105|||Both|N/A|N/A|No|||May 2011|June 10, 2011|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359137||104251|
NCT01359150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921129|A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo|A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Background Methotrexate||Pfizer|Yes|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|May 11, 2011|Yes|Yes||No|January 7, 2013|https://clinicaltrials.gov/show/NCT01359150||104250|
NCT01356641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCA2011/APAC|Antibiotic Treatment Alone for Acute Simple Appendicitis in Children|Antibiotic Treatment Alone for Acute Simple Appendicitis in Children; a Prospective Cohort Study Part of the Antibiotic Versus Primary Appendectomy in Children (APAC) Trial||VU University of Amsterdam|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|7 Years|17 Years|No|||December 2015|December 4, 2015|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01356641||104443|
NCT01356940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A randomized|A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis|A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis||Brown, Theodore R., M.D., MPH|No|Completed|November 2010|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|May 18, 2011|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01356940||104420|
NCT01356953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAIS0132008|Exercise Intensity and Type 2 Diabetics|Effects of Exercise Intensity on 24-h Ambulatory Blood Pressure in Type 2 Diabetics|EIT2D|Catholic University of Brasília|Yes|Completed|October 2008|August 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|45 Years|70 Years|No|||September 2008|May 19, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01356953||104419|
NCT01356654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saeys-1|Transcranial Direct Current Stimulation in Stroke Rehabilitation|The Use of Transcranial Direct Current Stimulation in the Recovery of Postural Control in Stroke||Universiteit Antwerpen|Yes|Recruiting|March 2010|June 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|80 Years|No|||May 2011|May 18, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01356654||104442|
NCT01357551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-040|Maintenance After Initiation of Nutrition TrAINing|Maintenance After Initiation of Nutrition TrAINing (MAINTAIN)|MAINTAIN|VA Office of Research and Development|No|Completed|August 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|573|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01357551||104373|
NCT01357252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23154|Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes|A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50mg qd to Placebo as add-on Therapy to Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy.||Novartis|Yes|Completed|April 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|80 Years|No|||April 2014|April 2, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01357252||104396|
NCT01357265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_27S|Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects|A Phase II Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine, Formulation 2011/2012, When Administered to Adult and Elderly Subjects||Novartis||Completed|May 2011|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|125|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 6, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01357265||104395|
NCT01357538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POFOBLE|Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis|Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis - a Multi-centre, Randomised, Double-masked, Parallel-group, Phase IV Comparison||Ursapharm Arzneimittel GmbH|No|Completed|February 2009|August 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||May 2011|May 19, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357538||104374|
NCT01357785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Periodontal Tissue Regeneration Using Autologous Periodontal Ligament Stem Cells|Periodontal Tissue Regeneration Using Autologous Periodontal Ligament Stem Cells: Randomized Controlled Clinical Trial|PDLSC|Fourth Military Medical University|Yes|Recruiting|April 2011|December 2014|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|65 Years|No|||September 2011|September 12, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357785||104355|
NCT01354301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR18T|Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate|Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate||Hospital do Rim e Hipertensão|No|Completed|May 2011|December 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354301||104621|
NCT01354613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0061|Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)|Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction||University of Wisconsin, Madison|Yes|Completed|April 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01354613||104597|
NCT01354626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiF-Pro|Dietary Protein and Hepatic Fat Accumulation|Influence of Increasing Dietary Protein on Hepatic Fat Accumulation and Postprandial Metabolism|LiF-Pro|Wageningen University|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 14, 2012|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354626||104596|
NCT01354925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc062/2011|Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan|Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan An Interventional, Community Based, Comparative Study|DMR|Meir Medical Center||Completed|September 2011|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|18 Years|N/A|No|||April 2013|April 11, 2013|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354925||104573|
NCT01362439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017578|Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years|Efficacy and Tolerability of Flexible Doses of Paliperidone ER in Symptomatic Subjects With Schizophrenia With Duration of Illness < 10 Years||Janssen-Cilag S.p.A.|No|Completed|January 2009|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|133|||Both|18 Years|45 Years|No|||April 2013|April 29, 2013|May 26, 2011|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01362439||103999|
NCT01361763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DABCAD2010|Safety Study of Dabigatran in CADASIL|Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL|SONICA|S. Andrea Hospital|Yes|Recruiting|June 2011|February 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2013|February 10, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01361763||104051|
NCT01361776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/4-31/2|Humoral Response to Tick-borne Encephalitis Vaccine in Elderly|Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses?||Sormland County Council, Sweden|Yes|Completed|September 2011|June 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361776||104050|
NCT01361789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004_01927 COX|COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined|COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined||Asker & Baerum Hospital|No|Completed|January 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|90 Years|No|||May 2011|May 26, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01361789||104049|
NCT01358877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25126|A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer|A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer||Hoffmann-La Roche||Active, not recruiting|November 2011|December 2023|Anticipated|December 2023|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4805|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358877||104271|
NCT01359163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1361002|A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study Of Commercial Femulen Tablets Versus Reformulated Femulen Tablets In Healthy Female Subjects||Pfizer|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Female|21 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 3, 2012|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359163||104249|
NCT01359176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0006376C|Capnography Data Collection From Healthy Participants|The Capnography Library: Data Collection From Healthy Participants||Shaare Zedek Medical Center|No|Suspended|May 2010|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult and pediatric healthy volunteers|May 2010|November 30, 2014|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01359176||104248|
NCT01359397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10B-DOCT|Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer|Phase II Study of Docetaxel, Oxaliplatin, Capecitabine With Bevacizumab and Trastuzumab in Case of Human Epidermal Growth Factor Receptor 2 (HER2)-Positivity in Patients With Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT Study)|B-DOCT|The Netherlands Cancer Institute|No|Active, not recruiting|March 2011|||May 2015|Actual|Phase 2|Interventional|N/A|2||||||Both|18 Years|N/A|No|||October 2015|November 3, 2015|May 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359397||104231|
NCT01356667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DARTNA|Drum-Assisted Therapy for Native Americans|Drum-Assisted Recovery Therapy for Native Americans||University of California, Los Angeles|Yes|Terminated|September 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|April 26, 2011||No|Study period is over and recruitment was stopped due to time constraints.|No|May 19, 2014|https://clinicaltrials.gov/show/NCT01356667||104441|
NCT01357564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-119|Tailored Activity Program-VA|Nonpharmacologic Management of Challenging Behaviors in Veterans With Dementia||VA Office of Research and Development|Yes|Active, not recruiting|August 2012|June 2016|Anticipated|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357564||104372|
NCT01357278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsteoActive|Active Rehabilitation in Osteoporotic Patients|Effect of Active Rehabilitation on Risk Factors for Fall, Bone Mineral Density, and the Quality of Life in Osteoporotic Patients. A Randomized, Controlled Intervention Study|ARO|Oslo University Hospital|No|Completed|January 2007|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|80|||Female|50 Years|N/A|No|||October 2015|October 14, 2015|April 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01357278||104394|
NCT01358032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 07-3-064|Evaluating an In-home Multicomponent Program to Manage Concerns About Falling in Frail Community Dwelling Older People|Evaluating the Effectiveness of an In-home Self-management Intervention to Prevent Psychological Distress in Frail Older People Living in the Community||Maastricht University Medical Center|Yes|Completed|March 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|389|||Both|70 Years|N/A|No|||July 2012|July 9, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01358032||104336|
NCT01358045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-2-088|Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma|Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma||Maastricht University Medical Center|Yes|Completed|November 2011|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|128|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01358045||104335|
NCT01357811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD03610|A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults|A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics and Safety and Tolerability of Digoxin in Healthy Adult Subjects||Sanofi|No|Completed|August 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357811||104353|
NCT01358019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2523355-001|A Study of LY2523355 in Patients With Solid Cancer|A Phase 1 Study of LY2523355 in Patients With Solid Cancer|2523355-001|Kyowa Hakko Kirin Company, Limited||Completed|May 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|N/A|No|||January 2013|January 25, 2013|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01358019||104337|
NCT01354054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENS/tops/sluka/rakel|TENS Effectiveness and Knee Osteoarthritis in Humans|Effects of a Single Treatment of High or Low Frequency TENS on Pain, Hyperalgesia and Function in Patients With Knee Osteoarthritis|TOPS|University of Iowa|Yes|Completed|November 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|100|||Both|30 Years|95 Years|Accepts Healthy Volunteers|||May 2011|May 12, 2011|May 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354054||104640|
NCT01354067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHM-2011-ANKW|Single Limb Resistance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effects of High-repetitive Single Limb Training on Exercise Capacity and Quality of Life in Patients With COPD Compared to a Control Group - A Prospective, Single Blind, Randomized Controlled Multicenter Trial|COPD|Umeå University|No|Completed|May 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|40 Years|N/A|No|||June 2012|June 19, 2012|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01354067||104639|
NCT01354080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03constip2011KASS|The Effectiveness of Massage in Treating Constipation|Comparison of the Effectiveness of Massage Based on the Tensegrity Rule and Classical Abdominal Massage in Persons With Constipation||University School of Physical Education in Wroclaw|No|Completed|June 2007|March 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|70 Years|No|||March 2010|May 13, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01354080||104638|
NCT01354314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00037283|Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder|Pilot Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder (HAND)|ParaFlu|Johns Hopkins University|Yes|Active, not recruiting|November 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354314||104620|
NCT01354327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A01169-46|Effects of Limicol on LDL-cholesterol|Study of the Effects of Limicol (a Food Supplement) on LDL-cholesterol in Moderate Hypercholesterolemia Subjects||Lescuyer Laboratory|Yes|Completed|December 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2011|May 13, 2011|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354327||104619|
NCT01354639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0082|Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy|Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy||Yonsei University|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|150|||Both|20 Years|N/A|No|Non-Probability Sample|papillary thyroid carcinoma patient who underwent conventional open or robotic bilateral        total thyroidectomy procedure and postoperative low dose RAI therapy|February 2014|February 4, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354639||104595|
NCT01354652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hanchu3915|Lactic Acidosis During Entecavir(ETV)Treatment|The Incidence of Lactic Acidosis During Entecavir Treatment in Chronic Hepatitis B Patients With Severe Cirrhosis or Hepatic Failure|ETV|Asan Medical Center|Yes|Terminated|May 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|5|||Both|18 Years|64 Years|No|||March 2015|March 3, 2015|May 11, 2011||No|Tenofovir has become available in Korea.|No|January 18, 2015|https://clinicaltrials.gov/show/NCT01354652||104594|
NCT01362465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDSICM|Characterization of Interventricular Conduction Measurements|Characterization of Interventricular Conduction Measurements|ICM|Medtronic Cardiac Rhythm Disease Management|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01362465||103997|
NCT01362751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OH_TMZ_2010|Orthostatic Hypotension in Elderly Nursing Home Residents|||Medical Research Foundation, The Netherlands|No|Completed|October 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|290|||Both|N/A|N/A|No|Non-Probability Sample|Nursing home residents|September 2012|September 2, 2012|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01362751||103975|
NCT01362426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018013|Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)|A Quality Use of Medicine Clinical Registry to Assess Clinical Outcomes in Patients With Schizophrenia Treated With Intramuscular Injections of Paliperidone Palmitate||Janssen-Cilag Pty Ltd||Completed|March 2011|May 2013|Actual|May 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|127|||Both|18 Years|99 Years|No|Non-Probability Sample|Australian patients with schizophrenia will be enrolled in the registry|March 2016|March 9, 2016|May 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362426||104000|
NCT01359189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1050|Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer|Initial Exploratory Evaluation of a Transrectal Scintigraphic Detector (ProxiScanTM) for Detection of Primary Prostate Cancer Utilizing a Prostate Specific Membrane Antigen (PSMA) Based Radiotracer (ProstaScint®)||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|May 2011|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Male|18 Years|75 Years|No|||October 2013|November 7, 2013|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359189||104247|
NCT01358890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30930081/C150502-LC|Low-Carbohydrate Diet Intervention on Body Weight|Effect of Low-Carbohydrate or Restricted-Calories Diet on Body Weight||Chinese Academy of Sciences||Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|65 Years|No|||February 2012|February 27, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01358890||104270|
NCT01359410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1192|Reinforced Staple Line on Leak Rate in Distal Pancreatectomy|Effect of a Reinforced Staple Line on Leak Rate in Distal Pancreatectomy||Washington University School of Medicine|No|Completed|June 2007|September 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||August 2013|August 9, 2013|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359410||104230|
NCT01356030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.048|Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer|Prospective Comparison of EUS-guided FNA and ERCP Tissue Sampling for the Diagnosis of Suspected Pancreato-biliary Neoplasms||California Pacific Medical Center Research Institute|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|51|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01356030||104490|
NCT01356043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HPS11D|CKD-828 Drug Interaction Study (S-amlodipine)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate the Pharmacokinetic Drug Interaction and Safety of S-amlodipine Between Free Combination of S-amlodipine and Telmisartan and S-amlodipine Monotherapy in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||August 2011|August 29, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356043||104489|
NCT01356056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-09-29-03EE|Tele-diagnostics for Remote Parkinson's Monitoring|||Great Lakes NeuroTechnologies Inc.||Completed|May 2011|||December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Parkinson's disease|March 2013|March 11, 2013|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356056||104488|
NCT01357291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP0311F07|Evaluating New Mexico's Recidivism Reduction Program|Evaluating New Mexico's Prison-Based Recidivism Reduction Program|RRP|Pepperdine University|No|Enrolling by invitation|March 2011|May 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|159|||Male|18 Years|N/A|No|||May 2011|May 19, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357291||104393|
NCT01356706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLM-MILS|Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors|||University Hospital, Gasthuisberg|No|Completed|October 2002|July 2012|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|274|Samples With DNA|Tissue samples for histopathology diagnosis & staging|Both|18 Years|90 Years|No|Probability Sample|Consecutive patients sufering from colorectal liever metastases (CRLM) who undergo        minimally invasive liver surgery (MILS) or open liver surgery (OLS)|July 2012|July 1, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356706||104438|
NCT01356979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052011/15|Outcome of Patients Undiagnosed Under Medical Thoracoscopy|Outcome of Patients Who Could Not Have Been Diagnosed by Medical Thoracoscopy||Eskisehir Osmangazi University|Yes|Completed|February 2002|June 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|355|||Both|20 Years|85 Years|No|Probability Sample|The patients with undiagnosed exudative pelural effusion by clinical, radiological or        laboratory investigations.|September 2012|September 24, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356979||104417|
NCT01356992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 117|Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation|A Multicenter, Randomized, Open-label, Non-inferiority Phase III Study, Between Low-Molecular Weight Heparins, Versa® (Enoxaparin - Eurofarma) and Clexane® (Enoxaparin - Sanofi-Aventis), in Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation.|VECOR|Eurofarma Laboratorios S.A.|No|Terminated|July 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|75 Years|No|||June 2015|June 17, 2015|May 18, 2011||No|Change in strategy regarding the product by the company|No||https://clinicaltrials.gov/show/NCT01356992||104416|
NCT01357824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glostrup Crich Study|Fibreoptic Intubation With and Without Sellick´s Maneuver|View af Larynx and Intubation With a Flexible Fibreoptic Scope With and Without Sellick´s Maneuver.||Glostrup University Hospital, Copenhagen|No|Completed|June 2011|November 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients admitted for elective surgery at Glostrup University Hospital|January 2012|January 29, 2012|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01357824||104352|
NCT01357577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLA-01-S09|Cognitive Behavioral Therapy (CBT) for PTSD in Veterans With Co-Occurring SUDs|CBT for PTSD in Veterans With Co-Occurring Substance Use Disorders|CBT|VA Office of Research and Development|Yes|Recruiting|October 2012|May 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357577||104371|
NCT01357590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAA-001|Evaluation of Thoraflex in the Treatment of Aneurysm or Penetrating Ulcer of the Descending Thoracic Aorta|Evaluation of the Vascutek Ltd. Thoracic Endovascular Stent Graft System (ThoraflexTM)in the Treatment of Aneurysm or Penetrating Ulcer of the Descending Thoracic Aorta||Vascutek Ltd.|Yes|Withdrawn||||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01357590||104370|
NCT01358305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-D-176|Protein Blends (Soy, Whey and Casein) for Muscle Synthesis|A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown||Solae, LLC|Yes|Completed|January 2011|March 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358305||104315|
NCT01358058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-439|Proton Radiation Therapy for Gliomas|Phase II Study of Proton Radiation Therapy for Low Grade and Favorable Grade 3 Gliomas||Massachusetts General Hospital|Yes|Recruiting|May 2011|May 2019|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01358058||104334|
NCT01358344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06558|A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)|A Study to Determine the Bioequivalence of SCH 530348 2.5 mg Tablets Containing a High and Low Percentage of Drug as the Free Base Within the Range Used in the Pivotal Phase 3 Efficacy and Safety Trials. (Protocol No. P06558)||Merck Sharp & Dohme Corp.|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|173|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358344||104312|
NCT01358318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIL1103|Effects of Soy Protein/Soy Fiber on Measures of Satiety|Effect of Addition of Soy Protein and Soy Fiber to a Snack Bar on Satiety and Food Intake||Solae, LLC||Completed|February 2011|September 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 6, 2012|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358318||104314|
NCT01354340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00145-36|Dose Effect of Limicol on (LDL)-Cholesterol Levels|Dose Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia||Lescuyer Laboratory|No|Completed|April 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01354340||104618|
NCT01354353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13565|A Study of Safety and Tolerability in Subjects With Schizophrenia|Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia||Eli Lilly and Company|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|7||Anticipated|120|||Both|18 Years|65 Years|No|||August 2012|August 9, 2012|May 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01354353||104617|
NCT01354366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3383-1|Growth and Tolerance of Hypoallergenic Formulas|The Effects on Growth and Tolerance of Hypoallergenic Formulas Fed to Term Infants||Mead Johnson Nutrition|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|511|||Both|N/A|16 Days|Accepts Healthy Volunteers|Probability Sample|Heatly, term infants|August 2013|August 28, 2013|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354366||104616|
NCT01354665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15307|Depression and Fatigue in MS Patients Treated With Betaferon.|The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.|FADO|Bayer|No|Completed|May 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|567|||Both|18 Years|N/A|No|Probability Sample|Adult patients with relapsing form of multiple sclerosis treated with Betaferon under        routine practice setting.|January 2015|January 19, 2015|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01354665||104593|
NCT01354379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-1008-002|Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer|A Phase 1 Randomized, Observer-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 in Healthy Adult Volunteers Administered by Nasal Sprayer and Pipette||NanoBio Corporation|Yes|Completed|May 2011|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|125|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2013|March 26, 2013|May 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354379||104615|
NCT01354951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-056|Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer|Phase II Study Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy Early Stage, Low Volume in Prostate Cancer||Memorial Sloan Kettering Cancer Center||Terminated|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Male|21 Years|N/A|No|||February 2016|February 4, 2016|May 16, 2011|Yes|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01354951||104571|
NCT01358903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25385|A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors|Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors||Hoffmann-La Roche||Completed|June 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358903||104269|
NCT01362725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10-029-ID-SC|Spinal Cord Stimulation For Heart Failure|Spinal Cord Stimulation For Heart Failure As A Restorative Treatment|SCS HEART|St. Jude Medical|Yes|Active, not recruiting|April 2011|January 2016|Anticipated|August 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|95 Years|No|||January 2016|January 18, 2016|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362725||103977|
NCT01362738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_BELIEF|Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation|Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation|BELIEF|Texas Cardiac Arrhythmia Research Foundation|No|Active, not recruiting|November 2010|December 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|75 Years|No|||August 2014|August 20, 2014|May 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362738||103976|
NCT01359436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007059R|e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer|e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer||National Taiwan University Hospital|No|Recruiting|July 2010|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2012|November 14, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359436||104228|
NCT01359423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0065|Comparison of Primary Long Full Coverage Stenting vs Primary Short Spot Stenting for Long Femoropopliteal Artery Disease.|||Yonsei University|Yes|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|20 Years|79 Years|No|||March 2014|March 4, 2014|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359423||104229|
NCT01359696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPM4957g|A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma|An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma||Genentech, Inc.||Completed|July 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359696||104208|
NCT01359709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASCC-CM-NRT|Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking|Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking||University of California, Los Angeles|No|Active, not recruiting|June 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359709||104207|
NCT01359995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010033R|Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis|Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis||National Taiwan University Hospital|No|Recruiting|November 2010|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|7|||Both|40 Years|90 Years|No|Non-Probability Sample|4 men, 3 women, aged 40-90 years old|May 2011|May 23, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01359995||104185|
NCT01356082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00170|CNAP™ Monitor Study|Accuracy of the CNAP™ Monitor in Providing Beat-to-beat Non-invasive Blood Pressure Readings||Nationwide Children's Hospital|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Both|5 Years|18 Years|No|Non-Probability Sample|Surgery patients at Nationwide Children's Hospital receiving an arterial line.|May 2012|May 1, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356082||104486|
NCT01356095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DI807|A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi|A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi||Dignitas International|No|Completed|March 2011|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|28|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2011|August 28, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356095||104485|
NCT01357005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099032-F|Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan|Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan||Far Eastern Memorial Hospital||Recruiting|October 2010|||December 2013|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|300|||Both|16 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Schizophrenia patients and their biological parents|May 2011|May 19, 2011|December 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01357005||104415|
NCT01357317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK 0036|Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction|Changes in Biochemical and Vascular Parameters w/Lanthanum Carbonate & Calcium Acetate Therapy Compared to Dietary Intervention in Pts w/Stage 3 & 4 Chronic Kidney Disease & Abnormal Phosphorus Homeostasis: a Randomized Controlled Trial||Salem Veterans Affairs Medical Center|Yes|Recruiting|June 2011|March 2014|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||April 2011|June 11, 2012|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01357317||104391|
NCT01357330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11742|Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase 1 Dose Escalation Study of Combination Therapy With Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors||Sanofi|No|Completed|May 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|May 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357330||104390|
NCT01357304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2011/95|10 Prescriptions an Hour. Group Treatment and Physical Activity Referral in a Primary Health Care Setting|Randomized Controlled Trial of Group Treatment With Physical Activity Referral in a Primary Health Care Setting|10PAR|Region Skane|No|Completed|March 2011|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|79 Years|No|||October 2012|November 23, 2012|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357304||104392|
NCT01357850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112670|A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure|A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure||GlaxoSmithKline|No|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|82|||Both|21 Years|75 Years|No|||June 2015|June 4, 2015|November 11, 2010|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01357850||104350|
NCT01358071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR018|Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer|NGR018: Randomized Phase II Study of NGR-hTNF Plus an Anthracycline Versus an Anthracycline Alone in Platinum-resistant Ovarian Cancer|NGR018|MolMed S.p.A.|No|Active, not recruiting|June 2011|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358071||104333|
NCT01357837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116918|Assessment of GRT6005 in Painful Osteoarthritis of the Knee|A Randomized 4 Week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee||Grünenthal GmbH|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|207|||Both|40 Years|75 Years|No|||January 2013|January 22, 2013|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01357837||104351|
NCT01358357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050296|Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex|A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder|PERSIST|Sunovion|Yes|Completed|June 2011|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|966|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358357||104311|
NCT01354093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48834|The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)|Utah Center for the Collaborative Study of the Role of the Macular Pigment Carotenoids in the Pathogenesis and Treatment of MacTel||University of Utah|Yes|Active, not recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Actual|8|||Both|50 Years|85 Years|No|Non-Probability Sample|Up to ten subjects of either gender who have MacTel (as confirmed by the MacTel central        study Reading Center) will be invited to participate. Only those who can conveniently        travel to the University of Utah for study evaluations will be approached since the        project does not have sufficient funding to reimburse for travel expenses. Participants        must agree to discontinue use of any other supplements containing substantial amounts of        carotenoids for one month prior to the baseline visit and for the duration of the study.|October 2015|October 7, 2015|May 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01354093||104637|
NCT01354106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-05-012247|Adhesive Tape Trauma Evaluation of Two Gentle Tapes|Adhesive Tape Trauma Evaluation of Two Gentle Tapes in Healthy Human Infant Subjects||3M|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|26|||Both|6 Months|4 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|May 13, 2011|No|Yes||No|July 20, 2012|https://clinicaltrials.gov/show/NCT01354106||104636|
NCT01354392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORH/PID/6265|AZD1152 in Diffuse Large B-cell Lymphoma|A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-cell Lymphoma||Oxford University Hospitals NHS Trust|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354392||104614|
NCT01354678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPI-1|Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia|Phase 1 Study to Evaluate the Efficacy and Safety of Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia|IMPI|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|No|Active, not recruiting|May 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|69 Years|No|||January 2014|August 13, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354678||104592|
NCT01358916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Swiss Federal Office of Health|Intervention Study to Improve Antibiotic Prescription in Outpatient Care|Improvement of Antibiotic Prescription in Outpatient Care: a Cluster-randomised Intervention Study Using a Sentinel Surveillance Network of Physicians|SAPI|University of Bern|No|Completed|November 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|140|||Both|N/A|N/A|No|||March 2013|March 27, 2013|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358916||104268|
NCT01362764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018067|A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers|A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation Under Fasted Condition in Healthy Adult Subjects||Cougar Biotechnology, Inc.|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362764||103974|
NCT01359449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA73|Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations|Safety and Immunogenicity of Two Doses of Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) or One Dose of Monovalent Meningococcal Group C Conjugate Vaccine Administered Concomitantly With Routine Immunizations Between 12 and 18 Months of Age in Canada||Sanofi|No|Completed|May 2011|November 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|123|||Both|12 Months|18 Months|Accepts Healthy Volunteers|||June 2015|June 16, 2015|May 23, 2011|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01359449||104227|
NCT01359722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0992/09|N-acetylcysteine to Prevent Renal Failure|N-acetylcysteine to Prevent Renal Failure in Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Surgery||Instituto do Coracao|Yes|Recruiting|March 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|30 Years|80 Years|No|||October 2009|May 24, 2011|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359722||104206|
NCT01360008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FREEZE|FREEZE Cohort Study|FREEZE Cohort Study||Stiftung Institut fuer Herzinfarktforschung|Yes|Active, not recruiting|April 2011|April 2017|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|4071|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with AF ablation targeting|February 2016|February 23, 2016|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01360008||104184|
NCT01356693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brom1|Bromelin, a Compound Prepared With Ananas Comocus Extract and Honey, for Acute Cough|Randomized,Double-blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of the Phytotherapic Compound "Bromelin" on Acute Irritative Cough|BROMETOSS|Universidade Federal de Pernambuco|No|Recruiting|June 2011|March 2012|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|102|||Both|2 Years|15 Years|No|||March 2011|June 27, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01356693||104439|
NCT01356966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00019181|Exercise Intolerance in Renal Failure|The Role of Neurovascular Dysfunction and Oxidative Stress in the Exercise Intolerance of Renal Failure|EIRF|Emory University|No|Completed|May 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|May 18, 2011|Yes|Yes||No|May 11, 2015|https://clinicaltrials.gov/show/NCT01356966||104418|
NCT01357018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099094-E|Quality of Life in Chronic Arthritis|A Study on Quality of Life in Patients With Chronic Arthritis||Far Eastern Memorial Hospital|No|Completed|November 2010|April 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|139|||Both|20 Years|N/A|No|Non-Probability Sample|Patient with rheumatoid arthritis or ankylosing spondylitis|February 2014|February 19, 2014|December 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01357018||104414|
NCT01357343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIZH003|Integrated Chiropractic and Acupuncture Treatment for Low Back Pain|Effect of an Integrative Approach of Chiropractic and Traditional Chinese Medicine Care on Low Back Pain: A Randomized Controlled Trial||Southern California University of Health Sciences|No|Completed|February 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|75 Years|No|||June 2015|June 24, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01357343||104389|
NCT01357603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glaritus/PK-PD/FDA/2011|Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM|A Randomized, Double-blind, Two Period, Cross Over Glucose Clamp Study to Test for Bioeqivalence Between Two Long Acting Insulin Analogs-Wockhardt's Glaritus™ (Insulin Glargine) and Lantus (Insulin Glargine) in Subjects With Type 1 Diabetes||Wockhardt|No|Completed|June 2011|August 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|111|||Both|18 Years|60 Years|No|||January 2013|January 24, 2013|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01357603||104369|
NCT01357616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-08-076|Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension|Comparison of Efficacy and Safety of Brinzolamide/Timolol Fixed Combination (AZARGA™) vs Brinzolamide (AZOPT®) and Timolol in Chinese Subjects With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|November 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|May 18, 2011|No|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT01357616||104368|
NCT01357629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF004E|Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease|Observational Follow-up Extension Study to Evaluate Long-term Safety and Tolerability of Immunizations With AFFITOPE AD02 Applied During AFFiRiS002 and AFF004A in Patients With Alzheimer's Disease||Affiris AG|No|Terminated|July 2011|November 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|11|Samples Without DNA|Serum|Both|N/A|N/A|No|Probability Sample|Patients with Alzheimer´s Disease|December 2013|December 10, 2013|March 21, 2011||No|The Study could not be done for every potential participant as planned in the protocol for    organizational reasons.|No||https://clinicaltrials.gov/show/NCT01357629||104367|
NCT01357642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-C|Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients|Epinephrine Inhalation Aerosol USP, an HFA-MDI: Clinical Study-C For Evaluation Of Efficacy And Safety In Asthma Patients||Amphastar Pharmaceuticals, Inc.|No|Completed|July 2011|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|373|||Both|12 Years|75 Years|No|||February 2016|February 11, 2016|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01357642||104366|
NCT01358084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NGR019|Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma|NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)|NGR019|MolMed S.p.A.|No|Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358084||104332|
NCT01358331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06203|A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)|A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203))||Merck Sharp & Dohme Corp.|No|Terminated|November 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358331||104313|
NCT01358097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1219|Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy|Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy||Icahn School of Medicine at Mount Sinai|No|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|33|Samples With DNA|Serum, peripheral blood mononuclear cells|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with new head and neck cancer, who reside in the tri-state area.|April 2014|April 8, 2014|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358097||104331|
NCT01358370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-1-NH01|A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype|A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype||Alexion Pharmaceuticals|No|Completed|November 2010|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Deceased patients diagnosed with LAL deficiency/Wolman phenotype in 1985 or later.|April 2013|April 30, 2013|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01358370||104310|
NCT01358383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00040|Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects||AstraZeneca||Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|May 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358383||104309|
NCT01354405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCLD 10-03|Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)|The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease|RESOLVE|Radboud University|Yes|Completed|May 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|Samples With DNA|Blood samples|Both|18 Years|70 Years|No|Non-Probability Sample|ADPKD patients in Radboud University Hospital|July 2014|July 8, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354405||104613|
NCT01354691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100101/CO15570|Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease|A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period||Avraham Pharmaceuticals Ltd|Yes|Completed|February 2011|March 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|201|||Both|60 Years|85 Years|No|||July 2013|July 22, 2013|May 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01354691||104591|
NCT01354977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-534|Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans|Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|March 2008|||March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||May 2011|May 16, 2011|May 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01354977||104569|
NCT01354990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-234|A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)|Sitagliptin (JANUVIA®) Post Marketing Surveillance Protocol||Merck Sharp & Dohme Corp.|No|Completed|February 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2974|||Both|N/A|N/A|No|Non-Probability Sample|Participants with type 2 diabetes mellitus who are treated with sitagliptin as per the        standard of care in a physician's practice|August 2015|August 26, 2015|May 16, 2011|No|Yes||No|February 1, 2012|https://clinicaltrials.gov/show/NCT01354990||104568|
NCT01358929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25742|A Study of RO6807952 in Patients With Diabetes Mellitus Type 2|A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients||Hoffmann-La Roche||Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358929||104267|
NCT01358942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25493|An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)|Observational, Epidemiological and Non Interventional Study Evaluating the Evolution of Lung Cancer Related Symptoms and Its Correlation With Disease Control Rate in Patients With Non-Small Cell Lung Cancer (NSCLC) Initiating First-line Treatment With Platinum Based Standard Chemotherapy.||Hoffmann-La Roche||Completed|May 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|156|||Both|18 Years|N/A|No|Probability Sample|Non-small cell lung cancer patients initiating treatment with platinum-based chemotherapy        +/- bevacizumab|March 2016|March 1, 2016|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01358942||104266|
NCT01359202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spotlight002|"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy|"Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy: SPOTLIGHT|SPOTLIGHT|Sunnybrook Health Sciences Centre|Yes|Recruiting|May 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359202||104246|
NCT01359462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-806-01|Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis|A Clinical Study of Multiple-dose Pharmacokinetics of Tolvaptan Tablets Administered Orally (15mg Daily) for Consecutively 7 Days in Chinese Patients With Hepatocirrhosis||Otsuka Beijing Research Institute|No|Completed|April 2009|January 2010|Actual|November 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||May 2011|May 23, 2011|March 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01359462||104226|
NCT01360073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FN00007|Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death|Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death - Nested Case Control Analyses in a Cohort of Patients With Acute Serious Coronary Heart Disease||AstraZeneca||Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|42542|||Both|50 Years|84 Years|No|Non-Probability Sample|Individuals aged 50-84 years who from 1 January 2000 to 31 December 2007 had a documented        evidence of a hospitalization for a serious acute coronary event (MI, revascularization of        coronary arteries or unstable angina) and who were alive 1 month after this event in two        primary care clinical practice databases in the UK: General Practice Research Database        (GPRD) and The Health Improvement Network (THIN).|November 2012|November 13, 2012|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360073||104179|
NCT01359735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-022|Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients|A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients||Healthpoint|No|Completed|May 2011|May 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359735||104205|
NCT01360021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589OC00003|New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day|A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy Safety, and Patient Use (User Study) of Symbicort® (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 μg Twice Daily Compared With Symbicort (Budesonide/Formoterol) AC (Actuation Counter) pMDI® 2x160/4.5 μg Twice Daily and Budesonide AC pMDI 2x160 μg Twice Daily in Adult and Adolescent Asthmatics|BAI|AstraZeneca||Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|214|||Both|12 Years|N/A|No|||January 2014|January 27, 2014|May 19, 2011|Yes|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01360021||104183|No. of participants in the safety analysis set is (71 for all the group) as 1 patients from the Budesonide group has not taken any dose of the IP, so not included in the Safety population.
NCT01360034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2011-04|Nifedipine Versus Indomethacin in the Treatment of Preterm Labour|Nifedipine vs. Indomethacin in the Treatment of Preterm Labour and Short Cervix. A Randomized, Controlled Trial.||Saint Thomas Hospital, Panama|No|Not yet recruiting|December 2015|June 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Female|N/A|N/A|No|||January 2015|January 1, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01360034||104182|
NCT01356420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAIR 7001|Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome|Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation|STAIR-SLOS|Oregon Health and Science University|Yes|Recruiting|January 2011|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|85 Years|No|||September 2012|September 18, 2012|May 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356420||104460|
NCT01356745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0900603|Efficacy of Premixed Nitrous Oxide and Oxygen in Patient With Out-of-hospital Moderate Acute Pain|Efficacy of Premixed Nitrous Oxide and Oxygen in Patient With Out-of-hospital Moderate Acute Pain: a Randomized Double-blind Study|MEOPA|University Hospital, Toulouse|No|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01356745||104435|
NCT01356758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|j-nr 20100249|Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents|Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents||University of Aarhus|No|Completed|March 2011|November 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|126|Samples With DNA|blood and skin samples.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with severe psoriasis recruited from a dermatological in- and out patient clinic.        Patients with severe atopic dermatitis.|August 2014|December 18, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01356758||104434|
NCT01357031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDUMAP|Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine|Double Blind Randomized Study Controlled by Placebo and Amitriptylin to Evaluate the Efficacy of Melatonin in the Preventive Treatment of Migraine|EDUMAP|Hospital Israelita Albert Einstein|Yes|Completed|May 2010|December 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|18 Years|65 Years|No|||December 2015|December 29, 2015|May 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01357031||104413|
NCT01357356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC-SER120-DB3-201101|Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia||Serenity Pharmaceuticals, Inc.|Yes|Completed|May 2011|December 2014|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|816|||Both|50 Years|N/A|No|||November 2015|November 23, 2015|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01357356||104388|
NCT01357655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-363|Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)|An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).||Bristol-Myers Squibb|No|Completed|September 2011|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01357655||104365|
NCT01357863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113960|Role of Early Versus Late Switch to Lapatinib-Capecitabine|Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil|(TYCO1)|GlaxoSmithKline|No|Terminated|July 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3|||Female|18 Years|N/A|No|Probability Sample|All cases of ErbB2 positive metastatic breast cancer, receiving approved standard        treatment with lapatinib-capecitabine, after trastuzumab-containing regimen progression in        community setting can participate in this observational study, for a period of 12 months        of observation since the start of the lapatinib-capecitabine treatment.        Centers from private and public settings, which have incorporated Lapatinib treatment in        their routine clinical practice, will be included in this study. Data on the country, type        of center, and facility name will be collected on the case report form for use in the data        analysis.|January 2012|January 12, 2012|May 19, 2011||No|This study was terminated because the National Ethics Committee has not approved the protocol.|No||https://clinicaltrials.gov/show/NCT01357863||104349|
NCT01358123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vwfcirr|Value of Von Willebrand Factor in Portal Hypertension|Von Willebrand Factor As Non-Invasive Predictor Of Clinically Significant Portal Hypertension And Mortality In Patients With Liver Cirrhosis||Medical University of Vienna||Recruiting|September 2006|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|98 Years|No|Probability Sample|Patients with liver cirrhosis of all etioloiges, routinely scheduled for routine HVPG        measurement will systematically be included during the study period|September 2015|September 24, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01358123||104329|
NCT01358396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-DME-1|Glycemic Control and Diabetic Macular Edema|The Effect of Glycemic Control on Visual and Anatomical Outcomes in Response to Therapy for Diabetic Macular Edema.||Cairo University|No|Completed|January 2010|October 2010|Actual|July 2010|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|20 Years|80 Years|No|Probability Sample|Diabetic patients with macular edema with central foveal thickness more than 250 microns        and no proliferative changes.|January 2010|May 20, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358396||104308|
NCT01354119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADdistal_graft|Long-term Benefit of Aortic Stent-graft in Patients With Distal Aortic Dissection|||Asan Medical Center|No|Terminated|January 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|N/A|75 Years|No|||January 2015|January 13, 2015|May 13, 2011||No|Not enough participants enrolled|No||https://clinicaltrials.gov/show/NCT01354119||104635|
NCT01354418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18124|Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)|A Randomized Crossover Bioequivalence Study Comparing a Single Dose of Phenylephrine HCl 30 mg Extended Release Tablet to Three Phenylephrine HCl 10 mg Immediate Release Tablets Each Consecutively Dosed Four Hours Apart Under Fed and Fasting Conditions||Bayer|No|Completed|May 2011|July 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|May 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01354418||104612|
NCT01354704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRENOXA_2011|Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin|Echo-Doppler Assessment of the Occurrence of Asymptomatic Deep Vein Thrombosis (DVT) in Orthopedic Replacement Surgery Under Enoxaparine (PRENOXA)|PRENOXA|Les Laboratoires des Médicaments Stériles|Yes|Completed|March 2011|October 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|153|||Both|18 Years|90 Years|No|||February 2012|November 2, 2015|May 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01354704||104590|
NCT01354717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spear 0.5%|Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo|Phase 3 Study of Brand Generic and Placebo in Treatment of Actinic Keratosis||Spear Pharmaceuticals|No|Completed|September 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|377|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|May 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354717||104589|
NCT01355003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-077|GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol||Merck Sharp & Dohme Corp.|No|Terminated|February 2008|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1080|||Both|9 Years|46 Years|Accepts Healthy Volunteers|Non-Probability Sample|Data will be collected from physicians who prescribed GARDASIL™ and who voluntarily agree        to provide information on their patients. Each physician can provide up to five reports        corresponding to five patients.|August 2015|August 11, 2015|May 16, 2011|No|Yes|Merck Sharp & Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing    surveillance (PMS) study|No||https://clinicaltrials.gov/show/NCT01355003||104567|
NCT01355016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-637-CP-101|A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 in Healthy Volunteers||MicroDose Therapeutx, Inc||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 10, 2012|May 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01355016||104566|
NCT01355276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYWC100602|Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia|A Randomized, Double-blind, Double-dummy, Active Drug Parallel Controlled, Multi-center Clinical Trial on the Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia||Eisai Inc.||Completed|October 2010|October 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|65 Years|No|||November 2011|November 29, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355276||104547|
NCT01358695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANT-1207-201-LCL|Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet|Clinical Trial To Evaluate ANT-1207 In Subjects With Lateral Canthal Lines||Anterios Inc.|Yes|Completed|May 2011|May 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|111|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358695||104285|
NCT01358955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CogMCI study|Efficacy Study of Cognitive Intervention in Amnestic Mild Cognitive Impairment|A Multicenter, Randomized Trial to Assess Efficacy of Home-based and Group Cognitive Intervention Programs in Amnestic Mild Cognitive Impairment|CogMCI|Inha University Hospital|No|Completed|March 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|293|||Both|50 Years|85 Years|No|||August 2013|August 27, 2013|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01358955||104265|
NCT01358968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13526|A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine|A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate||Eli Lilly and Company|No|Completed|June 2011|December 2012|Actual|April 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358968||104264|
NCT01359215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01926|Childhood Anesthesia and Cognitive Function|Is Pediatric Anesthesia Associated With Long-term Hippocampal Dysfunction?|UCSF-Anes-01|University of California, San Francisco|No|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children who received an anesthetic early in life|December 2013|December 11, 2013|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01359215||104245|
NCT01360320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRACLE|Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-|Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-|MIRACLE|Martin-Luther-Universität Halle-Wittenberg|Yes|Recruiting|November 2011|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2941|||Both|50 Years|80 Years|No|||April 2012|April 5, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360320||104160|
NCT01359748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K8-BP-31032011|Clinical Study About Blood Pressure Measurement Efficacy on Multifunction KEITO|Clinical Study About Blood Pressure Measurement Efficacy on Multifunction KEITO||Aguiflai Iberica, S.L.|No|Completed|March 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|89|||Both|18 Years|83 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|May 16, 2011||No||No|June 2, 2011|https://clinicaltrials.gov/show/NCT01359748||104204|
NCT01360047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FN00006|Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death|Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death - Nested Case Control Analyses in a Cohort of First-time Users of Low Dose ASA for Secondary Prevention of Cerebrovascular and Cardiovascular Outcomes.||AstraZeneca||Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|39513|||Both|50 Years|84 Years|No|Non-Probability Sample|All patients aged 50 to 84 years with a first ever prescription of low-dose ASA (defined        as 75-300 mg/day) for the secondary prevention of cardiovascular or cerebrovascular events        (defined as any previous ischemic cerebrovascular event or ischemic heart disease) from 1        January 2000 to 31 December 2007.|November 2012|November 13, 2012|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360047||104181|
NCT01360060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg_section|Analgesia After Cesarean Section|||Seoul National University Bundang Hospital||Completed|December 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|503|||Female|20 Years|50 Years|No|Non-Probability Sample|medical record review|May 2011|May 24, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01360060||104180|
NCT01356719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUNAR2011|Scoring Method for Describing the Position of a Tracheostomy Tube|LUNAR Study - Develop and Validate a Bedside Scoring Method for Describing the Position and Orientation of a Tracheostomy Tube Tip When Viewed Endoscopically From a Standardised Position||University Hospital of South Manchester NHS Foundation Trust|No|Not yet recruiting|July 2011|February 2012|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|16 Years|N/A|No|Non-Probability Sample|Adults (>16yrs) who have a tracheostomy performed as part of their intensive care        management|May 2011|May 18, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356719||104437|
NCT01357057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04806|Admission Bio-clinical Score to Predict One-year Outcomes in Coiled Subarachnoid Hemorrhage (SAH)|Biological Markers in Patients Presenting Aneurism Coiling for Subarachnoid Hemorrhage|ABCSAH|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2003|September 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|530|||Both|18 Years|N/A|No|Non-Probability Sample|Adult coiled SAH after ICU admission|May 2011|December 27, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01357057||104411|
NCT01357070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-bao|Effect of Broccoli Sprout on Blood Levels of Sulforaphane to Reduce Responsiveness of Immune System|Does Broccoli Sprout Consumption Result in Plasma Sulforaphane Levels That Can Attenuate Leukocyte Activation Ex-vivo in Healthy Human Volunteers?||Imperial College London|Yes|Recruiting|May 2011|August 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 19, 2011|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01357070||104410|
NCT01357382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02652|The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome|The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome||St. Paul's Hospital, Canada|No|Not yet recruiting|June 2011|July 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|19 Years|N/A|No|||April 2011|May 19, 2011|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01357382||104386|
NCT01357395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-0470-07|A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer|A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer Subjects Who Have Not Responded to Standard Treatment or Relapsed After Standard Treatment|ESCAPE|Astex Pharmaceuticals|No|Active, not recruiting|May 2011|May 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||September 2012|October 17, 2012|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01357395||104385|
NCT01357369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02252011-7482|Study of Drug Concentration of Ondansetron and Cefazolin in Mothers and Neonates|Pharmacokinetics and Placental Transfer of Ondansetron and Cefazolin: A Preliminary Analysis||Stanford University||Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Blood samples for pharmacokinetics.|Female|18 Years|45 Years|No|Non-Probability Sample|Generally health women at 37-42 weeks gestation, and their newborns.|June 2013|June 7, 2013|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01357369||104387|
NCT01357889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114856|Pharmacokinetics/Pharmacodynamics of Albiglutide|A Multidose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Pharmacokinetics and Pharmacodynamics of Albiglutide||GlaxoSmithKline|Yes|Completed|July 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|80 Years|No|||April 2014|May 29, 2014|May 19, 2011|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01357889||104347|
NCT01357876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114453|Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics|Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics||GlaxoSmithKline|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||August 2014|August 14, 2014|November 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01357876||104348|
NCT01358110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1234|Emergency Department-Based Palliative Care for Advanced Cancer Patients|Emergency Department-Based Palliative Care for Advanced Cancer Patients||Icahn School of Medicine at Mount Sinai|No|Completed|May 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|136|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358110||104330|
NCT01358409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTG_Neb01|Regression of Myocardial Steatosis by Nebivolol|||Cedars-Sinai Medical Center|Yes|Not yet recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|59 Years|No|||May 2011|May 20, 2011|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358409||104307|
NCT01354132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P-000460 BIDMC 42|N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis|Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial|NACPSY|Beth Israel Deaconess Medical Center|Yes|Completed|May 2011|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|35 Years|No|||May 2015|May 26, 2015|May 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354132||104634|
NCT01354444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG037504-01|Trial of Carvedilol in Alzheimer's Disease|Pilot Trial of Carvedilol in Alzheimer's Disease||Johns Hopkins University|Yes|Recruiting|June 2011|January 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|100 Years|No|||March 2016|March 7, 2016|May 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354444||104610|
NCT01354730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU10001|A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women|||Adimmune Corporation||Completed|June 2010|May 2011|Actual|April 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|398|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The target population was derived from medical centers in Taiwan: National Taiwan        University Hospital, Chang Gung Memorial Hospital - LinKou and China Medical University        Hospital.        The sample size for this study was planned to include 500 cases in exposed cohort and 500        cases in unexposed cohort. Actual recruitment depended on the volume of pregnancy women        received AdimFlu-S (A/H1N1) at each hospital. The size of unexposed cohort was be equal to        the exposed cohort.|May 2011|May 16, 2011|May 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01354730||104588|
NCT01354743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DysportPerlaneL-2010|Upper Facial Remodeling With Perlane-L and Dysport|Upper Facial Remodeling With Perlane-L and Dysport.|DPL-2010|Beer, Kenneth R., M.D., PA|No|Completed|December 2010|May 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 24, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01354743||104587|
NCT01355029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSN1101-000119|Evaluation of the Stroke Caregiver Education and Support Program|A Pilot Study of the Evaluation of the Family Informal Caregiver Stroke Self Management (FICSS) Research Project: Impact on Caregiver Psychosocial, Emotional and Health Needs|FICSS|March of Dimes, Canada|No|Completed|February 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|43|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01355029||104565|
NCT01359475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMC1505CTIL|A Clinical Trial of an Acetal Resin Crown for Restoration of Primary Molars|Phase 3- Clinical Trial on Children. PROTOCOL 465-549||Barzilai Medical Center|No|Completed|April 2010|July 2013|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||July 2013|July 2, 2013|May 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359475||104225|
NCT01358981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13747|A Study of LY2881835 in Healthy People and People With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 26, 2011|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358981||104263|
NCT01359228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salix Rifaximin Study|Rifaximin Treatment of Papulopustular Rosacea|Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study||University of California, San Francisco|No|Withdrawn|April 2013|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|April 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359228||104244|
NCT01360580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/110/HP|Swallowing Disorders After Prolonged Mechanical Ventilation|Current Care Study of Incidence and Consequences of Swallowing Disorders After Invasive Mechanical Ventilation|Deglutube|University Hospital, Rouen|No|Completed|January 2011|December 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|138|||Both|18 Years|N/A|No|Non-Probability Sample|More than 7d of invasive mechanical ventilation|January 2013|January 23, 2013|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360580||104141|
NCT01360593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-139|Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma|Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer||University of Pittsburgh|Yes|Active, not recruiting|July 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|May 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01360593||104140|
NCT01360606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-051|Stereotactic Body Radiation Therapy (SBRT) for Liver Mets|A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases||University of Pittsburgh|Yes|Recruiting|September 2011|June 2020|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|May 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01360606||104139|
NCT01360307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-XXX-2011/1|Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale|Psychometric Validation of the Spanish Version of the CUDOS Scale (Clinically Useful Depression Outcome Scale) in Major Depressive Disorder|CUDOS|AstraZeneca|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|330|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|December 2011|December 5, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01360307||104161|
NCT01360554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471009|ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer|Archer 1009: A Randomized, Double Blind Phase 3 Efficacy And Safety Study Of PF-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy|ARCHER 1009|Pfizer|Yes|Completed|June 2011|September 2015|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|877|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|April 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360554||104143|
NCT01360567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100002-63-020|The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia|Taipei City Hospital, Taipei, Taiwan||Taipei City Hospital|Yes|Completed|May 2011|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|20 Years|60 Years|No|||April 2013|April 27, 2013|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01360567||104142|
NCT01361126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL654_2004|A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B|A Phase I/II Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B||CSL Behring|Yes|Completed|July 2011|July 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Male|12 Years|65 Years|No|||November 2015|November 5, 2015|May 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01361126||104100|
NCT01356732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 162 02|Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients|Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients.|REANURSUF|University Hospital, Toulouse|No|Completed|January 2010|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|No|||February 2016|February 4, 2016|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01356732||104436|
NCT01357083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9460|The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder|The Study of Morning and Nocturnal Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder||Science & Research Islamic Azad University Branch Khozestan|Yes|Completed|August 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|92|||Both|22 Years|48 Years|Accepts Healthy Volunteers|Probability Sample|The individuals were chosen who referred to the industrial medical unit of one of big        company.|August 2009|May 19, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01357083||104409|
NCT01357408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080-18014-J66601|Heart Failure and Risk of Re-Admissions Determined by Abnormal REVEAL Parameters|Phase 4 Registry Study Will Evaluate the Ability of Cardiac Rhythm (Cardiac Compass) Data to Predict Future Cardiac Events in Heart Failure (HF) Patients Recently Discharged After a Hospitalization for Heart Failure Who Have or Plan to Have a Implanted Loop Recorder (ILR), Specifically, the Reveal XT Device.|HF-RADAR|Thomas Jefferson University|No|Terminated|May 2011|||December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|HF patients (with LV function ≥ 40%) admitted to an acute care facility (observation        status or hospital stay) for heart failure who either have a Reveal XT device in place or        plan to have the ILR device inserted for clinical indication within 14 days of discharge        from the hospitalization.|January 2013|January 4, 2013|May 18, 2011||No|enrollment futility|No||https://clinicaltrials.gov/show/NCT01357408||104384|
NCT01357668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-240|An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis|An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis||Bristol-Myers Squibb|No|Recruiting|January 2013|December 2029|Anticipated|December 2029|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|Samples Without DNA|Serum|Both|N/A|17 Years|No|Non-Probability Sample|Pediatric rheumatology clinics|December 2015|March 7, 2016|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357668||104364|
NCT01357902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115261|Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China|An Open Label, Randomized, Cross-Over Study to Investigate the Single Dose Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg) Compared to Lamotrigine Compressed/Standard Tablets (25mg) in Chinese Healthy Male Subjects||GlaxoSmithKline||Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|May 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357902||104346|
NCT01358136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-10|ThyrOp: A Study of Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter|ThyrOp: Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter - Focus on Weight Gain and Mitochondrial Dysfunction|ThyrOp|Naestved Hospital|No|Recruiting|May 2011|December 2013|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population is patients who meet the inclusion criteria and who are going to        undergo hemithyroidectomy at Slagelse Hospital in Region Zealand, Denmark. The study        subjects are are invited to participate by letter after the operation date is been        scheduled.|April 2012|April 24, 2012|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01358136||104328|
NCT01358422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBTAIN|Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery|Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery. A Prospective Observational Study (OBTAIN Study)|OBTAIN|European Society of Anaesthesiology|No|Completed|October 2011|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|830|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing non-cardiac surgery within four years of percutaneous coronary        intervention (PCI) with the placement of a bare metal or drug eluting stent will be        included in the study.|October 2015|October 12, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01358422||104306|
NCT01354145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/III-DMOAD-02|Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI|Twenty-four Month Exploratory Study of the Effect of Chondroitin Sulphate on Structural Changes in Knee Osteoarthritis Patients as Assessed by MRI|MOSAIC|Bioiberica|Yes|Completed|June 2011|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|40 Years|N/A|No|||July 2015|July 20, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354145||104633|
NCT01354431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-010|BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)|A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy||Bristol-Myers Squibb|No|Active, not recruiting|May 2011|July 2016|Anticipated|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|May 10, 2011|Yes|Yes||No|September 8, 2015|https://clinicaltrials.gov/show/NCT01354431||104611|
NCT01354756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/10-09-3921/52|Validation of Apnea LinkTM for Sleep Apnea Syndrome Screening in a Bariatric Population|Validation of Apnea LinkTM (ResMed Corporation, Poway, California) for Sleep Apnea Syndrome Screening in a Bariatric Population||Centre Hospitalier Universitaire Saint Pierre|No|Terminated|October 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|80 Years|No|Non-Probability Sample|obese patients, > 18y old, in whom a bariatric surgery is planified and who have to        undergo a polysomnography for OSA screening|March 2015|March 9, 2015|May 6, 2011||No|device was stolen|No||https://clinicaltrials.gov/show/NCT01354756||104586|
NCT01355042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-220268|Studies of Blood DNA in Patients With Severe Infection DYNAMICS|DYNAMICS: DNA as a Prognostic Marker in ICU Patients Study|DYNAMICS|Hamilton Health Sciences Corporation|No|Recruiting|November 2010|September 2015|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|plasma|Both|18 Years|N/A|No|Probability Sample|Patients admitted to academic intensive care units|September 2012|September 12, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355042||104564|
NCT01355315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95005|Enhanced External Counterpulsation|Enhanced External Counterpulsation for Ischemic Cardiomyopathy||Far Eastern Memorial Hospital|Yes|Completed|April 2006|||December 2007|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|Samples Without DNA|serum and plasma|Both|N/A|N/A|No|Probability Sample|Patients with ischemia coronary artery diseases and congestive heart failure not amenable        to standard procedures|June 2008|May 17, 2011|June 18, 2008||No||No||https://clinicaltrials.gov/show/NCT01355315||104544|
NCT01355328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97105|Evaluating Light-tissue Reaction and Transdermal Drug Delivery by Multiphoton Microscopy|Evaluating Light-tissue Reaction and Transdermal Drug Delivery by Multiphoton Microscopy||Far Eastern Memorial Hospital||Recruiting|February 2009|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|N/A|2||||||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2009|May 17, 2011|May 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01355328||104543|
NCT01360086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000699219|Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction|Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter.||National Cancer Institute (NCI)||Recruiting|May 2011|||April 2015|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|63|||Both|18 Years|75 Years|No|||December 2011|December 9, 2011|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01360086||104178|
NCT01360099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110156|Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study|Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study||National Institutes of Health Clinical Center (CC)||Recruiting|May 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1600|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 19, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01360099||104177|
NCT01360112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911143|Preventing the Spread of Malaria in Mali|Malaria Transmission Blocking Assay Development and Gametocyte Carriage in a Vaccine Testing Site in Mali||National Institutes of Health Clinical Center (CC)||Completed|April 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|3 Months|50 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01360112||104176|
NCT01359761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0106|Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors|Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors: A Multi-Site Randomized Controlled Trial||Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Recruiting|February 2011|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01359761||104203|
NCT01359774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-56|31P-MRS and Huntington Disease|31Phosphorus-Magnetic Resonance Spectroscopy and Huntington Disease|PRO-MH|Institut National de la Santé Et de la Recherche Médicale, France||Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 20, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359774||104202|
NCT01360619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K8-FAT-05062007|Clinical Study About Fat Measurement on Multifunction Keito by Comparison Versus Its Predicate K014009|||Aguiflai Iberica, S.L.|No|Completed|June 2007|October 2007||September 2007|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1||177|||Both|18 Years|82 Years|Accepts Healthy Volunteers|Probability Sample|To include the maximum types of patients, the selection was opened to all the general        public who could use the multifunction Keito in a public site, where is is intended to be        placed. The test was carried out following the user's manual rules about who can use the        device.|October 2007|May 24, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360619||104138|
NCT01360840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 62242-006|EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)|PERSEUS|EMD Serono|Yes|Completed|April 2011|July 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Male|18 Years|N/A|No|||November 2015|November 9, 2015|April 15, 2011|Yes|Yes||No|July 24, 2015|https://clinicaltrials.gov/show/NCT01360840||104121|
NCT01361412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR002A|Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy|An Optional Research Study to Identify Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy in Subjects Already Enrolled in Clinical Study TR002||Circassia Limited||Completed|March 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|5||Anticipated|20|||Both|18 Years|65 Years|No|||October 2011|October 6, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01361412||104078|
NCT01356472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSA-VAP YANG ZT CN|Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia|Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Vitro and in Ventilator-associated Pneumonia||Ruijin Hospital|Yes|Not yet recruiting|June 2011|||June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2011|May 18, 2011|May 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356472||104456|
NCT01357096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990179|Development and Efficacy Evaluation of Integrated Chronic Care and Health Promotion Model for Patients With Coronary Artery Disease in Taiwan|||Kaohsiung Medical University Chung-Ho Memorial Hospital||Recruiting|January 2011|||January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|N/A|85 Years|No|||July 2010|May 19, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357096||104408|
NCT01357109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BANDY 070112|Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes|Effect of Bosentan on Macro- and Microvascular Function in Patients With Type 2 Diabetes|BANDY|Karolinska Institutet|No|Completed|November 2007|January 2011|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|N/A|80 Years|No|||October 2007|May 18, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357109||104407|
NCT01357421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMX-103|Effects of TT301 on Cytokine Levels Post Endotoxin Challenge|A Phase 1 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effects of a Single Intravenous Dose of TT301 on LPS-induced Changes in Blood Cytokine Levels in Healthy Male Volunteers||Transition Therapeutics|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|May 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357421||104383|
NCT01357434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAND2010-0808|Comparing Calories at Fast Food Restaurants|Rating Fast Food on Healthiness||University of California, Los Angeles|No|Completed|May 2011|||May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|12 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents in a community in South Los Angeles.|May 2011|June 23, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357434||104382|
NCT01357681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023941-31|Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)|Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -|ETON|Charite University, Berlin, Germany|Yes|Completed|September 2011|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01357681||104363|
NCT01358175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2305|16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis|MEASURE 1|Novartis|Yes|Active, not recruiting|October 2011|February 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|372|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01358175||104325|
NCT01358435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wosulin 7030/PK-PD/HV/FDA/10/3|Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects|Randomized,Single Center,Double Blind,Two-period,Crossover Glucose Clamp Trial Study to Test Bioequivalence Between Two Recombinant Human Mixed Insulins-Wockhardt's Human/Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects||Wockhardt|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|53|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 26, 2012|May 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01358435||104305|
NCT01358149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.23.NRC|Trial of Cocoa-based Food in Children|Double Blind Controlled Trial of Cocoa-based Food in Children||Nestlé|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|8 Years|13 Years|Accepts Healthy Volunteers|||October 2013|October 29, 2013|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01358149||104327|
NCT01354158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01272|A Dose Titration of Droxidopa in Patients With Spinal Cord Injury|A Dose Response Trial of Droxidopa to Treat Hypotension in Persons With SCI||Bronx VA Medical Center|No|Completed|May 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||May 2011|July 29, 2013|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354158||104632|
NCT01354457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/12-H|Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+|Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy With 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients|RIT 90YEpra|Nantes University Hospital|No|Active, not recruiting|November 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|70 Years|No|||May 2011|June 24, 2014|July 17, 2009||No||No||https://clinicaltrials.gov/show/NCT01354457||104609|
NCT01354470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPMC-APRL-8B|A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence|A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence||California Pacific Medical Center Research Institute||Completed|October 2011|||February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|50 Years|No|||July 2013|July 1, 2013|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01354470||104608|
NCT01354769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0006746A|Capnography Library - Data Collection in the Critical Care Environment Stage 2|Capnography Library - Data Collection in the Critical Care Environment Stage 2||Shaare Zedek Medical Center|No|Suspended|June 2011|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Non-intubated and intubated patients being treated for severe illnesses in the intensive        care unit|May 2011|March 1, 2015|May 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01354769||104585|
NCT01355055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-MHH-ReD-EK5853|Sympathetic Activity and Renal Denervation|Influences of Catheter-based Renal Denervation on Central Sympathetic Nervous System Regulation in Refractory Hypertension|ReD|Hannover Medical School|No|Recruiting|March 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|26|||Both|18 Years|N/A|No|Probability Sample|Patients with refractory hypertension, in whom catheter-based renal denervation is        indicated and who are scheduled for this procedure, will be recruited from the outpatient        clinic.|March 2011|May 16, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355055||104563|
NCT01355068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4121010|A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Epanutin Infatabs 50 mg (Sourced From Germany) Verses Dilantin Infatabs 50 mg (Sourced From Australia) in Healthy Subjects||Pfizer|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|May 12, 2011|No|Yes||No|November 10, 2011|https://clinicaltrials.gov/show/NCT01355068||104562|
NCT01355341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE/HMP-01|Safety and Efficacy of Herbmed Plus in Patients withRenal Calculi|A Phase II, 28 Week, Randomized, Double- Blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 'Herbmed Plus' an Ayurvedic Formulation in Patients With Renal Calculi|HerbmedPlus|Amai Charitable Trust|No|Recruiting|April 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|84|||Both|10 Years|75 Years|Accepts Healthy Volunteers|||May 2011|May 17, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355341||104542|
NCT01355354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00026|Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects|An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily||AstraZeneca||Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|May 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01355354||104541|
NCT01360125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0106A|S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy|S0106A, Proteomic Signatures Associated With Complete Response (CR) and Complete Continuous Response at One Year (CCR1) Following Cytarabine-Based Induction Chemotherapy in Younger Adult Patients (18-60 Years of Age) With a Newly Diagnosed Non-M3 AML||Southwest Oncology Group|No|Active, not recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|310|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients enrolled in S0106 that consented to use of specimens for future reserach|March 2015|March 5, 2015|May 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01360125||104175|
NCT01360333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFVEX|Oral Fluid Volume Expansion|Oral Fluid: Absorption and Expansion of the Blood Volume|OFVEX|University Hospital, Linkoeping|No|Completed|May 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 11, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360333||104159|
NCT01351480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-306|Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients|Assessment of Structural Benefits of Injectable Abatacept as Measured by MRI in RA Patients Who Have Failed Prior Anti-Tumor Necrosis (TNF) Therapy and Correlated With Clinical Outcomes||Arthritis & Rheumatic Disease Specialties Research|Yes|Completed|June 2011|April 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 16, 2015|May 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01351480||104836|
NCT01351753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UI 201012738|Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity|Does Reversal of Visceral Obesity by Drug Therapy Improve Vascular Function?|REVIVE|University of Iowa|No|Recruiting|March 2011|December 2013|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|150|||Both|40 Years|75 Years|No|||April 2012|April 16, 2012|May 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01351753||104815|
NCT01360853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-22|Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer|A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer|ONTRAC|Onconova Therapeutics, Inc.|Yes|Completed|May 2011|December 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360853||104120|
NCT01360866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-238|Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)|A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial|Orion|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Active, not recruiting|October 2011|March 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3000|||Both|18 Years|65 Years|No|||September 2015|September 11, 2015|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360866||104119|
NCT01361139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP09|Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)|Detection and Characterization of Cardio-Pulmonary Patho-Physiological States and Diseases by Transthoracic Parametric Doppler (TPD)||Echosense Ltd.|No|Completed|August 2011|November 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to a large hospital-affiliated community lung clinic.|June 2012|January 14, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01361139||104099|
NCT01356771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PennSCAPE|Melanoma Risk Assessment & Tailored Intervention|Melanoma Risk Assessment and Skin Cancer Awareness, Prevention, and Education in a Primary Care Setting|PennSCAPE|University of Pennsylvania|No|Active, not recruiting|May 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 15, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01356771||104433|
NCT01357044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRB-SU-010|Effects of Plant Extracts on Semen Quality|An Extract of Pomegranate Fruit and Galangal Rhizome Increases the Numbers of Motile Sperm: A Prospective, Randomised, Controlled, Double-Blinded Trial||Horsens Hospital|No|Completed|May 2011|July 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 8, 2014|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01357044||104412|
NCT01357707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1_215_08|Clinical-genetic Investigations in Children With Early Infantile Epilepsies|Clinical-genetic Investigations in Children With Early Infantile Epilepsies||Charite University, Berlin, Germany|No|Recruiting|July 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|DNA isolated from blood cells or from saliva|Both|5 Years|10 Years|No|Probability Sample|Patients with infantile seizures without brain malformations, metabolic disorders of        lissencephaly who had a good outcome and are seizure free (with or without AEDs) after the        age of 5 years.|July 2013|July 5, 2013|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01357707||104361|
NCT01357915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115429|Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine|A Follow-up Study to Evaluate the Long-term Persistence of GSK Biologicals' Candidate CMV Vaccine Administered to Male Adults||GlaxoSmithKline||Completed|June 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01357915||104345|
NCT01358162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0111|Phase IC Study of Safety and PK of SQ109 300mg Daily|A Phase 1C, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 300 mg of SQ109 Given Once Daily for 14 Days in Normal, Healthy Male and Female Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|November 2010|April 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2011|May 10, 2013|November 18, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01358162||104326|
NCT01358188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-CFCT-01|Exploration of Immunity in Gaucher Disease|Prospective Study of Macrophage Activation and Cross Talk Between Immune System Elements in Subjects With Gaucher Disease||O & O Alpan LLC|No|Active, not recruiting|April 2011|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will include individuals with Gaucher disease, healthy controls and        individuals with primary immune dysfunction|May 2015|May 6, 2015|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01358188||104324|
NCT01358448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT8433B|A Pilot Study of the Efficacy and Program Cost-effectiveness of Prevention Plus for Childhood Obesity|A Pilot Study of the Efficacy and Program Cost-effectiveness of Prevention Plus for Childhood Obesity||University of Tennessee||Active, not recruiting|April 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|33|||Both|4 Years|8 Years|No|||May 2015|May 28, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01358448||104304|
NCT01358461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4900 (2010 - A01451-38)|Validation of a Non Invasive Blood Marker of SIDS and Vagal Disorders|Circulating Biomarker(s) of Muscarinic Receptor Overexpression and Vagal Disorders.||University Hospital, Strasbourg, France|No|Recruiting|May 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|240|Samples Without DNA|Blood|Both|1 Month|51 Years|Accepts Healthy Volunteers|Non-Probability Sample|University Hospital|June 2012|June 14, 2012|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01358461||104303|
NCT01354184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardoz-003|CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial)|An International, Multi-centre, Randomised, Stratified, Double-blinded, Placebo-controlled, 4-parallel Group Trial Investigating the Efficacy and Safety of Three Different Dose Levels of CRD007 (The AORTA Trial)||RSPR Pharma AB||Completed||||||Phase 2|Interventional|N/A|4||||||Both|50 Years|N/A||||November 2012|November 5, 2012|May 13, 2011||||No||https://clinicaltrials.gov/show/NCT01354184||104630|
NCT01354509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV_STL_001|Normothermia Protocol for Traumatic Brain Injury Patients|Normothermia Protocol for Traumatic Brain Injury Patients: An Outcome Study||Medivance, Inc.|Yes|Recruiting|May 2011|May 2013|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|85 Years|No|Non-Probability Sample|Severe TBI patients(GCS 3-9) admitted to ICU|May 2011|May 17, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01354509||104605|
NCT01354782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-101-EC|Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects|An Open, Single Centre, Single and Repeated Dose Study to Investigate the Pharmacokinetic Profile of Roflumilast and Roflumilast N-oxide After Administration of 500 μg Dose of Roflumilast in Healthy Chinese Subjects||Nycomed|No|Completed|May 2011|September 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|40 Years|N/A|No|||May 2012|May 4, 2012|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01354782||104584|
NCT01354483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN102B_KM|Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury|Feasibility and Safety of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Trial||China Spinal Cord Injury Network|No|Completed|September 2011|December 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|60 Years|No|||August 2014|August 20, 2014|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01354483||104607|
NCT01355692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUM.NOVUS SRT.01|Evaluation of the Effects of Selective Photocoagulation for the Treatment of Diabetic Macular Edema|Phase III Multi Center Study Study of the Effects of Selective Retinal Photocoagulation for the Treatment of Diabetic Macular Edema|SRT|Lumenis Ltd.|No|Recruiting|December 2009|June 2013|Anticipated|January 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|18 Years|N/A|No|||January 2012|January 15, 2012|May 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01355692||104515|
NCT01355705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMMYL0018|Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma|A Phase I/II Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma||Stanford University|Yes|Active, not recruiting|August 2011|July 2016|Anticipated|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||November 2014|November 22, 2014|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01355705||104514|
NCT01355952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103008158|An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia|An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia|ALA|Yale University|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||November 2015|November 4, 2015|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01355952||104496|
NCT01356303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08/068|Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer|A Phase II Study of Docetaxel Combined With Cisplatin as the First Line Chemotherapy in Patients With Metastatic Non-small Cell Lung Cancer|TAXIS01|National Guard Health Affairs|No|Recruiting|March 2009|December 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|March 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01356303||104469|
NCT01356316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU10T11A|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects|||Adimmune Corporation||Completed|August 2010|March 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 27, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01356316||104468|
NCT01356576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-039|Effect of Hemodialysis Membranes on Platelet Count|Effect of Hemodialysis Membranes on Platelet Count||Northwell Health|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|99|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients were being selected from the community where undergoing dialysis.|February 2014|February 6, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01356576||104448|
NCT01351207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB9795|The Effect of Eggs on Postprandial Metabolism|The Effect of Eggs on Postprandial Metabolism: A Randomized, Controlled Crossover Pilot Study in Older, Overweight Adults||Tufts University||Completed|April 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|20|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01351207||104857|
NCT01351220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGT CPPB-119384|Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention|Community Dissemination of an Evidence-based CRC Screening Intervention||University of California, Los Angeles|No|Completed|July 2010|June 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|1100|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01351220||104856|
NCT01351493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-030|Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Pressure Sore|A Randomized, Double-blind, Placebo-controlled Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Pressure Sore||China Medical University Hospital|Yes|Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|No|||July 2012|July 10, 2012|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351493||104835|
NCT01352923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201111373|Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations|Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations||Universitaire Ziekenhuizen Leuven|No|Recruiting|May 2011|||May 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 11, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352923||104727|
NCT01352026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD10/6-V|Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)||MetHTAP|Nantes University Hospital||Withdrawn|May 2011|||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|80 Years|No|||August 2012|August 3, 2012|May 10, 2011||No|Several therapeutic have been developed making more difficult the eligibility of patients -    Recruitment of new centers wasn't possible due to competing trials|No||https://clinicaltrials.gov/show/NCT01352026||104794|
NCT01352039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF098 - HEP-SC|A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery|A Phase III, Non-inferiority, Randomized, Double-blind Trial Comparing Eurofarma Unfractionated Sodium Heparin 5,000 IU to APP Pharmaceuticals Unfractionated Sodium Heparin 5,000 IU in the Thromboprophylaxis of Geriatric Patients Who Underwent Hip Fracture Surgery.|HEP-SC|Eurofarma Laboratorios S.A.|Yes|Terminated|October 2011|October 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|544|||Both|60 Years|85 Years|No|||October 2012|October 15, 2012|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352039||104793|
NCT01352338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-0630|Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)|A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma|REPEAT|UMC Utrecht|Yes|Completed|August 2011|February 2016|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01352338||104772|
NCT01352351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0534|Linking Microcredit, Technology, and Promotion of IYCF Breastfeeding Guidelines in Bauchi State, Nigeria|Linking Microcredit, Technology, and Promotion of IYCF Breastfeeding Guidelines in Bauchi State, Nigeria||University of North Carolina, Chapel Hill|No|Completed|May 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|485|||Female|15 Years|45 Years|No|||February 2013|February 6, 2013|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352351||104771|
NCT01356784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-154-32028|Returning to Work. Efficacy of "Tailored Physical Activity or" "Chronic Pain Self-management Program" in Sicklisted Citizens With Chronic Musculoskeletal Pain|Efficacy of "Tailored Physical Activity or" "Chronic Pain Self-management Program" on Returning to Work: a Randomized Controlled Trial in Sicklisted Citizens With Chronic Pain Related to the Spine or Upper Body||University of Southern Denmark|Yes|Completed|May 2011|April 2014|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|141|||Both|18 Years|66 Years||||April 2014|April 22, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01356784||104432|
NCT01358214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pfm 10k003 TiLOOP® Tape|Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)|Single-center, Non-randomized, Comparative, Post-marketing Surveillance Cohort Study on Validation of a Questionnaire on Quality of Life After Surgical Stabilization of the Urethra With Titanized Polypropylene Mesh (TiLOOP® Tape)||pfm medical ag|No|Terminated|May 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|21|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The indicated or treated population of women showing stress urinary incontinence that        should / has been treated with a surgical mesh.        The sample of patients treated with TiLOOP® Tape at the single center between 2007 and        2009 represents the patient population for which the medical device is intended. The        clinic continues to examine women with incontinence symptoms requiring a mesh implant.        This group of patients is assumed to be similar to the study arm of treated patients.        The Non-symptomatic Population consists of women comparable in age but without urinary        incontinence|August 2012|August 22, 2012|May 18, 2011||No|major recruitment failure|No||https://clinicaltrials.gov/show/NCT01358214||104322|
NCT01357694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIA|BRIA - Bridging Intervention in Anesthesiology|Open Monocentric Randomized Clinical Trial on the Efficacy of the Psychotherapeutic Bridging Intervention in Anesthesiology (BRIA)|BRIA|Charite University, Berlin, Germany|No|Completed|May 2011|September 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357694||104362|
NCT01357928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-CLN-100048C|Thromboelastography (TEG) Reference Range Study|Procedure for the Reference Range Study for Haemoscope Reagents||Haemonetics Corporation|No|Completed|April 2011|October 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|159|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|September 2012|September 4, 2012|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01357928||104344|
NCT01358474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-DAT-003|Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism|Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|July 2011|June 2016|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Investigators' clinical practice (e.g., neurology clinic, sleep disorder clinic, etc).|December 2015|December 3, 2015|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01358474||104302|
NCT01354171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURC-003|Active Surveillance Magnetic Resonance Imaging Study|Active Surveillance Magnetic Resonance Imaging Study|ASIST|Canadian Urology Research Consortium|Yes|Recruiting|November 2011|December 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Male|18 Years|N/A|No|||March 2012|March 21, 2012|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354171||104631|
NCT01354197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40-53-11|The Thai Surgical Intensive Care Study (Thai-SICU Study)|Multicenter Study of Outcome and Adverse Events in Surgical Intensive Care Unit of Thai University Hospital|THAI-SICU|Royal College of Anesthesiologists of Thailand|Yes|Recruiting|April 2011|May 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|All SICU admission patients|May 2011|May 20, 2011|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354197||104629|
NCT01354795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-07-219|Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass|Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass|EUS-FNA|Samsung Medical Center|Yes|Completed|September 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|85 Years|No|||May 2011|May 16, 2011|April 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01354795||104583|
NCT01355081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004/CCT-003|Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder||Takeda|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|366|||Both|20 Years|75 Years|No|||November 2014|November 4, 2014|May 16, 2011||No||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01355081||104561|
NCT01355367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14023|High Dose BAYA1040 CR: a Long Term Extension Study|A Multicenter, Open Label, Long Term Extension Study of Oral BAYA1040 CR 80 mg (40 mg Bid) for 44 Weeks in Patients With Essential Hypertension (Extension From Study 13176)||Bayer|No|Completed|January 2011|April 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|20 Years|N/A|No|||January 2014|January 28, 2014|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01355367||104540|
NCT01355380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15308|Efficacy of Ventavis Used in Real-life Setting.|The Efficacy of Inhaled Iloprost in Patients Treated Within the "Pulmonary Arterial Hypertension Therapeutic Programme".|SPHERA|Bayer|No|Active, not recruiting|August 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Probability Sample|Adult patients prescribed Ventavis within the Pulmonary Arterial Hypertension Therapeutic        Programme.|February 2016|February 23, 2016|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01355380||104539|
NCT01359826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110068|The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients|The Effect of Milnacipran on Fatigue and Quality of Life in a Lupus Cohort||Loma Linda University|No|Withdrawn|October 2011|November 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 17, 2015|April 19, 2011|No|Yes|PI has let the institution. We are unable to locate any study documents that would indicate    study enrollment|No||https://clinicaltrials.gov/show/NCT01359826||104198|
NCT01360138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jymoon0901|A Clinical Comparison in Cervical Epidural Pressure Changes Between Midline and Paramedian Approaches|Advantages of the Paramedian Approach for Cervical Epidural Steroid Injections: A Clinical Comparison in Cervical Epidural Pressure Changes Between Midline and Paramedian Approaches||Seoul National University Bundang Hospital|Yes|Recruiting|May 2011|August 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|20 Years|80 Years|No|||May 2011|May 24, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01360138||104174|
NCT01360346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SedaENvsIV|Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients|Multicentric, Single Blind, Randomized Controlled Trial on Enteral Sedation Versus Intravenous Sedation in Critically Ill High-risk ICU Patients||University of Milan|Yes|Recruiting|January 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01360346||104158|
NCT01352377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20RR016464|Impact of New CLSI Guidelines on Antibiotic Susceptability Pattern|A STUDY ASSESSING THE IMPACT OF THE NEW CLSI GUIDELINES ON ANTIBIOTIC SUSCEPTABILITY TESTING PATTERNS||University of Southern Nevada|Yes|Not yet recruiting|May 2011|July 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|21 Years|N/A|No|Non-Probability Sample|Age more than 21 years who are inpatients at UMC.|April 2011|May 10, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352377||104769|
NCT01352403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005054-20|Severe Obesity: Bariatric Surgery vs. Life-Style-Intervention|Severe Obesity: Bariatric Surgery vs. Life-Style-Intervention Wurzburg Adipositas Study - WAS|WAS|University of Wuerzburg|No|Recruiting|May 2011|June 2016|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2008|May 10, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352403||104767|
NCT01352416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-101, IN-US-259-0114|Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery|Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery||William Beaumont Hospitals|Yes|Recruiting|September 2010|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|240|||Both|22 Years|N/A|No|||July 2012|July 24, 2012|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352416||104766|
NCT01352637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005011047|Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer|Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer||Weill Medical College of Cornell University|Yes|Recruiting|May 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|70 Years|No|||September 2015|September 25, 2015|February 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352637||104749|
NCT01352650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104011617|Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)|Induction Therapy With Decitabine and Plerixafor Priming for Patients ≥ 60 Years With Acute Myeloid Leukemia||Weill Medical College of Cornell University|Yes|Recruiting|June 2011|June 2014|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|48|||Both|60 Years|N/A|No|||June 2011|June 29, 2011|April 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352650||104748|
NCT01352910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/082/HP|rTMS and Functional Paralysis||PARALYSTIM|University Hospital, Rouen|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|14 Years|N/A|No|||January 2016|January 22, 2016|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352910||104728|
NCT01353170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Basile calcium|Calcium Concentration in Bicarbonate Hemodialysis (HD)|Comparison Among Different Dialysate Calcium Concentrations in Bicarbonate Hemodialysis||Miulli General Hospital|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||December 2010|May 11, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01353170||104708|
NCT01353183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/4-U|Analysis of the Enteric Nervous System Using Colonic Biopsies|Analysis of the Enteric Nervous System Using Colonic Biopsies: a Useful Biomarker for the Differential Diagnosis of Parkinsonian Syndromes?|ColoBioParker|Nantes University Hospital|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|34|||Both|50 Years|80 Years|No|||September 2013|September 18, 2013|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01353183||104707|
NCT01356797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUAK-1|Selective Unilateral Spinal Anesthesia Versus Selective Sensory Spinal Anesthesia for Knee Arthroscopy Surgery|Selective Unilateral Spinal Anesthesia Versus Selective Sensory Spinal Anesthesia for Knee Arthroscopy Surgery||USP Hospital La Colina|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01356797||104431|
NCT01356810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06/11|Prophylactic Environmental Management of Delirium|Manejo Ambiental Profilactico Del Delirium Intrahospitalario|MAPDI|Universidad de Valparaiso|No|Completed|September 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|287|||Both|65 Years|N/A|Accepts Healthy Volunteers|||August 2009|May 20, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01356810||104430|
NCT01362309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AA017696|D-Cycloserine to Enhance Extinction to Alcohol Cues|D-Cycloserine to Enhance Extinction to Alcohol Cues||University of Georgia|No|Completed|November 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|37|||Both|21 Years|65 Years|No|||May 2011|February 14, 2014|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01362309||104009|
NCT01362322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114778|Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents|Immunogenicity and Safety Study of GSK Biologicals' Boostrix™ Vaccine Using a New Syringe Presentation in Healthy Adolescents Aged 10-15 Years||GlaxoSmithKline||Completed|July 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|671|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||July 2013|May 15, 2014|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362322||104008|
NCT01357941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS130511|Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)|Prospective Study Assessing the Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism|ROCITP2|Hamilton Health Sciences Corporation|Yes|Not yet recruiting|September 2011|September 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|203|||Female|18 Years|N/A|No|Non-Probability Sample|Consecutive pregnant women with prior VTE diagnosed with accurate testing.|June 2011|June 2, 2011|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357941||104343|
NCT01358201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PETHEMA LAL-07FRAIL|PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years|Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years||PETHEMA Foundation|Yes|Recruiting|May 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|55 Years|N/A|No|||September 2015|September 16, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01358201||104323|
NCT01354522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-Breast-TCX|TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer|A Randomized, Phase III Study Comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) With TCX ( Docetaxel, Cyclophosphamide, Capecitabine) as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer||Peking Union Medical College Hospital|Yes|Recruiting|May 2011|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|70 Years|No|||January 2014|January 14, 2014|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01354522||104604|
NCT01354535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13052011|Types of Fixation of Vancouver B1 Periprosthetic Fractures|Isolated Locked Compression Plating Versus Cable Plating and Strut Allografts With Cerclage Wiring for Vancouver B1 Periprosthetic Femoral Fractures: A Randomized Controlled Trial||St. Michael's Hospital, Toronto|No|Recruiting|February 2013|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|89|||Both|18 Years|90 Years|No|||November 2015|November 16, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354535||104603|
NCT01354496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14194|A Study of LY2409021 Formulations and the Effect of Food|LY2409021 Formulation Bridging and Food Effect Study||Eli Lilly and Company|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|42|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|May 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01354496||104606|
NCT01355094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-23706|Peritoneal Vacuum Therapy to Reduce Inflammatory Response From Abdominal Sepsis/Injury|Peritoneal Vacuum Therapy to Reduce the Systemic Inflammatory Insult From Intraperitoneal Sepsis/Injury/Hypertension: A Randomized Comparison of Baseline Wall Suction Versus the KCI AbThera™ Abdominal Dressing|SAD|University of Calgary|No|Active, not recruiting|June 2011|June 2018|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01355094||104560|
NCT01355393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7425|Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer|Phase I-II Study of HER2 Vaccination With Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients||University of Washington|No|Active, not recruiting|July 2011|||November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|50|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|May 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01355393||104538|
NCT01359839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002557|Effectiveness of a Relaxation-Response Based Cognitive Behavioral Therapy Group for Depressed Chinese Patients|Relaxation-Response Based Cognitive Behavioral Therapy Group for Depressed Chinese Patients in the Community||Massachusetts General Hospital|No|Completed|August 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 8, 2013|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01359839||104197|
NCT01360151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Lee|Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy|||Seoul St. Mary's Hospital|Yes|Recruiting|February 2011|May 2011|Anticipated|May 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|16|||Both|45 Years|N/A|Accepts Healthy Volunteers|||April 2011|May 27, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01360151||104173|
NCT01360359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01HD053632|Recurrent Low Back Pain: Linking Mechanism to Outcomes (RCT)|Recurrent Low Back Pain: Linking Mechanism to Outcomes (RCT)||Drexel University|No|Completed|May 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|65 Years|No|||March 2015|March 9, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01360359||104157|
NCT01360645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-228|Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial|Pyxis|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|July 2011|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|826|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|May 24, 2011|Yes|Yes||No|August 10, 2015|https://clinicaltrials.gov/show/NCT01360645||104136|
NCT01352663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3-GLR-IMSFDA-01|Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients|An Open Label, Randomized Comparison of Wockhardt's Recombinant Insulin Analogue With Innovator's Glargine in Type 1 Diabetic Patients.||Wockhardt|No|Not yet recruiting|May 2015|January 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|55 Years|No|||May 2014|May 28, 2014|May 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352663||104747|
NCT01362387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.4.3|R U OK? The Acceptability and Feasibility of New Communication Technologies for Follow-up After Medical Abortion|R U OK? The Acceptability and Feasibility of New Communication Technologies for Follow-up After Medical Abortion||Gynuity Health Projects|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|999|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|February 13, 2013|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01362387||104003|
NCT01353196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARA-024-10S|Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates|Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates|ACCOF|VA Office of Research and Development|No|Recruiting|May 2011|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|284|Samples With DNA|blood samples for inflammatory markers|Both|18 Years|N/A|No|Probability Sample|Patients eligible for the study will have asymptomatic >=50% carotid stenosis|December 2015|December 9, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353196||104706|
NCT01353443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDA Study|Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair|Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair. A Prospective, Randomised, Controlled Study||Universitätsklinikum Hamburg-Eppendorf|No|Active, not recruiting|February 2011|September 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|282|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01353443||104687|
NCT01353690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-013|Autologous Cell Therapy for Ischemic Heart Failure|A Prospective, Multicenter, Feasibility Study of Autologous Muscle-derived Cell (AMDC) Transplantation for Treatment of Advanced Ischemic Heart Failure||Cook||Terminated|May 2011|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||July 2014|July 28, 2014|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353690||104668|
NCT01353703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111157|Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa™ Vaccine in Healthy Infants in India||GlaxoSmithKline||Completed|April 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|214|||Both|6 Weeks|10 Weeks|Accepts Healthy Volunteers|||April 2013|July 10, 2014|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353703||104667|
NCT01357447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-110-3|Pulmozyme for Sjogren's Associated Cough|A Double-blind, Placebo-controlled Cross-over Trial of Pulmozyme for Sjogren's Associated Cough||University of Connecticut Health Center|No|Withdrawn|May 2011|||May 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|May 18, 2011|Yes|Yes|No patients enrolled.|No||https://clinicaltrials.gov/show/NCT01357447||104381|
NCT01362634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7R01DA019048|A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV|A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV||Nova Southeastern University|Yes|Active, not recruiting|August 2011|July 2017|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|750|||Both|18 Years|39 Years|No|||January 2016|January 4, 2016|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362634||103984|
NCT01358487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHR10-00059|Healthy Mood Internet Intervention Research Project|Internet Intervention to Prevent Major Depressive Episodes||University of California, San Francisco|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01358487||104301|
NCT01354210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA031053|Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth|Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth|TXTXT|Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|October 2010|February 2014|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|110|||Both|16 Years|29 Years|No|||January 2016|January 26, 2016|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01354210||104628|
NCT01354808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCEL-LOADING|ACCEL-LOADING-ACS Study|ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome||Gyeongsang National University Hospital|Yes|Completed|July 2010|||July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|80 Years|No|||September 2013|September 23, 2013|May 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01354808||104582|
NCT01359059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-HF-0248-11-CTIL|Pre- Versus Post-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Orthopedic Oncologic Patients|Pre- vs. Post-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Orthopedic Oncologic Patients: A Comparative, Randomized, Double Blind Study Protocol||Tel-Aviv Sourasky Medical Center||Not yet recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2011|June 9, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01359059||104257|
NCT01359319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX001-CL101|Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)|A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of Sialic Acid Extended Release (SA-ER) Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)||Ultragenyx Pharmaceutical Inc|No|Completed|July 2011|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|26|||Both|18 Years|70 Years|No|||February 2012|May 17, 2012|May 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359319||104237|
NCT01359540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJRC-OMNI Hip|Femoral Remodeling Following Total Hip Arthroplasty With Omni Apex Modular™, OMNI Apex ARC™ Stem, and Omni Apex "Conical Stem" Compared to Competitive Designs|A Dual Energy X-Ray Absorptiometry (Dxa) Evaluation Of Bone Density Changes After Hip Replacement Performance Of The Omni Apex Modulartm Hip Stem And The Omni Apex Arctm Hip Stem In Primary Total Hip Arthroplasty, Five-Year Clinical And Dxa Analysis||Spokane Joint Replacement Center|Yes|Recruiting|November 2009|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|75|||Both|N/A|80 Years|Accepts Healthy Volunteers|Probability Sample|Adult patients undergoing THA|December 2012|December 12, 2012|May 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01359540||104220|
NCT01359553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UltraRusto|Clinical Study of Novel Diagnostic Techniques for Knee Osteoarthritis|Comparison Between Intra-articular Ultrasound Imaging, Non-invasive Ultrasound Imaging, Quantitative MRI Imaging, Contrast-enhanced CT Imaging and Arthroscopy for Diagnostics of Knee Osteoarthritis||University of Oulu|No|Recruiting|May 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|20 Years|N/A|No|Non-Probability Sample|Patients will be selected from those referred to an arthroscopy because of pain symptoms        in the knee.|May 2011|May 22, 2011|May 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01359553||104219|
NCT01359566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XP-B-089|Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis|A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis||Indivior Inc.|No|Completed|May 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|228|||Both|18 Years|70 Years|No|||December 2015|December 28, 2015|May 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01359566||104218|
NCT01360671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481294|IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn|An Open Label Single Arm, Single Centre Study to Investigate the Safety and Efficacy of IV Sildenafil in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN)||Pfizer|Yes|Withdrawn|March 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|72 Hours|No|||May 2012|May 24, 2012|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01360671||104134|
NCT01360905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100_CT-045|Study to Support Fetal Heart Rate and Uterine Contraction for Preterm Labor in Singleton and Multiple Pregnancies|Study to Determine the Equivalence of the Monica AN24 Monitor to Predicate Devices for (FHR) and (UC) During Pre-term Labor and Multiples||Monica Healthcare Ltd|No|Terminated|May 2011|January 2014|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|8|||Female|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is women of >= 24 weeks of singleton pregnancy or women of >=24 weeks        of multiple pregnancy, that have been admitted to the Labor and delivery suite|January 2014|January 17, 2014|May 24, 2011||No|Difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT01360905||104116|
NCT01361503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000185|Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum Disorders|Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum Disorders||Massachusetts General Hospital|No|Completed|April 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|6 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from current patients of The Alan and Lorraine Bressler Clinic        for Autism Spectrum Disorders. We propose to contact by letter (via regular mail or email)        or telephone patients who have been identified by clinicians as expressing interest in the        study. Subjects who have participated in previous protocols in our program may also be        eligible to participate in this study. We propose to contact by letter or telephone past        study participants who have expressed interested in being contacted about future studies        they may be eligible for in our office. If a potential subject's clinician ascertains that        the patient has an interest in study participation, the clinician will only offer contact        information for the study to the patient and/or the patient's parents. The patient and/or        parent can then contact the study coordinator for more information on the actual study.|February 2015|February 3, 2015|November 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01361503||104071|
NCT01362088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 767|Microcirculation in Continuous Venovenous Hemofiltration Patients on the Intensive Care Unit|Evaluation of Sublingual Microcirculation by Means of SDF Imaging by Stepwise Ultrafiltration in CVVH Patients on the ICU||Medical Centre Leeuwarden|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive Care patients treated with CVVH|October 2012|October 31, 2012|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01362088||104026|
NCT01362400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI 504-14|A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer|A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer||Infinity Pharmaceuticals, Inc.|Yes|Completed|May 2011|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|226|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|May 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362400||104002|
NCT01352936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100007|Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy|Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy||Taipei Medical University WanFang Hospital|No|Active, not recruiting|January 2011|December 2011|Anticipated|||N/A|Observational|N/A||2|Anticipated|190|||Both|15 Years|N/A|No|Non-Probability Sample|Staphylococcus aureus patients|May 2011|May 11, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352936||104726|
NCT01353209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5708|Trial of Aromatase Inhibition in Lymphangioleiomyomatosis|A TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS|TRAIL|University of Cincinnati|Yes|Completed|May 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Female|18 Years|N/A|No|||August 2015|August 24, 2015|May 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353209||104705|
NCT01358539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMW 11510007|Palliation: the Effect of Education on Pain|Pain Education for Patients With Painful Bone Metastases Undergoing Palliative Radiotherapy: Reducing Pain by Increasing Patient's Knowledge and Self-management|PEEP|University Medical Center Groningen|Yes|Recruiting|September 2010|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01358539||104297|
NCT01358799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTPS-US10-001|Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System|Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System||Gen-Probe, Incorporated|No|Withdrawn|November 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|Samples With DNA|4 specimens will be collected from each female subject in the following order: 1 first-catch      urine specimen, 1 vaginal swab specimen (patient or clinician-collected), 1 cervical      specimen (using a broomlike collection device or a brush/spatula combination), and 1      endocervical swab specimen. An additional cervical specimen may be collected from female      subjects for other clinical trial purposes or research studies. Up to 2 specimens will be      collected from each male subject in the following order: 1 urethral swab specimen and 1      first-catch urine specimen.|Both|14 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Male and Females at least 14 years of age at the time of informed consent and sexually        active.|March 2013|March 8, 2013|May 20, 2011|Yes|Yes|Assay not evaluated for purpose of clearance|No||https://clinicaltrials.gov/show/NCT01358799||104277|
NCT01357148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-235|A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)|Sitagliptin Phosphate/Metformin HCl (JANUMET®) Post Marketing Surveillance Protocol||Merck Sharp & Dohme Corp.|No|Terminated|March 2009|May 2010|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|143|||Both|N/A|N/A|No|Non-Probability Sample|Participants with type 2 diabetes mellitus who are treated with sitagliptin        phosphate/metformin HCl as per the standard of care in a physician's practice|August 2015|August 7, 2015|May 18, 2011|No|Yes|Completion of MK-0431A-235 was rendered unnecessary, as the local oversight authority accepted    in its stead the results of another study [MK-0431-234].|No|February 1, 2012|https://clinicaltrials.gov/show/NCT01357148||104404|
NCT01357460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol D2.0 - 31.08.2010|Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency|Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency||Heidelberg University||Recruiting|May 2011|May 2012|Anticipated|May 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|30 Years|N/A|No|||May 2011|May 19, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01357460||104380|
NCT01356914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV203-010|Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden|Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients With Paroxysmal Atrial Fibrillation and Permanent Pacemaker||Bristol-Myers Squibb|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01356914||104422|
NCT01357226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0519|Using the Blood Pressure TRU in Clinical Settings: a Knowledge Translation Study|Using the Bp TRU in Clinical Settings: a Knowledge Translation Study||North Toronto Primary Care Research Network|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Patients presenting to a community-based primary care office for routine blood pressure        measurement.|January 2012|April 25, 2012|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01357226||104398|
NCT01362608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2358|Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective|A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective||Novartis||Completed|September 2002|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|85 Years|No|||October 2015|October 13, 2015|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01362608||103986|
NCT01362621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025BUS26|Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma|A 2-year Prospective, Multi-center, Observational and Epidemiologic Outcomes Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma||Novartis||Completed|February 2008|||February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|474|Samples With DNA|A venous blood sample was collected at either screening (Visit 1) or enrollment (Visit 2).      These samples were collected for DNA extraction. The extracted DNA is stored at Novartis      Pharmaceuticals Corporation for pharmacogenetic analysis and storage.|Both|6 Years|11 Years|No|Non-Probability Sample|Children aged 6 to less than 12 years old with moderate to severe allergic asthma for at        least 12 months, treated with inhaled corticosteroids for at least 3 months but remaining        symptomatic|June 2011|June 15, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01362621||103985|
NCT01358786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1995 08|Seroma at the Donor Site of the TRAM Flap, With or Without Quilting Suture: A Comparative Study Using Ultrasound|Seroma at the Donor Site of the TRAM Flap, With or Without Quilting Suture.|STRAMQUSG|Federal University of São Paulo|Yes|Completed|April 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|48|||Female|20 Years|65 Years|No|||June 2009|May 25, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01358786||104278|
NCT01357525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-123|Radiosurgery for Resected Pancreas|SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer||University of Pittsburgh|Yes|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|99 Years|No|||March 2016|March 5, 2016|May 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01357525||104375|
NCT01362881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-11-001|Study of the Surgical Treatment of Early Onset Scoliosis Using a Non-invasive Growing Rod|A Prospective Cohort Study of the Surgical Treatment of Early Onset Scoliosis Using a Remotely Expandable Device for Non-invasive Lengthening of a Growing Rod (Magec™) and Its Performance in Prevention of Progression of Scoliosis.||Ellipse Technologies, Inc.|No|Active, not recruiting|January 2012|June 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|2 Years|10 Years|No|Non-Probability Sample|Study population will be recruited from secondary care|January 2016|January 19, 2016|May 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01362881||103965|
NCT01358773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0135/04|The Effect of 1 Year of Multiprofessional Therapy on Obesity|Multiprofessional Impact on Body Composition, Central and Peripheric Adiposity, Lipid Profile, Hormonal Regulation, Lung, Sleep and Humor Disorders in Adolescents||Federal University of São Paulo|Yes|Recruiting|February 2004|December 2011|Anticipated|December 2004|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|15 Years|19 Years|No|||December 2010|May 23, 2011|December 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01358773||104279|
NCT01359579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-CVD2213|A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function|A Phase 1, Open-label, Pharmacokinetic, Safety, and Tolerability Study of a Single Oral Dose of Varespladib Methyl in Subjects With Normal Renal Function, and Subjects With Mild, Moderate, or Severe Renal Impairment||Anthera Pharmaceuticals|No|Terminated|June 2011|June 2012|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 19, 2012|May 19, 2011|No|Yes|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01359579||104217|
NCT01360164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKCR-HA-1.0(2010)|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia|Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia||Shenzhen Beike Bio-Technology Co., Ltd.|Yes|Recruiting|January 2010|December 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|65 Years|No|||November 2012|November 26, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360164||104172|
NCT01360372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Drexel18538|Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates|The Effect Of Methylnaltrexone (Relistor™) on Gut Motility and Tolerance to Tube Feeding in Patients Treated With Opiate Therapy||Drexel University|Yes|Withdrawn|October 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|March 16, 2011|No|Yes|No eligible subjects identified|No||https://clinicaltrials.gov/show/NCT01360372||104156|
NCT01360658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N/2010/57|Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria|Phase 2 Multicentric Study Evaluating the Efficacy of Polyvalent Intravenous Immunoglobulins in Idiopathic Severe and Refractory Solar Urticaria|IGUS|Centre Hospitalier Universitaire de Besancon|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||July 2013|July 29, 2013|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01360658||104135|
NCT01377168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XR-NTX ETOH|Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder|Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|May 2014|June 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|159|||Male|18 Years|N/A|No|||July 2015|July 9, 2015|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377168||102878|
NCT01368133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010M-010|The Observational Study of Growth Hormone-secreting Pituitary Tumors|The Observational Study of the Structures and Functions of Multiple Organs in Patients With Growth Hormone-secreting Tumors||Huashan Hospital|Yes|Recruiting|May 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Plasma, DNA and pituitary tumor tissues|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|The acromegaly patients at Huashan Hospital will be recruited anf followed up prior to        surgery and one month, 3 months, 6 months and 12 months after surgery.|September 2013|September 24, 2013|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368133||103565|
NCT01368406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/00464-6|Lifestyle Intervention for Weight Gain Management for Patients With Schizophrenia|Efficacy of a Non-pharmacological Intervention for Weight Gain Management for Patients With Schizophrenia: Multicentric, Randomized Clinical Trial||Federal University of São Paulo|No|Completed|August 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|160|||Both|18 Years|65 Years|No|||April 2013|April 12, 2013|May 17, 2011||No||No|September 12, 2012|https://clinicaltrials.gov/show/NCT01368406||103544|short duration of the intervention (12 weeks) and duration of follow up. This lifestyle intervention was previously conducted in all sites that participated of this study.
NCT01350557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRI-EX98-9404PI|Three Care Models for Elderly Patients With Hip Fracture|Three Care Models for Elderly Patients With Hip Fracture||Chang Gung Memorial Hospital|Yes|Completed|January 2005|July 2010|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|299|||Both|60 Years|N/A|No|||February 2012|February 10, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350557||104907|
NCT01382771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|319-2010|Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population|A Randomized, Double-Blind, Placebo Controlled Perspective Study of Intraarticular Lumbar Zygapophysial Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population||University of Florida|No|Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|45 Years|90 Years|No|||October 2013|October 10, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382771||102450|
NCT01382784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Psoriasis and comorbidity|Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study|Psoriasis and the Risk of Cardiovascular Disease. A Prospective Observational Study to Detect Cardiovascular Risk Factors||Oslo University Hospital|Yes|Enrolling by invitation|May 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood, tissue|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Patients who have had psoriasis for more than 5 years are being admitted to the study. The        assessments include: clinical data, treatment, platelet aggregation and blood viscosity,        serum markers and mediators of atherosclerosis, carotid IMT and plaque burden assessed by        Color Duplex ultrasound. The patients are recruited from our dermatological department (in        and outdoor patients)|May 2011|June 24, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382784||102449|
NCT01384110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-RD-01-CLN|Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human|Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human||innoVactiv Inc.|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|43|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 14, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01384110||102347|
NCT01384123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019-11-MMC|Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study|||Meir Medical Center|No|Recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|95 Years|No|Non-Probability Sample|Fifty consecutive Pulmonary sarcoidosis patients who are treated at the outpatient        interstitial lung disease clinic in MEIR Medical Center.        Pulmonary Sarcoidosis will be diagnosed according to the latest ATS/ERS/WASOG statement on        sarcoidosis.1 Diagnosis of pulmonary sarcoidosis. The morphologic diagnosis of pulmonary        sarcoidosis relies on three main findings: the presence of tight, well-formed granulomas        and a rim of lymphocytes and fibroblasts in the outer margin of granulomas; perilymphatic        interstitial distribution of granulomas (which allows transbronchial biopsies to be used        as sensitive diagnostic tools); and exclusion of an alternative cause|October 2013|April 8, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384123||102346|
NCT01383278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIRTCSVCU|Evaluation of a Computer-Delivered 5 A's Intervention for Smoking|Evaluation of a Computer-Delivered 5 A's Intervention for Smoking||Virginia Commonwealth University|Yes|Terminated|February 2012|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|June 24, 2011||No|Insufficient sample size to complete study and merged with parent grant funded study|No||https://clinicaltrials.gov/show/NCT01383278||102411|
NCT01383291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090041|Prolift Versus IVS for Pelvic Floor Prolapse|Postoperative Comparison Between Posterior Prolift Mesh Placement and Posterior IVS Sling Placement||Western Galilee Hospital-Nahariya|No|Withdrawn|February 2009|June 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Female|18 Years|95 Years|No|Non-Probability Sample|Women with pelvic floor prolapse|June 2014|June 19, 2014|June 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01383291||102410|
NCT01383512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REM_AVC|Rehabilitation Robotics After a Stroke|Medical and Economical Evaluation of Upper Limb's Rehabilitation Robotics After a Stroke|REM_AVC|University Hospital, Brest|Yes|Recruiting|June 2011|June 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383512||102393|
NCT01384058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|442006|Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes|The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes|EZE|University Hospital Freiburg|Yes|Completed|November 2007|June 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|75 Years|No|||June 2012|June 18, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01384058||102351|
NCT01370967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3611002|Gastrointestinal Tolerance And General Health Status Of Healthy Term Infants Fed A New Infant Formula|Gastrointestinal Tolerance And General Health Status Of Healthy Term Infants Fed A New Infant Formula: A Prospective, Observational Cohort Study In China||Nestlé|No|Completed|July 2011|July 2013|Actual|July 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|460|||Both|35 Days|49 Days|Accepts Healthy Volunteers|Non-Probability Sample|Healthy term infants aged approximately 42 days (range 35 - 49 days) who are brought to        the health clinic for their first normally-scheduled well-baby visit (i.e. typically age        42 days in China).|December 2013|December 23, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370967||103347|
NCT01370954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-003|NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)|NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)||Pamlab, Inc.|No|Completed|May 2011|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|204|||Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Early Memory Loss Who Have Been Prescribed CerefolinNAC®|May 2013|May 7, 2013|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01370954||103348|
NCT01368458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07I/C31|Conversion to Antipsychotic Monotherapy|A Randomized, Rater-Blind, Controlled, Clinical Trial of Conversion to Antipsychotic Monotherapy vs. Continued Polypharmacy for Patients With Schizophrenia or Schizoaffective Disorder|MOPE|Nathan Kline Institute for Psychiatric Research|No|Terminated|December 2007|July 2008|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||June 2011|June 6, 2011|July 1, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368458||103540|
NCT01368757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_CMML 1|Lenalidomide in Patients With Chronic Myelomonocytic Leukemia|A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Active, not recruiting|June 2010|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01368757||103517|
NCT01368991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00409|Clinical Trial of Kryptonite for Prevention of Sternal Complications in High Risk Patients Undergoing Cardiac Surgery|Randomized Clinical Trial of Kryptonite for Prevention of Sternal Complications in High Risk Patients Undergoing Cardiac Surgery|Kryptonite|Cardiology Research UBC|Yes|Not yet recruiting|July 2011|July 2013|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|90 Years|No|||April 2011|June 7, 2011|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01368991||103499|
NCT01367860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpJet2011|Percutaneous Diskectomy SpineJet x Open Microdiskectomy in Treatment of Lumbar Radiculopathy|Comparison of Percutaneous Diskectomy SpineJet x Open Microdiscectomy for Treatment of Lumbar Radiculopathy in Contained Disc Herniation: Randomized Clinical Trial|PDOP_TLR|University of Sao Paulo|Yes|Completed|June 2011|January 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|76 Years|Accepts Healthy Volunteers|||May 2014|May 19, 2014|May 31, 2011||No||No|April 1, 2013|https://clinicaltrials.gov/show/NCT01367860||103586|
NCT01367886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS473527|Comparative Urine Proteomic Studies of Overactive Bladder in Humans|Comparative Urine Proteomic Studies of Overactive Bladder in Humans||Washington University School of Medicine|Yes|Completed|August 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 10, 2015|May 19, 2011|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01367886||103584|No serious adverse events.
NCT01368172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HicksPAGs|Physical Activity Guidelines for People With Spinal Cord Injury (SCI)|Implementation and Evaluation of the New Physical Activity Guidelines for People With Spinal Cord Injury.||McMaster University|No|Completed|July 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368172||103562|
NCT01368146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-015|Human Repeat Insult Patch Test of Wound Dressings|||Covalon Technologies Inc.|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368146||103564|
NCT01368419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endu-201105|Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients|Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|May 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||April 2013|April 22, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01368419||103543|
NCT01368731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR-001-PEC|Prophylactic Coagulation for the Prevention of Bleeding in Endoscopic Mucosal Resection of Large Sessile Colonic Polyps|Prophylactic Endoscopic Coagulation for the Prevention of Bleeding in Endoscopic Mucosal Resection (EMR) of Large Sessile Colonic Polyps: A Multi-centre, Randomised Control Trial||Western Sydney Local Health District|No|Active, not recruiting|May 2011|January 2020|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|328|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368731||103519|
NCT01383525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8414-MG-CTIL|Direct Application of Selective Laser Trabeculoplasty Using the "DIO-DENT 10" in Open Angle Glaucoma|Direct Application of Selective Laser Trabeculoplasty,Using the "DIO-DENT 10" DENTAL DIODE LASER SYSTEM in Open Angle Glaucoma . Single Site Study|SLT|Sheba Medical Center|No|Recruiting|July 2011|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|21 Years|N/A|No|||December 2014|December 2, 2014|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01383525||102392|
NCT01383538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC#11455|FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma|A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma||University of California, San Francisco|Yes|Recruiting|November 2014|November 2018|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01383538||102391|
NCT01352676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS018322|Limit Computed Tomography (CT) Scanning in Suspected Renal Colic|Validation of a Decision Rule to Limit CT Scanning in Suspected Renal Colic|Prospective|Yale University|No|Completed|May 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|635|||Both|18 Years|N/A|No|Non-Probability Sample|The target population will be all patients aged 18 or above presenting to the Yale New        Haven Hospital (YNHH) ED and Shoreline Medical Center (SMC) ED for whom a FPP CT scan is        ordered by the treating physician for suspected renal colic. A total of 800-1000 patients        will be enrolled over a 1.5 year period 6-2011 to 1-2013, matching the sex/race/ethnicity        makeup of that found for the retrospective study.        The population of the primary catchment area for YNHH is 350,000 and includes a diverse        ethnic and cultural mix. Women and minorities are strongly represented in the population.        Women represent approximately 51% of the ED population. The racial mix is approximately        50% White, not of Hispanic Origin; 33% Black, not of Hispanic Origin, 15% Hispanic; 1%        Asian and 1% other. The ethnicity of SMC patients is mostly White and 54% female.|July 2014|July 8, 2014|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352676||104746|
NCT01384071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBP-2011|The Effects of Unstable Shoes on Chronic Low Back Pain|||University Hospital, Geneva|No|Completed|January 2011|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|65 Years|No|||February 2012|February 20, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01384071||102350|
NCT01384409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3357-006|A Phase 3 Clinical Study of KW-3357 in Patients With DIC|A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by Japanese Association for Acute Medicine-defined DIC Criteria|3357-006|Kyowa Hakko Kirin Company, Limited||Terminated|February 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|N/A|No|||March 2015|March 4, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384409||102324|
NCT01384682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-01-MAR|Maraviroc Switch Collaborative Study|Randomised, Openlabel Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well‐Controlled Plasma HIV‐RNA While Taking Their First N(t)RTI + PI/r Regimen of cART|MARCH|Kirby Institute|Yes|Completed|August 2011|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|399|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384682||102303|
NCT01384370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPVGTS-US10-002|APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results|Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens|AHPV-GT|Gen-Probe, Incorporated|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1260|Samples With DNA|Cervical specimens collected in ThinPrep Pap Test vials containing PreservCyt Solution      (Hologic, Inc., Marlborough, Massachusetts) with commercially available collection devices      (broom-type collection device or cytobrush/spatula combination)* may be tested with the      AHPV-GT Assay either pre- or post-Pap processing.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|AHPV Assay positive results (~310 from subjects with a consensus histology result of <CIN2        or indeterminate disease status and 70 from subjects with CIN2+)          -  150 randomly selected AHPV Assay negative samples from subjects with a consensus             histology result of <CIN2 and All AHPV Assay negative samples from subjects with             CIN2+ (~13 samples)          -  300 from subjects with a consensus histology result of <CIN2 or indeterminate disease             status, 15 from subjects with CIN2+, and 200 from subjects who did not attend the             colposcopy visit) Approximately 150 randomly selected APTIMA HPV Assay negative             samples from subjects with a consensus histology result of <CIN2 All APTIMA HPV Assay             negative samples from subjects with CIN2+ (approximately 5 samples)|October 2011|October 4, 2011|February 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01384370||102327|
NCT01384383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-248-0121|GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype|A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype||Gilead Sciences||Terminated|August 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|70 Years|No|||January 2014|January 2, 2014|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384383||102326|
NCT01384669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0212|Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis|Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis||Yonsei University|No|Recruiting|June 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|Samples With DNA|mRNA extract from Thyroid tissue 2mmx2mmx2mm (nomal thyroid and papillary thyroid      microcarcinoma >5mm)|Both|20 Years|N/A|No|Non-Probability Sample|patients who were diagnosed as papillary thyroid microcarcinoma with or without lateral        neck node metastasis|June 2013|June 1, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384669||102304|
NCT01371552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-371-C-100 v2|Performance Evaluation of a New Daily Disposable Silicone Hydrogel Lens|Performance Evaluation of a New Daily Disposable Silicone Hydrogel Lens (TUNGSTEN)|TUNGSTEN|Alcon Research|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|119|||Both|17 Years|N/A|No|||October 2012|October 2, 2012|June 9, 2011|Yes|Yes||No|October 2, 2012|https://clinicaltrials.gov/show/NCT01371552||103303|
NCT01371565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1073-405|Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome|Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome||Corcept Therapeutics|No|Completed|November 2010|September 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|June 7, 2011|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01371565||103302|
NCT01371227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018085|A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma|A Phase 1 of JNS002 (Doxorubicin HCl Liposome Injection) in Combination With Bortezomib for Japanese Patients With Relapsed or Refractory Multiple Myeloma||Janssen Pharmaceutical K.K.|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|20 Years|N/A|No|||July 2013|July 3, 2013|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01371227||103327|
NCT01367639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8400-EF-CTIL|Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers|Pilot Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers||Sheba Medical Center|No|Completed|March 2011|June 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Female|35 Years|70 Years|No|||November 2013|November 22, 2013|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01367639||103603|
NCT01367652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LETR-T25-PVFS-1|Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fasted Conditions||Roxane Laboratories|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367652||103602|
NCT01367912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB|Timing of Estrogen Support During the Luteal Phase of in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycle|Timing of Estrogen Support During the Luteal Phase of IVF / Intracytoplasmic Sperm Injection Cycle: a Randomized Controlled Trial||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|February 2008|November 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|301|||Female|N/A|40 Years|No|||November 2008|June 6, 2011|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367912||103582|
NCT01367925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJRC-CS/PS|Stryker Cruciate Substituting/Posterior Stabilized Outcomes Study|Triathlon® Cruciate Substituting Versus Posterior Stabilized Outcomes Study||Spokane Joint Replacement Center|Yes|Active, not recruiting|December 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|126|||Both|N/A|80 Years|Accepts Healthy Volunteers|Probability Sample|Adult patients undergoing TKA|December 2012|December 12, 2012|May 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01367925||103581|
NCT01368211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS-0063|Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)|PRESS Pathogen Reduction Extended Storage Study PRESS (Pathogen Reduction Extended Storage Study) A Pilot Study of Mirasol Platelets Treated in Platelet Additive Solution in Thrombocytopenic Patients|PRESS|Terumo BCTbio|Yes|Terminated|September 2010|May 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|June 6, 2011||No|Part 1 completed, part 2 not done due to slow enrollment|No|February 27, 2014|https://clinicaltrials.gov/show/NCT01368211||103559|Small numbers of subjects
NCT01368471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMD-07|Safety and Efficacy Study of MGuard Stent After a Heart Attack|MASTER: MGUARD for Acute ST Elevation Reperfusion|MASTER|InspireMD|Yes|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|433|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 28, 2013|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01368471||103539|
NCT01367600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 301EXT|Open-Label Treatment Extension of Protocol MNTX 301|A Three-Month Open-Label Treatment Extension of Protocol MNTX 301||Valeant Pharmaceuticals International, Inc.|Yes|Completed|February 2003|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367600||103606|
NCT01367613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 302EXT|Open-Label Treatment Extension of Protocol MNTX 302|A Three-Month Open-Label Treatment Extension of Protocol MNTX 302||Valeant Pharmaceuticals International, Inc.|Yes|Completed|March 2004|January 2006|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367613||103605|
NCT01367626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LETR-T25-PVFD-1|Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|March 2008|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367626||103604|
NCT01369576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSRM-0511|Effect of Zopiclone on Compliance With Continuous Positive Airway Pressure in Obstructive Sleep Apnea|A Double-blind, Randomized, Parallel Group Study to Determine the Effect of Initial Prescription of Zopiclone on the Level of Compliance With CPAP in Adult Patients Treated for OSA at 26 Weeks||OSR Medical Inc.|Yes|Completed|May 2011|November 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|264|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369576||103454|
NCT01368432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00020154|Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions|Escitalopram (Lexapro) for the Treatment of TBI Depression and Other Comorbid Psychiatric Conditions||Johns Hopkins University|Yes|Completed|April 2010|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01368432||103542|
NCT01368445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP433|A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Patients With Seasonal Allergic Rhinitis||Meda Pharmaceuticals|No|Completed|August 2006|April 2008|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|617|||Both|12 Years|N/A|No|||October 2011|October 5, 2011|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368445||103541|
NCT01368744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSNA-BC-002|Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology|Intraoperative Examination of Sentinel Lymph Nodes: Comparison of the OSNA Breast Cancer System to Extensive Frozen Section Histopathology||Sysmex America, Inc.|Yes|Completed|March 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Samples of the tissue homogenate will be retained and may be used for for further testing.|Both|18 Years|N/A|No|Probability Sample|Patients with a previous diagnosis of breast cancer scheduled for sentinel lymph node        dissection.|June 2011|June 6, 2011|June 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01368744||103518|
NCT01350258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10D.535|Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps|A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Using Melphalan for T-Cell Tolerization||Thomas Jefferson University|Yes|Terminated|April 2011|August 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|May 4, 2011|Yes|Yes|Poor accrual|No|October 21, 2014|https://clinicaltrials.gov/show/NCT01350258||104930|Study was terminated due to extreme toxicity. The study was closed before any data could be collected.
NCT01350271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P39/04/2010|Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections|Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections||University of Kelaniya|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|214|||Both|3 Years|N/A|No|||April 2013|April 18, 2013|May 6, 2011||No||No|August 23, 2011|https://clinicaltrials.gov/show/NCT01350271||104929|Small sample size owing to limitation in available funds.
NCT01383551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-163|"Becoming Parents": A Hospital-community Partnership|"Becoming Parents": A Hospital-community Partnership to Enhance Transition to Parenthood||The University of Hong Kong|No|Completed|June 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|290|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 12, 2013|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01383551||102390|
NCT01352689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HPS11K|CKD-828(80/2.5mg) Pharmacokinetic Study_2nd|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 80mg and S-Amlodipine 2.5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers||Chong Kun Dang Pharmaceutical||Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2011|June 6, 2011|May 11, 2011||||No||https://clinicaltrials.gov/show/NCT01352689||104745|
NCT01352702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. A01711|Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Dabi-ADP-2|Deutsches Herzzentrum Muenchen|No|Terminated|May 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|May 11, 2011||No|Slow recruitment; Study was terminated for futility reasons|No||https://clinicaltrials.gov/show/NCT01352702||104744|
NCT01352949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110120|Stereophotogrammetry of the Torso in Healthy Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity|Stereophotogrammetry of the Torso in Normal Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity||National Institutes of Health Clinical Center (CC)||Recruiting|April 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|525|||Both|2 Years|N/A|No|||October 2015|November 3, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352949||104725|
NCT01352962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110140|Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors|A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|99 Years|No|||September 2015|September 26, 2015|May 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01352962||104724|
NCT01384097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERAS_feasibility|An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery|An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery - a Feasibility Study|ERAS_feasi|Charite University, Berlin, Germany|No|Completed|September 2007|June 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|774|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing a surgical repair of hip fractures, open right hemicolectomy and        extended hemicolectomy, radical tumor debulking in primary ovarian cancer or a        pylorus-preserving pancreatic head resection.|September 2011|September 7, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384097||102348|
NCT01384396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3357-005|A Clinical Study of KW-3357 in Patients With DIC|A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by the Diagnostic Criteria for DIC Established by the Japanese Ministry of Health and Welfare|3357-005|Kyowa Hakko Kirin Company, Limited||Completed|December 2011|||April 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|N/A|No|||April 2013|April 24, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384396||102325|
NCT01353456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907176018|Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery|Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery||The University of Hong Kong|No|Completed|May 2008|September 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2013|April 2, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01353456||104686|
NCT01384968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-3-033|Acute Nitrate Supplementation in Cyclists|Acute Dietary Nitrate Supplementation to Improve Performance in Endurance Trained Athletes||Maastricht University Medical Center|No|Completed|July 2011|May 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01384968||102281|
NCT01349569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1115|Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission|Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction With a Lenalidomide Containing Regimen in Myeloma Patients With Near Complete Remission||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349569||104983|
NCT01367899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-LJH-002|CONSERVE Plus Post-Approval Study (PAS)|Conserve Plus Total Hip Resurfacing System: A Non-Randomized, Multi-center, NewEnrollement Post Approval Study||MicroPort Orthopedics Inc.|No|Terminated|November 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|199|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have already undergone hip resurfacing in the CONSERVE Plus IDE.|October 2014|October 24, 2014|May 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367899||103583|
NCT01368497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082864 HBRN IT Peds Trial|Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection|Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN)||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|September 2012|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|3 Years|18 Years|No|||October 2015|October 28, 2015|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368497||103537|
NCT01378026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-069|Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation|||China Medical University Hospital||Not yet recruiting|January 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|120|Samples With DNA|whole blood, serum and DNA|Both|32 Years|87 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients were from Taipei city hospital-ZhongXiao branch.|June 2011|June 20, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378026||102814|
NCT01377701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2010-259|The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor|The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor||Huashan Hospital|Yes|Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with pituitary adenomas at Huashan Hospital will be screened. Patients with loss        of visual field and receive trans-sphenoidal surgery will be included.|June 2011|June 20, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377701||102837|
NCT01369212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082864 HBRN Immune Active|Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B|Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B|HBRN|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|November 2012|October 2020|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|376|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369212||103482|
NCT01369225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2601003|Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease|A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001||Pfizer|No|Completed|July 2011|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|52|||Both|50 Years|90 Years|No|||September 2014|September 26, 2014|May 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01369225||103481|
NCT01369589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552-209S|An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness|An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's Syndrome||Parion Sciences|No|Completed|November 2010|April 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369589||103453|
NCT01369602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611011|Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532|A Phase 1, Single-Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532||Pfizer|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|27|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|June 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01369602||103452|
NCT01369862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHB-CS08|Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults|Randomised, Double-blind, Placebo-controlled, Phase I/II Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults||AVIR Green Hills Biotechnology AG|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2011|January 9, 2014|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01369862||103432|
NCT01370122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 35810|Pelvic Floor Disorders in Survivors of Gynecologic Malignancies|The Prevalence and Predictive Factors of Pelvic Floor Disorders in Gynecologic Malignancy Survivors||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|May 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Female|20 Years|N/A|No|Probability Sample|Women over the age of 20 with a history of uterine, ovarian, fallopian tube, peritoneal,        cervical, or vulvar cancers.|October 2012|October 11, 2012|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01370122||103412|
NCT01370135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LucNVG0108|Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma|An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma|LucNVG0108|University of Luebeck|Yes|Completed|November 2008|July 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01370135||103411|
NCT01370161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHDD 002|Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for High Risk Acute Variceal Bleeding in Cirrhotic Patients|Early Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene Covered Stents Versus Standard Medical Therapy for High Risk Acute Variceal Bleeding in Cirrhotic Patients||Fourth Military Medical University||Recruiting|July 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01370161||103409|
NCT01383304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22527|Aspirin Response in High Risk Patients With Coronary Artery Disease|Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?||University of Aarhus|No|Active, not recruiting|November 2007|January 2016|Anticipated|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|906|Samples With DNA|Whole blood, serum, plasma, urine|Both|18 Years|N/A|No|Non-Probability Sample|906 patients with CAD. In addition to CAD, all patients have at least one of the following        risc factors: previous myocardial infarction, type 2 diabetes mellitus and/or renal        insufficiency.        Eligible patients are identified in the Western Denmark Heart Registry.|May 2015|May 28, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01383304||102409|
NCT01383837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6183/6622|HIV/STI Prevention for Adolescents With Substance Use Disorders in Treatment|HIV/STI Prevention for Adolescents With Substance Use Disorders in Treatment|STYLEnS|New York State Psychiatric Institute|Yes|Completed|August 2010|August 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|86|||Both|13 Years|24 Years|No|||August 2015|August 27, 2015|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01383837||102368|
NCT01353768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115008|Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study|Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study||GlaxoSmithKline|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|113|||Both|N/A|N/A|No|Non-Probability Sample|350 patients previously treated with zanamivir aqueous solution as part of the CUP, at an        estimated 100 sites in over 15 countries are targeted for participation. Medical        information on safety and clinical outcomes from Tier 1 and Tier 2 patients will be        collected within this retrospective chart review study.|May 2013|May 9, 2013|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01353768||104662|
NCT01384422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-201|Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients|||Galapagos NV|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|70 Years|No|||August 2012|August 14, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384422||102323|
NCT01384435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPS1203|A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCD||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Anticipated|200|||Both|20 Years|N/A|No|||March 2012|November 29, 2012|June 23, 2011||||No||https://clinicaltrials.gov/show/NCT01384435||102322|
NCT01384448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-11-03-107|Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain|A Randomized Trial Comparing Coronary CT Angiography and Stress Echocardiography for Evaluation of Low-to-Intermediate Risk Emergency Department Chest Pain Patients||Montefiore Medical Center|Yes|Active, not recruiting|August 2011|February 2017|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|400|||Both|30 Years|N/A|No|||March 2016|March 14, 2016|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01384448||102321|
NCT01353469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12059|Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy|A Multicenter, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Insuman Comb 25 (Insulin Human) Versus Novolin® 30R Twice Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus Who Are Under Insulin Therapy|Insuman-C25-CN|Sanofi|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|485|||Both|18 Years|75 Years|No|||February 2013|February 26, 2013|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353469||104685|
NCT01353716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113125|Dolutegravir Renal Impairment Study|A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of Dolutegravir in Subjects With Renal Impairment and Healthy Matched Control Subjects (ING113125)||ViiV Healthcare|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|May 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01353716||104666|
NCT01353729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114346|A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers|A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) With Moxifloxacin as a Positive Control in Healthy Volunteers||GlaxoSmithKline|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|May 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01353729||104665|
NCT01349582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE10.206|Flow Diversion in Intracranial Aneurysm Treatment|A Randomized Trial Comparing Flow Diversion and Best-standard Treatment - the FIAT Trial|FIAT|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|April 2011|April 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|344|||Both|18 Years|75 Years|No|||July 2015|December 7, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01349582||104982|
NCT01349595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001487|Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation|Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation||Mayo Clinic|Yes|Terminated|December 2011|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4|||Both|18 Years|99 Years|No|||October 2015|October 5, 2015|May 5, 2011|Yes|Yes|Study halted due to lack of funding|No|August 10, 2015|https://clinicaltrials.gov/show/NCT01349595||104981|Although subjects completed the cycles of drug, long term follow-up visits were not possible due to funding discontinuation.
NCT01367301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02-064|Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer|A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|May 2011|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||January 2015|January 16, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367301||103629|
NCT01367314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0901|Safety and Efficacy of Topical NVC-422 Gel in Impetigo|A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo||NovaBay Pharmaceuticals, Inc.|No|Completed|August 2009|December 2010|Actual|May 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|129|||Both|2 Years|12 Years|No|||June 2011|June 6, 2011|June 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01367314||103628|
NCT01368224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1040341|Two Supplemented Against Skin Reactivity|PLACEBO-CONTROLLED STUDY OF THE EFFECT OF TWO FOOD SUPPLEMENTS ON SKIN REACTIVITY||L'Oreal|Yes|Completed|June 2004|March 2006|Actual|March 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||June 2011|June 6, 2011|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368224||103558|
NCT01377688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030501|Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes|Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes|DKDPilot|Duke University|No|Completed|October 2011|May 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|19|||Both|18 Years|75 Years|No|Non-Probability Sample|Diabetics with progressive kidney disease|March 2014|June 2, 2014|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377688||102838|
NCT01378013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/L0/686|SurgicAl Metabolic Phenotyping Longitudinal Evaluation Study|Metabolic Phenotyping and Systems Biology in Surgery|SaMPLE|Imperial College London|Yes|Completed|August 2011|March 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|Samples With DNA|1. Urine        2. Blood (plasma)        3. Stool / small bowel content        4. Tissue (Colon, small bowel,stomach,eosophagus, breast, lymph nodes)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Two separate clinical groups will be recruited for this trial. The first will be those        patients undergoing elective procedures, the second will be those undergoing emergency        procedures.        Elective surgery (n=200):        Acute surgery (n=200)|July 2011|March 24, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378013||102815|
NCT01377740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA11-001|Non-Invasive Reduction of Abdominal Fat Utilizing the CoolFlex and eZ App 6.3 Applicators|Non-Invasive Reduction of Abdominal Fat Utilizing the CoolFlex and eZ App 6.3 Applicators||Zeltiq Aesthetics|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01377740||102836|
NCT01377753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110158|MR Image Guided Therapy in Prostate Cancer|MR Image Guided Focal Therapy in Prostate Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2011|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|100 Years|No|||December 2015|January 1, 2016|June 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01377753||102835|
NCT01378039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/2004|Pathogenetic Mechanisms of Chronic Obstructive Pulmonary Diseases|Evaluation of Pathogenetic Mechanisms of Chronic Obstructive Pulmonary Diseases|CAPTA|Lithuanian University of Health Sciences|No|Completed|June 2004|June 2009|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|1||Actual|200|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01378039||102813|
NCT01368770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol version 1.1|Stress Testing Compared to Coronary Computed Tomographic Angiography in Patients With Suspected Coronary Artery Disease|Stress-rest Single Photon-Emission Computed Tomography(SPECT)Compared to Coronary Computed Tomographic Angiography in the Initial Evaluation of Patients With Suspected Coronary Artery Disease-A Pilot Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|No|Completed|July 2011|December 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|303|||Both|21 Years|N/A|No|||April 2015|April 1, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368770||103516|
NCT01368783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-ATV|Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers|Two Randomized, Open-labeled, Parallel Designed Multiple-dose Clinical Trials to Evaluate Pharmacokinetics of Ritonavir-unboosted and Ritonavir-boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers||Asan Medical Center||Not yet recruiting|June 2011|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|32|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2011|June 7, 2011|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01368783||103515|
NCT01368484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVI MUR 005-2009|Effect of Dietary DHA Supplementation on Sperm Quality|Effect of Dietary DHA Supplementation on Sperm Quality.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|December 2009|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Male|N/A|N/A|No|||June 2011|June 7, 2011|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01368484||103538|
NCT01369238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOMC 2010-04|East-West Collaborative Medicine Using Bee-Venom Acupuncture on Whiplash-Associated Disorders|Clinical Research on the Efficacy of East-West Collaborative Medicine Using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders After Traffic Collisions; A Randomized, Controlled, Parallel Trial||Korean Pharmacoacupuncture Institute|Yes|Not yet recruiting|June 2011|March 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|25 Years|55 Years|No|||June 2011|June 7, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01369238||103480|
NCT01369251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSaccoCordCare|Simple Hygiene Versus Alcohol Based Usual Care for Umbilical Cord|Simple Hygiene Versus Alcohol Based Usual Care for Umbilical Cord: a Randomized Clinical Trial||Ospedale L. Sacco – Polo Universitario|No|Recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|N/A|1 Day|No|||April 2011|June 7, 2011|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369251||103479|
NCT01369875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110163|Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma|Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion||National Institutes of Health Clinical Center (CC)|Yes|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||September 2015|October 6, 2015|June 8, 2011|Yes|Yes||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01369875||103431|
NCT01370148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-099|A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan|A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan||Cumberland Pharmaceuticals|No|Completed|April 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|17|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 30, 2014|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370148||103410|
NCT01369888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110170|Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma|A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)|No|Terminated|May 2011|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3|||Both|18 Years|66 Years|No|||January 2015|January 26, 2015|June 8, 2011|Yes|Yes|Closed this protocol due to autoimmune toxicity.|No|January 15, 2015|https://clinicaltrials.gov/show/NCT01369888||103430|
NCT01383317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00016978|Remote Ischemic PreConditioning Effect on Postsurgical Pain|Remote Ischemic Preconditioning (RIPC) and Its Effect on the Postoperative Pain Experience Following Intra-abdominal Surgery|RIPCEPP|Wake Forest Baptist Health|No|Recruiting|June 2011|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|30 Years|80 Years|No|||December 2015|December 31, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01383317||102408|
NCT01353482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/08/0359|A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma|A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma|MESO-02|University College, London||Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|May 11, 2011||No|UCL CTC were informed by Merck Sharp & Dohme on 22.08.11 that support for the trial had been    withdrawn in light of results from another trial with trial drug.|No||https://clinicaltrials.gov/show/NCT01353482||104684|
NCT01350141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481012|A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins|A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability of PF-04950615 (RN316) Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin||Pfizer|Yes|Completed|June 2011|June 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|May 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350141||104939|
NCT01352975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110147|Study of Dark Adaptation in Age-Related Macular Degeneration|Longitudinal Investigation of Dark Adaptation in Participants With Age-Related Macular Degeneration||National Institutes of Health Clinical Center (CC)||Recruiting|April 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|240|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|February 13, 2016|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352975||104723|
NCT01353222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N10-1|DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma|A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma||Dendreon|Yes|Completed|June 2011|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353222||104704|
NCT01349842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2009-03|Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer|CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer|CirCé01|Institut Curie|No|Recruiting|January 2010|||January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|568|||Female|18 Years|N/A|No|||April 2015|April 23, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349842||104962|
NCT01349855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR11626|Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus|A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Assess the Safety and Tolerability of Two Dose Levels of a New Formulation of Insulin Glargine and to Compare Its Pharmacodynamic and Pharmacokinetic Properties With 0.4 U/kg/Day Lantus® in an 8-days Multiple Dosing Regimen in Patients With Diabetes Mellitus Type 1||Sanofi|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||May 2011|May 31, 2011|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01349855||104961|
NCT01353742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114957|Lamivudine and Adefovir Dipivoxil Fixed Dose Combination|A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of Lamivudine and Adefovir Dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg)||GlaxoSmithKline|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 28, 2012|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01353742||104664|
NCT01353755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0906rP|2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma|Randomised Double Blind Placebo Controlled Pivotal Study to Evaluate Efficacy and Safety of rPhleum in Adult and Adolescent Patients Suffering From Rhinoconjunctivitis +/- Controlled Asthma||Allergopharma GmbH & Co. KG|No|Completed|October 2009|September 2014|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|195|||Both|12 Years|65 Years|No|||November 2014|November 12, 2014|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01353755||104663|
NCT01376934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2011/PC|Clinical Trial of Hysteroscopy in Postmenopausal Women to Compare Techniques|Phase 1 Study of Two Techniques in Hysteroscopy That Compare Carbon Dioxide Versus Saline Solution||University of Campinas, Brazil|No|Recruiting|March 2011|||March 2011|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|140|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 17, 2011|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376934||102895|
NCT01376947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/2011/PC|Comparison of the Difficulty on Insertion of IUD Devices Between Nulliparous and Multiparous Women|Comparison of the Difficulty on Insertion of IUD Devices Between Nulliparous and Multiparous and Evaluation of Cause of Failure of Insertion||University of Campinas, Brazil|No|Active, not recruiting|November 2010|October 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women that desire to use IUD as anticonceptional method|June 2011|June 17, 2011|April 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376947||102894|
NCT01367938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJRC-OK|Clinical Outcomes With Apex (OK) Knee System|Clinical Outcomes With Omni Apex (OK) Knee System||Spokane Joint Replacement Center|Yes|Recruiting|November 2009|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|56|||Both|N/A|80 Years|Accepts Healthy Volunteers|Probability Sample|Adult patients undergoing total knee replacement|December 2012|December 12, 2012|May 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01367938||103580|
NCT01367951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unstable chest wall injuries|Treatment of Acute, Unstable Chest Wall Injuries|A Multi Centered Randomized Controlled Trial of Operative Versus Non-operative Treatment of Acute, Unstable Chest Wall Injuries||St. Michael's Hospital, Toronto|No|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|16 Years|85 Years|No|||November 2015|November 16, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01367951||103579|
NCT01377467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZH-NEP 2.1|Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients|A Phase 3, Investigator-initiated, Randomized, Open-label Single-center Study of the Effect of Denosumab on the Prevention of Bone Mineral Density Loss After Renal Transplantation|POSTOP|University of Zurich|No|Active, not recruiting|June 2011|October 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|80 Years|No|||July 2014|July 28, 2014|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377467||102855|
NCT01377480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05267|A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)|Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)|STOP CHAGAS|Merck Sharp & Dohme Corp.|Yes|Completed|July 2011|January 2015|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|50 Years|No|||July 2015|July 13, 2015|May 13, 2011|No|Yes||No|July 13, 2015|https://clinicaltrials.gov/show/NCT01377480||102854|
NCT01378299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLC-001-10S|CYP19A1 Gene and Pharmacogenetics of Response to Testosterone Therapy|CYP19A1 Gene and Pharmacogenetics of Response||VA Office of Research and Development|Yes|Active, not recruiting|October 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|105|||Male|40 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01378299||102793|
NCT01378312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-004-402|A Study to Evaluate Safety and Immunogenicity of AERAS-402|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-402 When Administered to HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection||Aeras|Yes|Completed|February 2011|March 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|March 14, 2014|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01378312||102792|
NCT01378273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41122-B|Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)|Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)|PENUT|University of Washington|Yes|Recruiting|December 2013|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|940|||Both|24 Weeks|27 Weeks|No|||November 2015|November 30, 2015|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378273||102795|
NCT01378572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDMC060911|Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implantation of Defibrillators in Dilated Cardiomyopathy||EMOSIDD|Catholic University of the Sacred Heart|Yes|Recruiting|November 2009|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with dilated cardiomyopathy (NYHA II-III heart failure, left ventricular ejection        fraction <=35%) undergoing prophylactic ICD implantation.|June 2011|June 21, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01378572||102772|
NCT01369004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2013|The WEIGH Study: Weighing to Improve and Gain Health|The Use of Weight Tracking Technology to Promote Weight Loss Among Overweight Adults|WEIGH|University of North Carolina, Chapel Hill|No|Completed|February 2011|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 5, 2012|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01369004||103498|
NCT01369017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1026|Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers|A Study of the Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers|Kintox|University of North Carolina, Chapel Hill|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|June 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01369017||103497|
NCT01369277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611013|A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532|A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Dose Escalation Study In Japanese Healthy Subjects, And Open Label, Single Dose Study In Western Healthy Subjects To Investigate The Safety, Tolerability, And Pharmacokinetics of PF-04991532.||Pfizer|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 20, 2011|June 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01369277||103477|
NCT01369615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTR3002|Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001|An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study||Purdue Pharma LP|Yes|Completed|October 2011|May 2014|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|6 Years|17 Years|No|||August 2015|August 26, 2015|June 7, 2011|Yes|Yes||No|January 7, 2015|https://clinicaltrials.gov/show/NCT01369615||103451|Enrollment for study OTR3002 was closed by Purdue Pharma L.P. on 01-January-2014 due to administrative reasons not related to safety.Interpretation is limited by the small number of patients in each age group in this study.
NCT01379352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-015|Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia|Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia||Samsung Medical Center|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|35|||Both|20 Years|69 Years|No|Non-Probability Sample|Patients undergoing elective living donor liver transplantation|December 2013|December 24, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379352||102712|
NCT01383577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP-S/0001/2010|Comparison Between Single and Triple Rubber Band Ligation for the Treatment of Hemorrhoids|Double-blind Randomized Controlled Study of Single Versus Triple Rubber Band Ligation of Hemorrhoids||Federal University of Amazonas|Yes|Active, not recruiting|March 2010|November 2013|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||September 2013|September 24, 2013|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383577||102388|
NCT01352429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 18809|Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer|A Phase II Trial of Proton Radiation Therapy or Intensity-Modulated Radiation Therapy Using Mild Hypofractionation for Low-and Intermediate -Risk Adenocarcinoma of the Prostate||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|August 2009|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Male|18 Years|N/A|No|Probability Sample|Patients with non-metastatic adenocarcinoma of the prostate, presenting for definitive        proton or photon radiotherapy of the prostate.|January 2016|January 22, 2016|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01352429||104765|
NCT01349868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT005003|PT005 MDI Dose Ranging Versus Foradil Aerolizer Study|A Randomized, Double-Blind, Single Dose, Six-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Three Doses of PT005, in Patients With Moderate to Severe COPD, Compared With Foradil® Aerolizer® (12 and 24 µg Open-Label) as Active Controls||Pearl Therapeutics, Inc.|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|50|||Both|40 Years|80 Years|No|||September 2012|September 10, 2012|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349868||104960|
NCT01349881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0820|S0820, Adenoma and Second Primary Prevention Trial|A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)|PACES|Southwest Oncology Group|Yes|Recruiting|March 2013|July 2019|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|1340|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349881||104959|
NCT01349608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000356|Physical Activity Coaching in Chronic Obstructive Pulmonary Disease (COPD)|Physical Activity Coaching in COPD|PACC|Mayo Clinic|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|40 Years|N/A|No|||April 2013|April 1, 2013|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01349608||104980|
NCT01350700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MW2012-01-02|Long Term Follow up of Scars Formation and Quality of Life Assessment Study|Scar Formation and Quality of Life Assessment in Subjects (Adults & Children) Following Treatment With Debrase Compared to Standard of Care (SOC)||MediWound Ltd|No|Not yet recruiting|June 2011|January 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|148|||Both|4 Years|55 Years|No|Non-Probability Sample|Patients that have previously participated in MW2004-011-02 study|May 2011|May 9, 2011|May 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01350700||104896|
NCT01350713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060/2011K|The Counter-irritating Efficacy of Topical Povidone-iodine in Thermal Burns|Testing the Counter-irritating Efficacy of Topical Povidone-iodine in Thermal Burns; Comparison to Conventional Treatments||Meir Medical Center|No|Not yet recruiting|July 2011|July 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||May 2011|May 9, 2011|May 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01350713||104895|
NCT01350128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT001002|PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Chronic Dosing (7 Days), Three-Period, Six-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Four Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Atrovent® HFA Inhalation Aerosol (Open-Label) as An Active Control||Pearl Therapeutics, Inc.|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|103|||Both|40 Years|80 Years|No|||May 2013|May 23, 2013|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350128||104940|
NCT01376674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKT_RO_01|T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer|Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer||University Hospital Tuebingen|No|Completed|March 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|Samples With DNA|Peripheral blood mononuclear cells and serum are frozen and stored.|Male|18 Years|90 Years|No|Non-Probability Sample|Patients undergoing standard radiotherapy for localised prostate cancer at the University        Hospital of Tuebingen|August 2013|August 15, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376674||102915|
NCT01376687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMMGLOVE|Osteopathic Manipulative Medicine and Kinetics|||Michigan State University|No|Completed|September 2010|November 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HEalthy and no pain in cervical spine Pain of 3 or greater in cervical spine|November 2011|November 30, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376687||102914|
NCT01376700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061002|Early Prophylaxis Immunologic Challenge (EPIC) Study|A Phase 3b Clinical Study to Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients With Hemophilia A|EPIC|Baxalta US Inc.|Yes|Terminated|August 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Male|N/A|1 Year|No|||October 2014|June 26, 2015|June 17, 2011||No|It became unlikely to achieve the study objective of 50% reduction over published inhibitor    rates. The Data Monitoring Committee supported this decision.|No|September 17, 2014|https://clinicaltrials.gov/show/NCT01376700||102913|Early termination lead to:No statistical tests done on risk factors & inhibitor formation.FVIII consumption by participant not calculated due to large variation in # of EDs.FVIII-Specific Antibody Isotypes summary statistics not done.
NCT01377259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808010R|The Changes of Tissue Oxygen Saturation Under Spinal Anesthesia|The Changes of Tissue Oxygen Saturation Under Spinal Anesthesia||National Taiwan University Hospital|No|Recruiting|September 2008|June 2011|Anticipated|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients who receive operations under spinal anesthesia|May 2011|June 20, 2011|September 14, 2008||No||No||https://clinicaltrials.gov/show/NCT01377259||102871|
NCT01377272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200808048R|Spatial Epidemiology of HIV Infection|Spatial Epidemiology of HIV Infection||National Taiwan University Hospital|Yes|Completed|October 2008|August 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1264|||Both|N/A|N/A|No|Non-Probability Sample|NTUH patients|May 2011|July 1, 2011|October 22, 2008||No||No||https://clinicaltrials.gov/show/NCT01377272||102870|
NCT01378065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US011|Restorelle Direct Fix Anterior and Posterior (A&P) for Female Pelvic Organ Prolapse: A Prospective Post Market Study|Restorelle Direct Fix A&P for Female Pelvic Organ Prolapse: A Prospective Post Market Study|(A&P)|Coloplast A/S|No|Completed|June 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects satisfying criteria for inclusion in the study were enrolled.|September 2015|September 29, 2015|June 20, 2011||No||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01378065||102811|The study N was small.
NCT01378078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2011|Transcranial Direct Current Stimulation (tDCS) for Treatment of Negative Syndrome in Patients With Schizophrenia|Transcranial Direct Current Stimulation (tDCS) for Treatment of Negative Syndrome in Patients With Schizophrenia||Ludwig-Maximilians - University of Munich|No|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||July 2013|July 19, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01378078||102810|
NCT01378325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.SS.10|Variable Rate Phenylephrine Infusion for Prevention of Spinal-induced Hypotension for Cesarean Delivery|Crystalloid Coload Combined With Variable Rate Phenylephrine Infusion for Prevention of Hypotension During Spinal Anesthesia for Elective Cesarean Delivery vs Crystalloid Coload Alone||American University of Beirut Medical Center|Yes|Completed|July 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|80|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|June 10, 2011||No||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01378325||102791|
NCT01378338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GKR-ATC-2011/1|Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational|Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational Study|Refresh|AstraZeneca||Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|855|||Both|20 Years|80 Years|No|Probability Sample|Patients with typical reflux symptoms (heartburn or regurgitation) undergone upper        endoscopy|September 2013|September 30, 2013|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01378338||102790|
NCT01378052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-092|DNA Methylation and Urothelial Carcinoma|Level of DNA Methylation in People With Urothelial Carcinoma||China Medical University Hospital|Yes|Recruiting|June 2011|||June 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a hospital-based case-control study. Patients with urothelial carcinoma are        recruited by pathological verification of UC was done by routine urological practice        including endoscopic biopsy or surgical resection of urinary tract tumors followed by        histopathological examination by board-certified pathologists. Healthy controls without        evidence of UC or any other malignancy were recruited including those receiving adult        health examinations at China Medical University Hospital.|June 2011|June 21, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378052||102812|
NCT01378598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-171|Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer|Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer: A Feasibility Pilot Study||Dana-Farber Cancer Institute|Yes|Completed|September 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|December 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01378598||102770|
NCT01378286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAMF_C_05370|Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria|A Randomised Comparative Study to Assess the Efficacy and Tolerability of Blood Schizonticidal Treatments With Artesunate Amodiaquine Winthrop® / Coarsucam (ASAQ) Versus Chloroquine (CQ) for Uncomplicated Plasmodium Vivax Monoinfection Malaria||Sanofi|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|380|||Both|6 Months|N/A|No|||July 2013|July 17, 2013|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378286||102794|
NCT01369264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2827|The Effect of Repetitive Transcranial Magnetic Stimulation on Brain Activity in Healthy Human Volunteers|Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Brain Electrical Activity in Healthy Human Volunteers|ERP|St. Joseph's Healthcare Hamilton|No|Completed|July 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2007|June 7, 2011|September 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01369264||103478|
NCT01379066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1|Tuberculosis Volatile Organic Compounds|Detection of Mycobacteria in Lungs and Culture Using an Ultra-fast Gas Chromatograph|TBVOC|Landon Pediatric Foundation|No|Completed|August 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|15|||Both|1 Year|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Tuberculosis patients will be enrolled through the Tuberculosis Specialty Clinic in        Oxnard, Ca.|August 2014|August 12, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379066||102734|
NCT01379079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34954.058.10|Aspirin in Reduction of Tension II Study|Aspirin AM or PM in Reduction of Tension: a Randomized Cross-over Trial|ASPIRETENSION|Leiden University Medical Center|No|Completed|April 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|290|||Both|18 Years|75 Years|No|||May 2014|May 12, 2014|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01379079||102733|
NCT01379092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-01-LEV|An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging|An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging||Levine, Gary M. , M.D.|No|Recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|No|||March 2012|March 15, 2012|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379092||102732|
NCT01353235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|steroids in COPD exacerbation|Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|A Prospective Randomized Trial of Systemic Corticosteroids (Oral Prednisolone) in Severe Exacerbation of COPD Requiring Ventilatory Assistance||Hôpital Universitaire Fattouma Bourguiba|No|Recruiting|April 2010|||July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||May 2011|May 12, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01353235||104703|
NCT01353508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2223|Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers|A Randomized, Double-blind, Controlled, Crossover Study to Evaluate the Sodium Excretion of LCZ696 in Patients With Stable Heart Failure, in Patients With Hypertension, and in Healthy Volunteers||Novartis||Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|March 16, 2011|Yes|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT01353508||104682|Regarding LSM = 1218.56 for LCZ696 HTN cohort arm at Day 1, 1.0 hr post dose, the value was heavily inflated due to one participant with a very high change from baseline.
NCT01349660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI CNS 13|Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme|Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)||SCRI Development Innovations, LLC|No|Recruiting|December 2011|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349660||104976|
NCT01349621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA156166|Clinical Evaluation of Polarized Light Assisted Colposcopy|Clinical Evaluation of Polarized Light Assisted Colposcopy||Georgia Regents University|No|Completed|April 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|330|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy women with a previously detected abnormal cervical cytology or other indication        for colposcopy|September 2012|March 9, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349621||104979|
NCT01349634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1152-MCGUNI-01|The Effects of Iodized Salt on Cognitive Development in Ethiopia|A Study to Measure the Effect of Switching the Salt Supply From Non-iodized to Iodized on Cognitive Development in Ethiopia||McGill University|No|Completed|October 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4800|||Both|5 Months|61 Months|Accepts Healthy Volunteers|||May 2014|May 9, 2014|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01349634||104978|
NCT01350414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01|AIR2 Extension Study to Demonstrate Longer-term (> 1 Year) Durability of Effectiveness|AIR2 Extension Study to Demonstrate Longer-term (> 1 Year) Durability of Effectiveness|PAS1|Asthmatx, Inc.|Yes|Completed|October 2005|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|181|||Both|18 Years|65 Years|No|Non-Probability Sample|All Alair group subjects who have participated in the AIR2 Trial and were not lost to        follow-up at the end of the 12 month premarket visit, and those who are willing to comply        with the study protocol and routine visits for the duration of the study will be included        in the post-approval study.|March 2014|March 28, 2014|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01350414||104918|
NCT01350440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10|Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia|Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia||University of South Florida||Completed|August 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|10 Years|50 Years|No|||July 2013|July 19, 2013|April 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350440||104916|
NCT01350726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-Liver surgery -GSA|Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan|Functional-three-dimensional Reconstruction and Functional Evaluation of Liver by 99MTc-GSA-SPECT Scintigraphy|GSA|Peking Union Medical College Hospital|Yes|Recruiting|January 2008|July 2011|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|The subjects were from Peking Union Medical College Hospital from May, 2008 to the end of        the study.|May 2011|May 9, 2011|May 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01350726||104894|
NCT01350739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Umb11|The Umbilical Access in Laparoscopic Surgery|Comparative, Randomized, Open-label Study: Different Incisions to Access the Abdominal Cavity Within the Umbilicus||St John of God Hospital, Vienna|No|Withdrawn|May 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|70 Years|No|||November 2015|November 17, 2015|May 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01350739||104893|
NCT01351038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT Gastric-4|Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma|A Two Stage Multicenter Phase II Trial of Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Terminated||||||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|65 Years|No|||June 2013|June 3, 2013|May 9, 2011||No|REAL trial showed a significant difference in OS for reduced EOX and standard EOX|No||https://clinicaltrials.gov/show/NCT01351038||104870|
NCT01351051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-38-52014-185|A Study of the Potential Risk Factors Linked to the Development of Severe Forms of Endometriosis|A Multi-centre, Multinational, Cross-sectional, Incident Case-control Study on Factors Associated With the Development of Endometrioma and Deep Infiltrating Endometriosis|FEELING|Ipsen|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|1008|||Female|18 Years|41 Years|No|Probability Sample|Women who have undergone a laparoscopy/laparatomy for a benign gynaecological indication        excluding pregnancy in the last 3 months.|May 2013|May 29, 2013|April 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01351051||104869|
NCT01377025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STREAM|A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma|A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma|STREAM|University Hospital, Essen|No|Active, not recruiting|June 2011|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01377025||102888|
NCT01377285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200809041M|Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)|Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease|CKD|National Taiwan University Hospital|Yes|Recruiting|June 2010|December 2018|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Both|20 Years|80 Years|No|||August 2015|August 7, 2015|June 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01377285||102869|
NCT01377493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B116|Effects of a Chewing Gum Containing POs-Ca and Fluoride on Enamel|Effects of a Chewing Gum Containing POs-Ca and Fluoride on Remineralization of Enamel Subsurface Lesions in Situ||Tokyo Medical and Dental University|No|Completed|December 2009|June 2011|Actual|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|20 Years|31 Years|Accepts Healthy Volunteers|||June 2011|June 20, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377493||102853|
NCT01376960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121809A|Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures|Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures: A Prospective Comparison||OrthoCarolina Research Institute, Inc.|Yes|Active, not recruiting|June 2011|July 2016|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|101|||Both|N/A|N/A|No|||March 2016|March 23, 2016|July 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01376960||102893|
NCT01376973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|189/03|Efficiency of Two Occlusal Splints on TMD Treatment of Police Officers|Efficiency of Two Occlusal Splints on TMD Treatment: Randomised Clinical Trial||University of Campinas, Brazil|Yes|Completed|March 2008|November 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|28 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|police officers of the São Paulo State - Brazil filled up the Axis II of Research        Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) with TMD symptoms.|June 2011|June 17, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376973||102892|
NCT01377766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006CB504502-3|The Relationship Between Psychological Factors and Bell's Palsy|Study of Psychological Factors on the Occurence of Bell's Palsy||Huazhong University of Science and Technology|Yes|Recruiting|October 2008|November 2011|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|800|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|695 subjects were assigned to Cases Group (n=355) and Control Group (n=340).|November 2011|November 5, 2011|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377766||102834|
NCT01377779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2*13/09|Efficiency of Intercoat (Oxiplex/AP Gel)in Decreasing Intrauterine Adhesions|Intercoat (Oxiplex/AP Gel) for Preventing Intrauterine Adhesions Following Operative Hysteroscopy for Suspected Retained Products of Conception - a Prospective Randomized Pilot Study||Assaf-Harofeh Medical Center|Yes|Completed|September 2009|February 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|50 Years|No|||July 2009|June 20, 2011|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01377779||102833|
NCT01378091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB3212|Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer|Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Every Three Week Docetaxel (Taxotere®) In Subjects With Androgen Independent Prostate Cancer||Columbia University|Yes|Completed|August 2005|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Male|18 Years|N/A|No|||August 2012|June 22, 2015|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378091||102809|
NCT01378897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-11-059|Bariatric Surgery Telemedicine Study|A Telehealth Innovation to Support Weight Loss||Baystate Medical Center|No|Withdrawn|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|June 21, 2011||No|PI decided to not initiate this study.|No||https://clinicaltrials.gov/show/NCT01378897||102747|
NCT01378611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 05-232 (PF 218)|Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy?|Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy? A Randomized Clinical Study.||Epilepsiecentrum Kempenhaeghe|Yes|Active, not recruiting|March 2006|March 2013|Anticipated|March 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|4 Years|18 Years|No|||June 2011|June 28, 2011|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378611||102769|
NCT01378871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Imtox 25|A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma|Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma||Albert Einstein College of Medicine of Yeshiva University|No|Completed|September 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378871||102749|
NCT01378845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002127-17|Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands|Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy|Anti-Vasospasm|University of Freiburg|No|Recruiting|July 2011|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01378845||102751|
NCT01378858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-279|Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients|Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients||Albert Einstein College of Medicine of Yeshiva University|Yes|Active, not recruiting|July 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378858||102750|
NCT01352988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM 10_0020|Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus|Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Mono-Centre, Open-Label, Prospective Pilot Study|FumaCLE|University Hospital Muenster|No|Completed|July 2011|February 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|70 Years|No|||February 2014|February 27, 2014|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01352988||104722|
NCT01353781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3610C00004|Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid Malignancies||AstraZeneca|No|Completed|June 2011|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|20 Years|N/A|No|||July 2015|July 1, 2015|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353781||104661|
NCT01350180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-JGH-10-032|Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis|A Prospective Study Assessing the Predictive Value of TMPRSS2-ERG Gene Fusion and PTEN Deletion in High Risk Prostate Cancer Patients||Sir Mortimer B. Davis - Jewish General Hospital|No|Recruiting|September 2010|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|132|||Male|N/A|N/A|No|Non-Probability Sample|high risk prostate cancer patients having received radical radiation and hormonal therapy        in either biochemical failure or 3-year post end of hormonal therapy|May 2015|May 20, 2015|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01350180||104936|
NCT01350193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHI-2011|Manuka Honey Irrigation After Sinus Surgery|Manuka Honey Irrigation After Endoscopic Sinus Surgery||St. Paul's Hospital, Canada|No|Completed|June 2011|April 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|19 Years|N/A|No|||December 2013|December 2, 2013|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01350193||104935|
NCT01349894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011111|SNaP Wound Care System Over Skin Cancer Excision Sites and Split Thickness Skin Grafts (STSGs)|Post-Market Clinical Evaluation of the Spiracur SNaP™ Wound Care System for Treatment of Skin Cancer Excision Sites and Split Thickness Skin Grafts||Spiracur, Inc.|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|7|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will be selected from existing investigator patient population.|December 2012|December 11, 2012|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349894||104958|
NCT01350427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/04690-6|Branched-chain Amino Acids, and Resistance Exercise on Skeletal Muscle Signaling Pathways|Effects of Leucine, Branched-chain Amino Acids, and Resistance Exercise on Skeletal Muscle Remodelling Signaling Pathways: a Randomized, Double-blind, and Placebo-controlled Study||University of Sao Paulo|Yes|Completed|August 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|May 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350427||104917|
NCT01350765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1212-Ped/ERC|Naushero Feroze Neonatal Survival Project|Naushero Feroze Neonatal Survival Project: A Cluster Randomized Trial to Determine the Effectiveness of Package of Community Based Interventions to Reduce Neonatal Deaths Due to Birth Asphyxia, Low Birth Weight & Neonatal Sepsis|AKU|Aga Khan University|Yes|Completed|March 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|37201|||Both|N/A|28 Days|Accepts Healthy Volunteers|||December 2015|December 29, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350765||104891|
NCT01350778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2010-03|Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)|Evaluation of Effectiveness and Safety of BIOMATRIX in Routine Clinical Practice; A Multicenter, Prospective Observational Study||CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|May 2010|December 2020|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Patients receiving BioMatrix stents|November 2015|November 10, 2015|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01350778||104890|
NCT01350752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACT|Research on the Economics of Artemisinin Combination Therapy (ACTs) for the Treatment of Malaria|A Cost-effectiveness Analysis of Alternative Strategies for the Deployment of ACTs at the Community Level in Cameroon and Nigeria|REACT|London School of Hygiene and Tropical Medicine|No|Active, not recruiting|May 2011|April 2014|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|6513|||Both|6 Months|N/A|No|||October 2013|October 10, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350752||104892|
NCT01351077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICA_DevScreen_Study|CHICA Developmental Screening Study|||Indiana University|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|480|||Both|N/A|3 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351077||104867|
NCT01377298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007042M|Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase II Study of Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Refractory to Platinum-Based Chemotherapy||National Taiwan University Hospital|Yes|Recruiting|June 2011|May 2014|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|70 Years|No|||June 2011|June 20, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01377298||102868|
NCT01377506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104877|Translation of Obesity and Cognitive Program by Lay Health Educators|Translation of Obesity and Cognitive Research in a Rural State Via Senior Centers|Coaches|University of Arkansas|No|Completed|September 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|16|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2012|June 21, 2012|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377506||102852|
NCT01377792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSH-FQ1|Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis|Phase 4 Study of the Efficacy of Long-term Treatment With Hypertonic Saline on Pulmonary Exacerbations in Patients With Cystic Fibrosis||Hospital Universitario Ramon y Cajal|Yes|Completed|March 2009|September 2012|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|6 Years|N/A|No|||January 2013|January 29, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01377792||102832|
NCT01378624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-07 ZAP2|Ex Vivo Effect of Surfactant Protein D on Pulmonary Cells in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging|Ex Vivo Effect of Fragments and Modified Forms of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging||Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Completed|June 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01378624||102768|
NCT01378910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTEST|Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia|Use Of Genotypic HIV-1 Tropism Testing In Proviral DNA To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia||Fundacio Lluita Contra la SIDA|No|Completed|June 2011|May 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|74|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01378910||102746|
NCT01379131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 09-07b|Previous Cardiovascular Disease, Cardiovascular Risk Factors and Chest Pain in First Myocardial Infarction|MI as the First Manifestation of Coronary Heart Disease: Distribution of Previous Cardiovascular Disease, Cardiovascular Risk Factors and Chest Pain in First MI||London School of Hygiene and Tropical Medicine|Yes|Completed|September 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|9000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of patients registered at those GPRD practices that        agreed to the linkage with the MINAP database, and whose practices are "up to standard"        according to GPRD criteria. Practices taking part in the GPRD are chosen to be        representative of all UK practices, and 98% of people in the UK are registered with a GP.        Therefore the GPRD should be a representative sample of the UK population.|October 2015|October 1, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379131||102729|
NCT01378884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH 10-001|The Use of Domperidone for Gastroparesis|Monitoring Study for the Use of Gastroparesis for Patient Who Have Failed Standard Therapy||Allegiance Health|Yes|Withdrawn|March 2010|March 2014|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|February 3, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378884||102748|
NCT01379404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StJoseph - BIOVISION|Bioimpedance Analysis in Septic Intensive Care Unit (ICU) Patients|Does Bio-impedance Analysis Predict Volume Overload States and Clinically Relevant Outcomes in Septic Intensive Care Unit (ICU) Patients With Acute Kidney Injury? A Prospective Observational Study|BIOVISION|St. Joseph's Healthcare Hamilton|No|Completed|February 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|Blood only for chemistry.|Both|18 Years|N/A|No|Probability Sample|All adult patients (>17 years) admitted to the ICU at SJHH who present with SIRS requiring        positive pressure ventilation via endotracheal tube and have a clinical suspicion of        infection. Consecutive sampling.|May 2015|May 19, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01379404||102708|
NCT01378585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033|Safety and Efficacy of DLBS1033 in Healthy Subjects|A Randomized, Double Blind, Placebo Controlled, Cross-over, and Fixed Dose Study to Evaluate the Safety and Efficacy of DLBS1033 in Healthy Subjects||Dexa Medica Group||Completed|May 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01378585||102771|
NCT01379378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0035|Male Stress Urinary Incontinence and Sexual Health|Male Stress Urinary Incontinence and Sexual Health||Stanford University|Yes|Terminated|October 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|50|||Male|18 Years|N/A|No|Non-Probability Sample|Post-prostatectomy patients at least 6 months after either open radical retropubic        prostatectomy or robot assisted laparoscopic prostatectomy with bothersome stress urinary        incontinence will be initially screened with urodynamics, a 24 hour pad test, and a self        questionnaire to assess how bothersome their incontinence is.|February 2013|February 19, 2013|June 21, 2011||No|Too cumbersome to go through 2 review boards for a non-cancer study|No||https://clinicaltrials.gov/show/NCT01379378||102710|
NCT01353248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-248-0120|GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection|A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection||Gilead Sciences||Completed|May 2011|March 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|70 Years|No|||November 2013|November 26, 2013|April 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353248||104702|
NCT01353495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-BIO-001|Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers|A Prospective, Randomized Comparative Parallel Study of Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers||Wright Medical Technology|Yes|Completed|April 2010|April 2011|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||June 2011|June 6, 2011|May 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353495||104683|
NCT01353794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15246|Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer|Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar® in Advanced Renal Cell Carcinoma|POWER-NEXT|Bayer|No|Withdrawn|December 2014|April 2018|Anticipated|September 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample|Patients of advanced RCC|January 2015|January 29, 2015|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01353794||104660|
NCT01353807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-AA-20060182|Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health|Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health||Centre for Fetal Programming, Denmark|Yes|Completed|November 1989|May 2011|Actual|December 1990|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|533|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01353807||104659|
NCT01353820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU280|Effects of Lactobacillus Delbruckii Lactis DN111244 Fermented Milk Consumption on Plasma Lipids Levels in Hypercholesterolaemic Adults|Proof of Concept -Effects of Lactobacillus Delbruckii Lactis DN111244 Fermented Milk Consumption on Plasma Lipids Levels in Hypercholesterolaemic Adults.||Danone Research|No|Completed|September 2008|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2011|May 13, 2011|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01353820||104658|
NCT01350206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC0011|Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis|Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial||Sun Yat-sen University|Yes|Recruiting|April 2010|May 2013|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||April 2010|May 6, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350206||104934|
NCT01350154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHGLBMD|Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients|Does Modulation of the nNOS System in Patients With Muscular Dystrophy and Defect nNOS Signalling Affect Cardiac, Muscular or Cognitive Function?||Rigshospitalet, Denmark|Yes|Completed|November 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|80 Years|No|||April 2013|April 9, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01350154||104938|
NCT01350453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-PG-0909-20145|Development and Pilot Evaluation of a Web-supported Programme of Constraint Induced Therapy Following Stroke (LifeCIT)|Development and Pilot Evaluation of a Web-supported Programme of Constraint Induced Therapy Following Stroke (LifeCIT)||University of Southampton|No|Recruiting|May 2011|August 2013|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350453||104915|
NCT01350466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53127|Prospective Study Investigating the Role of Occupational Exposure on Sinus Surgery Outcome|Prospective Study Investigating the Role of Occupational Exposure on Sinus Surgery Outcome||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|August 2011|September 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|chronic rhinosinutis patients undergoing functional endoscopic sinus surgery|May 2011|May 6, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350466||104914|
NCT01350791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2010-04|Evaluation of Effectiveness and Safety of PROMUS Element Stent (IRIS-ELEMENT )|Evaluation of Effectiveness and Safety of PROMUS Element™ in Routine Clinical Practice; A Multicenter, PROSPECTIVE OBSERVATIONAL STUDY||CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|May 2010|April 2016|Anticipated|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3018|||Both|N/A|N/A|No|Non-Probability Sample|Coronary artery disease requiring drug eluting stents|September 2015|September 14, 2015|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01350791||104889|
NCT01351090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROX 2001-03|Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine (IN) for Postoperative Pain|A Phase 2, Double-blind, Randomized Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain||Luitpold Pharmaceuticals||Completed||October 2007|Actual|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|127|||Both|18 Years|N/A|No|||September 2012|September 14, 2012|May 9, 2011|Yes|Yes|||September 14, 2012|https://clinicaltrials.gov/show/NCT01351090||104866|
NCT01377805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61/3529|Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life|Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life -- a Retrospective Analysis||Genetic Disease Investigators|Yes|Withdrawn|June 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Multiple Sclerosis, no geographic limitations|April 2015|April 2, 2015|June 19, 2011||No|No participants|No||https://clinicaltrials.gov/show/NCT01377805||102831|
NCT01377519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids|Magnetic Resonance-Guided Focused Ultrasound to Treat Uterine Fibroids: A Pilot Randomized, Placebo-Controlled Trial|PROMISe|University of California, San Francisco|Yes|Completed|June 2011|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||January 2014|January 15, 2014|June 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377519||102851|
NCT01378351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-085|Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Survey|Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Study||Baylor Research Institute|No|Terminated|June 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|89 Years|No|Non-Probability Sample|Outpatient gastroenterology clinic|August 2013|August 22, 2013|June 21, 2011||No|Inadequate recruitment, investigator left institution|No||https://clinicaltrials.gov/show/NCT01378351||102789|
NCT01378637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7034|AMES Treatment of the Impaired Leg in Chronic Stroke Patients|AMES Treatment of the Impaired Leg in Chronic Stroke Patients|AMES|AMES Technology|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||January 2014|January 16, 2014|February 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01378637||102767|
NCT01380028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8545|Interest of Oral Corticosteroids in the Treatment of Chronic Subdural Hematomas|Interest of Oral Corticosteroids in the Treatment of Chronic Subdural Hematomas. Prospective Randomized Multicenter Trial|hemacort|University Hospital, Montpellier|No|Active, not recruiting|September 2010|December 2016|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01380028||102661|
NCT01379144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XALA-0091-166|A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension|A 4 Week, Dose-Ranging, Multi-Center, Randomized, Double-Masked, Parallel Study Comparing The Efficacy, Safety, And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma Aand Ocular Hypertension||Pfizer|No|Completed|January 2003|April 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|282|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|June 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01379144||102728|
NCT01379417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04.01.FR.INF|Probiotics Supplementation in Premature Infants|Probiotics Supplementation and Nutritional Benefit in Premature Infants||Nestlé|No|Completed|November 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|199|||Both|N/A|8 Days|No|||August 2011|August 26, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01379417||102707|
NCT01379105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0111|Electromyographic Responses by Static Stretching and Neural Mobilization|Electromyographic Responses of Sedentary Students Submitted to Static Stretching and Neural Mobilization||Euro-American Network of Human Kinetics|Yes|Completed|August 2010|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Male|17 Years|30 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01379105||102731|
NCT01379391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO-HSCT-2011|Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT|A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China|TPO|Nanfang Hospital of Southern Medical University|Yes|Recruiting|June 2010|||September 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||September 2015|October 7, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01379391||102709|
NCT01353521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEUSEVCRC|Contrast-enhanced Ultrasound for the Evaluation of Complex Renal Cysts|Contrast-enhanced Ultrasound for the Evaluation of Complex Renal Cysts||St. Joseph's Healthcare Hamilton|No|Recruiting|December 2013|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|March 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353521||104681|
NCT01353534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC82-102|Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine|A Phase 1/2, Randomized, Open-Label, Study to Assess the Immunogenicity and Safety of a Vaccine Enhancement Patch (VEP) When Administered With Two Doses of Intramuscular Inactivated Influenza H5N1 Vaccine in Healthy Adults||Intercell USA, Inc.|Yes|Completed|May 2011|October 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|276|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353534||104680|
NCT01349920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08143|Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)|An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)||Merck Sharp & Dohme Corp.|No|Completed|November 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|Samples With DNA|stool, serum, peripheral blood mononuclear cells (PBMC)|Both|18 Years|60 Years|No|Non-Probability Sample|Approximately 20 participants aged 18 to 60 years with Crohn's Disease will be enrolled        from gastrointestinal specialist clinics.|October 2015|October 8, 2015|May 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01349920||104956|
NCT01353846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901-C-055-MF|Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients|Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Recruiting|May 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01353846||104656|
NCT01350518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00579|Dietary Intervention for Visceral Adiposity|Dietary Intervention for Visceral Adiposity-Pilot|DIVA-Pilot|Wake Forest School of Medicine|Yes|Active, not recruiting|February 2011|July 2015|Anticipated|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|30|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||March 2011|January 5, 2015|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350518||104910|
NCT01349933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02581|Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma||National Cancer Institute (NCI)||Completed|April 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2014|December 23, 2014|May 6, 2011|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01349933||104955|
NCT01350167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3034-A|Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease|Screening for Hepatocellular Carcinoma With Triphasic Helical CT vs. US With Alpha-fetoprotein in Patients With Advanced Liver Disease||Minneapolis Veterans Affairs Medical Center|No|Recruiting|November 2001|December 2021|Anticipated|December 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2010|May 23, 2011|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01350167||104937|
NCT01351116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2011-BRACHY|A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy|A Phase III, Multi-centre, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy|BRACHY|Ontario Clinical Oncology Group (OCOG)|Yes|Recruiting|October 2011|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01351116||104864|
NCT01351103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGK974X2101|A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands|A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands||Novartis|No|Recruiting|December 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|170|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|May 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01351103||104865|
NCT01377818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/0530|Non Invasive Mechanical Ventilation Versus Respiratory Rehabilitation in Hypercapnic COPD|Prospective Aleatory Study of Non Invasive Mechanical Ventilation Versus Respiratory Rehabilitation in Hypercapnic Stable Severe COPD|COPD|Hospitales Universitarios Virgen del Rocío|No|Completed|March 2006|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|40 Years|90 Years|No|||March 2006|June 20, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01377818||102830|
NCT01377831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KET001|Study of Ketamine Administered Intravenously and by Sublingual Wafer|An Open Label, Two Way Crossover Study to Evaluate the Bioavailability and Clinical Tolerability of a Novel Sublingual Wafer Formulation of Ketamine in Healthy Male Volunteers||iX Biopharma Ltd.|Yes|Completed|June 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples With DNA|Whole blood will be drawn into Vacuette brand, lithium heparin separator tubes (green/yellow      top).|Male|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|8 Healthy Male Volunteers|March 2015|March 6, 2015|June 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01377831||102829|
NCT01378104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGASYS100:80|100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)|The Response of Reducing Dose of Peginterferon Alfa-2a in Koreans With Chronic Hepatitis C Genotype 1; Randomized Controlled Multicenter Study 100% Versus 80%||The Catholic University of Korea|Yes|Completed|October 2008|September 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||February 2013|February 3, 2013|June 16, 2011||No||No|December 14, 2012|https://clinicaltrials.gov/show/NCT01378104||102808|
NCT01378364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304.1|Phase I Study of AbGn-168H in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics Study of Single Rising Doses of AbGn-168H Administered by Intravenous Infusion (125 μg/kg, 500 μg/kg, 1 mg/kg, 2 mg/kg) or Subcutaneous Injection (125 μg/kg, 1 mg/kg) to Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|June 2011|||November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|June 21, 2011||||No||https://clinicaltrials.gov/show/NCT01378364||102788|
NCT01378377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200066-005|Combination Trial MSC1936369B With Temsirolimus|Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors||EMD Serono|No|Completed|June 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|June 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01378377||102787|
NCT01379430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC040|Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas|Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults in a Malaria Endemic Area||University of Oxford|Yes|Completed|June 2010|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01379430||102706|
NCT01379729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK_TX_07|Bet Cell Therapy in Diabetes Type 1|Functional Survival of Beta Cell Allografts After Transplantation in the Peritoneal Cavity of Non-uremic Type 1 Diabetic Patients||AZ-VUB|Yes|Recruiting|May 2011|May 2018|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||December 2013|December 27, 2013|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01379729||102683|
NCT01380652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGL-Ga-SW-0810|Vibration Training in Chronic Obstructive Pulmonary Disease (COPD)-Patients During a Three-week Rehabilitation|Effects of Whole Body Vibration Training on Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) III/IV-Patients During a Three-week Rehabilitation||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|September 2010|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01380652||102613|
NCT01380665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prevena2009-45|Prevena™ Incision Management System Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty|Prospective, Single Arm, Post-Marketing Trial to Examine the Safety and Functionality of the Prevena™ Incision Management System, A Negative Pressure Based Surgical Wound Management System, Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty|Prevena2009-45|KCI USA, Inc.|No|Withdrawn|October 2009|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 19, 2013|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380665||102612|
NCT01380691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12613|A Study of LY2216684 in Healthy Subjects|A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction of LY2216684 With Alcohol in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|28|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 16, 2011|June 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380691||102610|
NCT01379118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110158|Comparison of Clinical Outcomes and Performance of Total Knee Replacement Patients Before and After Surgery|Comparison of Clinical Scales and Quantitative Knee Motion Data in Assessing the Clinical Outcomes and Performance of Total Knee Replacement Patients Before and After Surgery|TKR|Loma Linda University|Yes|Not yet recruiting|July 2011|October 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male and female patients that are healthy and patients that need a unilateral total knee        replacement.|June 2011|June 22, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379118||102730|
NCT01380002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011063RC|Home-Care Needs in Liver or Renal Transplantation Recipients and Their Spouses|Home-Care Needs in Liver or Renal Transplantation Recipients and Their Spouses||National Taiwan University Hospital|Yes|Recruiting|December 2010|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|80 Years|No|Non-Probability Sample|-  liver transplant recipients or renal transplant recipients with 18 to 80 years old             who have regular follow up in organ transplant outpatient departments at National             Taiwan University Hospital in Northern Taiwan.          -  We will also recuit spouses who live with recruited patients.|June 2011|June 22, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380002||102663|
NCT01349647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-095|Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid|Immunization of Small Cell Lung Cancer Patients With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid||Memorial Sloan Kettering Cancer Center||Completed|May 2011|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01349647||104977|
NCT01349907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05898|Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)|A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Subjects With Acute Manic or Mixed Episodes Associated With Bipolar I Disorder|ADDRESS-98|Merck Sharp & Dohme Corp.|Yes|Completed|June 2011|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|322|||Both|10 Years|18 Years|No|||February 2016|February 19, 2016|May 5, 2011|No|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01349907||104957|
NCT01349946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02082011-7478|Diffusion Weighted Imaging Evaluation for Understanding Stroke Evolution Study-2 (DEFUSE-2)|Diffusion Weighted Imaging Evaluation for Understanding Stroke Evolution Study-2 (DEFUSE-2)||Stanford University||Completed|June 2008|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|138|||Both|18 Years|N/A|No|Probability Sample|population includes those people with acute ischemic stroke|May 2014|May 12, 2014|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349946||104954|
NCT01349959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02585|Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer|Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2011|||March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2015|February 19, 2016|May 6, 2011|Yes|Yes||No|February 19, 2016|https://clinicaltrials.gov/show/NCT01349959||104953|
NCT01350531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01HL097889|Interventionist Procedures for Adherence to Weight Loss Recommendations in Black Adolescents|Interventionist Procedures for Adherence to Weight Loss Recommendations in Black Adolescents, Phase Two||Wayne State University|Yes|Recruiting|September 2009|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||January 2011|May 6, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01350531||104909|
NCT01350544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD006058|Treatment Advocacy Intervention for HIV-Positive African Americans|Treatment Advocacy Intervention for HIV-Positive African Americans|TA|Children's Hospital Boston|No|Completed|April 2013|December 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350544||104908|
NCT01350479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-154|Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers|Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers||VA Office of Research and Development|No|Active, not recruiting|October 2012|December 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|203|Samples Without DNA|Swabs of the gowns and gloves of health care workers that interact with the participants      will be tested for MRSA and other types of bacteria. Swabs from body sites (e.g. nose) of      participants will be tested for MRSA and other types of bacteria.|Both|18 Years|N/A|No|Non-Probability Sample|Veterans residing in a participating VA Long Term Care Facility|February 2016|February 3, 2016|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350479||104913|
NCT01350804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2309|Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents.|A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents|NURTURE 1|Novartis|Yes|Completed|September 2011|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|551|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|May 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350804||104888|
NCT01351129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611009|Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers|A Phase 1, Single-Dose, Open-Label, Crossover Study To Estimate The Relative Bioavailability Of Two Controlled-Release Formulations Vs. An Immediate Release Formulation Of PF-04991532 In Healthy Adult Subjects||Pfizer|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|May 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01351129||104863|
NCT01351142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYTOCOGMA|Cytokines and Cognitive Decline in Alzheimer's Disease|||Poitiers University Hospital||Recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment|1||||||Both|N/A|N/A|No|||May 2011|May 10, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01351142||104862|
NCT01351389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01AA009892-16A1|Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk|Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk|SAFER|Brown University|Yes|Completed|May 2011|August 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|65 Years|No|||September 2014|September 12, 2014|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351389||104843|
NCT01351402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00012002|Effects of Massage Versus Rest on Hormones|Investigating the Effects of Massage vs. Rest on Oxytocin, ACTH, and B-endorphins||Claremont Graduate University|No|Completed|June 2006|January 2007|Actual|August 2006|Actual|N/A|Interventional|Allocation: Randomized, Masking: Single Blind, Primary Purpose: Basic Science|||Actual|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2005|May 9, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01351402||104842|
NCT01378650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2010-0800|A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus|A Randomized, Prospective, Placebo-controlled Double-blind, Pilot Study on the Effect of Cilostazol for 4 Weeks in Patients With Chronic Tinnitus|CITI-ESR|Asan Medical Center|No|Completed|July 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|N/A|No|||May 2014|May 21, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01378650||102766|
NCT01378117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048954a|DPP4 Inhibitor in the Hospital|Randomized Controlled Study of DPP4 Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes||Emory University|Yes|Completed|August 2011|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|80 Years|No|||June 2014|June 7, 2014|March 7, 2011|Yes|Yes||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01378117||102807|
NCT01379157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP 39337|Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia|The Pharmacodynamics of Imipenem in Critically Ill Patients With Ventilator-associated Pneumonia Following Administration by 4 h or 0.5 h Infusion||Prince of Songkla University|No|Recruiting|November 2011|May 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|20 Years|90 Years|No|||December 2011|December 27, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01379157||102727|
NCT01379170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC10-3-085|Thyroid Study Type 2 Diabetes Mellitus (T2DM)|Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus||Maastricht University Medical Center|No|Recruiting|June 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|17|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379170||102726|
NCT01379703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMOS-EAST-04-1|Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use|Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use|KaleEAST|Abbott|No|Completed|February 2004|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2288|||Both|2 Years|N/A|No|Non-Probability Sample|KaleEAST is non-interventional, observational study in which Kaletra® is prescribed in the        usual manner in accordance with the terms of the local marketing authorization with regard        to dose, population and indication.|October 2011|October 10, 2011|June 22, 2011||No||No|August 9, 2011|https://clinicaltrials.gov/show/NCT01379703||102685|
NCT01380366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00012123 0208-007|rHGH and Intestinal Permeability in Intestinal Failure|Influence of Recombinant Human Growth Hormone on Intestinal Permeability and Liver Injury in Intestinal Failure Patients Receiving Parenteral Nutrition (Serono Project)|rHGH|Northwestern University|No|Completed|October 2006|February 2015|Actual|February 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|80 Years|No|||January 2016|January 12, 2016|June 22, 2011|Yes|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT01380366||102635|Number of participants is low. Time period of evaluation may not have been adequate for evaluating the impact on liver injury. Parameters used to evaluate the impact of gut permeability changes on hepatic inflammation and injury were very limited.
NCT01380379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-04152011-7701|Self-Defense Training in Women With Trauma|A Pilot Study of Self-Defense Training in Women With Trauma||Stanford University|No|Completed|April 2011|November 2015|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Female|21 Years|65 Years|No|||November 2015|November 18, 2015|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01380379||102634|
NCT01380015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11JA040|Efficacy of Spearmint Tea in Relieving Osteoarthritis of the Knee|Human Clinical Trial to Investigate the Effects of High Rosmarinic Acid Spearmint Tea on Markers of Pain, Physical Function and Disease Activity in Osteoarthritis of the Knee||University of Guelph|No|Completed|July 2011|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|49|||Both|18 Years|N/A|No|||January 2013|January 21, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01380015||102662|
NCT01380327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-17|Biomarkers of Cockroach Sublingual Immunotherapy 2|A Biomarker-Based Pilot Study of Cockroach Sublingual Immunotherapy in Cockroach Sensitive Children With Asthma and/or Perennial Allergic Rhinitis|BioCSI-2|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|5 Years|17 Years|No|||June 2014|June 5, 2014|June 22, 2011|Yes|Yes||No|May 2, 2014|https://clinicaltrials.gov/show/NCT01380327||102638|
NCT01380951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|szwy20110610|Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)|Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B||The Fifth People's Hospital of Suzhou|No|Recruiting|May 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|65 Years|No|||June 2011|June 23, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01380951||102590|
NCT01379664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-440|Volatile Anesthetic Choice and Duration of Hospitalization: A Quality Improvement and Cost-control Project|Volatile Anesthetic Choice and Duration of Hospitalization: A Quality Improvement and Cost-control Project||The Cleveland Clinic|No|Recruiting|July 2011|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|4150|||Both|N/A|N/A|No|||March 2013|March 14, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01379664||102688|
NCT01379677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009Rb82UK|Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison|Diagnosis of Coronary Artery Disease With Rubidium-82 PET and Technetium-99m-MIBI SPET: A Head to Head Comparison, Versus Coronary CT Angiography||Advanced Accelerator Applications|Yes|Completed|February 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|135|||Both|40 Years|N/A|No|||May 2014|May 13, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01379677||102687|
NCT01380314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bol-2008/01|Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis|Treatment of Bolivian Cutaneous Leishmaniasis With a Combination of Oral Miltefosine Plus Topical Imiquimod 5%||Foundation Fader|No|Completed|March 2008|July 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|N/A|No|||June 2011|June 22, 2011|May 7, 2008||No||No||https://clinicaltrials.gov/show/NCT01380314||102639|
NCT01380626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAT2010|Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients|Effects of Exercise Training on Quadriceps Gene Expression in COPD-patients in Comparison to Alpha-1-Antitrypsin-deficiency-patients||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|February 2010|April 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|40 Years|75 Years|No|||December 2013|December 16, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380626||102615|
NCT01353560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT005065-01A1-1|Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study 1-Survey|Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study 1-Survey||Brigham and Women's Hospital|Yes|Completed|May 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1509|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. All new patients coming into the Osher Clinical Center (OCC) for any medical reason.          2. All physicians in the 5 included departments/divisions (Women's Health, Orthopedics,             Obstetrics and Gynecology, General Medicine, and Rheumatology) are eligible to             participate in the survey. Other BWH physicians whom OCC patients have identified as             their referring doctors and given us permission to contact, will also be eligible to             participate in the survey.|November 2014|November 11, 2014|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353560||104678|
NCT01349972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02587|Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. "7+3" for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML)||National Cancer Institute (NCI)||Completed|April 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|70 Years|No|||January 2014|October 10, 2014|May 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349972||104952|
NCT01350219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-037|Stem Cell Educator Therapy in Type 1 Diabetes|Phase 2 Study of Stem Cell Educator Therapy in Type 1 Diabetes||Tianhe Stem Cell Biotechnologies Inc.|Yes|Recruiting|September 2010|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|14 Years|60 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01350219||104933|
NCT01351194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC0012|Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm|Radiofrequency Ablation vs. Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm.A Prospective and Randomized Clinical Trial||Sun Yat-sen University|Yes|Recruiting|March 2010|May 2013|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||March 2010|May 24, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01351194||104858|
NCT01350492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-004-10S|Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans|Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans||VA Office of Research and Development|No|Recruiting|April 2013|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|35 Years|65 Years|No|||January 2016|January 22, 2016|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01350492||104912|
NCT01350505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E0773-P|Toileting at Night in Older Adults: Light to Maximize Balance, Minimize Insomnia|Toileting at Night in Older Adults: Light to Maximize Vision, Minimize Insomnia||VA Office of Research and Development|No|Recruiting|October 2013|June 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|40|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350505||104911|
NCT01350817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10004|Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer|Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy|TARSEQ|University Hospital, Limoges|Yes|Completed|May 2011|January 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350817||104887|
NCT01350830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIR-01|Preperitoneal Versus Pre-trasversalis Hernia Repair|Early and Late Results of Transinguinal Preperitoneal Patch Repair Versus Anterior Pre-Trasversalis Mesh Repair. A Randomised Study|PPTHR|San Bonifacio Hospital|Yes|Completed|November 2007|January 2011|Actual|December 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|N/A|No|||January 2011|May 9, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01350830||104886|
NCT01351428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03|Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia|Non-invasive Hemodynamic Monitoring and Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|50 Years|No|||November 2012|November 8, 2012|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351428||104840|
NCT01351415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22097|A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer|An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First (1st)-Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy||Hoffmann-La Roche||Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|487|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01351415||104841|
NCT01379183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004869|Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility|Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility||Mayo Clinic|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|June 15, 2011|Yes|Yes||No|December 11, 2013|https://clinicaltrials.gov/show/NCT01379183||102725|
NCT01378923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-01|Evaluation of Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates|Pilot Evaluation of the Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates|REVAMP|George Mason University|Yes|Active, not recruiting|April 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 3, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01378923||102745|
NCT01378936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014694-11|Jail-Based Impact of Crime Intervention|Phase 2 RCT of Jail-Based Impact of Crime Intervention to Reduce Recidivism, Substance Abuse and HIV Risk Behavior|IOC|George Mason University|Yes|Active, not recruiting|August 2009|June 2016|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 3, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01378936||102744|
NCT01379196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0427-10-RMC|Use of Azithromycin as Immunomodulatory Therapy in Grave's Orbitopathy|Use of Azithromycin as Immunomodulatory Therapy in Grave's Orbitopathy||Rabin Medical Center|Yes|Enrolling by invitation|May 2011|November 2012|Anticipated|July 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||May 2011|June 22, 2011|May 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379196||102724|
NCT01379755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|singleradius|Comparison of Stability and Outcomes in Single-radius Femoral Component for Total Knee Arthroplasty|Study of Compare Mid-flexion Stability and Clinical Outcomes in Single-radius Femoral Design or Multi-radius Femoral Design.||Chonnam National University Hospital|Yes|Active, not recruiting|August 2010|July 2011|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|213|||Both|48 Years|84 Years|Accepts Healthy Volunteers|Probability Sample|56 total knee arthroplasties(TKAs) with a single-radius femoral design (Scorpio NRG)        (single-radius(SR) group) and 59 total knee arthroplasties(TKAs) with multiradius femoral        design (NexGen CR) (multi-radius(MR) group)|June 2011|July 13, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01379755||102681|
NCT01379716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT/AMC-001|Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia and Healthy Controls|Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia (PHN) and Age and Gender-Matched Normal Controls|STTR|Albany Medical College|No|Recruiting|January 2011|||January 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Male|50 Years|95 Years|Accepts Healthy Volunteers|||December 2010|June 22, 2011|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379716||102684|
NCT01371799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113746|A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers|A Double Blind, Randomized, Placebo Controlled, Cross-over Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers|MAA113746|GlaxoSmithKline|No|Completed|December 2009|October 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|9|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01371799||103284|
NCT01367548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 203|Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus|A Phase II Double-Blind Randomized Parallel Group Study of Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus||Valeant Pharmaceuticals International, Inc.|No|Completed|July 2003|December 2004|Actual|December 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367548||103610|
NCT01380340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB# 2011-051|Seniors Driving Cessation Early Intervention Group|Study of the Effects of a New Concept of Early Intervention on the Driving Cessation, Mental Health, and Quality of Life of Senior Drivers||Fraser Health|No|Not yet recruiting|July 2011|May 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|65 Years|N/A|No|||June 2011|June 27, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380340||102637|
NCT01380678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKU-1007|Intralesional Bevacizumab Injection on Primary Pterygium|A Randomized Controlled Trial of Intralesional Bevacizumab Injection on Primary Pterygium: Preliminary Results|bevacizumab|Khon Kaen University|No|Recruiting|January 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|206|||Both|N/A|N/A|No|||July 2010|July 7, 2011|June 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01380678||102611|
NCT01380353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10B05|Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine|Pilot Study to Test Uniformity of Transdermal Drug Delivery to the Breast Using Diclofenac Epolamine as a Model||Northwestern University|Yes|Active, not recruiting|June 2011|July 2017|Anticipated|July 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|25|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|June 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380353||102636|
NCT01379690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChangiGH|Retrospective Study: Hip Fractures in Diabetic Patients|Association of HBA1C and Hip Fractures in Elderly Type 2 Diabetic Patients||Changi General Hospital|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|1162|||Both|N/A|N/A|No|Probability Sample|All diabetic patients on treatment with medications, seen at Changi General Hospital from        2005-2010|February 2012|February 21, 2012|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01379690||102686|
NCT01380301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-Bol-01|Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony|Treatment of Bolivian Cutaneous Leishmaniasis With a Combination of Short Courses of Miltefosine and Antimony||Foundation Fader|No|Terminated|March 2007|January 2009|Actual|August 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|12 Years|75 Years|No|||June 2011|June 22, 2011|January 28, 2009||No|Low efficacy rates|No||https://clinicaltrials.gov/show/NCT01380301||102640|
NCT01376804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25409|A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients|Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients||Hoffmann-La Roche||Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|57|||Both|4 Months|16 Years|No|||March 2014|March 27, 2014|June 17, 2011|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01376804||102905|
NCT01349673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFPS3073|The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis|A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2011|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|114|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349673||104975|
NCT01350232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09F.327|Treatment of Sickle Cell Anemia With Stem Cell Transplant|Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors||Thomas Jefferson University|Yes|Terminated|September 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|45 Years|No|||November 2014|November 13, 2014|May 4, 2011|Yes|Yes|Poor accrual|No|November 13, 2014|https://clinicaltrials.gov/show/NCT01350232||104932|Study was terminated due to poor accrual. No reportable data has been collected.
NCT01350245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10D.219|Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies in Remission From HLA Partially-Matched Related Donors||Thomas Jefferson University|Yes|Completed|July 2010|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|May 4, 2011|Yes|Yes||No|October 7, 2014|https://clinicaltrials.gov/show/NCT01350245||104931|
NCT01382303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-10-055|Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients|Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients : Prospective, Randomized, Double Blinded Active Control, Multicenter Study||Ajou University School of Medicine|Yes|Recruiting|September 2010|September 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|162|||Both|20 Years|80 Years|No|||June 2011|June 27, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01382303||102486|
NCT01350843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIS 100058b|The Effects of Orange Juice on Plasma Lipids|An Investigation Into the Effects of Orange Juice on Plasma Lipids - an Extension to J/06/2010||University of Nottingham|No|Completed|May 2011|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|36|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350843||104885|
NCT01351155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSAIPO2011|Prevention of Damage Induced by Facial Mask Ventilation|Comparison of Three Devices to Prevent Skin Damage Induced by Facial Mask Ventilation During Acute Respiratory Failure: a Multicenter Randomised Controlled Study|3PROSNIV|Ospedale San Donato|Yes|Recruiting|December 2011|October 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|252|||Both|21 Years|N/A|No|||December 2014|December 29, 2014|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01351155||104861|
NCT01351441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP1140411E|Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through Integrated Clinical Pharmacy Services in an Innovative Model of Community Practice|Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through Integrated Clinical Pharmacy Services in an Innovative Model of Community Practice||VascuScript Pharmacy|No|Recruiting|May 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 9, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351441||104839|
NCT01351714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3 MDCT angio|Safe D3 Right Hemicolectomy for Cancer Through Multidetector Computed Tomography (MDCT) Angio|Safe D3 Right Hemicolectomy for Cancer Through 3D MDCT Angiography Reconstruction||Sykehuset i Vestfold HF|Yes|Recruiting|May 2011|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|231|||Both|20 Years|75 Years|No|||January 2016|January 5, 2016|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351714||104818|
NCT01378676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 4024|A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)||Cytokinetics|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|50|||Both|18 Years|N/A|No|||March 2012|September 16, 2013|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378676||102764|
NCT01378689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X080529001|Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids|Improving Bone Health Among RA Patients on Chronic Glucocorticoids||University of Alabama at Birmingham|No|Completed|September 2010|December 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|4659|||Both|19 Years|N/A|No|||January 2013|January 14, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01378689||102763|
NCT01379443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008H00766|Rehabilitation of Children With Multiple Disabilities|The Comparative Effect and Expense of More and Less Integration of Services That Provide Treatment and Rehabilitation for Children With Multiple Disabilities: A Randomized Controlled Trial||Children's Treatment Network|No|Completed|April 2007|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|445|||Both|N/A|19 Years|No|||June 2011|June 22, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01379443||102705|
NCT01379456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2010/3265-3|Eva-Hip, Evaluation of Rehabilitation After Hip-fracture|The Effect on Gait and Activity Level of a Physiotherapy Intervention Aimed at Improving Mediolateral Stability 4 Months After a Hip Fracture|Eva-Hip|Norwegian University of Science and Technology|Yes|Active, not recruiting|February 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|223|||Both|70 Years|N/A|No|||September 2015|September 29, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01379456||102704|
NCT01371201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGR2010/1715|First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma|First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)|FIRSTMAPPP|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|December 2011|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371201||103329|
NCT01371461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112304|Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)|Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)||GlaxoSmithKline|No|Completed|January 2004|October 2004|Actual|July 2004|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|390|||Both|18 Years|N/A||Probability Sample|Subjects of 18 years or more diagnosed with depression or in a depressed state, who are        considered appropriate to prescribe paroxetine tablet according to the prescribing        information|June 2011|June 16, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371461||103309|
NCT01379469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09070279|Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency|A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency|CBZ|Washington University School of Medicine|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|14 Years|80 Years|No|||February 2016|February 2, 2016|June 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01379469||102703|
NCT01379482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/073|Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer|Phase II Study of Patients With Peritoneal Carcinomatosis From Gastric Cancer Treated With Preoperative Systemic Chemotherapy Followed by Peritonectomy and Intraperitoneal Chemotherapy||Uppsala University|No|Completed|January 2005|March 2009|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|N/A|80 Years|No|||May 2011|May 5, 2014|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01379482||102702|
NCT01367574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 251|Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction|A Phase II Double-Blind, Randomized, Parallel Group, Dose Ranging Study of Subcutaneous Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction||Valeant Pharmaceuticals International, Inc.|No|Completed|April 2002|May 2003|Actual|May 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367574||103608|
NCT01367587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 253|Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone|Safety and Gastrointestinal Effects of Multiple-Dosed Intravenous Methylnaltrexone in Healthy Human Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|April 2002|July 2002|Actual|July 2002|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367587||103607|
NCT01380041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669|Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients|Identification of Multiple Sclerosis Biomarkers in Human CSF by Means of Cytokine Array|CYTOSEP|University Hospital, Montpellier|No|Terminated|June 2011|June 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|101|Samples With DNA|Samples with DNA|Both|18 Years|N/A|No|Probability Sample|Clinically definite Multiple sclerosis patients (at least 2 relapses)Control patients        (lumbar puncture for headache…|June 2011|July 20, 2015|June 17, 2011||No|Results obtained are sufficient for a publication.|No||https://clinicaltrials.gov/show/NCT01380041||102660|
NCT01380977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA014694-1|Trial of Impact of Crime Group Intervention for Jail Inmates||IOC-1|George Mason University|Yes|Active, not recruiting|August 2002|July 2016|Anticipated|August 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Male|18 Years|N/A|No|||May 2013|May 3, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01380977||102588|
NCT01376856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0196|Characteristics of Mediastinal Lymph Node With False Positive FDG PET/CT Results in Lung Cancer Staging : Relation With TB and Latent TB Infection|Characteristics of Mediastinal Lymph Node With False Positive FDG PET/CT Results in Lung Cancer Staging : Relation With TB and Latent TB Infection||Yonsei University|No|Terminated|June 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|33|Samples Without DNA|whole blood for perfoming Quantiferon-TB Gold in tube assay|Both|20 Years|75 Years|No|Non-Probability Sample|person who performed PET/CT and surgical biposy of mediastinal lymph node for diagnosis of        primary lung cancer of metastatic lung cancer|June 2013|June 1, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376856||102901|
NCT01380938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAT-01-2010|Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)|RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE)|WRITE|Casa Sollievo della Sofferenza IRCCS|No|Recruiting|October 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|1150|||Both|18 Years|70 Years|No|||April 2012|April 14, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01380938||102591|
NCT01377129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/PM-03|Anterior Cruciate Ligament Reconstruction: Residual Rotational Laxity for Single Versus Double Bundle Techniques|Reconstruction of the Anterior Cruciate Ligament: a Comparative MRI Study Evaluating Residual Rotational Laxity for Single Versus Double Bundle Surgical Techniques|LCA IRM|Centre Hospitalier Universitaire de Nīmes|No|Terminated|October 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|June 17, 2011||No|Patient enrolment proved to be more difficult than foreseen and was stopped at 46 inclusions.|No||https://clinicaltrials.gov/show/NCT01377129||102881|
NCT01377142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-409|Vaginal Uphold Hysteropexy and Laparoscopic Sacral Hysteropexy for the Treatment of Uterovaginal Pelvic Organ Prolapse|Vaginal Uphold Hysteropexy and Laparoscopic Sacral Hysteropexy for the Treatment of Uterovaginal Pelvic Organ Prolapse|VAULT|The Cleveland Clinic|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|144|||Female|40 Years|75 Years|No|Non-Probability Sample|Adult women with symptomatic uterovaginal prolapse planning to undergo laparsocopic sacral        hysteropexy or vaginal uphold hysteropexy|July 2015|July 14, 2015|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01377142||102880|
NCT01349686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2011-03|Effect of Fluid Oral Intake During Labour|Fluid Oral Intake vs. Fasting During Labour: A Randomized, Controlled Trial.||Saint Thomas Hospital, Panama|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|348|||Female|N/A|N/A|No|||February 2013|February 17, 2013|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349686||104974|
NCT01349699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/189|Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia|Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia||Radboud University|Yes|Completed|February 2010|September 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349699||104973|
NCT01350869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0588|Evaluation of Everolimus-Eluting Stents (The K-XIENCE Registry)|Evaluation of Effectiveness and Safety of Everolimus-Eluting Stents in Routine Clinical Practice||CardioVascular Research Foundation, Korea|Yes|Completed|June 2008|June 2014|Actual|December 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|N/A|No|Probability Sample|The registry will be conducted at 33 centers in Korea. Data will be collected on        approximately 3,000 subjects treated with XIENCE stents.|November 2015|November 10, 2015|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01350869||104883|
NCT01350882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN07-YL RITUXERAH|Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation|Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation|RITUX-ERAH|University Hospital, Tours|No|Active, not recruiting|October 2008|October 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|February 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01350882||104882|
NCT01383044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carvedilol|Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding|Banding Ligation With Carvedilol vs. Carvedilol for the Prevention of First Bleeding in Cirrhotics With Moderate Varices||E-DA Hospital|Yes|Recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|20 Years|75 Years|No|||June 2011|June 27, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01383044||102429|
NCT01350856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1101|Tracking Resistance to Artemisinin (TRAC)|A Multicentre, Randomised Trial to Detect in Vivo Resistance of Plasmodium Falciparum to Artesunate in Patients With Uncomplicated Malaria.|TRAC|University of Oxford|Yes|Completed|May 2011|December 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1700|||Both|6 Months|65 Years|No|||May 2015|May 29, 2015|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01350856||104884|
NCT01351168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOL-PD|Use of Zolpidem in Parkinson's Disease|A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease||Rush University Medical Center|No|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|30 Years|75 Years|No|||November 2012|November 30, 2012|May 9, 2011|Yes|Yes|study not funded|No||https://clinicaltrials.gov/show/NCT01351168||104860|
NCT01351181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007489|Physical Activity Advice in Diabetics at Annual Review|A Case Control Study to Assess the Effectiveness of Written Advice to Increase Physical Activity Given to Type II Diabetics by Nursing Staff During the Diabetic Annual Review in UK General Practice|PAADAR|Ship Street Surgery|No|Not yet recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2011|May 9, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351181||104859|
NCT01352000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15725|Relapse-Prevention Booklets as an Adjunct to a Tobacco Telephone Helpline("Quitline")|Relapse-Prevention Booklets as an Adjunct to a Tobacco Quitline||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|December 2008|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|3830|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352000||104796|
NCT01352013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omega3-MGH|The Impact of Omega-3 Fatty Acid Supplements on Fibromyalgia Symptoms|The Impact of Omega-3 Fatty Acid Supplements on Fibromyalgia (FM) Symptoms: A Randomized, Double-blind, Placebo-controlled Exploratory Study.||McGill University Health Center|No|Completed|January 2012|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Female|18 Years|65 Years|No|||April 2015|April 15, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352013||104795|
NCT01352312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11P.166|Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma|Phase I Trial With Cohort Expansion of Pentostatin, Bendamustine and Ofatumumab (PBO) for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma||Thomas Jefferson University|Yes|Recruiting|May 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352312||104774|
NCT01351727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0916-01|Epidemiologic Follow Up Study of Newly Diagnosed Epilepsy Among Seniors|Epidemiologic Follow Up Study of Newly Diagnosed Epilepsy Among Seniors From Different Ethnic Groups||University of Arizona|No|Recruiting|January 2011|October 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|560|||Both|65 Years|N/A|No|Non-Probability Sample|Hospitals (including emergency departments), neurology specialist clinics, primary care        clinics, communities (in Cochise, Pima, Santa Cruz Counties)including nursing homes,        skilled nursing facilities, assisted living facilities.|January 2013|January 14, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351727||104817|
NCT01379209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGI-2001-02|Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)|A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)||Regimmune Inc.|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|June 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01379209||102723|
NCT01378975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO25743|A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases|An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases||Hoffmann-La Roche||Completed|July 2011|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|146|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378975||102741|
NCT01371214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04080-023906|Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot|Maintaining Independence in Alzheimer's Disease|PLIÉ-pilot|University of California, San Francisco|Yes|Completed|June 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Both|N/A|N/A|No|||June 2015|June 2, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01371214||103328|
NCT01371487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113709|GSK1120212 Food-effect Study|An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of the MEK Inhibitor, GSK1120212, in Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01371487||103307|
NCT01380054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8705|Pulmonary Hypertension, Quality of Life and Psychosocial Factors|Pulmonary Hypertension: Impact of the Evolution of a Rare Disease on the Quality of Life and Role of Variables Psychosocial as Predictive of the Current and Later Quality of Life||University Hospital, Montpellier|No|Active, not recruiting|May 2011|May 2016|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|80 Years|No|Probability Sample|Patients with PAH, aged between 18 and 80 years, stable since 3 months, no psychological        follow-up at the competence center.|November 2015|November 30, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01380054||102659|
NCT01380717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenVas|Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)|The Role of Renal and Peripheral Vascular Resistance in Chronic Kidney Disease|RenVas|University of Aarhus|Yes|Completed|February 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2012|February 26, 2014|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01380717||102608|
NCT01367561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 206|Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function|A Phase I Urodynamic Study of the Opioid Antagonist, Naloxone and Intravenous Methylnaltrexone Reverse Opioid Effects on Bladder Function in Healthy Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|October 2002|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 18, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367561||103609|
NCT01367847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0740|Technology-Enhanced Helping the Noncompliant Child|Technology Enhanced Delivery of Treatment for Early Conduct Problems|TE-HNC|University of North Carolina, Chapel Hill|No|Completed|September 2010|May 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01367847||103587|
NCT01368120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-014|Antimicrobial Activity of IV Clear™ Dressing - Prevention of Antimicrobial Regrowth|||Covalon Technologies Inc.|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368120||103566|
NCT01376817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELomega3|Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis|Comparative Study About the Impact of Two Oil Emulsions, One of Them Formulated With MCT, LCT, Olive Oil and Omega 3 Fatty Acids Versus Another One Formulated With MCT and LCT, Administered Intravenously on Severe Acute Pancreatitis Clinical Evolution||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|July 2008|December 2011|Anticipated|July 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|60|||Both|18 Years|N/A|No|||February 2009|June 17, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376817||102904|
NCT01380964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEE006.10|Research of Biomarkers in Duchenne Muscular Dystrophy Patients|Research of Biomarkers for Disease Diagnosis, Disease Monitoring and Therapeutic Treatment Response in Duchenne Muscular Dystrophy Patients|IBISD|Genethon|No|Recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|220|Samples With DNA|DNA, serum, t lymphocytes, urine|Male|3 Years|20 Years|Accepts Healthy Volunteers|Probability Sample|patients with Duchenne Muscular Dystrophy controls (healthy or patients with a non-related        disease)|June 2011|June 10, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01380964||102589|
NCT01349985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN275201000011C|Adaptive Goal-Directed Adherence Tracking and Enhancement|SBIR-PhaseII, "Adaptive Goal-Directed Adherence Tracking and Enhancement"|AGATE|Talaria, Inc|No|Completed|July 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|136|||Both|21 Years|55 Years|No|||May 2014|May 9, 2014|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349985||104951|
NCT01350570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CB5200-Fd|Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial|Acupuncture for Functional Bowel Disease||Chengdu University of Traditional Chinese Medicine|Yes|Completed|August 2011|September 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|449|||Both|18 Years|65 Years|No|||April 2015|April 9, 2015|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350570||104906|
NCT01350895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-PCOS-100002|Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group|Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group||Taipei Medical University WanFang Hospital|No|Completed|February 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|781|||Female|18 Years|46 Years|Accepts Healthy Volunteers|Non-Probability Sample|Reproductive age women|November 2013|November 4, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350895||104881|
NCT01383811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34749EP|Exercise in Treatment Resistant Depression (TRD): A Feasibility Study|Clinical and Neuroendocrine/Metabolic Benefits of Exercise in Treatment Resistant Depression (TRD): A Feasibility Study||Milton S. Hershey Medical Center|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||March 2014|March 5, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01383811||102370|
NCT01351454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA022974|Behavioral Depression Treatment for African American HIV-infected Substance Users|Behavioral Depression Treatment for African American HIV-infected Substance Users||University of Maryland|Yes|Recruiting|September 2008|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|65 Years|No|||May 2011|May 10, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351454||104838|
NCT01351467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23andMe_PD001|Web-based Genetic Research on Parkinson's Disease|Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives||23andMe, Inc.|No|Recruiting|April 2009|January 2025|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|25000|Samples With DNA|Saliva samples are collected for DNA analysis|Both|18 Years|N/A|No|Non-Probability Sample|Community Sample|August 2015|August 14, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351467||104837|
NCT01351740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03255|Switch to Unboosted Atazanavir With Tenofovir Study|Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study|SUAT|University of British Columbia|Yes|Active, not recruiting|July 2011|December 2015|Anticipated|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|N/A|No|||April 2015|April 7, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351740||104816|
NCT01383265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VANCHCS-GI-006|Combined Chromoendoscopy and Water Method for Screening Colonoscopy|Randomized Controlled Trial (RCT) to Compare Adenoma Detection Rate of Combined Chromoendoscopy (Indigo Carmine) With Water Infusion in Lieu of Air Insufflation (Water Method) vs. Water Method Alone in Screening Colonoscopy||VA Northern California Health Care System|No|Completed|March 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|1177|||Both|50 Years|75 Years|No|||June 2013|June 13, 2013|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383265||102412|
NCT01383499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.425|A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma|A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 µg, 2.5 µg and 5 µg) Delivered Via Respimat® Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma||Boehringer Ingelheim||Completed|August 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|101|||Both|6 Years|11 Years|No|||March 2015|March 26, 2015|June 20, 2011||Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01383499||102394|
NCT01352325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFBC11|Efficacy of System Constellations in a General Population|Randomized Controlled Trial on the Efficacy of System Constellations on Psychological Well-being in a General Population Based Sample||Heidelberg University|Yes|Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|216|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01352325||104773|
NCT01370642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-043|Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)|A Phase III Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Treatment-Naïve Patients With Chronic Hepatitis C Infection||Merck Sharp & Dohme Corp.|Yes|Completed|June 2011|March 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|294|||Both|20 Years|70 Years|No|||December 2015|December 21, 2015|June 8, 2011|Yes|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01370642||103372|
NCT01370655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7145-009|A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009 AM1)|A Phase Ib, Randomized, Double-Blind, 4-Treatment, 2-Period Incomplete Block Study to Evaluate the Multiple Dose Effects of MK-7145 and Hydrochlorothiazide Compared to Placebo on Blood Pressure in Male Patients With Hypertension||Merck Sharp & Dohme Corp.|No|Completed|June 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|46|||Male|18 Years|75 Years|No|||April 2015|April 20, 2015|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370655||103371|
NCT01379495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uspqueimados2011|Education Program for Burn Patients|Randomized Controlled Clinical Trial on Telephone Follow-up in Rehabilitation of Burn Patients: Impact on Health Status||University of Sao Paulo|Yes|Completed|July 2010|May 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|83|||Both|18 Years|80 Years|No|||May 2014|May 22, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379495||102701|
NCT01379742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Thin-1|Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy|Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer||Prostate Cancer Foundation of Chicago|Yes|Recruiting|April 2010|||February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|240|||Male|40 Years|N/A|No|||February 2013|February 11, 2013|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379742||102682|
NCT01371526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoSAv1.2:04_10: R&D#5252|Revival of Stem Cells in Addison's Study|Revival of Autochthonous Adrenocortical Stem Cells in Autoimmune Addison's Disease|RoSA|Newcastle University|Yes|Completed|September 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|16 Years|66 Years|No|||February 2013|February 5, 2013|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371526||103305|
NCT01371539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-319-C-021|Clinical Comparison of Two Multifocal Contact Lenses Made of Silicone Hydrogel Materials|Clinical Comparison of Two Multifocal Contact Lenses Made of Silicone Hydrogel Materials||Alcon Research|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|109|||Both|35 Years|N/A|No|||June 2012|June 28, 2012|June 9, 2011|Yes|Yes||No|June 28, 2012|https://clinicaltrials.gov/show/NCT01371539||103304|
NCT01371474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112308|Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)|Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)||GlaxoSmithKline|No|Completed|April 2006|June 2008|Actual|March 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1483|||Both|N/A|N/A||Probability Sample|Japanese subjects with depression or in a depressed state who are considered appropriate        to prescribe paroxetine tablet starting at 20mg/day according to the prescribing        information|June 2011|June 9, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371474||103308|
NCT01371513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113951|Korean Practice Patterns for Screening PCA(Prostate Cancer)|Korean's Practice Patterns for Screening PCA(Prostate Cancer) According to PSA(Prostate-specific Antigen) Level|RESPECT|GlaxoSmithKline|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Male|40 Years|N/A|No|Probability Sample|Subjects with PSA more than 2.5ng/ml in 2008 from urology department of clinic and general        hospital|October 2011|November 3, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01371513||103306|
NCT01367236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1733|Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa|A Randomised, Prospective Study, Assessing Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa.|CogUK|Imperial College London|Yes|Completed|January 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|June 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367236||103634|
NCT01367249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00124|Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery|Efficacy and Safety of Bromfenac Ophthalmic Solution vs. Placebo for the Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery.||Bausch & Lomb Incorporated|No|Completed|May 2011|December 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|June 1, 2011|Yes|Yes||No|April 4, 2014|https://clinicaltrials.gov/show/NCT01367249||103633|
NCT01367262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13736|Disposition of 14C-LY2886721 Following Oral Administration in Healthy Human Subjects|Disposition of [14C]-LY2886721 Following Oral Administration in Healthy Human Subjects||Eli Lilly and Company|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|8|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|August 9, 2011|June 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01367262||103632|
NCT01367275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0378|Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF|Phase II Study of Second-line Irinotecan Plus Brivanib, a Dual Tyrosine Inhibitor of VEGFR and FGFR, in Metastatic Colorectal Cancer Patients Enriched for Elevated Levels of Plasma FGF Following Progression on Bevacizumab-based Treatment||M.D. Anderson Cancer Center|No|Terminated|August 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|June 3, 2011|Yes|Yes|Sponsor closed study|No||https://clinicaltrials.gov/show/NCT01367275||103631|
NCT01367288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.568|Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers|Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers|NEOZOL|Hospices Civils de Lyon|Yes|Completed|April 2010|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Female|18 Years|N/A|No|||May 2014|May 28, 2014|September 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01367288||103630|
NCT01367834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2171|Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome|Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome||University of North Carolina, Chapel Hill|No|Recruiting|May 2010|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|25|||Female|11 Months|13 Months|No|||May 2013|May 23, 2013|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367834||103588|
NCT01368159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Classmousse1|Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein|Randomised, Comparative Trial in Parallel Groups and Blinded, to Compare Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the G.S V. Under Echography Control, Between Three Types of Medical Compression Hose||Le Club Mousse|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|120|||Female|18 Years|N/A|No|||September 2011|September 13, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01368159||103563|
NCT01367873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIA-3196-01|Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects|A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects||Madrigal Pharmaceuticals, Inc.|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|June 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01367873||103585|
NCT01380704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-674|Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of ABT-436 in Major Depressive Disorder Subjects||Abbott|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|55 Years|No|||November 2011|November 22, 2011|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380704||102609|
NCT01377363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONVERTHER/GEICAM 2009-03|Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis|Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis||Spanish Breast Cancer Research Group|No|Completed|December 2009|||||N/A|Observational|Time Perspective: Prospective||1|Actual|236|Samples Without DNA|primary tumor sample and metastasis sample|Female|18 Years|N/A|No|Non-Probability Sample|Female patients diagnosed of primary breast carcinoma with locally recurrent breast        carcinoma or metastasic|June 2011|June 20, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01377363||102863|
NCT01377376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ197-006|A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib|A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer With Wild-type Epidermal Growth Factor Receptor|ATTENTION|Kyowa Hakko Kirin Company, Limited||Active, not recruiting|July 2011|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|20 Years|N/A|No|||May 2015|May 26, 2015|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377376||102862|
NCT01350011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P030871|Tobacco Intervention in Buprenorphine Treatment|Extended Tobacco Dependence Intervention in Buprenorphine Treatment|IBIS|University of California, San Francisco|Yes|Active, not recruiting|April 2011|April 2015|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 8, 2014|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350011||104949|
NCT01383824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT09/02|A Multi-centre Study to Assess the Long-term Performance of the Silent Hip™ in Primary Total Hip Replacement Surgery|A Multi-centre, Prospective, Uncontrolled Post Market Clinical Follow-up Study (PMCFS) to Monitor the Survival and Performance of the Silent™ Hip in Subjects Requiring a Total Hip Replacement||DePuy International|No|Terminated|January 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|N/A|65 Years|No|||August 2014|August 4, 2014|June 27, 2011||No|Rationalization of the Silent Hip Prosthesis for business reasons only|No||https://clinicaltrials.gov/show/NCT01383824||102369|
NCT01384084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPerugia-1|Pelvic Organ Prolapse Repair Plus Mini-Sling Versus Pelvic Organ Prolapse Repair Alone|URINARY INCONTINENCE AND URO-GENITAL PROLAPSE: A RANDOMIZED TRIAL OF PELVIC ORGAN PROLAPSE REPAIR PLUS MINI-SLING VERSUS PELVIC ORGAN PROLAPSE REPAIR ALONE||University Of Perugia|No|Completed|June 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|75 Years|No|||May 2011|May 19, 2014|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384084||102349|
NCT01382498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88-8|Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy|||Tabriz University||Enrolling by invitation|November 2009|||June 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|90|||Both|40 Years|70 Years|No|||April 2011|June 24, 2011|May 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382498||102471|
NCT01383031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFH-007|Safety and Efficacy Study of Transumbilical Laparoendoscopic Single Site Cholecystectomy|Randomized Controlled Trial Of Transumbilical Laparoendoscopic Single Site Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy||Beijing Friendship Hospital|Yes|Recruiting|October 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|75 Years|No|||October 2010|July 6, 2011|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01383031||102430|
NCT01383798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSP 57149|How Does Iron Supplementation Affect Training and Performance in Female Collegiate Rowers?|How Does Iron Deficiency Without Anemia (IDNA) Affect Endurance Training In Female Collegiate Endurance Athletes?||Cornell University|No|Completed|August 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383798||102371|
NCT01383785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-2008/52|Thrombus Aspiration for OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab|Phase 4 Study of Primary Angioplasty Combined Distal Injection of Abciximab to Thrombus and Aspiration With Catheter|TOLEDO1|Hospital Virgen de la Salud|Yes|Recruiting|November 2009|December 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|186|||Both|18 Years|75 Years|No|||February 2012|February 20, 2012|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01383785||102372|
NCT01384045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0005|Outreach for Diabetes Cure|Randomized Trial of Health Promotion Outreach for Diabetes Cure||University of Colorado, Denver|No|Completed|February 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2800|||Both|18 Years|N/A|No|||June 2011|December 17, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384045||102352|
NCT01370668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI08/90094|Functional Remediation for Bipolar Disorder|Comparative Efficacy of Two Psychosocial Strategies of Intervention (Neurocognitive vs Psychoeducative) as add-on Therapy Versus Treatment as Usual in Bipolar Disorder||Centro de Investigación Biomédica en Red de Salud Mental|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|198|||Both|18 Years|55 Years|No|||June 2011|June 9, 2011|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01370668||103370|
NCT01370681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_VCM_102|A Pharmacokinetic Study of CJ30001 and HKB0701/SLM0807 in Healthy Subject|An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetics After Administration of CJ30001 and Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects||CJ HealthCare Corporation|No|Completed|October 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01370681||103369|
NCT01370941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chymo-01|The Effect of Chymosin on the Intestinal Absorption of Calcium|The Effect of Chymosin on the Intestinal Absorption of Calcium: A Randomized Controlled Cross-over Trial|Chymosin|University of Aarhus|No|Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|125|||Both|25 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01370941||103349|
NCT01368185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-366|Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)|A Retrospective Survey to Evaluate the Impact of Hyzaar on Uric Acid in the Management of Hypertensive Patients in Normal Practice||Merck Sharp & Dohme Corp.|No|Completed|November 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1705|||Both|20 Years|75 Years|No|Non-Probability Sample|Data from 33 physicians from different levels of hospitals were invited to provide        information on patients who received MK-0954A and had pre- and post-treatment serum uric        acid and lipid profile reports during the study period. Each physician could provide up to        30 clinical charts of patients matching the inclusion criteria for the study.|October 2015|October 9, 2015|June 6, 2011|No|Yes||No|August 2, 2011|https://clinicaltrials.gov/show/NCT01368185||103561|
NCT01368198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID11-10|Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion|The Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion||Alcon Research|No|Completed|March 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 31, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368198||103560|
NCT01371812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114660|GSK2239633 FTIH Study|A Randomised, Double-blind, Placebo-controlled, Cross-over Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of GSK2239633 in Healthy Male Subjects.||GlaxoSmithKline||Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator)|2||Actual|24|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|March 8, 2012|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01371812||103283|
NCT01352442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-P10-020B|Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes|A Prospective Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT Implanted Intrastromally for Modified Monovision in Presbyopic Subjects||AcuFocus, Inc.|No|Completed|May 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|151|||Both|45 Years|60 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|May 10, 2011||No||No|August 19, 2015|https://clinicaltrials.gov/show/NCT01352442||104764|
NCT01400646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018664|A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers|An Open-Label, Non-Randomized, Sequential Two-Treatment Period Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin||Janssen Research & Development, LLC||Completed|October 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400646||101082|
NCT01401179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-04-003|Antibiotics Study in Preterm Premature Rupture of the Membranes|Randomized Phase III Trial of Cefazolin or Combination of Cefazolin and Erythromycin or Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of the Membranes|PPROM|Samsung Medical Center|Yes|Completed|April 2005|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|101|||Female|N/A|N/A|No|||July 2011|August 5, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01401179||101041|
NCT01401478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-838|Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation|Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation||AbbVie|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|86|||Both|18 Years|65 Years|No|Non-Probability Sample|Hemodialysis centers|February 2014|February 28, 2014|July 22, 2011||No||No|January 14, 2014|https://clinicaltrials.gov/show/NCT01401478||101018|
NCT01401673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V001|Phase II Open-Label Pilot Study of V3381 in Chronic Cough|Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients Attending a Specialist Clinic||Vernalis (R&D) Ltd|No|Terminated|October 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||July 2011|July 22, 2011|July 21, 2011||No|Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01401673||101003|
NCT01389739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|020097|Intervention to Improve Continuity of Care in Lung Cancer Patients|Evaluation of a Multi-faceted Intervention to Improve Continuity of Care for Patients With Lung Cancer||Laval University|No|Completed|June 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|206|||Both|18 Years|N/A|No|||May 2013|March 31, 2015|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01389739||101917|
NCT01389752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12612|A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects|Effect of Activated Charcoal on the Pharmacokinetics of LY2216684 in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 23, 2011|July 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01389752||101916|
NCT01390038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G100284|Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty|Simpliciti IDE Trial||Tornier, Inc.|No|Completed|July 2011|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Both|22 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 13, 2015|May 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390038||101895|
NCT01398982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0969-A|TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT|The Use of Transversus Abdominis Plane (TAP) Block in Autologous Breast Reconstruction Donor Site: A Randomized, Double-blind, Placebo-controlled Trial||University Health Network, Toronto|No|Completed|July 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Female|18 Years|N/A|No|||March 2015|March 30, 2015|July 18, 2011||No||No|July 7, 2014|https://clinicaltrials.gov/show/NCT01398982||101210|The study limitations include the difficulty in capturing data at all points postoperatively. The repeated measure pain scores at rest and with movement were not recorded for all patients (recorded for 75% at rest and 53% with movement).
NCT01402583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSO-321|Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C|Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C - An Epidemiological Study|MEN_EPID|University of Modena and Reggio Emilia|No|Completed|July 2011|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1000|||Both|18 Years|75 Years|No|Non-Probability Sample|A group of 442 women (168 still in fertile age; 274 menopausal) with HCV-positive CAH who        underwent PEG IFN treatment in the last 5 years will be evaluated. For comparison, a group        of 548 HCV-positive males with CAH will be evaluated.|October 2011|October 20, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402583||100934|
NCT01402830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017656|Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)|DPRESS Study. Case-control Study in Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients||Janssen-Cilag, S.A.||Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|271|||Both|18 Years|N/A|No|Probability Sample|patients with cancer pain who experience depression and pain after cancer diagnosis|February 2013|February 8, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402830||100915|
NCT01402843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-PTV-301|Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia|A Randomized, Double Blind, Double Dummy, Placebo Controlled Phase III Trial to Evaluate the Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia(COCTAIL Study)|COCTAIL|JW Pharmaceutical|No|Completed|June 2011|January 2013|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|150|||Both|20 Years|N/A|No|||May 2014|May 12, 2014|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01402843||100914|
NCT01384955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS.136|HRQoL and Function of Adults Treated in Adolescence for Scoliosis With Physical Exercises|THE ASSESSMENT OF QUALITY OF LIFE AND FUNCTION OF ADULTS TREATED IN ADOLESCENCE FOR IDIOPATHIC SCOLIOSIS WITH PHYSICAL EXERCISES||Józef Piłsudski University of Physical Education|No|Completed|January 2010|June 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|143|||Both|22 Years|44 Years|Accepts Healthy Volunteers|Non-Probability Sample|Treatment group (retrospection - medical records) - patients diagnosed and / or treated in        the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between        1983 and 1994. Diagnosis: idiopathic scoliosis (IS) - adolescent idiopathic scoliosis        (AIS) or early onset idiopathic scoliosis (EOIS) A comparison (control) group: patients        with IS, age - and condition - matched, who were diagnosed at the same time, in the same        clinic, and by the same physician, and prescribed the same method of physiotherapy, but        did not start the exercise treatment.|March 2015|March 31, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384955||102282|
NCT01381302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033-11-WOMC|Trodat 1 SPECT and Dopamine Polymorphism|Association of Polymorphism in Genes Associated With Control of Dopamine Levels in Parkinson's Disease and Tc-99m-Trodat-1 SPECT Imaging.||Wolfson Medical Center|No|Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|Samples With DNA|Blood samples with DNA|Both|35 Years|80 Years|No|Non-Probability Sample|100 early Israeli PD patients Of jewish origin, males or females Undergoing DAT-scan        examination in Wolfson medical center at early stage of disease, accompanied by a UPDRS        evaluation at that stage,performed by a trained neurologist|February 2016|February 8, 2016|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01381302||102563|
NCT01381549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114688|GSK2251052 in Complicated Urinary Tract Infection|A Randomised, Double-blind, Dose-finding, Multicenter Study of the Safety, Tolerability, and Efficacy of GSK2251052 Therapy Compared to Imipenem-cilastatin in the Treatment of Adult Subjects With Febrile Complicated Lower Urinary Tract Infections and Acute Pyelonephritis||GlaxoSmithKline|Yes|Terminated|June 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||February 2014|July 24, 2014|June 9, 2011|Yes|Yes|Microbiological findings of resistance on therapy in patients with complicated urinary tract    infection|No||https://clinicaltrials.gov/show/NCT01381549||102544|
NCT01381575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114700|Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine When Administered According to Alternative 2-dose Schedules in 9 - 14 Year Old Females||GlaxoSmithKline||Completed|June 2011|November 2014|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1447|||Female|9 Years|25 Years|Accepts Healthy Volunteers|||August 2015|September 10, 2015|June 17, 2011|Yes|Yes||No|June 28, 2013|https://clinicaltrials.gov/show/NCT01381575||102542|
NCT01350362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP031112-10B04|Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimes of Tideglusib vs Placebo in Mild-to-Moderate AD Patients|ARGO|Noscira SA|Yes|Completed|April 2011|October 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|306|||Both|50 Years|85 Years|No|||October 2012|October 1, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350362||104922|
NCT01351012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2010:047|Canola Oil Multicentre Intervention Trial|Canola and Flax Oils in Modulation of Vascular Function and Biomarkers of Cardiovascular Disease Risk|COMIT|University of Manitoba|No|Completed|September 2010|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|140|||Both|18 Years|65 Years|No|||February 2014|February 18, 2014|March 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01351012||104872|
NCT01352741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247251|Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin|Evaluation of the Effectiveness, Safety, and Tolerability of Tapentadol PR Versus a Combination of Tapentadol PR and Pregabalin in Subjects With Severe Chronic Low Back Pain With a Neuropathic Pain Component||Grünenthal GmbH||Completed|March 2011|||January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|622|||Both|18 Years|N/A|No|||May 2011|August 9, 2012|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01352741||104741|
NCT01352754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0394-HMO-CTIL|Troponin T Elevation in Patient Undergoing Hip Fracture Surgery|Prognosis Significance of Troponin T Elevation as Detected by Highly Sensitive Assay in Patient Undergoing Hip Fracture Surgery||Hadassah Medical Organization|No|Active, not recruiting|April 2011|March 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|65 Years|N/A|No|Probability Sample|Patients admitted with traumatic femoral neck fracture|December 2013|December 11, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352754||104740|
NCT01352130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akulkarni1|Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc|Comparative Electrocardiographic Effects of Intravenous Ondansetron and Granisetron in Patients Undergoing Surgery for Carcinoma Breast: A Prospective Single Blind Randomised Trial||Tata Memorial Hospital|No|Completed|March 2007|April 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|60 Years|No|||May 2011|May 10, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01352130||104786|
NCT01352455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0596|More Frequent In-Center Hemodialysis in Pediatric End Stage Renal Disease|A Pilot Study of More Frequent In-Center Hemodialysis to Improve Outcomes in Pediatric End Stage Renal Disease||Children's Hospital of Philadelphia|No|Completed|March 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|3 Years|21 Years|No|||December 2013|December 27, 2013|May 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01352455||104763|
NCT01352468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R33MH085842|Development of a Multi-faceted Cognitive Training Program for Children With Attention Deficit Hyperactivity Disorder (ADHD)|Development of a Multi-faceted Cognitive Training Program for Children With ADHD||Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|April 2011|June 2016|Anticipated|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|7 Years|12 Years|No|||December 2015|December 28, 2015|March 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01352468||104762|
NCT01352728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC028|Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib|A Phase II Study of Transarterial Chemoembolisation and Axitinib for the Treatment of Unresectable Hepatocellular Carcinoma||Chinese University of Hong Kong|No|Active, not recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352728||104742|
NCT01400906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114748|Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.|A Randomized, Double Blind, Placebo-controlled Three-way Crossover Study in Mild Asthmatics to Evaluate the Effect of Smoking Status on the Attenuation by Inhaled Corticosteroids of the Allergen-induced Asthmatic Response.||GlaxoSmithKline|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|36|||Both|18 Years|55 Years|No|||April 2014|September 24, 2015|July 21, 2011||No||No|July 18, 2013|https://clinicaltrials.gov/show/NCT01400906||101062|
NCT01401192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-006|Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression|A Randomized Phase II Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Non-squamous Non-small Cell Lung Cancer||Samsung Medical Center|No|Recruiting|July 2011|||December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|304|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401192||101040|
NCT01401205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-028|The Predictor of Respiratory Discomfort After the Shoulder Arthroscopic Surgery|The Predictor of Respiratory Discomfort After the Shoulder Arthroscopic Surgery as Measured by Upper Airway Ultrasonography||Samsung Medical Center|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|20 Years|70 Years|No|Non-Probability Sample|patients undergoing elective shoulder arthroscopic surgery (rotator cuff repair)|December 2013|December 24, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401205||101039|
NCT01401725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS150411|Electronic Strategies to Enhance Venous Thromboemboli (VTE) Prophylaxis in Hospitalized Medical Patients|Electronic Strategies to Enhance Venous Thromboprophylaxis in Hospitalized Medical Patients|E-SENTRY|McMaster University|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|600|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01401725||101000|
NCT01401738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100008|Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule|Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule||Taipei Medical University WanFang Hospital|No|Active, not recruiting|May 2011|May 2013|Anticipated|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|170|||Both|20 Years|N/A|No|Non-Probability Sample|Shoulder Arthroscopic Surgery patients|July 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401738||100999|
NCT01401699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000203|Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction|Optical Coherence Tomography Based Screening and Surveillance of Esophagus and Gastroesophageal Junction||Massachusetts General Hospital|No|Completed|September 2006|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|110|||Both|N/A|N/A|No|||August 2014|August 4, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401699||101002|
NCT01390051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110042|Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?|Can Treatment With Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?|IUGR|University of Aarhus|No|Recruiting|July 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|204|||Female|18 Years|N/A|No|||March 2012|June 9, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01390051||101894|
NCT01402596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP-Sed-001|Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam|Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam - a Randomized Controlled Trial||University of Sao Paulo|No|Withdrawn|August 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|0|||Both|1 Month|3 Years|No|||July 2011|June 19, 2013|July 19, 2011||No|Institution decided on starting a new protocol of sedation, with another methods and that´s    why this study has not started.|No||https://clinicaltrials.gov/show/NCT01402596||100933|
NCT01402609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeamDis2010|Efficacy of a Web-based Seamless Discharge Tool|Efficacy of a Web-based Seamless Discharge Tool||Ward of the 21st Century|No|Not yet recruiting|September 2011|September 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|1400|||Both|18 Years|N/A|No|||October 2010|July 25, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402609||100932|
NCT01402856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-20071204|Teenage Driving Safety Study: An Emergency Medicine-Trauma Collaborative Study|Teenage Driving Safety Study: An Emergency Medicine-Trauma Collaborative Study||Lehigh Valley Hospital|No|Active, not recruiting|November 2007|May 2012|Anticipated|May 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3750|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Students in the tenth, eleventh, and twelfth grades|July 2011|July 25, 2011|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01402856||100913|
NCT01402869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110172|Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics|Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Prilocaine Versus Lidocaine||Loma Linda University|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|91|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|July 25, 2011|Yes|Yes||No|October 15, 2013|https://clinicaltrials.gov/show/NCT01402869||100912|Did not compare locals anesthetics with equivalent concentrations of epinephrine; unable to control length of time methemoglobin blood levels were monitored as all subjects varied in extent of restorative dental procedures needed.
NCT01350102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-35832|The Relationship of Hemoglobin A1c and Diabetic Wound Healing|The Relationship of Hemoglobin A1c and Diabetic Wound Healing||Milton S. Hershey Medical Center|No|Terminated|February 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|May 4, 2011|Yes|Yes|study closed due to recruitment problems|No||https://clinicaltrials.gov/show/NCT01350102||104942|
NCT01350388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00044016|Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease|Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease||University of Utah|Yes|Completed|May 2011|||October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|April 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350388||104920|
NCT01350661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B07620109010|Correlation Between Five Asthma Control Questionnaires|Assessment of Correlation Between Five Asthma Control Questionnaires||Centre Hospitalier Universitaire Saint Pierre|No|Completed|June 2010|June 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients seen at the consultation of pulmonology of a tertiary hospital.|August 2015|August 7, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350661||104899|
NCT01351597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG008|A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer|An Open-label, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of Combination Chemotherapy With DoceTaxel(Detaxel) and Oxaliplatin(Oxalitin)in Recurrent or Metastatic Breast Cancer|STORM|Korean Breast Cancer Study Group|Yes|Recruiting|April 2011|September 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Female|20 Years|70 Years|No|||May 2011|May 10, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351597||104827|
NCT01352481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33278.078.10|Early Intervention in Very Preterm Children|Early Intervention for Speech Sound Disorder in Very Preterm Children||Erasmus Medical Center||Recruiting|April 2011|||April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|24 Months|27 Months|No|||May 2011|May 11, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352481||104761|
NCT01353027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6002-us-101|Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus|A Phase I Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6002 in Healthy Adult Volunteers||Sarepta Therapeutics|Yes|Completed|May 2010|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|May 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01353027||104719|
NCT01353274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1235.38|Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension|Survey on Drug Use of Micamlo Combination Tablets AP in Patients With Hypertension||Boehringer Ingelheim||Completed|May 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1157|||Both|N/A|N/A|No|Non-Probability Sample|1200|July 2014|July 30, 2014|May 9, 2011||||No|July 30, 2014|https://clinicaltrials.gov/show/NCT01353274||104700|
NCT01353287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERITAS|Transcatheter Aortic Valve Intervention-Live Transmission|Transcatheter Aortic Valve Intervention-Live Transmission (VERITAS)Study|VERITAS|Medstar Research Institute|Yes|Completed|May 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|Patients, male or female, over 18 years of age who have either undergone live case or        video-taped transmission of TAVI procedure (Case), or have undergone the procedure without        procedure transmission(Control).|July 2013|July 30, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353287||104699|
NCT01353261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIMING|Platelet Function Monitoring in Patients With Acute Myocardial Infarction|Platelet Function Monitoring in Patients With Acute Myocardial Infarction||Medstar Research Institute|No|Completed|December 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|Seventy five subjects (25 patients undergoing elective PCI for stable CAD and 50 patients        undergoing urgent PCI for AMI(25 receiving clopidogrel and 25 receiving prasugrel - as        determined by the treating physicians)|October 2013|October 31, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353261||104701|
NCT01400919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-5684|DURABILITY™ Iliac Study|Protege® EverFlex™ and GPS™ Self-Expanding Iliac Study (DURABILITY™ Iliac)||Medtronic Endovascular||Completed|July 2011|January 2016|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|July 21, 2011|Yes|Yes||No|June 8, 2015|https://clinicaltrials.gov/show/NCT01400919||101061|
NCT01400932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115288|Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects|Study STF115288, a Clinical Confirmation Study of GI148512 (Benzoyl Peroxide 3% Gel) in the Treatment of Acne Vulgaris in Japanese Subjects.- A Multicenter, Randomized, Double-blinded, Vehicle-controlled, Parallel-group Study -||GlaxoSmithKline|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|360|||Both|12 Years|45 Years|No|||May 2012|July 10, 2014|July 21, 2011||No||No|July 10, 2014|https://clinicaltrials.gov/show/NCT01400932||101060|
NCT01401491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95019|Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine|Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine||Taipei Medical University Hospital|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|No|||July 2011|July 21, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01401491||101017|
NCT01401712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001678|Optimal Method of Pain Management in Patients With Multiple Rib Fractures|Thoracic Epidural Analgesia Compared to Thoracic Paravertebral Pump Infusion for Pain Management in Patients With Three or More Rib Fractures||Massachusetts General Hospital|No|Recruiting|October 2012|October 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|96|||Both|18 Years|N/A|No|||October 2013|October 28, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401712||101001|
NCT01402323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK Nr 105/2011|Gingival Clefts and Orthodontic Movement|A Prospective Split-mouth Designed Study on the Incidence of Gingival Clefts During Orthodontic Space Closure Into Recent or Healed Extraction Sockets.||Medical University of Vienna||Recruiting|July 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|25|||Both|10 Years|N/A|Accepts Healthy Volunteers|||July 2011|May 19, 2014|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402323||100954|
NCT01390285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tenssens|Transcutaneous Electrical Nerve Stimulation in Relation to Central Sensitization in Osteoarthritis of the Knee|Effect of Transcutaneous Electrical Nerve Stimulation in Relation to Central Sensitization in Patients With Osteoarthritis of the Knee: a Randomized Controlled Clinical Trial.|TENSSENS|Vrije Universiteit Brussel|No|Not yet recruiting|February 2012|March 2014|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|50 Years|N/A|No|||April 2011|July 6, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01390285||101876|
NCT01402622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0361|The Effect of Total Intravenous Anesthesia With Propofol on Postoperative Nausea and Vomiting in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy|The Effect of Total Intravenous Anesthesia With Propofol on Postoperative Nausea and Vomiting in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy||Yonsei University|No|Completed|December 2010|June 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|93|||Male|50 Years|70 Years|No|||July 2011|July 25, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402622||100931|
NCT01402635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUEMS201101|Can the Point-Of-Care Chemistry Test (POCT) Solve the Emergency Department (ED) Crowding?|A Randomized Controlled Trial Comparing Central Laboratory and Point-of-care Chemistry Test for Solving the Emergency Department Crowding|POCTED|Seoul National University Hospital|Yes|Completed|January 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|10244|||Both|15 Years|N/A|No|||July 2012|July 22, 2012|January 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01402635||100930|
NCT01402921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00322 BC 402|Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema|Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema. International, Multicentric, Randomised, Controlled, Double Blind Study, in Two Parallel Groups v0322 bc Versus Placebo||Pierre Fabre Medicament|No|Recruiting|January 2011|||December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01402921||100908|
NCT01399281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU 260353|Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate|Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated With Biologic Agents and/or Methotrexate. A PRINTO/PRES Registry|PharmaChild|Istituto Giannina Gaslini|Yes|Recruiting|December 2011|December 2021|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|9000|||Both|6 Months|30 Years|No|Probability Sample|Male and female JIA patients selected among the PRINTO centres as part of the routine        standard of care|February 2016|February 29, 2016|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399281||101187|
NCT01402882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN15088122|Clinical Randomisation of an Antifibrinolytic in Significant Head Injury|Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial|CRASH-3|London School of Hygiene and Tropical Medicine|Yes|Recruiting|September 2011|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10000|||Both|16 Years|N/A|No|||September 2015|September 7, 2015|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402882||100911|
NCT01399515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH_OT_VPA|Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa||VPA_RP|Seoul National University Hospital|Yes|Active, not recruiting|March 2011|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||April 2013|April 17, 2013|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01399515||101169|
NCT01381016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0293|Estrogen Sensitivity and Ovulatory Dysfunction in Obesity|Estrogen Sensitivity and Ovulatory Dysfunction in Obesity||University of Colorado, Denver|No|Completed|June 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|June 22, 2011|Yes|Yes||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01381016||102585|
NCT01350115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225B2209|Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)|A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome||Novartis|No|Completed|April 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|May 6, 2011||No||No|August 18, 2015|https://clinicaltrials.gov/show/NCT01350115||104941|
NCT01350375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX0805|Safety and Efficacy Study of Botox in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder|A Randomized Double-Blind Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder||The Research Center of Southern California|No|Recruiting|September 2009|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A||||April 2011|May 6, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350375||104921|
NCT01351324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMW-BB/E021816/1|A Study of Different Types of Fatty Acid on Risk Factors for Heart Disease|Acute Elevation of Non-esterified Fatty Acids on Endothelial Function and Insulin Sensitivity: A Comparison of Saturated and Long Chain n-3 Polyunsaturated Fatty Acids During the Postprandial Phase|eFAIRE|University of Reading|No|Completed|March 2009|May 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|59|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2011|May 9, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01351324||104848|
NCT01352494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG009|Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer|A Multi-center Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Chemotherapy With DoceTaxel(Doxotel) and Gemcitabine(Gemcibine)in Locally Advanced Breast Cancer|NeoTG|Korean Breast Cancer Study Group|Yes|Not yet recruiting|May 2011|May 2015|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99|||Female|20 Years|70 Years|No|||May 2011|May 25, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01352494||104760|
NCT01352520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0914|SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)|Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)||M.D. Anderson Cancer Center|No|Recruiting|June 2011|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352520||104758|
NCT01352793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971014|A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years|A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years||Pfizer|Yes|Completed|November 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5715|||Both|10 Years|25 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|May 11, 2011|Yes|Yes||No|February 25, 2015|https://clinicaltrials.gov/show/NCT01352793||104737|
NCT01353053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056410|Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection|Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection||Federal University of São Paulo|No|Recruiting|July 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|82|||Both|18 Years|70 Years|No|Non-Probability Sample|A randomized study of 82 patients transplanted in first transplant recipients of deceased        donor and in line for kidney transplantation.|May 2010|May 11, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353053||104717|
NCT01353001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSD-UPitt|Effect of Weight Loss on Cardiovascular Disease Risk Factors in Obese Women|The Effect of Weight Loss and Exercise on Cardiovascular Disease Risk Factors in Class II and III Obese Women||University of Pittsburgh|No|Completed|April 2011|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|24|||Female|30 Years|55 Years|No|||January 2016|January 4, 2016|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353001||104721|
NCT01353014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AElSohemy|Genetic Information and Dietary Intake Behaviour|Genetic Information and Dietary Intake Behaviour||University of Toronto|Yes|Completed|May 2011|September 2012|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|138|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||June 2014|June 29, 2014|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01353014||104720|
NCT01353833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101101|Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes|Dose-effect Relationship of Repeated Administration of Low-dose IL-2 Versus Placebo on the Kinetic of Regulatory T Cells in Patients With Type 1 Diabetes|DF-IL2|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2011|April 2012|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|50 Years|No|||May 2011|April 20, 2012|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353833||104657|
NCT01400945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGSPT P3|Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease|Double Blinded, Randomized, Active Drug Comparative, Therapeutic Confirmatory Clinical Study to Evaluate the Efficacy and Safety of AGSPT201 in GERD Patients|AGSPT|Ahn-Gook Pharmaceuticals Co.,Ltd|Yes|Completed|December 2009|September 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|154|||Both|18 Years|75 Years|No|||September 2011|September 19, 2011|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400945||101059|
NCT01393899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921084|The Safety And Efficacy Of Maintenance Therapy With CP-690,550|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease||Pfizer|Yes|Completed|March 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|178|||Both|18 Years|75 Years|No|||September 2015|September 24, 2015|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393899||101599|
NCT01393912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJPDGF|PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma|Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma||St. Jude Children's Research Hospital|No|Active, not recruiting|July 2011|March 2017|Anticipated|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Months|21 Years|No|||October 2015|October 21, 2015|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393912||101598|
NCT01402024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/38/011/RS|Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy|A Study to Evaluate the Anti-emetic Effect of Aprepitant Versus Placebo as an Add-on Therapy in Children and Adolescent Receiving Chemotherapy: A Randomized, Doubly Blinded Controlled Trial|Aprepitant|All India Institute of Medical Sciences, New Delhi|Yes|Completed|August 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|96|||Both|5 Years|18 Years|No|||January 2015|January 16, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01402024||100977|
NCT01394172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018804|A Novel Method of Non-invasive Ventilation in Children|Non-invasive Ventilation Generated by External Chest Pressure in Children||University of Alberta|No|Completed|June 2011|February 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|This is a prospective, cohort study with a sample size of approximately 100 pediatric        patients. The population will be stratified equally into the following age groups: neonate        (0-28 days or 44 post-conceptual weeks), infants (>1-12 months), toddlers (>12months-3        years), children (>3-8 years), pre-teen (>8-13 years) and adolescent (>13 years).|August 2015|August 11, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01394172||101578|
NCT01402336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS_IVF|GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer|'A Multicentre, Prospective Randomized Study to Assess the Effect When GnRH Antagonist is Started Either on Stimulation Day 1 and Day 6 vs. Conventional GnRH Agonist Long Protocol in Patients With Polycystic Ovary Syndrome Undergoing IVF-ET||Seoul National University Hospital|Yes|Recruiting|June 2011|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|267|||Female|20 Years|40 Years|No|||November 2014|November 27, 2014|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01402336||100953|
NCT01390298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00017394|Pain and Function After Orthopedic Surgery|Pain and Function After Orthopedic Surgery||Wake Forest School of Medicine|No|Recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|Plasma|Both|18 Years|N/A|No|Probability Sample|Adult patients scheduled for elective unicompartmental, total knee replacement or total        hip replacement surgery, will be included. Patients will be American Society of        Anesthesiologists physical status 1, 2, or 3.|December 2015|December 8, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01390298||101875|
NCT01390597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000703260|Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms|The Molecular Mechanisms of Transformation in Peripheral T-cell and NK Lymphomas||National Cancer Institute (NCI)||Not yet recruiting|August 2011|||September 2011|Anticipated|N/A|Observational|N/A|||Anticipated|32|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390597||101852|
NCT01390259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14758|Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System|Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System|MDB005|University of Virginia|No|Completed|January 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|11|||Both|12 Years|18 Years|No|||July 2014|July 24, 2014|July 6, 2011|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01390259||101878|
NCT01398995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXQ404|Managing Insulin Pumps for Exercise (Study 2)|To Consider the Effect of the Timing of a Reduction in Basal Insulin Infusion Rate to 50% of Normal Prior to Exercise on Glycaemic Control in People With Type 1 Diabetes Treated With CSII||Buckinghamshire Healthcare NHS Trust|No|Terminated|May 2011|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|6|||Both|18 Years|65 Years|No|||July 2011|July 20, 2011|July 20, 2011||No|Recruitment was terminated due to elevated levels of hypoglycaemia|No||https://clinicaltrials.gov/show/NCT01398995||101209|
NCT01399008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M102-21123|Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in Combination With Allopurinol in Gout Patients With an Inadequate Hypouricemic Response to Allopurinol Alone||CymaBay Therapeutics, Inc.|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|July 13, 2011|Yes|Yes||No|March 20, 2014|https://clinicaltrials.gov/show/NCT01399008||101208|
NCT01390792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112316|Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)|Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)||GlaxoSmithKline|No|Completed|January 2007|May 2009|Actual|February 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|622|||Both|N/A|N/A||Probability Sample|<Zanamivir prophylactic administration group> Subjects meeting all of the following        criteria and starting prophylactic administration of zanamivir          -  family or persons living with patients with influenza virus infection          -  subjects meeting any of the following criteria, elderly subjects ( 65 years old and             over), subjects with chronic cardiac disease, with metabolic disease (diabetes, etc.)             or with renal dysfunction          -  unvaccinated persons during the applicable seasons          -  subjects whose consent to write influenza diary was obtained        <Non-zanamivir prophylactic administration group>        - subjects meeting all of the above criteria and NOT starting prophylactic administration        of zanamivir|July 2011|July 14, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390792||101837|
NCT01390805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112319|Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)|Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)||GlaxoSmithKline|No|Completed|November 2006|March 2011|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|462|||Both|N/A|N/A|No|Probability Sample|Japanese subjects with recurrent genital herpes|July 2011|July 14, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390805||101836|
NCT01390818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200066-006|Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy With MSC1936369B and SAR245409 in Subjects With Locally Advanced or Metastatic Solid Tumors||EMD Serono|Yes|Completed|May 2011|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|April 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390818||101835|
NCT01349816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003004|PT003 MDI Dose Confirmation Study|A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls||Pearl Therapeutics, Inc.|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|185|||Both|40 Years|80 Years|No|||May 2013|May 23, 2013|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349816||104964|
NCT01351025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5275|Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells|A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL||AIDS Clinical Trials Group|Yes|Completed|April 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|November 8, 2010||No||No|May 1, 2015|https://clinicaltrials.gov/show/NCT01351025||104871|
NCT01352143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048151|Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass|Measurements of Thrombin Generation in Response to Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Neonatal Plasma After Cardiopulmonary Bypass||Emory University|Yes|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|24|Samples Without DNA|Blood samples only|Both|N/A|30 Days|No|Non-Probability Sample|Neonates (less than 30 days of age) undergoing complex congenital cardiac surgery        requiring cardiopulmonary bypass|November 2013|November 19, 2013|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01352143||104785|
NCT01352533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU38040|Closure Techniques and Scar Appearance|A Randomized Prospective Trial of 2-Octyl Cyanoacrylate (Derma-Bond) Tissue Adhesive Versus Running Subcuticular Suture Combined With Tissue Adhesive Versus Epidermal Sutures in Dermatologic Surgery Procedures of the Head and Neck||Northwestern University|Yes|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 28, 2015|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01352533||104757|
NCT01352546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTX-PV-01|Botox Injection for Treatment of Vaginismus|Open Label, Single Center, Pilot Study of the Use of BOTOX Injections, Sensorcaine Injections and Progressive Dilation Under Anesthesia for the Treatment of Primary Vaginismus||Plastic Surgery Professional Association|Yes|Completed|August 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 8, 2012|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352546||104756|
NCT01353079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLIT10-01|Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy|Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen||Greer Laboratories|No|Completed|April 2011|April 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|429|||Both|18 Years|55 Years|No|||January 2015|January 22, 2015|May 11, 2011|Yes|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01353079||104715|
NCT01352767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-PP-002|The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device|A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases||Insuline Medical Ltd.|No|Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||May 2012|September 4, 2014|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352767||104739|
NCT01352780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OsloUHBHR|Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters|Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters||Oslo University Hospital|Yes|Active, not recruiting|September 2011|June 2016|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|169|||Both|20 Years|70 Years|No|||October 2014|May 28, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352780||104738|
NCT01353547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p002561|Genes and Environment in Multiple Sclerosis|Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility|GEMS|Brigham and Women's Hospital|Yes|Recruiting|March 2010|March 2020|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|5000|Samples With DNA|Saliva Sample (required), Blood Sample (optional)|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|This large research study will ultimately enroll over 5000 subjects who are at risk of        developing MS. The study will last 20 years. We will recruit subjects from all over the        United States, as everything is done via mail, email, or/and phone.|January 2016|January 26, 2016|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353547||104679|
NCT01353300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN11B2|Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer|Investigation of DICER1 in Cystic Nephroma and Cystic Partially Differentiated Nephroblastoma||Children's Oncology Group|No|Active, not recruiting|May 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|31|||Both|N/A|120 Years|No|Non-Probability Sample|Patients with a diagnosis of pleuropulmonary blastoma syndrome.|May 2015|September 30, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353300||104698|
NCT01401218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-077|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Thoracic Aortic Surgery|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Thoracic Aortic Surgery||Samsung Medical Center|No|Completed|July 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|799|||Both|20 Years|N/A|No|Non-Probability Sample|patients who underwent thoracic aortic surgery durung 1994 to 2010 period|December 2013|December 24, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401218||101038|
NCT01401231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U19MH092201|Behavioral Activation for Perinatal Depression|Pilot Trial of Behavioral Activation Psychotherapy for Perinatal Depression||Group Health Cooperative|No|Active, not recruiting|August 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||August 2013|August 15, 2013|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401231||101037|
NCT01393925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FirstSunYetSen|Effect of Parecoxib on Postoperative Shoulder Pain After Gynecological Laparoscopy.|||First Affiliated Hospital, Sun Yat-Sen University|Yes|Completed|July 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|126|||Female|18 Years|65 Years|No|||November 2011|November 19, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393925||101597|
NCT01394185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00041251|Effects of Dronabinol (Oral THC) on Cannabis Use|Effects of Dronabinol (Oral THC) on Cannabis Use||Johns Hopkins University|No|Completed|February 2011|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 11, 2012|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01394185||101577|
NCT01402349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rhino-2010|Chronic Rhinosinusitis in a Danish Population: Evaluation of Causes of Disease, Progress and Treatment|Chronic Rhinosinusitis in a Danish Population: Evaluation of Causes of Disease, Progress and Treatment||Odense University Hospital|No|Completed|April 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5000|Samples With DNA|Blodsamples.|Both|18 Years|75 Years|No|Non-Probability Sample|As part of Ga2len (Global Asthma and Allergy European Network) a questionnaire on CRS was        posted to 5000 residents on Funen. From the completed and returned questionnaires self        reported CRS was evaluated. Respondents were invited for clinical examination. Patients        diagnosed with CRS were invited for a 1 year and 2 year follow up.|July 2011|August 1, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402349||100952|
NCT01402362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56-2011|Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study.|||Hillel Yaffe Medical Center||Not yet recruiting|September 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|25 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ethiopian immigrants to Israel living in Hadera.|June 2011|July 25, 2011|July 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01402362||100951|
NCT01390272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-383|Titrated Disease Management for Patients With Hypertension|Randomized Trial of Titrated Disease Management for Patients With Hypertension|TDM|VA Office of Research and Development|No|Active, not recruiting|July 2012|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01390272||101877|
NCT01390558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gait Parameters Down Syndrome|Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite|Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite||Oregon Health and Science University|Yes|Recruiting|June 2011|June 2020|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|2 Years|80 Years|No|Non-Probability Sample|Persons with Down Syndrome followed in Down Syndrome clinic Persons with Down Syndrome        recruited in the community|June 2011|November 6, 2014|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01390558||101855|
NCT01390532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0096|Rest/Stress Quantification Of Left Ventricular Dyssynchrony By 3D Gated Blood Pool D-SPECT|Left Ventricular Dyssynchrony: Rest/Stress 3D Blood-Pool Gated D-SPECT Quantification With a High-Speed Dedicated Cardiac Camera Before CRT||University Hospital, Clermont-Ferrand||Recruiting|August 2010|October 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|N/A|N/A|No|||July 2011|July 8, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390532||101857|
NCT01350401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP 01611|Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma|Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells Against Cancer-testis Antigens in Metastatic Melanoma||Adaptimmune|Yes|Recruiting|May 2011|May 2031|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|May 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01350401||104919|
NCT01350674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B07620109427|Role of EBUS-TBNA in Diagnosing TB in Mediastinal/Hilar Lymph Nodes|Role of EBUS-TBNA (Endobronchial Ultrasound Transbronchial Needle Aspiration- in Diagnosing Tuberculosis in Mediastinal and/or Hilar Lymph Nodes||Centre Hospitalier Universitaire Saint Pierre|No|Recruiting|December 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01350674||104898|
NCT01349829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA-V-A008|A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children|A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule||Crucell Holland BV|No|Completed|March 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|251|||Both|18 Months|47 Months|Accepts Healthy Volunteers|||August 2013|October 25, 2013|May 5, 2011||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01349829||104963|
NCT01350687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|farid.CTIL|Pulmonary Hypertension Prevention in Hemodialysis|New Phosphore Binders in Prevention of Pulmonary Hypertension||The Baruch Padeh Medical Center, Poriya|No|Not yet recruiting|June 2011|June 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|70 Years|No|Non-Probability Sample|40 patients on hemodialysis treated with Phosphore biders, non-calcium containig.|April 2011|May 9, 2011|May 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01350687||104897|
NCT01351623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-228|Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma|Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma||Memorial Sloan Kettering Cancer Center||Completed|May 2011|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|May 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01351623||104825|
NCT01351857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTN1102|Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes|Multicentre Randomized Controlled Trial of Structured Transition on Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes|TransClin|University of Western Ontario, Canada|Yes|Active, not recruiting|April 2012|April 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|17 Years|20 Years|No|||June 2015|June 1, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01351857||104807|
NCT01352182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIOSEPSIS1217|Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock|Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|October 2011|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|21|||Both|N/A|N/A|No|||January 2016|January 26, 2016|February 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01352182||104784|
NCT01352507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14035|A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China|An Evaluation of Tadalafil and Sildenafil Treatment in Men With Erectile Dysfunction in China||Eli Lilly and Company|No|Completed|June 2011|July 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|383|||Male|18 Years|65 Years|No|||March 2013|March 13, 2013|May 10, 2011|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT01352507||104759|
NCT01352559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001-11-03|Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype|Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype||Samsung Medical Center|Yes|Active, not recruiting|November 2001|December 2018|Anticipated|March 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|19 Years|89 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01352559||104755|
NCT01353092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26.04.2010|Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression|PEMF Treatment in Patients With Treatment Resistant Depression in On-going Antidepressant Drug Therapy. A Randomized, Double-blind, Clinically Controlled, Dose-response PEMF Trial for a Duration of Eight Weeks|PEMFII|Hillerod Hospital, Denmark|Yes|Completed|April 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|85 Years|No|||August 2015|August 25, 2015|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01353092||104714|
NCT01353066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCB-UOM-012011|Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM)|Multicenter Randomized Prospective Trial on the Effects of Intensive Medical Treatment of Type 2 Diabetes With and Without Roux-in-Y Gastric Bypass Surgery on Carotid Intima Media Thickness in Grade I Obesity (BMI 30,0-34,9 kg/m2)|EURDSS|Hospital Clinic of Barcelona||Not yet recruiting||||||Phase 2/Phase 3|Interventional|Primary Purpose: Treatment|2||Anticipated|240|||Both|35 Years|65 Years||||May 2011|May 11, 2011|May 11, 2011||||No||https://clinicaltrials.gov/show/NCT01353066||104716|
NCT01353313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0045|Hydrocortisone for BPD|A Randomized Controlled Trial of the Effect Of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age||NICHD Neonatal Research Network|Yes|Recruiting|September 2011|December 2018|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|800|||Both|N/A|30 Weeks|No|||July 2015|July 21, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01353313||104697|
NCT01353040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6003-us-101|Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6003 in Healthy Adult Volunteers||Sarepta Therapeutics|Yes|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|April 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01353040||104718|
NCT01353859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25536|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs|An Open Label, Local, Multicenter , Phase IIIb Interventional Study to Assess the Efficacy of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) in Indonesian Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs||Hoffmann-La Roche||Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|May 13, 2011|No|Yes||No|April 22, 2014|https://clinicaltrials.gov/show/NCT01353859||104655|
NCT01353872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00724-35|Nutrition Effects on Fatigue During Tennis Playing|Effects of Ingestion of Different Sports Drinks on Fatigue During Playing Tennis||Lescuyer Laboratory|Yes|Completed|October 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2011|May 13, 2011|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01353872||104654|
NCT01401751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3076823|Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting|Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting||Animas Corporation|No|Completed|July 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 23, 2012|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401751||100998|
NCT01401764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2271022|Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjects|Randomized, Double Blind, Crossover, Single Centre Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjects||Ablynx|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01401764||100997|
NCT01389544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25644|A Study on the Interaction Between Danoprevir/Ritonavir and Methadone|Investigation of the Effect of Multiple Doses of Danoprevir/Ritonavir on Methadone in Subjects on Stable Methadone Maintenance Therapy (MMT)||Hoffmann-La Roche||Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389544||101932|
NCT01394198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101123-001|Correlation of Somatic Dysfunction With Gastrointestinal Endoscopic Findings|Correlation of Somatic Dysfunction With Gastrointestinal Endoscopic Findings||A.T. Still University of Health Sciences|No|Completed|March 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|70|||Both|21 Years|N/A|No|Non-Probability Sample|Patients who are 21 years of age or older, of the Kirksville College of Osteopathic Family        Medicine Clinic, and are scheduled for upper or lower endoscopy based on clinical        symptomology or for routine screening based on age or risk factors.|June 2011|January 7, 2014|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01394198||101576|
NCT01389765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12620|A Study to Evaluate the Effect of Food on LY2216684|Effect of Food on the Pharmacokinetics of LY2216684 in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|July 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01389765||101915|
NCT01390064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110396|Vaccination of High Risk Breast Cancer Patients|Phase 1 Safety Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDE ISA 51 VG Adjuvant||University of Arkansas|Yes|Active, not recruiting|July 2011|February 2021|Anticipated|February 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|June 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390064||101893|
NCT01390623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0098|Efficacy and Safety Study of Short-term Antibiotic for Pyelonephritis in Women|Efficacy and Safety Study of Short Term Antibiotic During Seven Days With Ceftriaxone Intravenous the First Day Then Cefixime the Second Day Till the Seventh Day of Acute Uncomplicated Pyelonephritis in Women Between 18 and 65 Years Old||University Hospital, Clermont-Ferrand||Completed|July 2011|December 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|65 Years|No|||July 2014|July 4, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390623||101850|
NCT01390636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04126-11-C|Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns|Characterizing Diurnal Glucose Patterns of Individuals With Type 1 Diabetes and Eating Disorders|REACT5|HealthPartners Institute|No|Terminated|July 2011|May 2013|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|1|||Female|14 Years|N/A|No|Non-Probability Sample|Current Melrose Institute Patient|August 2013|November 25, 2015|June 29, 2011||No|The study was a collaboration that could not be effectively run.|No||https://clinicaltrials.gov/show/NCT01390636||101849|
NCT01390571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000702605|Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma|A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma||Cancer Research UK||Recruiting|July 2011|||May 2017|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390571||101854|
NCT01390584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000702859|Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma|Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)||National Cancer Institute (NCI)||Recruiting|April 2012|||June 2021|Anticipated|Phase 2|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|200|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390584||101853|
NCT01390896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112797|Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery|Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery||GlaxoSmithKline|No|Completed|September 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|329|||Both|N/A|N/A|No|Probability Sample|Japanese patients undergoing general surgery of the lower limb at high risk for venous        thromboembolism|July 2014|July 24, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390896||101829|
NCT01390545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VT-4001-001-SP|VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis|VELVET (Veltuzumab Various Doses Exploratory Trial), a Randomized, Double Blind, Placebo Controlled, Multicentre, Multinational Phase II Dose Range Finding Trial in Subjects With Moderate to Severe Rheumatoid Arthritis Insufficiently Controlled With Either Methotrexate Alone or Methotrexate Plus Anti-tumour Necrosis Factor Biological Treatment, Comparing 3 Different Subcutaneous Dosages of Anti-CD20 Monoclonal Antibody Veltuzumab to Placebo as an add-on Therapy to Methotrexate.|VELVET|Takeda||Terminated|August 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|300|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|July 5, 2011|Yes|Yes|Trial re-design; no safety issues identified|No||https://clinicaltrials.gov/show/NCT01390545||101856|
NCT01351337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07QA14008|Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area|Clinical Efficiency of Motor Pathway Mapping Using Diffusion Tensor Imaging Tractography and Intraoperative Subcortical Stimulation in Cerebral Glioma Surgery||Huashan Hospital|Yes|Completed|October 2008|February 2013|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|58|||Both|6 Years|75 Years|No|||April 2015|April 4, 2015|May 9, 2011||No||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01351337||104847|The imaged motor pathway was reconstructed based on pre-opimages. An additional study that integrates real-time DTI tractography with high-field intraoperative MRI and DsCS for eloquent cerebral glioma surgery is currently underway in our department.
NCT01351610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC_Apceth_001|Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia|Open, Randomized, Mono-Centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous Infusion of Human Bone Marrow Derived Autologous, CD34-Negative Mesenchymal Stem Cells for the Treatment of Critical Limb Ischemia in Patients With Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty||Apceth GmbH & Co. KG|Yes|Completed|March 2011|October 2015|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|80 Years|No|||December 2015|December 14, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01351610||104826|
NCT01351870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC2003-06|Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma|A Prospective Randomised Controlled Trial of Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma|SIOP-PNET-4|Institut Curie|Yes|Active, not recruiting|April 2004|December 2016|Anticipated|December 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|4 Years|22 Years|No|||January 2004|May 10, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351870||104806|
NCT01352195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15724|Extended Self-Help for Smoking Cessation|Extended Self-Help for Smoking Cessation||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|January 2009|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352195||104783|
NCT01352806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039910-HMO-CTIL|Identification of the Lumbar Interspinous Spaces; Palpation Versus Ultrasound Versus Fluoroscopy|Identification of the Lumbar Interspinous Spaces; Palpation Versus Ultrasound Versus Fluoroscopy||Hadassah Medical Organization|No|Not yet recruiting|September 2011|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|N/A|No|||April 2011|May 11, 2011|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01352806||104736|
NCT01353326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008058-01H|Bone Mineral Density (BMD) in Cemented Versus Cementless Hip Resurfacing|Randomized Clinical Trial of a Cemented Versus Cementless Femoral Component for Metal on Metal Hip Resurfacing Assessing Bone Mineral Density||Ottawa Hospital Research Institute|No|Completed|May 2009|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|September 30, 2009||No||No||https://clinicaltrials.gov/show/NCT01353326||104696|
NCT01353573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNG-001|Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases|A Randomized Trial of Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases|TRICK|Hamilton Health Sciences Corporation|No|Not yet recruiting|July 2011|July 2013|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2011|May 12, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01353573||104677|
NCT01353885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Depuy-05072|Outcomes Following Anterior Approach to Total Hip Arthroplasty|Outcomes Following Anterior Approach to Total Hip Arthroplasty: A Multi-Centre Observational Cohort Study|AAP|McMaster University|No|Terminated|February 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Men or women who are 18 years of age or older with a primary diagnosis of hip arthritis        (radiographically and clinically). Patients must be undergoing an unilateral THA and have        had no previous major hip surgery (hip arthroscopy is permitted) or hardware implanted in        their hip.|August 2014|August 12, 2014|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353885||104653|
NCT01393548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-DCN-03(03/10)|Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis|Multicenter Clinical Trial, Phase III, Randomized, Open, Parallel Group, Comparative for Evaluate the Efficacy and Safety of Fixed Dose Combinations of Brompheniramine Maleate + Phenylephrine Chlorhydrate in Different Dosage Forms Versus Fixed Dose Combination of Reference for the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis (Common Cold) and Allergic Reactions, in Patients From 2 to 12 Years Old||Ache Laboratorios Farmaceuticos S.A.|No|Recruiting|August 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|538|||Both|2 Years|12 Years|No|||March 2016|March 15, 2016|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01393548||101626|
NCT01393561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-DCN-03(04/10)|Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis|Multicenter Clinical Trial, Phase III, Randomized, Double-blind, Placebo Controlled, Comparative for Evaluate the Efficacy and Safety of Fixed Dose Combination of Brompheniramine Maleate + Phenylephrine Chlorhydrate for the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis (Common Cold) and Allergic Reactions, in Patients Over 12 Years Old||Ache Laboratorios Farmaceuticos S.A.|No|Completed|July 2014|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|167|||Both|12 Years|N/A|No|||March 2016|March 15, 2016|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01393561||101625|
NCT01389557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45114-2|Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra|Evaluation of Impact Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lempasing Village, Lampung Province, Southern Sumatra||Indonesia University|No|Completed|February 2011|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|77|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|March 22, 2012|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389557||101931|
NCT01389778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002945|Polycystic Ovary Syndrome Genetics and Treatment Response|Polycystic Ovary Syndrome Genetics and Treatment Response||Massachusetts General Hospital|Yes|Active, not recruiting|June 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|40 Years|No|||October 2015|October 5, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389778||101914|
NCT01390077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WLN02|Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria|Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria||University of California, San Diego|No|Active, not recruiting|January 2011|June 2021|Anticipated|January 2021|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|N/A|No|||November 2013|November 8, 2013|July 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390077||101892|
NCT01391208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54 #CA136429|Esophageal Protocol for Detection of Neoplasia in the Digestive Tract|A Phase I In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract||University of Michigan|Yes|Completed|February 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||October 2012|October 10, 2012|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391208||101805|
NCT01390909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113917|Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database|Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database||GlaxoSmithKline|No|Completed|May 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||6|Actual|12386|||Both|18 Years|N/A|No|Non-Probability Sample|The electronic records from adult patients with epilepsy who are enrolled in Medicaid in        Florida, Iowa, Kansas, Missouri or New Jersey or in a private health plan database.        Patient records will be classified into one of three mutually-exclusive cohorts:        uncontrolled epilepsy, well-controlled epilepsy, and intermediate epilepsy (not classified        as uncontrolled or well-controlled).|June 2012|October 4, 2012|July 7, 2011||No||No|October 13, 2011|https://clinicaltrials.gov/show/NCT01390909||101828|
NCT01390870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112597|Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence|Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence||GlaxoSmithKline|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|400|||Male|50 Years|N/A|No|Non-Probability Sample|Inclusion criteria:          -  Physician confirmed diagnosis of enlarged prostate (EP)          -  Age 50 or older          -  Resident of the United States with health insurance that covers prescription drugs          -  EP is consistently treated with a medication that was intiated within the previous 12             months        Exclusion criteria          -  age less than 50          -  receiving medication on an as needed basis          -  diagnosis of prostate cancer|June 2011|February 16, 2012|April 14, 2011||No||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01390870||101831|
NCT01390883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112721|Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)|Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)||GlaxoSmithKline||Completed|December 2008|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|475|||Both|N/A|N/A|No|Probability Sample|Japanese patients undergoing abdominal surgery in urology, obstetrics and gynecology        departments who are at high risk of venous thromboembolism|March 2015|March 26, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390883||101830|
NCT01351064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICA_ADHD_Study|Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)|Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)||Indiana University|No|Completed|July 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|84|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||December 2015|December 18, 2015|May 9, 2011||No||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01351064||104868|
NCT01351350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INK128-003|Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies|A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies||Millennium Pharmaceuticals, Inc.|No|Completed|March 2011|May 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|February 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01351350||104846|
NCT01351636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSPC-ALM-1101|Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients|Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients: An Open Labelled, Randomized, Multicentered, Controlled Trial|AHOCEP|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|Yes|Active, not recruiting|April 2011|September 2018|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01351636||104824|
NCT01351883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-98-089|Enteric Immune-nutrition Formula (ANOM®) for Patients Receiving Major Upper Gastrointestinal Surgery|Peri-operative Usage of Enteric Immune-nutrition Formula (ANOM®) Versus Standard Formula for Patients Received Major Upper Gastrointestinal Surgery|ANOM|National Cheng-Kung University Hospital|Yes|Recruiting|January 2010|December 2011|Anticipated|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|64|||Both|18 Years|80 Years|No|||May 2011|May 10, 2011|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01351883||104805|
NCT01352208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9521-CL-0002|Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients|Phase I/II, Multi-center, Open Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of ASP9521 in Patients With Metastatic Castrate-resistant Prostate Cancer||Astellas Pharma Inc|No|Terminated|March 2011|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|N/A|No|||December 2012|March 21, 2014|April 14, 2011||No|It was decided to discontinue the development in consideration of the results of a P1 study|No||https://clinicaltrials.gov/show/NCT01352208||104782|
NCT01352221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST10-01-302|Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)|A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Crohn's Disease Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 2)|AEGIS-2|Iron Therapeutics|No|Active, not recruiting|August 2011|November 2014|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352221||104781|
NCT01352819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-09-036-EU-DB|Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study|A Post Market Clinical Evaluation of Deep Brain Stimulation as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-responsive Parkinson's Disease That Are Not Adequately Controlled With Medication||St. Jude Medical||Completed|May 2011|December 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|80 Years|No|Non-Probability Sample|Libra™/LibraXP™ DBS System Eligible subjects in this study will be screened to confirm        that they meet the strict guidelines for advanced, levodopa-responsive Parkinson's disease        that are not adequately controlled with medication followed by surgery to implant the        Libra™/LibraXP™ deep brain simulation system.|August 2015|August 6, 2015|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01352819||104735|
NCT01353339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MOP 222493, 2010-292|Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study|Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study||Ottawa Hospital Research Institute|Yes|Completed|November 2011|October 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|154|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353339||104695|
NCT01353352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-86709|Evaluation of the Nursing C-Spine (Phase IV)|Evaluation of the Safety of C-Spine Clearance by Emergency Department Triage Nurses (Phase IV)||Ottawa Hospital Research Institute|Yes|Completed|January 2008|August 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3633|||Both|16 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 12, 2011|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01353352||104694|
NCT01353365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-09/CTIL|Surfactant Associated Protein - A Novel Marker for the Diagnosis of Pulmonary Embolism|Surfactant Associated Protein - A Novel Marker for the Diagnosis of Pulmonary Embolism||Rambam Health Care Campus|No|Not yet recruiting|June 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with PE at ER and Internal B department at the Rambam Medical Center|April 2011|May 12, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353365||104693|
NCT01353599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01349|Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury|Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury||James J. Peters Veterans Affairs Medical Center|No|Active, not recruiting|August 2011|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||October 2015|October 22, 2015|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353599||104675|
NCT01353586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFCC-133|REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation|REVOLUTION (WFCC-133): Clinical Workflow Study for the Evaluation of the Multi-Electrode Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation (PAF)|REVOLUTION|Biosense Webster, Inc.|Yes|Completed|March 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|186|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|May 12, 2011|Yes|Yes||No|September 20, 2015|https://clinicaltrials.gov/show/NCT01353586||104676|
NCT01353898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1972-003|Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1972 in HIV-1 Infected Patients||Merck Sharp & Dohme Corp.|No|Terminated|June 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|12|||Male|18 Years|55 Years|No|||January 2016|January 6, 2016|May 12, 2011|No|Yes||No|January 6, 2016|https://clinicaltrials.gov/show/NCT01353898||104652|
NCT01349712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOB 0158|Study to Test the Accuracy of a Prototype Handheld PT/INR Device|Correlation of Feasibility Batches Using Warfarinised Blood||Universal Biosensors Pty Ltd|No|Enrolling by invitation|May 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects currently receving coumadin(warfarin) treatment|May 2011|May 5, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01349712||104972|
NCT01349725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-502-102|A Safety Study of ARRY-502 in Healthy Subjects|||Array BioPharma|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 19, 2011|May 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01349725||104971|
NCT01393574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83/11|Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties|Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties||Assaf-Harofeh Medical Center|No|Recruiting|June 2011|||June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|6 Years|18 Years|No|||July 2011|July 12, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393574||101624|
NCT01393587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIC-2011|A New Exogenous Marker for Diagnosis of Oxidative Stress During Laproscopic Surgery|A New Exogenous Marker for Diagnosis of Oxidative Stress During Laproscopic Surgery||Western Galilee Hospital-Nahariya||Not yet recruiting||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 17, 2012|July 12, 2011||||No||https://clinicaltrials.gov/show/NCT01393587||101623|
NCT01393600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1101|NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Cross-Over Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder||Neurocrine Biosciences|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|65 Years|No|||May 2013|May 7, 2013|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393600||101622|
NCT01389791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg priming|MgSO4 Combined With Rocuronium Priming|MgSO4 Combined With Rocuronium Priming||Seoul National University Bundang Hospital|Yes|Recruiting|May 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|65 Years|No|||January 2012|January 6, 2012|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01389791||101913|
NCT01390363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01-0025|Study of Adolescent Immunization Recall Systems|Adolescent Immunization Recall Systems: A Randomized Controlled Trial||Children's Hospital Boston|No|Active, not recruiting|May 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|420|||Female|13 Years|17 Years|No|||July 2011|July 7, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390363||101870|
NCT01390922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114880|Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)|Special Drug Use Investigation for Botox® (Botulinum) Spasticity||GlaxoSmithKline|No|Completed|August 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1038|||Both|N/A|N/A|No|Probability Sample|Japanese subjects with upper or lower limb spasticity who are treated with botulinum        injection for the first time|March 2015|March 26, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390922||101827|
NCT01391507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100913|Pilot Study of COR-1 in Heart Failure|COR-1, an Anti-Beta1 Receptor Antibody Cyclopeptide in Heart Failure: a Phase II, Multicentre, Randomised, Double-Blind and Placebo-Controlled Study With Parallel Groups||Corimmun GmbH|Yes|Completed|October 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|75 Years|No|||October 2014|October 8, 2014|July 4, 2011||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT01391507||101782|Due to the decision to amend protocol to a pilot study coupled with the high study agent discontinuation rate, safety or efficacy of JNJ-54452840 could not be concluded due to the insufficient sample size and drug exposure to investigational agent.
NCT01391195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE - 0100.0.135.000-05|Effects of Low Level Laser Therapy (808nm) on Muscle Performance of Young Women Submitted to Physical Training|Effects of Low Level Laser Therapy (808nm) on Muscle Performance of Young Women Submitted to Physical Training||Universidade Federal de Sao Carlos|Yes|Completed|January 2006|October 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Female|18 Years|28 Years|Accepts Healthy Volunteers|||December 2005|July 12, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391195||101806|
NCT01351363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHLDR1|Prediction Of Post Operative Pain Following Arthroscopic Shoulder Surgery|PREDICTION OF POST OPERATIVE PAIN FOLLOWING ARTHROSCOPIC SHOULDER SURGERY||NHS Fife|No|Completed|March 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|43|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 9, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351363||104845|
NCT01351649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HL090705|Middle School Physical Activity Intervention for Girls|Middle School Physical Activity Intervention for Girls||Michigan State University|Yes|Completed|April 2009|June 2011|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Female|10 Years|14 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351649||104823|
NCT01351909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02590|Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer|Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer||National Cancer Institute (NCI)||Recruiting|May 2011|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||December 2015|March 11, 2016|May 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01351909||104803|
NCT01352572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-09-08|Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients|Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients||Samsung Medical Center|Yes|Active, not recruiting|January 2002|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01352572||104754|
NCT01353118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUCOSURG 2|The Effects of Glycemic Optimization Before Gastric Bypass Surgery|Investigation of the Effects of Glycaemic Optimisation Before Gastric Bypass Surgery on the Glycaemic Remission and Microvascular Complication Rates of Type 2 Diabetes Mellitus|GLUCOSURG2|Imperial College London|Yes|Active, not recruiting|May 2011|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|70 Years|No|||February 2016|February 25, 2016|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353118||104712|
NCT01353378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JYMZK-001|Use of Dexmedetomidine in Children Undergoing Oral Maxillofacial Surgery to Decrease Emergence Delirium|Use of Dexmedetomidine in Children Undergoing Oral Maxillofacial Surgery to Decrease Emergence Delirium||Shanghai 9th People's Hospital|Yes|Withdrawn|June 2011|December 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|90|||Both|3 Years|8 Years|Accepts Healthy Volunteers|||April 2011|August 2, 2011|April 21, 2011|Yes|Yes|The study was not approved by Hospital's Medical Ethics Committee considering    dexmedetomidine's indication range.|No||https://clinicaltrials.gov/show/NCT01353378||104692|
NCT01353950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007132|Costimulatory Molecules as Biomarkers in Cystic Fibrosis|Costimulatory Molecules as Biomarkers in Cystic Fibrosis||Oregon Health and Science University|No|Recruiting|July 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|Plasma, Serum, urine|Both|18 Years|80 Years|No|Non-Probability Sample|Adults with Cystic Fibrosis|July 2011|July 19, 2011|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353950||104648|
NCT01353612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN-003|Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes|Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes||Canadian Atherosclerosis Imaging Network|No|Active, not recruiting|January 2010|March 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|samples stored for potential correlation with imaging and cardiovascular outcomes endpoints      in subset of patients (optional)|Both|18 Years|N/A|No|Non-Probability Sample|Patients with clinical indication for coronary angiography|January 2015|February 2, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353612||104674|
NCT01353911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-003|Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)|A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection||Merck Sharp & Dohme Corp.|Yes|Completed|June 2011|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|368|||Both|18 Years|N/A|No|||December 2015|February 3, 2016|May 12, 2011|Yes|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01353911||104651|
NCT01349738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB in Transplants|Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants|Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants|ASB|Rice, James C., M.D.|Yes|Enrolling by invitation|May 2011|May 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|The investgators have a repository of bacteria specimens from transplant patients with UTI      and plan to save bacteria from this study. The investigators will also plan to save      discarded aliquots of supernatent of urine and discarded aliquots of blood, all samples from      centrifuged specimens devoid of human cells.|Both|18 Years|N/A|No|Probability Sample|Kidney Transplant Patients|August 2011|August 31, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01349738||104970|
NCT01349998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-1005|Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis|An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris||Tinea Pharmaceuticals|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|604|||Both|12 Years|N/A|No|||January 2013|January 22, 2013|May 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01349998||104950|
NCT01393938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN090691BE2010|Comparison of MRI Versus Three Dimensional Ultrasound in the Diagnosis of Mullerian Duct Anomalies|Comparison of MRI Versus Three Dimensional Ultrasound in the Diagnosis of Mullerian Duct Anomalies|MDA-3DUS|University Health Network, Toronto|No|Terminated|April 2010|February 2013|Actual|January 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Female|16 Years|N/A|No|||January 2015|January 6, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01393938||101596|
NCT01393951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7374-CL-0101|A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers|Study for Immunogenicity and Safety of ASP7374 for Subcutaneous and Intramuscular Vaccination in Healthy Adults||Astellas Pharma Inc|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|165|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01393951||101595|
NCT01392053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR259127|Massage for Pain Relief During the Active Phase of Labor|Assessment of the Effects of Massage Pain Relief in Nulliparous Women During the Active Phase of Labor||University of Sao Paulo|Yes|Completed|September 2009|July 2011|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|46|||Female|15 Years|30 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|July 11, 2011||No||No|May 16, 2012|https://clinicaltrials.gov/show/NCT01392053||101740|The influence of the pain of other women in labor or under the effect of childbirth analgesia; Accompanying with no physical or emotional preparation; Brazilian culture, which associates pain with suffering.
NCT01392066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDU-NFK-FK-2011|Psychosocial Adjustment of Patients and Their Partners Following Breast Cancer Diagnosis|Psychosocial Adjustment of Patients and Their Partners Following Breast Cancer Diagnosis. A Prospective Cohort Study.||University of Southern Denmark|No|Completed|July 2011|October 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1584|||Both|18 Years|N/A|No|Probability Sample|nationwide, population-based cohort of women diagnosed with breast cancer and their male        cohabiting partner/spouse|April 2014|April 22, 2014|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01392066||101739|
NCT01393379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S445/2009|ELVR in PH Patients With Severe Emphysema|Effect of Endoscopic Lung Volume Reduction (ELVR) on Pulmonary Hypertension (PH) in Patients With Severe Emphysema and Pulmonary Hypertension||Heidelberg University|No|Completed|April 2010|December 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|30 Years|N/A|No|Probability Sample|Patients with severe emphysema and PH, where ELVR is indicated|June 2015|June 19, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393379||101639|
NCT01390935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114993|SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World|SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real WorldMulticenter, Retrospective Observation Study in Korea|SUGAR|GlaxoSmithKline|No|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|20 Years|N/A|No|Probability Sample|admission for systolic heart failure in general hospital|November 2012|November 28, 2012|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01390935||101826|
NCT01401361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90064772|Clinical Evaluation of Contact™ Therapy™ Cool Path™ Cardiac Ablation System in Conjunction With EnSite Velocity Contact™ Technology for the Treatment of Typical Atrial Flutter|Clinical Evaluation of Contact™ Therapy™ Cool Path™ Cardiac Ablation System in Conjunction With EnSite Velocity Contact™ Technology for the Treatment of Typical Atrial Flutter|CONTACT AFL|St. Jude Medical|Yes|Completed|October 2011|September 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|July 21, 2011|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01401361||101027|
NCT01401374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-148/10-149x|Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo|Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo||St. Luke's-Roosevelt Hospital Center|No|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|N/A||2|Anticipated|1500|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals self-reporting vitiligo vulgaris and controls who do not have vitiligo        vulgaris|December 2015|December 29, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401374||101026|
NCT01392339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0985/08|Obstructive Sleep Apnea and Genes Expression|Sleep Apnea: Interface Between Basic and Clinical Research|HIP|Associacao Fundo de Incentivo a Psicofarmcologia|Yes|Recruiting|February 2011|October 2011|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Anticipated|35|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||March 2011|July 11, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01392339||101718|
NCT01351376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00923|LLLT Combined With CDT in Breast Cancer-Related Lymphedema|The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study||New York University School of Medicine|No|Active, not recruiting|May 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Female|21 Years|N/A|No|||November 2015|November 9, 2015|May 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01351376||104844|
NCT01351662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLESS|Balancing Lupus Experiences With Stress Strategies|An Intervention to Reduce Psychosocial and Biological Indicators of Stress in African American Lupus Patients: The Balancing Lupus Experiences With Stress Strategies (BLESS) Study|BLESS|Medical University of South Carolina|Yes|Completed|August 2010|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351662||104822|
NCT01351675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-0903|Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes|Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)|BEACON|Reata Pharmaceuticals, Inc.|Yes|Terminated|June 2011|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2185|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|December 3, 2010|Yes|Yes|IDMC recommendation for safety concerns|No||https://clinicaltrials.gov/show/NCT01351675||104821|
NCT01351896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02584|Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2011|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|79 Years|No|||November 2015|November 3, 2015|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01351896||104804|
NCT01352234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-11-108|Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia|Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Completed|September 2011|March 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|May 21, 2015|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01352234||104780|
NCT01352585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-703|Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®|An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)|EMIX|Shire|No|Completed|July 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|47|||Both|N/A|N/A|No|Non-Probability Sample|ET patients in Italy|June 2014|June 27, 2014|May 10, 2011||No||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01352585||104753|
NCT01353638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ala-Gln in PD|Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis|An Open Label, Randomized, Two-Period Crossover Study to Evaluate the Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solutions in Peritoneal Dialysis (PD) (Ala-Gln in PD)||Medical University of Vienna|Yes|Terminated|April 2011|May 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|19 Years|N/A|No|||September 2015|September 9, 2015|May 5, 2011||No|Primary endpoint (HSP) could not be analyzed with the specified method in the planned interim    analysis; a method of increased sensitivity had to be established.|No||https://clinicaltrials.gov/show/NCT01353638||104672|
NCT01353963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061038|Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients|An Open Label, Non-interventional Study Of The Safety Of Desvenlafaxine Succinate (Pristiq) In The Treatment Of Major Depressive Disorder (Mdd) And Vasomotor Symptoms (Vms) Associated With Menopause In Filipino Adult Patients: A Post Marketing Surveillance Study||Pfizer|No|Terminated|March 2012|August 2012|Actual|August 2012|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to        menopause prescribed with desvenlafaxine succinate|December 2015|December 4, 2015|May 12, 2011||No||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01353963||104647|Due to the low number of subjects with data available, only descriptive summaries have been presented. The outcomes measures were prioritized as per study team's discretion.
NCT01353976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079-2951-302|Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis|A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Interdigital Tinea Pedis||AmDerma|No|Completed|May 2011|August 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|264|||Both|12 Years|N/A|No|||December 2012|December 5, 2012|May 12, 2011|Yes|Yes||No|December 5, 2012|https://clinicaltrials.gov/show/NCT01353976||104646|
NCT01353625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-115-ST-001|Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.|A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies||Celgene|No|Active, not recruiting|April 2011|July 2016|Anticipated|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|144|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01353625||104673|
NCT01353924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2411.V2.2009|Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1|Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1||Medical University of Vienna|No|Not yet recruiting|August 2011|December 2013|Anticipated|August 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|20|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2011|May 12, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01353924||104650|
NCT01349751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SiEC 197/2549|Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution|Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution||Mahidol University|Yes|Completed|January 2007|February 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|20|||Female|18 Years|70 Years|No|||November 2013|November 5, 2013|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349751||104969|
NCT01350024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100631|Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid|Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid||Bascom Palmer Eye Institute|Yes|Recruiting|May 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|May 6, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01350024||104948|
NCT01393964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-007|Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function|PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis||Bristol-Myers Squibb|No|Active, not recruiting|January 2012|February 2016|Anticipated|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|July 12, 2011|No|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01393964||101594|
NCT01393015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FreeO2-COPD-5ePC|Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygentherapy in Patients With COPD Exacerbation|Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygentherapy in Patients With Exacerbations of Chronic Obstructive Pulmonary Disease.||Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|No|Recruiting|July 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|40 Years|N/A|No|||May 2011|July 12, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393015||101667|
NCT01391000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013483|Laser CO2 Versus TENS After Reconstruction of the Rotator Cuff|Light Amplification by Simulated Emission Radiation Carbon Dioxide (Laser CO2) Versus Transcutaneous Electrical Stimulation (TENS) for the Reduction of Pain in Patients After Reconstruction of the Rotator Cuff. A Randomized Controlled Trial||Istituto Ortopedico Rizzoli|No|Completed|July 2011|November 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|85 Years|No|||December 2013|October 1, 2014|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01391000||101821|
NCT01391273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-059|Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis|A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-Daily Application of Bimatoprost Solution 0.03% Compared to Vehicle in Increasing Overall Eyelash Prominence in Japanese Subjects With Hypotrichosis of the Eyelashes||Allergan|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|173|||Both|20 Years|N/A|No|||May 2013|May 21, 2013|July 8, 2011|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT01391273||101800|
NCT01391767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nuoss-15852|Histologic Evaluation of Healing Following Tooth Extraction With Ridge Preservation Using NuOss XC and NuOss Particulate|Histologic Evaluation of Healing Following Tooth Extraction With Ridge Preservation Using NuOss XC and NuOss Particulate||University of Oklahoma|No|Completed|July 2011|May 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|22|Samples Without DNA|Hard tissue histological evaluation|Both|18 Years|64 Years|No|Probability Sample|Periodontal Clinic Population at the University of Oklahoma College of Dentistry|July 2013|July 5, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01391767||101762|
NCT01401387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC 11-01|Pancreatic Enzyme Suppletion in Pancreatic Cancer|Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy|EPC|Foundation for Liver Research|No|Withdrawn|October 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|July 21, 2011||No|study never started|No||https://clinicaltrials.gov/show/NCT01401387||101025|
NCT01392027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50-CA13081001A2|Biospecimens for Identification of Diseases of the Pancreas.|Biospecimens for the Early Detection, Prevention, Diagnosis and Treatment of Diseases of the Pancreas.|SPORE-PANC|University of Michigan|Yes|Recruiting|April 2011|||September 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 23, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01392027||101742|
NCT01392040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIV_AI_10_001|Clinical Validation of a New Algorithm for Computerized Dosing of Vitamin K Antagonist Therapy|Clinical Validation of a New Algorithm for Computerized Dosing of Vitamin K Antagonist Therapy||University Of Perugia|Yes|Completed|November 2010|January 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|the conditions for the patients inclusion are: to take oral anticoagulant therapy for at        least 2 years; to be in stable conditions for at last 3 months|January 2013|January 16, 2013|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392040||101741|
NCT01351688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3760C00003|An Open Label Prostate Cancer Study in Japanese Patients|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer||AstraZeneca|No|Completed|August 2011|May 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|20 Years|N/A|No|||July 2013|July 2, 2013|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01351688||104820|
NCT01351922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3933|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in India and to Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in India (DiabCare India 2011)|DiabCare India|Novo Nordisk A/S|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|12000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes mellitus (both type 1 and type 2) being treated at general        hospitals, diabetes clinics and referral clinics will be selected according to inclusion        and exclusion criteria.|November 2011|November 1, 2011|May 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01351922||104802|
NCT01351935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVL-292-003|Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia|Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia||Celgene|No|Completed|July 2011|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01351935||104801|
NCT01352260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27855|Near-Infrared Spectroscopy Comparison Study|Validation of Near-Infrared Spectroscopy for Neuromonitoring During Moderate Hypothermic Circulatory Arrest for Total Aortic Arch Replacement: A Comparison of Two Technologies With Jugular Venous Bulb Oximetry||Nonin Medical, Inc|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|65 Years|No|Non-Probability Sample|Baylor College of Medicine and affiliated Hospitals|May 2012|May 18, 2012|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352260||104778|
NCT01353105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCOR-1232-09|Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion|Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion||InCor Heart Institute|No|Not yet recruiting|August 2011|August 2015|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|12 Years|70 Years|No|||October 2010|May 11, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353105||104713|
NCT01381484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Svarothai|Argireline in Treatment of Periorbital Wrinkles|Efficacy and Safety of Topical Argireline in the Treatment of Periorbital Wrinkles||Mahidol University|Yes|Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|35 Years|45 Years|Accepts Healthy Volunteers|||March 2011|June 23, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01381484||102549|
NCT01381497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112617|Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy|Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy||GlaxoSmithKline|No|Completed|March 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult males and females aged 18 to 65 with a diagnosis of migraine disorder who are        employed and scheduled to work at least 30 hours per week during a day time shift.        Patients must be treating migraines with either a combination therapy of sumatriptan and        naproxen sodium (SumaRT/Nap) or oral triptan monotherapy as prescribed prior to study        start. Patients will be recruited from up to 30 investigative sites.|August 2012|August 23, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381497||102548|
NCT01381809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018367|An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes||Janssen-Cilag International NV|Yes|Completed|October 2011|January 2016|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381809||102524|
NCT01349764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-325-BMB|Effect of Vitamin D Replacement in Patients With Urolithiasis|Effect of Vitamin D Replacement in Vitamin D Deficient Patients With History of Urolithiasis: A Randomized Controlled Trial||McGill University Health Center|Yes|Active, not recruiting|April 2011|April 2013|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|86|||Both|18 Years|N/A|No|Probability Sample|Patients presenting to the MUHC stone clinic and had inadequate vitamin D.|April 2011|June 3, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01349764||104968|
NCT01353937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02116|Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers|Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers|AMD3100|New York University School of Medicine|Yes|Withdrawn|April 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|0|||Both|35 Years|60 Years|No|||March 2016|March 2, 2016|May 12, 2011|No|Yes|Never Activated|No||https://clinicaltrials.gov/show/NCT01353937||104649|
NCT01382511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-09-TLV|Simvastatin Treatment of Pachyonychia Congenita|Simvastatin Treatment of Pachyonychia Congenita||Tel-Aviv Sourasky Medical Center||Not yet recruiting|July 2011|||December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2009|June 23, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01382511||102470|
NCT01390090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|700-2010|Ultrasound Confirmation of Fluoroscopically Guided Piriformis Muscle Injections|Ultrasound Confirmation of Fluoroscopically Guided Piriformis Muscle Injections: Does Accuracy Improve Efficacy?||University of Florida|No|Withdrawn|January 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|90 Years|No|Non-Probability Sample|Subjects will have failed conservative treatment, including, but not limited to oral        medications, physical therapy, manual manipulation, and/or alternative medicine.|April 2013|April 19, 2013|June 29, 2011||No|The Principal Investigator left the University|No||https://clinicaltrials.gov/show/NCT01390090||101891|
NCT01394068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 10-013 SICS|Prospective, Non-randomized Observational Trial of Selenium in Cardiac Surgery|SICS: A Prospective, Non-randomized Observational Trial of Selenium in Cardiac Surgery|SICS|RWTH Aachen University|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Procalcitonin, CRP, IL-6, IL-10, Leukocytes, Thrombocytes, Bilirubin, Creatinine, Lactate,      Albumin, AT-III|Both|18 Years|N/A|No|Non-Probability Sample|Approximately 100 adult patients (male and female), capable of consenting, undergoing        elective cardiac surgery on the heart-lung-machine|August 2011|August 17, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394068||101586|
NCT01389635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019-11-RMB-CTIL|Abdominoplasty Under Epidural Anesthesia|Abdominoplasty Under Epidural Anesthesia: Safer for the Patient, Easier for the Surgeon.||Rambam Health Care Campus|No|Completed|March 2009|April 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|31|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients that underwent abdominoplasty between January 2003 and March 2008 in a        private hospital by Dr. Yitshak Ramon.|July 2011|July 7, 2011|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389635||101925|
NCT01390129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI 2010-07|Remote Ischemic Preconditioning in Aortic Valve Surgery|Remote Ischemic Preconditioning in Aortic Valve Surgery (RIP-Valve)|RIP-Valve|University Hospital, Angers|Yes|Completed|July 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01390129||101888|
NCT01401140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908033|Comparing the Protective Effects of Two Cardioplegic Solutions, on Cardiac Metabolism, as Assessed Using Microdialysis|Coronary Surgery: Comparing the Protective Effects of Two Cardioplegic Solutions: Custodiol Versus St Thomas, on Cardiac Metabolism, as Assessed Using Microdialysis|Cardioplégie|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401140||101044|
NCT01401400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV10-03|Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study|Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study|GIANT-B|Foundation for Liver Research|No|Completed|May 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1350|Samples With DNA|whole blood samples from which DNA can be isolated|Both|18 Years|N/A|No|Probability Sample|Chronic hepatitis B patients treated with (peg-)interferon|August 2015|August 13, 2015|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401400||101024|
NCT01401413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU1640207B|Study to Determine Whether Ramelteon Helps People With REM Sleep Behavior Disorder|A Prospective Randomized, Placebo-Controlled Double-Blind Study to Determine the Efficacy of Ramelteon in REM Sleep Behavior Disorder||Sleep Medicine Centers of WNY|No|Completed|January 2008|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||July 2011|July 22, 2011|July 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401413||101023|
NCT01392638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0758.0.146.000-09|Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism|Influence of the Nitric Oxide Synthase T-786C Polymorphism on the Response to Acute Inhibition of Phosphodiesterase 5 in Resistant Hypertension||University of Campinas, Brazil|No|Completed|July 2010|September 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|35 Years|75 Years|No|||October 2012|October 29, 2012|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01392638||101696|
NCT01392651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090039|Tension-free-vaginal-tape-obturator (TVTO) Versus Tension-free-vaginal-tape-Secur (TVTS) for Treatment of SUI|Outcome of Treatment of Women With Urinary Stress Incontinence Treated by Tension-free-vaginal-tape-obturator (TVTO) Compared to Tension-free-vaginal-tape-Secur (TVTS)||Western Galilee Hospital-Nahariya|No|Completed|January 2009|June 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|200|||Female|18 Years|95 Years|No|Non-Probability Sample|Women with stress urinary incontinence who underwent surgery, by TVT methos, either TVTO        or TVTS.|July 2011|July 2, 2014|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01392651||101695|
NCT01351701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sunvalley Diabetic Foot Study|Bacteriological Study of Diabetic Foot and Antibiotic Sensitivity Pattern in Eastern India|An Observational, Prospective, Multicentre Study in Eastern India to Understand the Bacteriological Epidemiology in Diabetic Foot and Sensitivity Pattern of Antibiotics Along With the Pattern of Empirical Therapy||Sun Valley Hospital, Guwahati|No|Not yet recruiting|June 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Mixed-Rural/Urban in three eastern states of India|April 2011|May 10, 2011|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01351701||104819|
NCT01351948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC044|Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909|A Phase Ia Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines; AdCh63 AMA1, MVA AMA1 & AMA1-C1/Alhydrogel® +/- CPG 7909||University of Oxford|Yes|Completed|June 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|35|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351948||104800|
NCT01351961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01399-30|Vascular Alteration and Evolution of Cognitive Impairment|Arterial Function and Structure and Evolution of Cognitive Impairment in Elderly Hypertensive Subjects With Subjective Memory Complaints|ADELAHYDE2|Central Hospital, Nancy, France|No|Completed|April 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|131|||Both|65 Years|85 Years|No|||February 2014|February 24, 2014|April 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01351961||104799|
NCT01352247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0606/88|Total or Partial Knee Arthroplasty Trial|Total or Partial Knee Arthroplasty Trial|TOPKAT|University of Oxford|Yes|Active, not recruiting|January 2010|December 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|40 Years|N/A|No|||October 2013|December 2, 2014|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01352247||104779|
NCT01352832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X091029002|The Alabama NSAIDs Patient Safety Survey, Phase II: Reducing Disparities in Risk Awareness and Communication|Phase II of The Alabama NSAID Patient Safety Survey: Reducing Disparities in Risk Awareness and Communication||University of Alabama at Birmingham|No|Completed|May 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|422|||Both|19 Years|N/A|No|||March 2013|March 8, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352832||104734|
NCT01352845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971016|A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.|A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years|B1971016|Pfizer|Yes|Completed|May 2013|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|3301|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|May 11, 2011|Yes|Yes||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01352845||104733|
NCT01381822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-410|Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors|A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination With Sunitinib in Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors|TH-CR-410|Threshold Pharmaceuticals|No|Active, not recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01381822||102523|
NCT01381835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017953|TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435|Phase I, Open-label Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435||Tibotec Pharmaceuticals, Ireland|Yes|Completed|July 2011|January 2012|Actual|||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01381835||102522|
NCT01382069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN010|Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men|Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men|DMAUPhase1|Los Angeles Biomedical Research Institute|Yes|Recruiting|March 2012|February 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|December 2, 2014|March 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382069||102504|
NCT01382043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHQ09-002|Angiographic and IVUS Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals (AIFSIDDES)|||Liuhuaqiao Hospital|No|Completed|June 2009|January 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|48|||Both|18 Years|80 Years|No|Non-Probability Sample|The patiemts who underwent simultaneous implantation of one or more Endeavor stents and        one or more Excel stents during the same index procedure and were evaluated with coronary        angiography and intravascular ultrasound (IVUS) at least one year post-procedure.|June 2011|June 24, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382043||102506|
NCT01382056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:026|Effects of Pulse Varieties on Blood Vessel Function in Peripheral Artery Disease|Effects of Pulse Varieties on Blood Vessel Function in Individuals With Peripheral Artery Disease (PAD)|PULV-2011|University of Manitoba|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|62|||Both|34 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 11, 2014|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01382056||102505|
NCT01350037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|a002c|Alfentanil Versus Remifentanil in Patient-controlled Sedation During Endoscopic Retrograde Cholangiopancreatography (ERCP)|Alfentanil vs Remifentanil in Patient-controlled Sedation During ERCP.A Randomized Double-blind Study||Helsinki University Central Hospital|No|Completed|June 2009|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|70 Years|No|||July 2012|July 4, 2012|May 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01350037||104947|
NCT01383057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMTO 2011-2|Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery|Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery||Innovative Medical|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383057||102428|
NCT01392690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RegieRegionale-07-2000-05|Evaluation of a Primary Prevention Program for Anxiety Disorders Using Story Books|Evaluation of a Primary Prevention Program for Anxiety Disorders Using Story Books|TrucsDeDom|Universite du Quebec en Outaouais|No|Completed|March 2000|August 2002|Actual|August 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|73|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||July 2011|July 27, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01392690||101692|
NCT01392703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-352|Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations|Open-label, Randomized, 3-period, 3-treatment Crossover, Bioequivalence Study Comparing Dasatinib (BMS-354825) Liquid Formulation and the Dispersed Tablet Formulation Relative to the Reference Tablet Formulation in Health Subjects||Bristol-Myers Squibb|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|141|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|July 11, 2011|No|Yes||No|November 5, 2012|https://clinicaltrials.gov/show/NCT01392703||101691|
NCT01389648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|physiotherapyCTIL|Pre-operative Physiotherapy to Prevent Post-operative Complications|The Effect of Pre-operative Chest Physiotherapy on Post-operative Complications After Major Abdominal Surgery.||Rambam Health Care Campus|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|157|||Both|18 Years|N/A|No|||September 2013|September 15, 2013|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389648||101924|
NCT01389856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-391|Persistent Pulmonary Hypertension of the Newborn|Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)|FUTURE 4|Actelion|Yes|Terminated|December 2011|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|N/A|7 Days|No|||April 2015|April 9, 2015|June 30, 2011|Yes|Yes|To be compliant with the timelines as agreed with Paediatric Committee (PC) within the    Paediatric Investigational Plan|No|March 9, 2015|https://clinicaltrials.gov/show/NCT01389856||101908|
NCT01389869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1105-011-360|Appetite Regulation by Human Chemosignals From Tears and Plasma|||Seoul National University Hospital|Yes|Completed|June 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2013|December 5, 2013|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389869||101907|
NCT01390311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108380|Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant|A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation||Washington University School of Medicine|Yes|Completed|April 2012|April 2015|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390311||101874|
NCT01390324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-NRP-03(05/11)|Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine|A Multicenter, National, Double-blind, Randomized Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Naratriptan 2,5 mg + Naproxen 500 mg Relative to Efficacy and Safety of Each Monotherapy for the Acute Treatment of Migraine|Atenéia|Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|December 2011|||October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|564|||Both|18 Years|65 Years|No|||July 2011|August 18, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390324||101873|
NCT01401972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ultrasound Prostate Cancer|Conventional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients|Conventional and Contrast-Assisted Frequency Functional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients||Sunnybrook Health Sciences Centre|No|Recruiting|September 2008|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Prostate speciments are retained after radical prostatectomy surgery|Male|N/A|N/A|No|Non-Probability Sample|The study will investigate a population of 30 men with prostate cancer undergoing radical        prostatectomy surgery.|April 2012|April 25, 2012|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01401972||100981|
NCT01402492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-CTN-0048|Cocaine Use Reduction With Buprenorphine|Cocaine Use Reduction With Buprenorphine (CURB)|CURB|University of California, Los Angeles|Yes|Completed|September 2011|March 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402492||100941|
NCT01402505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081036, 141812|Transvaginal NOTES Sleeve Gastrectomy|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Trans-Vaginal Sleeve Gastrectomy||University of California, San Diego|No|Recruiting|October 2008|October 2018|Anticipated|October 2018|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|75 Years|No|Non-Probability Sample|Patients between the ages of 18-75 who present in the UC San Diego Surgical Specialties        clinic and have been cleared by the Bariatric and Metabolic Institute (BMI) team for        bariatric surgery will be evaluated for participation in this trial. If the inclusion and        exclusion criteria are met, the patients will be offered participation in the trial.|March 2016|March 17, 2016|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01402505||100940|
NCT01402518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091170, 150261|Per-Oral Endoscopic Myotomy|Observational Study of the Per-Oral Endoscopic Myotomy (POEM) Procedure|POEM|University of California, San Diego|No|Recruiting|November 2009|November 2019|Anticipated|November 2019|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients between the ages of 18-75 who present in the UC San Diego Surgical Specialties        clinic with the diagnosis of achalasia will be offered participation in this study.|March 2016|March 17, 2016|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01402518||100939|
NCT01393314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1KL2RR024990 - 2|A Trial of Telemonitoring in Adults With Heart Failure|A Randomized Controlled Trial of Telemonitoring in Older Adults With Heart Failure||University Hospital Case Medical Center|No|Completed|November 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|55 Years|N/A|No|||June 2011|July 12, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01393314||101644|
NCT01393327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-488/2009|Influence of Respiratory and Exercise Therapy on Oxygen Uptake and Right Heart Function in CTEPH Patients After PEA|Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Heart Function in Chronic Thromboembolic Pulmonary Hypertension After Thromboendarterectomy||Heidelberg University|No|Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|80 Years|No|||June 2015|June 19, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01393327||101643|
NCT01351974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-053|Sentinel Node Biopsy in Breast Cancer Patients|Cohort Study of Axillary Recurrences and Survival After Negative Negative Sentinel Node Biopsy Without Completion Axillary Clearance||Uppsala University|No|Completed|September 2000|January 2004|Actual|January 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3369|Samples Without DNA|Routine specimens from the surgery are kept at the respective pathology departments|Female|N/A|N/A|No|Non-Probability Sample|Consecutive patients with primary breast cancer in Swedish hospitals|June 2000|May 27, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01351974||104798|
NCT01352273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2102|MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations|A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations||Array BioPharma||Completed|June 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01352273||104777|
NCT01352286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP 01411|Redirected Auto T Cells for Advanced Myeloma|A Phase I/IIa, Dual-cohort, Two-site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma||Adaptimmune|Yes|Active, not recruiting|April 2011|April 2031|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|80 Years|No|||December 2015|December 14, 2015|May 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01352286||104776|
NCT01352598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-022|Stereotactic Body Radiotherapy for Prostate Cancer|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer||St. John's Mercy Research Institute, St. Louis|No|Recruiting|June 2011|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||May 2015|May 18, 2015|May 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01352598||104752|
NCT01352611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109397|Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen|Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen||University of Missouri-Columbia|No|Withdrawn|September 2014|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|10 Years|65 Years|No|||April 2015|April 28, 2015|May 10, 2011|No|Yes|No subjects enrolled.|No||https://clinicaltrials.gov/show/NCT01352611||104751|
NCT01353391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-106678|Metformin in Women With Type 2 Diabetes in Pregnancy Trial|Metformin in Women With Type 2 Diabetes in Pregnancy Trial|MiTy|Mount Sinai Hospital, Canada|Yes|Recruiting|May 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|45 Years|No|||October 2015|October 26, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01353391||104691|
NCT01353404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYO0805|Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)|Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg) in Normal Healthy Subjects||Samyang Biopharmaceuticals Corporation|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 16, 2012|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01353404||104690|
NCT01382524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-011427|Peripheral Intravenous Catheter Complication Rate Comparison of Two Different Catheter-Stabilization Systems|Peripheral I.V. Catheter Complication Rate Comparison of Two Different Catheter-Stabilization Systems|PIV Secural|3M|No|Completed|June 2011|September 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|682|||Both|18 Years|N/A|No|Probability Sample|The study population for this study will be male and female patients who are at least 18        years of age or an emancipated minor, require a peripheral IV catheter for an anticipated        three days (72 hours) or longer|June 2013|June 12, 2013|June 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01382524||102469|
NCT01382316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA014688|Making Alcoholics Anonymous Easier|Making Alcoholics Anonymous Easier: A Group TSF Approach|MAAEZ|Alcohol Research Group|Yes|Completed|July 2005|August 2007|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|508|||Both|18 Years|N/A|No|||June 2011|June 24, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382316||102485|
NCT01382329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811001|H5N1 Vaccine Study in Japanese Adults|A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years||Nanotherapeutics, Inc.|Yes|Completed|June 2011|May 2012|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|340|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||September 2012|October 7, 2015|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382329||102484|
NCT01383070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01_BFC|Evaluation of Effectiveness of Cell Phone Technology as Community Based Intervention to Improve Exclusive Breast Feeding|Effectiveness of Cell Phone Counseling to Improve Breast Feeding Indicators|BFC|Lata Medical Research Foundation, Nagpur|No|Recruiting|April 2010|November 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1036|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01383070||102427|
NCT01393717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11051|Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma|A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation||City of Hope Medical Center|Yes|Recruiting|October 2011|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|11 Years|N/A|No|||December 2015|December 9, 2015|July 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393717||101613|
NCT01400633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017842|An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome|A Prospective Multicenter Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome||Janssen Korea, Ltd., Korea||Completed|December 2010|March 2014|Actual|March 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|156|||Both|20 Years|N/A|No|Probability Sample|Secondary or tertiary hospitals in South Korea|May 2015|May 22, 2015|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400633||101083|
NCT01401985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-1211-0076|A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)|A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects With Opioid-Induced Constipation||Theravance Biopharma Antibiotics, Inc.|No|Completed|October 2011|August 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|95|||Both|18 Years|65 Years|No|||September 2014|September 3, 2014|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401985||100980|
NCT01401998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110414002|UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource|Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource (Hepato/Renal Fibrocystic Diseases Core Center (UAB HFRDCC))||Children's Research Institute|Yes|Recruiting|June 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Blood-derived DNA and lymphocytes for EBV-immortalized cell lines. Remnant tissue samples      affected with Hepato/Renal Fibrocystic Diseases|Both|N/A|35 Years|No|Non-Probability Sample|In view of the genetics and demographics of the recessive disorders comprising the        spectrum of hepato/renal fibrocystic diseases, we estimate that 50% of the subjects will        be female; that 90% of the subjects will be Caucasian and the remainder will belong to the        following racial/ethnic categories: 5% African-Americans; 3% Hispanics; 1% Asians; and 1%        or less will be other categories.|January 2016|January 26, 2016|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401998||100979|
NCT01401660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMI-2010-002|Study of Low Back Pain Using CERSR® Imaging Technology|Observational Study of the Electrophysiological Course of Low Back Pain Using CERSR® Imaging Technology||Verium Diagnostics, Inc.|No|Terminated|May 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|290|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects will be selected from employees of Summa Health System. Current employees as        well as new hires will be eligible to participate in the study.|July 2011|July 29, 2011|March 29, 2011||No|Principal Investigator withdrew from the study.|No||https://clinicaltrials.gov/show/NCT01401660||101004|
NCT01401933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-307|Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1 Study To Assess the Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors||Abbott|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|N/A|No|||October 2011|October 31, 2011|April 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401933||100984|
NCT01401946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-004-P|Soy Isoflavone Tablets: Effects on Sleep, Quality of Life, Symptoms and Cognitive Function in Menopausal Women|Soy Isoflavone Tablets: Effects on Questionnaire and Actigraphic Measures of Sleep, Symptoms as Measured by the Women's Health Questionnaire and Cognitive Function as Measured by Computerized Cognitive Performance Tests in Menopausal Women||Brigham and Women's Hospital|No|Completed|May 2000|January 2001|Actual|October 2000|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2011|July 25, 2011|December 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401946||100983|
NCT01401647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40605-B|Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia|Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT)|ALPS|University of Washington|Yes|Active, not recruiting|May 2012|March 2016|Anticipated|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|3000|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|July 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401647||101005|
NCT01402739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEART-PoC|Algorithm-Guided Transfusions in Cardiac Surgery Patients for Reduction of Drainage Blood Losses|Monocentric Pilot Study of Algorithm-Guided Transfusions in Cardiac Surgery Patients for Reduction of Drainage Blood Losses|HEART-PoC|Charite University, Berlin, Germany|No|Terminated|August 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||June 2015|June 12, 2015|July 25, 2011||No|Study terminated prematurely due to futility|No||https://clinicaltrials.gov/show/NCT01402739||100922|
NCT01351987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100006|An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL|An Observational Study of Dutasteride and Alpha-Blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL||Taipei Medical University WanFang Hospital|No|Active, not recruiting|December 2010|December 2013|Anticipated|||N/A|Observational|Observational Model: Case-Only||1|Anticipated|855|||Male|50 Years|N/A|No|Non-Probability Sample|Benign Prostatic Hyperplasia male paitents|May 2011|May 10, 2011|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01351987||104797|
NCT01352299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Akulkarni2|Glottic Visualization & Ease of Intubation With Different Laryngoscope Blades|Comparison of Visualisation of Laryngeal Inlet and Ease of Intubation With Different Laryngoscope Blades.||Tata Memorial Hospital|No|Completed|August 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|120|||Both|18 Years|70 Years|No|||May 2011|May 10, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01352299||104775|
NCT01353131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Johns Hopkins University|Personalized Risk Identification and Management for Arrhythmias and Heart Failure by ECG and MRI|Personalized Risk Identification and Management for Arrhythmias and Heart Failure by 12 Lead Electrocardiogram and Cardiac Magnetic Resonance Imaging.|PRIMERI|Johns Hopkins University|No|Active, not recruiting|May 2010|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples Without DNA|Whole blood, serum, plasma.|Both|18 Years|70 Years|No|Non-Probability Sample|We refined a risk stratification algorithm based on the electronic analysis of 69,088        routine 12-lead ECGs performed in a large medical institution during a 6 month period by        combining previously established indices of abnormal repolarization (wide QRS-T angle)        with validated measures of myocardial damage (Selvester QRS score).|September 2015|September 1, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01353131||104711|
NCT01381250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spelstudie2|Effects of Internet-based Treatment of Pathological Gambling|Prediction and Treatment Outcome of Internet-based Treatment of Pathological Gambling With Three-year Follow-up||Umeå University|No|Completed|May 2004|January 2009|Actual|January 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|284|||Both|18 Years|N/A|No|||January 2004|June 29, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01381250||102567|
NCT01381263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2010/047|Behavioral Medicine Treatment for Adolescents in Pain|Development, Evaluation and Cost Effectiveness of a Treatment Program With a Behavioural Medicine Approach for Adolescents With Persistent Pain.||Uppsala University|Yes|Recruiting|January 2011|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|16 Years|No|||June 2011|June 23, 2011|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01381263||102566|
NCT01381848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016192|A Study of Doripenem in Infants Less Than 12 Weeks of Age|An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age||Janssen Research & Development, LLC|No|Completed|October 2009|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Both|N/A|12 Weeks|No|||January 2013|January 8, 2013|April 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01381848||102521|
NCT01381861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105OC201|Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Tracon Pharmaceuticals Inc.|No|Completed|July 2011|December 2013|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|June 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01381861||102520|
NCT01382342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNSAZL0016|The Effect of Rasagiline on Cognition in Parkinson's Disease|||Brown University|No|Completed|June 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 3, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382342||102483|
NCT01382537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072131|Efficacy of the InterX 5000 in the Treatment of Chronic Neck Pain|Evaluation of the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain||Canadian Memorial Chiropractic College|No|Completed|January 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|September 21, 2009||No||No||https://clinicaltrials.gov/show/NCT01382537||102468|
NCT01382550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT 63/11|Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.|Prevention of Recurrent Venous Thromboembolism in Patients With Low Circulating Levels of Antithrombin. Extended Anticoagulation vs 12-Month Oral Anticoagulation||Federico II University|Yes|Recruiting|March 1993|||September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|||Both|18 Years|80 Years|No|Non-Probability Sample|subjects with a recent (<3 months) first VTE event enrolled for a long-term follow-up        (every 6 months).|September 2012|September 12, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382550||102467|
NCT01382797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK37-005|ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)|A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose Study to Evaluate the Safety, Tolerability, and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation||Alkermes, Inc.|Yes|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01382797||102448|
NCT01382810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Altaire2011|Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms|A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms||Innovative Medical|No|Recruiting|March 2011|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382810||102447|
NCT01383330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-ES 1101|A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition|Phase 1 Study of Daewon-ES(A) & Daewon-ES(B) in Healthy Male Volunteers Under Fed Condition||Asan Medical Center|No|Not yet recruiting|July 2011|||September 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|15|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 27, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01383330||102407|
NCT01383564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asthma OSA/Ng/2011|Continuous Positive Airway Pressure Use in Asthma With Moderate to Severe Obstructive Sleep Apnea Patients|Effect of Nasal Continuous Positive Airway Pressure in Uncontrolled Nocturnal Asthmatic Patients With Moderate Obstructive Sleep Apnea Syndrome|OSA|Chinese University of Hong Kong|No|Recruiting|January 2011|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||August 2015|August 11, 2015|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01383564||102389|
NCT01400620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-HNC-201-IL|Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer|Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer||Izun Pharma Ltd|No|Recruiting|March 2012|January 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400620||101084|
NCT01400867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-23|Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections|A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections||Forest Laboratories|Yes|Completed|December 2011|July 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|2 Months|17 Years|No|||January 2015|January 12, 2015|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400867||101065|
NCT01401153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COG0611DO|Cognition Intervention Study Dortmund|Cross-over Trial Determining the Short-term Effects of Lunch on Children's Cognitive Functioning|CogniDO|Research Institute of Child Nutrition, Dortmund|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|105|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|July 19, 2011||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01401153||101043|Open-label study, in which everyone involved knew about group assignmentOnly one cognitive assessment per test day
NCT01401127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXQ404(1)|Managing Insulin Pumps for Exercise - Study 1|A Comparison of Metabolism During Moderate Exercise Between Healthy Volunteers and People With T1DM Treated With CSII Using 70% of Their Usual Insulin Basal Rate||Buckinghamshire Healthcare NHS Trust|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|16|Samples Without DNA|All samples retained will be plasma samples. Any samples remaining after analysis will be      retained until the 3 trials in this research study have been completed, and will then be      destroyed.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants with Type 1 Diabetes treated with insulin pump therapy who exercise for at        least 1 hour each week and comparable participants without diabetes mellitus|November 2011|November 7, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401127||101045|
NCT01402011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00911|Study of 25% Dextrose Injections in Shoulder Ligaments and Tendons to Promote Their Healing|Prolotherapy in the Treatment of Rotator Cuff Tendinopathy, a Randomized Double-blind Placebo-controlled Study|Prolotherapy|University of British Columbia|No|Completed|November 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|72|||Both|19 Years|74 Years|Accepts Healthy Volunteers|||September 2013|September 2, 2013|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01402011||100978|
NCT01402245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|411/E5/02|Targeting of Immune Response After Pneumococcal Vaccination|Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination|PncHR|Helsinki University Central Hospital|Yes|Completed|January 2005|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|42|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2007|July 25, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402245||100960|
NCT01402258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-FORSS-2011-150291|Internet-administrated Treatment of Anxiety Symptoms for Young Adults|Tailored Internet-administrated Treatment of Anxiety Symptoms for Young Adults|NOVA-IV|Linkoeping University|No|Recruiting|April 2011|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|16 Years|25 Years|No|||April 2013|April 26, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01402258||100959|
NCT01401920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-05-093|The Influence of Passive Leg Elevation on the Cross-sectional Area of the Internal Jugular Vein in Infants or Young Children Undergoing Open Heart Surgery|The Influence of Passive Leg Elevation on the Cross-sectional Area of the Internal Jugular Vein in Infants or Young Children Undergoing Open Heart Surgery||Samsung Medical Center|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|N/A|5 Years|No|Non-Probability Sample|infants or children undergoing open heart surgery for congenital anomaly for study period|December 2013|December 24, 2013|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401920||100985|
NCT01401907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-434|Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies|Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Advanced Lung and Non-colorectal Gastrointestinal Malignancies||Massachusetts General Hospital|Yes|Active, not recruiting|May 2011|April 2018|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|350|||Both|18 Years|N/A|No|||June 2015|July 27, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401907||100986|
NCT01352624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G100145|Improving Money Management Skills for Veterans With Psychiatric Disabilities|Improving Money Management Skills for Veterans With Psychiatric Disabilities||University of North Carolina, Chapel Hill|No|Completed|April 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|183|||Both|18 Years|65 Years|No|||September 2014|September 5, 2014|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01352624||104750|
NCT01352858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AutoDECRA 1.0|Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA)|Phase 1 Study of Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis|AutoDECRA|Newcastle University|Yes|Recruiting|February 2012|December 2013|Anticipated|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|12|||Both|18 Years|N/A|No|||March 2013|March 10, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01352858||104732|
NCT01384643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0007|Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery|Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial||Yonsei University|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|112|||Both|20 Years|75 Years|No|||April 2013|April 10, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384643||102306|
NCT01384929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCCM01|Study of Intensive Care Units in India|Indian Intensive Care Case Mix and Practice Patterns Study|INDICAPS|Indian Society of Critical Care Medicine|No|Completed|July 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4236|||Both|N/A|N/A|No|Non-Probability Sample|All patients present in the ICU July 14, 2010, October 13, 2010, January 12, 2011 and        April 13, 2011|April 2011|June 28, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01384929||102284|
NCT01385241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028044|Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women|Feasibility of a Stigma Reduction Intervention for HIV-infected Women||Duke University|Yes|Completed|July 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|99|||Female|18 Years|N/A|No|||October 2014|October 20, 2014|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01385241||102260|
NCT01381510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113909|Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database|Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database||GlaxoSmithKline|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|54459|||Male|50 Years|N/A|No|Non-Probability Sample|The study is populated with claims data from male health plan members and Medicare        patients age 50 and older who were continuously enrolled in a health plan that feeds into        the MarketScan database between July 1, 2003 and May 1, 2009. Patient records were        analyzed for 6 months prior to and at least 150 days following the index date for the        first 5-alpha reductase inhibitor (5ARI) treatment|August 2012|August 23, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381510||102547|
NCT01350986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO 620/5-1|Guided Self-Help for Parents of Children With Externalizing Problem Behavior|Efficacy of Cognitive-Behavioral Based Guided Self-Help for Parents of Children With Externalizing Problem Behavior|FLOH|German Research Foundation|No|Recruiting|May 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|146|||Both|4 Years|11 Years|No|||May 2011|May 9, 2011|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01350986||104874|
NCT01350999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-085/OCT-001|Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia|A Phase 3, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Long-term Administration of TAK-085 to the Patients With Hypertriglyceridemia.||Takeda|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|503|||Both|20 Years|74 Years|No|||August 2011|August 23, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01350999||104873|
NCT01382108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/374/11/CCLR|Meibography and Tear Scan Using the Oculus Keratograph 4|Meibography and Tear Scan Using the Oculus Keratograph 4|KITCHENER|University of Waterloo|No|Completed|June 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|39|||Both|17 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Non-contact lens wearers will be recruited using CCLR records and advertising approved by        the UW Office of Research Ethics|October 2013|October 31, 2013|June 21, 2011|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01382108||102501|
NCT01382563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1579|Registry for Eosinophilic Gastrointestinal Disorders (REGID)|Registry for Eosinophilic Gastrointestinal Disorders (REGID)|EoE|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|November 2012|June 2051|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|10000|||Both|1 Year|12 Years|No|Non-Probability Sample|Eosinophilic Gastrointestinal Disorders|July 2015|July 30, 2015|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382563||102466|
NCT01382576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491-81-11/1539-1563|Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity|Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity: A Pathophysiological Link Between Inflammation and Impaired Insulin Sensitivity?||Gulhane School of Medicine|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|78|None Retained|No biospecimens were to be retained|Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|34 women with PCOS and 44 healty women as control group.|December 2010|March 9, 2012|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01382576||102465|
NCT01382823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMTO 2010|Laser Cataract Surgery With the Femtosecond Laser Technology|Laser Cataract Surgery With the Femtosecond Laser Technology||Innovative Medical|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2011|October 5, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382823||102446|
NCT01382836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-15|The Role of Epigenetics in Inner City Asthma|The Role of Epigenetics in Inner City Asthma (ICAC-15)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|200|Samples With DNA|DNA, RNA, serum, and plasma specimens|Both|6 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Black inner city children with:1.)persistent asthma and 2.) without asthma.|November 2015|November 5, 2015|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01382836||102445|
NCT01352104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DO 620/2-4|Effectiveness of the Teacher Module of the Prevention Program for Externalizing Problem Behaviour in Preschoolers|Effectiveness of Guiding Teachers in Individualized Behavioral Intervention Strategies With Preschool Children Indicated for Externalizing Problem Behavior|PEP-TE|German Research Foundation|No|Completed|January 2004|December 2006|Actual|March 2005|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|144|||Both|3 Years|6 Years|No|||April 2011|May 10, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01352104||104788|
NCT01352715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5273|Study of Options for Second-Line Effective Combination Therapy (SELECT)|Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)|SELECT|AIDS Clinical Trials Group|Yes|Completed|January 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|515|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|January 12, 2011|Yes|Yes||No|October 29, 2015|https://clinicaltrials.gov/show/NCT01352715||104743|
NCT01400399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZCC-2010|Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer|Phase II Evaluation of Hypofractionated Breast Irradiation in Patients Undergoing Standard Lumpectomy or Oncolytic Mammoplasty With Bilateral Breast Reduction||Coastal Carolina Radiation Oncology|No|Recruiting|August 2010|August 2020|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|84|||Female|50 Years|N/A|No|Non-Probability Sample|Breast cancer patients who have had a lumpectomy or bilateral reduction mammoplasty        followed by hypofractionated irradiation.|December 2015|December 8, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400399||101101|
NCT01400893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCD-003|Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury|A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)||CytoPherx, Inc|Yes|Terminated|August 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|80 Years|No|||September 2014|September 4, 2014|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400893||101063|
NCT01401452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-770|Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities|Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities|EPIC|AbbVie|No|Active, not recruiting|August 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|288|||Both|18 Years|99 Years|No|Non-Probability Sample|Hospital, Dermatology|January 2016|January 20, 2016|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01401452||101020|
NCT01400880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Conveng-001|Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability|Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability||Convergent Engineering, Inc.|No|Completed|July 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|103|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Laboring women in Labor and Delivery ward|February 2015|February 10, 2015|July 21, 2011||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT01400880||101064|
NCT01402895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-541|The Effect Of A Neurodynamic Treatment On Nerve Conduction In Clients With Low Back Pain|The Effect Of A Neurodynamic Treatment On Nerve Conduction In Clients With Low Back Pain||McMaster University|No|Completed|May 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||July 2011|February 7, 2012|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01402895||100910|
NCT01402908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-PI-31|A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection|A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel-group, International Multicenter Phase III Trial of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection|PATRON|Medigen Biotechnology Corporation|Yes|Active, not recruiting|August 2011|December 2015|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|520|||Both|18 Years|N/A|No|||October 2014|October 12, 2014|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402908||100909|
NCT01402271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-55092|Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma||European Organisation for Research and Treatment of Cancer - EORTC||Recruiting|July 2012|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Female|18 Years|N/A|No|||May 2015|May 18, 2015|July 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01402271||100958|
NCT01402284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110221|Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients|Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2011|September 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|99 Years|No|||February 2016|February 20, 2016|July 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402284||100957|
NCT01401959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 186|Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy|Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy||SCRI Development Innovations, LLC|No|Active, not recruiting|September 2011|July 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401959||100982|
NCT01402232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y20110721|Reduction of Risk for Contrast Nephropathy|Reduction of Risk for Contrast-Induced Nephropathy: A Multicentre Observational Study of Contrast-Induced Nephropathy Following Coronary Angiography or Percutaneous Coronary Intervention|REICIN|Guangdong General Hospital|Yes|Recruiting|January 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|We reviewed all consecutive patients who were undergoing coronary angiography|August 2015|August 20, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402232||100961|
NCT01402206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Madrs 2010|Management of Depression in Primary Care|Management of Depression in Primary Health Care: a Controlled Trial on the Effectiveness of Regular, Structured, Patient-centered Visits||Göteborg University|No|Recruiting|March 2010|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Both|20 Years|75 Years|No|||November 2015|November 9, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01402206||100963|
NCT01402219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008A030201002|Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients|Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients:A Multicentre Randomized Double-Blind Trail of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease|NEIHR|Guangdong General Hospital|Yes|Terminated|November 2008|May 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|204|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|July 25, 2011||No|There were few eligible subjects from other centers.|No||https://clinicaltrials.gov/show/NCT01402219||100962|
NCT01384357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100026-E|Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies|Real-time Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies||Far Eastern Memorial Hospital|No|Completed|July 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|116|||Both|20 Years|85 Years|No|Non-Probability Sample|Patients with malignant cervical lymphadenopathie with either US-FNA or US-CNB over a        3-year period from 2007 July to 2010 Dec were retrospectively reviewed. There are two        major study groups according to the treatment status of the patient's population,        including patients who had pathology proofed previous cancer and with clinically cervical        lymphadenopathies after treatment. The second group included patients with cervical        lymphaenopathies but without previous diagnosis of malignancy and treatment.|May 2011|June 27, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384357||102328|
NCT01384630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-PT019|Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis|A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Plaque Psoriasis||XBiotech, Inc.|No|Completed|September 2011|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01384630||102307|
NCT01384942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002645|Meaning-based Group Counselling for Bereavement|The Development and Pilot Testing of Meaning-based Group Counselling Intervention for Bereavement||Jewish General Hospital||Completed|June 2010|October 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|November 7, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01384942||102283|
NCT01381276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 223773-1|Vitamin A Absorption From Cassava in Women|Vitamin A Equivalence of Carotenoids From Cassava in Women|FL-80|USDA, Western Human Nutrition Research Center|Yes|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|10|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01381276||102565|
NCT01382082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URCC 10055|Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy|Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment,Post-Treatment and at Six Months Follow Up|CANTAB|University of Rochester|Yes|Recruiting|July 2011|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1432|Samples Without DNA|Blood|Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|During enrollment, the groups will be balanced on age and gender. Controls of the same age        and gender as the subject receiving chemotherapy will be enrolled at the same time.|November 2015|November 2, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01382082||102503|
NCT01382095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-16682|Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea|A Phase 1 Dose-Escalating Study of dscCfaE, Co-Administered With and Without LTR192G, by Transcutaneous Immunization (TCI) in Healthy Adult U.S. Volunteers||U.S. Army Medical Research and Materiel Command|No|Completed|July 2011|April 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01382095||102502|
NCT01351311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAAMC|Resistance Training Exercise Using the Swiss Ball in Ankylosing Spondylitis|Assessment of Effectiveness of Resistance Training Exercise Using the Swiss Ball in Patients With Ankylosing Spondylitis||Federal University of São Paulo|Yes|Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||November 2012|November 29, 2012|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351311||104849|
NCT01351584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM TMK|Breast Cancer Registry|Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany||iOMEDICO AG|No|Recruiting|February 2007|December 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4500|||Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer patients undergoing antineoplastic or antihormonal therapy.|February 2016|February 23, 2016|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351584||104828|
NCT01351285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0019|Comparison of Effect-site Concentration of Remifentanil for Preventing Cough Against Endotracheal Tube During Anesthetic Emergence According to Anesthetics (Sevoflurane, Desflurane, and Propofol)|||Yonsei University|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|78|||Female|20 Years|60 Years|No|||June 2013|June 1, 2013|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01351285||104851|
NCT01351298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00602|Nasal Prep for Nasendoscopy in Children|Intra-nasal Topical Local Anesthetic and Decongestant for Flexible Nasendoscopy in Children: a Randomised Double-blind Placebo Controlled Trial||Children's & Women's Health Centre of British Columbia|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|69|||Both|3 Years|12 Years|No|||December 2012|December 4, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01351298||104850|
NCT01351558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101.01|Exercise and Pain Sensitivity|Exercise and Alterations in Pain Sensitivity||Frederiksberg University Hospital|No|Terminated|May 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|33|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 4, 2012|May 9, 2011||No|Recruitment difficulties.|No||https://clinicaltrials.gov/show/NCT01351558||104830|
NCT01351571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25251|An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma|An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma||Hoffmann-La Roche||Completed|August 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Probability Sample|Patients with advanced and/or metastatic renal cell carcinoma treated with Avastin and        interferon alpha-2a|November 2015|November 2, 2015|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01351571||104829|
NCT01382849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A14|F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)|F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)||Sunnybrook Health Sciences Centre|No|Withdrawn|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Macrobleed patients will be selected from a prospectively maintained ICH database at        Sunnybrook Hospital.|November 2014|November 17, 2014|June 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01382849||102444|
NCT01400152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jpl1|Active Warming in Prehospital Trauma Care|The Effect of Active Warming in Prehospital Trauma Care During Road and Air Ambulance Transportation - a Clinical Randomized Trial||Umeå University|Yes|Completed|December 2007|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01400152||101120|
NCT01401166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO22982|Patients' Preference of Herceptin (Trastuzumab) Subcutaneous Versus Intravenous Administration in HER2-positive Early Breast Cancer|A Randomized, Multi-centre Cross-over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-positive Early Breast Cancer (EBC)||Hoffmann-La Roche||Active, not recruiting|October 2011|December 2015|Anticipated|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|488|||Female|18 Years|N/A|No|||June 2015|June 3, 2015|July 22, 2011|No|Yes||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01401166||101042|
NCT01401465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-302|Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray|A Randomized Two Period Two-Way Crossover Study To Evaluate Patient Preference, Satisfaction And Efficacy Of A Nasal Aerosol Versus An Aqueous Nasal Spray Used For The Treatment Of Allergic Rhinitis||Sunovion|No|Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|327|||Both|12 Years|N/A|No|||April 2013|April 29, 2013|July 21, 2011|Yes|Yes||No|November 9, 2012|https://clinicaltrials.gov/show/NCT01401465||101019|
NCT01401426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01039130|Randomized Prospective Trial: Single Port Laparoscopic Vertical Sleeve Gastrectomy Versus Conventional Five Port Laparoscopic Vertical Sleeve Gastrectomy Surgery|Randomized Prospective Trial: Single Port Laparoscopic Vertical Sleeve Gastrectomy Versus Conventional Five Port Laparoscopic Vertical Sleeve Gastrectomy Surgery||St. Luke's-Roosevelt Hospital Center||Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||July 2010|July 16, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401426||101022|
NCT01401439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131677|Assessment of Fat Free Mass Index and Its Impact on Health in Children With Cystic Fibrosis|Longitudinal Assessment of Fat Free Mass Index and Its Impact on Lung Health and Overall Health Metrics in Pediatric Patients With Cystic Fibrosis|GAIA|University of Arkansas|No|Active, not recruiting|June 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Blood sample|Both|7 Years|17 Years|No|Probability Sample|Children with cystic fibrosis 7-17 years followed at Arkansas Children's hospital Cystic        Fibrosis Care Center|August 2015|August 14, 2015|July 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01401439||101021|
NCT01402297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nowak-02|Hydrogen Peroxide and Nitrite Reduction in Exhaled Breath Condensate of COPD Patients|Hydrogen Peroxide and Nitrite Reduction in Exhaled Breath Condensate of COPD Patients||Medical Universtity of Lodz|No|Completed|October 2010|April 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|13|||Both|40 Years|80 Years|No|||April 2011|July 25, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01402297||100956|
NCT01402310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS_CL_40wk|Bishop Score, Cervical Length and Multiple Proteins in Cervicovaginal Fluid at 40 Weeks to Predict Onset of Labor|||Seoul National University Hospital|No|Completed|November 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|Samples Without DNA|cervicovaginal fluid|Female|N/A|N/A|No|Probability Sample|Single tertiary hospital|December 2013|December 8, 2013|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01402310||100955|
NCT01402570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPH-1051|Glutathione and Health With Post-Polio Syndrome|Oral Glutathione and Health Outcomes Among Persons With Post-Polio Syndrome||University of Michigan|No|Completed|August 2011|July 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|50 Years|65 Years|No|||August 2013|August 20, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402570||100935|
NCT01402557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0836|Telehealth for Weight Maintenance of African-American Women ("Exercise Your Faith")|Telehealth for Weight Maintenance of African-American Women||University of Illinois at Chicago|No|Completed|August 2007|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|88|||Female|35 Years|65 Years|No|||July 2011|July 25, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402557||100936|
NCT01402804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGP-0001|NSAIDs in Coronary Artery Disease Patients|Non-steroidal Anti-inflammatory Drugs Impair the Platelet Inhibiting Effect of Acetylsalicylic Acid in Coronary Artery Disease Patients||Heinrich-Heine University, Duesseldorf|No|Completed|July 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|85|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a stable CAD undergoing coronary angiography in the Universitätsklinik        Düsseldorf.|November 2013|November 8, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402804||100917|
NCT01384656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0689|Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome|Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome||Yonsei University|No|Completed|February 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Both|20 Years|75 Years|No|||March 2013|March 4, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01384656||102305|
NCT01381289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-770-901|VX-770 Expanded Access Program|VX-770 Expanded Access Program (EAP)||Vertex Pharmaceuticals Incorporated||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|6 Years|N/A||||February 2012|February 8, 2012|June 22, 2011|No|Yes||||https://clinicaltrials.gov/show/NCT01381289||102564|
NCT01381523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113913|A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data|A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data||GlaxoSmithKline|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1|||Both|18 Years|64 Years|No|Non-Probability Sample|This study will be conducted using retrospective health care claims data from insured        migraine patients aged 18 to 64. Patients with a pharmacy claim for a combination        treatment of sumatriptan and naproxen sodium (SumaRT/Nap) during the index period will be        identified. If the SumaRT/Nap prescription is not preceeded by a single-entity triptan        pharmacy claim in the 6-month, pre-index period, that patient will be included in the        triptan-naive cohort. Propensity score matching will be used to identify migraine patients        with new single-entity triptan claims as a comparator group. Patients with a pharmacy        claim for a single-entity triptan in the 6-month, pre-index period and a pharmacy claim        for SumaRT/Nap will be included in the triptan switch cohort. Propensity score matching        will be used to identify patients with similar characteristics who switch to a new triptan        as a comparator group.|February 2013|February 21, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01381523||102546|
NCT01381536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114243|Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)|GSK1550188, A Randomised, Single-blind, Placebo Controlled, Dose Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)||GlaxoSmithKline||Completed|July 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||October 2011|April 5, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01381536||102545|
NCT01381562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114689|GSK2251052 in the Treatment of Complicated Intra-abdominal Infections|A Prospective, Randomized, Double-blind, Multi-center, Dose-ranging Study of the Safety, Tolerability and Efficacy of GSK2251052 in the Treatment of Complicated Intra-abdominal Infections in Adults||GlaxoSmithKline|Yes|Terminated|October 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|N/A|No|||February 2014|July 24, 2014|June 9, 2011|Yes|Yes|Microbiological findings of resistance on therapy in patients with complicated urinary tract    infection|No||https://clinicaltrials.gov/show/NCT01381562||102543|
NCT01350648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110152|Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection|The Natural History of Liver Disease in a Cohort of Participants With Hepatitis B and/or Hepatitis C With or Without HIV Infection||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|May 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|413|||Both|18 Years|99 Years|No|||September 2015|November 17, 2015|May 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01350648||104900|
NCT01351844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-548|The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer|Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer|CEASE|Georgetown University|No|Terminated|May 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Female|18 Years|N/A|No|||August 2013|August 6, 2013|May 10, 2011||No|Unable to recruit sufficient patients|No||https://clinicaltrials.gov/show/NCT01351844||104808|
NCT01351818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-SOM-2004-01|Adipocyte Function and Somtropin Deficiency|The Fayds Project: Adipocyte Function and Somtropin Deficiency|FAYDS|Ferring Pharmaceuticals|No|Completed|May 2005|March 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|5 Years|12 Years|No|Non-Probability Sample|Children with GH deficiency|May 2011|May 10, 2011|May 2, 2011||||No||https://clinicaltrials.gov/show/NCT01351818||104810|
NCT01351831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-106|The Difference Between Rehabilitation With or Without Strength Training After Total Knee Replacement|The Difference Between Rehabilitation With or Without Progressive Strength Training After Fast-track Total Knee Arthroplasty: A Randomized Controlled Trial|TKA|Copenhagen University Hospital, Hvidovre|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|80 Years|No|||September 2013|September 10, 2013|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01351831||104809|
NCT01352117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5264|Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma|A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067||AIDS Clinical Trials Group|Yes|Recruiting|October 2011|October 2020|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|468|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01352117||104787|
NCT01351792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1007-PR-0045|A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)|A 12-week, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Symbicort® 200/6 (Budesonide 200 µg Plus Formoterol 6 µg/Actuation), 2 Inhalations b.i.d., on Parameters of Small Airway Function in Patients With Chronic Obstructive Pulmonary Disease.|FAIR|Chiesi Farmaceutici S.p.A.|No|Terminated|September 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|113|||Both|40 Years|N/A|No|||March 2015|March 18, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01351792||104812|
NCT01351805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR059086|Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain|Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain||Brigham and Women's Hospital|Yes|Active, not recruiting|January 2011|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25876|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 30, 2016|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01351805||104811|
NCT01393249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR240778PEGASP|PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL|PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL|AAP2008|Rigshospitalet, Denmark|No|Recruiting|July 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|1 Year|18 Years|No|Probability Sample|Children aged 1-17.9, diagnosed with ALL and undergoing treatment with Peg-Asparaginase.|June 2013|June 30, 2013|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393249||101649|
NCT01397435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008013|MR Spectroscopy and Disease Severity Score for Gaucher in Pediatric Population|Quantification of Bone Marrow Involvement in Gaucher Disease With Proton MR Spectroscopy, Correlation With Bone Marrow Burden Score, Genotype and Disease Severity Score for Pediatric Patients|MRS in Gaucher|Children's Hospital of Philadelphia|No|Completed|July 2011|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|5 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will enroll patients with a Diagnosis of Gaucher disease. Subjects will be between 5        and 20 years of age. We will recruit an equal number of age and gender matched healthy        volunteers.|February 2015|February 3, 2015|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01397435||101328|
NCT01397682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INRCA-01-2011|Epidemiological Observatory on the Health Conditions of Inpatients Aged 65 or Older at the INRCA Research Hospitals|Epidemiological Observatory on the Health Conditions of Inpatients Aged 65 or Older at the INRCA Research Hospitals|report-AGE|Istituto Nazionale di Ricovero e Cura per Anziani||Enrolling by invitation|September 2011|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|2250|Samples With DNA|plasma, serum, whole blood|Both|65 Years|N/A|No|Non-Probability Sample|Inpatients aged 65 or older at the INRCA research hospital facilities of Ancona, Fermo,        Casatenovo, Roma, Cosenza (Italy).|October 2012|October 16, 2012|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01397682||101309|
NCT01397669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR#1751 /RV304/ SEARCH013|Characteristics of Immune Cells in Gut Mucosa of HIV Negative and HIV Positive Thais|||South East Asia Research Collaboration with Hawaii|No|Recruiting|July 2011|September 2021|Anticipated|September 2021|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|61|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397669||101310|
NCT01397994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FZS NICORIL STUDY 01|Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.|A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina.||Ferozsons Laboratories Ltd.|No|Recruiting|September 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|65 Years|No|||December 2011|December 7, 2011|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397994||101285|
NCT01398254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRL-SS|Femoral Versus Radial Access for Primary PCI|The Safety and Efficacy of Femoral Access Versus Radial for Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (SAFARI-STEMI Trial)|SAFARI-STEMI|Ottawa Heart Institute Research Corporation|Yes|Recruiting|July 2011|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2770|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01398254||101265|
NCT01398566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0077|Clinical Trial of a Rehabilitation Game - SuperBetter|Clinical Trial of a Novel Rehabilitation Game (Phase I - Feasibility)|SuperBetter|Ohio State University|No|Completed|May 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|15 Years|25 Years|No|||April 2015|April 9, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398566||101241|
NCT01394315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-7-BRE|Diffuse Optical Tomography (DOT) for Monitoring Response to Neoadjuvant (Preoperative) Chemotherapy in Breast Cancer|Diffuse Optical Tomography (DOT) for Monitoring Response to Neoadjuvant (Preoperative) Chemotherapy in Breast Cancer|DOT|National Cancer Centre, Singapore|No|Terminated|August 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|Samples With DNA|Pre-operative biopsy specimens and definitive surgical specimens|Female|21 Years|N/A|No|Non-Probability Sample|Approximately 60 patients are prescribed neaodjuvant chemotherapy for breast cancer at        National Cancer Centre Singapore annually. Accrual is expected to be 10 patients per year.        Up to 10 patients will be recruited for this study.|May 2013|May 2, 2013|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394315||101567|
NCT01394575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-RT-001|Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients|Phase 2 Study of Whole Breast Irradiation With Inversely Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients|IMRT-SIB|Fudan University|No|Recruiting|July 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|190|||Female|18 Years|70 Years|No|||June 2011|March 26, 2013|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394575||101547|
NCT01391806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreopMR 2011|The Impact of Preoperative Breast MRI in Patients With Breast Cancer Selected for Breast Conserving Surgery|The Impact of Preoperative Breast MRI in Newly Diagnosed Breast Cancer. A Prospective Study of Treatment Outcome in Patients Selected for Breast Conserving Surgery in a Norwegian Multidisciplinary Breast Cancer Clinic.||Nordlandssykehuset HF|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|||Female|35 Years|75 Years|No|Probability Sample|Patients are selected from screening or they are referred to the Breast Diagnostic Clinic        for clinical symptoms. The clinic serves a population of 237.000 in Nordland county,        Norway. Patients selected for breast-conserving surgery based on conventional radiological        examination, that is bilateral mammography and ultrasonography with biopsy, are        consecutively included in the study and offered preoperative breast MRI.|January 2009|July 11, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01391806||101759|
NCT01392755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25291|A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers|A Study to Evaluate the Effects of Two Different Meal Types, Omeprazole and Ranitidine on Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Subjects||Hoffmann-La Roche||Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01392755||101687|
NCT01398956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01361|An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures|An Open-label, Multicenter, Long-term, Follow-up Study in Japan to Evaluate the Safety, Tolerability, and Efficacy of Adjunctive Treatment With Oral L059 (Levetiracetam) in Epilepsy Subjects With Generalized Tonic-clonic (GTC) Seizures||UCB Pharma|No|Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|4 Years|N/A|No|||July 2015|July 26, 2015|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398956||101212|
NCT01398969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI.HBT.1|Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI|A Prospective Randomized Multi-Centre Trial of Fresh vs. Frozen-and-Thawed Human Biotherapy (Fecal Transplant) for Recurrent Clostridium Difficile Infection||McMaster University|Yes|Completed|July 2012|March 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398969||101211|
NCT01391429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H29666|Testing a Video Decision Support Tool to Supplement Goals-of-Care Discussions|Testing a Video Decision Support Tool to Supplement Goals-of-Care Discussions With Patients and Surrogates Receiving an Inpatient Palliative Care Consult||Boston Medical Center|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|37|||Both|21 Years|N/A|No|||February 2016|February 22, 2016|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01391429||101788|
NCT01391442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01469-30|- 4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF|Family Heritability, Investigating Gene-gene and Gene-environment Interactions in the Field of Cardiovascular Diseases - 4th VISIT (at 17 Years) of the STANISLAS COHORT|STANISLASV4|Central Hospital, Nancy, France|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|4006|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01391442||101787|
NCT01391975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Access 6|Surveillance and Proactive Intervention for Dialysis Access|A Multi Centre Randomized Controlled Trial of the Clinical and Cost Effectiveness of Duplex Ultrasound Surveillance With Proactive Intervention Versus no Surveillance and Reactive Intervention for the Management of Stenosis in Arterio-venous Fistulae for Dialysis Vascular Access.|SPIDA|University of Hull|No|Not yet recruiting|May 2012|October 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|850|||Both|18 Years|N/A|No|||July 2011|July 11, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01391975||101746|
NCT01392261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHF-Altitude-001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2009|||||N/A|N/A|N/A||||||||||||||July 8, 2011|March 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392261||101724|
NCT01392248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34275.068.11 / MEC 11-2-006|Prediction of Pain After Breast Cancer Surgery With EEG|EEG as a Predictor for Postoperative Pain and the Development of Chronic Postsurgical Pain After Breast Cancer Surgery||Maastricht University Medical Center|No|Terminated|July 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|||Female|18 Years|65 Years|No|Non-Probability Sample|One hundred and fifty female patients undergoing elective breast cancer surgery in        day-case surgery.|November 2013|November 26, 2013|June 1, 2011||No|funding and recruiting problems|No||https://clinicaltrials.gov/show/NCT01392248||101725|
NCT01392586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOOG 2010-05|Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer|Systemic Therapy With or Without Up Front Surgery of the Primary Tumor in Breast Cancer Patients With Distant Metastases at Initial presenTation|SUBMIT|Jeroen Bosch Ziekenhuis|Yes|Terminated|February 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 2, 2014|July 5, 2011||No|due to low accrual rate|No||https://clinicaltrials.gov/show/NCT01392586||101700|
NCT01392599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026/2009|Surgical Treatment Of Complex Regional Pain Syndrome Type II (CRPS II)|Surgical Treatment of Complex Regional Pain Syndrome Type II (CRPS II) by Regional Subcutaneous Venous Sympathectomy||Medical University of Vienna|No|Recruiting|January 2009|October 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||June 2011|July 11, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01392599||101699|
NCT01393275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gi-01-2010|Effects of Exercise Intervention and Rehabilitation Exercise Intervention in Patients With Type 2 Diabetes|Effects of Exercise Intervention in Patients With Type 2 Diabetes - Strength Endurance Exercise Intervention Versus Combination of Strength Endurance Exercise Intervention and Rehabilitation Exercise Intervention||University of Giessen|No|Completed|February 2010|October 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||November 2011|November 5, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393275||101647|
NCT01393613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-230|Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed-dose OPC-34712 in the Treatment of Adults With Acute Schizophrenia|BEACON|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|July 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|674|||Both|18 Years|65 Years|No|||October 2015|October 26, 2015|July 11, 2011|Yes|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01393613||101621|
NCT01397461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-110880-01|Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo|A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo||Ferrer Internacional S.A.|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|465|||Both|2 Years|N/A|No|||February 2014|February 18, 2014|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397461||101326|
NCT01397214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGF-BR-CT-101|Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Cross-over Study to Investigate Safety and Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers|MGF|Boryung Pharmaceutical Co., Ltd|No|Completed|July 2011|January 2012|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 29, 2012|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01397214||101345|
NCT01397474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34607.078.10|Peripheral Perfusion Targeted Fluid Management|Peripheral Perfusion Targeted Fluid Management in Critically Ill Patients: a Pilot Study||Erasmus Medical Center|Yes|Recruiting|October 2011|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|85 Years|No|||January 2014|January 3, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01397474||101325|
NCT01397695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090666|Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)||University of California, San Diego|Yes|Recruiting|June 2009|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397695||101308|
NCT01397708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA1001|Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma|A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma||Ziopharm|No|Completed|August 2011|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2014|January 23, 2015|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01397708||101307|
NCT01391299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTXC-10-002|Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines|A Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Single Treatment Cycle Study of BOTOX® Cosmetic (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects With Forehead and Glabellar Rhytides||Allergan|No|Completed|June 2011|February 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|19 Years|N/A|No|||October 2012|October 26, 2012|July 8, 2011|Yes|Yes||No|October 26, 2012|https://clinicaltrials.gov/show/NCT01391299||101798|
NCT01398007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUT2503|Use of the Camouflage Syringe to Reduce Dental Anxiety and Fear in Children|Evaluation of the Efficacy of Camouflage Syringe in Reducing Dental Anxiety and Fear in Children||Government Dental College and Hospital, India|Yes|Completed|October 2005|April 2006|Actual|April 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|2 Years|14 Years|No|||July 2011|March 10, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398007||101284|
NCT01391286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-067|Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis|A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-daily Application of Bimatoprost Solution 0.03% Compared to Vehicle to Treat Chemotherapy-induced Hypotrichosis of the Eyelashes in Japanese Subjects||Allergan|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|20 Years|N/A|No|||May 2013|May 21, 2013|July 8, 2011|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT01391286||101799|
NCT01391546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTV03C|Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Subjects Aged From 50 Years Old|An Open-label, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ZOSTAVAX When Administered by Intramuscular Route or Subcutaneous Route to Subjects of 50 Years of Age and Older||Sanofi Pasteur MSD|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|354|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391546||101779|
NCT01392417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090043|Anterior Prolift Versus Posterior Prolift for Pelvic Floor Prolapse|||Western Galilee Hospital-Nahariya|No|Completed|February 2009|June 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|140|||Female|18 Years|95 Years|No|Non-Probability Sample|Women with pelvic floor prolapse who underwent surgery with Prolift|July 2011|July 2, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01392417||101713|
NCT01392742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25670|An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin||Hoffmann-La Roche||Completed|May 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|443|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C treated with Pegasys and ribavirin|November 2015|November 9, 2015|July 11, 2011||No||No|November 9, 2015|https://clinicaltrials.gov/show/NCT01392742||101688|
NCT01392118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP38634|Recurrent ESBL-producing Enterobacteriaceae Bacteremia: Risk Factor, Molecular Character and Susceptibility Change|Recurrent ESBL-producing Enterobacteriaceae Bacteremia: Risk Factor, Molecular Character and Susceptibility Change||Chang Gung Memorial Hospital|No|Not yet recruiting|July 2011|December 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|400|Samples Without DNA|ESBL strains of E. coli or K. pneumoniae from blood cultures under normal practice|Both|18 Years|N/A|No|Non-Probability Sample|In a tertiary care hospital, every adult patient with at least one episode of ESBL-EK        bloodstream infection from August 2004 to July 2010 will be recruited into this study.        Patients who died within 48h after first episode of ESBL-EK bloodstream infection will be        excluded.|January 2011|July 11, 2011|July 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01392118||101735|
NCT01391117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017992|TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin|A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin||Tibotec BVBA|No|Terminated|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|10||Actual|14|||Both|18 Years|65 Years|No|||October 2012|October 25, 2012|June 13, 2011||No|Antiviral activity was considered insufficient to warrant further clinical development of    TMC649128.|No||https://clinicaltrials.gov/show/NCT01391117||101812|
NCT01391130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14241|A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma|Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma||Eli Lilly and Company|No|Active, not recruiting|August 2011|March 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391130||101811|
NCT01399723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEMRI_CT_2010/0014|Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia|Amoxicillin Versus Benzyl Penicillin for Severe Childhood Pneumonia Amongst Inpatients: An Open Label Randomised Controlled Non-inferiority Trial||KEMRI-Wellcome Trust Collaborative Research Program|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|561|||Both|2 Months|59 Months|No|||January 2015|January 28, 2015|July 12, 2011||No||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01399723||101153|
NCT01399736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Compare-Acute|Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.|Fractional Flow Reserve Guided Primary Multivessel Percutaneous Coronary Intervention to Improve Guideline Indexed Actual Standard of Care for Treatment of ST-elevation Myocardial Infarction in Patients With Multivessel Coronary Disease|CompareAcute|Maasstad Hospital|Yes|Active, not recruiting|July 2011|November 2018|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|885|||Both|18 Years|85 Years|No|||October 2015|October 2, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399736||101152|
NCT01391715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01July2011|Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD|Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD: a Randomized Controlled Trial|DRNERD|Inje University|No|Withdrawn|August 2011|December 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 16, 2012|July 11, 2011||No|patients could not be recuited within study duration|No||https://clinicaltrials.gov/show/NCT01391715||101766|
NCT01392274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-2011-FOCUS|pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture|pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture|FOCUS|Mauna Kea Technologies|No|Completed|April 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|121|||Both|18 Years|N/A|No|Non-Probability Sample|Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde        Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Bile Duct Cancers|December 2014|December 2, 2014|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392274||101723|
NCT01392612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPO1|Erythropoietin and Platelet Activation Markers|The Effect of Erythropoietin on Platelet Activation Markers: a Prospective Study in Healthy Volunteers||Medical University of Vienna|Yes|Completed|November 2006|July 2007|Actual|February 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2011|July 13, 2011|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01392612||101698|
NCT01392625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100968|PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)|A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy.|PoseidonDCM|University of Miami|Yes|Active, not recruiting|June 2011|August 2016|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|95 Years|No|||September 2015|September 10, 2015|June 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392625||101697|
NCT01393977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-01-19SCI|Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China|Efficacy Difference Between Rehabilitation Therapy and Umbilical Cord Derived Mesenchymal Stem Cells Transplantation in Patients With Acute or Chronic Spinal Cord Injury in China||General Hospital of Chinese Armed Police Forces|Yes|Recruiting|January 2011|May 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|20 Years|50 Years|No|||October 2011|October 7, 2011|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393977||101593|
NCT01393990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12284|A Study of LY2228820 in Patients With Advanced Cancer|A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|August 2008|December 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01393990||101592|
NCT01393288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA163074-01A1|Developing Individualized Strategies to Prevent Nausea and Vomiting|Developing Individualized Strategies to Prevent Nausea and Vomiting|PDNVF|University of California, San Francisco|Yes|Withdrawn|November 2013|November 2015||November 2014||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|0|||Both|21 Years|70 Years|No|||November 2013|November 12, 2013|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393288||101646|
NCT01393626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921083|A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease||Pfizer|Yes|Completed|October 2011|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|280|||Both|18 Years|75 Years|No|||June 2015|June 15, 2015|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393626||101620|
NCT01397227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAL-V-A001|A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model|A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-escalation Clinical Study Evaluating Safety, Tolerability and Immunogenicity of Two Dose Levels of Recombinant Adenoviral Serotype Ad35 and Serotype Ad26 Vectors Expressing the Malaria Plasmodium Falciparum Circumsporozoite Antigen Administered as Heterologous Prime-boost Regimen, and Assessing Protective Efficacy of the Higher Dose in a Malaria Challenge Model in Unblinded Conditions||Crucell Holland BV|Yes|Completed|June 2011|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 3, 2012|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397227||101344|
NCT01391013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017575|A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients|A Randomised, Controlled, Open-Label Trial to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg O.D. Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Subjects With Undetectable Plasma HIV-1 RNA on Their Current Treatments.|MONARCH|Janssen-Cilag S.p.A.|No|Completed|June 2009|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|June 23, 2011||No||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01391013||101820|
NCT01391312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTXC-11-001|Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines|A Pilot Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Glabellar Lines - Establishing Patient Satisfaction||Allergan|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|65 Years|No|||August 2012|August 24, 2012|July 8, 2011|Yes|Yes||No|August 24, 2012|https://clinicaltrials.gov/show/NCT01391312||101797|
NCT01391559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS22812|Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease|Efficacy of Inhaling Bronchodilator Medications in Patients With Chronic Obstructive Pulmonary Disease Who Have a Low Peak Inspiratory Flow Rate||Dartmouth-Hitchcock Medical Center|Yes|Completed|July 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|60 Years|90 Years|No|||July 2013|July 5, 2013|July 8, 2011||No||No|April 1, 2013|https://clinicaltrials.gov/show/NCT01391559||101778|
NCT01391572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011ESO_FU_01|A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer|A Randomized Phase II Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Locoregionally Advanced Thoracic Esophageal Squamous Cell Carcinoma||Fudan University|Yes|Recruiting|April 2011|||December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||March 2011|July 20, 2011|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391572||101777|
NCT01391819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112994|Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children|An Epidemiological Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children||GlaxoSmithKline||Completed|September 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|2000|||Both|5 Years|13 Years|Accepts Healthy Volunteers|||February 2015|February 26, 2015|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391819||101758|
NCT01391325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-401|Allopurinol Outcome Study|Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)|LASSO|Ardea Biosciences, Inc.|No|Completed|July 2011|March 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1735|||Both|18 Years|85 Years|No|||May 2014|May 16, 2014|July 7, 2011|Yes|Yes||No|April 1, 2014|https://clinicaltrials.gov/show/NCT01391325||101796|
NCT01392105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC2-Version 6.0|Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction|A Randomized, Open-label, Multicenter Trial for the Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction|SEED-MSC|Yonsei University|Yes|Completed|March 2007|May 2010|Actual|May 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||July 2009|July 11, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01392105||101736|
NCT01391832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092010-035|Novel Treatment of Emotional Dysfunction in Post Traumatic Stress Disorder (PTSD)|Novel Treatment of Emotional Dysfunction in PTSD||The University of Texas at Dallas|Yes|Enrolling by invitation|July 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|July 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391832||101757|
NCT01392131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP1|Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)|Study to Evaluate Safety and Therapeutic Efficacy of a Nutritional Supplement 'Oncoxin' in Patients With Hepatocellular Carcinoma||Clinical Research Organization, Dhaka, Bangladesh|Yes|Active, not recruiting|July 2011|July 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||December 2012|December 11, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01392131||101734|
NCT01392443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2202|Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF|A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis||Novartis||Active, not recruiting|August 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392443||101711|
NCT01391143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-MGA271-01|Safety Study of MGA271 in Refractory Cancer|A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer||MacroGenics|No|Recruiting|July 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|151|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|July 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01391143||101810|
NCT01391169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|seromuscular flap|Pedicled Seromuscular Flap For Enforcement Of High Risk Intestinal Anastomoses|Pedicled Seromuscular Flap For Enforcement Of High Risk Intestinal Anastomoses||Mansoura University|Yes|Completed|April 2009|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2009|July 8, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01391169||101808|
NCT01391455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mesh isolation|Isolation of the Spermatic Cord in Mesh Inguinal Hernia Repair|Isolation of the Spermatic Cord Following Mesh Inguinal Hernia Repair||Chatham Kent Health Alliance|Yes|Recruiting|July 2011|August 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Male|21 Years|N/A|No|||July 2011|July 11, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01391455||101786|
NCT01391988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133/2008 HCB|Trial Comparing Electric and Harmonic Scalpel in Mastectomy|Prospective Trial Comparing the Use of Conventional Electric Scalpel and Harmonic Scalpel in Mastectomy|Harmonic|Barretos Cancer Hospital|No|Completed|January 2008|November 2008|Actual|November 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|97|||Female|18 Years|N/A|No|||March 2014|March 6, 2014|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01391988||101745|
NCT01392001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25634|An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)|Evaluation of Glucocorticoid Sparing Effect in Patients Receiving RoActemra® for Rheumatoid Arthritis in Real Life.||Hoffmann-La Roche||Completed|March 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|322|None Retained|unknown|Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients on treatment with RoActemra/Actemra and > 5 mg/day        prednisone (or equivalent)|March 2016|March 1, 2016|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01392001||101744|
NCT01392300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201/SP/3001|Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Upper Limb|PURE|Merz Pharmaceuticals GmbH|Yes|Completed|September 2011|February 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|July 7, 2011|Yes|Yes||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01392300||101721|
NCT01392313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03-068|Measurement of Renal Function With Iohexol in Subjects Ingesting Carnitine|Measurement of Glomerular Filtration Rate (GFR) Using Iohexol in Healthy Subjects Taking Creatinine Supplements||Montefiore Medical Center|No|Withdrawn|May 2010|June 2010|Anticipated|June 2010|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|July 11, 2011|July 11, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01392313||101720|
NCT01393639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9391010|Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis|A Phase 2, Randomized, Double Blind Assessment Of Efficacy And Safety Of PF-04171327 (1, 5, 10, 15 Mg Dose, Daily) Compared To 5 Mg And 10 Mg Prednisone Daily And Placebo Daily In Subjects With Rheumatoid Arthritis Over An 8 Week Period Followed By A 4 Week Period Of Tapering Of Study Drug||Pfizer|Yes|Completed|September 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|323|||Both|19 Years|N/A|No|||August 2014|August 12, 2014|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393639||101619|
NCT01393652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3351001|Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679|A Phase I, Randomized, Placebo-Controlled, Dose Escalating Cross Over Study To Evaluate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of PF-05105679 Under Fasted Conditions In Healthy Volunteers|SINGLE DOSE|Pfizer|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 30, 2011|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01393652||101618|
NCT01389830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0436|End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer|End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer||M.D. Anderson Cancer Center|No|Recruiting|June 2011|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Survey of 200 older Latino Medicare beneficiaries from the greater Houston area enrolled        in a larger national Cancer Prevention and Treatment Demonstration Project (CPTD).|October 2015|October 13, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389830||101910|
NCT01389843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1102-072-352|Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)|Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)|KorAHF|Seoul National University Hospital||Recruiting|March 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5626|||Both|N/A|N/A|No|Non-Probability Sample|acute decompensated heart failure|May 2015|May 19, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389843||101909|
NCT01392898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lir-HJCJ-03|Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes|The Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)|ELEGANT|Radboud University||Active, not recruiting|February 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||July 2011|August 1, 2013|July 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392898||101676|
NCT01392911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PanACEA - RUNMC - HR1|Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB|A Phase IIA Dose Ranging Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Higher Doses of Rifampicin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|HR1|Radboud University|Yes|Active, not recruiting|June 2011|||September 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|128|||Both|18 Years|65 Years|No|||June 2014|June 6, 2014|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392911||101675|
NCT01392924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11883|Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors|An Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of SAR245408 Administered Orally Daily in Patients With Solid Tumors||Sanofi|No|Completed|August 2011|November 2014|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||December 2014|December 2, 2014|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01392924||101674|
NCT01389804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW10/115,GC 1127|Parents of Pediatric Solid Organ Transplant Recipients: Transition to Home and Chronic Illness Care|Parents of Pediatric Solid Organ Transplant Recipients: Transition to Home and Chronic Illness Care||Medical College of Wisconsin|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Parents of pediatric solid organ transplant recipients (heart, kidney, liver or lung)|April 2012|April 19, 2012|September 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01389804||101912|
NCT01390649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgPro10_4001|A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)|An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis||CSL Behring|Yes|Completed|November 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|65 Years|No|||September 2015|September 16, 2015|July 7, 2011|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT01390649||101848|
NCT01390389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000980|Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression|Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression: A 31 Phosphorus MR Spectroscopy Study||Mclean Hospital|Yes|Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|19|||Both|55 Years|89 Years|Accepts Healthy Volunteers|||August 2013|October 30, 2013|July 7, 2011|No|Yes||No|August 26, 2013|https://clinicaltrials.gov/show/NCT01390389||101868|
NCT01390402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0099|Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG|Natural Killer (NK) Cells and Nonmyeloablative Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)||M.D. Anderson Cancer Center|No|Completed|January 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|70 Years|No|||January 2016|January 4, 2016|July 7, 2011|Yes|Yes||No|November 25, 2015|https://clinicaltrials.gov/show/NCT01390402||101867|
NCT01390662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26992|Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression|Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression|D3-vit-dep|Region Syddanmark|Yes|Recruiting|March 2011|December 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||July 2011|March 27, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01390662||101847|
NCT01391026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-143|Computer Assisted Symptom Evaluation of Complex Patients|Computer Assisted Quality of Life and Symptom Assessment of Complex Patients|CASE|John H. Stroger Hospital|No|Completed|June 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391026||101819|
NCT01391338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0019|A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)|A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS|AZURE|Astellas Pharma Inc|Yes|Completed|June 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|239|||Male|18 Years|N/A|No|||March 2013|March 19, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391338||101795|
NCT01391585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24HS019453-01PRM|Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management|Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management||Denver Health and Hospital Authority|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|135|||Both|18 Years|75 Years|No|||February 2014|February 10, 2014|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391585||101776|
NCT01391845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ist1979|Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern|Effect of Ulipristal Acetate Administration on Serum Progesterone Levels and Glycodelin-A Endometrial Pattern in Women Undergoing Controlled Ovulation Stimulation.||Programa de Asistencia Reproductiva de Rosario|Yes|Not yet recruiting|July 2011|June 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Anticipated|16|||Female|21 Years|35 Years|Accepts Healthy Volunteers|||May 2011|July 19, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01391845||101756|
NCT01391858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0643|Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica|Effects of Oral Pregabalin Versus Placebo on Postoperative Pain and Morphine Consumption After Mastectomy||University of Texas Southwestern Medical Center|Yes|Completed|December 2006|June 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Female|18 Years|70 Years|No|||August 2014|August 8, 2014|June 27, 2011|Yes|Yes||No|December 31, 2013|https://clinicaltrials.gov/show/NCT01391858||101755|
NCT01393132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003008179|Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye|Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye||Michigan Cornea Consultants, PC|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|90 Years|No|||December 2015|December 21, 2015|July 7, 2011|Yes|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT01393132||101658|
NCT01391468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-99-IRB-308|Beneficial Effect of Probiotics on Chronic Kidney Disease|Beneficial Effect of Probiotics on Chronic Kidney Disease||China Medical University Hospital|Yes|Completed|August 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|47|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|July 8, 2011|Yes|Yes||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01391468||101785|
NCT01391728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20102011|Active Lifestyle All Your Life-an Intervention Programme for Preventing Fall Injuries|||Karolinska Institutet||Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|65 Years|N/A|No|||June 2011|February 6, 2013|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01391728||101765|
NCT01392014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45114|Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases|Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia|DHP+PQ|Indonesia University|No|Completed|December 2008|October 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|374|||Both|4 Years|N/A|No|||August 2008|July 8, 2011|June 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392014||101743|
NCT01392287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001094|Treatment Resistant Geriatric Depression in Primary Care|Treatment Resistant Geriatric Depression in Primary Care: Is NAAG (N-Acetylaspartylglutamate), Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) at 3 Tesla, a Predictor of Treatment Response?||Mclean Hospital|No|Active, not recruiting|August 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|55 Years|89 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|July 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01392287||101722|
NCT01393301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA031038-01A1|Integrated Treatment for Smoking Cessation & Anxiety in People With HIV Phase 1|Integrated Treatment for Smoking Cessation & Anxiety in People With HIV Phase 1|Project Quit|Massachusetts General Hospital|Yes|Completed|October 2011|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393301||101645|
NCT01393691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6191|A Clinical Research Studying Interventions for Nighttime Fears in Preschool Children|Interventions for Nighttime Fears in Preschool Children: Assessment of Predictors and Outcomes||Rabin Medical Center|No|Completed|June 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|4 Years|6 Years|No|||July 2015|July 8, 2015|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01393691||101615|
NCT01393704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000264/1|Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial|Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial||Brigham and Women's Hospital|No|Completed|July 2011|June 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|152|||Female|18 Years|60 Years|No|||July 2015|July 20, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393704||101614|
NCT01390350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885DDE03T|Ilaris® Effects in Schnitzler Syndrome (ILESCH)|A Multi-center, Double-blind, Placebo-controlled Phase II Study of the Efficacy and Safety of Canakinumab in Subjects With Schnitzler Syndrome|ILESCH|Charite University, Berlin, Germany|Yes|Active, not recruiting|July 2011|April 2018|Anticipated|January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390350||101871|
NCT01391247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52610|Validation of Retinal Oximetry in Glaucoma Patients: a Structural and Functional Correlation|Validation of Retinal Oximetry in Glaucoma Patients: a Structural and Functional Correlation||Universitaire Ziekenhuizen Leuven|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|primary care clinic|December 2010|February 5, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01391247||101802|
NCT01389570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/176|Postoperative Nausea/Vomiting and Acupressure|Postoperative Nausea/Vomiting and Acupressure Can Acupressure With Wristbands Reduce the Use of Antiemetics for the Treatment of Postoperative Nausea and Vomiting?|Acunausea|National Research Centre of Complementary and Alternative Medicine, Norway|No|Not yet recruiting|September 2011|June 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|1 Year|80 Years|Accepts Healthy Volunteers|||June 2011|July 15, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01389570||101930|
NCT01390974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101203|Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome|Bedside Genetic Approach to Identify Clopidogrel CYP2C19 Metabolizer and Optimize Maintenance Thienopyridine Treatment After an Acute Coronary Syndrome: The GAMMA Study|GAMMA|Assistance Publique - Hôpitaux de Paris|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|||Both|18 Years|N/A|No|Non-Probability Sample|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel        or clopidogrel therapy.|February 2014|February 7, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390974||101823|
NCT01391793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK087870|Corticosteroids for Children With Febrile Urinary Tract Infections|Corticosteroids for Children With Febrile Urinary Tract Infections|STARRS|University of Pittsburgh|Yes|Recruiting|September 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|390|||Both|2 Months|6 Years|No|||November 2015|November 30, 2015|July 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391793||101760|
NCT01390155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|058/11|Characterization of Ischemia Related Changes in Esophageal Electrocardiography|Characterization of Ischemia Related Changes in Esophageal Electrocardiography||University Hospital Inselspital, Berne|No|Completed|July 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|45|||Both|18 Years|N/A|No|Probability Sample|Patients referred for elective coronary angiography due to suspected or known coronary        artery disease.|May 2013|May 23, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01390155||101886|
NCT01390168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-FAS-2008-1145|Internet-administrated Treatment of Anxiety Disorders|Tailored Internet-administrated Treatment of Anxiety Disorders - A Randomised Controlled Trial (NOVA II)|NOVA II|Umeå University||Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01390168||101885|
NCT01390415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954-365|A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)|A Retrospective Survey to Evaluate the Renoprotective Effect of Losartan in Type II Diabetic Patients With Microalbuminuria and Hypertension in Real Life||Merck Sharp & Dohme Corp.|No|Completed|September 2008|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|136|||Both|20 Years|70 Years|No|Non-Probability Sample|Adult participants with diabetes mellitus and hypertension treated with losartan 50 mg or        100 mg for at least 6 months in a hospital setting in Taiwan|October 2015|October 20, 2015|July 7, 2011|No|Yes||No|August 9, 2011|https://clinicaltrials.gov/show/NCT01390415||101866|
NCT01390428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-013|Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)|An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172)||Merck Sharp & Dohme Corp.|No|Completed|July 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|February 3, 2016|July 7, 2011|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01390428||101865|
NCT01390675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE DHM-AN-OR-2011/04|Anesthesia for Catheter Aortic Valve ImplantATIOn Registry||AVIATOR|Deutsches Herzzentrum Muenchen|No|Recruiting|June 2011|May 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing transcatheter aortic valve implantation (TAVI)|January 2016|January 19, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01390675||101846|
NCT01390688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2011-031|Brain-derived Neurotrophic Factor and Cogntive Function|Brain-derived Neurotrophic Factor: A Link to Obesity, Insulin Resistance and Cognitive Dysfunktion?||Rigshospitalet, Denmark|Yes|Active, not recruiting|June 2009|March 2012|Anticipated|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|200|Samples With DNA|Plasma, Serum, DNA, Muscle tissue and fat tissue|Both|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be selected from newspapers.|June 2009|July 7, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01390688||101845|
NCT01391039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ07062011|Diagnostic Study of Early Breast Cancer Using Ultrasound|Microbubble Contrast Ultrasound and Transient Elastography Imaging of Early Breast Cancer||Sunnybrook Health Sciences Centre|No|Terminated|September 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Female|18 Years|80 Years|No|||November 2015|November 26, 2015|June 15, 2011||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT01391039||101818|
NCT01391871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAT-TRICK-OCT|Vascular Healing of DES at 3 Months|A Randomized Prospective Multicenter Trial to Compare Vascular Healing and Vasodilation at 3 Months After Deployment of PRO-Kinetic Drug-eluting Stent and Endeavor Resolute Zotarolimus-eluting Stent in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography and Coronary Flow Reserve|HAT-TRICK-OCT|University of Turku|No|Completed|June 2011|July 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|46|Samples With DNA|Serum, plasma|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with acute coronary syndrome treated with PRO-Kinetic DES or Endeavor Resolute        DES during index PCI.|August 2013|August 1, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391871||101754|
NCT01391351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|miRSa|Search for Predictors of Therapeutic Response in Ovarian Carcinoma|Search for Predictors of Therapeutic Response in Patients With Carcinoma of the Ovary, the Fallopian Tube or Peritoneal Serous-type Advanced|miRSa|Centre Francois Baclesse|No|Active, not recruiting|June 2011|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|107|||Female|18 Years|N/A|No|||April 2013|July 3, 2014|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391351||101794|
NCT01391364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|691|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2011|||||N/A|N/A|N/A||||||||||||||August 10, 2012|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391364||101793|
NCT01391598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FibromialgiaGiraldes|Lidocaine on Pain Relief and IL and Substance P in Fibromyalgia|Evaluation of the Effect of Intravenous Lidocaine on Pain Relief and Plasma Concentrations of Interleukins (IL-1 and IL-6) and Substance P in Patients With Fibromyalgia||Federal University of São Paulo|Yes|Recruiting|January 2010|December 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||December 2009|July 11, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01391598||101775|
NCT01392482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NIT-XXX-2011/1|IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder|IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder|IBIS|AstraZeneca|No|Completed|July 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|751725|||Both|18 Years|N/A|No|Non-Probability Sample|All patients from 40 LHU|September 2012|September 14, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01392482||101708|
NCT01392820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4131C00003|A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers|A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers||AstraZeneca|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|48|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 14, 2011|July 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01392820||101682|
NCT01390831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SZ0118|Renal Denervation in Patients With Uncontrolled Hypertension in Chinese|Renal Denervation in Patients With Uncontrolled Hypertension in Chinese||The Second People's Hospital of Chengdu|Yes|Not yet recruiting|November 2011|June 2015|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2011|July 8, 2011|July 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390831||101834|
NCT01391481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGH-PFC|Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome|The Randomized Controlled Trial (RCT) on the Vaporized Perfluorocarbon (PFC) Inhalation Treatment of Acute Respiratory Distress Syndrome With the Invasive Mechanical Ventilation（IMV）||Chinese PLA General Hospital|Yes|Recruiting|August 2011|April 2015|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||April 2012|April 9, 2012|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391481||101784|
NCT01391741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123SmOkE|The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD)|The Effect of High-Volume Walking With Visual Cues on Gait in People With Parkinson´s Disease. A Randomized Controlled Trial||University of Iceland|No|Completed|April 2008|September 2008|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|N/A|79 Years|No|||March 2010|July 11, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391741||101764|
NCT01392950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10-491|Clinical Study of Clariti Monthly Contact Lens|Clinical Performance of the Clariti Monthly Contact Lens for Daily Wear||Sauflon Pharmaceuticals Ltd|No|Completed|September 2010|March 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|90|||Both|19 Years|63 Years|Accepts Healthy Volunteers|||July 2011|July 27, 2011|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392950||101672|
NCT01392963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-021|The Treatment of Depression With Botulinum Type A Toxin|The Treatment of Depression With Botulinum Type A Toxin (Botox): A Randomized, Double Blind, Crossover Study||Seton Healthcare Family|Yes|Completed|July 2011|June 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||January 2014|January 22, 2014|July 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392963||101671|
NCT01391221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011005|Inflammatory Markers and Cognitive Function in Major Depression|Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study||Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine|No|Recruiting|July 2011|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|20 Years|50 Years|No|||July 2011|July 17, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391221||101804|
NCT01392352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A091962|HYPAZ: Hypertension Induced by Pazopanib|HYPAZ: An Open-label Investigation Into Hypertension Induced by Pazopanib Therapy|HYPAZ|Cambridge University Hospitals NHS Foundation Trust|Yes|Terminated|April 2011|September 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 30, 2011||No|Following DMC review, due to slow recruitment of evaluable patients.|No||https://clinicaltrials.gov/show/NCT01392352||101717|
NCT01392664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090040|TVTO Versus TVTFFM for Urinary Stress Incontinence|||Western Galilee Hospital-Nahariya|No|Completed|February 2009|July 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|200|||Female|18 Years|95 Years|No|Non-Probability Sample|Women with Urinary Stress Incontinence treated by TVT|July 2011|July 2, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01392664||101694|
NCT01389609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0351069|Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition|Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition||Pfizer|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|July 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01389609||101927|
NCT01389622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC01|Effect of Self-administered Auricular Acupressure on Smoking Cessation—a Pilot Study|Effect of Self-administered Auricular Acupressure on Smoking Cessation—a Pilot Study||Queen's University|No|Recruiting|July 2011|January 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|November 17, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01389622||101926|
NCT01391260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-S10-09|Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations||ZhuGuangYing|No|Recruiting|July 2011|July 2017|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||August 2011|August 1, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391260||101801|
NCT01390987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBsurvey-001|Access to Care and Adherence Tuberculosis (TB) Survey|Survey Nazionale Sui Determinanti Del Ritardato Accesso Alle Cure e Della Mancata Aderenza al Trattamento Antitubercolare (National Survey on the Determinats of Delayed Access to Care and Non-adherence to Tuberculosis Treatment)|TBsurvey|Azienda Ospedaliera San Gerardo di Monza|No|Completed|June 2011|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|137|||Both|18 Years|N/A|No|Non-Probability Sample|All new tuberculosis (any site) diagnosed in the study time-frame, regardless of previous        treatment history.|January 2014|January 17, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390987||101822|
NCT01389895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100037|Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus||Amgen|No|Terminated|October 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|70 Years|No|||January 2014|January 9, 2014|June 23, 2011|Yes|Yes|slow enrollment|No||https://clinicaltrials.gov/show/NCT01389895||101905|
NCT01389908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sh-03-11|A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder|||Shalvata Mental Health Center|Yes|Recruiting|June 2011|||July 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|2|||Both|18 Years|65 Years|No|||June 2011|July 7, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01389908||101904|
NCT01390181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00048364|The Effect of Losartan in Bicuspid Aortic Valve Patients|The Effect of Losartan Treatment on Matrix Metalloproteinase Levels and Outcomes in Bicuspid Aortic Valve Patients||University of Michigan||Recruiting|September 2011|||December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||January 2013|January 3, 2013|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01390181||101884|
NCT01391377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|126-11|Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease|The Effects of Chronic High-density Lipoprotein (HDL) Elevation With Extended Release Niacin on Peripheral Arterial Disease||Bayside Health|No|Terminated|July 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|7|||Both|40 Years|N/A|No|||February 2013|February 25, 2013|April 5, 2011|Yes|Yes|Tredaptive has been suspended worldwide|No||https://clinicaltrials.gov/show/NCT01391377||101792|
NCT01391390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJ-7072035|Melatonin Treatment for Tardive Dyskinesia in Schizophrenia|The Effect of Melatonin Treatment on Tardive Dyskinesia and Oxidative Stress: A Double-Blind Placebo-Controlled Trial||Beijing HuiLongGuan Hospital|Yes|Completed|September 2008|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||November 2013|November 10, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391390||101791|
NCT01391611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIST0003|Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)|A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)||Stanford University|Yes|Active, not recruiting|July 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391611||101774|
NCT01391624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omega3-chocolate-001|Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers|Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers|OMEGA3CHOCO|Federal University of São Paulo|Yes|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391624||101773|
NCT01391884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2009-158-UREMINC|Elimination of Incretin Hormones in Patients With Severe Kidney Failure|Elimination and Biodegradation of the Incretin Hormones GLP-1 and GIP in Patients With End-stage Renal Disease||Rigshospitalet, Denmark|Yes|Completed|June 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|24|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Hemodialysis patients          2. Healthy control subjects|September 2012|September 18, 2012|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01391884||101753|
NCT01392144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0446|Phase II Evaluation of Exhaled Nitric Oxide (NO)|Phase II Evaluation of Exhaled Nitric Oxide as a Predictive Biomarker for Radiation Pneumonitis||M.D. Anderson Cancer Center|No|Completed|August 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Lung and esphageal cancer patients receiving radiation therapy, at UT MD Anderson Cancer        Center in Houston, Texas|April 2013|April 1, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01392144||101733|
NCT01392469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQTI571A2102|Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients|A Non-randomized, Multiple Dose, Three Treatment Period, Open-label, Single Sequence, Single Group Study to Evaluate the Pharmacokinetic Effect of Two Doses of QTI571 (Imatinib) on the Co-administered Drugs Sildenafil and Bosentan in Pulmonary Arterial Hypertension (PAH) Patients||Novartis||Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||April 2013|April 30, 2013|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392469||101709|
NCT01392807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00010|Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function|An Open-label, Single-center Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function Following Administration of a Single Dose of 25mg NKTR-118||AstraZeneca||Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 13, 2014|July 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01392807||101683|
NCT01392157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/2011/PC|Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector|Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector||University of Campinas, Brazil|No|Completed|June 2011|July 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01392157||101732|
NCT01390844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07063|Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)|Safety and Efficacy of Boceprevir in Combination With Peginterferon Plus Ribavirin for Treatment of Asia Pacific Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Pegylated Interferon Plus Ribavirin (Protocol No. P07063)||Merck Sharp & Dohme Corp.|No|Completed|October 2011|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|282|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390844||101833|
NCT01390857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112323|Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)|Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)||GlaxoSmithKline|No|Completed|November 2007|May 2010|Actual|September 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|379|||Both|N/A|14 Years|No|Probability Sample|Japanese pediatric patients with chickenpox (aged less than 15 years old)|October 2011|October 11, 2011|July 7, 2011||No||No|August 18, 2011|https://clinicaltrials.gov/show/NCT01390857||101832|
NCT01391156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REH-54015|Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss|Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study||Mae Fah Luang University Hospital|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|50 Years|No|||July 2012|July 19, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01391156||101809|
NCT01391754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH065667|Effectiveness Trial for Project SafeCare for Child Neglect|Effectiveness Trial for Project SafeCare for Child Neglect||University of Oklahoma|Yes|Completed|October 2003|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2175|||Both|14 Years|75 Years|No|||July 2011|July 8, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01391754||101763|
NCT01394003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12451|A Study of LY2584702 in Patients With Advanced Cancer|A Phase I Study of LY2584702 in Patient With Advanced or Metastatic Cancer||Eli Lilly and Company|No|Terminated|November 2008|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|June 1, 2011|No|Yes|The pharmacokinetic properties of the molecule do not allow for further dose escalation or    development.|No||https://clinicaltrials.gov/show/NCT01394003||101591|
NCT01394016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13199|A Phase 1 Study of LY2835219 In Participants With Advanced Cancer|A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer||Eli Lilly and Company|No|Active, not recruiting|December 2009|October 2016|Anticipated|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01394016||101590|
NCT01392326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2306|Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis|FUTURE 1|Novartis|Yes|Completed|September 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|606|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 7, 2011|Yes|Yes||No|October 20, 2015|https://clinicaltrials.gov/show/NCT01392326||101719|
NCT01392937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S09-469|Clinical Performance of All-in-One Light Multi-purpose for Silicone Hydrogel Contact Lenses|The Clinical Performance of the All-in-One Light Multi-purpose Care Regimen for Silicone Hydrogel Contact Lenses||Sauflon Pharmaceuticals Ltd|No|Completed|March 2010|March 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|257|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392937||101673|
NCT01391234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15625|Rapid Radiation Therapy for Painful Osseous Metastatic Disease|Phase II Pilot Single Arm Prospective Clinical Trial of Rapid Institution of Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease||University of Virginia|Yes|Completed|June 2011|May 2015|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391234||101803|
NCT01393340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006/240|Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma|Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma||University Hospital, Ghent|No|Completed|December 2006|December 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||July 2011|July 11, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01393340||101642|
NCT01393353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHBS|Cognitive Training in Parkinson's Disease|A Computerized, Multidimensional and Disease Specific Training of Cognition in Patients With M. Parkinson||University Hospital, Basel, Switzerland|No|Completed|May 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|39|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 12, 2014|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01393353||101641|
NCT01393366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1030903|Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy|Facing Obstacles to RDI(Relative Dose Intensity)Through Telephone Intervention Strategy|FORTIS|University Hospital, Toulouse|No|Active, not recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01393366||101640|
NCT01390116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGE-84403|The Effect of Aged Garlic Extract Supplementation on Immune System|The Effect of Aged Garlic Extract Supplementation on Immune System||University of Florida|No|Completed|February 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 12, 2013|July 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390116||101889|
NCT01400126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Ultrapure Water System for Hemodialysis Therapy|The Effect of Ultrapure Water System on Hemodialysis Therapy- a Single Center Trial||Tel Aviv Medical Center|No|Not yet recruiting|August 2011|January 2013|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic hemodialysis patients|November 2010|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400126||101122|
NCT01400139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYD3003|Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.|An Open-label, Multicenter Study to Assess the Long -Term Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain||Purdue Pharma LP|Yes|Completed|July 2011|October 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|922|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 20, 2011|Yes|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01400139||101121|
NCT01391533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11449|Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors|Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic, First in Man Study, of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors|SARMET|Sanofi||Active, not recruiting|July 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391533||101780|
NCT01389934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MASTEC-002|Infusion of a Local Anaesthetic in the Surgical After Modified Radical Mastectomy With Expander|Infusion of a Local Anaesthetic in the Surgical After Modified Radical Mastectomy With Expander||Basque Health Service|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|80 Years|No|||July 2011|February 2, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389934||101902|
NCT01391052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90378|Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding|Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding|Mirena IUD|Scott and White Hospital & Clinic|No|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|July 7, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391052||101817|
NCT01390727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2010/06921-2|Effects of Slow Breathing on Blood Pressure and Autonomic Function|Effects of Slow Breathing on Blood Pressure and Autonomic Function in Hypertensive Patients||Fundação de Amparo à Pesquisa do Estado de São Paulo|No|Recruiting|May 2011|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||May 2011|July 8, 2011|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390727||101842|
NCT01391065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMH-IRB 843|MR-PET Guided Biologically Optimised Interstitial Brachytherapy|MR-PET Guided Biologically Optimised Interstitial Brachytherapy for Postoperative Recurrent Cervical Cancers|MR-PET Brachy|Tata Memorial Hospital|Yes|Recruiting|March 2011|March 2017|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|60|||Female|18 Years|65 Years|No|||June 2011|July 7, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01391065||101816|
NCT01391403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRI 05T-726|Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia|A Double-Blind, Randomized, Placebo-Controlled Trial of Artemisinin as an Add-on Therapy to Risperidone in the Treatment of Drug-Naive First-Episode Patients With Schizophrenia||Beijing HuiLongGuan Hospital|Yes|Completed|September 2008|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|65 Years|No|||October 2013|October 15, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391403||101790|
NCT01391637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N02-PMD|Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)|Long-Term Follow-Up Safety and Preliminary Efficacy Study of Human Central Nervous System Stem Cell (HuCNS-SC®) Transplantation in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)||StemCells, Inc.|No|Active, not recruiting|June 2011|June 2016|Anticipated|February 2016|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4|||Male|N/A|N/A|No|Non-Probability Sample|PMD Subjects who underwent transplantation of HuCNS-SC cells under CL-N01-PMD study|January 2015|January 13, 2015|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391637||101772|
NCT01391650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBVSB|Stability of the Knee Joint After Single and Double Bundle Anterior Cruciate Ligament Reconstruction|Rotational and Anteroposterior Stability of the Knee Joint After Single- and Double- Bundle ACL Reconstruction||Hospital Znojmo|No|Completed|March 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|53 Years|No|||May 2012|May 22, 2012|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01391650||101771|
NCT01391897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-EK-5689|Epigenetics of Posttraumatic Stress Disorder and Somatoform Disorders in the Course of Psychotherapy||TREPS|Hannover Medical School|No|Recruiting|January 2011|September 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|whole blood|Both|18 Years|65 Years|No|Non-Probability Sample|The present study includes all patients selected for multi-modal inpatient or day-clinic        treatment in the department of psychosomatic medicine (as part of the centre of        psychiatry)of the hannover medical school - given the informed consent of the patients.        The patients treated in this unit are first seen in primary care and sent to us because of        e.g. depression, somatization, eating-disorders, panic disorders, PTSD, or other        psychiatric diseases commonly refered to as "psychosomatic" in Germany. They are subject        to at least 2 diagnostic sessions in which further treamtment options are assessed.        For about one third of the patients with grave psychiatric disorders, intensive        "multimodal" psychotherapy in an inpatient or day-clinic setting is recommended.|June 2011|July 11, 2011|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391897||101752|
NCT01392521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12876|Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer|Phase Ib Trial of the Combination of PI3K Inhibitor BAY 80-6946 and Allosteric-MEK Inhibitor BAY 86-9766 in Subjects With Advanced Cancer||Bayer|No|Completed|July 2011|April 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01392521||101705|
NCT01392534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15297|Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting|Evaluation of the Real-life Efficacy and Safety of a Fixed-dose Telmisartan/Hydrochlorothiazide, Including Its Effect on Plasma Potassium and on Glucose and Lipid Metabolism Parameters in Patients With Essential Arterial Hypertension|POTASSIUM|Bayer|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1586|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic hypertensive patients not treated with telmisartan/hydrochlorothiazide        for approx. 3 mths.|July 2012|July 3, 2012|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01392534||101704|
NCT01391182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001111|Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)|Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)||Mayo Clinic|Yes|Completed|July 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 25, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391182||101807|
NCT01394029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2301|Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox|International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting||Novartis||Completed|July 2011|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|120|||Both|2 Years|N/A|No|Non-Probability Sample|Patients treated with deferasirox for transfusional hemosiderosis according to the local        prescribing information.|February 2016|February 1, 2016|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394029||101589|
NCT01390103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|711-2010|Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain|Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain||University of Florida|No|Completed|March 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|90 Years|No|Non-Probability Sample|Potential subjects will be all patients receiving a hip injection for hip pain.|April 2013|April 18, 2013|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01390103||101890|
NCT01390337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2689-CL-0005|A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)|A Phase 1 Study of AC220 (ASP2689) in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia||Daiichi Sankyo Inc.|No|Completed|October 2011|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|60 Years|No|||October 2015|October 29, 2015|July 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390337||101872|
NCT01391780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011|Pelvic Floor Muscle Evaluation in Women With Stress Urinary and Urgency Urinary Incontinence|Pelvic Floor Muscle Evaluation in Women With Stress Urinary and Urgency Urinary Incontinence. A Prospective Trial||UPECLIN HC FM Botucatu Unesp|No|Completed|March 1997|December 1998|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|51|||Female|18 Years|65 Years|No|Probability Sample|The sample size was established considering a significance level of 5%, the test power of        80%, and the estimated error of 10%. According to these results and considering the range        between percentages of answers as the casual error, each group was established with        approximately 20 participants.|March 2011|December 10, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391780||101761|
NCT01392677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1693C00005|Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea|A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea||AstraZeneca|No|Completed|October 2011|August 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|311|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|July 11, 2011|Yes|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT01392677||101693|For participants who did not complete 8 and/or 24 weeks, respectively, last observation carried forward (LOCF) was used for analyses of secondary endpoints. All endpoints were evaluated by excluding data after rescue.
NCT01394042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proxiscan|Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint|Exploratory Evaluation of a Transrectal Scintigraphic Detector (Proxiscan) for Detection of Primary Prostate Cancer Utilizing a Radiotracer Targeting Prostate Specific Membrane Antigen (PMSA)||Radiological Associates of Sacramento Medical Group Inc.|Yes|Enrolling by invitation|June 2011|March 2012|Anticipated|December 2011|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|1||Anticipated|12|||Male|18 Years|N/A|No|||July 2011|July 12, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01394042||101588|
NCT01394055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-003|Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis|Official Title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis||Rhythm Pharmaceuticals, Inc.|No|Completed|July 2011|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||March 2013|March 6, 2013|July 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01394055||101587|
NCT01399866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000411|Cognitive Remediation With D-Cycloserine|Cognitive Remediation With D-cycloserine to Improve Smoking Cessation Outcomes||Massachusetts General Hospital|Yes|Completed|May 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|July 19, 2011||No||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01399866||101142|
NCT01399879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21AT005249|Measuring Skin Electrical Potential With the Kelvin Probe: Minimizing Noise|Measuring Skin Electrical Potential With the Kelvin Probe: Minimizing Noise||Massachusetts General Hospital|No|Completed|September 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers|July 2011|July 20, 2011|March 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01399879||101141|
NCT01399645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE09.159|Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes|Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study|LIRAINS|Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|May 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399645||101159|
NCT01392365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0380|Development of a Score for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease|Development of a Score for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease||Asan Medical Center|No|Recruiting|July 2011|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|120|||Both|16 Years|N/A|No|Probability Sample|Patients who have common features of crohn's disease and intestinal tuberculosis|November 2013|November 8, 2013|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392365||101716|
NCT01390701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HyperTENSion|Blood Pressure Lowering Effect of Transcutaneous Electrical Nerve Stimulation|Blood Pressure Lowering Effect of Low-frequency Transcutaneous Electrical Nerve Stimulation and Felodipin|HyperTENSion|Sahlgrenska University Hospital, Sweden|No|Completed|January 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||June 2011|July 7, 2011|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390701||101844|
NCT01390714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3710-A001-003|Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects|An Open-label, Cross-over, Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects||Eisai Inc.||Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|June 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390714||101843|
NCT01390467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0095|Cognitive Impact of Paracetamol in Healthy Volunteers|Cognitive Impact of Paracetamol in Healthy Volunteers|ICP|University Hospital, Clermont-Ferrand||Completed|July 2011|January 2012|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|44|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390467||101862|
NCT01390480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENM-DA-017|Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes|Placebo Controlled Pilot Study on Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes on Immunological, Endocrine and Metabolic Parameters: Step 2 in the Austrian Diabetes Prevention Programme||Medical University of Graz|Yes|Completed|November 2010|February 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|31|||Both|6 Years|60 Years|No|||April 2015|April 16, 2015|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01390480||101861|
NCT01391078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sensimed Triggerfish11/01|Comparison of Sensimed Triggerfish With Goldmann Applanation Tonometry and Perkins Tonometry|Comparison of Sensimed Triggerfish (TF) 24 Hour IOP Monitoring With Goldmann Applanation Tonometry (GAT) and Perkins Tonometry in Glaucoma Patients||Johannes Gutenberg University Mainz|No|Completed|June 2011|February 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|12|||Both|18 Years|N/A|No|||November 2012|November 27, 2012|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01391078||101815|
NCT01391091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI-CONFIRM|Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine|Effect of Catheter Ablation on the Prevalence, Clinical Manifestation and MRI Findings of Migraine in AF Patients With or Without a Previous History of Migraine|CONFIRM|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|December 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||May 2015|May 20, 2015|May 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01391091||101814|
NCT01391416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VJR-0002|Prevalence Of Hyperhomocysteinemia In Thai Chronic Kidney Disease (CKD) Patients|Prevalence Of Hyperhomocysteinemia In Thai CKD Patients And Relationship To Cardiovascular Events: Subgroup Analysis From Thai SEEK Study||Bangkok Metropolitan Administration Medical College and Vajira Hospital|Yes|Completed|June 2010|January 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|98|Samples Without DNA|serum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Ninety eight subjects from CKD stages 3-4 were randomly sampling from Thai- SEEK study        database. Thai-SEEK study is a community-based cross-sectional survey that was conducted        between August 2007-june 2008 in four regions of Thailand (i.e Northern, Northeastern,        Central and Southern) and Bangkok (Metropolitan).|May 2010|July 11, 2011|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391416||101789|
NCT01391663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322_106|Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Dose Study of the Pharmacokinetics and Pharmacodynamics of Alogliptin 12.5 mg, 25 mg and 50 mg in Healthy Korean Subjects||Takeda|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 17, 2013|July 8, 2011||No||No|October 29, 2012|https://clinicaltrials.gov/show/NCT01391663||101770|
NCT01391676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD OCT-TE|Imaging of Trabeculectomy Blebs Using the Spectral Domain Optical Coherence Tomography|Imaging of Blebs After Trabeculectomy With Mitomycin C 0,02% Using the Spectral Domain Optical Coherence Tomography|SDOCT-TE|Technische Universität Dresden|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|glaucoma patients who need a trabeculectomy with mitomycin C 0,02% for further reduction        of intraocular pressure (IOP)|September 2013|September 9, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391676||101769|
NCT01391910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40578-E/A|Response Shift in Sinus Surgery Outcomes|Response Shift in Sinus Surgery Outcomes||University of Washington|No|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be surgery patients from Dr. Davis' clinic at the University of Washington.        They will have undergone FESS for treatment of CRS.|December 2013|December 11, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01391910||101751|
NCT01391923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA11-002|Non-Invasive Reduction of Fat in the Arms With the CoolFlex Applicator|Non-Invasive Reduction of Fat in the Arms With the CoolFlex Applicator||Zeltiq Aesthetics|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|July 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01391923||101750|
NCT01392170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0184|Pegasys in Patients With Chronic Myeloid Leukemia (CML)|Phase II Study of Pegylated Ifná-2a (Pegasys) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors||M.D. Anderson Cancer Center|No|Terminated|October 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|16 Years|N/A|No|||April 2015|April 13, 2015|July 8, 2011|Yes|Yes|Slow Accrual|No|March 31, 2015|https://clinicaltrials.gov/show/NCT01392170||101731|Early termination due to slow accrual, no analysis possible.
NCT01392872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0094|Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant|Evaluation of Cognitive Disability and Quality of Life of Patients Suffering From Multiple Scleroses and Treat With Immunosuppressant|CoQualSEP|University Hospital, Clermont-Ferrand||Recruiting|November 2009|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|No|||July 2011|July 12, 2011|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01392872||101678|
NCT01391494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV71-KMB17-I-IMB-CAMS|A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants|A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants||Chinese Academy of Medical Sciences|Yes|Completed|February 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|15||Actual|288|||Both|6 Months|49 Years|Accepts Healthy Volunteers|||January 2011|April 26, 2012|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391494||101783|
NCT01389817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO14842|Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)|Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)|LHON|Medical College of Wisconsin|No|Terminated|July 2011|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|July 6, 2011|Yes|Yes|Unable to record n95 pERG peak (primary measure), as LHON subjects are unable to focus on    target.|No|September 23, 2014|https://clinicaltrials.gov/show/NCT01389817||101911|
NCT01393002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFI_ICU|Perception and Prevalence of Fungal Infections in Berlin - Brandenburg|Web-based Structured Survey of Retrospective Data of Invasive Mycosis in Intensive Care Patients in Berlin - Brandenburg|IFI_ICU|Charite University, Berlin, Germany|No|Completed|July 2011|July 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|N/A|N/A|No|Non-Probability Sample|Intensive care units of different primary and secondary care hospitals in the region of        Berlin-Brandenburg.|October 2013|October 17, 2013|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01393002||101668|
NCT01399632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL095964|Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake|Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake||Brigham and Women's Hospital|No|Completed|August 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|21|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01399632||101160|
NCT01399411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911196|Agricultural Health Study Follow-up|||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|||||N/A|Observational|N/A|||Anticipated|89656|||Both|24 Years|N/A|Accepts Healthy Volunteers|||November 2015|December 15, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399411||101177|
NCT01399918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-226|Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)|A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)||Memorial Sloan Kettering Cancer Center||Recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399918||101138|
NCT01400165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-2010023|Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations|Examination of the Pharmacokinetic Properties of Three Generic Medications and Their Respective Brand Preparations in Healthy Male Volunteers||University of Ottawa|No|Recruiting|July 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400165||101119|
NCT01400386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.04.Met|Bioavailability of Chlorogenic and Phenolic Acids From Soluble Coffees|Bioavailability of Chlorogenic and Phenolic Acids From Soluble Coffees||Nestlé|Yes|Completed|November 2010|June 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|14|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400386||101102|
NCT01390207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1971|Earlier Triggering in Rec-FSH/GnRH Antagonist Cycles|Does Earlier Administration Of Human Chorionic Gonadotropin (hCG) Improve The Probability Of Pregnancy In Cycles Stimulated With Rec-FSH AND GnRH Antagonists? A Prospective Randomized Trial|16mm|Universitair Ziekenhuis Brussel|No|Completed|January 2010|May 2011|Actual|April 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|100|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||July 2011|August 3, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01390207||101882|
NCT01390740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 586|Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey|Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey|E2T3A|French Cardiology Society|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1412|||Both|65 Years|N/A|No|Non-Probability Sample|The study proposed a list of centers selected by the Scientific Committee in the complete        list of locations being in France, the subsidiary of echocardiography Echocardiography of        the French Society of Cardiology. These centers number 500 are representative of the        French centers, geographically and by type of centers.        This is a cross-sectional epidemiological investigation, assembling evidence from a        routine ultrasound screening for AAA at the waning of echocardiograms performed during a        specific day|June 2012|June 13, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390740||101841|
NCT01391104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESPONS PAH|Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension|Reproducibility and Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension|RESPONS|Laval University|Yes|Completed|April 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|80 Years|No|||October 2012|October 3, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01391104||101813|
NCT01391689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0366-04|Diindolylmethane in Treating Patients With Breast Cancer|Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study||University of Arizona|Yes|Active, not recruiting|February 2011|July 2016|Anticipated|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|144|||Female|19 Years|N/A|No|||October 2015|October 21, 2015|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391689||101768|
NCT01391936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/RlOST/04|A Trial of Plate Fixation Versus Tension Band Wire for Olecranon Fractures|A Prospective Randomised Trial of Plate Fixation Versus Tension Band Wire for Olecranon Fractures||Royal Infirmary of Edinburgh|No|Active, not recruiting|September 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|74 Years|No|||May 2015|May 14, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01391936||101749|
NCT01392183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0358|Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)|A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma||M.D. Anderson Cancer Center|Yes|Recruiting|October 2012|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392183||101730|
NCT01392196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP085|Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment Clinical Trial|Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment|SymplicityHF|Medtronic Vascular|Yes|Active, not recruiting|October 2011|December 2017|Anticipated|June 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01392196||101729|
NCT01392209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-057|Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma|A PHASE I DOSE ESCALATION STUDY OF HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY WITH BEVACIZUMAB IN THE TREATMENT OF RECURRENT MALIGNANT GLIOMA||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|July 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01392209||101728|
NCT01392547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1731-3562|Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors|Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors|adept™2|Novo Nordisk A/S|No|Completed|July 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Male|12 Years|N/A|No|||December 2014|December 12, 2014|July 8, 2011|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01392547||101703|
NCT01397591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007042|Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma|Phase II Trial of Ofatumumab and Bortezomib in Subjects With Relapsed Cluster of Differentiation Antigen 20 (CD20)+ Diffuse Large B Cell Lymphoma, Follicular Lymphoma, or Mantle Cell Lymphoma||OHSU Knight Cancer Institute|Yes|Terminated|October 2011|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|July 13, 2011|Yes|Yes|Study closed by PI due to lower than expected accrual.|No|June 18, 2014|https://clinicaltrials.gov/show/NCT01397591||101316|
NCT01397604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYI-0736|The Effects of GLA on Human Volunteers|A Randomized, Blinded, Placebo-Controlled Phase 1 Study to Evaluate the Safety and Immunogenicity of GLA in Healthy Volunteers||Rockefeller University|No|Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397604||101315|
NCT01392976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-101-004|Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors|A Phase I, Open-Label, Two-stage, Randomized, Crossover, Comparative Pharmacokinetic and Safety Study of Two Formulations of CO-1.01 for Injection in Patients With Advanced Solid Tumors||Clovis Oncology, Inc.|No|Completed|April 2011|April 2013|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392976||101670|
NCT01392989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT217|Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders|Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders||Stanford University|Yes|Recruiting|March 2011|May 2017|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|50 Years|N/A|No|||February 2015|February 3, 2015|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392989||101669|
NCT01390610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04111-11-C|Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition|Observational Evaluation Using Continuous Glucose Monitoring to Determine Timing and Frequency of Self-Monitored Blood Glucose by Therapy Type in Patients With Type 2 Diabetes (REACT-4 Matrix Definition Study)|REACT4|HealthPartners Institute|No|Completed|June 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|Twenty seven persons with type 2 diabetes age 18 and older.|April 2013|November 25, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01390610||101851|
NCT01390948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25041|A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma|A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, Or Peduncular High-Grade Glioma||Hoffmann-La Roche||Active, not recruiting|October 2011|March 2020|Anticipated|March 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|6 Months|18 Years|No|||March 2016|March 1, 2016|July 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390948||101825|
NCT01390961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-000256|Comparison of Tolerability Between Two Allergy Drops|Comparison of Tolerability Between Two Allergy Drops||Hom, Milton M., OD, FAAO|No|Enrolling by invitation|August 2011|January 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Months|N/A|Accepts Healthy Volunteers|||July 2011|July 7, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390961||101824|
NCT01399398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110202|Imaging of CB1 Receptors Using (11C)SD5024|PET Imaging of CB1 Receptors Using [11C]SD5024||National Institutes of Health Clinical Center (CC)||Terminated|June 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|February 19, 2014|July 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01399398||101178|
NCT01399151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 213949-1|Assessment of Vitamin D Supplementation and Immune Function|Assessment of Vitamin D Supplementation and Immune Function|FL-82|USDA, Western Human Nutrition Research Center|Yes|Completed|January 2011|April 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|23|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||April 2014|April 21, 2014|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01399151||101197|
NCT01399658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-098|Image-Guided Gynecologic Brachytherapy|A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO)|AMIGO|Dana-Farber Cancer Institute|Yes|Recruiting|September 2011|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||July 2015|July 30, 2015|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01399658||101158|
NCT01399671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA10I220044|Study of the Effectiveness of Vestibular Stimulation as a Coadjuvant Treatment in Major Depression|Clinical Randomized Trial to Evaluate the Efficacy of Vestibular Stimulation as Coadjuvant Therapy in Major Depression||Fuerza Aérea de Chile|Yes|Completed|March 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|70 Years|No|||March 2011|March 2, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01399671||101157|
NCT01400438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HER-ception|Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer|Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer: Fatigue and Quality of Life During and Waning of Treatment, Psychosocial Aspects (Environment, Work)|HER-ception|Centre Francois Baclesse|No|Active, not recruiting|July 2011|May 2016|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|70|||Female|18 Years|N/A|No|||June 2012|July 3, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01400438||101098|
NCT01399892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-002142|Effect of Fiber Supplementation in Children With Type 1 Diabetes|Effects of Fiber Supplementation on Glycemic Excursions and Incidence of Hypoglycemia in Children With Type 1 Diabetes||Mayo Clinic|No|Completed|September 2008|December 2010|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|4 Years|16 Years|No|||July 2011|July 21, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399892||101140|
NCT01399905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aldred4133|High and Low Dose Carbidopa Treatment of Parkinson's Disease|A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.||Oregon Health and Science University|No|Completed|March 2009|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|35 Years|85 Years|No|||July 2011|July 21, 2011|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399905||101139|
NCT01390220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P261-401|Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters|A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters. ARTEMIS-1: Acute Rescue Therapy in Epilepsy With Midazolam Intranasal Spray-1|ARTEMIS1|Upsher-Smith Laboratories|Yes|Recruiting|June 2011|||February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|165|||Both|12 Years|N/A|No|||January 2016|January 19, 2016|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390220||101881|
NCT01390493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEUROAN|Therapeutic Effects of Neurofeedback in Anorexia Nervosa|Therapeutic Effects of Alpha-neurofeedback in the Treatment of Anorexia Nervosa||Medical University of Graz|No|Completed|October 2010|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|12 Years|18 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390493||101860|
NCT01390753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFANT-001|Role of Human Milk Bank in the Protection of Severe Respiratory Disease in Very Low Birth Weight Premature Infants|Preventing Respiratory Disease Hospitalizations in Premature Infants Fed Donor Human Milk||Fundacion Infant|No|Active, not recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|300|||Both|N/A|1 Month|No|||March 2015|March 6, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390753||101840|
NCT01390766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112305|Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)|Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)||GlaxoSmithKline|No|Completed|August 2002|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|41|||Both|N/A|N/A||Probability Sample|The following subjects to whom azathioprine tablet is administered for "the suppression of        liver transplant rejection";          -  Subjects on whom liver transplantation is performed and to whom azathioprine tablet             is administered within 1 year after transplant surgery from the approval date of the             additional indication of azathioprine tablet for liver transplantation (20 June 2001)             to May 2010.          -  Subjects on whom liver transplantation is performed before the approval date of the             additional indication of azathioprine tablet for liver transplantation (20 June 2001)             and to whom azathioprine tablet is administered within 1 year after transplant             surgery.|August 2012|August 30, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01390766||101839|
NCT01396200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09411|Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine|A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine in Patients With Relapsed or Refractory Multiple Myeloma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|June 2011|October 2012|Actual|October 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396200||101423|
NCT01396460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01231087|Respiratory Quotient in Post Roux-en-Y Gastric Bypass Patients|Respiratory Quotient in Post Roux-en-Y Gastric Bypass Patients|RQ|Gastrocirurgia, Brazil|No|Completed|May 2011|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|69|||Both|20 Years|65 Years|No|Probability Sample|Bariatric post operative population|September 2012|September 7, 2012|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01396460||101403|
NCT01396473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18046|Study on Out of School Nutrition and Physical Activity Environments|Study on Out of School Nutrition and Physical Activity Environments|OSNAP|Harvard School of Public Health|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|590|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||July 2011|July 15, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01396473||101402|
NCT01396785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-1000-02|Topical Antifungal Treatment for Tinea Pedis|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis||Medicis Global Service Corporation|No|Completed|July 2011|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|321|||Both|12 Years|N/A|No|||August 2013|August 20, 2013|July 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396785||101378|
NCT01396798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52996|Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E.|Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in a High Prevalent Setting: the Paediatric A&E.|ERNIE3|Katholieke Universiteit Leuven|No|Completed|February 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|||Both|1 Month|16 Years|No|Probability Sample|Children aged 1 month to 16 years, attending the A&E department of the UZLeuven Hospital        with an acute illness episode of maximum 5 days|September 2012|September 13, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396798||101377|
NCT01396811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-1000-03|Topical Antifungal Treatment for Tinea Pedis|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis||Medicis Global Service Corporation|No|Completed|July 2011|March 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|322|||Both|12 Years|N/A|No|||August 2013|August 20, 2013|July 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396811||101376|
NCT01397071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAB-001|Effects of Avocado When Added to a Meat Patty on Inflammation in Healthy Men|Hass Avocado Flesh Inhibition of Appearance of Lipid Peroxidation Products When Added to a Ground Beef Patty Consumed by Healthy Volunteers||University of California, Los Angeles|No|Completed|August 2011|August 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 8, 2013|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397071||101356|
NCT01397344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCRC-IRB-2011008|Patients' Preferences for Traditional Medicine Doctor's Attire|Patients' Preferences for Traditional Medicine Doctor's Attire||Korean Medicine Hospital of Pusan National University|No|Completed|July 2011|December 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|175|||Both|19 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|People in the Outpatient Waiting Room|September 2015|September 1, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01397344||101335|
NCT01397617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-117|Randomized, Open Investigation Evaluating the Efficacy of Nobel Biocare SFB and CFB Implants|Evaluation of NobelBiocare SFB and CFB Implants||Nobel Biocare|No|Completed|April 2006|September 2014|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|177|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|July 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01397617||101314|
NCT01393665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-PENNEL 2|Study to Evaluate Efficacy, Safety and Tolerability of PENNEL Capsule in the Patients With Chronic Liver Disease|Multicenter, Randomized, Placebo-Controlled, Double-blind Phase 2 Study to Evaluate the Short-term Efficacy, Safety and Tolerance and to Find an Optimal Dosage of the PENNEL Capsule for the Patients With Chronic Liver Disease||PharmaKing|Yes|Completed|December 1996|October 1997|Actual|May 1997|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|20 Years|65 Years|No|||July 2011|July 12, 2011|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01393665||101617|
NCT01393678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMK-PENNEL 3|Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease|A Multicenter, Randomized, Double-blind, 2 Parallel Group, Phase 3 Study of PENNEL Capsule in Chronic Liver Disease||PharmaKing|Yes|Completed|November 1997|May 1998|Actual|March 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|20 Years|65 Years|No|||July 2011|July 12, 2011|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01393678||101616|
NCT01398865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002032|Escitalopram Neuroimaging Supplement|Cerebral Metabolic Correlates of Treatment Response to Escitalopram in Body Dysmorphic Disorder||Massachusetts General Hospital|No|Completed|December 2008|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|64 Years|No|Non-Probability Sample|Participants will be 24 subjects with BDD newly enrolled, but not yet treated, in a        multi-site (MGH and Rhode Island Hospital) clinical study of escitalopram for BDD        (NCT00149799/R01MH072854), Dr. Wilhelm, PI). All BDD subjects will be drawn from this        clinical study, in order to best ensure that they have all received a comparable regimen        of SSRI treatment. BDD subjects will have been recruited via the BDD Clinic at        Massachusetts General Hospital (MGH)/Harvard Medical School and Rhode Island        Hospital/Brown Medical School.|March 2015|March 12, 2015|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01398865||101219|
NCT01398878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02007|Assessing the Impact of a Change to the Work Schedule of Resident Physicians: a Mixed Methods Study|Assessing the Impact of a Change to the Work Schedule of Resident Physicians: a Mixed Methods Study||University of British Columbia|No|Recruiting|July 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01398878||101218|
NCT01399125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713D2344|A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease|A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)||Novartis||Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|501|||Both|50 Years|85 Years|No|||July 2014|July 10, 2014|July 19, 2011||No||No|May 5, 2014|https://clinicaltrials.gov/show/NCT01399125||101199|
NCT01391520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRMD001-3001|Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Deferiprone in the Reduction of Morbidity and Mortality in Patients With Chronic Kidney Disease Undergoing Diagnostic or Interventional Cardiac Procedures and Receiving an Iodinated Radiocontrast Agent||CorMedix||Not yet recruiting|January 2012|June 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||July 2011|July 8, 2011|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391520||101781|
NCT01399138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC10014|The Effect of Blueberry Powder Supplementation on Cardiovascular Risk Factors in Subjects With the Metabolic Syndrome|||Pennington Biomedical Research Center|No|Active, not recruiting|July 2010|April 2014|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|20 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 4, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01399138||101198|
NCT01398891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002826|Development of a Positive Psychology Intervention to Reduce Suicide Risk|Development of a Positive Psychology Intervention to Reduce Suicide Risk|HOPE|Massachusetts General Hospital|No|Completed|May 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01398891||101217|
NCT01399424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911214|Shigella Sonnei OSPC-rDT Conjugate Vaccine|Shigella Sonnei OSPC-rDT Conjugate Vaccine||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|49 Years|No|||April 2012|May 10, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399424||101176|
NCT01400178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00725998|Cochlear Implants in Post-lingually Children: Results After 10 Years|Cochlear Implants in Post-lingually Children: Results After 10 Years||University of Sao Paulo|Yes|Completed|November 2009|February 2011|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|The age at evaluation was 19,3 to 29,2 years. The age at cochlear implant surgery was 5,4        to 16,10 years. The etiology of the deafness was: meningitis (5), ototoxic (1), mumps (2)        and unknown (2).|April 2011|July 21, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01400178||101118|
NCT01400191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF 379|The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1|The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1 (OCT1) in Healthy Volunteers||University of Southern Denmark|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 25, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400191||101117|
NCT01400204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ppo-010-212|Naturalistic Study Into the Hangover Effects of MDMA|A Naturalistic Study Comparing the Hangover Effects of MDMA, Other Drugs, and Alcohol in a Sample of Recreational Polydrug Users||Utrecht Institute for Pharmaceutical Sciences|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recreational poly-drug users who were guests at a privat New Years Eve party|July 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400204||101116|
NCT01400451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-161 ST|Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)|A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma||Bristol-Myers Squibb|No|Terminated|November 2011|December 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|July 21, 2011|Yes|Yes|More than 2 of 6 patients treated experienced dose limiting toxicities.|No|April 21, 2014|https://clinicaltrials.gov/show/NCT01400451||101097|In Phase 1 of the study, MTD was not reached because more than 2 of 6 treated participants experienced DLTs with the combination therapy. Enrollments in Phase 1 were terminated and Phase 2 was not started so only overall safety was summarized.
NCT01400412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5303|Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen|A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1||AIDS Clinical Trials Group|Yes|Completed|December 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|July 21, 2011|Yes|Yes||No|June 17, 2015|https://clinicaltrials.gov/show/NCT01400412||101100|
NCT01400425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A17|Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline|Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline||Avid Radiopharmaceuticals|No|Completed|July 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|239|||Both|50 Years|N/A|No|||March 2013|March 22, 2013|June 9, 2011|Yes|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01400425||101099|
NCT01390506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRP2011|Selenium to Improve Neurological Outcome After Cardiac Arrest|Effect of High Dose Selenium on Inflammation and Neurological Outcome After Cardiac Arrest: A Randomized, Double Blind Placebo Controlled Phase 2a Study|SCPR|Medical University of Graz|Yes|Not yet recruiting|January 2016|July 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|52|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01390506||101859|
NCT01395914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-ANAM-303|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study||Helsinn Therapeutics (U.S.), Inc|Yes|Completed|July 2011|February 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|345|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395914||101444|
NCT01395927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018604|A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers|An Open-Label, Fixed-Sequence Study to Assess Effects of Steady-State Rifampin on the Single-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01395927||101443|
NCT01395940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLH1201|A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)|A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(1)||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|20 Years|N/A|No|||October 2013|October 29, 2013|July 14, 2011||||No||https://clinicaltrials.gov/show/NCT01395940||101442|
NCT01396213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin1001-012|A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease|A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Different Doses of Larazotide Acetate for the Treatment of Celiac Disease||Alba Therapeutics|No|Completed|October 2011|November 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|342|||Both|18 Years|75 Years|No|||July 2014|July 16, 2014|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396213||101422|
NCT01396486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001937|Inositol and Omega-3 Fatty Acids in Pediatric Mania|A Randomized Controlled Trial of Inositol and Omega-3 Fatty Acids in Pediatric Mania||Massachusetts General Hospital|Yes|Recruiting|February 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|5 Years|12 Years|No|||February 2016|February 12, 2016|July 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396486||101401|
NCT01396824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICREC-2011-01|Nutritional Status and Prognosis in Heart Failure.|Nutrition Status and Body Composition in Ambulatory Patients With Heart Failure and Its Prognostic Significance (PLiegues en Insuficiencia Cardiaca-PLICA).|PLICA|Germans Trias i Pujol Hospital|No|Completed|June 2011|September 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|214|||Both|18 Years|N/A|No|Probability Sample|Consecutive heart failure patients attending the HF clinic of a university hospital.|July 2015|July 23, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396824||101375|
NCT01397084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HL00002|To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole|An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole||AstraZeneca|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|20 Years|N/A|No|||February 2013|February 18, 2013|July 18, 2011||No||No|January 16, 2013|https://clinicaltrials.gov/show/NCT01397084||101355|
NCT01397097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13363|LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study|Multicenter, Open-label, Randomized, Controlled Parallel-group Study to Assess Discontinuation Rates, Bleeding Patterns, User Satisfaction and Adverse Event Profile of LCS12 in Comparison to Etonorgestrel Subdermal Implant Over 12 Months of Use in Women 18 to 35 Years of Age||Bayer|No|Completed|September 2011|April 2015|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|766|||Female|18 Years|35 Years|No|||May 2015|May 12, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397097||101354|
NCT01397357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESREFO02|Cardiac Magnetic Resonance Utilities in the Evaluation of Ischemic Heart Disease|CARDIAC MAGNETIC RESONANCE UTILITIES IN THE EVALUATION OF ISCHEMIC HEART DISEASE: Topographical Correlation Between Ischemic Territory Injury and Coronary Angiography|CARDIO-RM|Ettore Sansavini Health Science Foundation|Yes|Active, not recruiting|July 2011|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|146|||Both|N/A|N/A|No|Non-Probability Sample|Patients who refer to the clinic within 12 months, with diagnosis of suspected coronary        artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina        symptoms and/or cardiac conventional stress test, and the presence of at least two risk        factors.|May 2014|May 18, 2014|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397357||101334|
NCT01398449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011ESO_FU_02|Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0|Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial||Fudan University|Yes|Recruiting|April 2011|December 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|874|||Both|18 Years|70 Years|No|||March 2011|July 19, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01398449||101250|
NCT01398462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JW-231A-101|Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients|A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hypomethylating Treatment, and High-Risk Myelofibrosis||JW Pharmaceutical|Yes|Completed|July 2011|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398462||101249|
NCT01398475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14016|A Relative Bioavailability and Food Effect Study of New Formulations|Relative Bioavailability of the LY3009104 Free Base Test Formulation Compared to the Reference Phosphate Salt Formulation and the Effect of Food on the Bioavailability of the Test Formulation in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|16|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|July 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01398475||101248|
NCT01389583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2211|A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients|A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy||National Health Research Institutes, Taiwan|Yes|Recruiting|October 2011|October 2019|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|75 Years|No|||September 2013|February 23, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389583||101929|
NCT01389596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081041|A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years|A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures|PERIWINKLE|Pfizer|Yes|Recruiting|September 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|225|||Both|4 Years|16 Years|No|||February 2016|February 16, 2016|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389596||101928|
NCT01402531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100295|Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)||University of California, San Diego|Yes|Recruiting|July 2010|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402531||100938|
NCT01402752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/CLM-02|System for Measuring Non-invasive Blood Flow in the Tracheobronchial Mucosa: Validation of Reproducibility|System for Measuring Non-invasive Blood Flow in the Tracheobronchial Mucosa: Validation of Reproducibility||Centre Hospitalier Universitaire de Nīmes|No|Withdrawn|November 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 24, 2015|July 25, 2011||No|20131209 Regulatory authorization is currently blocked at the ANSM.|No||https://clinicaltrials.gov/show/NCT01402752||100921|
NCT01402765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/EV-06|Interface Pressure Measures for Matresses: Nimbus 3 Versus Summit|Interface Pressure Measures for Matresses: a Randomized, Cross-over, Non-inferiority Study Comparing the Nimbus 3 Versus Summit Matresses||Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|60 Years|N/A|No|||March 2015|March 25, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402765||100920|
NCT01398904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002912|Attentional Bias in Body Dysmorphic Disorder|Attentional Bias in Body Dysmorphic Disorder|VAB|Massachusetts General Hospital|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|51|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will include 40 participants, consisting of 20 BDD participants and 20 matched        healthy controls.|December 2014|December 2, 2014|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01398904||101216|
NCT01399164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 242621-1|Cobalamin Absorption From Fortified Food|Cobalamin Absorption From Fortified Food in Older Adults With and Without Proton Pump Inhibitor Induced Achlorhydria|FL-72|USDA, Western Human Nutrition Research Center|Yes|Completed|January 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|60 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 21, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399164||101196|
NCT01399177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3177|Influence of Changes in Food Group Variety on Food Cravings, Energy Intake, and Weight Loss After Bariatric Surgery|Influence of Changes in Food Group Variety on Food Cravings, Energy Intake, and Weight Loss After Bariatric Surgery||University of Tennessee|No|Recruiting|June 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Bariatric Surgery Patients associated with the University of Tennessee Medical Center|January 2016|January 26, 2016|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399177||101195|
NCT01399931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P-HD-10 STUDY|Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions|Dual Point Acquisition in the Interim Pet Scan Performed During ABVD Treatment, in Early-Stage Hodgkin's Lymphoma Patients With Bulky Lesions|2P-HD-10|Ospedale Santa Croce-Carle Cuneo|Yes|Recruiting|January 2012|January 2017|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|60 Years|No|Non-Probability Sample|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions.|October 2015|October 16, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01399931||101137|
NCT01399944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813211|The Molecular Basis for a Broad Range of Phenotypes Related to hTAS2R38|The Molecular Basis for a Broad Range of Phenotypes Related to hTAS2R38||Monell Chemical Senses Center|No|Completed|July 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|70|Samples With DNA|Saliva and taste tissue will be collected from individuals enrolled in the study.|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults of all races and both genders (N=100) will be involved in the proposed research.        Typically, our population of subjects is approximately 45% African American, 45%        Caucasian, 6% Hispanic, and 4% Asian. This increased representation of under-represented        minorities in our subject populations is reflective of the greater Philadelphia region and        has been achieved, in part, through our outreach efforts advertising in local newspapers        throughout the city.|September 2014|September 15, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399944||101136|
NCT01400464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-004896-23|Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis|Study the Link Between Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis|PREDICORT|University Hospital, Caen|No|Active, not recruiting|July 2009|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|50 Years|N/A|No|||April 2014|April 8, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400464||101096|
NCT01400659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPS2008|Pizza-Salami Study in Children and Adolescents With Type 1 Diabetes|The PIZZA-Salami Trial: Monocentric Randomised Cross-over Study of Carb Counting vs. Carb Plus Fat/Protein Counting Based Insulin Bolus Used for Sensor-augmented Continuous Subcutaneous Insulin Infusion (CSII) in Pediatric Patients||Kinderkrankenhaus auf der Bult|No|Completed|March 2009|November 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|6 Years|21 Years|No|||December 2015|December 17, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400659||101081|
NCT01395615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22686|An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia|Utility Measurement Study for Patients With Chronic Lymphocytic Leukaemia||Hoffmann-La Roche||Completed|October 2008|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic lymphocytic leukaemia|March 2016|March 1, 2016|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395615||101467|
NCT01395901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-10-14|Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients|A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients.||Helsinn Healthcare SA|Yes|Completed|June 2011|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|670|||Both|N/A|16 Years|No|||July 2014|July 29, 2014|July 14, 2011|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01395901||101445|
NCT01395953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000703|Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders||Massachusetts General Hospital|No|Withdrawn|November 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|6 Years|17 Years|No|||April 2015|April 6, 2015|July 14, 2011|Yes|Yes|This study was withdrawn due to competing research interests and slow recruitment.|No||https://clinicaltrials.gov/show/NCT01395953||101441|
NCT01396499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0874|Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias|A Phase I Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, in Patients With Advanced Leukemias||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2012|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|July 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396499||101400|
NCT01396512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEC12|Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers|Immunogenicity and Safety of a Single Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) in Comparison With a Single Dose of SA14-14-2 Vaccine (CD.JEVAX™, Chengdu Institute of Biological Products, China) Administered in Healthy Toddlers in South-Korea||Sanofi|No|Completed|July 2011|June 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|274|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||March 2014|March 24, 2014|July 14, 2011||No||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01396512||101399|
NCT01396837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD003|A Prospective, Open Label Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.|A Prospective, Open Label Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.||RedDress Ltd.|No|Recruiting|May 2014|June 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|July 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396837||101374|
NCT01397110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-07-12|Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects|Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life in Patients With Severe Associated Pulmonary Arterial Hypertension (APAH) as Part of a Congenital Heart Defect With / Without Eisenmenger's Syndrome||Heidelberg University|No|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|80 Years|No|||June 2015|June 19, 2015|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01397110||101353|
NCT01397370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0492-CL-102|Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects|Double Blind, Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0492 in Healthy Subjects||Galapagos NV|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 17, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397370||101333|
NCT01397630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-521|Accelerated Titration of Oxytocin for Nulliparous Patients With Labour Dystocia: ACTION Pilot Study|Accelerate Versus Gradual Titration of Oxytocin Dose for Labour Dystocia: A Pilot Study|ACTION|Ottawa Hospital Research Institute|Yes|Terminated|April 2012|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|79|||Female|18 Years|N/A|No|||June 2015|June 23, 2015|July 7, 2011||No|Due to budgetary concerns, the TSC decided it best to adjust sample size as there was    sufficient data to assess feasibility. Recruitment was terminated early.|No||https://clinicaltrials.gov/show/NCT01397630||101313|
NCT01397890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589BL00023|Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Parallel-group, Open-label, Multicentre, 3-month Phase IV, Efficacy and Tolerability Study of Budesonide/Formoterol (Symbicort® Turbuhaler® 160/4.5μg/Inhalation, 2 Inhalations Twice Daily) Added to Tiotropium (SpirivaTM 18 μg/Inhalation, 1 Inhalation Once Daily) Compared With Tiotropium (SpirivaTM18 μg/Inhalation, 1 Inhalation Once Daily) Alone in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients|SECURE 1|AstraZeneca||Completed|July 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|793|||Both|40 Years|N/A|No|||March 2015|March 25, 2015|June 27, 2011||No||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01397890||101293|
NCT01398163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU271|A f-MRI Study Of Affective Changes Associated With Four Weeks Consumption Of A Fermented Dairy Product In Healthy Women|A f-MRI STUDY OF AFFECTIVE CHANGES ASSOCIATED WITH FOUR WEEKS CONSUMPTION OF A FERMENTED DAIRY PRODUCT IN HEALTHY WOMEN||Danone Research|No|Completed|April 2009|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|3|||45|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2011|July 19, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398163||101272|
NCT01398176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-95320|Immune Benefits From Mushroom Consumption|Immune Benefits From Mushroom Consumption||University of Florida|No|Completed|October 2011|December 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|52|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|July 18, 2011||No||No|September 25, 2013|https://clinicaltrials.gov/show/NCT01398176||101271|No specific limitations outside of the normal limitations to human interventions studies.
NCT01394237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SakPexFup|Laparoscopic Sacrocolpopexy: Long Term Follow-up|Laparoscopic Sacrocolpopexy: Long Term Results With Special Focus on Anatomical Results and Quality of Life||Kantonsspital Aarau|Yes|Completed|June 2011|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|||Female|20 Years|N/A|No|Probability Sample|Patients operated for vaginal vault prolapse at our institution by laparoscopic        sacrocolpopexy between 2003 and 2007|March 2014|March 11, 2014|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394237||101573|
NCT01394250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007970|Vibrating, Cold Device for Pediatric Intravenous (IV) Cannulation Pain Relief|Testing the Efficacy of a Vibrating, Cold Device for Pediatric IV Cannulation Pain Relief in the Emergency Department||Children's Hospital of Philadelphia|No|Completed|June 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|4 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 14, 2015|June 3, 2011||No||No|March 27, 2015|https://clinicaltrials.gov/show/NCT01394250||101572|
NCT01402193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-RT-002|Study of Arimidex and Radiotherapy Sequencing|A Prospective, Randomized, Bi-center Study to Compare the Outcome of Adjuvant Radiotherapy With Concomitant or Sequential Arimidex in Postmenopausal Women With Breast Cancer||Fudan University|Yes|Recruiting|July 2011|July 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Female|18 Years|70 Years|No|||June 2014|June 24, 2014|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402193||100964|
NCT01402778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-VBTSPK-2011|Fixation of Thoracic Epidurals Influencing Catheter-related Infections and Dislocation|Fixation of Thoracic Epidural Catheters Influencing Catheter-related Infections and Dislocation|TDPAFD|Heinrich-Heine University, Duesseldorf|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|140|||Both|18 Years|N/A|No|Probability Sample|Patients aged > 18 years|December 2011|December 19, 2011|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01402778||100919|
NCT01402791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/SD-05|Endometriosis: Sexual Dysfunction and Adaptation Strategies Among Couples|Endometriosis: Sexual Dysfunction and Adaptation Strategies Among Couples|DYSEXTRIOSE|Centre Hospitalier Universitaire de Nīmes|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Couples for whom the women have been surgically treated for deep endometriosis at the        Nîmes University Hospital|March 2015|March 25, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402791||100918|
NCT01399190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25523|An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer|An Open Label Study of the Effect of First Line Treatment With Bevacizumab in Combination With Capecitabine and Oxaliplatin on Progression-free Survival in Patients With Metastatic Cancer of the Colon and Rectum||Hoffmann-La Roche||Completed|July 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|68|||Both|18 Years|N/A|No|Probability Sample|Patients with colorectal cancer on first-line treatment with Avastin in combination with        Xeloda and oxaliplatin|March 2016|March 1, 2016|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399190||101194|
NCT01399203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009X41|Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention|Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention|CONVIN|Guangdong General Hospital|Yes|Recruiting|January 2010|January 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|21 Years|N/A|No|Probability Sample|The investigators reviewed all consecutive patients who were undergoing percutaneous        coronary intervention|January 2010|August 2, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399203||101193|
NCT01399684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEF4982g|A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer||Genentech, Inc.||Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399684||101156|
NCT01399697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27828|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With MTX Versus Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 > 3,2)||Hoffmann-La Roche||Completed|September 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||May 2015|June 18, 2015|July 20, 2011||No||No|June 18, 2015|https://clinicaltrials.gov/show/NCT01399697||101155|
NCT01400217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007/11|Qvar Versus Clenil, a General Practice Research Database Study|HFA Beclomethasone in Asthma, a General Practice Research Database Study: Real-life Observational Evaluation of Extra-fine With Standard Particle Size Beclometasone Dipropionate Using the Propellant Hydrofluoroalkane 134a for the Management of Asthma in a Representative UK Primary Care Population||Research in Real-Life Ltd|Yes|Completed|January 1991|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||6|Actual|56985|||Both|4 Years|80 Years|No|Non-Probability Sample|All patients are aged between 4-80 years and have evidence of asthma and subsequent        therapy.|October 2012|October 29, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400217||101115|
NCT01400698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20184|Saizen in Intra-uterine Growth Retardation|An Open Study of the Safety and Efficacy of Saizen®, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height||Merck KGaA||Completed|November 1998|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|91|||Both|N/A|N/A|No|||September 2013|September 9, 2013|July 21, 2011|Yes|Yes||No|June 27, 2012|https://clinicaltrials.gov/show/NCT01400698||101078|
NCT01400672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009LS136|Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma|Imiquimod/BTIC Lysate-Based Vaccine Immunotherapy for Diffuse Intrinsic Pontine Glioma in Children and Young Adults||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|July 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|N/A|No|||February 2016|February 12, 2016|July 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01400672||101080|
NCT01395628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B13|Cell Samples From Patients With Leukemia|Xenotransplantation of Primary Leukemia Samples Into Zebrafish||Children's Oncology Group|No|Active, not recruiting|July 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10|Samples With DNA|cell samples|Both|N/A|30 Years|No|Non-Probability Sample|Patients diagnosed with myeloid disease.|May 2015|May 8, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395628||101466|
NCT01396850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor497310ctil|Measurments Of BBB Breakdown In The Pathogenesis Of Psychiatric Disorders|THE ROLE OF BBB BREAKDOWN IN THE PATHOGENESIS OF PSYCHIATRIC DISORDERS||Soroka University Medical Center||Not yet recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|120|||Both|16 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Psychotic, affective disorders or anxiety disorders patients admitted to Soroka Medical        Center from the psychiatric hospital or self admissions to the Psychiatric department.|July 2011|July 18, 2011|July 17, 2011||||No||https://clinicaltrials.gov/show/NCT01396850||101373|
NCT01397123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1845|The Impact of an Intervention Taught by Trained Teachers on Childhood BMI z Score|||University of Minho|Yes|Completed|September 2007|June 2009|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|464|||Both|5 Years|12 Years|No|||July 2011|July 18, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01397123||101352|
NCT01397643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/R/OST/05|A Trial of Non-operative Versus Operative Management of Olecranon Fractures in the Elderly|A Prospective Randomised Trial of Non-operative Versus Operative Management of Olecranon Fractures in the Elderly||Royal Infirmary of Edinburgh|No|Active, not recruiting|October 2010|October 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|75 Years|N/A|No|||May 2015|May 14, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397643||101312|
NCT01397942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-067129|Maximising the Taste and Health Value of Plant Food Products|Maximising the Taste and Health Value of Plant Food Products - Impact on Vegetable Consumption, Consumer Preferences and Human Health Factors.|MAXVEG|Aarhus University Hospital|Yes|Completed|May 2011|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|92|||Both|30 Years|70 Years|No|||March 2015|March 10, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397942||101289|
NCT01397903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NGR-XXX-2011/1|Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response|A Cross-sectional Observational Study to Describe Treatment Management of Patients With Major Depressive Disorder (MDD) and Inadequate Response to Antidepressants in Greece|MADDRE|AstraZeneca||Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|545|||Both|18 Years|65 Years|No|Probability Sample|Psychiatric patients|June 2012|June 22, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397903||101292|
NCT01397916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL-IDO|Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)|The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)|KLL3|Tampere University Hospital|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|73|Samples With DNA|Ido expression|Both|15 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Patients with CLL|March 2012|March 29, 2012|May 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01397916||101291|
NCT01397929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDI-CS-001|An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors|An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors||Basilea Pharmaceutica|No|Active, not recruiting|June 2011|April 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01397929||101290|
NCT01398189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH 04-2011-050|F-18 Altanserin PET Study of Patients Receiving Clozapine|Validation of Molecular Imaging Technologies for Early Clinical Trials|APC|Seoul National University Bundang Hospital|Yes|Recruiting|July 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|19 Years|45 Years|No|||November 2013|November 19, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398189||101270|
NCT01398488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V 2.0 16/03/2011|Patient Education After Lung Transplantation Via Tablet Computers Versus Conventional Education|Patient Education After Lung Transplantation Via Tablet Computers Versus Conventional Education - a Randomized Open Controlled Trial||Hannover Medical School|No|Completed|July 2011|May 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Both|N/A|N/A|No|||June 2013|June 5, 2013|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01398488||101247|
NCT01394848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNOVATION_v5.0|Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy|EndothelIal progeNitor Cell Capture steNt With 1-mOnth Dual Antiplatelet Therapy Versus eVerolimus-eluting Stent With stAndard 12-month Dual anTIplatelet Therapy in Elderly (≥ 70 Year) With Stable corONary Artery Disease - INNOVATION Trial|INNOVATION|Yonsei University|Yes|Terminated|October 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1|||Both|70 Years|N/A|No|||December 2013|December 3, 2013|July 11, 2011||No|Previous other study including EPC capture stent raised the issue of safety (significant high    incidence of instent restenosis)|No||https://clinicaltrials.gov/show/NCT01394848||101526|
NCT01394861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-GI2011-04|Endoscopic Submucosal Dissection (ESD)- Master Slave Robotic System - Human Study||ESD|Asian Institute of Gastroenterology, India|Yes|Completed|June 2011|October 2011|Actual|July 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|25 Years|60 Years|No|||March 2012|March 4, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394861||101525|
NCT01402544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100471|Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab.||COMPASS|University of California, San Diego|Yes|Recruiting|July 2011|September 2012|Anticipated|August 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|50 Years|N/A|No|||July 2011|July 25, 2011|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402544||100937|
NCT01398917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DILSTENT2|Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis|Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|May 2011|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||July 2012|July 5, 2012|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01398917||101215|
NCT01399463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUWCard18022011|Pressure-wire Guided PTCA: Drug Eluting Stent Versus Drug Eluting Balloon (WinDEB Study)|Pressure Wire-guided Percutaneous Coronary Intervention of Small Vessels or Side Branches: Functional Outcome of Drug-Eluting Stent (DES) Versus Drug-Eluting Balloon (DEB) With Provisional Bare Metal Stent Implantation||Medical University of Vienna||Not yet recruiting|August 2011|||||N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind|2||||||Both|18 Years|N/A|No|||July 2011|July 20, 2011|July 20, 2011||||No||https://clinicaltrials.gov/show/NCT01399463||101173|
NCT01399476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1056|Endoscopic Myotomy of the Lower Esophageal Sphincter for Achalasia|Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia|POEM|The Oregon Clinic|No|Recruiting|September 2010|September 2013|Anticipated|September 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||April 2012|April 12, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399476||101172|
NCT01399957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0003|Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients|Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell MS Center: Characterizing Clinical Predictors of Response and Identifying Additional Outcomes||Mount Sinai Rehabilitation Hospital|No|Completed|August 2010|September 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|52|Samples With DNA|15 mL of blood will be collected into an EDTA tube from participants at assessment      appointments. Both serum and cells will be frozen and stored in a -80 degree freezer.|Both|18 Years|N/A|No|Non-Probability Sample|Persons with MS who have been prescribed ampyra at the Mandell Center for Multiple        Sclerosis.|November 2015|November 9, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399957||101135|
NCT01400477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0459|Nicotinic Receptors and Schizophrenia|Nicotinic Receptors and Schizophrenia: Phase II||University of Colorado, Denver|Yes|Completed|July 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|65 Years|No|||June 2015|June 16, 2015|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400477||101095|
NCT01401244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3939|Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers|A Trial to Examine the Bioequivalence of Norditropin® Versus Genotropin® in Healthy Adult Volunteers||Novo Nordisk A/S|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|40 Years|No|||December 2012|April 23, 2013|July 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01401244||101036|
NCT01401257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN-PXT3003-01|Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A|A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A.||Pharnext, SAS|Yes|Completed|December 2010|December 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|65 Years|No|||July 2011|September 11, 2013|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401257||101035|
NCT01400685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-016|Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL|Lenalidomide in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma(CLL/SLL): a Phase I Study||Massachusetts General Hospital|Yes|Active, not recruiting|December 2012|December 2015|Anticipated|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|80 Years|No|||January 2015|January 26, 2015|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400685||101079|
NCT01395966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF289III/10IA02|Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients|Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients||Salvat|No|Completed|June 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|331|||Both|6 Months|12 Years|No|||September 2015|September 22, 2015|July 8, 2011|Yes|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01395966||101440|
NCT01396226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4120C00002|A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure||AstraZeneca||Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|80 Years|No|||November 2012|November 22, 2012|July 13, 2011|Yes|Yes||No|September 24, 2012|https://clinicaltrials.gov/show/NCT01396226||101421|
NCT01397656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011358-01H|Bystander Fatigue and CPR Quality Using Continuous Compressions Versus 30:2 Compressions to Ventilation|Comparison of Bystander Fatigue and CPR Quality When Using the 2010 Continuous Chest Compression Versus the 2005 30:2 Chest Compression to Ventilation Resuscitation Guidelines for Laymen: A Randomized Crossover Trial||Ottawa Hospital Research Institute|No|Completed|July 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|62|||Both|55 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 1, 2012|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01397656||101311|
NCT01397955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15075|Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan|Drug Use Investigation of Julina Tablets 0.5 mg (Postmenopausal Osteoporosis)||Bayer|No|Completed|January 2009|April 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|148|||Female|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who have received a prescription of Julina        on the basis of the decision of the treating gynecologist. The study is expected to        collect data of 100 patients in about 20 gynecological practices in Japan.|April 2015|April 16, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01397955||101288|
NCT01398202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111|Dietary Supplementation With 25-hydroxyvitamin D3 in Older Adults|Comparison of the Bioefficacy of Oral 25-hydroxyvitamin D3 and Vitamin D3 Supplements on Vitamin D Status in Older Adults||University College Cork|Yes|Completed|January 2011|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|56|||Both|45 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398202||101269|
NCT01398501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-114|Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant|Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation||Massachusetts General Hospital|Yes|Active, not recruiting|August 2011|August 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|75 Years|No|||January 2016|January 14, 2016|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398501||101246|
NCT01398514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001314|Influence of Escitalopram on Fear Conditioning|Pharmacologic Influence of Escitalopram on the Reduction of Fear Acquisition and Triggered Renewal During Fear Conditioning: a Model for the Prevention and Persistence of Learned Fear and Anxiety in Response to Trauma and Stress||Massachusetts General Hospital|No|Completed|October 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|65|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|July 12, 2011|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01398514||101245|
NCT01394263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302|Study of Histrelin Subdermal Implant in Patients With Prostate Cancer|Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate Cancer||Endo Pharmaceuticals|No|Completed|May 2000|December 2003|Actual|December 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Male|45 Years|N/A|No|||September 2012|September 27, 2012|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394263||101571|
NCT01394549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11320|Causes, Analysis of the Sub-evaluating Coronary Syndromes Acute and Disparities in France in Women|Causes, Analysis of the Sub-evaluating Coronary Syndromes Acute and Disparities in France in Women|CASSANDRE|French Cardiology Society|Yes|Completed|June 2011|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|319|||Both|N/A|N/A|No|Probability Sample|The study will be conducted in cardiac services regardless of the type of hospital where        they are|June 2012|June 20, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394549||101549|
NCT01394874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B100003-2|Can Computer-based Telephone Counseling Improve Long-term Adherence to Strength Training in Elders With Knee OA?|Can Computer-based Telephone Counseling Improve Long-term Adherence to Strength Training in Elders With Knee OA?|BOOST|Boston University|No|Recruiting|July 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|55 Years|N/A|No|||May 2013|May 1, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01394874||101524|
NCT01402817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104-07|Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas|A Pilot Study of Sutent®/Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Subjects With NF-1 Plexiform Neurofibromas||Indiana University|Yes|Suspended|March 2012|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|3 Years|65 Years|No|||August 2015|August 25, 2015|July 25, 2011|Yes|Yes|1 patient died of uncertain cause but possibly related to drug. Regulatory currently reviewing|No||https://clinicaltrials.gov/show/NCT01402817||100916|
NCT01399229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRT-11-01|Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women|Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women||Reproductive Research Technologies, LP|No|Completed|January 2007|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|30|||Female|18 Years|40 Years|No|Non-Probability Sample|Pregnant women with uncomplicated singleton pregnancies|August 2013|August 28, 2013|July 19, 2011||No||No|November 15, 2012|https://clinicaltrials.gov/show/NCT01399229||101191|
NCT01399489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R15HL096097-01|Aerobic Training and Arterial Stiffness in Chronic Kidney Disease (CKD) Patients|The Effect of Short-term Aerobic Training on Arterial Stiffness and Blood in Chronic Kidney Disease (CKD) Patients||Springfield College|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|51|||Both|35 Years|70 Years|No|||January 2014|January 22, 2014|January 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01399489||101171|
NCT01399502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0931313|Promotion of Self-help Strategies for Depression|||Orygen Youth Health Research Centre|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1736|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 9, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399502||101170|
NCT01399437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911470|Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia|Default Network Dysfunction Underlying Visuospatial Attention Deficits in Schizophrenia||National Institutes of Health Clinical Center (CC)||Completed|July 2011|December 2014||||N/A|Observational|N/A|||Anticipated|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 25, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399437||101175|
NCT01399450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-KOR-9015|Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients|Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study||Seoul National University Hospital|Yes|Recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399450||101174|
NCT01400230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-2-1010-049|Diagnostic Performances of Computed TomographIc Coronary Angiography and Intravascular Ultrasound|Diagnostic Performances of the Computed Tomographic Coronary Angiography and IntraVascular UltraSound to Evaluate Ischemia Causing Coronary Artery Stenosis|IMAGES-FFR|Seoul National University Hospital|No|Completed|March 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|20 Years|83 Years|No|Non-Probability Sample|Consecutive patients who underwent CCTA, IVUS and FFR Stable clinical condition|March 2015|March 23, 2015|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01400230||101114|
NCT01400243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NIDA 1R01DA031006 - 01|Nicotine Patch for Marijuana Withdrawal|Nicotine for Marijuana Withdrawal|NMW|Southern Illinois University Carbondale|Yes|Completed|April 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|127|||Both|18 Years|50 Years|No|||April 2015|April 16, 2015|March 21, 2011|No|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01400243||101113|The modest sample size limited the ability to precisely characterize how the effects of patch type may be modified by tobacco smoker status, gender, personality traits, and individual differences in marijuana use history.
NCT01400711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1VA|Enhanced Recovery After Surgery in Major Intrabdominal Procedures.|Enhanced Recovery After Surgery (ERAS) Versus Conventional Postoperative Care in Patients Undergoing Major Intra-abdominal Surgery.||St. Andrew's General Hospital, Patras, Greece|No|Completed|October 2010|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|20 Years|89 Years|No|||August 2010|July 21, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400711||101077|
NCT01400971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14056|An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes|A Multinational Observational Study Assessing Insulin Use: Understanding the Challenges Associated With Progression of Therapy - The MOSAIc Type 2 Diabetes Study|MOSAIc|Eli Lilly and Company|No|Completed|July 2011|September 2015|Actual|September 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|4530|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Type 2 diabetes attending primary care and diabetes specialty clinics.|October 2015|October 26, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400971||101057|
NCT01392560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.46|Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration|An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial)||Boehringer Ingelheim||Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|July 11, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01392560||101702|
NCT01392573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-3912|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes|A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes|DUAL™ II|Novo Nordisk A/S|No|Completed|November 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|414|||Both|18 Years|N/A|No|||July 2014|August 14, 2014|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01392573||101701|
NCT01400958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16233|Nuvigil or Placebo in Newly Diagnosed Malignant Glioma|A Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Nuvigil® (Armodafinil) in Newly Diagnosed Malignant Glioma Patients Experiencing Fatigue Secondary to External Beam Radiation Therapy and Concurrent Temozolomide||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|December 2010|September 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|6|||Both|18 Years|N/A|No|||October 2013|October 25, 2013|July 21, 2011|Yes|Yes|Slow Accrual, Initiating Principal Investigator (PI) left Moffitt|No|August 6, 2013|https://clinicaltrials.gov/show/NCT01400958||101058|Planned accrual of 60 participants for analysis was not met. Recruitment was closed early due to slow accrual and initiating Principal Investigator (PI) leaving Moffitt.
NCT01396525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-107 Omnilink Elite Arm (OE)|Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery|A Prospective, Non-randomized, Two Arm, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System and the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.|MOBILITY OE|Abbott Vascular|Yes|Completed|March 2009|June 2014|Actual|September 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|153|||Both|18 Years|89 Years|No|||December 2015|January 8, 2016|July 14, 2011|Yes|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01396525||101398|
NCT01396538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100028|Prevalence of Occult HBV Infection Among Anti-HBc Alone Group in Northern Taiwan|Prevalence of Occult HBV Infection Among Anti-HBc Alone Group in Northern Taiwan||Taipei Medical University WanFang Hospital|Yes|Active, not recruiting|June 2011|May 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|anti-HBc alone（HBsAg(-)；Anti-HBs(-)；Anti-HBc(+)）；occult HBV infection（the presence of HBV        DNA in the liver and blood, in the absence Occult HBV of detectable HBsAg|October 2011|October 11, 2011|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01396538||101397|
NCT01397383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10014|Vitamin D and Functional Outcomes After Total Hip Arthroplasty (THA)|The Effect of Serum Vitamin D Level and the Short Term Functional Outcomes After Total Hip Arthroplasty||Hospital for Special Surgery, New York|Yes|Recruiting|March 2010|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who are scheduled for primary total hip replacement will be identified at the        preoperative visit.|July 2011|July 18, 2011|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01397383||101332|
NCT01397396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52852|Effects of Inspiratory Muscle Training in COPD|Effects of Inspiratory Muscle Training in Patients With Chronic Obstructive Pulmonary Disease - a Randomized Controlled Trial|IMTCO|Katholieke Universiteit Leuven||Recruiting|September 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|40 Years|90 Years|No|||February 2016|February 1, 2016|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397396||101331|
NCT01397409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150998-001|Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)|||Allergan|No|Completed|September 2011|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|271|||Both|50 Years|N/A|No|||May 2015|June 2, 2015|July 18, 2011|Yes|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT01397409||101330|
NCT01397422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADS-PAR-AM201|Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)|Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)|EASED|Adamas Pharmaceuticals, Inc.|Yes|Completed|July 2011|October 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|83|||Both|30 Years|85 Years|No|||April 2014|April 7, 2014|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397422||101329|
NCT01397968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YKP3089C013|Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures|A Phase 2 Multicenter, Double-Blind, Randomized, Adjunctive Placebo Controlled Trial to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures||SK Life Science|Yes|Completed|May 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|222|||Both|18 Years|65 Years|No|||November 2014|November 17, 2014|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397968||101287|
NCT01398215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081038, 150520|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Transvaginal Ventral Hernia Repair|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Transvaginal Ventral Hernia Repair|NOTES|University of California, San Diego|No|Recruiting|January 2009|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Female|18 Years|75 Years|No|Non-Probability Sample|All patients who come to the UC San Diego Surgical Specialties clinic and have chosen to        undergo a ventral hernia repair will be evaluated for participation in this tria|March 2016|March 17, 2016|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01398215||101268|
NCT01398228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPACS-3|Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3|Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3|CPACS-3|The George Institute for Global Health, China|Yes|Active, not recruiting|September 2011|June 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|20000|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398228||101267|
NCT01398527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 09-215|Vitamin D Osteoporosis Long-Term Care Study|An Interdisciplinary Knowledge Translation Intervention in Long-term Care: The Vitamin D and Osteoporosis Study (ViDOS) Pilot Cluster Randomized Controlled Trial|ViDOS|McMaster University|No|Completed|July 2009|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|N/A|N/A|No|||May 2013|May 2, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398527||101244|
NCT01398540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IX-sensesc 1.2|Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine|Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine.||Medical University of Vienna||Enrolling by invitation|November 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2010|July 19, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398540||101243|
NCT01394276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25728|An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)|RheumaToid arthRitis Patients Treated With tocilizUmab in Real Clinical Practice: effectiveneSs and safeTy||Hoffmann-La Roche||Completed|April 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|322|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra|November 2015|November 2, 2015|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394276||101570|
NCT01394289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6041-PR-PRI-182|Biological Standardization of Lolium Perenne Allergen Extract|Biological Standardization of Lolium Perenne Allergen Extract to Determine the Biological Activity in HEP Units||Laboratorios Leti, S.L.|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|50 Years|No|||August 2011|August 24, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394289||101569|
NCT01394536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0063|Overnight Use of Electroacustimulation on Postoperative Nausea and Vomiting in the Outpatient Surgery Population|The Effect of Overnight Use of Electroacustimulation on Postoperative Nausea and Vomiting in the Outpatient Surgery Population||University of Wisconsin, Madison|No|Withdrawn|June 2011|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|89 Years|No|||October 2012|October 16, 2012|June 28, 2011|No|Yes|The study was closed prior to enrollment of any subjects. No subjects were enrolled in this    study.|No||https://clinicaltrials.gov/show/NCT01394536||101550|
NCT01394835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAT-02|Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients|||Rabin Medical Center||Not yet recruiting|September 2011|September 2013|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||July 2011|July 13, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01394835||101527|
NCT01394900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI5452|Connect 'n Unite: Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM|Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM|CNU|Columbia University|No|Active, not recruiting|July 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|424|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394900||101522|
NCT01398930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-127|Acupuncture as an Adjunctive Therapy to the Pharmacological Treatment in Patients With Chronic Pain in Osteoarthritis of the Knee: a Three Armed Randomized Placebo Controlled Trial|||National and Kapodistrian University of Athens|No|Completed|September 2007|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|120|||Both|35 Years|75 Years|No|||July 2008|July 20, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01398930||101214|
NCT01399216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-420|Effects of a Supplement Containing Fucoidan on Basal Body Temperature|Effects of a Supplement Containing Fucoidan as a Major Component on Basal Body Temperature: a Placebo Controlled, Cross-over Study||Hiroshima University|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Female|55 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399216||101192|
NCT01399242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EL-1254|Efficacy of Certican® in Combination With Myfortic® in Renal|Efficacy and Safety of Certican® in Combination With Myfortic® in Adult Renal Allograft Recipients Following Calcineurin Inhibitor Withdrawal at Week 16 Compared to Patients Who Are Maintained on Tacrolimus and Myfortic®|HUSJ1|Hospital Universitário São José|Yes|Not yet recruiting|August 2011|June 2013|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2011|July 20, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399242||101190|
NCT01399255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Listro/PK-PD/FDA/2011|Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects|||Wockhardt|No|Withdrawn|November 2011|June 2012|Anticipated|May 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|July 19, 2011|Yes|Yes|Study was not initiated|No||https://clinicaltrials.gov/show/NCT01399255||101189|
NCT01399983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-069 ex 10/11|Standardization of 6 Minute Walk Test|Assessment of Exercise Capacity and Standardization of Six Minute Walk Test in Patients With Pulmonary Hypertension||Medical University of Graz|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|29|||Both|18 Years|90 Years|No|Non-Probability Sample|patients with pulmonary hypertension or exercise-induced pulmonary hypertension assessed        by right heart catheterisation|March 2012|March 8, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01399983||101133|
NCT01399710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD COLON 001|Impact of Computer-Aided Detection (CAD) as Second Reader in CT Colonography|Measure of Performances of CT Colonography With Computer-Aided Detection (CAD) as Second Reader in Detecting Colorectal Lesion|CAD-IMPACT|im3D S.p.A.|Yes|Completed|July 2007|March 2010|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|651|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01399710||101154|
NCT01399970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02|Use of Mobile Teledermatology in the Care of Acne Patients|Use of Mobile Teledermatology in the Care of Acne Patients - A Randomized Controlled Trial|Teleacne|Medical University of Graz|No|Completed|April 2011|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|69|||Both|12 Years|30 Years|No|||January 2014|January 12, 2014|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01399970||101134|
NCT01400490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRA 2010-01|Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study|Evaluation of the Biologic Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)-Enriched Oils (EPA-DHA Study)||Cardiovascular Research Associates|No|Active, not recruiting|September 2010|September 2011|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|120|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400490||101094|
NCT01392222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-108|Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others|Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All participants will be recruited from Dr. Mike Tuttle's clinic.|July 2015|July 21, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01392222||101727|
NCT01392235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTN-II-NPC|Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)|A Single-arm, Open, Multicenter, Phase II Study of Famitinib as ≥Third Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)||Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|June 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|70 Years|No|||July 2011|February 8, 2012|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01392235||101726|
NCT01401504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3026-CL-0102|Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors|A Phase I, Non-randomized, Open-label, Repeat Oral Administration Study of ASP3026 in Patients With Solid Tumors||Astellas Pharma Inc|Yes|Completed|May 2011|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|20 Years|N/A|No|||June 2014|June 10, 2014|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01401504||101016|
NCT01396876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-SR-525-CTIL|The Effects of Medical Clowns in Children Undergoing Blood Tests|Evaluation of the Effect of Hospital Clown's Performance in the Procedure Room of a Pediatric Emergency Department: A Randomized Controlled Trial||Tel-Aviv Sourasky Medical Center|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|3 Years|10 Years|No|||June 2014|June 18, 2014|July 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01396876||101371|
NCT01396889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Echinacea in URIs|Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years|Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years in Bandarabbas Children' Hospital||Hormozgan University of Medical Sciences|Yes|Completed|May 2010|July 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||May 2010|July 20, 2011|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396889||101370|
NCT01397162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1248.5|Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 22.7, 45.5 and 90.9 Doses b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA MDI 88 mcg b.i.d. in Patients With Asthma Inadequately Controlled on SABA Therapy||Boehringer Ingelheim||Terminated|July 2011|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|29|||Both|12 Years|65 Years|No|||April 2014|April 30, 2014|July 18, 2011||||No||https://clinicaltrials.gov/show/NCT01397162||101349|
NCT01397981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07142011-8086|Gait Retraining to Reduce Knee Osteoarthritis Pain|Evaluation of Haptic Technologies for Movement Retraining||Stanford University|Yes|Completed|July 2011|November 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|No|||March 2013|March 5, 2013|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397981||101286|
NCT01398241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25214|A Study of RO5267683 in Healthy Subjects|Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5267683 in an Adaptive, Randomized, Investigator-blind and Subject-blind, Multiple-ascending Dose, Placebo-controlled, Study Following Oral Administrations in Healthy Subjects for 28 Days||Hoffmann-La Roche||Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|2||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01398241||101266|
NCT01398553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gesundheitsbezirk Bozen|Automated Versus Standard Physiotherapy for Upper Limb Rehabilitation in Patients With Acquired Brain Lesions|Armeo® Versus Standard Physiotherapy for Upper Limb Rehabilitation in Patients With Acquired Brain Lesions||Krankenhaus Bozen|No|Recruiting|March 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|85 Years|No|||July 2011|August 23, 2011|November 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01398553||101242|
NCT01394302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|054/2011ק|The Functional Profile of People Suffering From Trigger Finger|Functional Profile of People Suffering From Trigger Finger||Meir Medical Center|No|Not yet recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|20 Years|N/A|No|Non-Probability Sample|patients who come to visit The hand Specialist doctor and receive a diagnosis of TF.|June 2011|July 13, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394302||101568|
NCT01394562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-CARS-04|Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure|Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency|EFFECT-HF|Vifor Inc.|Yes|Active, not recruiting|July 2011|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|174|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394562||101548|
NCT01392079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cll2O|Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine|A Prospective, Multi-center Phase II Study of Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Stem-cell Transplantation, in Chronic Lymphocytic Leukemia Which is Associated With 17p Deletion or is Refractory to Fludarabine||University of Ulm|Yes|Active, not recruiting|February 2008|December 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01392079||101738|
NCT01392092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-1|Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers (NAC)|Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers|NAC|Wayne State University|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|55 Years|No|Non-Probability Sample|Cocaine abusing or dependent research volunteers|January 2016|January 25, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392092||101737|
NCT01398943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA00115CS|Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)|Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach||Georgia Regents University|Yes|Completed|September 2010|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 10, 2016|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398943||101213|
NCT01399268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSS-28116|Steroids in Bilateral Total Knee Replacement|Effect of Steroids Given Over 24 Hours on Cytokine Release and Urinary Desmosine Levels in Patients Undergoing Bilateral Total Knee Replacement||Hospital for Special Surgery, New York|No|Completed|February 2009|February 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|34|||Both|50 Years|90 Years|No|||September 2012|September 24, 2012|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01399268||101188|
NCT01400256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489A US71|Blood Pressure Lowering in Acute Stroke Trial|The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Affects on Cerebral Blood Flow|BLAST|Stanford University|Yes|Withdrawn|August 2007|February 2008|Anticipated|||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2011|July 21, 2011|July 20, 2011|Yes|Yes|lack of recruitment/patient population|No||https://clinicaltrials.gov/show/NCT01400256||101112|
NCT01391702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00901|How Sweet is it? Measurement of Glucose in Epidural and Spinal Fluid|How Sweet is it? Measurement of Glucose in Epidural Fluid and Fluid Obtained During Spinal Anesthesia After a Failed Epidural Using a Bedside Monitor||University of British Columbia|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Female|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy pregnant women who are admitted to the hospital in labour who receive an epidural        for pain relief|April 2012|April 5, 2012|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01391702||101767|
NCT01391949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001404|Pedaling Exercises for Disability and Activity Limitations|UCFit Pedaling Exercises to Limit Disability in the Outpatient Setting|PEDAL|University of California, Los Angeles|No|Enrolling by invitation|July 2011|September 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01391949||101748|
NCT01391962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110200|Sunitinib or Cediranib for Alveolar Soft Part Sarcoma|A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Years|120 Years|No|||October 2015|March 2, 2016|July 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01391962||101747|
NCT01392885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231233-BSB|Brain Health and Exercise in Schizophrenia|Brain Health: Effects of Exercise on Hippocampal Volume and Memory Deficits in Persons With Schizophrenia|PEHP|BC Mental Health and Addictions Research Institute|No|Enrolling by invitation|July 2011|December 2016|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|No Biospecimens to be retained|Both|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sixty in-patients with chronic schizophrenia will be recruited at UBC Hospital and 60 age        and gender-matched healthy (asymptomatic) community volunteers will be recruited through        local community paper advertisements or posters at local community centres.|July 2015|July 20, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01392885||101677|
NCT01393262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001019|Orthopaedic Hand Service Data Repository|Orthopaedic Hand Service Data Repository||Massachusetts General Hospital|Yes|Enrolling by invitation|November 2009|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|2000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All individuals will be over the age of 18 and English speaking, excluding vulnerable        populations (mental disabilities, prisoners etc.). Patients may be traumatic or        non-traumatic.|January 2016|January 5, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393262||101648|
NCT01393223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhaseII LP-08 IC/BPS|Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome|A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)||Lipella Pharmaceuticals, Inc.|Yes|Recruiting|April 2015|April 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393223||101651|
NCT01393236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2010-011a|Heart Rate Variability During Sleep After Fast-track Surgery|||Rigshospitalet, Denmark|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|10|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|We selected patients undergoing fasttrack hip and knee arthoplasty in fast-track setip.        The underwent sleep monotoring for 1 preoperative night and continously during        hospitalisation, and for 1 night at home after surgery.|December 2011|December 13, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393236||101650|
NCT01378221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005|VItamin D Metabolism in SEnescent Cardiac Surgery Patients|Vitamin D Metabolism in Senescent Cardiac Surgery Patients|VISE|Heart and Diabetes Center North-Rhine Westfalia|No|Completed|September 2009|May 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|75|||Both|18 Years|N/A|No|Probability Sample|elective cardiac surgery patients receiving isolated coronary artery bypass grafting or        combined coronary artery bypass grafting and heart valve surgery|December 2013|December 11, 2013|June 20, 2011||No||No|December 11, 2013|https://clinicaltrials.gov/show/NCT01378221||102799|
NCT01377948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X10-06-0278|Reducing Aggression in Children and Adolescent on an Inpatient Unit|Phase 1 Study of Anger Control Therapy Augmented With RAGE-Control (Regulate and Gain Emotional-Control)Delivered on an Inpatient Psychiatric Unit||Gonzalez-Heydrich, Joseph, M.D.|No|Completed|June 2010|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|8 Years|17 Years|No|||March 2012|March 8, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01377948||102820|
NCT01378208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK-H-3-2011-023|How Often Should We Eat|VEK-H-3-2011-023. Fasting and Meal Frequency Project||Rigshospitalet, Denmark|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2013|November 19, 2013|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01378208||102800|
NCT01368965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-112|Lifting and Tightening of the Face in Subjects With Skin of Darker Color|Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity in Patients With Fitzpatrick Skin Phototypes 3 Through 6||Ulthera, Inc|No|Completed|March 2011|August 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|54|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 10, 2014|June 6, 2011|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01368965||103501|Study Limitations:Masked assessment was not completed as photos were not usable, i.e., poor image quality, positioning and timing.Site staffing changes.Overburdened site staff.Poor photography qualitySubject selection
NCT01369186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023761-22|Drug Drug Interactions of Aspirin and P2Y12-inhibitors|Drug Drug Interactions of Antiplatelet Drugs and Morphine||Medical University of Vienna|No|Completed|May 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369186||103484|
NCT01369537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuroVISION Pilot|Neurological Impact of Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN Pilot Study|Neurological Impact of Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN Pilot Study||McMaster University|No|Completed|November 2011|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|65 Years|N/A|No|Non-Probability Sample|Patients aged 65 years and older undergoing noncardiac surgery and staying in hospital        overnight.|September 2013|September 5, 2013|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369537||103457|
NCT01369550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR-10-263|Efficacy Study of Stearidonic Acid (SDA) Soybean Oil-containing Foods on Red Blood Cell Fatty Acid Content|A Randomized, Controlled Trial to Assess the Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels of Red Blood Cells and the Omega-3 Index||Monsanto Company, LLC|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|127|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01369550||103456|
NCT01369823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.0 - 12/Sep/2008|Diabetes Multicenter Observational Study (DIAMOND-1-)|Prospective, Multicenter, Non-interventional Post Market Release Study , to Examine Whether Pump Treatment Combined With the Use of Continuous Glucose Monitoring System is a Mean to Normalize Glycaemic Control.|DIAMOND-1|Medtronic Hellas Medical Devices ΑEE|No|Enrolling by invitation|June 2009|December 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|12 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|This is an observational pilot study that does not have a statistically powered primary        hypothesis. The data collected during this study are for the purpose of accumulating        information that may generate research ideas and lead to publications. For this reason a        sample size of 100 subjects has been defined. The statistical analysis will be descriptive        statistics and will be described in a separate statistical analysis plan. Moreover any        enrolled patient that has a sensor usage % in the end of the study that is less than 65%        will be excluded from the analysis.|June 2011|June 8, 2011|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369823||103435|
NCT01370096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-LR-001|Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension|Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension||University of Alberta|Yes|Recruiting|February 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|18 Years|No|||March 2016|March 14, 2016|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370096||103414|
NCT01370382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOSCH2|Comparison Between the New Highly Sensitive Troponin T and the Conventional Troponin T Test in Elderly Patients|Comparison Between the New Highly Sensitive Troponin T and the Conventional Troponin T Test of the 4th Generation for the Early Identification of Myocardial Necrosis in Elderly Patients With Acute Coronary Syndromes Without ST-segment Elevation|BOSCH2|University of Erlangen-Nürnberg Medical School|No|Completed|January 2011|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|Samples Without DNA|Serum and plasma blood samples|Both|70 Years|N/A|No|Probability Sample|Emergency department of the Klinikum Nürnberg (50,000 attendances per year; the department        caters to an urban population of approximately 1 million).|April 2013|April 16, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370382||103392|
NCT01370694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8808-001|Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)|An Open-Label, Single Arm Study of MK-8808 in Patients With Advanced CD20-Positive Follicular Lymphoma||Merck Sharp & Dohme Corp.|No|Terminated|August 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|May 18, 2011|No|Yes|The study was terminated for business reasons.|No|October 23, 2015|https://clinicaltrials.gov/show/NCT01370694||103368|The study was terminated for business reasons. Not all planned analyses were performed
NCT01370369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000011|Efficacy, Pharmacokinetics and Safety of Testosterone|A Phase 2 Open-label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes of Topical Testosterone in Hypogonadal Males||Ferring Pharmaceuticals|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|65 Years|No|||January 2016|January 13, 2016|June 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370369||103393|
NCT01376219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113553|European Cost of Asthma Treatment|EU-COAST STUDY: European Cost of Asthma Treatment Economic Impact of Asthma Control|EU-COAST|GlaxoSmithKline|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2752|||Both|18 Years|N/A|No|Probability Sample|patients diagnosed with asthma for at least 12 months and at least one antiasthmatic        treatment during the last 12 months|August 2014|August 11, 2014|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376219||102950|
NCT01380730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101155|LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy|LAPLACE TIMI 57 - A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects|LAPLACE|Amgen|Yes|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|631|||Both|18 Years|80 Years|No|||August 2015|September 1, 2015|June 23, 2011|Yes|Yes||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01380730||102607|
NCT01380743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT2220-010|Drug-drug Interaction Study|An Open-Label, Multi-Center, Study to Investigate Drug-Drug Interactions Between AT2220 (Duvoglustat Hydrochloride) and Alglucosidase Alfa in Patients With Pompe Disease||Amicus Therapeutics|Yes|Completed|October 2011|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|65 Years|No|||December 2013|December 5, 2013|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380743||102606|
NCT01380990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-MI-29|Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency|Phase I/II, Non-controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1αS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells From ADA-deficient Individuals||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Recruiting|November 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|N/A|5 Years|No|||September 2015|September 11, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01380990||102587|
NCT01377207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27/01/2011|Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty. The OCTAVIA Trial|Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty. The OCTAVIA Trial|OCTAVIA|Italian Society of Invasive Cardiology|Yes|Completed|January 2011|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01377207||102875|
NCT01377181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-1233-RV|Laparoscopic Hernia Repair With Lateral Umbilicus Ligament for Children|Phase 3 Study of Laparoscopic Hernia Repair With Lateral Umbilicus Ligament for Children||The Second People's Hospital of GuangDong Province|Yes|Completed|January 2000|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|575|||Both|2 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|All patients between 2 years and 17 years of age undergoing laparoscopic inguinal hernia        repair at our institution by a single surgeon from January, 2000 to August, 2005 were        prospectively followed for outcome.|January 2000|June 21, 2011|September 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01377181||102877|
NCT01377623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02185|Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion|Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion||New York University School of Medicine|No|Completed|September 2010|June 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level        spinal fusion surgery will be screened for eligibility to participate in the study.        Subject will be screened, recruited and randomized during the preadmission visit or the        day of surgery. Eligible subjects will be randomized to one of the two treatment group        in1:1 ratio to receive either DEX or matching placebo (PBO, LR).|January 2015|January 26, 2015|January 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377623||102843|
NCT01377961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-065|Effect of Lycopene and Isoflavones on Glucose Metabolism|Effect of Lycopene and Isoflavones on Glucose Metabolism||The University of Texas Medical Branch, Galveston|Yes|Withdrawn|September 2010|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|March 30, 2011|Yes|Yes|FDA needs more information from the manufacturing company of the supplements.|No||https://clinicaltrials.gov/show/NCT01377961||102819|
NCT01378234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08121903-IRB02|Enhanced Discharge Planning Program -- Prospective|The Impact of a Social Work Driven Transitional Care Model on Health Outcomes for At-Risk Older Adults|EDPP|Rush University Medical Center|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|740|||Both|65 Years|N/A|No|||June 2011|June 21, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01378234||102798|
NCT01378494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110105006|Bone Mineral Density in HIV+ Patients|Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)||University of Alabama at Birmingham|No|Completed|June 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|19 Years|N/A|No|Non-Probability Sample|ART-naïve patients or patients followed since their first exposure to HIV treatment at the        1917 Clinic|January 2015|January 26, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01378494||102778|
NCT01378507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110526004|Endoscopic Submucosal Dissection for Gastrointestinal Neoplasms|Endoscopic Submucosal Dissection for Gastrointestinal Neoplasms||Chinese PLA General Hospital|Yes|Recruiting|January 2009|April 2013|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|90 Years|No|||May 2011|June 21, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378507||102777|
NCT01368978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G090175|Pediatric Diabetics Type 1 Using InsuPatch|Evaluation of the Effect of lnsuPatch on the Pharmacokinetic and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Given as a Bolus by Continuous Subcutaneous Insulin Infusion (CSII)||Insuline Medical Ltd.|No|Completed|December 2009|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|12 Years|17 Years|No|||May 2012|September 4, 2014|December 21, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368978||103500|
NCT01369199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK082864 HBRN IT Adult Trial|Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B|Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B|HBRN|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Active, not recruiting|May 2012|May 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369199||103483|
NCT01369563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MX028|Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis|Non-interventional Clinical Trial, to Assess the Efficacy, Safety and Tolerability of Ciclesonide 200 Mcg Once Daily, Applied as a Nasal Spray for Four Weeks, in the Treatment of Intermittent and Persistent Rhinitis|SISRIP|Takeda|Yes|Completed|August 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1630|||Both|18 Years|50 Years|No|Non-Probability Sample|Male or female external patients over 18 years and under 50 years with active rhinitis        (anterior or posterior rhinorrhea, sneezing, nasal congestion and itching) persistent (≥ 4        days a week for 4 consecutive weeks) or intermittent (<4 days a week for ≤ 4 consecutive        weeks), with medical history of rhinitis 2 years prior to their participation in this        study and whose nasal symptoms have been severe enough to require continuous or        intermittent treatment (it requires a patient's symptoms need treatment at least for a 4        weeks period). All patients have to sign the informed consent or give verbal confirmation        prior to their inclusion in the study.|September 2012|September 14, 2012|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369563||103455|
NCT01369836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461009|Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects|An Investigator And Subject-Blind Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06291826 (Tafamidis) After Single Oral Administration To Japanese And Western Healthy Subjects||Pfizer|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369836||103434|
NCT01369849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02675|Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2011|||February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2015|August 24, 2015|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369849||103433|
NCT01370109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 34810|Cardiovascular Effects of Sunitinib Therapy (CREST)|The Cardiovascular Effects of Sunitinib Therapy: Off Target Changes in Cardiac Metabolism and Ventricular Vascular Mechanics (CREST)||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Our target population is patients with renal cell carcinoma who are newly initiating        therapy with the oral tyrosine-kinase inhibitor sunitinib.|June 2015|June 15, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01370109||103413|
NCT01370395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOSCH1|Assessment of Biomarkers for Diagnosis in Geriatric Patients|Assessment of Biomarkers for Diagnosis in Geriatric Patients With the Symptom of Chest Pain in the Emergency Room|BOSCH1|University of Erlangen-Nürnberg Medical School|No|Active, not recruiting|January 2011|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Serum and plasma blood samples|Both|70 Years|N/A|No|Probability Sample|Emergency department of the Klinikum Nürnberg (50,000 attendances per year; the department        caters to an urban population of approximately 1 million).|September 2012|September 28, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370395||103391|
NCT01370980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|139/10|Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment|Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment||Policlinique Médicale Universitaire|No|Recruiting|July 2010|September 2014|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with cancer treated by oral medication in swiss-romande hospitals and private        oncologists, and enrolled in the adherence program in one of the thirty studies        pharmacies.|July 2012|July 16, 2012|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01370980||103346|
NCT01370993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-FOB under MAC|The Prediction Model of Hypoxemia for Safe Bronchoscopy|The Prediction Model of Hypoxemia for Safe Bronchoscopy Under MAC Anesthesia||Seoul National University Bundang Hospital|Yes|Recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|16 Years|N/A|No|Probability Sample|Patienst who are planned to get fiberoptic bronchoscopy under MAC anesthesia in Seoul        National University Bundang Hospital|May 2011|June 9, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01370993||103345|
NCT01370707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_VCM_301|A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients|A Randomized, Double-blind, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Patients With Type 2 Diabetes and Inadequate Glycemic Control ; Phase III Study||CJ HealthCare Corporation|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|187|||Both|20 Years|69 Years|No|||February 2013|February 13, 2013|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01370707||103367|
NCT01376245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113684|A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD|A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily Via a Dry Powder Inhaler Compared With Placebo in Subjects of Asian Ancestry With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Completed|April 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|646|||Both|40 Years|N/A|No|||January 2014|January 15, 2015|June 9, 2011|Yes|Yes||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01376245||102948|
NCT01380392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201101063RC|The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma|The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma||National Taiwan University Hospital|No|Recruiting|February 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|20 Years|N/A|No|Non-Probability Sample|HCC patients who accept surgical or medical treatment.|June 2011|June 23, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380392||102633|
NCT01381003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-MI-03|Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)|Phase I/II Gene Therapy Protocol for X-Linked Chronic Granulomatous Disease||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Withdrawn|November 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|N/A|30 Years|No|||June 2012|June 1, 2012|June 23, 2011||No|Study is withdrawn before recruting participants, new trial will be multi centre, sponsored by    different organisation.|No||https://clinicaltrials.gov/show/NCT01381003||102586|
NCT01376882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24G4|Cognitive and Cerebral Blood Flow Effects of 2-week Caffeine Abstinence or Maintenance|Behavioural and Cerebral Haemodynamic Effects of Caffeine Withdrawal and Caffeine Administration Following 2-week Maintenance or Abstinence||Northumbria University|No|Completed|March 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|110|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 28, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376882||102899|
NCT01377194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVM-MD-10|Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|568|||Both|18 Years|75 Years|No|||August 2013|August 22, 2013|June 10, 2011|Yes|Yes||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01377194||102876|
NCT01376895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POWER|Project Power: An HIV Risk Reduction Intervention for Black Men Who Have Sex With Men and Women (BMSM/W)|Developing and Testing of an HIV Prevention Intervention Targeting Black Men Who Have Sex With Men and Women (BMSM/W)|Power|Nova Southeastern University|No|Completed|July 2011|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|211|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376895||102898|
NCT01377415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bupi-placebo|Continuous Subacromial Bupivacaine|The Analgesic Effect of Continuous Subacromial Bupivacaine Infusion After Arthroscopic Shoulder Surgery: a Randomized Controlled Trial||Turku University Hospital||Completed|January 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|70 Years|No|||June 2011|June 21, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377415||102859|
NCT01377636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H#: 09-0440|Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol|Study to Measure BIS and Awareness in Patients Receiving Isoproterenol During Catheter Ablation for Atrial Fibrillation||New York University School of Medicine|No|Completed|August 2009|October 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|March 22, 2010|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT01377636||102842|
NCT01377974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILTHUB|Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis|Randomized Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis at Federal District, Brazil||Brasilia University Hospital|No|Completed|July 2009|December 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|12 Years|90 Years|No|||June 2015|June 8, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377974||102818|
NCT01378533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-012|The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC|Randomized Phase Ⅲ Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel With Paclitaxel Plus Carboplatin as Adjuvant Therapy for Triple-negative Breast Cancer.||Chinese Academy of Medical Sciences|Yes|Recruiting|May 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|65 Years|No|||December 2011|December 27, 2011|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378533||102775|
NCT01378520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS22775|Effect of Ketoconazole on Breathlessness|The Effect of Ketoconazole on Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease|KetoRLB|Dartmouth-Hitchcock Medical Center|Yes|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|N/A|No|||September 2013|September 11, 2013|June 16, 2011||No||No|September 11, 2013|https://clinicaltrials.gov/show/NCT01378520||102776|
NCT01370408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSH 940|Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients|A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy||Northside Hospital, Inc.|No|Recruiting|February 2012|June 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|85|||Both|18 Years|85 Years|No|||February 2016|February 29, 2016|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370408||103390|
NCT01370733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NND3001|Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder|Evaluation of Low Emission NeoSync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Sham-Controlled, Trial|NEST-MDD|NeoSync, Inc.|No|Completed|May 2012|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|22 Years|65 Years|No|||October 2015|October 5, 2015|June 8, 2011|Yes|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT01370733||103365|
NCT01370746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOTC-05|Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation|Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation (CTOTC-05)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|502|||Both|N/A|21 Years|No|Non-Probability Sample|Adolescents and pediatric patients after solid organ transplantation (heart, liver, or        lung)|September 2015|September 21, 2015|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370746||103364|
NCT01371006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.20|Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers|Effect of Multiple Dosing With 240mg q 12hrs BI 201335 on the Pharmacokinetics of 50 mg Single Dose Efavirenz and Effect of Multiple Dosing With 600mg QD Efavirenz on Cyp 3A4 and the Pharmacokinetics of BI 201335 in Healthy Volunteers||Boehringer Ingelheim||Completed|June 2011|||September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|June 9, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01371006||103344|
NCT01371019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sera - 004|Proteomic Assessment of Preterm Birth|Proteomic Assessment of Preterm Birth|PAPR|Sera Prognostics, Inc.|Yes|Completed|April 2011|April 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5500|Samples Without DNA|Serum, plasma|Female|18 Years|60 Years|No|Probability Sample|Pregnant women who are receiving prenatal care.|June 2015|June 9, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01371019||103343|
NCT01371266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC021|Glycemic Effects of Honey|Glycemic Effects of Honey||USDA Grand Forks Human Nutrition Research Center|Yes|Completed|June 2011|August 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|55|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01371266||103324|
NCT01371578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-256-0124|Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy Using Combinations of Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol GS US 256 0124)||Gilead Sciences|Yes|Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|18 Years|80 Years|No|||January 2014|January 14, 2014|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371578||103301|
NCT01371240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC00035|Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity|Evaluation of Efficiency of Secretin-Assisted Computed Tomography Scan and Secretin-Assisted Magnetic Resonance Imaging in Improving Pancreatic Enhancement and Tumor Conspicuity: Prospective Study||University Hospital Case Medical Center||Recruiting|June 2011|June 2012|Anticipated|December 2011|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2011|June 10, 2011|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371240||103326|
NCT01371253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wii1|10 Weeks of NIntendo wIi Fit balanCe Training Improved Postural balANce and Muscle Strength in Elderly Individuals|10 Weeks of NIntendo wIi Fit balanCe Training Improved Postural balANce and Muscle Strength in Elderly Individuals: Double Blinded, Randomised Controlled Trial|WIICAN|Aalborg Universitetshospital|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|65 Years|N/A|No|||January 2012|January 18, 2012|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371253||103325|
NCT01380405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRISA II. EPOC-Inhaladores|Educational Intervention for Managing Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effectiveness of an Educational Intervention for Managing Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Patients in Primary Care: A Randomized Clinical Trial||Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|No|Recruiting|May 2011|June 2012|Anticipated|February 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|864|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380405||102632|
NCT01380756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101351|Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia|A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia||Amgen|No|Completed|July 2011|January 2015|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||January 2015|February 18, 2015|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380756||102605|
NCT01380782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-055|BIBF 1120 for Recurrent High-Grade Gliomas|Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas||Dana-Farber Cancer Institute|Yes|Completed|May 2012|July 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|June 21, 2011|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01380782||102603|The trial intended to enroll 14 participants onto Arm A GBM, but only 10 enrolled due to futility. In addition, 10 AG participants were to be enrolled onto each Arm as exploratory cohorts, but again due to futility only 4 enrolled onto Arm B.
NCT01376609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCM-002H-ND|The Correlation Between Outcome and Infarct Growth in Patients With Acute Ischemic Stroke|A MRI-based Study of Ischaemic Penumbra: the Correlation Between Outcome and Infarct Growth in Patients With Acute Ischemic Stroke|COIG|Beijing Hospital of Traditional Chinese Medicine|No|Not yet recruiting|August 2011|August 2013|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|85 Years|No|Probability Sample|Patients with acute ischaemic stroke admitted to ASU.|June 2011|July 29, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376609||102920|
NCT01377441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01188|Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.|Randomized, Double-blind, Pilot Study on the Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia: Correlation With Clinical Outcomes||New York University School of Medicine|Yes|Terminated|September 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|June 17, 2011|Yes|Yes|Samples lost during Hurricane Sandy. Study now taking place at other medical centers.|No|December 12, 2014|https://clinicaltrials.gov/show/NCT01377441||102857|
NCT01377428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BDE03|Efficacy of Indacaterol 150 µg Versus Formoterol|A 12-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Parallel-group Study to Assess the Efficacy of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 μg b.i.d.) as an Active Control||Novartis||Withdrawn|September 2011|February 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|N/A|No|||May 2012|May 2, 2012|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377428||102858|
NCT01377987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000049/1|Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients|Physiological Study to Predict Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients|HF-ACZ|Brigham and Women's Hospital|No|Recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|85|||Both|18 Years|89 Years|No|||January 2016|January 5, 2016|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377987||102817|
NCT01378247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNR-20110068-3|Multicenter Study of Family Nursing to Treat Heart Failure|Family Focused Nursing for Outpatients With Heart Failure||University of Southern Denmark|No|Recruiting|June 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|468|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01378247||102797|
NCT01378819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMH|3-midline-ports Cholecystectomy|Three Ports Placed in the Line Alba of the Abdomen (3-midline-ports Technique): an Alternative Approach for Laparoscopic Cholecystectomy||Universidad Miguel Hernandez de Elche|No|Completed|February 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|N/A|N/A|No|||February 2010|June 21, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378819||102753|
NCT01379053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRSA1|Volatile Organic Compounds in Staphylococcus Aureus Patients|Detection of Methicillin Resistant Staphylococcus Aureus Colonization Using the zNose®, an Ultra-fast Gas Chromatograph|MRSAVOC|Landon Pediatric Foundation|No|Completed|August 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10|||Both|1 Year|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be selected upon suspicion of MRSA or MSSA infection or colonization.        Increased concentration will be give to selection of persons from the following high risk        groups:          -  It has been documented that the patient has been previously discharged from a general             acute care hospital within 30 days prior to the current hospital admission.          -  The patient will be admitted to an intensive care unit or burn unit of the hospital.          -  The patient receives inpatient dialysis treatment.          -  The patient is being transferred from a skilled nursing facility|August 2014|August 12, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379053||102735|
NCT01378793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVPR-235500|Acupressure for Insomnia|Acupressure for Chronic Insomnia in Adults With Chronic Low Back Pain|AcuSnooze|University of Michigan|No|Suspended|June 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|65 Years|No|||June 2013|June 17, 2013|June 16, 2011||No|Inadequate enrollemnt|No||https://clinicaltrials.gov/show/NCT01378793||102755|
NCT01378806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0436|Family Partners for Health|Children and Parents Partnering Together to Manage Their Weight|WEIGHT|University of North Carolina, Chapel Hill|Yes|Completed|April 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|718|||Both|7 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 12, 2012|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01378806||102754|
NCT01370421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p000978|Prediction of Outcomes Following Total Knee Replacement|Prediction of Outcomes Following Total Knee Replacement|POKR|Brigham and Women's Hospital|No|Recruiting|April 2011|December 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|saliva and blood|Both|50 Years|N/A|No|Non-Probability Sample|Potential participants for this study will be recruited via flyers posted in hospital        clinics, on electronic announcement boards and various other media mediums. Potential        subjects will be informed about the study purpose and procedures when they call, and        interested subjects will then go through a telephone screening.|April 2014|April 2, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01370421||103389|
NCT01370434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-34|Two Cycles of PAD Combination by AHCT in MM|Two Cycles of Pad Combination (Ps-341/Bortezomib, Adriamycin, and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients|PADinMM|Cooperative Study Group A for Hematology|Yes|Completed|July 2006|January 2009|Actual|January 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|15 Years|65 Years|No|||June 2011|June 9, 2011|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01370434||103388|
NCT01370720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM&D Pharma Limited|Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients|Effect of the Oral Administration in IBS Patients of the Association of 200 mg Micronised Palmitoylethanolamide (PEA) and 20 mg Polydatin, on Parameters of Intestinal Inflammation and Visceral Hyperalgesia.|CMD-IBS09(2)|CM&D Pharma Limited|No|Recruiting|February 2010|January 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 16, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370720||103366|
NCT01371279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Stec|EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography|EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography|ActionICE|Medical Centre of Postgraduate Education, Poland|No|Recruiting|June 2011|March 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|75 Years|No|||March 2011|June 16, 2011|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01371279||103323|
NCT01371591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWIRB#: 080933|Capsule Endoscopy for Hemorrhage in the Emergency Room|Pilot Study to Investigate the Use of Wireless Capsule Endoscopy for Emergency Department Patients With Suspected Acute Upper Gastrointestinal Bleeding|CHEER|George Washington University|No|Active, not recruiting|March 2011|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2011|August 17, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371591||103300|
NCT01371604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2355-005|Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)|A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection||Merck Sharp & Dohme Corp.|Yes|Completed|July 2011|October 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|65 Years|No|||February 2015|February 5, 2015|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371604||103299|
NCT01367327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0971762466|Effects of Therapeutic Music Combined With Loaded Sit-to-Stand Resistance Exercise for Children With Spastic Diplegia|Effects of Therapeutic Music Combined With Loaded Sit-to-Stand Resistance Exercise for Children With Spastic Diplegia||National Taiwan University Hospital|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|5 Years|13 Years|No|||February 2012|May 16, 2012|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01367327||103627|
NCT01367340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0993702914|Effect of Physical Activity Intervention Children With Spastic Diplegia After Resistance Training|Effect of Physical Activity Intervention on Mobility Changes and Participation for School-Age Children With Spastic Diplegia and After Resistance Training||National Taiwan University Hospital|No|Active, not recruiting|August 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|5 Years|13 Years|No|||February 2012|May 16, 2012|August 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01367340||103626|
NCT01367665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO25616|STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)||Hoffmann-La Roche||Active, not recruiting|July 2011|October 2017|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|501|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|May 30, 2011|No|Yes||No|July 7, 2015|https://clinicaltrials.gov/show/NCT01367665||103601|
NCT01367678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schulthess_Anä_1|Mucosal Pressure of the Laryngeal Mask Airway Supreme Versus the i-Gel in Paralyzed Anesthetized Female Patients|Directly Measured Mucosal Pressure for Two Different Extraglottic Airway Devices||Schulthess Klinik|Yes|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Female|19 Years|65 Years|No|||August 2011|August 23, 2011|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367678||103600|
NCT01380769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX-002|A Phase 2 Study of CRLX101 in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy||Cerulean Pharma Inc.|No|Completed|June 2011|October 2014|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|157|||Both|18 Years|N/A|No|||September 2013|March 2, 2015|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380769||102604|
NCT01380444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14032012_INSITE_v2.0|Intramedullary Nail Versus Sliding Hip Screw Inter-Trochanteric Evaluation|A Multi-Center Randomized Controlled Trial of Intramedullary Nails Versus Sliding Hip Screws in the Management of Intertrochanteric Fractures of the Hip|INSITE|Stryker Trauma GmbH|No|Active, not recruiting|December 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|880|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01380444||102629|
NCT01377246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALADIN 2|Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency|A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY|ALADIN 2|Mario Negri Institute for Pharmacological Research|No|Active, not recruiting|May 2011|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|75 Years|No|||April 2015|April 8, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377246||102872|
NCT01378000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010CZTCWM|Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction|Study Effects of Ultra-slow Continuous Intravenous Infusion of Unfractionated Heparin on Progressive Cerebral Infarction - a Clinical Study|UHPCI|Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine|Yes|Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|480|Samples With DNA|serum|Both|35 Years|70 Years|No|Probability Sample|From May 2003 to October 2009 480 patients of acute progressive cerebral infraction that        matched the standards above were included in the research.|September 2010|June 20, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01378000||102816|
NCT01377649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007524|Contrast Ultrasound Perfusion Imaging in Peripheral Arterial Disease (PAD)|Contrast Ultrasound Perfusion Imaging in Peripheral Arterial Disease||Oregon Health and Science University|Yes|Recruiting|July 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with peripheral arterial disease who are referred for diagnostic angiography        and/or revascularization procedures|October 2015|October 23, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377649||102841|
NCT01377662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030921|PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)|PHASE IIA: Randomized, Double Blind, Placebo Controlled, Single Center Clinical Trial of a Combination of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)||Duke University|No|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|No|||September 2014|September 27, 2014|June 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377662||102840|
NCT01378546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB2528|Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP|Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes With 3, 4-Diaminopyridine||Columbia University|No|No longer available|May 2005|||May 2015|Anticipated|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||July 2013|July 17, 2013|June 20, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01378546||102774|
NCT01378559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Titan-2011|Patient Satisfaction and Complications With the New Titan® One Touch Release (OTR) Penis Prosthesis|Patient Satisfaction and Complications With the New Titan® One Touch Release (OTR) Penis Prosthesis||Copenhagen University Hospital at Herlev|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|26|||Male|18 Years|N/A|No|Non-Probability Sample|Men who have had a Titan one touch release penis prosthesis implanted at Herlev Hospital /        Frederikssund Hospital.|February 2012|February 21, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01378559||102773|
NCT01378832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jruiztovar|Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Colorectal Cancer Infection in Elective Surgery|Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Infection in Elective Surgery|lavage|Universidad Miguel Hernandez de Elche|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|102|||Both|N/A|N/A|No|||January 2010|June 21, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378832||102752|
NCT01372761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-003AUS|Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers|Phase 1b Trial of Beloranib, a Novel Methionine Aminopeptidase 2 (MetAP-2) Inhibitor for Treatment of Extreme Obesity: Randomized, Double-Blind, Placebo-Controlled, Escalating Doses in Female Volunteers||Zafgen, Inc.|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 28, 2011|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01372761||103210|
NCT01373008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0110-10|Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD)|Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD); Prospective, Double Blind, Randomized Placebo-control, Multi-center Study||Bnai Zion Medical Center|No|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|12 Weeks|No|||August 2015|August 11, 2015|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373008||103191|
NCT01373021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sunrud1129|The Effect of Dexmedetomidine on Postoperative Analgesia|Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia||Seoul National University Hospital||Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|95|||Both|20 Years|74 Years|No|||March 2012|March 6, 2012|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373021||103190|
NCT01379326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/374|Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2|The Efficacy of a Single-dose Mebendazole Against Soil-transmitted Helminths in School Children|ConWorm|University Ghent|No|Completed|December 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|4 Years|18 Years|No|||December 2014|December 4, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01379326||102714|
NCT01379339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0646(0001)(01)|Cabazitaxel - PF Induction Chemotherapy|Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Icahn School of Medicine at Mount Sinai|Yes|Completed|April 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|June 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01379339||102713|
NCT01370174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045644|Intervention to Enhance Lateral Balance Function and Prevent Falls in Aging|Intervention to Enhance Lateral Balance Function and Prevent Falls in Aging|LIFT|University of Maryland|Yes|Recruiting|July 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|100|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 17, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370174||103408|
NCT01379911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11AP036|Developing Methods for Completing Future Satiety Studies|Developing and Validating a Method for Satiety Studies||University of Guelph|No|Completed|February 2013|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01379911||102670|
NCT01371032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024542|Study: Study to Compare Video Miller Device to Direct Laryngoscopy|A Randomized, Prospective Study to Compare the Video Miller Device to Direct Laryngoscopy Using a Standard Pediatric Miller Blade for Tracheal Intubation of Children < 3 Years of Age Undergoing General Anesthesia||Cedars-Sinai Medical Center|No|Enrolling by invitation|June 2011|December 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Anticipated|120|||Both|N/A|3 Years|No|||September 2015|September 3, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371032||103342|
NCT01370759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIL - RD-400|Feasibility Study to Evaluate the Performance of Flocculation-Adsorption System for Colon Cleansing Enhancement|Flocculation-Adsorption System for Colon Cleansing Enhancement: A Feasibility Study|RD-400|Given Imaging Ltd.|No|Terminated|September 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|81|||Both|23 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|June 9, 2011||No|Terminated due to sponsor desicioun|No||https://clinicaltrials.gov/show/NCT01370759||103363|
NCT01371045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024880|Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs|Hormonal and Metabolic Responses to Oral Glucose During Somatostatin Analog Use||Cedars-Sinai Medical Center|No|Recruiting|June 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|36|Samples With DNA|Blood will be drawn (approx. 64cc) to gather baseline hormone and metabolic panels. Blood      will again be collected (approx. 36cc) during the Oral Glucose Tolerance Test.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Enrollment will include subjects diagnosed with acromegaly or carcinoid syndrome who are        taking long-acting somatostatin analogs for at least three months prior to study        enrollment.|June 2011|June 9, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371045||103341|
NCT01371292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02513|A Transformational Teaching Intervention: Adolescents in Motion (AIM) Trial|A Transformational Teaching Intervention: Adolescents in Motion (AIM) Trial|AIM|University of British Columbia|No|Completed|January 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|2160|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01371292||103322|
NCT01380821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/004/11|DNA Double-strand Breaks After SPECT|DNA Double-strand Breaks Following Myocardial Scintigraphy|DSB-SPECT|Charite University, Berlin, Germany|No|Completed|March 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|19 Years|N/A|No|Non-Probability Sample|Patients clinically indicated to undergo myocardial SPECT.|April 2013|May 2, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380821||102600|
NCT01376661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-009 Active Surveillance|Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study|Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study||St. Joseph Hospital of Orange|No|Recruiting|May 2009|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Male|18 Years|90 Years|No|Non-Probability Sample|Men with low risk prostate cancer.|September 2012|September 12, 2012|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01376661||102916|
NCT01380093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-01-10-4005|Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users|A Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Way Crossover Study to Determine the Abuse Potential of Oral Administration of Crushed EMBEDA Relative to Crushed Controlled-Release Morphine Sulfate and Placebo in Non Dependent, Recreational Opioid Users||Pfizer|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|April 26, 2012|June 22, 2011|No|Yes||No|April 26, 2012|https://clinicaltrials.gov/show/NCT01380093||102656|
NCT01380106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MM-PI-0345|Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma|A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma||Boston VA Research Institute, Inc.|Yes|Active, not recruiting|August 2010|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380106||102655|
NCT01380431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11508|A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study|Randomized, Open-label, Three Treatment Crossover Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study||Par Pharmaceutical, Inc.|No|Completed|August 1999|October 1999|Actual|October 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|18|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 22, 2011|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01380431||102630|
NCT01376635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoreEdRTNephrology|Depressed Cardiac Autonomic Modulation in Patients With Chronic Kidney Disease Diagnosed by Spectral Analysis|Depressed Cardiac Autonomic Modulation in Patients With Chronic Kidney Disease Diagnosed by Spectral Analysis of Heart Rate Variability Upon Postural Stress|HRV|Core Educational Research and Treatment in Nephrology|Yes|Completed|May 2008|May 2009|Actual|||N/A|Observational|Observational Model: Case-Crossover||1|Actual|46|||Both|44 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with CKD stages 3, 4 and 5 not yet on dialysis (CKD group) and age-matched        healthy subjects (CON group)|May 2008|June 17, 2011|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01376635||102918|
NCT01376908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700773-003|Kuvan® in Phenylketonuria Patients Less Than 4 Years Old|A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patients <4 Years Old.|SPARK|Merck KGaA|No|Active, not recruiting|June 2011|February 2017|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|N/A|4 Years|No|||August 2014|August 13, 2014|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376908||102897|
NCT01375504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001775|Effect of Self Regulation With Mindfulness Training on Body Mass Index and Cardiovascular Risk Markers in Obese Adults|Enhancing Self Regulation With Mindfulness Training and Its Effect on Body Mass Index and Cardiovascular Risk Markers in Obese Adults: A Randomized Pilot Clinical Trial||Mayo Clinic|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01375504||103004|
NCT01377220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020221|Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma|Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma|CHOLPET|Commissariat A L'energie Atomique|No|Not yet recruiting|June 2011|June 2014|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2011|June 20, 2011|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01377220||102874|
NCT01377233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13946A|Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia|A Randomised, Double-blind, Parallel-group, Explorative Study of the Safety, Tolerability, and Pharmacokinetics of Daily Dosing Compared to Weekly Dosing of Zicronapine in Patients With Schizophrenia||H. Lundbeck A/S|Yes|Completed|July 2011|||February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|46|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|June 20, 2011|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT01377233||102873|
NCT01376024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC0826|Basal Joint Arthritis Prospective|Multicenter Prospective Study on Basal Joint Arthritis of the Thumb|BJAM|Columbia University|No|Recruiting|March 2007|August 2025|Anticipated|August 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|The study subject population will consist of patients who are diagnosed with CMC arthritis        of the thumb stages I, II, III, or IV. Recruitment of subjects will be the responsibility        of the operating surgeon or a member of his clincal staff.|March 2015|March 11, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376024||102965|
NCT01378260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40153-D|Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)|Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)||University of Washington|No|Active, not recruiting|July 2011|March 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1100|||Both|21 Years|N/A|No|Non-Probability Sample|patients being seen by a physician with newly diagnosed or established claudication|November 2013|November 6, 2013|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01378260||102796|
NCT01372189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011SDU-QILU-G01|Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy|In Vivo Molecular Imaging of Epidermal Growth Factor Receptor in Patients With Colorectal Neoplasia Using Confocal Laser Endomicroscopy||Shandong University|Yes|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|40|Samples With DNA|Take biospecimen during colonoscopy.|Both|18 Years|80 Years|No|Non-Probability Sample|patients known to have large polypoid lesions in colon or rectum from previous        examinations from outpatients and inpatients at Qilu Hospital were enrolled into the study|January 2012|January 30, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01372189||103254|
NCT01372774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N107C|Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery|A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease||Alliance for Clinical Trials in Oncology|Yes|Recruiting|July 2011|||March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|June 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372774||103209|
NCT01373320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24MD002757|Faith Moves Mountains: A Community Based Participatory Research (CBPR) Appalachian Wellness & Cancer Prevention Program|Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program||University of Kentucky|No|Completed|March 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1415|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 21, 2013|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01373320||103168|
NCT01379612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20100028|Ultrasound Elastography in Patients With Rectal Cancer|Ultrasound Elastography of Rectal Cancer Patients Treated With Preoperative Chemoradiation||Vejle Hospital|No|Completed|May 2010|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|Rectal cancer patients planned for preoperative chemoradiation at the Dept. of Oncology,        Vejle Hospital, Denmark.|June 2013|June 14, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01379612||102692|
NCT01379924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 APHPA002033-10-00|Young Parents Program, Project Connect|Young Parents Program, Project Connect|YPP ProCon|Children's Hospital Boston|Yes|Recruiting|September 2007|August 2012|Anticipated|August 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|250|||Both|13 Years|25 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01379924||102669|
NCT01379937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115115|A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children|Safety and Immunogenicity Study of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine GSK1562902A in Children Aged 3 to 17 Years||GlaxoSmithKline||Completed|July 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|520|||Both|3 Years|17 Years|Accepts Healthy Volunteers|||June 2015|November 9, 2015|June 17, 2011|Yes|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT01379937||102668|
NCT01370772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL 2010 FMP|Intensified Rituimab Prephase Before FCR in Untreated B-CLL|Phase II Multicentric, Randomized Trial, Exploring Intensified Rituximab Prephase Monotherapy Before Standard Fludarabine-Cyclophosphamide-Rituximab Regimen in Previously Untreated Symptomatic B-cell Chronic Lymphocytic Leukemia||French Innovative Leukemia Organisation|Yes|Completed|May 2011|March 2016|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01370772||103362|
NCT01370785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld||||||N/A|N/A|N/A||||||||||||||June 9, 2011|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370785||103361|
NCT01380548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-396|Effects of 5-Aminolevulinic Acid on Iron Deficiency Anemia|A Double-blind, Placebo Controlled Study to Assess Efficacy of 5-Aminolevulinic Acid in Subjects With Iron Deficiency Anemia||Hiroshima University||Completed|June 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|135|||Female|20 Years|49 Years|No|||March 2013|March 26, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01380548||102621|
NCT01380561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMP1001|A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers|A Metabolite Identification, Mass Balance, and Pharmacokinetic Study of a Single Oral Dose of [14C]-Asimadoline Followed by Twice Daily Oral Dosing of 0.5 mg Asimadoline to Healthy Adult Male Volunteers||Tioga Pharmaceuticals|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|56 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|June 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380561||102620|
NCT01380834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10060554|Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Pediatric Patients|Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Laparoscopic Cholecystectomy: a Prospective, Randomized Clinical Study||Children's Hospital of Pittsburgh|Yes|Completed|November 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|June 22, 2011||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01380834||102599|
NCT01376726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 088|Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials|A Phase I Open-Label Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Subtype C gp140 Vaccine With MF59 Adjuvant in Healthy, HIV-1 Uninfected Adult Participants Previously Primed or Unprimed With HIV-1 Subtype B Envelope Subunit Vaccines With MF59||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|July 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01376726||102911|
NCT01380795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0416-1cobr10|Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas|Biological Study of Feasibility Concerning the Research for Mutation of the Gene of EGFR and for K-Ras in Circulating Tumoral Cells(CTCs) of the Patients Carriers of Metastatic Non Small Cells Bronchial Carcinomas|CTC-Poumon|Centre Georges Francois Leclerc|Yes|Completed|March 2011|||February 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2014|March 25, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380795||102602|
NCT01376622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AUS29T|Changes in Pituitary Iron and Volume With Deferasirox|Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload||Children's Hospital Los Angeles|No|Completed|November 2008|||||N/A|Observational|Time Perspective: Prospective||2|Actual|130|||Both|2 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Transfusion Dependent Anemia|July 2010|June 17, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376622||102919|
NCT01376921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-525|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Spain|ECOS ESP|Merck KGaA|No|Active, not recruiting|September 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|300|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376921||102896|
NCT01376037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_ARMBC|Efficacy Study of the Effect of Low Level Laser Light Therapy on Reducing Upper Arm Circumference|An Evaluation of the Effectiveness of the Erchonia ML Scanner (MLS) as a Non-invasive Dermatological Aesthetic Treatment for the Reduction of Circumference of the Upper Arms Clinical Study||Erchonia Corporation|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|June 16, 2011|Yes|Yes||No|April 11, 2013|https://clinicaltrials.gov/show/NCT01376037||102964|
NCT01376050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_VSU|Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Venous Stasis Ulcers||Erchonia Corporation|No|Terminated|June 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|N/A|No|||November 2015|November 7, 2015|June 16, 2011|Yes|Yes|recruitment difficulties|No|July 10, 2015|https://clinicaltrials.gov/show/NCT01376050||102963|
NCT01377454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7419|Balance and Mild Traumatic Brain Injury (TBI)|Wearable Sensor to Detect Postural Instability in People After Mild Traumatic Brain Injury (mTBI)||Oregon Health and Science University|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|47|||Both|12 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy controls or individuals with mild Traumatic Brain Injury (mTBI) or concussion.|August 2012|August 7, 2012|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377454||102856|
NCT01377675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WipeCOPD|Web-based, Interactive Professional Education for Chronic Obstructive Pulmonary Disease|Assessment of an Interactive Education Tool to Disseminate Best Practice Recommendations on Chronic Obstructive Pulmonary Disease to Primary Care|WipeCOPD|The University of Texas Health Science Center at San Antonio|No|Completed|April 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Third year internal medicine residents|December 2014|December 1, 2014|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377675||102839|
NCT01371877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271-11-FB|The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment|The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment||University of Nebraska|No|Completed|November 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|19 Years|N/A|No|||December 2014|December 12, 2014|June 1, 2011||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01371877||103278|
NCT01372202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J10130|CHFR Methylation Status Esophageal Cancer Study|A Phase 2 Study of Paclitaxel With Cisplatin Versus Fluoropyrimidine With a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies|J10130|Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|June 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|75 Years|No|||April 2015|April 15, 2015|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372202||103253|
NCT01372215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUNYUMU 5907|Multi-Compression Spot Mammography|Multi-Compression Spot Mammography||State University of New York - Upstate Medical University|No|Terminated|May 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|3|||Female|45 Years|N/A|No|Non-Probability Sample|Women 45 years of age and older who have a suspicious mammagraphy requiring a biopsy|May 2015|May 12, 2015|June 10, 2011||No|Referral physician no longer available|No||https://clinicaltrials.gov/show/NCT01372215||103252|
NCT01372228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-14070-010611|Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders|Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders||University of Louisville|Yes|Active, not recruiting|April 2011|April 2028|Anticipated|April 2025|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|N/A|No|||November 2015|November 2, 2015|June 10, 2011|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01372228||103251|
NCT01373047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWH 335-99|CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells|Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases|HITM|Roger Williams Medical Center|Yes|Completed|June 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01373047||103188|
NCT01372488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-004|Are Patients Willing and Capable of Removing Their Own Non-absorbable Sutures|Are Patients Willing and Capable of Removing Their Own Non-absorbable Sutures||Fraser Health|No|Completed|April 2010|October 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 22, 2011|February 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01372488||103231|
NCT01372501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3|Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner|A Pilot Trial of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner||GI Dynamics|No|Completed|September 2010|September 2012|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|55 Years|No|||May 2013|February 13, 2016|June 10, 2011|Yes|Yes||No|February 13, 2016|https://clinicaltrials.gov/show/NCT01372501||103230|
NCT01372787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0267|Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer||Gynecologic Oncology Group||Active, not recruiting|April 2011|||January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Female|18 Years|N/A|No|Probability Sample|patient with ovarian, fallopian tube or peritoneal cancer|March 2016|March 17, 2016|June 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01372787||103208|
NCT01379625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD003895|Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder|Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders|Triheptanoin|Oregon Health and Science University|Yes|Completed|September 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|7 Years|N/A|No|||April 2015|April 20, 2015|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379625||102691|
NCT01380249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017133-21|PDM08 Clinical Trial in Advanced Solid Tumors|Phase I Study, Open, Dose Escalation, in Adult Patients With Advanced Solid Tumours, to Evaluate Tolerability, Pharmacokinetics and Pharmacodynamics of PDM08 Administered Twice a Week Cycles of 4 Weeks.||Prodimed S.A.|Yes|Completed|June 2011|January 2013|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2013|January 4, 2013|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01380249||102644|
NCT01380197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-076|Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally|Choosing Opioid Management for Pain and Analyzing ACS Rates Equally|COMPARE|Children's Healthcare of Atlanta|No|Active, not recruiting|May 2010|January 2016|Anticipated|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|6 Years|19 Years|No|||February 2015|February 2, 2015|June 22, 2011||No||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01380197||102648|
NCT01380860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2011/MP-01|Primary Prevention of Peristomial Hernias Via Parietal Prostheses|Primary Prevention of Peristomial Hernias Via Parietal Prostheses: a Randomized, Multicentric Study|GRECCAR 07|Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|November 2012|November 2018|Anticipated|November 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380860||102597|
NCT01380873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_VCM_103|A Pharmacodynamic Study of SLM0807, HKB0701 and CJ30001 in Healthy Subject|||CJ HealthCare Corporation|No|Completed|January 2010|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 23, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01380873||102596|
NCT01380535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005|A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease|A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)||Therakos|Yes|Active, not recruiting|November 2011|March 2017|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380535||102622|
NCT01376986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OKM/98/627/2010|Activation of Young Men - Population-Based Randomised Controlled Trial|Activation of Young Men - Population-Based Randomised Controlled Trial|MOPO|University of Oulu|Yes|Completed|September 2013|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|507|||Male|17 Years|18 Years|No|||June 2014|June 26, 2014|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376986||102891|
NCT01376999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UREP-01-2009|Step Up Versus Step Down in Controlled Ovarian Stimulation|Step Up Versus Step Down in Controlled Ovarian Stimulation for Intrauterine Insemination. A Controlled Randomised Trial.||Parc de Salut Mar|No|Completed|April 2010|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Female|18 Years|37 Years|No|||November 2015|November 3, 2015|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376999||102890|
NCT01377012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2302|Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents|A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.|REASSURE|Novartis|Yes|Completed|August 2011|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|637|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377012||102889|
NCT01376648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2009-257|Thyroid Hormones Effect on Brown Adipose Tissue|Study on the Relationship Between the Thyroid Hormones and the Activity of Brown Adipose Tissue in Human||Huashan Hospital|Yes|Recruiting|December 2009|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|TSH, TT3, TT4, fT3, fT4,      γT3,Norepinephrine,Blood-fat,FPG,Insulin,Leptin,Aadiponectin,Retinol-binding protein 4,Fatty      acid binding protein 4,IL-6,TNF-α,CRP,Monocyte chemotactic protein 1|Both|18 Years|N/A|No|Non-Probability Sample|Twenty Graves' disease-caused hyperthyroid patients who were newly diagnosed and untreated        were included. All hyperthyroid patients were treated with Methimazole and had been        followed up until their symptoms disappeared and the thyroid hormone levels went back to        normal range.|November 2009|June 17, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376648||102917|
NCT01375218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041101A|Efficacy and Satisfaction Comparing Two Braces in the Treatment of Developmental Dysplasia of the Hip (DDH) in Infants|Efficacy and Satisfaction Comparing Two Braces in the Treatment of DDH in Infants: A Randomized Clinical Trial||OrthoCarolina Research Institute, Inc.|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|2 Months|No|||December 2013|January 16, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01375218||103026|
NCT01375764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090159|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects|A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor|GAUSS|Amgen|Yes|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|160|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|June 16, 2011|Yes|Yes||No|September 2, 2015|https://clinicaltrials.gov/show/NCT01375764||102985|
NCT01376063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-037|Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects|A Phase 1, Single-Center, One-Sequence, Open-Label Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects||FibroGen|No|Completed|March 2010|June 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2011|June 17, 2011|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376063||102962|
NCT01376076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-02|Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia|Evaluation of the Effects of Sequential Multiple-Dose Regimens of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia||Forest Laboratories|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|129|||Both|18 Years|50 Years|No|||February 2012|February 7, 2012|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01376076||102961|
NCT01375751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090158|Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial Hypercholesterolemia|RUTHERFORD|Amgen|Yes|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|168|||Both|18 Years|75 Years|No|||August 2015|August 28, 2015|June 16, 2011|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01375751||102986|
NCT01376375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110188|Acupuncture to Reduce Signs of Inflammation in Participants With Chronic Low Back Pain|A Pilot Study to Evaluate the Effect of Acupuncture on Epigenetic Regulation of Inflammatory Mediators in Participants With Chronic Low Back Pain||National Institutes of Health Clinical Center (CC)||Completed|June 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2013|May 1, 2015|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376375||102938|
NCT01376388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115362|Long-term Safety Study for GSK573719/GW642444 in Japanese|A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily in Combination With GW642444 25 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.|DB2115362|GlaxoSmithKline|No|Completed|August 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|131|||Both|40 Years|N/A|No|||December 2013|February 13, 2014|June 9, 2011||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01376388||102937|
NCT01376401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BenVelPres|Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma|||PETHEMA Foundation|Yes|Active, not recruiting|July 2011|December 2015|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||April 2015|April 8, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01376401||102936|
NCT01371890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|092018-018|Mechanisms and Treatment of Intradialytic Hypertension - Sodium|Mechanisms and Treatment of Intradialytic Hypertension - Sodium|MATCH-Sodium|University of Texas Southwestern Medical Center|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|18|Samples Without DNA|Samples stored for nitric oxide and endothelin-1 measurements|Both|18 Years|85 Years|No|Probability Sample|Our study population will include up to 45 ESRD patients whose BP increases during        hemodialysis. Patients who dialyze at any of the 3 UT Southwestern-affiliated dialysis        units will be screened for possible enrollment.|January 2014|January 27, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371890||103277|
NCT01372800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xj050503|Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases|Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases||Xijing Hospital|No|Recruiting|May 2011|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|None Retained|blood|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|volunteer|November 2011|November 19, 2013|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372800||103207|
NCT01372813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080039|Vandetanib to Treat Advanced Kidney Cancer|A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma||National Institutes of Health Clinical Center (CC)|No|Terminated|December 2007|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|June 11, 2011|Yes|Yes|Terminated for insufficient accrual.|No|December 19, 2011|https://clinicaltrials.gov/show/NCT01372813||103206|Study was designed to accrue up to 37 patients but only 3 were enrolled. Study was terminated due to low accrual.
NCT01373060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-2001|A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese Subjects|A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of ASP1941 in Healthy Male Taiwanese Subjects||Astellas Pharma Inc|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|56|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01373060||103187|
NCT01373346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|seungho-1|Safety and Efficacy of Long Limb Roux-en Y Reconstruction|Long Limb Roux-en Y Reconstruction After Gastrectomy As A Potential Cure for Type 2 Diabetes Mellitus in Non-Obese Gastric Cancer Patients - a Pilot Project to Validate a Prospective Randomized Control Trial|LoLiRoRe|Gangnam Severance Hospital|Yes|Completed|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||August 2012|August 30, 2012|June 13, 2011||No||No|March 11, 2012|https://clinicaltrials.gov/show/NCT01373346||103166|One mortality due to early recurrence leading to reduced number of subject analyzed.
NCT01379365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-4500|Cryo-Touch III Refinement Study Investigational Plan|||MyoScience, Inc|No|Completed|June 2011|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01379365||102711|
NCT01379950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|perio1-HMO-CTIL|Role of Macrophage in Inflammation Resolution in Periodontal Patients|The Role of Macrophages in the Inflammatory Resolution Phase in Periodontal Patients||Hadassah Medical Organization|No|Not yet recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients coming to the periodontal clinic in the dental school in order to attend a        periodontal treatment|June 2011|June 22, 2011|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01379950||102667|
NCT01380262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STLDD-1|Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment|Prospective Phase II Study on Skin Toxicity on Low-Dose Doxycycline in Metastatic Colorectal Cancer Patients During Cetuximab and Panitumumab Treatment|STLDD-1|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Recruiting|June 2010|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|85 Years|No|Probability Sample|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab        based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of        doxycycline daily.|June 2011|June 24, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380262||102643|
NCT01380275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-08-322|Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.|Docetaxel, Irinotecan, Recurrent, Refractory, Bone and Soft Tissue Sarcomas||National Cancer Center, Korea|Yes|Recruiting|April 2008|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|5 Years|49 Years|No|||September 2014|September 23, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01380275||102642|
NCT01380210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-012|MRI Findings of Encephalopathy Associated With Carbon Dioxide (CO2) Intoxication|||China Medical University Hospital|Yes|Active, not recruiting|February 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|6|||Both|N/A|N/A|No|Non-Probability Sample|University Hospital|July 2011|July 6, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380210||102647|
NCT01380223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 1111|A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers|A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy Volunteers||Cytokinetics|No|Completed|August 2005|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|35|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|June 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01380223||102646|
NCT01380236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASM8-A-208|A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma|A Phase II, Two-centre, Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Adult Subjects With Moderate to Severe Asthma||Pharmaxis|No|Withdrawn|November 2011|May 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||November 2012|November 29, 2012|June 22, 2011||No|Protocol not progressed. Study not implemented.|No||https://clinicaltrials.gov/show/NCT01380236||102645|
NCT01380886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK92|Growth and Tolerance of Young Infants Fed Infant Formulas|Growth and Tolerance of Young Infants Fed Infant Formulas||Abbott Nutrition|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|209|||Both|N/A|8 Days|Accepts Healthy Volunteers|||February 2013|February 14, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01380886||102595|
NCT01380899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UASLP-PD001|Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.|Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.||Universidad Autonoma de San Luis Potosí|Yes|Active, not recruiting|February 2011|December 2015|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|23|||Both|50 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patients will be selected from the department of neurology.|May 2015|May 29, 2015|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01380899||102594|
NCT01380847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 09045|Prediction of Chronic Allograft Nephropathy|Early Prediction of Chronic Allograft Nephropathy by Non Invasive Monitoring of Urinary Cell mRNAs|Prefigur|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2011|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|300|Samples With DNA|RNA profiling of urinary cells in kidney transplant recipients|Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients from Necker Hospital|January 2016|January 29, 2016|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01380847||102598|
NCT01376713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2010-023277-19|Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma|CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study||Medical University of Vienna|Yes|Completed|June 2011|May 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||October 2015|October 4, 2015|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376713||102912|
NCT01377038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 HUM00044644|OASIS: Osteoarthritis Sensitivity Integration Study|Central Pain Mechanisms in Osteoarthritis: A Randomized, Double-blind, Crossover Study to Evaluate the Effectiveness of Topical Diclofenac Versus Duloxetine for Chronic Osteoarthritis Pain|OASIS|University of Michigan|Yes|Active, not recruiting|September 2011|June 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|50 Years|N/A|No|||June 2015|June 5, 2015|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01377038||102887|
NCT01374893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGUGregorioMaranon|Physical Training in Hospitalized Elderly|Effects of an Intrahospital Exercise Program in Functional Capacity of Old Inpatients|AGECAR|Hospital General Universitario Gregorio Marañon|No|Not yet recruiting|September 2011|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Both|75 Years|N/A|No|||May 2011|June 15, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01374893||103049|
NCT01374906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230G2304|Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease|A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease||Novartis||Active, not recruiting|November 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01374906||103048|
NCT01375777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101154|Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels|A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less|MENDEL|Amgen|Yes|Completed|July 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|411|||Both|18 Years|75 Years|No|||September 2015|September 3, 2015|June 16, 2011|Yes|Yes||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01375777||102984|
NCT01375556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110180|Genetics of the Acute Response to Alcohol in Social Drinkers|Genetics of the Acute Response to Alcohol in Humans||National Institutes of Health Clinical Center (CC)||Terminated|May 2011|June 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|33|||Both|21 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375556||103001|
NCT01375790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERIAPLAT/1|Whole-body Vibration Training in Older People|Neuromuscular Training With Whole Body Vibration in Older People: A Randomized Multicentre Clinical Trial With Blinded to Evaluator|GERIAPLAT|Asociacion Colaboracion Cochrane Iberoamericana|No|Completed|November 2010|March 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|65 Years|N/A|No|||August 2012|August 28, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375790||102983|
NCT01376440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGS13/15/11|Acceptability and Effectiveness of Household Water Treatment in Reducing Diarrhea Among Under Five Children|Acceptability and Effectiveness of Household Water Chlorination in Reducing the Prevalence of Diarrhea Among Under Five Children in Eastern Ethiopia||Haramaya Unversity|Yes|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|845|||Both|1 Month|59 Months|No|||January 2012|January 23, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376440||102933|
NCT01376414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#: 111050|H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department|Pilot Study to Estimate the Prevalence of Helicobacter Pylori (H. Pylori) Infection in Patients Presenting With Non-specific Upper Abdominal Pain to the Emergency Department (ED.)||George Washington University|No|Completed|March 2011|March 2015|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|212|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients (>18 years) presenting to the ED with symptoms of abdominal pain will        be screened for eligibility. The ED is a single site urban academic level one trauma        center.|August 2012|April 1, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376414||102935|
NCT01371903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2792|The Effects of Patient Features on Opioid Induced End-Tidal CO2|The Effect of Patient Features on Opioid Induced End-Tidal CO2|Capno|Albany Medical College|Yes|Completed|August 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|278|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving opioid such as morphine, fentanyl, or dilaudid during their emergency        department visit.|June 2011|March 20, 2014|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01371903||103276|
NCT01371916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xijing004|Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF|Diagnosis of Tuberculous Meningitis by a Secretory Antigenic Target 6 (ESAT-6) in CSF||Xijing Hospital|No|Completed|September 2010|January 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|316|||Both|14 Years|75 Years|No|Probability Sample|All the patients described in this study were admitted to the Department of Neurology,        Xijing Hospital of the Fourth Military Medical University, Xi'an, Shaanxi, China.|August 2014|August 18, 2014|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01371916||103275|
NCT01372241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA108696|Faith Moves Mountains: An Appalachian Cervical Cancer Prevention Project|An Appalachian Cervical Cancer Prevention Project|FMM|University of Kentucky|No|Completed|December 2005|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|345|||Female|40 Years|64 Years|No|||June 2011|June 10, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01372241||103250|
NCT01372514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|995|Institutional Registry of Thromboembolic Disease|Institutional Registry of Thromboembolic Disease|IRTD|Hospital Italiano de Buenos Aires|Yes|Recruiting|August 2006|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4500|||Both|17 Years|N/A|No|Probability Sample|The eligible population is all patients equal or older than 17 years, evaluated and        followed in the Hospital Italiano de Buenos Aires, with an episode of pulmonary embolism        suspected by the medical examiner or confirmed diagnosis of DVT or PE. The aim is to        include the entire population that meets the criteria for inclusion and no exclusion.|December 2015|December 16, 2015|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372514||103229|
NCT01372826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00009|Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function|An Open-Label, Parallel-Group, Phase I Study to Compare the Pharmacokinetics of NKTR-118 Following a Single Oral Dose in Subjects With Renal Impairment and Subjects With Normal Renal Function||AstraZeneca|No|Completed|June 2011|November 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|May 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01372826||103205|
NCT01373723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/01275|Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer|Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer in the County of Valles Occidental: CRICERVA Clinical Trial.|CRICERVA|Jordi Gol i Gurina Foundation|Yes|Recruiting|September 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|20994|||Female|30 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 14, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01373723||103137|
NCT01373112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPACERKNEE|Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection|Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection||Rush University Medical Center|No|Recruiting|December 2011|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|June 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01373112||103183|
NCT01373359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDC/DOME/3707|Prevention of Postpartum Haemorrhage With Sublingual Misoprostol or Oxytocin|A One Year Double Blind Randomized Controlled Trial of Sublingual Misoprostol (400 µg) Versus Intramuscular Oxytocin (10 IU) in the Prevention of Postpartum Bloodloss at KLE Hospital, Belgaum||Jawaharlal Nehru Medical College|No|Completed|March 2007|January 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|652|||Female|18 Years|35 Years|No|||January 2008|June 13, 2011|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373359||103165|
NCT01379638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20080035|Best Cardiac Output During Cardiopulmonary Bypass|Best Cardiac Output During Cardiopulmonary Bypass||Aalborg Universitetshospital|No|Completed|December 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients to be admitted to Aalborg Hospital, department of cardiac surgery for scheduled        cardiac surgery|December 2008|June 22, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01379638||102690|
NCT01379963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22014|A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)|Non-interventional Study of Six-month Retrospective Reporting of Hemoglobin Levels in Patients With Renal Anaemia Who Are Treated With MIRCERA® (Methoxy-polyethylene-glycol-epoetin Beta)||Hoffmann-La Roche||Completed|April 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|780|||Both|18 Years|N/A|No|Probability Sample|Patients with renal anemia on treatment with Mircera|November 2015|November 20, 2015|June 22, 2011||No||No|November 20, 2015|https://clinicaltrials.gov/show/NCT01379963||102666|
NCT01379976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022021-15|Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer|Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Assess the Efficacy and Safety of Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer||Mario Negri Institute for Pharmacological Research|Yes|Terminated|April 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||July 2014|April 23, 2015|June 16, 2011||No|Recruitment was prematurely stopped due to difficulty of recruitment encountered by the    experimental centers|No||https://clinicaltrials.gov/show/NCT01379976||102665|
NCT01379989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET-D-009-10|INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer|Phase III International, Randomized Study of Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) Versus Carboplatin Plus PLD in Patients With Ovarian Cancer Progressing Within 6-12 Months of Last Platinum|INOVATYON|Mario Negri Institute for Pharmacological Research|Yes|Recruiting|June 2011|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|588|||Female|18 Years|N/A|No|||September 2014|April 24, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01379989||102664|
NCT01380912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2009-137|Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer|Can Injection of Methylprednisoloneacetate 80 mg, in the Cavity After Mastectomy for Primary Breast Cancer, at the Time of Removal of the Drain, Prevent Seroma Formation?||Copenhagen University Hospital at Herlev|Yes|Recruiting|August 2010|August 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|160|Samples Without DNA|seroma will be analysed for concentration of cytokines, and eventual growth of bacteria|Female|18 Years|90 Years|No|Probability Sample|Patients operated for primary breast cancer with mastectomy and eihter axillary dissection        or Sentinel Node operation|June 2011|June 23, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01380912||102593|
NCT01380574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23|Safety of Cardioversion of Acute Atrial Fibrillation|Safety of Cardioversion of Acute Atrial Fibrillation|FinCV|Turku University Hospital|No|Completed|June 2011|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|7700|||Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to emergency room because of acute AF in whom electrical or        pharmacological cardioversion was attempted <48 from the beginning of the symptoms.|June 2012|June 26, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01380574||102619|
NCT01377064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NR011281|Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk|Home-based Exercise for Management of HIV-associated Cardiovascular Disease||University of South Carolina|Yes|Completed|March 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01377064||102885|
NCT01376739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15035|Magnevist Post-marketing Surveillance in Japan|Drug Use Investigation of Magnevist||Bayer|No|Completed|August 2007|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2051|||Both|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who received Magnevist for MR angiography.        The study is expected to collect data of 2,000 patients in approximately 150 hospitals in        Japan.|June 2011|June 16, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01376739||102910|
NCT01376752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEDEGYN 02 / 0410-CHIPOR|Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment|A Phase III Randomized Study of Phase III Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer|CHIPOR|UNICANCER|Yes|Recruiting|April 2011|December 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|444|||Female|18 Years|N/A|No|||December 2015|December 17, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01376752||102909|
NCT01377051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654CEC|Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea|Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects.||University of Milan|Yes|Completed|May 2011|September 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|50 Years|85 Years|No|||October 2014|October 28, 2014|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01377051||102886|
NCT01377532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CompUse MIBG Pheo|Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma|Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma||University of California, San Francisco|Yes|Available|August 2009|August 2021|Anticipated|August 2020|Anticipated|N/A|Expanded Access|N/A|||||||Both|2 Years|N/A|No|||December 2014|December 23, 2014|June 13, 2011|Yes|Yes|Study has been suspended after the event of an serious adverse event.|||https://clinicaltrials.gov/show/NCT01377532||102850|
NCT01375530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110164|Screening Volunteers for Clinical Trials|VRC 500:Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes||National Institutes of Health Clinical Center (CC)||Recruiting|May 2011|||||N/A|Observational|N/A|||Anticipated|3000|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 19, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375530||103003|
NCT01375803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFIS-09-001|Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity|Novel Fiber Effects on Glucose Metabolism and Insulin Sensitivity for Individuals at High Risk for Diabetes||Cargill|No|Completed|June 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|45|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||June 2011|June 16, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375803||102982|
NCT01376089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-012-097|Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis|A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis||GE Healthcare|Yes|Completed|May 2011|February 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|304|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|June 16, 2011|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01376089||102960|
NCT01376453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16475|Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer|Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|June 2011|December 2016|Anticipated|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01376453||102932|
NCT01371929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDAbs 11-001|Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study|Evaluation of the PliNOSa® Test as an Aid in the Risk Assessment for the Onset of Sepsis|PliNOSa® Test|Research & Diagnostic Antibodies|Yes|Suspended|February 2013|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|heparinized plasma samples|Both|18 Years|N/A|No|Probability Sample|The study population will consist of 290 consecutively enrolled critically ill ICU        patients who are considered to be at risk of becoming septic based upon their clinical        presentation due to trauma, or a surgical procedure, or threatened or actual respiratory        failure, or hemodynamic instability; and recruited from three clinical sites. The first 40        study subjects will comprise the pilot cohort and the remaining 250 study subjects will        comprise the pivotal cohort.|May 2015|May 8, 2015|June 8, 2011|Yes|Yes|NIH funding ended prior to full enrollment in the clinical study|No||https://clinicaltrials.gov/show/NCT01371929||103274|
NCT01372254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGT1101101CPPD|Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment|Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment|BA-DAS|University of Maryland|No|Recruiting|January 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||July 2011|July 12, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372254||103249|
NCT01372527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS018161|Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT|Technology for Optimizing Population Care in a Resource-limited Environment|TopCare|Massachusetts General Hospital|No|Completed|June 2011|January 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|103870|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372527||103228|
NCT01372540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0144|Arry-520 + Carfilzomib for Multiple Myeloma (MM)|A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma||M.D. Anderson Cancer Center|No|Recruiting|February 2012|||February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|76|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|June 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01372540||103227|
NCT01373372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 05-069|Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia|CRH Responsiveness in Children With Functional Dyspepsia: A Pilot Study||Children's Mercy Hospital Kansas City|No|Not yet recruiting|December 2014|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|8 Years|17 Years|Accepts Healthy Volunteers|||September 2014|September 3, 2014|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373372||103164|
NCT01373385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-049|Prospective Pediatric Vesicoureteral Reflux Surgery Database|Prospective Pediatric Vesicoureteral Reflux Surgery Database||Connecticut Children's Medical Center|No|Recruiting|July 2010|December 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|18 Years|No|Non-Probability Sample|All patients receiving a surgical procedure for viesicoureteral reflux at Connecticut        Children's Medical Center.|July 2012|July 3, 2012|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01373385||103163|
NCT01373398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD901_01|Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)|Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetics of Intravesical Instillation of EO9 in Patients With Non-muscle Invasive Bladder Cancer(NMIBC)||Handok Pharmaceuticals Co., Ltd.|No|Completed|May 2011|||February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|20 Years|74 Years|No|||March 2012|March 12, 2012|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01373398||103162|
NCT01374061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100205|Pre Hospital Evaluation of Video Laryngoscopy|Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger®|EVE|Assistance Publique - Hôpitaux de Paris|No|Withdrawn|June 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|May 25, 2011||No|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01374061||103112|
NCT01379651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBFBN|Time-limited Specific Oral Tolerance Induction in Children With Severe Egg Allergy|Specific Oral Tolerance Induction in Children With Severe Egg Allergy: A Randomized Controlled Trial Using a 6 Months Protocol|EGGSOTI|Ospedale Buon Consiglio Fatebenefratelli|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|5 Years|11 Years|No|||September 2011|September 19, 2011|June 20, 2011||No||No|June 24, 2011|https://clinicaltrials.gov/show/NCT01379651||102689|
NCT01380613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR-DA022961-03|Neighborhoods, Networks, Depression, and HIV Risk|The Impact of Neighborhoods, Networks, and Depression on Drug Users' HIV Risk|Workshop|Johns Hopkins Bloomberg School of Public Health|Yes|Completed|September 2007|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|965|||Both|18 Years|55 Years|No|||September 2013|September 4, 2013|March 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01380613||102616|
NCT01377077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNIP punchgrafting study|Punchgrafting Techniques for Vitiligo|Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize|MiniSNIP|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|35|||Both|18 Years|N/A|No|||June 2011|June 20, 2011|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377077||102884|
NCT01380587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCL1 in ALL|Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia|Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia|XCL1|Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|November 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples With DNA|whole blood, serum, white cells, blasts|Both|1 Year|N/A|No|Non-Probability Sample|We will invite patients with newly diagnosed acute lymphoblastic leukemia , who had not        received anticancer therapy and regardless the subtype and immunophenotype of the disease.|August 2013|August 26, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380587||102618|
NCT01380600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-IV-CRC014|Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma|A Phase 1b Dose Escalation Study of JX-594 (Thymidine Kinase-Inactivated Vaccinia Virus Plus GM-CSF) Administered by Biweekly (Every Two Weeks) Intravenous Infusion in Patients With Metastatic, Refractory Colorectal Carcinoma||SillaJen, Inc.|No|Completed|July 2010|December 2015|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2012|January 6, 2016|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01380600||102617|
NCT01377844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-1442-C-418|Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus|Efficacy and Safety of EGT0001442 Compared With Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Diet and Exercise and up to One Oral Anti-diabetes Agent||Theracos|Yes|Completed|December 2011|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|288|||Both|18 Years|70 Years|No|||March 2015|March 4, 2015|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377844||102828|
NCT01377857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10562983|HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies|HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies||University of California, San Francisco|No|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|10||Actual|8572|||Both|13 Years|64 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|June 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01377857||102827|
NCT01376765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0100|Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study|Phase I, Double-Blinded, Placebo-Controlled, Dose- Escalation Study of the Safety and Immunogenicity of Recombinant SARS-CoV deltaTM S Protein Vaccine Formulated With and Without Alhydrogel® in Healthy Adults When Administered by the Intramuscular Route||National Institute of Allergy and Infectious Diseases (NIAID)||Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|February 14, 2013|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01376765||102908|
NCT01375244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11506|Comparative Bioavailability Study of Lisinopril Tablets, 10 mg|Randomized, Open-label, Two-treatment Crossover, of a 10 mg Single Oral Dose, Study to Compare the Lisinopril Plasma Levels Produced After Administration of the Test Formulation With Those Produced After Administration of a Marketed Reference Product, Zestril(R), Under Fasting Conditions.||Par Pharmaceutical, Inc.|No|Completed|June 1999|October 1999|Actual|October 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2008|June 16, 2011|April 1, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01375244||103024|
NCT01375543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110179|Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols|Next Generation Sequencing to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|||||N/A|Observational|N/A|||Anticipated|100|||Both|N/A|N/A|No|||April 2015|July 24, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01375543||103002|
NCT01376427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-07OPH|Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years|PROTOCOL TREATMENT for Acute Lymphoblastic Leukemia Ph '(BCR / ABL) POSITIVE PATIENTS AGED> 55 YEARS||PETHEMA Foundation|Yes|Recruiting|January 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|55 Years|N/A|No|||September 2015|January 16, 2016|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01376427||102934|
NCT01372553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-05-1-0383|Guilford Genomic Medicine Initiative (GGMI)|Guilford Genomic Medicine Initiative (GGMI)|GGMI|The Moses H. Cone Memorial Hospital|No|Completed|October 2009|April 2012|Actual|April 2012|Actual|Phase 4|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|1184|Samples With DNA|Total number of project participants that completed family health history tool was 1,184..      Out of the 1,184 subjects, 75 DNA saliva samples were collected.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study takes place in two Primary care practices. Patient's that come in for        well-visits are invited to participate in the study.|April 2014|April 15, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01372553||103226|
NCT01372566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU34547|Effect of Platelet Rich Plasma on Photoaged Skin|Effect of Autologous Platelet-rich Plasma on Photoaged Skin: A Prospective Randomized Controlled Trial (Phases A and B)||Northwestern University|Yes|Active, not recruiting|May 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|23|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01372566||103225|
NCT01372839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xj050511|Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome|The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome|PCI|Xijing Hospital|No|Recruiting|July 2010|||July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|85 Years|No|||July 2010|June 11, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372839||103204|
NCT01373073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK37|Evaluation of a Novel Human Milk Fortifier in Preterm Infants|Evaluation of a Novel Human Milk Fortifier in Preterm Infants||Abbott Nutrition|Yes|Completed|August 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|N/A|21 Days|No|||February 2013|February 19, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01373073||103186|
NCT01373086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFF269X2201|LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension||Novartis|No|Terminated|May 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|75 Years|No|||November 2012|November 30, 2012|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373086||103185|
NCT01372852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xjyy110501|Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated Type 2 Diabetes Mellitus|Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated T2DM Patients in Chinese Population||Xijing Hospital|No|Recruiting|May 2010|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|300|Samples Without DNA|blood，abdominal fat tissue|Both|30 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|This study enrolls a group of 30-70years patients from primary care clinic who have        diabetes history within 12 months and without taking any treatment.|May 2010|June 13, 2011|June 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01372852||103203|
NCT01373099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPACERHIP|Study of Antibiotic Spacer Design to Treat Infection After Hip Replacement|Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Hip Infection|SPACERHIP|Rush University Medical Center|Yes|Recruiting|August 2011|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01373099||103184|
NCT01373762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCS-21041|The Fitness, Game Bike Adherence, Motivation and Exercise Study|Interactive Videogame Bikes and Their Effect on Exercise Adherence and Health Related Fitness Among Families|FitGAME|University of Victoria|Yes|Completed|January 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|74|||Both|10 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 11, 2014|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01373762||103134|
NCT01373775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|740/2551(EC1)|Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department Siriraj Hospital|Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department in Siriraj Hospital: The One Year Period.||Mahidol University|No|Completed|April 2009|February 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|533|||Both|18 Years|N/A|No|Non-Probability Sample|Medical records of 533 patients,who visited the emergency department with the diagnosis of        HF (ICD-10 I500, I501 and I509) in the period from 1st Jan 2008 to 31st Dec 2008, were        reviewed.|June 2011|June 14, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01373775||103133|
NCT01373736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02695|123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors|||Vancouver Coastal Health|Yes|Not yet recruiting||||||Phase 3|Interventional|Primary Purpose: Diagnostic|||||||Both|N/A|N/A|No|||June 2011|June 13, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373736||103136|
NCT01373749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1991660|Nitro Oxide Inhalation Continued With Sildenafil on Neonatal Persistent Pulmonary Hypertension|Compare of Continued Nitro Oxide Inhalation and Nitro Oxide Inhalation Continued With Oral Sildenafil on Treatment of Neonatal Persistent Pulmonary Hypertension||Third Military Medical University|Yes|Recruiting|March 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|28 Days|No|||January 2011|June 14, 2011|May 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373749||103135|
NCT01380288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|neuropark|Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine|Changes of Cognitive Function in Patients With Mild to Moderate Alzheimer's Disease Associated With or Without White Matter Changes After Rivastigmine Patch Therapy - Multi-center, Prospective, Open-label Clinical Trial|CAREER|Dong-A University|Yes|Active, not recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|50 Years|90 Years|No|||April 2011|August 14, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01380288||102641|
NCT01376791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHC-PDCV|Assess the Effect of Treating Periodontal Disease on Cardiovascular Function in Young Adults|Oral Flora, Periodontitis, and Vascular Dysfunction in Young Native Americans.||San Diego State University|No|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|92|Samples With DNA|Serum, dental scrapings and saliva|Both|21 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|The study population comprises 200 Native Americans seeking health care at the Indian        Health Council.|April 2013|April 19, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376791||102906|
NCT01377324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUG2010-2611|Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites|In Vivo Imaging of the Effect of Fulvestrant on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Tumor Lesions Using FES-PET||University Medical Center Groningen|No|Completed|May 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01377324||102866|
NCT01376778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD36801-CMV|A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)|A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)|CMV|The George Washington University Biostatistics Center|Yes|Recruiting|April 2012|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|800|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|June 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376778||102907|
NCT01378429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-308|Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis|A 6-Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR)||Sunovion|No|Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|6 Years|11 Years|No|||April 2014|April 29, 2014|June 20, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01378429||102783|
NCT01378130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 180/2011|Central Serous Chorioretinopathy: Etiology, Course and Prognosis|Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis||Medical University of Vienna|No|Completed|April 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with an acute episode of central serous chorioretinopathy are recruited from the        Department of Ophthalmology at the Medical University of Vienna.|April 2013|April 25, 2013|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378130||102806|
NCT01378143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-103-C|Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy|A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment||Oncozyme Pharma Inc.|Yes|Completed|March 2011|July 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||February 2013|October 20, 2014|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01378143||102805|
NCT01377311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32MD02|The Application of Cultured Cornea Stem Cells in Patients Suffering From Corneal Stem Cell Insufficiency|Phase 1 Study of Cornea Stem Cells Cultured on Amniotic Membrane Transplanted on Patients Suffering From Corneal Stem Cell Insufficiency||National Taiwan University Hospital|Yes|Terminated|July 2008|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||June 2011|June 20, 2011|April 21, 2011||No|We didn't use this tech in patient.|No||https://clinicaltrials.gov/show/NCT01377311||102867|
NCT01377545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Infraclav Needle vs Catheter|Continuous Infraclavicular Nerve Blocks: Needle Versus Catheter Local Anesthetic Bolus|Continuous Infraclavicular Nerve Blocks: Needle Versus Catheter Local Anesthetic Bolus||University of California, San Diego|No|Withdrawn|January 2013|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|June 17, 2011|Yes|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01377545||102849|
NCT01375816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000701454|Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|A Randomized Phase II Study of PEP02 or Irinotecan in Combination With Leucovorin and 5-Fluorouracil in Second Line Therapy of Metastatic Colorectal Cancer|PEPCOL|Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)|Yes|Terminated|May 2011|December 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|75 Years|No|||November 2013|June 3, 2015|June 16, 2011||No|efficacy interim analysis as per protocol|No||https://clinicaltrials.gov/show/NCT01375816||102981|
NCT01375829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02907|Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of Ixabepilone and Temsirolimus in Adult Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Active, not recruiting|June 2011|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 2, 2015|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01375829||102980|
NCT01376102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111412|BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Injection Administered in Korean Patients According to the Prescribing Information|BONINJPMS|GlaxoSmithKline|No|Completed|November 2007|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|657|||Female|N/A|N/A|No|Probability Sample|Patients administrated BONVIVA(ibandronate) injection with postmenopausal osteoporosis|June 2014|June 12, 2014|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376102||102959|
NCT01371942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99064|Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management|Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management||Taipei Medical University WanFang Hospital|No|Active, not recruiting|May 2010|May 2013|Anticipated|||N/A|Observational|N/A||1|Anticipated|300|||Both|20 Years|N/A|No|Non-Probability Sample|Colorectal cancer patients|June 2011|June 10, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01371942||103273|
NCT01371955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1020|Impact of c242T Polymorphism of p22phox in Diabetic type1 Nephropathy|Impact of c242T Polymorphism of p22phox in the Development of Diabetic Nephropathy,in Caucasian Diabetic Type 1 Patient.|NEPHRODIANOX|University Hospital, Grenoble|Yes|Completed|January 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|162|Samples With DNA|We will include 60 patients to reach the required number. We take 2 blood samples: one for      genetic analysis and one to determine HBA1c and plasma creatinine. We also take one urinary      sample to determine the urinary albumine / creatinine ratio|Both|18 Years|N/A|No|Probability Sample|caucasian diabetic type 1 patients with more than 20 years of diabetes duration|November 2013|November 14, 2013|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01371955||103272|
NCT01372293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-245|71A/G HSD17B5 SNP and Effects of Oral Contraceptive Pill in PCOS Women|17-hydroxysteroid Dehydrogenase Type 5 Gene Polymorphism (71A/G HSD17B5 SNP) and Effects of Oral Contraceptive Pill on Hirsutism, Androgens and Metabolic Profile in Non-obese PCOS Women: a Pilot Study|17b-ACO|Federal University of Rio Grande do Sul|No|Completed|January 2005|December 2010|Actual|January 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Female|15 Years|40 Years|No|||September 2011|September 8, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372293||103246|
NCT01372306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA21897|Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2004|November 2004|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2004|June 29, 2011|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372306||103245|
NCT01372579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10B07|Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients|Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients||Northwestern University|Yes|Active, not recruiting|August 2011|June 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|June 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372579||103224|
NCT01373411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01452|Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery|Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG)|TAP-CABG|Cardiology Research UBC|Yes|Completed|September 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|70|||Both|19 Years|80 Years|No|||March 2013|March 24, 2015|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373411||103161|
NCT01373424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046266|Dystonia Coalition Projects|Natural History and Biospecimen Repository for Dystonia; Comprehensive Rating Tools for Cervical Dystonia; Validity & Reliability of Diagnostic Methods & Measures of Spasmodic Dysphonia|DCP|Emory University|No|Recruiting|January 2011|||October 2017|Anticipated|N/A|Observational|N/A||7|Anticipated|5000|Samples With DNA|Whole blood, DNA, white blood cells, cell lines|Both|18 Years|N/A|No|Non-Probability Sample|People with dystonia are eligible to participate as long as they are above age 18 and fit        the eligibility criteria. The coordinator at the site you contact can tell you more about        this.|December 2015|December 3, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01373424||103160|
NCT01374087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52014-177|Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer|Proof-of-concept Multicentre, Prospective, Randomised, Open-label and Parallel Group Clinical Trial to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5 mg Six-monthly in Patients With Recurrence of Prostate Cancer Previously Treated With Radiotherapy|ANABRAQ|Ipsen|No|Terminated|November 2011|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Male|18 Years|75 Years|No|||April 2015|April 1, 2015|June 14, 2011||No|Slow enrollment of patients.|No||https://clinicaltrials.gov/show/NCT01374087||103110|
NCT01374438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSDC-0160-C006|3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease|A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease||Metabolic Solutions Development Company|No|Completed|July 2011|May 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|55 Years|85 Years|No|||November 2014|November 5, 2014|June 14, 2011|Yes|Yes||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01374438||103083|
NCT01380639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGL-Ga-6MGT-0810|Effects of Vibration Training on Exercise Capacity in COPD-patients|Effects of Vibration Training During a Three-week Rehabilitation on Exercise Capacity in Chronic Obstructive Pulmonary Disease (COPD) III/IV-Patients||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|September 2010|||April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|75 Years|No|||September 2013|September 27, 2013|April 1, 2011||No||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01380639||102614|
NCT01380925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG090937|The Jewels in Our Genes Study - an African American Family Study of Breast Cancer|Search for Novel Breast Cancer Susceptibility Genes in Pedigrees of African Ancestry||University at Buffalo||Completed|October 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|330|Samples With DNA|Saliva sample|Female|18 Years|N/A|No|Non-Probability Sample|African American breast cancer survivors.|August 2012|August 13, 2012|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01380925||102592|
NCT01377571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rotavin02|A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants|A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam||National Institute of Hygiene and Epidemiology, Vietnam|Yes|Completed|October 2009|April 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|200|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||June 2011|June 20, 2011|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01377571||102847|
NCT01377558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gi-03-2011|Effects of Different Types of Exercise Interventions in Patients With Type 2 Diabetes|Effects of Different Types of Exercise Interventions in Patients With Type 2 Diabetes - Aerobic Endurance Training Versus Strength Endurance Training Versus Combined Aerobic Endurance and Strength Endurance Training -||University of Giessen|Yes|Active, not recruiting|April 2011|June 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|N/A|No|||April 2011|June 22, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01377558||102848|
NCT01378663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-00058|Review of Pain Management After Congenital Cardiac Surgery|Review of Pain Management After Congenital Cardiac Surgery||Nationwide Children's Hospital|No|Completed|April 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|92|||Both|N/A|N/A|No|Probability Sample|All patients that underwent congenital cardiac surgery from 2004 till 2010 and required        PCA or NCA.|March 2012|March 19, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01378663||102765|
NCT01378390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX-401/FATT2|Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease|Randomized, Single-blind, Placebo Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Expanded Autologous Adipose-derived Stem Cells (ASCs) (CX-401), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease|FATT|Cellerix|Yes|Terminated|December 2008|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||June 2011|June 21, 2011|June 21, 2011||No|After the investigators and experts in the field imput it became apparent that the protocol    was not reflective of clinical reality. No safety issues reported.|No||https://clinicaltrials.gov/show/NCT01378390||102786|
NCT01378403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-07-4545-RA-CTIL|Evaluation of Dorsal Visual Stream in Patients With Schizophrenia|Evaluation of Dorsal Visual Stream in Patients With Schizophrenia||Sheba Medical Center|No|Completed|September 2007|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|35 Years|No|Non-Probability Sample|Patients suffering from schizophrenia|June 2011|June 21, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378403||102785|
NCT01375842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCD4989g|A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies||Genentech, Inc.||Recruiting|June 2011|April 2019|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|604|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01375842||102979|
NCT01376492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017518|FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain|Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain||Janssen-Cilag, S.A.||Completed|November 2010|July 2011|Actual|July 2011|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|709|||Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with schizophrenia seen in outpatient mental health care facilities        distributed all over the country, with and without sleep disturbances at the time of the        visit.|March 2013|March 7, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376492||102929|
NCT01371968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alfentanil LMA|Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia|Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia||University of Malaya|Yes|Recruiting|February 2011|November 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|30|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2011|June 10, 2011|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01371968||103271|
NCT01371981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02670|Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD||National Cancer Institute (NCI)|No|Suspended|June 2011|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|16||Anticipated|1750|||Both|N/A|29 Years|No|||March 2016|March 24, 2016|June 10, 2011|Yes|Yes|Other - Approaching current patient accrual goals|No||https://clinicaltrials.gov/show/NCT01371981||103270|
NCT01372605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019233|Trial of Collaborative Depression Care Management for HIV Patients|SLAM DUNC: Strategies to Link Antidepressant and Antiretroviral Management at Duke University, University of Alabama at Birmingham, Northern Outreach Clinic (Henderson, NC), and University of North Carolina|SLAM DUNC|Duke University|Yes|Completed|April 2010|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|65 Years|No|||December 2013|March 27, 2015|June 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01372605||103222|
NCT01372267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA029587-01A1|Psychosocial Pain Management During Addictions Treatment to Improve Outcomes|||University of Michigan|No|Active, not recruiting|October 2011|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|452|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01372267||103248|
NCT01372280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA21896|Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2004|November 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2011|June 29, 2011|January 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372280||103247|
NCT01372865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 119|A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)|A Phase III, Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis With Eurofarma Mometasone or Reference Mometasone.||Eurofarma Laboratorios S.A.|Yes|Not yet recruiting|December 2011|August 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|364|||Both|12 Years|N/A|No|||June 2011|June 13, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01372865||103202|
NCT01373437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|345/2553(EC4)|Ultrasonography in Confirming Proper Position of Endotracheal Tube|Ultrasonography in Confirming Proper Position of Endotracheal Tube in Emergency Department at Siriraj Hospital: Applicability and Accuracy||Mahidol University|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|The patients who visited the emergency department, Siriraj hospital and needed ETT        intubation as their adequate treatment. In the period from September 2010 to November        2010.|June 2011|June 14, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01373437||103159|
NCT01373450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-222|Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)|Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|12|||Male|18 Years|64 Years|No|||September 2015|September 1, 2015|June 13, 2011|No|Yes||No|May 20, 2013|https://clinicaltrials.gov/show/NCT01373450||103158|
NCT01373801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor517911ctil|Hemcon© Bandage for Postpartum Bleeding Due to the Multiple Vaginal Lacerations|THE EFFICACY AND SAFETY OF HEMCON© BANDAGE FOLLOWING SURGICAL REPAIR IN MANAGEMENT OF POSTPARTUM BLEEDING DUE TO THE MULTIPLE VAGINAL LACERATIONS||Soroka University Medical Center|No|Recruiting|July 2011|||July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Female|18 Years|N/A|No|||April 2011|August 9, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373801||103132|
NCT01377090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-521|Digital Ulceration|A Multicenter, Prospective Cohort Study Using Nailfold VideoCAPillaroscopy(NVC) and Other Factors to Determine the Risk of Developing Digital Ulceration in Patients With Systemic Sclerosis (SSc)|CAP|Actelion|No|Completed|January 2011|August 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|630|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Systemic Sclerosis with or without a history of digital ulcers (DU)|July 2013|July 11, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377090||102883|
NCT01377103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT-1|Testosterone Therapy in Heart Failure|Cardiovascular and Functional Effects of Testosterone Therapy for Hypogonadal Patients With Heart Failure||Cedars-Sinai Medical Center|No|Not yet recruiting|July 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|36 Years|79 Years|No|||April 2011|July 7, 2011|May 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377103||102882|
NCT01377337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013-09-RMB|Sodium Bicarbonate in Cardiopulmonary Resuscitation|Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial|SB CAT|Rambam Health Care Campus|Yes|Not yet recruiting|December 2011|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 6, 2011|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377337||102865|
NCT01377584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23HL105887-01A1|COMMunication and Education for the New CPAP Experience|COMMENCE Study: COMMunication and Education for the New CPAP Experience|COMMENCE|University of Pittsburgh|No|Recruiting|March 2014|July 2016|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|60|||Both|21 Years|N/A|No|||December 2014|December 2, 2014|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377584||102846|
NCT01378156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV-TH-01|A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test||GeoVax, Inc.|No|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|50 Years|No|||August 2015|August 10, 2015|July 30, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01378156||102804|
NCT01378416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACO-018|Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|A Phase I Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome||Eisai Inc.||Completed|April 2005|June 2007|Actual|January 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2011|July 2, 2011|September 30, 2008|Yes|Yes||No|September 30, 2008|https://clinicaltrials.gov/show/NCT01378416||102784|
NCT01377870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royn-nerve-001|Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis|Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis||Royan Institute|Yes|Completed|December 2011|April 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|No|||August 2010|April 24, 2014|June 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01377870||102826|
NCT01378169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM09143|SIRS and Bacterial Sepsis Discrimination by Biomarkers in ICU|Early Detection and Diagnostic Performance of Bio-markers During Bacterial Sepsis: Multicentre Cohort Study in Intensive Care|Captain|Groupe Hospitalier Paris Saint Joseph|No|Recruiting|January 2011|June 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|blood, urin, CSF, BAL|Both|18 Years|95 Years|No|Non-Probability Sample|ICU patients whatever was their admission indication presenting a SIRS with or without        sepsis.|October 2011|October 7, 2011|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01378169||102803|
NCT01378949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2259-11-HYMC|Psoas Compartment Block Versus Fascia Iliaca Block After Total Hip Arthroplasty|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|90|||Both|45 Years|90 Years|No|||June 2011|June 22, 2011|June 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01378949||102743|
NCT01378962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25514|A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)|Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (EGFR) - (TRIGGER)||Hoffmann-La Roche||Completed|March 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|June 21, 2011|No|Yes||No|September 30, 2015|https://clinicaltrials.gov/show/NCT01378962||102742|
NCT01376466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080129|Impact of CT on Diagnosis of Acute Appendicitis|The Impact Of Computed Tomography On The Diagnoses Of Acute Appendicitis||University of Aarhus|Yes|Completed|February 2009|October 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|N/A|No|Non-Probability Sample|Admitted patients with acute appendicitis.|November 2012|November 8, 2012|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376466||102931|
NCT01376479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-EVR-101|Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71|Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults||Takeda|No|Completed|August 2011|April 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376479||102930|
NCT01371994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-UC-050|A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy|A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy||Astellas Pharma Inc|No|Completed|August 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|640|||Male|18 Years|N/A|No|||October 2014|October 6, 2014|June 10, 2011|Yes|Yes||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01371994||103269|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01372007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/267|Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma|Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma||University Hospital, Ghent|No|Recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||June 2015|June 2, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01372007||103268|
NCT01372319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|085/2011B02|Assessment of Advanced Glaucomatous Visual Field Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|Assessment of Advanced Glaucomatous Visual Field Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|GlaucomaEXPLOR|University Hospital Tuebingen|No|Completed|June 2011|April 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|First year: 10 glaucoma patients, with advanced binocular visual loss and 10 age-related        (+ 5 years of age) and gender-matched normal subjects. Second year: Extension to a total        number 30 glaucoma patients, with advanced binocular visual loss and 30 age-related (+ 5        years of age) and gender-matched normal subjects (according to the sample size        estimation), if additional budget available.|May 2014|May 27, 2014|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372319||103244|
NCT01372345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B045907|Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions|Single Dose, Randomized, Two-period, Two-treatment, Two-sequence Crossover Relative Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets Under Fasting Condition||Dr. Reddy's Laboratories Limited|No|Completed|February 2005|March 2005|Actual|February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|June 10, 2011|January 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372345||103242|
NCT01372618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-00641|Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor|Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor||New York University School of Medicine|Yes|Completed|June 2011|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|21 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01372618||103221|
NCT01372358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B045908|Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions|Single Dose, Randomized, Two-period, Two-treatment, Two-sequence Crossover Relative Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets Under Non-Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Completed|January 2005|February 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|June 10, 2011|January 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372358||103241|
NCT01372592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.REG1101|Spine TRACK Registry|Spine TRACK (Translating Radiographic and Clinical Knowledge) Registry: Outcomes Data Collection in Degenerative, Deformity, and Trauma Patients||NuVasive|No|Enrolling by invitation|March 2011|||December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|All patients who are evaluated and scheduled to undergo surgical treatment for a        spine-related condition are eligible to participate in this registry.|December 2015|December 8, 2015|March 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01372592||103223|
NCT01372878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-204|Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon|MA-204: Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon||Given Imaging Ltd.|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|1||Actual|884|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||July 2012|May 13, 2014|June 5, 2011||No||No|April 2, 2014|https://clinicaltrials.gov/show/NCT01372878||103201|
NCT01372891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xjyy110502|Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy|Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy||Xijing Hospital|No|Recruiting|April 2010|December 2014|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|serum,urine|Both|18 Years|80 Years|No|Probability Sample|This study enrolls a group of patients> 18 who have ST elevation myocardial infarction        (STEMI) undergoing primary PCI.|November 2011|November 21, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372891||103200|
NCT01373164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13663|A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer|A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)||Eli Lilly and Company|No|Active, not recruiting|June 2011|December 2016|Anticipated|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|168|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373164||103179|
NCT01373125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1951|Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?|Is the Neosquamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?||University of North Carolina, Chapel Hill|No|Completed|June 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|99|Samples With DNA|esophageal biopsies|Both|18 Years|80 Years|No|Non-Probability Sample|Potential subjects will be identified by their gastrointestinal (GI) physician and        approached by a study coordinator, nurse, or their GI physician regarding this study on        the day of their scheduled procedure at UNC hospitals/GI clinic.|September 2015|September 21, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01373125||103182|
NCT01373138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50630|Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D® 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|April 2006|May 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2006|June 13, 2011|June 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373138||103181|
NCT01373151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM133-001|Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate|A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.||Alder Biopharmaceuticals, Inc.|Yes|Completed|June 2011|June 2015|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|418|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01373151||103180|
NCT01373463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101466|Cisplatin and Pemetrexed With Radiation Followed by Lobectomy|A Phase I Trial of Preoperative Carboplatin or Cisplatin and Pemetrexed With Thoracic Radiation Therapy Followed by Lobectomy in Resectable Stage III Patients With Non-Squamous Non Small Cell Lung Cancer (NSCLC)|CisPemXetSrg|Medical University of South Carolina|Yes|Terminated|May 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|90 Years|No|||July 2012|July 24, 2012|June 13, 2011||No|Investigator left site|No||https://clinicaltrials.gov/show/NCT01373463||103157|
NCT01373476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008L11200|Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy|Multicentre,Randomized,Double-blind, Multiple-dose, Placebo-controlled, Parallel-Group Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy With Blood Stasis Syndrome and Deficiency of Qi-Yin Syndrome||Chengdu University of Traditional Chinese Medicine|Yes|Completed|March 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|30 Years|70 Years|No|||May 2013|May 10, 2013|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01373476||103156|
NCT01373814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1163|Nutritional Therapy for Diabetic Cardiomyopathy|Nutritional Therapy for Diabetic Cardiomyopathy||Washington University School of Medicine|Yes|Enrolling by invitation|September 2010|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|blood samples|Both|35 Years|65 Years|No|Probability Sample|Patients with known T2DM and who are not taking exogenous insulin.|December 2015|December 22, 2015|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373814||103131|
NCT01373827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SST2011-2|Protocol To Evaluate Patient Measurements After Ultrasonic Treatment|Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.||Sound Surgical Technologies, LLC.|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7|||Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|All subjects presenting to the investigator for treatment using the MC1 are potential        study candidates and will be screened for eligibility. Every effort will be made to        establish eligibility of the participants before enrollment. Subjects who do not meet all        inclusion/exclusion criteria will not be enrolled. Enrollment in the study occurs at the        time the patient is randomized to the assigned treatment.|March 2012|March 23, 2012|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01373827||103130|
NCT01376830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1697|Characteristics That Identify Exacerbation Risk Following Colds in COPD Patients|Biomarkers and Clinical Characteristics That Identify the Risk of an Exacerbation Following Viral Upper Respiratory Tract Infections in COPD Patients||Imperial College London|No|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|Samples Without DNA|Sputum,nasal lavage, serum|Both|40 Years|85 Years|No|Non-Probability Sample|COPD patients|June 2011|August 21, 2015|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01376830||102903|
NCT01376843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0161|Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers|Conversion Rate of TST and Quantiferon-TB Gold In Tube Assay in Health Care Workers||Yonsei University|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|53|Samples Without DNA|whole blood for perfoming Quantiferon-TB Gold in tube assay|Both|20 Years|75 Years|No|Non-Probability Sample|health care workers who performed TST or Quantiferon-TB Gold In tube assay before|March 2013|March 4, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376843||102902|
NCT01377155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCC 03-11|A Comparison of Two Initial Dosing Formulas|A Comparison of Two Initial Dosing Formulas for Basal Insulin in Type 2 Diabetes Mellitus||Diabetes Care Center|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01377155||102879|
NCT01377350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0550-10ctil|Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System|Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System||Rambam Health Care Campus|No|Not yet recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|20 Years|N/A|No|||March 2011|June 20, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01377350||102864|
NCT01377597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002E2301|Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion|A 3-month, Phase III, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Monthly Intravitreal Injections as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Branch or Central Retinal Vein Occlusion (RVO)|RVO in Japan|Novartis||Completed|June 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377597||102845|
NCT01377883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL_BTX2011|Clown Care for Botulinum Toxin (BTX)|||Shaare Zedek Medical Center||Completed|January 2010|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|2 Years|18 Years|No|||June 2011|June 21, 2011|June 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01377883||102825|
NCT01377896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NZA-XXX-2011/1|The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours|The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours||AstraZeneca|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|221|||Both|N/A|N/A|No|Probability Sample|Patients with cardiovascular events|June 2011|June 27, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01377896||102824|
NCT01369511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11671|A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement|A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty||Eli Lilly and Company|Yes|Completed|July 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|384|||Both|50 Years|N/A|No|||March 2014|April 14, 2014|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369511||103459|
NCT01378182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110S153|Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis|Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis||Gulhane Military Medical Academy|No|Completed|April 2011|December 2014|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||December 2014|December 30, 2014|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378182||102802|
NCT01378455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-3193B|Effectiveness of Handwriting Training Program on Handwriting Performance in Cerebral Palsy|Effectiveness of Interactive Computerized Handwriting Training Program on Handwriting Performance in Children With Cerebral Palsy||Chang Gung Memorial Hospital|Yes|Recruiting|March 2010|July 2015|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||May 2011|June 10, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01378455||102781|
NCT01378702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|viscum-1|Safety and Immunological Effects of Two Mistletoe Preparations in Healthy Volunteers|Safety and Immunological Effects of Iscucin Populi and Viscum Mali e Planta Tota in Healthy Volunteers||University Hospital Freiburg|Yes|Completed|January 2008|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|71|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2007|June 20, 2011|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01378702||102762|
NCT01378442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-1164B|The Relationship of Bone Strength and Fitness Training in Children With Cerebral Palsy|The Relationship of Bone Strength and Fitness Training in Children With Cerebral Palsy||Chang Gung Memorial Hospital|Yes|Completed|August 2007|July 2009|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|3 Years|18 Years|No|||May 2011|June 10, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01378442||102782|
NCT01378715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-134/10|Rosuvastatin Pre-Treatment Influences the Risk of Coronary Intervention Study|Rosuvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study (TIPS-3)|TIPS-3|University Hospital, Motol|No|Recruiting|June 2010|August 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2011|June 20, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01378715||102761|
NCT01376141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112324|Drug Use Investigation for IMIGRAN Tablet|Drug Use Investigation for IMIGRAN Tablet||GlaxoSmithKline|No|Completed|September 2001|November 2005|Actual|February 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3571|||Both|N/A|N/A||Probability Sample|Male and female Japanese subjects with migraine disorders who were considered appropriate        to prescribe sumatriptan tablet according to the prescribing information were eligible for        this surveillance study.|June 2011|June 16, 2011|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01376141||102956|
NCT01376154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112335|Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)|Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)||GlaxoSmithKline|No|Completed|June 2006|February 2011|Actual|December 2009|Actual|N/A|Observational|N/A||1|Actual|342|||Both|N/A|N/A|No|Probability Sample|Japanese subjects with hepatitis B virus-induced liver cirrhosis, in whom lamivudine        tablet was administered alone for 6 months or longer, or those in whom lamivudine tablet        was expected to be administered alone for 6 months or longer.|June 2011|June 16, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376154||102955|
NCT01376518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.041.10 1|Influence Positive End-expiratory Pressure on Autoregulation in Patients With Respiratory Insufficiency|Influence of Positive End-expiratory Pressure on the Cerebrovascular Autoregulation in Patients With Respiratory Failure|dARICUPEEP|Johannes Gutenberg University Mainz|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Adult patients on intensive care unit with acute respiratory failure|August 2010|June 17, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01376518||102927|
NCT01376531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.041.10 2|Influence Continuous Veno-venous Hemodialysis the Autoregulation|Influence of Continuous Veno-venous Hemodialysis on Cerebrovascular Autoregulation in Patients With Acute Renal Failure|dARICUCVVH|Johannes Gutenberg University Mainz|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Probability Sample|Patients at ICU with acute renal failure and the need of continuos veno-venous        hemodialysis|April 2013|April 12, 2013|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01376531||102926|
NCT01372020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fepar-04|Neuromuscular Electrical Therapy in Venous Ulcers|The Effect of Neuromuscular Electrical Therapy on Pain in Patients With Venous Ulcers: a Controlled Clinical Trial||Faculdade Evangelica do Parana|No|Completed|February 2011|November 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|50 Years|85 Years|No|||December 2013|December 21, 2013|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01372020||103267|
NCT01372332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|086/2011BO2|Assessment of Homonymous Visual Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|Assessment of Homonymous Visual Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|Hemi-Drive|University Hospital Tuebingen|No|Completed|June 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|30 patients with homonymous visual field defects and 30 age-related (+ 5 years of age) and        gender-matched normal subjects. All subjects are free to stop participation of the tests        at any time without any consequences on the future treatment of the patient. The        circumstances of any discontinuation will be documented.|May 2014|May 27, 2014|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372332||103243|
NCT01372371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1119-9648|Efficacy of Local Powder Prophylactics|Effects of Applying Powdered Prophylactics Verses Intravenous Antibiotics Only on Post-operative Infection Rate||Ganga Hospital|No|Recruiting|June 2011|June 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1844|||Both|10 Years|N/A|No|||June 2011|June 10, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372371||103240|
NCT01372631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028284|A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins|A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins||Duke University||Recruiting|April 2011|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|210|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01372631||103220|
NCT01372904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIS 4/2011|Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment|Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment.||Meir Medical Center|No|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|N/A|No|||July 2014|July 16, 2014|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01372904||103199|
NCT01373177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007937|Differences Between the Bayley-II and the Bayley-III in Very Preterm Infants at 2 Years|A Randomized Crossover Study to Evaluate Differences Between the Bayley-II and the Bayley-III in Very Preterm Infants at 2 Years||Children's Hospital of Philadelphia|No|Completed|January 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|211|||Both|18 Months|22 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants 18-22 months of age who weighed <2000 grams at birth and who were <32 weeks        gestational age. Enrollment will reflect the ethnic and racial background of the maternal        and neonatal populations at this institution.|August 2014|March 17, 2015|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373177||103178|
NCT01377935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-157|Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments|Comparison of Risk of Hospitalization for Acute Kidney Injury Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments||Bristol-Myers Squibb|No|Completed|August 2009|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|113505|||Both|18 Years|N/A|No|Non-Probability Sample|This study will carried out using databases containing administrative claims data [        HealthCore Integrated Research DatabaseSM (HIRD) and Medicare in the U.S.] and electronic        medical records [ General Practice Research Database (GPRD) and The Health Improvement        Network (THIN) in the UK]. The US population includes patients from health plans in the        northeast, southeastern, mid-Atlantic, central, mid-western, and western regions (HIRD) as        well as US citizens 65 years of age and older (Medicare). The UK population includes        patients seeking medical care from general practitioners (GPRD and THIN).|January 2016|January 19, 2016|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01377935||102821|
NCT01373840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102481|Role of Dopamine Receptors in Primary Focal Dystonias|Role of Dopamine Receptors in Primary Focal Dystonias||Washington University School of Medicine|No|Not yet recruiting|September 2011|||April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any healthy control or patient with primary focal dystonia or arm or face.|August 2011|August 2, 2011|June 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01373840||103129|
NCT01377909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bader 15859|HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity|An Investigator-initiated Pilot Study Using Statins to Improve the Anti-HCV Response to Peginterferon Alfa 2-b and Ribavirin in Previous Non-responders||Bader, Ted, M.D.|No|Terminated|March 2012|August 2013|Actual|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|70 Years|No|||August 2013|August 21, 2013|June 20, 2011|Yes|Yes|Principal Investigator retiring|No||https://clinicaltrials.gov/show/NCT01377909||102823|
NCT01377922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMS-002|A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)|A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)||Catalyst Pharmaceuticals, Inc.|Yes|Active, not recruiting|June 2011|August 2016|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377922||102822|
NCT01368705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000012920|Nitrogen Balance in Infants After Post Cardiothoracic Surgery|Determination of Protein Needs Using Nitrogen Balance in Infants Immediately Post Cardiothoracic Surgery||The Hospital for Sick Children|Yes|Completed|August 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|24|||Both|N/A|12 Months|No|||August 2013|August 16, 2013|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368705||103521|
NCT01368939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSC-CPDC-001|Investigation of High Resolution Nuclear Breast Imaging Camera (MBI) in Patients Administered Tc-99m Sestamibi (ROSE)|A Pilot, Single Centre, Prospective Clinical Study Investigation of the Acceptability of a Dedicated High Resolution Nuclear Breast Imaging Camera (MBI) in Breast Imaging of Patients Administered Tc-99m Sestamibi (ROSE)|ROSE|Hamilton Health Sciences Corporation|No|Recruiting|March 2012|June 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who have completed a cardiac stress test with Tc-99m Sestamibi (same day) will be        eligible for enrollment into the study. Females over the age of 18 and signed consent        form. Subjects will be recruited from the cardiac care clinic on Site.|April 2012|April 20, 2012|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01368939||103503|
NCT01369160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261-2005|Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease|Curative vs Disease-Modifying Therapies in Children With Severe Sickle Cell Disease: A Pilot, Cross-Sectional Study|SCD_Cross|Emory University|Yes|Completed|May 2005|March 2014|Actual|May 2007|Actual|N/A|Observational|N/A||4|Actual|33|||Both|3 Years|23 Years|No|||May 2014|May 23, 2014|April 22, 2009||No||No||https://clinicaltrials.gov/show/NCT01369160||103486|
NCT01369498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB0024-102|Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis|A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis||Gilead Sciences|No|Completed|June 2011|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|54|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369498||103460|
NCT01369771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S001-2010|The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma|An Open-label, Phase IV, Pilot Study, to Evaluate Confocal Microscopic Findings of Cornea, Ocular Signs and Symptoms in Patients With OH or OAG Switching From Latanoprost 0.005% to Preservative Free Tafluprost 0.0015% Eye Drops||FinnMedi Oy|No|Completed|August 2010|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|90 Years|No|||October 2014|October 27, 2014|July 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01369771||103439|
NCT01369784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-R-IPI|Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma|Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma|PRO-R-IPI|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Completed|February 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|158|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with refractory/relapsed diffuse large B-cell lymphoma|June 2011|June 8, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01369784||103438|
NCT01370044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARDIF|Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures|Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures|CARDIF|Charite University, Berlin, Germany||Terminated|August 2012|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|12 Months|5 Years|No|||July 2015|July 27, 2015|May 20, 2011||No|results of interim analysis (not safety relevant)|No||https://clinicaltrials.gov/show/NCT01370044||103418|
NCT01370070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC024|MK-2206 in Recurrent Nasopharyngeal Carcinoma|Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma|MC1079|Chinese University of Hong Kong||Active, not recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01370070||103416|
NCT01378988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-11-01|Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months|A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and Pharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged 12 Months Through <24 Months||Hospira, Inc.|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|12 Months|23 Months|No|||June 2015|June 29, 2015|June 20, 2011|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01378988||102740|
NCT01370057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAIST HK PROTOCOL VER1|The Use of Thoraco-lumbo-sacral Orthoses (TLSOs) in the Treatment of Adolescent Idiopathic Scoliosis (AIS)|The Use of TLSOs in the Treatment of Adolescent Idiopathic Scoliosis: A Prospective, Randomized Controlled Study||Chinese University of Hong Kong|No|Terminated|May 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|10 Years|15 Years|No|||February 2015|February 2, 2015|May 20, 2011||No|Failure of Subject Recruitment|No||https://clinicaltrials.gov/show/NCT01370057||103417|
NCT01376505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09138|Vaccine Therapy in Treating Patients With Metastatic Solid Tumors|Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2011|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01376505||102928|
NCT01376544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0808/147|Trial of Weaning by Synchronized Ventilation|Randomised Trial Comparing Assist Control Ventilation to Pressure Support Ventilation During Weaning||King's College London|No|Completed|August 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|N/A|14 Days|No|||June 2011|June 17, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01376544||102925|
NCT01376557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-202-DM|Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy||Lexicon Pharmaceuticals|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|299|||Both|18 Years|75 Years|No|||October 2014|October 29, 2014|June 16, 2011|Yes|Yes||No|October 27, 2014|https://clinicaltrials.gov/show/NCT01376557||102924|
NCT01372033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA017729|Effects of Manualized Treatment in a Seamless System|Effects of Manualized Treatment in a Seamless System of Care: Handling Probation|Man Tx|George Mason University|Yes|Completed|June 2007|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|251|||Both|18 Years|65 Years|No|||June 2009|June 10, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372033||103266|
NCT01372046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018759|Implementing & Testing Assessment and Referral Technologies in Juvenile Justice||JAARP|George Mason University|Yes|Completed|February 2008|May 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1000|||Both|18 Years|N/A|No|||June 2009|June 10, 2011|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01372046||103265|
NCT01372384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25423|A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations|Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor||Hoffmann-La Roche||Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|June 10, 2011|No|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01372384||103239|
NCT01372644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R6-937|Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial|Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial||New York University School of Medicine||Completed||||||Phase 1|Interventional|N/A|1||||||Female|21 Years|N/A||||June 2011|June 14, 2011|June 9, 2011||Yes||||https://clinicaltrials.gov/show/NCT01372644||103219|
NCT01372657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 304/10|Intraocular Lens (IOL) Calculation Improvement|Intraocular Lens (IOL) Formula Calculation Improvement||University Hospital, Basel, Switzerland|No|Terminated|April 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|cataract patients|January 2015|January 7, 2015|June 7, 2011||No|slow recruitment|No||https://clinicaltrials.gov/show/NCT01372657||103218|
NCT01372917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.064|Evaluating AlloMax in Immediate Expander-Based Breast Reconstruction Study|Evaluating Sterile Human Acellular Dermal Matrix in Immediate Expander-Based Breast Reconstruction: A Multi-centered Prospective Cohort Study||National Center for Plastic Surgery, Virginia|No|Completed|January 2010|August 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|39|Samples Without DNA|A 1 cm square of AlloMax will be harvested from the first 20 patients for histologic      examination to determine wether or not there is neovascularization and collagen deposition.|Female|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer patients who opt for immediate breast reconstruction with tissue expanders        from clinic.|June 2012|June 11, 2012|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01372917||103198|
NCT01377389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0378|Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer|A Phase II Study of Ipilimumab PLUS Androgen Deprivation Therapy in Castrate Sensitive Prostate Carcinoma||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2011|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Male|18 Years|N/A|No|||October 2015|October 15, 2015|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377389||102861|
NCT01373190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU Epilepsy Study|Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy|Thermographic Examination of Low Back and Abdominal Area Skin Temperatures in Individuals With and Without Focal Onset Epilepsy||Atlantic University|No|Completed|May 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|50 individual with diagnosis of focal onset epilepsy 50 normal matched control subjects|June 2011|June 20, 2013|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01373190||103177|
NCT01378195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pz-A103a|iCare Stress Management e-Training for Dementia Family Caregivers|iCare Stress Management e-Training for Dementia Family Caregivers|iCare|Photozig, Inc.||Completed|May 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|150|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 22, 2013|June 17, 2011||No||No|August 30, 2012|https://clinicaltrials.gov/show/NCT01378195||102801|
NCT01368718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/191|Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing|The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing||University Hospital, Ghent|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368718||103520|
NCT01368952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGHCEAH-IRB-286|The Effect of Pure Prone Positioning Therapy for the Patients With Mild to Moderate Obstructive Sleep Apnea|Efficacy Study of Pure Prone Positioning Therapy in Patients With Mild to Moderate Obstructive Sleep Apnea||Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|No|||May 2011|June 7, 2011|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368952||103502|
NCT01369173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IR 7099|COMIDAS Comparing Original Mexican Diets and Standard US Diets|Metabolic Response to Western vs. Indigenous Diets in Hispanic Women|COMIDAS|Fred Hutchinson Cancer Research Center|No|Completed|October 2011|April 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|50|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01369173||103485|
NCT01369524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 732|Effect of Fluid Resuscitation and Microcirculation|Evaluation of Effect of Fluid Resuscitation on Sublingual Microcirculation by SDF Imaging in Intensive Care Patients, a Pilot Study||Medical Centre Leeuwarden|No|Completed|January 2011|May 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|All patients admitted on the ICU and a need of fluids|May 2011|June 8, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01369524||103458|
NCT01369797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10010|Prospective Randomized Study of the Impact on the Autonomy of the Elderly of 75 Years of Age and Older by the UPSAV|Prospective Randomized Study of the Impact on the Autonomy of the Elderly of 75 Years of Age and Older by the Unit for Prevention, Monitoring and Analysis of Aging (UPSAV).|GEROPASS|University Hospital, Limoges|No|Completed|May 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|440|||Both|75 Years|N/A|No|||February 2016|February 23, 2016|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01369797||103437|
NCT01369810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RSE-DUM-2010/2|Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or Chronic Obstructive Pulmonary Disease|Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or COPD in Iceland||AstraZeneca|No|Completed|July 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|20000|||Both|N/A|N/A|No|Non-Probability Sample|All patients who was on treatment with fixed combination asthma or COPD therapy by January        1 2010|November 2013|November 29, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369810||103436|
NCT01370083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI-SRRL-0411-TPPT|Tongue Pressure Profile Training for Dysphagia Post Stroke|Tongue Pressure Profile Training for Dysphagia Post Stroke|TPPT|Toronto Rehabilitation Institute|No|Completed|September 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|June 3, 2011||No||No|November 24, 2015|https://clinicaltrials.gov/show/NCT01370083||103415|
NCT01370356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051075|A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction|A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction||Pfizer|Yes|Completed|July 2011|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|1510|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|June 8, 2011|Yes|Yes||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01370356||103394|Two cases of fetal exposure during pregnancy occurred but are not included in the SAE section as they did not meet the criteria of serious in the safety database. One of them relates to a non-study participant who was the study participant`s partner.
NCT01376193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112924|Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet|Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet||GlaxoSmithKline|No|Completed|April 2009|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|N/A|N/A|No|Probability Sample|Japanese subjects with migraine headache|May 2013|May 16, 2013|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01376193||102952|
NCT01376206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113407|Drug Use Investigation for ALLERMIST|Drug Use Investigation for ALLERMIST||GlaxoSmithKline|No|Completed|December 2009|May 2011|Actual|September 2010|Actual|N/A|Observational|N/A||1|Actual|2000|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who have allergic rhinitis for which the indication of ALLERMIST has been        approved and who are using ALLERMIST for the first time.|June 2011|June 16, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01376206||102951|
NCT01376570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032110|Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment|A Randomized Trial of an Abstinence-reinforcing Contingency Management Intervention to Suppress HIV Viral Load|Project FIRST|Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|202|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376570||102923|
NCT01372059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B41-f 1027/09|The Effects of a Rhythm and Music-based Therapy Program and Therapeutic Riding in Late Recovery Phase Following Stroke|The Effects of a Rhythm and Music-based Therapy Program and Therapeutic Riding in Late Recovery Phase Following Stroke||Göteborg University|Yes|Recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|123|||Both|50 Years|75 Years|No|||February 2016|February 4, 2016|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01372059||103264|
NCT01372072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ1 11/N141|A Study to Investigate the Effects of Heated Humidification During Non-Invasive Ventilation|A Pilot Study to Investigate the Physiological and Clinical Effects of Heated Humidification During Non-Invasive Ventilation||Guy's and St Thomas' NHS Foundation Trust|No|Not yet recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||March 2011|June 10, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01372072||103263|
NCT01372085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14318|Single Dose Study in Healthy Volunteers to Investigate the Safety and Absorption of LY2584702|A Single Ascending Dose and Relative Bioavailability Study of LY2584702 in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|June 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01372085||103262|
NCT01372098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MacMillan_NFP_IPVI_RCT|Nurse-family Partnership (NFP) Curriculum Study|Development and Evaluation of an Intervention for Intimate Partner Violence in the Context of Nurse Home Visits||McMaster University|Yes|Completed|May 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|492|||Female|16 Years|N/A|No|||June 2015|June 8, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01372098||103261|
NCT01376869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21AO1|Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants|Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants||Northumbria University|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|150|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2012|June 22, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01376869||102900|
NCT01372670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04091-11|Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder|Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study||HealthPartners Institute|Yes|Withdrawn|January 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|25 Years|No|||February 2016|February 17, 2016|June 10, 2011||No|Due to unforseen recruiting difficulties, the study was closed.|No||https://clinicaltrials.gov/show/NCT01372670||103217|
NCT01377402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRA-RACS|ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study|ARgentinean Risk Assessment Registry in Acute Coronary Syndrome; the ARRA-RACS Study.|ARRA-RACS|Helse Stavanger HF|Yes|Completed|November 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|982|Samples Without DNA|Serum, Citrated plasma, EDTA-plasma and packed red blood cells are kept in suitable aliquots      at -80 degrees Celcius.|Both|18 Years|N/A|No|Probability Sample|982 men and women admitted with chest pain and potential acute cornary syndrome (ACS) at        nine hopitals in Salta, Argenitna between November 2005 and November 2008.|November 2015|November 16, 2015|June 20, 2011||No||No|July 28, 2015|https://clinicaltrials.gov/show/NCT01377402||102860|
NCT01373203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99077|The Role of Fibrocytes in Acute Lung Injury|The Role of Fibrocytes in Acute Lung Injury||Taipei Medical University WanFang Hospital|No|Active, not recruiting|January 2011|December 2011|Anticipated|||N/A|Observational|Observational Model: Case-Only||1|Anticipated|20|||Both|20 Years|N/A|No|Non-Probability Sample|Acute Lung Injury patients|June 2011|June 13, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01373203||103176|
NCT01377610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6374/DA030484|Improved Strategies for Outpatient Opioid Detoxification|Long-acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone vs. Buprenorphine||New York State Psychiatric Institute|Yes|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01377610||102844|
NCT01371097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-KA-2006-0144|Progressive Resistance Strength Training (PRT) in Hospitalised Elderly Patients|The Effect of Progressive Resistance Strength Training in Hospitalised Elderly Patients|B15|Glostrup University Hospital, Copenhagen|Yes|Completed|September 2006|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|60 Years|N/A|No|||March 2015|March 9, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371097||103337|
NCT01371708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061030|A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD|A 6-month, Open-label, Multi-center, Flexible Dose Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder||Pfizer|Yes|Active, not recruiting|February 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|7 Years|17 Years|No|||February 2016|February 19, 2016|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371708||103291|
NCT01367431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT005294|Xanthohumol and Metabolic Syndrome|Xanthohumol and Metabolic Syndrome||Oregon State University|Yes|Completed|August 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men and women in the Portland, Oregon area|July 2015|July 23, 2015|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01367431||103619|
NCT01367444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU13583|Phase I/IIa Study of SAR422459 in Patients With Stargardt's Macular Degeneration|A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration||Sanofi|Yes|Recruiting|June 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|46|||Both|6 Years|N/A|No|||March 2016|March 15, 2016|June 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367444||103618|
NCT01368068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161/11|Investigation of Tibolone and Escitalopram in Perimenopausal Depression|Double-Blind Randomised Investigation of Tibolone or Escitalopram in First Onset Perimenopausal Depression||The Alfred|Yes|Terminated|July 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2|||Female|45 Years|55 Years|No|||March 2015|March 29, 2015|June 3, 2011||No|Difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT01368068||103570|
NCT01368042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-776|Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous|Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe)|QUALITIZE|AbbVie|No|Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|265|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic kidney disease stage 5 on hemodialysis and diagnosed with secondary        hyperparathyroidism, who were prescribed paricalcitol intravenous according to the        approved Summary of Product Characteristics|July 2014|July 29, 2014|June 6, 2011||No||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01368042||103572|
NCT01368380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NFK-SDU-2011-5|Hand in Hand. Psychological Support and Counseling to Breast Cancer Patients and Their Partners|Hand in Hand. Psychological Intervention for Breast Cancer Patients and Their Partners. A Randomised, Controlled Trial.|HIH|University of Southern Denmark|Yes|Completed|October 2011|May 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|198|||Female|18 Years|N/A|No|||February 2015|February 25, 2015|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01368380||103546|
NCT01368666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPS001|Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark|Perceval S Valve Clinical Trial for Extended CE Mark|CAVALIER|LivaNova|Yes|Active, not recruiting|February 2010|September 2018|Anticipated|October 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|658|||Both|65 Years|N/A|No|||May 2015|May 21, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01368666||103524|
NCT01368900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-111|Reducing Wrinkles Around the Eyes Using the Ulthera® System|Evaluation of the Ulthera® System for Obtaining a Reduction of Wrinkles Around the Eyes||Ulthera, Inc|No|Completed|March 2011|January 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|68|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|June 6, 2011|Yes|Yes||No|April 17, 2013|https://clinicaltrials.gov/show/NCT01368900||103506|FWCS scores assessed globally, not per eye, leading to limited data for analysis.FWCS protocol amended to 3+ after enrollment of 19 subjects with FWCS of 2.Unacceptable lighting, focus, exposure making some photos impossible to evaluate.
NCT01368913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000018|MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis|MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis With Special Focus on Patient Satisfaction|MELT|Ferring Pharmaceuticals|No|Completed|June 2011|May 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|138|||Both|5 Years|N/A|No|Non-Probability Sample|Patients with primary nocturnal enuresis|June 2013|June 11, 2013|June 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01368913||103505|
NCT01369121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDS 1001|Tolerability Study of Xerecept® in Pediatric Patients|A Phase I/II Open Label Individual Dose Titration Trial of the Human Corticotropin- Releasing Factor (hCRF), Corticorelin Acetate Injection (Xerecept®), to Determine the Tolerability of Xerecept® in a Pediatric Population||Celtic Pharma Development Services|No|Terminated|June 2010|March 2013|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|1 Year|18 Years|No|||July 2013|July 29, 2013|June 7, 2011|No|Yes|Single subject remained on study - transferred to compassionate use|No||https://clinicaltrials.gov/show/NCT01369121||103489|
NCT01369446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TST-1057-p|Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage|Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage|Eeva|Progyny, Inc.|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|160|||Female|18 Years|N/A|No|Non-Probability Sample|Women in the United States who undergo IVF treatment and imaging of their embryos with the        Eeva System.|July 2012|July 20, 2012|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369446||103464|
NCT01369745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z102-008|A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis|A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis|Synergy|Zalicus|Yes|Completed|June 2011|September 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|294|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|June 7, 2011|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01369745||103441|The study did not progress past the first stage of adaptive randomization. The number of subjects allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg arms was insufficient to allow analysis of the secondary objectives.
NCT01370005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.48|12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|825|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|June 8, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01370005||103421|
NCT01370317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1029-006|Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma|Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma||Merck Sharp & Dohme Corp.|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|65 Years|No|||January 2016|January 19, 2016|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370317||103397|
NCT01397578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABE4955g|A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease||Genentech, Inc.||Completed|August 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|50 Years|80 Years|No|||March 2016|March 1, 2016|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397578||101317|
NCT01387958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908A2214|A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients|Double-blind, Randomized, Placebo-controlled, Multi-center Trial, to Determine the Safety and Antiviral Effect of 14 Days of LCQ908 Monotherapy in Hepatitis C Infected Patients||Novartis||Terminated|July 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|No|||May 2012|May 6, 2012|July 1, 2011||No|Terminated early due to futility|No||https://clinicaltrials.gov/show/NCT01387958||102054|
NCT01388478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCU-KU-ADDF-2011|Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease|Safety/Tolerability and Effects on Cognitive Impairment, Impaired Cerebral Cortical Metabolism and Oxidative Stress of R(+)Pramipexole Administered to Subjects With Early Alzheimer's Disease||Virginia Commonwealth University|Yes|Completed|July 2011|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|55 Years|N/A|No|||September 2015|September 1, 2015|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01388478||102014|
NCT01388231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GV1001|Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice|Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice (SophoPrax)||Technische Universität Dresden|Yes|Recruiting|September 2010|June 2013|Anticipated|June 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|70 Years|No|||July 2011|July 7, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01388231||102033|
NCT01388452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0441|HIV Diagnosis in Hospitalized Malawian Infants|Presumptive and Definitive Virologic HIV Diagnosis in Hospitalized Malawian Infants||University of North Carolina, Chapel Hill|Yes|Completed|June 2011|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|300|||Both|N/A|12 Months|No|||May 2013|May 13, 2013|June 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01388452||102016|
NCT01388959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M39012|A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma|Multicentre, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab in Patients Suffering From Follicular Non-Hodgkin's Lymphoma (FNHL) With Residual Minimal Disease After Autologous Transplantation of hematopoïetic Stem Cell (Bone Marrow or Peripheral Blood)||Hoffmann-La Roche||Completed|November 1998|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01388959||101977|
NCT01389206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-428|Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program|Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program|PAH QuERI Ext|Actelion|No|Active, not recruiting|June 2011|March 2018|Anticipated|January 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|N/A|No|Non-Probability Sample|PAH patients and Physician practices|March 2016|March 1, 2016|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389206|3 Years|101958|
NCT01389219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|770-Ped/ERC-06|Post Partum Maternal and Neonatal Intervention Package|Post Partum Maternal and Neonatal Intervention Package: A Cluster Randomized Control Trial in District Sukkur, Pakistan||Aga Khan University|No|Completed|October 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|1200|||Both|N/A|28 Days|Accepts Healthy Volunteers|||October 2007|July 7, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389219||101957|
NCT01394718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-08095|Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients|Analgesia Efficacy of Repeated Doses of Intravenous Acetaminophen (Paracetamol) in the Pediatric Spinal Fusion Population|IV APAP SF|Children's Hospital of Philadelphia|No|Completed|July 2011|July 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|10 Years|18 Years|No|||September 2015|September 30, 2015|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394718||101536|
NCT01371396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RL-1DK081187|Effect of Dietary Macronutrient Composition|Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|September 2007|June 2014|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|20 Years|65 Years|No|||April 2012|April 20, 2012|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01371396||103314|
NCT01371721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061031|A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD|A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder||Pfizer|Yes|Completed|February 2012|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|270|||Both|7 Years|17 Years|No|||January 2016|January 25, 2016|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371721||103290|
NCT01371734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061032|A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-release (Dvs Sr) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder||Pfizer|Yes|Completed|August 2011|November 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|363|||Both|7 Years|17 Years|No|||December 2015|December 1, 2015|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371734||103289|
NCT01367457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1771017|INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus|Inhibitor - Estudio Retrospectivo De Casos Clinicos De Pacientes Con Carcinoma De Celulas Renales Y Con Linforma De Celulas Del Manto Tratados Con Temsirolimus||Pfizer|No|Completed|January 2011|April 2015|Actual|April 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|243|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with        Temsirolimus as per clinical practice.|April 2015|April 30, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367457||103617|
NCT01368081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.52|Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus|A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|1162|||Both|20 Years|N/A|No|||May 2014|May 16, 2014|May 19, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01368081||103569|
NCT01368094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRCIR10-PR-REGIMBEAU|Early (4 Days) Versus Standard Drainage of the Abdominal Cavity After Pancreaticoduodenectomy|Early (4 Days) Versus Standard Drainage Removal of the Abdominal Cavity After Pancreaticoduodenectomy- - A Randomized Multicenter Study||Centre Hospitalier Universitaire, Amiens|No|Recruiting|June 2011|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|138|||Both|18 Years|N/A|No|||December 2011|December 19, 2011|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368094||103568|
NCT01367782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8470-OC-CTIL|A Double Blind Sham-controled Study to Evaluate the Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease|A Double Blind Sham-controled Study to Evaluate the Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease||Sheba Medical Center|No|Recruiting|May 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|51|||Both|40 Years|85 Years|No|||September 2014|September 10, 2014|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01367782||103592|
NCT01368679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scitech 003|A Clinical Study to Evaluate the Safety and Performance of the Modular AAA Stent-Graft System|Phase III of the Prospective, Non-randomized and Multicenter Clinical Evaluation of the Safety and Performance of the Modular AAA Stent-Graft System When Used in the Treatment of Subjects With Abdominal Aortic Aneurysms (AAA)|Stent-Graft|Scitech Produtos Medicos Ltda|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|75 Years|No|||November 2014|November 18, 2014|June 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01368679||103523|
NCT01368692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1103-124-357|Effect of Shoulder Retraction on Success Rate of Subclavian Vein Catheterization|||Seoul National University Hospital|No|Completed|June 2011|January 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|362|||Both|16 Years|82 Years|No|||January 2013|January 14, 2013|May 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01368692||103522|
NCT01368640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA-01|Generation of Prediction Equations to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)|Generation of Prediction Equations to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)||Seca GmbH & Co. Kg.|Yes|Completed|April 2011|August 2012|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|153|Samples Without DNA|whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Data of 130 healthy adults are planned to be collected.|October 2012|October 2, 2012|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01368640||103526|
NCT01368653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA026511|Evaluation of Learning-Theory-Based Smoking Cessation Strategies|Evaluation of Learning-Theory-Based Smoking Cessation Strategies||Rutgers University|No|Completed|June 2012|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|93|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|June 6, 2011||No||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01368653||103525|
NCT01368926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25713|A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects|A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics, Safety and Tolerability of RO4917523 Conducted in 2 Phases: a Single-Dose, Cross-Over Administration to Healthy Japanese Subjects and a Multiple-Dose Administration to Healthy Japanese and Caucasian Subjects.||Hoffmann-La Roche||Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368926||103504|
NCT01369134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-10-014|Clinical Evaluation of a Self-etch Adhesive Using a Selective Etch Technique|Clinical Evaluation of 3M ESPE Adper Easy Bond Self-Etch Adhesive Using a Selective Etch Technique||3M|No|Completed|January 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|Dental patients|May 2014|May 29, 2014|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369134||103488|
NCT01369147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049495|The Energy Dose Study|Comparative Effectiveness of Energy Doses in Critical Illness||Emory University|Yes|Recruiting|July 2011|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|90 Years|No|||February 2016|February 14, 2016|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01369147||103487|
NCT01369459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASA2011MIP|Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder|Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD|MIP|The National Center on Addiction and Substance Abuse at Columbia University|Yes|Completed|November 2011|December 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369459||103463|
NCT01369472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125HPS11E|Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule|A Randomized, Open-label, Single Dose, Dose-rising 10-sequence, 3-period Balanced Incomplete Blocked Clinical Trial to Evaluate Dose-proportionality of Dilatrend SR in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Male|20 Years|54 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01369472||103462|
NCT01369485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10-0009|Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder|Multi-center, Prospective, Randomized, Double-blind, Sham-controlled Clinical Study to Evaluate Safety and Effectiveness of a Transcutaneous, High-frequency, Amplitude-modulated, Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Subjects With Overactive Bladder (OAB)|Beacon|Ethicon Endo-Surgery|No|Completed|June 2011|December 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|May 24, 2011|Yes|Yes||No|April 14, 2014|https://clinicaltrials.gov/show/NCT01369485||103461|There was a higher than anticipated rate of patient withdrawals observed in both groups due to skin irritation.
NCT01387945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01242319|Pilot Study of Home Blood Pressure Control Program|E-health BP Control Program|eBPcontrol|Memorial Hospital of Rhode Island|No|Completed|September 2010|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|28|||Both|18 Years|80 Years|No|||April 2015|April 7, 2015|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387945||102055|
NCT01388738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIB-NBS-C|Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.|Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.|3C|Clinical Institute of the Brain, Russia|Yes|Completed|January 2011|November 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|30|||Both|18 Years|70 Years|No|||December 2011|December 22, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01388738||101994|
NCT01388751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001506|Mallet Finger Splinting Study|Night Splinting After 6 to 8 Weeks of Continuous Splinting for Mallet Finger||Massachusetts General Hospital|Yes|Completed|November 2008|September 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388751||101993|
NCT01388985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITMC0211|Simplifying the Rabies Pre-exposure Vaccination|Simplifying the Rabies Pre-exposure Vaccination||Institute of Tropical Medicine, Belgium|No|Completed|October 2011|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|500|||Both|18 Years|47 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388985||101975|
NCT01388998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.308.10(7317)|Fluid Management Study to Evaluate Changes in Intravascular Volume After Applying Various Pressure Levels on the Caval Vein|External Pressure Applied on the Caval Vein and Its Effects on Difference in Pulse Pressure (dPP) and Pleth Variability Index (PVI)||Johannes Gutenberg University Mainz|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|24|||Both|18 Years|80 Years|No|||April 2012|April 22, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388998||101974|
NCT01388725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090923-001,20100701-002|Comparison the Value of Several Biomarkers of Sepsis|Comparison of the Value of Serum sTREM-1, sCD163, PCT, CRP Concentrations, WBC Count and SOFA Score During Sepsis and Their Clinical Informative Value in Predicting Outcome||Chinese PLA General Hospital|Yes|Completed|September 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|130|||Both|18 Years|N/A|No|Probability Sample|Between September 2009 and July 2011, inpatients were included who were in the intensive        care units (ICU) of the Department of Respiratory Disease, the Emergency Department, and        the Department of Surgery of the Chinese People's Liberation Army General Hospital.|July 2010|July 6, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388725||101995|
NCT01388972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1656|Assessment of Food Environment and Physical Activity Opportunities in Three Neighbourhoods of Buenos Aires City|Assessment of Food Environment and Physical Activity Opportunities in Three Neighbourhoods of Buenos Aires City||Hospital Italiano de Buenos Aires|No|Completed|February 2011|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|2924|||Both|N/A|N/A|No|Probability Sample|A community sample of Recoleta, Almagro and Constitucion neighborhoods of Buenos Aires,        Argentina has been conveniently selected by major representation of different        socioeconomic stratus. The value of the square meter of the property (2 rooms apartments)        was used as indirect indicator of socioeconomic level.|January 2012|March 22, 2015|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388972||101976|
NCT01389232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURE-002|The SeriScaffold® Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery in Europe|||Allergan||Completed|June 2011|February 2015|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Female|18 Years|N/A|No|||April 2015|April 24, 2015|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389232||101956|
NCT01389245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-0001|Study on OsseoSpeed™ TX Implants in the Upper Jaw in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate the OsseoSpeed™ TX Implant With an Early Loading Protocol in Patients With Tooth Loss in the Posterior Maxilla. A 3-years Follow-up Study.||Dentsply Implants||Active, not recruiting|June 2011|||October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|75 Years|No|||March 2016|March 23, 2016|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389245||101955|
NCT01367496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 103|Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose|An Open-Label, Phase I Study of the Pharmacokinetics and Bioavailability of Single, Ascending Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose in Normal, Healthy Male Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2002|August 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367496||103614|
NCT01367795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 10/10|Surgical Procedures for Advanced Tumor Disease. A Prospective Study Evaluating Quality of Life|Surgical Procedures for Advanced Tumor Disease. A Prospective Study Evaluating Quality of Life||University Hospital, Basel, Switzerland|No|Completed|July 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in a known tumorrelated palliative situation will be included when an operation        is discussed for relieve of symptomatic localised tumor growth . Patients will be        recruited from clinics or the emergency room.|March 2015|March 26, 2015|July 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01367795||103591|
NCT01368107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELYPSE 7|Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients|A Randomised, Multicentric, Phase 2a Study Evaluating the Impact of an Immunotherapy by IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients||Centre Leon Berard|Yes|Completed|June 2011|June 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Female|18 Years|N/A|No|||December 2013|February 6, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368107||103567|
NCT01368354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICONZ-UNZA|Taenia Solium Control Case Study in Zambia|Impact of Community-Led Total Sanitation on the Control of Taenia Solium and Soil Transmitted Helminths in the Eastern Province of Zambia|SANTOSOIL|University of Zambia|No|Completed|April 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1197|||Both|N/A|N/A|No|||February 2015|February 10, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01368354||103548|
NCT01400022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUB-125|Topical 0.05% Clobetasol Propionate in Vaseline Versus UVA-1 Phototherapy in Vulvar Lichen Sclerosus|A Randomized Clinical Study Comparing Topical 0.05% Clobetasol Propianate in Vaseline With UVA-1 Phototherapy in the Treatment of Vulvar Lichen Sclerosus||Ruhr University of Bochum|No|Completed|August 2010|February 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|N/A|No|||May 2013|May 29, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400022||101130|
NCT01399996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE PROBIOTIC|Influence of a Delivery System on the Efficacy of a Probiotic Intervention|Influence of a Delivery System on the Efficacy of a Probiotic Intervention||Penn State University|No|Completed|April 2012|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399996||101132|
NCT01400009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-STAT-2010|Vitamin D Replacement in Statin-Induced Myopathy|Vitamin D Replacement in Statin-Induced Myopathy||McGill University Health Center|No|Withdrawn|October 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|July 20, 2011||No|lack of enrollment|No||https://clinicaltrials.gov/show/NCT01400009||101131|
NCT01400269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11022010-7169|An Evaluation of a Developmentally-Based Parent Training Program for Children With Autism|An Evaluation of a Developmentally-Based Parent Training Program for Children With Autism||Stanford University|No|Completed|September 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Months|6 Years|No|||December 2015|December 2, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01400269||101111|
NCT01400282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHC-JCH|Analgesic Efficacy of High Frequency Spinal Cord Stimulation|Analgesic Efficacy of High Frequency Spinal Cord Stimulation: a Placebo-controlled Study||Ensemble Hospitalier de la Côte|Yes|Recruiting|July 2011|September 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A||||June 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400282||101110|
NCT01400503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018469|A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease|An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease||Janssen Research & Development, LLC|No|Active, not recruiting|April 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|April 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400503||101093|
NCT01400724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOFOLIC-NRT|Inofolic NRT and the Metabolic Syndrome|Effects of Inofolic NRT on Post-menopausal Women Affected by the Metabolic Syndrome||University of Messina|No|Completed|June 2011|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|80|||Female|50 Years|60 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01400724||101076|
NCT01387672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062011|Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study|Nitrates and Bone Turnover (NABT): Trial to Select the Best Nitrate Preparation|NABT;NABT-B|University of Toronto|Yes|Completed|September 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|265|||Female|50 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 6, 2015|June 30, 2011||No||No|February 17, 2015|https://clinicaltrials.gov/show/NCT01387672||102076|
NCT01387685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920090042|Treatment of Pelvic Organ Prolapse by PIVS Versus Surgeon Cut Mesh|||Western Galilee Hospital-Nahariya|No|Withdrawn|February 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Female|18 Years|95 Years|No|Non-Probability Sample|Women who underwent surgery for pelvic floor prolapse who underwent surgery by eithe        surgeon-cut-mesh or by PIVS|June 2014|June 19, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387685||102075|
NCT01387698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999907 CS09|Prospective, Longitudinal Multicentric Survey in the Therapeutic Care of Mild to Moderate Ulcerative Colitis|Observatoire Prospectif, Longitudinal Dans la Prise en Charge Thérapeutique de La Rectocolite Hémorragique légère à Modérée|OPTIMUM|Ferring Pharmaceuticals|No|Completed|June 2011|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|812|||Both|18 Years|N/A|No|Non-Probability Sample|All patients at least 18 years old suffering from mild to moderate active ulcerative        colitis (whatever the extension)|October 2015|October 28, 2015|June 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01387698||102074|
NCT01388257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNFCP-001|Anal Crohn Fistula Surgery|A National, Multicenter, Randomized Open-Label Study of Proctological Surgery Efficacy on Anoperineal Fistulas Healing in Crohn's Disease Patients Treated With Adalimumab. (Official French Title: "Étude Nationale, Multicentrique, randomisée et en Ouvert de l'efficacité de la Chirurgie Proctologique Sur la Cicatrisation Des Fistules anopérinéales de la Maladie de Crohn Chez Des Patients traités Par Adalimumab")|FACC|French Society of Coloproctology|No|Recruiting|October 2011|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01388257||102031|
NCT01388491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSG-HSP-201|A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women|A Multinational, Multicenter, Randomized, Open-label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women||Teva Pharmaceutical Industries|No|Completed|October 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|293|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|July 1, 2011|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01388491||102013|
NCT01388777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0986|Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy|A Pilot Study to Determine the Efficacy of Cryoablation for the Treatment of Invasive Breast Carcinoma Following Neoadjuvant Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2012|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Female|18 Years|N/A|No|||October 2015|October 15, 2015|July 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01388777||101991|
NCT01388790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 062202-058|Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer|Open-label, Single-arm, Multicenter Phase II Trial Investigating Cetuximab in Combination With S-1 and Cisplatin as First-line Treatment for Patients With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction||Merck KGaA|Yes|Completed|June 2011|May 2013|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|N/A|No|||September 2013|September 9, 2013|June 24, 2011||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT01388790||101990|
NCT01388764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011D001591|Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids|Pilot Study: To Assess the Safety, Tolerability and Effects of L-Arginine on Muscles in Boys With Dystrophinopathy on Corticosteroids||Massachusetts General Hospital|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Male|7 Years|11 Years|No|||June 2012|June 30, 2012|July 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01388764||101992|
NCT01389258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-0006|Study on OsseoSpeed™ TX Narrow Implants in the Upper Jaw in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate OsseoSpeed™ TX Single Implant 3 mm Diameter in the Anterior Maxilla. A 3-years Follow-up Study.||Dentsply Implants||Active, not recruiting|June 2011|||August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|75 Years|No|||March 2016|March 23, 2016|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389258||101954|
NCT01389271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14990|Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years|Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years|OPTION|Bayer|No|Recruiting|February 2011|April 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Probability Sample|Primary (idiopathic and familial) pulmonary hypertension and PAH secondary to scleroderma        without significant interstitial pulmonary disease classified as New York Heart        Association (NYHA) functional class III and IV|February 2016|February 25, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01389271||101953|
NCT01389284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15142|Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium|A Randomized, Double-Blind, Placebo Controlled Trial to Assess the Analgesic Efficacy and Safety of Extended Release Naproxen Sodium Tablets in Postsurgical Dental Pain|VERNE|Bayer|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|300|||Both|15 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 12, 2015|July 6, 2011|Yes|Yes||No|September 14, 2012|https://clinicaltrials.gov/show/NCT01389284||101952|
NCT01367509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1105|Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function|A Phase 1, Open-Label Study to Evaluate Single Dose Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function||Valeant Pharmaceuticals International, Inc.|No|Completed|March 2004|June 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367509||103613|
NCT01367808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55/180/2010|Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine|Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine: A Three-phase Cross-over Study in Healthy Subjects|PosaBupre|Turku University Hospital|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2010|June 6, 2011|May 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01367808||103590|
NCT01399528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCSI_LCM|A Pharmacogenomic Exploration of Lacosamide Response|A Pharmacogenomic Exploration of Lacosamide Response||Royal College of Surgeons, Ireland|No|Recruiting|September 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort||5|Anticipated|660|Samples With DNA|Collecting DNA from blood samples|Both|18 Years|65 Years|No|Non-Probability Sample|patients with epilepsy recruited from five tertiary referral centres.|December 2012|December 5, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399528||101168|
NCT01368367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETPB1|Exercise Training Post Burn Injury|Safety and Efficacy of Exercise Training Post Burn Injury: a Randomized Controlled Trial||The University of Queensland|No|Active, not recruiting|December 2007|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||November 2010|June 6, 2011|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01368367||103547|
NCT01400750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP1|Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis|Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.|CCTOBI|Universitaire Ziekenhuizen Leuven|No|Completed|August 2001|May 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|N/A|18 Years|No|||July 2011|August 3, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01400750||101074|
NCT01401010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DORIBAC4006a|Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients|Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection||Michigan State University|Yes|Completed|August 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|July 14, 2011|Yes|Yes||No|March 6, 2012|https://clinicaltrials.gov/show/NCT01401010||101054|
NCT01400295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100917|PREdictive Value of COntrast voluMe to creatinINe Clearance Ratio|Predictive Value of the Contrast Media Volume to Creatinine Clearance Ratio for the Risk of Contrast-Induced Nephropathy After Coronary Angiography|PRECOMIN|Guangdong General Hospital|Yes|Completed|December 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3000|||Both|18 Years|N/A|No|Probability Sample|The investigators reviewed all consecutive patients who were undergoing coronary        angiography|September 2014|September 14, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400295||101109|
NCT01400516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002691|Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial|Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial|TERA|Brigham and Women's Hospital|Yes|Active, not recruiting|August 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|N/A|No|||November 2015|November 24, 2015|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400516||101092|
NCT01400529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|906297|Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey|Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey. Programme de Recherche du Groupe Qualité de Vie, de la Section Epidémiologie et de la Section Arthrose de la Société Française de Rhumatologie|3000ARTHROSE|Central Hospital, Nancy, France|Yes|Completed|March 2007|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|3000|||Both|40 Months|75 Years|No|Probability Sample|population based|July 2007|July 21, 2011|July 5, 2007||No||No||https://clinicaltrials.gov/show/NCT01400529||101091|
NCT01400737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-09-ibuprofen|Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants|Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants|OIP|Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|200|||Both|23 Weeks|28 Weeks|No|||July 2011|July 21, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01400737||101075|
NCT01400997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-527|Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Czech Republic|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Czech Republic|ECOS CZ|Merck KGaA|No|Active, not recruiting|September 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|209|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400997||101055|
NCT01401283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|797726|GDT by Cardiac Index Trending Via a Radial Arterial Line in General Surgery|Multi-center, Prospective, Randomized Outcome Study Comparing Continuous Cardiac Index Trending Via a Radial Arterial Line Versus Standard Care in General Surgical Patients||Universitätsklinikum Hamburg-Eppendorf|No|Completed|July 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 8, 2011||No||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01401283||101033|
NCT01401543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13326|A Bioavailability Study of LY2452473 and Tadalafil|LY2452473 Formulation Exploratory Bioavailability Study||Eli Lilly and Company|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|July 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01401543||101013|
NCT01401816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alpert 3442-3|Advanced Provision of Emergency Contraception: Utilizing Technology to Increase Prescription Fill Rates|Advanced Provision of Emergency Contraception: Utilizing Technology to Increase Prescription Fill Rates||Boston Medical Center|No|Completed|July 2011|May 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|60|||Female|13 Years|21 Years|No|||June 2011|July 6, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401816||100993|
NCT01388244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSE|Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE)|Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE)|ROSE|Odense University Hospital|Yes|Active, not recruiting|January 2010|January 2020|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|35000|||Female|65 Years|80 Years|Accepts Healthy Volunteers|||June 2011|October 23, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01388244||102032|
NCT01388465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11020492|Text-message Support to Improve Oral Antibiotic Adherence After ED Discharge|Feasibility of Using Text-Message Support to Improve Antibiotic Adherence After ED Discharge|ImpACT|University of Pittsburgh|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|N/A|No|||May 2012|May 18, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388465||102015|
NCT01388504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/030/10|Nitrites in Acute Myocardial Infarction|Does Sodium Nitrite Administration Reduce Ischaemia-reperfusion Injury in Patients Presenting With Acute ST Segment Elevation Myocardial Infarction?|NIAMI|University of Aberdeen|Yes|Completed|July 2011|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||November 2015|January 20, 2016|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388504||102012|
NCT01389050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 10-0854-CE|High Precision RT For Soft-Tissue Sarcoma|Use of High Precision Radiotherapy in the Management of Soft-Tissue Sarcomas||University Health Network, Toronto|No|Active, not recruiting|June 2011|June 2021|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01389050||101970|
NCT01389037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_0030717|Understanding Health Care Information for African Americans With High Blood Pressure|Promoting Health Literacy of African Americans With High Blood Pressure||Johns Hopkins University|No|Not yet recruiting|October 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2011|July 6, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389037||101971|
NCT01389011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS_001|Perfusion Index (PI) and Pleth Variability Index (PVI) in Patients With Interscalene Blocks in Orthopedic Surgery|An Evaluation of PI and PVI (Masimo) in Patients With Interscalene Blocks in Orthopedic Surgery|PI-PVI|Johannes Gutenberg University Mainz|No|Completed|September 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for surgery of the shoulder and the upper arm.|July 2011|September 6, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389011||101973|
NCT01389024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00041623|Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease|Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children|HUPrevent|Johns Hopkins University|Yes|Recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|40|||Both|12 Months|54 Months|No|||September 2015|September 5, 2015|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389024||101972|
NCT01385566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-051|A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)|A Partially Blinded Randomized Clinical Trial to Study the Immunogenicity and Safety of Intradermal Administration of ZOSTAVAX™ (V211)||Merck Sharp & Dohme Corp.|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|6||Actual|223|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|June 28, 2011|No|Yes||No|December 11, 2012|https://clinicaltrials.gov/show/NCT01385566||102236|
NCT01385254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019788|Mother Sibling Interactions Following Very Low Birth Weight (VLBW) Infant Homecoming|Mother Sibling Interactions Following Very Low Birth Weight (VLBW) Infant Homecoming||Duke University|Yes|Completed|January 2010|October 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|300|||Both|N/A|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|Mothers who give birth at Duke University Medical Center, Durham Regional Hospital, or        Wake Medical Center, and their siblings.|December 2013|December 10, 2013|January 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01385254||102259|
NCT01385527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00016545|Pediatric Atopic Dermatitis (AD) Internet Survey|Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis||Wake Forest School of Medicine|No|Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|40|||Both|2 Years|8 Years|No|||December 2015|December 9, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385527||102239|
NCT01367522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1107|Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function|A Phase 1, Open-Label, Study to Evaluate Single Dose Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Volunteers With Impaired Hepatic Function||Valeant Pharmaceuticals International, Inc.|No|Completed|March 2004|July 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367522||103612|
NCT01367535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 1108|Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan|A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan||Valeant Pharmaceuticals International, Inc.|No|Completed|March 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|54|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367535||103611|
NCT01367821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10040|Immune Function in Patients With Obstructive Jaundice|Quorum Sensing Signal Molecules (QSSMs) and Immune Dysfunction in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) for Obstructive Jaundice||University of Nottingham|No|Recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|Plasma Bile|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients referred to tertiary hepatopancreaticobiliary centre for investigation of        obstructive jaundice and Healthy volunteers|October 2012|October 4, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01367821||103589|
NCT01399762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endostroke_01|International Multicenter Registry for Mechanical Recanalization Procedures in Acute Stroke|International Multicenter Registry for Mechanical Recanalization Procedures in Acute Stroke (ENDOSTROKE)|ENDOSTROKE|Goethe University|Yes|Recruiting|January 2011|||||N/A|Observational|Observational Model: Cohort||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with acute ischemic stroke being treated with mechanical recanalization devices        for proximal vessel occlusion of brain supplying arteries (i.e. MCA main stem occlusion,        basilar artery occlusion, distal ICA occlusion)|July 2011|July 21, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01399762||101150|
NCT01368393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010.404|Electroacupuncture Analgesia for Colonoscopy|Electroacupuncture Analgesia for Colonoscopy: a Prospective, Randomized, Double-blind, Sham-controlled Study||Chinese University of Hong Kong|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368393||103545|
NCT01401023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1481739|Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)|Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)||Michigan State University|Yes|Completed|July 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|June 16, 2011||No||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01401023||101053|
NCT01401296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deprexis|Evaluation of the Effectiveness of a Web-based Treatment Program for Depression for the Reduction of Depressive Symptoms|Evaluation of the Effectiveness of a Web-based Treatment Program for Depression (Deprexis) for the Reduction of Depressive Symptoms. A Randomized Controlled Trial||Universitätsklinikum Hamburg-Eppendorf|No|Completed|May 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||December 2014|December 11, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401296||101032|
NCT01401556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018520|C-STOP Fracture Trial|Comparing Strategies Targeting Osteoporosis to Prevent Recurrent Fractures: C-STOP# Randomized Trial|C-STOP#|University of Alberta|No|Recruiting|September 2012|January 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|360|||Both|50 Years|N/A|No|||July 2015|July 24, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01401556||101012|
NCT01387724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL11B1|Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma|Neuropeptide Y and Its Receptors in Neuroblastoma||Children's Oncology Group|No|Active, not recruiting|June 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|blood and tissue|Both|1 Year|10 Years|No|Non-Probability Sample|Children with newly diagnosed neuroblastoma or ganglioneuroblastoma.|May 2015|May 8, 2015|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387724||102072|
NCT01387984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002053R|YKL-40 and Complications in Type 2 Diabetes|Association Study of the Plasma Concentration of YKL-40 and Vascular Complications in Patients With Type 2 Diabetes||National Taiwan University Hospital|No|Completed|April 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|473|||Both|N/A|N/A|No|Non-Probability Sample|The type 2 diabetic patient who receives follow-up at NTUH diabetics caring network|June 2011|July 5, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387984||102052|
NCT01388803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012143RC|The Depth of Right Bronchial Blocker Placement in Taiwanese in Video-assisted Thoracoscopic Surgery(VATS)|Right Side Bronchial Blocker in Video-assisted Thoracoscopic Surgery||National Taiwan University Hospital|No|Completed|January 2010|December 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|60|||Both|18 Years|77 Years|No|Non-Probability Sample|Patients receiving right side VATS( video-assisted thoracoscopic surgery) with right side        bronchial blocker|July 2011|July 19, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388803||101989|
NCT01388816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRL-17822/CD/004|A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients With Type II Hyperlipidemia||Dr. Reddy's Laboratories Limited|No|Completed|July 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|176|||Both|18 Years|70 Years|No|||March 2014|March 18, 2014|July 5, 2011|No|Yes||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01388816||101988|
NCT01389336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAFA|Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone|Kontrollierte Klinische Nicht-randomisierte Pilotstudie Zur Komplexen Āyurveda-Therapie Beim Fibromyalgiesyndrom im Vergleich Zur Konventionellen Standardbehandlung|KAFA|Charite University, Berlin, Germany|Yes|Completed|July 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|31|||Both|18 Years|70 Years|No|Non-Probability Sample|Men and Women with Fibromyalgia-Syndrome between 18 und 70 years of age|May 2013|May 7, 2013|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389336||101948|
NCT01389349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2322|Acupuncture for Tonsillectomy Pain|Acupuncture for Tonsillectomy Pain||Children's ENT of San Diego, Inc.|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|2 Years|17 Years|No|||May 2012|May 17, 2012|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389349||101947|
NCT01389310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-450|Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe|Post-marketing Safety Surveillance Program in HIV-infected Children Exposed to Atazanavir in Europe||Bristol-Myers Squibb|No|Completed|July 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|249|||Both|N/A|17 Years|No|Non-Probability Sample|Primary care clinic|December 2014|December 22, 2014|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389310||101950|
NCT01389323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-038|BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C|Open-Label, Single Arm Evaluation of BMS-790052 (Daclatasvir) in Combination With Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos and White-Caucasians With Chronic Hepatitis C Genotype 1 Infection||Bristol-Myers Squibb|No|Completed|September 2011|January 2014|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|448|||Both|18 Years|N/A|No|||September 2015|September 19, 2015|July 6, 2011|Yes|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01389323||101949|
NCT01389297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRWebCourseRCT|Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery|Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery||Behavior Therapy Associates, LLP|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|189|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389297||101951|
NCT01385904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-137|Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain|Plasma Concentrations of Ketamine and Norketamine in Patients Using Topical Application of 10% Ketamine for Neuropathic Pain.||Lawson Health Research Institute|No|Recruiting|June 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|80 Years|No|Probability Sample|Patients attending the St Josephs Hospital pain clinic with chronic neuropathic pain.|June 2011|June 29, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385904||102210|
NCT01385540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106289|Exploration of Cortical Neural Network in Patients With Bothersome Tinnitus|Exploration of Cortical Neural Network in Patients With Bothersome Tinnitus||Washington University School of Medicine|No|Terminated|July 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|7|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Target population will consist of 12 adult participants - 6 with moderately, severely or        worse, bothersome tinnitus, based on both a global bothersome score (i.e. How bothered are        you by your tinnitus?) and the Tinnitus Handicap Index (THI). THI is a 25-question survey        designed to assess how much tinnitus affects a person-possible scores range from 0-100,        with a score 38 falling in the 75th percentile. The other six participants (Control group)        will be age-matched without tinnitus.|February 2012|February 29, 2012|June 28, 2011||No|Study tasks to difficult for subjects to complete.|No||https://clinicaltrials.gov/show/NCT01385540||102238|
NCT01399021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01434|Timing of Postoperative Drain Removal Following Parotidectomy - a Prospective Randomized Controlled Study|Timing of Postoperative Drain Removal Following Parotidectomy and Its Effects on Hematoma and Infection Rate and Length of Hospital Stay- a Prospective Randomized Controlled Study||University of British Columbia|No|Not yet recruiting|July 2011|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||July 2011|July 20, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399021||101207|
NCT01399294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Constipation/TCM2010|Cross Sectional Study of Constipation in Advanced Cancer Patients|Traditional Chinese Medicine Syndrome Distribution of Advanced Cancer Patients With Constipation||Yan Chai Hospital|Yes|Completed|May 2010|February 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|255|||Both|18 Years|N/A|No|Non-Probability Sample|Advanced cancer patients (aged 18 or above) under the care of palliative care units who        are on laxatives and who have constipation during recruitment.|July 2011|July 19, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01399294||101186|
NCT01399749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLPTRA-2009-01|Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects|A Comparative Clinical Trial for the Repair of Chondral Knee Defects: Transplantation of Autologous Cultured Chondrocytes vs. Autologous Mesenchymal Stem Cells Derived From Adipose Tissue|ASCROD|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|No|Not yet recruiting|September 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||July 2011|July 21, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399749||101151|
NCT01400308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-G-H-0903|Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA)|Clinical Trial to Compare the Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by MRSA (Methicillin Resistant Staphylococcus Aureus)||B. Braun Medical SA|No|Terminated|February 2010|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|July 19, 2011||No|The differences seen between treatments led to recalculation of the sample, unattainable in a    reasonable time|No||https://clinicaltrials.gov/show/NCT01400308||101108|
NCT01400321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAST|PEERS Multicenter Osseospeed TM TX Profile Implant: German Astra Soft Tissue (GAST) Maintenance Study|PEERS Multicenter OsseoSpeedTM TX Profile Implant: German Astra Soft Tissue (GAST) Maintenance Study An Open, Prospective Observational Study to Evaluate Implant Stability, Marginal Bone and Soft Tissue Maintenance of the Astra Tech Dental Implant System: OsseoSpeedTM TX Profile Implant in Patients With Tooth Loss in the Aesthetic Zone or the Posterior Atrophied Mandible|GAST|Johannes Gutenberg University Mainz|No|Recruiting|July 2011|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with tooth loss in the aesthetic zone or in the distal mandible with socket like        atrophy. The antagonists should be natural teeth or a fixed prosthesis.|November 2012|November 15, 2012|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01400321||101107|
NCT01400555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018712|A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|mCRPC|Cougar Biotechnology, Inc.|Yes|Active, not recruiting|September 2011|December 2016|Anticipated|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|22|||Male|18 Years|N/A|No|||January 2016|January 6, 2016|July 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01400555||101089|
NCT01400763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYEPOWDER|Lutein Bioavailability From Fresh and Dried Beverages|Bioavailability of Lutein From a Lutein-enriched Egg-yolk-beverage and Its Dried Re-suspended Versions.|METC-11/07|Wageningen University|Yes|Completed|May 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|1||Actual|103|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2011|July 21, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400763||101073|
NCT01401036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110629|Nobori And Uncoated Stent In Coronary Attack|Clinical Trial of Nobori Versus Uncoated Stents In Acute Myocardial Infarction||NAUSICA Investigators|Yes|Recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|20 Years|N/A|No|||November 2014|November 27, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401036||101052|
NCT01401309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRMC 10-07|PET Respiratory Gating to Detect Hepatic Metastasis in Patients With Colon Cancer|Effects of Respiratory Gating on FDG/PET Detection of Hepatic Metastasis in Patients With Colon Cancer||Southwestern Regional Medical Center|Yes|Completed|January 2011|March 2013|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|81|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colon cancer|February 2014|February 20, 2014|January 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01401309||101031|
NCT01387997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201005076R|e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses|Nano-mechanical and Nano-electrosensing Devices Based Interaction Force and Interaction Kinetics Analysis of Oncogenic Human Papilloma Viruses||National Taiwan University Hospital|No|Recruiting|June 2010|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|72|||Female|N/A|N/A|No|||November 2012|November 19, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387997||102051|
NCT01388010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU325|Study of the Effect of a Fermented Dairy Product on Gastrointestinal Well Being in Adult Women|"Effect of the Consumption of a Fermented Dairy Product on Gastrointestinal Well-being in a Healthy Population of Women With Minor Digestive Symptoms"||Danone Research|No|Completed|September 2009|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2|||380|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01388010||102050|
NCT01388270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3019-2|Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis|The Effect of a Heparin-coated Dialysis Filter (Evodial) on Clotting and Intravascular Coagulation During Hemodialysis (HD) When Compared to a Conventional Polyflux Filter (170H)||Oslo University Hospital|No|Completed|September 2011|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|90 Years|No|||February 2016|February 3, 2016|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01388270||102030|
NCT01389063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MASTER2010|Maraviroc Abacavir STudy - Effect on Endothelial Recovery|Maraviroc Abacavir STudy - Effect on Endothelial Recovery|MASTER|UMC Utrecht|No|Recruiting|January 2012|October 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389063||101969|
NCT01385345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM61G0293|Vitamin D Replacement in Insulin Resistant South Asians|Can Vitamin D Replacement Reduce Insulin Resistance In South Asians With Vitamin D Deficiency?|VITALITY|University of Leicester|Yes|Terminated|August 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|3|||Both|25 Years|75 Years|No|||January 2013|June 9, 2015|June 14, 2011||No|Recommended by DMEC. Poor recruitment, changes in current clinical management of Vit D    deficiency. Research question no longer relevant|No||https://clinicaltrials.gov/show/NCT01385345||102252|
NCT01385319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEUS-10-II|Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study|Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study|ZEUS|Università degli Studi di Ferrara|Yes|Active, not recruiting|June 2011|December 2017|Anticipated|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1606|||Both|18 Years|N/A|No|||October 2012|October 6, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01385319||102254|
NCT01385332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UREP-ONCO-2010|A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors|A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors||Parc de Salut Mar|No|Completed|March 2010|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01385332||102253|
NCT01385293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027410|BKM120 in Metastatic Castration-resistant Prostate Cancer|Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer||Duke University|No|Active, not recruiting|August 2011|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Male|18 Years|N/A|No|||November 2015|November 18, 2015|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385293||102256|
NCT01385306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-SA-01|Noninvasive Neurostimulation of the Vagus Nerve for the Relief of Acute Bronchoconstriction Due to Asthma|Noninvasive Neurostimulation of the Vagus Nerve With the AlphaCore System for the Relief of Acute Bronchoconstriction Due to Asthma|BC-SA-01|ElectroCore LLC|Yes|Terminated|June 2011|July 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|6|||Both|18 Years|70 Years|No|||February 2016|February 17, 2016|June 17, 2011||No|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01385306||102255|
NCT01386203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8663-NP-CTIL|Exhaled Breath Biomarkers in Lung Cancer|Early Detection of Lung Cancer - Exhaled Breath Nano-Analysis||Sheba Medical Center|No|Recruiting|June 2011|May 2018|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|Samples Without DNA|exhaled breath and CTC and biomarkers|Both|18 Years|95 Years|No|Non-Probability Sample|Lung cancer patients vs. post therapy vs. COPD controls|February 2012|February 28, 2012|May 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01386203||102187|
NCT01399320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MansouraU|Ghnnam Excision Technique for Pilonidal Sinus|Ghnnam Excision Technique for Pilonidal Sinus||Mansoura University|No|Completed|August 2008|June 2010|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|N/A|No|||August 2008|July 20, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399320||101184|
NCT01399541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59081001|Recovery and Rehabilitation After Lung Cancer Surgery|Recovery and Rehabilitation After Lung Cancer Surgery||Oslo University Hospital|No|Recruiting|October 2010|April 2013|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Eligible patients are lung cancer patients above the age of 18 that have been treated with        surgery, who are able to speak and understand Norwegian, and who suffer no cognitive        impairment. The patients in the study must give written informed consent to participation        in the study. It is estimated that we need 300 patients.|May 2011|July 20, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01399541||101167|
NCT01400035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMS2010C|Chinese Assessment for Vinpocetine In Neurology|The Investigation of Vinpocetine (Cavinton) for Treatment of Acute Cerebral Infarction, an Open, Multicenter, Randomized, Control Study|CAVIN|Shanghai Rxmidas Pharmaceuticals Co. Ltd.|Yes|Completed|May 2010|May 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|610|||Both|40 Years|80 Years|No|Probability Sample|Totally 610 subjects were recruited, 469 in test group and 141 in control group.|August 2013|August 14, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01400035||101129|
NCT01400048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aloe Vera AVH200|Aloe Vera in Irritable Bowel Syndrome|Aloe Vera Versus Placebo for Patients With Irritable Bowel Syndrome||Sahlgrenska University Hospital, Sweden|No|Recruiting|January 2010|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01400048||101128|
NCT01400542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002050|Sleep Apnea in Early to Mid-Stage Alzheimer's Disease|Sleep Apnea in Early to Mid-Stage Alzheimer's Disease: What Impact of Treatment on the Cognitive Functions of Elderly Patients With Memory Loss?|AZAP|Centre Hospitalier Universitaire de Saint Etienne|No|Recruiting|December 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|65 Years|N/A|No|Non-Probability Sample|Elderly patients with a early or mid-Stage Alzheimer's disease with or without SAOS.|February 2016|February 19, 2016|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400542||101090|
NCT01400568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06 LOPS|Suitability of a Low Dose Lipopolysaccharide (LPS) Inhalation as a Challenge Model|A Methodological Pilot Study to Assess the Suitability of a Low Dose LPS Inhalation as a Challenge Model in Early Translational Drug Development||Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01400568||101088|
NCT01400776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-04409.3|Safety & Efficacy WC3011 in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women|A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of WC3011 in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women|VENUS|Warner Chilcott|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|722|||Female|35 Years|N/A|No|||February 2015|February 24, 2015|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400776||101072|
NCT01400789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Listro Mix50/50/PK-PD/FDA/2011|Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects|||Wockhardt|No|Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|July 20, 2011|Yes|Yes|Study was not initiated|No||https://clinicaltrials.gov/show/NCT01400789||101071|
NCT01401049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09-0742|Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol|Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol||New York University School of Medicine|No|Completed|August 2010|January 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|65 Years|No|||March 2015|March 30, 2015|June 17, 2011||No||No|December 22, 2014|https://clinicaltrials.gov/show/NCT01401049||101051|
NCT01401335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12082010-7279|HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth|A PILOT STUDY Integrating HIV Prevention and Care With Treatment of Psychological Trauma in Vulnerable Rwandan Youth: A Community-based Pilot Intervention||Stanford University|No|Completed|October 2009|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|15 Years|25 Years|No|||July 2011|July 21, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01401335||101029|
NCT01388036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397-27.05.05|Genetic Determinants of Hemodynamic Response to Esmolol|A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol||Hadassah Medical Organization|No|Recruiting|July 2011|||May 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01388036||102048|
NCT01388283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INMARPE11|Inflammatory Markers in Pregnant Women Destined to Develop Preeclampsia|||Oslo University Hospital|No|Completed|January 1999|June 2011|Actual|May 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|129|Samples Without DNA|serum|Female|20 Years|43 Years|Accepts Healthy Volunteers|Non-Probability Sample|Case-control study consisting of 43 women developping preeclampsia and 86 women not        developping this disorder. All were of Caucasian origin and were nulliparous.|June 2011|July 5, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01388283||102029|
NCT01388517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-CALTAC|Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba|A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba||Universidad Autonoma de San Luis Potosí|No|Completed|January 2008|January 2011|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|39|||Both|2 Years|18 Years|No|||September 2012|September 25, 2012|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01388517||102011|
NCT01389362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.581|The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes|The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes: A Randomized, Placebo-Controlled Study||Chinese University of Hong Kong|Yes|Completed|May 2009|May 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|75 Years|No|||July 2011|July 27, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389362||101946|
NCT01385358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CI004B|Catheter Versus Thoracoscopic Surgical Ablation Strategy in Persistent Atrial Fibrillation|A Study to Assess Catheter Ablation Versus Thoracoscopically Assisted Surgical Ablation in Persistent Atrial Fibrillation|CASA-AF|Royal Brompton & Harefield NHS Foundation Trust|No|Enrolling by invitation|April 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 29, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385358||102251|
NCT01385605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Toxins FF 2015|Analysis of Toxins in Follicle Fluid|Analysis of Toxins in Follicle Fluid From Women With Unfulfilled Pregnancy||Infertility Treatment Center Dortmund|No|Recruiting|August 2015|February 2017|Anticipated|December 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|250|Samples Without DNA|follicular fluid|Female|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|female patients seeking ICSI treatment because of male subfertiliy|August 2015|August 28, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385605||102233|
NCT01385618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-ERP2010|Gene-polymorphisms Relating to Human Subfertility|Analysis of Gene-polymorphisms Relating to Human Subfertility: Estradiol-receptor-polymorphism and Progesterone-receptor-polymorphism||Infertility Treatment Center Dortmund|No|Completed|October 2010|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control||3|Actual|150|Samples With DNA|buccal swabs|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Female patients at reproductive age seeking IVF treatment|March 2015|March 24, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385618||102232|
NCT01385579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00015652|Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population|A Randomized Controlled Trial of a Direct-to-Patient Outreach Program to Improve Rates of Colorectal Cancer Screening in a Low Income and Racially Diverse Population||Northwestern University|No|Completed|January 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|202|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 18, 2013|June 28, 2011||No||No|November 18, 2013|https://clinicaltrials.gov/show/NCT01385579||102235|Single site study
NCT01385592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2222|Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease||Novartis||Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|30 Years|80 Years|No|||December 2012|December 6, 2012|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385592||102234|
NCT01386216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART 10-001|Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)|Phase I, Non-Randomized, Feasibility Study for the Use of Bone Marrow Cell Concentrate Prepared Using the Magellan System for the Treatment of Critical Limb Ischemia|CLI|Arteriocyte, Inc.|Yes|Active, not recruiting|April 2011|June 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||March 2016|March 7, 2016|June 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01386216||102186|
NCT01386229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA-10-114|A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery|||Baskent University|No|Recruiting|March 2011|March 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|80 Years|No|||June 2011|June 30, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01386229||102185|
NCT01385267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08074|Fetal Lung Maturation in Twin Gestations|Fetal Lung Maturation in Twin Gestations Based on Birth Order and Weight Discordance||TriHealth Inc.|Yes|Completed|June 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|A sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each      amniotic sac will be aspirated by the obstetrician and sent to the laboratory for      determination of fetal lung maturity index and lamellar body count. Fetal lung maturity      index and lamellar body count will be correlated to see if there is an association between      Twin A and Twin B.      Fetal Lung Maturity index and lamellar body count will be calculated and compared based on      fetal weight, sex, zigosity, and birth order. Demographic information, maternal obstetrical      and medical history, newborn/fetal data, indications for cesarean section and twin A and B      outcomes will be obtained through OB Traceview or patient chart.|Female|18 Years|N/A|No|Non-Probability Sample|Participants will include pregnant patients, greater than 24 completed weeks with        diamniotic twin gestations, at Good Samaritan and Bethesda North Hospitals. Patients will        be scheduled for a cesarean section by their primary MD prior to being approached for        inclusion into the study.|February 2014|February 17, 2014|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385267||102258|
NCT01385280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0906-04|Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer|A Pilot Study Of Estradiol Followed By Exemestane For Post-Menopausal Hormone Receptor Positive Metastatic Breast Cancer After Prior Failed Endocrine Therapy: Reversing Endocrine Resistance||University of Arizona|Yes|Completed|February 2011|October 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|N/A|N/A|No|||December 2015|December 2, 2015|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385280||102257|
NCT01399775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87703|Evaluation of Ridge Dimensional Changes After Immediate Implantation and Efficacy of This Procedure|Evaluation of Implant Stability and Dimensional Changes in Alveolar Ridge Following Immediate Implantation||Mashhad University of Medical Sciences|Yes|Completed|May 2010|February 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01399775||101149|
NCT01399788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3801002|A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults|An Open Label, Single Dose, 2-Way Cross-Over Randomized Bioequivalence Study Comparing a Fixed Dose Combination Formulation, Myrin®-p Forte, (Contains 150 Mg Rifampicin, 75 Mg Isoniazid, 275 Mg Ethambutol and 400 Mg Pyrazinamide Per Tablet) to an Equivalent Dose of Single Drug Reference Preparations of Rifampicin, Isoniazid, Ethambutol and Pyrazinamide Following Oral Administration in Healthy Adults Under Fasting Conditions||Pfizer|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|July 13, 2011||No||No|February 22, 2012|https://clinicaltrials.gov/show/NCT01399788||101148|
NCT01400061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bor1|Relation of Blood-boron Levels With Body Mass Index|Phase 1 Study of Blood Boron Levels According to Body Mas Index||SB Istanbul Education and Research Hospital|No|Not yet recruiting|August 2011|December 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|80|Samples Without DNA|blood serum analyses|Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Normal: 19-24 Overweight: 25-29 Obes: 30-40 Morbid Obes: >40|July 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400061||101127|
NCT01400074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AKR01T|Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib|A Phase III Multi-center, Open-label, Randomized Study of the Efficacy of Nilotinib Versus Imatinib in Adult Patients With Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib|RE-NICE|Seoul St. Mary's Hospital|Yes|Recruiting|January 2009|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400074||101126|
NCT01400334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL76252|Prediction of ARrhythmic Events With Positron Emission Tomography|Hibernating Myocardium and Sudden Cardiac Death|PAREPET|State University of New York at Buffalo|Yes|Completed|July 2004|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|257|Samples Without DNA|serum and plasma|Both|18 Years|N/A|No|Non-Probability Sample|Residents of Western New York referred for an implantable cardiac defibrillator,        transthoracic echocardiography, and/or coronary angiography|December 2015|December 8, 2015|July 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01400334||101106|
NCT01400815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-22-201|Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid|A Prospective, Double-blind, Randomized, Active Controlled, Parallel Group, Multicenter Phase II Clinical Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid||22nd Century Limited, LLC|No|Active, not recruiting|July 2011|January 2012|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|65 Years|No|||October 2011|October 25, 2011|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400815||101069|
NCT01401062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S11-00533|Fresolimumab and Radiotherapy in Metastatic Breast Cancer|Fresolimumab and Radiotherapy in Metastatic Breast Cancer||New York University School of Medicine|Yes|Active, not recruiting|July 2011|March 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401062||101050|
NCT01401075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-AVQ20-1.0|RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients|Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation||Abnoba Gmbh|No|Completed|March 2006|April 2008|Actual|April 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|32|||Both|19 Years|70 Years|No|||July 2011|November 6, 2012|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401075||101049|
NCT01401608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-CLIN-015|Stereotaxis Idiopathic Ventricular Tachycardia (VT) Study|RF Ablation of Idiopathic VT and PVCs Using Remote Magnetic Navigation||Stereotaxis|No|Terminated|March 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients will be diagnosed with any ventricular tachycardia or symptomatic PVCs of        non-ischemic origin.|May 2015|May 18, 2015|July 20, 2011|Yes|Yes|Difficult to recruit eligible subjects|No||https://clinicaltrials.gov/show/NCT01401608||101008|
NCT01401868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-143-001|Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors|Phase I Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors||MEI Pharma, Inc.|Yes|Completed|September 2011|January 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|July 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01401868||100989|
NCT01402141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SunChang-TCKJ-001|A Human Trial to Evaluate the Effects of Chungkookjang on Histamine-induced Wheal Size in Healthy Subjects|Efficacy and Safety of Chungkookjang, a Fermented Soy Paste, on Histamine-induced Wheal Size||Chonbuk National University Hospital|Yes|Completed|October 2010|September 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|July 21, 2011||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT01402141||100968|
NCT01402154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2010/SD-01|EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients|The Pre-treatment Detection of Circulating, Functional, Prostate Cells Among Adenocarcinoma Patients: an Evaluation of the EPISPOT Technique||Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|January 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|361|Samples Without DNA|Following the completion of the biological analyses required for this study, leftover tubes      may be placed in the Nîmes University Hospital biological collection for future ancillary      studies, if patients are agreed with this. The samples concerned include EDTA and CellSave      tubes for each patient.|Male|18 Years|N/A|No|Non-Probability Sample|Patients with histologically proven, localized, adenocarcinoma of the prostate who accept        a curative treatment.|November 2015|November 5, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402154||100967|
NCT01402479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0408-131-005|An Open-labeled Trial of Ramipril in Patients With Migraine|An Open-labeled Trial of Ramipril in Patients With Migraine||Seoul National University Hospital|No|Completed|October 2004|July 2005|Actual|July 2005|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|70 Years||||July 2011|August 5, 2011|July 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01402479||100942|
NCT01388530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA-TNS/ADHD|Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)|An Eight-Week, Open Trial Pilot Investigation of Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)||University of California, Los Angeles|No|Recruiting|July 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|9 Years|14 Years|No|||October 2012|October 18, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01388530||102010|
NCT01388543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0428|Genetics and HIV-1 Protease Inhibitors|Genetic-determinants of Protease Inhibitor Pharmacology||University of Colorado, Denver|Yes|Completed|September 2006|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01388543||102009|
NCT01388829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611015|Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532|A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of 2 Different Formulations Of PF-04991532||Pfizer||Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 9, 2011|July 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01388829||101987|
NCT01389375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE No. PCD00111|Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial|Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial|ISAR-CLOSURE|Deutsches Herzzentrum Muenchen|No|Active, not recruiting|July 2011|July 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4524|||Both|18 Years|85 Years|No|||May 2014|May 15, 2014|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389375||101945|
NCT01389388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2219|Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease|Cholesterol Plaques in Carotid and Coronary Arteries and the Effect of Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases|RORAAS|Diakonhjemmet Hospital|No|Completed|January 2013|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|114|||Both|35 Years|80 Years|No|||May 2015|May 6, 2015|April 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389388||101944|
NCT01396096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00634|Comparison of Obesity Alleles Among Diverse Demographic Patients|Comparison of Obesity Alleles Among Diverse Demographic Patient Populations Undergoing Bariatric Surgery||New York University School of Medicine|No|Recruiting|June 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2500|Samples With DNA|DNA will be extracted from 0.35ml of EDTA-anticoagulated whole blood using the Qiagen      MagAttract DNA Blood Midi M48 Kit and Qiagen BioRobot M48 Workstation (Qiagen, Valencia,      California) according to the manufacturer's directions.|Both|N/A|N/A|No|Non-Probability Sample|NYUMC/Bellevue: All patients seen in the Bariatric Surgery Program at Bellevue NYU Langone        Weight Management Program: All patients who are at least post-op 2 years|March 2016|March 3, 2016|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01396096||101431|
NCT01385631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUH-OCTIVUS|Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.|The Effect Of Ezetimibe In Addition To Optimal Cholesterol-Lowering Statin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction - Assessed By Optical Coherence Tomography And Intravascular Ultrasound.|OCTIVUS|Odense University Hospital|Yes|Completed|June 2011|September 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|87|||Both|18 Years|81 Years|No|||September 2014|September 1, 2014|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385631||102231|
NCT01385917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHN007.10|Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping|Study of Clinical and Radiological Changes in Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping|pre U7-53|Genethon|No|Recruiting|October 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|None Retained|Total blood count with differential leukocyte count Assay of immunoglobulins and the various      sub-classes (IgG, IgM, IgA, IgE) Test for immunisation against all AAV serotypes Serum urea,      creatinine, AST/ALT , GammaGT, bilirubin, CK, alkalin phosphatase|Male|6 Years|20 Years|No|Non-Probability Sample|Patients with theoretically exon 53 skipping-treatable DMD|September 2013|September 30, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385917||102209|
NCT01385930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Halm30118|Dietary Advice on Prescription in Kungsbacka|A New Concept for Lifestyle Change, Dietary Advice on Prescription (DAP) in Combination With Motivational Interviewing (MI), Social Support and Mobile Services|DAP_K|Halmstad University|No|Recruiting|March 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2011|July 1, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385930||102208|
NCT01397487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/0416|Effects of Day 3 Blastomere Biopsy on Human Embryos|Effects of the Blastomere Biopsy of Day 3 Human Embryos on Blastocyst Percentage, Cell Number of Obtained Blastocyst and Implantation Rate|BB|Fundacion Para La Investigacion Hospital La Fe|Yes|Recruiting|July 2011|September 2013|Anticipated|January 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|22|||Female|18 Years|35 Years|No|||July 2011|July 27, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397487||101324|
NCT01398020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00688|Comparing 2L Bi-Pegyte to 4L PegLyte Regiments for Outpatient Colonic Preparation|Oral 2L Bi-PegLyte Versus 4L PegLyte Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial||University of British Columbia||Completed|July 2011|September 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|318|||Both|19 Years|N/A|No|||September 2013|September 17, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01398020||101283|
NCT01385891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM001|Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children|Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients|CLOVE|Istituto Giannina Gaslini|Yes|Completed|August 2008|February 2010|Actual|December 2009|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|1 Month|20 Years|No|||July 2008|July 6, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01385891||102211|
NCT01399567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR009100|Nursing Home Pain Management Algorithm Clinical Trial|Nursing Home Pain Management Algorithm Clinical Trial||Swedish Medical Center|Yes|Completed|September 2006|January 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|396|||Both|65 Years|N/A|No|||July 2011|July 21, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01399567||101165|
NCT01399801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R09-284IL|Optimizing Left Ventricular Lead To Improve Cardiac Output|Optimizing the Left Ventricular Contractility in Cardiac Resynchronization Therapy Using a Doppler Wire|CARE/VOLCANO|Main Line Health|Yes|Recruiting|December 2010|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||July 2012|July 17, 2012|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399801||101147|
NCT01400087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPSTUDY|Cap-attached Colonoscopy Versus Regular Colonoscopy for Trainees|||Showa University|No|Recruiting|June 2011|||November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|500|||Both|18 Years|N/A|No|||June 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400087||101125|
NCT01400581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA018702|Considering Healthier Drinking Options in Collaborative Care|Collaborative Care for Primary Care Patients With Alcohol Use Disorders|CHOICE|Group Health Cooperative|Yes|Completed|November 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01400581||101087|
NCT01400802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Listro Mix75/25/PK-PD/FDA/2011|Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects|||Wockhardt|No|Withdrawn|November 2011|June 2012|Anticipated|May 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|July 20, 2011|Yes|Yes|Study was not initiated|No||https://clinicaltrials.gov/show/NCT01400802||101070|
NCT01402167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/PK-04|Evaluating Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures|Evaluating Transcutaneous Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures: a Randomized Pilot Study Using Catscan Volumetry||Centre Hospitalier Universitaire de Nīmes|No|Withdrawn|September 2014|August 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||March 2015|March 24, 2015|July 25, 2011||No|Patients refuse randomization.|No||https://clinicaltrials.gov/show/NCT01402167||100966|
NCT01402726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAN-HF|Renal Sympathetic Modification in Patients With Heart Failure|Renal Sympathetic Modification in Patients With Heart Failure||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|July 2011|April 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||May 2013|May 2, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402726||100923|
NCT01399112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDSS|A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis|A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis||Northwell Health|No|Completed|May 2010|March 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|11|||Both|15 Years|30 Years|No|||December 2012|December 31, 2012|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01399112||101200|
NCT01388842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/MBA/2011/NO|Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children|Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide (iNO) as Adjunctive Treatment for Cerebral Malaria in Children: A Randomized Open Label Phase II Clinical Trial||Epicentre|Yes|Completed|September 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|2 Months|12 Years|No|||February 2016|February 29, 2016|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01388842||101986|
NCT01389076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2010.098|Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma|Phase II Trial of Low-Dose Methotrexate and Iodine I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma||University of Michigan Cancer Center|Yes|Suspended|July 2011|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|July 5, 2011|Yes|Yes|Bexxar isn't being produced by the manufacturer as of Feb. 2014|No||https://clinicaltrials.gov/show/NCT01389076||101968|
NCT01395771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSCDC2011HIV/AIDS|Effects of a Phone Call Intervention to Promote HAART Adherence|Effects of a Phone Call Intervention to Promote HAART Adherence in Baoshan, China|EPCIPHA|Baoshan Prefecture Center for Disease Control and Prevention|No|Recruiting|May 2011|October 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2011|July 15, 2011|June 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01395771||101455|
NCT01396356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12164|Atrial Fibrillation Ablation on Gastric Motility "The AF Gut Study"|Impact of Atrial Fibrillation Ablation on Gastric Motility "The AF Gut Study"||University of Kansas Medical Center|No|Completed|August 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|If you agree to participate in the study, you will undergo a series of tests about a week        before the expected ablation procedure. The same tests will be repeated 24-48 hours after        the ablation. These tests include esophageal manometry, gastric emptying scan, sham        feeding test and completing a symptoms questionnaire.|January 2013|January 8, 2013|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01396356||101411|
NCT01385943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/4714|VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine|VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine|EUNET|Lucid, Inc.|No|Active, not recruiting|April 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples Without DNA|Cutaneous tissue specimens in the form of histopathology slides and tissue blocks, clinical      pictures, dermoscopic pictures and confocal microscopy images|Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients from private dermatology clinics and university dermatology practices throughout        Europe that have a skin lesion suspicious for malignancy under clinical non-aided        examination.|September 2013|September 27, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385943||102207|
NCT01386190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL110163-01A1|Impact of Exercise on Body Composition in Premature Infants|Impact of Exercise on Body Composition in Premature Infants: New Approaches||University of California, Irvine|Yes|Recruiting|June 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|29 Weeks|34 Weeks|No|||July 2011|July 1, 2011|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01386190||102188|
NCT01399580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-830|A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy|A Phase 2b, Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy||AbbVie|No|Completed|August 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399580||101164|
NCT01399593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-001|Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization|A Randomized, Open-label, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Living Donor Kidney Transplant Recipients Requiring Desensitization Therapy||Alexion Pharmaceuticals|Yes|Active, not recruiting|September 2011|April 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399593||101163|
NCT01400828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCD159|Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis|Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With Seasonal Allergic Rhinitis||Yuhan Corporation|No|Completed|June 2011|May 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|239|||Both|12 Years|70 Years|No|||July 2014|July 8, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01400828||101068|
NCT01401088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PN1011049|Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma|Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma|AADI|Aurolab|No|Recruiting|July 2011|December 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401088||101048|
NCT01401101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH082768|Violence and Stress Assessment (ViStA) Project to Improve Post Traumatic Stress Disorder Management in Primary Care|Improving PTSD Management in Primary Care|ViStA|RAND|No|Active, not recruiting|June 2010|March 2015|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|August 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01401101||101047|
NCT01402180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010ESO_FU|Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy|A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence|Nimotuzumab|Fudan University|Yes|Recruiting|December 2010|December 2015|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|75 Years|No|||November 2010|July 25, 2011|July 25, 2011||||No||https://clinicaltrials.gov/show/NCT01402180||100965|
NCT01367366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201004018R|Dx Mediastinal Malignant LAP:Compare PET and EBUS-TBNA|Dx Mediastinal Malignant LAP:Compare PET and EBUS-TBNA||National Taiwan University Hospital|No|Recruiting|May 2010|||April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Suspected malignant mediastinal lymphadenopathy|May 2011|June 6, 2011|May 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01367366||103624|
NCT01401348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12142010-7318|Stanford Universities: The Stanford HIV Aging Cohort|The Stanford HIV Aging Cohort (SHAC)||Stanford University|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|PBMC's|Both|18 Years|N/A|No|Non-Probability Sample|300 HIV-infected participants whose virus is controlled on antiretroviral medications from        the Stanford Positive Care Clinic. Five (150) patients over 50 years old and five (150)        patients less than 50 years old|July 2015|July 15, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01401348||101028|
NCT01401621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813606-1|The Effect of a Scratch Off Prompt on Health Engagement|The Effect of a Scratch Off Prompt on Health Engagement||University of Pennsylvania|No|Completed|July 2014|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|84953|||Both|18 Years|N/A|No|||September 2015|October 8, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401621||101007|
NCT01371305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203PF201|STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Biogen|Yes|Recruiting|June 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|84 Years|No|||October 2015|October 23, 2015|June 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371305||103321|
NCT01367353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902010R|Characterization of Ovarian Cancer Stem Cell|Characterization of Ovarian Cancer Stem Cell: Focus on Identification of Biomarker and Drug Resistance||National Taiwan University Hospital|No|Recruiting|January 2010|December 2013|Anticipated|December 2011|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|250|||Female|15 Years|80 Years|No|||May 2011|June 6, 2011|December 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01367353||103625|
NCT01367691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206/10|Cardiac MR (CMR) in Cardiac Resynchronization Therapy Non-responders|Cardiac MR (CMR) in Cardiac Resynchronization Therapy (CRT) Non-responders: Therapy Optimization by Means of Tissue Characterization, Hemodynamic Analysis and Analysis of Myocardial Activation||University Hospital, Bonn|No|Terminated|June 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01367691||103599|
NCT01367704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11060186|Evaluation Of "Coaching Boys Into Men" (CBIM) Program|A Randomized Controlled Trial of an Adolescent Relationship Abuse Prevention Program Entitled "Coaching Boys Into Men"|CBIM|University of Pittsburgh|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2006|||Male|14 Years|18 Years|No|||July 2014|July 16, 2014|June 1, 2011||No||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01367704||103598|
NCT01367964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-14518|Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)|Early Treatment of Infants at High Risk of Developing West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)|PREVENT-WS|Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|July 2011|||June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|28|||Both|2 Months|12 Months|No|||February 2015|February 3, 2015|June 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01367964||103578|
NCT01368237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210/R/CAR/11|Dynamic Myocardial Perfusion Imaging by 320 Multidetector Computed Tomography|Dynamic Myocardial Perfusion Imaging by 320 Multidetector Computed Tomography||University of Edinburgh|No|Completed|May 2006|||June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients awaiting invasive coronary angiography|October 2014|October 27, 2014|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368237||103557|
NCT01368523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107APL01|Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial|An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial||Novartis||Completed|December 2008|||January 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2011|September 20, 2011|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368523||103535|
NCT01388855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-028|Pilot Study of Vitamin D Supplementation in Heart Failure|A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin D in Heart Failure: A Pilot Study||Fraser Health|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|65 Years|N/A|No|||June 2015|June 18, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01388855||101985|
NCT01389089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|616|Effective Treatment of Posttraumatic and Postoperative Edema|Effective Treatment of Posttraumatic and Postoperative Edema in Patients With Ankle- and Hindfoot Fractures. A Randomized Controlled Trial Comparing Multi-layer Compression Therapy and A-V Impulse Compression to the Standard Treatment With Ice||Luzerner Kantonsspital|Yes|Completed|January 2007|January 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|65 Years|No|||July 2011|July 6, 2011|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389089||101967|
NCT01396642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1258-CHS/ERC-09|Topical Emollient Therapy|Effect of Topical Emollient Therapy on Clinical Outcomes in Preterm Neonates - A Clinical Trial||Aga Khan University|Yes|Completed|July 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|258|||Both|N/A|72 Hours|No|||April 2015|April 5, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01396642||101389|
NCT01396655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-PET-2010-0022299|PET in Breast Cancer Receiving Neoadjuvant Chemotherapy|Analysis of Clinical Outcome, Predictive and Prognostic Factors of Therapeutic Responses in Patients Who Treated With Doxorubicin & Docetaxel Neoadjuvant Chemotherapy in Clinical Stage II or III Breast Cancer|DA-PET|Seoul National University Hospital||Completed|July 2006|June 2011|Actual|September 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Female|20 Years|70 Years|No|||July 2011|July 15, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01396655||101388|
NCT01396967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV-0065-10|Trying a New Device for Performing Capsulorhexis in Cataract Surgery Surgery|The Efficiency of a New Device for Performing Capsulorhexis in Cataract Surgery||Ziv Hospital|Yes|Enrolling by invitation|July 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01396967||101364|
NCT01396954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREED-ENDO|Cirrhosis-Diabetes|Prevalence and Clinical Characteristics of the Patients With Liver Cirrhosis and Different Glucose Metabolism Disorders - A Prospective Study.|CH-DM|Hospital Universitario Dr. Jose E. Gonzalez|No|Active, not recruiting|November 2007|August 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Probability Sample|We prospectively included patients with compensated liver cirrhosis who were admitted in        the Regional Center for the Study of Digestive Diseases and the Liver Unit of the        University Hospital and Faculty of Medicine|November 2007|July 18, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396954||101365|
NCT01397240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_ABS002P|The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients|The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients Taking Low-dose Aspirin, A Pilot Study|AL-PA|Daewoong Pharmaceutical Co. LTD.|Yes|Recruiting|July 2011|June 2013|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|20 Years|80 Years|No|||July 2011|January 8, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397240||101343|
NCT01397721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD6395|Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary|Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)|MESA-COPD|Columbia University|Yes|Active, not recruiting|May 2009|July 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|360|Samples With DNA|Blood will be stored at Columbia and at University of Vermont, identified only by study ID      and following standard procedures. It will be accessible only to study investigators and, if      the participant approves, outside investigators following MESA/NIH protocols and with IRB      approval. Blood will be kept indefinitely.|Both|50 Years|79 Years|No|Non-Probability Sample|Approximately Study Subjects:        MESA COPD will recruit approximately 360 participants from EMCAP at Columbia, and from        MESA at Columbia; JH University; North Western University; and University of California.        Cases will be defined according to the current American Thoracic Society/European        Respiratory Society (ATS/ERS) definition of COPD of a post-bronchodilator capacity        (FEV1/FVC) ratio < 0.70 and classified as mild, moderate and severe as post-bronchodilator        FEV1 of 80-100% predicted, 50-80% predicted and < 50% predicted, respectively.        Controls will be defined in the above sampling frame as those with normal lung function        (pre-bronchodilator FEV1/FVC ratio >= 0.70, and no restrictive ventilatory defect.|April 2015|April 22, 2015|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01397721||101306|
NCT01397734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-107|Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)|Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML||Dana-Farber Cancer Institute|Yes|Recruiting|September 2011|||September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397734||101305|
NCT01386476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110195|(18F)FCWAY and the Blood-Brain Barrier|The Serotonin-1A Receptor Radioligand (18F)FCWAY as a Potential Substrate for Efflux Transport at the Blood-Brain Barrier||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|||||N/A|Observational|N/A|||Anticipated|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01386476||102167|
NCT01400594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTU-520-US01|Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail|A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety & Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail||Hisamitsu Pharmaceutical Co., Inc.|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|70 Years|No|||May 2015|May 12, 2015|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400594||101086|
NCT01371318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS019218-01|Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics|Wound EMR to Decrease Limb Amputations in Persons With Diabetes|OWEMR|New York University School of Medicine|Yes|Completed|July 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1609|||Both|18 Years|N/A|No|||December 2014|December 29, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371318||103320|
NCT01371331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0403|A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation|A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus Granules) in de Novo Paediatric Allograft Recipients|OPTION|Astellas Pharma Inc|No|Completed|June 2011|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Both|N/A|12 Years|No|||October 2015|October 23, 2015|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371331||103319|
NCT01401881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITEMMRI|Ischemic Time and Extent of Myocardial Infarction (MI) With Cardiac Magnetic Resonance Imaging (CMRI) in Patients With ST Elevation Myocardial Infarction (STEMI) and Primary Percutaneous Coronary Intervention (PCI) Study|Ischemic Time and Extent of Myocardial Infarction With Cardiac Magnetic Resonance Image in Patients With STEMI and Primary Percutaneous Coronary Intervention Study|ITEMMRI|Medstar Research Institute|No|Active, not recruiting|December 2009|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of adult patients with acute STEMI and primary PCI with        clear identification of symptoms onset, willing to participate in the research protocol        and not having any of the exclusion criteria. Patient screening will take place after the        primary PCI in the cardiac catheterization laboratory or in the coronary care unit.        Participation will be offered to all those who meet eligibility criteria.|April 2013|April 22, 2013|May 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01401881||100988|
NCT01367730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Majumdar #39637|Assessment of Bone Micro-Architecture Using HR-pQCT|Non-Invasive Assessment of Bone Micro-architecture and Strength Changes in Men With Osteopenia and Osteoporosis||University of California, San Francisco|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Male|50 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community UCSF VA Medical Center|December 2014|December 1, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01367730||103596|
NCT01371617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-926-08|A Phase 2 Study With IPI-926 in Patients With Myelofibrosis|A Phase 2 Study of IPI-926 in Patients With Myelofibrosis||Infinity Pharmaceuticals, Inc.|No|Completed|October 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|90 Years|No|||November 2012|November 14, 2012|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371617||103298|
NCT01367717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-09|Effect of Creatine on Serum and Urine Creatinine|Effect of Creatine Monohydrate and Creatine Ethyl Ester on Serum and Urinary Creatinine|ECSUC|Beth Israel Medical Center|Yes|Completed|May 2009|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 14, 2012|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01367717||103597|
NCT01367977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61/3528|Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life|Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia ("POTS" -- Postural Orthostatic Tachycardia Syndrome)Later in Life -- a Retrospective Analysis||Genetic Disease Investigators|Yes|Completed|May 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|21|||Both|5 Years|N/A|No|Non-Probability Sample|Patients with Classic or Hypermobile Ehlers-Danlos Syndrome with dysautonomia, found        through social media forums, internet advertising, local support groups, physicians        working with this subset of patients.|April 2015|April 2, 2015|June 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01367977||103577|
NCT01367990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-5|Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy|Alopecia Prevention Trial of Topical Vasoconstrictor Therapy in Head and Neck Cancer Patients Treated With Intensity Modulated Radiotherapy (IMRT)||ProCertus BioPharm, Inc|No|Terminated|July 2011|April 2012|Anticipated|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|3|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|June 5, 2011|No|Yes|Study site has terminated the study due to the complexity of the study|No||https://clinicaltrials.gov/show/NCT01367990||103576|
NCT01368250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|056/11|SWISS TAVI Registry|SWISS TAVI Registry: Prospective, National, Multi-Center Registry of Patients Undergoing Transcatheter Aortic Valve Implantation||University Hospital Inselspital, Berne|Yes|Recruiting|February 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|N/A|No|Non-Probability Sample|Patients with severe aortic valve stenosis or degenerated aortic bioprosthesis scheduled        to undergo transcatheter aortic valve implantation (TAVI) using the commercially available        devices with the CE approval are eligible for enrollment in the registry. The TAVI        procedure can be performed using all available access routes (transfemoral, transapical,        trans-subclavian, trans-aortic).|June 2015|June 2, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368250||103556|
NCT01368536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPV100AUS05|Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes|A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes|VALENCIA|Novartis|No|Terminated|May 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|975|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|June 6, 2011|Yes|Yes|Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with    an ACE inhibitor or ARB, in diabetics with renal impairment|No|February 14, 2013|https://clinicaltrials.gov/show/NCT01368536||103534|
NCT01395199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AmloThal RCT|Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major|Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial|AmloThal|University of Campinas, Brazil|No|Completed|August 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|6 Years|80 Years|No|||September 2015|September 4, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01395199||101499|
NCT01395472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBI-1858/09|Influence of Physical Exercise on Cognitive Functioning of Traumatic Brain Injury Patients|Influence of Physical Exercise on Cognitive Functioning of Traumatic Brain Injury Patients||Federal University of São Paulo|No|Recruiting|January 2010|February 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2011|July 27, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01395472||101478|
NCT01397253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3130920|Virtual Continuity and Its Impact on Complex Hospitalized Patients' Care|Virtual Continuity and Its Impact on Complex Hospitalized Patients' Care||University of Pittsburgh|No|Completed|August 2010|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|835|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|July 15, 2011||No||No|March 12, 2015|https://clinicaltrials.gov/show/NCT01397253||101342|
NCT01397266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1339/09|Study of the Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence|Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence.|TMSCOCAINE|University of Sao Paulo General Hospital|No|Recruiting|March 2010|July 2013|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|35 Years|No|||August 2010|July 18, 2011|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01397266||101341|
NCT01397513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|151:2005/76316|Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes|Effects of Low and High Doses of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes and Possible Influence of the Glycemic Control.||Karolinska Institutet|Yes|Completed|March 2006|February 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|30 Years|70 Years|No|||March 2006|July 18, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01397513||101322|
NCT01397747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exact Sciences 2011-01|Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer|Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer: DeeP-C Study|DeeP-C|Exact Sciences Corporation|No|Completed|June 2011|May 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12776|Samples With DNA|Residual stool samples may be archived for further research. Clinical data and samples will      be kept in a manner that preserves anonymity of the subjects, using the subject ID as the      only tracking information. Specimens will be stored in a commercial biorepository contracted      by Exact Sciences or at Exact Sciences and may be used for future research.|Both|50 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients at average risk of developing colorectal cancer.|November 2015|December 1, 2015|July 18, 2011|Yes|Yes||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01397747||101304|
NCT01397760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iara fiks 1|Retrospective Study for Description of The Use Of Omalizumab In Patients With Difficult To Control Asthma|Retrospective Study for Description of The Use Of Omalizumab In Patients With Difficult To Control Asthma||Fiks, Iara Nely, M.D.|No|Not yet recruiting|August 2011|September 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|18 Years|70 Years|No|Probability Sample|20 PATIENTS WITH difficult to treat asthma|July 2011|July 19, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01397760||101303|
NCT01397500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS/Muenchen 02|Hormone Treatment in Growth Hormone and Testosterone Deficient Patients|Growth Hormone and Gonadotropin Deficiency After Brain Injury (Traumatic Brain Injury, Subarachnoidal Hemorrhage, Ischemic Stroke): the Effects of Hormone Replacement on Cognition, Quality of Life and Body Composition||Max-Planck-Institute of Psychiatry|No|Terminated|November 2011|March 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|May 17, 2011||No|Recruitment problems due to change of patient population at site.|No||https://clinicaltrials.gov/show/NCT01397500||101323|
NCT01386489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110197|Immune Responses to Two Experimental HIV Vaccines in Healthy Adults|VRC 016: A Phase 1b Open-Label, Randomized Clinical Trial to Evaluate Early Innate and Adaptive Immune Responses to the Investigational HIV-1 Vaccines: VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP in Ad5 Seronegative Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|June 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|36|||Both|18 Years|50 Years|No|||March 2014|November 19, 2015|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01386489||102166|
NCT01401634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-00223|Oral Hydration for Mild to Moderate Hyperglycemia in the Emergency Department|||University of Southern California||Completed|January 2011|||June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2011|July 22, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01401634||101006|
NCT01371344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F506-CL-0404|A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients|A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients|PROGRESSION|Astellas Pharma Inc|No|Active, not recruiting|June 2011|July 2020|Anticipated|July 2020|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|48|||Both|N/A|12 Years|No|||March 2016|March 3, 2016|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01371344||103318|
NCT01371643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11104|Surgical Debulking of Pituitary Adenomas|Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study||New York University School of Medicine||Completed|April 2004|December 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|41|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371643||103296|
NCT01401894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-219|Perception Prognosis, Goals of Treatment, and Communication|Pilot Study to Investigate Advanced Cancer Patient's Perspective of Their Prognosis, Goals of Treatment, and Quality of Communication With Their Oncologists||Massachusetts General Hospital|No|Completed|October 2010|June 2014|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with a recent diagnosis of advanced gastric, esophageal, pancreatic and        hepatobiliary cancer, not being treated with curative intent and receiving their cancer        care at Massachusetts General Hospital.|August 2014|August 5, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01401894||100987|
NCT01367743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017081-23|Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock|Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine|OptimaCC|Central Hospital, Nancy, France|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01367743||103595|
NCT01368003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-333|STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling|A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling||Dana-Farber Cancer Institute|Yes|Withdrawn|April 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||August 2015|August 29, 2015|April 21, 2011|Yes|Yes|Loss of funding.|No||https://clinicaltrials.gov/show/NCT01368003||103575|
NCT01368263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106141|Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer|A Multisite International Collaborative Phase 2 Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women With Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer||Washington University School of Medicine|Yes|Terminated|September 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Female|18 Years|N/A|No|||March 2015|March 16, 2015|June 2, 2011|Yes|Yes|Due to funding source and lack of accrual|No|January 23, 2015|https://clinicaltrials.gov/show/NCT01368263||103555|
NCT01368276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005/05-E|An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma|An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05||BioVex Limited||Completed|October 2010|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|April 20, 2011|No|Yes||No|September 22, 2015|https://clinicaltrials.gov/show/NCT01368276||103554|
NCT01368549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-005|Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)|Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)||Pamlab, Inc.|No|Active, not recruiting|January 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Diabetic Peripheral Neuropathy Who Have Been Prescribed Metanx®|January 2012|January 9, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01368549||103533|
NCT01368822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK078702-02|Effect of Obesity on Long-term Clinical Outcomes After Kidney Donation||R-21|University of California, San Francisco|No|Completed|June 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|all patients who underwent donor nephrectomy at UCSF more than 5 years ago and a 2-kidney        control group which consist of prospective donors evaluated at UCSF who were found to be        eligible for donation on the basis of a medical screening evaluation, but then were        excluded due to ABO-incompatibility or positive crossmatch with the recipient.|November 2012|November 8, 2012|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368822||103512|
NCT01369056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARTH07237|HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence|HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence||University of Tartu|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01369056||103494|
NCT01396109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-gyn-01|GYNECARE PROSIMA* Procedure Versus Modified Total Pelvic Floor Reconstructive Surgery for Uterine Prolapse Stage III|A Prospective, Multicenter Trial to Compare GYNECARE PROSIMA* Pelvic Floor Repair System Procedure With Modified Total Pelvic Floor Reconstruction Surgery Concomitantly With TVH to Treat Symptomatic POP-Q Stage III Uterine Prolapse||Peking Union Medical College Hospital|No|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|60 Years|N/A|No|||March 2011|December 25, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01396109||101430|
NCT01396369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12459|Flaxseed Lignan (Brevail)|Impact of Flaxseed Lignan (Brevail) on Polycystic Ovarian Syndrome||University of Kansas Medical Center|No|Completed|June 2011|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Female|18 Years|40 Years|No|||January 2016|January 6, 2016|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01396369||101410|
NCT01397279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAVA|Assessment of Liver Glucose Metabolism in Diabetic Subjects|Assessment of Liver Glucose Metabolism in Diabetic Subjects|CLAVA|German Diabetes Center|Yes|Active, not recruiting|July 2011|December 2012|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|35 Years|69 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397279||101340|
NCT01397526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063.09 (REK)|Colloid Osmotic Pressure During Heart Surgery in Children|Colloid Osmotic Pressure During Heart Surgery in Children||Oslo University Hospital|No|Completed|July 2011|December 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|Interstitial fluid Serum|Both|N/A|13 Years|No|Non-Probability Sample|Children scheduled for open heart surgery with the use of Cardiopulmonary Bypass at Oslo        University Hospital|June 2014|June 30, 2014|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397526||101321|
NCT01397539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221AD101|Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease|A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease||Biogen|Yes|Completed|June 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|55 Years|85 Years|No|||March 2015|March 19, 2015|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01397539||101320|
NCT01398059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/01E|The Metabolic Effects of Breaks in Sedentary Time|The Metabolic Effects of Breaks in Sedentary Time||Children's Hospital of Eastern Ontario|No|Completed|July 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398059||101280|
NCT01398345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|364/2003|Exercise and Respiratory Training as Supportive Treatments for Patients With Chronic Pulmonary Hypertension|Phase 3 Study of Physical Exercise and Respiratory Training as Supportive Treatments for Patients With Severe Chronic Pulmonary Hypertension||Heidelberg University||Completed|April 2003|||December 2006|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||July 2014|July 1, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398345||101258|
NCT01398033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FW-014-1|Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis|Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis|BAIR|Herz-Zentrums Bad Krozingen|Yes|Withdrawn|April 2012|September 2014|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|90 Years|No|||August 2015|August 3, 2015|July 19, 2011||No|Study stopped due to lack of patient inclusion|No||https://clinicaltrials.gov/show/NCT01398033||101282|
NCT01398046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dasatinib-63-03|Effects of Gastric pH on the Pharmacokinetics of Dasatinib|Effects of Gastric pH on the Pharmacokinetics of Dasatinib in Healthy Volunteers||University of California, San Francisco|Yes|Completed|August 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|10|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01398046||101281|
NCT01398332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT 10-12|Evaluation of the GORE® C3 Delivery System Module|Global Registry for Endovascular Aortic Treatment(GREAT)||W.L.Gore & Associates|Yes|Active, not recruiting|January 2011|November 2022|Anticipated|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|N/A|N/A|No|Non-Probability Sample|Patients who undergo endovascular treatment for aortic pathologies with the GORE®        EXCLUDER® AAA Endoprosthesis with C3 Delivery System.|December 2015|December 9, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398332||101259|
NCT01398293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25298|A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects|A Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of Danoprevir With Low Dose Ritonavir (DNV/r) on the QT/QTc Interval in Healthy Subjects||Hoffmann-La Roche||Completed|August 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|4||Actual|52|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398293||101262|
NCT01398605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200709026R|Physical Activity in Postmenopausal Women|Physical Activity and Exercise Dose-response on Cardiovascular Risk Factors in Postmenopausal Women||National Taiwan University Hospital|Yes|Completed|September 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|200|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||July 2011|August 16, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01398605||101238|
NCT01371058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NH-20110530|Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI)|Study of Policosanol to Improve High on Clopidogrel Platelet Reactivity After Percutaneous Coronary Stent Implantation(Spirit)|spirit|Shenyang Northern Hospital|Yes|Completed|March 2011|September 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|350|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01371058||103340|
NCT01371669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090206|Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension|Study Searching for Hypoxemic Sleep Breathing Disorders in a Cohort of Patients With Idiopathic Pulmonary Arterial Hypertension (IPAH) and Chronic Post-embolic Pulmonary Hypertension (CPEPH)|Sommeil_HTAP|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with IPAH or CPEPH hospitalized in our pulmonary department for a standard        follow-up. They have to be in a stable condition, as defined by the New York Heart        Association classes for dyspnea and the six minutes walking test. Furthermore, no changes        in medical therapy could have been made during the last three months.|March 2013|March 27, 2013|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01371669||103294|
NCT01371630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0991|Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)|Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-intensity Chemotherapy in Elderly Patients With Acute Lymphoblastic Leukemia (ALL)||M.D. Anderson Cancer Center|No|Recruiting|August 2011|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|N/A|N/A|No|||December 2015|December 28, 2015|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371630||103297|
NCT01367756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25679|A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers|A Single Center, Randomized, Double-blind, Parallel-design Study to Investigate the Safety and Tolerability of RO4995819 in Combination With Citalopram Following Oral Administration in Healthy Volunteers||Hoffmann-La Roche||Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01367756||103594|
NCT01368016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP2012|Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Therapy and Nicotine Gum|Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Product and Nicotine Gum 4 mg. A Study in Healthy Smokers||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|346|||Both|19 Years|55 Years|No|||July 2012|July 6, 2012|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368016||103574|
NCT01368289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE/EMR|Australian Multicentre Colonic Endoscopic Mucosal Resection Study|Australian Multicentre Colonic Endoscopic Mucosal Resection (ACE/EMR) Study|ACEEMR|Western Sydney Local Health District|No|Recruiting|September 2008|September 2020|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Any patient who presents to the Unit with the intention to treat large sessile colonic        polyps equal to or greater than 20mm.|December 2015|December 15, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368289||103553|
NCT01368302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|949-2010|Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)|Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)||Tel Aviv University|No|Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|52|||Male|N/A|N/A|No|||December 2014|December 1, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01368302||103552|
NCT01368562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 901|Compassionate Use Study of Methylnaltrexone|A Compassionate Use Study of Methylnaltrexone in Patients With Opioid-Induced Side Effects||Valeant Pharmaceuticals International, Inc.|No|Completed|January 2003|June 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||July 2011|July 17, 2011|May 27, 2011|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01368562||103532|
NCT01368835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-106|Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue|Evaluation of the Ulthera™ System For Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity||Ulthera, Inc|Yes|Completed|July 2010|April 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|103|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|June 6, 2011|Yes|Yes||No|March 25, 2013|https://clinicaltrials.gov/show/NCT01368835||103511|
NCT01396980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO 776|Microcirculation During Haemodialysis|Sublingual Microcirculatory Flow Measurements During Haemodialysis in Relation to Blood Volume Change||Medical Centre Leeuwarden|No|Completed|September 2011|February 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Stable hemodialysis patients with dialysis dependancy for more than 3 months, with        adequate access|February 2012|February 20, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01396980||101363|
NCT01396993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iTOP|Prospective Non-randomized Evaluation of Oncoplastic Surgery|Prospective Trial Evaluating Cosmetic And Oncologic Outcome Of Immediate Techniques For Oncoplastic Surgery In Breast Cancer|iTOP|Medical University of Vienna|Yes|Active, not recruiting|July 2011|August 2016|Anticipated|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with a BIRADS IV, V or VI breast lesion are preoperatively asked to take part in        this study if more than 10% of breast tissue will be excised or mastectomy and immediate        reconstruction is planned. Patients with planned mastectomy without immediate        reconstruction are not included. Patients scheduled for breast conservation can decide        whether they undergo regular breast conservation (BCT) or BCT using immediate techniques        of oncoplastic surgery (iTOP). A contralateral correction may be performed in both groups        at any time of the trial. The use of a contralateral correction of patients without an        immediate oncoplastic procedure does not initiate a change into the other group (intention        to treat analyses).|September 2015|September 22, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396993||101362|
NCT01397773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTX-HASEKI|Pentraxin-3 in Chronic Renal Failure|The Role Pentraxin-3 in the Inflammatory Process in Chronic Renal Failure, and the Association With Other Inflammatory Parameters||Haseki Training and Research Hospital|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|85|Samples Without DNA|Serum|Both|16 Years|80 Years|No|Non-Probability Sample|Patients will be selected among those who are followed up in our clinic.|July 2011|July 19, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397773||101302|
NCT01398072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0078|Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Single-blind, Randomised Placebo Controlled Trial of Long Term Therapy in Patients With Stable COPD Using Moxifloxacin, Azithromycin and Doxycycline: a Bayesian Decision Analysis, Including Other Criteria, Will be Used to Distinguish the Optimal Antibiotic Treatment||University College, London|No|Recruiting|December 2011|April 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Anticipated|200|||Both|45 Years|80 Years|No|||May 2012|May 31, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398072||101279|
NCT01398358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04785|Enhancing Self Regulation as a Strategy for Obesity Prevention in Head Start Preschoolers|Enhancing Self Regulation as a Strategy for Obesity Prevention in Head Start Preschoolers||University of Michigan|No|Completed|March 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|957|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398358||101257|
NCT01398670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3-LIS-IMSFDA-01|Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics|Comparison of the Immunogenicity of Wockhardt's Insulin Analogue Lispro and Lispro Mix With Eli Lilly's Insulin Analogue Humalog® and Humalog® Mix in Type 1 Diabetic Patients||Wockhardt|No|Withdrawn|February 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||January 2013|January 24, 2013|July 19, 2011|Yes|Yes|Study was not initiated|No||https://clinicaltrials.gov/show/NCT01398670||101233|
NCT01398657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103057MB|Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer|Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy for High-Risk Localized Prostate Cancer — Open-Label Randomized Clinical Study||National Taiwan University Hospital|No|Recruiting|July 2011|June 2016|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Male|20 Years|N/A|No|||March 2012|November 13, 2012|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01398657||101234|
NCT01398306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230520112|Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.|Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.|BANN|University Medical Center Groningen|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|40|Samples With DNA|2 x 10mL whole blood, stored as platelet rich and platelet poor plasma.|Both|18 Years|N/A|No|Probability Sample|Patients with clear cell renal cell carcinoma with metastases and patients with low grade        neuroendocrine tumours with metastases.|May 2012|May 7, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398306||101261|
NCT01398319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20100149H-1|Prevention of Alcohol Related Incidents in Air Force Technical Training|Predictors of Smokeless Tobacco and Dual Use in the US Military and the Prevention of Alcohol Related Incidents Using a Brief Alcohol Intervention in Air Force Technical Training|AFIV|University of Tennessee|Yes|Recruiting|October 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|35000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01398319||101260|
NCT01371071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK1/2011|Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis|Clinically Isolated Syndrome and Newly Diagnosed Multiple Sclerosis: Diagnostic, Prognostic and Therapy - Response Markers - a Prospective Observational Study (Berlin CIS-COHORT)|CIS-COHORT|Charite University, Berlin, Germany|No|Recruiting|January 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|blood samples (serum and plasma, with DNA), urine, saliva, CSF (if routine lumbar puncture      was performed, no additional lumbar punctures for the study)|Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruted at neurological outpatient clinics and neurologcial clinics of        the charité and neurologists' medical practices.|June 2011|June 9, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01371071||103339|
NCT01371682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112771|A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda|An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda||GlaxoSmithKline|No|Completed|September 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|June 10, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371682||103293|
NCT01371656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL0934|Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation|A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)||Children's Oncology Group|Yes|Recruiting|June 2011|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|740|||Both|6 Months|21 Years|No|||February 2016|February 24, 2016|June 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01371656||103295|
NCT01367379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104059RC|The Effect of the Duty Loading on the Stress Response of Physician|The Effect of the Duty Loading on the Stress Response of Physician||National Taiwan University Hospital||Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|15|||Male|30 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Attending physicians of internal medicine of Taipei municipal hospital, certified by        Taiwan society of internal medicine. We will compare those results of outcome variables of        different amount of duty area.|January 2012|January 3, 2012|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367379||103623|
NCT01368328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM2|Effect of the Chromium Nicotinate on Type 2 Diabetes|Effect of Chromium Supplementation on Insulin Sensitivity in Patients With Type 2 Diabetes||Universidade Federal de Goias|No|Active, not recruiting|March 2010|September 2011|Anticipated|July 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|57|||Both|30 Years|60 Years|No|||February 2011|June 6, 2011|April 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01368328||103550|
NCT01368029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010 P 001694|Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine|Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine||Massachusetts General Hospital|Yes|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368029||103573|
NCT01368315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 327 AD 01-09|CT 327 in the "Atopy Patch Test" Model|CT 327 in the "Atopy Patch Test" Model|CT327 AD01-09|Creabilis SA|No|Withdrawn||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|66 Years|No|||June 2011|June 6, 2011|June 6, 2011||No|Strategic decision|No||https://clinicaltrials.gov/show/NCT01368315||103551|
NCT01368575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIME-002|Surgical Treatment of Ischemic Mitral Regurgitation|The Effect of Different Surgical Methods in the Treatment of Patients With Ischemic Mitral Regurgitation and Assess the Dynamics of Heart Failure and the Effectiveness of Surgical Treatment of Mitral Valve.|TIME|Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|May 2011|November 2015|Anticipated|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|420|||Both|30 Years|75 Years|No|||September 2015|September 21, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01368575||103531|
NCT01368588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG-0924|Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer|Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial||Radiation Therapy Oncology Group|Yes|Recruiting|July 2011|||July 2027|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2580|||Male|18 Years|N/A|No|||October 2015|October 13, 2015|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368588||103530|
NCT01368848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_NSCLC 1|Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)|Phase II Study to Investigate the Treatment of Patients With NSCLC Stage IIIB and IV Without the Option of Surgery With a Combination of Cisplatin, Docetaxel and Bevacizumab||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||August 2013|August 29, 2013|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01368848||103510|
NCT01369082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CIT-08|Extended Follow-Up After Islet Transplantation in T1D|Extended Follow-Up After Islet Transplantation in Type 1 Diabetes (CIT-08)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Enrolling by invitation|May 2011|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|Samples With DNA|Participants are given the option to provide consent for:        1. the collection and storage of blood samples for future research studies        2. the collection and storage of blood samples for future genetic (i.e., DNA) testing.|Both|18 Years|65 Years|No|Probability Sample|Cohort from Clinical Islet Transplantation (CIT) parent studies (refer to inclusion        criteria) who continue:          -  to have islet graft function and          -  are on prescribed immunosuppression medications to prevent rejection of their             transplant.|August 2015|August 26, 2015|June 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01369082||103492|
NCT01396694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00061869|An Evaluation of Psychological Parameters That May Influence the Outcome Following Arthroscopy and Arthroplasty for Temporomandibular Joint Surgery|Phase 4 Study of the Influence of Psychological Factors on the Outcomes Following Arthroscopy and Arthroplasty for Temporomandibular Joint Dysfunction||Emory University|No|Completed|June 2009|December 2015|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|105|||Both|18 Years|90 Years|No|Non-Probability Sample|18 yrs|February 2016|February 16, 2016|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01396694||101385|
NCT01396707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-1101|Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC)|A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer|Her+XELOX|Asan Medical Center|No|Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|20 Years|N/A|No|||March 2016|March 9, 2016|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396707||101384|
NCT01396720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0255-HMO-CTIL|Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel|Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel, a Randomized, Double-blind, Crossover Trial||Hadassah Medical Organization|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 26, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01396720||101383|
NCT01397552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 5824|Dexamethasone Versus Depo Medrol in Lumbar Epidurals|A Prospective, Randomized, Double-Blind Study to Compare the Effects of Dexamethasone Versus Depo-Medrol When Used in Lumbar Epidural Injections||State University of New York - Upstate Medical University|No|Terminated|September 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|8|||Both|21 Years|N/A|No|||September 2013|September 6, 2013|July 15, 2011||No|Low enrollment, too many subjects getting second injection|No||https://clinicaltrials.gov/show/NCT01397552||101319|
NCT01397786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-237|Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia|A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia|ZENITH|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Enrolling by invitation|September 2011|March 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|65 Years|No|||May 2015|May 8, 2015|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397786||101301|
NCT01398085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/10/0299|IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients|Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients|IoN|University College, London|No|Recruiting|May 2012|January 2021|Anticipated|November 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|570|||Both|16 Years|N/A|No|||November 2015|November 30, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01398085||101278|
NCT01398098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCOL 111|Measurement of Gastric Emptying During and After COLOKIT® Intake|Gastric Emptying Time Assessment During Bowel Preparation With COLOKIT®||Laboratoires Mayoly Spindler|No|Completed|October 2011|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|75 Years|No|||November 2012|November 28, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01398098||101277|
NCT01398371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|257/11|Digoxin Withdrawal in Stable Heart Failure|A Randomised, Blinded, Placebo Controlled Trial to Assess the Effect of Digoxin Withdrawal in Stable Heart Failure Patients Receiving Optimal Background Therapy||The Alfred|No|Completed|August 2011|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398371||101256|
NCT01398683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104080RC|Comparison Epidural Anesthesia and General Anesthesia in Laparoscopic Cholecystectomy|Comparison Epidural Anesthesia and General Anesthesia in Laparoscopic Cholecystectomy||National Taiwan University Hospital|Yes|Enrolling by invitation|April 2011|April 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|70 Years|No|Probability Sample|Underwent laparoscopic cholecystectomy in patients|July 2011|November 15, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398683||101232|
NCT01398696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|n° IRB 5891|Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour|Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour : a Randomised Controlled Trial in Primary Care.|PIL|University Hospital, Grenoble|No|Completed|November 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|400|||Both|N/A|N/A|No|||October 2011|October 11, 2011|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398696||101231|
NCT01394406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0670|Effect of Ketamine Added to Intravenous Patient-controlled Analgesia on Postoperative Pain, Nausea and Vomiting in Patients Undergoing Lumbar Spinal Surgery|Effect of Ketamine Added to Intravenous Patient-controlled Analgesia on Postoperative Pain, Nausea and Vomiting in Patients Undergoing Lumbar Spinal Surgery||Yonsei University|Yes|Completed|January 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|20 Years|65 Years|No|||March 2014|March 4, 2014|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394406||101560|
NCT01394419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0135|Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft|Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft||Yonsei University|Yes|Completed|September 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|115|||Both|20 Years|N/A|No|||March 2013|March 4, 2013|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394419||101559|
NCT01370811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-014-201|A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease|A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease||Orient Pharma Co., Ltd.|No|Completed|August 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|40 Years|80 Years|No|||June 2013|June 14, 2013|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370811||103359|
NCT01370824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 112041 (35344.068.11)|Clinical Diagnosis of Basal Cell Carcinoma Subtype|Clinical Diagnosis Versus Histological Diagnosis by Punch Biopsy to Determine the Subtype of Basal Cell Carcinoma||Maastricht University Medical Center|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|150|Samples Without DNA|A punch biopsy and surgical excision of the BCC will be performed. Both biospecimens will be      prepared with either frozen section histology, or paraffin embedded fixed tissue pathology.|Both|18 Years|N/A|No|Non-Probability Sample|Eligible are patients (men and women) ≥18 years of age who visit the outpatient department        of dermatology of the Maastricht University Medical Centre because of a clinically        suspected BCC. The subtype will be determined by clinical diagnosis, histopathological        examination of tissue derived from a PB and SE/MMS. Recruitment of the required number of        patients (150 histological proven BCC, see below) should present no problems.|May 2013|May 16, 2013|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01370824||103358|
NCT01371357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN-214E-S10|The Effects of 8-week Choline, Betaine, and Folic Acid Supplementation on Plasma Homocysteine Concentration During Guanidinoacetic Acid Loading in Young Healthy Volunteers|||Center for Health, Exercise and Sport Sciences, Serbia|Yes|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2011|December 18, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371357||103317|
NCT01367769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS2154|Venous Vascularization and Inflammation on Contrast-enhanced Ultrasound (CEUS) in Patients With Thrombosis|Evaluation of Perivascular Venous Vascularization and Inflammation by Contrast-enhanced Ultrasound (CEUS) in Patients With Acute Deep Vein Thrombosis and Superficial Thrombophlebitis - a Pilot Study||University Hospital, Basel, Switzerland|No|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|The investigators will also determine level of inflammatory markers as the cytokines      interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant-1 (MCP-1), Vascular      cellular adhesion molecule-1 (VCAM-1), von Willebrand factor (vWF) and C-reactive protein      (CRP) at each visit (baseline, 2 weeks, and 3 months).|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|20 patients with unilateral proximal DVT and 10 patients with SVT of the lower-extremity        will be included in this study. As control, 10 volunteers without DVT or SVT, and without        history of thromboembolism, will be recruited.|November 2015|November 5, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01367769||103593|
NCT01367392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACST-2011-1|Effectiveness and Safety of CT-guided Needle Placement in the Liver With the Aid of the ActiSight Needle Guidance System|Confirmation of Clinical Effectiveness and Safety of CT-guided Needle Placement in the Liver With the Aid of the ActiSight Needle Guidance System||ActiViews Ltd.|No|Completed|June 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|80 Years|No|||February 2012|February 14, 2012|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01367392||103622|
NCT01367405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36977.091.11|Comparing Surgical Decompression Versus Conservative Treatment in Incomplete Spinal Cord Injury|COSMIC: Conservative or Early Surgical Management of Incomplete Cervical Cord Syndrome Without Spinal Instability. Randomized Controlled Trial|COSMIC|Radboud University|No|Recruiting|October 2013|December 2017|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01367405||103621|
NCT01368055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1103-PR07|Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer|An Expanded Phase II Study of Hypofractionated Dose Intense Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate|PR07|University of Florida|Yes|Active, not recruiting|September 2011|September 2036|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Male|18 Years|N/A|No|||March 2016|March 7, 2016|June 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01368055||103571|
NCT01368601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFLATOR|Effects of Intraoperative Continuous Airway Pressure (CPAP) on the Inflammatory Response to One-lung Ventilation|Effects of Intraoperative Continuous Airway Pressure (CPAP) on the Inflammatory Response of the Lung With Cancer Undergoing Lobectomy. A Randomised Placebo-controlled Trial||Parc de Salut Mar|No|Recruiting|May 2011|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||November 2015|November 26, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01368601||103529|
NCT01368861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVMS|Effective Analgesia During Routine Immunizations|Effective Analgesia Using the 5 S's During Routine Immunizations at 2 and 4 Months||Children's Hospital of The King's Daughters|No|Completed|June 2010|March 2012|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|230|||Both|2 Months|4 Months|Accepts Healthy Volunteers|Probability Sample|All patients were enrolled from the General Academic Pediatric outpatient practice located        at The Children's Hospital of The King's Daughters in Norfolk, VA. This practice serves a        predominantly urban, Medicaid enrolled, African-American population and has approximately        30,000 annual visits per year.|July 2015|July 28, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01368861||103509|
NCT01369095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN162-007|Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression|A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).||Bristol-Myers Squibb|Yes|Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|976|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369095||103491|
NCT01369407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVIVE-IT REGISTRY (REVIVAL)|REGISTRY EVALUATION OF VITAL INFORMATION FOR VADs IN AMBULATORY LIFE|REVIVE-IT Registry (REVIVAL: Registry Evaluation of Vital Information For VADs in Ambulatory Life)|REVIVAL|University of Michigan|No|Recruiting|July 2015|June 2019|Anticipated|June 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Biomarker Samples will be collected at the Baseline B assessment. Samples for Genomic      Analysis will be collected at the Baseline B visit for subjects that consented to collection      of this sample type.|Both|18 Years|80 Years|No|Non-Probability Sample|Medical records should be reviewed to assess for potential enrollment into the REVIVE-IT        Registry. Heart failure subjects that meet all criteria should be approached to consent        for this study.|January 2016|January 13, 2016|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01369407|2 Years|103467|
NCT01369420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-208|NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer|A Safety Evaluation of the NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer - A Pilot Study||Angiodynamics, Inc.|No|Active, not recruiting|May 2011|May 2012|Anticipated|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2012|March 13, 2012|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369420||103466|
NCT01397292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13603|Registry for Patients Undergoing Pulmonary Procedures|Registry Examining Retrospective and Prospective Data for Patients Undergoing Pulmonary Procedures||Virginia Commonwealth University|No|Terminated|July 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|220|||Both|18 Years|N/A|No|Non-Probability Sample|ONLY ADULT PATIENTS (>18 YEARS OLD) that have a planned PULMONARY PROCEDURE will be        potential participants. This will also include a special group, prisoners.|July 2011|March 15, 2013|July 15, 2011||No|funding/ enrollment|No||https://clinicaltrials.gov/show/NCT01397292||101339|
NCT01397305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-MC-091|Modufolin (6R 5,10-Methylenetetrahydrofolate) and Pemetrexed for Neoadjuvant Rectal Cancer Treatment|An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer||Isofol Medical AB|No|Completed|April 2011|||November 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01397305||101338|
NCT01397565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-053-SDR|Minilaparoscopic Versus Conventional Laparoscopic Cholecystectomy|Minilaparoscopic Versus Conventional Laparoscopic Cholecystectomy: A Randomized Trial||McGill University Health Center|No|Completed|February 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||September 2015|September 26, 2015|July 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397565||101318|
NCT01397799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KX01-03-11|Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)|A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy||Kinex Pharmaceuticals Inc|No|Completed|December 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|60 Years|N/A|No|||December 2015|December 4, 2015|July 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01397799||101300|
NCT01398111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1101-PR-0056|Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers|Open-label, Randomized, Single-dose, Placebo-controlled, 4-way Crossover Study to Investigate the Pharmacokinetic Interaction of Glycopyrrolate and Formoterol in Healthy Subjects.|TRIPLE 1|Chiesi Farmaceutici S.p.A.|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01398111||101276|
NCT01398124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 08-008|Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer|A Pilot Study of Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Patients With Resectable Non-Small Cell Lung Cancer||Milton S. Hershey Medical Center|Yes|Withdrawn|December 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|July 19, 2011|Yes|Yes|We will not be pursuing this study.|No||https://clinicaltrials.gov/show/NCT01398124||101275|
NCT01398384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCC2010.01|Effects of Nitric Oxide for Inhalation in Myocardial Infarction Size|The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size|NOMI|Universitaire Ziekenhuizen Leuven|Yes|Completed|October 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398384||101255|
NCT01398397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-006|Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype|Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype|ECP-006|Edimer Pharmaceuticals|No|Completed|April 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|11|||Both|N/A|N/A|No|Non-Probability Sample|The study will enroll up to fifty HED/XLHED affected individuals.|June 2012|June 26, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398397||101254|
NCT01398709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guch-011|Effect of Rewarming Rate During Cardiopulmonary Bypass on Clinical Prognosis of Infants Undergoing Cardiac Surgery|Study of the Relationship Between Rewarming Rate During Cardiopulmonary Bypass and Clinical Prognosis in Infants Undergoing Cardiac Surgery||Xijing Hospital|Yes|Not yet recruiting|August 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|100|||Both|N/A|3 Years|No|||July 2011|July 19, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01398709||101230|
NCT01398722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guch-012|Effect of Intensive Insulin Therapy on Clinical Prognosis of Infants Undergoing Cardiac Surgery|Study of the Relationship Between Intensive Insulin Therapy and Clinical Prognosis in Infants Undergoing Cardiac Surgery||Xijing Hospital|Yes|Not yet recruiting|August 2011|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|800|||Both|N/A|3 Years|No|||July 2011|July 19, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01398722||101229|
NCT01394458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Al452-0005|Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution: A Pilot Study|Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution to Prevent Hemodialysis Catheter-Related Infections: A Pilot Study||University of Manitoba|Yes|Completed|August 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01394458||101556|
NCT01394432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBI-1749|"ESTIMATION Study" for Endocardial Mesenchymal Stem Cells Implantation in Patients After Acute Myocardial Infarction|Endocardial Mesenchymal Stem Cells Implantation in Patients After Acute Myocardial Infarction|ESTIMATION|Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|July 2011|November 2016|Anticipated|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|75 Years|No|||September 2015|September 21, 2015|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01394432||101558|
NCT01394445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-510ex09/10|Pilot Study of Physostigmine-Enhanced Opioid Analgesia|Influence of Physostigmine on Patient-Controlled Analgesia|PHANOS|Medical University of Graz|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2012|February 20, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394445||101557|
NCT01371084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|212112|Pedal@Work: A Worksite Wellness Program|Pilot Study to Test the Efficacy of a Worksite Intervention for Reducing Daily Sedentary Time and Improving Risk Factors for Cardiometabolic Disease Among Sedentary, Overweight, Full-time Working Adults|Pedal@Work|East Carolina University|No|Completed|June 2011|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01371084||103338|
NCT01371370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.5485|Low-intensity Resistance Exercise and Diet on Arterial Function and Blood Pressure|Effects of Low-intensity Resistance Exercise Training and Diet on Central Hemodynamics and Arterial Stiffness in Obese Middle-aged Women With High Blood Pressure||Florida State University|No|Completed|December 2010|June 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Actual|41|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371370||103316|
NCT01367470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|486Baldassarre|Influence of Probiotic VSL#3 Administration on Metabolic and Immunological Profile of the Milk of Breastfeeding Mothers|Effects on Cytokines, Immunoglobulins, Antibodies, Sphingomyelinase and PAF Hydrolysis Capacity in the Maternal Milk After Probiotic VSL#3 Administration in the Last Four Weeks of Gestation and First Month of Lactation||Policlinico Hospital|Yes|Completed|April 2010|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|67|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01367470||103616|
NCT01367418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110601|Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy|Comparison Between Epidural and Patient Controlled Analgesia on Immunological and Inflammatory Systems Following Radical Retropubic Prostatectomy|AIMS|Örebro University, Sweden|Yes|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|26|||Male|50 Years|78 Years|No|||March 2012|March 16, 2012|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01367418||103620|
NCT01368627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.0|The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions|A Prospective, Multinational Investigation of the Supralimus® Sirolimus-Eluting Stent for the Treatment of Unselected Patients With Coronary Lesions in the "Real- World" Clinical Practice||Sahajanand Medical Technologies Pvt. Ltd.|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1274|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01368627||103527|
NCT01368341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT 2010-023747|Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice|Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline.|NorTick_EM|University of Oslo|Yes|Completed|June 2011|December 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368341||103549|
NCT01368614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1006-AVAPS-AE-MS|AVAPS-AE Efficacy Study|Randomized Controlled Trial Evaluating the Feasibility of AVAPS-AE vs. CPAP vs.Bilevel Pressure Support Ventilation in Obesity Hypoventilation Syndrome||Philips Respironics|No|Completed|July 2011|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|70 Years|No|||August 2015|September 18, 2015|May 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01368614||103528|
NCT01368874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-110|Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck||Ulthera, Inc|No|Completed|March 2011|January 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|71|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|June 6, 2011|Yes|Yes||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01368874||103508|
NCT01368887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DermiPsor 2008-103|Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis|Phase II Study of a Non-Steroidal Novel Treatment for Scalp Psoriasis||DermiPsor, Ltd.|Yes|Suspended|April 2013|April 2014|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|160|||Both|18 Years|N/A|No|||June 2011|June 7, 2011|June 6, 2011|Yes|Yes|Sponsor seeking additional financial support before starting the study|No||https://clinicaltrials.gov/show/NCT01368887||103507|
NCT01369108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-10-013|Clinical Study on a New Flowable Composite as a Restorative in Adult Teeth|Clinical Evaluation of a Low Shrinkage Flowable Resin Composite in Adult Teeth||3M|No|Completed|January 2011|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|N/A|No|||July 2013|January 22, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369108||103490|
NCT01397318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100005|Effects of Modified TaiChi Exercise on Maternal Stress, Fatigue, Sleep Quality, Biomarkers, and Infant Gestational Age and Birthweight|Effects of Modified TaiChi Exercise on Maternal Stress, Fatigue, Sleep Quality, Biomarkers, and Infant Gestational Age and Birthweight||Taipei Medical University WanFang Hospital|No|Active, not recruiting|September 2010|July 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|||Female|17 Years|N/A|No|Probability Sample|pregnant women|July 2011|July 18, 2011|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01397318||101337|
NCT01397812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR-2011-03|Heartsbreath Test for Heart Transplant Rejection|Validation of Heartsbreath Test for Heart Transplant Rejection|Heartsbreath|Menssana Research, Inc.|No|Active, not recruiting|December 2010|September 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Probability Sample|Subject is the recipient of a heart transplant within the previous 12 months and is        scheduled for a routine endomyocardial biopsy|April 2015|April 6, 2015|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397812||101299|
NCT01388218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROactive WP4|Non-interventional Cross-over Study to Reduce Items of PROactive Tools Measuring Physical Activity in Chronic Obstructive Pulmonary Disease (COPD)|Non-interventional Cross-over Study to Reduce Items of the Draft PROactive Tools as a Measure of Physical Activity in Daily Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Centre for Research in Environmental Epidemiology, Spain|Yes|Completed|July 2011|December 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|236|||Both|40 Years|N/A|No|Probability Sample|Stable COPD patients from Outpatients clinics and Primary care clinic        Exacerbated COPD patients from Inpatients|July 2015|July 30, 2015|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01388218||102034|
NCT01388439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAM 027|Pharmacokinetics of Oseltamivir in Newborns and Infants|Pharmacokinetics of Oseltamivir in Newborns and Infants||St. Louis Children's Hospital|No|Completed|January 2011|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|Samples With DNA|Two whole blood samples (0.5 mL) were obtained at steady state (day 3 of therapy or later),      collected in K3EDTA mini-collection tubes labeled with a sample identification number.      Plasma specimens were separated by centrifugation of 1500 g for 10 minutes at 4 degrees      Celsius within 60 minutes of sample collection. Plasma supernatant was transferred into a      cryovial labeled with the same sample identification number. Cryovials were immediately      stored at -70 degrees Celsius. Sample obtainment and processing was directly supervised by      the principle investigator.      The blood samples are currently being stored at -70 degrees Celsius in a research laboratory      operated by medical faculty of the Washington University School of Medicine Department of      Pediatrics Division of Infectious Diseases in the McDonnell Medical Sciences Building.|Both|N/A|6 Months|No|Non-Probability Sample|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital        experienced respiratory decompensation and tested positive for influenza virus type A by        fluorsescent antibody stain performed on a nasopharyngeal swab. This infant received        treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir        prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared        a primary medical team, nursing care, respiratory therapist, physical therapist, or        occupational therapist with the influenza A positive infant. Prophylaxis was deemed        necessary by the attending neonatologist after consultation with the Infectious Diseases        Division of the Department of Pediatrics at the Washington University School of Medicine.|June 2011|July 5, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01388439||102017|
NCT01388699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF_NCRC_Migraine&ED|Migraine and Endothelial Dysfunction|Migraine and Endothelial Dysfunction||Charite University, Berlin, Germany|No|Recruiting|October 2010|September 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|female migraineurs from outpatient clinic|June 2011|July 6, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388699||101997|
NCT01388712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZDGA23.01.2011|Lactobacillus Reuteri in Children With Constipation|The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial||Children's Memorial Health Institute, Poland|Yes|Recruiting|July 2011|December 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Both|3 Years|7 Years|No|||April 2012|April 1, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388712||101996|
NCT01410422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103010RC|Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis|Exhaled Breath Analysis in Patients With COPD and Bronchiectasis||National Taiwan University Hospital|No|Recruiting|May 2011|April 2014|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|Samples Without DNA|Breath condensate, blood, urine|Both|20 Years|N/A|No|Non-Probability Sample|Patients with COPD and bronchiectasis|May 2011|August 4, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01410422||100332|
NCT01410682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORAL CARE|Oral Care and Gram-negative Pathogen in Children|Oral Care and Oropharyngeal and Tracheal Colonization by Gram-negative Pathogens in Children||Federal University of São Paulo|No|Completed|June 2005|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|74|||Both|N/A|18 Years|No|||July 2011|August 4, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01410682||100312|
NCT01410149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-106|Sleep Quality in Mechanically Ventilated Patients|The Influence of Mode and Patient-ventilator Interaction on Sleep Quality in the ICU||Lawson Health Research Institute|No|Completed|April 2007|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|75 Years|No|||August 2012|August 13, 2012|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410149||100353|
NCT01411020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ricardo Fuentes|Target-controlled Infusion of Propofol for Induction of Pediatric Anesthesia|Target-controlled Infusion (TCI) of Propofol for Induction in Children 3 to 11 Years||Pontificia Universidad Catolica de Chile||Completed|October 2009|November 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|60|||Both|3 Years|11 Years|No|||August 2009|May 14, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411020||100286|
NCT01407276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-009|A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)|An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function||Merck Sharp & Dohme Corp.|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|49|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|July 29, 2011|No|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01407276||100573|
NCT01407289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinDiab-02|A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia|An Open, Single-centre, Controlled Trial to Investigate the Efficacy and Usability of Published Best Practice to Control Glycaemia in Hospitalised Patients With Type 2 Diabetes||Medical University of Graz||Completed|June 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|90 Years|No|||April 2012|February 4, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01407289||100572|
NCT01407588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3345-2|Manual Compared to Magnetic Navigation in Ablation for Atrial Fibrillation|Manual Compared to Magnetic Navigation in Ablation for Atrial Fibrillation||Norwegian University of Science and Technology|No|Active, not recruiting|August 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 5, 2016|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01407588||100549|
NCT01407601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 111/07|Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients|Food Supplementation With Vitamin K2 to Activate MGP as an Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients||RWTH Aachen University|No|Completed|January 2008|July 2009|Actual|May 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|53|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407601||100548|
NCT01407302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-024|Optimal Head Rotation and External Landmark for Internal Jugular Vein Cannulation After Placement of Proseal Laryngeal Mask Airway|Optimal Head Rotation and External Landmark for Internal Jugular Vein Cannulation After Placement of Proseal Laryngeal Mask Airway||Samsung Medical Center|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|20 Years|70 Years|No|Non-Probability Sample|patients undergoing general anesthesia with laryngeal mask airway insertion|December 2013|December 24, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01407302||100571|
NCT01408901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00049675|Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)|PROgenitor Cell Release Plus Exercise to Improve functionaL Performance in PAD: The PROPEL Study|PROPEL|Northwestern University|Yes|Recruiting|September 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|N/A|N/A|No|||October 2015|October 27, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408901||100448|
NCT01417754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tore3D|Changes in Breast 3D Ultrasound Measurements Using Toremifene|Volume and Circulation Changes of The Breast in 3D Ultrasound During Toremifene Versus Nonmedicated Menstrual Cycle||Satakunta Central Hospital|No|Completed|September 2010|June 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01417754||99775|
NCT01409694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024506-35|Alzheimer's Disease - Input of Vitamin D With mEmantine Assay|Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré|AD-IDEA|University Hospital, Angers|Yes|Recruiting|September 2011|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|60 Years|N/A|No|||March 2011|October 10, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409694||100388|
NCT01409707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0071|Mechanisms of Change, Motivation, and Treatment Outcome in Alcohol Dependence - Posttraumatic Stress Disorder|Mechanisms of Change, Motivation, and Treatment Outcome in AD-PTSD||University of Mississippi Medical Center|No|Completed|July 2008|May 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|60 Years|No|||January 2014|January 28, 2014|August 2, 2011||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01409707||100387|Unclear whether results will generalize to outpatient sample.
NCT01408407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-052|Alkagin Paste in the Prevention of Radiation Dermatitis|A Phase II Study Designed to Evaluate the Value of Alkagin Paste in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy||Sir Mortimer B. Davis - Jewish General Hospital|No|Terminated|December 2011|||May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408407||100486|
NCT01370330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CompUse MIBG|131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol|131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol||University of California, San Francisco|No|Available|April 2000|May 2016|Anticipated|May 2016|Anticipated|N/A|Expanded Access|N/A|||||||Both|1 Year|N/A|No|||June 2012|June 14, 2012|May 27, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01370330||103396|
NCT01370018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R06-005|Therapy to Elevate CD4 Counts in HIV-1 Disease|Zemaira (Alpha-1-Proteinase Inhibitor) Therapy in HIV-1 Disease||Cabrini Medical Centre|No|Completed|December 2006|February 2007|Actual|February 2007|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|30 Years|70 Years|No|||December 2006|June 8, 2011|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370018||103420|
NCT01370031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1008-PR-0049|Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices|Pilot, Open-Label, Randomized, Repeated Dose, 4-Way Cross-Over, Clinical Pharmacology Study of Beclomethasone Dipropionate (Clenil® Modulite®) 250 µg HFA pMDI Using the Aerochamber Plus™ Spacer Device Versus the Volumatic™ Spacer Device Without or With Charcoal Block in Asthmatic Adults Patients||Chiesi Farmaceutici S.p.A.|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|65 Years|No|||December 2011|December 21, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01370031||103419|
NCT01402414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUB-126|Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis|Study Comparing the Effectiveness of Narrow-band UVB vs. Bath-PUVA and Narrow-band UVB + Salt Water Baths in Atopic Dermatitis||Ruhr University of Bochum|No|Terminated|April 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|July 19, 2011||No|Difficulties with the Recruitement|No||https://clinicaltrials.gov/show/NCT01402414||100947|
NCT01402427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCCARD-001|Is Verapamil In TransRadial Interventions OmittabLe?|Omission of Prophylactic Verapamil Use in Transradial Coronary Interventions|VITRIOL|State Health Center, Hungary|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|591|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|July 21, 2011||No||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01402427||100946|The trial was conducted in a single, high-volume institution by experienced operators. The results may not be applicable to lower-volume centers or to operators with less experience.
NCT01401777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_CRYO_V7|Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study|Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study||Philips Healthcare|No|Suspended|December 2014|December 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Promary Care Clinic|May 2013|May 28, 2013|July 21, 2011||No|On hold pending product development|No||https://clinicaltrials.gov/show/NCT01401777||100996|
NCT01402648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD-CRC09(2)|Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence|Effects of the Dietary Supplementation With a Blend of ER Beta Agonists on the Expression of ER Beta and Related Biomarkers of Cell Proliferation and Apoptosis, in Sporadic Colon Adenopolyposis|CRC|CM&D Pharma Limited|No|Completed|October 2009|April 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|50 Years|70 Years|No|||July 2011|July 25, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402648||100929|
NCT01402375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02-066|Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge|Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge||Montefiore Medical Center|No|Recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Anticipated|480|||Both|21 Years|64 Years|No|||June 2013|June 1, 2013|July 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402375||100950|
NCT01402388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0201/100|Lifestyle Intervention in Patients With New Onset Type 2 Diabetes.|Effect of Intensive Lifestyle Intervention on Hormonal Factors Regulating Food Intake and Blood Glucose Control in Patients With New Onset Type 2 Diabetes.||The Royal Bournemouth Hospital|No|Completed|October 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||July 2011|July 25, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402388||100949|
NCT01402401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2205|Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients|An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer||Novartis||Terminated|November 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|July 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402401||100948|
NCT01399307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACEP001|Extraction of Stromal Vascular Fraction and Stem Cells From Fat Tissue|A Proof of Concept Study to Demonstrate the Effectiveness of Antria Cell Preparation Process (Ace Process) in Extraction of Stromal Vascular Fraction From Adipose Tissue||Antria|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Both|18 Years|65 Years|No|||January 2012|January 18, 2012|July 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01399307||101185|
NCT01410123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1105008544|Integrated Stepped Care for Unhealthy Alcohol Use in HIV|Integrated Stepped Care for Unhealthy Alcohol Use in HIV||Yale University|Yes|Recruiting|January 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|642|||Both|21 Years|N/A|No|||January 2016|January 27, 2016|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01410123||100355|
NCT01410136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2010-14B|Chondrofix Osteochondral Allograft Prospective Study|A Post Market Study to Evaluate the Chondrofix® Osteochondral Allograft Utilized for Treatment of Subjects With Cartilage Lesions in the Knee||Zimmer Orthobiologics, Inc.|No|Terminated|April 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|70 Years|No|||August 2014|August 7, 2014|August 2, 2011||No|Inadequate enrollment and decreased need for clinical data to support product|No||https://clinicaltrials.gov/show/NCT01410136||100354|
NCT01409915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1273|Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease|Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease||University of Colorado, Denver|Yes|Recruiting|March 2011|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|55 Years|85 Years|No|||February 2016|February 11, 2016|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409915||100371|
NCT01411033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPS1999|Poznan Prospective Study of Type 1 Diabetic Patients|Poznan Prospective Study of Type 1 Diabetic Patients Treated With Intensive Insulin Therapy From the Onset of the Disease.|PoProStu|Poznan University of Medical Sciences|No|Active, not recruiting|January 1994|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|serum|Both|18 Years|35 Years|No|Non-Probability Sample|100 Caucasian patients with newly diagnosed type 1 diabetes admitted to the Department of        Internal Medicine and Diabetology, Poznan University of Medical Sciences in years        1994-1999, treated from the onset of the disease with intensive insulintherapy.|September 2014|September 10, 2014|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01411033||100285|
NCT01410513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD12012|Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia|A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia||Sanofi||Completed|December 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|N/A|No|||September 2014|September 2, 2014|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410513||100325|
NCT01408134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIVA 1|Viability Imaging in Volumetric Angiography (VIVA 1)|Viability Imaging in Volumetric Angiography (VIVA 1): A Single Center Trial of the Detection of Delayed Hyperenhancement on CT Angiography|VIVA 1|Medstar Research Institute|No|Terminated|June 2011|February 2013|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|July 28, 2011||No|PI/Project director no longer at facility|No||https://clinicaltrials.gov/show/NCT01408134||100507|
NCT01418014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD052102 - PH200|Adolescent Master Protocol|Adolescent Master Protocol|AMP|Harvard School of Public Health|No|Active, not recruiting|March 2007|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|678|Samples With DNA|Serum, cell pellets, plasma, saliva, and urine|Both|7 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-infected and -uninfected children from 7 years of age (7th birthday) up to but not        including the 16th birthday at the time of enrollment born to HIV-infected mothers.        Participants will be children previously enrolled in any of the studies included on the        list of approved studies for co-enrollment into AMP noted above, or another study with        Protocol Team approval or has medical record documentation since birth of key medical data        related to their HIV infection.|January 2016|January 14, 2016|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01418014||99755|
NCT01409967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 10060|The Impact of Red Packed Cells Transfusion on the Main Biological Markers to Determine the Etiology of Anemias|The Impact of Red Packed Cells Transfusion on the Main Biological Markers to Determine the Etiology of Anemias|BÉA/T|Assistance Publique - Hôpitaux de Paris|No|Completed|May 2011|August 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|40|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Probability Sample|Anemic patient with decision of red packed cells transfusion for the current episode.|August 2013|August 23, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409967||100367|
NCT01369758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP 200905|MyoSure Hysteroscopic Tissue Removal System Registry Study|MyoSure Hysteroscopic Tissue Removal System Registry Study||Hologic, Inc.|No|Active, not recruiting|November 2010|November 2013|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Female|18 Years|65 Years|No|||September 2012|November 20, 2012|November 11, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369758||103440|
NCT01401270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-256-2|Prize Contingency Management for Cocaine-Dependent Methadone Patients|Prize Contingency Management for Cocaine-Dependent Methadone Patients||University of Connecticut Health Center|No|Recruiting|November 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401270||101034|
NCT01401517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TheraVasc-TV1001-002|Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC|A Randomized, Double-blinded, Placebo-controlled, Phase IIa Dose-ranging Study to Assess the Safety, Pharmacokinetics, and Tolerability of Multiple Doses of Sodium Nitrite in Patients With Peripheral Arterial Disease (PAD) - SONIC||TheraVasc Inc.|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|35 Years|85 Years|No|||May 2014|May 29, 2014|June 28, 2011|Yes|Yes||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01401517||101015|
NCT01402661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corrona-RA-100|The Corrona RA Data Collection Program|The Corrona RA Data Collection Program|CORRONA|The Consortium of Rheumatology Researchers of North America, Inc.|No|Enrolling by invitation|February 2002|||December 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33312|||Both|18 Years|N/A|No|Non-Probability Sample|Patients are enrolled in the CORRONA Data Collection Program during regularly-scheduled        office visits. Selected rheumatologists are invited to participate as investigators in the        CORRONA Data Collection Program. Physicians are selected carefully in an effort to ensure        enrollment of subjects that represent a reasonable representation of a cross-section of        the population throughout the country with rheumatic diseases. All potential sites are        screened for clinical research experience and adherence to GCP (Good Clinical Practice)        guidelines|June 2015|June 8, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402661||100928|
NCT01398787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-383-C-004|Evaluation of the Cosmetic Performance of AIR OPTIX® COLORS|Cosmetic Validation (US): AIR OPTIX® COLORS Among Habitual Wearers of FRESHLOOK®||Alcon Research|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|198|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|July 19, 2011|Yes|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01398787||101225|
NCT01399047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3908|Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis|Phase II, Randomized, Placebo Controlled Trial of the Safety and Tolerability of Mycophenolate in Children With Juvenile Neuronal Ceroid Lipofuscinosis|JUMP|University of Rochester|Yes|Completed|July 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|25 Years|No|||December 2015|December 4, 2015|July 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399047||101205|
NCT01402947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-115|Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Ciprofloxacin XR Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects||Shire||Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|July 21, 2011|No|Yes||No|June 1, 2012|https://clinicaltrials.gov/show/NCT01402947||100906|
NCT01399554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03AA020194|Exercise as Alcohol Use Disorders Intervention for Non-Treatment Seeking Adults|Exercise as Alcohol Use Disorders Intervention for Non-Treatment Seeking Adults||St. Louis University|Yes|Completed|April 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|21 Years|55 Years|No|||April 2014|April 4, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399554||101166|
NCT01409668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2007:070|Efficacy of Two Yogurt Formulations in Healthy Humans|Efficacy of Two Yogurt Formulations as Health Promoting Agents in Healthy Humans|MPH|University of Manitoba|Yes|Completed|September 2007|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2007|August 3, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01409668||100390|
NCT01410734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fluorescence Bliliary ID|Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree (up to 2-weeks Post-operatively)|A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree||Intuitive Surgical|Yes|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|72|||Both|18 Years|80 Years|No|||December 2012|December 19, 2012|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410734||100308|
NCT01408680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40428-A|CoQ10 Biomarker Trial|Assessing the Effect of the Dietary Supplement Coenzyme Q10 on Biomarkers of Oxidative Stress, Systemic Inflammation, and Endothelial Function in Hemodialysis Patients||University of Washington|Yes|Completed|November 2011|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|66|||Both|18 Years|85 Years|No|||December 2014|December 2, 2014|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01408680||100465|
NCT01409720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISPO|Isometric Muscle Training in Patients With Spinal Bony Metastases Under Radiation Therapy|Isometric Muscle Training of the Spine Musculature in Patients With Spinal Bony Metastases Under Radiation Therapy|DISPO|Heidelberg University|No|Completed|September 2011|September 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||August 2011|March 19, 2014|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409720||100386|
NCT01409733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pereira-DE-2010|TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients|TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients||Heidelberg University|No|Recruiting|June 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2011|August 3, 2011|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409733||100385|
NCT01409746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0989|Early Brain Development in Twins|Early Brain Development in Twins||University of North Carolina, Chapel Hill|No|Active, not recruiting|April 2004|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|buccal swabs; MRIs, ultrasounds|Both|N/A|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|medical center and community sample|December 2015|December 3, 2015|April 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01409746||100384|
NCT01410006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1036|Neurofibromatosis Type 1 Patient Registry|Neurofibromatosis Type 1 Patient Registry|NPRI|Washington University School of Medicine|No|Recruiting|May 2011|||December 2040|Anticipated|N/A|Observational [Patient Registry]|N/A||1|Anticipated|5000|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is all individuals diagnosed with Neurofibromatosis Type 1.|December 2015|December 7, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01410006|50 Years|100364|
NCT01408654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CE001942-01|Social Connections and Healthy Aging (The Senior Connection)|Social Connections and Healthy Aging (The Senior Connection)|TSC|University of Rochester|Yes|Active, not recruiting|March 2011|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|60 Years|N/A|No|||November 2015|November 20, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408654||100467|
NCT01417767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHG－DAC 001|Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS|Phase 2/3 Study of Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS||Shanghai Sixth People's Hospital|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|80 Years|No|||September 2011|September 1, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417767||99774|
NCT01417975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmokingTopography1114|Effect of an Acute Bout of Exercise on Smoking Satisfaction|Does an Acute Bout of Exercise Affect Smoking Satisfaction?||University of Western Ontario, Canada|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|43|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2012|December 15, 2014|August 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01417975||99758|
NCT01418261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP125|Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)|||Medtronic Vascular|Yes|Active, not recruiting|September 2011|||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|530|||Both|18 Years|80 Years|No|||October 2015|October 14, 2015|August 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418261||99736|
NCT01410474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_49|Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan|A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan||Novartis||Completed|August 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|341|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|August 3, 2011|Yes|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT01410474||100328|
NCT01400984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-526|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Slovakia|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Slovakia|ECOS SVK|Merck KGaA|No|Active, not recruiting|December 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|88|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400984||101056|
NCT01402050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-10-0012|Foley Catheter Versus Cervidil for Induction of Labor at Term|A Randomized Controlled Trial of Transcervical Foley Balloon Compared to Controlled Release Prostaglandin (Cervidil) for Labor Induction and Cervical Ripening in Term and Near Term Women||Mednax Center for Research, Education and Quality|Yes|Active, not recruiting|June 2010|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 17, 2014|April 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402050||100975|
NCT01402063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 244|PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation|PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study||Brown University|Yes|Completed|September 2011|June 2015|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|July 8, 2011|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01402063||100974|
NCT01402453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008320|Monetary Incentives and Intrinsic Motivation to Sustain Hypertension Control|Monetary Incentives and Intrinsic Motivation to Sustain Hypertension Control Pilot Study||University of California, Los Angeles|No|Completed|August 2011|September 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|207|||Both|18 Years|N/A|No|||March 2015|March 7, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402453||100944|
NCT01402674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11061-01|Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal|Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal|PC-II|Center for Weight Management, California|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|269|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|July 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01402674||100927|
NCT01398800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000113|Early Clinical Results of Mobile-Bearing Revision Total Knee Arthroplasty|Early Clinical Results of Mobile-Bearing Revision Total Knee Arthroplasty|MBT|Colorado Joint Replacement|No|Active, not recruiting|July 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|320|||Both|N/A|N/A|No|Non-Probability Sample|All patients of Colorado Joint Replacement|September 2015|September 25, 2015|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398800||101224|
NCT01398813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-008|X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey|Survey of X-Linked Hypohidrotic Ectodermal Dysplasia Carrier Women's Outlook Towards Reproduction, Potential XLHED Treatments and Genetic Testing|X-CORS|Edimer Pharmaceuticals|No|Completed|July 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|The study will enroll XLHED carrier females|July 2013|July 7, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398813||101223|
NCT01398826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TT1-001|Glycemic Response to Road Cycling in Type 1 Diabetes|A Pilot Study Assessing the Glycemic Response and Its Relationship to Performance During Road Cycling in Elite Athletes With Type 1 Diabetes and Non-Diabetic Controls||Team Type 1, Inc.|No|Active, not recruiting|May 2011|August 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Professional cyclists on TeamType 1 cycling teams|July 2011|July 20, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398826||101222|
NCT01399333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003|Comparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method|Comparison of Meal Replacements Versus Protein Supplements and Utilizing the PDCAAS Method in the Bariatric Patient|PDCAAS|Southeast Bariatrics, PA|No|Recruiting|January 2010|January 2012|Anticipated|August 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2011|July 22, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399333||101183|
NCT01399346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRINK-01|Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes|A Single-center, Randomized, Controlled, 2-period Cross-over, Open-labelled Trial to Evaluate the Impact of Different Application Volumes on Pharmacokinetic and Pharmacodynamic Properties of Insulin Aspart in Subjects With Type 1 Diabetes||Medical University of Graz|Yes|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|60 Years|No|||April 2012|April 19, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01399346||101182|
NCT01410448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AIT25|Everolimus in de Novo Kidney Transplant Recipients|A 3-month, Multicenter, Randomized, Open Label Study to Evaluate the Impact of Early Versus Delayed Introduction of Everolimus on Wound Healing in de Novo Kidney Transplant Recipients With a Follow-up Evaluation at 12 Month After Transplant (NEVERWOUND Study)|NEVERWOUND|Novartis||Active, not recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|383|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|August 2, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01410448||100330|
NCT01410760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0505/95|PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases|Perfusion Computed Tomography Pilot Study in the NCRN FOXFIRE Clinical Trial to Determine Blood Flow to Liver Metastases|PERFORM|University of Oxford|No|Recruiting|April 2011|||April 2013|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410760||100306|
NCT01407640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081223|Diagnosis and Physiopathology of Insulin Allergy|Diagnosis and Physiopathology of Insulin Allergy (IA)|Allerdiab|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01407640||100545|
NCT01411046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCR-RA-CSI|Difference in GC-induced Adrenal Insufficiency in RA Related to Polymorphisms in the Glucocorticoid Receptor Gene|Observational Cohort Study on Difference in Glucocorticoid-induced Adrenal Insufficiency in Patients With Rheumatoid Arthritis Related to Different Sensitivity Polymorphisms in the Glucocorticoid Receptor Gene||Rigshospitalet, Denmark|Yes|Recruiting|April 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|blood samples and DNA from gene analyses|Both|18 Years|70 Years|No|Non-Probability Sample|50 consecutive patients with rheumatoid arthritis|October 2014|October 26, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01411046||100284|
NCT01410253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG090650|Effects of Cardiac Rehabilitation on Postoperatory of Coronary Artery Bypass Graft.|Evaluation of the Effects of Different Physical Therapy on Cardiac Rehabilitation in Post Operatory Period of Coronary Artery Bypass Graft: Randomized Clinical Trial.||Hospital de Clinicas de Porto Alegre|Yes|Completed|January 2011|March 2016|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01410253||100345|
NCT01410266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.5|Reducing the Need for In-Clinic Follow-Up for Medical Abortion in Moldova and Uzbekistan|The Acceptability and Feasibility of Reducing the Need for In-Clinic Follow-Up for First Trimester Medical Abortion in Moldova and Uzbekistan||Gynuity Health Projects|No|Completed|September 2010|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2400|||Female|16 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410266||100344|
NCT01411293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-124|Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome|Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome||University of Connecticut|No|Completed|August 2011|October 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01411293||100265|
NCT01407848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1488|Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea|Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea||University of Cologne|Yes|Completed|January 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||September 2015|September 22, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01407848||100529|
NCT01417702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0007|Endoscopy for Assessment of Mucosal Healing in IBD|Advanced Endoscopic Imaging Using HD+ Endoscopy and i-Scan for Assessment of Mucosal Healing in IBD||University of Erlangen-Nürnberg Medical School|Yes|Recruiting|August 2011|November 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|232|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with Crohn´s disease and ulcerative colitis were prospectively included.|January 2013|January 23, 2013|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01417702||99779|
NCT01418066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-4673 AHIB|Ayurvedic Herbs in Diarrhea Predominant Irritable Bowel Syndrome|Feasibility and Safety of Ayurvedic Herbs in Diarrhoea-predominant Irritable Bowel Syndrome|AHIB|Universität Duisburg-Essen|No|Completed|August 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418066||99751|
NCT01418274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25643|A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers|A Study to Investigate the Effect of Multiple Doses of Danoprevir/Ritonavir (DNV/RTV) on the Pharmacokinetics (PK) of Escitalopram (ESC) and S-Demethylcitalopram (S-DCT) in Healthy Subjects||Hoffmann-La Roche||Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01418274||99735|
NCT01418547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180/09|Bioequivalence Study of Torrent Pharmaceutical Limited's Isosorbide Mononitrate 120 mg ER Tablets Under Fed Conditions|An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA in Healthy, Adult, Male, Human Subjects Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 16, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01418547||99714|
NCT01401790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUSTEJUSTINE2644|Use of a Telehomecare Program for Young Patients With New Onset Type 1 Diabetes|Use of a Telehomecare Program for Young Patients With New Onset Type 1 Diabetes||Huot, Celine, M.D.|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|86|||Both|6 Months|18 Years|No|||July 2011|July 22, 2011|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01401790||100995|
NCT01401803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrowDysport2011|Brow Lifting With Dysport|Brow Lifting With Dysport||Beer, Kenneth R., M.D., PA|No|Completed|September 2011|December 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|25 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 24, 2013|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401803||100994|
NCT01402440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COEB071X2101|Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma|An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma||Novartis||Terminated|November 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|July 5, 2011|No|Yes|Study terminated due to enrolment challenges and availability of other options for DLBCL    patients. The termination is not a consequence of any safety concern.|No||https://clinicaltrials.gov/show/NCT01402440||100945|
NCT01402102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Doul-BGarlic-001|A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia|Efficacy and Safety of Aged Garlic Powder on Lipids||Chonbuk National University Hospital|Yes|Completed|July 2010|July 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|60|||Both|20 Years|80 Years|No|||October 2012|October 11, 2012|July 21, 2011||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01402102||100971|
NCT01402466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12690|Urban Health Study II|Finding, Testing and Treating High-Risk Probationers and Parolees With HIV||RTI International|No|Active, not recruiting|August 2011|December 2015|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|49|||Both|18 Years|70 Years|No|||July 2015|July 8, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01402466||100943|
NCT01402687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-236|SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)|Single Nucleotide Polymorphism (SNP)-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants||Dana-Farber Cancer Institute|Yes|Completed|October 2010|June 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|181|Samples With DNA|Saliva sample|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have undergone autologous HSCT for Hodgkin's or non-Hodgkin's lymphoma or        multiple myeloma at Dana Farber Cancer Institute from 1/1/2006 through 6/30/2010.|June 2013|July 15, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402687||100926|
NCT01398839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-002|Safety Study of the VEGA UV-A System to Treat Ectasia|||Topcon Medical Systems, Inc.|No|Terminated|December 2010|||July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|July 10, 2011|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01398839||101221|
NCT01399060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812923|Cough Sensitivity and Taste Preferences|Cough and Taste Preferences in Adolescents and Adults|CAP|Monell Chemical Senses Center|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|80|Samples With DNA|Saliva samples will be obtained from the subjects, if consented. These saliva samples will      be genotyped at the Monell Center for genes that may play a role in chemical irritation and      flavor-perception. This testing is exploratory in nature.|Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 50 parent-child dyads (N=100 subjects total) will be tested on two days        separated by at least 2-3 days. The children will be between the ages of 10 and 17 years.        Half of sample will be children whose mothers are current smokers and the other have will        be children whose mothers and fathers never smoked in their lifetimes.|October 2013|October 23, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399060||101204|
NCT01399073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMS-Neglect|Virtual Reality for Neglect Diagnostics|Virtual Reality for Neglect Diagnostics|KMS-Neglect|Charite University, Berlin, Germany|No|Completed|May 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|27|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with acute (< 2 wks after stroke), subacute (2 wks- 3 months after stroke)or        chronic (3- 24 months after stroke)stroke with neglect or hemianopsia.        Healthy, age-matched controls.|January 2016|January 20, 2016|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01399073||101203|
NCT01399359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP-DMP-1|Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer|A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer||NSABP Foundation Inc|No|Completed|August 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1023|||Female|35 Years|N/A|No|Non-Probability Sample|Women at increased risk for breast cancer.|March 2015|March 5, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399359||101181|
NCT01407328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-031|The Effect of the Shoulder Arthroscopic Surgery on Respiratory Mechanics|The Effect of the Shoulder Arthroscopic Surgery on Respiratory Mechanics||Samsung Medical Center|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|20 Years|69 Years|No|Non-Probability Sample|patients undergoing arthroscopic shoulder rotator cuff repair surgery|April 2013|April 28, 2013|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01407328||100569|
NCT01408446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZS01167261|Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients|A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of DANSHU Capsule(Menthol) and Placebo on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients|ESMAB|Third Military Medical University|Yes|Recruiting|August 2012|April 2014|Anticipated|October 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 27, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01408446||100483|
NCT01416896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BME-1|New Needle for Two-Needle Hemodialysis|New Needle for Two-Needle Hemodialysis|BME-1|Biomedical Enterprises Inc|Yes|Recruiting|August 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||August 2011|August 12, 2011|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01416896||99839|
NCT01407614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15378|The Tilburg Vasospasm Study|Prevention of Secondary Ischemia After Aneurysmal Subarachnoid Hemorrhage With Cerebrospinal Fluid Drainage. A Randomized Controlled Trial||Elisabeth-TweeSteden Ziekenhuis|Yes|Terminated|December 2007|June 2009|Actual|March 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|No|||August 2011|August 1, 2011|January 10, 2011||No|patient enrollment too slow|No||https://clinicaltrials.gov/show/NCT01407614||100547|
NCT01417455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCRAAS|Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis|Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis||Instituto de Medicina Molecular|No|Completed|January 2012|May 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|101|Samples With DNA|Blood and bone samples|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with RA diagnosis (according to the revised American Rheumatism Association        criteria, 1988) and AS diagnosis (according to the European Spondyloarthropathy Study        Group criteria, 1991)|February 2016|February 29, 2016|August 15, 2011||No||No|January 3, 2016|https://clinicaltrials.gov/show/NCT01417455||99797|
NCT01417715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0008|Endomicroscopy for Assessment of Mucosal Healing|Advanced Endoscopic Imaging Using Endomicroscopy for Assessment of Mucosal Healing in IBD||University of Erlangen-Nürnberg Medical School|Yes|Recruiting|August 2011|August 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|84|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with Crohn´s disease and ulcerative colitis in the active and quiescent phase of        the disease.|January 2013|January 23, 2013|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01417715||99778|
NCT01417728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mudter2011|Endomicroscopy in IBD Patients|Endomicroscopy for Assessment of Structural and Functional Changes in IBD Patients Treated With Anti-TNFalpha - Insights in the Process in Mucosal Healing|EARLY|University of Erlangen-Nürnberg Medical School|No|Recruiting|May 2011|August 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|70 Years|No|Non-Probability Sample|trusted IBD diagnosis (Crohn`s disease of ulcerative colitis)|November 2012|November 29, 2012|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417728||99777|
NCT01418651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007|Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population|Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population: an Open-label Study||Banner Health|No|Terminated|March 2011|August 2011|Anticipated|August 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|65 Years|N/A|No|||January 2011|August 16, 2011|March 28, 2011|Yes|Yes|Lack of subjects|No||https://clinicaltrials.gov/show/NCT01418651||99706|
NCT01417988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIGHD_001|Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment|Prevention of Early Mortality by Presumptive TB Treatment in HIV-infected Patients Initiating Antiretroviral Therapy|PrOMPT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Terminated|August 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|July 25, 2011||No|Study was terminated prematurely due to insufficient enrolment.|No||https://clinicaltrials.gov/show/NCT01417988||99757|
NCT01418001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-104|Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)|A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)||Memorial Sloan Kettering Cancer Center||Terminated|August 2011|November 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 15, 2011|Yes|Yes|Lack of accrual|No|January 19, 2016|https://clinicaltrials.gov/show/NCT01418001||99756|
NCT01401829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROG-SIU-11-004|Psychosocial Benefits of Exercise in Endometrial Cancer Survivors|Psychosocial Benefits of Exercise in Endometrial Cancer Survivors||University of Alabama at Birmingham|No|Terminated|July 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|2|||Female|18 Years|70 Years|No|||May 2015|May 11, 2015|July 21, 2011||No|Terminated due to lack of funding required to continue the study.|No||https://clinicaltrials.gov/show/NCT01401829||100992|
NCT01401322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-19607|Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia|Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)||Stanford University|Yes|Terminated|January 2011|May 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|July 20, 2011|Yes|Yes|low accrual|No|October 27, 2014|https://clinicaltrials.gov/show/NCT01401322||101030|
NCT01402076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-1110|A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects|An Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes Using Midazolam and Rosiglitazone as Substrates in Healthy Subjects||Vanda Pharmaceuticals|No|Completed|August 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|July 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01402076||100973|
NCT01402089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG 327/10|Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients|Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients||Cantonal Hospital of St. Gallen|Yes|Completed|January 2012|November 2015|Actual|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01402089||100972|
NCT01402115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glu-POLYCAN-001|A 12-week Human Trial to Compare the Efficacy and Safety of Polycan on Bone Metabolism|Efficacy and Safety Study of Polycan on Bone Metabolism||Chonbuk National University Hospital|Yes|Completed|November 2008|May 2009|Actual|February 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|60|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|July 21, 2011||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01402115||100970|
NCT01402128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTB-bG-001|Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects|The Effect of Barley Beta-glucan on Serum Lipids and Body Weight||Chonbuk National University Hospital|Yes|Completed|June 2010|May 2011|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|80|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|July 21, 2011||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01402128||100969|
NCT01399372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1114|Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma||Radiation Therapy Oncology Group|Yes|Active, not recruiting|September 2011|||December 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399372||101180|
NCT01399606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-10 / BF2.649|Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)|An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up)|HARMONYIII|Bioprojet|Yes|Active, not recruiting|May 2011|December 2015|Anticipated|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01399606||101162|
NCT01399814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NLY031|Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer|||Nanjing PLA General Hospital|No|Completed|May 2009|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|179|||Both|65 Years|N/A|No|||May 2009|July 21, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01399814||101146|
NCT01399827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002435|Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits|Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial||Massachusetts General Hospital|No|Active, not recruiting|February 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|55 Years|No|||September 2015|September 23, 2015|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01399827||101145|
NCT01400100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4033-11|Effects of Intraarterial Octreotide on Pancreatic Texture|Changes in Pancreatic Texture After Single-shot Administration of 500 µg Octreotide in the Gastroduodenal Artery During Pancreatoduodenectomy - a Double-Blinded Randomized Controlled Trial||St. Josef Hospital Bochum|Yes|Completed|August 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|90 Years|No|||March 2012|March 4, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01400100||101124|
NCT01399086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/10.10|Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer|A Retrospective Study of Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer in Greece (The 'RESPONSE' Study)||Hellenic Oncology Research Group|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|140|||Female|18 Years|N/A|No|Probability Sample|Retrospective chart-review study that will be based on the collection of data from        electronical or paper-based medical records with available data on patients that fulfil        the following-mentioned eligibility criteria and have initiated therapy with fuvestrant        after January 1st of 2007. All necessary information for the purposes of the present study        will be collected with the use of a paper-Case Record Form|March 2012|March 12, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01399086||101202|
NCT01400347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMGMarko|Electromyography During Common Exercises Used in Rehabilitation|Influence of Fatigue and Speed on Electromyographic Activity of Lower Extremity Muscles During Selected Weight Bearing Exercises Commonly Used for Fitness and Rehabilitation||State University of New York - Upstate Medical University|Yes|Not yet recruiting|July 2012|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit healthy, young (18-35 y.o.) subjects. Following signing the inform        consent, potential participants will be given a health risk questionnaires to identify        possible cardiovascular and/or orthopedic risks to strength training exercise. Answering        YES to any of the questions on the PAR Q will be considered an exclusion criterion. In        addition we will use a MEDICAL HISTORY QUESTIONNAIRE (included at the end of this form).        Specifically, subjects who are at risk due to recent (within the last year)        neuro-musculo-skeletal injury to lower extremities will be excluded from the study. Also,        we will exclude subjects who reported any significant respiratory-cardiovascular disease,        which is not yet under control..|November 2009|July 20, 2011|November 18, 2009||No||No||https://clinicaltrials.gov/show/NCT01400347||101105|
NCT01408160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-04-146|Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia|A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|April 2013|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408160||100505|
NCT01409174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0073|IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma|IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2013|||February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|65 Years|No|||September 2015|September 25, 2015|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409174||100428|
NCT01409187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0074|IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma|IPI-Biotherapy for Patients With Metastatic Melanoma Previously Treated With Cytotoxic Drugs||M.D. Anderson Cancer Center|No|Withdrawn|October 2011|||October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||January 2012|January 25, 2012|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409187||100427|
NCT01409200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0231|Neoadjuvant Axitinib in Prostate Cancer|Pre-surgical Androgen Deprivation Therapy With or Without Axitinib in Previously Untreated Prostate Cancer Patients With Known or Suspected LymphNode Metastasis||M.D. Anderson Cancer Center|Yes|Recruiting|March 2012|||March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Male|18 Years|N/A|No|||January 2016|January 4, 2016|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409200||100426|
NCT01417208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011711|Clinical Evaluation of the SNaP Wound Care System in Promoting Healing in Chronic Wounds|Clinical Evaluation of the SNaP Wound Care System in Promoting Healing in Chronic Wounds||Spiracur, Inc.|No|Active, not recruiting|June 2011|||December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diabetic foot ulceration, venous or mixed aetiology lower limb ulceration        who are receiving out-patient treatment from the Section of Wound Healing, Cardiff        University, Wales.|December 2012|December 11, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01417208||99816|
NCT01417468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVDMaryland-001|How Well do Patients With Traumatic Brain Injury Learn New Material Using Learning Styles in Online Science Classrooms?|Instructional Design Strategies to Support Adult Patients/Students (Civilian & Military) With Traumatic Brain Injury (TBI).|CVD|Center for Vision Development, New Market, Maryland|Yes|Active, not recruiting|May 2011|December 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|50 Years|No|||December 2012|December 15, 2012|August 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01417468||99796|
NCT01417481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glycine in CF|Effect of Glycine in Cystic Fibrosis|Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis||Instituto Nacional de Enfermedades Respiratorias|Yes|Terminated|March 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|5 Years|15 Years|No|||October 2014|October 30, 2014|August 15, 2011||No|Some of the researchers finished their participation in the study.|No|September 9, 2014|https://clinicaltrials.gov/show/NCT01417481||99795|
NCT01417494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000706869|1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer|Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO||Federation Francophone de Cancerologie Digestive|Yes|Active, not recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|75 Years|N/A|No|||March 2013|March 3, 2014|August 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01417494||99794|
NCT01417741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APOM-7605|Acupuncture and Nausea/Vomiting in Pediatric Patients|Is Intra-operative Acupuncture at P6 Plus IV Antiemetics More Effective Than IV Antiemetic Therapy Alone in Preventing Postoperative Vomiting in Pediatric Patients Following Tonsillectomy With or Without Adenoidectomy?||Oregon Health and Science University|Yes|Recruiting|August 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|3 Years|9 Years|No|||April 2014|April 9, 2014|August 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417741||99776|
NCT01411202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008362-01H|Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population|Outpatient Pleurodesis Using Sclerosants(OPUS):Comparing Doxycycline Pleurodesis to Continued Drainage With the Pleurx Catheter System in the Treatment of Malignant Pleural Effusions in the Outpatient Setting|OPUS|Ottawa Hospital Research Institute|Yes|Recruiting|June 2011|November 2018|Anticipated|November 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411202||100272|
NCT01418027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD011|Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD)|Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease||Shanghai Jiao Tong University School of Medicine|No|Completed|August 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|220|||Both|40 Years|65 Years|No|||August 2014|August 28, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418027||99754|
NCT01418300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC2010-088|Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial|||Jeil Pharmacy Co.||Completed|August 2010|December 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|80 Years|No|||August 2011|April 26, 2015|August 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01418300||99733|
NCT01418313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 01-1032|Non-Invasive Imaging of Atherosclerosis|In Vivo Molecular Imaging (MRI) of Atherothrombotic Lesions||Icahn School of Medicine at Mount Sinai|No|Recruiting|September 2011|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|159|Samples With DNA|Whole Blood, Endarterectomy Specimens|Both|20 Years|N/A|No|Non-Probability Sample|Subjects in the New York area referred by primary care physician, or recruited through        Lifeline Screening or ResearchMatch.org, or Mount Sinai Broadcast emails and flyers.|December 2015|December 22, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01418313||99732|
NCT01401569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8608|Efficacy of Exercise and Counseling Intervention on Relapse in Smoker With Depressive Disorders|STOB-ACTIV: The Efficacy of Exercise and Counseling for Depressed Patients as an Aid for Smoking Cessation, a Randomized Controlled Trial|STOB-ACTIV|University Hospital, Montpellier|No|Terminated|October 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||June 2013|June 12, 2013|July 21, 2011||No|Difficulties for recruiting patients|No||https://clinicaltrials.gov/show/NCT01401569||101011|
NCT01401582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZNE_DelpHi-MV_001|Intervention Study to Improve Life and Care for People With Dementia and Their Caregivers in Primary Care|Dementia: Life- and Personcentered Help in Germany|DelpHi|German Center for Neurodegenerative Diseases (DZNE)|Yes|Not yet recruiting|September 2011|||January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1000|||Both|70 Years|N/A|No|||August 2011|August 10, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01401582||101010|
NCT01401842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10193004|Reduction of Risk for Low Back Injury in Theater of Operations|Reduction of Risk for Low Back Injury in Theater of Operations||University of South Florida|Yes|Completed|June 2012|March 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|582|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|June 15, 2011||No||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01401842||100991|
NCT01399099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA003|A Study of a Novel Silicone Dressing to Minimize Scar Formation|Scar Prevention and the Clinical Effectiveness of a Novel Mechanomodulating Polymer|REFINE|Neodyne Biosciences, Inc.|No|Completed|June 2011|March 2013|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|67|||Both|18 Years|65 Years|No|||December 2014|December 17, 2014|June 27, 2011|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01399099||101201|The Neodyne Dressing is referred to as the embrace device.Grant/Funding source: Armed Forces Institute of Regenerative Medicine is funded by US Army Medical Research and Materiel Command (our collaborator) http://www.afirm.mil/
NCT01400113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00184|Treating Acutely Agitated Patients With Asenapine Sublingual Tablets|Treating Acutely Agitated Patients With Asenapine Sublingual Tablets: A Single-Dose, Randomized, Double-Blind Placebo Controlled Trial||St. Joseph Hospital Health Center|Yes|Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||January 2013|January 16, 2013|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400113||101123|
NCT01400373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRINCESS 2010/383-32|Prehospital Resuscitation Intra Nasal Cooling Effectiveness Survival Study|PRINCESS - Prehospital Resuscitation Intra Nasal Cooling Effectiveness Survival Study|PRINCESS|Karolinska Institutet|No|Recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|79 Years|No|||April 2015|April 24, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01400373||101103|
NCT01400607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISTO NEO-01-09-01|Neocartilage Implant to Treat Cartilage Lesions of the Knee|Randomized Controlled Trial to Evaluate the Efficacy of a Neocartilage Implant in the Management of ICRS Grade 3 to 4 Articular Cartilage Lesions of the Knee||ISTO Technologies, Inc.|Yes|Active, not recruiting|July 2011|July 2019|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|60 Years|No|||May 2014|March 23, 2015|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01400607||101085|
NCT01370187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Montelukast for bronchiolitis|Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing|Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing in Infants 3 to 12 Months of Age in Bandar Abbas Children' Hospital||Hormozgan University of Medical Sciences|Yes|Completed|July 2010|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|146|||Both|3 Months|12 Months|No|||June 2010|June 13, 2011|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370187||103407|
NCT01400841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSE 300|HAART Model 300 Annuloplasty Ring|A Prospective, Non-randomized, Multi-center Trial to Evaluate the Safety and Effectiveness of the HAART Model 300 Annuloplasty Ring When Used to Surgically Repair a Leaking Aortic Valve Using a 3-D Intra-annular Mounting Frame||Biostable Science & Engineering|Yes|Completed|January 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|50 Years|N/A|No|||July 2013|July 8, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400841||101067|
NCT01400854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25608/5008|Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability|ERKENTNIS: Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability|ERKENTNIS|Teva Pharmaceutical Industries|No|Completed|July 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|Adult cancer patients (in- or out-patients) that are suffering from breakthrough pain|October 2012|October 23, 2012|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400854||101066|
NCT01400360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannWGUH_IMCVS|Invasive Diagnostic and Therapeutic Management of Cerebral Vasospasm After Aneurysmatic Subarachnoid Hemorrhage|Invasive Diagnostic and Therapeutic Management of Cerebral Vasospasm After Aneurysmatic Subarachnoid Hemorrhage|IMCVS|Johann Wolfgang Goethe University Hospitals|No|Recruiting|August 2009|||August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|75 Years|No|||May 2011|July 21, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01400360||101104|
NCT01401114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15041|Wellnara Post-marketing Surveillance in Japan|Drug Use Investigation of Wellnara Tablet|WELLNARA|Bayer|No|Completed|March 2009|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|411|||Female|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who have received a prescription of        Wellnara on the basis of the decision of the treating gynecologist. The study is expected        to collect data of 400 patients in about 80 gynecological practices in Japan.|September 2015|September 25, 2015|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01401114||101046|
NCT01408927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VASP|Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population|Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary PCI and CABG Population|VASP|Medstar Research Institute|No|Recruiting|October 2008|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|1000 patients, male or female, older than 18 years of age, who are scheduled for or        underwent percutaneous coronary intervention (PCI) or CABG and have been treated with a        loading dose of a thienopyridine or on a maintenance dose of a thienopyridine.|August 2014|August 8, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01408927||100446|
NCT01409434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEAR Follow-Up|Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study|Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study||University of Florida|No|Completed|June 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|44|||Both|18 Years|75 Years|No|||October 2014|October 10, 2014|August 1, 2011|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT01409434||100408|
NCT01416662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000703689|Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery|Pharmacogenetics of Gemcitabine: Study of the Impact of Genetic Polymorphism of Cytidine Deaminase (CDA) on Toxicity in Resected Pancreatic Adenocarcinomas||Federation Francophone de Cancerologie Digestive|No|Active, not recruiting|June 2011|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||August 2011|March 3, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416662||99857|
NCT01416675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPI-ICU|Delirium Assessment in the Pediatric Intensive Care Unit|Delirium Assessment in the Pediatric Intensive Care Unit|DIPI-ICU|Charite University, Berlin, Germany|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|73|||Both|5 Years|17 Years|No|Probability Sample|Pediatric Intensive Care Unit Patients|June 2014|June 5, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416675||99856|
NCT01416688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1013|S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride|S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities||Southwest Oncology Group|Yes|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|120 Years|No|Non-Probability Sample|Limited institutions from the SWOG membership.|October 2015|October 15, 2015|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416688||99855|
NCT01416909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15712|Managing Medication-induced Constipation in Cancer: A Clinical Trial|Managing Medication-induced Constipation in Cancer: A Clinical Trial||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|November 2008|January 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|601|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416909||99838|
NCT01417221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAN-HT|Renal Sympathetic Modification in Patients With Essential Hypertension|Renal Sympathetic Modification in Patients With Essential Hypertension||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|August 2011|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||May 2013|May 2, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417221||99815|
NCT01417507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0925|Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery|Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients With Supratentorial Low-Risk Grade II Glioma||Radiation Therapy Oncology Group||Completed|October 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|Samples With DNA|Tissue will be submitted to the RTOG Biospecimen Resource for the purpose of central review      of pathology (mandatory fo eligibility), tissue banking, and translational research (highly      recommended). For central review, H&E slide and tumor block must be submitted. For tissue      banking and translational research, remaining tissue from the central review will be used      and plasma, whole blood and urine will be collected.|Both|18 Years|N/A|No|Non-Probability Sample|Central pathology-confirmed diagnosis of supratentorial grade II oligodendroglioma,        astrocytome or mixed oligoastrocytoma prior to Step 2 registration.        The patient must be within one of the following categories:        Maximal safe resection with minimal residual disease defined as follows:          -  Removal of T2/FLAIR abnormalities thought to be primarily tumor, with a residual ≤ 2             cm maximal tumor diameter/T2 FLAIR abnormality on MRI to be done within 84 days             postoperatively.          -  Patients who require a second surgery to obtain a maximal safe resection will be             eligible if the second surgery is performed within 84 days of the inital diagnostic             procedure.        OR Age <40 (any extent of resection) OR Age <50, preoperative tumor diameter <4 cm (any        extent of resection)|March 2015|March 17, 2015|August 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01417507||99793|
NCT01417780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATB-201|Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients|Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections||Atox Bio Ltd|Yes|Completed|December 2011|December 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417780||99773|
NCT01411501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011CB505202|Efficacy and Safety of Acupuncture for Functional Constipation|Efficacy and Safety of Acupuncture for Functional Constipation: a Multi-center Randomized Controlled Trial||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|September 2011|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|684|||Both|18 Years|75 Years|No|||November 2015|November 8, 2015|July 28, 2011|Yes|Yes||No|September 25, 2015|https://clinicaltrials.gov/show/NCT01411501||100249|Unblinding of participants in the acupuncture and mosapride groups;an insufficient duration to assess the long term effect or risks;a missing assessment of electrocardiograms for possible cardiovascular harm of mosapride
NCT01418040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS MET-10-0030|PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)|A Phase 2 Clinical Trial Exploring 3-Dimensional Imaging of Androgen Deprivation Induced Osteoporosis, Radiotherapy Hypofractionation and the Prognostic Significance of Micrometastatic Disease in Men With Prostate Cancer|PROCITT|Toowoomba Regional Cancer Research Centre|No|Recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Male|N/A|N/A|No|Non-Probability Sample|Patients from Radiation Oncology Queensland Toowoomba outpatient clinics will be offered        recruitment into the study by Radiation Oncologists.|June 2011|August 15, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418040||99753|
NCT01418053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-4627 CarO|The Effect of Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome|Randomised Controlled Study on the Effect of a Kneipp Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome|CarO|Universität Duisburg-Essen|No|Completed|August 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418053||99752|
NCT01401595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806753|Brain Imaging and Treatment Studies of the Night Eating Syndrome|Brain Imaging and Treatment Studies of the Night Eating Syndrome|NES|University of Pennsylvania|Yes|Completed|December 2009|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01401595||101009|
NCT01401855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29527|Use of an In Vivo Optical Probe to Discriminate Benign From Malignant Thyroid Nodules|Optical Probe In Thyroid Cancer||Boston Medical Center|No|Recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects, male and female, undergoing thyroid fine needle aspiration biopsy at Boston        Medical Center ages 18 and older. Study population includes all ethnic groups.|February 2013|February 13, 2013|July 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01401855||100990|
NCT01399853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT005|A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants|A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|July 2011|May 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|10||Actual|1200|||Both|6 Months|36 Months|No|||May 2012|May 29, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01399853||101143|
NCT01369290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESP-3152|Electroencephalography (EEG) Signal Processing|EEG Signal Processing as a Predictor of Antidepressant Response|EEG-SP|St. Joseph's Healthcare Hamilton|No|Recruiting|October 2009|October 2013|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|150|||Both|18 Years|70 Years|No|Probability Sample|Outpatients with Major Depressive Disorder from the Greater Hamilton Area|November 2011|November 28, 2011|September 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01369290||103476|
NCT01369303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-113|Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel|Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Using the Bat 24 Regimen Versus Daily and Pericoital Dosing||CONRAD|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|194|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|June 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01369303||103475|
NCT01369628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700461_014|Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil|A Phase Ib, Multicenter, Open Label, Dose-Escalating, Repeat-Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept When Administered to Subjects With Lupus Nephritis on a Stable Regimen of Mycophenolate Mofetil (MMF) With or Without Corticosteroids||EMD Serono|Yes|Terminated|June 2011|||November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2013|October 21, 2013|June 7, 2011|Yes|Yes|Please see Purpose Statement below|No||https://clinicaltrials.gov/show/NCT01369628||103450|
NCT01370200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111/09/09|Regional Citrate Anticoagulation in Plasma Exchange Treatment|Regional Citrate Anticoagulation in Plasma Exchange Treatment||University Medical Centre Ljubljana|No|Completed|April 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01370200||103406|
NCT01370447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI-2009-1|EPI-743 for Mitochondrial Respiratory Chain Diseases|Emergency Use Protocol for EPI-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care||Edison Pharmaceuticals Inc|No|Active, not recruiting|February 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|1 Year|N/A|No|||March 2016|March 18, 2016|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370447||103387|
NCT01370798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.608|Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications|Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications.|HYPOSPADES|Hospices Civils de Lyon|Yes|Recruiting|May 2011|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|485|||Male|9 Months|36 Months|No|||September 2015|September 21, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370798||103360|
NCT01416168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15641|Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery|Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|December 2008|November 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|15|||Both|60 Years|N/A|No|||November 2013|November 26, 2013|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416168||99895|
NCT01416415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 00051931|Glaucoma Eye Drop Instillation: Impact of Education|Glaucoma Eye Drop Instillation: Impact of Education||Northwestern University|No|Active, not recruiting|August 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|40 Years|85 Years|No|||October 2015|October 6, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416415||99876|
NCT01416454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11192010-7216|Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery|Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Elective Cesarean Delivery.||Stanford University|No|Completed|October 2010|November 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|46|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Our study population will be obstetric patients undergoing delivery on the labor and        delivery unit at Lucile Packard Children's Hospital (LPCH).|March 2013|March 20, 2013|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416454||99873|
NCT01416701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DvitKOL01022011|Vitamin D and Chronic Obstructive Lung Disease|Vitamin D and COPD. A Randomised, Double-blind, Placebo-controlled Trial of the Effect of Vitamin D on Withdrawal From Pulmonary Rehabilitation and Exercise Endurance||Hvidovre University Hospital|Yes|Withdrawn|September 2011|December 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|50 Years|N/A|No|||April 2013|April 8, 2013|August 12, 2011||No|It was not possible to enroll the planned amount of subjects. Many patients with chronic    obstructive pulmonary disease already took large doses of vitamin D.|No||https://clinicaltrials.gov/show/NCT01416701||99854|
NCT01416922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKON 0801|oncoFISH Cervical Test for Detection of 3q26 Region Gain|The oncoFISH Cervical Test for Detection of 3q26 Region Gain||Ikonisys, Inc.|Yes|Enrolling by invitation|June 2009|December 2011|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|||Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients 21 years of age or greater with LSIL cytology diagnosis who are scheduled for a        colposcical assessment.|August 2011|August 12, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416922||99837|
NCT01416935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAM|Necessity of Anti-Arrhythmic Medication After Surgical Ablation for Atrial Fibrillation|Anti-Arrhythmic Medication (Amiodarone) Post Surgical Ablation for Atrial Fibrillation - Is it Necessary?||Inova Health Care Services|No|Active, not recruiting|January 2011|January 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01416935||99836|
NCT01417234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102110|Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds|Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds||Spiracur, Inc.|No|Active, not recruiting|June 2011|||February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will be selected from exisiting investigator patient population.|December 2012|December 11, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01417234||99814|
NCT01417793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-129|Effects of a Smoking Cessation Program for Prison Inmates|Effects of a Smoking Cessation Program for Prison Inmates-A Case Study of a Prison in Central Taiwan||China Medical University Hospital|No|Recruiting|August 2011|July 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|500|||Male|20 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 15, 2011|August 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01417793||99772|
NCT01411228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-06-006|A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease|A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease||Protalix|Yes|Completed|September 2011|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|2 Years|18 Years|No|||December 2015|December 11, 2015|August 4, 2011|Yes|Yes||Yes|November 6, 2015|https://clinicaltrials.gov/show/NCT01411228||100270|
NCT01407510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15519|HPA Axis Study in Japanese Adults|A Multicenter, Open-label Study to Evaluate the Adrenal Suppression Potential of Mapracorat 0.1% Ointment in Japanese Adults With Atopic Dermatitis||Bayer|No|Completed|May 2011|April 2012|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||February 2015|February 15, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407510||100555|
NCT01418365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-116|Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Metronidazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects||Shire||Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 15, 2011|No|Yes||No|July 16, 2012|https://clinicaltrials.gov/show/NCT01418365||99728|
NCT01402700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1000|VISIBILITY™ Iliac Study|Visi-Pro™ Balloon Expandable Iliac Study (VISIBILITY™ Iliac)||Medtronic Endovascular||Completed|July 2011|September 2015|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|July 25, 2011|Yes|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01402700||100925|
NCT01402713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1107_P2/3|To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children|Randomized, Double Blind, Multicenter, Phase II/III Study to Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children||Green Cross Corporation|No|Completed|August 2011|November 2013|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|311|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402713||100924|
NCT01398852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-003|Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia|Long Term Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Post-Refractive Corneal Ectasia||Topcon Medical Systems, Inc.|No|Terminated|December 2010|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|500|||Both|12 Years|N/A|No|||December 2012|January 25, 2013|July 11, 2011|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01398852||101220|
NCT01369030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-009|Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)|Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)||Pamlab, Inc.|No|Completed|November 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|554|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients with Depression Who Have Been Prescribed Deplin®|May 2014|May 8, 2014|May 17, 2011||No||No|April 18, 2013|https://clinicaltrials.gov/show/NCT01369030||103496|Patients self-enrolled in the program and data presented was based on self-reported close-ended questions; selection bias may be present for those who chose not to enroll or complete the surveys. No clinical evaluations were conducted.
NCT01369641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.99|The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy|A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy||Thomas Jefferson University|Yes|Terminated|August 2011|August 2017|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|June 7, 2011|Yes|Yes|Poor accrual|No|January 24, 2014|https://clinicaltrials.gov/show/NCT01369641||103449|Study terminated due to poor accrual, prior to subjects being analyzed.
NCT01370239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52/2009|HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy|A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy||Instituto do Cancer do Estado de São Paulo|Yes|Suspended|November 2013|October 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||August 2015|August 11, 2015|May 25, 2011||No|futility|No||https://clinicaltrials.gov/show/NCT01370239||103403|
NCT01370213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS027|NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases|Multi-Center Phase II Trial of NK Cell Based Non-Myeloablative Haploidentical Transplantation for Patients With High-Risk Acute Myeloid Diseases||Masonic Cancer Center, University of Minnesota|No|Active, not recruiting|September 2011|January 2019|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||March 2016|March 24, 2016|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370213||103405|
NCT01370226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA018659|Health Explorer - Optimizing Alcohol Brief Interventions|Optimizing Alcohol Brief Interventions in the ED: Computer vs. Clinician Delivery||University of Michigan|No|Active, not recruiting|January 2012|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|750|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 28, 2015|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01370226||103404|
NCT01370460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 6669|Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty|Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty||Henry Ford Health System|No|Completed|June 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|June 3, 2011|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01370460||103386|Blood loss was calculated taking change in hemoglobin as described (units g/dL) and converting to blood loss (mL) according to the formulas includes in the papers cited in this entry (Good 2003 Br J Anesthesia; Nadler 1962 Surgery).
NCT01416441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-10-274|Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|August 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|7 Years|18 Years|No|||March 2015|March 25, 2015|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416441||99874|
NCT01416194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1781044|Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)|Cohort Study Of Venous Thromboembolism And Other Clinical Endpoints Among Osteoporotic Women Prescribed Bazedoxifene, Bisphosphonates Or Raloxifene In Europe||Pfizer|No|Active, not recruiting|July 2011|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|Women aged 45 or over who have records of receiving bazedoxifene, bisphosphonates or        raloxifene in the Cegedim database in Italy and Spain.|March 2016|March 16, 2016|August 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01416194||99893|
NCT01416207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108HV105|A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects|A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects||Biogen|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 3, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01416207||99892|
NCT01416948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-CREATE|Cognitive REmediation After Trauma Exposure Trial = CREATE Trial|Randomized Controlled Trial of Galantamine, Methylphenidate, and Placebo for the Treatment of Cognitive Symptoms in Patients With Traumatic Brain Injury (TBI) and/or Posttraumatic Stress Disorder (PTSD)|CREATE|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Terminated|August 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|18 Years|55 Years|No|||April 2013|April 24, 2013|August 12, 2011||No|The funding agency, DoD, determined that the study could not meet its enrollment numbers by    the end of the grant.|No||https://clinicaltrials.gov/show/NCT01416948||99835|
NCT01417247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAN-MS|Renal Sympathetic Modification in Patients With Metabolic Syndrome|Renal Sympathetic Modification in Patients With Metabolic Syndrome.||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|August 2011|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||May 2013|May 2, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417247||99813|
NCT01417520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110207|Clinical and Basic Investigations Into Erdheim Chester Disease|Clinical and Basic Investigations Into Erdheim-Chester Disease||National Institutes of Health Clinical Center (CC)||Recruiting|July 2011|||||N/A|Observational|N/A|||Anticipated|100|||Both|2 Years|80 Years|No|||November 2015|November 17, 2015|August 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01417520||99792|
NCT01418378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT07/04|Sigma CR150 Versus Sigma CR Knee RCT|A Double-blinded Randomised Controlled Trial Comparing the Performance of the Sigma® CR150 and Sigma® CR Knee Systems, When Used in Fixed Bearing Primary Cruciate Retaining Total Knee Arthroplasty for the Treatment of Osteoarthritis||DePuy International|No|Active, not recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|50 Years|75 Years|No|||July 2015|July 29, 2015|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418378||99727|
NCT01407523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01378|An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures|An Open-label, Multicenter Study to Evaluate the Safety of Adjunctive Treatment With Intravenous Levetiracetam (L059 IV) in Epilepsy Patients Aged ≥ 16 Years With Partial Onset Seizures||UCB Pharma|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|16 Years|N/A|No|||January 2013|January 30, 2013|July 29, 2011|Yes|Yes||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01407523||100554|
NCT01407549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11114119KCTIL|The Influence of Mindfulness Based Intervention on Pain Perception in Chronic Pain Patients|The Influence of Mindfulness Based Intervention on Pain Perception in Chronic Pain Patients Evaluating Personal Characteristics and Possible Mechanism||Meir Medical Center|No|Completed|November 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|24 Years|70 Years|No|||June 2012|June 28, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01407549||100552|
NCT01418950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00010267|Improving Parental Knowledge: Supplementation of Prematurity Counseling With Written Information|Improving Parental Knowledge: Randomized Trial of Supplementation of Prematurity Counseling With Written Information||Medical College of Wisconsin|No|Completed|April 2009|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 16, 2013|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01418950||99683|
NCT01418963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25694|A Study of RO5285119 in Healthy Volunteers|A Single- and Multiple Ascending-Dose, Randomized, Double-Blind, Placebo-Controlled Study in Two Single-Center Study Parts to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5285119 Following Oral Administration in Healthy Subjects||Hoffmann-La Roche||Completed|July 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|2||Actual|77|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418963||99682|
NCT01399385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110168|New Heart Imaging Techniques to Evaluate Possible Heart Disease|Magnetic Resonance of Body, Arterial Wall and Angiography Imaging for Non-Invasive Assessment of Arterial Distensibility, Endothelial Dysfunction and Atherosclerotic Disease Using 1.5T High Field (3T) MRI: A Technical Development Study of Cardiac and Body||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|||||N/A|Observational|N/A|||Anticipated|99999999|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|June 9, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01399385||101179|
NCT01399619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.19|Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)|Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.||Boehringer Ingelheim||Completed|September 2011|June 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|310|||Both|18 Years|70 Years|No|||August 2015|August 6, 2015|July 20, 2011||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01399619||101161|
NCT01399840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-002|Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies|Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies||Medivation, Inc.||Terminated|June 2011|May 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|July 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01399840||101144|
NCT01369316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR-002-CSI|Circumferential Submucosal Incision Endoscopic Mucosal Resection Versus Conventional Endoscopic Mucosal Resection of Colonic Polyps|Circumferential Submucosal Incision Endoscopic Mucosal Resection Versus Conventional Endoscopic Resection for the Removal of Large Laterally Spreading Tumours and Sessile Polyps of the Colon|CSIEMR|Western Sydney Local Health District|No|Recruiting|June 2011|June 2021|Anticipated|June 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|95 Years|No|||December 2015|December 15, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01369316||103474|
NCT01369667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITD/CD/01|Vitamin D Supplementation in Adult Crohn's Disease|Vitamin D and Immunomodulation: Effects in Crohn's Disease|VITD-CD|University of Dublin, Trinity College||Completed|April 2012|May 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|75 Years|No|||June 2011|August 15, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369667||103447|
NCT01369940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911178|The NICHD Fetal Growth Study: Twin Gestations|NICHD Fetal Growth Study: Twin Gestations||National Institutes of Health Clinical Center (CC)||Completed|May 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|350|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|December 2, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369940||103426|
NCT01370252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2011:070|Arthroscopic Ankle Arthrodesis: Measuring Post-operative Pain to Assess the Potential for Outpatient Surgery.|Arthroscopic Ankle Arthrodesis: Measuring Post-operative Pain to Assess the Potential for Outpatient Surgery.||Hammond, Allan, M.D.|No|Recruiting|June 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Patients selected from the surgeons waitlist.|June 2011|June 8, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370252||103402|
NCT01369901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110171|Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy|Effect of Functional Exercise in Patients With Spinal and Bulbar Muscular Atrophy||National Institutes of Health Clinical Center (CC)||Completed|May 2011|March 2014|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|61|||Male|18 Years|90 Years|No|||February 2016|February 26, 2016|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369901||103429|
NCT01369914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110173|The Natural History of Graft-Versus-Host Disease in the Eyes|The Natural History of Ocular Graft-Versus Host Disease||National Institutes of Health Clinical Center (CC)||Completed|May 2011|February 2016||||N/A|Observational|Time Perspective: Prospective|||Actual|61|||Both|18 Years|N/A|No|||February 2016|February 6, 2016|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369914||103428|
NCT01369927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911138|Shigella Sonnel O-SPC/rBRU Conjugate Vaccine|Shigella Sonnel O-SPC/rBRU Conjugate Vaccine||National Institutes of Health Clinical Center (CC)||Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||April 2013|February 19, 2014|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01369927||103427|
NCT01370837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 11-2-044|Neurogenic Inflammation in Diabetes|Neurogenic Inflammation in Diabetic Polyneuropathy and Charcot Neuro-osteoarthropathy: Response to Intracutaneous Candida Albicans||Maastricht University Medical Center|No|Completed|May 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|41|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|June 7, 2011||No||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01370837||103357|
NCT01416181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS326|A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension|ASCEND in SPMS|Biogen|Yes|Terminated|September 2011|April 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|889|||Both|18 Years|58 Years|No|||November 2015|November 12, 2015|July 21, 2011|Yes|Yes|The ASCEND Study did not achieve statistical significance on the primary or secondary    endpoints.|No||https://clinicaltrials.gov/show/NCT01416181||99894|
NCT01416428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001|Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies|Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies||Onyx Pharmaceuticals|Yes|Active, not recruiting|September 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|364|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|August 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01416428||99875|
NCT01415973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS IRB #132559|Nutrient Synergy in Beef and Stimulation of Protein Synthesis in Elderly|Nutrient Synergy in Beef and Stimulation of Protein Synthesis in Elderly||University of Arkansas|No|Completed|July 2011|January 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 17, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415973||99910|
NCT01416714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16294A|Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy|Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy||University of Chicago|Yes|Recruiting|July 2008|October 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||10|Anticipated|1000|Samples With DNA|blood, tissue, DNA|Both|N/A|N/A|No|Non-Probability Sample|Any patient having a biopsy or having surgery|January 2016|January 6, 2016|August 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01416714||99853|
NCT01417260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08092011-8247|Effects of Breast Feeding on Post-Cesarean and Post-Vaginal Delivery Pain|Effects of Breast Feeding on Post-Cesarean and Post-Vaginal Delivery Pain||Stanford University||Completed|August 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|130|||Female|18 Years|40 Years|No|Non-Probability Sample|30 patients posy cesarean delivery. 100 patients post vaginal delivery.|April 2015|April 10, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01417260||99812|
NCT01417806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230DUS21T|Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer|A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer||South Florida Veterans Affairs Foundation for Research and Education|Yes|Recruiting|July 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||July 2011|August 15, 2011|August 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417806||99771|
NCT01418079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2010001|Accuracy of the O2 MedTech PMS-3000 Monitor|Accuracy of the O2 MedTech PMS-3000 Monitor for the Non-invasive Measurement of Cerebral and Tissue Oxygenation Using Phase-modulated Infrared Spectroscopy||O2 MedTech, Inc.|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|August 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418079||99750|
NCT01410916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-001|Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)|An Open-Label, Multi-Center Trial of Eculizumab in Patients With Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)|STEC-HUS|Alexion Pharmaceuticals|No|Completed|July 2011|June 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|198|||Both|2 Months|N/A|No|||April 2013|April 4, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410916||100294|
NCT01410929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-10-001|Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma|Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma|MM|DFINE Inc.|No|Withdrawn|May 2011|||||Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|N/A|No|||January 2012|January 11, 2012|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410929||100293|
NCT01407562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051101|Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors|Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors||Rutgers, The State University of New Jersey|No|Suspended|August 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|July 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01407562||100551|
NCT01411488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1098|Comparative Study Between Two Fecal Management Systems|||The Cleveland Clinic|No|Recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|N/A|No|Non-Probability Sample|hospitalized adult patients who have a fecal managment systems ordered|August 2011|August 5, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411488||100250|
NCT01368510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH085900|Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder|Cognitive-Behavioral Therapy and Glutamate in Cingulate Gyrus in OCD||University of California, Los Angeles|No|Recruiting|July 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368510||103536|
NCT01368796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01457|Comparison of 4 Influenza Vaccines in Seniors|Controlled Comparison in Canadian Seniors of Seasonal Influenza Vaccines for 2011-2012|PCIRNRT09|University of British Columbia|No|Completed|July 2011|May 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|953|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01368796||103514|
NCT01369680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KETA-2011|Oral Ketamine for Control of Chronic Pain in Children|Oral Ketamine for Control of Chronic Pain in Children|KETA-2011|University of Rochester|No|Completed|May 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|8 Years|22 Years|No|||February 2013|February 11, 2013|May 23, 2011|Yes|Yes||No|October 24, 2012|https://clinicaltrials.gov/show/NCT01369680||103446|Three subjects were lost to follow-up, limiting the data available for neuro-cognitive assessment at the last visit.
NCT01369953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911185|Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants|Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants||National Institutes of Health Clinical Center (CC)||Completed|May 2011|January 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|40|||Both|18 Years|65 Years|No|||January 2014|October 23, 2014|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369953||103425|
NCT01370876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10CT006A|Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Trial Evaluating Efficacy and Safety of Opatin® (Oxaliplatin)/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer||Nang Kuang Pharmaceutical Co., Ltd.|Yes|Terminated|September 2010|May 2012|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Male|20 Years|75 Years|No|||December 2013|December 9, 2013|March 28, 2011||No|company policy|No||https://clinicaltrials.gov/show/NCT01370876||103354|
NCT01370473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1050|Institutional Registry of Hyponatremia|Institutional Registry of Hyponatremia|Hyponatremia|Hospital Italiano de Buenos Aires|No|Completed|December 2006|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with hyponatremia|March 2015|March 19, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01370473||103385|
NCT01370850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTVue Validation Study|Clinical Validation Study of RTVue Features|Clinical Validation Study of RTVue Features||Optovue|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers with various ocular pathology or no ocular pathology|June 2011|June 9, 2011|April 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01370850||103356|
NCT01370863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD557-202|An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients|An Explorative, Randomized, Placebo-controlled, DB, Parallel-group Trial, to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Subjects With GERD & With Persistent Symptoms Despite Taking a Stable Dose of PPIs||Shire|No|Terminated|December 2010|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|70 Years|No|||April 2014|June 25, 2014|May 31, 2011||No|This study was terminated early due to recruitment difficulties. There were no safety    concerns.|No|April 15, 2013|https://clinicaltrials.gov/show/NCT01370863||103355|Results data should be interpreted with caution since the study’s early termination affects the statistical power to detect true differences between treatment groups.
NCT01420146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJBMNZrT003|Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients|Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients : Correlation With FDG-PET/CT and Anatomopathological Results|IJBMNZrT003|Jules Bordet Institute|No|Completed|August 2011|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||January 2015|February 23, 2016|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01420146||99591|
NCT01420159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEOF-001|Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma|A Randomised, Double Blind, Multi-centre, Placebo Controlled Study to Evaluate the Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Patients Presenting to an Emergency Department With Minor Trauma|STOP!|Medical Developments International Limited|Yes|Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|12 Years|N/A|No|||October 2012|October 30, 2012|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420159||99590|
NCT01416467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPPGAL|Characterization of the Patient Population With Galactosialidosis|Characterization of the Patient Population With Galactosialidosis|CPPGAL|St. Jude Children's Research Hospital|No|Recruiting|December 2011|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|35|Samples With DNA|Blood for PPCA gene mutation and AAV2 and AAV8 antibody titer|Both|6 Months|N/A|No|Non-Probability Sample|Individuals with suspected or diagnosed galactosialidosis.|January 2016|January 19, 2016|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416467||99872|
NCT01416727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/051|Simulation Training vs Workplace-Based Supervision in Psychiatry|A Randomised Trial of Simulation Training vs Workplace-Based Supervision for Junior Doctors in Psychiatry|EPIC-OSkER|King's College London|No|Active, not recruiting|August 2011|December 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|48|||Both|22 Years|N/A|Accepts Healthy Volunteers|||August 2011|September 6, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416727||99852|
NCT01416961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005|Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)|Phase I Study of High Linear Energy Transfer (Neutron) Therapy Followed by Concurrent Chemotherapy and Standard Photon Thoracic RT (TRT) in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|August 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|August 10, 2011|No|Yes|Neutron therapy has become unavailable|No||https://clinicaltrials.gov/show/NCT01416961||99834|
NCT01416974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-048|Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab|A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01416974||99833|
NCT01410071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-05-130E|Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction|Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction: Evaluation of the Differences Between Those Undergoing Endoscopic Therapy vs.Conservative Care||Wisconsin Center for Advanced Research|No|Terminated|September 2005|August 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|153|||Both|18 Years|N/A|No|Non-Probability Sample|physician's private practice/clinic patients presenting with suspected sphincter of oddi        dysfunction|August 2011|August 3, 2011|August 2, 2011||No|Analysis of designed comparison groups not viable|No||https://clinicaltrials.gov/show/NCT01410071||100359|
NCT01410357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH085665|Improving Outcomes for Individuals With Serious Mental Illness and Diabetes|Improving Outcomes for Individuals With Serious Mental Illness and Diabetes|TTIM|Case Western Reserve University|Yes|Completed|July 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|208|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01410357||100337|
NCT01410604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010-08|Adipokines in Obese Adolescents With Insulin Resistance|Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial||Hospital Regional de Alta Especialidad del Bajio|No|Completed|January 2007|March 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|9 Years|18 Years|No|||April 2012|April 23, 2012|August 4, 2011||No||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01410604||100318|During the recruitment phase, 83 children who were diagnosed with obesity and acanthosis nigricans were evaluated. Of these, 45 did not have the insulin concentration values (>15 µU/mL) required to biochemically define Insulin Resistance.
NCT01411215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801044|A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department|A Non-Interventional Study of the Treatment With Etanercept in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) Subjects in Rheumatology Department|ENBREL NIS CN|Pfizer|No|Terminated|January 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|160|||Both|18 Years|N/A|No|Non-Probability Sample|outpatient RA and AS patients in China|January 2014|January 23, 2014|May 13, 2011||No|See termination reason in detailed description.|No|January 23, 2014|https://clinicaltrials.gov/show/NCT01411215||100271|
NCT01407471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071011|Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy|Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy|SPIREPI|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|26|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2015|July 2, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407471||100558|
NCT01368809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024484|Effect of Fentanyl on Coughing and Recovery After Anesthesia With an LMA Laryngeal Mask Airway)for Airway Management|Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of Fentanyl on the Incidence of Coughing and Recovery After Propofol-Desflurane Anesthesia With an LMA for Airway Management|LMA|Cedars-Sinai Medical Center|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|80 Years|No|||February 2016|February 11, 2016|June 7, 2011||No||No|September 10, 2015|https://clinicaltrials.gov/show/NCT01368809||103513|
NCT01369043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC503|The Effects of Vitamin E and Vitamin C and Exercise|Modulation of Insulin and Exercise Responses by Vitamin E and Vitamin C||USDA Grand Forks Human Nutrition Research Center|Yes|Terminated|May 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|1|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|June 6, 2011||No|Lack of successful recruiting, budget cuts, and potential study flaws.|No||https://clinicaltrials.gov/show/NCT01369043||103495|
NCT01369342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018418|A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)||Janssen Research & Development, LLC|Yes|Completed|July 2011|October 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|638|||Both|18 Years|99 Years|No|||November 2015|November 23, 2015|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369342||103472|
NCT01369966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911467|Brain Circuits in Schizophrenia and Smoking|Brain Circuits in Schizophrenia and Smoking||National Institutes of Health Clinical Center (CC)||Completed|May 2011|December 2014||||N/A|Observational|N/A|||Anticipated|300|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||December 2014|December 25, 2014|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369966||103424|
NCT01370499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12849|A Study of LY2216684 in Patients With Major Depression Disorder|Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients With Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment||Eli Lilly and Company|No|Completed|August 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|237|||Both|18 Years|N/A|No|||January 2014|April 14, 2014|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370499||103383|
NCT01370512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008810|Droxidopa / Pyridostigmine in Orthostatic Hypotension|Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension||Mayo Clinic|No|Recruiting|November 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01370512||103382|
NCT01370525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961RC00001|Efficacy of Esomeprazole in Patients With Frequent Heartburn|A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Esomeprazole 20 mg Once Daily in Subjects With Frequent Heartburn|NEXT1|AstraZeneca||Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|June 1, 2011|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT01370525||103381|
NCT01370538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961RC00002|Efficacy of Esomeprazole in Patients With Frequent Heartburn|A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Esomeprazole 20 mg Once Daily in Subjects With Frequent Heartburn|NEXT2|AstraZeneca||Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|341|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|June 1, 2011|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT01370538||103380|
NCT01370551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806109|Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients|A Clinical Study of Pharmacokinetics, Efficacy and Safety of Vaginal Application of Lyophilised Lactobacilli and 0.03 mg Estriol (Gynoflor®) on Atrophic Vaginitis in Postmenopausal Breast Cancer Patients Treated With Aromatase Inhibitors|Gynoflor|Medinova AG|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|52 Years|75 Years|No|||January 2011|August 21, 2012|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01370551||103379|
NCT01370486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25/10|Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects|Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects||Institution de Lavigny|No|Not yet recruiting|August 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|6|||Both|18 Years|55 Years|No|||June 2011|June 9, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370486||103384|
NCT01371383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH94F044|The Effect of Fish Oil in Major Depressive Disorder|The Effect of Fish Oil in Major Depressive Disorder: a Double-blind Placebo-controlled Monotherapy Trail to Demonstrate the Therapeutic Effects of Depression||National Science Council, Taiwan|Yes|Completed|January 2005|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|No|||May 2012|May 11, 2012|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01371383||103315|
NCT01371695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|onc11-03-164|Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer|Phase 1 of Serum IGF II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer||Onconix, Inc|No|Enrolling by invitation|May 2011|September 2013|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|Samples With DNA|frozen serum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|university clinic|June 2011|June 10, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371695||103292|
NCT01416220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoodDig-001|Lithium Versus Paroxetine in Major Depression|A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide||Nova Scotia Health Authority|Yes|Completed|September 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416220||99891|
NCT01416480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG1321001_ACP3|Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule 300mg" as an Antitussive Agent in Acute Cough Patients.||Ahn-Gook Pharmaceuticals Co.,Ltd|Yes|Completed|May 2010|May 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||August 2011|August 12, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416480||99871|
NCT01409837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHF/GrS/99/S.3|The Effect and Safety of Lisinopril in Non-hypertensive Men With Infertility From Low Sperm Count|A 5-year Prospective, Placebo-controlled, Crossover Evaluation of the Efficacy and Tolerability of Low-dose Lisinopril in Normotensives With Idiopathic Oligospermic Infertility||University Of Nigeria Teaching Hospital|Yes|Completed|March 1998|December 2006|Actual|December 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Male|24 Years|34 Years|No|||September 2013|September 21, 2013|August 2, 2011||No||No|June 22, 2013|https://clinicaltrials.gov/show/NCT01409837||100377|The sample size of the study is small thereby limiting the reliability of generalizing the findings. In addition, three subjects who started the study terminated prematurely and it is difficult to assess how this fact has affected the study results.
NCT01410370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endu-201107|Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases|Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy for the Treatment of Patients With Brain Metastases||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||April 2013|April 22, 2013|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01410370||100336|
NCT01410383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBT 009|Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care|A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care|AKKA|Karo Bio AB|Yes|Terminated|October 2011|October 2014|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|236|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410383||100335|
NCT01410617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THC-473|The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass|||Imam Khomeini Hospital||Recruiting|August 2011|December 2013|Anticipated|September 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|80 Years|No|||March 2013|March 25, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410617||100317|
NCT01410630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMIMG0001|FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma|FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma||Stanford University|Yes|Recruiting|September 2011|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|137|||Both|N/A|N/A|No|||February 2014|February 14, 2014|July 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01410630||100316|
NCT01410942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0389|Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy|Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy||M.D. Anderson Cancer Center|Yes|Active, not recruiting|February 2012|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|175|||Male|18 Years|N/A|No|||January 2016|January 8, 2016|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410942||100292|
NCT01410643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB|Puberty Related Intervention to Improve Metabolic Outcomes (The PRIMO Study)|Puberty Related Intervention to Improve Metabolic Outcomes (The PRIMO Study)|PRIMO|University of Alabama at Birmingham|No|Completed|March 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|92|||Female|7 Years|11 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01410643||100315|
NCT01410955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900450001|Prevention of Irinotecan Induced Diarrhea by Probiotics|Prevention of Irinotecan Induced Diarrhea by Probiotics. A Phase III Study||Monsea Ltd.|No|Completed|December 2011|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01410955||100291|
NCT01408108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONMU-1|Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias|Prospective Randomized Phase III Study of Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias|LARGE|Odessa National Medical University|No|Active, not recruiting|January 2013|July 2016|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||October 2015|October 13, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408108||100509|
NCT01408121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA Genetic|African-American Pharmacogenetics|African-American Pharmacogenetics|AA Genetic|Medstar Research Institute|No|Active, not recruiting|November 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|African-american versus Caucasian patients undergoing percutaneous coronary intervention        and receiving clopidogrel or prasugrel.|August 2014|August 8, 2014|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01408121||100508|
NCT01409122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR001-CS04|Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects|A Phase 1, Placebo Controlled, Blinded, Multiple Dose Escalation Study of AIR001 (Sodium Nitrite Inhalation Solution) in Healthy Subjects, an Assessment of the Tolerability in Combination With Oral Sildenafil, and an Open-Label Study of Multiple Dose AIR001 in Patients With Pulmonary Arterial Hypertension||Aires Pharmaceuticals, Inc.|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|56 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|August 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01409122||100432|
NCT01407211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89/8/18-10033|Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient|The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients|MS|Tehran University of Medical Sciences|Yes|Enrolling by invitation|April 2011|September 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|20 Years|45 Years|No|||July 2012|July 17, 2012|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407211||100578|
NCT01369329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018415|A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)||Janssen Research & Development, LLC|Yes|Completed|July 2011|July 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|769|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369329||103473|
NCT01369654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03107|Development and Pilot Test of an Elective Bilateral Salpingo-Oophorectomy (BSO) Decision Support Guide|Development and Pilot Test of an Elective Bilateral Salpingo-Oophorectomy (BSO) Decision Support Guide|BSO|University of California, San Francisco|No|Completed|May 2011|December 2014|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|63|||Female|40 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01369654||103448|
NCT01369992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99048|Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites|Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites||Taipei Medical University WanFang Hospital|No|Active, not recruiting|May 2011|May 2013|Anticipated|||N/A|Observational|N/A||1|Anticipated|20|||Both|20 Years|N/A|No|Non-Probability Sample|cancer patients|June 2011|June 8, 2011|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369992||103422|
NCT01370902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8765-3658|Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Single-dose and Multiple-dose, Dose-escalation Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis||Innate Pharma|No|Completed|May 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|75 Years|No|||December 2014|December 20, 2014|May 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370902||103352|
NCT01371136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH10-059|Developing a Curriculum to Teach Laparoscopic Colorectal Surgery|||St. Michael's Hospital, Toronto|No|Completed|June 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|25|||Both|N/A|N/A|No|||November 2015|November 16, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01371136||103334|
NCT01371110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1113|Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder|Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder||Icahn School of Medicine at Mount Sinai|Yes|Terminated|June 2012|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|21 Years|65 Years|No|||October 2015|October 13, 2015|June 7, 2011|No|Yes|no funding|No||https://clinicaltrials.gov/show/NCT01371110||103336|
NCT01371123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000025865|Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition|Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition: Is There a Problem in Canada?||The Hospital for Sick Children|No|Completed|June 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|None Retained|serum|Both|6 Weeks|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients followed in the Home-TPN program at the Hospital for Sick Children|July 2013|July 26, 2013|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01371123||103335|
NCT01416233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.27|Autologous Fat Augmentation of Orbital Volume Using a Closed Cannula Technique|Autologous Fat Augmentation of Orbital Volume Using a Closed Cannula Technique||Fox, Donald Munro, M.D., P.C.|Yes|Recruiting|September 2010|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01416233||99890|
NCT01409551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Theagenio Thoracic Surgery 2|Video-assisted Hyperthermic Pleural Chemoperfusion vs Talc Pleurodesis for Refractory Malignant Pleural Effusions.|Video-assisted Hyperthermic Pleural Chemoperfusion Versus Bed-side Talc Slurry Pleurodesis for Refractory Malignant Pleural Effusions.||Theagenio Cancer Hospital|No|Completed|August 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|75 Years|No|||November 2014|November 14, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409551||100399|
NCT01409824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-173/2008|Health Care Intervention Research- Improving Pre-natal and Maternal Care|Health Care Intervention Research-Quality of Prenatal and Maternal Care: Bridging the Know-do Gap (QUALMAT)|QUALMAT|Heidelberg University|Yes|Recruiting|May 2009|April 2014|Anticipated|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|36|||Female|12 Years|45 Years|No|||February 2010|August 3, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409824||100378|
NCT01410084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#14152|Improving Vitamin D Status in Home-bound Elders|Improving Vitamin D Status in Home-bound Elders: a Pilot Study|MOW VitD|Wake Forest School of Medicine|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|68|||Both|65 Years|N/A|No|||November 2013|November 14, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410084||100358|
NCT01410097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG033087|Physical and Cognitive Function - Look AHEAD Ancillary Study|Intentional Weight Reduction and Physical and Cognitive Function - A Look AHEAD Ancillary Study||Wake Forest School of Medicine|No|Completed|September 2009|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1095|||Both|45 Years|74 Years|No|||December 2015|December 10, 2015|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01410097||100357|
NCT01410110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011007601|Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment|Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment||Yale University|No|Completed|December 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||December 2014|January 14, 2015|August 2, 2011||No||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01410110||100356|Use of WT limited recruitment to only those willing to participate in a work program for 13 weeks, reducing generalizability. WT may have powerful effects on sobriety that obscured benefits of CRT. As a pilot, this study was not adequately powered.
NCT01410396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lifewatch|Occult Paroxysmal Atrial Fibrillation in Patients With Non-cardioembolic Ischemic Stroke of Determined Mechanism|Occult Paroxysmal Atrial Fibrillation in Patients With Non-cardioembolic Ischemic Stroke of Determined Mechanism||Northwestern University|No|Completed|April 2010|May 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|49|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with history of stroke of known mechanism age greater than 50|August 2013|August 14, 2013|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410396||100334|
NCT01411241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD33|Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers|Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico||Sanofi|Yes|Completed|July 2011|April 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|720|||Both|9 Months|12 Months|Accepts Healthy Volunteers|||January 2015|January 9, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411241||100269|
NCT01411254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01021103|Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)|A Randomized, Multicenter, Sham Controlled, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema||Santen Pharmaceutical Co., Ltd.||Completed||||||Phase 2/Phase 3|Interventional|N/A|3||||||Both|20 Years|N/A|No|||July 2014|July 17, 2014|August 4, 2011||||No||https://clinicaltrials.gov/show/NCT01411254||100268|
NCT01407224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000076-AT10,EMI|Assessing Cost and Effectiveness of Training and Supervision of Front Line Workers on Early Breastfeeding Practices|Assessing the Cost and Effectiveness of Training and Supervision of Front Line Workers on Early Breastfeeding Practices (Bangladesh)|iycfch|Eminence|Yes|Completed|May 2010|June 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Actual|1200|||Both|N/A|5 Months|Accepts Healthy Volunteers|||July 2011|July 31, 2011|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407224||100577|
NCT01409135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-22M6E-11-1|A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4|A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E or ASG-22CE Given as Monotherapy Followed by Expansion Cohorts in Subjects With Malignant Solid Tumors That Express Nectin-4||Astellas Pharma Inc|No|Completed|June 2011|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|34|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|July 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01409135||100431|
NCT01409148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2625A|Radioimmunoimaging of AL Amyloidosis|Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4||University of Tennessee|No|Completed|November 2008|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|38|||Both|21 Years|90 Years|No|||August 2011|October 10, 2012|July 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409148||100430|
NCT01408069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHEMS0211|Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia|Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane® Versus Parcel ® For Treatment Of Tensional Cephaleia||EMS|Yes|Suspended|March 2014|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|65 Years|No|||March 2013|March 25, 2013|August 1, 2011||No|Study suspended by decision strategically.|No||https://clinicaltrials.gov/show/NCT01408069||100512|
NCT01408342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE11015|Alemtuzumab and Rituximab in Aplastic Anemia|Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Withdrawn|July 2011|January 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Months|N/A|No|||January 2014|January 3, 2014|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01408342||100491|
NCT01369069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15959|Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial|Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial|SHINE|University of Virginia|Yes|Recruiting|April 2012|July 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1400|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01369069||103493|
NCT01369355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018421|A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease||Janssen Research & Development, LLC|No|Active, not recruiting|September 2011|November 2019|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1316|||Both|18 Years|99 Years|No|||January 2016|January 25, 2016|June 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369355||103471|
NCT01369368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allo-Relapse-2011|Treatment of Acute Leukemia Relapse After Allotransplantation|Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation: Disease Stabilization Through Chemotherapy, Immunomodulatory Treatment and Immunotherapy||University of Bergen|Yes|Recruiting|August 2013|October 2020|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||June 2015|June 23, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369368||103470|
NCT01370265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006377|Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress|Quantification of Myocardial Blood Flow by Positron Emission Tomography and N-13 Ammonia During Regadenoson vs Adenosine Stress||Mayo Clinic|No|Completed|February 2011|June 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|12|||Both|30 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 3, 2013|June 6, 2011|Yes|Yes||No|October 6, 2012|https://clinicaltrials.gov/show/NCT01370265||103401|Small sample size; Subjects had no evidence of overt coronary artery disease, occult coronary artery disease affecting stress drug induced hyperemic PET MBF is a possibility; however, hyperemic MBF with both stress drugs would be equally affected.
NCT01370278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0990|Clearance Of Mucus In Stents|Clearance Of Mucus In Stents (COMIS)||M.D. Anderson Cancer Center|Yes|Recruiting|June 2011|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 13, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370278||103400|
NCT01371149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0716/67|Patient -Ventilator Interaction in Chronic Respiratory Failure|A Clinical Trial to Optimise Patient-ventilator Interaction in Patients With Chronic Respiratory Failure||Guy's and St Thomas' NHS Foundation Trust|No|Completed|January 2011|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|16 Years|N/A|No|||April 2014|April 2, 2014|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371149||103333|
NCT01371162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25733|A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C|A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HCV Nucleoside Inhibitor RO5428029 in Healthy Subjects and in CHC Genotype 1 Infected Patients||Hoffmann-La Roche||Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|4||Actual|42|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01371162||103332|
NCT01370889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02593|Resveratrol in Postmenopausal Women With High Body Mass Index|Pilot Study of Resveratrol in Postmenopausal Women With High Body Mass Index||National Cancer Institute (NCI)||Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|46|||Female|35 Years|N/A|Accepts Healthy Volunteers|||April 2014|October 8, 2014|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370889||103353|
NCT01371747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLY5016-205|Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)|A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone|AMETHYST-DN|Relypsa, Inc.|No|Completed|June 2011|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|324|||Both|30 Years|80 Years|No|||November 2015|November 11, 2015|June 9, 2011|Yes|Yes||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01371747||103288|
NCT01367483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNTX 102|Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX|An Open-Label, Phase I, Single Dose Study of the Pharmacokinetics, Mass Balance and Disposition of Intravenously Administered 14C-Methylnaltrexone in Normal, Healthy Volunteers||Valeant Pharmaceuticals International, Inc.|No|Completed|June 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 17, 2011|May 27, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01367483||103615|
NCT01409304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTMS-ERB10/18-2011|Effectiveness of Deep Transcranial Magnetic Stimulation in Depression|Effectiveness of Deep Transcranial Magnetic Stimulation for Treating Major Depression: a Pilot Study||Douglas Mental Health University Institute|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|60 Years|No|||January 2013|January 16, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409304||100418|
NCT01409850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHeidelberg|Comparison Study of Two Splints Used for Treatment of Acute Temporomandibular Pain.|Pilot Clinical Trial on the Treatment Effectiveness of Two Splints for Acute Temporomandibular Pain.||Heidelberg University|No|Terminated|July 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 3, 2011||No|Very slow enrollment of participants|No||https://clinicaltrials.gov/show/NCT01409850||100376|
NCT01409577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1102-032-350|Outcome of FFR-guided Intervention Strategy|Clinical Outcome of Fractional Flow Reserve-guided Coronary Intervention Strategy in Koreans||Seoul National University Hospital|Yes|Recruiting|March 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with intermediate coronary stenosis by visual estimation|November 2011|November 19, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409577||100397|
NCT01409863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001M75732|Fractional Laser Therapy and Dermabrasion for Scar Revision|A Comparison Evaluation of Fractional Laser Therapy an Dermabrasion for Scar Revision||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn|March 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 21, 2015|August 2, 2011|Yes|Yes|PI has left University of Minnesota.|No||https://clinicaltrials.gov/show/NCT01409863||100375|
NCT01410656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-0006611|Prostate Cancer Survivors Moving Toward Exercise (PROMOTE) Trial|Prostate Cancer Survivors MOving Toward Exercise (PROMOTE) Trial|PROMOTE|University of Alberta|No|Active, not recruiting|May 2011|November 2011|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|423|||Male|18 Years|90 Years|Accepts Healthy Volunteers|||August 2011|August 4, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01410656||100314|
NCT01410669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R49CE000924-03|Motivational Interviewing Intervention for Intimate Partner Violence|Is Motivational Interviewing an Effective Intervention for Women Coping With Intimate Partner Violence|ISIS|University of Iowa|Yes|Completed|December 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|305|||Female|18 Years|N/A|No|||August 2011|August 3, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01410669||100313|
NCT01410968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101498|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma||Medical University of South Carolina|Yes|Active, not recruiting|August 2011|||November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410968||100290|
NCT01407237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000250|Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV|Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV||Massachusetts General Hospital||Completed|January 2012|||March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|50 HIV-infected and 50 non-HIV-infected male and female volunteers, ages 18-65 years old.|October 2015|October 27, 2015|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01407237||100576|
NCT01407536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC-96-2314-B-037-028-MY3|Effect of Thermal Stimulation on Cortical Excitability and Motor Function in Chronic Stroke Patients|||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|August 2009|September 2010|Actual|June 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||June 2011|August 1, 2011|June 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01407536||100553|
NCT01369381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102721|Cervical Spine Biomechanics During Endotracheal Intubation|Intubation Mechanics of the Stable and Unstable Cervical Spine||University of Iowa|Yes|Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|80 Years|No|||August 2012|August 3, 2012|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01369381||103469|
NCT01369394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186564|Making Decisions About the Measles-Mumps-Rubella Vaccine|Developing a Computer-based Intervention That Provides Individually-tailored Educational Information for MMR Vaccine-hesitant Parents||University of Michigan|Yes|Completed|June 2011|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|79|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 8, 2014|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01369394||103468|
NCT01369693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004/3|In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus|In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Four Brands of Swedish 'Snus' in Regular Snus Users.|SMWS03|Contract Research Organization el AB|No|Completed|May 2004|April 2005|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2011|June 8, 2011|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01369693||103445|
NCT01370564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPC|Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures|Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures|IPC|Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|June 2011|February 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370564||103378|
NCT01370577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RKR-XXX-2011/1|The Predictors for Asthma Control by Stepwise Treatment During 6 Months in Korean Elderly|The Predictors for Asthma Control by Stepwise Treatment During 6 Months in Korean Elderly|Prelude|AstraZeneca|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|297|||Both|60 Years|N/A|No|Probability Sample|Subjects aged over 60 years, articulate in Korean, and diagnosed with asthma at least 1        year in duration|January 2013|January 11, 2013|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01370577||103377|
NCT01370590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653C-185|A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)|A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin 10 mg/20 mg Fixed-Dose Combination Tablet Compared to Co-administration of Marketed Ezetimibe 10 mg and Atorvastatin 20 mg in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|406|||Both|18 Years|79 Years|No|||January 2015|January 21, 2015|June 8, 2011|Yes|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01370590||103376|
NCT01370291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110526-08|Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients|Repetitive Transcranial Magnetic Stimulation (rTMS) for First-episode Schizophrenia Patients:A Double-blinded , Randomized and Functional Magnetic Resonance Imaging (fMRI)Study|rTMSfMRI|Xijing Hospital|Yes|Recruiting|June 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370291||103399|
NCT01370304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110526-09|Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder|Repetitive Transcranial Magnetic Stimulation (rTMS) Compared or Associated With Venlafaxine for Depressive Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study||Xijing Hospital|Yes|Recruiting|June 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||February 2012|February 13, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01370304||103398|
NCT01371175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI 010|A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers|A Randomized, Placebo-Controlled, Dosage-Escalating Phase 2A Study, Double-Blinded With Respect to Assignment to Either Vaccine or Placebo, to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Administered Intramuscularly Followed by an MVA HIV-1 Vaccine Administered at Three Different Dosage Levels and by Three Different Routes to HIV-Uninfected, Healthy, Volunteers.||International AIDS Vaccine Initiative|Yes|Completed|April 2003|||May 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|9||Actual|115|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2011|June 9, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01371175||103331|
NCT01371188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mendonca|Effects of Exposure to Biomass-burning Air Pollution on Lung Function, Heart Rate Variability and Inflammatory Markers in Sugarcane Workers|Effects of Exposure to Outdoor Air Pollution From Biomass Burning on Lung Function, Heart Rate Variability and Systemic Inflammatory Blood Markers in Sugarcane Workers||InCor Heart Institute|No|Completed|December 2008|February 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||2|Actual|222|Samples With DNA|Whole blood.|Male|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population from the city of Mendonça, São Paulo-Brazil, divided into the following groups:        sugarcane workers (those who work in sugarcane plantations) and controls (healthy        volunteers from the same city)|June 2011|June 9, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371188||103330|
NCT01371409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-00368|Interhemispheric Inhibitory Interactions|Interhemispheric Contributions to Neuroplasticity and Motor Learning After Stroke|InHIb|University of British Columbia|No|Active, not recruiting|April 2011|March 2016|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|40 Years|75 Years|No|||April 2015|April 15, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01371409||103313|
NCT01371760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S. Anna Hospital|BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis)|Randomized Multi-centered Study for Evaluating the Efficacy and Safety of Angioplastic Surgery of the Extracranial Veins in the Treatment of Multiple Sclerosis. Studio Randomizzato Multicentrico Per la Valutazione Dell'Efficacia e Sicurezza Dell'Intervento di Disostruzione Delle Vene Extracraniche Nel Trattamento Della Sclerosi Multipla|BRAVE-DREAMS|S. Anna Hospital|Yes|Completed|August 2012|December 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|65 Years|No|||December 2015|December 16, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01371760||103287|
NCT01409564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2009-145|Cilostazol Augmentation Study in Dementia|Cilostazol Augmentation Study In Dementia (CASID): A Randomized, Placebo-controlled Pilot Study to Compare the Efficacy Between Donepezil Monotherapy and Cilostazol Augmentation Therapy in Alzheimer's Disease Patients With Subcortical White Matter Hyperintensities||Seoul National University Hospital||Completed|May 2010|July 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|60 Years|N/A|No|||April 2014|April 14, 2014|August 3, 2011||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01409564||100398|
NCT01409590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-05-3627-RA-CTIL|Exercise and Diet Program for Schizophrenia Patients Who Are Taking Atypical Antipsychotic Medications|Exercise and Diet Program for Schizophrenia Patients Who Are Taking Atypical Antipsychotic Medications||Sheba Medical Center|No|Completed|May 2005|August 2009|Actual|September 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|35 Years|No|||August 2011|August 3, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409590||100396|
NCT01409603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-039|To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects|A Phase I, Open-Label, Randomized 3-Period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Interactions Between YM150 on Naproxen at Steady-State||Astellas Pharma Inc|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|August 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01409603||100395|
NCT01410409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110024|Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement|Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement. A Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up|MEDIC|Northern Orthopaedic Division, Denmark|No|Completed|September 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|N/A|N/A|No|||December 2015|December 19, 2015|August 2, 2011||No||No|December 19, 2015|https://clinicaltrials.gov/show/NCT01410409||100333|
NCT01410981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101565|Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma|Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma||Medical University of South Carolina|Yes|Recruiting|July 2011|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|Samples With DNA|The patients will not have bone marrow biopsy or aspirate solely for this study. When the      patients undergo routine bone marrow aspirate and biopsy for the purpose of initial      diagnosis, followup or restaging, they will be asked and consented for participation in the      study. The patient will then be treated with standard chemotherapy including      Bortezomib-based, Revlimid-based, Thalidomide-based chemoregimen. The bone marrow aspirate      from patients who consent to be in the study will be stained for CXCR4, CD47, pS6, in      addition to standard study flow cytometry panel for multiple myeloma. The staining and flow      cytometry analysis will be performed at the Clinical Flow Cytometry Facility (Director: Dr.      Sally Self) according to the standard flow cytometry procedure. Sphingolipid gene expression      levels will be measured. A small aliquot may be sent to collaborators in Genentech Corp for      measurement of pS6 and Pim kinase expression. The sample information will be de-identified.|Both|18 Years|N/A|No|Non-Probability Sample|There will be three different population of patients: 1) newly diagnosed, 2) relapsed, 3)        refractory multiple myeloma|April 2013|April 24, 2013|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01410981||100289|
NCT01410994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102-06|Bariatric Surgery and the Kidney|Study of Renal Parameters After Bariatric Surgical Weight Loss||Indiana University|No|Completed|April 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|serum, urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|bariatric surgery patients in the Indianapolis region|August 2015|August 26, 2015|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01410994||100288|
NCT01411267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2009-004|A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia|A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Completed|August 2011|May 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|1 Month|21 Years|No|||May 2013|May 17, 2013|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411267||100267|
NCT01410721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT100071|Neural Markers and Rehabilitation of Executive Functioning in Veterans With Traumatic Brain Injury and Posttraumatic Stress Disorder|Neural Markers and Rehabilitation of Executive Functioning in Veterans With TBI and PTSD||University of North Carolina, Chapel Hill|No|Active, not recruiting|January 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||September 2015|September 3, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410721||100309|
NCT01411280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HD049244-01|Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)|Ameliorating Attention Problems in Children With SCD||Temple University||Completed|June 2006|May 2009|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|6 Years|16 Years|No|||August 2011|April 29, 2015|July 20, 2006||No||No||https://clinicaltrials.gov/show/NCT01411280||100266|
NCT01407250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Commwell PG 101|PhysioGlove Versus Clinic Electrocardiogram Comparison|Reliability of Outpatient Electrocardiogram Recordings in Patients Refered for a Cardiology Consultation|CommwellPG|Meir Medical Center|No|Not yet recruiting|August 2011|March 2012|Anticipated|November 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|95 Years|No|Probability Sample|Adult male and female patients|July 2011|July 31, 2011|July 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01407250||100575|
NCT01407263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-096|Trial of Modifications to Radical Prostatectomy|A Randomized Trial of Modifications to Radical Prostatectomy||Memorial Sloan Kettering Cancer Center||Recruiting|July 2011|July 2021|Anticipated|July 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1400|||Male|21 Years|N/A|No|||December 2015|December 21, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407263||100574|
NCT01409408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAALIDH|Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan|Comparison Between Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan: Effects on Endothelial Function and Renin Concentration and Activity||Hospital Universitario Pedro Ernesto|No|Withdrawn|April 2011|December 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|70 Years|No|||April 2011|March 5, 2012|August 1, 2011||No|Due to preliminary results of Altitude Trial.|No||https://clinicaltrials.gov/show/NCT01409408||100410|
NCT01407796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJHF/ICTS 7326-01|PET Imaging of Endotoxin-induced iNOS Activation|PET Imaging of Endotoxin-induced iNOS Activation in Healthy Volunteers||Washington University School of Medicine|Yes|Completed|December 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|19|||Both|19 Years|44 Years|Accepts Healthy Volunteers|||April 2014|April 17, 2014|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01407796||100533|
NCT01369706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-007|Safety of Screening Procedures With Hand-held Metal Detectors Among Patients With Implanted Cardiac Rhythm Devices|Safety of Screening Procedures With Hand-held Metal Detectors Among Patients With Implanted Cardiac Rhythm Devices||Deutsches Herzzentrum Muenchen|No|Completed|September 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|388|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|June 6, 2011||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT01369706||103444|Convenience sample of patients
NCT01369719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Desferal versus Osveral|Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload|Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload Patients With β-Thalassemia and Intermediate Thalassemia in Bandarabbas||Hormozgan University of Medical Sciences|No|Completed|February 2010|May 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|138|||Both|2 Years|N/A|No|||January 2010|June 13, 2011|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01369719||103443|
NCT01369979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100284|Hepatic Sugar Metabolism Measured by PET/CT in Patients and Healthy Subjects|Hepatic Glucose Metabolism Measured by FDG PET/CT in Patients With Liver Disease and Healthy Subjects||University of Aarhus|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|13|Samples Without DNA|Plasma for measuring levels of ICG, insulin, c.peptide, FFA, glucagon,and 3H-glucose.|Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Recruited via 2 newspapers: Århus Onsdag and Århus Stiftstidende, and so will be based in        the area these newspapers are distributed in.|June 2012|June 25, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01369979||103423|
NCT01370603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653C-190|A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)|A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy of Ezetimibe/Atorvastatin 10 mg/40 mg Fixed-Dose Combination Tablet Compared to Co-Administration of Marketed Ezetimibe 10 mg and Atorvastatin 40 mg in Patients With Primary Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|328|||Both|18 Years|79 Years|No|||January 2015|January 21, 2015|June 8, 2011|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT01370603||103375|
NCT01370343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611010|Single Dose Study Of The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Health Volunteers|A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Healthy Adult Subjects||Pfizer|No|Completed|July 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 3, 2011|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370343||103395|
NCT01370915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-06-012|Perioperative Administration of Pregabalin for Pain After Septoplasty|Perioperative Administration of Pregabalin for Pain After Septoplasty||Samsung Medical Center|No|Recruiting|September 2010|December 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|20 Years|65 Years|No|||June 2011|June 9, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01370915||103351|
NCT01402037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD_BF_02|Beta Cell Function in (Pre)Type 1 Diabetes|Relation Between Residual Beta Cell Function and Glycemic Variability in (Pre) Type 1 Diabetes.||AZ-VUB|No|Recruiting|July 2011|July 2016|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|100|||Both|5 Years|39 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01402037||100976|
NCT01371422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02017|Trial Comparing the Effect of a Paravertebral Block on Pain Post Percutaneous Nephrolithotomy|Randomized Controlled Trial Comparing the Effect of a Paravertebral Block on Pain Post Percutaneous Nephrolithotomy||University of British Columbia|No|Terminated|August 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|3|||Both|19 Years|N/A|No|||March 2015|March 23, 2015|February 10, 2011||No|There was no resources to complete the study at this time|No||https://clinicaltrials.gov/show/NCT01371422||103312|
NCT01371786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-102|A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler|A Phase 1, Open Label, Two Period, Randomized, Cross Over Scintigraphy Study Assessing Nasal Deposition of a Single Dose of a Ciclesonide Radiolabeled Solution Following Nasal Inhalation of a Novel Nasal Metered Dose Inhaler (MDI) and of a Mometasone Furoate Monohydrate Radiolabeled Suspension Via an Aqueous (AQ) Nasal Spray||Sunovion|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||September 2012|September 5, 2012|June 9, 2011||No||No|August 3, 2012|https://clinicaltrials.gov/show/NCT01371786||103285|Both the formulations used in this study were radiolabeled and not the individual corticosteroid molecules. Therefore the distribution of the corticosteroid molecules over 10 minutes post-administration was not quantified.
NCT01409330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDIET3521|German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET)|Short Term Diet Intervention in Newly Diagnosed Type 2 Diabetes. a Randomised, Multicentric, Controlled, Clinical Trial|DDIET|German Diabetes Center|No|Recruiting|February 2011|December 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|69 Years|No|||August 2012|August 21, 2012|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01409330||100416|
NCT01409343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXMab73101|TrasGEX™: Dose Escalation Study|A Phase I Dose-Escalation and Pharmacokinetic Study of TrasGEX™ in Patients With Locally Advanced or Metastatic HER-2-positive Cancer||Glycotope GmbH|Yes|Completed|July 2011|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|July 18, 2011||||No||https://clinicaltrials.gov/show/NCT01409343||100415|
NCT01409876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HistoBrachy1|HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy|HistoScanning- Based Dose-painting Image-guided Interstitial PDR-brachytherapy in Prostate Cancer - a Phase II Trial||University Hospital Erlangen||Not yet recruiting|September 2011|September 2016|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Male|18 Years|N/A|No|||March 2011|August 3, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409876||100374|
NCT01409889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI 5-27805|Comparing Diabetes Prevention Programs|Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study||University of Rochester|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409889||100373|
NCT01410695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB06012|A Phase 2b/3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Methotrexate in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate or to Any Disease-Modifying Antirheumatic Drug|A 24-week With Possible Extension, Prospective, Multicenter, Randomised, Double-blind, Controlled, 3-parallel Groups, Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib at 3 and 6 mg/kg/Day to Methotrexate, With a Randomisation 1:1:1, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including at Least One Biologic Drug if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Biologic Drugs||AB Science|Yes|Recruiting|July 2011|December 2015|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410695||100311|
NCT01410435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-IBD-01-Extension|Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease|An Open-label, Multi-Centre, Non-Randomised Extension Study to Assess the Ability to Maintain a Stable Haemoglobin and to Assess Safety of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease||Pharmacosmos A/S|Yes|Completed|June 2011|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01410435||100331|
NCT01410708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-1-0103|TORI 104 Pre-Surgical Dasatinib|A Pre-Surgical Study to Evaluate Molecular Changes That Occur in Human Breast Cancer Tissue After Short Term Exposure to Dasatinib and To Correlate These Alterations With Pharmacokinetics Parameters||AHS Cancer Control Alberta|Yes|Withdrawn||||||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||August 2011|February 12, 2016|August 4, 2011||||No||https://clinicaltrials.gov/show/NCT01410708||100310|
NCT01411007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR#19231|The Impact of Real-time fMRI Feedback on Response to Nicotine Cues|The Impact of Real-time fMRI Feedback on Response to Nicotine Cues|RTSmoking|Medical University of South Carolina|Yes|Recruiting|March 2010|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult nicotine dependant smokers and Healthy controls|July 2011|August 4, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01411007||100287|
NCT01407575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP-TRD|Buprenorphine for Treatment Resistant Depression|Buprenorphine For Treatment Resistant Depression|BUP-TRD|University of Pittsburgh|No|Completed|September 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|21 Years|N/A|No|||February 2016|February 18, 2016|July 29, 2011|Yes|Yes||No|January 5, 2016|https://clinicaltrials.gov/show/NCT01407575||100550|
NCT01407822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG 1103|Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer|A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of Gemcitabine Plus Cisplatin as (Neo)Adjuvant Treatment in Stage IIIA-N2 Non-small-cell Lung Cancer With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING)|EMERGING|Guangdong Association of Clinical Trials|Yes|Recruiting|July 2011|March 2016|Anticipated|March 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407822||100531|
NCT01407835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6038-PR-PRI-181|Biological Standardization of Dactylis Glomerata Allergen Extract|Biological Standardization of Dactylis Glomerata Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units||Laboratorios Leti, S.L.|No|Completed|October 2011|June 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|50 Years|No|||August 2012|August 8, 2012|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407835||100530|
NCT01408420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-1 13|Perfusion - Pressure - Creatinine Trial|Impact of Perfusion Pressure During Extracorporeal Circulation on Postoperative Kidney Function|PPC|Rigshospitalet, Denmark|No|Completed|April 2011|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|70 Years|N/A|No|||March 2014|March 26, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01408420||100485|
NCT01407809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004011008|Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy|Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy|VSSIIH|Weill Medical College of Cornell University|Yes|Recruiting|January 2012|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 16, 2016|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407809||100532|
NCT01369433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-09-901|A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols|A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols||AVEO Pharmaceuticals, Inc.|No|Active, not recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|March 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01369433||103465|
NCT01369732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0086|Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest|Prevention of Acute Kidney Injury by Erythropoietin in Patients Undergoing Thoracic Aorta Surgery With Hypothermic Cardiac Arrest||Yonsei University|No|Completed|May 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Both|20 Years|N/A|No|||July 2013|July 24, 2013|June 3, 2011||No||No|July 10, 2013|https://clinicaltrials.gov/show/NCT01369732||103442|
NCT01370616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0826-061|Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults||Merck Sharp & Dohme Corp.|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|565|||Both|18 Years|80 Years|No|||December 2015|December 3, 2015|June 8, 2011|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01370616||103374|
NCT01401530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7777-J081-101|E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma|Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma||Eisai Inc.||Completed|July 2011|January 2016|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|20 Years|79 Years|No|||February 2016|February 5, 2016|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01401530||101014|
NCT01370629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6621-049|Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)|A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate||Cardiome Pharma|Yes|Recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Participants treated with intravenous vernakalant in acute care and inpatient hospital        settings per usual care|October 2015|October 9, 2015|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01370629||103373|
NCT01370928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCF-Y0014-L|Colonoscopy Screening Using a Novel Slim Colonoscope - a Randomized Controlled Trial|Colonoscopy Screening Using a Novel Slim Colonoscope - a Randomized Controlled Trial||Sorlandet Hospital HF|No|Completed|March 2011|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|190|||Both|54 Years|64 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|March 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01370928||103350|
NCT01371435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112301|Drug Use Investigation for PAXIL Tablet|Drug Use Investigation for PAXIL Tablet||GlaxoSmithKline||Completed|April 2001|December 2005|Actual|September 2005|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3708|||Both|N/A|N/A||Probability Sample|Japanese subjects with depression/depressed state or panic disorder who were indicated for        PAXIL|June 2011|June 9, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01371435||103311|
NCT01371448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112302|Special Drug Use Investigation for PAXIL Tablet (Long-term)|Special Drug Use Investigation for PAXIL Tablet (Long-term)||GlaxoSmithKline||Completed|May 2001|September 2005|Actual|September 2004|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|339|||Both|N/A|N/A||Probability Sample|Patients with depression/depressed state or panic disorder which are the indications of        PAXIL for long-term use|June 2011|June 9, 2011|June 9, 2011||||No||https://clinicaltrials.gov/show/NCT01371448||103310|
NCT01371773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBAhk_headrot|Repositioning Method for Left-sided Double Lumen Tubes|Repositioning Method for Left-sided Double Lumen Tubes Introduced Into Right Mainstem Bronchus||Seoul National University Hospital|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||December 2011|December 7, 2011|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01371773||103286|
NCT01402934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_PPV|Pulse Pressure Variation in Spontaneously Breathing Patients|The Ability of Pulse Pressure Variation to Predict Fluid Responsiveness in Spontaneously Breathing Patients Undergoing Thoracic Surgery||Seoul National University Hospital|No|Recruiting|May 2011|October 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|80 Years|No|||July 2011|July 28, 2011|May 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01402934||100907|
NCT01399034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0749|Epigenetics, DNA Methylation Patterns and Periodontal Disease|Host DNA Methylation Patterns in Association With Periodontal Disease : MiRNA Changes in Obesity|SZU|University of North Carolina, Chapel Hill|No|Completed|October 2007|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|98|Samples With DNA|-  Gingiva biopsy samples (epithelium, connective tissue)        -  Gingival crevicular fluid        -  Saliva        -  Plaque samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Ninety-eight subjects will be recruited from the Graduate Periodontics Clinic and Dental        Faculty Practice at the University of North Carolina School of Dentistry and if needed        from the general population. Subjects must present with either chronic periodontitis or        periodontal health.|July 2011|July 20, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01399034||101206|
NCT01409616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-035|To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects|A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State||Astellas Pharma Inc|No|Completed|April 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|8||Actual|100|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|March 19, 2013|August 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01409616||100394|
NCT01409629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4325|Influence of a Computer Game on Youth's Choices of Activities|Influence of a Computer Game on Youth's Choices of Activities||University at Buffalo|No|Terminated|February 2011|March 2012|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|12 Years|14 Years|Accepts Healthy Volunteers|Probability Sample|Healthy adolescents ages 12-14|September 2011|September 28, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409629||100393|
NCT01409642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH085058|Family Focused Treatment of Pediatric Obsessive Compulsive Disorder|Pilot Feasibility Trial of Positive Family Interaction Therapy|PFIT|University of California, Los Angeles|No|Recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|17 Years|No|||September 2015|September 1, 2015|October 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01409642||100392|
NCT01410565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1011|Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer|A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)||Spectrum Pharmaceuticals, Inc|No|Active, not recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|658|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410565||100321|
NCT01410864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVDRSS0002|DuraSeal Exact Spine Sealant System Post-Approval Study|DuraSeal Exact Spine Sealant System Post-Approval Study|DuraSeal PAS|Integra LifeSciences Corporation|No|Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort||2|Anticipated|931|||Both|18 Years|N/A|No|Non-Probability Sample|DuraSeal group will be patients that undergo a spinal procedure where a dural opening        occurrs and is treated with DuraSeal Exact Spine Sealant System. Control group will be        patients that have undergone a spinal procedure where a dural opening occurred and was        treated with anything other than DuraSeal Sealant (Spine or Dural). These subjects may be        enrolled retrospectively (through a chart review of past cases) or prospectively.|March 2016|March 24, 2016|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410864||100298|
NCT01411150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000642|Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study|Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study|Pre-CREST-X|Massachusetts General Hospital|Yes|Completed|May 2009|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|26 Years|N/A|No|||January 2014|January 10, 2014|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411150||100276|
NCT01411397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|strangulated hernia|Mesh Hernioplasty Of Strangulated Hernias With Intestinal Resection|Mesh Hernioplasty Of Strangulated Hernias With Intestinal Resection||Mansoura University|Yes|Completed|June 2005|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2005|August 5, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01411397||100257|
NCT01411410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12874|Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer|A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3΄-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy||Bayer|No|Completed|August 2011|June 2015|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||July 2015|July 3, 2015|August 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01411410||100256|
NCT01407380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWT33597-101|Study of PWT33597 Mesylate in Subjects With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered PWT33597 Mesylate in Subjects With Advanced Malignancies||Pathway Therapeutics, Inc.|No|Completed|June 2011|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2012|October 23, 2012|July 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01407380||100565|
NCT01407393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/K/003411|Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects||InQpharm Group|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 7, 2013|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407393||100564|
NCT01407705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22962|High-Resolution Diffusion Tensor Imaging (DTI) of the Cervical Spinal Cord in the Setting of Spinal Cord Injury (SCI)|High-Resolution Diffusion Tensor Imaging (DTI) of the Cervical Spinal Cord in the Setting of Spinal Cord Injury (SCI)||University of Utah|No|Completed|May 2007|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|31|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects will not be randomized, as treatment will follow the doctor's "standard of        care." Patients will be selected and offered enrollment based upon the clinical diagnosis        of spinal cord injury, either due to degenerative disease or trauma. Enrollment will be        based on the chronology of patient presentation.|May 2014|May 19, 2014|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407705||100540|
NCT01407939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|809789|Efficacy of Bitter Blockers on Taste Perception in Children and Adults|Efficacy of Bitter Taste Blockers on Flavor Acceptance in Pediatric Populations|BL|Monell Chemical Senses Center|No|Completed|April 2011|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|215|Samples With DNA|Saliva|Both|3 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Total number of subjects to be enrolled into the study: 300 mothers and 300 children (ages        3-10) =600 total subjects.        Mothers will be recruited from the community of greater Philadelphia through newspaper and        online ads and initial interviews are conducted over the telephone.|March 2016|March 14, 2016|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01407939||100522|
NCT01408199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016508-21|Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus|Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus|ORDI-02|Hospital Universitari Vall d'Hebron Research Institute|Yes|Completed|January 2010|August 2011|Actual|August 2010|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||August 2011|August 2, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01408199||100502|
NCT01408498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHL-Diss-1|Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance|Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance||University of Texas at Austin|Yes|Completed|January 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|120|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|August 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01408498||100479|
NCT01407315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMD_03|Accuracy, Reliability and Safety of GlucoMen®Day, a New Generation Microdialysis Continuous Glucose Monitor|Accuracy, Reliability and Safety of GlucoMen®Day, a New Generation Microdialysis Continuous Glucose Monitor||Medical University of Graz|Yes|Completed|November 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01407315||100570|
NCT01408147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 DK087889-01A1|Prevention of Postpartum Weight Retention in Low Income WIC Women|Prevention of Postpartum Weight Retention in Low Income WIC Women||California Polytechnic State University-San Luis Obispo|Yes|Active, not recruiting|July 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|430|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01408147||100506|
NCT01419470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCD173|Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044|Phase Ⅰ/Ⅱ Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044 After Oral Administration in Premature Ejaculation Patients||Yuhan Corporation|No|Completed|February 2011|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Male|20 Years|60 Years|No|||July 2012|July 31, 2012|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01419470||99643|
NCT01419795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2467.00|Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant|A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab||Fred Hutchinson Cancer Research Center|Yes|Terminated|May 2012|||September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|August 15, 2011|No|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT01419795||99618|
NCT01419808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULCscaphoid|Vascularized Versus Non-Vascularized Bone Grafts in Treating Proximal Pole Scaphoid Non Unions|Vascularized vs. Non-vascularized Bone Grafting in the Treatment of Proximal Pole Scaphoid Non Unions: A Prospective Randomized Trial||Hand and Upper Limb Clinic, Canada|No|Recruiting|September 2007|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||August 2011|August 17, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01419808||99617|
NCT01420120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-REM-03-003|Remedy, Biodegradable Peripheral Stent Registry|A Prospective Multicenter Registry to Evaluate Safety and Performance of REMEDY, Biodegradable Peripheral Stent for the Treatment of Occluded or Stenotic Superficial Femoral Arteries.||be Medical|No|Completed|January 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with documented symptomatic occlusion and/or > 70% stenosis of SFA.|July 2015|July 15, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01420120||99593|
NCT01415947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH1-1|V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse|V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse||Valtech Cardio Ltd||Terminated|November 2010|March 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|75 Years|No|||December 2014|December 22, 2014|August 10, 2011||No|Company business decision|No||https://clinicaltrials.gov/show/NCT01415947||99912|
NCT01410318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PESA CNIC-SANTANDER|Progression of Early Subclinical Atherosclerosis|Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors|PESA|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|Yes|Active, not recruiting|June 2010|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4184|Samples With DNA|-  Orine (4 x 5 mL)        -  Blood (8 x 0.6 mL)        -  Serum (8 x 0.6 mL)        -  EDTA plasma (8 x 0.6 mL)        -  Buffy Coat (2 x 0.6 mL)        -  Non insultated RNA (2 x 5 mL PAXgene)        -  Insulated DNA (2 x 0.3 mL, 150 ng/microL + 1 x 0.3 mL, 75 ng/microL)|Both|40 Years|54 Years|Accepts Healthy Volunteers|Non-Probability Sample|The target population of the study consists of employees (N= 4000) of the Banco de        Santander Group in the Madrid region (65% males and 35% females, aged 40-54 years).|July 2014|July 9, 2014|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01410318||100340|
NCT01410578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090923-001|The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO|The Value of Soluble TREM-1, Procalcitonin, and C-reactive Protein Serum Levels as Markers for the Detection of Sepsis and Bacteremia Among Patients With a Fever of Unknown Origin in Intensive Care Units||Chinese PLA General Hospital|Yes|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|144|||Both|18 Years|N/A|No|Probability Sample|Between September 2009 and March 2011, inpatients were included who were in the intensive        care units (ICU) of the Department of Respiratory Disease, the Emergency Department, and        the Department of Surgery of the Chinese People's Liberation Army General Hospital.|March 2011|August 4, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410578||100320|
NCT01410877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13708|Assessment of Inspiratory Profiles Through Airflow Resistances Designed to Mimic Inhalers|Assessment of Inspiratory Profiles Through Airflow Resistances Designed to Mimic Inhalers||Virginia Commonwealth University|Yes|Completed|August 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Greater Richmond Area, Virginia|June 2013|June 4, 2013|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01410877||100297|
NCT01411163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000511|Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability|Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability|Pre-CREST-2X|Massachusetts General Hospital|Yes|Completed|April 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|26 Years|N/A|No|||January 2014|January 10, 2014|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411163||100275|
NCT01411423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15038|Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan|Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma)||Bayer|No|Completed|April 2008|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3305|||Both|N/A|N/A|No|Non-Probability Sample|This study is all cases investigation of which the enrollment period is 15 months, and all        patients who received Nexavar for unresectable or advanced RCC will be recruited.|June 2014|June 20, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411423||100255|
NCT01411436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15039|Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan|Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma)||Bayer|No|Completed|May 2009|February 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1637|||Both|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who received Nexavar for unresectable HCC.|March 2015|March 3, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411436||100254|
NCT01407406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211HV102|Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers|A Single-Dose, Randomized, Double-Blind, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers||Biogen|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|September 12, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01407406||100563|
NCT01407718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43060|The Parapatellar Approach to Intramedullary Tibial Nailing|The Parapatellar Approach to Intramedullary Tibial Nailing: Is There a Difference in Anterior Knee Pain When Compared to a Traditional Flexed Approach?||University of Utah|No|Active, not recruiting|June 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients will be indicated for intramedullary tibial nailing according to their fracture        pattern.|January 2016|January 4, 2016|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01407718||100539|
NCT01407952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEAT_protocol1|Hydrogel Endovascular Aneurysm Treatment Trial|New Generation Hydrogel Endovascular Aneurysm Treatment Trial|HEAT|Northwestern University|Yes|Recruiting|April 2012|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|75 Years|No|||July 2015|July 10, 2015|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01407952||100521|
NCT01408212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCRC-IRB-2011009 & L-2011-170|Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients|||Korean Medicine Hospital of Pusan National University||Terminated|July 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|July 28, 2011||No|low recruiting|No||https://clinicaltrials.gov/show/NCT01408212||100501|
NCT01408511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15446|HPA Axis Study in Adults|A Multicenter, Open Label Study to Evaluate the Adrenal Suppression Potential of Mapracorat 0.1% Ointment in Adults With Atopic Dermatitis||Bayer|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408511||100478|
NCT01408524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|594/2552(EC4)|Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem|A Comparative Study in the Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol (Avexa) and Diltiazem||Mahidol University|No|Completed|February 2010|December 2013|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01408524||100477|
NCT01418859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCR-01|Clinical Study in Post-operation Treatment of Cervical Cancer|Status and the Application of Topotecan at Post-operation Treatment of Cervical Cancer||Xi’an Jiaotong University College of Medicine|Yes|Recruiting|August 2011|December 2015|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|183|||Female|20 Years|70 Years|No|Probability Sample|patients who underwent the cervical cancer radical surgery in three months have higt risk        factors which including deep stromal invasion,large primary tumour and/or lymphovascular        spase invasion.|March 2012|March 19, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418859||99690|
NCT01419158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFT-001|Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)|Targeted Detection of Alpha-1 Antitrypsin Deficiency in Patients Referred for Pulmonary Function Testing|PFT|Alpha-1 Foundation|No|Completed|January 2008|January 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3457|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals reporting for pulmonary function testing who meet criteria for the diagnosis        of chronic obstructive pulmonary disease|September 2011|January 18, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419158||99667|
NCT01419496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B1|Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia|Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML||Children's Oncology Group|No|Active, not recruiting|September 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|30 Years|No|Non-Probability Sample|Patients with acute myeloid leukemia|May 2015|May 8, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419496||99641|
NCT01419821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol 5.3|Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5|Supplemental Vitamin D Administered to One Year Old Vitamin D Deficient Infants Until Age 3 and Its Affect on Growth Rates and Bone Mineral Density Until Age 5|VitD|Meir Medical Center|No|Not yet recruiting|September 2013|September 2016|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|9 Months|15 Months|Accepts Healthy Volunteers|||August 2011|February 21, 2013|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419821||99616|
NCT01419834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-009|Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors|Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors||Memorial Sloan Kettering Cancer Center|Yes|Recruiting|August 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|2 Years|N/A|No|||February 2016|February 15, 2016|August 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01419834||99615|
NCT01420133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K080906|Is a Diet Necessary When Corticosteroid Treatment is Prescribed?|Is a Low Salt Diet and Low Sugar Content Necessary When Corticosteroid Treatment is Prescribed?|Cortisel|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2011|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01420133||99592|
NCT01415960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP/C/05/PRO|Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer|Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate Cancer||GP-Pharm|No|Active, not recruiting|September 2011|August 2013|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Male|18 Years|N/A|No|||August 2013|August 26, 2013|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01415960||99911|
NCT01410344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN0903|Allogeneic Transplant in HIV Patients (BMT CTN 0903)|Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)||Medical College of Wisconsin|Yes|Active, not recruiting|September 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|15 Years|N/A|No|||December 2015|December 28, 2015|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410344||100338|
NCT01410591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T8/10CSVB|TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding|The Effect of TIPS With 8- or 10-mm Covered Stent for Preventing Variceal Rebleeding in Cirrhotic Patients.|T8/10SVB|Fourth Military Medical University||Completed|July 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|75 Years|No|||January 2016|January 23, 2016|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01410591||100319|
NCT01410890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU07710|Pharmacokinetics of Alglucosidase Alfa in Patients Aged 8-18 Years of Age|A Phase IV Prospective Study to Characterize the Pharmacokinetics of Alglucosidase in Patients Aged 8-18 Years of Age|PAPAYA|Sanofi|Yes|Recruiting|November 2014|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|8 Years|18 Years|No|||December 2015|December 8, 2015|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410890||100296|
NCT01410903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAS - SSc 2010|Immunoadsorption in Patients With Severe Systemic Sclerosis|Immunoadsorption in Addition to the Established Therapy in Patients With Systemic Sclerosis||GWT-TUD GmbH|No|Terminated|April 2011|August 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|85 Years|No|||August 2015|August 18, 2015|August 4, 2011||No|inadequately recruitment rate, funding is not secured|No||https://clinicaltrials.gov/show/NCT01410903||100295|
NCT01411176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPO-11-02/C-02|Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy|Phase III Placebo-controlled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (Randomized, Double-blind, Parallel-assignment, Placebo-controlled Study)||Nihon Pharmaceutical Co., Ltd|No|Completed|September 2011|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|20 Years|N/A|No|||June 2012|June 27, 2012|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01411176||100274|
NCT01411189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPO-11-02/S-02|Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy|Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy||Nihon Pharmaceutical Co., Ltd|No|Completed|September 2011|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|20 Years|N/A|No|||June 2012|June 27, 2012|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411189||100273|
NCT01411449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15040|Primovist Post-marketing Surveillance in Japan|Drug Use Investigation of EOB-Primovist Inj. Syringe|PRIMOVIST|Bayer|No|Completed|March 2008|December 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2030|||Both|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who received Primovist for liver MRI. The        study is expected to collect data of 2,000 patients in about 150 hospitals in Japan.|July 2012|July 26, 2012|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411449||100253|
NCT01411462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMG-007|VIBE-assisted DEB Registry|Vascular Imaging Balloon Catheter-assisted Drug-eluting Balloon Angioplasty Prospective Registry|VIBER|Ospedale Santa Maria Goretti|No|Recruiting|August 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with symptomatic coronary artery disease|August 2011|September 9, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411462||100252|
NCT01411475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMG-009|Prognostic Assessment of Different Pattern of Bifurcation Restenosis|Classification of Bifurcation Restenosis: a Prognostic Assessment|LATINA|Ospedale Santa Maria Goretti|No|Recruiting|August 2011|August 2012|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Coronary artery disease|August 2011|August 5, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411475||100251|
NCT01407419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEIRB 11-216|The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population|Treating to Target (T2T) for Patients With Rheumatoid Arthritis in a US Population: Outcomes and Feasibility||The Consortium of Rheumatology Researchers of North America, Inc.|No|Completed|July 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|538|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407419||100562|
NCT01407731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL11B4|Protein Expression in Human Neuroblastoma Tumor Samples|Analysis of Intersectin Expression in Primary Human Neuroblastomas||Children's Oncology Group|No|Active, not recruiting|July 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Diagnosed with neuroblastoma.|May 2015|May 8, 2015|July 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407731||100538|
NCT01412216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sedentarism|The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance|The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance|Bedrest|University of California, San Francisco||Terminated|September 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|August 5, 2011|Yes|Yes|Funding Depleted.|No||https://clinicaltrials.gov/show/NCT01412216||100194|
NCT01407965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adip-2010|Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.|Offene, Monozentrische, Nicht Kontrollierte Und Nicht Randomisierte Phase IV-Studie Zur Bestimmung Der Pharmakokinetik Von Carbapenemen in adipösen Patienten.||University of Ulm|Yes|Recruiting|April 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407965||100520|
NCT01407978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUVAL P-H-07|Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents|Tolerability and Immunogenicity Study of FLUVAL P H1N1 Monovalent Influenza Vaccine of Omninvest in Children and Adolescents||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|Yes|Completed|August 2009|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|58|||Both|3 Years|18 Years|Accepts Healthy Volunteers|||May 2012|May 18, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01407978||100519|
NCT01408225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10115|Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource|Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis|B-SCR-MM|Ohio State University Comprehensive Cancer Center|Yes|Recruiting|March 2011|||March 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated or diagnosed within the state of Ohio|December 2015|December 3, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408225|10 Years|100500|
NCT01408537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JE0153|Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children|Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children|JE0153|Mahidol University|No|Completed|May 2010|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|152|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||November 2014|November 14, 2014|August 2, 2011||No||No|April 23, 2013|https://clinicaltrials.gov/show/NCT01408537||100476|
NCT01418872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1668-BK-148|A Clinical Trial Of Two Educational Strategies In Cardiovascular Health In Child Population|A Cluster-Randomized Clinical Trial Of Two Educational Strategies In Cardiovascular Health (CVH) In Child Population. The Savinghearts Project|SAVINHEARTS|Agencia Lain Entralgo|No|Completed|January 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1730|||Both|7 Years|9 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01418872||99689|
NCT01419171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2215|The OMEGA Clinical Trial|OMEGA: A Prospective, Multicenter Single-Arm Trial to Assess the OMEGA™ Coronary Stent System for the Treatment of a Single De Novo Coronary Artery Lesion||Boston Scientific Corporation|No|Completed|October 2011|January 2014|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|328|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|August 16, 2011|Yes|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01419171||99666|
NCT01419184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3009-015|Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA|A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA)|DAPHEOR1006|Cubist Pharmaceuticals LLC|No|Completed|August 2011|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|August 16, 2011|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01419184||99665|
NCT01419483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102772|Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer|A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer.|KETOPAN|University of Iowa|Yes|Suspended|July 2011|July 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|July 28, 2011|Yes|Yes|suspension pending protocol amendment|No||https://clinicaltrials.gov/show/NCT01419483||99642|
NCT01418885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dongyanhong85989995|Cognitive Impairment , Neuroimaging and Inflammatory Markers in Patients With Subcortical Ischemic Vascular Disease|Correlation Exploration Between Cognitive Impairment and Neuroimaging and Inflammatory Markers in Patients With Subcortical Ischemic Vascular Disease||Hebei General Hospital|Yes|Active, not recruiting|September 2010|December 2011|Anticipated|September 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|100|None Retained|serum|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with SIVD diagnosed according to the MRI criteria of Erkinjuntti ,25 normal        elderly controls matched in age and gender.|August 2010|August 16, 2011|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418885||99688|
NCT01419197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDM4997g|A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy|A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy|TH3RESA|Hoffmann-La Roche||Active, not recruiting|February 2011|June 2015|Anticipated|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|602|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|August 16, 2011|Yes|Yes||No|February 7, 2014|https://clinicaltrials.gov/show/NCT01419197||99664|
NCT01419509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST11B1|DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma|DNA Methylation-based Assays for Detecting Disease Spread in Rhabdomyosarcoma||Children's Oncology Group|No|Active, not recruiting|August 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|170|Samples With DNA|Tumor, Blood, and Bone Marrow Samples|Both|N/A|18 Years|No|Non-Probability Sample|Diagnosed with rhabdomyosarcoma|May 2015|May 8, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419509||99640|
NCT01419522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110203|Treadmill Training at Constant or Different Speeds for People With Traumatic Brain Injury|Effect of Time Varying Walking Velocity in Body-Weight Supported Treadmill Training||National Institutes of Health Clinical Center (CC)||Terminated|July 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2014|June 27, 2014|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419522||99639|
NCT01419535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110208|Mifepristone for Metabolic Syndrome|Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals||National Institutes of Health Clinical Center (CC)||Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|80|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||December 2015|January 22, 2016|August 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419535||99638|
NCT01419548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110215|ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems|An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2011|December 30, 2011|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419548||99637|
NCT01419847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02082C (10856)|Topical Penlac Nail Lacquer for Onychomycosis in Children|A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children||Rady Children's Hospital, San Diego|No|Completed|March 2002|May 2006|Actual|December 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|2 Years|16 Years|No|||May 2006|August 17, 2011|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419847||99614|
NCT01420172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0214|Pulmonary Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation|Pulmonary Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation.||Ohio State University|No|Active, not recruiting|August 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|A patient record captured during 01Jan2000 and 30Jun2011 from the medical record at The        Ohio State University Medical Center who were seen post hematopoietic stem transplant.|October 2015|October 13, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01420172||99589|
NCT01414751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGH001|Influence of Intervention Methodologies on Patient Choice of Therapy|Interventions for Chronic Diseases: Effect of Patient Values and Effectiveness Information on Patients' Choice of Therapy, Adherence to Therapy and Satisfaction With Therapy|IMPACT|University of Southern Denmark|No|Active, not recruiting|November 2009|August 2013|Anticipated|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|248|||Both|40 Years|69 Years|No|||January 2013|January 9, 2013|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01414751||100004|
NCT01414985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005011054|AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis With Uncommon Genotypes or Moderate/Severe Impairment|Direct CNS Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human CLN2 cDNA to Children With LINCL With Uncommon Genotypes and/or Moderate to Severe Impairment||Weill Medical College of Cornell University|Yes|Recruiting|December 2010|December 2022|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8|||Both|3 Years|18 Years|No|||October 2015|December 9, 2015|December 13, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414985||99986|
NCT01415284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoubertHMR2011/01|ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia|ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia||Maisonneuve-Rosemont Hospital|No|Recruiting|October 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Female|N/A|N/A|No|||February 2013|February 12, 2013|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415284||99963|
NCT01415557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFTSJRI2011|Effect of Regular Consumption of Micronutrient Fortified Beverage on the Micronutrient Status of Indian Schoolchildren|The Effects of Regular Consumption of a Multiple Micronutrient Fortified Beverage on the Micronutrient Status of Indian Schoolchildren and on Their Mental and Physical Performance||Mondelēz International, Inc.|No|Completed|August 2011|September 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|227|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01415557||99942|
NCT01415791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6874L00026|Oral Mucosal Absorption of ICI176,334-1|Oral Mucosal Absorption of ICI176,334-1 in Japanese Healthy Male Subjects||AstraZeneca||Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 29, 2012|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01415791||99924|
NCT01411709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC287|A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress|A Pilot Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress Assessed Under Laboratory Conditions And In Everyday Life||University of Surrey|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 27, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01411709||100233|
NCT01407432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100108|Impact of Folates in the Care of the Male Infertility|Impact of Folates in the Care of the Male Infertility|FOLFIV|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|November 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|368|||Both|18 Years|60 Years|No|||September 2015|September 30, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01407432||100561|
NCT01412229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1103|Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|February 2012|February 2018|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01412229||100193|
NCT01407991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007863|Nasogastric/Oral Gastric Tube Placement in Infants: Comparing 2 Measurement Methods|Placement of NG or OG Tube in Infants by Length Versus Traditional Measuring Methods||Children's Hospital of Philadelphia|No|Terminated|July 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|9|||Both|N/A|6 Months|No|||November 2015|November 9, 2015|July 25, 2011||No|Study terminated due to change in clinical practice affecting recruitment. For majority of    patients, NJ tubes are now used instead of NG tubes.|No||https://clinicaltrials.gov/show/NCT01407991||100518|
NCT01408238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6049-PR-PRI-184|Biological Standardization of Secale Cereale Allergen Extract|Biological Standardization of Secale Cereale Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units||Laboratorios Leti, S.L.|No|Completed|October 2011|June 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|35|||Both|18 Years|50 Years|No|||August 2012|August 8, 2012|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408238||100499|
NCT01408251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193070|Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate Measurements in the Intensive Care Unit|Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate in the Intensive Care Unit||Olive View-UCLA Education & Research Institute|Yes|Completed|January 2008|July 2008|Actual|July 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Probability Sample|Intensive Care Unit patients requiring both an arterial line and central venous line as        part of their clinical care|August 2011|August 1, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408251||100498|
NCT01413061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlloSource Subtalar Fusion RCT|Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft|Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft||AlloSource|No|Active, not recruiting|June 2010|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|80 Years|No|||December 2015|December 29, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413061||100130|
NCT01418625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-002|Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test Formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150mg Capsule (Reference Formulation, Wyeth Pharmaceuticals Inc., USA) Administered as the Contents of Capsule Sprinkled Over Apple Sauce in Healthy Volunteers Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years||||August 2011|August 16, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01418625||99708|
NCT01418898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP 1011|Nutrient Fortified Oat Drink|The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children||PepsiCo Global R&D|No|Recruiting|August 2011|April 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|5 Years|7 Years|Accepts Healthy Volunteers|||August 2011|August 16, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418898||99687|
NCT01419210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15221|Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer|A Pilot Program to Personalize Care by Integrating Traditional and Complementary Medicine for Women With Ovarian Cancer||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|January 2010|September 2015|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|28|||Female|18 Years|N/A|No|||September 2015|September 23, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419210||99663|
NCT01419561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110220|History of the KSHV Inflammatory Cytokine Syndrome (KICS)|Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies||National Institutes of Health Clinical Center (CC)||Recruiting|August 2011|||||N/A|Observational|Time Perspective: Prospective||3|Anticipated|80|||Both|18 Years|99 Years|No|||December 2015|January 9, 2016|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419561||99636|
NCT01419860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microcirculation of colon|Evaluation of Microcirculation in Colon Wall and Bowel Anastomosis by Laser Induced Fluorescence Video Angiography|Evaluation of Microcirculation in Colon Wall and Bowel Anastomosis by Laser Induced Fluorescence Video Angiography of Indocyanine Green||Ostfold Hospital Trust|Yes|Active, not recruiting|January 2010|December 2016|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|4|||Both|18 Years|N/A|No|||August 2011|August 17, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01419860||99613|
NCT01415986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS IRB 114294|Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers|Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers - PHASE II PILOT STUDY||University of Arkansas|No|Terminated|November 2010|March 2012|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|95 Years|No|||November 2012|November 15, 2012|August 10, 2011|Yes|Yes|The patient was "lost to follow-up" and the PI left the institution.|No|May 11, 2012|https://clinicaltrials.gov/show/NCT01415986||99909|Early termination leading to small numbers of subjects analyzed.
NCT01415570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14100|Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)|Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD) - A Prospective Data Collection Study|MADRAD|Los Angeles Biomedical Research Institute|No|Recruiting|August 2011|November 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1050|Samples With DNA|Blood samples|Both|18 Years|85 Years|No|Probability Sample|Adult (18-85 yrs) patients, hemodialysis (HD) > 4 weeks|May 2015|May 20, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415570||99941|
NCT01415804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00525356|Investigation of Stent-grafts in Aortic Dissection (INSTEAD)|A Randomized Comparison of Strategies for Type B Aortic Dissection - the INvestigation of STEnt-grafts in Aortic Dissection (INSTEAD) Trial|INSTEAD|University of Rostock|Yes|Completed|February 2002|March 2011|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|90 Years|No|||March 2011|August 11, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01415804||99923|
NCT01411722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EADIWEANIG299|Electrical Activity of the Diaphragm During the Weaning Period|Electrical Activity of the Diaphragm in Mechanically Ventilated Patients During the Weaning Period||University of Turin, Italy|No|Completed|September 2008|June 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411722||100232|
NCT01411956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G0804|The Effect of a Targeted Video Intervention on Beliefs Regarding Hypertension|The Effect of a Targeted Video Intervention on Beliefs Regarding Hypertension||University of Pittsburgh|No|Completed|October 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 5, 2011|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01411956||100214|
NCT01412242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2188P|Simplification of the Diagnosis of Deep Vein Thrombosis|Identification of the Optimal Approach to the Ultrasound Diagnosis of Deep Vein Thrombosis of the Lower Extremities in Symptomatic Patients|PALLADIO|University of Padova|Yes|Completed|March 2011|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1100|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01412242||100192|
NCT01411943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13194|Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer|Epigenetic Factors Associated With Symptoms and Complications of Chronic Disorders||Virginia Commonwealth University|No|Completed|January 2011|July 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples With DNA|This study will be examining cytokine and c-reactive protein levels, DNA methylation, DNA      repair proteins, telomere length and chromosomal instability.|Female|21 Years|81 Years|No|Non-Probability Sample|Patients will be recruited from oncology treatment clinics|December 2015|December 7, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411943||100215|
NCT01412827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI Protocol #2010127-01H|Accuracy of Half of the Usual Radiotracer Dose in SPECT|Diagnostic and Prognostic Accuracy of Stress SPECT Myocardial Perfusion Imaging With Half the Usual Radiotracer Dose|SPECT-Light|Ottawa Heart Institute Research Corporation|No|Completed|April 2010|September 2014|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01412827||100148|
NCT01412515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C06-46|A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma|A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma||Institut National de la Santé Et de la Recherche Médicale, France|No|Terminated|June 2008|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||August 2011|December 29, 2011|August 8, 2011||No|results from interim analysis conducted to study interruption|No||https://clinicaltrials.gov/show/NCT01412515||100172|
NCT01412814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC 11 MS 0569-10-TLV CTIL|Biomechanics of Gait Pattern Adaptation in Patients After Total Knee Arthroplasty|Biomechanics of Gait Pattern Adaptation in Patients After Total Knee Arthroplasty||Tel-Aviv Sourasky Medical Center||Completed|July 2011|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|90 Years|No|||December 2015|December 21, 2015|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412814||100149|
NCT01418287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI002|Characterization of Influenza-like Illness in Mexico|An Observational Study to Characterize Children and Adults With Influenza Like Illness (ILI) in Mexico||Mexican Infectious Disease Network|No|Completed|April 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5819|Samples With DNA|Plasma, PBMC and Nasopharingeal aspirates|Both|N/A|N/A|No|Non-Probability Sample|Patients with influenza-like illness presenting to clinical sites in Mexico|September 2014|September 10, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418287||99734|
NCT01418924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-4|Sex Hormones & Serum Sclerostin Level|Effects Of Sex Hormones On Serum Sclerostin Level During Menstrual Cycle|SHSCL|Bagcilar Training and Research Hospital|No|Completed|August 2011|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Premenopausal healthy women|October 2011|October 19, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418924||99685|
NCT01418937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114379|Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study||GlaxoSmithKline||Completed|May 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|164|||Female|26 Years|N/A|Accepts Healthy Volunteers|||October 2015|November 19, 2015|August 12, 2011|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01418937||99684|
NCT01418560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWAN-RF|Renal Sympathetic Modification in Patients With Chronic Renal Failure|Renal Sympathetic Modification in Patients With Chronic Renal Failure||The Second Affiliated Hospital of Chongqing Medical University|Yes|Recruiting|August 2011|August 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||May 2013|May 2, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418560||99713|
NCT01418573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-BNH-0100|Glycemic Response After Palaeolithic-type Meals|Glycemic Response After Two Palaeolithic-type Meals Compared to a Modern-type Meal Composed According to WHO Guidelines||Unilever R&D|No|Completed|August 2011|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|August 12, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418573||99712|
NCT01418586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-06-106|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets vs. Sanofi's Uroxatral ER Tablets in Healthy Human Subjects Under Fasted Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years||||August 2011|August 16, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418586||99711|
NCT01418599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-06-107|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets vs. Sanofi's Uroxatral ER Tablets in Healthy Human Subjects Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years||||August 2011|August 26, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418599||99710|
NCT01419574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110224|Ultrasound and Other Images of Artery Blockages|Contrast-Enhanced Ultrasound Imaging of Carotid Plaque Neovascularization||National Institutes of Health Clinical Center (CC)||Completed|July 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|12|||Both|21 Years|N/A|No|||April 2015|May 2, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419574||99635|
NCT01419873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URA/08/06/039|Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates|Pilot Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates||Christchurch Women's Hospital|No|Completed|August 2008|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||August 2011|August 25, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01419873||99612|
NCT01420185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-28 ICSCA|Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28|Molecular Predictors of Loco-Regional Recurrence in Node Positive Breast Cancer||NSABP Foundation Inc|No|Active, not recruiting|October 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1300|||Female|18 Years|78 Years|No|Non-Probability Sample|Stored tissue from participants in protocol NSABP B-28.|May 2015|May 6, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420185||99588|
NCT01415999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-289|Cardiovascular Function in Adult Survivors of Childhood Malignancies|Novel Imaging and Circulation Biomarkers for Comprehensive Evaluation of Cardiovascular Function in Adult Survivors of Childhood Malignancies||The University of Hong Kong|No|Recruiting|August 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|Samples With DNA|plasma, serum|Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Patients will be recruited from the 5 public hospitals in Hong Kong (Prince of Wales        Hospital, Princess Margaret Hospital, Queen Elizabeth Hospital, Queen Mary Hospital, and        Tuen Mun Hospital) that treat the vast majority of childhood cancers, with the number of        patients recruited from each hospital proportional to the respective new case-loads in the        past 10 years.|February 2012|February 22, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415999||99908|
NCT01415310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVALAP (QualGeP)|Quality Register for Geriatric Psychiatry|Quality Register for Geriatric Psychiatry in Viken Research Network for Geriatric Psychiatry|KVALAP|Norwegian Centre for Ageing and Health|No|Recruiting|April 2011|December 2030|Anticipated|December 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|19000|||Both|65 Years|N/A|No|Non-Probability Sample|Patients submitted to the geriatric psychiatry units in the Viken Research network for        Geriatric Psychiatry|April 2015|April 24, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415310||99961|
NCT01415596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALMUS2011|The Effect of High Dose Salbutamol on Muscle Performance|The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males||Bispebjerg Hospital|Yes|Active, not recruiting|August 2011|August 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|August 11, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01415596||99939|
NCT01415583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03-016|Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy|Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy||Massachusetts Eye and Ear Infirmary|Yes|Completed|July 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|314|||Both|3 Years|18 Years|No|||April 2012|April 19, 2012|October 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01415583||99940|
NCT01411514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NC.10.04|Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis|Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort||Ospedale Civico, Lugano|No|Terminated|August 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|80 Years|No|||December 2015|December 17, 2015|May 26, 2011||No|Difficulties to recruit patients|No||https://clinicaltrials.gov/show/NCT01411514||100248|
NCT01411735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 AG18915-01|Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure|Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure|PIE-I|Wake Forest School of Medicine|Yes|Completed|July 2003|July 2008|Actual|June 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|60 Years|N/A|No|||August 2011|August 5, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411735||100231|
NCT01411748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|demirel98|Comparison of Saccharomyces Boulardii and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants|||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|July 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|140|||Both|N/A|90 Days|No|||July 2011|August 5, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411748||100230|
NCT01411969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306/03|Impact of External Nasal Dilator on the Rhinogram|Acoustic Rhinometry: Impact of External Nasal Dilator on the Two First Notches of the Rhinogram|ARENDS|University of Sao Paulo General Hospital|No|Completed|June 2010|December 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|32 nasal cavities of 16 normal adult Caucasian individuals|June 2011|August 5, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01411969||100213|
NCT01411982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S52866|Role of PACAP in Nehprotic Syndrome|Role of PACAP in Increased Platelet Count and Aggregability in Childhood Nephrotic Syndrome||Universitaire Ziekenhuizen Leuven|No|Completed|September 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|Samples Without DNA|Blood and urine|Both|N/A|18 Years|No|Non-Probability Sample|New patients with nephrotic syndrome of patients during a relapse of nephrotic syndrome.|January 2015|January 8, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411982||100212|
NCT01412528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZU-EASY-001|Phase II Study to Standardize Allergen Extracts: Determination of Biological Activity in HEP Units|||University of Zurich||Terminated|August 2009|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Both|18 Years|65 Years|No|||January 2011|August 8, 2011|April 28, 2010||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT01412528||100171|
NCT01412554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3339|Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up|Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow-up|INFO|Oslo University Hospital|No|Completed|August 2011|March 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|103|Samples Without DNA|whole blood, serum, white cells, urine, fat tissue cells|Male|30 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|158 healthy young men measured insulin sensitivity at Center of Cardiovascular and Renal        Research, Division of Medicine, Oslo University Hospital, Ullevål in the period 1991-2002.|January 2016|January 11, 2016|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01412554||100169|
NCT01412840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|787-08|Sterile Water Injections for Relieving Ureterolithiasis Pain|Sterile Water Injections as a Complementary Method for Relieving Ureterolithiasis Pain- a Randomized Controlled Trial||University of Skövde|No|Not yet recruiting|August 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|60 Years|No|||August 2014|August 7, 2014|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01412840||100147|
NCT01413074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-RENAL-CTPIV-2010-106|Survival on Peritoneal Dialysis (PD) Versus Hemodialysis (HD) in China|A Prospective, Randomized, Multicenter, Open-Label, Interventional Study Comparing Survival in Subjects Receiving Peritoneal Dialysis vs Hemodialysis in China||Baxter Healthcare Corporation|Yes|Active, not recruiting|June 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1370|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01413074||100129|
NCT01413334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1106-076-366|Transluminal Attenuation Gradient Versus CT Fractional Flow Reserve|Noninvasive Diagnosis of Ischemia Causing Coronary Stenosis Using Coronary CT Angiograms (CCTA) : Comparison of Transluminal Attenuation Gradient (TAG) and Fractional Flow Reserve Computed From CCTA (FFR CT)||Seoul National University Hospital|No|Recruiting|May 2011|December 2011|Anticipated|August 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with suspected or known coronary artery disease (CAD) who underwent coronary CT        angiography, invasive coronary angiography, and fractional flow reserve measurement        between May, 2010 and January, 2011|August 2011|August 9, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413334||100110|
NCT01418326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008350|Cancer Mortality Affected by the Choice of Anesthetic Drugs?|Cancer Mortality Affected by the Choice of Anesthetic Drugs?||Uppsala University|No|Completed|November 2010|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|3284|||Both|N/A|N/A|No|Non-Probability Sample|All patients operated on for cancer in breast, colo-rectally, or in skin at a single        institution from Jan 1, 1998 to Dec 31, 2009.|May 2015|May 28, 2015|May 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01418326||99731|
NCT01418339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-10-272|Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|July 2011|January 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|7 Years|17 Years|No|||November 2014|November 4, 2014|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418339||99730|
NCT01418352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-10-273|Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|July 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|83|||Both|7 Years|17 Years|No|||May 2015|May 6, 2015|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418352||99729|
NCT01419587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102773|Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)|A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Non-small Cell Lung Cancer||University of Iowa|Yes|Suspended|July 2011|July 2019|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|July 29, 2011|Yes|Yes|suspension pending protocol amendment|No||https://clinicaltrials.gov/show/NCT01419587||99634|
NCT01418911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23/2011|Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control|Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control||Assuta Hospital Systems|Yes|Not yet recruiting|August 2011|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|300|||Both|40 Years|70 Years|No|Non-Probability Sample|type 2 diabetes 40-70 years of age Hebrew speaking members of maccabi healthcare services|July 2011|April 30, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418911||99686|
NCT01416012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-06|Health Related Quality of Life Effects of Off-the-shelf Computer Gaming in Alzheimer and Related Disorders Populations|Health Related Quality of Life Effects of Off-the-shelf Computer Gaming in Alzheimer and Related Disorders Populations||Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2011|September 2013|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|180|||Both|60 Years|N/A|No|||June 2011|April 23, 2013|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01416012||99907|
NCT01408550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-01-06/C-01|Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III)||Nihon Pharmaceutical Co., Ltd|No|Completed|August 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|20 Years|N/A|No|||October 2013|October 15, 2013|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01408550||100475|
NCT01408771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35/11|"Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing Maneuver|"Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing Maneuver||Assaf-Harofeh Medical Center|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|30 Years|N/A|No|Non-Probability Sample|Patients who are sedignated for urodynamic study with overactive bladder symptoms|July 2011|August 7, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408771||100458|
NCT01408784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|172011|A New Method for Self-assessment of Daily Calorie Intake|Evaluating the Validity of the "Categories" Method: a New Method for Self-report Assessment of Daily Calorie Intake||Assuta Hospital Systems|Yes|Recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|135|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|July 2011|April 30, 2012|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408784||100457|
NCT01409031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1211|Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension|Phase II Trial of Sildenafil in Newborns With Persistent Pulmonary Hypertension||University of Colorado, Denver|Yes|Terminated|July 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|N/A|72 Hours|No|||March 2016|March 22, 2016|July 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409031||100439|
NCT01415609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000160|Endoscopic Submucosal Dissection Registry|Establishment of Registry for Endoscopic Submucosal Dissection for Superficial Gastrointestinal Neoplasia|ESD Registry|Mayo Clinic|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for endoscopic treatment of gastrointestinal neoplasia.|November 2012|November 7, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415609||99938|
NCT01411527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KF01282214|The COPENHAGEN Puberty Study Providing Normative Data of Healthy Danish Children and Adolescents|The COPENHAGEN Puberty Study||Rigshospitalet, Denmark|No|Active, not recruiting|January 2006|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2020|Samples With DNA|serum, white cells, urine|Both|5 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|In the cross sectional study, all children at randomly selected schools in Copenhagen were        invited (6203 children). 1864 accepted to participate.        In the longitudinal study, children at two schools with the highest participating rate        were invited to participate in the follow-up study. Ongoing recruitment was continued        until at least 100 boys and 100 girls were enrolled in the logitudinal study.|December 2013|December 6, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411527||100247|
NCT01411761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|demirel9800|Effect of Saccharomyces Boulardii on Indirect Hyperbilirubinemia and Phototherapy Duration in Very Low Birth Weight Infants|Phase 4 Study of Saccharomyces Boulardii on Indirect Hyperbilirubinemia||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|May 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|N/A|15 Days|No|||June 2011|August 5, 2011|August 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01411761||100229|
NCT01411774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH093381|D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)|1/2 D-cycloserine Augmentation of CBT for Pediatric OCD||University of South Florida|Yes|Active, not recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|June 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411774||100228|
NCT01411995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105067|Cervical Lidocaine for Intrauterine Device Insertion Pain|RCT of Cervical Lidocaine for Intrauterine Device Insertion Pain|CLIIP|Washington University School of Medicine|Yes|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411995||100211|
NCT01412281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADD-V-A002|Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers|Randomized, Parallel-group, Double-blind, Single-center Phase III Study to Assess the Immunogenicity and Safety of the 2011/2012-season Influenza Vaccine Formulated With HA Antigen From Two Suppliers, in Elderly and Young Adult Subjects Using the Current EMA Regulations as Guideline||Crucell Holland BV|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|440|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|August 8, 2011||No||No|October 23, 2012|https://clinicaltrials.gov/show/NCT01412281||100190|
NCT01412567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHMC-1|Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers|Comparison of Recombinant Hepatitis B Vaccine Plus Hepatitis B Immune Globulin (HBIG) Versus Vaccine Plus Placebo for Prophylaxis of Hepatitis B Infection in Newborns of Hepatitis B Surface Antigen (HBsAg) Positive Mothers||Govind Ballabh Pant Hospital|No|Completed|October 2005|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|259|||Both|N/A|1 Day|Accepts Healthy Volunteers|||August 2011|August 8, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412567||100168|
NCT01412268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAVUGC-1|Does Bariatric Surgery Changes Eating Habits and Addiction in Morbid Obesity?|Study of Eating Habits and Addiction Changes in Short and Long Time Follow-up in Morbidly Obese Patients Who Undergo Bariatric Surgery.||Bezmialem Vakif University||Not yet recruiting|August 2011|August 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|35|||Both|19 Years|N/A|No|Non-Probability Sample|Patients with BMI > 40 kg/m2 Patients with BMI > 35 kg7m2 < 40 kg/m2 but with comorbidity        Patients > 18 years old Patients who sign the inform consent Patients who have no        psychiatric disease Patients who have no endocrine disorders|August 2011|August 10, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412268||100191|
NCT01412541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0002-01|Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries|A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries|LEVANT 2|C. R. Bard|Yes|Active, not recruiting|July 2011|December 2016|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|476|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412541||100170|
NCT01413100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2533.00|Scleroderma Treatment With Autologous Transplant (STAT) Study|A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis|STAT|Fred Hutchinson Cancer Research Center|Yes|Recruiting|September 2011|||September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|70 Years|No|||January 2016|January 25, 2016|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413100||100127|
NCT01413373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B40320083938|3D Craniofacial Cephalometric Analysis|Clinical Validation of the Three-dimensional Computer Tomography Based Craniofacial Cephalometric Analysis|ACRO3D|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Recruiting|August 2008|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|40 Years|No|||October 2012|October 15, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01413373||100107|
NCT01413087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-PAN-02|Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma|A Multi-Center, Open-Label, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma|LAPC-BC-819|BioCancell Ltd.|No|Active, not recruiting|September 2011|September 2015|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||May 2012|August 9, 2012|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413087||100128|
NCT01413347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_DLT_pillow|The Method to Reduce Displacement of Double-lumen Tube|The Method to Reduce Displacement of Double-lumen Tube During Patient Positioning||Seoul National University Hospital||Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2011|December 7, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413347||100109|
NCT01413360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitC|The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients|Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients||Seoul National University Hospital|No|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||November 2014|November 26, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413360||100108|
NCT01413672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5075-O|Preliminary Evaluation of CASTLE Barrier North American Prototype|Peristomal Skin Irritation: A Preliminary Evaluation of CASTLE Barrier North American Prototype||Hollister Incorporated|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|subjects currently known to investigators|December 2011|December 9, 2011|August 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01413672||100084|
NCT01418612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-001|Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test Formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150mg Capsule (Reference Formulation, Wyeth Pharmaceuticals Inc., USA) in Healthy Volunteers Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 16, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01418612||99709|
NCT01418638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-11 ZIV|The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder|The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder||Ziv Hospital|No|Recruiting|May 2012|||October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|65 Years|No|Probability Sample|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.|February 2013|February 19, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418638||99707|
NCT01407744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS11B1|Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial|Examination of the Multiple Genetic and Molecular Targets as Therapeutic Options for Patients With Ependymoma Treated by the Phase II Children's Oncology Group Study ACNS0121||Children's Oncology Group|No|Active, not recruiting|March 2012|||April 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|80|Samples With DNA|Archived tumor tissue|Both|1 Year|21 Years|No|Non-Probability Sample|Patients with ependymoma treated on the Children Oncology Group ACNS0121 trial|May 2015|May 6, 2015|July 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407744||100537|
NCT01419223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST- Beliefs and Attitudes|Patient Participation Beliefs and Post-Traumatic Stress Disorder (PTSD)|Patient Beliefs and Attitudes That Influence Participation in PTSD-TBI Clinical Trials||INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Completed|July 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Active military and/or veterans ages 18 or over who have recently considered participating        in an outpatient clinical trial for PTSD or TBI.|October 2013|October 25, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419223||99662|
NCT01419236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13981|A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels|A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Explore the Impact of Testosterone Solution 2% on Symptoms of Ejaculatory Dysfunction in Men With Testosterone Deficiency||Eli Lilly and Company|No|Completed|August 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|76|||Male|26 Years|N/A|No|||December 2014|December 12, 2014|August 16, 2011|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01419236||99661|
NCT01408264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WGC|A Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation|A Prospective Randomised Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation||Chinese University of Hong Kong|No|Completed|August 2010|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408264||100497|
NCT01408563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-085|Reduced Intensity Double Umbilical Cord Blood Transplantation|A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation||Massachusetts General Hospital|Yes|Recruiting|September 2011|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|70 Years|No|||March 2015|March 27, 2015|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408563||100474|
NCT01408797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAWN-2011-TJM|Clonal Deletion on Living-Relative Donor Kidney Transplantation|A Prospective, Open-Label, Pilot Study of Clonal Deletion on Living-Relative Donor Kidney Transplantation|DAWN|Fuzhou General Hospital|Yes|Recruiting|March 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|60 Years|No|||February 2011|August 19, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408797||100456|
NCT01408810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06120|Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis|Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients|HERICA|Grupo de Estudo da Doença Inflamatória Intestinal|No|Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|64 Years|No|||December 2012|December 17, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01408810||100455|
NCT01409317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTMS-ERB11/28-2011|Neural Predictors and Longitudinal Neural Correlates of Deep Transcranial Magnetic Stimulation for Treating Major Depression|Neural Predictors and Longitudinal Neural Correlates of Clinical Improvement After Standard or Deep Transcranial Magnetic Stimulation in Major Depression: A Randomized Study||Douglas Mental Health University Institute|Yes|Completed|April 2013|January 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|25 Years|50 Years|No|||May 2015|May 26, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409317||100417|
NCT01411787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122010-150|Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer|Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer "Can we Kick Down Ki-67, Punch Out Insulin Resistance, and Increase Survival?"|Bootcamp|University of Texas Southwestern Medical Center|No|Active, not recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|10|||Female|18 Years|70 Years|No|||September 2015|September 24, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01411787||100227|
NCT01412008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002010863|Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle|Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion||New York Presbyterian Hospital|No|Completed|March 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5|||Both|18 Years|80 Years|No|||September 2013|September 27, 2013|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412008||100210|
NCT01412294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRIN-GC1106-XParTS|XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer|Phase II Study to Evaluate Efficacy and Safety of Capecitabine/Cisplatin Combination Therapy in Gastric Cancer Patients Who Relapsed After S-1 Adjuvant Chemotherapy (XParTS)||Epidemiological and Clinical Research Information Network|Yes|Active, not recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Weeks|74 Years|No|||February 2016|February 2, 2016|July 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01412294||100189|
NCT01412307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEBEN-HL|A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma|A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine (LEBEN) in Relapsed and Primary Refractory Hodgkin Lymphoma|LEBEN|Fondazione Giovanni Pascale|Yes|Active, not recruiting|July 2011|July 2016|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||August 2015|August 8, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01412307||100188|
NCT01412580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F19899-101|The Contribution of Health in Utero to Capacity Formation, Education and Economic Outcomes: Experimental Evidence From Tanzania|The Contribution of Health in Utero to Capacity Formation, Education and Economic Outcomes: Experimental Evidence From Tanzania|CDS|Harvard University|No|Active, not recruiting|April 2002|June 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|1200|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||October 2010|August 8, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412580||100167|
NCT01412879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000707601|S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma|A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With Previously Untreated Mantle Cell Lymphoma||Southwest Oncology Group|No|Terminated|November 2011|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|August 6, 2011|Yes|Yes|toxicity in one arm|No||https://clinicaltrials.gov/show/NCT01412879||100144|
NCT01412892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090502|Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas|A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery|NFitor|Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2011|October 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||November 2014|November 13, 2014|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412892||100143|
NCT01412853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0203-1crgi 07/005-046|Spectro-IRM and Evaluation Response to Prostatic Radiotherapy|Evaluation of the Response to Irradiation With MR-Spectroscopy for Localised Prostate Cancer Patients (The ERIS Trial)|ERIS|Centre Georges Francois Leclerc||Recruiting|February 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Male|18 Years|N/A|No|||September 2014|March 20, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412853||100146|
NCT01412866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDSS1|Electronic Decision Support Systems for Smokers With Severe Mental Illness|||Dartmouth-Hitchcock Medical Center|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|75 Years|No|||September 2012|September 26, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01412866||100145|
NCT01413399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeckHypo2011|A Pilot Study of Intra-arrest Therapeutic Hypothermia in Patients Suffering Non-Traumatic Out of Hospital Cardiac Arrest|A Pilot Study of Intra-arrest Therapeutic Hypothermia in Patients Suffering Non-Traumatic Out of Hospital Cardiac Arrest||Carolinas Medical Center|Yes|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|363|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413399||100105|
NCT01413412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/227-31/3|Full-thickness Skin vs. Synthetic Mesh in the Repair of Large Incisional Hernia|Full-thickness Skin vs. Synthetic Mesh in the Repair of Large Incisional Hernia - a Prospective Randomized Controlled Study||Karolinska Institutet|No|Active, not recruiting|December 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||September 2015|September 28, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413412||100104|
NCT01413386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRA-001|Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent|A Randomized Clinical Trial Comparing Patency and Safety of the Paclitaxel Eluting Covered Metallic Biliary Stent (Niti-S Mira-Cover II Biliary Stent) to the Common Covered Metallic Biliary Stent.|MIRAII|Taewoong Medical Co., Ltd.|No|Recruiting|September 2011|December 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|150|||Both|19 Years|90 Years|No|||January 2012|January 11, 2012|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413386||100106|
NCT01413711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13453A|An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms|An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms||Lundbeck LLC|No|Withdrawn|June 2012|||September 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|1 Month|6 Months|No|||September 2012|September 12, 2012|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413711||100081|
NCT01413724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/747a|Survey of Postoperative Pain and Pain Management in Norwegian Hospitals|Survey of Postoperative Pain and Pain Management in Norwegian Hospitals||Norwegian University of Science and Technology|No|Completed|June 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who had surgery the previous day and still are hospitalized. Patients must        give informed consent to participate.|November 2014|November 27, 2014|July 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01413724||100080|
NCT01414049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE10.151|Patency-Coronary Trial|PATency assessmENt of Grafts by Computerized tomographY in CORONARY Patients: the PATENCY-CORONARY Trial|PATENCY|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|August 2011|September 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|1200|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414049||100057|
NCT01419249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200104_010|First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study|First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study||Merck KGaA|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|458|||Both|N/A|18 Years|No|||November 2013|November 26, 2013|August 16, 2011||No||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01419249||99660|No genetic markers were identified, therefore data for the secondary outcome measures was not analyzed.
NCT01408043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2410|Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma|A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma||Case Comprehensive Cancer Center|Yes|Recruiting|October 2011|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|78 Years|No|||February 2016|February 15, 2016|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408043||100514|
NCT01419886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-93685, CCSRI-020190|Testing of a New Scale Measuring Medical Outcomes of Dysphagia (MOD) in Adult Patients With Swallowing Disorders|||University Health Network, Toronto|No|Recruiting|October 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Inpatients and outpatients of the University Health Network who have a diagnosis of        dysphagia.|June 2012|June 18, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01419886||99611|
NCT01408303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM-EPA-004|[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL|A 6-Week, Randomized, Double-Blind, Placebo(Olive Oil)-Controlled Study to Assess the Efficacy and Safety of Add-On Epanova® to Statin Therapy in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease|ESPRIT|AstraZeneca|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|646|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|August 1, 2011|Yes|Yes||No|June 21, 2013|https://clinicaltrials.gov/show/NCT01408303||100494|
NCT01408576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0012|Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus|A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects|EMBODY4|UCB Pharma|No|Completed|July 2011|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1253|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408576||100473|
NCT01408823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008205|Pharmacokinetics of Aminocaproic Acid in Scoliosis Surgery|Pharmacokinetics of Epsilon-Aminocaproic Acid in Children and Adolescents With Scoliosis Undergoing Posterior Spinal Fusion||Children's Hospital of Philadelphia|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|8 Years|18 Years|No|Non-Probability Sample|Children and Adolescents scheduled to have posterior spinal fusion surgery at The        Children's Hospital of Philadelphia|August 2013|August 7, 2013|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01408823||100454|
NCT01408836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMH4-CT97-2328|Plasma Exchange for Renal Vasculitis|Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis|MEPEX|Cambridge University Hospitals NHS Foundation Trust|No|Terminated|March 1995|December 2003|Actual|June 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||July 2011|August 2, 2011|August 2, 2011||No|Completed|No||https://clinicaltrials.gov/show/NCT01408836||100453|
NCT01411800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1033.1-103-NRM|An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects|A Phase 1, Randomized, Open-Label, Two-Way Crossover Study of Two Oral Formulations of LX1033 in Healthy Human Subjects||Lexicon Pharmaceuticals|No|Completed|August 2011|May 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411800||100226|
NCT01412021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-769|Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis|Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis||AbbVie||Recruiting|August 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|99 Years|No|Non-Probability Sample|All patients who receive Humira for the treatment of Juvenile idiopathic arthritis|January 2016|January 27, 2016|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01412021||100209|
NCT01412320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESRD_2010|Cocoa Flavanols in Renal Disease|The Impact of Dietary Flavanols on Cardiovascular Dysfunction in End-stage Renal Disease||Heinrich-Heine University, Duesseldorf|Yes|Completed|August 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01412320||100187|
NCT01412593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDRC001SC|Intra-hepatic Artery Bone Marrow Derived Stem Cells Infusion for the Treatment of Advanced Liver Cirrhosis|||King Saud University|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||May 2011|August 8, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412593||100166|
NCT01412606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG2|Endometrial Scratching in Couples With Unexplained Subfertility|Endometrial Scratching in Couples With Unexplained Subfertility|ESUS|Mansoura University|No|Completed|July 2009|June 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Female|20 Years|39 Years|No|||August 2012|August 28, 2012|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412606||100165|
NCT01413126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTBRA|Peanuts Second Meal Glycemic Response|Acute and Second Meal Effects of Peanuts on Glycemic Response and Appetite in Obese Women With High Type 2 Diabetes Risk: a Randomized Crossover Trial||Federal University of Vicosa|No|Completed|October 2009|February 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Female|18 Years|50 Years|No|||August 2011|August 8, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413126||100125|
NCT01413139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-100701|4-EVER : a Trial Investigating the Safety of 4F Endovascular Treatment of Infra-Inguinal Arterial Stenotic Disease|4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease|4-EVER|Flanders Medical Research Program|No|Completed|July 2010|September 2013|Actual|May 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|July 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01413139||100124|
NCT01413425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110194|A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome|Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2011|October 2014||||N/A|Observational|N/A|||Actual|0|||Both|N/A|N/A|No|||October 2014|October 21, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413425||100103|
NCT01413750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2010-02203|Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Terminated|November 2010|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2013|July 22, 2015|August 5, 2011|Yes|Yes|Slow Accrual|No|June 5, 2015|https://clinicaltrials.gov/show/NCT01413750||100078|Study was terminated early by NCI due to slow accrual.
NCT01413113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7529|Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery|A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake||University of Washington|No|Completed|December 2011|October 2015|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|July 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01413113||100126|
NCT01414595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000706375|Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer|Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)||Alliance for Clinical Trials in Oncology||Withdrawn|March 2012|||March 2017|Anticipated|N/A|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414595||100016|
NCT01414608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZGOG-0902/GOG-0274/RTOG-1174|Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer|A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial||Gynecologic Oncology Group||Recruiting|January 2012|||July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|780|||Female|18 Years|N/A|No|||March 2016|March 17, 2016|August 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414608||100015|
NCT01413737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2005.1826|Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days|Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days||Norwegian University of Science and Technology||Completed|January 2002|December 2004||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1||118|||Both|N/A|N/A|No|Non-Probability Sample|lung cancer patients after surgery at university hospital|August 2011|August 9, 2011|September 22, 2005||No||No||https://clinicaltrials.gov/show/NCT01413737||100079|
NCT01415076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGH-C99-062|The Optimal Timing of Carbon Dioxide Insufflation During Colonoscopy in Unsedated Patients|The Optimal Timing of Carbon Dioxide Insufflation During Colonoscopy in Unsedated Patients||Tri-Service General Hospital|Yes|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2012|September 3, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415076||99979|
NCT01415375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA104223|Prostate Cancer Education in African American Men|Prostate Cancer Education in African American Men||Temple University|Yes|Completed|September 2004|July 2009|Actual|July 2007|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|490|||Male|45 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415375||99956|
NCT01407445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fcmscsp-tribulus|Effects of Tribulus Terrestris on Sexual Function in Post-menopausal Women|Study of the Effects of Tribulus Terrestris on Sexuality in Postmenopausal Women||Faculdade de Ciências Médicas da Santa Casa de São Paulo|No|Completed|January 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Female|40 Years|70 Years|No|||November 2015|November 9, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407445||100560|
NCT01407458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0043-11-HYMC|The Impact of a Structured Physical Activity Program on Bone Strength and Psycho-Motor Learning of Young Children|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|October 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|6 Years|9 Years|Accepts Healthy Volunteers|||August 2011|August 1, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01407458||100559|
NCT01407783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH083085-02|Systems of Care for New Moms: Integrating Depression Treatment|Systems of Care for New Moms: Integrating Depression Treatment|NUMOMS|Washington University School of Medicine|Yes|Enrolling by invitation|August 2008|June 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||July 2011|July 29, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01407783||100534|
NCT01408849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maytenus2011|Use of Maytenus Ilicifolia in the Treatment of Dyspepsia|Use of Maytenus Ilicifolia Mart. ex Reiss in the Treatment of Dyspepsia||Casa Espirita Terra de Ismael|No|Suspended|February 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 29, 2011||No|Lack of adherence and huge loss of follow up.|No||https://clinicaltrials.gov/show/NCT01408849||100452|
NCT01408004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35303.041.11|Rotating Pazopanib and Everolimus to Avoid Resistance|A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer|ROPETAR|Netherlands Working Group on Immunotherapy of Oncology|Yes|Completed|November 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|April 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408004||100517|
NCT01408017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-10-0003|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2011|||||N/A|N/A|N/A||||||||||||||January 9, 2013|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408017||100516|
NCT01408030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHSU 1008041|North American Study of Epistaxis in HHT|North American Study of Epistaxis in HHT (NOSE)|NOSE|Georgia Regents University|Yes|Completed|August 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|121|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408030||100515|
NCT01408316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-866-006|Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers|A Phase 1 Two-way Cross-over Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules Administered in the Fasting State, and of Crystalline PX-866 Tablets Administered Fed and Fasting, in Healthy Subjects||Oncothyreon Inc.|No|Completed|July 2011|January 2012|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 15, 2012|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01408316||100493|
NCT01408329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRI0016|Effects of Cyclic Variations in Altitude Conditioning (CVAC) on Wellness and Activity Measures|Effects of Cyclic Variations in Altitude Conditioning (CVAC) on Wellness and Activity Measures|CVAC|Palo Alto Veterans Institute for Research|No|Completed|January 2007|August 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|28|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|July 28, 2011||No||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01408329||100492|Small Sample size
NCT01408589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5089|A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol|A Pharmacotherapy Study: A Dose Response Effect of Atomoxetine on Alcohol-elicited Craving and Sensitivity to the Acute Effects of Alcohol|ATX_COMT|University of Colorado, Boulder|Yes|Terminated|June 2005|December 2007|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|86|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 2, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01408589||100472|
NCT01409902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105827|Using a Sheathed Speculum to Visualize and Access the Cervix In Women With Excessive Vaginal Tissue|Using a Sheathed Speculum to Visualize and Access the Cervix In Women With Excessive Vaginal Tissue||University of South Florida|Yes|Completed|June 2008|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|excessive vaginal tissue|April 2013|April 22, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409902||100372|
NCT01409044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110201|Effect of Music on Pain and Anxiety After Surgery|The Effect of Music Listening on the Amount of Opioids Used in Surgical Intensive Care Patients||National Institutes of Health Clinical Center (CC)||Completed|June 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|62|||Both|18 Years|99 Years|No|||November 2015|December 15, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409044||100438|
NCT01413152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOO 370-41|Residual Risk Assessment Of HIV Transmission|EVALUATION DU RISQUE RESIDUEL DE TRANSMISSION DU VIH CHEZ DES HSH TRAITES AYANT UNE CHARGE VIRALE PLASMATIQUE INDETECTABLE|EP 49 EVARIST|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Completed|July 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|167|||Male|18 Years|65 Years|No|||December 2012|December 26, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01413152||100123|
NCT01413178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0071|A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma|A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma||M.D. Anderson Cancer Center|Yes|Recruiting|September 2011|||September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|205|||Both|18 Years|70 Years|No|||December 2015|December 28, 2015|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413178||100122|
NCT01413438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110204|Bevacizumab With or Without Surgery for Adult Glioblastomas|Prospective, Randomized Controlled Trial of Surgical Resection Prior to Bevacizumab Therapy for Recurrent Glioblastoma Multiforme||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|February 19, 2014|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01413438||100102|
NCT01413763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW01-1001|Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis|A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis||Medicis Global Service Corporation|No|Active, not recruiting|July 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413763||100077|
NCT01414075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-053|Study of FG-4592 to Correct Anemia in New Dialysis Patients|||FibroGen|Yes|Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|80 Years|No|||April 2014|April 18, 2014|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414075||100055|
NCT01414062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE9701|Cocinar Para su Salud! (Cook for Your Life!)|Cocinar Para su Salud! (Cook for Your Life!): Implementing Dietary Change Among Hispanic Breast Cancer Survivors||Columbia University|Yes|Active, not recruiting|January 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|82|||Female|21 Years|N/A|No|||June 2015|June 30, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01414062||100056|
NCT01414335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyb10/09|Amino Acid Composition Reduces Frequency of Common Cold. Results of a Controlled Completely Masked Trial|Amino Acid Composition Reduces Frequency of Common Cold. Results of a Controlled Randomized Completely Masked Trial||Kyberg Vital GmbH|No|Completed|October 2009|September 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2011|August 10, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414335||100036|
NCT01414621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14547|Expression of Angiogenic Factors in Myocardial Tissue|IRB #14547: Expression of Angiogenic Factors in Myocardial Tissue in Diabetic and Non-diabetic Patients Undergoing Coronary Bypass Surgery||University of Virginia|No|Completed|August 2009|August 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|Samples With DNA|During the cannulation process before the initiation of CPB(cardiopulmonary bypass) a small      piece of right atrial tissue is cut in order to insert venous drainage cannula to the right      atrium. This small piece of tissue is discarded and is not sent for pathology.|Both|18 Years|N/A|No|Non-Probability Sample|diabetic & non-diabetic CABG patients|March 2016|March 7, 2016|September 17, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414621||100014|
NCT01414855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAO4915g|A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)|A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy||Genentech, Inc.|Yes|Active, not recruiting|August 2011|February 2017|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 10, 2011|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01414855||99996|
NCT01414842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFR-AE-2006|HFR A-equilibrium on Cardiovascular Stability|Randomized Controlled Study on the Effect of the Hemodiafiltration Plasma Sodium Biofeedback System on Cardiovascular Stability in Hemodialysis Patients|AIMS|Azienda Ospedaliera di Lecco|No|Completed|April 2007|December 2008|Actual|October 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|85 Years|No|||January 2007|August 26, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414842||99997|
NCT01415661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRH 01|Efficacy of Cricoid Pressure in Occluding the Esophageal Entrance: A Glidescope ® Study|Efficacy of Cricoid Pressure in Occluding the Esophageal Entrance: A Glidescope ® Study|CP|Procare Riaya Hospital|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|89|||Both|18 Years|60 Years|No|||April 2012|April 7, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01415661||99934|
NCT01415674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEP11/1010|Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients|Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients|PREDICTOR|UNICANCER|No|Active, not recruiting|January 2012|February 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415674||99933|
NCT01407757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B10|Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531|Pharmacogenetics of Gemtuzumab Ozogamicin (GO) Therapy in Acute Myeloid Leukemia||Children's Oncology Group|No|Active, not recruiting|July 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|N/A|29 Years|No|Non-Probability Sample|Diagnosed with acute myeloid leukemia.|May 2015|May 8, 2015|July 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407757||100536|
NCT01407770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU97609|Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer|Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity||Wake Forest NCORP Research Base|Yes|Completed|September 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1000|Samples With DNA|blood and urine samples|Female|18 Years|N/A|No|Probability Sample|Race/ethnicity to include Whites*, Black/African Americans (AA), Hispanic/Latinos,        Asians/Native Hawaiians/Pacific Islanders, and Native American or Alaskan|December 2013|December 16, 2013|July 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407770||100535|
NCT01409070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1012-015-342|Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome|Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome: Retrospective, Multicenter Study|H-1012-015-342|Seoul National University Hospital||Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|300|||Both|18 Years|80 Years|No|Probability Sample|MDS patients who are diagnosed at SNUH|October 2012|October 13, 2012|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01409070||100436|
NCT01408368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN/501/ZKL/67/L|Subtotal Versus Total Thyroidectomy for Graves' Disease|Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.||Jagiellonian University|Yes|Completed|January 2000|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|No|||August 2011|August 2, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408368||100489|
NCT01408277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-030|Using Santyl on Diabetic Foot Ulcers|A Comparison of Collagenase Santyl® Ointment Used Adjunctively to Sharp Surgical Debridement and Sharp Surgical Debridement in the Care of Diabetic Foot Wounds||Healthpoint|No|Completed|August 2011|March 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|August 2, 2011|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT01408277||100496|
NCT01408290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FluvalAB-H-14|Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People|A Randomized, Double Blind, Multicentre Study to Evaluate Safety and Immunogenicity of Four Fluval AB-Like Influenza Vaccines With 3.5 μgHA, 6 μgHA, 9 μgHA Or 15 μgHA Of A/H1N1, A/H3N2 and B Influenza Antigens in Adult and Elderly Subjects||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|256|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 18, 2012|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408290||100495|
NCT01409655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA031643|Centralized Off-Site Adherence Enhancement Program|Centralized Off-Site Adherence Enhancement Program|CARE|University of California, Los Angeles|No|Completed|August 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|42|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01409655||100391|
NCT01409083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8207-IK-CTIL|Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Children|Evaluating the Use of Intravenous Bicarbonate as a Tool to Verify the Intravascular Position of an IV Catheter in Children||Sheba Medical Center|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|18|||Both|2 Years|8 Years|No|||December 2012|December 11, 2012|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409083||100435|
NCT01409928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 102010-093|A Study of the Laparoscopically-placed Adjustable Gastric Band for the Management of Obesity in Adolescent Patients|A Study of the Laparoscopically-placed Adjustable Gastric Band for the Management of Obesity in Adolescent Patients||University of Texas Southwestern Medical Center|No|Terminated|March 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|14 Years|17 Years|No|||March 2016|March 22, 2016|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409928||100370|
NCT01409057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 10-086 SEOPCAB|Effect of Heart-lung-machine on Selenium Status of Cardiac Surgical Patients Undergoing Coronary Bypass Surgery|SEOPCAB: Effect of Heart-lung-machine on Selenium Status of Cardiac Surgical Patients Undergoing Coronary Bypass Surgery|SEOPCAB|RWTH Aachen University|No|Completed|June 2010|December 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|46|||Both|18 Years|N/A|No|Probability Sample|Approximately 100 adult patients (male and female), capable of consenting, undergoing        cardiac surgery.|December 2012|December 11, 2012|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409057||100437|
NCT01412905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWDI-Retinal|Telemedicine Retinal Screening Utilizing a Mobile Medical Unit|Telemedicine Retinal Screening Utilizing a Mobile Medical Unit With a Trained Technician Accurately Detects Disease in High Risk Ethnically Diverse Populations: Results of a Project Dulce™ Retinal Screening Study||Scripps Whittier Diabetes Institute||Completed|February 2007|August 2009|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1229|||Both|16 Years|80 Years|No|Non-Probability Sample|Men and Women, ages 16-80 with type 1 and type 2 diabetes mellitus identified from 8        community health centers in San Diego County.|August 2011|August 8, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412905||100142|
NCT01412918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00014763|Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression|Clinical Evaluation of the Inhibitor Tinnitus Treatment Masking Device & SCN9 Gene Expression||Medical College of Wisconsin|No|Terminated|September 2011|January 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|July 6, 2011||No|Lack of support to continue|No|June 23, 2014|https://clinicaltrials.gov/show/NCT01412918||100141|
NCT01414088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-JMJ-2011-1|The Effects of Isotonic and Hypertonic Saline Infusion on Renal Biomarkers in Healthy Young Subjects|The Effects of Isotonic and Hypertonic Saline Infusion on Renal Biomarkers for the Measurement of Sodium and Water Channel Activity in the Nephron in Healthy Young Subjects|NARA|Regional Hospital Holstebro|Yes|Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|23|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414088||100054|
NCT01414361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1106-077-366|Fractional Flow Reserve and Intravascular Ultrasound in Evaluating Intermediate Coronary Lesions|Comparison of Fractional Flow Reserve (FFR) and Minimal Luminal Area (MLA) by Intravascular Ultrasound (IVUS) in Evaluating Intermediate Coronary Artery Stenosis: International Multi-center Study||Seoul National University Hospital|No|Recruiting|March 2009|November 2011|Anticipated|November 2011|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with intermediate coronary stenosis who underwent both FFR and IVUS|August 2011|August 10, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414361||100034|
NCT01414634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|inims-oo1|Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells|Establish Tolerance in Multiple Sclerosis With Peptide-coupled, Peripheral Blood Mononuclear Cells - A MRI-controlled, Single Center, Phase I Trial in Relapsing-remitting MS Patients|ETIMS|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|February 2010|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|9|||Both|18 Years|55 Years|No|||April 2015|April 8, 2015|August 8, 2011||No||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01414634||100013|
NCT01414868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTD4-BPT20110806|Leukotriene D4 Bronchial Provocation Test (LTD4-BPT) as an Indicator for the Use of Leukotriene Receptor Antagonist (LTRA)|Could Leukotriene D4 Bronchial Provocation Test be a Clear Indicator for Predicting Therapeutic Outcomes of Leukotriene Receptor Antagonist A Pilot Study||Guangzhou Institute of Respiratory Disease|No|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|32|||Both|18 Years|65 Years|No|||December 2009|August 17, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01414868||99995|
NCT01414348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB1120|Managing Dysexecutive Syndrome (DS): CIHR 2011-2014|Managing the Dysexecutive Syndrome Following Traumatic Brain Injury: An Ecologically Valid Rehabilitation Approach||Baycrest|Yes|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414348||100035|
NCT01415401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-199|Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Canada||Alcon Research|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|August 10, 2011|No|Yes||No|May 30, 2014|https://clinicaltrials.gov/show/NCT01415401||99954|
NCT01415414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15515|Observational Study of Ultravist in Patients Requiring CECT|The Image Quality and Radiation Dose of CECT With Ultravist® in Patients With Abdominal Pelvic Disease - INDEX|INDEX|Bayer|No|Completed|September 2011|November 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11660|||Both|N/A|N/A|No|Probability Sample|Patients undergoing contrast enhanced CT Imaging with Ultravist (iopromide) in abdomen and        pelvis, including relevant vessels|January 2015|January 19, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415414||99953|
NCT01415687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23798|Split Dose Pico-Salax + Bisacodyl vs. PEG Split Dose|A Randomized Prospective Trial Comparing Pico-Salax (Magnesium Citrate) Plus Bisacodyl Versus Split Dose Polyethylene Glycol-Based Lavage In Preparation Of Patients For Colonoscopy|BP|University of Calgary|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|171|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01415687||99932|
NCT01407484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081215|Male Infertility Related With Post Infection Inflammatory Syndrome|Diagnosis and Treatment of Male Infertility Related to Inflammatory Syndrome: Therapeutic Trial|SIGMA|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2011|November 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Male|18 Years|N/A|No|||August 2015|August 28, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407484||100557|
NCT01407497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAMOVAC-01-MZ|Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine|A Phase I Trial to Assess Safety and Immunogenicity of i.d. DNA Priming and i.m. MVA Boosting in Healthy Volunteers in Mozambique and to Develop Further HIV Vaccine Trial Capacity Building in Mozambique||Instituto Nacional de Saúde, Mozambique|Yes|Completed|August 2011|August 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407497||100556|
NCT01408381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMo/ICC/2009|Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).|Multicenter Phase II, Randomized Open Clinical Trial on the Therapeutic Use of Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Chronic Ischemia of Lower Limbs (CLI).||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Completed|January 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|38|||Both|18 Years|89 Years|No|||March 2016|March 15, 2016|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408381||100488|
NCT01408056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007923|Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)|The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas|TOUCH|Children's Hospital of Philadelphia|No|Withdrawn|February 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Month|8 Months|No|||January 2014|January 16, 2014|March 10, 2011||No|Difficulty with recruitment|No||https://clinicaltrials.gov/show/NCT01408056||100513|
NCT01409356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPORTDIET|Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis|Effects of Weight Loss on Portal Pressure in Patients With Compensated Cirrhosis and Overweight/Obesity|SPORTDIET|Hospital Clinic of Barcelona|No|Completed|October 2011|December 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|75 Years|No|||March 2015|March 17, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409356||100414|
NCT01409369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25485|A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819|A Single-Center, Open-Label, Two-Period Crossover Study to Investigate the Effect of Multiple Doses of Activated Charcoal on the Pharmacokinetics of a Single Oral Dose of RO4995819 in Healthy Subjects.||Hoffmann-La Roche||Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|26|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409369||100413|
NCT01409941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS_RS_2008-2009 - ScO2|The Relation Between Preoperative ScO2 and the Postoperative Course of Humoral Organ Dysfunction Markers.|The Prognostic Relevance of N-terminal Pro B-type Natriuretic Peptide(NTproBNP), Cerebral Oxygen Saturation (ScO2), and Preoperative Creatinine Clearance in Cardiac Surgery Patients - Amendment 2: the Role of NTproBNP and ScO2 in Predicting Mortality and Postoperative Organ Dysfunction.||University of Luebeck|No|Completed|January 2009|December 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|765|Samples Without DNA|Plasma and urinary samples.|Both|18 Years|N/A|No|Probability Sample|Patients scheduled for cardiac surgery|December 2014|December 22, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409941||100369|
NCT01409382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000416-09-08-2010|Maternal Lifestyle and Neonatal Hypoglycemia|Repercussion of Maternal Lifestyle on Obstetric and Neonatal Outcomes||Hospital dos Servidores do Estado do Rio de Janeiro|Yes|Completed|March 2011|October 2015|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|480|||Both|N/A|40 Years|No|||December 2015|December 13, 2015|May 27, 2011||No||No|April 26, 2013|https://clinicaltrials.gov/show/NCT01409382||100412|Our population is very poor and there were complaints about the necessity of buying protein-rich food. It seems that a sponsored study could improve results
NCT01413776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00801|Effects of a Fortified Dietary Supplement for Pregnant Women on Maternal and Newborn Outcomes in Kampong Chhnang Province, Cambodia|Effects of a Fortified Dietary Supplement for Pregnant Women on Maternal and Newborn Outcomes in Kampong Chhnang Province, Cambodia||University of British Columbia|No|Completed|August 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|547|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413776||100076|
NCT01413789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/350|Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels and One Gel Cream|Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels: BAP Scar Gel, Dermatix, Kelocote and One Gel- Cream: Alhydran||University Hospital, Ghent|No|Completed|June 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 15, 2013|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413789||100075|
NCT01413477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02854|Nickel Desensitization Using Topical Therapy|Nickel Desensitization Using Topical Therapy||University of British Columbia|No|Not yet recruiting|August 2011|June 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|24|||Both|19 Years|N/A|No|||August 2011|August 8, 2011|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01413477||100099|
NCT01413802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/371|Intra Operative Continuous Laryngeal Nerve Monitoring During Thyroid Surgery and Interpretation of the Post-operative Voice Quality in Relation to the Electromyography Data Obtained During Surgery|Intra Operative Continuous Laryngeal Nerve Monitoring During Thyroid Surgery and Interpretation of the Post-operative Voice Quality in Relation to the Electromyography Data Obtained During Surgery|CoNeMoTS|University Hospital, Ghent|No|Enrolling by invitation|September 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413802||100074|
NCT01414101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 329993-CS3|Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis||Ionis Pharmaceuticals, Inc.|No|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|75 Years|No|||May 2013|May 16, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01414101||100053|
NCT01414374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANEMIA2011|Hibiscus Sabdariffa and Centella Asiatica in the Treatment of Anemia by Iron Deficiency|Prevalence of Genetic Polymorphisms of DMT1 and Ferroportin Enzymes in Adults With Anemia by Iron Deficiency, and Its Influence on the Efficacy of Conventional and Herbal Treatments||Casa Espirita Terra de Ismael|No|Completed|January 2012|March 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|50 Years|No|||February 2015|February 12, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414374||100033|
NCT01414387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11GRNT7960035|Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting|Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting||Dallas VA Medical Center|No|Recruiting|October 2011|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01414387||100032|
NCT01414647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|124//2005|The Health Effect of Diet Rich in Nordic Berries|The Effect of Diet Rich in Nordic Berries on Gut Microbiota, Glucose and Lipid Metabolism and Metabolism on Fenolic Compounds|Berry|University of Eastern Finland|Yes|Completed|January 2006|March 2010|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|56|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414647||100012|
NCT01414881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPO1600810|Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects|A Phase 1 Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects||Sanofi|No|Completed|September 2011|November 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2015|January 16, 2015|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01414881||99994|
NCT01415089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA138725|Tailored Web-Based Intervention for Cancer Patients and Family Caregivers|Tailored Web-Based Intervention for Cancer Patients and Family Caregivers|FOCUS-WEB|University of Michigan|Yes|Completed|May 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|63|||Both|18 Years|N/A|No|||October 2013|June 15, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415089||99978|
NCT01415102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2031001|A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.|A Double Blind (3rd Party Open), Randomised, Placebo-Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Single Inhaled Doses Of Pf-05212372 In Healthy Subjects||Pfizer|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 12, 2011|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01415102||99977|
NCT01415427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-005|Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)||BioMarin Pharmaceutical|Yes|Active, not recruiting|July 2011|December 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|173|||Both|5 Years|N/A|No|||April 2014|April 22, 2014|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01415427||99952|
NCT01415700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070155|Comparison Between Implanted Functional Electrical Stimulation and Foot Orthosis|Implanted Functional Electrical Stimulation of the Levators of the Ankle Versus Orthosis in the Treatment of Chronic Foot Neurological STEPPAGE-gait by Central Attack|STEPSTIM|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2010|January 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|75 Years|No|||July 2014|July 25, 2014|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01415700||99931|
NCT01408355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4381001|A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose.|An Exploratory, Open Label, Fixed Sequence Study To Investigate The Pharmacokinetics Of Single Intravenous And Oral Micro Doses Of PF-06273588 In Healthy Male Subjects||Pfizer|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|5|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 8, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01408355||100490|
NCT01408602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC2011-001|A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients|A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis||Molecular Research Center, Inc.|No|Active, not recruiting|November 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408602||100471|
NCT01408875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-03|Cardiac Rehabilitation and Low Frequency Electrical MyoStimulation in Chronic Heart Failure|Cardiac Rehabilitation and Low Frequency Electrical MyoStimulation in Chronic Heart Failure|CREMS-HF|French Cardiology Society|Yes|Completed|October 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|94|||Both|18 Years|75 Years|No|||March 2015|March 6, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408875||100450|
NCT01408615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08165|A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)|Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of ELONVA in Usual Practice||Merck Sharp & Dohme Corp.|No|Recruiting|September 2011|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3600|||Female|N/A|N/A|No|Non-Probability Sample|Women participating in an ART program consisting of COS in combination with a GnRH        antagonist in a general clinical setting.|March 2016|March 22, 2016|June 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01408615||100470|
NCT01409395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6968|Drug-Drug Interaction Study With Metformin and Nizatidine|The Pharmacokinetic Interaction Between Metformin and Nizatidine in Healthy Volunteers||University of California, San Francisco|Yes|Completed|September 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|July 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409395||100411|
NCT01408862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC-PL-01|Effects of Incretins on Human Platelet Function|Effects of Incretins on Human Platelet Function||National Council of Scientific and Technical Research, Argentina|No|Completed|December 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects|September 2014|September 19, 2014|August 1, 2011||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01408862||100451|Albeit at high concentrations presumably well above of the physiological range, the use of native and rapidly degradable forms of these peptides may impose a limitation of this study
NCT01410175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCALPEL 01|Comparison of the Impact of Electric Scalpels Versus Cold Scalpels|"Impact on the Incidence of Surgical Site Infection in Abdominal Gynecological Surgery by Comparing the Skin and Subcutaneous Tissue Incision With Cold Scalpel and Electrocautery in a Period of Two Years."|SCL01|Barretos Cancer Hospital|No|Completed|July 2010|January 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|163|||Female|18 Years|N/A|No|||May 2014|May 22, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01410175||100351|
NCT01410188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPA-6566-101|Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension|An Investigator-Masked, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension||Acucela Inc.|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|160|||Both|18 Years|75 Years|No|||February 2014|February 7, 2014|July 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410188||100350|
NCT01410162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-647|Advagraf/Prograf Conversion Trial|A Randomized, Open Label, Cross Over Study to Examine the Impact of Prograf and Advagraf on Tacrolimus Exposure, Mycophenolic Acid Pharmacokinetics, Renal Allograft Function or Adverse Effects.|SG#153|Lawson Health Research Institute|No|Completed|December 2010|December 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01410162||100352|
NCT01413204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-05|Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TA-7284 as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|July 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|272|||Both|20 Years|N/A|No|||May 2014|May 27, 2014|August 4, 2011||No||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01413204||100120|
NCT01413464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3440|The Risk of Venous Clotting in Patients After Renal Transplant|The Risk of Thromboembolism in Patients Post Renal Transplantation (REPORT) Study|REPORT|St. Joseph's Healthcare Hamilton|Yes|Active, not recruiting|March 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|Samples With DNA|Plasma samples from participants are being banked at various timepoints.|Both|18 Years|N/A|No|Probability Sample|Consecutive patients admitted to St. Joseph's Healthcare Hamilton (McMaster University        affiliated teaching hospital) to the Renal Transplant Ward for renal transplantation.|July 2013|July 18, 2013|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413464||100100|
NCT01414114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-4169-005|Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects|A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder||KAI Pharmaceuticals|No|Completed|December 2011|August 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414114||100052|
NCT01414140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15036|Mirena Post-marketing Surveillance in Japan|Drug Use Investigation of Mirena||Bayer||Completed|May 2007|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|567|||Female|N/A|N/A|No|Non-Probability Sample|The target population of this study is women who patients who are inserted Mirena for        intrauterine contraception. The study is expected to collect data of 550 women.|January 2014|January 8, 2014|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414140||100051|
NCT01414400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07272011-8148|Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).|Prospective Study of Bacteremia and Infection Rates Following Cholangioscopy With the Spyglass Cholangioscope||Stanford University|Yes|Recruiting|August 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|80 Years|No|||August 2011|August 11, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414400||100031|
NCT01414660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009_09/0940|Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation|Adipocytes, Insulin Resistance and Immunity: Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation|IL-7tran|University Hospital, Lille|No|Completed|June 2010|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only||3|Actual|49|Samples With DNA|wholeblood and tissue bank|Both|18 Years|65 Years|No|Non-Probability Sample|Patients undergoing a transplantation in Endocrinology Metabolism department, Nephrology        department and Liver Transplantation department in Lille University Hospital, Amiens        University Hospital, Caen University Hospital, Rouen University Hospital and Reims        University Hospital.|June 2015|June 17, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414660||100011|
NCT01414894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37222-A|Intensive Management of Pressure and Volume Expansion in Patients With Subarachnoid Hemorrhage|Intensive Management of Pressure and Volume Expansion in Patients With Subarachnoid Hemorrhage|IMPROVES|University of Washington|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|20|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|April 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01414894||99993|
NCT01414907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP-LU-2011|Study of Effectiveness of Adding the Health Promotion and Rehabilitation for Treatment for Alcohol and Drug Abusers|VIP (Very Important Patient) Project on Alcohol and Drug Abusers - RCT of Efficacy of the Adding the Health Promotion and Rehabilitation for Treatment of Alcohol and Drug Abusers|VIP|Skane University Hospital|No|Active, not recruiting|October 2010|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414907||99992|
NCT01415141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-219|Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism|A Randomized Trial of Telaprevir, Peginterferon, and Ribavirin Versus Peginterferon and Ribavirin for Treatment of Genotype 1 Hepatitis C Virus With Host Interleukin 28B CC Polymorphism||University of Vermont|No|Terminated|July 2011|June 2014|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 1, 2011||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01415141||99974|
NCT01415154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|44-03001-000|Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder|A 12-Month Prospective Randomized Dual-Arm Pilot Study of Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder||Neuronetics|No|Completed|August 2011|July 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|70 Years|No|||November 2015|November 11, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415154||99973|
NCT01415115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2702|Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications|A Cross-Sectional Study to Test the Feasibility of Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications|MARC|VeraLight, Inc.|No|Completed|March 2007|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|250|None Retained|Blood samples will be drawn for laboratory-based quantification of HbA1c and lipids. Urine      samples will be collected to determine urine creatinine and microalbumin|Both|18 Years|N/A|No|Probability Sample|Potential subjects for the study will have type 1 or type 2 diabetes.|August 2011|August 10, 2011|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01415115||99976|
NCT01415128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-018|Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects|A PHASE I, SINGLE-CENTER, OPEN-LABEL, CROSSOVER STUDY OF THE EFFECT OF AVANAFIL ON THE PHARMACOKINETICS OF OMEPRAZOLE, DESIPRAMINE AND ROSIGLITAZONE IN HEALTHY MALE SUBJECTS||VIVUS, Inc.|No|Completed|April 2010|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 10, 2011|March 28, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01415128||99975|
NCT01415440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6235|Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD|Examining the Effects of Stimulant Medication on Emotional Lability in Patients With Attention Deficit Hyperactivity Disorder (ADHD)||New York State Psychiatric Institute|Yes|Recruiting|August 2011|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Years|25 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01415440||99951|
NCT01411865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shah-2|Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Diabetes|Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Diabetes||Sunnybrook Health Sciences Centre|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|933789|||Both|40 Years|N/A|No|||November 2014|November 21, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01411865||100221|
NCT01408082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-502-004|Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis|A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 Compared to AzaSite Alone, Dexamethasone Alone, and Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis|DOUBle|InSite Vision||Completed|October 2011|June 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|917|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408082||100511|
NCT01408095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14090|A Study in Patients With Type 2 Diabetes|A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2608204 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Withdrawn|September 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||August 2011|August 23, 2011|August 1, 2011|Yes|Yes|Trial terminated no patients were screened or enrolled|No||https://clinicaltrials.gov/show/NCT01408095||100510|
NCT01409096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122009-069|Study Using Pregnenolone to Treat Bipolar Depression|A Randomized, Double Blind, Placebo-controlled Trial of Pregnenolone for Bipolar Depression||University of Texas Southwestern Medical Center|Yes|Completed|March 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|75 Years|No|||April 2013|April 29, 2013|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409096||100434|
NCT01408888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14361|A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes|Study to Evaluate the Effect of LY2189265 on Sitagliptin Pharmacokinetics in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|75 Years|No|||October 2014|October 3, 2014|August 2, 2011|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01408888||100449|
NCT01409109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062010-095|Database Registry to Examine Brain Connections and Brain Function in Mental Disorders and Neural Network Biomarkers for Relational Memory and Psychosis in Schizophrenia|Database Registry to Examine Brain Connections and Brain Function in Mental Disorders and Neural Network Biomarkers for Relational Memory and Psychosis in Schizophrenia|Imaging|University of Texas Southwestern Medical Center|Yes|Recruiting|March 2010|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1000|||Both|15 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals who have been diagnosed with the following disorders will be enrolled in this        study: Schizophrenia and Schizoaffective disorder.|May 2015|May 26, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01409109||100433|
NCT01409681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2010.105|A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer|A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer|EBUS|University of Michigan Cancer Center|Yes|Terminated|May 2011|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|Samples With DNA|Bronchial brush samples Bronchoscopy samples for RNA extraction and RT-PCR expression Blood      samples        -  7 mL for measurement of Serum total Vit-D levels and 1,25 (OH)2 D3 levels;        -  5 ml collected in EDTA tube for CYP24A1 genotype analysis (common metabolizing agent           for calcitriol) and CYP24 polymorphisms analysis|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with early-stage non-small cell lung cancer undergoing a broncoscopy at the        University of Michigan Health Center or at the Ann Arbor Veteran's Administration Hospital|March 2014|March 28, 2014|July 22, 2011|No|Yes|PI decided to terminate the study|No||https://clinicaltrials.gov/show/NCT01409681||100389|
NCT01410487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01998|Effects of Weight Loss on Cardio-respiratory Function|Effects of Weight Loss on Cardio-respiratory Function and Patient-centered Outcomes in an Underserved, Minority Population With Clinically Severe Obesity||New York University School of Medicine|No|Completed|September 2011|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients utilizing the Bariatric Clinic services at Bellevue (City/Public) Hospital.|December 2014|December 1, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410487||100327|
NCT01410500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002|Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease|Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease||Onyx Pharmaceuticals||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||May 2015|May 1, 2015|August 2, 2011|No|Yes||||https://clinicaltrials.gov/show/NCT01410500||100326|
NCT01410461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMV-0232-10|Identifying Predictors of Treatment Success in Painful Bladder Syndrome|Prospective Observational Study That Evaluates Predictor Tests for the Success of Myofascial Pelvic Floor Muscles for the Treatment of PBS|PBS|Rambam Health Care Campus|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|||Female|18 Years|75 Years|No|Non-Probability Sample|Patients with clinical diagnosis of painful bladder syndrome|August 2011|August 4, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01410461||100329|
NCT01410747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGN01|A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations|Post Marketing Surveillance For Long Term Treatment With Tacrolimus in Steroid Resistant Lupus Nephritis|TRUST|Astellas Pharma Inc|No|Active, not recruiting|January 2007|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1484|||Both|N/A|N/A|No|Non-Probability Sample|patients receiving tacrolimus for the treatment of lupus nephritis|September 2015|September 10, 2015|August 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01410747||100307|
NCT01413815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE-KP 2009/001|Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients|Effect of Oral Supplementation With the Amino Acid L-arginine on Peri- Operative Cardio-vascular Risk in Non-selected Patients - Role of Pre-operative Determination of Plasma ADMA Levels for Therapeutic Stratification.||Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|October 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|269|||Both|30 Years|75 Years|No|||January 2016|January 13, 2016|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413815||100073|
NCT01414673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAS11|HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles|Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing Intrauterine Insemination: a Prospective Randomized Study.||Universitair Ziekenhuis Brussel|Yes|Completed|April 2009|August 2011|Actual|July 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||August 2011|August 10, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01414673||100010|
NCT01414920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_202|Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination With Sitagliptin 100 mg in Subjects With Type 2 Diabetes Mellitus||Takeda|No|Completed|August 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|368|||Both|18 Years|80 Years|No|||December 2012|December 13, 2012|August 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414920||99991|
NCT01415167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10PLK13|PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy|Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy||Prometheus Laboratories|No|Recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients starting high dose IL-2 or Proleukin therapy are eligible to participate|November 2015|November 19, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01415167||99972|
NCT01415180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeattleChildrens|Life After Pediatric Sepsis Evaluation|Life After Pediatric Sepsis Evaluation|LAPSE|Seattle Children's Hospital|No|Withdrawn|June 2013|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|1 Month|18 Years|No|Non-Probability Sample|Children aged 0-18 admitted to a PICU for septic shock|May 2013|May 24, 2013|August 10, 2011||No|No funding|No||https://clinicaltrials.gov/show/NCT01415180||99971|
NCT01415193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-02-002|Tibial Nerve Versus Sciatic Nerve Block|Selective Tibial Nerve Block vs Popliteal Sciatic Nerve Block in Patients Having Total Knee Arthroplasty||Saint Francis Care|No|Completed|March 2009|December 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|85 Years|No|||August 2011|March 17, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01415193||99970|
NCT01415466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1276001|Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male Volunteers|A Randomized, Open Label, Multiple-Dose, Cross-over Clinical Study to Investigate Pharmacokinetics and Drug-Drug Interaction Between Rosuvastatin and CS-866 in Healthy Male Volunteers||Daewoong Pharmaceutical Co. LTD.|No|Completed|August 2011|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|36|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01415466||99949|
NCT01415479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCDA-10-085-01-A|Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer Screening|Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer Screening||Indiana University|No|Completed|August 2011|March 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|212|||Both|50 Years|75 Years|No|||April 2013|April 29, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01415479||99948|
NCT01411085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AA019534-01A1|Risperidone and Desipramine in Alcohol Use and Schizophrenia|Alcoholism and Schizophrenia: A Translational Approach to Treatment|RADIAUS|Dartmouth-Hitchcock Medical Center|Yes|Completed|December 2011|September 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||April 2015|April 17, 2015|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411085||100281|
NCT01415453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1650|Evoked Retinal Response|Evoked Visual Response Using Pulsed Ultrasound||Columbia University|No|Terminated|July 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1|||Both|18 Years|60 Years|No|||March 2013|March 1, 2013|July 25, 2011||No|Poor enrollment.|No|June 21, 2012|https://clinicaltrials.gov/show/NCT01415453||99950|Difficulty in recruiting appropriate volunteers. Study terminated due to poor enrollment.
NCT01411345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101056|A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial|A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial|MAPS|University of Miami|Yes|Recruiting|June 2011|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|35 Years|85 Years|No|||February 2016|February 3, 2016|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411345||100261|
NCT01415713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1211|The Study of Metastatic Pancreatic Adenocarcinoma|Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma||National Health Research Institutes, Taiwan|Yes|Enrolling by invitation|August 2011|February 2013|Anticipated|February 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|20 Years|75 Years|No|||August 2011|August 11, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01415713||99930|
NCT01411618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/2010/SC|Efficacy of Essential Oil Mouthwash With and Without Alcohol: a 3-Day Plaque Accumulation Model|Efficacy of Essential Oil Mouthwash With and Without Alcohol: a 3-Day Plaque Accumulation Model||University of L'Aquila|Yes|Completed|June 2010|December 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2010|August 5, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411618||100240|
NCT01407653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100302|Analgesic Effect of a Prototype Device of Virtual Reality in a Population of Patients With Chronic Low Back Pain|Evaluation of the Analgesic Effect of a Prototype Device of Virtual Reality in a Population of Patients With Chronic Low Back Pain. A Randomized Controlled Trial Using a Modified ZELEN Method|REVLOC|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2011|April 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|60 Years|No|||March 2015|April 20, 2015|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01407653||100544|
NCT01408394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY401|Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam|A Phase 1, Single Center, Randomized (2-Sequence), Single Blind, 3-Period Study Comparing the Safety, Tolerability, and Pharmacokinetics of Ecopipam Controlled Release Capsules With Ecopipam HCl Immediate Release Tablets in Male Adult Volunteers||Psyadon Pharma|No|Completed|August 2011|May 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|16|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|August 1, 2013|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408394||100487|
NCT01408628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12634|The I-KAN Study: Internet Insulin Education for Kansans|The I-KAN Study: Internet Initiation of Insulin for Type 2 Diabetes in Kansas|I-KAN|University of Kansas Medical Center|Yes|Completed|August 2011|January 2015|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|August 1, 2011||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01408628||100469|This was a pilot study designed to compare rates of hypoglycemia among Internet managed type 2 patients to those from large clinical trials. It was not a placebo controlled trial.
NCT01408641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047672 (UMD IRB#)|Topiramate for Alcohol Use in Posttraumatic Stress Disorder|A 14-week Randomized, Placebo-controlled Study of Topiramate for Alcohol Use Disorders in Veterans With Posttraumatic Stress Disorder||University of Maryland|Yes|Recruiting|September 2012|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|21 Years|64 Years|No|||September 2012|September 10, 2012|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408641||100468|
NCT01407861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aerobic-Relax-Migraine|Aerobic Endurance Training vs. Relaxation Training in Patients With Migraine|Aerobic Endurance Training Versus Relaxation Training in Migraine Prophylaxis|ARMIG|Universität Duisburg-Essen|No|Completed|July 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407861||100528|
NCT01407874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCX4208-204|A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency|A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency||BioCryst Pharmaceuticals|Yes|Completed|September 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|69 Years|No|||October 2013|October 28, 2013|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407874||100527|
NCT01408667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT/P015/CMR/2010/02_01|Hyperinsulinemic Euglycemic Clamp Protocol|A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk||Torrent Pharmaceuticals Limited|No|Completed|November 2011|||March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|30 Years|65 Years|No|||July 2012|July 6, 2012|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01408667||100466|
NCT01409954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46970|Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells|Defining the Osteogenic Potential of Mesenchymal Stem Cells and Their Progenitors During Spinal Decompression and Posterolateral Lumbar Fusion||University of Utah|No|Enrolling by invitation|October 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Aliquots of bone marrow aspirates and bone fragments|Both|18 Years|N/A|No|Non-Probability Sample|Specialty clinic, University of Utah Orthopaedic Center|January 2016|January 11, 2016|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409954||100368|
NCT01411332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100635|A Phase III Trial of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial|A Phase III Trial of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial|HEIGHT|University of Miami|Yes|Recruiting|May 2011|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Male|35 Years|85 Years|No|||February 2016|February 18, 2016|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411332||100262|
NCT01414413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLW-089673|Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi|Home Assessment and Initiation of ART: a Cluster-randomised Trial in Blantyre, Malawi|CONDA-YAPA|Liverpool School of Tropical Medicine|No|Completed|January 2012|April 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|16660|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|August 10, 2011||No||No|February 19, 2014|https://clinicaltrials.gov/show/NCT01414413||100030|
NCT01410279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09032|Inspiratory Muscle Training in Pulmonary Hypertension|Inspiratory Muscle Training Effect on the Functional Capacity and the Quality of Life in Chronic Pulmonary Hypertension||Hospital de Clinicas de Porto Alegre|No|Recruiting|December 2009|December 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|75 Years|No|||August 2011|August 4, 2011|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01410279||100343|
NCT01410838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 222718-2|Effects of Monosodium Glutamate on Energy Balance and Eating Behavior|Effects of Ingesting Monosodium Glutamate (MSG) on Energy Balance and Eating Behavior Following Moderate Energy Restriction and Weight Loss in Overweight Women||USDA, Western Human Nutrition Research Center|No|Completed|August 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|44|||Female|19 Years|50 Years|Accepts Healthy Volunteers|||August 2014|May 19, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410838||100300|
NCT01410526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1354_9/5/2011|Assessment of Peritoneal Immune Response in Patients With Severe Intra-abdominal Sepsis Managed With Laparostomy and Vacuum Assisted Closure (VAC)|Assessment of Peritoneal Immune Response in Patients With Severe Intra-abdominal Sepsis Managed With Laparostomy and Vacuum Assisted Closure (VAC)||Aristotle University Of Thessaloniki|Yes|Recruiting|May 2011|August 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|In all patients that the origin of sepsis confirmed pre-operative as abdominal, laparotomy        will be required.|May 2011|August 4, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01410526||100324|
NCT01410825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB-P00000148|Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome|Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome||Children's Hospital Boston|Yes|Recruiting|July 2011|July 2031|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Male|3 Months|35 Years|No|||July 2014|July 23, 2014|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410825||100301|
NCT01410799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813246|Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly|Three Month Treatment of GHRH (Growth Hormone Releasing Hormone) in the Elderly||University of Pennsylvania|Yes|Terminated|May 2011|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2011|October 20, 2015|June 17, 2011|Yes|Yes|Funding ended|No||https://clinicaltrials.gov/show/NCT01410799||100303|
NCT01410812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813970|Tying Devices as a Means of Increasing Exercise|Tying Devices as a Means of Increasing Exercise||University of Pennsylvania|No|Completed|September 2011|September 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|226|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410812||100302|
NCT01411358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU11T12A|Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2011-2012, in Non-Elderly Adult and Elderly Subjects||Adimmune Corporation|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 10, 2012|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411358||100260|
NCT01407341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0S-09-12|Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer|ChronOS Stability Study: For Metastatic Cancer||University of Southern California|Yes|Terminated|June 2011|August 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|N/A|N/A|No|||August 2012|February 5, 2014|July 29, 2011||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01407341||100568|
NCT01407354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047439|Comparison of Lokomat and Aquatic Exercise for Individuals With Chronic Incomplete Spinal Cord Injury|Lokomat and Aquatic Therapy in Chronic Motor Incomplete Spinal Cord Injury||University of Maryland|Yes|Active, not recruiting|April 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||May 2014|May 19, 2014|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01407354||100567|
NCT01407926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHE-101531|Nurse-Led Interprofessional Mental Health Promotion Intervention for Older Home Care Clients|The Effects of a Nurse-Led Interprofessional Mental Health Promotion Intervention Among Older Home Care Clients||McMaster University|No|Active, not recruiting|May 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|70 Years|N/A|No|Probability Sample|Older home care clients receiving personal support services through a home care program in        Southern Ontario|August 2011|August 1, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407926||100523|
NCT01410201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZURDEX ERM|Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane|Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane|OZURDEX2|Barnes Retina Institute|No|Terminated|August 2011|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|N/A|N/A|No|||December 2015|December 21, 2015|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410201||100349|
NCT01411306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110957|Screening for Swallowing Problems in Patients Following Prolonged Intubation: Validation of the Toronto Bedside Swallowing Screening Test (TOR-BSST©)|||University Health Network, Toronto|No|Recruiting|May 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Med/Surg ICU inpatients who have received endotracheal intubation lasting 48 hours or        longer|June 2012|June 18, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01411306||100264|
NCT01408433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2011-01|Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer|Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer: A Randomized Controlled Trial||Reproductive Medicine Associates of New Jersey|No|Completed|August 2011|December 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|175|||Both|18 Years|43 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408433||100484|
NCT01409161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0981|Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin|Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)||M.D. Anderson Cancer Center|No|Recruiting|October 2011|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|10 Years|N/A|No|||March 2016|March 17, 2016|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409161||100429|
NCT01409421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0122|RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence|An Assessment of the Impact of Motivational Interviewing Via Glaucoma Educator on Glaucoma Treatment Adherence and Persistence||University of Colorado, Denver|Yes|Completed|April 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|3||Actual|201|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409421||100409|
NCT01411059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT004869-01|Yoga Empowers Seniors Study|Safe and Effective Yoga Prescription of Seniors: Biomechanical Considerations|YESS|University of Southern California|Yes|Completed|July 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|27|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2011|August 4, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01411059||100283|
NCT01411072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panc002/ethics 25823|Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer|Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer||AHS Cancer Control Alberta|No|Recruiting|September 2011|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411072||100282|
NCT01411319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100389|A Phase I Trial of MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer|A Phase I Trial of MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer|LEAD|University of Miami|Yes|Active, not recruiting|October 2010|||October 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|35 Years|85 Years|No|||February 2016|February 18, 2016|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411319||100263|
NCT01410292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG 10-0472|Glycemic and Satiety Response to Fiber and Glycemic Index of Meals in Diabetes|Glycemic and Satiety Response to Meals With Different Fiber Content and Glycemic Index in Type 2 Diabetic Patients||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|March 2011|January 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|20|||Both|18 Years|80 Years|No|||August 2011|August 4, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410292||100342|
NCT01409759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10104 and 10110|Perforator Based Interposition Plasty|Perforator Based Interposition Flaps for Sustainable Release of Burn Scar Contracture: a Reliable, Simple and Versatile Technique. A Randomised Controlled Trial.||Association of Dutch Burn Centres|Yes|Completed|July 2011|November 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 25, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409759||100383|
NCT01410539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOST Study|Mechanism Of Stent Thrombosis (MOST) Study|Mechanism Of Stent Thrombosis (MOST) Study, a Prospective Multicentre Non-randomized Registry|Most|Careggi Hospital|Yes|Completed|January 2010|October 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01410539||100323|
NCT01410851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PURENet:-Pulses and Satiation|Pulses, Satiation, Food Intake and Blood Glucose|The Acute Effects of Pulse Consumption on Glycaemic Responses and Measures of Satiety and Satiation||University of Toronto|No|Completed|September 2009|October 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|24|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||July 2011|August 3, 2011|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01410851||100299|
NCT01411124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114111|Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects|A Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Study Assessing the Effect of 600 mg Gabapentin Enacarbil on Simulated Driving in Healthy Subjects||XenoPort, Inc.|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|July 15, 2013|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01411124||100278|
NCT01411137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX066-B11-01|Carbidopa-Levodopa Extended-Release (CD-LD ER) Alone or in Combination With Carbidopa-Levodopa Immediate Release (IR) to IPX066 Followed by Extension Safety Study of IPX066 in Subjects With Advanced Parkinson's Disease|An Open Label Conversion Study of Carbidopa-Levodopa Extended-Release (CD-LD ER) Taken Alone or in Combination With Carbidopa-Levodopa Immediate Release (IR) to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Subjects With Advanced Parkinson's Disease||IMPAX Laboratories, Inc.|No|Completed|August 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|30 Years|N/A|No|||September 2013|September 27, 2013|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411137||100277|
NCT01411371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q0605/47|Catheter Ablation Versus Medical Treatment of AF in Heart Failure|Catheter Ablation Versus Medical Treatment of AF in Heart Failure|CAMTAF|Barts & The London NHS Trust|No|Recruiting|March 2005|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2010|August 5, 2011|July 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01411371||100259|
NCT01411384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/21-07-2011|Evaluation of Corneal Hysteresis and Corneal Resistance Factor After Corneal Cross-linking for Keratoconus|Evaluation of Corneal Hysteresis and Corneal Resistance Factor After Corneal Cross-linking for Keratoconus||Democritus University of Thrace|No|Completed|April 2008|April 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label|1||Actual|80|||Both|15 Years|N/A|No|||July 2011|February 21, 2012|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01411384||100258|
NCT01411098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7506|Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase I Dose-Intensification Study Using Radiation Therapy and Concurrent Cisplatin and Etoposide for Patients With Inoperable Non-small Cell Lung Cancer||University of Washington|No|Terminated|October 2011|||March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||November 2015|November 3, 2015|August 4, 2011|No|Yes|Low accrual|No||https://clinicaltrials.gov/show/NCT01411098||100280|
NCT01411111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112362|A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin|An Open Label, Sequential, Single Cohort, Repeat Dose Study to Investigate the Potential Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects.||GlaxoSmithKline|No|Completed|January 2011|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|August 23, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01411111||100279|
NCT01407679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM 10_0019|Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus|Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study|AliCLE|University Hospital Muenster|No|Terminated|August 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|75 Years|No|||May 2014|May 21, 2014|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407679||100542|
NCT01407692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 221594-1|Menstrual Cycle Hormones and Eating Behavior|Effect of Menstrual Cycle Hormone Changes on Eating Behavior and Nutrient Metabolism|FL-84|USDA, Western Human Nutrition Research Center|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|24|Samples Without DNA|Serum, plasma and urine samples may be retained for future testing.|Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, premenopausal women.|February 2013|February 7, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01407692||100541|
NCT01407367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00048532|Safe Kidney Care Cohort Study|Does Under-recognition of Kidney Disease Affect Patient Safety?||University of Maryland|No|Active, not recruiting|April 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples Without DNA|At each yearly research clinic visit (up to 4), 30 cc (6 teaspoons) of blood will be      processed and stored for future assays related to kidney function.      At first research clinic visit, 9 cc urine will be processed and stored for future assays      related to kidney function.      At each yearly research clinic visit, 1 swab of both nares, 1 pharyngeal swab and 1 skin      swab will be obtained, processed and stored with future testing for multiple antibiotic      resistant (MAR) organisms.|Both|21 Years|N/A|No|Non-Probability Sample|Participants will be recruited from a variety of chronic kidney disease (CKD) management        and primary care setting. Some participants will be self-referrals.|November 2015|November 30, 2015|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01407367||100566|
NCT01407666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOD09070393-01 / PRO09070393|Comparison Between Epidural and Bilateral Paravertebral Blocks in Liver Resection|Prospective Randomized Comparative Study Between Epidural and Bilateral Paravertebral Blocks for Perioperative Pain Management in Patients Undergoing Open Liver Resection||University of Pittsburgh|Yes|Completed|August 2010|November 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|February 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01407666||100543|
NCT01408485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90067869|Clinical Evaluation of Therapy™ Cool Flex™ Irrigated Ablation System for the Treatment of Typical Atrial Flutter|Clinical Evaluation of Therapy™ Cool Flex™ Irrigated Ablation System for the Treatment of Typical Atrial Flutter|FLEXION AFL|St. Jude Medical|Yes|Completed|November 2011|October 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|July 22, 2011|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01408485||100480|
NCT01410773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D-2010-2011.32|User Performance Evaluation of an Investigational Blood Glucose Monitoring System|Ninja 2 User Performance Evaluation||Ascensia Diabetes Care|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|110|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|August 3, 2011|Yes|Yes||No|July 31, 2012|https://clinicaltrials.gov/show/NCT01410773||100305|
NCT01410786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHO.CR.GK1 (407)|Oxford Partial Knee Comparative Instrument Pilot Study|A Comparison of Signature Guides and Conventional Instrumentation With the Oxford Partial Knee System Pilot Study||Biomet, Inc.|No|Completed|June 2013|December 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01410786||100304|
NCT01407627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCalgary Sugar Study|Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans|Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans||University of Calgary|No|Recruiting|July 2011|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407627||100546|
NCT01408914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0050|Trial of High-Dose Rifampin in Patients With TB|Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB|HIRIF|Harvard University Faculty of Medicine|Yes|Active, not recruiting|September 2013|February 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|60 Years|No|||February 2016|February 16, 2016|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408914||100447|
NCT01409980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49246|Triphalangeal Thumbs in the Pediatric Population: Long Term Outcomes Following Surgical Intervention|Triphalangeal Thumbs in the Pediatric Population: Long Term Outcomes Following Surgical Intervention||University of Utah|No|Completed|July 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|3|||Both|1 Year|18 Years|No|Non-Probability Sample|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit)        at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and        Hutchinson operated on with a delta phalanx.|June 2014|June 22, 2014|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409980||100366|
NCT01409993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110206|Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis|||Vanderbilt University|Yes|Recruiting|August 2011|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|260|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409993||100365|
NCT01410214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-LCSG-001|Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations|A Phase II Trial of Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation in Exon 19 or 21 and Wild-type K-ras||Chinese Lung Cancer Surgical Group|No|Recruiting|May 2011|July 2017|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||December 2011|December 21, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01410214||100348|
NCT01410227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071001|Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)|A Phase 3 Clinical Study to Determine the Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor : Recombinant Factor VIII (rVWF:rFVIII) and rVWF in the Treatment of Bleeding Episodes in Subjects Diagnosed With Von Willebrand Disease||Baxalta US Inc.|Yes|Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|49|||Both|18 Years|65 Years|No|||February 2016|February 5, 2016|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410227||100347|
NCT01410240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|611001|Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty|A Prospective, Randomized, Controlled, Single-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of FLOSEAL for Hemostasis in Primary Unilateral Total Knee Arthroplasty (TKA)||Baxter Healthcare Corporation|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|80 Years|No|||May 2014|May 15, 2014|August 1, 2011|Yes|Yes||No|February 28, 2014|https://clinicaltrials.gov/show/NCT01410240||100346|
NCT01407887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFB544A8|Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children|Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children||Heidelberg University|Yes|Completed|August 2011|December 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|6 Months|59 Months|No|||June 2011|December 4, 2012|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01407887||100526|
NCT01410032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOT-HCFMUSP|Reconstruction Plate Compared With Flexible Intramedullary Nailing for Midshaft Clavicular Fractures|Reconstruction Plate Compared With Flexible Intramedullary Nailing for Midshaft Clavicular Fractures: a Prospective, Randomized Clinical Trial||University of Sao Paulo|Yes|Completed|July 2010|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Both|16 Years|65 Years|No|||April 2014|April 25, 2014|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01410032||100362|
NCT01410552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS ICD - ITSY09|Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination|Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination|ISIS-ICD|LivaNova||Active, not recruiting|October 2011|August 2016|Anticipated|August 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1013|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410552||100322|
NCT01410305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1Ro1HD070490-01|Vit D and HIV-Cardiovascular Disease in Children and Young Adults Vitamin D and HIV-CVD in Children and Young Adults|Vitamin D Metabolism Inflammation, and Cardiovascular Risk in HIV-infected Children and Young Adults||University Hospital Case Medical Center|No|Completed|September 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|290|Samples With DNA|plasma, serum, PBMCs, urine|Both|8 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Any HIV+ patient between the ages of 8 and 25 and matched HIV- controls matched by age and        race.|May 2015|May 26, 2015|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01410305||100341|
NCT01394380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171/11|Reduction of Sweetened Beverages and Intrahepatic Fat|Effects of a Reduction of Sweetened Beverages Consumption in Overweight High Consumers on Cardiometabolic Risk Factors|REDUCS|University of Lausanne|No|Completed|October 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|29|||Both|18 Years|40 Years|No|||June 2014|June 3, 2014|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394380||101562|
NCT01394393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALUD-2010-1-140220|Virtual Environments For Supporting Obesity Treatment|Ambientes Virtuales Como Auxiliares en el Tratamiento de la Obesidad|AVATOB|Universidad Nacional Autonoma de Mexico|Yes|Recruiting|January 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|40|||Female|18 Years|50 Years|No|||May 2012|May 30, 2012|June 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394393||101561|
NCT01394367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-472/2009|Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Ventricular Function in Severe Pulmonary Hypertension|Study of Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Ventricular Function in Severe Pulmonary Hypertension||Heidelberg University|No|Recruiting|June 2010|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|18 Years|75 Years|No|||July 2014|July 1, 2014|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01394367||101563|
NCT01394640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 72/09|Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients|Evaluation of Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Oncologic and Hematologic Patients||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|October 2009|January 2011|Actual|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|124|Samples Without DNA|Serum and blood sample|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, nonpregnant adults, or patients affected by hematologic malignancies and older        than 18 years, were eligible.|October 2009|July 29, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01394640||101542|
NCT01394978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO09-100|NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study|AirTight: A Prospective Controlled Post-Approval Study of NeoMend ProGEL™ Pleural Air Leak Sealant in the Treatment of Visible Pleural Air Leaks After Standard Pleural Closure||C. R. Bard|Yes|Completed|June 2011|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|444|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394978||101516|
NCT01394991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR010543|A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia|A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|January 2006|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|504|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|September 10, 2010||No||No|September 10, 2010|https://clinicaltrials.gov/show/NCT01394991||101515|
NCT01395004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCH115397|A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis|A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis||Accenture|No|Active, not recruiting|November 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|12 Years|N/A|No|||May 2013|May 15, 2013|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395004||101514|
NCT01395264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/0366|Saccadometry in Primary Headache Syndromes|Saccadometry in Primary Headache Syndromes||University College London Hospitals|No|Not yet recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|162|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|From hospital Headache clinics (secondary and tertiary)|May 2011|July 14, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395264||101494|
NCT01395888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115247|A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD|A 12week Study to Evaluate the Effect of Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) on Arterial Stiffness Compared With Tiotropium Bromide 18 mcg Delivered Once Daily Via a HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).||GlaxoSmithKline|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|40 Years|80 Years|No|||August 2013|July 10, 2014|July 14, 2011|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01395888||101446|
NCT01395511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOMC MIRB2009-05|Acupuncture for Whiplash Associated Disorder|Acupuncture for Whiplash Associated Disorder: a Randomised, Waiting-list Controlled, Open-label, Parallel-group Pilot Trial||Kyunghee University Medical Center|No|Completed|December 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|No|||December 2009|July 14, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395511||101475|
NCT01395524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00007|A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation|A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)||AstraZeneca|No|Completed|July 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|84 Years|No|||May 2015|June 15, 2015|June 28, 2011|Yes|Yes||No|October 13, 2014|https://clinicaltrials.gov/show/NCT01395524||101474|
NCT01395862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112278|Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)|Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)||GlaxoSmithKline|No|Completed|November 2007|September 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1001|||Both|N/A|N/A|No|Probability Sample|Japanese patients with asthma who are expected to use fluticasone and salmeterol for        long-term.|August 2013|August 20, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395862||101448|
NCT01396447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-56|Safety, Tolerability, and Efficacy of Cariprazine in Patients With Bipolar Depression|A Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression||Forest Laboratories|No|Completed|July 2011|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|584|||Both|18 Years|65 Years|No|||February 2015|February 27, 2015|July 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396447||101404|
NCT01396759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10088|Use of Bubble Continuous Positive Airway Pressure Compared to Nasal Prong Oxygen or Humidified High Flow in Children Under Five With Severe Pneumonia and Hypoxaemia|Use of Bubble CPAP Compared to Nasal Prong Oxygen or Humidified High Flow in Children Under Five With Severe Pneumonia and Hypoxaemia: a Randomized Trial||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|July 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|975|||Both|N/A|5 Years|No|||June 2015|July 26, 2015|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396759||101380|
NCT01396772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT-2010-012|PREPARE: "Prediabetes Research and Education Promoting Activity & Responsible Eating"|A Community-based Healthy Lifestyle Patient-centred Education Program for Middle & Older Adults With Prediabetes, Which Strengthens the Delivery of Health Services and Assists Individuals at High-risk for Diabetes in London, Ontario.|PREPARE|Brescia University College|Yes|Recruiting|May 2011|||June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|30 Years|N/A|No|||July 2011|July 18, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396772||101379|
NCT01397032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009340|Attention Bias Modification Treatment for Children With Social Anxiety|Attention Bias Modification Treatment for Children With Social Anxiety||Tel Aviv University|No|Completed|April 2011|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|67|||Both|7 Years|18 Years|No|||May 2015|May 25, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01397032||101359|
NCT01397045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Theagenio Thoracic Surgery 1|Fast Track Rehabilitation Following Video-assisted Lung Segmentectomy|||Theagenio Cancer Hospital||Completed|July 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|120|||Both|N/A|80 Years|No|||March 2014|March 26, 2014|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01397045||101358|
NCT01397058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAthens|Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress|Observational Study of CMV Reactivation in Immunocompetent Children and Adult ICU Patients|RECYSTRESS|University of Athens|Yes|Recruiting|June 2011|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|275|Samples With DNA|As described above, whole blood will be collected on a weekly basis and DNA will be      extracted to detect CMV-DNA. The remaining DNA will be retained|Both|2 Years|N/A|No|Probability Sample|ICU patients|July 2011|August 12, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397058||101357|
NCT01397331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7199-SP-CTIL|Influence of Anesthesia on Mechanical Efficiency of Left Ventricle in Patients Undergoing Open Heart Surgery|Influence of Anesthesia on Mechanical Efficiency of Left Ventricle in Patients Undergoing Open Heart Surgery||Sheba Medical Center|No|Recruiting|July 2010|April 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2011|July 18, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01397331||101336|
NCT01392391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00048469|Exercise For Sub-acute Stroke Patients in Jamaica|Jamaica and Maryland Mobility in Stroke|JAMMS|Baltimore VA Medical Center|Yes|Recruiting|July 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|85 Years|No|||August 2013|August 22, 2013|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392391||101714|
NCT01393418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM41529|Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery|EPO: A Renal Biomarker After Cardiac Surgery|EPO|University of Michigan|No|Recruiting|November 2010|||December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|80|Samples Without DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Cardiac surgery patients.|December 2010|July 12, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393418||101636|
NCT01392768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-LPT-03(09/10)|Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization|A Double-blind, Phase III, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam as Adjunctive Therapy, in Partial Seizures Control Associated With Refractory Focal Epilepsy|Mozart|Ache Laboratorios Farmaceuticos S.A.|No|Completed|January 2013|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|4 Years|65 Years|No|||March 2015|March 7, 2016|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01392768||101686|
NCT01393756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(R2-CHOP2)|Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma|A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma|R2-CHOP2|The Lymphoma Academic Research Organisation|Yes|Completed|December 2010|November 2015|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01393756||101610|
NCT01393769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJD-RTB-QTIA|Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage|An Open, Single-centre Non-randomized Phase II Clinical Trial on Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage||Hospital Sant Joan de Deu|No|Terminated|November 2009|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|6 Months|6 Years|No|||September 2013|February 14, 2014|July 7, 2011||No|Only 5 subjects could be enrolled. The sample of 25 subjects could not be achieved due to it    is a rare disease.|No||https://clinicaltrials.gov/show/NCT01393769||101609|
NCT01394120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARGTHPANC 001|Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer|Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer||Grupo Hospital de Madrid|Yes|Recruiting|August 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2012|March 24, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01394120||101582|
NCT01393834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-053|Delayed Umbilical Cord Clamping Versus Cord Milking in Preterm Neonate|Delayed Umbilical Cord Clamping Versus Cord Milking in Preterm Neonate - a Randomized, Controlled Trial||Medstar Research Institute|Yes|Terminated|December 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|2|||Female|18 Years|N/A|No|||February 2013|February 20, 2013|June 1, 2011||No|difficulty with enrollment|No||https://clinicaltrials.gov/show/NCT01393834||101604|
NCT01393782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111016|Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study|Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study|ATHOS|George Washington University|No|Completed|July 2011|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|N/A|No|||February 2014|February 18, 2014|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01393782||101608|
NCT01389687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV35 (EFC12403)|Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan|Immunogenicity and Safety of the SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan||Sanofi|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|74|||Both|3 Months|68 Months|Accepts Healthy Volunteers|||March 2013|March 28, 2013|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389687||101921|
NCT01389973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018748|A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects With Primary Biliary Cirrhosis Who Had an Inadequate Response to Ursodeoxycholic Acid (UDCA)||Janssen Research & Development, LLC||Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|July 7, 2011|Yes|Yes||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01389973||101900|Based on the efficacy results of Part 1, Part 2 of the study was not initiated and as per the study design, the study was considered completed after part 1.
NCT01394679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-05-236|A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer|A Multicenter Phase 3 Study Comparing the Diagnostic Accuracy of 99mTc EC DG SPECT/CT Versus 18F FDG PET/CT for Diagnosing and Staging Patients Who Have Clinical and Radiological (CT) Evidence Consistent With a Diagnosis of Lung Cancer||Cell>Point LLC|Yes|Recruiting|April 2013|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|154|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394679||101539|
NCT01394692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWG-EK 239/07|Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery|Resection Control of Primary Brain Tumours Using a Low-Field Intraoperative MRI||Goethe University|No|Completed|October 2007|January 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|July 13, 2011||No||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01394692||101538|
NCT01394653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-209|A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake|Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion With Water -||Astellas Pharma Inc|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|July 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01394653||101541|
NCT01394666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-240|Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)|Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily||Bristol-Myers Squibb|No|Active, not recruiting|May 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Primary care clinic, academic and community oncology centers|February 2015|February 3, 2015|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01394666||101540|
NCT01395303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2011-2|Polymorphisms in the Vitamin D System and Health|Polymorphisms in the Vitamin D System and Health||University of Tromso|No|Active, not recruiting|April 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||8|Anticipated|9700|Samples With DNA|DNA from blood clots|Both|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Subjects from the fourth Tromsø study performed in 1994-1995 who had blood samples taken        for later DNA analyses|December 2015|December 2, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395303||101491|
NCT01395316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-490B|Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis|Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis||University of Chicago|Yes|Active, not recruiting|June 2011|July 2017|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|50 Years|No|||January 2015|January 15, 2015|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395316||101490|
NCT01395277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-05-0029|Role of Flavanols In Cardiovascular Function in Healthy Aging|Effects of Dietary Flavanols on Cutaneous, Peripheral, and Cerebral Vascular Function in Young and Old Humans||University of Texas at Austin|No|Completed|September 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|July 13, 2011||No||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01395277||101493|
NCT01386827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|382/E7/07|Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis|Ability of the New Vero-cell-derived Inactivated Japanese Encephalitis Vaccine (IXIARO) to Elicit a Booster Response in Travellers Previously Vaccinated With Traditional Mouse-brain Derived Vaccine (JE-MB)||Helsinki University Central Hospital|Yes|Completed|January 2008|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 27, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386827||102140|
NCT01396174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCA158877A|A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors|A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors||Temple University||Completed|August 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|184|||Female|21 Years|64 Years|No|||April 2015|April 16, 2015|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01396174||101425|
NCT01387438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2009-279|The Incidence,Factors,and Importance of Brown Adipose Tissue in Chinese Adults|Cross-sectional Study on the Incidence,Factors,and Importance of Brown Adipose Tissue in Adult Chinese||Huashan Hospital|Yes|Active, not recruiting|December 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples Without DNA|plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who underwent scanning PET-CT at Huashan Hospital Medical Centre from 2009 to        2013|November 2009|July 1, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387438||102094|
NCT01387659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-244|Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations|Study to Evaluate Tolerability of Myfortic With Simulect Induction and Tacrolimus Without Steroids in Three Patient Populations; 1: Kidney/Pancreas Transplants,2: Diabetic Kidney Transplants, and 3: Non-diabetic Kidney Transplants||The University of Texas Medical Branch, Galveston|Yes|Terminated|March 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|65 Years|No|||September 2013|September 30, 2013|June 8, 2011|Yes|Yes|Study terminated due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01387659||102077|
NCT01393054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS2602|Effect of Nigella Sativa Seed Extract on the Blood Pressure of Elderly With Hypertension|Effect of Nigella Sativa Seed Extract on the Blood Pressure of Elderly With Hypertension||Indonesia University|Yes|Recruiting|July 2011|December 2011|Anticipated|October 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|76|||Both|60 Years|N/A|No|||July 2011|July 12, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393054||101664|
NCT01393067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|148/10|Covered, Self-expandable Metal Stents (cSEMS) vs. Non-Expandable Plastic Stents (NEPS) in Endoscopic Treatment of Stenosis of the Bilio-biliary Anastomosis After Liver Transplantation|Comparison of Use of Covered, Self-expandable Metal Stents (cSEMS) and Non-expandable Plastic Stents (NEPS) in Temporary Endoscopic Treatment of Stenosis of the Bilio-biliary Anastomosis After Liver Transplantation||Johann Wolfgang Goethe University Hospitals|No|Completed|March 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|90 Years|No|||June 2015|June 11, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393067||101663|
NCT01392781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14/1-3-2011|Markers and Calculation of Cardiovascular Risk in the Distinct Phenotypes of Polycystic Ovary Syndrome|||Aristotle University Of Thessaloniki|Yes|Recruiting|April 2011|January 2012|Anticipated|October 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|300|Samples Without DNA|blood serum|Female|15 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient women with PCOS (normalweight, overweight plus obese) Healthy volunteers        controls (normalweight, overweight plus obese)|July 2011|July 12, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01392781||101685|
NCT01393080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-IST-NSCLC-053|Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients|The Study of Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for Patient With the Advanced Non-small Cell Lung Cancer( NSCLC)|NSCLC|Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||February 2013|February 14, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393080||101662|
NCT01393093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-IR-002|Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas|Clinical Trial of Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas|TACE-KMG|Tianjin Medical University Cancer Institute and Hospital|No|Recruiting|March 2011|December 2016|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|2840|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2010|February 14, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393093||101661|
NCT01393119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200710|Phase II, Dose Finding Study of GTx-758|Phase II, Open-label, Loading and Maintenance Dose Finding Study of GTx-758 in Men With Prostate Cancer||GTx|No|Terminated|August 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|43|||Male|45 Years|80 Years|No|||April 2014|April 23, 2014|July 11, 2011|Yes|Yes|FDA Clinical Hold|No||https://clinicaltrials.gov/show/NCT01393119||101659|
NCT01393847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110189|Nitric Oxide and Sickle Cell Pain|Biochemical and Genetic Mechanisms for Etiology of Sickle Cell Pain||National Institutes of Health Clinical Center (CC)||Terminated|June 2011|December 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|October 9, 2014|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393847||101603|
NCT01393860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEORUS0081|Real-world Aliskiren Use in Diabetic Patients|Aliskiren Use in Diabetic Patients: Who's Using it, Why, and How is it Working ?||Novartis||Completed|December 2010|||June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Diabetic patients with hypertension who were initiated on aliskiren|July 2011|July 13, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393860||101602|
NCT01393808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCEED|Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes|A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor Therapy|PROCEED|Mario Negri Institute for Pharmacological Research|No|Completed|September 2011|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|80 Years|No|||July 2015|July 22, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393808||101606|
NCT01389713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clomid re-007|Clomifene Citrate as First Line Treatment in in Vitro Fertilization Cycles for Patients With Lower Ovarian Reserve|Patients With Reduced Ovarian Reserve and In Vitro Fertilization (IVF) Cycles. A Randomized Multicentric Comparison of a Protocol With High Doses of Gonadotropins and a Protocol With Clomiphene Citrate Only. Evaluation of Clinical Effectiveness and Economic Issues|clomid|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|No|Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|289|||Female|18 Years|42 Years|No|||July 2011|July 11, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01389713||101919|
NCT01389986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUM-ET/OV|Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer|Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer: a Randomized Controlled Trial||Chiang Mai University|No|Recruiting|July 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|220|||Female|18 Years|80 Years|No|||January 2012|January 4, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389986||101899|
NCT01390233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-60|Comparison of Pre-Induction Cervical Ripening|Comparison of Pre-Induction Cervical Ripening Using Prepidil Gel Administered Through a Urinary Balloon Catheter.||University of South Carolina|No|Completed|July 2010|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|102|||Female|18 Years|N/A|No|||May 2014|May 1, 2014|February 11, 2011||No||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01390233||101880|Limits included: patients enrolled who did not meet inclusion criteria (Bishop score too favorable, but recruited by clinician), patients who were enrolled but catheter could not be placed, patient enrolled who ultimately decided to undergo cesarean.
NCT01394705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00000416|FITT Exercise Counseling With Interactive Accelerometry and Physical Activity in Adolescents at Increased Risk of Early Cardiovascular Disease: A Pilot Study|FITT Exercise Counseling With Interactive Accelerometry and Physical Activity in Adolescents at Increased Risk of Early Cardiovascular Disease: A Pilot Study||Children's Hospital Boston|Yes|Recruiting|June 2011|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|60|||Both|13 Years|21 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01394705||101537|
NCT01395017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|287-11-201|Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer|Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer|LAPC|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|June 2011|March 2015|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|July 8, 2011|Yes|Yes||No|October 24, 2014|https://clinicaltrials.gov/show/NCT01395017||101513|There were 10 participants remaining in the study at the time of event-driven data cut-off. The 5 participants were told the study results and were instructed to indicate “sponsor discontinued study” if they did not want to continue.
NCT01395290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIT-ENDO-2011-1|Vitamin D and Staphylococcus Aureus in the Diabetes Study|Vitamin D and Staphylococcus Aureus in the Diabetes Study||University of Tromso|No|Completed|April 2011|August 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|280|||Both|20 Years|85 Years|No|||September 2012|September 3, 2012|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395290||101492|
NCT01395329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYS-MD-57|Nebivolol and the Endothelin (ET)-1 System|Nebivolol and the Endothelin (ET)-1 System|NETS|University of Colorado, Boulder|Yes|Active, not recruiting|May 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|48|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395329||101489|
NCT01395563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GermanCRC|Strength Training on Pancreatic Cancer|Strength Training on Pancreatic Cancer|STOPC|German Cancer Research Center|Yes|Withdrawn|January 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||March 2015|March 12, 2015|December 4, 2009||No||No||https://clinicaltrials.gov/show/NCT01395563||101471|
NCT01386372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSERT|Tolvaptan for In-hospital Hyponatremia|A Pilot Study To Evaluate The Incidence Of Hyponatremia In A Medical-Surgical Hospital And To Explore The Efficacy And Safety Of Tolvaptan In The Clinical Practice|INSERT|Mario Negri Institute for Pharmacological Research|No|Terminated|June 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|80 Years|No|||February 2013|February 21, 2013|June 24, 2011||No|futility|No||https://clinicaltrials.gov/show/NCT01386372||102174|
NCT01396187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2901002|Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes|A Phase 1, Placebo-Controlled Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes Mellitus||Pfizer|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|70 Years|No|||December 2014|December 30, 2014|July 6, 2011|No|Yes||No|December 30, 2014|https://clinicaltrials.gov/show/NCT01396187||101424|
NCT01396434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851076|Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos|A Non-interventional Study Of The Safety Of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) In The Philippines: A Post Marketing Surveillance Study||Pfizer|No|Completed|December 2011|May 2014|Actual|May 2014|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|3006|||Both|6 Weeks|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Filipino patients prescribed with the vaccine|June 2015|June 15, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01396434||101405|
NCT01387139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0835|Ketamine Versus Co-administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department|Comparison of Ketamine Versus Co-Administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department||University of Colorado, Denver|Yes|Completed|January 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|3 Years|21 Years|No|||January 2016|January 20, 2016|May 20, 2011|Yes|Yes||No|December 3, 2015|https://clinicaltrials.gov/show/NCT01387139||102116|
NCT01387152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0383|Prognosis of Very Low Dose SPECT|Prognosis of Very Low Dose Stress First Myocardial Perfusion SPECT in Patients With Chest Pain Using an Alcyone Camera||Columbia University|No|Completed|November 2011|January 2015|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Study subjects will be patients who have presented to NYPH- Columbia University Medical        Center with chest pain.|February 2015|February 2, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387152||102115|
NCT01387165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105407|Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina|A Multi-center, Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latin America|DEAL|GlaxoSmithKline|No|Completed|October 2004|October 2005|Actual|October 2005|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|3592|||Both|18 Years|75 Years|No|Probability Sample|Males and females 18-75 years of age, inclusive, with T2DM, as defined by the criteria of        the American Diabetes Association (2003), under oral anti-diabetics (OAD) or insulin        treatment for diabetes and that have given written informed consent.        The total number of patients planned for this study was up to 6,000 patients: Mexico -        1,500, Argentina - 1,000, Brazil - 1,500, CariCam - 1,100 (Colombia, Costa Rica, Ecuador,        Guatemala, Honduras, Peru, Dominican Republic and Venezuela) and Chile - 500.|June 2011|June 30, 2011|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01387165||102114|
NCT01387477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAAM 2011-01|Lactate and Hypoglycemia|Comparison of Two Strategies of Hypoglycemia Correction in ICU||Institut d'Anesthesiologie des Alpes Maritimes|No|Recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||June 2011|July 1, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387477||102091|
NCT01387451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2010-115|The Detection and Factors of Brown Adipose Tissue in Different Locations of Adults|Cross Sectional Study on the Detection and Factors of Brown Adipose Tissue in Different Locations of Adults||Huashan Hospital|Yes|Active, not recruiting|October 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|Samples Without DNA|Adipose tissue, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Subjects who underwent surgical therapy from 2010 to 2013 in Huashan Hospital and the        operation scope includes brown adipose tissue sample sites.|April 2010|July 1, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387451||102093|
NCT01387464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-303-002|Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery|A Double-Masked Clinical Study To Determine The Aqueous Humor Concentration Of Bromfenac Sodium In Subjects Administered Multiple Topical Ocular Doses Of ISV-303 Or Bromday™ Once Daily (QD) Prior To Cataract Surgery||InSite Vision|No|Completed|July 2011|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|June 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387464||102092|
NCT01392430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OI prophylaxis|Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients|Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients Who Had CD4+ Cell Count <200 Cells/mm3 But Undetectable Plasma HIV-1 RNA||Chiang Mai University|No|Completed|June 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392430||101712|
NCT01392794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060-CL-208|A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet|Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion Without Water||Astellas Pharma Inc|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||July 2011|July 11, 2011|July 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01392794||101684|
NCT01393106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-11|Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma|A Phase 2 Study to Assess the Efficacy and Safety of GS-1101 (CAL-101) in Patients With Relapsed or Refractory Hodgkin Lymphoma||Gilead Sciences|No|Completed|September 2011|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|12 Years|N/A|No|||November 2015|November 20, 2015|July 11, 2011|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01393106||101660|There were no limitations affecting the analysis or results.
NCT01393444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10010149|ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis|Acute Electrocorticography (ECoG) Direct Brain Interface for Individuals With Upper Limb Paralysis||University of Pittsburgh|Yes|Completed|May 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393444||101634|
NCT01394146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110118001|Impact of Food Additives on Phosphorus Metabolism|Impact of Food Additives on Phosphorus Metabolism||University of Alabama at Birmingham|No|Completed|April 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|54|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394146||101580|
NCT01389700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD11791|Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients|A Randomized, Double-blind, Placebo-controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation||Sanofi||Terminated|October 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|7|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|July 6, 2011|Yes|Yes|Difficulty in patient recruitment in the participating sites|No||https://clinicaltrials.gov/show/NCT01389700||101920|
NCT01389999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/AD-02|Validation of the French Version of the Back Belief Questionnaire|Validation of the French Version of the Back Belief Questionnaire|BBQ|Centre Hospitalier Universitaire de Nīmes|No|Terminated|January 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|18 Years|N/A|No|Non-Probability Sample|Patients consulting for back pain, present for at least three months.|March 2015|March 24, 2015|July 7, 2011||No|difficult recruitment curve|No||https://clinicaltrials.gov/show/NCT01389999||101898|
NCT01390519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001LNO03|A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor|Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment|OSAT|Novartis||Completed|June 2011|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|None Retained|None Retained|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced renal cell cancer whose disease has progressed on or after one        VEGF-TKI therapy|January 2016|January 12, 2016|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01390519||101858|
NCT01390779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/09|Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor|Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor||Sensimed AG|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|July 7, 2011|No|Yes||No|June 4, 2013|https://clinicaltrials.gov/show/NCT01390779||101838|
NCT01395043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20100001|Transversus Abdominis Plane Catheter: a Study of Method|TAP-catheter With Intermittent Bolus Injections of Bupivacain, an Alternative to Epidural Catheter Infusion After Colon Surgery?||Aalborg Universitetshospital|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|15|||Both|18 Years|N/A|No|||January 2012|January 5, 2012|July 13, 2011||No||No|October 6, 2011|https://clinicaltrials.gov/show/NCT01395043||101511|Not randomised or blinded. Limited number of patients. Dermatome level of the block and the incidence of postoperative nausea and vomiting was not registered. The study does not compare TAP-catheter and epidural catheter.
NCT01395030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2011-025|Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer|Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer||Queen's Medical Centre|Yes|Recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01395030||101512|
NCT01395589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1036|Correction of Vitamin D in Asthma Control|Correction of Vitamin D in Asthma Control in Vitamin D Deficient Children With Moderate-severe Asthma||Hamad Medical Corporation|Yes|Recruiting|February 2011|June 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|105|||Both|2 Years|14 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01395589||101469|
NCT01395602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #13952|Effect of Cabergoline on Weight and Glucose Tolerance|Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults||Columbia University|No|Completed|April 2002|July 2011|Actual|September 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395602||101468|
NCT01395576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENU-HMO-CTIL|Evaluation of the Genu Neurexa Orthosis in Post Stroke Patients|Evaluation of the Genu Neurexa Orthosis in Post Stroke Patients||Hadassah Medical Organization||Terminated|February 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||October 2012|May 18, 2014|July 3, 2011||No|statistical significance of the results was reached for the 34 subjects who participated in    teh study.|No||https://clinicaltrials.gov/show/NCT01395576||101470|
NCT01386385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02592|Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)|Yes|Suspended|June 2011|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 30, 2011|Yes|Yes|CTEP Initiated Action|No||https://clinicaltrials.gov/show/NCT01386385||102173|
NCT01386853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TATPITA20101005|Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients|A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, Non-inferiority Study to Compare the Efficacy and Safety of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients||Tai Tien Pharmaceuticals Co., Ltd.|No|Not yet recruiting|July 2011|July 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|20 Years|75 Years|No|||June 2011|June 30, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386853||102138|
NCT01386645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK092568-01|Effect of Dietary Glycemic Index on Beta-cell Function|Effect of Dietary Glycemic Index on Beta-cell Function|GIdiet|Seattle Institute for Biomedical and Clinical Research|No|Recruiting|July 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 11, 2015|June 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01386645||102154|
NCT01386840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02_ISPOT|IndiaCLEN Multicentre Trial of Home Versus Hospital Oral Amoxicillin for Management of Severe Pneumonia in Children|IndiaCLEN Multicentric Trial of Home Versus Hospital Oral Amoxicillin for Management of Severe Pneumonia in Children|ISPOT|Lata Medical Research Foundation, Nagpur|Yes|Completed|January 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1118|||Both|3 Months|59 Months|No|||May 2015|May 15, 2015|June 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01386840||102139|
NCT01387711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-02|PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology|A Phase I, Single-centre, Open Label, Within-subject Comparison Trial to Explore the Biological Effects of PEP005 (Ingenol Mebutate) Gel, 0.05%, Applied Once Daily for 2 Consecutive Days in Patients With Actinic Keratosis on the Upper Extremity||LEO Pharma|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387711||102073|
NCT01387971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910001R|Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders|Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders||National Taiwan University Hospital|No|Recruiting|September 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|12 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|various ocular surface disorders|April 2011|July 5, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387971||102053|
NCT01392456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|507-207|Validation and Cross-Cultural Adaptation of the Romanian Version of Oral Health Impact Profile in Edentulous Adults|Patient Satisfaction With the Use of Three Different Systems as Retention for Implant Supported Mandibular Overdentures.|ROM-OHIP-ED|Concordia Dent Srl|No|Completed|June 2004|February 2015|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|69|||Both|21 Years|N/A|No|||February 2015|February 2, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392456||101710|
NCT01393821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC10C9|Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab|A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress||Mayo Clinic|Yes|Active, not recruiting|January 2012|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|June 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01393821||101605|
NCT01393483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-037|Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)|A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)||Memorial Sloan Kettering Cancer Center||Recruiting|March 2011|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|Samples Without DNA|tissue and serum|Both|18 Years|N/A|No|Non-Probability Sample|Any patient seen in the gastroenterology and thoracic clinics who fits the inclusion        criteria will be approached by the treating physician, the protocol investigator, or        thoracic research team at Memorial Sloan-Kettering Cancer Center (MSKCC|January 2016|January 20, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393483||101631|
NCT01390012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVID|Oral Versus Intravenous Dexamethasone|Oral Versus Intravenous Dexamethasone in Community-Acquired Pneumonia|OVID|St. Antonius Hospital|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01390012||101897|
NCT01390025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCN-032-001|Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza|Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers||Theraclone Sciences, Inc.|Yes|Completed|September 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|July 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390025||101896|
NCT01394133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F10102815|Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women|Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women||University of Alabama at Birmingham|Yes|Withdrawn|July 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|5 mL of plasma|Female|21 Years|40 Years|No|Non-Probability Sample|HIV-infected women will be selected from the primary care office|April 2013|April 29, 2013|July 12, 2011||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01394133||101581|
NCT01395056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTX+TSPA+CBP|Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients|Study of Chemotherapy Combined With Adoptive Cellular Therapy With Dendritic and Cytokine-induced Killer Cells in Triple Negative Breast Cancer Patients|DCCIK|Beijing Cancer Hospital|Yes|Completed|July 2011|June 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|None Retained|about 4ml peripheral vein blood，paraffin section on metastatic tissue，|Female|18 Years|80 Years|No|Non-Probability Sample|female patients with metastatic breast cancer|July 2015|July 20, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395056||101510|
NCT01395355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH086922-01A2|An Integrative Intervention for Loss of Control Eating Among Adolescent Girls|An Integrative Intervention for Binge Eating Among Adolescent Girls||Virginia Commonwealth University|Yes|Completed|August 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|59|||Female|13 Years|22 Years|No|||May 2015|May 6, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01395355||101487|
NCT01395342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/2011/PC|Assessment of Physical Exercise Using Stationary Bicycle for Pregnant Women With Risk for Preeclampsia Development|Assessment of Physical Exercise Using Stationary Bicycle for Pregnant Women With Risk for Preeclampsia Development||University of Campinas, Brazil|Yes|Completed|January 2008|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|116|||Female|18 Years|45 Years|No|||July 2012|July 11, 2012|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01395342||101488|
NCT01385826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081210|Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis|Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial|ADJUVITE|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2011|June 2016|Anticipated|November 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|4 Years|N/A|No|||January 2016|January 14, 2016|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01385826||102216|
NCT01386632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCA 2010|Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma|Phase II Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Stage III-IV Squamous Cell Carcinoma of the Head and Neck||Sanford Health|Yes|Active, not recruiting|May 2011|January 2019|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|May 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386632||102155|
NCT01386866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080639|Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors|An Open-label, Single Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labelled AMG 706 (Motesanib) Followed by Extended Treatment With Motesanib in Patients With Advanced Solid Tumors||Amgen||Completed|May 2009|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|April 14, 2011||||No||https://clinicaltrials.gov/show/NCT01386866||102137|
NCT01387178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111267|Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease|Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Completed|July 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|22223|||Both|40 Years|N/A|No|Non-Probability Sample|Patient records for commercially-insured patients with chronic obstructive pulmonary        disease (COPD) aged 40 and older. For the risk-analysis population, patients were required        to have at least 12 months of continuous enrollment prior to the index date and at least 3        months of continuous enrollment after the index date. A subgroup analysis was conducted        for costs that included patients in the total population who also had at least 12 months        of continuous coverage following the index date (the cost-analysis population).|November 2011|November 23, 2011|June 16, 2011||No||No|September 21, 2011|https://clinicaltrials.gov/show/NCT01387178||102113|
NCT01387191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112300|Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg|Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg||GlaxoSmithKline|No|Completed|August 1999|July 2009|Actual|April 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|748|||Both|N/A|N/A||Probability Sample|All Japanese subjects with pulmonary arterial hypertension who are treated with        epoprostenol injection|June 2011|June 30, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387191||102112|
NCT01387490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-CONTACT|CONcussion Treatment After Combat Trauma (CONTACT)|The Effect of Telephone Follow up on Outcome for Service Members With Mild TBI/PTSD|CONTACT|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Completed|June 2011|February 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|366|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387490||102090|
NCT01392495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQTI571A2102E1|Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)|An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension||Novartis|Yes|Terminated|June 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|N/A|No|||July 2015|July 13, 2015|July 11, 2011|Yes|Yes|Novartis discontinued the development of imatinib in PAH due to requirement of regulatory    authorities for additional data to secure marketing approval in PAH.|No|March 24, 2015|https://clinicaltrials.gov/show/NCT01392495||101707|
NCT01392508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-FMHBP-001|IMproved PREdiction of Severe Sepsis in the Emergency Department|Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.|IMPRESSED|Axis Shield Diagnostics Ltd|No|Completed|March 2011|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|759|Samples With DNA|Plasma (LiHep and citrate)|Both|18 Years|N/A|No|Probability Sample|Patients presenting to emergency department with suspected infection|September 2015|September 1, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392508||101706|
NCT01393470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115006 (HPV-027)|Evaluation of Long-term HPV Vaccine Efficacy|A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland||University of Tampere|No|Enrolling by invitation|May 2011|December 2024|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|10000|Samples With DNA|Cytological cervical (liquid based and/or conventional) samples. Colposcopy directed      cervical biopsy samples fixed in formalin.|Female|16 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|Trial Cohort (16-17 years at baseline) - the cohort of Finnish subjects who participated        in the GSK Biologicals' HPV-008 trial (NCT00122681):        Cohort A: subjects who received HPV-16/18 L1 VLP AS04 vaccine between May 2004 and May        2005.        Cohort B: subjects who received the Hepatitis A control vaccine. All subjects were offered        the HPV-16/18 L1 VLP AS04 vaccine at the end of the study (age 21-22):        Cohort B1: subjects who received the Hepatitis A control vaccine and then received        cross-over HPV vaccination at HPV-008 study end.        Cohort B2: subjects who received the Hepatitis A control vaccine and who did not receive        cross-over HPV vaccination at HPV-008 study end.        Referent cohort (18-19 years at baseline):        Cohort C: A population-based reference cohort of female subjects from Finland who have not        been exposed to any HPV vaccine enrolled in this study in May 2005, immediately after        recruitment of the HPV-008 clinical trial subjects had been stopped (approximately 9,000        subjects).|May 2014|May 14, 2014|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01393470||101632|
NCT01393145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-LLN-03(06/10)|Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD|Multicenter, Phase III, Randomized, Open Label Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).||Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|336|||Both|40 Years|N/A|No|||July 2011|July 12, 2011|March 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01393145||101657|
NCT01393158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-PI-AD-0034|Apremilast for Atopic Dermatitis|Apremilast for Atopic Dermatitis - A Pilot Study in Adults||Oregon Health and Science University||Completed||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|No|||April 2010|July 12, 2011|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393158||101656|
NCT01393171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB4358|Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis|Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis|OARS|Kaiser Permanente|No|Active, not recruiting|October 2005|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 10, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01393171||101655|
NCT01393873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-02084|Progression of Diabetic Retinopathy Post Bariatric Surgery (BS)|The Effect of Bariatric Surgery on the Progression of Diabetic Retinopathy||New York University School of Medicine|No|Terminated|July 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with type 2 diabetes in the bariatric service awaiting metabolic surgery for        weight reduction/glucose control therapy.|September 2012|September 26, 2012|July 12, 2011||No|Investigator has moved to other state.|No||https://clinicaltrials.gov/show/NCT01393873||101601|
NCT01394159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110506010|22G FNA Needle vs. 22G ProCore Needle|Randomized Trial Comparing the 22-gauge Aspiration and 22-gauge Biopsy Needles for EUS-guided Sampling of Solid Pancreatic Mass Lesions||Florida Hospital|No|Completed|July 2011|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|56|||Both|19 Years|N/A|No|||March 2015|March 30, 2015|July 12, 2011||No||No|March 18, 2015|https://clinicaltrials.gov/show/NCT01394159||101579|
NCT01394471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0259|Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia|Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia|OTS-12WK|University of North Carolina, Chapel Hill|Yes|Completed|July 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|65 Years|No|||June 2015|June 9, 2015|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394471||101555|
NCT01394731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08-052|Analgesic Effects of Intravenous Paracetamol on Labor Pain|Analgesic Effects of Intravenous Acetaminophen on Labor Pain||King Abdulaziz University||Completed|December 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||||||Female|18 Years|60 Years|No|||July 2011|July 13, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394731||101535|
NCT01389726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR012256|Comparing Interventions To Improve The Well-Being Of Custodial Grandfamilies|Comparing Interventions To Improve The Well-Being Of Custodial Grandfamilies|COPE|Kent State University|Yes|Not yet recruiting|January 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|504|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2011|July 6, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389726||101918|
NCT01395069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNK|Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery|Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK)|PNK|Queen's University|No|Completed|February 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|162|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01395069||101509|
NCT01395082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-406-003|ACAM2000® Myopericarditis Registry|ACAM2000® Myopericarditis Registry||Sanofi|No|Recruiting|April 2011|November 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Eligible participants will have received previous vaccination with ACAM2000® but will not        receive any vaccination as part of the registry.|March 2016|March 16, 2016|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395082||101508|
NCT01395641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTUH-AADC-010|A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC|A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC|AADC|National Taiwan University Hospital|Yes|Enrolling by invitation|August 2014|September 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|24 Months|N/A|No|||December 2014|December 2, 2014|June 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01395641||101465|
NCT01389505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEP16249|Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Structural and Functional Evaluation of the Macula in Patients With Proliferative Diabetic Retinopathy Treated With Panretinal Photocoagulation and Bevacizumab (Avastin ®)||Instituto do Coracao|No|Recruiting|February 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2011|July 7, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389505||101935|
NCT01389518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-492|Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome|Evaluation of the Efficacy and Safety of Fixed Combination of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Symptomatic Common Cold and Flu Syndrome in Adults||Hospital de Clinicas de Porto Alegre|Yes|Completed|May 2009|November 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|60 Years|No|||November 2011|November 24, 2011|February 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389518||101934|
NCT01385488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110032|Bioelectrical Impedance for Self-monitoring of Lymphedema|Bioelectrical Impedance for Self-monitoring of Breast Cancer Related Lymphedema||Vanderbilt University|No|Completed|May 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|72|||Both|21 Years|N/A|Accepts Healthy Volunteers|||June 2011|November 21, 2013|April 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385488||102242|
NCT01385813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFLAMMARPE11|Inflammatory Markers in Preeclampsia|||Oslo University Hospital|No|Completed|January 1999|May 2004|Actual|May 2004|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|129|||Female|20 Years|43 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study comprised 43 pregnant women who developed preeclampsia and 86 pregnant women who        fulfilled a normotensive pregnancy.        All women were of Caucasian origin, and were nulliparous.|May 2011|July 15, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385813||102217|
NCT01385839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0533|Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata|Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata||Emer, Jason, M.D.|Yes|Recruiting|October 2009|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2011|June 29, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385839||102215|
NCT01386099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSN821-202|A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)|A Phase IIa Study to Build an Understanding of the Pharmacokinetic-Pharmacodynamic Relationship of PSN821 in Type 2 Diabetes Patients (T2DM).||Prosidion Ltd.||Completed|May 2011|May 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|75 Years|No|||August 2012|August 16, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386099||102195|
NCT01386658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-FIR-086|A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema|A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents With Hereditary Angioedema||Shire|No|Active, not recruiting|December 2011|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|17 Years|No|||November 2015|November 24, 2015|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386658||102153|
NCT01386671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlyMet01_13062011|Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes|Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients|COMET|Laboratorios Silanes S.A. de C.V.|No|Active, not recruiting|August 2011|October 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||February 2014|February 19, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386671||102152|
NCT01386879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.48|Evaluation of Above the Cuff Suctioning During General Anesthesia|Evaluation of Microaspiration and Efficacy of Above the Cuff Suctioning During General Anesthesia: A Comparison of Two Endotracheal Tubes With Suction Above Cuff With a Standard Endotracheal Tube||Thomas Jefferson University|No|Terminated|July 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|60|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|June 27, 2011||No|The study was terminated because of slower than anticipated enrollment|No||https://clinicaltrials.gov/show/NCT01386879||102136|
NCT01387204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113708|Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212|An Open-label Mass Balance Study to Investigate the Absorption, Distribution, Metabolism and Elimination of a Single Oral Dose of MEK Inhibitor [14C]GSK1120212 in Male Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|February 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|18 Years|N/A|No|||April 2012|April 3, 2012|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01387204||102111|
NCT01387737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-06|Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus|An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus||Mitsubishi Tanabe Pharma Corporation|No|Completed|May 2011|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1299|||Both|20 Years|N/A|No|||May 2014|May 27, 2014|June 28, 2011||No||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01387737||102071|
NCT01387750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTS2223|Mentholated Cream Containing Oxygenated Glycerol Triesters on Acute Pain of the Muscles and Joints|Evaluating the Efficacy, Tolerance and Acceptability of a Mentholated Cream Containing Oxygenated Glycerol Triesters (OGT) on Acute Pain in Subjects Suffering From a Recent Inflammation of the Muscles and/or Joints||NEMA Research, Inc.|Yes|Completed|May 2007|June 2007|Actual|June 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|75 Years|No|||June 2011|July 5, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387750||102070|
NCT01392846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2011-07|The IRIS-Resolute Integrity (IRIS-Integrity)|Evaluation of Effectiveness and Safety of Resolute Integrity DES in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study (IRIS-Integrity)||CardioVascular Research Foundation, Korea|Yes|Active, not recruiting|July 2011|October 2020|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3000|||Both|N/A|N/A|No|Non-Probability Sample|patients with coronary artery disease requiring drug eluting stents|September 2015|September 9, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392846||101680|
NCT01392859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105783-01|Characterization of the Role of Histamine in Children With Asthma|Characterization of the Role of Histamine in Children With Asthma||Children's Mercy Hospital Kansas City|Yes|Recruiting|June 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|204|||Both|7 Years|17 Years|No|||July 2011|July 12, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01392859||101679|
NCT01392833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgAzaIRC|Steroids and Azathioprine in Advanced IgAN|Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial||A. Manzoni Hospital|No|Completed|December 1999|January 2008|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|16 Years|70 Years|No|||March 2011|July 12, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01392833||101681|
NCT01393496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG Fr 1455/6-1|Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants|Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants (ETTNO)- a Blinded Randomized Controlled Multicenter Trial|ETTNO|University Hospital Tuebingen|Yes|Active, not recruiting|July 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|920|||Both|N/A|3 Days|No|||January 2015|January 19, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01393496||101630|
NCT01398748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-H32B11|Intranasal Glutathione in Parkinson's Disease|A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease||Bastyr University|Yes|Completed|July 2012|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|34|||Both|21 Years|100 Years|No|||January 2016|January 14, 2016|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398748||101228|
NCT01394484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 201018566-1|Dairy Foods Compared to Dietary Supplements and Bone Health|Milk and Yogurt vs. Calcium and Vitamin D Supplements for Bone Health of Women|FL-83|USDA, Western Human Nutrition Research Center|No|Completed|December 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 25, 2013|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394484||101554|
NCT01390246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-217|Bupropion for Smoking Cessation During Pregnancy|Bupropion for Smoking Cessation During Pregnancy||The University of Texas Medical Branch, Galveston|Yes|Active, not recruiting|July 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|June 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390246||101879|
NCT01395979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH095624-01|HIV Prevention and Trauma Treatment for Men Who Have Sex With Men With Childhood Sexual Abuse Histories||THRIVE|Massachusetts General Hospital|Yes|Recruiting|October 2011|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Male|18 Years|N/A|No|||December 2015|December 8, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01395979||101439|
NCT01396239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4658-us-201|Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Efficacy, Safety, Tolerability and Pharmacokinetics Study of AVI-4658(Eteplirsen),in the Treatment of Ambulant Subjects With Duchenne Muscular Dystrophy||Sarepta Therapeutics|No|Completed|July 2011|June 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Male|7 Years|13 Years|No|||July 2015|October 12, 2015|July 8, 2011|Yes|Yes||No|July 2, 2013|https://clinicaltrials.gov/show/NCT01396239||101420|Due to the small number of study participants, a single adverse event (AE) in 1 patient exceeds the reporting threshold of 5%. Refer to the "Post-Hoc Outcome Measures" #4 and #5 for a summary of frequent and related AEs.
NCT01396252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN162-014|Japanese Phase 1 Multiple Ascending Dose (MAD) Study|Randomized, Placebo-Controlled, Double-Blind, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Japanese Subjects and Japanese Patients With Depression||Bristol-Myers Squibb|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 7, 2013|July 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396252||101419|
NCT01396265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.152|Drug Interaction Study With Rifampicin and Afatinib|Relative Bioavailability of a Single Oral Dose of 40 mg Afatinib Given Alone and After Multiple Doses of Rifampicin - an Open-label, Two-period, Fixed Sequence Clinical Phase I Trial in Healthy Male Volunteers||Boehringer Ingelheim||Completed|July 2011|||August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|June 3, 2014|July 15, 2011||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01396265||101418|
NCT01389531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTESE 10-0515|Efficacy and Safety Evaluation of HCPA-1 Silicone Stent in the Treatment of Central Airway Obstructions|Evaluation of the Efficacy and Safety of the HCPA-1 Silicone Stent in the Treatment of Central Airway Obstructions||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|April 2011|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|110|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01389531||101933|
NCT01385501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA 1111|Educational Intervention to Improve Vaccine Acceptance|||Vanderbilt University|No|Completed|June 2011|December 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|155|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01385501||102241|
NCT01385514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1042-2011|Staphylococcus Aureus Skin and Soft Tissue Infections|Evaluating Strategies to Prevent Staphylococcus Aureus Skin and Soft Tissue Infections in Soldiers During Infantry Training||Medical Corps, Israel Defense Force|No|Recruiting|July 2011|December 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1050|Samples Without DNA|nasal swabs to detect Staphylococcus aureus skin infection to detect Staphylococcus aureus|Male|18 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|the population of the study will be selected from infantry training bases in the IDF|March 2012|March 22, 2012|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385514||102240|
NCT01386398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-21082|Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma|Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study.||European Organisation for Research and Treatment of Cancer - EORTC||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|June 30, 2011||No|Company withdrew interest|No||https://clinicaltrials.gov/show/NCT01386398||102172|
NCT01386112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-021|Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE)||Forest Laboratories||Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|12 Years|55 Years|No|||October 2012|October 31, 2012|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386112||102194|
NCT01386125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05604|A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Nasal Polyps (Protocol No. P05604)||Merck Sharp & Dohme Corp.|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|748|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 9, 2011|No|Yes||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01386125||102193|
NCT01386892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0007|Immunological Characterization of Blood of Normal Individuals|Immunological Characterization of Blood of Normal Individuals||Ohio State University|No|Active, not recruiting|March 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|Samples With DNA|Blood Saliva Urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants may also be recruited by word of mouth or via public advertising. This study        is open to all eligibile healthy adult volunteers regardless of gender, age and ethnicity.|February 2014|February 10, 2014|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01386892||102135|
NCT01387217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114070|GSK2018682 FTIH in Healthy Volunteers|A Single-blind, Placebo-controlled, Two Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of GSK2018682 in Healthy Volunteers|P1A114070|GlaxoSmithKline|No|Completed|May 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01387217||102110|
NCT01387503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT 80/09|Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging|Controlled Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging Procedures: a Randomized Trial (XXL Trial)||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|January 2011|January 2014|Anticipated|January 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Both|18 Years|65 Years|No|||June 2011|July 1, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387503||102089|
NCT01387763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|daliah2011|A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms|Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms.|DALIAH|Odense University Hospital|Yes|Recruiting|January 2012|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01387763||102069|
NCT01388023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1910552HMO-CTIL|Day Long Prevention of Oral Malodor With a Palatal Patch (SmellX) Containing A Herbal Formula|Phase 2 Clinical Study of a Day Long Effect of SmellX Palatal Patch Containing A Herbal Formula on Malodor|SmellX|Hadassah Medical Organization|No|Completed|January 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|January 17, 2008||No||No||https://clinicaltrials.gov/show/NCT01388023||102049|
NCT01393197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-CIH-IR-003|Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)|Clinical Trial of Transcatheter Arterial Chemoembolization (TACE)With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas|TACE-KMG|Tianjin Medical University Cancer Institute and Hospital|No|Recruiting|March 2011|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|2480|||Both|18 Years|75 Years|No|||November 2010|December 17, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393197||101653|
NCT01393210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPChM-11-01|Beta-glucan and Insulin Sensitivity|The Influence of Beta-glucan 1.3D-1.6D, Added to the Low-calorie Diet, on Insulin Sensitivity and the Expression of Selected Proinflammatory Cytokines in Adipose Tissue and Peripheral Blood Mononuclear Cells in Obese Humans||Polish Academy of Sciences|No|Recruiting|May 2011|September 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|50 Years|No|||June 2011|July 27, 2011|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393210||101652|
NCT01393184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-IST-SCCHN-040|Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN|Prospective, Randomized, Controlled, Phase II，Multiple Centered Clinical Trial of Nimotuzumab Combined With Radiotherapy for Senile Locally Advanced SCCHN||Peking University|Yes|Enrolling by invitation|March 2011|March 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|65 Years|85 Years|No|||March 2011|July 12, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01393184||101654|
NCT01393509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-041|The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies|The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies||Memorial Sloan Kettering Cancer Center||Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01393509||101629|
NCT01393886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-00797|LGCP (Laparoscopic Greater Curvature Plication)|A Prospective, Open-label Study to Evaluate the Safety and Efficacy of Laparoscopic Greater Curvature Plication (LGCP) in the Treatment of Obese Patients|LGCP|New York University School of Medicine|Yes|Withdrawn|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 1, 2013|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01393886||101600|
NCT01398761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002915|Development of a Sign-Out Tool to Improve Handoffs in Care|Development and Pilot Testing of a Web-Based, Multi-Disciplinary Sign-Out Tool to Improve Handoffs in Care||Brigham and Women's Hospital|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|295|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 24, 2014|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01398761||101227|
NCT01398774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007972|Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a|Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study||Children's Hospital of Philadelphia|Yes|Active, not recruiting|June 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|5 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with Pseudohypoparathyroidism 1a|April 2015|April 8, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398774||101226|
NCT01394744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1739 / IIS2009029|Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement|Determination of Metal Ion Levels in the Serum and Assessment of the Respective Cytokine Production of Peripheral Blood Cells in Patients With a Hard-on-hard Bearing Total Hip Replacement||Ludwig-Maximilians - University of Munich|No|Recruiting|August 2011|January 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Blood serum samples for metal ion and cytokine measurement; blood cells for cytokine-RNA      assessment|Both|18 Years|75 Years|No|Non-Probability Sample|total of 30 subjects; 10 with metal-on-metal, 10 with ceramic-on-ceramic and 10 with        ceramic-on-metal hip replacement;|May 2011|August 18, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394744||101534|
NCT01396863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK20100228|Brain Swelling During Dialysis|Acute Brain Volume Changes in Haemodialysis: Comparison of Low Flux Haemodialysis With Pre-dilution Haemodiafiltration|BRASE|University of Aarhus|Yes|Completed|July 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2012|March 21, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01396863||101372|
NCT01397136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFI2011_PS|Cell-free DNA: a Non-invasive Test for Assessing Embryo Quality|Cell-free DNA: a Non-invasive Test for Assessing Embryo Quality||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Completed|July 2011|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|Samples With DNA|After normally fertilized oocytes will be identified, they will be transferred into Sydney      IVF Cleavage Medium (Cook Medical) for culture from day 1 to day 3 (up to 8 cell stage). For      a subset of embryos we will also perform culture until blastocyst stage. For this purpose,      embryos will be transferred into Sydney IVF Blastocist medium (Cook Medical) from day 3 to      day 5/6. We will focus on embryo development in a single embryo culture medium. Embryos will      be cultured at 37°C, 6.0% CO2, 5.0% O2 into Galaxy 48R incubators (New Brunswick      Scientific). At the moment of transfer of embryos into the uterine cavity, we will collect      embryo culture media into DNase- and RNase-free 1.5 ml tubes (Eppendorf AG). The media will      be immediately frozen and stored at -20° until nucleic acid purification.|Both|N/A|7 Days|No|Probability Sample|Culture media from human embryos collected at day 2-7 after in-vitro fertilization.|February 2015|February 4, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01397136||101351|
NCT01397149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL2S|Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)|A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy||University of Ulm|Yes|Terminated|October 2011|November 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 30, 2011||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01397149||101350|
NCT01385852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005|CME With Different Fluidic Parameters|Impact of Different Fluidic Parameters on Development of Cystoid Macular Edema Following Phacoemulsification||Iladevi Cataract and IOL Research Center|Yes|Completed|May 2010|August 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385852||102214|
NCT01386138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA030565|Treating South African Pregnant Women for Methamphetamine|Treating South African Pregnant Women for Methamphetamine||RTI International|Yes|Completed|July 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|60|||Female|18 Years|N/A|No|||October 2013|October 16, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386138||102192|
NCT01386411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-086|Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer|Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|June 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|108|Samples With DNA|peripheral blood leucocytes and/or mouthwash-collected buccal epithelial cells)|Female|18 Years|50 Years|No|Non-Probability Sample|This is a prospective study of women who meet a subset of the NCCN criteria for genetic        testing and are presenting to the Breast Surgery Clinic for treatment of a newly diagnosed        breast cancer.|January 2016|January 15, 2016|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386411||102171|
NCT01386684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-811|Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study|Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study||AbbVie|No|Active, not recruiting|June 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|550|||Male|18 Years|99 Years|No|Non-Probability Sample|Patients will be enrolled from the offices of university or community        urologists/oncologists across Canada treating patients with PCa.|January 2016|January 26, 2016|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386684||102151|
NCT01386697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 13910|DIBH Proton Planning|A Prospective Radiation Oncology Planning Study For Lung, Gastrointestinal And Lymphomatous Malignancies Using Proton Radiotherapy As Compared To 3D Conformal And Intensity-Modulated X-Ray Therapy For Dosimetric Evaluation Of Tumoral Coverage And Dose To Organs-At-Risk.||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|November 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|This registry study will enroll patients who are 18 years of age or older who select to        undergo external beam radiation therapy as definitive or adjuvant treatment for their        diagnosis of lung, breast, gastropintestinal or lymphomatous malignancies in the        Department of Radiation Oncology.|October 2014|October 10, 2014|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386697||102150|
NCT01386905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPSS-I-0409-B|A Study of the TransPyloric Shuttle™ (TPS™) for Weight Reduction in Obese Subjects|A Study of the TransPyloric Shuttle™ (TPS™) for Weight Reduction in Obese Subjects (ENDObesity™ I Study)||BaroNova, Inc.|Yes|Completed|June 2011|May 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|55 Years|No|||March 2014|March 11, 2014|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386905||102134|
NCT01387230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115408|Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD|A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|40 Years|N/A|No|||May 2013|December 19, 2013|June 30, 2011|No|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01387230||102109|
NCT01387243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W5350856|Survey on the Pharmacy Follow-up of Alli Purchasers|Survey on the Pharmacy Follow up of Alli Purchasers||GlaxoSmithKline|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Probability Sample|Consumers purchasing orlistat in a pharmacy setting|October 2012|October 25, 2012|March 29, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01387243||102108|
NCT01387516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA020731|Motivation and Skills for Detained Teen Smokers|Motivation and Skills for Detained Teen Smokers||University of Rhode Island|Yes|Completed|July 2007|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|314|||Both|13 Years|19 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01387516||102088|
NCT01388049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007053R|e- Ab Sensor - Based Real-time Diagnosis of Enterovirus Type 71|e- Ab Sensor - Based Real-time Diagnosis of Enterovirus Type 71||National Taiwan University Hospital|No|Recruiting|July 2010|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|72|||Both|N/A|N/A|No|||November 2011|December 26, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388049||102047|
NCT01388296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRH 03|Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients|Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients||Procare Riaya Hospital|No|Recruiting|June 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|30|None Retained|Bisbectral index (BIS)|Both|20 Years|40 Years|No|Probability Sample|Morbidly obese patients weighting BMI 40-70 k/m2|December 2013|December 2, 2013|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01388296||102028|
NCT01397825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14011|MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine|A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|August 2011|December 2015|Anticipated|February 2015|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|July 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397825||101298|
NCT01397838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBCS-001|Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women|Phase 1 Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women||OsteoBuild Ltd.|No|Not yet recruiting|September 2011|January 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Female|45 Years|65 Years|No|||July 2011|July 19, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397838||101297|
NCT01397851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATH Outgrowers|Stimulating Private Sector Malaria Control|Stimulating Private Sector Malaria Control: The Outgrower Opportunity|Outgrowers|PATH|No|Completed|December 2010|December 2013|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|81597|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|June 21, 2011||No||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01397851||101296|
NCT01393522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-25|Milnacipran for Migraine Pain|A Randomized Double Blind Placebo Control Trial of Milnacipran for Migraine Pain||Mercy Health Research|No|Completed|June 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|65 Years|No|||December 2013|December 16, 2013|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393522||101628|
NCT01393535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guch-013|Study of the Relationship Between Serum Adiponectin and Clinical Prognosis in Patients Undergoing Cardiac Surgery|Study of the Relationship Between Serum Adiponectin and Clinical Prognosis in Patients Undergoing Cardiac Surgery||Xijing Hospital|Yes|Not yet recruiting|July 2011|August 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|N/A|No|Probability Sample|Patients underwent cardiac surgery in cardiovascular surgery department of xijing        hospital.|July 2011|July 11, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393535||101627|
NCT01398410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-309|Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)|Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial-||Eisai Inc.||Completed|December 2011|February 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|405|||Both|20 Years|N/A|No|||November 2015|November 19, 2015|July 18, 2011||No||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01398410||101253|
NCT01395667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103126MB|Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX|A Phase I Dose Escalation Trial of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy(IMRT)in Combination With Bevacizumab-FOLFOX for Patients With Locally Advanced Rectal Cancer||National Taiwan University Hospital|No|Recruiting|June 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|20 Years|70 Years|No|||April 2014|April 15, 2014|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395667||101463|
NCT01395680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105004RC|Trajectories of Regenerating Family Resilience in Adolescents With Cancer|Trajectories of Regenerating Family Resilience in Adolescents With Cancer||National Taiwan University Hospital|Yes|Not yet recruiting|August 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|12 Years|20 Years|No|Non-Probability Sample|cancer adolescent aged 12-20 years old|June 2011|July 14, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395680||101462|
NCT01395368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103191|Cognitive Speed as an Objective Measure of Tinnitus|Cognitive Speed as an Objective Measure of Tinnitus|COMeT|Washington University School of Medicine|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|80 Years|No|Non-Probability Sample|The study population will include men and women between the ages of 18-80 years who have        subjective, unilateral or bilateral, non-pulsatile tinnitus of 6 month's duration or        longer.|July 2012|July 18, 2012|July 13, 2011||No||No|April 13, 2012|https://clinicaltrials.gov/show/NCT01395368||101486|Tinnitus subjects with moderate or greater depression were excluded from the study. This study may not be reflective of the population of bothersome tinnitus patients due to this exclusion
NCT01395381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJM-albendazole|Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition|Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Benefit of Antihelminthic Therapy in the Community-Based Treatment of Severe Acute Malnutrition in Malawian Children||Washington University School of Medicine|No|Withdrawn|January 2013|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|59 Months|No|||January 2014|January 24, 2014|July 1, 2011||No|not funded|No||https://clinicaltrials.gov/show/NCT01395381||101485|
NCT01394757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P14193ONB|Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)|Brain Network Dysfunction as a Model for Schizophrenia: Connectivity Alterations Using Ketamine and Pharmacological Magnetic Resonance Imaging||Medical University of Vienna|No|Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2013|December 29, 2013|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394757||101533|
NCT01396291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06384|Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)|A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phase 3B, Protocol P06384)||Forest Laboratories|No|Completed|December 2011|June 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|561|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396291||101416|
NCT01396564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-3606-0003|Pioglitazone and Metformin in Diabetic Children|Comparison of the Effects of Pioglitazone and Metformin on Resistin Plasma Levels in Children With Type 2 Diabetes||Coordinación de Investigación en Salud, Mexico|No|Completed|October 2005|July 2011|Actual|October 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|8 Years|17 Years|No|||January 2005|July 18, 2011|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01396564||101395|
NCT01385865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLE_Biofood_2|Effect of Mulberry Leaf Extract on Blood Glucose|Effect of Mulberry Leaf Extract on Blood Glucose in Subjects With Impaired Fasting Glucose||Ewha Womans University|Yes|Completed|January 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|40|||Both|20 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 27, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385865||102213|
NCT01386151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM MED 0879|A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients|Safety and Efficacy of Parenteral KGF in Moderate Asthmatic Subjects||University Hospital Southampton NHS Foundation Trust.|No|Recruiting|August 2009|July 2011|Anticipated|July 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||June 2010|June 29, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01386151||102191|
NCT01386164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTN0001|Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults|Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults|HIPAVAC|University of Aarhus|Yes|Completed|August 2011|August 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01386164||102190|
NCT01386424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110183|Screening Volunteers for Influenza Challenge Studies|Screening of Volunteers for Influenza Human Challenge Studies||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2000|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386424||102170|
NCT01387256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2.1|Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone|Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone-3 Hour Intervals||Gynuity Health Projects|No|Completed|May 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|441|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2011|July 18, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01387256||102107|
NCT01387269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-ANAM-301|Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C||Helsinn Therapeutics (U.S.), Inc|Yes|Completed|July 2011|February 2015|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|484|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387269||102106|
NCT01387776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-PRN-10-01|Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21|Study for the Evaluation of the Benefits of 1 st Trimester Risk Markers in Detecting Early Onset Pre-eclampsia and the Use of the Placental Growth Factor (PlGF) as a Potential Marker for Trisomy 21 and Other Aneuploidies|PlGF|OVO R & D|No|Terminated|June 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|370|Samples Without DNA|serum|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|women in 1st trimester of pregnancy coming to clinique OVO for prenatal screening|July 2015|July 24, 2015|January 31, 2011||No|The technique has been approved and validated|No||https://clinicaltrials.gov/show/NCT01387776||102068|
NCT01388075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-0451-10|Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9|||Hadassah Medical Organization|No|Not yet recruiting|July 2011|||June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 5, 2011|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01388075||102045|
NCT01388062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007054R|e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus|e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus||National Taiwan University Hospital|No|Recruiting|August 2010|October 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|N/A|No|||November 2012|December 26, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388062||102046|
NCT01388309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25524|An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs|DAS Evaluation of RA Activity in Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|July 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis and an inadequate response to DMARDs who are initiated        on treatment with RoActemra/Actemra|March 2016|March 1, 2016|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01388309||102027|
NCT01388556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD4PD-09-0168|PD4PD:Partnered Dance for Parkinson Disease|PD4PD:Partnered Dance for Parkinson Disease|PD4PD|Washington University School of Medicine|Yes|Completed|July 2009|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|30 Years|N/A|No|||December 2015|December 7, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01388556||102008|
NCT01397864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1 1412|C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks|C1 Inhibitor Treatment Registry to Assess the Safety and Immunological Profile of Ruconest in the Treatment of HAE Attacks||Pharming Technologies B.V.|No|Recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|The aim is to recruit 300 patients treated with Ruconest. Additionally, the study will        continue until 100 patients have been exposed to Ruconest for at least 3 attacks.        Enrolment in the pdC1INH arm will be unrestricted.|November 2015|February 15, 2016|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397864||101295|
NCT01397877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOPIK|GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer|Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy|ENDOPIK|ARCAGY/ GINECO GROUP|Yes|Completed|December 2011|March 2016|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01397877||101294|
NCT01398137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR003|Ragweed Observational Study|An Observational Multi-Centre Field Study to Assess Symptom Scores and Rescue Medication Usage in Subjects With a History of Ragweed Allergen-Induced Rhinoconjunctivitis||Circassia Limited|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects with a history of ragweed allergy for at least 2 years and which required        symptomatic treatment for at least 1 year|October 2011|October 26, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01398137||101274|
NCT01398423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV144-201|INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria|A 12 Week, Phase II Trial of the Safety, Pharmacokinetics, and Efficacy of INV-144 Compared With Losartan Potassium in Patients With Hypertension and Type 2 Diabetes Mellitus With Nephropathy||InVasc Therapeutics, Inc.|No|Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|85 Years|No|||August 2012|August 5, 2012|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398423||101252|
NCT01398436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/999/CE/2010|Hemoglobin Saturation in Superior Vena Cava and Right Atrium|Comparison Between Hemoglobin Saturation in the Superior Vena Cava and in the Right Atrium||Catholic University of the Sacred Heart|No|Completed|March 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|61|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398436||101251|
NCT01395407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049695|Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases|Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases||Emory University|Yes|Completed|July 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01395407||101483|
NCT01395420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00009|Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma|A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid (ELF) and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers||AstraZeneca|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395420||101482|
NCT01395992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05692|Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)|A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])||Forest Laboratories|No|Completed|April 2012|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395992||101438|
NCT01396005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08123|A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)|An Open-Label, One-Period Study in Patients Receiving Methadone or Buprenorphine/Naloxone Maintenance Therapy to Evaluate the Effect of SCH 503034 (Boceprevir) on Either Methadone or Buprenorphine/Naloxone Plasma Concentrations (Protocol No. P08123)||Merck Sharp & Dohme Corp.|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||February 2015|February 25, 2015|June 28, 2011|No|Yes||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01396005||101437|
NCT01395654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010025M|Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment|Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment||National Taiwan University Hospital|No|Recruiting|July 2011|December 2015|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2012|December 26, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01395654||101464|
NCT01396902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-018|Text Reminders for Immunization Compliance in Kids (TRICKS) Pilot Study|Text Reminders for Immunization Compliance in Kids||University of Kansas Medical Center|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 9, 2012|July 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01396902||101369|
NCT01396915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101010282|Effects of Increased, Egg-Based Protein Intake on Muscle Composition,|Effects of Increased, Egg-Based Protein Intake on Muscle Composition,|S25|Purdue University|No|Completed|February 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|22|Samples With DNA|whole blood, serum, and muscle tissue|Both|55 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and Women between the ages of 65-80|May 2013|February 2, 2016|February 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01396915||101368|
NCT01397175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOICE|BES, EES, and ZES-R in Real World Practice|A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice|CHOICE|Yonsei University|Yes|Recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|2580|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01397175||101348|
NCT01385553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003006541|Fathers for Change for Men With Co-occurring Domestic Violence and Substance Abuse|Randomized Trial of Fathers for Change: An Intervention for Fathers With Co-Occuring Domestic Violence and Substance Abuse||Yale University|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|60 Years|No|||February 2014|February 18, 2014|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01385553||102237|
NCT01385878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICIRC-1.8 VS 2.2|Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial|Intraoperative Performance & Postoperative Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial||Iladevi Cataract and IOL Research Center|Yes|Recruiting|January 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|50 Years|80 Years|No|||June 2011|June 29, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385878||102212|
NCT01386710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012011410|Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma|Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma||Northwell Health|Yes|Suspended|September 2011|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|June 13, 2011|Yes|Yes|In the process of transferring IRB to PI's current institution|No||https://clinicaltrials.gov/show/NCT01386710||102149|
NCT01386918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127/2003|Repetitive Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia|A Randomized Double-Blind Sham-Controlled Trial of Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia||Centre for Addiction and Mental Health|No|Completed|February 2004|January 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|144|||Both|18 Years|65 Years|No|||January 2012|January 4, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386918||102133|
NCT01388088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED.RES.HOS.2010.02.SKM|The Effect of Amiloride and Spironolactone in Patients With Hypertension|Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study.|hass|Regional Hospital Holstebro|Yes|Completed|September 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|45 Years|70 Years|No|||March 2012|March 27, 2012|May 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01388088||102044|
NCT01388101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007073R|Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)|Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)||National Taiwan University Hospital|No|Recruiting|September 2010|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|20 Years|75 Years|No|||December 2012|December 20, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388101||102043|
NCT01388322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOPPE‐Trial|Low Weight Heparin prOphylaxis for Placental‐Mediated Complications of PrEgnancy|Enoxaparin for the Prevention of Placental‐Mediated Complications of Pregnancy in Women With Obstetric History or Abnormal Uterine Artery Doppler at First Trimester Ultrasound and Without Thrombophilia: a Multicenter Randomized Controlled Trial|HOPPE|Hospital Universitari Vall d'Hebron Research Institute|No|Recruiting|March 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|361|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01388322||102026|
NCT01388569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000703098|Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim|Immune Counter-Regulation in Melanoma Patients Vaccinated With GM-CSF||National Cancer Institute (NCI)||Not yet recruiting|August 2011|||September 2011|Anticipated|N/A|Observational|N/A|||Anticipated|48|||Both|18 Years|N/A|No|||July 2011|July 7, 2011|July 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01388569||102007|
NCT01394211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0269-04|Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer|Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer||University of Arizona|Yes|Terminated|July 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|June 28, 2011|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01394211||101575|
NCT01394224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01377|Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects|A Single Site, Open-label, Randomized, Single-dose, Two-way Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence, Safety & Tolerability of Levetiracetam Administered as an Oral Tablet or Intravenous Infusion||UCB Pharma|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|25|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01394224||101574|
NCT01398150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-79545|Cranberry Enhances Human Immune Function and Reduces Illness|Cranberry Enhances Human Immune Function and Reduces Illness||University of Florida|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|54|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2010|September 16, 2011|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398150||101273|
NCT01394783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3282-CER|Videolaryngoscope vs Classic Laryngoscope in Teaching Neonatal Endotracheal Intubation: a Randomized Controlled Trial.|Videolaryngoscope vs Classic Laryngoscope in Teaching Neonatal Endotracheal Intubation: a Randomized Controlled Trial.||St. Justine's Hospital|Yes|Completed|July 2011|June 2014|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|268|||Both|N/A|1 Year|No|||November 2014|November 17, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01394783||101531|
NCT01395095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2010-391|OPTImal CArdiac REhabilitation (OPTICARE) Following Acute Coronary Syndromes|OPTImal CArdiac REhabilitation (OPTICARE)Following Acute Coronary Syndromes: A Randomized, Controlled Trial to Investigate the Benefits of an Expanded Educational and Behavioural Intervention Program.|OPTICARE|Erasmus Medical Center|No|Completed|September 2011|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|914|||Both|N/A|N/A|No|||March 2016|March 14, 2016|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395095||101507|
NCT01396044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUIRBSTU00013313|Daily Checklists and Outcome in the Intensive Care Unit|Daily Checklists and Outcome in the Intensive Care Unit||Northwestern University|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|451|||Both|N/A|N/A|No|||November 2012|November 5, 2012|July 13, 2011||No||No|November 5, 2012|https://clinicaltrials.gov/show/NCT01396044||101435|
NCT01395693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA200611|Performance of the Salt Lake Mask System|Assessment of the Performance of the Salt Lake Mask System as a Patient Interface in the Provision of Positive Airway Pressure (PAP) Therapy||ResMed|Yes|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01395693||101461|
NCT01395706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PULSION-001|ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes|Determination of the Sensitifity of ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer - a Monocenter Prospective Open-label Clinical Trial||Pulsion Medical Systems SE|Yes|Not yet recruiting|September 2011|March 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|125|||Both|18 Years|80 Years|No|||July 2011|July 15, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395706||101460|
NCT01396278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1248.7|Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).|A Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 90.9, 181.8 and 363.6 µg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA MDI 440 µg b.i.d. in Patients With Asthma Inadequately Controlled on Medium Dose ICS Therapy||Boehringer Ingelheim||Terminated|July 2011|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|9|||Both|12 Years|65 Years|No|||April 2014|April 30, 2014|July 15, 2011||||No||https://clinicaltrials.gov/show/NCT01396278||101417|
NCT01396551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMT - 01-10|Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy|Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy||Varian Medical|No|Active, not recruiting|October 2010|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|69|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396551||101396|
NCT01396031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05172011-7782|Feasibility Study of Exercises for Myeloablative Allogeneic Blood and Marrow Transplantation (BMT) Patients|Matched-Status Exercise Program in Patients Undergoing Myeloablative Allogeneic Blood and Marrow Transplantation: A Feasibility Study||Stanford University|Yes|Active, not recruiting|January 2010|July 2011|Anticipated|July 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|16|||Both|18 Years|N/A|No|||July 2011|July 14, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01396031||101436|
NCT01396928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGD-01/2000|Study of Two Techniques of Rectal Reservoir in Low Anterior Resection of Rectum|Prospective Randomized Study of Two Techniques of Rectal Reservoir in Low Anterior Resection of Rectum||Hospital Universitari de Bellvitge|No|Completed|November 2000|July 2010|Actual|December 2005|Actual|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|106|||Both|18 Years|N/A|No|Probability Sample|Patients wiht low or middle rectal adenocarcinoma after neoadyuvant radio-chemotherapy|November 2000|October 1, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396928||101367|
NCT01397188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19741016|Effect of Monitoring of Pulse Index Continuous Cardiac Output (PiCCO) on Shock Patients in Intensive Care Unit|Effect of Monitoring of Pulse Index Continuous Cardiac Output on Shock Patients in ICU|PiCCO|Zhejiang University|No|Recruiting|August 2011|August 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|85 Years|No|||August 2013|August 20, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01397188||101347|
NCT01397201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1248.6|Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 45.5, 90.9 and 181.8 mcg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA 220 mcg b.i.d. in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy||Boehringer Ingelheim||Terminated|July 2011|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|30|||Both|12 Years|65 Years|No|||April 2014|April 30, 2014|July 18, 2011||||No||https://clinicaltrials.gov/show/NCT01397201||101346|
NCT01397448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3810-J081-308|Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)|Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial-||Eisai Inc.||Completed|July 2011|June 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|472|||Both|20 Years|N/A|No|||October 2014|November 25, 2014|July 18, 2011||No||No|October 20, 2014|https://clinicaltrials.gov/show/NCT01397448||101327|
NCT01386177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 65/11|Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)|Interactive Effects of Doxazosin and 3,4-Methylenedioxymethamphetamine (MDMA) in Healthy Subjects||University Hospital, Basel, Switzerland|Yes|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01386177||102189|
NCT01386437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110187|Natural History of Individuals With Immune System Problems That Lead to Fungal Infections|The Natural History, Immunologic Correlates and Genetic Defects in Patients With Mucocutaneous and Invasive Fungal Infections||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|700|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|January 20, 2016|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386437||102169|
NCT01387282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-ANAM-302|Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C||Helsinn Therapeutics (U.S.), Inc|Yes|Completed|July 2011|February 2015|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|495|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387282||102105|
NCT01387295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA 0918|Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease|Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer A Phase II Trial in Patients With Limited Extrahepatic Disease||Herlev Hospital|Yes|Recruiting|April 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|March 20, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01387295||102104|
NCT01387542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015976|Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants|An Open-label, PRospective Study to Evaluate Social Function and Overall Improvement of Paliperidone ER Treatment in Thai Schizophrenia PatieNT (PRESENT)|PRESENT|Janssen-Cilag Ltd.,Thailand|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|June 30, 2011|Yes|Yes||No|January 29, 2013|https://clinicaltrials.gov/show/NCT01387542||102086|Study had an open-label trial design with lack of a comparator arm; therefore it was difficult to conclude the efficacy and safety results.
NCT01387529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-15|Reference Values for Non-invasive Hydration Status Markers H10-14|Reference Values for Non-invasive Hydration Status Markers||U.S. Army Medical Research and Materiel Command|Yes|Completed|June 2011|September 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Approximately 150 volunteers (military and civilians) will complete this experiment. A        sample size of 120 volunteers is recommended for characterizing a sample reference        population and constructing reference intervals (Fraser, 2001). A sample size of 150 will        allow for the potential loss of data due to equipment or handling errors, and 'bad'        samples resulting from volunteer non-compliance. A subset of as many as 50 volunteers will        undergo repeat testing (3 days; ~3 hours) for the purpose of determining within-subject        variance.|March 2014|March 6, 2014|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387529||102087|
NCT01387789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-265|A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia|An Observational Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia|RELIVE|AbbVie|No|Completed|August 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|18 Years|N/A|No|Non-Probability Sample|Rheumatology clinic|April 2014|April 21, 2014|July 1, 2011||No||No|March 14, 2014|https://clinicaltrials.gov/show/NCT01387789||102067|
NCT01398579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E\10\703|Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy|Prospective Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy for the Diagnosis of Gastric Pre-neoplastic and Neoplastic Lesions (pCLE-GCEP)|pCLE-GCEP|National University Hospital, Singapore|No|Recruiting|September 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|50 Years|90 Years|No|||August 2011|July 10, 2012|June 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01398579||101240|
NCT01398592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237ADE02|Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy|Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus®/Eucreas®) and Sitagliptin (Januvia®/Janumet®) After Two Weeks|FPG-VISIT|Novartis||Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|85 Years|No|||February 2013|February 11, 2013|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01398592||101239|
NCT01394588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006006996|Continuous Glucose Monitoring Technology in the Perioperative Period During Cardiac Surgery|A Prospective Observational Trial of Continuous Glucose Monitoring Technology in the Perioperative Period During Cardiac Surgery||Yale University|No|Withdrawn|August 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Competent adults scheduled for elective cardiac surgery.|May 2014|May 2, 2014|July 12, 2011||No|On further investigation, it was found that the continuous glucose monitors required a    calibration period that precluded reliable data collection.|No||https://clinicaltrials.gov/show/NCT01394588||101546|
NCT01394601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NRU-ATC-2011/1|A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia|RECONNECT-S ALPHA: A Non-interventional Study to Observe Real-life Allocation of Antipsychotics in the Acute Inpatient Management of Schizophrenia|RECONNECT-S|AstraZeneca|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|600|None Retained|Clinical Practice|Both|18 Years|N/A|No|Non-Probability Sample|Clinical Practice|November 2012|November 2, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394601||101545|
NCT01394913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETAEMS0411|Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis|A Prospective, Double-blind, Randomized Study to Compare Efficacy of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis||EMS|Yes|Suspended|August 2013|June 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|70 Years|No|||March 2013|March 1, 2013|July 12, 2011||No|Study suspended by decision strategically.|No||https://clinicaltrials.gov/show/NCT01394913||101521|
NCT01395186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Varicocelectomy To Treat Pain,|Varicocelectomy To Treat Pain, Predictors Of Success|Varicocelectomy To Treat Pain, Predictors Of Success : A Prospective Study||Mansoura University|Yes|Completed|April 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Male|N/A|N/A|Accepts Healthy Volunteers|||April 2009|July 14, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01395186||101500|
NCT01394796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGCG/DYRC1A/DS/IMIM/1|Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.|Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.||Parc de Salut Mar|No|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|14 Years|29 Years|No|||March 2013|March 12, 2013|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01394796||101530|
NCT01394497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1635P|Use of N-Acetylcysteine During Liver Procurement|Infusione Sistemica e Loco-regionale di N-Acetilcisteina Nel Prelievo di Fegato: Uno Studio Prospettico Randomizzato Controllato. Fase II.||Azienda Ospedaliera di Padova|Yes|Completed|December 2006|July 2009|Actual|July 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||February 2013|February 15, 2013|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394497||101553|
NCT01394770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-AM dial|Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients|Cardiovascular Events in Hypertensive Hemodialysed Patients: Aliskiren Versus Amlodipine. A Randomized, Double-blind Study.||Second University of Naples|No|Active, not recruiting|September 2009|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|80 Years|No|||July 2012|July 9, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394770||101532|
NCT01395394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046153|Phenylketonuria, Oxidative Stress, and BH4|The Ability of Kuvan® (Sapropterin Dihydrochloride) to Prevent Meal-induced Lipid Peroxidation and Endothelial Dysfunction in Patients With Phenylketonuria: a Pilot Study||Emory University|Yes|Terminated|June 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|12|||Both|10 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|June 23, 2011|Yes|Yes|Difficulty with recruitment and agreed with Sponsor to report completed data as case reports|No|July 30, 2014|https://clinicaltrials.gov/show/NCT01395394||101484|Early termination leading to small number of subjects analyzed.
NCT01396057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002EDE17|Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)|A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO)|COMRADE-B|Novartis||Completed|July 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|July 14, 2011||No||No|June 13, 2014|https://clinicaltrials.gov/show/NCT01396057||101434|
NCT01396070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0089|Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level|Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level||Stanford University|Yes|Active, not recruiting|June 2011|October 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396070||101433|
NCT01396304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4835-W|Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers|Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers||Hollister Wound Care LLC|No|Terminated|October 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|July 14, 2011|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT01396304||101415|
NCT01396577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-039|Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects|A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects||Eisai Inc.||Completed|December 2010|April 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|May 2, 2012|July 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396577||101394|
NCT01396590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-A001-040|Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects|A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects||Eisai Inc.||Completed|December 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|May 2, 2012|July 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396590||101393|
NCT01396603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001254|Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease|||Massachusetts General Hospital|No|Recruiting|December 2008|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for bronchoscopy procedures in the Pulmonary and Critical Care        Department at Massachusetts General Hospital for the evaluation of known or suspected        pulmonary malignancy will be enrolled in this study. Study patients will receive standard        of care for pulmonary disease consistent with national guidelines.|March 2016|March 14, 2016|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01396603||101392|
NCT01396629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8PN1011155|Clinical Evaluation of a New Cartridge for the Implantation of Foldable Intraocular Lenses|Clinical Evaluation of a New Cartridge for the Implantation of Foldable Intraocular Lenses||Aurolab|No|Completed|July 2011|October 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|99|||Both|40 Years|60 Years|No|Non-Probability Sample|Patient with senile cataract or Nuclear Sclerosis grade I and grade II and age between        40-60|November 2012|November 15, 2012|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01396629||101390|
NCT01396941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HL096832|Effects of Sleep Duration and Architecture on Insulin Sensitivity|Effects of Sleep Duration and Architecture on Insulin Sensitivity||University of California, San Francisco|No|Recruiting|May 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 25, 2014|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01396941||101366|
NCT01386450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110191|AZD6244 in Children With Low-Grade Gliomas|Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma||National Institutes of Health Clinical Center (CC)||Recruiting|June 2011|November 2018|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|3 Years|21 Years|No|||September 2015|October 6, 2015|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01386450||102168|
NCT01386723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003010950|"End of EXTEND: Observing for Cure in Patients With Chronic ITP"|"End of EXTEND: Observing for Cure in Patients With Chronic ITP"||Weill Medical College of Cornell University|No|Recruiting|June 2011|August 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood specimens|Both|18 Years|N/A|No|Non-Probability Sample|ITP patients discontinuing the use of eltrombopag|December 2012|December 20, 2012|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01386723||102148|
NCT01386931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103016|On-site Cytopathology EUS-FNA|The Clinical Impact of Immediate On-site Cytopathology Evaluation During Endoscopic Ultrasound-Guided Fine Needle Aspiration of Pancreatic Mass: A Multicenter, Prospective Randomized Controlled Trial||Washington University School of Medicine|Yes|Enrolling by invitation|June 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|238|||Both|18 Years|N/A|No|Probability Sample|Potential participants for this study include patients presenting to each of the three        tertiary referral centers for an Endoscopic Ultrasound-guided Fine Needle Aspiration.|September 2012|September 5, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01386931||102132|
NCT01386944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1009|Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation|Non Interventional Observational Study to Collect Data for the Effect of Switching to Neupro® on Severity of Restless Leg Syndrome (RLS) Symptoms and Augmentation as Well as the Change in Treatment Regimen Used, in RLS Patients With Previous Augmentation|AURORA|UCB Pharma|No|Completed|July 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|N/A|No|Probability Sample|Adult patient with a diagnosis of moderate to severe idiopathic Restless Leg Syndrome        (RLS).        Patient must be experiencing augmentation due to a prior dopaminergic treatment.        Every consecutive, eligible patient to be treated with Neupro® as per physician's        decision.|July 2014|July 24, 2014|June 29, 2011|No|Yes||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01386944||102131|
NCT01387308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00018|Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets|An Open-label, Partially Randomized, 5-way Crossover Study in Healthy Volunteers to Assess the Relative Bioavailability of 100 and 150 mg Fostamatinib Tablets Compared With 50 mg Fostamatinib Tablets||AstraZeneca||Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01387308||102103|
NCT01387555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-HEP018|A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib|A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment|TRAVERSE|Jennerex Biotherapeutics|Yes|Completed|December 2008|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|June 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387555||102085|
NCT01387802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-672|Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis|Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis (Complete - AS)|Complete-AS|AbbVie|No|Recruiting|July 2011|July 2022|Anticipated|July 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1120|||Both|18 Years|99 Years|No|Non-Probability Sample|Offices of community rheumatologists|January 2016|January 20, 2016|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387802||102066|
NCT01387815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-678|Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis|Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis|Complete-PS|AbbVie|No|Recruiting|August 2011|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|660|||Both|18 Years|99 Years|No|Non-Probability Sample|Offices of community dermatologists|January 2016|January 20, 2016|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387815||102065|
NCT01395212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUW|MYSTAR-5-YEAR: Long-term Follow-up of Patients With Ischemic Heart Disease Treated With Cell Therapy|Long-term Follow-up of Patients With Ischemic Heart Disease Treated With Combined Delivery of Autologous Bone-marrow Mononuclear Cells: 5-year Clinical Outcome of the MYSTAR Study|MYSTAR-5-YEAR|Medical University of Vienna|No|Completed|July 2011|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|80 Years|No|Probability Sample|Patients included into the MYSTAR randomized study|October 2013|October 26, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395212||101498|
NCT01395485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101281|Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescent (12 to <18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma||Amgen||Withdrawn|June 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|0|||Both|12 Years|50 Years|No|||November 2013|November 20, 2013|May 5, 2011|||The study had been cancelled and replaced with protocol 20130250.|No||https://clinicaltrials.gov/show/NCT01395485||101477|
NCT01395498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0009-CTIL|Prevalence of Pneumocystis Jirovecii and of Cytomegalovirus in Bronchial Wash Fluid of Patients Undergoing Bronchoscopy|Prevalence of Positive DNA of Pneumocystis Jirovecii and of Cytomegalovirus in Bronchial Wash Fluid of Patients Undergoing Fiberoptic Bronchoscopy|PCP-CMV|Carmel Medical Center|No|Recruiting|July 2011|December 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|samples of bronchoalveolar lavage fluid and blood.|Both|18 Years|N/A|No|Probability Sample|The study population will consist of patients cared for in the pulmonology outpatients        clinic and for whom a fiberoptic bronchoscopy is indicated.|February 2013|February 10, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395498||101476|
NCT01395784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6106|Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone|Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone||New York State Psychiatric Institute|Yes|Completed|August 2010|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|32|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||November 2013|January 26, 2016|July 13, 2011|Yes|Yes||No|August 31, 2015|https://clinicaltrials.gov/show/NCT01395784||101454|
NCT01395797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6255|Pioglitazone for Heroin and for Nicotine Dependence|Effects of Pioglitazone, a PPARγ Agonist, on the Abuse Liability of Heroin and of Nicotine||New York State Psychiatric Institute|Yes|Completed|March 2011|June 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|88|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||November 2013|March 24, 2015|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395797||101453|
NCT01395108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-C-1|Clinical Study on Oral Nemonoxacin Malate Capsules|Phase I Clinical Study on Oral Nemonoxacin Malate Capsules||TaiGen Biotechnology Co., Ltd.|No|Completed|January 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|76|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2011|July 13, 2011|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395108||101506|
NCT01395121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2009/10020|A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread|A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma|NICAM|Institute of Cancer Research, United Kingdom|Yes|Recruiting|December 2009|||June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2011|May 18, 2012|April 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01395121||101505|
NCT01395719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121369|Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function|Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function|Context|University of Aarhus|No|Active, not recruiting|June 2011|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395719||101459|
NCT01395745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-SLE3331|CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus|CHABLIS-SC1|Anthera Pharmaceuticals|Yes|Recruiting|February 2013|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395745||101457|
NCT01395758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-218|Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer||ArQule|No|Active, not recruiting|July 2011|August 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|July 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395758||101456|
NCT01396317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11081|Study of Tocilizumab to Treat Polymyalgia Rheumatica|Phase IIa of Tocilizumab In the Treatment of Polymyalgia Rheumatica||Hospital for Special Surgery, New York|Yes|Active, not recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|N/A|No|||March 2015|March 18, 2015|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396317||101414|
NCT01396330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSOD|Effect of Mental Stress on Glucose Control in Patients With Diabetes Mellitus|Effect of Prolonged Mental Stress During Safe Driving Training Courses on Glucose Control in Patients With Diabetes Mellitus Type 2|EMSOD|University Hospital, Basel, Switzerland|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|N/A|No|||February 2012|February 28, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01396330||101413|
NCT01396616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1PN1011037|Clinical Evaluation of Toric Intraocular Lens Made by Aurolab|Clinical Evaluation of Toric Intraocular Lens Made by Aurolab|TORICIOL|Aurolab|No|Recruiting|August 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|40 Years|65 Years|No|||July 2011|January 7, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01396616||101391|
NCT01390142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2011-06|Remote Ischemic Preconditioning Combined to Local Ischemic Postconditioning in Acute Myocardial Infarction|Remote Ischemic Preconditioning Combined to Local Ischemic Postconditioning in Acute Myocardial Infarction (RIRE-1)|RIRE-1|University Hospital, Angers||Completed|July 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||October 2013|October 17, 2013|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01390142||101887|
NCT01390376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOH99-TD-I-111-TM001|DAAOI-1 Treatment for Treatment-resistant Schizophrenia|DAAOI-1 Treatment for Treatment-resistant Schizophrenia||China Medical University Hospital|No|Recruiting|September 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|65 Years|No|||July 2013|July 31, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390376||101869|
NCT01386736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0902010250|Vitamin D and Glucose Metabolism in Pediatrics|Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics||Weill Medical College of Cornell University|No|Recruiting|April 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01386736||102147|
NCT01386957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNI-NET 2011|Steroid Treatment of Idiopathic Nephrotic Syndrome|Steroid Treatment of Childhood Idiopathic Nephrotic Syndrome: Epidemiology, Therapeutic Adequacy, Medium and Long Term Outcomes. A Prospective Observational Cohort Study.||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Recruiting|July 2011|July 2015|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Whole Blood and Urine|Both|6 Months|18 Years|No|Non-Probability Sample|Children aged 6 months - 18 years, diagnosed with an initial episode of idiopathic        nephrotic syndrome (proteinuria> 40mg/m2/h or urine protein/creatine ratio > 2 mg/mg and        hypoalbuminemia <2.5g/dL).        Subjects will be enrolled from the first of July 2011 to the 31st of June 2013 from the        following Italian regions Emilia Romagna, Lombardia, Toscana, Trentino Alto Adige, Friuli        Venezia Giulia, Marche and Sicilia; the follow-up of each subject will continue for 24        months.|March 2012|March 7, 2012|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386957||102130|
NCT01386970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-1101|Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics|Sex and Disease Dependent Nucleoside Analog Toxicity||University of Colorado, Denver|Yes|Completed|May 2005|July 2010|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|51|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01386970||102129|
NCT01387321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719X1101|A Study of BYL719 in Adult Patients With Advanced Solid Malignancies|A Study of BYL719 in Adult Patients With Advanced Solid Malignancies||Novartis||Completed|September 2011|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01387321||102102|
NCT01394614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Narco-H1N1|Risk of Narcolepsy Associated With Administration of H1N1 Vaccine|Risk of Narcolepsy Associated With Administration of Inactivated Adjuvanted (AS03) A/H1N1 Pandemic Influenza Vaccine in Quebec||Hopital du Sacre-Coeur de Montreal|No|Completed|June 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|24|Samples With DNA|HLA typing|Both|6 Months|N/A|No|Non-Probability Sample|The study population includes persons more than 6 months of age residing in the province        of Quebec.|May 2015|May 12, 2015|July 12, 2011||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01394614||101544|Small number of subjects; Impossibility to completely exclude a confounding effect of the A/H1N1 virus infection itself.
NCT01398267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25328|A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Aleglitazar 150 µg in Type 2 Diabetic Patients Treated With Lisinopril 20 mg on Renal Function, the Renin-angiotensin System and the Pharmacokinetics of Lisinopril||Hoffmann-La Roche||Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Masking: Double Blind (Subject, Investigator)|2||Actual|55|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01398267||101264|
NCT01398280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100867|Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation|A Single Site Evaluation of the Effect of Topical Application of Aminocaproic Acid (ACA) to Inhibit Kallikrein 5 Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation.|ACA|University of California, San Diego|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|70 Years|No|||January 2013|January 14, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398280||101263|
NCT01396122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-gyn-02|Clinical Performance of GYNECARE PROSIMA* Pelvic Floor Repair System for Symptomatic Pelvic Organ Prolapse|A Prospective, Multicenter Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Symptomatic POP-Q Stage II-III Pelvic Organ Prolapse||Peking Union Medical College Hospital|No|Recruiting|March 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Female|18 Years|N/A|No|||July 2011|December 25, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01396122||101429|
NCT01396135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3331019|A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects|A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Single- And Multiple-Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects||Pfizer|No|Withdrawn|August 2011|October 2011|Anticipated|October 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|19|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 3, 2011|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396135||101428|
NCT01396382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110588|68Ga-DOTATATE PET Scan in Neuroendocrine Cancer|68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Neuroendocrine Tumors|68Ga|Vanderbilt University|Yes|Active, not recruiting|August 2011|March 2014|Anticipated|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|99|||Both|18 Years|N/A|No|||December 2013|December 16, 2013|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396382||101409|
NCT01396668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0412-138-005|Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer|Phase Ⅱ Trial of Fixed Dose Rate Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Capecitabine in Patients With Locally Advanced Pancreatic Cancer||Seoul National University Hospital|No|Completed|December 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|75 Years|No|||July 2011|July 15, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01396668||101387|
NCT01396681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0412-138-006|Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer|Phase Ⅱ Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Gemcitabine in Patients With Resected Pancreatic Cancer||Seoul National University Hospital|No|Completed|December 2004|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||July 2011|July 15, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01396681||101386|
NCT01394510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACStudy001|Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes|Effect of Anti-oxidants on Beta-cell Function in Humans||Utzschneider, Kristina, M.D.|No|Recruiting|June 2011|October 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|75 Years|No|||August 2014|August 15, 2014|July 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01394510||101552|
NCT01394523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00363|Caudal Versus Rectus Sheath Study|A Prospective, Double-blinded, Randomized Comparison of Caudal Analgesia Versus Ultrasound Guided Rectus Sheath Blocks for Umbilical Herniorrhaphy in the Pediatric Population||Nationwide Children's Hospital|No|Enrolling by invitation|August 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|N/A|N/A|No|||March 2016|March 4, 2016|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394523||101551|
NCT01394809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01 EC 1007D|Effects of Motor Cognitive Training on Functional Loss After Osteoporotic Wrist Fractures|Effects of Motor Cognitive Training on Functional Loss Through Immobilization After Osteoporotic Distal Radius Fractures: a Randomised Clinical Pilot Study in Elderly Patients|PROFinD-TP4|University of Stuttgart|No|Completed|August 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Female|65 Years|85 Years|No|||December 2014|December 2, 2014|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394809||101529|
NCT01394822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NINDS-K23NS062892|Neuromuscular Ultrasound for Focal Neuropathies|Neuromuscular Ultrasound for Focal Neuropathies||Wake Forest School of Medicine|No|Completed|September 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals presenting to the Diagnostic Neurology Laboratory at Wake Forest Baptist        Medical Center for evaluation of focal nerve disease.|December 2014|December 8, 2014|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394822||101528|
NCT01395732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-427|Bosentan in Systemic Sclerosis|Effects of Bosentan in a Homogenous Population of Systemic Sclerosis Subjects With a Predefined Restriction of Blood Flow in the Hands|HOME|Actelion|No|Completed|March 2011|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|July 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01395732||101458|
NCT01393392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23DA025049|Developing a Smoking Cessation Intervention for Methadone Maintained Smokers|Developing a Smoking Cessation Intervention for Methadone Maintained Smokers||Rutgers, The State University of New Jersey|Yes|Completed|October 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01393392||101638|
NCT01393405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-2044|Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis|Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)|Merit-UC|University of North Carolina, Chapel Hill|Yes|Recruiting|February 2012|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|70 Years|No|||February 2016|February 11, 2016|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393405||101637|
NCT01396083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002EDE18|Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)|A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Central Retinal Vein Occlusion (CRVO)|COMRADE-C|Novartis||Completed|August 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|July 14, 2011||No||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01396083||101432|
NCT01396343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NS071463|Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis|Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis||University of California, San Francisco|No|Recruiting|October 2011|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1920|Samples With DNA|Total 41ml sample: 17ml plasma/DNA, 10ml serum, 9ml lymphocytes and 5ml RNA frozen.|Both|3 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Case patients seen at the 16 participating Pediatric MS Center Clinics. Control patients        seen at the Pediatric Clinics of the same institution as MS cases.|December 2015|December 1, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01396343||101412|
NCT01389674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIB-Study|Hybrid Intraprocedural Imaging Based on 2 Different Imaging Methods|Hybrid Intraprocedural Imaging From 2D-Strain-echocardiography and X-ray Based Biplane Coronary Angiography for Guiding Interventional Revascularization Therapy||RWTH Aachen University|No|Withdrawn|April 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|February 3, 2009||No||No||https://clinicaltrials.gov/show/NCT01389674||101922|
NCT01389921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25/2009|Study of Electroencephalogram (EEG) Measurement During Different Stimulations of the Lower Urinary Tract|Investigation of Lower Urinary Tract Afferent and Cortical Brain Activity During Lower Urinary Tract Stimulation Using Electroencephalogram Measurements||University of Zurich|No|Completed|February 2011|April 2014|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|83|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01389921||101903|
NCT01386749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|470410|Effect of Low-Magnitude, High Frequency Vibration Treatment on Femoral Shaft Fracture Healing|The Efficacy of Low-Magnitude, High Frequency Vibration Treatment on Accelerating the Healing of Femoral Shaft Fracture - A Prospective Randomized Controlled Clinical Trial||Chinese University of Hong Kong|No|Completed|February 2011|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|40 Years|No|||July 2015|July 27, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01386749||102146|
NCT01386983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112599|Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment|Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment||GlaxoSmithKline|No|Completed|March 2009|June 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|332|||Male|50 Years|N/A|No|Non-Probability Sample|This study will identify eligible patient data between April 1, 2000, and December 31,        2007, and allows for patient data to be followed for 3 months prior to and up to 1 year        following index prescription date.|July 2011|August 11, 2011|February 28, 2011||No||No|February 28, 2011|https://clinicaltrials.gov/show/NCT01386983||102128|
NCT01395225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00748|Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer|Standardising an Approach for Analysis of Lymph Node Specimens From Radical Cystectomy With Pelvic Lymph Node Dissection Through the Use of an Organic Fat-emulsifying Agent||University of British Columbia|No|Completed|August 2011|December 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who undergo radical cystectomy with lymph node dissection at the Vancouver        General Hospital (VGH) for clinical stage T1-4,N0,M0 bladder cancer will be invited to        participate in this prospective study.|March 2014|March 12, 2014|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01395225||101497|
NCT01395238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CE001653|Enhancing Father's Ability to Support Their Preschool Child|Enhancing Father's Ability to Support Their Preschool Child||Queens College, The City University of New York|No|Recruiting|September 2010|August 2012|Anticipated|August 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|125|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|July 14, 2011|May 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01395238||101496|
NCT01394926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-191-001|Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease|A Multi-Center, Open-Label, Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease||GE Healthcare|No|Terminated|June 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||April 2014|April 16, 2014|July 13, 2011|Yes|Yes|Lack of Subject Recruitment|No|March 7, 2014|https://clinicaltrials.gov/show/NCT01394926||101520|
NCT01394939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-CRC019|Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma|A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.||SillaJen, Inc.|No|Completed|January 2012|October 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394939||101519|
NCT01395836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047554a|Management of New-Onset Postoperative Atrial Fibrillation|Management of New-Onset Postoperative Atrial Fibrillation Utilizing Insertable Cardiac Monitor Technology to Observe Recurrence of AF|Monitor-AF|Emory University|Yes|Active, not recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing isolated CABG at Emory University Hospital Midtown will be followed        post-operatively and screened for inclusion to the trial.|December 2015|December 10, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395836||101450|
NCT01395849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112277|Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)|Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)||GlaxoSmithKline|No|Completed|October 2007|March 2011|Actual|September 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2116|||Both|N/A|N/A||Probability Sample|Japanese patients with asthma|June 2011|July 14, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395849||101449|
NCT01396148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181196|A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor|A Phase I/II Study Of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor||Pfizer|No|Recruiting|June 2012|November 2019|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|20 Years|No|||March 2016|March 7, 2016|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01396148||101427|
NCT01396408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I206|A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours|A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours||Canadian Cancer Trials Group|No|Active, not recruiting|July 2011|November 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|16 Years|N/A|No|||March 2016|March 22, 2016|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01396408||101407|
NCT01396395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200101-501|Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina|A Prospective, Multi-center, Random, Open-label Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina||Merck KGaA||Completed|July 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|403|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01396395||101408|
NCT01395134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN/501/ZKL/1446|Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.|Randomized Controlled Trial of Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.||Jagiellonian University|Yes|Completed|September 2009|December 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Female|18 Years|N/A|No|||July 2011|July 14, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01395134||101504|
NCT01395433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13154A|Bioequivalence Study Comparing Two Formulations of Escitalopram|A Single-dose, Open-label, Randomised, Crossover Bioequivalence Study in Healthy Young Men Comparing Two Formulations of Escitalopram||H. Lundbeck A/S|No|Completed|January 2010|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 7, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01395433||101481|
NCT01395446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28062009|Application of an Electronic Nose in the Early Detection of ASpergillosis|The Application of an Electronic Nose in the Early Detection of ASpergillosis|AENEAS|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|January 2010|December 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52|Samples Without DNA|BAL|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients that will undergo treatment for a hematological malignancy expected to result in        grade 4 neutropenia of prolonged duration|June 2015|June 23, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01395446||101480|
NCT01393431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBC pH in ICU|Futility of Exhaled Breath Condensate pH Measurements in Ventilated Patients in Intensive Care Unit (ICU)|Exhaled Breath Condensate pH in Mechanically Ventilated Patients||Universidad Nacional de Rosario|Yes|Terminated|August 2007|April 2008|Actual|April 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Adults (age >18) Acute critically ill patients that required endotracheal intubation and        mechanical ventilation for at least 48 hours due to a non-pulmonary cause.|May 2008|August 3, 2011|July 1, 2011|No|Yes|IRB recommended to stop the trial becasue none of the 4 procedures showed a predictive value    for VAP, duration of MV or mortality.|No||https://clinicaltrials.gov/show/NCT01393431||101635|
NCT01393730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-448|Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer|Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2011|September 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01393730||101612|
NCT01389882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VENT-01-NAVA|Randomized Crossover Study of Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants|Application of Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants and Assessment of Its Benefits Compared to Synchronized Intermittent Mandatory Ventilation (SIMV) With Pressure Support (PS)||Seoul National University Hospital|Yes|Completed|March 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|26|||Both|N/A|12 Weeks|No|||January 2012|January 5, 2012|July 1, 2011||No||No|September 18, 2011|https://clinicaltrials.gov/show/NCT01389882||101906|Two patients were excluded prior to the study and five patients were interrupted the study because of a developed exclusion criterion during the protocol. Because of eliminated participants, the number of subjects analyzed was reduced.
NCT01390194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246-10|A Rapid 10-minute Liver MRI|A Rapid 10-minute Liver MRI||University of Nebraska|No|Completed|July 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|25|||Both|19 Years|N/A|No|Non-Probability Sample|patients with an underlying liver disease|November 2015|November 12, 2015|July 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01390194||101883|
NCT01390441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8808-002|A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 EXT 1)|A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With Rituximab (MabThera™ and Rituxan™) in Patients With Rheumatoid Arthritis (RA)||Merck Sharp & Dohme Corp.|No|Completed|July 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|100|||Both|18 Years|65 Years|No|||April 2015|April 21, 2015|July 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01390441||101864|
NCT01390454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2010/AD-03b|Relationships Between Ultrasound Data and the Impact of Lateral Epicondylar Pain|Study of the Relationship Between Functional Ultrasound Data and the Impact of Lateral Epicondylar Pain|EPICORE|Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01390454||101863|
NCT01389661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TerCel0002|Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)|Regeneration of Maxillary Bone Cystic Cavities by Bio Implant of MSHV-H Cells Associated to a Cross-linked Serum Scaffold|BIOMAX|Red de Terapia Celular|Yes|Active, not recruiting|April 2011|October 2015|Anticipated|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||September 2015|September 30, 2015|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389661||101923|
NCT01398618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010017M|Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)|Comparing the Efficacy of Two Preventive Regimens for Adult Household Contacts With Latent Tuberculosis Infection||National Taiwan University Hospital|Yes|Active, not recruiting|May 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2011|July 19, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01398618||101237|
NCT01394627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002054|Hypoglycemia and the Mineralocorticoid Receptor|Hypoglycemia and the Mineralocorticoid Receptor|HypoMR|Brigham and Women's Hospital|Yes|Recruiting|January 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01394627||101543|
NCT01394328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03AG023216-01A1|Delirium in Persons With Dementia|Delirium in Persons With Dementia||Penn State University|No|Completed|April 2006|November 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|308|||Both|65 Years|N/A|No|Probability Sample|165 hospitalized older adults at Mount Nittany Medical Center, age 65 and older with        Dementia.|July 2011|July 13, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01394328||101566|
NCT01394341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-032|Liraglutide Treatment to Patients With Severe Renal Insufficiency|Safety and Effect of Liraglutide in Patients With Type 2 Diabetes and Severe Renal Insufficiency||Rigshospitalet, Denmark|Yes|Completed|September 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|85 Years|No|||October 2013|October 8, 2013|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394341||101565|
NCT01395537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2310|Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)|Phase I/II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ)||Case Comprehensive Cancer Center|Yes|Terminated|August 2011|||December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|July 12, 2011|Yes|Yes|Research Cancelled|No||https://clinicaltrials.gov/show/NCT01395537||101473|
NCT01395550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CZA-XXX-2011/1|Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event|Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event.||AstraZeneca|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|88|||Both|N/A|N/A|No|Probability Sample|Patients with cardiovascular events|August 2011|August 29, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395550||101472|
NCT01395810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7999-3775|Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773|Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B|paradigm™ 4|Novo Nordisk A/S|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|71|||Male|13 Years|70 Years|No|||September 2014|September 3, 2014|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01395810||101452|
NCT01395823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCI-0002|Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients|Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial||Dialysis Clinic, Inc.|No|Completed|June 2011|June 2015|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|470|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|July 14, 2011||No||No|January 8, 2016|https://clinicaltrials.gov/show/NCT01395823||101451|
NCT01396161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731007|A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Oral Doses Of PF-05175157 In Healthy Volunteers And In Patients With Type 2 Diabetes Mellitus (T2DM)||Pfizer|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|June 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01396161||101426|
NCT01396733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC_THY_001|Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer|Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake|RALT|Asan Medical Center|Yes|Recruiting|April 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|75 Years|No|||July 2011|July 18, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01396733||101382|
NCT01397006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N11-507|Fibromyalgia of Less Than One Year Duration. Study of Pregabalin|Fibromyalgia of Less Than One Year Duration in Primary Care: Treatment Response in a Double Blind, Placebo Controlled Study of Pregabalin||Newton-Wellesley Hospital|No|Withdrawn|September 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|July 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397006||101361|
NCT01394887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-718-0018|Metformin & Inflammation in Pre-diabetic Children|Metformin Decreases Plasma Resistin Concentrations in Pediatric Patients With Impaired Glucose Tolerance: A Placebo-controlled Randomized Clinical Trial||Coordinación de Investigación en Salud, Mexico|No|Completed|July 2002|July 2011|Actual|July 2003|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|52|||Both|4 Years|17 Years|No|||July 2002|July 15, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394887||101523|
NCT01395160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/0438|Female Experiences and Brain Activity|Female Experiences and Brain Activity: an EEG Investigation Across Psychiatric Disorders|FEBA|King's College London|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|60|Samples With DNA|Buccal swab samples will be collected for DNA extraction.|Female|25 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be recruited through primary care clinics and existing research        participant databases.|August 2013|August 30, 2013|May 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01395160||101502|
NCT01395147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004/OCT-001|Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder|An Open-label, Long-Term Extension Study to Assess the Safety and Efficacy of Lu AA21004 in Patients With Major Depressive Disorder (Extension to Lu AA21004/CCT-003 Study)||Takeda|No|Completed|July 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|20 Years|75 Years|No|||November 2013|November 2, 2013|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01395147||101503|
NCT01392716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M39006|A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma|An Open-label Study of MabThera on Objective Overall Tumor Response in Treatment-naïve Patients With Non-bulky Follicular Non-Hodgkin's Lymphoma||Hoffmann-La Roche||Completed|October 1997|February 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01392716||101690|
NCT01395459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15622|A Sustainable Approach to Increasing Cancer Screening|A Sustainable Approach to Increasing Cancer Screening|CATCH|Harvard School of Public Health|No|Completed|September 2008|October 2013|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|13675|||Both|21 Years|86 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|July 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01395459||101479|
NCT01393028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRESCENT-11|Computed Tomography Versus Exercise Testing in Suspected Coronary Artery Disease|Computed Tomography Versus Exercise Testing in Suspected Coronary Artery Disease|CRESCENT|Erasmus Medical Center|Yes|Terminated|July 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|350|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|June 27, 2011||No|Insufficient funds|No||https://clinicaltrials.gov/show/NCT01393028||101666|
NCT01393457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA030787|Cognitive Remediation for Cocaine Dependence|Cognitive-enhancing DA Medications for Cocaine Dependence||The University of Texas Health Science Center, Houston|Yes|Recruiting|June 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|55 Years|No|||December 2015|December 28, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01393457||101633|
NCT01393795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1824|Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients|A Double-blind, Randomized, Crossover Clinical Study to Assess the Efficacy of Qutenza® for the Reduction of Site Pain Caused by Continuous Subcutaneous Infusion of Remodulin®, in Pulmonary Arterial Hypertension Patients||Imperial College London|Yes|Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01393795||101607|
NCT01394094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10OCT010402|Effects of Gum Chewing on Recovery of Bowel Function Following Benign Gynecologic Surgery|Effects of Gum Chewing on Recovery of Bowel Function Following Benign Gynecologic Surgery: a Randomized Controlled Trial||ChaingMai University|Yes|Not yet recruiting|July 2011|October 2013|Anticipated|October 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|124|||Female|18 Years|80 Years|No|||July 2011|July 13, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394094||101584|
NCT01398631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z-08.27|A Comparison of the TIMI, GRACE and HEART Scores|A Prospective Comparison of the TIMI, GRACE and HEART Scores for Predicting Cardiovascular Events in Chest Pain Patients in the Emergency Room|HEART|R&D Cardiologie|No|Completed|June 2009|July 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2440|||Both|N/A|N/A|No|Probability Sample|All patients presentating with chest pain in one of the participating hospitals.|February 2016|February 16, 2016|June 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01398631||101236|
NCT01394354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00658, MK-0683-201|Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)|Safety of Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma, A Phase I/II Study, Short Title: VBDD|VBDD|University Hospital Freiburg|No|Recruiting|August 2011|March 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01394354||101564|
NCT01394965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004825|Electrocardiographic Mapping and Imaging|Electrocardiographic Mapping and Imaging||Mayo Clinic|No|Withdrawn|October 2013|October 2013|Actual|October 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01394965||101517|
NCT01394952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13438|Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)|The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)|REWIND|Eli Lilly and Company|Yes|Active, not recruiting|July 2011|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|9622|||Both|50 Years|N/A|No|||September 2015|September 14, 2015|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01394952||101518|
NCT01395251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TryCort|Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis|Phase II/III Study of Oral Prednisolone Test in Patients With Rheumatoid Arthritis|TryCort|Rheumazentrum Ruhrgebiet|Yes|Completed|February 2012|December 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|130|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01395251||101495|
NCT01395875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113901|Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment|Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment||GlaxoSmithKline|No|Completed|March 2011|June 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2849|||Both|40 Years|N/A|No|Non-Probability Sample|Data from January 1, 2003 to March 31, 2009 will be available and termed as the study        period. Patients with at least one moderate exacerbation defined as a physician/outpatient        visit with a primary diagnosis of COPD (ICD-9 diagnosis codes) and having an oral        corticosteroid (OCS) or antibiotic (ABX) prescription within 5 days of        physician/outpatient visit will be identified as the target population. The date of this        first moderate exacerbation will serve as the patient's index date, and will be identified        during an identification period of January 1, 2004 to March 31, 2008 allowing for a        maximum of a 1-year period before (pre-period) and after the index date (follow-up). The        specific dates for the pre- and follow-up periods will be different for each patient        depending on their index date. Furthermore this index moderate exacerbation should be the        first medical claim with a primary diagnosis of COPD to ensure that only patients with        moderate exacerbations will be captured.|July 2011|July 14, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01395875||101447|
NCT01396421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-231|Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia|VECTOR|Otsuka Pharmaceutical Development & Commercialization, Inc.||Completed|July 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|636|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|July 11, 2011|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01396421||101406|
NCT01396746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54-2011|Cardiovascular Function in Sub Maximal Exercise and Performance in Three Daily Activity Tests After Stroke|Cardiovascular Function in Sub Maximal Exercise and Performance in Three Daily Activity Tests in Persons With Post Stroke Conditions||Hillel Yaffe Medical Center|Yes|Recruiting|June 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|40 Years|69 Years|No|Non-Probability Sample|Participants are recruited in community centers designated for Disabled populations. They        are leading a physically active life style, usually facilitated by an assistant.|July 2011|July 17, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01396746||101381|
NCT01397019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSG 2010-01|Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours|Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours||Odense University Hospital|Yes|Recruiting|October 2011|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|75 Years|No|||September 2015|September 23, 2015|July 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01397019||101360|
NCT01395173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00087|Position Changes During Colonoscope Withdrawal and Polyp Detection|Position Changes During Colonoscope Withdrawal to Increase Polyp Detection: a Prospective Randomized Trial||University of British Columbia|No|Completed|July 2011|December 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|776|||Both|40 Years|N/A|No|||September 2014|September 29, 2014|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01395173||101501|
NCT01392378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851047|Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®|A Phase 4, Randomized, Open-Label Trial To Assess The Impact Of Prophylactic Antipyretic Medication On The Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations In Healthy Infants||Pfizer|No|Completed|August 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|908|||Both|56 Days|98 Days|Accepts Healthy Volunteers|||January 2014|January 10, 2014|July 8, 2011|Yes|Yes||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01392378||101715|
NCT01392729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25255|An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)|An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)||Hoffmann-La Roche||Completed|September 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|No|Probability Sample|Patients with previously untreated metastatic renal cell cancer|March 2016|March 1, 2016|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01392729||101689|
NCT01393041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901|St. Jude Medical Angio-Seal VIP Vascular Closure Device|Clinical Study of the St. Jude Medical Angio-Seal VIP Vascular Closure Device Following Diagnostic and/or Interventional Endovascular Procedures||St. Jude Medical|No|Completed|June 2011|December 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01393041||101665|
NCT01393743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-332|A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures||Eisai Inc.||Completed|September 2011|November 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|12 Years|N/A|No|||November 2015|December 7, 2015|July 12, 2011|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01393743||101611|
NCT01394081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00134|Alabama Veterans Rural Health Initiative|Alabama Veterans Rural Health Initiative|AVRHI|Tuscaloosa Research & Education Advancement Corporation|No|Active, not recruiting|September 2009|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|700|||Both|19 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 30, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01394081||101585|
NCT01394107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMWH_jB|Evaluation of the LMWH Thromboprophylaxis in Pregnancy|Evaluation of the Impact of the Thromboprophylactic Dose of LMWH on Coagulation in Pregnant Women.||Charles University, Czech Republic|No|Recruiting|January 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|Samples With DNA|whole blood, serum|Female|18 Years|40 Years|No|Probability Sample|pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age        18-40 years|July 2015|July 27, 2015|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01394107||101583|
NCT01389947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2010/105|Microcirculation During Extracorporeal Circulation|Study of Non Major Microcirculation During Extracorporeal Circulation : Relation Between Endothelial Dysfunction and Digestive|CITRON4|Centre Hospitalier Universitaire de Besancon|Yes|Completed|March 2011|February 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|66|Samples Without DNA|Plasma measurments Tissular oxygen saturation using NIRS probe|Both|18 Years|N/A|No|Non-Probability Sample|Patients who need surgical revascularization of coronary arteries. Patients can not not        benefit of percutaneous coronary intervention and need a cardiac surgery of coronary        artery bypass grafting|February 2012|February 8, 2012|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389947||101901|
NCT01398644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-2-104|Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients|Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Patients With Hereditary Hemochromatosis; a Randomised, Single Blinded Sequential, Cross-over Trial||Sanquin Research & Blood Bank Divisions|No|Active, not recruiting|May 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01398644||101235|
NCT01419028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENB-011-10|A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)|A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)||Alexion Pharma GmbH|No|Completed|August 2012|February 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|48|||Both|N/A|N/A|No|Non-Probability Sample|Patients with perinatal and/or infantile onset HPP. Thirty-six patients were invasively        ventilated or died, and 12 patients were censored.|July 2014|July 17, 2014|August 16, 2011||No||No|June 11, 2014|https://clinicaltrials.gov/show/NCT01419028||99677|This was an observational study and, as such, serious and/or other [non-serious] adverse events were not collected/assessed.
NCT01419041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081020|A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function|A Phase I, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function||Pfizer|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|August 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01419041||99676|
NCT01418703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14356|Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus|Feasibility Study of a Modular Control to Range System in T1DM|MDB003|University of Virginia|No|Completed|October 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|38|||Both|21 Years|65 Years|No|||November 2014|November 9, 2014|July 8, 2011|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT01418703||99702|
NCT01419665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP13-301|GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma|A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma|ASSIST_FL|Sandoz|Yes|Active, not recruiting|December 2011|March 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|618|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419665||99628|
NCT01419951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-0666|Launch II: A Pilot Randomized Control Trial of a Clinic and Clinic Plus Home Intervention for Preschool Obesity|LAUNCH II: Learning About Activity and Understanding Nutrition for Better Child Health||Children's Hospital Medical Center, Cincinnati|No|Completed|May 2009|October 2014|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01419951||99606|
NCT01419977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00023305|Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo|Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo||Duke University|Yes|Completed|May 2011|July 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|August 17, 2011|Yes|Yes||No|January 30, 2015|https://clinicaltrials.gov/show/NCT01419977||99604|Limitations to our pilot study include the small study sample size, which leads to difficulty in determining significant differences in the outcome measurements.
NCT01416064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|810P203|Open-Label, Extension Study to 810P202|Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)||Supernus Pharmaceuticals, Inc.|No|Completed|September 2011|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|6 Years|12 Years|No|||May 2013|May 22, 2013|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416064||99903|
NCT01416298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarker/CRRT Study|Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI|Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) to Optimize Fluid Dosing, Continuous Renal Replacement Therapy (CRRT) Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury (AKI)||Children's Hospital Medical Center, Cincinnati|No|Recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|1 Year|25 Years|No|||August 2012|August 1, 2012|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01416298||99885|
NCT01416792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multiple-pass hemofiltration|Centrifugation vs. Multiple-pass Hemofiltration of the Residual Cardiopulmonary Bypass Volume|Outcomes & Biochemical Parameters Following Cardiac Surgery: Effects of Transfusion of Residual Blood Using Centrifugation and Multiple-Pass Hemofiltration||University of Saskatchewan|No|Completed|March 2011|October 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|61|||Both|40 Years|75 Years|No|||September 2011|March 29, 2013|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01416792||99847|
NCT01403571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2103038AJ|Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes|Efficacy and Safety of Whole Grain Salba (Salvia Hispanica L.) on Weight Loss and Maintenance in Overweight and Obese Individuals With Type 2 Diabetes|LOSS|St. Michael's Hospital, Toronto||Active, not recruiting|October 2009|October 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|132|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403571||100858|
NCT01403584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-4225|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2011|||||N/A|N/A|N/A||||||||||||||August 4, 2015|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403584||100857|
NCT01403597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCP-1|Evaluation of Non-ablative and Fractional Combination Treatment for Improvement in Skin's Appearance|Clinical Evaluation of the Impact of Non-ablative and Fractional Ablative Combination Treatment: a Prospective, Open Label, Single Group With Before-after Study Design||Syneron Medical|No|Completed|January 2011|July 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 28, 2014|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403597||100856|
NCT01403805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|803121|Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist|The Interventional Study in the Effects of Oral Care With Vaccines at Nursing Home; the Role of the Partnership With Physician, Dentist and Other Co-medical Stuff||Yubari Kibounomori|Yes|Completed|November 2009|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|199|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2012|April 29, 2012|July 25, 2011||No||No|August 2, 2011|https://clinicaltrials.gov/show/NCT01403805||100840|small numbers of subjects analyzed
NCT01403610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 11-24|Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab|A Phase 2, Investigator Initiated Study to Determine the Safety, Efficacy and CNS Penetration of TH-302 in Recurrent High Grade Astrocytoma Following Bevacizumab||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|June 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|34|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|July 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403610||100855|
NCT01403831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-00084|Trial to Examine Text-message Based mHealth in Emergency Department Patients With Diabetes|Trial to Examine Text-message Based mHealth in Emergency Department Patients With Diabetes|TExT-MED|University of Southern California|Yes|Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|200|||Both|18 Years|80 Years|No|||June 2013|June 18, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403831||100838|
NCT01403844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC022|Carotenoid Response to the Intake of Vegetables and Fruits|Skin Carotenoid Response to Intake of Vegetables and Fruits Recommended by the Dietary Guidelines||USDA Grand Forks Human Nutrition Research Center|Yes|Active, not recruiting|June 2011|June 2016|Anticipated|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|31|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01403844||100837|
NCT01404143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-352|Comparison of Two Methods of Subscapularis Management in Shoulder Arthroplasty: Tenotomy Versus Peel|Comparison of Two Methods of Subscapularis Management in Shoulder Arthroplasty: Tenotomy Versus Peel: A Multicenter, Randomized Controlled||Ottawa Hospital Research Institute|No|Active, not recruiting|August 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||March 2015|September 21, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404143||100814|
NCT01404104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-003-09|Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma|A Pilot Study of Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy: Analysis if Serum and Tissue Biomarkers||St. Joseph's Healthcare Hamilton|No|Completed|September 2008|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01404104||100817|
NCT01418716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRSQ-22424|TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care|A Program to TRANSform InTerprofessional Clinical Practices to Improve Cardiovascular Prevention in Primary Care|TRANSIT|Fonds de la Recherche en Santé du Québec|No|Active, not recruiting|April 2011|October 2017|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|759|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418716||99701|
NCT01418729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTAHEP-2010|Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma|Phase-II, Multicenter, Randomized, Double-Blind, Parallel-Group Trial to Compare the Efficacy and Safety of Sorafenib Plus Pravastatin Against Sorafenib Plus Placebo in Patients With Advanced Hepatocarcinoma|ESTAHEP-2010|Hospital Donostia|Yes|Recruiting|September 2011|September 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|216|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418729||99700|
NCT01419054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHFG|Understanding Hand Hygiene Behavior at Unidad Nacional Oncologia Pediatrica|Understanding Hand Hygiene Behavior at Unidad Nacional Oncologia Pediatrica: A Focus Group Approach|HHFG|St. Jude Children's Research Hospital|No|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Health-care providers|November 2013|November 21, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01419054||99675|
NCT01419327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15077|Fosrenol Post-marketing Surveillance for Hemodialysis in Japan|Special Drug Use Investigation of Fosrenol (Long-term Investigation for Patients With Hemodialysis)|FOSRENOL-HD|Bayer|No|Active, not recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3267|||Both|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who have received a prescription of        Fosrenol on the basis of the decision of the physician. The study is expected to collect        data of 3,000 patients in about 300 practices in Japan.|March 2016|March 10, 2016|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419327||99654|
NCT01419301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Teva186557-1|Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)|Mindfulness Based Stress Reduction in MS||Stony Brook University|No|Completed|May 2011|November 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|31|||Both|18 Years|70 Years|No|||November 2014|November 19, 2014|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01419301||99656|
NCT01419652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bds1|Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography|Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography With or Without Percutaneous Coronary Intervention||New York University School of Medicine|No|Completed|July 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|351|||Both|N/A|N/A|No|||June 2012|June 8, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01419652||99629|
NCT01419678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10110232|Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients|Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients||University of Pittsburgh|Yes|Completed|October 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01419678||99627|
NCT01419691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12838|Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)|A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL)||University of Kansas Medical Center|Yes|Completed|September 2011|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419691||99626|
NCT01415843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0504/80|Observation of Physiotherapy Treatment Sessions - Exploring What Happens in Physiotherapy for Patients After Stroke.|Do Implicit and Explicit Learning Strategies Applied During Gait Re-education Influence Concurrent Expression of Associated Reactions in Individuals With Hemiplegia? Phase 1a||University of Southampton|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with stroke will be recruited from two NHS Trusts - Royal Bournemouth and        Christchuch Hospitals NHS Foundation Trust and Southampton City Primary Care Trust.|July 2009|August 11, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01415843||99920|
NCT01416584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIDA-23864-1|A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment|||Johns Hopkins University|No|Active, not recruiting|October 2008|April 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|162|||Both|18 Years|65 Years|No|||April 2010|March 25, 2013|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416584||99863|
NCT01416805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS018665|Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers|Utilizing Health Information Technology to Improve Health Care Quality: Implementation of a Computerized Cognitive Behavioral Therapy Protocol for Childhood Anxiety||University of South Florida|No|Completed|August 2011|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|188|||Both|7 Years|13 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416805||99846|
NCT01416818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008XYRCT|Treatment of Depression in Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled Study of "Xiaoyao Pill" Treatment of Depression in Patients With Parkinson's Disease||Xuanwu Hospital, Beijing|No|Recruiting|May 2008|December 2011|Anticipated|October 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|30 Years|80 Years|No|||August 2011|August 11, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416818||99845|
NCT01417156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.40|Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)|A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis||Boehringer Ingelheim||Completed|September 2011|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|N/A|No|||November 2015|November 30, 2015|August 15, 2011||||No||https://clinicaltrials.gov/show/NCT01417156||99820|
NCT01417650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89342|The Effect of Low Level Laser Therapy on Improvement of Temporomandibular Joint Osteoarthritis|A Randomized Clinical Trial of the Effect of Low Level Laser Therapy on Improvement of Temporomandibular Joint Osteoarthritis||Mashhad University of Medical Sciences|Yes|Active, not recruiting|January 2011|January 2012|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|60 Years|No|||June 2010|August 15, 2011|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417650||99783|
NCT01417663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT-711-0529B|Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and Function|Combining Exercise Training With a Drug to Break AGE-crosslinks; Effects on Cardiovascular Structure and Function and Related Mechanisms||Radboud University|Yes|Completed|November 2008|June 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 6, 2013|June 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417663||99782|
NCT01417676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRRO IP080210|DAPROCA Pelvic Lymph Node Irradiation to Prostate for High Risk Prostate Cancer: Phase I/II Study|Pelvic Lymph Node Irradiation With Simultaneous Integrated Boost to Prostate for High Risk Prostate Cancer Patients: A Phase I/II Study|Propel|University of Aarhus|No|Active, not recruiting|April 2011|December 2021|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Male|18 Years|75 Years|No|||November 2012|November 22, 2012|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417676||99781|
NCT01417390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSHNG-1108|Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma|Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma||First People's Hospital of Foshan|Yes|Recruiting|November 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||March 2014|March 6, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417390||99802|
NCT01418196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-3462|Relation of Diet to Heart Disease Risk Factors in Children|Relation of Diet to Heart Disease Risk Factors in Children||Children's Hospital & Research Center Oakland|Yes|Completed|September 2011|July 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Actual|92|||Both|7 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population will consist of children (>7 years of age) and their parents who are        generally healthy. Parents are not required to participant in the study. We will include        all ethnicities.|March 2015|March 25, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418196||99741|
NCT01418209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MsFLASH-03|MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms|MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms||Fred Hutchinson Cancer Research Center|Yes|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|339|||Female|40 Years|62 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|August 15, 2011|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01418209||99740|Findings may be specific to the particular dose of each agent used, treatment period, as well as the preparation and oral administration of estrogen therapy.
NCT01403038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-673|An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females|A Phase 1, Open-Label Study of the Effects of Elagolix on Ovarian Activity, Ovulation and Ovarian Reserve in Premenopausal Females||AbbVie|No|Completed|June 2011|November 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|7||Actual|216|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|June 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01403038||100899|
NCT01403324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOSIMETA IGR2010/1645|Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer|Comparison of Dosimetry Following Preparation With Either rhTSH or After Withdrawal of Thyroid Hormone Suppression Therapy in Patients With Metastatic or Locally Advanced Differentiated Thyroid Cancer|DOSIMETA|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|35|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403324||100877|
NCT01403623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 003|Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates|A Randomized Trial to Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates in Developing Countries||University of Alabama at Birmingham|Yes|Completed|August 2011|December 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|106|||Both|N/A|N/A|No|||August 2013|August 19, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01403623||100854|
NCT01403857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 235561-1|Evaluating Liking, Acceptability and Health Benefits of Grain Products|Evaluating Liking, Acceptability and Health Benefits of Grain Products|FL75|USDA, Western Human Nutrition Research Center|No|Completed|April 2010|December 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|45|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 21, 2014|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01403857||100836|
NCT01404156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA 174431-7|Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma|PreOperative Treatment With chEmotheRapy or chemoRAdiatioN in esophaGeal or gastroEsophageal adenocaRcinoma|POWERRANGER|CancerCare Manitoba|Yes|Recruiting|September 2015|February 2018|Anticipated|February 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||October 2015|October 22, 2015|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404156||100813|
NCT01404715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6367|Drug-drug Interaction Study With Metformin and Imatinib|Pharmacokinetic Interaction Between Metformin and Imatinib in Healthy Volunteers.||University of California, San Francisco|Yes|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|11|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404715||100770|
NCT01418742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMIHO-010/2009|SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment|SKIP - A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects With Advanced or Metastatic Colorectal Carcinoma Receiving Panitumumab||Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|No|Terminated|August 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||March 2013|July 11, 2014|August 3, 2011||No|Recruitement did not meet expectations. Prev. differentiation of RAS-wild-type and mutated RAS    are not in accordance with the scientific rank anymore.|No||https://clinicaltrials.gov/show/NCT01418742||99699|
NCT01419340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-116|Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Aricept® (Donepezil Hydrochloride) Tablets 10mg [Reference Formulation, Eisai Inc.), in Healthy Human Volunteers Under Fasting Conditions.||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 17, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419340||99653|
NCT01419704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-13881-012011|Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies|Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies||University of Louisville|Yes|Suspended|May 2011|May 2030|Anticipated|May 2025|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|45 Years|No|||November 2015|November 2, 2015|August 16, 2011|Yes|Yes|Study completed at site, no active participants. IDE open for future enrollment|No||https://clinicaltrials.gov/show/NCT01419704||99625|
NCT01419730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34834|Vitamin D and Physical Activity on Bone Health|The Effect of High-Dose Vitamin D and Physical Activity on Bone Health in Breast Cancer Patients Receiving Hormonal Therapy||University of Rochester|Yes|Recruiting|August 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|105|||Female|18 Years|99 Years|No|||October 2015|October 22, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01419730||99623|
NCT01419314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16196|Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy|Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy||Texas Woman's University|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|August 10, 2011||No||No|September 13, 2012|https://clinicaltrials.gov/show/NCT01419314||99655|The contrast between the splinting group and liner group was statistically underpowered. The data was collected and analyzed by the primary investigator. The clinical diagnosis of peripheral neuropathy was not confirmed with EMG or punch skin biopsy.
NCT01420003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-GNE-07222011|Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics|Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics||Hamilton Health Sciences Corporation|No|Completed|November 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420003||99602|
NCT01416324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114985|First Time in Human Study Using GSK2330672|A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers||GlaxoSmithKline|No|Completed|June 2011|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|March 8, 2012|June 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416324||99883|
NCT01416831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-062A|Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.|Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma|SBRT/IL-2|Providence Health & Services|No|Recruiting|July 2011|October 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|August 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416831||99844|
NCT01416844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH&S IRB 10-090|Study of Immune Responses in Patients With Metastatic Melanoma|Phase II Exploratory Study of Immune Responses in Patients With Metastatic Melanoma Treated With Mouse Monoclonal Anti-OX40||Providence Health & Services|No|Withdrawn|September 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|August 12, 2011|Yes|Yes|Change in the development plan for the anti-OX40 antibody.|No||https://clinicaltrials.gov/show/NCT01416844||99843|
NCT01417143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1012-047-344|Dovitinib in Adenoid Cystic Carcinoma|Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma||Seoul National University Hospital||Completed|September 2011|November 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01417143||99821|
NCT01417403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13713|Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases|A Phase 1 Study of Hydroxychloroquine in Patients With Solid Tumors Receiving Radiotherapy for Bone Metastases||Virginia Commonwealth University|Yes|Terminated|August 2011|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2015|February 1, 2015|August 10, 2011|No|Yes|Recently published data that has shown HCQ to be safe when combined with chemo and or    radiation at even higher doses than what is used in this study.|No||https://clinicaltrials.gov/show/NCT01417403||99801|
NCT01417416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/08/236|Changes in the Permeability of the Blood Brain Barrier and Intestinal Barrier in Humans During Conditions of Stress and Immune Activation: in Vivo Studies|||National University Hospital, Singapore||Completed||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Male|18 Years|50 Years||Probability Sample|Healthy male troops during combat training|February 2009|August 15, 2011|August 15, 2011||||No||https://clinicaltrials.gov/show/NCT01417416||99800|
NCT01417962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR07|Magnetic Resonance Imaging Autopsy Study|Post Mortem Magnetic Resonance Imaging in the Fetus, Infant and Child: A Comparative Study With Conventional Autopsy|MARIAS|Thayyil, Sudhin|No|Completed|March 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|N/A|18 Years|No|Non-Probability Sample|This study will be performed across two hospital sites: Great Ormond Street Hospital for        Children (GOSH) and University College London Hospitals (UCLH). Both of these hospitals        are associated with a single academic institution - University College London (UCL).        Consecutive fetuses, newborns and children referred for autopsy at these two hospitals        will be eligible for recruitment. All recruited cases will have conventional post-mortem        MR imaging at 1.5 Tesla and conventional autopsy. CT imaging will be performed in        suspected traumatic injuries and skeletal dysplasias.|April 2013|April 19, 2013|August 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01417962||99759|
NCT01418222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27827|FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer|Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer||Genentech, Inc.||Completed|September 2011|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418222||99739|
NCT01418235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 086/SAAVI 103|Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults|A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Subtype C gp140 With MF59 Adjuvant in Various Vaccination Schedules in HIV-uninfected Healthy Vaccinia-naïve Adult Participants in South Africa||HIV Vaccine Trials Network|Yes|Active, not recruiting|June 2011|June 2015|Anticipated|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|184|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|June 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01418235||99738|
NCT01403051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5280|High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART|A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)||AIDS Clinical Trials Group|Yes|Completed|September 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|167|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 25, 2011|Yes|Yes||No|February 5, 2014|https://clinicaltrials.gov/show/NCT01403051||100898|
NCT01403337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|411652941|Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery|Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery (CRIPES)|CRIPES|Minnesota Veterans Research Institute|Yes|Completed|July 2011|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403337||100876|
NCT01403870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001|Post Market Study of the Electrophysiological Course of Low Back Pain Using CERSR Technology|Post Market Study of the Electrophysiological Course of Low Back Pain Using CERSR Technology||Verium Diagnostics, Inc.|No|Terminated|April 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|70 Years|No|Non-Probability Sample|Test subjects will be recruited from individuals who are currently have Volusia Health        Network (VHN) medical coverage.|November 2011|November 17, 2011|July 25, 2011||No|Company no longer has funding for the study.|No||https://clinicaltrials.gov/show/NCT01403870||100835|
NCT01404169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-C086-339|A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease|A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease||Eisai Inc.||Completed|September 2011|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|313|||Both|50 Years|90 Years|No|||November 2015|November 2, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404169||100812|
NCT01404468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84-7.33|The Phonophoresis of Lidocaine Gel and Its Effect on Sensory Blockage|Effect of Lidocaine Phonophoresis on Sensory Blockade: Pulsed or Continuous Mode of Therapeutic Ultrasound?||Shiraz University of Medical Sciences|Yes|Completed|March 2006|October 2010|Actual|September 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|93|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||March 2011|July 27, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01404468||100789|
NCT01404442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12611000729921|Evaluation of the Analgesic Effect of Midazolam and Ketamine as an Additive to Intrathecal Bupivacaine in Patients Undergoing Cesarean Section|||Qazvin University Of Medical Sciences|Yes|Completed|May 2011|December 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Female|18 Years|45 Years|No|||May 2012|May 16, 2012|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404442||100791|
NCT01419067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2CR|A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection|A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection||St. Jude Children's Research Hospital|No|Recruiting|August 2011|August 2022|Anticipated|August 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|N/A|21 Years|No|||March 2016|March 8, 2016|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419067||99674|
NCT01420016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-096|Prioritized Clinical Decision Support to Reduce Cardiovascular Risk|Prioritized Clinical Decision Support to Reduce Cardiovascular Risk||HealthPartners Institute|Yes|Completed|July 2012|July 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|29950|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|November 25, 2015|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420016||99601|
NCT01419717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110113|Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer|Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer||Amgen|No|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01419717||99624|
NCT01419990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-102|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects|Double-blind Placebo Controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Dosing of GLPG0634 in Healthy Subjects||Galapagos NV|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419990||99603|
NCT01416077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USANOP001|Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection|Perioperative Goal Directed Fluid Therapy During Esophageal Resection A Prospective Randomized Controlled Open Multi-centre Trial to Study the Effect on Postoperative Complications||University Hospital, Linkoeping|Yes|Completed|October 2011|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||June 2015|December 1, 2015|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416077||99902|
NCT01416311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114877|Drug Use Investigation for REVOLADE (ITP)|Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)||Novartis|No|Active, not recruiting|December 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|All Japanese subjects with chronic idiopathic thrombocytopenic purpura who recieve        REVOLADE|March 2016|March 16, 2016|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01416311||99884|
NCT01416597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115997|A Systematic Review of Studies of the Effect of Influenza Vaccine Against Mismatched Strains|Effect of Influenza Vaccine Against Mismatched Strains: Systematic Review||GlaxoSmithKline||Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|N/A||1|Actual|1|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects vaccinated with an influenza vaccine.|December 2012|December 13, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416597||99862|
NCT01417169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-1102|Micafungin Prevention Study for Invasive Fungal Disease in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation|Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation||Seoul National University Hospital|Yes|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|112|||Both|N/A|21 Years|No|||July 2014|July 11, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01417169||99819|
NCT01388335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9763|A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin|The Effect of Enzastaurin on CYP2C9: Enzastaurin - S-Warfarin Drug Interaction Study in Patients With Cancer||Eli Lilly and Company|No|Completed|August 2011|December 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|60 Years|No|||December 2012|December 17, 2012|July 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01388335||102025|
NCT01388348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mmc 022-2011|Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study|Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration "Holter" in Comparison to Pressure Flow Study||Meir Medical Center|No|Not yet recruiting|July 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|100|||Male|18 Years|N/A|No|||July 2011|July 4, 2011|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01388348||102024|
NCT01417429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1001006227|Galantamine Effects on Nicotine Responses in Smokers|Galantamine Effects on Nicotine Responses in Smokers||Yale University|Yes|Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|No|||July 2015|July 7, 2015|April 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417429||99799|
NCT01417442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/5|BRAF V600E Mutations In Papillary Thyroid Carcinoma|Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma||Bezmialem Vakif University|No|Recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|N/A|N/A|No|||August 2011|August 13, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01417442||99798|
NCT01417689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oftalmo_Glaucoma_001|Eyedrop Instillation Technique|Eyedrop Instillation Technique: A Randomizaed Controlled Trial||Oftalmologia Hospital Sotero del Rio|No|Recruiting|August 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||August 2011|August 15, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417689||99780|
NCT01418248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004186|Study of Exercise and Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease|Evaluation of Exercise Intolerance and Right Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease|EXEC|Mayo Clinic|No|Completed|August 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|Samples With DNA|Serum, plasma|Both|18 Years|N/A|No|Non-Probability Sample|Cardiac Catheterization Laboratory|January 2014|January 8, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418248||99737|
NCT01403350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5911|Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan|Effectiveness of Community Level Deployment of Rapid Diagnostic Tests for Malaria in Afghanistan: Cluster Randomised Trial||London School of Hygiene and Tropical Medicine|Yes|Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|2421|||Both|N/A|N/A|No|||February 2014|February 6, 2014|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403350||100875|
NCT01403636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD12130|A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia|A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma||Sanofi|Yes|Completed|October 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|167|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403636||100853|
NCT01404182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FluvalAB-H-YL2011|Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons|Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine (Trivalent, Seasonal, Active Ingredient Content: 15 μg HA/Strain/0.5 mL) in Adults and Elderly Persons||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|121|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 18, 2012|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404182||100811|
NCT01404494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110137|Testing Devices That Involve the Sense of Touch in Subjects With Traumatic Brain Injury|Testing Subjects With Traumatic Brain Injury Using Haptic Technology||National Institutes of Health Clinical Center (CC)||Completed|April 2011|February 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|19|||Both|18 Years|N/A|No|||February 2015|February 7, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404494||100787|
NCT01413854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eudraCT number 2010-021024-10|Diclofenac add-on to Treatment as Usual for Suicidal Patients|"Antiinflammatoriska läkemedels Effekt för Att Minska Suicidalitet Hos Deprimerade Patienter Som Nyligen Har Gjort självmordsförsök"||Region Skane|Yes|Not yet recruiting|August 2011|||April 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||August 2011|August 10, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413854||100070|
NCT01404767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0713-A|Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol|Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol: A Study Comparing the Post Op Continuation of the Preoperative Oral Dose Beta Blockers to Intravenous Esmolol Titrated to a Target Heart Rate (HR)||University Health Network, Toronto|Yes|Terminated|April 2011|December 2013|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|80 Years|No|||April 2015|April 17, 2015|June 21, 2011||No|Enrollment slow over 2 years a change in the population less on metoprolol than initially    anticipated|No||https://clinicaltrials.gov/show/NCT01404767||100766|
NCT01405027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDF-MER-001-00|Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy|Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program|OPTIMAL|Chronic Liver Disease Foundation|Yes|Completed|December 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|July 25, 2011|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01405027||100746|Smaller sample size than expected due to changing treatment landscape for HCV during course of study.
NCT01404455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1-2010-0039|Effect of Wide Pulse Pressure on the Predictability of Stroke Volume Variation for Fluid Responsiveness in Patients Undergoing Off-pump Coronary Artery Bypass Graft|||Severance Hospital||Completed|December 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|66|||Both|20 Years|N/A|No|||January 2012|January 16, 2012|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01404455||100790|
NCT01419353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antagonist_prog|Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol|Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol||Meir Medical Center|No|Completed|August 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Female|N/A|38 Years|Accepts Healthy Volunteers|||August 2011|December 23, 2013|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01419353||99652|
NCT01419366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-07-132|Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Aricept® (Donepezil Hydrochloride) Tablets 10mg [Reference Formulation, Eisai Inc.), in Healthy Human Volunteers Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 21, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419366||99651|
NCT01420029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0664|Hospital-Based Phthalate Exposure in Very Low Birth Weight Neonates|Hospital-Based Phthalate Exposure in Very Low Birth Weight Neonates||Icahn School of Medicine at Mount Sinai|No|Completed|August 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|Samples With DNA|Urine, whole blood|Both|N/A|N/A|No|Non-Probability Sample|Neonates born at birthweights less than 1500 grams will be included.|September 2013|September 19, 2013|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420029||99600|
NCT01415856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Salvagno 20100977|Use of Pulsed Electromagnetic Fields for Postoperative Knee Pain|A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Non-Invasive Pulsed Electromagnetic Fields (PEMF) on Postoperative Pain Following Total Knee Arthroplasty||Center for Joint Surgery and Sports Medicine, Maryland|Yes|Recruiting|October 2010|||May 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2011|August 11, 2011|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01415856||99919|
NCT01416090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12534|Syndactyly Repair: Comparison of Skin Graft and No Skin Graft Techniques|Syndactyly Repair: Comparison of Skin Graft and No Skin Graft Techniques||University of Utah|No|Active, not recruiting|July 2004|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|6 Months|6 Years|No|Non-Probability Sample|Syndactyly is a relatively common congenital abnormality of the hand occurring        approximately 1 out of 2500 live births. We will utilize children under the age of 6 years        and over the age of 6 months. Most will likely be less than 2.5 years of age. This surgery        is usually performed when the patient is still a child.|February 2016|February 2, 2016|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01416090||99901|
NCT01416337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115064|Absolute Bioavialability of GSK1120212|Determination of the Absolute Bioavailability of GSK1120212 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microdose of GSK1120212 in Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||March 2012|April 12, 2012|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416337||99882|
NCT01416857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004006652|Emergency Department (ED) Disability Diagnostic Tool|ED Disability Diagnostic Tool: a Health Information Technology Feasibility Study||Yale University|No|Completed|August 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|635|||Both|65 Years|N/A|No|||July 2014|July 8, 2014|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416857||99842|
NCT01417182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1057|Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer|Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA Based PET in Patients With Advanced Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2010|||September 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|10|||Male|18 Years|90 Years|No|||June 2014|June 16, 2014|November 8, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417182||99818|
NCT01388361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3948|Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin|A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart With the Largest Meal to Insulin Degludec, Both in Combination With Metformin, in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification (BEGIN™: VICTOZA® ADD-ON)|BEGIN™|Novo Nordisk A/S|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|413|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|July 4, 2011|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01388361||102023|
NCT01388621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMIHO-008/2009_AG56|Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer|PROVE A Randomized Phase II Trial of Standard Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer|PROVE|WiSP Wissenschaftlicher Service Pharma GmbH|Yes|Recruiting|October 2011|July 2015|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||August 2013|August 19, 2013|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01388621||102003|
NCT01388582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/2011/PC|The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth|The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women||University of Campinas, Brazil|No|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01388582||102006|
NCT01388868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-010|Strategy for Maintaining Partial Neuromuscular Blocking Adequate for Motor Evoked Potential During Neurosurgery|Determination of ED50 and ED95 of Vecuronium Infusion Dose for Maintaining Response of Train of Four Less Than 2 During the MEP Monitoring for Neurosurgery||Samsung Medical Center|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|90|||Both|20 Years|70 Years|No|||May 2012|May 11, 2012|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01388868||101984|
NCT01403649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0589|Collaborative Efforts to Increase Flu Vaccination|Strategies to Vaccinate All Children for Influenza in a Practice Setting|CollabFlu|University of Colorado, Denver|No|Completed|August 2009|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|117175|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01403649||100852|
NCT01403883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UK10005|Psychological and Enterostomal Therapy Care|Impact of Psychological and Enterostomal Therapy Care for Patient Undergoing Rectal Cancer Resection With a Temporary Stoma. Monocentric Randomized Study|PROSPER|Association de Recherche Experimentale et Clinique en Chirurgie Digestive|No|Recruiting|October 2011|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|75 Years|No|||January 2015|January 15, 2015|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01403883||100834|
NCT01403896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC001|Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor|A Pilot Study To Design a Clinical Trial That Will Compare the Ability of Plerixafor Alone Versus Plerixafor Plus G-CSF To Generate a Bone Marrow Versus Blood Transplant Product In Normal Healthy Adults||Nova Scotia Health Authority|No|Not yet recruiting|September 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2011|July 26, 2011|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403896||100833|
NCT01404481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/STG/176|Clean Intermittant Self Catheterisation: A Trial Comparing Single Use vs Reuse of Nelaton Catheters|Clean Intermittant Self Catheterisation: A Randomised Control Trial Comparing Single Use vs Reuse of Nelaton Catheters|SURE|St George Hospital, Australia|No|Completed|March 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|23|||Both|18 Years|N/A|No|Probability Sample|Continence clinic, community patients, hospital patients|July 2015|July 22, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404481||100788|
NCT01414166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-108|Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)|A 16-Week, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Extended Release Niacin/Laropiprant in South and Southeast Asians Not on a Lipid Modulating Agent, With Decreased High-Density Lipoprotein Cholesterol and Low- Density Lipoprotein Cholesterol at or Below NCEP ATP III Goal||Merck Sharp & Dohme Corp.|No|Terminated|September 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|August 9, 2011|Yes|Yes|In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a    significant increase in incidence of some types of non-fatal SAEs|No|November 21, 2013|https://clinicaltrials.gov/show/NCT01414166||100049|Due to the small number of participants completing the study (n=70), the resulting underpowered nature of any analyses that might be conducted, and the fact that data are not going to be used, no efficacy analyses were performed.
NCT01413867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No sponsor|Safety and Short Term Effectiveness of EEA Versus PPH Stapler for III Degree Hemorrhoids|Safety and Short Term Effectiveness of EEA Stapler vs PPH Stapler in the Treatment of III Degree Haemorrhoids. Prospective Randomized Controlled Trial|EEA/PPH2011|Societa Italiana di Chirurgia ColoRettale|No|Completed|March 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||December 2013|December 10, 2013|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413867||100069|
NCT01414426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0265|Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions|Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck||University of Chicago|No|Recruiting|January 2012|January 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|54|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414426||100029|
NCT01414686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robert Wood Johnson Foundation|Virtual Environment Rehabilitation for Chronic Stroke|Commercially-Available Interactive Video Games for Individuals With Chronic Mobility and Balance Deficits Post-Stroke|VEHAB|University of South Carolina|No|Completed|May 2008|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2011|August 10, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01414686||100009|
NCT01404754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1|Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers|A Phase 1 Placebo-Controlled, Double-Blind Crossover Study to Assess Psychological Effects of MDMA When Administered to Healthy Volunteers|MT-1|Multidisciplinary Association for Psychedelic Studies|No|Enrolling by invitation|March 2011|October 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2015|October 2, 2015|July 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01404754||100767|
NCT01419743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moy 2011 Vit D|Effect of Vitamin D Supplementation on In-vitro Fertilization (IVF) Outcomes|Randomized Controlled Trial: The Effects of Vitamin D Supplementation on In-vitro Fertilization Outcomes||Northwestern University|No|Terminated|August 2011|January 2014|Actual|January 2014|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|102|||Female|18 Years|38 Years|No|Non-Probability Sample|Infertile women aged ≤ 38 years undergoing fresh in-vitro fertilization cycles|February 2014|February 16, 2014|August 16, 2011||No|Low recruitment numbers|No||https://clinicaltrials.gov/show/NCT01419743||99622|
NCT01416103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61110- 1986 (tryg, p7)|Alcohol and Employment|Alcohol and Employment - a Randomized Controlled Trial||University of Southern Denmark|Yes|Completed|October 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|113|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416103||99900|
NCT01415869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003334|Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients|Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients||Mayo Clinic|No|Recruiting|July 2011|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|N/A||2|Anticipated|195|||Both|18 Years|N/A|No|Non-Probability Sample|-  Group 1 Patients with implanted non-pulsatile ventricular assist devices of any type             and at any time after implantation          -  Group 2 Patients with usual VAD indications will be invited to participate, when, in             the opinion of their treating physician a VAD will be highly likely within one month.|April 2014|April 16, 2014|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01415869||99918|
NCT01415882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1181|Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib|Phase 2 Trial of MLN9708 (Ixazomib) in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib||Mayo Clinic|Yes|Recruiting|January 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|144|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01415882||99917|
NCT01416610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25159|An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy|A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD) Plus COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing an Opioid Maintenance-Therapy With Special Focus on Patient Compliance and Quality of Life|PEGHOPE|Hoffmann-La Roche|No|Completed|April 2010|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|No|Probability Sample|Participants with chronic hepatitis C (CHC), Genotype 2, 3, 1 or 4, undergoing an opioid        maintenance therapy|November 2015|November 4, 2015|August 12, 2011||No||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01416610||99861|
NCT01416623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNTN-I|A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies|A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies||Jiangsu HengRui Medicine Co., Ltd.|Yes|Terminated|September 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|70 Years|No|||December 2012|December 20, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416623||99860|
NCT01416870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6874L00012|Bioequivalence of Bicalutamide New Formulation in Japan|Bioequivalence Study of ICI176,334-1 (Bicalutamide New Formulation) in Japanese Healthy Male Subjects - Evaluation of Bioequivalence of ICI176,334-1 and Casodex Tablet (80mg)||AstraZeneca||Terminated|July 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|102|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416870||99841|
NCT01388114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010020R|Clinical Evaluation of e- Ab Sensor - Based Real-time Diagnosis of Serum Procalcitonin Level|Clinical Evaluation of e- Ab Sensor - Based Real-time Diagnosis of Serum Procalcitonin Level||National Taiwan University Hospital|No|Completed|November 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|200|||Both|18 Years|N/A|No|||November 2012|November 15, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388114||102042|
NCT01388634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Køge hospital|Prolonged Hospital Stay and Readmission After Elective Ventral Hernia Repair|Nationwide Analysis of Prolonged Hospital Stay and Readmission After Elective Ventral Hernia Repair|LOSHERNIA|University Hospital Koge|No|Completed|June 2010|August 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2258|||Both|18 Years|N/A|No|Non-Probability Sample|All patients registered in The Danish Ventral Hernia Database in 2008|November 2011|November 30, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01388634||102002|
NCT01388595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAI002|Fluticasone and Salmeterol in Allergic Rhinitis|A Proof of Concept Study to Evaluate Effects of Intranasal Salmeterol and Fluticasone Given Alone and in Combination in Allergic Rhinitis||University of Dundee|Yes|Completed|November 2006|October 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|65 Years|No|||December 2013|April 21, 2014|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388595||102005|
NCT01388881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0433/10|Effects of Music Education for Children With Reading Difficulties|Effects of Music Education on Domain of Reading and Cognitive Abilities in Children With Reading Difficulties: a Cluster Randomized Clinical Trial||Federal University of São Paulo|Yes|Active, not recruiting|March 2011|December 2011|Anticipated|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|270|||Both|8 Years|10 Years|No|||July 2011|July 22, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01388881||101983|
NCT01412723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFHA-01|Ferrous Sulfate Versus Iron Amino Acid Chelate|EFICACIA DEL HIERRO AMINOQUELADO COMPARADO CON EL SULFATO FERROSO COMO COMPLEMENTO ALIMENTARIO EN PREESCOLARES CON DEFICIENCIA DE HIERRO.||CES University|No|Completed|October 2011|April 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|64|||Both|2 Years|5 Years|No|||April 2012|April 10, 2012|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01412723||100156|
NCT01412996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Single access chOLECYSTECTOMY|Quality of Life Measures After Single Access Vs Conventional Laparoscopic Cholecystectomy: Prospective Randomized Study.|Single Access Laparoscopic Cholecystectomy||Mansoura University|Yes|Completed|November 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 24, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01412996||100135|
NCT01413243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIOMS-01|Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome|Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial|TRIOMS|Charite University, Berlin, Germany|No|Recruiting|September 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||May 2015|May 7, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413243||100117|
NCT01413529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00049374|HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users|HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users||University of Maryland|No|Not yet recruiting|September 2011|September 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|65 Years|No|||August 2011|August 9, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413529||100095|
NCT01413542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL079184|Pharmacogenetics of Ace Inhibitor-Associated Angioedema|Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1||Vanderbilt University|Yes|Completed|November 2011|July 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|August 8, 2011|Yes|Yes||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01413542||100094|
NCT01414439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-chf|Group Psychotherapy Among Congestive Heart Failure Patients|Group Psychotherapy Among Congestive Heart Failure Patients as a Way to Reduce Psychological Distress and Increase Psycho-social Adjustment||Meir Medical Center|No|Not yet recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|patients diagnosed with heart failure disorder at levels III and IV|August 2011|August 27, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01414439||100028|
NCT01414699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8585B|The Influence of Dietary Variety and Course Sequence on Fruit Intake in Preschool-Aged Children|The Influence of Dietary Variety and Course Sequence on Fruit Intake in Preschool-Aged Children||University of Tennessee|No|Completed|August 2011|December 2015|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414699||100008|
NCT01405313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA231210|Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV|Comparison of Modified Adaptive Servoventilation Therapy With Conventional Adaptive Servoventilation Therapy in Patients With Periodic Breathing||ResMed|No|Recruiting|July 2011|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|21 Years|N/A|No|||March 2012|March 13, 2012|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01405313||100724|
NCT01415895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT110491|Efficacy of ATNC05 in Reducing Back Pain Compared With Placebo|ATNC05, A Composition to Reduce Back Pain, A Proof-of-Concept, Randomized, Double-Blind - Placebo Controlled Study||Allodynic Therapeutics, LLC|Yes|Completed|July 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|19 Years|70 Years|No|||June 2014|June 24, 2014|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01415895||99916|
NCT01416116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTZ-EC-0002|Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch|Tolerability of QUTENZATM When Applied After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A Randomized, Multi-center, Assessor-blinded Study|LIFT|Astellas Pharma Inc|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|90 Years|No|||January 2016|January 7, 2016|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416116||99899|
NCT01416129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6140101600|Southern Bone & Joint Study - Brimless Sockets|Biomechanical Superiority of Brimless Versus Ischial Ramus Containment (IRC) Sub Atmospheric Transfemoral Interfaces||University of South Florida|No|Completed|October 2010|October 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 6, 2014|August 11, 2011||No||No|October 19, 2012|https://clinicaltrials.gov/show/NCT01416129||99898|
NCT01416350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115360|A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin|A Single and Repeat Dose Pharmacokinetics/ Pharmacodynamics (PK/PD) Study to Characterise theBiomarker Response in Healthy Subjects Treated With the AntiinflammatoryMacrolide Azithromycin||GlaxoSmithKline|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01416350||99881|
NCT01416636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116-02|Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)|A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH)|CTREPH|SciPharm SàRL|No|Recruiting|March 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416636||99859|
NCT01387828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOB 01-11|Comparison Between Open and Laparoscopic Splenic Aneurysms Repair|Prospective Randomized Comparison of Open Versus Laparoscopic Management of Splenic Artery Aneurysms. A Ten-Year Study||Azienda Ospedaliera Spedali Civili di Brescia|Yes|Completed|January 2001|April 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|N/A|N/A|No|||June 2011|July 6, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387828||102064|
NCT01388127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0048-11 WOMC|Minocycline Treatment in Acute Hemorrhagic Stroke|Minocycline Treatment in Acute Hemorrhagic Stroke for Evaluation of Treatment Efficacy and Blood Brain Barrier Permeability|Minocycline|Wolfson Medical Center|No|Not yet recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|90 Years|No|Probability Sample|150 patients after acute hemorrhagic stroke. Half treated with Minocycline.|June 2011|July 5, 2011|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01388127||102041|
NCT01389154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMT-SPiN_01|Pilot Study to Measure Lung Biopsy Diagnostic Yield Using Always On Electromagnetic Tip Tracked Devices|A Pilot Prospective Study Evaluating the SPiN Drive(TM)Electromagnetic Tip Tracked Devices Used in Diagnostic Bronchoscopy|ALOSPNDY|Veran Medical Technologies|Yes|Withdrawn|June 2011|November 2011|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|0|||Both|50 Years|N/A|No|||July 2014|July 16, 2014|July 1, 2011|Yes|Yes|Product Enhancements completed|No||https://clinicaltrials.gov/show/NCT01389154||101962|
NCT01385410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26370|Providing Peer Mother Support Through Cell Phone and Group Meetings to Increase Exclusive Breastfeeding in Kenya|Effectiveness of a Baby-friendly Hospital Based Mothers' Support Group, and a Cell-phone Based Peer Support Program in Supporting Exclusive Breastfeeding in an Urban Kenyan Community.||University of Toronto|No|Completed|June 2011|January 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|3||Actual|823|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 24, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385410||102247|
NCT01413009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|590-10|Awakening-Breathing Coordination, Delirium Monitoring/Management & Early Mobility (ABCDE) Protocol|Awakening-Breathing Coordination, Delirium Monitoring/Management & Early Mobility (ABCDE) Protocol|ABCDE|University of Nebraska|No|Active, not recruiting|November 2010|October 2013|Anticipated|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|19 Years|N/A|No|Non-Probability Sample|Critical care services|January 2013|January 3, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01413009||100134|
NCT01413256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015-11-RMB|Allergenic Effect of Ambrosia in Israel|||Rambam Health Care Campus|No|Not yet recruiting|October 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|respiratory allergic patients|August 2011|August 9, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413256||100116|
NCT01413555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHRPP - 101722|Multicenter Blood Culture Quality Improvement|Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department||Vanderbilt University|No|Completed|August 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14889|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413555||100093|
NCT01414179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00549-30|NESCAV Nutrition Environment and Cardiovascular Health|Nutrition Environnement et Santé Cardio Vasculaire NESCAV|NESCAV|Central Hospital, Nancy, France|No|Recruiting|October 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|800|Samples Without DNA|Blood and urinary biological taking away: glycemia, HbA1C, insulin (specific study      analyzes), total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,      apolipoproteines A1 and B, numeration of blood picture, creatinin, uric acid, gamma WP, GOT,      GPT, CRP; and a urinary collection (a micturition) in order to proportion the      microalbuminurie. A plasmathèque will be made up, in order to measure later on biomarqueurs      of the cardiovascular risk (biological collection stored with the CIC). A measurement of      pollutants and poisons will be carried out starting from taking away of hair.|Both|18 Years|69 Years|Accepts Healthy Volunteers|Probability Sample|general population|August 2010|August 10, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414179||100048|
NCT01414452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAntwerpen|Role of Adiponectin and Endothelial Progenitor Cells in Reperfusion Injury in Patients With Acute Myocardial Infarction|Reperfusion Injury and Cardiac Remodelling After Myocardial Infarction in Relation to Adiponectin Level, Circulating Endothelial Progenitor Cells and Endothelial Microparticles|R²ACE|Universiteit Antwerpen|No|Completed|April 2011|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|Samples Without DNA|blood samples|Both|N/A|N/A|No|Probability Sample|ST elevetion myocardial infarction patients|July 2015|July 19, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414452||100027|
NCT01414712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 032011-212|Circulating Tumor Cells in Prostate Cancer Patients|Circulating Tumor Cells in Patients Undergoing Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer||University of Texas Southwestern Medical Center|Yes|Terminated|July 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|Samples Without DNA|blood|Male|18 Years|N/A|No|Non-Probability Sample|Low- and Intermediate-Risk Prostate Cancer wo undergo stereotactic body radiation therapy|March 2013|March 4, 2013|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01414712||100007|
NCT01414959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dori_MD_ICU|Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients|Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients||Medical University of Vienna|No|Recruiting|August 2011|July 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|Samples Without DNA|plasma broncheoalvoeolar lavage microdialysates|Both|18 Years|N/A|No|Non-Probability Sample|intubated patients, intensive care|September 2011|September 5, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414959||99988|
NCT01415245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-01-01|Vein External Support Trial|Vein External Support Trial|VEST|Vascular Graft Solutions Ltd.|Yes|Completed|October 2011|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|50 Years|80 Years|No|||May 2014|May 18, 2014|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415245||99966|
NCT01414933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRT01/0710 SAFIR-01|High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents|High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents|SAFIR-01|UNICANCER|Yes|Completed|May 2011|May 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|423|Samples With DNA|Metastasis biopsy and DNA from biopsy|Both|18 Years|70 Years|No|Non-Probability Sample|women or men with metastatic breast cancer|January 2014|January 10, 2014|June 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01414933||99990|
NCT01415908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medtronic P05-06|INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine|A Prospective, Multi-center, Pivotal Trial for INFUSE® Bone Graft With CAPSTONE® Spinal System and Posterior Supplemental Fixation to Treat 1- or 2-level Advanced Degenerative Disease of the Lumbosacral Spine For a TLIF Approach|TLIF|Medtronic Spinal and Biologics|Yes|Terminated|July 2011|January 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 10, 2011|Yes|Yes|Due to study design challenges including DMC enrollment suspension as required by the protocol    stopping rules and recommended changes to the surgical technique|No|September 25, 2015|https://clinicaltrials.gov/show/NCT01415908||99915|A total of 534 ± 10 subjects were planned for enrollment. However, this study was terminated early with only 15 enrolled patients, leading to small numbers of subjects analyzed.
NCT01415921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL103988-01A1|Safety Study of Pyridostigmine in Heart Failure|Augmentation of Parasympathetic Signaling With Pyridostigmine in Heart Failure|APP-HF|New York University School of Medicine|Yes|Active, not recruiting|October 2011|February 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|75 Years|No|||October 2015|October 8, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415921||99914|
NCT01416142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|701E|A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens|A Study to Evaluate the Product Performance of the PureVision®2 HD Contact Lens||Bausch & Lomb Incorporated|No|Completed|July 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|15 Years|30 Years|No|||November 2013|November 7, 2013|August 11, 2011|Yes|Yes||No|February 13, 2013|https://clinicaltrials.gov/show/NCT01416142||99897|
NCT01416155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS204|Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis|A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis||Biogen|Yes|Completed|October 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|March 24, 2011|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT01416155||99896|
NCT01416376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115830|Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation|A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects||GlaxoSmithKline|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|39|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01416376||99879|
NCT01416363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115517|Healthy Volunteer Study Using 3 Different Formulations of Firategrast|A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers||GlaxoSmithKline|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|March 8, 2012|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01416363||99880|
NCT01416883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6874L00016|Oral Mucosal Absorption Study of Bicalutamide New Formulation|Oral Mucosal Absorption Study of ICI176,334-1 (Bicalutamide New Formulation) in Japanese Healthy Male Subjects||AstraZeneca||Terminated|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 12, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416883||99840|
NCT01417195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999906 CS12|Menopur Mixed Protocol|A Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Combination of Menopur® and Bravelle® With Menopur® Alone in Subjects Undergoing Assisted Reproductive Technology (ART)|COMBINE|Ferring Pharmaceuticals|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Female|18 Years|42 Years|No|||May 2014|May 6, 2014|July 28, 2011|Yes|Yes||No|March 20, 2014|https://clinicaltrials.gov/show/NCT01417195||99817|
NCT01387841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y010810|Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting|Comparison of Yoga Versus Relaxation on Chemotherapy Induced Nausea and Vomiting (CINV) Outcomes Following Chemotherapy||Bharath Charitable Cancer Hospital and Institute|Yes|Completed|May 2010|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|120|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387841||102063|
NCT01388894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-01|Functional MRI and MRA in Migraine With Aura|Functional MRI and MRA in Migraine With Aura||Glostrup University Hospital, Copenhagen|No|Recruiting|December 2010|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients diagnosed with migraine with aura|May 2011|July 5, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388894||101982|
NCT01386060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB7364|Mindfulness Meditation in Chronic Stress|Mindfulness Meditation in Chronic Stress: Measures of Adherence, Ability & Stress||Oregon Health and Science University|No|Active, not recruiting|June 2011|June 2017|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01386060||102198|
NCT01389128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR443033|Non-pharmacological Resources in Assisting Labor|Application of Non-pharmacological Resources in Assisting Labor: Randomized Controlled Trial||University of Sao Paulo|Yes|Recruiting|October 2011|December 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|60|||Female|15 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 29, 2012|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01389128||101964|
NCT01389427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T³|Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).|A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Torisel-Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (T-R-CHOP), Torisel-Rituximab-Fludarabine-Cyclophosphamide (T-R-FC) and Torisel-Rituximab-Aracytine High Dose-Dexamethasone (T-R-DHA) for the Treatment of Patients in Relapsed/Refractory Mantle Cell Lymphoma|T³|The Lymphoma Academic Research Organisation|Yes|Active, not recruiting|November 2011|October 2016|Anticipated|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|63|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01389427||101941|
NCT01385436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHID-02|Distribution of Human Papillomavirus (HPV) Genotypes in Patients With Cervical Cancer From Croatia|Pre-vaccination Distribution of Human Papillomavirus (HPV) Genotypes in Patients With High Grade Cervical Squamous Intraepithelial Lesion (HSIL) and Cervical Cancer From Croatia|HPV-cancer|University Hospital for Infectious Diseases, Croatia|No|Recruiting|May 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|Samples With DNA|DNA isolates from biopsy specimens of cervical lesions.|Female|18 Years|65 Years|No|Probability Sample|Women aged 18-65 with a cytological diagnosis of CIN2+cervical lesions from all over        Croatia that are referred to the National Reference Center because of HSIL or malignant        cytology findings.|June 2011|June 29, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01385436||102245|
NCT01413568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112026|Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies|A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies||Polyphor Ltd.|Yes|Completed|April 2012|December 2015|Actual|November 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|75 Years|No|||February 2016|February 25, 2016|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413568||100092|
NCT01413880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI 8972 (JHOC 1101)|Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly (AML)|Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly Diagnosed Acute Myelogenous Leukemia (AML)|FlAM|Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|May 2011|December 2015|Anticipated|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|May 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01413880||100068|
NCT01413893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-749|An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors|An Extension Study of Linifanib in Subjects With Advanced or Metastatic Solid Tumors||Abbott|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|18 Years|N/A|No|||June 2012|August 1, 2012|June 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413893||100067|
NCT01414972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-01-27-10471|The Effect of Vitamin A on Atherosclerosis|The Effect of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by T CD4+ Lymphocyte in Atherosclerotic Patients||Tehran University of Medical Sciences|Yes|Enrolling by invitation|May 2010|November 2011|Anticipated|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|45|||Both|35 Years|70 Years|No|||August 2011|August 10, 2011|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414972||99987|
NCT01415271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Point Grey Trial|3-Month Trial Observation of A1c Change|Assessment of an Internet Blood Glucose Management Program in a Chronic Care Hospital||Endocrine Research Society|No|Terminated|October 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|N/A|N/A|No|||August 2015|August 10, 2015|August 10, 2011||No|Preliminary exploration of research concept did not prove to be viable.|No||https://clinicaltrials.gov/show/NCT01415271||99964|
NCT01415544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0020|Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References|An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References||InLight Solutions|No|Active, not recruiting|June 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|None Retained|capillary glucose measurements|Female|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|The Human Subject population consists of female subjects between the ages of 20 and 50.        Subjects must have been diagnosed with either Type I, Type II, or Gestational diabetes and        may utilize healthy individuals for the validation phase. Up to 100 subjects may be        recruited to participate in this study. Subjects will be recruited from the community and        will be selected to ensure a representative sample of the projected intended use        population. Efforts will also be made to ensure a broad and even distribution of ages        (between 20 and 50 years old) and ethnicities.|February 2012|February 23, 2012|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01415544||99943|
NCT01415778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6874L00025|Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects|Bioequivalence Study of ICI176,334-1 in Japanese Healthy Male Subjects - Evaluation of Bioequivalence of ICI176,334-1 and Casodex 80 mg Tablet -||AstraZeneca||Completed|August 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 29, 2012|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01415778||99925|
NCT01414946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-2011|The Effect of Intravenous Nutrition in Patients Undergoing Abdominal Surgery|THE PROTEIN SPARING EFFECT OF PERIOPERATIVE NUTRITION: How Important is the Patient's Catabolic State Before Surgery and do we Need Glucose?||McGill University Health Center|No|Completed|November 2009|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2011|August 10, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414946||99989|
NCT01415934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRC-001.1|Statin Discontinuation in Advanced Illness|Multisite Randomized Controlled Trial of Continuing vs. Discontinuing Statins||Palliative Care Research Cooperative Group|Yes|Completed|May 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|380|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415934||99913|
NCT01386996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103004|Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler|Pharmacokinetic Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 320/9 Microg/Inhalation and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 21, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01386996||102127|
NCT01387009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 10-0049|Acquisition of Normative Data for Musculoskeletal Ultrasound in Children|||Children's Hospital of Eastern Ontario||Enrolling by invitation|June 2011|January 2017|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|2 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy children will be recruited via invitation by investigators|January 2016|January 26, 2016|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387009||102126|
NCT01416389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12847|A Study of LY2523355 in Patients With Breast Cancer|A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy||Eli Lilly and Company|No|Completed|August 2011|September 2013|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2013|January 7, 2014|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416389||99878|
NCT01416402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M102-21124|Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients|A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout||CymaBay Therapeutics, Inc.|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|75 Years|No|||March 2015|March 9, 2015|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416402||99877|
NCT01416649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-051-A|Impact of Exenatide on Sleep Duration|Impact of Exenatide on Sleep Duration and Quality in Type 2 Diabetes||University of Chicago|No|Recruiting|February 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|18 Years|75 Years|No|Non-Probability Sample|Convenience Sample|December 2014|December 30, 2014|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416649||99858|
NCT01387568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUH-AD-1-2011|Lidocaine Infusion for Major Abdominal Pediatric Surgery|The Effects of Intravenous Lidocaine Infusion During and After Major Abdominal Pediatric Surgery. A Randomized Double-blinded Study||Mansoura University|Yes|Completed|March 2010|February 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|1 Year|6 Years|No|||April 2012|April 18, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387568||102084|
NCT01388608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StepcountETN|Standard Disease Activity Parameters and Step Activity in Patients With Rheumatoid Arthritis Receiving Etanercept|Correlation of Standard Disease Activity Parameters in Rheumatoid Arthritis With Activities of Daily Living Measured With the Step Activity Monitor, Based on the Influence of Etanercept Therapy on the Disease Activity||University Hospital Muenster|No|Completed|June 2009|April 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|76 Years|No|Non-Probability Sample|Patients with active rheumatoid arthritis, who are eligible to a treatment with etanercept        according to the local german guidelines|July 2011|August 20, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01388608||102004|
NCT01388387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022488-36|Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)|Impact of Donor and Recipient CYP3A5 Genetic Polymorphism on Tacrolimus Exposure in Patients With Hepatic Transplant||Rennes University Hospital|Yes|Recruiting|January 2012|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388387||102021|
NCT01386073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Focus2011-001|Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity|Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity||Innovative Medical|No|Recruiting|July 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386073||102197|
NCT01386086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-623|Aripiprazole and Resistant Postpartum Depression|Augmentation Therapy of Resistant Postpartum Depression With Aripiprazole||Lawson Health Research Institute|No|Completed|June 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Female|18 Years|45 Years|No|||March 2016|March 15, 2016|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01386086||102196|
NCT01388907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLI 9821-2|Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery|Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Prospective Multicentre Randomized Comparative Study||Sofradim Production|No|Completed|May 2006|June 2011|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Female|20 Years|42 Years|No|||July 2011|July 7, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388907||101981|
NCT01386580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2B3-101-CR-001|An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.|An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.||BBB-Therapeutics B.V.|No|Completed|July 2011|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386580||102159|
NCT01386593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB-89/11|Pharmacokinetic Study to Characterize Phenotyping Metrics of the "Basel" Cocktail After CYP Induction or Inhibition|Single-center, Randomized, Open-label, Two-way Crossover Study to Characterize Phenotyping Metrics of the "Basel" Cocktail After CYP Induction or Inhibition in Healthy Male Subjects||University Hospital, Basel, Switzerland|No|Completed|May 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386593||102158|
NCT01386606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-204|The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)|A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men||Repros Therapeutics Inc.|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|60|||Male|18 Years|65 Years|No|||August 2015|August 21, 2015|June 29, 2011|Yes|Yes||No|June 13, 2014|https://clinicaltrials.gov/show/NCT01386606||102157|
NCT01414465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMED0010|Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females|Orlistat Induced Modulation on the Fatty Acid Composition of the Red Blood Cell Membrane and Plasma Phospholipids, Triglyceride and Cholesteryl Esters in Obese Females||University of Campinas, Brazil|No|Completed|October 2009|June 2011|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|17|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 10, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414465||100026|
NCT01414725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0106/88|Core Stability Training in Multiple Sclerosis|Core Stability Training in Ambulant Individuals With Multiple Sclerosis: a Multi-centre Randomised Controlled Trial.||University of Plymouth|Yes|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01414725||100006|
NCT01414738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 042011-050|Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases|Phase II Trial of Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases||University of Texas Southwestern Medical Center|Yes|Recruiting|October 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|102|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|August 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414738||100005|
NCT01406106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/001|Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia|EFFECT OF PLANT STEROLS ON THE LIPID PROFILE OF PATIENTS WITH HYPERCHOLESTEROLAEMIA. RANDOMISED, EXPERIMENTAL STUDY||Gerencia de Atención Primaria, Albacete|No|Active, not recruiting|January 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||July 2011|July 28, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406106||100663|
NCT01406119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-326|An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors|An Extension Study of ABT-806 for Subjects With Advanced Solid Tumors||AbbVie|No|Active, not recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|99 Years|No|||January 2016|January 23, 2016|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406119||100662|
NCT01406418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-M6-C001|Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR6261, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose Intravenous Administration||Crucell Holland BV|Yes|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406418||100639|
NCT01406431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JW-PTV-102|Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects|A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatin and Valsartan Co-administration and Livalo® Fixed Combination Drug in Healthy Male Subjects||JW Pharmaceutical|No|Completed|August 2011|October 2012|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 1, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01406431||100638|
NCT01406704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCMC-04-14|Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH|Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis)||Seoul St. Mary's Hospital|Yes|Terminated|January 2004|December 2013|Anticipated|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|26|||Both|20 Years|70 Years|No|||January 2004|August 18, 2011|July 27, 2011|Yes|Yes|because of withdrawal of Avandia sale due to its risks outweigh its benefits|No||https://clinicaltrials.gov/show/NCT01406704||100617|
NCT01406977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPS804A2202|Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)|An Open-label, Intra-patient Dose-escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP).||Novartis|No|Completed|July 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|70 Years|No|||March 2013|March 18, 2013|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406977||100596|
NCT01406990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16154|Aspirin Responsiveness in Women With Coronary Artery Disease|Aspirin Responsiveness in Women With Coronary Artery Disease||Creighton University|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Female|45 Years|85 Years|No|Non-Probability Sample|Women between 45 and 85 years of age with known CAD on low dose Aspirin (81 mg) seen at        the Cardiac Center of Creighton University|August 2012|August 28, 2012|July 13, 2011||No||No|August 28, 2012|https://clinicaltrials.gov/show/NCT01406990||100595|
NCT01407185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_HF_STUDY|Efficacy of a Home-Based Exercise Program for Heart Failure|Efficacy of a Home-Based Exercise Program in the Management of Heart Failure: An Evidenced-Based Multi-Disciplinary Approach||Catholic Home Care|Yes|Terminated|June 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Both|60 Years|85 Years|No|||December 2012|December 31, 2012|July 27, 2011||No|Lack of enrollment. Difficult to obtain Physician approval.|No||https://clinicaltrials.gov/show/NCT01407185||100580|
NCT01387581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101|Does the Aid of MelaFind Affect Clinical Management Decisions|To Excise or Not?: Comparing Clinical Management Decisions for Melanoma Between Dermatologists With and Without the Aid of MelaFind||MELA Sciences, Inc.|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|227|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|130 dermatologists will enter by way of general invitation and will be randomly placed in        either Arm 1 (Without MelaFind) or Arm 2 (With MelaFind). Another group, up to 30        Pigmented Skin Lesion Experts, will be prospectively identified by the Principal        Investigator of this study prior to any participant recruitment, and will be invited to        participate in the study by the PI after the general recruitment is completed.|November 2014|November 5, 2014|June 28, 2011|Yes|Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01387581||102083|A limitation of this study is the reader study format. Lesions were presented to participating dermatologists as photographs via the online system. This presentation can only approximate an in-person clinical exam.
NCT01386762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85756|Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury|Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury||California State University, San Marcos|No|Recruiting|June 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|45 Years|No|||June 2011|June 30, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386762||102145|
NCT01386775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-007|Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation||Edimer Pharmaceuticals|No|Completed|June 2011|September 2011|Actual|July 2011|Actual|N/A|Observational|N/A||2|Actual|64|||Male|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Attendees of the National Foundation for Ectodermal Dysplasia's (NFED) 2011 Annual Family        Conference|June 2012|June 26, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386775||102144|
NCT01388140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012003RB|Psychopathology of Dissociative Disorders|A Psychopathological Study of Dissociative Disorders in Psychiatric Inpatients at an Acute Stage||National Taiwan University Hospital|Yes|Recruiting|March 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|20 Years|60 Years|No|Non-Probability Sample|psychiatric inpatients in a acute stage|January 2011|July 5, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388140||102040|
NCT01387334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prince of Songkla University|The Effectiveness of Resistance Exercise for Glycemic Control in Type 2 Diabetes Mellitus Patients|The Effectiveness of a Home-Based Resistance Exercise Training Program With Rubber Bands for Glycemic Control in Individuals With Type 2 Diabetes Mellitus|RE|Prince of Songkla University|No|Completed|February 2007|April 2011|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01387334||102101|
NCT01387594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7281008|Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs|A Multi-center, Phase 1, Open-label Evaluation Of The Effect Of Pf-00547659 (Anti Madcam Monoclonal Antibody) On The Cerebrospinal Fluid (Csf) Lymphocytes In Volunteers With Crohn's Disease Or Ulcer Ulcerative Colitis Who Are Anti-tnf Inadequate Responders (Tosca)|TOSCA|Pfizer|Yes|Completed|May 2012|November 2015|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|49|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01387594||102082|
NCT01388374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-82800-98-227|The (Cost-)Effectiveness of Nurse Practitioners Working at the Primary Out of Hours Emergency Service|A Study on the (Cost-)Effectiveness of Nurse Practitioners Working at the Primary Out of Hours Emergency Service and the Feasibility of Implementing These Nurses||Radboud University|No|Completed|December 2010|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|12092|||Both|1 Year|N/A|Accepts Healthy Volunteers|||April 2015|April 21, 2015|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01388374||102022|
NCT01388153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15624|A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet|Randomized, Non-blinded, 3-fold Crossover Study to Investigate the Bioequivalence Between Glucobay ODT Taken Without and With Water and the Glucobay Standard Tablet Following Single Oral Dosing in Healthy Male Subjects||Bayer|No|Completed|June 2011|August 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|33|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01388153||102039|
NCT01388920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH9507-CTR-1025|Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting||Theratechnologies|No|Terminated|September 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|3|||Both|40 Years|75 Years|No|||April 2014|April 4, 2014|July 5, 2011|Yes|Yes|The study was terminated based on a non-safety related corporate decision.|No|April 4, 2014|https://clinicaltrials.gov/show/NCT01388920||101980|
NCT01389453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-17 stroke|The Clinical Trial Research of Stem Cell Transplantation Treats Cerebral|Umbilical Cord Mesenchyma Stem Cell Transplantation in Patients With Cerebral Hemorrhage and Cerebral Infarction||General Hospital of Chinese Armed Police Forces|Yes|Withdrawn|April 2011|December 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|65 Years|No|||October 2011|February 26, 2013|July 6, 2011|Yes|Yes|There were not enough number of patients recruited till DEC 31th in 2012.|No||https://clinicaltrials.gov/show/NCT01389453||101939|
NCT01386619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-DLI Allo-Tx|NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)|Natural Killer Cell Selected T-cell Depleted Donor Lymphocyte Infusions (NK-DLI) in Patients After HLA-haploidentical Allogeneic Stem Cell Transplantation||University Hospital, Basel, Switzerland|No|Completed|January 2004|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||September 2015|September 14, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01386619||102156|
NCT01416987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200061-507|A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)|A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)||Merck KGaA||Completed|August 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|291|||Female|N/A|N/A|No|Non-Probability Sample|Infertile patients|July 2014|July 1, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416987||99832|
NCT01405586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILES-3|MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer|Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.|MILES-3|National Cancer Institute, Naples|No|Recruiting|March 2011|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|70 Years|N/A|No|||November 2015|November 25, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01405586||100703|
NCT01405599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPJ5004-01/2011 (HEP)|Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects|Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ulimorelin in Subjects With Mild, Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects||Norgine|Yes|Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01405599||100702|
NCT01405807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL1.1|Alemtuzumab for ANCA Associated Refractory Vasculitis|Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy|ALEVIATE|Cambridge University Hospitals NHS Foundation Trust|No|Recruiting|February 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|60 Years|No|||July 2011|July 28, 2011|July 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405807||100686|
NCT01406444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DK052625|IGF-1 and Bone Loss in Women With Anorexia Nervosa|IGF-1 and Bone Loss in Women With Anorexia Nervosa||Massachusetts General Hospital|Yes|Recruiting|October 2011|||October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|200|||Female|18 Years|45 Years|No|||February 2016|February 8, 2016|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406444||100637|
NCT01406717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_10_33|Safety and Efficacy of Exenatide Injection in Subjects With Type 2 Diabetes Mellitus|Safety and Efficacy of Exenatide Injection in Subjects With Type 2 Diabetes Mellitus: a Randomized, Double Blind, Placebo-controlled, Parallel Groups, Multicentric, 24-week Trial||Sun Pharmaceutical Industries Limited|No|Active, not recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|20 Years|N/A|No|||October 2015|October 20, 2015|July 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406717||100616|
NCT01407003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIK066X2101|Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)|A Randomized, Double-blind, Placebo-controlled, 4-part, Interwoven Single- and Multiple-ascending Dose Study to Assess Safety, Tolerability, PK and PD of LIK066 in Healthy Subjects and in Patients With T2DM||Novartis||Completed|June 2011|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|138|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407003||100594|
NCT01407198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-072|Nilotinib With Radiation for High Risk Chordoma|Phase I Study of Nilotinib Given With Radiation For Patients With High Risk Chordoma||Massachusetts General Hospital|Yes|Active, not recruiting|August 2011|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407198||100579|
NCT01387061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|multipleHCC|Resection for Multiple Hepatocellular Carcinomas (HCC)|Hepatic Resection for Multiple Hepatocellular Carcinoma on Cirrhosis||University of Milan||Completed|June 2001|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|87|||Both|N/A|N/A|No|||September 2011|September 18, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387061||102122|
NCT01387074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/NS/SPA/018|Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity|A Prospective, Non-interventional, Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity||Allergan|No|Completed|June 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with upper limb spasticity following stroke who are eligible to receive        botulinum toxin Type A treatment|December 2013|December 13, 2013|June 30, 2011|Yes|Yes||No|December 13, 2013|https://clinicaltrials.gov/show/NCT01387074||102121|
NCT01387087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-HV01|A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP015K Following Single Oral Doses to Healthy Volunteers||Astellas Pharma Inc|No|Completed|July 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|12||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2011|June 30, 2011|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01387087||102120|
NCT01387854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASB-00-03|Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02|A Re-Survey Study of Patients With MPS VI (Maroteaux-Lamy Syndrome) Who Previously Participated in ASB-00-02||BioMarin Pharmaceutical|No|Completed|June 2011|February 2013|Actual|October 2012|Actual|N/A|Observational|N/A||1|Actual|59|||Both|N/A|N/A|No|Non-Probability Sample|Patients with MPS VI who previously participated in ASB-00-02|March 2014|March 31, 2014|June 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01387854||102062|
NCT01387620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP - 0111 - 09|Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2%|Intraindividual Randomized Clinical Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2% in Phacoemulsification||University of Sao Paulo|No|Completed|June 2009|December 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|39|||Both|50 Years|90 Years|No|||December 2010|June 30, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01387620||102080|
NCT01387607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081241|A Study For Pregabalin In Patients With Fibromyalgia|A 14-week, Randomized, Double-blind Placebo-controlled Study For Pregabalin In Subjects With Fibromyalgia||Pfizer|No|Recruiting|February 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|324|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387607||102081|
NCT01387867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOA-ISMC|Exercise in Patients With Osteoarthritis of the Hip|Effects of Strength Training and Nordic Walking in Patients With Osteoarthritis of the Hip||Bispebjerg Hospital|No|Completed|October 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|152|||Both|60 Years|N/A|No|||July 2013|February 5, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387867||102061|
NCT01388647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSSNBC1006|Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer|Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer||Vector Oncology|No|Terminated|August 2011|September 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||December 2014|July 30, 2015|July 5, 2011|Yes|Yes|Closed early due to increased hematologic toxicity and possible reduced efficacy|No|May 28, 2015|https://clinicaltrials.gov/show/NCT01388647||102001|Although MTD of eribulin with carboplatin & trastuzuamb as neoadjuvant therapy was determined by protocol definitions, study closed early due to increased hematologic toxicity & possible reduced efficacy. Phase II of this trial was not initiated.
NCT01385787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-MRD|MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia|The Role of Minimal Residual Disease Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia||Center for International Blood and Marrow Transplant Research|Yes|Active, not recruiting|October 2011|February 2018|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|N/A|21 Years|No|Non-Probability Sample|Participating institutions (transplant centers)|September 2015|September 3, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385787||102219|
NCT01420198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/36|Efficiency and Cost-effectiveness of a Culturally Adopted Lifestyle Intervention Program - the MEDIM Study.|A Middle Eastern Immigrant Population At-risk for Diabetes; Contributing Risk Factors and the Efficiency and Cost-effectiveness of a Culturally Adopted Lifestyle Intervention Program - the MEDIM Study.|MEDIM|Region Skane|No|Completed|January 2015|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|96|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||October 2015|November 9, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01420198||99587|
NCT01420211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primovist - OATP1B1|Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®|Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® in Healthy Volunteers and in Patients With Liver Disease||University Medicine Greifswald|No|Completed|October 2006|July 2010|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 18, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01420211||99586|
NCT01386346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012011450|Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer|Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer|VEOX|Weill Medical College of Cornell University|Yes|Recruiting|June 2011|June 2013|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|16|||Both|18 Years|75 Years|No|||June 2011|June 29, 2011|May 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386346||102176|
NCT01416246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-105|Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant|Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|75 Years|No|||August 2015|August 11, 2015|August 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01416246||99889|
NCT01416493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REUMAP|Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis|An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase (bIAP), an Inflammation Modulating Moiety, in RA Patients|ALS-003-2008|Alloksys Life Sciences B.V.|Yes|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416493||99870|
NCT01405833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103NS102|Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.|Phase 1: A Multi-Centered, Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of BG00010 (Neublastin) in Subjects With Sciatica||Biogen|Yes|Completed|July 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|85 Years|No|||September 2014|September 5, 2014|July 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405833||100684|
NCT01405846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01425|Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib|Tyrosine Kinase Inhibitors in DyplAsia of Lung Epithelium|TIDAL1|Papworth Hospital NHS Foundation Trust|Yes|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||October 2015|October 19, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405846||100683|
NCT01406132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK03|A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects|A Phase 1, Open-Label, Mass Balance Study to Evaluate the Pharmacokinetics of ASP015K After a Single Oral Dose of 14C-Labeled ASP015K in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|December 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406132||100661|
NCT01406145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0777-CL-0030|A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil|A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil||Astellas Pharma Inc|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|50 Years|N/A|No|||November 2011|November 17, 2011|July 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406145||100660|
NCT01406158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-080|A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation|A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation B) Versus Solifenacin Liquid Suspension 10 mg (Formulation A) and to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation A and B) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet in Healthy Volunteers||Astellas Pharma Inc|No|Completed|May 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 23, 2011|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406158||100659|
NCT01406171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0023|Drug Interaction Study of Isavuconazole and Midazolam|A Phase 1, Open-Label, Drug Interaction Study of the Pharmacokinetics of Isavuconazole and Midazolam After Separate and Concomitant Administration to Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|July 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406171||100658|
NCT01406457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04-21-01|Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage|Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage|MODISH|University of Cincinnati|No|Completed|June 2010|March 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7||No specimens are to be retained.|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with subarachnoid hemmorhage clinical symptoms|October 2015|October 20, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406457||100636|
NCT01406730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAU-IMP-4463|Running Effect on Cardiovascular and Muscular Parameters|Effect of 16 Weeks of Running Exercise on Parameters Related to the Cardiovascular System, Blood and Muscle in Untrained Males 30-50 Years Old. A Randomized Controlled Study||University of Erlangen-Nürnberg Medical School|Yes|Completed|July 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 11, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01406730||100615|
NCT01407016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6831006|A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects|A Phase 1, Open Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Following Single And Multiple Intravenous Infusion In Healthy Japanese Adult Subjects||Pfizer||Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 27, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01407016||100593|
NCT01402960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-000990|Exploration of Parameters of Transcranial Direct Current Stimulation (tDCS) in Chronic Pain|Exploration of Parameters of tDCS in Chronic Pain Patients||Spaulding Rehabilitation Hospital|No|Completed|April 2011|||February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|64 Years|No|||April 2013|April 22, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01402960||100905|
NCT01403207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001468|An Analysis of Potential Sex Differences in Knee Osteoarthritis|An Analysis of Potential Sex Differences in Knee Osteoarthritis||Mayo Clinic|Yes|Completed|August 2011|March 2014|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|65 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patient enrollment will consist of 10 females and 10 male patients stratified by age.        Enrollment is anticipated to be completed over a 12 month time period. Only non Hispanic        White patients will be included in the study. Patients must be between 65 and 75 years of        age. Patients with a BMI greater than 30 will be excluded|March 2014|March 12, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01403207||100886|
NCT01387100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B100003-1|A Modified Rehabilitation Intervention for Working Persons With Arthritis|Efficacy of a Modified Vocational Rehabilitation Intervention for Work Disability|Work It|Boston University|No|Active, not recruiting|June 2011|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|300|||Both|25 Years|63 Years|No|||February 2015|February 20, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01387100||102119|
NCT01387373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA 0919|Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer|Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer. A Phase II Trial||Herlev Hospital|No|Recruiting|April 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||June 2013|March 20, 2014|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01387373||102098|
NCT01387633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diabetes2011|Educational Intervention and Social Support in Diabetes Mellitus|||University of Sao Paulo|Yes|Recruiting|June 2011|||June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|264|||Both|40 Years|70 Years|No|||February 2010|July 1, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01387633||102079|
NCT01387347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-DE-202|Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye|A Double-Masked, Randomized, Single-Center Study Evaluating the Safety and Efficacy of 0.1% Tβ4 Ophthalmic Solution Compared to Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model||ReGenTree, LLC|No|Completed|August 2011|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|85 Years|No|||December 2012|June 10, 2015|June 29, 2011|Yes|Yes||No|November 29, 2012|https://clinicaltrials.gov/show/NCT01387347||102100|There were no limitations to trial RGN-DE-202 entitled:"Safety and Efficacy of Thymosin beta 4 Ophthalmic Solution in Patients with Dry Eye". All subjects were enrolled.
NCT01387360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107|Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes|A Prospective Study to Evaluate the Safety and Effectiveness of the Supracor Presbyopic Treatment Algorithm for Pseudophakic Eyes Using Lasik|SUPRACOR|Technolas Perfect Vision GmbH|Yes|Completed|June 2011|October 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|45 Years|85 Years|No|||May 2015|May 19, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01387360||102099|
NCT01388166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.483|ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice|ADESPI: Adherence to Spiriva® in Patients With COPD, Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice in Central & Eastern European Region||Boehringer Ingelheim||Completed|September 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1253|||Both|18 Years|N/A|No|Non-Probability Sample|COPD|November 2014|November 28, 2014|July 1, 2011||||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01388166||102038|
NCT01388179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-AUTISM|Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children.|Deep rTMS(Repetitive Transcranial Magnetic Stimulation) for Treatment of Autism Symptoms in Children With Low Functioning ASD (Autism Spectrum Disorders)||Brainsway|No|Recruiting|March 2014|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|10 Years|18 Years|No|||July 2011|February 4, 2015|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01388179||102037|
NCT01388400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5120-HW-CTIL|Enriched Environments for Upper Limb Stroke Rehabilitation|Enriched Environments for Stroke Rehabilitation; Pilot Study to Determine Appropriate Outcome Measures and Their Sensitivity to Different Training Protocols||Sheba Medical Center|No|Completed|May 2009|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 10, 2011|June 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01388400||102020|
NCT01389466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG1109_P1/2|Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers|Randomized Phase I/II Study to Evaluate the Safety and Immunogenicity of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers||Green Cross Corporation|No|Completed|February 2010|December 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|346|||Both|18 Years|58 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|June 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01389466||101938|
NCT01385449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0098|Prospective Evaluation of Interscalene Nerve Catheters vs. Single Injection Blocks|Continuous Interscalene Block (CISB) Versus Single Injection Interscalene Block in Those Undergoing Shoulder Surgery in the Ambulatory Setting||University of Wisconsin, Madison|No|Active, not recruiting|June 2011|December 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|79 Years|No|||October 2015|October 6, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385449||102244|
NCT01385774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171102025;ZonMw|SUPER Study; SUPERvised Exercise or Angioplasty for Intermittent Claudication Due to an Iliac Artery Obstruction.|SUPERvised Exercise Therapy (SET) or Immediate Percutaneous Transluminal Angioplasty (PTA) for Intermittent Claudication (IC) in Patients With an Iliac Artery Obstruction: A Randomized Controlled Trial. SUPER Study|SUPER|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|November 2010|April 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2011|July 7, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385774||102220|
NCT01385800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG002|ToleroMune Grass Exposure Unit Study|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit||Circassia Limited|No|Completed|August 2011|August 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|280|||Both|18 Years|65 Years|No|||August 2013|August 14, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385800||102218|
NCT01420224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxford in-flight 2011|Study of the Effects of Commercial Air Travel on the Lungs|Study of the Effects of Commercial Air Travel on Pulmonary Artery Pressure in Healthy Passengers and in a Patient With Chuvash Polycythaemia||University of Oxford|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient with Chuvash polycythaemia recruited from previous study participants with the        disease.|August 2011|August 18, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420224||99585|
NCT01416272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROC2-11-024|Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses|Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses||Bausch & Lomb Incorporated|No|Terminated|April 2011|February 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|August 11, 2011|No|Yes|Study was terminated due to a business decision to cancel the entire project.|No|November 18, 2014|https://clinicaltrials.gov/show/NCT01416272||99887|
NCT01386359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-076|Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant|Evaluating Nulojix Long-Term Safety in Transplant|ENLIST|Bristol-Myers Squibb|No|Recruiting|February 2012|April 2019|Anticipated|April 2019|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1130|||Both|18 Years|N/A|No|Non-Probability Sample|All adult de novo EBV-seropositive kidney transplant recipients|March 2016|March 10, 2016|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01386359||102175|
NCT01416519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1123-6476|Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation|Incentive Spirometry Decreases Respiratory Complications After Myocardial Revascularization||Santa Casa de Votuporanga|Yes|Completed|September 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|16 Years|N/A|No|||November 2014|November 17, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416519||99868|
NCT01405859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39432|MRI Study of Tic Remission in Tourette Syndrome|Neuroimaging to Elucidate the Mechanism of Tic Resolution in Tourette Syndrome||University of Utah|No|Recruiting|January 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|30|||Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young adult males (aged 18-35) with a history of Tourette syndrome, including at least        moderate disability from tics during childhood.|June 2012|June 1, 2012|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405859||100682|
NCT01406184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020974|Durham Connects Evaluation|Evaluation of the Durham Connects Nurse Home Visiting Program||Duke University|Yes|Active, not recruiting|July 2009|March 2017|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2329|||Both|N/A|6 Months|No|||August 2015|August 5, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406184||100657|
NCT01402973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGE Dietary Intervention|Pilot Study of a Dietary Intervention Based Upon Advanced Glycation End Products|||USDA Beltsville Human Nutrition Research Center|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|24|||Both|50 Years|69 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01402973||100904|
NCT01403220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/PJ-02|The Efficacity of Hemodiafiltration Versus Hemofiltration for Renal Insufficiency During Intensive Care|The Efficacity of Hemodiafiltration Versus Hemofiltration for Renal Insufficiency During Intensive Care: a Randomized, Open, Cross-over Study||Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403220||100885|
NCT01403233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-06-01-STEV|Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects|An Open-label, Sequential Supplementation Study Comparing the Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects|StevReb-PK|DSM Nutritional Products, Inc.|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01403233||100884|
NCT01403506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|186|Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL)|Phase 3 Study of N-acetyl Cysteine as an Antioxidant and Glutathione Synthesis Inducer on Biomarkers of Delayed Renal Graft Function Including NGAL and IL-18||hahid Beheshti University of Medical Sciences|Yes|Recruiting|April 2011|November 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|N/A|No|||January 2011|July 26, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403506||100863|
NCT01403753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260608322|Children's Familiarity With Snack Foods Changes Expectations About Fullness|Children's Familiarity With Snack Foods Changes Expectations About Fullness||University of Bristol|No|Completed|August 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|70|||Both|11 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Community sample|July 2011|August 12, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403753||100844|
NCT01388192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104028RC|Effects of Pancreaticoduodenectomy on Glucose Metabolism|Effects of Pancreaticoduodenectomy on Glucose Metabolism||National Taiwan University Hospital|Yes|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving pancreaticoduodenectomy|January 2016|January 24, 2016|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01388192||102036|
NCT01388413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI06-LB/PACHIU|Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder|A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder|PACHIU|University Hospital, Tours|Yes|Active, not recruiting|August 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01388413||102019|
NCT01387880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI 0923 ICE|Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer|Phase II Examination of Irinotecan, Cetuximab and Everolimus to Chemotherapy Resistent Patients With Metastatic Colorectal Cancer and KRAS Mutations or After Progression With KRAS Wildtype on Irinotecan and Cetuximab - Effect and Biological Markers|ICE|Herlev Hospital|Yes|Completed|January 2010|March 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2012|March 18, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01387880||102060|
NCT01387893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-07PFren-01-H|A Self-Administered Maneuver to Relieve Symptoms Suggestive of Benign Prostatic Hyperplasia|Study of a Self-Administered Maneuver to Initiate and Maintain Urine Flow Impeded by Benign Prostatic Hyperplasia||Kaiser Permanente|No|Completed|May 2008|November 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Male|45 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387893||102059|
NCT01388933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU100P2T2|A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease|A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects With Moderate Crohn's Disease||Tsumura USA|No|Terminated|September 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|July 5, 2011|Yes|Yes|Study stopped due to low enrollment|No||https://clinicaltrials.gov/show/NCT01388933||101979|
NCT01389167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907005456|Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia|Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia||Yale University|Yes|Active, not recruiting|September 2011|May 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01389167||101961|
NCT01389479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDB-707-105|Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults|Active-control Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ S/F Influenza Vaccine in Healthy Adults Aged 18-64 Years of Age||GlaxoSmithKline||Completed|January 2005|May 2005|Actual|May 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Actual|1000|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2011|July 6, 2011|July 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01389479||101937|
NCT01389492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWPP09-HMO-CTIL|The Effect of Meat and Food Drived Polyphenols on Oxidize LDL Level|Nutritional Study:The Effect of Meat and Food Drived Polyphenols on Oxidize LDL Level||Hadassah Medical Organization|Yes|Completed|October 2010|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2009|July 6, 2011|July 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01389492||101936|
NCT01389180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0907005504|Behavioral Drug and HIV Risk Reduction Counseling With MMT in China|Behavioral Drug and HIV Risk Reduction Counseling With MMT in China||Yale University|No|Recruiting|December 2010|September 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|20 Years|65 Years|No|||November 2015|November 5, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01389180||101960|
NCT01385475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTFunction|Resistance Training to Improve Physical Function in the Elderly|Efficacy of Resistance Training Guidelines to Improve Function in Older Adults||University of Wisconsin, Milwaukee|No|Completed|June 2009|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||June 2011|June 28, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01385475||102243|
NCT01419899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21DA28645-2|Increasing Viral Testing in the Emergency Department|Phase 2/3 Clinical Trial of the Effect of a Brief Intervention on Uptake of Rapid Testing for HIV and Hepatitis C Among Emergency Department Patients|InVITED|Rhode Island Hospital|Yes|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|398|||Both|18 Years|64 Years|No|||August 2013|August 5, 2013|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01419899||99610|
NCT01419925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVX-005|A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers|A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.||BiondVax Pharmaceuticals ltd.|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 12, 2014|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419925||99608|
NCT01419938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/167|Does Cognitive Behaviour Therapy (CBT) Improve the Effect of Light Therapy|Does CBT Improve the Effect of Light Therapy in Delayed Sleep Phase Syndrome Compared to Only Light Therapy - Short and Long Term Follow up||Uppsala University|No|Completed|August 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|16 Years|26 Years|No|||April 2013|April 24, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01419938||99607|
NCT01416285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-1154B|Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure|The Impact of Heart Failure Center Program on The Progression of Biomarkers, Changes in Life Quality, Left Ventricular Ejection Fraction, and Cardiac Outcomes in Patients With Congestive Heart Failure||Chang Gung Memorial Hospital|Yes|Recruiting|June 2009|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples Without DNA|At baseline and every 6-month visits, 3 ml of venous blood will be collected. At baseline      and each 6-month visit, urinary albumin amount will be measured in the core lab in the      hospital.|Both|20 Years|80 Years|No|Non-Probability Sample|Patients hospitalized due to acute cardiogenic pulmonary edema will be consecutively        enrolled in the HF center of Chang Gung Memorial Hospital.|February 2015|February 13, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416285||99886|
NCT01416025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00041916|A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing|A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing|VoriTDM|Johns Hopkins University|No|Completed|January 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|12 Years|N/A|No|||January 2015|January 19, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416025||99906|
NCT01416766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONDUIT-001|CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes|CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes|CONDUIT-HID|University of Massachusetts, Worcester|Yes|Completed|August 2011|July 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|196|||Both|18 Years|80 Years|No|||September 2015|September 15, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01416766||99849|
NCT01406743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/26|Spine Reference Parameters on EOS Imaging|PARAMETRES GLOBAUX DE REFERENCE DU RACHIS CALCULES SUR DES PATIENTS ASYMPTOMATIQUES PAR IMAGERIE EOS™|EOS-SPINE|University Hospital, Bordeaux|No|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|161|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|subject without spine pathology|January 2015|January 13, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406743||100614|
NCT01407029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R3H01|R3® Acetabular System in Patients With Degenerative Hip Disease|A Prospective, Multicenter, Non-randomized, Clinical Outcomes Study of the R3® Acetabular System in Patients With Degenerative Hip Disease||Smith & Nephew, Inc.|No|Active, not recruiting|October 2009|April 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|158|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|This clinical study can fulfill its objectives only if appropriate subjects are enrolled.        All relevant medical and non-medical conditions should be taken into consideration when        deciding whether a particular patient is suitable.|May 2015|May 1, 2015|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01407029||100592|
NCT01402986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-CAT-354-1049|A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma|A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma||MedImmune LLC|No|Completed|August 2011|February 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|689|||Both|18 Years|75 Years|No|||March 2014|March 20, 2014|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01402986||100903|
NCT01403246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL0709|Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)|Phase I-II Multicenter Study to Assess the Efficacy and Safety of the Chlorambucil + Lenalidomide Combination and Lenalidomide Maintenance Therapy in Untreated Elderly Pts With CLL. EudraCT Number 2009-013415-35||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|November 2011|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|60 Years|65 Years|No|||January 2015|January 27, 2015|January 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01403246||100883|
NCT01403532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD005|Sequential Therapy for Hypogonadotropic Hypogonadism|Efficacy and Safety of Human Chorionic Gonadotropin (HCG) and Follicle Stimulating Hormone (FSH) in the Treatment of Hypogonadotropic Hypogonadism||Shanghai Jiao Tong University School of Medicine|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Male|16 Years|45 Years|No|||February 2014|February 10, 2014|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01403532||100861|
NCT01403519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|437-10CTIL|Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized|Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized||Rambam Health Care Campus|No|Not yet recruiting|July 2011|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|70|Samples Without DNA|Blood and CSF|Both|45 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|We estimate that about 30 patients with Alzheimer's disease, 20 patients with        frontotemporal dementia and 20 controls will be included.|July 2011|July 26, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01403519||100862|
NCT01404052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-001977|Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound on Osteoarthritis Pain of the Knee|Effects of Transcranial Direct Current Stimulation and Transcranial Ultrasound on the Perception of Pain Due to Osteoarthritis of the Knee||Spaulding Rehabilitation Hospital|No|Active, not recruiting|January 2011|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|64 Years|No|||July 2015|July 24, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01404052||100821|
NCT01404065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-001978|Effects of Transcranial Direct Current Stimulation (tDCS) and Visual Illusion on Chronic Pain Due to Spinal Cord Injury|Investigation of the Mechanisms of Transcranial Direct Current Stimulation of Motor Cortex Coupled With Visual Illusion for the Treatment of Chronic Pain in Spinal Cord Injury||Spaulding Rehabilitation Hospital|No|Terminated|December 2010|||August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|June 29, 2011||No|Recruitment difficulties and stopped funding|No||https://clinicaltrials.gov/show/NCT01404065||100820|
NCT01388205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIT-NUS-10-520|Trial of a Novel Family-Based Intervention to Increase Outdoor Time and Fitness|An Exploratory Randomized Controlled Trial of a Novel Family-Based Intervention to Increase Outdoor Time for the Prevention of Myopia and Increase Physical Activity Among Singapore Youth|FIT|National University, Singapore|Yes|Completed|April 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|285|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01388205||102035|
NCT01388426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R746|Moisture Chamber Glasses for Dry Eye in Asian Population|Moisture Chamber Glasses for Dry Eye in Asian Population||Singapore National Eye Centre|Yes|Completed|July 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|21 Years|N/A|No|||January 2013|January 8, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01388426||102018|
NCT01388673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 11-02|Safety and Preliminary Effectiveness of the BaroSense Articulating Circular Endoscopic (ACE) Stapler for Plication of Dilated Post-surgical Gastric Anatomy|Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for Plication of Dilated Post-surgical Gastric Anatomy||BaroSense Inc.|No|Withdrawn|October 2011|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|60 Years|No|||February 2012|February 7, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01388673||101999|
NCT01388660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA006|Pharmacokinetic Assessment of Simultaneous Administration of Clopidogrel and Aspirin|A Randomized, Open-label, Single-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a Tablet Containing 75 mg of Clopidogrel and 100 mg of Aspirin and The Simultaneous Administration of The Separate Formulations of The Two Drugs in Healthy Male Volunteers||Ajou University School of Medicine|No|Recruiting|June 2011|December 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388660||102000|
NCT01388946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Σ-147/03-08-10|Perioperative Ropivacaine Wound Infusion in Laparoscopic Cholecystectomy|||University of Athens|No|Recruiting|May 2010|September 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|30 Years|70 Years|No|||March 2012|March 20, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01388946||101978|
NCT01389193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBU-003|Ibudilast in the Treatment of Patients With Chronic Migraine.|Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST|IBU-003|Aalborg University|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|33|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01389193||101959|
NCT01419600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1883C00006|To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD8683 After Single Ascending Doses Administered Via Turbuhaler in Healthy Subjects||AstraZeneca||Completed|October 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|38|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01419600||99633|
NCT01419912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|soymilk and nephropathy|Comparison of Soy-milk and Cow Milk Consumption on Inflammatory Factors, Cardiovascular Factors ,Renal Factors, Fibrinolytic Indice and Oxidative Stress Among Type-2 Diabetic Patients With Nephropathy Stage 1 and 2|||Isfahan University of Medical Sciences||Completed||||||Phase 3|Interventional|Intervention Model: Crossover Assignment|2||||||Both|28 Years|81 Years||||January 2011|August 29, 2011|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419912||99609|
NCT01416558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 65|Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)|A Multicenter Non-randomized Phase II Study to Evaluate Nab-paclitaxel in Metastatic Brest Cancer Patients Failing a Solvent Based Taxane as (Neo-)Adjuvant Treatment (Tiffany)||German Breast Group|Yes|Terminated|July 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Female|18 Years|N/A|No|||May 2013|May 21, 2013|August 11, 2011||No|Study was terminated because of extrem low recruitment|No||https://clinicaltrials.gov/show/NCT01416558||99865|
NCT01416571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112691|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults|Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years||GlaxoSmithKline||Completed|August 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|78|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|August 12, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01416571||99864|
NCT01416259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPA C2011-01|A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin|A Randomized, Placebo-Controlled, Four-Period Crossover Definitive QT Study Of The Effects of APF530 Exposure, High-Dose IV Granisetron and Moxifloxacin on QTc Prolongation||Heron Therapeutics|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Male and Female Subjects|August 2015|August 3, 2015|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01416259||99888|
NCT01416779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-154|A Finding Balance Writing Intervention for Older Bereaved Caregivers|Finding Balance: The Experience of Hope for Bereaved Caregivers of Palliative Cancer Patients||University of Saskatchewan|Yes|Completed|February 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|23|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 15, 2012|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01416779||99848|
NCT01406756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL1131|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia|A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (NSC# 606869) in the Very High Risk Stratum||Children's Oncology Group|Yes|Recruiting|February 2012|||August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|14||Anticipated|4895|||Both|1 Year|30 Years|No|||February 2016|February 3, 2016|July 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406756||100613|
NCT01406769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0269|Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy|A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer||Gynecologic Oncology Group|Yes|Active, not recruiting|July 2012|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|July 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406769||100612|
NCT01407042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFJ-UKA-1|Patellofemoral Pain After Unicondylar Knee Arthroplasty|||Medical University Innsbruck||Recruiting|September 2011|||December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|consecutive patients scheduled for unicondylar knee arthroplasty at the Dept. for        orthopaedic surgery of our medical university|April 2015|April 7, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01407042||100591|
NCT01403259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNTG 11-02|SOX as Salvage Treatment in Nasopharyngeal Carcinoma|Phase II Study of SOX in Patients With Platinum-resistant Nasopharyngeal Carcinoma||Fudan University|No|Terminated|July 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|75 Years|No|||August 2014|August 19, 2014|July 26, 2011||No|poor accrual of eligible patients|No||https://clinicaltrials.gov/show/NCT01403259||100882|
NCT01403545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipocurc1001|Evaluation of Liposomal Curcumin in Healthy Volunteers|Safety, Tolerability and Pharmacokinetics of Liposomal Curcumin in Healthy Volunteers - A Phase I Dose Escalation Study||SignPath Pharma, Inc.|Yes|Completed|August 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403545||100860|
NCT01403792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC282|A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects|A Double-Blind, Placebo-Controlled, Randomised, Dose-Escalation Phase I Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects||University of Surrey|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|11|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 21, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403792||100841|
NCT01418391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-990400|the Effect of the Transversus Abdominis Plane (TAP) Block on the Minimal Laparotomy : a Randomized Controlled Trial|the Effect of the Transversus Abdominis Plane (TAP) Block on the Minimal Laparotomy : a Randomized Controlled Trial||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|August 16, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418391||99726|
NCT01418664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|786|Prevention of Adverse Pregnancy Outcome With Vitamin D Supplementation During Pregnancy|Prevention of Adverse Pregnancy Outcome With Vitamin D Supplementation During Pregnancy||Dow University of Health Sciences|Yes|Active, not recruiting|September 2010|March 2012|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|45 Years|No|||August 2011|August 16, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418664||99705|
NCT01418677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-106|An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function|An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function||Eisai Inc.|No|Completed|August 2011|August 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|N/A|No|||September 2014|September 29, 2014|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418677||99704|
NCT01418690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00509|Changes in Tissue Oxygenation Following Regional Anesthesia|Changes in Tissue Oxygenation Following Regional Anesthesia||Nationwide Children's Hospital||Completed|September 2011|June 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|29|||Both|N/A|N/A|No|Non-Probability Sample|Patients requiring regional anesthetics.|June 2012|June 22, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418690||99703|
NCT01388686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAC_BLOOD|Prevalence of CVC-associated Sepsis and Use of Blood Cultures in Berlin - Brandenburg|Retrospective Analysis of Proven Bacteremia, CVC-associated Infections and Sepsis||Charite University, Berlin, Germany|No|Recruiting|July 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Patients with bacteremia on intensive care units of different primary and secondary care        hospitals in the region of Berlin-Brandenburg.|January 2015|January 27, 2015|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01388686||101998|
NCT01418976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-Walking and Balance|Walking and Balance Post-TBI|IMPROVING WALKING AND BALANCE IN VETERANS WITH TRAUMATIC BRAIN INJURY: A PILOT STUDY EXAMINING FEASIBILITY AND DOSAGE||INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Completed|July 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418976||99681|
NCT01419262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000025147|DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers|DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers|DO IT|The Hospital for Sick Children|Yes|Completed|September 2011|October 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|703|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419262||99659|
NCT01419275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-06152011-7929|Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients|Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients||Stanford University||Completed|April 2009|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|120|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2013|November 27, 2013|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419275||99658|
NCT01419288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0573-1|Treadmill Training With Lower Extremity Amputees|||Stony Brook University|No|Completed|June 2009|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|21 Years|70 Years|No|||January 2013|January 8, 2013|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01419288||99657|
NCT01419613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16265|Promoting a Healthier Lifestyle Among Breast Cancer Survivors|Motivational Interviewing to Promote Physical Activity in Breast Cancer Survivors||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|August 2010|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|68|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 22, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419613||99632|
NCT01419626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNKPLT0008|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2011|||||N/A|N/A|N/A||||||||||||||September 15, 2011|August 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419626||99631|
NCT01419639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD001 NF2 (11-00587)|Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2|Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2||New York University School of Medicine|Yes|Completed|October 2011|December 2013|Actual|December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|3 Years|N/A|No|||July 2015|July 8, 2015|August 17, 2011||No||No|July 8, 2015|https://clinicaltrials.gov/show/NCT01419639||99630|
NCT01416038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC-DPX-Survivac-01|Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer|Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer||ImmunoVaccine Technologies, Inc.|Yes|Active, not recruiting|December 2011|||May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01416038||99905|
NCT01417130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREITNERBJ18CO|Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial|Alzheimer's Disease Anti-Inflammatory Prevention Trial Follow-Up Study|ADAPT-FS|Seattle Institute for Biomedical and Clinical Research|No|Active, not recruiting|August 2009|August 2012|Anticipated|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1650|Samples With DNA|Specimens retained from the ADAPT trial include plasma, serum, urine and cerebrospinal fluid      (the latter from a smaller sample of volunteers). Additional collection of cerebrospinal      fluid from prior donors and from a new panel of volunteers is conducted under a different      sub-study of ADAPT.|Both|75 Years|N/A|No|Non-Probability Sample|Living members of the cohort previously enrolled in the Alzheimer's Disease        Anti-inflammatory Prevention Trial (ADAPT)|January 2012|January 5, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01417130||99822|
NCT01416532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1107-131-104|Evaluation of Subclinical COronary Atherosclerosis for Risk Stratification Using Coronary Computed Tomography (CT) Angiography|Prognostic Value of Coronary CT Angiography in Relation to Evaluation of Subclinical Coronary Atherosclerosis for Risk Stratification in Asymptomatic Individuals From ESCORT Study|ESCORT|Seoul National University Bundang Hospital|Yes|Recruiting|January 2006|December 2015|Anticipated|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|20 Years|N/A|No|Non-Probability Sample|Asymptomatic adults without previous coronary artery disease|July 2011|August 17, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416532||99867|
NCT01417117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11011402|Effect of Ischemic Strokes on Recovery From Intracerebral Hemorrhages|The Effect of Diffusion Weighted Imaging Abnormalities on Outcomes in Patients With Spontaneous Intracerebral Hemorrhage||Rush University Medical Center|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|174|||Both|19 Years|79 Years|No|Non-Probability Sample|Subjects for this study will be selected from patients admitted with a primary        intracerebral hemorrhage to Rush University Medical Center's Neurosciences Intensive Care        Unit.|November 2014|November 6, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01417117||99823|
NCT01407055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG RI574/21-1|Optimizing Expectations in Cardiac Surgery Patients|Clinical Applications of Placebo Research: Optimizing Expectation Effects in Cardiac Surgery Patients||Philipps University Marburg Medical Center|No|Completed|July 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|80 Years|No|||February 2016|February 2, 2016|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01407055||100590|
NCT01402999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-528|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Hungary|ECOS HUN|Merck KGaA|No|Active, not recruiting|May 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|79|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01402999||100902|
NCT01403272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA/DUKE 01457|Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting|Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting||Precision Fabrics Group, Inc.|No|Completed|September 2010|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|75|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2011|July 26, 2011|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01403272||100881|
NCT01403285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA950-102|Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma|A Phase 1 Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM)||immatics Biotechnologies GmbH|Yes|Terminated|August 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|July 21, 2011|No|Yes|Due to poor accrual. This decision was taken without any safety reasons. Since beginning of    the study (June 2011) only six patients were enrolled.|No||https://clinicaltrials.gov/show/NCT01403285||100880|
NCT01403558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2071a|Personality and Eating Behaviors in Morbidly Obese Patients|Personality and Eating Behaviors in Morbidly Obese Patients|PSYMO|Sykehuset i Vestfold HF|No|Active, not recruiting|September 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01403558||100859|
NCT01404429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKG/992|Study of Two Different Starting Doses of Methotrexate When Starting Treatment in Rheumatoid Arthritis|Randomized Controlled Trial of Two Different Starting Doses of Methotrexate in Rheumatoid Arthritis|DMIRA|Postgraduate Institute of Medical Education and Research|No|Completed|May 2011|July 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||September 2014|September 5, 2014|July 26, 2011||No||No|August 9, 2014|https://clinicaltrials.gov/show/NCT01404429||100792|
NCT01403766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gentian-Cystatin-UCLA|Comparison of Markers of Kidney Function|Comparison of Estimated GFR Using Cystatin C Versus Creatinine in Pediatric Renal Transplant Patients||University of California, Los Angeles|No|Not yet recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|1 Year|18 Years|No|Non-Probability Sample|Subjects will be recruited from UCLA pediatric kidney transplant patients with stable        allograft function that come in for routine surveillance biopsy. Patients will be induced        with either daclizumab, basiliximab, or thymoglobulin and maintained on tacrolimus,        mycophenolate mofetil, and steroid-free or steroid-based immunosuppression.|July 2011|July 26, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403766||100843|
NCT01403779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-KOSIMA-01|Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated IMRT in Treatment of Breast Cancer|Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated Intensity Modulated Radiotherapy (IMRT) in Treatment of Breast Cancer: The KOSIMA Trial|KOSIMA|Universitätsmedizin Mannheim|No|Recruiting|July 2010|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Female|60 Years|N/A|No|||December 2015|December 29, 2015|October 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01403779||100842|
NCT01418118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-000073-37 5579|Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery|An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study|Free4Flow|Oxford University Hospitals NHS Trust|Yes|Completed|October 2008|February 2010|Actual|February 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|17 Years|N/A|No|||August 2011|August 15, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418118||99747|
NCT01418404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRI-EX99-9907PI|The Application of Thermal Stimulation on Functional Recovery of Stroke Patients|The Application of Thermal Stimulation on Functional Recovery of Stroke Patients||Kaohsiung Medical University Chung-Ho Memorial Hospital|No|Completed|January 2010|December 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|220|||Both|18 Years|80 Years|No|||April 2015|April 6, 2015|June 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01418404||99725|
NCT01418989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25539|A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers|An Open-label, Multi-center Study to Compare the Relative Bioavailability of Tocilizumab in Healthy Subjects Following Single Dose Subcutaneous (SC) Administration Via Disposable Auto-Injector (DAI) Device vs Pre-filled Glass Syringe (PFS)||Hoffmann-La Roche||Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01418989||99680|
NCT01419002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NetPac|Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer|Neoadjuvant Radiotherapy in Patients With Primary Resectable Adenocarcinoma of the Pancreatic Head Plus Adjuvant Chemotherapy: a Randomized Controlled Phase III Trial|Net-Pac|CHIR-Net|No|Terminated|October 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 13, 2011||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01419002||99679|
NCT01419015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EW-P-002|Transfemoral Placement of 20mm Aortic Balloon Expandable Transcatheter Valve Trial (JAPAN)|A Clinical Trial of a 20mm Transcatheter Bioprosthetic Valve for Patients With Aortic Stenosis|PREVAIL20JAPAN|Edwards Lifesciences|Yes|Active, not recruiting|June 2011|September 2017|Anticipated|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|N/A|No|||February 2014|February 19, 2014|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419015||99678|
NCT01419964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-VTL-03(09/11)|Efficacy and Safety of ACH24 in the Treatment of Vitiligo|Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo||Ache Laboratorios Farmaceuticos S.A.|No|Withdrawn|January 2012|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||March 2016|March 15, 2016|August 17, 2011||No|The Brazilian regulatory agency - ANVISA has requested the cancellation of the phase 3 study    for conducting a phase 1 study first.|No||https://clinicaltrials.gov/show/NCT01419964||99605|
NCT01415817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000433|Endoscopic Quality Improvement Program|The Effect of an Intensive Endoscopic Quality Improvement Program (EQUIP) on Improved Detection and Classification of Non-polypoid (Flat and Depressed) and Polypoid Colorectal Adenomas. ("EQUIP" Study)|EQUIP|Mayo Clinic|No|Completed|August 2010|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 11, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01415817||99922|
NCT01415830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIRMEX-ECA-03-2011|Compare Two Anti-Scorpion Venom Serum In Children|Randomized Controlled Trial To Evaluate Efficacy And Safety Of The Polyvalent Anti-scorpion Venom Serum Of Birmex Versus Other Commercial Venom Serum In Children Population||Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.|Yes|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|120|||Both|1 Year|15 Years|No|||February 2013|February 5, 2013|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01415830||99921|
NCT01416051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 25001|Efficacy of Olibra: A 12 Week Controlled Trial|Efficacy of Olibra: A 12 Week Randomized Controlled Trial, and Review of Prior Studies||Pennington Biomedical Research Center|No|Completed|January 2005|November 2006|Actual|November 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|82|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416051||99904|
NCT01417949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT Nr. 2010-022413-26|Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events|Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study)|IDEAL|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|August 2011|||October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||May 2013|May 27, 2013|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01417949||99760|
NCT01416545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/17450-3|Children Education and Cardiovascular Risk Reduction in Their Parents|Children Education as Therapeutic Instrument for Cardiovascular Risk Reduction in Their Parents|CETICARP|University of Sao Paulo|No|Completed|January 2010|June 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|520|||Both|5 Years|11 Years|No|||August 2011|August 12, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01416545||99866|
NCT01417637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88563|The Effect of Low Level Laser Therapy (LLLT) in Myofacial Pain Syndrome|A Randomized Clinical Trial of the Effect of Low Level Laser Therapy in Myofacial Pain Syndrome||Mashhad University of Medical Sciences|Yes|Active, not recruiting|August 2010|November 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|N/A|N/A|No|||June 2010|August 15, 2011|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417637||99784|
NCT01407068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-864|Administration of Two Injections for Multiple Dupuytren's Contractures|An Open-label Study to Assess the Safety and Efficacy of Concurrent Administration of Two Injections of AA4500 0.58 mg Into the Same Hand of Subjects With Multiple Dupuytren's Contractures||Endo Pharmaceuticals|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|July 29, 2011|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01407068||100589|
NCT01403311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-ALA-01|A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|ALA|Legacy Health System||Active, not recruiting|October 2010|March 2015|Anticipated|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403311||100878|
NCT01403012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOS-1168-WEI-0080-I|BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis|Differential Analysis of Metabolomic Profiles in Patients With Chronic Plaque Psoriasis Undergoing Systemic Treatment|Bostrip|Technische Universität München|No|Terminated|August 2011|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|Samples With DNA|Psoriasis patients|Both|18 Years|80 Years|No|Non-Probability Sample|Psoriasis patients|March 2016|March 16, 2016|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01403012||100901|
NCT01403818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0074|A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration|Pharmacokinetic Study of ASP1941 -A Pharmacokinetic Study to Assess Drug-Drug Interaction Between ASP1941 and Mitiglinide Calcium Hydrate||Astellas Pharma Inc|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|July 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01403818||100839|
NCT01404117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAQ-MS-201|A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability|||Teva Pharmaceutical Industries||Withdrawn|March 2012|January 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|55 Years|No|||August 2013|August 26, 2013|July 26, 2011||No|Study is being redesigned|No||https://clinicaltrials.gov/show/NCT01404117||100816|
NCT01404130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/S0802/135|A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory|A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory||University of Aberdeen|No|Completed|September 2008|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|16 Years|N/A|No|||July 2011|July 26, 2011|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404130||100815|
NCT01433978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-305|A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)|A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)||Eisai Inc.|Yes|Terminated|April 2012|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|September 13, 2011|Yes|Yes|Study terminated by the Sponsor|No||https://clinicaltrials.gov/show/NCT01433978||98535|
NCT01433991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-G000-901|E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)|An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)||Eisai Inc.||Active, not recruiting|October 2011|||February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Both|N/A|N/A|No|||June 2015|June 30, 2015|September 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433991||98534|
NCT01435941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112630|Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine|Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine||GlaxoSmithKline|No|Completed|September 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|11249|||Both|18 Years|N/A|No|Non-Probability Sample|The American Migraine Prevalence and Prevention (AMPP) study is a multi-year longitudinal        population-based study that follows a cohort of headache sufferers with severe headaches.        From 2004 to 2009, respondents with headaches completed mailed questionnaires. Respondents        had been screened from 120,000 US households and 24,000 individuals with severe headaches        were invited to respond to annual questionnaires. Within the 2005 EM cohort a transition        was defined to have occurred if in the observed year a respondent was CM and in the year        immediately preceding that year a subject was EM. Participants were followed for up to 4        years with the provision that the individual provided data in 2005 and then in at least        one subsequent year (2006-2009).|September 2011|September 21, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01435941||98385|
NCT01428219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.069|Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone|A Phase II Trial of Cabozantinib (XL184) in Patients With Castrate-Resistant Prostate Cancer Metastatic to Bone||University of Michigan Cancer Center|Yes|Active, not recruiting|February 2012|November 2015|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Male|18 Years|N/A|No|||August 2015|August 31, 2015|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428219||98973|
NCT01427920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3878|Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes|A 20 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group Comparison of Twice Daily Subject Driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Versus Twice Daily Investigator-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Both in Combination With Metformin in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin Analogues|SimpleMix™|Novo Nordisk A/S|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|348|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|August 31, 2011|Yes|Yes||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01427920||98996|
NCT01428765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.114|GLORIA-AF Registry Program (Phase I)|GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase I)||Boehringer Ingelheim||Completed|May 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1096|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients with non-valvular atrial fibrillation at risk for stroke|January 2014|January 21, 2014|August 25, 2011||||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01428765||98931|
NCT01428791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P50HL105189-01|Reducing Disparities in Late Life Depression and Metabolic Syndrome|BRIGHTEN Heart: Reducing Disparities in Late Life Depression and Metabolic Syndrome|BRIGHTEN-Heart|Rush University Medical Center|No|Active, not recruiting|March 2011|December 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 12, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428791||98929|
NCT01424657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC. 97-026|Magnetic Resonance Cholangiopancreatography Versus Endoscopic Retrograde Cholangiopancreatography in the Approach to Patients With Suspected Biliary Obstruction|||McGill University Health Center|No|Terminated|October 1997|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|378|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|August 23, 2011||No|The study was terminated before reaching the estimated sample size because of trial fatigue.|No||https://clinicaltrials.gov/show/NCT01424657||99245|
NCT01424839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM08_0057|Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors|SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors|SIOPCNSGCTII|University Hospital Muenster|Yes|Recruiting|October 2011|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|400|||Both|N/A|N/A|No|||June 2015|June 3, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01424839||99231|
NCT01424852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotics study7.4.2011|Does Administration of Probiotics During Infancy Increase the Caries Risk of a Child|Early Administration of Bifidobacterium Lactis BB-12 and the Caries Occurence of Children a 4 Years of Age||University of Turku|Yes|Withdrawn|January 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||February 2012|February 21, 2012|August 26, 2011||No|Too few of the invited subjects wanted to participate|No||https://clinicaltrials.gov/show/NCT01424852||99230|
NCT01425138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921142|Systematic Review And Meta-Analysis Of Psoriasis Treatments.|Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis||Pfizer|No|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|0|||Both|18 Years|N/A|No|Non-Probability Sample|Moderate-to-severe plaque psoriasis published trials.|September 2011|September 28, 2011|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425138||99208|
NCT01425151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schulthess_Anä_2|The i-GelTM. A Randomized, Crossover Study With the Laryngeal Mask Airway ProSealTM in Anesthetized Pediatric Patients|||Schulthess Klinik|No|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Months|6 Years|No|||September 2011|September 20, 2011|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425151||99207|
NCT01425424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10036|Prediabetes, Prehypertension and Vitamin D Supplementation - A Practice Based Clinical Intervention Pilot Study|Prediabetes, Prehypertension and Vitamin D Supplementation - A Practice Based Clinical Intervention Pilot Study||Pennington Biomedical Research Center|No|Terminated|April 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 10, 2011||No|The PI was leaving Pennington|No||https://clinicaltrials.gov/show/NCT01425424||99186|
NCT01418508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELPD-CKD|Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease (CKD)- ELPD Study|Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease(CKD)- ELPD Study|ELPD-CKD|Peking Union Medical College Hospital|Yes|Recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|75 Years|No|||August 2011|August 16, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418508||99717|
NCT01418820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS-PP-2011-02-16-001|Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions|Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions||University of Magdeburg|No|Active, not recruiting|March 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||November 2013|November 29, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418820||99693|
NCT01419132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tra-HSS-Fur|Troponin I Release After High Diuretic Doses|Effects of High Furosemide Doses Alone or With Hypertonic Saline on Troponin I Myocardial Release in Acute Decompensated Heart Failure: a Double Blind Study.|Tra-HSS-Fur|University of Palermo|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|95 Years|No|||October 2011|October 29, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01419132||99669|
NCT01419145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2620 (REK)|A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study|A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study||Norwegian University of Science and Technology|No|Completed|October 2011|November 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|46|||Both|18 Years|80 Years|No|||November 2014|November 3, 2014|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419145||99668|
NCT01419431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOCS3 mRNA|Attenuated Inflammatory Response in Laparoscopic Colon Surgery|Increased SOCS 3 mRNA in Monocytes From Patients Subjected to Laparoscopic Colon Surgery||Oslo University Hospital|No|Completed|January 2007|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Colon cancer stage I-III|December 2011|December 15, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01419431||99646|
NCT01419444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHMTD2011|Telemedicine Versus Traditional Treatment of Muscle Tension Dysphonia|Telemedicine Versus Traditional Treatment of Muscle Tension Dysphonia||University of Arkansas|Yes|Completed|August 2011|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|21 Years|N/A|No|||December 2013|December 17, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419444||99645|
NCT01386502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110198|CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors|Phase I Trial of Escalating Doses of Anti-PD1 Monoclonal Antibody (CT-011) in Combination With p53 Vaccine in Adults With Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Withdrawn|June 2011|October 2011|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2011|December 30, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386502||102165|
NCT01427569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWH-DFU-101-IL|Efficacy Study of IZN-6D4 Gel for the Treatment of Diabetic Foot Ulcers|A Randomized, Placebo-controlled, Double-blind Phase II Study to Evaluate the Efficacy of IZN-6D4 Gel for the Treatment of Diabetic Foot Ulcers||Izun Pharma Ltd|No|Completed|March 2012|August 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427569||99022|
NCT01435369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-2011-01|Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma|Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma||Medivation, Inc.|Yes|Completed|November 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435369||98429|
NCT01427907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COS-002|Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients|Randomized,Multi-center,Phase IV, 2-arm,Open-Label,Cross-over Study to Demonstrate the Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients|COS-002|Fresenius Medical Care North America|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|August 31, 2011||No||No|March 11, 2015|https://clinicaltrials.gov/show/NCT01427907||98997|The Last Patient Last Visit (LPLV) was on 06-July-2012 and last site close out visit was 31 May 2013. Due to inadvertent study deviations, no reliable conclusions can be drawn from the study.
NCT01427933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14392|A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer|An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy||Eli Lilly and Company|Yes|Completed|November 2011|June 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Female|18 Years|N/A|No|||July 2014|July 29, 2014|August 31, 2011|Yes|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01427933||98995|
NCT01428492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115125|Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma|A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma|PKB115125|Novartis|No|Completed|December 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01428492||98952|
NCT01428505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115241|[18F]PBR111 and Microglial Activation in Multiple Sclerosis|A Study to Characterize the Novel TSPO PET Radioligand [18F]PBR111 as an in Vivo Marker of Microglial Activation in Multiple Sclerosis||GlaxoSmithKline|No|Terminated|July 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|September 1, 2011||No|The Study was terminated because there was insufficient data to complete the study objectives|No||https://clinicaltrials.gov/show/NCT01428505||98951|
NCT01428518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115324|Special Drug Use Investigation for LAMICTAL Bipolar|Special Drug Use Investigation for LAMICTAL Bipolar||GlaxoSmithKline|No|Active, not recruiting|November 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|Japanese patients with bipolar disorder prescribed lamotrigine tablets for the first time|March 2015|March 26, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428518||98950|
NCT01425476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200806|Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors|Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study)||The University of Texas Health Science Center at Tyler|No|Recruiting|July 2008|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|45|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 19, 2014|April 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425476||99182|
NCT01424865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP B-31 ICSCA|Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial|Evaluation of the Co-Expression of the Cancer Stem Cell Marker ALDH1 and of HER2 as a Predictor of Adjuvant Trastuzumab Response in Breast Cancers of Women in NSABP B31||NSABP Foundation Inc|No|Active, not recruiting|November 2011|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1874|||Female|18 Years|N/A|No|Non-Probability Sample|Primary cancer tissue from participants in protocol NSABP B-31.|May 2015|May 6, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01424865||99229|
NCT01424878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910167|Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients|Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients||National Institutes of Health Clinical Center (CC)||Completed|July 2010|February 2014||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|200|||Both|2 Years|80 Years|No|||February 2014|March 16, 2016|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01424878||99228|
NCT01425164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVA-ISCHEMIA|Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol|Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study||Second University of Naples|No|Recruiting|January 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|220|||Both|30 Years|85 Years|No|||June 2012|June 27, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01425164||99206|
NCT01425437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tirgan 11-02|Keloid Tissue Bank|Keloid Tissue Bank - Longitudinal Clinical Data Repository; A Genomic and Molecular Research to Identifying Molecular Markers and Signal Transduction Pathways in Keloid; and Correlations With the Natural History of the Disease.||Tirgan, Michael H., M.D.|No|Terminated|June 2012|December 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|78|Samples With DNA|Sample of keloid tissue and small amount of normal appearing skin from an area that is      adjacent to the keloid will be collected from each participant. Each patient may undergo one      or more biopsies during the span of this study. Tissue biopsy may be repeated from the same      or a different keloid in the same patient. Patients may be re-contacted for additional blood      or other tissue samples.|Both|13 Years|N/A|No|Non-Probability Sample|Patient with a clinical diagnosis of keloid who are 13 years or older.|November 2014|November 14, 2014|August 23, 2011||No|Poor Enrollment|No||https://clinicaltrials.gov/show/NCT01425437||99185|
NCT01418521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0058.CTIL|Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery|Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) Versus Albumin Solution for Volume Replacement in Patients After Cardiac Surgery||Rambam Health Care Campus|No|Not yet recruiting|August 2011|August 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2011|August 16, 2011|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418521||99716|
NCT01418534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|179/09|Bioequivalence Study of Torrent Pharmaceutical Limited's ISMN 120 mg ER Tablets Under Fasting Condition|An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA in Healthy, Adult, Male, Human Subjects Under Fasting Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 16, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01418534||99715|
NCT01418833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7258|Preliminary Experience of Routine Voriconazole Therapeutic Drug Monitoring (TDM) in a Tertiary Care Centre|Preliminary Experience of Routine Voriconazole Therapeutic Drug Monitoring (TDM) in a Tertiary Care Centre.||Universitaire Ziekenhuizen Leuven|No|Completed|October 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|160|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with voriconazole, in whom at least 1 voriconazole plasma level was        determined|February 2015|February 6, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418833||99692|
NCT01418846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7401|Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients|Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients.||Universitaire Ziekenhuizen Leuven|No|Completed|October 2012|November 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|11|||Both|5 Years|N/A|No|Non-Probability Sample|Patients hospitalized at the pneumology ward, adult hematology ward and all hospitalized        pediatric patients, treated with voriconazole.|February 2013|January 12, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418846||99691|
NCT01385657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1026|Safety and Tolerability of REGN668 (SAR231893) in Patients With Moderate to Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Atopic Dermatitis||Regeneron Pharmaceuticals|Yes|Completed|July 2011|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||April 2012|September 27, 2013|June 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385657||102229|
NCT01385670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InterSEPT|InterSEPT: In‐Tunnel SeptRx European PFO Trial|InterSEPT: In‐Tunnel SeptRx European PFO Trial: A Prospective, Multi‐Center Study to Evaluate the Safety and Performance of the SeptRx IPO PFO Closure System|InterSEPT|SeptRx, Inc.|Yes|Recruiting|June 2011|||June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|70 Years|No|||June 2011|June 29, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385670||102228|
NCT01385956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16456|SOM 230 and Gemcitabine in Advanced Pancreatic Cancer|Phase I Study of Combination of SOM 230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|June 2011|November 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|June 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385956||102206|
NCT01419457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T705aUS109|Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment|A Phase I, Open-Label, Parallel-Group, Multiple-Dose Study to Determine the Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment and in Healthy Control Volunteers||MDVI, LLC|Yes|Completed|August 2011|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|36|||Both|19 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 20, 2015|August 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419457||99644|
NCT01385969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001506|LMA Cuff Pressure and LMA-induced Complications|Using the Natural Recoil of the Inflating Syringe as a Safety Valve to Limit LMA Cuff Pressure and Decrease LMA-Induced Complications||Mayo Clinic|No|Completed|June 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|360|||Both|18 Years|99 Years|No|Probability Sample|Patients scheduled to undergo a surgical procedure less than 2 hours in duration|November 2015|November 5, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385969||102205|
NCT01386788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EML015722-600|European Survey: Risk of Cyanide Poisoning in Smoke Inhalation|European Survey: Risk of Cyanide Poisoning in Smoke Inhalation, Symptoms, Key Treatment and Outcome (RISK)|RISK|Dr. Ernst MW Koch|No|Recruiting|April 2009|February 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|Patients with smoke inhalation|June 2011|June 30, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01386788||102143|
NCT01387048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-HAU-2011|Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin|Phase IV An Evaluator-Blind Controlled Parallel-Group Study To Assess Efficacy And Safety Of Skinoren® 15% Gel And Differin® 0,1% Gel For The Treatment And Maintenance Treatment Of Facial Acne Vulgaris And Late-Type Acne In Females|SKADI|University of Magdeburg|Yes|Completed|August 2011|October 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|45 Years|No|||July 2013|July 5, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387048||102123|
NCT01387022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA 009|Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression|Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression|TOAST|Centre for the AIDS Programme of Research in South Africa|Yes|Completed|June 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387022||102125|
NCT01387035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-360/2009|Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases|Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases||Heidelberg University|No|Recruiting|January 2010|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Included are all patients who fulfill the current definition of a collagen vascular        disease according to the actual guidelines of the American College of Rheumatology (ACR)        and who are 18 years or older.|July 2014|July 1, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01387035||102124|
NCT01433731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-141-001|Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma||TetraLogic Pharmaceuticals|Yes|Completed|November 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|N/A|No|||January 2016|February 23, 2016|September 9, 2011|No|Yes||No|December 15, 2015|https://clinicaltrials.gov/show/NCT01433731||98552|
NCT01427894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mc(0023)(2011)ctil|Maternal Singing During Kangaroo Care in Preterm Infants|The Combined Effects of Maternal Singing During Skin to Skin Contact (Kangaroo Care) in Preterm Infants in the Neonatal Intensive Care Unit Environment.||Meir Medical Center|No|Completed|November 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|6 Months|No|||September 2011|March 15, 2016|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01427894||98998|
NCT01427621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0648|Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery|Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery||Yonsei University|No|Completed|March 2010|May 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|20 Years|80 Years|No|||August 2011|August 31, 2011|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427621||99018|
NCT01427634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0152|Proactive Palliative Care for Patients With Ventricular Assist Devices (VAD) and Their Families|Randomized Controlled Trial of Proactive Palliative Care for Patients With Ventricular Assist Devices and Their Families||Icahn School of Medicine at Mount Sinai|No|Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|18|||Both|21 Years|N/A|No|||September 2013|September 5, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01427634||99017|
NCT01428245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14100|Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition|Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition in Early Pubertal Girls (JCM026)|JCM026|University of Virginia|No|Recruiting|January 2009|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Female|8 Years|14 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428245||98971|
NCT01428232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000076-AT11-123-UNC-DRC|Effectiveness of Well-child Clinics as the "Community" Basis of Step 10 of the Baby Friendly Hospital Initiative|Comparison of Two Clinic-based Interventions to Promote Early Initiation and Exclusive Breastfeeding Through 6 Months After Birth in Kinshasa, Democratic Republic of Congo||University of North Carolina, Chapel Hill|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|992|||Both|N/A|3 Days|Accepts Healthy Volunteers|||October 2013|October 10, 2013|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01428232||98972|
NCT01428817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02|Carbetocin at Elective Cesarean Delivery Part 2|Carbetocin at Elective Cesarean Delivery: A Dose Finding Study (Part 2)||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|120|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428817||98927|
NCT01424891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SimEze|Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe|Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe||Heidelberg University|No|Completed|April 2004|August 2011|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|31|||Both|35 Years|80 Years|No|||August 2011|August 25, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01424891||99227|
NCT01424904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0626-F1V|DGB-01 Effects on Endurance Exercise|DGB-01 Effects on Endurance Exercise||University of Kentucky|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|29|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01424904||99226|
NCT01425996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC388.2|A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma|A Phase I/II, Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma||Taiwan Liposome Company|Yes|Recruiting|July 2011|October 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|70 Years|No|||April 2013|April 16, 2013|August 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425996||99142|
NCT01425450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPI-HF1020-01|Safety Study of Four Doses of the Study Drug, HF1020 in Healthy Volunteers|A Randomised, Double-blind Placebo-controlled Study to Assess the Safety of Four Single Ascending Doses of HF1020 in Healthy Male Subjects||Trident Pharmaceuticals Inc|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 28, 2011|August 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425450||99184|
NCT01425463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0986|A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects|A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy||UCB Pharma|No|Completed|March 2011|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|256|||Both|16 Years|75 Years|No|||May 2015|May 8, 2015|August 26, 2011||No||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01425463||99183|
NCT01389401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cescsp179/04|Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis|Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis: Final Results||Faculdade de Ciências Médicas da Santa Casa de São Paulo|No|Completed|January 2009|July 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|36|Samples Without DNA|whole saliva|Both|19 Years|72 Years|Accepts Healthy Volunteers|Non-Probability Sample|25 adults with reflux laryngitis 13 healthy controls|March 2013|March 5, 2013|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389401||101943|
NCT01385371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08067|A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma (Protocol No. P08067)||Merck Sharp & Dohme Corp.|Yes|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1501|||Both|5 Years|65 Years|No|||September 2015|September 2, 2015|April 6, 2011|Yes|Yes||No|July 1, 2013|https://clinicaltrials.gov/show/NCT01385371||102250|
NCT01385644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC/09/QPCH/105|A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis|A Phase I Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis|MSC in IPF|The Prince Charles Hospital|Yes|Completed|October 2010|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|40 Years|80 Years|No|||November 2015|November 24, 2015|May 4, 2011||No||No|October 20, 2015|https://clinicaltrials.gov/show/NCT01385644||102230|
NCT01385982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000035|Improving Management of Outpatient Actionable Test Results|Improving Management of Outpatient Actionable Test Results|OutptATR|Brigham and Women's Hospital|Yes|Completed|July 2011|January 2013|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|6000|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01385982||102204|
NCT01386255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baclofen-07-02-0077|Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy|Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy||Children's Hospital Boston|Yes|Recruiting|April 2009|||April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Years|18 Years|No|||June 2011|June 29, 2011|June 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386255||102183|
NCT01386801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIHC-2009-01|Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana|Multicenter Research Study to Build a Repository That Will Allow Researchers to Study Chronic Diseases in the Population of Central Indiana|IHS|Fairbanks Institute|Yes|Active, not recruiting|December 2009|June 2050|Anticipated|December 2049|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|Samples With DNA|DNA = 1 Serum = 2 Plasma = 2 RNA = 2|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|People living in the state of Indiana|August 2013|September 5, 2013|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386801||102142|
NCT01434758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09TB|Evaluating Diagnostics for Paediatric Tuberculosis by Blood Culture|Evaluating Diagnostics for Paediatric Tuberculosis by Blood Culture||Oxford University Clinical Research Unit, Vietnam|No|Recruiting|April 2011|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|795|Samples With DNA|-  sputum        -  gastric aspirate        -  blood        -  urine        -  cerebrospinal fluid|Both|N/A|15 Years|No|Non-Probability Sample|Study population is children aged 0-15 years presenting to NHP thought to have TB        infection according to inclusion criteria listed in this protocol.|November 2013|November 22, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01434758||98475|
NCT01435057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEN|Effects of Different Exercise Training Regimens on Visceral Fat Dynamic and Resting Energy Expenditure in Obese Patients|Monocentric, Randomized, Controlled Study for Reduction on Visceral Fat Dynamic and Resting Energy Expenditure in Obese Patients Via Strength Versus Endurance Training (STEN Study - STrength Versus ENdurance Training)||University of Leipzig|No|Recruiting|April 2011|April 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||May 2015|May 27, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01435057||98453|
NCT01427946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-504-15|Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer|A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC||Infinity Pharmaceuticals, Inc.|No|Completed|July 2011|October 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427946||98994|
NCT01428557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/2011|BREATHE Registry - I Brazilian Registry of Heart Failure|BREATHE Registry - I Brazilian Registry of Heart Failure|BREATHE|Hospital do Coracao|Yes|Active, not recruiting|March 2011|July 2014|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|||Both|18 Years|N/A|No|Non-Probability Sample|Public and Private Hospitals|March 2014|March 5, 2014|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428557||98947|
NCT01428531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115489|Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment|Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment||GlaxoSmithKline|No|Completed|January 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|200|||Both|N/A|N/A|No|Probability Sample|Japanese patients with acute pulmonary thromboembolism or acute deep venous thrombosis|July 2015|July 13, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428531||98949|
NCT01428544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115490|Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)|Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)||GlaxoSmithKline|No|Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|5|||Both|N/A|N/A|No|Probability Sample|Japanese patients with acute pulmonary thromboembolism or acute deep venous thrombosis        whose body weight is 100 kg or more, or to whom fondaparinux was injected 10 mg/day.|July 2015|July 13, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428544||98948|
NCT01425177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSH 0909|Effect of Saline Irrigation to DEcrease Rate Of Residual Common Bile Duct Stones|Effect of Saline Irrigation to Decrease Rate of Residual Common Bile Duct Stones|SIDEROD|Seoul National University Hospital|Yes|Recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 26, 2011|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425177||99205|
NCT01424930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018715|A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer|An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer||Janssen-Ortho Inc., Canada|Yes|Completed|October 2011|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Male|18 Years|N/A|No|||July 2014|July 14, 2014|August 26, 2011||No||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01424930||99224|
NCT01424943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QIC-EC Coop Agreement 90CA1763|Family Networks Project Study One: An Efficacy Study of Stepping Stones Triple P for Children Under Age Two|The Family Networks Project Study One: Supporting Family Confidence, Competence, and Community Connections||University of South Carolina|No|Completed|December 2010|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|49|||Both|11 Months|23 Months|No|||October 2014|December 9, 2014|July 27, 2011||No||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01424943||99223|
NCT01424917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0802M27524|Noninvasive Predictors of Transplant Vasculopathy|Noninvasive Predictors of Transplant Vasculopathy|CAV|University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|March 2008|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Transplant Subjects|March 2013|March 13, 2013|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01424917||99225|
NCT01425723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9HB01EXT|Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B|An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B|B-YOND|Biogen|No|Enrolling by invitation|December 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Male|N/A|N/A|No|||January 2016|January 14, 2016|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425723||99163|
NCT01425489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK07/2011|Biomarker for Krabbe Disease|Biomarker for Krabbe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioKrabbe|University of Rostock|Yes|Recruiting|August 2011|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml      EDTA blood and a dry blood spot filter card are taken. To proof the correct Krabbe diagnosis      in those patients where up to the enrollment in the study no genetic testing has been done,      sequencing of Krabbe will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|1 Year|N/A|No|Probability Sample|Patients with Krabbe Disease|November 2015|November 10, 2015|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01425489||99181|
NCT01425502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011PS05|Data-driven Quality Improvement in Primary Care - Trial|Data-driven Quality Improvement in Primary Care: Cluster Randomised Controlled Trial to Test the Effectiveness of a Multifaceted Intervention in Reducing High Risk Prescribing of Non-steroidal Anti-inflammatory Drugs and Antiplatelet Agents|DQIP|University of Dundee|Yes|Completed|September 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 31, 2016|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425502||99180|
NCT01426282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHH 001|The Effects of Health Education in Cardiovascular Diseases Prevention and Treatment|The Effects of Health Education Given by Nurse on Out-patient Compliance in Cardiovascular Diseases Prevention and Treatment in China||Harbin Medical University|No|Completed|February 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|5|||Both|30 Years|74 Years|No|||August 2011|August 29, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01426282||99120|
NCT01426295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/06-C|Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital|Pharmaco-economic Cost-effective Prospective Randomized Trial Evaluating the Open Interest Caphosol ® Mouthwashes in the Prevention and Treatment of Severe Oral Mucositis in Patients Receiving High-dose Chemotherapy in Hematology|Caphosol|Nantes University Hospital|Yes|Completed|April 2011|April 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|92|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01426295||99119|
NCT01385384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuRx-055110|Diaphragmatic Pacemaker in Tetraplegic Patients With Spinal Cord Injuries|Evaluation of the NeuRx RA/4 Diaphragmatic Pacemaker in Tetraplegic Patients With Spinal Cord Injuries in Ventilator Support||University of Sao Paulo|Yes|Completed|June 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||March 2013|March 18, 2013|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01385384||102249|
NCT01385397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-109|Integrated Obesity Care Management System|Integrated Obesity Care Management System||Université de Sherbrooke|No|Completed|September 2006|||November 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 13, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385397||102248|
NCT01385683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008073|Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin|Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin|IMAGINE|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|10|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 21, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01385683||102227|
NCT01386528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7999-3773|Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B|An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B|paradigm™ 3|Novo Nordisk A/S|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|13 Years|70 Years|No|||September 2014|September 2, 2014|June 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386528||102163|
NCT01386541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5-8012-101-RD|Multiple Ascending Dose Trial of BYK324677 in Healthy Volunteers|Investigation of Safety/Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Doses of BYK324677 in Healthy Volunteers. A Monocentre, Placebo-controlled, Cross-over, Double-blind, Randomised Trial||Nycomed||Completed|June 2011|November 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|45 Years|No|||May 2012|May 4, 2012|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01386541||102162|
NCT01387906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Latisse2010|Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo|Latisse(Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo||Beer, Kenneth R., M.D., PA|Yes|Completed|March 2011|June 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|July 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387906||102058|
NCT01387919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10.164|Time Course and Nature of Nutrient Sensing During Fasting in Humans|Time Course and Nature of Nutrient Sensing During Fasting in Humans||Leiden University Medical Center|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|19 Years|29 Years|Accepts Healthy Volunteers|||January 2011|July 8, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01387919||102057|
NCT01427361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-CR-135|Clinical Outcome of Birmingham Hip Resurfacing (BHR) Using VISIONAIRE Femoral Alignment Guide|Prospective, Multi- Site, Clinical Study of Clinical Outcomes Following Hip Resurfacing Using VISIONAIRE Femoral Alignment Guide|BHR|Smith & Nephew, Inc.|No|Completed|October 2009|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patient population considered for this study is patients requiring total hip        resurfacing. The following inclusion and exclusion criteria will be used to identify study        candidates.|September 2012|September 17, 2012|August 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01427361||99038|
NCT01426828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07409|Id-KLH Vaccine + T Cells|Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Subjects With Myeloma Undergoing Autologous Transplant||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|August 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426828||99079|
NCT01427608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOP-PD-II|Sustaining Remission of Psychotic Depression|Sustaining Remission of Psychotic Depression|STOP-PD|Weill Medical College of Cornell University|Yes|Recruiting|October 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|392|||Both|18 Years|85 Years|No|||March 2016|March 16, 2016|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427608||99019|
NCT01427374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000387|Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients|Clinical, Biochemical and Genetic Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients (CKDCS/LUCID)||University of Alberta|No|Recruiting|May 2011|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7000|Samples With DNA|Blood and urine will be obtained at baseline, 6 months and annually thereafter. Blood      samples will be immediately divided into multiple aliquots, from which plasma, DNA, RNA      and/or cells will be extracted and separately stored. Urine specimens will also be aliquoted      to allow future measurement of genetic and cellular material. Specimens will be labeled      using unique study identifiers to maintain confidentiality.|Both|18 Years|N/A|No|Non-Probability Sample|Incident hemodialysis and peritoneal dialysis patients|November 2014|November 26, 2014|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427374||99037|
NCT01427387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0456-CL-0012|A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects|Phase I Study of ASP0456 - A Double-blind, Placebo-controlled, Multiple Ascending Dose Study / Investigational Study for Dose Timing Selection in Non Elderly Healthy Subjects-||Astellas Pharma Inc|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|44|||Both|20 Years|44 Years|Accepts Healthy Volunteers|||September 2011|September 22, 2011|August 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01427387||99036|
NCT01428258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0165|Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria|Phase 2 Study of Glycomacropeptide vs. Amino Acid Diet for the Management of PKU|PKU|University of Wisconsin, Madison|No|Active, not recruiting|September 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|12 Years|45 Years|No|||September 2015|September 22, 2015|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428258||98970|
NCT01424670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242-09-213|Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis|A Phase 3, Multicenter,Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Active, not recruiting|September 2011|May 2017|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|511|||Both|18 Years|69 Years|No|||October 2015|October 13, 2015|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01424670||99244|
NCT01425190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07614|Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)|Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (Phase 1b); Protocol No. P07614||Merck Sharp & Dohme Corp.|No|Terminated|January 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|3 Years|17 Years|No|||September 2015|September 4, 2015|August 26, 2011|No|Yes|The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free    regimens in pediatric studies of HCV infection.|No|October 3, 2014|https://clinicaltrials.gov/show/NCT01425190||99204|
NCT01389102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EST-01|Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Estradiol Metered-Dose Transdermal Spray (MDTS) in the Treatment of Vasomotor Symptoms in Postmenopausal Women||Lumara Health, Inc.|No|Completed|December 2004|November 2006|Actual|November 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|454|||Female|35 Years|N/A|No|||June 2012|June 8, 2012|July 5, 2011|Yes|Yes||No|February 29, 2012|https://clinicaltrials.gov/show/NCT01389102||101966|
NCT01389115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Iul_LC|Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation|Fatty Acids Lipidome and Oxidative Stress Markers as Indicators of Liver Transplant Outcome||University of Roma La Sapienza|Yes|Recruiting|July 2001|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|320|Samples With DNA|Blood samples and liver biopsy specimens|Both|15 Years|69 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. 150 cirrhotic patients, including Hepatocellular Carcinoma (HCC), Hepatitis C Virus             (HCV) positive patients          2. 80 healthy controls          3. 100 liver donors|December 2015|December 10, 2015|May 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01389115||101965|
NCT01385995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL075077|Effects of Treatment of Sleep Apnea on Metabolic Syndrome|A Controlled Trial of Continuous Positive Airway Pressure (CPAP) Therapy on Metabolic Control in Individuals With Impaired Glucose Tolerance and Sleep Apnea||Brigham and Women's Hospital|No|Completed|January 2004|September 2008|Actual|September 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||February 2014|February 10, 2014|June 23, 2011||No||No|February 21, 2012|https://clinicaltrials.gov/show/NCT01385995||102203|
NCT01386008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-10-50|Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens|||Coopervision, Inc.|No|Terminated|May 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 4, 2014|May 22, 2011|No|Yes|unexpected adverse events|No|November 1, 2013|https://clinicaltrials.gov/show/NCT01386008||102202|Incomplete data sets / Data not analyzed / Not all subjects completed the study measures at each outcome measurement time frame before the study was terminated. 20 participants completed V1 and only 1 participant completed the V2 follow-up.
NCT01386268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14927|Kogenate FS Regulatory Post-Marketing Surveillance|KOGENATE® FS , Local Post Authorization Safety Study|KG0910KR|Bayer|No|Completed|June 2011|August 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|64|||Both|N/A|N/A|No|Non-Probability Sample|Patients with hemophilia A in Korea|August 2014|August 20, 2014|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01386268||102182|
NCT01386281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15073|Julina Post-marketing Surveillance for Climacteric Symptoms in Japan|Drug Use Investigation of Julina Tablets 0.5 mg (Postmenopausal Osteoporosis)|JULINA-CLIMA|Bayer|No|Completed|October 2008|April 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|506|||Female|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who have received a prescription of Julina        on the basis of the decision of the treating gynecologist. The study is expected to        collect data of 100 patients in about 20 gynecological practices in Japan.|July 2012|July 10, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01386281||102181|
NCT01386294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACTS 001|Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection|A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection||CONRAD|Yes|Completed|October 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2059|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|June 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01386294||102180|
NCT01386307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1670|Prevalence of Pain in Inpatient at the Hospital Italiano de Buenos Aires|¿Cuál es la Prevalencia de Dolor en internación en el Hospital Italiano?|Pain|Hospital Italiano de Buenos Aires|No|Completed|March 2011|April 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|800|||Both|18 Years|N/A|No|Probability Sample|Patients older than 18 years, hospitalized at the Hospital Italiano de Buenos Aires and        admitted 24 to 72 hours before the evaluation.|March 2015|March 19, 2015|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01386307||102179|
NCT01387113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERFUSE|The PERFusion Use in Stroke Evaluation Study|Expanding the Time Window for IV Thrombolysis With Rt-PA in Acute Ischemic Stroke Patients Using Computed Tomography Perfusion Imaging: The PERFusion Use in Stroke Evaluation (PERFUSE) Study|PERFUSE|California Pacific Medical Center Research Institute|No|Recruiting|May 2011|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|All acute ischemic stroke patients who present to the emergency room at CPMC who receive        IV rt-PA within 6 hours of symptom onset|February 2016|February 1, 2016|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01387113||102118|
NCT01387126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004|Effects of a High Viscosity Dietary Fibre, as Part of a Medically Supervised Weight Management Program|A Randomized, Controlled Trial Evaluating the Effects of a High Viscosity Dietary Fibre, as Part of a Medically Supervised Weight Management Program, on Body Weight in Overweight and Obese Individuals||Canadian Center for Functional Medicine||Suspended|March 2017|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|20 Years|55 Years|No|||September 2015|September 30, 2015|June 30, 2011||No|The study is suspended as funding is being seeked for the execution of this clinical trail.|No||https://clinicaltrials.gov/show/NCT01387126||102117|
NCT01426841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI Yee 25708|Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer|Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer||AHS Cancer Control Alberta|Yes|Active, not recruiting|August 2011|April 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01426841||99078|
NCT01427114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1010258|R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)|Open-labeled, Multicenter Phase II Study of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients With Non-conjunctival Ocular Adnexal MALT Lymphoma||Konkuk University Medical Center|No|Active, not recruiting|July 2011|August 2016|Anticipated|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427114||99057|
NCT01427075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018/11|Evaluation Of The Pharynx in Patients Undergoing Lateral Pharyngoplasty|Evaluation of the Pharynx Through MRI in Patients Undergoing Lateral Pharyngoplasty for Treatment of Obstructive Sleep Apnea||Hospital do Servidor Publico Estadual|No|Active, not recruiting|March 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||April 2012|April 7, 2012|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427075||99060|
NCT01427088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS-sBDNF-SPR-2011|rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia|Short-Term Response of Serum Brain-Derived Neurotrophic Factor to Repetitive Transcranial Magnetic Stimulation in Patients With Chronic Schizophrenia||Jeonbuk Provincial Maeumsarang Hospital|No|Completed|August 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|25 Years|60 Years|No|||February 2015|February 15, 2015|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01427088||99059|
NCT01427101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/073-PMP-Andréasson|Results of CRS and Debulking in PMP Patients|Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei||Uppsala University|No|Active, not recruiting|September 1993|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1||||Patients treated from 1993 are included and during these years treatment strategy has      changed. The different strategies are compared but its juts one cohort of patients. No      completion date are set due to that reports from other centres show that there are longtime      survivers in both treatment groups.|Both|20 Years|80 Years|No|Probability Sample|Patients with Pseudomyxoma Peritonei, sceduled for surgical treatment at Uppsala        University Hospital.|August 2011|August 31, 2011|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427101||99058|
NCT01427647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Complutense University 1|Inflammatory Response After Colorectal Cancer Surgery|Inflammatory Response Following Colorectal Cancer Surgery Depends on the Type of Anesthesia and Surgery|CRC|Complutense University|Yes|Completed|June 2007|February 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|N/A|No|||August 2011|August 31, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01427647||99016|
NCT01428869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1000AE|Combination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate Cancer|The Effect of Combination Statin, Acetylsalicylic Acid and Dutasteride Use on Prostate Cancer - a Sub Analysis of the REDUCE Trial||University Health Network, Toronto|No|Completed|August 2011|August 2011|Actual|||N/A|Observational|Time Perspective: Retrospective||4|Actual|8231|Samples Without DNA|Specimens were retained as part of the REDUCE protocol, but no biospecimens are required for      the current protocol.|Male|N/A|N/A|No|Non-Probability Sample|Participants of the REDUCE trial (negative prostate biopsy at baseline) who had at least        one post-baseline prostate biopsy.|September 2011|September 8, 2011|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01428869||98924|
NCT01428830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A65783|Non-inferiority of Short-term Catheterization Following Fistula Repair Surgery|Non-inferiority of Short-term Catheterization Following Fistula Repair Surgery||EngenderHealth|Yes|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|524|||Female|N/A|N/A|No|||January 2015|January 15, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01428830||98926|
NCT01428843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2009-2|Comparison of Ferrisat vs Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy|A Controlled, Randomised, Double-blind, Multicenter Study, Comparing Ferrisat Versus Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy|FER|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|No|Terminated|January 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2015|June 21, 2015|August 30, 2011||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01428843||98925|
NCT01424683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oddershede-1|Development of a Method for Converting Visual Analogue Scale (VAS) Scores for Pain and Mobility to EQ-5D Answers|Development of a Method for Converting VAS Scores for Pain and Mobility to EQ-5D Answers||Aalborg Universitetshospital|Yes|Completed|August 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|217|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing CABG|June 2013|June 4, 2013|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424683||99243|
NCT01424956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USI2011001|CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study|To Determine the Impact on Reader Performance, as Defined by the Area Under the Receiver Operating Characteristic Curve, When Automated Breast Ultrasound and a Screening Mammogram Are Combined, Compared to a Screening Mammogram Alone in Asymptomatic Women With >50% Parenchymal Density and a Screening Mammogram Assigned a BI-RADS Assessment Category 1 (Negative) or 2 (Normal With Benign Findings).||U-Systems, Inc.|No|Completed|July 2011|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|17|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|17 Interpreting Physicians (Readers) qualified by training and experience, who are in        breast imaging practices in the United States.|April 2013|April 16, 2013|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424956||99222|
NCT01425216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tirgan 11-05|Sorafenib for Patients With Extensive Keloids|Phase II Trial of Sorafenib in Patients With Extensive Keloids||Tirgan, Michael H., M.D.|No|Terminated|March 2013|September 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|50 Years|No|||December 2013|December 16, 2013|August 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425216||99202|
NCT01425736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-IST-SCCHN-008|Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma|Phase 2 Study of Nimotuzumab in Combination With TPF for Head and Neck Squamous Cell Carcinoma||Shanghai 9th People's Hospital|Yes|Completed|January 2009|March 2013|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|No|||June 2014|June 1, 2014|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01425736||99162|
NCT01425749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15398|Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI|T Cell Activation and Immune Cell Function in Melanoma Patients Treated With recMAGE-A3 + AS15 Immunological Adjuvant System|Mel55|University of Virginia|Yes|Active, not recruiting|June 2011|December 2013|Anticipated|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|27|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425749||99161|
NCT01425528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48052|Study of Kuvan Treatment in Adults With GTPCH Deficiency|Pilot Study to Assess Impact of Kuvan® Supplementation as an Adjunct Treatment in Subjects With Dominantly-inherited GTPCH Deficiency on Mood, Behavioral and Motor Phenotypes||University of Utah|Yes|Completed|August 2011|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|August 25, 2011|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT01425528||99178|
NCT01426009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-101-03|Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101 in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 in Subjects With Moderate to Severe COPD||Sunovion Respiratory Development Inc.|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|275|||Both|40 Years|75 Years|No|||May 2014|May 7, 2014|August 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426009||99141|
NCT01389414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017428-17|Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma|Phase II, Open-label, Randomized Clinical Trial of Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX) Versus GEMOX Alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma|Vecti-BIL|Fondazione del Piemonte per l'Oncologia|No|Completed|May 2010|May 2015|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|89|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01389414||101942|
NCT01385423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010LS063|Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)|Haploidentical Donor Natural Killer (NK) Cell Infusion With Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)||Masonic Cancer Center, University of Minnesota|Yes|Completed|September 2011|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01385423||102246|
NCT01385722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THOR0004|Molecular Analysis of Thoracic Malignancies|Molecular Analysis of Thoracic Malignancies||Stanford University|Yes|Enrolling by invitation|August 2011|June 2031|Anticipated|June 2031|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|The potential tumor tissues to be collected include paraffin-embedded tissue, frozen      tissues, or fresh tissue. These will be stored in conjunction with the Stanford Tissue Bank.|Both|18 Years|N/A|No|Non-Probability Sample|Participants will be identified who come to the Stanford Cancer Center seeking a Thoracic        Oncology medical opinion for their disease.|November 2015|November 16, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01385722||102224|
NCT01385735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-TevAzi|Emotion, Mood and Executive Function in Parkinson`s Disease (PD)|Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson`s Disease|RasQ|St. Josef Hospital Bochum|Yes|Not yet recruiting|October 2011|April 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|75 Years|No|||June 2011|June 29, 2011|June 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385735||102223|
NCT01386021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVG1101.001-M|Saphenous Vein Allografts for Coronary Bypass|Single Center Evaluation of CryoVein Saphenous Vein Allografts for Coronary Artery Bypass Grafting||CryoLife, Inc.|No|Completed|June 2011|November 2011|Actual|October 2011|Actual|N/A|Observational|N/A||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having a previous implant of CryoVein Saphenous Vein allografts for CABG between        2008 - 2010, at a single instituion|December 2011|December 20, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386021||102201|
NCT01386554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QSC01-MN-01|Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients|A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)|CHART|Mallinckrodt||Recruiting|August 2011|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|June 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386554||102161|
NCT01386567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-203 Extension|A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203|A One Year Open Label Study of Androxal in the Treatment of Secondary Hypogonadism in Men Who Have Completed Protocol ZA-203||Repros Therapeutics Inc.|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|21 Years|65 Years|No|||May 2013|May 16, 2013|June 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01386567||102160|
NCT01417819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China1|Effect of Mobile Communication on Childhood Cataract Follow-up Adherence|Effect of a Mobile Phone Short Message Service (SMS) on Childhood Cataract Follow-up Adherence in China||Sun Yat-sen University|Yes|Completed|December 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|258|||Both|N/A|18 Years|No|||August 2011|August 27, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01417819||99770|
NCT01417832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOC_20080328131018|Radiographic Progression of Sealed and Infiltrated Caries Lesions in Vivo|Radiographic Progression of Sealed and Infiltrated Caries Lesions in Vivo||Universidad El Bosque, Bogotá|Yes|Completed|January 2008|March 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|16 Years|35 Years|No|||August 2011|August 15, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01417832||99769|
NCT01387646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA019180-01|Behavioral Intervention for Minority Adolescent Women|Behavioral Intervention for Minority Adolescent Women||The University of Texas Health Science Center at San Antonio|Yes|Completed|October 2004|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|562|||Female|14 Years|18 Years|Accepts Healthy Volunteers|||June 2011|July 1, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387646||102078|
NCT01387932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-P3-11-01|HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer|Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma|HiQuality|Merit Medical Systems, Inc.|Yes|Recruiting|April 2011|December 2022|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|520|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387932||102056|
NCT01427127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMS|Effect of Ramosetron on Bowel Motility After Colorectal Resection|Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection||Kyunghee University Medical Center|Yes|Recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|64|||Both|20 Years|70 Years|No|||August 2011|August 30, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01427127||99056|
NCT01427400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03166|The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction|The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial|Botox|University of British Columbia|No|Recruiting|October 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Female|21 Years|N/A|No|||September 2015|September 1, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01427400||99035|
NCT01427959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10027|Tampere Traumatic Head and Brain Injury Study|Tampere Traumatic Head and Brain Injury Study|TheBrainS|Tampere University Hospital|No|Active, not recruiting|August 2010|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|1. 10ml whole blood        2. 10ml EDTA-blood x2|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Community sample consisting of consecutive mild traumatic brain injury patients metting        the enrollment criteria.|July 2015|July 10, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01427959||98993|
NCT01427972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14350|A Study of LY2623091 in Male and Females With Chronic Kidney Disease|Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients||Eli Lilly and Company|No|Completed|September 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|75 Years|No|||March 2013|April 30, 2013|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427972||98992|
NCT01428648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133272|Impact of Dance Therapy on Parkinson's Disease|Impact of Dance Therapy on Parkinson's Disease||University of Arkansas|No|Withdrawn|August 2012|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|September 2, 2011||No|Recruitment slow|No||https://clinicaltrials.gov/show/NCT01428648||98940|
NCT01425203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08160|The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)|Safety and Efficacy of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Chronic Hepatitis C Genotype 1 in Russia: Previously Untreated Patients and Patients Who Failed Prior Treatment With Pegylated-Interferon Plus Ribavirin||Merck Sharp & Dohme Corp.|No|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|238|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|August 26, 2011|No|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01425203||99203|
NCT01425515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0395|Improving Care for Patients With High Blood Pressure|Heart Healthy Lenoir: Improving Care for Patients With High Blood Pressure||University of North Carolina, Chapel Hill|Yes|Completed|September 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|535|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425515||99179|
NCT01424722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_420|ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients|ST Monitoring to Detect ACS Events in ICD Patients|AnalyzeST|St. Jude Medical|Yes|Active, not recruiting|August 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|5228|||Both|18 Years|N/A|No|||November 2015|November 1, 2015|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01424722||99240|
NCT01425229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K318|Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During Clarithromycin|Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Steady State Bosentan Before and During CYP3A4-inhibition by Clarithromycin||Heidelberg University|No|Completed|June 2011|December 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy subjects|July 2015|July 7, 2015|August 26, 2011||No||No|July 8, 2014|https://clinicaltrials.gov/show/NCT01425229||99201|
NCT01425242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-PET/CT vumc|Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension|An Open-label PET-observer-blinded Pilot Study of the Effect of Aliskiren- Versus Amlodipine-based Antihypertensive Treatment in Patients With Small Abdominal Aortic Aneurysm and Mild to Moderate Hypertension on Aneurysmal FDG-uptake|PISA|VU University Medical Center|No|Terminated|September 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|75 Years|No|||December 2014|December 8, 2014|August 26, 2011||No|Insufficient number of participants|No||https://clinicaltrials.gov/show/NCT01425242||99200|
NCT01425255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0077-11-WOMC|The Impact of Continuous Glucose Monitoring Use on Sleep in Parents of Children With Type 1 Diabetes Mellitus|Prospective Exploratory Study Evaluating Sleep Quality and Sleep-Wake Patterns in Parents of Children With Type 1 Diabetes Before and Several Weeks After Initiating Using RT-CGM of Their Children.||Wolfson Medical Center|No|Recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Juvenile Diabetes Clinics|August 2011|August 26, 2011|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425255||99199|
NCT01425268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-0003 AirXpanders|Patient Controlled Tissue Expansion for Breast Reconstruction|AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction|XPAND|AirXpanders, Inc.|Yes|Completed|October 2011|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 5, 2015|August 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425268||99198|
NCT01425762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08172011-8271|Influence of Patient Choice of Intrathecal Morphine on Post-cesarean Delivery Pain.|Influence of Patient Choice of Intrathecal Morphine on Post-cesarean Delivery Pain.||Stanford University|Yes|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01425762||99160|
NCT01385696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/32|Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients|Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in COPD Diagnosed Patients||Almirall, S.A.||Completed|June 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|130|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|June 17, 2011||No||No|January 14, 2013|https://clinicaltrials.gov/show/NCT01385696||102226|
NCT01385709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0310006393|The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels|The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels||Weill Medical College of Cornell University|No|Recruiting|August 2008|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Whole blood will be drawn.|Female|18 Years|40 Years|No|Non-Probability Sample|The specific psychiatric diagnoses anticipated in the subject pool include the conditions        that lithium and sertraline are indicated to treat, including Bipolar Affective Disorders,        Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic        Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder,        Premenstrual Dysphoric Disorder, and Social Anxiety Disorder.|June 2011|June 28, 2011|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01385709||102225|
NCT01386034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/5-W|Effects of Oral Citrulline on Protein Metabolism in Patients With Intestinal Failure (Citrugrêle 2)|Effects of Oral Citrulline on Protein Metabolism in Patients With Intestinal Failure : a Prospective, Randomized, Double-blind, Cross-over Study|CITRUGRELE 2|Nantes University Hospital|No|Recruiting|July 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|75 Years|No|||September 2014|September 17, 2014|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01386034||102200|
NCT01386047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO-09-0337|Evidence Based Decision Making: Integrating Clinical Prediction Rules|Evidence Based Decision Making: Integrating Clinical Prediction Rules Into Electronic Health Records|iCPR and EHR|Northwell Health|No|Completed|August 2010|July 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|168|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2012|October 3, 2012|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01386047||102199|
NCT01386320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0929 10/1304/1|Ultrasound Guided Ankle Block Versus Medial Forefoot Block for Forefoot Surgery|A Randomised, Blinded Comparison of an Ultrasound Guided Ankle Block Compared to a Nerve Stimulator Guided Ankle Block for Pain Relief After Forefoot Surgery.|USGAB|Hull and East Yorkshire Hospitals NHS Trust|No|Completed|February 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|85 Years|No|||April 2015|April 15, 2015|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386320||102178|
NCT01386333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-232|Safety Study of Intranasal Oxytocin in Frontotemporal Dementia|A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF|FTDOXY10EF|Lawson Health Research Institute|No|Completed|June 2011|||October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|23|||Both|30 Years|80 Years|No|||November 2013|November 1, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01386333||102177|
NCT01417546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110225|NHS-IL12 for Solid Tumors|First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|July 2011|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|100 Years|No|||February 2016|February 17, 2016|August 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01417546||99790|
NCT01417572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199|Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia|||Isfahan University of Medical Sciences||Recruiting|January 2010|September 2011|Anticipated|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2010|August 15, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01417572||99789|
NCT01418092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK37-007|ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)|A Phase 2b Randomized, Double-blind, Placebo-controlled, 12-week Study to Evaluate the Safety and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation||Alkermes, Inc.|Yes|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|August 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418092||99749|
NCT01418105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85/2010|Dysphagia and Cervical Spine Disorders in Patients With Brain Lesions|Dysphagia and Cervical Spine Disorders in Patients With Neurologic Deficits Due to Brain Lesions|DysphagCerv|University of Ioannina|Yes|Recruiting|January 2011|November 2016|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Anticipated|100|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01418105||99748|
NCT01427140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS-2011-LPG|Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN)|Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN): a Randomized Double-Blind Controlled Study|LIPOGAIN|Uppsala University|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|41|||Both|20 Years|38 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01427140||99055|
NCT01427660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS019256-01|iDecide.Decido: Diabetes Medication Decision Support Study|Technologically Enhanced Community Health Worker (CHW) Delivery of Personalized Diabetes Information|iDecide|University of Michigan|No|Completed|September 2011|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|190|||Both|21 Years|N/A|No|||September 2014|September 8, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427660||99015|
NCT01428570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN|Comparison of the Pentax AWS® With the Macintosh Laryngoscopic Intubation in Obstructive Sleep Apnea Syndrome Patients|Comparison of the Pentax AWS® With the Macintosh Laryngoscope for Tracheal Intubation in Patients With Obstructive Sleep Apnea Syndrome: a Randomized Comparative Study||Kyunghee University Medical Center|Yes|Recruiting|August 2011|October 2011|Anticipated|September 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|50|||Both|20 Years|70 Years|No|||September 2011|September 2, 2011|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428570||98946|
NCT01428583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-02-10-3001|Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain|A Multicenter, 12-Month, Open-Label, Single-Arm, Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain||Pfizer|No|Completed|December 2010|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|396|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428583||98945|
NCT01428661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-2301|Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder|MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension|MAGELLAN|Vanda Pharmaceuticals|No|Completed|September 2011|May 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|507|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|August 31, 2011|Yes|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01428661||98939|
NCT01425294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OCN-FAS-2011/1|Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment|A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice||AstraZeneca|Yes|Active, not recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|245|||Female|N/A|N/A|No|Non-Probability Sample|Medical units|November 2015|November 16, 2015|August 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425294||99196|
NCT01424969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29598|The Effects of Platelet Rich Plasma on the Integrity of Rotator Cuff Repair|Effects of Platelet-Rich Fibrin Matrix on Repair Integrity of At-Risk Rotator Cuff Tears||University of Utah|No|Completed|August 2008|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|37|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with symptomatic rotator cuff tears identified by clinical exam and MRI that        measure greater than two centimeters or are retracted medially to the level of the humeral        head cartilage that meet the inclusion/exclusion criteria were asked to participate.|February 2014|February 12, 2014|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01424969||99221|
NCT01425801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/100977/202|Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients|A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.||Almirall, S.A.|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|54|||Both|18 Years|70 Years|No|||May 2015|May 28, 2015|August 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425801||99157|
NCT01425814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/100977/25|Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population|A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Almirall, S.A.|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|60|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01425814||99156|
NCT01425541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8588|Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition|Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition in Normal and Hyperandrogenemic Adolescent Girls (JCM010)||University of Virginia|No|Completed|April 2000|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Female|8 Years|18 Years|No|||September 2015|September 3, 2015|August 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425541||99177|
NCT01417026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008241|Intranasal Oxytocin and Learning in Autism|Promoting Social Perceptual Learning With Oxytocin in Autism||Children's Hospital of Philadelphia|Yes|Active, not recruiting|September 2011|April 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Male|12 Years|17 Years|No|||September 2015|September 16, 2015|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417026||99829|
NCT01417052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX3305.1-106-RA|A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA)||Lexicon Pharmaceuticals|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|10|||Both|18 Years|75 Years|No|||August 2012|August 1, 2012|August 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417052||99828|
NCT01417325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bciqcic-fw-01|Beijing Percutaneous Coronary Intervention Registry|A Registry Study of Percutaneous Coronary Intervention Treatment in Beijing Area of P.R. China|BJPCI Registry|Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|January 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|700000|||Both|N/A|N/A|No|Non-Probability Sample|All the patients receiving coronal artery angiography or percutaneous coronary        intervention therapy in selected 48 hospitals of Beijing, P.R.China.|July 2015|July 27, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417325||99807|
NCT01387399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No.: 2010-024652-28|Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer|Phase I Study of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion With Cisplatin in Patients With Recurrent Ovarian Cancer|HIPEC ROC I|University Hospital, Bonn|Yes|Active, not recruiting|June 2011|July 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Female|18 Years|70 Years|No|||February 2013|February 14, 2013|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01387399||102097|
NCT01387412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP 39619|The Role of Genital Warts in HIV Acquisition in Peru|The Role of Genital Warts in HIV Acquisition Among MSM in Peru"|VIVA|University of California, Los Angeles|No|Completed|April 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|Samples With DNA|serum, lesion biopsies|Male|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|November 2015|November 30, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01387412||102096|
NCT01387425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-017599-26|Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)|Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: A Double-Blind, Placebo-Controlled, Randomized, Trial|DIASMOKE|Universita degli Studi di Catania||Completed|June 2011|||December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|June 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01387425||102095|
NCT01418131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tacro001|Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis|A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis||The University of Western Australia|Yes|Recruiting|October 2012|November 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|August 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418131||99746|
NCT01418144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-HT-2010|Effect of Transversus Abdominis Plane (TAP) Block After Laparoscopic Colon Surgery|Effect of Transversus Abdominis Plane (TAP) Block as Postoperative Pain Management After Laparoscopic Colon Surgery||Copenhagen University Hospital at Herlev|Yes|Completed|August 2010|July 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||August 2013|August 21, 2013|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01418144||99745|
NCT01417845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCA-IRB-11-077|The Effect of Exercise Training Intensity in Patients With Type 2 Diabetes|The Effect of Moderate Versus High Intensity Exercise Training on Physical Fitness and Physical Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial||University of Central Arkansas|No|Completed|September 2011|||August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|69 Years|No|||January 2014|January 31, 2014|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01417845||99768|
NCT01418417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200/07|Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fasting Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delayed Release Tablets of Wyeth Pharmaceuticals Inc, in Healthy Human Adult Subjects, Under Fasting Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 15, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01418417||99724|
NCT01427413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS4e|Identification and Standardization of a Method That Would Allow the Study of the Metabolic Profile of Blastocoele Lays the Foundation to Assess Blastocyst Metabolomic Profile and Its Relation With Embryo Morphology and Embryo Implantation|Identification and Standardization of a Method That Would Allow the Study of the Metabolic Profile of Blastocoele Lays the Foundation to Assess Blastocyst Metabolomic Profile and Its Relation With Embryo Morphology and Embryo Implantation||Cervesi Hospital, Cattolica, Italy|Yes|Recruiting|September 2011|December 2015|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|Samples With DNA|blastocoele fluid|Female|18 Years|45 Years|No|Probability Sample|All the patients that are unable to be subjected to embryo transfer due to her ovarian        hyperstimulation. In those cases the embryos will be vitrified and during this procedure        we collapse the blastocyst sucking the fluid.|August 2011|July 30, 2013|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01427413||99034|
NCT01428271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0337|Comparison Between the Expected Site of Sacral Hiatus by Conventional Method and the Real Site by Ultrasonography for Caudal Block in Children|||Yonsei University|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|80|||Both|N/A|6 Years|No|Non-Probability Sample|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorraphy        under general anesthesia|June 2013|June 1, 2013|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01428271||98969|
NCT01428297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPR277X2101|A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome|A First-In-human Study to Evaluate Safety and Tolerability of Topical BPR277 in Healthy Volunteers, and Proof of Concept (PoC) Studies to Evaluate the Safety, Tolerability, and Efficacy of Topical BPR277 in Patients With Atopic Dermatitis and Netherton Syndrome|3|Novartis||Completed|May 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428297||98967|
NCT01428609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUI79275|Blood Mercury Levels Following Retrograde Amalgam Surgeries|Blood Mercury Levels Following Retrograde Amalgam Surgeries||Isfahan University of Medical Sciences|Yes|Completed|September 2009|December 2010|Actual|December 2009|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01428609||98943|
NCT01428635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0319|Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML)|Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML)||M.D. Anderson Cancer Center|No|Recruiting|January 2012|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428635||98941|
NCT01424696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BONUS-IP-11|Baby Observational and Nutritional Study|Baby Observational and Nutritional Study (BONUS)|BONUS|Seattle Children's Hospital|Yes|Completed|December 2011|April 2015|Actual|April 2015|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|231|Samples With DNA|-  serum and/or plasma        -  urine        -  stool        -  oropharyngeal swab (OP swab)        -  saliva        -  sweat        -  buccal brushings|Both|N/A|3 Months|No|Non-Probability Sample|Infants diagnosed with CF who attend regular clinic visits during the first year of life|September 2015|September 25, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424696||99242|
NCT01424709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAVO study|Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)|Individualized 1st Line Chemotherapy Based on BRCA1 and RRM1 mRNA Expression Levels for Advanced Non-small Cell Lung Cancer|BRAVO|Tongji University|Yes|Active, not recruiting|December 2010|December 2014|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||September 2014|September 23, 2014|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01424709||99241|
NCT01428882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDP11|Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy|Phase 4, Prospective, Randomized, Double-blinded, Placebo-controlled Study Comparing Propofol vs. Midazolam Plus Propofol for Nonanesthesiologist Targeted Moderate Sedation in Outpatient Colonoscopy|MIDAPROP|Infante, Javier Molina, M.D.|Yes|Completed|June 2011|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428882||98923|
NCT01424748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBRA5124|Clinical Trial of Tahitian Noni Juice Safety|A Single Centre, Double-blind, Three Dose Level, Parallel Group, Placebo Controlled Safety Study With Tahitian Noni Juice in Healthy Subjects||Tahitian Noni International, Inc.|Yes|Completed|April 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|96|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|August 26, 2011|February 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01424748||99238|
NCT01425827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed116619163|Duloxetine for Pain in Older Adults With Knee Osteoarthritis (OA)|||Faculty of Medicine, University of Alexandria|Yes|Completed|November 2010|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|288|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||August 2011|August 27, 2011|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425827||99155|
NCT01425554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20/2011|Doppler Sonography, MR Venography, Plethysmography for the Diagnosis of CCSVI|Doppler Sonography, Magnetic Resonance Venography, Air-plethysmography in the Non-invasive Diagnostics of Chronic Cerebrospinal Venous Insufficiency (CCSVI)||Euromedic Specialist Clinics, Poland|Yes|Completed|August 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|126|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|August 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425554||99176|
NCT01427803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15647|Actual Use Trial of Naproxen Sodium|An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID|Kiefer AUT|Bayer|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|778|||Both|12 Years|N/A|Accepts Healthy Volunteers|||April 2014|September 24, 2015|August 31, 2011|No|Yes||No|February 5, 2013|https://clinicaltrials.gov/show/NCT01427803||99005|
NCT01427816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCT1202|A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome|A Randomized, Double Blind, Placebo Controlled, Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3|||180|||Both|20 Years|N/A|No|||October 2013|October 29, 2013|September 1, 2011||||No||https://clinicaltrials.gov/show/NCT01427816||99004|
NCT01426061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20040206|Clinical Effect of Reflexology and Homeopathy Added to Conventional Asthma Management|Effect of Reflexology, Homeopathy and Conventional Medical Treatment in Asthma: A Randomised Controlled, Parallel Group Trial.||University of Aarhus|Yes|Completed|May 2006|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01426061||99137|
NCT01426373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-11-26|Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area|Multicenter, Open-label Study of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Completed|August 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|August 26, 2011|Yes|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT01426373||99113|
NCT01389141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBRU-ARB 003|Age-related Changes in Ovarian Follicular Wave Dynamics|Ovarian Follicular Wave Dynamics During The Menstrual Cycle: Relationship To Age, Reproductive Hormones And Musculoskeletal Health||University of Saskatchewan|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|70|Samples Without DNA|Serum samples are isolated and frozen for retrospective analyses.|Female|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Seventy healthy women, exhibiting all inclusion criteria and no exclusion criteria will be        enrolled in this study. Women will be grouped into 1 of the following age categories:          1. . Mid-reproductive age (MRA): 18-35 years          2. . Late reproductive age-1 (LRA1): 36-44 years          3. . Late reproductive age -2 (LRA2): 45-55 years (this group will include women in the             LRA, EMT and LMT groups, as previously characterized by STRAW)|August 2011|August 11, 2011|May 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01389141||101963|
NCT01389440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD1003|Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer|Phase II Study Open, Not Randomized to Evaluate the Efficacy and Safety of Neoadjuvant Treatment With Gemcitabine and Erlotinib Followed by Gemcitabine, Erlotinib and Radiotherapy in Patients With Resectable Pancreatic Adenocarcinoma|GEMCAD1003|Grupo Espanol Multidisciplinario del Cancer Digestivo|Yes|Active, not recruiting|May 2011|December 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||September 2013|September 6, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01389440||101940|
NCT01385748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA2009/28/01|Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis|A Phase II, Multi-center, Randomised, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Lauriad® 50 μg and 100 μg Mucoadhesive Buccal Tablet (MBT) Applied Once Daily to Those of Placebo in the Prevention and Treatment of Chemoradiation Therapy Induced Oral Mucositis in Patients With Head and Neck Cancer||Onxeo|No|Completed|April 2010|December 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|183|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|June 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01385748||102222|
NCT01386814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1110/08|Neuropsychological Sleep Physical Exercise Hypoxia|Aspects of Neuropsychological Assessment, Standard and Sleep Efficiency in People Exposed to Altitude|Hypoxia|Federal University of São Paulo|Yes|Not yet recruiting|July 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|60|||Male|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Participants in this study 30 healthy male volunteers, aged 20 to 40 years, regular        physical activity, constituting three groups: 1 - without exercise-hypoxia group 10        volunteers who not be subjected to any kind of physical exercise in hypoxia and remain all        day of experiment, 2 - group exercise at sea level, is composed of 10 volunteers who will        undergo a protocol exercicio physical sea-level, 3 - group exercise and hypoxia - 10        volunteers who will carry out a protocol exercise on a treadmill, being the same in        condition of hypoxia. All groups on the first day of the experiment will undergo baseline        assessments, laboratory blood analysis salivary and spirometric testing.|May 2009|June 30, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386814||102141|
NCT01417585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/727-31/1|A Trial of a Client-centered Intervention Aiming to Improve Functioning in Daily Life After Stroke|A Randomized Controlled Trial of a Client-centered Intervention Aiming to Improve Functioning in Daily Life After Stroke|LAS-2|Karolinska Institutet|No|Completed|September 2009|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|280|||Both|N/A|N/A|No|||January 2012|April 14, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417585||99788|
NCT01418157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04NP|A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent|Double Blind, Placebo Controlled Randomised Trial of Acetazolamide Versus Placebo in the Prevention of Acute Mountain Sickness During Rapid Ascent||Oxford University Clinical Research Unit, Vietnam|Yes|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|380|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418157||99744|
NCT01418430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHOP-Z|Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)|HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)||King's College Hospital NHS Trust|Yes|Completed||||||Phase 4|Interventional|Primary Purpose: Treatment|1||||||Both|18 Years|75 Years|No|||July 2011|August 19, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418430||99723|
NCT01418443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201/07|Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fed Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delayed Release Tablets of Wyeth Pharmaceuticals Inc, in Healthy Human Adult Subjects, Under Fed Conditions||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 16, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01418443||99722|
NCT01427985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULMNEONIRS02|Influence of Premedication Protocols for Neonatal Endotracheal Intubation on Cerebral Oxygenation|The Influence of Two Different Premedication Protocols for Endotracheal Intubation in Neonates on Cerebral Oxygenation||University of Ulm|No|Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|44 Weeks|No|||July 2012|July 24, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427985||98991|
NCT01427998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMC1111|Effect of Olive Leaves as Hypoglycemic Agents in Diabetic Subjects|A Phase Three Clinical Intervention Trial of Olive Leaves and Their Extracts in Human Diabetic Subjects||Wolfson Medical Center|Yes|Completed|August 1999|August 2001|Actual|August 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|80 Years|No|||September 2011|September 1, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01427998||98990|
NCT01428596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A010|Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects|A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX™) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy|GCHT01|GeneCure Biotechnologies|Yes|Recruiting|September 2010|||December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|60 Years|No|||March 2015|March 9, 2015|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428596||98944|
NCT01428310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-006|Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke|A Single Center, Single-Blind, Randomized, Crossover Pilot Study to Evaluate the Safety and Effects of Anatabloc™, a Dietary Supplement, in Reducing the Urge to Smoke in Daily Smokers Followed by an Open-Label Extension||Rock Creek Pharmaceuticals, Inc.|No|Completed|September 2011|December 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|109|||Both|23 Years|72 Years|Accepts Healthy Volunteers|||October 2015|October 29, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428310||98966|
NCT01428349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-2011-0103|Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing Inmates|Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing Inmates||University of Wisconsin, Madison|Yes|Completed|May 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|180|||Male|18 Years|45 Years|No|||November 2011|May 29, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01428349||98963|
NCT01428362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-201|VI-1121 for the Treatment Alzheimer's Disease|A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease|AD-201|VIVUS, Inc.|No|Completed|August 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|60 Years|85 Years|No|||November 2013|November 15, 2013|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428362||98962|
NCT01428713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27934 TA vs COCP Study|Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study|Prospective Crossover Trial of Oral Tranexamic Acid and Combined Oral Contraceptive in Adolescents With Menorrhagia - A Pilot Study||Baylor College of Medicine|Yes|Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Female|N/A|21 Years|No|||August 2015|August 24, 2015|September 1, 2011|Yes|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01428713||98935|
NCT01428895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCREB 09-004|Femoral Bone Metastases|A Prospective Cohort Study of the Role of Surgery and/or Radiotherapy for Bone Metastases of the Femur at High Risk of Pathological Fracture||University Health Network, Toronto|No|Recruiting|March 2009|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01428895||98922|
NCT01424735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21234EH|TLR-9 Antagonism in Steroid Resistant Optic Neuritis|Outcomes of TLR-9 Antagonism in Steroid Resistant Optic Neuritis; A Pilot Study||Sudhalkar Eye Hospital|Yes|Completed|July 2006|May 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|N/A|N/A|No|||August 2011|August 26, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424735||99239|
NCT01424982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0030|Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)||M.D. Anderson Cancer Center|No|Recruiting|October 2011|||October 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|August 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01424982||99220|
NCT01425281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-393|ABSORB II Randomized Controlled Trial|ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions|ABSORB II|Abbott Vascular|Yes|Active, not recruiting|November 2011|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|501|||Both|18 Years|85 Years|No|||December 2015|December 7, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01425281||99197|
NCT01426399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL009|Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects||LG Life Sciences||Completed|August 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 27, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01426399||99111|
NCT01426412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13980|A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Subjects With Elevated LDL-C||Eli Lilly and Company|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|68|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 15, 2013|August 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01426412||99110|
NCT01426698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mercer - 9625|18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study|18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study|18mo|University of Rhode Island|Yes|Completed|August 2011|December 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|208|||Both|24 Weeks|31 Weeks|No|||December 2014|December 3, 2014|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01426698||99089|
NCT01426711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREST-004405-02|Critical Care Excellence in Sepsis and Trauma|Critical Care Excellence in Sepsis and Trauma|CREST|Medical University of South Carolina|Yes|Enrolling by invitation|September 2009|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|2600|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is adult patients presenting to rural community hospital's emergency        departments wth possible sepsis or severe sepsis and/or blunt or penetrating trauma.|July 2011|August 30, 2011|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01426711||99088|
NCT01428401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR96-IRB-126|Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke|||China Medical University Hospital|Yes|Completed|January 2008|March 2011|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|30 Years|75 Years|No|||September 2011|September 2, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428401||98959|
NCT01428700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-07|Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C|Development of Gene Expression Signatures for the Diagnosis of Liver Allograft Rejection and Recurrent Hepatitis C Disease (CTOT-07)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|August 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|275|Samples With DNA|Liver tissue, whole blood, and serum specimens|Both|N/A|N/A|No|Non-Probability Sample|Patients enrolled in ITN030ST (NCT00135694)|December 2015|December 2, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428700||98936|
NCT01385761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#2011-14642|LMA Unique TM & the Self Pressurized Air-Q TM Intubating Laryngeal Airway in Children|A Prospective, Randomized Non- Crossover Investigation of the LMA Unique TM and the Self Pressurized Air-Q TM Intubating Laryngeal Airway in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|June 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|3 Years|9 Years|Accepts Healthy Volunteers|Probability Sample|Children weighing 20 to 30 kg undergoing surgery requiring a supraglottic airway device|March 2012|March 9, 2012|June 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01385761||102221|
NCT01417000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADU-CL-01|Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer|A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma||Aduro Biotech, Inc.|Yes|Active, not recruiting|September 2011|March 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417000||99831|
NCT01417273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8887|Impact of Vitamin A on Multiple Sclerosis (MS)|Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients|MS|Tehran University of Medical Sciences|Yes|Enrolling by invitation|February 2010|August 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|45 Years|No|||August 2011|August 12, 2011|November 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01417273||99811|
NCT01417598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2011-69P-20908-02-4|BETA Study: Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity|Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity- a Randomized Controlled Study.|BETA|Karolinska Institutet|No|Active, not recruiting|January 2010|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|200|||Both|60 Years|N/A|No|||September 2015|September 7, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417598||99787|
NCT01417533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110218|A Natural History Study of Patients With GNE Myopathy|A Natural History Study of Patients With GNE Myopathy||National Institutes of Health Clinical Center (CC)||Recruiting|July 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|August 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01417533||99791|
NCT01417286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041001|Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer|Accelerated, Hypofractionated Post-Mastectomy Radiation Therapy in Women With Breast Cancer: A Phase II Trial||Rutgers, The State University of New Jersey|No|Active, not recruiting|December 2010|December 2020|Anticipated|December 2020|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417286||99810|
NCT01418469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 02-059.3|Disturbances in BCAA Metabolism and the Effects of Feeding and Exercise in COPD|The Effects of Exercise on the Metabolic Fate of Branched Chain Amino Acids in Relation to Aging and Chronic Disease.||Maastricht University Medical Center|No|Completed|December 2002|December 2004|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|24|||Male|45 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 16, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01418469||99720|
NCT01418768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT2011|Effects of an Inpatient Rehabilitation for Patients With Chronic Obstructive Pulmonary Disease (COPD) III/IV|||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|August 2011|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|75 Years|No|||February 2013|February 1, 2013|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01418768||99697|
NCT01418456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KADFUT|Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics|A Prospective Single Blind Randomised Controlled Study to Compare the Outcomes of Patients With Diabetes and Clinically Non-infected Neuro-ischaemic and Neuropathic Foot Ulcers Treated With and Without Oral Antibiotics.|KADFUT|King's College Hospital NHS Trust|Yes|Not yet recruiting|August 2011|February 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2011|August 16, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418456||99721|
NCT01428024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GE1102|Study to Evaluate Efficacy, Safety and Injection Technique of Restylane Lip Volume and Restylane Lip Refresh|An Open, Multi-center Study Evaluating Efficacy, Safety and Injection Technique of Restylane Lip Products for Lip Enhancement and Lip Rejuvenation||Q-Med AB|No|Completed|September 2011|June 2012|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428024||98988|
NCT01428284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018736|A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers|An Open-Label, Fixed-Sequence Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|September 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01428284||98968|
NCT01428323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.4529.10|Study of the Aerosol Deposition With Vented and Unvented Jet Nebulizer in Healthy Subjets|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|January 2011|September 2011|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|7|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 1, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428323||98965|
NCT01428622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1249.7|Olodaterol Bridging Study in Asthma|Single Dose Comparison of 3 Doses of Olodaterol in Double Fixed Dose Combination With BI54903 vs. 3 Doses of Olodaterol Mono in Free Combination||Boehringer Ingelheim||Withdrawn|October 2011|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|7||Actual|0|||Both|18 Years|75 Years|No|||November 2011|November 21, 2011|August 25, 2011||||No||https://clinicaltrials.gov/show/NCT01428622||98942|
NCT01428375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARACETAMOL-INTRAPARTUM|Intravenous Infusion of Paracetamol for Intrapartum Analgesia of Labor|Evaluation of Intravenous Infusion of Paracetamol as Intrapartum Analgesic in the First Stage of Labor: a Double-blind Randomized Trial||Ain Shams University|Yes|Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|35 Years|No|||February 2013|February 4, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01428375||98961|
NCT01428674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFUIRB00015699|Time, Touch, Attention and the Autonomic Nervous System|The Impact of Interpersonal Mindful Compassion on Autonomic Nervous System Function||Wake Forest School of Medicine|Yes|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 2, 2011|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01428674||98938|
NCT01428687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01CA150387 - Study 2|Short Term Effects of Increasing Sleep Duration|Increasing Sleep Duration: A Novel Approach to Weight Control||The Miriam Hospital|No|Active, not recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428687||98937|
NCT01428947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KI-angio-2|Does Coronary Angiography Cause Cognitive Dysfunction?|Study of Cognitive Function Before and After Coronary Angiography||Karolinska Institutet|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|80|||Both|35 Years|90 Years|No|Probability Sample|Patients scheduled for elective coronary angiography at one center|February 2016|February 23, 2016|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01428947||98918|
NCT01424800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/208|Influence of Variations in Systemic Blood Flow and Blood Pressure on Cerebral Oxygenation Measured by Cerebral Oximetry|Influence of Variations in Systemic Blood Flow and Blood Pressure on Cerebral Oxygenation Measured by Cerebral Oximetry||University Hospital, Ghent|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|34|||Both|21 Years|N/A|No|||March 2012|March 5, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01424800||99234|
NCT01424761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10241|Coenzyme Q10 in Relation to the Antioxidative Vitamins, Oxidative Stress and Inflammation in Coronary Artery Disease Patients During Statin Therapy|||Taichung Veterans General Hospital|Yes|Completed|August 2011|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|51|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424761||99237|
NCT01426997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00039107|Phenotype Depression Study|Phenotyping Major Depression With Increased Inflammation||Emory University|Yes|Active, not recruiting|July 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|135|Samples With DNA|Diurnal plasma samples are collected hourly from 9 am to 9 pm once; Cerebrospinal fluid      once; mRNA from peripheral blood leuckocytes collected 5 times; DNA for analysis of genetic      polymorphisms is collected once.|Both|21 Years|65 Years|No|Non-Probability Sample|One hundred and thiry-five patients with major depression diagnosed based on DSM-IV TR        criteria between the ages of 21 and 65 (males, females and minorities) will be recruited.        Forty-five patients with high inflammation as defined by a CRP >3 mg/L will be enrolled        along with 45 depressed patients with medium inflammation (CRP=1-3mg/L) and 45 depressed        patients with low inflammation (CRP<1mg/L)|January 2016|January 8, 2016|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01426997||99066|
NCT01427257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB1023-PT-CL-0002|Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus|Phase 1 Open-Label Two-Way Cross Over Study to Assess the Pharmacokinetic Profile of Two Formulations of PB1023 Injection Following a Single Dose Administered By Subcutaneous Injection in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)||PhaseBio Pharmaceuticals Inc.|Yes|Completed|February 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|75 Years|No|||September 2012|September 28, 2012|August 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01427257||99046|
NCT01427517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6721|Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease|Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 2, 2013|August 30, 2011|No|Yes||No|May 22, 2013|https://clinicaltrials.gov/show/NCT01427517||99026|
NCT01427530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMN_DBS|Local Field Potentials Recorded From Deep Brain Stimulating (DBS) Electrodes|Local Field Potentials Recorded From Deep Brain Stimulating Electrodes Implanted for the Treatment of Parkinson's Disease||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|August 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Parkinson's disease patients undergoing DBS implantation.|October 2013|October 29, 2013|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427530||99025|
NCT01428921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW11-044|Long Term Efficacy of Education Programme on Continuous Positive Airway Pressure Treatment|Long-term Efficacy of Extended Education Programme on Improving Treatment Adherence to Continuous Positive Airway Pressure in Obstructive Sleep Apnea||The University of Hong Kong|Yes|Completed|August 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428921||98920|
NCT01424774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGEN-105|Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning|A Prospective Study to Estimate Inadvertent Radiation Exposure From Strontium Isotopes in Patients Who Have Undergone CardioGen-82® PET MPI Scanning||Bracco Diagnostics, Inc|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|||Both|18 Years|N/A|No|Non-Probability Sample|The study population would come from sites who administered CardioGen-82® during the time        period of January 2011 to July 2011. The patient population is expected to be patients        (i.e., target date patients) who were administered Caridogen-82 that had been eluted from        the generator on the last usage day the generator was used prior to the generator that was        recalled (i.e., target date generator). It is planned to enroll 100 patients in this        study. Each site that agrees to participate will be encouraged to enroll at least 1        patient. Depending on the number of sites agreeing to participate, the enrollment time        frame may be extended to include the last 3 to 5 days of generator usage.|August 2012|August 13, 2012|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01424774||99236|
NCT01425008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C28001|Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma|An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma||Millennium Pharmaceuticals, Inc.|No|Recruiting|September 2011|July 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|142|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|August 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425008||99218|
NCT01417013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-10-07|Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time|A Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time||Alcon Research|No|Withdrawn|July 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 6, 2012|August 12, 2011||No|Management Decision|No||https://clinicaltrials.gov/show/NCT01417013||99830|
NCT01416506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15465|Community-Acquired Pneumonia (CAP) Surveillance|Community-Acquired Pneumonia (CAP) Mycoplasma Surveillance||Bayer|No|Completed|September 2010|January 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|560|Samples With DNA|whole blood, serum|Both|18 Years|N/A|No|Non-Probability Sample|Chinese adult (male or female) >/= 18 years old|November 2013|November 4, 2013|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416506||99869|
NCT01416753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK.-Nr. 365/2011|Response Options to Blood Volume Monitoring in Fluid Overloaded Hemodialysis Patients|A Randomized Controlled Clinical Trial Comparing, in Fluid-Overloaded Hemodialysis Patients, Three Strategies of Fluid Removal: Regulation of Ultrafiltration and Dialysate Conductivity, Regulation of Ultrafiltration and Temperature, and Standard Hemodialysis|BVM-Reg|Medical University of Vienna|No|Completed|September 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01416753||99850|
NCT01416740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31905|A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation|A Prospective Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation||Milton S. Hershey Medical Center|No|Withdrawn|December 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|70 Years|No|||August 2011|March 24, 2014|August 11, 2011||No|difficulty with recruitment, PI left the institution|No||https://clinicaltrials.gov/show/NCT01416740||99851|
NCT01417611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUMCHSN02|The Usefulness of I-scan in Screening Colonoscopy|The Usefulness of I-scan in Screening Colonoscopy: A Randomized Controlled Trial||Konkuk University Hospital|Yes|Completed|September 2010|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|389|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 15, 2011|July 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01417611||99786|
NCT01417897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDR_L_05719|Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study|Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study|HERMES|ikfe-CRO GmbH|No|Active, not recruiting|September 2011|May 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|30 Years|75 Years|No|||March 2012|March 2, 2012|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417897||99764|
NCT01417299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0260-11-HMO|The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements||CVS|Hadassah Medical Organization|No|Withdrawn|October 2011|October 2018|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||August 2011|September 20, 2015|August 15, 2011||No|This record is an additional copy of the study listed above|No||https://clinicaltrials.gov/show/NCT01417299||99809|
NCT01417858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0299.0.208.000-10|Intraocular Pressure Control After Anterior Segment Laser - Comparison Between 2 Drugs|Short-term Intraocular Pressure Control After YAG Iridotomy - Comparison Between Brimonidine 0.1% vs. 0.2%||Universidade Federal do Paraná|Yes|Recruiting|November 2010|July 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|50|||Both|40 Years|N/A|No|||June 2011|August 15, 2011|August 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417858||99767|
NCT01419093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K07CA126985|Communication Intervention Physical Activity|A Communication Intervention for Physical Activity in Underserved Communities||University of Rochester|No|Completed|September 2008|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|325|||Both|30 Years|50 Years|No|||September 2015|September 16, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01419093||99672|
NCT01418755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT12057|Study of Platelet-rich Plasma in Treating Patients With Tibiofemoral Cartilage Degeneration|Platelet-rich Plasma in Patients With Tibiofemoral Cartilage Degeneration||Hospital Znojmo|Yes|Completed|January 2009|July 2011|Actual|November 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|31 Years|75 Years|No|||September 2011|September 14, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418755||99698|
NCT01428037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-MS-01RCT|Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor|A Randomized,Double-blind,Placebo-controlled, Multicenter Study of the Efficacy and Safety of Vaginal Misoprostol for Cervical Ripening and Induction of Labor||Regenex Pharmaceutical, China|No|Completed|March 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|225|||Female|20 Years|N/A|No|||November 2013|November 21, 2013|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428037||98987|
NCT01428050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jefferson Hypertonic|The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy|Prospective Randomized Controlled Trial on the Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy||Thomas Jefferson University|Yes|Recruiting|May 2011|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|264|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428050||98986|
NCT01428336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1945|Value of 25 mcg Cortrosyn Stimulation Test|The Value of 25 mcg Cortrosyn Stimulation Test to Assess Adult HPA Axis|25CST|The Cleveland Clinic|Yes|Completed|September 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428336||98964|
NCT01427283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONU3705|A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation Who Require Around-the-clock Opioid Therapy||Purdue Pharma LP|No|Completed|August 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|450|||Both|18 Years|N/A|No|||February 2015|February 11, 2015|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427283||99044|
NCT01424995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32047|The Natural History of Congenital Trigger Thumbs|The Natural History of Congenital Trigger Thumbs||University of Utah|No|Active, not recruiting|December 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|5 Years|No|Non-Probability Sample|The study will evaluate all patients who present to our institution with congenital        trigger thumb over a one year period and choose not to have a surgical intervention|February 2016|February 2, 2016|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424995||99219|
NCT01428908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT007|Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children|A Phase III Clinical Trial the Immunogenicity and Safety Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children.||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|September 2011|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|2394|||Both|6 Months|5 Years|No|||April 2012|April 17, 2012|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01428908||98921|
NCT01425567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2011-0211T|Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury|Compassionate Use of an Intravenous Lipid Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Children|Omegaven|The University of Texas Health Science Center at San Antonio|Yes|Recruiting|August 2011|||August 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|24 Months|No|||July 2015|July 13, 2015|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425567||99175|
NCT01435642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3956|A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes|Diabcare Paediatric - A Survey-study on Diabetes Management, Complications and Psychosocial Aspects of Type 1 Childhood Diabetics|Diabcare|Novo Nordisk A/S|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|349|||Both|N/A|18 Years|No|Non-Probability Sample|Children with type 1 diabetes mellitus being treated at diabetes clinics will be selected        according to the inclusion and exclusion criteria.|January 2015|January 26, 2015|August 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435642||98408|
NCT01435655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461010|The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin|The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study||Pfizer|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|75 Years|No|||August 2015|August 10, 2015|September 13, 2011|Yes|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01435655||98407|
NCT01428102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-CLN-100267A|RapidTEG MA Validation|Validation of the RapidTEG™ MA Compared to Kaolin in Trauma and Cardiac Patients.|R-TEG MA|Haemonetics Corporation|No|Terminated|July 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|17|||Both|18 Years|N/A|No|Probability Sample|Patient is either a Trauma patient OR is diagnosed with known cardiovascular disease.|September 2013|September 13, 2013|September 1, 2011||No|Terminiated for trial redesign|No||https://clinicaltrials.gov/show/NCT01428102||98982|
NCT01428115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-705|Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab|Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab|RELAX|AbbVie|No|Completed|December 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|83|||Both|18 Years|65 Years|No|Non-Probability Sample|The investigational sites were centers with a high level of experience in the treatment of        Crohns disease patients.|October 2014|October 31, 2014|September 1, 2011||No||No|October 2, 2014|https://clinicaltrials.gov/show/NCT01428115||98981|
NCT01428128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20110177H|Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector|A Phase II Study of Low Dose Arsenic Trioxide in Patients With Malignancies as a Potential Chemotherapy Protector||The University of Texas Health Science Center at San Antonio|Yes|Completed|April 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|June 17, 2011|Yes|Yes||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01428128||98980|
NCT01436149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-322|Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder|The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant||Shire||Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1262|||Both|18 Years|65 Years|No|||November 2014|April 13, 2015|September 15, 2011|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01436149||98369|
NCT01436162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-323|Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder|The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant||Shire||Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1105|||Both|18 Years|65 Years|No|||November 2014|November 6, 2014|September 15, 2011|Yes|Yes||No|October 31, 2014|https://clinicaltrials.gov/show/NCT01436162||98368|
NCT01425333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D: DHRD/2010/089|The Impact of Surgical Treatment of Endometriomas on Ovarian Reserve|The Impact of Surgical Treatment of Ovarian Endometriomas on Ovarian Reserve: a Randomised Controlled Trial of Laparoscopic Ovarian Cystectomy Versus Cyst Ablation - a Pilot Study||Derby Hospitals NHS Foundation Trust|Yes|Recruiting|April 2011|February 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||August 2011|August 26, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01425333||99193|
NCT01417065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0259|Temsirolimus In Phase 0|Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets||M.D. Anderson Cancer Center|No|Completed|August 2010|||June 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01417065||99827|
NCT01417091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPS804A2201|Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta|A Randomized, Open Label Intra-patient Dose Escalation Study With an Untreated Reference Group to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Infusions of BPS804 in Adults With Moderate Osteogenesis Imperfecta||Novartis||Completed|June 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||January 2015|January 2, 2015|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417091||99825|
NCT01417078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DZNS-ARS-103|A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode|An Open-Label Study to Determine the Pharmacokinetics of a Single Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode for Which Acute Treatment With a Benzodiazepine is Clinically Indicated||Acorda Therapeutics|No|Completed|September 2011|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|No|||January 2014|January 27, 2014|August 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417078||99826|
NCT01417312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS_GTE|Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients|||Charite University, Berlin, Germany|No|Completed|July 2011|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|20 Years|60 Years|No|||January 2016|January 20, 2016|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417312||99808|
NCT01417923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0042-11-MMC|The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain|The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain||Meir Medical Center|No|Recruiting|September 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|80 Years|No|||November 2012|November 4, 2012|August 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01417923||99762|
NCT01417871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abcmetsyn1|ABC Program in Patients With Metabolic Syndrome|||University of Magdeburg|No|Completed|February 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|140|Samples Without DNA|blood samples for parameter of lipid metabolism|Both|25 Years|75 Years|No|Probability Sample|patients with metabolic syndrome|February 2010|August 15, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01417871||99766|
NCT01417884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TuePIC012011|Monocentric Registry to Investigate the Role of Platelet Function, Platelet Pharmacogenomics, Proteomics and Metabonomics in Ischemic and Non-ischemic Heart Disease|Development of a Prospective Cardiovascular Patient Cohort and Biobank and Provision of Genomic Analyses With Focus on Platelet Function and Platelet Mediated Inflammatory Processes|TuePIC|University Hospital Tuebingen|Yes|Recruiting|January 2012|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|Samples With DNA|Blood, salivatory|Both|18 Years|N/A|No|Probability Sample|In-hospital patients and outpatients|August 2011|January 13, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01417884||99765|
NCT01419756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011041|Assessment of Right Ventricular Volume in Tetralogy of Fallott (TOF) Patients|Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Tetralogy of Fallott Following Repair; A Comparison Study to cMRI|VMS TOF|VentriPoint Diagnostics Ltd.|No|Completed|August 2011|August 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|109|||Both|N/A|N/A|No|Non-Probability Sample|Primary Care Clinic Cardiac Clinic|July 2013|October 3, 2014|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419756||99621|
NCT01419769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD00744|AXIOS Stent & Delivery System Study|A Prospective, Multi-center, Non-blinded, Single-arm (Nonrandomized) Study of the AXIOS Stent and Delivery System||Xlumena, Inc.|Yes|Completed|August 2011|April 2013|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||September 2015|September 2, 2015|August 15, 2011|Yes|Yes||No|November 12, 2014|https://clinicaltrials.gov/show/NCT01419769||99620|
NCT01419080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-533|Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)|Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT Registry)|PORTRAIT|Saint Luke's Health System|No|Active, not recruiting|October 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|||Both|21 Years|N/A|No|Non-Probability Sample|Patients presenting to a PAD specialty clinic with new-onset exertional leg symptoms, or        recent exacerbations of symptoms, will be screened for enrollment at 10 specialty PAD        clinics. Trained study coordinators will have access to the outpatient clinic's schedule        and be able to identify potentially eligible patients a priori so as to review medical        records and identify potential patients. The diagnostic enrollment criterion includes a        Doppler resting ankle-brachial index (ABI) ≤0.9026 or a significant drop in post-exercise        ankle pressure of ≥20 mmHg. Patients will be asked to participate upon first visiting the        PAD clinic, before treatment is started.        Study coordinators at each center will obtain informed consent and perform the baseline        interview at the outpatient clinic.|November 2015|November 16, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419080||99673|
NCT01427751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF-AGN-OPH-RET-004|Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion|||Allergan|No|Completed|October 2011|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 31, 2011|Yes|Yes||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01427751||99008|
NCT01428063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-026|Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials|An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C||Bristol-Myers Squibb|No|Completed|September 2011|December 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|228|||Both|18 Years|N/A|No|||April 2014|February 6, 2015|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428063||98985|
NCT01428076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAP.VV008|Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)|An Open-Label Single-Center Study in Patients With Great Saphenous Vein Incompetence to Investigate the Pharmacokinetic Properties of Polidocanol Endovenous Microfoam (PEM)||BTG International Inc.|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|August 30, 2011|Yes|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT01428076||98984|
NCT01425047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0219|Bioavailability of Xanthones From Mangosteen|Bioavailability and Anti-inflammatory Activities of Mangostins: a Pilot Study||Ohio State University|Yes|Completed|November 2010|February 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|10|Samples Without DNA|Sera and urine|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|5 female and 5 male healthy, non-smoking subjects admitted to the Clinical Research Center        at The Ohio State University.|August 2011|August 31, 2011|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425047||99215|
NCT01434472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2398.00|High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma|A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma||Fred Hutchinson Cancer Research Center|No|Recruiting|November 2011|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434472||98497|
NCT01425307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28572 TWiTCH|Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea|TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities|TWiTCH|Children's Hospital Medical Center, Cincinnati|Yes|Terminated|August 2011|January 2016|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|159|||Both|4 Years|15 Years|No|||November 2015|November 4, 2015|August 19, 2011|Yes|Yes|The study was stopped early due to successfully meeting the primary endpoint|No||https://clinicaltrials.gov/show/NCT01425307||99195|
NCT01426074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 05209|DCE-MRI PET Bevacizumab Study in Rectal Cancer|A Phase II/Pharmacodynamic Study of Preoperative or Definitive FOLFOX Plus Bevacizumab, With the Additional Pharmacodynamic Goal of Assessing Tumor Blood Flow as Measured by Dynamic Contrast-enhanced MRI, and the Induction of Hypoxia and Apoptosis as Measured by PET in Patients With Rectal Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|August 2011|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|August 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426074||99136|
NCT01435668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/11-01 - AURAIA|AURAIA Study : Impact Evaluation at 3 Months Follow-up of a Brief Motivational Intervention in Reducing Alcohol Consumption Among Adolescents Aged 16-24 in Pontchaillou Hospital Emergency Department in Rennes, France|Impact Evaluation at 3 Months Follow-up of a Brief Motivational Intervention in Reducing Alcohol Consumption Versus Simple Written Advice Only Among Adolescents Aged 16-24 in Pontchaillou Hospital Emergency Department in Rennes, France|AURAIA|Rennes University Hospital|No|Completed|September 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|258|||Both|16 Years|24 Years|No|||January 2014|January 3, 2014|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01435668||98406|
NCT01435902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106847|A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise|A Randomized, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Asthmatic Adolescent and Adult Subjects With Exercise-Induced Bronchoconstriction||GlaxoSmithKline|No|Withdrawn|January 2012|August 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|50 Years|No|||June 2014|June 19, 2014|September 15, 2011|Yes|Yes|Study was cancelled prior to enrolling any subjects|No||https://clinicaltrials.gov/show/NCT01435902||98388|
NCT01435915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112558|Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects|A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects||GlaxoSmithKline||Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2012|September 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435915||98387|
NCT01436422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 279|Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|112|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|September 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01436422||98348|
NCT01436409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P050304|Rates of Fetal Extractions Between Only Vaginal Touch Usually Realized and Vaginal Touch + Echography|Comparison of the Rates of Fetal Extractions Between a Systematic Practice of an Echography of Presentation and the Only Vaginal Touch Usually Realized During the Labor|PINKFINGER|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2005|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1900|||Female|18 Years|50 Years|No|||July 2011|November 25, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01436409||98349|
NCT01417104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AUS33T|Aliskiren Effect on Aortic Plaque Progression|Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE): A Double Blind Placebo Controlled Trial|ALPINE|Ohio State University|No|Terminated|October 2009|January 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|45 Years|N/A|No|||November 2012|November 28, 2012|August 8, 2011|Yes|Yes|Safety concerns with approved medication identified in an unrelated trial|No|October 29, 2012|https://clinicaltrials.gov/show/NCT01417104||99824|
NCT01417338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIFuwaiHospital|Registry for Pulmonary Hypertension in China|National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|August 2009|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3079|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive patients who were firstly diagnosed as pulmonary arterial hypertension or        chronic thromboembolic pulmonary hypertension at 53 participating institutions in China|August 2009|August 15, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01417338||99806|
NCT01417910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVD10|Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients|Prognostic Markers of Outcome in Patients Undergoing Infra-inguinal Revascularisation. A Prospective Observational Study.||York Teaching Hospitals NHS Foundation Trust|No|Completed|September 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|99 Years|No|Non-Probability Sample|Patients diagnosed with peripheral vascular disease in a secondary care setting scheduled        to undergo infra inguinal revascularisation.|February 2015|January 26, 2016|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01417910||99763|
NCT01418170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112027|Dose Response Effects of Cervical Spinal Manipulative Therapy (SMT) on Pressure Sensitivity of Myofascial Trigger Points|Dose Response Effects of Cervical SMT on Pressure Sensitivity of Myofascial Trigger Points||Canadian Memorial Chiropractic College|No|Not yet recruiting|September 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|26|||Both|21 Years|40 Years|No|||August 2011|August 17, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01418170||99743|
NCT01420068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2365E2|52-104 Week Off-therapy Second Extension to Study CSPP100A2365|A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1||Novartis||Recruiting|August 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|18|||Both|6 Years|17 Years|No|Non-Probability Sample|pediatric hypertensive patients 6 - 17 years of age previously treated with aliskiren in        studies CSPP100A2365 and/or CSPP100A2365E1|March 2016|March 21, 2016|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420068||99597|
NCT01419379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-401-KR|This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiology Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Korea|Epidemiologic Review and Prospective Observation of COPD and Health in Korea|EPOCH|Takeda|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|1118|||Both|40 Years|N/A|No|Probability Sample|Patients with COPD|April 2013|April 16, 2013|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419379||99650|
NCT01420042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-2566-HV-005|Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration|A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NNZ-2566 in Healthy Subjects, Following Oral Administration||Neuren Pharmaceuticals Limited|Yes|Completed|February 2012|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|August 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01420042||99599|
NCT01427764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456|Dentin Hypersensitivity Following Non-surgical Periodontal Therapy With Hand or Ultrasonic Instruments|Dentin Hypersensitivity Following Non-surgical Periodontal Therapy With Hand or Ultrasonic Instruments||Escola Bahiana de Medicina e Saude Publica||Completed|February 2009|June 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|14|||Both|35 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 31, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01427764||99007|
NCT01425619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOWN 1|The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests|||Meir Medical Center|No|Completed|October 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|1 Year|18 Years|No|||September 2012|October 7, 2015|August 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01425619||99171|
NCT01426113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-056|A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma|||Allergan|Yes|Terminated|September 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|2 Months|17 Years|No|||September 2015|September 2, 2015|August 29, 2011|Yes|Yes|Study terminated due to corporate decision.|No|June 29, 2015|https://clinicaltrials.gov/show/NCT01426113||99133|
NCT01428427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112111|Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors|A Phase IB Combination Study of MEK Inhibitor GSK1120212 With Gemcitabine in Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|August 2009|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2011|September 27, 2012|December 10, 2009|No|Yes||No||https://clinicaltrials.gov/show/NCT01428427||98957|
NCT01436188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100658|A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease|A Biomarker Study to Measure CSF Proteins Upon Application of an Indwelling Lumbar Catheter for 36 Hours in Elderly Healthy Subjects and Subjects With Mild Cognitive Impairment or Alzheimer's Disease||Janssen Research & Development, LLC||Completed|September 2011|June 2013|Actual|||Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|5|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||March 2014|March 15, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01436188||98366|
NCT01436201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11550|A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants|Effect of Dulaglutide (LY2189265) on the Pharmacokinetics of Digoxin in Healthy Subjects||Eli Lilly and Company|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|September 15, 2011|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01436201||98365|
NCT01435005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACF:24404|Breast Cancer and Exercise Trial in Alberta|Breast Cancer and Exercise Trial in Alberta: The BETA Trial|BETA|AHS Cancer Control Alberta|No|Completed|March 2010|June 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Female|50 Years|74 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01435005||98457|
NCT01435018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5263|Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS|A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings||AIDS Clinical Trials Group|Yes|Recruiting|August 2013|June 2027|Anticipated|June 2027|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|706|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|September 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435018||98456|
NCT01435031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-394|EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions|Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions|EXPERT CTO|Abbott Vascular|No|Active, not recruiting|September 2011|February 2018|Anticipated|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|250|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|September 13, 2011|Yes|Yes||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01435031||98455|
NCT01435317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT2011-08-26|Acoustic Coordinated Reset (CR®) Neuromodulation for the Treatment of Chronic Tonal Tinnitus ("RESET Real Life")|Prospective Clinical Study for Confirmation of Efficacy and Safety of Acoustic CR®-Neuromodulation by CE Marked ANM T30 CR®-System in a "Real Life" Patient Population With Chronic Tonal Tinnitus|RRL|ANM Adaptive Neuromodulation GmbH|Yes|Completed|November 2011|July 2014|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01435317||98433|
NCT01435330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBVS857X2101|Safety and Tolerability of BVS857 in Subjects With Insulin Resistance|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Parenterally Administered BVS857 in Healthy Subjects Without and With Insulin Resistance||Novartis||Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|43|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|September 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435330||98432|
NCT01435343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLERIFLAG|Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia|Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML||PETHEMA Foundation|Yes|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|65 Years|No|||September 2015|January 16, 2016|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435343||98431|
NCT01428999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-100-039|Effects of Probiotics on Improving the Gastrointestinal Function and Intestinal Bacterial Flora|Effects of Probiotics on Improving the Gastrointestinal Function and Intestinal Bacterial Flora||National Cheng-Kung University Hospital|No|Not yet recruiting|September 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||June 2011|September 2, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01428999||98914|
NCT01435928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050238|PEARL Schizophrenia Maintenance|A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia||Sunovion|Yes|Completed|September 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|676|||Both|18 Years|75 Years|No|||October 2014|October 2, 2014|September 15, 2011|Yes|Yes||No|July 25, 2014|https://clinicaltrials.gov/show/NCT01435928||98386|
NCT01436175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-329|SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study|A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant||Shire||Terminated|February 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1570|||Both|18 Years|65 Years|No|||March 2014|February 5, 2015|September 15, 2011|No|Yes|SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination    was not related to any new safety findings.|No|February 5, 2015|https://clinicaltrials.gov/show/NCT01436175||98367|The study was terminated on 11 Feb 2014. SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.
NCT01437462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Satu_Pokkinen_01_2011|Sevoflurane, Propofol, Postoperative Pain|Postoperative Pain After Propofol Sevoflurane Anaesthesia: a Prospective, Randomized, Single-blinded Trial||Tampere University Hospital|No|Completed|October 2008|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|168|||Female|18 Years|69 Years|No|||April 2013|April 9, 2013|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437462||98268|
NCT01437475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-DA-0277-CITL|Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients|Efficiency of the Novel Hepatitis B Vaccine Sci-B-Vac in HIV Positive Patients, a Prospective Cohort Study||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2011|November 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|18 Years|N/A|No|||October 2011|October 5, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437475||98267|
NCT01436773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVV-ACE-01|Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events|Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events||University of Pittsburgh|Yes|Recruiting|May 2009|December 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with documented coronary artery disease and/or recent acute coronary event who        undergo left heart catheterization, and patients with history and previous testing that        cannot rule out coronary artery disease and undergo elective left heart catheterization.|September 2011|September 20, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01436773||98321|
NCT01417377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25368|An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)|Non-Interventional Study to Document the Efficacy in Routine Clinical Practice of Mircera in Pakistan (NORM)||Hoffmann-La Roche||Completed|May 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic kidney disease|November 2015|November 4, 2015|August 5, 2011||No||No|September 24, 2015|https://clinicaltrials.gov/show/NCT01417377||99803|As none of the enrolled participants in the study achieved the endpoint of maintaining Hb level between 11-12 g/dL during the final 2 months of study, therefore efficacy parameters were not analyzed.
NCT01417351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217516|Effects of Vitamin D Supplementation During Pregnancy on Clinical Outcomes and Immune Function|Assessment of Inflammatory Markers and Pregnancy Outcomes in Vitamin D-Supplemented Women at Risk of Vitamin D Deficiency: A Double-Blind, Randomized Controlled Trial||USDA, Western Human Nutrition Research Center|No|Completed|August 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01417351||99805|
NCT01417364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-132|The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men|The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men||The University of Texas Medical Branch, Galveston|Yes|Withdrawn|January 2016|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Male|60 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|August 12, 2011|Yes|Yes|Unable to identify any qualifying subjects willing to enroll into this study.|No||https://clinicaltrials.gov/show/NCT01417364||99804|
NCT01418482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxB Ag 02|Evaluation of Antimicrobial Soft Silicone, Silver Containing, Foam Dressing, Mepilex Border Ag, in Second Degree Burns|An Open Non-controlled Post-marketing Investigation Evaluating the Experience of Using a Self- Adherent Antimicrobial Soft Silicone, Silver Containing, Foam Dressing, Mepilex Border Ag, in Second Degree Burns||Molnlycke Health Care AB|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2011|August 16, 2011|January 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01418482||99719|
NCT01419106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1590|Sonography in Hypotension and Cardiac Arrest in the Emergency Department.|SHoC-ED 1: Sonography in Hypotension and Cardiac Arrest in the Emergency Department.|SHoC-ED 1|Horizon Health Network|Yes|Recruiting|August 2011|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|400|||Both|19 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 18, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01419106||99671|
NCT01418183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-0548A3|Pain Control After Orthognathic Surgery|Intra-operative Trigeminal Nerve Block For Post-operative Pain Control After Orthognathic Surgery|PCOGS|Chang Gung Memorial Hospital|Yes|Recruiting|July 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|20 Years|40 Years|No|||June 2011|September 4, 2011|August 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01418183||99742|
NCT01419782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-5|Effects of Unilateral WBV on Muscleactivity of Contralateral Hip Adductor|The Effects Of Femur On The Resting Myoelectrical Activity Of Contralateral Adductor Muscle During Unilateral Lower Extremity Vibration: Bone Myoregulation Reflex|WBV-BM|Bagcilar Training and Research Hospital|No|Completed|March 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|20|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01419782||99619|
NCT01420055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DFR03|Fingolimod -Response According to Coping - Evaluation|A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France|GRACE|Novartis||Completed|August 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Both|18 Years|65 Years|No|||January 2014|January 17, 2014|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420055||99598|
NCT01428089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13660|Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone|Suppression of Daytime and Nighttime LH Frequency by Progesterone in Early Pubertal Girls With and Without Hyperandrogenemia (JCM024)||University of Virginia|No|Recruiting|May 2008|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Female|7 Years|14 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428089||98983|
NCT01427023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATVPS-US11-001|Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing|Prospective Collection of Female First-catch Urine, Vaginal Swab, Endocervical Swab, and Cervical Specimens for Testing With the APTIMA Trichomonas Vaginalis Assay||Gen-Probe, Incorporated|No|Completed|August 2012|December 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|532|Samples With DNA|urine specimen, vaginal swab specimen, endocervical swab specimen and PreservCyt specimen|Female|14 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Women attending participating US OB/GYN, family planning, or STD clinics will be eligible        to participate.|February 2014|February 5, 2014|August 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427023||99064|
NCT01428388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAVE1|Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion|Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion|CRAVE|Barnes Retina Institute|Yes|Active, not recruiting|September 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428388||98960|
NCT01434745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL073980|SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation|Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiving Cholesterol Supplementation||Oregon Health and Science University|Yes|Recruiting|September 2011|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|16|||Both|1 Year|89 Years|No|||March 2012|March 21, 2012|September 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01434745||98476|
NCT01435044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2938-0721|Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection|QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Infection|QUANTUM|Gilead Sciences|No|Completed|September 2011|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|239|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435044||98454|
NCT01436435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1465|The Jetstream (JET) Post-market Registry|Jetstream NAVITUS™ System Endovascular Therapy Post-market Registry (JET)|JET|Boston Scientific Corporation|No|Completed|September 2011|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|178|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01436435||98347|
NCT01435356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAU RF 2010-01|Safety and Efficacy Study of Cancer Immunotherapeutic MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy|A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy|MAGNOLIA|European Association of Urology Research Foundation|Yes|Active, not recruiting|August 2011|August 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|273|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01435356||98430|
NCT01436786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12900|Effectiveness of Guided Imagery Intervention on Factors Associated With Maternal Stress and Preterm Birth|Guided Imagery Effects on Pregnancy Symptoms and Outcomes||Virginia Commonwealth University|Yes|Completed|June 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|73|||Female|18 Years|50 Years|No|||May 2014|May 14, 2014|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01436786||98320|
NCT01429012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJT1101|Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting|Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting. A Randomized, Double-blind, Controlled Study||University Hospital of Liege|No|Not yet recruiting|October 2013|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429012||98913|
NCT01425086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03222011-7607|Clinical Performance of the Embrace Isothermal Mattress|Clinical Performance of the Embrace Isothermal Mattress in Stabilizing Temperatures of the Preterm Infants During Thermal Weaning|KBW|Stanford University|Yes|Recruiting|March 2011|December 2012|Anticipated|September 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|36|||Both|N/A|120 Days|No|||May 2012|May 21, 2012|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01425086||99212|
NCT01425099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115696|Drug Interaction Study Between Dolutegravir and Prednisone|An Adaptive, Two Part, Two Period, Single Sequence, Drug Interaction Study Between Dolutegravir 50 mg and Prednisone in Adult Healthy Volunteers||ViiV Healthcare|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|November 3, 2011|August 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425099||99211|
NCT01437735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039A2206|Dose Finding Study for QAW039 in Asthma|A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.||Novartis|No|Completed|August 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|15||Actual|1043|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|September 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437735||98247|
NCT01437748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|629CEC|Closing Volume Interpretation and Bronchodilators Effect|Small Airways Evaluation and Peripherical Effect of Two Bronchodilators in Healthy Subjects and Stable COPD Patients||University of Milan|Yes|Completed|August 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|85 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01437748||98246|
NCT01417936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sym004-02|Sym004 in Subjects With Squamous Cell Carcinoma of Head and Neck (SCCHN) Failing Anti-Epidermal Growth Factor Receptor (Anti-EGFR) Based Therapy|An Open-label, Single Arm, Phase II Trial to Investigate the Safety and Efficacy of Sym004 in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Anti-EGFR Monoclonal Antibody-based Therapy||Merck KGaA|Yes|Completed|July 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|July 15, 2011|Yes|Yes||No|December 29, 2015|https://clinicaltrials.gov/show/NCT01417936||99761|
NCT01417624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBH2011HS008B|Cardiac Magnetic Resonance Imaging Guided Left Ventricular Lead Placement|The Assessment of Cardiac Magnetic Resonance Imaging Guided Left Ventricular Lead Placement During the Implantation of Cardiac Resynchronisation Therapy on Clinical Outcomes in Patients With Chronic Heart Failure||Royal Brompton & Harefield NHS Foundation Trust|Yes|Recruiting|August 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|70|||Both|18 Years|90 Years|No|||August 2011|August 15, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01417624||99785|
NCT01419392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahmed-2004|Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages|Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages: a Randomized Clinical Trial||Ain Shams University|Yes|Active, not recruiting|September 2011|June 2012|Anticipated|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|35 Years|No|||April 2012|April 14, 2012|August 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01419392||99649|
NCT01418781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVAMC-3669A|CLinical Prediction Rule Score in Veterans|Development of CLinical Prediction Rule Score in Veterans: A Study of Impact of Gout on Health Care Utilization and Costs||Minneapolis Veterans Affairs Medical Center|No|Withdrawn|January 2008|March 2010||March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with and without gout from the Veterans Upper Midwest SF-36 survey database will        be included in the analyses for Study questions 1 and 5. This is approximately 3000 gout        patients and 67,000 non-gout patients Patients with SF-36 data from the above cohort will        be included in the analyses for Study aims 2-4. This is approximately 1500 gout patients        and 38,000 non-gout patients|March 2016|March 14, 2016|August 15, 2011||No|Funding withdrawn by the funding agency; study could not be performed.|No||https://clinicaltrials.gov/show/NCT01418781||99696|
NCT01386242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JH-RC-001|Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer|Phase II/III Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Second-Line and More Than Second-line Treatment||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Completed|May 2011|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|108|||Both|18 Years|N/A|No|||April 2015|January 4, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01386242||102184|
NCT01420081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1271004|A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer|A Randomized Phase 2 Non-comparative Study Of The Efficacy Of Pf-04691502 And Pf-05212384 In Patients With Recurrent Endometrial Cancer||Pfizer|No|Terminated|January 2012|December 2015|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|67|||Female|20 Years|N/A|No|||June 2015|June 3, 2015|August 17, 2011|Yes|Yes|See termination reason in detailed description.|No|April 30, 2015|https://clinicaltrials.gov/show/NCT01420081||99596|On 09Oct12, Pfizer decided to discontinue clinical development of PF-04691502 and stop participants enrollment in this arm. Hence limited primary and secondary endpoints summaries were performed in this arm and no efficacy endpoints were evaluated.
NCT01420094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15529|Evaluate Onset of Action of a Fast Release Aspirin|Comparative Onset of Action of a Fast Release Aspirin Tablet in a Dental Impaction Pain Model|TAROT compare|Bayer|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|510|||Both|16 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01420094||99595|
NCT01425346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM2-002-CTP|ClearPath DS-120 Clinical Study Protocol|Freedom Meditech ClearPath DS-120 Clinical Study Protocol FM2-002-CTP||Freedom Meditech|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|128|||Both|21 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy, normal subject population with healthy eyes as determined by standard        comprehensive ophthalmic examination.|August 2011|August 26, 2011|August 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01425346||99192|
NCT01425606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039-2011|Pseudohyponatremia of Multiple Myeloma is True Hyponatremia|a Study to Evaluate the Electrolyte Changes in Particular Sodium,in Multiple Myeloma and the Effect of the m- Proteins on the Strong Ion Difference||Meir Medical Center|No|Not yet recruiting|September 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|patients with gammaglobulinemia and\or multiple myeloma.|August 2011|August 28, 2011|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01425606||99172|
NCT01427842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH.4.11.076|Dose Enhancement of Vancomycin IN Everyday Patients|A Single-centred Randomised Trial of a New Vancomycin Dosing Method Compared to Standard Care in Everyday Patients Receiving Vancomycin|DEVINE|The Canberra Hospital|No|Recruiting|August 2011|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Both|16 Years|N/A|No|||August 2011|September 1, 2011|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427842||99002|
NCT01434186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-147|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone||Bristol-Myers Squibb|Yes|Active, not recruiting|November 2011|April 2017|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|7|||Both|10 Years|17 Years|No|||March 2016|March 4, 2016|September 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01434186||98519|
NCT01434199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2011.125-T|Does Endoscope Position Detecting Unit Facilitate a Complete Colonoscopy Examination|Does Endoscope Position Detecting Unit Facilitate Caecal Intubation? A Randomized Controlled Trial|UPD-3|Chinese University of Hong Kong|Yes|Recruiting|July 2011|July 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|870|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01434199||98518|
NCT01428193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12632|Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone|Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)||University of Virginia|No|Completed|September 2006|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Female|13 Years|17 Years|No|||August 2015|August 25, 2015|August 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428193||98975|
NCT01428206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP001|Liverpool Care Pathway for the Dying at Residential Care Homes|Liverpool Care Pathway for the Dying at Residential Care Homes||Umeå University|No|Completed|June 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|260|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2013|June 13, 2013|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01428206||98974|
NCT01436448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111012MED|Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy|Effects of Probiotics (Lactobacillus Rhamnosus) In Reducing Glucose Intolerance During and After Pregnancy: A Double Blind Randomized Controlled Trial in Antenatal Clinic of Karachi-Pakistan (GRIP)|GRIP|Aga Khan University|No|Not yet recruiting|October 2011|May 2013|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|45 Years|No|||September 2011|September 19, 2011|September 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436448||98346|
NCT01436461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2012|||||N/A|N/A|N/A||||||||||||||May 28, 2013|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436461||98345|
NCT01428479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115070|Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males|Phase1 Study of GR121167- A Double Blind, Placebo Controlled, Randomized, Dose Ascending, Single and Multiple Dose Study to Investigate the Safety and Pharmacokinetics Following Intravenous Administration of GR121167 in Healthy Japanese Males-||GlaxoSmithKline||Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|18|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||October 2011|April 5, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01428479||98953|
NCT01436799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2466|Desflurane Versus Propofol in the Sitting Position|International Review Board of Gachon University Gil Hospital||Gachon University Gil Medical Center|Yes|Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|65 Years|No|||August 2013|August 25, 2013|September 15, 2011||No||No|February 5, 2013|https://clinicaltrials.gov/show/NCT01436799||98319|limitations of this study is that the ventilation was adjusted according to ETCO2 value instead of the arterial carbon dioxide tensions (PaCO2).
NCT01428778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Berlin Beat|Berlin Beat of Running Study|Berlin Beat of Running Study - Frequency of Cardiac Arrhythmias & Cerebral Lesions in Marathon Runners||Charite University, Berlin, Germany|No|Completed|September 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|Samples Without DNA|Whole blood samples|Both|35 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Experienced marathon runners|August 2013|August 6, 2013|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428778||98930|
NCT01428804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPRESCO|Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression|Pilot Study of Feasibility of the Effect of Treatment With tDCS in Patients Suffering From Resistant Depression|DEPRESCO|Centre Hospitalier Universitaire de Besancon|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||February 2015|February 26, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01428804||98928|
NCT01424644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_40|A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents|A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine||Novartis|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|801|||Both|11 Years|18 Years|Accepts Healthy Volunteers|||January 2014|January 21, 2014|August 23, 2011|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01424644||99246|
NCT01437124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|960558216|Metal Ions in Ceramic on Metal Total Hip Arthroplasty|Measurement of Metal Ion Levels and Chromosome Abnormalities in Ceramic on Metal Total Hip Arthroplasty in Vivo|COM|Wirral University Teaching Hospital NHS Trust|Yes|Not yet recruiting|October 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|83|||Both|18 Years|N/A|No|Probability Sample|Those who have received a ceramic on metal total hip arthroplasty|September 2011|September 19, 2011|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01437124||98294|
NCT01437137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0052|The Clinical Efficacy of Recently Developed Supraglottic Airway Device, I-gel™, in Neonates and Infants: Comparison With Classic-laryngeal Mask Airway (c-LMA)|||Yonsei University|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|54|||Both|N/A|1 Year|No|||June 2013|June 1, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01437137||98293|
NCT01425112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31234EH|Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy|Clinical Trial Comparing Subconjunctival and Topical Bevacizumab as Adjuncts to Trabeculectomy in Improving Outcomes for Primary Open Angle Glaucoma||Sudhalkar Eye Hospital|Yes|Completed|December 2007|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|180|||Both|42 Years|N/A|No|||August 2011|August 26, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01425112||99210|
NCT01425125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10029|Fractional Urate Excretion in Nonedematous Hyponatremia|Study of Nonedematous Hyponatremia and the Utility of Fractional Urate Excretion in Hyponatremia and Suspected Renal Salt Wasting Without Hyponatremia-||Winthrop University Hospital|No|Withdrawn|November 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425125||99209|
NCT01425398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|statins_inflammation_CVsurgery|A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery|A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery||McGill University Health Center|No|Not yet recruiting|November 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||August 2011|August 29, 2011|August 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425398||99188|
NCT01425411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vals262626|Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy|Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy||Mustafa Kemal University||Completed|November 2006|November 2008|Actual|November 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|75 Years|No|||August 2011|August 29, 2011|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425411||99187|
NCT01418495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02975|Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma|Pharmacokinetics of the Chimeric Anti-GD2 Antibody, ch14.18, in Children With High-Risk Neuroblastoma||National Cancer Institute (NCI)||Completed|May 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|N/A||1|Actual|12|||Both|N/A|15 Years|No|Non-Probability Sample||June 2014|July 30, 2015|August 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01418495||99718|
NCT01418794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNH-20101010|Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease|||Shenyang Northern Hospital|Yes|Recruiting|October 2010|||November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|606|||Both|18 Years|85 Years|No|||October 2010|August 16, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418794||99695|
NCT01418807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mini-LPS Specimen extraction|Transumbilical Versus Transvaginal Specimen Retrieval at Minilaparoscopy|||Università degli Studi dell'Insubria||Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Female|N/A|N/A|No|||February 2012|February 23, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01418807||99694|
NCT01419119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIDI 2|Vitamin Deficiency in Immigrants, a Treatment Study|A Study, Four Parallel Arms, Included Two Arms Open Randomisation to Different Doses of Vitamin D, for Assessment of Efficacy of Treatment With Vitamin D at Vitamin D Deficiency, Vitamin D Insufficiency and Suboptimal Levels of Vitamin D|VIDI2|Umeå University|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|160|||Both|25 Years|65 Years|No|||December 2012|December 10, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01419119||99670|
NCT01419405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1380-1|Pregabalin and Remifentanil - Analgesia and Ventilation|Pregabalin Has Additive Analgesic and Ventilatory Depressive Effects in Combination With Remifentanil||Oslo University Hospital|No|Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01419405||99648|
NCT01419418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1361|Patients' Perspectives of Factors That Support the Management of Peripheral Arterial Disease for Improved Outcomes|A Study of Patients' Perspectives of Factors That Support the Management of Cardiac Care for Improved Outcomes in a Peripheral Arterial Disease Population||VA Eastern Colorado Health Care System|No|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|89 Years|No|Non-Probability Sample|A purposive sampling technique, meaning the sample will be selected according to the        participant's diagnosis of the specific disease, will be utilized to enroll up to 24        Peripheral Arterial Disease patients from the VA Peripheral Arterial Disease clinic.|January 2016|January 22, 2016|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01419418||99647|
NCT01386515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911177|The Role of Family Functioning in Promoting Adaptation in Siblings of Individuals With Duchenne Muscular Dystrophy (DMD)|The Role of Family Functioning in Promoting Adaptation in Siblings of Individuals With Duchenne Muscular Dystrophy (DMD)||National Institutes of Health Clinical Center (CC)||Terminated|June 2011|January 2016||||N/A|Observational|N/A|||Anticipated|50|||Both|13 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 8, 2016|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01386515||102164|
NCT01420107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123456789|Video Recording in the Delivery Room in Very Preterm Infants (Video Apgar Trial)|Video Recording in the Delivery Room in Very Preterm Infants (Video Apgar Trial)||University Medicine Greifswald|Yes|Recruiting|August 2010|April 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|32 Weeks|No|Probability Sample|preterm infants <32;0 weeks of gestational age|August 2011|August 18, 2011|February 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01420107||99594|
NCT01426750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPM 1463/7|Enteral Nutrition Support in Children and Adolescents With Cancer|Enteral Nutrition Support in Children and Adolescents With Cancer: a Non-randomized Controlled Clinical Trial||Grupo de Apoio ao Adolescente e a Crianca com Cancer|Yes|Completed|June 2002|June 2006|Actual|June 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|1 Year|N/A|No|||August 2011|August 29, 2011|March 28, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426750||99085|
NCT01426763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-204|A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase|An Open-label Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Hereditary Angioedema||Shire|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|12|||Both|12 Years|N/A|No|||March 2014|March 19, 2014|August 25, 2011|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT01426763||99084|
NCT01428167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-112|Hashimotos Thyroiditis and Thyroid Cancer|Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?|Thyroid Cancer|The University of Texas Medical Branch, Galveston|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|Plasma samples with be stored to measure anti inflammatory factors.|Both|18 Years|80 Years|No|Non-Probability Sample|All patients undergoing thyroidectomy for a variety of indications at University of Texas        Medical Branch in Galveston between June 2011-May 2012|June 2012|June 5, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01428167||98977|
NCT01430234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAPES|Enzyme Suppletion in Exocrine Pancreatic Dysfunction|Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen|SAPES|Foundation for Liver Research|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|90 Years|No|||March 2015|March 10, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01430234||98820|
NCT01431131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0352|Ridge Preservation Comparing and Intrasocket Graft Alone to an Intrasocket Graft Plus a Facial Overlay Graft|Ridge Preservation Comparing the Clinical and Histologic Healing of an Intrasocket Mineralized Cancellous Allograft vs. an Intrasocket Mineralized Cancellous Allograft Plus a Facial Overlay Graft Using Bovine Xenograft With a Bioabsorbable Barrier Membrane||University of Louisville|No|Not yet recruiting|September 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 8, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431131||98751|
NCT01430858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15516|Does Vibration Therapy Induce Higher Than Normal Bone Strains and Strain Rates Than Those Experienced During Habitual Daily Activities|Measurement of Induced Strains in the Human Tibia During Vibration Therapy and Habitual Activities||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|March 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 14, 2012|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430858||98772|
NCT01430871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15805|Effects of Serotonin Excess on Bone in Carcinoid Syndrome|Effects of Serotonin Excess on Bone in Carcinoid Syndrome||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|52|Samples Without DNA|24 hour urine collections serum samples whole blood samples blood spot on cards|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women age 18 years or older with carcinoid syndrome attending the Sheffield        neuro-endocrine tumour clinic Healthy men and women individually matched to the patients        by gender, age, height and BMI|June 2012|June 14, 2012|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01430871||98771|
NCT01431157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00049080|Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure|Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure||University of Maryland|No|Terminated|November 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|September 7, 2011||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01431157||98749|
NCT01431638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2361E1|Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients|A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients||Novartis|Yes|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|233|||Both|18 Years|85 Years|No|||June 2014|June 13, 2014|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01431638||98712|
NCT01431911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113898|Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation|Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation||GlaxoSmithKline|No|Completed|October 2010|March 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|3806|||Both|40 Years|N/A||Non-Probability Sample|Patients meeting study criteria mentioned belowwere classified into two cohorts, early and        delayed, based on timing of (maintenance treatment) MTx after the index date - 0 to 30        days and 31 to 180 days, respectively. A 30-day period was chosen to define early        initiation based on sample size considerations and recent evidence demonstrating the        increased risk of subsequent exacerbations during an 8-week period following an initial        exacerbation [Hurst JR 2009]. Outcomes were computed for and compared between these two        cohorts. An incremental analysis evaluating the effect of delaying MTx by every 30 days        was also done classifying patients into six categories based on 30-day increments of        starting MTx (0 to 30 days, 31 to 60 days, 61 to 90 days, 91 to 120 days, 121 to 150 days,        and 151 to 180 days) (Figure 1). Outcomes were then compared across the 6 categories        thereby allowing assessment for every 30-day increment up to 180 days after the index        date.|September 2011|September 8, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01431911||98691|
NCT01432353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRF4998g|A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma|An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma||Genentech, Inc.||Completed|September 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01432353||98657|
NCT01426139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1002|BIOFLOW-INDIA Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in Single de Novo Coronary Artery Lesions|BIOTRONIK-Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in the Treatment of Patients With Single de Novo Coronary Artery Lesions in an Indian Population||Biotronik AG|Yes|Completed|August 2011|February 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|80 Years|No|||April 2013|April 3, 2013|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01426139||99131|
NCT01426152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prog2006-2011|Progesterone on the Day of Ovulation Induction is Associated With Pregnancy Outcome|Association Between Progesterone Levels on the Day of Ovulation Induction and IVF Outcome: Retrospective Study With 2500 Controlled Ovarian Stimulations Cycles|ProgBBN|Bollmann Bruckner Noss|Yes|Completed|January 2006|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|2555|||Female|18 Years|N/A|No|Probability Sample|Female patients with infertility undergoing assisted reproduction techniques, i.e. in        vitro fertilization.|August 2011|August 29, 2011|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01426152||99130|
NCT01432925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BURULIVENI|Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics|Timing of the Decision on Surgical Intervention for Buruli Ulcer Patients Treated With Rifampicin/Streptomycin|Burulitime|University Medical Center Groningen|Yes|Active, not recruiting|September 2011|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|260|||Both|3 Years|N/A|No|||January 2015|January 12, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432925||98614|
NCT01425684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045716|Brain Circuits in Schizophrenia and Smoking|Brain Circuits in Schizophrenia and Smoking||University of Maryland|No|Recruiting|January 2011|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|800|Samples With DNA|-  Whole Blood        -  Saliva|Both|12 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Smokers, nonsmokers, schizophrenia patients, family members|November 2015|November 30, 2015|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01425684||99166|
NCT01425944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00038014|Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome|The Brain Vascular Malformations Clinical Research Network: Predictors of Clinical Course, Project 2: Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|September 2010|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|600|Samples With DNA|Aim 1 retains data and samples without DNA. Aim 2 retains data without DNA. Aim 3 retains      anonymous data with DNA.|Both|1 Month|N/A|Accepts Healthy Volunteers|Non-Probability Sample|For Aim 1, the population will be subjects with Sturge-Weber Syndrome and diagnosed brain        involvement. There will be a separate group made up of family members of those with        Sturge-Weber syndrome brain involvement to have as a control for the urine portion of Aim        1. For the optical coherence tomography (OCT) portion of Aim 1, the population will be        subjects with Sturge-Weber Syndrome eye involvement. For Aim 2, the population will be        subjects that have Sturge-Weber Syndrome with brain involvement. For Aim 3, the population        will be subjects with Sturge-Weber Syndrome, diagnosed brain involvement, and V1        distribution Port-Wine Stain.|October 2015|October 12, 2015|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01425944||99146|
NCT01426243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-014921-17|The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.|The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient|EP46 NOVAA|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Active, not recruiting|July 2011|July 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|71|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|February 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01426243||99123|
NCT01426568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-CMC-4876|A Trial of Multi-convergent Therapy for Functional Symptoms and Stress in Patients With Inflammatory Bowel Disease|A Randomised Controlled Trial of Multi-convergent Therapy for Inflammatory Bowel Disease Patients With Functional Abdominal Symptoms and High Perceived Stress||Cardiff and Vale University Health Board|Yes|Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|65 Years|No|||August 2013|August 27, 2013|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01426568||99099|
NCT01426893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RRS-XXX-2011/1|Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct|Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct||AstraZeneca|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|310|||Both|18 Years|N/A|No|Non-Probability Sample|Speciality care clinics|March 2012|March 28, 2012|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426893||99074|
NCT01426880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 66|Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer|A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer|GeparSixto|German Breast Group|Yes|Completed|August 2011|August 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|595|||Female|18 Years|N/A|No|||February 2016|February 12, 2016|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01426880||99075|
NCT01429636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARMR-Sympts|Applied Relaxation (AR) Technique Versus Its Modified Version for Treating Menopausal Symptoms|Phase 3 Study of Applied Relaxation (AR) Technique That Treating Menopausal Symptoms||Chiang Mai University|Yes|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|45 Years|65 Years|No|||December 2011|December 28, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429636||98865|
NCT01430247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30082011/2011|Vision Screening for the Detection of Amblyopia|Vision Screening of the Four Year Old Children for the Detection of Amblyopia in The Town of Zagreb||General Hospital Sveti Duh|No|Enrolling by invitation|September 2011|September 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|7000|||Both|48 Months|54 Months|No|||September 2011|September 6, 2011|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01430247||98819|
NCT01430260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HANDOK2010.07|Omnaris Versus Levocetirizine Phase 4 Study|A Multi-center, Open, Randomized, Three-arm, Parallel-group, Phase IV Study to Compare the Efficacy of Ciclesonide Nasal Spray and Levocetirizine, Alone and in Combination for the Patient With Allergic Rhinitis||Handok Pharmaceuticals Co., Ltd.|Yes|Completed|January 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|349|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430260||98818|
NCT01430585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1271003|Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer|An Open-Label, Randomised Phase 1b/2 Study Of PF-04691502 In Combination With Letrozole Compared With Letrozole Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Early Breast Cancer||Pfizer|No|Terminated|March 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Female|18 Years|N/A|No|||July 2014|July 18, 2014|August 18, 2011|Yes|Yes|See termination reason in detailed description.|No|July 18, 2014|https://clinicaltrials.gov/show/NCT01430585||98793|Study was prematurely terminated due to PF-04691502 tolerability findings that prompted Sponsor to re-evaluate strategic goals of program. Unexpected frequency of severe skin toxicity was observed and no participant was enrolled in phase 2 of study.
NCT01430611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPS01|Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children|Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China||Sanofi|No|Completed|August 2011|November 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|666|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||April 2014|April 9, 2014|September 6, 2011||No||No|February 28, 2014|https://clinicaltrials.gov/show/NCT01430611||98791|
NCT01430624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT023099|Prevention of Post Sexual Assault Stress|Prevention of Postrape Drug Abuse: Replication Study||Medical University of South Carolina|No|Completed|May 2009|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|245|||Female|15 Years|90 Years|No|||April 2015|April 21, 2015|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430624||98790|
NCT01431352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Letrozole|Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)|The Effects of Chinese Herbal Medicine and Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome:A Double-blind Randomized Controlled Trial||Heilongjiang University of Chinese Medicine|No|Recruiting|September 2009|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Female|20 Years|40 Years|No|||November 2013|November 4, 2013|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01431352||98734|
NCT01432132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0558|Mirror Grant - Understanding of Body Image Adaptation|Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2011|||August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|35|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be drawn from the Head and Neck Center at MD Anderson Cancer Center in        Houston, Texas|November 2015|November 6, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432132||98674|
NCT01426464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brown Rabbit 2011-0001|Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy|Phase 2 Study of Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy||Nanduri, Padma, M.D., FACS|No|Not yet recruiting|September 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|22|||Both|21 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 29, 2011|August 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426464||99106|
NCT01426477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-004|Veritas in Non-Bridging Ventral Hernia Repair|Veritas in Non-Bridging Ventral Hernia Repair|VIBE|Synovis Surgical Innovations|No|Recruiting|August 2011|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Study surgeons will recruit patients from within their own practice, or through their        typical referring sources.|May 2013|May 29, 2013|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426477||99105|
NCT01426490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10251|The Effects of Vitamin B-6 Status on Homocysteine, Oxidative Stress, One-carbon Metabolism and Methylation: Cross-section, Case-control, Intervention and Follow-up Studies in Colorectal Cancer|||Taichung Veterans General Hospital|Yes|Recruiting|August 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Anticipated|300|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2011|February 17, 2014|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426490||99104|
NCT01433198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7560|Aquatic Training in Patients With Severe Scarring|Aquatic Training in Patients With Severe Scarring||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|September 2011|||December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01433198||98593|
NCT01425697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB 25962|Eliminate Risk of Cardiac Surgical Site Events|Randomized,Prospective Evaluation of 2% Chlorhexidine Gluconate Cloths to Reduce Surgical Site Infections in Cardiothoracic Surgery Patients|ERASE|University of Rochester|No|Completed|November 2008|September 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|739|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 28, 2013|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425697||99165|
NCT01425957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP5P001|Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment|Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment: a Two-part Clinical Study. PartA: Multisite MRI Acquisition, Protocol Harmonization. PartB: Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment: a Clinical Study||Qualissima|No|Completed|December 2011|October 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|229|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425957||99145|
NCT01425970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-003|Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin|A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus®) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects||Bristol-Myers Squibb|Yes|Terminated|May 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|210|||Both|18 Years|65 Years|No|||October 2015|October 12, 2015|August 25, 2011|Yes|Yes|Termination of study was due to safety reasons|No||https://clinicaltrials.gov/show/NCT01425970||99144|
NCT01426269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10183|Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo|Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea||Galderma Laboratories, L.P.|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|235|||Both|18 Years|80 Years|No|||July 2014|July 8, 2014|August 26, 2011||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01426269||99121|
NCT01427426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00426|Does a Nutritional Supplement Increase Vitality, Energy and Perceived Well Being?|Does a Nutritional Supplement Increase Vitality, Energy and Perceived Well Being?||University of British Columbia|No|Completed|January 2012|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|120|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 14, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01427426||99033|
NCT01427673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USAF|Continuous Positive Airway Pressure Versus Noninvasive Ventilation in Patients With Overlap Syndrome|Phase III Single-blind Randomized Controlled Trial of Bipap Versus CPAP in Overlap Syndrome|OS|United States Air Force|No|Not yet recruiting|December 2011|February 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|35 Years|80 Years|No|||August 2011|August 31, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01427673||99014|
NCT01427153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113703|A Comparison of Manual Physical Therapy and Corticosteroid Injections for Knee Osteoarthritis|Orthopaedic Manual Physical Therapy Versus Corticosteroid Injections for Osteoarthritis of the Knee|SMART|Madigan Army Medical Center|No|Recruiting|March 2012|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|156|||Both|38 Years|N/A|No|||February 2016|February 2, 2016|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427153||99054|
NCT01429935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|504|Anti Inflammatory and Analgesic Effect of Ginger Powder in Dental Pain Model|Comparison of The Anti Inflammatory and Analgesic Effect of Ginger and Ibuprofen in Post Surgical Pain Model; a Randomized,Placebo-controlled,Double-blind Clinical Trial|GPE|Qazvin University Of Medical Sciences|Yes|Active, not recruiting|June 2010|October 2011|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01429935||98843|
NCT01430598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME 11 0021|Study Comparing Patient Function and Satisfaction With Arthroscopic Subacromial Decompression Before and After Repair of Complete Rotator Cuff Tears|Randomized Single Blinded Study Comparing Patient Function and Satisfaction With Arthroscopic Subacromial Decompression Before and After Repair of Complete Rotator Cuff Tears||Genesys Regional Medical Center|No|Recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||September 2011|September 7, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01430598||98792|
NCT01430884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP-04|Analysis of Human Coronary Aspirate|Human Coronary Aspirate: Characterization of Particular and Soluble Substances and the Impact on Microvascular Obstruction|AHCA|Universität Duisburg-Essen|No|Recruiting|April 2004|November 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|-  coronary arterial blood distal to the lesion before stent implantation        -  coronary aspirate blood during stent implantation|Both|N/A|N/A|No|Non-Probability Sample|Consecutive, symptomatic patients with a significant stenosis in a native coronary vessel        or a saphenous vein aortocoronary bypass graft.|December 2014|December 2, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01430884||98770|
NCT01431170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120110184|Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children|A Prospective, Double-Blinded, Parallel-Group, Randomized Study to Assess the Safety and Efficacy of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children||Rutgers, The State University of New Jersey|Yes|Completed|September 2011|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|1 Month|12 Months|No|||September 2014|October 1, 2014|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431170||98748|
NCT01430897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261-11-22082011|Right Ventricular Hypertrophy After Atrial Switch and Cardiovascular Magnetic Resonance (CMR) Findings|Right Ventricular Hypertrophy After Atrial Switch Operation and Its Role in a Systemic RV: Normal Adaptation Process or Risk Factor? A Cardiovascular Magnetic Resonance Study||University of Leipzig|Yes|Completed|April 2007|September 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|37|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Thirty-seven consecutive patients who came to regular outpatient visits at our tertiary        care institution were referred to CMR.        Patient parameters were compared to a control group of 25 healthy age matched volunteers.|September 2011|September 7, 2011|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01430897||98769|
NCT01431144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0355|Implant Placement With Simultaneous Gum Grafting|The Effect of Implant Placement and Simultaneous Soft Tissue Augmentation in the Esthetic Zone Using Either Connective Tissue Autograft or Acellular Dermal Matrix Allograft on Peri-implant Hard and Soft Tissue Healing||University of Louisville|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 7, 2013|September 7, 2011||No||No|July 7, 2013|https://clinicaltrials.gov/show/NCT01431144||98750|There were no adverse events. There were 2 cases of implant mobility and these was treated as a potential expected complication and handled with routine clinical practice guidelines.
NCT01431365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SmokingTopography210|Effect of an Acute Bout of Exercise on Smoking Topography|Does an Acute Bout of Exercise Affect Smoking Topography?||University of Western Ontario, Canada|No|Completed|August 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|September 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431365||98733|
NCT01431378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106-2010-GES-0010|Pilot Study of Model Based Iterative Reconstruction Using 64-Slice|Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen|MBIR|GE Healthcare|No|Terminated|September 2011|August 2015|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||4|Actual|92|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Population to include women or men 30 years of age or older referred for a CT scan|December 2015|December 10, 2015|September 7, 2011||No|Feasibility study, sufficient amount of data collected.|No||https://clinicaltrials.gov/show/NCT01431378||98732|
NCT01425879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02974|MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery|A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers||National Cancer Institute (NCI)||Completed|April 2011|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|August 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425879||99151|
NCT01425866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/CHR/03|Two Years Maintenance of Structured Group Self-management Education in Type 2 Diabetes : a Randomized Controlled Trial|Multicenter Randomized Trial of Structured Educational Intervention at the Community Level in Insufficiently Controlled Patients With Type 2 Diabetes in Reunion Island|ERMIES|Centre Hospitalier Universitaire de la Réunion|No|Active, not recruiting|October 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425866||99152|
NCT01430715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8556|Estimating Energy Expenditure in Active Video Gaming Compared to Unstructured, Outdoor Play in Children|Active Video Gaming Compared to Unstructured, Outdoor Play in Children: Measurements of Estimated Energy Expenditure and Measured Percent Time in Moderate-to-Vigorous Physical Activity||University of Tennessee|Yes|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|5 Years|8 Years|No|||April 2012|April 19, 2012|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01430715||98783|
NCT01430728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULMNEONIRS04|Cerebral Tissue Oxygenation in Very Low Birthweight Infants in the First 3 Days of Life|Cerebral Tissue Oxygen Saturation in Preterm Neonates Below 1500g Birth Weight During the First 72 Hours||University of Ulm|No|Recruiting|April 2011|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|Very low birthweight infants treated in our hospital|July 2012|July 24, 2012|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430728||98782|
NCT01430975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGEN-104|Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites|A Prospective Study to Estimate Inadvertent Radiation Exposure From Strontium Isotopes in Patients Who Have Undergone CardioGen-82® PET MPI Scanning at Two Clinical Sites||Bracco Diagnostics, Inc|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Both|N/A|N/A|No|Non-Probability Sample|The study population would come from the two sites who administered CardioGen-82® to the        index patients. Each site that agrees to participate will enroll patients administered        CardioGen-82 2 days before and 2 days after the use of that generator.|April 2012|April 24, 2012|September 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430975||98763|
NCT01431235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-130|Investigating Cognitive Behavioral Therapy in Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders|Investigating the Efficacy of Cognitive Behavioral Therapy in Patients With Substance Use Disorder and Comorbid ADHD. A Randomized Controlled Trial With Cognitive Behavioral Therapy||Arkin|No|Recruiting|August 2011|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|No|||September 2011|September 8, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01431235||98743|
NCT01427036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI/09/PR/MISSvsPHS|On the Impact of Bleeding on Two Strategies Osteosynthesis of Trochanteric Fractures|Impact Sur le Saignement Per et Post opératoire de 2 stratégies d'ostéosynthèse Des Fractures du Massif trochantérien du Sujet > 65 Ans : Essai randomisé Comparant le système MISS et le système PHS|MISSvsPHS|University Hospital, Tours|Yes|Completed|June 2010|November 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Both|65 Years|N/A|No|||January 2016|January 5, 2016|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427036||99063|
NCT01425710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pheo|Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma|Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma||Medical University of Vienna|No|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|15|Samples Without DNA|whole blood, serum|Both|18 Years|80 Years|No|Non-Probability Sample|Patients suffering from pheochromocytoma will be recruited by the Department of Surgery,        Medical University of Vienna|February 2014|February 12, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01425710||99164|
NCT01425983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kyberg-02|Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01)|Dietary Intervention of Stress-Induced Neurovegetative Disorders in Men and Women With a Specific Amino Acid Composition With Micronutrients|asn01|Kyberg Vital GmbH|No|Completed|March 2011|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||September 2015|September 4, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425983||99143|
NCT01426256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052829|Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)|Vitamin D for Enhancing the Immune System in Cystic Fibrosis|DISC|Emory University|Yes|Recruiting|October 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|16 Years|N/A|No|||December 2015|December 16, 2015|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426256||99122|
NCT01427166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-279|Non-Invasive Imaging for Cording in Breast Cancer Patients|Evaluation of Non Invasive Imaging for Assessing the Pathophysiology of Cording in Patients Treated for Breast Cancer||Massachusetts General Hospital|Yes|Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01427166||99053|
NCT01427439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13504A|A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder|A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder|PERFORM|H. Lundbeck A/S|No|Completed|February 2011|||February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1455|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients will be recruited from outpatient clinics (General Practitioner (GP) or        psychiatrist)|July 2015|July 7, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01427439||99032|
NCT01427712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-893|Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis||Mylan Inc.||Recruiting|December 2011|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|99 Years|No|Non-Probability Sample|Patients who receive LipaCreon for the replacement of pancreatic digestive enzymes in        pancreatic exocrine insufficiency|December 2015|December 14, 2015|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427712||99011|
NCT01427686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULMNEONIRS01|Dopamine Versus Dobutamine for Treatment of Arterial Hypotension in Term and Preterm Neonates|Effect of Dobutamine as Compared to Dopamine on Cerebral Oxygenation, Mean Arterial Pressure and Cerebral Hemodynamics in Term and Preterm Neonates With Arterial Hypotension||University of Ulm|No|Recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|44 Weeks|No|||July 2012|July 24, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427686||99013|
NCT01427699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-PT011|A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes|A Phase II Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes||XBiotech, Inc.|No|Completed|June 2011|||October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|70 Years|No|||October 2012|October 29, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427699||99012|
NCT01430273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10028|Assessment of Blood Loss With a Point Of Care Device|Assessment of Blood Loss With a Point Of Care Device During Hip/Knee Surgery Performed On Dual/Single Antiplatelet Therapy|BLOOD|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2013|July 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|salivary kit (Oragnèe-DNA approved by FDA) or blood (2 tubes 2.5ml)|Both|18 Years|N/A|No|Non-Probability Sample|This study targets CAD patients exposed to antiplatelelt mono/bitherapy who need planned        or emergency knee/hip athroplasty. This innovative study will bring new insights on how        works antiplatelet therapy during the perioperative period according to drug exposition        and metabolizer profile.        Patients ethnicity will be recorded and defined according to the place of birth of the        participants and of their parents given the identification of the metabolizer profile with        respect to the CYP 2C19*2 carriage. The analysis will bestratified according to ethnicity        to avoid biases.|April 2015|April 2, 2015|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01430273||98817|
NCT01429675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR206-01|Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers|Randomized, Open-label Crossover Study to Evaluate Comparative Pharmacokinetics of Ibandronate Between DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 Complex Tablet) and a 150mg Ibandronate Tablet in Healthy Adult Volunteers||Alvogen Korea|No|Enrolling by invitation|August 2011|October 2011|Anticipated|October 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|84|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 5, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01429675||98862|
NCT01429974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8479-AO-CTIL|Detection of Meconium in Amniotic Fluid in Post Term Pregnancies|Detection of Meconium in Amniotic Fluid in Post Term Pregnancies||Sheba Medical Center|No|Recruiting|September 2011|||January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Female|N/A|N/A|No|Non-Probability Sample|Post term pregnant females|January 2013|January 23, 2013|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01429974||98840|
NCT01429987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP304-20210|The Plecanatide Chronic Idiopathic Constipation (CIC) Study|Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation||Synergy Pharmaceuticals Inc.|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|951|||Both|18 Years|75 Years|No|||May 2013|May 28, 2013|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01429987||98839|
NCT01430286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081002|Web-based Psycho-Educational Program to Support Carers of Alzheimer's Patients|Evaluation of a Web-based Psycho-Educational Program for Informal Caregivers of Patients With Alzheimer's Disease (AD).|DIAPASON|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2011|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|49|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01430286||98816|
NCT01430299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACC3-US-2010-1|Efficacy and Safety of Accell Evo3 DBM in Instrumented Posterolateral Lumbar Spine Fusion|Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix Instrumented Posterolateral Lumbar Spine Fusion||Integra LifeSciences Corporation|No|Active, not recruiting|June 2011|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|August 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430299||98815|
NCT01431391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P10-2|Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer|A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy||Dendreon|No|Completed|September 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Male|18 Years|N/A|No|||February 2015|February 11, 2015|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431391||98731|
NCT01431664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000709775|AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia|A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia||Cancer Research UK||Completed|September 2011|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|18 Years|No|||December 2014|December 1, 2014|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01431664||98710|
NCT01431677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910221|Muscle Biopsies in Healthy Volunteers|Muscle Biopsies in Healthy Volunteers: a Pilot Study||National Institutes of Health Clinical Center (CC)||Terminated|May 2010|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|March 2, 2016|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01431677||98709|
NCT01430429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0801-03|Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody|An Open Label Single Arm Study to Investigate the Safety and Efficacy of Multiple Administrations of NI-0801, a Fully Human Anti-CXCL10 Monoclonal Antibody in PBC Patients With an Incomplete Response to Ursodeoxycholic Acid|PIANO|NovImmune SA|No|Terminated||||||Phase 2|Interventional|N/A|1||||||Both|18 Years|N/A|No|||June 2012|April 3, 2014|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01430429||98805|
NCT01426165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-10-2271|Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients|Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients||CAMC Health System|No|Terminated|April 2011|December 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|August 24, 2011|Yes|Yes|Issues with recruitment. PI decided to terminate study|No||https://clinicaltrials.gov/show/NCT01426165||99129|
NCT01430988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ahead™ M-100 B-AHEAD UK|Observational Study of the BrainScope® Ahead™ M-100 in UK Emergency Department Patients With Head Injury|An Observational Clinical Study of the BrainScope® Ahead™ M-100 Hand Held Electroencephalogram in Emergency Department Patients With Head Injury (B-AHEAD UK Trial)||BrainScope Company, Inc.|No|Terminated|September 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|318|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients who present to the Emergency Department or Accident & Emergency within the        selected hospitals participating in the study.|May 2012|May 2, 2012|September 7, 2011||No|The trial was terminated prematurely following a suspected data processing concern in the    study device. The concern did not pose a patient safety issue.|No||https://clinicaltrials.gov/show/NCT01430988||98762|
NCT01431001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-CPS-TRMD-1|Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression|Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study||Cervel Neurotech, Inc.|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||May 2014|May 15, 2014|September 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431001||98761|
NCT01431248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEACE|PPROM Erythromycin Versus Azithromycin|Preterm Premature Rupture of Membranes: Erythromycin Versus Azithromycin. A Randomized Trial Comparing Their Efficacy to Prolong Latency|PEACE|University of Oklahoma|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|7|||Female|18 Years|50 Years|No|Probability Sample|Pregnant women with the diagnosis of PPROM will be enrolled in this protocol.|January 2013|January 15, 2013|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431248||98742|
NCT01426789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2208|A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients|A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension||Novartis||Completed|August 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|August 12, 2011|Yes|Yes||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01426789||99082|
NCT01426802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237AEG01|Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin|A 12 Week Multi Center, Open Label, Single Arm Study to Assess the Safety and Efficacy of Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin||Novartis||Completed|October 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||August 2011|August 30, 2011|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01426802||99081|
NCT01426581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0248|Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)|Effectiveness of Interventions to Teach Respiratory Inhaler techNique (E-TRaIN)|E-TRaIN|University of Chicago|Yes|Completed|August 2011|February 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|100|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426581||99098|
NCT01426594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-CARDIO-NIS002|Real-life Experience of the Use of Isomers as METPURE XL (S (-) Metoprolol Succinate) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients||XPERT|Closter Pharma||Recruiting|August 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care adults|August 2011|August 30, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426594||99097|
NCT01426906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL007|Pharmacokinetic Drug Interaction Study in Healthy Male Subjects|A Randomized, Open-Label, Drug-Drug Interaction Study To Evaluate The Effect Of Ketoconazole Or Rifampicin On The Pharmacokinetic Characteristics And Safety Of Lc15-0444 In Healthy Male Volunteers||LG Life Sciences|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||August 2011|August 31, 2011|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01426906||99073|
NCT01427179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000160|Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)|Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)||Mayo Clinic|No|Recruiting|May 2011|December 2020|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Family-Based||1|Anticipated|1000|Samples With DNA|A 30 ml sample of blood from a vein or an existing catheter will be drawn at Mayo Clinic or      another medical center and returned through the mail in a kit. Alternatively, a saliva      sample will be collected and returned through the mail in a kit. An additional 10 ml (2      teaspoons) of blood, buccal smear, and/or available tissue samples may also be collected.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women diagnosed with spontaneous coronary artery dissection (SCAD) or and their        biological parents.|December 2015|December 30, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427179||99052|
NCT01427452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000286|Kidney Donor Outcomes Cohort (KDOC) Study|Kidney Donor Outcomes Cohort (KDOC) Study|KDOC|Beth Israel Deaconess Medical Center|No|Active, not recruiting|August 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|720|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 280 living kidney donors, 280 LDKT recipients, and 160 healthy comparison        subjects meeting all eligibility criteria will be enrolled.        We will enroll both English and Spanish speaking participants into the study. All        questionnaire outcomes will be translated into Spanish using conventional translational        procedures and we will ensure that an interviewer at BIDMC is fluent in Spanish. It is        important to emphasize that not all of the questionnaires used in this study have been        validated in Spanish or with Hispanic patients. While this is an important limitation, we        feel that this limitation is outweighed by the potential benefits of including primarily        Spanish-speaking participants in the study.|March 2016|March 21, 2016|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427452||99031|
NCT01427725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-894|Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency|Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Pancreatectomy and Other Conditions Except Cystic Fibrosis||Mylan Inc.||Completed|October 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|562|||Both|N/A|N/A|No|Non-Probability Sample|Patients who receive LipaCreon for the replacement of pancreatic digestive enzymes in        pancreatic exocrine insufficiency|May 2015|June 9, 2015|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427725||99010|
NCT01428011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00311|Patient-Provider Communication and Medication Adherence|Racial Differences in Patient-Provider Communication and Medication Adherence|MEDCHAT|New York University School of Medicine|Yes|Active, not recruiting|March 2016|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from Primary Care Clinics in New York City|March 2016|March 9, 2016|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428011||98989|
NCT01429688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-SACL-I-003|Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers|A Randomized, Single-dose, 2-sequence, 2-period Crossover Study to Investigate the Food-effect Pharmacokinetics of Sarpogrelate HCl Controlled Release Tablet in Healthy Male Subjects||Alvogen Korea|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01429688||98861|
NCT01430312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15853|21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation|A Randomized, Double-blind, Vehicle-controlled Phase 1 Dermal Safety Study Using a 21 Day Cumulative Irritant Patch Test Design to Evaluate the Local Tolerability of Azelaic Acid Pre-Foam Formulation in Healthy Volunteers||Bayer||Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|September 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430312||98814|
NCT01430650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UREP-PREPENDO-2010|Endometrial Priming for Embryo Transfer|A Randomised Control Trial to Evaluate Efficacy and Safety of Two Different Protocols of Endometrial Priming for Embryo Transfer.||Parc de Salut Mar|No|Completed|July 2010|July 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|50 Years|No|||November 2015|November 2, 2015|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01430650||98788|
NCT01430910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00011|A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately|A Phase I, 2-Part, Open-Label, Pharmacokinetic and Drug-Drug Interaction Study of CAZ104 (Avibactam and Ceftazidime in Healthy Subjects)||AstraZeneca||Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|43|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 19, 2012|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430910||98768|
NCT01431196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEND/CM|Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer|Phase II Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer||Clinica Universidad de Navarra, Universidad de Navarra|No|Active, not recruiting|February 2011|December 2013|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|75 Years|No|||December 2013|November 28, 2013|April 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01431196||98746|
NCT01431404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAGLE-I-11|Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects|Randomized,Double-blind,Single-dosing,Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 With Active Comparator||Hanwha Chemical|No|Completed|August 2011|June 2013|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|September 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431404||98730|
NCT01425359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0133|Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina|A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus|TERISA|Gilead Sciences|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|949|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|August 24, 2011|Yes|Yes||No|October 20, 2014|https://clinicaltrials.gov/show/NCT01425359||99191|
NCT01425632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAU-284-17|A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis|A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)||Mitsubishi Tanabe Pharma Corporation|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|490|||Both|7 Years|15 Years|No|||September 2015|November 10, 2015|August 28, 2011||No||No|September 17, 2015|https://clinicaltrials.gov/show/NCT01425632||99170|
NCT01430442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN170-003|Dose Ranging Study of a Drug for the Treatment of Acute Migraine|Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine||Bristol-Myers Squibb|No|Completed|October 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|885|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|September 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430442||98804|
NCT01430741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 11-240|MISSION-Vet HUD-VASH Implementation Study|MISSION-Vet HUD-VASH Implementation Study||VA Office of Research and Development|No|Active, not recruiting|October 2012|June 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|150|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01430741||98781|
NCT01430754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-3203|Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder|A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD||Vanda Pharmaceuticals|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||October 2014|October 8, 2014|August 30, 2011|Yes|Yes||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01430754||98780|
NCT01431014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-2811-B-182A-003|Effect of Steroid for the Postoperative Swelling After Orthognathic Surgery|The Effect of Steroid on Reducing Facial Swelling After Orthognathic Surgery||Chang Gung Memorial Hospital|Yes|Completed|August 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|56|||Both|15 Years|N/A|Accepts Healthy Volunteers|||September 2011|February 6, 2014|August 28, 2011|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01431014||98760|
NCT01431040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X100928005|Patient Experience and Bowel Preparation for Transvaginal Surgical Management of Vaginal Prolapse|Patient Experience and Bowel Preparation for Transvaginal Surgical Management of Vaginal Prolapse||University of Alabama at Birmingham|No|Completed|January 2011|August 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Female|19 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 13, 2014|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431040||98758|
NCT01431261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WADNECXT|Neck Exercises, Training and Pain Management as a Treatment for Whiplash Patients With Chronic Neck Pain|Neck Exercises, Physical and Cognitive Behavioural Graded Activity as a Treatment for Adult Whiplash Patients With Chronic Neck Pain|WADNECXT|University of Southern Denmark|No|Active, not recruiting|January 2012|March 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01431261||98741|
NCT01426308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cyto-001|Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test|Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test||Illumina, Inc.||Active, not recruiting|August 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|900|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Leftover, de-identified DNA extracted from EDTA or heparin anticoagulated whole blood        samples.|September 2011|September 26, 2011|August 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426308||99118|
NCT01426321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTCLIN01|Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment|Individually Tailored Cardiac Resynchronization Therapy - Combing Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in Cardiac Resynchronization Therapy|CRT clinic|Region Skane|No|Recruiting|August 2011|December 2018|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426321||99117|
NCT01426607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2010-06|VASO-AM :Impact of Oral Appliance Therapy on Endothelial Function in Obstructive Sleep Apnea|VASO-AM :Impact of Oral Appliance Therapy on Endothelial Function in Obstructive Sleep Apnea|VASO-AM|University Hospital, Angers|Yes|Recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|150|||Both|18 Years|70 Years|No|||August 2011|August 30, 2011|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01426607||99096|
NCT01426620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-LUN-BIT-2|Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer|Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer|BIT-2|James Graham Brown Cancer Center|Yes|Terminated|June 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|August 27, 2011||No|slow accrual|No||https://clinicaltrials.gov/show/NCT01426620||99095|
NCT01426919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-06|Evaluation of Biomarkers of Traumatic Brain Injury|A Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury|ALERT-TBI|Banyan Biomarkers, Inc|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2011|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects eligible for study participation will be over the age of 18 and present to the        health care facility with a head injury at a time such that sample collection can be        completed within 12 hours of injury. Subjects who will be permitted into the study include        those who will meet all the inclusion criteria and will have none of the exclusion        criteria.|September 2015|September 2, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01426919||99072|
NCT01427192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSRPH|Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension|Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension (CSRPH)|CSRPH|University of Zurich|Yes|Completed|November 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|23|||Both|20 Years|80 Years|No|||August 2011|December 11, 2012|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01427192||99051|
NCT01427205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0680|Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase II Study of Cetuximab With or Without OSI-906, a Dual Insulin-like Growth Factor-1 Receptor and an Insulin Receptor Inhibitor, in Platinum-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma||M.D. Anderson Cancer Center|Yes|Withdrawn|June 2013|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427205||99050|
NCT01427218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010100590|Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease|A Prospective Evaluation of a Medication Therapy Management Clinic Versus Usual Medical Care in Patients Post Acute Coronary Syndrome: The MUMPS Study|MUMPS|Middle Tennessee Research Institute|No|Recruiting|November 2010|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|170|||Both|60 Years|90 Years|No|||August 2011|August 31, 2011|January 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01427218||99049|
NCT01427738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5265|Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis|A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Gentian Violet Oral Solution to That of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings||AIDS Clinical Trials Group|Yes|Completed|June 2011|January 2014|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|November 3, 2010||No||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01427738||99009|
NCT01430637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST11B5|Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1|Comprehensive Genome Sequencing of Desmoplastic Small Round Cell Tumors||Children's Oncology Group|No|Active, not recruiting|September 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|50 Years|No|Non-Probability Sample|Patients registered on COG-D9902 or COG-ABTR01B1.|May 2015|May 8, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430637||98789|
NCT01430663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGIHO BAL GM PCR 2007|Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples|Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples||Heidelberg University|No|Completed|April 2007|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|87|||Both|5 Years|80 Years|No|Non-Probability Sample|hematological patients at high risk for invasive aspergillosis|April 2014|April 4, 2014|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430663||98787|
NCT01430923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LATANOPROST/CIP/002/2011|Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost|Randomized,Active Comparator-Controlled,Three Months,Open Label Clinical Trial to Compare Efficacy and Safety of Refrigeration-Free Latanoprost (0.005%) and Latanoprost (0.005%) Stored at Refrigeration Temperature in Patients With OAG or OHT||Aurolab|No|Active, not recruiting|September 2011|August 2012|Anticipated|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||July 2012|July 11, 2012|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430923||98767|
NCT01431183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U01IP000132|Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions|Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions||University of Michigan|No|Completed|October 2008|December 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|3618|||Both|24 Months|60 Months|No|||September 2011|September 7, 2011|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01431183||98747|
NCT01431417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNS-DORE 13DPD6_135061|Validation of a Kinematic Functional Shoulder Score Including Only Essential Movements|Validation of a Kinematic Functional Shoulder Score Including Only Essential Movements||Haute Ecole Cantonale Vaudoise de Santé|No|Completed|August 2011|May 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|108|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients consulting at the specialized shoulder consultation of the University Hospital of        Lausanne|June 2015|June 2, 2015|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01431417||98729|
NCT01425372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13UK|Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months|A Prospective Study to Evaluate the Immune Response of UK Infants Receiving the 13-valent Pneumococcal Conjugate Vaccine as Part of Their Routine Primary Immunisation Schedule at 2 and 4 Months|P13UK|Public Health England|Yes|Completed|November 2010|June 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|93|||Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|Healthy infants who have received their primary immunisation schedule at appropriate        intervals|July 2015|July 22, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425372||99190|
NCT01425645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXX|Families Defeating Diabetes|Families Defeating Diabetes: Canadian Intervention for Family-Centered Diabetes Prevention Following Gestational Diabetes (GDM)|FDD|Lawson Health Research Institute|Yes|Active, not recruiting|January 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|August 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01425645||99169|
NCT01430455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6333|Tranylcypromine Treatment of Bipolar Depression|Tranylcypromine Treatment of Bipolar Depression||New York State Psychiatric Institute|Yes|Recruiting|May 2011|||May 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||September 2011|December 14, 2011|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430455||98803|
NCT01430468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 10-582|Patient Specific Instruments Versus Standard Surgical Instruments|Comparison of Glenoid Component Position Using Patient Specific Instruments Versus Standard Surgical Instruments: A Randomized Prospective Clinical Trial|TIOSO - GPS|The Cleveland Clinic|No|Active, not recruiting|August 2010|November 2011|Anticipated|September 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|N/A|N/A|No|||September 2011|September 7, 2011|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430468||98802|
NCT01430767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFBMC-Psych-17564|Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder|Measuring Adherence to Standard-of-Care Medication for Depression and ADHD in a College Student Population||Wake Forest Baptist Health|No|Completed|September 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Twenty male and female subjects, ten with depression and ten with ADHD, will be recruited.        Subjects will be recruited from the Student Health Clinic at Wake Forest University, as we        plan to assess adherence in a typical population of college students with depression or        ADHD.|December 2015|December 17, 2015|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430767||98779|
NCT01431053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-011|Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer|Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer||Chinese Academy of Medical Sciences|No|Recruiting|July 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Female|50 Years|80 Years|No|||March 2013|March 12, 2013|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431053||98757|
NCT01431274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.5|Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]||Boehringer Ingelheim||Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|2624|||Both|40 Years|N/A|No|||June 2015|June 19, 2015|September 8, 2011||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01431274||98740|
NCT01426334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03454|Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate|Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia (ESCAPE1b)||National Cancer Institute (NCI)||Terminated|September 2011|||June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||June 2013|April 1, 2014|August 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01426334||99116|
NCT01426633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISG-02|Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas|Phase I Dose Escalating Trial Evaluating the Combination of Gemcitabine and Trabectedin in Patients With Advanced and/or Metastatic Leiomyosarcoma or Liposarcoma||Heidelberg University|No|Completed|November 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426633||99094|
NCT01426932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HITVNG|The Head Impulse Test in the Screening of Vestibular Function|The Head Impulse Test in the Screening of Vestibular Function||Meir Medical Center|No|Enrolling by invitation|October 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Tertiary center patients|February 2012|June 27, 2013|August 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01426932||99071|
NCT01426945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST11B3|Protein Expression in Samples From Young Patients With Rhabdomyosarcoma|Evaluating Candidate Protein Expression in Human Rhabdomyosarcoma (RMS)||Children's Oncology Group|No|Active, not recruiting|November 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|77|Samples With DNA|Tumor tissue|Both|N/A|N/A|No|Non-Probability Sample|Children with rhabdomyosarcoma (RMS) enrolled in the Children's Oncology Group clinical        trials|May 2015|May 8, 2015|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01426945||99070|
NCT01426958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.151|Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects|Relative Bioavailability of a Single Oral Dose of 40 mg Afatinib Given Alone Compared to Concomitant and Timed Administration of Multiple Oral Doses of Ritonavir - an Open-label, Randomised, Three-way Crossover Trial in Healthy Male Volunteers||Boehringer Ingelheim||Completed|August 2011|||December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|June 3, 2014|August 30, 2011||||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01426958||99069|
NCT01426971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBUCA_L_05619|Ibuprofen Versus Ibuprofen Plus Caffeine in the Treatment of Migraine.|National, Controlled, Randomized, Double-blind, Parallel Study to Investigate the Efficacy of 2 Capsules of Ibuprofen 400mg in Association With Caffeine 100mg in Fixed Dose Combination Compared to Two Capsules of Ibuprofen 400mg in the Treatment of Migraine||Sanofi||Withdrawn|December 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||November 2012|November 23, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01426971||99068|
NCT01427231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36813.081.11|Short-term Effect of Glucose and Sacharose Ingestion on Cognitive Performance and Mood in Elderly|The Short-term Effect of Glucose and Sacharose Ingestion on Cognitive Performance and Mood in Elderly Subjects||Wageningen University||Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|43|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 20, 2012|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01427231||99048|
NCT01427465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2007-U-0085|Brief Integrative Alcohol Interventions for Adolescents|Brief Integrative Alcohol Interventions for Adolescents|Brief|University of Florida|Yes|Withdrawn|September 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 21, 2011|July 22, 2010||No|PI left University of Florida|No||https://clinicaltrials.gov/show/NCT01427465||99030|
NCT01430676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH-2|Risk Factors for Morbidity After Incisional Hernia Repairs|Risk Factors for Morbidity After Incisional Hernia Repairs||University Hospital Koge|No|Completed|January 2007|November 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3460|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All incisional hernia repairs registered in tha Danish National Hernia Database from        January 1st 2007 to December 31st 2010|November 2011|November 30, 2011|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01430676||98786|
NCT01430338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAT|Different Metabolic Characteristics in the Presence of Brown Adipose Tissue in Humans|Different Metabolic Characteristics in the Presence of Brown Adipose Tissue in Humans||Korea University|Yes|Completed|December 2010|||December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|90|Samples Without DNA|plasma and serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients who underwent 18FDG-PET/CT scan year between 2008-2010.|September 2011|March 16, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01430338||98812|
NCT01430689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00049582|Maternal Flu Vaccine Trial in Bamako, Mali|Prospective, Randomized, Controlled, Observer-Blind Trial to Measure the Efficacy, Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine and the Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Diphtheria Conjugate Vaccine in Pregnant Malian Women and Their Infants up to 6 Months of Age||University of Maryland|Yes|Active, not recruiting|September 2011|September 2016|Anticipated|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4192|||Female|N/A|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430689||98785|
NCT01430936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVN-111|Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices|Remote Monitoring of Heart Failure Patients (REMOTE-HF-1) Study - to Assess Utility of a Mobile Device for Improved Management of At-risk Patients|REMOTE-HF-1|Aventyn, Inc.|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Non-Probability Sample|Tertiary care population|July 2012|July 9, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01430936||98766|
NCT01425060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA030534|Improving Effective Contraceptive Use Among Opioid-maintained Women|Improving Effective Contraceptive Use Among Opioid-maintained Women||University of Vermont|Yes|Completed|October 2011|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|31|||Female|18 Years|44 Years|No|||March 2015|March 13, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01425060||99214|
NCT01425658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12611000909921|Comparison of Postoperative Analgesic Effect of Intrathecal Clonidine and Fentanyl Added to Bupivacaine in Patients Undergoing Cesarean Section|||Qazvin University Of Medical Sciences||Completed|August 2011|February 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Female|18 Years|45 Years|No|||May 2012|May 16, 2012|August 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01425658||99168|
NCT01425892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110172|The Pathogenesis and Natural History of Sjogren s Syndrome|The Pathogenesis and Natural History of Sjogren s Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|July 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|16 Years|70 Years|No|||June 2015|June 5, 2015|August 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01425892||99150|
NCT01430481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-018|Rosehip Powder for Knee Osteoarthritis|Comparing Different Preparations and Dosages of Rosehip Powder in Patients With Painful Osteoarthritis of the Knee: An Exploratory Randomised Controlled Trial||Frederiksberg University Hospital|No|Recruiting|August 2011|July 2012|Anticipated|April 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|40 Years|N/A|No|||September 2011|September 7, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01430481||98801|
NCT01430780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009A062|A Prospective Study to Evaluate the Effect of Chronic Nitrate Therapy on Vasodilation Function in Coronary Heart Disease|A Prospective Study to Evaluate the Influence of Oxygen Free Radical Injury Induced by Long-term Nitrates Therapy on Vasodilation Function of Patients With Coronary Heart Disease||Zhejiang University|Yes|Recruiting|August 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|68|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with catheterization confirmed coronary artery disease.|March 2013|March 21, 2013|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01430780||98778|
NCT01431027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F101215002|Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic Function|Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic Function||University of Alabama at Birmingham|Yes|Completed|August 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|45|||Both|19 Years|N/A|No|Non-Probability Sample|Patients scheduled for cardiac catheterization.|August 2015|August 15, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01431027||98759|
NCT01431287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.6|Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2]||Boehringer Ingelheim||Completed|September 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|2539|||Both|40 Years|N/A|No|||June 2015|June 19, 2015|September 8, 2011||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01431287||98739|
NCT01431508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0954A-373|A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)|An Open-label, Single Arm, Prospective Study to Evaluate the Safety and Anti-hypertensive Efficacy of Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination in Patients With Mild to Moderate Essential Hypertension||Merck Sharp & Dohme Corp.|No|Completed|August 2007|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|20 Years|N/A|No|||October 2015|October 20, 2015|September 7, 2011|No|Yes||No|October 13, 2011|https://clinicaltrials.gov/show/NCT01431508||98722|
NCT01431521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4074-008|Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)|An Exploratory Study to Evaluate Changes in Hepatic Fat Following Multiple-Dose Administration of MK-4074 and Pioglitazone Hydrochloride||Merck Sharp & Dohme Corp.|No|Completed|October 2011|October 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|60 Years|No|||February 2016|February 24, 2016|September 7, 2011|No|Yes||No|February 24, 2016|https://clinicaltrials.gov/show/NCT01431521||98721|
NCT01431534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-056|A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)|A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Active, not recruiting|January 2012|August 2016|Anticipated|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|6 Years|17 Years|No|||February 2016|February 24, 2016|September 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431534||98720|
NCT01426022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P9334|Effect of Moderate Alcohol Consumption on Postprandial Mood|The Effect of Moderate Alcohol Consumption With a Meal in Different Ambiances on Postprandial Mood, Evaluated by Subjective and Physiological Responses||TNO|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01426022||99140|
NCT01426347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDRA|Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis|Vitamin Therapy in Rheumatoid Arthritis||Johns Hopkins University|No|Active, not recruiting|January 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|75 Years|No|||August 2011|August 30, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426347||99115|
NCT01426035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPSEMS0110_cream|Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate Cream In The Superficial Varicose Veins Treatment|Phase III of Safety and Efficacy Study of Topic Mucopolysaccharide Polysulfate Cream 5mg/g in the Superficial Varicose Veins Treatment||EMS|Yes|Suspended|September 2014|February 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|80 Years|No|||March 2013|March 1, 2013|May 9, 2011||No|Study suspended by decision strategically.|No||https://clinicaltrials.gov/show/NCT01426035||99139|
NCT01426646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACSPGC-01|S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer|Randomized Multicenter Phase II Trial of S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy After Curative Resection of Stage II-IV(M0) Gastric Cancer||Kyungpook National University|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|70 Years|No|||January 2012|January 3, 2012|January 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01426646||99093|
NCT01426659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/089/HP|Language and Motor Skills of Preterm Infants in Pre-school Age: Diagnosis and Early Intervention|Evaluation of Language and Sensorimotor Constraints of Very Premature Babies at the Age of 3 Years 1 / 2 Without Cerebral Palsy. Randomised Study of Stimulation Training Implicit in Children Vulnerable|LAMOPRESCO|University Hospital, Rouen|Yes|Completed|September 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|139|||Both|34 Months|38 Months|No|||June 2015|June 2, 2015|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426659||99092|
NCT01426672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0289-EMargolin|Monovision for the Treatment of Diplopia|Monovision for Treatment of Diplopia||Mount Sinai Hospital, Canada|No|Completed|January 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2011|August 30, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01426672||99091|
NCT01427491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0142-11-U358|Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers|A Prospective, Multi-center, Randomized, Comparative Clinical Study to Compare Aquacel® Ag vs. Mepilex® Border Ag to Manage Bioburden in Leg Ulcers.||ConvaTec Inc.|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01427491||99028|
NCT01427504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1046|Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers|A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/(Hepatitis C Virus) (HCV) Negative Volunteers||University of Colorado, Denver|No|Completed|August 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|26|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|August 24, 2011||No||No|November 16, 2012|https://clinicaltrials.gov/show/NCT01427504||99027|Healthy volunteer study does not take into account other medications being prescribed to treat the co-infected population.An interaction at the level of enzyme induction is difficult to rule out since we sampled etravirine over 12 hours.
NCT01427478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBW2992 ORL|Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck|A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02|BIBW2992ORL|Centre Leon Berard|Yes|Recruiting|September 2011|September 2021|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|315|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427478||99029|
NCT01430351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0374|Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)|A Phase I lead-in to a 2x2x2 Factorial Trial of Dose Dense Temozolomide, Memantine, Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2011|||September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Anticipated|144|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430351||98811|
NCT01430949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEP-4409-2010|GENESIS Feasibility Study of the BARD Over-the-Wire Mesh Ablation System for the Treatment of Paroxysmal Atrial Fibrillation|A Single-Arm Multi-Center Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard Over-the-Wire Ablation System|GENESIS|C. R. Bard|Yes|Completed|November 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|September 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430949||98765|
NCT01431209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|283-11|Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma|A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-cell and Peripheral T-cell Non-Hodgkin Lymphoma||University of Nebraska|Yes|Recruiting|August 2011|August 2025|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|19 Years|N/A|No|||December 2014|December 2, 2014|September 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431209||98745|
NCT01425385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU-010|Autoregulation Assessment During Liver Transplantation|Non-Invasive Assessment of Cerebral Blood Flow Autoregulation in Patients Undergoing Liver Transplantation||Johns Hopkins University|No|Completed|September 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|In this pilot study we will enroll 20 patients undergoing orthotopic liver transplantation        at The Johns Hopkins Hospital. Patients will receive standard care during the procedure.        Study related procedures are non-invasive and observational. There will be no        interventions based on the results of the study data. The study will include only the        immediate operative period. The patients will have transcranial Doppler monitoring and        near infrared spectroscopy monitoring during surgery beginning before anesthesia induction        and continued until the end of surgery.|August 2015|August 31, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425385||99189|
NCT01429506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|922861|Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes|Effect of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes||Postgraduate Institute of Medical Education and Research|Yes|Completed|January 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|70 Years|No|||October 2015|October 23, 2015|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01429506||98875|
NCT01429792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21779|A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)|A Multi-Center Study Evaluating the Rate of Genotype 1, 2, 3 & 4 Chronic Hepatitis C Patients With Slow Response / Non-rapid Viral Response to Anti-Viral Treatment of Pegasys (Peginterferon Alfa 2a) in Combination With Copegus (Ribavirin)||Hoffmann-La Roche||Completed|September 2008|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|940|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01429792||98853|
NCT01430078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK15|A Study to Assess the Bioavailability of ASP015K|A Phase 1, Open-Label, 4-Way Crossover Regional Drug Absorption Study to Assess the Bioavailability of ASP015K in Healthy Subjects||Astellas Pharma Inc|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430078||98832|
NCT01430091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13040|A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet|Relative Bioavailability of a Prasugrel Paediatric Orally Disintegrating Tablet Formulation Compared to the Tablet in Healthy Adult Subjects||Eli Lilly and Company|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 5, 2012|September 6, 2011|No|Yes||No|October 5, 2012|https://clinicaltrials.gov/show/NCT01430091||98831|
NCT01430104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14454|A Study of Teriparatide in Japanese Osteoporosis Patients|A Study to Assess the Effects on Serum Calcium When Teriparatide is Used With Active Vitamin D in Osteoporosis Patients||Eli Lilly and Company|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|55 Years|N/A|No|||November 2012|January 7, 2013|September 6, 2011||No||No|November 27, 2012|https://clinicaltrials.gov/show/NCT01430104||98830|
NCT01430117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6045-PR-PRI-183|Biological Standardization of Poa Pratensis Allergen Extract|Biological Standardization of Poa Pratensis Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units||Laboratorios Leti, S.L.|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|50 Years|No|||August 2012|August 20, 2012|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430117||98829|
NCT01430793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM100404|Determination of Effective Vitamin D Replacement and Monitoring Strategies in Vitamin D Deficiency State|Vitamin D Dosing and Monitoring Study|EVIREST-D|Aga Khan University|No|Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|99|||Both|18 Years|70 Years|No|||April 2014|April 7, 2014|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430793||98777|
NCT01431066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01828|ActiPatch Plantar Fasciitis Clinical Trial|Continuous Low Energy Pulsed Radio Frequency Electromagnetic Field Therapy for the Treatment of Plantar Fasciopathy||University of British Columbia|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||September 2011|February 27, 2014|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431066||98756|
NCT01430819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC48|Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults|Safety and Immunogenicity Among Adults of Fluzone®, Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route)||Sanofi|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 16, 2013|September 7, 2011|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01430819||98775|
NCT01431079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11083108|A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men|Designing and Evaluating a Health Belief Model Based Intervention to Increase Intent of HPV Vaccination Among College Men: Use of Qualitative and Quantitative Methodologies||University of Cincinnati|No|Completed|September 2011|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|September 3, 2011||No||No|September 30, 2012|https://clinicaltrials.gov/show/NCT01431079||98755|Overall limitation of the trial were due to attrition at the one month follow up.This was due to the end of school year.This meant that students were busy preparing for finals, starting co-ops/internships, moving back home, or lack of interest.
NCT01431300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022334|Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants|Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants||Duke University|No|Completed|August 2011|July 2013|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|October 20, 2013|September 7, 2011|Yes|Yes||No|August 1, 2013|https://clinicaltrials.gov/show/NCT01431300||98738|
NCT01431547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-062|Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)|A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|February 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|3 Years|17 Years|No|||January 2015|January 19, 2015|September 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431547||98719|
NCT01425775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed116618166|The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE)|||Faculty of Medicine, University of Alexandria|Yes|Completed|April 2010|May 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|248|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2011|August 27, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01425775||99159|
NCT01425788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-G-01|Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense|Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense|Osiris|ALK-Abelló A/S|No|Completed|August 2011|February 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|236|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425788||99158|
NCT01426048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/180/2008|Long-term Outcome of the TVT Procedure Without Preoperative Urodynamic Examination|Long-term Outcome of the TVT Procedure Without Preoperative Urodynamic Examination||Turku University Hospital||Completed|November 2008|June 2011|Actual|||Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|138|||Female|N/A|N/A|No|Probability Sample|191 female patients with genuine or recurrent stress urinary incontinence or mixed        incontinence operated on with the TVT procedure at the mean of 10.5 years ago.|January 2013|January 21, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01426048||99138|
NCT01426360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH-38|Instant and Lasting Relief Effects of Strontium Chloride/Potassium Nitrate Dentifrice on Dentin Hypersensitivity|A Randomized, Double-blind Clinical Trial to Assess the Instant and Lasting Relief Effects of a Dentifrice Containing 2% Strontium Chloride and 5% Potassium Nitrate on Dentin Hypersensitivity||Sun Yat-sen University|Yes|Completed|September 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|70 Years|No|||November 2011|November 14, 2011|August 29, 2011||No||No|October 1, 2011|https://clinicaltrials.gov/show/NCT01426360||99114|
NCT01427244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004006704|Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease|A Phase II Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease||Yale University|Yes|Withdrawn|August 2011|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||June 2014|June 12, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01427244||99047|
NCT01428414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27770|Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer|Multicenter, Randomized, Open-label Phase II Study to Compare the Efficacy and Safety of Trastuzumab and Paclitaxel Based Regimen Plus Carboplatin or Epirubicin as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients||Fudan University|Yes|Active, not recruiting|August 2011|February 2015|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|69 Years|No|||August 2012|August 21, 2012|August 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428414||98958|
NCT01427777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-030-1|3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China|The Thirty-six-Month Immunogenicity Evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years||Guangxi Center for Disease Control and Prevention|No|Not yet recruiting|September 2011|June 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|9 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who participated in V501-030 in Per-protocol population|September 2011|September 1, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01427777||99006|
NCT01430702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FY2010-007|Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults|Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults That Require Medication Assistance During Transition Form Hospital to Home|EMMA|University of Pittsburgh|Yes|Withdrawn|September 2011|April 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|65 Years|N/A|No|||January 2013|January 14, 2013|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01430702||98784|
NCT01428960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMU R 069/2011|Study of Acute Effects of Sn-1 and Sn-3 Palmitic Acid-rich or Stearic Acid-rich Fats on Metabolic Markers|Acute Effects of Sn-1 and Sn-3 Palmitic Acid-rich or Stearic Acid-rich Fats on Postprandial Lipemia, Haemostatic and Inflammatory Markers, Gut Hormone Concentrations, Satiety, and Insulinemic Response in Human Volunteers||Malaysia Palm Oil Board|No|Completed|June 2011|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|36|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2013|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01428960||98917|
NCT01424813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-301|A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma|A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma||Teva Pharmaceutical Industries|No|Completed|December 2012|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|12 Years|N/A|No|||May 2015|May 28, 2015|August 25, 2011|Yes|Yes||No|May 1, 2015|https://clinicaltrials.gov/show/NCT01424813||99233|
NCT01429519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-WH-001|Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds|A PRELIMINARY OPEN CLINICAL STUDY, TO ASSESS THE SAFETY AND EFFICACY OF RPh201 APPLIED TOPICALLY FOR THE TREATMENT OF HARD TO HEAL CHRONIC ULCERATED WOUNDS||Regenera Pharma Ltd|No|Terminated|December 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||October 2012|October 15, 2012|September 4, 2011||No|Due to slow recruitment|No||https://clinicaltrials.gov/show/NCT01429519||98874|
NCT01429805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR01662|Balloon Assisted Hip Arthroscopy - Clinical Evaluation of a New Tool for Hip Arthroscopy|Balloon Assisted Hip Arthroscopy - Clinical Evaluation of a New Tool for Hip Arthroscopy|BAHA-I|Pivot Medical Inc.|No|Completed|September 2011|April 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01429805||98852|
NCT01429818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET-GLI01|Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients|Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients. Positron Emission Tomography Assessment(PET)||Laboratorios Silanes S.A. de C.V.|No|Completed|July 2007|January 2008|Actual|January 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01429818||98851|
NCT01430130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA005|Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE)|Investigation of a Novel Mechanomodulating Polymer to Maximize the Outcomes of Scar Revision Procedures|IMPROVE|Neodyne Biosciences, Inc.|No|Completed|September 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|65 Years|No|||November 2014|November 21, 2014|September 6, 2011|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01430130||98828|The Neodyne Dressing is referred to as the "embrace device."
NCT01430143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FourINonE|Physical Activity for a Long and Healthy Life|Physical Activity for a Long and Healthy Life - Project FINE|FINE|University of Copenhagen|No|Active, not recruiting|September 2009|December 2012|Anticipated|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|64|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01430143||98827|
NCT01430520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL-04-11|Analgesic Effect of Escitalopram in Total Knee Arthroplasty (TKA)|Analgesic Effect of Perioperative Escitalopram for Patients With High Preoperative Level of Pain Catastrophising in Total Knee Arthroplasty||Hvidovre University Hospital|Yes|Completed|September 2011|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||June 2013|June 4, 2013|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430520||98798|
NCT01430806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6402|Dronaderone to Prevent Recurrent Implantable Cardioverter Defibrillator (ICD) Shocks|Dronedarone for Patients With Recurrent ICD Shocks Due to Ventricular Arrhythmia Resistant to Their Antiarrhythmic Drug Therapy or Ablation||Rabin Medical Center|No|Not yet recruiting|October 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2011|September 7, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430806||98776|
NCT01431313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11080686|Inhaled Nitrite in Subjects With Pulmonary Hypertension|A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension||University of Pittsburgh|Yes|Recruiting|April 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|78 Years|No|||November 2015|November 20, 2015|September 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431313||98737|
NCT01431573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5491|Wake Therapy in the Treatment of Depression|Combined Wake Therapy, Light Therapy, and Lithium for Bipolar and Refractory Depression||New York State Psychiatric Institute|No|Recruiting|July 2011|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||April 2012|April 26, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01431573||98717|
NCT01431833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-124|A PK and Safety Study in Subjects With Hepatic Impairment|A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment||Trius Therapeutics LLC|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2011|June 6, 2012|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431833||98697|
NCT01432041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHSPH-H.31.02.04.03.B2|Brief Child Safety Interventions in Emergency Departments (Safety in Seconds)|Brief Child Safety Interventions in Emergency Departments (Safety in Seconds)||Johns Hopkins Bloomberg School of Public Health|No|Completed|September 2004|December 2005|Actual|December 2005|Actual|N/A|Interventional|Primary Purpose: Prevention|||Actual|901|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 9, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432041||98681|
NCT01426386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000009|A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multi-national, Multi-centre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Women Undergoing an ART Programme||Ferring Pharmaceuticals|Yes|Completed|September 2011|March 2013|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|265|||Female|18 Years|37 Years|No|||June 2013|June 17, 2013|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426386||99112|
NCT01425021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43277|Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery|Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery||University of Utah|Yes|Completed|August 2010|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|199|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing revision total joint surgery.|August 2015|August 17, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01425021||99217|
NCT01426685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1539/31/06|Prognosis of Type 2 Diabetic Patients|Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology|ARTEMIS|University of Oulu|No|Active, not recruiting|August 2007|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1880|Samples With DNA|Blood samples are stored for analysis of various biomarkers and for extracting DNAs.|Both|18 Years|75 Years|No|Probability Sample|1200 diabetic patients with coronary artery disease and 600 non-diabetic patients with        coronary artery disease.|December 2015|December 9, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01426685||99090|
NCT01425840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112/2007|Liposomal Lidocaine Gel for Oral Topical Anesthesia|Efficacy of Liposome Lidocaine Gel for Topical Anesthesia in the Palatal Mucosa||University of Campinas, Brazil|Yes|Completed|March 2008|March 2009|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|1||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2011|August 27, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01425840||99154|
NCT01426984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA -0011-11|A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults|A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With Borderline Personality Disorder (BPD) Compared to Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Healthy Adults||Shalvata Mental Health Center|Yes|Recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|20|||Both|21 Years|50 Years|No|||August 2012|August 22, 2012|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01426984||99067|
NCT01427543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-10-00590|The HJ MILE HIV Prevention Intervention for Post-incarcerated Men|The HJ MILE HIV Prevention Intervention for Post-incarcerated Bisexual African American Men||University of Southern California|Yes|Completed|July 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|212|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 15, 2014|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427543||99024|
NCT01427556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 213098-1|The Hormonal and Behavioral Impact of Eating Breakfast|CCRC: The Hormonal and Behavioral Impact of Eating Breakfast|FL-74|USDA, Western Human Nutrition Research Center|No|Completed|August 2009|August 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Serum and saliva samples will be retained.|Female|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|One hundred and twenty pre-menopausal women, aged 20 to 45y, who report eating breakfast        regularly or skipping breakfast regularly.|August 2014|August 15, 2014|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427556||99023|
NCT01424787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-OSV-01-EU|Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)|Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)|Steering|Fresenius Medical Care Deutschland GmbH|No|Completed|October 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|324|||Both|18 Years|N/A|No|Non-Probability Sample|Dialysis patients (HD, HDF, or PD) being treated with OsvaRen for hyperphosphataemia|March 2015|March 5, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01424787||99235|
NCT01425034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49860|Postoperative Rehabilitation Following Trapeziectomy and Ligament Reconstruction Tendon Interposition|Postoperative Rehabilitation Following Trapeziectomy and Ligament Reconstruction Tendon Interposition: a Prospective, Randomized Multi-center Study|LRTI|University of Utah|No|Enrolling by invitation|September 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|210|||Both|40 Years|80 Years|No|||February 2016|February 2, 2016|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01425034||99216|
NCT01428726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-KO-003-2010-01|A Phase IIa Study of NT-KO-003 for Multiple Sclerosis|A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis||Neurotec Pharma|No|Completed|June 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|55 Years|No|||March 2014|March 15, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428726||98934|
NCT01428739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23701|Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer|Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer||AHS Cancer Control Alberta|Yes|Completed|December 2007|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|October 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01428739||98933|
NCT01424826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoL000643|The Effect of Intermittent Rifampicin on Raltegravir|A Single Arm, 3 Phase Study to Determine the Effect of Intermittent Dosing of Rifampicin on the Pharmacokinetics of Raltegravir in Healthy Volunteers|RIFRAL|University of Liverpool|Yes|Completed|January 2012|July 2013|Actual|June 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 30, 2013|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424826||99232|
NCT01433250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457B2201E1|A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis|An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis||Novartis|No|Completed|February 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|55 Years|No|||February 2016|February 16, 2016|August 26, 2011|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01433250||98589|Further development of secukinumab in MS is not being pursued and the extension study , CAIN457B2201E1, further enrollment stopped . Not completing enrollment of this study was not related to the safety or tolerability concerns observed in the study.
NCT01425073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40461-B|Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya|Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya: a Randomized Trial||University of Washington|Yes|Completed|February 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01425073||99213|
NCT01429532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCPMOH2010-China2|Outcomes of 3 Incision-size-dependent Phacoemulsification Systems|Clinical Evaluation of Three Incision-size-dependent Phacoemulsification Systems||Sun Yat-sen University|Yes|Completed|July 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|120|||Both|55 Years|85 Years|No|Probability Sample|This prospective randomized study comprised 120 patients (120 eyes) with age-related        cataract enrolled for surgeries between July 2010 and January 2011 at the Zhongshan        Ophthalmic Center, Guangzhou, China.|June 2014|June 6, 2014|September 4, 2011||No||No|December 25, 2012|https://clinicaltrials.gov/show/NCT01429532||98873|
NCT01429831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-TWB-1101i|Aripiprazole for the Augmentation of Antidepressant Therapy|Aripiprazole for the Augmentation of Antidepressant Therapy: An Observational, Outpatients Study in Inadequate Responders Diagnosed With Major Depressive Disorder||Taiwan Otsuka Pharm. Co., Ltd||Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|300|||Both|20 Years|65 Years|No|||May 2014|May 19, 2014|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429831||98850|
NCT01430494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-10-291|Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease|A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression|OVERTURE|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|June 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3409|||Both|12 Years|70 Years|No|Non-Probability Sample|Subjects will be identified by participating clinics (primarily nephrology clinics)        treating patients with ADPKD.|April 2015|April 22, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01430494||98800|
NCT01430507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 4039-203|A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis|A Phase IIb, 12 Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Revamilast in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|TERRA|Glenmark Pharmaceuticals Ltd. India|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|406|||Both|18 Years|65 Years|No|||August 2012|December 27, 2012|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430507||98799|
NCT01431092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024065-46|Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia|Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial|SMART|University of Copenhagen|No|Completed|October 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01431092||98754|
NCT01432275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-PMS-INX-11011|Ease of Use of New Blood Glucose Meter With In-built Insulin Calculator at Home Study|Ease of Use of New Blood Glucose Meter With In-built Insulin Calculator at Home Study|IHUT|Abbott Diabetes Care|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|179|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01432275||98663|
NCT01432548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JLendoire2|Ischemic Preconditioning. Prospective Comparison|Ischemic Preconditioning Versus Intermittent Portal Triad Clamping in Liver Resection. Prospective Randomized Comparison|IP|Hospital General de Agudos “Dr. Cosme Argerich”|Yes|Recruiting|July 2011|October 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||September 2011|September 12, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01432548||98642|
NCT01425320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|225678-003|Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne|||Allergan|No|Withdrawn|January 2013|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|0|||Both|18 Years|64 Years|No|||November 2012|November 16, 2012|August 26, 2011|Yes|Yes|Study was never initiated due to company decision. No study subjects were ever enrolled or    dosed.|No||https://clinicaltrials.gov/show/NCT01425320||99194|
NCT01425853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRO/IV-ART-01|Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis|Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis|MOVES|Bioiberica|Yes|Completed|September 2011|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|606|||Both|40 Years|N/A|No|||January 2016|January 29, 2016|August 25, 2011||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT01425853||99153|
NCT01426425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICY-AVNRT|Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia|ICY-AVNRT (Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia)||Medtronic Atrial Fibrillation Solutions|Yes|Active, not recruiting|March 2012|May 2018|Anticipated|September 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|572|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426425||99109|
NCT01426724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15043|Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease|Effects of Active Form of Vitamin D on Renal Blood Flow, Glomerular Filtration Rate, Proteinuria and Inflammation in Patients With Chronic Kidney Disease and Hyperparathyroidism||University of Virginia|No|Withdrawn|September 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|75 Years|No|||May 2014|May 20, 2014|August 29, 2011|Yes|Yes|Difficult to enroll eligible subjects.|No||https://clinicaltrials.gov/show/NCT01426724||99087|
NCT01426737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ACH02T|The Swiss Glucose Variability Study|The Swiss Glucose Variability Study||University of Zurich|Yes|Recruiting|April 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|30 Years|75 Years|No|||August 2011|August 29, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01426737||99086|
NCT01428154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090302|Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease|An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin Alfa in Paediatric Subjects From Birth to Less Than 1 Year of Age With Anemia Due to Chronic Kidney Disease||Amgen|No|Not yet recruiting|April 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|1 Year|No|||February 2016|February 29, 2016|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428154||98978|
NCT01426126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOSG-AMC-0702|Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum|Phase II Study of Genexol-PM, a Cremophor-free, Polymeric Micelle Formulation of Paclitaxel for Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum||Asan Medical Center|No|Completed|December 2007|August 2011|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426126||99132|
NCT01426451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR/IRSC-229984|Assessment of a Drama Workshop Program for Immigrant and Refugee Adolescents|Assessment of a Drama Workshop Program for Immigrant and Refugee Adolescents||McGill University Health Center||Completed|November 2011|||December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|464|||Both|12 Years|17 Years|No|||March 2014|March 26, 2014|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01426451||99107|
NCT01428752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADENOMA 30-49 YO|Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer|Prevalence of Colorectal Adenoma in 30- to 49-year-old Asymptomatic Subjects With a First Relative History of Colorectal Cancer||Asan Medical Center|Yes|Recruiting|September 2011|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples Without DNA|whole blood and serum Colorectal polyp/cancer tissue|Both|30 Years|49 Years|No|Non-Probability Sample|30- to 49-year-old asymptomatic subjects undergoing first screening colonoscopy because of        a first relative history of colorectal cancer|September 2011|September 8, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01428752||98932|
NCT01428973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJB1016P1|Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens|Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donors After Reduced-intensity Conditioning: a Phase II Randomized Study Comparing 2 GVHD Prophylaxis Regimens||University Hospital of Liege|No|Recruiting|September 2011|September 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|16 Years|75 Years|No|||May 2015|May 29, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428973||98916|
NCT01428986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00005823-MVCBone2009|Safety Study of Maraviroc's Effect on Human Osteoclasts|Safety Study of Maraviroc's Effect on Human Osteoclasts|MVC-Bone|National Center for Global Health and Medicine, Japan|Yes|Completed|November 2009|March 2014|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|16|Samples Without DNA|Blood serum, blood plasma, urine|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Treatment group: primary care clinic, Non-treatment group: primary care clinic and        community sample|September 2014|September 24, 2014|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01428986||98915|
NCT01433263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338X2202|Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas|A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas||Novartis||Completed|August 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 24, 2011|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01433263||98588|
NCT01429272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBR 2011-002|Minocycline and Aspirin in the Treatment of Bipolar Depression|Minocycline and Aspirin in the Treatment of Bipolar Depression|Minocycline|Laureate Institute for Brain Research, Inc.|Yes|Completed|September 2011|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429272||98893|
NCT01429285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 08-11-387|Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain|Safety and Efficacy of Intravenous Hydromorphone Using Incremental Doses of 0.5 mg in Elderly ED Patients With Acute Severe Pain||Montefiore Medical Center|No|Recruiting|July 2009|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|350|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 6, 2011|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429285||98892|
NCT01429545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/95|Single Versus Combination Therapy in Acute Tocolysis|Phase 2 Study of Clinical Utility of Combination Tocolysis in Preterm Labor||Tawam Hospital|Yes|Completed|April 2007|March 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429545||98872|
NCT01429558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0290-03|Electrophysiological Recording for Patients Receiving Deep Brain Stimulation Electrode for Treatment-resistant Obsessive-compulsive Disorder|||University of Arizona|No|Completed|August 2011|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The subjects in this study are suffering from treatment-resistant OCD|April 2013|April 23, 2013|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01429558||98871|
NCT01430156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOT-2011|Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation|A Randomised Placebo-Controlled Trial to Investigate the Effect of Pre-treatment With Haem Arginate (Normosang) on Heme-Oxygenase 1 (HO-1) Upregulation in Recipients of Deceased Donor Kidneys|HOT|University of Edinburgh|Yes|Completed|January 2012|August 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01430156||98826|
NCT01430169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-805|Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease|A Phase 2, Open-Label Study to Assess the Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease||Endo Pharmaceuticals|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|N/A|No|||April 2015|April 20, 2015|September 6, 2011|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01430169||98825|
NCT01430182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28734|Intraoperative Methadone vs Morphine for Postoperative Pain Control in Patients Undergoing Surgery of the Tibia|Intraoperative Methadone Versus Morphine for Postoperative Pain Control in Patients Undergoing Intramedullary Nailing or Open Reduction and Internal Fixation of the Tibia||Baylor College of Medicine|No|Terminated|September 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|50 Years|No|||March 2015|March 19, 2015|September 6, 2011||No|Shortages of study drug, difficulty enrolling patients|No||https://clinicaltrials.gov/show/NCT01430182||98824|
NCT01431846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 11-242|Transition From Hospital to Home Post Cardiac Condition|Pilot Intervention to Improve the Transition From Hospital to Home||VA Office of Research and Development|No|Completed|August 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||September 2014|April 6, 2015|June 23, 2011||No||No|November 19, 2014|https://clinicaltrials.gov/show/NCT01431846||98696|
NCT01432574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16593|Study of Gardasil in Mid-Adult Males (MAM)|A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Male|27 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|September 9, 2011|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01432574||98640|Participants were followed for just 7 months post-dose one of the vaccine; therefore, investigators were unable to assess the durability of the vaccine response in men vaccinated at an older age.
NCT01432496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 06 2010 Colectomy|Peritoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Colectomy|A Multicentric, Randomized, Controlled, Double Blinded, Phase III Clinical Trial; Comparing Peritoneal Nebulization of Ropivacaine 150 mg With Peritoneal Nebulization of Saline||San Gerardo Hospital|No|Terminated|September 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|80 Years|No|||February 2013|February 22, 2013|September 9, 2011||No|There was insuficient recruitment in two centers|No||https://clinicaltrials.gov/show/NCT01432496||98646|
NCT01432509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_0385|Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)|DiabeNord: A 5-year Prospective Follow-up Cohort Study in Pre-diabetic Subjects for the Identification of New Biomarkers|DiabeNord|Nantes University Hospital|No|Active, not recruiting|September 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|207|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01432509||98645|
NCT01432522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078/2550|A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine|Comparison of Absorption of Epinephrine Into the Circulation After Epinephrine Intranasal Spray Administration and After Intramuscular Injection|Epinephrine|Siriraj Hospital|No|Completed|July 2010|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||September 2011|September 12, 2011|January 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01432522||98644|
NCT01425580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-nr 2010-022695-31|Liraglutide and Heart Failure in Type 2 Diabetes|Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin||Karolinska Institutet|No|Recruiting|January 2012|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01425580||99174|
NCT01425593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0118-08-mmc|T Cell Function in Chronic Idiopathic Urticaria|T Cell Function in Chronic Idiopathic Urticaria||Meir Medical Center|Yes|Recruiting|March 2009|December 2012|Anticipated|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|venous blood sample|Both|18 Years|N/A|No|Non-Probability Sample|patients with chronic urticaria|November 2012|November 4, 2012|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01425593||99173|
NCT01426438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5293|Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate|Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate||AIDS Clinical Trials Group|Yes|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 30, 2011|Yes|Yes||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01426438||99108|
NCT01427270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONU3704|Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation Who Require Around-the-clock Opioid Therapy||Purdue Pharma LP|No|Completed|August 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|455|||Both|18 Years|N/A|No|||November 2014|November 6, 2014|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427270||99045|
NCT01428934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/01088|Improving Intermediate Risk Management. MARK Study|Improving Intermediate Risk Management. MARK Study|MARK|Jordi Gol i Gurina Foundation|Yes|Recruiting|July 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2688|Samples Without DNA|Blood sample: Cholesterol and triglycerides concentration, HDL cholesterol, LDL cholesterol,      Glucose concentration, glycated hemoglobin and creatinine Urine sample:urine albumin, to      calculate the albumin/creatinine index. Postprandial glucose (mg / dl) will be self-measured      by patients at home 2 hours after meals (breakfast, lunch and dinner) for one day using an      Accu-chek ® glucometer.|Both|35 Years|74 Years|Accepts Healthy Volunteers|Probability Sample|Population aged 35 to 74 which have an intermediate cardiovascular risk.|September 2011|September 2, 2011|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428934||98919|
NCT01433497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB07002|A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis|A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib 6 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis||AB Science|Yes|Recruiting|August 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|September 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433497||98570|
NCT01433510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-15|Tolerability of Grazax in Patients With Hayfever in Real Life Settings|Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings|GRAAL|ALK-Abelló A/S|No|Completed|November 2007|December 2010|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|628|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433510||98569|
NCT01432652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|176/11|The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery|Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance||University of Lausanne Hospitals|No|Completed|September 2011|May 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|Vascular surgery patients|September 2011|July 27, 2015|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01432652||98634|
NCT01432665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB82|Lybrido for Female Sexual Dysfunction|||Emotional Brain NY Inc.|No|Completed|September 2011|||May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|7||Actual|196|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|August 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01432665||98633|
NCT01432678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|744/2553(EC1)|Vitamin D Status in Pediatric Asthma|Vitamin D Status in Pediatric Asthma||Mahidol University|Yes|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|whole blood, serum|Both|6 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|allergy clinic in tertiary hospital|September 2014|September 8, 2014|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01432678||98632|
NCT01432990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCIstemcell|Robotic Gait Training VS.Conventional Rehabilitation in SCI|Robotic Gait Training VS. Conventional Physical Therapy in Spinal Cord Injury Patients.||Prasat Neurological Institute|Yes|Not yet recruiting|January 2013|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|80 Years|No|||July 2012|July 15, 2012|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01432990||98609|
NCT01433237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B1|Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma|A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma||Children's Oncology Group|No|Active, not recruiting|September 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|40|||Both|N/A|N/A|No|Non-Probability Sample|Rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS.|May 2015|May 8, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433237||98590|
NCT01433276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009/IGK-KAL/09|Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock|The Clinical Efficacy and Safety of a Proprietary Solution Containing Hypertonic Sodium Lactate (Totilac®) Infusion for Resuscitation of Patients With Hemorrhagic Shock Due to Multiple Injuries||Innogene Kalbiotech Pte. Ltd|No|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|65 Years|No|||August 2011|September 12, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01433276||98587|
NCT01429298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC 09-11-346|Comparing Intravenous Hydromorphone to Usual Care|Randomized Clinical Trial Comparing IV Hydromorphone to Usual Care||Montefiore Medical Center|No|Active, not recruiting|March 2010|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|350|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429298||98891|
NCT01429311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADRN-01|Interferon Responses in Eczema Herpeticum|Investigation of Reduced Interferon Responses in Peripheral Blood Mononuclear Cells of Participants With Atopic Dermatitis and a History of Eczema Herpeticum (ADRN-01)|ADRN-01|National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|April 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|120|Samples With DNA|Blood samples, RNA, serum, protein and cells will be retained.|Both|6 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|40 ADEH+, 40 ADEH-, and 40 non-atopic controls ages 6 to 65 years. Initially, 20 ADEH- and        20 non-atopic control participants will be gender- and age-matched (plus or minus 10        years) to 20 ADEH+ participants. Afterwards, additional participants will be enrolled such        that the gender ratio and the age distribution of the ADEH+ participants will be similar        to that of the ADEH- and non-atopic control participants|November 2015|November 10, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01429311||98890|
NCT01429844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAILTx Tac vs. CsA in LuTx|Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation|Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients|EAILTX|Universitätsklinikum Hamburg-Eppendorf|No|Completed|January 2001|August 2010|Actual|October 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|274|||Both|18 Years|66 Years|No|||September 2011|September 6, 2011|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01429844||98849|
NCT01429857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hom-AHF-Troponin|Prognostic Relevance of High-sensitivity Troponin in Patients With Acute Decompensated Heart Failure|Prognostic Relevance of High-sensitivity Troponin in Patients With Acute Decompensated Heart Failure||University Hospital, Saarland|No|Completed|June 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|304|||Both|18 Years|89 Years|No|Probability Sample|Primary care clinic|June 2013|June 13, 2013|February 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429857||98848|
NCT01429870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPSO|Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis|A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB (Ultraviolet B) and Dithranol Combination Treatment of Psoriasis (DIPSO)|DIPSO|University of Zurich|No|Suspended|August 2011|August 2021|Anticipated|August 2021|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|August 18, 2011||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01429870||98847|
NCT01430845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8458-LG-CTIL|Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay|Predicting Developmental Disability Type and Mental Retardation Level in Children Who Were Diagnosed in General Developmental Delay||Sheba Medical Center|No|Completed|September 2011|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|150|||Both|N/A|N/A|No|Non-Probability Sample|The study will be conducted at the Child Development Center in Tel-Hashomer hospital        (Ramat-Gan, Israel). The target population is all children who were diagnosed at the        hospital with GDD (in two axis' at least) between the years 2003 to 2005. They must also        have undergone the BSID test in its second or third version. The data must be available on        all assessments (N~150). The children were 1.5-3 years old at diagnosis and diagnosed by a        doctor and psychologist. Today these children are 5-7 years old. Some of them are still        being treated in Tel-Hashomer. The children live all over the country|February 2016|February 22, 2016|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430845||98773|
NCT01431586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDTic-001|First in Humans Study of JDTic|A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic in Healthy Male Subjects||RTI International|Yes|Terminated||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|August 31, 2011|No|Yes|No further subjects will be enrolled due to adverse events.|No||https://clinicaltrials.gov/show/NCT01431586||98716|
NCT01432054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VACP2007-24|Human Tissue Repository for Wound Care|Human Tissue Repository for Wound Care||KCI USA, Inc.|No|Withdrawn||||||N/A|Observational|N/A||1|Actual|0|Samples With DNA|wound biopsy|Both|18 Years|75 Years|No|Non-Probability Sample|Eligible subjects with acute or chronic wounds and whose wounds encompass one of the        following wound types will be enrolled: traumatic, diabetic, pressure ulcer, burns, or        dehisced wounds. Enrollment will continue up to 5 years. KCI may determine at any time        that sufficient samples have been obtained and cease enrollment.|September 2011|June 24, 2015|September 8, 2011||No|business decision|No||https://clinicaltrials.gov/show/NCT01432054||98680|
NCT01432067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/23|Physical Activity Advices to Prevent Loss of Autonomy in Cancer Treated Elderly Patients. An Intervention Randomized Study||CAPADOGE|University Hospital, Bordeaux|No|Active, not recruiting|October 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|400|||Both|70 Years|N/A|No|||September 2014|September 29, 2014|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432067||98679|
NCT01432535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05655|Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)|A Single Dose Study to Assess Pharmacokinetics of SCH 54031 in Patients With Renal Impairment (P05655)||Merck Sharp & Dohme Corp.|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 9, 2011|No|Yes||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01432535||98643|
NCT01432886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-J081-107|A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer|A Phase 1 Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer||Eisai Inc.||Completed|October 2011|December 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|20 Years|74 Years|No|||May 2015|June 18, 2015|September 12, 2011||No||No|March 19, 2015|https://clinicaltrials.gov/show/NCT01432886||98617|
NCT01432899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110246|Studying Childhood-Onset Hemidystonia|Characteristics and Mechanism of Childhood-Onset Hemidystonia||National Institutes of Health Clinical Center (CC)||Completed|August 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|21|||Both|7 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 22, 2016|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01432899||98616|
NCT01432834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23/29-07-11|Efficacy of the Wavefront Optimized (WFO) Profile in Non-anterior Astigmatisms|Evaluation of the Efficacy of the Allegretto Wave and the Wavefront Optimized Ablation Profile in Non-anterior Astigmatisms||Democritus University of Thrace|No|Completed|April 2010|April 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||September 2011|September 12, 2011|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01432834||98621|
NCT01426087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105467801|Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices|Investigator Sponsored Study of Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices||Chinese PLA General Hospital|Yes|Recruiting|July 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|126|||Both|18 Years|75 Years|No|||August 2011|August 31, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426087||99135|
NCT01426100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HT11B|CKD-828 Telmisartan Non-Responder Trial|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy||Chong Kun Dang Pharmaceutical||Completed|August 2011|August 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|183|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|August 30, 2011||||No||https://clinicaltrials.gov/show/NCT01426100||99134|
NCT01427010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/536|A Feasibility Study on Adaptive 18F-FDG-guided Radiotherapy for Recurrent and Second Primary Head and Neck Cancer in the Previously Irradiated Territory.|A Feasibility Study on Adaptive 18F-FDG-guided Radiotherapy for Recurrent and Second Primary Head and Neck Cancer in the Previously Irradiated Territory.||University Hospital, Ghent|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01427010||99065|
NCT01427829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA-25340|Computer-assisted Psychosocial Risk Assessment (CaPRA) for Refugee Health and Settlement|Computer-assisted Psychosocial Risk Assessment (CaPRA) for Refugee Health and Settlement - Evaluation Phase|CaPRA|University of Toronto|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|September 1, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01427829||99003|
NCT01428141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7050-J081-110|A Phase I Study of E7050 in Subjects With Solid Tumors|A Phase I Study of E7050 in Subjects With Solid Tumors||Eisai Inc.||Completed|September 2011|July 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|20 Years|74 Years|No|||February 2014|February 13, 2014|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01428141||98979|
NCT01437696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HW-11-02|How Much Vitamin D is Required to be Protective Against Deficiency During the Winter Months?|How Much Vitamin D is Required to be Protective Against Deficiency During the Winter Months? - An Investigation in Veterans Living at Ste-Anne's Hospital||McGill University|No|Completed|October 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|77|||Male|70 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 4, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01437696||98250|
NCT01434212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008ZX10004-002-jida01|Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy|Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort|sIFN-pred1|First Hospital of Jilin University|Yes|Active, not recruiting|May 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Blood serum,Peripheral blood mononuclear cells (PBMC)|Both|20 Years|80 Years|No|Non-Probability Sample|Patients are from the northeast of China. Most of the patients have been infected by the        hepatitis c virus due to the drug abuse. Many of them share the same syringe for drug        intravenous injection. However, HIV infection has been rarely detected.|October 2011|October 27, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01434212||98517|
NCT01434485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00010|Nexium Capsules Clinical Experience Investigation|Nexium Capsules Clinical Experience Investigation||AstraZeneca||Completed|September 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3691|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with Nexium for the first time due to gastric ulcer, duodenal ulcer,        anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison        syndrome.|April 2014|April 14, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01434485||98496|
NCT01432691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19761979|Hemi Artificial Hipjoint Versus Total Artificial Hipjoint|Clinical and RSA Comparison of Hemi Versus Total Hip Arthroplasty After Displaced Femoral Neck Fracture. A Randomized Double-Blind Study|THA|Hvidovre University Hospital|Yes|Recruiting|June 2010|June 2015|Anticipated|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|70|||Both|70 Years|N/A|No|||September 2011|September 12, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01432691||98631|
NCT01433003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259509|The Plasma Large-Volume Exchange RCT|The Plasma Large-Volume Exchange Randomized Controlled Trial (PLEX-RCT)|PLEX-RCT|London Health Sciences Centre|Yes|Withdrawn|April 2012|March 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|September 9, 2011||No|Funding not obtained|No||https://clinicaltrials.gov/show/NCT01433003||98608|
NCT01429025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N1088|Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma|A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL||Alliance for Clinical Trials in Oncology|Yes|Active, not recruiting|May 2012|||November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01429025||98912|
NCT01429584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00026846|The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function|Investigation Into the Effect of 0.25% Bupivacaine for Interscalene Peripheral Nerve Block vs 0.125% Bupivacaine on Pulmonary Function||University of Utah|No|Completed|May 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 9, 2013|August 27, 2011|Yes|Yes||No|June 16, 2012|https://clinicaltrials.gov/show/NCT01429584||98869|
NCT01429597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FaCard06/2011|Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation|Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation AN INTERNATIONAL,MULTICENTER, EPIDEMIOLOGICAL STUDY|FaCard|University of Rostock|Yes|Recruiting|August 2011|September 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|The laboratory examinations of the blood samples for measuring the lyso-Gb3-level will be      done at the Laboratory of the Albrecht-Kossel-Institute, University of Rostock in      collaboration with associated diagnostic laboratory partners. This laboratory offers an      existing infrastructure, a highly standardized quality of the workflow, a short examination      time of the samples and a long period of experiences in the assessment of the biological      impact of mutations and polymorphism, as evidenced recently in the sifap1-study.|Both|18 Years|N/A|No|Probability Sample|All Patients with a diagnosis of Fabry disease with N215S|October 2015|October 6, 2015|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01429597||98868|
NCT01429610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KALLA0804|Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia|Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia|RADICAL|Asan Medical Center|No|Recruiting|November 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|15 Years|N/A|No|||July 2015|July 1, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01429610||98867|
NCT01430546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-RV-MM-10-06|Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line|Phase IV Study on QoL in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide||Karolinska University Hospital|Yes|Completed|November 2010|||January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|133|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|March 2016|March 24, 2016|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430546||98796|
NCT01430832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8121-LG-CTIL|Developmental Outcomes of Extreme Prematurity, 5-15 Years Postpartum|The Long-Term Developmental Outcomes of Extreme Prematurity: Correlations With Maternal Post-Traumatic Symptoms, Parental Stress and Post-Traumatic Growth, 5-15 Years Postpartum||Sheba Medical Center|No|Terminated|September 2011|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|95|||Both|N/A|N/A|No|Non-Probability Sample|Participants are children born at Sheba Medical center between the years 1995-2006.|February 2016|February 22, 2016|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430832||98774|
NCT01431599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KROG 11-02|Short-course Preoperative Chemoradiotherapy for Rectal Cancer|Two Week-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Rectal Cancer: Phase II Multicenter Clinical Trial (KROG 11-02)|KROG 11-02|Seoul St. Mary's Hospital|Yes|Recruiting|September 2011|October 2017|Anticipated|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01431599||98715|
NCT01431612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Esmolol study|Effects of Adrenergic Drugs on the Fluid Balance During Surgery|The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery||Sodertalje Hospital|No|Completed|November 2008|October 2010|Actual|October 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|3||Actual|60|||Female|20 Years|50 Years|No|||September 2011|September 7, 2011|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01431612||98714|
NCT01431859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/143/FREW|Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit?|A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients||Royal Sussex County Hospital|No|Recruiting|July 2012|November 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01431859||98695|
NCT01431872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131471|Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors|Systemic DKK1 During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors||University of Arkansas|No|Completed|April 2011|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Female|18 Years|N/A|No|Probability Sample|Post menopausal breast cancer patients who are planning to be treated with aromatase        inhibitors.|November 2015|November 3, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01431872||98694|
NCT01432093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002918|Intensive Glycemic Management and Outcomes Following Liver Transplantation|Intensive Glycemic Management and Outcomes Following Liver Transplantation: A Randomized Controlled Trial||Mayo Clinic|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01432093||98677|
NCT01432080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1102|Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant|Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study||Maisonneuve-Rosemont Hospital|No|Suspended|September 2011|October 2016|Anticipated|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|September 8, 2011|Yes|Yes|Not meeting recruitment targets|No||https://clinicaltrials.gov/show/NCT01432080||98678|
NCT01432288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFUIRB00016834|Touch and Attention MRI Study|Effects of Touch and Attention on Central Nervous System Resting State Network (RSN) Activity||Wake Forest School of Medicine|Yes|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|10|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be healthy individuals, 18< 40 years old, and can understand and respond        to verbal directions while in an fMRI. Individuals over the age of 40 are excluded to        provide a more homogeneous sample, to make this sample comparable to other research        conducted at this institution and to decrease abnormalities in the outcome measures due to        age-related changes.|March 2012|March 9, 2012|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432288||98662|
NCT01436747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-06-2011|Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients|Efficacy and Safety of Selective Vitamin D Receptor Activation With Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients: a Randomized Controlled Trial||University Medical Centre Ljubljana|Yes|Completed|July 2012|December 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436747||98323|
NCT01436760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132-2011|Genetic Contribution of Pain and Inflammation in IBS|Genetic Contribution of Pain and Inflammation in Irritable Bowel Syndrome.||University of Florida|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|72|Samples With DNA|The delinked blood/DNA is stored in the genetics laboratory and they will be analyzed for      possible polymorphisms|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Generic laboratory blood bank|March 2012|March 23, 2012|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01436760||98322|
NCT01437085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25837|A Study to Measure Needle Bending and Changes in Prostate Shape During a Prostate Seed Implant|Quantifying Needle Deflection and Tissue Deformation in Transperineal Interstitial Permanent Prostate Brachytherapy: A Basis for Development of Next-Generation Implant Technique||AHS Cancer Control Alberta|No|Recruiting|October 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Male|18 Years|N/A|No|Non-Probability Sample|Patients having a prostate brachytherapy implant at the Cross Cancer Institute.|October 2014|October 1, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437085||98297|
NCT01437098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-2111|Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis|Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis||Medtronic Cardiovascular|Yes|Active, not recruiting|October 2011|July 2017|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|N/A|No|||January 2013|January 28, 2013|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01437098||98296|
NCT01437111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0217A-329|Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)|A Phase III (Phase IV Program) Open-Label, Multicenter Clinical Trial in Thailand to Study the Effect of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) for 6 Months on 25-Hydroxyvitamin D Levels in the Treatment of Osteoporosis in Postmenopausal Women and Men||Merck Sharp & Dohme Corp.|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|50 Years|N/A|No|||April 2015|April 27, 2015|September 19, 2011|No|Yes||No|December 3, 2013|https://clinicaltrials.gov/show/NCT01437111||98295|
NCT01437423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I59|Regulatory Post-Marketing Surveillance Study for TETRAXIM™|Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis)||Sanofi|No|Completed|June 2011|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|600|||Both|2 Months|6 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437423||98271|
NCT01433523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-04|House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma|Efficacy of ALK House Dust Mite Allergy Immunotherapy Tablet in Subjects With House Dust Mite Induced Asthma. The MITRA Trial|MITRA|ALK-Abelló A/S|No|Completed|August 2011|February 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|834|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|August 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433523||98568|
NCT01433744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5209/2009|Short-term Changes on C-Reactive Protein (CRP) Levels After Non-surgical Periodontal Treatment|Short-term Changes on C-Reactive Protein (CRP) Levels After Non-surgical Periodontal Treatment||State University of Maringá|Yes|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2011|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433744||98551|
NCT01434004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD17-03-1-0139|Eating, Activity, and Stress Education|A Diet, Physical Activity, and Meditation Intervention in Men With Rising Prostate-specific Antigen|EASE|University of South Carolina|No|Completed|January 2003|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|58|||Male|18 Years|N/A|No|||April 2015|April 8, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01434004||98533|
NCT01427062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD-001|Effects of an Innovative Balance Training Programme in Enhancing Postural Control and Reducing Falls in Patients With Parkinson's Disease|||The Hong Kong Polytechnic University||Recruiting|March 2009|June 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|45 Years|N/A|No|||August 2011|August 30, 2011|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427062||99061|
NCT01432704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-001958-99|Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)|Phase IV Study of Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS|100207MS-H|University of Turku||Completed|March 2008|August 2011|Actual|May 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|50 Years|No|||September 2011|September 12, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01432704||98630|
NCT01433016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-BID-0411|Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI|Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement in Patients With Chronic Liver Disease to Differentiate Between Presence and Absence of HCC Determined by MRI|OBT for HCC|Exalenz Bioscience LTD.|No|Terminated|November 2011|May 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|September 11, 2011|Yes|Yes|Due to budgetary issues, the company has decided to focus on other applications at this stage.|No|February 11, 2014|https://clinicaltrials.gov/show/NCT01433016||98607|Early termination leading to small numbers of subjects analyzed.
NCT01429324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mod11-000295-03|Near Infrared Spectroscopy (NIRS)|Validation of Near Infrared Spectroscopy (NIRS) Neuro-monitoring During Deep Hypothermic Circulatory Arrest for Aortic Arch Surgery||Nonin Medical, Inc|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Mayo Clinic and affiliated hospitals|May 2012|May 18, 2012|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429324||98889|
NCT01429571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antibiotics in hand infections|The Role of Antibiotics After Surgical Treatment of Simple Hand Infections: A Prospective Study|||BG Trauma Center Tuebingen||Completed|August 2009|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|90|||Both|18 Years|80 Years|No|Non-Probability Sample|Adult patients with simple hand infections (no infection of the bone, tendon or joint)|September 2011|September 6, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429571||98870|
NCT01429337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPKC412A2116|Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function|An Open-label, Multiple Dose, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function||Novartis||Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429337||98888|
NCT01429896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.31.09.2011|The Effect of Extrinsic Factors on Food Allergy|The Effect of Extrinsic Factors on Food Allergy|Ex-Factor|Cambridge University Hospitals NHS Foundation Trust|Yes|Recruiting|October 2012|October 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|100|||Both|18 Years|45 Years|No|||January 2015|January 13, 2015|August 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01429896||98845|
NCT01430208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUMREP-11-0778|A New Alternative to Traditional Hysteroscopy|New Mini-resectoscope as Alternative to Traditional Hysteroscopy in the Treatment of Uterine Lesions||Catholic University of the Sacred Heart|No|Completed|January 2010|June 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|401|||Female|18 Years|75 Years|No|||September 2011|September 7, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01430208||98822|
NCT01430533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15854|Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation|A Randomized, Double-blind, Vehicle Controlled Phase 1 Dermal Safety Study to Evaluate the Sensitizing Potential of Topically Applied Azelaic Acid Pre-foam Formulation in Healthy Subjects Using a Human Repeated Insult Patch Test Design||Bayer||Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|240|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430533||98797|
NCT01431326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029638|Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care|Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care|PTN_POPS|Duke University|Yes|Recruiting|November 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|whole blood|Both|N/A|21 Years|No|Non-Probability Sample|Children (<21 years of age) receiving drugs per standard of care as prescribed by treating        caregiver|February 2016|February 4, 2016|August 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431326||98736|
NCT01431885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010010|Two Methods of Diagnosing Preterm Labor|Randomized Controlled Trial of Two Methods of Diagnosing Preterm Labor||University of California, San Francisco|Yes|Recruiting|August 2011|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|136|||Female|16 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 14, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01431885||98693|
NCT01431898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-257-0102|Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection|A Phase 1b, Randomized, Single-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection||Gilead Sciences||Completed|September 2011|May 2012|Actual|December 2011|Actual|Phase 1|Interventional|Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|82|||Both|18 Years|65 Years|No|||March 2012|July 23, 2012|September 1, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01431898||98692|
NCT01432314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCLee3915|Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)|A Phase II Trial of Radiation Therapy, Followed by Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Invading 1st or 2nd Order Branch of Portal Vein|RTANDTACE|Asan Medical Center|Yes|Withdrawn|October 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|69 Years|No|||June 2014|June 24, 2014|September 7, 2011|Yes|Yes|Another phase 2 randomized study has been started by other investigators.|No||https://clinicaltrials.gov/show/NCT01432314||98660|
NCT01432327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KULEUVEN_RTFDB|The Impact of Real-time Feedback on Physical Activity Patterns in Flemish Employees|The Impact of Real-time Feedback on Physical Activity Patterns in Flemish Employees: an Intervention Study||Katholieke Universiteit Leuven|No|Completed|August 2010|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|227|||Both|18 Years|68 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|September 9, 2011||No||No|February 15, 2012|https://clinicaltrials.gov/show/NCT01432327||98659|Malfunction of the SenseWear Armband: 4 out of the 320 baseline measurements
NCT01432340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIRD-5933|Seasonal Influenza Vaccine Effectiveness Study in Kenya|Seasonal Influenza Vaccine Effectiveness Study in the Kenyan Communities of Kibera and Lwak||Centers for Disease Control and Prevention|No|Recruiting|June 2010|March 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|Samples With DNA|Nasopharyngeal and oropharyngeal swabs.Potentially has DNA and RNA retained.|Both|6 Months|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Vaccine will be made available to children six months of age to 10 years in the Kibera and        Lwak catchment areas enrolled in the International Emerging Infectious Disease Program(        IEIP) conducted by KEMRI/CDC.|September 2011|September 9, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01432340||98658|
NCT01432600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16705|Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide|Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|November 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01432600||98638|
NCT01432301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401.10.001|Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination|An Open-Label Protocol for the Use of Uridine Triacetate as an Antidote to Treat Patients at Excess Risk of 5-Fluorouracil Toxicity Due to Overdosage or Impaired Elimination||Wellstat Therapeutics||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||March 2016|March 3, 2016|September 8, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01432301||98661|
NCT01437436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCHBC-11501|The Effect of Obesity on Ventilation Tube Insertion|The Effect of Obesity on Ventilation Tube Insertion||Soonchunhyang University Hospital|No|Enrolling by invitation|October 2010|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|||Both|2 Years|15 Years|No|Non-Probability Sample|Residents of bucheon city in South Korea|September 2011|September 21, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437436||98270|
NCT01437449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENT0033|Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With SCCHN||Stanford University|Yes|Recruiting|October 2011|January 2021|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|16 Years|N/A|No|||March 2015|March 30, 2015|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01437449||98269|
NCT01437709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-050|Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant|Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant||Memorial Sloan Kettering Cancer Center||Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437709||98249|
NCT01437722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-014|Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)|A Double-blind, Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel®) Administered Vaginally to Prevent the Recurrence of Bacterial Vaginosis||Starpharma Pty Ltd||Completed|August 2011|||December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|205|||Female|18 Years|45 Years|No|||October 2013|October 27, 2013|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437722||98248|
NCT01426178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0099|Neurally Adjusted Ventilatory Assist (NAVA) in NonInvasive Ventilation (NIV)|Neurally Adjusted Ventilatory Assist (NAVA) in NonInvasive Ventilation (NIV)||University Hospital, Clermont-Ferrand||Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 4, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01426178||99128|
NCT01426815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/529|Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria|Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria|CRESPA|University Hospital, Ghent|No|Recruiting|March 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01426815||99080|
NCT01432730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-006|A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough|A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough||Afferent Pharmaceuticals, Inc.|No|Completed|August 2011|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|70 Years|No|||January 2014|January 3, 2014|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01432730||98628|
NCT01433029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0595|Objective Assessment of Technical Skills in Cardiothoracic Surgery|Objective Assessment of Technical Skills in Cardiothoracic Surgery||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2011|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiothoracic surgical trainee in their 1st, 2nd, or 3rd year of training. Experienced        faculty are cardiothoracic surgeons who regularly perform coronary artery bypass (CAB)        procedures and have at least 10 years of post-training experience.|December 2015|December 14, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01433029||98606|
NCT01430195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV102|Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)|Proof of Concept Study to Compare Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Nonsegmental Vitiligo|CUV102|Clinuvel Pharmaceuticals Limited|No|Completed|June 2011|November 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430195||98823|
NCT01431105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD-Atorvastatin|Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities|Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease||University of California, San Diego|Yes|Recruiting|July 2012|December 2018|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|2 Years|17 Years|No|||December 2015|December 1, 2015|September 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01431105||98753|
NCT01431118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gi-02-2011|Iron Metabolism in Dragon Boat Athletes|Iron Metabolism in Dragon Boat Athletes - An Analysis of Changes in Blood Count Parameters Under Sport-specific Stress||University of Giessen|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 21, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01431118||98752|
NCT01431339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUR001-302|Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections||Durata Therapeutics Inc., an affiliate of Allergan plc|No|Completed|July 2011|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|739|||Both|18 Years|85 Years|No|||December 2013|December 27, 2013|September 8, 2011|Yes|Yes||No|December 27, 2013|https://clinicaltrials.gov/show/NCT01431339||98735|
NCT01431651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSIRB2011010|Probiotics Improve Gastrointestinal Symptoms After Roux-en-Y Gastric Bypass: A Prospective Randomized Trial|Asian Pacific Weight Loss and Metabolic Surgery Center||Min-Sheng General Hospital|Yes|Recruiting|October 2011|July 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|N/A|N/A|No|||May 2012|May 5, 2012|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431651||98711|
NCT01432106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPP100AUS20T|The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome|A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome|SAAVE|University of Michigan|No|Withdrawn|February 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 14, 2013|September 8, 2011||No|Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the    ALTITUDE clinical trial found a higher incidence of adverse events.|No||https://clinicaltrials.gov/show/NCT01432106||98676|
NCT01432587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFNS01|The Effect of Diflunisal on Familial Transthyretin Amyloidosis|The Effect of Diflunisal on Familial Transthyretin Amyloidosis: An Open Label Extension Study of "the Diflunisal Trial" (IND 68092), and an Open Label Observational Study on Previously Untreated Patients With Familial Transthyretin Amyloidosis.|DFNS01|Umeå University|No|Completed|August 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|Samples Without DNA|Serum Whole blood Urine|Both|18 Years|N/A|No|Probability Sample|Patients visiting the Units for Familal amyloidosis in Umeå, Piteå and Skellefteå|August 2015|August 21, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01432587||98639|
NCT01432938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11549|A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants|The Effect of Dulaglutide (LY2189265) on the Pharmacokinetics and Pharmacodynamics of Single Dose Warfarin in Healthy Subjects||Eli Lilly and Company|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|September 9, 2011|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01432938||98613|
NCT01432951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13322|A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma|Pharmacokinetics of Enzastaurin HCl in Native Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma||Eli Lilly and Company|No|Active, not recruiting|November 2011|March 2017|Anticipated|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01432951||98612|
NCT01432873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HORCSCT-9001|Oral Selenium Therapy for the Prevention of Mucositis|A Randomized Double Blinded Placebo Controlled Oral Selenium Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Hematopoietic Stem Cell Transplantation||Tehran University of Medical Sciences|Yes|Recruiting|June 2011|December 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|65 Years|No|||May 2012|May 31, 2012|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01432873||98618|
NCT01433536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-100|Evaluation of Circulating Osteogenic Factors in Trauma Patients|Evaluation of Circulating Osteogenic Factors in Trauma Patients (BMP-9)|BMP-9|Centre Hospitalier Universitaire de Sherbrooke|Yes|Active, not recruiting|December 2010|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Anticipated|60|Samples Without DNA|blood samples|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients arriving at the emergency room at the CHUS that present pathologies associated        with the different cohorts described and responding to inclusion criteria.|January 2016|January 26, 2016|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433536||98567|
NCT01425905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110239|Mood and Insulin Resistance in Adolescents At-Risk for Diabetes|Mood and Insulin Resistance in Adolescents At-Risk for Diabetes||National Institutes of Health Clinical Center (CC)||Completed|August 2011|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|174|||Female|12 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|August 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01425905||99149|
NCT01426191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090095|Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|A Open Multi-center Clinical Study on Cefotaxime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary Tract Infection|SWSB|Xiangbei Welman Pharmaceutical Co., Ltd|Yes|Enrolling by invitation|August 2011|November 2013|Anticipated|August 2013|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|hospitalized patients or outpatients|September 2012|September 10, 2012|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01426191||99127|
NCT01426542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|216534|Preventing Brain Injury in Infants With Congenital Heart Disease|Pilot Study of Topiramate Prophylaxis in Infants Undergoing Surgery for Congenital Heart Disease||University of California, Davis|No|Recruiting|June 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|N/A|2 Months|No|||November 2014|November 28, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01426542||99101|
NCT01426516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG1-0001/2|Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)|A Six-month Study of the Genecept Assay vs. Treatment as Usual to Evaluate Efficacy of Using Assay Guided Treatment in Outpatient Adults With Treatment Resistant Depression|PAGE-1_AG1|Genomind, LLC|Yes|Terminated|September 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|29|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|August 29, 2011|Yes|Yes|Invalid data collection|No|August 25, 2015|https://clinicaltrials.gov/show/NCT01426516||99103|
NCT01426529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002187|Caveolin-1 and Vascular Dysfunction|Caveolin-1 and Vascular Dysfunction||Brigham and Women's Hospital|Yes|Recruiting|October 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|65 Years|No|||February 2013|February 14, 2013|August 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01426529||99102|
NCT01433042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-304|PillCam SB3 Capsule- Feasibility Study|Assessment the Performance of PillCam SB3 Capsule in Detecting Small Bowel Lesions in Patients||Given Imaging Ltd.|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|225|||Both|18 Years|N/A|No|||December 2013|December 15, 2013|September 7, 2011||No||No|February 12, 2013|https://clinicaltrials.gov/show/NCT01433042||98605|
NCT01429350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 4338|Assess the Penumbra System in the Treatment of Acute Stroke|The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke|THERAPY|Penumbra Inc.|Yes|Active, not recruiting|May 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|692|||Both|18 Years|85 Years|No|||June 2015|June 15, 2015|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429350||98887|
NCT01429038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJT1106P1|Mesenchymal Stem Cells After Renal or Liver Transplantation|Infusion of Third-party Mesenchymal Stem Cells After Renal or Liver Transplantation. A Phase I-II, Open-label, Clinical Study||University Hospital of Liege|No|Recruiting|February 2012|February 2017|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||January 2013|January 17, 2013|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429038||98911|
NCT01429051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-1301-032-SP|A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain|A Dose Titrated Clinical Trial With a Placebo-controlled, Double-blind, Randomised, Cross-over Phase to Demonstrate the Efficacy of 400 μg Intranasal Fentanyl (INFS) Dose Strength, and to Evaluate 12 Weeks Safety and Nasal Tolerability of All Dose Strengths Between 50 μg and 400 μg, in Cancer Patients With Breakthrough Pain.|NOSE-400|Takeda|No|Completed|August 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|September 1, 2011||No||No|January 1, 2014|https://clinicaltrials.gov/show/NCT01429051||98910|
NCT01430559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001449|Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee|A Double-Blind Placebo-Controlled Multicentre Parallel Group Study Of The Effect Of Meloxicam In Mainland Chinese Patients With Osteoarthritis Of The Knee||Pfizer|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|353|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01430559||98795|
NCT01430572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0322|Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients|Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients With Advanced Solid Tumors Refractory to Standard Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|October 2011|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|16 Years|N/A|No|||March 2016|March 24, 2016|September 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430572||98794|
NCT01431625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/0529|Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype|Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype||Hospitales Universitarios Virgen del Rocío|Yes|Recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|45 Years|85 Years|No|||September 2011|September 8, 2011|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01431625||98713|
NCT01432119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0552|Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib|Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases||M.D. Anderson Cancer Center|No|Withdrawn|December 2012|||December 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 8, 2013|September 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01432119||98675|
NCT01432613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K071204|Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies|Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies|DARWIM|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2010|July 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01432613||98637|
NCT01426776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30971319|Effect of Heart Valve Replacement on Cheyne-Stokes Respiration|Effect of Heart Valve Replacement on Cheyne-Stokes Respiration in Patients With Rheumatic Heart Disease|CSR|Nanjing Medical University|No|Completed|September 2010|July 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Actual|26|||Both|18 Years|70 Years|No|||July 2012|July 24, 2012|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01426776||99083|
NCT01433172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16439|Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer|A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination With CCL21 for Patients With Stage IV Adenocarcinoma of the Lung||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|73|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|September 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433172||98595|
NCT01432912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Maccabi-14/2011|Study Evaluating the Effect of Physician Education on Smoking Cessation Counselling|Pilot Study Evaluating the Influence of Physician Education Regarding the 5A's Smoking Cessation Counselling Strategy, as Evaluated by Patient Interpretation of the Strategy Principles||Assuta Hospital Systems|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|98|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|June 18, 2013|September 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01432912||98615|
NCT01425671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043082|Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States|Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States||University of Maryland|No|Recruiting|January 2011|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|800|Samples With DNA|Blood sample|Both|14 Years|62 Years|Accepts Healthy Volunteers|Probability Sample|Schizophrenic patients, family members, controls|March 2015|March 3, 2015|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01425671||99167|
NCT01425918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00050400|Social Cognitive Development in Young Children With Autism|Effects of Self-Generated Experiences on Social Cognitive Development in Young Children With Autism||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|January 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|24 Months|42 Months|Accepts Healthy Volunteers|||December 2015|December 30, 2015|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01425918||99148|
NCT01425931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|O2C-001AHK|Gastrointestinal Microcirculation During Cardiopulmonary Bypass|||Johann Wolfgang Goethe University Hospitals|No|Completed|June 2014|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|80 Years|No|Probability Sample|Cardiac surgery patients with ecc|August 2014|August 5, 2014|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01425931||99147|
NCT01426204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-BIO-NIS001|Efficacy, Safety and Adherence of Patients Infected With Hepatitis C Virus in Retreat With INFERGEN (Interferon Alfacon1)||OBSERVER|Closter Pharma|No|Not yet recruiting|September 2011|August 2013|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from Gastrointestinal Practices as well as hepatologyst practice. Academic        Centers have been asked to participate.|August 2011|August 30, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01426204||99126|
NCT01426217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22743|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2011|||||N/A|N/A|N/A||||||||||||||December 13, 2011|August 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01426217||99125|
NCT01426230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0067|Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia|A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice||Depomed|No|Completed|September 2011|April 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|201|||Both|18 Years|N/A|No|Probability Sample|Patients currently suffering from Post Herpetic Neuralgia|March 2013|March 18, 2013|August 29, 2011|Yes|Yes||No|January 11, 2013|https://clinicaltrials.gov/show/NCT01426230||99124|
NCT01426555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109241|FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)|FES-Rowing Versus Zoledronic Acid to Improve Bone Health in SCI: A Comparative Clinical Trial||Boston VA Research Institute, Inc.|No|Terminated|February 2011|February 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|No|||March 2016|March 8, 2016|June 8, 2011|Yes|Yes|Incomplete data set & analysis|No|January 14, 2016|https://clinicaltrials.gov/show/NCT01426555||99100|No Data Safety Monitor Board established for this project. Incomplete data set and analysis.
NCT01426854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-026|Nepafenac Compared to Placebo for Ocular Pain and Inflammation|Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.1% Compared to Placebo for the Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery in Adult Chinese Subjects||Alcon Research|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||May 2013|May 10, 2013|August 30, 2011|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01426854||99077|
NCT01426867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-002|A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%|A Descriptive Comfort Study of Brinzolamide 1% / Brimonidine Tartrate 0.2% Fixed Combination Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension and Brimonidine Tartrate 0.2% Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|103|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|August 24, 2011|Yes|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01426867||99076|
NCT01429064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3104002|Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001|Safety and Tolerability of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Extension Study to Study 3104001||Orion Corporation, Orion Pharma|Yes|Completed|June 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Male|18 Years|N/A|No|||January 2016|January 11, 2016|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429064||98909|
NCT01429077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G070074|Augmenting Language Therapy for Aphasia: Levodopa|Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy||Rehabilitation Institute of Chicago|No|Completed|October 2007|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|21 Years|N/A|No|||November 2013|November 27, 2013|August 2, 2011||No||No|June 5, 2013|https://clinicaltrials.gov/show/NCT01429077||98908|Dosage and timing of the L-dopa in relation to the behavioral treatment may not have been optimum.Efficacy of the behavioral treatment in both arms may have overridden the enhancing effect of the l-dopa in one arm
NCT01429909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0097|Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease|Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease: T2* Measurement in the Cortex and the Basal Ganglia|2014-A01184-43|University Hospital, Clermont-Ferrand||Completed|February 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|19|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01429909||98844|
NCT01430221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016540|Mindfulness-based Personalized Health Planning for Reducing Risk of Heart Disease and Diabetes|Mindfulness-based Personalized Health Planning for Reducing Risk of Heart Disease and Diabetes|AWARENESS|Duke University|Yes|Active, not recruiting|May 2011|February 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01430221||98821|
NCT01429623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO17730|A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)|A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)||Avraham Pharmaceuticals Ltd|Yes|Active, not recruiting|January 2012|September 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|55 Years|85 Years|No|||July 2013|July 22, 2013|September 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01429623||98866|
NCT01429883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESWTRUZ01|Extracorporeal Shock Wave Treatment - Can the Pain be Reduced?|Extracorporeal Shock Wave Treatment - Can the Pain be Reduced?||University of Zurich|Yes|Completed|July 2011|January 2015|Actual|January 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|36|||Both|18 Years|N/A|No|Probability Sample|Patients with Fascititis plantaris, Achillodynie, Periarthropathia humerosacpularis        calcarea or Epikondylopathia humeri /radii, who got the shock wave therapy.|May 2015|June 2, 2015|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01429883||98846|
NCT01404351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-00133|Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction|A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade® 4.0 in Bilateral Breast Reduction||Medtronic Surgical Technologies|No|Withdrawn|May 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|July 25, 2011|Yes|Yes|Study terminated due to the acquisition of PEAK Surgical by Medtronic|No||https://clinicaltrials.gov/show/NCT01404351||100798|
NCT01404910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000467/1|Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery|Phase 1b Proof-of-Concept Study of Apheresis to Reduce Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women With Preeclampsia Using a Dextran Sulfate Adsorption (DSA) Column (LIPOSORBER® LA-15 System)|RAAPID-II|Massachusetts General Hospital|Yes|Completed|May 2013|September 2015|Actual|September 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Female|18 Years|45 Years|No|||September 2015|September 25, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404910||100755|
NCT01405196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0151006|Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus|A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)|BUTTERFLY|Pfizer|Yes|Completed|December 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|183|||Both|18 Years|75 Years|No|||December 2015|December 14, 2015|July 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405196||100733|
NCT01405183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08406|Association Between Hepatitis C Infection and Renal Cell Carcinoma|Association Between Hepatitis C Infection and Renal Cell Carcinoma, a Case Control Study||Henry Ford Health System|Yes|Completed|January 2011|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|240|Samples Without DNA|Hepatits C antibody Hepatitis C RNA quantitative Hepatitis C Genotype|Both|18 Years|N/A|No|Probability Sample|Renal cell carcinoma patients will be identified from the urology clinic and from the        hospital wards.        Colorectal cancer patient will be identifed from the hospital wards, pathology reports and        gastroenterology endoscopy suits.|September 2014|September 16, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405183||100734|
NCT01405209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1713|Electrocardiogram Variations in the Prediction of Development of Atrial Fibrillation|Variaciones En El Elctrocardiograma Como Prediccion Del Desarrollo De Fibrilacion AURIC|EKG|Hospital Italiano de Buenos Aires|No|Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients belonging to Health Plan Hospital Italiano de Buenos Aires active members        who have ambulatory monitoring after the last follow-up ECG|March 2015|March 19, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405209||100732|
NCT01405677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA 001 FU|Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine|A Phase II Open, Randomised, Controlled Study to Evaluate the Safety and Immunogenicity of a Paediatric Dose (0.25 mL) and the Standard Dose (0.5 mL) of Epaxal® With Reference to Havrix Junior® Healthy in Healthy Children and Adolescents (>=12 Months - 16 Years of Age) Using a 0/6 Month Schedule||Crucell Holland BV|Yes|Completed|June 2004|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|308|||Both|12 Months|16 Years|Accepts Healthy Volunteers|||December 2013|July 28, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405677||100696|
NCT01406522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA029787|Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics|Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics||Midwest Biomedical Research Foundation|Yes|Withdrawn|October 2012|November 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|21 Years|50 Years|No|||December 2013|December 17, 2013|July 28, 2011|Yes|Yes|One of the study medications, tacrine, is no longer clinically available|No||https://clinicaltrials.gov/show/NCT01406522||100631|
NCT01406535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUWCard23022011|Improvement of Myocardial Blood Flow by PhosphoDiesterase 5 Inhibition in Coronary Artery Disease|Sustained Improvement of MYocardial Blood Flow by Intermittent PhosphoDiesterase 5 INhibition in REfractory Coronary ArterY Disease Suggests Enhanced Angiogenesis (SYDNEY)|SYDNEY|Medical University of Vienna||Temporarily not available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2011|July 29, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406535||100630|
NCT01406587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP4001.301|Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg PP4001 Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated With Uncomplicated Urinary Tract Infection||Pinnacle Pharmaceuticals, Inc.|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|261|||Female|18 Years|75 Years|No|||October 2011|October 18, 2011|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406587||100626|
NCT01406600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hCG dose_oocyte maturity|Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles|Optimal rhCG(Ovidrel®) Dose for Final Oocyte Maturation Triggering in Poor Responder During IVF and ICSI Cycles||Seoul National University Hospital|No|Recruiting|September 2011|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|21 Years|44 Years|No|||April 2013|April 11, 2013|July 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01406600||100625|
NCT01406847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|439-2010|Central Mechanisms of Intervention for Low Back Pain|Central Mechanisms of Body Based Intervention for Musculoskeletal Low Back Pain||University of Florida|Yes|Recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|170|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01406847||100606|
NCT01403025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3772|Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes|A Multi-centre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Victoza® in Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Active, not recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4121|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects, who are        considered to need treatment with liraglutide (Victoza®)|January 2016|January 22, 2016|July 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01403025||100900|
NCT01403298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA021532|Project RAP: Family-based HIV Prevention in the Juvenile Drug Court|Project RAP: Family-based HIV Prevention in the Juvenile Drug Court|Project RAP|Rhode Island Hospital|Yes|Completed|December 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01403298||100879|
NCT01408758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033339|Virtual Clinician Research Tool|Creating a Virtual Clinician Research Tool|VCRT|University of Rochester|Yes|Completed|January 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|N/A|No|||June 2013|October 8, 2015|January 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01408758||100459|
NCT01409018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-R-0804|Pharmacokinetics of Itraconazole in Pediatric Cancer Patients|Pharmacokinetics of Itraconazole in Pediatric Cancer Patients||Seoul National University Hospital|Yes|Completed|June 2009|December 2011|Actual|December 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|N/A|No|||November 2013|November 17, 2013|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01409018||100440|
NCT01409278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-07-002|Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement|The Evaluation of the Efficacy of Local Infiltration Analgesia and Infusion for Total Hip Arthroplasty||Saint Francis Care|No|Completed|August 2009|June 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|80 Years|No|||August 2009|August 3, 2011|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01409278||100420|
NCT01413594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11204|Bimanual Training in Children With Hemiplegia|Randomized Clinical Trial of Hand Arm Bimanual Intensive Therapy (HABIT)|HABIT|Columbia University|No|Recruiting|July 2011|December 2014|Anticipated|August 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Months|16 Years|Accepts Healthy Volunteers|||September 2011|September 8, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413594||100090|
NCT01409538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 AT001424-05A|Brain Imaging and Pain: Analysis of Placebo Analgesia|Brain Imaging and Pain: Analysis of Placebo Analgesia||University of Florida|No|Completed|January 2010|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|140|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 19, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409538||100400|
NCT01414205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAO4768g|A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE)|An Open-label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia||Genentech, Inc.||Active, not recruiting|October 2011|March 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|August 10, 2011|Yes|Yes||No|March 21, 2014|https://clinicaltrials.gov/show/NCT01414205||100046|
NCT01415024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO/01/2011|Resynchronization in Paced Heart Failure Patients With Implantable Cardioverter Defibrillator (ICD) Indication|Resynchronization in Paced Heart Failure Patients With ICD Indication|CRTICD Dual LV|Schuechtermann-Klinik|No|Recruiting|May 2011|||May 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||August 2011|August 10, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01415024||99983|
NCT01403480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0064-11-RMB-CTIL|Rates of Positive Basal Cell Carcinomas (BCCs) in Re-excisions|Rates of Positive BCCs in Re-excisions||Rambam Health Care Campus|No|Completed|January 2008|February 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|600|||Both|18 Years|N/A|No|Probability Sample|All patients that underwent an incomplete BCC excision during the years 2008-2010.|February 2011|July 26, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403480||100865|
NCT01403493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-487-02 amendment|Multidisciplinary Versus a Nurse Based Patient Education For Patients With Irritable Bowel Syndrome|A Comparison of a Short Nurse Based and a Long Multidisciplinary Version of Structured Patient Education in Irritable Bowel Syndrome.||Sahlgrenska University Hospital, Sweden|No|Completed|August 2007|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||July 2011|August 9, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403493||100864|
NCT01404663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-nerve-002|Side Effects of Bone Marrow Derived CD133 Transplantation in Cerebral Palsy|Evaluation the Side Effects of Bone Marrow Derived CD133 Cells Transplantation in Cerebral Palsy Patients||Royan Institute|Yes|Completed|October 2011|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|4 Years|12 Years|No|||August 2010|March 13, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404663||100774|
NCT01404403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-07-01-RR|Safety Study of the Rapid System for Acute Ischemic Stroke|||Rapid Medical||Completed|August 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|85 Years|No|||November 2013|November 4, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404403||100794|
NCT01404689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-129-012|Study to Determine if the Midazolam-Meperidine-Dexmedetomidine is Superior to the Midazolam-Meperidine for Sedation During ERCP|Midazolam With Meperidine and Dexmedetomidine vs Midazolam With Meperidine for Sedation During ERCP|DEMMER|Seoul National University Hospital|Yes|Completed|August 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|110|||Both|20 Years|80 Years|No|||July 2013|July 13, 2013|July 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01404689||100772|
NCT01404923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTO901|Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)|Assessment of On-demand MeteoSpasmyl® Use Effectiveness in Irritable Bowel Syndrome||Laboratoires Mayoly Spindler|No|Completed|December 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|436|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|July 27, 2011||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01404923||100754|
NCT01405222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25042011|Cough Frequency in Chronic Obstructive Pulmonary Disease|Objective Measure of COPD Exacerbation Using the Hull Automated Cough Recorder. Verifying Use of Automated Recording Systems in Measuring Symptoms Associated With a COPD Exacerbation||Hull and East Yorkshire Hospitals NHS Trust|No|Completed|January 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24|||Both|40 Years|80 Years|No|Non-Probability Sample|Hospital admissions|December 2013|December 16, 2013|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405222||100731|
NCT01405443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE Hamburg Endoscopy PV3656|Simulator Training for Gastrointestinal Endoscopy|Simulator Training for Gastrointestinal Endoscopy - How Much Simulator Training is Required to Acquire Proficiency in Gastrointestinal Endoscopy?||Universitätsklinikum Hamburg-Eppendorf|Yes|Terminated|January 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Physicians in residency or fellowship programs requiring training in flexible endoscopy        (gastroenterology, internal medicine, surgery) with no experience in flexible endoscopy|April 2014|April 15, 2014|April 15, 2011||No|invalid data|No||https://clinicaltrials.gov/show/NCT01405443||100714|
NCT01405950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT10-ZC-08|Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy|Single-Dose, Phase 1b Study to Assess Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects With Mild to Moderate Spasticity Due to Cerebral Palsy||Acorda Therapeutics|Yes|Terminated|May 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|2 Years|16 Years|No|||June 2013|June 10, 2013|July 25, 2011|Yes|Yes|Please see 'Further study details as provided by Acorda Therapeutics' for explanation of why    study stopped.|No|March 27, 2013|https://clinicaltrials.gov/show/NCT01405950||100675|
NCT01405963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101183|Double-blind, Multiple Dose Study in Subjects With Mild Atopic Asthma|A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma||Amgen|No|Completed|September 2011|June 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|60 Years|No|||September 2013|September 16, 2013|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405963||100674|
NCT01406275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112283|Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)|Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)||GlaxoSmithKline|No|Completed|January 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|363|||Both|N/A|14 Years|No|Probability Sample|Japanese pediatric patients who have superficial skin infection, deep skin infection,        lymphangitis, lymphadenitis, chronic pyoderma, pharyngitis, laryngitis, tonsillitis, acute        bronchitis, cystitis, pyelonephritis other than otitis media, and treated with amoxicillin        and clavulanate|July 2011|July 28, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01406275||100650|
NCT01406288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2011/26|Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4|Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 in Bordeaux Urban Area, June 2011: Evaluation of Diagnostic, Prognostic and Pathophysiological Data|SHU O104 CUB|University Hospital, Bordeaux|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|2 Years|N/A|No|Non-Probability Sample|dinner guest to a collective meal on June 8th, 2011 in Bègles, a city of Bordeaux urban        area (CUB).|November 2012|November 19, 2012|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406288||100649|
NCT01406613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15387|Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis|A 2-year Observational Study of Bone Density and Bone Turnover After Prior Treatment With Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care||Sheffield Teaching Hospitals NHS Foundation Trust|No|Enrolling by invitation|March 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|A venous blood sample will be collected from each participant at each visit to analyse      biochemical bone markers, and basic biochemistry analysis for eligibility screening.      Two urine samples will be collected from each participant at each study visit, one collected      on the morning prior to the study visit and a second sample on the morning of the study      visit.|Female|N/A|87 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants of previous TRIO study - women who either received treatment with        alendronate, ibandronate and risedronate for postmenopausal osteoporosis in secondary        care. Control premenopausal women will also be recruited.|June 2012|June 14, 2012|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406613||100624|
NCT01406860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201008798|Droperidol Versus Metoclopramide for the Treatment of Primary Headaches|Droperidol Versus Metoclopramide for the Treatment of Primary Headaches in the Emergency Department: A Prospective Randomized, Double-blinded Trial.||University of Iowa|Yes|Terminated|July 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|September 22, 2010|Yes|Yes|lack of enrollment/drug shortages|No||https://clinicaltrials.gov/show/NCT01406860||100605|
NCT01407120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH071707-04|15 Year Follow-up of New Beginnings Program for Divorced Families|Effects of NBP for Children of Divorce 15 Years Later|NBF15|Arizona State University|No|Completed|July 2006|September 2009|Actual|September 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|240|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||July 2011|August 1, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407120||100585|
NCT01406834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06004|Treatment for the Mental Health Impact of Killing in War|Treatment for the Mental Health Impact of Killing in War: Augmentation of Existing Evidence-Based Mental Health Interventions||University of California, San Francisco|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|70 Years|No|Non-Probability Sample|Combat veterans|August 2014|August 14, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01406834||100607|
NCT01407094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092010-151|Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression|Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) for Depression|EMBARC|University of Texas Southwestern Medical Center|Yes|Active, not recruiting|September 2010|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01407094||100587|
NCT01412801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_05|Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings|A Phase II Open-Label, Multi-Center Study of a Group B Streptococcus Vaccine in HIV Positive and HIV Negative Pregnant Women||Novartis||Completed|September 2011|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|270|||Female|18 Years|40 Years|No|||September 2014|September 5, 2014|August 8, 2011||No||No|June 20, 2014|https://clinicaltrials.gov/show/NCT01412801||100150|
NCT01413048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1001AGCVSP3|Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension|Phase III Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 Versus Carvedilol in Patient With Stage 1 to 2 Essential Hypertension||Ahn-Gook Pharmaceuticals Co.,Ltd|Yes|Recruiting|January 2011|September 2012|Anticipated|March 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|260|||Both|19 Years|N/A|No|||August 2011|August 8, 2011|August 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01413048||100131|
NCT01413295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCBRVP|Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer|Randomized Phase II Trial in Patients With Progressive Stage IV Colorectal Cancer to Two Lines of Chemotherapy, in Order to Compare the Best Supportive Treatment Versus Treatment With Dendritic Cells Plus the Best Supportive Treatment||Fundacion Clinic per a la Recerca Biomédica|Yes|Completed|August 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413295||100113|
NCT01414218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|humor1|The Impact of a Humor Seminar on General Well Being, Quality of Life and Psychological Distress Among Community Dwelling Elders|Influence of Humor as a Way of Life on Well Being, Quality of Life and Immune Function||Happy Nation Society|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2011|August 10, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01414218||100045|
NCT01414491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#11-001957|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2006|||||N/A|N/A|N/A||||||||||||||January 26, 2016|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414491||100024|
NCT01414504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCVFU927|Pneumococcal Conjugate Vaccine Followup|Pneumococcal Conjugate Vaccine Followup: Investigation of Serotype-specific Antibody Persistence and B Cell Memory at Age 3-5 Years Following 23valent Pneumococcal Polysaccharide Vaccine at Age 9 Months in PNG Children Previously Primed With 7valent Pneumococcal Conjugate Vaccine|PCVFU|Papua New Guinea Institute of Medical Research|No|Completed|December 2009|September 2012|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|280|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01414504||100023|
NCT01413932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-2157-107|Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder|A Two-part Study: Part 1 is a Multiple-dose (7-day), Open-label Evaluation of the Safety, Tolerability, and Pharmacokinetics of HT-2157 in Healthy Subjects. Part 2 is a Randomized, Double-blind, Placebo-controlled, Multiple (21-day) Ascending-dose Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HT-2157 in Patients With Major Depressive Disorder||Dart NeuroScience, LLC|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 17, 2015|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413932||100065|
NCT01414998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|qmul1606|Sensorimotor Replacement With Electronic and De-nicotinised Cigarettes|The Effect of Non-nicotine Sensorimotor Replacement on Withdrawal and Craving: Studies With Electronic and De-nicotinised Cigarettes|SenRep|Queen Mary University of London|No|Completed|May 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 19, 2013|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414998||99985|
NCT01415011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/09/0426|Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients|Trial of Afatinib (BIBW 2992) in Suspected or Confirmed Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy|TIMELY|University College, London|Yes|Active, not recruiting|December 2012|August 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415011||99984|
NCT01415323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute agitation|Agitation in the Acute Psychiatric Department|Agitation in the Acute Psychiatric Department||Norwegian University of Science and Technology|Yes|Active, not recruiting|September 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood samples are collected for storage and analyses both at admittance and discharge from      the psychiatric acute department.|Both|18 Years|90 Years|No|Probability Sample|All acutely admitted psychiatric in-patients from a defined catchment area.|May 2015|May 18, 2015|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01415323||99960|
NCT01415336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH-Breast- AX|AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer|AX (Doxorubicin, Capecitabine) Versus AC (Doxorubicin, Cyclophosphamide) as Adjuvant Treatment for Node-Negative Breast Cancer||Peking Union Medical College Hospital|Yes|Recruiting|March 2010|||March 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|70 Years|No|||August 2011|August 10, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01415336||99959|
NCT01404039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-001256|Investigating Motor Cortex Processing for Pain Modulation|Investigating Motor Cortex Processing for Pain Modulation||Spaulding Rehabilitation Hospital|No|Active, not recruiting|September 2010|||December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|150|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||April 2014|April 14, 2014|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01404039||100822|
NCT01404364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGCR-20101|Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye|Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye||Hospital Governador Celso Ramos|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Both|15 Years|N/A|No|||July 2011|July 27, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01404364||100797|
NCT01404676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-02-053|The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes|The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes||Samsung Medical Center|Yes|Recruiting|June 2010|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|46|||Both|18 Years|70 Years|No|||July 2011|July 27, 2011|June 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01404676||100773|
NCT01404936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM96-060|Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease|A Phase II Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) for Patients With Hodgkin's Disease||M.D. Anderson Cancer Center|No|Completed|July 1996|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|N/A|N/A|No|||January 2013|January 30, 2013|July 26, 2011|Yes|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT01404936||100753|
NCT01405235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFG-01-0106|Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma|A Prospective, Randomized Phase III Study to Compare the Effects of Paclitaxel and Topotecan to Those of Cisplatin and Topotecan for Treatment of Patients With Recurrent and Persistent Cervical Cancer|AGO-Zervix-1|Institut fuer Frauengesundheit|Yes|Active, not recruiting|September 2006|January 2015|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|312|||Female|18 Years|N/A|No|||September 2006|April 11, 2012|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405235||100730|
NCT01405690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0033-BE|The Role Of Noninvasive 320-Row Multidetector Computer Tomography|A Pilot Study: The Role Of Noninvasive 320-Row Multidetector Computer Tomography Coronary Angiogram In Predicting Perioperative Cardiac Complications In Patients Referred For Noncardiac Surgery||University Health Network, Toronto|No|Active, not recruiting|September 2008|February 2016|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|- stable patients undergoing intermediate or high risk elective non-cardiac surgical        procedure according to the American Heart Association/American College of Cardiology        (AHA/ACC) Guideline for Perioperative Cardiovascular Evaluation for Non-Cardiac Surgery.|February 2016|February 9, 2016|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405690||100695|
NCT01405976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI080346|Alternative of Treatment in Obesity Hypoventilation Syndrome|Mid-and Long-term Efficacy of Ventilation Non-invasive and Continuos Positive Airway Pressure in Obesity Hipoventilation Syndrome||Sociedad Española de Neumología y Cirugía Torácica|Yes|Recruiting|November 2009|January 2016|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|440|||Both|15 Years|80 Years|No|||December 2012|June 3, 2015|July 3, 2008||No||No||https://clinicaltrials.gov/show/NCT01405976||100673|
NCT01406301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113652|Fondaparinux EU-RMP (Adherence)|Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA® (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP||GlaxoSmithKline||Completed|March 2008|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|Hospitals with the capacity to perform cardiac catheterizations and PCIs will be        identified. Sites will be further qualified based upon the expectation of an adequate        number of ACS patients and the known or potential use of fondaparinux by the site. A        minimum of 5 sites per country will be targeted in order to achieve a within-country        representative sample. The study is planned for 7 countries in Europe and North America.        Based on sample size estimates, approximately 32 physicians per country (6 to 7 per site)        and approximately 256 patients per country (assuming an average of 8 patients per        physician) will be targeted for inclusion, yielding a study total of approximately 1800        patients.|April 2015|April 23, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406301||100648|
NCT01403090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR-001|Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism|A Single Treatment, Open Label, Multicenter, Safety Study of the Angel™ Catheter in Hospitalized Human Subjects With a Temporary Risk of Pulmonary Embolism||BiO2 Medical|Yes|Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|N/A|No|||April 2013|April 10, 2013|July 25, 2011|No|Yes||No|August 15, 2012|https://clinicaltrials.gov/show/NCT01403090||100895|
NCT01403103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2210|Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer|Evaluation of the Effect of 25-OH-Vitamin D3 Therapy on 15-Prostaglandin Dehydrogenase Expression in Primary Tumor and Normal Colorectal Mucosa in Patients With Colorectal Cancer||Case Comprehensive Cancer Center|Yes|Withdrawn|April 2012|January 2014|Actual|January 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|July 25, 2011|No|Yes|Slow Accrual|No||https://clinicaltrials.gov/show/NCT01403103||100894|
NCT01403363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC1111311KCTIL|Use of Fentanyl Patch in Partial Doses Than the Original|Use of Fentanyl Patch in Partial Doses Than the Original||Meir Medical Center|No|Active, not recruiting|March 2012|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|95|||Both|18 Years|N/A|No|||June 2015|June 14, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403363||100874|
NCT01407107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122010-172|Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer|Phase I Dose Escalation Trial of Nitroglycerin in Addition to 5-flourouracil and Radiation Therapy for Neo-adjuvant Treatment of Operable Rectal Cancer||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|90 Years|No|||October 2015|October 9, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407107||100586|
NCT01413308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0148CTIL|Pulmonary Functions Test in Patients After Fontan Operation|Long-term Effects on Pulmonary Function in Post- Fontan Operation||Rambam Health Care Campus|Yes|Enrolling by invitation|September 2011|September 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|10 Years|N/A|No|Probability Sample|A total number of 15 Fontan patients , aged 10 years and older , with 1-2 NYHA class        functional capacity. All will have total pulmonary function tests according to recognized        pulmonary protocols. Results will be normalized to age-dependent pulmonogram. Exclusion        criteria includes patients with acute pulmonary illness.        Generation of Data:          1. Spirometry-Spirometry will be performed in accordance with ATS/ERS (American Thoracic             Society/ European Respiratory Society) Task Force          2. Whole Body Plethysmography- FRCpleth will be measured          3. MCT - Methacholine challenge tests will be performed          4. FENO: Measurement of FENO will be performed by portable electrochemical analyzer NIOX             MINO (Aerocrine AB, Smidesvägen, Sweden),[10] and according to ATS recommendations .|August 2011|August 9, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413308||100112|
NCT01413321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8315-MZ-CTIL|Assessing Special Features of Impaired Gait After Acquired Brain Injury With an Instrumented Treadmill|The Reproducibility and Special Features of Hemiparetic Gait in People With Acquired Brain Injury (ABI) Assessed With an Instrumented Treadmill (Zebris)||Sheba Medical Center|No|Recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from inpatient and outpatient clinics at the Sheba Medical        Center|January 2015|January 16, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01413321||100111|
NCT01413607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dalhousieurosrs-2011|The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy|The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy||Nova Scotia Health Authority|No|Not yet recruiting|September 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|250|||Both|N/A|N/A|No|||August 2011|August 9, 2011|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413607||100089|
NCT01413620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitE2011|Vitamin E Supplementation in Burn Patients|Vitamin E Supplementation in Burn Patients||Shriners Hospitals for Children|Yes|Recruiting|August 2011|August 2014|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|70 Years|No|||March 2012|March 10, 2012|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413620||100088|
NCT01414231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML 2002 #061|Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a|Randomised Comparison of OSHO Induction vs. the German AML Intergroup Standard, Randomised Comparison of AraC/Mtx vs. Flu/AraC/Mtx in Pts Without CR After One Induction Cycle and Randomized Comparison of One vs. Two Consolidation Therapies.|OSHO#061|University of Leipzig|Yes|Recruiting|April 2002|July 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|850|||Both|18 Years|60 Years|No|||April 2008|August 10, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01414231||100044|
NCT01414764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/75|Does Autologous Conditioned Plasma Enhance Rotator Cuff Tendon Healing After Surgery?|Does Autologous Conditioned Plasma Enhance Rotator Cuff Tendon Healing After Surgery? A Radomized Control Trial.||The University of Western Australia|Yes|Enrolling by invitation|May 2011|February 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|75 Years|No|||December 2014|December 7, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01414764||100003|
NCT01414777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14583|Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients|IRB-HSR# 14583: Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients||University of Virginia|No|Enrolling by invitation|November 2009|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|68|||Female|18 Years|45 Years|No|||August 2011|August 10, 2011|September 16, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414777||100002|
NCT01411540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-434|Effects of a Wholegrain Diet on Body Composition and Energy Balance|Effects of Diet on Body Composition||The Cleveland Clinic|No|Completed|June 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01411540||100246|
NCT01404377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TenonH|Wound Infiltration and Breast Cancer Surgery|Double Blind Randomized Trial of Wound Infiltration With Ropivacaine After Breast Cancer Surgery||Tenon Hospital, Paris|No|Completed|January 2006|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||May 2011|July 27, 2011|April 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01404377||100796|
NCT01404078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPS K|Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium|A RCT With Factorial Design to Compare Safety and Efficacy of 2 Capsules of the Indian Polycap Versus a Single Capsule Along With or Without Oral Potassium Among Patients With Stable Cardiovascular Disease|TIPSK|St. John's Research Institute|Yes|Completed|April 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|518|||Both|40 Years|N/A|No|||November 2014|November 26, 2014|July 24, 2011||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01404078||100819|
NCT01404091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14333|A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects|Assessment of Nociceptin/Orphanin FQ Peptide Receptor Occupancy After Single Oral Doses of LY2940094 as Measured by Positron Emission Tomography With the Radioligand LY2959530 in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|July 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01404091||100818|
NCT01404702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1051|Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma|Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells||University of Alabama at Birmingham|Yes|Terminated|August 2011|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|2 Years|21 Years|No|||December 2014|December 1, 2014|July 13, 2011|Yes|Yes|Accrual slower than anticipated|No||https://clinicaltrials.gov/show/NCT01404702||100771|
NCT01405261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9926-3894|Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects|Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|101|||Male|18 Years|50 Years|No|||November 2013|November 27, 2013|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405261||100728|
NCT01405703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36814|Percutaneous Versus Open Plate Fixation of Diaphyseal Clavicle Fractures|Percutaneous Versus Open Plate Fixation of Diaphyseal Clavicle Fractures||University of Utah|No|Completed|July 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|35|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients treated surgically for diaphysial clavicle fracture.|July 2015|July 8, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405703||100694|
NCT01405989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-037|To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)|An Open-label, Randomized, Two-period Crossover Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Pharmacokinetics of Darexaban and Metabolites in Young Healthy Male Subjects||Astellas Pharma Inc|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2011|March 3, 2014|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405989||100672|
NCT01406002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-045|To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)|An Open-label, One-sequence Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Pharmacokinetics of YM150 (Darexaban) and Metabolites in Young Healthy Male Subjects||Astellas Pharma Inc|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|April 9, 2013|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406002||100671|
NCT01407133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004.365|Conventional Repetitive Transcranial Magnetic Stimulation for Tinnitus Treatment|Assessment of Conventional Repetitive Transcranial Magnetic Stimulation for the Treatment of Chronic Tinnitus|MagTIN|Hospices Civils de Lyon|No|Completed|May 2005|September 2009|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|No|||July 2011|August 9, 2012|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01407133||100584|
NCT01403064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD518-CLIN-009|Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy||Alder Biopharmaceuticals, Inc.|Yes|Completed|July 2011|March 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|81|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403064||100897|
NCT01403077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI-SFA2011-01|480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions|A Safety Assessment of the 480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo SFA Lesions|STANCE|480 Biomedical, Inc.|Yes|Completed|October 2011|October 2015|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403077||100896|
NCT01413997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ctmmp1-R43AT006085|Connective Tissue Motion Measure|Feasibility Study of Connective Tissue Motion Measure - a Biomarker for Perimuscular Connective Tissue Pathology.|CTMM1|Stromatec, Inc.|Yes|Completed|April 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|39|||Both|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community Sample|August 2011|August 9, 2011|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01413997||100061|
NCT01414010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000319|Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota|Effects of Mushroom Extract, S Boulardii and Amoxicillin on the Human Microbiome||Beth Israel Deaconess Medical Center|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|August 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01414010||100060|
NCT01414530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-03-018|Oral Contraceptive During Menopausal Transition|Effects of Oral Contraceptive on Muscle or Joint Ache in Women During Menopausal Transition||Samsung Medical Center|No|Recruiting|April 2010|||June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01414530||100021|
NCT01414517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0715/61|Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.|A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy.||University College London Hospitals|Yes|Recruiting|August 2010|August 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|220|||Both|N/A|N/A|No|||August 2010|August 10, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414517||100022|
NCT01415037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3057|Annular Array Ultrasound in Ophthalmology|High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging||Columbia University|No|Enrolling by invitation|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|University-based Ophthalmology Practice|April 2015|April 15, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01415037||99982|
NCT01411553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clevelandCF|ECG Leadwires: Disposable Versus Cleaned, Reusable|ECG Leadwires: Do Disposable Leadwires Reduce the Incidence of Bacterial Infections in ICU Patients and Provide Adequate Signaling in Stepdown/Telemetry Environment Compared to Cleaned Reusable ECG Leadwires?|ECG-LW|The Cleveland Clinic|No|Completed|September 2011|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4056|||Both|N/A|N/A|No|||February 2016|February 21, 2016|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411553||100245|
NCT01404390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15205|Japanese BAY80-6946 Monotherapy Phase I Study|An Open Label, Single Centre, Phase I Study of PI3K Inhibitor BAY80-6946 to Evaluate the Safety, Tolerability and Pharmacokinetics in Japanese Patients With Advanced or Refractory Solid Tumours||Bayer|No|Completed|August 2011|July 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|80 Years|No|||July 2014|July 14, 2014|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404390||100795|
NCT01405248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPRIAS|Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting|Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting|BPRIAS|Jinling Hospital, China|Yes|Completed|July 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|40 Years|85 Years|No|||October 2015|October 22, 2015|July 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405248||100729|
NCT01405274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-287-PED|Impact of Physiotherapy Intervention for Children With Ankle Sprains|Exploring the Impact of a Physiotherapy Intervention on the Risk of Re-injury and Recovery in Children and Adolescents With Acute Ankle Sprains: a Randomized Controlled Trial||McGill University Health Center|No|Recruiting|July 2011|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|7 Years|18 Years|No|||December 2015|December 11, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405274||100727|
NCT01405287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-0509|Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT|A Prospective Randomized Study to Compare Vascular Healing After Deployment of the Abluminal Sirolimus Coated Bio-Engineered (Combo) Stent Versus the Everolimus Eluting Stent in Patients With Acute Coronary Syndrome by Means of OCT|REMEDEE-OCT|OrbusNeich|Yes|Completed|October 2011|January 2014|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||March 2014|March 21, 2014|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405287||100726|
NCT01405456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002095|Eplerenone in HIV Associated Abdominal Fat Accumulation|Randomized Placebo-controlled Trial to Investigate the Effects of Eplerenone in Patients With HIV-associated Abdominal Fat Accumulation||Massachusetts General Hospital|Yes|Recruiting|January 2012|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|30 Years|65 Years|No|||December 2015|December 10, 2015|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405456||100713|
NCT01405469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE Hamburg Endoscopy PV3725|Endoscopic Peroral Myotomy for Treatment of Achalasia|Endoscopic Peroral Myotomy for Treatment of Achalasia: Pilot Study|POEM|Universitätsklinikum Hamburg-Eppendorf|Yes|Active, not recruiting|November 2010|November 2015|Anticipated|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|May 26, 2011||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01405469||100712|Occurrence of therapy-associated mortality or a rate of severe complications requiring surgical intervention (perforation, heavy bleedings) of two cases in a total number of at least 10 interventions.
NCT01405716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09100150|Aging Successfully With Pain|Effectiveness of a Mind-Body Program for Older Adults With Chronic Low Back Pain||University of Pittsburgh|Yes|Completed|February 2011|September 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|282|||Both|65 Years|N/A|No|||February 2016|February 23, 2016|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01405716||100693|
NCT01406015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000311|Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications|Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications||Brigham and Women's Hospital|No|Completed|February 2009|||August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|70 Years|No|||August 2013|August 12, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01406015||100670|
NCT01406028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p-001214|Does Emotional Support Decrease In Vitro Fertilization Stress?|Does Emotional Support During the Luteal Phase Decrease the Stress of IVF?||Brigham and Women's Hospital|No|Completed|September 2009|June 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|131|||Female|18 Years|45 Years|No|||July 2011|July 28, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406028||100669|
NCT01411878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP2AH000010-01-00|Louisville Teen Pregnancy Prevention Project|Creating Healthy Adolescents Through Meaningful Prevention Services|CHAMPS|University of Louisville|Yes|Enrolling by invitation|September 2011|April 2017|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1300|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01411878||100220|
NCT01412424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-ACM-01|Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly|Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs||Chiasma, Inc.|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|75 Years|No|||October 2015|October 28, 2015|August 5, 2011|Yes|Yes||No|October 28, 2015|https://clinicaltrials.gov/show/NCT01412424||100179|
NCT01412437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMRN 9956|Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria|Multimodal Neuroimaging and Neurocognitive Assessment of Biomarkers and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria|PKU|Children's Research Institute|Yes|Withdrawn|April 2011|December 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|40 Years|No|||December 2014|December 16, 2014|August 1, 2011||No|poor recruitment|No||https://clinicaltrials.gov/show/NCT01412437||100178|
NCT01412450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-100702|Efficacity Study With the Protégé EverFlex Stent in Popliteal Lesions|DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions|DUR-POP|Flanders Medical Research Program|Yes|Completed|July 2010|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|July 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01412450||100177|
NCT01412125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090302|Study of Biomarkers That Predict the Evolution of Huntington's Disease|Study of Biomarkers That Predict the Evolution of Huntington's Disease|BIOHD|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|September 2003|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1800|Samples With DNA|-  Blood (for DNA analysis) and plasma sample at inclusion visit        -  Plasma sample every year|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients suffering from Huntington disease (carrying the gene) versus healthy controls|October 2014|October 8, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01412125||100201|
NCT01413633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|how to do it|A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic Cholecystectomy|A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic Cholecystectomy||Mansoura University|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413633||100087|
NCT01413646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-15|Effects of Walnuts on Endothelial Function in Overweight Adults With at Least One Factor of Metabolic Syndrome|Effects of Walnuts on Endothelial Function in Overweight Adults With at Least One Factor of Metabolic Syndrome: A Randomized, Controlled, Cross-Over Trial|Walnut2|Griffin Hospital|No|Completed|February 2010|December 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|25 Years|75 Years|No|||August 2011|August 9, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01413646||100086|
NCT01413659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUMS-89619|Evaluation of the Effect of Preoperative Symbiotic Bowel Conditioning on Surgical Site Infection After Elective Colorectal Surgery|||Mashhad University of Medical Sciences||Not yet recruiting|September 2011|February 2013|Anticipated|December 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Anticipated|150|||Both|14 Years|N/A|No|||July 2011|August 24, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413659||100085|
NCT01414283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMA ADC 1301|Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer|A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer||Progenics Pharmaceuticals, Inc.|No|Completed|October 2008|September 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Male|18 Years|N/A|No|||October 2013|October 31, 2013|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414283||100040|
NCT01414296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMA ADC 1301EXT|Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer|Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer||Progenics Pharmaceuticals, Inc.|No|Completed|January 2009|November 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||November 2013|November 12, 2013|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414296||100039|
NCT01413945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-216B|Ileocecal Sphincter Reflex by Cecal Distension During Colonoscopy|Evaluation of the Ileocecal Valve in Patients With and Without Irritable Bowel Syndrome.(IBS)||Feinstein Institute for Medical Research|No|Recruiting|October 2010|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with who are undergoing routine screening colonoscopies.|June 2015|June 23, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413945||100064|
NCT01413958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18125|Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)|A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis||Bayer|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|575|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|August 9, 2011|Yes|Yes||No|October 8, 2012|https://clinicaltrials.gov/show/NCT01413958||100063|
NCT01413984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU 11-18|Substance Abuse and Trauma in Incarcerated Women|Substance Abuse and Trauma in Incarcerated Women: An Effectiveness Study||University of Tulsa|Yes|Completed|November 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|95|||Female|18 Years|N/A|No|||March 2014|March 17, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01413984||100062|
NCT01414803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0390|Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia|||Yonsei University|No|Completed|March 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|20 Years|70 Years|No|||August 2011|August 10, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01414803||100000|
NCT01414790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|luowen228|The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome|The Use of Human Acellular Dermal Matrix in the Prevention of Infraauricular Depressed Deformities and Frey's Syndrome Following Total Parotidectomy||West China Hospital|Yes|Completed|January 2004|January 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|10 Years|79 Years|No|||January 2011|August 10, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414790||100001|
NCT01415622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101028|Feasibility, Efficacy, and Safety of Venous Ulcer Treatment Using a Hand Plasma Generator (PlasmaDerm) Chronisch venöser Ulzerationen (PlasmaDerm)|||Cinogy GmbH|Yes|Completed|April 2011|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|N/A|No|||August 2011|November 16, 2012|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01415622||99937|
NCT01413451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110212|Amatuximab for High Mesothelin Cancers|A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers||National Institutes of Health Clinical Center (CC)||Terminated|July 2011|November 2013|Actual|November 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||November 2013|February 19, 2014|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01413451||100101|
NCT01404416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5119001|Effect of Antenatal Iron-contained Multiple Micronutrient Supplementation, Cesarean Delivery, and CDMR on Child Health|Effect of Antenatal Iron-contained Multiple Micronutrient Supplementation, Cesarean Delivery, and CDMR on Child Health- A Post-trial Follow-up Chinese Study||Peking University|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17000|||Both|1 Year|5 Years|No|Probability Sample|all livebirths born to women of our previous trial (NCT00133744) who were from Laoting,        Fengrun, Xianghe, Mancheng, and Yuanshi counties of China.|June 2015|June 4, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404416||100793|
NCT01404975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB #: 11-0260-B|TAVI Protocol - Paravertebral Block Study|Reducing Delirium After Trans-Apical Aortic Valve Replacement (TAVI): A Multifaceted Approach of Perioperative Care|TAVI PVB|University Health Network, Toronto|Yes|Recruiting|June 2011|July 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01404975||100750|
NCT01405521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2011/02|Understanding Typhoid Disease After Vaccination|Understanding Typhoid Disease After Vaccination: a Single Centre, Randomised, Doubleblind, Placebo Controlled Study to Evaluate M01ZH09 in a Healthy Adult Challenge Model, Using Ty21a Vaccine as a Positive Control.||University of Oxford|Yes|Active, not recruiting|December 2011|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|99|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405521||100708|
NCT01406041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The department of Neurosurgery|Disturbance of Water and Sodium Metabolism After Surgery of Sellar Lesions, and Correspond Clinical Strategy|||Southern Medical University, China|Yes|Recruiting|February 2011|January 2014|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|350|||Both|N/A|N/A|No|Probability Sample|All patients presented in our department suffered with sellar diseases|April 2011|July 28, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406041||100668|
NCT01405482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00407|Botulinum Toxin Injections for Thoracic Outlet Syndrome|Botulin Toxin Type A Injections for Thoracic Outlet Syndrome: A Double-Blind, Randomized Control Trial||University of British Columbia|Yes|Not yet recruiting|August 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|No|||July 2011|July 28, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01405482||100711|
NCT01405729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39977|Medial Patellofemoral Ligament Reconstruction: A Review of Technique, Accuracy, and Outcome|Medial Patellofemoral Ligament Reconstruction: A Review of Technique, Accuracy, and Outcome|MPFL|University of Utah|No|Completed|May 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|13|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|A single surgeon experience beginning in 2005 with patient's undergoing MPFL        reconstruction using intra-operative fluoroscopy for proper placement of the femoral        tunnel.|February 2014|February 12, 2014|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405729||100692|
NCT01406873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3716|Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1|A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1)||University of Rochester|Yes|Recruiting|June 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2016|March 17, 2016|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406873||100604|
NCT01412749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR11-0131|TEST: Registry for Endoscopic Head and Neck Surgery|Transoral Endoscopic Surgery Trial (TEST): A Registry for Endoscopic Head and Neck Surgery (eHNS)|TEST|M.D. Anderson Cancer Center|No|Terminated|April 2011|||June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Both|N/A|N/A|No|Non-Probability Sample|Individuals diagnosed with head and neck cancer and are a candidate to have endoscopic        head and neck surgery (eHNS) for definitive resection of the primary tumor.|June 2013|June 27, 2013|August 8, 2011||No|Low Accrual|No||https://clinicaltrials.gov/show/NCT01412749||100154|
NCT01413022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201124|FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma|Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma||Washington University School of Medicine|Yes|Active, not recruiting|April 2012|September 2016|Anticipated|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|July 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01413022||100133|
NCT01412736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4563-003|A Phase IIa Study of KHK4563|A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma|4563-003|Kyowa Hakko Kirin Company, Limited|No|Completed|August 2011|October 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|106|||Both|20 Years|75 Years|No|||December 2014|December 21, 2014|August 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01412736||100155|
NCT01413685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071004|Calcineurin Activity in Renal Recipients|Interest of Calcineurin Activity for the Therapeutic Tacrolimus Monitoring in Renal Recipients||Assistance Publique - Hôpitaux de Paris|Yes|Terminated|January 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|23|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|June 24, 2011||No|no patient corresponding to criteria|No||https://clinicaltrials.gov/show/NCT01413685||100083|
NCT01414569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTB-002|Dexamethasone for Pain After Shoulder Surgery|High Dose Dexamethasone as Pain Treatment After Arthroscopic Shoulder Surgery: A Randomised, Blinded Clinical Trial||University of Aarhus|No|Completed|November 2011|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|97|||Both|18 Years|90 Years|No|||June 2013|June 3, 2013|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414569||100018|
NCT01414582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H0604/98|Transcranial Stimulation and Motor Training in Stroke Rehabilitation|Transcranial Direct Current Stimulation (tDCS) as a Potential Adjunct Intervention in Stroke Rehabilitation|tDCS|University of Oxford|No|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||June 2012|June 19, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01414582||100017|
NCT01414244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-271|Glutamine for the Treatment of Patients With Irritable Bowel Syndrome|Randomized, Placebo-Controlled Trial of Glutamine for the Treatment of Patients With Irritable Bowel Syndrome|AT005291|The University of Texas Medical Branch, Galveston|Yes|Recruiting|November 2010|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|72 Years|No|||March 2015|March 12, 2015|July 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414244||100043|
NCT01414257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3211003|Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)|Rheumatrex High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|May 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2882|||Both|17 Years|99 Years|No|Probability Sample|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the        treatment of Rheumatoid Arthritis.|September 2015|September 25, 2015|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01414257||100042|
NCT01415063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-0013|Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma|Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Recruiting|February 2011|March 2014|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||February 2011|August 10, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415063||99980|
NCT01415050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPM-022|Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women|Multicentered, Randomized Study of Safety and Efficacy of Whole-body Vibration as add-on to Standard Pharmacological Treatment of Osteoporosis in Post-menopausal Women||X-pert Med GmbH|Yes|Completed|January 2009|July 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|N/A|N/A|No|||August 2011|August 10, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01415050||99981|
NCT01415349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD557-101|SSP-002358 Drug Interaction Study With Omeprazole|A Phase 1, Open-label, Randomized, 2-period Crossover Drug Interaction Study in Healthy Adult Subjects to Evaluate the Effect of the Proton Pump Inhibitor Omeprazole on the Pharmacokinetics of SSP-002358||Shire||Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2014|June 6, 2014|August 10, 2011||No||No|June 1, 2012|https://clinicaltrials.gov/show/NCT01415349||99958|
NCT01415635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-048|Fortified Hospital Food as Nutritional Support|Positive Effect of Fortified Hospital Food on Nutritional Intake in Patients at Nutritional Risk. A Randomized Controlled Trial.|DHH|Copenhagen University Hospital at Herlev|Yes|Completed|October 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|84|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01415635||99936|
NCT01412619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A 11-131 CSINVOS|Non-invasive Measurement of Regional Intracerebral Tissue Oxygenation in Elective Cardiac Surgeries|CSINVOS: Non-invasive Measurement of Regional Intracerebral Tissue Oxygenation in Elective Cardiac Surgeries|CSINVOS|RWTH Aachen University|No|Completed|December 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Cytokine IL-6 Cytokine IL-10 Procalcitonin (PCT) S-100-Protein|Both|18 Years|N/A|No|Non-Probability Sample|Approximately 100 adult patients (male and female), capable of consenting, undergoing        elective cardiac surgery at heart-lung-machine|December 2011|December 24, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01412619||100164|
NCT01412944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2307|Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis|A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab|STATURE|Novartis||Completed|December 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|August 5, 2011|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01412944||100139|
NCT01412957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100007|Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer|A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer||Amgen|Yes|Active, not recruiting|September 2011|June 2016|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|377|||Both|18 Years|N/A|No|||November 2015|December 2, 2015|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412957||100138|
NCT01404949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-040|Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy|Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|July 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404949||100752|
NCT01404962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V37_11|Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children|A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem™Hib When Administered According to the Prescribing Information in Korea||Novartis||Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|764|||Both|2 Months|5 Years|Accepts Healthy Volunteers|||September 2012|September 10, 2012|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01404962||100751|
NCT01404988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 11-238|Veterans Intensive Personalized Treatment in Heart Failure|VIP (Veterans Intensive Personalized) Treatment in Heart Failure|VIP|VA Office of Research and Development|No|Completed|November 2011|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|99|||Both|21 Years|N/A|No|||May 2015|May 6, 2015|July 27, 2011||No||No|February 23, 2015|https://clinicaltrials.gov/show/NCT01404988||100749|
NCT01405001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2005.055et|Registry of Emergency Airways Arriving at Combat Hospitals|Registry of Emergency Airways Arriving at Combat Hospitals (REACH)|REACH|William Beaumont Army Medical Center|No|Completed|December 2004|March 2007|Actual|||N/A|Observational|Time Perspective: Prospective|||Actual|292|||Both|18 Years|N/A||||September 2007|July 27, 2011|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405001||100748|
NCT01405495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRI/10/WEH/COPTSD|PTSD Among Victims of Sexual Abuse and Changes in Structural and Functional Brain Connectivity|Posttraumatic Stress Disorder (PTSD) Among Victims of Sexual Abuse and Changes in Structural and Functional Brain Connectivity: A Cognitive and Neuroanatomical Markers Study Using fMRI,(DTI) and(ASL)|COPTSD|University Hospital, Tours|Yes|Active, not recruiting|February 2012|August 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples Without DNA|Salivary cortisol|Female|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|PTSD related to sexual abuse vs trauma-exposed vs controls, in right-handed females.|January 2016|January 5, 2016|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01405495||100710|
NCT01406626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA030781|Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care|Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care|LINK LA|University of California, Los Angeles|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Male|18 Years|N/A|No|||January 2016|January 15, 2016|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406626||100623|
NCT01411631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0026|A Study to Investigate the Effect of Concord Grape Juice on Cognitive Function in Mums of Preteen Children|A Study to Investigate the Effect of Concord Grape Juice on Cognitive Function in Mums of Preteen Children||University of Leeds|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|25|||Female|40 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01411631||100239|
NCT01413282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEACON-11|Better Evaluation of Acute Chest Pain With Computed Tomography Angiography|Better Evaluation of Acute Chest Pain With Computed Tomography Angiography - A Randomized Controlled Trial|BEACON|Erasmus Medical Center|Yes|Active, not recruiting|July 2011|August 2014|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|500|||Both|30 Years|80 Years|No|||February 2014|February 20, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413282||100114|
NCT01413581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVT.BSSL-030|Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants|A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age|LAIF|Swedish Orphan Biovitrum|Yes|Terminated|May 2011|August 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|415|||Both|N/A|10 Weeks|No|||July 2015|July 29, 2015|June 8, 2011||No|Primary endpoint showed no stat significant difference. FU > M12 terminated.|No||https://clinicaltrials.gov/show/NCT01413581||100091|
NCT01413269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-013|Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery|Phase 3 Open-labeled Randomized Clinical Study of Comparing Hypofractionated and Conventional Radiotherapy for Breast Cancer Patients After Breast Conservative Surgery||Chinese Academy of Medical Sciences|Yes|Recruiting|June 2010|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|720|||Female|18 Years|70 Years|No|||January 2016|January 29, 2016|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413269||100115|
NCT01413698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSI-IL-HHZ-CCF-01|Cough Count Validation|||KarmelSonix Ltd.||Not yet recruiting|September 2011|September 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|20|||Both|2 Years|80 Years|No|Non-Probability Sample|Patients with chronic cough|August 2011|August 9, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413698||100082|
NCT01415648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STIC/10/02|Medico-economic Evaluation of Preoperative Cerebral Oximetry Monitoring During Carotid Endarterectomy|Medico-economic Evaluation of Preoperative Cerebral Oximetry Monitoring During Carotid Endarterectomy.|EMOCAR|Nantes University Hospital|No|Terminated|April 2011|April 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|876|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 11, 2011||No|Recruitment time expired.|No||https://clinicaltrials.gov/show/NCT01415648||99935|
NCT01414543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEL1|Psychologists' Lived Experience of Client Violence|Counselling and Clinical Psychologists Lived Experience of Client Violence||University of East London|Yes|Recruiting|October 2009|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|10|||Both|24 Years|65 Years|Accepts Healthy Volunteers|||August 2009|August 10, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01414543||100020|
NCT01414556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2009-078|GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes|Effects of Glucose-dependent Insulinotropic Polypeptide at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes|GIP-HYPO-T2DM|University Hospital, Gentofte, Copenhagen|No|Completed|May 2011|November 2012|Actual|July 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Male|18 Years|70 Years|No|||March 2013|March 31, 2013|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01414556||100019|
NCT01412034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-001-CLIN-003|Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects|Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)|MODE|Cerenis Therapeutics, SA|No|Completed|November 2011|August 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|12 Years|N/A|No|||July 2015|July 28, 2015|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412034||100208|
NCT01412047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M07-003|Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study|A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria||Alexion Pharmaceuticals|No|Completed|March 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|75|||Both|N/A|N/A|No|Non-Probability Sample|Patients with PNH previously enrolled in study E05-001, who have a eculizumab naive serum        sample available for comparison, and who are currently receiving treatment with commerical        Soliris.|July 2013|July 9, 2013|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01412047||100207|
NCT01415362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-000289|Closed-loop System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy|Development of a Closed-loop Detect-and-treat System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy||Spaulding Rehabilitation Hospital|No|Completed|July 2011|||July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|February 29, 2016|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01415362||99957|
NCT01412632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023843-13|Comparing Two Types of Sedation to Gynaecological Patients|Deep Sedation in Spontaneously Breathing Patients Combined With Local Anesthesia Versus General Anesthesia in Gynecological Patients at Same Day Surgical at Hospitalsenheden Horsens||University of Aarhus|Yes|Completed|November 2011|August 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|153|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|September 30, 2014|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01412632||100163|
NCT01413191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02228|Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye|Phase II Study of IMC-A12 in Metastatic Uveal Melanoma||National Cancer Institute (NCI)||Completed|August 2011|June 2014|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|17 Years|N/A|No|||June 2014|June 25, 2015|August 9, 2011|Yes|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01413191||100121|
NCT01413490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002781-21|Hepatitis C Rimantadine and Antiviral Combination Therapy|A Clinical Study to Evaluate the Biological Effects of Administering Rimantadine in Patients With Hepatitis C Virus (HCV) Infection Alongside Standard Combination Therapy With Pegylated Interferon and Ribavirin|HepRiACT|The Leeds Teaching Hospitals NHS Trust|Yes|Completed|May 2012|March 2015|Actual|March 2015|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|blood samples of patients undegoing standard combination therpay for hepatits c virus      infection|Both|18 Years|65 Years|No|Non-Probability Sample|patients with hepatitis c virus infection who are attending the department of hepatology        for treatment with standard combination therpay|March 2015|March 30, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413490||100098|
NCT01413503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phase II Pheo|A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors|A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors||University of California, San Francisco|Yes|Completed|May 1991|May 2009|Actual|May 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|4 Years|N/A|No|||January 2015|January 9, 2015|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413503||100097|
NCT01404728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0454.cc|Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy|Prospective Longitudinal Evaluation of Vaginal Stenosis and Sexual Function in Women With Pelvic Malignancies Treated With and Without Pelvic Radiation Therapy||University of Colorado, Denver|Yes|Recruiting|June 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|Women being treated for pelvic malignancies in the primary care clinic.|December 2015|December 3, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404728||100769|
NCT01405300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKE PPNUT|The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function|The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function||Penn State University|No|Completed|August 2011|June 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405300||100725|
NCT01405508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01258|Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy|A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy||UCB Pharma|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|105|||Both|16 Years|70 Years|No|||July 2013|August 26, 2014|July 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405508||100709|
NCT01405742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10020178|Hemophilia Adult Prophylaxis Study|R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A||University of Pittsburgh|Yes|Terminated|July 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Male|18 Years|N/A|No|||June 2014|June 5, 2014|July 25, 2011|Yes|Yes|study was non-feasible per DSMB|No||https://clinicaltrials.gov/show/NCT01405742||100691|
NCT01405755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000076-AT10-7USC|Partnering With Media and Vaccination Program to Improve Infant and Young Child Feeding|Partnering With Media and Vaccination Program to Improve Infant and Young Child Feeding||University of South Carolina|No|Completed|September 2010|March 2013|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|420|||Female|18 Years|45 Years|No|||April 2013|April 1, 2013|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405755||100690|
NCT01406314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114527|SAP Depleter Dose Assessment Study in Patients|A Phase 1, Open Label, Dose Characteristic Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intravenous and Subcutaneous Doses of GSK2315698A in Patients With Systemic Amyloidosis||GlaxoSmithKline|No|Completed|October 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|18 Years|80 Years|No|||December 2012|December 13, 2012|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01406314||100647|
NCT01415726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-010|Stem Cell Educator Therapy in Type 2 Diabetes|||University of Illinois at Chicago||Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|14 Years|65 Years|Accepts Healthy Volunteers|||July 2011|February 16, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415726||99929|
NCT01411891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0444|Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch|Prospective Randomized Control Trial of Post-Operative Colonization Rates of Femoral Nerve Catheters With the Use of Chlorhexidine-Impregnated Patch||University of Wisconsin, Madison|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|85 Years|No|||June 2012|October 1, 2015|May 17, 2011|Yes|Yes||No|April 20, 2012|https://clinicaltrials.gov/show/NCT01411891||100219|
NCT01412138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-C-073-CS-F|Somatic Stem Cells in Endometriosis|"Identification, Characterization and Isolation of Somatic Stem Cells in Human Endometrium of Women With Endometriosis"||Igenomix|No|Active, not recruiting|March 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|endometrial biopsy|Female|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with endometrial infertility factor, undergoing ART.|April 2015|April 21, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01412138||100200|
NCT01404845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00922-39|Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation|Assessment of the Evolution of Macular Pigment Density in Two Distinct Populations, Before and After Supplementation With Nutrof Total Versus Dietary Supplement Without Lutein and Zeaxanthin, Using the Macular Pigment Module of Visucam 200 or Visucam 500 (Zeiss).||Affordance|No|Completed|September 2011|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|200|||Both|55 Years|N/A|No|||June 2015|June 23, 2015|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01404845||100760|
NCT01405079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-TONG 1104|Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation|A National, Multi Center, Randomized, Open-label, Phase III Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutation|ADJUVANT|Guangdong Association of Clinical Trials|Yes|Recruiting|July 2011|August 2018|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|75 Years|No|||September 2013|September 5, 2013|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405079||100742|
NCT01405092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09-097|Continuous Versus Conventional Volume Management During CRRT (Continuous Renal Replacement Therapy)|||Dallas VA Medical Center|No|Completed|April 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|21 Years|N/A|No|||August 2012|August 7, 2012|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405092||100741|
NCT01413906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA194-010|Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors|Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors||Bristol-Myers Squibb|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||May 2013|May 31, 2013|August 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01413906||100066|
NCT01414192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-204|A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)|Model-Observation Bridging Study (MOBS) for Ezetrol® and Inegy®|MOBS|Merck Sharp & Dohme Corp.|No|Completed|November 2008|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|3215|||Both|18 Years|N/A|No|Non-Probability Sample|The resident population of Continental France being treated for hypercholesterolemia in a        general practice setting.|November 2015|December 2, 2015|August 9, 2011|No|Yes||No|September 14, 2015|https://clinicaltrials.gov/show/NCT01414192||100047|
NCT01414023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-2487|Assessing the Effects of a Neurobehavioral Intervention on Symptoms of Obsessive Compulsive Disorder||CCT-OC|Boston University|No|Completed|July 2011|||July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 20, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414023||100059|
NCT01414036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR025771|Pilot Study of Patient Navigation to Promote Smoking Cessation|Primary Care-based Patient Navigation to Promote Smoking Cessation Treatment: a Pilot Randomized Controlled Trial||Boston University|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|47|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|August 9, 2011||No||No|January 26, 2016|https://clinicaltrials.gov/show/NCT01414036||100058|
NCT01414270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108-V19_PT03-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2011|||||N/A|N/A|N/A||||||||||||||January 29, 2014|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414270||100041|
NCT01412060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-06|Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia|A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study of Cariprazine(RGH-188) in the Prevention of Relapse in Patients With Schizophrenia||Forest Laboratories|No|Completed|August 2011|November 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|766|||Both|18 Years|60 Years|No|||September 2015|September 25, 2015|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412060||100206|
NCT01414816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14839|Betaferon® Regulatory Post-Marketing Surveillance|Betaferon® Regulatory Post-Marketing Surveillance||Bayer|No|Completed|April 2008|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|355|||Both|12 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of Multiple Sclerosis or Clinically Isolated Syndrome who have        been or will be treated with Betaferon.|August 2014|August 20, 2014|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01414816||99999|
NCT01414829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|paritsky1.ct.il|Efficacy of Gastric Biopsy for Culture and Antibiotic Sensitivity Assessment|Efficacy of Gastric Biopsy for Culture and Antibiotic Sensitivity Assessment and Comparing of Different Methods for Helicobacter Pylori Disclosure||The Baruch Padeh Medical Center, Poriya|No|Withdrawn|August 2011|January 2012||January 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|gastric biopsies|Both|10 Years|N/A|No|Probability Sample|Patient referred for gastroscopy because of clinical reasons|December 2012|December 2, 2012|August 10, 2011||No|difficulty in recruiting parients|No||https://clinicaltrials.gov/show/NCT01414829||99998|
NCT01411566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Koeln-Fortune 104/2010|Clinical Intervention Psychosis and Addiction|Evaluation of an Integrative Therapeutic Concept for Schizophrenic Patients With Comorbid Substance Use Disorder|KLIPS|University of Cologne|No|Recruiting|January 2011|December 2011|Anticipated|November 2011|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|60 Years|No|||February 2011|August 5, 2011|March 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01411566||100244|
NCT01412645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIRMOI|Long-term Investigation of Resveratrol in Obesity|Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds|LIRMOI|University of Aarhus|No|Completed|August 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|76|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01412645||100162|
NCT01412333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA21093|A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis|A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis||Hoffmann-La Roche||Active, not recruiting|September 2011|January 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|835|||Both|18 Years|55 Years|No|||March 2016|March 1, 2016|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412333||100186|
NCT01412658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX_Safety_study|Clinical Safety of a Novel Milk Protein Peptide|Safety Study of Milk Peptide Supplementation in Healthy Volunteers: a Randomized Placebo Controlled Clinical Trial||Ambryx Biotechnology|Yes|Completed|November 2006|February 2007|Actual|January 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|73|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||August 2011|August 8, 2011|August 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01412658||100161|
NCT01412671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15037|Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program|Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma: Early Access Program)||Bayer|No|Completed|February 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|117|||Both|N/A|N/A|No|Non-Probability Sample|The target population of this study is patients who received Nexavar for unresectable or        advanced RCC.|April 2012|April 10, 2012|August 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01412671||100160|
NCT01414153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1009-Oph-003|Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD|Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With CNV Secondary to AMD|Nexus|Lpath, Inc.|Yes|Completed|August 2012|June 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|158|||Both|50 Years|N/A|No|||September 2015|September 15, 2015|August 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01414153||100050|
NCT01404741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VidazaAlloStudy|5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)|Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability||Universitätsklinikum Hamburg-Eppendorf|No|Recruiting|June 2011|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|55 Years|70 Years|No|||May 2015|May 12, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01404741||100768|
NCT01415492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1810|Multiple Risk Behavior Intervention in Health Care Settings|Multiple Risk Behavior Intervention in Health Care Settings|HD2|Dana-Farber Cancer Institute|No|Completed|March 2009|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|2440|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 30, 2014|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415492||99947|
NCT01415505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-MD-02|Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension|A Multicenter, Open-Label, Single-Arm, Free Tablet Combination, Long-Term Study to Evaluate the Safety of Nebivolol in Combination With Valsartan in Patients With Stage 1 or Stage 2 Essential Hypertension||Forest Laboratories|No|Completed|August 2011|April 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|812|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01415505||99946|
NCT01415739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-151102|Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer|Evaluation of a Novel Molecular NSCLC Classification System||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|October 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|261|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with non-small cell lung cancer registered on CALGB 9761|July 2015|July 23, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01415739||99928|
NCT01406054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2011-14570|Role of Neuromuscular Training in Reducing Sports Injuries and Improving Fitness Among Chicago Public Elementary and Middle School Students|Role of Neuromuscular Training in Reducing Sports Injuries and Improving Fitness Among Chicago Public Elementary and Middle School Students|KIPP at CPS|Ann & Robert H Lurie Children's Hospital of Chicago|No|Active, not recruiting|July 2011|July 2016|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|905|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406054||100667|
NCT01412151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P000530|Creatine Safety & Tolerability in Huntington's Disease|Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD|CREST-X|Massachusetts General Hospital|No|Completed|April 2005|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|August 5, 2011|Yes|Yes||No|November 28, 2012|https://clinicaltrials.gov/show/NCT01412151||100199|
NCT01412164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARGET II|Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)|A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II||Shanghai MicroPort Medical (Group) Co., Ltd.|Yes|Active, not recruiting|August 2011|February 2017|Anticipated|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|730|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|August 5, 2011||No||No|February 19, 2016|https://clinicaltrials.gov/show/NCT01412164||100198|
NCT01412463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-101208|DURABILITY+ : a Prospective, Multi-center, Controlled Study With the Everflex+ Stent in SFA Lesions|DURABILITY+ : a Prospective, Multi-center, Controlled Study Measuring the Durability in Lesions of the Superficial Femoral Artery of the Protégé Everflex+ Stent|DURABILITY+|Flanders Medical Research Program|Yes|Completed|May 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412463||100176|
NCT01412476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS09155|Coenzyme Q10 and Vitamin A, C, E in Relation to the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome|||Chung Shan Medical University|Yes|Completed|August 2010|March 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|72|Samples Without DNA|Blood samples|Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|The investigators recruited MS patients (case group, n = 100). The inclusion criteria of        MS are according to the Bureau of Health Promotion, Department of Health in Taiwan (2007).        The health subject were recrited from previous study (n = 105).|March 2012|March 23, 2012|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412476||100175|
NCT01405118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921143|Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers|A Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers||Pfizer|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 17, 2011|July 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405118||100739|
NCT01405131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0121006|A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder for Oral Suspension 4 mg/mL to Methylprednisolone 32 mg Tablet Under Fasted Conditions||Pfizer|No|Withdrawn|January 2012|February 2012|Anticipated|February 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 24, 2011|July 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405131||100738|
NCT01405378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wessex Innovative Grant P09|Non-invasive Brain Stimulation for People With Stroke|Combining Transcranial Direct Current Stimulation (tDCS) With Robot Therapy for the Impaired Upper Limb in Stroke Rehabilitation.||University of Southampton|Yes|Completed|October 2011|February 2014|Actual|January 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|80 Years|No|||May 2011|December 3, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01405378||100719|
NCT01405365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq-402335/2008-2|The Impact of Obesity on Nonsurgical Periodontal Therapy|The Impact of Obesity on Nonsurgical Periodontal Treatment of Destructive Periodontal Diseases||Federal University of Rio Grande do Sul|No|Recruiting|August 2009|December 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|96|||Female|35 Years|55 Years|Accepts Healthy Volunteers|||August 2010|July 28, 2011|August 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01405365||100720|
NCT01405612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPJ5004-02/2011 (DDI)|Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers|An Open-label, Single Centre, Randomised, Cross-over Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam After Repeat Dose Administration of Ulimorelin in Healthy Volunteers||Norgine|Yes|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01405612||100701|
NCT01414309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP 1137|Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea|Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea||Respicardia, Inc.|No|Terminated|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2015|January 5, 2015|August 9, 2011||No|Change in company priorities|No||https://clinicaltrials.gov/show/NCT01414309||100038|
NCT01414322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSI-IL-HHZ-ER-01|Documentation of Continuous Wheeze and Cough Dynamics in Pediatric ER SOB Patients|||KarmelSonix Ltd.|No|Not yet recruiting|September 2011|September 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|45|||Both|N/A|15 Years|No|Non-Probability Sample|Pediatric emergency room patients ages 0 - 15 with shortness of breath upon arrival at the        hospital|August 2011|August 10, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01414322||100037|
NCT01415388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSI 1102-16|Study to Investigate the Effects of Krill Oil on Fasting Serum Triglycerides|A Double-blind, Randomized, Multi-centre, Placebo-controlled Study to Investigate the Effects of Superba(TM) Krill Oil on Fasting Serum Triglycerides||Aker Biomarine Antarctic AS|Yes|Completed|August 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|300|||Both|21 Years|79 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415388||99955|
NCT01411813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6267|Alprazolam and Eating Behavior in Anorexia Nervosa|Alprazolam and Eating Behavior in Anorexia Nervosa||New York State Psychiatric Institute|Yes|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|19|||Both|18 Years|60 Years|No|Probability Sample|Patients with Anorexia Nervosa hospitalized at NYSPI 4-C unit|November 2012|November 1, 2012|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01411813||100225|
NCT01412346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPHIKTL_022011|Health Effects of a Nordic Diet Rich in Plant-based Foods and Fish|Health Effects of a Nordic Diet Rich in Plant-based Foods and Fish||National Institute for Health and Welfare, Finland|No|Completed|January 2011|September 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01412346||100185|
NCT01412073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|582011|Control of Blood Loss During Caesarean Section|A Randomized Trial to Determine the Best Strategy for the Control of Blood Loss at Elective Caesarean Section||Cairo University|Yes|Completed|September 2011|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|600|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 4, 2014|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412073||100205|
NCT01412086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-068|Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale|||Allergan|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|September 2012|September 27, 2012|August 5, 2011|Yes|Yes||No|September 27, 2012|https://clinicaltrials.gov/show/NCT01412086||100204|
NCT01412931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0570|Protein and Ultrasound Indicators of Preterm Birth|Protein and Ultrasound Indicators of Preterm Birth||University of Colorado, Denver|Yes|Active, not recruiting|September 2011|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Cervicovaginal fluid and placental membranes will be retained for study.|Female|14 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women with a single intrauterine pregnancy with good gestational age dating, and        live fetus with no indications for preterm delivery will be enrolled. Three groups of        subjects will be recruited: a) 50 women with uncomplicated pregnancies and no history of        preterm birth, b) 50 multiparous women with history of spontaneous preterm labor or        preterm premature rupture of membranes (PPROM) c) 20 women evaluated on the labor and        delivery unit because they are deemed to be at high risk for preterm birth. Pregnant women        of all races and ethnicities will be recruited into the study.|January 2016|January 13, 2016|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412931||100140|
NCT01412970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG3171_2-1|Non-invasive Measurement of Central Hemodynamics by Electrical Impedance Tomography|Non-invasive Measurement of Central Hemodynamics and Heart-lung Interactions by Electrical Impedance Tomography||Universitätsklinikum Hamburg-Eppendorf|No|Not yet recruiting|July 2016|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412970||100137|
NCT01413217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC10010|Which is a Better Breakfast? Egg or Cereal?|"Which is a Better Breakfast? Egg or Cereal?"||Pennington Biomedical Research Center|No|Completed|July 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||2|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|In the community area of Baton Rouge, LA area exclusively random process to guarantee that        each participant or population has specified chance of selection.|February 2012|February 7, 2012|July 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01413217||100119|
NCT01409447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200707007D|Repair of Articular Osteochondral Defect|Repair of Articular Osteochondral Defect||National Taiwan University Hospital|Yes|Recruiting|March 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||August 2011|August 19, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409447||100407|
NCT01409460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-10-003|Obturator Nerve Block With Femoral and Sciatic Block|Is an Obturator Nerve Block Required for Every Patient Having Total Knee Arthroplasty With Femoral and Sciatic Nerve Block?||Saint Francis Care|No|Completed|October 2008|July 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|85 Years|No|||October 2008|August 3, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409460||100406|
NCT01405014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTHMT-ABI|Outcome Study of Hold Me Tight Program With Acquired Brian Injury (ABI) Populations|Pilot Study of the Hold Me Tight Relationship Enhancement Program With Couples Where One Partner Has an Acquired Brian Injury||Nova Scotia Health Authority|No|Withdrawn|January 2012|July 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||September 2011|March 6, 2012|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405014||100747|
NCT01405534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VVC|Evaluation of the Occurrence of Acute Complications Caused by a Central Venous Catheter Placement|Evaluation of the Occurrence of Acute Complications Caused by a Central Venous Catheter Placement: Observational, Prospective, Monocentric Study|VVC|Centre Leon Berard|No|Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1780|||Both|18 Years|N/A|No|Non-Probability Sample|All the patient who require the placement of a central venous catheter|September 2014|September 11, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405534||100707|
NCT01415752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1411|Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma|Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)||Eastern Cooperative Oncology Group|Yes|Recruiting|May 2012|||March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|332|||Both|60 Years|120 Years|No|||May 2015|March 22, 2016|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01415752||99927|
NCT01411670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2112|Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.|Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock: Effects on Microcirculation and Organ Function.||University of Roma La Sapienza|No|Completed|January 2011|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411670||100236|
NCT01411657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090300|NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement|||University of California, San Diego|Yes|Completed|April 2011|October 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|40 Years|N/A|No|||December 2014|December 25, 2014|August 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01411657||100237|
NCT01411644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 05-047|Pheno- & Genotyping POF (WHO III)|Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives||UMC Utrecht|No|Recruiting|January 2005|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|650|Samples With DNA|whole blood, serum and litium heparine|Female|12 Years|N/A|No|Non-Probability Sample|Women with WHO III status who attend the outpatient clinic of participating hospitals.|December 2015|December 2, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411644||100238|
NCT01412762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-087|Measuring Patient Expectations for Thyroid Surgery|Measuring Patient Expectations for Thyroid Surgery: Development of a Patient-Reported Outcomes Instrument||Memorial Sloan Kettering Cancer Center||Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing surgery for thyroid cancer will be recruited by the attending Head and        Neck Surgeons and Research Study Assistants in the Head and Neck Clinic|December 2015|December 4, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01412762||100153|
NCT01412775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11XXX-XXCTIL|Psychological Group Intervention to Reduce Stress and Burnout Among Cardiac Intensive Care Nurses|The Contribution of a Short-term Psychological Group Intervention to Reduce Stress and Burnout Among Cardiac Intensive Care Nurses: A Pilot Study||Meir Medical Center|No|Not yet recruiting|August 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|24|||Both|N/A|N/A|No|||August 2011|August 29, 2011|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01412775||100152|
NCT01413035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diabetes|Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes|Safety/Efficacy Assessed Study on Transplantation Therapy Using Human Umbilical Cord/Placenta-derived Mesenchymal Stem Cells for Type 2 Diabetes Mellitus||Shandong University|Yes|Recruiting|July 2011|July 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2011|August 8, 2011|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01413035||100132|
NCT01405144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carol2011|5fluorouracil for Advanced Photoaging|Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging||Federal University of São Paulo|Yes|Recruiting|August 2010|March 2012|Anticipated|September 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||May 2011|July 28, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01405144||100737|
NCT01405391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-A-005-11|Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 on Days 1 and 8 Every Three Weeks (q3wk) in Non-Colorectal Cancer (Non-CRC) Patients||PharmaMar|No|Completed|November 2011|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405391||100718|
NCT01405820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS206|Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)|A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis|REFINE|Biogen|Yes|Completed|August 2011|October 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|290|||Both|18 Years|55 Years|No|||August 2015|August 3, 2015|July 14, 2011|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01405820||100685|
NCT01411826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0305|Online Programs to Promote Colon Cancer Screening|Online Programs to Promote Colon Cancer Screening||The University of Texas Health Science Center, Houston|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|306|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01411826||100224|
NCT01411579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWIPRECHEMOUT|Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma|Assessment of Diffusion-weighted Magnetic Resonance (MR) Imaging to Predict Chemotherapy Outcome in Liver Metastases and Hepatocellular Carcinoma (HCC)||University of Florence|Yes|Completed|February 2011|February 2013|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|57|||Both|18 Years|80 Years|No|Probability Sample|Patients with liver metastases in chemotherapy and with hepatocarcinoma in therapy with        Sorafenib|December 2014|December 9, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411579||100243|
NCT01411592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ivoclar ZirCAD Adh.bruecken|Single Retainer All-Ceramic Resin-bonded Fixed Dental Protheses|Randomized Clinical Trial on Single Retainer All-Ceramic Resin-bonded Fixed Dental Protheses: Impact of the Bonding System||University of Kiel|Yes|Active, not recruiting|October 2006|April 2018|Anticipated|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|14 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 4, 2014|August 3, 2011||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01411592||100242|
NCT01411839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35279-C|Depression and ART Adherence in HIV+ Latinos|Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border||University of Washington|Yes|Active, not recruiting|July 2008|September 2011|Anticipated|August 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2011|August 23, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01411839||100223|
NCT01412372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39402|The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study|The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study|Mesalamine|University of Utah|Yes|Recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|75 Years|No|||February 2016|February 9, 2016|June 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01412372||100183|
NCT01412385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170903|Immune Globulin Subcutaenous (Human), 20%|A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases||Baxalta US Inc.|No|Completed|August 2011|May 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|2 Years|N/A|No|||April 2015|June 26, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412385||100182|
NCT01412359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08080394|Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury|Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury||University of Pittsburgh|No|Enrolling by invitation|June 2009|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Months|10 Years|No|||May 2015|May 26, 2015|August 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412359||100184|
NCT01413828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH- Breast-AH|Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer|Safety and Efficacy Evaluation of Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer||Peking Union Medical College Hospital|Yes|Recruiting|August 2011|August 2015|Anticipated|May 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|70 Years|No|||May 2014|May 20, 2014|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01413828||100072|
NCT01413841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DELUCA2|Effect of Oxygen During Percutaneous Coronary Intervention for Pain Relief|Phase II Randomised Study of Nasal Oxygen Treatment for Pain Relief During Percutaneous Coronary Interventions|OXYPAIN|Region Skane|No|Completed|July 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|N/A|N/A|No|||August 2012|August 9, 2012|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01413841||100071|
NCT01415206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01298|The Total Health Study|Extended Care Treatment of Multiple Risk Behaviors in Complex Patients||University of California, San Francisco|Yes|Active, not recruiting|August 2011|July 2015|Anticipated|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01415206||99969|
NCT01415219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007_0712|Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis|Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis||University Hospital, Lille|Yes|Completed|March 2008|December 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||December 2014|December 17, 2014|April 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01415219||99968|
NCT01411917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0249|Transversus Abdominis Plane Blocks for Ileostomy Takedown: A Prospective Study|Transversus Abdominis Plane Blocks for Ileostomy Takedown: A Prospective Study||University of Wisconsin, Madison|No|Enrolling by invitation|August 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2014|October 1, 2015|August 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411917||100217|
NCT01412177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-201102|OTO-104 for the Treatment of Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2b Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease||Otonomy, Inc.|Yes|Completed|November 2013|April 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|80 Years|No|||August 2015|August 18, 2015|July 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412177||100197|
NCT01412190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GR0803|Study to Evaluate Restylane Vital Light Using an Injector Device|An Open, Randomized, Single-centre, Intra-individual Controlled, Explorative, Safety and Efficacy Study Comparing Restylane Vital White With no Treatment in the Face, Back of the Hands and décolletage, Using an Injector Device||Q-Med AB|No|Completed|April 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01412190||100196|
NCT01411904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-049|A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia|A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia||University of New Mexico|No|Withdrawn|August 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|N/A|No|||December 2015|December 10, 2015|April 18, 2011||No|The NPs that we have been buying from a vendor show lot to lot variation. We are making our    own NPs, need to characterize them before we enroll new patients.|No||https://clinicaltrials.gov/show/NCT01411904||100218|
NCT01404273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002052|Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder|Functional MRI of an Open Trial of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder|ADHD|Massachusetts General Hospital||Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|49 Years|No|||July 2013|July 29, 2013|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01404273||100804|
NCT01404559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10193006|Measures of Gait Efficiency of Three Multi-Axial, Vertical Shock and Energy Storing-Return Prosthetic Feet During Simple & Complex Mobility Activities|Metabolic and Biomechanical Measures of Gait Efficiency of Three Multi-Axial, Vertical Shock and Energy Storing-Return Prosthetic Feet During Simple & Complex Mobility Activities||University of South Florida|Yes|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|28|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|May 31, 2011||No||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01404559||100782|
NCT01405638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00427|Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention|Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention|FAITH-CRC|New York University School of Medicine|Yes|Completed|March 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|451|||Male|50 Years|N/A|No|||November 2015|November 11, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405638||100699|
NCT01405872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108MS402|Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.|An Observational Study to Assess Persistence, Adherence, Quality of Life, and Treatment Satisfaction in Patients Beginning Therapy With the Avonex® PEN™.|PERSIST|Biogen|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|||Both|N/A|N/A|No|Non-Probability Sample|Multiple Sclerosis patients who have made the decision, along with their health care        provider, to begin therapy with Avonex PEN.|September 2014|September 5, 2014|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405872||100681|
NCT01405885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-101|A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus|Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA®-3P in Healthy Adults||Inovio Pharmaceuticals|No|Completed|May 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|10||Actual|116|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 28, 2014|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405885||100680|
NCT01405625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0358|Improving Parent Understanding of Instructions About Asthma Care|Improving Parent Understanding of Instructions About Asthma Care||New York University School of Medicine|Yes|Active, not recruiting|July 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 3, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01405625||100700|
NCT01411605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0718|Influence of Cardio-ventilatory Factors on Exercise Intolerance in Obese Adolescents: Effects of Exercise Training|Influence of Cardio-ventilatory Factors on Exercise Intolerance in Obese Adolescents: Effects of Exercise Training|VENTILOBE|University Hospital, Grenoble|No|Completed|September 2007|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01411605||100241|
NCT01411852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41071-B|Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma|Field Trial of Hypotensive Resuscitation Versus Standard Resuscitation in Patients With Hemorrhagic Shock After Trauma: A Pilot Trial|HypoResus|University of Washington|Yes|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|192|||Both|15 Years|N/A|No|||December 2014|December 30, 2014|August 3, 2011|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01411852||100222|One patient was determined to have been in police custody at the time of enrollment, which was a protocol violation. This patient was randomized to the controlled resuscitation group but was not included in the primary or secondary outcome analyses.
NCT01412099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03CA139943|Nutrition and Physical Activity Counseling for Nontraditional College Students|Feasibility of a Health Promotion Program for Nontraditional College Students||Boston Medical Center|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 2, 2012|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01412099||100203|
NCT01412112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3010-ACL|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2010|||||N/A|N/A|N/A||||||||||||||February 8, 2012|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01412112||100202|
NCT01413230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Record AP|Vitamin D Supplementation in Systemic Lupus Erythematosus|Evaluation of Immunologic Response After Vitamin D Supplementation in Patients With Systemic Lupus Erythematosus|VITALUP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|Samples With DNA|blood with RNA|Both|18 Years|N/A|No|Probability Sample|Patient with SLE|June 2011|November 23, 2011|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01413230||100118|
NCT01412684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU1196577|Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors|Pilot Study of Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors Arising in the Body and Tail of the Pancreas||University of Missouri-Columbia|No|Not yet recruiting|September 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|80 Years|No|Non-Probability Sample|surgical oncology clinic|August 2011|August 8, 2011|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412684||100159|
NCT01412697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#8520369|An Intervention Targeting Fruit and Vegetable Intake Among Rural Youth|Fruit and Vegetable Intake Among Rural Youth Following a School-based Randomized Controlled Trial||Virginia Commonwealth University|Yes|Completed|September 2008|November 2010|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1119|||Both|N/A|N/A|No|||February 2016|February 26, 2016|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01412697||100158|
NCT01409213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-199|A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)|Standardized Non-interventional Register Investigating the Daily Clinical Practice for the Treatment of Patients With Diabetes Mellitus Type 2 (SIRTA)|SIRTA|Merck Sharp & Dohme Corp.|No|Completed|August 2009|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1523|||Both|18 Years|N/A|No|Probability Sample|Participants with type 2 diabetes mellitus being treated in an office setting with        metformin at the individual maximal tolerated dose (at least four weeks on stable dose)        and had a resultant HbA1c >6.5% were selected for this study. The first five eligible        participants per site with type 2 diabetes mellitus and treatment with metformin were to        be enrolled.|August 2015|August 26, 2015|August 2, 2011|No|Yes||No|December 15, 2011|https://clinicaltrials.gov/show/NCT01409213||100425|
NCT01410019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071204|Gene Therapy for X-linked Severe Combined Immunodeficiency|Protocol No. 2 of Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self Retroviral Vector - SCID2|SCID2|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|December 2010|April 2016|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Male|N/A|12 Months|No|||November 2015|November 30, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01410019||100363|
NCT01415518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D589BL00022|Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients|Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.|SECURE2|AstraZeneca||Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|581|||Both|40 Years|N/A|No|||August 2014|August 11, 2014|August 8, 2011|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01415518||99945|
NCT01412203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H05-80505|Evaluating the Effectiveness of the Dissemination of Action Schools! BC|Evaluating the Effectiveness of the Dissemination of Action Schools! BC: A Socio-ecological Intervention to Increase Physical Activity and Healthy Eating in School Children|AS!BC|University of British Columbia|No|Completed|April 2005|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1529|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01412203||100195|
NCT01412502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-N/2009/CB-01|Post Traumatic Stress Among Relatives of Brain-dead, Withdrawal of Life Support, and Sudden Death Patients|Evaluation of Post Traumatic Stress Among the Nearest Relatives of Brain-dead, Withdrawal of Life Support, and Sudden Death Patients||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|June 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|294|||Both|18 Years|N/A|No|Non-Probability Sample|Participants are the nearest relatives (or "person-of-trust") of a patient who has passed        away in an intensive care unit (ICU) due to: (1) brain death with multiple organ donation        +/- tissues or (2) death via limitation and / or cessation of active treatment (LATA)        without brain death or (3) sudden death of a previously healthy patient (no physical or        mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor        brain death|October 2015|November 4, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01412502||100173|
NCT01412489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K 100801|Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel|Prevention of Postsurgical Uterine Synechia With HyalobarrierR Gel Endo in Hysteroscopic Myomectomy : a Prospective Multicenter Study|HYGEM|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|August 2011|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|189|||Female|18 Years|45 Years|No|||February 2016|February 23, 2016|May 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01412489||100174|
NCT01404572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-466|Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects|Randomized, Double Blind, Crossover Taste Assessment Study of Two Atazanavir Powder Formulations As Compared to a Reference Atazanavir Powder Formulation in Healthy Subjects||Bristol-Myers Squibb|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|12|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|July 27, 2011|Yes|Yes||No|March 13, 2013|https://clinicaltrials.gov/show/NCT01404572||100781|This was a taste assessment only; participants did not swallow any treatment blends.
NCT01404585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM126-004|Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate|RA|Bristol-Myers Squibb|Yes|Completed|September 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|123|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404585||100780|
NCT01404858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC2011|The Impact of Lifestyle Behavior on in Vitro Fertilization (IVF) Outcome|The Impact of Lifestyle Behavior on in Vitro Fertilization (IVF) Outcome||Boston IVF|No|Completed|September 2011|November 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12800|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women undergoing IVF at a infertility clinic who uses eIVF, an electronic medical        record collection entity specifically for IVF patients|February 2016|February 3, 2016|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404858||100759|
NCT01405105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVAMC-09-010|Exacerbating Factors in Inflammatory Bowel Disease|Exacerbating Factors in Inflammatory Bowel Disease||Dallas VA Medical Center|Yes|Completed|August 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|134|||Both|18 Years|N/A|No|Probability Sample|Flare of Crohn's disease Flare of ulcerative colitis Quiescent IBD (control)|February 2014|February 13, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01405105||100740|
NCT01405911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-105|Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)|A Phase II, Randomized, Placebo-Controlled, Parallel-group, Double-Blind, Dose Response Finding Clinical Trial to Study the Efficacy and Safety of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance Who Have Inadequate Glycemic Control on Diet/Exercise Therapy||Merck Sharp & Dohme Corp.|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|251|||Both|20 Years|N/A|No|||October 2015|October 30, 2015|July 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405911||100678|
NCT01406496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP1|Best Timing of Insulin Bolus Before Meals of Different Contents|The Effect of Food Content and Optimal Timing of Pre-meal Insulin Bolus on the Postprandial Glycemic Control in Children With Type 1 Diabetes||Kaplan Medical Center|Yes|Recruiting|August 2011|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|8 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 21, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01406496||100633|
NCT01406470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIG_SN_P3|Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency|An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in Subjects With Primary Immunodeficiency||Green Cross Corporation|Yes|Completed|September 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|2 Years|70 Years|No|||January 2014|January 9, 2014|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406470||100635|
NCT01412398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15076|Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan|Special Drug Use Investigation of Fosrenol (Investigation for Patients With Continuous Cyclic Peritoneal Dialysis)|FOSRENOL-CAPD|Bayer|No|Active, not recruiting|April 2009|October 2016|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|This study is all case investigation of which the enrollment period is one year, and all        patients in CCPD who received Fosrenol for hyperphosphatemia will be recruited.|March 2016|March 7, 2016|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01412398||100181|
NCT01412411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|480/Peds-ERC-05|Appropriate Complmentary Feeding Strategies in Infants|Appropriate Complementary Feeding Strategies in Infants: An Evaluation of Various Strategies to Assess the Growth and Health of the Infants.|CFS|Aga Khan University|Yes|Completed|October 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|470|||Both|6 Months|8 Months|Accepts Healthy Volunteers|||March 2008|August 8, 2011|August 3, 2011||||No||https://clinicaltrials.gov/show/NCT01412411||100180|
NCT01412710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIU-032511-01|The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes Mellitus|The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes||Florida International University|Yes|Completed|July 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|92|||Both|30 Years|70 Years|No|||March 2015|March 24, 2015|August 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01412710||100157|
NCT01412983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|713E|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens||Bausch & Lomb Incorporated|No|Completed|August 2011|October 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|August 8, 2011|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01412983||100136|
NCT01408693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHBS-TRAUMA-68/11|Minimal Invasive Anterior Approach Versus Trans-gluteal Approach for Hemi-arthroplasty in Femoral Neck Fractures|Minimal Invasive Anterior Approach Versus Trans-gluteal Approach for Hemi-arthroplasty in Femoral Neck Fractures - A Prospective Randomized Trial|MIS-CLAS|University Hospital, Basel, Switzerland|Yes|Recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|60 Years|N/A|No|||January 2016|January 19, 2016|June 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01408693||100464|
NCT01413516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIP|Varenicline In-Patient Study|A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization|VIP|Stanford University|Yes|Completed|August 2011|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 31, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01413516||100096|
NCT01409785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA unique vs LMA supreme|A Comparison of the LMA Unique and LMA Supreme in Children|A Prospective, Randomized Comparison of the LMA Unique and LMA Supreme in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|6 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|Children weighing 10 to 25 kg undergoing surgical or medical procedures under anesthesia        requiring a supraglottic airway device|October 2011|October 4, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409785||100381|
NCT01415232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10070214|A Novel Way to Estimate Epidural Depth in Morbidly Obese Parturient|The Use of Ultrasound With the Epidural Depth Equation (EQ-US) to Estimate Epidural Depth (Est-D) in Morbidly Obese Parturients (BMI>40Kg/m2) Will Have a High Correlation With Actual Epidural Needle Depth (ND)||University of Pittsburgh|Yes|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|160|||Female|14 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|August 9, 2011||No||No|February 1, 2013|https://clinicaltrials.gov/show/NCT01415232||99967|
NCT01415765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110216|MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma|Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2011|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|February 19, 2014|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01415765||99926|
NCT01403714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813650|Study of Percutaneous Renal Artery Intervention for Patient With Heart Failure|A Randomized Trial of Percutaneous Renal Intervention With Stenting for Patients With Heart Failure and Hemodynamically Significant Renal Artery Stenosis|STRETCH|University of Pennsylvania|No|Withdrawn|June 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|July 21, 2011|Yes|Yes|Inability to recruit eligible subjects|No||https://clinicaltrials.gov/show/NCT01403714||100847|
NCT01403974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1280.1|Phase I Trial of BI 836845 for Various Solid Cancer|A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit||Boehringer Ingelheim||Completed|July 2011|December 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 12, 2011||||No||https://clinicaltrials.gov/show/NCT01403974||100827|
NCT01403987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29983|Improving Performance of Paracentesis in Medical Residency Training|Improving Performance of Paracentesis in Medical Residency Training||Boston Medical Center|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|136|||Both|N/A|N/A|No|||September 2012|September 30, 2012|July 26, 2011||No||No|July 9, 2012|https://clinicaltrials.gov/show/NCT01403987||100826|Large number of participants lost to analysis because they forgot their secret personal ID number. The IRB had required we not have a way to link surveys to particular residents, and so lost power with loss of many residents.
NCT01412788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCH- BCS|Safety and Aesthetic Outcomes of Breast Conserving Surgery With Peri-areolar Incision Approach|Randomized Controlled Trial of Safety and Aesthetic Outcomes of Breast-conserving Surgery With the Peri-areolar Incision Approach||Peking Union Medical College Hospital|Yes|Recruiting|January 2007|||January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|60 Years|No|||August 2011|August 8, 2011|August 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01412788||100151|
NCT01404598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT 3012-X-114|Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male|A Phase 1 Study to Assess the Pharmacokinetics of Nitrates and Gamma-Hydroxybutyric Acid (GHB) After Oral Administration of Therapeutic and Supratherapeutic Doses of Naproxcinod in Healthy Male Subjects||NicOx|No|Completed|January 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 10, 2011|June 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01404598||100779|
NCT01404611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF289III/10IA04|Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients|A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution Compared to DF289 Otic Solution and to DF277 Otic Solution in the Treatment of Acute Otitis Media With Tympanostomy Tubes (AOMT) in Pediatric Patients||Salvat|No|Completed|June 2011|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|331|||Both|6 Months|12 Years|No|||October 2015|October 22, 2015|July 22, 2011|Yes|Yes||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01404611||100778|
NCT01404871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCF-Richter|Predicting Medication Response in Obsessive Compulsive Disorder|Predicting Medication Response in Obsessive Compulsive Disorder||Sunnybrook Health Sciences Centre|No|Completed|April 2009|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|26|||Both|18 Years|65 Years|No|||January 2013|January 30, 2013|February 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01404871||100758|
NCT01405924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-030|Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)|EMEND® IV In Salvage Treatment of Chemotherapy-Induced Vomiting|EVADE|Merck Sharp & Dohme Corp.|No|Terminated|October 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|111|||Female|18 Years|N/A|No|||October 2015|October 1, 2015|July 28, 2011|No|Yes|Low enrollment|No|October 24, 2014|https://clinicaltrials.gov/show/NCT01405924||100677|
NCT01407900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008619|Effects of Chimeric Natriuretic Peptide Versus Placebo in Stable Heart Failure and Moderate Renal Dysfunction|A Human Physiologic Study to Evaluate the Renal and Neurohumoral Effects of Dual NPR-A and NPR-B Activation With a Novel Chimeric Natriuretic Peptide (CD-NP)in Subjects With Stable Chronic Heart Failure and Moderate Renal Dysfunction||Mayo Clinic|No|Withdrawn|January 2014|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|45 Years|N/A|No|||June 2014|June 16, 2014|July 27, 2011|Yes|Yes|New technique for administration of drug, this is the old technique of administration.|No||https://clinicaltrials.gov/show/NCT01407900||100525|
NCT01407913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191/2010|Caudal Epidural Steroid Injections for Low Back Pain/Sciatic Lumbar Pain|Efficacy Study of Caudal Epidural Steroid Injections in Patients With Low Back Pain/Radiculopathy|FIA1|University of Ioannina|No|Completed|October 2010|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|85 Years|No|||May 2015|May 26, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407913||100524|
NCT01408173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-11-1|Clinical Study of Caffeine for Apnea of Prematurity|A Phase III Clinical Study of NPC-11 in the Treatment of Apnea of Prematurity. - Investigation of Safety, Efficacy and Pharmacokinetics of Caffeine Citrate -||Nobelpharma|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|28 Weeks|33 Weeks|No|||October 2013|October 29, 2013|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01408173||100504|
NCT01408459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPH2006|Adherence Dynamics for Whole Food Interventions in African-American Men|Adherence Dynamics for Whole Food Interventions in African-American Men|DAPH|University of Illinois at Chicago|Yes|Completed|January 2007|September 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Male|50 Years|N/A|Accepts Healthy Volunteers|||July 2011|August 2, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01408459||100482|
NCT01409473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511-03|Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer|A Prospective Protocol of Stereotactic Body Irradiation With Concurrent Intraprostatic Lesion Boost Utilizing Intensity Modulated Radiotherapy for Patients With Low- and Intermediate-Risk Prostate Cancer|Prostate SBRT|Rocky Mountain Cancer Centers|No|Withdrawn|August 2011|August 2022|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||February 2014|February 10, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409473||100405|
NCT01409486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0290-09-RMB-CTIL|Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry|Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry|LC-MS-MS|Rambam Health Care Campus|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|10000 full-term newborns born in Northern Israel|August 2011|August 3, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01409486||100404|
NCT01408953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tirgan 11-03|Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue|A Therapeutic Trial of Intralesional Bevacizumab in Patients With Non-pedunculated Keloids||Tirgan, Michael H., M.D.|No|Terminated|February 2012|April 2015|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|50 Years|No|||December 2012|December 3, 2012|July 29, 2011|Yes|Yes|Very low accrual rate.|No||https://clinicaltrials.gov/show/NCT01408953||100445|
NCT01410045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081204|Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome|Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome : Karyotypic, Clinical and Hormonal Criteria to Screen Patients|CRYO-X0|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|January 2011|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|47|||Female|1 Year|25 Years|No|||October 2015|October 15, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01410045||100361|
NCT01415258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VULNERABILITE-1103|Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre|Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre||Centre Oscar Lambret|No|Completed|March 2011|April 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|209|||Both|70 Years|N/A|No|Non-Probability Sample|This study concerns elderly patients (≥70 years) with solid tumors|May 2012|May 15, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01415258||99965|
NCT01415531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEB-MD-28|Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years) Who Have Stage 1 or 2 Essential Hypertension||Forest Laboratories|No|Completed|August 2011|April 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|641|||Both|18 Years|54 Years|No|||March 2013|March 18, 2013|August 10, 2011|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01415531||99944|
NCT01411930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080225|Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics|Acute Impact of IM Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics||Veterans Medical Research Foundation|No|Completed|March 2009|August 2011|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Male|40 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|September 15, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01411930||100216|
NCT01403727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_MtSinai_BiopTrial_V2|Electromagnetic Tracking of Devices During Biopsy Procedures|Electromagnetic Tracking of Devices During Biopsy Procedures||Philips Healthcare|No|Completed|November 2011|May 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing a liver biopsy procedure|May 2013|May 28, 2013|July 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403727||100846|
NCT01404000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL0801|Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal|Phase II Study Exploring Efficacy and Safety of Iodinated Activated Charcoal in COPD||PharmaLundensis AB|Yes|Completed|November 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|45 Years|80 Years|No|||November 2013|November 14, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404000||100825|
NCT01404013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP 39227|Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma|Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Leukotriene Modulator Montelukast Alone or Combined With Inhaled Corticosteroid on Cough Variant Asthma||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|February 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|99|||Both|18 Years|75 Years|No|||November 2012|July 11, 2014|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404013||100824|
NCT01404286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1059/06|Resistance Training and Sleep in the Elderly|The Effects of a Session of Resistance Training on Sleep Patterns in the Elderly||Federal University of São Paulo|No|Completed|January 2008|November 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|65 Years|80 Years|Accepts Healthy Volunteers|||January 2008|July 27, 2011|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01404286||100803|
NCT01404884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105|SUPRACOR for Myopia and Myopic Astigmatism|A Prospective Study To Evaluate The Safety And Effectiveness Of The SUPRACOR Presbyopic Treatment Algorithm For Myopia And Myopic Astigmatism Using LASIK|SUPRACOR|Technolas Perfect Vision GmbH|No|Active, not recruiting|June 2011|April 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|45 Years|85 Years|No|||May 2015|May 19, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404884||100757|
NCT01405157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0121007|A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 mg/mL To Methylprednisolone 16 Mg Tablet Under Fasting Conditions||Pfizer|No|Withdrawn|January 2012|February 2012|Anticipated|February 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|July 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405157||100736|
NCT01405170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0121008|A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 mg/mL To Methylprednisolone 32 mg Tablet Under Fed Conditions||Pfizer|No|Withdrawn|October 2011|October 2011|Anticipated|October 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|July 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405170||100735|
NCT01405404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L05031502|Engaging Low-Income Families in Prevention Programs|Engaging Low-Income Families in Prevention Programs||Rush University Medical Center|Yes|Completed|January 2007|June 2012|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|323|||Both|2 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 6, 2013|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01405404||100717|
NCT01405651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-6950POU002|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd|No|Completed|July 2011|||October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|July 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405651||100698|
NCT01405898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0703/91 Chronic|The Chronic Effects of Beetroot Juice in Hypertensive Subjects|The Chronic Effects of Beetroot Juice on Circulating Plasma Nitrate and Nitrite Levels and Blood Pressure in Hypertensive Subjects||Queen Mary University of London|No|Completed|January 2010|May 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|68|||Both|18 Years|85 Years|No|||December 2015|December 8, 2015|July 28, 2011||No||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01405898||100679|
NCT01406808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07272011-8149|Personal Genomics for Preventive Cardiology|A Pilot Randomized Trial of Personal Genomics for Preventive Cardiology||Stanford University|No|Active, not recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406808||100609|
NCT01406821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10162010-7109|Treatment of Acute and Chronic Ligament and Tendon Injuries With Platelet Rich Plasma|Randomized, Double-blind Clinical Trial of Platelet Rich Plasma for Treatment of Acute and Chronic Patellar Tendinosis||Stanford University||Recruiting|August 2009|June 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||July 2011|July 29, 2011|July 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406821||100608|
NCT01406210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025618|RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol|Prospective and Retrospective Study to Develop a Multi-center Randomized Study, to Determine if Prevention of GERD Related Aspiration by Surgical Fundoplication Improves Lung Allograft Function|RESULT|Duke University|No|Completed|September 2011|August 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only||2|Actual|647|Samples Without DNA|The bronchiolar lavage fluid (BALF) will be drawn during the bronchoscopy site and      approximately up to 10 ml of the bronchiolar lavage (BAL) fluid will be placed in 7 storage      vials (approximately 1.5 ml per vial), frozen using liquid nitrogen as the freezing agent,      and shipped on dry ice to Duke University Medical Center and/or University of Toronto.      Frozen samples will be stored at -80 °C to -85 °C until shipping, and the time between      collection and freezing will be recorded.      The tests used to assess the bronchiolar lavage fluid (BALF) may include, but are not      limited to the following: Gastrin, Pepsinogen I, Pepsinogen II, Lipopolysaccharide (LPS),      Bile acids (colorimetric and enzymatic approaches), and proteome assessment by mass      spectrometry.|Both|16 Years|N/A|No|Non-Probability Sample|Male or non-pregnant female subject ≥16 years of age with a double-lung transplant who        have undergone a 24-hour esophageal pH and/orimpedance probe study within 12 months prior        to transplant and/or within 12 months following transplantation.|September 2014|September 10, 2014|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406210||100655|
NCT01406223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028331|Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation|Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation|ConNicBrain|Duke University|Yes|Completed|July 2011|June 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|282|||Both|18 Years|50 Years|No|||June 2015|June 18, 2015|June 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406223||100654|
NCT01406509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT006|Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children|A Phase I Clinical Trial for Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|August 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|6 Months|5 Years|No|||April 2012|April 17, 2012|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01406509||100632|
NCT01406197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#10OB059|Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor|Uterine Abdominal Electromyography Measurements Before and After Progesterone Treatments for Preterm Labor||St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|July 2011|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|17 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|March 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406197||100656|
NCT01406483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Serial CABG|Platelet Reactivity in Patients on a Thienopyridine and Awaiting Coronary Artery Bypass Grafting|Platelet Reactivity in Patients on a Thienopyridine and Awaiting Coronary Artery Bypass Grafting|Serial CABG|Medstar Research Institute|No|Active, not recruiting|September 2010|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2013|August 8, 2014|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01406483||100634|
NCT01408186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APH Study|H2RA VS PPI for the Prevention of Ulcer Bleeding Associated With Low-dose Aspirin in Patients With Very High Ulcer Risk|Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Ulcer Bleeding Associated With Low-dose Aspirin in Patients With Very High Ulcer Risk (ASP (PPI_H2RA) Study)||Chinese University of Hong Kong|No|Recruiting|January 2011|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|332|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408186||100503|
NCT01408472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090257|NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement|CNTF Cell Implants For Glaucoma: A Phase I Study||University of California, San Diego|Yes|Completed|April 2011|October 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||December 2014|December 25, 2014|August 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01408472||100481|
NCT01408706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-019-ASH|The Prostate Immobilization Device Study|The Prostate Immobilization Device Study||Wheaton Franciscan Healthcare|No|Completed|August 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|N/A|No|||April 2015|April 13, 2015|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408706||100463|
NCT01408966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DarkChocolateinHTP2008|Effects of Dark vs. White Chocolate on the Postprandial Increase in Portal Pressure in Cirrhosis|Effects of Dark vs. White Chocolate on the Postprandial Increase in Portal Pressure in Cirrhosis||Hospital Clinic of Barcelona|No|Completed|August 2008|June 2009|Actual|October 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|80 Years|No|||August 2011|August 2, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408966||100444|
NCT01409772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-FB|Evaluation of the Clinical Practice of Using of a 70% Ethanol Lock Solution for the Prevention of Catheter Related Blood Stream Infections in Pediatric Patients Undergoing Intestinal Rehabilitation|Evaluation of the Clinical Practice of Using of a 70 % Ethanol Lock Solution for the Prevention of Catheter Related Blood Stream Infections in Pediatric Patients Undergoing Intestinal Rehabilitation||University of Nebraska|No|Withdrawn|December 2009|December 2011|Anticipated|June 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|N/A|25 Years|No|Non-Probability Sample|Short Bowel Syndrome|June 2012|June 15, 2012|May 22, 2009||No|PI decided to withdraw study|No||https://clinicaltrials.gov/show/NCT01409772||100382|
NCT01409499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011PTAHCC|Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)|A Prospective Multicenter Non-randomized Controlled Study of Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma|2011PTAHCC|Sun Yat-sen University|Yes|Recruiting|January 2011|January 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01409499||100403|
NCT01410058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO 001|Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction|Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo.||University of Zimbabwe|Yes|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|19|Samples With DNA|Whole blood, plasma, urine|Both|18 Years|N/A|No|Probability Sample|HIV Opportunistic infections clinic|December 2014|December 2, 2014|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01410058||100360|
NCT01410331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTCS-002|Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia|A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection to Cohorts of Adults With Critical Limb Ischemia||Juventas Therapeutics, Inc.|Yes|Completed|March 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|40 Years|N/A|No|||October 2014|October 22, 2014|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01410331||100339|
NCT01411683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORP-PT-004|Mandibular Overdentures Retained by Conventional or Mini Implants|Mandibular Overdentures Retained by Conventional or Mini Implants: a Randomized Clinical Trial||University of Sao Paulo|No|Active, not recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|45 Years|N/A|No|||July 2014|July 24, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01411683||100235|
NCT01411696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-OZU-09-011|Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)|||Allergan|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|289|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who received at least 2 injections of OZURDEX® to treat macular edema due to RVO        in at least one eye.|March 2013|March 4, 2013|August 5, 2011|Yes|Yes||No|March 4, 2013|https://clinicaltrials.gov/show/NCT01411696||100234|
NCT01403428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAS-SIU-11-005|Non Invasive Positive Pressure Ventilation in Status Asthmaticus|Effect Of Early Initiation Of Noninvasive Positive Pressure Ventilation On ICU Length Of Stay In Children With Status Asthmaticus, A Prospective Randomized Trial||Southern Illinois University|Yes|Withdrawn|June 2011|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|1 Year|18 Years|No|||December 2014|December 11, 2014|July 25, 2011||No|In a pilot of early noninvasive positive pressure ventilation, the children did so well that    early NPPV is now used in all children who meet criteria.|No||https://clinicaltrials.gov/show/NCT01403428||100869|
NCT01403441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12012010-7249|Radiosurgical Neuromodulation for Refractory Depression|Radiosurgical Neuromodulation for Refractory Depression||Stanford University||Enrolling by invitation|July 2010|December 2011|Anticipated|November 2011|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2|||Both|22 Years|65 Years|No|||July 2011|July 26, 2011|July 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01403441||100868|
NCT01404026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-001209|Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Due to Burn Injury|Cortical Modulation With Transcranial Direct Current Stimulation (tDCS) for Neuropathic Symptoms Following Burn Injury.||Spaulding Rehabilitation Hospital|No|Completed|June 2011|||January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|3|||Both|18 Years|64 Years|No|||April 2013|April 22, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01404026||100823|
NCT01404637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-02-052|Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)|The Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic BPH||Samsung Medical Center||Not yet recruiting|July 2011|October 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Male|45 Years|80 Years|Accepts Healthy Volunteers|||July 2011|July 30, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404637||100776|
NCT01404325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ADE36|Efficacy of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients|A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, MPA and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients|4EVERLUNG|Novartis|Yes|Recruiting|February 2012|February 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|232|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01404325||100800|
NCT01404338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0422|Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis|An Investigator-Initiated, Double-Blind, Vehicle-Controlled Study: Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis|Tachyphylaxis|Patel, Rita Vikram, M.D.|No|Completed|June 2011|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|N/A|No|||July 2011|July 27, 2011|July 25, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01404338||100799|
NCT01404299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCHC_FRAIL|Effects of a Nutritional Supplementation on the Functional Status of Frail Elders With Low Socioeconomic Status (SES)|Effects of a Protein-Energy Nutritional Supplementation on the Functional Status of Frail Older Adults With Low Socioeconomic Status: A Community-based Randomized Trial||Gangbuk-gu Community Health Center|Yes|Completed|August 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|87|||Both|65 Years|N/A|No|||January 2012|January 10, 2012|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404299||100802|
NCT01404312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5279|Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection|Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|May 2012|||November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3000|||Both|13 Years|N/A|No|||December 2015|December 28, 2015|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404312||100801|
NCT01405417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKE HH Endoscopy PV3725mc|Endoscopic Peroral Myotomy for Treatment of Achalasia|Endoscopic Peroral Myotomy for Treatment of Achalasia: Multicenter Study||Universitätsklinikum Hamburg-Eppendorf|Yes|Active, not recruiting|April 2011|April 2017|Anticipated|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01405417||100716|
NCT01405664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WBOCD|Study of the Effect of Weight Bearing Status on Patient Outcomes After Surgery for Osteochondral Defects of the Ankle|A Randomized, Controlled Clinical Trial to Evaluate the Effect on Patient Outcomes of Weight Bearing Status After Forage of Osteochondral Defects of the Ankle||Nova Scotia Health Authority|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||July 2011|August 11, 2011|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01405664||100697|
NCT01407081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2012-040|SMARTease Trial: Evaluating Stroke Help Distance Interventions to Improve Cognitive Performance Post-Stroke|SMARTease Trial - Turning SMART Goals Into Smart Actions: Evaluating Stroke Help Distance Interventions to Improve Cognitive Performance Post-Stroke|SMARTease|Nova Scotia Health Authority|No|Terminated|August 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|N/A|No|||July 2014|July 31, 2014|June 23, 2011||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01407081||100588|
NCT01406782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000706811|DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402|The Influence of KIR and HLA Genotype on the Response to Rituximab Immunotherapy in Patients With Follicular Lymphoma||National Cancer Institute (NCI)||Not yet recruiting|August 2011|||September 2011|Anticipated|N/A|Observational|N/A|||Anticipated|200|||Both|18 Years|N/A|No|||July 2011|July 29, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406782||100611|
NCT01408719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2010:216|Effect of Beta-Glucan on Cholesterol Lowering|Effect of Beta-Glucan Molecular Weight and Viscosity on the Mechanism of Cholesterol Lowering in Humans||University of Manitoba|No|Completed|November 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|45|||Both|18 Years|78 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|August 2, 2011||No||No|August 12, 2013|https://clinicaltrials.gov/show/NCT01408719||100462|
NCT01408979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MgSO4|Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia|Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial|MgSO4|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|August 2011|February 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|11 Years|50 Years|No|||April 2012|August 20, 2012|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01408979||100443|
NCT01408992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE541135|Thai-version Five Minute Hearing Test|The Evaluation of Thai-version Five Minute Hearing Test to Screen Hearing in Community|Thai_FMHT|Khon Kaen University|No|Completed|July 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|558|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 17, 2014|August 1, 2011||No||No|December 29, 2011|https://clinicaltrials.gov/show/NCT01408992||100442|
NCT01409265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-3385B|The Impact of Perceptual Impairment on Social Participation in Stroke Patients|The Impact of Perceptual Impairment on Social Participation in Stroke Patients||Chang Gung Memorial Hospital|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|40 Years|N/A|No|Probability Sample|the rehabilitation department of hospitals|September 2014|February 10, 2015|March 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01409265||100421|
NCT01409226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0051|3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women|A Study to Evaluate 3.0 Tesla Magnetic Resonance Imaging of the Breasts in High Risk Women||New York University School of Medicine||Withdrawn|August 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|70 Years|No|||April 2012|April 3, 2012|August 2, 2011|Yes|Yes|Due to slow accrual|No||https://clinicaltrials.gov/show/NCT01409226||100424|
NCT01409239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTS869|Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes|||Ohio State University|No|Completed|July 2011|December 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||November 2013|November 11, 2013|August 2, 2011|Yes|Yes||No|July 2, 2013|https://clinicaltrials.gov/show/NCT01409239||100423|Since this was a pilot study no formal power analysis was possible. It was hypothesized that IV insulin would be associated with lower LF/HF HRV.
NCT01409252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW007|Long Term Outcome After Hemorrhagic Stroke Surgery|Long Term Neurological and Cognitive Outcome After Neurosurgical Operation for Hemorrhagic Stroke (Intracerebral Hemorrhage)||Chinese University of Hong Kong|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|191|||Both|18 Years|N/A|No|Non-Probability Sample|Spontaneous intracerebral hemorrhage with neurosurgical operations|January 2013|January 10, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409252||100422|
NCT01409798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|324-10-EP|The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry|The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry||University of Nebraska|No|Recruiting|June 2010|June 2030|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Both|19 Years|N/A|No|Probability Sample|Otolaryngology, Head and Neck Surgery clinic patients|May 2015|May 27, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01409798||100380|
NCT01414478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10070074|High Protein Intake to Decrease Emesis and Promote Patient Satisfaction in Labor|A Prospective, Randomized Trial to Evaluate the Efficacy of High Protein Intake on the Incidence of Emesis and Promotion of Patient Satisfaction After Epidural Analgesia for Labor||University of Pittsburgh|Yes|Completed|August 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|150|||Female|14 Years|50 Years|Accepts Healthy Volunteers|||February 2013|February 1, 2013|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01414478||100025|
NCT01403181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZOSPA|Effect of Boceprevir on HCV-specific T Cell Responses|Effect of Boceprevir Therapy on HCV-specific T Cell Responses: Perspectives of Immune Monitoring and Immune Therapy|Boce-Par|Azienda Ospedaliero-Universitaria di Parma|Yes|Completed|April 2012|||October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|Samples With DNA|Sera and peripheral blood lymphomononuclear cells|Both|18 Years|70 Years|No|Probability Sample|Naïve genotype 1 chronic hepatitis C patients|November 2013|November 5, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403181||100888|
NCT01403454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-3536|Web-based Interactive Health Communication Application (IHCA) for Successful Home Dialysis|Web-based IHCA for Successful Home Dialysis|WISHED|St. Joseph's Healthcare Hamilton|Yes|Recruiting|March 2012|January 2014|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|152|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01403454||100867|
NCT01403467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-52-28|Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation|Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation||Ramathibodi Hospital|Yes|Completed|April 2009|January 2011|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|19 Years|75 Years|No|||December 2010|July 26, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403467||100866|
NCT01404650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 148|Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor|A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor||SCRI Development Innovations, LLC|No|Completed|December 2011|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404650||100775|
NCT01404897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM3274|Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals|Effects of a Modified Lower Carbohydrate, Higher Fat DASH Diet Plan on Plasma Lipids, Lipoprotein Particle Size, and Blood Pressure in Healthy Adults||Children's Hospital & Research Center Oakland|No|Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|22 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01404897||100756|
NCT01404624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-01-016|Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic Obesity|Increased Density of Ghrelin-Expressing Cells in the Gastric Fundus and Body in Prader-Willi Syndrome||Samsung Medical Center|Yes|Completed|January 2005|December 2006|Actual|||N/A|Observational|Observational Model: Case Control||1|Actual|58|||Both|5 Years|11 Years|Accepts Healthy Volunteers|Probability Sample|Sixteen PWS patients [age, 8.1 +- 2.6 yr; 12 males, 4 females; body mass index (BMI),        25+-1.5 kg/m2], 19 healthy normal lean subjects (age, 8.9 +- 1.4 yr; 14 males, 5 females;        BMI, 16.5 +- 0.42 kg/m2), 13 GHD patients (age, 9.1 +- 1.8 yr; 9 males, 4 females; BMI, 27        +- 1.8 kg/m2), and 10 healthy normal obese subjects (age, 8.7 +- 2.3 yr; 7 males, 3        females; BMI, 26 +- 1.7 kg/m2) were enrolled in the study. The subjects had no history of        GH treatment and were not being treated with GH at study commencement.|July 2011|July 27, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404624||100777|
NCT01405430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVECC|Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab|Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab|AVECC|Centre Leon Berard|No|Completed|May 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|63|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01405430||100715|
NCT01405937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-044|Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)|A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Concomitantly Administered With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Relapsed After Previous Treatment||Merck Sharp & Dohme Corp.|Yes|Completed|August 2011|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|20 Years|70 Years|No|||December 2015|December 23, 2015|July 28, 2011|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01405937||100676|
NCT01406236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030109|SAFE-PCI for Women|Study of Access Site for Enhancement of PCI for Women (SAFE-PCI for Women)|SAFE-PCI|Duke University|Yes|Terminated|August 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1787|||Female|18 Years|N/A|No|||January 2015|January 16, 2015|June 20, 2011||No|Study stopped for Statistical Futility. Low rate of bleeding events made it unlikely there    would be statistical power to show a difference in the 2 arms.|No||https://clinicaltrials.gov/show/NCT01406236||100653|
NCT01406249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRIN-GC1107-XParTS II|XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer|A Randomized Phase II Trial Comparing Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer (XParTS II)||Epidemiological and Clinical Research Information Network|Yes|Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|74 Years|No|||February 2016|February 2, 2016|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406249||100652|
NCT01406262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107085|Albiglutide Thorough ECG Study in Healthy Volunteers|A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)||GlaxoSmithKline|Yes|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|94|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 5, 2012|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406262||100651|
NCT01406548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPS804A2203|Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density||Novartis||Completed|July 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|44|||Female|45 Years|85 Years|No|||February 2015|February 18, 2015|July 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406548||100629|
NCT01406561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS103-MEN-002|Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy|A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy||Omeros Corporation|No|Completed|August 2011|December 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|344|||Both|18 Years|75 Years|No|||January 2013|January 3, 2013|July 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01406561||100628|
NCT01406574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252-11-001|Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma|A Multicenter, Open-label, Non-randomized, Dose-escalation, Therapeutic Exploratory Trial to Evaluate the Safety and Efficacy of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma||Otsuka Pharmaceutical Co., Ltd.|Yes|Completed|July 2011|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|79 Years|No|||May 2015|May 21, 2015|July 28, 2011||No||No|April 14, 2015|https://clinicaltrials.gov/show/NCT01406574||100627|
NCT01406795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-01312011-7377|The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses|Evaluation of GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface for the Treatment of Venous Occlusions and Stenoses||Stanford University||Recruiting|December 2010|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|July 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01406795||100610|
NCT01408732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sclerotherapy for Epistaxis|Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia|Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|July 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01408732||100461|
NCT01408745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-0802|Sternal Closure With STERNUMFIX in Patients With High Risk|Multicenter Controlled Study on the Safety and Efficacy of Sternal Closure With STERNUMFIX in Patients With High Risk|STEPHIX|Aesculap AG|No|Terminated|June 2008|November 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|166|||Both|N/A|N/A|No|||April 2015|April 13, 2015|July 19, 2011||No|terminatedd due to insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01408745||100460|
NCT01409005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-SNU-2011-01|Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer|A Phase II Trial of Gemcitabine Plus UFTE Combination Chemotherapy as Salvage Treatment in Oxaliplatin, Irinotecan and Fluoropyrimidine-Refractory Metastatic Colorectal Cancer||Seoul National University Bundang Hospital|No|Completed|June 2011|||February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||January 2014|February 10, 2014|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01409005||100441|
NCT01409291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16171|Impact of a Financial Success Education Program in Women and Children|Impact of a Financial Success Education Program on Perceived Financial Well-being, Hopefulness, Financial Competency, Financial Goal Achievement, Quality of Life, and Quantitative Health Outcomes in Women and Children: A Pilot Study||Creighton University|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|64|||Both|3 Years|N/A|No|Non-Probability Sample|Women enrolled in the Financial Success Program and their children|August 2014|August 11, 2014|July 29, 2011||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT01409291||100419|
NCT01409525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0233.CTIL|Rate of Microbial Colonization Over Native Calcified Cardiac Valves|Observational, Prospective, Exploratory Study to Evaluate the Rate of Microbial Colonization Over Native Calcified Cardiac Valves||Rambam Health Care Campus|No|Not yet recruiting|August 2011|October 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|cardiac valve tissue|Both|50 Years|N/A|No|Non-Probability Sample|Up to 200 eligible adult subjects, scheduled to undergo elective cardiac surgery in RAMBAM        medical center.|August 2011|August 3, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01409525||100401|
NCT01409512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117/2011|Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder|Observational Study on the Effect of Anticholinergic on the Autonomic System in Women With OAB||Rambam Health Care Campus|No|Not yet recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|75 Years|No|Non-Probability Sample|Patients were diagnosed as having OAB syndrome by an urogynecologist based on their        clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary        frequency or nocturia).|August 2011|August 3, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01409512||100402|
NCT01409811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10192|Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid|A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer||City of Hope Medical Center|Yes|Active, not recruiting|September 2012|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|N/A|N/A|No|||June 2015|June 23, 2015|August 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01409811||100379|
NCT01415297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP-1339-09-002|Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors|A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment||Niiki Pharma Inc.|No|Active, not recruiting|September 2009|May 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2012|December 31, 2012|August 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01415297||99962|
NCT01403194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004698|Continuous Positive Airway Pressure and Cardiometabolic Risk|Impact of Treatment of Sleep Disordered Breathing With Continuous Positive Airway Pressure (CPAP) on Cardiometabolic Risk Markers||Mayo Clinic|No|Terminated|March 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|11|||Both|8 Years|18 Years|No|||April 2014|April 14, 2014|April 6, 2011||No|Analysis was not done because only 1 subject was able to come back for the 3 month follow up    visit.|No|April 14, 2014|https://clinicaltrials.gov/show/NCT01403194||100887|Analysis was not done because only 1 subject was able to come back for the 3 month follow up visit.
NCT01403740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/HEM/001|Turkish Acquired Haemophilia Registry|Observational Acquired Haemophilia Registry|EHEM|Turkish Society of Hematology|No|Not yet recruiting|September 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|250|Samples Without DNA|Blood sample for coagulation factor determination|Both|N/A|N/A|No|Non-Probability Sample|Patients with acquired haemophilia diagnosed and/or treated in haematology clinics|June 2011|July 26, 2011|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403740||100845|
NCT01406678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WDHZ-TC-0801|Remote Ischemic Preconditioning in Coronary Artery Bypass Grafting With Cold Crystalloid Cardioplegic Arrest|Effect of Remote Ischemic Preconditioning in Patients Undergoing On-pump Coronary Artery Bypass Graft Surgery With Crystalloid Cardioplegic Arrest||University Hospital, Essen|Yes|Recruiting|July 2008|July 2015|Anticipated|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||April 2013|April 25, 2013|December 1, 2009||No||No||https://clinicaltrials.gov/show/NCT01406678||100619|
NCT01406691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kidflash|Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)|Treating Sleep Disruption in Teens With Millisecond Light Exposure During Sleep||VA Palo Alto Health Care System|No|Recruiting|December 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|57|||Both|15 Years|19 Years|No|||December 2015|December 7, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406691||100618|
NCT01437150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGH OD 11|Treatment of Acetabular Posterior Wall Fracture With Anatomical Locking Plate|Treatment of Acetabular Posterior Wall Fracture With Anatomical Locking Plate||Chinese PLA General Hospital|No|Completed|August 2011|February 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01437150||98292|
NCT01437163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ApiraTH655|Treatment of Androgenetic Alopecia in Males and Females|The Growth of Human Scalp Hair Mediated By Visible Red Light Laser and LED Sources.|LLLT|Apira Science, Inc.|No|Recruiting|September 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|September 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437163||98291|
NCT01437176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGH OD 12|Treatment of Intertrochanteric Fracture With New Type of Intramedullary Nail|Treatment of Intertrochanteric Fracture With New Type of Intramedullary Nail||Chinese PLA General Hospital|No|Recruiting|September 2011|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01437176||98290|
NCT01437501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003494|Broccoli Sprout Intervention in Qidong, P.R. China|Broccoli Sprout Intervention in Qidong, P.R. China||Johns Hopkins Bloomberg School of Public Health|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|291|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|September 15, 2011|Yes|Yes||No|May 2, 2013|https://clinicaltrials.gov/show/NCT01437501||98265|
NCT01433289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21490|Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals|Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects||Baylor College of Medicine|Yes|Recruiting|December 2010|July 2015|Anticipated|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433289||98586|
NCT01434303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03222|Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only|Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed||National Cancer Institute (NCI)|Yes|Active, not recruiting|January 2012|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|September 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434303||98510|
NCT01433562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1425-0310|Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients|Combination of DLBS1425 With Anthracyclin-based Regimen as a Neoadjuvant Therapy in Subjects With Stage II or III Breast Cancer||Dexa Medica Group|Yes|Completed|August 2011|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|65 Years|No|||May 2013|May 10, 2013|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433562||98565|
NCT01433575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25274|A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers|A Single-center, Open-label, Single Dose, Randomized, Two-way Cross-over Study to Investigate the Pharmacokinetics, Safety, and Tolerability of RO4917838 in Healthy Chinese Volunteers||Hoffmann-La Roche||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01433575||98564|
NCT01433796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LU-2010/672|Screening for Tuberculosis in HIV-infected Patients Eligible for Antiretroviral Treatment|Tuberculosis in HIV-infected Patients Managed in Health Centres in Ethiopia - Identification of a Screening Algorithm for Active Tuberculosis and Determination of Outcome of Combined Antituberculosis and Antiretroviral Treatment||Lund University|No|Completed|October 2011|December 2015|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|812|Samples Without DNA|Aliquoted plasma samples from consenting participants are stored at -80 C for analysis of      biomarkers of tuberculosis and for prognostic markers. Stool and urine samples are stored at      -20 C for analysis of alternative biomarkers of active tuberculosis.|Both|18 Years|N/A|No|Probability Sample|HIV-infected patients managed in health centres|March 2016|March 6, 2016|September 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01433796||98548|
NCT01435148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1759|Deep Brain Stimulation in Treatment Resistant Depression|A Double Blind Randomised Pilot Study of Deep Brain Stimulation in Patients With Treatment Resistant Unipolar Major Depressive Disorder.||North Bristol NHS Trust|Yes|Active, not recruiting|December 2006|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|8|||Both|18 Years|N/A|No|||September 2011|September 14, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01435148||98446|
NCT01435460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|634|Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)|A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC)||Bausch & Lomb Incorporated|No|Completed|August 2010|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|September 14, 2011|Yes|Yes||No|February 17, 2012|https://clinicaltrials.gov/show/NCT01435460||98422|
NCT01435473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000020203|Clinical Assessment of Thrombosis in Children After Heart Surgery|Clinical Assessment of Thrombosis in Children After Heart Surgery: The CATCH Study|CATCH|The Hospital for Sick Children|Yes|Completed|July 2011|December 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|N/A|18 Years|No|Non-Probability Sample|Children Undergoing Pediatric Heart Surgery at the Hospital for Sick Children who agree to        participate in the CATCH research study.|January 2016|January 29, 2016|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01435473||98421|
NCT01423032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISP_RI05|Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)|Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV||WiSP Wissenschaftlicher Service Pharma GmbH|No|Completed|September 2001|May 2009|Actual|May 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||August 2011|August 24, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01423032||99370|
NCT01423331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110409R|An Evaluation and Factor Analysis for Maternal Mental Health|An Evaluation and Factor Analysis for Maternal Mental Health - The Analytic Study of the Shin Kong Wu Ho-Su Memorial Hospital||Shin Kong Wu Ho-Su Memorial Hospital|Yes|Not yet recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|200|||Female|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|the pregnant women or mothers within six months after birth|August 2011|August 24, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423331||99347|
NCT01420315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDGT-01|The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease|The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease: a Crosssectional Multicenter Study in Turkey|DEVIT-ALZ|Gulhane Military Medical Academy|Yes|Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|502|||Both|50 Years|N/A|No|Probability Sample|The patients with Alzheimer's dementia will be included in the study.|February 2013|February 15, 2013|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420315||99578|
NCT01435967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114061|Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™|Observational, Ecological, Database Study on Epidemiology of Hospitalisations With Rotavirus Gastroenteritis Confirmed in Children Aged ≤5 Years, and Any Impact in the Change From Lyophilised to Liquid Formulation of Rotarix™, in Belgium||GlaxoSmithKline||Completed|September 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|5 Years|No|Non-Probability Sample|Children hospitalised due to laboratory confirmed rotavirus gastroenteritis in        approximately 8 hospitals across Belgium.|March 2015|March 6, 2015|September 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435967||98383|
NCT01436253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653-179|Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)|Non-Interventional Study In Hyperlipidemic Patients Who Do Not Reach Satisfactory Lipid Values With Existing Hypolipemic Therapy||Merck Sharp & Dohme Corp.|No|Completed|December 2008|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2196|||Both|30 Years|N/A|No|Non-Probability Sample|Croatian participants with inadequately controlled hyperlipidemia being treated in the        primary care setting|March 2015|March 27, 2015|September 15, 2011|No|Yes||No|December 3, 2013|https://clinicaltrials.gov/show/NCT01436253||98361|
NCT01435681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|405-2011|Can Short Latency Afferent Inhibition Give us Clues to Better DYT 1 Dystonia Treatments?|Can Short Latency Afferent Inhibition Give us Clues to Better Dystonia Treatments?||University of Florida|Yes|Active, not recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|5|||Both|10 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects scheduled to undergo pallidal deep brain stimulation surgery for DYT1 dystonia        will be enrolled up to 12 months for this pilot trial. Genetic test results confirming        DYT1 gene mutation will be reviewed prior to consenting research subjects. Patients who        are diagnosed with DYT1 dystonia and are candidates for DBS surgery will be indentified as        candidates for the research study. Additionally, subjects who have already undergone DBS        surgery will be identified as candidates.|March 2016|March 17, 2016|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435681||98405|
NCT01406366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R40MC05267-01-00|Evaluation of a Bright Futures Oral Health Intervention|Evaluation of a Bright Futures Oral Health Intervention for Pediatric Residents|BFOH|Continuity Research Network|No|Completed|September 2005|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|27|||Both|12 Months|35 Months|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric categorical residents in continuity clinics associated with CORNET practices        that volunteer to participate will be asked to participate in the study. Resident        inclusion criteria will include pediatric residents in their 1st or 2nd year of        categorical training. Parent-child dyad inclusion criteria include children between 12-35        months of age, accompanied by a legal guardian, who presents for a scheduled health        maintenance visit with their primary care provider who is a pediatric resident. Families        must have a means by which to be contacted (i.e., telephone, cell phone, or beeper number)        for follow-up. At least 2 numbers for communication will need to be solicited.|August 2010|July 29, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406366||100643|
NCT01406392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUBMISO|Sublingual Misoprostol for Induction of Labor|Sublingual Misoprostol 12,5 Mcg Versus Vaginal Misoprostol 25 Mcg for Induction of Labour of Alive and Term Fetus : Randomized Controlled Trial|SUBMISO|Professor Fernando Figueira Integral Medicine Institute|Yes|Recruiting|March 2011|December 2011|Anticipated|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||March 2011|July 29, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406392||100641|
NCT01406405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPNI2001-2|PEEK and Allograft Spacers Evaluation in Spinal Fusion Surgeries|Prospective Randomized Clinical Trial Comparing PEEK and Allograft Spacers in Patients Undergoing Spinal Intervertebral Fusion Surgeries|PEEK|Justin Parker Neurological Institute|No|Recruiting|July 2011|July 2016|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|240|||Both|18 Years|70 Years|No|Probability Sample|Boulder Neurosurgical Associates patients|August 2015|August 31, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01406405||100640|
NCT01436812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2551|Effect of Positive End Expiratory Pressure (PEEP) on Cerebral Oxymetry During Laparoscopy|International Reveiw Board of Gachon Univerity Gil Hospital||Gachon University Gil Medical Center|Yes|Completed|September 2011|June 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|20 Years|60 Years|No|||August 2013|August 8, 2013|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01436812||98318|
NCT01436825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15453|Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients|A Validation Study of the OPTIMS Pharmacokinetic Calculator for Clinician Use in Prophylactic Treatment of Patients With Haemophilia A.|OPTIMS|Bayer|No|Completed|October 2011|July 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|69|||Both|N/A|N/A|No|Non-Probability Sample|-  Patient with severe haemophilia A defined as residual factor VIII activity < 1%          -  or Patient with moderate haemophilia A (residual factor VIII activity >1% and <5%)             with clinical signs of frequent, severe bleeding episodes          -  Patient treated prophylatically with the same plasma or recombinant factor VIII for             at least 6 months|August 2015|August 7, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436825||98317|
NCT01437189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1851055|The Effects of Sertraline on Depression in Parkinson's Disease|Clinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's Disease|PD; PDD|Zhejiang University|No|Recruiting|August 2011|March 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|35 Years|75 Years|No|||August 2011|September 19, 2011|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01437189||98289|
NCT01434056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1341-11|Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging|Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging||Hospital Israelita Albert Einstein|Yes|Not yet recruiting|November 2011|February 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients waiting for liver transplantation with chronic end stage liver disease.|September 2011|September 13, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434056||98529|
NCT01434069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16569|Phase I Trial of Combination of FOLFIRI and SOM 230|Phase I Trial of Combination of FOLFIRI and SOM 230 in Advanced Gastrointestinal Malignancies||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2011|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|September 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434069||98528|
NCT01434316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03458|Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors|Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors||National Cancer Institute (NCI)|Yes|Recruiting|November 2011|||June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434316||98509|
NCT01434563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS HAND Study|The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -|The CNS HAND Study: The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort|CNS HAND|Holdsworth House Medical Practice|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|326|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients attending Holdsworth House Medical Practice, Sydney, Australia|October 2012|October 22, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01434563||98490|
NCT01434576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1025-C1106|Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics and Safety of HGS1025, a Human Monoclonal Anti-CCR5 Antibody, in Subjects With Ulcerative Colitis||Human Genome Sciences Inc.|No|Withdrawn|December 2011|||December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|September 1, 2011|No|Yes|Sponsor withdrew study for business reasons|No||https://clinicaltrials.gov/show/NCT01434576||98489|
NCT01434589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE 2248/10-1|Effects of a Manualized Short-term Treatment of Internet and Computer Game Addiction|Effects of a Manualized Short-term Treatment of Internet and Computer Game Addiction|STICA|Johannes Gutenberg University Mainz|Yes|Recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|192|||Male|17 Years|55 Years|No|||May 2015|May 7, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01434589||98488|
NCT01434602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160011|Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas|A Phase I-II Trial of Everolimus and Sorafenib in Patients With Recurrent High-Grade Gliomas||National Institutes of Health Clinical Center (CC)||Recruiting|October 2015|July 2020|Anticipated|July 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|118|||Both|18 Years|99 Years|No|||October 2015|January 26, 2016|September 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434602||98487|
NCT01434823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn 814063|24 Hour Intensivist Coverage in the Medical Intensive Care Unit|The Effects of 24-hour Intensivist Coverage in the Medical ICU||University of Pennsylvania|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1609|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 30, 2011||No||No|March 1, 2013|https://clinicaltrials.gov/show/NCT01434823||98470|
NCT01434836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS_Training|Neuro-modulation of the Depressed Brain Using Working Memory Training and Transcranial Direct Current Stimulation (tDCS)|Neuro-modulation of the Depressed Brain Using Working Memory Training and tDCS||University of Sao Paulo|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||May 2013|May 30, 2013|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01434836||98469|
NCT01435161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTP-AF|Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF|The Effect of Nifedipine Versus Telmisartan on Prevention of Atrial Fibrillation Recurrence in Hypertensive Patients With Paroxysmal Atrial Fibrillation by Intensive Lower Blood Pressure||The Second Affiliated Hospital of Chongqing Medical University|Yes|Completed|May 2007|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|160|||Both|40 Years|65 Years|No|||November 2012|November 15, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435161||98445|
NCT01435486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#11146/11|Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants|Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants: A Randomized, Double Blind, Controlled Trial (RCT)||Hamad Medical Corporation|Yes|Completed|November 2011|November 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|N/A|4 Months|No|||May 2014|March 31, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01435486||98420|
NCT01435499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1112|Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma|A Feasibility and Toxicity Study of a Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Secreting Allogeneic Melanoma Vaccine Administered Alone or in Combination With Cyclophosphamide in Subjects With Surgically Resected At-Risk Melanoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2011|September 2014|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|19|||Both|18 Years|N/A|No|||August 2013|August 26, 2013|September 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435499||98419|
NCT01435746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TROLL11|Transfusion Requirements After Orthotopic Liver Transplantation|A Randomized, Controlled Pilot Trial of Transfusion Requirements After Orthotopic Liver|TROLL|University Medical Center Goettingen|No|Not yet recruiting|November 2011|November 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435746||98400|
NCT01421966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-102|Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes|A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus||Macrocure Ltd.|Yes|Completed|August 2011|October 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|285|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|August 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421966||99452|
NCT01421979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED2011|Clinical Trial on the Effects of Caffeine and Taurine From Energy Drinks (EDs) to Parameters of the Cardiovascular System in Humans|||University of Hohenheim||Completed|April 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421979||99451|
NCT01424163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223HV101|Dexpramipexole Japanese PK Study|A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects||Knopp Biosciences|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01424163||99283|
NCT01420627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STP-2279-002|EZN-2279 in Patients With ADA-SCID|A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency||Sigma Tau Pharmaceuticals, Inc.|Yes|Recruiting|December 2013|March 2018|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|N/A|N/A|No|||November 2015|November 16, 2015|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420627||99555|
NCT01420640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT006367-01A1|Tai Chi and Aerobic Exercise for Fibromyalgia (FMEx)|Tai Chi and Aerobic Exercise for Fibromyalgia|FMEx|Tufts Medical Center|Yes|Completed|January 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Both|21 Years|N/A|No|||February 2016|February 9, 2016|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420640||99554|
NCT01420653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFT-MX-6|Maxigesic 325 Acute Dental Pain Study|Maxigesic 325 Acute Dental Pain Study: A Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 Versus Acetaminophen, Ibuprofen and Placebo in Participants With Acute Dental Pain||AFT Pharmaceuticals, Ltd.|No|Completed|April 2013|January 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|408|||Both|18 Years|60 Years|No|||January 2015|January 13, 2015|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420653||99553|
NCT01420666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFT-MX-7|Maxi-Analgesic Osteoarthritis (OA) Study|Maxi-Analgesic OA Study: Multicentre, Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 With Acetaminophen or Ibuprofen on Patients With Pain From Osteoarthritis||AFT Pharmaceuticals, Ltd.|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|45 Years|80 Years|No|||January 2016|January 4, 2016|August 16, 2011|Yes|Yes|The study was withdrawn for administrative reason|No||https://clinicaltrials.gov/show/NCT01420666||99552|
NCT01436266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30452|Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion|Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester|Preop Miso|Boston University|No|Terminated|July 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|2|||Female|18 Years|50 Years|No|||March 2014|March 18, 2014|September 15, 2011|Yes|Yes|Slow enrollment|No||https://clinicaltrials.gov/show/NCT01436266||98360|
NCT01437215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0002|Pilot Study of the Endologix Fenestrated Stent Graft System|Prospective, Multicenter, Single Arm Feasibility and Initial Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms||Endologix|No|Active, not recruiting|November 2010|August 2016|Anticipated|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|September 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01437215||98287|
NCT01436214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC-100-01|Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer|Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer||Adamis Pharmaceuticals Corporation|Yes|Active, not recruiting|August 2011|August 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||July 2015|July 15, 2015|August 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01436214||98364|
NCT01436227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0465|Pazopanib in Von Hippel-Lindau (VHL) Syndrome|A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome||M.D. Anderson Cancer Center|No|Recruiting|January 2012|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436227||98363|
NCT01436474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002062|Pilot Study of Varenicline to Treat Opioid Dependence|The Role of Varenicline in Treating Opioid Dependence: A Pilot Study||Mayo Clinic|Yes|Completed|June 2011|December 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|21|||Both|21 Years|N/A|No|||January 2013|January 22, 2013|June 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01436474||98344|
NCT01436487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B01-02|Study to Examine the Effects of MultiStem in Ischemic Stroke|Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke||Athersys, Inc|Yes|Completed|October 2011|December 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|140|||Both|18 Years|83 Years|No|||February 2016|February 12, 2016|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436487||98343|
NCT01436838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15916|China Betaferon Adherence, Coping and Nurse Support Study|Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin With Multiple Sclerosis||Bayer|No|Completed|March 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|75 Years|No|Non-Probability Sample|MS center located in general hospital|October 2015|October 23, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01436838||98316|
NCT01436851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/265|Nasal Provocation Testing in Occupational Rhinitis|Nasal Provocation Testing With Nasal Lavage in Allergic and Non-allergic Occupational Rhinitis|NPT|Haukeland University Hospital|No|Active, not recruiting|August 2011|December 2014|Anticipated|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2014|January 5, 2014|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01436851||98315|
NCT01437514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pSRT-201106|Effective Study of Preoperative Short-course Radiotherapy for the Advanced Resectable Rectal Cancer|the Effect of the Preoperative Short-course Radiotherapy for the cT3/cN+ Mid-lower Rectal Cancer: a Prospective Randomized Study||West China Hospital|Yes|Recruiting|August 2011|July 2018|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|320|||Both|18 Years|80 Years|No|||June 2015|June 18, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01437514||98264|
NCT01433835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001|Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers|Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers||Microbiotix, Inc.|No|Completed|September 2011|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|September 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01433835||98546|
NCT01434329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S8600-S9031-S9333-A|S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia|S8600-S9031-S9333-A, Identification of Differentially Methylated Genomic Regions That Are Prognostically Significant in AML||Southwest Oncology Group|No|Active, not recruiting|October 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled on S8600, S9031 or S9333 who consented to use of specimens for future        research|March 2015|March 5, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434329||98508|
NCT01434342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99211|Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients|Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study||Wake Forest NCORP Research Base|Yes|Active, not recruiting|October 2011|January 2015|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|146|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434342||98507|
NCT01434615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASHFR|Medtronic South Asian Systolic Heart Failure Registry|SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients.|SASHFR|Medtronic Cardiac Rhythm Disease Management|No|Active, not recruiting|October 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|502|||Both|N/A|N/A|No|||November 2012|November 8, 2012|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434615||98486|
NCT01434849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20110333H|Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)|Phase 1 Study of Topical Beta Blocker to Prevent the Proliferative Stage of Infantile Hemangioma|TiPPIH|The University of Texas Health Science Center at San Antonio|Yes|Terminated|July 2012|September 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26|||Both|N/A|6 Months|No|||January 2016|January 12, 2016|August 31, 2011||No|Difficulty with enrolled patients to complete trial.|No||https://clinicaltrials.gov/show/NCT01434849||98468|
NCT01434862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15401|Pramlintide Combined With Model Predictive Control Algorithm|Pramlintide Combined With Model Predictive Control Algorithm|ALM002|University of Virginia|No|Terminated|February 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Both|21 Years|65 Years|No|||April 2014|April 30, 2014|September 7, 2011|No|Yes|Modified study; created new study as a result of these modifications|No||https://clinicaltrials.gov/show/NCT01434862||98467|
NCT01435174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0123, HUM00051141|Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients|Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients||University of Michigan|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|74 Years|No|||June 2014|June 24, 2014|September 14, 2011|No|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01435174||98444|
NCT01435811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN-002|Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)|Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)|CIN-002|Children's Hospital Medical Center, Cincinnati|Yes|Completed|August 2011|November 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|60|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435811||98395|
NCT01435512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT073945|Strength At Home: Veterans' Program (PTSD-Focused Therapy for Anger and Relationship Conflict Among OEF/OIF Veterans)|Strength At Home: Veterans' Program (Formerly: Post-Traumatic Stress Disorder (PTSD)-Focused Therapy for Anger and Relationship Conflict Among Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans)||Boston VA Research Institute, Inc.|Yes|Completed|March 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 6, 2009||No||No||https://clinicaltrials.gov/show/NCT01435512||98418|
NCT01435772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POM-002|Extension Study for Patients Who Have Participated in a BMN 701 Study|A Long-Term Study for Extended BMN 701 Treatment of Patients With Pompe Disease Who Have Participated in a BMN 701 Study||BioMarin Pharmaceutical|Yes|Active, not recruiting|August 2011|September 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|13 Years|N/A|No|||February 2015|February 24, 2015|September 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435772||98398|
NCT01422707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBS003|Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess|Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)||University of Virginia|No|Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|7 Years|18 Years|No|||June 2012|June 12, 2012|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01422707||99395|
NCT01422720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-401|Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients|Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients||Bial - Portela C S.A.|No|Completed|April 2010|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|65 Years|N/A|No|||June 2015|June 17, 2015|July 29, 2011||No||No|May 9, 2014|https://clinicaltrials.gov/show/NCT01422720||99394|
NCT01424449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113549|A PET Study in Healthy Volunteers|A Positron Emission Tomography Study in Healthy Male Subjects to Examine the Test-retest Reliability of the D2/3 Agonist Radiotracer [11C]PHNO||GlaxoSmithKline|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|7|||Male|22 Years|55 Years|Accepts Healthy Volunteers|||March 2012|December 13, 2012|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01424449||99261|
NCT01423591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04578|Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica|Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica: a Double Blind Placebo Controlled Trial||Hospital Universitario Marqués de Valdecilla|Yes|Active, not recruiting|June 2007|December 2011|Anticipated|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|50 Years|No|||August 2011|August 25, 2011|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01423591||99327|
NCT01423877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00808|Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35|||New York University School of Medicine|Yes|Completed|August 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|55|||Both|18 Years|80 Years|No|Probability Sample|Bariatric Clinic at Bellevue Hospital|March 2014|March 31, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423877||99305|
NCT01421277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0974-076|Study of Treatment Used for Migraine Headaches (MK-0974-076)|Migraine Attack Study of Treatment, Efficacy and Resource Use (MASTER) - McKesson Substudy (MK-0974-076)|MASTER|Merck Sharp & Dohme Corp.|No|Terminated|May 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|216|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with physician-diagnosed migraine (with or without aura) who have had at        least two, but not more than 8 moderate to severe migraines during the 30 days prior to        screening. Participants must have received a triptan prescription 3 months (± 2 weeks)        prior to being identified by the physician, must have been triptan-naïve prior to that        initial prescription, and must have taken triptan medication at least once within 6 months        prior to the date of informed consent for screening.|October 2015|October 1, 2015|July 28, 2011|No|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01421277||99505|
NCT01437228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gungorduk13|Does Preoperative Vaginal Preparation With Povidone-iodine Before Cesarean Delivery Reduce the Risk of Endometritis?|||Erzincan Military Hospital||Completed|October 2010|April 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|668|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 16, 2011|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437228||98286|
NCT01436240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-133|Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients will be recruited from five different collaborating sites: MSKCC/Ralph        Lauren Center for Cancer Care and Prevention, MD Anderson, University of Miami, Stroger        Hospital, and St. Joseph's Hospital. Approximately 40 participants will be enrolled at        MSKCC; 120 participants will be enrolled in total.|June 2015|June 25, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436240||98362|
NCT01436500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-IFE-001|Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients|A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome||Cumberland Pharmaceuticals|Yes|Completed|October 2011|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|55|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436500||98342|
NCT01436513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2811002|A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.|Phase 1, Open-Label, Randomized, Single-Dose, Crossover Bioequivalence And Food Effect Study For A New Formulation Of Premarin Compared With A Reference Tablet In Japanese Healthy Postmenopausal Women||Pfizer||Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|72|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 14, 2012|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01436513||98341|
NCT01437202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-H-64|Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia|Retrospective Study to Validate Pharmacogenetics Model for Imatinib Metabolism in Patients With Chronic Myeloid Leukemia|VATIC|Asan Medical Center|No|Completed|September 2011|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|100|Samples With DNA|whole blood 4cc|Both|18 Years|N/A|No|Non-Probability Sample|Patients who were diagnosed as chronic myeloid leukemia, treated with imatinib more than 3        months, at Asan Medical Center, Seoul, Korea.|July 2014|July 8, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437202||98288|
NCT01433809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002846|Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm|Biomarkers in Thyroid Cancer||Mayo Clinic|No|Completed|June 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|Samples With DNA|Blood, RNA/DNA from fine needle aspirate biopsies of thyroid nodules, fresh frozen surgical      tissue, formalin fixed paraffin embedded tissue.|Both|18 Years|90 Years|No|Non-Probability Sample|All individuals undergoing fine needle biopsy for diagnosis of thyroid cancer, who provide        written consent to enter the study.|January 2014|January 20, 2014|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433809||98547|
NCT01434095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81004|Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy|||Surugadai Nihon University Hospital|No|Completed|October 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|30 Years|80 Years|No|||September 2011|September 14, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434095||98526|
NCT01434082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JIA|Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis|Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis|JIA|University of Washington|Yes|Recruiting|September 2011|February 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|150|Samples With DNA|Morning urine and saliva|Both|6 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Children with arthritis will be recruited from the Division of Pediatric Rheumatology             at Seattle Children's Hospital.          -  Children without arthritis will be recruited from the King COunty community.|September 2011|September 12, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01434082||98527|
NCT01434914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT-UKE-2011|Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds|Randomized, Double-blind, Single-center, Placebo-controlled Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds||Schülke & Mayr GmbH|No|Terminated|October 2011|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|September 13, 2011||No|early termination due to poor recruitment|No||https://clinicaltrials.gov/show/NCT01434914||98464|
NCT01435187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813839|Prematurity and Respiratory Outcomes Program (PROP)|Prematurity and Respiratory Outcomes Program (PROP) Core Database Protocol|PROP|University of Pennsylvania|Yes|Active, not recruiting|August 2011|April 2016|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|Samples With DNA|Saliva for DNA, Urine and Tracheal Aspirate|Both|N/A|7 Days|No|Non-Probability Sample|Infants admitted to the Neonatal Intensive Care Unit who are < 29 weeks gestational age|July 2015|July 14, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435187||98443|
NCT01434888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201150|Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops|A Phase I, Randomized, Double-masked, 3-period Cross-over Clinical Study to Compare the Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops to Those of Preservative-free Tafluprost 0.0015% and Timolol 0.5% Eye Drops in Healthy Volunteers||Santen Oy|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01434888||98466|
NCT01434901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0861C|The Effects of Bethanechol on Glucose Homeostasis|The Effects of Bethanechol, a Muscarinic Agonist, on Plasma Insulin, Glucagon, and Glucose Levels in Humans With and Without Type 2 Diabetes Mellitus||Washington University School of Medicine|Yes|Active, not recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434901||98465|
NCT01435824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000021187|Bioavailability of Amoxicillin Dissolved in Human Milk|Bioavailability of Amoxicillin Dissolved in Human Milk: An Adult Volunteer Study as a First Step Towards Defining Drug Doses for Infants||The Hospital for Sick Children|No|Completed|June 2011|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435824||98394|
NCT01436084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0427|SB1518 for Patients With Myelodysplastic Syndrome (MDS)|Phase II Study of SB1518 for Patients With Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Terminated|December 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|September 15, 2011|Yes|Yes|Colloborating sponsor decision.|No||https://clinicaltrials.gov/show/NCT01436084||98374|
NCT01436071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115283|Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma|A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled Corticosteroids||GlaxoSmithKline|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|248|||Both|12 Years|N/A|No|||August 2014|September 4, 2014|September 15, 2011|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01436071||98375|
NCT01422733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBS004|Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction|Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction in Overweight Early Pubertal Girls With Androgen Excess (CBS0004)||University of Virginia|No|Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|7 Years|16 Years|No|||June 2012|June 12, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422733||99393|
NCT01422746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBS005|Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess|Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess (CBS005)||University of Virginia|No|Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|7 Years|18 Years|No|||June 2012|June 12, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422746||99392|
NCT01422759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBS006|Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess|Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess (CBS006)||University of Virginia|No|Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|7 Years|18 Years|No|||June 2012|June 12, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422759||99391|
NCT01421290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/399|Treatment of Cartilage Lesions in Flanders Today|Clinical Outcome After Treating Cartilage Defects in the Knee by Surgical or Conservative Means||University Hospital, Ghent|No|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|50 Years|No|||June 2015|June 2, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01421290||99504|
NCT01421303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A3-4675|Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.|Work Productivity In A Cohort Of Employed Ankylosing Spondylitis Patients Treated With Etanercept|AS@WORK|Pfizer|No|Completed|October 2009|December 2013|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Probability Sample|AS patients visiting the rheumatologist for which the decision has been taken to prescribe        Enbrel|December 2014|December 5, 2014|August 19, 2011||No||No|December 5, 2014|https://clinicaltrials.gov/show/NCT01421303||99503|
NCT01424436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113043|Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient|Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment||GlaxoSmithKline|No|Completed|May 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|19|||Both|55 Years|85 Years|No|||May 2012|September 5, 2013|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01424436||99262|
NCT01421862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC-9140|Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment|The Genetics of "Non-Response" in Adult AML||National Cancer Institute (NCI)||Not yet recruiting|September 2011|||October 2011|Anticipated|N/A|Observational|N/A|||Anticipated|400|||Both|18 Years|65 Years|No|||August 2011|July 9, 2013|August 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01421862||99460|
NCT01436903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|743/2010|Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length|Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length, a Questionnaire Investigation on 290 Patients||Medical University of Vienna|No|Completed|September 2010|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|290|||Female|30 Years|55 Years|No|||March 2013|March 7, 2013|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01436903||98311|
NCT01436916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0023051981|Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus|Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency||Postgraduate Institute of Medical Education and Research|Yes|Completed|September 2011|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|50|||Both|20 Years|N/A|No|||October 2015|October 23, 2015|September 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436916||98310|
NCT01436526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14588|Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban|Single-dose, Open-label, Randomized, 2-way Crossover Pivotal Bioequivalence Study of 2x5 mg Tablets Rivaroxaban Versus 1x10 mg Tablet Rivaroxaban Under Fasted Condition in Healthy Subjects||Bayer|No|Completed|August 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|September 16, 2011||No||No|November 18, 2011|https://clinicaltrials.gov/show/NCT01436526||98340|
NCT01436864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHSWKH902005|A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD|A Phase 3 Clinical Trial of Intravitreal Injections of Human Recombinant Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|PHOENIX|Chengdu Kanghong Biotech Co.,Ltd.||Completed|August 2011|November 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|50 Years|N/A|No|||March 2014|March 21, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01436864||98314|
NCT01433588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALMERP|The Calmer Project|Calmer: A Novel Approach for Treating Infant Pain||Children's & Women's Health Centre of British Columbia|No|Recruiting|October 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|27 Weeks|36 Weeks|No|||August 2015|August 11, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433588||98563|
NCT01433601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DotArv_Vietnam|Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure|A Randomised Controlled Trial to Assess Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure|DotArv|Karolinska Institutet|Yes|Active, not recruiting|August 2007|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|640|||Both|18 Years|59 Years|No|||September 2011|September 13, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433601||98562|
NCT01433614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEX trial|Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer|Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study|TEX|Karolinska University Hospital|Yes|Completed|December 2002|December 2013|Actual|June 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01433614||98561|
NCT01434940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMAD|Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression|Early Oculomotor Markers in Alzheimer's Disease: Test of Predictive Value in the Differential Diagnosis Depression/Alzheimer|MOMAD|Centre Hospitalier Universitaire de Besancon|Yes|Recruiting|April 2010|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|288|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 15, 2011|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01434940||98462|
NCT01434953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC6382|Prehypertension Labeling|Diagnostic Labeling: Effect on White Coat Hypertension||Columbia University|No|Active, not recruiting|July 2009|May 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 14, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01434953||98461|
NCT01434355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEPI10N1|DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings|Molecular Epidemiology of Pediatric Germ Cell Tumors||Children's Oncology Group|No|Recruiting|November 2011|||November 2015|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|932|Samples With DNA|Saliva and tissue|Both|N/A|19 Years|No|Non-Probability Sample|Patients with a primary diagnosis of germ cell tumor (GCT) meeting other criteria.|November 2015|November 16, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434355||98506|
NCT01434927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07CE2009|The Clinical Acceptability of Unsedated Colonoscopy|Unsedated Colonoscopy: An Option For Some But Not For All||Valduce Hospital|No|Completed|October 2009|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|964|||Both|18 Years|80 Years|No|Non-Probability Sample|all consecutive 18-80 year-old outpatients presenting to undergo open-access colonoscopy        for routine indications were considered eligible to enter the study.|September 2011|September 13, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01434927||98463|
NCT01435564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0030018|Pilot Study: Mobile Phone Based Physical Activity in Sedentary Men and Women|Innovations in Mobile Phone Based Physical Activity- A Pilot of Clinical Trial in Sedentary Men and Women||University of California, San Francisco|No|Withdrawn|June 2011|June 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|21 Years|69 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435564||98414|
NCT01435200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV iron 2|Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy|Prevention of Blood Transfusion With Intravenous Iron in Gynecologic Cancer Patients Receiving Platinum Based Chemotherapy||Chulalongkorn University|No|Completed|June 2011|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Female|20 Years|70 Years|No|||July 2013|July 22, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435200||98442|
NCT01435213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3099002|Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline|Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline - a PET Study in Healthy Human Subjects|AIMI|University of Turku|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|10|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||February 2013|February 15, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435213||98441|
NCT01435226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-248-0131|GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared With GS-5885, GS-9451 With Tegobuvir or RBV in Treatment-Experienced Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection||Gilead Sciences|Yes|Completed|September 2011|July 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|170|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|September 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435226||98440|
NCT01435525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00011|Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication||AstraZeneca||Completed|September 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|369|||Both|N/A|N/A|No|Non-Probability Sample|Patients to whom triple therapy for H.pylori eradication to stomach is started after        endoscopic treatment for gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic        thrombocytopenic purpura, or early gastric cancer as the approved indication of Nexium.        Patients with H.pylori negative at the time when the triple therapy is started are        excluded.|April 2014|April 14, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435525||98417|
NCT01435798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1NS41503|Clinical Neuropharmacology of Pain in Spinal Cord Injury|Clinical Neuropharmacology of Pain in Spinal Cord Injury||Brigham and Women's Hospital|Yes|Completed|August 2000|January 2008|Actual|January 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|16||Actual|24|||Both|18 Years|70 Years|No|||September 2011|September 16, 2011|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435798||98396|
NCT01436643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE06|Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression|A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression|REGAIN|Novartis||Terminated|November 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|54|||Both|18 Years|65 Years|No|||September 2014|September 24, 2014|September 16, 2011||No|Due to slow enrollment the study was terminated early|No|September 1, 2014|https://clinicaltrials.gov/show/NCT01436643||98331|
NCT01436656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGX818X2101|A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma|A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma||Array BioPharma|No|Active, not recruiting|September 2011|||October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01436656||98330|
NCT01436669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC 10/H0724/14|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2011|||||N/A|N/A|N/A||||||||||||||October 17, 2012|September 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436669||98329|
NCT01436682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN11-073|Assisted Nerve Blocks|||McGill University Health Center|No|Completed|September 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|90 Years|No|Non-Probability Sample|Patient undergoing surgery which necessitates a peripheral nerve block to relieve        postoperative pain.|October 2013|October 24, 2013|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01436682||98328|
NCT01423604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18424-262|Study of Ruxolitinib in Pancreatic Cancer Patients|A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)|RECAP|Incyte Corporation|Yes|Active, not recruiting|August 2011|June 2016|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423604||99326|
NCT01423344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFE-05-02|Clinical Evaluation of the Serum Free Light Chain Analysis|Assessment of the Value of the Free Kappa and Free Lambda Light Chain Assay in Clinical Evaluation of Response to Treatment||University of Southern Denmark|Yes|Recruiting|February 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|serum and urine|Both|N/A|N/A|No|Non-Probability Sample|Newly diagnosed patients with multiple myeloma, with medical needs and known patients with        multiple myeloma at there 1st relapse and medical needs|August 2011|August 24, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423344||99346|
NCT01420718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p/439/d|Partial Pulpotomy on Caries Free Human Teeth|Partial Pulpotomy on Caries Free Human Teeth Using iRootBP and White ProRoot MTA: a Randomized Controlled Trial||Islamic Azad University, Tehran|No|Completed|June 2011|March 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||March 2012|March 25, 2012|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01420718||99548|
NCT01420328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED7120311A|To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects|To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects||Kaleida Health|No|Active, not recruiting|May 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01420328||99577|
NCT01420341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE541074|Co-trimoxazole as Maintenance Therapy for Meliodosis|A Comparison Between 12 vs. 20 Weeks of Co-trimoxazole as Maintenance Therapy for Melioidosis||Khon Kaen University|No|Recruiting|August 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|15 Years|N/A|No|||November 2015|November 17, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420341||99576|
NCT01421316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/504|Hair-sparing Whole Brain Radiotherapy|Reducing Hair Loss With Volumetric Arc Therapy in Patients Treated With Whole Brain Radiotherapy: a Phase II Trial||University Hospital, Ghent|No|Terminated|January 2013|October 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|August 17, 2011||No|No reduction in hair loss 1 month after treatment|No||https://clinicaltrials.gov/show/NCT01421316||99502|
NCT01421329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813970-1|A Program to Increase Exercise|||University of Pennsylvania|No|Not yet recruiting|September 2011|September 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|280|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 17, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01421329||99501|
NCT01437254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DX-CPERT-001/Ethics 25831|A Prospective Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer|To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer||AHS Cancer Control Alberta|No|Active, not recruiting|October 2011|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|79 Years|No|||September 2014|September 29, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437254||98284|
NCT01437527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D465|Body Image Therapy in Anorexia Nervosa|Body Image Therapy in Anorexia Nervosa|PIPA|Centre Hospitalier St Anne|No|Completed|December 2011|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Female|18 Years|N/A|No|||February 2016|February 11, 2016|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01437527||98263|
NCT01433302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0455|Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass|Determination of the Effect of Lymphatico-venous Bypass Surgery on Inflammatory Responses and Tissue Fibrosis||M.D. Anderson Cancer Center|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|UT MD Anderson Cancer Center patients, 18 years of age or older, undergoing        lymphatico-venular bypass for stage II or greater lymphedema.|May 2015|May 5, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01433302||98585|
NCT01433315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002121|Physiologic Effects of Sleep Restriction|Physiologic Effects of Sleep Restriction||Mayo Clinic|No|Recruiting|October 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01433315||98584|
NCT01433848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arquivo1|Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Events|Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Adverse Events||Rio de Janeiro State University|No|Enrolling by invitation|June 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Will be selected patients with cirrhosis (diagnosed by clinical criteria and ultrasound        and / or liver biopsy) at different evolutionary stages os disease in the hepatology`s        service at the University Hospital Pedro Ernesto.|September 2011|September 13, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433848||98545|
NCT01434966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT11-16215|Changes in Quadriceps Function Following Local or Distant Interventions in Individuals With Patellofemoral Pain|Changes in Quadriceps Function Following Local or Distant Interventions in Individuals With Patellofemoral Pain||Creighton University|No|Completed|September 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|47|||Both|15 Years|50 Years|No|||December 2015|December 10, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01434966||98460|
NCT01435837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09433|Interaction of Caffeine and Hydration on Voice|Effects of the Interaction of Caffeine and Hydration on Voice Performance||Southern Illinois University Carbondale|No|Completed|October 2010|May 2013|Actual|May 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|September 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01435837||98393|
NCT01436097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WTE-814279|Randomized Trial of Healthy Eating Interventions|Financial Incentives for Healthy Eating: A Randomized Pilot Study|WTE|University of Pennsylvania|Yes|Completed|October 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 14, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436097||98373|
NCT01435538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPA-EQCP-003|European Quality of Care Pathways Study on the Effect of Care Pathways on Interprofessional Teamwork (EQCP-TEAM)|The Impact of Care Pathways on Interprofessional Teamwork: an International Cluster Randomized Controlled Trial|EQCP-TEAM|European Pathway Association|Yes|Enrolling by invitation|May 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|475|||Both|N/A|N/A|No|||September 2011|September 15, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435538||98416|
NCT01436708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100034-F|The Association of Pelvic Organ Prolapse Severity and Urinary Symptoms/Sexual Function|||Far Eastern Memorial Hospital||Recruiting|June 2011|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Female|20 Years|99 Years|No|Probability Sample|all women with pelvic organ prolapse , especially with cystocele, in our outpatient        department or the room of urodynamic studies.|February 2016|February 22, 2016|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01436708||98326|
NCT01437020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-I-N222|SCH708980 With and Without AmBisome for Visceral Leishmaniasis|A Phase I/II Clinical Trial To Assess the Safety and Biologic Activity of the Anti-IL-10 Monoclonal Antibody, SCH708980, in Combination With AmBisome(Registered Trademark), Versus That of Placebo in Combination With Ambisome(Registered Trademark), in Subjects With Visceral Leishmaniasis (VL)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|60 Years|No|||August 2013|August 26, 2013|September 16, 2011|No|Yes|Drug Product no longer available.|No||https://clinicaltrials.gov/show/NCT01437020||98302|
NCT01423643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00033421|HCV/HIV Coinfection: Antiviral Therapy and Fibrosis|HCV/HIV Coinfection: Antiviral Therapy and Fibrosis||Johns Hopkins University|No|Completed|March 2001|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1250|Samples Without DNA|Frozen serum and plasma samples. Liver biopsy fixed slides.|Both|18 Years|99 Years|No|Non-Probability Sample|Adults with HIV and Hepatitis C in the metropolitan Baltimore area. Preference given to        those enrolled in the Johns Hopkins Infectious Diseases Outpatient Clinic.|February 2016|February 22, 2016|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423643||99323|
NCT01423903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|266-09-202|Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer|Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|February 2010|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423903||99303|
NCT01423890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2011-ONCOTYPEDX|A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer|A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer|ONCOTYPEDX|Ontario Clinical Oncology Group (OCOG)|No|Completed|January 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1011|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423890||99304|
NCT01421342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|576|VA Augmentation and Switching Treatments for Improving Depression Outcomes|CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)|VAST-D|VA Office of Research and Development|Yes|Active, not recruiting|December 2012|April 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1518|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01421342||99500|
NCT01421355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03DK094510-01|A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus|A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus||Brigham and Women's Hospital|Yes|Completed|May 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|August 19, 2011||No||No|June 23, 2014|https://clinicaltrials.gov/show/NCT01421355||99499|
NCT01421888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110217|The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity|The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity||National Institutes of Health Clinical Center (CC)||Terminated|August 2011|April 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|4|||Both|2 Years|N/A|Accepts Healthy Volunteers|||April 2013|February 19, 2014|August 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01421888||99458|
NCT01421901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRA CT Number 2011-002977-44|Antibiotics Versus Surgery in Acute Appendicitis|Antibiotics vs.Surgery in Acute Appendicitis;an Intention to Treat Prospective Randomised Study. The ASAA-study|ASAA|A.O. Ospedale Papa Giovanni XXIII|Yes|Recruiting|August 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|18 Years|65 Years|No|||June 2014|June 16, 2014|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01421901||99457|
NCT01437267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01_05TP|Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants|A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants||Novartis|Yes|Completed|October 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|120|||Both|6 Weeks|59 Months|Accepts Healthy Volunteers|||March 2014|March 5, 2014|September 19, 2011||No||No|March 5, 2014|https://clinicaltrials.gov/show/NCT01437267||98283|
NCT01437280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28686-GOAT|GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers|GOAT; Phase I Single-Center Open Label Dose Escalation Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Therapy of Advanced Cancers|GOAT|Baylor College of Medicine|Yes|Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|September 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01437280||98282|
NCT01437293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6141 P50 DA 009236-16|Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)|Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)|COST|New York State Psychiatric Institute|Yes|Completed|August 2010|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|15|||Both|21 Years|50 Years|No|||October 2012|October 25, 2012|November 18, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437293||98281|
NCT01437241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFL-ETR-2010-01|Etravirine Plus 2 Analogs in HIV-infected Patients|Virological Efficacy and Safety of Etravirine Plus 2 Active Nucleos(t)Ide Reverse-transcriptase Inhibitors (NRTIs) in HIV-1-infected Patients||Hospitales Universitarios Virgen del Rocío|Yes|Completed|January 2009|September 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|175|Samples Without DNA|plasma|Both|18 Years|80 Years|No|Non-Probability Sample|HIV-infected patients who strated an antirretroviral regimen based on etravirine plus 2        NRTIs between January 2009 and June 2010|October 2011|October 30, 2011|September 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01437241||98285|
NCT01437540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-MD-32|Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)|LAC|Forest Laboratories|Yes|Completed|September 2011|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|590|||Both|40 Years|N/A|No|||April 2013|April 5, 2013|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437540||98262|
NCT01433627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFBU 11-I|Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX|Phase IIIb Study Minimizing Adverse Haemmhorragic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)|MATRIX|Italian Society of Invasive Cardiology|Yes|Active, not recruiting|October 2011|December 2015|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|7200|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433627||98560|
NCT01433861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBHGS|Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy|Phase III Prospective Randomized Clinical Trial of Laparoscopy-assisted Proximal Gastrectomy (LAPG) and Laparoscopy-assisted Total Gastrectomy (LATG) for Upper Gastric Cancer. (Multicenter Study)|PRAPT|Seoul National University Bundang Hospital|Yes|Recruiting|July 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|194|||Both|20 Years|80 Years|No|||December 2013|December 6, 2013|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01433861||98544|
NCT01435863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-02L01|A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)|A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)||Solasia Pharma K.K.|No|Completed|September 2011|July 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|20 Years|N/A|No|||August 2015|August 11, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01435863||98391|
NCT01435876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12132EH|Surgery and Convergence Insufficiency Intermittent Exotropia|Treatment for Convergence Insufficiency Intermittent Exotropia; A Randomized Trial||Sudhalkar Eye Hospital|Yes|Completed|May 2006|May 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|76|||Both|N/A|N/A|No|||September 2011|September 15, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01435876||98390|
NCT01435616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12141|A Study in Patients With Type 2 Diabetes Mellitus|A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study|IMAGINE 2|Eli Lilly and Company|Yes|Completed|October 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1516|||Both|18 Years|N/A|No|||February 2014|April 14, 2014|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435616||98410|
NCT01434628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-03|Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by Nurses|One Arm, Open Label, Prospective, Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by Nurses in Resource Limited Settings for HIV Prevention||Ministry of Health, Rwanda|No|Completed|July 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|590|||Male|21 Years|54 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01434628||98485|
NCT01434641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGA-10K09|Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography|Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial SPECT||St. Luke's-Roosevelt Hospital Center|No|Recruiting|July 2011|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||July 2011|September 14, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01434641||98484|
NCT01435577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|295054|Intravenous Tapentadol in Post-Bunionectomy Pain|A Randomized, Double-blind, Placebo-controlled Parallel Group, Multicenter Trial to Evaluate the Efficacy and Safety of Multiple Dose Administration of an Intravenous Formulation of Tapentadol in the Treatment of Acute Pain Following Bunionectomy.||Grünenthal GmbH|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|65 Years|No|||June 2013|June 24, 2013|September 15, 2011|Yes|Yes||No|March 5, 2013|https://clinicaltrials.gov/show/NCT01435577||98413|
NCT01435590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 11-029|Endocervical Evaluation With the Curette Versus Cytobrush for the Diagnosis of Dysplasia of the Uterine Cervix|||University Hospital, Geneva|No|Completed|September 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|||Anticipated|180|||Female|21 Years|70 Years|No|||May 2015|May 27, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01435590||98412|
NCT01435850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D10056-2-F|Safety and Efficacy of the SL PLUS and the SL PLUS MIA Hip Stem|"Enfoncement de la Tige SL-PLUS et de la Tige SL-PLUS MIA:Etude Comparative"|SL-PLUS|Smith & Nephew, Inc.|Yes|Completed|April 2009|November 2014|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|80|||Both|18 Years|80 Years|No|||April 2015|April 1, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01435850||98392|
NCT01436357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0069|Staged Phase I/II Hepatitis C Prophylactic Vaccine|A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|March 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|March 17, 2016|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436357||98353|
NCT01437384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-A001-008|Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.|An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects||Eisai Inc.||Completed|September 2011|||March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 18, 2012|September 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01437384||98274|
NCT01420354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02934|Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients|Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients||University of British Columbia|No|Recruiting|August 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples Without DNA|Urine collected over 24 hour period|Both|19 Years|N/A|No|Non-Probability Sample|Patients receiving care at Vancouver General Hospital for their kidney stone disease.|December 2015|December 10, 2015|October 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01420354||99575|
NCT01420679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-017|Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients|A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy||Spectrum Pharmaceuticals, Inc|Yes|Terminated|August 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420679||99551|
NCT01424176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223RI101|Dexpramipexole Renal PK Study|A Multicenter, Open-Label, Single-dose, Pharmacokinetic and Safety Study of Dexpramipexole (BIIB050) in Healthy Subjects and Subjects With Renal Impairment||Knopp Biosciences|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|75 Years|No|||November 2014|November 24, 2014|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01424176||99282|
NCT01424189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-036|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2011|||||N/A|N/A|N/A||||||||||||||July 17, 2013|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01424189||99281|
NCT01421641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU RES 7148|Tenaculum Pain Control Study|The Effect of Intracervical Lidocaine Injection Versus Topical Lidocaine Gel on the Pain Experienced by Patients Undergoing Tenaculum Application to the Cervix at the Time of an Office Gynecologic Procedure||Oregon Health and Science University|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|74|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 18, 2014|August 9, 2011|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01421641||99477|There are several limitations to this study, including potential selection bias, difficulty with blinding the intervention, timing of the intervention for maximal effect, and the limitations inherent in measuring pain.
NCT01420952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110229|Imaging of Brain Receptors Using (11C)mGlu1|PET Imaging of Brain mGlu1 Receptors Using [11]LY2428703||National Institutes of Health Clinical Center (CC)||Terminated|July 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|October 24, 2014|August 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01420952||99530|
NCT01420965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11C0231|Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer|A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered With or Without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men With Advanced Castrate-Resistant Prostate Cancer||Georgia Regents University|Yes|Recruiting|September 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|57|||Male|18 Years|N/A|No|||August 2014|August 12, 2014|August 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01420965||99529|
NCT01422382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.07US|Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin|Drug-Drug Interaction Study to Assess the Effects of Steady-State Cardizem LA (Diltiazem Hydrochloride) and Steady-State Pitavastatin on Their Respective Pharmacokinetics in Healthy Adult Volunteers||Kowa Research Institute, Inc.|No|Completed|May 2011|July 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|August 22, 2011|Yes|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01422382||99420|
NCT01437319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005016|Mucin Balls and Corneal Inflammation Events|||Johnson & Johnson Vision Care, Inc.||Completed|September 2011|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|289|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|September 16, 2011|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01437319||98279|
NCT01437332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0356-11-RMB|Molecular Mediators of Nerve Injury Signaling|Molecular Mediators of Nerve Injury Signaling||Rambam Health Care Campus|Yes|Enrolling by invitation|September 2011|||September 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Anticipated|50|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing surgical procedures at Rambam Health Care Campus wherein the surgeon        and PI determine appropriateness for study|September 2011|September 19, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437332||98278|
NCT01437579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS/IC Bot1|Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions|Randomized Controlled Trial for Efficacy of Botulinum Toxin Type A in Treatment of Patients Suffering Bladder Pain Syndrome/Interstitial Cystitis With Hunners' Lesions||Moscow State University of Medicine and Dentistry|No|Recruiting|June 2011|June 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2011|September 20, 2011|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01437579||98259|
NCT01437553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSCI-01|Imaging Whole Coronary Artery With Intravascular Ultrasound (Ivus) And Imap For Plaque Tissue Composition In Patients With Acute Myocardial Infarction|Registry Using IVUS and iMAP to Evaluate Atherosclerotic Coronary Plaque in Acute Coronary Syndromes|iWONDER|Federal University of São Paulo|Yes|Recruiting|August 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|75 Years|No|||September 2011|September 21, 2011|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01437553||98261|
NCT01433328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGH-11-096|Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain|Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain||Jewish General Hospital|No|Terminated|January 2012|April 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||April 2012|April 4, 2012|September 9, 2011||No|Safety considerations|No||https://clinicaltrials.gov/show/NCT01433328||98583|
NCT01433341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc06611TIL|Evaluation of Postural Control After Exercise in Athletes Using Tetra Axial Posturography (tetrax1)|||Meir Medical Center|Yes|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Male|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Thirty basketball and football players between the ages of 12 and 18 years old.|November 2013|November 10, 2013|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433341||98582|
NCT01433354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056B2278|Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)|An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome||Novartis|Yes|Terminated|November 2011|September 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Both|12 Years|18 Years|No|||February 2016|February 24, 2016|August 31, 2011|Yes|Yes|The study treatment failed to demonstrate efficacy in target population in two other clinical    studies (CAFQ056B2214 and CAFQ056A2212).|No|September 14, 2015|https://clinicaltrials.gov/show/NCT01433354||98581|The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).
NCT01433640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01|Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study|Evaluation of Contrast-enhanced Mammography and Contrast-enhanced Breast Tomosynthesis: Comparison to Contrast-enhanced Breast MRI- A Pilot Study||Hologic, Inc.|No|Completed|July 2011|February 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|||Female|25 Years|N/A|No|Non-Probability Sample|The study population includes females of any race and ethnicity. The subjects must ba at        least 25 years old and has a lesion of BIRADS 5 or BIRADS 6 as determined by a        radiologist.|March 2015|March 17, 2015|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433640||98559|
NCT01433653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-KlinPsy001|Cognitive Behavioral Therapy for Complicated Grief|Randomized Controlled Clinical Trial of Cognitive Behavioral Therapy for Complicated Grief|CG-CBT|Ludwig-Maximilians - University of Munich|Yes|Completed|May 2005|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01433653||98558|
NCT01434108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP_GIB|Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding|Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding||Hospital Universitari Vall d'Hebron Research Institute|No|Completed|October 2011|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|75 Years|No|||March 2015|March 19, 2015|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01434108||98525|
NCT01434368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110251|A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty|A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty||National Institutes of Health Clinical Center (CC)||Recruiting|September 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|344|||Both|8 Years|35 Years|Accepts Healthy Volunteers|||May 2015|November 20, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434368||98505|
NCT01435629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3907|A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin|Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]||Novo Nordisk A/S|No|Completed|May 1997|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|54|||Both|N/A|N/A|No|Non-Probability Sample|Patients enrolled in the GH-1941 study (NCT01516229) expected to achieve the adult height        by 2015 and available for follow-up by the investigator|January 2016|January 14, 2016|September 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435629||98409|
NCT01406886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-28|Combined Effects of Energy Density and Eating Rate on Appetite|Combined Effects of Energy Density and Eating Rate on Energy Intake and Biomarkers of Satiety||United States Army Research Institute of Environmental Medicine|No|Completed|December 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01406886||100603|
NCT01435239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0046|The Comparison of Two Different Methods of Partial Inflation of Cuff for Facile Insertion of Laryngeal Mask Airway in Pediatric Patients|||Yonsei University|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|78|||Both|N/A|9 Years|No|||March 2014|March 4, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435239||98439|
NCT01435551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALZ2012JB|Using Hypnotherapy For Dementia & Alzheimer's|Phase 1 a One Year Study of Using Hypnotherapy to Control Beta-amyloid Buildup That Causes Alzheimer's & Dementia CANCELLED||Families To The Rescue||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||February 2016|February 2, 2016|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01435551||98415|
NCT01436110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115285|Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma|A Randomised, Double-blind, Double-dummy, Placebo Controlled Multi-centre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder and Fluticasone Propionate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents Not Currently Treated With Inhaled Corticosteroids||GlaxoSmithKline|No|Completed|September 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|351|||Both|12 Years|N/A|No|||August 2013|August 21, 2014|September 15, 2011|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01436110||98372|
NCT01436383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 1189|Oxidative Stress in Hypobaric Hypoxia|Oxidative Stress in Hypobaric Hypoxia and Influence on Vessel-tone Modifying Mediators||University Hospital Inselspital, Berne|Yes|Completed|March 2005|February 2010|Actual|December 2005|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2011|September 20, 2011|September 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436383||98351|
NCT01436370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0076|TIV and High Dose TIV in Subjects With Rheumatoid Arthritis|A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2011|June 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|102|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2013|December 4, 2014|September 15, 2011|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01436370||98352|
NCT01436695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPC - 01|Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers|Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers||Epicall LTD|No|Not yet recruiting|November 2011|||June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|1 Year|18 Years|No|Non-Probability Sample|Hospitalized patients who diagnosed with epilepsy and meet all of the eligibility criteria        will be recruited for the study.|September 2011|September 19, 2011|September 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01436695||98327|
NCT01420705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-BHP-LBW-BCG-atopy|Bacille Calmette-Guérin (BCG) Vaccine and Atopy|The Effect of Giving BCG Vaccine at Birth to Low Birth-weight Infants on Development of Allergy and Asthma in Childhood - Follow up of a Randomised Trial in Guinea-Bissau||Bandim Health Project|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|487|Samples Without DNA|Faecal samples are collected for analyses of parasites and microbes|Both|3 Years|9 Years|No|Probability Sample|Children previously enrolled in NCT00146302 living within Bandim Health Project study        area, Bissau|December 2011|December 27, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01420705||99549|
NCT01420692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110S119|The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes|The Effects of Insulin Detemir and Gliclazide-MR Treatments in Addition to Life-style Modification and Metformin Therapy on Endothelial Functions in Patients With Type 2 Diabetes : An Open-labelled Randomized Prospective Study||Ankara University|Yes|Completed|June 2010|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|20 Years|65 Years|No|||August 2012|August 13, 2012|October 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01420692||99550|
NCT01422395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLFC-001|Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development|A Study to Compare Vitrified/Warmed Oocytes vs. Fresh Sibling Oocytes Collected Following Controlled Ovarian Stimulation Using Follistim AQ and Ganirelix Acetate on Fertilization Rates, Zygote Quality, Embryo Quality and Embryo Development||Main Line Fertility Center|No|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|40|||Female|21 Years|37 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01422395||99419|
NCT01421602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKMRC-11-001|A Prospective Observational Study on the Use of a Self Fixating Lightweight Polyester Mesh in Open Inguinal Hernia|A Prospective Observational Study on the Use of a Self Fixating Lightweight Polyester Mesh in Open Inguinal Hernia||De La Salle University Medical Center|No|Recruiting|September 2011|December 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Probability Sample|Potential study subjects will be patients who are:        18 - 80 years old; Has confirmed with the informed consent; Has a primary inguinal hernia        (either unilateral or bilateral) which is reducible and amenable to local or regional        hernia repair|September 2011|September 21, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421602||99480|
NCT01433432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2/13/DR-6MP-02 EXT|Open Label Extension Study to Protocol C2/13/DR-6MP-02|Clinical Efficacy and Safety of Delayed Release 6-Mercaptopurine (DR-6MP) for Targeted Ileal Delivery in Patients With Moderately Active Crohn's Disease - Open Label Extension Study|OLE|Teva GTC|No|Withdrawn|October 2011|August 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||March 2013|March 5, 2013|September 12, 2011||No|Sponsor withdrew support for study due to reorganization and project prioritization|No||https://clinicaltrials.gov/show/NCT01433432||98575|
NCT01437566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDC4950g|Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy|A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy||Genentech, Inc.||Active, not recruiting|October 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|208|||Female|18 Years|N/A|No|||September 2015|September 1, 2015|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437566||98260|
NCT01433367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA-CP-0904|A Clinical Trial Evaluating a Total Disc Replacement in Patients With Cervical Disc Disease|A Prospective Observational Study Evaluating the Performance of the CerPass® Total Disc Replacement in Patients With Single-Level Cervical Disc Disease|CerPass|NuVasive|No|Terminated|May 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|60 Years|No|Non-Probability Sample|Volunteers will be selected from the surgeon's existing clinic patients.|April 2015|April 17, 2015|June 10, 2011|No|Yes|Marketing of CE marked device has been discontinued.|No||https://clinicaltrials.gov/show/NCT01433367||98580|
NCT01433380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731004|A Study To Evaluate PF-05175157 In Healthy Volunteers|Phase 1 Study To Evaluate The Effect Of Single Doses Of Pf-05175157 On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers||Pfizer|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|August 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01433380||98579|
NCT01433874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-03-001|Decreasing Upper and Shoulder Pain After Laparoscopic Surgery|Maneuvers to Decrease Upper and Shoulder Pain After Gynecologic Laparoscopic Surgery||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|February 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Female|20 Years|80 Years|No|||July 2011|September 13, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01433874||98543|
NCT01433887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAH5010G6HCV|Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6|Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic||Third Affiliated Hospital, Sun Yat-Sen University|No|Completed|November 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|535|||Both|16 Years|65 Years|No|||November 2014|November 14, 2014|September 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01433887||98542|
NCT01434381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-I-N237|Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)|Open Label Phase 1 Study in Malaria Naive Adults of the Safety and Immunogenicity of Pfs25-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 10, 2014|September 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434381||98504|
NCT01406899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JC0008|Computer-Based Training in Cognitive Behavior Therapy (CBT4CBT)|Computer-Assisted Cognitive Behavior Therapy for Veterans With Substance Use Disorder||VA Connecticut Healthcare System|Yes|Completed|January 2010|December 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2012|December 22, 2014|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01406899||100602|
NCT01435252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Add-On cetuximab|A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab|A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab||University of Zurich|Yes|Recruiting|September 2011|July 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||December 2014|December 8, 2014|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01435252||98438|
NCT01436123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NANOM PCI|Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting|Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis With The Use of Gold Nanoparticles With Iron Oxide-Silica Shells Versus Stenting|NANOM PCI|Ural Medical University|Yes|Terminated|December 2010|October 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|45 Years|65 Years|No|||May 2015|May 17, 2015|September 14, 2011|Yes|Yes|The study was terminated under the political pressure of the Federal Security Service of the    Russian Federation (FSB) and the Russian Society of Cardiology|No||https://clinicaltrials.gov/show/NCT01436123||98371|
NCT01436396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD29|Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers|Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru||Sanofi|Yes|Completed|September 2011|March 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|792|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||April 2014|April 1, 2014|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01436396||98350|
NCT01437033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911243|Breath Test for Chemicals (Volatile Organic Compounds)|A Pilot Study of a Breath Test for Assessment of Volatile Organic Compounds||National Institutes of Health Clinical Center (CC)||Completed|August 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5|||Both|30 Years|60 Years|No|||July 2015|July 25, 2015|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01437033||98301|
NCT01436721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI-125-001|Use of an Oxidized Regenerated Cellulose After Hepatic Surgery|The Randomized Clinical Trial of Surgicel® Absorbable Haemostat Covering the Raw Cut Surface During the Hepatectomy||Fudan University|Yes|Recruiting|August 2011|December 2011|Anticipated|December 2011|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|70 Years|No|||September 2011|September 19, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01436721||98325|
NCT01436734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2009-0078|Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125|||University Hospital, Gentofte, Copenhagen|Yes|Completed|July 2011|May 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|5|||Male|18 Years|70 Years|No|||July 2015|July 10, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01436734||98324|
NCT01424488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHRussianRailways|Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade|Randomized, Parallel-group, Placebo-controlled, Safety-assessor Blinded Trial in Adult Subjects Evaluating the Efficacy and Safety of Sugammadex for Reversal of Pipecuronium-induced Neuromuscular Blockade in Subjects Undergoing Abdominal Surgery Under General Anesthesia||Central Clinical Hospital #1 of LLC Russian Railways|No|Not yet recruiting|September 2011|February 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01424488||99258|
NCT01420393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|231888|Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation|A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and High Burden Atrial Fibrillation|RAFT-AF|Ottawa Heart Institute Research Corporation|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420393||99573|
NCT01420978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002713|Cerebrospinal Fluid (CSF) Drainage Study|High Volume Cerebrospinal Fluid Diversion in the Management of Aneurysmal Subarachnoid Hemorrhage: A Pilot Study||Mayo Clinic|No|Completed|August 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||May 2013|May 12, 2013|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01420978||99528|
NCT01420991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003509|Brain and Abdominal Aneurysm Study|Brain and Abdominal Aneurysm Study (BAAS)|BAAS|Mayo Clinic|No|Active, not recruiting|August 2011|December 2024|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|81|||Both|18 Years|N/A|No|Non-Probability Sample|We will enroll 81 patients who present to MCH with aSAH.|December 2015|December 31, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01420991||99527|
NCT01429480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0065-11-HYMC|Comparison of TAP (Transversus Abdominis Plane) and Ilioinguinal/Iliohypogastric Nerve Block for Analgesia of Open Inguinal Herniorrhaphy|Comparison Between Two Ultrasound-guided Blocks (Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve Blocks) for Pain Relief After Open Inguinal Herniorrhaphy|TAP|Hillel Yaffe Medical Center|Yes|Recruiting|August 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Male|18 Years|N/A|No|||September 2011|September 6, 2011|September 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429480||98877|
NCT01429766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747|A Prospective Study of Variation in Breath Holding Times at Various Phases of Respiration During the Course of Radiotherapy Including the Effect of Respiratory Training in Lung Cancer Patients|A Prospective Study of Variation in Breath Holding Times at Various Phases of Respiration During the Course of Radiotherapy Including the Effect of Respiratory Training in Lung Cancer Patients||Tata Memorial Hospital|Yes|Recruiting|June 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|N/A|N/A|No|||September 2011|September 6, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01429766||98855|
NCT01421004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2128|Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors|A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors||Novartis||Completed|December 2011|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|August 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01421004||99526|
NCT01422616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X11-0123|Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)|An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke|ENCHANTED|The George Institute|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|3300|||Both|18 Years|N/A|No|||November 2015|November 8, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422616||99402|
NCT01422629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/F/FA/Dec2010|High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma|High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma: a Feasibility Study. A Multicentric, Open, Uncontrolled Study||Theraclion|Yes|Completed|October 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Female|18 Years|N/A|No|||April 2014|April 8, 2014|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01422629||99401|
NCT01422642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LPS-Flex vs LPS|Do We Need High-Flexing Total Knee Arthroplasty to Improve the Survivorship and to Decrease the Incidence of Osteolysis?|Do We Need High-Flexing Total Knee Arthroplasty to Improve the Survivorship and to Decrease the Incidence of Osteolysis? A Minimum of Ten Years of Follow-up||Ewha Womans University|No|Completed|January 2001|June 2011|Actual|April 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|111|||Both|48 Years|85 Years|No|||June 2011|August 29, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422642||99400|
NCT01433913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00243|Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery|Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort||National Cancer Institute (NCI)|Yes|Completed|November 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|N/A|No|||May 2014|April 29, 2015|September 9, 2011|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01433913||98540|
NCT01437592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-1999|Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects|A Trial Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects||Novo Nordisk A/S|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|No|||September 2015|September 24, 2015|September 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01437592||98258|
NCT01433393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875/CCT-003|Double-blind Comparative Study of TAK-875|||Takeda||Completed||September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment|3||Actual|192|||Both|20 Years|N/A||||November 2012|November 7, 2012|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433393||98578|
NCT01433406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875/OCT-002|Long-term Study of TAK-875|||Takeda|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment|2||Actual|1222|||Both|20 Years|N/A|No|||January 2014|January 24, 2014|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433406||98577|
NCT01433419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875/OCT-003|Open-label Study of TAK-875|||Takeda||Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment|2||Actual|333|||Both|20 Years|N/A||||March 2013|March 21, 2013|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433419||98576|
NCT01433666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC11-3-035|Roflumilast and Cognition|Effects of Roflumilast on Cognition in Healthy Adults: a Behaviour-EEG Study|EEGrofl|Maastricht University Medical Center|Yes|Completed|September 2011|September 2013|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|22|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|June 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01433666||98557|
NCT01434121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM12903|Ascorbic Acid (Vitamin C) Infusion in Human Sepsis|Ascorbic Acid (Vitamin C) Infusion in Human Sepsis||Virginia Commonwealth University|Yes|Completed|May 2010|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||May 2014|May 30, 2014|August 9, 2011||No||No|March 4, 2014|https://clinicaltrials.gov/show/NCT01434121||98524|
NCT01434654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/192|Efficacy of Neuro-HAART in Patients With HIV|The Efficacy of Neuro-HAART in HIV Infected Individuals|HANDobs|St Vincent's Hospital, Sydney|No|Not yet recruiting|September 2011|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|170|Samples Without DNA|Cerbrospinal fluid and bloods|Both|18 Years|N/A|No|Non-Probability Sample|HIV positive participants on HAART who attend outpatient primary care clinics.|October 2012|October 7, 2012|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01434654||98483|
NCT01435889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2005/R-1906|Long Term (1 Year) Respiratory Sequelae in Children Surviving an Acute Respiratory Distress Syndrome|Long Term (1 Year) Respiratory Sequelae in Children Surviving Acute Respiratory Distress Syndrome||University Hospital, Lille|No|Completed|June 2006|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|1 Year|16 Years|No|Probability Sample|children hospitalised in PICU with ARDS and surviving 1 year after the acute phase|December 2015|December 1, 2015|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01435889||98389|
NCT01436136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reducing CVD risk in HIV|Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months|Effectiveness of Team Intervention Over 12 Months in Reducing Modifiable CVD Risk Factors on Framingham 10yr Risk Scores Outcomes in HIV-1 Subjects on Antiretroviral Therapy|CVD|Holdsworth House Medical Practice|No|Completed|October 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Both|50 Years|N/A|No|||May 2015|May 10, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436136||98370|
NCT01403376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY11684|Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide|Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide Treatment and Using a Population of Patients With Multiple Sclerosis as a Reference|TERIVA|Sanofi|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|128|||Both|18 Years|59 Years|No|||January 2016|January 21, 2016|July 14, 2011|No|Yes||No|January 22, 2013|https://clinicaltrials.gov/show/NCT01403376||100873|
NCT01403662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3420337|Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression|A Pilot, Open-label, 8-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Minocycline for the Treatment of Bipolar Depression||University Health Network, Toronto|No|Recruiting|July 2011|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||July 2011|July 25, 2011|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01403662||100851|
NCT01403909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/DC-04|Effect of Pneumatic Intermittent Venous Compression on Fluid Volumes Infused During Major Abdominal Surgery|Effect of Pneumatic Intermittent Venous Compression on Fluid Volumes Infused During Major Abdominal Surgery in Non-obese American Soceity of Anesthesiologists (ASA) 1-3 Patients||Centre Hospitalier Universitaire de Nīmes|Yes|Withdrawn|November 2014|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|July 26, 2011||No|We need somebody to replace the principal inestigator.|No||https://clinicaltrials.gov/show/NCT01403909||100832|
NCT01403922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00010|To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension|A Phase I Randomised, Placebo-Controlled, Double-Blind Study in Hypertensive Patients of the Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors)||AstraZeneca||Terminated|August 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|80|||Both|18 Years|65 Years|No|||October 2012|October 1, 2012|July 26, 2011|No|Yes|Sponsor's decision to terminate|No||https://clinicaltrials.gov/show/NCT01403922||100831|
NCT01420419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26044|Evaluating Lanolin for the Treatment of Nipple Pain Among Breastfeeding Women|A Randomized Controlled Trial Evaluating Lanolin for the Treatment of Nipple Pain Among Breastfeeding Women|LanP|University of Toronto|No|Completed|May 2011|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|186|||Female|18 Years|N/A|No|||January 2013|January 14, 2013|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01420419||99571|
NCT01420731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbms1|Back Pain and Male Sexual Disfunction|Phase 4 Study Back Pain and Male Sexual Disfunction||Bezmialem Vakif University|No|Not yet recruiting|September 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|54|||Male|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|20-45 years old,male patients with active sexual life|August 2011|August 19, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01420731||99547|
NCT01420406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHNRC 200816672|Vitamin A Bioavailability in Lactating Women With Marginal Vitamin A Status|Impact of Daily Feeding of Food Sources of Cryptoxanthin (CX) and Beta-carotene (BC) on Plasma and Breast Milk Concentrations of CX, BC, and Retinol (VA) in Lactating Women With Marginal Vitamin A Status||USDA, Western Human Nutrition Research Center|No|Completed|June 2010|June 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|140|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420406||99572|
NCT01421693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03NP|Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever|Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever.||Oxford University Clinical Research Unit, Vietnam|Yes|Active, not recruiting|September 2011|January 2015|Anticipated|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|2 Years|45 Years|No|||November 2014|November 26, 2014|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421693||99473|
NCT01421706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-073|Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects|Effects of Clopidogrel and Clarithromycin on the Disposition of Sibutramine and Its Active Metabolites M1 and M2 in Relation to CYP2B6*6 Polymorphism|sibu|Inje University|No|Completed|July 2008|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Male|19 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 16, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421706||99472|
NCT01421628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HanzeUnlc|Enhancement of Physical Fitness in Older Adults|The Effectiveness of a Trainings Program on ADL Performance, Physical Fitness, Wellbeing, and Nocturnal Cramp in Elderly People|NLC2010|Hanze University|No|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|180|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2010|August 22, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421628||99478|
NCT01421914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unifesp-USG Axillary block|Determining the Minimum Effective Volume of Local Anesthetic for Ultrasound-guided Axillary Brachial Plexus Block|Determining the Minimum Effective Volume of Local Anesthetic for Ultrasound-guided Axillary Brachial Plexus Block||Federal University of São Paulo|Yes|Completed|December 2010|August 2012|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|19|||Both|18 Years|65 Years|No|||November 2012|November 16, 2012|August 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01421914||99456|
NCT01430377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBPS|Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS)|Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS)|SBPS|Medica Cor Heart Hospital|Yes|Recruiting|August 2011|May 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|90 Years|No|||September 2011|September 7, 2011|September 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01430377||98809|
NCT01430390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-038|In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies|A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies||Memorial Sloan Kettering Cancer Center||Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|N/A|18 Years|No|||January 2016|January 6, 2016|September 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430390||98808|
NCT01434420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA03/IPC 2010-003|Triple Negative Breast Cancer: Study of Molecular and Genetic Factors|Triple Negative Breast Cancer: Study of Molecular and Genetic Factors||Institut Paoli-Calmettes|No|Active, not recruiting|March 2011|March 2020|Anticipated|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Female|18 Years|N/A|No|||December 2014|December 30, 2014|September 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01434420||98501|
NCT01434433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSTE-9012|Alere Triage fs B-type Natriuretic Peptide (BNP) Method Comparison Evaluation|Alere Triage fs BNP Method Comparison Evaluation|ABC|Alere San Diego|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|360|||Both|18 Years|N/A|No|Non-Probability Sample|Emergency Department, Hospital|September 2011|January 12, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434433||98500|
NCT01433679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLZZ-001|The Effect of a Web-Based Behavioral Intervention on Physical Activity Levels in Adolescents|The Effect of a Web-Based Behavioral Intervention on Physical Activity Levels in Adolescents||HopeLab Foundation|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|448|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433679||98556|
NCT01433900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSD-007|Switching From Preserved to Preserved-free Treatments for Glaucoma.|The Advantage of Switching From Preserved to Preserved-free Treatments in Glaucoma. A Clinical and Confocal Study.||University of Milan|No|Recruiting|May 2012|June 2014|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2011|May 15, 2014|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433900||98541|
NCT01434394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9thShanghai|Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer|Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer|EAGLE|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|August 2011|February 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|243|||Both|18 Years|75 Years|No|||November 2011|November 30, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01434394||98503|
NCT01435265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 08-0104|Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab|The Effectiveness of Nurse Education and Its Impact on Treatment Adherence in Subjects With Moderate to Severe Psoriasis Undergoing Treatment With Adalimumab||Wake Forest School of Medicine|No|Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|7|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|September 13, 2011||No||No|December 19, 2012|https://clinicaltrials.gov/show/NCT01435265||98437|
NCT01435278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/017011|Efficacy and Safety of Glucosanol in Maintaining Body Weight|Open-label Clinical Investigation to Evaluate the Safety and Efficacy of Glucosanol in Maintaining Body Weight Loss in Overweight and Obese Subjects||InQpharm Group|No|Completed|September 2011|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01435278||98436|
NCT01434667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HG002213|Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV|Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV||Brigham and Women's Hospital|No|Active, not recruiting|January 2010|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|360|||Both|55 Years|90 Years|No|||July 2013|July 30, 2013|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01434667||98482|
NCT01434680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V14_57|Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers|A Phase 2, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of the New Liquid Formulation of Novartis Meningococcal C Conjugate Vaccine and of the Novartis Lyophilized Meningococcal C Conjugate Vaccine Manufactured at Two Different Sites, in Healthy Toddlers||Novartis||Completed|September 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|992|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||February 2014|February 24, 2014|September 14, 2011||No||No|July 18, 2013|https://clinicaltrials.gov/show/NCT01434680||98481|
NCT01434693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNDO 201-002|Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease|A Sequential Dose-Escalation, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Single Doses of 3 Different Doses of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease||Coronado Biosciences, Inc.|No|Completed|November 2011|September 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|55 Years|No|||April 2013|May 17, 2013|September 13, 2011|Yes|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01434693||98480|
NCT01406639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091219|Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)||University of California, San Diego|No|Withdrawn|July 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 26, 2013|July 29, 2011|Yes|Yes|Study withdrawn due to lack of study population.|No||https://clinicaltrials.gov/show/NCT01406639||100622|
NCT01406652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-016 (NAC 11-004)|Optimisation of the Treatment of Infectious Bursitis|One-stage Versus Two-stage Surgical Treatement of Infectious Bursitis||University Hospital, Geneva|Yes|Recruiting|May 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|240|||Both|18 Years|N/A|No|||June 2011|July 29, 2011|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01406652||100621|
NCT01407146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HL085328-04|Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study|Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study||Yale University|No|Recruiting|July 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2314|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study is designed to gather detailed information on the care-seeking behavior of ACS        patients from a sample of sufficient size to allow testing of study hypotheses and provide        points of intervention in the ACS care-seeking process. To obtain these data the study        will employ a self-administered, self-tailoring web based survey instrument and a sampling        design incorporating sampling quotas calculated from NHANES 1999-2000 and 2001-2002        studies to represent the population of the United States with AMI by age, gender, and        race, and 2] over sampling of selected groups to meet calculated sampling quotas.|July 2011|July 29, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01407146||100583|
NCT01403116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-09007|Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men|Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men||Clarus Therapeutics, Inc.|No|Completed|July 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|325|||Male|18 Years|75 Years|No|||December 2013|December 17, 2013|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403116||100893|
NCT01403129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF1497|Keratoconus Detection|Early Detection of Keratoconus||Columbia University|No|Enrolling by invitation|December 2010|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|1000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to CUMC associated physicians and the London Vision Clinic.|April 2015|April 15, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403129||100892|
NCT01403389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSM 10-1600|A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant|Pilot Study of the Clinical Activity of Eculizumab for Prevention of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation||Schroppel, Bernd, M.D.|Yes|Recruiting|August 2011|February 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403389||100872|
NCT01403675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11214|Human Ovarian Autotransplantation|Human Ovarian Autotransplantation Using Cryopreserved Ovarian Tissue in Women Treated for Cancer||University of Kansas Medical Center|Yes|Completed|May 2009|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|1|||Female|18 Years|40 Years|No|||December 2014|December 2, 2014|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01403675||100850|
NCT01403935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1172|Sepsis Institutional Registry in Hospital Italiano de Buenos Aires|Sepsis Institutional Registry in Hospital Italiano de Buenos Aires|SIR|Hospital Italiano de Buenos Aires|No|Completed|December 2007|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7472|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with sepsis|March 2015|March 19, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403935||100830|
NCT01421030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/210|Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques|Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques.|MEQC|Oslo University Hospital|Yes|Recruiting|September 2011|September 2014|Anticipated|September 2012|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|40|||Both|7 Years|50 Years|No|||September 2012|September 24, 2012|June 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01421030||99524|
NCT01421368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A10-114|Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use|Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users||CONRAD|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|72|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|August 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01421368||99498|
NCT01420744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGMA Study 982|Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)|CIGMA|Biotest|Yes|Completed|August 2011|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01420744||99546|
NCT01421017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 11-00598|Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases|Phase I/II Study of TLR7 Agonist Imiquimod, Cyclophosphamide, and Radiotherapy in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases||New York University School of Medicine|Yes|Recruiting|August 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|55|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|August 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421017||99525|
NCT01421953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/01|Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers|Assessment of Four-dimensional (4D) 18F-fluoro-deoxy-glucose (FDG) Positron Emission Tomography and Computed Tomography System (PET-CT) in Radiotherapy for Non Small Cell Lung Cancers (NSCLC)|PULMOTEP|University Hospital, Bordeaux|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|7|||Both|18 Years|N/A|No|||October 2014|October 22, 2014|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01421953||99453|
NCT01422135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL15|Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females|A Pharmacokinetic Study of the Agile TCDS AG200-15 Following Weekly Application to Three Anatomical Sites (Abdomen, Buttock and Upper Torso) in Healthy Female Volunteers||Agile Therapeutics|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 16, 2011|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01422135||99439|
NCT01430052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TatsuyaIoka|Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer|Randomized Phase II Study Comparing Gemcitabine/S-1 Combination Chemoradiotherapy With Gemcitabine/S-1 Combination Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer.||Osaka Medical Center for Cancer and Cardiovascular Diseases|Yes|Active, not recruiting|April 2009|September 2015|Anticipated|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|20 Years|80 Years|No|||April 2015|April 20, 2015|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01430052||98834|
NCT01434160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14371|LCS12 Adolescent Study|Multi-center, Single-arm Study to Assess the Safety, Efficacy, Discontinuation Rate and Pharmacokinetics of the Low-dose Levonorgestrel Intrauterine Contraceptive System (LCS12) in Post-menarcheal Female Adolescents Under 18 Years of Age for 1 Year, and an Optional 2-year Extension Phase||Bayer|No|Completed|September 2011|May 2015|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|304|||Female|12 Years|17 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434160||98521|
NCT01434134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2709001/90005|Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy|Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol|PRADA|University Hospital, Akershus|Yes|Completed|September 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|130|||Female|18 Years|70 Years|No|||October 2014|October 21, 2014|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01434134||98523|
NCT01434407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M200|Effects of Advanced Glycation Endproducts on Satiety and Inflammation|Crossover Meal Study Investigating Effects of Advanced Glycation Endproducts on Satiety and Inflammation|AGE-1|University of Copenhagen|Yes|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|19|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 3, 2012|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434407||98502|
NCT01434979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G191FY|Exertional Heat Illness: Biomarkers for Prediction and Return to Duty||Heat3|Henry M. Jackson Foundation for the Advancement of Military Medicine||Recruiting|July 2011|||January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The target population will include both civilian DOD beneficiary and active duty military        men and women, of any race or ethnicity, between the ages of 18 and 45 years.|January 2015|January 6, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01434979||98459|
NCT01434992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHU-HP-2011|Detection of Helicobacter Pylori Infection by High Resolution Endoscopy|Detection of Helicobacter Pylori Infection by Non-magnifying High Resolution Endoscopy is Possible Within the Gastric Corpus||Kyunghee University Medical Center|Yes|Completed|August 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|585|Samples Without DNA|Gastric mucosa for detecting Helicobacter pylori|Both|20 Years|70 Years|No|Non-Probability Sample|Patients who underwent upper endoscopy in the Kyung Hee University Hospital|April 2012|April 19, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01434992||98458|
NCT01435603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00056501|Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study|Community Translation of a Lifestyle Intervention to Improve Health in Diabetes|I-D-HEALTH|Northwestern University|Yes|Active, not recruiting|August 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|350|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01435603||98411|
NCT01403142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1023|Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant|Optical Coherence Tomography to Evaluate Cardiac Allograft Vasculopathy in Patients Undergoing Clinically Indicated Angiographies Post Heart Transplant|OCTCAV|Columbia University|No|Active, not recruiting|July 2011|January 2022|Anticipated|July 2021|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Post heart transplant|April 2015|April 20, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01403142||100891|
NCT01406912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-188C|Efficacy of Virtual Reality Exercises in STroke Rehabilitation: A Multicentre Study (EVREST Multicentre)|Efficacy of Virtual Reality Exercises Using Wii Gaming Technology in STroke Rehabilitation: A Multicentre Randomized Clinical Trial (EVREST Multicentre)||St. Michael's Hospital, Toronto|Yes|Completed|July 2011|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|141|||Both|18 Years|85 Years|No|||November 2015|November 11, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01406912||100601|
NCT01406925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-02/2006(SD)|Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers|A Randomised, Placebo-controlled, Double-blind, Cross-over Study in Healthy Men and Women to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intra-anal Doses of NRL001 for Three Doses Using a Cream Formulation Relative to a Matched Placebo Formulation for Reference||Norgine|No|Completed|April 2007|June 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|12|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||July 2011|July 29, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406925||100600|
NCT01407159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSIST|A Study in SurvIvors of Type B Aortic Dissection Undergoing Stenting|ASSIST - A Study in SurvIvors of Type B Aortic Dissection Undergoing Stenting|ASSIST|JOTEC GmbH||Completed|November 2011|January 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Probability Sample|Male and female patients with complicated type B aortic dissection involving the        infra-diaphragmatic aorta|April 2014|April 25, 2014|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01407159||100582|
NCT01403948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1270.2|BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)|A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin||Boehringer Ingelheim||Recruiting|August 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 26, 2011||||No||https://clinicaltrials.gov/show/NCT01403948||100829|
NCT01404221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 07-077|Biochemical Markers and 2 and 3D Ultrasound to ID Maternal & Fetal Complications|The Combination of Biochemical Markers and Two and Three Dimensional Ultrasound Using Geometric Morphometrics in the Identification of Congenital Anomalies and Maternal or Fetal Complications||Northwell Health|Yes|Terminated|March 2009|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women presenting for a comprehensive ultrasound at approximately 20 weeks|April 2015|April 13, 2015|July 26, 2011||No|No safety issues. Need to rewrite protocol|No||https://clinicaltrials.gov/show/NCT01404221||100808|
NCT01404234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-205-0160|Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways|Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways|PALS|Gilead Sciences|Yes|Completed|December 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|N/A|12 Years|No|||May 2014|May 12, 2014|July 26, 2011|Yes|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01404234||100807|
NCT01404546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI2010-1|Cost Free Pharmacotherapy for Smoking Cessation in Stroke Patients|A Randomized Controlled Pilot Study of Standardized Counselling and Cost-free Pharmacotherapy for Smoking Cessation Among Stroke and TIA Patients||Ottawa Heart Institute Research Corporation|No|Completed|August 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Both|18 Years|N/A|No|||July 2011|March 10, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404546||100783|
NCT01404819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/JRGC|Evaluation of Brain Damage Resulting From Carotid Endarterectomy With Xenon Anesthesia|Evaluation of Brain Damage Resulting From Carotid Endarterectomy With Xenon Anesthesia||Centre Hospitalier Universitaire de Nīmes|Yes|Completed|April 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|86|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404819||100762|
NCT01421654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-03-11-01|Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy|Evaluation of Positive Airway Pressure (PAP) Feature to Improve Patient Adherence to Therapy||ResMed|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2013|March 10, 2013|August 19, 2011||No||No|January 31, 2013|https://clinicaltrials.gov/show/NCT01421654||99476|
NCT01421381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-II-003-OFU|RHODOS Follow-up Single-visit Study|A Single Visit, Observational, Follow-up Study of Patients With Leber's Hereditary Optic Neuropathy Following Participation in SNT-II-003 Trial|RHODOS-OFU|Santhera Pharmaceuticals||Completed|September 2011|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|15 Years|69 Years|No|Non-Probability Sample|Patients who participated in study SNT-II-003|May 2013|May 24, 2013|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421381||99497|
NCT01421394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10069|Spinal Cord Injury Series of Tampere - Retrospective Study|Spinal Cord Injury Series of Tampere - Retrospective Study|scissors|Tampere University Hospital|No|Recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|spinal cord injured patients in "PSHP"(pirkanmaan sairaanhoitopiiri) area|July 2011|November 18, 2014|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01421394||99496|
NCT01422148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH-09-176|Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery|Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery (MINA)|MINA|Baystate Medical Center|Yes|Recruiting|October 2011|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01422148||99438|
NCT01422421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H21-rinsho shiken ippan-017|Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease|Intensive Blood Pressure and LDL Lowering for Better Survival and Cardiovascular Outcome in Diabetic Patients With Coronary Artery Disease: Randomized Controlled Trial||Kyoto University, Graduate School of Medicine|Yes|Recruiting|August 2011|December 2022|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1000|||Both|20 Years|N/A|No|||January 2016|January 5, 2016|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422421||99417|
NCT01421927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/01|Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma|Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma|REVALLO|University Hospital, Bordeaux|Yes|Completed|August 2011|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||July 2015|July 22, 2015|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421927||99455|
NCT01421940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUHCRC002|The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer|||Kyungpook National University|Yes|Completed|October 2009|October 2013|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|80|||Male|20 Years|65 Years|No|||March 2015|March 9, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01421940||99454|
NCT01433965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#227|Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome|Phase I Trial of Maintenance Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Post Allogeneic Bone Marrow Transplantation||University of California, Davis|Yes|Recruiting|August 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|65 Years|No|||January 2016|January 22, 2016|September 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01433965||98536|
NCT01434706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1414|Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection|NAT: The Early Test Program: Implementation of NAT Screening to Identify Acute and Early HIV Infection at San Diego Public HIV Counseling and Testing Sites||University of California, San Diego|No|Recruiting|December 2006|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12000|||Both|13 Years|N/A|No|||December 2014|December 2, 2014|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434706||98479|
NCT01434719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02ZN|Human Suis and Pig Diseases in Northern Vietnam|Spatial and Temporal Associations Between Human Streptococcus Suis Infections and Pig Diseases in Northern Vietnam, 2010||Oxford University Clinical Research Unit, Vietnam|No|Recruiting|November 2010|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|350|||Both|N/A|N/A|No|Non-Probability Sample|Population under study is the population from which cases of S.suis infection admitted to        NHTD arise. Sepsis patients are selected to present the population of interest under the        following assumptions:          -  they are representative of the background exposure rate of the population from which             cases come from,          -  their diagnosis is independent of the exposure of interest,          -  they are similar to the S.suis cases in terms of care seeking and referral patterns.|November 2013|November 21, 2013|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01434719||98478|
NCT01434732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORDMILK|Effects of Milking the Umbilical Cord on Systemic Blood Flow|A Randomized Controlled Trial of Umbilical Cord Milking Versus Immediate Cord Clamping on Systemic Blood Flow in Premature Infants||Sharp HealthCare|Yes|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|No|||December 2013|December 3, 2013|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01434732||98477|
NCT01435291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-07|AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation|Prospective Pharmacokinetic and Pharmacogenetic Analysis of Advagraf After Transplantation|AADAPT|Centre Hospitalier Universitaire de Nice|No|Completed|October 2011|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|70 Years|No|||August 2011|July 28, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435291||98435|
NCT01435304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 3914|The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass|The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass||Maine Medical Center|Yes|Completed|September 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01435304||98434|
NCT01403402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMDPROS1|Congenital Muscle Disease Study of Patient and Family Reported Medical Information|Congenital Muscle Disease Patient and Proxy Reported Outcome Study|CMDPROS|Cure CMD|No|Recruiting|September 2009|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|Participants in CMDPROS will be selected from the CMD International Registry (CMDIR) and        currently include patients and families with congenital muscle disease from 25 countries.|October 2015|October 5, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403402||100871|
NCT01403688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11357|Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin|Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin in Women at High Risk for Breast Cancer||University of Kansas Medical Center|No|Completed|June 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|9|||Female|21 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Infertility Patients undergoing COH treatment and at high risk for breast cancer|September 2014|September 16, 2014|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01403688||100849|
NCT01403701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09015-09-020|Physical Therapy on Quality of Life and Function Following Vaginal Surgery Reconstructive Surgery|Effects of Physical Therapy on Quality of Life and Function Following Vaginal Reconstructive Surgery; a Randomized Trial|PT and QOL|TriHealth Inc.|No|Completed|July 2009|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||February 2014|February 17, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01403701||100848|
NCT01403961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439|Hemoglobin A1c and Immediate Postsurgical Complications Diabetes Type 2|Hemoglobin A1c and Immediate Postsurgical Complications Diabetes Type 2 (HbA1c)|HbA1c|Hospital Italiano de Buenos Aires|Yes|Recruiting|July 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1760|||Both|18 Years|N/A|No|Probability Sample|adult diabetic patients|December 2015|December 16, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01403961||100828|
NCT01404247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14069-01|Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates|Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates|OCT|University of California, Los Angeles|Yes|Completed|January 2011|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|38 Weeks|42 Weeks|No|||December 2015|December 30, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01404247||100806|
NCT01404260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTONG 1102|Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer|Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study|ISCAN|Guangdong Association of Clinical Trials|Yes|Completed|June 2011|October 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|75 Years|No|||November 2015|November 19, 2015|July 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404260||100805|
NCT01433211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBA-2011(1)|Nutrition and Frailty in Older Persons|Relation Between Nutrition and Frailty in Community-dwelling Older Persons||University of Erlangen-Nürnberg Medical School|No|Completed|August 2009|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|206|||Both|75 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Community-living persons aged 75 years or older|September 2011|September 11, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01433211||98592|
NCT01429246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSN268200900027C|China Salt Substitute Study in Tibet|China Salt Substitute Study in Tibet: Efficacy of Salt Substitute in Reducing Blood Pressure in Hypertensive Adults|CSSS-Tibet|The George Institute for Global Health, China|No|Completed|February 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|282|||Both|40 Years|N/A|No|||September 2011|September 2, 2011|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429246||98895|
NCT01422174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA098|Clinical Registry on Sudden Death Primary Prevention at Latin America|Clinical Registry on Sudden Death Primary Prevention at Latin America (rEgiStro Clinico en America Latina de Prevencion Primaria en muErte Subita)|ESCAPE-ICD|Biotronik SE & Co. KG|No|Withdrawn|March 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at Latin American countries that fulfill MADIT, MADIT II and/or MUSTT criteria.|March 2015|March 2, 2015|August 18, 2011||No|Study stopped due to lost of interest.|No||https://clinicaltrials.gov/show/NCT01422174||99436|
NCT01422187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-06-007|A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease|A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease||Protalix|No|Completed|August 2011|September 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|August 22, 2011|Yes|Yes||Yes|November 6, 2015|https://clinicaltrials.gov/show/NCT01422187||99435|
NCT01422434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCB 0903|LEO 90105 Ointment in Japanese Subjects With Psoriasis|Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris||LEO Pharma|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|676|||Both|20 Years|N/A|No|||March 2015|March 25, 2015|August 15, 2011||No||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01422434||99416|
NCT01422447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZhao-001|Research of Prevention and Intervention of Mental Health Problems|Prevention and Mental Health Education for Mental Health Problems in Community: A Model of Common Mental Health Problems in Seven Metropolis of China|RPIMHP|Shanghai Mental Health Center|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|42016|||Both|13 Years|65 Years|No|||November 2015|November 24, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01422447||99415|
NCT01405560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-045|Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)|A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Were Non-responders to Previous Treatment||Merck Sharp & Dohme Corp.|Yes|Completed|September 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|70 Years|No|||September 2015|September 7, 2015|July 28, 2011|No|Yes||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01405560||100705|
NCT01405547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|488057|Gestational Metabolic Abnormalities and Maternal and Infant Nutrition and Health|Impact of Maternal Metabolic Abnormalities in Pregnancy on Human Milk and Subsequent Infant Metabolic Development||University of Toronto||Completed|March 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|271|||Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women are recruited in outpatient clinic waiting areas at Mount Sinai Hospital in        Toronto, Canada, a large tertiary care centre.|December 2012|December 19, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01405547||100706|
NCT01434446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEK 08252011|The Effect of Sound Stimulation on Hearing Ability|The Effect of Sound Stimulation on Hearing Ability||Earlogic Korea, Inc.||Completed|September 2011|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01434446||98499|
NCT01434459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047233a|Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin|Phase I Trial of Gemcitabine With TheraSphere® (Yttrium-90) in Patients With Hepatic Tumors of Pancreatobiliary Origin||Emory University|Yes|Terminated|September 2011|September 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|September 12, 2011||No|PI moved to different institution|No||https://clinicaltrials.gov/show/NCT01434459||98498|
NCT01406353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0432|Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis|Early Percutaneous Mitral Intervention Versus Conventional Management in Asymptomatic Moderate Mitral Stenosis|MITIGATE|Asan Medical Center|Yes|Active, not recruiting|July 2011|December 2023|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|166|||Both|20 Years|70 Years|No|||December 2015|December 29, 2015|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406353||100644|
NCT01406327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114782|Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)|Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)||GlaxoSmithKline|No|Active, not recruiting|December 2010|April 2020|Anticipated|January 2020|Anticipated|N/A|Observational|N/A||1|Anticipated|900|||Both|N/A|N/A|No|Probability Sample|All Japanese subjects who have received ambrisentan for the first time for the treatment        of pulmonary arterial hypertension (PAH) and have given their consent to participate in        the study.|June 2013|July 24, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406327||100646|
NCT01406340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115573|Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment|A Repeat-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Impaired Renal Function||GlaxoSmithKline|No|Terminated|August 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|July 26, 2011|No|Yes|Difficulty enrolling last cohort of subjects|No||https://clinicaltrials.gov/show/NCT01406340||100645|
NCT01407172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-110|Hydrogen Sulfide and Peripheral Arterial Disease|Hydrogen Sulfide and Peripheral Arterial Disease||Louisiana State University Health Sciences Center Shreveport|No|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|252|Samples Without DNA|Plasma for additional biomarker evaluation will be stored.|Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing cardiac catheterization or peripheral angiogram via a major arterial        approach at the LSUHSC cardiac catheterization laboratory meeting the inclusion and        exclusion criteria will be eligible and given an opportunity to participate.|April 2013|April 26, 2013|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01407172||100581|
NCT01403155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU-002|A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001|PHASE I, OPEN-LABEL, SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF AN H5 INFLUENZA PLASMID VACCINE (INO-3401) IN HEALTHY ADULTS PREVIOUSLY VACCINATED WITH VGX-3400X||Inovio Pharmaceuticals|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|22|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 26, 2012|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01403155||100890|
NCT01403168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSTEOPATHIE|Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology|Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology|OSTEOPATHIE|Centre Leon Berard|No|Terminated|April 2011|April 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|N/A|No|||June 2015|June 26, 2015|July 21, 2011||No|Recruitment difficulties|No||https://clinicaltrials.gov/show/NCT01403168||100889|
NCT01433549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-373-C-104|Lens Wear Schedules and End-of-Day Comfort|Effect of Recovery Periods on Ocular Comfort During Daily Lens Wear|INVERMERE|Alcon Research|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|44|||Both|17 Years|N/A|No|||April 2013|April 30, 2013|September 12, 2011|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01433549||98566|
NCT01403415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02679|Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma|A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma||National Cancer Institute (NCI)|Yes|Completed|September 2011|||May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|1 Year|21 Years|No|||March 2015|July 9, 2015|July 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01403415||100870|
NCT01434017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-51-08|Comparison of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting (PONV) in Children|Comparison of Three Different Prophylactic Treatments of PONV in Children||Centre Hospitalier Universitaire Vaudois|No|Completed|November 2008|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|300|||Both|2 Years|10 Years|No|||February 2014|February 26, 2014|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434017||98532|
NCT01434225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08NR26|NEMO1:NEonatal Seizure Using Medication Off-patent|NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent|NEMO1|Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Completed|August 2011|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|48 Hours|No|||September 2015|September 11, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01434225||98516|
NCT01434524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVACT 0801|Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids|The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids||Kochi University|Yes|Completed|April 2007|June 2011|Actual|October 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|16 Years|90 Years|Accepts Healthy Volunteers|||September 2011|September 14, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434524||98493|
NCT01434797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89/11|Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection|Prospective Study on the Usefulness and Diagnostic Value of F-18-FDG PET/CT in the Diagnosis of Permanent Central Venous Catheters Infection||University of Lausanne Hospitals|No|Recruiting|September 2011|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with pathology requiring permanent central venous catheter will be selected        mainly from nephrology and oncology departments . They might also be selected from other        deparments.|January 2016|January 24, 2016|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01434797||98472|
NCT01430065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK02|Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers|A Phase 1, Open Label, Single Sequence, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Volunteers||Astellas Pharma Inc|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 6, 2011|June 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01430065||98833|
NCT01430403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ICAC-20|Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations|Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-20)|PROSE|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2011|March 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|478|||Both|6 Years|17 Years|No|||January 2016|January 22, 2016|September 1, 2011|Yes|Yes||No|August 14, 2015|https://clinicaltrials.gov/show/NCT01430403||98807|
NCT01430416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COEB071X2102|Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients|A Phase 1 Study of AEB071, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma||Novartis||Active, not recruiting|December 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01430416||98806|
NCT01422460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11003011CTIL|The Efficacy of Platelets Rich Plasma Injection With PRGF Method in the Treatment for Osteoarthritis of the Subtalar Joint|||Meir Medical Center|No|Not yet recruiting|August 2011|June 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2011|August 23, 2011|August 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01422460||99414|
NCT01422694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110223|Natural History and Development of Spondyloarthritis|Studies on the Natural History and Pathogenesis of Spondyloarthritis||National Institutes of Health Clinical Center (CC)||Recruiting|August 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|999999999|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 28, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422694||99396|
NCT01423318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB25741|A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Doses of Lebrikizumab in Healthy Japanese and Caucasian Volunteers||Genentech, Inc.||Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423318||99348|
NCT01405794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50310|In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm|||University of Utah|Yes|Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|12|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|July 19, 2011|Yes|Yes||No|July 12, 2013|https://clinicaltrials.gov/show/NCT01405794||100687|
NCT01405781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46622|Functional and Radiographic Outcomes After Shoulder Surgery|Functional and Radiographic Outcomes After Shoulder Surgery||University of Utah|No|Enrolling by invitation|May 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|550|||Both|18 Years|N/A|No|Non-Probability Sample|Patients whose primary presenting complaint of shoulder pain and who then undergo        arthroscopic rotator cuff repair performed by the principal investigator for full        thickness rotator cuff tear will be eligible for inclusion. All patients who have        undergone reverse total shoulder arthroplasty, total shoulder arthroplasty utilizing a        lesser tuberosity osteotomy, acromioclavicular joint reconstruction, arthroscopic        scapulothoracic bursectomy or arthroscopic rotator cuff repair by the PI (RZT) will also        be eligible for inclusion in the study. These will include patients both at the University        of Utah as well as the Veteran's Administration Hospital in Salt Lake City.|February 2016|February 3, 2016|July 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01405781||100688|
NCT01434173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14705|Risk of Acute Liver Injury in Users of Antimicrobials|Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population||Bayer|No|Completed|July 2001|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1299056|||Both|18 Years|N/A|No|Non-Probability Sample|The source of study cohort will be the HealthCore Integrated Research DatabaseTM (HIRD)        population, which comprises a broad, clinically rich and geographically diverse spectrum        of longitudinal claims data from health plans in the United States of America (US)|July 2014|July 7, 2014|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01434173||98520|
NCT01406067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THAV-Study 1|Treatment of Children With Peer Related Aggressive Behavior|Treatment of Children With Peer Related Aggressive Behavior With the Treatment Programme THAV - a Randomized Controlled Trial||University of Cologne|No|Completed|January 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Male|6 Years|12 Years|No|||April 2014|April 14, 2014|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01406067||100666|
NCT01406665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAF-tree-IGTDM11|Skin Autofluorescence (AF) Decision Tree in Detecting Impaired Glucose Tolerance (IGT) or Diabetes Mellitus (DM)|Assessment of Value of Skin Autofluorescence in Detecting Diabetes Mellitus or Impaired Glucose Tolerance. Comparison With Fasting Plasma Glucose and Glycated Hb||University Medical Center Groningen|No|Completed|October 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|218|None Retained|none retained|Both|20 Years|N/A|No|Non-Probability Sample|Subjects identified from an outpatient (vascular, lipid) hospital-based group, with an        intermediate risk of (pre)diabetes, as defined by an age >35 years, and additionally at        least one criterion from the metabolic syndrome, or at least once an increased glucose or        HbA1c value in the preceding two years, but these outside the range of diabetes/IGT|July 2011|July 29, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406665||100620|
NCT01406938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2304|Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens|A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen|SCULPTURE|Novartis|Yes|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|967|||Both|18 Years|N/A|No|||April 2015|April 30, 2015|July 12, 2011|Yes|Yes||No|February 13, 2015|https://clinicaltrials.gov/show/NCT01406938||100599|A limitation of this study is the lack of a placebo group; however, because the placebo response is very low in psoriasis, it is inappropriate to maintain patients on placebo for 52 weeks. .
NCT01437761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-11|Sorbent Treatment Prescriptions Pilot Study|Hemodialysis With the 2008 Sorbent System: A Pilot Evaluation of Different Treatment Prescriptions|Sorb 2|Renal Research Institute|Yes|Recruiting|August 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|88 Years|No|||February 2014|February 18, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437761||98245|
NCT01433770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-11-06|Alefacept in Kidney Transplant Recipients|Effects of Alefacept on Donor-Specific Memory in Kidney Transplant Recipients||University Hospital Case Medical Center|No|Withdrawn|October 2011|October 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|65 Years|No|||February 2012|February 17, 2012|September 8, 2011|Yes|Yes|The drug will no longer be available in the United States.|No||https://clinicaltrials.gov/show/NCT01433770||98549|
NCT01433757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301-2011|Ampicillin for DYT-1 Dystonia Motor Symptoms|A Pilot, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Determine the Safety and Efficacy of Ampicillin in Treating Primary Dystonia Symptoms||University of Florida|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|14|||Both|7 Years|80 Years|No|||March 2016|March 17, 2016|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01433757||98550|
NCT01434251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 33865.041.10|Treatment of Hypotension of Prematurity (TOHOP)|Treatment of Hypotension of Prematurity: a Randomized, Non-blinded Cohort Clinical Trial|TOHOP|UMC Utrecht|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|24 Weeks|30 Weeks|No|||May 2015|May 26, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01434251||98514|
NCT01434264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-065176/DSF|Evaluating Personalized Effect of an Individualized Intervention|Cross-disciplinary Evaluation of Efficacy and Effectiveness of Individualized Complementary Therapies: Evaluating Personalized Effect of Energy Healing as an Individualized Intervention||University of Southern Denmark|Yes|Completed|September 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|247|||Both|18 Years|80 Years|No|||March 2014|March 7, 2014|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434264||98513|
NCT01434537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VENSCAN|Evaluation of a Touchless Vein Scanner for Venepuncture and Cannulation in Pediatric Patients|Venepuncture and Vein Cannulation With Support of the AccuVein AV300 Vein Scanner in Paediatric Patients in a Pre-operation Setting|VENSCAN|Charite University, Berlin, Germany|No|Completed|January 2011|July 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|238|||Both|N/A|17 Years|No|Non-Probability Sample|All patients from 0 to 17 years in a peripoerative setting in the pediatric operation room        with need for peripheral venous access.|September 2011|September 14, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01434537||98492|
NCT01434810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108M03601|Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates|Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1273|||Both|N/A|14 Days|Accepts Healthy Volunteers|||June 2015|June 1, 2015|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01434810||98471|
NCT01421433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FQM 01/11|A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol|Non Inferiority,Phase III,Multicentric,Double Blind,Randomized,Parallel Study,Comparing Dolamin Flex (Lysine Clonixinate+Cyclobenzaprine) and Tandrilax(Caffeine +Carisoprodol+Diclofenac+Paracetamol)in Pain Reduction in Patients With Lumbago||Farmoquimica S.A.|No|Not yet recruiting|May 2012|January 2013|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||March 2012|March 7, 2012|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01421433||99493|
NCT01421719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000124|Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease|Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy||Stanford University|No|Completed|February 2009|July 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|50 Years|85 Years|No|||August 2011|August 22, 2011|August 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01421719||99471|
NCT01423851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-018-101|Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF|A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF||NS Pharma, Inc.|Yes|Recruiting|June 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|August 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01423851||99307|
NCT01423864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906014R|Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome|Retrospective Study of Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome|IP steroid|National Taiwan University Hospital|No|Completed|June 2005|June 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|16 Years|87 Years|No|||August 2011|August 25, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01423864||99306|
NCT01435954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113908|Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy|Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy||GlaxoSmithKline|No|Completed|August 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13551|||Male|50 Years|N/A|No|Non-Probability Sample|Insured male patients, aged 50 and older, with a diagnosis of benign prostatic hyperplasia        (BPH) as identified by International Classification of Diseases, 9th Revision, Clinical        Modification (ICD-9) codes for BPH (ICD-9 = 222.2x or 600.xx)|July 2011|September 15, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435954||98384|
NCT01406093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC1-11|Early- and Late-onset Candidemia|Early- and Late-onset Candidemia: A Retrospective Study||University of Turin, Italy|No|Completed|May 2011|June 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|The selection of patients for inclusion will be based on microbiological data (with        suscesptibilty patterns of the various antifungals) extracted from the computerized        archive with search for Candida spp. and "blood" either peripheral or from a central        venous catheter. Candida isolated from a removed CVC tip will not be considered. The        candidemia will also be defined early or late based on the time elapsed between hospital        admission and diagnosis (≤ 10 days early, > 10 days late candidemia).|December 2014|December 2, 2014|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406093||100664|
NCT01405768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104269|Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs)|A Randomized Trial of Buffered vs Nonbuffered Lidocaine With Epinephrine for Cervical Loop Excision||Washington University School of Medicine|No|Completed|July 2011|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|56|||Female|18 Years|N/A|No|||June 2014|June 26, 2014|July 28, 2011|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01405768||100689|Small sample - may have missed a significant difference when one really existsProcedures performed by 2nd year residents vs. procedure performed by more skilled surgeon (less pain)Used needle extenders/27-gauge needles vs. Potocki needles
NCT01406080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR.10.002|A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging|Single-blinded, Multicenter, Randomized, Comparative Study of Efficacy and Safety of Adapalene Gel 0.3% Versus Tretinoin Emollient Cream 0.05% in the Treatment of Cutaneous Photoaging.|FOTEN|Galderma Brasil Ltda.|Yes|Recruiting|January 2013|November 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|35 Years|55 Years|No|||January 2013|January 22, 2013|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01406080||100665|
NCT01406379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prophylatic clip|Comparison of Prophylactic Clip and Detachable Snare|Comparison of Clip and Detachable Snare in Preventing Postpolypectomy Bleeding for Pedunculated Colonic Polyps: a Prospective, Randomized Study||The Catholic University of Korea|Yes|Completed|July 2010|February 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|N/A|N/A|No|||August 2013|August 18, 2013|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406379||100642|
NCT01406951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301PLAGH-20090923001|Diagnostic Value of sTREM-1 and PCT Level as Well as CPIS Score for Ventilator-Associated Pneumonia Among ICU Sepsis Patients|||Chinese PLA General Hospital|Yes|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|92|||Both|18 Years|N/A|No|Probability Sample|All subjects were selected from among inpatients who were hospitalized between March 2010        and March 2011 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's        Liberation Army (CPLA) General Hospital.|September 2009|July 29, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406951||100598|
NCT01406964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLC-JD-0904-025|Chlamidia Antibodies Test for Tubal Factor Screening|Chlamidia Antibodies Test for Tubal Factor Screening||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01406964||100597|
NCT01437488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.392|Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy|A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy||Thomas Jefferson University|Yes|Active, not recruiting|February 2012|September 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437488||98266|
NCT01437774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112310|ReStore Thrombectomy Trial for Flow Restoration in Acute Ischemic Stroke Patients|Prospective Mult-center Randomized Study of the Reverse Medial ReStore Device for Flow Restoration in Arteries of Patients Experiencing Acute Ischemic Stroke||Reverse Medical Corporation|Yes|Suspended|October 2011|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|22 Years|85 Years|No|||September 2012|September 4, 2012|September 19, 2011|Yes|Yes|DSMB recommendation to suspend trial due to control device|No||https://clinicaltrials.gov/show/NCT01437774||98244|
NCT01434030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14956|Development of a Behavioral Observer for Type 1 Diabetes Mellitus|Development of a Behavioral Observer for Type 1 Diabetes Mellitus|Phase1|University of Virginia|No|Completed|April 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|57|||Both|21 Years|65 Years|No|||August 2014|August 25, 2014|September 12, 2011||No||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01434030||98531|
NCT01434238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 0907000316|Evaluation of an Infant Feeding Intervention for HIV-exposed Haitian Infants|Evaluation of an Infant Feeding Support Strategy for HIV-exposed Infants 6-12 Months Old in Urban Haiti||Cornell University|No|Completed|June 2008|May 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|82|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||September 2011|September 14, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01434238||98515|
NCT01434043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40326-B|Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging|Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging||University of Washington|No|Recruiting|September 2011|||September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|20 Years|80 Years|No|Probability Sample|Adults with suspected or known myocardial ischemia|December 2014|December 1, 2014|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01434043||98530|
NCT01434277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNKEDI0003|Safety Evaluation of a New Preservative in a Lubricating Eye Drop|A Single-Center Study Evaluating the Safety of a New Preservative in an OTC Lubricant Eye Drop Used QID in Healthy Adults and in Subjects Diagnosed With Dry Eye||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|April 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 13, 2011|September 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01434277||98512|
NCT01434290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 0938|Radiation Therapy in Treating Patients With Prostate Cancer|A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|September 2011|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Male|18 Years|N/A|No|||November 2015|November 14, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434290||98511|
NCT01434550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16459|Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer|Phase II Study of First-line Stereotactic Body Radiation Therapy (SBRT) in Patients With Non-Metastatic Unresectable Pancreatic Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Withdrawn|March 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|September 13, 2011|Yes|Yes|research cancelled|No||https://clinicaltrials.gov/show/NCT01434550||98491|
NCT01435135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 305|Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144|Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: "Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults"||U.S. Army Medical Research and Materiel Command|No|Active, not recruiting|April 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|162|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435135||98447|
NCT01421732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13DX|Laboratory Diagnosis and Prognosis of Severe Dengue|Laboratory Diagnosis and Prognosis of Severe Dengue||Oxford University Clinical Research Unit, Vietnam|No|Recruiting|October 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|13500|||Both|1 Year|15 Years|No|Probability Sample|Patient presenting to outpatient department of participating hospitals with symptoms of        dengue fever|June 2014|June 25, 2014|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421732||99470|
NCT01422200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-2319|Flu Vaccine Study in Neuromuscular Patients 2011|Comparison of the Immunogenicity of Intramuscular Versus Subcutaneous Administration of Trivalent Inactivated Influenza Vaccine in Individuals With Neuromuscular Diseases||Children's Hospital Medical Center, Cincinnati|No|Recruiting|August 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|3 Years|35 Years|No|||August 2011|August 22, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422200||99434|
NCT01423006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16584|Pilot Study on Focal Prostate Radio-Frequency Ablation|Pilot Study on Focal Prostate Radio-Frequency Ablation for the Treatment of Very-Low Risk Prostate Cancer||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|August 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||November 2013|November 13, 2013|August 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01423006||99372|
NCT01423019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nutratech - 60|A Comparative Effectiveness Study Evaluating the Effects of Thermogenic Supplements on Body Composition|A Comparative Effectiveness Study Evaluating the Effects of Two Thermogenic Supplements on Body Composition Using a Double-Blinded Placebo-Controlled Protocol||Integrative Health Technologies, Inc.|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Anticipated|75|||Both|21 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 20, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01423019||99371|
NCT01423305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103008|Phase I Pharmacokinetic Study (BF-BLOCK)|Effect of Charcoal on Gastrointestinal Absorption of Budesonide and Formoterol|BF-BLOCK|Orion Corporation, Orion Pharma|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423305||99349|
NCT01424150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|164/11|REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study|Restrictive Versus Liberal Fluid Therapy in Major Abdominal Surgery|RELIEF|Bayside Health|Yes|Recruiting|July 2013|November 2018|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|2800|||Both|18 Years|N/A|No|||December 2015|February 1, 2016|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424150||99284|
NCT01424423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112988|NOGO-A in Multiple Sclerosis FTIH|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Patients With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy.||GlaxoSmithKline|No|Terminated|February 2010|February 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|55 Years|No|||September 2011|May 10, 2012|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01424423||99263|
NCT01446731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR1121|Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer|Dendritic Cell Vaccination in Combination With Docetaxel for Patients With Cancer Prostate - a Randomized Phase II Study||Herlev Hospital|Yes|Active, not recruiting|October 2011|April 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|N/A|No|||August 2015|August 17, 2015|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01446731||97568|
NCT01446744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-605|Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)|Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial|SABR-COMET|Lawson Health Research Institute|Yes|Recruiting|November 2011|November 2020|Anticipated|November 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|99|||Both|18 Years|N/A|No|||October 2015|October 18, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01446744||97567|
NCT01446718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|(MISP)IISP 51802|A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years|A Longitudinal Observational Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 9-14 Years in Kenya||Kenyatta National Hospital|No|Enrolling by invitation|December 2014|December 2019|Anticipated|November 2018|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|179|None Retained|Plasma for HPV antibody testing there will be no long term sample storage|Both|9 Years|14 Years|No|Non-Probability Sample|Study participants will be enrolled from the paediatric HIV-care clinic|October 2015|October 27, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446718||97569|
NCT01442610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-RaSPar-051|Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease|Effects of Rasagiline on Sleep Disturbances in PD: A Single Center, Randomized, Double-blind, Placebo run-in, Polysomnographic Clinical Phase IV Trial|RaSPar|Technische Universität Dresden|Yes|Completed|October 2011|September 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|85 Years|No|||January 2016|January 20, 2016|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442610||97873|
NCT01442623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoyalCSI DMeldrum|Conventional Versus Virtual Reality Based Vestibular Rehabilitation|Conventional Versus Virtual Reality Based Vestibular Rehabilitation; Effect on Dizziness, Gait and Balance||Royal College of Surgeons, Ireland|No|Completed|February 2011|December 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01442623||97872|
NCT01442883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNA-CKD3-5|Renal Nerve Ablation in Chronic Kidney Disease Patients|Understanding the Mechanisms of Progressive Decrease in Blood Pressure After Renal Nerve Ablation||University of Erlangen-Nürnberg Medical School|No|Recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Non-Probability Sample|treatment resistant hypertensive adults with chronic kidney disease 3 - 5|October 2015|October 8, 2015|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01442883||97852|
NCT01443130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0112|Chloroquine for Malaria in Pregnancy|A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|February 2012|January 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|900|||Female|N/A|99 Years|No|||May 2015|October 1, 2015|September 1, 2011|Yes|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01443130||97833|The observed placental malaria rate was lower than expected causing the study to be under powered. After review of a futility analysis, the Sponsor and DSMB recommended allowing the study to conclude as planned and not to increase the sample size.
NCT01443676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTE|Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma|Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma|ARTE|University of Zurich|Yes|Recruiting|October 2011|September 2016|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|65 Years|N/A|No|||August 2014|August 18, 2014|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01443676||97791|
NCT01443416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2011/05|An Alternative Booster Vaccine Against Meningitis and Ear Infections|An Alternative Booster Vaccine Against Meningitis and Ear Infections.||University of Oxford|Yes|Completed|April 2012|||August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|178|||Both|12 Months|13 Months|Accepts Healthy Volunteers|||November 2015|November 6, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443416||97811|
NCT01443429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100CRS03|A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment|A Pharmacokinetic Study of TRK-100STP -A Single Oral Administration Study in Japanese Patients With Renal Impairment as Compared to Subjects With Normal Renal Function||Toray Industries, Inc|No|Completed|August 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|24|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01443429||97810|
NCT01443962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA 2568|The Effect of Positive End Expiratory Pressure (PEEP) During Laparoscopic Cholecystectomy|The Effect of PEEP on Regional Cerebral Oxygen Saturation During Laparoscopic Cholecystectomy|lapaPEEP|Gachon University Gil Medical Center|Yes|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|65 Years|No|||February 2013|February 2, 2013|September 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01443962||97769|
NCT01444261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFe10D|Prevention of Iron Deficiency in Breastfed Infants|Prevention of Iron Deficiency in Breastfed Infants||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|December 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|133|||Both|N/A|9 Months|Accepts Healthy Volunteers|||April 2012|April 26, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444261||97746|
NCT01444274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-1000-0012|Pilot Study to Evaluate A Novel Gastric Space Occupying Device|A Single-Center 60-day Observational, Non-randomized Study to Evaluate Safety and Preliminary Efficacy of a Novel Gastric Space Occupying Device as an Aid for Weight Loss||Obalon Therapeutics, Inc.|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|64 Years|No|Non-Probability Sample|Overweight or obese individuals who have failed routine dieting in the past|September 2011|September 28, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444274||97745|
NCT01444560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|microRNA4|miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi|The miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi||Ruhr University of Bochum|Yes|Completed|December 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|21|Samples With DNA|human skin|Both|1 Year|N/A|No|Non-Probability Sample|Patients with cutaneous melanoma, cutaneous melanoma metastases, benign melanocytic nevi|October 2012|October 15, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444560||97723|
NCT01443715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6432|A Stepped Care Model of Adolescent Depression Treatment in Primary Care|A Stepped Care Model of Adolescent Depression Treatment in Primary Care|SCIPT-A|New York State Psychiatric Institute|Yes|Completed|September 2011|July 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|13 Years|20 Years|No|||April 2013|September 2, 2014|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443715||97788|
NCT01435759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-209|SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder|A Phase 2, Multicenter, Double- Blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant||Shire||Completed|October 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1197|||Both|18 Years|65 Years|No|||February 2015|February 3, 2015|September 15, 2011|Yes|Yes||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01435759||98399|
NCT01436032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1539-05|Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of Intravenous N1539 in Subjects After Abdominal Laparoscopic Surgery||Alkermes, Inc.|No|Terminated|October 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|80 Years|No|||March 2012|March 12, 2012|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436032||98378|
NCT01436058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-007|Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoartritis|Phase 1 Study of Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Patients With Ankle Joint Osteoarteritis||Royan Institute|Yes|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||May 2010|September 16, 2011|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436058||98376|
NCT01436591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEP-Sein|Comparison of Diagnostic Performance of an Algorithm and a High Definition Classical Iterative Algorithm Positron Emission Tomography (PET) to 18Fluoro-deoxy-glucose (18FDG) in the Evaluation of Axillary Lymph Node Invasion of Breast Tumors|Comparison of Diagnostic Performance of an Algorithm and a High Definition Classical Iterative Algorithm Positron Emission Tomography (PET) to 18Fluoro-deoxy-glucose (18FDG) in the Evaluation of Axillary Lymph Node Invasion of Breast Tumors|TEP-Sein|Centre Francois Baclesse|Yes|Terminated|March 2009|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|63|||Female|18 Years|N/A|No|Non-Probability Sample|Preoperative assessment of breast cancer.|September 2012|September 7, 2012|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01436591||98335|
NCT01436942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diakonhjemmet Hospital|Effect of Exercise on Disease Activity and Cardiovascular Risk Factors in Patients With Ankylosing Spondylitis|Effect of Exercise on Disease Activity and Cardiovascular Risk Factors in Patients With AS: A Single Blind Randomized Controlled Trail||Diakonhjemmet Hospital|Yes|Completed|September 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|No|||March 2013|February 2, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01436942||98308|
NCT01445847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-11-491|The Effect of Intravenous Lidocaine on Post-extubation Laryngospasm|Effect of Intravenous Lidocaine on the Incidence of Post-extubation Laryngospasm: A Randomised Controlled Trial||King Saud University|Yes|Terminated|January 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|400|||Both|18 Years|60 Years|No|||January 2015|January 1, 2015|September 29, 2011||No|Patient Safety Concerns|No|June 11, 2012|https://clinicaltrials.gov/show/NCT01445847||97635|Early termination of the trial led to small numbers of subjects that received allocated intervention, (i.e., 99 total participants).Additionally, protocol violation led to reduce the analyze subjects to 36 for each group.
NCT01446120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFRI01-CTIL-HMO|Insulin Loaded Orally Dissolved Films (Insulin-ODF)|||Hadassah Medical Organization|No|Not yet recruiting||||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|7|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01446120||97615|
NCT01446133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0509|Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)|Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2011|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446133||97614|
NCT01446393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-Promoteur 2010-01|Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)|Functional and Structural Characterization of the Peripheral Arteriopathy in Pseudoxanthoma Elasticum (PXE)|Ca-Art-PXE|University Hospital, Angers|No|Completed|May 2010|December 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|71|Samples With DNA|Blood samples for genetic and serum analysis|Both|18 Years|N/A|No|Non-Probability Sample|Patients with phenotypically and genetically (ABCC6) proved PXE and Control patients        paired for age (+/- 5 yeas) and gender.|November 2012|November 14, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446393||97594|
NCT01446406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-056|The MONARCA Project (MONitoring, treAtment and pRediCtion of bipolAr Disorder Episodes)|Electronic Daily Self-monitoring of Subjective and Objective Symptoms in Bipolar Disorder - The MONARCA Project (MONitoring, treAtment and pRediCtion of bipolAr Disorder Episodes)|MONARCA|Psychiatric Centre Rigshospitalet|Yes|Recruiting|October 2011|October 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||February 2012|February 27, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01446406||97593|
NCT01449539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2010-43|Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization|Pilot Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization||University of Arkansas|Yes|Terminated|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|September 6, 2011|Yes|Yes|Study was terminated early because the site that administered the hyperbaric oxygen treatment    closed and an alternative site could not be identified.|No|November 21, 2014|https://clinicaltrials.gov/show/NCT01449539||97353|Study was terminated early because the site that administered the hyperbaric oxygen treatment closed and an alternative site could not be identified. Only four subjects completed the trial.
NCT01442324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2252P|Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma|Studio Clinico Pilota Con Uso di Elettroporazione Irreversibile (IRE) Nel Trattamento di Lesioni Neoplastiche Epatiche Con Localizzazione ad accessibilità Limitata o ad Alto Rischio||Azienda Ospedaliera di Padova|Yes|Recruiting|February 2011|||September 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01442324||97895|
NCT01442636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-101021|Drug Eluting Stents In The Critically Ischemic Lower Leg 2|a Prospective, Multicenter, Controlled Trial Evaluating the Implant of a Drug Eluting Stent (XIENCE PRIME, Abbott Vascular) in the Critically Ischemic Lower Leg|DESTINY 2|Flanders Medical Research Program|Yes|Completed|July 2011|November 2014|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01442636||97871|
NCT01442649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE 18 / ACCORD 22/0906|Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab|Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab||UNICANCER|Yes|Active, not recruiting|December 2010|December 2018|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01442649||97870|
NCT01442896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111223|STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk (STARFISH)|STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk (STARFISH)|STARFISH|University of California, San Diego|No|Recruiting|September 2011|September 2015|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Primary Open Angle Glaucoma Health Individuals|September 2011|September 28, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442896||97851|
NCT01444326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2010-155|Impact of Dairy Consumption on Inflammation: a Clinical Study (PLI)|Impact of Dairy Consumption on Inflammation: a Clinical Study|PLI|Laval University|No|Completed|March 2010|December 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|140|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444326||97741|
NCT01443702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shirazums CT-90-5677|Use of Lapis Judaicus to Dissolve Kidney Stones|||Shiraz University of Medical Sciences|Yes|Completed|January 2011|||December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||November 2013|November 29, 2013|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01443702||97789|
NCT01443975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110043|Clinical Evaluation on the Use of the X-pander Device|Clinical Evaluation on the Use of the X-pander Device|X-Pander|Northern Orthopaedic Division, Denmark|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|all patients for primary THA|March 2014|March 28, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01443975||97768|
NCT01443988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-022|Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost|A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004%||Glaukos Corporation|No|Active, not recruiting|September 2011|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443988||97767|
NCT01444001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPR01|Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers|||Sanofi|Yes|Completed|February 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|63|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444001||97766|
NCT01443468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110255|Clinical and Genetic Studies of Li-Fraumeni Syndrome|Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome||National Institutes of Health Clinical Center (CC)||Recruiting|September 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5000|||Both|N/A|100 Years|Accepts Healthy Volunteers|||January 2016|February 13, 2016|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443468||97807|
NCT01435785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propofol TCI in Geriatric|Performance Evaluation of Four Pharmacokinetic-Pharmacodynamic(PKPD) Models of Propofol in Elderly Patients|Derivation and Prospective Validation of Four Pharmacokinetic-Pharmacodynamic Models of Propofol in Elderly Patients|TCIGeriatric|Universidad del Desarrollo|Yes|Enrolling by invitation|April 2011|December 2011|Anticipated|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|14|Samples With DNA|whole blood will be centrifugated, the plasma will be frozen and all the samples where      analysed wiht HPLC technique|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients older than 65 years, ASA 1,2 programed for elective sugery|September 2011|September 16, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435785||98397|
NCT01436604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRTOX|Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging|Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging|MRTOX|Centre Francois Baclesse|Yes|Terminated|February 2012|December 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|19|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|September 15, 2011||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01436604||98334|
NCT01436955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25543|A Study of RG1662 in Individuals With Down Syndrome|A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Investigate Safety and Tolerability of RG1662 in Individuals With Down Syndrome||Hoffmann-La Roche||Completed|November 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|30 Years|No|||March 2015|March 2, 2015|August 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01436955||98307|
NCT01437306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1004|Lofexidine Food Effect Study in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Food Effect Study of Lofexidine 400 μg (2 x 200 μg) Tablets||US WorldMeds LLC|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|September 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437306||98280|
NCT01445860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0171013|Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics|A Phase 1, Open-Label, Fixed-Sequence Study To Estimate The Effect Of Repeated Dosing Of PF-03882845 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects||Pfizer|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2011|September 30, 2011|July 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445860||97634|
NCT01446146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28111|Increasing Engagement in PTSD Treatment Through Patient Education and Patient Choice|||Michael Debakey Veterans Affairs Medical Center||Completed|October 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|27|||Both|N/A|N/A|No|||July 2013|July 22, 2013|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01446146||97613|
NCT01446159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI-573-1030|Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer|A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)||MedImmune LLC|Yes|Active, not recruiting|June 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|188|||Female|18 Years|99 Years|No|||March 2016|March 23, 2016|September 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446159||97612|
NCT01446419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 0003|SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain|A Prospective Randomized, Double-blind, Controlled Investigation Evaluating the Intracept Intraosseous Nerve Ablation System for the Reduction of Pain in Patients With Chronic Axial Low Back Pain|SMART|Relievant Medsystems, Inc.|Yes|Active, not recruiting|October 2011|June 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|25 Years|70 Years|No|||May 2015|May 4, 2015|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446419||97592|
NCT01446432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11011|Validation of Two New Questionnaires for Dupuytren's Disease|A Prospective Study to Validate Two New Patient Reported Outcome Measures for Dupuytren's Disease in Patients Treated With XIAFLEX||Hospital for Special Surgery, New York|No|Active, not recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|35 Years|N/A|No|Non-Probability Sample|Patients receiving treatment with XIAFLEX for Dupuytren's Disease|April 2015|April 1, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446432||97591|
NCT01449799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113423|An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers|A Randomised, Double-blind, Double-dummy, Single Dose, Four Way Cross-over Study to Compare the Pharmacokinetics and Pharmacodynamics of GSK961081 and Fluticasone Propionate When Administered Alone, Concurrently and as a Combination Blend in Healthy Subjects||GlaxoSmithKline|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449799||97333|
NCT01442337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8597-CL-0201|A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients|A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de Novo Kidney Transplant Recipients||Astellas Pharma Inc|Yes|Terminated|December 2011|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|21|||Both|18 Years|70 Years|No|||June 2014|June 17, 2014|September 16, 2011|Yes|Yes|Study was terminated by sponsor decision|No||https://clinicaltrials.gov/show/NCT01442337||97894|
NCT01442350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fabry-Myocardial|Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers|Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers|FAMY|Hospital Universitario Virgen de la Arrixaca|Yes|Not yet recruiting|October 2011|April 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Genotyping of relatives of mutation-known Fabry probands: in order to know which are the      relatives carrying mutations. (The investigators have already started this task).|Both|N/A|N/A|No|Probability Sample|This task will be performed at the monographic hypertrophic cardiomyopathy clinic. The        investigators intention is to include 12 families for testing the biomarkers elevation        correlation with the presence of disease. The investigators plan to achive the inclusion        of 30 families with Fabry diagnosed probands, including up to 130 relatives for        verification and the polimorfisms' study.|September 2011|September 27, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442350||97893|
NCT01442662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARCOME 11/1101|Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas|Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas|LMS03|UNICANCER|Yes|Recruiting|September 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|94|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01442662||97869|
NCT01442675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA77|Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine|Safety and Immunogenicity of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine||Sanofi|No|Completed|September 2011|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|834|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|September 26, 2011|Yes|Yes||No|November 11, 2014|https://clinicaltrials.gov/show/NCT01442675||97868|
NCT01442909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-02-09|Pemetrexed Followed by Docetaxel or in Reverse Sequence|Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy||Taipei Veterans General Hospital, Taiwan|Yes|Completed|March 2008|September 2009|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||September 2011|September 27, 2011|May 25, 2008||No||No||https://clinicaltrials.gov/show/NCT01442909||97850|
NCT01444924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0274|Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery|Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial||University of Wisconsin, Madison|Yes|Completed|September 2011|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|75|||Female|18 Years|N/A|No|||September 2014|September 15, 2014|September 29, 2011|Yes|Yes||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01444924||97695|Unilateral placement of block may decrease overall effectiveness. Sample size was small, from single institution, and encompassed a variety of diagnoses and procedures. Analysis also included intraoperative medications.
NCT01443143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO-2010-02|Blood Glucose Stability and Variability on Two Diets|A Comparison of Glycemic Stability and Variability During Consumption of Usual Diet or a Commercially Available Portion-controlled Diet Among Patients With Type 2 Diabetes||Nutrisystem, Inc.|No|Recruiting|December 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|65 Years|No|||September 2011|September 27, 2011|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443143||97832|
NCT01443156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU eIRB7542|The Effects of Work Schedule and Sleep Patterns on Caregivers' Health|||Oregon Health and Science University||Completed|January 2012|||February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|211|Samples With DNA|Mouthwash swish containing buccal cells.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cohort participants will be recruited from employees at a local health care center. Job        categories may include, but are not limited to:          -  Administrative services          -  Clinical services (radiology, laboratory, pharmacy, etc.)          -  Clinical support services (aide, clerk, processing, records, etc.)          -  Practitioner (physician, physician assistant, nurse practitioner, etc.)          -  Non-clinical services (food, nutrition, housekeeping, etc.)          -  Nursing services—registered nurse          -  Nursing services—certified nursing assistant          -  Rehabilitative services (occupational therapy, speech therapy, physical therapy,             etc.)|February 2013|February 14, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01443156||97831|
NCT01443442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-06-11|Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis|A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis||Southern California College of Optometry|No|Completed|October 2011|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443442||97809|
NCT01442701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17756|Stanford's Outcomes Research in Kids|Stanford's Outcomes Research in Kids (STORK)|STORK|Stanford University|No|Recruiting|March 2010|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood, saliva, skin swabs, stool, urine.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be enrolled from the population of pregnant women attending        obstetric clinics for the first antenatal visit. Each woman will be followed throughout        her pregnancy and then she and her baby will be followed over the first three years of the        baby's life (and more if possible).|September 2011|September 26, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01442701||97866|
NCT01436617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgES|Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab|Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab|IgES|Centre Francois Baclesse|Yes|Completed|January 2010|March 2013|Actual|March 2013|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|303|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with colon cancer or upper aero-digestive tract and candidates for treatment with        cetuximab|March 2013|March 7, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436617||98333|
NCT01436630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDS-2809|Step Test and Six Minute Walk Test in Stroke|Comparação Entre o Teste de Caminhada de Seis Minutos e o Teste do Degrau de Seis Minutos em Pacientes Com Acidente Vascular Encefálico||Faculdades Metropolitanas Unidas|No|Completed|February 2010|December 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|12|||Both|18 Years|N/A|No|Probability Sample|Post-stroke patients|September 2011|September 19, 2011|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01436630||98332|
NCT01436318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HK 176-2011|Respiratory Muscle Strength and Function in Healthy Kids|Respiratory Muscle Strength and Function in Healthy Children||University of Florida|No|Completed|April 2011|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|7|||Both|4 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Children|September 2014|September 22, 2014|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01436318||98356|
NCT01436331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1682|A Large Pragmatic Cluster Randomized Controlled Trial of a Multi-element Psychosocial Intervention for Early Psychosis|A Pragmatic Cluster Randomized Controlled Trial of a Multi-element Psychosocial Intervention for Early Psychosis in a 10 Million Inhabitant Catchment Area Aimed to Measure the Treatment's Feasibility and Effectiveness: GET UP-PIANO Trial|GETUP-PIANO|Universita di Verona|No|Completed|April 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|626|||Both|18 Years|54 Years|No|||January 2013|January 7, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436331||98355|
NCT01437345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH0311|A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset Facioscapulohumeral Muscular Dystrophy|A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset Facioscapulohumeral Muscular Dystrophy|FSHD|Cooperative International Neuromuscular Research Group|Yes|Active, not recruiting|July 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|53|Samples With DNA|Blood samples for DNA and RNA analysis are optional.|Both|N/A|N/A|No|Non-Probability Sample|Individuals with infantile onset (diagnosed at birth until 10 years of age) and        genetically confirmed FSHD will be recruited. This will include children and youth (less        than 18 years old) with FSHD who are currently followed in pediatric neuromuscular        centers, as well as adults (18 years or older) with FSHD who are identified as having        infantile onset of disease by chart review, clinical exam, and genetic confirmation.|July 2015|July 27, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437345||98277|
NCT01437605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16545|Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC|A Randomized Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC in Patients With Resected MAGE-A3 Positive, Stage IV Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|October 2011|January 2019|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437605||98257|
NCT01437618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAF-0809-TRIBV|First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer|FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation||Azienda Ospedaliero, Universitaria Pisana||Completed|June 2009|May 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|75 Years|No|Probability Sample|BRAF mutant mCRC|September 2011|September 20, 2011|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01437618||98256|
NCT01445249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H1304/118|Medial Forefoot Block for Analgesia After Foot Surgery|A Randomised, Blinded Comparison of a Nerve Stimulator Guided Ankle Block Compared to a Landmark Guided Ankle Block for Pain Relief After Forefoot Surgery.||Hull and East Yorkshire Hospitals NHS Trust|No|Completed|March 2007|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|85 Years|No|||September 2011|September 30, 2011|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01445249||97675|
NCT01445262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115066|Drug Use Investigation for XYZAL®|Drug Use Investigation for XYZAL||GlaxoSmithKline|No|Completed|February 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10728|||Both|N/A|N/A|No|Probability Sample|Japanese male and female subjects without age restriction who were considered appropriate        to prescribe levocetirizine tablet according to the prescribing information were eligible        for this surveillance study.|August 2015|August 10, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01445262||97674|
NCT01445626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/RET/010|A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)|||Allergan|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|87|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who received at least 2 injections of OZURDEX® to treat macular oedema due to        branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in at least        1 eye.|January 2013|January 14, 2013|September 30, 2011|Yes|Yes||No|January 14, 2013|https://clinicaltrials.gov/show/NCT01445626||97651|
NCT01442727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTU-JES-1|Selenium in the Treatment of Arsenic Toxicity and Cancers|Selenite in the Detoxification of Arsenic and the Prevention of Arsenical Melanosis and Cancers Amongst Bangladeshi Arsenicosis Patients: A 48-week, Randomized, Double-blinded, Placebo-controlled Phase III Trial|SETAC|Texas Tech University|Yes|Completed|December 2006|April 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|819|||Both|12 Years|55 Years|No|||October 2011|October 6, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01442727||97864|
NCT01442948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD16PHAMOS|CD16+ Monocytes in Coronary Heart Disease (CHD)|CD16+ Monocytes in Patients With Coronary Heart Disease|PHAMOS|Martin-Luther-Universität Halle-Wittenberg|No|Completed|May 2007|December 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with angiographically proven coronary heart disease, admitted to the Department        of Medicine or Department of Cardiothoracic Surgery of the Martin Luther-University        Halle-Wittenberg|September 2011|September 28, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01442948||97847|
NCT01445873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1321051|Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)|Non-Interventional (NI) Drug Study Protocol: Three-Country Pilot Study For Retrospective Chart Review Of Effectiveness Of Thelin® (Sitaxsentan) In Patients With Pulmonary Arterial Hypertension (PAH)||Pfizer|No|Completed|December 2009|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|36|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Pulmonary Arterial Hypertension (PAH) (Idiopathic or secondary to connective        tissue disease), receiving sitaxentan sodium (Thelin) for treatment of their PAH for at        least 6 months.|September 2011|May 9, 2012|September 30, 2011||No||No|February 14, 2012|https://clinicaltrials.gov/show/NCT01445873||97633|
NCT01450046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16153|Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects|A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Multiple Dose Administration in Healthy Subjects||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|October 2011|December 2016|Anticipated|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 29, 2016|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01450046||97315|
NCT01450319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 062202-529|A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype|Phase II Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favourable FcγR IIa (CD32) Genotype|MUTEX|Merck KGaA||Completed|September 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450319||97294|
NCT01446445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCV2010|Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.|Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirus(CMV)Infection Using Bayesian Prediction.||Hospital Universitari de Bellvitge|No|Completed|December 2011|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01446445||97590|
NCT01442922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37-2011|Intervertebral Disc Augmentation With Minimally Invasive Surgical Procedure|Intervertebral Disc Nucleus Augmentation With Allograft Meniscus With Minimally Invasive Surgical Procedure||University of Florida|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|44 Years|No|Non-Probability Sample|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo        surgery for HMA implantation to replace the nucleus pulposus.|December 2012|January 16, 2013|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01442922||97849|
NCT01443169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081286|A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted|A Phase 1, Randomized, Open Label, Single Dose, 5-treatment, 5- Period Crossover Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release Pregabalin Tablet Formulations Administered Following an Evening Meal and the Immediate Release Formulation Administered Fasted||Pfizer|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 17, 2012|September 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01443169||97830|
NCT01445652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-370-C-091 / CB11-500|A Lifestyle Investigation With Spectacles and Daily Disposable Contact Lenses in Young Patients|A Lifestyle Investigation With Spectacles and Daily Disposable Contact Lenses in Young Patients||Alcon Research|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|13 Years|19 Years|No|||September 2013|September 11, 2013|September 30, 2011|Yes|Yes||No|June 28, 2013|https://clinicaltrials.gov/show/NCT01445652||97649|
NCT01445275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-8030|Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199|A Comparative Effectiveness Study of Cancer Risk Management for Women at Elevated Genetic Risk of Ovarian Cancer||Gynecologic Oncology Group||Not yet recruiting|January 2100|||January 2100|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|2605|||Female|30 Years|N/A|No|Non-Probability Sample|Patients with ovarian cancer who participated in GOG-0199|May 2015|May 27, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445275||97673|
NCT01446185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00577-32|Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients|Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients|SWITCH|Genomic Health®, Inc.|No|Completed|January 2011|May 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Female|18 Years|N/A|No|||April 2013|April 17, 2013|September 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01446185||97610|
NCT01446458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051215|Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer|Phase I Study of Stereotactic Body Radiation Therapy and 5-Fluorouracil, Oxaliplatin and Irinotecan (FOLFIRINOX) in the Neoadjuvant Therapy of Pancreatic Cancer||Emory University|Yes|Completed|November 2011|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|21 Years|N/A|No|||March 2016|March 21, 2016|September 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446458||97589|
NCT01443182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL31098.097.10|Treatment of Posttraumatic Stress Disorder (PTSD) in Adult Survivors of Early Chronic Interpersonal Trauma|Treatment of PTSD in Adult Survivors of Early Chronic Interpersonal Trauma||VU University of Amsterdam|No|Recruiting|September 2011|September 2015|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||October 2013|October 31, 2013|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443182||97829|
NCT01443728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE3244|Vitamin D for Sickle-cell Respiratory Complications|Vitamin D for Sickle-cell Respiratory Complications||Columbia University|Yes|Active, not recruiting|December 2011|May 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|3 Years|20 Years|No|||February 2016|February 27, 2016|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443728||97787|
NCT01443741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2009- 03|Evaluation of Interests of FIT Therapy on Diabetics Children Insulin-dependent|Evaluation of Interests of the Functional Insulin Therapy (FIT Therapy) on Metabolic Control, Hypoglycemia Prevention and Life Quality of Diabetics Children Insulin-dependent Treated With Insulin Pump.|DIABFIT|University Hospital, Angers|No|Not yet recruiting|January 2012|July 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|1 Year|17 Years|No|||September 2011|September 28, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443741||97786|
NCT01437358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0100|Epidural Analgesia in Intensive Care Unit (APD-REA: Analgesie PeriDurale en REAnimation)|Epidural Analgesia in Intensive Care Unit Patients: an Observational Prospective Multicenter Feasibility and Safety Study||University Hospital, Clermont-Ferrand||Completed|August 2011|January 2012|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|80|||Both|18 Years|95 Years|No|Non-Probability Sample|patients requiring epidural analgesia, whether the epidural analgesia catheter is inserted        in the ICU or outside the ICU, e.g. in the operating room|February 2012|February 27, 2012|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01437358||98276|
NCT01436968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrTK03|Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer|A Randomized Controlled Trial of ProstAtak™ as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer|PrTK03|Advantagene, Inc.|Yes|Recruiting|September 2011|||September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|711|||Male|18 Years|N/A|No|||March 2016|March 2, 2016|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436968||98306|
NCT01433445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589X2106|Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis|A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)||Novartis|No|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01433445||98574|
NCT01433692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0103|CANABIC : CANnabis and Adolescents, a Brief Intervention (BI) to Reduce Their Consumption|Does a BI Conducted by General Practitioners Reduce Consumption of Canabis in 15 to 25 Years Old ?|CANABIC|University Hospital, Clermont-Ferrand|No|Recruiting|March 2012|July 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|750|||Both|15 Years|25 Years|No|||January 2013|January 11, 2013|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433692||98555|
NCT01442402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000734|APOL1 Gene Variants in African American Kidney Transplant Recipients|Impact of APOL1 Gene Variants in African American Kidney Transplant Recipients: A Study of Clinical Outcomes and Molecular Mechanisms||Brigham and Women's Hospital|No|Recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|190|Samples With DNA|Aims 1 and 2:      Subjects will collect a saliva specimen in an Oragene®•DNA sample collection kit for      genotyping. We will also collected any discarded (no longer utilized for clinical purposes)      tissue from biopsies.      Aim 3:      Prior to transplant, subjects will collect saliva in an Oragene®•DNA sample collection kit      for genotyping and 10cc of blood will be drawn into a Na heparin collection tube for APOL1      protein analysis. When applicable, plasmapheresis effluent will be collected. We will also      collected any discarded (no longer utilized for clinical purposes)tissue from biopsies.|Both|18 Years|N/A|No|Non-Probability Sample|African American Renal Transplant Patients|February 2013|February 14, 2013|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01442402||97889|
NCT01442714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEM0022|Azacitidine + Lenalidomide Combo in the Elderly Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS)|Azacitidine Plus Lenalidomide Combination in Elderly Patients With Previously Treated AML and High-Risk MDS (VIREL2 Trial)||Stanford University|Yes|Terminated|August 2011|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|60 Years|N/A|No|||March 2014|March 16, 2014|September 23, 2011||No|Lack of efficacy - Inability to meet the primary response endpoint|No||https://clinicaltrials.gov/show/NCT01442714||97865|
NCT01448616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41250-J|Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding|Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial||University of Washington|Yes|Completed|February 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|73|||Female|18 Years|50 Years|No|||December 2015|December 2, 2015|September 14, 2011|Yes|Yes||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01448616||97423|The study was not powered to detect differences in lesion rate; the study was appropriately powered to detect a 50% decrease in viral shedding only, and therefore may have been underpowered to detect significant findings for secondary outcomes.
NCT01448629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP214OC|Safety and Performance of a New 1-piece Ostomy Product Compared to Standard Care Ostomy Products in Subjects Ileostomy|An Open-labelled, Randomised, Controlled, Comparative, Explorative, Cross-over Study Investigating Safety and Performance of a New 1-piece Ostomy Product Compared Standard Care Ostomy Products in Subjects With Ileostomy||Coloplast A/S|No|Withdrawn|May 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|August 18, 2011||No|The study was withdrawn because of problems found with the baseplate|No||https://clinicaltrials.gov/show/NCT01448629||97422|
NCT01448083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-MIBG-005|Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours|||Nuclear Medicine Consultants, Inc.|No|Recruiting|October 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|Neuroendocrine Tumor Clinic|September 2012|September 16, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01448083||97464|
NCT01448096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chonbuk058|Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma|Multi-center Phase II Study of the Combination of R-CHOP (RItuximab Plus Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) and Prophylactic Intrathecal Chemotherapy With Methotrexate in Patients With CD20+ Primary Breast Diffuse Large B-cell Lymphoma||Chonbuk National University Hospital|No|Recruiting|August 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Female|20 Years|75 Years|No|||February 2016|February 5, 2016|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448096||97463|
NCT01446757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/41-31|Ambulatory Geriatric Evaluation - Frailty Intervention Trial|Effectiveness of a Comprehensive CGA on Frailty in Community-dwelling Elderly People - A Randomised, Controlled Trial|AGE-FIT|Linkoeping University|No|Completed|March 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|383|||Both|75 Years|N/A|No|||March 2014|March 29, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01446757||97566|
NCT01446770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-0127|Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181|A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision||Halscion, Inc.|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|15 Years|50 Years|No|||March 2012|March 12, 2012|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01446770||97565|
NCT01446172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hedley-1|Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia|Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Panic Disroder and Agoraphobia||Modum Bad|Yes|Completed|November 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|132|||Both|18 Years|65 Years|No|Probability Sample|Patients diagnosed with panic disorder with or without agoraphobia and/or agoraphobia        without history of panic disorder who have accepted treatment at an inpatient psychiatric        hospital|April 2012|April 20, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446172||97611|
NCT01442688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-114|Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Amoxicillin Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects||Shire||Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|September 26, 2011|No|Yes||No|August 16, 2012|https://clinicaltrials.gov/show/NCT01442688||97867|
NCT01444027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNR012213A|Hospice Problem Solving Intervention|A Problem Solving Intervention for Hospice Caregivers||University of Washington|No|Active, not recruiting|October 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|300|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444027||97764|
NCT01446822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-OBT-01|Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors|Transurethral Resection of Bladder Tumors Without Obturator Nerve Block or Relaxation: Extent of Adductor Muscle Contraction With Monopolar Versus Bipolar Resection Technique||Cantonal Hospital of St. Gallen|Yes|Recruiting|October 2011|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446822||97561|
NCT01445886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG2A0191|Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis|Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract and Calcipotriol Solution in Patients With Nail Psoriasis||Chang Gung Memorial Hospital|Yes|Completed|January 2011|March 2013|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01445886||97632|
NCT01442376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALO-10-20|Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients|A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC||Helsinn Healthcare SA|Yes|Completed|September 2011|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|502|||Both|N/A|16 Years|No|||August 2014|August 4, 2014|September 21, 2011|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01442376||97891|
NCT01442389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0819|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2011|||||N/A|N/A|N/A||||||||||||||August 24, 2012|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442389||97890|
NCT01442974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX271-PA09EU|Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer|Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer||Grupo Hospital de Madrid|Yes|Completed|January 2011|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|June 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01442974||97845|
NCT01436344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|084/11|Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography|Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography||University Hospital Inselspital, Berne|No|Completed|September 2011|April 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|50|||Both|18 Years|N/A|No|Probability Sample|The study population consists of patients hospitalized on the cardiology ward (for any        reasons). Additionally, also patients referred to the cardiology ambulatorium for a        long-term ECG will be asked to participate the study.|July 2015|July 22, 2015|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01436344||98354|
NCT01436981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAV002-AHK|Pharmacokinetics of Pavaverine After Intraluminal Administration|Observational Study on Papaverine During Cardiac Surgical Procedures||Johann Wolfgang Goethe University Hospitals|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Probability Sample|CABG patients|June 2013|June 3, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436981||98305|
NCT01437657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25620|MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy|A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment||Hoffmann-La Roche||Completed|October 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|319|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437657||98253|
NCT01437631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0653|EFficacy of Prophylactic Clip Application in Decrease of Immediate Postpolypectomy Bleeding and Delayed Postpolypectomy Bleeding After Colonoscopic Removal for a Large Pedunculated Polyps|Does a Prophylactic Clip Application Decrease IPPB(Immediate Postpolypectomy Bleeding) and DPPB(Delayed Postpolypectomy Bleeding) After Colonoscopic Removal for a Large Pedunculated Polyps (>1cm)?||Asan Medical Center|No|Recruiting|September 2011|December 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|384|||Both|20 Years|N/A|No|||June 2015|June 22, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437631||98255|
NCT01437644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023240-33|The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial|Post-operative Pain in Children With Cerebral Palsy Following Major Hip Surgery: a Double Blind Randomised Placebo Controlled Trial of Pre-operative Botulinum Toxin Type A|POPPIES|Guy's and St Thomas' NHS Foundation Trust|Yes|Completed|October 2011|January 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|2 Years|15 Years|No|||April 2015|April 30, 2015|September 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01437644||98254|
NCT01433926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LongHer|Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years|Observational, Cross-sectional Study to Analyze the Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete Remission, Partial Remission or Stabilization of Disease During More Than 3 Years|LongHer|Asociación para el Progreso de la Oncología en Málaga|Yes|Completed|September 2009|September 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|114|Samples With DNA|primary tumor, preserved in paraffin|Female|18 Years|N/A|No|Non-Probability Sample|Women with disseminated breast cancer, HER-2 3+ or FISH+.|September 2011|September 13, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01433926||98539|
NCT01434147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABCSG R05|Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy|Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin) Followed by Capecitabine (Xeloda) Plus Radiotherapy (RTx)||Austrian Breast & Colorectal Cancer Study Group|Yes|Completed|October 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|80 Years|No|||March 2014|March 6, 2014|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01434147||98522|
NCT01433952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132653|Pharmacokinetics of Oral Thiamine|Pharmacokinetics of High Dose Oral Thiamine||Baystate Medical Center|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2011|September 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01433952||98537|
NCT01443208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061137|Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet|A Phase 1, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, Parallel-Group, Single and Multiple-Dose Study of Desvenlafaxine in Korean Healthy Subjects||Pfizer|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 29, 2011|September 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01443208||97827|
NCT01443481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2124|Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function|A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function||Novartis|No|Completed|November 2011|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|38|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|September 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443481||97806|
NCT01448902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC000459/007/06|A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis|A Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis||Oxagen Ltd|No|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|50 Years|No|||October 2011|October 6, 2011|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01448902||97401|
NCT01450332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACLPPS01 Rev 4|Safety and Efficacy of the Knee-T-nol Anterior Cruciate Ligament (ACL) Prosthesis|A Single Arm, Prospective, Single Center, Study To Evaluate The Safety And Efficacy Of Tavor ACL Prosthesis In Patient With ACL Rupture||Tavor Ltd.|Yes|Recruiting|March 2011|January 2013|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||October 2011|October 11, 2011|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01450332||97293|
NCT01445327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070111|Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers|A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies||National Institutes of Health Clinical Center (CC)||Terminated|February 2007|January 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|9|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445327||97669|
NCT01445717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0317|Rapid Diagnostic Test for Detection of Group B Streptococcus in Pregnancy|Use of a New Rapid Method, BioNanoPore, for Growth and Detection of Group B Streptococcus in Pregnant Patients|GBS|The University of Texas Health Science Center, Houston|No|Completed|November 2010|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|358|Samples Without DNA|Specimens are to be retained for one month, frozen in LIM broth, and will be held for use if      reprocessing specimens is required.|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant patients who present to the UT resident or attending clinic between 35-37 weeks        for routine follow-up will be asked to enroll.|May 2013|May 2, 2013|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445717||97645|
NCT01442363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCD-02|A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease|||Braintree Laboratories|No|Terminated|November 2011|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442363||97892|
NCT01443455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08080012|Adherence and Health Effects of Video Dance in Postmenopausal Women|Phase 2 Trial of Video Dance Versus Walking in Postmenopausal Sedentary Overweight Women||University of Pittsburgh|Yes|Recruiting|January 2010|September 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|168|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 28, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443455||97808|
NCT01444612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113164|Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery|Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery||GlaxoSmithKline|No|Completed|February 2010|November 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4068|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 years or older with at least one primary inpatient discharge diagnosis of        cancer who experienced a cancer-related surgery during the hospitalization were the        initial target population.|October 2011|October 6, 2011|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01444612||97719|
NCT01442428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS967180|Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial|Randomized Controlled Trial for Corticosteroids Versus NSAIDs With or Without Adjunctive Atorvastatin for the Treatment for Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome||University of Minnesota - Clinical and Translational Science Institute|Yes|Withdrawn|January 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|August 30, 2011||No|2011 Thailand flooding led to loss of GMP pharmacy, project delays, and further regulatory    challenges.|No||https://clinicaltrials.gov/show/NCT01442428||97887|
NCT01442441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0809-67|Correlation of Chronic Pancreatitis Pathology Features With Endoscopic Ultrasound (EUS) Criteria|How Pathologic Features of Chronic Pancreatitis Corelate With Endoscopic Ultrasound (EUS) Criteria for Diagnosing Chronic Pancreatitis||Indiana University|No|Completed|February 2009|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Retrospective surgery cases who had chronic pancreatitis|September 2014|September 3, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442441||97886|
NCT01446471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REASON01|REASON 1 Trial: Sonography in Cardiac Arrest|REASON 1 Trial: Sonography in Cardiac Arrest||University of Massachusetts, Worcester|No|Completed|January 2010|November 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|793|||Both|N/A|N/A|No|Non-Probability Sample|Patients in cardiac arrest|November 2015|November 30, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01446471||97588|
NCT01446783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-010|IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients|IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients||Bispebjerg Hospital|No|Completed|September 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 19, 2012|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01446783||97564|
NCT01442935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE 14 / ACCORD 21/0905|Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases|Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases||UNICANCER|Yes|Active, not recruiting|February 2011|February 2019|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|256|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01442935||97848|
NCT01443234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/SC/0278|OxIGen: Oxford Imagery Generation: Investigating the Effects of an Internet Based Computer Program in Depression|OxIGen: Oxford Imagery Generation: Investigating the Effects of an Internet Based Computer Program in Depression|OxIGen|University of Oxford|No|Completed|February 2012|December 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|65 Years|No|||June 2013|January 8, 2014|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443234||97825|
NCT01436994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTH 2759|Antithyroid Drug Treatment of Thyrotoxicosis in Young People|A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Active, not recruiting|July 2004|December 2015|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|2 Years|16 Years|No|||May 2015|May 7, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01436994||98304|
NCT01437007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110240|TKM 080301 for Primary or Secondary Liver Cancer|A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic||National Institutes of Health Clinical Center (CC)||Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2012|February 19, 2014|September 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01437007||98303|
NCT01433471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R#11-02470|Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova|Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova|MUCUS|New York University School of Medicine|Yes|Completed|August 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|4|||Both|18 Years|72 Years|No|||June 2015|June 1, 2015|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433471||98572|
NCT01433458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2101|Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects|A Single-dose, Open-label Parallel Study to Assess the Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects||Novartis||Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|55|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 20, 2013|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433458||98573|
NCT01433718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ohio_U11F024|Decreasing Knee Injury Risk Factors With Neuromuscular Training|The Effectiveness of Neuromuscular Training on Modifiable Anterior Cruciate Ligament Injury Risk Factors||Ohio University|No|Recruiting|September 2011|June 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|20 Years|Accepts Healthy Volunteers|||September 2011|September 13, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433718||98553|
NCT01448369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R815/10/2011|Eyelid Warming Technology for Meibomian Gland Dysfunction|Eyelid Warming Technology for Relief of Meibomian Gland Dysfunction in an Asian Population||Singapore National Eye Centre|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|21 Years|90 Years|No|||June 2014|June 9, 2014|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01448369||97442|
NCT01444664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20137|Aneurysm Wall Histology Registry|Aneurysm Wall Histology and Correlation With Cerebrospinal Fluid and Blood Plasma Registry||Medical University of South Carolina|No|Completed|June 2010|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|80 Years|No|||April 2015|March 23, 2016|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444664||97715|
NCT01449240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-HIT-072|Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome|A Cerebrospinal Fluid Collection Study in Pediatric and Adult Patients With Hunter Syndrome||Shire|No|Completed|March 2011|May 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|CSF and urine samples will be retained and analyzed for glycosaminoglycans (GAGs), including      sulfated DS/HS oligosaccharides, GAG-degradation products, and other biomarkers of CNS or      lysosomal function.|Male|N/A|70 Years|No|Non-Probability Sample|The study population will consist of pediatric (<18 years of age) and adult (≥18 years of        age) male patients with Hunter syndrome. Up to approximately 60 patients (approximately 30        adults and 30 children) may be enrolled in this study.|March 2014|October 6, 2015|October 6, 2011||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01449240||97376|
NCT01449526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|661|A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design|A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design||Bausch & Lomb Incorporated|No|Completed|August 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|166|||Both|18 Years|40 Years|No|||February 2015|February 13, 2015|October 6, 2011|Yes|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01449526||97354|
NCT01445977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN006|SoundBite Hearing System Long Term Multi Site Patient Use Study|SoundBite Hearing System Long Term Multi Site Patient Use Study||Sonitus Medical Inc||Active, not recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|All trial subjects are individuals that have decided to purchase SoundBite Hearing System        for treatment of their Single Sided Deafness or Conductive Hearing Loss and are willing to        participate in this study.|August 2013|August 1, 2013|September 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01445977||97626|
NCT01445938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY11737|Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria|An Open-label, Randomized Multicenter Study to Investigate the Anti-parasitic Activity, Pharmacokinetic and Safety of IM SAR97276A With Oral ACTs as Positive Control in Children Presenting With Symptomatic Plasmodium Falciparum Uncomplicated Malaria||Sanofi|Yes|Terminated|October 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|20|||Both|2 Years|17 Years|No|||December 2012|December 12, 2012|September 26, 2011|Yes|Yes|Data Monitoring Committee recommendation|No||https://clinicaltrials.gov/show/NCT01445938||97629|
NCT01445951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-171|Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period|A Phase 3, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With a Basal Insulin Versus Insulin Aspart in Combination With a Basal Insulin in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period||Mannkind Corporation|Yes|Completed|September 2011|June 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|518|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|September 30, 2011|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01445951||97628|
NCT01446211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO005-NK103|Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis|Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)|SPARROW|Nordic Pharma SAS|Yes|Terminated|November 2011|January 2015|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|75 Years|No|||January 2015|May 28, 2015|September 20, 2011|Yes|Yes|Change of design consideration|No||https://clinicaltrials.gov/show/NCT01446211||97608|
NCT01446510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTERiskMA8011|Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients|Systematic Review and Meta-Analysis of Venous Thromboembolism Risk Assessment Models in Hospitalized Medical Patients||Intermountain Health Care, Inc.|No|Withdrawn|September 2011|April 2013|Anticipated|October 2012|Anticipated|N/A|Observational|N/A||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult hospitalized medical patients|September 2011|April 17, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446510||97585|
NCT01446523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endotoxins in MHE|S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE|Serum Endotoxins, Inflammatory Mediators and MR Spectroscopy Before and After Treatment in Minimal Hepatic Encephalopathy|endtxninHE|Govind Ballabh Pant Hospital|Yes|Completed|October 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|15 Years|70 Years|No|||April 2012|April 9, 2012|September 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446523||97584|
NCT01446809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7487|Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma|The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging||University of Washington|No|Recruiting|April 2012|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|21|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|September 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446809||97562|
NCT01442454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008-15|Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis|Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis: A Prospective Correlation With Intraoperative Findings and Surgical Pathology||Indiana University|No|Terminated|October 2010|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing EUS|February 2016|February 29, 2016|September 26, 2011||No|The PI left and then the PI who would be taking over has left. No other investigator wanted to    take the study since not sponsored|No||https://clinicaltrials.gov/show/NCT01442454||97885|
NCT01442766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1793|Donepezil Trial for Motor Recovery in Acute Stroke|A Randomised-controlled Trial of Donepezil for Motor Recovery in Acute Stroke||Imperial College London|Yes|Not yet recruiting|November 2011|May 2014|Anticipated|November 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2011|September 29, 2011|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442766||97861|
NCT01442415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104M98872|Vikings Fitness Playbook: A Family Based Lifestyle Modification Program for Overweight and Obese Youth|Vikings Fitness Playbook: A Family Based Lifestyle Modification Program for Overweight and Obese Youth||University of Minnesota - Clinical and Translational Science Institute|Yes|Terminated|October 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|8 Years|16 Years|Accepts Healthy Volunteers|||October 2012|October 22, 2012|August 30, 2011||No|Unable to achieve enrollment goal.|No||https://clinicaltrials.gov/show/NCT01442415||97888|
NCT01442740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTP-2011|15-Degree Tilt, Head Up, Feet Down Body Position for Sinus Surgery Patients|15-Degree Reverse Trendelenburg Position for FESS|RTP|St. Paul's Hospital, Canada|No|Completed|October 2011|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Both|19 Years|N/A|No|||August 2013|August 28, 2013|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442740||97863|
NCT01443247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dengue fever pgimer trial|Role of Andi-d in Dengue Fever: a Pilot Study|Role of Andi-d in Dengue Fever: a Pilot Study||Postgraduate Institute of Medical Education and Research|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2011|September 28, 2011|September 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443247||97824|
NCT01437371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0102|Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?|Is There a Benefit to Optimize HF (Heart Failure) Treatment in Aged Over 80 Year's Old Patients?|HF 80|University Hospital, Clermont-Ferrand||Completed|August 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|N/A|N/A|No|||September 2014|September 30, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01437371||98275|
NCT01437397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-MD-31|Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)|LAC|Forest Laboratories|No|Completed|September 2011|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1692|||Both|40 Years|N/A|No|||April 2013|April 5, 2013|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437397||98273|
NCT01437410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-01-044|Endoscopic Ultrasound-guided Fine Needle Aspiration of Solid Masses: Histological and Immunohistochemical Evaluation|Endoscopic Ultrasound-guided Fine Needle Aspiration of Solid Masses: Histological and Immunohistochemical Evaluation||Samsung Medical Center||Completed|January 2009|||July 2010|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|116|Samples Without DNA|cytopathologic result acquired by endoscopic ultrasound-guided fine needle aspiration      (EUS-FNA).|Both|30 Years|N/A|No|Non-Probability Sample|patients who underwent EUS-FNA to evaluate solid pancreatic or peripancreatic lesions from        January 2009 to July 2010 in Samsung Medical Center,|September 2011|September 19, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01437410||98272|
NCT01437683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01122-55|PariS-TBI Study : Paris Severe Traumatic Brain Injury Study|Four Year Outcome After Severe Traumatic Brain Injury in the Parisian Area|PariS-TBI|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2010|June 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|252|||Both|15 Years|N/A|No|Non-Probability Sample|traumatic brain injury patients|November 2010|October 12, 2012|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01437683||98251|
NCT01433705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00016183|Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Florine-18 Fluorodeoxyglucose in Normal Volunteers|Evaluation of the Normal Distribution of Rubidium-82(Rb-82), Nitrogen-13 (N-13)Ammonia, and Florine-18 Fluorodeoxyglucose (F-18FDG)in Normal Volunteers||University of Michigan|No|Recruiting|November 2011|December 2018|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|145|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01433705||98554|
NCT01433939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01597|Position Changes During Colonoscope Insertion Increases Patient Comfort|Position Changes During Colonoscope Insertion Increases Patient Comfort: a Prospective Trial||University of British Columbia|No|Active, not recruiting|September 2011|September 2014|Anticipated|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|19 Years|N/A|No|Probability Sample|Patients referred to gastroenterologists for colonoscopy.|March 2014|March 12, 2014|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433939||98538|
NCT01405326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE100002011|REstore Working Ability in RheumatoiD Arthritis|The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work|REWARD|The Rheumatological Center of Helsinki|No|Recruiting|May 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|160|||Both|25 Years|55 Years|No|||July 2011|July 28, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01405326||100723|
NCT01444391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005022|inVENT-visIOn Study|A Clinical Study of the Acclarent Tympanostomy Tube Delivery and Iontophoresis Systems In-Office|inVENT-visIOn|Acclarent|No|Completed|October 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|6 Months|N/A|No|||September 2014|September 20, 2014|September 23, 2011|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01444391||97736|
NCT01444404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20060347|A Study of AMG 820 in Subjects With Advanced Solid Tumors|A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors||Amgen||Completed|September 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444404||97735|
NCT01444417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080279|Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects|A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)||Amgen|Yes|Completed|December 2011|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|1 Year|17 Years|No|||January 2016|January 13, 2016|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444417||97734|
NCT01445340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070133|Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma|Phase I Study of Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma||National Institutes of Health Clinical Center (CC)||Terminated|April 2007|June 2012||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||June 2012|October 23, 2014|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445340||97668|
NCT01445639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTH-NICU-2011-02|Dexmedetomidine in Patients After Intracranial Surgery|Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients After Intracranial Surgery (Prophylactic Analgesia and Sedation Trial, PASTrial)||Capital Medical University|Yes|Completed|October 2011|February 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|N/A|No|||January 2014|January 25, 2014|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445639||97650|
NCT01445990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01262-55|Efficacy Study of Free Flap Monitoring Using Capillary Lactate and Glucose Measurements|Evaluation of Free Tissue Flaps Viability With Capillary Glucose and Lactate Measurements Compared With Clinical Examination||Centre Hospitalier Universitaire Dijon|Yes|Completed|January 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|N/A|No|||October 2011|October 5, 2011|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445990||97625|
NCT01446003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8457-004|A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)|A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients||Merck Sharp & Dohme Corp.|No|Completed|November 2011|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446003||97624|
NCT01445964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT11_ATE|Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean|An Open-label, Single-dose, Three-treatment, Three-period Study to Investigate the Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean||Seoul National University Hospital|No|Completed|May 2011|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|April 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01445964||97627|
NCT01446224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114428|Cardiovascular and Torsades de Pointes Monitoring for Pazopanib|Postmarketing Cardiovascular Ischemia and Torsades de Pointes Monitoring for Pazopanib Using Observational Databases||GlaxoSmithKline|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Study cohorts will be created in two healthcare databases to follow the outcomes of        interest in (i) Pazopanib users, and (ii) users of other marketed anti-VEGF drugs        (Bevacizumab, Sorafenib, Sunitinib).|March 2015|March 26, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446224||97607|
NCT01446536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-02|Effect of Quality Improvement Tools in Congestive Heart Failure (CHF)|Decreased Readmissions and Improved Quality of Care With Use of Inexpensive Checklist in Heart Failure||St. Joseph Mercy Oakland Hospital||Completed|August 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Masking: Single Blind (Investigator)|2||Actual|96|||Both|18 Years|N/A|No|||March 2012|March 18, 2012|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01446536||97583|
NCT01446549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-051|Motor Performance in Parkinson's Disease After High Intensive Exercise or Deep Brain Stimulation|Quantitative Modeling of Motor Performance in Parkinson's Disease After High Intensive Antigravity Locomotor Exercise or Deep Brain Stimulation||University of Copenhagen|Yes|Completed|July 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 22, 2013|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01446549||97582|
NCT01446562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEVISS|Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma|Phase II Trial of Y90 Ibritumomab Tiuxetan Post Rituximab-Cyclophosphamide, Doxobrubicn, Vincristine and Prednisone (R-CHOP) Chemotherapy for Newly Diagnosed Patients With Advanced Stage Follicular Lymphoma|ZEVISS|Sunnybrook Health Sciences Centre|No|Recruiting|May 2007|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2011|October 4, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01446562||97581|
NCT01446835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-418-C-003|Asian Clinical Evaluation of an Investigational Contact Lens for Cosmetic Effect|||Alcon Research|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|151|||Female|18 Years|30 Years|No|||January 2012|June 26, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446835||97560|
NCT01442467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16085|Study of Echocardiogram Accuracy in Patients With Mitral Valve Calcification|Correlation Between Echocardiographic Indices of Diastolic Function (E/E`) and Left Ventricular End Diastolic Pressure (LVEDP) in Patients With Mitral Annular Calcification||Creighton University|No|Terminated|June 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|4|||Both|19 Years|N/A|No|Non-Probability Sample|elective/planned cardiac catheterization|March 2013|March 28, 2013|August 8, 2011||No|Subject accrual too difficult|No||https://clinicaltrials.gov/show/NCT01442467||97884|
NCT01442753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010NTLS088|Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth|Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth: A CBPR RCT||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|800|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01442753||97862|
NCT01442987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-IBAT-301|Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia|Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia||Hanmi Pharmaceutical Company Limited|No|Completed|May 2011|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|230|||Both|19 Years|75 Years|No|||August 2013|August 12, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01442987||97844|
NCT01443000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI08014|Survey of Patients With Idiopathic Orbital Inflammation Syndrome|Survey of Patients With Idiopathic Orbital Inflammation Syndrome (IOIS): Clinical, Morphological and Pathological Features and Treatment Outcomes|SIOI|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|March 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|87|Samples With DNA|Blood samples will be frozen to form a serum storage and a DNAthèque. These samples will      achieve further analysis based on the evolution of knowledge on mechanisms contributing to      the orbital inflammation.|Both|18 Years|N/A|No|Non-Probability Sample|Patients followed for IOIS|October 2015|October 5, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01443000||97843|
NCT01443260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genelux - PO2|A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis|Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis||Genelux Corporation|Yes|Completed|February 2012|September 2014|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2014|March 9, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01443260||97823|
NCT01437670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2011-0585|Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin|A Prospective, Multicenter, Observation Study to Estimate the Dry Mouth in OAB Patients With Solifenacin|OAB|Asan Medical Center|Yes|Completed|September 2011|December 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|262|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients with overactive bladder          1. male or female patients with 20 years of age or older          2. clinical history of OAB for at least 3 months prior to visit 2          3. more than 3 in total score and 2 in Q 3 index from OABSS questionnaire|May 2014|May 28, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01437670||98252|
NCT01437046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101000328|Doxazosin an a1 Antagonist for Alcohol Dependence|Doxazosin an a1 Antagonist for Alcohol Dependence||Brown University||Completed|November 2011|March 2015|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437046||98300|
NCT01404507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICAT_ver_1.2|Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI|Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in Patients With Acute ST-segment Elevation Myocardial Infarction; ICAT Trial|ICAT|Yonsei University|Yes|Completed|December 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|80 Years|No|||January 2013|January 14, 2013|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404507||100786|
NCT01404520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-046|Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL)|Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL) Health Promoting Rehabilitation. A Multimodal Exercise-based Intervention in Patients With Acute Leukaemia Undergoing Re-induction or Consolidation Chemotherapy|PACE-AL|Universitetshospitalernes Center for Sygepleje|Yes|Completed|June 2011|May 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|70|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01404520||100785|
NCT01404780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0270-B|Comparison of the Glidescope and Macintosh Laryngoscope for Double Lumen Endotracheal Tube Intubation|Comparison of the Glidescope and Macintosh Laryngoscope for Double Lumen Endotracheal Tube Intubation||University Health Network, Toronto|No|Completed|June 2011|February 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|70|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01404780||100765|
NCT01433484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0395LS|Heart-Healthy Lenoir Lifestyle Study|Community-Based Lifestyle Intervention to Reduce CVD Risk & Disparities in Risk||University of North Carolina, Chapel Hill|Yes|Completed|September 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|339|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 27, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01433484||98571|
NCT01405339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMAD2011|Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray|The Effect of Budesonide Spray Via Mucosal Atomization Device on the Hypothalamic-Pituitary Axis||St. Paul's Hospital, Canada|No|Completed|August 2011|January 2014|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|N/A|No|||March 2014|March 7, 2014|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01405339||100722|
NCT01445015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5T32HS000066|Stress Management Intervention in Inner City Adolescents With Asthma|Pilot Study: Stress Management Intervention as a Tool for Managing Persistent Asthma in Inner City Adolescent Patients.|SIPIICAA|Weill Medical College of Cornell University|No|Recruiting|July 2011|June 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||September 2011|September 30, 2011|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01445015||97691|
NCT01445366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/591|Solute Removal With High Volume Hemodiafiltration Versus Long High Flux Hemodialysis|Solute Removal With High Volume Hemodiafiltration Versus Long High Flux Hemodialysis||University Hospital, Ghent|No|Recruiting|April 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01445366||97667|
NCT01445379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080007|Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer|A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer||National Institutes of Health Clinical Center (CC)||Completed|October 2007|November 2015|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|3 Years|21 Years|No|||November 2015|November 14, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445379||97666|
NCT01445002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-BM32-002|Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy|Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis||Biomay AG|No|Completed|October 2011|October 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|79|||Both|18 Years|60 Years|No|||January 2013|January 10, 2013|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01445002||97692|
NCT01446263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#11‐063|RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention (RADIAL-CABG) Trial|A Randomized Comparison of RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention (RADIAL-CABG) Trial|RADIAL-CABG|North Texas Veterans Healthcare System|Yes|Completed|October 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|128|||Both|18 Years|90 Years|No|||October 2013|October 27, 2013|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01446263||97604|
NCT01446237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115576|U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne|An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne||GlaxoSmithKline|No|Completed|June 2011|February 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|12 Years|35 Years|No|||April 2012|April 19, 2012|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01446237||97606|
NCT01446575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ampyra-TM-1|Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis|Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis||Johns Hopkins University|Yes|Terminated|July 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|70 Years|No|||April 2015|April 16, 2015|September 27, 2011|Yes|Yes|This study was redesigned to be more statistically rigorous.|No||https://clinicaltrials.gov/show/NCT01446575||97580|
NCT01442142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHC FRD 06-32|A Study to Determine the Effectiveness of a Self-regulation Program to Treat Pediatric Obesity|Self-Regulation Treatment for Pediatric Obesity|ROC|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No|Completed|May 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|236|||Both|8 Years|12 Years|Accepts Healthy Volunteers|||September 2011|September 26, 2011|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01442142||97909|
NCT01443039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100506|Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass|Phenotypical Approach of the Drug Metabolizing Hormones Activity (CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4 and P-gp) Before and After Roux-en Y-Gastric Bypass. The SODA Protocol: Surgery for Obesity and Drug Availability|SODA|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|September 2011|January 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|60 Years|No|||May 2014|May 30, 2014|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01443039||97840|
NCT01442779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00190|Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis|Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis||Texas Tech University Health Sciences Center|No|Completed|September 2000|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|50 Years|N/A|No|||April 2012|April 18, 2012|September 23, 2009|Yes|Yes||No|September 23, 2009|https://clinicaltrials.gov/show/NCT01442779||97860|
NCT01443013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI08031|Analysis of Foxp3 and Vimentin Expression in Renal Transplant Recipient|Predictive Value Analysis of Messenger Ribonucleic Acid (mRNA) Urinary Expression of Foxp3 and Vimentin on Graft Outcome in Renal Transplant Recipient: National Prospective Study|TUFEV|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2010|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|266|Samples Without DNA|Urine for mRNA extraction and congelation|Both|18 Years|N/A|No|Non-Probability Sample|All Renal transplant recipients|October 2015|October 18, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01443013||97842|
NCT01443832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/12 Fonio Study Benin|Iron Absorption From Iron-fortified Fonio Porridge: a Stable Isotope Study|Effect of Dephytinisation of Fonio With Intrinsic Wheat Phytase on Iron Absorption in Beninese Women||Wageningen University|No|Completed|September 2010|February 2011|Actual|January 2011|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|16|Samples Without DNA|2 samples of 8 ml venous blood per subject|Female|18 Years|30 Years|No|Probability Sample|apparently healthy young women of reproductive age (18-30y)|October 2011|October 29, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01443832||97779|
NCT01437059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-PCS02-001|Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)|A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)||Alnylam Pharmaceuticals|No|Completed|September 2011|September 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437059||98299|
NCT01437072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3934|Changing Diabetes® World Tour|Changing Diabetes® World Tour Protocol for a Study on the Association of Risk Factors and the Presence of Undiagnosed Diabetes in the Middle East, Northern Africa and Europe||Novo Nordisk A/S|No|Completed|November 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|8304|||Both|30 Years|75 Years|No|Non-Probability Sample|The Changing Diabetes® World Tour is designed as a mobile screening clinic staying for a        minimum of 14 days in each location such as malls, public squares, etc. Subjects included        in the study are either actively seeking to be screened, or are invited by subjects in        their network already included in the study.|December 2011|December 22, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01437072||98298|
NCT01404533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTBI women|Iron Interventions and Non-transferrin-bound Iron (NTBI) in Women|The Influence of Iron Interventions on Formation of Non-transferrin-bound Iron (NTBI) in Women|NTBIwomen|Swiss Federal Institute of Technology|No|Completed|November 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|32|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 5, 2016|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01404533||100784|
NCT01404793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 11-0325-BE|SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation|The Use Of Solid Phase Micro Extraction For Metabolomic Profiling And Concomitant Measurements Of Rocuronium Bromide Levels In Recipients Of Orthotopic Liver Transplantations||University Health Network, Toronto|No|Completed|September 2011|April 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving liver transplants at University Health Network, Toronto General        Hospital.|April 2015|April 23, 2015|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01404793||100764|
NCT01404806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1011|GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects|A Phase 1, Open Label, Study in Healthy Female Subjects to Describe GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue Following Single and Multiple Dosing of GSK1349572||University of North Carolina, Chapel Hill|No|Completed|August 2011|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|July 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01404806||100763|
NCT01405040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIM-0906-0001|Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess Thermodilution Cardiac Output, Global End Diastolic Volume and Extravascular Lung Water|Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess TPTD, GEDV and EVLW||Edwards Lifesciences|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will include all ICU patients requiring cardiac preload and lung        water assessment.|April 2013|April 1, 2013|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01405040||100745|
NCT01444677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB12066_002|Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers|A Dose Block-randomized, Double-blind, Placebo-controlled, Single or Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects||KT&G Life Sciences Corp|Yes|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|5||Anticipated|40|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01444677||97714|
NCT01444690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-004-DIPANAP|Dimiracetam in Painful Neuropathies Affecting AIDS Patients|Dimiracetam in Painful Neuropathies Affecting AIDS Patients. A Double-blind, Placebo-controlled, Parallel-group, Randomised, Multi-centre Study|DIPANAP|Neurotune AG|No|Not yet recruiting|January 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|244|||Both|18 Years|75 Years|No|||September 2011|September 30, 2011|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444690||97713|
NCT01445028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEI-DELIVER|Isotretinoin for Proliferative Vitreoretinopathy|Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy|DELIVER|Wills Eye|No|Active, not recruiting|September 2011|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|September 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445028||97690|
NCT01445392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080026|SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma|A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2007|September 2016|Anticipated|January 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|100 Years|No|||November 2015|November 13, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445392||97665|
NCT01445756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0062|Topical Lidocaine for Pain Control With Intrauterine Device (IUD) Insertion|Topical Lidocaine for Pain Control With IUD Insertion: A Randomized Controlled Trial||University of Wisconsin, Madison|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01445756||97642|
NCT01445730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1010K0029|Fructose Consumption and Metabolic Dysregulation|Fructose Consumption Aggravates Dysregulation of Postprandial Lipid Metabolism in Obese Hypertriglyceridemic Men With High Cardiometabolic Risk Profile and Associates With Liver Fat Deposition||Helsinki University Central Hospital|No|Active, not recruiting|August 2011|June 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|128|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01445730||97644|
NCT01446250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2307|Study of DEB025/Alisporivir Plus Pegylated Interferon alfa2a and Ribavirin and Boceprevir Plus Pegylated Interferon alfa2a and Ribavirin in African American Chronic Hepatitis C Genotype 1 Patients That Have Never Received Treatment for Their Hepatitis C|A Randomized, Open Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-INFα2a/RBV) and Boceprevir in Combination With Peg-INFα2a/RBV in African American Treatment-naϊve Patients With Chronic Hepatitis C Genotype 1||Novartis||Completed|December 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|70 Years|No|||October 2013|October 12, 2013|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446250||97605|
NCT01446588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00041019|Ocular Hypertension And Yoga Study|Ocular Hypertension And Yoga Study|OHAYS|Johns Hopkins University|No|Withdrawn|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2014|May 23, 2014|September 20, 2011||No|No Funding was acquired.|No||https://clinicaltrials.gov/show/NCT01446588||97579|
NCT01446601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-005|Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea|Pivotal Study of the Apnex Medical™ Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea||Apnex Medical, Inc.|Yes|Terminated|August 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|21 Years|80 Years|No|||December 2011|April 14, 2015|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446601||97578|
NCT01442155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25526|An Observational Study of Adjuvant Treatment With Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Stage III Colon Cancer|An Open Label Study of the Effect of Adjuvant Treatment With Capecitabine in Combination With Oxaliplatin on Disease-free Survival in Patients With Stage III Colon Cancer||Hoffmann-La Roche||Completed|October 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|No|Probability Sample|Patients with Stage III colon cancer|March 2016|March 1, 2016|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442155||97908|
NCT01442168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sevuparin/DF02_TSM02|Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria|A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria||Dilaforette AB|Yes|Terminated|September 2011|January 2014|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|65 Years|No|||August 2014|August 18, 2014|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01442168||97907|
NCT01443052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC1002|Gait Parameters Analysis in Post-stroke Patients and in Elderly Fallers|Study of the Temporospatial Gait Parameters With the Electronic Carpet "GAITRite" in Patients With Walking Impairment After Stroke and in Old Faller Subjects|GAITRITE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|90|||Both|65 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|subjects aged 65-80 years : 30 healthy people, 30 patients at least one year post-stroke,        and 30 fallers|April 2014|April 11, 2014|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01443052||97839|
NCT01442792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15572|Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention|Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention|X-PLORER|Bayer|Yes|Completed|October 2011|March 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|108|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01442792||97859|
NCT01443026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0828|The Effects of Lycopene on High Risk Prostatic Tissue|R01 CA90759: The Effects of Lycopene on High Risk Prostatic Tissue||University of Illinois at Chicago|No|Completed|February 2006|April 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|66|||Male|40 Years|N/A|No|||December 2015|December 1, 2015|September 27, 2011|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01443026||97841|
NCT01443845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF-MD-07|Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)|Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)||Forest Laboratories|No|Active, not recruiting|September 2011|February 2016|Anticipated|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2354|||Both|40 Years|N/A|No|||December 2015|December 23, 2015|September 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443845||97778|
NCT01443858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030282|Meclizine as a Potential Smoking Cessation Treatment|Meclizine as a Potential Smoking Cessation Treatment||Duke University|Yes|Completed|August 2011|July 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|146|||Both|18 Years|65 Years|No|||July 2014|July 29, 2014|September 29, 2011|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01443858||97777|
NCT01404195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVVV-Log-01|Hyperprotein Nutritional Intervention in Elderly Patients With Hip Fracture and Sarcopenia|High-protein Nutritional Intervention Based on β-hydroxy-β-methylbutirate, Vitamin D3 and Calcium on Obese and Lean Aged Patients With Hip Fractures and Sarcopenia. The HIPERPROT-GER Study.|HIPERPROT|Hospital Viamed Valvanera, Spain|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|65 Years|N/A|No|||February 2016|February 4, 2016|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01404195||100810|
NCT01405066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GroupHealthCoop Foundation2011|Radiation Dose Audit Reports to Reduce Radiation Exposure From CT Exams|CT Technologists Dose Audit Reports and Educational Seminar to Reduce Patient Radiation Exposure From Medical Imaging||Group Health Cooperative|No|Completed|November 2010|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|19|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01405066||100743|
NCT01405352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-04-27-11869|The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity|The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals||Tehran University of Medical Sciences|Yes|Enrolling by invitation|February 2010|August 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|84|||Both|20 Years|52 Years|Accepts Healthy Volunteers|||July 2011|July 28, 2011|February 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405352||100721|
NCT01405053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2080-G000-303|Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs|A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome||Eisai Inc.||Completed|June 2011|November 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|1 Year|3 Years|No|||February 2016|March 21, 2016|July 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01405053||100744|
NCT01444703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332/2010|Comparison of Licorice Versus Sugar-water Gargle for Prevention of Postoperative Sore Throat and Postextubation Coughing|Randomized, Double-blind Comparison of Licorice Versus Sugar-water Gargle for Prevention of Postoperative Sore Throat and Postextubation Coughing||Outcomes Research Consortium|No|Completed|October 2010|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|236|||Both|18 Years|90 Years|No|||September 2011|September 29, 2011|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01444703||97712|
NCT01445405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080071|Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer|Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2008|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|90 Years|No|||February 2013|October 23, 2014|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445405||97664|
NCT01445418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080092|AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer|A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers (Familial Breast and Ovarian Cancer) and Sporadic Triple Negative Breast Cancer and Ovarian Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2008|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|100 Years|No|||January 2016|February 5, 2016|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445418||97663|
NCT01446276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110172A|Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease|Long-term Investigation of Resveratrol on Lipid Turnover in Obese Men With Nonalcoholic Fatty Liver Disease. Effects on Liver Fat Content and Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism||University of Aarhus|No|Completed|November 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|26|||Male|25 Years|65 Years|No|||October 2013|April 25, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446276||97603|
NCT01446289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V98_04|Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings|A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women||Novartis||Completed|September 2011|October 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|86|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|September 27, 2011||No||No|June 20, 2014|https://clinicaltrials.gov/show/NCT01446289||97602|
NCT01445743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN11-009|Immunogenicity and Safety of an Acellular DPT Vaccine During Pregnancy|Immunogenicity and Safety of an Acellular DPT Vaccine in Pregnant Women in Nuevo Leon, Mexico||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|September 2011|February 2014|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|204|||Female|18 Years|38 Years|No|||February 2014|February 12, 2014|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01445743||97643|
NCT01446614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-2011-10|Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease|PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease.||Guangzhou General Hospital of Guangzhou Military Command|Yes|Recruiting|October 2011|June 2014|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|30 Years|65 Years|No|||October 2011|October 4, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01446614||97577|
NCT01446627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-GEN-11-0169|Use of Insorb Absorbable Vicryl Staples in Skin Closure for Cesarean Section|Comparison of Vicryl Absorbable Sutures and Metal Staples Used in Skin Closure Following Cesarean Section||The University of Texas Health Science Center, Houston|No|Completed|January 2010|December 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|300|||Female|14 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women undergoing cesarean section who have their skin incision closed with staples.|May 2013|May 2, 2013|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01446627||97576|
NCT01442181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|433-2009|Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation|Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation||University of Florida|No|Completed|March 2010|November 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|80 Years|No|||July 2015|July 17, 2015|October 5, 2010|Yes|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01442181||97906|
NCT01442480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omegacon|Cardioprotective Effects of Omega-3 Fatty Acids Supplementation in Healthy Older Subjects Exposed to Air Pollution Particles|||Environmental Protection Agency (EPA)||Completed|June 2009|||August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|29|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2011|September 27, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442480||97883|
NCT01442493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01DA015842|Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment|Reengineering Methadone Treatment: A Randomized Clinical Trial||Friends Research Institute, Inc.|Yes|Active, not recruiting|September 2011|April 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01442493||97882|
NCT01442805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080102|Use of Virtual Reality in the Treatment of Flying Phobia|Etude contrôlée Des Effets de la réalité Virtuelle Sur Les symptômes et Les paramètres Physiologiques de Certaines Phobies spécifiques||Centre de Recherche Public de la Sante, Luxembourg|Yes|Active, not recruiting|October 2008|March 2012|Anticipated|September 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||September 2011|September 28, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01442805||97858|
NCT01443338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHINA201002016-2|Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2|A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris||Ministry of Health, China|Yes|Recruiting|September 2011|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|720|||Both|18 Years|75 Years|No|||September 2011|September 28, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01443338||97817|
NCT01443273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0041-11-EMC|Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010|Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010||HaEmek Medical Center, Israel|No|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|1 Year|No|Probability Sample|All newborns (Term and Premature) diagnosed with Neonatal Thrombotic events between year        1990 to 2010.|August 2015|August 30, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443273||97822|
NCT01443286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA041011|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2016|||||N/A|N/A|N/A||||||||||||||March 6, 2016|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443286||97821|
NCT01443299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA230911|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2011|||||N/A|N/A|N/A||||||||||||||December 8, 2014|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443299||97820|
NCT01443572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0436|The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation|||Yonsei University|Yes|Completed|September 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|1 Year|No|||July 2014|July 20, 2014|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01443572||97799|
NCT01443585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALsCTIL|Clinical Evaluation of a Progressive Addition Lens (PAL)|Clinical Performance Evaluation of a Progressive Addition Lens Among Presbyopic Patients||Ziv Hospital|Yes|Enrolling by invitation|September 2012|||November 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|90 Years|No|||September 2011|March 14, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01443585||97798|
NCT01443884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816801-2|Anti-Inflammatory Activities of Grapes in Humans at Risk for Cardiovascular Disease|Anti-Inflammatory Activities of Grapes in Humans at Risk for Cardiovascular Disease||USDA, Western Human Nutrition Research Center|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443884||97775|
NCT01404208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000875|2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD|2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD||Massachusetts General Hospital|Yes|Active, not recruiting|July 2011|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|7 Years|17 Years|No|||April 2015|April 28, 2015|July 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01404208||100809|
NCT01404832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAIRB06-093|The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors|The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors||Dallas VA Medical Center|No|Terminated|October 2007|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|July 27, 2011|Yes|Yes|Inadequate recruitment|No|February 26, 2013|https://clinicaltrials.gov/show/NCT01404832||100761|
NCT01434771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110031|Monitoring Blood Flow and Breathing Using a New Device (RFII) Compared to the Gold Standard Device in Post Operative Cardiac Patients|Simultaneous Hemodynamic and Ventilatory Monitoring Using Radio Frequency Impedance Interrogation (RFII), Thoracic Impedance Cardiography and Invasive Hemodynamic Monitoring Methods in Post Operative Cardiac Patients||University of Florida|No|Withdrawn|December 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for open heart surgery|October 2013|October 15, 2013|September 13, 2011||No|Sponsor never funded study.|No||https://clinicaltrials.gov/show/NCT01434771||98474|
NCT01434784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Koller Lung 03/2010|Update of the EORTC QLQ-LC13 Quality of Life Questionnaire|Update of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) Phases I - III||University Hospital Regensburg|No|Completed|September 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||9|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|patients with confirmed diagnosis of lung cancer|June 2015|June 25, 2015|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01434784||98473|
NCT01435070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS2010025|Functional Outcome Following Fracture of the Distal Radius|A Correlation of Functional Outcome Measures of Fractures of the Distal Radius Following Operative Management||University of Warwick|No|Recruiting|January 2011|October 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients presenting to University Hospital Coventry with an acute fracture of        the distal radius requiring operative management|September 2011|September 14, 2011|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01435070||98452|
NCT01405573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOOST|Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma|Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial|BOOST|National Cancer Institute, Naples|Yes|Recruiting|July 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|February 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01405573||100704|
NCT01444716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0520|Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL)|Phase II Study of Ofatumumab as Front-line Treatment in Elderly, Unfit Patients With Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2011|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|65 Years|N/A|No|||December 2015|December 11, 2015|September 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444716||97711|
NCT01444729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1531005|Post Approval Commitment Study|A Non-Interventional Post Approval Commitment Study To Evaluate The Outcomes Of The Various Treatment Options For Dupuytren's Contracture||Endo Pharmaceuticals|No|Active, not recruiting|March 2012|March 2018|Anticipated|March 2018|Anticipated|Phase 4|Observational|Time Perspective: Prospective||2|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|- Adults with a palpable cord eligible for the treatment of Dupuytren's contracture|July 2013|March 31, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01444729||97710|
NCT01446029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Minn-VAMC-4292-A|Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)|Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease||Minneapolis Veterans Affairs Medical Center|Yes|Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|601|||Both|18 Years|85 Years|No|||August 2014|August 1, 2014|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01446029||97622|
NCT01446042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-1-2011-03|Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism|A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days||Trimel Biopharma SRL|Yes|Active, not recruiting|September 2011|December 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Male|18 Years|80 Years|No|||June 2012|June 13, 2012|September 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446042||97621|
NCT01446302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGFHD2-2011|Metabolic and Inflammatory Responses to Hemodialysis and the Effect of a Meal|Metabolic and Inflammatory Responses to Hemodialysis and the Effect of a Meal||University of Aarhus|No|Completed|October 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 13, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01446302||97601|
NCT01446016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811-0147|Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)|Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy.|CAT|The Methodist Hospital System|No|Recruiting|September 2011|||September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|47|||Female|18 Years|N/A|No|||September 2015|October 7, 2015|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446016||97623|
NCT01442207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBX 0018|Cerclage for Prevention on Preterm Birth in Women With Placenta Previa|Cerclage Placement for the Prevention of Preterm Birth in Women With Placenta Previa - A Multicenter Randomized Controlled Trial||Mednax Center for Research, Education and Quality|Yes|Withdrawn|March 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 17, 2014|September 15, 2011||No|Lack of randomized participants|No||https://clinicaltrials.gov/show/NCT01442207||97904|
NCT01442220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2011-277|Genome-wide Association Study of Pituitary Tumors|Genome-wide Association Study of Pituitary Tumors||Huashan Hospital|Yes|Recruiting|September 2011|July 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|12500|Samples With DNA|DNA samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with pituitary adenomas and healthy controls will be included.|September 2011|September 27, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442220||97903|
NCT01442194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTY720D2403|Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies|Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy|PASSAGE|Novartis||Recruiting|August 2011|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3600|||Both|N/A|N/A|No|Non-Probability Sample|Patients with relapsing forms of MS that have been recently initiated on fingolimod by        their treating physician or patients that are treated with other disease-modifying        therapies as part of their MS treatment in accordance with the respective local        prescribing information and routine clinical practice|January 2016|January 15, 2016|August 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442194||97905|
NCT01442506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.237.09|Acetic Acid Guided Biopsies Compared With High Definition Endoscopy in the Detection of Barrett`s Esophagus|Acetic Acid Guided Biopsies Compared With High Definition Endoscopy||Johannes Gutenberg University Mainz|No|Recruiting|April 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients with suspected barrettes esophagus|September 2011|September 27, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01442506||97881|
NCT01442818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10072|Patient Satisfaction and Pain Control Following Reconstructive Vaginal Surgery|Patient Satisfaction and Pain Control Following Reconstructive Vaginal Surgery: A Randomized Trial Comparing Patient-Controlled Intravenous Analgesia (PCA) to Scheduled Intravenous Analgesia||TriHealth Inc.|Yes|Completed|September 2010|October 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Female|18 Years|70 Years|No|||July 2015|July 9, 2015|September 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01442818||97857|
NCT01443078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-106|Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)|Phase II Trial of Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)||Memorial Sloan Kettering Cancer Center||Completed|October 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443078||97837|
NCT01443312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0047-10-EMC|Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia|||HaEmek Medical Center, Israel|No|Completed|October 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|28|Samples With DNA|DNA samples will be obtained to analyze the beta and alfa globin genes and the xmn1      polymorphism.|Both|1 Year|40 Years|No|Non-Probability Sample|Patients with beta Thalassemia Intermedia.|August 2015|August 30, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443312||97819|
NCT01443325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-051|Lidocaine Patch for Treatment of Persistent Inguinal Postherniorrhaphy Pain|||Rigshospitalet, Denmark|Yes|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||June 2012|June 21, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01443325||97818|
NCT01443598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERMOP-002|Pulmonary Hypertension in Interstitial Lung Disease|Observational Study of Patients With Pre Capillary Pulmonary Hypertension|HYPID|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|No|Recruiting|July 2010|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|whole blood, serum and plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with pre capillary pulmonary hypertension and interstitial lung disease at HRCT|September 2011|October 3, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443598||97797|
NCT01443897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201017924-1|Effect of Consumption of Post-harvest UV-B Treated Mushrooms on Vitamin D Status of Healthy Adults|Effect of Consumption of Post-harvest UV-B Treated Mushrooms on Vitamin D Status of Healthy Adults||USDA, Western Human Nutrition Research Center|No|Completed|May 2010|June 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|48|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||September 2011|September 28, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443897||97774|
NCT01434498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-248-0132|GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b HCV Infection (Protocol No. GS US 248 0132)||Gilead Sciences|Yes|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|163|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01434498||98495|
NCT01434511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBI-1-302|Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A|Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients With Congenital Hemophilia A With Factor VIII Inhibitors||Baxalta US Inc.|Yes|Terminated|August 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|6 Years|N/A|No|||December 2014|June 26, 2015|September 13, 2011|Yes|Yes||No|December 11, 2014|https://clinicaltrials.gov/show/NCT01434511||98494|
NCT01435421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALF-BID-1108-HMO-CTIL|Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery|Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery||Hadassah Medical Organization||Not yet recruiting|October 2011|||December 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|112|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that are hospitalaized.|September 2011|September 15, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435421||98425|
NCT01435694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISM_grant_2010|Robot-assisted Gait Training in Multiple Sclerosis Subjects|The Effects of Robot-assisted Gait Training on Locomotor Function and Motor Unit Firing in Multiple Sclerosis Subjects With Severe Gait Impairments. A Randomized Control Trial||University Hospital of Ferrara|Yes|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||January 2014|January 15, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435694||98404|
NCT01435382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481006|A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 in Subjects With Hypercholesterolemia|A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess The Pharmacokinetics and Pharmacodynamics of PF-04950615 Following Subcutaneous and Intravenous Doses in Adult Subjects With Hypercholesterolemia||Pfizer|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|49|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|September 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435382||98428|
NCT01435395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014595|Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme|Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme||Emory University|Yes|Active, not recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|September 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435395||98427|
NCT01435408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DANAMI-3|DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction|A Randomised Comparison of the Clinical Outcome After Postconditioning or Deferred Stent Implantation Versus Conventional Treatment|DANAMI-3|Rigshospitalet, Denmark|Yes|Active, not recruiting|April 2011|February 2021|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|2000|||Both|N/A|N/A|No|||May 2015|May 4, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435408||98426|
NCT01445431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED 2011-01-03-005|A Trial on the Efficacy and Safety of Virgin Coconut Oil Compared to Mineral Oil in the Treatment of Uremic Xerosis|A Randomized Controlled Trial on the Efficacy and Safety of Virgin Coconut Oil Compared to Mineral Oil in the Treatment of Uremic Xerosis||University of the Philippines|Yes|Completed|April 2011|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|19 Years|65 Years|No|||September 2011|September 29, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01445431||97662|
NCT01446640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-2011-09|Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury|PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Spinal Cord Injury.|MSC|Guangzhou General Hospital of Guangzhou Military Command|Yes|Recruiting|October 2011|June 2014|Anticipated|June 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|60 Years|No|||October 2011|October 4, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446640||97575|
NCT01446653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12794|Reducing Alcohol Exposed Pregnancy Risk: EARLY Randomized Controlled Trial|Reducing Alcohol Exposed Pregnancy Risk|EARLY RCT|University of Virginia|No|Completed|February 2007|September 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|232|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01446653||97574|
NCT01442519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTV-119-1993|Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer|Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study|BCG/EMDA-MMC|University of Rome Tor Vergata|Yes|Completed|January 1994|June 2002|Actual|June 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|90 Years|No|||September 2011|September 27, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01442519||97880|
NCT01442532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100669|A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam|A Double-Blind, Randomized, Single- and Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Healthy Adult Male Subjects and an Open-Label Drug-Drug Interaction Study to Evaluate the Effect of JNJ-38518168 on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate||Janssen Research & Development, LLC|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|94|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|September 27, 2011|No|Yes||||https://clinicaltrials.gov/show/NCT01442532||97879|
NCT01442831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-106|Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects|An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-TR-701 in Healthy Adult Male Subjects||Trius Therapeutics LLC|No|Completed|September 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|June 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442831||97856|
NCT01443065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRODIGE 17 / ACCORD 20/0904|MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma|MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial|MEGA|UNICANCER|Yes|Active, not recruiting|January 2011|January 2019|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|162|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01443065||97838|
NCT01443091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMNPSU-35083|Oropharyngeal Colostrum for Immune Stimulation in Very Low Birth Weight Infants|Oropharyngeal Colostrum for Immune Stimulation in Very Low Birth Weight Infants||Milton S. Hershey Medical Center|No|Active, not recruiting|January 2011|||January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|3 Days|Accepts Healthy Volunteers|||April 2015|April 8, 2015|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01443091||97836|
NCT01443377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-0001021|Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer|Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer|NEOREC-1|National Center for Tumor Diseases, Heidelberg|Yes|Completed|July 2011|September 2013|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||April 2012|May 6, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01443377||97814|
NCT01443611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0138-10-EMC|The Relevance of Performing Lumbar Puncture in Infants Aged 3 to 12 Months With First Episode of Febrile Convulsion|||HaEmek Medical Center, Israel|No|Completed|June 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|122|||Both|3 Months|12 Months|No|Probability Sample|Infants aged 3 to 12 months who presents with First Episode of Febrile Convulsions|August 2015|August 30, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443611||97796|
NCT01443871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP-5102031|Effect of Essential Oils in Aromatherapy on Emotional Relaxation|Effect of Essential Oils in Aromatherapy on Emotional Relaxation||University of Phayao|Yes|Completed|September 2011|December 2014|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443871||97776|
NCT01443910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110238|Weight Management Interactions in a Virtual Clinical Environment|Weight Management Interactions in a Virtual Clinical Environment||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 2011|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|318|||Female|20 Years|50 Years|No|||April 2015|May 14, 2015|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01443910||97773|
NCT01435083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/566|Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study|Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study||University Hospital, Ghent|No|Completed|November 2011|July 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01435083||98451|
NCT01435096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-55-52905-701|BN80927 in Patients With Advanced Malignant Solid Tumors|A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors||Ipsen||Completed|November 2004|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||September 2011|September 13, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01435096||98450|
NCT01435434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lieb001-CTIL-HMO|Mononucleotide Autologous Stem Cells and Demineralized Bone Matrix in the Treatment of Non Union/Delayed Fractures|||Hadassah Medical Organization|No|Not yet recruiting||||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|65 Years|No|||March 2014|March 3, 2014|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01435434||98424|
NCT01435720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS01-T-001|Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)|Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies||Senesco Technologies, Inc.|Yes|Active, not recruiting|September 2011|December 2014|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|15|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|September 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01435720||98402|
NCT01435707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-08-058|The Effect of Epidural Steroid Injections on Glycemic Control in Diabetic Patients According to the Doses of Steroids|The Effect of Epidural Steroid Injections on Glycemic Control in Diabetic Patients According to the Doses of Steroids||Samsung Medical Center|No|Completed|September 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|125|||Both|20 Years|N/A|No|||December 2013|December 24, 2013|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435707||98403|
NCT01435980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|the south west Hospital2|Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes|Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes||Third Military Medical University|Yes|Recruiting|February 2008|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|60 Years|No|||March 2015|March 25, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01435980||98382|
NCT01445795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-006|Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects|A Multi-center, Placebo-controlled, Multiple Dose, Study of the Safety and Pharmacokinetics and Pharmacodynamics of INX-08189 Dosed Either QD, BID or Adjunctively With Ribavirin, and a Study of the Food Effect, in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects|INH-189-006|Bristol-Myers Squibb||Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|50|||Both|18 Years|65 Years|No|||October 2015|October 12, 2015|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01445795||97639|
NCT01445769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18424-261|Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis|An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis||Incyte Corporation|No|Completed|September 2011|April 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||September 2014|September 16, 2014|September 23, 2011|Yes|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01445769||97641|This was a single arm pilot study. The patient population differed from Phase III studies of ruxolitinib in myelofibrosis and therefore comparisons to standard dosing cannot be made from this study.
NCT01445782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3060C00002|AZD2115 Multiple Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects||AstraZeneca||Completed|October 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 5, 2012|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01445782||97640|
NCT01446055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGResQ082011|Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia|Transplantation of Autologous BM-MNC Processed by ResQ Separator and Conventional Manual Method for Patients With Chronic Limb Ischemia: a Multi-center Randomized Controlled Trial||Xuanwu Hospital, Beijing|Yes|Not yet recruiting|October 2011|April 2013|Anticipated|April 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||October 2011|October 8, 2011|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01446055||97620|
NCT01446068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRICHIP-1|Comparison of Postprandial Inflammation in Lean and Obese Subjects|||Agroscope Liebefeld-Posieux Research Station ALP|Yes|Completed|March 2011|January 2013|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|36|||Male|25 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01446068||97619|
NCT01446315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS018431|Assessing Decision Maker Tools for Asthma: the Asthma APGAR||Asthma APGAR|Olmsted Medical Center|No|Enrolling by invitation|October 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1500|||Both|5 Years|60 Years|No|||October 2011|October 4, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446315||97600|
NCT01446666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC2011-0587|Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients|A Prospective Intra-individual Cohort Study to Compare Gadoxetic Acid (Primovist®)-Enhanced Magnetic Resonance Image and Ultrasonography for the Surveillance of Early Stage Hepatocellular Carcinoma in Patients at High-risk|PRIUS|Asan Medical Center|Yes|Completed|November 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|423|Samples With DNA|Buffy coat and serum|Both|20 Years|N/A|No|Non-Probability Sample|Hospital out-patient clinic|June 2015|June 23, 2015|September 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01446666||97573|
NCT01446679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIP003|Special Drug Use-Results Survey of Lipitor Tablets|Special Drug Use-Results Survey of Lipitor Tablets|ALWAYS|Astellas Pharma Inc|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|24050|||Both|N/A|N/A|No|Non-Probability Sample|Patients with hypercholesterolemia who have not achieved the category-specific target        lipid level in other statin therapies|February 2013|February 20, 2013|September 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446679||97572|
NCT01442233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/46|Plasma Exchanges in Multiple Sclerosis (MS) Relapses|Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment|PLASMASEP|University Hospital, Bordeaux|Yes|Recruiting|March 2012|July 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01442233||97902|
NCT01442545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018613|A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants|A Study to Investigate the Effect of Multiple Doses of JNJ 39758979 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients on a Stable Methotrexate Dose||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|August 2011|December 2011|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|75 Years|No|||March 2013|March 12, 2013|August 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01442545||97878|
NCT01442558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0081-2011-HYMC|Comparison of Quality of Supraclavicular, Infraclavicular and Axillary Approach of Ultrasound-guided Brachial Plexus Block|||Hillel Yaffe Medical Center|Yes|Completed|December 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|101|||Both|19 Years|N/A|No|||September 2011|January 20, 2015|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01442558||97877|
NCT01442844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p002614|Secondary Intention Wound Healing Versus Micrografting in Patients Undergoing Mohs Surgery|Secondary Intention Wound Healing Versus Micrografting in Patients Undergoing Mohs Surgery|MomelanMohs|Massachusetts General Hospital|No|Terminated|September 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|40 Years|75 Years|No|||June 2014|June 18, 2014|September 27, 2011||No|The study sponsor was acquired by a company that focuses on chronic wounds|No|June 18, 2014|https://clinicaltrials.gov/show/NCT01442844||97855|
NCT01443104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065/11|Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents|A Randomized Comparison of a Sirolimus-eluting Stent With Biodegradable Polymer Versus an Everolimus-eluting Stent With a Durable Polymer for Percutaneous Coronary Revascularization||University Hospital Inselspital, Berne|Yes|Active, not recruiting|February 2012|May 2018|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2119|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01443104||97835|
NCT01443117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1091|Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women|Administration of Polysaccharide or Conjugated Pneumococcal Vaccines to HIV-Infected Pregnant Women: Safety and Magnitude, Persistence, and Transplacental Transfer of Vaccine-Serotype Pneumococcal Anti-Capsular Antibodies||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn||||August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|0|||Female|13 Years|39 Years|No|||May 2014|May 5, 2014|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443117||97834|
NCT01443351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO-SJ-227|Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)|Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Primary Immune Thrombocytopenia (ITP)||Roskilde County Hospital|No|Recruiting|March 2012|March 2020|Anticipated|March 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Whole blood samples will be collected, seru, plasma and mononuclear cells will be stored in      a biobank for further research use|Both|18 Years|N/A|No|Non-Probability Sample|Patinets will be selected from Departments of Hematology|February 2015|February 4, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01443351||97816|
NCT01443364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0069|Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis|Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA)|SPEED|UCB Pharma|No|Completed|December 2011|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|September 27, 2011|Yes|Yes||No|January 4, 2016|https://clinicaltrials.gov/show/NCT01443364||97815|
NCT01443624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101104|Evaluation of Oxidative Stress Induced by Iron Injection in Healthy Volunteers and Critical Care Patients|Evaluation of Oxidative Stress Induced by Iron Injection in Healthy Volunteers Versus Critical Care Patients|SOFI|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2011|August 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443624||97795|
NCT01444573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVL-001-32|Rate Ventricular Control Therapy in Patients With Permanent Atrial Fibrillation|Rate Ventricular Control Therapy by Implantable Continuous Monitor in Patients With Permanent Atrial Fibrillation|REVEAL|Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|September 2011|September 2015|Anticipated|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||September 2015|September 21, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444573||97722|
NCT01444872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP120027.1002|Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction|A Randomized, Single-Blind, Placebo-Controlled, Adaptive, Ascending Dose Study to Evaluate the Effects of TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Mild to Moderate Renal Dysfunction||Trevena Inc.||Completed|August 2011|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|17|||Both|18 Years|74 Years|No|||August 2012|August 24, 2012|September 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01444872||97699|
NCT01435109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00022836|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care|PRIMO|Duke University|No|Active, not recruiting|July 2011|March 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|560|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01435109||98449|
NCT01435122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16692|A Study of Axitinib in Advanced Carcinoid Tumors|A Phase II Study of Axitinib in Advanced Carcinoid Tumors||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|September 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01435122||98448|
NCT01435993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114840|Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis|A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.||GlaxoSmithKline|No|Terminated|September 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|60 Years|No|||April 2015|April 15, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01435993||98381|
NCT01436006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDCTDOSE/SIRM|Adult and Paediatric Patient Radiation Doses From Multidetector Row Computed Tomography Scans: a National Survey|Adult and Paediatric Patient Radiation Doses From Multidetector CT Scans: a National Survey|MDCTDOSE|University of Palermo|Yes|Completed|February 2011|June 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|6700|||Both|N/A|N/A|No|Non-Probability Sample|Patient that will need a CT scan between March 2011 and February 2012|September 2015|September 3, 2015|July 28, 2011||No||No|May 26, 2014|https://clinicaltrials.gov/show/NCT01436006||98380|
NCT01436279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31032|Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks|Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks|SaMi2|Boston University|Yes|Completed|July 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|50 Years|No|||March 2014|March 18, 2014|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436279||98359|
NCT01436539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ditan-2011-01|Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients|A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients||Capital Medical University|Yes|Not yet recruiting|September 2011|July 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||September 2011|September 16, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01436539||98339|
NCT01436877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-01|Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia|One-arm Feasibility and Prospective Pivotal Study to Assess the Safety and Efficacy of MediTate Temporary Implantable Nitinol Device (TIND) in Subjects Presenting Bladder Outlet Obstruction Secondary to BPH||Medi-Tate Ltd.|No|Active, not recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|50 Years|95 Years|No|||April 2015|April 14, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436877||98313|
NCT01436890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 4039-204|A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma|A Phase II, 12-week Randomized, Double-blind, Triple Dummy, Parallel Group, Placebo-controlled, Dose Range Finding Study to Evaluate Safety, Tolerability and Efficacy of Revamilast in Patients With Chronic Persistent Asthma||Glenmark Pharmaceuticals Ltd. India|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|273|||Both|18 Years|65 Years|No|||June 2013|June 20, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436890||98312|
NCT01445522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090048|ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer|A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Completed|December 2008|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2012|October 9, 2014|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445522||97658|
NCT01445535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090065|Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas|Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2009|October 2016|Anticipated|April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||May 2015|June 10, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445535||97657|
NCT01445808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 837.274.11 (7816)|Psychodynamic Motivation and Training Program|Psychodynamic Motivation and Training Program (PMT) as Secondary Prevention in Patients With Stable Coronary Heart Disease|PMT|Johannes Gutenberg University Mainz|No|Completed|October 2011|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|75 Years|No|||February 2016|February 25, 2016|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445808||97638|
NCT01446081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML 003|An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy|A Phase II Exercise RCT for AML Patients Undergoing Induction Chemotherapy||University Health Network, Toronto|No|Completed|June 2011|May 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|83|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01446081||97618|
NCT01446328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3387|Bergen Psychosis Project 2 - The Best Intro Study|Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study|BP2|Haukeland University Hospital|Yes|Recruiting|October 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|16 Years|N/A|No|||December 2015|December 4, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446328||97599|
NCT01446341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01150|Cast Immobilization Versus Functional Therapy for Acute, Severe Lateral Ankle Sprains|A Pilot Study Towards a Randomized Clinical Trial of Cast Immobilization Versus Functional Therapy for Acute, Severe Lateral Ankle Sprains||University of British Columbia|No|Not yet recruiting|November 2011|||May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|October 4, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01446341||97598|
NCT01446692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-XXX-2011/2|Badalona Major Depressive Disorder Database Study|Therapeutic Strategies for the Management of Patients With Major Depressive Disorder (MDD) and Suboptimal Response to Antidepressant Drugs in Primary Care: the Badalona Database Study||AstraZeneca|No|Completed|November 2011|January 2012|Actual|||N/A|Observational|Time Perspective: Retrospective||2|Actual|2260|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2012|January 11, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01446692||97571|
NCT01442298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/757-31/1-4|A Comparison Between an Individual Low Tourniquet Pressure Versus a Standard Pressure During Total Knee Arthroplasty|A Comparison Between an Individual Low Tourniquet Pressure Versus a Standard Pressure During Total Knee Arthroplasty. A Randomized Controlled Study||Karolinska Institutet|Yes|Completed|October 2008|October 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|N/A|75 Years|No|||September 2011|September 27, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01442298||97897|
NCT01442246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFU-GETUG 20/0310|Benefit Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.|Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard® 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.||UNICANCER|Yes|Active, not recruiting|June 2011|January 2023|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Male|18 Years|N/A|No|||September 2011|September 27, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01442246||97901|
NCT01442259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2124|An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects|An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Age, Sex, and Body Weight-matched Healthy Subjects||Novartis||Completed|January 2011|||August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|48|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 21, 2011|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442259||97900|
NCT01442571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sports01-CTIL-HMO|Hyaluronic Acid Injection Post Arthroscopy - Does it Improve Immediate Function? Double Blind Controlled Prospective Study|||Hadassah Medical Organization|No|Not yet recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||August 2011|September 27, 2011|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01442571||97876|
NCT01442584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ovarian transplant- HMO-CTIL|Transplantation of Ovarian Cortex to Restore Fertility|Transplantation of Ovarian Cortex to Restore Fertility|ovatrspl|Hadassah Medical Organization|No|Recruiting|July 2011|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|5|||Female|20 Years|54 Years|No|||July 2011|September 27, 2011|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01442584||97875|
NCT01442857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-04115A|The Axillary Region in a High Resolution MRI|The Axillary Region in a High Resolution MRI. Imaging Before and After Brachial Plexus Block||Diakonhjemmet Hospital|No|Completed|June 2008|December 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01442857||97854|
NCT01443689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKCR-BURN-1.0(2011)|Allogenic Stem Cell Therapy in Patients With Acute Burn|A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Acute Burn||Shenzhen Beike Bio-Technology Co., Ltd.|Yes|Recruiting|July 2011|July 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|65 Years|No|||November 2012|November 26, 2012|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443689||97790|
NCT01443923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110253|Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV|An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1||National Institutes of Health Clinical Center (CC)||Terminated|September 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|September 29, 2011|Yes|Yes|Unable to complete enrollment due to newly approved treatment options.|No|February 25, 2015|https://clinicaltrials.gov/show/NCT01443923||97772|
NCT01443390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI-CA_004|An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer|An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advanced Refractory Cancer||Scottsdale Healthcare|No|Completed|September 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|N/A||1|Actual|11|Samples With DNA|Biopsy of an accessible lesion|Both|18 Years|N/A|No|Non-Probability Sample|Patients with advanced refractory cancer|May 2014|May 12, 2014|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443390||97813|
NCT01443637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTG1|The CONFIRM Registry|COronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter Registry|CONFIRM|Weill Medical College of Cornell University|No|Enrolling by invitation|June 2003|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|N/A|No|Probability Sample|The study population consist of patients at multiple international centers undergoing        clinically-indicated coronary CT angiography as part of their standard of care.|July 2015|July 29, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443637||97794|
NCT01444287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-0918 (JKN 0927)|Daytime Corneal Swelling During Wear of Narafilcon B Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|January 2010|March 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|22|||Both|18 Years|80 Years|No|||May 2015|May 5, 2015|September 27, 2011|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01444287||97744|
NCT01435447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH-ALL-2011|Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult ALL|Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With ALL Undergoing Allogeienc Stem Cell Transplantation||Shanghai Jiao Tong University School of Medicine|No|Recruiting|April 2011|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|60 Years|No|||May 2015|May 20, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01435447||98423|
NCT01436019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTC-PK-1|Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis|Analysis of Anti-infliximab, Anti-adalimumab and Anti-etanercept Antibodies in Children and Young Adolescents With Juvenile Idiopathic Arthritis||Blood Transfusion Centre of Slovenia|Yes|Not yet recruiting|October 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Serum samples|Both|1 Year|16 Years|No|Non-Probability Sample|primary care clinic|September 2011|September 16, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01436019||98379|
NCT01436045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-111|Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.|A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.||HealthPartners Institute|Yes|Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|65 Years|85 Years|No|||September 2015|September 25, 2015|September 16, 2011||No||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01436045||98377|
NCT01436292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10.239|Hypoalbuminemia in Burn Patients|Hypoalbuminemia in Burn Patients: Should we Care? - A Randomized Controlled Clinical Pilot Trial|Halburns|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|September 2011|October 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|18 Years|N/A|No|||September 2011|September 16, 2011|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01436292||98358|
NCT01436552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1001104-10|Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia|Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia|FPRMCI|Centre Hospitalier Esquirol|Yes|Recruiting|February 2010|February 2014|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|392|||Both|50 Years|N/A|No|Probability Sample|Patients with MCI will be recruited in different memory clinics (Limoges and others)|February 2010|September 16, 2011|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01436552||98338|
NCT01445548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110249|Sirolimus for Advanced Age-Related Macular Degeneration|Pilot Study of the Evaluation of Intravitreal Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration|SIRGA2|National Institutes of Health Clinical Center (CC)|Yes|Completed|September 2011|February 2014|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|56 Years|N/A|No|||May 2014|May 15, 2014|September 30, 2011|Yes|Yes||No|April 7, 2014|https://clinicaltrials.gov/show/NCT01445548||97656|
NCT01445821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSIST IIb|Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial|Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb)|DIScl2011|Northwestern University|Yes|Recruiting|September 2011|September 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|17 Years|60 Years|No|||March 2016|March 21, 2016|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01445821||97637|
NCT01446094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006077|Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease|Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease||The Methodist Hospital System|No|Recruiting|August 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446094||97617|
NCT01446354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|347/10|Goal-orientated Coagulation Management in Hypothermic Cardiac Arrest Surgery|Does the Intraoperative Thromboelastometry-guided Coagulation Management Reduce the Administration of Allogeneic Blood Products in Cardiac Surgery With the Help of Hypothermic Cardiac Arrest? A Retrospective Data Analysis||University Hospital, Basel, Switzerland|No|Completed|January 2011|February 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest|October 2012|October 23, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01446354||97597|
NCT01446367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cornea vs Vit-buckle|Corneal Changes After Retinal Surgery|Corneal Topographic Changes After 20-gauge Pars Plana Vitrectomy Associated With Scleral Buckling for the Treatment of Rhegmatogenous Retinal Detachment||Universidade Federal do Paraná|No|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with rhegmatogenous retinal detachments|October 2011|October 4, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446367||97596|
NCT01442311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-224|Directly Observed Hepatitis C Treatment in Methadone Clinics|Directly Observed Hepatitis C Treatment in Methadone Clinics||Albert Einstein College of Medicine of Yeshiva University|No|Completed|October 2007|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01442311||97896|
NCT01442272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEFROVID2010|Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D|Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D|NEFROVID2010|Hospital Universitario de Canarias|Yes|Recruiting|January 2012|October 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|174|||Both|18 Years|N/A|No|||September 2011|May 18, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442272||97899|
NCT01442285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHADRO|The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)|The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)|MHADRO|University of Massachusetts, Worcester|No|Completed|April 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1000|||Both|18 Years|N/A|No|||April 2014|April 8, 2015|April 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01442285||97898|
NCT01442597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004006632|Computer Based Training in Cognitive Behavioral Therapy Web-based|Computer Based Training in Cognitive Behavioral Therapy Web-based|Man VS Machine|Yale University|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442597||97874|
NCT01442870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin Anticancer + Chemo|Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy|Prospective Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy||Tufts Medical Center|Yes|Completed|September 2011|November 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|79 Years|No|||December 2014|December 8, 2014|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442870||97853|
NCT01443403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107V9221|A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy||Shionogi Inc.|No|Completed|August 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|244|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443403||97812|
NCT01443936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110259|Experimental AD4-H5-VTN Vaccine in Healthy Volunteers|Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|September 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01443936||97771|
NCT01443949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911466|Teenagers, Drug Addiction, and Reward and Impulse Control|Individual Differences in Reward and Impulse Control Circuitry as Risk Factors for Addiction||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2011|April 2013||||N/A|Observational|Time Perspective: Retrospective|||Actual|0|||Both|13 Years|17 Years|No|||April 2013|February 19, 2014|September 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01443949||97770|
NCT01443650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD12275|Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects|A Randomized Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Different Single-Dose Subcutaneous Treatments of SAR236553/REGN727 in Healthy Subjects||Sanofi|No|Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|June 27, 2013|September 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01443650||97793|
NCT01443663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 277|Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine|Immunogenicity and Safety Study of a 45 Micrograms Dose of Inactivated, Unadjuvanted H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H5N1 and H7N3 Influenza Vaccines and in H5 and Live Attenuated Vaccine Naïve Individuals||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2011|March 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|69|||Both|22 Years|54 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|September 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01443663||97792|
NCT01435733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8552-LG-CTIL|Parenting a Child With Autism Spectrum Disorder and Marital Status|Parenting a Child With Autism Spectrum Disorder and Marital Status||Sheba Medical Center|No|Recruiting|September 2011|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Couples who have children with ASD will be recruited to participate in this study from the        Weinberg Child Development Center in the Edmond and LilySafra Children'shospital,        ShebaMedical Center, Ramat-Gan, Israel. Parents will be contacted through the telephone        and provided with a brief explanation about the study. Participation will be voluntary        with no monetary compensation. Parents who volunteer to participate will then be presented        with a short telephone survey, asking them about their marital status and other variables        related to the link between parenting an ASD child and their marital status.|July 2014|July 17, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01435733||98401|
NCT01436305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-10|Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation|Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|September 2011|March 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|65 Years|No|||December 2015|December 31, 2015|September 13, 2011|Yes|Yes|Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.|No||https://clinicaltrials.gov/show/NCT01436305||98357|
NCT01436565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD11721|A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers|A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers||Sanofi|No|Completed|November 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|September 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01436565||98337|
NCT01436578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08547|Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)|Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of NOXAFIL Oral Suspension in Usual Practice||Merck Sharp & Dohme Corp.|No|Completed|February 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|273|||Both|N/A|N/A|No|Non-Probability Sample|Participants enrolled will be all who are treated with posaconazole oral suspension per        the current local label by participating investigators during the pre-specified        surveillance period.|July 2015|July 6, 2015|September 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01436578||98336|
NCT01436929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRMH-06-2011-75|Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs|Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs|PESOHHERZ|Seoul National University Hospital|No|Recruiting|September 2011|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|35 Years|N/A|No|||December 2012|December 13, 2012|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01436929||98309|
NCT01445834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH2011/0299/0|Age-stratified Outcome of Pelvic Floor Muscle Exercise for Urinary Incontinence|Retrospective Study About the Age-stratified Outcome of Pelvic Floor Muscle Exercise for Stress (SUI), Mixed (MUI) and Urgency Urinary Incontinence (UUI) 2003-2008||University of Zurich|No|Completed|June 2011|November 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|150|||Female|18 Years|99 Years|No|Probability Sample|women from a tertiary referral center with urodynamically proven incontinence willig to        perform physiotherapy|December 2015|December 1, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01445834||97636|
NCT01446107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW06-402T/1427|Effectiveness of Fissure Sealant and Topical Fluoride Application in Preventing Dental Caries|A Randomized Controlled Trial on the Effectiveness of Fissure Sealant and Topical Fluoride Application in Preventing Dental Caries||The University of Hong Kong|No|Completed|December 2007|December 2010|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|502|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||September 2011|October 4, 2011|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01446107||97616|
NCT01446380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC 2008 871|Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort|Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort||University Hospital, Angers|No|Recruiting|June 2008|January 2021|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Sera,Plasma,DNA,skin biopsy|Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed for a PXE disease from any part of France and requesting a follow-up        and clinical management of there disease (opthalmic and vascular complications mainly).|October 2009|October 3, 2011|February 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01446380||97595|
NCT01446705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-058|Evaluation of VLER-Indiana Health Information Exchange Demonstration Project|Evaluation of VLER_Indiana Health Information Exchange Demonstration Project|VLER-IHIE|VA Office of Research and Development|No|Active, not recruiting|December 2012|January 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|57073|||Both|N/A|N/A|No|Non-Probability Sample|Veteran's receiving care at the Indianapolis VAMC|December 2015|December 22, 2015|April 27, 2011||No||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01446705||97570|
NCT01450865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2007-007314-10|Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo|Evaluation of the Effect of the K+-Channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo: a Randomised Controlled Trial||Ludwig-Maximilians - University of Munich|Yes|Completed|October 2009|August 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01450865||97252|
NCT01451086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080808|Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China|Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|October 2011|August 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1200|||Both|2 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451086||97235|
NCT01447368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-2015|Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients|Comparison of Medical (Oral Cinacalcet) Therapy Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Study||The University of Hong Kong|Yes|Recruiting|May 2010|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||September 2015|September 6, 2015|October 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01447368||97519|
NCT01447849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA-LUB-125|Lubiprostone and Mucus Secretion in Patients With Chronic Constipation|The Impact of Lubiprostone on Mucus Secretion in Asymptomatic Volunteers and Patients With Chronic Constipation||Texas Tech University Health Sciences Center, El Paso|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|September 14, 2011|Yes|Yes||No|November 9, 2012|https://clinicaltrials.gov/show/NCT01447849||97482|
NCT01447576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-08-212|Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder|A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients With Major Depressive Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|September 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1036|||Both|18 Years|65 Years|No|||October 2015|October 6, 2015|September 29, 2011|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01447576||97503|
NCT01447589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-TSC-651|Radical Lung Radiotherapy Plus Nelfinavir|A Phase I Dose Escalation Study of the HIV Protease Inhibitor, Nelfinavir, Given Concomitantly With Radical Radiotherapy (RT) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)|NelfLung|Oxford University Hospitals NHS Trust|No|Withdrawn|February 2012|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|July 18, 2011||No|failed to recruit, no suitable patients|No||https://clinicaltrials.gov/show/NCT01447589||97502|
NCT01447836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLICG|Indocyanine Clearance Rate and Septic Liver Injury|Prognostic Value of Indocyanine Clearance Rate for Sepsis Patients in ICU||Sun Yat-sen University|Yes|Recruiting|July 2011|November 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Blood for transaminase, hemoglobin, prothrombin time, lactate and oxygen pressure test.|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to SICU of our clinical center|October 2011|October 5, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447836||97483|
NCT01448122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 4140 A 2011 176|Avene Compact Honey for Prevention of Pigmentation From Visible Light|A Randomized, Single-blind Study of the Ability of Avène Compact Honey to Prevent Pigmentation Induced by Visible Light in Subjects With Skin Phototype III or IV||Pierre Fabre Dermo Cosmetique|No|Completed|October 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 26, 2013|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448122||97461|
NCT01448408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26/27-09-2011|Corneal Biomechanical Properties and Anterior Segment Parameters, in Forme Fruste Keratoconus|Evaluation of the Sensitivity, Specificity, and Test Accuracy of Corneal Biomechanical Metrics, Anterior Segment Data and a Combination Model, in Differentiating Forme Fruste Keratoconus (FFK) From Healthy Corneas.||Democritus University of Thrace|No|Completed|May 2007|July 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|||||Both|18 Years|50 Years|No|Non-Probability Sample|All participants were recruited from the Outpatients Cornea service of the EIT in a        consecutive if eligible basis|October 2011|October 5, 2011|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448408||97439|
NCT01449305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nanoone|Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea|Research on Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea||Chen Yi Enterprise, Co., Ltd.||Completed|October 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|44|||Female|13 Years|40 Years|No|||August 2011|February 1, 2013|October 6, 2011||No||No|December 28, 2012|https://clinicaltrials.gov/show/NCT01449305||97371|
NCT01449318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANES.MA.13|Predictors of Postoperative Pain|Predictors of Postoperative Pain Following Abdominal Hysterectomy||American University of Beirut Medical Center|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|60|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||September 2013|May 15, 2014|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01449318||97370|
NCT01449279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL0005|Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy|A Pilot Study of Ipilimumab in Subjects With Stage IV Melanoma Receiving Palliative Radiation Therapy||Stanford University|Yes|Recruiting|October 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449279||97373|
NCT01449292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C11-003PLV|Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)|Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)|ASPIRE|Aeris Therapeutics|Yes|Terminated|June 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|N/A|No|||November 2013|November 13, 2013|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449292||97372|
NCT01449877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356591|Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis|Influence of Trimethoprim-sulfamethoxazole for the Recurrence of Retinochoroiditis Toxoplasma Gondii|ISROT|University of Campinas, Brazil|Yes|Completed|October 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|141|||Both|18 Years|60 Years|No|||February 2016|February 11, 2016|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449877||97328|
NCT01444885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STELLA|Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of PletaalÒ(Cilostazol) in Subjects With Vasospastic Angina (STELLA)|STELLA|Korea Otsuka Pharmaceutical Co.,Ltd.|No|Completed|October 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|80 Years|No|||July 2012|July 13, 2012|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01444885||97698|
NCT01444586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16002|Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)|Prospective Multicentre Non-interventional Study on Compliance and Patient/Doctor Behavior of VTE Prevention in Major Orthopedic Surgery|SOPRANO|Bayer|No|Completed|October 2011|July 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2293|||Both|18 Years|N/A|No|Non-Probability Sample|The patients will be treated according to the routine practice. All the patients meeting        the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are        fit for participation in this non-interventional study.|July 2015|July 2, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01444586||97721|
NCT01444976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yuksel-dogan-2011|The Effect of Sedation During Transesophageal Echocardiography on Heart Rate Variability|The Effect of Sedation During Transesophageal Echocardiography on Heart Rate Variability:A Comparison of Hypnotic Sedation With Medical Sedation||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|No|Completed|December 2010|March 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|76|||Both|18 Years|83 Years|No|||September 2011|September 30, 2011|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01444976||97694|
NCT01445288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060219|Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors|An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|July 2006|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|150|||Both|N/A|21 Years|No|||September 2015|October 6, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445288||97672|
NCT01445899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QRK202|PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)|An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination With Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE STUDY)|MATISSE|Quark Pharmaceuticals|Yes|Completed|February 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|258|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|September 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01445899||97631|
NCT01445925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LHCH901|Substrate Ablation and Remodelling in Non-paroxysmal Atrial Fibrillation (AF)|Substrate Modification With Ablation and Antiarrhythmic Drugs in Non-Paroxysmal Atrial Fibrillation|SMAAN-PAF|Liverpool Heart and Chest Hospital NHS Foundation Trust|No|Active, not recruiting|September 2011|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||August 2013|August 21, 2013|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445925||97630|
NCT01446796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026676|Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)|Hemodynamic and Clinical Effects of Continuous Right Ventricular Pacing in the Early Post-operative Period After Left Ventricular Assist Device Implantation||Duke University|Yes|Terminated|September 2011|October 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|3|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|September 14, 2011|Yes|Yes|Recruitment futility|No|June 21, 2013|https://clinicaltrials.gov/show/NCT01446796||97563|
NCT01450566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lidocaine Beiko|Intraureteral Lidocaine for Post-Ureteroscopy Pain|Intraureteral of Alkalinized Lidocaine as Novel Approach to Post-Ureteroscopy Pain: Double-blind Prospective Randomized Controlled Trial||Queen's University|No|Recruiting|September 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01450566||97275|
NCT01450579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7373-CL-0106|A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers|Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults||Astellas Pharma Inc|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|180|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01450579||97274|
NCT01446861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2857-7|Exocrine Pancreatic Function Testing in Cystic Fibrosis|Pancreatic Failure in Patients With Cystic Fibrosis A Multimodal Study of Exocrine Pancreatic Failure in Cystic Fibrosis||Haukeland University Hospital|No|Recruiting|January 2011|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|Samples With DNA|Duodenal juice Serum, full Blood Saliva|Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cystic fibrosis patients over the age of 15 years Healthy controls between 18 and 67 years|January 2016|January 21, 2016|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01446861||97558|
NCT01448161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0858|A Machine Learning Approach to Continuous Vital Sign Data Analysis|A Machine Learning Approach to Continuous Vital Sign Data Analysis||University of Colorado, Denver|No|Enrolling by invitation|December 2011|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|31 Days|89 Years|No|Non-Probability Sample|Pediatric and Adult ICU patients|December 2015|December 3, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448161||97458|
NCT01447069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTA-HF-01|Use of Beta-agonists in Stable Severe Congestive Heart Failure|||Rabin Medical Center|No|Not yet recruiting|October 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|80 Years|No|||August 2011|October 2, 2011|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01447069||97542|
NCT01447082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1444C00006|General Practice Research Database Seroquel XR Safety Study|Epidemiology Study to Assess the Safety of a New Slow-release Form of Seroquel (Quetiapine) in the Post-marketing Phase in the UK|GPRD SeroquelS|AstraZeneca||Completed|October 2008|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|37372|||Both|18 Years|85 Years|No|Non-Probability Sample|A sample of the general population in the UK consisting of 3 millions inhabitants.|February 2014|February 6, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01447082||97541|
NCT01448707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018370|A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment|PROTEAse Inhibitor (DRV/Rtv) in Mono- or Triple Therapy in Suppressed HIV-1 Infected Subjects|PROTEA|Janssen-Cilag International NV|Yes|Completed|March 2012|March 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|274|||Both|18 Years|N/A|No|||January 2016|February 1, 2016|June 2, 2011|Yes|Yes||No|October 30, 2015|https://clinicaltrials.gov/show/NCT01448707||97416|
NCT01448733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Coria Combo|Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris|A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the Treatment of Facial Acne Vulgaris.||Zeichner, Joshua, M.D.|Yes|Active, not recruiting|July 2011|October 2011|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|12 Years|N/A|No|||October 2011|October 6, 2011|October 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01448733||97414|
NCT01448135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1205|Tolerance and Efficacy of a Predigested, High Protein, High Omega 3 Fat Enteral Feeding Formula Versus a Standard Formula In Multiple Intensive Care Unit Settings|Pilot Study Evaluating the Efficacy, Tolerance and Safety of VITAL AF (Semi Elemental, High Protein, High Omega 3 Fat Enteral Formula) Versus Osmolite 1.2 (High Protein Enteral Formula) in Multiple ICU Settings (Medical, Surgical, Cardiothoracic)||Columbia University|No|Completed|October 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|June 22, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01448135||97460|
NCT01448434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM/OA/10-11/001|Allogeneic Mesenchymal Stem Cells for Osteoarthritis|A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee||Stempeutics Research Pvt Ltd|Yes|Active, not recruiting|September 2011|February 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|20 Years|70 Years|No|||October 2012|October 1, 2012|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01448434||97437|
NCT01448447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mammosite ML|Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®|Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast|Mammosite ML|St. John's Mercy Research Institute, St. Louis|No|Recruiting|December 2009|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|45 Years|N/A|No|||December 2012|December 12, 2012|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01448447||97436|
NCT01448668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISC-4.1.6|Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)|Prospective Epidemiological Study to Expand Knowledge on Efficacy and Safety of a Routine Post-operative Supportive Therapy With the Mistletoe Extract Iscador® Qu Within Oncological Treatment of Pancreatic Cancer Stages UICC II-IV||IFAG AG|No|Active, not recruiting|September 2010|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|220|||Both|18 Years|85 Years|No|Non-Probability Sample|All patients visiting the center with pancreatic cancer stage UICC II-IV and meeting the        eligibility criteria will be asked to participate.|July 2013|July 1, 2013|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01448668||97419|
NCT01450137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|168/10|Tocilizumab for Patients With Giant Cell Arteritis|A Phase II, Randomized, Double-blind, Placebo Controlled Study of Tocilizumab in Patients With Giant Cell Arteritis||University Hospital Inselspital, Berne|Yes|Completed|September 2011|September 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|50 Years|N/A|No|||September 2015|September 23, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01450137||97308|
NCT01449604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAMART0111|Stereotactic Radiation in Vestibular Schwannoma|Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma||Ramathibodi Hospital|No|Active, not recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|No|||October 2011|October 6, 2011|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01449604||97348|
NCT01450631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHS.2011.Prevena.Heine.03|The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions|A Prospective, Randomized, Evaluation of the Prevena™ Incision Management System on Closed Incisions in Obese Subjects Undergoing Cesarean Section Surgery||KCI USA, Inc.|No|Completed|February 2012|||December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|92|||Female|18 Years|N/A|No|||August 2014|August 15, 2014|October 10, 2011|Yes|Yes||No|July 3, 2014|https://clinicaltrials.gov/show/NCT01450631||97270|
NCT01450644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR3669|Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease|A Fast-track Randomised Controlled Trial to Evaluate a Hospital2Home Palliative Care Service for Patients With Advanced Progressive Idiopathic Fibrotic Interstitial Lung Disease|H2H-ILD|Royal Marsden NHS Foundation Trust|Yes|Recruiting|October 2011|January 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|52|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450644||97269|
NCT01444014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-015|YF476 and Type I Gastric Carcinoids (Norway)|A Single Centre, Pilot Trial of YF476 in Patients With Chronic Atrophic Gastritis, Hypergastrinaemia and Type I Gastric Carcinoids||Trio Medicines Ltd.|No|Terminated|June 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|September 28, 2011||No|Difficulties with recruitment|No||https://clinicaltrials.gov/show/NCT01444014||97765|
NCT01445678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7625A-004|Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections||Cubist Pharmaceuticals LLC|No|Completed|December 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|494|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|September 26, 2011|Yes|Yes||No|January 9, 2015|https://clinicaltrials.gov/show/NCT01445678||97648|Two identical P3 protocols were initiated (NCT01445678 and NCT01445665) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.
NCT01445691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051663|More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery|A Multicenter Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas||Icahn School of Medicine at Mount Sinai|Yes|Not yet recruiting|November 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|133|||Both|18 Years|80 Years|No|||October 2015|October 30, 2015|September 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01445691||97647|
NCT01446497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1008-059-327|Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma|Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients||Seoul National University Hospital|Yes|Recruiting|October 2010|August 2012|Anticipated|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|N/A|No|||October 2011|October 3, 2011|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01446497||97586|
NCT01442961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09003|Vaginal Hysterectomy, Laparoscopic Hysterectomy, Postoperative Pain|Postoperative Pain After Vaginal or Laparoscopic Hysterectomy: a Prospective Trial||Tampere University Hospital|No|Completed|January 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|188|||Female|18 Years|69 Years|No|||April 2013|April 9, 2013|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01442961||97846|
NCT01450592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15922|Study To Assess the Dietary Carbohydrate Content of Indian Diabetic Population|Epidemiological Study to Evaluate the Dietary Composition of Indian Type-2 Diabetic Patients Compared to Non-diabetic Population|STARCH|Bayer|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|796|||Both|18 Years|N/A|No|Probability Sample|Type-2 diabetic and non-diabetic population|December 2013|December 26, 2013|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01450592||97273|
NCT01450891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-3-038|Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease|Novel Diagnostic Approaches for the Diagnosis of Alzheimer's Disease: Technology Assessment and Clinical Effectiveness||Maastricht University Medical Center|No|Completed|September 2009|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|304|Samples Without DNA|Cerebrospinal fluid|Both|18 Years|N/A|No|Non-Probability Sample|304 consecutive patients, of four academic memory clinics specialized in the diagnosis and        treatment of memory disorders, who were suspected of having a primary neurodegenerative        disease were approached for participating in the study. This included all patients with        subjective and/or objective memory complaints. Eligibility criteria were chosen to        represent current clinical situation and enable generalisability to clinical practice.|May 2015|May 27, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01450891||97250|
NCT01447875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011ZDLLKY02.1|The Effects of Sedative on the Fluid Responsiveness in Critically Ill Patients|The Effects of Propofol and Dexmedetomidine Infusion on the Fluid Responsiveness in Critically Ill Patients||Southeast University, China|Yes|Completed|May 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|80 Years|No|||May 2012|January 28, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01447875||97480|
NCT01447888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3436-3|Perioperative Pain Management In Spine Surgery Patients: Part I|Perioperative Pain Management In Spine Surgery Patients: Part I||Abbott Northwestern Hospital|No|Recruiting|September 2011|May 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|September 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01447888||97479|
NCT01448174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALGN-001|Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients|Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients||Poznan University of Medical Sciences|No|Completed|October 2011|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|3||Actual|310|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 5, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448174||97457|
NCT01447381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH 2011-14488|Systemic Therapies for Pediatric Atopic Dermatitis|Systemic Therapies for Pediatric Atopic Dermatitis||Rady Children's Hospital, San Diego|Yes|Recruiting|October 2011|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|250|||Both|2 Years|17 Years|No|Probability Sample|Ages 2 to 17 (inclusive) with moderate to severe atopic dermatitis and who require        treatment with cyclosporine, azathioprine, mycophenolate mofetil, and/or methotrexate.        Both male and female. Non-pregnant females and minorities will be included without        restriction.|November 2012|November 1, 2012|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01447381||97518|
NCT01449058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2109|A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors|A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors||Array BioPharma||Recruiting|March 2012|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|138|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01449058||97390|
NCT01447602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6238|A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior|An Open Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior|IPT-A-CSP|New York State Psychiatric Institute|No|Completed|September 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|12 Years|19 Years|No|||April 2013|September 2, 2014|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01447602||97501|
NCT01447862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Verna-Ibu-AF|Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation|Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation||Medical University of Vienna|No|Completed|October 2011|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|90 Years|No|||May 2015|May 12, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01447862||97481|
NCT01448148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRIUGM-002|Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment|Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment||Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|Yes|Completed|November 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|145|||Both|55 Years|N/A|No|||January 2016|January 26, 2016|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01448148||97459|
NCT01448460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.356|Oocyte Vitrification for In Vitro Fertilization (IVF) Patients and Women With Fertility Threatening Conditions|Oocyte Vitrification for IVF Patients and Women With Fertility Threatening Conditions||University of Louisville|Yes|Completed|September 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8||oocytes|Female|14 Years|42 Years|No|Non-Probability Sample|IVF patients who desire to have extra eggs, in excess of what is needed for their IVF        cycle, or subjects requesting fertility preservation due to fertility threatening        conditions such as cancer, advanced age or other.|January 2013|January 23, 2013|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448460||97435|
NCT01448681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1412|A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension|A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension||University of Colorado, Denver|No|Enrolling by invitation|August 2011|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|89 Years|No|Non-Probability Sample|Surgical intensive care unit patients|December 2015|December 3, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448681||97418|
NCT01448694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1421|Non-invasive Hemodynamic Monitoring During Blood Donation for Developing Models of Early Blood Loss|Non-invasive Hemodynamic Monitoring During Blood Donation for Developing Models of Early Blood Loss.||University of Colorado, Denver|No|Completed|November 2011|September 2014|Actual|October 2013|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|320|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults|December 2014|December 1, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448694||97417|
NCT01448993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BICMS/PR/11/127|Effect of Azithromycin on Oesophageal Hypomotility|Effect Of Azithromycin On Oesophageal Function In Patients With Dysphagia Or Gastro-Oesophageal Reflux Associated With Frequent Oesophageal Hypomotility||Queen Mary University of London|Yes|Completed|August 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01448993||97395|
NCT01449006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/066|A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)|A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Maraviroc in HIV Virally Suppressed Patients With Cognitive Impairment|HANDmac|St Vincent's Hospital, Sydney|Yes|Not yet recruiting|October 2011|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2012|October 7, 2012|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449006||97394|
NCT01449019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPI|The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)|The Contribution of Glucagon-like Peptide 1 (GLP-1) to the Entero-insulinar Axis in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)|DFG_5|Ludwig-Maximilians - University of Munich|Yes|Completed|December 2006|July 2010|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01449019||97393|
NCT01450150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS-ERB08/04-2011|Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression|Transcranial Direct Current Stimulation (tDCS) as an Augmenting Intervention for Treatment-Resistant Major Depression: A Randomized, Double-Blind and Sham-Controlled Trial||Douglas Mental Health University Institute|No|Not yet recruiting|January 2016|October 2018|Anticipated|October 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||January 2016|January 19, 2016|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01450150||97307|
NCT01450163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreOx|Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy|PHASE III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin in Prevention and Reduction of Oxaliplatin-induced Painful Neuropathy|PreOx|University of Sao Paulo|Yes|Enrolling by invitation|August 2011|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|April 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01450163||97306|
NCT01450410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CompHDL2011|Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL|Efecto Del ácido nicotínico Sobre la composición de Las lipoproteínas de Alta Densidad (HDL) y la función Del Endotelio Arterial en Los Pacientes Con cardiopatía isquémica Prematura y Concentraciones Elevadas de Colesterol-HDL|11MSP011|Hospital Universitari de Bellvitge|Yes|Terminated|July 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Both|25 Years|N/A|No|||November 2011|January 28, 2013|October 7, 2011||No|Study terminated (halted prematurely) as recomended by the drug supplier and medical agencies|No||https://clinicaltrials.gov/show/NCT01450410||97287|
NCT01450657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIB002|Observational Study of Kibow Biotics in Chronic Kidney Failure Patients|Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Chronic Kidney Failure Patients, in Conjunction With Standardized Care of Treatment||Kibow Biotech Inc.|Yes|Recruiting|July 2011|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood plasma and serum|Both|18 Years|75 Years|No|Probability Sample|Outpatient hospital setting.|May 2012|May 2, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01450657||97268|
NCT01444040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-027|Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost|A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004%||Glaukos Corporation|No|Recruiting|September 2011|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444040||97763|
NCT01444053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-201010|Retrospective Study of the Health Benefits of Ultra-Violet Filtering Contact Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|41|||Both|18 Years|43 Years|No|Non-Probability Sample|Subject selection is based on a history of wearing one of two types of contact lenses for        at least five years. Age-matching subjects into 4 age-brackets will be attempted with a        target of five subjects in each age bracket among the two types of lenses.|May 2012|May 7, 2012|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444053||97762|
NCT01446198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHPVPS-US11-003|Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System|Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System||Gen-Probe, Incorporated|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|11816|Samples With DNA|Cervical specimens collected in ThinPrep Pap Test vials containing PreservCyt Solution      (Hologic, In., Marlborough, MA) with commercially available collection device or      cytobrush/spatula combination may be tested with the HPV Assay either pre- or post-Pap      processing.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with AHPV Assay positive results and subjects with AHPV negative results|June 2012|June 29, 2012|October 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446198||97609|
NCT01446484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSMU-001|Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection|Phase 1 Pilot Study Using Autologous CD4+CD25+FoxP3+ T Regulatory Cells and Campath-1H to Induce Renal Transplant Tolerance||The Russian State Medical University|No|Recruiting|October 2011|November 2014|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|1 Year|18 Years|No|||November 2011|November 17, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446484||97587|
NCT01443195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0035-11-EMC|Iron Metabolism in Small Pre Term Newborns|Iron Metabolism in Small Pre Term Newborns||HaEmek Medical Center, Israel|No|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|N/A|6 Months|No|||August 2015|August 30, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443195||97828|
NCT01446874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106336|Prevention of Post-operative Pneumonia (POPP)|Prevention of Postoperative Pneumonia (POPP Study: A Study to Evaluate the Use of a Prophylactic Clinical Strategy to Prevent Postoperative Pneumonia in Patients Undergoing Thoracic Surgery|POPP|Washington University School of Medicine|Yes|Active, not recruiting|September 2011|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|330|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01446874||97557|
NCT01447121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-PRO-2011-005-01|User Study of an Investigational Blood Glucose Monitoring System|Tatsu/Tradewind System User Performance Evaluation||Ascensia Diabetes Care|No|Completed|September 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|118|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|October 4, 2011|Yes|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01447121||97538|
NCT01447394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-013|Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C|A Double-Blinded Randomized Control Study Evaluating the Efficacy and Safety of Pegylated Lambda Interferon Compared to Pegylated Alfa-2a Interferon, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 or 4 Chronic Hepatitis C Subjects||Bristol-Myers Squibb|No|Withdrawn|March 2012|August 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||February 2012|February 2, 2012|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01447394||97517|
NCT01448499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMCH-014-11|Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients|Clozapine Versus Amisulpride Versus Their Combination in the Treatment of Drug-resistant Schizophrenia Patients|ClozAmi|Geha Mental Health Center|No|Withdrawn|October 2011|||October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||December 2015|December 8, 2015|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01448499||97432|
NCT01448772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-10-012|Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions|A Single-Dose, Replicate Crossover Design Comparative Bioavailability Study of Dronabinol Oral Solution 5 mg Versus Marinol Capsules 5 mg Under Fasted Conditions||INSYS Therapeutics Inc|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|October 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448772||97411|
NCT01448473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4vs2|Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients|Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients With Minor Head Trauma?|4vs2|St. Justine's Hospital|No|Completed|October 2011|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|14|||Both|N/A|18 Years|No|||March 2013|March 18, 2013|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448473||97434|
NCT01449084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPDSR|Early Pancreatic Duct Stent Removal in Preventing Post-endoscopic Pancreatitis|Immediate Pancreatic Duct Stent Removal Does Not Prevent Pancreatitis After Accidental Pancreatic Duct Cannulation - A Prospective Randomized Trial||Nuovo Ospedale Civile S.Agostino Estense|No|Completed|December 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||October 2011|October 10, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01449084||97388|
NCT01449032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyStromalCell|MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)|MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)|MyStromalCell|Rigshospitalet, Denmark|Yes|Completed|April 2010|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|30 Years|80 Years|No|||June 2014|June 7, 2014|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449032||97392|
NCT01449045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEN11.16|Trial of Malaria Seasonal IPTc Combined With Community Case Management|Cluster Randomized Trial of Malaria Seasonal IPTc Combined With Community Case Management in Saraya District, SE Senegal||Cheikh Anta Diop University, Senegal|Yes|Completed|July 2011|February 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4554|||Both|3 Months|10 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|September 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01449045||97391|
NCT01449331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 09006|The Use of Palliative Non Invasive Ventilation in Acute Respiratory Failure. OVNI Study.|Qualitative Outcomes After Palliative Noninvasive Mechanical Ventilation : OVNI Study|OVNI|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1450|||Both|18 Years|N/A|No|Probability Sample|Patients with non invasive ventilation in ICU|November 2012|November 19, 2012|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449331||97369|
NCT01449344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL2005-01|Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL|Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma|(R-HAD)|European Mantle Cell Lymphoma Network|No|Recruiting|November 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01449344||97368|
NCT01449617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniPG|Residual Platelet Reactivity in Patients on Antiplatelet Therapy After Carotid Angioplasty With Stenting|Observational Study on Predictive Value for Vascular Events of Residual Platelet Aggregation in Patients on Antiplatelet Therapy After Carotid Angioplasty With Stenting|ARS|Azienda Ospedaliera di Perugia|No|Recruiting|August 2010|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|272|Samples Without DNA|Whole blood samples, plasma samples, serum samples, urines.|Both|18 Years|80 Years|No|Probability Sample|506 patients undergoing stenting for critical carotid stenosis, either symptomatic        (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.|July 2014|July 16, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01449617||97347|
NCT01449630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14283|A Study of LY3031207 in Healthy Subjects|A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3031207 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|42|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|October 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01449630||97346|
NCT01449890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRV0422/00-40-65-50-24|Randomized Trial of Depression Follow-up Care by Email|Randomized Trial of E-mail Follow-up Care After Cognitive Behavioural Treatment for Depression||Universitätsklinikum Hamburg-Eppendorf|No|Completed|September 2012|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449890||97327|
NCT01450670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIB003|Observational Study of Kibow Biotics in Dialysis Patients|Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Dialysis Patients, in Conjunction With Standardized Care of Treatment||Kibow Biotech Inc.|Yes|Recruiting|May 2011|July 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood serum and plasma.|Both|18 Years|75 Years|No|Probability Sample|Out patient hospital setting|May 2012|May 2, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01450670||97267|
NCT01450423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110080|Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy|Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Aged 15-50: A Randomized Controlled Trial|EFA|University of Southern Denmark||Recruiting|September 2011|May 2012|Anticipated|May 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|15 Years|50 Years|No|||October 2011|October 9, 2011|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01450423||97286|
NCT01450956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJXZ2011-010|The Protective Effects of Sevoflurane in Pediatric Cardiac Surgery|The Protective Effects of Sevoflurane Application During CPB on Pediatric Patients Underwent Cardiac Surgery: a Randomized, Controlled, Blinded Clinical Trial||Xijing Hospital|Yes|Recruiting|September 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|1 Month|24 Months|No|||November 2011|November 24, 2011|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450956||97245|
NCT01446913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101007811|Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure|Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure|Sleep Tight|Yale University|Yes|Completed|May 2011|April 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|255|||Both|18 Years|N/A|No|||November 2013|July 30, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446913||97554|
NCT01444625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Callebaut-10151|Flavanols and Skin Photo Protection: a Clinical Trial|Flavanols and Skin Photo Protection: a Double Blind Clinical Trial|CHOCOPO|Laval University|No|Completed|June 2011|May 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|78|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 28, 2013|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01444625||97718|
NCT01444638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-594|Evaluation of Ultrasound (US) Assistance for Anesthesia Trainees for Caesarean Section Spinal Placement|Evaluation of US Assistance for Anesthesia Trainees for Spinal Placement in Parturients Having Caesarean Section: A Randomized Control Trial||Lawson Health Research Institute|No|Completed|January 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|80|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 12, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01444638||97717|
NCT01443767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S188/2011|Correlation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection|Pilot Study to Examine the Correlation of 'Estimated Continuous Cardias Output' (esCCO) With Pulse Contour Analysis of the Arterial Waveform (Picco) in Partial Liver Resection||Heidelberg University|No|Completed|July 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients scheduled for partial liver resection|February 2012|February 12, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01443767||97784|
NCT01444079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0808|Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation|Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation||Yonsei University|Yes|Completed|April 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|None Retained|Whole blood (serum)|Both|20 Years|70 Years|No|Non-Probability Sample|Adult recipients who will undergo liver transplantation during study period|January 2015|January 26, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01444079||97760|
NCT01444430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5896C00027|A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents|A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma||AstraZeneca||Completed|December 2011|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|12463|||Both|12 Years|130 Years|No|||February 2016|February 12, 2016|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444430||97733|
NCT01447407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NDV3-002|Study to Assess the Effect of Adjuvant and Route of Administration on the Safety, Tolerability, and Immunogenicity of NDV-3 Vaccine Against S.Aureus and Candida|Phase 1b Partially-blind,Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of NDV-3, A Recombinant Alum Adjuvanted Vaccine for S. Aureus and Candida Infections, Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults||NovaDigm Therapeutics, Inc.|No|Completed|September 2011|December 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|160|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01447407||97516|
NCT01447654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001191-19|Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy|INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.|INHERIT|Rigshospitalet, Denmark|Yes|Completed|November 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447654||97497|
NCT01447901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-AMT-011-04|Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies|Prospective, Non-interventional, Non-randomised, Open-label, Adult Study to Assess the Long Term Biological Therapeutic Response to Alipogene Tiparvovec in Lipoprotein Lipase Deficiency (LPLD) and Comparing Postprandial Chylomicron Metabolism Following a Radiolabeled Meal in LPLD Subjects Previously Treated With Alipogene Tiparvovec (Studies CT-AMT-011-01 or -02) to Untreated LPLD Subjects (Study PREPARATION-02) and to Healthy Volunteers||Amsterdam Molecular Therapeutics|No|Terminated|September 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|19|Samples With DNA|whole blood, serum, urine, faeces|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Lipoprotein Lipase Deficiency (LPLD) Patients          -  Healthy volunteers (community sample)|March 2015|March 27, 2015|September 28, 2011||No|Business reason|No||https://clinicaltrials.gov/show/NCT01447901||97478|
NCT01447914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03470|Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma|A Phase II Study of the c-Met Inhibitor ARQ 197 in Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|November 2011|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2014|March 12, 2015|October 4, 2011|Yes|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT01447914||97477|
NCT01447615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA11950|Bridges to the Future: Economic Empowerment for AIDS-Orphaned Children in Uganda|Bridges to the Future: Economic Empowerment for AIDS-Orphaned Children in Uganda||Columbia University|No|Active, not recruiting|February 2012|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|1440|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447615||97500|
NCT01447628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1811|IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients|What is the Effect of Intravenous Iron Supplementation on Cardiopulmonary Haemodynamics, Exercise Capacity and Quality of Life in Patients With IPAH and Iron Deficiency?||Imperial College London|No|Recruiting|October 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|75 Years|No|||August 2015|October 27, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447628||97499|
NCT01447641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC301|Sleep, Circadian Rhythms and Cluster Headache|Characterisation of Sleep and Circadian Physiology in Individuals With Cluster Headache||University of Surrey|No|Recruiting|August 2011|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|36|Samples With DNA|Blood hormonal and circulating lymphocyte mRNA assays|Both|16 Years|75 Years|No|Non-Probability Sample|Cluster headache sufferers (both of the episodic and chronic cluster headache) Related        headache disorders|December 2015|December 1, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447641||97498|
NCT01448785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-007-P|Abiliti™ Treatment in Obese Subjects|Abiliti™ Treatment in Obese Subjects: A Randomized Post-Market Surveillance Multicenter Study||IntraPace, Inc|No|Recruiting|April 2011|January 2015|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Both|18 Years|60 Years|No|||October 2011|October 27, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01448785||97410|
NCT01448798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AnPro|Athermal Nerve-sparing During Robotic-assisted Radical Prostatectomy Using a Hemostatic Matrix.|Prospective Randomized Investigation of Athermal Nerve-sparing During Robotic-assisted Laparoscopic Prostatectomy Using a Hemostatic Gelatin-thrombin Matrix|AnPro|Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|October 2011|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|No|||October 2011|October 6, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448798||97409|
NCT01448486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/033|A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV|A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Raltegravir in HIV Virally Suppressed Patients With Cognitive Impairment|HANDral|St Vincent's Hospital, Sydney|Yes|Terminated|October 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|October 5, 2011||No|Funding withdrawn based on unacceptably slow recruitment rate.|No|November 13, 2013|https://clinicaltrials.gov/show/NCT01448486||97433|Early termination leading to incomplete dataset with sample size too small to produce any meaningful statistical analysis.
NCT01448720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017977|Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate|Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate - A Pilot Study||Janssen-Cilag Farmaceutica Ltda.|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|142|||Both|18 Years|49 Years|No|||September 2014|September 17, 2014|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448720||97415|
NCT01449396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU2010|Acupuncture, Chinese Traditional Medicine, in Embryo Transfer|Chinese Traditional Medicine Contribution to Improve In-vitro Fertilization (IVF) Results: Acupuncture in Embryo Transfer||Instituto de Investigacion Sanitaria La Fe|Yes|Recruiting|October 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|252|||Female|18 Years|37 Years|No|||July 2015|July 21, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01449396||97364|
NCT01449071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0026|Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)|A Phase1/2, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Pharmacokinetics of One 12 Week Treatment Cycle of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects With Moderate to Severe Disease||UCB Pharma|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|64 Years|No|||January 2014|January 16, 2014|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449071||97389|
NCT01449357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN210|Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors|A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients With Non-Small Cell Lung Cancer Who Have Progressive Disease After Treatment With Tyrosine Kinase Inhibitors||Genmab|No|Withdrawn||||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|September 29, 2011|Yes|Yes|Trial never initiated|No||https://clinicaltrials.gov/show/NCT01449357||97367|
NCT01449370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INK1117-001|Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer|A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|October 2011|January 2016|Anticipated|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|124|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01449370||97366|
NCT01449643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE-0280.0.172.000-10|The Influence of Inspiratory Muscular Training (IMT) on Diaphragmatic Mobility in Morbidly Obese|The Influence of Inspiratory Muscular Training on Diaphragmatic Mobility, Lung Function and Quality of Life in Obese Individuals||Universidade Federal de Pernambuco|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 28, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449643||97345|
NCT01449656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLMA vs SLMA|A Comparison of the Laryngeal Mask Airway (LMA) Proseal and LMA Supreme in Children|A Randomized Trial Comparing the Laryngeal Mask Airway-SupremeTM With the Laryngeal Mask Airway-ProsealTM in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|6 Months|6 Years|Accepts Healthy Volunteers|Probability Sample|Children weighing 10 to 20 kg undergoing surgical or medical procedures under anesthesia        requiring a supraglottic airway device|December 2011|December 9, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01449656||97344|
NCT01449903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proth-003|Survival of Different Core Build-up Materials|Core Build-up Materials: a Randomized Clinical Study||Heidelberg University|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Both|18 Years|80 Years|No|Probability Sample|Patients of the department of porsthodontics, university of heidelberg|May 2015|May 27, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449903||97326|
NCT01450176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-04-11|Comparing Patient Satisfaction With Pataday or Bepreve|Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID||McCabe Vision Center|No|Completed|September 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 8, 2014|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450176||97305|
NCT01450683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-19413|Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy|A Phase 2 Study of Itraconazole in Castrate-resistant Prostate Cancer Post-chemotherapy||Stanford University|Yes|Terminated|September 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||August 2014|August 29, 2014|September 30, 2011|Yes|Yes|Low accrual|No|August 29, 2014|https://clinicaltrials.gov/show/NCT01450683||97266|
NCT01450696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO27798|HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer|||Hoffmann-La Roche||Recruiting|December 2011|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|October 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450696||97265|
NCT01450969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-052|New Fabric Attenuation Device in Endovascular Interventional Radiology (PREFER)|Prospective Randomized Evaluation of a New Fabric Attenuation Device in Endovascular Interventional Radiology (PREFER)|PREFER|Baptist Health South Florida|No|Completed|September 2011|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All operators are Interventional Radiologists and Co-Investigators. Prior to start of the        study, all operators are asked to provide written informed consent to participate in the        study.|September 2014|September 23, 2014|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01450969||97244|
NCT01444339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPR05|Study of Two Investigational Pneumococcal Vaccines in Healthy Adults|||Sanofi|No|Completed|February 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|131|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444339||97740|
NCT01444352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPR06|Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults|||Sanofi|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444352||97739|
NCT01445301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115287|Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects|Study STF115287, a Clinical Confirmation Study of GSK2585823 (Clindamycin 1%-Benzoyl Peroxide 3% Gel) in the Treatment of Acne Vulgaris in Japanese Subjects. - A Multicenter, Randomized, Single-blind, Active-controlled, Parallel-group Study -||GlaxoSmithKline|No|Completed|September 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|800|||Both|12 Years|45 Years|No|||August 2012|August 16, 2012|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01445301||97671|
NCT01444092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9422C00001|Safety Study of Entocort for Children With Crohn's Disease|A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive||AstraZeneca||Completed|November 2011|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|5 Years|17 Years|No|||September 2014|October 1, 2014|September 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01444092||97759|
NCT01444443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2106-07-0034|DiaCon Overnight Closed-Loop Glucose Control Study|DiaCon Closed-Loop Study|DiaCon2|Hvidovre University Hospital|No|Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||November 2012|November 19, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444443||97732|
NCT01444456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101123|Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia|Electronic Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia: An International Prospective Observational Study (eAQUA)||Amgen|No|Completed|October 2011|October 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1262|||Both|18 Years|N/A|No|Probability Sample|Adults with either breast, colorectal, ovarian, prostate, lung, bladder, endometrial,        renal, pancreatic, esophageal or gastric cancer who will receive darbepoetin alfa        (Aranesp®) or other erythropoiesis-stimulating agent (ESA) for the treatment of        symptomatic chemotherapy-induced anaemia (CIA) in routine clinical practice.|July 2014|July 24, 2014|September 29, 2011||No||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01444456||97731|
NCT01447667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRE|Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)|Magnetic Resonance Elastography Score Reflecting Hepatic Fibrosis as an Independent Predictor for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Therapy|MRE|Seoul National University Hospital|Yes|Recruiting|October 2011|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|72|||Both|18 Years|80 Years|No|||May 2015|May 19, 2015|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01447667||97496|
NCT01447927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03451|Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus|Randomized Double Blind Placebo Controlled Trial of Barrett's Esophagus Chemoprevention With Metformin||National Cancer Institute (NCI)||Completed|June 2012|September 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|93|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|October 5, 2011|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT01447927||97476|
NCT01447940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC10 20|Prospective Assessment of Meos Telemedicine E-portal on Ambulatory Care of Type 1 Diabetic Patients|Prospective Assessment of Meos Telemedicine E-portal on Ambulatory Care of Type 1 Diabetic Patients|TELEDIAB-3|University Hospital, Grenoble|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|720|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01447940||97475|
NCT01448213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0329|Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)|Comparison Of Two Corticosteroid Dosing Regimens For Prevention Of Corneal Transplant Rejection Episodes After Descemet's Membrane Endothelial Keratoplasty||Price Vision Group|Yes|Completed|October 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|264|||Both|18 Years|N/A|No|||August 2014|August 22, 2014|October 4, 2011|No|Yes||No|August 4, 2014|https://clinicaltrials.gov/show/NCT01448213||97454|
NCT01448187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OFR-IRE-2011/1|Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa|Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa|EPIDAURE|AstraZeneca|No|Active, not recruiting|January 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|N/A|No|Probability Sample|Hospital, clinic|August 2013|August 21, 2013|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01448187||97456|
NCT01448200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-668-101|A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1|A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection||Presidio Pharmaceuticals, Inc.|Yes|Completed|October 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|82|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 14, 2012|October 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448200||97455|
NCT01449409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 5808|Reduce IDentified UNcontrolled Asthma|Reduce IDentified UNcontrolled Asthma: A Real-time Randomized Administrative Outreach Study to Promote Asthma Guideline Implementation (RIDUNA)|RIDUNA|Kaiser Permanente|No|Active, not recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3000|||Both|12 Years|56 Years|No|||April 2015|April 2, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01449409||97363|
NCT01449422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-11-02-310 3082|Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.|Evaluation Of The Efficacy, Tolerance And Acceptability Of URGO Dressing 310 3082 Versus A Hydrofibre Dressing In The Local Management Of Venous Or Predominantly Venous Mixed Leg Ulcers||Laboratoires URGO|No|Completed|May 2011|||January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|N/A|No|||March 2013|March 28, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01449422||97362|
NCT01448746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUMC-GC2011|Optimal Prophylactic Method of Venous Thromboembolism (VTE)|Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients||The Catholic University of Korea|Yes|Recruiting|October 2011|September 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|682|||Both|20 Years|75 Years|No|||January 2014|January 28, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448746||97413|
NCT01448759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2011-03|Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel|Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion|ALCOOTAX|Institut Curie|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448759||97412|
NCT01449955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-049|Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory|mTOR Kinase as a Therapeutic Target in Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory||University of Texas Southwestern Medical Center|Yes|Completed|August 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|54|||Male|18 Years|N/A|No|||March 2014|March 1, 2014|September 16, 2011|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01449955||97322|Timing of medication administration may not have been optimal and relatively small sample size
NCT01449383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBBE-2007-2-2-07_WP2.4|Effect of Diet on Intestinal Microbiota and Obesity Markers in Adults|Molecular Targets Open for Regulation by the Gut Flora - New Avenues for Improved Diet to Optimize European Health (TORANDO): WP2 Individual Intervention Studies- Effect of Diet on Intestinal Microbiota and Obesity Markers in Adults|TORNADO|German Institute of Human Nutrition|No|Completed|November 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 13, 2012|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449383||97365|
NCT01449669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007976|Surgical Site Infection Study|Skeletal Muscle and Plasma Concentrations of Cefazolin During Pediatric Cardiac Surgery Utilizing Cardiopulmonary Bypass, Deep Hypothermic Cardiac Arrest, and Modified Ultrafiltration|SSI|Children's Hospital of Philadelphia|Yes|Completed|September 2011|February 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|14|||Both|3 Months|6 Months|No|Non-Probability Sample|Males or females with single ventricle physiology undergoing their second palliation        procedure (typically performed between 3-6 months of age)|February 2014|February 7, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01449669||97343|
NCT01449916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSSP|Simplified Severe Sepsis Protocol in Zambia|Improving Sepsis Diagnosis and Treatment: Simplified Severe Sepsis Protocol (SSSP)|SSSP|Vanderbilt University|Yes|Recruiting|February 2012|November 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|348|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449916||97325|
NCT01450436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG/11/80|Impact of Preterm Body Composition at Discharge on 2 Years Neurological Development (ASQ Evaluation)|Impact of Preterm Body Composition at Discharge on 2 Years Neurological Development (ASQ Evaluation)|EPIPOD|Nantes University Hospital|No|Recruiting|September 2011|September 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|189|||Both|25 Weeks|35 Weeks|No|Non-Probability Sample|Preterm infants (< 35 weeks gestation)|November 2012|November 16, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01450436||97285|
NCT01446926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPR02|Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants|||Sanofi|Yes|Completed|September 2011|June 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|11||Actual|280|||Both|6 Weeks|50 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446926||97553|
NCT01447212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-01455|Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)|SALOME: Multi-Centre, Double Blind Randomized Controlled Trial Comparing The Effectiveness Of Diacetylmorphine Vs. Hydromorphone For The Treatment Of Long-Term Injection Opioid Users Who Do Not Benefit From Available Therapies|SALOME|University of British Columbia|Yes|Active, not recruiting|December 2011|January 2016|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|19 Years|N/A|No|||May 2015|May 27, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447212||97531|
NCT01443221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-KAD-05|Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.|Open-label, Randomized, Single-dose, 2-way Crossover Study to Investigate Safety and Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.||JW Pharmaceutical|Yes|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||October 2010|September 28, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443221||97826|
NCT01443520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97/180/2011|Effect of Duloxetine and Venlafaxine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol: A Three-phase Randomized Balanced Cross-over Study in Healthy Volunteers|||Turku University Hospital||Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443520||97803|
NCT01444105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-028|Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty|A Prospective, Randomized, Controlled, Parallel Groups Evaluation of Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty||Glaukos Corporation|No|Active, not recruiting|September 2011|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444105||97758|
NCT01444118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BV-NSCLC-001|A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients|Phase III, Open-label, Multicentre, Randomised Trial to Establish Safety and Efficacy of an EGF Cancer Vaccine in Inoperable, Late Stage (IIIb/IV) NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care.|NSCLC|Bioven Sdn. Bhd.|Yes|Terminated|November 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Masking: Open Label|2||||||Both|20 Years|65 Years|No|||July 2015|July 20, 2015|September 29, 2011||No|The early termination is not related to safety/toxicity but to initiate new Phase III with    biomarker to enrich population & to further strengthen OS benefit|No||https://clinicaltrials.gov/show/NCT01444118||97757|
NCT01444469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001093-26|AZithromycin Against pLacebo in Exacerbations of Asthma|A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients With Acute Exacerbations of Asthma|AZALEA|Imperial College London|Yes|Completed|September 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|199|||Both|18 Years|N/A|No|||November 2013|July 22, 2014|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01444469||97730|
NCT01448226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aspergillus PCR BAL Study|Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy|Diagnosing Invasive Aspergillosis by PCR Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy||Heidelberg University|No|Completed|January 2000|May 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|221|Samples With DNA|Aliquots of BAL Samples including fungal DNA|Both|5 Years|85 Years|No|Probability Sample|immunocomprimised patients with lung infiltrates and high risk for invasive aspergillosis|October 2011|October 6, 2011|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448226||97453|
NCT01448239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD12010|Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)|||Sanofi|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|June 27, 2013|October 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448239||97452|
NCT01448525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LTS-11-002|Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence|||Allergan|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Female|18 Years|65 Years|No|||April 2013|April 5, 2013|October 6, 2011|Yes|Yes||No|April 5, 2013|https://clinicaltrials.gov/show/NCT01448525||97430|
NCT01448811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS96-024|Auditory Evoked Potential Monitoring on Bronchoscopy|Impact of Auditory Evoked Potential Index Monitoring on Bronchoscopic Examination in the Mechanical Ventilated Patients - A Prospective, Randomized, Controlled Study||Kaohsiung Veterans General Hospital.||Completed|March 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|37|||Both|18 Years|N/A|No|||October 2011|October 7, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448811||97408|
NCT01448512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P30AI073961-S|Promoting Male Involvement to Improve Prevention of Mother to Child Transmission (PMTCT) Uptake and Reduce Antenatal Infection|University of Miami Developmental Center for AIDs Research Promoting Male Involvement to Improve PMTCT Uptake and Reduce Antenatal Infection||University of Miami|No|Completed|September 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|478|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 20, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01448512||97431|
NCT01449435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGU-238/11|Predictors of Asthma Exacerbations in Children|Asthma Exacerbations in Young Children With Moderate Asthma - Prospective Evaluation of Predictors||Johann Wolfgang Goethe University Hospitals|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|75|||Both|4 Years|6 Years|No|Non-Probability Sample|Outpatients of departement of Pediatric Pulmonology and Allergology.|April 2013|April 24, 2013|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01449435||97361|
NCT01449097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2-PJ-11|Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength and Mobilization in Healthy Volunteers|Comparison of the Efficacy of the Adductor-Canal-Blockade Versus the Femoral Nerve Block on Muscle Strength and Mobilization in Healthy Volunteers: a Randomized Study||Rigshospitalet, Denmark|Yes|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||December 2011|December 21, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449097||97387|
NCT01449968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 10 16|Provision of a Mobile Geriatric Team Extra-Community Hospital|Provision of a Mobile Geriatric Team Extra-Community Hospital in Assessing and Regulating the Hospitalization of Frail Elderly Patients With Complex Medical and Social Situation|UMG|University Hospital, Grenoble|No|Completed|June 2011|November 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|334|||Both|75 Years|N/A|No|Non-Probability Sample|The study population includes patients over 75 years in medical condition or psycho-social        complex, followed by a general practitioner to population centers include: Grenoble,        Annecy and Roanne.|April 2014|April 25, 2014|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01449968||97321|
NCT01449682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-287|Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.|Efficacy of an Intravitreal Dexamethasone Implant on Macular Function in Retinal Vein Occlusion Following Treatment With Intravitreal Anti-VEGF Injections.||Retina Macula Institute|No|Active, not recruiting|October 2011|September 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 13, 2013|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449682||97342|
NCT01449929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114915|Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects|A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naïve Adult Subjects|FLAMINGO|ViiV Healthcare|No|Active, not recruiting|October 2011|December 2016|Anticipated|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|488|||Both|18 Years|N/A|No|||September 2015|February 4, 2016|October 6, 2011|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT01449929||97324|
NCT01450189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 11-0815|A Key Link for Transmission Prevention|Acute HIV Infection - A Key Link for Transmission Prevention: A Randomized Pilot Study|MP3|University of North Carolina, Chapel Hill|Yes|Completed|October 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|115|||Both|18 Years|65 Years|No|||July 2014|July 31, 2014|September 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450189||97304|
NCT01450449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33033|Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme|A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme||International Atomic Energy Agency|Yes|Completed|February 2009|November 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|115|||Both|50 Years|N/A|No|||March 2015|March 23, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01450449||97284|
NCT01446939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIEP1436-11|Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor|Role of Diffusion Tensor Imaging and Transcranial Sonography in the Parkinson's Disease and Essential Tremor||Hospital Israelita Albert Einstein|Yes|Recruiting|October 2012|July 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|150|||Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|50 Parkinson´s Disease Patients 50 Essential Tremor Patients 50 Healthy Volunteers|October 2012|October 26, 2012|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01446939||97552|
NCT01447225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-06-01-06 (TCD11694)|Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors|A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors||Merrimack Pharmaceuticals|No|Completed|October 2011|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|43|||Both|18 Years|N/A|No|||December 2015|February 3, 2016|October 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01447225||97530|
NCT01447238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS2010-7729|Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound With Fine Needle Aspiration (EUS/FNA), Direct Visualization, and Confocal Laser-induced Endomicroscopy—A Pilot Study|Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound With Fine Needle Aspiration (EUS/FNA), Direct Visualization, and Confocal Laser-induced Endomicroscopy—A Pilot Study||University of California, Irvine|Yes|Recruiting|September 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients underoing EUS-FNA procedure for pancreatic cyst.|October 2011|October 4, 2011|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01447238||97529|
NCT01443533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WakeMed 864|Study of Birth Control Use After Childbirth|A Randomized Controlled Trial of a Brief Educational Script on Postpartum Contraceptive Uptake||WakeMed Health and Hospitals|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|800|||Female|14 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01443533||97802|
NCT01443780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KiSel-10|Intervention With Selenium and Q10 on Cardiovascular Mortality and Cardiac Function in the Elderly Population in Sweden|Kisel-10- a Prospective Randomized Double-blind Placebo Controlled Study of the Results of Intervention With Selenium and Coenzyme Q10 Combined, Regarding Effect With Emphasis on Cardiovascular Mortality and Morbidity.|KiSel-10|University Hospital, Linkoeping|No|Completed|January 2003|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|443|||Both|70 Years|87 Years|Accepts Healthy Volunteers|||September 2011|September 30, 2011|September 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443780||97783|
NCT01444131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VarNic|Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation|A 26-Week Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation||University of Stellenbosch|Yes|Completed|April 2011|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|75 Years|No|||March 2014|March 25, 2014|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01444131||97756|
NCT01445080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|060233|Sorafenib (BAY 43-9006) to Treat Children With Solid Tumors or Leukemias|A Phase I/II Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias||National Institutes of Health Clinical Center (CC)||Completed|August 2006|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2|||Both|2 Years|21 Years|No|||August 2015|October 2, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445080||97686|
NCT01448538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15785|Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany|Non-Persistence/Non-Adherence of German wAMD Patients Related to Their Anti-VEGF Injections: Extent, Explanations and Patients' Preferences||Bayer|Yes|Completed|August 2011|February 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|480|||Both|18 Years|N/A|No|Non-Probability Sample|German wAMD patients with Anti-VEGF therapy included by centers responsible for        intravitreal injections|September 2015|September 11, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01448538||97429|
NCT01448824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14460|A Study of LY2484595 on Pharmacokinetics in Healthy Subjects|A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448824||97407|
NCT01449110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEBAS-CSIC-1|Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Prevention of Cardiovascular Disease|A Randomized, 12 Months Follow-up, Dose-response, Placebo-Controlled, Double-Blind, 6-Arms Parallel Trial to Evaluate the Safety and Efficacy of a Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Patients of Cardiovascular Disease|FUNGRAPE|National Research Council, Spain|No|Completed|April 2009|March 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|150|||Both|18 Years|80 Years|No|||November 2011|November 15, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449110||97386|
NCT01449734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Jena FS-ICU|Family Satisfaction (FS) in the Intensive Care Unit|Observational Study of Family Satisfaction in the Intensive Care Unit Using the German-language FS-ICU||Center for Sepsis Control and Care, Germany|No|Completed|April 2011|November 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|217|||Both|N/A|N/A|No|Non-Probability Sample|Visiting family members of patients being treated in the ICU|September 2013|September 4, 2013|September 30, 2011||No||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01449734||97338|
NCT01449695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34338|Intervention to Improve Medication Adherence in Cardiovascular Patients|Nurse- and Web Based Intervention to Improve Medication Adherence in High Risk Cardiovascular Patients.||Radboud University|No|Recruiting|November 2011|||October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449695||97341|
NCT01449942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU-863-DZ|Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma|Phase I/II Study of EBV-LMP1 Targeted DNAzyme in Nasopharyngeal Carcinoma|NPC-DZ|Xiangya Hospital of Central South University|Yes|Completed|May 2009|September 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||October 2011|October 6, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01449942||97323|
NCT01450241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RabinMC6249|Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia|Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia: Randomized-controlled Trial||Rabin Medical Center|Yes|Withdrawn|January 2012|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|September 17, 2011||No|slow recruitment, no funding|No||https://clinicaltrials.gov/show/NCT01450241||97300|
NCT01450202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oct 2011-01|Safety and Efficacy of Carbon Dioxide Insufflation During Colonoscopy With Consecutive Esophagogastroduodenoscopy in Reduction of Abdominal Pain in Sedated Outpatients|Carbon Dioxide Insufflation During Colonoscopy With Consecutive EGD is Safe and Decreases Abdominal Pain in Sedated Outpatients: a Randomized, Double-blind, Controlled Trial|COCE|Inje University|No|Completed|November 2011|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|70 Years|No|||June 2012|June 24, 2012|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01450202||97303|
NCT01450215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-RV-MM-10-07/ RV-MM-PI 0627|Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma|||Karolinska University Hospital|Yes|Completed|March 2011|||January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|September 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01450215||97302|
NCT01450462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2RR025754-ANT|Vitamin D and Sexual Health|Vitamin D and Sexual Health (the DASH Study)|DASH|Ohio State University|Yes|Completed|September 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450462||97283|
NCT01450709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIB004|Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis|Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment||Kibow Biotech Inc.|Yes|Recruiting|April 2011|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Blood serum, plasma and lymphocytes.|Both|18 Years|75 Years|No|Probability Sample|Out patient hospital setting|May 2012|May 2, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01450709||97264|
NCT01450982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018655|A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants|A Study to Investigate the Effects of JNJ-38518168 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Participants on a Stable Methotrexate Dose||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|June 2011|October 2011|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||May 2013|May 3, 2013|June 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01450982||97243|
NCT01447251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110089H|Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea|Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea|OSA & DM|Mike O'Callaghan Federal Hospital|No|Completed|September 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 10, 2014|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01447251||97528|
NCT01447498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Projekt ASA|Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment|Effect of a Systematic Screening for Risk-factors for Ulcer Bleeding Before Post-PCI Anti-thrombotic Treatment||Odense University Hospital|No|Completed|April 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|2024|||Both|N/A|N/A|No|||November 2015|November 9, 2015|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01447498||97509|
NCT01443546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011011394|Study of Dual Trigger Ovulation in Oocyte Donors|A Randomized Prospective Trial of Dual Trigger Ovulation in Oocyte Donors|DUALTRIGGER|Weill Medical College of Cornell University|Yes|Recruiting|January 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Female|21 Years|55 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|August 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01443546||97801|
NCT01443793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pneumo01|Longitudinal Pattern of Streptococcus Pneumoniae Nasopharyngeal Carriage and Antimicrobial Susceptibility in Healthy Children Aged Less Then 5 Years, in the Area of Milan and Surroundings, Lombardy, Italy.|Longitudinal Pattern of Streptococcus Pneumoniae Nasopharyngeal Carriage and Antimicrobial Susceptibility in Healthy Children Aged Less Then 5 Years, in the Area of Milan and Surroundings, Lombardy, Italy.||University of Milan|No|Recruiting|September 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|||Both|3 Months|5 Years|No|Probability Sample|The sample size is calculated to detect at baseline at least 100 nasopharyngeal swab        specimens positive for Streptococcus pneumoniae, and possibly further 100 positive swabs        at both 6 and 12 months after recruitment. A probability sample of at least 1,300 children        will be recruited. Children will be selected using a randomization list of assisted        children less than 5 years-old that will be computer generated for any of participant        Family Pediatrician, based on the Lombardy Regional Health Databases and using the        National Insurance Number.|October 2011|October 2, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01443793||97782|
NCT01445106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070047|A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors|A Phase I Trial of Nelfinavir (Viracept) in Adults With Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 2006|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445106||97685|
NCT01445119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070053|A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas|A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas||Eli Lilly and Company||Completed|January 2007|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445119||97684|
NCT01445132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070064|Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation|Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes||National Institutes of Health Clinical Center (CC)||Completed|January 2007|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|75 Years|No|||April 2013|October 23, 2014|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445132||97683|
NCT01444781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3L27|Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants|Evaluation of Antibody Persistence Following a Primary Series at 2, 4, and 6 Months on Trial A3L24 and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ Concomitantly Administered With Prevenar™ at 12 to 24 Months of Age in Healthy Latin American Infants||Sanofi|Yes|Completed|September 2011|October 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|1106|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||July 2014|July 14, 2014|September 29, 2011||No||No|June 12, 2014|https://clinicaltrials.gov/show/NCT01444781||97706|
NCT01445041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024650|Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome|Autologous Cord Blood Cells for Patients With HLHS: Phase I Study of Feasibility and Safety||Duke University|No|Suspended|September 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|2 Days|No|||November 2015|November 12, 2015|September 15, 2011|No|Yes|Pending Additional Funding|No||https://clinicaltrials.gov/show/NCT01445041||97689|
NCT01445054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070101|111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer|A Phase 0 Trial of (111)Indium CHX-A DTPA Trastuzumab Imaging in Cancer||National Institutes of Health Clinical Center (CC)||Completed|February 2007|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|13|||Female|18 Years|100 Years|No|||June 2015|November 18, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445054||97688|
NCT01448837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5134|24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice|24-Hour Intraocular Pressure Control Obtained With the Bimatoprost/Timolol Fixed Combination Compared With Latanoprost as First Choice Therapy in Subjects With Exfoliation Syndrome, or Exfoliative Glaucoma||Aristotle University Of Thessaloniki|No|Completed|April 2010|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|21 Years|80 Years|No|||May 2014|May 9, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01448837||97406|
NCT01449136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1535/07|Use of Antibacterial Cement in Infected Dentin|Phase 1 Study of Clinical and Radiographic Success of Antibacterial Cement in Infected Dentin of Deciduous Teeth|AC|University of Pernambuco|Yes|Completed|January 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|45|||Both|5 Years|8 Years|No|||September 2011|October 5, 2011|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01449136||97384|
NCT01449123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT4501|Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations|An Open-label Single Site Single Dose Pilot Study Using Mannitol Challenge Test With the Purpose to Explore Treatment With Fixed Dose Combinations in Adult Subjects With Asthma in Primary Care in Sweden||Mundipharma AB|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|65 Years|No|||August 2012|August 8, 2012|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01449123||97385|
NCT01449461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP26113-11-101|A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113|A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113||Ariad Pharmaceuticals|No|Active, not recruiting|September 2011|September 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|175|||Both|18 Years|N/A|No|||August 2014|August 21, 2014|September 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449461||97359|
NCT01449708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3766 - 6886|Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery|Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting (PONV) in Bariatric Surgery||Coastal Anesthesiology Consultants|Yes|Completed|November 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|124|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|October 6, 2011||No||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01449708||97340|
NCT01449721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESHOCK|Preemptive Resuscitation for Eradication of Septic Shock|Preemptive Empiric Resuscitation Protocol for the Prevention of Disease Progression in the Treatment of Sepsis||Christiana Care Health Services|No|Terminated|September 2011|January 2016|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|September 29, 2011||No|Insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01449721||97339|
NCT01449994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Activator in Austria|Efficacy of Instrumental Chiropractic Treatment Using Activator Methods for Pain and Dysfunction in Juvenile Athletes|Efficacy of Instrumental Chiropractic Treatment Using Activator Methods for Pain and Dysfunction.A Randomized Placebo-controlled Clinical Study on Juvenile Athletes With Leg Pain||Medical University of Graz|Yes|Completed|July 2010|February 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|26|||Both|10 Years|17 Years|Accepts Healthy Volunteers|||February 2012|February 7, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01449994||97319|
NCT01450228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-CC-8302|Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients|A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Phase III Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in ≥ 55 Years Old Insomnia Patients||Kuhnil Pharmaceutical Co., Ltd.|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|55 Years|N/A|No|||April 2012|April 23, 2012|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01450228||97301|
NCT01450475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mazuike-18|Study of Remote Ischemic Postconditioning|A Randomized Control Trial of Effect of Remote Ischemic Postconditioning on Children Undergoing Cardiac Surgery||Xijing Hospital|Yes|Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Both|N/A|12 Years|No|||July 2013|July 22, 2013|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01450475||97282|
NCT01450722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5063524|Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery|Paclitaxel Eluting Stent in Long Superficial Femoral Artery Obstruction: a Prospective, Randomized Comparison With Bypass Surgery Using PTFE Graft in a Finnish Multicenter Study|finnptx|Kuopio University Hospital|Yes|Recruiting|October 2011|October 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|100 Years|No|||October 2015|January 22, 2016|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450722||97263|
NCT01450995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113403|Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex|Open-label, 6 Month Crossover Study Evaluating Migraine Patient Satisfaction Comparing Treximet to 2 Aleve and 100mg Imitrex Taken Concomitantly||Wesley Headache Clinic|Yes|Completed|December 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||October 2011|October 10, 2011|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450995||97242|
NCT01447511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807M38361|Pharmacogenetics of Warfarin Induction and Inhibition|Pharmacogenetics of Warfarin Induction and Inhibition||University of Minnesota - Clinical and Translational Science Institute|No|Completed|May 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|39|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|January 29, 2010||No||No|July 30, 2014|https://clinicaltrials.gov/show/NCT01447511||97508|
NCT01447771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00046799|Decision Support for Women With Breast Cancer|Decision Support for Women With Breast Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|September 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|14|||Female|18 Years|N/A|No|||April 2014|April 8, 2014|September 21, 2011||No|Lack of funds to continue and volunteer recruitment member left position|No||https://clinicaltrials.gov/show/NCT01447771||97488|
NCT01443559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIXM-XKFPC-20110901|Xenogenic Keratoplasty From Porcine Cornea|Phase I Study of Xenogenic Keratoplasty From Porcine Cornea in the Treatment of Infectious Corneal Ulcer|XKFPC|Xiamen University|Yes|Suspended|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||July 2015|July 16, 2015|September 19, 2011||No|there was not enough patients recruited in this study|No||https://clinicaltrials.gov/show/NCT01443559||97800|
NCT01444144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146-2011|Ankle Fracture Treatment in the Elderly|Ankle Fracture Treatment in the Elderly, at Risk Population||University of Florida|No|Active, not recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|150|||Both|55 Years|85 Years|No|Non-Probability Sample|At-risk population, at least 55 years of age at time of surgery receiving treatment for        ankle fractures.|January 2016|January 21, 2016|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01444144||97755|
NCT01443806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA 026|Characterisation of the Human Carboxylesterase 1 (CES1) Mutations in Thailand|Characterisation of the Human Carboxylesterase 1 (CES1) Mutation(s) Which May be Responsible for Markedly Reduced Conversion of Oseltamivir Phosphate to Oseltamivir Carboxylate||University of Oxford|No|Recruiting|July 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2012|June 28, 2012|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01443806||97781|
NCT01443819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09232011-8446|Lumbar Transforaminal Epidural Corticosteroid Injection(s) Versus Defined Physical Therapy|Randomized, Prospective Study of Lumbar Transforaminal Epidural Corticosteroid Injection(s) Versus Defined Physical Therapy for the Treatment of Subacute Lumbar Radicular Pain Due to Disc Protrusion||Stanford University|No|Terminated|May 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|64 Years|No|||December 2015|December 14, 2015|September 26, 2011||No|recruitment problem|No||https://clinicaltrials.gov/show/NCT01443819||97780|
NCT01444742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0660|Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)|Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, or Are Refractory to, Hypomethylator Therapy||M.D. Anderson Cancer Center|No|Active, not recruiting|November 2011|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|September 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444742||97709|
NCT01445145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070085|An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection|An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection||National Institutes of Health Clinical Center (CC)||Completed|January 2007|September 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|63|||Both|16 Years|30 Years|No|||September 2014|September 26, 2014|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445145||97682|
NCT01444794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52120-159|Adult Subjects Suffering From Lower Limb Spasticity Following Stroke|A National, Prospective Cohort to Document the Effectiveness of One BoNT-A Injection Cycle Based on Attainment of Individual Person-centred Goals in Adult Subjects Suffering From Lower Limb Spasticity Following Stroke|VALGAS|Ipsen||Completed|September 2011|February 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|June 2013|June 19, 2013|September 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01444794||97705|
NCT01445444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRT/TTM|Habit Reversal Training for Children and Adolescents With Trichotillomania|Habit Reversal Training for Children and Adolescents With Trichotillomania: A Controlled Trial||University of South Florida|No|Completed|September 2011|March 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|7 Years|17 Years|No|||March 2016|March 9, 2016|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01445444||97661|
NCT01448564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD|Effects of Laser Therapy on Muscle Function in COPD Patients|Effects of Light-emitting Diodes (LED) on Peripheral Muscle Function, Exercise Tolerance and Cardiorespiratory Response During Exercise in Patients With Chronic Obstructive Pulmonary Disease|LTCOPD|University of Nove de Julho|Yes|Recruiting|June 2012|December 2013||December 2013||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|27|||Both|40 Years|90 Years|No|||September 2013|September 3, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01448564||97427|
NCT01448850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-MEDI8968-1103|A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease|A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease|SPRING|MedImmune LLC|Yes|Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|464|||Both|45 Years|80 Years|No|||March 2014|March 31, 2014|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01448850||97405|
NCT01449448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Impingement|Subacromial Injection With Corticosteroid Versus Nonsteroidal Anti-inflammatory Drugs (NSAID) in Shoulder Impingement Syndrome|A Double-blind Randomized Controlled Trial Comparing the Effects of Subacromial Injection With Corticosteroid Versus NSAID in Patients With Shoulder Impingement Syndrome|NSAID|Madigan Army Medical Center|Yes|Completed|September 2000|September 2005|Actual|September 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 7, 2011|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01449448||97360|
NCT01449981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIAAA R01AA019664|Development and Testing of Adolescent Twelve-Step Facilitation|Development and Testing of Adolescent Twelve-Step Facilitation||Massachusetts General Hospital|Yes|Active, not recruiting|October 2011|May 2015|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|14 Years|21 Years|No|||April 2015|April 6, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01449981||97320|
NCT01450488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB04011|Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS)|A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis||AB Science|No|Completed|June 2005|January 2010|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|60 Years|No|||October 2011|October 10, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01450488||97281|
NCT01450748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTYALG1101|Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Alginos Oral Suspension (Sodium Alginate 50 mg/ml) for the Treatment of Patients With Laryngopharyngeal Reflux (LPR)||TTY Biopharm|Yes|Completed|October 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|12 Years|75 Years|No|||June 2015|June 3, 2015|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450748||97261|
NCT01450735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA001|Evaluation of the MANOS Carpal Tunnel Release System in Patients With Carpal Tunnel Syndrome|||Thayer Intellectual Property, Inc.|Yes|Terminated|October 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||January 2013|January 13, 2013|October 6, 2011|Yes|Yes|Enrollment did not reach our intended sample size due to availability of CTR with MANOS    outside of the study.|No||https://clinicaltrials.gov/show/NCT01450735||97262|
NCT01451008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARP-002|Compression Anastomosis Using the Compression Anastomotic Ring-locking Procedure (CARP)|Safety Study of Compression Anastomotic Ring-locking Procedure (CARP) in Patients Undergoing Colonic Resection||Region Skane|Yes|Completed|June 2009|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|90 Years|No|||July 2013|July 5, 2013|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01451008||97241|
NCT01446952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16152|Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects|A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Single Dose Administration in Healthy Subjects||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|September 2011|August 2016|Anticipated|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|September 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01446952||97551|
NCT01447264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSaoPaulo-01|Effectiveness of Water Exercises on Isokinetic Muscle Strength|Comparison of the Effectiveness Between Land and Water Exercises on Isokinetic Muscle Strength of Lower Limbs in Women With Rheumatoid Arthritis: a Randomized Controlled Trial||Federal University of São Paulo|No|Completed|February 2009|April 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01447264||97527|
NCT01448057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|381-A-301|Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu|A Prospective, Randomized, Investigator-Blind Study to Compare Three Days of Treatment With Paracetamol (500 mg) / Dimethindene Maleate (1 mg) / Phenylephrine Hydrochloride (10 mg) Tablets Versus Paracetamol 500 mg Alone in the Treatment of Nasal Congestion and Other Symptoms Due to Cold and Flu||Novartis|No|Completed|July 2013|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|341|||Both|18 Years|65 Years|No|||October 2015|October 1, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448057||97466|
NCT01448317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU12190|Ascending Dose Study of the Safety and Tolerability of Alirocumab SAR236553 (REGN727) in Japanese Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered SAR236553 in Japanese Healthy Male Subjects||Sanofi|No|Completed|June 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Male|20 Years|65 Years|Accepts Healthy Volunteers|||February 2012|June 27, 2013|September 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448317||97446|
NCT01448330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-CPAS-101|A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin|A Sequence-randomized, Open-label, Single Dose, Crossover Study to Evaluate Pharmacokinetics and Safety After Oral Administration of Clopidogrel and Aspirin in Free Combination and Fixed-dose Combination as HCP0911 in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||September 2011|December 28, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01448330||97445|
NCT01448343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWJung_FMS|Effect of Rapid Transfusion With Fluid Management System 2000® (FMS)|Effect of Rapid Transfusion With FMS(Fluid Management System 2000®) on the Plasma Potassium Concentration in Adult Liver Transplantation Recipients)|FMS|Seoul National University Hospital|Yes|Completed|October 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|10|||Both|16 Years|80 Years|No|||April 2013|April 15, 2013|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01448343||97444|
NCT01444482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISC-Influenza-001|Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers|A Phase I Single Blinded Randomised Exploratory Trial in Elderly Volunteers to Assess and Compare Safety and Immunogenicity of Adjuvanted Seasonal Influenza Vaccine (Investigational Vaccine) to Standard Seasonal Influenza Vaccine.||Isconova AB|No|Active, not recruiting|May 2011|||November 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|110|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01444482||97729|
NCT01444755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNEAH-01-08|The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer|Neoadjuvant Chemotherapy Versus Surgery Alone in Locally Advanced Gastric Cancer: A Randomized Controlled Study||Haydarpasa Numune Training and Research Hospital|No|Active, not recruiting|January 2009|April 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|None Retained|Resected stomach specimen of the patients.|Both|18 Years|90 Years|No|Probability Sample|Primary care clinic|September 2011|September 29, 2011|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444755||97708|
NCT01445067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN170-004|Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition|Phase I, Open-Label, Randomized, Single Sequence Study With Two Dose Groups to Compare the Pharmacokinetics of BMS-927711 in Migraine Subjects During an Acute Migraine Attack and During Non-Migraine Period||Bristol-Myers Squibb|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||June 2013|June 7, 2013|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445067||97687|
NCT01444807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP1|Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases|A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma (RCC) After a Radical Resection of the Metastases||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|December 2011|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01444807||97704|
NCT01445483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080214|Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases|A Pilot Study to Evaluate Neuropsychological Outcome Measures and Their Relationship With Prognosis in Patients Receiving Radiation Therapy for Brain Metastases||National Institutes of Health Clinical Center (CC)||Recruiting|September 2008|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|60|||Both|18 Years|90 Years|No|||May 2015|June 5, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445483||97660|
NCT01445509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090019|Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors|A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Active, not recruiting|October 2008|January 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|100 Years|No|||December 2015|December 31, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445509||97659|
NCT01449474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si050/2554(EC2)|Accuracy of MRI-based Patients Matched Instruments vs Jig-based Instruments in Total Knee Arthroplasty (TKA)|Accuracy of MRI-based Patients Matched Instruments and Jig-based Instruments in Total Knee Arthroplasty||Mahidol University|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|40 Years|85 Years|No|||February 2013|February 21, 2013|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01449474||97358|
NCT01449760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09_116|Ankle Sprain Rehabilitation With the Wii Balance Board|||University Hospital, Geneva|Yes|Active, not recruiting|March 2010|July 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|64 Years|No|||December 2014|December 8, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449760||97336|
NCT01450007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001266|Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery|Perineural Versus Systemic Dexamethasone as an Analgesic Adjunct to Ultrasound-Guided Ropivacaine Interscalene Blockade in Arthroscopic Rotator Cuff Repair||Mayo Clinic|No|Completed|May 2012|July 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|120|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|October 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450007||97318|
NCT01449149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01310|Proton Radiation for Chordomas and Chondrosarcomas|Proton Radiation For Chordomas and Chondrosarcomas||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|March 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449149||97383|
NCT01450254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0091-11-EMC|Effects of Foot Center of Pressure Manipulation on Hip Osteoarthritis Patients During Gait|Effects of Foot Center of Pressure Manipulation on Hip Biomechanics, Muscle Activation Patterns, and Energy Consumption During Gait in Hip Osteoarthritis Patients||HaEmek Medical Center, Israel||Completed|August 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|50 Years|N/A|No|||July 2015|July 6, 2015|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450254||97299|
NCT01450514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNB02-C201|POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia|POC Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks||PharmaNeuroBoost N.V.|No|Completed|March 2012|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|65 Years|No|||November 2014|November 18, 2014|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450514||97279|
NCT01449747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCENDO-01|Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus|Mechanism of Reduced Response to DPP-4 Inhibitor in Patients With Type 2 Diabetes Mellitus||The Catholic University of Korea|No|Completed|December 2011|July 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|70 Years|No|||November 2015|November 10, 2015|September 29, 2011||No||No|August 23, 2015|https://clinicaltrials.gov/show/NCT01449747||97337|
NCT01450501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-51800-98-013|Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)|Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)|QAAD|Jeroen Bosch Ziekenhuis|No|Active, not recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|999|Samples With DNA|Blood and tissue will be investigated using Polymerase Chain Reaction. Serology for      C.burnetii will be investigated in blood using Immunofluorecense assay (focus diagnostics).|Both|18 Years|N/A|No|Probability Sample|This cohort will be selected from patients with an abdominal aortic disease living in an        endemic area after an outbreak of acute Q-fever.|July 2013|July 22, 2013|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01450501||97280|
NCT01450774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1012-PR-0051|Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children|A Single Centre, Randomised, Double-blind, Double-dummy, 2-way Cross Over Study to Compare Safety Assessed by Knemometry and Urinary Cortisol Measurements of CHF1535 50/6 Pmdi (Fixed Combination of Beclomethasone Dipropionate and Formoterol Fumarate) and the Free Combination of Licensed Beclomethasone Dipropionate and Formoterol Fumarate in Asthmatic Children Already Treated With Inhaled Corticosteroids||Chiesi Farmaceutici S.p.A.|No|Completed|September 2011|February 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|5 Years|11 Years|No|||April 2014|April 29, 2014|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01450774||97259|
NCT01450761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-156|Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone|Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)||Bristol-Myers Squibb|Yes|Active, not recruiting|December 2011|March 2017|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1125|||Both|18 Years|N/A|No|||August 2015|February 10, 2016|October 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450761||97260|
NCT01450787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000322|Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics|Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics||COA Research Foundation, INC|No|Terminated|January 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|63|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Existing clinic population from our practice|August 2013|August 8, 2013|October 10, 2011||No|Principle investigator changed practice location and discontinued study|No|March 9, 2013|https://clinicaltrials.gov/show/NCT01450787||97258|
NCT01451021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0002011|A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss||Aderans Research Institute|No|Completed|October 2008|||June 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|August 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451021||97240|
NCT01446965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90D0114|Vest Prevention of Early Sudden Death Trial and VEST Registry|Prevention of Sudden Death After Myocardial Infarction Using a LifeVest Wearable Cardioverter-defibrillator|VEST|University of California, San Francisco|Yes|Recruiting|July 2008|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1900|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01446965||97550|
NCT01447524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/2009|Caloric Restriction and Insulin Secretion|Very Low Calorie Diet: a Quick Therapeutic Tool to Improve Beta Cell Function in Morbidly Obese Patients With Type 2 Diabetes Mellitus||University of Rome Tor Vergata|Yes|Completed|January 2010|March 2011|Actual|March 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|30 Years|80 Years|No|||October 2011|October 5, 2011|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01447524||97507|
NCT01448044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-042|Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C|A Phase 3 Evaluation of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 4||Bristol-Myers Squibb|No|Completed|December 2011|January 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|October 5, 2011|Yes|Yes||No|August 7, 2015|https://clinicaltrials.gov/show/NCT01448044||97467|
NCT01448356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R857/52/2011|Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation|Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation||Singapore Eye Research Institute|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||November 2012|November 14, 2012|October 4, 2011||No||No|July 17, 2012|https://clinicaltrials.gov/show/NCT01448356||97443|
NCT01444495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cracow Rectal Cancer Trial|Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer|Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer||Jagiellonian University|No|Completed|January 1999|December 2010|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||June 2014|June 15, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444495||97728|
NCT01444508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003270-80|Effect of Colloid Versus Crystalloid on Coagulation|Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery||Rigshospitalet, Denmark|No|Recruiting|September 2011|December 2013|Anticipated|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2013|December 12, 2013|September 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444508||97727|
NCT01444768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000308|Prospective Evaluation of Computerized Physician Order Entry in the Emergency Department|Prospective Evaluation of Computerized Physician Order Entry in the Emergency Department|CPOE|Beth Israel Deaconess Medical Center|No|Not yet recruiting|March 2012|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who are registered in the emergency department > 18 years of age who do not        elope, left without being seen, or leave AMA.|January 2012|January 10, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444768||97707|
NCT01444833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MinHealth|Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker|Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension|ADIRAS|Slovak Academy of Sciences|No|Recruiting|October 2008|December 2012|Anticipated|March 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Male|25 Years|50 Years|No|||September 2011|September 29, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01444833||97702|
NCT01444846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1005-202|Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift|Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift||Sound Pharmaceuticals, Incorporated|Yes|Completed|September 2011|March 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|83|||Both|18 Years|31 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444846||97701|
NCT01445158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070086|Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures|Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures||National Institutes of Health Clinical Center (CC)||Recruiting|January 2007|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|20|||Both|10 Years|26 Years|No|||August 2015|September 18, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445158||97681|
NCT01445171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-01|Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve|Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve|TRITON|Edwards Lifesciences|Yes|Active, not recruiting|January 2010|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|295|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01445171||97680|
NCT01449773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-117.05.01|Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes|Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes|DBB48|Laval University|No|Completed|April 2008|January 2013|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Male|18 Years|55 Years|No|||February 2013|February 28, 2013|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449773||97335|
NCT01450020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11115|Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors|Sister Survivor: Improving the Survivorship Care of African-American Women With Breast Cancer||City of Hope Medical Center|Yes|Active, not recruiting|October 2011|||October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|145|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01450020||97317|
NCT01450267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM7K7XZB|Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis|Randomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cystic Fibrosis||Second University of Naples|Yes|Recruiting|June 2010|December 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|6 Years|45 Years|No|||October 2011|October 12, 2011|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01450267||97298|
NCT01450800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00025269|Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)|Antibiotic Prophylaxis for Urinary Tract Infection in Patients Requiring Catheterization After Urogynecologic Surgery|STOPP UTI|Duke University|Yes|Completed|August 2011|September 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|163|||Female|21 Years|N/A|No|||March 2014|March 31, 2014|October 10, 2011|Yes|Yes||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01450800||97257|Limitations of our study include recall bias and selection bias. Our findings have limited applicability to elderly patients undergoing pelvic reconstructive surgery.
NCT01450813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVMOPR0176|The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy|The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy||Medtronic - MITG|Yes|Completed|September 2011|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|8||Actual|90|||Both|18 Years|75 Years|No|||February 2015|February 2, 2015|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01450813||97256|
NCT01451047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0002012|A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss||Aderans Research Institute|No|Completed|July 2009|||April 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451047||97238|
NCT01451034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-08-022|Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion|Clinical Outcomes of Endoscopic Resection for Treating Extremely Well Differentiated Intestinal-type Adenocarcinoma (WHYX Lesion)||Samsung Medical Center|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|872|||Both|18 Years|N/A|No|||October 2011|October 12, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01451034||97239|
NCT01446978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rombo - 2|Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs|Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate||Sormland County Council, Sweden|Yes|Active, not recruiting|September 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446978||97549|
NCT01447277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06776|Prospective Evaluation of Femoral Versus Femoral and Sciatic Nerve Block for Ambulatory Anterior Cruciate Ligament (ACL) Reconstruction|The Addition of a Preoperative Sciatic Nerve Block to a Femoral Nerve Block for Ambulatory Arthroscopic ACL Reconstruction||University of California, San Francisco||Recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01447277||97526|
NCT01447290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110165H|Comparison of Random Spot Urine Protein:Creatinine Ratio to 24-Hour Timed Urine Protein Collection in the Evaluation of Preeclampsia|Comparison of Random Spot Urine Protein:Creatinine Ratio to 24-Hour Timed Urine Protein Collection in the Evaluation of Preeclampsia|P:C Ratio|Mike O'Callaghan Federal Hospital|No|Completed|May 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Female|18 Years|45 Years|No|Non-Probability Sample|18-45 year-old pregnant women (Active Duty Military or DoD beneficiaries) attending the        new Obstetrics Orientation class.|October 2014|October 10, 2014|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447290||97525|
NCT01447810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJCIT|Constraint-Induced Movement Therapy in a Pediatric Oncology Population|Constraint Induced Movement Therapy in a Pediatric Oncology Population (SJCIT): A Pilot Study|SJCIT|St. Jude Children's Research Hospital|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|2 Years|12 Years|No|||September 2014|January 12, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447810||97485|
NCT01447784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH002|ToleroMune House Dust Mites (HDM) Exposure Chamber Study|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber.||Circassia Limited|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|172|||Both|18 Years|65 Years|No|||July 2013|July 16, 2013|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01447784||97487|
NCT01447797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-IBAT-104|A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin|Single Dose Open-label Comparative Pharmacokinetic Study to Assess the Pharmacokinetic Characteristics of Irbesartan and Atorvastatin Between Irbesartan/Atorvastatin Combination Tablet and Coadministration of Irbesartan and Atorvastatin Tablets in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|September 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2011|April 1, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01447797||97486|
NCT01448070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN729-1511|Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers|A Single Centre, Randomized, Balanced Double Blind, Cross-over Trial Investigating the Bioequivalence of Actrapid® Produced by the Current Process and Human Insulin With the Same Formulation as Actrapid®, Produced by the NN729 Process||Novo Nordisk A/S|No|Completed|October 2002|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|October 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448070||97465|
NCT01439438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116144|Topiramate Bioequivalence Study Brazil - Fast|A Relative Bioavailability Study of Two Formulations of Topiramate 100 mg Coated Tablet in Healthy Male Volunteers, the Test Formulation Produced by Dr. Reddy's Laboratories Ltd. and the Reference Formulation (Topamax®) Marked by Janssen-Cilag Farmacêutica Ltda.||GlaxoSmithKline|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 23, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439438||98116|
NCT01439698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108011875|Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry|Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry|RFA-Registry|Weill Medical College of Cornell University|No|Recruiting|September 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects over the age of 18 and suffering from pancreaticobiliary disorders, including        malignancies such as Cholangiocarcinoma and Pancreatic Cancer|June 2015|June 1, 2015|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439698|1 Year|98096|
NCT01444521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-017|Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer|Genotype-drive Phase II Study of Novel Irinotecan-Cisplatin Combination as First-line Therapy for Advanced Gastric Cancer||Chinese Academy of Medical Sciences|Yes|Completed|April 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|70 Years|No|||May 2014|May 2, 2014|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01444521||97726|
NCT01444859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110725-SUS-NIP-GIS-RA|Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms|Effect of Trenev Trio®/Healthy Trinity® in Otherwise Healthy Adults With Recurrent Gastrointestinal Symptoms: a Double-blind, Randomized, Placebo-controlled, Parallel Group Study||Sprim Advanced Life Sciences|No|Active, not recruiting|February 2012|November 2012|Anticipated|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|October 23, 2012|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444859||97700|
NCT01445197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-BIO-10-67|Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development|A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostate®) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (≤ 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors)||CSL Behring||Terminated|December 2012|December 2013|Actual|||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|N/A|11 Years|No|||May 2014|May 7, 2014|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445197||97679|
NCT01449786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TK01/2011|Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy|||Medical University of Vienna|Yes|Not yet recruiting|December 2011|January 2014|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|50 Years|No|||October 2011|October 7, 2011|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449786||97334|
NCT01450033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008336|Peers for Promoting Adolescent Transplant Health|A Peer Mentoring Intervention to Improve Adherence and Quality of Life in Adolescents With Solid Organ Transplants|Peers4PATH|Children's Hospital of Philadelphia|Yes|Active, not recruiting|September 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|74|||Both|14 Years|23 Years|No|||June 2015|June 15, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01450033||97316|
NCT01450280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC038|Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS|A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and With MVA CS||University of Oxford|Yes|Completed|December 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01450280||97297|
NCT01450293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC042|AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area|Safety and Immunogenicity of Heterologous Prime-boost Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Infants in a Malaria- Endemic Area||University of Oxford|Yes|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|6||Actual|72|||Both|10 Weeks|12 Months|Accepts Healthy Volunteers|||December 2013|December 11, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01450293||97296|
NCT01450306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVE003220HU|Exposure, D-cycloserine Enhancement, and fMRI in Snake Phobics|Exposure, D-cycloserine Enhancement, and fMRI in Snake Phobics||Hartford Hospital|Yes|Active, not recruiting|July 2010|November 2011|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2011|October 11, 2011|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450306||97295|
NCT01450527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/Med/ARDS|Etiology and Outcomes of Tropical Acute Respiratory Distress Syndrome|Etiology and Outcomes of Acute Respiratory Distress Syndrome in Medical ICU in AIIMS||All India Institute of Medical Sciences, New Delhi|No|Completed|July 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|64|||Both|N/A|N/A|No|Probability Sample|Patient admitted in medical ICU|January 2013|January 12, 2013|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01450527||97278|
NCT01450540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-1112-AGPAP-MS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2011|||||N/A|N/A|N/A||||||||||||||July 31, 2012|October 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450540||97277|
NCT01450826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031206|Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide|A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen||Duke University|No|Recruiting|December 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450826||97255|
NCT01450839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2022-J081-002|E2022 Patch Formulation Multiple Dose Study|E2022 Patch Formulation Multiple Dose Phase I Study||Eisai Inc.||Completed|September 2011|February 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|65 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 30, 2012|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01450839||97254|
NCT01451060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2300-11|Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean|Maternal and Neonatal Outcomes After the Use of Vasopressors to Correct Hypotension During Cesarean Section Under Spinal Anesthesia in Pregnant Women With Severe Preeclampsia: Randomized Clinical Trial|Vasopressors|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Recruiting|June 2011|July 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|55|||Female|18 Years|45 Years|No|||October 2011|October 13, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01451060||97237|
NCT01441804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAHG1IL-28BCC|A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism|||Third Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|May 2011|August 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|65 Years|No|||September 2013|September 28, 2013|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01441804||97935|
NCT01446991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-08172|Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy|Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy||British Columbia Cancer Agency|No|Recruiting|April 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Male|40 Years|80 Years|No|||January 2016|January 14, 2016|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01446991||97548|
NCT01447303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|293-2009|Functional and Quality of Life Outcomes Following Viscosupplementation for Knee Osteoarthritis|Functional and Quality of Life Outcomes Following Hyaluronic Acid (HA) Viscosupplementation for Knee Osteoarthritis||University of Florida|No|Terminated|August 2009|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|43|||Both|21 Years|85 Years|No|Non-Probability Sample|Patients with symptomatic knee osteoarthritis.|January 2014|January 24, 2014|September 29, 2011||No|Inability to recruit subjects|No||https://clinicaltrials.gov/show/NCT01447303||97524|
NCT01447537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PEF-2010-50|Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis|||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|80 Years|No|||December 2015|December 11, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01447537||97506|
NCT01438567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN3506|A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy|A Randomised, Double-blind, Double-dummy, Parallel-group Multicenter Study to Demonstrate Improvement in Symptoms of Constipation and Non-inferiority in Analgesic Efficacy in Subjects With Non-malignant or Malignant Pain That Require Around-the-clock Opioid Therapy Taking 50/25 - 80/40 mg Twice Daily as Oxycodone/Naloxone Prolonged Release (OXN PR) Tablets Compared to Subjects Taking 50 - 80 mg Twice Daily Oxycodone Prolonged Release (OxyPR) Tablets Alone||Mundipharma Research GmbH & Co KG||Completed|September 2011|September 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|270|||Both|18 Years|N/A|No|||January 2014|October 13, 2014|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01438567||98183|
NCT01439113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|usivedrn|Single-operator Ultrasound-guided IV Placement by Emergency Nurses|A Randomized Trial of Single-Operator Ultrasound-Guided vs. Standard-of-Care IV Placement by Emergency Nurses||Tufts Medical Center|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2011|September 21, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439113||98141|
NCT01439126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHN-KAP-401|Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder|A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY™ (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD||Concordia Pharmaceuticals Inc., Barbados|No|Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|6 Years|17 Years|No|||October 2014|October 15, 2014|September 13, 2011|Yes|Yes||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01439126||98140|
NCT01439139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUSS-04|Bone UltraSonic Scanner (BUSS): Validation Study|Portable Bone Ultrasonometer for Osteoporosis Assessment||Artann Laboratories|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|130|||Female|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Postmenopausal women|March 2014|March 27, 2014|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439139||98139|
NCT01439152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15051|Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.|An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors||Bayer|No|Active, not recruiting|September 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|147|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01439152||98138|
NCT01444157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FamCope2011|Family and Coping Oriented Palliative Homecare Nursing Aimed at Advanced Cancer Patients|Family and Coping Oriented Palliative Homecare Nursing as a Supplement to Standard Homecare Nursing Aimed at Advanced Cancer Patients - a Randomized Intervention Trial|FamCope|Bispebjerg Hospital|Yes|Completed|October 2011|April 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|700|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|September 29, 2011||||No||https://clinicaltrials.gov/show/NCT01444157||97754|
NCT01444170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-316-2006|Nutritional Supplement, Eccentric Exercise and Recovery|A Single Site Double Blind Placebo Controlled Study of the Effects of a Dietary Supplement on Muscle Recovery Following Exercise-Induced Muscle Damage||University of Florida||Completed|July 2006|July 2007|Actual|July 2007|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|January 30, 2008||No||No||https://clinicaltrials.gov/show/NCT01444170||97753|
NCT01444534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pameijer-2011|Mobile Phone Applications and Quality of Life|Influence of a Mobile Phone Application on Quality of Life of Patients With Type 1 Diabetes Mellitus: a Randomized Controlled Trial||Medical Research Foundation, The Netherlands|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|65|||Both|18 Years|70 Years|No|||October 2012|October 23, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01444534||97725|
NCT01444820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCS V|Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate|Phase III Study of Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate, Using 3D-CRT or Intensity-Modulated Radiotherapy||Sir Mortimer B. Davis - Jewish General Hospital|Yes|Active, not recruiting|January 2012|January 2023|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|329|||Male|18 Years|N/A|No|||July 2015|July 13, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444820||97703|
NCT01445561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110268|Ultra Low Dose Interleukin-2 in Healthy Volunteers|The Safety and the Tolerability of Ultra Low Dose Interleukin-2 in Healthy Volunteers||National Institutes of Health Clinical Center (CC)||Completed|September 2011|July 2013|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 30, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445561||97655|
NCT01440751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAE-CT-USA-2010-02|Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery|||Aeon Astron Europe B.V.||Active, not recruiting|February 2010|||February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|128|||Both|30 Years|N/A|No|||December 2013|December 24, 2013|September 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440751||98015|
NCT01440985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6431085|A Study on the Effects of Two Nicotine Replacement Products on Tooth Staining|An Evaluator-Blinded, Randomized, Parallel Controlled Study of Nicorette® Freshmint Gum Versus Nicorette® Microtab in Healthy Smokers Motivated to Quit Smoking With Visible Staining of Teeth||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|July 2005|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|200|||Both|18 Years|65 Years|No|||July 2012|July 6, 2012|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01440985||97997|
NCT01440998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03275|Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer|Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer||National Cancer Institute (NCI)||Active, not recruiting|September 2011|||July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||December 2015|December 22, 2015|September 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440998||97996|
NCT01441011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12633|Rural Women Connecting for Better Health|Group Phone-Based Weight Control for Rural Breast Cancer Survivors||University of Kansas Medical Center|Yes|Active, not recruiting|August 2011|May 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|208|||Female|N/A|75 Years|No|||April 2015|May 26, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01441011||97995|
NCT01441544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8630B|The Effect of Variety on Physical Activity|The Effect of Variety on Physical Activity||University of Tennessee|No|Active, not recruiting|September 2011|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01441544||97955|
NCT01441817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|224-01077(REK)|Non--operative Treatment of the Medial Malleolus in bi- and Trimalleolar Ankle Fractures|Non--operative Treatment of the Medial Malleolus in bi- and Trimalleolar Ankle Fractures. A Randomized Controlled Trial||Oslo University Hospital|No|Completed|May 2002|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|N/A|No|||September 2011|September 27, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01441817||97934|
NCT01447004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hushhirb|a Case-control Study of the Association Between Heavy Mental and Children With Attention Deficit Hyperactivity Disorder in Korea|a Case-control Study of the Association Between Heavy Mental and Children With Attention Deficit Hyperactivity Disorder in Korea||Hallym University Medical Center|No|Recruiting|March 2010|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Subjects must meet DSM-IV criteria for ADHD based-on the K-Schedule for affective disorder        and schizophrenia(K-SADS-PL-K) interview|February 2010|October 4, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447004||97547|
NCT01447316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|332-2009|Bariatric Surgery on Short Term Weight Loss- Related Changes in Gait|Impact of Bariatric Surgery on Short Term Weight Loss- Related Changes in Gait and Quality of Life||University of Florida|No|Completed|August 2009|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|21 Years|65 Years|No|Non-Probability Sample|All subjects will be patients already scheduled to undergo bariatric surgery for weight        loss.|January 2013|January 16, 2013|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447316||97523|
NCT01447550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT03112011|Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan|Treatment of Thromboangiitis Obliterans (Buerger's Disease) With Bosentan||Hospital Universitario Getafe|Yes|Completed|January 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||October 2011|October 11, 2011|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01447550||97505|
NCT01438281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYL1001_I|Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers|Phase I Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers||Sylentis, S.A.|No|Completed|July 2011|June 2012|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438281||98205|
NCT01447563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLOPI Tabs No. 60-06|Comparative Bioavailability Study of Two Oral Formulations of Clopidogrel|Bioavailability of Two Oral Formulations of Clopidogrel: A Randomized, Open Label, Single Dose, Two-Period, Crossover Comparison in Healthy Mexican Volunteers||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Terminated|May 2008|August 2008|Actual|June 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|32|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447563||97504|
NCT01438840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-302|Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenia Purpura)||Eisai Inc.|Yes|Completed|March 2012|March 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||March 2014|June 29, 2015|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438840||98162|
NCT01438853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-832.201|Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome|The Safety, Pharmacokinetics, and Pharmacodynamic Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome||Altor Bioscience Corporation|Yes|Completed|December 2004|February 2008|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||September 2011|September 21, 2011|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438853||98161|
NCT01448109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-CCT372273|ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock|A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock|ADRENAL|The George Institute|Yes|Recruiting|June 2012|July 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|3800|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|October 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01448109||97462|
NCT01444183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07-296E|Stress Management Intervention for Living With Epilepsy (SMILE)|Pre-emptive Treatment in Epilepsy Using Electronic Diaries: Towards a New Frontier in Epilepsy Therapy|SMILE|Montefiore Medical Center|Yes|Completed|January 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|95|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01444183||97752|
NCT01444196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-005746-22|Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria|Multi-center, Double Blind, Dose Escalating Study to Compare the Effects of 5 mg, 10mg and 20mg of Desloratadine in Patients With Acquired Cold Urticaria (ACU)|AECUDATT|Charite University, Berlin, Germany|Yes|Completed|August 2009|May 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||September 2011|September 30, 2011|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444196||97751|
NCT01444209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 042011-075|Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas|Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas||University of Texas Southwestern Medical Center|Yes|Recruiting|October 2011|December 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444209||97750|
NCT01444547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-021|A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin|A Phase Ⅱ Study on Low-expression and High-expression of ERCC1 in Recurrent or Metastastic Esophageal Cancer Patients Treated With Biweekly Paclitaxel and Cisplatin||Chinese Academy of Medical Sciences|Yes|Recruiting|January 2007|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|70 Years|No|||May 2014|May 2, 2014|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444547||97724|
NCT01445210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0184|Saphenous Nerve Block: Single Shot Versus Continuous Infusion to Supplement a Continuous Sciatic Nerve Block After Major Ankle Surgery|A Randomized Comparison of Single Injection vs. Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block in Postoperative Pain Treatment After Major Ankle Surgery: Clinical Outcome and Cost Analysis||University of Aarhus|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01445210||97678|
NCT01445223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Northiv protocol 3.66|A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)|A Study on ART Naïve Patients On Different Regimens to Treat Hiv (a Phase 4 Study)||Göteborg University|Yes|Completed|April 2004|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|242|||Both|16 Years|N/A|No|||October 2011|October 2, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01445223||97677|
NCT01445587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115340|A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma|An Open-Label, Single Arm, Phase Ib/II Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma||GlaxoSmithKline|No|Withdrawn|November 2011|November 2011|Anticipated|November 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 22, 2012|August 25, 2011|No|Yes|Based on the clinical activity, not safety data, of the AKT inhibitor, GSK has decided at this    time to suspend further development of GSK2110183 as monotherapy.|No||https://clinicaltrials.gov/show/NCT01445587||97654|
NCT01440517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-078-101|Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction|An Open-Label, Multicenter, Proof of Concept, Phase 2 Study Evaluating the Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF)||GE Healthcare|No|Terminated|August 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|80 Years|No|||January 2014|January 2, 2014|September 22, 2011|Yes|Yes|Lack of Subject Recruitment|No|August 30, 2013|https://clinicaltrials.gov/show/NCT01440517||98033|
NCT01440764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000027/1|Aerosol Inhalation Treatment for Dyspnea|Aerosol Inhalation Treatment for Dyspnea||Beth Israel Deaconess Medical Center|No|Completed|September 2011|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 5, 2015|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440764||98014|
NCT01440777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 11-860|Effectiveness and Adherence to an Online Sleep Program|Effectiveness and Adherence to an Online Sleep Program - A Pilot Study||The Cleveland Clinic|No|Completed|October 2011|June 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|101|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01440777||98013|
NCT01450345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|toh2c79@Pregabalin|Efficacy of Pre-operative Oral Pregabalin in Ambulatory Inguinal Hernia Repair for Post Operative Pain|Efficacy of Pre-operative Oral Pregabalin in Ambulatory Inguinal Hernia Repair for Post Operative Pain||University of Malaya|No|Recruiting|September 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|72|||Both|12 Years|75 Years|No|||October 2011|October 11, 2011|September 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450345||97292|
NCT01450358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR multiplex|Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture.|Evaluation of Antimicrobial Use and Time of Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction (PCR) in Real Time Multiplex to the Conventional Blood Culture for Etiologic Agents Identification. Randomized Clinical Trial.||Instituto do Coracao|No|Recruiting|January 2012|January 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|70 Years|No|||March 2013|March 4, 2013|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01450358||97291|
NCT01441219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2 in SB|Evaluation the Performance of Given Diagnostic System in Detection of Bleeding Events in the Small Bowel|Evaluation the Performance of Given Diagnostic System in Detection of Bleeding Events in the Small Bowel: a Single-arm Prospective Cohort Study.||Chinese University of Hong Kong|No|Terminated|January 2011|January 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||March 2013|March 4, 2013|August 2, 2011||No|Results were obtained in another project.|No||https://clinicaltrials.gov/show/NCT01441219||97980|
NCT01441232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-105-DM|A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics|A Phase 1, Open-label, 3-period, 3-treatment, Single Dose Crossover Study to Evaluate the Pharmacodynamic Effects of LX4211 When Administered Concurrently With JANUVIA® (Sitagliptin) in Subjects With Type 2 Diabetes Mellitus||Lexicon Pharmaceuticals|No|Completed|October 2011|||November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|65 Years|No|||January 2012|January 26, 2012|September 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441232||97979|
NCT01450553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-110|Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease|Research and Development Study: Tissue Collection From Patients Who Are Undergoing Surgery for Non-Small Cell Lung Cancer||Precision Therapeutics|No|Recruiting|October 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|450|Samples With DNA|Human tumor tissues will be collected and preserved in three different tissue formats:        -  Fresh Frozen        -  FFPE        -  RNAlater|Both|18 Years|N/A|No|Non-Probability Sample|Non-Small Cell Lung Cancer patients undergoing surgery for resection of disease from        hospital based locations.|January 2012|January 9, 2012|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450553||97276|
NCT01450852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSU-IRB # 3005|Strength Training Induced Alterations in Markers of Immune Function|Strength Training Induced Alterations in Markers of Immune Function||Louisiana State University Health Sciences Center in New Orleans|No|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|42|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||October 2011|October 10, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01450852||97253|
NCT01442103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ngel Ag 01|Clinical Utility of a New Silver Gel for Use on Chronic Wounds|Open, Non Comparative, Single Center Investigation Exploring the Clinical Utility of a New Silver Gel for Use on Chronic Wounds||Molnlycke Health Care AB|No|Completed|September 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||November 2012|October 16, 2013|September 13, 2011||No||No|July 1, 2013|https://clinicaltrials.gov/show/NCT01442103||97912|Small study population, 2 patients lost to follow-up.
NCT01442116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT60|Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential Hypertension|Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential Hypertension||Mustafa Kemal University||Completed|June 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|60|||Both|18 Years|75 Years|No|||September 2011|September 28, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01442116||97911|
NCT01438021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09201|Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease|Characterization of the Pharmacokinetics and Efficacy of Intraventricular Methotrexate Continuously Delivered Via a Mini Pump for Treatment of Leptomeningeal Disease||City of Hope Medical Center|Yes|Withdrawn|September 2012|||November 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 8, 2012|September 19, 2011|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01438021||98225|
NCT01438294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMAPED|Exercise Training in Asthma Children|Effects of Exercise Training on Markers of Lung Inflammation and Clinical Crontrol in Asthma Children||Hospital Sirio-Libanes|No|Completed|November 2011|November 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Both|5 Years|11 Years|No|||October 2014|October 5, 2014|September 18, 2011|Yes|Yes||No|July 5, 2014|https://clinicaltrials.gov/show/NCT01438294||98204|
NCT01448421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMT 8005|SMT Embolic Deflection CE Mark Trial DEFLECT I|A Prospective, Single Arm Feasibility Study to Evaluate the Safety and Performance of the SMT Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)||Keystone Heart|No|Not yet recruiting|January 2012|July 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|36|||Both|18 Years|80 Years|No|||September 2011|October 6, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01448421||97438|
NCT01448954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC3680-04|A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma|A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma||Pulmagen Therapeutics|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|55 Years|No|||February 2012|February 17, 2012|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01448954||97397|
NCT01447823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH Nr 2011-0192|Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring|Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring||University of Zurich|Yes|Recruiting|August 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|90 Years|No|Probability Sample|All patients undergoing upper endoscopy for removal of a food bolus are asked to sign the        standard clinical informed consent form for interventional endoscopy of the Division of        Gastroenterology at the University Hospital Zurich. After Diagnosis of food impaction has        been made, the food bolus has been removed and the endoscopy has been completed, the        patient will be informed of the Diagnosis and the standard procedure of care (High        resolution manometry, pH-monitoring, blood sampling) will be explained, and an appointment        for these procedures will be given (1-4days thereafter).|October 2011|October 7, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01447823||97484|
NCT01448928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15042|Zevalin Post-marketing Surveillance in Japan|Drug Use Investigation of Zevalin|ZEVALIN-DUI|Spectrum Pharmaceuticals, Inc|No|Recruiting|September 2008|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|400cases: This study is all case investigation of which the enrollment period is five        years, and all patients who received Zevalin for relapsed or refractory, CD20+, low grade        B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma will be recruited.|October 2015|October 30, 2015|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01448928||97399|
NCT01448941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206025 (REK-ID)|Arthrodesis Versus Extra-articular Plate Fixation in Lisfranc Injury|Arthrodesis Versus Extra-articular Bridge Plating of the First Tarsometatarsal Joint After Acute Lisfranc Injury||Oslo University Hospital|No|Active, not recruiting|October 2011|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||October 2014|September 9, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448941||97398|
NCT01444222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s53471|Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart|Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|October 2011|August 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||8|Anticipated|120|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  Pulmonary Arterial Hypertension          -  Pulmonic Valve Stenosis          -  Pulmonic valve insufficiency          -  Atrium Septum Defect          -  Ebstein's Anomaly          -  Transvalvular RV pacemaker/ shock lead          -  Control|September 2011|September 30, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01444222||97749|
NCT01444898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI 11-00227|Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome|Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome||Children's Hospital Los Angeles|No|Active, not recruiting|March 2012|December 2013|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|13 Years|20 Years|No|||July 2013|July 25, 2013|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444898||97697|
NCT01445236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Weaning-Biomarkers|Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance|Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance||Hospital Clinic of Barcelona|Yes|Terminated|September 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||December 2013|December 19, 2013|September 29, 2011||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01445236||97676|
NCT01445600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115579|ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information|ALTARGOPMS|GlaxoSmithKline|No|Completed|November 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3612|||Both|9 Months|N/A|No|Probability Sample|Patients administrated ALTARGO(retapamulin) with primary impetigo or secondarily infected        traumatic lesions in Korea|September 2015|September 21, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01445600||97653|
NCT01445613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-720|Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy|CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy|CANOPY|Abbott Vascular|No|Active, not recruiting|October 2011|December 2016|Anticipated|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1200|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01445613||97652|
NCT01449552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si463/2007|Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT|Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.||Mahidol University|No|Completed|June 2008|November 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|240|||Both|40 Years|85 Years|No|||November 2011|November 4, 2011|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01449552||97352|
NCT01449812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114386|Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine|Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) in Healthy Chinese Toddlers||GlaxoSmithKline||Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|831|||Both|18 Months|24 Months|Accepts Healthy Volunteers|||July 2012|November 26, 2014|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449812||97332|
NCT01449825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114430|Hepatic Monitoring for Pazopanib|Postmarketing Hepatic Monitoring for Pazopanib Using Observational Databases||GlaxoSmithKline|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of adult (18+years) new users of pazopanib, sunitinib,        bevacizumab, and sorafenib.        Two U.S. healthcare databases and one Dutch-linked medical registry system will contribute        de-identified and anonymised data from electronic medical records to the surveillance        program.|April 2014|April 17, 2014|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449825||97331|
NCT01450059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31082011 FRA Mat Fet Chim|Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section|Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section||Johann Wolfgang Goethe University Hospitals|No|Completed|August 2011|August 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|54|Samples With DNA|Umbilical Cord blood Blood from peripheral vene|Both|N/A|10 Minutes|No|Non-Probability Sample|Approximately 30 HiV exposed newborns born via spontaneuous delivery or cesarean section.|February 2016|February 19, 2016|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450059||97314|
NCT01446848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC-2011-1026|Oral Iron Supplementation in Pulmonary Hypertension|Oral Iron Supplementation in Pulmonary Hypertension||The Cleveland Clinic|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|21 Years|N/A|No|||August 2014|August 11, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01446848||97559|
NCT01447056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28361-MALTED|Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases|Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases|MALTED|Baylor College of Medicine|Yes|Active, not recruiting|February 2012|February 2020|Anticipated|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|N/A|No|||February 2016|February 3, 2016|August 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01447056||97543|
NCT01447095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002798-50|Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage|Effect of Prostacyclin Infusion on Cerebral Vessels, Cerebral Bloodflow and Cerebral Metabolism in Patients With Subarachnoid Haemorrhage||Rigshospitalet, Denmark|Yes|Completed|October 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01447095||97540|
NCT01441245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diuretic1|Loop Diuretics Administration and Acute Heart Failure|Continuous Versus Intermittent Loop Diuretics Infusion Dosing in Acute Heart Failure: Effects on Renal Function, Outcome and BNP Levels|diurHF|University of Siena|Yes|Active, not recruiting|April 2010|September 2018|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|80 Years|No|||January 2016|January 2, 2016|September 22, 2011||No||No|January 26, 2015|https://clinicaltrials.gov/show/NCT01441245||97978|Our study didn't explain the reasons of renal dysfunction during treatment. Concurrent evaluation of BUN could further clarify the primary defect.The multivariate analysis could be inadequate for small sample; we intend to continue enrollment.
NCT01447030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMS1|Long Time Follow up After HJ Following Iatrogenic Bile Duct Injuries|Langtidsopfølgning Efter Kirurgisk Behandling af Iatrogene galdevejslæsioner opstået i Forbindelse Med Cholecystektomi||Odense University Hospital|No|Completed|October 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|139|||Both|N/A|N/A|No|Probability Sample|All patients with iatrogenic bile duct injury (BDI) after cholecystectomy reconstructed        with hepatojejunostomia. Collecting data from 5 Danish tertiary hepato-biliary centres        from january 1995 to may 2009.|October 2014|October 19, 2014|October 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01447030||97545|
NCT01447043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15913|Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)|AURA Study: A Retrospective Non-interventional Study (NIS) to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration (wAMD)|AURA|Bayer|No|Completed|January 2009|November 2012|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|2609|||Both|18 Years|N/A|No|Non-Probability Sample|Patients must have been diagnosed to suffer from wet AMD and must have started anti-VEGF        treatment with ranibizumab between January 1, 2009, and August 31, 2009.|January 2014|January 24, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01447043||97544|
NCT01447355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03469|Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation|Pilot Study on the Bioactivity of Vitamin D in the Skin After Oral Supplementation||National Cancer Institute (NCI)||Completed|August 2012|June 2013|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|40 Years|N/A|Accepts Healthy Volunteers|||September 2013|October 7, 2014|October 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01447355||97520|
NCT01451073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0002013|A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss||Aderans Research Institute|No|Completed|January 2009|||August 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451073||97236|
NCT01447017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCS-002|A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis|A Randomised, Parallel-group, Double-blind, Placebo-controlled Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis||DermaGen AB||Completed|November 2011|November 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|12 Years|N/A|No|||October 2013|October 18, 2013|September 22, 2011||No||No|October 18, 2013|https://clinicaltrials.gov/show/NCT01447017||97546|
NCT01447329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20110169H|Ear Acupuncture for Pain Associated With Ambulatory Arthroscopic Knee Surgery|Ear Acupuncture for Post-operative Pain Associated With Ambulatory Arthroscopic Knee Surgery - A Randomized Controlled Trial|BFAKnee|Mike O'Callaghan Federal Hospital|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447329||97522|
NCT01447342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS-4400|A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines|||MyoScience, Inc|No|Completed|September 2011|August 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01447342||97521|
NCT01448980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si205/2011|Efficacy of Massage in Stroke Spasticity|The Efficacy of Thai Traditional Massage in Decreasing Spasticity for Elderly With Stroke||Mahidol University|Yes|Completed|May 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|396|||Both|50 Years|N/A|No|||June 2014|June 5, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448980||97396|
NCT01448655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISC-4.1.5|Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)|Prospective Epidemiological Study to Expand Knowledge on Efficacy and Safety of a Routine Post-operative Supportive Therapy With the Mistletoe Extract Iscador® Qu Within Oncological Treatment of Colorectal Cancer Stages UICC II-IV||IFAG AG|No|Recruiting|September 2010|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|85 Years|No|Non-Probability Sample|All patients visiting the center with colorectal cancer stage UICC II-IV and meeting the        eligibility criteria will be asked to participate.|July 2013|July 1, 2013|March 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01448655||97420|
NCT01449578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223HV103|Dexpramipexole SAD/MAD Study|A Randomized, Blinded, Placebo-Controlled Ascending Dose Study of the Safety and Pharmacokinetics of Dexpramipexole in Healthy Volunteers||Knopp Biosciences|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|63|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|September 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01449578||97350|
NCT01449591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBFH772A2203|Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients|A Proof of Concept (PoC) Study to Evaluate the Safety, Tolerability, and Efficacy of 12 Week Administration of BFH772 Ointment in Rosacea Patients||Novartis||Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|65 Years|No|||April 2012|April 27, 2012|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449591||97349|
NCT01444235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-N-CSM-III/01/08|Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery|A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N Versus Custodiol||Dr. F. Köhler Chemie GmbH|Yes|Completed|March 2011|July 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|35 Years|80 Years|No|||May 2013|May 16, 2013|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444235||97748|
NCT01444248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HANDOK2009.02|Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy|A Multi-center, Open, Randomized, Parallel-group Study to Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy||Handok Pharmaceuticals Co., Ltd.|No|Completed|August 2010|May 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|168|||Both|18 Years|75 Years|No|||August 2012|August 21, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01444248||97747|
NCT01444300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNEUR0637A|Dalfampridine for Imbalance in Multiple Sclerosis|Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study||Oregon Health and Science University|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|59 Years|No|||May 2014|May 16, 2014|September 20, 2011|Yes|Yes||No|January 13, 2014|https://clinicaltrials.gov/show/NCT01444300||97743|
NCT01444313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-201009|Prospective Study of the Health Benefits of Ultra-Violet Filtering Contact Lenses|Prospective Study of the Health Benefits of Ultra-Violet Filtering Contact Lenses||Johnson & Johnson Vision Care, Inc.||Completed|January 2011|||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||October 2014|October 28, 2014|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444313||97742|
NCT01444599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IB-1110-048|VH-IVUS Plaque Composition Analysis By Fractional Flow Reserve|Virtual Histology (VH)-Intravascular Ultrasound (IVUS) Tissue Characteristics Analysis of the Intermediate Coronary Artery Stenosis Lesion Predicting Physiologic Myocardial Ischemia by Myocardial Fraction Flow Reserve (FFR)||Inje University|Yes|Completed|March 2010|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|100|||Both|20 Years|85 Years|No|Probability Sample|Patients who underwent coronary angiography for the diagnostic purposes because of        clinical angina pectoris. Patient who underwent simultaneous virtual        histology-intravascular ultrasound (VH-IVUS)and fractional flow reserve (FFR) measurement        at the time of coronary angiography would be enrolled consecutively.|March 2015|March 23, 2015|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01444599||97720|
NCT01444911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0217|Evaluation of The Vaginal Renewal™ Program in Gynecologic Cancer Patients Experiencing Sexual Dysfunction|Evaluation of a Multifaceted Vaginal Renewal™ Program Utilizing Vibrating Wands in Gynecologic Cancer Patients Experiencing Sexual Dysfunction: A Randomized Controlled Trial||University of Wisconsin, Madison|Yes|Terminated|August 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|29|||Female|18 Years|N/A|No|||June 2015|June 5, 2015|September 29, 2011||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT01444911||97696|
NCT01450878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I09002 FRETEP|Renal Graft Function After Treatment With Erythropoietin (EPO)|Interest of a High Dose of Erythropoietin Administered During Graft Processing for Early Graft Outcome in Kidney Transplant Recipients.|FRETEP|University Hospital, Limoges|No|Terminated|December 2011|November 2013|Anticipated|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||December 2011|April 16, 2013|October 10, 2011||No|Lack of patients eligible for the study.|No||https://clinicaltrials.gov/show/NCT01450878||97251|
NCT01447108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-8601-11-MZ-CTIL|Surface Acoustic Wave Ultrasound in Trigeminal Neuralgia Pain|Examining the Efficacy of Low Intensity Low Frequency Surface Acoustic Wave Ultrasound(LILF/SAWU) in Trigeminal Neuralgia Pain||Sheba Medical Center|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2012|December 26, 2012|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01447108||97539|
NCT01441258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001088|Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression|Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression||Massachusetts General Hospital|No|Completed|October 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01441258||97977|
NCT01422941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0271|Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study|A PROSPECTIVE, MULTI-CENTER CLINICAL EVALUATION TO ASSESS SAFETY AND PERFORMANCE OF CAVU MEDICAL, INC.'S ATTUNE TUBING WHEN USED WITH NEWLY-IMPLANTED LAPAROSCOPIC ADJUSTABLE GASTRIC BANDS (LAGBs)||Cavu Medical, Inc.|Yes|Completed|October 2010|||June 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||August 2011|July 27, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422941||99377|
NCT01422954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMw2|Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis|Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis||Radboud University|Yes|Completed|January 2012|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 26, 2013|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422954||99376|
NCT01423734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-122|The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases|Pilot Study To Assess The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases||Memorial Sloan Kettering Cancer Center||Active, not recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423734||99316|
NCT01431690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM-EPA-006|Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals|An Open-label, 2-cohort Study to Evaluate the Effect of Multiple Doses of Epanova® on the Single Dose Pharmacokinetics and Pharmacodynamics of Warfarin and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple-dose Administrations of Epanova® Compared to Lovaza® in Healthy Normal Subjects||AstraZeneca|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 23, 2015|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431690||98708|
NCT01431703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk0923|The Learning Curve of NBI With Magnification in the Diagnosis of Colorectal Lesions|The Learning Curve of NBI With Magnification in the Diagnosis of Colorectal Lesions||Shanghai Jiao Tong University School of Medicine||Completed|May 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10050956|Samples Without DNA|if the lesion is neoplastic or sm deeper cancer, we just take biopsy.If the lesion is      adenomatous or sm1-2 cancer,we do polypectomy, EMR or ESD to get the specimen.|Both|16 Years|85 Years|No|Non-Probability Sample|academic hospital endoscopist of digestive department|September 2011|September 8, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01431703||98707|
NCT01432639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTDC/DES/113753/2009|Effects of Exercise Training on Endothelial Function, Inflammation, Arterial Stiffness and Autonomic Function in CAD|Effects of Exercise Training on Endothelial Function, Inflammation, Arterial Stiffness and Autonomic Function in Coronary Artery Disease Patients||Universidade do Porto|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|N/A|N/A|No|||June 2013|June 5, 2013|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01432639||98635|
NCT01431924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113903|Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients|Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients||GlaxoSmithKline|No|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|7779|||Both|12 Years|65 Years|No|Non-Probability Sample|Asthma subjects identified from the IMS Health/Pharmetrics database, which is a        comprehensive, de-identified United States (US) healthcare claims database that is        representative of the non-elderly, insurance-carrying population, The total population is        35.4 million. The average length of follow-up is 2.7 years mean (2.2 years median).        Subjects will be identified using asthma ICD-9 codes (493.xx) and use of asthma        medications. Subjects will be between the ages of 12 and 65 without comorbid chronic        obstruction pulmonary disease. To be included in the analysis, subjects will need a        dispensing history of either fluticasone propionate/salmeterol xinafoate 250 mcg/50 mcg or        100mcg/50mcg combinations or fluticasone propionate 110 mcg or 220 mcg.|February 2013|February 21, 2013|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01431924||98690|
NCT01431937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114347|Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers|A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers|P1A114347|GlaxoSmithKline|No|Completed|October 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01431937||98689|
NCT01433224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCT11B2|Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression|Genomic Signatures of Malignant Germ Cell Tumor Progression: A Retrospective Study of Banked Specimens||Children's Oncology Group|No|Active, not recruiting|October 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|90|||Both|N/A|N/A|No|Non-Probability Sample|Patients registered on the Children Oncology Group (COG) Germ Cell Tumor Protocols.|May 2015|May 8, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433224||98591|
NCT01429259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUTI003498HE|Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children|An Open Label Study to Assess the Population Pharmacokinetics, Safety, and Practicality of Administering Meropenem as a Prolonged Infusion to Cystic Fibrosis Children Admitted With an Acute Pulmonary Exacerbation||Hartford Hospital|No|Completed|February 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|6 Years|17 Years|No|||March 2015|March 26, 2015|September 2, 2011||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01429259||98894|
NCT01420796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96/10|Swallowing and Breathing Exercises for Dysphagia in Parkinson Disease|Effect of Oral Motor Exercises and Breathing Exercises for Dysphagia in Parkinson Disease: Randomized Clinical Trial||Federal University of Bahia|Yes|Recruiting|November 2013|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|N/A|N/A|No|||August 2015|August 26, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420796||99542|
NCT01421446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSI-LBH 1735|Study to Validate a Computerized Neuropsychological Test Battery|Reliability and Validity of Umea Computerized Neuropsychological Battery||LifeBridge Health|No|Terminated|September 2011|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1|||Both|60 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy elderly subjects without significant neurologic, psychiatric, cardiovascular, or        other systemic disease that impairs neurologic function or cognitive function|March 2015|March 30, 2015|August 19, 2011||No|Insufficient subject recruitment|No||https://clinicaltrials.gov/show/NCT01421446||99492|
NCT01433185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41186-E/G|Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV|Improving Uptake of Early Infant Diagnosis of HIV for PMTCT: a Randomized Trial of a Text Messaging Intervention|SMS4PMTCT|University of Washington|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|388|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 19, 2015|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01433185||98594|
NCT01429194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90891629|The ACE Follow-up Study|Continuation of Follow-up for Patients Who Were Previously Enrolled in the Clinical Study: "Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity - (Protocol 11-03)."||Boston Scientific Corporation|No|Completed|April 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|18 Years|50 Years|No|||June 2015|June 15, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429194||98899|
NCT01429454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAPLS- Omega3|NAPLS Omega-3 Fatty Acid Versus Placebo Study|Randomized Double-Blind Trial of Omega 3 Fatty Acid Versus Placebo in Individuals at Risk for Psychosis||University of California, San Diego|Yes|Active, not recruiting|August 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|128|||Both|12 Years|30 Years|No|||November 2015|November 30, 2015|August 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01429454||98879|
NCT01430039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03.09.11.01|Syndecan-1 a Surrogate Marker for IBD|Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease|syndecan1|Meir Medical Center|No|Completed|October 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|42|None Retained|Venous blood sample for syndecan-1 levels, blood count, CRP levels,serum albumin and total      protein|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal population, having no known inflammatory disease|March 2012|April 7, 2015|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01430039||98835|
NCT01430364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOSS LIM|BIfurcation Optimal Treatment Strategy With LYMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study|BIfurcation Optimal Treatment Strategy With LIMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study|BIOSS LIM|Medica Cor Heart Hospital|Yes|Recruiting|September 2011|May 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|90 Years|No|||December 2013|December 24, 2013|September 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01430364||98810|
NCT01430962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27545|Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Performed Under General Anesthesia Versus Moderate Sedation|Randomized Controlled Trial Comparing Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Performed Under General Anesthesia Versus Conscious Sedation|EBUS-GA-MS|Baylor College of Medicine|No|Completed|November 2011|February 2014|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|149|||Both|18 Years|N/A|No|Non-Probability Sample|Adult individuals with suspected mediastinal or hilar lymphadenopathies or masses referred        for endobronchial ultrasound-guided biopsy.|July 2015|July 22, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01430962||98764|
NCT01423201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08012011-8167|Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk|TIA Triage Trial and Evaluation of Vascular-Specific Inflammatory BiomarkerLp-PLA2 as a Stratification Tool for TIA Triage and Stroke Risk||Stanford University|No|Recruiting|September 2010|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|First 100 cases:      2 tiger top or gold top tubes 2 lavender top tubes        -  Blood specimens should be inverted 10 times before processing.        -  Centrifuge and separate within four hours of venipuncture.        -  Transfer 1.0 ml into 2 transfer tubes      Freeze at -70 C      Additional 80 cases:      3 PAXgene tubes (total 16cc) - containing 7.5 cc preservative to stabilize RNA immediately.      Invert 20 times then sit at room temperature overnight Place into a -70C freezer until      processed      2 tiger top or gold top tubes 2 lavender top tubes        -  Blood specimens should be inverted 10 times before processing.        -  Centrifuge and separate within four hours of venipuncture.        -  Transfer 1.0 ml into 2 transfer tubes      Freeze at -70 C|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients admitted to the ED with symptoms of acute TIA|August 2014|August 15, 2014|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01423201||99357|
NCT01423552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK4220|Pharmacology of Immunosuppressants Following Heart Transplantation|Correlation of Immunosuppressant Pharmacokinetics, Pharmacodynamics, Pharmacogenomics and Outcomes Following Heart Transplantation||University Hospital Birmingham|No|Not yet recruiting|November 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Myocardial biopsy, whole blood, peripheral lymphocytes|Both|18 Years|N/A|No|Non-Probability Sample|Heart transplantation at the Queen Elizabeth Hosptial Birmingham.|August 2011|August 25, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423552||99330|
NCT01423747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALL-SZT- BFM 2003|Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia|Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia||St. Anna Kinderkrebsforschung|Yes|Active, not recruiting|July 2003|September 2016|Anticipated|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|400|||Both|3 Months|18 Years|No|||June 2015|June 25, 2015|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423747||99315|
NCT01432171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTTC11-01|Lacosamide for Seizure Prophylaxis in High-Grade Gliomas|Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas||M.D. Anderson Cancer Center|Yes|Recruiting|July 2012|||July 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|302|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|September 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01432171||98671|
NCT01432392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GBG-XXX-2011/1|Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease|A Prospective, Observational Study to Describe Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease (GERD)||AstraZeneca|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1000|||Both|18 Years|N/A|No|Probability Sample|primary care setting|May 2012|May 9, 2012|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01432392||98654|
NCT01423760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 63325-011|Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials|An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials||Merck KGaA||Terminated|January 2012|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|August 23, 2011|Yes|Yes|The study is terminated prematurly as the sponsor decided to discontinue program with    Tecemotide in NSCLC.|No||https://clinicaltrials.gov/show/NCT01423760||99314|
NCT01432977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10 005|Drug Interactions Between Paracetamol and Setrons in Pain Management|Paracetamol and Setrons : Drug Interactions in the Management of Pain After Tonsillectomy in Children|PARATRON|University Hospital, Limoges|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|72|||Both|2 Years|7 Years|No|||October 2012|October 30, 2012|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01432977||98610|
NCT01424605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980393|The Comparison of Glidescope® and the Direct Laryngoscopy in the Insertion of the Double Lumen Endotracheal Tube|The Comparison of Glidescope® and the Direct Laryngoscopy in the Insertion of the Double Lumen Endotracheal Tube|Glidescope|Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 26, 2011|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01424605||99249|
NCT01420471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FISHNET-2011|Medicated Punctured-Glove-Finger Spacer Study|Medicated Punctured-Glove-Finger Spacer Study|FISHNET|St. Paul's Hospital, Canada|No|Completed|September 2011|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|N/A|No|||October 2012|October 26, 2012|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420471||99567|
NCT01421082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0012|Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema|Evaluation of Physiologic Parameters to Study the Mechanism of Action of the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) in Subjects With Homogeneous Emphysema||PneumRx, Inc.|No|Completed|February 2012|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|35 Years|N/A|No|||December 2012|March 11, 2014|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01421082||99520|
NCT01422473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 4957|Comparison Study of Hemorrhoid Surgery Using the Enseal Device to Standard Hemorrhoid Surgical Techniques|Hemorrhoidectomy Using the Enseal Device: A Comparison to Open Hemorrhoidectomy Techniques||Swedish Medical Center|No|Terminated|August 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||June 2013|June 4, 2013|August 22, 2011|Yes|Yes|Terminated due to poor accrual.|No||https://clinicaltrials.gov/show/NCT01422473||99413|
NCT01429207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43NS071882-01A1|Capturing Parkinson's Disease Medication Side Effects During Daily Activities|Phase I Study: Monitoring Levodopa-Induced Dyskinesia Using Accelerometer & Gyroscope-based Motion Detection System||Great Lakes NeuroTechnologies Inc.||Completed|August 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|15|||Both|18 Years|90 Years|No|Non-Probability Sample|Idiopathic PD demonstrating levodopa-induced dyskinesias|June 2012|June 28, 2012|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429207||98898|
NCT01429220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44AG033520-03|Automated Parkinson's Disease (PD) Motor Symptom Assessment for Deep Brain Stimulation (DBS) Programming|||Great Lakes NeuroTechnologies Inc.||Completed|August 2011|||April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|21 Years|90 Years|No|Non-Probability Sample|Parkinson's disease|September 2014|September 12, 2014|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429220||98897|
NCT01429233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-CARDIO-NIS001|Real Life Experience of the Use of Isomers as ALENCAL (Levamlodipine) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients|Real Life Experience of the Use of Isomers as ALENCAL(Levoamlodipine) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients|XPRES|Closter Pharma|No|Recruiting|August 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care adults in Colombia|September 2011|September 6, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01429233||98896|
NCT01429467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT/V01/010911|Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation|Improving Glucose Variability in Type 1 Diabetes and Its Effect on the Underlying Homeostatic Metabolic Pathways of Angiogenesis|INDIGO 2|University of Dundee|Yes|Active, not recruiting|August 2012|December 2015|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|5 Years|18 Years|No|||December 2014|December 5, 2014|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429467||98878|
NCT01429753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0802/126|PRISM Cardiac Resynchronisation Therapy (CRT) Randomised Controlled Trial|A Prospective Randomised Study of Advanced Imaging Guided Cardiac Resynchronisation Therapy (CRT) vs Conventional CRT Implantation in Patients With Chronic Heart Failure||Guy's and St Thomas' NHS Foundation Trust|Yes|Not yet recruiting|October 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01429753||98856|
NCT01428180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULMNEONIRS03|Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants|Changes of Cerebral Tissue Oxygen Saturation During Treatment of Patent Ductus Arteriosus in Neonates||University of Ulm|No|Recruiting|April 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|34 Weeks|No|Probability Sample|Preterm neonates with patent ductus arteriosus treated in our hospital|July 2012|July 24, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01428180||98976|
NCT01428440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113236|PET Study to Study Tumour Apoptosis|A Positron Emission Tomography (PET) Study to Evaluate 18FML10 as an Imaging Agent for Tumour Apoptosis||GlaxoSmithKline|No|Terminated|December 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|24|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|August 25, 2011||No|Study data not produced not supporting objectives. Results found to be less significant than    expected so decision made to terminate|No||https://clinicaltrials.gov/show/NCT01428440||98956|
NCT01422408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7265|Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy|Phase II Study of the Effect of the Topical Corticosteroid Fluocinonide in Patients on Endocrine Therapy for Either Breast Cancer or an Increased Risk for Breast Cancer With Symptoms of Vaginal Dryness and Dyspareunia||OHSU Knight Cancer Institute|Yes|Completed|September 2011|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|35|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01422408||99418|
NCT01423214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUHCRC003|A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer||COLRAR|Kyungpook National University|Yes|Recruiting|June 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|80 Years|No|||March 2015|March 9, 2015|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01423214||99356|
NCT01424059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAS-11|Induction of Women With Fear of Labor|Planned Induction of Women With Fear of Labor and Evaluation of the Experience of Delivery||Uppsala University Hospital|No|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|N/A|No|Non-Probability Sample|Parous women with cercvical status allowing amniotomy as method for induction. Parous        women planned for cesarean section.|August 2011|August 24, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01424059||99291|
NCT01424072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE: 0060.0.198.000-09|Auriculotherapy as a Coping Strategy in Professional Nursing|Applicability of Auriculotherapy as a Strategy for Stress and Coping in Nursing Professionals||University of Sao Paulo|No|Completed|January 2010|September 2011|Actual|July 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|75|||Both|23 Years|61 Years|Accepts Healthy Volunteers|||April 2013|April 22, 2013|August 23, 2011|Yes|Yes||No|January 28, 2013|https://clinicaltrials.gov/show/NCT01424072||99290|Number of the participants(reduced sample)
NCT01431716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-066A301|Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension|A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to EFI/ACT-385781A in Patients With Pulmonary Arterial Hypertension|EPITOME-2|Actelion|No|Completed|March 2011|July 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|September 7, 2011|Yes|Yes||No|January 2, 2015|https://clinicaltrials.gov/show/NCT01431716||98706|
NCT01431950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114496|Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents|A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids.||GlaxoSmithKline|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|238|||Both|12 Years|N/A|No|||August 2014|September 4, 2014|August 25, 2011|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01431950||98688|
NCT01423513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16018|Effects of Ankle Support on Muscle Activation and Function|Effects of Ankle Support on Muscle Activation and Function||Creighton University|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|16 Years|45 Years|No|||April 2012|March 3, 2016|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01423513||99333|
NCT01423526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWP10292|A Single Dose Study of DWP10292 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo Controlled, Single-dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of DWP10292 After Oral Administration in Healthy Male Subjects||Daewoong Pharmaceutical Co. LTD.|Yes|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|52|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2011|February 23, 2014|August 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01423526||99332|
NCT01424345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997050|The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient|A Randomized, Controlled Trial Evaluating the Role of ImmuKnow® in the Management of Immunosuppressants Regarding Opportunistic Infections and Acute Rejection in the Renal Transplant Patient||CAMC Health System|No|Terminated|December 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|80 Years|No|||October 2012|October 4, 2012|August 24, 2011||No|The PI is relocating to another State/ another hospital|No||https://clinicaltrials.gov/show/NCT01424345||99269|
NCT01424020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-P 2011-06|Walking Estimated Limitation Calculated by History - Study 2|Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs|WELCH-2|University Hospital, Angers|No|Recruiting|September 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 16, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01424020||99294|
NCT01424332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-034|To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects|A Randomized, Open Label, Three-way Crossover Study to Evaluate the Pharmacodynamic Interactions Between Darexaban (YM150)/Darexaban Glucuronide (YM-222714) and Acetyl Salicylic Acid (ASA) in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|December 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 25, 2011|August 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01424332||99270|
NCT01420484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S234/2009|CNAP in Heart Surgery|Noninvasive Blood Pressure Measuring||Heidelberg University|No|Completed|January 2010|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted for elective transfemoral implantation of the aortic valve in        analgosedation will be included. The patients' primary diagnosis was severe aortic        stenosis, that was defined as a valve area of <1cm² or a mean pressure gradient >50mmHg.        Exclusion criteria for the study will be an advanced dysfunction of peripheral perfusion        (i.e. pronounced arterial peripheral artery occlusive disease or Raynaud's syndrome),        arterio-venous shunts for haemodialysis, and vascular surgery of the upper extremities.        Before including patients in the present study, blood pressure will be measured on both        arms noninvasively by oscillometry to exclude any significant arterial stenosis between        the upper extremities. Differences of less than 10 mmHg will be accepted.        All patients won't receive any sedative drugs preoperatively and were allowed to drink        fluids up to 2 hours before surgery.|December 2013|December 18, 2013|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420484||99566|
NCT01420809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112285|Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection|Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection||GlaxoSmithKline|No|Completed|September 2007|August 2009|Actual|May 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1280|||Both|N/A|N/A|No|Probability Sample|Subjects undergoing orthopedic surgery of the lower limb at high risk of developing venous        thromboembolism|August 2011|August 18, 2011|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01420809||99541|
NCT01420822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113406|Special Drug Use Investigation for ALLERMIST (Long Term)|Special Drug Use Investigation for ALLERMIST (Long Term)||GlaxoSmithKline|No|Completed|December 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|500|||Both|N/A|N/A|No|Probability Sample|The target subjects shall be those who with allergic rhinitis for which the indication of        ALLERMIST has been approved and who are using ALLERMIST for the first time and also who        are expected to use ALLERMIST for long-term (1 year).|March 2015|March 26, 2015|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01420822||99540|
NCT01421745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16206|Construct Validity, Responsiveness, and Demographic Predictors of the IAPCC-SV|Construct Validity, Responsiveness, and Demographic Predictors of the Inventory for Assessing the Process of Cultural Competence Among Healthcare Professionals - Student Version (IAPCC-SV)||Texas Woman's University|No|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|40|||Both|N/A|N/A|No|||May 2012|May 14, 2012|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421745||99469|
NCT01421758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1122|Testing the Efficacy of an Online Social Network Intervention to Increase Social Support for Physical Activity|Using Facebook to Increase Social Support for Physical Activity: The INSHAPE Study|INSHAPE|University of North Carolina, Chapel Hill|No|Completed|December 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|134|||Female|17 Years|24 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421758||99468|
NCT01422486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.2107|Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome|Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome||Telik|No|Terminated|October 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|August 18, 2011|Yes|Yes|Study TLK199.2107 was terminated for business reasons.|No||https://clinicaltrials.gov/show/NCT01422486||99412|
NCT01427296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSBP4011|Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing|A Phase 4, Randomized, Active Comparator, Open-Label, Multicenter Study to Assess the Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing||Valeant Pharmaceuticals International, Inc.|Yes|Active, not recruiting|August 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|70 Years|No|||May 2014|May 30, 2014|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427296||99043|
NCT01427309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM12|A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults|Efficacy Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults||Sanofi|Yes|Completed|September 2011|November 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|31989|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|August 30, 2011|Yes|Yes||No|July 8, 2014|https://clinicaltrials.gov/show/NCT01427309||99042|
NCT01427322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13711|Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease|A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease||Virginia Commonwealth University|Yes|Terminated|September 2011|July 2015|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|August 30, 2011|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01427322||99041|
NCT01427582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05- EAP- STS|YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access|YONDELIS(Trabectedin) Single Patient Compassionate Use / Expanded Access in Soft Tissue Sarcoma||University of Texas Southwestern Medical Center||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|90 Years||||August 2011|August 30, 2011|August 30, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01427582||99021|
NCT01427855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL106003-01A1|Dietary Protein Sources and Atherogenic Dyslipidemia|Saturated Fat and Protein Effects on Atherogenic Dyslipidemia||Children's Hospital & Research Center Oakland|Yes|Recruiting|January 2012|November 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Anticipated|180|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 3, 2015|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427855||99001|
NCT01427868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-BVCL009|Bioequivalence of LB80380 Free Base and Maleate Salt Tablets|An Open-label, Phase I Study in Healthy Male Subjects to Compare the Pharmacokinetics of LB80331 and LB80317, Metabolites of LB80380, After a Single Oral Administration of LB80380 Free Base 150 mg (60 mg + 90 mg) Tablet or LB80380 Maleate Tablet 183 mg (150 mg as a Free Base)||LG Life Sciences|No|Completed|September 2010|December 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 1, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01427868||99000|
NCT01427881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2541.00|Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies|A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation||Fred Hutchinson Cancer Research Center|Yes|Completed|September 2011|||June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|N/A|65 Years|No|||August 2015|August 4, 2015|August 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01427881||98999|
NCT01428453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114458|A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease|A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease||GlaxoSmithKline|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|50 Years|80 Years|No|||August 2013|April 27, 2015|September 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01428453||98955|
NCT01428466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114849|Japanese Phase 1 Study of GSK2585823|Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl Peroxide 3% Gel) With Healthy Japanese Male and Female Subjects|JPN P1|GlaxoSmithKline|No|Completed|November 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|20|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||July 2013|August 1, 2013|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01428466||98954|
NCT01422967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109/2011|Changes Of Sleep on the Sensoriomotor and Cytokine In Patients With Osteoarthritis|Changes of Sleep on the Sensorimotor and Cytokine in Patients With Knee Osteoarthritis||Universidade Federal de Sao Carlos|Yes|Recruiting|June 2010|December 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Male|40 Years|60 Years|Accepts Healthy Volunteers|||August 2011|August 24, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01422967||99375|
NCT01431222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IsarClip|Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery|Interventional Strategy to Abrogate Mitral Regurgitation Using the MitraClip System in High-Risk Patients Considered Unsuitable for Surgery (ISAR-CLIP)|ISAR-CLIP|Deutsches Herzzentrum Muenchen|Yes|Not yet recruiting|September 2011|September 2014|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2011|September 8, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431222||98744|
NCT01424085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40912-B|Antibiotic Prophylaxis Before Percutaneous Gastrostomy|Antibiotic Prophylaxis Before Percutaneous Gastrostomy: A Randomized, Controlled Clinical Trial||University of Washington|Yes|Recruiting|May 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|128|||Both|18 Years|90 Years|No|Probability Sample|Anyone referred to Interventional Radiology for percutaneous gastrostomy is in the study        population (with inclusion and exclusion criteria below).|December 2015|December 3, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424085||99289|
NCT01423227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HomeBase|Benefits and Costs of Home-based Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease|Benefits and Costs of Home-based Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease|HomeBase|La Trobe University|Yes|Recruiting|October 2011|October 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|40 Years|N/A|No|||July 2012|July 24, 2012|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01423227||99355|
NCT01424033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00049434|A Clinical Trial for CTD-ILD Treatment|Clinical Trial of Oral Medication for CTD-ILD Treatment|ENACT|University of Michigan|Yes|Terminated|December 2011|February 2018|Anticipated|February 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|August 24, 2011|Yes|Yes|Departure of study team|No|January 14, 2016|https://clinicaltrials.gov/show/NCT01424033||99293|
NCT01420510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Saginil in vaginitis|Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis|Saginil in Vaginal Cannulas vs. Placebo for the Prevention of Vaginitis in Gynecologic Oncologic Patients Receiving Chemotherapy: a Randomized Controlled Trial.||Università degli Studi dell'Insubria|Yes|Recruiting|September 2011|December 2014|Anticipated|November 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Female|N/A|N/A|No|||June 2013|June 20, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01420510||99564|
NCT01420523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002483-24|Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy|Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).|ROCnRAL|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Terminated|December 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420523||99563|
NCT01420549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH-TRZ-03(06/11)|Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|Phase III, Multicenter, Randomized, Open-label, Comparative, Parallel Group Study of the Efficacy and Safety of Rosuvastatin + Ezetimibe Versus Simvastatin + Ezetimibe in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|LANCE|Ache Laboratorios Farmaceuticos S.A.|No|Not yet recruiting|February 2012|||October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||August 2011|August 18, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420549||99561|
NCT01424618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39604|A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs|A Novel Approach to Endometrial Preparation in Recipients of Donor Cycles||Kelly, Maureen, M.D.|Yes|Recruiting|January 2006|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||August 2011|August 25, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424618||99248|
NCT01424631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lap appendectomy 123|Single Incision Versus Conventional Laparoscopic Appendectomy|||Mansoura University||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|10 Years|80 Years||||August 2011|August 26, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424631||99247|
NCT01421095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORT study|Ovarian Reserve Testing in Female Young Adult Cancer Survivors|Ovarian Reserve Testing in Female Young Adult Cancer Survivors||University of California, San Diego|No|Recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|34|||Female|18 Years|35 Years|No|||June 2015|June 4, 2015|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01421095||99519|
NCT01421459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13713|A Study in Adults With Type 2 Diabetes|A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 2 Study|ELEMENT 2|Eli Lilly and Company|Yes|Completed|September 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|759|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 19, 2011|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01421459||99491|
NCT01421992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFM-12117|Methylphenidate in Myotonic Dystrophy Type 1|Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1||Laval University|No|Completed|June 2008|September 2010|Actual|August 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|65 Years|No|||June 2011|August 22, 2011|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01421992||99450|
NCT01422213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14122A|Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose Study on the Efficacy of [Vortioxetine] Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (MDD)|FOCUS|H. Lundbeck A/S|No|Completed|December 2011|||May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|598|||Both|18 Years|65 Years|No|||July 2014|July 8, 2014|August 22, 2011|Yes|Yes||No|May 14, 2014|https://clinicaltrials.gov/show/NCT01422213||99433|
NCT01423045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCONC|Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease|Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease||Meir Medical Center|No|Not yet recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with CKD and estimated GFR of less then 50 mL per minute.|August 2011|August 24, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423045||99369|
NCT01423058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YM387-II-02|Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis|A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis||Gilead Sciences|Yes|Completed|August 2011|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423058||99368|
NCT01427049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-189|The Effect of Renal Denervation on Biological Variables|The Evaluation of Renal Denervation on Several Biological Variables in Patients With Uncontrolled Hypertension. An Observational Feasibility Study.||UMC Utrecht|Yes|Recruiting|August 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug        regimen including 3 or more antihypertensive medications, including a diuretic, or        inability to follow a stable drug regimen due to unacceptable side-effects of        antihypertensive medication.        This current study is an observational exploratory-study.|August 2011|August 31, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01427049||99062|
NCT01427335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192011|Calcium for Prevention of Ovarian Hyperstimulation Syndrome|Does Intravenous Calcium Infusion Effectively Prevent OHSS : a Randomised Controlled Trial|OHSS|Cairo University|Yes|Completed|October 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427335||99040|
NCT01427348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_dental injury|Maintaining the Head Extension by an Assistant Decreases Dental Contact|Maintaining the Head Extension by an Assistant Decreases Dental Contact Between Laryngoscope Blade and Maxillary Incisors During Direct Laryngoscopy||Seoul National University Hospital||Completed|September 2011|May 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|68|||Both|18 Years|80 Years|No|||May 2012|May 28, 2012|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01427348||99039|
NCT01427595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13789|Effect of Metformin on Sensitivity of the Gonadotropin-releasing Hormone (GnRH) Pulse Generator to Suppression by Estradiol and Progesterone|Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)||University of Virginia|No|Recruiting|July 2008|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Female|10 Years|17 Years|No|||December 2013|December 9, 2013|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01427595||99020|
NCT01432405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21068|Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes|Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus||Baylor College of Medicine|No|Completed|June 2007|June 2009|Actual|July 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|70 Years|No|||September 2011|September 12, 2011|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01432405||98653|
NCT01422161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01126|Study of Botulinum Toxin and Recovery of Hand Function After Stroke|Botulinum Toxin Type A Therapy as a Plasticity Inducing Agent for Recovery of Hand Function After Stroke||New York University School of Medicine|Yes|Completed|April 2010|April 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|24|||Both|18 Years|75 Years|No|||April 2015|April 13, 2015|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01422161||99437|
NCT01422993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16557|Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy|A Pilot Study of a Strength and Balance Training Program for Persons With Oxaliplatin Induced Peripheral Neuropathy||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422993||99373|
NCT01423565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|386150-HMO-CTIL|Comparison of Constant Current to Constant Voltage Stimulation in Subthalamic Deep Brain Stimulation for Parkinson's Disease|Comparison of Constant Current to Constant Voltage Stimulation in Subthalamic DBS for Parkinson's Disease||Hadassah Medical Organization|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|8|||Both|30 Years|80 Years|No|||March 2015|March 17, 2015|August 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01423565||99329|
NCT01422655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TcB_Patr_2011|Transcutaneous Bilirubinometry in Neonates|Accuracy of Transcutaneous Bilirubin Determinations in Neonates: The Effect of Gestational Age, Time and Site of Measurement||University of Patras|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|255|||Both|N/A|120 Hours|No|Probability Sample|Term and preterm neonates from birth to 120 postnatal hours|January 2012|January 22, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422655||99399|
NCT01423240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050305|Major Depressive Disorder With Mixed Features|A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features|RESOLVE2|Sunovion|Yes|Withdrawn|January 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||December 2012|December 11, 2012|August 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423240||99354|
NCT01424384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105012|Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic|Emotional Processing in Healthy Male Volunteers Treated With GSK424887. A Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study||GlaxoSmithKline|No|Completed|September 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|February 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01424384||99266|
NCT01424397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111924|Intranasal SB-705498 in Allergic Rhinitis (AR) Patients|A Randomized, Double-blind, Placebo Controlled, Incomplete Block, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of SB-705498 When Administered Alone or in Conjunction With Intranasal Fluticasone Propionate on the Symptoms of Rhinitis in the Vienna Allergen Challenge Chamber||GlaxoSmithKline|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|70|||Both|18 Years|65 Years|No|||May 2014|May 29, 2014|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01424397||99265|
NCT01423773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-367-C-800|Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression|Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression||Alcon Research|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|20|||Both|18 Years|N/A|No|||November 2012|June 20, 2013|August 25, 2011|Yes|Yes||No|November 21, 2012|https://clinicaltrials.gov/show/NCT01423773||99313|The sample size may be small for establishing relationship between ocular comfort and other measurable variables.
NCT01420237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70|Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study|Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study With Long Term Data Collection for the Accolade® II Hip Stem||Stryker Orthopaedics|No|Recruiting|June 2011|June 2026|Anticipated|June 2026|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|March 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420237||99584|
NCT01420497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gylperi|Systemic Effects of Epidural Methylprednisolone Injection on Glucose Tolerance in Diabetic Patients|||Centre Hospitalier Universitaire Vaudois|Yes|Completed|August 2008|June 2010|Actual|September 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|25|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||August 2011|August 18, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420497||99565|
NCT01420848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISNEP CAAE 0107.0.360.000-11|Auriculotherapy Effectiveness on Stress and Anxiety in Nursing Student|The Effectiveness of the Auriculotherapy on Reducing Stress and Anxiety in Nursing Student: Randomized Clinical Trial||University of Sao Paulo|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|71|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 9, 2013|August 19, 2011||No||No|January 30, 2013|https://clinicaltrials.gov/show/NCT01420848||99538|The limitation of the trial was the reduced number of the sample.
NCT01420835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SISNEP CAAE 0050.0.196.196-11|Chinese Auriculotherapy on Stress and Quality of Life in Nursing Professionals: Randomized Clinical Trial|Randomized Clinical Trial: Chinese Auriculotherapy With and Without Protocol on Stress and Quality of Life in Nursing Professionals||University of Sao Paulo|No|Completed|September 2011|December 2012|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|175|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2013|January 17, 2013|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420835||99539|
NCT01421472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-02-02-07 (ARD11918)|A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer|A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer||Merrimack Pharmaceuticals|Yes|Completed|August 2011|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Female|18 Years|N/A|No|||February 2016|February 14, 2016|August 19, 2011|Yes|Yes||No|February 14, 2016|https://clinicaltrials.gov/show/NCT01421472||99490|
NCT01421485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH087520-01A2|Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth|Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth|ITP|Rhode Island Hospital|Yes|Active, not recruiting|August 2011|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||February 2015|May 5, 2015|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421485||99489|
NCT01421771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK083424-01A1|Blood Pressure in Dialysis Patients|Blood Pressure in Dialysis Patients (BID Study)|BID|University of New Mexico|Yes|Recruiting|September 2011|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2011|March 28, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01421771||99467|
NCT01422226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1060|Intra Uterine Device Insertion in Nulliparous Women|IUD Insertion in Nulliparous Women: A Randomized, Placebo-Controlled Trial of Misoprostol for Cervical Priming||University of Colorado, Denver|No|Terminated|July 2011|August 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 11, 2015|August 22, 2011||No|Unable to recruit participants|No|February 11, 2015|https://clinicaltrials.gov/show/NCT01422226||99432|
NCT01431443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC096501|Consumption of Chocolate in Pregnant Women.|Consumption of Chocolate in Pregnant Women at High Risk for Preeclampsia.|CHOCENTA|Laval University|Yes|Completed|May 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|160|||Female|18 Years|40 Years|No|||April 2015|April 8, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01431443||98727|
NCT01431729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|honey propolis 421|Honey and a Mixture of Honey, Beeswax and Olive Oil-propolis Extract in Treatment of Chemotherapy-induced Oral Mucositis|Honey and a Mixture of Honey, Beeswax and Olive Oil-propolis Extract in Treatment of Chemotherapy-induced Oral Mucositis: a Randomized Controlled Pilot Study||Ain Shams University|Yes|Completed|June 2010|July 2011|Actual|June 2011|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|2 Years|18 Years|No|Non-Probability Sample|Eligible patients were randomly allocated by a computer-generated list of random numbers        to be assigned into one of three treatment groups; 30 patients each. Group (1) received an        empirical dose of 15 gm honey applied topically to the affected oral mucosa three times        daily until healing or for 10 days, which ever comes first. Group (2) received an        empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax        (HOPE) applied topically to the oral mucosa three times daily until healing or for 10        days, which ever comes first. Group (3) served as controls and received benzocaine 7.5%        gel applied topically to areas of ulcers three times daily.|September 2011|September 19, 2011|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431729||98705|
NCT01431963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115376|Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy|A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy in Newly Diagnosed Epilepsy or Recurrent Epilepsy (Currently Untreated)||GlaxoSmithKline|No|Completed|September 2011|September 2014|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|16 Years|N/A|No|||April 2015|May 11, 2015|September 1, 2011||No||No|September 26, 2013|https://clinicaltrials.gov/show/NCT01431963||98687|
NCT01432184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICM 08-1009|Feasibility Trial to Maintain Normal Cerebral Oxygen Saturation in High-Risk Cardiac Surgery|Perioperative Interventions to Optimize Cerebral Oxygen Saturation (rSO2) in High-risk Patients Undergoing Cardiac Surgery Should Have a Beneficial Systemic Effect for Enhancing Global Tissue Perfusion and Improve Outcomes.|Tête-à-coeur|Montreal Heart Institute|Yes|Completed|July 2010|October 2013|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01432184||98670|
NCT01432418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230378|Effectiveness of a Wheelchair Skills Training Program for Power Mobility Users: A Randomized Controlled Trial|Effectiveness of a Wheelchair Skills Training Program for Power Mobility Users: A Randomized Controlled Trial||Nova Scotia Health Authority|No|Completed|June 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|116|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432418||98652|
NCT01422668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAEU: GI Dates Study|Effect of Coffee Consumption on the Glycemic Index of Khalas Dates Tested in Healthy and Diabetic Subjects|Effect of Coffee Consumption on the Glycemic Index of Khalas Dates Tested in Healthy and Diabetic Subjects||United Arab Emirates University|Yes|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|23|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2011|August 23, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01422668||99398|
NCT01423253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050306|Major Depressive Disorder With Mixed Features - Extension|A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features|RESOLVE3|Sunovion|Yes|Completed|September 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|75 Years|No|||September 2015|September 15, 2015|August 23, 2011|Yes|Yes||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01423253||99353|
NCT01423539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP27814|A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)|A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma||Genentech, Inc.||Withdrawn|October 2011|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 24, 2011|Yes|Yes|The NAVIGATE study has been terminated due to non-safety related reasons.|No||https://clinicaltrials.gov/show/NCT01423539||99331|
NCT01420588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGLN|Diagnosis of Gastric Lesions With Na-nose|Study of the Exhaled Breath of Patients With Malignant and Benign Lesions With Na-Nose||Anhui Medical University|Yes|Recruiting|August 2011|December 2014|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Anticipated|960|Samples Without DNA|exhaled breath of volunteers|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|160 volunteers who undergo gastroscopy examination in The First Affiliated Hospital of        Anhui Medical University,Hefei,China and 800 patients with dyspeptic symptoms referred for        upper endoscopy or patients suspected for gastric cancer referred for surgery in the        clinical sites of University of Latvia (Riga East University hospital and/or Digestive        Diseases Centre GASTRO), Riga, Latvia|June 2013|June 23, 2013|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420588||99558|
NCT01424358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16008|Web-based Education on Oral Cancer for Primary Care Physicians in Ohio|Web-based Education on Oral Cancer for Primary Care Physicians in Ohio||Creighton University|No|Completed|July 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|March 23, 2015|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01424358||99268|
NCT01420250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.243|Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer|Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the Prostate||Thomas Jefferson University|Yes|Active, not recruiting|September 2011|September 2018|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|18 Years|N/A|No|||October 2015|October 8, 2015|August 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01420250||99583|
NCT01420536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unesp-PT-001|Canine Guidance vs Bilateral Balanced Occlusion in Complete Denture|A Cross-over Randomized Clinical Trial of Canine Guidance and Bilateral Balanced Occlusion in Complete Denture Wearers||University of Sao Paulo|No|Completed|February 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|45 Years|N/A|No|||August 2011|August 18, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01420536||99562|
NCT01421147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13712|A Study in Adults With Type 1 Diabetes|A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus|ELEMENT 1|Eli Lilly and Company|Yes|Completed|August 2011|April 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|536|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|August 19, 2011|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01421147||99515|
NCT01421160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|citrate1|Regulating Urine pH Levels to Alleviate Chronic Joint Pain|A Pilot Study to Assess the Effects of Regulating Urine pH Levels for Alleviating Chronic Joint Pain||Texas Tech University Health Sciences Center|No|Withdrawn|July 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|80 Years|No|||December 2012|December 14, 2012|July 20, 2011||No|PI left the institution prior to any data being collected|No||https://clinicaltrials.gov/show/NCT01421160||99514|
NCT01420861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200707|GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer|Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy||GTx|No|Terminated|September 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|8|||Male|18 Years|80 Years|No|||April 2014|April 23, 2014|August 18, 2011|Yes|Yes|FDA Clinical Hold|No||https://clinicaltrials.gov/show/NCT01420861||99537|
NCT01421108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12611000885998|The Effectiveness of Gain- Versus Loss-framed Health Messages to Improve Oral Health Among Iranian Adolescents|The Effectiveness of Gain- Versus Loss-framed Health Messages to Improve Oral Health Among Iranian Adolescents:A Randomized Controlled Trial||Qazvin University Of Medical Sciences|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|372|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||March 2012|March 4, 2012|August 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421108||99518|
NCT01421121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV71-1001-II|Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants|||Sinovac Biotech Co., Ltd|Yes|Completed|June 2011|December 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|5||Actual|540|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||November 2012|November 26, 2012|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421121||99517|
NCT01421134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050304|Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose|A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features|RESOLVE 1|Sunovion|Yes|Completed|September 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|211|||Both|18 Years|75 Years|No|||November 2015|November 13, 2015|August 17, 2011|Yes|Yes||No|September 10, 2015|https://clinicaltrials.gov/show/NCT01421134||99516|
NCT01421784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 042011-034|Using Rapid Cine-MRI for Monitoring Moving and Deforming Tumors|Investigating the Feasibility of Using Rapid Cine-MRI for Monitoring Moving and Deforming Tumors||University of Texas Southwestern Medical Center|Yes|Recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|August 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421784||99466|
NCT01422005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00118|Study of the Recovery of Muscle Function in the Arm/Hand After a Stroke|Simultaneous Bimanual Training to Improve Motor Function Post-Stroke||New York University School of Medicine|Yes|Recruiting|January 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|20|||Both|21 Years|75 Years|No|||February 2016|February 24, 2016|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01422005||99449|
NCT01422499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-2007-11-02-1004|Vorinostat in Children|Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children With Relapsed Solid Tumor, Lymphoma or Leukemia||National Center for Tumor Diseases, Heidelberg|Yes|Recruiting|March 2012|December 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|18 Years|No|||October 2015|October 22, 2015|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01422499||99411|
NCT01422785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1602|A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne|A Pilot Study to Evaluate the Efficacy of Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Alone Versus Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Plus Benzoyl Peroxide 6% Foaming Cloths in the Treatment of Facial Acne Vulgaris||Zeichner, Joshua, M.D.|Yes|Recruiting|July 2011|||December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|N/A|No|||August 2011|August 22, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01422785||99389|
NCT01422798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/MBA/2011/TBKidcohort|An Open Cohort of Childhood Tuberculosis in Mbarara National Referral Hospital, Uganda|An Open Cohort of Childhood Tuberculosis in Mbarara National Referral Hospital, Uganda||Epicentre|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|396|||Both|1 Month|14 Years|No|Non-Probability Sample|Children aged one month to 14 years and identified as TB suspect will be eligible to the        study. Definition of TB suspect was adapted from the definitions proposed by WHO        guidelines (World Health Organisation 2006).|February 2016|February 29, 2016|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01422798||99388|
NCT01423370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHD1023-201|Safety and Efficacy of YHD1023 in Erectile Dysfunction|Multi-center, Randomized, Double-blind, Placebo/Active-controlled, Phase II Clinical Trial to Assess the Safety and Efficacy of YHD1023 in Patients With Erectile Dysfunction||Yuhan Corporation|Yes|Completed|November 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|104|||Male|20 Years|N/A|No|||May 2013|July 30, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423370||99344|
NCT01431456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DARINA|Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery|A Randomized Pilot Study Comparing the Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery|DARINA|Martini Hospital Groningen|Yes|Not yet recruiting|October 2011|||October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|N/A|No|||September 2011|September 8, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431456||98726|
NCT01431469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6001|Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil|||Mead Johnson Nutrition||Completed|September 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|250|||Both|12 Months|48 Months|Accepts Healthy Volunteers|||December 2012|December 5, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01431469||98725|
NCT01431742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUP-306|Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain|An Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Low Back Pain||BioDelivery Sciences International|No|Withdrawn|July 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431742||98704|
NCT01431976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115377|Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents|A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy on Newly Diagnosed Typical Absence Seizures in Children and Adolescents||GlaxoSmithKline|No|Completed|September 2011|November 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|2 Years|15 Years|No|||December 2015|December 14, 2015|September 1, 2011||No||No|August 14, 2014|https://clinicaltrials.gov/show/NCT01431976||98686|
NCT01432197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT Occup Cancer|Occupational Therapy for Cancer Patients: a Randomised, Controlled Study|Occupational Therapy for Cancer Patients: A Randomised Controlled Study||University of Southern Denmark|No|Completed|March 2010|||June 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|116|||Both|18 Years|N/A|No|||September 2011|September 9, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432197||98669|
NCT01432431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11110|Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff|Archstone Spiritual Care Demonstration Project: Outcomes for Patients, Families, and Staff||City of Hope Medical Center|Yes|Completed|October 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 4, 2013|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432431||98651|
NCT01422681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECOPD1|Extracorporeal CO2 Removal in COPD Exacerbation|Extracorporeal Carbon Dioxide Removal in Patients With Severe COPD Exacerbation Failing Noninvasive Ventilation|DECOPD|University of Turin, Italy|No|Completed|May 2011|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|90 Years|No|||January 2014|January 20, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01422681||99397|
NCT01422980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU345|Effect of Consumption of Dairy Product on Upper Gastric Discomfort|Effect of Consumption of Dairy Product on Upper Gastric Discomfort||Danone Research|No|Completed|November 2010|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|2|||450|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||August 2011|August 23, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01422980||99374|
NCT01423266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL093466-01|Effects of a High Protein Diet on Clinical Outcomes in Heart Failure|Examining the Effects of a High Protein Diet on Adiposity and Cardiac Structure in Patients With Heart Failure, Obesity, and Diabetes Mellitus||University of California, Irvine|Yes|Active, not recruiting|December 2009|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|78|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01423266||99352|
NCT01423279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11-0074CTIL|The Effect of a Diabetic- and a Kidney-like Environment on Gene and Protein Expression in Cultured EC and SMC|The Effect of a Diabetic- and a Kidney-like Environment on Gene and Protein Expression in Mono- and Co-cultured Endothelial and Smooth Muscle Cells||Meir Medical Center|No|Recruiting|February 2013|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|20|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Women after normal birth|March 2016|March 15, 2016|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423279||99351|
NCT01423292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-557|Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection|||National Cancer Center, Korea||Completed|August 2011|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|20 Years|80 Years|No|||August 2012|August 2, 2012|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01423292||99350|
NCT01423786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00446|Early Oral Nutrition in Mild Acute Pediatric Pancreatitis|Early Oral Nutrition in Mild Acute Pediatric Pancreatitis||Nationwide Children's Hospital||Recruiting|August 2011|||March 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|2 Years|21 Years|No|||August 2011|August 25, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423786||99312|
NCT01424046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC4 pitt 1|Health Care for Type 1 Diabetes in Developing World|Evaluation of Differing Type 1 Diabetes Regimens in Youth in the Developing World||University of Pittsburgh|Yes|Completed|May 2011|November 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|1 Year|24 Years|No|||December 2014|December 4, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424046||99292|
NCT01421537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 10.148|Evaluation Of Enoxaparin Pharmacokinetic For Thromboprophylaxis In Burn Care Patients|Evaluation Of Enoxaparin Pharmacokinetic For Thromboprophylaxis In Burn Care Patients||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients in :          -  general medical ward          -  mixte intensive care unit          -  burn patient intensive care unit|August 2011|August 22, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421537||99485|
NCT01424371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-071|Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)|A Case-Control Study to Evaluate the Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine in the Elderly Aged ≥65 Years.||Fraser Health|No|Recruiting|November 2011|June 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|1000|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All elderly over 65 years in the lower mainland of British Columbia presenting with an        influenza-like-illness|September 2012|September 28, 2012|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424371||99267|
NCT01420263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 004|Re-feeding Gastric Residuals in Preterm Infants|Re-feeding Residuals Versus Feeding Fresh Formula/Milk for Feeding Intolerance in Premature Infants||University of Alabama at Birmingham|Yes|Completed|August 2011|January 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|N/A|7 Days|No|||February 2013|February 7, 2013|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420263||99582|
NCT01420575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAM-00730|Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia|Using a Visual Decision Aid (DA) to Facilitate Shared Decision Making (SDM) During Antipsychotic Treatment in Schizophrenia.||VA Nebraska Western Iowa Health Care System|No|Terminated|October 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Female|19 Years|65 Years|No|||September 2012|September 17, 2012|August 18, 2011||No|Low enrollment rate.|No||https://clinicaltrials.gov/show/NCT01420575||99559|
NCT01420874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-025|Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)|Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib)||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|August 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01420874||99536|
NCT01421797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12702|Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation|Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation (JCM022)||University of Virginia|No|Recruiting|October 2006|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|84|||Female|7 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421797||99465|
NCT01421498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118-KCS-200|Safety and Efficacy Study of SAR 1118 to Treat Dry Eye|A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)|OPUS-1|Shire|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|588|||Both|18 Years|N/A|No|||April 2014|April 25, 2014|August 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421498||99488|
NCT01421511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-113|TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of IV to Oral 6-Day TR-701 Free Acid and IV to Oral 10-Day Linezolid for the Treatment of ABSSSI||Trius Therapeutics LLC|Yes|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|666|||Both|18 Years|N/A|No|||August 2014|August 31, 2014|August 19, 2011|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01421511||99487|
NCT01422239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHW-WHRY-526|A Smoking Cessation Treatment for Adult Women|A Smoking Cessation Treatment for Adult Women||Yale University|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Female|18 Years|64 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|August 19, 2011||No||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01422239||99431|Small sample size, half to two-thirds of participants dropped out of the active study phase, half to one quarter did not complete the one month follow up. Female participants only results can not be generalized to men.
NCT01422512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58_25S|Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects|A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture, Formulation 2011/2012, When Administered to Adult and Elderly Subjects||Novartis|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 10, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422512||99410|
NCT01422772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM202RY-VM01|Safety Study of Gene Therapy for Ischemic Heart Disease in Korea|Open-label, Dose-escalation, Phase 1 Trial to Evaluate the Safety of VM202RY Gene Medicine Injected Into Myocardial Territory With Incomplete Revascularization During Coronary Artery Bypass Graft in Patients With Ischemic Heart Disease||ViroMed Co., Ltd. dba VM BioPharma|No|Completed|January 2007|August 2014|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|19 Years|75 Years|No|||January 2015|January 25, 2015|August 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01422772||99390|
NCT01423383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tirgan 11-04|Epidemiology Study of Keloid|Epidemiology Study of Keloid||Tirgan, Michael H., M.D.|No|Recruiting|September 2011|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|100000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|General population will be sampled randomly|June 2012|June 6, 2012|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423383||99343|
NCT01423617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/005611|Efficacy and Safety of Zenoctil in Reducing Body Weight|Double-blind, Randomized, Placebo-controlled, Bicentric Study to Evaluate the Safety and Efficacy of Zenoctil in Reducing Body Weight of Overweight Subjects||InQpharm Group|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|August 24, 2011||No||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01423617||99325|
NCT01423630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/517|Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver|Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver||Region Skane|No|Recruiting|August 2011|August 2018|Anticipated|August 2014|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||August 2013|August 5, 2013|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423630||99324|
NCT01431482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6010|Evaluation of the Composition of Human Milk and Health Outcomes in Children|Evaluation of the Composition of Human Milk and Health Outcomes in Children||Mead Johnson Nutrition|No|Completed|August 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|245|Samples Without DNA|Human milk samples|Both|N/A|2 Years|Accepts Healthy Volunteers|Probability Sample|Children up to 2 years of age|May 2013|May 1, 2013|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431482||98724|
NCT01431755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GE1101|A Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride|A Randomised, Subject-blinded Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride 0.3%||Q-Med AB||Completed|September 2011|October 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 23, 2014|September 6, 2011||No||No|October 16, 2013|https://clinicaltrials.gov/show/NCT01431755||98703|
NCT01431768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP11001|Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B|Clinical Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B in the Primary Health Setting||Respirio Pty Ltd|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|250|||Both|7 Years|80 Years|No|||April 2014|April 28, 2014|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431768||98702|
NCT01431989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115954|Amoxicillin Bioequivalence Study Brazil - Fast|Evaluation of Pharmaceutical Bioequivalence of Amoxicillin Trihydrate - Clamoxyl 500mg/5mL (Glaxo Wellcome Production.) in the Form Powder for Oral Suspension Versus Amoxil ® 500mg/5mL (GlaxoSmithKline Mexico SA) in the Form of Powder for Oral Suspension in Healthy Volunteers and Fasting, Using Techniques of Liquid Chromatography||GlaxoSmithKline|No|Completed|May 2011|June 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 4, 2013|September 8, 2011||No||No|January 5, 2012|https://clinicaltrials.gov/show/NCT01431989||98685|
NCT01432210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0159|Provitamin A Absorption and Conversion With Avocados|Enhancing Human Intestinal Absorption of Carotenoids and Bioconversion of Carotene to Vitamin A in the Presence of Hass Avocados||Ohio State University|No|Completed|September 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01432210||98668|
NCT01432444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-11-283|Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole|Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting|ARRIVE US|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|493|||Both|18 Years|65 Years|No|||April 2015|April 20, 2015|September 9, 2011|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01432444||98650|
NCT01432717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A536-02|Study of ACE-536 in Healthy Postmenopausal Women|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women||Acceleron Pharma, Inc.|No|Completed|September 2011|October 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 5, 2012|September 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01432717||98629|
NCT01424124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHD001-201|Safety and Efficacy of YHD001 in Asthma|Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 Following 8 Weeks Oral Administration of YHD001 in Patients With Partially Controlled Asthma||Yuhan Corporation|No|Completed|November 2011|January 2014|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|20 Years|N/A|No|||July 2014|July 8, 2014|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424124||99286|
NCT01424137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3106002|Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)|Inspiratory Flow Parameters With Placebo Dry Powder Inhalers, Easyhaler and Diskus; an Open, Randomised, Multicentre Study in Patients With Asthma or COPD|SALIF|Orion Corporation, Orion Pharma|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|227|||Both|4 Years|N/A|No|||February 2012|February 2, 2012|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424137||99285|
NCT01423799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.54.CLI|Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment|Immunonutrition to Improve Quality of Life of Upper Gastrointestinal Cancer Patients Undergoing Oncological Treatment|Neoimmune|Nestlé|No|Completed|July 2012|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|300|||Both|18 Years|75 Years|No|||November 2015|November 11, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423799||99311|
NCT01423812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC114HIV4063|DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects|DRIVESHAFT : Darunavir/Ritonavir In Virologically-suppressed Experienced Subjects Halving an Antiretroviral by Finetuning Therapy - A Phase IV Randomized, Open-Label Study to Evaluate in HIV-1 Infected , Virologically-suppressed Patients on Regimens With Darunavir 600mg/ Ritonavir 100mg Twice-daily Switching to Darunavir 800mg/ Ritonavir 100mg Once-daily Versus Continuing Darunavir 600mg/ Ritonavir 100mg Twice-daily Containing Regimens|DRIVESHAFT|Ruth M. Rothstein CORE Center|Yes|Completed|January 2012|April 2015|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|August 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423812||99310|
NCT01421550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUCIAL trial|Conservative Treatment Versus Elective Repair of Umbilical Hernia in Patients With Ascites and Liver Cirrhosis|Conservative Treatment Versus Elective Repair of the Umbilical Hernia in Patients With Ascites and Liver Cirrhosis, a Randomized Controlled Trial|CRUCIAL|Erasmus Medical Center|Yes|Recruiting|January 2011|December 2015|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||August 2011|August 22, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421550||99484|
NCT01421563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-SACL-I-001|Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers|A Randomized, Open-label, Two-Sequence, Two-Period Crossover Study to Assess the Pharmacokinetic Characteristics of Sarpogrelate HCl Controlled Release Tablet Compared With Sarpogrelate HCl Immediate Release Tablet in Healthy Male Subjects||Alvogen Korea|No|Completed|February 2011|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01421563||99483|
NCT01420562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7267|Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis|Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis||Universitaire Ziekenhuizen Leuven|No|Recruiting|September 2011|||March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|55|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients on the hematology ward who will receive an allogeneic stem cell transplantation.|February 2013|January 13, 2015|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01420562||99560|
NCT01420887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000601|Preservation of Joint Function Using Postoperative Continuous Passive Motion (CPM) A Pilot Study|Preservation of Joint Function Using Postoperative Continuous Passive Motion (CPM) A Pilot Study|CPM|Mayo Clinic|No|Not yet recruiting|September 2016|April 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|13 Years|N/A|No|||January 2016|January 15, 2016|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420887||99535|
NCT01421186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR202C101|A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma|A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma||MorphoSys AG|Yes|Recruiting|July 2011|May 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01421186||99512|
NCT01421524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-122-ST-001|Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma|A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier (PPM) CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.||Celgene|Yes|Recruiting|September 2011|October 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|274|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|August 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01421524||99486|
NCT01422252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100202|Evaluation of a Fall Detection Device in Isolated Elderly|Evaluation of Falls Occurring at Home in People Over 75 Equipped or Non-equipped With a Precocious Detection Device. Prospective Interventional Study.|VIGI91|Assistance Publique - Hôpitaux de Paris|No|Terminated|October 2011|August 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|33|||Both|76 Years|N/A|No|||April 2015|April 20, 2015|August 22, 2011||No|no more inclusions|No||https://clinicaltrials.gov/show/NCT01422252||99430|
NCT01422265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28066|Patient Reported Symptoms in Ovarian Cancer (PRECISION)|Patient Reported Symptoms in Ovarian Cancer||Genentech, Inc.||Completed|June 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Female|18 Years|N/A|No|Probability Sample|Patients with platinum-sensitive ovarian cancer in maintenance phase of second-line        treatment|March 2016|March 1, 2016|August 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01422265||99429|
NCT01422018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC11MISI0439|Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy|||Seoul St. Mary's Hospital|Yes|Recruiting|August 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||September 2011|September 22, 2011|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01422018||99448|
NCT01422811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aopr-rct-los|Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation|Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation||Azienda Ospedaliero-Universitaria di Parma|No|Completed|February 2008|February 2010|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|3862|||Both|N/A|N/A|No|||August 2011|August 23, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422811||99387|
NCT01423071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WI_PH+COPD_73/2011|Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life|Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität||Wissenschaftliches Institut Bethanien e.V|No|Completed|August 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|220|||Both|18 Years|N/A|No|Probability Sample|In- and out-patients at the investigational center|June 2015|June 17, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423071||99367|
NCT01423357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLACE|Targeting Interventions at Venues Where Risk of HIV Transmission is High|Targeting Interventions at Venues Where Risk of HIV Transmission is High|PLACE|University of Zambia|No|Completed|February 2009|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|537|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|August 24, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423357||99345|
NCT01424462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114107|Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.|An Open Label, Randomised Healthy Volunteer Study to Assess the Single Dose Safety and Pharmacokinetics of Three Modified Release Dosage Forms of Firategrast||GlaxoSmithKline|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2011|March 8, 2012|April 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01424462||99260|
NCT01431495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPP-study|Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)|Clinical Assessment of Pidogrel® Versus Plavix®|(CAPP)|Les Laboratoires des Médicaments Stériles|Yes|Completed|April 2010|July 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|N/A|No|||September 2011|September 8, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01431495||98723|
NCT01431781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02324789755|The Prophylactic Effect of Stilamin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis|A Prospective, Multi-center, Investigator Sponsored, Randomized Controlled Trial-- The Prophylactic Effect of Stilamin on Post-ERCP Pancreatitis||Changhai Hospital|Yes|Recruiting|August 2011|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|908|||Both|18 Years|N/A|No|||September 2011|September 25, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01431781||98701|
NCT01432002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG 07-153|FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer|Application of 18F-[FDG] PET/CT to Simulation and Planning of Radiotherapy (RT) for Breast Cancer. Definition of Target Volume for 3-D RT and for Partial Breast Irradiation (PBI) by IMRT Technique||University Hospital, Geneva|No|Active, not recruiting|November 2007|December 2015|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|19 Years|N/A|No|Non-Probability Sample|Women with operable clinically node-negative breast cancer|September 2014|September 7, 2014|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01432002||98684|
NCT01432223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMC-BC01|Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab|Phase II Study of Primary Chemotherapy With Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients With HER2 Positive Breast Cancer||Osaka Medical College|Yes|Completed|September 2011|May 2014|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Female|20 Years|70 Years|No|||April 2015|April 21, 2015|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01432223||98667|
NCT01432743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005126|Cartomerge Versus NavX Fusion in Catheter Ablation of Atrial Fibrillation|Cartomerge Versus NavX Fusion in Catheter Ablation of Atrial Fibrillation|CAVERN|Barts & The London NHS Trust|No|Completed|September 2007|April 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|80 Years|No|||September 2011|September 12, 2011|February 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01432743||98627|
NCT01420302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOGIC-Insulin 1.1.1.|LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness|LOGIC-Insulin Computerized Algorithm-guided Versus Nurse-directed Blood Glucose Control in Critically Ill Patients: the LOGIC-1 Randomized Controlled Trial|LOGIC-1|Katholieke Universiteit Leuven|Yes|Completed|August 2011|March 2012|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420302||99579|
NCT01420601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1771016|Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)|Torisel 25mg For Intravenous Drip Infusion Special Investigation - Survey On Long-term Use -||Pfizer|No|Completed|September 2011|September 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|127|||Both|18 Years|N/A|No|Probability Sample|Patients treated with Torisel (patients with metastatic and/or radically unresectable or        advanced renal cell carcinoma).|October 2015|October 12, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420601||99557|
NCT01423578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15245|Effects of Yoga and Cardiovascular Exercise on Smoking Motivation|Effects of Yoga and Cardiovascular Exercise on Smoking Motivation||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|August 2007|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|79|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423578||99328|
NCT01423825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 073E/SAAVI 102|Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)|A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 22, 2016|August 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01423825||99309|
NCT01423838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Solifenacin vs Oxybutynin|Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder|Comparison of Oxybutynin and Solifenacin in the Treatment of Overactive Bladder: a Randomized Controlled Multicenter Trial||Adana Numune Training and Research Hospital|Yes|Not yet recruiting|September 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Female|18 Years|70 Years|No|||August 2011|August 25, 2011|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423838||99308|
NCT01424098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Goldstein_OTSBalanceRCT_2012|Balance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized Controlled Trial of Balance Training in Patients With Chronic Obstructive Pulmonary Disease||West Park Healthcare Centre|No|Recruiting|August 2011|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|N/A|N/A|No|||August 2011|August 24, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01424098||99288|
NCT01424111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-CS-0007|Exploring Biomarkers for Depression|Exploring Biomarkers for Depression||Wyss Institute at Harvard University|No|Active, not recruiting|August 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients seeking treatment for Major Depressive Disorder at the Depression Clinical and        Research Program at Massachusetts General Hospital. This study also enrolls a limited        number of healthy controls.|December 2015|December 7, 2015|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01424111||99287|
NCT01422551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19930536|Facilitating Positive Adaptation to Breast Cancer|Facilitating Positive Adaptation to Breast Cancer||University of Miami|Yes|Completed|September 1999|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|240|||Female|21 Years|75 Years|No|||August 2011|August 22, 2011|August 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01422551||99407|
NCT01422564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL 006|Metal on Metal Versus Metal on Highly Crossed Linked Polyethylene Sytem|A Randomized Multicentre Clinical Trial Comparing The Metal on Metal Hip System Versus The Metal on Highly Crossed Linked Polyethylene System|MOM|Nova Scotia Health Authority|No|Terminated|January 2007|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|41|||Both|65 Years|N/A|No|||March 2014|May 14, 2015|August 12, 2011||No|Components were recalled by Depuy|No||https://clinicaltrials.gov/show/NCT01422564||99406|
NCT01421173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0407|Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies|Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Completed|August 2011|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|78|||Both|12 Years|65 Years|No|||November 2015|November 17, 2015|August 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01421173||99513|
NCT01421810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15298|Ovarian Contribution to Androgen Production in Adolescent Girls|Ovarian Contribution to Androgen Production in Adolescent Girls|CBS001|University of Virginia|No|Recruiting|December 2010|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Female|7 Years|18 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01421810||99464|
NCT01422031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-366|Study on Primary Care Health Service Utilization in Hong Kong|Utilization Pattern of Primary Health Care Services in Hong Kong - Does Having a Family Doctor Make Any Difference?||The University of Hong Kong|No|Completed|September 2007|August 2008|Actual|August 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3148|||Both|N/A|N/A|No|Non-Probability Sample|5174 eligible households were contacted by telephone but 1532 refused to be interviewed        and 494 did not complete the interview. 3148 (60.8%) subjects, with 1616 and 1532 in the        first and second phases, respectively, completed the cross-sectional survey. 1131 people        (480 by additional telephone sampling) were invited to the longitudinal study but only 708        eventually agreed to take part and 327 returned the diaries (all by completion). 319        subjects had complete cross-sectional and longitudinal data for the final analysis.|January 2015|January 23, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01422031||99447|
NCT01422278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2004.164|Rehabilitation of Conversion Gait Disorder|Patients With Conversion Gait Disorder - Effect on Treatment and Common Gait Patterns. Randomized Clinical Trial||Oslo University Hospital|Yes|Active, not recruiting|September 2007|December 2011|Anticipated|September 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|69 Years|No|||August 2011|August 22, 2011|January 16, 2006||No||No||https://clinicaltrials.gov/show/NCT01422278||99428|
NCT01422291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|serinken 002|IV Paracetamol, Dexketoprofen or Morphine for the Treatment of Low Back Pain|Pamukkale University Medical School,Dept. of Emergency Medicine||Pamukkale University|No|Completed|January 2011|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|120|||Both|16 Years|55 Years|No|||August 2011|August 22, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422291||99427|
NCT01422525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT-TET|Changes of the Peripapillary Retinal Nerve Fiber Layer After Filtration Surgery in Glaucoma Patients|Effect of Trabeculectomy on Peripapillary Retinal Nerve Fiber Layer Thickness Using Spectral Domain Optical Coherence Tomography||University Eye Hospital, Würzburg|No|Terminated|November 2011|||February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|N/A|No|Probability Sample|glaucoma patients|December 2014|December 1, 2014|August 21, 2011||No|short of study staff|No||https://clinicaltrials.gov/show/NCT01422525||99409|
NCT01422837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-025|ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry|VIvitrol's Cost and Treatment Outcomes RegistrY|VICTORY|Alkermes, Inc.|No|Completed|August 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|403|||Both|18 Years|N/A|No|Non-Probability Sample|The VIVITROL Registry will enroll patients who have been prescribed VIVITROL for the        prevention of relapse to opioid dependence, following opioid detoxification.|August 2014|August 6, 2014|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422837||99385|
NCT01423084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_41|Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years|A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years||Novartis|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|344|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|August 23, 2011||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01423084||99366|None reported
NCT01420367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1123-7877|Are Post-operative Antibiotics Indicated in Simple Appendicitis?|Are Post-operative Antibiotics Indicated in Simple Appendicitis? A Prospective Randomized Trial||Monash University|No|Not yet recruiting|November 2011|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|4 Years|17 Years|No|||August 2011|August 18, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420367||99574|
NCT01431794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1130|Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma|Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma.||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2011|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|52|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|July 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431794||98700|
NCT01432015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOA-NVM1|Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting|A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer||Gynecologic Oncology Associates|No|Completed|September 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|N/A|No|||May 2015|May 22, 2015|September 7, 2011||No||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01432015||98683|
NCT01431820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-1009-S|Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis|Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study|SOLUTION|Topica Pharmaceuticals|No|Completed|May 2012|August 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|334|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01431820||98698|
NCT01432236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081275|A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression|A Phase 3b Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study Of Pregabalin In The Treatment Of Fibromyalgia With Concurrent Antidepressant Therapy For Comorbid Depression (Protocol A0081275)||Pfizer|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|September 8, 2011|Yes|Yes||No|May 12, 2014|https://clinicaltrials.gov/show/NCT01432236||98666|
NCT01432457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2061028|Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)|A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder||Pfizer|No|Completed|October 2011|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|924|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|September 9, 2011|Yes|Yes||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01432457||98649|
NCT01432470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OxyPeP-001|Study of Oxytocin to Treat Vaginal Atrophy in Postmenopausal Women|A Double-blind, Placebo Controlled Multi-centre Study to Evaluate the Effects of Topical Oxytocin on Vaginal Atrophy in Postmenopausal Women||PeP-Tonic Medical AB|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Female|40 Years|N/A|No|||September 2011|September 12, 2011|August 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01432470||98648|
NCT01433055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00048900|Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients|Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients||University of Maryland|Yes|Completed|July 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2014|January 27, 2014|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01433055||98604|
NCT01420614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-03ER|RadIal Versus Femoral InvEstigation in ST Elevation Acute Coronary Syndrome|RadIal Versus Femoral Randomized InvEstigation in ST Elevation Acute Coronary Syndrome|RIFLE-STEACS|Policlinico Casilino ASL RMB|No|Active, not recruiting|January 2009|July 2012|Anticipated|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1001|||Both|18 Years|N/A|No|||February 2012|February 5, 2012|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01420614||99556|
NCT01424410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERI019729-THRASHER|Health Benefits of Repeated Treatment in Pediatric Schistosomiasis|Health Benefits of Repeated Treatment in Pediatric Schistosomiasis||University of Edinburgh|No|Completed|February 2012|November 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|360|||Both|1 Year|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Zimbabwean children|June 2015|June 4, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01424410||99264|
NCT01420276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gbpk1|Female Sexual Function and Back Pain|||Bezmialem Vakif University||Not yet recruiting|September 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|54|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Female with active sexual life|August 2011|August 18, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420276||99581|
NCT01420289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-HPIPC-09|Effect of HPIPC for the Treatment of Ischemic Ulcers in Subjects With PAD|A Randomized, Controlled Trial to Evaluate High Pressure Rapid Sequence, Intermittent Pneumatic Compression (HPIPC) for the Treatment of Intermittent Claudication, Pain and Ulcer Healing in Subjects With PAD||Calvary Hospital, Bronx, NY|No|Completed|January 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|90 Years|No|||August 2011|January 6, 2012|August 18, 2011||No||No|August 22, 2011|https://clinicaltrials.gov/show/NCT01420289||99580|
NCT01421823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDD 111|A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence|||RDD Pharma Ltd|No|Withdrawn|August 2011|||April 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||December 2013|December 11, 2013|August 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01421823||99463|
NCT01422044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402/2009BO2-1|Risk Prediction in Aortic Stenosis|Risk Prediction in Aortic Stenosis by Cardiac Autonomic Function|PREDICT-AS|Thebiosignals.com|No|Completed|September 2009|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|423|||Both|N/A|N/A|No|Non-Probability Sample|Patients with at least moderate aortic stenosis|February 2014|February 5, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01422044||99446|
NCT01422057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402/2009BO2-2|Risk Prediction in Type II Diabetics With Ischemic Heart Disease|Risk Prediction in Type II Diabetics With Ischemic Heart Disease by Cardiac Autonomic Function||Thebiosignals.com|No|Recruiting|January 2010|January 2016|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|80 Years|No|Non-Probability Sample|Consecutive patients with diagnose of ischemic heart disease and type-2 diabetes are        included.|February 2014|February 5, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01422057||99445|
NCT01423396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008_28/0914|Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease|Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease|COVARAD|University Hospital, Lille|Yes|Recruiting|March 2010|January 2020|Anticipated|January 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|406|||Both|60 Years|N/A|No|||December 2015|December 3, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423396||99342|
NCT01422538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-113|Ultherapy™ Treatment Following Sculptra® Treatment|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Following Sculptra® Treatment||Ulthera, Inc|No|Completed|May 2011|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|August 22, 2011|Yes|Yes||No|June 19, 2013|https://clinicaltrials.gov/show/NCT01422538||99408|Entrance criteria possibly restricted to a population with too little skin laxity to assess a difference.Group C time from Sculptra to Ultherapy may be too long to discern any added benefit of both treatments.
NCT01422824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25067|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis|An Observational. Non-interventional Study to Observe the Safety and Efficacy of MIRCERA in the Treatment of Chronic Renal Anemia in Maintenance ESA Treated Patients on Haemodialysis (STABILE)||Hoffmann-La Roche||Completed|June 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|185|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic renal anemia on haemodialysis in maintenance ESA treatment|November 2015|November 2, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422824||99386|
NCT01423916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-242|Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder|A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|July 2011|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|218|||Both|18 Years|55 Years|No|||September 2015|September 29, 2015|August 8, 2011|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01423916||99302|
NCT01424202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIEICU-08112010|Effects of Mechanical Insufflation-Exsufflation in Preventing Respiratory Failure After Extubation|Effects of Mechanical Insufflation-Exsufflation in Preventing Respiratory Failure After Extubation|MIEICU|Hospital Sao Joao|No|Completed|September 2008|October 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|92|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424202||99280|
NCT01424228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0001-C401|Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years|A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Long-term Treatment (24 Weeks) With Prucalopride in Subjects Aged ≥18 Years With Chronic Constipation|SPD555-401|Shire|No|Completed|June 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|364|||Both|18 Years|N/A|No|||April 2014|August 13, 2014|August 25, 2011||No||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01424228||99278|
NCT01424241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAC0246|Effects of Sandostatin LAR® in Acromegaly|Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range||Columbia University|No|Active, not recruiting|August 2006|August 2013|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2012|August 8, 2012|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01424241||99277|
NCT01431560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|National Police Hospital|Outcomes of Operative Treatment of Unstable Ankle Fracture - Comparison Between Metallic and Biodegradable Implants|Outcomes of Operative Treatment of Unstable Ankle Fracture - Comparison Between Metallic and Biodegradable Implants||National Police Hospital|Yes|Completed|June 2008|August 2011|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|16 Years|N/A|No|||September 2011|September 8, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01431560||98718|
NCT01431807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-472/OCT-001|Long-term Study of SYR-472|An Open-label, Multicenter, Long-term Phase 3 Study to Evaluate the Safety and Efficacy of Long-term Treatment With SYR-472 in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Diet and/or Exercise Therapies or Treatment With an Existing Oral Anti-diabetic Drug Added to Diet and/or Exercise Therapies||Takeda|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|680|||Both|20 Years|N/A|No|||November 2013|November 5, 2013|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01431807||98699|
NCT01432028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05053|Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women|Polymorphisms in Genes Encoding the Estrogen Metabolism Enzymes and Effects of Hormone Therapy for Oral Low Dose or Not Oral on Variables Related Endothelial Function, Inflammation and Metabolic Profile in Patients in Recent Menopause Study Pharmacogenetic||Federal University of Rio Grande do Sul|No|Completed|March 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Female|42 Years|58 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01432028||98682|
NCT01432249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801135|Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis|Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis||Pfizer|No|Withdrawn|March 2013|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|8 Years|17 Years|No|Non-Probability Sample|pediatric patients (ages of 8~17)|November 2013|November 14, 2013|August 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01432249||98665|
NCT01432483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7272-A001-401|Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)|Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)||Eisai Inc.||No longer available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||January 2015|January 22, 2015|September 7, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01432483||98647|
NCT01432756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R34MH090790-02|A South African Pilot Worksite Parenting Program to Prevent HIV Among Adolescents|A South African Pilot Worksite Parenting Program to Prevent HIV Among Adolescents||Children's Hospital Boston|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|132|||Both|11 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 7, 2015|September 7, 2011||No||No|July 10, 2015|https://clinicaltrials.gov/show/NCT01432756||98626|
NCT01432769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1001-24|Enteral Nutrition After Cardiovascular Surgery|Effect of Enteral Nutrition in the Outcome of Patients With Cardiovascular Surgery||Instituto Mexicano del Seguro Social|Yes|Recruiting|January 2011|March 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||September 2011|September 9, 2011|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01432769||98625|
NCT01429363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC 760-220411|Targeted Disc Decompression (TDD) for Contained Herniated Lumbar Discs|Targeted Disc Decompression (TDD) for Contained Herniated Lumbar Discs. A Prospective Clinical Series|TDD|Rijnstate Hospital|No|Recruiting|August 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||September 2011|May 4, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429363||98886|
NCT01429376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC-607-070409|Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, and Systemic Inflammation in Chronic Heart Failure With or Without COPD|1) Pulmonary Function in CHF; 2) COPD Prevalence, Underdiagnosis and Overdiagnosis in CHF Patients and Its Independent Predictors; 3) Are There Signs of Systemic Inflammation in CHF With or Without COPD?||Rijnstate Hospital|No|Completed|October 2009|June 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|234|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429376||98885|
NCT01421251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICID-2011-H1N1-01|H1N1 Vaccine Safety in Manitoba, Canada|The Safety of GSK Biological's H1N1 Pandemic Vaccine in Manitoba, Canada||International Centre for Infectious Diseases, Canada|No|Active, not recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800000|None Retained|None collected|Both|6 Months|N/A|No|Non-Probability Sample|Residents of the Province of Manitoba, population approximately 1.2 million|September 2012|September 11, 2012|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421251||99507|
NCT01421264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU3280611A|Gabapentin's Effects on Insomnia in Patients With Recent Concussion|||University at Buffalo|No|Completed|August 2011|June 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|14 Years|N/A|No|||June 2013|June 21, 2013|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01421264||99506|
NCT01420900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|man2if|Ceramic-on-Ceramic Total Hip Arthroplasty and Squeaking: Influence of Component Design|Ceramic-on-Ceramic Total Hip Arthroplasty and Squeaking: A Prospective, Blinded, Randomized Clinical Trial of Influence of Component Design||Vejle Hospital|No|Recruiting|September 2011|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|204|||Both|18 Years|64 Years|No|||December 2015|December 10, 2015|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01420900||99534|
NCT01420913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YCD207|Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects|Randomized,Open-label,Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects||Yuhan Corporation|No|Completed|August 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|28|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2011|August 19, 2011|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01420913||99533|
NCT01421199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTO-Myr|Device Study to Evaluate the Detection and Characterization of Middle Ear Fluid in Children|A Prospective, Multi Center, Non-randomized Clinical Trial to Evaluate the Ear Effusion Detection and Characterization System (EEDCS) to Detect and Characterize Middle Ear Fluid in Children||OtoSonics Inc.|No|Not yet recruiting|September 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|125|||Both|6 Months|17 Years|No|||August 2011|August 19, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01421199||99511|
NCT01421212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nabi-4204|Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation|Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine||Biotest Pharmaceuticals Corporation|No|Completed|November 1999|February 2002|Actual|February 2002|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|||Actual|30|||Both|18 Years|N/A|No|||August 2011|August 19, 2011|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421212||99510|
NCT01422070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-2011|European Mortality & Length Of Intensive Care Unit (ICU) Stay Evaluation (ELOISE)|A Multi-centre European Observational Study to Assess Whether Patients Admitted to the ICUs With Availability of Intermediate Care Unit (IMCU) Have Lower Hospital Mortality Than Those Admitted to the ICUs Without Availability of IMCU|ELOISE|Università degli Studi di Ferrara|No|Completed|November 2011|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6433|||Both|16 Years|N/A|No|Probability Sample|All adult patients consecutively admitted to the Study Units during one month (from 7th        November to 4th December 2010)|July 2015|July 31, 2015|August 19, 2011||No||No|February 12, 2015|https://clinicaltrials.gov/show/NCT01422070||99444|
NCT01422850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV002|Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy|A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering Repeated Doses of ALECSAT to Prostate Cancer Patients.|ALECSAT|CytoVac A/S|No|Completed|August 2011|October 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|N/A|No|||March 2014|March 26, 2014|August 23, 2011||No||No|August 5, 2013|https://clinicaltrials.gov/show/NCT01422850||99384|
NCT01423097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RPO-XXX-2011/2|Magnitude of Osteoarthritis disadVantage on pEoples liveS|Magnitude of Osteoarthritis disadVantage on pEoples liveS|MOVES|AstraZeneca|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|1015|||Both|45 Years|N/A|No|Probability Sample|community sample|October 2012|October 9, 2012|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423097||99365|
NCT01423110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338X2205|Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis|A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis||Novartis||Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|40 Years|80 Years|No|||August 2012|August 16, 2012|August 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423110||99364|
NCT01423123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP FB-8|Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer|A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer||NSABP Foundation Inc|No|Completed|May 2011|March 2014|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|N/A|No|||July 2014|July 7, 2014|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423123||99363|
NCT01423409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVA SOURD study|Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People|Assessment of an Innovative Visual Analogue Scale of Pain (Pictorial VAS) Versus the Usual VAS (VAS) Among Deaf People|EVA_SOURD|University Hospital, Grenoble|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|289|||Both|18 Years|N/A|No|||April 2013|July 22, 2013|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01423409||99341|
NCT01423656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 29102-C06|Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102|||LEO Pharma|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|102|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01423656||99322|
NCT01424215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/08/VA01|The Use of Fluorescent Imaging for Intraoperative Cholangiogram During Laparoscopic Cholecystectomy|The Use of Fluorescent Imaging for Intraoperative Cholangiogram During Laparoscopic Cholecystectomy||Maimonides Medical Center|Yes|Completed|January 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|65 Years|No|||August 2015|August 12, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01424215||99279|
NCT01424475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114500|LRRK2 Mutation and Parkinson's Disease|LRRK2 Mutation and Parkinson's Disease: A Functional Neuroimaging and Behavioural Study Characterising the Neurocognitive Phenotype||GlaxoSmithKline|No|Terminated|August 2011|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|June 23, 2011||No|Following extensive efforts to increase recruitment, it will not be possible to complete the    study protocol within a reasonable time|No||https://clinicaltrials.gov/show/NCT01424475||99259|
NCT01424501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114886|Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease|Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease||GlaxoSmithKline||Terminated|November 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|142|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||April 2015|December 3, 2015|August 25, 2011|Yes|Yes|Due to a safety signal found at a planned interim safety review, further conduct of this    safety study is not recommended hence the study was terminated.|No||https://clinicaltrials.gov/show/NCT01424501||99257|
NCT01424514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114974|SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis|A Randomised, Double Blind Placebo Controlled, 2 Way Cross Over Study in Adults With Non-allergic Rhinits to Evaluate the Effect of Once Daily Administration of Intranasal SB-705498 12mg for Two Weeks and the Response to a Chamber Challenge of Cold Dry Air||GlaxoSmithKline|No|Completed|December 2010|May 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||March 2012|March 29, 2012|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01424514||99256|
NCT01432262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851048|13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico|A Phase 3, Open Label, Single Arm, Multicenter, Trial to Assess The Safety, Tolerability And Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine In Healthy Adults Aged => 50 Years of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine in Mexico.||Pfizer|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|324|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 18, 2013|June 22, 2011|Yes|Yes||No|December 4, 2012|https://clinicaltrials.gov/show/NCT01432262||98664|
NCT01432782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BotoxDES|Botulinum Toxin Injection to Treat Diffuse Esophageal Spasm|Prospective Randomised Double-blind Sham Study on the Use of Botox for the Treatment of Diffuse Esophageal Spasm|Botox|Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||September 2011|September 9, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01432782||98624|
NCT01433068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBTXR3-101|NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity|An Open-Label, Single Arm, Feasibility And Safety Phase I Study With Nbtxr3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall||Nanobiotix|Yes|Completed|October 2011|February 2015|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433068||98603|
NCT01433081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00032878|The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients|The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients||Northwestern University|No|Completed|February 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|64 Years|No|||February 2014|February 19, 2014|September 9, 2011|Yes|Yes||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01433081||98602|We only examined subjects with normal kidney function that were at low risk for magnesium toxicity. It is possible that the current intervention regimen could have led to toxic levels in higher risk patients.
NCT01429090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAMB0199|Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution|||University Medicine Greifswald||Completed|October 1999|January 2000|Actual|November 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2011|September 2, 2011|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429090||98907|
NCT01429649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kj2011001|Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO)|A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity|pGGO|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|Yes|Recruiting|September 2011|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||September 2011|September 6, 2011|September 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01429649||98864|
NCT01421589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000770|Growth Hormone Treatment on Phosphocreatine Recovery in Obesity|The Effects of Short Term Growth Hormone Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity||Massachusetts General Hospital|Yes|Completed|September 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|60 Years|No|||May 2014|May 29, 2014|August 19, 2011||No||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01421589||99481|
NCT01420926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-02987|Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia|A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients ≥ 60 Years Old With Acute Myeloid Leukemia (AML)||National Cancer Institute (NCI)||Active, not recruiting|November 2011|||June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|60 Years|N/A|No|||January 2016|March 14, 2016|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420926||99532|
NCT01420939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110213|Developing Therapies for Traumatic Brain Injury|Biomarkers-Driven Development of Experimental Therapeutics for Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Terminated|July 2011|May 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|19|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|November 27, 2013|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01420939||99531|
NCT01421576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-SACL-I-002|Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions|A Randomized, Single-dose, 2-sequence, 2-period Crossover Study to Investigate the Food-effect Pharmacokinetics of Sarpogrelate HCl Controlled Release Tablet in Healthy Male Subjects||Alvogen Korea|No|Completed|July 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01421576||99482|
NCT01421225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00000231|Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age|Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age||Children's Hospital Boston|No|Recruiting|August 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Both|6 Months|7 Years|No|||August 2011|August 19, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421225||99509|
NCT01421238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB8193|Framing and Decision Making in Neonatology|Framing and Perinatal Decision Making at Extremes of Prematurity||Columbia University|No|Completed|May 2006|April 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|350|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01421238||99508|
NCT01422330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017860|A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients|An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etravirine (ETR) in Combination With Other Antiretrovirals (ARVs) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects||Janssen R&D Ireland|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|211|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|May 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01422330||99424|
NCT01422863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIZA|Lifestyle Interventions for Seniors With Apnea|Effects of Weight Loss Through Diet and Exercise on Sleep Apnea Severity and Cardiovascular Risk in Older Adults||Johns Hopkins University|Yes|Recruiting|October 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|60 Years|75 Years|Accepts Healthy Volunteers|||August 2011|August 23, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422863||99383|
NCT01423422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|frequency medicine for angina|Effects of Low Frequency Magnetic Field on Exercise Induced Angina|Effects of Low Frequency Electromagnetic Field on Patients With Exercise Induced Angina||Aerotel Ltd|No|Not yet recruiting|November 2011|October 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|35 Years|75 Years|No|Non-Probability Sample|Patients enrolled at the Cardiac Rehabilitation Institute, sheba Medical Center|August 2011|August 25, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423422||99340|
NCT01423929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001452-11|Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion|Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion|SOCCER|Region Skane|No|Active, not recruiting|January 2012|January 2016|Anticipated|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||November 2015|November 18, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01423929||99301|
NCT01423955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001673-70|Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery|EPO to Protect Renal Function After Cardiac Surgery. A Phase II Double Blind Randomized Controlled Study.|EPRICS|Region Skane|No|Completed|October 2011|April 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423955||99299|
NCT01420757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLIBRI trial|Laparoscopic Versus Open Incisional Hernia Repair|Laparoscopic Versus Open Incisional Hernia Repair : A Randomized Clinical Trial|COLIBRI|Erasmus Medical Center|Yes|Completed|May 1999|July 2011|Actual|December 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||August 2011|August 19, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01420757||99545|
NCT01432795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH2010-0329/5|Practicability of Gliding Aids for Medical Compression Stockings|Gliding Aids for Medical Compression Stockings - Practicability in Elderly Patients With Chronic Venous Insufficiency||University of Zurich|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|65 Years|N/A|No|||June 2013|June 21, 2013|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01432795||98623|
NCT01432821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-27|Blinking and Yawning in Epilepsy: The Role of Dopamine|Dopaminergic Reactivity In Idiopathic Generalized Epilepsy: A "Proof Of Concept" Clinical, Pharmacological And Neurophysiological Study|BYE BYE DOPA|Institut National de la Santé Et de la Recherche Médicale, France|No|Active, not recruiting|September 2011|April 2016|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01432821||98622|
NCT01433094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIFA FARM892ZXE|Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia|Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia|SPERA-S|University of Cagliari|Yes|Recruiting|September 2012|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|55 Years|No|||May 2015|May 27, 2015|August 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01433094||98601|
NCT01433107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|727-D-301|Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis||Novartis|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|290|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|September 8, 2011||No||No|April 8, 2013|https://clinicaltrials.gov/show/NCT01433107||98600|
NCT01429103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Weber K23|Hormones and Cognition in the Menopausal Transition|Hormones and Cognition in the Menopausal Transition||University of Rochester|No|Active, not recruiting|May 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|90|Samples Without DNA|Subjects will have 20 mL of blood drawn by venipuncture by a trained nurse|Female|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women between the ages of 40 and 60.|August 2015|August 18, 2015|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01429103||98906|
NCT01429389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-T21-107|Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy|Collection of Whole Blood Specimens From Pregnant Women at Increased Risk of Fetal Chromosomal Aneuploidy for Use in Development of the SEQureDx Trisomy 21 Test in the Detection of the Relative Quantity of Chromosome 21 Circulating Cell-Free DNA Extracted From Maternal Plasma||Sequenom, Inc.|No|Recruiting|May 2011|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole blood specimens will be collected and processed to plasma. DNA will be extracted from      the plasma.|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women between 10 and 22 weeks of gestation who are scheduled to undergo a CVS or        amniocentesis procedure and will receive the fetal FISH, karyotype and/or QF-PCR results        from the procedure.|September 2015|September 15, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429389||98884|
NCT01429948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-02-046|Identification the Cause of Silent Cerebral infarctiON in Healthy Subjects (ICONS)|Novel Biomarkers for Personalized Therapy in Korean Patients With Ischemic Stroke|ICONS|Samsung Medical Center|Yes|Completed|April 2008|May 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|581|||Both|20 Years|N/A|No|Probability Sample|Tertiary Hospital|September 2011|September 6, 2011|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01429948||98842|
NCT01429961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1010-054-336|Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma|Phase II Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma||Seoul National University Hospital|No|Recruiting|May 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||September 2011|September 6, 2011|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01429961||98841|
NCT01422083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/372|Glenohumeral Internal Rotation Deficit (GIRD)|Correlation Between Loss of Internal Rotation Range of Motion and Size of the Subacromial Space and the Influence of a Home Stretching Program.|GIRD|University Ghent|No|Recruiting|September 2010|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422083||99443|
NCT01421836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-03-101-001|Prospective Study Comparing EUS vs ERCP Stent Insertion for Malignant Biliary Obstruction|Prospective Study Comparing EUS Guided Biliary Drainage and ERCP With Stent Placement for Malignant Biliary Obstruction||Samsung Medical Center|No|Recruiting|May 2011|August 2014|Anticipated|August 2013|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421836||99462|
NCT01422304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07038|Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)|A Randomized, Controlled, Parallel-group, Double-blind Trial of Sugammadex or Usual Care (Neostigmine or Spontaneous Recovery) for Reversal of Rocuronium- or Vecuronium-induced Neuromuscular Blockade in Patients Receiving Thromboprophylaxis and Undergoing Hip Fracture Surgery or Joint (Hip/Knee) Replacement (Protocol No. P07038)||Merck Sharp & Dohme Corp.|Yes|Completed|October 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1198|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|August 22, 2011|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01422304||99426|
NCT01422317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OFAMI1995|Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction|Effects of a High-dose Concentrate of n-3 Fatty Acids or Corn Oil Introduced Early After an Acute Myocardial Infarction on Serum Triacylglycerol and High-density Lipoprotein (HDL)- Cholesterol|OFAMI|Helse Stavanger HF|Yes|Completed|September 1995|December 2002|Actual|December 1997|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|N/A|No|||February 2012|February 18, 2012|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01422317||99425|
NCT01422577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-NBI|Diagnosis of Colonic Adenomas by Bright Narrow Band Imaging (B-NBI)|A Randomized Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in the Diagnosis of Colonic Adenomas in Asymptomatic Subjects Undergoing Screening Colonoscopy||Chinese University of Hong Kong|No|Completed|October 2010|March 2014|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1006|||Both|40 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01422577||99405|
NCT01422590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-071|Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin|Pharmacodynamics After Concomitant Administration With Mitiglinide and Sitagliptin Compared to Mitiglinide, Sitagliptin Single Administration in Patients With Type 2 Diabetes||Samsung Medical Center|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|20 Years|70 Years|No|||September 2011|September 6, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01422590||99404|
NCT01422876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1275.1|Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients|A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|August 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|1405|||Both|18 Years|N/A|No|||March 2015|April 1, 2015|August 23, 2011||||No|January 15, 2015|https://clinicaltrials.gov/show/NCT01422876||99382|
NCT01423136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009521-01H|Remote Electrocardiographic (ECG) ST-Monitoring (PROSE 3)in Post-op Patients|Postop Remote ECG ST-Monitoring (PROSE 3)|PROSE 3|Ottawa Hospital Research Institute|No|Completed|October 2010|October 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|89|||Both|55 Years|N/A|No|Probability Sample|Patients under-going non-cardiac Sx with moderate to high risk of postoperative        cardiovascular complications|May 2014|May 30, 2014|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01423136||99362|
NCT01423149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMD-213|Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia|A Phase II, Dose Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of Combretastatin A4 Phosphate for Treating Subfoveal Choroidal Neovascularization in Subjects With Pathologic Myopia||OXiGENE|Yes|Completed|March 2005|January 2007|Actual|January 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|50 Years|No|||October 2011|October 28, 2011|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423149||99361|
NCT01423435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|533-CL-006|Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males|A Pharmacokinetic Study of TRK-100STP -A Single Oral Administration Study in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males -||Astellas Pharma Inc|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|36|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||October 2011|October 2, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423435||99339|
NCT01423448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMHR-123|Effectiveness of an Online Bulletin Board for Depression: a Longitudinal Randomized Controlled Trial|A Randomized Controlled Trial of an Online Bulletin Board for Depression|ShareIT|Australian National University|No|Withdrawn||||||Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|August 23, 2011||No|Recruitment of participants did not commence due to lack of available staff to run the trial.|No||https://clinicaltrials.gov/show/NCT01423448||99338|
NCT01423708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1956P|Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study|Terapia Con Everolimus Nel Trapianto de Novo di Fegato: Uno Studio Multicentrico Randomizzato|EPOCAL|Azienda Ospedaliera di Padova|Yes|Recruiting|February 2010|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|117|||Both|18 Years|70 Years|No|||July 2012|July 17, 2012|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01423708||99318|
NCT01423682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/482|The Influence of Eccentric Training on the Volume and Vascularisation of the Rotator Cuff in Patients With Rotator Cuff Tendinopathy and Healthy Subjects|The Influence of Eccentric Training on the Volume and Vascularisation of the Rotator Cuff in Patients With Rotator Cuff Tendinopathy and Healthy Subjects||University Ghent|No|Recruiting|April 2012|June 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423682||99320|
NCT01424280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UR2115642|Single Dose Study of GSK1440115 in Patients With Asthma|A Phase 1, Randomized, Placebo Controlled, Crossover Study to Evaluate the Efficacy of GSK1440115 After a Single Oral Dose in Patients With Asthma||Accenture|No|Completed|August 2011|||November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|65 Years|No|||December 2011|December 1, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01424280||99274|
NCT01423669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epi-2010|Epidemiology Study of Psychosis|The Hong Kong Morbidity Survey 2010 Part 3: Epidemiology Study of Psychosis Disorder and Sub-clinical Psychotic Experiences||The University of Hong Kong|No|Recruiting|August 2010|December 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|5000|||Both|16 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|The sample for this survey is planned to represent community dwelling adult population in        Hong Kong. The age range will be from 16-75 years. People residing in institutions will        not be covered. The survey will adopt a multi-stage sampling design. The sampling frame        will consist of a random selection of addresses quarters generated with the help of the        Censes and Statistics Department of the Government of Hong Kong SAR. The addresses would        be stratified with geographical location and nature of premises. For each address        identified, an advance letter with return envelop or contact information will be sent. The        advance letter will inform the residents about the nature of the study with an invitation        for participation.|August 2011|August 25, 2011|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01423669||99321|
NCT01423942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0215-11|Maturation of the Autonomic Nervous System in Prematures|Maturation of the Autonomic Nervous System in Prematures||Rambam Health Care Campus|No|Completed|October 2011|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|||Both|N/A|100 Days|Accepts Healthy Volunteers|Probability Sample|Prematures|May 2015|May 7, 2015|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423942||99300|
NCT01424254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC#03-025|The Effectiveness of Video-capsule Endoscopy in Gastrointestinal Bleeding of Obscure Origin|||McGill University Health Center|No|Completed|October 2003|March 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|79|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01424254||99276|
NCT01421407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU/E/HPT2/Jan2011|Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism|Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Uncontrolled Secondary Hyperparathyroidism in Chronic Haemodialysis Patients||Theraclion|No|Withdrawn|August 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01421407||99495|
NCT01433120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-244 LuCamp|Targeting the Gut Microbiome to Investigate the Pathways of Progression From Obesity to Metabolic Diseases in an At-risk Population.|Targeting the Gut Microbiome to Investigate the Pathways of Progression From Obesity to Metabolic Diseases in an At-risk Population.||University of Copenhagen|No|Completed|September 2011|August 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|58|||Female|40 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01433120||98599|
NCT01429116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-3204|Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception|An Extension Open-Label Safety Study of a 24-month 20 mg Dose Regimen of Tasimelteon for the Treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception Who Have Enrolled in Other Tasimelteon Clinical Trials||Vanda Pharmaceuticals|No|Completed|October 2011|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|August 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429116||98905|
NCT01429129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029/2011|Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers|Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers||Centre for Addiction and Mental Health|No|Completed|May 2012|May 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1000|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429129||98904|
NCT01429402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-2237C|Botulinum Toxin to Improve Results in Cleft Lip Repair|Botulinum Toxin to Improve Results in Cleft Lip Repair||Chang Gung Memorial Hospital|Yes|Recruiting|July 2000|August 2013|Anticipated|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|3 Months|45 Years|No|||August 2011|September 6, 2011|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01429402||98883|
NCT01429662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRLE-HTN|Modified Relaxation (MR) Technique for Treating Hypertension in Postmenopausal Women|Phase 3 Study of Modified Relaxation (MR) Technique for Treating Hypertension in Postmenopausal Women||Chiang Mai University|Yes|Completed|August 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|429|||Female|45 Years|65 Years|No|||May 2012|May 27, 2012|September 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01429662||98863|
NCT01429415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000024908|Magnesium Nebulization Utilization in Management of Pediatric Asthma|Magnesium Nebulization Utilization in Management of Pediatric Asthma|MAGNUMPA|The Hospital for Sick Children|Yes|Recruiting|September 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|816|||Both|2 Years|17 Years|No|||November 2015|November 19, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429415||98882|
NCT01421615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ board of health|Effect of Different Courses of Lactobacilli Treatment on Bacterial Vaginosis and Pregnancy Outcomes|Effect of Different Courses of Lactobacilli Treatment on Bacterial Vaginosis and Related Pregnancy Outcomes|BV|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine|Yes|Recruiting|January 2011|May 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|5000|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||August 2011|August 22, 2011|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421615||99479|
NCT01421849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/381|Mandibular Single Implant Overdenture: a Prospective Clinical Trial|Patient Satisfaction and Clinical Outcomes Following Mandibular Single-implant-retained Overdenture Treatment in Residents of Nursing Homes: a Prospective Clinical Trial||University Hospital, Ghent|No|Active, not recruiting|August 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|70 Years|90 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01421849||99461|
NCT01422096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBS007|Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess|Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)||University of Virginia|No|Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|7 Years|18 Years|No|||June 2012|June 12, 2012|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01422096||99442|
NCT01422109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14659-101|Comparative Pharmacokinetics of YH14659|Comparative Pharmacokinetics After Single Oral Administration of YH14659, a Fixed Dose Combination Versus Coadministration of Separate Constituents in Healthy Male Volunteers|YH14659|Yuhan Corporation|Yes|Completed|July 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 5, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01422109||99441|
NCT01422356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSHC-174/10|Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men|Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men|HYPER|The Alfred|No|Completed|September 2010|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Genital samples (genital swabs from anus, penis), oral rinse, and serum.|Male|16 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young same sex attracted men 16-20 years of age from Melbourne|December 2013|December 19, 2013|August 16, 2011||No||No|October 27, 2013|https://clinicaltrials.gov/show/NCT01422356||99422|The findings from this study may or may not extend to other populations of teenage MSM.
NCT01422889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2065|ION US Post-Approval Study|A U.S. Post-Approval Study of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System||Boston Scientific Corporation|No|Completed|September 2011|February 2015|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1120|||Both|18 Years|110 Years|No|Non-Probability Sample|Consented subjects admitted to the cardiac catheterization laboratory for percutaneous        transluminal coronary angioplasty and who are eligible to receive an ION™        Paclitaxel-Eluting Platinum Chromium Coronary Stent.|January 2016|January 6, 2016|August 22, 2011|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT01422889||99381|
NCT01423162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP 1009|Iron Bioavailability of Fortified Oat Drink|Iron Bioavailability Study Of Fortified Oat Drink||PepsiCo Global R&D|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|21|||Both|6 Years|6 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|August 23, 2011||No||No|August 22, 2012|https://clinicaltrials.gov/show/NCT01423162||99360|One of the isotopes was not detected in blood sample of 1 participant, therefore data from this participant was excluded from final per protocol analysis
NCT01423175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClAraC-SCT-01|ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS|Randomized, Multi-centre, Phase II Trial to Compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients With High Risk AML or Advanced MDS Scheduled for Allogeneic Stem Cell Transplantation|ClAraC-SCT|Hannover Medical School|No|Recruiting|July 2011|||January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||August 2011|August 26, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423175||99359|
NCT01423981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tirgan 11-01|Web Based Investigation of Natural History of Keloid; An Online Survey of Patients With Keloid|Web Based Investigation of Natural History of Keloid; An Online Survey of Patients With Keloid||Tirgan, Michael H., M.D.|No|Active, not recruiting|November 2011|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|10000|||Both|N/A|N/A|No|Non-Probability Sample|Patients with keloid disorder.|November 2014|November 14, 2014|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01423981||99297|
NCT01424267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-006|Zenith® LP Abdominal Aortic Aneurysm (AAA) Post-Market Registry|Zenith® LP AAA Endovascular Graft Post-Market Registry||Cook||Terminated|July 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with a CE-Marked Zenith® Low Profile AAA Endovascular Graft|October 2012|October 10, 2012|August 23, 2011||No|The registry was discontinued due to significant resources required.|No||https://clinicaltrials.gov/show/NCT01424267||99275|
NCT01424527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115114|Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation Study|Validation of the New COPD Assessment Test Translated Into Korean in Patients With Chronic Obstructive Pulmonary Disease|CAT|GlaxoSmithKline|No|Completed|December 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|100|None Retained|none retained|Both|40 Years|N/A|No|Non-Probability Sample|Males and females 40 years of age or older with a diagnosis of COPD are eligible. Subjects        will complete questionnaires and perform spirometry at a single visit.|October 2011|October 13, 2011|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01424527||99255|
NCT01423968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B/12/2010|Effect of Lipopolysaccharide on Skeletal Muscle Functions|Impact & Time-Course of Effect of Intravenous Lipopolysaccharide Infusion on Skeletal Muscle Protein Turnover and Insulin Sensitivity in Healthy Human Volunteers|LPS|University of Nottingham|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|6|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01423968||99298|
NCT01420432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhangni|Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis (AS)|Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat AS||Shandong University|Yes|Recruiting|January 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|60 Years|No|||April 2011|August 18, 2011|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420432||99570|
NCT01432964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011/09|Use of a Low Profile Titanium Mesh in Orbital Reconstruction|Low Profile Titanium Mesh in the Use of Orbital Reconstruction||University Hospital Inselspital, Berne|No|Completed|December 2008|October 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|27|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with facial fractures, treated at the Department of Oral and Maxillofacial        Surgery, University Hospital Bern, Bern, Switzerland.|September 2011|September 12, 2011|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01432964||98611|
NCT01432561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111011|Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™|Food-Effect on Bioavailability of Cystagon™ in Normal, Healthy Adults||University of California, San Diego|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 23, 2013|September 9, 2011||No||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01432561||98641|
NCT01432847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110245|Cell Collection to Study Eye Diseases|Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls||National Institutes of Health Clinical Center (CC)||Recruiting|August 2011|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|930|||Both|1 Year|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01432847||98620|
NCT01432860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU17005|A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination|A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination||Northwestern University|No|Completed|September 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|4||Actual|1000|||Both|18 Years|80 Years|No|||June 2015|June 15, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01432860||98619|
NCT01433133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-002-02|Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients|Phase I-II, Open Label, Uncontrolled, Dose Escalation Study of the Safety, Tolerability and Biologic Activity of the INFRADURE Biopump Secreting Sustained Interferon Alpha-2b (IFNα), in Combination With Oral Ribavirin for Genotype 3 Newly Diagnosed Hepatitis C Patients||Medgenics Medical Israel Ltd.|No|Terminated|October 2012|March 2014|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|80 Years|No|||October 2015|October 20, 2015|September 5, 2011||No|Company strategic decision|No||https://clinicaltrials.gov/show/NCT01433133||98598|
NCT01429142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIMS_171002208|AIMS Study: Improving HIV Treatment Adherence|AIMS Study: Cost-effectiveness of a Nurse-based Intervention to Support HIV-treatment Adherence|AIMS|Wageningen University|No|Active, not recruiting|September 2011|January 2015|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|226|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01429142||98903|
NCT01430000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-002-01|Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump|Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump||Medgenics Medical Israel Ltd.|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||April 2014|April 16, 2014|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01430000||98838|
NCT01422122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1479-Ped-ERC-2010|Study of Vitamin D Supplementation on Improvement of Gums Health|The Effect of Vitamin D Supplementation on the Periodontal Health and Associated Outcomes in Pregnant Women|VitaminD|Aga Khan University|Yes|Completed|June 2010|December 2011|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Female|18 Years|45 Years|No|||August 2012|August 8, 2012|August 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01422122||99440|
NCT01422343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068/09|Microparticles and the Risk of Re-stenosis Following Balloon Angioplasty in Patients With Peripheral Arterial Disease|Correlation of Microparticles With Risk of Early Re-stenosis After Percutaneous Transluminal Angioplasty in Patients With Peripheral Arterial Disease||University Hospital Inselspital, Berne|No|Withdrawn|May 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|60 Years|85 Years|No|Non-Probability Sample|Patients (male and female) with peripheral arterial disease presenting at the angiology        clinic, Bern University Hospital|September 2014|September 8, 2014|March 28, 2011||No|Shortage of personnel / main study initiator no longer available|No||https://clinicaltrials.gov/show/NCT01422343||99423|
NCT01423487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUXXEYYJYS-051|Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea|Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea:a 24-week, Randomized, Placebo-controlled, Double-blind, Fixed-dose Study||Central South University|Yes|Withdrawn|August 2011|August 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|40 Years|No|||July 2012|July 31, 2012|August 18, 2011||No|Difficult to obtain informed consent|No||https://clinicaltrials.gov/show/NCT01423487||99335|
NCT01423721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65.129|Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study)|Relative Bioavailability of Bromhexine for Oral Administration of 16 mg of Bromhexine Hydrochloride Granules Compared to 16 mg of Bromhexine Hydrochloride Syrup in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Replicate Design Phase I Study With Two Treatments in Four Crossover Periods)||Boehringer Ingelheim||Completed|August 2011|||October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|August 25, 2011||||No||https://clinicaltrials.gov/show/NCT01423721||99317|
NCT01423188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX222-CS-008|The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation|Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations|SUSTAIN|Resverlogix Corp|Yes|Completed|August 2011|August 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01423188||99358|
NCT01423461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L2005-0254|Personalized Asthma Care Team|Individualized Health Care for Children With Common Chronic Diseases|PACT|Brigham and Women's Hospital||Completed|July 2005|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|||Both|4 Years|18 Years|No|Probability Sample|All children seen at the pediatric pulmonology department with a diagnosis of asthma or        symptoms of persistent wheeze, unexplained by an etiology other than asthma, ages 4 to 18        years will be recruited.|August 2011|August 25, 2011|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01423461||99337|
NCT01423474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50-2011|Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time|Randomized Phase II Study of 2 Hypofractionated Radiotherapy Schedules for Low- and Intermediate-Risk Prostate Cancer|PATRIOT|CancerCare Manitoba|Yes|Active, not recruiting|January 2012|||October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Male|18 Years|N/A|No|||December 2015|December 4, 2015|August 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423474||99336|
NCT01423695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISP_RO78|Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer|Weekly Application of Trastuzumab and Paclitaxel in the Treatment of HER2-overexpressing Metastatic Breast Cancer||WiSP Wissenschaftlicher Service Pharma GmbH|No|Completed|February 2001|December 2009|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||August 2011|August 25, 2011|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01423695||99319|
NCT01424553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100117|Respiratory Outcome at Adolescence of Very Low Birthweight Infants|Respiratory Outcome at Adolescence of Very Low Birthweight Infants : the EPIPAGE Cohort|EPIPAGEADO|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2011|April 2015|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|355|||Both|14 Years|15 Years|No|||April 2015|April 20, 2015|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01424553||99253|
NCT01424566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCA1103|A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer|A Two-part, Placebo-controlled, Study of the Safety and Efficacy of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Have Inadequate Analgesia Even With Optimized Chronic Opioid Therapy.||GW Pharmaceuticals Ltd.|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||January 2014|May 19, 2015|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01424566||99252|
NCT01420445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHD001-202|Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis|Randomized, Double-blind, Placebo/Active-controlled, Multi-center, Phase 3 Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 After Oral Administration in Patients With Acute or Chronic Bronchitis||Yuhan Corporation|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|118|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01420445||99569|
NCT01432145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCTO_016|A Clinical Trial in Patients With BRCA Defective Tumours|Phase II Clinical Trial Of 6-Mercaptopurine (6MP) and Low-Dose Methotrexate In Patients With Known BRCA Defective Tumours|6MP|University of Oxford|No|Completed|May 2011|May 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01432145||98673|
NCT01424540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115535|Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805|A Randomized, Double Blind, Single Dose, Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 in Healthy Adult Volunteers||GlaxoSmithKline|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|August 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01424540||99254|
NCT01420770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD11936|Phase 2 Study of SAR302503 in Patients With Myelofibrosis|A Phase 2 Randomized, Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly||Sanofi|No|Completed|August 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420770||99544|
NCT01421043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6781003|A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Triazolam Liquid Oral Drops at a Dose of 0.25 Mg Versus Triazolam 0.25 Mg Tablet in Healthy Subjects||Pfizer|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421043||99523|
NCT01432626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10080198|Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG|The Evaluation of the Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG Imaging||University of Pittsburgh|Yes|Completed|September 2011|June 2015|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|September 7, 2011||No||No|March 21, 2016|https://clinicaltrials.gov/show/NCT01432626||98636|
NCT01429779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1-039|The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme|The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial||Maastricht University Medical Center|Yes|Recruiting|July 2012|||October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|80 Years|No|||April 2014|April 10, 2014|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429779||98854|
NCT01433146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65422-SU-CE|Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients. Effetti Del Temperamento, Dell'Ansia e Della Depressione Sulla Sopravvivenza Globale e Sulla Risposta Immunitaria Del Paziente Affetto da Adenocarcinoma Colo-Rettale.|Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients.||University of Roma La Sapienza|Yes|Completed|September 2011|June 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|Blood samples for cell-mediated immunity evaluaion|Both|30 Years|80 Years|No|Non-Probability Sample|Primary care clinic|June 2012|June 4, 2012|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01433146||98597|
NCT01433159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-101-09-043|Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury|Comparison of HP011-101 to Standard Care in the Management of Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury||Healthpoint|No|Terminated|September 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|12 Years|N/A|No|||January 2014|January 10, 2014|September 12, 2011|Yes|Yes|Business decision|No|October 9, 2013|https://clinicaltrials.gov/show/NCT01433159||98596|
NCT01429155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6975|Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B|Post Transplant Course of Hepatitis C Patients After Living Donor Liver Transplant in Association With Interleukin 28 B||Henry Ford Health System|Yes|Completed|August 2011|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|36|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Chronic hepatitis C patients that required a living donor liver transplant will be        identified from the liver tranplant registry.        Living liver donors will be indentified from the liver tranplant registry.|September 2014|September 16, 2014|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429155||98902|
NCT01429168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-142|A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)|The Randomized Etoricoxib Study in Patients With Osteoarthritis Not Responding to Analgesic Drugs - THE RESPOND-EUROPE STUDY|RESPOND-EUROPE|Merck Sharp & Dohme Corp.|No|Withdrawn|October 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|0|||Both|50 Years|N/A|No|||April 2015|April 8, 2015|September 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01429168||98901|
NCT01429428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIGVARIS|Far-IR Emitted by Compression Stockings for Cellulitis Treatment|Randomized and Controlled Study About Efficacy and Safety of Far-Infra Red Radiation Emitted by Compression Stockings for Cellulitis Treatment||Federal University of São Paulo|Yes|Active, not recruiting|July 2011|March 2012|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 4, 2011|August 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01429428||98881|
NCT01429701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREEMS0711|Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous|Unicentric Comparing Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol to Betamethasone + Gentamicin + Tolnaftate + Clioquinol in Acute and Sub-acute Dermatitis Eczematous||EMS|Yes|Completed|May 2012|August 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|40 Years|No|||March 2013|March 1, 2013|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01429701||98860|
NCT01430013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2367240|Trial of Endostar Combined With CHOPT for T Cell Lymphoma|Phase II Trial of Endostar Combined With CHOPT for T Cell Lymphoma||Tianjin Medical University Cancer Institute and Hospital|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||September 2011|November 2, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01430013||98837|
NCT01430325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1023955|Test of Chamber Pressure to Divers and Chamber Attendants|Test of Chamber Pressure to Divers and Chamber Attendants: A Blinded Trial to Investigate if "Pressure-familiar" Individuals Can Determine Pressure|TOP-DIVER|Intermountain Health Care, Inc.|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|February 12, 2013|September 2, 2011|No|Yes||No|January 3, 2013|https://clinicaltrials.gov/show/NCT01430325||98813|Smaller sample size; enrollment was stopped at 42 participants when investigators had exhausted the planned recruitment methods. Very few inside attendants enrolled. Pressures in this study were relatively close.
NCT01422915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002253|Sorbent Therapy of the Cutaneous Porphyrias|Sorbent Therapy of the Cutaneous Porphyrias||Brigham and Women's Hospital|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|22 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 29, 2013|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01422915||99379|
NCT01421875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000709403|Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia|Genetic and Epigenetic Determinants of Chemotherapy Resistance and Adverse Outcome in Elderly Patients With AML||National Cancer Institute (NCI)||Not yet recruiting|September 2011|||October 2011|Anticipated|N/A|Observational|N/A|||Anticipated|257|||Both|61 Years|N/A|No|||August 2011|August 20, 2011|August 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01421875||99459|
NCT01423500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2005-005106-23|ALL-SCT BFM International- HSCT in Children and Adolescents With ALL|Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia|ALL-SCT-BFMi|St. Anna Kinderkrebsforschung|Yes|Active, not recruiting|January 2007|September 2016|Anticipated|September 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|405|||Both|3 Months|18 Years|No|||June 2015|June 25, 2015|August 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423500||99334|
NCT01422603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM CAN0638|Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)|A Pilot Study of Clofarabine Pre-conditioning Prior to Full or Reduced Intensity Allogeneic Transplantation in the Treatment of High Risk Acute Myeloid Leukaemia and Myelodysplasia.||University Hospital Southampton NHS Foundation Trust.|No|Recruiting|February 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|November 21, 2014|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422603||99403|
NCT01422902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPI-1001-11|Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults|Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults, A Remediation-based Approach|e-CAeSAR|Posit Science Corporation|No|Completed|April 2012|June 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01422902||99380|
NCT01423994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR#230880|Syncope: Pacing or Recording in the Later Years|Syncope: Pacing or Recording in the Later Years (SPRITELY)|Spritely|University of Calgary|Yes|Active, not recruiting|August 2011|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||May 2015|May 21, 2015|August 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01423994||99296|
NCT01424293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004va09|Fluorescent Evaluation of Colorectal Anastamoses|The Use of Fluorescent Imaging to Evaluate Bowel Anastomotic Perfusion||Maimonides Medical Center|No|Active, not recruiting|May 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|18 Years|65 Years|No|||August 2015|August 6, 2015|September 29, 2010||No||No||https://clinicaltrials.gov/show/NCT01424293||99273|
NCT01432158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/04B|Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines|A Detailed Kinetics Study to Assess the Antibody and the B Cell Response to Either a 13-valent Conjugate Vaccine or a 23-valent Plain Pneumococcal Polysaccharide Vaccine Administered to Healthy Adults Without Prior Pneumococcal Vaccination||University of Oxford|No|Completed|January 2012|||August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01432158||98672|
NCT01432366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-4746|Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA)|Subcutaneous Anti-tnf-αlpha In Rheumatoid Arthritis: Analyze The Correlation Between Objective Measures Of Disease Activity And Safety And A Subjective Measure Such As Patient Beliefs About A Medicine|CONTENT|Pfizer|No|Completed|October 2010|January 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|460|||Both|18 Years|N/A|No|Probability Sample|rheumatoid arthritis patients treated with SC anti-TNF capable of completing some        questionnaires|December 2015|December 14, 2015|August 18, 2011||No||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01432366||98656|
NCT01432379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-110|BOTOX® Prophylaxis in Patients With Chronic Migraine|||Allergan|No|Completed|September 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1160|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Chronic Migraine|May 2015|May 13, 2015|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01432379||98655|
NCT01429493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/541|Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases|Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial||University Hospital, Ghent|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01429493||98876|
NCT01421069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801023|Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis|An Open-label Extension Study To Assess The Long-term Safety And Clinical Benefit Of Etanercept In Children And Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled In Protocol 0881a1-3338-ww(b1801014)|CLIPPER2|Pfizer|Yes|Active, not recruiting|October 2011|February 2021|Anticipated|January 2021|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|109|||Both|2 Years|30 Years|No|||January 2016|January 11, 2016|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421069||99521|
NCT01429181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP10-001|Efficacy & Safety Study of Nonracemic Methadone for the Relief of Chronic Peripheral Neuropathic Pain|Pilot Study to Evaluate Efficacy, Tolerability and Safety Nonracemic Methadone HCl in Patients With Chronic Peripheral Neuropathic Pain: Double-Blind, Placebo-Controlled, Crossover Study Followed by Open-Label, Single-Arm Extension||MetaPharm, Inc.|No|Not yet recruiting|January 2012|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2011|September 2, 2011|August 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01429181||98900|
NCT01429441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-MV-014|Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole|A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole|OASIS|ThromboGenics|Yes|Completed|October 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||January 2016|February 18, 2016|September 2, 2011|Yes|Yes||No|October 29, 2015|https://clinicaltrials.gov/show/NCT01429441||98880|
NCT01429714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2-026|The Ideal Deep Venous Thrombosis (DVT) Study|Individually Tailored Elastic Compression Therapy After Deep Venous Thrombosis in Relation to the Incidence of Post Thrombotic Syndrome, a Randomized Multicenter Trial|IDEAL|Maastricht University Medical Center|No|Active, not recruiting|March 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|847|||Both|18 Years|N/A|No|||July 2015|September 28, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01429714||98859|
NCT01429727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001852|The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry|The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry|SCAD|Mayo Clinic|No|Recruiting|July 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women with spontaneous coronary artery dissection (SCAD) as confirmed on        angiogram.|December 2015|December 30, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01429727||98858|
NCT01429740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3441001|A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults|A Phase 1, Placebo-Controlled, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-05180999 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects||Pfizer|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 10, 2012|August 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01429740||98857|
NCT01430026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004/2554(EC3)|Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis|Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis||Mahidol University|No|Completed|March 2011|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|40|||Both|N/A|N/A|No|Non-Probability Sample|pediatric allergy clinic in siriraj hospital|September 2015|September 17, 2015|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01430026||98836|
NCT01422928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA- H10-02105|Acupuncture for the Immune System in Radiation Cancer Patients|Does Radiation Therapy Adversely Affect the Immune System, and Can Acupuncture Ameliorate the Effect? A Pilot Study||British Columbia Cancer Agency|No|Withdrawn|December 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||May 2015|May 22, 2015|August 23, 2011||No|Study was not approved by research ethics board.|No||https://clinicaltrials.gov/show/NCT01422928||99378|
NCT01422369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.06US|Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin|Drug-Drug Interaction Study to Assess the Effects of Steady-State Darunavir/Ritonavir on Steady-State Pitavastatin in Healthy Adult Volunteers||Kowa Research Institute, Inc.|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|August 22, 2011|Yes|Yes||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01422369||99421|
NCT01431430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100103|VITamine D Supplementation in RenAL Transplant Recipients - VITALE|Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients|VITALE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|538|||Both|18 Years|75 Years|No|||January 2016|January 22, 2016|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01431430||98728|
NCT01454726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJT2010-22|Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease|A Random Controlled Clinical Trial:l Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease|TCDMD|Beijing Administration of Traditional Chinese Medicine Bureau|Yes|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|70 Years|No|||January 2012|November 23, 2012|June 1, 2011||No||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01454726||96955|Our study focused only on the effect of Diaoshi Jifa on Meniere's disease after one-time treatment. There still possibilities that after several days' treatment, both experimental and control groups have similar improvement in their DHI scores.
NCT01454440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007−002617−39|The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)|A RANDOMIZED TRIAL COMPARING EPTIFIBATIDE AND PLACEBO IN PATIENTS WITH DIFFUSE CORONARY DISEASE UNDERGOING DRUG-ELUTING STENTING|INSTANT|University of Turin, Italy|Yes|Terminated|October 2007|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|October 6, 2011||No|The study was stopped prematurely due to slow enrolment without code breaking.|No||https://clinicaltrials.gov/show/NCT01454440||96977|
NCT01454999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-05/PJJ 0001|Cell Phone-Based Expert Systems for Smoking Cessation|Cell Phone-Based Expert Systems for Smoking Cessation|TXT|VA Pacific Islands Health Care System|No|Completed|September 2009|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|446|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454999||96934|
NCT01455012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0977|Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome|Multicenter, Double-Blind, Placebo-Controlled, Two-Arm, Randomized, Parallel, Treatment Intervention, Sleep Lab Phase 4 Study to Assess the Effect of Rotigotine on Nocturnal Blood Pressure in Patients With Idiopathic Restless Legs Syndrome|ENCORE|UCB Pharma|No|Completed|September 2011|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|75 Years|No|||July 2013|July 19, 2013|October 10, 2011|Yes|Yes||No|May 14, 2013|https://clinicaltrials.gov/show/NCT01455012||96933|
NCT01455324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST1288 Study 2|Evaluation of the Development of an Advanced, Conformable Prosthetic Socket, Study II|||Infoscitex Corporation|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Subject will be selected from one prosthetic fabrication facility and recruited by their        prosthetist|March 2012|March 1, 2012|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01455324||96909|
NCT01455597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-04509|Evaluate Long-Term Safety and Efficacy WC3011|A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of WC3011 in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women||Warner Chilcott|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|309|||Female|35 Years|N/A|No|||February 2015|February 24, 2015|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455597||96888|
NCT01455610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMS-001|Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study|Preoperative Evaluation of Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study||Shanghai Zhongshan Hospital|Yes|Not yet recruiting|October 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|N/A|N/A|No|Probability Sample|Out-patients or in-patients,with(or suspected) pancreatic head cancer, both have MDCT        examinaton and receive surgery treatment|October 2011|October 19, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455610||96887|
NCT01451658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V99C1-026;V100C-024|Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma|||Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|December 2009|October 2012|Anticipated|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||October 2011|October 13, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451658||97191|
NCT01451671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD002|Development of a Prenatal Test for Fetal Aneuploidy Detection|Prenatal Test for Fetal Aneuploidy Detection||Ariosa Diagnostics, Inc|No|Recruiting|November 2010|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|1500|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women carrying a fetus with an abnormal chromosomal condition that has been        confirmed by invasive testing.|August 2015|August 12, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451671||97190|
NCT01453361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL 114|Phase II FANG™ in Advanced Melanoma|Phase II Trial of FANG™ Autologous Tumor Cell Vaccine in Advanced Melanoma||Gradalis, Inc.|Yes|Active, not recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|August 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453361||97060|
NCT01452776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/OCT-001|Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis|A Phase 3, Randomized, Single-Blind, Multicenter Study to Evaluate the Safety of TAK-438 (10 and 20 mg Once-daily) in a 52-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE)||Takeda|No|Completed|September 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|305|||Both|20 Years|N/A|No|||November 2013|November 2, 2013|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01452776||97105|
NCT01453933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASSTER2010|RAltegravir Switch STudy: Effects on Endothelial Recovery|Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml|RASSTER|UMC Utrecht|No|Recruiting|January 2012|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||December 2013|December 17, 2013|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01453933||97016|
NCT01453296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112776|Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects|A Randomized, Double-blind, Placebo-controlled, Two-way Crossover 7-day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25 μg (Micrograms) in Children Aged 5-11 Years With Persistent Asthma.||GlaxoSmithKline|No|Completed|August 2010|April 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|5 Years|11 Years|No|||June 2013|August 15, 2013|September 1, 2011|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01453296||97065|
NCT01453309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-N0216|Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions|Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions||Norton Leatherman Spine Center|No|Not yet recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||October 2011|October 14, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01453309||97064|
NCT01441375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670A2418|Sickle Cell Disease: A Retrospective Chart Review|Complications in Patients With Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review||Novartis||Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|261|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with Sickle cell anemia|October 2012|October 17, 2012|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01441375||97968|
NCT01441388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081030|A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.|A Phase 1B, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Crizotinib (PF-02341066) Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.||Pfizer|No|Withdrawn|December 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||December 2011|December 19, 2011|September 23, 2011|No|Yes|Business/Operational issues|No||https://clinicaltrials.gov/show/NCT01441388||97967|
NCT01441674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAT-IRB#1011-089|Animal Assisted Therapy in a Pediatric Setting|The Effectiveness of Animal Assisted Therapy for Children Hospitalized in a Pediatric Setting|AAT|Children's Hospitals and Clinics of Minnesota|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|N/A|No|||February 2014|February 13, 2014|January 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441674||97945|
NCT01454492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMUH-3485|The Relationship Between Allergic Rhinitis and Geographic Tongue||AR-GT|China Medical University Hospital|Yes|Recruiting|September 2011|September 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|||Both|20 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group 1: Allergy rhinitis Group 2: Non-allergy rhinitis|October 2011|October 18, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01454492||96973|
NCT01453881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC 034/11|Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation|Randomized Clinical Trials to Compare Asthma Control Efficacy of the Fine-particle Combination Formoterol/Beclomethasone by pMDI Administered With and Without Spacer.|EFFECT-EV|Universidade Federal de Pernambuco|No|Completed|April 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|65 Years|No|||March 2015|March 29, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453881||97020|
NCT01454193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078-08|Are we Loading Our Patients With Sodium During Hemodialysis Treatments?|||Renal Research Institute|No|Completed|January 2001|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10000|||Both|18 Years|88 Years|No|Non-Probability Sample|Hemodialysis patients at Renal Research Institute and Fresenius clinics|October 2011|October 18, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01454193||96996|
NCT01454206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeASAR app RFADA12008|Integration of (iSBIRT) for Teen Drug Use Into a Pediatric Network|Integration of Internet-facilitated Screening, Brief Intervention, Referral to Treatment (iSBIRT) for Teen Drug Use Into a Pediatric Network||Children's Hospital Boston|Yes|Withdrawn|July 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||January 2013|January 2, 2013|October 5, 2011||No|The project was not funded|No||https://clinicaltrials.gov/show/NCT01454206||96995|
NCT01454219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIFA|Measurement of Glycaemic Responses of Bakery and Confectionery Products|Measurement of Glycaemic Responses of Bakery and Confectionery Products|GIFA|Clinical Life Sciences Ltd.||Completed|August 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|February 14, 2012|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454219||96994|
NCT01454180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIO-GI-01-2011|Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets|Ensayo Fase II de selección Individualizada Del Tratamiento de Quimioterapia en Pacientes Con Carcinoma de páncreas Avanzado en función de la determinación de Dianas terapéuticas en el Tejido Tumoral||Centro Nacional de Investigaciones Oncologicas CARLOS III|Yes|Completed|October 2011|December 2014|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||October 2015|October 8, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01454180||96997|
NCT01454739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8HA01EXT|Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A|An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A|ASPIRE|Biogen|Yes|Enrolling by invitation|December 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|194|||Male|N/A|N/A|No|||January 2016|January 14, 2016|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454739||96954|
NCT01455025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primal study|Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia|A Phase 1, Dose Escalation Study of Plerixafor in Combination With Induction and Consolidation Chemotherapy in Patients With Relapsed Acute Myeloid Leukemia|PRIMAL|French Innovative Leukemia Organisation|Yes|Terminated|January 2012|August 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||August 2015|March 15, 2016|June 24, 2011||No|no recruitment on time|No||https://clinicaltrials.gov/show/NCT01455025||96932|
NCT01455038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A090116|Heart Rate Variability of Patients With Bipolar Disorder in Subsyndromal Depressive Phase|Heart Rate Variability of Patients With Bipolar Disorder in Subsyndromal Depressive Phase||Asan Medical Center||Completed|January 2010|April 2010|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|92|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Thirty three (10 males, 23 females) patients in clinically remitted state diagnosed with        bipolar disorder based on DSM-IV criteria were enrolled at one outpatient psychiatric        clinic and 59 healthy controls (23 males, 36 females) from health promotion center in a        university-affiliated general hospital. We defined an individual patient as being in        subsyndromal depressive phase when the patient had a Montgomery-Åsberg depression rating        scale (MADRS) score of 10 or less and Clinical Global Impression severity (CGI-S) of 3 or        less for last one month. Healthy controls had no history of psychiatric disorder and had        no psychiatric symptom when interviewed by a board-certified psychiatrist.|October 2011|October 18, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455038||96931|
NCT01451099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0002062|A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss||Aderans Research Institute|No|Completed|June 2009|||September 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451099||97234|
NCT01451372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SW01|Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study|Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study||Medtronic|Yes|Completed|June 2011|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|69|||Both|N/A|69 Years|No|Non-Probability Sample|Population will be selected from Primary Care Clinics.|November 2012|November 6, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01451372||97213|
NCT01451385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV15000181|Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain|An Open Label Safety Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain||Mallinckrodt|No|Completed|September 2011|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|376|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451385||97212|
NCT01452178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VaMIS|Vastmanland Myocardial Infarction Study (VaMIS)|Observational Study on Peripheral Vascular Disease, Glucometabolic Status, and Type D Personality in Patients With Acute Myocardial Infarction.|VaMIS|Uppsala University|Yes|Completed|November 2005|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1008|Samples With DNA|Whole blood and serum.|Both|18 Years|N/A|No|Probability Sample|Consecutive patients hospitalized for acute myocardial infarction. Control subjects,        matched to the patients for age, sex, and municipality, were randomly selected from the        general population.|October 2011|October 11, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452178||97151|
NCT01452789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11F.193|Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome|A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome||Thomas Jefferson University|Yes|Recruiting|November 2011|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||February 2016|February 4, 2016|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452789||97104|
NCT01453374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK21-028|A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration|A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration||Alkermes, Inc.|No|Completed|January 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|October 13, 2011|Yes|Yes||No|May 21, 2015|https://clinicaltrials.gov/show/NCT01453374||97059|The outcome measure of opioid dependence was not analyzed.
NCT01453673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100014|Results of Knee Arthroscopic Surgery for Treatment of Cruciate Ligament and Meniscus|Results of Knee Arthroscopic Surgery for Treatment of Cruciate Ligament and Meniscus||Taipei Medical University WanFang Hospital|No|Active, not recruiting|May 2011|May 2013|Anticipated|||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|210|||Both|20 Years|N/A|No|Non-Probability Sample|Knee Arthroscopic Surgery patients|October 2011|October 13, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453673||97036|
NCT01453634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA018-2007|Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)|A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis|2007|OPKO Health, Inc.|No|Withdrawn|January 2013|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||September 2014|September 19, 2014|October 13, 2011|Yes|Yes|The company is no longer pursuing this study.|No||https://clinicaltrials.gov/show/NCT01453634||97039|
NCT01441089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110242|Collection of Blood From Cancer Patients for Genetic Analysis|Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition||National Institutes of Health Clinical Center (CC)||Recruiting|August 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|99 Years|No|||November 2015|December 15, 2015|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01441089||97990|
NCT01441401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9451175|Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Gabapen For Pediatric (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Completed|December 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|82|||Both|3 Years|15 Years|No|Probability Sample|The study whom an investigator involving A9451175 prescribes the Gabapentin|August 2015|August 3, 2015|September 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441401||97966|
NCT01441414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1131004|PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma|A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (ANG-2) Inhibitor In Combination With AG-013736 (Axitinib) In Patients With Previously Treated Metastatic Renal Cell Carcinoma||Pfizer|No|Terminated|November 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|August 26, 2011|Yes|Yes|See termination reason in detailed description.|No|March 27, 2015|https://clinicaltrials.gov/show/NCT01441414||97965|On 06 Nov 2012, based on Part I safety findings and due to strategic considerations, Pfizer decided not to open enrolment onto Part II of the study and terminated the study. For primary OM, AEs reported in ≥2 participants overall are presented.
NCT01441960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001154|Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)|Optimal Control of Muscle Strength for Electroconvulsive Therapy: A Comparison of Succinylcholine Versus Rocuronium-induced Neuromuscular Blockade||Massachusetts General Hospital|Yes|Completed|May 2011|February 2015|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|80 Years|No|||June 2015|June 1, 2015|September 20, 2011|Yes|Yes||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01441960||97923|
NCT01441973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-011|Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma|A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma||Bristol-Myers Squibb|No|Active, not recruiting|December 2011|March 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|September 27, 2011|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT01441973||97922|
NCT01454804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0650|Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors|Phase I Study of Pazopanib in Combination With Lapatinib or Trastuzumab in Subjects With Solid Tumors||M.D. Anderson Cancer Center|No|Completed|October 2011|||March 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|N/A|N/A|No|||March 2015|March 13, 2015|October 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454804||96949|
NCT01454817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSM 10-00041|A Study of Symptoms and Quality of Life in Patients With Implantable Cardiac Defibrillators (ICDs) and Their Caregivers|A Study of Symptoms and Quality of Life in Patients With ICDs and Their Caregivers||Icahn School of Medicine at Mount Sinai|No|Recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1200|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454817||96948|
NCT01454466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-05-011|Partial Posterior Hyaloidectomy in Macular Surgery|Partial Posterior Hyaloidectomy in Macular Surgery : A Modified Procedure of Vitrectomy to Prevent Retinal Break Related to Induction of a Posterior Vitreous Detachment||Samsung Medical Center|No|Completed|November 2009|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|20 Years|70 Years|No|||October 2011|October 18, 2011|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01454466||96975|
NCT01454479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-3771A3|A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma|A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|March 2011|April 2014|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|20 Years|75 Years|No|||October 2011|October 18, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01454479||96974|
NCT01454765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmb-maza0001-ctil|Generation of Haploid Stem Cells From Human Germ Cells|Generation of Haploid Stem Cells From Human Germ Cells||Rambam Health Care Campus|No|Recruiting|December 2011|August 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Germ cells and Stem cells|Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male volunteers|December 2013|December 10, 2013|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01454765||96952|
NCT01454778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pac 1|Paclitaxel Reduces Effects of Intimal Hyperplasia|Paclitaxel Reduces Effects of Intimal Hyperplasia Status Post Lower Extremity Revascularization|Pac1|Sanford Health|Yes|Active, not recruiting|April 2011|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|90 Years|No|||December 2013|December 31, 2014|April 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454778||96951|
NCT01454453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2167SR|Optimisation of Antipsychotic Drug Use in Older People|Rationalisation of Antipsychotic Drug Use in Older People, Using [18F]-Fallypride PET||Institute of Psychiatry, London|No|Recruiting|May 2012|March 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|60 Years|95 Years|No|||March 2015|March 24, 2015|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454453||96976|
NCT01454752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WT-Clarke-Sen2011|Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition|Intermittent Parasite Clearance (IPC) in Schools: a Randomised Double-blind Placebo-controlled Trial of the Impact of IPC on Malaria, Anaemia and Cognition Amongst School Children in Kedougou, Senegal||London School of Hygiene and Tropical Medicine|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|860|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01454752||96953|
NCT01455051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETH-CLL4|Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation|Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC||Grupo Espanol de trasplantes hematopoyeticos y terapia celular|No|Recruiting|October 2011|October 2017|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|70 Years|No|||January 2012|January 10, 2012|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455051||96930|
NCT01455064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC11-106|Navigator II Continuous Glucose Monitor Home Use Study|FreeStyle Navigator II Continuous Glucose Monitor Home Use Evaluation (FSNv2)||Abbott Diabetes Care|No|Completed|October 2011|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with type 1 or 2 diabetes requiring multiple daily insulin injections or using an        insulin pump|May 2013|May 13, 2013|October 15, 2011||No||No|February 7, 2013|https://clinicaltrials.gov/show/NCT01455064||96929|
NCT01455337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111|Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline|Principal Investigator||Inje University|No|Enrolling by invitation|January 2009|December 2011|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|126|||Both|20 Years|75 Years|No|||October 2011|October 18, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01455337||96908|
NCT01451398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-175|Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus|A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Technosphere Inhalation Powder in Insulin Naïve Subjects With Type 2 Diabetes Mellitus Poorly Controlled With Oral Antidiabetic Agents Over a 24 Week Treatment Period||Mannkind Corporation|Yes|Completed|November 2011|July 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|353|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|October 7, 2011|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01451398||97211|
NCT01451411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087-CL-096|A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia||Cumberland Pharmaceuticals|Yes|Terminated|February 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|2 Years|17 Years|No|||February 2016|February 1, 2016|October 5, 2011|Yes|Yes|Enrollment goals were not met.|No|December 18, 2015|https://clinicaltrials.gov/show/NCT01451411||97210|
NCT01451684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD003|Development of a Non-invasive Prenatal Test|Development of a Non-invasive Prenatal Test||Ariosa Diagnostics, Inc|No|Recruiting|June 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|||Female|18 Years|N/A|No|Non-Probability Sample|This study will include women who have a singleton pregnancy.|August 2015|August 12, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451684||97189|
NCT01451931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSB-1002670|Study of Tomography of Nephrolithiasis Evaluation|Randomized Controlled Trial of Ultrasound Versus CT (Computed Tomography) for Patients in the Emergency Department With Suspected Renal Colic|STONE|University of California, San Francisco|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|2776|||Both|18 Years|75 Years|No|||December 2014|December 2, 2014|October 11, 2011||No||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01451931||97170|
NCT01452191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11007|Helping Children's Centres to Enhance Home Safety|Keeping Children Safe at Home: Cluster Randomised Controlled Trial of the Implementation of an Injury Prevention Briefing in Children's Centres for the Prevention of Fire-related Injuries||University of Nottingham|Yes|Recruiting|June 2011|||March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1080|||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 4, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01452191||97150|
NCT01452802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC07272011|Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management|Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients|ROADMAP|Thoratec Corporation|No|Active, not recruiting|October 2011|May 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|HM II implanting centers and community/referral heart failure clinics|March 2016|March 18, 2016|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452802||97103|
NCT01452815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-102-CL-G003|Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis||Tranzyme, Inc.|No|Completed|September 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|80 Years|No|||August 2012|April 24, 2013|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452815||97102|
NCT01453647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12211|Study to Explore the Relationships Among Immunity and Stress and the Symptoms of Fatigue, Pain, and Mood Following Guided Imagery in Women With Fibromyalgia|Self-Efficacy, Stress, Immunity and Symptoms of Fibromyalgia||Virginia Commonwealth University|Yes|Completed|January 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|N/A|No|||October 2011|October 13, 2011|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01453647||97038|
NCT01453686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0020020248|A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata|A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata||The Hospital for Sick Children|No|Completed|August 2002|August 2003|Actual|August 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|41|||Both|2 Years|16 Years|No|||December 2013|December 6, 2013|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453686||97035|
NCT01453712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-DHM-PROTV|Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study -|Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study -|PROTECTION-V|Deutsches Herzzentrum Muenchen|Yes|Recruiting|October 2011|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|95 Years|No|||October 2011|October 17, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01453712||97033|
NCT01454284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12147|A Study in Patients With Type I Diabetes Mellitus|The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study|IMAGINE 3|Eli Lilly and Company|Yes|Completed|January 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|1113|||Both|18 Years|N/A|No|||February 2014|April 14, 2014|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454284||96989|
NCT01454544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-06|A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet||MT-06|ALK-Abelló A/S|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||||||Both|18 Years|65 Years|No|||March 2014|March 21, 2014|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01454544||96969|
NCT01441102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110244|Dextromethorphan for Diabetic Macular Edema|A Pilot Phase I/II Study for the Evaluation of Dextromethorphan as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema (MiDME2)|MiDME2|National Institutes of Health Clinical Center (CC)|No|Active, not recruiting|August 2011|December 2015|Anticipated|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|September 24, 2011|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01441102||97989|
NCT01441726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-114881|Palliative and End-of-life Care in Advanced Dementia: Evaluation of a Program of Organization of Care in Long-term Care|Palliative and End-of-life Care in Advanced Dementia: Evaluation of a Program of Organization of Care in Long-term Care Settings||Laval University|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|175|||Both|N/A|N/A|No|Non-Probability Sample|Residents in long term care settings|March 2015|March 30, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01441726||97941|
NCT01441999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGC11-001|Proximal Junctional Kyphosis Following Long Instrumented Spinal Fusion: The Effect of Implant Selection|Proximal Junctional Kyphosis Following Long Instrumented Spinal Fusion: The Effect of Implant Selection|PJK|Globus Medical Inc|No|Recruiting|October 2011|September 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 11, 2015|September 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441999||97920|
NCT01441986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0533-DXM|Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects|A Phase IIa, Double-blind, Placebo-controlled, Randomised, Fourfold Crossover Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test|DXM/AMT|Profil Institut für Stoffwechselforschung GmbH|Yes|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Male|45 Years|70 Years|No|||July 2012|July 11, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01441986||97921|
NCT01454791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB 20101775|Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate|Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate: A Randomized Controlled Double- Blind Crossover Trial||Brown, Theodore R., M.D., MPH|No|Completed|January 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||January 2015|February 12, 2015|August 9, 2011|Yes|Yes||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01454791||96950|
NCT01455103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA210-002|Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma|A Phase I Study of the Biologic Effects of BMS-936559 Treatment in Subjects With Unresectable Stage III or IV Melanoma|PD-L1|Bristol-Myers Squibb|No|Withdrawn|November 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|0|||Both|18 Years|N/A|No|||October 2011|December 12, 2011|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01455103||96926|
NCT01451177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0004669|A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects.||Aderans Research Institute|No|Completed|May 2010|||January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451177||97228|
NCT01455077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP0290/11|Portable Monitoring Device for the Diagnosis of Sleep Apnea in Obese Patients|Validation of a Portable Monitoring System for the Diagnosis of Obstructive Sleep Apnea Syndrome in Patients With Level II and III Obesity||Associacao Fundo de Incentivo a Psicofarmcologia|No|Recruiting|January 2011|January 2012|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Adults BMI > 35 Male and female|October 2011|October 18, 2011|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01455077||96928|
NCT01455090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI443-014|Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications|Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Completed|November 2011|July 2015|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|13||Actual|320|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455090||96927|
NCT01455350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-115028|Efficacy of a Physiotherapy Treatment in Women Suffering From Provoked Vestibulodynia|Efficacy of Treatments for Provoked Vestivulodynia : a Randomised Clinical Trial Comparing Multimodal Physiotherapy Treatments to Topical Lidocaine||Université de Sherbrooke|No|Recruiting|October 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|234|||Female|18 Years|45 Years|No|||December 2014|December 4, 2014|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01455350||96907|
NCT01451112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0002899|A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects||Aderans Research Institute|No|Completed|August 2009|||August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451112||97233|
NCT01451125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0004512|A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil||Aderans Research Institute|No|Completed|May 2010|||March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451125||97232|
NCT01451697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIMA003472HI|Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding|Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding||Hartford Hospital|No|Recruiting|July 2011|October 2012|Anticipated|July 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||October 2011|October 11, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451697||97188|
NCT01451944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0320|Effect of Home Health Case Management on Asthma Morbidity|Effect of Home Health Nurse Case Management on Asthma Morbidity||University of Louisville|No|Withdrawn|October 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|0|||Both|3 Years|17 Years|No|||December 2014|December 1, 2014|October 4, 2011||No|no one enrolled|No||https://clinicaltrials.gov/show/NCT01451944||97169|
NCT01453088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO# 1307|Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older|(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older||Hackensack University Medical Center|Yes|Recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|398|||Both|60 Years|N/A|No|||August 2015|August 21, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01453088||97081|
NCT01453101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO1261|Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma|A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib|Flu-Mel-Vel|Hackensack University Medical Center|Yes|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|69 Years|No|||August 2015|August 21, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453101||97080|
NCT01453075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-001A-10F|Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)|Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and Herpes Simplex Virus 2 (HSV-2) Infection (Phase I)||VA Office of Research and Development|No|Completed|November 2011|December 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|October 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453075||97082|
NCT01453985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zell04|Full-Thickness-Gastroplication For The Treatment Of Gastroesophageal Reflux Disease GERD|||General Public Hospital Zell am See||Recruiting||||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A||||October 2011|October 14, 2011|October 12, 2011||||No||https://clinicaltrials.gov/show/NCT01453985||97012|
NCT01453660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-140|Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls|A Pilot Study Measuring Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|44|Samples Without DNA|Blood, urine|Male|18 Years|N/A|No|Non-Probability Sample|The Cisplatin-Based Chemotherapy Group will be recruited from the Genitourinary (GU)        oncology clinics. The GU Oncology section has a large clinical service which ensures        adequate recruitment.        The Surgery-Only Group will consist of patients with a diagnosis of GCT who have recently        had surgical management of their disease and are not planned to receive radiation or        chemotherapy. Potentially eligible patients will be recruited from the GU Oncology and        Urology clinics since they are seen by both services.|April 2015|April 28, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453660||97037|
NCT01441739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 04-197|Intestinal Failure in Necrotising Enterocolitis|Intestinal Failure in Necrotising Enterocolitis||Maastricht University Medical Center||Recruiting|September 2004|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Neonates with abdominal signs suspected of NEC All neonates admitted to the NICU of the        Maastricht University Medical Center between July 2007 and July 2008|December 2013|December 17, 2013|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01441739||97940|
NCT01442012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE6-ACU-2011-01|Utility of Acupuncture in the Treatment of Postoperative Nausea and Vomiting in Ambulatory Surgery|Randomized Clinical Trial to Evaluate the Utility of Acupuncture in the Treatment of Postoperative Nausea and Vomiting (PONV) in Ambulatory Surgery|PUCTURE-NVPO|Group G-6|No|Recruiting|September 2011|April 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|270|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 2, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442012||97919|
NCT01437930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H51_11|Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients|Influence of Intervention With n-3 PUFA-supplemented Products in Moderate Hypertriglyceridemic Patients on Cardiovascular Risk Factors||University of Jena|Yes|Completed|September 2011|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|80 Years|No|||March 2012|July 28, 2014|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437930||98232|
NCT01455116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-086|The Cooling And Surviving Septic Shock Study (CASS)|Randomized Trial to Determine Whether Mild Induced Hypothermia Can Reduce Mortality in Adult Patients With Septic Shock|CASS|Danish Procalcitonin Study Group|Yes|Recruiting|November 2011|October 2017|Anticipated|October 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Both|50 Years|120 Years|No|||March 2016|March 7, 2016|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01455116||96925|
NCT01455129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.467|Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China|Early Intervention With Tiotropium （Spiriva） in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel, Multicentre Trial|Tie-COPD|The First Affiliated Hospital of Guangzhou Medical University|No|Active, not recruiting|November 2011|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|40 Years|85 Years|No|||August 2014|August 16, 2014|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01455129||96924|
NCT01455142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1045-3834|A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes|A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|64 Years|No|||February 2015|February 19, 2015|October 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01455142||96923|
NCT01455376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-001.2011|Effect of Exogenous Lactate on Neurocognitive in Brain Trauma|Effect of Exogenous Lactate Infusion on Neurocognitive Function of Patients With Mild Traumatic Brain Injury||Universitas Padjadjaran|Yes|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|14 Years|60 Years|No|||October 2011|October 20, 2011|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01455376||96905|
NCT01455389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0432|FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer|Phase I/II Clinical Trial Combining FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer||Genprex, Inc.|No|Recruiting|February 2014|||March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455389||96904|
NCT01451190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0005995|A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)|A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects||Aderans Research Institute|No|Completed|July 2011|||March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451190||97227|
NCT01451437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07649|Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)|A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005))||Merck Sharp & Dohme Corp.|No|Terminated|November 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|October 11, 2011|No|Yes|The study was terminated early due to business reasons.|No|February 5, 2016|https://clinicaltrials.gov/show/NCT01451437||97208|
NCT01455363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2011-01|Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma|Etude peropératoire de la Perfusion Sanguine Des Carcinomes Basocellulaires Par Imageur Laser Doppler, au Cours de la Manipulation de l'Influx artériel Tumoral - Recherche d'un phénomène d'hyperémie Tumorale Post-occlusive|HPOB|Institut Curie|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|N/A|No|||September 2011|April 3, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01455363||96906|
NCT01451138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0004541|A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects||Aderans Research Institute|No|Completed|November 2010|||October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451138||97231|
NCT01451151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0004542|A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects||Aderans Research Institute|No|Completed|December 2010|||June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451151||97230|
NCT01451164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-002|A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia|A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|October 2011|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||||||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451164||97229|
NCT01451424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPV-200|Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids|A Phase 2, 3 Arm, Randomized, Double-Blind Study to Evaluate the Safety, PK and Efficacy of Proellex® Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids||Repros Therapeutics Inc.|No|Completed|February 2012|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|40|||Female|18 Years|47 Years|No|||August 2014|August 8, 2014|October 11, 2011|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT01451424||97209|
NCT01452503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9928|Preference Among 3 Female Condoms|Assessing Preference for 3 Female Condoms: A Comparative Evaluation of the PATH Woman's Condom, FC2 and the Reddy 6||FHI 360|No|Completed|May 2007|April 2008|Actual|February 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|170|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 14, 2011|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01452503||97126|
NCT01452230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-112|Prebariatric Surgery Physical Activity Program|Effectiveness and Efficacity of Presurgery Supervised Physical Activity Training on Health of Obese Individuals Waiting for Bariatric Surgery||Université de Sherbrooke|No|Active, not recruiting|October 2011|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|65 Years|No|||June 2015|June 18, 2015|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01452230||97147|
NCT01452516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B01-2010|Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions|A Prospective, Multi-Center, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages With Autograft in Conjunction With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive||Pioneer Surgical Technology, Inc.|No|Terminated|July 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|September 2, 2011|Yes|Yes|Study was terminated due to slow accrual rate.|No||https://clinicaltrials.gov/show/NCT01452516||97125|
NCT01453049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113263|An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients|A Multi-center, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy and Safety of Fixed-dose Rosiglitazone/Glimepiride Combination Therapy With Glimepiride Monotherapy for 24 Weeks in Drug Naive Subjects With Type 2 Diabetes||GlaxoSmithKline|No|Terminated|April 2010|October 2010|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|75 Years|No|||December 2011|March 22, 2012|October 13, 2011|||US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic|No|October 27, 2011|https://clinicaltrials.gov/show/NCT01453049||97084|
NCT01453062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114429|Phase IV Observational Study in Chronic Lymphocytic Leukemia|Phase IV Observational Study in Chronic Lymphocytic Leukemia Patients Receiving Ofatumumab in the European Union||GlaxoSmithKline|No|Completed|September 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|A total of 100 patients with CLL who have previously received Arzerra, whether alive or        deceased, and have either completed the full course of Arzerra therapy or discontinued        treatment early.|July 2014|July 3, 2014|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453062||97083|
NCT01452828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-123|A Pharmacokinetics and Safety Study in Subjects With Renal Impairment|A Phase I Open-Label Study With 200 mg Intravenous TR-701 Free Acid to Assess Safety and Pharmacokinetics in Advanced Renal Impairment Subjects||Trius Therapeutics LLC|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|75 Years|No|||October 2011|June 7, 2012|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452828||97101|
NCT01453114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P002161|Cognitive-Behavioral Therapy (CBT) in Women Discontinuing Antidepressant for Pregnancy|Cognitive-Behavioral Therapy in Women Discontinuing Antidepressant for Pregnancy||Massachusetts General Hospital|No|Completed|November 2008|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 6, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01453114||97079|
NCT01453387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200064-001|MSC2015103B in Solid Tumors|A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered With Two Different Treatment Schedules in Subjects With Advanced Solid Tumors||EMD Serono|No|Completed|September 2011|||July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||September 2013|September 10, 2013|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453387||97058|
NCT01453400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15772|Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain|Onset of Action of a Fast Release Aspirin Tablet and Acetaminophen Caplet in Sore Throat Pain|Tarot|Bayer|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|177|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01453400||97057|
NCT01453413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD PRO 2011-003-01|Blood Glucose Testing and You|Blood Glucose Testing and You||Ascensia Diabetes Care|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|297|||Both|18 Years|N/A|No|||February 2013|February 21, 2013|September 30, 2011|No|Yes||No|November 12, 2012|https://clinicaltrials.gov/show/NCT01453413||97056|
NCT01454336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-liver-003|Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone|Phase 1 Trial of Combined Pioglitazone Plus Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients With Compensated Cirrhosis||Royan Institute|Yes|Completed|June 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|65 Years|No|||February 2010|May 10, 2014|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01454336||96985|
NCT01441440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2411263|Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)|A Randomized, Double-blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder||Pfizer|No|Completed|November 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|538|||Both|20 Years|N/A|No|||March 2015|March 2, 2015|September 23, 2011||No||No|March 2, 2015|https://clinicaltrials.gov/show/NCT01441440||97963|
NCT01441453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FibroBoResect-01|Transient Elastography in Hepatectomy for Hepatocellular Carcinoma|Value of Transient Elastography in Predicting Postoperative Liver Failure in Patients Undergoing Liver Resection for Hepatocellular Carcinoma.||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Not yet recruiting||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|N/A|N/A|No|||September 2011|September 26, 2011|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01441453||97962|
NCT01441713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeH.750.19-25|Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer|Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer||Copenhagen University Hospital at Herlev|No|Completed|September 2011|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|178|||Male|18 Years|N/A|No|Non-Probability Sample|Men who are receiving pharmaceutical castration treatment (hormone treatment) at Herlev        Hospital for advanced prostate cancer and men who have undergone surgical castration        (Orchiectomy) and are in clinical control at Herlev Hospital.|December 2012|December 4, 2012|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01441713||97942|
NCT01441752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC 001|Efficacy Study of Integrated TCM Combined With Chemotherapy in Postoperative NSCLC Patients|State Administration of Traditional Chinese Medicine of Shanghai||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|November 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01441752||97939|
NCT01442025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETAID 2010-2|Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease|A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease|TAILORIX|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|Yes|Completed|June 2012|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|121|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01442025||97918|
NCT01442038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0116|Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization|RIVER-PCI|Gilead Sciences|Yes|Completed|October 2011|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2653|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442038||97917|
NCT01442051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-149|Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer|A Pilot Study of Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Female|18 Years|69 Years|No|||December 2015|December 10, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01442051||97916|
NCT01437943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000005|Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients|P-MR Spectroscopy Evaluation of the Effect of Short-Term Treatment With Aliskiren on Kidney β-ATP/Pi Level in Kidney Transplant Patients||Brigham and Women's Hospital|No|Terminated|April 2010|September 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||January 2012|January 3, 2012|September 20, 2011||No|Novartis has have decided to terminate all clinical investigator-initiated research projects    involving aliskiren|No||https://clinicaltrials.gov/show/NCT01437943||98231|
NCT01437956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0104|KL-6 Protein as a Biomarker of Lung Injury in Viral Bronchiolitis|Acute Bronchiolitis in Infants: Analysis of a Biomarker of Epithelial Lung Injury - Clinical and Virological Correlation||University Hospital, Clermont-Ferrand||Not yet recruiting|October 2011|October 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|1 Year|Accepts Healthy Volunteers|Probability Sample|infants aged under 1 year|September 2011|September 20, 2011|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01437956||98230|
NCT01454843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21220|LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser vs AMO Visx Wavefront-Guided Excimer Laser|A Prospective Eye to Eye Comparison of LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser Versus AMO Visx Wavefront-Guided Excimer Laser|LASIK|Stanford University|No|Active, not recruiting|June 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454843||96946|
NCT01455402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ID-MEDI-557-1089|An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF|An Observational Study to Assess Respiratory Syncytial Virus (RSV)-Associated Illness in Adults With Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF)|CD-1089|MedImmune LLC|No|Completed|July 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|476|Samples Without DNA|serum, whole blood, plasma, nasal swab, sputum|Both|50 Years|N/A|No|Non-Probability Sample|The study population consists of adults with severe COPD and/or CHF who expect to have        contact with children. Potential subjects will be identified through the medical record        and extended invitations to volunteer.|July 2014|July 8, 2014|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01455402||96903|
NCT01451203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDP870-275-11-001|Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors||Astellas Pharma Inc|No|Completed|October 2011|October 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|319|||Both|20 Years|64 Years|No|||December 2015|December 22, 2015|September 25, 2011||No||No|October 18, 2015|https://clinicaltrials.gov/show/NCT01451203||97226|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01451710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1102|The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy|The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy||Nanjing University School of Medicine|Yes|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||July 2012|July 9, 2012|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01451710||97187|
NCT01451723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23AT004433-02|Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II|Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS|POEMS|Louisiana State University Health Sciences Center in New Orleans|Yes|Terminated|July 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|60 Years|No|||January 2014|January 30, 2014|October 11, 2011|Yes|Yes|Unusual high frequency of elevated liver function tests.|No|December 10, 2013|https://clinicaltrials.gov/show/NCT01451723||97186|The study was halted prematurely because of the high incidence of liver function abnormalities
NCT01451957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-0165|Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity|Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity||University of Michigan|No|Active, not recruiting|August 2003|October 2016|Anticipated|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|7|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451957||97168|
NCT01452204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEMF01|Pulsed Electromagnetic Field (PEMF) in Impingement Shoulder|Pulsed Electromagnetic Field in Patients With Impingement Shoulder: A Randomized, Placebo-Controlled Clinical Trial|PEMF|Faculdade de Ciências Médicas da Santa Casa de São Paulo|No|Recruiting|July 2009|March 2012|Anticipated|December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 13, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01452204||97149|
NCT01451983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 09-624|Genetics, Brain Structure and Thinking Skills in Autism|Genetic, Biochemical, Behavioral and Neuroimaging Phenotypes of Autism Spectrum Disorders (ASDs)||The Cleveland Clinic|Yes|Completed|May 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|138|Samples With DNA|About 6 tubes of blood or up to 50 ml (3-4 tablespoons) and 30 mL of urine will be      collected.|Both|2 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|We anticipate recruiting 80 participants with autism spectrum disorder and large head        size, 80 participants with autism spectrum disorder without large head size and 40 healthy        siblings. Biological parents are expected to be recruited only as genetic changes are        identified in individuals with autism spectrum disorders to better understand the nature        of these genetic changes.|January 2015|January 7, 2015|October 11, 2011||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01451983||97166|Modest PTEN-ASD sample size and difficulty in closely matching each PTEN patient to one or more patients from each comparison group; Lack of comprehensively characterized PHTS patients without ASD is also a limitation.
NCT01452529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYD3002|Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain|A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Low Back Pain||Purdue Pharma LP|Yes|Completed|October 2011|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|905|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|October 12, 2011|Yes|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01452529||97124|
NCT01452542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD03811|A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects|A Pilot, Phase 1, Single-site, Single-dose, Randomized, Open-label, Two-treatment, Two-sequence, Four-period Replicated Crossover Study Evaluating the Within-subject Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects.||Sanofi|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|October 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01452542||97123|
NCT01452555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21NR011997|Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos|Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos||Rhode Island Hospital||Recruiting|August 2011|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2011|October 12, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01452555||97122|
NCT01452841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0695-02|A Grapefruit Feeding Trial in Healthy, Overweight Adults|Efficiency of Daily Grapefruit Exposure in Reducing Body Weight and Inflammatory Markers||University of Arizona|Yes|Completed|August 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 14, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01452841||97100|
NCT01452854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF 10-03288|Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide|Ovarian Aging in Women Newly Diagnosed With Low Grade Glioma Treated With Temozolomide (Temodar®)|OVA-LGG|University of California, San Francisco|Yes|Terminated|October 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Female|18 Years|44 Years|No|Non-Probability Sample|The study cohort will include adult women of childbearing potential with a diagnosis of        low grade glioma (WHO grade II) who are being treated with temozolomide (Temodar).|August 2014|August 13, 2014|October 12, 2011||No|Low recruitment, sponsor withdrew funding.|No|June 10, 2014|https://clinicaltrials.gov/show/NCT01452854||97099|
NCT01453725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07642|Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02).|GO-AHEAD|Merck Sharp & Dohme Corp.|No|Completed|February 2012|January 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|45 Years|No|||February 2016|February 16, 2016|October 13, 2011|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01453725||97032|
NCT01453738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRPL/OA/09-10/001|Allogeneic Mesenchymal Stem Cells in Osteoarthritis|A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee||Stempeutics Research Pvt Ltd|Yes|Active, not recruiting|November 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|70 Years|No|||November 2012|November 24, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453738||97031|
NCT01453426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV108|Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers|An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers|109HV108|Biogen|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|71|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|September 12, 2013|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453426||97055|
NCT01453699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2009|Long-term Consequences of Bereavement in Children, Adolescents and Young Adults|Bereavement in Children, Adolescents and Young Adults. - A Study of Health and Psychosocial Well-being in Adults Who Have Experienced Early Parental Death||Danish Cancer Society|No|Completed|September 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1225660|||Both|15 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Nationwide population-based cohort (Denmark)|August 2014|August 11, 2014|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01453699||97034|
NCT01454037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107059RB|Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy|Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy||National Taiwan University Hospital||Recruiting|October 2011|October 2015|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|160|||Male|20 Years|N/A|No|Non-Probability Sample|Taiwanese organ-confined or locally advanced prostate cancer patients|March 2012|November 12, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01454037||97008|
NCT01454050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55|Lumax 740 Master Study|PME/Master Study of the Lumax 740 ICD Family|Lumax 740|Biotronik SE & Co. KG|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|189|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with standard ICD indication who are referred to the hospital.|November 2012|November 27, 2012|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454050||97007|
NCT01441466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bronchiolitis|Cohort Isolation and Cross-infection in Bronchiolitis|Cross-infection in Children Hospitalized for Bronchiolitis: Incidence, Symptoms en Effect of Cohort Isolation||Princess Amalia Children's Clinic|No|Completed|November 2011|May 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|48|Samples Without DNA|sputum|Both|N/A|24 Months|No|Non-Probability Sample|Infants admittted for bronchiolitis under 2 years of age|July 2015|July 10, 2015|September 23, 2011||No||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01441466||97961|
NCT01441479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0142-01|Strep A Fluorescent Immunoassay and Analyzer Field Study|Strep A Fluorescent Immunoassay and Analyzer Field Study||Quidel Corporation|No|Completed|June 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1282|||Both|3 Years|N/A|No|Non-Probability Sample|Subjects must be greater than 3 years of age and exhibiting symptoms characteristic of        pharyngitis, possibly Group A Streptococcus.|December 2012|February 5, 2013|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441479||97960|
NCT01441765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-178|PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine|Phase II Study of PD-1 Blockade Alone or In Conjunction With the Dendritic Cell (DC)/Renal Cell Carcinoma (RCC) Fusion Cell Vaccination||Dana-Farber Cancer Institute|Yes|Active, not recruiting|November 2011|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441765||97938|
NCT01442064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF3426g (Cohort 2)|An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)|An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study||Genentech, Inc.||Completed|July 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|608|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|September 26, 2011|Yes|Yes||No|December 5, 2011|https://clinicaltrials.gov/show/NCT01442064||97915|
NCT01437969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPAT-IL28B|Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.|Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Chronic Infection naïve to Antiviral Treatment.||Casa Sollievo della Sofferenza IRCCS||Recruiting|September 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|DNA from blood sample|Both|18 Years|70 Years|No|Probability Sample|HCV infected patients previously untreated|April 2012|April 14, 2012|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01437969||98229|
NCT01437982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|628|A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%|A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%||Bausch & Lomb Incorporated|No|Active, not recruiting|February 2011|July 2014|Anticipated|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|690|||Both|N/A|N/A|No|||November 2013|November 22, 2013|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437982||98228|
NCT01455441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60 - TrainIncretin|The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes|Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?||University Hospital, Gentofte, Copenhagen|Yes|Completed|October 2011|June 2014|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||May 2015|May 28, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01455441||96900|
NCT01451229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-PK003|Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects|An Open-Label, Single-dose Administration Study of the Pharmacokinetics and Pharmacodynamics of Higenamine, Administered Intravenously Injection to Healthy Chinese Subjects||Peking Union Medical College Hospital|Yes|Completed|June 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 12, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451229||97224|
NCT01455155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si290/2011|Creative Therapy to Affect Stroke Outcomes|Efficacy of Creative Therapy for Stroke Patients||Mahidol University|No|Not yet recruiting|November 2011|May 2014|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Both|50 Years|85 Years|No|||October 2011|October 15, 2011|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01455155||96922|
NCT01455415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081268|Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain|A Study Of Pregabalin In The Treatment Of Subjects With Painful Diabetic Peripheral Neuropathy With Background Treatment Of Nsaid For Other Pain Conditions||Pfizer|No|Completed|December 2011|December 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|October 17, 2011|Yes|Yes||No|October 30, 2014|https://clinicaltrials.gov/show/NCT01455415||96902|
NCT01455428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081276|Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)|An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn )||Pfizer|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|October 17, 2011|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01455428||96901|
NCT01451450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031A2208|Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy|A Phase II, Randomized, Double Blind, Placebo-controlled, Parallel Design, Dose Ranging, Multi-center Trial of Four Levels of Exposure of QGE031 s.c. for 16 Weeks in Subjects Aged 18-50 Years of Age With Peanut Allergy||Novartis||Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|0|||Both|18 Years|50 Years|No|||July 2012|July 20, 2012|October 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451450||97207|
NCT01451736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50 MH066286 Phase II|Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia|Clinical and Cognitive Effects of Paliperidone Palmitate vs. Oral Risperidone in First-Episode Schizophrenia||University of California, Los Angeles|No|Recruiting|October 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 9, 2013|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451736||97185|
NCT01451970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N009310|Dietary Fatty Acid Composition and Obesity-related Metabolic Abnormalities|Assessing the Effects of Two Diets Enriched in Either Saturated or Unsaturated Fatty Acids to Determine the Cellular and Molecular Mechanisms in Insulin Sensitivity||University of Michigan|No|Active, not recruiting|August 2007|January 2020|Anticipated|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451970||97167|
NCT01452217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D/07/2010|Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers|The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers||University of Nottingham|No|Completed|September 2010|October 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 13, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01452217||97148|
NCT01452568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-080/04|Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin|Early Anticoagulation Therapy After Bioprosthetic Aortic Valve Implantation: Comparing Warfarin Versus Aspirin||Rigshospitalet, Denmark|No|Completed|June 2005|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|370|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|September 22, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452568||97121|
NCT01453127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001999|DaTSCAN Imaging in Aging and Neurodegenerative Disease|DaTSCAN Imaging in Aging and Neurodegenerative Disease||Mayo Clinic|No|Enrolling by invitation|October 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|8||Anticipated|130|||Both|40 Years|90 Years|No|||January 2016|January 7, 2016|September 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01453127||97078|
NCT01453478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115550|A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced|A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bioenhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion||GlaxoSmithKline|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|20|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453478||97051|
NCT01454011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-012011|The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups|Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups.||Gulhane School of Medicine|No|Completed|September 2008|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Male|N/A|N/A|Accepts Healthy Volunteers|||October 2011|October 14, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01454011||97010|
NCT01454024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPEN3-3882|Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice|A Study Evaluating the Safety of NovoPen®3 and FlexPen® in Subjects With Type 1 and Type 2 Diabetes. A 24-week, Prospective, Multi-centre, Open-labelled, Non-interventional Study||Novo Nordisk A/S|No|Completed|November 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1031|||Both|N/A|N/A|No|Non-Probability Sample|The selection of the subjects will be at the discretion of the individual physician based        on clinical judgement.|June 2015|June 11, 2015|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454024||97009|
NCT01454362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QMUL111111|Effect of the Electronic Cigarette on Withdrawal Symptoms|Phase 4 Study to Compare of the Effects of the Electronic Cigarette and Nicotine Inhalator on Tobacco Withdrawal Symptoms Over 24 Hours of Abstinence|ECIG24|Queen Mary University of London|Yes|Completed|December 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 21, 2013|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01454362||96983|
NCT01441492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28324|Pancreas Resection With and Without Drains|A Randomized Prospective Multicenter Trial of Pancreas Resection With and Without Routine Intraperitoneal Drainage||Baylor College of Medicine|Yes|Recruiting|September 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|570|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01441492||97959|
NCT01441778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-PE-2-CR038-038/53|Efficacy of Buffered Hypertonic Saline(BHS)Nasal Irrigation in Allergic Rhinitis (AR) Children|Efficacy of Buffered Hypertonic Saline Nasal Irrigation in Children With Symptomatic Allergic Rhinitis : A Randomized Double-blind Study.||Thammasat University|No|Completed|June 2010|December 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||September 2011|September 27, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01441778||97937|
NCT01438268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0050-E|TRAM Procedure in Ambulatory Surgical Facility: Quality of Recovery Outcomes|Expedited Discharge of Patients Undergoing Pedicled TRAM Flap Breast Reconstruction Procedure in Ambulatory Surgical Facility: Quality of Recovery Outcomes|TRAM|Women's College Hospital|No|Active, not recruiting|July 2011|January 2014|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|75 Years|No|Probability Sample|Reconstructive breast cancer patients|November 2013|November 15, 2013|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01438268||98206|
NCT01437995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV115922|Long-acting Beta Agonist Step Down Study|Long-acting Beta Agonist Step Down Study|LASST|Johns Hopkins University|Yes|Completed|March 2012|October 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|459|||Both|12 Years|N/A|No|||February 2016|February 26, 2016|September 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437995||98227|
NCT01438255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALVESCO-OS01|Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice|||Handok Pharmaceuticals Co., Ltd.|No|Completed|July 2010|||July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|274|||Both|6 Years|18 Years|No|Probability Sample|outpatients|August 2012|August 21, 2012|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01438255||98207|
NCT01455194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-9709-301-RD|Effect of High Dose Ciclesonide on Asthma Control|Control of Moderate or Severe Asthma With 160, 320 and 640 μg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.|CONTRAST|Takeda|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|367|||Both|12 Years|70 Years|No|||April 2015|April 10, 2015|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01455194||96919|
NCT01455454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123/10|Heparin's Influence on ROTEM® Analysis|Evaluation of the Feasibility of Rotational Thromboelastrometry During Cardiopulmonary Bypass Using a Heparinase Modified ROTEM® Assay||University of Lausanne Hospitals|No|Completed|September 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Whole blood|Both|18 Years|85 Years|No|Probability Sample|Patients undergoing coronary artery bypass grafting using cardiopulmonary bypass|October 2011|October 19, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455454||96899|
NCT01451242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8790-OK-CTIL|The Reliability of Heart Rate Variability Among Patients With Brain Injury as Measured by POLAR RC810XE Compared to HOLTER|The Reliability of Heart Rate Variability Measurements Among Patients With Acquired Brain Injury as Measured During Physical Activity by POLAR RC810XE Compared to HOLTER EKG||Sheba Medical Center|No|Not yet recruiting|October 2011|||||N/A|Observational|Observational Model: Cohort||1|Anticipated|30|||Both|18 Years|80 Years|No|Non-Probability Sample|30 patients following brain injury hospitalized in sheba medical center in the Brain        injury rehabilitation unit.|October 2011|October 12, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451242||97223|
NCT01455467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-024|Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery|A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery||Glaukos Corporation|No|Active, not recruiting|September 2011|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01455467||96898|
NCT01451476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSA_GEP|Human Skin Aging: Clinical Parameters and Gene Expression Profiling|Human Skin Aging: Clinical Parameters and Gene Expression Profiling|GEP|Stanford University|No|Active, not recruiting|May 2010|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|120|Samples With DNA|Blood and skin samples|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy females age 18 or older|February 2015|February 5, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451476||97205|
NCT01451762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00044695|A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery|A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery||Northwestern University|No|Completed|September 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Female|18 Years|64 Years|No|||February 2014|February 14, 2014|September 20, 2011|Yes|Yes||No|October 28, 2013|https://clinicaltrials.gov/show/NCT01451762||97183|We did not obtain preoperative quality of recovery scores of patients therefore we could not examine whether the effect of diphenhydramine was dependent upon patient's baseline characteristics.
NCT01451216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8745-OK-CTIL|The Evaluation of Balance Control by Quantification of Temporospatial Measures While Forward and Side Reaching|The Evaluation of Balance Control by Quantification of the Temporospatial Measures of Functional Reach Test||Sheba Medical Center|No|Not yet recruiting|November 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|40|||Both|20 Years|70 Years|No|Non-Probability Sample|Acquired Brain patients who are hospitalized in the Brain Injury department in Sheba        Medical Center Israel for rehabilitation. Males and females, from them 20 aged 25-50, 20        aged 50-70.All the participents are able to stand without assistance for at list 10 sec.        and can walk with or without walking aid. In addition they will not have any limitation of        the upper or lower limbs range of motion.|October 2011|October 17, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451216||97225|
NCT01451463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0312|Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease|Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease||Ohio State University|No|Completed|April 2010|April 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals with Huntington's disease who are already on Xenzaine (tetrabenazine) or who        have recently been prescribed the medicaion.|May 2013|May 7, 2013|October 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451463||97206|
NCT01451749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFDA2001ZL116-SW|Efficacy and Safety Study of Shenwu Capsule|Phase III Study of Shenwu Capsule in Treating Amnestic Mild Cognitive Impairment||North China Pharmaceutical Group Corporation|Yes|Completed|September 2008|May 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|324|||Both|55 Years|80 Years|No|||October 2014|October 9, 2014|October 11, 2011|Yes|Yes||No|November 24, 2013|https://clinicaltrials.gov/show/NCT01451749||97184|First, there was no placebo group. As all subjects knew that they were being treated with one of two drugs, and all of the individuals who assessed the patients knew this as well, the results may have been influenced by a positive response bias.
NCT01452243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006001|Prevention of Falls and Fractures in Old People by Administration of Calcium and Vitamin D. Randomized Clinical Trial|Prevention of Falls and Fractures in Old People by Administration of Calcium and Vitamin D. Randomized Clinical Trial (ANVITAD)|ANVITAD|Gerencia de Atención Primaria, Albacete|No|Active, not recruiting|November 2008|April 2012|Anticipated|November 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|704|||Both|65 Years|N/A|No|||October 2011|October 11, 2011|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01452243||97146|
NCT01452256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH Nr.2011-0092|Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery|Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery||University of Zurich||Completed|December 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01452256||97145|
NCT01452867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLS VENT 2011/04|Comparison of Ventilation With Bag-Valve-Mask, Laryngeal Tube S-D and Laryngeal Mask Airway Supreme|Comparison of Ventilation With Bag-Valve-Mask, Laryngeal Tube S-D and Laryngeal Mask Airway Supreme||Krankenhaus Bruneck|Yes|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|90 Years|No|||October 2011|October 14, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452867||97098|
NCT01453491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115951|A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis|A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects With Mild to Moderate Ulcerative Colitis||GlaxoSmithKline|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|75 Years|No|||July 2013|August 1, 2013|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453491||97050|
NCT01453439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH091078|Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder|CBT Versus Supportive Psychotherapy for Body Dysmorphic Disorder||Massachusetts General Hospital|Yes|Recruiting|August 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01453439||97054|
NCT01453452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1008|S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors|S1008: Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention In Breast and Colorectal Cancer Survivors, Phase II||Southwest Oncology Group|Yes|Active, not recruiting|March 2012|June 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Female|N/A|N/A|No|||September 2015|September 17, 2015|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01453452||97053|
NCT01453465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTR12B1|Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor|Gene Expression (GE) and MicroRNA (MIRNA) Expression Profiles of Malignant Rhabdoid Tumors (MRT) of the Kidney (RTK) and Atypical Teratoid Rhabdoid Tumor (ATRT||Children's Oncology Group|No|Withdrawn|September 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|120 Years|No|Non-Probability Sample|Rhabdoid tumor|February 2016|February 19, 2016|October 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01453465||97052|
NCT01453751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-DI-US-001|Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Via Catheter Into the Pancreatic Artery and/or Intravenously in Patients With Type II Diabetes||Ageless Regenerative Institute|No|Recruiting|March 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|80 Years|No|||July 2014|July 10, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01453751||97030|
NCT01453764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-003|Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intrathecally and Intravenously Into Patients With Multiple Sclerosis||Ageless Regenerative Institute|No|Not yet recruiting|October 2014|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||January 2014|March 19, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01453764||97029|
NCT01455259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002:CD40L|Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors|Phase I/IIa AdCD40L Immunogene Therapy for Patients With Advanced Malignant Disease.||Uppsala University|No|Completed|September 2011|January 2016|Actual|January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01455259||96914|
NCT01441505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 10409|A Study of Ketamine as an Antidepressant|A Study of Ketamine as an Antidepressant||The University of New South Wales|No|Recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01441505||97958|
NCT01438008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123942|Pilot Study of Sucrose to Reduce Pain in Sick Babies|Be Sweet to Sick Babies: Analgesic Effects of Oral Sucrose and Concomitant Opioid Analgesics; a Pilot Randomized Controlled Trial||Children's Hospital of Eastern Ontario|Yes|Recruiting|May 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 9, 2016|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01438008||98226|
NCT01469741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103176|Rehabilitation of Everyday Memory Impairment in Parkinson Disease: A Pilot Study|Rehabilitation of Everyday Memory Impairment in Parkinson Disease: A Pilot Study|REMI-PD|Washington University School of Medicine|No|Completed|June 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|74|||Both|50 Years|N/A|No|||June 2015|June 1, 2015|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469741||95809|
NCT01438541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Window 02|A Multi-centre Evaluation of the Performance of Window Dressings on Subjects With High Risk Pressure Ulceration|A Multi-centre, Post CE-mark, Open Study to Evaluate the Performance of Thin Self-adherent Dressing Coated With a Soft Silicone Layer on Subjects With High Risk of Category 2 or Above Pressure Ulceration||Molnlycke Health Care AB|No|Completed|September 2011|April 2012|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|29|||Both|18 Years|N/A|No|||July 2012|July 2, 2012|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01438541||98185|
NCT01438554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1162|Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma|Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma||Sidney Kimmel Comprehensive Cancer Center||Active, not recruiting|October 2011|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|111|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|August 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01438554||98184|
NCT01451268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589 BDE05T|Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)|Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk MDS or AML (PANOBEST)|PANOBEST|Johann Wolfgang Goethe University Hospitals|No|Recruiting|January 2011|August 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01451268||97221|
NCT01451255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002576|Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging|Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging||Mayo Clinic||Completed|August 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|90|||Both|18 Years|99 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population will consist of a total of 90 subjects separated evenly into the following        subgroups: 1) Mild PAH, 2) Moderate or Severe PAH, and 3) Normal Controls.|March 2016|March 15, 2016|October 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01451255||97222|
NCT01451489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJCT-1101|The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis|A Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental Glomerulosclerosis|FSGS|Nanjing University School of Medicine|Yes|Recruiting|October 2011|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|14 Years|65 Years|No|||March 2015|March 31, 2015|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01451489||97204|
NCT01451775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.79|Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.|Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet and Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets in an Open, Randomised, Single Dose, Three-period Cross-over Study in Healthy Male and Female Subjects||Boehringer Ingelheim||Completed|October 2011|||November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|October 11, 2011||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01451775||97182|
NCT01451996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16171A|The Efficacy of Claritin in Healthy Subjects|The Efficacy of Claritin in Healthy Subjects||University of Chicago|No|Completed|October 2011|December 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|1||Actual|490|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451996||97165|
NCT01452009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-151|Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%|Three Month Safety and Efficacy Study of TRAVATAN® vs Travoprost Ophthalmic Solution, 0.004%||Alcon Research|No|Withdrawn|November 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|October 12, 2011|Yes|Yes|Management Decision|No||https://clinicaltrials.gov/show/NCT01452009||97164|
NCT01452269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deaf Weight Wise|Study of a Healthy Lifestyle Intervention for Deaf Adults Who Are Overweight or Obese|Deaf Weight Wise: A Healthy Lifestyle Intervention for Deaf Adults|DWW|University of Rochester|Yes|Completed|October 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|September 21, 2011||No||No|June 16, 2015|https://clinicaltrials.gov/show/NCT01452269||97144|
NCT01452581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2011-058|Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty|Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty||Rigshospitalet, Denmark|No|Terminated|October 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|October 10, 2011||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01452581||97120|
NCT01453140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TREG - Pro2219|In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease|Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease|T-REG|Hackensack University Medical Center|Yes|Completed|August 2011|July 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|70 Years|No|||July 2013|July 17, 2013|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453140||97077|
NCT01454089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGX-427-02|A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer|A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma||OncoGenex Technologies|No|Completed|October 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454089||97004|
NCT01453777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-DL-001|Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Via Catheter Into the Internal Carotid Artery and Intravenously in Patients With Diffuse Lesions in the Brain||Ageless Regenerative Institute|No|Recruiting|May 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||October 2013|October 28, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01453777||97028|
NCT01454063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS302 ILR 003|Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|OMS302-ILR-003|Omeros Corporation|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|October 13, 2011|Yes|Yes||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01454063||97006|
NCT01454076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16009|Phase 1 Pharmacokinetics Study of Oral IXAZOMIB in Patients With Advanced Nonhematologic Malignancies or Lymphoma|A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|November 2011|April 2016|Anticipated|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454076||97005|
NCT01441518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-52|Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia|A Prospective Randomized Trial of Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia||UPECLIN HC FM Botucatu Unesp||Completed|May 2010|November 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|45 Years|No|||September 2011|July 7, 2015|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01441518||97957|
NCT01469533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-2011020|Pressure Pain Thresholds and Basal Electromyographic Activities Following Spinal Mechanical Manipulation|Changes in Pressure Pain Thresholds and Basal Electromyographic Activities Following Spinal Mechanical Manipulation in Asymptomatic Subjects||RenJi Hospital|Yes|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 8, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01469533||95825|
NCT01469754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107011786|Longitudinal Survey Analysis in Lymphoma Survivors|Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors|CLEAR Stress|Weill Medical College of Cornell University|No|Completed|September 2011|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Lymphoma survivors who have completed initial treatment within the last 3 months|May 2014|May 1, 2014|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469754||95808|
NCT01470001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0513|The Effect of Solifenacin on Post Void Dribbling in Women|The Effect of Solifenacin on Post Void Dribbling in Women: A Randomized Controlled Multicenter Trial||University of Wisconsin, Madison|Yes|Completed|November 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|89 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470001||95789|
NCT01451281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110261|Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular Dystrophy|Evaluation of Skeletal Muscle, Cardiac, and Diaphragm Imaging Biomarkers for GSK2402968 Effects in Ambulatory Boys With Duchenne Muscular Dystrophy||National Institutes of Health Clinical Center (CC)||Completed|September 2011|||||N/A|Observational|N/A|||Actual|35|||Male|5 Years|17 Years|Accepts Healthy Volunteers|||May 2015|December 11, 2015|October 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01451281||97220|
NCT01451502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS079|Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units|Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units||Masonic Cancer Center, University of Minnesota|No|Recruiting|October 2011|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|250|||Both|N/A|N/A|No|||January 2016|January 21, 2016|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451502||97203|
NCT01451801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJF0001|Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders|Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders||University of Aarhus|Yes|Active, not recruiting|October 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 25, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01451801||97180|
NCT01451788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TurkuUH|Effect of Human Thrombin With Gelatin Matrix on Perioperative Blood Loss in Scoliosis Surgery|Effectiveness Of Gelatin Matrix With Human Derived Thrombin On Blood Loss, Surgical Time, Hospital Stay And Complications In Adolescents Undergoing Spine Surgery For Adolescent Idiopathic Scoliosis: A Randomized Clinical Trial.||Turku University Hospital|No|Recruiting|November 2011|December 2016|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|10 Years|20 Years|No|||November 2014|November 14, 2014|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01451788||97181|
NCT01452022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDOUS1001|Performance of Inductigraft in Spinal Fusion|A Prospective Open-label Non-randomdised Multi-centre Clinical Study to Evaluate the Performance of Inductigraft in Posterolateral Fusion|APOLLO|Apatech, Inc.|No|Completed|October 2011|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|18 Years|N/A|No|||August 2015|March 10, 2016|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01452022||97163|
NCT01452035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DK077966 - MX|Exercise Dose Response for Improving Insulin Sensitivity|Comparing the Effects Exercise Intensity and Energy Expended During a Single Exercise Session on Insulin Sensitivity and Fatty Acid Partitioning Within Skeletal Muscle the Next Day in Obese Adults.||University of Michigan|No|Completed|January 2009|December 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452035||97162|
NCT01452282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP - 0175/11|Ankle-Brachial Index Estimating Cardiac Complications After Surgery|Ankle-Brachial Index Estimating Cardiac Complications After Non-Cardiac Surgery|ABRACOS|University of Sao Paulo|No|Completed|October 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|196|Samples Without DNA|Whole blood samples will be retained for future exams.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Both sex patients aged 18 or older, undergoing non-cardiac and non-vascular surgery will        be referred for the study.|November 2013|November 9, 2013|October 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01452282||97143|
NCT01452594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKR-0742|Analysis of Diphenylcyclopropenone (DPCP) in Normals|Analysis of Immune Reactions Occurring in Normal Volunteers Upon Administration of the Topical Immunomodulator Diphenylcyclopropenone||Rockefeller University|No|Completed|October 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Skin Biopsy|Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers|September 2013|September 4, 2013|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452594||97119|
NCT01452607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1005-101|Study to Evaluate the Safety and Pharmacokinetics of SPI-1005|A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects||Sound Pharmaceuticals, Incorporated|Yes|Completed|May 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|32|||Both|19 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01452607||97118|
NCT01452620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-10-01|Endovascular Abdominal Aortic Aneurysm Repair by Interventional Cardiologists||EVAR|St. Joseph Mercy Oakland Hospital||Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|170|||Both|18 Years|N/A|No|Non-Probability Sample|Study patients comprised of all patients undergoing endovascular abdominal aortic aneurysm        repair performed primarily by Interventional Cardiologists in our community setting.|October 2011|October 14, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452620||97117|
NCT01452880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|francesco cannata|Remifentanil in Extracorporeal Shock Wave Lithotripsy|Total Intravenous Anaesthesia Using Remifentanil In Extracorporeal Shock Wave Lithotripsy (ESWL). Comparison of Two Dosages.|ESWL|University of Roma La Sapienza|Yes|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|228|||Both|18 Years|70 Years|No|||October 2011|October 12, 2011|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01452880||97097|
NCT01453153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Halo-109-201|Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer|A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer||Halozyme Therapeutics|No|Completed|September 2011|May 2015|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||September 2013|October 12, 2015|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453153||97076|
NCT01454102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-012|Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)|A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)||Bristol-Myers Squibb|No|Active, not recruiting|December 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|19||Anticipated|412|||Both|18 Years|N/A|No|||July 2015|March 11, 2016|September 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454102||97003|
NCT01454115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN156-001|Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Subjects and a Comparison to Elderly Male and Female Subjects||Bristol-Myers Squibb|No|Completed|June 2007|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|14||Actual|116|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 18, 2011|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454115||97002|
NCT01454375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01625|Emergency Department Smoking Cessation Study|Emergency Department Tobacco Cessation Counseling: Implementation and Evaluation of a Community-Based Program||University of British Columbia|No|Completed|November 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1301|||Both|19 Years|N/A|No|||October 2014|October 2, 2014|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01454375||96982|
NCT01454934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-G000-302|A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer|||Eisai Inc.|No|Active, not recruiting|September 2011|July 2014|Anticipated|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|540|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454934||96939|
NCT01454947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC4AG039115-01|Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)|Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)|BEARI|University of Southern California|Yes|Enrolling by invitation|August 2011|September 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|550|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01454947||96938|
NCT01454674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0820-02|The Vegetable Dose Response Study: Effects of Consumption on Inflammation and Oxidative Stress|The Vegetable Dose Response Study: Effects of Consumption on Inflammation and Oxidative Stress||University of Arizona|No|Completed|October 2007|August 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|75|||Female|50 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 18, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01454674||96959|
NCT01454687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 22005|Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes|Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes||Stanford University|No|Withdrawn|October 2011|||April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 10, 2014|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01454687||96958|
NCT01442077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0359-11-RMB|Low Intensity Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction- 4 Arms|Low Intensity Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction- 4 Arms||Rambam Health Care Campus|No|Recruiting|November 2011|November 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Male|20 Years|80 Years|No|||January 2012|January 17, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01442077||97914|
NCT01442090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4973g|Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy|A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy||Genentech, Inc.||Completed|October 2011|July 2015|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01442090||97913|
NCT01469273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU 0932 BL|Prophylaxis of Gastrointestinal Infections With EcN|Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle|PIURA|Hospital San Bartolome|No|Not yet recruiting|November 2011|December 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|198|||Both|N/A|12 Months|Accepts Healthy Volunteers|||November 2011|November 9, 2011|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469273||95844|
NCT01469520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RU 2010-73|Bioequivalence Study of Pediatric Formulations to Treat HIV Infection|Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers||Elim Pediatric Pharmaceuticals Inc.|Yes|Active, not recruiting|October 2010|December 2011|Anticipated|November 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|22 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 8, 2011|November 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469520||95826|
NCT01439971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3051001|A Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Subjects With Hemophilia A Or B|An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics/Pharmacodynamics Of Pf-05280602, A Recombinant Factor Viia Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors||Pfizer|Yes|Completed|December 2011|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|24|||Male|18 Years|64 Years|No|||July 2015|July 1, 2015|August 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01439971||98075|
NCT01440543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 01|Combination of Water Immersion and Carbon Dioxide Insufflation for Minimal Sedation Colonoscopy|Combination of Water Immersion and Carbon Dioxide Insufflation for Minimal Sedation Colonoscopy - a Prospective, Randomized, Single-center Trial|Water/CO2|Vitkovice Hospital|No|Completed|January 2011|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Actual|420|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|September 19, 2011||No||No|December 19, 2012|https://clinicaltrials.gov/show/NCT01440543||98031|There were no procedure- or sedation-related complications recorded in the study.
NCT01470014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK 2011-0099|Cardiac Computed Tomography: Characteristics of Isolated Left Ventricular Non-compaction|||University of Zurich||Completed|October 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|39|||Both|30 Years|90 Years|No|Non-Probability Sample|Patients will be recruited from the Department of Cardiology and Cardiac Imaging Division.        They will be asked if they want to participate in this study.|December 2015|December 9, 2015|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01470014||95788|
NCT01451528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBIUCB|Allogeneic Umbilical Cord Blood Therapy for Chronic TBI|The Efficacy and Safety of Allogeneic Umbilical Cord Blood Therapy for Chronic Traumatic Brain Injury Patients||Bundang CHA Hospital|No|Withdrawn|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|October 11, 2011||No|The research fund, which is yet to be raised and expected to take for a while|No||https://clinicaltrials.gov/show/NCT01451528||97201|
NCT01451541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP060-306|A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).|A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis||Sunovion|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|848|||Both|6 Years|11 Years|No|||April 2014|April 4, 2014|October 11, 2011|Yes|Yes||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01451541||97200|
NCT01451515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL16|NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma|NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma||St. Jude Children's Research Hospital|No|Recruiting|May 2012|May 2027|Anticipated|May 2027|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|N/A|21 Years|No|||March 2016|March 23, 2016|August 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451515||97202|
NCT01451814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-156241-1|Development of Positive Psychotherapy for Smoking Cessation|Development of Positive Psychotherapy for Smoking Cessation||Brown University|No|Completed|October 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 6, 2015|October 11, 2011||No||No|February 23, 2015|https://clinicaltrials.gov/show/NCT01451814||97179|
NCT01451827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-09-290|8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Immediate-release Formulations in Subjects With Autosomal Dominant Polycystic Kidney Disease|NOCTURNE|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|178|||Both|18 Years|50 Years|No|||June 2014|June 12, 2014|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451827||97178|
NCT01452048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DK077966 - OC|Relationship Between Systemic Fatty Acid Availability and Insulin Sensitivity|||University of Michigan|No|Recruiting|September 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|Samples With DNA|frozen tissue, plasma|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|UM Health System patients from Dr. Amy Rothberg and colleagues UM Investigational Weight        Management Clinic (IWMC) Community Sample|December 2015|December 2, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452048||97161|
NCT01452061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 11-949|Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder|Understanding Genetic Differences Associated With Autism Spectrum and Attention Deficit/Hyperactivity Disorder||The Cleveland Clinic|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|456|Samples With DNA|Genetic material via a cheek swab will be collected.|Both|1 Year|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|About 600 people will take part in this study - 300 individuals with an autism spectrum        disorder, 75 individuals with attention deficit/hyperactivity disorder or another        developmental or psychiatric disorder, 100 healthy siblings, and 125 unrelated individuals        without a developmental or psychiatric disorder.|January 2014|January 27, 2014|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452061||97160|
NCT01452295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-207|Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion|Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817)||Vital Therapies, Inc.|No|Withdrawn|June 2010|September 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|65 Years|No|||December 2013|December 3, 2013|October 11, 2011|Yes|Yes|Subjects from lead-in study VTI-206 - NCT00973817 lost to follow-up before enrollment in    VTI-207 (NCT1452295)|No||https://clinicaltrials.gov/show/NCT01452295||97142|
NCT01452633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241577-1|Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy|Effect of Preincisional Local Analgesia on Post-Operative Pain in 10-12mm Lateral Port Sites||Stony Brook University|No|Recruiting|November 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|100|||Female|21 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 6, 2013|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452633||97116|
NCT01452646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML1310|Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia|Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia. GIMEMA Protocol AML1310. EudraCT Number 2010-023809-36|AML1310|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|January 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|237|||Both|18 Years|60 Years|No|||June 2015|June 11, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452646||97115|
NCT01452893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANDI-1|Counterregulatory Hormone Production in Adrenal Insufficiency and Diabetes Type I|Counterregulatory Hormone Production and Cognitive Function in Patients With Adrenal Insufficiency and Diabetes Mellitus Type I|CANDI|University of Wuerzburg|No|Completed|March 2011|December 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|40|Samples Without DNA|blood samples for hormonal analysis|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Four groups:        Patients with Addison's disease alone patients with diabetes mellitus type I alone        patients with both, Addison's disease and Diabetes mellitus type I healthy controls|January 2014|January 3, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01452893||97096|
NCT01453790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214808-7|Parent Specific Depression Education and Motivation|Effectiveness of Parent Specific Depression Education and Motivation on Intent to Seek Follow-Up Care for Potential Depression Symptoms||University of California, Davis|No|Completed|April 2011|January 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|104|||Female|18 Years|65 Years|No|||June 2012|June 12, 2012|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01453790||97027|
NCT01454700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-122|Effect of CSII and CGM on Progression of Late Diabetic Complications|The Effect of Sensor-Augmented Continuous Subcutaneous Insulin Infusion Compared to Multiple Daily Insulin Injections in Prevention of Increasing Urinary Albumin Excretion Rate in Type 1 Diabetes Mellitus||Steno Diabetes Center|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||January 2015|January 13, 2015|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01454700||96957|
NCT01454388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|breakfast colonoscopy study|A Trial Comparing Breakfast Versus no Breakfast Prior to Colonoscopy|A Randomized Controlled Trial Comparing Breakfast Versus no Breakfast||Queen's University|Yes|Completed|January 2010|||May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|496|||Both|18 Years|90 Years|No|||December 2015|December 16, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01454388||96981|
NCT01455285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0377.0.045.000-10|Effectiveness of the Transcutaneous Electrical Nerve Stimulation in Dysmenorrhea|Investigation of the Effectiveness of Different Modulations of Pulse Frequency Transcutaneous Electrical Nerve Stimulation in Dysmenorrhea||Universidade Federal do Piauí|Yes|Completed||||||N/A|Interventional|Primary Purpose: Treatment|||||||Female|16 Years|33 Years|No|||May 2011|October 18, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01455285||96912|
NCT01455298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.664|Liver Disease in Adults With Alpha-1 AT Deficiency|Research of Infra Clinical Liver Injuries in Adult Patients Presented With Alpha-1 AT Deficiency|LIDIA-A1AT|Hospices Civils de Lyon|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|33|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01455298||96911|
NCT01455571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-PHI-101|Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors|Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B||Hanmi Pharmaceutical Company Limited|No|Completed|November 2009|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|19 Years|N/A|No|||February 2014|February 24, 2014|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455571||96890|
NCT01451333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCHECR-ENCORE1-CNS|The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1|The EFV Central Nervous System Exposure Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks|ENCORE1-CNS|Kirby Institute|Yes|Completed|September 2011|February 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|16 Years|N/A|No|||May 2013|May 10, 2013|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01451333||97216|
NCT01473342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029579|Mila Blooms Intervention Study|Mila Blooms Intervention Study: An App for Promoting Physical Activity and Health Diet Among Adolescent Survivors of Childhood Cancer||Duke University|Yes|Completed|April 2011|July 2014|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Both|12 Years|19 Years|No|||October 2014|October 23, 2014|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473342||95534|
NCT01473628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0283|Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II|Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II||M.D. Anderson Cancer Center|No|Recruiting|May 2013|||May 2027|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473628||95512|
NCT01473641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG2011_03|Nexplanon Observational Risk Assessment Study (NORA)|Nexplanon Observational Risk Assessment Study (NORA)|NORA|Center for Epidemiology and Health Research, Germany|Yes|Active, not recruiting|November 2011|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7384|||Female|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women using the contraceptive implant Nexplanon|January 2016|January 21, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01473641||95511|
NCT01440556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBMDR-MM-2011|Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma|Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: a Study From the Italian Bone Marrow Transplantation Donor Registry|MM2011|Azienda Ospedaliera San Giovanni Battista|No|Completed|October 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|196|||Both|18 Years|80 Years|No|Non-Probability Sample|Multiple Myeloma patients|July 2013|July 10, 2013|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01440556||98030|
NCT01440569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-216-0130|Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults|A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and -Experienced Adults With No Darunavir Resistance-associated Mutations||Gilead Sciences|No|Completed|September 2011|October 2015|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|314|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|September 22, 2011|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT01440569||98029|
NCT01440283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBIMRT|A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma|A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma||St. Jude Children's Research Hospital|No|Terminated|September 2011|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|6 Months|18 Years|No|||November 2015|February 3, 2016|September 20, 2011|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT01440283||98051|The study was closed to accrual in January 2014 due to the principal investigator leaving St. Jude. It was expected to re-open to accrual, however, in September 2015, the decision was made to permanently close the trial to participant enrollment.
NCT01451853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-3005-201|SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss|Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss||Sound Pharmaceuticals, Incorporated|No|Not yet recruiting|July 2016|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|19 Years|80 Years|No|||November 2015|November 30, 2015|October 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451853||97176|
NCT01451840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM2012-001|Efficacy of Alkalinized Lidocaine Compared to Remifentanil on the Incidence of Coughing During Emergence of Anesthesia|Efficacy of Alkalinized Lidocaine in the Endotracheal Tube Cuff Compared to a Bolus Dose of Intravenous Remifentanil on the Incidence of Coughing During Emergence of Anesthesia||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|85|||Both|18 Years|80 Years|No|||October 2012|October 25, 2012|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451840||97177|
NCT01452087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DK077966 - R|Health Benefits of Chronic vs. Acute Exercise in Overweight Adults|||University of Michigan|No|Completed|May 2009|October 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|43|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452087||97158|
NCT01452347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.113|Dabigatran Etexilate in Patients With Mechanical Heart Valves|A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt|RE-ALIGN|Boehringer Ingelheim||Terminated|October 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|328|||Both|18 Years|75 Years|No|||July 2014|July 11, 2014|October 11, 2011||||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01452347||97138|This study was terminated prematurely due to safety concerns arising during conduct of the trial.
NCT01452074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01 DK077966 - PA|Progressive Metabolic Adaptations to Low Intensity Exercise Training and Weight Loss|||University of Michigan|No|Active, not recruiting|July 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452074||97159|
NCT01452308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-321-0101|Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis|A Phase 2a, Pilot, Open-Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624 in Subjects With Fibrosis of the Liver||Gilead Sciences|Yes|Completed|November 2011|August 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||January 2014|January 2, 2014|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452308||97141|
NCT01452659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385/CCT-001|Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids|A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Uterine Fibroids||Takeda|No|Completed|October 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|216|||Female|20 Years|N/A|No|||January 2013|January 17, 2013|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01452659||97114|
NCT01452919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14326|A Physical Dependence Study in Schizophrenia|A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia||Eli Lilly and Company|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||October 2012|January 11, 2013|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452919||97094|
NCT01453166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2011|Brazilian Heart-Prevent Meal - A Pilot Randomized Clinical Trial|The Effect of Brazilian Heart Prevent Meal Program Accessible for the Population to Prevent New Cardiovascular Events: A Pilot Randomized Clinical Trial||Hospital do Coracao|Yes|Completed|September 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|122|||Both|45 Years|N/A|No|||July 2012|July 16, 2012|October 11, 2011||No||No|March 15, 2012|https://clinicaltrials.gov/show/NCT01453166||97075|Small numbers of subjects analyzed, We did not evaluate the patient’s adherence to food intake, The high purchasing power of patients, Randomization with opaque envelope technique, Low statistical power.
NCT01453179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X-03016-3284|Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)|Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma|LEIDA 2|MEDA Pharma GmbH & Co. KG|No|Completed|October 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01453179||97074|
NCT01453504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-R3i|Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma|A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)|HD-R3i|University of Cologne||Recruiting|August 2012|August 2018|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|60 Years|No|||December 2015|December 2, 2015|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01453504||97049|
NCT01453803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-PK-001|Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal in Patients With Parkinson's Disease|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Vertebral Artery and Intravenously in Patients With Parkinson's Disease||Ageless Regenerative Institute|No|Recruiting|May 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||October 2013|October 28, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01453803||97026|
NCT01453816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-RF-001|Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Renal Artery and Intravenously in Patients With Renal Failure||Ageless Regenerative Institute|No|Recruiting|May 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||October 2013|October 28, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01453816||97025|
NCT01421056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1014-PR-0053 OLEP|Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)|A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment||Chiesi Pharmaceuticals Inc.|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|79 Years|No|||January 2014|January 7, 2014|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421056||99522|
NCT01451619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524-155|A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)|A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Assess the Pharmacodynamics of MK-0524 in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea. (Protocol No. 155)||Merck Sharp & Dohme Corp.|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|October 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01451619||97194|
NCT01454973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta Cell - Protocol 1a|Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects|Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects||Foundation for the National Institutes of Health|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|25|||Both|30 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy obese individuals|August 2012|August 9, 2012|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01454973||96936|
NCT01454986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-002|Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects|A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of ALXN1007 in Healthy Subjects||Alexion Pharmaceuticals|Yes|Completed|November 2011|October 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|64|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 22, 2013|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454986||96935|
NCT01421667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-012|A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)||Seattle Genetics, Inc.|No|Completed|August 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|176|||Both|6 Years|N/A|No|||June 2015|June 22, 2015|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01421667||99475|
NCT01421680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSK1101|The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients|A Prospective Randomized Controlled Trial Evaluating the Effects of Preoperative and Postoperative Oral Nutritional Supplements (ONS) in Malnourished Post-gastrectomy Patients||Seoul National University Hospital|Yes|Completed|August 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|144|||Both|20 Years|N/A|No|||March 2014|March 12, 2014|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01421680||99474|
NCT01452386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99081|Modified Functional Magnetic Stimulation Treatment for Constipation Improvement|Modified Functional Magnetic Stimulation Treatment for Constipation Improvement||Taipei Medical University WanFang Hospital|No|Active, not recruiting|January 2011|February 2012|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|140|||Both|20 Years|60 Years|No|Probability Sample|constipation patients|October 2011|October 13, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452386||97135|
NCT01452399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107008825|A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients|A Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients||Yale University|Yes|Active, not recruiting|October 2011|October 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|251|||Female|18 Years|90 Years|No|||February 2015|February 24, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01452399||97134|
NCT01439477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TuftsU-9289|StrongWomen- Healthy Hearts: A Community Based Program for Midlife and Older Women|StrongWomen- Healthy Hearts: A Community Based Program for Midlife and Older Women||Tufts University|Yes|Completed|December 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|763|||Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women greater than 40 years old who are overweight or obese and sedentary|November 2015|November 17, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439477||98113|
NCT01439737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108051RC|Metabolomic Analysis of Exhaled Breath Condensate in Asthmatics|Metabolomic Analysis of Exhaled Breath Condensate, Plasma and Urine Specimens in Adult Asthmatics||National Taiwan University Hospital|No|Not yet recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Exhaled breath condensates, serum, urine|Both|20 Years|90 Years|No|Non-Probability Sample|Adult asthmatics|September 2011|September 22, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439737||98093|
NCT01440582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0192|Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients|Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM)||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2013|||February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|September 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01440582||98028|
NCT01440803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2251|Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women|Randomized Controlled Trial of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women||Columbia University|Yes|Recruiting|January 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|45 Years|No|||November 2015|November 2, 2015|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440803||98011|
NCT01451580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LD0411|Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer|A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer||TTY Biopharm||Recruiting|September 2005|||||Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|||Anticipated|47|||Both|20 Years|N/A|No|||October 2011|October 12, 2011|October 11, 2011||||No||https://clinicaltrials.gov/show/NCT01451580||97197|
NCT01451593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/11/0083|Neuroprotection With Phenytoin in Optic Neuritis|A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis||University College, London|Yes|Completed|November 2011|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|60 Years|No|||September 2015|September 8, 2015|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451593||97196|
NCT01452100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003701|Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)|Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)|MECCORT|University Hospital, Toulouse|Yes|Recruiting|June 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01452100||97157|
NCT01452360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100009|A Research Proposal to Set up an Integrated National Data Bank and Monitoring System and to Establish the Indicators and Risk Factors for Chronic Kidney Disease|A Research Proposal to Set up an Integrated National Data Bank and Monitoring System and to Establish the Indicators and Risk Factors for Chronic Kidney Disease||Taipei Medical University WanFang Hospital|No|Active, not recruiting|May 2011|May 2014|Anticipated|||N/A|Observational|N/A||3|Anticipated|700|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|chronic kidney disease patients|October 2011|October 11, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452360||97137|
NCT01452321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0588/07|Repetitive Transcranial Magnetic Stimulation in Postpartum Depression|Repetitive Transcranial Magnetic Stimulation Effects on Clinical, Cognitive and Social Performance in Postpartum Depression|rTMSPPD|University of Sao Paulo General Hospital|No|Completed|August 2007|September 2009|Actual|July 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|36 Years|No|||October 2011|October 10, 2011|November 22, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452321||97140|
NCT01452334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA210-003|Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy|A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-Ligand 1 (PD-L1) Antibody (BMS-936559) in Subjects With Relapsed or Refractory Hematologic Malignancy||Bristol-Myers Squibb|No|Withdrawn|November 2011|November 2014|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|October 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01452334||97139|
NCT01452672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3.30.25|Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer|Resource-sparing Radiotherapy for Breast Cancer||International Atomic Energy Agency|Yes|Recruiting|March 2007|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|81 Years|No|||October 2011|October 14, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01452672||97113|
NCT01452906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-DDI-003|A Drug-Drug Interaction Study of Omeprazole and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Omeprazole in Healthy Male and Female Adults||Vifor Inc.|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|45|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452906||97095|
NCT01453192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001004-35|Renal Transplantation and Raltegravir in HIV-Infected Patients|National, Multicenter, Phase III Prospective Trial About Clinical and Immunological Follow-up After Renal Transplantation in HIV-1 Infected Patients With End Stage Chronic Renal Insufficiency|ANRS153TREVE|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|December 2011|November 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|70 Years|No|||October 2014|October 28, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01453192||97073|
NCT01453517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004976|A Psychological and Behavioral Intervention for Post-Bariatric Patients|Dialectical Behavior Therapy (DBT) for Post-Bariatric Patients Experiencing Weight Regain||Mayo Clinic|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|26|||Both|18 Years|75 Years|No|||October 2011|October 13, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01453517||97048|
NCT01454401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-090|LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers|LeucoPatch™ Study. A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers||Reapplix|Yes|Completed|October 2010|January 2013|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454401||96980|
NCT01451632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-05-01-05 (TCD11696)|A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers|A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers||Merrimack Pharmaceuticals|No|Completed|October 2011|June 2014|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01451632||97193|
NCT01451645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-GA-1103|Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol|||Regeneron Pharmaceuticals|No|Completed|October 2011|September 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|70 Years|No|||April 2014|April 7, 2014|October 10, 2011|Yes|Yes||No|September 24, 2013|https://clinicaltrials.gov/show/NCT01451645||97192|This clinical trial was not directly related to the development of an investigational/medicinal product.
NCT01421420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30AG019610|Alzheimer's Disease Core Center|Arizona Alzheimer's Disease Core Center|ADCC|University of Arizona|No|Recruiting|July 2001|July 2025|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|900|Samples With DNA|blood, saliva, brain tissue|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with Alzheimer's disease, mild cognitive impairment, other forms of dementia,        and normal elderly individuals.|January 2015|June 10, 2015|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01421420||99494|
NCT01452139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010364-01H|Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)|ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction|RAPID STEMI|Ottawa Heart Institute Research Corporation|Yes|Completed|September 2011|March 2013|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|18 Years|75 Years|No|||April 2013|April 23, 2013|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01452139||97154|
NCT01452152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047385|Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study|Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy|PAPI-2|University of Maryland|Yes|Terminated|February 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|20 Years|74 Years|No|||January 2013|January 25, 2013|October 10, 2011|Yes|Yes|Terminated by study sponsor.|No||https://clinicaltrials.gov/show/NCT01452152||97153|
NCT01439984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-PE-01|Trial of PED-1 in Male Patients With Premature Ejaculation|A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped, Multi-center Clinical Study to Evaluate the Safety and Efficacy of PED-1 in Male Patients With Premature Ejaculation||Symyoo|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|159|||Male|20 Years|65 Years|No|||October 2012|October 1, 2012|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01439984||98074|
NCT01440296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN-001|Magnetic Resonance Imaging (MRI) Characterization of Carotid Plaque and Prediction of End-organ and Clinical Outcomes|Magnetic Resonance Imaging (MRI) Characterization of Carotid Plaque and Prediction of End-organ and Clinical Outcomes||Sunnybrook Health Sciences Centre||Recruiting|March 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients from tertiary care centre|September 2011|September 23, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440296||98050|
NCT01440829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOLA-TIPS|The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS|The Effectiveness of L-ornithine-L-aspartate on Plasma Ammonia in Cirrhotic Patients After TIPS Procedure: a Prospective, Randomized, Controlled, Open-label Clinical Trial||Fourth Military Medical University|Yes|Completed|December 2011|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||December 2012|December 18, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01440829||98009|
NCT01444651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-001519|A Trial of Tadalafil and Glycemic Traits|Phase 3 Randomized Trial of Tadalafil and Glycemic Traits||Massachusetts General Hospital|Yes|Completed|August 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444651||97716|
NCT01451866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA09_DLP|Comparison Between Classic Leg-press Training and Complex Leg-press Training on a Dynamic Leg-press|Comparison of a Classic Leg-press Training Compared to a Complex Training on a Dynamic Leg-press With Visual Feed-back. Pilot-study|dlp|University of Applied Sciences of Western Switzerland|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01451866||97175|
NCT01452373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERC-207|Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women|DHEA + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women (Placebo Controlled, Double Blind and Randomized Phase III Study to Evaluate the Effects of 12-Week Treatment With DHEA (Prasterone) and Acolbifene on Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women)||EndoCeutics Inc.|No|Completed|October 2011|May 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|238|||Female|40 Years|75 Years|No|||December 2013|December 10, 2013|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452373||97136|
NCT01452698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-002|Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis|A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to AG-1749 (30mg Once-Daily) in Patients With Erosive Esophagitis||Takeda|No|Completed||August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|409|||Both|20 Years|N/A|No|||November 2012|November 7, 2012|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01452698||97111|
NCT01452685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385/OCT-101|A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis|A Phase II, Multicenter, Long-term Extension Study to Compare the Safety and Efficacy of TAK-385 (10, 20, and 40 mg) Following Oral Administration for 12 Weeks or More in the Treatment of Endometriosis||Takeda|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|397|||Female|20 Years|N/A|No|||May 2014|May 7, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01452685||97112|
NCT01452932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCESCOPD|Muscle Training Effectiveness in the Degree of Dyspnea and Aerobic Capacity in COPD|Muscle Training Effectiveness in the Degree of Dyspnea and Aerobic Capacity in COPD in an Institution Health Service Provider in the Department of Antioquia||CES University|No|Active, not recruiting|June 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|N/A|No|||June 2012|June 22, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01452932||97093|
NCT01453842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diet oil|Diet Oil Induced Stimulation of GLP-1|Diet Oil Induced Stimulation of GLP-1||University of Copenhagen|No|Completed|March 2011|March 2012|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453842||97023|
NCT01454128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-2546B|The Role of Exercise-Periodic-Breathing (EPB) in Impaired Ventilation Regulation Dysfunction in Heart Failure Patients|The Role of Exercise-Periodic-Breathing in Impaired Ventilation Regulation Dysfunction in Patients With Heart Failure||Chang Gung Memorial Hospital|Yes|Recruiting|April 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2010|October 17, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454128||97001|
NCT01454141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-2182E|Cognitive Control Training for Depression|||Boston University|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 14, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01454141||97000|
NCT01424579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC-P07/22|Diacutaneous Fibrolysis and Subacromial Syndrome|Effectiveness of Diacutaneous Fibrolysis for the Treatment of Subacromial Impingement Syndrome: a Randomised Controlled Trial||Jordi Gol i Gurina Foundation|No|Completed|February 2008|December 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||April 2013|April 3, 2013|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424579||99251|
NCT01420458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV107|Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012|A Randomized, Two-Period Crossover Study in Healthy Volunteers to Establish the Bioequivalence of Two Formulations of BG00012.||Biogen|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 3, 2011|August 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01420458||99568|
NCT01420783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD12042|Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia|A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea||Sanofi|No|Completed|October 2011|May 2014|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|81|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01420783||99543|
NCT01451905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP1-PSO|GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis|||University Hospital, Gentofte, Copenhagen||Recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|12|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451905||97172|
NCT01451918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESV10-0537-A|Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol|Regulation of Intestinal (and Hepatic) Lipoprotein Secretion by Resveratrol||University Health Network, Toronto|No|Completed|October 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|8|||Both|23 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 5, 2014|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451918||97171|
NCT01451879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMN 439-2008|Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies|Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy||University of Florida|No|Recruiting|October 2008|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|Residual blood specimens from GAA Ab testing|Both|N/A|65 Years|No|Non-Probability Sample|The study population will consist of male and female patients age 0-65 years, with a        diagnosis of early-onset Pompe Disease. Up to 25 subjects will be enrolled.|July 2015|July 1, 2015|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01451879||97174|
NCT01452451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EXC-202|Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus|A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy||Hanmi Pharmaceutical Company Limited|Yes|Completed|December 2011|||June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||February 2014|February 6, 2014|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452451||97130|
NCT01452113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004003|Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy|Effect of a DPP-IV Inhibitor Treatment on the Secretion of Glucagon in Patients Presenting With Type 1 Diabetes Mellitus With or Without Autonomic Neuropathy|DPPNAC|University Hospital, Toulouse|Yes|Completed|October 2010|March 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|75 Years|No|||March 2014|March 11, 2014|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01452113||97156|
NCT01452126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNM HRRC 11-030|Minimum Effective Concentration of Ropivacaine for Brachial Plexus Block Via the Supraclavicular and Infraclavicular Approach, Femoral Nerve Block, Sciatic Nerve Block Via the Popliteal and Parasacral Approach|Minimum Effective Anesthetic Concentration of Supraclavicular Block, Infraclavicular Block, Femoral Nerve Block and Sciatic Nerve Block Via the Popliteal and Parasacral Approach|MEAC|University of New Mexico|Yes|Suspended|June 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|October 11, 2011||No|Study suspended for sample size re-analysis|No||https://clinicaltrials.gov/show/NCT01452126||97155|
NCT01439997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/567|Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study|Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study||University Hospital, Ghent|No|Recruiting|February 2013|July 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01439997||98073|
NCT01440309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008BAI59B03/2011AA020119|Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis|Phase I Clinical Trial, Randomized, Controlled, to Evaluate the Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells From Bone Marrow for Patients With Refractory Primary Biliary Cirrhosis|MSCsTreatPBC|Chinese Academy of Medical Sciences|Yes|Recruiting|November 2011|December 2013|Anticipated|November 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||September 2011|August 1, 2012|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01440309||98049|
NCT01440842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASSIC 01|Closed Loop Glucose Control in Intensive Care Unit|An Open-label, Single-centre, Randomised Controlled Trial to Assess the Safety and Efficacy of Automated Closed-loop Blood Glucose Control in Comparison With Standard Care in Adults in Intensive Care Unit|CLASSIC|University of Cambridge|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2012|December 31, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440842||98008|
NCT01453218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATG-IRA-HVH.10|Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction|Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction|ATG_HVH|Hospital Vall d'Hebron|No|Recruiting|October 2011|November 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|70 Years|No|||January 2016|January 2, 2016|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453218||97071|
NCT01453855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-034|Travoprost 3-Month Safety and Efficacy Study|A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients With Open-Angle Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1099|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|October 13, 2011|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01453855||97022|
NCT01454154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPI 202|Glyburide (RP-1127) for Traumatic Brain Injury (TBI)|A Randomized Clinical Trial of Glyburide (RP-1127) for TBI||Remedy Pharmaceuticals, Inc.|Yes|Active, not recruiting|November 2011|September 2015|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||May 2015|May 5, 2015|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454154||96999|
NCT01444989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00017619|Development and Validation of a Quality of Life Instrument for Actinic Keratosis|Development and Validation of a Quality of Life Instrument for Actinic Keratosis|AKRQ|Wake Forest School of Medicine|No|Completed|September 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 19, 2013|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01444989||97693|
NCT01454167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-13-0130-CTIL|Acid Base and Electrolytes Patterns in Drains Operational Wounds and Its Relation to Complications|Acid Base and Electrolytes Patterns in Drains of Different Operational Wounds and Its Relation to Specific Infections and Seroma Formation||Carmel Medical Center|Yes|Recruiting|May 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|all post operational patients who have a vacuum drain/s|May 2015|May 25, 2015|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454167||96998|
NCT01445314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070110|Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments|Analysis of Stored Data Collected From Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|February 2007|||||N/A|Observational|N/A|||Actual|381|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 30, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01445314||97670|
NCT01454427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122/10|Influence of Anesthesia Drugs on Impedance Aggregometry|The Influence of Drugs Routinely Used in Cardiac Anesthesia on Impedance Aggregometry.||University of Lausanne Hospitals|No|Completed|October 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|October 2011|October 18, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01454427||96978|
NCT01453205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI-551-1088|A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL||MedImmune LLC|Yes|Active, not recruiting|February 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|184|||Both|18 Years|99 Years|No|||November 2015|November 12, 2015|October 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01453205||97072|
NCT01453530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35385.091.11|Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Blockade|Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Rest Blockade With Sugammadex|SFINX|Radboud University|Yes|Recruiting|October 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|30|||Both|18 Years|65 Years|No|||September 2011|October 17, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453530||97047|
NCT01453829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ST-ME-001|Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Internal Carotid Artery and Intravenously in Patients After Stroke||Ageless Regenerative Institute|No|Not yet recruiting|October 2014|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||October 2013|March 19, 2014|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01453829||97024|
NCT01424306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHLBI R21 HL108257|Diet and Systemic Inflammation|Diet and Systemic Inflammation|DASI|Fred Hutchinson Cancer Research Center|No|Completed|October 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424306||99272|
NCT01424319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-812|Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan|Reducing Residual Albuminuria in Subjects With Diabetes & Nephropathy With Atrasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety & Efficacy in Japanese Subjects||AbbVie|Yes|Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|58|||Both|20 Years|N/A|No|||February 2013|February 12, 2013|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424319||99271|
NCT01424592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHHS IRB 11-027|In-Hospital Portable Sleep Monitoring for the Evaluation of Obstructive Sleep Apnea (OSA)|Inpatient Portable Sleep Apnea Testing of Hospitalized Medical Patients for the Evaluation of Obstructive Sleep Apnea Prospectively Compared to Outpatient Laboratory-based Polysomnography||John H. Stroger Hospital|No|Active, not recruiting|April 2011|March 2016|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the hospital under the general medicine service referred for        evaluation of suspected obstructive sleep apnea.|August 2015|August 31, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01424592||99250|
NCT01451346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Psoriasis Pilot Study|Study in Patients With Mild to Moderate Psoriasis|B.Infantis 35624 in Patients With Mild to Moderate Chronic Plaque Psoriasis -a Pilot Study|AH-PSR-01|Alimentary Health Ltd|Yes|Completed|January 2008|August 2011|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|60 Years|No|||October 2011|October 12, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01451346||97215|
NCT01451606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F1J-US-X062|Duloxetine for the Treatment of Chronic Pelvic Pain|Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain||University of Maryland|Yes|Active, not recruiting|June 2011|December 2015|Anticipated|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|50 Years|No|||April 2015|April 2, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451606||97195|
NCT01452464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_34OB|Safety of MenACWY-CRM Vaccination in Adolescents|A Phase IV Study to Assess the Safety of Menveo Vaccine Being Used by HMO Subjects Aged 11-21 Years of Age||Novartis||Completed|September 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55397|||Both|11 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population is selected from the Health Maintenance Organization population of        the Kaiser Permanente Southern California (KPSC) HMO in Pasadena, CA, USA.|February 2015|February 25, 2015|September 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01452464||97129|
NCT01451892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-072|Dance Therapy and Obesity|The Effect of Dance Therapy on the Functional Capacity of Patients With Advanced Obesity||University Hospital, Geneva|Yes|Completed|July 2010|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01451892||97173|
NCT01453036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUK|Clarithromycin Resistant Tailored Therapy|Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance||The Catholic University of Korea|Yes|Completed|August 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|924|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|September 29, 2011||No||No|June 7, 2012|https://clinicaltrials.gov/show/NCT01453036||97085|
NCT01453322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1009|Video Documentation of Localized Complications|Video Documentation of Localized Complications in IV Cannulation Using Near-Infrared Technology||Christie Medical Holdings, Inc.|No|Completed|September 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers|October 2011|October 17, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01453322||97063|
NCT01452438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_54OB|Safety Surveillance of MenACWY-CRM Vaccine in Children|Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (Menveo) Vaccination in Children 2 Through 10 Years of Age||Novartis||Completed|September 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|393|||Both|2 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population is selected from the Health Maintenance Organization population of        the Kaiser Permanente Southern California (KPSC) HMO in Pasadena, CA, USA.|August 2015|August 5, 2015|September 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01452438||97131|
NCT01440322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-383-C-003 (C-11-032)|AIR OPTIX® COLORS Registration Trial|||Alcon Research|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Both|N/A|N/A|No|||April 2014|April 24, 2014|September 22, 2011|Yes|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01440322||98048|
NCT01440595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-012|Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)|A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection||Merck Sharp & Dohme Corp.|No|Terminated|November 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|5|||Both|18 Years|N/A|No|||December 2015|February 3, 2016|September 22, 2011|Yes|Yes|Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to    elevated transaminase levels in treatment with grazoprevir.|No|February 3, 2016|https://clinicaltrials.gov/show/NCT01440595||98027|
NCT01441947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-208|Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer|A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone||Massachusetts General Hospital|Yes|Recruiting|October 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441947||97924|
NCT01453231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATedesco|Quality of Life and Body Image in Women Underwent Thighplasty|Quality of Life and Body Image in Women Underwent Thighplasty||Federal University of São Paulo|Yes|Completed|March 2009|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|35 Years|50 Years|No|||May 2013|May 27, 2013|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453231||97070|
NCT01453582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FJ2011-1.1|Efficacy and Safety Study of Total Flavonoids of Propolis Dropping Pill to Treat Angina Pectoris|Phase III Study of Total Flavonoids of Propolis Dropping Pill in Angina Pectoris: A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Clinical Trial on Efficacy and Safety.||Shanghai Greenvalley Pharmaceutical Co., Ltd.|No|Not yet recruiting|December 2011|September 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|480|||Both|35 Years|70 Years|No|||May 2012|May 27, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453582||97043|
NCT01453569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9712011-1|Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease|Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease||Shanghai Greenvalley Pharmaceutical Co., Ltd.|No|Completed|October 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|255|||Both|50 Years|85 Years|No|||January 2015|January 25, 2015|September 30, 2011||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT01453569||97044|
NCT01454414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1027|Tick-borne Illness and Clothing Study|Preventing Exposure to Ticks and Tick-borne Illness in Outdoor Workers|TICS|University of North Carolina, Chapel Hill|No|Completed|October 2010|April 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|159|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|October 10, 2011||No||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01454414||96979|
NCT01453868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-HEA-HMS-002|The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis|The Effects of Neuromuscular Training on Balance in Patients With Multiple Sclerosis|NIA|Nelson Mandela Metropolitan University|Yes|Recruiting|October 2011|June 2012|Anticipated|March 2012|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|20 Years|60 Years|No|||October 2011|October 17, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453868||97021|
NCT01454713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001|Retrospective Analysis of Veritas in Breast Reconstruction|Retrospective Analysis of Veritas in Breast Reconstruction (RAVE)|RAVE|Synovis Surgical Innovations|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|54|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients who have undergone single-stage or two-stage breast reconstruction        surgery with Veritas|October 2011|October 17, 2011|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01454713||96956|
NCT01445704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006473|Use of Probiotics to Aid in Weight Loss|Use of Probiotics to Aid in Weight Loss|Probiotics|Greenville Health System|No|Completed|June 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 8, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01445704||97646|
NCT01424007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U54CA155435-1|Metabolism, Exercise and Nutrition at UCSD (MENU Study)|Diet Composition and Genetics: Effects on Weight, Inflammation and Biomarkers|MENU|University of California, San Diego|Yes|Active, not recruiting|December 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|234|||Female|21 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 9, 2015|August 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01424007||99295|
NCT01455311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-15973|Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors|Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in the Diagnosis of Cystic Pancreatic Tumors||H. Lee Moffitt Cancer Center and Research Institute|No|Terminated|September 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|21|Samples With DNA|Cataloguing the proteins that are expressed in pancreatic cyst fluid will provide      preliminary data that will be used for identification of candidate biomarkers to predict      malignant transformation.|Both|18 Years|85 Years|No|Non-Probability Sample|The study design will be prospective, and will include 48 consecutive adult patients        between the ages of 18 and 85 years, with pancreatic cystic tumors identified on        crosssectional imaging and referred for EUS evaluation per the following inclusion and        exclusion criteria.|February 2013|February 12, 2013|October 17, 2011||No|funding unavailable|No||https://clinicaltrials.gov/show/NCT01455311||96910|
NCT01455584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-PHI-102|Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors|Phase Ⅰ Study to Determine the Maximum Tolerated Dose of HM781-36B Continuously Given in Patients With Advanced Solid Tumors and to Assess the Food Effect on Pharmacokinetic Profile||Hanmi Pharmaceutical Company Limited|No|Completed|June 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|19 Years|N/A|No|||April 2013|May 22, 2013|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455584||96889|
NCT01451359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s51545|Endobronchial Valves in Persistent Air Leak|Efficacy of Endobronchial Valves in Persistent Air Leak After Anatomical Pulmonary Resection for Cancer.||Universitaire Ziekenhuizen Leuven|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2011|October 8, 2013|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01451359||97214|
NCT01452477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tanshinone-HLJUCM|Tanshinone in Polycystic Ovary Syndrome|Effect of Tanshinone on Hormonal and Metabolic Features in Women With Polycystic Ovary Syndrome (PCOS)||Heilongjiang University of Chinese Medicine|Yes|Recruiting|October 2011|July 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|36 Years|No|||September 2013|September 3, 2013|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452477||97128|
NCT01452490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4-11-F|Diode Laser Treatment of Onychomycosis|Study of the V-Raser Diode Laser System in the Treatment of Onychomycosis||Cynosure, Inc.|No|Completed|October 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||March 2014|March 25, 2014|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452490||97127|
NCT01452165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADVa|Peripheral Artery Disease in Vastmanland|Observational Study on Cardiac Morphology and Function in Patients With Peripheral Artery Disease in Vastmanland County, Sweden(PADVa).|PADVa|Uppsala University|Yes|Completed|May 2006|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|457|Samples With DNA|Whole blood and serum.|Both|18 Years|N/A|No|Probability Sample|Consecutive patients referred to the Ultrasound laboratory of the Vascular Surgery        Department for evaluation of known or suspected vascular disease.|October 2011|October 11, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01452165||97152|
NCT01453335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1001|Percentage Venous Options in Pediatrics & Adults|Utilizing a Near Infrared Vein Visualization Device To Increase Peripheral Intravenous Access Targets in Pediatric & Adult Patients (% Venous Options)||Christie Medical Holdings, Inc.|No|Completed|June 2011|December 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|300|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric & Adult patients presenting at the Emergency Department that do not have an        acute or critical medical illness or injury that required immediate evaluation and/or        treatment.|December 2011|December 21, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01453335||97062|
NCT01453348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_53|Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM|A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults||Novartis|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|252|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|October 3, 2011|Yes|Yes||No|October 22, 2013|https://clinicaltrials.gov/show/NCT01453348||97061|
NCT01452763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-302|Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin|A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin||Takeda|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|621|||Both|20 Years|N/A|No|||January 2014|January 17, 2014|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01452763||97106|
NCT01452997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA351|Evaluation of Anti-inflammatories in the Reduction of Bite Reactions|Evaluation of Topical Ibuprofen and Steroid in the Reduction of Local Reactions and Symptoms From an Aedes Aegypti Mosquito Bite||London School of Hygiene and Tropical Medicine|No|Completed|November 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 30, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452997||97088|
NCT01453010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H0302/8|Self-directed Upper Limb Training Using a SaeboFlex in Acute Stroke|Self-directed Upper Limb Training Using a SaeboFlex With Acute Stroke Patients: 8 Single Case Reviews|SaeboFlex|Colchester Hospital University NHS Foundation Trust|No|Recruiting|May 2011|||May 2012|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|16 Years|N/A|No|||October 2011|October 13, 2011|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01453010||97087|
NCT01440335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911153|Initial Study of Fenoterol as a Treatment for Heart Failure|A Study of (R, R') and (S,S': R,R')- Fenoterol: Initial Clinical Evaluation for Pharmacokinetics, Pharmacodynamics, and Safety||National Institutes of Health Clinical Center (CC)||Completed|July 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|250|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|September 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01440335||98047|
NCT01440348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPH2010-001|Simultaneous Multiple Cruciate Ligament Reconstructions Using a Single Achilles Allograft|Simultaneous Multiple Cruciate Ligament Reconstructions Using a Single Achilles Allograft||National Police Hospital|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Male|N/A|N/A|No|||September 2011|September 23, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01440348||98046|
NCT01440608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJM-zincalbendazole|Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy|Randomized, Double-blind, Placebo-controlled Trial Evaluating the Impact of High-dose Zinc Therapy and Albendazole in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children||Washington University School of Medicine||Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||March 2012|March 2, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440608||98026|
NCT01441661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFC20110815|Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma|Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma: a Multicenter, Non-interventional, Retrospective Survey||Cancer Foundation, China|Yes|Completed|November 2007|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|400|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with RCC and treated with Sunitinib from 2008 to present will be        eligible. This will include current active patients as well as patients who have expired        and have medical records available.|September 2007|March 15, 2013|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01441661||97946|
NCT01441687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08239|Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome|Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome||City of Hope Medical Center|Yes|Recruiting|July 2009|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|260|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01441687||97944|
NCT01441700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC/CT/1/2010|Prone Position Emergence From Anaesthesia in Lumbar Disc Surgery|A Comparative Study of Haemodynamic Changes Between Prone and Supine Emergence From Anaesthesia in Lumbar Disc Surgery||KVG Medical College and Hospital|No|Completed|August 2010|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|No|||September 2011|September 27, 2011|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01441700||97943|
NCT01453595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-080|BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)|A Phase 1b/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)||Memorial Sloan Kettering Cancer Center|Yes|Terminated|October 2011|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 13, 2011|Yes|Yes|Given the number of toxicities seen and the difficulty with patient retention in the dose    escalation portion, the sponsor decided to close the trial.|No|December 14, 2015|https://clinicaltrials.gov/show/NCT01453595||97042|Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.
NCT01454232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100111|Adaptation of Human Gut Microbiota to Energetic Restriction|Modification of Human Gut Microbiota in Massive Obesity After Bariatric Surgery: the Role of Energetic Restriction|microbaria|Assistance Publique - Hôpitaux de Paris|No|Recruiting|June 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|180|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01454232||96993|
NCT01463670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-107|Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance|A Phase II Clinical Trial of Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|October 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463670||96272|
NCT01463683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V232-062|Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)|A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process||Merck Sharp & Dohme Corp.|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|722|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|October 28, 2011|Yes|Yes||No|October 9, 2013|https://clinicaltrials.gov/show/NCT01463683||96271|
NCT01463956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011- 001089 -17|Clinical Trial to Evaluate the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT)|Pilot Study on the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT)||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|January 2012|January 2015|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01463956||96250|
NCT01463969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23.10.2011|High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome (PCOS)|High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome||Gulhane School of Medicine|No|Completed|May 2010|May 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|40 PCOS patients and 40 healty controls|October 2011|November 1, 2011|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01463969||96249|
NCT01464229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002043|Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability|A Placebo-Controlled Crossover Study of Iloperidone Augmentation of SSRIs for Residual Anger and Irritability in Major Depressive Disorder||Massachusetts General Hospital|Yes|Completed|April 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464229||96229|
NCT01464554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA019938-01|Brief Substance Use Intervention for Youth in Teen Court|Brief Substance Use Intervention for Youth in Teen Court||RAND|No|Completed|January 2009|August 2014|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|193|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01464554||96204|
NCT01460446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD001333|ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?|A Prospective, Multi-centre Study With Diabetic Patients Randomized to 24 Weeks Treatment Supported by Either Accu-Chek® Aviva Expert Blood Glucose Meter With an Integrated Bolus Advisor or MDI Standard Therapy With Accu-Chek® Aviva Nano Meter (Without Bolus Advisor)|ABACUS|Hoffmann-La Roche||Completed|October 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|218|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|September 22, 2011|Yes|Yes||No|November 14, 2013|https://clinicaltrials.gov/show/NCT01460446||96517|
NCT01460459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35308.075.11|Self-monitoring of Blood Glucose in Insulin-treated Patients With Type 2 Diabetes|Self-monitoring of Blood Glucose in Insulin-treated Patients With Type 2 Diabetes: a 9-month Randomised Controlled Trial||Medical Research Foundation, The Netherlands|No|Recruiting|May 2011|July 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01460459||96516|
NCT01465815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6901 (5466)|Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)|Phase I/II Study of Postoperative Adjuvant Chemoradiation for cSCCHN||OHSU Knight Cancer Institute|Yes|Withdrawn|December 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|October 26, 2011|Yes|Yes|Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and    OSI-906 in other oncology studies was determined to be unfavorable.|No||https://clinicaltrials.gov/show/NCT01465815||96108|
NCT01466946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-109|Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients|Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients||Memorial Sloan Kettering Cancer Center||Completed|November 2011|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|No|Non-Probability Sample|Self-identified Hispanic/Latino patients with biopsy-proven primary lung cancer treated at        MSKCC.|February 2016|February 10, 2016|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01466946||96021|
NCT01467531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116181|A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects|A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects||ViiV Healthcare|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|November 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467531||95976|
NCT01467830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|absorbable suturesCTIL|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures||Rambam Health Care Campus|No|Withdrawn|December 2011|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||December 2011|July 3, 2014|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01467830||95953|
NCT01468415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/11|Efficiency Comparison Between Methylprednisolone and Phenol 8% Treatment Using a Trans Sacral Approach - on Lower Back Pain and Limbs|Efficiency Comparison Between Methylprednisolone and Phenol 8% Treatment Using a Trans Sacral Approach - on Lower Back Pain and Limbs||Assaf-Harofeh Medical Center|Yes|Recruiting|June 2011|||June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||May 2011|November 8, 2011|November 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01468415||95909|
NCT01465347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP100-202|Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)|Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy||Diffusion Pharmaceuticals LLC|Yes|Active, not recruiting|February 2012|September 2016|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465347||96144|
NCT01466088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-1734-226-CRD-006|Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)|Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type||Targacept Inc.|No|Completed|October 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|386|||Both|60 Years|85 Years|No|||July 2014|May 11, 2015|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466088||96087|
NCT01454557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8846-OK-CTIL|The Effect of Auditory Stimuli on Heart Rate Variability (HRV) Among Patients With Acquired Brain Injury (ABI)|The Effect of Auditory Stimuli on Heart Rate Variability (HRV) During Resting and During Physical Activity Among Patients With Acquired Brain Injury (ABI)||Sheba Medical Center|No|Not yet recruiting|November 2011|||November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2011|October 31, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01454557||96968|
NCT01454830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37007|Tailored Intervention to Promote Positive Airway Pressure Adherence|Phase I Double-blind Randomized Controlled Trial: Sociocultural and Cognitive Perception Intervention to Promote Positive Airway Pressure Adherence|SCIP-PA|Milton S. Hershey Medical Center|No|Active, not recruiting|November 2011|February 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||December 2013|December 29, 2013|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01454830||96947|
NCT01454505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-094|Safety and Efficacy of AL-53817 Nasal Spray Solution|Safety and Efficacy of AL-53817 Nasal Spray Solution in Ragweed Sensitive Subjects in an Environmental Exposure Chamber (EEC)||Alcon Research|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 29, 2013|October 17, 2011||No||No|March 29, 2013|https://clinicaltrials.gov/show/NCT01454505||96972|
NCT01454518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-08-003|Local Infiltration Analgesia for Hip Arthroscopy|Effectiveness of Ultrasound Guided Hip Infiltration With Local Anesthetic Solution for Pain Control After Hip Arthroscopy||Saint Francis Care|No|Completed|October 2011|February 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|80 Years|No|||March 2013|March 8, 2013|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01454518||96971|
NCT01454531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-G-01|An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy||ALK-Abelló A/S|No|Completed|June 2011|April 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|199|||Both|18 Years|65 Years|No|||February 2015|February 23, 2015|October 13, 2011||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01454531||96970|
NCT01462357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115411|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females||GlaxoSmithKline||Active, not recruiting|November 2011|December 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|1074|||Female|9 Years|14 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462357||96373|
NCT01462370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-145|Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)|A Phase III, Randomized, Active-Comparator-Controlled, 2-period, Crossover, Double-Blind Study in China to Assess the Safety and Efficacy of Etoricoxib 120 mg Versus Ibuprofen up to 2400 mg (600 mg Q6h) in the Treatment of Patients With Primary Dysmenorrhea||Merck Sharp & Dohme Corp.|No|Completed|November 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|139|||Female|18 Years|N/A|No|||October 2015|October 8, 2015|October 27, 2011|Yes|Yes||No|May 21, 2013|https://clinicaltrials.gov/show/NCT01462370||96372|
NCT01462383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR11-0061|The Role of the EKG in Anticancer Drug Development|The Role of the EKG in Anticancer Phase I Drug Development||M.D. Anderson Cancer Center|Yes|Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|525|||Both|N/A|N/A|No|Probability Sample|The study population will consist of patients in the Department of Investigational Cancer        Therapeutics diagnosed with a malignancy and registered at MDACC for medical care on IRB        approved sponsored protocols active between January 1, 2006 and December 31, 2009.|December 2011|December 9, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462383||96371|
NCT01462981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COBRA|Cohort of Hepatitis B Research of Amsterdam|Cohort of Hepatitis B Research of Amsterdam|COBRA|Public Health Service of Amsterdam|No|Recruiting|September 2011|July 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|172|Samples With DNA|Serum, White cells|Female|18 Years|65 Years|No|Non-Probability Sample|Women between 18 - 65 year in the study period with chronic hepatitis B who were HBsAg        positive during pregnancy screening of which serum samples are stored at the Public Health        Service.|November 2011|November 1, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01462981||96325|
NCT01463202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP5-1|Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression|Effect of Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding Continuation, Contraceptive Continuation, and Postpartum Depression: a Randomized Trial|DEPO-ABCD|University of Pittsburgh|No|Recruiting|November 2011|March 2018|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|184|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01463202||96308|
NCT01463423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0048|Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)|Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)||Stanford University|Yes|Recruiting|October 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463423||96291|
NCT01463709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-049|Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer|Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer|NPEF|Children's Hospital & Research Center Oakland|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01463709||96269|
NCT01463722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-20|Accuracy of Amniotic Fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity|Study of Accuracy of Amniotic Fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity||Isfahan University of Medical Sciences|Yes|Completed|March 2010|February 2011|Actual|February 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|128|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2011|November 1, 2011|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01463722||96268|
NCT01463982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OTE-103|Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies|A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Cancer||Hanmi Pharmaceutical Company Limited|No|Completed|December 2010|December 2013|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|19 Years|N/A|No|||April 2015|April 8, 2015|October 31, 2011||No||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01463982||96248|
NCT01464242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222951928964|Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis|Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis|GT|Centro Internacional de Entrenamiento e Investigaciones Médicas|Yes|Recruiting|November 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||March 2014|March 11, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01464242||96228|
NCT01465061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED01032011|A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis|A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis||University of the Philippines|No|Completed|February 2011|August 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|124|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Members of virtual psoriasis local support networks (Yahoo-based Psoriasis Philippine        Online Community, Inc. and Facebook Psoriasis Online Support Group) will be the main        subjects of the study.|November 2011|November 1, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01465061||96165|
NCT01465074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICPAS#024/2011|Effects of Acute Nicotine Treatment on Neuroplasticity and Memory in Patients With Schizophrenia|Effects of Acute Nicotine on Long-term Potentiation in the Dorsolateral Prefrontal Cortex of Patients With Schizophrenia and Healthy Controls|NIC-PAS|Centre for Addiction and Mental Health|No|Terminated|November 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 9, 2013|November 1, 2011|Yes|Yes|Limited staff and operating resources|No||https://clinicaltrials.gov/show/NCT01465074||96164|
NCT01466374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM129-008|Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease|A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease||Bristol-Myers Squibb|Yes|Completed|December 2011|December 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|121|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466374||96065|
NCT01466387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_38|A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults|A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults||Novartis|Yes|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|552|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|November 3, 2011|Yes|Yes||No|August 21, 2013|https://clinicaltrials.gov/show/NCT01466387||96064|
NCT01466647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXL004|A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)|A Phase I Pilot Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Squamous Non-small-cell Lung Cancer||Axelar AB|Yes|Completed|January 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01466647||96044|
NCT01467544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13605|Reduce Cardiovascular Risk in Women Through Tai Chi Intervention|Exploring the Effects of Tai Chi on Cardiometabolic Risk in Women||Virginia Commonwealth University|Yes|Completed|June 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|96|||Female|35 Years|50 Years|No|||May 2013|May 17, 2013|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01467544||95975|
NCT01468428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAarhus - VCF|Small Intestinal Function in Patients With Cystic Fibrosis|Small Intestinal Function in Patients With Cystic Fibrosis||University of Aarhus|Yes|Enrolling by invitation|October 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|-  15 CF patients with severe mutations and pancreatic insufficiency, without having             diabetes or intestinal resection, with stable weight and no antibiotic treatment 14             days up to examination.          -  15 age- and gender matched healthy controls|November 2011|November 10, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468428||95908|
NCT01469000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14034|A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)|A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations||Eli Lilly and Company|No|Active, not recruiting|February 2012|December 2017|Anticipated|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469000||95865|
NCT01469013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14116|Oral JAK1/JAK2 Selective Inhibitor Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of LY3009104 in Japanese Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy||Eli Lilly and Company|No|Completed|November 2011|December 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|144|||Both|20 Years|75 Years|No|||January 2014|January 24, 2014|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469013||95864|
NCT01464320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-107|A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.|A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single-Dose of ABT-614 and the Effect of ABT-614 on Glomerular Filtration Rate in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Albuminuria||Abbott|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|19 Years|70 Years|No|||April 2012|August 21, 2012|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464320||96222|
NCT01453946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9422C00002|Safety and Maintenance Study of Entocort for Children With Crohn's Disease|A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive||AstraZeneca||Completed|December 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|5 Years|17 Years|No|||June 2015|June 3, 2015|October 14, 2011|No|Yes||No|February 11, 2015|https://clinicaltrials.gov/show/NCT01453946||97015|
NCT01454297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMRF-11-001|Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile|A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles|CoMMpass|Multiple Myeloma Research Foundation|No|Active, not recruiting|July 2011|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Bone marrow, Peripheral Blood|Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed, symptomatic, multiple myeloma, candidates for systemic treatment|September 2015|September 11, 2015|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01454297||96988|
NCT01454570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJPVAMC: SPU-09-11|The ReWalk Exoskeletal Walking System for Persons With Paraplegia|The ReWalk Exoskeletal Walking System for Persons With Paraplegia|VA_ReWalk|James J. Peters Veterans Affairs Medical Center|No|Recruiting|February 2011|November 2015|Anticipated|April 2015|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|1. Do you have paraplegia?          2. Is your SCI greater than 6 months?          3. Are you between the ages of 18 to 65y?          4. Is your height between 63 and 75 inches?          5. Do you weigh less than 220 pounds?          6. Are you legally able to sign for your own consent?        Persons who answer "no" to any of the above questions will not be eligible for the study|April 2015|April 8, 2015|September 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454570||96967|
NCT01462721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001|The eSVS® Mesh Randomized Post-Market Study|Post-market Study to Evaluate Post-implant Patency Rates of the External Saphenous Vein Support (eSVS®) Mesh in the Treatment of Saphenous Vein Grafts (SVGs) During Coronary Artery Bypass Grafting (CABG) Versus SVGs Without the eSVS Mesh.||Kips Bay Medical, Inc.|Yes|Terminated|October 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|N/A|N/A|No|||February 2014|February 27, 2014|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462721||96345|
NCT01462734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No. 461|MicroRNA Expression in Human Blood Serum and Vitreous Body|MicroRNA Expression in Human Blood Serum and Vitreous Body||Kyorin University|No|Completed|October 2011|||December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|Samples With DNA|3ml of blood serum and 1ml of vitreous|Female|N/A|N/A|No|Non-Probability Sample|Female pateints undergoing vitrectomy for macula hole without previous ocular or systemic        disease|March 2015|March 31, 2015|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01462734||96344|
NCT01462994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BDE78T|Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)|Prospective, Explorative Trial for the Detection of Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)Harboring Activating Mutations of CKIT or PDGFRA Pre/Post Surgery or Pre/Under Treatment With a Tyrosine Kinase Inhibitor or Progressive Disease Irrespective of Current or Planned Treatment. An Open-label, Non-randomized, Multicenter Phase IIIb Clinical Trial||Technische Universität München|No|Completed|November 2011|March 2016|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01462994||96324|
NCT01463215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-Ambroxol-002|Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease|An Open-Label, Dose Escalation With 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Type I Gaucher Disease||Exsar Corporation|No|Suspended|December 2012|August 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|16 Years|N/A|No|||February 2012|February 12, 2013|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463215||96307|
NCT01463228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100636|A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of FDC Tablets of Canagliflozin and Metformin IR (2x150 mg/1000 mg) With Respect to the Individual Components of Canagliflozin (1x300 mg) and Metformin IR (2x1000 mg) Tablets in Healthy Fed Subjects||Janssen Research & Development, LLC||Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01463228||96306|
NCT01463436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Usakti|The Effect of Soy Isoflavone Supplementation on Endothelial Function|Study of Soy Isoflavone 100 mg/Day in Postmenopausal Women to Elaborate the Effect of Soy Isoflavone in Endothelial Function and to Reduce Oxidative Stress||Trisakti University|No|Completed|January 2010|February 2011|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|47 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 1, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01463436||96290|
NCT01463696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07650|Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)|A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors||Merck Sharp & Dohme Corp.|No|Completed|December 2011|March 2015|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01463696||96270|
NCT01463735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 10-099|Vitamin E Supplement in Patients With Cirrhosis and Acanthocytosis|||University Hospital, Geneva|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01463735||96267|
NCT01463995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|proNICU cohort|Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort)|Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort)|proNICU|Charite University, Berlin, Germany|No|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Blood samples (serum, plasma), cerebrovascular fluid|Both|18 Years|N/A|No|Probability Sample|patients with severe neurological diseases treated on a neurological intensive care unit|January 2016|January 20, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01463995||96247|
NCT01464008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTH-XY001|The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C|The Predictive Values of Rapid Virus Response and Complete Early Virus Response for Sustained Virus Response in Chronic Hepatitis C Treated With Individual Therapeutic Programme||Beijing Ditan Hospital|Yes|Completed|January 2004|September 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|297|||Both|11 Years|75 Years|No|Non-Probability Sample|Consecutive patients with chronic hepatitis C who were admitted to hospital or treated as        outpatients at Beijing Ditan Hospital were eligible for the study.|October 2011|November 1, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01464008||96246|
NCT01464255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-OMC-01|Comparative Study of Two Marketed 1-day Soft Contact Lenses|Clinical Performance of Ocufilcon D With a Wetting Agent to Ocufilcon B||Coopervision, Inc.|No|Completed|August 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|71|||Both|18 Years|40 Years|No|||August 2014|August 15, 2014|October 26, 2011|No|Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01464255||96227|
NCT01467219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0211-C|Pilot Study Using a PET Gamma Probe to Evaluate Lymph Nodes in Endometrial Cancer|Intra-operative Lymph Node Evaluation Using a Hand Held PET Gamma Probe in Endometrial Cancer Surgery - A Pilot Study||University Health Network, Toronto|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Female|20 Years|90 Years|No|||June 2015|June 19, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01467219||96000|
NCT01468090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|562_2003_2004|Disease Course in an IBD Cohort in the Era of Biological Treatment|Risk of Surgery Among Patients Wih Ulcerative Colitis and Croh'ns Disease After Seven Years of Follow-up in the Era of Biological Treatment.||Hvidovre University Hospital|No|Completed|October 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|192|Samples With DNA|Whole blood and faeces will be retained for biobank|Both|N/A|N/A|No|Non-Probability Sample|562 patients diagnosed with Crohn's disease, Ulcerative colitis or indeterminant colitis        in 2003-2004 i Copenhagen City and County and registered in a database.|September 2014|September 15, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468090||95934|
NCT01463540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMN1PEG|Gastrostomy Tube Placed After Gastropexy Versus Gastrostomy Tube Placed Using the Traditional Push/Pull Techniques|A Multicentric, Randomised Clinical Trial Comparing Short and Long Time Outcome of Gastrostomy Tube Placed After Gastropexy, Versus Gastrostomy Tube Placed Using the Traditional Push/Pull Techniques||Arcispedale Santa Maria Nuova-IRCCS|No|Completed|September 2010|May 2014|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|85 Years|No|||August 2015|August 17, 2015|October 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463540||96282|
NCT01463332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC/CT/3/2011|Effect of Dexmedetomidine on Pain Due to Propofol Injection|Effect of Dexmedetomidine on Pain Due to Propofol Injection:A Randomised, Double-blind, Controlled Clinical Trial||KVG Medical College and Hospital|Yes|Active, not recruiting|August 2011|October 2011|Anticipated|October 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|60 Years|No|||October 2011|October 31, 2011|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01463332||96298|
NCT01463787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPan|Comparison of Outcomes of Two Approaches in Microsurgical Varicocelectomy in Chinese Infertile Males: A Prospective Randomized, Controlled Trial|||Nanjing Medical University|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Male|20 Years|46 Years|No|||April 2013|April 8, 2013|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01463787||96263|
NCT01464073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIPOXmax|Effectiveness of Individualized Exercise Program, Combined With a Balanced Diet on the Evolution of Body Fat|Evaluation of the Effectiveness of Individualized Exercise Program, Combined With a Balanced Diet Rich in Fruits and Vegetables, on the Evolution of Body Fat in Overweight or Obese Women, as Part of Type 2 Diabetes Prevention in Reunion Island.|LIPOXmax-RUN|Centre Hospitalier Universitaire de la Réunion|Yes|Completed|November 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|137|||Female|20 Years|40 Years|No|||July 2015|July 28, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01464073||96241|
NCT01464086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET2011/1748|LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)||LIFSCREEN|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|September 2011|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|110|||Both|5 Years|71 Years|No|||February 2016|February 9, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464086||96240|
NCT01463800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARE-GUCH|Rehabilitation in Patients With Congenital Heart Disease|Cardiac Rehabilitation in Patients With Complex Congenital Heart Disease: Improvement of Exercise Intolerance|CARE-GUCH|University Hospital, Basel, Switzerland|No|Recruiting|May 2011|May 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|166|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01463800||96262|
NCT01454310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPRA-VS-STSG-2010|An Acellular Epithelial Skin Substitute in Deep Partial-thickness Burns|A Prospective Noninferiority Trial to Compare an Acellular Epithelial Skin Substitute With Autologous Split-thickness Skin Grafts in Deep Partial-thickness Burns||Medical University of Vienna|No|Completed|November 2010|September 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01454310||96987|
NCT01454583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3A-Registry|Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany|3A-Register Zur Ambulanten Therapie Mit RAS-Inhibitoren in Patienten Mit Arterieller Hypertonie in Deutschland|3A|Stiftung Institut fuer Herzinfarktforschung|No|Completed|October 2008|July 2012|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|15337|||Both|N/A|N/A|No|Non-Probability Sample|Consecutive outpatients with arterial hypertension and treatment with a renin inhibitor,        ACE inhibitor, ARB, or without RAS blockade.        In order to collect enough information on Aliskiren treatment ratio between therapy        alternatives should be 4 (Aliskiren) to 1 (ACE inhibitor/ARB) to 1 (no RAS blockade)|August 2014|August 5, 2014|September 21, 2011||No||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01454583||96966|
NCT01454856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/30MAI/218|Perioperative Evaluation of Immuno-inflammatory Parameters|Perioperative Evaluation of Immuno-inflammatory Parameters||Université Catholique de Louvain|Yes|Recruiting|October 2011|January 2025|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|Samples Without DNA|Plasma and cells (PBMCs) frozen in cryotubes|Both|18 Years|N/A|No|Probability Sample|Cohort of patients|December 2014|December 1, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01454856||96945|
NCT01455168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H23-75|Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome|Prospective Study to Examine the Efficacy of a Capsular Tension Ring (CTR) in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome (XFS) With no Zonular Weakness|Effect of CTR|University of Occupational and Environmental Health|No|Active, not recruiting|September 2004|October 2013|Anticipated|May 2006|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Outpatients with cataract and exfoliation syndrome|October 2011|October 19, 2011|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01455168||96921|
NCT01455181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAR-C10-009|A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary|A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study|REPEAT|Shire|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|85 Years|No|||March 2015|November 10, 2015|September 15, 2011|No|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01455181||96920|
NCT01454869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-04-129-12415|The Effect of Heparin on Inhalation Injury|Efficacy of Heparin Nebulization on Lung Injury Score in Inhalation Burn Injury||Tehran University of Medical Sciences|Yes|Withdrawn|February 2012|June 2014|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2012|December 14, 2012|October 17, 2011||No|Due to insufficient funds|No||https://clinicaltrials.gov/show/NCT01454869||96944|
NCT01462747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KULIST-001|Efficacy and Safety Study of a Medical Device (KULIST)to Treat Perianal Fistulas|An Open Prospective Study Evaluating the Efficacy and Safety of a Medical Device,KULIST, for the Treatment of Chronic, Non-complicated Perianal Fistulas||Nordic Drugs AB|No|Completed|December 2011|January 2013|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|75 Years|No|||February 2013|February 12, 2013|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01462747||96343|
NCT01463007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 251|Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer|ACCELERATED PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (ACCUBOOST) FOR EARLY STAGE BREAST CANCERS: A TOXICITY ASSESSMENT||Brown University|Yes|Active, not recruiting|August 2011|December 2018|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|50 Years|N/A|No|||February 2016|February 12, 2016|July 21, 2011|Yes|Yes||No|June 24, 2015|https://clinicaltrials.gov/show/NCT01463007||96323|
NCT01463241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH085963-03|Behavioral and Affective Skills in Coping (BASIC) Open Trial|Behavioral and Affective Skills in Coping: Practice-Adapted Child Psychotherapy|BASIC|Judge Baker Children's Center|No|Completed|November 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|8 Years|15 Years|No|||April 2015|April 15, 2015|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01463241||96305|
NCT01463449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17913|"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"|"Influence of Obesity, Weight Loss, and Diet on Low Grade Inflammation With Particular Focus on the Macrophage Marker, Soluble-CD163 - a New Predictor of Diabetes.Can s-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"|sCD163|University of Aarhus|Yes|Completed|November 2011|August 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|31|Samples With DNA|Blood, adipose tissue|Both|30 Years|60 Years|No|Non-Probability Sample|The cohorts will be selected from the department of Endokrinology at Aarhus University        Hospital.|August 2014|August 12, 2014|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01463449||96289|
NCT01463748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS11074|Effects of Graptopetalum Paraguayense E. Walther on the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome|||Chung Shan Medical University|Yes|Completed|July 2011|||April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|54|||Both|20 Years|85 Years|No|||July 2013|July 2, 2013|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01463748||96266|
NCT01467804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|y00741015-zjx|Randomized Double Blinding Controlled Study on" Jia Wei Xiao Yao Jiaonang" Treating Mild to Moderate Major Depressive Disorder|Randomized Double Blinding Controlled Study on" Jia Wei Xiao Yao Jiaonang" Treating Mild to Moderate Major Depressive Disorder||China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|November 2011|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||January 2010|November 9, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01467804||95955|
NCT01464827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-652|ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients|A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects With Genotype 1 Chronic Hepatitis C Virus Infection||AbbVie|Yes|Completed|October 2011|September 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|14||Actual|580|||Both|18 Years|70 Years|No|||April 2015|April 2, 2015|September 28, 2011|Yes|Yes||No|December 23, 2014|https://clinicaltrials.gov/show/NCT01464827||96183|
NCT01465334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-304|Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL|A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL||Dana-Farber Cancer Institute|Yes|Active, not recruiting|November 2011|December 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465334||96145|
NCT01465555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA026469|Evaluation of Web-Based Recovery Monitoring With Clinical Alerts|Evaluation of Web-Based Recovery Monitoring With Clinical Alerts||Treatment Research Institute|Yes|Completed|January 2010|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|389|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465555||96128|
NCT01463319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASL07_WW-2011|Warm Water and Unsedated Colonoscopy|Warm Water Colonoscopy: a Novel Method for Unsedated Colonoscopy|WW|Presidio Ospedaliero Santa Barbara|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|818|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2013|February 7, 2013|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01463319||96299|
NCT01463527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0904005003|Using Capnography to Reduce Hypoxia During Pediatric Sedation|Using Capnography to Reduce the Incidence of Hypoxia in Children During Moderate Sedation in the Pediatric Emergency Department: A Randomized Controlled Trial||Yale University|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|167|||Both|1 Year|20 Years|No|||July 2014|July 8, 2014|October 24, 2011||No||No|January 14, 2014|https://clinicaltrials.gov/show/NCT01463527||96283|No serious adverse events were recorded. Since these events are rare and this study was not powered to detect them, we are unable to predict how capnography may have impacted staff behavior and patient outcomes for these less frequent events.
NCT01463813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIND|Finnish Vitamin D Trial (FIND)|Finnish Vitamin D Trial (FIND)|FIND|University of Eastern Finland|Yes|Active, not recruiting|September 2012|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2495|||Both|60 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01463813||96261|
NCT01463553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z111107058811089|Improving Primary Spontaneous Pneumothorax (PSP) Treatment Techniques in VATS|||Beijing Haidian Hospital|Yes|Recruiting|July 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|320|||Both|10 Years|45 Years|No|||November 2013|November 10, 2013|October 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463553||96281|
NCT01464359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT2011-15|T-Cell Depleted Double UCB for Refractory AML|T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia||Masonic Cancer Center, University of Minnesota|No|Terminated|October 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|2 Years|45 Years|No|||April 2015|April 29, 2015|November 1, 2011|Yes|Yes|Slow accrual|No|April 29, 2015|https://clinicaltrials.gov/show/NCT01464359||96219|
NCT01464372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMK0910|Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder|Electrical Field Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder - Version: 3.0 Dated 16 APR 2012.|ELEC STIM|EMKinetics, Inc|No|Terminated|October 2011|January 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Female|18 Years|N/A|No|||January 2013|January 30, 2013|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464372||96218|
NCT01454323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMMo/CIC/2009|Intracoronary Infusion of Bone Marrow Mononuclear Cells in Patients With Previous Myocardial Infarction.|Phase II Clinical Trial on the Effect of Intracoronary Infusion of Bone Marrow Mononuclear Cells on Functional Recovery in Patients With Myocardial Chronic Back and Severely Depressed Left Ventricular Function.||Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Yes|Completed|December 2010|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||November 2014|June 29, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01454323||96986|
NCT01454596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110266|CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII|A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII||National Institutes of Health Clinical Center (CC)||Recruiting|September 2011|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|107|||Both|18 Years|70 Years|No|||January 2016|February 10, 2016|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454596||96965|
NCT01455480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-BWH-001|Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn|Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn||Regenera Pharma Ltd|No|Withdrawn|December 2014|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2011|January 23, 2014|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01455480||96897|
NCT01455493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIM4972g|A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma|A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for The Treatment of Recurrent or Persistent Endometrial Carcinoma||Genentech, Inc.||Completed|December 2011|February 2014|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455493||96896|
NCT01462760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-11|Contribution of Actigraphy for the Evaluation of Elbow Range of Motion in the Joint Assessment in Gerontology|Contribution of Actigraphy for the Evaluation of Elbow Range of Motion in the Joint Assessment in Gerontology|BIOVAL|Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2011|August 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|85|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 27, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01462760||96342|
NCT01463020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-PC-KHL|Behavioural Activation-Based Treatment Administered Through Smartphone|Behavioural Activation-Based Guided Self-Help Treatment Administered Through a Smartphone Application||Linkoeping University|No|Completed|February 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|65 Years|No|||June 2013|June 18, 2013|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01463020||96322|
NCT01463254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10231|A Prospective Observational Study of the Clinical Performance of Femplant in Pakistan|A Prospective Observational Study of the Clinical Performance of Femplant in Pakistan||FHI 360|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|724|||Female|18 Years|44 Years|Accepts Healthy Volunteers|Probability Sample|women using Femplant as a primary method of contraception in Pakistan|July 2013|July 11, 2013|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01463254||96304|
NCT01463462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF IRB 00001841|Electronic Catheter Stethoscope|Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery||University of South Florida|Yes|Active, not recruiting|February 2011|March 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Current patients having gynecological surgery|March 2015|March 11, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01463462||96288|
NCT01467258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:073|Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers|Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers||University of Manitoba|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01467258||95997|
NCT01467271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-55-003|Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration|Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration|NSsaFe|Guerbet|No|Active, not recruiting|April 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|540|||Both|N/A|N/A|No|Non-Probability Sample|-  Patients with moderate to severe and end stage renal impairment or dialysis          -  Patients scheduled for a contrast enhanced MRI with DOTAREM|September 2015|September 23, 2015|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01467271||95996|
NCT01468662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study 1569|CMR Repeatability in STEMI|Cardiovascular Magnetic Resonance Scan Repeatability in ST Segment Elevation Myocardial Infarction||University of Bristol|No|Completed|November 2011|||April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Female|18 Years|85 Years|No|Probability Sample|ST segment elevation myocardial infarction|October 2014|October 27, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468662||95890|
NCT01468675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002762|Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care|Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care||Brigham and Women's Hospital|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6075|||Both|18 Years|75 Years|No|||February 2015|February 5, 2015|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01468675||95889|
NCT01468688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571X2101|A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients|A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib||Novartis||Active, not recruiting|April 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|November 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468688||95888|
NCT01462500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2229-519-28930|Pharmacokinetics of Miltefosine in Children and Adults|Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.|PK|Centro Internacional de Entrenamiento e Investigaciones Médicas|No|Recruiting|October 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|2 Years|60 Years|No|||March 2014|March 11, 2014|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01462500||96362|
NCT01466075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D-2011-2012-0.03|Study of an Investigational Glucose Meter System|Clinical Study of the Apollo Evolution BGMS With Tatsu Blood Glucose Test Strips||Ascensia Diabetes Care|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|207|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|October 28, 2011|Yes|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT01466075||96088|
NCT01463345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001949|Blood Conservation in Cardiac Surgery|Blood Conservation in Cardiac Surgery||Hackensack University Medical Center|Yes|Terminated|November 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|900|||Both|21 Years|N/A|No|||February 2014|February 2, 2014|October 27, 2011||No|PI left and closed study at Hackensack went to RUTGERS - Robert Wood Johnson Medical Center|No||https://clinicaltrials.gov/show/NCT01463345||96297|
NCT01463111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00050442|Decision-Making in Bipolar Disorder|Decision-Making in Bipolar Disorder||Emory University|Yes|Active, not recruiting|May 2011|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|June 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463111||96315|
NCT01464385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK98|Nutrition Beverage Tolerance Study|Nutrition Beverage Tolerance Study||Abbott Nutrition|Yes|Completed|October 2011|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|121|||Both|45 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 30, 2012|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01464385||96217|
NCT01460251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006492ctil|OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277|OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 in Patients Who Have Completed Study 901 and Study 910 (Extension to 901 Phase III Study||Rabin Medical Center|No|Terminated|January 2012|February 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|50 Years|No|||July 2014|March 18, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01460251||96532|
NCT01464112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018661|A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma|A Phase 1b Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Subjects With Relapsed Multiple Myeloma||Janssen Research & Development, LLC|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|99 Years|No|||January 2016|January 8, 2016|August 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01464112||96238|
NCT01460264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIG3-Region_Skane|An Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study|BIG3 - An Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study|BIG3|Region Skane|No|Enrolling by invitation|October 2012|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|10000|Samples With DNA|whole blood, serum|Both|45 Years|75 Years|No|Non-Probability Sample|Community sample,residents in Skåne county Sweden.|August 2015|August 26, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460264||96531|
NCT01453959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP 2010/170726|Fludrocortisone's Test in Salt Sensitivity|Fludrocortisone's Test in the Identification of Salt Sensitivity||Fundação de Amparo à Pesquisa do Estado de São Paulo|Yes|Recruiting|July 2011|June 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|40 Years|65 Years|No|||October 2011|October 20, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01453959||97014|
NCT01453972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRENO|Effects of Exercise-intensity on Physiological Adaptations in Overweight and Obese|Effects of Exercise-intensity on Physiological Adaptations in Overweight and Obese|TRENO|Norwegian University of Science and Technology|No|Completed|October 2011|December 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01453972||97013|
NCT01454882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1324|Measuring Free-living Energy Expenditure Using Direct Calorimetry|Measuring Free-living Energy Expenditure Using Direct Calorimetry||University of Colorado, Denver|Yes|Completed|January 2012|January 2016|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study #1: Lean (body mass index (BMI) < 25.0 kg/m2), adult men and women (18-45 yrs) in        stable health will be studied.        Study #2 & #3: A heterogenous sample of adult men and women in stable health will be        studied. We will study subjects across a wide range of weight (up to 300 lbs) and age        range (≥ 18 yrs).|January 2016|January 7, 2016|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454882||96943|
NCT01455207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00495-36|From Uncomplicated Alcoholism to Korsakoff's Syndrome|From Uncomplicated Alcoholism to Korsakoff's Syndrome: Clinical, Genetic, Neuropsychological and Brain Examinations|ALCOBRAIN|University Hospital, Caen|Yes|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|220|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 8, 2014|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455207||96918|
NCT01455220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-TYS-10-10057|The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis|The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis|Tysex|University of South Florida|No|Completed|January 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|45|||Both|18 Years|60 Years|No|||December 2014|December 2, 2014|October 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01455220||96917|
NCT01455506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Decitabine plus mini-FluBu|PRO#0118: Decitabine Plus Mini Flu-Bu|PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies||Hackensack University Medical Center|Yes|Completed|May 2009|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|45 Years|80 Years|No|||February 2014|February 1, 2014|June 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01455506||96895|
NCT01466634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010101|Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis|Bioabsorbable Versus Permanent Polymer Bare Metal Stents in Saphenous Vein Graft Disease: Insights From a Meta-analysis of 6221 Patients||Azienda Ospedaliero Universitaria Maggiore della Carita|No|Completed|August 2011|October 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|6221|||Both|18 Years|90 Years|No|Probability Sample|Patients with coronary artery disease with indication to percutaneous coronary        intervention|November 2011|November 4, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01466634||96045|
NCT01463033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS45656|Levetiracetam to Prevent Post-Traumatic Epilepsy|Pilot: Levetiracetam to Prevent Post-Traumatic Epilepsy||Children's Research Institute|Yes|Completed|April 2005|February 2010|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|126|||Both|6 Years|N/A|No|||December 2015|December 11, 2015|October 12, 2011|Yes|Yes||No|November 11, 2014|https://clinicaltrials.gov/show/NCT01463033||96321|
NCT01463046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112512|Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome|A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome||University of California, San Francisco|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463046||96320|
NCT01463059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0083|Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy|A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy||UCB Pharma|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|119|||Both|20 Years|N/A|No|||March 2013|March 19, 2013|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463059||96319|
NCT01463267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|194822-4|Study of Reminding to Improve Medication Adherence in Heart Failure|Heart iRx This Short Non-descriptive Title is the Real Title|Heart iRx|Kent State University|No|Recruiting|November 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|60|||Both|45 Years|90 Years|No|||October 2011|October 28, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01463267||96303|
NCT01463475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0104|University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol|University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol||University of Wisconsin, Madison|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01463475||96287|
NCT01467518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115698|Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.|A Phase 1, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD With Dolutegravir (GSK1349572) 50 mg Twice Daily in Opiate-Dependent, HIV Seronegative Adult Subjects.||ViiV Healthcare|No|Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|11|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|April 5, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01467518||95977|
NCT01468389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGC001-307PLAH-XJM|Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction|A Randomized Multicenter Phase III Study:Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone vs.Taxanes or Platinum Combined With Capecitabine in Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction.||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|Yes|Recruiting|November 2011|June 2013|Anticipated|January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||November 2011|November 8, 2011|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01468389||95911|
NCT01462513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LICC01|L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases|LICC: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases - a Randomized, Placebo-controlled, Multicenter, Multinational, Double Blinded Phase II Trial|LICC|Johannes Gutenberg University Mainz|Yes|Active, not recruiting|August 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462513||96361|
NCT01462851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3941001|A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults|A Phase 1, Randomized Investigator-And-Subject-Blind, Sponsor Open, Placebo Controlled Two-Part Study To Characterize The Pharmacokinetics And Pharmacodynamics Of Single Doses Of Pf-05297909 In Healthy Adult Subjects||Pfizer|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|51|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|September 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01462851||96335|
NCT01462825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC11-3-049|The Effect of Tomato Ketchup on Inflammation|The Protective Effect of Tomato Ketchup Consumption on Inflammation Induced Ex-vivo in Human Blood||Maastricht University Medical Center|No|Completed|November 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|6|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 17, 2012|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01462825||96337|
NCT01463826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|br82622/08|Respiratory Problems and Caries in Children With Bruxism|Association Between Respiratory Problem and Dental Caries in Children With Bruxism|RPCB|University of Nove de Julho|No|Completed|May 2010|August 2011|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|90|||Both|4 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with either the complete primary or mixed dentition who were not in dental        treatment were included in the study and divided into two groups: those with bruxism and        those without bruxism. For the diagnosis of bruxism, a questionnaire was administered to        determine the occurrence of teeth clenching/grinding and a physical exam was performed for        the determination of dental wear based on the criteria of the American Academy of Sleep        Medicine. Dental caries were determined based on the criteria of the World Health        Organization|October 2011|November 1, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01463826||96260|
NCT01463566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU2011-05K|Gender Solutions Natural Knee Post-Market Study|Prospective Multicenter Post-market Study of the Zimmer Gender Solutions Natural Knee Flex System||Zimmer, Inc.|No|Suspended|January 2012|January 2025|Anticipated|July 2024|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|75 Years|No|Non-Probability Sample|Each investigator will screen from his patient population patients suffering from severe        knee pain and disability who meet the inclusion/exclusion criteria for study        participation.|March 2012|March 21, 2012|October 24, 2011||No|Suspended pending internal review/direction of the company's focus.|No||https://clinicaltrials.gov/show/NCT01463566||96280|
NCT01460277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|275/2011|Τhe Effectiveness of Hydrotherapy Exercises on the Rehabilitation of Hemiplegic Patients||hydro|University of Ioannina||Recruiting|August 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|75 Years|No|||May 2015|May 26, 2015|October 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01460277||96530|
NCT01460589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUHCRC004|Early Commencement of Adjuvant Chemotherapy for Colon Cancer|Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Trial|ECTX|Kyungpook National University|Yes|Recruiting|November 2011|December 2018|Anticipated|October 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|198|||Both|18 Years|70 Years|No|||September 2015|September 11, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460589||96507|
NCT01453998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114843|Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)|Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)||GlaxoSmithKline||Completed|October 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|657|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||June 2014|July 24, 2014|October 6, 2011|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01453998||97011|
NCT01454609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100745483-1910201028464726|Safety and Efficacy of Bilateral Superficial Cervical Plexus Block in Thyroidectomy|Safety and Efficacy of Bilateral Superficial Cervical Plexus Block in Thyroidectomy - a Double Blind Randomized Controlled Trial||Jawaharlal Institute of Postgraduate Medical Education & Research|Yes|Completed|January 2009|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|20 Years|65 Years|No|||October 2011|October 18, 2011|October 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01454609||96964|
NCT01454622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100680|A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Fed Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|October 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454622||96963|
NCT01454895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00027046|Test of a Web-based Intervention to Promote Hearing Protector Use|Test of a Web-based Intervention to Promote Hearing Protector Use||University of Michigan|No|Completed|November 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|498|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454895||96942|
NCT01454908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-U-005|Oxford Partial Knee Kinematics Gait Analysis Study|Investigation of Unicompartmental Knee Arthroplasty and Functional, Daily Activities: A Quantitative Assessment of Gait, Sit-to-Stand, and Stair Climbing||The CORE Institute|No|Active, not recruiting|April 2006|December 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 18, 2011|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454908||96941|
NCT01455233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STB-01|2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery|Phase IV Study: A Prospective Two-Site Study to Evaluate the Safety and Tolerance of Besivance Versus Vigamox Prophylactically Pre and Post Operatively in Subjects Undergoing Routine Cataract Surgery|STB-01|Ophthalmology Consultants, Ltd.|Yes|Completed|September 2010|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|60|||Both|18 Years|N/A|No|||December 2010|October 18, 2011|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455233||96916|
NCT01451294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-195|Effect of Blood Pressure on rSO2 in Carotid Endarterectomy (CEA)|The Effect of Phenylephrine Versus Ephedrine on Cerebral Perfusion During Carotid Endarterectomy||UMC Utrecht||Not yet recruiting|November 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||October 2011|October 12, 2011|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01451294||97219|
NCT01467843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AT006226-01A1|Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain|Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain||Group Health Cooperative|No|Completed|June 2012|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|342|||Both|20 Years|70 Years|No|||December 2015|December 9, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01467843||95952|
NCT01468103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19831105gaoxinbo|Laser Iridotomy Versus Surgical Iridectomy in Early Angle Closure|Laser Peripheral Iridotomy Versus Surgical Peripheral Iridectomy in Early Angle Closure:a Randomized Clinical Trial||Sun Yat-sen University|No|Recruiting|August 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|50 Years|80 Years|No|||November 2011|November 8, 2011|November 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468103||95933|
NCT01468116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITBypass|The Effect of Roux-en-Y Gastric Bypass on Mitochondrial Function in Type 2 Diabetes|||Hvidovre University Hospital|No|Recruiting|March 2011|December 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|serum, plasma|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from the outpatient clinic of endocrinology and the gastrosurgical        clinic at Hvidovre University Hospital|November 2011|November 7, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468116||95932|
NCT01465100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10100525|Liver Cell Transplant for Phenylketonuria|Hepatocyte Transplantation for Phenylketonuria||University of Pittsburgh|Yes|Recruiting|December 2011|December 2015|Anticipated|November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465100||96162|
NCT01466686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11120|Low Dose Radiation Therapy for Glioblastoma Multiforme|A Phase II Trial of Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|18 Years|100 Years|No|||March 2016|March 8, 2016|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466686||96041|
NCT01466699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1916673|The Study of Blood Pressure Variability to Impact Arterial Stiffness and Carotid Atherosclerosis|The Relationship of Blood Pressure Variability, Arterial Stiffness and Carotid Atherosclerosis in Beijing Residents||Capital Medical University|Yes|Enrolling by invitation|January 2012|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1235|||Both|N/A|80 Years|No|Probability Sample|Participants in this study are community residents from Being in China|November 2011|November 7, 2011|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01466699||96040|
NCT01468402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIAE|Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma|Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma||Hospital Israelita Albert Einstein|No|Completed|September 2008|August 2009|Actual|April 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Female|18 Years|45 Years|No|Non-Probability Sample|Women from the Leiomyoma Service, with eligible criteria and chose this kind of treatment        between september 2008 and march 2009.|November 2011|November 8, 2011|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01468402||95910|
NCT01468935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120016|Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning|Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning||National Institutes of Health Clinical Center (CC)||Recruiting|October 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|July 1, 2015|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01468935||95870|
NCT01468948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120024|Octanoic Acid for Essential Tremor|Dose Escalation Study of Oral Octanoic Acid in Patients With Essential Tremor||National Institutes of Health Clinical Center (CC)||Completed|October 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|21 Years|N/A|No|||July 2012|October 15, 2014|November 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468948||95869|
NCT01468961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBRO-P|Pilot Study of Internet-based Cognitive Behavior Therapy for Fibromyalgia|Pilot Study of Internet-based Cognitive Behavior Therapy for Fibromyalgia||Karolinska Institutet|No|Active, not recruiting|November 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2011|February 9, 2012|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01468961||95868|
NCT01468974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-113|ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System|A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System for the Treatment of Subjects With Symptomatic Claudication From Occlusive Vascular Disease of the Superficial Femoral (SFA) or Common or External Iliac Arteries.||Abbott Vascular|Yes|Completed|November 2011|December 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|80 Years|No|||January 2016|January 28, 2016|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01468974||95867|
NCT01462864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0209|Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome|StructUred eduCation Programme to Improve Cardiovascular Risk in womEn With polycyStic Ovary Syndrome; SUCCESS Study|SUCCESS|University of Leicester|Yes|Completed|September 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|162|||Female|18 Years|50 Years|No|||October 2011|December 3, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01462864||96334|
NCT01463137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOFIE-11|Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder|Computerized Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder|SOFIE-11|Umeå University|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|129|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01463137||96313|
NCT01462838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VicOryx|Immune Therapy of HPV-induced Cancers|Phase I/IIa Study of Immunization With a p16INK4a Peptide Combined With MONTANIDE ISA-51 VG in Patients With Advanced HPV-associated Cancers||Oryx GmbH & Co. KG|Yes|Completed|August 2011|May 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01462838||96336|
NCT01464138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP012|Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children|Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children||Jomaa Pharma GmbH|Yes|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|6 Months|3 Years|No|||November 2011|November 2, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01464138||96236|
NCT01464125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP011|Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults|Evaluation of Fosmidomycin and Azithromycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria|JP011|Jomaa Pharma GmbH|No|Active, not recruiting|November 2008|December 2011|Anticipated|October 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|15 Years|55 Years|No|||October 2011|October 31, 2011|October 26, 2009||No||No||https://clinicaltrials.gov/show/NCT01464125||96237|
NCT01460290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39358|Asenapine in the Treatment of Older Adults With Bipolar Disorder|Asenapine in the Treatment of Older Adults With Bipolar Disorder||University Hospital Case Medical Center|Yes|Completed|October 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|60 Years|N/A|No|||December 2014|December 8, 2014|October 24, 2011|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT01460290||96529|
NCT01460602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05266|Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma|Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma||Louisiana State University Health Sciences Center Shreveport|No|Terminated|May 2010|October 2014|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||October 2011|October 25, 2011|June 10, 2010|Yes|Yes|Investigator has relocated to MD Anderson|No||https://clinicaltrials.gov/show/NCT01460602||96506|
NCT01460615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11009M|Cortisone Treatment for the Prevention of Postoperative Pancreatitis and Pancreatitis-induced Complications After Pancreaticoduodenectomy (Whipple Operation)|||Tampere University Hospital||Completed|February 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|N/A|||||||Both|18 Years|N/A||||October 2011|July 1, 2015|October 25, 2011||||No||https://clinicaltrials.gov/show/NCT01460615||96505|
NCT01454349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRX302-2-06|Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)|A Randomized Dose-Escalation, Multicenter Safety and Efficacy Study of a Single Transrectal Intraprostatic Treatment of PRX302 for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)||Sophiris Bio Corp|Yes|Completed|September 2011|August 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|50 Years|80 Years|No|||August 2013|August 19, 2013|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01454349||96984|
NCT01454635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-GEC-84|Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder|Treatment Response Study of Sertraline to Treat Japanese Major Depressive Disorder|AFADTRMDD|Showa University|No|Completed|June 2008|March 2010|Actual|March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|96|||Both|20 Years|N/A|No|||October 2011|October 27, 2011|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01454635||96962|
NCT01454921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 089|Development of an Empowerment Intervention for Young Women Living With HIV|A Secondary Prevention Empowerment Intervention for Young Women Living With HIV||Westat|Yes|Completed|February 2010|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Female|16 Years|24 Years|No|||March 2016|March 1, 2016|August 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01454921||96940|
NCT01455246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2059P|Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis|Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial||University of Padova|No|Terminated|October 2010|July 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||October 2014|October 11, 2014|October 13, 2011||No|Decision of independent monitoring committee after interim analysis: Risk of failure    significantly higher in ceftazidime group.|No||https://clinicaltrials.gov/show/NCT01455246||96915|
NCT01451554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-003653|Portion Control Treatment for Obesity|Portion Control for the Treatment of Obesity in the Primary Care Setting||Mayo Clinic|No|Completed|January 2009|December 2010|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 19, 2011|October 11, 2011||No||No|October 19, 2011|https://clinicaltrials.gov/show/NCT01451554||97199|small sample size and inability to blind staff/study subject to the intervenion
NCT01451567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19505|The Effect of a Structured Personalised Ergonomic Intervention for Hospital Nurses With Musculoskeletal Complains|Study That Examined the Effect of a Structured Personalised Ergonomic Intervention Program for Hospital Nurses With Musculoskeletal Complains.||Tel Aviv University|Yes|Completed|June 2005|March 2006|Actual|October 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|31|||Female|N/A|N/A|Accepts Healthy Volunteers|||May 2005|October 15, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01451567||97198|
NCT01468714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621011|A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects|A Phase I, Open-Label, Fixed Sequence Study To Estimate The Steady-State Effect Of Ketoconazole On The Single-Dose Pharmacokinetics Of PF-04937319 In Healthy Adult Subjects||Pfizer|No|Completed|October 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 11, 2011|October 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468714||95886|
NCT01468727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A110449|Study on Use of Xylitol-wipes to Prevent Dental Caries|Effectiveness of Xylitol Wipes on Infants in Reducing Bacterial Transmission and Colonization From Mother to Child|WIPE|University of California, San Francisco|No|Completed|January 2007|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|88|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||November 2011|November 14, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468727||95885|
NCT01464619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-007271|Enhancing Parenting for Depressed Caregivers|Enhancing Parenting for Depressed Caregivers|EPDC|Children's Hospital of Philadelphia|No|Completed|July 2011|November 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|July 19, 2011||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01464619||96199|Outcomes are assessed by maternal report measures only. Incentives were given for completing the adapted IY group. There was poor attendance at IY sessions. The study was conducted in only one geographic area .
NCT01464866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK56|Effect of Nutritional Supplementation on Pediatric Burn Patients|Effect of Nutritional Supplementation on Pediatric Burn Patients||Abbott Nutrition|Yes|Completed|February 2010|September 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|1 Year|10 Years|No|||November 2011|September 4, 2012|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01464866||96180|
NCT01467570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/191/2008|Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis|Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis: Randomized, Double-Blind Controlled Trial||Medical University of Warsaw|Yes|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|4 Months|48 Months|No|||November 2013|February 14, 2014|October 27, 2011||No||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01467570||95973|Potential limitations included lack of perfect blinding. Because of technological reasons, it was not feasible to produce study products that were identical in colour, smell and taste.
NCT01466985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-005|A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-1439 in HIV-1 Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Male|18 Years|55 Years|No|||October 2015|October 1, 2015|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01466985||96018|
NCT01466998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT005491|Menopausal Treatment Using Relaxation Exercises (MaTURE)|Menopausal Treatment Using Relaxation Exercises (MaTURE)|MaTURE|University of California, San Francisco|Yes|Completed|January 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Female|40 Years|59 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01466998||96017|
NCT01461863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD057614-03|DarDar Nutrition Study in HIV Breastfeeding Women|Effects of Protein-calorie Supplementation on HIV Disease in Breastfeeding Women|DarDar2B|Dartmouth-Hitchcock Medical Center|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Female|18 Years|N/A|No|||September 2014|September 26, 2014|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01461863||96411|
NCT01462188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAPS-09-I|Optimizing Infarct Size by Transforming Emergent Stenting Into an Elective Procedure Study|Immediate Versus Delayed Stenting in Patients With ST-Elevation Myocardial Infarction Undergoing Mechanical Intervention|OPTIMASTRATEGY|Università degli Studi di Ferrara|Yes|Recruiting|October 2011|October 2015|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2011|October 28, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01462188||96386|
NCT01462201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-0711|A Multicenter,2-Arm,Randomized,Controlled Study Evaluate the Effectiveness of the UltraShape® Contour I VER 3.1 System for Non-Invasive Reduction in Abdominal Circumference|A Multicenter,Two-Arm,Randomized,Controlled Study for the Evaluation of the Treatment of Adipose Tissue Using a Focused Ultrasound Device||UltraShape|Yes|Completed|July 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 10, 2013|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462201||96385|
NCT01463124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HL110208|School Nurse Intervention and After School Exercise Program for Overweight Teens|School Nurse Intervention and After School Exercise Program for Overweight Teens||University of Massachusetts, Worcester|Yes|Completed|September 2012|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|126|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01463124||96314|
NCT01464151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-050|Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study|Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study||UMC Utrecht|No|Recruiting|July 2011|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|biopsies, blood, stool|Both|18 Years|70 Years|No|Non-Probability Sample|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis        between 18 and 70 years of age. Patients should have an indication for surveillance        according to the current guidelines, which means a disease duration of at least 8 years        and involvement of at least 30% of the colon.|December 2015|December 4, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464151||96235|
NCT01464398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34145EP|Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS)|Stress Reduction for PCOS and Non-PCOS Women||Milton S. Hershey Medical Center|Yes|Completed|November 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|N/A|No|||May 2015|May 13, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464398||96216|
NCT01460641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC0006|Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer|Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer||Stanford University|Yes|Recruiting|November 2011|November 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|Samples With DNA|If the patient undergoes surgery to remove the lesion in the rectum, the surgical specimen      will be examined by the pathologist, who will perform a variety of tests to detect evidence      of new blood vessel growth. The sample will be stored per routine protocol of the Stanford      Department of Pathology.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced rectal cancer undergoing standard CT for pre-treatment        planning|November 2014|November 13, 2014|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01460641||96503|
NCT01460628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-001055|Effect of Nuvigil on Fatigue|The Effect of Armodafinil (Nuvigil) on Fatigue and Quality of Life in Peri- and Postmenopausal Women||Massachusetts General Hospital||Recruiting|October 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 21, 2013|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460628||96504|
NCT01454648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09161|Prehospital Traumatic Brain Injury|Severe Traumatic Brain Injury - Comparison of Outcome in Paramedic Versus Physician Staffed Emergency Medical Services||Tampere University Hospital|No|Completed|January 2005|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|458|||Both|N/A|N/A|No|Non-Probability Sample|primary care clinic|November 2014|January 15, 2016|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01454648||96961|
NCT01454661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETMK 104/180/2011|Probiotics and Early Microbial Contact in Preterm Neonates|Probiotic Modulation of Early Microbial Contact in Premature Infants|ProPre|Turku University Hospital|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|100|||Both|N/A|3 Days|Accepts Healthy Volunteers|||April 2014|April 29, 2014|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01454661||96960|
NCT01451307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01072011FraMal|Follow-up of Children With Gastrointestinal Malformations and Postnatal Surgery|Follow-up Study of Children Aged 2 Years With Gastrointestinal Malformations and Postnatal Surgery|FraMal|Goethe University|Yes|Completed|September 2011|August 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80|||Both|18 Months|36 Months|Accepts Healthy Volunteers|Non-Probability Sample|The study is purely exploratory and based on the number of patients born in our hospital        with the malformations mentioned above (approximately 40).        Each patient is compared against a healthy child of the same gestational age, weight class        and gender (control group).|September 2013|September 4, 2013|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01451307||97218|
NCT01451320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11|Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis|Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis|TROIA|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|No|Completed|January 1993|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|182|||Both|N/A|N/A|No|||October 2011|October 11, 2011|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01451320||97217|
NCT01465360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHTAD/003|Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center|Performance of AclarusDx™, A Blood-Based Transcriptomic Test for Alzheimer's Disease, in US-based Patients Suffering From Memory Impairment and Newly Referred to A Reference Memory Center, for AD Diagnostic Workup—A Pilot Descriptive Study||Exonhit|No|Completed|November 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|160|Samples With DNA|Whole blood samples collected in PAXgene® blood RNA tubes|Both|21 Years|N/A|No|Probability Sample|Caucasian patients that are newly referred to a Reference Memory Center with a complaint        of memory impairment will be enrolled in the study.|July 2012|July 4, 2012|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01465360||96143|
NCT01465581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228683|Treatment of Neurogenic Incontinence by Surgery to Cut the Filum Terminale|A Prospective Trial of Division of the Filum Terminale for Neurogenic Bladder Dysfunction With a Normal Conus|NICNOC|Nemours Children's Clinic|No|Terminated|July 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|5 Years|16 Years|No|Non-Probability Sample|The target population of this study is children with primary or secondary daytime urinary        incontinence, who have failed to improve adequately despite compliance with at least 6        months of standard medical therapy. These children will have abnormal urodynamics, a        normal bladder ultrasound and an MR imaging showing that the conus medullaris of the        spinal cord is at a normal position and that there is no other significant dysraphic        lesion present. The entry criteria are designed to separate this very specific subset of        patients from the much larger, more general group of children presenting for evaluation        and management of incontinence.|November 2011|April 16, 2015|October 26, 2011||No|Insufficient patient accrual.|No||https://clinicaltrials.gov/show/NCT01465581||96126|
NCT01466413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELAPR P1B|Two Formulations of ELAPR Compared to Restylane® Vital Light Following Repeat Implants in the Upper Arm Dermis|A Phase 1B Study to Assess the Safety and Efficacy of Two Formulations of ELAPR Compared to Restylane® Vital Light Following Repeat Implants in the Upper Arm Dermis||Elastagen Pty Ltd|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|16|||Both|35 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01466413||96062|
NCT01467206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205309/H10|Life After STroke - the LAST Study|Life After STroke - the LAST Study. A Norwegian Multi Centre Randomized Controlled Trial|LAST|Norwegian University of Science and Technology|No|Completed|November 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|95 Years|No|||February 2016|February 22, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01467206||96001|
NCT01467505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-950-117|An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients|A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation||Vertex Pharmaceuticals Incorporated|No|Terminated|February 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||June 2015|June 1, 2015|November 3, 2011|Yes|Yes|The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify    the drug development plan.|No|May 2, 2015|https://clinicaltrials.gov/show/NCT01467505||95978|It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.
NCT01461876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020911|Obesity in HIV After Antiretroviral Therapy|Changes in Overweight/Obesity Status, hsCRP, and D-dimer in HIV-infected Patients After 12 Months of Initial Antiretroviral Treatment||Duke University|No|Completed|November 2009|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|200|Samples Without DNA|These samples represent residual plasma retained after clinical testing (HIV RNA PCR) has      been completed. Since the samples were obtained as part of routine clinical care, they are      part of the HIV samples repository at Duke University Medical Center.|Both|18 Years|N/A|No|Non-Probability Sample|Adult subjects (≥ 18 years of age) infected with HIV-1 treated in the Infectious Disease        Clinic at Duke University Medical Center between 3/1/98 to 3/1/08 who meet eligibility        criteria.        Adult subjects (≥ 18 years of age), followed in primary care clinics within the Duke        Health System between 3/1/98 to 3/1/08, who meet eligibility criteria. Control subjects        must have data for weight 12 months after baseline visit.|May 2014|October 11, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01461876||96410|
NCT01461889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1453|INR-Triggered Transfusion In GI Bleeders From ER|Transfusion-related Acute Lung Injury in Patients With Liver Disease|I-TRIGER|University of Colorado, Denver|Yes|Recruiting|July 2011|August 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|72|||Both|18 Years|75 Years|No|||October 2015|October 13, 2015|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461889||96409|
NCT01462214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/016|Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer|Phase 1-2 Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer.||VU University Medical Center|No|Recruiting|October 2011|January 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01462214||96384|
NCT01463579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0291|Exercise After Intensive Care Unit: a Randomised Controlled Trial|Effectiveness of a Programme of Exercise on Physical Function in Survivors of Critical Illness Following Discharge From the Intensive Care Unit (ICU): a Randomised Controlled Trial|REVIVE|University of Ulster|Yes|Completed|December 2011|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01463579||96279|
NCT01463592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REN1|To Study the Efficacy and Safety of Renessans in Chronic HCV Patients|An Open Labelled, Active Controlled, Three Arm, Parallel- Group Study of the Safety and Efficacy of Renessans Administered Alone and in Combination With Standard Interferon Therapy in Patients Chronic HCV Hepatitis||MTI Medical Private Limited, Pakistan|Yes|Active, not recruiting|June 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|55 Years|No|||October 2011|November 21, 2011|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01463592||96278|
NCT01463358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDT-20040601-PRESS-1|Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block|Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block|PRESS|Boston Scientific Corporation|Yes|Completed|March 2005|May 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||October 2011|January 5, 2016|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01463358||96296|
NCT01464164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02-199 - 06A|Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia|Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia|ACE-011-DBA|Northwell Health|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464164||96234|
NCT01464450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100688|Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants|PK Study of Oral Rivaroxaban in Healthy Subjects||Janssen Scientific Affairs, LLC|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|55|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 5, 2012|November 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01464450||96212|
NCT01464411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCSG-03|Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan|Phase II Clinical Trial of Dasatinib First Line Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase|D-First|Kanto CML Study Group|Yes|Recruiting|July 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Copy numbers of bcr-abl mRNA in patients with dasatinib treatment will be measured by      real-time RT-PCR to evaluate the efficiency of dasatinib.      For patients resistant to dasatinib therapy, DNA mutation analysis of the bcr-abl gene      associated with drug-resistancy will be performed.|Both|20 Months|N/A|No|Probability Sample|Patients with newly diagnosed chronic-phase chronic myelogenous leukemia in Japan|November 2011|November 2, 2011|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01464411||96215|
NCT01464424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-003|Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)|Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)||Alcon Research|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||September 2013|September 5, 2013|November 1, 2011|Yes|Yes||No|June 26, 2013|https://clinicaltrials.gov/show/NCT01464424||96214|
NCT01464437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100761|AMG 151 Amgen Protocol Number 20100761|A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects With Type 2 Diabetes Mellitus||Amgen|Yes|Completed|September 2011|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|236|||Both|18 Years|75 Years|No|||April 2014|April 24, 2014|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464437||96213|
NCT01460940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10049|A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2011|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460940||96480|
NCT01460914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11271|Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment|Outcomes of Cutaneous T-Cell Lymphoma and Chronic Graft-Versus-Host Disease in Patients Treated With Extracorporeal Photopheresis||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|October 2011|October 2050|Anticipated|September 2050|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who receive ECP treatment at DHMC|May 2015|September 16, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01460914||96482|
NCT01460927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TriActive+RF-DEKA-092011|TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides|Clinical Study to Evaluate the Performance of TriActive+ RF for the Non-invasive Treatment of Wrinkles & Rhytides||Deka Medical, Inc.|Yes|Completed|October 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 4, 2014|October 24, 2011||No||No|September 6, 2013|https://clinicaltrials.gov/show/NCT01460927||96481|
NCT01454960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC4AG039115-01-2|Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Pilot Study)|Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Pilot Study)|BEARI|University of Southern California|Yes|Enrolling by invitation|July 2011|May 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|8||Anticipated|45|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01454960||96937|
NCT01455519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIC_Cov_2011|True Functional Restoration and Analgesia in Non-Radicular Low Back Pain|True Functional Restoration and Analgesia in Non-Radicular Low Back Pain: a Prospective Double Blind, Placebo-controlled Study of Hydromorphone ER|Covidien|Rehabilitation Institute of Chicago|Yes|Completed|October 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|October 11, 2011|Yes|Yes||No|May 26, 2015|https://clinicaltrials.gov/show/NCT01455519||96894|
NCT01455532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED11746|A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors|A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors||Sanofi|No|Completed|November 2011|April 2014|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|N/A|No|||October 2014|October 21, 2014|October 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455532||96893|
NCT01455545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUGU ASMA 001|Impact of Adherence to Treatment in Asthma Control|Impact of Adherence to Treatment in Asthma Control Using ASK-20 Questionnaire and Prescription Account.||Sociedad Española de Neumología y Cirugía Torácica|Yes|Completed|January 2011|August 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|100|||Both|14 Years|80 Years|No|Non-Probability Sample|Patients with ASTHMA will be categorized into two subgroups: a) 50 patients with good        asthma control according to the Asthma Control Test (ACT) score; b) 50 patients with bad        control asthma according to the ACT score.|June 2013|June 4, 2013|October 10, 2011||No||No|August 17, 2012|https://clinicaltrials.gov/show/NCT01455545||96892|This is an observational (cross-sectional )study, with the limitations and biases associated. Patients have not been randomized.
NCT01455558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCF_PP-101|Safety and Pharmacokinetic Comparison of Cilostazol SR and IR Formulations in Healthy Korean Volunteers|||Severance Hospital||Completed|February 2009|September 2009|Actual|August 2009|Actual|Phase 1|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||October 2011|October 18, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01455558||96891|
NCT01444365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-237|A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee|A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of ABT-652 as an Add On Therapy in Subjects With Osteoarthritis of the Knee Experiencing Partial Benefit of a Nonsteroidal Anti-Inflammatory Drug||AbbVie|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|202|||Both|40 Years|75 Years|No|||May 2013|May 7, 2013|September 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444365||97738|
NCT01444378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-110|Absolute Pro® MOMENTUM™|Absolute Pro® Peripheral Self-Expanding Stent System and the Absolute Pro® LL Peripheral Self-Expanding Stent Systems in the Treatment of Subjects With Atherosclerotic De Novo or Restenotic Lesions in the Native Superficial Femoral Artery and/or Native Proximal Popliteal Artery.|MOMENTUM|Abbott Vascular|Yes|Completed|October 2011|May 2015|Actual|November 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|143|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01444378||97737|
NCT01460784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00031720|STAGES Trial: Study of Adiposity, Growth and Endocrine Stages|Changes in Adipokines and Adiposity During Puberty and Young Adulthood|STAGES|University of Utah|Yes|Completed|June 2010|March 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|575|Samples With DNA|Buffy coat in -80F long-term storage|Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy, obese young adults|December 2015|December 1, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460784||96492|
NCT01465841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 4492|Study of the Penumbra Coil 400 System to Treat Aneurysm|ACE: An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System|ACE|Penumbra Inc.|No|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|N/A|N/A|No|||March 2016|March 15, 2016|October 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465841||96106|
NCT01466101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00025229|Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy|Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy||Northwestern University|No|Withdrawn|January 2011|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|64 Years|No|||February 2012|February 17, 2012|April 20, 2010|Yes|Yes|PI left the institution. No subjects screened or enrolled.|No||https://clinicaltrials.gov/show/NCT01466101||96086|
NCT01466920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02117|Why Are so Many Patients Dissatisfied With Knee Replacement Surgery? Exploring Variations of the Patient Experience|Why Are so Many Patients Dissatisfied With Knee Replacement Surgery? Exploring Variations of the Patient Experience||University of British Columbia||Active, not recruiting|November 2011|December 2015|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|515|||Both|19 Years|N/A|No|Non-Probability Sample|Patients undergoing total knee arthroplasty|April 2015|April 7, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466920||96023|
NCT01466933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB#420-0510|Responsive Parenting Program for Infants in Rural Bangladesh|Design, Implementation and Evaluation of a Parent Support/Counselling Program With a Focus on Responsive Stimulation for Infants and Young Children in Rural Bangladesh||McGill University|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|474|||Both|6 Months|14 Months|Accepts Healthy Volunteers|||July 2013|July 16, 2013|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01466933||96022|
NCT01468077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27901|A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment|Multicenter, Randomized, Parallel Group Study to Compare the Incidence of Tocilizumab Related Infusion Reactions in Patients With Moderate to Severe Active RA, When Infusion is Given Over 31 Minutes Compared to 1 Hour||Hoffmann-La Roche||Completed|November 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|November 7, 2011|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT01468077||95935|
NCT01468376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLU-00-2010-1|GLU-xx Formulations in Individuals With Impaired Glucose Tolerance|An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance||Afexa Life Sciences Inc|No|Terminated|February 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|17|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|November 7, 2011||No|Sponsor company was acquired and new owner chose not to proceed with clinical study|No||https://clinicaltrials.gov/show/NCT01468376||95912|
NCT01462240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU2010-27K|LPS Flex Porous Femoral Components|Prospective Multicenter Post-market Study of the Zimmer NexGen LPS-Flex Porous Femoral Components||Zimmer, Inc.|No|Suspended|December 2011|December 2024|Anticipated|June 2024|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|75 Years|No|Non-Probability Sample|Each investigator will screen from this patient populatin patients suffering from severe        knee pain and disability who meet the inclusion/exclusion criteria for study        participation.|March 2012|March 21, 2012|October 24, 2011||No|Suspended pending internal review/direction of the company's focus.|No||https://clinicaltrials.gov/show/NCT01462240||96382|
NCT01462539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00364|Adenotonsillectomy and Obstructive Sleep Apnea Study|Factors That Increase Length of Stay After Outpatient Surgery of 3-6 Year Olds With OSAS Symptoms Versus Without OSAS Symptoms After Adenotonsillectomy||Nationwide Children's Hospital|No|Completed|October 2011|October 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|3 Years|6 Years|No|Non-Probability Sample|Patients undergoing adenotonsillectomy only with no concurrent surgery|November 2012|November 29, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462539||96359|
NCT01462526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00044899|The Detection of Glaucoma Using Pupillography|The Detection of Glaucoma Using Pupillography|RAPiD|Johns Hopkins University|No|Active, not recruiting|March 2011|September 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|645|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with glaucoma, glaucoma suspects, or ocular hypertension who present to the        glaucoma service at the Johns Hopkins Wilmer Eye Institute. We will also recruit normal        subjects from the accompanying persons of patients attending examinations who are not        blood relatives of the patient.|November 2015|November 12, 2015|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462526||96360|
NCT01463605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-49/484|Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial|Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Phase II Clinical Trial||Chinese Academy of Medical Sciences|Yes|Active, not recruiting|October 2011|October 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|70 Years|N/A|No|||October 2011|November 1, 2011|October 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463605||96277|
NCT01463618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-373-C-007 sub 1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2011|||||N/A|N/A|N/A||||||||||||||June 26, 2012|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463618||96276|
NCT01463839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hab026/2010|Sleep Disorder and Oral Habits in Children|Association Between Quality of Sleep and Harmful Oral Habits Among Children|SOHab|University of Nove de Julho|No|Completed|September 2010|June 2011|Actual|October 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|50|||Both|3 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo|October 2011|November 1, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01463839||96259|
NCT01460329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1178|Comparing Cardiac Output Measurements in Critically Ill Children Using USCOM and Transthoracic ECHO|Comparing Cardiac Output Measurements in Critically Ill Children Using Ultrasonic Cardiac Output Monitor and Transthoracic Echocardiography.||University of North Carolina, Chapel Hill|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|N/A|17 Years|No|Non-Probability Sample|The subjects for this study can be either male or female and not limited by race or        ethnicity. They will include critically ill pediatric patients, less than 18 yrs of age,        being treated in the Pediatric intensive care unit.|May 2013|May 3, 2013|October 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460329||96526|
NCT01460342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14101|Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia||Eli Lilly and Company|No|Completed|December 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|610|||Male|45 Years|N/A|No|||July 2013|July 23, 2013|October 24, 2011|Yes|Yes||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01460342||96525|
NCT01460303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13523|Patient-operated Valved Catheter Versus Indwelling Transurethral Catheter|Clinical Trial of Patient Operated Valved Catheter Compared With Standard Indwelling Transurethral Catheter for Postoperative Bladder Management||University of Massachusetts, Worcester|No|Completed|January 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||March 2016|March 2, 2016|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01460303||96528|
NCT01460316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00346-35|Conotruncal Cardiac Defects and Nutrigenetic Etiopathogeny|Conotruncal Cardiac Defects and Metabolism, Nutrigenetic Factors of Etiopathogeny of Conotruncal Cardiac Defects|CCOMET|Central Hospital, Nancy, France|Yes|Completed|October 2011|||May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|1 Month|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Conotruncal cardiac defects population and theirs mothers|January 2016|January 26, 2016|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460316||96527|
NCT01461512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.2 2008-006967-35|Heme Arginate in Functional Magnetic Resonance Imaging (fMRI)|The Effects of Intravenous Heme Arginate on Functional Magnetic Resonance Imaging During Ischemia||Medical University of Vienna|Yes|Active, not recruiting|January 2009|December 2011|Anticipated|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Male|18 Years|46 Years|Accepts Healthy Volunteers|||October 2011|October 26, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01461512||96438|
NCT01461239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPEL-PPGO0010|Clinical Comparison of Endodontically Treated Teeth Restored With Fiber Posts or Cast Metal Posts|Randomized Clinical Comparison of Endodontically Treated Teeth Restored With Fiber Posts or Cast Metal Posts||Federal University of Pelotas|No|Recruiting|July 2009|July 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01461239||96459|
NCT01443494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SoutheastUChina2011ZDllKY03.0|High MAP in Septic Shock With Hypertension|High Mean Arterial Pressure Target Improves Microcirculation in Septic Shock Patients With Previous Hypertension||Southeast University, China|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|September 28, 2011||No||No|February 27, 2014|https://clinicaltrials.gov/show/NCT01443494||97805|Firstly, cardiac output was monitored by NICOM system to minimize the invasive operation.Secondly, the number of patients enrolled in the study was relatively small. Next, immediate changes of the increase in MAP were investigated.
NCT01443507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2959|Effect of Exercise With Low Intensity and Longer Duration Versus High Intensity Interval Training|Does Endurance Exercise With Low Intensity and Longer Duration Improve Aerobic Capacity to the Same Extent as High Intensity Interval Training?||Volda University College|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|22|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01443507||97804|
NCT01455272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPH IRB [2010] (78)|New Therapy for Advanced Stage Leukemia After Stem Cell Transplantation|Clinical Study of Granulocyte Colony-stimulating Factor (G-CSF)-Primed, Peripheral-blood Progenitor Cells for the Prevention of Relapse Advanced Stage Leukemia||Peking University People's Hospital|Yes|Completed|July 2009|March 2015|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|N/A|60 Years|No|||April 2015|April 5, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01455272||96913|
NCT01444066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106053|The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy|The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy||Washington University School of Medicine|Yes|Enrolling by invitation|September 2011|December 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01444066||97761|
NCT01453543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/460|The Effect of Deep Friction Massage on the Achilles Tendon Blood Flow|The Effect of Deep Friction Massage on the Achilles Tendon Blood Flow|Friction|University Ghent|No|Completed|November 2010|July 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01453543||97046|
NCT01453556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intraextra01|Intracorporeal Versus Extracorporeal Mechanical Anastomosis in Laparoscopic Right Colectomy|Intracorporeal Versus Extracorporeal Mechanical Anastomosis in Laparoscopic Right Colectomy. A Prospective Randomized Controlled Clinical Trial||Scientific Institute San Raffaele|Yes|Recruiting|October 2011|September 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453556||97045|
NCT01460797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glycemic index and Metformin|Metabolic Effects of a Caloric Restriction High/Low Glycemic Index Diet Plus Metformin in Overweight/Obese Subjects|Effects of a Caloric Restriction High/Low-glycemic Index Diets and in Combination With Metformin on Glucose Metabolism, Lipid Profile and Body Composition in Overweight/Obese Subjects||University of Brasilia|Yes|Completed|October 2004|October 2006|Actual|June 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|41|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 25, 2011|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01460797||96491|
NCT01461148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MicOryx|Vaccination Against MSI Colorectal Cancer|Phase I/IIa Study of Immunization With Frameshift Peptides Administered With Montanide® ISA-51 VG in Patients With Advanced MSI-H Colorectal Cancer||Oryx GmbH & Co. KG|Yes|Completed|August 2011|May 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01461148||96466|
NCT01461161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1004|A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl|A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl||Reata Pharmaceuticals, Inc.||Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461161||96465|
NCT01461395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107209|Polscope Sperm: A Non-invasive Method to Assess DNA Damage in Individual Sperm|A Non-invasive Method to Assess DNA Damage in Individual Sperm||University of South Florida|Yes|Completed|October 2008|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|Samples With DNA|sperm|Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|IVF patients already undergoing therapy and providing a semen sample for sperm count|August 2012|August 23, 2012|February 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01461395||96447|
NCT01461668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCRT10049|Retapamulin for Reducing MRSA Nasal Carriage|Retapamulin for Reducing MRSA Nasal Carriage||University of California, Irvine|Yes|Active, not recruiting|July 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461668||96426|
NCT01461915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX-ODSH-2011-PC1|Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane|A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer|PGPC1|Cantex Pharmaceticals|No|Recruiting|November 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||November 2012|November 9, 2012|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461915||96407|
NCT01462552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115270|Physician Liver Function Test (LFT) Monitoring for Tykerb Pts|Assessment of Physician Compliance to Recommended Liver Function Test Monitoring for Tykerb Patients||GlaxoSmithKline|No|Completed|December 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1|||Female|19 Years|N/A|No|Probability Sample|Female adults age >= 19 years of age with a diagnosis of metastatic breast cancer and who        initiated lapatanib from January 1, 2007 - December 31, 2009|April 2015|April 14, 2015|May 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01462552||96358|
NCT01462565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115332|Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)|A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.)||GlaxoSmithKline|No|Completed|November 2011|November 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|75 Years|No|||October 2013|May 15, 2014|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462565||96357|
NCT01462877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W13-254|A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic|An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Statin-fenofibrate Combination Therapy in Dyslipidemic Chinese Patients||Abbott|No|Completed|October 2011|March 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|506|||Both|18 Years|80 Years|No|||February 2015|February 25, 2015|October 28, 2011||No||No|February 6, 2015|https://clinicaltrials.gov/show/NCT01462877||96333|
NCT01462890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-OVAR 17|Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer|A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer|BOOST|AGO Study Group|Yes|Active, not recruiting|November 2011|November 2021|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Female|18 Years|N/A|No|||December 2015|December 22, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01462890||96332|
NCT01463644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP11-3588|Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis|Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial||McMaster University|No|Completed|January 2012|September 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|40 Years|80 Years|No|||September 2015|September 21, 2015|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01463644||96274|
NCT01463852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11199|A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)|A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation Status in Patients With Chronic Lymphocytic Leukemia (CLL)||Dartmouth-Hitchcock Medical Center|Yes|Terminated|October 2012|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Both|18 Years|N/A|No|||February 2014|May 8, 2015|October 31, 2011||No|Enrollment underperformance.|No||https://clinicaltrials.gov/show/NCT01463852||96258|
NCT01463865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-057|Selective Block of the Axillary Nerve in Postoperative Pain Management|Selective Block of the Axillary Nerve in Postoperative Pain Management, a Randomised, Blinded, Placebo-controlled Trial||Hillerod Hospital, Denmark|No|Completed|November 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||March 2015|March 19, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01463865||96257|
NCT01460953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB00007828|Use of a Training Video to Teach Medical Students About Health Literacy|Use of a Training Video to Teach Medical Students About Health Literacy||Oregon Health and Science University|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|110|||Both|N/A|N/A|No|||October 2015|October 14, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460953||96479|
NCT01460654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-988|Testosterone and Alendronate in Hypogonadal Men|Testosterone and Alendronate in Hypogonadal Men||Massachusetts General Hospital|Yes|Recruiting|October 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|100|||Male|60 Years|85 Years|Accepts Healthy Volunteers|||June 2014|June 25, 2014|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460654||96502|
NCT01461278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-007|Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery|A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery||Glaukos Corporation|Yes|Recruiting|October 2011|April 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1200|||Both|45 Years|N/A|No|||March 2016|March 23, 2016|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461278||96456|
NCT01461291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-008|Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery|A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery||Glaukos Corporation|Yes|Active, not recruiting|October 2011|October 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1200|||Both|45 Years|N/A|No|||October 2015|October 23, 2015|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461291||96455|
NCT01461772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRTCICA-CXCA|Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer|Comparison of Concurrent Chemoradiation Therapy With Weekly Cisplatin and Concurrent Chemoradiation Therapy With Weekly Carboplatin in Locally Advanced Cervical Cancer: Phase III Multicenter Prospective Randomized Controlled Trial||Asan Medical Center|No|Recruiting|December 2009|November 2015|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|154|||Female|20 Years|75 Years|No|||October 2011|October 27, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461772||96418|
NCT01452711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-101|Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer|A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Gastric Ulcer.||Takeda|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|482|||Both|20 Years|N/A|No|||June 2013|June 19, 2013|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01452711||97110|
NCT01443754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESREFO04|Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease|Hybrid Revascularisation by Combined CABG and PCI in Multivessel Coronary Disease. An Observational Study.|HYBRID|Ettore Sansavini Health Science Foundation|No|Recruiting|September 2011|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|70 Years|N/A|No|Non-Probability Sample|Patients referred to participating sites with clinical indication to revascularization and        with clinical characteristics and multi-vessel disease amenable to hybrid        revascularization|February 2015|February 24, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01443754||97785|
NCT01460225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-033L|Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation|Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2007|January 2011|Actual|December 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|19|||Both|18 Years|N/A|No|||February 2012|February 24, 2012|July 19, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460225||96534|
NCT01460563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mg_orfil|Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia|Effects of Valproic Acid and Magnesium Sulphate on Rocuronium Requirement and Postoperative Analgesia in Patients Undergoing Craniotomy for Cerebrovascular Surgery||Seoul National University Bundang Hospital|No|Recruiting|October 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|60|||Both|18 Years|65 Years|No|||December 2011|December 26, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01460563||96509|
NCT01460810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0366|Study Of Surgical Radiation Shielding With Vitrectomy And Silicone Oil Tamponade For The Protection Of Radiation Induced Ocular Injury|A Prospective Pilot Study of Surgical Radiation Shielding With Vitrectomy and Silicone Oil Tamponade for the Protection of Radiation-induced Ocular Injury in the Treatment of Choroidal Melanoma With Radioactive Iodine-125 Plaque Brachytherapy||University of Colorado, Denver|No|Recruiting|July 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460810||96490|
NCT01461421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK087704-01A1|Acceptance Based Behavioral Intervention for Weight Loss: A Randomized Trial|Acceptance Based Behavioral Intervention for Weight Loss: A Randomized Trial||The Miriam Hospital|Yes|Recruiting|July 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||October 2015|October 30, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01461421||96445|
NCT01461954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FST100-AVC-005|FST-100 in the Treatment of Acute Viral Conjunctivitis|A Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Viral Conjunctivitis||Shire|No|Completed|May 2013|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||March 2015|September 14, 2015|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461954||96404|
NCT01461174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP1P001|Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers|Effects of 15-day Donepezil and Memantine on Cognitive Functions After a 24 Hours Sleep Deprivation Challenge in Healthy Volunteers: a Double-blind, Placebo-controlled, Randomised, Cross-over Study, With Modafinil as Positive Control||Qualissima|Yes|Completed|November 2011|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|36|||Male|25 Years|40 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01461174||96464|
NCT01461408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-IISP-39187|Promoting Human Papillomavirus (HPV) Vaccination Through African American Beauty Salons|Promoting HPV Vaccination Through African American Beauty Salons: a Pilot Test of a Culturally-Competent Education and Empowerment Strategy||MEE Productions, Inc.|Yes|Completed|May 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|16||Actual|240|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2013|October 9, 2013|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01461408||96446|
NCT01461681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06859|Improving Care of Patients With Heart Failure|A Randomized Controlled Trial for Patients With Heart Failure||University of California, San Francisco|Yes|Completed|March 2012|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||May 2014|May 13, 2014|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01461681||96425|
NCT01461902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027860|Vasospasm in Pediatric Traumatic Brain Injury|Measuring Vasospasm, Biomarkers, and Neurocognitive Outcomes in Pediatric Traumatic Brain Injury|PTBI|Duke University|Yes|Completed|September 2011|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|N/A|15 Years|No|Probability Sample|Pediatric patients who have been admitted for a traumatic brain injury to Duke University        Hospital.|January 2015|January 30, 2015|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461902||96408|
NCT01462227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC1006006927|Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia|The Effect of Opiate Blockade With Naltrexone on Counterregulatory Mechanisms in Hypoglycemia||Yale University|No|Completed|August 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|55 Years|No|||February 2016|February 17, 2016|October 26, 2011||No||No|January 20, 2016|https://clinicaltrials.gov/show/NCT01462227||96383|
NCT01463371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/2004/0144|Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis|Effects of Long-Term Azithromycin Treatment on Airway Oxidative Stress Markers in Patients With Stable Non-Cystic Fibrosis Bronchiectasis||Instituto de Investigacion Sanitaria La Fe|Yes|Completed|October 2006|September 2007|Actual|April 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|16 Years|80 Years|No|||October 2011|October 31, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01463371||96295|
NCT01463384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LKW-AB34|Minocycline in Patients With Alzheimer's Disease|MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy||Huntington Medical Research Institutes|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|October 25, 2011||No||No|October 25, 2012|https://clinicaltrials.gov/show/NCT01463384||96294|
NCT01464177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT-01/2011|Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme|Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme|GBM Hypo RT|University of Sao Paulo|Yes|Recruiting|October 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01464177||96233|
NCT01464190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-CL-05B|A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients|An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A (NCT01324128)||Vifor Inc.|Yes|Completed|September 2011|April 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|659|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|September 12, 2011|Yes|Yes||No|December 20, 2013|https://clinicaltrials.gov/show/NCT01464190||96232|
NCT01463878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANUS1014|Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study|Enteral Nutrition and Glycemic Variability NICU Study|ANUS1014|Eastern Virginia Medical School|No|Terminated|November 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|89 Years|No|||October 2012|October 3, 2012|October 24, 2011||No|Unlikely to show statistical significance and slow recruitment.|No|June 22, 2012|https://clinicaltrials.gov/show/NCT01463878||96256|
NCT01461252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUC10-BNE01|Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases|Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases||Galil Medical|No|Withdrawn|April 2013|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|October 25, 2011|No|Yes|No patients were treated due to enrollment challenges.|No||https://clinicaltrials.gov/show/NCT01461252||96458|
NCT01460979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGO-GYN 8|Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma|Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma||AGO Study Group|No|Completed|October 2011|November 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460979||96477|
NCT01461304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08020019|Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease|Dietary Therapy for Inherited Disorders of Mitochondrial Fatty Acid Oxidation and Glycogenosis||University of Pittsburgh||Available|December 2009|||November 2019|Anticipated|N/A|Expanded Access|N/A|||||||Both|1 Month|N/A|No|||December 2015|December 3, 2015|October 25, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01461304||96454|
NCT01461317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA27927|Study to Evaluate the Long-term Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis|A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Rhumab Beta7 in Patients With Moderate to Severe Ulcerative Colitis||Genentech, Inc.||Active, not recruiting|November 2011|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|116|||Both|18 Years|75 Years|No|||February 2015|February 4, 2015|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461317||96453|
NCT01461525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR-SPS trial|Comparison of Sphincter Preservation Surgery and Abdominoperineal Resection (APR): Prospective Clinical Trial|Comparison of Sphincter Preservation Surgery Versus Abdominoperineal Resection for Low Rectal Cancer: Prospective Clinical Trial||Seoul National University Hospital|Yes|Recruiting|October 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|294|||Both|20 Years|80 Years|No|||July 2015|July 21, 2015|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01461525||96437|
NCT01452412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-2009-408|Alkali Therapy in Chronic Kidney Disease|Placebo-controlled Randomized Clinical Trial of Alkali Therapy in Patients With Chronic Kidney Disease||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|October 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|19 Years|N/A|No|||February 2015|February 12, 2015|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01452412||97133|
NCT01452425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B40320107753|In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome|In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome.||Université Catholique de Louvain|Yes|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|October 11, 2011||No||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01452425||97132|
NCT01452724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-102|Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer|A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer||Takeda|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|372|||Both|20 Years|N/A|No|||August 2013|August 19, 2013|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01452724||97109|
NCT01452945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002000|Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing|Prospective Observational Study Evaluating the Use of Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department With Wheezing||Children's Research Institute|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|N/A|24 Months|No|Non-Probability Sample|Children 0-24 months presenting to a pediatric Emergency Department with wheezing|May 2015|May 19, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01452945||97092|
NCT01452958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/0604|Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on Central Nervous System (CNS) Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?|Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on CNS Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?||Aarhus University Hospital|Yes|Completed|June 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|24|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01452958||97091|
NCT01460823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111114|Percutaneous Cochlear Implantation: Implementation of Technique|Percutaneous Cochlear Implantation: Implementation of Technique|PCI-I|Vanderbilt University|Yes|Terminated|October 2011|July 2014|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||December 2014|December 15, 2014|October 24, 2011||No|Currently in the process of submitting IDE to the FDA|No||https://clinicaltrials.gov/show/NCT01460823||96489|
NCT01462279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000312|Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness|The Effect of Thiamine on VO2 Levels in Critically Ill Patients|VO2|Beth Israel Deaconess Medical Center|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 4, 2012|October 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01462279||96379|
NCT01461967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP25752|A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers|A Single-Center, Randomized, Double-Blind, Single and Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food) and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects.||Hoffmann-La Roche||Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator)|3||Actual|49|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01461967||96403|
NCT01461694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN11SU380|Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser|Comparison of Intense Pulsed Light System 650 Advance Hand-Piece and Alexandrite Laser for Female Facial Hair Reduction||NHS Greater Glasgow and Clyde|No|Enrolling by invitation|November 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Female|16 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 11, 2012|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01461694||96424|
NCT01461928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO25455|A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera|||Hoffmann-La Roche||Active, not recruiting|December 2011|March 2019|Anticipated|March 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|694|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01461928||96406|
NCT01462253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1610|Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults|"A Phase II Study With a Sequential Clofarabine-cyclophosphamide Combination Schedule as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) in Adult Patients"|LAL1610|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|60 Years|No|||September 2015|September 29, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01462253||96381|
NCT01462266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-260|Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin||Merck Sharp & Dohme Corp.|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|660|||Both|18 Years|80 Years|No|||April 2015|April 20, 2015|October 27, 2011|Yes|Yes||No|January 8, 2014|https://clinicaltrials.gov/show/NCT01462266||96380|
NCT01463163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-8|Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)||University of Patras|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|95 Years|No|||April 2012|April 9, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01463163||96311|
NCT01463397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT11917|Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain|Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain|Alchemilla|Sanofi|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|191|||Both|18 Years|85 Years|No|||January 2016|January 28, 2016|October 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463397||96293|
NCT01463631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13513|A Study of LY3007113 in Participants With Advanced Cancer|A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01463631||96275|
NCT01463891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL01S|Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)|Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer||Eisai Inc.||Completed|July 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|963|||Both|N/A|N/A|No|Non-Probability Sample|Hospitals and clinics in Japan|April 2015|April 17, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01463891||96255|
NCT01464476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZM-MD-302|Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)|Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator|SHIELD-2|Forest Laboratories|Yes|Terminated|November 2011|June 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464476||96210|
NCT01464463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG RI 574/23-1|The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients With Major Depression|The Impact of Psychological Interventions (With and Without Exercise) on Psychometric and Immunological Measures in Patients With Major Depression||Philipps University Marburg Medical Center|No|Recruiting|August 2011|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01464463||96211|
NCT01460667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV APAP LRYGBP Study|Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients|A Randomized, Double-Blind, Placebo-Controlled, Single Center Study of IV Acetaminophen for the Treatment of Post-Operative Pain After Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP)|IV APAP|McLaren Regional Medical Center|Yes|Recruiting|October 2011|||October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|65 Years|No|||October 2011|October 26, 2011|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460667||96501|
NCT01460966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D110922004|Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)|Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)|VAMPIRE3|Yokohama City University Medical Center|Yes|Recruiting|July 2012|January 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||January 2015|January 28, 2015|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01460966||96478|
NCT01461265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUC10-BNE11|Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases|Cryoablation for the Palliation of Painful Bone Metastases||Galil Medical|No|Completed|November 2011|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|29|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|October 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01461265||96457|
NCT01461564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cracow CO2 Trial|Carbon Dioxide During Screening Unsedated Colonoscopy|Randomized Clinical Trial to Compare Air Versus Carbon Dioxide in Screening Unsedated Colonoscopy.||Jagiellonian University|No|Completed|January 2010|June 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|200|||Both|50 Years|65 Years|No|||June 2014|June 15, 2014|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461564||96434|
NCT01461538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGN35-013|Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies|A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies||Seattle Genetics, Inc.|No|Completed|October 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|84|||Both|6 Years|N/A|No|||February 2016|February 5, 2016|October 24, 2011|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01461538||96436|
NCT01461551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPCAB|Anesthesia and Lymphocytes Apoptosis|Different Effects of Sevoflurane, Propofol and Combine of Sevoflurane and Propofol Maintained Anesthesia on Peripheral Blood Lymphocytes During Off-pump Coronary Artery Bypass Graft Surgery|OPCAB|Ruijin Hospital|Yes|Completed|October 2011|October 2014|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|105|||Male|18 Years|80 Years|No|||May 2015|May 6, 2015|October 19, 2011|No|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01461551||96435|
NCT01452737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02318|Comparing 4L Golytely to 2L Golytely With 15mg Bisacodyl Regimens for Inpatient Colonic Preparation|2L Golytely and Oral Bisacodyl 15 mg Versus 4L Golytely Regimen for Inpatient Colonoscopy Bowel Preparation: A Randomized, Non-Inferiority Open Trial||University of British Columbia||Withdrawn|November 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|N/A|No|||September 2013|September 17, 2013|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01452737||97108|
NCT01452750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-301|Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)|A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID).||Takeda|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|642|||Both|20 Years|N/A|No|||February 2014|February 4, 2014|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01452750||97107|
NCT01452984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07311|Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project|Experience of Patients With Non-Melanoma Skin Cancer of the Head and Neck Undergoing Mohs Surgery||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|July 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|This study involves non-melanoma skin cancer patients who have undergone or are about to        undergo Mohs surgery, who are treated within the University of Pennsylvania Health System.|March 2015|March 18, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01452984||97089|
NCT01452971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-196|A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer|A Study of the Interaction Between Tumor Susceptibility Gene GNMT and Lung Cancer||China Medical University Hospital|Yes|Not yet recruiting|October 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|October 2011|October 14, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01452971||97090|
NCT01453244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-037|Pharmacogenomic Research in Korean Patients With Hepatitis C|Pharmacogenomic Research for Prediction of Drug Response in Korean Patients With Hepatitis C||Inje University|No|Completed|July 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|373|Samples With DNA|DNA extracted from blood|Both|18 Years|N/A|No|Non-Probability Sample|Korean patients with chronic hepatitis C|May 2013|May 30, 2013|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453244||97069|
NCT01461707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06992|The MOTHER (Mobile Technologies to Help Enhancing Regular Physical Activity) Trial for Pregnant Women|A Pilot Study of a Mobile Phone-Based Physical Activity Program in Pregnant Women||University of California, San Francisco|Yes|Completed|October 2012|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461707||96423|
NCT01461941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E6005-J081-201|A Phase 2 Study of E6005 in Patients With Atopic Dermatitis|A Phase 2 Study of E6005 in Patients With Atopic Dermatitis||Eisai Inc.||Completed|December 2011|January 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|78|||Both|20 Years|64 Years|No|||January 2014|January 31, 2014|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461941||96405|
NCT01461980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971015|A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age|A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Mcv4, Tdap Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged > = 10 To <13 Years||Pfizer|Yes|Completed|September 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2648|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||May 2015|May 7, 2015|September 28, 2011|Yes|Yes||No|May 7, 2015|https://clinicaltrials.gov/show/NCT01461980||96402|
NCT01461993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971011|A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17|A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Gardasil (Registered) (Hpv) Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged >=11 To <18 Years||Pfizer|Yes|Completed|September 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|2499|||Both|11 Years|17 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|September 28, 2011|Yes|Yes||No|November 21, 2014|https://clinicaltrials.gov/show/NCT01461993||96401|
NCT01462578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUD-RELA02-048|Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)|Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)|RELAZA2|Technische Universität Dresden|No|Recruiting|September 2011|June 2020|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01462578||96356|
NCT01462591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC2011.6686|L-citrulline Supplementation & Cold Exposure|The Effects L-citrulline Supplementation on Arterial Stiffness, Wave Reflection, and Cardiac Autonomic Responses to Cold Exposure With Isometric Exercise||Florida State University|No|Completed|May 2011|May 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462591||96355|
NCT01462903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SenU-200902002-2|A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors|A Phase I Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors||Sun Yat-sen University|Yes|Recruiting|September 2011|December 2014|Anticipated|November 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||November 2014|November 21, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01462903||96331|
NCT01463150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-7|Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)|Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)||University of Patras|No|Completed|October 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|95 Years|No|||April 2012|July 10, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01463150||96312|
NCT01463176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.6797|Music Therapy as Procedural Support for Young Children Undergoing Immunizations|Music Therapy as Procedural Support for Young Children Undergoing Immunizations: A Randomized Controlled Study||Florida State University|No|Completed|October 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|150|||Both|48 Months|72 Months|Accepts Healthy Volunteers|||August 2015|August 10, 2015|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01463176||96310|
NCT01463904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMMA-08 Sánchez-Pernaute|Single-Anastomosis Duodeno-Ileal Bypass With Sleeve Gastrectomy (SADI-S) for the Treatment of Morbid Obesity and Its Metabolic Complications|Single-Anastomosis Duodeno-Ileal Bypass With Sleeve Gastrectomy (SADI-S) for the Treatment of Morbid Obesity and Its Metabolic Complications|SADI-S 250|Hospital San Carlos, Madrid|No|Recruiting|April 2007|April 2015|Anticipated|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Samples of subcutaneous and visceral fat, and samples of liver tissue.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Morbid obesity patients and patients with obesity and T2DM|October 2011|November 1, 2011|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01463904||96254|
NCT01463917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hypertonic off pump CABS|Hypertonic Solution in Off Pump Coronary Artery Bypass Graft Surgery|Use of Hypertonic Versus Isotonic Solutions in Off Pump Coronary Artery Bypass Graft Surgery Targeting the Left Marginal Branch||Hospital Pitangueiras|Yes|Recruiting|September 2011|April 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||October 2011|October 31, 2011|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463917||96253|
NCT01464489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-11-074|Intubation Time With Low Dose Rocuronium|Study of Intubation Time Required for Excellent Tracheal Intubation With Low Dose Rocuronium During Propofol Anaesthesia in Children With and Without Atropine||Gachon University Gil Medical Center|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|44|||Both|3 Years|10 Years|No|||November 2011|November 1, 2011|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464489||96209|
NCT01460381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14397|A Study to Evaluate the Effect of Genotype on LY2216684|A Study to Investigate the Effect of CYP2C19 Phenotype on the Pharmacokinetics of LY2216684 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|October 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460381||96522|
NCT01460355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unicamp-CEP- 427/2006|Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone|Surgery Associated to Intraoperative Botulinum Toxin A for Large Angle Horizontal Strabismus: a Pilot Study||University of Campinas, Brazil|No|Completed|September 2006|June 2008|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|60 Years|No|||October 2011|October 25, 2011|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01460355||96524|
NCT01460368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14149|A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart|A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Supratherapeutic Dose of LY2409021 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|68|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460368||96523|
NCT01460680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0391-11-TLV|Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE)|Association of Membrane Polyunsaturated Fatty Acid Content and Intracellular Magnesium Concentration With Mental and Physical Symptoms in Fibromyalgia and SLE: a Case-control Study||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2011|June 2013|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|300|Samples Without DNA|Blood samples|Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|100 female patients attending the Fibromyalgia clinic 100 female patients diagnosed with        SLE attending the rheumatology clinic 100 healthy female volunteers|October 2011|October 25, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01460680||96500|
NCT01460992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49|ProMRI AFFIRM Study of the EVIA/ENTOVIS Pacemaker With Safio S Pacemaker Leads|Master Study for the MRI Compatibility of the EVIA/ENTOVIS Pacemaker in Combination With Safio S Pacemaker Lead|ProMRIAFFIRM|Biotronik SE & Co. KG|Yes|Completed|March 2012|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|121|||Both|18 Years|N/A|No|Non-Probability Sample|The patients selected for participation should be from the investigator's general patient        population according to the inclusion and exclusion criteria.|November 2013|November 27, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01460992||96476|
NCT01461330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA 10-0411|Lifestyle Changes in Patients With Type 2 Diabetes Mellitus and Hypertension|Lifestyle Changes in Patients With Type 2 DM and Hypertension: DASH Diet and Exercise Effects||Hospital de Clinicas de Porto Alegre|No|Recruiting|February 2011|February 2013|Anticipated|January 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|30 Years|90 Years|No|||October 2011|October 27, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01461330||96452|
NCT01461577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LANTU_L_05477|Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure|A Multicenter, Open-label, Single-arm, 24 Week Phase IV Study Evaluating the Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure|GAUDI|Sanofi|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|30 Years|75 Years|No|||January 2013|January 29, 2013|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461577||96433|
NCT01461590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEMRI_CT_2011/0015|Study of Safe Blood Transfusion Volumes to Correct Acute Severe Anaemia|Phase II Trial of Transfusion Volumes in Children With Acute Severe Anaemia|Tx30|KEMRI-Wellcome Trust Collaborative Research Program|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|60 Days|12 Years|No|||March 2015|March 31, 2015|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461590||96432|
NCT01453023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112777|Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study|A Randomized, Double-blind, Repeat Dose, Two Period Crossover Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Inhaled Fluticasone Furoate/Vilanterol 100/25 Micrograms in Children Aged 5 to 11 Years With Persistent Asthma||GlaxoSmithKline|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|5 Years|11 Years|No|||June 2013|August 15, 2013|October 6, 2011|No|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01453023||97086|
NCT01453270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGONIST|Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial|Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial|AGONIST|National University Hospital, Singapore|No|Completed|November 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|21 Years|N/A|No|||September 2014|September 23, 2014|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01453270||97067|
NCT01453283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070054|Tabectedin to Treat Children and Adolescents With Cancer|A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS [R], ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|December 2006|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Primary Purpose: Treatment|1||Actual|12|||Both|4 Years|16 Years|No|||April 2012|April 5, 2012|October 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01453283||97066|
NCT01453257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C62 202-878|Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients|A Phase 2 Study of Target-Guided Personalized Chemotherapy in Metastatic Colorectal Cancer Patients|TT|Grupo Hospital de Madrid|No|Completed|October 2009|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|80 Years|No|||October 2011|October 18, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453257||97068|
NCT01461720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-115-2011|Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct|An Open Lable, Phase II Exploratory Study Assessing the Efficacy of Intravenous Autologous Mesenchymal Stem Cells in Patients With Middle Cerebral Artery Infarct||National University of Malaysia|No|Recruiting|March 2012|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|75 Years|No|||March 2015|March 30, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01461720||96422|
NCT01462006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15282|Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)|Double-blind Placebo-controlled Pilot Study of Sirolimus in IPF||University of Virginia|Yes|Recruiting|October 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|21 Years|85 Years|No|||July 2015|July 1, 2015|October 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01462006||96400|
NCT01462292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114876|A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)|An Exploratory Study to Assess Two Doses of GSK2402968 in the Treatment of Ambulant Boys With Duchenne Muscular Dystrophy (DMD)|DMD114876|GlaxoSmithKline|Yes|Completed|October 2011|November 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|51|||Male|5 Years|N/A|No|||April 2014|April 27, 2015|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462292||96378|
NCT01462604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115553|Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer|PROACTYVE Pilot:Pilot Study of Patient's Adherence to TYKERB™/TYVERB™+Capecitabine in Metastatic Breast Cancer-Observation of Patient Adherence and Evaluation of Predictive Factors for Patient Adherence After Providing Educational Programme||GlaxoSmithKline|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|27|||Female|18 Years|N/A|No|Non-Probability Sample|Women older than 18 years old with metastatic or advanced breast cancer|July 2013|July 30, 2013|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01462604||96354|
NCT01462617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115117|Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557|A Single-centre. Double-blind, Placebo Controlled Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Repeat Doses of Nebulised GSK2269557 in Healthy Male Subjects||GlaxoSmithKline|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|61|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01462617||96353|
NCT01462916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP 123|Honey in Chronic Immune Thrombocytopenia|Effect of Honey Bee Honey Intake on Children With Chronic Immune Thrombocytopenia||Ain Shams University|Yes|Suspended|October 2014|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|30|||Both|5 Years|15 Years|No|Probability Sample|Thirty patients suffering from chronic immune thrombocytopenic purpura (ITP) will be        recruited from the Hematology Clinic of the Pediatric Hospital of Ain Shams        University,Egypt. The age of the patients will range from 5 to 15 years, and they will be        of both sexes.|December 2015|December 28, 2015|October 21, 2011|Yes|Yes|problem with the candidate (investigator)|No||https://clinicaltrials.gov/show/NCT01462916||96330|
NCT01463657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELAPR P2|Split-face Comparison Study to Assess ELAPR Compared to Juvéderm® for the Treatment of Nasolabial Folds|A Phase 2 Bilateral (Split-face) Comparison Study to Assess Two Formulations of ELAPR Compared to Juvéderm® Ultra Plus for the Treatment of Moderate to Severe Nasolabial Folds||Elastagen Pty Ltd|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|25 Years|65 Years|No|||January 2013|January 22, 2013|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01463657||96273|
NCT01464203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADICAL Trial|Role of Cardiac CT in Rapid Access Chest Pain Clinics (RADICAL)|Randomized Controlled Trial to Evaluate the Cost and Clinical Effectiveness of CT Coronary Angiography in Patients With Stable Angina Pectoris (RADICAL Trial)|RADICAL|Wellington Hospital|Yes|Recruiting|February 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Both|40 Years|N/A|No|||October 2011|October 31, 2011|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01464203||96231|
NCT01464502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1879|Pressure Wire Guided Cardiac Resynchronisation Therapy|A Prospective Randomised Controlled Trial of Cardiac Resynchronisation Therapy Guided by Invasive dP/dT: Radi-CRT Study||Guy's and St Thomas' NHS Foundation Trust|Yes|Recruiting|September 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|282|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464502||96208|
NCT01464515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-0021|Efficiency of Deep Transcranial Magnetic Stimulation on Patients With Mild Cognitive Impairment|Feasibility Study in Order to Test the Efficiency of Deep TMS on Patient With MCI||Brainsway|No|Recruiting|November 2011|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|30|||Both|55 Years|80 Years|No|||November 2011|January 26, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01464515||96207|
NCT01460394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-02|Normative Data of Brain Network Activation in Adolescents and Young Adults|Establishment of Normative Data of Brain Network Activation (BNA) Using Evoked Response Potentials in Adolescents and Young Adults||ElMindA Ltd|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|15 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Experimental subjects will include males and females recruited from the Kansas City        metropolitan area, Vince & Associates Clinical Research's database and from referrals.|August 2012|August 20, 2012|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01460394||96521|
NCT01460693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4443|Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia|A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia|SPIRIT2|Newcastle University|Yes|Recruiting|August 2008|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|810|||Both|18 Years|N/A|No|||October 2011|October 26, 2011|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01460693||96499|
NCT01460706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77/180/2010|Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT|PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC|DOTAGLI|Turku University Hospital|Yes|Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|70 Years|No|||December 2013|December 11, 2013|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460706||96498|
NCT01461005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dynamic Stabilization System|A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)|A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS)|DSS|Paradigm Spine|No|Recruiting|September 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|21 Years|85 Years|No|||October 2015|October 19, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461005||96475|
NCT01461018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgPro20_3006|Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)|A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects With Primary Immunodeficiency||CSL Behring||Completed|October 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|N/A|75 Years|No|||November 2014|November 25, 2014|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461018||96474|
NCT01461031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nefopam-orthognathic|Effect of Nefopam on Acute Postoperative Pain in Patients Undergoing Orthognathic Surgery|Effect of Nefopam on Acute Postoperative Pain in Patients Undergoing Orthognathic Surgery||The Catholic University of Korea|Yes|Recruiting|October 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|40|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 4, 2012|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01461031||96473|
NCT01468701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.129|GLORIA-AF Registry Program - Second and Third Phases|GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)||Boehringer Ingelheim||Recruiting|November 2011|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|28002|||Both|18 Years|N/A|No|Non-Probability Sample|patients with non-valvular AF|March 2016|March 21, 2016|October 28, 2011||||No||https://clinicaltrials.gov/show/NCT01468701||95887|
NCT01468987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12145|A Study in Participants With Type 2 Diabetes Mellitus|The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin With Insulin Lispro: a Double-Blind, Randomized, 26-week Study - The IMAGINE 4 Study|IMAGINE 4|Eli Lilly and Company|Yes|Completed|December 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1325|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468987||95866|
NCT01465087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0083-CTIL|Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples|Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis, In Comparison to Other Autoimmune and Neurological Diseases by Exhalation Samples||Carmel Medical Center|Yes|Completed|December 2011|January 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|314|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01465087||96163|
NCT01453621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1828|Traumatic Brain Injury - Knowledge Translation|Implementation of the Pediatric Emergency Care Applied Research Network (PECARN) Traumatic Brain Injury Prediction Rules Using Computerized Clinical Decision Support: An Interrupted Time Series Trial|TBI-KT|Columbia University|No|Completed|November 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|28669|||Both|N/A|N/A|No|||April 2015|April 15, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01453621||97040|
NCT01453907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH105|Placebo-Controlled, Sequential Group, Single Dose, Dose-Escalation Study to Evaluate the Safety and PK of ETI-204|A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects||Elusys Therapeutics|Yes|Completed|October 2011|December 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|May 22, 2013|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01453907||97018|
NCT01453608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FER-CARS-05|A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency|A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency|CONFIRM-HF|Vifor Inc.|Yes|Completed|October 2011|January 2015|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453608||97041|
NCT01453894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P01HS021141-01-Project1|Improving Rates of Repeat Colorectal Cancer Screening|Center for Advancing Equity in Clinical Preventive Services Project 1: Improving Rates of Repeat Colorectal Cancer Screening||Northwestern University|Yes|Completed|March 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|450|||Both|51 Years|75 Years|No|||July 2014|July 24, 2014|October 13, 2011||No||No|July 24, 2014|https://clinicaltrials.gov/show/NCT01453894||97019|
NCT01461733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA5936 Heart and Stroke|Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit|Atrial Fibrillation WITHOUT Hemodynamic Stability|AFIB|Ottawa Hospital Research Institute|No|Completed|July 2007|December 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|August 19, 2010||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT01461733||96421|
NCT01462656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115981|Risk of Urinary Retention With Retigabine|A Post Marketing Surveillance Study to Monitor the Risk of Urinary Retention in Retigabine Users||GlaxoSmithKline|No|Active, not recruiting|February 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|The study cohorts of interest will be identified from the HealthCore Integrated Research        Database (HIRD). The HIRD contains fully adjudicated paid claims from the largest        commercially insured population in the US, with dates of service for all non-capitated        ambulatory, emergency department, inpatient, and outpatient encounters (including        administrative claims for laboratory tests) for members with eligibility at the time of        service.|November 2015|November 5, 2015|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01462656||96350|
NCT01462305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-1033-SADGO-MS|30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder|30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder|SAD|Philips Respironics|No|Terminated|December 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|21 Years|64 Years|No|||August 2012|August 6, 2012|October 27, 2011||No|enrollment targets having been met|No||https://clinicaltrials.gov/show/NCT01462305||96377|
NCT01462318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205MS302|An Immunogenicity and Pharmacokinetics (PK) Study of BIIB019 (Daclizumab High Yield Process (DAC HYP)) Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS)|A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics (PK) of (BIIB019) Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)|OBSERVE|Biogen|Yes|Completed|November 2011|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|133|||Both|18 Years|65 Years|No|||February 2016|February 19, 2016|July 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462318||96376|
NCT01462630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OER-SAR-043|Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma|Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma||Fox Chase Cancer Center|Yes|Recruiting|September 2011|||December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462630||96352|
NCT01462643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H553000-1101|Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test|A 22 Day Controlled, Randomized Clinical Study (PPT) Investigating the Anti-psoriatic Efficacy and the Tolerability of an Ointment Containing a Retinoid and a Steroid in Different Concentrations|PPT4|Almirall, S.A.|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|22|||Both|18 Years|75 Years|No|||October 2011|October 28, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01462643||96351|
NCT01462929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/39|Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose, Double-blind, Double-dummy, Placebo Controlled, Parallel Clinical Trial to Assess the Efficacy and Safety of Twice Daily Inhaled Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Almirall, S.A.|No|Completed|November 2011|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|414|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|October 28, 2011||No||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01462929||96329|
NCT01462942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/40464/30|Long-term Efficacy and Safety of Aclidinium/Formoterol Fixed-Dose Combination|Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.||Almirall, S.A.|No|Completed|October 2011|January 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|1731|||Both|40 Years|N/A|No|||May 2015|May 29, 2015|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01462942||96328|
NCT01462955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11398|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2011|||||N/A|N/A|N/A||||||||||||||November 5, 2012|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462955||96327|
NCT01463930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMARCOT01_2011|Audiovisual Videodisc Education and Modification of Expectations With Total Knee Replacement (TKR)|Effects of an Educational Audiovisual Videodisc on Patients' Pre-operative Expectations With Total Knee Replacement: a Randomized Study||Parc de Salut Mar|No|Completed|January 2009|April 2010|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|92|||Both|N/A|N/A|No|||February 2016|February 18, 2016|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01463930||96252|
NCT01463943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 121|Non-Inferiority Trial Comparing Eurofarma's Experimental Product Saccharomyces Boulardii Versus Floratil® in the Prevention of Antibiotic-Associated Diarrhea|"An Open-Label, Non-Inferiority, Phase III Trial Comparing Eurofarma's Experimental Product Saccharomyces Boulardii Versus Floratil® (S. Boulardii - Merck) in the Prevention of Antibiotic-Associated Diarrhea."|ACROSS|Eurofarma Laboratorios S.A.||Withdrawn|February 2012|December 2012|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|65 Years|No|||October 2011|July 24, 2015|October 27, 2011||No|Change company strategy|No||https://clinicaltrials.gov/show/NCT01463943||96251|
NCT01464216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-2010/1656|MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness|MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness|FuncProst|Oslo University Hospital|No|Recruiting|October 2011|December 2030|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|Blood, bone marrow, lymph nodes, prostate tissue, urine|Male|N/A|N/A|No|Non-Probability Sample|Prostate cancer patients referred for surgical treatment.|January 2016|January 22, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464216||96230|
NCT01464528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYALOBARRIER- HMO-CTIL|Safety Study of Use of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery|Use Of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery||Hadassah Medical Organization|Yes|Not yet recruiting|November 2011|May 2012|Anticipated|March 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|10|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2011|November 2, 2011|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01464528||96206|
NCT01464541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-0046-11|Orbital Fractures Measurement: Intraoperative Versus Computed Tomography (CT) Scan|||HaEmek Medical Center, Israel|No|Not yet recruiting|December 2011|||November 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01464541||96205|
NCT01460407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14401|A Study to Evaluate the Effect of Clarithromycin on LY2216684|Effect of Clarithromycin on the Pharmacokinetics of LY2216684 in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|April 24, 2012|October 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460407||96520|
NCT01460420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMN-alloRIC2010|Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation|European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients|EMN-alloRIC|European Myeloma Network|Yes|Recruiting|November 2011|May 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|70 Years|No|||February 2015|February 25, 2015|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01460420||96519|
NCT01460433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712M22449|Problems With Immune Recovery in the Gut Tissue|A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution (C)||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2008|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|Samples Without DNA|Blood, lymphatic tissues and anogenital swabs.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV+, antiretroviral-treated individuals who have been exposed to Herpes Simplex Type 2        and Cytomegalovirus and HIV- individuals who have been exposed to Herpes Simplex Type 2        and Cytomegalovirus.|September 2014|September 4, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01460433||96518|
NCT01460719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-013|A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With HM Receiving Treatment With Anti-CD20 Monoclonal Antibodies (V212-013)|A Phase I, Open-Label, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies Receiving Treatment With Anti-CD20 Monoclonal Antibodies||Merck Sharp & Dohme Corp.|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|80|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|October 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460719||96497|
NCT01466660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.123|LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung|A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung||Boehringer Ingelheim||Active, not recruiting|December 2011|December 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|319|||Both|18 Years|90 Years|No|||January 2016|January 6, 2016|November 4, 2011||||No||https://clinicaltrials.gov/show/NCT01466660||96043|
NCT01461044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27760|An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer|An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin® (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.||Hoffmann-La Roche||Completed|September 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|228|||Both|18 Years|N/A|No|Probability Sample|Patients (triple negative or HR+) with HER2- metastatic or locally advanced breast cancer,        treated with Avastin 1st line for at least 12 months and without progression for at least        12 months.|December 2015|December 18, 2015|October 24, 2011|No|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT01461044||96472|
NCT01467817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-009|Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)|Obesity/Overweight in Persons With Early and Chronic SCI: A Randomized Multi-Center Controlled Lifestyle Intervention||University of Miami|Yes|Active, not recruiting|September 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|80|||Both|18 Years|65 Years|No|||February 2016|February 17, 2016|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01467817||95954|
NCT01464840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F101111007|The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery|The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery|PKAZ|University of Alabama at Birmingham|No|Completed|November 2011|August 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|30|Samples Without DNA|Maternal blood, maternal adipose tissue, maternal myometrium, maternal breast milk, amniotic      fluid, and fetal cord blood.|Female|19 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant women 19 years and older undergoing scheduled cesearean sections|November 2013|November 18, 2013|October 26, 2011|No|Yes||No|November 2, 2013|https://clinicaltrials.gov/show/NCT01464840||96182|
NCT01464853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK54|Effect of Enteral Nutrition Support for Critically Ill Patients|Effect of Enteral Nutrition Support for Critically Ill Patients||Abbott Nutrition|No|Terminated|April 2010|May 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|70 Years|No|||March 2011|November 2, 2011|November 1, 2011||No|Interim analysis indicated significant additional subjects needed to demonsate statistical    difference in primary outcome.|No||https://clinicaltrials.gov/show/NCT01464853||96181|
NCT01465568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC/984/11|Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis|Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial||Tuen Mun Hospital|Yes|Completed|December 2011|June 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01465568||96127|
NCT01453920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0686-AE|Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing|Choroidal Neovascular Membrane Recurrence Rate in Wet AMD Patients Stable on Three Month Ranibizumab Dosing||University Health Network, Toronto|Yes|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|N/A|No|||August 2012|August 27, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01453920||97017|
NCT01454258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDIZ IV I|Indication for Intraoperative Volume Therapy|Indication for Intraoperative Volume Therapy|INDIZ IV I|Johann Wolfgang Goethe University Hospitals||Completed|October 2011|March 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10100|||Both|N/A|N/A|No|Non-Probability Sample|All patients of participating hospitals that will undergo surgery and receive intravenous        fluid or volume treatment(cristalloid or colloid) will be included.        Participating hospitals are the university teaching hospitals of the Goethe University        Hospital|October 2015|November 5, 2015|October 14, 2011||No||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01454258||96991|
NCT01454271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERAVERBIO11|Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate|Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate||Laboratoire Ceraver-Osteal|No|Not yet recruiting|January 2017|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01454271||96990|
NCT01454245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018676|A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers|An Open-Label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of JNJ-39439335 Capsule Formulations Administered as a Single Oral Dose in Healthy Male Adult Subjects||Janssen Research & Development, LLC|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|43|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|July 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01454245||96992|
NCT01462331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11VBHB|the Dietary Effects of VitaSugar/VitaFiber-IMO in Healthy Adults|Double-blind, Randomized, Placebo Controlled Study to Investigate the Dietary Effects of VitaSugar/VitaFiber-IMO in Healthy Adults||BioNeutra Inc.|No|Completed|November 2010|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462331||96375|
NCT01462344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115358|6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old|A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma|VESTRI|GlaxoSmithKline|Yes|Completed|November 2011|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|6250|||Both|4 Years|11 Years|No|||March 2016|March 17, 2016|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462344||96374|
NCT01462669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115860|Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects|An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwanese Subjects||GlaxoSmithKline|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 29, 2013|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462669||96349|
NCT01462682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herlev-1234|Perception of Fatigue Among Surgeons During Night Shifts|Perception of Fatigue Among Surgeons During Night Shifts, a Focus Group Study.||Herlev Hospital|No|Completed|July 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|13|||Both|22 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Doctors working at a department of surgical gastroenterology|December 2011|June 20, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462682||96348|
NCT01462968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110037|Interruptions in the Coagulationsystem in Relation With Cardiac Surgery - A Study Comparing Two Heparinization Strategies During On-pump Cardiac Surgery|Interruptions in the Coagulationsystem in Relation With Cardiac Surgery -A Randomized Study Comparing Two Heparinization Strategies During On-pump Cardiac Surgery||Aalborg Universitetshospital|No|Withdrawn|November 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||October 2011|June 25, 2015|October 17, 2011||No|The study never started due to problems with Laboratory facilities in collaborating center|No||https://clinicaltrials.gov/show/NCT01462968||96326|
NCT01463189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44AR061191|Web-based Support to Manage Arthritis Pain|Web-based Support to Manage Arthritis Pain||Inflexxion, Inc.|Yes|Completed|September 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|228|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 7, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01463189||96309|
NCT01463410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROT-015|Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler|Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler||Skyline Diagnostics BV|No|Terminated|October 2011|March 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|264|Samples With DNA|RNA from bone marrow samples will be retained.|Both|18 Years|N/A|No|Probability Sample|Bone marrow samples will be used in the study only from AML,APL or RAEB subjects. Written        informed consent by subjects will be obtained for use of their bone marrow samples in this        study. Each site will follow their own bone marrow aspiration procedure.|May 2013|May 27, 2013|October 28, 2011|Yes|Yes|The required number of banked samples could not be met due to limited availability. There is    no realistic possibility to complete the study succesfully.|No||https://clinicaltrials.gov/show/NCT01463410||96292|
NCT01464944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11202|Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin|A Randomized, Double-blind, Double-dummy, Single-dose, Parallel Group, Multicenter Study to Compare the Antipyretic Efficacy of Acetylsalicy-lic Acid 500 mg and 1,000 mg (2 x 500 mg) and Paracetamol 500 mg and 1,000 mg (2 x 500 mg) With Placebo in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin.||Bayer|No|Completed|November 2003|April 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|392|||Both|18 Years|65 Years|No|||November 2011|November 7, 2011|May 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01464944||96174|
NCT01465217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS019092-01|Text Messaging to Improve Hypertension Medication Adherence in African Americans|Text Messaging to Improve Hypertension Medication Adherence in African Americans||Wayne State University|No|Completed|March 2011|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465217||96153|
NCT01465230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105008515|Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia|Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia||Yale University|Yes|Terminated|March 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|90 Years|No|||October 2014|October 22, 2014|October 28, 2011|Yes|Yes|This study was unsuccessful in enrolling the target number of subjects during the funding    period.|No|August 26, 2014|https://clinicaltrials.gov/show/NCT01465230||96152|
NCT01465711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33/01|The Value of PSP in Predicting Outcome in ICU Surgical Peritonitis Patients|Diagnostic Accuracy of Pancreatic Stone Protein in Predicting Severe Outcome in Patients With Peritonitis at the Intensive Care Unit||University of Magdeburg|Yes|Completed|July 2007|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|137|Samples Without DNA|Whole blood, serum, plasma|Both|18 Years|90 Years|No|Non-Probability Sample|Primary care clinics|November 2011|December 2, 2014|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01465711||96116|
NCT01465984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACET1390|Efficacy of Intravenous (IV) Paracetamol for Treatment of Acute Pain|Comparison of IV Paracetamol With Intravenous Morphine Sulfate in Treatment of Acute Pain Due to Limb Trauma||Tehran University of Medical Sciences|Yes|Completed|November 2011|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465984||96095|
NCT01466270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97211|Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction|A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy||Wake Forest NCORP Research Base|Yes|Completed|April 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Female|18 Years|N/A|No|||December 2014|December 31, 2014|November 2, 2011||No||No|December 31, 2014|https://clinicaltrials.gov/show/NCT01466270||96073|
NCT01465971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ExpedMed#1-2011|Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude|Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During the Sleep in High Altitude|PerOxySleep|Goethe University|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|6|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|participants of an expedition to Mount Kilimanjaro|April 2012|April 4, 2012|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01465971||96096|
NCT01466569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbGenomics-2010.007.01|An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors|A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors||AbGenomics B.V Taiwan Branch|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|13|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466569||96050|
NCT01466582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL30802.018.09|Comorbidity and Aging With HIV|Comorbidity and Aging With HIV, the agehIV Cohort Study|agehIV|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1148|Samples With DNA|whole blood, serum (EDTA/heparin/citrate), PBMCs, urine|Both|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The HIV-positive patients are recruited at the HIV outpatient clinic of the Academic        Medical Center The HIV-negative controls are recruited at the STD-clinic of the Public        Health Service Amsterdam and at the existing Amsterdam Cohort Studies.|January 2016|January 4, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01466582||96049|
NCT01467752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XZhang201111|Metacarpophalangeal Joint Reconstruction Using a Vascularized Cartilage and Bone Graft|Phase 1 Study for Reconstruction of Metacarpophalangeal Joint Using a Vascularized Cartilage and Bone Graft From the Third Metacarpal|MJRUVCBG|The Second Hospital of Qinhuangdao|Yes|Completed|January 2005|December 2009|Actual|January 2005|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2011|November 8, 2011|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01467752||95959|
NCT01467765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elental study|The Effect of Elemental Diet on Gastric Emptying|The Comparative Study of Elemental Diet and Regular Liquid Diet on Gastric Emptying in Patients With Percutaneous Endoscopic Gastrostomy|Elental|Showa Inan General Hospital|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|N/A|N/A|No|||August 2012|August 7, 2012|November 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01467765||95958|
NCT01467128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRA_HSR/2010/14(a)|Adverse Drug Event Prevention Using Structured Pharmacist Review|Title of Study: Adverse Drug Event (ADE) Incidence in Older Patients Following Hospital Admission and Pharmacist Review to Older Persons' Prescriptions and Its' Effect on ADE Reduction in Hospital: a Randomised Controlled Trial||University College Cork|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|720|||Both|65 Years|N/A|No|||June 2012|June 5, 2012|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01467128||96007|
NCT01467141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1415|Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes|Meal-related Insulin Aspart Therapy Versus Meal-related Human Insulin Therapy in Children 2-6 Years of Age With Type 1 Diabetes Mellitus: A Multi-centre Randomised, Open-labelled, Cross-over, Safety and Efficacy Trial||Novo Nordisk A/S|No|Completed|June 2002|October 2003|Actual|October 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|2 Years|6 Years|No|||January 2012|January 25, 2012|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467141||96006|
NCT01467440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT_PG_2011|Efficacy of Selective Laser Trabeculoplasty in Patients Under Treatment With Topical Prostaglandines|||University of Zurich||Enrolling by invitation|November 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|glaucoma patients|December 2014|January 5, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01467440||95983|
NCT01467453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Triggerfisch-001|Clinical Application of Sensimed Triggerfish Sensor (TS) With Wireless Signal Transmission for Continuous Intraocular Pressure Measurement|||University of Zurich||Enrolling by invitation|November 2011|December 2012||||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|patients with a diagnosis of glaucoma|November 2011|November 14, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01467453||95982|
NCT01468584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A11|Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Subjects With Genotype 2 Hepatitis C, Who Did Not Respond to Previous Treatment||Mitsubishi Tanabe Pharma Corporation|No|Completed|November 2011|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|65 Years|No|||October 2014|October 29, 2014|November 2, 2011||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01468584||95896|
NCT01466959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID24009|The Effect of Citrasate Dialysate on Heparin Dose in Hemodialysis|The Effect of Citrasate Dialysate on Heparin Dose: A Randomized Cross Over Trial in Hemodialysis Patients.||University of Calgary|Yes|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|N/A|No|||March 2013|March 23, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01466959||96020|
NCT01466972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117513|Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib|Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib||University of California, San Francisco|Yes|Recruiting|April 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||March 2015|March 3, 2015|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466972||96019|
NCT01460550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOPAS01|A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction|Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial||Kobe University|Yes|Recruiting|November 2011|March 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|240|||Both|18 Years|80 Years|No|||March 2015|March 31, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01460550||96510|
NCT01460771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCS2011|Transcranial Direct-Current Stimulation in Childhood Dystonia|Pilot Open-label and Blinded Clinical Trial of Transcranial Direct-current Stimulation in Childhood Dystonia||University of Southern California|No|Recruiting|September 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|21 Years|No|||May 2014|May 20, 2014|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01460771||96493|
NCT01467947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1145_4001|Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert|Prospective Open-label Uncontrolled Multi-center Post-marketing Study to Assess Inhibitory Antibody Formation in Subjects With Congenital C1-INH Deficiency and Acute Hereditary Angioedema (HAE) Attacks Treated With Berinert® , a C1-esterase Inhibitor||CSL Behring||Completed|November 2011|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|12 Years|N/A|No|||October 2015|October 16, 2015|November 7, 2011|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01467947||95945|
NCT01468207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-313|Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa|A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I|PIONEER I|AbbVie|Yes|Completed|November 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|307|||Both|18 Years|99 Years|No|||October 2015|October 15, 2015|November 7, 2011|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT01468207||95925|
NCT01468519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDC/Pump/020/2011|Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients|Effects of Continuous Subcutaneous Insulin Infusion (CSII) on Erectile Dysfunction in T2DM Patients: A Prospective, Exploratory, Controlled Trial|ECSIITED|Jothydev's Diabetes and Research Centre|Yes|Completed|January 2012|November 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|25 Years|65 Years|No|||December 2014|December 10, 2014|July 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468519||95901|
NCT01468844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110264|Minocycline to Treat Central Retinal Vein Occlusion|A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions||National Institutes of Health Clinical Center (CC)||Suspended|September 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2016|March 11, 2016|October 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468844||95876|
NCT01464723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080693|Study EvAluating Genotypes While Using Lucentis 2|VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis|SEAGUL2|University of California, San Diego|Yes|Completed|May 2008|January 2013|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|50 Years|N/A|No|||January 2013|January 22, 2013|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464723||96191|
NCT01464957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-0014|Skin Cancer Prevention in a Pediatric Population|Skin Cancer Prevention in a Pediatric Population||University of Colorado, Denver|No|Completed|November 2003|September 2008|Actual|September 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|867|||Both|5 Years|6 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|August 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01464957||96173|
NCT01464970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN11CA415|Influence of the Superficial Inferior Epigastric System in Deep Inferior Epigastric Perforator (DIEP) Flaps|The Potential Role of the Superficial Inferior Epigastric Vascular System in the Perfusion of Zone IV of Deep Inferior Epigastric Perforator (DIEP) Flaps||NHS Greater Glasgow and Clyde|No|Enrolling by invitation|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|12|||Female|18 Years|70 Years|No|||May 2012|May 11, 2012|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01464970||96172|
NCT01465243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV01|Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose|An Open , Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy||Betta Pharmaceuticals Co.,Ltd.|Yes|Completed|September 2011|February 2014|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|75 Years|No|||February 2014|February 13, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465243||96151|
NCT01466296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT 5283 152/09|The Middle East "Stepping Forward" Project (MESF)|Improving Treatment of People With Movement Disorders in the Middle East|MESF|Assaf-Harofeh Medical Center|Yes|Recruiting|October 2010|April 2012|Anticipated|April 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|14 Years|69 Years|No|||November 2011|November 3, 2011|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01466296||96071|
NCT01466595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5286|Rifaximin as a Modulator of Microbial Translocation and Immune Activation|A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy||AIDS Clinical Trials Group|Yes|Completed|September 2011|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|65 Years|No|||November 2013|November 8, 2013|October 6, 2011|Yes|Yes||No|September 3, 2013|https://clinicaltrials.gov/show/NCT01466595||96048|
NCT01466855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IARB1|A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma|A Pilot Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma|IARB1|Children's Hospital Medical Center, Cincinnati|Yes|Terminated|October 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|N/A|15 Years|No|||August 2015|August 3, 2015|October 19, 2011|No|Yes|Competing studies|No||https://clinicaltrials.gov/show/NCT01466855||96028|
NCT01466283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B2|Biomarkers in Patients With Rhabdomyosarcoma|Integrative Epigenomic Approach to Gene Discovery in Rhabdomyosarcoma (RMS)||Children's Oncology Group|No|Active, not recruiting|October 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Cooperative Human Tissue Network (CHTN)|May 2015|May 8, 2015|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01466283||96072|
NCT01467167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPV_Utility_V7|Utility of the Smart Pilot View in Clinical Practice: A Two Center Prospective Observational Study|Utility of the Smart Pilot View in Clinical Practice: A Two Center Prospective Observational Study||University Medical Center Groningen|No|Recruiting|October 2011|September 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients undergoing surgery under general anesthesia scheduled for neurosurgery,        gynecology and ear nose and throat surgery.|December 2015|December 9, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01467167||96004|
NCT01467739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88/11|Evaluation of the Ambu ® aScope® for Tracheal Intubation in Difficult Airways|Evaluation of the Ambu ® aScope® for Tracheal Intubation During Cervical Spine Immobilization With a Cervical Collar, in Comparison With a Conventional Reusable Fiberscope.||University of Lausanne Hospitals|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100|||Both|16 Years|N/A|No|||December 2013|December 13, 2013|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01467739||95960|
NCT01468064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZJH-001|Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke|Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Patients With Ischemic Stroke: a Randomized Controlled Trial|AMETIS|Southern Medical University, China|No|Recruiting|November 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|80 Years|No|||November 2015|November 12, 2015|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01468064||95936|
NCT01468298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|249/2010|Global Posture Reeducation (GPR) Compared To Isostretching in Chronic Low Back Pain Patients|Comparing the Global Posture Reeducation With Isostretching in Chronic Low Back Pain Patients||Centro Universitario de Maringa|No|Active, not recruiting|August 2010|December 2011|Anticipated|October 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||October 2011|November 7, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01468298||95918|
NCT01468311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120003|Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma|Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin s Lymphoma||National Institutes of Health Clinical Center (CC)||Suspended|October 2011|September 2021|Anticipated|September 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|99 Years|No|||February 2016|March 4, 2016|November 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468311||95917|
NCT01468597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-202 ex 09/10|Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery|Does Platelet Inhibition Predict Surgery Related Bleeding in Patients Undergoing Emergent Cardiac Surgery During Dual Antiplatelet Therapy - a Pilot Study||Medical University of Graz|No|Completed|January 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|161|||Both|30 Years|80 Years|No|Non-Probability Sample|Patients needing emergent cardiac surgery under dual antiplatelet therapy|January 2015|January 26, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01468597||95895|
NCT01468610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02646|Neurocognition and Work Productivity in Major Depressive Disorder (MDD)|Neurocognition and Work Productivity in Major Depressive Disorder||University of British Columbia|No|Completed|January 2012|December 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|19 Years|55 Years|No|||April 2015|April 8, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468610||95894|
NCT01468337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120013|Topical Interferon Gamma-1b for Central Serous Chorioretinopathy|Pilot Phase I/II Study of the Treatment of Classic Central Serous Chorioretinopathy With Topical Interferon Gamma-1b||National Institutes of Health Clinical Center (CC)|No|Completed|October 2011|February 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|November 5, 2011|Yes|Yes||No|November 12, 2014|https://clinicaltrials.gov/show/NCT01468337||95915|After study completion, a participant presented with a cataract on 4/12/13 (last study dose:10/3/12 and TOTAL study dosage received: 2758 µg). Although age (58) was consistent with the possibility of cataract, relatedness to drug cannot be ruled out.
NCT01460199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP505.1003|Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease|A Multi Center, Double-Blind, Two-Arm,Placebo Controlled, Randomized Safety and Tolerability Study of CTP-499 in Non-Dialysis Patients With Stage 3 Chronic Kidney Disease||Concert Pharmaceuticals|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||May 2013|May 23, 2013|October 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460199||96536|
NCT01460537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12875|Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer|A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy||Bayer|No|Completed|November 2011|December 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460537||96511|
NCT01464346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP247|A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use|A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use||Medtronic Diabetes|Yes|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|75 Years|No|Non-Probability Sample|Type 1 or type 2 diabetes mellitus adult subjects 18-75 years of age|May 2012|May 24, 2012|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464346||96220|
NCT01460212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QYK09184|Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder|Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder||Nanjing Medical University|Yes|Recruiting|December 2011|October 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01460212||96535|
NCT01467960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Melitta-ApoD-2011|Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease|Detection of Apolipoprotein D (ApoD) in Human Serum as Marker of Parkinson's Disease|ApoD|Privatklinik Villa Melitta|No|Enrolling by invitation|November 2011|November 2013|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Cohort||6|Actual|180|Samples With DNA|Serum|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All the recruited subjects will be either healthy people group or patients with a defined        diagnosis of Parkinson (classification of Hoehn and Yahr).|September 2013|September 23, 2013|October 30, 2011||No||No|June 11, 2013|https://clinicaltrials.gov/show/NCT01467960||95944|
NCT01468220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypoxitrain 1|Normobaric Hypoxic Training and Metabolic Syndrome|Normobaric Hypoxic Training Compared to Ambient Training on the Course of the Metabolic Syndrome||Charite University, Berlin, Germany||Not yet recruiting|January 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|60 Years|No|||November 2011|November 7, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01468220||95924|
NCT01468532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-031|Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC).||Barbara Ann Karmanos Cancer Institute|No|Active, not recruiting|October 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|N/A|No|||February 2016|February 8, 2016|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468532||95900|
NCT01468857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110265|Physical and Emotional Health of Caregivers for People Who Have Had Stem Cell Transplants|A Pilot Study to Examine Physiological and Clinical Markers of Chronic Stress in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients||National Institutes of Health Clinical Center (CC)||Completed|September 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 25, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01468857||95875|
NCT01464736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFSCar|Noninvasive Ventilation on Chronic Obstructive Pulmonary Disease (COPD) Patient Functionality|Impact of Aerobic Physical Training Associated With Noninvasive Ventilation on COPD Patient Functionality - A Controlled Randomized Study|kmarrara|Universidade Federal de Sao Carlos|No|Completed|January 2006|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Male|60 Years|80 Years|No|||October 2011|October 31, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01464736||96190|
NCT01464983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11220|Placebo and Active Controlled, Double Dummy Study to Compare Efficacy of Aspirin and Ibuprofen in Treatment of Episodic Tension-type Headache|A Multicentre Randomised Parallel-groups Double-blind Double-dummy Single-dose Study to Compare Acetylsalicylic Acid 500 mg and 1,000 mg With Ibuprofen 200 mg and 400 mg and Placebo for Tolerability and Efficacy in the Treatment of Episodic Tension-type Headache||Bayer|No|Completed|January 2004|August 2004|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|1115|||Both|18 Years|65 Years|No|||December 2014|December 23, 2014|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01464983||96171|
NCT01465256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KASIDPOLYP|Postpolypectomy Bleeding in Patients With Antiplatelet Therapy|Postpolypectomy Bleeding in Patients Undergoing Colonoscopy on Antiplatelet Therapy. - Multicenter, Prospective Observational Study -||Soonchunhyang University Hospital|Yes|Recruiting|April 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 25, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465256||96150|
NCT01465464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taiho132150|Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma|A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma|ORIENTAL|Taiho Pharmaceutical Co., Ltd.||Terminated|December 2010|November 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|888|||Both|20 Years|N/A|No|||February 2016|February 23, 2016|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465464||96135|
NCT01466881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03551|Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma|Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma||National Cancer Institute (NCI)|No|Completed|October 2011|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||January 2015|February 9, 2016|November 3, 2011|Yes|Yes||No|February 9, 2016|https://clinicaltrials.gov/show/NCT01466881||96026|
NCT01467180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1490|Myoglobin Removal by High Cut-off CVVHD|Myoglobin Reduction by High Cut-off (HCO) Continuous Veno- Venous Hemodialysis (CVVHD) in Patients With Rhabdomyolysis and an Increased Risk for Acute Kidney Injury|HicoRhabdo|Gambro Dialysatoren GmbH|No|Completed|November 2011|May 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01467180||96003|
NCT01466868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKTIL|Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma|A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma|AKTIL|Centre Leon Berard|Yes|Terminated|November 2011|June 2014|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|90 Years|No|||July 2014|July 9, 2014|October 28, 2011||No|Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions|No||https://clinicaltrials.gov/show/NCT01466868||96027|
NCT01467154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008DR4057|Evaluation of Intravenous N-acetylcysteine to Prevent Contrast Media Induced Nephrotoxicity in an Emergency Center|Does Ultra-High Dose i.v. N-acetylcysteine Prevent Contrast Nephropathy in Patients With Chronic Kidney Disease Undergoing Emergency Contrast Tomography.||University Hospital, Geneva|No|Completed|May 2008|November 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|124|||Both|18 Years|N/A|No|Probability Sample|emergency center patients|November 2011|November 8, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01467154||96005|
NCT01459640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-114-2011|Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis|Phase 2 Study Assessing the Efficacy of Intra-Articular Autologous Mesenchymal Stem Cells in Patients With Mild to Moderate Osteoarthritis||National University of Malaysia|No|Recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|50|||Both|18 Years|70 Years|No|||October 2011|October 24, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459640||96579|
NCT01468051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|507|Two Schedules of Hepatitis B Vaccination in Predialysis Chronic Renal Failure Patients|A Randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysis Chronic Renal Failure Patients||Tehran University of Medical Sciences|Yes|Completed|October 2008|October 2008|Actual|October 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|51|||Both|25 Years|70 Years|No|||November 2011|November 8, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01468051||95937|
NCT01468324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120005|AZD7451 for Recurrent Gliomas|Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)||National Institutes of Health Clinical Center (CC)||Completed|October 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2014|October 24, 2014|November 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468324||95916|
NCT01468623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFUSE-2011|Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6|A Prospective, Randomized, Open-label Trial Comparing OnDose® AUC Optimized 5-FU Based Administration Versus Standard Body Surface Area (BSA) Dosing in Metastatic Colorectal Cancer Patients (mCRC) Treated With mFOLFOX6|PROFUSE|Myriad Genetic Laboratories, Inc.|Yes|Terminated|September 2011|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|November 1, 2011||No|Study terminated due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT01468623||95893|
NCT01464099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-3501|Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes|A Single Center, Randomized, Double-blind, Balanced Two-period Cross-over Trial to Test for Bioequivalence Between a Marketed NovoLog® Formulation Containing 100 U/mL Versus a New NovoLog® Formulation Containing 200 U/mL in a Combined Regimen of a Continuous Subcutaneous Infusion and a Meal-time Bolus in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|June 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||November 2011|November 2, 2011|October 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01464099||96239|
NCT01464333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-170|Special Investigation on Long-term Treatment in Patients With Crohn's Disease|Special Investigation (Long-term Investigation) in Patients With Crohn's Disease||AbbVie||Active, not recruiting|December 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|16 Years|99 Years|No|Non-Probability Sample|Those who are receiving Humira in accordance with its indications for treatment and dosage        regimens.|January 2016|January 27, 2016|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01464333||96221|
NCT01460576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110833|Improving Prematurity-Related Respiratory Outcomes at Vanderbilt|Improving Prematurity-Related Respiratory Outcomes at Vanderbilt: The Prematurity and Respiratory Outcomes Program (PROP)|IMPROV|Vanderbilt University|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|saliva for DNA, plasma, red blood cells, urine and tracheal aspirates|Both|N/A|7 Days|No|Non-Probability Sample|Infants admitted to the Neonatal Intensive Care Unit who are < 29 weeks gestational age|December 2013|December 17, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01460576||96508|
NCT01467973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHA4|Gulf Acute Heart Failure Registry|Gulf aCute heArt failuRe rEgistry (Gulf CARE)|GulfCARE|Gulf Heart Association|Yes|Completed|February 2012|November 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5005|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to various hospitals in the Middle-East with acute heart failure.|April 2014|April 20, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01467973||95943|
NCT01468233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-810|Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa|A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II|PIONEER II|AbbVie|Yes|Completed|November 2011|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|326|||Both|18 Years|99 Years|No|||October 2015|October 15, 2015|November 7, 2011|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT01468233||95923|
NCT01468545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15554|Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System|Prospective, Non-interventional, Multi-centre Study. The Observation Period for Each Subject Covers 1 Year of Treatment. One Initial Visit and 4 Follow-up Visits Every 3 Months and One Extra Educational Reinforcement at Baseline and at 6 Months Will be Given to a Group of Patients.|Inventa|Bayer|No|Completed|October 2011|June 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|50 PAH patients in treatment with Ventavis.|August 2014|August 28, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468545||95899|
NCT01468883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790111|The Treatment of Stage I and II Breast Cancer With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Radiotherapy|The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Definitive Irradiation||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 1979|July 2080|Anticipated|July 2079|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|256|||Female|18 Years|99 Years|No|||November 2015|February 3, 2016|October 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01468883||95874|
NCT01464749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multiple Sclerosis TOCT|Task-oriented Circuit Class Training in Multiple Sclerosis Subjects|||University Hospital of Ferrara|Yes|Completed|May 2011|October 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||April 2014|April 9, 2014|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464749||96189|
NCT01464996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kerr-XTR-11|Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive|Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive (OptiBond XTR)|XTR|University of North Carolina, Chapel Hill|No|Completed|December 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 24, 2015|October 25, 2011|Yes|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01464996||96170|
NCT01465997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0994|Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older|A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.||UCB Pharma|No|Active, not recruiting|May 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|551|||Both|N/A|N/A|No|||March 2016|March 8, 2016|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465997||96094|
NCT01466894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH-Immuron-002|Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis|A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis||Immuron Ltd.|No|Withdrawn|December 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||December 2012|December 4, 2012|November 2, 2011|Yes|Yes|Sponsor administrative decision|No||https://clinicaltrials.gov/show/NCT01466894||96025|
NCT01466907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MaStrokeFup0809|Secondary Prevention and Health Promotion After Stroke|Secondary Prevention and Health Promotion After Stroke A Nurse-led Randomized Controlled Open Trial||Skane University Hospital|No|Completed|February 2008|April 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|597|||Both|N/A|N/A|No|||January 2014|January 22, 2014|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01466907||96024|
NCT01467193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|234/10|The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.|The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.||University Hospital Inselspital, Berne|No|Recruiting|August 2011|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Athletes:Endurance trained athletes: minimal >50 mlO2/KG body weight        GH-deficient adult patients: NO GH-replacement therapy during the last 6 months        Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient        patients) healthy control subjects|September 2014|September 8, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01467193||96002|
NCT01467492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-950-116|Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C|An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Interferon-Based Therapy||Vertex Pharmaceuticals Incorporated|No|Terminated|January 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|70 Years|No|||June 2015|July 13, 2015|November 3, 2011|Yes|Yes|It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy    endpoint as part of a decision to modify drug development plan.|No|June 1, 2015|https://clinicaltrials.gov/show/NCT01467492||95979|It was decided by Sponsor on 13 January 2014 to terminate the study early as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.
NCT01467466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|578|Prevention of Serious Adverse Events Following Angiography|CSP #578 - Prevention of Serious Adverse Events Following Angiography (PRESERVE)|PRESERVE|VA Office of Research and Development|Yes|Recruiting|February 2013|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|8680|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|October 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467466||95981|
NCT01467479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-950-115|A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)|An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1)||Vertex Pharmaceuticals Incorporated|Yes|Terminated|December 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|185|||Both|18 Years|65 Years|No|||March 2015|March 3, 2015|November 3, 2011|Yes|Yes|It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy    endpoint as part of a decision to modify drug development plan.|No|March 3, 2015|https://clinicaltrials.gov/show/NCT01467479||95980|It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.
NCT01467778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELAPR-P1|Safety Study of Three Formulations of the Dermal Implant ELAPR|A Phase I Study to Assess the Safety of Three Formulations of the Dermal Implant ELAPR in Healthy Subjects||Elastagen Pty Ltd|No|Completed|December 2010|May 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Actual|14|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01467778||95957|
NCT01459939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV 01/11|A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip|A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip||Hyben Vital ApS|No|Completed|October 2011|May 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|40 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 5, 2012|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459939||96556|
NCT01468350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALF-CP-1002|Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy|A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER||Acorda Therapeutics|No|Completed|December 2011|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|70 Years|No|||May 2014|May 22, 2014|November 7, 2011|No|Yes||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01468350||95914|
NCT01468363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZKU 2011-77-21/06|Hypervolemia in ESRD Patients in Zonguldak (Prospective Study)|Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study)||Zonguldak Karaelmas University|No|Recruiting|November 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|550|||Both|18 Years|80 Years|No|||November 2011|November 9, 2011|November 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01468363||95913|
NCT01468649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-105|Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer|Phase II Real-Time NIR-Guided Sentinel Lymph Node Mapping in Breast Cancer||Beth Israel Deaconess Medical Center|No|Completed|June 2011|December 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Female|18 Years|N/A|No|||February 2014|February 25, 2014|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01468649||95891|
NCT01460238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11065|Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia|Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia||Dartmouth-Hitchcock Medical Center|Yes|Suspended|October 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|10 cc of peripheral blood and Archived lymph node tissue or bone marrow samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center with CLL|September 2015|September 14, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01460238||96533|
NCT01467986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIST-rNB-2011|Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma|Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma|RIST-rNB-2011|University of Regensburg|Yes|Recruiting|August 2013|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|N/A|25 Years|No|||January 2016|January 14, 2016|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01467986||95942|
NCT01468246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-169|The Young Women's Breast Cancer Study|Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study|HOHO|Dana-Farber Cancer Institute|No|Recruiting|November 2006|January 2026|Anticipated|November 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1300|Samples With DNA|The investigators are collecting blood and tumor specimens.|Female|18 Years|40 Years|No|Non-Probability Sample|This study includes women who are newly-diagnosed with breast cancer. They must be 40 or        younger at their diagnosis.|January 2016|January 3, 2016|November 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01468246||95922|
NCT01468558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAP0004-CL-P104|Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole|A Phase I Evaluation of the Effect of Ketoconazole on the Pharmacokinetics and Safety of Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004) in Healthy Volunteers Compared to DHE Delivered Intravenously (DHE 45®)||Allergan|No|Completed|July 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|October 28, 2011|No|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01468558||95898|
NCT01464775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-2011-57|A Comparison of Narrow Band Imaging (NBI) and Standard White Light Laporoscopy to Detect Endometriosis|Diagnostic Yield of Narrow Band Imaging (NBI) and Standard Visible White Light Laparoscopy for the Detection of Endometriosis||Mercy Medical Center|Yes|Completed|September 2011|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|156|||Female|18 Years|49 Years|No|||January 2015|January 21, 2015|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01464775||96187|
NCT01465269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT100068|Treatment of Social Competence After Traumatic Brain Injury|Treatment of Social Competence in Military Veterans, Service Members, and Civilians With Traumatic Brain Injury||Craig Hospital|No|Completed|July 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465269||96149|
NCT01465477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0332-11-TLV|Influenza Vaccination in Fibromyalgia Patients|Influenza Vaccination in Patients Suffering From Fibromyalgia||Tel-Aviv Sourasky Medical Center||Not yet recruiting|November 2011|November 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||October 2011|November 1, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01465477||96134|
NCT01465724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-265|Denervation of the REnal Artery in Metabolic Syndrome|Sympathetic Denervation of the Renal Artery for the Treatment of Obesity-related Hypertension and Insulin Resistance|DREAMS|UMC Utrecht|No|Completed|November 2011|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2014|December 28, 2014|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01465724||96115|
NCT01466608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCPT11_Rosuvastatin_Pt|Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients|Lipid Lowering Effect, and Lipidomic Profiles by Genotype of OATP1B1 and BCRP After Administration of Rosuvastatin in Patients With Hyperlipidemia||Seoul National University Hospital|Yes|Completed|November 2011|August 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|35 Years|55 Years|No|||May 2014|May 15, 2014|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01466608||96047|
NCT01458561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BFM0801-C|Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery|An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding By Means of an Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery|BARRIER|CryoLife, Inc.|Yes|Terminated|October 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|June 7, 2011|Yes|Yes|Sponsor terminated due to signif. difficulty with pilot investigation enrollment|No|July 5, 2013|https://clinicaltrials.gov/show/NCT01458561||96662|Early termination leading to small number of subjects evaluated (n=1).
NCT01458821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110046|Cognitive Training for Firefighters With Tinnitus|Investigating the Impact of Cognitive Training for Firefighters With Tinnitus|FEMAICT|Washington University School of Medicine|No|Completed|March 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 7, 2014|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01458821||96642|
NCT01459133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND110021|Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System|Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere||South Orange County Endocrinology|No|Withdrawn|May 2013|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|October 21, 2011|Yes|Yes|Unable to register Treatment IND with the US Food And Drug Administration's new process of    establishing TLS encryption for email correspondence.|No||https://clinicaltrials.gov/show/NCT01459133||96618|
NCT01467791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESAPH 1|Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)|Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)|RESAPH|University of Cincinnati|No|Recruiting|November 2011|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Serum samples|Both|18 Years|100 Years|No|Non-Probability Sample|Patients with sarcoidosis associated pulmonary hypertension|December 2015|December 4, 2015|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01467791||95956|
NCT01455909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-110|A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes||Intarcia Therapeutics||Withdrawn|February 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||December 2012|December 21, 2012|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455909||96864|
NCT01455922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-112|A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes||Intarcia Therapeutics||Withdrawn|February 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||December 2012|December 21, 2012|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455922||96863|
NCT01459926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0084|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation||Theravance Biopharma R & D, Inc.|No|Completed|November 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|217|||Both|18 Years|65 Years|No|||June 2015|June 4, 2015|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459926||96557|
NCT01460160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-372|Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia|A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia||Bristol-Myers Squibb|Yes|Active, not recruiting|January 2012|May 2021|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|1 Year|17 Years|No|||September 2015|March 11, 2016|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460160||96539|
NCT01460836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEORUS0017|Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis|Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis||Novartis||Completed|April 2010|||October 2010|Actual|N/A|Observational|Time Perspective: Retrospective||2|||||Both|6 Years|N/A|No|Non-Probability Sample|Cystic fibrosis|October 2011|October 26, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460836||96488|
NCT01460849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEORUS0088|Assess Increased Mortality Risk With Each Year of Delayed Tobramycin Solution (TIS) Initiation, and Effect of TIS on Mortality Across Study Centers|Assess the Increased Mortality Risk With Each Year of Delayed TIS Initiation, and the Effect of TIS on Mortality Across Study Centers||Novartis||Active, not recruiting|March 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|6 Years|N/A|No|Non-Probability Sample|Cystic fibrosis|March 2016|March 23, 2016|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460849||96487|
NCT01460862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEORUS0091|Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations|Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations Among Patients With Uncontrolled Asthma Receiving High Dose Inhaled Corticosteroids||Novartis||Active, not recruiting|May 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|12 Years|N/A|No|Non-Probability Sample|Patients with uncontrolled asthma and using high-dose ICS prior to initiating omalizumab.|March 2016|March 23, 2016|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460862||96486|
NCT01461200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-712-A|Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome|A Parallel Group Observational Study of the Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome||University of Chicago|No|Completed|March 2011|February 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with seasonal allergies and healthy controls from the community.|March 2014|March 26, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01461200||96462|
NCT01461187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Líliancsilveira|Effects in Type of Birth of Physical Exercise During Pregnancy|Effects in Type of Birth of Physical Exercise During Pregnancy||Hospital do Servidor Publico Estadual|Yes|Completed|April 2008|April 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|66|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||October 2011|October 26, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01461187||96463|
NCT01461434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRAF-01-SCCT|Graz Study on the Risk of Atrial Fibrillation|Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients|GRAF|Medical University of Graz|No|Active, not recruiting|November 2011|January 2016|Anticipated|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|82|||Both|18 Years|N/A|No|||December 2015|December 20, 2015|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01461434||96444|
NCT01467999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6393|Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence|Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence|GUAN|New York State Psychiatric Institute|Yes|Completed|February 2012|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|60 Years|No|||March 2015|March 30, 2015|November 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467999||95941|
NCT01468012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6022|Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence|Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence|COST|New York State Psychiatric Institute|Yes|Completed|July 2014|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2014|October 5, 2015|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468012||95940|
NCT01468259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Droxidopa NOH103|A Multi-Center, Open-Label Study|A Phase I, Multi-Center, Open-Label Study to Examine the Pharmacokinetics of a Single Dose of Droxidopa in Subjects With Renal Impairment Compared to Healthy Volunteers||Chelsea Therapeutics|No|Withdrawn|October 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|November 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468259||95921|
NCT01468272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1103-PR-0058|Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old|A Single-dose,Open-label,Randomized,2-way Cross-over,Clinical Pharmacology Study of CHF1535 50/6 NEXT DPI® Fixed Combination of Beclomethasone Dipropionate 50µg Plus Formoterol Fumarate 6µg)Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Children|PAED4|Chiesi Farmaceutici S.p.A.|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|5 Years|11 Years|No|||April 2014|April 29, 2014|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01468272||95920|
NCT01465009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11381|Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold|Double-blind, Randomized, Placebo-controlled, Single Dose, Parallel Group Study Evaluating Efficacy and Safety of 1000 mg Acetylsalicylic Acid and 1000 mg Paracetamol in Adult Patients With Sore Throat Associated With a Common Cold||Bayer|No|Completed|November 2003|March 2005|Actual|||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|508|||Both|18 Years|N/A|No|||November 2011|December 10, 2014|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01465009||96169|
NCT01465490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA021154|Monitoring and Feedback in Substance Abuse Treatment|Monitoring and Feedback in Substance Abuse Treatment||Treatment Research Institute|Yes|Completed|September 2007|August 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|327|||Both|18 Years|N/A|No|||November 2011|November 1, 2011|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465490||96133|
NCT01465737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103107RC|Epidemiology of Uterine Cancer in Taiwan|Importance of Cohort and Histologic Type for Secular Trends in Rising Incidence and Different Survival of Uterine Cancer -a Taiwan Population-based Registry From 1979 to 2008||National Taiwan University Hospital|No|Recruiting|April 2011|April 2013|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10000|||Female|N/A|N/A|No|Non-Probability Sample|All uterine cancer patients in Taiwan between 1979-2008|November 2011|November 2, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01465737||96114|
NCT01465750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103108RC|Epidemiology of Ovarian Cancer in Taiwan|Epidemiology of Ovarian Cancer in Taiwan||National Taiwan University Hospital|No|Recruiting|April 2011|April 2014|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10000|||Female|15 Years|85 Years|No|Non-Probability Sample|ovarian cancer patients|April 2011|November 2, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01465750||96113|
NCT01466010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53583|Treatment Outcome After Surgical Treatment of Osteoid Osteoma|Treatment Outcome After Surgical Treatment of Osteoid Osteoma, a Retrospective Study||Universitaire Ziekenhuizen Leuven|Yes|Completed|January 1998|January 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|150|||Both|2 Years|70 Years|No|Non-Probability Sample|Patient with osteoid osteoma at any location.|September 2011|November 4, 2011|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01466010||96093|
NCT01466023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53423|The Reduced Thyroid Function of the Premature Newborn: Relation With Molecular Changes in the Placenta and Maternal Thyroid Hormone Status and Neurodevelopmental Implications|The Reduced Thyroid Function of the Premature Newborn: Relation With Molecular Changes in the Placenta and Maternal Thyroid Hormone Status and Neurodevelopmental Implications||Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2011|October 2015|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Placenta and blood samples|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women in a tertiairy hospital|July 2011|April 26, 2012|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01466023||96092|
NCT01466309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Somnoguard in Thai OSA|Efficacy of Adjustable Thermoplastic Oral Appliances in Patient With OSA|The Efficacy of Adjustable Thermoplastic Oral Appliances in Thai Patient With OSA|ThaiSomnoguard|Mahidol University|No|Enrolling by invitation|July 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2011|November 6, 2011|November 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01466309||96070|
NCT01466322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114919|A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.|An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers|P1A114919|GlaxoSmithKline|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|February 2, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466322||96069|
NCT01466621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCRM110009(Boston Sci Corp)|Response to Cardiac Resynchronization Therapy of Previously Right Ventricular Paced Heart Failure Patients|Response to Cardiac Resynchronization Therapy of Previously Right Ventricular Paced Heart Failure Patients||Allina Health System|No|Completed|October 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|743|||Both|18 Years|N/A|No|Non-Probability Sample|A retrospective review of patients receiving CRT at United Heart & Vascular Clinic between        2003 and 2009.|February 2016|February 23, 2016|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01466621||96046|
NCT01458834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU-2453|Attentional Training for Smoking Cessation Via Handheld Device or Personal Computer|Attentional Training for Smoking Cessation Via Handheld Device or Personal Computer||Boston University|No|Recruiting|September 2011|||July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2011|October 22, 2011|October 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01458834||96641|
NCT01459146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRCIRB098|Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana|The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana|ACTIPT|Navrongo Health Research Centre, Ghana|Yes|Recruiting|December 2010|November 2012|Anticipated|October 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|345|||Both|6 Years|12 Years|No|||October 2011|October 22, 2011|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459146||96617|
NCT01459159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLK199.2108|Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome|Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome||Telik|No|Terminated|October 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|162|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|October 11, 2011|Yes|Yes|Study TLK199.2108 was terminated for business reasons.|No||https://clinicaltrials.gov/show/NCT01459159||96616|
NCT01459406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L/7/2011|Effects of FODMAPs on Small Bowel Water Content: an MRI Study|Effects of FODMAPs (Fermentable Oligo-, Di-, and Mono-saccharides, And Polyols) on Small Bowel Water Content: an MRI Study|FODMAPs|University of Nottingham|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459406||96597|
NCT01459393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-ALAAK|Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment|Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis||Barretos Cancer Hospital|Yes|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01459393||96598|
NCT01456845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/DIH/2011|Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity|Estimation of Plasma Free and Total Drug Levels of Rifampicin, Isoniazid and Pyrazinamide in Patients on Antituberculosis Therapy and Its Correlation With Development of Drug Induced Hepatotoxicity||All India Institute of Medical Sciences, New Delhi|No|Completed|August 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|110|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects: Patients with diagnosis of pulmonary/extrapulmonary Tuberculosis attending the        out-patient department of the All India Institute of Medical Sciences, New Delhi, will        form the study population.        Cases - those patients who develop DIH while on regular treatment with anti-TB drugs        Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs|August 2012|August 30, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01456845||96792|
NCT01460173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DASS2011|Divided Attention Steering Simulator Alertness Test|Aufmerksamkeitstest Mittels Fahrsimulation Bei Normalpersonen Und Patienten Mit Obstruktivem Schlafapnoesyndrom|DASS|Institut für Pneumologie Hagen Ambrock eV|No|Completed|February 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|200|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460173||96538|
NCT01460875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07033|Recombinant Interferon Alfa-2b in Treating Patients With Melanoma|Pilot Study of IFN-alpha-2b Dose Reduction With Dose Optimization||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|April 2008|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|12 Years|N/A|No|||April 2015|April 6, 2015|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460875||96485|
NCT01460888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10_DOG03_194|Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus|Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.|ROCOCO|Christie Hospital NHS Foundation Trust|Yes|Recruiting|July 2013|August 2018|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|36|||Both|18 Years|N/A|No|||December 2011|August 16, 2013|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460888||96484|
NCT01461213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHM09/01|Gene Therapy for Blindness Caused by Choroideremia|An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)||University of Oxford|Yes|Active, not recruiting|October 2011|June 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Male|18 Years|N/A|No|||March 2016|March 16, 2016|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01461213||96461|
NCT01461447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVIS 06|Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines|Safety and Immunogenicity Following Further Boosting With HIV-1 MVA-CMDR Vaccine to HIVIS03 Volunteers Who Were Primed With HIV-1 DNA Low Dose Intradermally or 'Standard' Dose Intramuscularly and Boosted With MVA-CMDR Vaccine|HIVIS06|Muhimbili University of Health and Allied Sciences|Yes|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01461447||96443|
NCT01461460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-115|A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects|A Phase 1 Blinded, Placebo-controlled Crossover Study to Evaluate the Effects of Oral TR 701 Free Acid on the Electrocardiogram||Trius Therapeutics LLC|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|4||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461460||96442|
NCT01468571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H24178|Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension|Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension||Baylor College of Medicine|Yes|Recruiting|July 2011|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468571||95897|
NCT01468896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03631|Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery|A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck||National Cancer Institute (NCI)||Active, not recruiting|October 2011|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||January 2016|February 11, 2016|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468896||95873|
NCT01464762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017233|Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis|Early Access of TMC207 in Combination With Other Anti-Tuberculosis (TB) Drugs in Subjects With Extensively Drug Resistant (XDR) or Pre-XDR Pulmonary Tuberculosis||Janssen Infectious Diseases BVBA||Temporarily not available||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|99 Years|No|||March 2016|March 24, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464762||96188|
NCT01465503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCTCM02|Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients|Bivalirudin in Patient at High Risk of Bleeding Undergoing Percutaneous Coronary Interventions.|NAPLESIII|Clinica Mediterranea|Yes|Completed|January 2008|December 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|837|||Both|18 Years|N/A|No|||April 2014|April 6, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465503||96132|
NCT01465516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38950|Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir|Response Guided Therapy (RGT) for Boceprevir Combined With Peginterferon Alpha-2b Plus Ribavirin in Naïve Hispanic Patients With Genotype 1 Hepatitis C Infection||Arrowhead Regional Medical Center|No|Terminated|November 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|105|Samples With DNA|Blood|Both|18 Years|65 Years|No|Non-Probability Sample|Hispanic patients >18 years of age with cirrhosis or bridging fibrosis with Hepatitis C        Infection whom are treatment naive.|June 2015|June 27, 2015|November 2, 2011||No|The study was terminated and recruitment was capped because of the new changes in hepatitis C    market|No||https://clinicaltrials.gov/show/NCT01465516||96131|
NCT01465763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921094|A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis|OCTAVE|Pfizer|Yes|Completed|April 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|614|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465763||96112|
NCT01466036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-274|Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors|An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors||Massachusetts General Hospital|Yes|Recruiting|July 2012|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466036||96091|
NCT01466335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115166|An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers|A Randomized, Double Blind, Parallel Group, Single Center, Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist) for Durations Not to Exceed 28 Days, Versus Placebo in Healthy Human Volunteers.||GlaxoSmithKline|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|6||Actual|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|October 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01466335||96068|
NCT01466348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C6930943|Effects of a Common Cold Treatment on Cognitive Function|Effects of a Common Cold Treatment on Cognitive Function||GlaxoSmithKline|No|Completed|February 2011|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||September 2013|September 25, 2013|November 3, 2011||No||No|June 27, 2013|https://clinicaltrials.gov/show/NCT01466348||96067|Apparent carryover effect from the paracetamol/ caffeine treatment taken in Period 1 into the baseline assessment of Period 2 was observed, hence the statistical analysis was amended after unblinding the statistician.
NCT01457963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5891|Prevalence of Pulmonary Embolism in ICU|Pulmonary Embolism in Mechanically Ventilated Patients Requiring Computed Tomography: Prevalence, Risk Factors and Outcome|PEICU|University Hospital, Grenoble|No|Completed|December 2009|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|176|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in ICU, mecanically ventilated with a CT scab with iodine injection|October 2011|October 21, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457963||96708|
NCT01458262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE10.192|Observational Study on the Clinical Impact of Desaturation During Liver Surgery|Observational Study on the Clinical Impact of Systemic and Cerebral Desaturation During Liver Transplantation and Hepatectomy||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2011|January 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|patient undergoing hepatic surgery or liver transplantation|January 2014|January 27, 2014|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01458262||96685|
NCT01459172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0375-04|Human Breast Tissue Bioavailability of Topically Applied Limonene|Human Breast Tissue Bioavailability of Topically Applied Limonene||University of Arizona|No|Completed|October 2007|||May 2010|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|103|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 21, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01459172||96615|
NCT01459419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISM-10-06|Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects|A Phase IIa Safety Study of Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects, a Single-blind, Randomized, Controlled Multi-center Study.||Inspira Medical AB|No|Not yet recruiting|November 2011|October 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||October 2011|October 23, 2011|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01459419||96596|
NCT01459666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mann-Cohen Version 2|Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer|A Prospective, Dual-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of abobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer||AboutSkin Dermatology and DermSurgery, PC|Yes|Recruiting|September 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01459666||96577|
NCT01459679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOS-KXL-001|A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery|A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery||American-European Congress of Ophthalmic Surgery|No|Terminated|July 2012|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1719|||Both|12 Years|N/A|No|||December 2015|December 23, 2015|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459679||96576|
NCT01459952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV 02/11|A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold|A Double-blind, Randomised, Parallel Group, Phase III Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold||Hyben Vital ApS|No|Completed|November 2011|May 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 5, 2012|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01459952||96555|
NCT01459653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP06-502|Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor|International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.|Monitor-GCSF|Sandoz|No|Completed|March 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1496|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients treated with chemotherapy and who are prescribed commercially available        filgrastim biosimilar (EP2006) for primary or secondary prophylaxis for febrile        neutropenia.|December 2015|December 9, 2015|August 30, 2011||No||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01459653||96578|
NCT01455623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC-6604|Development and Validation of a Disability Severity Index for CMT|Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease|6604|University of Iowa|No|Completed|June 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|291|||Both|8 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Two cohorts:          1. Patients self identified as having CMT and have chosen to be a part of the Inherited             Neuropathies Consortium Contact Registry, housed by the Rare Disease Clinical             Research Network.          2. Healthcare Providers working in the field of CMT.|March 2014|March 25, 2014|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01455623||96886|
NCT01465594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|catheterstudy001|Study Comparing Urinary Diversion (Transurethral/Suprapubic) After Radical Prostatectomy|Randomized Study Comparing Urinary Diversion by Suprapubic Catheter With Transurethral Catheter in Patients After Radical Prostatectomy||Heinrich-Heine University, Duesseldorf|No|Completed|November 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|106|||Male|18 Years|N/A|No|||May 2015|May 19, 2015|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01465594||96125|
NCT01465386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2529.00|Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission|A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission||Fred Hutchinson Cancer Research Center|No|Terminated|November 2011|||August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||October 2014|October 30, 2014|October 10, 2011|No|Yes|Closed early due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01465386||96141|
NCT01456273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Guedes, FG 01|From the Biomedical to the Biopsychosocial Model, From Theory to Practice|Evaluation of the Efficacy of the Integral Approach (Therapeutic Encounter) Versus the Conventional Medical Approach (Medical Consultation) in Patients With Functional Dyspepsia||Faculdade de Medicina do ABC|No|Recruiting|March 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|65 Years|No|||October 2011|October 19, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01456273||96836|
NCT01456520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4571001|Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco|An Open Label, Single Dose, Randomized, Two-Period, Two-Way Crossover Study to Evaluate the Pharmacokinetics and Bioequivalence of Vycavert Tablets Compared to Norco® Tablets in Healthy Subjects||Pfizer|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 7, 2012|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01456520||96817|
NCT01460901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STALLONe|Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma|Phase I Study of Donor Derived,Gene Modified, Multi-virus-specific, Cytotoxic T-Lymphocytes Redirected to the Tumor Marker GD2 for Relapsed/Refractory Neuroblastoma Post-allogeneic Stem Cell Transplantation With a Submyeloblative Conditioning Regimen|STALLONe|Children's Mercy Hospital Kansas City|Yes|Completed|October 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Months|17 Years|No|||February 2015|February 4, 2015|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460901||96483|
NCT01461486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1300/11|Continuous Positive Airway Pressure and Oral Appliances Treatments in Mild Obstructive Sleep Apnea|Effectiveness of Continuous Positive Airway Pressure and Oral Appliances in Mild Obstructive Sleep Apnea: a Randomized, Parallel, Single Blind and Controlled Study|OSAS|Associação Fundo de Incentivo à Pesquisa|Yes|Recruiting|October 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||January 2013|January 23, 2013|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01461486||96440|
NCT01461473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10182011-8536|Comparative Outcomes Management With Electronic Data Technology (COMET) Study|RO1: Comparative Outcomes Management With Electronic Data Technology (COMET) Study|COMET|Stanford University|Yes|Completed|December 2011|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01461473||96441|
NCT01461746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSGOG-001|Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer|A Phase II Trial of Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients, With High-risk Endometrial Carcinoma After Staging Surgery||Asan Medical Center|No|Recruiting|October 2011|September 2015|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Female|20 Years|75 Years|No|||October 2011|October 27, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01461746||96420|
NCT01465022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-151|Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial|Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial||University of New Mexico|No|Completed|January 2005|June 2008|Actual|June 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|197|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|November 1, 2011||No||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01465022||96168|
NCT01465282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT327-2003|Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris|A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris||Creabilis SA|No|Completed|December 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|160|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465282||96148|
NCT01465295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF001|Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis|Prospective Trial to Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis||SpineForm LLC|Yes|Active, not recruiting|August 2011|January 2021|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|10 Years|N/A|No|||November 2015|November 25, 2015|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01465295||96147|
NCT01465529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2375|A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis|A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa|OligoG|AlgiPharma AS|Yes|Completed|May 2011|November 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01465529||96130|
NCT01457079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tirgan 11-06|Keloid Radiation Registry|Keloid Radiation Registry||Tirgan, Michael H., M.D.|No|Active, not recruiting|December 2011|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|This study intends to enroll all patients who have had, or will be receiving radiation        therapy for their keloid(s).|November 2014|November 14, 2014|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457079||96775|
NCT01457391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1DA027650|Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment|A Stage II Efficacy Study of Cognitive Behavioral Therapy for PTSD in Community Addiction Treatment||Dartmouth-Hitchcock Medical Center|Yes|Completed|December 2010|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|443|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01457391||96752|
NCT01457716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103007|Pharmacokinetic Pilot Study on Budesonide/Formoterol|Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|October 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|17|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|September 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457716||96727|
NCT01457950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114163|A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab|A Six Month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study With a Six Month Open-Label Extension to Evaluate the Efficacy and Safety of Denosumab in Korean Postmenopausal Women With Osteoporosis||GlaxoSmithKline|No|Completed|November 2011|June 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|135|||Female|60 Years|90 Years|No|||February 2014|April 17, 2014|October 20, 2011||No||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01457950||96709|
NCT01458249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-J081-217|An Open Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma (Study E7389-J081-217)|An Open Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced Soft Tissue Sarcoma||Eisai Inc.||Active, not recruiting|November 2011|April 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|N/A|No|||July 2014|July 16, 2014|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01458249||96686|
NCT01458275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP060-305|A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)|A 2-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6 to 11 Years With Seasonal Allergic Rhinitis||Sunovion|No|Completed|November 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|847|||Both|6 Years|11 Years|No|||April 2014|April 16, 2014|October 20, 2011|Yes|Yes||No|March 10, 2014|https://clinicaltrials.gov/show/NCT01458275||96684|
NCT01458288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-0054-03|A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease|||TaiGen Biotechnology Co., Ltd.||Completed|October 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||December 2014|December 25, 2014|October 13, 2011|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01458288||96683|
NCT01458574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921096|A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis|OCTAVE|Pfizer|Yes|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|654|||Both|18 Years|N/A|No|||March 2016|March 12, 2016|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458574||96661|
NCT01458587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0106|Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)|A Phase II Study of Photodynamic Therapy (PDT)With LEVULAN® Topical Solution + Blue Light Versus LEVULAN® Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities||DUSA Pharmaceuticals, Inc.|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|October 21, 2011|Yes|Yes||No|December 21, 2012|https://clinicaltrials.gov/show/NCT01458587||96660|
NCT01459965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9307-04|Stenting Malignant Jaundice for Quality of Life|Endoscopic Palliation of Malignant Biliary Tract Obstruction: Emphasis on Improvement in Quality of Life||Indiana University|No|Completed|July 1993|November 2004|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|164|||Both|N/A|N/A|No|||October 2011|October 25, 2011|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459965||96554|
NCT01455935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU 3200411A|Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention|Wake up Symptomatic Stroke in Acute Brain Ischemia (WASSABI) Trial|WASSABI|Jacobs Neurological Institute|Yes|Recruiting|November 2011|February 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|80 Years|No|||March 2012|March 29, 2012|October 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455935||96862|
NCT01455948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JJMC-001|Canadian Health Economics, Outcome, and Effectiveness Comparison of Treatment in Patients With Chronic Rhinosinusitis|Canadian Health Economics, Health Outcome, and Effectiveness Comparison of Treatment of the Frontal Sinus Ostium and Recess and Other Sinuses With Functional Endoscopic Sinus Surgery (FESS) or Balloon Sinuplasty in Patients With Chronic Sinusitis (CRS)|CHEC|Johnson & Johnson Medical Companies|No|Terminated|February 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|25|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01455948||96861|
NCT01456286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEHYLIC|Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension|Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension||Fundacion Clinic per a la Recerca Biomédica|Yes|Completed|October 2011|October 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|75 Years|No|||October 2013|October 1, 2013|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01456286||96835|
NCT01455896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-107|A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650|A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes||Intarcia Therapeutics|Yes|Active, not recruiting|March 2013|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4000|||Both|40 Years|N/A|No|||July 2015|July 29, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455896||96865|
NCT01465880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIPA_CEMA_01|Smoking Research Study|A Single-centre, Dose Titration Study in Healthy Volunteers (Smokers and Non-smokers) to Evaluate the Capacity of 2-cyanoethylmercapturic Acid (CEMA) to Detect Low Level of Cigarette Smoking Exposure||Philip Morris Products S.A.|No|Completed|July 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|88|||Both|23 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 20, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01465880||96103|
NCT01465893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|isfahan medical university|Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography|The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography||Isfahan University of Medical Sciences||Recruiting|July 2011|December 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|50 Years|No|||November 2011|November 21, 2011|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01465893||96102|
NCT01457170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/CARD/04|Effects of Apelin on the Lung Circulation in Pulmonary Hypertension|Investigating the Acute Pulmonary Vascular Haemodynamic Effects of Apelin in Pulmonary Hypertension||Golden Jubilee National Hospital|Yes|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 12, 2013|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457170||96769|
NCT01461226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 11/11/100|Endothelial Dysfunction in Obese Children|Adolescent Obesity: What Determines Vascular Endothelial Dysfunction And Is The Process Reversible?|EDOC|University Hospital, Antwerp|No|Recruiting|June 2011|September 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|18 Years|No|||October 2011|October 28, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01461226||96460|
NCT01461759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANSGOG-002|Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer|A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer||Asan Medical Center|No|Recruiting|October 2011|September 2015|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Female|20 Years|75 Years|No|||October 2011|October 27, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01461759||96419|
NCT01462019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0239.0.213.000-07|Photobiomodulation as a New Approach for the Treatment of Nipple Traumas|||Pontifícia Universidade Católica de Minas Gerais||Completed|February 2006|November 2006|Actual|August 2006|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|35 Years||||October 2011|October 26, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01462019||96399|
NCT01464801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIRMOI 3|Resveratrol in Patients With Non-alcoholic Fatty Liver Disease|Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds, Study 3|LIRMOI3|University of Aarhus|Yes|Completed|September 2011|June 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|70 Years|No|||August 2013|June 12, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01464801||96185|
NCT01465035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flu003|A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine|A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine||University of Oxford|Yes|Completed|October 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|24|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 28, 2012|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01465035||96167|
NCT01465308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-HANHS-86|The Effect of Honey on Xerostomia and Oral Mucositis|A Randomized Control Trial for the Effect of Honey on Radiotherapy Induced Xerostomia and Oral Mucositis in Patients With Head and Neck Cancers|AC-H|Cyprus University of Technology|No|Completed|August 2011|October 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|70 Years|No|||October 2014|October 7, 2014|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01465308||96146|
NCT01457092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/1530/2005|Self-expandable, Fully Covered Metal Stents in Biliary Strictures Due to Chronic Pancreatitis|Self-expandable, Fully Covered Metal Stents in Biliary Strictures Due to Chronic Pancreatitis Not Responding to Plastic Stenting: a Prospective Study With Two Years Follow-up.||Catholic University of the Sacred Heart|No|Completed|January 2007|September 2009|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457092||96774|
NCT01457404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1DA030102|Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders|Integrated Cognitive Behavioral Therapy for Co-Occurring PTSD and Substance Use Disorders||Dartmouth-Hitchcock Medical Center|Yes|Completed|February 2011|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01457404||96751|
NCT01457417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100|A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors|A Two Part, Phase 1, Multicenter, Open-label Study of DKN-01 Given Intravenously. Part A: A Dose-Escalation Study in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)||Leap Therapeutics, Inc.|No|Completed|October 2011|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|39|||Both|30 Years|N/A|No|||June 2014|June 26, 2014|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01457417||96750|
NCT01457729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGO2011|Ergometer Training in Patients With OSA|Telemedizinisches Trainings-Monitoring Von Patienten Mit Obstruktivem Schlafapnoesyndrom||Institut für Pneumologie Hagen Ambrock eV|No|Completed|February 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|80 Years|No|||September 2012|September 17, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457729||96726|
NCT01457976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814399|A Survey on Attitudes on Financial Incentives|A Survey on Attitudes on Personal Responsibility and the Use of Financial Incentives for Health Promotion||University of Pennsylvania|No|Enrolling by invitation|September 2011|October 2011|Anticipated|October 2011|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||3|Anticipated|3000|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|adult American and Germans|October 2011|October 20, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01457976||96707|
NCT01458301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-385/CCT-101|Efficacy and Safety of TAK-385 in the Treatment of Endometriosis|A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Endometriosis||Takeda|No|Completed|October 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|487|||Female|20 Years|N/A|No|||February 2014|February 24, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01458301||96682|
NCT01458600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005 02 23|Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)|Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)|aGO|Region Skane|Yes|Completed|September 2006|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Both|18 Years|75 Years|No|||February 2016|February 23, 2016|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01458600||96659|
NCT01458847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL08003|Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer|A Single Dose, Dose-escalating, Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Intravesical Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer||BioCis Pharma Ltd|Yes|Completed|October 2009|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|80 Years|No|||November 2012|November 9, 2012|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01458847||96640|
NCT01468740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-HL 2004|Prospective Study on HIV-related Hodgkin Lymphoma|A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma||Harlachinger Krebshilfe e.V.||Recruiting|March 2004|July 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|75 Years|No|||November 2011|November 7, 2011|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01468740||95884|
NCT01464879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000024|A Clinical Trial to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator|A Phase 2, Open-Label, Sequential Dose Escalation Study in Adult Hypogonadal Males to Evaluate the Pharmacokinetics of Three Volumes of FE 999303 (Testosterone Gel), Applied to the Shoulder/Upper Arm, Using an Applicator Compared With Hand Application||Ferring Pharmaceuticals|No|Completed|December 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|75 Years|No|||May 2013|May 13, 2013|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464879||96179|
NCT01465113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE12209|Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus|Effect of Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus||Case Comprehensive Cancer Center|Yes|Completed|May 2010|February 2016|Actual|February 2016|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|26|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465113||96161|
NCT01465126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Registry Identifier|Enalapril in Collagen Type 4 Nephropathy|Collagen Type 4-related Nephropathies: From Alport to Thin Membrane Nephropathy. A Series of Cases Treated With Angiotensin Converting Enzyme Inhibitor||University of Sao Paulo|No|Completed|January 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|19|||Both|N/A|18 Years|No|Probability Sample|Patients with Collagen type 4 nephropathies and proteinuria followed in Pediatric        Nephrology Unit of Instituto da Criança - HCFMUSP|November 2011|November 1, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01465126||96160|
NCT01456559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vers 2011-07-11|Detection of Hypovolemia Using Pleth Variability Index (PVI)|Non-invasive Detection of Mild Hypovolemia Using Pleth Variability Index (PVI) During Spontaneous Breathing||University Hospital, Linkoeping|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects between 18-30 years old without any medications affecting circulatory or        respiratory system|January 2013|January 16, 2013|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01456559||96814|
NCT01466166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M0401|Observational Study of the Use of KRYSTEXXA® in Refractory Chronic Gout|Observational Study of the Use of KRYSTEXXA® (Pegloticase)in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy|EyesOnGOUT|Crealta Pharmaceuticals LLC|No|Recruiting|October 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|Samples Without DNA|Serum samples|Both|18 Years|N/A|No|Non-Probability Sample|The patient population in this study will be hyperuricemic (serum uric acid (SUA) > 6        mg/dL) adult men and women (age 18 or greater) diagnosed with chronic gout and who are        refractory to conventional therapy. Gout refractory to conventional therapy occurs in        patients who have failed to normalize SUA and whose signs and symptoms are inadequately        controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or        for whom these drugs are contraindicated. To enter this study, the patient and the        physician must have decided to begin treatment with KRYSTEXXA.|June 2014|June 6, 2014|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01466166||96081|
NCT01465854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1002 BioCAST|French Biological Observatory on Lung Cancer in Never Smokers|French Biological Observatory on Lung Cancer in Never Smokers|BioCAST|Intergroupe Francophone de Cancerologie Thoracique|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|422|Samples With DNA|whole blood, serum, plama, white cells|Both|18 Years|N/A|No|Non-Probability Sample|Never smokers with newly diagnosed lung cancer|July 2013|March 22, 2016|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01465854||96105|
NCT01461499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-2|Shiga Microalbuminuria Reduction Trial-2|Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2||Shiga University|Yes|Completed|October 2011|||August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|237|||Both|20 Years|75 Years|No|||October 2014|October 21, 2014|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01461499||96439|
NCT01462396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STALLO|Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors|Phase I Study of Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using Major Histocompatibility Complex (MHC) Mismatched Related Donors and Sub-Myeloablative Regimen|STALLO|Children's Mercy Hospital Kansas City|Yes|Active, not recruiting|October 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|6 Months|17 Years|No|||February 2015|February 4, 2015|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462396||96370|
NCT01462695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03536|Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma|A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients||National Cancer Institute (NCI)||Completed|January 2012|March 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|1 Year|21 Years|No|||June 2015|August 18, 2015|October 27, 2011|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01462695||96347|
NCT01462032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R33MH085898-03|Non-pharmacological Interventions for Preschoolers With Attention Deficit Hyperactivity Disorder (ADHD)|Training Executive, Attention, and Motor Skills (TEAMS): Preliminary Studies|NIPA|Queens College, The City University of New York|No|Completed|April 2011|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|48 Months|71 Months|Accepts Healthy Volunteers|||June 2014|June 3, 2014|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01462032||96398|
NCT01465542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAP & NAC 2008-2011|Treatment of APAP Toxicity With IV and Oral NAC 2008-2011|Treatment of Acetaminophen Toxicity With Intravenous vs. Oral N-acetylcysteine: A Retrospective Review||Akron Children's Hospital|No|Completed|June 2011|November 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|47|||Both|N/A|N/A|No|Non-Probability Sample|Pediatric and adolescent patients with acetaminophen toxicity.|November 2011|November 2, 2011|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01465542||96129|
NCT01465776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0497|Freeze-Dried Black Raspberries in Treating Patients With Oral Squamous Cell Cancer Undergoing Surgery|A Phase 1b Pilot Study Evaluating Oral Administration of Freeze-Dried Black Raspberries in Pre-Surgical Patients With Oral Squamous Cell Carcinoma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|January 2005|||February 2010|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465776||96111|
NCT01465789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCS 102.2|Noninvasive Biomarkers for Monitoring Cardiometabolic Risk in Children|Noninvasive Biomarkers for Monitoring Cardiometabolic Risk in Children||West Virginia School of Osteopathic Medicine|No|Terminated|July 2011|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|Samples Without DNA|saliva|Both|4 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children participating in the CARDIAC Boot Camp program at the Robert C. Byrd Clinic in        Lewisburg WV|August 2013|August 5, 2013|July 5, 2011||No|Loss of participants to follow-up|No||https://clinicaltrials.gov/show/NCT01465789||96110|
NCT01457430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001768|Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema|Open Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema (IHA)|IHA|Massachusetts General Hospital|Yes|Completed|December 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457430||96749|
NCT01457443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP09/2011|Biomarker for Pompe Disease|Biomarker for Pompe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioPompe|University of Rostock|Yes|Recruiting|October 2011|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml      EDTA blood,sputum tube and a dry blood spot filter card are taken. To proof the correct      Pompe diagnosis in those patients where up to the enrollment in the study no genetic testing      has been done, sequencing of Pompe will be done. The analyses are done in the      Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20,      18055 Rostock (Germany)|Both|12 Months|N/A|No|Probability Sample|Patients with Pompe Disease based upon biochemical and/or genetic criteria|November 2015|November 10, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01457443||96748|
NCT01457742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ivivi-OAPain-001|Effectiveness Study of the Ivivi SofPulse for Pain Amelioration in Adults With Mild to Moderate Knee Osteoarthritis|Non-thermal Pulsed Radio Frequency for Pain Amelioration in Adults With Knee Osteoarthritis: A Double-blind, Randomized, Sham-controlled Trial||Amp Orthopedics, Inc.|No|Terminated|October 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|40 Years|80 Years|No|||July 2012|July 6, 2012|October 19, 2011|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01457742||96725|
NCT01457989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115476|Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304|Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extensions of Studies VRX-RET-E22-301 and VRX-RET-E22-302)||GlaxoSmithKline|No|Completed|August 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients with partial onset seizures who have successfully completed the transition        phase of VRX-RET-E22-301 and VRX-RET-E22-302.|October 2012|October 25, 2012|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457989||96706|
NCT01458613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BML10/2011|Biomarker for Maroteaux-Lamy Disease|Biomarker for Maroteaux-Lamy Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioMaroteaux|University of Rostock|Yes|Recruiting|October 2011|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|For the development of the new biomarkers using the technique of mass-spectometry 7,5 ml      EDTA blood, a dry blood spot filter card and a sputum tube are taken. To proof the correct      Maroteaux-Lamy diagnosis in those patients where up to the enrollment in the study no      genetic testing has been done, sequencing of Maroteaux-Lamy will be done as routine      diagnostic.      The analyses are done in the      Albrecht-Kossel-Institute for Neuroregeneration Centre for Mental Health University of      Rostock Gehlsheimerstrasse 20 D-18147 Rostock Germany|Both|12 Months|N/A|No|Probability Sample|Patients with Maroteaux-Lamy Disease|November 2015|November 10, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01458613||96658|
NCT01459432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2011/03|Understanding Immunity Persistence After Adolescent MenC Vaccination|A Study to Evaluate the Persistence of Antibody Seven Years After a Booster Dose of Either a Glycoconjugate or a Polysaccharide Vaccine Against Serogroup C Neisseria Meningitidis Given to Adolescents||University of Oxford||Completed|November 2011|||April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|134|||Both|20 Years|23 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young adults, approximately 20 - 23 years old.|November 2015|November 6, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459432||96595|
NCT01459692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR15863|Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological Handicaps|Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological Handicaps||Medical University of South Carolina|Yes|Completed|February 2005|January 2008|Actual|January 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|5 Years|90 Years|No|||October 2011|October 25, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459692||96575|
NCT01464658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8184|Prospective Study of Functional and Quality of Life Outcomes in Panniculectomy Patients|Prospective Study of Functional and Quality of Life Outcomes in Panniculectomy Patients||Wake Forest School of Medicine|No|Terminated|March 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|80 Years|No|||August 2011|November 2, 2011|August 9, 2010||No|Due to complexity and cost of study (no outside funding)|No||https://clinicaltrials.gov/show/NCT01464658||96196|
NCT01464632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-707|Post-Market Study of the EPIK Knee System|Prospective, Open Label Study of the Short-and Midterm Safety and Efficacy of the EPIK Uni-Compartmental Knee System in Community Practice|EPIK|Encore Medical, L.P.|No|Withdrawn|November 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients who are between 18 years of age and 60 years of age at time of consent and have        one side of the knee joint affected by compartmental primary degenerative or        post-traumatic degenerative disease, previous tibial condyle or plateau fractures or        deformity.|May 2012|May 14, 2012|November 2, 2011|Yes|Yes|Unable to enroll any study participants.|No||https://clinicaltrials.gov/show/NCT01464632||96198|
NCT01464892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-KP-877|Imagery Rescripting in the Treatment of Post Traumatic Stress Disorder (PTSD) Following Early Chronic Interpersonal Trauma|Rescripting With vs. Without Prior Stabilization in PTSD Following Early Chronic Interpersonal Trauma||VU University of Amsterdam|Yes|Active, not recruiting|October 2011|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01464892||96178|
NCT01465373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-019|Vaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs|Comparison of the Effectiveness of Micronized Vaginal Progesterone (Endometrin, Ferring) Vs. Progesterone in Oil for Luteal Phase Support in Donor Egg Recipient IVF Cycles Utilizing Previously Vitrified Donor Oocytes||Fertility Centers of Illinois|No|Completed|February 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Female|21 Years|49 Years|Accepts Healthy Volunteers|||November 2011|November 2, 2011|May 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01465373||96142|
NCT01465607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH087054|Implementation of an Efficacious Intervention for High Risk Women in Mexico|Implementation of an Efficacious Intervention for High Risk Women in Mexico||University of California, San Diego|No|Completed|November 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1228|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01465607||96124|
NCT01465906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG1015TLT|Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease|||Shanghai Zhongshan Hospital|Yes|Active, not recruiting|November 2010|November 2011|Anticipated|November 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|40 Years|80 Years|No|||November 2011|November 8, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01465906||96101|
NCT01462045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSC027-2|Efficacy Study of Mindfulness-Based Exercise for Posttraumatic Stress Disorder (PTSD)|The Efficacy of Mindfulness-Based Stretching and Breathing Exercise as a Complementary Therapy for Posttraumatic Stress Disorder: A Prospective Randomized Study||University of New Mexico|No|Completed|October 2011|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 15, 2014|October 7, 2011||No||No|June 5, 2013|https://clinicaltrials.gov/show/NCT01462045||96397|
NCT01462058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-301115|The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff||D3-vit-SAD|Region Syddanmark|Yes|Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01462058||96396|
NCT01462708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB1-01|Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects|Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls|MK9470|Institute for Neurodegenerative Disorders|No|Completed|May 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|June 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01462708||96346|
NCT01462409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Climateline2011|Humidity Under Continuous Positive Airway Pressure|Luftfeuchtigkeit Unter CPAP Mit Temperatur- Und Feuchtigkeitskontrolle||Institut für Pneumologie Hagen Ambrock eV|No|Completed|March 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|19|||Male|20 Years|70 Years|No|||September 2012|September 17, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01462409||96369|
NCT01456481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR#243314|Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV|Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4)|POST 4|University of Calgary|Yes|Recruiting|November 2011|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||July 2014|July 10, 2014|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456481||96820|
NCT01456806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1374/2006 (ACC)|Educative Intervention to Improve Type 2 Diabetes Mellitus Control in Corrientes|Programme of Diabetes Education in the City of Corrientes (PRODIACOR): Clinical, Metabolic and Economic Outcomes of a Prospective-randomized Trial Based on Different Patient-centered Educational Strategies for People With Type 2 Diabetes|PRODIACOR|Centro de Endocrinologia Experimental y Aplicada|Yes|Completed|December 2006|July 2010|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|4||Actual|468|||Both|18 Years|75 Years|No|||October 2011|October 20, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01456806||96795|
NCT01458860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV-11-0041|Aortic Calcification - is it a Marker for Carotid Artery Stenosis?|Aortic Calcification - is it a Marker for Carotid Artery Stenosis?||Ziv Hospital|No|Not yet recruiting|February 2012|February 2014|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|200|||Both|40 Years|N/A|No|Non-Probability Sample|Group A - patients who had a CT scan Group B - patients who have severe carotid artery        stenosis|October 2011|October 31, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01458860||96639|
NCT01459185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R000007795|A Feasibility Study of Oral Adjuvant Chemotherapy With S-1|A Feasibility Study of Adjuvant Chemotherapy With Oral Fluoropyrimidine S-1 for Non-small Cell Lung Cancer||Nagasaki University|No|Completed|June 2005|March 2012|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|20 Years|79 Years|No|||September 2014|September 23, 2014|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459185||96614|
NCT01468454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-006211|Phase II Safety and Efficacy Study of F-DOPA PET/CT in Children With Hyperinsulinemic Hypoglycemia|A Phase II Safety and Efficacy Study of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Children With Hyperinsulinemic Hypoglycemia|F-DOPA PET|Children's Hospital of Philadelphia|No|Active, not recruiting|January 2009|December 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|128|||Both|N/A|N/A|No|||February 2016|February 18, 2016|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468454||95906|
NCT01465165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIBR08-PJC|Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression|Comparison of [F-18] FDG Positron Emission Tomography and Multinuclear (31P and 1H) Magnetic Resonance Spectroscopy as Complementary Bioenergetic Imaging Modalities in Healthy Human Brain and Major Depressive Disorder||University of Utah|No|Recruiting|June 2009|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|November 2011|November 3, 2011|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465165||96157|
NCT01464645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-804|Post-Market Study of the Modular Revision Hip System|Prospective Multicenter Open Label Study Examining the Short-term Safety and Efficacy of the Modular Revision Hip System (MRHS)|MRHS|Encore Medical, L.P.|No|Terminated|January 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible subjects will be at least 18 years of age at the time of consent and meet the        inclusion criteria for a total hip revision arthroplasty due to poor bone stock, or due to        deficiencies of the femoral head, neck or portions of the proximal femur.|January 2016|January 19, 2016|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464645||96197|
NCT01464905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-NU100-01.00|Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis||Nuron Biotech Inc.|No|Active, not recruiting|October 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|60 Years|No|||September 2013|September 20, 2013|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464905||96177|
NCT01465399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIBEA-01-EC/11/ALV|Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-Extraction Sockets|Randomized Clinical Trial, Controlled With Conventional Treatment, of Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-extraction Sockets in Simple Extractions of Molars in the Mandible||Fundación Eduardo Anitua||Completed|June 2011|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Both|18 Years|N/A||||December 2012|December 24, 2012|October 27, 2011||||No||https://clinicaltrials.gov/show/NCT01465399||96140|
NCT01465139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX301-02|A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers|A Phase 1 Safety, Pharmacokinetic, and Immunologic Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers||Celldex Therapeutics|No|Completed|October 2011|January 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 7, 2013|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01465139||96159|
NCT01466491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU SFP 7688|Refining Paracervical Block Techniques for Pain Control in First Trimester Surgical Abortion|Refining Paracervical Block Techniques for Pain Control in First Trimester Surgical Abortion||Oregon Health and Science University|No|Recruiting|October 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|350|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 5, 2013|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466491||96056|
NCT01466777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10081|Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy|Robotic-assisted vs. Traditional Laparoscopic Surgery in Treatment of Endometrial Cancer Patients||Tampere University Hospital|No|Active, not recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|30 Years|85 Years|No|||May 2015|March 23, 2016|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01466777||96034|
NCT01466140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EffectsPS1|Effects of Writing Down the Request for Help on Patient Satisfaction in General Practices|Effects of Writing Down the Request for Help With Regard to Patient Satisfaction in General Practices||Medical Research Foundation, The Netherlands|No|Completed|January 2011|May 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|209|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 4, 2011|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01466140||96083|
NCT01461785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWJSLIPOFILLING|The Use of Activated Platelet Rich Plasma (PRP) in Human Autologous Fat Transfer|The Use of Activated Platelet Rich Plasma (PRP) in Human Autologous Fat Transfer||Bergman Clinics|No|Recruiting|April 2012|November 2013|Anticipated|June 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|32|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 14, 2012|October 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01461785||96417|
NCT01462071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|039-08|Red Blood Cell Lifespan|Red Blood Cell Lifespan and Inflammation in Dialysis Patients|RBC|Renal Research Institute|No|Terminated|May 2008|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|Samples Without DNA|Plasma|Both|18 Years|88 Years|No|Probability Sample|The study population comprises adult patients (at least 18 years of age) who perform        chronic peritoneal dialysis treatment or hemodialysis treatment. Both men and women can        participate in the study, and no race or ethnic group will be excluded. No subjects that        require special protections will be involved.|February 2016|February 22, 2016|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01462071||96395|
NCT01462084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-01-10|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2011|||||N/A|N/A|N/A||||||||||||||August 16, 2012|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462084||96394|
NCT01462422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.16|Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India|Two Community Strategies Comparing Use of Misoprostol for Secondary Prevention to Primary Prevention for Postpartum Hemorrhage: A Randomized Cluster Non-Inferiority Study in Bijapur District, Karnataka, India||Gynuity Health Projects|Yes|Completed|December 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3032|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462422||96368|
NCT01456819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FF-113-2011|Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia|Phase II Efficacy Study of Intramuscular Autologous Bone Marrow Mononuclear Cells Plus Mesenchymal Stem Cell Implantation Versus Autologous Bone Marrow Mononuclear Cells Implantation Only in Patients With Chronic Critical Limb Ischemia||National University of Malaysia|No|Recruiting|March 2011|February 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||April 2015|April 9, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01456819||96794|
NCT01457105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/1531/05|Covered Self-expandable Metal Stents for Palliation of Malignant Biliary Strictures: Evaluation of a New Type of Stent|PARTIALLY COVERED NITINOL "ComVi" STENT FOR PALLIATION OF MALIGNANT NON HILAR BILIARY OBSTRUCTION||Catholic University of the Sacred Heart|No|Completed|November 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||October 2011|October 20, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457105||96773|
NCT01457118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PIR-09|An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies|An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies||Nektar Therapeutics|No|Recruiting|October 2011|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|October 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01457118||96772|
NCT01458626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP # 39888|Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement|A Double-blind, Active-controlled, Randomized Study Comparing Mirtazapine Combined With Paroxetine or Paroxetine Monotherapy in Patients With Major Depressive Patients Without Early Improvement in the First 2 Weeks||Capital Medical University|Yes|Recruiting|April 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|540|||Both|18 Years|60 Years|No|||July 2015|July 27, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01458626||96657|
NCT01458639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYC-008|Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism|A Comparison of Technegas® Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging in Subjects Being Evaluated for Pulmonary Embolism||Cyclomedica Australia PTY Limited|Yes|Terminated|August 2012|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|18|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|October 19, 2011|Yes|Yes|Decision to change trial design.|No|July 20, 2015|https://clinicaltrials.gov/show/NCT01458639||96656|PE adjudication by Independent Committee for final clinical diagnosis and blinded readings of Xe-133 and Technegas Ventilation and Tc-99m MAA Perfusion images were not performed due to early trial termination. No efficacy data available.
NCT01458314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTS/10/01|Non Invasive Mechanical Ventilation in Chronic Respiratory Insufficiency Patients During Rehabilitation|Evaluation of the Additional Effect of Non Invasive Mechanical Ventilation During a Rehabilitative Program With Cycloergometer in Patients With Chronic Respiratory Insufficiency Using Nocturnal Home Ventilation||Fondazione Salvatore Maugeri|Yes|Completed|March 2011|October 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|40 Years|79 Years|No|||November 2015|November 12, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01458314||96681|
NCT01458327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP1-E2|Additional MDMA-assisted Psychotherapy for People Who Relapsed After MDMA-assisted Psychotherapy Trial|An Open-Label Proof-of-Principle Study Testing the Use of an Additional MDMA-Assisted Psychotherapy Session in People Who Relapsed After Participating in a Phase 2 Clinical Trial of MDMA-Assisted Psychotherapy to Treat Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)||Multidisciplinary Association for Psychedelic Studies|No|Completed|November 2011|February 2016|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458327||96680|
NCT01467856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMP-MN-010|Sleep Disordered Breathing|Sleep Disordered Breathing (SDB) in Persons With Chronic Tetraplegia: Characterization and Treatment|SDB|University of Miami|Yes|Completed|October 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|304|Samples Without DNA|Insulin Sensitivity (SI) and Lipid/Inflammation panels: (30 minutes, Taken at Baseline, 1      month, and 3 month time points) SI will be calculated using the Quantitative Insulin      Sensitivity Check Index (QUICKI) method177 that requires single fasting blood glucose and      insulin values. The same blood sample will be used to assay for a lipid panel containing      total cholesterol, LDL, HDL, and triglycerides and an inflammatory panel testing hs-CRP and      IL-6.|Both|18 Years|65 Years|No|Probability Sample|Persons with Chronic Spinal Cord Injury who are asymptomatic for acute treable illness.|July 2014|July 21, 2014|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01467856||95951|
NCT01468129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11UJPAR|Cell Saver Use in Bilateral Total Hip Arthroplasty (THA)|A Prospective, Randomized Controlled Trial to Evaluate the Efficacy of Cell Saver to Redue Blood Loss in One-stage Bilateral Total Hip Arthroplasty (THA)||Rothman Institute Orthopaedics|No|Recruiting|November 2011|December 2012||December 2012||N/A|Interventional|N/A|2||||||Both|21 Years|N/A|No|||November 2011|November 8, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468129||95931|
NCT01468142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1282-31/1|Pulmonary Pathophysiology and Inflammatory Response in Patients Treated With Ecmo for Severe Respiratory Failure|Pulmonary Pathophysiology and Inflammatory Response in Patients Treated With Ecmo for Severe Respiratory Failure||Karolinska University Hospital|No|Recruiting|February 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|3 Years|N/A|No|Non-Probability Sample|General hospitals, district hospitals, specialized hospitals,|August 2015|August 31, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468142||95930|
NCT01468766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEST|Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy|Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy - A Randomised Controlled Intervention Trial|BEST|German Cancer Research Center||Completed|February 2011|July 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Female|18 Years|N/A|No|||March 2015|March 10, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01468766||95882|
NCT01468779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09256|Effect of Probiotics in Patients Undergoing Surgery for Periampullary Neoplasms|Effect of the Probiotics Use in Patients Undergoing Surgery for Periampullary Neoplasia - A Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Active, not recruiting|February 2010|May 2012|Anticipated|December 2011|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|58|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01468779||95881|
NCT01465659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 11I03|Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery|A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)||Northwestern University|Yes|Recruiting|November 2011|August 2018|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|39|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465659||96120|
NCT01465152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1411|Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes|Multicentre, Randomised, Comparative, Open, Three Armed Parallel Group Study on the Use of Metformin, Repaglinide or the Combination of Both in Type 2 Diabetic Patients After Failure of Dietary Measures||Novo Nordisk A/S|No|Completed|March 2002|October 2004|Actual|October 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|182|||Both|35 Years|75 Years|No|||November 2011|November 3, 2011|October 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01465152||96158|
NCT01465633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K069|Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets|Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets||Heidelberg University|No|Completed|August 2003|November 2003|Actual|November 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 4, 2011|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01465633||96122|
NCT01465646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K069-2|Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 100 μg/ 75 μg Tablets|||Heidelberg University|No|Completed|June 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 4, 2011|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01465646||96121|
NCT01465620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM01|Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study|Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study||Henri Mondor University Hospital|No|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01465620||96123|
NCT01466764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10312011-8587|Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain|Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain||Stanford University|Yes|Recruiting|October 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2011|November 7, 2011|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466764||96035|
NCT01461798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ben2011|Assessment of the Efficacy of Plant Stanol Esters in Reducing Cholesterol, Medellin 2011|Assessment of the Efficacy of Plant Stanol Esters in Reducing Cholesterol, Medellin 2011|Ben2011|CES University|Yes|Not yet recruiting|October 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|50 Years|No|||October 2011|October 26, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01461798||96416|
NCT01462097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00045276|Exercise Trial in Chronic Kidney Disease|Randomized Trial of Aerobic Exercise Training on Cognitive and Physical Function in Chronic Kidney Disease|AWARD|University of Maryland|Yes|Recruiting|March 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|120|||Both|60 Years|85 Years|No|||December 2014|December 1, 2014|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01462097||96393|
NCT01462110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAEBBA0001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2011|||||N/A|N/A|N/A||||||||||||||December 20, 2011|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462110||96392|
NCT01462435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIC3-08-04|Study of Diclofenac Capsules to Treat Pain Following Bunionectomy|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy||Iroko Pharmaceuticals, LLC|No|Completed|October 2011|August 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|428|||Both|18 Years|65 Years|No|||January 2014|January 2, 2014|October 26, 2011|Yes|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT01462435||96367|
NCT01457755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-248-0122|Gilead Sustained Virologic Response (SVR) Registry|A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection||Gilead Sciences|No|Enrolling by invitation|April 2012|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7000|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Participants who have achieved sustained virologic response (SVR) while participating in a        previous Gilead sponsored HCV study.|February 2016|February 25, 2016|October 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01457755||96724|
NCT01457768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-248-0123|A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response|A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection||Gilead Sciences|No|Enrolling by invitation|December 2011|July 2019|Anticipated|July 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|650|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Non-Probability Sample|Participants who have failed to achieve sustained virologic response (SVR) while receiving        at least one Gilead OAV in a previous Gilead-sponsored HCV study.|February 2016|February 25, 2016|October 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01457768||96723|
NCT01458002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA119195|Online Tailored Interventions & Relational Agents for Exercise and Sun Protection|Online Tailored Interventions & Relational Agents for Exercise and Sun Protection|Project RAISE|University of Rhode Island||Active, not recruiting|April 2009|September 2014|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|1360|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 20, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01458002||96705|
NCT01458015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TapOxy01|Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain|Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain||University of Schleswig-Holstein|No|Terminated|October 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|5|||Both|18 Years|N/A|No|||March 2014|March 25, 2014|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01458015||96704|
NCT01467583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112050|Fondaparinux in Critically Ill Patients With Renal Failure|Use of Fondaparinux in Critically Ill Patients With Renal Failure||Wayne State University|No|Completed|November 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|32|||Both|18 Years|89 Years|No|||June 2015|June 18, 2015|November 3, 2011|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01467583||95972|
NCT01458873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8716-IK-CTIL|Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Spontaneously Breathing Adult Volunteers|Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Spontaneously Breathing Adult Volunteers||Sheba Medical Center|No|Recruiting|October 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2011|October 30, 2011|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01458873||96638|
NCT01468155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 18098|DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation|Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation|DAPPARAF|Lawson Health Research Institute|Yes|Recruiting|November 2011|July 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 16, 2012|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468155||95929|
NCT01468168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-005|A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients|A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease||Santen Inc.||Completed|October 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|183|||Both|18 Years|N/A|No|||December 2012|December 14, 2012|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468168||95928|
NCT01468467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2689-CL-0011|A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)|A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant||Daiichi Sankyo Inc.|No|Completed|April 2012|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|November 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468467||95905|
NCT01468753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30 AIO27763|Pilot Study: Acceptability, Feasibility and Efficacy of Vaginal Insemination in HIV Discordant Couples (Female Positive, Male Negative) Desiring Conception in Kisumu, Kenya|Pilot Study: Acceptability, Feasibility and Efficacy of Vaginal Insemination in HIV Discordant Couples (Female Positive, Male Negative) Desiring Conception in Kisumu, Kenya||University of California, San Francisco|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Female|18 Years|34 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468753||95883|
NCT01464918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E11/058|Safety and Efficacy of Using MASTER to Perform Endoscopic Submucosal Dissection in Human|Safety and Efficacy of Using MASTER, a Novel Robotics Enhanced Endosurgical System to Perform Endoscopic Submucosal Dissection in Human||National University Hospital, Singapore|No|Not yet recruiting|November 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|21 Years|65 Years|No|||October 2011|November 1, 2011|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01464918||96176|
NCT01465412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06513|A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)|An Open-label, Single Dose, Oral Administration, Sequential Two Parts Study to Compare the Pharmacokinetics of SCH 420814 / MK-3814 in Subjects With Mild and Moderate Chronic Hepatic Impairment With Their Respectively Matching Healthy Volunteers||Merck Sharp & Dohme Corp.|Yes|Completed|November 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|42|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 22, 2015|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01465412||96139|
NCT01466179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT103-211|Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)||Amgen Research (Munich) GmbH|Yes|Active, not recruiting|December 2011|June 2017|Anticipated|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|225|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|October 28, 2011|Yes|Yes||No|December 21, 2014|https://clinicaltrials.gov/show/NCT01466179||96080|
NCT01466192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G060-A10|Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 2 Hepatitis C, Who Relapsed After Previous Treatment||Mitsubishi Tanabe Pharma Corporation|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|108|||Both|20 Years|65 Years|No|||October 2014|October 29, 2014|November 2, 2011||No||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01466192||96079|
NCT01465919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2011-130|Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C|Phase 4 Open-labeled Study to Compare the Anti-depressive Efficacy Between Mirtazapine and Psychotherapy for Patients With Interferon-related Depression During Antiviral Therapy for Hepatitis C||Seoul National University Boramae Hospital|No|Active, not recruiting|August 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|20 Years|75 Years|No|||May 2015|May 18, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01465919||96100|
NCT01466504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11004|Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin|A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin||Dartmouth-Hitchcock Medical Center|Yes|Terminated|May 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|Samples Without DNA|skin biopsies will be performed using a 4mm biopsy punch. Participants will undero 2 skin      biopsies - one prior to starting sorafenib or regorafenib, the other once rash develops. If      a rash does not develop within 84 days a biopsy of normal skin will be done.|Both|18 Years|N/A|No|Non-Probability Sample|Cancer diagnosis of Renal Cell Carcinoma (RCC) or Hepatocellular Carcinoma (HCC) or        Colorectal Carcinoma|March 2013|April 11, 2013|October 31, 2011||No|Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study.    The goal of 30 subjects was not attainable.|No||https://clinicaltrials.gov/show/NCT01466504||96055|
NCT01466517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4371005|A Relative BioavailabilityStudy Of Ibuprofen 40mg/ml (laboratórios Pfizer Ltda) In The Oral Suspension Form.|A Phase IV, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Relative Bioavailability Of Ibupirac 40 mg/ml (Laboratorios Pfizer LTDA) Oral Suspension Form Versus Alivium® 50mg/ml (Mantecorp Industria Quimicae Farmaceutica LTDA.) Oral Suspension Form, Under Fasted Conditions In Healthy Volunteers.|B4371005|Pfizer|No|Completed|November 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 7, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466517||96054|
NCT01467063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRC# 11-29|Glutamine and Insulin Sensitivity in Type I Diabetes|Dietary Amino Acids and Insulin Sensitivity in Children With Type 1 Diabetes||Nemours Children's Clinic|No|Active, not recruiting|October 2011|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|13 Years|19 Years|No|||May 2013|May 2, 2013|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01467063||96012|
NCT01461811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-035 (P-415-C-003)|Prospective Study of an Investigational Toric Soft Contact Lens|ARES Registration Trial||Alcon Research|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|154|||Both|N/A|N/A|No|||August 2013|August 9, 2013|October 26, 2011|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01461811||96415|
NCT01466049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-35|New Biomarkers Evaluating Ovarian Cancer|Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass||Fujirebio Diagnostics, Inc.|Yes|Completed|December 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|280|||Female|18 Years|N/A|No|Probability Sample|Women with an adnexal mass, presenting to a general surgeon or obstetrician/ gynecologist        at a general or specialty center within the United States, for whom a decision to proceed        with surgery to remove the mass has been made.|August 2014|August 4, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466049||96090|
NCT01466062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-420|Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions|Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions||AbbVie|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|28|||Both|N/A|24 Months|No|||June 2013|June 13, 2013|September 12, 2011||No||No|April 25, 2013|https://clinicaltrials.gov/show/NCT01466062||96089|
NCT01466361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S7120994|Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving|Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving||GlaxoSmithKline|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|187|||Both|18 Years|N/A|No|||October 2012|November 8, 2012|November 3, 2011|Yes|Yes||No|August 23, 2012|https://clinicaltrials.gov/show/NCT01466361||96066|
NCT01458353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGUElche1|Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer|Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer: Are There Differences in the Peritoneal Contamination After Performing a Stapled or a Handsewn Anastomosis?||Hospital General Universitario Elche|Yes|Not yet recruiting|November 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|80|||Both|N/A|N/A|No|||October 2011|October 21, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01458353||96678|
NCT01458366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.404|Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas|Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas||Thomas Jefferson University|Yes|Recruiting|November 2011|October 2017|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458366||96677|
NCT01467284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA132941|School Worksite Weight Gain Prevention Intervention Study|School Worksite Weight Gain Prevention Intervention Study||University of Massachusetts, Worcester|Yes|Completed|July 2009|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|844|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2014|July 17, 2014|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01467284||95995|
NCT01467596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2011-005432-26|Ultrasound-guided Supraclavicular Brachial Plexus Block in Elderly|Effects of Age on Minimum Effective Volume of Local Anesthetic for Ultrasound-guided Supraclavicular Brachial Plexus Block (US-SCB)|US-SCB|Šarić, Jadranka Pavičić, M.D.|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|95 Years|No|||November 2012|November 14, 2012|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01467596||95971|
NCT01467869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19910013|Male Fertility Program|The Miami Project Male Fertility Program|MFP|University of Miami|Yes|Recruiting|January 1991|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|||Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Spinal cord injured men|December 2015|December 15, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01467869||95950|
NCT01467882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 8206-CPP-301|Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty|An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty||Debiopharm International SA|No|Completed|April 2012|July 2014|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|2 Years|9 Years|No|||August 2015|August 5, 2015|November 7, 2011|Yes|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01467882||95949|
NCT01467908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-fMRI-NBS|Navigated Brain Stimulation in Diagnosis of Minimally Conscious State|Navigated Brain Stimulation in Diagnosis of Minimally Conscious State|C-fMRI-NBS|Clinical Institute of the Brain, Russia|Yes|Completed|June 2011|October 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|20 Years|85 Years|No|||February 2013|February 12, 2013|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01467908||95948|
NCT01468181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13991|A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus|A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|394|||Both|20 Years|N/A|No|||January 2015|January 16, 2015|November 7, 2011|Yes|Yes||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01468181||95927|
NCT01468480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p/261/d|Human Pulpal Response After Pulp Capping With Four Different Agents|Comparison of Human Pulpal Response After Pulpal Exposure to Common Treatments and Single-visit MTA||Islamic Azad University, Tehran|Yes|Completed|June 2010|March 2011|Actual|February 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Both|10 Years|16 Years|Accepts Healthy Volunteers|||November 2011|November 8, 2011|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01468480||95904|
NCT01465178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0601|Improving the Understanding of the Response to Vitamin D Supplementation|Improving the Understanding of the Response to Vitamin D Supplementation||University of Wisconsin, Madison|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|62|||Female|50 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01465178||96156|
NCT01465425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN 7151|Extracolonic Findings on Computed Tomography (CT) Colonography|Incidence and Significance of Extracolonic Findings on CT Colonography: Retrospective Analysis of "National CT Colonography Trial" Data|ACRIN 7151|American College of Radiology Imaging Network|Yes|Enrolling by invitation|September 2011|April 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|520|||Both|50 Years|N/A|No|Non-Probability Sample|All participants originally enrolled in the ACRIN 6664 National CT Colonography Trial are        eligible for the ACRIN 7151 trial. The target study data set for the ACRIN 7151 trial is        520 participants, assigned to one of three cohorts: an E3/E4 Case Group (n = 141)        excluding pulmonary nodules, an E3/E4 Pulmonary Nodules Case Group (n = 119), and an E1        Control Group (n = 260).|January 2013|January 25, 2013|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01465425||96138|
NCT01465672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COOP Study|Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis|Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis||University Hospital, Basel, Switzerland|Yes|Completed|October 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|15 Years|N/A|No|Non-Probability Sample|Patients undergoing transphenoidal pituitary adenoma resection and patients with        transcranial surgery of tumors close to the pituitary gland and hypothalamus.|May 2014|May 19, 2014|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01465672||96119|
NCT01465932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uspombro01|Effectiveness of Physical Therapy Program to Treat Rotator Cuff Disorders Among Nursing Professionals|Evaluation of the Effectiveness of Physical Therapy Program to Treat Rotator Cuff Disorders Among Nursing Professionals According to Indicators of Quality of Life and Job Satisfaction||University of Sao Paulo|Yes|Completed|July 2010|August 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|60 Years|No|||October 2011|November 4, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01465932||96099|
NCT01466205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0110|Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder|Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder|SPD|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2011|January 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||July 2012|July 19, 2012|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466205||96078|
NCT01466543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2011-05-042|Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity|Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects|SMCZN01|Samsung Medical Center|Yes|Not yet recruiting|November 2011|November 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466543||96052|
NCT01466556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80-2010-HYMC|The Incidence of Metabolic Syndrome Among Obese Children in Our Region|||Hillel Yaffe Medical Center|Yes|Recruiting|November 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|70|||Both|2 Years|18 Years|No|Probability Sample|Children who visit our outpatient clinic or a routine visit to the ER|November 2011|November 7, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466556||96051|
NCT01467076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0046|Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)|Pilot Randomized Clinical Trial of Inhaled PGE1 in Neonates With Sub-Optimal Response to Inhaled Nitric Oxide||NICHD Neonatal Research Network|Yes|Terminated|November 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|7|||Both|N/A|7 Days|No|||July 2015|July 27, 2015|October 17, 2011|Yes|Yes|The study was halted due to futility concerns based on the unmet benchmarks as specified in    the pilot study protocol.|No||https://clinicaltrials.gov/show/NCT01467076||96011|
NCT01465802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471042|Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO|Archer 1042: A Phase 2 Study Of Dacomitinib In Advanced Non-small Cell Lung Cancer (Post-chemotherapy Or Select First Line Patients) To Evaluate Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes|ARCHER 1042|Pfizer|No|Completed|December 2011|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|236|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465802||96109|
NCT01466673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015448|An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment|Comparative Study of the Effect on Acne With Norgestimate Containing Triphasic Oral Contraceptive and Biphasic Preparation Containing Desogestrel||Janssen-Cilag Ltd.,Thailand|No|Completed|December 2008|March 2010|Actual|March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|201|||Female|18 Years|45 Years|No|||June 2013|June 14, 2013|October 24, 2011|Yes|Yes||No|February 22, 2013|https://clinicaltrials.gov/show/NCT01466673||96042|
NCT01467557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005059|Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY|1•DAY ACUVUE® TruEye™ Brand Contact Lenses & 1•DAY ACUVUE® MOIST® Brand Contact Lenses With LACREON® TECHNOLOGY Daily Disposable Performance Overview Registry -TEMPO Study|TEMPO|Johnson & Johnson Vision Care, Inc.|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1171|||Both|8 Years|N/A|No|Non-Probability Sample|Patients who have recently been fit with 1-Day ACUVUE® TruEye™ or 1- Day ACUVUE® MOIST®        daily disposable lenses.|October 2015|October 22, 2015|October 26, 2011|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT01467557||95974|
NCT01467011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Myfortic with Prograf|Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation|An Open-label Study of the Pharmacokinetics of Mycophenolic Acid as Myfortic (Enteric-coated Mycophenolate Sodium) When Used in Combination With Prograf (Tacrolimus) and Corticosteroids in Patients Undergoing de Novo Liver Transplantation||The Methodist Hospital System|No|Completed|December 2010|December 2013|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|Samples Without DNA|Serum will be retained and frozen for MPA levels|Both|18 Years|N/A|No|Probability Sample|Patients with end stage liver disease who are receiving a liver transplant at The        Methodist Hospital in Houston, Texas and who satify the inclusion/exclusion criteria will        be considered for the study.|February 2014|February 21, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01467011||96016|
NCT01467297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1|Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB)|Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB). Multi-centre, Open-label, Randomised, Pilot Study to Evaluate the Effects of the Treatment on Serum Inflammatory Biomarkers||University of Milan|Yes|Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|75 Years|No|||June 2012|June 2, 2012|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01467297||95994|
NCT01467310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1122|Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212|Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Female|18 Years|N/A|No|||January 2016|January 17, 2016|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467310||95993|
NCT01467934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ0504|FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging|FeverText: Assessing Fever Rates After Influenza and Pneumococcal Vaccination During the 2011-12 Influenza Season Using Text Messaging||Columbia University|No|Completed|November 2011|June 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|530|||Both|6 Months|23 Months|No|Non-Probability Sample|6-23 months old visiting study sites|July 2014|July 19, 2014|November 7, 2011||No||No|June 22, 2014|https://clinicaltrials.gov/show/NCT01467934||95946|
NCT01467921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-07-206|Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma|A Randomized Phase II Study of Leucovorin, 5-fluorouracil With or Without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma.||Samsung Medical Center|No|Recruiting|December 2010|||February 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|20 Years|N/A|No|||November 2011|November 14, 2011|November 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01467921||95947|
NCT01468493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGH-1-1|A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients|A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis|SuparSDRF|Guangdong General Hospital|Yes|Recruiting|January 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|||Both|14 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|1)the patients with steroid-sensitive FSGS;2)the cyclosporine A-treated patients with        steroid-dependent and steroid-resistant FSGS;3)the healthy volunteers|February 2016|February 18, 2016|October 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01468493||95903|
NCT01468792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-409 ex 10/11|Hemodynamic Changes in Connective Tissue Disease|Hemodynamic Changes in Connective Tissue Disease||Medical University of Graz|No|Completed|September 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|85|||Both|18 Years|N/A|No|Probability Sample|patients with known systemic sclerosis and without known pulmonary hypertension|February 2014|February 18, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468792||95880|
NCT01465438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUPSA HUM 05-040|HUmira in Psoriatic Arthritis|Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Psoriatic Arthritis Patients Receiving Adalimumab?|HUPSA|Glostrup University Hospital, Copenhagen|Yes|Completed|November 2006|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|80 Years|No|||February 2011|November 3, 2011|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01465438||96137|
NCT01465685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 228/11|Emotional Effects of Methylphenidate and MDMA in Healthy Subjects|Emotional Effects of Methylphenidate and MDMA in Healthy Subjects||University Hospital, Basel, Switzerland|Yes|Completed|December 2011|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01465685||96118|
NCT01465945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEMPEST|Study of Unsutured Versus Sutured Closure of Rectal Defects After Rectal Lesion Excisions Using Transanal Endoscopic Microsurgery|A Randomized Clinical Trial of Open Versus Suture Closure in Patients With Rectal Lesions Excised Using Transanal Endoscopic Microsurgery||St. Paul's Hospital, Canada|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||July 2014|July 19, 2014|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01465945||96098|
NCT01466231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCTSK002|Everolimus in Refractory Testicular Germ Cell Cancer|Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.||National Cancer Institute, Slovakia|Yes|Completed|November 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|N/A|No|||January 2016|January 11, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01466231||96076|
NCT01466530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2|Sublingual Misoprostol & Isoflurane During Caesarean Section|Effects of Preoperative Sublingual Misoprostol on Uterine Tone During Isoflurane Anaesthesia for Caesarean Section||Mansoura University|Yes|Completed|January 2006|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|366|||Female|18 Years|35 Years|No|||November 2011|November 6, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01466530||96053|
NCT01466829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/386|Treatment With PTH After Sternotomy in Cardiac Surgery Patients|Clinical Effects of Parathyroid Hormone as Adjuvant Therapy for Bone Healing After Sternotomy.|PAATH|University of Aarhus|Yes|Completed|October 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Male|50 Years|N/A|No|||August 2013|May 30, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01466829||96030|
NCT01466842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFLIT-PAF 1.2|Ablation as First Line Treatment in Paroxysmal Atrial Fibrillation|Ablation as First Line Treatment in Paroxysmal Atrial Fibrillation|AFLIT-PAF|Maastricht University Medical Center||Not yet recruiting|January 2012|January 2016|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|65 Years|No|||November 2011|November 7, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466842||96029|
NCT01466790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018724|A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients|An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects|COSMOS|Janssen R&D Ireland|Yes|Completed|January 2012|January 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|168|||Both|18 Years|70 Years|No|||January 2015|January 26, 2015|November 3, 2011|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01466790||96033|
NCT01466803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oralbupre|Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects|Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects||Turku University Hospital||Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 27, 2013|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466803||96032|
NCT01467089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-243B|The Assessment of Movement Disorders Utilizing Live Two-Way Video|The Assessment of Movement Disorders Utilizing Live Two-Way Video||Northwell Health|No|Active, not recruiting|November 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|40 patients with schizophrenia will be recruited via in- and outpatient psychiatry service        of The Zucker Hillside Hospital.|September 2015|September 21, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01467089||96010|
NCT01467401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1394|Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes|A Multi-National, Multi-Centre, Randomised, Open-Labelled, Parallel Trial Comparing Efficacy and Safety of NovoMix® 30 FlexPen® and Mixtard® 30 Twice Daily Injections in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|August 2002|May 2003|Actual|May 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|292|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467401||95986|
NCT01465828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESET GENE|Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial|PhaRmacodynamic Effects of Switching thErapy in paTients With High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose Versus Prasugrel RESET GENE Trial|RESET GENE|University of Roma La Sapienza|Yes|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||November 2011|March 24, 2012|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01465828||96107|
NCT01467232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN-CCR-002|IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting|Implantation of Autologous CD133+ Stem Cells in Patients Undergoing CABG|IMPACT-CABG|University Health Network, Toronto|Yes|Completed|September 2011|October 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01467232||95999|
NCT01467245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09SG04|Open or Keyhole Surgery Through the Chest for Newborn Babies: Effect on Blood Gases|Hypercapnia During Thoracoscopy or Open Surgery for Repair of Oesophageal Atresia With Tracheo-oesophageal Fistula or Congenital Diaphragmatic Hernia in Neonates: Pilot Randomised Controlled Trial|The CO2|Great Ormond Street Hospital for Children NHS Foundation Trust||Recruiting|August 2009|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|1 Month|No|||June 2012|June 8, 2012|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01467245||95998|
NCT01466738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018733|A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers|Clinical Characterization of a Human Rhinovirus Type 16 Challenge Pool Following Intranasal Administration to Healthy Adult Subjects||Centocor Ortho Biotech Services, L.L.C.||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01466738||96037|
NCT01467024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-EIA-HTLV-001B|Evaluation of the MP Diagnostics HTLV Blot 2.4|Evaluation of the MP Diagnostics HTLV Blot 2.4||MP Biomedicals, LLC|Yes|Enrolling by invitation|November 2011|June 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|All populations are from whole blood donors.|November 2011|November 7, 2011|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01467024||96015|
NCT01467609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk2319|PillCam Colon Capsule Endoscopy for Ulcerative Colitis|PillCam Colon Capsule Endoscopy Versus Conventional Colonoscopy for the Detection of the Severity and Extent of Ulcerative Colitis||Shanghai Jiao Tong University School of Medicine|No|Completed|July 2009|November 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|regular biopsy was taken during conventional colonoscopy according to the activity and      position of ulcerative colitis involved.|Both|18 Years|70 Years|No|Non-Probability Sample|academic hospital endoscopist of digestive department|November 2011|November 4, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01467609||95970|
NCT01468805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110230|Childhood Asthma Reduction Study|Childhood Asthma Reduction Study||National Institutes of Health Clinical Center (CC)||Withdrawn|September 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|5 Years|14 Years|No|||November 2013|February 19, 2014|September 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01468805||95879|
NCT01468818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110260|Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma|A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma||National Institutes of Health Clinical Center (CC)||Recruiting|September 2011|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|70 Years|No|||December 2015|January 7, 2016|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468818||95878|
NCT01468194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gi-04-2011|Change in Peripheral Oxygen Saturation by Using Different Breathing Procedures in High Altitude|||University of Giessen|No|Completed|July 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 8, 2011|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01468194||95926|
NCT01464931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101361|Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis|An Open-label Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg Administered Subcutaneously in Subjects With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis||Amgen|No|Completed|November 2011|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|October 17, 2011|No|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01464931||96175|
NCT01465191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI2804|Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section|Effect of OPRM1 Genotype on the Dose Response to Spinal Morphine for Post-Cesarean Analgesia||Columbia University|No|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Female|18 Years|45 Years|No|||January 2015|January 15, 2015|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465191||96155|
NCT01465204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1095420|Impact Evaluation of Large-Scale Sanitation and Hygiene Interventions|Impact Evaluation of Large-Scale Sanitation and Hygiene Interventions in Peru, Tanzania, Senegal, Vietnam, Indonesia, and India||Water and Sanitation Program, World Bank||Active, not recruiting|November 2007|July 2012|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|21878|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2011|November 3, 2011|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465204||96154|
NCT01465451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU 5010-2010016 IOCCRC|Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety|A Prospective,Single-center,Randomized,Controlled Phase III Clinical Study Comparing Efficacy and Safety of Intraoperative Chemotherapy With 5-Fluorouracil Plus Curative Resection Versus Surgery Alone for Patients With Colorectal Cancer|IOCCRC|Sun Yat-sen University|Yes|Recruiting|March 2011|December 2019|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1246|||Both|18 Years|75 Years|No|||November 2011|November 3, 2011|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01465451||96136|
NCT01465698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08157|Prevention of Chronic Low Back Pain in Female Nurses|Effectiveness and Financial Feasibility of Neuromuscular Exercise and Counselling Interventions on Pain, Movement Dysfunction, and Fear-avoidance Behaviour in Female Nurses With Non-specific Low Back Pain|NURSE-RCT|UKK Institute|No|Completed|November 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|219|||Female|40 Years|55 Years|No|||January 2016|January 21, 2016|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01465698||96117|
NCT01465958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T5004-401|Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency|An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency|KIDS|Grifols Therapeutics Inc.|No|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|2 Years|16 Years|No|||February 2015|February 23, 2015|October 24, 2011|Yes|Yes||No|January 19, 2015|https://clinicaltrials.gov/show/NCT01465958||96097|
NCT01466218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0618|World Trade Center (WTC) CHEST|Pulmonary Abnormalities, Diastolic Dysfunction, and World Trade Center Exposure: Implications for Diagnosis and Treatment||Icahn School of Medicine at Mount Sinai|Yes|Completed|November 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1012|||Both|40 Years|N/A|No|Non-Probability Sample|World Trade Center rescue and recovery workers and volunteers who are enrolled in the        World Trade Center Health Program-Clinical Center of Excellence, formerly known as the        Medical Monitoring Treatment Program|June 2014|June 27, 2014|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01466218||96077|
NCT01466244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000715505|Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397|PTEN Determination in Squamous Cell Cancer of The Head and Neck Treated on E5397, A Randomized Phase III Trial of Cisplatin Plus Placebo Versus Cisplatin Plus C225 (Cetuximab) in Metastatic/Recurrent Head and Neck Cancer||National Cancer Institute (NCI)||Not yet recruiting|December 2011|||January 2012|Anticipated|Phase 3|Observational|N/A|||Anticipated|42|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466244||96075|
NCT01466257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000715520|Biomarkers in Patients With Head and Neck Cancer|Detection of DNA Mutations in Head and Neck Squamous Cell Carcinoma||National Cancer Institute (NCI)||Not yet recruiting|December 2011|||January 2012|Anticipated|N/A|Observational|N/A|||Anticipated|70|||Both|18 Years|N/A|No|||November 2011|November 2, 2011|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01466257||96074|
NCT01468038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SentraPM102|A Double-blind Placebo Controlled Trial of Sentra PM, a Medical Food|Sentra PM (a Medical Food) and Trazadone in the Management of Sleep Disorders||Targeted Medical Pharma|Yes|Completed|April 2008|December 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|111|||Both|18 Years|75 Years|No|||November 2011|November 8, 2011|November 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468038||95938|
NCT01466816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-3-030|Lipids and Insulin Sensitivity|Skeletal Muscle Lipid Metabolism and Insulin Sensitivity: Can Dietary Fatty Acid Composition Modulate Muscle Lipid Storage?||Maastricht University Medical Center||Completed|October 2008|August 2011|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|10|||Male|35 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 3, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01466816||96031|
NCT01467102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|euCPSP PAIN-OUT|euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT Study|euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT|PAIN-OUT|European Society of Anaesthesiology|No|Completed|July 2011|December 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3618|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patient 18 years old and above Patient from European centres Patient able to fill in        questionnaire on his\her own, unaided (for exception see protocol) Patient is capable of        participating in the CPSP incidence study (i.e. capable to fill the questionnaires on the        website at 6 and 12 months after surgery).        Patient has not undergone repeat surgery (same organ) during current hospitalization.        Patient has undergone a surgery included in the list of surgeries(see list in eligibility        criteria)|July 2014|July 16, 2014|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01467102||96009|
NCT01467115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19834|INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER|INDUCTION CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL FOLLOWED BY CONCOMITANT CETUXIMAB AND RADIATION THERAPY FOR LOCOREGIONALLY ADVANCED SQUAMOUS CELL CANCER OF THE HEAD AND NECK: A PHASE II TRIAL|DREXNECK|Drexel University|Yes|Recruiting|March 2010|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467115||96008|
NCT01466400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-18-F|Fermentation Rate of Infant Formula|||Boys Town National Research Hospital|No|Completed|November 2011|August 2013|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|13|||Both|2 Months|6 Months|Accepts Healthy Volunteers|Probability Sample|Healthy infants.|July 2015|July 21, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466400||96063|
NCT01468441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fert-LG-Doutorado|Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days|Effect of Ovarian Stimulation Using Recombinant FSH and GHRH Antagonist in Alternate Days on ICSI Outcomes|Gonapeptyl|Fertility - Assisted Fertilization Center|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|96|||Female|N/A|35 Years|No|||July 2012|July 12, 2012|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01468441||95907|
NCT01467037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCH-ID-11-01|Vaccine Effectiveness of RV1 in a Naïve Population|Vaccine Effectiveness of RV1 in a Naïve Population||McGill University Health Center|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|374|Samples Without DNA|stool sample|Both|8 Weeks|3 Years|No|Non-Probability Sample|The Montreal Children's Hospital and the CHU Sainte-Justine are the 2 main pediatric        hospitals in Montreal. With these 3 sites, 30% of the Quebec birth cohort will be captured        and, given the concentration of children in the Montreal area, the participating hospitals        will ensure that the study remains efficient in terms of resources. We elected Sherbrooke        as an intermediate area; Montreal will represent an urban population.|December 2015|December 18, 2015|November 4, 2011||No||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01467037||96014|
NCT01467323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA/DCD/038|Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes|An Open-labelled, Randomised, Parallel Group, Multicentre, Multinational Efficacy and Safety Comparison of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30/70 as Meal Related Insulin in a Twice Daily Regimen in Type 1 and Type 2 Diabetic Subjects||Novo Nordisk A/S|No|Completed|April 1998|September 1998|Actual|September 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467323||95992|
NCT01467336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4964|Supra-spinatus Rehabilitation Program Comparison|Prospective Randomized Study Comparing 3 Post-operative Rehabilitation Programs After Arthroscopic Supra-spinatus Tendon Repair||University Hospital, Strasbourg, France|No|Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|294|||Both|40 Years|65 Years|No|||February 2012|February 8, 2012|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01467336||95991|
NCT01468506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPSAC version 17 Jul 2011|Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)|Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)|UPSAC|Baptist Health South Florida|No|Withdrawn|September 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients selected for this protocol must have the necessity to undergo surgery to receive        an Arterio-Venos Fistula (AVF) for hemodialysis in either arm.|September 2014|September 23, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01468506||95902|
NCT01468831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110263|Minocycline to Treat Branch Retinal Vein Occlusion|A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions||National Institutes of Health Clinical Center (CC)||Suspended|September 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|October 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468831||95877|
NCT01464710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080585|Genetic Assessment of Early to Late Macular Degeneration Study|Genetic Assessment of Early to Late macuLar dEgeneration studY 2|GALLEY2|University of California, San Diego|Yes|Completed|April 2008|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|170|Samples With DNA|Specimen collected for genotype analysis.|Both|45 Years|N/A|No|Non-Probability Sample|Subjects with a diagnosis of advanced AMD in one eye (either CNV or geographic atrophy)        and soft confluent drusen in the study eye OR subjects with bilateral large soft drusen.|February 2016|February 18, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464710||96192|
NCT01464671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119778 (IRB ID)|Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention|STATUS-PCI: Stable Angina Therapy With Angiomax® or Unfractionated Heparin for patientS Undergoing Percutaneous Coronary Intervention|STATUS PCI|Stony Brook University|Yes|Terminated|July 2009|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|October 31, 2011|Yes|Yes|DSMB halted the study early due to futility. There were no safety concerns.|No||https://clinicaltrials.gov/show/NCT01464671||96195|
NCT01464684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132624|Body Composition of Infants: Follow-up to Placenta and Cord Blood Analyses|Body Composition of Infants: Follow-up to Placenta and Cord Blood Analyses||University of Arkansas||Withdrawn|October 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood, urine, and a cheek swab may be collected from study participants|Both|3 Months|21 Months|Accepts Healthy Volunteers|Non-Probability Sample|infants age 12 months (+/- 9 months)|April 2012|April 30, 2012|October 31, 2011|No|Yes|determined not enough participants would be able to be enrolled and not enough data collected    for good analyses|No||https://clinicaltrials.gov/show/NCT01464684||96194|
NCT01464697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02975|Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms|Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms||University of British Columbia|Yes|Recruiting|October 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Female|35 Years|58 Years|No|||December 2015|December 10, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01464697||96193|
NCT01437826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST-1988|Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial|Evaluation of the Efficacy of a Combination of Micronutrients (Vitamin A, C, E, Selenium and Zinc) in Reducing the Incidence of Colorectal Metachronous Adenomas. A Double Blind, Phase III, Randomized, Placebo-controlled Trial||IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Terminated|March 1988|June 1996|Actual|June 1996|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|411|||Both|25 Years|75 Years|No|||September 2011|September 19, 2011|September 14, 2011||No|50% of eligible patients refused to enter the study|No||https://clinicaltrials.gov/show/NCT01437826||98240|
NCT01437839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0661019|Food Effect Study For Apixaban Commercial Image Tablets|An Open Label, Randomized, 2-period Crossover Study Evaluating Single Dose Food Effect On Apixaban Commercial Image Tablets In Healthy Subjects||Pfizer|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 21, 2011|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437839||98239|
NCT01437813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLMT13-SIL|BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet Study|Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) After a High Fat Diet, in Healthy Mexican Volunteers|GLMT13|Laboratorios Silanes S.A. de C.V.|Yes|Completed|January 2011|March 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|September 20, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437813||98241|
NCT01438099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18894|Reliability of Ultrasound Assisted Epidural Analgesia in Obese and Normal Weight Parturients|Reliability of Ultrasound Assisted Epidural Analgesia in Obese and Normal Weight Parturients||Università degli Studi dell'Insubria|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|300|||Female|18 Years|50 Years|No|Probability Sample|all women after thirty weeks of pregnancy, experiencing spontaneous or induced labor|August 2013|August 23, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438099||98219|
NCT01438385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104011642|Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders|Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound and Interventional Endoscopy in Pancreatico-biliary, Gastrointestinal and Esophageal Disorders||Weill Medical College of Cornell University|No|Recruiting|July 2011|September 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15000|||Both|18 Years|N/A|No|Non-Probability Sample|Any subject that underwent Interventional Endoscopy for Pancreatico-biliary,        Gastrointestinal or Esophageal disorders.|June 2015|June 1, 2015|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438385||98197|
NCT01438658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-HMO-CTIL|Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma|Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma|UM|Hadassah Medical Organization|No|Recruiting|September 2011|December 2040|Anticipated|December 2040|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|sera from patients|Both|N/A|N/A|No|Non-Probability Sample|All patients diagnosed with uveal melanoma being treated at our center|September 2011|September 27, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01438658||98176|
NCT01440049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRA6140035|Patient's Management Receiving Eplerenone Therapy|Assessment Of Follow-Up Methods For Patients Treated In The Long-Term With A Specific Aldosterone Receptor Antagonist|PERGAME|Pfizer|No|Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|160|||Both|18 Years|95 Years|No|Non-Probability Sample|The following patients may be selected to participate in the survey:          -  Those undergoing treatment with eplerenone in accordance with the MA or not, with a             known start date.          -  Those likely to be followed by the same physician for a minimal period of twelve             months.|December 2012|December 21, 2012|September 14, 2011||No||No|December 21, 2012|https://clinicaltrials.gov/show/NCT01440049||98069|
NCT01440361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114870|A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.|A Clinical and Mechanistic Proof of Efficacy Study With Belimumab in Chronic Immune Thrombocytopenia (ITP) Patients.||GlaxoSmithKline|No|Withdrawn|March 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|0|||Both|18 Years|75 Years|No|||July 2014|July 24, 2014|September 22, 2011||No|This study was Cancelled Before Active|No||https://clinicaltrials.gov/show/NCT01440361||98045|
NCT01440374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114968|A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia|A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)|ASPIRE|GlaxoSmithKline|Yes|Active, not recruiting|September 2011|January 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|163|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440374||98044|
NCT01440387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115418|A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older|A Phase IIIA Study of Immunogenicity and Safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older||GlaxoSmithKline||Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|112|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 29, 2015|September 8, 2011|Yes|Yes||No|September 5, 2013|https://clinicaltrials.gov/show/NCT01440387||98043|
NCT01439529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEST|ECG Optimization of CRT: Evaluation of Mid-term Response|Optimization of Response to Cardiac Resynchronization Therapy by Electrocardiogram: an Assessment of Medium-term Response|BEST|Hospital Clinic of Barcelona|Yes|Recruiting|April 2009|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|99 Years|No|||March 2016|March 15, 2016|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01439529||98109|
NCT01441115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110248|ECI301 and Radiation for Advanced or Metastatic Cancer|Phase I Trial of ECI301 in Combination With Radiation in Patients With Advanced or Metastatic Cancer||National Institutes of Health Clinical Center (CC)||Terminated|September 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||April 2013|February 19, 2014|September 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441115||97988|
NCT01441427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMASU 548/2010|Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial|||Ain Shams University||Completed|January 2010|August 2011|Actual|April 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|93|||Both|N/A|1 Month|No|||September 2011|September 26, 2011|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01441427||97964|
NCT01441076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110241|Anakinra for Behcet s Disease|A Pilot Study of Anakinra in Behcet's Disease (BD)||National Institutes of Health Clinical Center (CC)||Completed|September 2011|November 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||November 2015|November 24, 2015|September 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441076||97991|
NCT01450930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHYSCA-1|Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency|Pharmacokinetics of Hydrocortisone After Subcutaneous Administration Compared With Intramuscular Injection in Chronic Adrenal Insufficiency|PHYSCA|University of Wuerzburg|Yes|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|64 Years|No|||July 2012|July 31, 2012|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450930||97247|
NCT01450943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-04-00618|VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic Foot Ulcers|A Comparative Efficacy Study: Treatment of Non-Healing Diabetic Foot|DOLCE|VA Northern California Health Care System|No|Recruiting|October 2011|October 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|171|||Both|18 Years|85 Years|No|||June 2015|June 15, 2015|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01450943||97246|
NCT01446887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJDVTS|Prophylactic Anticoagulation for Preventing Deep Vein Thrombosis After Total Hip Arthroplasty|Phase II Study of Prophylactic Anticoagulation for Preventing Deep Vein Thrombosis After Total Hip Arthroplasty||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Completed|January 2007|February 2011|Actual|December 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|35 Years|90 Years|No|||October 2011|October 8, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01446887||97556|
NCT01447147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL005_140|A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy||ChemoCentryx|Yes|Completed|October 2011|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|332|||Both|18 Years|75 Years|No|||December 2014|December 12, 2014|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01447147||97536|
NCT01447420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25592|A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)|Clinical Study to Compare Sustained Virological Response in Function of Expression Profile of IL28-b in naïve Patients With Chronic Infection by HCV Genotype 1, With Hepatitis C, Receiving Pegasys and Ribavirin||Hoffmann-La Roche||Completed|February 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|69 Years|No|||December 2015|December 1, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447420||97515|
NCT01441336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBHGS02|Laparoscopic Gastrectomy for Advanced Gastric Cancer|||Seoul National University Bundang Hospital|Yes|Active, not recruiting|November 2008|July 2015|Anticipated|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|20 Years|80 Years|No|||December 2013|December 6, 2013|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01441336||97971|
NCT01441349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-527|Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer|A Randomized Phase II Study of Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer||National Cancer Center, Korea|No|Recruiting|August 2011|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||November 2011|October 18, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01441349||97970|
NCT01441362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_DLT_180|Double-lumen Tube Intubation Technique to Reduce Laryngeal Injuries|A Comparison of Two Methods for Intubation With Double-lumen Endobronchial Tube to Reduce Laryngeal Injuries||Seoul National University Hospital||Completed|September 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|154|||Both|20 Years|75 Years|No|||February 2012|February 16, 2012|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01441362||97969|
NCT01441037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110209|Danazol for Genetic Bone Marrow and Lung Disorders|Male Hormones for Telomere Related Diseases||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2011|March 2020|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|2 Years|N/A|No|||December 2015|December 30, 2015|September 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441037||97993|
NCT01441297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-10-525|BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer|A Phase II Study Of BIBF 1120 as Second-line Treatment for Patients With Small Cell Lung Cancer||National Cancer Center, Korea|No|Recruiting|December 2011|January 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01441297||97974|
NCT01441635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-663|Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids|Phase 2a Proof Of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids||AbbVie|No|Completed|September 2011|February 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|271|||Female|20 Years|49 Years|No|||November 2014|November 25, 2014|September 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441635||97948|
NCT01441622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALMED-10-MD-030|Evaluation of a New Medical Device AL539 in Patients With Obstructive Apneas Sleep Syndrome|In-hospital Assessment of the New Medical Device AL539 Developed for the Home Monitoring of Continuous Positive Airway Pressure (CPAP) Treatment in Patients With Obstructive Sleep Apnea Syndrome by Comparison With Respiratory Polygraphy|AL539|Air Liquide Santé International|No|Completed|June 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01441622||97949|
NCT01438671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1179437|Wii Fit Balance Training Compared to Traditional Balance Training in Patients With SCI/TBI/CVA|Does Wii Fit Balance Training Significantly Improve Standing Balance Compared to Traditional Balance Training and Is Wii Fit Balance Training Preferred Over Traditional Balance Training by Patients With SCI/TBI/CVA?||University of Missouri-Columbia|No|Terminated|September 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|August 2, 2011||No|Facility where study was taking place closed.|No||https://clinicaltrials.gov/show/NCT01438671||98175|
NCT01438684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026011- HMO-CTIL|The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study|Phase 1 Study of RPh201 in Patients With Chronic Vegetative or Minimal Conscious State|RPh-in-CVS|Hadassah Medical Organization||Recruiting|September 2012|October 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|80 Years|No|||August 2015|August 30, 2015|September 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01438684||98174|
NCT01438112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12154|Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer|An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG|BOND|Cold Genesys, Inc.|Yes|Active, not recruiting|March 2014|June 2019|Anticipated|November 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438112||98218|
NCT01438957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-303|Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation|Phase III Randomized Placebo-controlled Double Blind Comparative Study to Investigate the Efficacy and Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation Under Monitored Sedation Care||Hospira, Inc.|No|Completed|June 2011|February 2012|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|120|||Both|20 Years|N/A|No|||November 2015|November 2, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01438957||98153|
NCT01439243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70186|Donepezil 10 mg Tablets Under Fed Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Donepezil (Test) 10 mg Tablet and Aricept® (Reference) Following a 10 mg Dose in Healthy Subjects Under Fed Conditions||Teva Pharmaceuticals USA|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 20, 2011|September 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01439243||98131|
NCT01439542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-220|FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer|FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer|FASTR|Lawson Health Research Institute|Yes|Terminated|September 2011|||December 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|N/A|No|||July 2014|July 22, 2014|September 21, 2011||No|Higher then expected Gr3 GU/GI toxicity|No||https://clinicaltrials.gov/show/NCT01439542||98108|
NCT01439815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-100-0007|An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo|A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model||ORA, Inc.|Yes|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|21|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439815||98087|
NCT01440036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0032-11-ZIV|The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque|The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque||Ziv Hospital|No|Recruiting|October 2011|October 2014|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Atherosclerotic plaque from carotid arteries Blood sample (5cc)|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing CEA|December 2011|December 15, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440036||98070|
NCT01440075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.593|Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease|Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease|Kawasaki|Hospices Civils de Lyon|No|Recruiting|September 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 15, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01440075||98067|
NCT01440400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ch3151105|Ultrasound Guided Spinal Anesthesia in Non Obese Obstetric Patients|The Use of Ultrasound to Guide Spinal Anesthesia in Obstetrics. Is There an Advantage Over Landmark Technique in Non-obese Patients?||Corniche Hospital|Yes|Completed|October 2011|October 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|150|||Female|N/A|N/A|No|||March 2013|March 11, 2013|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440400||98042|
NCT01440621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ModCRF|Modafinil in Cancer Related Fatigue|Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy|ModCRF|Indira Gandhi Medical College||Completed|August 2010|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|217|||Both|18 Years|70 Years|No|||March 2012|March 21, 2012|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01440621||98025|
NCT01441128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110250|-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer|A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)||Terminated|September 2011|February 2015|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||February 2015|February 27, 2015|September 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441128||97987|
NCT01447160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSao Paulo|Effectiveness of Facet Joint Infiltration in Low Back Pain|Effectiveness of Facet Joint Infiltration in Low Back Pain||Federal University of São Paulo|No|Not yet recruiting|October 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||July 2011|October 5, 2011|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01447160||97535|
NCT01447173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VDAS|Vitamin and Asthma Study|||Georgia Regents University||Completed|December 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|7 Years|17 Years|No|||October 2012|October 22, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01447173||97534|
NCT01447433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011Z-02|Effect of Calcium + Vitamin D Supplementation on Weight Management in Very-low Calcium Consumers|A Randomized, Open-label, Parallel Groups-controlled Clinical Trial to Evaluate the Effect of Calcium Plus Vitamin D Supplementation on Weight Management in Overweight and Obese Very-low Calcium Consumers||Changhai Hospital|No|Completed|April 2011|February 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|October 4, 2011||No||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01447433||97514|The study sample was mostly women.
NCT01441323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195-1642394A1|Strength Training and Nutrition Development for African American Youth|USC Center for Transdisciplinary Research on Energetics and Cancer or Obesity-Related Metabolic Disease Risk: Response to Exercise in Minority Youth|STAND|University of Southern California|Yes|Completed|June 2007|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|62|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||September 2011|September 26, 2011|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01441323||97972|
NCT01437852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STRATA2011|StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns|An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting||Stratatech|Yes|Completed|September 2011|October 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||December 2015|December 21, 2015|September 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01437852||98238|
NCT01441921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV11059S|Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus|Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus|EPIRDEM|Institut Investigacio Sanitaria Pere Virgili|No|Recruiting|September 2011|September 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|25 Years|65 Years|No|||September 2011|September 26, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01441921||97926|
NCT01438125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAL-0082|MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures|A Pilot Study to Evaluate the Safety and Preliminary Efficacy of MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures||Halscion, Inc.|No|Completed|February 2009|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|60 Years|No|||March 2013|March 28, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438125||98217|
NCT01438970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-AAR-003|Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function|Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function in Patients With Cirrhosis and Recurrent or Refractory Ascites||Sequana Medical AG|No|Active, not recruiting|September 2011|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||March 2015|June 24, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438970||98152|
NCT01439256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28783|Telehealth & Remote Measurement Technologies to Improve Medication Adherence in Hypertension|Telehealth & Remote Measurement Technologies to Improve Medication Adherence in Hypertension|HTN MedTrack|Boston Medical Center|No|Completed|September 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|207|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01439256||98130|
NCT01439555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13748|Endothelial Facilitation in Alzheimer's Disease|Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.||University of Massachusetts, Worcester|No|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|55 Years|85 Years|No|||January 2016|January 15, 2016|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01439555||98107|
NCT01439568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14242|A Study of LY2510924 in Patients With Extensive-Stage Small Cell Lung Carcinoma|A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide Versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung Carcinoma||Eli Lilly and Company|No|Active, not recruiting|September 2011|March 2016|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439568||98106|
NCT01439828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081120|Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal|Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal|MUCOCRAV|Assistance Publique - Hôpitaux de Paris|No|Not yet recruiting|February 2012|February 2015|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|55 Years|No|||January 2012|January 18, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439828||98086|
NCT01440062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVIDIMS|Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)|Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis||Charite University, Berlin, Germany|No|Active, not recruiting|December 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||January 2016|January 20, 2016|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01440062||98068|
NCT01439841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProGut1.0|The Effect of Probiotics in HIV-1 Infection|The Effect of Probiotics on Microbial Translocation and Immune Activation in HIV-1 Infection. A Randomised Placebo-controlled Trial|ProGut|Oslo University Hospital|No|Recruiting|October 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01439841||98085|
NCT01440088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-406/SARC021|A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma|A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma||Threshold Pharmaceuticals|Yes|Active, not recruiting|September 2011|April 2015|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|620|||Both|15 Years|N/A|No|||March 2014|March 6, 2014|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440088||98066|
NCT01440634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0830128N|Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.|Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.||University of Texas Southwestern Medical Center|No|Completed|February 2008|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|347|||Both|70 Years|N/A|No|||November 2015|November 30, 2015|September 22, 2011||No||No|March 8, 2013|https://clinicaltrials.gov/show/NCT01440634||98024|This study was limited by the lack of patients compliance to follow the schedule for the exercise sessions. Patients did not assisted regularly to the walking sessions, and the schedule was completed in 70 % of the plan.
NCT01440933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 10-093|Efficacy of Sugammadex in Magnesium Pretreated Patients|Efficacy of Sugammadex for the Reversal of Moderate and Deep Rocuronium Induced Neuromuscular Block in Patients Pretreated With Magnesium Sulphate|MagSug|University Hospital, Geneva|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|60 Years|No|||July 2012|July 6, 2012|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01440933||98001|
NCT01440855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB06803|Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting|Efficacy and Feasibility of a Psychosocial Intervention Within CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment (CCOP:Community Clinical Oncology Program)||Fox Chase Cancer Center|Yes|Completed|February 2005|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|340|||Both|18 Years|N/A|No|||September 2011|September 30, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440855||98007|
NCT01440868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-2011|Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome|SLI STUDY: Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome. A RCT Study|SLIS|University of Florence|Yes|Not yet recruiting|October 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|276|||Both|N/A|15 Minutes|No|||September 2011|September 26, 2011|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01440868||98006|
NCT01446900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S523/110|R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma|Rituximab-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma||European Institute of Oncology|No|Terminated|January 2011|December 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|June 15, 2011||No|low rate in patient accrual|No||https://clinicaltrials.gov/show/NCT01446900||97555|
NCT01447186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0747|Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men|Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2012|||September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Male|45 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The target population is Spanish-speaking Hispanic males, over 45 who have no personal        history of prostate cancer who are or will soon be candidates for screening.|February 2016|February 15, 2016|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01447186||97533|
NCT01447680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-2011-HIV, Version 4|Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing|Clinical Trial Comparing Two Types of Blood Samples (Plasma and SMARTplasma) for HIV and HCV Antibody Testing||G & W Laboratories Inc.|No|Completed|August 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|1600|Samples Without DNA|Plasma and SMARTplasma (SMARTplasma is plasma sample from whole blood treated with      SMARTstim)|Both|18 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Laboratory Sample from low risk population (i.e., blood donors), high risk population and        known positive patients.|September 2015|September 4, 2015|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01447680||97495|
NCT01447953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALAR-2009RS|Activity and Life-role Targeted Pain Rehabilitation in Primary Health Care|Activity and Life-role Targeted Pain Rehabilitation in Primary Health Care: a Randomized Controlled Trial||Uppsala University|No|Terminated|October 2011|June 2015|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|60 Years|No|||December 2015|December 14, 2015|September 9, 2011||No|Organizational changes in health care made further recruitment to the treatment options    unpossible.|No||https://clinicaltrials.gov/show/NCT01447953||97474|
NCT01441934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARC209|SPHERIC-1. Sildenafil and Pulmonary HypERtension In COPD|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Sildenafil in the Treatment of Patients With Pulmonary Hypertension Associated to Chronic Obstructive Lung Disease|SPHERIC-1|Italian Association of Hospital Pneumologists|Yes|Recruiting|October 2010|February 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|80 Years|No|||February 2013|February 1, 2013|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01441934||97925|
NCT01441648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-IRB-007-XD|Influence of Cosmetic Color Tinted Contact Lenses on the Ocular Surface|Influence of Cosmetic Color Tinted Contact Lenses on the Ocular Surface||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|20 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3)        previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria        includes: (1) subjects with previous Rigid Gas Permeable wear (2) any ocular inflammation        or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication        instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.|December 2011|January 17, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01441648||97947|
NCT01438138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML11B12|Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia|Validation of a Classifier for the Prediction of Risk of Relapse Using Single Cell Network Profiling (SCNP) Assays for Childhood AML||Children's Oncology Group|No|Active, not recruiting|September 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|98|Samples With DNA|bone marrow|Both|N/A|21 Years|No|Non-Probability Sample|Patients with confirmed non-M3 acute myeloid leukemia treated on COG-AAML03P1 or        COG-AAML0531 protocols|May 2015|May 5, 2015|September 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01438138||98216|
NCT01438398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10035|Efficacy & Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) in the Treatment of Patients With Achalasia|A Prospective, Single Center, Proof of Concept Pilot Study of the Efficacy and Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) Technique in the Treatment of Patients With Achalasia||Winthrop University Hospital|Yes|Recruiting|January 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01438398||98196|
NCT01439269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD0389|Family Nurture Intervention (FNI) in Neonatal Intensive Care Unit (NICU)|Enhancement of Co-regulation Between Mother and Infant Via Family Nurture Intervention (FNI) in the NICU: Short and Long Term Effects on Development||Columbia University|No|Recruiting|June 2008|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|26 Weeks|34 Weeks|No|||February 2016|February 19, 2016|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01439269||98129|
NCT01439282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7389-A001-212|Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer|A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer||Eisai Inc.||Completed|August 2011|July 2014|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|September 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01439282||98128|
NCT01439295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Montreal|Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia|Urinary Ascorbyl Peroxide as an Early Biological Marker of Bronchopulmonary Dysplasia in Preterm Infants Less Than 33 Weeks of Gestation||St. Justine's Hospital|No|Completed|August 2010|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|Samples With DNA|Urine sample (650 µl) Blood sample (500 µl)|Both|23 Weeks|32 Weeks|No|Non-Probability Sample|Preterm infants less than 33 weeks of getation|November 2015|November 17, 2015|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01439295||98127|
NCT01439308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111925|Intranasal SB-705498 in Non-allergic Rhinitis Patients|A Randomized, Double Blind, Placebo Controlled Study to Assessthe Effect of Intranasal Single Dose SB-705498 on the Response Tointranasal Capsaicin Challenge in Non-allergic Rhinitis Patients||GlaxoSmithKline|No|Completed|December 2009|April 2010|Actual|April 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||March 2012|March 22, 2012|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01439308||98126|
NCT01439581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Interface Pressure Mapping|Utility of Interface Pressure Mapping|||Henry Ford Health System|No|Completed|August 2011|September 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|216|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01439581||98105|
NCT01439594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000793|Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation|Pilot Study to Evaluate Optical Frequency Domain Imaging as a Tool for Assessing the Tissue Response to Radiofrequency Ablation|OFDI|Massachusetts General Hospital|No|Completed|October 2008|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439594||98104|
NCT01440426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGOPerio 11-01|Connective Tissue Graft Versus Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects|Connective Tissue Graft vs Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects Randomized Controlled Clinical Trial Assessing Superiority in Health Related Quality of Life and Non-Inferiority in Root Coverage||The European Research Group on Periodontology (ERGOPerio)|No|Recruiting|September 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|70 Years|No|||September 2011|September 23, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440426||98040|
NCT01440114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSUEA1|The Effect of Intravenous Fentanyl Prior the End of Surgery on Emergence Agitation in Paediatric Patients After General Anesthesia|The Effect of Intravenous Fentanyl Prior the End of Surgery on Emergence Agitation in Paediatric Patients After General Anesthesia||Prince of Songkla University|No|Completed|March 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|144|||Both|2 Years|9 Years|No|||September 2011|September 22, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440114||98064|
NCT01440660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2011-01|Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)|Phenotypes of Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Patients Identified by Optical Coherence Tomography, Colour Fundus Photography, Fluorescein Leakage and Multifocal Electrophysiology (DIAMARKER Project: Genetic Susceptibility for Multi-systemic Complications in Diabetes Type-2: New Biomarkers for Diagnostic and Therapeutic Monitoring).||Association for Innovation and Biomedical Research on Light and Image|No|Completed|January 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of 20 patients, male and female over 18 years-old, with        type-2 diabetes mellitus and NPDR with signs of DR progression (RT increase and/or MA        turnover) (according to the inclusion/exclusion criteria).|October 2015|October 7, 2015|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440660||98022|
NCT01440413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREAST IMMUN|Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer|Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer|BREAST IMMUN|Centre Leon Berard|No|Active, not recruiting|December 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Female|18 Years|N/A|No|||October 2014|October 29, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01440413||98041|
NCT01440881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70-2010|Does Nesiritide Provide Renal Protection|Does Nesiritide Provide Renal Protection By Attenuating the Inflammatory Response||University of Florida|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|37|||Both|18 Years|80 Years|No|||May 2014|May 16, 2014|February 10, 2011|Yes|Yes||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01440881||98005|
NCT01440894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TranstekGBFA11003|Clinical Trail of Transtek Glass Body Fat Analyzer|Verify the Functions and Efficiency of Transtek Glass Body Fat Analyzer, GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, GBF-950-D.|GBFA|BTS International|No|Completed|February 2011|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The subject population included patients whose age is above 18 years old. Male or Female.|September 2011|September 25, 2011|September 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01440894||98004|
NCT01447199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM94-060|The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)|The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)||M.D. Anderson Cancer Center|No|Recruiting|September 1994|||September 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Anticipated|2000|Samples With DNA|Participants will have a single sample (8-10 teaspoons) of blood collected at M. D.      Anderson, depending upon current health status. In the case of individuals not coming to the      clinic, a blood drawing kit will be sent to the participant's home, which will include      instructions and a postage-paid return express mail envelope. If participant unable or      unwilling to give a blood sample, saliva samples can be collected instead.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Referrals from Departments of GI Oncology, GI Medicine and Nutrition, GI Surgery, GYN        Oncology, Cancer Prevention and from the Genetic Counselors at UT MD Anderson Cancer        Center, families and spouses.|February 2016|February 18, 2016|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447199||97532|
NCT01447446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV25599|An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C|Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C||Hoffmann-La Roche||Completed|September 2011|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4429|||Both|18 Years|N/A|No|Probability Sample|Chronic hepatitis C patients (naïve or treatment experienced and HIV HCV co-infected)        receiving combination therapy with pegylated interferons plus ribavirin or treatment        regimens containing direct-acting antivirals|March 2016|March 1, 2016|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447446||97513|
NCT01447693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130/06|Treatment of Uremic Pruritus by Olive-omega 3 Ointment|||Assaf-Harofeh Medical Center|No|Not yet recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|20|||Both|18 Years|90 Years|No|||October 2011|October 5, 2011|December 31, 2007||||No||https://clinicaltrials.gov/show/NCT01447693||97494|
NCT01447706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-121-04-02-08 (ARD11586)|A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers|A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers||Merrimack Pharmaceuticals|No|Active, not recruiting|October 2011|April 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Female|18 Years|N/A|No|||June 2013|June 18, 2013|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01447706||97493|
NCT01448252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCV-HMO-CTIL|T Cell Vaccination in Patients With Progressive Multiple Sclerosis|Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis||Hadassah Medical Organization|No|Completed|May 2002|March 2009|Actual|September 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||October 2011|October 6, 2011|October 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01448252||97451|
NCT01437878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-063B201|Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Inhaled Iloprost on Endurance Time During Cardiopulmonary Exercise Testing in Patients With Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease||Actelion|No|Terminated|March 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|40 Years|75 Years|No|||October 2015|October 16, 2015|September 20, 2011|Yes|Yes|low recruitment|No|December 12, 2014|https://clinicaltrials.gov/show/NCT01437878||98236|
NCT01437865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2-016|Gadofosveset for Axillary Staging in Breast Cancer Patients|Non-invasive Nodal Staging in Breast Cancer With MRI Lymphography Using Gadofosveset; a Pilot-study||Maastricht University Medical Center|No|Completed|September 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Female|18 Years|N/A|No|||April 2012|April 5, 2012|September 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01437865||98237|
NCT01438424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-901|Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials|A Preliminary Assessment of Safety and Antiviral Activity of Open-label Entecavir in Subjects With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials||Bristol-Myers Squibb|No|Completed|January 2001|April 2011|Actual|December 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1053|||Both|16 Years|N/A|No|||July 2012|July 19, 2012|September 16, 2011|Yes|Yes||No|June 12, 2012|https://clinicaltrials.gov/show/NCT01438424||98194|
NCT01438411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAC-002-01|Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis|An Open Label, Single Center, Nonrandomized Continuation Study of Cholic Acid Capsules to Treat Subjects With Inborn Errors of Bile Acid Synthesis||Retrophin, Inc.|No|Active, not recruiting|January 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|N/A|No|||April 2015|October 26, 2015|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438411||98195|
NCT01438697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15704|An Interactive Internet Intervention for Adults With Insomnia|An Internet Intervention for Insomnia: Efficacy and Dissemination|SHUTi|University of Virginia|Yes|Completed|October 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|303|||Both|21 Years|65 Years|No|||January 2016|January 7, 2016|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438697||98173|
NCT01438710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro 3003|Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)|Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)|STRATO|Veloxis Pharmaceuticals|No|Completed|December 2011|July 2015|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|65 Years|No|||September 2015|September 15, 2015|September 20, 2011|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01438710||98172|
NCT01438983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uni43|Oral Candida in Infants and Dietary Type|Evaluation the Effect of Dietary Type on Oral Candida Carriage in Infants||Shahid Sadoughi University of Medical Sciences and Health Services|Yes|Completed|July 2009|June 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|90|Samples With DNA|infants with unremarkable health histories, normal weight, free of sign or symptom of oral      candidiasis or other mucosal disease.their mothers were also healthy and without sign or      symptom of vagina or mammary candidiasis.|Both|1 Month|24 Months|Accepts Healthy Volunteers|Non-Probability Sample|The investigators evaluated 90 infants in 1-24 months (45 breastfeeding and 45 bottle        feeding infants) who attended to Yazd nikoopur clinic for regular pediatric appointment.|September 2011|September 21, 2011|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01438983||98151|
NCT01439854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 R01 DK024092-27/NIH Prot IV|Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action|Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM|DAPA MITO|The University of Texas Health Science Center at San Antonio|No|Recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|70 Years|No|||January 2016|January 11, 2016|August 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439854||98084|
NCT01440101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS203|Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)|Multicenter Study of BG00002 in Japanese Subjects With RRMS, Consisting of a Multiple-Dose, Open-Label Evaluation of Its Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part A) and a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Evaluation of Safety and Efficacy (Part B)|Tysabri Japan|Biogen|Yes|Completed|November 2010|August 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|106|||Both|18 Years|65 Years|No|||October 2014|October 20, 2014|April 14, 2011|No|Yes||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01440101||98065|
NCT01440127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin CCSC|Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers|Randomized Clinical Trial Evaluating the Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers||Tufts Medical Center|Yes|Terminated|August 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|79 Years|No|||March 2015|March 25, 2015|September 21, 2011|Yes|Yes|Unable to accrue all planned subjects in a timely fashion, but data collected will still be    analyzed.|No||https://clinicaltrials.gov/show/NCT01440127||98063|
NCT01440673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2085|Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy|||Gachon University Gil Medical Center|Yes|Completed|March 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Female|21 Years|60 Years|No|||September 2011|September 23, 2011|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440673||98021|
NCT01440686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGR10I_1|Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers|A Dose Block-randomized, Double-blinded, Placebo-controlled, Single-dose, Dose-escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of HL-032 in Healthy Male Volunteers|HL-032|HanAll BioPharma Co., Ltd.|Yes|Completed|September 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|40|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 15, 2012|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01440686||98020|
NCT01440907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C023699-22|Study of the Impact of a Hospital Discharge Care Coordination Program in an Elderly Population|The Effect of an HIE-Supported Care Coordination Package on Hospital Re-Admission Rates in an Elderly Population||Weill Medical College of Cornell University|No|Active, not recruiting|May 2011|July 2013|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1800|||Both|65 Years|N/A|No|||December 2012|December 20, 2012|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01440907||98003|
NCT01441141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110252|Genetics and Pain Severity in Sickle Cell Disease|Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Recruiting|September 2011|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|August 18, 2015|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01441141||97986|
NCT01441154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110256|Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment|Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone||National Institutes of Health Clinical Center (CC)||Completed|September 2011|||||Phase 1|Observational|Time Perspective: Prospective|||Actual|16|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01441154||97985|
NCT01441167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110257|Experimental PfSPZ Vaccine in Adults Without Malaria|VRC 312: A Phase 1, Open-Label, Dose-Escalation Clinical Trial With Experimental Challenge to Evaluate Intravenous Administration of the PfSPZ Vaccine in Malaria-Naive Adults||National Institutes of Health Clinical Center (CC)||Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|64|||Both|18 Years|45 Years|No|||June 2013|August 6, 2014|September 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441167||97984|
NCT01447459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asthma IHOP - 2011|Effects of Educational Intervention on Long-Term Outcomes of Hospitalized Children With Asthma|Effects of Educational Intervention on Long-Term Outcomes of Hospitalized Children With Asthma|IHOP|University of Louisville|No|Completed|February 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|144|||Both|5 Years|12 Years|No|||July 2012|May 22, 2013|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01447459||97512|
NCT01447719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A16|Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07|Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07||Avid Radiopharmaceuticals|No|Completed|March 2010|July 2011|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|110|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|May 20, 2011|Yes|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01447719||97492|
NCT01447966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YC-OCD|Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder|Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder||University of South Florida|Yes|Completed|May 2011|March 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|3 Years|8 Years|No|||March 2014|March 24, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01447966||97473|
NCT01448551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F022685-1|MPOWERed Messages: Tailored Mobile Messages to Enhance Weight Loss for Teens|Novel Individually Tailored Mobile Messages to Enhance Weight Loss for Teens||University of Michigan|No|Active, not recruiting|October 2011|January 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|12 Years|18 Years|No|||November 2015|November 30, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448551||97428|
NCT01437891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWF001|Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)|An Open-label Clinical Outcomes Study to Determine the Safety and Efficacy of Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder and Gulf War Fibromyalgia|GWF001|Targeted Medical Pharma|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Male and female military veterans age 18 to 75 experiencing moderate to severe PTSD        symptoms including cognitive dysfunction, sleep disorders and mood disorders.|February 2012|February 2, 2012|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437891||98235|
NCT01438151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0693|Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease|Association of Serum Infliximab and Antibodies Toward Infliximab (ATI) to Clinical Outcomes in Crohn's Disease||Icahn School of Medicine at Mount Sinai|No|Terminated|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|7 Years|N/A|No|||March 2014|March 4, 2014|September 20, 2011|Yes|Yes|terminated due to poor enrollment|No|January 6, 2014|https://clinicaltrials.gov/show/NCT01438151||98215|Study was terminated without completion due to poor enrollment.
NCT01438164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP0460/05|Cost-effectiveness of FDG-PET|Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET||University of Sao Paulo|No|Completed|June 2005|September 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|13 Years|N/A|No|Non-Probability Sample|500 oncologic patients|September 2011|September 20, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438164||98214|
NCT01438723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetCAB|The Metformin in Coronary Artery Bypass Graft (CABG) (MetCAB) Trial|The Metformin in CABG (MetCAB) Trial|MetCAB|Radboud University|Yes|Completed|November 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||November 2011|July 28, 2014|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438723||98171|
NCT01438996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H01_04E1TP|Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults|A Phase 2, Open-label, Single-center, Extension Study to Evaluate the Booster Response Induced by Vi-CRM197 After Priming With Either Vi-CRM197 or Typherix Administered in Adult Subjects in H01_04TP Study (NCT01193907)||Novartis|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|51|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||February 2014|February 4, 2014|September 19, 2011||No||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01438996||98150|
NCT01439009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-10-005|Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients|A Multi-center,_double-blind,_pararel-group Comparison Trial to Investigate the Effect of Short-term Administration of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients (Phase_4 Study)||Otsuka Pharmaceutical Co., Ltd.|No|Completed|September 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|20 Years|85 Years|No|||July 2014|July 9, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01439009||98149|
NCT01439321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113922|Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim|Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim||GlaxoSmithKline|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|280|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will include adult patients with a diagnosis of immune (idiopathic)        thrombocytopenic purpura (ITP) who switched to eltrombopag or romiplostim.|June 2012|June 21, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439321||98125|
NCT01439607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081102|Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease|Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells, Macrophages and Plasma Cell Biology in Gaucher Disease.|MGMC|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2009|March 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|N/A|No|||April 2014|May 22, 2014|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01439607||98103|
NCT01439334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-U-689|Multiple Behavior Screening, Brief Intervention and Referral to Treatment (SBIRT) Model of Drug Abuse in Primary Care|Multiple Behavior SBIRT Model of Drug Abuse in Primary Care|SBIRT|University of Florida|Yes|Withdrawn|December 2009|July 2011|Anticipated|June 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|0|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||September 2011|September 21, 2011|July 22, 2010||No|PI left UF|No||https://clinicaltrials.gov/show/NCT01439334||98124|
NCT01439620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-000794|Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging|Pilot Study to Evaluate Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging||Massachusetts General Hospital|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|75 Years|No|||April 2015|April 16, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439620||98102|
NCT01439867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110100|Safety & Tolerability of Cinacalcet in Pediatric Subjects With Chronic Kidney Disease & Secondary Hyperparathyroidism|An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis||Amgen|No|Recruiting|June 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|2189 Days|No|||January 2016|January 13, 2016|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439867||98083|
NCT01440712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ileus_gastro|Study of the Effect of Water Soluble Oral Contrast (Gastrografin) on Postoperative Ileus After Colorectal Surgery|Prospective Randomized Double Blind Study of the Effect of Gastrografin on Postoperative Ileus After Colorectal Surgery||Hospital Universitari de Bellvitge|Yes|Completed|December 2011|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|58|||Both|18 Years|N/A|No|||July 2014|July 12, 2014|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01440712||98018|
NCT01440920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311-10-001|A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients|A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia||Otsuka Pharmaceutical Co., Ltd.|No|Completed|September 2011|July 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|60 Years|N/A|No|||November 2013|November 10, 2013|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01440920||98002|
NCT01441180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110258|GS-7977 With Ribavirin for Hepatitis C (SPARE)|A Randomized Controlled Study To Assess Safety, Tolerability And Efficacy Of GS-7977 In Combination With Full or Low Dose RBV In HCV Genotype 1, Monoinfected Treatment Naive Participants||National Institutes of Health Clinical Center (CC)|No|Completed|September 2011|July 2014|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|September 24, 2011|Yes|Yes||No|April 23, 2014|https://clinicaltrials.gov/show/NCT01441180||97983|
NCT01447472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIMFTCL/MDMA/6|-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms|Human Study of the Metabolic Changes Induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in the Metabolism of Dextromethorphan and Caffeine||Parc de Salut Mar|No|Completed|May 2003|May 2011|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 5, 2011|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01447472||97511|
NCT01447485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489K1101|Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients|A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age||Novartis||Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|6 Years|14 Years|No|||May 2012|May 6, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01447485||97510|
NCT01447732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP-37250/KHK2804-001|Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors|Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|October 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01447732||97491|
NCT01447745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MOP-114920|Abdominal Fat and Imaging Measurements of Heart Disease|Visceral Obesity/Ectopic Fat and Non-invasive Markers of Atherosclerosis: A Cardiometabolic-cardiovascular Imaging Study||Laval University|No|Recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Whole blood, serum, plasma, white cells|Both|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Random sample of adult men and women representative of the population of asymptomatic        adult men and women aged from 35-65 years living in the Québec City metropolitan area|November 2015|November 26, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01447745||97490|
NCT01447979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01096-35|Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Montpellier|Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing|HomeCTR1_1|University of Virginia|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|21 Years|65 Years|No|||November 2012|November 28, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01447979||97472|
NCT01447992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2433P|Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Padova|Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing|HomeCTR1_2|University of Virginia|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|65 Years|No|||June 2014|June 17, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01447992||97471|
NCT01448577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-AMT-011-03|Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies|A Clinical Records Review Study of the Frequency and Severity of Acute Abdominal "Pancreatitis" Episodes Reported From LPLD Subjects Previously Recruited to Clinical Studies PREPARATION-02, CT-AMT-011-01 and CT-AMT-011-02||Amsterdam Molecular Therapeutics|No|Enrolling by invitation|November 2010|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who previously enrolled in studies PREPARATION-02 (observational), CT-AMT-011-01        and CT-AMT-011-02|October 2011|October 6, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01448577||97426|
NCT01437904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCNL Beiko|A Pilot Study Assessing The Feasibility Of Outpatient Tubeless Percutaneous Nephrolithotomy (PCNL)|A Pilot Study Assessing The Feasibility Of Outpatient Tubeless Percutaneous Nephrolithotomy (PCNL)||Queen's University|No|Completed|March 2011|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01437904||98234|
NCT01437917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/11-05 - NOMAC|NOMAC : New Tools for Managing the Fate of Cereal Nutrients in the Gut : Effects of Amylose Content on Glycemic Index.|NOMAC : New Tools for Managing the Fate of Cereal Nutrients in the Gut : Effects of Amylose Content on Glycemic Index.|NOMAC|Rennes University Hospital|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|10|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01437917||98233|
NCT01438177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU# 10-02008|Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma|A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma||New York University School of Medicine|Yes|Completed|October 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|September 8, 2011|Yes|Yes||No|May 14, 2015|https://clinicaltrials.gov/show/NCT01438177||98213|
NCT01438437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-16/11/2001|Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis|||All India Institute of Medical Sciences, New Delhi|No|Recruiting|March 2001|September 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|12 Years|70 Years|No|||July 2012|July 12, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438437||98193|
NCT01438450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMR- D.O No.5/8/7/26/99-ECD-1|Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma|RCT Of Oral Thalidomide And Capecitabine Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (BCLC D)|OTCHCC|All India Institute of Medical Sciences, New Delhi|No|Recruiting|October 2007|September 2014|Anticipated|August 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|12 Years|70 Years|No|||July 2012|July 12, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438450||98192|
NCT01438736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2011-001492-39|Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?|A Randomized Study to Evaluate the Predictive Impact of Using Cerazette Progestin Only Pill Before Nexplanon Insertion Regarding Bleeding Pattern||VL-Medi Oy||Not yet recruiting|September 2011|||November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|90|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2011|September 21, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438736||98170|
NCT01439022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSG_EXPD_11/SC/0267|Exercise Interventions in Parkinson's Disease|Longer-term Exercise Interventions in People With Parkinson's Disease||Oxford Brookes University|No|Completed|September 2011|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01439022||98148|
NCT01439347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTX404|A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL|Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)||Spectrum Pharmaceuticals, Inc|No|Terminated|March 2012|August 2017|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|60 Years|N/A|No|||April 2015|April 23, 2015|September 20, 2011|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01439347||98123|
NCT01439880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110110|Open Label Study of Long Term Evaluation Against LDL-C Trial|A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)|OSLER|Amgen|No|Active, not recruiting|October 2011|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1324|||Both|18 Years|75 Years|No|||January 2016|January 29, 2016|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439880||98082|
NCT01439893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-01-303|Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure||Zensun Sci. & Tech. Co., Ltd.|Yes|Terminated|June 2011|December 2012|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|75 Years|No|||July 2012|August 1, 2012|September 21, 2011||No|Sponsor has designed another study with different endpoint to replace the current study|No||https://clinicaltrials.gov/show/NCT01439893||98081|
NCT01440140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANGELA03|Closing the Loop in Adults With Type 1 Diabetes in the Home Setting|An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Real-time Continuous Subcutaneous Glucose Monitoring Combined With Overnight Closed-loop Glucose Control in the Home Setting in Comparison With Real-time Continuous Subcutaneous Glucose Monitoring Alone in Adults With Type 1 Diabetes on Subcutaneous Insulin Infusion Pump Therapy||University of Cambridge|Yes|Completed|December 2012|January 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||January 2014|January 28, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01440140||98062|
NCT01440153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZA-DRCT-2011|Additional Exercise Program in Professional Dancers|Influence of an Additional Intervention Targeting Physical Fitness, Endurance and Motor Control, on Physical Condition and Musculoskeletal Injuries in Contemporary Dancers||University College of Antwerp|No|Active, not recruiting|September 2009|November 2011|Anticipated|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Both|17 Years|27 Years|Accepts Healthy Volunteers|||September 2011|September 23, 2011|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01440153||98061|
NCT01440166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-1004-101|Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers|A Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers||Catabasis Pharmaceuticals|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|9||Actual|52|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440166||98060|
NCT01440465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVI|Management of Nausea and Vomiting Chemotherapy-induced in Normandy|Management of Nausea and Vomiting Chemotherapy-induced in Normandy|NAVI|Centre Francois Baclesse|Yes|Completed|July 2011|February 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with first line chemotherapy with intravenous (IV) to solid tumors or        hematologic.|February 2013|February 7, 2013|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01440465||98037|
NCT01440478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12322|The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects|Impact of Variations in Urinary pH on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects||Eli Lilly and Company|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 7, 2011|August 31, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01440478||98036|
NCT01440439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXQ425|Comparing Long-acting Insulins During Exercise in Type 1 Diabetes|Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes||Buckinghamshire Healthcare NHS Trust|No|Recruiting|November 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||November 2011|November 7, 2011|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440439||98039|
NCT01440699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALLO-ASC-101|Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula|Phase I Study of Dose Escalation of Human Allogenic Adipose-derived Stem Cells (ALLO-ASC) to Evaluate Safety and Efficacy in Patients With Crohn's Fistula|ALLO-ASC|Anterogen Co., Ltd.|Yes|Recruiting|September 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|60 Years|No|||September 2011|September 23, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01440699||98019|
NCT01441206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-2314|Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants|Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants||University of North Carolina, Chapel Hill|Yes|Terminated|September 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|2|||Both|N/A|121 Days|No|||September 2012|September 13, 2012|September 19, 2011|No|Yes|Study to be redesigned.|No||https://clinicaltrials.gov/show/NCT01441206||97981|
NCT01447758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 29102-C26|Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.|Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. A Multicentre, Prospective, Randomised Phase Ib Study in Subjects Investigating Safety,Tolerability and Pharmacokinetics of LEO 29102 Cream (2.5 mg/g) When Treating Atopic Dermatitis Lesions Twice Daily for 7 Days (Cohorts I, II and III) and 6 Weeks (Cohort IV)||LEO Pharma|No|Terminated|September 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|65 Years|No|||April 2013|April 30, 2013|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01447758||97489|
NCT01448005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90D0107|LifeVest Post-CABG Registry|Post-market Release Registry of Wearable Defibrillator Use in Patients With Ventricular Dysfunction Following CABG Surgery||Zoll Medical Corporation|No|Terminated|February 2011|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|69|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone CABG surgery during current hospitalization and have an        ejection fraction ≤ 35% following the surgery.|December 2014|December 12, 2014|October 4, 2011|No|Yes|Enrollment|No||https://clinicaltrials.gov/show/NCT01448005||97470|
NCT01448863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005-C-070-JB|Metabolomic Embryo Profiles of Obese in Vitro Fertilization (IVF) Patients and Their Relationship With Polycystic Ovary Syndrome (PCO)|||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|October 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|28|||Both|18 Years|38 Years|Accepts Healthy Volunteers|Probability Sample|45 women divided into three groups: A)15 Obese women without Polycystic Ovarian Syndrome:        BMI > 30 kg/m2 , age < 38 years old, normal basal hormonal profile (FSH, LH, estradiol,        testosterone, androstenedione, insulin, SHBG, glucose, AMH, and antral follicle count(> 5        FA for each ovary), menses every 25-35 days.        B)15 Obese women with Polycystic Ovarian Syndrome: BMI > 30 kg/m2, age < 38 years old,        basal hormonal profile with or without hyperandrogenism and ultrasound ovary aspect of        PCO.        C)15 Fertile women (egg-donors): BMI 20-24.9 kg/m2. All the patients have normal uterine        conditions, are not smokers, without endometriosis or hidrosalpinx. All the male partners        have sperm parameters: count(> 5 mill/ml,15% motility,> 0% normal morphology)and BMI < 28        kg/m2.|March 2015|March 9, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448863||97404|
NCT01449188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115458|To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects|A Randomized, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous Ondansetron, a 5-HT3 Antagonist, on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects.||GlaxoSmithKline|No|Completed|August 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|58|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449188||97380|
NCT01448265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRYO-MAP|Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter|Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter|CRYO-MAP|Heidelberg University|No|Completed|September 2011|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||July 2013|July 24, 2013|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01448265||97450|
NCT01448278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR112010|Pain Evaluation After Anterior Cruciate Ligament (ACL) Ligamentoplasty|Pain Evaluation After ACL Ligamentoplasty: "All-inside" Versus Classical Technique. A Prospective Randomised Comparative Study||Hospital Ambroise Paré Paris|No|Completed|November 2010|April 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01448278||97449|
NCT01438203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walsh 10-24|Thrust Manipulation Versus Non-Thrust Manipulation|Early Use of Thrust Manipulation Versus Non-Thrust Manipulation: A Randomized Clinical Trial||Walsh University|No|Completed|February 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|149|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01438203||98211|
NCT01438190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/2011|Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF|A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization||University of Modena and Reggio Emilia|No|Active, not recruiting|June 2013|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|35 Years|No|||July 2013|July 11, 2013|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01438190||98212|
NCT01438749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25259|A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users|Human Abuse Liability Study in Recreational Drug Users to Investigate the Abuse Liability Potential of RO4917838||Hoffmann-La Roche||Completed|October 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Masking: Double Blind (Subject, Investigator)|3||Actual|177|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438749||98169|
NCT01439035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000938|Evaluate the Use of Optical Frequency Domain Imaging (OFDI) for Celiac Disease in Children, Adolescents and Young Adults|Pilot Study to Evaluate Use of Optical Frequency Domain Imaging (OFDI) for Duodenal Imaging in Celiac Disease in Children, Adolescents and Young Adults||Massachusetts General Hospital|No|Completed|August 2009|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|7 Years|N/A|No|||August 2014|August 4, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439035||98147|
NCT01439360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115345|An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children|An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children||GlaxoSmithKline||Completed|October 2011|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12045|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||December 2015|January 21, 2016|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439360||98122|
NCT01439373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115519|Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects|Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4||GlaxoSmithKline|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|17|||Both|18 Years|70 Years|No|||June 2012|November 15, 2012|July 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439373||98121|
NCT01439633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000553|Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus|Pilot Study to Evaluate OFDI Surveillance and Image Guided Biopsy of the Esophagus||Massachusetts General Hospital|No|Completed|October 2010|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|22|||Both|18 Years|N/A|No|||July 2014|July 25, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439633||98101|
NCT01440179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11603|SAR3419 in Acute Lymphoblastic Leukemia|Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|MYRALL|Sanofi||Terminated|October 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|16 Years|N/A|No|||May 2014|August 26, 2014|September 21, 2011|Yes|Yes|The study is stopped due to very modest activity compared to competitors|No||https://clinicaltrials.gov/show/NCT01440179||98059|
NCT01440192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCT-PDA001-SAR-001|Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis|A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis||Celgene|Yes|Terminated|September 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|75 Years|No|||July 2014|July 14, 2014|September 19, 2011|No|Yes|Study Terminated by Sponsor|No||https://clinicaltrials.gov/show/NCT01440192||98058|
NCT01440452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00041441|CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies|CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies|FIRST-STIM|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|November 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|105|||Both|18 Years|65 Years|No|||February 2013|February 4, 2013|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440452||98038|
NCT01440738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09/90746|Effectiveness of a Group Intervention to Promote Health Through a Clinical Trial|Effectiveness of a Group Intervention to Promote Health Through a Clinical Trial||Jordi Gol i Gurina Foundation|Yes|Recruiting|September 2011|September 2012|Anticipated|September 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|376|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2011|September 23, 2011|June 21, 2010||No||No||https://clinicaltrials.gov/show/NCT01440738||98016|
NCT01440946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9HB02PED|Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B|An Open-label, Multicenter Evaluation of Safety, Pharmacokinetics and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B|Kids B-LONG|Biogen|Yes|Completed|June 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|N/A|11 Years|No|||July 2015|July 21, 2015|September 16, 2011|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01440946||98000|
NCT01440959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258AKR01T|Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST)|A Phase II Trial of TKI258 in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib(CTKI258AKR01T)||Asan Medical Center|No|Completed|September 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|N/A|No|||January 2014|January 13, 2014|September 8, 2011||No||No|November 12, 2013|https://clinicaltrials.gov/show/NCT01440959||97999|
NCT01441193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS P-002|A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)|A Phase I, Open Label, Safety and Immunogenicity Vaccine Trial Based on the Association of Recombinant HIV-1 Biologically Active Tat and V2-deleted Env Proteins in HIV Uninfected Healthy Adult Volunteers.||Istituto Superiore di Sanità|Yes|Terminated|September 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|11|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 26, 2011||No|Enrollments were suspended due to delta-V2 Env unavailability, following the    EMA/CHMP/BWP/534898/2008 guideline, not allowing the use of a retest date|No||https://clinicaltrials.gov/show/NCT01441193||97982|
NCT01441791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROVHILO|PROVHILO:Protective Ventilation During General Anesthesia for Open Abdominal Surgery|Protective Ventilation During General Anesthesia for Open Abdominal Surgery - a Randomized Controlled Trial|PROVHILO|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|February 2011|April 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|900|||Both|18 Years|N/A|No|||December 2014|December 7, 2014|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01441791||97936|
NCT01448018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-011403-23|Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion|Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis|CHIC-3|Centre Hospitalier Intercommunal Creteil|Yes|Completed|January 2010|December 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|75 Years|No|||August 2014|August 12, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01448018||97469|
NCT01448031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961FC00012|A Healthy Female and Male Volunteers Aspirin Study|A Phase I, Open-label, Randomized, Two Way Crossover Pharmacokinetic Study Comparing the Bioavailability of Acetylsalicylic Acid (ASA) After 5 Days Repeated Once Daily Administration of a Fixed Dose Combination Capsule of ASA 81 mg/Esomeprazole 20 mg and ASA 80 mg (European Aspirin Reference Product)||AstraZeneca||Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|54|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01448031||97468|
NCT01448291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-NVR11|Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers|The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers||Eastern Virginia Medical School|No|Recruiting|October 2011|March 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|July 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01448291||97448|
NCT01448304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD12011|Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)|||Sanofi|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|June 27, 2013|October 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448304||97447|
NCT01449201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0434|PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma|Phase II Trial of PF-00299804 in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy||Yonsei University|No|Completed|October 2011|March 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||September 2014|September 28, 2014|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01449201||97379|
NCT01449162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB07015|A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids|A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and the Safety of Masitinib at 6 mg/kg/Day Versus Placebo in the Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids||AB Science|Yes|Recruiting|June 2011|December 2015|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449162||97382|
NCT01449175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C11-001PLV|A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema|A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema||Aeris Therapeutics|No|Terminated|January 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|54|||Both|40 Years|N/A|No|Non-Probability Sample|All patients participating in the Registry Study must have been enrolled in either Group 4        (homogeneous emphysema) or Group 5 (heterogeneous emphysema) of Aeris' Investigational        Study 03-C08-003PLV and completed 48 week follow-up in the AeriSeal post market follow-up        Continuation Study (03-C10-001PLV).|November 2013|November 13, 2013|April 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01449175||97381|
NCT01438216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANIPKIC001|Anidulafungin Pharmacokinetics in Intensive Care Unit Patients|Anidulafungin Population Kinetics in the Intensive Care Population|ANICK|VU University Medical Center|No|Recruiting|September 2011|March 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|Samples Without DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Intensive Care patients|September 2011|September 19, 2011|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438216||98210|
NCT01438463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM/0037|PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis||HAL Allergy|Yes|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|290|||Both|18 Years|60 Years|No|||May 2013|May 28, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438463||98191|
NCT01438476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0146|Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas|Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection||M.D. Anderson Cancer Center|Yes|Recruiting|January 2012|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438476||98190|
NCT01438762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110020|Early Intervention for Adolescents With Patellofemoral Pain Syndrome|Early Intervention for Adolescents With Patellofemoral Pain Syndrome - a Cluster Randomized Trial||Northern Orthopaedic Division, Denmark|No|Completed|June 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|15 Years|19 Years|No|||March 2016|March 23, 2016|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01438762||98168|
NCT01438775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX02-0020|Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)|Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart||Nymox Corporation|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|192|||Male|45 Years|N/A|No|||April 2014|April 1, 2014|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438775||98167|
NCT01439048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 09/102, GC 900|Placental and Cord Blood Markers Associated With Premature Birth and Disorders of Premature Birth in Newborn Infants|Study of Environmental Toxicants and Inflammatory Markers in Prematurity and Diseases of Prematurity||Medical College of Wisconsin|No|Completed|June 2009|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|82|Samples With DNA|whole blood, placenta|Both|N/A|3 Months|Accepts Healthy Volunteers|Probability Sample|Infants who are born both premature (less than 37 weeks gestation) and full term infants        (greater than 37 weeks gestation).|August 2015|August 27, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439048||98146|
NCT01439386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCAI_APPROVAL|Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter|Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter|APPROVAL|Texas Cardiac Arrhythmia Research Foundation|No|Active, not recruiting|September 2011|July 2016|Anticipated|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|75 Years|No|||July 2014|July 31, 2014|September 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01439386||98120|
NCT01439399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL-48h|Analgesic Efficacy of Intravenous Lidocaine and/or Ketamine|Analgesic Efficacy of Intravenous Perfusion of Lidocaine, Ketamine or a Combination After Laparotomy in a Placebo-controlled, Randomized, Double-blind Prospective Study||University of Lausanne Hospitals|No|Completed|December 2005|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|52|||Both|20 Years|75 Years|No|||September 2011|September 21, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439399||98119|
NCT01439646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rdhar India|Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy|Observational, Retrospective Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy||Fortis Hospital, India|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|100|||Both|18 Years|75 Years|No|Non-Probability Sample|100 patients , nonneutropenic in ICU who have risk factors for fungal infections and are        started empiricaly on antifungals|August 2015|August 11, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439646||98100|
NCT01439659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID00-420|Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer|A Randomized Phase II Study of the Nutritional Supplements Juice Plus + and Juice Plus + Complete in Ovarian Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2003|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Female|21 Years|N/A|No|||March 2016|March 14, 2016|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439659||98099|
NCT01439906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVOD.SCOLIOSI DEGENERATIVA|Surgical Treatment for Degenerative Scoliosis|Evaluation of Pain Relief and Functional Improvement After the Surgical Treatment for Low Back Pain Due to Degenerative Kyphoscoliosis - Pilot Study||Istituto Ortopedico Rizzoli|No|Completed|January 2010|August 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Both|40 Years|75 Years|No|Probability Sample|Community sample|September 2014|April 27, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439906||98080|
NCT01439919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT11705|A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain|ACT11705|Sanofi|Yes|Terminated|January 2012|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|September 7, 2011|Yes|Yes|due to strategic reasons|No||https://clinicaltrials.gov/show/NCT01439919||98079|
NCT01440205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813606-2|Licensing Flu Shot Study|||University of Pennsylvania|No|Not yet recruiting|October 2011|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|7000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 17, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440205||98057|
NCT01440218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-5769|Idiopathic Diseases of Man|Idiopathic Diseases of Man (IDIOM)|IDIOM|Scripps Translational Science Institute|Yes|Enrolling by invitation|September 2011|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Blood, saliva, or tissue will be obtained after informed consent is completed.|Both|N/A|N/A|No|Non-Probability Sample|Patients with idiopathic diseases, referred by their physician.|October 2015|October 14, 2015|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01440218||98056|
NCT01472692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110806|Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure|Treatment of Uric Acid With the Xanthine Oxidase Inhibitor Febuxostat: Effects on Blood Pressure, Metabolic Markers, and Aortic Stiffness in Prehypertensive||University of California, San Diego|Yes|Completed|October 2011|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 31, 2014|November 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472692||95583|
NCT01472705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003-REP-CER-FR|Everolimus- Versus Biolimus-Eluting Stents in All-Comers|Long-Term Comparison of Everolimus-Eluting and Biolimus-Eluting Stents in All-Comer Patients|EverBio|University of Freiburg|No|Completed|November 2010|November 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|814|||Both|18 Years|120 Years|No|Probability Sample|All consecutive patients treated at our institution with at least one BES or EES|December 2015|December 1, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01472705||95582|
NCT01440725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRP-RICE|Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma|Multicenter Double Blind, With Evaluator Blinding, Parallel, Randomized Clinical Trial, to Assess the Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma|PRP-RICE|Institut de Terapia Regenerativa Tissular|No|Completed|October 2009|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||January 2013|January 8, 2013|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440725||98017|
NCT01441531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28860|Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension|Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension During Orif of Tibia Fracture Under General Anesthesia||Baylor College of Medicine|No|Withdrawn|January 2012|June 2014|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|64 Years|No|||March 2015|March 13, 2015|September 21, 2011||No|Unable to recruit patient due to surgical case type. Not worth continuing study.|No||https://clinicaltrials.gov/show/NCT01441531||97956|
NCT01473329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-464|Structured Diabetes Self-Management Education in Primary Care and Metabolic Control|Structured Diabetes Self-Management Education in Primary Care and Metabolic Control: a Randomized Clinical Trial.||Hospital de Clinicas de Porto Alegre|Yes|Completed|January 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Both|18 Years|80 Years|No|||November 2011|November 18, 2011|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01473329||95535|
NCT01473615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001699|Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression|Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression||Massachusetts General Hospital|No|Active, not recruiting|November 2011|June 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01473615||95513|
NCT01448590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHSC-Haslam-PDPH|Post Dural Puncture Headache After Accidental Dural Puncture|Systematic Review: Post Dural Puncture Headache After Accidental Dural Puncture: Does Insertion of Spinal Catheter Decrease Incidence of Headaches?||Sunnybrook Health Sciences Centre|No|Active, not recruiting|June 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|1|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Obstetrical population|November 2014|November 25, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01448590||97425|
NCT01448876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Incure|Incubation Time and Test of Cure of Chlamydia Trachomatis|Time to Cure Chlamydia Trachomatis: Prospective Cohort Study on Detection of Chlamydial RNA and DNA in Anorectal and Cervicovaginal Infections During 8 Weeks After Directly Observed Treatment With Azithromycin|Incure|Maastricht University Medical Center|No|Completed|June 2009|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|52||self-taken cervicovaginal and snorectal swabs|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|By convenience sampling at our outpatient STD clinic, 46 non-pregnant women and 6 men were        included, contributing 45 cervicovaginal and 15 anorectal infections.|October 2011|February 15, 2016|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01448876||97403|
NCT01449214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-03|Ultrasound-Guided Technique for Thoracic Epidural Insertion|Ultrasound-Guided Technique for Thoracic Epidural Insertion: A Randomized Controlled Trial||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449214||97378|
NCT01449227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108-095-374|Natural Course of Adhesive Capsulitis of Hip|Natural Course of Adhesive Capsulitis of Hip||Seoul National University Hospital||Recruiting|September 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|20 Years|70 Years|No|Probability Sample|community sample painful hip with limited ranage of motion|October 2011|October 10, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449227||97377|
NCT01449487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aros-001|Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid|A Randomized, Double-blind, Cross-over Trial in Patients With Irritable Bowel Syndrome Investigating the Efficacy and Safety of PPC-5650 on Sensation and Pain During Standardized Stimulation of the Rectosigmoid||Aros Pharma ApS|Yes|Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|25|||Both|18 Years|70 Years|No|||May 2014|May 20, 2014|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01449487||97357|
NCT01438229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10-045-ID-HT|Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients|Ablation-induced Renal Sympathetic Denervation Trial|EnligHTN-I|St. Jude Medical|Yes|Completed|October 2011|July 2014|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|80 Years|No|||February 2014|May 24, 2015|September 19, 2011||No||No|April 17, 2015|https://clinicaltrials.gov/show/NCT01438229||98209|
NCT01438242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1|An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression|An Open Label Study of the Genecept™ Assay to Evaluate Efficacy of Using Assay Guided Treatment in Outpatient Adults With Treatment Resistant Depression||Genomind, LLC|No|Withdrawn|January 2015|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|65 Years|No|||March 2015|March 20, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438242||98208|
NCT01438489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-MEDI-546-1013|A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus|A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus||MedImmune LLC|Yes|Completed|January 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|626|||Both|18 Years|75 Years|No|||July 2015|July 10, 2015|September 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438489||98189|
NCT01438788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOR-0018156|Low Protein Diet in Patients With Collagen VI Related Myopathies|Low Protein Diet to Correct Defective Autophagy in Patients With Collagen VI Related Myopathies|LPD|Istituto Ortopedico Rizzoli|No|Completed|October 2011|September 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2013|November 13, 2013|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01438788||98166|
NCT01439074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMA 418|An Open, Randomized, Multi-centre Investigation With Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.|An Open, Randomized, Comparative, Multi-centre Investigation Evaluating the Efficacy and Tolerance of Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.||Molnlycke Health Care AB|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|5 Years|65 Years|No|||December 2013|September 26, 2014|September 21, 2011||No||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01439074||98144|
NCT01439061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-529|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy|Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment in Italy|ECOS ITA|Merck KGaA||Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|221|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439061||98145|
NCT01439412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acuback|Acupuncture in Acute Nonspecific Low Back Pain|Acupuncture in Acute Nonspecific Low Back Pain; a Randomized Controlled Multicenter Study in General Practice|Acuback|University of Oslo|No|Recruiting|March 2014|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|236|||Both|20 Years|55 Years|No|||December 2015|December 17, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439412||98118|
NCT01439672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15131|Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability|Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability|BPK005|University of Virginia|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|21 Years|64 Years|No|||March 2015|March 30, 2015|September 20, 2011||No||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01439672||98098|
NCT01439932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11XXX-XXKCTIL|Effectiveness of Manual Therapy Combined With Standard Treatment in the Management of Plantar Fasciitis|Effectiveness of Manual Therapy Combined With Standard Treatment in the Management of Plantar Fasciitis, a Randomized Control Trial||Meir Medical Center|No|Completed|October 2011|February 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||September 2011|February 17, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439932||98078|
NCT01440231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 700461-018|Atacicept Demonstrating Dose RESponSe|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Dose-Response Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)|ADDRESS|EMD Serono|Yes|Withdrawn|February 2012|February 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440231||98055|
NCT01440491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1871/07|Orientation Booklet for Low Back Pain|Effect of Orientation Through a Booklet of Exercise in Patients With Low Back Pain||Federal University of São Paulo|No|Completed|May 2008|September 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||January 2008|September 23, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01440491||98035|
NCT01440972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109738|Assessment of Efficacy of Low Intensity Resistance Training in Women at Risk for Symptomatic Knee Osteoarthritis|Assessment of Efficacy of Low Intensity Resistance Training in Women at Risk for Symptomatic Knee Osteoarthritis|PBFR2|University of Iowa|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|45|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 2, 2015|September 21, 2011||No||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01440972||97998|
NCT01472718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-DCT-201001|Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)|Efficacy of Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention||University of Pisa|No|Completed|February 2009|March 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|90 Years|No|||May 2012|May 24, 2012|November 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01472718||95581|
NCT01472978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C diff 101|Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy|Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy|c diff|State University of New York at Buffalo|No|Recruiting|December 2011|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Both|7 Years|21 Years|No|||June 2012|June 11, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01472978||95561|
NCT01472991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5619-238-CRD-004|Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Inattentive-Predominant Attention Deficit/Hyperactivity Disorder (ADHD)||Targacept Inc.|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 22, 2013|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472991||95560|
NCT01448603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR002B|ToleroMune Ragweed Follow up Study|An Optional One Year Follow-up Study to Evaluate the Continued Efficacy of ToleroMune Ragweed in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber.||Circassia Limited|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|109|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects previously randomised in study TR002 and completed all dosing visits and the Post        Treatment Challenge (PTC).|May 2012|May 16, 2012|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448603||97424|
NCT01439711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-40903|Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ|Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)||Alliance for Clinical Trials in Oncology|Yes|Recruiting|February 2012|||June 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Female|18 Years|N/A|No|||September 2015|September 18, 2015|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439711||98095|
NCT01448889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cino2|Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy|Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy.||Assaf-Harofeh Medical Center|No|Recruiting|September 2009|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|80 Years|No|||October 2011|October 6, 2011|April 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448889||97402|
NCT01440244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 11.092|Cervical Video Assisted Thoracoscopic Surgery (C-VATS)|Cervical Video Assisted Thoracoscopic Surgery (C-VATS)Using a Flexible Endoscope for Thoracoscopy|CT0030|Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|September 2011|February 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01440244||98054|
NCT01449500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUB0028|Supplementation With L. Reuteri in H. Pylori Infected Adults|Effect of Dietary Supplementation With L. Reuteri ProGastria in H. Pylori-infected Adult Subjects Treated Only With Proton Pump Inhibitors||Lama Medical Care s.r.o.|No|Not yet recruiting|October 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|56|||Both|18 Years|70 Years|No|||October 2011|October 7, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01449500||97356|
NCT01449513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-03|PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy|A Phase 1, Two-stage, Single-centre, Open Label, Within- and Between-subject Comparison Trial to Explore the Biological Effects of PEP005 (Ingenol Mebutate) Gel, 0.05%, Applied Once Daily for 2 Consecutive Days in Subjects With Actinic Keratosis on the Upper Extrem-ity. A Single-arm First Stage Followed by a Two-arm, Parallel Group, Randomized, Placebo (Vehicle) -Controlled Second Stage||LEO Pharma|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|October 6, 2011||No||No|October 8, 2013|https://clinicaltrials.gov/show/NCT01449513||97355|
NCT01438528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-530|Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone Treatment|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "easypodTM" Electromechanical Device for Growth Hormone Treatment in China|ECOS CHN|Merck KGaA||Active, not recruiting|December 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438528||98186|
NCT01438502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/491|"The Effect of Reduced Fluid Load After Cardiac Surgery"|"The Impact of Hypertonic Saline/ Colloids Infusion During Cardio-pulmonary-bypass in Patients Expected Long CPB-time"||Haukeland University Hospital|Yes|Withdrawn||||||Phase 0|Observational|N/A||1|Actual|0|||Both|18 Years|N/A|No|||November 2013|November 23, 2013|September 19, 2011||No|Changes in staff resulted in logistic difficulties to perform the study|No||https://clinicaltrials.gov/show/NCT01438502||98188|
NCT01438515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1265|Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization|Randomized Controlled Trial of Chlorhexidine Gluconate, Intranasal Mupirocin, Rifampin and Doxycycline Versus Chlorhexidine Gluconate and Intranasal Mupirocin Alone for the Eradication of Methicillin-resistant Staphylococcus Aureus Among an Ambulatory Patient Population||Horizon Health Network|No|Recruiting|August 2008|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01438515||98187|
NCT01439087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-000946|Optical Frequency Domain Imaging for Assessing Colonic Polyps|Pilot Study to Evaluate Optical Frequency Domain Imaging as a Tool for Assessing Colonic Polyps||Massachusetts General Hospital|No|Completed|July 2009|August 2010|Actual|October 2009|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||September 2011|September 21, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439087||98143|
NCT01470235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hypodontovariancancer2011|Hypodontia and Ovarian Cancer|Hypodontia and Ovarian Cancer - the Connection Between Dental Agenesis and Epithelial Cancers, Especially Ovarian Cancer.||University of Aarhus|Yes|Recruiting|September 2011|August 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Anticipated|200|Samples With DNA|5ml EDTA full blood for DNA analysis.      1 PAX-tube for RNA analysis. Biopsi from removed tumor-tissue for DNA analysis. Both      preserved in Danish Cancer Biobank for later analysis.|Female|18 Years|N/A|No|Probability Sample|All women referred to the department of obstetrics/gynecology under the diagnosis ovarian        cancer obs. pro.|October 2013|October 31, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470235||95771|
NCT01439425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRP|Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis|Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study||Universita di Verona|No|Not yet recruiting|November 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|75 Years|No|||September 2011|September 21, 2011|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01439425||98117|
NCT01439685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106011779|Comparison of Biliary Stenting Alone vs. Stenting With Photodynamic Therapy (PDT) During ERCP|Comparison of Biliary Stenting Alone vs. Stenting With Photodynamic Therapy During Endoscopic Retrograde Cholangiopancreatography (ERCP): A Retrospective and Prospective Analysis|PDT|Weill Medical College of Cornell University|No|Withdrawn|July 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects suffering from Cholangiocarcinoma|June 2015|June 1, 2015|September 20, 2011|Yes|Yes|A single cohort, alternative trial was started.|No||https://clinicaltrials.gov/show/NCT01439685||98097|
NCT01471496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|konuk-001|Prophylactic Injection Therapy Reduces Recurrent Bleeding In Forrest Type IIb Duodenal Ulcers|Prophylactic Injection Therapy Reduces Recurrent Bleeding Rate In Forrest Type IIb Duodenal Ulcer Bleeding||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|Yes|Completed|January 2003|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|N/A|N/A|No|||November 2011|November 10, 2011|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01471496||95675|
NCT01471509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|676|Protein, Amino Acids & Insulin & Glucagon Secretion in Humans|The Effect of Ingestion of Foods on the Plasma Glucose and Insulin Response in Subjects With Type 2 Diabetes: Protein, Amino Acids & Insulin & Glucagon Secretion in Humans||Minneapolis Veterans Affairs Medical Center|No|Recruiting|August 1982|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2011|November 18, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471509||95674|
NCT01471834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360016|Barostim Neo System in the Treatment of Resistant Hypertension|Neo Non-Randomized Hypertension Study||CVRx, Inc.|Yes|Active, not recruiting|June 2011|July 2016|Anticipated|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|21 Years|80 Years|No|||December 2015|December 22, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471834||95649|
NCT01471847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235B2203|A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab|A Phase Ib/Randomized Phase II Study of BEZ235 and Trastuzumab Versus Lapatinib and Capecitabine in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Failed Prior to Trastuzumab||Novartis||Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|N/A|No|||November 2012|November 30, 2012|October 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471847||95648|
NCT01471860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360029|Barostim Neo System in the Treatment of Heart Failure|Neo Randomized Heart Failure Study||CVRx, Inc.|Yes|Active, not recruiting|February 2012|May 2017|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|94|||Both|21 Years|N/A|No|||June 2015|June 11, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471860||95647|
NCT01472445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0024|Vitamin D and Breast Cancer: Does Weight Make a Difference?|Vitamin D and Breast Cancer: Does Weight Make a Difference?||Stanford University|Yes|Terminated|November 2011|October 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|41|||Female|18 Years|N/A|No|||December 2014|December 17, 2014|November 11, 2011|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01472445||95602|
NCT01472159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-28|Can Glucose Monitoring Improve (CGMi Study)|Optimizing CGM Use and Metabolic Outcomes in Youth With Type 1 Diabetes||Joslin Diabetes Center|Yes|Completed|October 2011|August 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|8 Years|17 Years|No|||January 2016|January 7, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01472159||95624|
NCT01472172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-0002|Pleural Cryobiopsies During Semirigid Thoracoscopy: A New Technique|Pleural Cryobiopsies During Semirigid Thoracoscopy: A New Technique||The University Clinic of Pulmonary and Allergic Diseases Golnik|Yes|Completed|February 2010|November 2013|Actual|November 2013|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01472172||95623|
NCT01472185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0131|Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus||Gilead Sciences|Yes|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|465|||Both|18 Years|75 Years|No|||October 2014|October 15, 2014|November 11, 2011|Yes|Yes||No|October 8, 2014|https://clinicaltrials.gov/show/NCT01472185||95622|
NCT01472965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETHEL|Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection|A Double-Blind, Randomized, Placebo-Controlled, Trial of Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line Associated Bloodstream Infection (CLABSI) in Children and Adolescents||St. Jude Children's Research Hospital|No|Recruiting|December 2011|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|138|||Both|6 Months|25 Years|No|||November 2015|November 16, 2015|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472965||95562|
NCT01438866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD03/10|Use of Fissure Sealants on Primary Molars|The Effectiveness of Sealants in Prevention of Occlusal Caries on Primary Molars||Kuwait University|No|Completed|October 2011|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|148|||Both|42 Months|52 Months|Accepts Healthy Volunteers|||October 2012|March 16, 2014|September 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438866||98160|
NCT01438879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11077|Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR)|Molecular Methods in the Etiological Diagnostics of Acute Central Nervous System Infections: Lymphocytic Herpesviruses and PCR||PaijatHame Central Hospital|No|Not yet recruiting|October 2011|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|CSF white cells + CSF supernatant, Blood white cells and serum|Both|16 Years|80 Years|No|Non-Probability Sample|Residents of the district of Paijat-Hame (200 000 inhabitants).|September 2011|September 21, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01438879||98159|
NCT01439165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td537|Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose|Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose||Sanofi|No|Active, not recruiting|November 2011|October 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1332|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439165||98137|
NCT01439464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA04-CP01|Study of Bioactive Glass-ceramic Intervertebral Spacer (Bonglass-SS) in Posterior Lumbar Interbody Fusion|Clinical Efficacy and Safety of Bioactive Glass-ceramic Intervertebral Spacer (Bonglass-SS) in Posterior Lumbar Interbody Fusion and, Titanium Cage Controlled, 1-year, Single-Blind, Non-Inferiority Trial||BioAlpha Inc.|No|Recruiting|October 2010|June 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|86|||Both|30 Years|80 Years|No|||September 2011|September 22, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01439464||98114|
NCT01439451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARZI1729|Effect of Perturbation Training on Balance Control in Elderly Persons|Effect of Balance Perturbation to Improve Gait and Balance Control and Prevent Falls in Elderly Persons -A Randomized Control Trial|BaMPer|Barzilai Medical Center|Yes|Completed|August 2011|August 2015|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|September 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439451||98115|
NCT01439945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N10C2|Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes||Alliance for Clinical Trials in Oncology|Yes|Completed|September 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|4||Actual|288|||Female|18 Years|N/A|No|||July 2015|July 31, 2015|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01439945||98077|
NCT01439958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12011.203|Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)|A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy||Pari Pharma GmbH|No|Terminated|February 2012|December 2014|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|September 22, 2011||No|Core study 12011.201 was terminated.|No||https://clinicaltrials.gov/show/NCT01439958||98076|
NCT01440504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-737 ex vivo|Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors|Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors|ABT737 exvivo|Centre Francois Baclesse|Yes|Completed|April 2010|January 2013|Actual|January 2013|Actual|Phase 2|Observational|Time Perspective: Prospective||1|Actual|36|||Female|18 Years|N/A|No|Non-Probability Sample|Patient, any chemotherapy naive or ovarian surgery, ovarian cancer with at least five        tumor samples does not affect the diagnostic|February 2013|February 6, 2013|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01440504||98034|
NCT01440257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL007_140|A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria|A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects With Type 2 Diabetes Mellitus||ChemoCentryx|No|Completed|September 2011|September 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|75 Years|No|||January 2015|January 8, 2015|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01440257||98053|
NCT01438814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.60|Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control|A Randomised, Double-blind, Double-dummy, Active-comparator Controlled Study Investigating the Efficacy and Safety of Linagliptin Co-administered With Metformin QD at Evening Time Versus Metformin BID Over 14 Weeks in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|November 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|689|||Both|18 Years|80 Years|No|||November 2014|November 13, 2014|September 21, 2011||||No|February 28, 2014|https://clinicaltrials.gov/show/NCT01438814||98164|
NCT01438827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-G-02|Avanz Phleum Pratense Maintenance Dose|Avanz Phleum Pratense Maintenance Dose||ALK-Abelló A/S||Completed|September 2011|January 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|450|||Both|18 Years|64 Years|No|||January 2014|January 20, 2014|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01438827||98163|
NCT01438801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-95-58035-017|Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)|Predictive Value of Baseline and Stimulated Serum IGF-1 and IGFBP-3 During a Dose-escalation IGF-1 Generation Test for the 1 Year Growth Response to Growth Hormone (GH) Therapy in Short Children With Low IGF-1 and a Normal GH Peak in a Provocation Test||Ipsen|Yes|Withdrawn|May 2013|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|2 Years|10 Years|No|||December 2013|December 19, 2013|August 24, 2011||No|Participant enrollment was not feasible|No||https://clinicaltrials.gov/show/NCT01438801||98165|
NCT01470248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00050301|Study of Arsenic Trioxide in Small Cell Lung Cancer|A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer||Emory University|Yes|Completed|August 2011|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470248||95770|
NCT01470859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2011-283|The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease|a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease||Huashan Hospital|Yes|Completed|December 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|30 Years|75 Years|No|||September 2015|September 21, 2015|November 9, 2011||No||No|June 23, 2015|https://clinicaltrials.gov/show/NCT01470859||95723|In the further study, a larger sample size and strict enrollment of early PD patients may enhance the accuracy of clinical trial conclusions.
NCT01471171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/34273/40|Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose, Randomised, Double-blind, Placebo Controlled, 2 Period Crossover Clinical Trial to Assess the Effect of Aclidinium Bromide 400 μg BID on Exercise Endurance in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Almirall, S.A.|No|Completed|November 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|40 Years|N/A|No|||May 2015|May 28, 2015|November 10, 2011||No||No|May 21, 2013|https://clinicaltrials.gov/show/NCT01471171||95700|
NCT01471535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTH-XY002|HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated|HBsAg Loss/Seroconversion in Inactive Chronic Hepatitis B Carriers Treated With Peginterferon Alpha-2a||Beijing Ditan Hospital|Yes|Completed|May 2008|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|60 Years|No|||March 2015|March 8, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01471535||95672|
NCT01471548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A1101|Phase I Dose Escalating Study of TKI258|A Phase I Dose Escalating Study to Evaluate TKI258 Administered Orally on a 5 Days on/2days Off Schedule in Japanese Patients With Advanced Solid Tumors||Novartis||Completed|September 2008|May 2012|Actual|September 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|20 Years|N/A|No|||May 2013|May 8, 2013|November 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471548||95671|
NCT01471873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25/27-09-2011|Variability of Pentacam-derived Back Elevation Measurements in Keratoconus and Cross-linked Corneas|Variability of Pentacam-derived Back Elevation Measurements in Keratoconus and Cross-linked Corneas||Democritus University of Thrace|No|Completed|March 2011|November 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|67|||Both|18 Years|N/A|No|Probability Sample|Participants were recruited from the Cornea service of the EIT in a        consecutive-if-eligible basis.|November 2011|November 10, 2011|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471873||95646|
NCT01438034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001453|Kisspeptin in the Evaluation of Delayed Puberty|Kisspeptin in the Evaluation of Delayed Puberty||Massachusetts General Hospital|Yes|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|12 Years|17 Years|No|||September 2015|September 30, 2015|August 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438034||98224|
NCT01438307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110512012 (UAB 1021)|Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer|Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients||University of Alabama at Birmingham|Yes|Completed|September 2011|September 2015|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|19 Years|N/A|No|||January 2016|January 8, 2016|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438307||98203|
NCT01472458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPARC - PremaTOR|Premature Termination of Resuscitation in Survivors of Cardiac Arrest|Premature Termination of Resuscitation in Survivors of Cardiac Arrest|PremaTOR|Sunnybrook Health Sciences Centre|No|Completed|November 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|560|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01472458||95601|
NCT01439490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUG2011-0704|FES-PET to Determine ER-expression in Epithelial Ovarian Cancer|Feasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer||University Medical Center Groningen|No|Completed|August 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|15|||Female|18 Years|N/A|No|||April 2014|April 17, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439490||98112|
NCT01439750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 10-011|Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)|Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011)||Milton S. Hershey Medical Center|Yes|Recruiting|May 2012|October 2017|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2013|April 29, 2015|August 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01439750||98092|
NCT01448382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-401|Evaluation of PillCam With Blood-Sensing Feature: A Feasibility Study|Evaluation of PillCam With Blood-Sensing Feature: A Feasibility Study||Given Imaging Ltd.|No|Terminated|October 2011|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01448382||97441|
NCT01448395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00008|Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104|An Open Label Single-Dose Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104||AstraZeneca||Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01448395||97440|
NCT01439724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCABrazil|Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients|Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation||Instituto Nacional de Cancer, Brazil|Yes|Completed|June 2007|December 2010|Actual|June 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|94|||Both|18 Years|75 Years|No|||February 2013|March 7, 2014|September 20, 2011||No||No|March 7, 2014|https://clinicaltrials.gov/show/NCT01439724||98094|
NCT01448915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00029706|Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)|Management of Hepatitis C in HIV Infected IDUs||Johns Hopkins University|Yes|Recruiting|September 2009|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||October 2011|October 6, 2011|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01448915||97400|
NCT01440270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 622022237|Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer|Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer||Shanghai Jiao Tong University School of Medicine|Yes|Active, not recruiting|July 2011|October 2019|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|145|||Both|18 Years|75 Years|No|||May 2014|May 12, 2014|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440270||98052|
NCT01470261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011PW02|Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects|Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects|ADDUCE|NHS Tayside|Yes|Active, not recruiting|February 2012|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1398|||Both|5 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Attention Deficit Disorder clinic|October 2015|October 5, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470261||95769|
NCT01470274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1792|Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients|Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients||Norwegian University of Science and Technology|No|Completed|November 2011|February 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|18|Samples Without DNA|Blood samples|Both|18 Years|75 Years|No|Non-Probability Sample|Stable, optimally medicated coronary artery disease and COPD patients with LVEF ≥ 0.40        will be recruited|April 2012|April 4, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470274||95768|
NCT01439100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXN2504|A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain|||Mundipharma Research GmbH & Co KG||Completed|October 2011|October 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|172|||Both|25 Years|N/A|No|||February 2014|February 5, 2014|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439100||98142|
NCT01470885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zsdxxhnk20110707|Relation of Glucose and Acute Pancreatitis|the Influence of Glucose to the Prognosis of Patients of Acute Pancreatitis|ROGAAP|Huashan Hospital|Yes|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Both|15 Years|85 Years|No|Probability Sample|primary care clinic|May 2014|May 2, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470885||95722|
NCT01471184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2JH09001|The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo|A Double-Blind, Randomized, Cross-Over Study of The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo, in Patients With Allergic Rhinitis and Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model|PPL-003|Bitop AG|No|Completed|September 2009|||March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|65 Years|No|||November 2011|November 18, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471184||95699|
NCT01471197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-124 ST|Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer|A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy||Bristol-Myers Squibb|No|Terminated|July 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||April 2014|April 14, 2014|November 10, 2011|Yes|Yes|Administrative reasons|No|March 6, 2014|https://clinicaltrials.gov/show/NCT01471197||95698|At the time of the early termination of this study, most participants only had only one on-study tumor assessment performed. Therefore, the tumor response-related endpoints were too immature to report.
NCT01471522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00498|International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)|International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)|ISCHEMIA|New York University School of Medicine|Yes|Recruiting|July 2012|May 2019|Anticipated|May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|8000|||Both|21 Years|N/A|No|||January 2016|January 29, 2016|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471522||95673|
NCT01441830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/5347|Radial Extracorporeal Shock Wave Therapy (rESWT) Treatment of Subacromial Shoulder Pain|Treatment of Subacromial Shoulder Pain||Oslo University Hospital|No|Active, not recruiting|September 2011|||May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|25 Years|70 Years|No|||December 2014|December 17, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01441830||97933|
NCT01441843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL3253507810|Resistance Under the Microscope|Resistance Under the Microscope; a Randomized Placebo Controlled Parallel Group Design||Erasmus Medical Center|No|Completed|October 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|September 22, 2011||No||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01441843||97932|
NCT01442129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1078-00006|The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation|LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function||Icahn School of Medicine at Mount Sinai|Yes|Completed|April 2012|August 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|September 26, 2011|Yes|Yes||No|October 7, 2014|https://clinicaltrials.gov/show/NCT01442129||97910|
NCT01438320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#10-04-063-01|Q-Trial in Patients With Hepatitis C|A Phase 1 Study of Quercetin in Patients With Hepatitis C|Q|University of California, Los Angeles|Yes|Completed|July 2011|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438320||98202|
NCT01438593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR97-IRB-178-4|Study of Purified Umbilical Cord Blood CD34+ Stem Cell on Chronic Ischemic Stroke|An Exploratory Clinical Trial to Assess Treatment of Chronic Ischemic Stroke With Brain Transplants of Purified CD34+ Umbilical Cord Blood Stem Cells||China Medical University Hospital|Yes|Not yet recruiting|January 2013|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|35 Years|70 Years|No|||December 2011|July 31, 2012|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01438593||98181|
NCT01438606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 090|Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of VSV-Indiana HIV Gag Vaccine Given Intramuscularly in Healthy, HIV-1-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|October 2011|||January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|10||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|September 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01438606||98180|
NCT01438892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921144|Impact Of RA Therapy Compliance On Patient-Reported Outcomes|Impact Of RA Therapy Compliance On Patient-Reported Outcomes||Pfizer|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|396|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with modertate to severe Rheumatoid Arthritis|April 2013|April 4, 2013|September 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01438892||98158|
NCT01438580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30900602|The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation|||Nanjing Medical University|Yes|Completed|January 2010|April 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|260|||Both|75 Years|94 Years|Accepts Healthy Volunteers|||May 2012|May 18, 2012|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438580||98182|
NCT01439503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0204-F3R|Safer Sex Program for Young African-American Men|A Brief, Clinic-Based, Safer Sex Program for Young African-American Men||University of Kentucky|No|Recruiting|September 2012|May 2019|Anticipated|May 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|620|||Male|15 Years|29 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01439503||98111|
NCT01439763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-027|Assessment of Bullying in Children|Assessment of Bullying in Children With Psychiatric Symptoms: An ED Based Evaluation|ABC|New York City Health and Hospitals Corporation|No|Recruiting|September 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|8 Years|18 Years|No|Probability Sample|Children 8-18 years of age referred from school to the Emergency Department due to        Behavior Problems|October 2015|October 5, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439763||98091|
NCT01449266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-44-054|Safety and Dialysability of Dotarem® in Dialysed Patients|Safety and Dialysability of Dotarem® in Dialysed Patients - Phase 1 Clinical Study||Guerbet|Yes|Completed|November 2011|June 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|95 Years|No|||June 2015|June 9, 2015|October 3, 2011||No||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01449266||97374|
NCT01448642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|185/2011|Statins Evaluation in Coronary Procedures and Revascularization Trial|A Randomized, Multicenter Clinical Trial to Assess the Effect of Atorvastatin in Patients With Acute Coronary Syndrome and Intended Percutaneous Coronary Intervention|SECURE-PCI|Hospital do Coracao|Yes|Recruiting|April 2012|November 2019|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|4192|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01448642||97421|
NCT01450072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSG1730210B|Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE|Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE|PREMiSE|University at Buffalo Neurosurgery|Yes|Recruiting|June 2010|December 2012|Anticipated|December 2011|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||October 2011|October 7, 2011|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01450072||97313|
NCT01449253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pulmonary hypertension|Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia|Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia||All India Institute of Medical Sciences, New Delhi|No|Recruiting|August 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01449253||97375|
NCT01470287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V66_05|Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age|A Phase-III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine (DTwP-Hib-HepB Vaccine) When Administered to Indian Infants at 6, 10, and 14 Weeks of Age||Novartis||Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|175|||Both|42 Days|64 Days|Accepts Healthy Volunteers|||April 2012|April 30, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470287||95767|
NCT01470300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoodED401|Reducing Energy Density by Different Methods to Decrease Energy Intake|Reducing Energy Density by Different Methods to Decrease Energy Intake||Penn State University|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|62|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470300||95766|
NCT01470560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047159|Mindfulness-Based Stress Reduction Techniques and Yoga for Treatment of Urinary Urge Incontinence (MBSR-Yoga)|Mindfulness-Based Stress Reduction Techniques and Yoga for Treatment of Urinary Urge Incontinence (MBSR-Yoga)|MBSR-Yoga|University of Utah|No|Completed|February 2011|February 2013|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||||||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 10, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470560||95746|
NCT01470573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeRSO09|Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Cells of Sclerocorneal Limbus Amplified ex Vivo|Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo|MeRSO09|Fundacion Clinic per a la Recerca Biomédica|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2012|December 7, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470573||95745|
NCT01470534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11040|Mechanisms Underlying Postoperative Insulin Resistance and Inflammation|Investigating Whether the Magnitude of Postoperative Inflammatory and Insulin Resistant Responses is Related to Body Composition and Physiological Function of Skeletal Muscle & Adipose Tissue||University of Nottingham|Yes|Recruiting|November 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|32|||Both|18 Years|75 Years|No|||October 2012|October 4, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470534||95748|
NCT01470547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMI PRO-LIVER|Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry|Portal Vein Thrombosis Relevance On Liver Cirrhosis: Italian Venous Thrombotic Events Registry|PRO-LIVER|University of Roma La Sapienza|Yes|Recruiting|April 2012|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1100|Samples Without DNA|Plasma and serum samples (in ancillary study)|Both|18 Years|90 Years|No|Probability Sample|Liver cirrhosis patients|March 2016|March 8, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470547||95747|
NCT01471223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-089|Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study|Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)|CTS|Bristol-Myers Squibb|No|Active, not recruiting|March 2012|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing 1st kidney only transplantation, whose transplant centers participate        in CTS and who are treated with Belatacept or a CNI based regimen at the time of        transplantation|January 2016|January 28, 2016|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471223||95696|
NCT01471236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0002|Evaluation of the Agili-C Biphasic Implant in the Knee Joint|Evaluation of the Agili-C Bi-phasic Implant Performances in the Repair of Cartilage and Osteochondral Defects||Cartiheal (2009) Ltd|No|Active, not recruiting|June 2011|March 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|18 Years|55 Years|No|||February 2014|April 19, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471236||95695|
NCT01441557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004656-19|Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism|Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism||Centre Hospitalier Universitaire, Amiens||Completed|September 2011|March 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|3|||Both|18 Years|N/A|No|||June 2012|June 22, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01441557||97954|
NCT01437787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12153|Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly|JAKARTA|Sanofi||Completed|December 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|289|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|September 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01437787||98243|
NCT01438047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p001607|Optical Frequency Domain Imaging (OFDI) in Dermatology|OFDI in Dermatology||Massachusetts General Hospital|No|Withdrawn|September 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients undergoing pulsed-dye laser for the treatment of capillary malformations at        Brigham and Women's Hospital will be eligible for recruitment in this study.|April 2014|April 3, 2014|September 19, 2011||No|The study was closed due to a shift in research priorities and a lack of resources available    for the project.|No||https://clinicaltrials.gov/show/NCT01438047||98223|
NCT01438619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11162KFDA162|Research for the Improvement in Measurement Methods and the Effect of Sodium Intake on Cardiovascular Health|Sodium Intake: Research for the Improvement in Measurement Methods and the Effect of Sodium Intake on Cardiovascular Health||DongGuk University|No|Completed|April 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|620|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|1. Representative population of Goyang city who were randomly selected by digit dialing             (RDD) method          2. Volunteers who are reside in Goyang city|January 2013|January 21, 2013|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01438619||98179|
NCT01438905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16058|Effect of Joint Mobilization in the Treatment of Chronic Ankle Instability|Effect of Joint Mobilization on Muscle Activation and Function in Individuals With Chronic Ankle Instability||Creighton University|No|Completed|September 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438905||98157|
NCT01439178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC11MISI0391|Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab|Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab||Seoul St. Mary's Hospital|Yes|Recruiting|August 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|80 Years|No|||September 2011|September 21, 2011|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01439178||98136|
NCT01439516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00011846|Providing Resources to Enhance African American Patients' Readiness to Make Decisions About Kidney Disease (PREPARED) Study|Information and Financial Interventions for Kidney Donation in African Americans|PREPARED|Johns Hopkins University|Yes|Completed|August 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|92|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01439516||98110|
NCT01439776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25569|Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients|A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin|Addwin|Hanyang University|No|Not yet recruiting|September 2011|August 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Both|20 Years|75 Years|No|||September 2011|September 22, 2011|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01439776||98090|
NCT01439789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-01-304|Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure||Zensun Sci. & Tech. Co., Ltd.|Yes|Terminated|June 2011|December 2012|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|146|||Both|18 Years|75 Years|No|||July 2012|August 1, 2012|September 21, 2011||No|Sponsor has designed another study with different endpoint to replace the current study|No||https://clinicaltrials.gov/show/NCT01439789||98089|
NCT01440010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TARGIT BQR|TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry|TARGeted Intraoperative radioTherapy With the INTRABEAM-System as an Advanced Boost in Patients With Breast Cancer - A Quality Control Registry in Germany (TARGIT BQR)|TARGIT_BQR|Universitätsmedizin Mannheim|No|Recruiting|September 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|1000|||Female|18 Years|85 Years|No|Non-Probability Sample|All patients with breast cancer and a tumor diameter < 3,5 cm plannend for breast        conserving surgery. Intraoperative radiotherapy (IORT) is applied as an advanced boost        with 20 Gy during surgery. Its feasibility was already shown. The IORT as a boost is        included in several recommendations for breast cancer treatment (St. Gallen Conference        2011).|January 2016|January 7, 2016|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01440010||98072|
NCT01449864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09211|Proton Radiotherapy for Upper Gastrointestinal Malignancies|A Feasibility and Registration Study of Proton Radiotherapy for Upper Gastrointestinal Malignancies||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Primary Purpose: Treatment|||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|October 7, 2011||||No||https://clinicaltrials.gov/show/NCT01449864||97329|
NCT01449565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA031678|Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)|Extended-Release Naltrexone (XR-NTX, VIVITROL) for the Treatment of Actively-Using Methamphetamine-Dependent Men Who Have Sex With Men|TREX|San Francisco Department of Public Health|Yes|Active, not recruiting|September 2012|March 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Male|18 Years|65 Years|No|||February 2016|February 2, 2016|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01449565||97351|
NCT01449838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114490|Phase I Study of Colistin Methanesulfonate Sodium|Phase I Study of Colistin Methanesulfonate Sodium (CMS-Na) -A Randomized, Double Blind, Placebo Controlled, Single and Repeat Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CMS-Na in Healthy Japanese Male Subjects -||GlaxoSmithKline|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator)|2||Actual|22|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2012|March 6, 2014|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01449838||97330|
NCT01450384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-13874|Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors|Phase I Study of Pemetrexed and Sorafenib in Advanced Malignancy||Virginia Commonwealth University|Yes|Completed|October 2011|September 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01450384||97289|
NCT01450618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-435|Comparative Tolerability of Protease Inhibitors|Comparative Tolerability of Protease Inhibitors and the Associated Impact on Persistence, Healthcare Utilization, and Healthcare Costs||Bristol-Myers Squibb|No|Completed|March 2011|October 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|26000|||Both|18 Years|64 Years|No|Non-Probability Sample|Employees and dependents with employer-based health insurance coverage|December 2012|December 4, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01450618||97271|
NCT01450371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0374|Interferential Electrical Stimulation and Vasodilatation in Healthy Individuals|Interferential Electrical Stimulation Improves Peripheral Vasodilatation in Healthy Individuals: A Randomized Crossover Study|InterM|Hospital de Clinicas de Porto Alegre|No|Completed|July 2011|October 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|11|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects without degenerative diseases.|January 2013|January 23, 2013|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01450371||97290|
NCT01440530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0173|Technology Intervention for Diabetes Engagement & Self-Care (TIDES)|Technology Intervention for Diabetes Engagement & Self-Care (TIDES):Comparative Effectiveness Randomized Clinical Trial in Primary Care for Type 2 Diabetes to Improve Engagement, Knowledge, and Self-Care|TIDES|Geisinger Clinic|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|170|||Both|18 Years|64 Years|No|||September 2011|September 23, 2011|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01440530||98032|
NCT01440790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25401TW|The Effect of Continuous Sipping of a Glucose Solution on Markers of Oxidation in Men and Women|The Effect of Continuous Sipping of a Glucose Solution on Markers of Oxidation in Men and Women|AOGI|University of Toronto|No|Completed|August 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2013|March 11, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01440790||98012|
NCT01470898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12377KBD|Bispectral Index (BIS) Monitoring in Abdominal Surgery|Effect of Bispectral Index (BIS) Monitoring on Faster Recovery Time and Analgesic Consumption in Abdominal Surgery Patients||University Hospital Dubrava|No|Active, not recruiting|February 2011|February 2013|Anticipated|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2011|July 9, 2012|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01470898||95721|
NCT01470911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB010/01/2011|Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects|Phase-I Study in Healthy Male Subjects to Investigate Safety, Tolerability and Pharmacokinetics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation.||Sterna Biologicals GmbH & Co. KG|Yes|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01470911||95720|
NCT01471210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA186-011|Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)||Bristol-Myers Squibb|No|Active, not recruiting|February 2012|March 2019|Anticipated|March 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|122|||Both|18 Years|N/A|No|||December 2015|February 25, 2016|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471210||95697|
NCT01441570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001638|The Impact of Nebivolol Versus Metoprolol on Quality of Life|The Impact of Nebivolol Versus Metoprolol on Quality of Life Measures and Cost-effectiveness in Stable Renal Transplant Recipients||Brigham and Women's Hospital|No|Terminated|February 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||July 2013|July 15, 2013|September 26, 2011|Yes|Yes|due to slow enrollment|No||https://clinicaltrials.gov/show/NCT01441570||97953|
NCT01441583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-CL-07202011-B-H|Ingenio Device Algorithm Study|Ingenio Device Algorithm Study|IVORY|Boston Scientific Corporation|No|Completed|October 2011|April 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01441583||97952|
NCT01441596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.67|Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases|Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy||Boehringer Ingelheim||Completed|October 2011|August 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|121|||Female|18 Years|N/A|No|||August 2015|August 25, 2015|September 26, 2011||||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01441596||97951|
NCT01441856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36215.068.11|The ORANGE II PLUS - Trial: Open Versus Laparoscopic Hemihepatectomy|The ORANGE II PLUS - Trial: an International Multicenter Randomized Controlled Trial of Open Versus Laparoscopic Hemihepatectomies.||Maastricht University Medical Center|Yes|Recruiting|October 2013|October 2018|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|April 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01441856||97931|
NCT01441869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1681C00004|Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc|Bioequivalence Study of the Fixed-dose Combination of Saxagliptin/Metformin XR Tablets Relative to Saxagliptin (Onglyza� ) Tablets and Australia-sourced Diabex XR Tablets Coadministered to Healthy Subjects in the Fed State During Steady-state Administration||AstraZeneca||Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 7, 2012|September 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01441869||97930|
NCT01438060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN138-006|Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type|A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|August 2000|July 2010|Actual|July 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|232|||Both|55 Years|95 Years|No|||November 2013|November 7, 2013|September 2, 2011|Yes|Yes||No|February 1, 2012|https://clinicaltrials.gov/show/NCT01438060||98222|Limitations of the study, such as early termination leading to small numbers of subjects analyzed and technical problems with measurement leading to unreliable or uninterpretable data
NCT01438073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001564|Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling|Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling||Massachusetts General Hospital|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|156|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|August 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01438073||98221|
NCT01438333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/CE/2011|Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection|Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection: a Randomized, Double Masked, Placebo Controlled Clinical Trial||University of L'Aquila|Yes|Completed|September 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|15|||Both|21 Years|70 Years|No|||June 2015|June 16, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01438333||98201|
NCT01438346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00027696|Behavioral Treatment for Substance Abuse|A Pilot Study of Two Group-based Intervention Programs for Patients With Substance Abuse Problems||University of Utah|No|Completed|August 2011|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|55 Years|No|||April 2013|April 19, 2013|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01438346||98200|
NCT01438632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKPD_INSJ_2|Pharmacology of Insulin Injected With Jet-injection in Diabetes|Pharmacology of Rapid-acting Insulin Injected by Needle-free Jet-injection in Patients With Diabetes||Radboud University|Yes|Completed|September 2011|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||August 2011|March 11, 2013|September 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438632||98178|
NCT01438645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ScopeGuide 01|ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy|ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy for Improved Endoscopic Performance and Enhanced Patient Experience||University of Alberta|No|Completed|September 2011|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|250|||Both|18 Years|N/A|No|||January 2013|January 16, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01438645||98177|
NCT01438918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6171017|X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee|A Long-term, Confirmatory, Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Investigate The Safety And Efficacy Of Orally Administered Sd-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee||Pfizer|Yes|Withdrawn|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|40 Years|N/A|No|||January 2012|January 24, 2012|September 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438918||98156|
NCT01438931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-301|Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation|Phase III Randomized Placebo-controlled Double Blind Comparative Study to Investigate the Efficacy and Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation Under Monitored Sedation Care||Hospira, Inc.|No|Completed|July 2011|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|162|||Both|20 Years|N/A|No|||July 2015|July 23, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01438931||98155|
NCT01439191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C302MBCⅡ|Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer|An Open-Label Randomized Phase II Study of Cipterbin® or Cipterbin® in Combination With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (MBC)||Shanghai CP Guojian Pharmaceutical Co.,Ltd.|Yes|Completed|July 2005|May 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|70 Years|No|||June 2005|September 21, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439191||98135|
NCT01439802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-345-002|Copper Intrauterine Device (IUD) Insertion at Cesarean Delivery|Transcesarean IUD Insertion: A Prospective Cohort Study||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|August 2008|May 2010|Actual|November 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|90|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2011|September 22, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439802||98088|
NCT01440023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSA-2011-Lee|Developing Cognitive Training for Tourette Syndrome|Developing Effective Response Inhibition Training for Symptom Relief in Tourette Syndrome||University of Wisconsin, Milwaukee|No|Completed|August 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|9 Years|17 Years|No|||January 2015|January 13, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01440023||98071|
NCT01450124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|inims-03|Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)|Safety, Tolerability And Mechanism Of Action Of Boswellic Acids In Multiple Sclerosis and Clinically Isolated Syndrome: A MRI-Controlled, Multicenter, Baseline-To-Treatment, 32-Weeks, Open-Label, Phase IIa Trial|SABA|Universitätsklinikum Hamburg-Eppendorf|Yes|Completed|September 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|65 Years|No|||March 2015|March 16, 2015|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01450124||97309|
NCT01450085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI093316-01A1|Chepetsa TB - Reducing TB Among HIV-Infected Malawians|Impact of a New Molecular Tuberculosis (TB) Test on TB/HIV Outcomes Among HIV-||Johns Hopkins University|Yes|Recruiting|September 2012|||September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|2000|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450085||97312|
NCT01450098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13697|A Study of LY2484595 in Healthy Subjects|Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects||Eli Lilly and Company|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01450098||97311|
NCT01450111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0952|To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects|Single-site, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single/Repeated Dose Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects||UCB Pharma|No|Completed|November 2008|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|51|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 13, 2011|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01450111||97310|
NCT01450904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si051/2554(EC2)|The Recovery Time of Quadriceps Strength After Total Knee Arthroplasty (TKA): The Effect of Quadriceps Incision Length|The Recovery Time of Quadriceps Strength After Total Knee Arthroplasty: The Effect of Quadriceps Incision Length||Mahidol University|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|40 Years|85 Years|No|||October 2011|October 10, 2011|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01450904||97249|
NCT01440816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS-I110|IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer|A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma|MCC|OncoSec Medical Incorporated|Yes|Active, not recruiting|November 2011|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|September 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01440816||98010|
NCT01441284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOK_KA_2011_pramipexole|Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor|Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor: a Double-blind, Cross-over, Placebo-controlled Multicenter Study||University of Pecs|No|Not yet recruiting|March 2016|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||January 2016|January 14, 2016|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01441284||97975|
NCT01441271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000138/1; MGH|Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis|Diverting Loop Ileostomy and Colonic Lavage: An Alternative To Total Abdominal Colectomy For The Treatment Of Fulminant Clostridium Difficile Colitis. A Randomized Controlled Trial.||Massachusetts General Hospital|Yes|Terminated|September 2012|September 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|September 17, 2011||No|Numer of eligible patients markedly decreased since the initiation of the study.|No||https://clinicaltrials.gov/show/NCT01441271||97976|
NCT01441882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-6146|A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity|A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity||OHSU Knight Cancer Institute|Yes|Recruiting|October 2011|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441882||97929|
NCT01441895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGN02-FEMTO|Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser|A Post Market Pilot Study To Evaluate Corneal Sensation And The Incidence Of Dry Eye In Subjects Undergoing Refractive Cataract Extraction With The Femtosecond Laser For Arcuate Relaxing Incisions||Ophthalmic Consultants of Long Island|No|Recruiting|September 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Private Practice|September 2011|November 16, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01441895||97928|
NCT01437800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLMT12-SIL|BIOAVAILABILITY OF GLI/METXR (4/850 mg)|Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) in Healthy Mexican Volunteers|GLMT12-SIL|Laboratorios Silanes S.A. de C.V.|Yes|Completed|January 2011|March 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2011|September 20, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01437800||98242|
NCT01438086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCC-IGF-001|Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack|A Randomised Trial Evaluating the Safety and Efficacy of a Single Low Dose of Intracoronary Insulin-like Growth Factor-1 Following Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction (RESUS-AMI)|RESUS-AMI|University College Cork|Yes|Recruiting|October 2011|August 2016|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|75 Years|No|||July 2015|July 11, 2015|September 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01438086||98220|
NCT01438359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-DDI-002|A Drug-Drug Interaction Study of Furosemide and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Furosemide in Healthy Male and Female Adults||Vifor Inc.|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|42|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||September 2011|September 29, 2011|September 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438359||98199|
NCT01438372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108010039|IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD|Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease||Wayne State University|Yes|Withdrawn|November 2011|March 2012|Anticipated|February 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|17 Years|No|||September 2011|January 4, 2014|September 14, 2011|Yes|Yes|The study was terminated prior to enrolling patients as we were unable to secure enough    funding to complete the study.|No||https://clinicaltrials.gov/show/NCT01438372||98198|
NCT01438944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011039|Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction|Evaluation of Nicotine Receptor Up-regulation Activity Through Metabolic Induction and Changes in Responsiveness Using Surrogate Evaluation Methods||The Queen Elizabeth Hospital|Yes|Recruiting|July 2011|September 2013|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|September 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01438944||98154|
NCT01439217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1064|Endothelial Function, Arterial Stiffness and Components|Endothelial Function, Arterial Stiffness and Components of Metabolic Syndrome in Acute Lymphoblastic Leukemia (ALL) Survivors||Sidney Kimmel Comprehensive Cancer Center|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|32|||Both|8 Years|28 Years|Accepts Healthy Volunteers|Non-Probability Sample|This descriptive, healthy sibling control study will utilize a convenience sample of 20        childhood ALL survivors, recruited from the Survivorship Program at Johns Hopkins (SPJH).        The study will be introduced to survivors/parent/guardians during routine clinic visits.        If they are interested in participation the consent form for both the survivor and sibling        will be reviewed and taken home to discuss with the sibling and other family members.        Follow-up phone call and questions will be encouraged. If all parties agree to participate        an appointment will be set up to enroll the survivor/sibling and face to face informed        consent will be obtained.        A second method for recruitment will include mailings (see attached) to ALL survivors        seen/treated at Johns Hopkins. Letters will include phone and email contacts to acquire        further information and a post card to decline further contact.|April 2013|April 15, 2013|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01439217||98133|
NCT01439230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70185|Donepezil 10 mg Tablets Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Donepezil 10 mg Tablet and Aricept® (Reference) Following a 10 mg Dose in Healthy Subjects Under Fasting Conditions||Teva Pharmaceuticals USA|No|Completed|June 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2011|September 20, 2011|September 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01439230||98132|
NCT01439204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-292|Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb|A Randomized, Open-label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of Abatacept (BMS-188667) Drug Products Using Active Pharmaceutical Ingredient Manufactured at Devens, MA Site Relative to Active Pharmaceutical Ingredient Manufactured at Lonza, New Hampshire (NH) in Healthy Subjects||Bristol-Myers Squibb|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|223|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 21, 2014|September 21, 2011|No|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01439204||98134|
NCT01440647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-0090|Study of Nasal Ventilation In Preterm Infants To Decrease Time on The Respirator|Nasal Intermittent Positive Pressure Ventilation Allows Early Extubation In Infants Less Than 28 Weeks Gestation: A Pilot Study||Women and Infants Hospital of Rhode Island|Yes|Completed|November 2007|January 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|N/A|48 Hours|No|||February 2013|February 7, 2013|September 22, 2011||No||No|December 26, 2012|https://clinicaltrials.gov/show/NCT01440647||98023|
NCT01450917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si442/2552(EC2)|Diaphragmatic Height Index: the New Diagnostic Test for Phrenic Nerve Dysfunction|Diaphragmatic Height Index: the New Diagnostic Test for Phrenic Nerve Dysfunction||Mahidol University|No|Completed|September 2009|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|245|||Both|18 Years|60 Years|No|Non-Probability Sample|220 brachial plexus injured patients who underwent the neurotization and 80 non-brachial        plexus injury patients who underwent the orthopaedic operation were retrospectively        reviewed. With using nerve electrical stimulator (Aesculap Nerve Stimulator GN 24,        Tuttlingen, Germany), in neurotization procedures, phrenic nerve dysfunction is defined by        no any diaphragmatic contraction was observed intraoperatively. The enrolled patients were        classified into three main groups: (A) BPI patients with phrenic nerve dysfunction group,        (B) BPI patients with normal phrenic nerve function group and (C) non-BPI patients group.        In group A and B, we further subgroubed into: (1) for the right and (2) for the left side.|October 2011|October 10, 2011|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01450917||97248|
NCT01450397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11052|MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex|MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex||Hospital for Special Surgery, New York|No|Completed|March 2011|February 2012|Actual|January 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|35 Years|N/A|No|||May 2014|May 19, 2014|October 10, 2011||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01450397||97288|
NCT01450605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-414|Korean Post-marketing Surveillance for Reyataz®|Korean Post-marketing Surveillance for Reyataz®||Bristol-Myers Squibb|No|Recruiting|December 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of        enrollment and have never been participated in this study previously or who are initiating        Reyataz® treatment for the first time in the real-life conditions in its registered        indication(s) as required by KFDA|March 2016|March 8, 2016|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01450605||97272|
NCT01447134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB99-3338A|RGD-K5 in Head and Neck Cancer Patients|Phase II Study of [18F]RGD-K5 in Head and Neck Cancer Patients||Chang Gung Memorial Hospital|Yes|Enrolling by invitation|June 2011|June 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|100|||Both|20 Years|N/A|No|Non-Probability Sample|Up to 100 patients would be included. Group A would be those to undergo surgical excision        or biopsy (n=20); Group B would be those with N2c-3M0 disease to receive chemotherapy        followed by concurrent chemoradiotherapy (n=40); and Group C would be those with M1        disease to receive biotherapy or chemotherapy (n=40). Group A patients could be included        into Group B or C if qualified.|October 2011|October 5, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01447134||97537|
NCT01441063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110233|Tocilizumab for KSHV-Associated Multicentric Castleman Disease|Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease||National Institutes of Health Clinical Center (CC)||Recruiting|August 2011|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|18 Years|99 Years|No|||January 2016|February 13, 2016|September 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441063||97992|
NCT01441024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110205|DAS181 in Patients With Parainfluenza|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of DAS181 in Patients With Parainfluenza Infection||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 28, 2014|September 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01441024||97994|
NCT01441310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBHGS01|Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer|Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer|SNNS|Seoul National University Bundang Hospital|Yes|Active, not recruiting|July 2010|August 2016|Anticipated|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|80 Years|No|||July 2014|July 29, 2014|September 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01441310||97973|
NCT01441609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCWJ201103|Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination|Effect of the Expression Level of Th9 Cells and IL-9 In Poor/Non-responsiveness to Hepatitis B Vaccination||Beijing Municipal Science & Technology Commission|Yes|Recruiting|August 2011|May 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case Control||4|Anticipated|94|||Both|3 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|94 subjects divided into 4 groups|September 2011|September 27, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01441609||97950|
NCT01441908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAI-001|Longitudinal Study of Multi-Analyte Profile for Dyslipidemia|Determining Cardiovascular Health Using a Multi-Analyte Profile in a Longitudinal Study of a Statin Intervention for Dyslipidemia||MaiHealth Inc|No|Active, not recruiting|June 2011|April 2012|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|40|||Both|30 Years|65 Years|No|||April 2012|April 13, 2012|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01441908||97927|
NCT01472198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-324-0101|A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma|A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma||Gilead Sciences|Yes|Completed|November 2011|February 2015|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|250|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|November 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472198||95621|
NCT01471587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERICA WP1b|Fibre Specific Signalling in the Locomotor Myopathy of Chronic Obstructive Pulmonary Disease|Fibre Specific Signalling in the Locomotor Myopathy of COPD||Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|December 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|muscle and blood|Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with COPD|December 2011|December 1, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471587||95668|
NCT01473420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOE-10-13|A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin|A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|AiME - 13|Hospira, Inc.|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|80 Years|No|||May 2015|May 1, 2015|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473420||95528|
NCT01473433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICREC-2011-02|Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial)|Randomized Trial to Evaluate the Safety and Efficacy of a New Surgical Approach to Cardiac Regeneration: Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial)|adiFLAP|Germans Trias i Pujol Hospital||Completed|January 2012|December 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473433||95527|
NCT01469104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4177|Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes|Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes|CHO-free diet|Minneapolis Veterans Affairs Medical Center|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|7|||Both|45 Years|75 Years|No|||November 2011|November 9, 2011|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469104||95857|
NCT01469117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.03.US.HCN|Feeding Trial in Pediatric Patients|Enteral Formula Tolerance In Pediatric Patients With Developmental Disabilities||Nestlé|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Both|1 Year|13 Years|No|Non-Probability Sample|Pediatric patients with developmental disabilities|August 2014|August 6, 2014|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469117||95856|
NCT01469065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611005|A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes|A 2-week, Phase 1, Placebo-Controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Oral Doses Of PF-04991532 Given As Monotherapy To Adult Patients With Type 2 Diabetes Mellitus||Pfizer|No|Completed|December 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|82|||Both|18 Years|70 Years|No|||September 2013|September 26, 2013|October 25, 2011|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01469065||95860|
NCT01469078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-PK-CKD-05|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D) (PK-CKD-05)||Pharmacosmos A/S|Yes|Completed|October 2011|November 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|N/A|No|||November 2012|November 7, 2012|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469078||95859|
NCT01469091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roc-2010|Tobacco's Impact on Postoperative Complications in Acute Surgery|Tobacco's Impact on Postoperative Complications in Acute Vascular Surgery. A Randomized Clinical Trial|ROC|Rigshospitalet, Denmark|No|Terminated|February 2011|August 2014|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|160|||Both|20 Years|90 Years|No|||March 2015|March 12, 2015|October 27, 2011|Yes|Yes|Lack of patient inclusion|No||https://clinicaltrials.gov/show/NCT01469091||95858|
NCT01469598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-03-053|Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer|Phase II Study of Docetaxel and Gemcitabine in Previously Treated Metastatic Esophageal Squamous Cell Cancer||Samsung Medical Center|No|Completed|August 2011|January 2015|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01469598||95820|
NCT01469585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH DOXY RTRN|Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial MMPs|Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial MMPs||University of Hawaii|No|Active, not recruiting|November 2011|December 2014|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469585||95821|
NCT01469793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMO4993g|A Study of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer|A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer||Genentech, Inc.||Active, not recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469793||95805|
NCT01470352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migrain-0265-11CTIL|Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention|||Rambam Health Care Campus|Yes|Recruiting|December 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470352||95762|
NCT01470677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TACH-01|Tachosil for the Prevention of Symptomatic Lymph Cysts|A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial||Ruhr University of Bochum|No|Completed|November 2011|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|220|||Female|18 Years|70 Years|No|||January 2016|January 19, 2016|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01470677||95737|
NCT01470989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2357E3|An Open-label Extension Study With Canakinumab on the Treatment and Prevention of Gout Flares up to 3 Years|An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective|B-Relieved|Novartis||Completed|November 2011|||May 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|229|||Both|18 Years|85 Years|No|||May 2014|May 15, 2014|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470989||95714|
NCT01457807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0490C00003|To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers|A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers||AstraZeneca||Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|24|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01457807||96720|
NCT01458067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115717|A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency|A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency||GlaxoSmithKline|No|Active, not recruiting|November 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458067||96700|
NCT01470027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109011912|N-Acetylcysteine for Neuroprotection in Parkinson's Disease|N-Acetylcysteine for Neuroprotection in Parkinson's Disease|NAC for PD|Weill Medical College of Cornell University|No|Recruiting|January 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|November 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470027||95787|
NCT01470313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6261008|A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus|A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE)||Pfizer|No|Terminated|November 2011|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|21 Years|70 Years|No|||January 2014|January 27, 2014|November 9, 2011|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01470313||95765|
NCT01471275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|368|Chinese Medicine Treatment of Obesity With Type 2 Diabetes, Dyslipidemia|The Study of TCM in Prevention and Promote of Community-based Diabetes||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|November 2011|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|30 Years|65 Years|No|||December 2011|December 5, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01471275||95692|
NCT01470586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1948-08|Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer|Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer||G. Hatzikosta General Hospital|Yes|Completed|May 2009|June 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|60|||Both|25 Years|80 Years|Accepts Healthy Volunteers|||November 2011|November 10, 2011|November 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01470586||95744|
NCT01470599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921086|A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease|A Open-label Extension Study Of Cp-690,550 As Maintenance Therapy In Patients With Crohn's Disease||Pfizer|Yes|Recruiting|April 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|76 Years|No|||March 2016|March 11, 2016|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470599||95743|
NCT01470924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLL-180361|Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007|High Curability Via Intensive Reinduction Chemotherapy and Stem Cell Transplantation in Young Adults With Relapsed Acute Lymphoblastic Leukemia in Sweden 2003-2007||University Hospital Orebro||Completed|January 2003|June 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Both|18 Years|66 Years|No|Probability Sample|All adults with relapsed ALL|November 2011|November 10, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01470924||95719|
NCT01470937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9705-34|Early Diabetes Intervention Program|Early Diabetes Intervention Program|EDIP|Indiana University|Yes|Completed|February 1998|September 2004|Actual|September 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|25 Years|80 Years|No|||November 2011|November 10, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01470937||95718|
NCT01471574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-043|Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus|A Phase 3, Open Label Study of Safety and Efficacy With BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected With Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV)||Bristol-Myers Squibb|No|Completed|December 2011|September 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|549|||Both|18 Years|70 Years|No|||December 2015|December 22, 2015|November 4, 2011|Yes|Yes||No|August 18, 2015|https://clinicaltrials.gov/show/NCT01471574||95669|
NCT01471886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTREMS0611|Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment|Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment||EMS|Yes|Recruiting|June 2013|February 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|65 Years|No|||September 2013|September 23, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471886||95645|
NCT01472510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27906|Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy|Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy||Vitreo-Retinal Associates, PC|Yes|Completed|December 2011|January 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||March 2014|March 13, 2014|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472510||95597|
NCT01472783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Veli-BRCA|Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation|Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer|Veli-BRCA|Vejle Hospital|Yes|Active, not recruiting|November 2011|August 2016|Anticipated|January 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01472783||95576|
NCT01473082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFNA augmented|Proximal Femoral Nail Antirotation (PFNA) Versus PFNA Augmentation|Comparison of Proximal Femoral Nail Antirotation (PFNA) Versus PFNA Augmentation for the Treatment of Closed Unstable Trochanteric Fractures - A Randomized-controlled Trial||AO Clinical Investigation and Documentation|Yes|Completed|February 2012|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|251|||Both|75 Years|N/A|No|||February 2016|February 12, 2016|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01473082||95553|
NCT01473095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 092-101|Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma|A Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma||ArQule|No|Recruiting|November 2011|October 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473095||95552|
NCT01473446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/947/REK Vest|Traditional Versus Goal Directed Perioperative Fluid Therapy in High Risk Patients|Traditional Versus Goal Directed Perioperative Fluid Therapy in High Risk Patients. A Randomized, Assessor-blinded Study||Haukeland University Hospital|No|Terminated|January 2012|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2013|March 27, 2015|November 14, 2011||No|High exclusion rate|No||https://clinicaltrials.gov/show/NCT01473446||95526|
NCT01473459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0078-11-HYMC|Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients|Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome||Hillel Yaffe Medical Center|Yes|Not yet recruiting|April 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473459||95525|
NCT01469338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-11-3|Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel|A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel||University of Southern California|Yes|Terminated|July 2012|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|9|||Male|18 Years|N/A|No|||November 2014|November 21, 2014|November 1, 2011|Yes|Yes|lack of funding|No||https://clinicaltrials.gov/show/NCT01469338||95839|
NCT01469351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-000794-31|Identifying Potential Effects of Liraglutide on Degenerative Changes|Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes||University of Aarhus|Yes|Completed|January 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|50 Years|80 Years|No|||April 2013|April 18, 2013|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01469351||95838|
NCT01469364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030559|Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)|Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation|AZLI|Duke University|No|Completed|March 2013|April 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 8, 2011|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01469364||95837|
NCT01469806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-400|Patello-Femoral Joint Post Market Clinical Follow-up Within the Knee Registry|Zimmer(R) Gender Solutions(TM) Patello-Femoral Joint Prothesis Used Within the Knee Registry Protocol|PFJ PMCF|Zimmer, Inc.|No|Suspended|November 2011|October 2023|Anticipated|October 2023|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patient has patellofemoral joint(s) affected by disease process and /or injury and        qualifying for primary unilateral or bilateral replacement of the femoral trochlea based a        primary diagnosis|March 2012|March 21, 2012|October 24, 2011||No|Suspended pending internal review/direction of the company's focus.|No||https://clinicaltrials.gov/show/NCT01469806||95804|
NCT01469819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUB-119|Lubiprostone Effect on Gastrointestinal (GI) Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation|The Effect of Lubiprostone on Transit Times Within the Alimentary Tract, Measured by Novel Smartpill Methodology in Patients With Chronic Constipation||Texas Tech University Health Sciences Center, El Paso|No|Completed|June 2012|February 2015|Actual|February 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|65 Years|No|||November 2015|November 20, 2015|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01469819||95803|
NCT01470066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET2005-01|Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas|||Chonnam National University Hospital|Yes|Recruiting|August 2004|May 2012|Anticipated|May 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|This study is the observational study for the response assessments on interim PET/CT        during the treatment of peripheral T cell lymphomas. Thus, first analysis of clinical data        will be performed at the time of 80 patients enrolled or after a median follow-up of more        than 12 months.|September 2005|November 10, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01470066||95784|
NCT01470079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDM-001-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||November 10, 2011|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470079||95783|
NCT01470092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|485/11|Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Perimenopausal Depression|Double-Blind Randomised Investigation of Tibolone in Adjunct to Standard Antidepressant Treatment for Relapsed and Persistent Depression in Peri and Post Menopausal Women||The Alfred|Yes|Recruiting|July 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Female|45 Years|65 Years|No|||January 2016|January 21, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470092||95782|
NCT01470365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OER-RT-042|3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors|Phase I Study of Pulsed Low Dose Rate Reirradiation Delivered With 3DCRT/IMRT for Palliation of Recurrent Tumors||Fox Chase Cancer Center|Yes|Completed|November 2011|||August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470365||95761|
NCT01458418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH 11 01-007|A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children|A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children||Children's Mercy Hospital Kansas City|No|Terminated|December 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|4|||Both|2 Years|17 Years|No|||February 2015|February 17, 2015|October 18, 2011|Yes|Yes|Inability to complete enrollment due to difficulty in finding subjects|No||https://clinicaltrials.gov/show/NCT01458418||96673|
NCT01470612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921139|Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis|A Multi-center, Open-label Study Of Cp-690,550 In Subjects With Moderate To Severe Ulcerative Colitis|OCTAVE|Pfizer|Yes|Recruiting|October 2012|July 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470612||95742|
NCT01470625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-I LIG|Improving Quality of Care for the Dying Patient in Hospice: A Quasi Experimental Trial in Liguria Region|||Regional Palliative Care Network|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|282|||Both|N/A|N/A|No|||January 2013|January 11, 2013|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01470625||95741|
NCT01470638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flt3-L SS|A Study of Flt3-Ligand Levels in Sjögrens Syndrome|Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases||Göteborg University|No|Recruiting|June 2009|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples Without DNA|Serum, cerebrospinal fluid|Both|18 Years|N/A|No|Non-Probability Sample|The rheumatology clinic at Sahlgrenska University hospital, Gothenburg, Sweden|January 2016|January 7, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470638||95740|
NCT01470950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMStudy|Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy|Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy||Clinique Romande de Readaptation||Active, not recruiting|May 2010|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|28|||Both|18 Years|60 Years|No|||February 2015|February 4, 2015|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01470950||95717|
NCT01470963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HST1026-11|Practical Health Co-operation - The Impact of a Referral Template on Quality of Health Care|Practical Health Co-operation - a Randomised Controlled Intervention Study. The Impact of a Referral Template on Quality of Care and Health Care Co-operation Between Primary and Secondary Care||University Hospital of North Norway|No|Completed|September 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 10, 2014|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01470963||95716|
NCT01471288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88498|Effect of Carum Carvi on Thyroid Hormones and TSH Level|Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls.||Mashhad University of Medical Sciences|Yes|Recruiting|May 2011|||December 2011|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|November 14, 2011|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01471288||95691|
NCT01471600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00255-50|Safety and Efficacy of Carbohydrate Drink Ingested Two Hours Before Upper Endoscopy Under General Anaesthesia|Randomized Control Study : Safety and Efficacy of Carbohydrate Drink Ingested Two Hours Before Upper Endoscopy Under General Anaesthesia|ENDOGLUcide|University Hospital, Caen|Yes|Completed|May 2008|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|119|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 26, 2013|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01471600||95667|
NCT01471938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA-02|Application and Adaption of Device Specific Body Composition Formulas to Various Ethnic Groups|Application and Adaption of Device Specific Body Composition Formulas to Various Ethnic Groups||Seca GmbH & Co. Kg.|Yes|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||4|Actual|130|Samples Without DNA|whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Data of 130 healthy adults are planned to be collected.|February 2012|February 8, 2012|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01471938||95641|
NCT01472237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PICNIC-2011|Nutritional Intervention Program in Malnourished Patients Admitted for Heart Failure|Randomized Cotrolled Trial of Nutritional Intervention Program in Malnourished (Mini Nutritional Assessment < 17) Patients Admitted for Heart Failure|PICNIC|Hospital San Juan de la Cruz||Terminated|March 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|November 11, 2011||No|Randomization was stopped early because a significant beneficial effect of nutritional    intervention was found in the interim analysis|No||https://clinicaltrials.gov/show/NCT01472237||95618|
NCT01471249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 11.039|Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer|Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer (CT0023)||Centre hospitalier de l'Université de Montréal (CHUM)|No|Active, not recruiting|June 2011|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients referred to the thoracic clinic or in-patient|January 2016|January 26, 2016|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471249||95694|
NCT01471262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHV080501|Right Hepatectomy in Patients Beyond 70 Years Old|Right and Extended Right Hepatectomy in Patients Beyond 70 Years of Age - Liver Function and Outcome||Centre Hospitalier Universitaire Vaudois|Yes|Enrolling by invitation|January 2006|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|90|||Both|18 Years|N/A|No|Probability Sample|All patients that will undergo right or extended right hepatectomy for benign or malignant        diseases.|November 2011|November 21, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471262||95693|
NCT01473056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK853-U-09-002|Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects|Phase I,Randomized,Double-blind,Placebo-controlled,Multiple Dose Study Evaluating Safety,Tolerability,Pharmacokinetics and Antiviral Activity of JTK-853 in HCV Genotype 1 Infected Subjects,Followed by a Genotypic Resistance Monitoring Study||Akros Pharma Inc.|No|Completed|August 2010|September 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|29|||Both|18 Years|65 Years|No|||November 2011|November 17, 2011|November 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473056||95555|
NCT01473069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK853-U-10-003|Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of JTK-853 Administered for Two Weeks in Healthy Subjects||Akros Pharma Inc.|No|Terminated|March 2010|July 2010|Actual|July 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|41|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 17, 2011|November 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473069||95554|
NCT01473108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13786|Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862|Study to Investigate the Effectiveness of Different Single Oral Doses of BAY94-8862 on Natriuresis After Administration of 0.5 mg Fludrocortisone (Astonin H®) With 50 mg Eplerenone (Inspra®) as Active Control in Healthy Male Subjects in a Randomized, Single-blind, Placebo-controlled, Combined 3-fold Crossover and Parallel-group Design||Bayer|No|Completed|March 2010|May 2011|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|5||Actual|68|||Male|18 Years|46 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01473108||95551|
NCT01473121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15807|Hepatocellular Carcinoma Registry for Turkey (3K Trial)|Profile of the Hepatocellular Carcinoma Patients in Turkey||Bayer|No|Active, not recruiting|August 2012|October 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that are diagnosed with hepatocellular carcinoma in last 3 months|February 2016|February 23, 2016|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01473121||95550|
NCT01473134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE: G100123|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2011|||||N/A|N/A|N/A||||||||||||||June 24, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473134||95549|
NCT01473472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002645-35|On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men|On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men|IPERGAY|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Suspended|January 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1900|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|July 27, 2015|November 8, 2011||No|DSMB recommendations: stop of Placebo arm. Truvada available for all participants.|No||https://clinicaltrials.gov/show/NCT01473472||95524|
NCT01473485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT003|ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors|A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors||InSightec|No|Recruiting|April 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|75 Years|No|||March 2015|March 12, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473485||95523|
NCT01469130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X1101|A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors|A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors||Array BioPharma||Active, not recruiting|November 2011|||April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469130||95855|
NCT01469143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3977|A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|64 Years|No|||February 2015|February 20, 2015|November 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01469143||95854|
NCT01469377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGH-MD-75|Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder|A Double-Blind, Placebo-Controlled Study Of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder||Forest Laboratories|No|Completed|December 2011|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|819|||Both|18 Years|65 Years|No|||February 2014|February 26, 2014|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469377||95836|
NCT01469611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC IRB 2009-06-055|A Trial of JX-594 in Refractory Colorectal Carcinoma|A Phase 1b Dose Escalation Study of JX-594 (Thymidine Kinase-Inactivated Vaccinia Virus Plus GM-CSF) Administered by Biweekly (Every Two Weeks) Intravenous Infusion in Patients With Metastatic, Refractory Colorectal Carcinoma||Samsung Medical Center|No|Active, not recruiting|September 2010|October 2013|Anticipated|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01469611||95819|
NCT01469832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT hESC-RPE SMD 01 EU|Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)|A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)||Ocata Therapeutics|Yes|Active, not recruiting|November 2011|December 2015|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469832||95802|
NCT01470105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-121|Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases|Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases||Memorial Sloan Kettering Cancer Center||Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|440|Samples Without DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|Potential subjects will be recruited by the Orthopaedic Service of the Department of        Surgery.|January 2016|January 21, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470105||95781|
NCT01470118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LAS-011-001|A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis|||Allergan|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|127|||Both|10 Years|N/A|No|||January 2013|January 18, 2013|November 9, 2011|Yes|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01470118||95780|
NCT01470378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP_LILIA|Manual Lymphatic Drainage in Women Undergone to Thigh Lifting|Manual Lymphatic Drainage in Women Undergone to Thigh Lifting After Bariatric Surgery|Thight_lift|Federal University of São Paulo|Yes|Recruiting|January 2011|November 2013|Anticipated|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Female|30 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01470378||95760|
NCT01470391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-PJ-11|Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength, Pain and Mobilization After Total Knee Replacement|"A Comparison of the Efficacy of the Adductor-Canal-Blockade Versus the Femoral Nerve Block on Muscle Strength, Pain and Mobilization After Total Knee Arthroplasty: a Randomized Study||Rigshospitalet, Denmark|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|50 Years|85 Years|No|||December 2012|December 17, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470391||95759|
NCT01458951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921095|A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.|OCTAVE|Pfizer|Yes|Completed|June 2012|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|547|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458951||96632|
NCT01458964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-032f|Quetiapine Compared With Placebo in the Management of Fibromyalgia|Quetiapine Compared With Placebo in the Management of Fibromyalgia||East Tennessee State University|No|Completed|January 2008|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|60 Years|No|||July 2014|July 8, 2014|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01458964||96631|
NCT01470976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0565/11|Goal-directed Resuscitation in High-risk Patients Undergoing Cardiac Surgery|Randomized Controlled Trial of Goal-directed Resuscitation in High-risk Patients Undergoing Cardiac Surgery|GRICS|University of Sao Paulo|No|Completed|November 2011|July 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|126|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01470976||95715|
NCT01471327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115705|Japanese Phase 1 Study of Mepolizumab|A Single Blind, Placebo Controlled, Parallel Group, Single Ascending Intravenous Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-240563 (Mepolizumab) in Healthy Japanese Male Subjects.||GlaxoSmithKline|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|5||Actual|35|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2013|June 6, 2013|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471327||95688|
NCT01471301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABuosi|Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus|Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus||Federal University of São Paulo|No|Recruiting|June 2011|||November 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|120|Samples With DNA|serum|Both|18 Years|60 Years|No|Non-Probability Sample|ambulatory rheumatology|November 2011|November 14, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471301||95690|
NCT01471613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN102c|Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury|Safety and Effect of Lithium, Umbilical Cord Blood Cells and the Combination in the Treatment of Acute and Sub-acute Spinal Cord Injury : a Randomized, Double-Blinded Placebo-Controlled Clinical Trial||China Spinal Cord Injury Network||Completed|September 2011|January 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|65 Years|No|||January 2014|January 27, 2014|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01471613||95666|
NCT01471626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK/-10-81/4077|Real-time Attended Home-polysomnography Through Telematic Data Transmission|Real-time Attended Home-polysomnography Through Telematic Data Transmission|sleepbox|Centre Hospitalier Universitaire Saint Pierre|No|Completed|December 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|October 10, 2011||No||No|May 29, 2012|https://clinicaltrials.gov/show/NCT01471626||95665|-technical problems with the Skype® connection
NCT01471951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/0329|Single Human Embryo Transfer in Assisted Reproduction Programs|Single Human Embryo Transfer: Comparison of Morphologic and Morphometric Parameters for Day 2 Embryo Selection Before Transference.|SET|Fundacion Para La Investigacion Hospital La Fe|Yes|Recruiting|November 2011|June 2014|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|154|||Female|18 Years|35 Years|No|||November 2011|November 15, 2011|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471951||95640|
NCT01472263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCT-DT|Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases|Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response.|Pentox|Hospital Universitário Professor Edgard Santos|Yes|Completed|September 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|80 Years|No|||March 2015|March 17, 2015|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472263||95616|
NCT01472250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG1002|A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China|A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China||Peking University|No|Recruiting|November 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|the tumor tissue samples were collected to do gene mutation analysis|Both|18 Years|85 Years|No|Non-Probability Sample|patients with advanced gastric cancer|May 2015|May 17, 2015|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01472250||95617|
NCT01473498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091103|Personalized Mean Arterial Pressure Management on Renal Function During Septic Shock|Personalized Haemodynamic Management of Septic Shock: Influence of Mean Arterial Pressure Level on Renal Function: Randomized Controlled Trial|DORESEP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2013|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473498||95522|
NCT01469169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15503|Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study|A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of BAY q 6256 (Iloprost) Inhalation in Patients With Pulmonary Arterial Hypertension (PAH)|IBUKI|Bayer|No|Active, not recruiting|June 2012|October 2016|Anticipated|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469169||95852|
NCT01469156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVF4916s|Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy|Treatment of Polypoidal Choroidal Vasculopathy With High Dose Ranibizumab (Lucentis): A Phase I Safety Study.||Southeast Retina Center, Georgia|No|Active, not recruiting|September 2011|February 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 19, 2014|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469156||95853|
NCT01469637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD476-117|Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects||Shire||Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|November 4, 2011|No|Yes||No|September 26, 2012|https://clinicaltrials.gov/show/NCT01469637||95817|
NCT01469624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-01-01-2507|Evaluating the Protective Effect of Pentoxifylline on Contrast Induced Nephropathy|Evaluating the Protective Effect of Pentoxifylline on Contrast Induced Nephropathy||Shiraz University of Medical Sciences|Yes|Recruiting|April 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||||||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|November 8, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01469624||95818|
NCT01469845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH/1/016|The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis|Hypertonic Saline in Acute Bronchiolitis: Randomised Controlled Trial and Economic Evaluation|SABRE|Sheffield Children's NHS Foundation Trust|Yes|Completed|October 2011|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|N/A|12 Months|Accepts Healthy Volunteers|||March 2015|March 24, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01469845||95801|
NCT01470404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-05-053|Pharmacogenomic Study (Adjuvant Chemotherapy)|Pharmacogenomic Study to Predict Toxicity and Response in Gastric Cancer Patients Treated With Adjuvant Chemotherapy||Samsung Medical Center|No|Recruiting|July 2008|||May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Patients enrolled on to the adjuvant trial will be considered as candidates for the study.        Once the patient signed written informed consent, 10cc blood will be drawn in EDTA tube        for DNA extraction.|June 2013|June 12, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470404||95758|
NCT01470729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100125|Biomarkers in Autosomal Dominant Cerebellar Ataxia|Identification of Biomarkers in Patients With Autosomal Dominant Cerebellar Ataxia|BIOSCA|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2011|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||4|Actual|102|Samples With DNA|blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Spinocerebellar Ataxia Type 1 (SCA1) Spinocerebellar Ataxia Type 2 (SCA2) Spinocerebellar        Ataxia Type 3 (SCA3) Spinocerebellar Ataxia Type 7 (SCA7)|June 2014|December 15, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470729||95733|
NCT01470742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-04-118|Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer|A Randomized, Phase III, Multicenter Clinical Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer||Samsung Medical Center|No|Active, not recruiting|September 2010|December 2015|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|70 Years|N/A|No|||April 2015|April 30, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01470742||95732|
NCT01471054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wills IRB# 11-089|Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma|Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma||Wills Eye|No|Recruiting|April 2014|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|November 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471054||95709|
NCT01458977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TULIP|Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors|Prospective, Randomised, Crossover, Double-Blind, Placebo-Controlled Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors||Fundacio Lluita Contra la SIDA|No|Completed|January 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|65 Years|No|||June 2014|June 18, 2014|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01458977||96630|
NCT01458990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAJAJ004|Proton Pump Inhibitors and Dysbiosis in Cirrhosis|||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Completed|October 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01458990||96629|
NCT01459003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00811-40|Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer|Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer|BEAUTY|Gustave Roussy, Cancer Campus, Grand Paris||Completed|October 2011|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|400|||Female|18 Years|N/A|No|||May 2014|May 5, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459003||96628|
NCT01471639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUI-S4|An Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain|A Prospective, Open-label, Nonrandomized Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain|Sprix|The Cleveland Clinic|No|Active, not recruiting|November 2011|June 2016|Anticipated|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|64 Years|No|||February 2016|February 1, 2016|November 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471639||95664|
NCT01471652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ0702|Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder|Chronic Fatigue Syndrome: Correction of Mitochondrial Dysfunction by Conditioning Exercise and Nutraceutical Therapy.|CFS:M|Columbia University|Yes|Withdrawn|March 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|25 Years|55 Years|No|||April 2015|April 9, 2015|November 9, 2011|Yes|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT01471652||95663|
NCT01471340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06241|A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)|A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)|SPIRO|Merck Sharp & Dohme Corp.|Yes|Recruiting|January 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|11664|||Both|12 Years|N/A|No|||March 2016|March 23, 2016|November 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471340||95687|
NCT01471964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OER-TH-036|Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer|A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer||Fox Chase Cancer Center|Yes|Recruiting|October 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|November 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471964||95639|
NCT01471977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB|Treatment Adherence of Tuberculosis Medicines|Interventions to Promote Adherence to Tuberculosis Treatment Among Patients Attending Basic Medical Unit of Taluka Gambat, Pakistan|TBAD|Gambat Institute of Medical Sciences|No|Completed|January 2004|February 2010|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1280|||Both|18 Years|N/A|No|||November 2011|November 15, 2011|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01471977||95638|
NCT01472276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10041MMcK-OPMS|Effect of a Unique Web-based Behaviour Change Program on Weight Loss and Cardiovascular Risk Factors|Effect of a Unique Web-based Behaviour Change Program for Physical Activity and Weight Management on Weight Loss and Cardiovascular Risk Factors in Overweight or Obese Adults at High Risk of Cardiovascular Disease||Queen's University, Belfast|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01472276||95615|
NCT01472536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01CK000185-01|A Study of Exclusion Criteria in a University Population|A Randomized Study of Exclusion Criteria in a University Population|eX-FLU|University of Michigan|Yes|Completed|November 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 24, 2016|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472536||95595|
NCT01472523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZOR07H0607101|A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood|A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood|ZORAGEN|Loxbridge Research LLP|Yes|Recruiting|April 2007|July 2013|Anticipated|||N/A|Observational|N/A||2|Anticipated|600|Samples With DNA|Maternal peripheral blood samples taken in EDTA with that required for existing analysis.      Approx 1ml of fluid from amniocentesis/chorionic villus sampling is taken additional.      Patients will be followed up for 1 year after sample taken.|Female|16 Years|N/A|No|Probability Sample|Mothers attending clinic for routine screening. Followed up at around 1 years duration.|November 2011|November 15, 2011|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472523||95596|
NCT01472796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100AUS41T|Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension|Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH)|VDATH|Wayne State University|Yes|Recruiting|July 2011|March 2014|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|92|||Both|30 Years|74 Years|No|||November 2011|November 11, 2011|November 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472796||95575|
NCT01472809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYGK1/1001|A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers|A Randomized, Double Blind Placebo Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYGK1, a Novel Glucokinase Activator, Following Oral Administration in Healthy Volunteers||Cadila Healthcare Limited|Yes|Suspended|December 2011|||December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|November 9, 2011|No|Yes|Not achieved the objective till 4 mg single dose|No||https://clinicaltrials.gov/show/NCT01472809||95574|
NCT01469182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05751|A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)|A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)||Merck Sharp & Dohme Corp.|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|914|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|October 21, 2011|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01469182||95851|
NCT01469416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07522|Drug Interaction Study of Clopidogrel and Rosuvastatin|The Effects of Administering Clopidogrel on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers||University of California, San Francisco|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 16, 2014|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01469416||95834|
NCT01469429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07085|Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.|Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|September 2007|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|140|||Both|21 Years|N/A|No|||December 2015|December 15, 2015|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469429||95833|
NCT01469403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKABMI|Weight Loss Intervention Before Total Knee Replacement|Weight Loss Intervention Before Total Knee Replacement, a Randomized Controlled Trial||University of Aarhus|No|Completed|August 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|76|||Both|18 Years|N/A|No|||November 2011|March 16, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01469403||95835|
NCT01469897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 11-291|Cost of Care for Juvenile Idiopathic Arthritis|Cost of Care for Juvenile Idiopathic Arthritis||The Cleveland Clinic|No|Not yet recruiting|November 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|Children, adolescents, and young adults with JIA within Cleveland Clinic Health System and        at several other participating study sites.|November 2011|November 17, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01469897||95797|
NCT01469910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-101|Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects|Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01469910||95796|
NCT01469858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044811HMO|Perception and Multisensory Integration in Neurological Patients Using fMRI|Perception and Multisensory Integration in Neurological Patients Using fMRI||Hadassah Medical Organization|No|Not yet recruiting|November 2011|November 2015|Anticipated|November 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2011|November 8, 2011|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01469858||95800|
NCT01469871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEJ-481|Evaluation of Three Types of Dressings After Hip Surgery|Reduction of Tape Blisters After Hip Surgery. A Prospective Evaluation of Three Types of Dressings.||Hopital de l'Enfant-Jesus|No|Completed|February 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|150|||Both|45 Years|N/A|No|||November 2011|November 9, 2011|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01469871||95799|
NCT01469884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001|Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients|A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients.|CONCERVIC|Irmandade Santa Casa de Misericórdia de Porto Alegre|No|Completed|November 2011|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|November 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01469884||95798|
NCT01470131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB06002|A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma|A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase 3 Study to Compare Efficacy and Safety of Masitinib 6 mg/kg/Day in Combination With Bortezomib and Dexamethasone to Placebo in Combination With Bortezomib and Dexamethasone in the Treatment of Patients With Relapsing Multiple Myeloma Who Received One Previous Therapy||AB Science|Yes|Recruiting|May 2011|December 2014|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470131||95779|
NCT01470144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-066A302|Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension|An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)|Epitome2ext|Actelion|No|Completed|June 2011|July 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|N/A|N/A|No|||December 2015|December 14, 2015|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01470144||95778|
NCT01470755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100504|Study of Dose-response to Bronchodilator and Dose-finding in Child 2.5 to 6 Years - Study Golden|Study on Dose-response to Bronchodilator Then Bronchodilator Dose-finding Using the Flow Interruption Technique in Children Aged 2.5 TO 6 Years|DORESI|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|90|||Both|2 Years|6 Years|No|||July 2011|May 22, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470755||95731|
NCT01458730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT No 2006-004772-12|Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma|Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomide.||University of Aarhus|No|Active, not recruiting|May 2007|October 2020|Anticipated|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|75 Years|No|||November 2012|November 15, 2012|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01458730||96649|
NCT01459016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14162|A Non-drug Methods Study in Patients With Alzheimer's Disease|An Exploratory Study of Brain Imaging Biomarkers in Patients With Alzheimer's Pathology Receiving Standard of Care||Eli Lilly and Company|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|57|||Both|55 Years|N/A|No|||February 2015|February 12, 2015|October 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01459016||96627|
NCT01459029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|043211- HMO-CTIL|High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia|High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia : A Randomized, Double-Blind, Placebo-Controlled Study|SATROS|Hadassah Medical Organization|No|Not yet recruiting|November 2011|October 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|30 Years|No|||October 2011|October 24, 2011|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01459029||96626|
NCT01471015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49096|Darbe Administration in Newborns Undergoing Cooling for Encephalopathy|Darbe Administration in Newborns Undergoing Cooling for Encephalopathy|DANCE|University of Utah|Yes|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|N/A|12 Hours|No|||May 2015|May 6, 2015|November 2, 2011|Yes|Yes||No|May 6, 2015|https://clinicaltrials.gov/show/NCT01471015||95712|Due to the small number of participants, infrequent adverse events may not have been detected. There is a lack of long-term follow up to assess for long-term safety concerns.
NCT01471353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC2010-23|Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer|Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer|SorCape|University of Florida|Yes|Active, not recruiting|November 2011|December 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|November 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471353||95686|
NCT01471665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115134|GSK2190915 Neutrophilic Asthma Study|A Randomised, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effect of Treatment With Repeat Dose GSK2190915 as an add-on to Current Therapy on the Percentage of Neutrophils in Induced Sputum in Asthmatic Patients With Elevated Sputum Neutrophils||GlaxoSmithKline||Completed|June 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01471665||95662|
NCT01471990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-023|Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance|The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner||Glostrup University Hospital, Copenhagen|Yes|Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Both|18 Years|40 Years|No|||August 2012|August 28, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471990||95637|
NCT01472003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-849|An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types|An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR)||AbbVie|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|18|||Both|18 Years|N/A|No|||January 2013|January 10, 2013|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01472003||95636|
NCT01472289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPSC/POC/BMSC/CLI/2010/1b|Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia|To Study and Demonstrate the Safety and Efficacy of RES-Q Prepared Bone Marrow Mononuclear Cells Injected Into Ischemic Tissue of Patients With Non-Reconstructable Critical Limb Ischemia (CLI).||TotipotentSC Scientific Product Pvt. Ltd.|Yes|Completed|February 2011|July 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||October 2015|October 16, 2015|July 18, 2011||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT01472289||95614|
NCT01472549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB ID #: 201105161|The Skin Prep Study|Antiseptic Skin Preparation for Preventing Surgical Site Infection at Cesarean Delivery: a Randomized Comparative Effectiveness Trial||Washington University School of Medicine|Yes|Completed|September 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1147|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 8, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01472549||95594|
NCT01472562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103011566|Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma|Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma||Weill Medical College of Cornell University|No|Active, not recruiting|June 2011|December 2015|Anticipated|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|March 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472562||95593|
NCT01472822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOYD-KA-SCHISANDRA|Efficacy of Omija (Schisandra Chinensis) Extract in Subjects With Knee Osteoarthritis|Efficacy and Safety of Omija Extract on Gonarthritis||Chonbuk National University Hospital|Yes|Completed|March 2011|December 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 27, 2012|November 14, 2011||No||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01472822||95573|
NCT01469195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD410OSH|A Lead Rectangle to Lower the Operator's Radiation Exposure|A Lead Rectangle to Lower the Radiation Exposure for Operators Who Uses Radial Approach in Coronary Procedures.||Sunnybrook Health Sciences Centre|No|Not yet recruiting|December 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|75 Years|No|Probability Sample|elective or acute coronary syndrome patients who go through percutaneous coronary        intervention at one tertiary centre|November 2011|November 7, 2011|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01469195||95850|
NCT01469650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|419-11|Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants|Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants||University of Nebraska|No|Not yet recruiting|January 2012|July 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|23 Weeks|32 Weeks|No|||November 2011|November 9, 2011|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469650||95816|
NCT01469663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5910|Event Related Potentials in Borderline Personality Disorder and Major Depression|Event Related Potentials in Borderline Personality Disorder and Major Depression||State University of New York - Upstate Medical University|No|Recruiting|July 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females between age 18 to 45 recruited from staff (healthy controls) or from Upstate        Medical University primary care outpatients, psychiatry outpatients, psychiatry inpatients|November 2011|November 9, 2011|October 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01469663||95815|
NCT01470157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22/11|A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair|A Randomized, Clinical Trial of Oral Midazolam Plus Placebo Versus Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair||Assaf-Harofeh Medical Center|No|Recruiting|July 2011|July 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|10 Years|No|||November 2011|November 9, 2011|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01470157||95777|
NCT01470417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIN-1|Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma|GAIN-1 Study: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma|GAIN-1|University of Florida|Yes|Active, not recruiting|October 2011|January 2019|Anticipated|January 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|90 Years|No|||October 2015|October 15, 2015|November 9, 2011|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01470417||95757|
NCT01470430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISOR Study|VEGF In Systemic Circulation Of ROP-infants|Study to Measure Systemic VEGF Levels in ROP Infants Following Intravitreal Anti-VEGF Therapy or Retinal Laser Treatment||University Hospital Freiburg|No|Withdrawn|March 2012|||March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|prematurely born infants with retinopathy of prematurity requiring treatment|January 2014|January 26, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470430||95756|
NCT01470443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-05-070|Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma|A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma||Samsung Medical Center|No|Recruiting|December 2011|||July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470443||95755|
NCT01458743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00005|Ceftaroline China Pharmacokinetics Study|A Phase I, Single Center, Open Label, Two Groups Study to Assess the Safety and Pharmacokinetics of Ceftaroline in Healthy Chinese Volunteers Following Single and Multiple Administration of 600 mg Ceftaroline Fosamil as 60-minute Intravenous Infusion Every 12 Hours and as 120-minute Intravenous Infusion Every 8 Hours|CeftarolineChi|AstraZeneca||Completed|October 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01458743||96648|
NCT01459042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19830409|Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China|Prevalence of Primary Aldosteronism and Status of Renin-Angiotensin System in Resistant Hypertension:An Observational Study in China||Shanghai Jiao Tong University School of Medicine|Yes|Completed|January 2010|||October 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|2000|Samples With DNA|blood samples,including serum, plasma and whole blood.|Both|18 Years|65 Years|No|Probability Sample|Patients with resistant hypertension from different provinces of China|October 2011|October 24, 2011|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459042||96625|
NCT01459055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRO01|Long-term Follow-up in Patients Affected With Acrofacial Vitiligo|Long-term Ten Years Follow-up in Patients Affected With Acrofacial Vitiligo||Irmandade da Santa Casa de Misericordia de Curitiba|No|Recruiting|August 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients of both genders affected by acrofacial vitiligo diagnosed by one single        dermatologist.|October 2011|February 28, 2012|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459055||96624|
NCT01471028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-208|Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure|A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)||Vital Therapies, Inc.|Yes|Completed|February 2013|August 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|203|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471028||95711|
NCT01471041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA 024|Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae|Vital Access Venous Window Needle Guide for Salvage of AV FistulaE (SAVE) Trial|SAVE|Vital Access Corp.|Yes|Completed|December 2011|June 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||August 2013|August 27, 2013|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471041||95710|
NCT01471366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMO-0003|Method of Fish Oil Administration on Patient Compliance|What is the Best Way to Take Fish Oil?||University of Mississippi, Oxford|No|Completed|November 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|4||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471366||95685|
NCT01471678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115707|Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.|An Open-label, Randomized, Single Dose, Four-Period Crossover Study to Compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) With 10% and 15% of Enteric Coated Pellets With Harnal-D Tablets and Harnal Capsules Co-administered With Dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian Ancestry|ARI115707|GlaxoSmithKline|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01471678||95661|
NCT01471691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27847|Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab|Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)|RAVEN|Hanscom, Thomas, M.D.|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|November 9, 2011|Yes|Yes||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01471691||95660|
NCT01472016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-375|Study of ABT-700 in Subjects With Advanced Solid Tumors|A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors||AbbVie|No|Active, not recruiting|October 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|124|||Both|18 Years|99 Years|No|||February 2016|February 15, 2016|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472016||95635|
NCT01472029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-STO-0310|Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach|Multicenter, Explorative Phase II Study of Perioperative 5-FU, Leucovorin, Docetaxel, and Oxaliplatin (FLOT) in Combination With Trastuzumab in Patients With HER2-positive, Locally Advanced, Resectable Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT)|HerFLOT|AIO-Studien-gGmbH|Yes|Active, not recruiting|December 2011|February 2017|Anticipated|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01472029||95634|
NCT01472302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGCEAH-ICU 2|Closed Loop Ventilation Strategy in Intensive Care Unit (ICU) Patients|Effect of a Closed Loop Ventilation Strategy on Reducing the Total Duration of Mechanical Ventilation of Intubated Intensive Care Unit Patients: A Randomized Controlled Trial||Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital|No|Completed|April 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|229|||Both|19 Years|N/A|No|||March 2014|March 5, 2014|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472302||95613|
NCT01472315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2000-15|Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities|Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities||Turku University Hospital||Completed|January 2000|November 2000|Actual|November 2000|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Female|42 Years|77 Years|No|||March 2013|March 8, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01472315||95612|
NCT01472835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00045905|Effect of Sedation on Diagnostic Injections|Randomized, Cross-over Study Evaluating the Effect of Sedation on Pain Relief After Diagnostic Injections||Johns Hopkins University|No|Completed|March 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|73|||Both|18 Years|75 Years|No|||April 2011|May 19, 2014|April 25, 2011||No||No|March 19, 2014|https://clinicaltrials.gov/show/NCT01472835||95572|
NCT01473147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG3A0911|Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients|Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients|AGAC2|Chang Gung Memorial Hospital|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|20 Years|80 Years|No|||November 2011|July 28, 2013|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473147||95548|
NCT01473511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4839|Strongest Families Ontario (Formerly the Family Help Program)|Delivering Intervention for Pediatric Behaviour Problems at a Distance: a Randomized Trial of Strongest Families Ontario|SF-ON|IWK Health Centre|Yes|Completed|February 2010|December 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01473511||95521|
NCT01473524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|747-301|Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis|A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis|POISE|Intercept Pharmaceuticals|Yes|Active, not recruiting|January 2012|June 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|217|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473524||95520|
NCT01469208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110096A|Music Therapy: An Adjunct To Gastroschisis Infants' Care|The Effect of Music Therapy On Infants Born With Gastroschisis|MAGIC|Children's Hospitals and Clinics of Minnesota|No|Recruiting|October 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|6 Months|No|Non-Probability Sample|30 infants born with gastroschisis will be enrolled over a 2yr period. All babies will be        newborns admitted to the NICU. The babies enrolled will be both male and female and        diverse in race and ethnicity.|July 2013|July 31, 2013|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469208||95849|
NCT01469442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 114 01|Postoperative Biliary Fistula Prevention After Hepatectomy|Postoperative Biliary Fistula Prevention After Hepatectomy by External Biliary Duct Stent:Prospective Multicenter Randomized Trial||University Hospital, Toulouse|No|Recruiting|May 2009|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|304|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01469442||95832|
NCT01469676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leukocyte Filtration|Effects of Cardiopulmonary Bypass (CPB)-Leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function|Effects of CPB-leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function.|PulmFunction|University of Sao Paulo|No|Completed|February 2007|October 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|22|||Both|N/A|70 Years|No|||November 2011|November 9, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01469676||95814|
NCT01469923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3870C00002|To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses|A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 After Administration of Multiple Ascending Doses||AstraZeneca||Terminated|March 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 23, 2012|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01469923||95795|
NCT01470170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-1538A3|Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy|The Optimal Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy：a Prospective Randomized, Double-blind, Placebo-controlled Trial||Chang Gung Memorial Hospital|No|Completed|October 2010|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|5||Actual|173|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|October 27, 2011||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01470170||95776|
NCT01470469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-210|SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).||Shire||Completed|January 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|6 Years|17 Years|No|||April 2014|April 24, 2014|November 9, 2011|Yes|Yes||No|April 24, 2014|https://clinicaltrials.gov/show/NCT01470469||95753|Efficacy endpoints were exploratory. No statistical testing was performed because the study was not powered.
NCT01470794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tg 511-11-01|Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor|A P1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC||Tocagen Inc.|Yes|Active, not recruiting|January 2012|July 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01470794||95728|
NCT01470807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0054961|Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing|Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes||University of Virginia|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|65 Years|No|||November 2012|November 28, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470807||95727|
NCT01459068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003601|Mental Health Assessment Project on the Thailand-Burma Border|Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border|MHAP|Johns Hopkins Bloomberg School of Public Health|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|347|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|October 21, 2011||No||No|April 16, 2014|https://clinicaltrials.gov/show/NCT01459068||96623|
NCT01459302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13019|Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders|Family Studies in Neuromuscular Disorders||University of Massachusetts, Worcester|No|Recruiting|January 2009|October 2018|Anticipated|October 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|6000|Samples With DNA|DNA(plus Serum, frozen cells when available) will be obtained from the initial blood or      saliva sample for genetic study. RNA, skin cells or lymphoblast cells may be obtained and      stored.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals diagnosed with ALS, motor neuron disease, PLS, ALS with dementia, Miyoshi        Myopathy, some muscular dystrophies and spouse/population controls. Some family members        may be eligible to participate as well.|February 2016|February 8, 2016|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459302||96605|
NCT01471704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-005|Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers|A Phase 1b, Drug-Drug Interaction Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers|INX-189-005|Bristol-Myers Squibb|Yes|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|November 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471704||95659|
NCT01471717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-004|Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects|A Phase Ib, Single-Center, Randomized, Two-Sequence, Placebocontrolled, Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects|INX-189-004|Bristol-Myers Squibb|Yes|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|6||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|November 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471717||95658|
NCT01472042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATO-07|A Evaluation Of Biomarkers Associated With Sports Induced Concussions In College Student Athletes|A Prospective Evaluation Of Biomarkers Associated With Sports Induced Concussions In College Student Athletes|GATOR|Banyan Biomarkers, Inc|No|Recruiting|November 2011|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples Without DNA|Serum Whole Blood and Plasma|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will enroll athletes at the University of Florida, Gainesville. Teams considered        for inclusion in the study are men's football, women's lacrosse and women's soccer.|January 2015|January 26, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01472042||95633|
NCT01472328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROS Paradoxon|Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes|Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes||German Diabetes Center|No|Not yet recruiting|March 2012|August 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|30|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 20, 2011|November 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01472328||95611|
NCT01472588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAMS IRB#: 99099|Translating the Diabetes Prevention Program (DPP) Lifestyle Intervention to Rural African-American Communities (HEALTHY Ways)|Translating the DPP Lifestyle Intervention to Rural African-American Communities||University of Arkansas||Completed|September 2007|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|277|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 30, 2014|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01472588||95591|
NCT01472861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903010293|Autologous Endometrial Coculture (AECCT)|A Randomized Controlled Trial Evaluating Autologous Endometrial Coculture (AECC) As An Effective Tool For Young Patients With Poor Ovarian Reserve|AECCT|Weill Medical College of Cornell University|No|Terminated|October 2009|June 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|November 11, 2011||No|poor recruitment|No||https://clinicaltrials.gov/show/NCT01472861||95570|
NCT01473160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-347-C-014v2|Daily Disposable Contact Lens Tear Film Study|DAILIES TOTAL1 Pre-Lens Tear Film Performance - Pilot Trial||Alcon Research|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||January 2013|April 16, 2013|November 14, 2011|Yes|Yes||No|November 19, 2012|https://clinicaltrials.gov/show/NCT01473160||95547|Pilot study. Small number of participants analyzed.
NCT01473199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1151001|BioPoly RS Knee Registry Study for Cartilage Defect Replacement|Multi-centre, Open Label, Prospective, Consecutive Series Registry Database of BioPoly RS Partial Resurfacing Knee Implant||BioPoly LLC|No|Recruiting|November 2011|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|21 Years|N/A|No|||April 2015|April 23, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01473199||95544|
NCT01473537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDM 2011/1|Optimised Fluoride Prevention by Double Rinse With Fluoride and Calcium|A Double Blind, Randomized, Cross Over Designed Trial of Fluoride Prevention by Double Rinse With Calcium and Fluoride|Fluor-Ca|Karolinska Institutet|Yes|Completed|October 2011|September 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|9|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 21, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473537||95519|
NCT01473550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18451|Mental Health Engagement Network (MHEN)|Mental Health Engagement Network (MHEN): Connecting Clients With Their Health Team|MHEN|Lawson Health Research Institute|No|Completed|November 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|400|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473550||95518|
NCT01469481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2611007|Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532|An Open Label, Single-Period, Phase 1 Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance And Metabolism Of [14c]-PF-04991532 In Healthy Adult Male Subjects||Pfizer|No|Completed|November 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 27, 2012|October 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01469481||95829|
NCT01469455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DT01-01|DNA Repair Inhibitor & Irradiation on Melanoma|An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Local Metastatic Melanoma With Relapsed Cutaneous/Subcutaneous Tumors Including Melanoma-in-transit|DRIIM|DNA Therapeutics|Yes|Active, not recruiting|October 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2014|October 15, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01469455||95831|
NCT01469468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731012|A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects|A Phase 1, Open-Label, Fixed-Sequence Study To Estimate The Effect Of Repeated Dosing Of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects||Pfizer|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 27, 2011|October 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01469468||95830|
NCT01469949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEBUNIV001|Mental Imagery Enhances Proprioception in Patients With Low Back Pain|Effect of Mental Imagery in Improvement of the Repositioning Accuracy and Proprioception in Patients With Low Back Pain|MI|Lebanese University|Yes|Completed|May 2011|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|55|||Both|18 Years|21 Years|No|Non-Probability Sample|Fifty-five patients, with a history of common low back pain, have participated to the        study. The subjects have been randomly distributed in two experimental groups and one        control group. The gender, age, weight and height characteristics of the three groups        (Visual Imagery Group, VIG; Kinesthetic Imagery Group, KIG; and Control Group, CG) are        presented in Table 1. The patients presented no history of neurological or psychiatric        disease, and gave their informed written consent.|November 2011|November 9, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01469949||95793|
NCT01469936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00971-38|Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia|Study of the Effect of the Food Supplement PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia (a Pilot, Double-blind, Randomized, Placebo-controlled Study)|L2009-03|Lescuyer Laboratory|No|Active, not recruiting|November 2011|August 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Female|18 Years|60 Years|No|||March 2016|March 3, 2016|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01469936||95794|
NCT01470183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1090|Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients|Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients||Columbia University|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|46|||Both|18 Years|80 Years|No|Non-Probability Sample|Approximately 50 adult patients, 25 with lupus nephritis 25 control patients who have        greater than 1 gram per day proteinuria and non-SLE diagnoses, and who qualify for this        study based upon the stated inclusion/exclusion criteria will be recruited from the        Glomerular Center at Columbia University Medical Center.|February 2014|February 5, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01470183||95775|
NCT01470456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD12333|Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma|An Open Label, Multicenter Phase II Study of Intravenous SAR3419, an Anti-CD19 Antibody-Maytansine Conjugate, in Combination With Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphomas||Sanofi|No|Completed|November 2011|September 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|November 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01470456||95754|
NCT01470820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20090014|Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a "Saturation Point"|Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a "Saturation Point"?||University of Aarhus|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|151|||Both|33 Weeks|N/A|No|||November 2011|November 10, 2011|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01470820||95726|
NCT01471145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60-60600-97-301|Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT|Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients|XRNT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|January 2013|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 10, 2014|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471145||95702|
NCT01459588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10146X-001|Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease|||Allergan|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|315|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|October 24, 2011|Yes|Yes||No|February 11, 2013|https://clinicaltrials.gov/show/NCT01459588||96583|
NCT01459601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CabergolinDM|Cabergoline Effect on Blood Sugar in Type 2 Diabetics|Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics||Mashhad University of Medical Sciences|No|Not yet recruiting|January 2012|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||October 2011|October 24, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459601||96582|
NCT01459861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-003|Early Ambulation After Adductor Canal Block for Total Knee Arthroplasty|Assessment of Early Ambulation in Patients Receiving Continuous Adductor Canal Block With Ultrasound Guided Posterior Capsular Knee Injection vs. Femoral Nerve Block With Tibial Nerve Block Following Total Knee Replacement||Saint Francis Care|No|Terminated|October 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|80 Years|No|||February 2013|March 4, 2013|October 6, 2011||No|Administratively closed early|No||https://clinicaltrials.gov/show/NCT01459861||96562|
NCT01459874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HomeGuide|Evaluation of an Organizational Model for Remote Monitoring of Pacemaker and Implantable Cardioverter Defibrillator Recipients|Prospective Registry for the Evaluation of an Organizational Model for Remote Monitoring of Pacemaker and Implantable Cardioverter Defibrillator (ICD) Recipients in the Clinical Practice||San Filippo Neri General Hospital|Yes|Completed|March 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1650|||Both|N/A|N/A|No|Non-Probability Sample|Cardiac Implantable Device recipients|March 2013|March 26, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459874||96561|
NCT01471730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-020-MR|The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery|The ZEroPLASmaTrial (ZEPLAST): a Randomized, Controlled Trial on Transfusion Avoidance in High Transfusion-risk Cardiac Surgery Patients|ZEPLAST|IRCCS Policlinico S. Donato|No|Completed|November 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|119|||Both|18 Years|N/A|No|||March 2015|March 29, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01471730||95657|
NCT01472055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-SCT-1101|Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation|Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation||Seoul National University Hospital|Yes|Recruiting|October 2011|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|N/A|19 Years|No|||August 2014|August 18, 2014|November 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01472055||95632|
NCT01472068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-11-1014|A Pilot Study to Evaluate Safety and Performance of Neuromuscular Electrical Stimulation With the Inko RS Device for the Treatment of Stress Urinary Incontinence|A Pilot Study to Evaluate the Safety and Performance of Neuromuscular Electrical Stimulation (NMES) With the Inko RS Device for the Treatment of Stress Urinary Incontinence||Bio-Medical Research, Ltd.|No|Completed|December 2011|October 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Female|18 Years|100 Years|No|||February 2016|February 2, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01472068||95631|
NCT01472341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-113|Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)|Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes|BETADECLINE|Merck Sharp & Dohme Corp.|No|Completed|November 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|507|||Both|41 Years|N/A|No|Non-Probability Sample|Participants visiting a diabetologist as part of their routine care. Investigator's        prescription is not influenced by the study: Investigator decides about what is the best        treatment for any single participant independently of the study.|February 2015|February 4, 2015|November 11, 2011||No||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01472341||95610|
NCT01472354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S61110000013230|Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults|Feasibility of a HCV Decision-Making Intervention Among HIV-infected Adults|LEAP-C|University of Massachusetts, Worcester|No|Completed|October 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||May 2013|May 29, 2013|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01472354||95609|
NCT01472367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-170|A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)|A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)||Merck Sharp & Dohme Corp.|Yes|Recruiting|December 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|10 Years|17 Years|No|||March 2016|March 18, 2016|November 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472367||95608|
NCT01472575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38070|Impact of Rotavirus Vaccine Introduction for South Australian Children|An Observational, Cross-sectional, Cohort Study to Assess the Impact of the Rotavirus Vaccine Introduction on Severe Gastroenteritis in South Australian Children||Women's and Children's Hospital, Australia|No|Active, not recruiting|May 2009|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|1200|||Both|N/A|6 Years|No|Non-Probability Sample|males and females aged 0-less than 6 years of age admitted to SA hospital with ICD10-AM        separation codes consistent with rotaviral infection or gastroenteritis of any cause.        - for severity component, admissions to the Women's and Children's Hospital will be        examined.|November 2011|November 15, 2011|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01472575||95592|
NCT01472848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2201010|A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects|A Randomized, Double-Blind, Outpatient, Placebo-Controlled, Dose Titration Study Of Gastrointestinal Tolerability Of Pf 05212389 (Oap-189) In Obese Subjects||Pfizer|No|Withdrawn|April 2011|August 2011|Anticipated|July 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|0|||Both|18 Years|75 Years|No|||November 2011|November 11, 2011|March 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01472848||95571|
NCT01472874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORPH-SYP-001|Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease|Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease||Yale University|No|Completed|January 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|November 11, 2011|No|Yes||No|April 21, 2014|https://clinicaltrials.gov/show/NCT01472874||95569|
NCT01473173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_APA_101|Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study, to Investigate the Safety, Tolerability, PK and PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects||CJ HealthCare Corporation|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|59|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473173||95546|
NCT01473186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15116|Study of Menstrual Irregularities and Endometrial Pathology in Women Undergoing Bariatric Surgery|Prevalence of Menstrual Irregularities and Endometrial Pathology in Women Who Are Candidates for Bariatric Surgery: Correlation With Perceived Risk, Biomarkers, and Weight Loss||University of Virginia|Yes|Completed|January 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood, omentum, endometrium, adipose tissue|Female|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who are candidates for bariatric surgery at the University of Virginia Center of        Digestive health who are 18 or older|May 2015|May 29, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473186||95545|
NCT01473225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30AG034546|Can Calorie Labels Increase Caloric Intake|Can Calorie Labels Increase Caloric Intake? A Test of Possible Perverse Effects of Calorie Labels||Carnegie Mellon University||Withdrawn|November 2011|September 2014||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|November 10, 2011||No|Funding was pulled after unsuccessful pilot study|No||https://clinicaltrials.gov/show/NCT01473225||95543|
NCT01473251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VARI 2011 002|Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration|Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration||Vitreo-Retinal Associates, Michigan|No|Completed|November 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|16|||Both|18 Years|85 Years|No|||December 2014|December 16, 2014|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473251||95541|
NCT01473563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14079|A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)|Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed After Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study||Eli Lilly and Company|No|Completed|December 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|November 2, 2011||No||No|June 12, 2014|https://clinicaltrials.gov/show/NCT01473563||95517|A thorough literature search revealed that no specific validated questionnaire was available to assess participant and physician satisfaction with home care or resource utilization, therefore specific questions were created by the sponsor for use.
NCT01469221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-1012|Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)|A Phase 3 International, Double-Bind Trial Evaluating Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)||Spectrum Pharmaceuticals, Inc|Yes|Active, not recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|658|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469221||95848|
NCT01469234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18126|A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)|A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber||Bayer|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|255|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|November 8, 2011|Yes|Yes||No|February 12, 2013|https://clinicaltrials.gov/show/NCT01469234||95847|
NCT01469494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:120|Breast and Abdominal Related Morbidity of DIEP and SIEA Flaps|A Randomized Clinical Trial Comparing Breast and Abdominal Related Morbidity of DIEP and SIEA Flaps||University of Manitoba|Yes|Active, not recruiting|February 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|91|||Female|18 Years|N/A|No|||August 2014|March 19, 2015|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01469494||95828|
NCT01469689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR103348-101|Raising Awareness of Online Therapies for Depression: Pilot Study|Raising Awareness of Online Therapies for Depression: Pilot Study||University of Plymouth|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|8231|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2014|May 29, 2014|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469689||95813|
NCT01469702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-MG-0232-11-TLV-CTIL|The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease|Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|December 2011|||August 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|14 Years|60 Years|No|||November 2011|November 10, 2011|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01469702||95812|
NCT01470209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048549|A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies|A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies||Emory University|Yes|Recruiting|January 2012|February 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|63|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|October 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01470209||95773|
NCT01470196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-279|Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia|Carfilzomib, Rituximab, and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia|CaRD|Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2011|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470196||95774|
NCT01470482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ledin01|Does Tourniquet Use in Total Knee Replacement Improve Fixation|Does Tourniquet Use in Total Knee Replacement Improve Fixation||University Hospital, Linkoeping|Yes|Completed|August 2006|May 2010|Actual|May 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|85 Years|No|||June 2015|June 8, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01470482||95752|
NCT01470495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|swhb005|Combined Treatment of RFA and Sorafenib on Recurrent HCC|Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy|REPEAT|Southwest Hospital, China|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|2||Anticipated|430|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470495||95751|
NCT01471483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-164|Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer|Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Female|65 Years|N/A|No|Probability Sample|The MSKCC Gynecologic clinic|October 2015|October 15, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471483||95676|
NCT01459887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304NHL-050617|Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma|An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL||Shanghai CP Guojian Pharmaceutical Co.,Ltd.|Yes|Completed|September 2006|February 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|70 Years|No|||October 2011|October 25, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01459887||96560|
NCT01460134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX1127-01|A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers|A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors||Celldex Therapeutics|No|Active, not recruiting|October 2011|December 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460134||96541|
NCT01471405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-79-52030-742|One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma|Retrospective Non-interventional Study Evaluating Treatment Adaption During a One Year Follow-up After Completion of the 2-79-52030-207 Study in a Group of Acromegalic Patients With Macroadenoma Who Received 12 Injections of Lanreotide Autogel® 120 mg||Ipsen|No|Completed|January 2012|August 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|54|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatients|March 2014|March 27, 2014|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471405||95682|
NCT01471418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813671|The Use of PET/CT to Evaluate Synovitis in the Temporomandibular Joint (TMJ)|Investigation of the Use of Positron Emission Tomography With 18F-FDG PET/CT for the Diagnosis of Synovitis in the Temporomandibular Joint||University of Pennsylvania|No|Withdrawn|December 2011|October 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|November 10, 2011|Yes|Yes|29-Apr-14 UPENN IRB granted approval to close study due to lack of funding|No||https://clinicaltrials.gov/show/NCT01471418||95681|
NCT01471743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002602|GI Surgery Pre-Operative Nutrition|The Effect of Pre-Operative Immunonutrition With "Impact Advanced Recovery (R)" on Patients Undergoing Major GI Cancer Surgery||James A. Haley Veterans Administration Hospital|Yes|Completed|November 2011|February 2016|Actual|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|108|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471743||95656|
NCT01471756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008104|Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia|Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps||Mayo Clinic|Yes|Completed|October 2011|May 2014|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|66|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471756||95655|
NCT01472081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-016|Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)|A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma||Bristol-Myers Squibb|No|Active, not recruiting|January 2012|June 2017|Anticipated|February 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|175|||Both|18 Years|N/A|No|||January 2016|March 10, 2016|October 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01472081||95630|
NCT01472094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11127|Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults|Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults||City of Hope Medical Center|Yes|Recruiting|September 2011|||September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|Whole blood|Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Outpatient clinic practices (City of Hope, Memorial Sloan-Kettering Cancer Center, Yale        University School of Medicine, University of Rochester, University of North Carolina, Wake        Forest University, and Case Western Reserve University)|February 2016|February 1, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01472094||95629|
NCT01472614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS3233-0411|Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus|Effect of Add-on Therapy With DLBS3233 on Glycemic Control, Lipid Profile, and Adiponectin in Patients With Type-2 Diabetes Mellitus||Dexa Medica Group|Yes|Completed|September 2011|April 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|40 Years|70 Years|No|||May 2013|May 24, 2013|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472614||95589|
NCT01472601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-098|A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile|A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile in Patients Receiving Adjuvant Therapy With FOLFOX-6 After Curative Resection of Colon Cancer||Samsung Medical Center|No|Recruiting|June 2011|April 2017|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2660|||Both|18 Years|N/A|No|Probability Sample|Patients should sign a written informed consent for this translational study before or        during participating in a randomized phase III study investigating the role of oxaliplatin        duration (6 cycles versus 12 cycles) in modified FOLFOX-6 regimen as adjuvant therapy for        patients with stage II/III colon cancer|June 2013|June 12, 2013|November 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01472601||95590|
NCT01472887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD10248|SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients|An Open Label Non-Randomized Phase 2 Study Evaluating SAR3419, an Anti-CD19 Antibody - Maytansine Conjugate, Administered as Single Agent by Intravenous Infusion to Patients With Relapsed or Refractory CD19+ Diffuse Large B-Cell Lymphoma|STARLYTE|Sanofi|No|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472887||95568|
NCT01473576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-3-057|Impact of Nitrate Ingestion on Protein Synthesis|The Impact of Dietary Nitrate Ingestion on Muscle Protein Synthesis in Elderly Type II Diabetics|PRO-Nitrate|Maastricht University Medical Center|No|Active, not recruiting|November 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|25|||Male|70 Years|85 Years|No|||October 2012|October 22, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01473576||95516|
NCT01469247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0804|Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)|Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma||M.D. Anderson Cancer Center|Yes|Recruiting|December 2011|||December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|17 Years|No|||September 2015|September 30, 2015|November 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01469247||95846|
NCT01469962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/079/HP|Evaluation of Liver Fibrosis Following Surgical-induced Weight Loss|Evolution of Fibrosis Scores During Weight Loss in a Population of Patients Operated on for Morbid Obesity|FIBROTEST|University Hospital, Rouen|Yes|Completed|November 2011|February 2014|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|255|||Both|18 Years|60 Years|No|Non-Probability Sample|obese patients|June 2014|June 18, 2014|November 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01469962||95792|
NCT01470222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9279|The Healthy Weight for Life Program|The Healthy Weight for Life Program|HWL|Tufts University|No|Completed|September 2010|October 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 10, 2011|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470222||95772|
NCT01470521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08126|Worms for Immune Regulation of Multiple Sclerosis|Worms for Immune Regulation of Multiple Sclerosis (WIRMS)|WIRMS|University of Nottingham|Yes|Completed|December 2011|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470521||95749|
NCT01470508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0773|Engaging Latino Families in Eating Disorders Treatment|Engaging Latino Families in Eating Disorders Treatment|PAS|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|No|||November 2014|June 10, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470508||95750|
NCT01470833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASR2011|Non-operative Treatment of Acute Achilles Tendon Rupture Using Dynamic Rehabilitation. Influence of Early Weight-bearing Compared With Non-weight-bearing|Non-operative Treatment of Acute Achilles Tendon Rupture Using Dynamic Rehabilitation. The Influence of Early Weight-bearing Compared With Non-weight-bearing||Hvidovre University Hospital|No|Completed|April 2011|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|60 Years|No|||August 2013|August 17, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470833||95725|
NCT01464021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-194|A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China|A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China||AbbVie|No|Terminated|December 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|Samples Without DNA|Whole blood, serum|Both|18 Years|N/A|No|Non-Probability Sample|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease        duration) who meet the requirements per the local label for treatment with adalimumab.        Participants must be naïve to adalimumab at the Baseline visit.|February 2014|February 3, 2014|October 31, 2011||No|This study was prematurely terminated due to low enrollment|No|December 11, 2013|https://clinicaltrials.gov/show/NCT01464021||96245|The study was terminated early due to low enrollment and high drop-out rate. Only serious adverse events and events leading to discontinuation were collected.
NCT01464034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMyC 10-MM-01|A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma||Academic Myeloma Consortium|No|Recruiting|November 2011|June 2020|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|117|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|October 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01464034||96244|
NCT01459900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110071|Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial|Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial|ReSET|Aarhus University Hospital Skejby|Yes|Active, not recruiting|September 2011|April 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|70 Years|No|||October 2014|October 1, 2014|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459900||96559|
NCT01459913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-950-114|Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype|A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype|CONCISE|Vertex Pharmaceuticals Incorporated|No|Terminated|November 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|239|||Both|18 Years|70 Years|No|||May 2015|May 14, 2015|October 24, 2011|Yes|Yes|The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify    the drug development plan.|No|January 26, 2015|https://clinicaltrials.gov/show/NCT01459913||96558|The study was terminated early at the primary efficacy endpoint (SVR12), by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.
NCT01460147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001001|Osteoporosis and MRI Study in Hemophilia|Bone and Joint Health in an Adult Hemophilia Population||Baxalta US Inc.|No|Terminated|October 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Male|25 Years|N/A|No|||April 2012|June 26, 2015|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01460147||96540|
NCT01487382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1945|Special Survey for Paediatric Subjects|Special Survey for Paediatric Subjects||Novo Nordisk A/S|No|Completed|April 2002|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|241|||Both|N/A|15 Years|No|Non-Probability Sample|Children under 15 years of age requiring insulin therapy with no treatment history of        insulin aspart (NovoRapid®)|March 2016|March 3, 2016|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487382||94456|
NCT01471769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 10/156|Video Education Intervention in the Emergency Department|Video Education Intervention in the Emergency Department||Medical College of Wisconsin|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|4 Years|18 Years|No|||December 2012|December 17, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01471769||95654|
NCT01472107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL0511|Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy|Observational Study on Number and Outcome of Pregnancy in Childbearing Age Female Patients Treated With Chemotherapy for APL (Studies AIDA 0493, AIDA 2000)|APL0511|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Female|18 Years|50 Years|No|Non-Probability Sample|The patients enrolled in studies AIDA0493, AIDA2000 in CR .|February 2015|February 22, 2015|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472107||95628|
NCT01472380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-028-11-1001|A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz|An Open-label, Drug Interaction Study to Investigate the Effects of Steady-State Fenofibric Acid on the Single-Dose Pharmacokinetics of Efavirenz in Healthy Subjects||Mutual Pharmaceutical Company, Inc.|No|Completed|November 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|November 11, 2011|Yes|Yes||No|June 15, 2012|https://clinicaltrials.gov/show/NCT01472380||95607|
NCT01472393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP.BONE|Creatine on Bone Mass in Postmenopausal Women|A Randomized Controlled Trial: Effects of Creatine Supplementation on Bone Mass and Turnover and Muscle Function in Healthy Postmenopausal Women||University of Sao Paulo|No|Recruiting|November 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|50 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472393||95606|
NCT01472627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-272|Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro|Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2010|||October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Peripheral blood samples, bone marrow|Both|18 Years|N/A|No|Non-Probability Sample|Receiving standard of care treatment with a regimen containing bortezomib at Beth Israel        Medical Center or Dana-Farber Cancer Institute|January 2016|January 14, 2016|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01472627||95588|
NCT01472900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERYAG-AC01|2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne|A Randomized Split-Face Controlled Trial Comparing Efficacy of 2940 Nanometer Er:YAG Laser to 2.5% BP Gel for the Treatment of Inflammatory Acne||Chulalongkorn University||Completed|October 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|45 Years|No|||June 2012|June 17, 2012|November 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01472900||95567|
NCT01473238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSP_Appendix_2|Desktop Versus Mobile Data Collection in Clinical Trial|Desktop vs. Mobile Data Collection in a Prospective Multicenter Clinical Trial||University of Zurich|Yes|Not yet recruiting|January 2014|August 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 22, 2013|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473238||95542|
NCT01469507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00220 IA 0 01|Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis|Comparative Study of Efficacy and Safety of Three Intra Articular Injections of V0220 Versus Hyalgan® in Patients Suffering From Symptomatic Knee Osteoarthritis. A Multinational Multicentric, Randomised, Double-blind, Parallel-group Study|VESTA|Pierre Fabre Medicament|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|80 Years|No|||February 2013|February 20, 2013|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01469507||95827|
NCT01462123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD 2010|Resect and Discard Strategy in Clinical Practice|||Valduce Hospital||Completed|February 2011|||||N/A|Observational|Time Perspective: Prospective||1|Actual|286|||Both|18 Years|80 Years|No|Probability Sample|Consecutive adult outpatients undergoing colonoscopy for routine clinical indications|October 2011|October 28, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462123||96391|
NCT01462136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-490-004|PK Study of ACHN-490 Injection in Renally Impaired Subjects|A Phase 1 Study To Assess The Pharmacokinetics, Safety, And Tolerability of Intravenous ACHN-490 Injection in Volunteers With Varying Degrees of Renal Dysfunction Compared to Healthy Volunteers||Achaogen, Inc.|No|Completed|September 2011|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|September 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01462136||96390|
NCT01469715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15696|A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)|A Clinical Study of the Warm-Up, Accuracy, and Lag Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)|SMA002|University of Virginia|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|21 Years|65 Years|No|||July 2015|July 3, 2015|November 7, 2011|No|Yes||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01469715||95811|
NCT01469728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107/07|Comparison of Thoracoscopic Talc Pleurodesis by Thoracic Epidural or General Anesthesia|Randomized Study of Thoracoscopic Talc Pleurodesis Performed by Thoracic Epidural or General Anesthesia||University of Rome Tor Vergata|No|Completed|November 2007|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||November 2011|November 8, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01469728||95810|
NCT01469975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNFRIZZ|First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10|First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas|SYNFRIZZ|Centre Leon Berard|Yes|Active, not recruiting|December 2011|January 2018|Anticipated|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01469975||95791|
NCT01469988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82-VH-01|The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial|The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial|VITA-HF|University of Alberta|Yes|Terminated|November 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|318|||Both|40 Years|N/A|No|||April 2014|April 25, 2014|November 2, 2011||No|Feasibility|No||https://clinicaltrials.gov/show/NCT01469988||95790|
NCT01463280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klein-LidoLipo|Effect of Tumescent Lidocaine on Platelet Function|Tumescent Lidocaine Effects on Platelet Function Following Liposuction Surgical Trauma: a Prospective Controlled Dosage-response Phase I Clinical Trial||Klein, Jeffrey A., M.D.|No|Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 23, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01463280||96302|
NCT01470846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10030 PERIDIGE|Postoperative Analgesia in Abdominal Surgery: a Medico-economic Study|Epidural Analgesia vs. Morphine Patient-controlled Analgesia in Abdominal Surgery Under Laparotomy : a Medico-economic Study|PERIDIGE|University Hospital, Limoges|No|Terminated|November 2011|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|November 8, 2011||No|Lack of patients eligible for the study|No||https://clinicaltrials.gov/show/NCT01470846||95724|
NCT01471158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-18|Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma|Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Patients With Open-Angled Glaucoma or Ocular Hypertension||Alcon Research|No|Completed|September 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2011|July 9, 2014|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471158||95701|
NCT01463774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100674|A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers|Pivotal BE CANA/MET IR FDC - Low Strength||Janssen Research & Development, LLC||Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|September 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01463774||96264|
NCT01464047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-370|Korean Post-marketing Surveillance for Sprycel®|Korean Post-marketing Surveillance for Sprycel®||Bristol-Myers Squibb|No|Recruiting|October 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute        lymphoblastic leukemia (Ph+ ALL) who were never treated with Sprycel®|March 2016|March 8, 2016|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01464047||96243|
NCT01491165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12-07 liver cirrhosis|Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis|Safety and Efficacy of Umbilical Cord Mesenchyma Stem Cell Transplantation in Liver Cirrhosis Patients||General Hospital of Chinese Armed Police Forces|Yes|Recruiting|December 2011|June 2014|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|60 Years|No|||October 2012|October 25, 2012|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491165||94166|
NCT01491178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.130|Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation|Post-Marketing Surveillance on the Long-Term Use of Prazaxa® Capsules in Patients With Nonvalvular Atrial Fibrillation||Boehringer Ingelheim||Active, not recruiting|December 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6100|||Both|N/A|N/A|No|Non-Probability Sample|5000|March 2016|March 1, 2016|December 12, 2011||||No||https://clinicaltrials.gov/show/NCT01491178||94165|
NCT01487395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_41|Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development|Effect of a 15-day Donepezil Treatment on Biomarkers of AD in Healthy Volunteers|PharmacogWP3|University Hospital, Lille|No|Completed|December 2011|December 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487395||94455|
NCT01487408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1944|Special Survey for Type 1 or Type 2 Diabetic Patients|Special Survey for Type 1 or Type 2 Diabetic Patients||Novo Nordisk A/S|No|Completed|April 2002|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1463|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 1 or type 2 diabetes.|March 2016|March 3, 2016|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487408||94454|
NCT01471782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT103-205|Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|A Single-Arm Multicenter Phase II Study Preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)||Amgen Research (Munich) GmbH|Yes|Active, not recruiting|January 2012|July 2016|Anticipated|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Both|N/A|17 Years|No|||July 2015|July 23, 2015|October 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471782||95653|
NCT01472120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH-macrophage|Adiponectin and Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease (NAFLD)|The Relationship of Adiponectin With Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease||Gulhane School of Medicine|No|Not yet recruiting|December 2011|January 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|160|||Male|20 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|A sample of male outpatients with histologically proven NAFLD, who attended the outpatient        clinic of the Gastroenterology Department, Gulhane School of Medicine, Ankara, Turkey|August 2011|November 15, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472120||95627|
NCT01472406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK085628|Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)|Artificial Pancreas Device Feasibility Study for Type 1 Diabetes Patients Using Model-predictive Control and Health Monitoring System Algorithms With an Approved Subcutaneous Insulin Delivery Pump and Subcutaneous Continuous Glucose Monitor||William Sansum Diabetes Center|Yes|Recruiting|November 2011|March 2014|Anticipated|March 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||June 2012|May 22, 2013|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472406||95605|
NCT01472653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORL-01-11|Treatment Selection According to Skin Reaction to Cetuximab|Skin Reaction to Cetuximab as Criteria for Treatment Selection in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase 2 Study||Institute of Oncology Ljubljana|No|Recruiting|December 2011|December 2016|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|70 Years|No|||December 2011|December 11, 2011|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01472653||95586|
NCT01472666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-DairyHealth|Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth"|Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth"||University of Aarhus|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|63|||Both|18 Years|N/A|No|||July 2013|February 29, 2016|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01472666||95585|
NCT01472939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD557-206|Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)|A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) With Persistent Regurgitation With or Without Heartburn||Shire|Yes|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|480|||Both|18 Years|70 Years|No|||April 2014|April 25, 2014|November 14, 2011|Yes|Yes||No|March 4, 2014|https://clinicaltrials.gov/show/NCT01472939||95564|
NCT01472913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2009-69|Fibrin Sealant in Bilateral Simultaneous Total Knee Arthroplasty With Focus on Blood Loss, Pain, Swelling and Strength|Fibrin Sealant in Bilateral Simultaneous Total Knee Arthroplasty. A Prospective Randomised Double-blinded Study Focus in on: Blood Loss, Pain, ROM, Swelling and Strength||Hvidovre University Hospital|Yes|Completed|August 2010|September 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472913||95566|
NCT01472926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024541-67|Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)|Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis - Pilot Phase (ATTEST)|ATTEST|NHS Greater Glasgow and Clyde|Yes|Recruiting|December 2011|January 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||August 2012|August 9, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01472926||95565|
NCT01473264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC10-2000-001|Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)|Safety and Tolerability of Recombinant Human Clara Cell 10kDa Protein (rhCC10) Delivered Intratracheally to Premature Neonates With Respiratory Distress Syndrome||Clarassance, Inc.|Yes|Completed|January 2000|December 2003|Actual|June 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|22|||Both|24 Weeks|29 Weeks|No|||November 2011|November 16, 2011|November 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473264||95540|
NCT01461824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00583|Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects|Relationship Between Drug Exposure and DNA Markers With Depot Medroxyprogesterone Acetate-associated Side Effects in Adolescents||Nationwide Children's Hospital|Yes|Active, not recruiting|September 2011|April 2016|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|12 Years|21 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461824||96414|
NCT01462461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20448|Virtual Integrated Environment in Decreasing Phantom Limb Pain|Pilot Study of the Efficacy of a Virtual Integrated Environment in Decreasing Phantom Limb Pain|VIE|Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Completed|October 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Seven unilateral, upper-extremity amputees completed the study. These subjects were either        trans-radial (n=4) or trans-humeral (n=3) amputees.|October 2015|October 14, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01462461||96365|
NCT01462474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMTN-I-LNPC|Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma|Phase I Study of Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma|FMTN-I-LNPC|Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|October 2011|||July 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|65 Years|No|||November 2011|November 14, 2011|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462474||96364|
NCT01462448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20429|Study to Identify the Genetic Variations Associated With Phantom Limb Pain|Study to Identify the Genetic Variations Associated With Phantom Limb Pain||Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Recruiting|March 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1000|Samples With DNA|Whole blood, serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects to be recruited at WRNMMC will be military health care beneficiaries age 18 and        older who have sustained one or more amputations. To minimize within group genetic        variability, the study focuses on European American populations only.|October 2015|October 14, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01462448||96366|
NCT01462773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-04105|Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma|A Phase I Study of PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma.||Ohio State University Comprehensive Cancer Center|Yes|Completed|January 2006|April 2013|Actual|October 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||December 2014|December 30, 2014|October 19, 2011|Yes|Yes||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01462773||96341|
NCT01462786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX-101-11-30|To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101|Phase 1, Open-Label, Crossover, Safety and Pharmacokinetic Study of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Injections in the Submental and Abdominal Areas||Kythera Biopharmaceuticals|No|Completed|October 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01462786||96340|
NCT01463488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU11685|Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part I|A Two Part Protocol to Assess, Using Double Blind Placebo Control, the Safety, Tolerability, and Pharmacokinetics of Ascending Single Doses of a New Intra-articular Administration Formulation of SAR113945 (IKK Inhibitor) Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose in Patients With Knee Osteoarthritis||Sanofi|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|40 Years|N/A|No|||August 2012|August 22, 2012|October 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01463488||96286|
NCT01463761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908073|Autonomic Nervous System, Fatigue and Intolerance to Physical Training, and Overtraining in High-Level Athletes|Autonomic Nervous System, Fatigue and Intolerance to Physical Training, and Overtraining in High-Level Athletes. A Multicentre Study||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|July 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|High-level athlete, enrolled in a Ministry-recognized Pôle|March 2013|March 5, 2013|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01463761||96265|
NCT01464307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201/SP/3002|Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Lower Limb|PLUS|Merz Pharmaceuticals GmbH|Yes|Completed|December 2011|May 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|289|||Both|18 Years|80 Years|No|||July 2015|July 31, 2015|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464307||96223|
NCT01487421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1934|An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime|The Physiological Therapy of Type 2 Diabetes - NovoRapid® FlexPen® Before Meals, Additionally Levemir® FlexPen® in the Evening or at Bedtime if Needed||Novo Nordisk A/S|No|Completed|July 2003|October 2006|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2134|||Both|N/A|N/A|No|Non-Probability Sample|Patients with insufficiently controlled type 2 diabetes mellitus treated with diet, OAD        (oral anti-diabetes drug), long acting insulin, premixed insulin or a combination|June 2014|June 23, 2014|November 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487421||94453|
NCT01487668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-340|Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders|Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders||VA Office of Research and Development|No|Completed|December 2011|May 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|304|||Both|18 Years|99 Years|No|||December 2015|December 15, 2015|November 21, 2011||No||No|November 10, 2015|https://clinicaltrials.gov/show/NCT01487668||94434|
NCT01472133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1667|Validation of Respiration Rate Algorithms|Validation of Respiration Rate Algorithms||Guy's and St Thomas' NHS Foundation Trust|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|130|||Both|18 Months|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers and hospital outpatients|February 2014|February 11, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01472133||95626|
NCT01472419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMCESOPROGNOSIS|Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma|Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients||Samsung Medical Center|No|Completed|March 2012|March 2013|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|239|||Both|18 Years|N/A|No|Probability Sample|Between January 2000 to December 2010, 239 patients were diagnosed of recurrent,        metastatic esophageal SCC and received either FP or XP as first-line chemotherapy.|April 2013|April 7, 2013|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472419||95604|
NCT01472640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKprotokol(LIVE)v5|The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus|A Randomised, Double-blind, Placebo-controlled Study of the Effect of LIraglutide on Left VEntricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes (The LIVE-study)||Flyvbjerg, Allan, DMSc|No|Completed|November 2011|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|30 Years|85 Years|No|||October 2015|October 9, 2015|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472640||95587|
NCT01472952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-211N-MA|System-level Monitoring of Immune Activation Concerning Susceptibility to Sepsis in Trauma Patients|||Universitätsmedizin Mannheim|Yes|Withdrawn|February 2012|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|Blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Critical care patients with multiple trauma|October 2014|October 20, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01472952||95563|
NCT01473303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000716301|Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer|Phase IB/Randomized Phase II Study of Folfirinox Plus AMG-479 (Ganitumab) or Placebo in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma||Alliance for Clinical Trials in Oncology||Withdrawn|August 2012|||August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2012|April 4, 2013|November 15, 2011|No|Yes|CALGB 81003 closed about a week after it was activated because of withdrawal of support. No    patients were registered on this study.|No||https://clinicaltrials.gov/show/NCT01473303||95537|
NCT01473316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP27913|Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980|An Open-Label, Fixed-Sequence, 2-Period Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980||Genentech, Inc.||Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473316||95536|
NCT01473277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004682-32|Botulinum Toxin Type A (BT-A) in Hemiplegic Shoulder Pain Versus Steroid|Intra-articular Injection of Botulinum Toxin Type A in Hemiplegic Shoulder Pain: a Multicentric, Double Blind Randomised, Versus Steroid Study||The Foundation Institute San Raffaele G. Giglio of Cefalù|Yes|Not yet recruiting|January 2012|January 2013|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|70 Years|No|||November 2011|November 14, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01473277||95539|
NCT01473290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N10CB|Probiotic Therapy in Preventing Gastrointestinal Complications in Patients Undergoing Chemotherapy and Pelvic Radiation Therapy|A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy||Alliance for Clinical Trials in Oncology||Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|November 15, 2011|Yes|Yes|The study was not activated.|No||https://clinicaltrials.gov/show/NCT01473290||95538|
NCT01473589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13467|Effect of Teriparatide on Hip Fracture Healing|Effect of Teriparatide on Femoral Neck Fracture Healing||Eli Lilly and Company|Yes|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|50 Years|N/A|No|||April 2015|April 10, 2015|November 14, 2011|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01473589||95515|
NCT01469260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22651|Pedometer Use to Prevent Excessive Pregnancy Weight Gain in Overweight Women|Effective Pedometer Use to Prevent Excessive Gestational Weight Gain in Overweight/Obese Women||Stanford University|No|Not yet recruiting|November 2011|November 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|480|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 8, 2011|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469260||95845|
NCT01462149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEODOCA-OVCA|Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer|Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer||Asan Medical Center|No|Recruiting|October 2011|March 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Female|20 Years|80 Years|No|||October 2011|October 27, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01462149||96389|
NCT01462162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27833|A Prospective Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|Prospective Observational Study to Assess Impact on Fatigue of RA Patients Treated With Roactemra in the Real Life Setting||Hoffmann-La Roche||Completed|September 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|122|||Both|18 Years|N/A|No|Probability Sample|Patients with Rheumatoid Arthritis|October 2015|October 1, 2015|October 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01462162||96388|
NCT01462487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114791|Safety of Inhaled Zanamivir in Pregnancy|Assessing the Safety of Inhaled Zanamivir Exposure in Pregnant Women||GlaxoSmithKline|No|Completed|July 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|1|||Female|N/A|N/A|No|Non-Probability Sample|The observed population will include pregnant women who have received zanamivir and        pregnant women who have not received influenza antiviral therapy.        Subject pregnancies will be identified on the basis of pregnancy completion occurring from        December 2009 through November 2010 and zanamivir exposure (or the absence of it).        Follow-up data on live-born infants will be obtained at the time of delivery and for a        maximum of 28 days after birth.        The subject pregnancies' data will be obtained from the following four European data        systems: Danish National Linked Databases, CSD MR UK (formerly known as EPIC), a        subsidiary of Cegedim Strategic Data, PHARMO Network (Institute for Drug Outcomes        Research), and Swedish Medical Birth Register.|April 2014|April 17, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01462487||96363|
NCT01462799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COR-PRIM-Dnr 2010/128-3|COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care|COR-PRIM: Problem-based Learning in Patient Education After an Event of Coronary Heart Disease. A Randomised Study in Primary Care of Long-term Effects on Self-care|CORPRIM|Linkoeping University|No|Recruiting|September 2011|March 2019|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|N/A|N/A|No|||October 2011|October 27, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01462799||96339|
NCT01463098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-001|A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006|A 2-Part, Randomized, Double-blind, Placebo- and Active- Controlled, Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Subjects and Otherwise Healthy Subjects With Primary Insomnia||Eisai Inc.||Completed|October 2011|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|122|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||March 2013|May 20, 2013|October 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01463098||96316|
NCT01463072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11139|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer|Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast Cancer||City of Hope Medical Center|Yes|Active, not recruiting|June 2012|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|65 Years|N/A|No|||February 2016|February 9, 2016|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463072||96318|
NCT01463085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRV-11022|Clinical Trial to Assess the Effects of Low-fat Dairy on Systolic Blood Pressure|A Randomized, Controlled, Trial to Assess the Effects of Low-fat Dairy Intake on Endothelial Function and Blood Pressure in Subjects With Pre-hypertension or Stage 1 Hypertension||Dairy Research Institute|No|Active, not recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|65|||Both|20 Years|69 Years|No|||May 2012|May 23, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01463085||96317|
NCT01463293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-SUS-02-FON-02|B. Lactis HN019 for Functional Constipation|Effects of 4-week Bifidobacterium Lactis HN019 Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults With Constipation: A Double-blind, Randomized, Placebo-controlled Dose-ranging Trial|CTT|Fonterra Research Centre|No|Completed|March 2012|May 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|224|||Both|18 Years|70 Years|No|||June 2014|June 26, 2014|October 28, 2011||No||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01463293||96301|A substantial number of protocol violations occurred for the primary end-point. Only 39 out of 224 subjects consumed sufficent radio-opaque markers for baseline and post-intervention transit time.Therefore, the study failed to yield evaluable data.
NCT01463501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH09|Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer|Prospective Randomized Phase Ⅱ Trial Comparing Preoperative Chemoradiotherapy (Paclitaxel and Carboplatin) Followed by Surgery to Surgery Followed by Postoperative Chemoradiotherapy (Paclitaxel and Carboplatin) for Esophageal Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|October 2011|December 2016|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||September 2011|May 11, 2013|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01463501||96285|
NCT01469286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEA-Gastroparesis|Transcutaneous Electroacupuncture for Gastroparesis|Transcutaneous Electroacupuncture for Gastroparesis|TEA|Transtimulation Research, Inc|Yes|Completed|March 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469286||95843|
NCT01487434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00035771|A Randomized Study to Abate Truancy and Violence in Grades 3-9 in Chicago Public Schools|Preventing Truancy in Urban Schools Through Provision of Social Services by Truancy Officers||Northwestern University|No|Active, not recruiting|September 2011|September 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|600|||Both|5 Years|16 Years|No|||March 2016|March 23, 2016|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01487434||94452|
NCT01487681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP 40192|Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China|Prevaccination Distribution of Cervical Human Papillomavirus (HPV) Types and Their Associations With Invasive Cervical Cancer and Its Precursors in Yangtze River Delta Area, China||Zhejiang University|No|Recruiting|November 2011|October 2013|Anticipated|October 2012|Anticipated|N/A|Observational|N/A||3|Anticipated|4000|Samples With DNA|The biospecimens are remainder tissue and exfoliated cervical cells of standard diagnosis      and surgery.|Female|18 Years|65 Years|No|Non-Probability Sample|Women with histologically confirmed CIN1, CIN2, CIN3 or invasive cervical cancer (ICC)|December 2011|December 6, 2011|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01487681||94433|
NCT01487694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si573/2011|Black Cohosh Extract for the Management of Moderate to Severe Menopausal Symptoms in Thai Women|Cimicifuga Racemosa Rhizome and Root Extract for the Management of Moderate to Severe Menopausal Symptoms in Thai Women: a Randomized Controlled Trial||Mahidol University|Yes|Recruiting|December 2011|October 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Female|40 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 24, 2011|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487694||94432|
NCT01472432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT 345461|DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes|Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes||Second University of Naples|No|Active, not recruiting|May 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|106|||Both|40 Years|70 Years|No|||May 2015|May 19, 2015|November 7, 2011||No||No|May 19, 2015|https://clinicaltrials.gov/show/NCT01472432||95603|
NCT01472679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-161R|Body Composition: a Predictor of Mortality in Subjects Over 65 Years|Body Composition: a Predictor of Mortality in Subjects Over 65 Years||University Hospital, Geneva|No|Active, not recruiting|October 2011|December 2016|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|4500|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a historical cohort study of prospectively collected measurements of body        composition performed by bioelectrical impedance analysis, between 1990 and 2011.|June 2015|June 1, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01472679||95584|
NCT01461057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27836|A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer|An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer||Hoffmann-La Roche||Active, not recruiting|December 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461057||96471|
NCT01461343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001880/1|Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging|Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Arterial Hypertension Using Functional Positron Emission Tomography Imaging||Massachusetts General Hospital|No|Recruiting|February 2013|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|15|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01461343||96451|
NCT01473602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14125|Second Study of the Effect of Teriparatide on Hip Fracture Healing|Second Study of the Effect of Teriparatide on Femoral Neck Fracture Healing||Eli Lilly and Company|Yes|Completed|January 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|50 Years|N/A|No|||April 2015|April 10, 2015|November 14, 2011|Yes|Yes||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01473602||95514|
NCT01461603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110177|Local Effects of Amino Acids and 3-hydroxybutyrate in the Bilaterally Perfused Human Leg|Local Effects of Amino Acids and 3-hydroxybutyrate in the Bilaterally Perfused Human Leg||University of Aarhus|Yes|Active, not recruiting|September 2011|July 2016|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|10|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||January 2016|March 2, 2016|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01461603||96431|
NCT01462175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP27872|A First-In-Human Study of RO5503781 in Patients With Advanced Malignancies, Except Leukemia|A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia||Hoffmann-La Roche||Completed|November 2011|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01462175||96387|
NCT01472471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171086-4|Urinary 8-isoprostane is Elevated in Acute Childhood Asthma|Urinary 8-isoprostane is Elevated in Acute Childhood Asthma||Stony Brook University|No|Completed|November 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|52|Samples Without DNA|urine|Both|4 Years|18 Years|No|Non-Probability Sample|Group 1:        25 subjects will be recruited from among the children seen at the Stony Brook University        Pediatric Pulmonary and Allergy Clinic.        Group 2 25 subjects will be recruited from among the children admitted to Stony Brook        University Hospital with a diagnosis of acute asthma exacerbation or reactive airway        disease from Monday at 12 AM to Friday at 5 PM.|June 2013|June 5, 2013|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01472471||95600|
NCT01462812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-SUM-MIG-3301|Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura||Optinose US Inc.|No|Completed|January 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|223|||Both|18 Years|65 Years|No|||August 2012|April 20, 2015|October 27, 2011|Yes|Yes||No|April 20, 2015|https://clinicaltrials.gov/show/NCT01462812||96338|
NCT01473004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10D.95|SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver|An Open-Label, Single Institution, Phase II Study Using Radioactive Yttrium90 Microsphere (SIR-Sphere®) in Uveal Melanoma Patients With Hepatic Metastasis||Thomas Jefferson University|Yes|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473004||95559|
NCT01473017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/NHS/0055|Improving Mental Health in Diabetes: A Guided Self-Help Study|Improving Mental Health in Diabetes: A Guided Self-Help Study||University of Edinburgh|Yes|Not yet recruiting|November 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||November 2011|November 14, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473017||95558|
NCT01463306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081106|A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures|A 12-month Open-label Study To Evaluate The Safety And Tolerability Of Pregabalin As Adjunctive Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-clonic Seizures||Pfizer|No|Recruiting|February 2012|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|1 Month|65 Years|No|||March 2016|March 7, 2016|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01463306||96300|
NCT01463514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIRS_Study_1|Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension|Noninvasive Determination Of Cerebral Tissue Oxygenation And Cerebral Blood Flow With Near-Infrared Spectroscopy In Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization||University of Zurich|No|Completed|September 2011|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|4||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01463514||96284|
NCT01464060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INHIBRICON14|14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication|Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance||Infante, Javier Molina, M.D.|Yes|Recruiting|September 2011|January 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||December 2012|December 27, 2012|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01464060||96242|
NCT01469299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Anderson|Prospective Study Measuring Clinical Outcomes of Knee Arthroplasty Using the VERASENSE™ Knee System|Prospective Study Measuring Clinical Outcomes of Knee Arthroplasty Using the VERASENSE™ Knee System||Orthosensor, Inc.|No|Active, not recruiting|October 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|50 Years|N/A|No|Probability Sample|Primary care clinic|October 2015|October 7, 2015|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469299||95842|
NCT01487447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSMT003|Customized Acoustic Stimulation for the Treatment of Tinnitus|||University of California, Irvine||Active, not recruiting|January 2010|||July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487447||94451|
NCT01487460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP311X2101|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients|A First-in-human Randomized, Double-blind, Placebo-controlled, 4-part Study to Assess Safety, Tolerability, Pharmacokinetics (Including Open Label Study of Food Effect and Interaction With Simvastatin) and Pharmacodynamics of Interwoven Single- and Multiple-ascending Doses of TAP311 in Healthy Subjects and Dyslipidemic Patients.||Novartis||Completed|November 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|137|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01487460||94450|
NCT01487707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|019368-001|Community Based Strategies to Reduce Maternal Mortality in Northern Nigeria|Strengthening the Midwife Service Scheme With Community Focused Interventions: Evidence From a Randomized Controlled Field Trial in Nigeria||Abdul Latif Jameel Poverty Action Lab|No|Active, not recruiting|December 2011|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|7200|||Female|15 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01487707||94431|
NCT01487720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOSG-AMC-0802|GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer|A Prosepctive Phase II Study of Gemcitabine and Oxaliplatin in Combination With Prednisolone for the Treatment of Hormone Refracotry Metastatic Prostate Cancer Previously Treated With Docetaxel Regimen||Asan Medical Center|No|Completed|October 2008|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Male|18 Years|N/A|No|||November 2013|November 30, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01487720||94430|
NCT01460472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-AR-1E10 MAb-301|Immunotherapy With Racotumomab in Advanced Lung Cancer|A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy With Racotumomab Plus Best Support Treatment Versus Best Support Treatment in Patients With Advanced Non-small Cell Lung Camcer.||Recombio SL|Yes|Recruiting|September 2010|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1082|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01460472||96515|
NCT01460498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0254|Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)|Phase I-II Study of Low-Dose Azacitidine (Vidaza) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors (VZ-CML-PI-0236)||M.D. Anderson Cancer Center|No|Active, not recruiting|August 2012|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|16 Years|N/A|No|||March 2016|March 7, 2016|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460498||96514|
NCT01460732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOCTURNAL|Home Versus Ambulatory Monitoring, Diurnal Blood Pressure Profile, Detection of Non-Dippers|Home Versus Ambulatory Monitoring in the Assessment of the Diurnal Blood Pressure Profile and the Detection of Non-Dippers||University of Athens|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|81|||Both|30 Years|N/A|No|||July 2012|July 8, 2012|October 25, 2011||No||No|February 5, 2012|https://clinicaltrials.gov/show/NCT01460732||96496|
NCT01461070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911235|Intestine Bacteria and Breast Cancer Risk|BRANCH:Fecal Microbiota Among Participants in a Pre-paid Health Plan||National Institutes of Health Clinical Center (CC)||Completed|August 2011|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|200|||Female|50 Years|69 Years|No|||June 2015|July 31, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01461070||96470|
NCT01461083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPPF|Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a|Phase I Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a in Subjects With Parkinson Disease and Healthy Subjects|MPPF|Institute for Neurodegenerative Disorders|Yes|Completed|September 2011|May 2014|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|19|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|September 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01461083||96469|
NCT01461356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-001613|Minimally Invasive Surgical Approaches In Total Knee Arthroplasty|Prospective, Randomized, Controlled, Blinded Functional Outcomes Of Two Contemporary Surgical Approaches In Total Knee Arthroplasty||Mayo Clinic|No|Completed|March 2007|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|45 Years|75 Years|No|||October 2011|October 27, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01461356||96450|
NCT01461616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPH-Detemir-Glargine-2011|Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis|Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on IGFBP-1 Production and Serum IGF-I in Subjects With Type 1 Diabetes Mellitus: An Open-label, Randomised, Triple Cross-over Trial||University of Aarhus|No|Completed|February 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|65 Years|No|||December 2012|December 3, 2012|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01461616||96430|
NCT01461837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC526-4090|Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease|Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)|HaploSCD|New York Medical College|Yes|Recruiting|January 2012|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|2 Years|20 Years|No|||March 2016|March 10, 2016|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461837||96413|
NCT01472211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSF_zinc_study|Water-based Zinc Intervention Trial in Zinc Deficient Children|An Efficacy Trial of a Gravity-fed Household Water Treatment Device as a Delivery System for Zinc in Zinc Deficient Preschool Children and Pregnant Women From Rural Settings With Poor Access to Potable Water in Benin.||Swiss Federal Institute of Technology|Yes|Terminated|September 2011|September 2012|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|317|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|November 9, 2011||No|Zn released from vehicle led to fortification levels higher than planned. New filter will be    developed.|No||https://clinicaltrials.gov/show/NCT01472211||95620|
NCT01471912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-003|Elongation of Foveal Tissue After Macular Hole Surgery|Asymmetric Elongation of Foveal Tissue After Macular Hole Surgery and Its Impact on Metamorphopsia||Samsung Medical Center|No|Completed|September 2009|October 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|30 Years|75 Years|No|||November 2011|November 16, 2011|November 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01471912||95643|
NCT01472224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-069|Volume Measurement and Progression Surveillance of Intracerebral Haemorrhage Using Transcranial Ultrasound|Volume Measurement and Progression Surveillance of Intracerebral Haemorrhage Using Transcranial Ultrasound||Bispebjerg Hospital|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Acutely admitted stroke patients with intracerebral hemorrhage. Hemorrhage not older than        4,5 hours|July 2013|July 22, 2013|November 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01472224||95619|
NCT01472731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1008|Safety and Imaging Study of GC1008 in Glioma|Guiding GC1008 Treatment of Primary Brain Tumors by 89Zr-GC1008 PET Imaging.||University Medical Center Groningen|Yes|Completed|December 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|75 Years|No|||November 2012|November 13, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01472731||95580|
NCT01472744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R37AG025667|Fit & Active Seniors Trial|Influence of Fitness on Brain and Cognition II|FAST|University of Illinois at Urbana-Champaign|Yes|Completed|August 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|247|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|August 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01472744||95579|
NCT01472757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR506/2/002|Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma||Vectura Limited||Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|374|||Both|12 Years|65 Years|No|||May 2014|May 9, 2014|November 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01472757||95578|
NCT01472770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GemCap|A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer|A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer|GemCaP|Vejle Hospital|Yes|Completed|October 2011|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01472770||95577|
NCT01473355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHN-0003|Study on OsseoSpeed™ TX Narrow Implants in the Lower Jaw in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate OsseoSpeed™ TX Single Implant 3 mm Diameter in the Anterior Mandible. A 3-years Follow-up Study.||Dentsply Implants||Active, not recruiting|October 2011|||November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|75 Years|No|||March 2016|March 21, 2016|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473355||95533|
NCT01473368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000389-Bioclinica|Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota|Open Label, Randomized Pilot Study to Examine The Effects of the Probiotic Saccharomyces Boulardii, the Antibiotic Amoxicillin/Clavulanate and the Combination on the Gut Microbiota of Healthy Volunteers||Beth Israel Deaconess Medical Center|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|53|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|November 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473368||95532|
NCT01469026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K36|CUP Project PET/CT|The Value of Early PET/CT in Patients With Metastasising Cancer of Unknown Primary||Odense University Hospital|Yes|Not yet recruiting|November 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|220|||Both|18 Years|N/A|No|||November 2011|November 9, 2011|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01469026||95863|
NCT01469039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK9072-003|A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia||Alkermes, Inc.|Yes|Completed|December 2011|March 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|623|||Both|18 Years|70 Years|No|||December 2015|December 16, 2015|November 8, 2011|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01469039||95862|
NCT01469052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG013736-001|First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors|Phase I, Open-Label, Multicenter, Dose-Escalation Study Of The Tyrosine Kinase Inhibitor Of VEGFR-2, AG013736, In Patients With Advanced Solid Tumors||Pfizer|No|Completed|November 2002|August 2004|Actual|July 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|N/A|No|||February 2012|February 25, 2012|November 2, 2011|No|Yes||No|February 25, 2012|https://clinicaltrials.gov/show/NCT01469052||95861|
NCT01469312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4231|Effect of Pasta on Blood Glucose Response in Normal Subjects|Effect of Pasta on Blood Glucose Response in Normal Subjects||Minneapolis Veterans Affairs Medical Center|No|Completed|April 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|20|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2011|November 9, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01469312||95841|
NCT01469572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051599|Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases|Phase IB/II Study of Pasireotide, Everolimus and Selective Internal Radioembolization Therapy (SIRT) for Unresectable Neuroendocrine Hepatic Metastases||Emory University|Yes|Active, not recruiting|December 2011|March 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01469572||95822|
NCT01488006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5360|Columbia Shoulder Study (CSS)|5- Year Follow-up in Total Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis: A Prospective Multicenter Study|CSS|Columbia University|No|Completed|April 2001|November 2012|Actual|October 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|207|||Both|18 Years|N/A|No|Probability Sample|Subjects will be recruited when the decision to undergo shoulder arthroplasty is made. The        surgeon will confirm that the subject is appropriate for inclusion in the study. The        surgeon will confirm that the subject is appropriate for inclusion in the study.|July 2015|July 7, 2015|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01488006||94408|
NCT01488266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASCADE|Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder|Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study||Korea University|No|Active, not recruiting|November 2011|March 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|20 Years|N/A|No|||December 2011|December 6, 2011|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01488266||94388|
NCT01460511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-D|Evaluation of Efficacy and Safety of E004 in Children With Asthma|Phase III Study of Epinephrine Inhalation Aerosol for Evaluation of Efficacy and Safety of E004 in Children With Asthma||Amphastar Pharmaceuticals, Inc.|No|Completed|October 2011|July 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|4 Years|11 Years|No|||July 2012|July 11, 2012|October 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01460511||96513|
NCT01460745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR062202-546|A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice|A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice|RESECT|Merck KGaA||Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|February 2014|February 3, 2014|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460745||96495|
NCT01461369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIC3-08-05|Study of Diclofenac Capsules to Treat Osteoarthritis Pain|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy and Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip||Iroko Pharmaceuticals, LLC|No|Completed|October 2011|October 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|305|||Both|40 Years|N/A|No|||April 2014|April 29, 2014|October 26, 2011|Yes|Yes||No|March 12, 2014|https://clinicaltrials.gov/show/NCT01461369||96449|
NCT01461382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003809|Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss|Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss||Mayo Clinic|No|Completed|May 2008|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2011|October 27, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01461382||96448|
NCT01461642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L7 - 3653 - ASTHMA|E-support for Healthcare Processes - ASTHMA|E-support for Healthcare Processes - ASTHMA|E-ASTHMA|The University Clinic of Pulmonary and Allergic Diseases Golnik|No|Recruiting|October 2011|April 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|70 Years|No|||October 2011|October 27, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461642||96428|
NCT01461655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0045-01|Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris|Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model||LEO Pharma|No|Completed|November 2011|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|35 Years|No|||October 2013|October 7, 2013|October 25, 2011||No||No|April 17, 2013|https://clinicaltrials.gov/show/NCT01461655||96427|
NCT01461629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10217650|Self-management and Cognitive Function in Adults With Heart Failure|Cognitive Impairment and Self-management in Adults With Heart Failure|Heart ABC|Kent State University||Recruiting|June 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|55 Years|85 Years|No|Non-Probability Sample|50-85 years of age, documented diagnosis of systolic heart failure (EF </= 35%) at least        12 months prior to enrollment|October 2011|October 27, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01461629||96429|
NCT01471561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP00099|Analysis of Cataract Surgery Induced Dry Eye|Retrospective Analysis of Cataract Surgery-induced Dry Eye Using Tear Osmolarity Testing||TearLab Corporation|No|Completed|October 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Male or female, eighteen years of age or older          2. Confirmed diagnosis of cataract with cataract surgery performed in at least one eye|February 2016|February 2, 2016|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471561||95670|
NCT01461850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|789/11|Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm|Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm|SCORPION|Catholic University of the Sacred Heart|No|Recruiting|September 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|166|||Female|18 Years|75 Years|No|||August 2015|August 23, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01461850||96412|
NCT01471899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRGEMS0611|Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment|Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment||EMS|Yes|Not yet recruiting|October 2013|September 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|65 Years|No|||September 2013|September 24, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471899||95644|
NCT01471925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 095|Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC|A Phase III, Randomized, Open-label, Superiority Study Comparing the Incremental Product Esomeprazole Associated With Sodium Bicarbonate Made by Eurofarma and Nexium® in the Treatment of Gastroesophageal Reflux Disease||Eurofarma Laboratorios S.A.|No|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2011|July 24, 2015|October 31, 2011||No|Change company strategy|No||https://clinicaltrials.gov/show/NCT01471925||95642|
NCT01473043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4061061|Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment|Clinical Study With Axitinib (AG 013736) In Patients With Metastatic Renal Cell Carcinoma After Failure Of One Prior Systemic First-Line Therapy||Pfizer|No|No longer available|March 2012|March 2014|Actual|March 2014|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||May 2014|May 28, 2014|November 14, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01473043||95556|
NCT01473394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-03|Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder|A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|518|||Both|18 Years|70 Years|No|||February 2014|February 21, 2014|November 14, 2011|Yes|Yes||No|February 21, 2014|https://clinicaltrials.gov/show/NCT01473394||95530|
NCT01473407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOE-10-01|A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin|A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|AiME - 01|Hospira, Inc.|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|612|||Both|18 Years|80 Years|No|||May 2015|May 1, 2015|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473407||95529|
NCT01472484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lpa_586/8X87|Impact of Bean Polyphenols and Phytic Acid on Iron Absorption|A Stable Iron Isotope Study to Investigate the Impact of Phytic Acid and Polyphenols on Iron Absorption From Beans in Humans||Swiss Federal Institute of Technology|No|Completed|December 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01472484||95599|
NCT01472497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIO and HTN|Effects of Pioglitazone in Hypertensive Patients|Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -||Tottori University Hospital|No|Completed|April 2007|March 2012|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|N/A|No|||June 2012|June 3, 2012|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01472497||95598|
NCT01469325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-03-49-14937|Sequential Left Prefrontal Repetitive Transcranial Magnetic Stimulation, With High Frequency, for Treatment-Resistant Depression|Effectiveness of of Sequential Left Prefrontal Repetitive Transcranial Magnetic Stimulation, With High Frequency, for Treatment-Resistant Depression, in TMS Unit, Neurcognitive Lab, Iranian National Center for Addiction Studies (INCAS), in 2011. A Randomized, Controlled Trial.||Tehran University of Medical Sciences|Yes|Not yet recruiting|November 2011|February 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||November 2011|November 20, 2011|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01469325||95840|
NCT01473030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0646|Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue|Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue||University of Illinois at Chicago|No|Active, not recruiting|November 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|80||Biopsy tissue (Year 2 and Year 4) already collected in REDUCE trial|Male|50 Years|75 Years|No|Probability Sample|Cross-sectional comparison of biomarkers in prostate biopsy tissue (Year 2 and Year 4)        already collected in REDUCE trial|December 2015|December 1, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473030||95557|
NCT01473381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-01|Safety and Efficacy of Vilazodone in Major Depressive Disorder|A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder|VLZ-MD-01|Forest Laboratories|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1162|||Both|18 Years|70 Years|No|||August 2014|August 6, 2014|November 14, 2011|Yes|Yes||No|June 13, 2014|https://clinicaltrials.gov/show/NCT01473381||95531|
NCT01470053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_NSFX_301|Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis|A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Mometasone Furoate/Azelastine Hydrochloride Combination Group and Mometasone Furoate and Azelastine Hydrochloride Group 4 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Perennial Allergic Rhinitis Patient.||Hanlim Pharm. Co., Ltd.|No|Completed|March 2011|November 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|347|||Both|12 Years|N/A|No|||November 2011|August 26, 2013|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01470053||95785|
NCT01470339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0462-10-RMB.CTIL|Improvement the Anti-migraine Treatment Efficacy by Tailoring the Drug to Individual's Pain Modulation Profile|||Rambam Health Care Campus|Yes|Completed|December 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470339||95763|
NCT01457794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D208|OPUS School Meal Study|OPUS(Optimal Well-being, Development and Health for Danish Children Through a Healthy New Nordic Diet) School Meal Study||University of Copenhagen|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|834|||Both|8 Years|11 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457794||96721|
NCT01458054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115711|Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults|Phase 1, Open Label Study to Evaluate the Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults||GlaxoSmithKline|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|28|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01458054||96701|
NCT01458379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R092670SCH4005|Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia|Brain Myelination Effects of Paliperidone Palmitate vs. Oral Risperidone in First Episode Schizophrenia||University of California, Los Angeles|No|Not yet recruiting|August 2012|December 2015|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458379||96676|
NCT01458392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A041-03|Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck|An Open-label Phase 2 Study of Dalantercept in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck||Acceleron Pharma, Inc.|Yes|Completed|October 2011|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458392||96675|
NCT01460758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-ACDC01|Effectiveness of rTMS With Double-Cone-Coil in Patients With Major Depression|Effectiveness of Medial Frontal Repetitive Transcranial Magnetic Stimulation With Double-Cone-Coil in Patients With Major Depression|ACDC|University of Regensburg|No|Completed|April 2011|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|75 Years|No|||April 2014|April 25, 2014|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01460758||96494|
NCT01461096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5298|Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men and Women|A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men and Women||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|March 2012|January 2016|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|576|||Both|27 Years|N/A|No|||March 2016|March 14, 2016|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01461096||96468|
NCT01461109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlyT1-01|Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls|Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects||Institute for Neurodegenerative Disorders|No|Completed|August 2011|May 2014|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|September 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01461109||96467|
NCT01481818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTERD2011|Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis|Phase Ⅰ,ⅡStudy of Topically Applied Green Tea Extract for Prevention and Treatment of Radio Dermatitis and Radiation Mucositis||Shandong Cancer Hospital and Institute|No|Enrolling by invitation|September 2011|April 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|15|||Both|18 Years|75 Years|No|||March 2014|May 20, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01481818||94884|
NCT01481285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA-03 / BCA-04|Generation of Normal Ranges to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)|Generation of Normal Ranges to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)||Seca GmbH & Co. Kg.|Yes|Completed|October 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|992|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Data of 992 healthy adults are planned to be collected.|October 2012|October 2, 2012|July 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481285||94925|
NCT01482390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV27779|A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C|A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH TELAPREVIR AND PEGASYS®/COPEGUS® IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUS INFECTION WHO WERE PRIOR NULL RESPONDERS TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN||Hoffmann-La Roche||Completed|December 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482390||94840|
NCT01482403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV27780|A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C|A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION WITH BOCEPREVIR AND PEGASYS®/COPEGUS® IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUS INFECTION WHO WERE PRIOR NULL RESPONDERS TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN||Hoffmann-La Roche||Completed|November 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482403||94839|
NCT01478763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitreous1|Vitrous Analysis in Proliferative Diabetic Retinopathy|Analysis of Vitreous Proteins in Patients Undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy||St. Erik Eye Hospital|No|Completed|January 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples With DNA|Vitreous samples|Both|12 Years|N/A|No|Probability Sample|Patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy|September 2014|September 24, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478763||95118|
NCT01478776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15176|The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics|The Impact of Omega-3 Supplementation on Acylation Stimulating Protein(ASP), Retinol-binding Protein 4 (RBP4) and Lipocalin-2 (LCN2) Gene Expression of ASP Receptor (C5L2) in WBC of Patient With Diabetes Type 2||Tehran University of Medical Sciences|Yes|Enrolling by invitation|December 2011|September 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|65 Years|No|||November 2012|November 30, 2012|November 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478776||95117|
NCT01479023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202074|Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors|A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287||Washington University School of Medicine|No|Terminated|April 2012|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|12|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|November 17, 2011|No|Yes|treatment was not working|No||https://clinicaltrials.gov/show/NCT01479023||95098|
NCT01484691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07039|Role of microRNAs in T Cell-Driven Inflammation in Asthma|Role of miRNAs in Th2-driven Inflammation in Asthma|RITA|University of California, San Francisco|No|Recruiting|October 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01484691||94663|
NCT01484964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK19|A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation|A Phase I, Single-Dose, Open-Label, Three-Period, Randomized, Crossover Study to Compare the Relative Bioavailability Between Two Tablet Formulations of ASP015K and to Assess the Food Effect on a New Formulation in Healthy Volunteers||Astellas Pharma Inc|No|Completed|September 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 1, 2011|December 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01484964||94642|
NCT01484977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0980|eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam|Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures|VERVE|UCB Pharma|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|December 1, 2011|Yes|Yes||No|November 20, 2014|https://clinicaltrials.gov/show/NCT01484977||94641|
NCT01484938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-017|Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers|Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers||Alcon Research|No|Completed|February 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|175|||Both|18 Years|N/A|No|||October 2012|October 5, 2012|December 1, 2011|Yes|Yes||No|September 6, 2012|https://clinicaltrials.gov/show/NCT01484938||94644|
NCT01484951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-10-11|AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure|Assessing the Safety and Efficacy of Switching to AZARGA® (Brinzolamide/Timolol Fixed Combination) as Replacement Therapy in Patients With Uncontrolled Intraocular Pressure in Taiwan||Alcon Research|No|Completed|May 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|20 Years|N/A|No|||April 2013|April 25, 2013|December 1, 2011|No|Yes||No|March 12, 2013|https://clinicaltrials.gov/show/NCT01484951||94643|
NCT01485471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2010-8015|Spectroscopic Evaluation of Middle Ear Infection|Spectroscopic Evaluation of Middle Ear Infection||University of California, Irvine|No|Withdrawn|June 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|UCI otolaryngology clinic|August 2015|August 5, 2015|August 2, 2011||No|No paticipants enrolled|No||https://clinicaltrials.gov/show/NCT01485471||94603|
NCT01485731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100153|Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer|Phase 1 Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)||University of Miami|Yes|Completed|January 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01485731||94583|
NCT01470690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 10.06|Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)|Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)|PROMO|Radboud University|No|Completed|October 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01470690||95736|
NCT01470703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRCB 2009-A01026-51|Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome|Extracorporeal Membrane Oxygenation(ECMO) for Severe Acute Respiratory Distress Syndrome (ARDS)|EOLIA|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|October 2011|February 2017|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|331|||Both|18 Years|N/A|No|||July 2015|November 11, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01470703||95735|
NCT01479192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S462/109|Fenretinide in Healthy Young Women at Genetic and Familial Risk|Breast Cancer Prevention With Fenretinide in Young Women at Genetic and Familil Risk. A Phase III Randomized Clinical Trial||European Institute of Oncology|No|Terminated|December 2009|December 2024|Anticipated|December 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Female|20 Years|46 Years|No|||December 2015|January 21, 2016|November 22, 2011||No|very low rate of patient accrual|No||https://clinicaltrials.gov/show/NCT01479192||95085|
NCT01479777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00016421|Functional Electrical Stimulation (FES) Driven Stepping in Individuals With Spinal Cord Injury|FES Driven Stepping in Individuals With Spinal Cord Injury||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Completed|April 2011|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|No|||September 2014|September 9, 2014|November 15, 2011||No||No|August 1, 2013|https://clinicaltrials.gov/show/NCT01479777||95041|
NCT01479998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104008332|Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes|Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes||Yale University|Yes|Terminated|November 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|85 Years|No|||January 2014|January 10, 2014|November 4, 2011||No|Reevaluating recruitment strategies|No||https://clinicaltrials.gov/show/NCT01479998||95024|
NCT01480245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114349|Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of GSK2402968 in Subjects With Duchenne Muscular Dystrophy||GlaxoSmithKline|No|Terminated|September 2011|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|233|||Male|5 Years|N/A|No|||September 2014|September 25, 2014|November 23, 2011||No|The study was formally terminated given that GSK is not submitting an application for    regulatory approval for drisapersen in Duchenne Muscular Dystrophy.|No||https://clinicaltrials.gov/show/NCT01480245||95005|
NCT01480817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAP|Sorafenib VS TACE in HCC Patients With Portal Vein Invasion|An Open Label, Phase 2 Trial Comparing Sorafenib And TACE in Advanced Hepatocellular Carcinoma With Portal Vein Invasion||Seoul National University Hospital|No|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|79 Years|No|||December 2013|November 26, 2014|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01480817||94961|
NCT01480557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|liq75tor|Aqualase Versus Torsional ip. A Study on Endothelial Cells, Corneal Edema and Corneal Sensitivity|Liquefaction Versus Torsional ip. A Comparative Study on Endothelial Cells, Corneal Edema and Corneal Sensitivity||Democritus University of Thrace|No|Completed|April 2011|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|75|||Both|55 Years|95 Years|No|||November 2011|November 28, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01480557||94981|
NCT01480570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elipses-1218|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2011|||||N/A|N/A|N/A||||||||||||||February 9, 2015|September 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480570||94980|
NCT01481831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhiruo|Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting|A Multi-center, Stratified Randomized, Controlled Study to Evaluate the Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in China|ESPNV|Shanghai Changzheng Hospital||Completed|July 2011|||August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|599|||Both|18 Years|75 Years|No|||December 2012|December 28, 2012|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01481831||94883|
NCT01482091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-343|Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis|Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial||Montefiore Medical Center|Yes|Completed|December 2011|||February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|3 Years|21 Years|No|||December 2015|December 18, 2015|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482091||94863|
NCT01478438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-002|A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers|A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers||Novian Health Inc.||Active, not recruiting|April 2012|||December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|80 Years|No|||March 2016|March 21, 2016|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478438||95143|
NCT01478451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA02|Acute Effect of Massage and Exercise on Muscle Tenderness|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace||National Research Centre for the Working Environment, Denmark|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|20|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01478451||95142|
NCT01478464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA03|Effect of Massage on Hamstring Muscle Soreness|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|IRMA|National Research Centre for the Working Environment, Denmark|No|Completed|December 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Male|18 Years|67 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01478464||95141|
NCT01482949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-003-005|A Rollover Protocol for Subjects Previously Treated With AGS-003|A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006||Argos Therapeutics|No|Enrolling by invitation|September 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|7|||Both|18 Years|N/A|No|||January 2013|December 18, 2014|November 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482949||94797|
NCT01483248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEB-1115-LC|Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis|Phase 1/2 Study of Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation for the Evaluation of the Efficacy and Safety in Patients With Liver Cirrhosis||S-Evans Biosciences Co.,Ltd.|Yes|Enrolling by invitation|October 2010|October 2015|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|20 Years|50 Years|No|||June 2012|June 6, 2012|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483248||94774|
NCT01483534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-001|Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation|Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study|IPS-I|Holaira|Yes|Active, not recruiting|October 2011|March 2016|Anticipated|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|40 Years|N/A|No|||February 2016|February 17, 2016|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483534||94752|
NCT01483547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BISnch2011|Reliability of BIS Monitoring in Neurosurgical Patients|Reliability of Bispectral Index for Depth of Anesthesia Monitoring in Neurosurgical Patients||Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Yes|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|405|||Both|18 Years|65 Years|No|Non-Probability Sample|patients undergoing elective craniotomy and elective spinal cord and column surgery.|February 2013|February 15, 2013|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01483547||94751|
NCT01485497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2011-8075|Evaluation of Obstructive Sleep Apnea With Long Range 3D Endoscopic Fourier Domain Optical Coherence Tomography (FDOCT)|Evaluation of Obstructive Sleep Apnea With Long Range 3D Endoscopic Fourier Domain Optical Coherence Tomography (FDOCT)||University of California, Irvine|Yes|Withdrawn|May 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 5, 2015|August 2, 2011||No|no participants enrolled|No||https://clinicaltrials.gov/show/NCT01485497||94601|
NCT01486043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-11-00295|Metformin and Transient Hyperglycemia|Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy||Children's Hospital Los Angeles|Yes|Terminated|December 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|10 Years|21 Years|No|||January 2015|January 20, 2015|November 30, 2011||No|The research project was terminated due to lower than projected patient recruitment within the    period of time allowed for the study.|No|January 13, 2015|https://clinicaltrials.gov/show/NCT01486043||94559|Early termination leading to small numbers of subjects analyzed.
NCT01485211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BQ - 5 - 11 -ARVO|Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin|Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Hypo-osmolar Riboflavin Solution in Thin Corneas||Instituto de Olhos de Goiania|Yes|Completed|January 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|35 Years|No|||November 2011|December 2, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01485211||94623|
NCT01470716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-561|Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations|A Phase II Study of Neo-adjuvant Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lunc Cancer With Epidermal Growth Factor Receptor Activation Mutations||National Cancer Center, Korea|No|Recruiting|January 2012|September 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||November 2011|April 27, 2012|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01470716||95734|
NCT01479790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R845/40/2011|Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography|Repeatability and Agreement of Visante and Cirrus Anterior Segment Optical Coherence Tomography and Functional Infrared Thermography||Singapore National Eye Centre|No|Completed|June 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|40|||Both|21 Years|90 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01479790||95040|
NCT01479803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00578-33|Comparison of Two Needles (ProCore vs EchoTip) for the Diagnosis of Pancreatic Solid Mass Under EUS|COMPARATIVE STUDY OF DIAGNOSTIC VALUE FOR THE ECHOTIP® PROCORE™ 22 Gauge NEEDLE VERSUS ECHOTIP® 22 Gauge IN THE DIAGNOSIS OF PANCREATIC SOLID TUMORS UNDER ENDOSCOPIC ULTRASONOGRAPHY : THE "PICORE" STUDY|PICORE|Société Française d'Endoscopie Digestive|Yes|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|80|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01479803||95039|
NCT01479166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|85/11|Bronchial Inflammation of Small Airways in Patients With Cystic Fibrosis|Bronchial Inflammation of Small Airways in Patients With Cystic Fibrosis|FRA-MUKO|Johann Wolfgang Goethe University Hospitals|No|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|20|Samples With DNA|whole blood, serum and Sputum|Both|6 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study is carried out in CF children and adults (6 to 60 years) and healthy controls        (6-60 years). Both patients (40) and healthy subjects (20) are recruited from the        Christiane Herzog CF outpatient clinic of Johann Wolfgang Goethe-University, Frankfurt/M,        Germany.|October 2014|October 28, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479166||95087|
NCT01479179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0542|Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab|Phase I/II Study of Trastuzumab in Combination With AMG 479, A Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R), in Patients With HER-2 Overexpressing Metastatic Breast Cancer Progressing on Trastuzumab-Based or Lapatinib-based Therapy||M.D. Anderson Cancer Center|No|Withdrawn|November 2012|||November 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||October 2012|October 2, 2012|November 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479179||95086|
NCT01480297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALP|Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy|A Pilot Study to Determine the Effects of 12 Weeks of Treatment With Salsalate on Measures of Peripheral Neuropathy in Type 1 Diabetes|SALP|University of Michigan|No|Completed|November 2011|September 2014|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||April 2015|April 23, 2015|November 23, 2011|Yes|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01480297||95001|
NCT01480310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA27909|Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers|A Phase Ia, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers||Genentech, Inc.||Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01480310||95000|
NCT01480323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5027000|A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2|A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma||University Hospital Tuebingen|Yes|Completed|February 2012|June 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480323||94999|
NCT01480011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1101|A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation|A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation||All India Institute of Medical Sciences, New Delhi|No|Completed|November 2011|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|10 Years|70 Years|No|||February 2013|February 19, 2013|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01480011||95023|
NCT01481051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 12|A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma|PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|November 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481051||94943|
NCT01481298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVNC 2011|Value of Cardiac Magnetic Resonance (CMR) Derived Parameters for Diagnosing Left Ventricular Non-compaction Cardiomyopathy|Value of Different Myocardial Parameters to Differentiate Left Ventricular Noncompaction Cardiomyopathy From Other Cardiomyopathies and Healthy Controls by Cardiac Magnetic Resonance||University of Leipzig|No|Completed|December 2004|October 2008|Actual|July 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|57|||Both|14 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Twelve patients (3 male, 27%) with proven LVNC, two with familial LVNC, were included into        the study. The patients initially presented with symptoms of heart failure and were        referred to the department of cardiology for further evaluation. All patients underwent        echocardiography performed by experienced specialists and fulfilled the LVNC criteria of        Jenni. CMR imaging was performed within 3 days after echocardiography. Exclusion criteria        were co-existing cardiac anomalies and usual CMR contraindications such as implanted        defibrillators/pacemakers. The investigators furthermore included 10 consecutive patients        (4 male, 36%) with HCM and 11 consecutive patients (3 male, 27%) with DCM. The diagnosis        of HCM and DCM was established according to current guidelines Patient parameters were        compared to a control group of 25 healthy age matched volunteers (12 male, 48%) without        history of cardiovascular disease and without clinical symptoms.|November 2011|November 28, 2011|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01481298||94924|
NCT01481558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0679/11|Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease|Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's: a Randomized, Sham-controlled Clinical Trial||University of Sao Paulo|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|N/A|No|||December 2013|December 9, 2013|November 21, 2011||No||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01481558||94904|
NCT01482130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK-2011/2039|High Intensity Strength Training & Bone Mineral Density in Young Women|Preventing Osteoporosis: The Effect of High Intensity Strength Training on Bone Mineral Density in Young and Healthy Women||Norwegian University of Science and Technology|No|Completed|November 2011|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||September 2012|September 19, 2012|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01482130||94860|
NCT01482104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-004|New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)|A Randomized Controlled Blinded Multi-centre Study of Photodynamic Therapy With Methyl-aminolevulinate Comparing a Simplified Regime With the Approved Regime in Patients With Clinical Low-risk Superficial and Nodular Basal Cell Carcinoma.||Norwegian University of Science and Technology|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|277|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01482104||94862|
NCT01482117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-105|The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers|Randomized, Open-label, Crossover Study to Evaluate the Effect of Genetic Polymorphism on Pharmacokinetic & Pharmacodynamic Interactions of Clopidogrel and Cilostazol in Korean Healthy Adult Volunteers||Inje University|No|Completed|November 2011|February 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|28|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 31, 2013|November 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01482117||94861|
NCT01482962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14012|Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma|A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma||Millennium Pharmaceuticals, Inc.|Yes|Active, not recruiting|June 2012|February 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|271|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482962||94796|
NCT01483573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120100079|Effect of Hamstring Stretching and Neural Mobilization on Range of Motion and Low Back Pain|Effect of Hamstring Stretching and Neural Mobilization on Range of Motion and Low Back Pain||Rutgers, The State University of New Jersey|No|Terminated|May 2010|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|October 7, 2010||No|Insufficient recruitment over time|No||https://clinicaltrials.gov/show/NCT01483573||94749|
NCT01483872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101094|Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections|Phase II Trial of a Novel Catheter Lock Solution For Adjunctive Treatment of Hemodialysis Catheter-Associated Bacteremia.||University of California, San Diego|Yes|Terminated|March 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|70 Years|No|||October 2015|October 6, 2015|November 26, 2011||No|The study was stopped due to poor enrollment.|No||https://clinicaltrials.gov/show/NCT01483872||94726|
NCT01484145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-10|Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail|An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail||Nitric BioTherapeutics, Inc|No|Completed|December 2011|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|25|||Both|18 Years|65 Years|No|||October 2012|October 18, 2012|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484145||94705|
NCT01484158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gait Speed Outcome Study|Gait Speed for Predicting Cardiovascular Events After Myocardial Infarction|Gait Speed for Predicting Cardiovascular Events After Myocardial Infarction||Yokohama City University Medical Center|No|Completed|October 2001|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|450|Samples Without DNA|We retain only blood sample only in this study.|Both|30 Years|N/A|No|Probability Sample|Patients with acute myocardial infarction.|January 2015|January 20, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484158||94704|
NCT01484392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00001280|Determinants of Compliance With Glaucoma Therapy|Determinants of Compliance With Glaucoma Therapy||Legacy Health System|No|Completed|August 2006|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with open angle glaucoma.|March 2016|March 7, 2016|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484392||94686|
NCT01486628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND0612/001 and 001b|Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers|A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers||NeuroDerm Ltd.|Yes|Active, not recruiting|April 2012|September 2013|Anticipated|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01486628||94514|
NCT01483066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024283|Clinical Outcomes and Cost-effectiveness Analysis of ShapeMatch Technology|A Prospective, Randomized, Post-market, Multi-center Study and Cost-effectiveness Analysis of ShapeMatch Technology A Prospective, Randomized, Post-market, Multi-center Study and Cost-effectiveness Analysis of ShapeMatch Technology||University of Alberta|No|Suspended|June 2012|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|18 Years|80 Years|No|||December 2014|December 22, 2014|November 25, 2011||No|FDA recall - Canadian system did voluntary suspension of study|No||https://clinicaltrials.gov/show/NCT01483066||94788|
NCT01482754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Ref. 2011/02052|Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma|Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma||National University Hospital, Singapore|Yes|Completed|May 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||December 2013|December 8, 2013|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482754||94812|
NCT01482767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5294 (BIRTH)|Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection|A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482767||94811|
NCT01483053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|498/11|Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)|A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder.||Baker IDI Heart and Diabetes Institute|No|Not yet recruiting|January 2014|February 2015|Anticipated|February 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||December 2013|December 16, 2013|November 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483053||94789|
NCT01471379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1105-UNC|Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Milnacipran in the Treatment of Irritable Bowel Syndrome||University of North Carolina, Chapel Hill|No|Terminated|April 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2|||Female|18 Years|79 Years|No|||November 2013|November 5, 2013|November 10, 2011|Yes|Yes|Due to recruitment difficulties the study is terminated.|No|July 3, 2013|https://clinicaltrials.gov/show/NCT01471379||95684|
NCT01479829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203368|Bipolar Depression and Inflammation|Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers||Loyola University|Yes|Recruiting|March 2011|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|65 Years|No|||July 2014|July 30, 2014|September 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479829||95037|
NCT01480050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTC-1101 CDR0000716313|Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma|A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment||Sidney Kimmel Comprehensive Cancer Center||Completed|April 2012|||August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|120 Years|No|||December 2015|December 22, 2015|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01480050||95020|
NCT01479478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18840|Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy|Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.||Stanford University|No|Recruiting|November 2011|November 2018|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|372|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 18, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479478||95064|
NCT01480596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115123|The Evaluation of Belimumab in Myasthenia Gravis (MG)|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects With Generalized Myasthenia Gravis (MG)||GlaxoSmithKline|No|Completed|April 2013|October 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|October 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480596||94978|
NCT01480583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1005B016|GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases|A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases|GRABM-B|Angiochem Inc|No|Active, not recruiting|October 2011|July 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2015|August 4, 2015|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480583||94979|
NCT01481311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCA-05|Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)|Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)||Seca GmbH & Co. Kg.|Yes|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|62|||Both|18 Years|65 Years|No|Probability Sample|Data of 50 patients suffering from kidney disease are planned to be collected.|October 2012|October 2, 2012|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01481311||94923|
NCT01481571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitrolife-oocyte-vitri 01|Performance Study of New Media for Vitrification of Human Oocytes|Performance Study of New Media for Vitrification of Human Oocytes||Vitrolife|No|Completed|January 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Female|18 Years|37 Years|No|||February 2014|February 24, 2014|November 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481571||94903|
NCT01486784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 15411|A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia|A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|November 2011|||November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|2||Anticipated|37|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486784||94502|
NCT01482416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E.FR - 245365|Vascular Effect of Estrogens Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery|Flow-mediated Evaluation of the Brachial Artery of Climacteric Women Using Estradiol and Placebo. Randomized, Double Blinded, Placebo Controlled Study.|EDILA|Federal University of Minas Gerais|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482416||94838|
NCT01482429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Desmame|Evaluation of a Systematic Approach to Weaning From Mechanical Ventilation|Implantation of a Multidisciplinary Ventilator-weaning Protocol in a Intensive Care Unit of Teaching Hospital of Federal University of Uberlandia||Federal University of Uberlandia|Yes|Completed|January 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|235|||Both|18 Years|N/A|No|||January 2013|January 27, 2013|November 27, 2011||No||No|January 12, 2013|https://clinicaltrials.gov/show/NCT01482429||94837|The lack of sedation protocol in the intensive care unit.
NCT01483287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nogasin|The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in Irritable Bowel Syndrome (IBS)|The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in IBS||Sahlgrenska University Hospital, Sweden||Completed|November 2011|August 2013|Actual|June 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||November 2014|November 17, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01483287||94771|
NCT01483586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-069|Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer|Efficacy and Safety of Oral Kanglaite (KLTc)in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy||KangLaiTe USA|Yes|Terminated|November 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Male|18 Years|N/A|No|||April 2014|April 11, 2014|November 28, 2011|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01483586||94748|
NCT01483885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0208.0.045.000-11|Comparison of the Analgesic Effects of Acupuncture and Modulated Electroanalgesia in Cold Induced Pain|Comparison of the Analgesic Effects of Acupuncture and Modulated Electroanalgesia in Cold Induced Pain.||Universidade Federal do Piauí|Yes|Completed|July 2011|October 2011|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|7||Actual|82|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 29, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01483885||94725|
NCT01483898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI 55-1009-1|An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization|REVIVE|Vericel Corporation|Yes|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|35 Years|90 Years|No|||December 2015|December 7, 2015|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483898||94724|
NCT01484171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MST-AML-307PLAH-ASH|HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia|HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|No|Recruiting|August 2011|December 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|7 Years|60 Years|No|||March 2013|March 27, 2013|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01484171||94703|
NCT01484418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG-GL 607|Exposure-based Treatment for Avoidant Back Pain Patients|Exposure Therapy in Chronic Low Back Pain Patients|ETABP|Philipps University Marburg Medical Center|No|Recruiting|August 2011|March 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|65 Years|No|||October 2014|October 30, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01484418||94684|
NCT01484431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12917|A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension|A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension||Eli Lilly and Company|Yes|Recruiting|July 2012|April 2018|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|6 Months|17 Years|No|||January 2016|January 7, 2016|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484431||94683|
NCT01485744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-164|LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer|A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose||Massachusetts General Hospital|Yes|Recruiting|December 2011|||September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|72 Years|No|||December 2011|December 20, 2011|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485744||94582|
NCT01485757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00035716|Prospective L-arginine Study|Effect of Chronic Oral L-arginine Supplementation on Peripheral Endothelial Function and Exercise Tolerance in a Population of Young Heart Transplant Patients.||University of Michigan|Yes|Terminated|July 2011|||July 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|8 Years|N/A|No|||June 2015|June 11, 2015|November 29, 2011|No|Yes|Technical difficulty with Endo-PAT machine|No||https://clinicaltrials.gov/show/NCT01485757||94581|
NCT01486277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018640|A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma|A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma||Janssen Research & Development, LLC|No|Active, not recruiting|November 2011|November 2015|Anticipated|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486277||94541|
NCT01486290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-03|Identifying and Overcoming Barriers to Diabetes Management in the Elderly: A Cost-effective Intervention Study|Identifying and Overcoming Barriers to Diabetes Management in the Elderly: A Cost-effective Intervention Study|DISCO|Joslin Diabetes Center|Yes|Completed|July 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|69 Years|N/A|No|||March 2014|March 26, 2014|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01486290||94540|
NCT01483079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29522|Post-Discharge Growth of Infants Who Received Donor Human Milk Products in the Neonatal Intensive Care Unit (NICU)|Evaluation of Post-Discharge Growth and Development of Infants Who Received Donor Human Milk Products in the NICU|NICU|Baylor College of Medicine|No|Enrolling by invitation|December 2011|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|A cohort of infants less than or equal to 1250 grams birth weight that received donor        human milk products in the NICU will be recruited and followed. Some infants recruited        will be from a previously studied population of very low birth weight infants receiving        donor human milk products in the NICU at Texas Children's Hospital.|April 2015|April 6, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01483079||94787|
NCT01483339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT_OCD_2011|Metacognitive Therapy for Patients With Obsessive-Compulsive Disorder|Metacognitive Therapy Versus Exposition With Response Prevention for Patients With Obsessive-Compulsive Disorder||Philipps University Marburg Medical Center|No|Recruiting|November 2011|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||November 2015|November 3, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01483339||94767|
NCT01483352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD001211|Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes|Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes||Hoffmann-La Roche||Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|November 15, 2011|Yes|Yes||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01483352||94766|
NCT01483365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0087-11-WOMC-|The Need for Luteal Support in NC-FET|The Use of Luteal Support After NC-FET||Wolfson Medical Center|Yes|Recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Female|18 Years|39 Years|No|||June 2014|June 15, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483365||94765|
NCT01471392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDTG-100|Identigene STD Test Collection Kit Validation Study|Identigene STD Test Collection Kit Validation Study||Identigene|No|Recruiting|November 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|3000|||Both|14 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 31, 2013|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471392||95683|
NCT01480349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|46249|Shunt Outcomes of Post-Hemorrhagic Hydrocephalus|Shunt Outcomes of Post-Hemorrhagic Hydrocephalus: A Network Pilot Study|SOPHH|University of Utah|No|Recruiting|January 2011|August 2020|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|325|||Both|N/A|180 Days|No|Non-Probability Sample|All premature neonates with grade III or IV intraventricular hemorrhage who primarily        present or are referred prior to surgical intervention for post hemorrhagic hydrocephalus        to HCRN Clinical Centers.|February 2013|February 21, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480349||94997|
NCT01480024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131386|Effect of Body Composition and Metabolism on Oocyte Gene Expression|Effect of Body Composition and Metabolism on Oocyte Gene Expression||Arkansas Children's Hospital Research Institute|No|Recruiting|April 2011|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples With DNA|oocytes and follicular fluid|Female|18 Years|38 Years|Accepts Healthy Volunteers|Non-Probability Sample|women of childbearing age undergoing fertility treatment|September 2015|September 9, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480024||95022|
NCT01480037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LONG-2011|Genetic and Physiological Aspects of Oxidative Profile in Sleep and Well-succeed Aging|Genetic and Physiological Aspects of Oxidative Profile in Sleep and Well-succeed Aging||Associação Fundo de Incentivo à Pesquisa|Yes|Completed|March 2010|February 2013|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|38|Samples With DNA|Blood samples collected for DNA and RNA extraction, as well as for laboratory examinations|Male|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of São Paulo city, Brazil|January 2015|January 13, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480037||95021|
NCT01480843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-05|Simplified Insulin Protocol Using Lantus in Elderly|Simplification of Diabetes Regimen in Elderly Patients Using Glargine|SIMPLE|Joslin Diabetes Center|Yes|Completed|June 2011|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Both|70 Years|N/A|No|||February 2016|February 22, 2016|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480843||94959|
NCT01480830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT12345678|The Use of Magnetic Endoscopic Imaging for Improving Quality Indicators in Outpatient Colonoscopy|The Use of Magnetic Endoscopic Imaging for Improving Quality Indicators in Outpatient Colonoscopy|SCOPE GUIDE|Nova Scotia Health Authority|No|Completed|January 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|633|||Both|18 Years|N/A|No|||December 2013|December 1, 2013|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480830||94960|
NCT01481038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRBSI FFG Bridge|Anticipative Diagnosis of Central Venous Catheter Related Bloodstream Infections|Anticipative Diagnosis of Central Venous Catheter Related Bloodstream Infections Using Biphasic PNA FISH and Gram Stain/AOLC Tests||Medical University of Graz|No|Active, not recruiting|October 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples With DNA|Serum samples PBMCs Lung Tissue samples fungi|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing hemodialysis using a central venous catheter and Patients with        underlying hematooncologic disease with central venous catheters|April 2015|April 2, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01481038||94944|
NCT01481584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H43-10|Nutritional Evaluation of Canola Protein in Comparison With Soy Protein|Comparison of the Bioavailability the of a Single Administration of Two Canola Proteins (Hydrolyzate, Isolate) and Soy Protein in Healthy Men.||University of Jena|Yes|Completed|May 2010|November 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|4||Actual|28|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481584||94902|
NCT01481844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor006811ctil|Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection|||Soroka University Medical Center|Yes|Completed|November 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||July 2015|July 5, 2015|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01481844||94882|
NCT01482975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA020112|Tailored Interventions to Prevent Substance Abuse|Tailored Interventions to Prevent Substance Abuse|Project BEST|University of Rhode Island|No|Completed|September 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|4158|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||November 2011|November 29, 2011|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01482975||94795|
NCT01482689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-04340|Bioavailability of Vitamin D in Cod Liver Oil and Multivitamin Tablets in Healthy Subjects in Norway|Bioavailability of Vitamin D in Cod Liver Oil and Multivitamin Tablets in Healthy Subjects in Norway||University of Oslo|No|Completed|February 2005|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|74|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 28, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01482689||94817|
NCT01482702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-031|Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors|Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors|VCC0910|University of Vermont|No|Completed|October 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|72|||Female|40 Years|65 Years|No|||January 2013|January 14, 2013|April 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01482702||94816|
NCT01482494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZ-2011-10784|Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia|Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia||Hospital Vall d'Hebron|No|Not yet recruiting|December 2011|||December 2012|Anticipated|N/A|Observational|N/A||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Prospectively, patients who go to an Internal Medicine clinic for suspected limb-girdle        myopathy or patients with asymptomatic hyper-CK-emia shall be included.        Retrospectively, patients with a prior diagnosis of polymyositis and patients with a        myopathy of uncertain origin accompanied by respiratory insufficiency shall be included.        Before being included in the study, all patients will be asked to give informed consent.        Acid maltase activity shall be determined by tests performed on leukocytes obtained from        peripheral blood samples (5 mL).|November 2011|November 30, 2011|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482494||94832|
NCT01483612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR/FRN-114125|Evaluation of Clinical Outcomes and Costs of a Lifestyle Intervention in Obese Infertile Women|"Evaluation of Clinical Outcomes and Costs of a Transferable Interdisciplinary Lifestyle Intervention Pre- and Per-pregnancy in Obese Infertile Women"|OF|Université de Sherbrooke|No|Active, not recruiting|November 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|128|||Female|18 Years|40 Years|No|||June 2015|June 29, 2015|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01483612||94746|
NCT01483625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.479|Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection|A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Patients With Newly Diagnosed and/or Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection (TICARI 1: Tiotropium In COPD Patients With an Acute Respiratory Infection 1)||Boehringer Ingelheim||Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|140|||Both|40 Years|N/A|No|||March 2014|June 3, 2014|November 30, 2011|Yes|Yes||No|December 23, 2013|https://clinicaltrials.gov/show/NCT01483625||94745|
NCT01483638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-11-01|Axitinib as Maintenance Treatment in Patients With Metastatic CRC|A Phase II Study of Axitinib as Maintenance Treatment for Patients With Metastatic Colorectal Carcinoma|TTD-11-01|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Active, not recruiting|February 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483638||94744|
NCT01484743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parastoma|Risk Factors for Morbidity After Parastomal Hernia Repair|Nationwide Prospective Study of Surgical Risk Factors for Poor Outcome After Parastomal Hernia Repair|PAHEREP|University Hospital Koge|No|Completed|January 2007|October 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|199|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All incisional hernia repairs registered in the Danish National Hernia Database from        January 1st 2007 to December 31st 2010|December 2011|December 1, 2011|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484743||94659|
NCT01485237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pandemic001|Severe Pandemic H1N1 Infection in ICU: Comparative Resource Utilization|Severe Pandemic H1N1 Infection in ICU: Comparative Resource Utilization||University of Manitoba|No|Completed|October 2009|December 2012|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with severe adult H1N1 pneumonia undergoing antiviral and oxygen therapy,        mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO,        HFO) in critically ill patients in Winnipeg. Patients with other similar disorders (viral        pneumonia, bacterial pneumonia, septic shock, ARDS)that may require some of the same        treatments.|November 2015|December 1, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485237||94621|
NCT01480713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPIM|Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors|Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors. A 24-week Open-label, Proof-of-concept Pilot Clinical Trial.||IrsiCaixa|No|Completed|May 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|65 Years|No|||June 2014|June 27, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01480713||94969|
NCT01482507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM 10-0120 (DWI101)|Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis|Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis||Optimus Clinical Research|No|Recruiting|August 2011|August 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Newly diagnosed Patients with active Rheumatoid Arthritis|November 2011|November 29, 2011|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482507||94831|
NCT01481207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV-11-11-002981|Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy|Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy||University Children's Hospital, Zurich|No|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|2 Weeks|No|Non-Probability Sample|neonates with suspected hypoxic ischemic encephalopathy|December 2015|December 7, 2015|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01481207||94931|
NCT01471067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0658|Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies|Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies||M.D. Anderson Cancer Center|No|Recruiting|July 2012|||July 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|80 Years|No|||March 2016|March 16, 2016|November 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471067||95708|
NCT01470768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6005|Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based (AA) Formulas|Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based Formulas||Mead Johnson Nutrition|No|Withdrawn|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|0|||Both|N/A|6 Months|No|||March 2012|March 20, 2012|October 26, 2011||No|Sponsor cancelled study|No||https://clinicaltrials.gov/show/NCT01470768||95730|
NCT01471080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|swhb004|A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver|A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver：RFA Versus Laparoscopic Hepatectomy.||Southwest Hospital, China|No|Completed|November 2011|January 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||November 2012|July 1, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471080||95707|
NCT01471093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037E-11-004|Safety Study of OPC-12759 Ophthalmic Solution|Safety Study of OPC-12759 Ophthalmic Solution in Healthy Subjects||Otsuka Pharmaceutical Co., Ltd.|No|Completed|November 2011|February 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 23, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01471093||95706|
NCT01480362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWT_1_GKV|Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds|Randomized, Controlled Clinical Trial Evaluating the Efficacy and Clinical Effectiveness of Negative Pressure Wound Therapy for the Treatment of Diabetic Foot Wounds When Compared to Standard Wound Therapy|DiaFu|University of Witten/Herdecke|Yes|Active, not recruiting|November 2011|April 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480362||94996|
NCT01480375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0053-11-BNZ|A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy|A 3D Navigation Technology for Improved TRUS Prostate Biopsy|NaSBxP01|UC Care, Ltd.|No|Recruiting|September 2011|||September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Male|18 Years|N/A|No|||January 2013|January 15, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480375||94995|
NCT01480063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218MS401|An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice|A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE)|LIBERATE|Biogen||Recruiting|April 2012|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|This post marketing study will be carried out by neurologists in routine clinical        settings.|July 2015|July 23, 2015|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01480063||95019|
NCT01480336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLUG003330HE|The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot|The Pharmacokinetics and Electrocardiographic Implications of Adjunctive Amiodarone and Ranolazine Therapy in Patients on Implantable Cardioverter Defibrillators: The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot||Hartford Hospital|No|Completed|February 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|19|||Both|N/A|N/A|No|||March 2013|March 18, 2013|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480336||94998|
NCT01480856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/2-H|Cobedding in Daily Weight Gain of Neonate Twins|Evaluation of the Efficacy of Cobedding in Daily Weight Gain of Neonate Twins|Cobedding|Nantes University Hospital|Yes|Completed|September 2008|February 2014|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|64|||Both|N/A|4 Days|Accepts Healthy Volunteers|||October 2014|October 14, 2014|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01480856||94958|
NCT01481064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R0000869|Effect and Cost Evaluation of a Multifaceted Approach With a Patient-centredness Questionnaire in Fertility Care|Effect and Cost Evaluation of a Multifaceted Approach Including Audit and Feedback With a Patient-centredness Questionnaire in Fertility Care.||University Medical Center Nijmegen|No|Active, not recruiting|April 2011|October 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|870|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 22, 2013|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01481064||94942|
NCT01481077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPL GLAU 13|A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma|PPL GLAU 13: A Randomized Phase 2 Study of the Effect of Plug Placement on Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)||Mati Therapeutics Inc.|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|77|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|November 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481077||94941|
NCT01486212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IROX-NH|Ischemia-reperfusion Injury Model on Healthy Volunteers and Measurement of Oxidative and Inflammatory Markers|Ischemia-reperfusion Injury Model on Healthy Volunteers and Measurement of Oxidative and Inflammatory Markers|IROX-NH|Herlev Hospital|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|N/A||1|Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers. Male aged 18-40 years. Non smokers. No known history of familiar        cardio/vascular diseases. No intake of prescription medicine.|December 2012|December 11, 2012|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01486212||94546|
NCT01486225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVE401-10|Tolerance Study of the Silicone Bands on Medical Compression Stockings|Exploratory Comparative Single-blind Study Evaluating Tolerability of the Silicone Bands on Medical Compression Stockings||Laboratoires Innothera|No|Terminated|November 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||July 2012|August 7, 2014|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01486225||94545|
NCT01486511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beaujon|Pulmonary Embolism After Liver Resection|Pulmonary Embolism After Liver Resection: A Prospective Analysis of Risk Factors||Beaujon Hospital|Yes|Enrolling by invitation|January 2007|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All consecutive patients that will undergo liver resection for any type of liver disease.|December 2011|December 5, 2011|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01486511||94523|
NCT01486524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGX301|Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis|A Multicenter Pharmacogenomic Biomarker Study in Matched Patients With Severe Sepsis Treated With or Without Recombinant Human Activated Protein C [Xigris®, Drotrecogin Alfa (Activated)]||Sirius Genomics Inc.|No|Active, not recruiting|October 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|3000|Samples With DNA|Minimum 700 ng DNA required, extracted from blood samples. Two Improved Response      Polymorphisms (IRPs) will be tested in this study. IRP A is comprised of two single      nucleotide polymorphisms (SNPs), RYR2 (ryanodine receptor 2 gene) rs684923 and ACIN1      (apoptotic chromatin condensation inducer 1 gene)rs3751501. IRP B is comprised of two SNPs,      SPATA7 (spermatogenesis associated 7 gene) rs3179969 and FLI1 (Friend leukemia virus      integration 1 gene) rs640098. An individual patient will be considered to be biomarker      positive if they have the responsive genotype for either of the SNPs or for both of the SNPs      in the IRP.|Both|18 Years|N/A|No|Non-Probability Sample|The indicated-patients population (INDICATED) population will be the primary population        for this study and it will include those DrotAA-treated patients who have documented        severe sepsis and high risk of death, defined in keeping with the regulatory approvals in        the EU and US, and their matched controls. Documented organ dysfunction will be defined        according to published criteria. A secondary severe sepsis population (SEVSEP) will have        had documented severe sepsis, but not necessarily a high risk of death. The INDICATED        population will be a subset within the broader SEVSEP population.The SEVSEP population        will be analyzed only if at least 10% larger than the INDICATED population.|December 2011|December 5, 2011|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486524||94522|
NCT01482728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15809|Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer|A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer||University of Virginia|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|May 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|18 Years|90 Years|No|||May 2015|May 26, 2015|November 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01482728||94814|
NCT01483261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREC23-2011|An RCT of Trauma Focused-Cognitive Behavioral Therapy With Sexually Exploited, War-affected Girls in the DRC|Is Trauma-Focused Cognitive Behavioral Therapy Effective in Reducing Post-traumatic Stress and Psychosocial Distress Among Sexually Exploited, War-affected Girls in the Democratic Republic of Congo.||Queen's University, Belfast|No|Completed|May 2011|November 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|10 Years|18 Years|Accepts Healthy Volunteers|||December 2011|December 1, 2011|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483261||94773|
NCT01483274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13.0376|Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation|Pharmacologic Upregulation of Cancer Testis Antigens Followed by Vaccine Therapy for Patients With Relapsed Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation|AML|University of Louisville|Yes|Withdrawn|March 2015|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|November 3, 2011|Yes|Yes|Adult patient population barriers.|No||https://clinicaltrials.gov/show/NCT01483274||94772|
NCT01483560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN10DI406|REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)|Phase 3 Study of Metformin in Adults With Type 1 Diabetes|REMOVAL|University of Glasgow|Yes|Active, not recruiting|December 2011|July 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|502|||Both|40 Years|N/A|No|||May 2015|May 20, 2015|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01483560||94750|
NCT01483313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-20111005|Intelligence Changes Following Minor Surgery|Intelligence Performance in Adolescence After Early Exposure to Anesthesia and Minor Surgery||RenJi Hospital|Yes|Withdrawn|November 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Male|6 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|The investigators would like chose the Children who undergone minor surgery in Renji        hospital 4-6years ago and their friends who never had any surgery.|March 2012|February 9, 2014|October 13, 2011||No|No patients enrolled.|No||https://clinicaltrials.gov/show/NCT01483313||94769|
NCT01483326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25411|An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)|FAct: A Non-interventional Multi-center Study to Follow Patients Starting With RoActemra Assessing the Long Term Efficacy, Effectiveness and Safety of RoActemra||Hoffmann-La Roche||Active, not recruiting|August 2009|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|215|||Both|18 Years|N/A|No|Probability Sample|Participants in the ACT SURE clinical trial or patients with moderate to severe rheumatoid        arthritis starting or receiving RoActemra/Actemra|March 2016|March 1, 2016|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01483326||94768|
NCT01484197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDD001A2201|A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device|A Multi-centre, Randomized, Double-blind, Double-dummy, Multiple-dose, Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered as Either PulmoSphere or Lactose-blend Powder Via the Concept1 Device in Adult Patients With Persistent Asthma||Novartis|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|November 15, 2011|Yes|Yes||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01484197||94701|
NCT01484730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2011-8370|A Pilot Study to Evaluate Multi-Spectral Imaging and Laser Speckle Imaging During Vascular Occlusion|A Pilot Study to Evaluate Multi-Spectral Imaging and Laser Speckle Imaging During Vascular Occlusion||University of California, Irvine|No|Recruiting|November 2011|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from University of California Irvine, student and staff        member.|February 2016|February 5, 2016|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01484730||94660|
NCT01480492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV20111115|Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection|Study the Effect of Nucleoside on Host Immune in Patients With CHB||Changhai Hospital|Yes|Completed|January 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|56|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01480492||94986|
NCT01480193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030594|New Therapy for Patients With Severe Tinnitus|Preliminary Clinical Trial of an Integrative Therapy With Severe Tinnitus||Duke University|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||November 2011|November 26, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480193||95009|
NCT01480726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N20110023|Long-term Results Following Endoscopic Vein Harvesting in Coronary Artery Bypass Surgery|Endoscopic Versus Open Vein Harvest in Coronary Artery Bypass Grafting. Clinical and CT-angiographic Long-term Result From a Randomized Study.||Aalborg Universitetshospital|No|Completed|November 2011|January 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|132|||Both|43 Years|90 Years|No|Non-Probability Sample|A total of 132 patients who underwent CABG 4-7 years ago. All patients participated in a        randomized study focusing on wound complications from the leg following either open or        endoscopic vein harvest.|November 2011|April 13, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480726||94968|
NCT01480947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS98-CT1-11|The Treatment Effect of Bio-Three on Children With Enteritis|The Treatment Effect of Bio-Three on Children With Enteritis Due to Salmonella or Rotavirus or Any Unknown Reason|Bio-three|Kaohsiung Veterans General Hospital.|Yes|Completed|February 2009|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|3 Months|14 Years|No|||November 2011|November 28, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480947||94951|
NCT01481194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDU/VS-HKU/CTC-2011-01|ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma|An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination With Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients With Newly Diagnosed Multiple Myeloma|ACVDL|Vejle Hospital|Yes|Active, not recruiting|November 2011|December 2019|Anticipated|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01481194||94932|
NCT01481467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125030012|Evaluation of an Influenza Vaccination Implementation Strategy for Hospital Health Care Workers|Evaluation of a Multi-faceted Influenza Vaccination Implementation Strategy for Health Care Workers in Hospitals||University Medical Center Groningen|No|Recruiting|April 2009|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|6|||Both|N/A|N/A|No|||December 2011|December 19, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01481467||94911|
NCT01481701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Folfox|A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma|A Non Randomized Stratified Phase II Trial Evaluating Efficacy and Safety of Oxaliplatin in Combination With 5-Fluorouracil in Patients With Platinum-sensitive and Platinum-resistant Recurrent Ovarian Carcinoma||Jules Bordet Institute|No|Completed|October 2008|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Female|18 Years|N/A|No|||September 2013|October 14, 2014|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01481701||94893|
NCT01470781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23MH091210-01A1|Treatment to Enhance Cognition in Bipolar Disorder|Efficacy of a Cognitive Remediation Treatment Program for Bipolar Disorder|TREC-BD|Mclean Hospital|No|Recruiting|June 2011|||July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|40 Years|No|||November 2011|November 9, 2011|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01470781||95729|
NCT01471106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0794|Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer|Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer||M.D. Anderson Cancer Center|Yes|Recruiting|January 2014|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|66|||Female|18 Years|N/A|No|||October 2015|October 5, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471106||95705|
NCT01471431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813859|Extubation Readiness Study in Very Low Birthweight Infants|A Randomized Trial of the Spontaneous Breathing Trial to Extubate Very Low Birthweight Infants||University of Pennsylvania|Yes|Recruiting|August 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|90|||Both|N/A|14 Weeks|No|||September 2015|September 28, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471431||95680|
NCT01471444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0628|Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2011|||November 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|3 Years|70 Years|No|||January 2016|January 26, 2016|November 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471444||95679|
NCT01484912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCCD05014A|Phase II Study of STA-2 in Patients With Chronic Stable Angina|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of STA-2 in Patients With Chronic Stable Angina||Sinphar Pharmaceutical Co., Ltd|No|Completed|May 2007|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|79|||Both|20 Years|N/A|No|||December 2011|December 1, 2011|May 9, 2007|No|Yes||No|November 11, 2010|https://clinicaltrials.gov/show/NCT01484912||94646|
NCT01485172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111662|A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease|A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease|TANDEM-662|GlaxoSmithKline|No|Completed|January 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|186|||Both|30 Years|N/A|No|||March 2015|March 9, 2015|December 1, 2011|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01485172||94626|
NCT01480609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115214|Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite|An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR).||GlaxoSmithKline|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||September 2012|September 20, 2012|October 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01480609||94977|
NCT01485679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/6-P|18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas|Evaluation of 18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas||Nantes University Hospital||Completed|January 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|126|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01485679||94587|
NCT01481324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC-Lex-101|Outcomes of Compliance With Brace Wear in Clubfoot|Measurement of Compliance in Clubfoot Bracing Via a Novel Pressure Sensor||Shriners Hospitals for Children|No|Completed|October 2009|October 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|67|||Both|N/A|3 Years|No|Non-Probability Sample|All clubfoot patients scheduled to be placed in a foot ankle orthosis (FAO)|November 2014|November 17, 2014|November 15, 2011||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01481324||94922|As shown in the monthly completion numbers, most families complied during the first month of treatment. After the first month, not only did the wear rates drop significantly, but also the number of subjects reporting sensor and diary data.
NCT01486550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASK-1-2011|Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy|Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery|VONE|Regional Hospital Holstebro|Yes|Terminated|December 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|December 4, 2011||No|Lack of patient enrollment|No||https://clinicaltrials.gov/show/NCT01486550||94520|
NCT01486797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXA12C201|NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)|A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bendamustine and Rituximab (BR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)||NOXXON Pharma AG|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01486797||94501|
NCT01482715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-338-010|A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)|A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor||Clovis Oncology, Inc.|No|Recruiting|November 2011|||April 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482715||94815|
NCT01482468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC11MISI0109|Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting|Effect of Continuous Infusion of Palonosetron Following Single Prophylactic Injection of Palonosetron for Preventing Postoperative Nausea and Vomiting||Incheon St.Mary's Hospital|Yes|Recruiting|March 2012|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|132|||Female|20 Years|N/A|No|||March 2012|March 21, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482468||94834|
NCT01484444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-07-089|Biomarker Analysis of Gastrointestinal Cancer|Biomarker Analysis of Gastrointestinal Cancer||Samsung Medical Center|No|Recruiting|September 2011|||August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|Gastrointestinal cancer Patients.|December 2011|December 4, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01484444||94682|
NCT01484704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63/180/2010|The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer|||Turku University Hospital||Recruiting|February 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Newly diagnosted breast cancer patients|November 2011|December 1, 2011|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484704||94662|
NCT01484990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S187.1.002|A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease|A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease||Abbott|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|19|||Both|30 Years|N/A|No|||November 2011|December 2, 2011|July 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01484990||94640|
NCT01482988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/WA/0340|Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients|Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients|Dectin-1|Cardiff and Vale University Health Board|No|Not yet recruiting|December 2011|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|Critical care patients predicted to stay more than 72 hours|November 2011|November 30, 2011|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01482988||94794|
NCT01483001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIVONCO 2011/001|Feasibility Study on Stem Cells Sensitivity Assay|STELLA: a Feasibility Study on Stem Cells Sensitivity Assay|STELLA|Associazione Oncologia Traslazionale|No|Completed|November 2011|December 2013|Actual|September 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01483001||94793|
NCT01483924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP03-0210|Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis||ApoPharma|Yes|Completed|November 2011|October 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||February 2015|February 9, 2015|November 30, 2011|Yes|Yes||No|January 20, 2015|https://clinicaltrials.gov/show/NCT01483924||94722|
NCT01485003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101MS407|Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants|A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients|STRIVE|Biogen||Active, not recruiting|February 2012|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|229|||Both|18 Years|65 Years|No|Non-Probability Sample|Study participants will be recruited by participating neurologists from among their MS        patients who opt to begin treatment with Tysabri.|January 2016|January 14, 2016|December 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01485003||94639|
NCT01485016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-32|Physiological and Biomechanical Data Collection Study in Epilepsy Subjects|Observational Study Collecting Physiological and Biomechanical Data in Ambulatory Subjects With Epilepsy||Cyberonics, Inc.|No|Completed|November 2011|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|6 Years|N/A|No|Non-Probability Sample|Adult and pediatric epilepsy patients willing to provide physiological and biomechanical        data|August 2012|August 20, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01485016||94638|
NCT01480505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brice 01|Primary Vitrectomy for the Treatment of Retinal Detachment in Highly Myopic|||Centre Hospitalier Universitaire Dijon|No|Completed|October 1999|February 2005|Actual|February 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|840|||Both|18 Years|90 Years|No|Non-Probability Sample|On the basis of axial length greater than 30 mm, 67 eyes of 67 patients with at least        six-month follow-up in our department were selected.|November 2011|November 28, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01480505||94985|
NCT01482000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Daoyin therapy for COPD|Does Pulmonary Daoyin of China Give Additional Benefit Over Usual Therapy in Management of Stable Chronic Obstructive Pulmonary Disease?|Detection and Intervention on Mild/Moderate Chronic Obstructive Pulmonary Disease by Traditional Chinese Medicine Treatment and Application||Henan University of Traditional Chinese Medicine|Yes|Not yet recruiting|November 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|464|||Both|40 Years|80 Years|No|||October 2011|November 29, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01482000||94870|
NCT01480960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTX2011|Effects of a Whole Body Vibration Training in Patients After Lung Transplantation|Effects of a Whole Body Vibration Training on the Exercise Performance in Patients After Lung Transplantation||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|January 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480960||94950|
NCT01481220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023663-18|Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)|A Pilot Phase I Dose Finding Safety Study of a Thrombopoietin-receptor Agonist, Eltrombopag, in Patients With Myelodysplastic Syndrome Treated With Azacitidine|NMDSG10A|Nordic MDS Group|Yes|Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2013|May 2, 2013|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01481220||94930|
NCT01478308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1011|Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer|Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer||New Mexico Cancer Care Alliance|Yes|Withdrawn|June 2011|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||March 2013|March 5, 2013|September 2, 2011|Yes|Yes|No accrual in initial period, PI decided to close study.|No||https://clinicaltrials.gov/show/NCT01478308||95153|
NCT01471119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOLWO-CT-A1.0|Sublingual Immunotherapy in Patients With Atopic Dermatitis|Usefulness and Safety of Sublingual Dermatophagoides Farinae Drops in Patients With Atopic Dermatitis:A Randomized,Double-blind,Placebo-controlled Study.||Zhejiang University|No|Completed|October 2011|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|240|||Both|18 Years|60 Years|No|||August 2015|August 11, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01471119||95704|
NCT01471132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPEC-GCOT|Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis|Phase 2 Study of Sequential Hyperthermic Intraperitoneal Chemotherapy of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis or Positive Free Cancer Cells in Abdomen|SHOP-G01|Peking University|Yes|Recruiting|September 2011|September 2015|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2012|December 6, 2012|November 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01471132||95703|
NCT01471457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-028|Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis|The Use of Trimo-San Gel for the Prevention of Pessary-associated Bacterial Vaginosis|TBVAP|University of New Mexico|Yes|Recruiting|September 2009|September 2013|Anticipated|September 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|March 4, 2013|November 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01471457||95678|
NCT01485185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115484|Gabapentin and Donepezil Combination on Experimental Human Pain Models|A Randomized, Double Blind, Placebo Controlled Study to Investigate the Effect of Donepezil and Gabapentin Combination on an Experimental Pain Model in Healthy Subjects||GlaxoSmithKline|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485185||94625|
NCT01480622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115515|Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects|An Open-label Single and Repeat Dose Study to Investigate the Pharmacokinetic Profiles of Tenofovir Disoproxil Fumarate 300 mg in Healthy Chinese Subjects|PK of TDF|GlaxoSmithKline|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01480622||94976|
NCT01485692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UE0001|Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation|Safety and Efficacy of Four Intramuscular Interventions for the Management of Acute Psychomotor Agitation||University of Sao Paulo|No|Completed|February 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|55 Years|No|||February 2009|December 1, 2011|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485692||94586|
NCT01485705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 08/6-T|Retrospective Examination of Initial Care of Severe Bacterial Infections of the Child|Frequency, Consequences and Determinants of Sub-optimal Care in the Initial Care of Severe Bacterial Infections of the Child|Diabact|Nantes University Hospital|No|Completed|August 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|270|||Both|1 Month|16 Years|No|||July 2014|July 1, 2014|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01485705||94585|
NCT01485978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARLY_PRO-TECT_ALPORT|Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome|Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|Yes|Recruiting|March 2012|August 2019|Anticipated|February 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|120|||Both|24 Months|18 Years|No|||August 2014|August 7, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01485978||94564|
NCT01486563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASK-2-2011|Hydroxyethyl Starch and Renal Function After Radical Prostatectomy|Effect of Hydroxyethyl Starch on Renal Handling of Sodium and Water, Vasoactive Hormones,Biomarkers and the Circulatory System in Patients Undergoing Radical Prostatectomy|VORA|Regional Hospital Holstebro|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|40|||Male|18 Years|N/A|No|||September 2013|September 16, 2013|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01486563||94519|
NCT01486576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASK-3-2011|Hydroxyethyl Starch and Renal Function After Hip Replacement Surgery|Effect of Hydroxyethyl Starch on Renal Handling of Sodium and Water, Vasoactive Hormones,Biomarkers and the Circulatory System in Patients Undergoing Hip Replacement Surgery|VOHO|Regional Hospital Holstebro|Yes|Completed|January 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01486576||94518|
NCT01483027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-102|Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer|A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy|EPOCH|BTG International Inc.|Yes|Recruiting|January 2012|February 2019|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|N/A|No|||October 2015|February 16, 2016|November 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483027||94791|
NCT01483300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC001|Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer|||Harbin Medical University|Yes|Recruiting|November 2011|November 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|70 Years|No|||January 2012|January 22, 2012|November 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483300||94770|
NCT01485224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudratCT 2011-004096-36|Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia|Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|THALI-HHT|IRCCS Policlinico S. Matteo|Yes|Active, not recruiting|November 2011|June 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||August 2015|February 27, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01485224||94622|
NCT01485484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/LAMMP-2011-8295|Development and Validation of a NIRS-based Sinusitis Screening|Development and Validation of a NIRS-based Sinusitis Screening||University of California, Irvine|No|Recruiting|September 2011|July 2018|Anticipated|July 2018|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population will be selected from outpatient clinic at Otolaryngology Clinic at the        University of California, Irvine Medical Center.|February 2016|February 5, 2016|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01485484||94602|
NCT01486615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2/18 (Acd. 796/067/068)|Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone|Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone: a Randomized, Double Blind Placebo Controlled Study||B.P. Koirala Institute of Health Sciences|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|November 10, 2011||No||No|May 20, 2012|https://clinicaltrials.gov/show/NCT01486615||94515|The study was not designed to measure drug plasma concentrations. We did not perform a battery of tests to evaluate psychomotor and amnesic performances. We only did an orientation score and assessed delayed visual episodic memory.
NCT01480180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7088-3859|Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A|A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A|pathfinder™2|Novo Nordisk A/S|No|Active, not recruiting|January 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|186|||Male|12 Years|N/A|No|||December 2015|December 8, 2015|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480180||95010|
NCT01480479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX110-04|Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma|An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma|ACT IV|Celldex Therapeutics|Yes|Active, not recruiting|November 2011|||November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|November 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480479||94987|
NCT01479946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREATE-01|Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin|An International Randomized Phase II Study Comparing Early Electrochemotherapy to Delayed or No Electrochemotherapy in Patients With Cutaneous Breast Cancer Metastases||Uppsala University Hospital|No|Withdrawn|October 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|November 14, 2011||No|ECT equipment not available at study center|No||https://clinicaltrials.gov/show/NCT01479946||95028|
NCT01481714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITRA-SPLIT|Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies|Phase IV, Prospective, Randomized Study Comparing Preparation the Day Before and Split-dose Regimen With Sodium Picosulphate/Magnesium Citrate for Morning Colonoscopies||Infante, Javier Molina, M.D.|Yes|Recruiting|November 2011|June 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|N/A|No|||November 2011|November 28, 2011|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01481714||94892|
NCT01482312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-373-C-900|Effect of Contact Lenses on Tear Osmolarity in a Controlled Low Humidity Chamber|||Alcon Research|No|Completed|December 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|29|||Both|18 Years|70 Years|No|||June 2012|June 26, 2012|November 28, 2011|Yes|Yes||No|May 22, 2012|https://clinicaltrials.gov/show/NCT01482312||94846|
NCT01482325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118.02-2011-GES-0002|SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement|SNIPE:SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement|SNIPE|GE Healthcare|No|Terminated|November 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 20, 2014|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482325||94845|
NCT01482299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-1104|RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression|A Phase II Trial of RAD001 (Everolimus) for 2nd Line Treatment After Failure of Fluoropyrimidine Plus Platinum Chemotherapy in Patients With Metastatic or Recurrent Gastric Cancer With pS6 Ser 240/4 Expression||Asan Medical Center|No|Completed|November 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|75 Years|No|||January 2015|January 11, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01482299||94847|
NCT01478646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAT 2011|The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) III-IV|The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy on Dyspnoea and Activity in Patients With COPD III-IV||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|August 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|45 Years|75 Years|No|||November 2011|November 22, 2011|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01478646||95127|
NCT01471470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC ONCGI-1003|Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer|A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer||Asan Medical Center|No|Active, not recruiting|July 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|70 Years|No|||November 2015|November 26, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01471470||95677|
NCT01471795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1093 HP|The Epidemiology of Ventricular Assist Device-Related Infections|The Epidemiology of Ventricular Assist Device-Related Infections||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Probability Sample|Patients with end-stage heart failure who demonstrate the need for intermediate or        long-term support with a VAD.|November 2011|November 15, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01471795||95652|
NCT01485718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-117|Effect of Daily Glucomannan in Overweight Patients|Effect of Daily Glucomannan in Overweight Patients||ProMedica Health System|No|Active, not recruiting|October 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 9, 2011|November 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01485718||94584|
NCT01485432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IROR|Goal Directed Hemodynamic Management and Renal Outcome After Renal Transplant Surgery|Can Goal Directed Hemodynamic Management Improve Renal Outcome After Renal Transplant Surgery?|IROR|Technische Universität München|Yes|Recruiting|October 2011|October 2015|Anticipated|||N/A|Observational|Time Perspective: Prospective||2|Anticipated|98|||Both|65 Years|N/A|No|Probability Sample|Patients undergoing renal transplant surgery|January 2013|January 16, 2013|November 11, 2011||||No||https://clinicaltrials.gov/show/NCT01485432||94606|
NCT01486238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESERVE|Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study|Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study|PRESERVE|Valley Retina Institute|No|Completed|April 2009|October 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||June 2013|June 12, 2013|December 2, 2011|Yes|Yes||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01486238||94544|
NCT01486537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pulpastrop-HMO-CTIL|Acidity Level of Blood From Primary Molar's Pulp While Undergoing Pulpotomy or Pulpectomy Procedure|Characterization of Blood Drawn From the Pulp of Primary Molar Undergoing Pulpotomy or Pulpectomy.||Hadassah Medical Organization|Yes|Recruiting|December 2011|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|None Retained|blood specimens which are undergoing Astrop test (acidity level .po2 pco2)|Both|3 Years|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy children undergoing dental treatment by residents in Hadassah hospital Jerusalem.        Ages between 3-13 years old.|August 2015|August 18, 2015|December 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01486537||94521|
NCT01482780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASY-TRIAL|Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery|EASY-TRIAL: Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery||Medical University of Vienna|No|Terminated|March 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|85 Years|No|||April 2015|April 6, 2015|November 29, 2011||No|Logistic reasons, lack of funding|No||https://clinicaltrials.gov/show/NCT01482780||94810|
NCT01484184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIN-01|Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury|Tri-therapy (SPINALON)-Elicited Spinal Locomotor Network Activation: Phase I-IIa Clinical Trial in Patients With Chronic Spinal Cord Injury||Nordic Life Science Pipeline Inc.|Yes|Completed|July 2013|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||August 2015|August 19, 2015|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01484184||94702|
NCT01486030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX_000012|Exercise Stress Testing on Peripheral Gene Expression Using CORUS™ CAD Diagnostic Test|Effect of Exercise Stress Testing on Peripheral Gene Expression Using CORUS™ CAD Diagnostic Test|EXERCISE|CardioDx|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|RNA PAXgene|Both|45 Years|75 Years|No|Probability Sample|Acute exercise, exercise stress test affect the peripheral gene expression levels of the        23 genes in the CORUS CAD algorithm and the time frame at which, gene levels change.|November 2014|November 25, 2014|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01486030||94560|
NCT01483040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-1130|PeerScope B System™ Clinical Protocol|a Prospective Clinical Study to Establish the Usability of the PeerScope B System™ When Used During Standard Colonoscopy Procedure||PeerMedical Ltd.|Yes|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483040||94790|
NCT01479699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLE study|Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations|Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations||University of Reading|Yes|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479699||95047|
NCT01479712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM11572|Intra-abdominal at Cesarean Section: A Randomized Controlled Trial|Intra-abdominal at Cesarean Section: A Randomized Controlled Trial||Virginia Commonwealth University|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|263|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 22, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479712||95046|
NCT01479959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optipep -10-007|Impact of Patient Controlled Positive End-expiratory Pressure on Speech in Tracheostomized Ventilated Patients|Determination of Optimal PEEP Level Under Patient Control in Tracheostomized Ventilated Patients|OptiPEP|University of Versailles|No|Completed|June 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|N/A|No|||November 2011|November 22, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01479959||95027|
NCT01482026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.682/25|Attention-Deficit Hyperactivity Disorder (ADHD) Rating Scale and Epilepsy|Sensitivity of ADHD-IV Rating Scale in the Evaluation of the Evolution of Attention Disorders Associated With Childhood Epilepsy : a Validation Study||Hospices Civils de Lyon|No|Completed|November 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|173|||Both|6 Years|16 Years|No|||January 2016|January 20, 2016|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01482026||94868|
NCT01482039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sonographic Cervical Length|Patient Attitudes Toward Ultrasound Measurement of Cervical Length|Patient Attitudes Regarding Abdominal Versus Transvaginal Ultrasonography for Assessment of the Cervical Length in Low Risk Patients: a Randomized Trial|TVUS|Intermountain Women and Children's Research|No|Recruiting|November 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|210|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 28, 2011|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01482039||94867|
NCT01482338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMS 068/54|Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone|A Comparative Efficacy of Low-dose Combine Oral Contraceptives Containing Desogestrel 150 mg and Drospirenone 3 mg on Premenstrual Symptoms||Chulalongkorn University|No|Completed|June 2011|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482338||94844|
NCT01478321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 11C02|Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas|A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas||Northwestern University|Yes|Recruiting|November 2011|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478321||95152|
NCT01478659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIB|The Effect of Fiber Snack Foods on Dietary Intake in Healthy Adults|The Effect of Fiber Snack Foods on Dietary Intake in Healthy Adults|FIB|University of Florida|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|97|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01478659||95126|
NCT01471808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13560475186|Effects of Different Early Intensive Therapies on Long-term β-cell Function|Effects of Oral Hypoglycemic Agents Combined With Short-term CSII on Glycemic Control in Newly-diagnosed Type 2 Diabetic Patients||Sun Yat-sen University|Yes|Enrolling by invitation|October 2011|December 2021|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|336|||Both|25 Years|65 Years|No|||April 2013|April 8, 2013|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01471808||95651|
NCT01471821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLE|Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression|Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up|OLE|Hospital Clinic of Barcelona|Yes|Completed|October 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01471821||95650|
NCT01472146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zo-neo2011|ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer|Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer||Instituto Nacional de Cancer, Brazil|Yes|Recruiting|October 2011|November 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Female|18 Years|75 Years|No|||March 2013|March 4, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01472146||95625|
NCT01486264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS 60201 4073 1|Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex|An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment||Merz Pharmaceuticals, LLC|No|Active, not recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|424|||Both|18 Years|81 Years|No|||May 2015|May 11, 2015|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486264||94542|
NCT01485445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115440|Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination|An Open-label, Randomised, Replicate, Six-way Crossover, Single Dose Study to Determine the Bioequivalence of Fluticasone Furoate (FF) Inhalation Powder (Single Strip Configuration) Compared With FF Inhalation Powder (Two Strip Configuration) and Compared With FF / Vilanterol (VI) Inhalation Powder Administered Via the Novel Dry Powder Inhaler.||GlaxoSmithKline||Completed|December 2011|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 5, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485445||94605|
NCT01485991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100677|TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy|Phase III in Partial and Null Responders|ATTAIN|Janssen R&D Ireland|Yes|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|771|||Both|18 Years|70 Years|No|||April 2015|April 9, 2015|November 25, 2011|Yes|Yes||No|March 27, 2015|https://clinicaltrials.gov/show/NCT01485991||94563|
NCT01486004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100683|A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen|A Phase-I, Open-label Trial in Healthy Female Subjects to Investigate the Effect of TMC435 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone||Tibotec Pharmaceuticals, Ireland|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|October 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486004||94562|
NCT01486251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001151-37|Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer|Assessment of the Tumor Vascular Effects of the Pan-vegfr Tyrosine Kinase Inhibitor Axitinib Using Dynamic Contrast-enhanced Ultrasonography (Dce-us) in Patients With Refractory Metastatic Colorectal Cancer|AXUS|Gustave Roussy, Cancer Campus, Grand Paris|No|Completed|September 2011|September 2014|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01486251||94543|
NCT01482741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-185|Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging|Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging||Memorial Sloan Kettering Cancer Center||Completed|November 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatient clinical practices at MSKCC.|June 2015|June 24, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482741||94813|
NCT01483014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BBR10|Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)|Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)|CONVERT|Novartis||Completed|June 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||August 2013|August 18, 2013|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483014||94792|
NCT01484717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-132-2|Interactive Voice Response Technology to Mobilize Contingency Management for Smoking Cessation|Interactive Voice Response Technology to Mobilize Contingency Management for Smoking Cessation||University of Connecticut Health Center|Yes|Completed|January 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484717||94661|
NCT01479933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitDmet|Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes|Randomized Controlled Trial of Vitamin D Supplementation on Glucose Metabolism in Subjects With Components of the Metabolic Syndrome|VitDmet|University of Eastern Finland|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|73|||Both|60 Years|N/A|No|||March 2013|March 3, 2013|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01479933||95029|
NCT01481233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSHCI 09-023|Oral Colchicine in Men With Castrate Resistant Prostate Cancer|Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy||Milton S. Hershey Medical Center|Yes|Withdrawn|May 2013|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||September 2013|September 26, 2013|November 11, 2011|Yes|Yes|Due to funding|No||https://clinicaltrials.gov/show/NCT01481233||94929|
NCT01481480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16nov2011|Latissimus Dorsi Tendon Transfer or Partial Arthroscopic Repair of Massive Rotator Cuff Tears|A Multicenter, Randomized Controlled Trial Comparing Functional Outcomes After Latissimus Dorsi Tendon Transfer or Partial Arthroscopic Repair of Massive Rotator Cuff Tears||St. Michael's Hospital, Toronto|No|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|40 Years|65 Years|No|||November 2015|November 16, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481480||94910|
NCT01482052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JN-NM-001|Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis|A Double-Blind, Randomized, Controlled, Two Arm Phase 1 Clinical Trial of the Safety and Immunogenicity of Group A, C, Y & W-135 Meningococcal Polysaccharide DT Conjugate Vaccine: NmVac4-A/C/Y/W-135-DT™||JN-International Medical Corporation|Yes|Completed|November 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01482052||94866|
NCT01478347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V72_37|A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults|A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults||Novartis|No|Completed|May 2013|November 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|November 21, 2011|Yes|Yes||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01478347||95150|
NCT01478672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTU-Medium health coaching|Medium Term Health Coaching and Life-long Monitoring in Cardiovascular Disease in Norrbotten|Medium Term Health Coaching and Life-long Monitoring in Cardiovascular Disease in Norrbotten||Luleå Tekniska Universitet|Yes|Completed|March 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|741|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01478672||95125|
NCT01478685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-ST-001|A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors|A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors||Celgene Corporation|No|Completed|November 2011|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|169|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478685||95124|
NCT01478334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2011|Exercise-induced Improvements of Inflammatory Status in Patients With Rheumatoid Arthritis|Exercise-induced Improvements of Inflammatory Status in Patients With Rheumatoid Arthritis - Improvements of Cardiovascular Risk Factors and Quality of Life||Norwegian University of Science and Technology|No|Completed|March 2011|May 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Female|20 Years|50 Years|No|||May 2015|May 28, 2015|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01478334||95151|
NCT01479205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAITASIT|Induction of Allergen Specific Bronchial Immunotolerance After Specific Immunotherapy|Security of the Bronchial Allergen Provocation With Mite and Aspergillus and Predictors for a Positive Reaction.|ITASIT|Johann Wolfgang Goethe University Hospitals|No|Completed|July 2010|September 2011|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|Samples Without DNA|serum|Both|5 Years|17 Years|No|Non-Probability Sample|Children aged 6-17 years of age with house dust mite allergy|November 2011|November 23, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479205||95084|
NCT01464268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEI-EpiCXL|Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia|Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia||Cornea and Laser Eye Institute|No|Recruiting|November 2011|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|November 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464268||96226|
NCT01464567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVEDPOC-001|Spontaneous Breathing Trials Using Pressure-Support or T-Tube in Chronic Obstructive Pulmonary Disease Patients Weaning Mechanical Ventilation|Comparison Between Spontaneous Breathing Trials Through Pressure-Support Ventilation or "T" Tube in the Weaning of Mechanical Ventilation in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial||Hospital Nossa Senhora da Conceicao|Yes|Recruiting|January 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|190|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464567||96203|
NCT01464580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA011111|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2016|||||N/A|N/A|N/A||||||||||||||March 6, 2016|October 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01464580||96202|
NCT01464593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-10-201|Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)|Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions|ABLATE|Celsion|Yes|Terminated|September 2011|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|November 1, 2011|Yes|Yes|trial design contingent on RFA optimization|No||https://clinicaltrials.gov/show/NCT01464593||96201|
NCT01483937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-221:1.2|Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium|Clinical Trial Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium|SEMD|BalanceSense LLC|No|Completed|November 2011|August 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|84 Years|No|||June 2014|June 26, 2014|November 30, 2011|Yes|Yes||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01483937||94721|Small number of subjects recruited because of lengthy study commitment.
NCT01484210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-FLUSAL-EL-02|Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®|Phase III Therapeutic Evaluation Study Comparing the Efficacy and Safety of the Fluticasone/Salmeterol (500/50 μg) Combination Administered With Elpenhaler® (Rolenium®) Versus the Innovative One (Seretide Diskus®) in Patients With Asthma.||Elpen Pharmaceutical Co. Inc.|No|Completed|March 2008|October 2008|Actual|August 2008|Actual|Phase 3|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|28|||Both|N/A|N/A|No|||November 2011|August 30, 2012|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01484210||94700|
NCT01485250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910061|A Cross-Cultural Assessment of the Motivations of Healthy Participants in Phase I Research|A Cross-Cultural Assessment of the Motivations of Healthy Participants in Phase I Research||National Institutes of Health Clinical Center (CC)||Completed|February 2010|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1200|||Both|18 Years|N/A|No|||September 2015|November 5, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01485250||94620|
NCT01486641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sebastian-12|Anterolateral Versus Posterolateral Approach to the Fractured Hip Arthroplasty|Anterolateral Versus Posterolateral Approach to the Fractured Hip Arthroplasty - a Change in Approach at Sundsvall Hospital.|APAF|Sundsvall Hospital|Yes|Active, not recruiting|February 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|65 Years|N/A|No|||April 2014|October 23, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486641||94513|
NCT01482520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-06-050|Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma|Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma||Samsung Medical Center|No|Completed|August 2008|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|200|||Both|N/A|N/A|No|Probability Sample|All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular        targeted therapy will be candidates for the study.        Once the patient signed written informed consent, two bottles of 5 cc blood will be drawn        and subsequently extracted DNA and serum will be stored until genetic analysis.|May 2014|May 12, 2014|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01482520||94830|
NCT01483911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-0171-1.1/11|ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers|Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers||Ablynx|Yes|Completed|December 2011|||May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|February 26, 2013|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01483911||94723|
NCT01478880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-H 1|Efficacy and Safety of Bilateral Theta Burst Stimulation for the Treatment of Auditory Hallucinations|Efficacy and Safety of Bilateral Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation) for the Treatment of Auditory Hallucinations|TBS-H|University Hospital Tuebingen|No|Completed|May 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|70 Years|No|||July 2013|July 13, 2013|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478880||95109|
NCT01478893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEL-068/101|Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacodynamics of Increasing Subcutaneous Doses of SEL-068 in Healthy Non-Smoker and Smoker Adults||Selecta Biosciences, Inc.||Completed|November 2011|March 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01478893||95108|
NCT01479673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4329|TICACOS International|Tight Caloric Balance in ICU Patients: a Multicenter, Prospective, Randomized, Controlled Study.|P2 -RMCS|Rabin Medical Center|Yes|Recruiting|November 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|560|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479673||95049|
NCT01479686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XBR2011022|iMRI Guided Resection in Cerebral Glioma Surgery|3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial||Huashan Hospital|Yes|Recruiting|September 2011|July 2021|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|303|||Both|18 Years|70 Years|No|||March 2015|March 21, 2015|November 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01479686||95048|
NCT01479413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMRPG891561|Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs|Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs||Chang Gung Memorial Hospital|No|Completed|August 2009|September 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|77|Samples With DNA|Blood|Both|18 Years|65 Years|No|Non-Probability Sample|This study will be conducted in our clinical setting. By a semi-structured interview for        DSM-IV criteria, about 300 schizophrenic patients will be recruited in this study.|September 2013|September 10, 2013|July 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01479413||95069|
NCT01481493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|979|Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)|A Multi-center, Double-blind, Randomized, Placebo-controlled, Dose-finding Study in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable MTX Doses to Investigate Efficacy and Safety of SC BT061||Biotest|Yes|Completed|December 2010|November 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|127|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01481493||94909|
NCT01481727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-18-10NIRD|Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation|Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation||National Institute of Respiratory Diseases, Mexico|No|Active, not recruiting|December 2011|December 2015|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|20|||Both|45 Years|85 Years|No|||May 2015|May 22, 2015|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01481727||94891|
NCT01482013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPP854-104|Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease|A Double-blind, Randomized, Placebo-controlled, Phase I , Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease||High Point Pharmaceuticals, LLC.|No|Terminated|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|7|||Both|50 Years|85 Years|No|||August 2012|August 29, 2012|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01482013||94869|
NCT01478360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457D2204|Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma|A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Administration of Secukinumab (AIN457) in Patients With Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting Beta-agonists.||Novartis||Terminated|March 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|November 17, 2011|Yes|Yes|Further investigations would require changes in study design; the use of different endpoints,    a different IL-17 antibody or a different patient population.|No|October 20, 2015|https://clinicaltrials.gov/show/NCT01478360||95149|
NCT01478373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258AIC02|Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib|DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib||Novartis|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|November 16, 2011||No||No|July 14, 2015|https://clinicaltrials.gov/show/NCT01478373||95148|
NCT01478698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tPADNase 1|The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients|A Phase 1, Open Label, Non Randomised Safety Trial of Intraperitoneal tPA and DNase in Peritoneal Dialysis Patients With Peritonitis||Sir Charles Gairdner Hospital|No|Active, not recruiting|January 2016|July 2021|Anticipated|December 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|100 Years|No|||February 2016|February 19, 2016|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478698||95123|
NCT01478971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX01-18|Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis|A Phase 3b Single-Arm, Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis|DIAMOND|Takeda|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|184|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|November 22, 2011|Yes|Yes||No|February 6, 2014|https://clinicaltrials.gov/show/NCT01478971||95102|
NCT01479218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Occlutech-PDA1|Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus|Phase 1 Study for Safety and Effectiveness of the New Occlutech PDA Occluder, for Non Surgical Closure of Patent Ductus Arteriosus||Occlutech International AB|No|Completed|November 2011|May 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|6 Months|70 Years|No|||May 2013|October 15, 2014|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01479218||95083|
NCT01479231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003759|Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis|Predictors of PPI Response in Eosinophilic Esophagitis||Mayo Clinic|Yes|Withdrawn|March 2012|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||April 2012|April 18, 2012|November 22, 2011||No|Souces of funding have been terminated|No||https://clinicaltrials.gov/show/NCT01479231||95082|
NCT01464281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27928|A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml|A Randomized, Multicenter Study Evaluating HBsAg Clearance in CHB Patients Achieving HBeAg Loss and HBV DNA <200copies/ml on Treatment With Nucleotide Analogues and Switched to Peginterferon Alfa-2a|New Switch|The Second Affiliated Hospital of Chongqing Medical University|No|Active, not recruiting|October 2011|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||November 2011|November 1, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01464281||96225|
NCT01464294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3M ESPE CR-10-019|Clinical Evaluation of Chairside CAD/CAM Nano-ceramic Restorations|Clinical Evaluation of Chairside CAD/CAM Nano-ceramic Restorations||3M|No|Terminated|October 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients attending and/or under clinical treatment at the University of Michigan Dental        Clinics|December 2013|January 26, 2015|October 27, 2011||No|not a required sutudy to be posted|No||https://clinicaltrials.gov/show/NCT01464294||96224|
NCT01464606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPB Reg Tx-Biol-001|International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry|International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Protocol||Children's Hospitals and Clinics of Minnesota|No|Recruiting|September 2011|September 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|N/A|21 Years|No|||February 2016|February 1, 2016|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01464606||96200|
NCT01485029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-APN-01|Streptococcus Pneumoniae Nasopharyngeal Carriage|Streptococcus Pneumoniae Nasopharyngeal Carriage Among Children Attending Day-care Centres in the Alpes Maritimes. Substudy: Enterobacterial Intestinal Carriage and Susceptibility to 3rd Generation Cephalosporins||Centre Hospitalier Universitaire de Nice|No|Recruiting|January 2012|January 2013|Anticipated|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|3 Months|4 Years|Accepts Healthy Volunteers|||December 2011|December 17, 2012|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01485029||94637|
NCT01485770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX-N05 201|A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness|A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness||Aerial BioPharma, LLC|No|Completed|December 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||March 2013|March 8, 2013|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485770||94580|
NCT01483092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INOL|Effect of Inulin on Iron Absorption in Humans|Inulin Modifies Gut Microbiota, Fecal Lactate Concentration and Fecal pH But Does Not Influence Iron Absorption in Women With Low Iron Status||Swiss Federal Institute of Technology|No|Completed|August 2011|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01483092||94786|
NCT01482533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIUJPar01-2011|Tissue Culture Versus Swab Culture in Prosthetic Joint Infections|||Rothman Institute Orthopaedics|No|Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing revision surgery for an infection in their knee or hip components.|November 2011|November 29, 2011|November 28, 2011||||No||https://clinicaltrials.gov/show/NCT01482533||94829|
NCT01479400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU30971052|Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective Study|Safety Study for Infants Who Exposed to Antipsychotics as Fetus||Central South University|Yes|Completed|October 2007|May 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|152|||Both|N/A|1 Day|Accepts Healthy Volunteers|Probability Sample|76 infants who were exposed to antipsychotics as fetus was compared to 76 matched control        infants who were not exposed to antipsychotics as fetus.|November 2011|November 22, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01479400||95070|
NCT01480518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEWS11B2|Biomarkers in Tissue Samples From Patients With Ewing Sarcoma|Analysis of GGAA-Microsatellites in Ewing Sarcoma||Children's Oncology Group|No|Completed|December 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|166|Samples With DNA|Tissue|Both|N/A|50 Years|No|Non-Probability Sample|Ewing sarcoma.|May 2015|May 8, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01480518||94984|
NCT01479140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03186|Prevalence and Long-term Impact of Non-atherosclerotic CAD|Prospective Registry of Young Women With MI: Evaluating the Prevalence and Long-term Impact of Non-atherosclerotic CAD (PRYME)|PRYME|Cardiology Research UBC|No|Recruiting|December 2011|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|19 Years|55 Years|No|Non-Probability Sample|Women aged 55 or younger with a troponin positive acute coronary syndrome (ST and non-ST        elevation myocardial infarction or Acute Coronary Syndrome (ACS)) having a coronary        angiogram        Negative pregnancy test|September 2015|September 24, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479140||95089|
NCT01480973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 11-0079-CE|Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer|MRI Assessment of Post-Radiation Change Following Stereotactic Body RT for Non-Small Cell Lung Cancer: A Pilot Study||University Health Network, Toronto||Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|August 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480973||94949|
NCT01481506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29/2009 ComEt CBM - SweetAge|Multiparametric Telemonitoring In Elderly People With Chronic Obstructive Pulmonary Disease|Efficacy Of Multiparametric Telemonitoring On Respiratory Outcomes In Elderly People With Chronic Obstructive Pulmonary Disease.|SweetAge|Campus Bio-Medico University|Yes|Completed|January 2010|June 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|65 Years|N/A|No|||November 2011|November 28, 2011|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01481506||94908|
NCT01481766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000027782|Iron Treatment for Young Children With Non-anemic Iron Deficiency|Optimizing Early Child Development in the Primary Care Practice Setting: Pragmatic Randomized Trial of Iron Treatment for Young Children With Non-anemic Iron Deficiency (OptEC)|OptEC|The Hospital for Sick Children|No|Recruiting|June 2012|December 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|230|||Both|12 Months|40 Months|Accepts Healthy Volunteers|||November 2015|November 16, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01481766||94888|
NCT01481740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4999-01460|Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)|A Double Blind Randomized Controlled Trial of Phenylephrine for the Prevention of Spinal Induced Hypotension in Obese Parturients||IWK Health Centre|Yes|Completed|November 2010|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Female|18 Years|N/A|No|||April 2015|April 1, 2015|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01481740||94890|
NCT01481753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00021168|Pancreaticoduodenectomy With or Without Braun Enteroenterostomy: Comparison of Postoperative Pancreatic Fistula and Delayed Gastric Emptying|||Johns Hopkins University|Yes|Recruiting|December 2009|||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|304|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01481753||94889|
NCT01478386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Knee OA Treatments|Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis|Randomized Trail to Assess the Effectiveness of an Off-Loading Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis||OAD Orthopaedics|No|Terminated|December 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 22, 2013|November 21, 2011||No|The study was terminated due to poor enrollment|No||https://clinicaltrials.gov/show/NCT01478386||95147|
NCT01479244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeuVax™ PH3-01, BB-IND 009187|Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence|PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment|PRESENT|Galena Biopharma, Inc.|Yes|Active, not recruiting|November 2011|April 2025|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|700|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|November 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479244||95081|
NCT01478984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMILE|Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction (NSTEMI) Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention (PCI)|Impact of One Stage Compared With Multistaged PCI Complete Revascularization on Clinical Outcome in Multivessel NSTEMI Patients. Smile Trial|SMILE|University of Roma La Sapienza|Yes|Recruiting|October 2011|||October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|247|||Both|18 Years|95 Years|No|||November 2011|November 21, 2011|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01478984||95101|
NCT01479842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10052|Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma|A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|December 2011|||December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|November 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01479842||95036|
NCT01460186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StoRM|Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer|Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer : a Multicenter Non-randomized Prospective Cohort Study|StoRM|Centre Leon Berard|No|Active, not recruiting|December 2011|December 2023|Anticipated|December 2023|Anticipated|N/A|Interventional|N/A|1||Anticipated|1000|||Female|18 Years|N/A|No|||October 2014|October 29, 2014|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01460186||96537|
NCT01460524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bronchiolitis-saline|Nebulized Hypertonic Saline for Bronchiolitis|Observational Study on the Use of Hypertonic Saline for the Treatment of Bronchiolitis||Hôpital Armand Trousseau|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2580|||Both|N/A|1 Year|No|Non-Probability Sample|For the prospective part of the study, all infants up to 1 year of age presenting to the        ED for bronchiolitis from November 1st, 2011 to March 30th, 2012 will be included in this        observational study. For the retrospective part of the study, data of all infants up to 1        year of age who were seen in the ED for bronchiolitis from November 1st, 2009 and March        30th, 2010 and from November 1st, 2010 and March 30th, 2011 will be analyzed.|June 2015|June 23, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460524||96512|
NCT01484457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF 22-2009-796|Controlled Insulin Delivery: Combining Technology With Treatment|Controlled Insulin Delivery: Combining Technology With Treatment||William Sansum Diabetes Center|Yes|Completed|July 2008|January 2010|Actual|January 2010|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484457||94681|
NCT01484470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202041|Umbilical Cord Transplantation for the Elderly Population|An Open Label,Double Arm,Single Center Pilot Study to Evaluate the Safety and Efficacy of Transplantation of Either StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded ex Vivo, or an Unmanipulated Cord Blood Unit in the Elderly Population With Hematologic Malignancies Using Reduced Intensity Regimen||Loyola University|Yes|Active, not recruiting|January 2010|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|55 Years|73 Years|No|||April 2014|April 24, 2014|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484470||94680|
NCT01486056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-35|ECG Vector Determination|ECG Vector Determination for Model 106 Generator Implant Site Selection||Cyberonics, Inc.|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|29|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects 12 years and older in general good health, preferably with epilepsy and on at        least 1 antiepileptic medication.|August 2012|August 20, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01486056||94558|
NCT01486303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB2011-007|Facial Cosmetic Acupuncture on Skin Rejuvenation|Efficacy and Safety of Facial Cosmetic Acupuncture on Skin Rejuvenation||Kyunghee University|Yes|Active, not recruiting|August 2011|||December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|40 Years|59 Years|Accepts Healthy Volunteers|||December 2011|December 5, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01486303||94539|
NCT01486316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDENTIFY-HF|Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure|Integrated Diagnostic Evaluation in Non-Therapy DevIces For the studY of Heart Failure|IDENTIFY-HF|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|November 2011|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01486316||94538|
NCT01486329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXM01-01-DE|VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer|VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01||Vaximm GmbH|Yes|Completed|December 2011|December 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486329||94537|
NCT01486589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|577/2011BO1|Cardiac Autonomic Function For Risk Stratification in the Emergency Room|Risk Stratification in the Emergency Room by Cardiac Autonomic Function|PREDICT-ER|Thebiosignals.com|No|Completed|October 2010|||June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6521|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients presenting at the emergency department of the University Hospital of        Tübingen|February 2014|February 5, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486589||94517|
NCT01482481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI070865|Effectiveness of Nursing Care Plans Based in Nursing Diagnoses in Metabolic Control of Type 2 Diabetes Mellitus|Effectiveness of Implementing Nursing Care Plans Based on Scientific Methodology in Improving Metabolic and Blood Pressure Control of Type 2 Diabetes Mellitus Patients.||Hospital Carlos III, Madrid|No|Completed|January 2008|November 2011|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23488|||Both|30 Years|N/A|No|Non-Probability Sample|23,488 DM2 patients (full universe).|November 2011|November 29, 2011|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482481||94833|
NCT01478607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E05-CL-3002|A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients|A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZATM Plus Standard of Care Versus Standard of Care Alone in Subjects With Painful Diabetic Peripheral Neuropathy|PACE|Astellas Pharma Inc|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|468|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478607||95130|
NCT01480531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030060|Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection|Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection.|Clevidipine|Duke University|No|Withdrawn|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||January 2013|February 7, 2013|October 14, 2011|Yes|Yes|We elected to stop this study due to our inability to recruit suitable subjects.|No||https://clinicaltrials.gov/show/NCT01480531||94983|
NCT01480765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reda 007583|Preventing Pain After Heart Surgery|Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery.||Barts & The London NHS Trust|Yes|Recruiting|November 2011|December 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|80 Years|No|||May 2012|November 11, 2012|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480765||94965|
NCT01480739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3550C00017|AZD5069 Neutrophil Function Study|A Randomised, Double-blind, Placebo-Controlled, Two-way Cross-over, Single Centre Study in Healthy Subjects to Assess the Effect of Oral Dosing of AZD5069 on Neutrophil Number and Function in Peripheral Blood and the Ability to Recruit Neutrophils Into the Circulation After Exercise and Subcutaneous||AstraZeneca||Completed|December 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|November 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01480739||94967|
NCT01480986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJT-NEC-001|IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC|a Prospective Study on the Efficacy and Safety Using Sequential Therapy of Irinotecan Combined With Cisplatin (IP)and Octretide Lar in the First Line Treatment of Metastatic or Inoperable Gastrointestinal Poorly Differentiated Neuroendocrine Carcinoma: the IPO-NEC Trial||Peking University|No|Completed|September 2011|December 2013|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01480986||94948|
NCT01481246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ΑΝΘΡΩ/ΚΟΙΝΩ/0308(ΒΕ)/07|Neurocognitive Study for the Aging|The Neurocognitive Study for the Aging|NEUROAGE|University of Cyprus|Yes|Recruiting|July 2009|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|APOE phenotyping|Both|60 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal older adults and adults with cognitive decline are recruited in this study|December 2015|December 1, 2015|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01481246||94928|
NCT01481779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12146|A Study in Participants With Type 1 Diabetes Mellitus|The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study|IMAGINE 1|Eli Lilly and Company|Yes|Completed|January 2012|June 2014|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481779||94887|
NCT01481792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH-Ophthalmology-2011-01|Efficacy and Safety of ReLEx Smile for Laser Correction of Myopia|Use of the VisuMax Femtosecond Laser for the Correction of Myopia With Small Incision Lenticular Extraction||University of Aarhus|No|Active, not recruiting|February 2011|October 2015|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients referred to the Department of Ophthalmology, Aarhus University Hospital, for        keratorefractive surgical correction of myopia|May 2015|May 27, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01481792||94886|
NCT01481805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-055|Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients|Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients||Samsung Medical Center|No|Active, not recruiting|August 2008|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Hepatocellular carcinoma patients treated with sorafenib|May 2014|May 12, 2014|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01481805||94885|
NCT01482065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00048965|The Sleep, Liver Evaluation and Effective Pressure Study|The Sleep, Liver Evaluation and Effective Pressure Study (SLEEP)|SLEEP|Johns Hopkins University|Yes|Active, not recruiting|November 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|21 Years|N/A|No|||April 2015|April 7, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01482065||94865|
NCT01482351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7584|Mild Cognitive Impairment and Obstructive Sleep Apnea|Mild Cognitive Impairment and Obstructive Sleep Apnea|MEMORIES|George Mason University|Yes|Completed|February 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|86|||Both|55 Years|89 Years|No|||March 2015|March 10, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482351||94843|
NCT01478997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA/110114/FLX/OA|A Study for Moderate Osteoarthritis of the Knee|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Centric Study to Determine Whether Flexsure is Safe, Tolerable and Effective in Relieving Symptoms of Moderate Osteoarthritis of the Knee|Flexsure|Vedic Lifesciences Pvt. Ltd.|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|30 Years|65 Years|No|||May 2012|May 15, 2012|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01478997||95100|
NCT01479257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0696|Determinants of Multiple Health Risk Behaviors Among Latinos|Determinants of Multiple Health Risk Behaviors Among Latinos||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2012|||January 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Bilingual Latinos in the Houston, Texas metropolitan area|October 2015|October 9, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479257||95080|
NCT01479270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10-01517|Transversus Abdominal Plane Block at Total Laparoscopic Hysterectomy: Effect on Quality of Recovery|Randomized Trial of Transversus Abdominal Plane (TAP) Block at Total Laparoscopic Hysterectomy: Effect of Regional Analgesia on Quality of Recovery|TAP|MetroHealth Medical Center|No|Completed|May 2011|January 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|58|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479270||95079|
NCT01479530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13445A|Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China|CHORAL|H. Lundbeck A/S|No|Completed|December 2011|||June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|321|||Both|30 Years|N/A|No|||May 2014|May 23, 2014|November 22, 2011||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01479530||95060|
NCT01479855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/698 (REK)|Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type|Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type|ALZ-vit|Oslo University Hospital|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|Samples With DNA|Whole blood, serum, urine, cerebrospinal fluid|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients referred consequtively to the Memory Clinic, Oslo University Hospital, Ullevål|November 2013|November 26, 2013|September 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01479855||95035|
NCT01469546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.053|Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer|Phase II Trial Evaluating Axitinib (AG-013736) In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|January 2012|January 2016|Anticipated|April 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|October 24, 2011|Yes|Yes||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01469546||95824|
NCT01469559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCALG-IIDPN|Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy|A Phase IIa Dose Escalation Pilot Study to Investigate the Safety and Tolerability of Intranasal Insulin in Subjects With Diabetic Polyneuropathy.|IIDPN|University of Calgary|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|70 Years|No|||August 2012|August 9, 2012|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469559||95823|
NCT01469767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00018876|Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis|Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis||Wake Forest School of Medicine|No|Recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|12 Years|N/A|No|||December 2015|December 9, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01469767||95807|
NCT01485510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZH/4/629|Evaluation of the New Orleans Intervention for Infant Mental Health|Evaluation of the New Orleans Intervention for Infant Mental Health in Glasgow|BEST?|University of Glasgow|No|Recruiting|December 2011|June 2020|Anticipated|June 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|6 Months|60 Months|No|||June 2014|June 10, 2014|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01485510||94600|
NCT01481974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10050268|Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation|An Evaluation of the Safety and Preliminary Efficacy of Perioperative Treprostinil in Preventing Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplant Recipients||University of Pittsburgh|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||July 2015|December 15, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481974||94872|
NCT01486602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB 31102|Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|March 2012|||March 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486602||94516|
NCT01483599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100673|A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis|A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)|X-PLORE|Janssen Inc.|Yes|Completed|November 2011|August 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|293|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483599||94747|
NCT01479972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPM1002-ZA-2.12TB|Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa|Phase II Open Label, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-unexposed, BCG Naive Newborn Infants in South Africa||Vakzine Projekt Management GmbH|Yes|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Both|N/A|8 Days|Accepts Healthy Volunteers|||October 2013|October 28, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01479972||95026|
NCT01480778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEEUNI0811|Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.|Pharmacodynamic Assessment to Drug Ciclo 21 (Levonorgestrel + Ethinyl Estradiol) Market by União Química Farmacêutica Nacional S/A Compared to Drug Nordette of Wieth Indústria Farmacêutica Ltda.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Completed|July 2014|June 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|62|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01480778||94964|
NCT01480752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCT201108017191N1|Reduction of Post-operative Endodontic Pain|the Effect of Intraligamentary Injection of Lornoxicam on the Intensity of Post-operative Endodontic Pain in the Tooth With Symptomatic Irreversible Pulpitis||Islamic Azad University, Tehran|Yes|Completed|September 2011|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|60|||Both|16 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480752||94966|
NCT01480791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100ACA03T|Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries|A Double-Blind, Randomized, Parallel Design Study of Aliskiren Versus Hydrochlorothiazide in Mild-to Moderate Hypertensive Type II Diabetes Mellitus Patients on Remodeling of Resistance Arteries||Sir Mortimer B. Davis - Jewish General Hospital|No|Withdrawn|January 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 18, 2015|November 5, 2011||No|Because of results of Altitude trial, this trial was cancelled.|No||https://clinicaltrials.gov/show/NCT01480791||94963|
NCT01481259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIKLC-201004|Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer|Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Stage IIIb/IV Nonsquamous Non-small Cell Lung Cancer||People's Hospital of Guangxi|Yes|Recruiting|January 2010|July 2013|Anticipated|January 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||July 2012|July 2, 2012|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481259||94927|
NCT01482078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02970|Magnesium for Neonatal Neuroprotection and Mothers|Prospective Observational Study, Maternal Effects of Magnesium Sulphate for Neonatal Neuroprotection in Women Having Cesarean Section Under Neuraxial Anesthesia|MnMs|University of British Columbia|No|Recruiting|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Female|19 Years|N/A|No|Non-Probability Sample|Obstetric patients planning to deliver at British Columbia's Women's Hospital          -  MgSO4 infusion cohort             -Eligible parturients at less than 34 weeks gestational age with potential pre-term             labor, pre-term rupture of membranes or intrauterine growth restriction.          -  Non-MgSO4 infusion cohort -We will approach a control group of subjects: i.e.             parturients undergoing cesarean section (elective or emergency) with neuraxial             anesthesia.|November 2015|November 3, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482078||94864|
NCT01479010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13729|Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension|Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension||Virginia Commonwealth University|Yes|Terminated|November 2011|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|November 7, 2011|Yes|Yes|recruitment issues, critical investigators left institution|No|May 20, 2015|https://clinicaltrials.gov/show/NCT01479010||95099|
NCT01483846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSG-CL-002|Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers|A Phase 1b, Single-Site, Randomized, Double-Blind,Placebo-Controlled, Dose-Escalation Study: Safety, Pharmacokinetics, and Antihyperalgesic Activity of Multiple Doses of AV-101 on Capsaicin-Induced Pain in Healthy Volunteers||VistaGen Therapeutics, Inc.|No|Completed|December 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|November 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01483846||94728|
NCT01479543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SETOPROB|Effects of Probiotics in Immune System of Healthy Adults|Colonization, Safety, Tolerance, and Effects of Three Probiotic Strains on the Immune System of Healthy Adults|SETOPROB|Hero Institute for Infant Nutrition|Yes|Completed|November 2011|December 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|103|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|November 18, 2011||No||No|August 19, 2014|https://clinicaltrials.gov/show/NCT01479543||95059|
NCT01479556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNP-02-2011|Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain|Assessment of Pregabalin Efficacy for the Treatment and Prevention of At-level Non-evoked and Evoked Spinal Cord Injury Neuropathic Pain||Hospital Nacional de Parapléjicos de Toledo|No|Not yet recruiting|December 2011|October 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|70 Years|No|||November 2011|November 22, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01479556||95058|
NCT01484353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPTLC Pilot|Intensive Lifestyle Intervention for Type 2 Diabetics: The KP TLC Pilot|Intensive Lifestyle Intervention for Type 2 Diabetics: The Kaiser Permanente TLC Pilot|KPTLCP|Kaiser Permanente|No|Withdrawn||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 30, 2011||No|This study was cancelled.|No||https://clinicaltrials.gov/show/NCT01484353||94689|
NCT01469780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9806003392|Assessing Pain as a Mediator of Behavior Change in Post-coronary Angioplasty Patients|Assessing Pain as a Mediator of Behavior Change in Post-coronary Angioplasty Patients||Weill Medical College of Cornell University|No|Completed|April 1999|February 2005|Actual|August 2003|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|660|||Both|18 Years|N/A|No|Probability Sample|The is a database study of a cohort of 660 patients with cardiovascular disease who had        recently undergone coronary angioplasty.|March 2012|March 7, 2012|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01469780||95806|
NCT01470040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0528-10-HMO-CTIL|Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?|Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?||Hadassah Medical Organization|No|Not yet recruiting|February 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|50 Years|N/A|No|||January 2012|January 17, 2012|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01470040||95786|
NCT01470326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1781007|Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)|Viviant®20mg Special Investigation (Regulatory Post Marketing Commitment Plan)|VIOLINE|Pfizer|No|Active, not recruiting|November 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3000|||Female|N/A|N/A|No|Probability Sample|The subjects whom an investigator involving B1781007 prescribes the Bazedoxifene Tablets.|March 2016|March 12, 2016|November 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01470326||95764|
NCT01481675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPDLSG002|Diabetes Resolution and Hormone Changes After BPDLL and LSG|Resolution of Diabetes and Hormonal Changes Following Biliopancreatic Diversion Long Limbs and Laparoscopic Sleeve Gastrectomy. A Comparative Prospective Study.||University of Patras|No|Completed|May 2007|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|24|||Both|20 Years|60 Years|No|Non-Probability Sample|Twelve patients with diabetes mellitus type 2 and BMI> 50kg/m2 will undergo BPDLL and 12        patients with diabetes mellitus type 2 and BMI 40-50kg/m2 will undergo LSG|November 2011|November 29, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481675||94895|
NCT01481688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/WA/0112|Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise|Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial.||Bangor University|No|Recruiting|November 2011|January 2012|Anticipated|January 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|14|||Both|18 Years|N/A|No|||November 2011|November 28, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481688||94894|
NCT01478919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 02|Risk Factors for Residual Neoplasia After Endoscopic Mucosal Resection|Risk Factors for Local Residual Neoplasia After Convetional Endoscopic Mucosal Resection of Laterally Spreading Tumors||Vitkovice Hospital|No|Completed|January 2010|November 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|127|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for Endoscopic Mucosal Resection (EMR) of Laterally Spreading Tumors        (LST.)|September 2013|September 19, 2013|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478919||95106|
NCT01479153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID RCB 2010-A00813-36|Venous Site for Central Catheterization|Comparison of Subclavian, Femoral and Internal Jugular Venous Catheterization in Term of Complications in the Intensive Care Unit: a Randomized Controlled Trial|3SITES|University Hospital, Caen|No|Completed|October 2011|February 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|3471|||Both|18 Years|N/A|No|||July 2015|February 9, 2016|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479153||95088|
NCT01482260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|microRNA5|Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma|Comparative Microarray Analysis of microRNA Expression Profiles in Primary Cutaneous Malignant Melanoma, Cutaneous Malignant Melanoma Metastases and Benign Melanocytic Naevi||Ruhr University of Bochum|Yes|Completed|December 2011|||January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|21|Samples With DNA|skin biopsy|Both|1 Year|N/A|No|Non-Probability Sample|Patients with          -  Primary Cutaneous Malignant Melanoma          -  Cutaneous Malignant Melanoma Metastases          -  Benign Melanocytic Naevi|November 2012|November 5, 2012|November 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01482260||94850|
NCT01482273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150/11|Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis|The BERN Ultrasound-enhanced Thrombolysis for Ilio-Femoral Deep Vein Thrombosis versUs Standard Catheter Directed thromboLysis Trial (BERNUTIFUL-Trial)|BERNUTIFUL|University Hospital Inselspital, Berne|No|Completed|November 2011|November 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|75 Years|No|||July 2015|July 16, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482273||94849|
NCT01478282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCRB|Reversal of the Antithrombotic Action of New Oral Anticoagulants|Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers|REVANT|Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|January 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|10|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01478282||95155|
NCT01480804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-15|Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study|Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study|DISCO|Joslin Diabetes Center|No|Completed|November 2006|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|69 Years|N/A|No|||March 2014|March 26, 2014|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01480804||94962|
NCT01480999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0447-CE|Comparing Robotics and Laparoscopy With Laparotomy/Open Surgery for Endometrial Cancer|A Prospective Study Evaluating Surgical and Quality of Life Outcomes in Robotics and Laparoscopy Compared to Laparotomy in Early Stage Endometrial Cancer|GOC2|University Health Network, Toronto|Yes|Active, not recruiting|November 2011|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|550|||Female|18 Years|N/A|No|Non-Probability Sample|New patients in the gynecologic oncology clinic will be offered the surgery that is deemed        appropriate by their individual surgeon based on the patient's medical and surgical        histories, type of malignancy, and the surgeon's expertise in open surgery, laparoscopy        and/or robotic surgery.|May 2015|May 26, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01480999||94947|
NCT01481519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0664.0.146.000-11|A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis|A Randomized, Double-Masked Trial of Topical Dexamethasone 0.1%/Povidone-iodine 0.4% Versus Artificial Tears for Treatment of Viral Conjunctivitis||University of Campinas, Brazil|Yes|Completed|December 2011|February 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||December 2014|December 2, 2014|November 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01481519||94907|
NCT01482364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-01-2011|BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem|BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem|BEAUTY|Hemo Sapiens, Inc.|No|Completed|October 2011|January 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|75 Years|No|||November 2011|March 23, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482364||94842|
NCT01482377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27771|A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors|Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotininb (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-positive Solid Tumors of Ephitelian Cell Origin||Hoffmann-La Roche||Active, not recruiting|December 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|184|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482377||94841|
NCT01478399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB1023-PT-CL-0003|Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function|Phase 1 Open-Label Pharmacokinetic, Safety and Tolerability Study of a Single Subcutaneous Dose of Glymera (PB1023) Injection in Subjects With Normal Renal Function and Subjects With Impaired Renal Function||PhaseBio Pharmaceuticals Inc.|Yes|Completed|December 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||April 2013|April 12, 2013|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478399||95146|
NCT01478711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007241|Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants|Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants|PreemieCDS|Children's Hospital of Philadelphia|No|Completed|September 2009|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1517|||Both|20 Weeks|35 Weeks|No|||February 2013|February 25, 2013|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478711||95122|
NCT01478724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SORBONE|Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention|Effects of Proteins Fraction Derived From Milk on Bone Mineral Density and Bone Metabolism in Healthy Postmenopausal Women||Soredab|Yes|Completed|November 2011|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|291|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 22, 2015|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478724||95121|
NCT01479569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120025|Pericardiocentesis With Magnetic Resonance Imaging|Real-time MRI Pericardiocentesis Using Passive Needles||National Institutes of Health Clinical Center (CC)||Recruiting|November 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|September 10, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479569||95057|
NCT01484132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01ES019155|Composites and Urinary Bisphenol-A Study|Health Effects of Dental Composites in Children|CUBS|New England Research Institutes|No|Completed|February 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|3 Years|17 Years|No|||March 2015|July 6, 2015|November 16, 2011||No||No|May 15, 2015|https://clinicaltrials.gov/show/NCT01484132||94706|
NCT01484119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-060B307|Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis|Multi-center, Double-blind, Double-dummy, Randomized, Placebo-controlled, Active-reference, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-129968 in Adolescent, Adult & Elderly Patients With Seasonal Allergic Rhinitis|SAR|Actelion|No|Completed|December 2011|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|630|||Both|12 Years|76 Years|No|||March 2013|March 27, 2013|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484119||94707|
NCT01484665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011NTLS071|Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening|Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening||University of Minnesota - Clinical and Translational Science Institute|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|72|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 21, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01484665||94665|
NCT01470651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/6285|Armodafinil for Patients Starting Hepatitis C Virus Treatment|Armodafinil for Patients Starting Hepatitis C Treatment||Research Foundation for Mental Hygiene, Inc.|Yes|Terminated|October 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|70 Years|No|||May 2015|May 4, 2015|October 13, 2011|Yes|Yes|European Medicines Agency issued a drug/drug interaction: sofosbuvir/modafinil|No||https://clinicaltrials.gov/show/NCT01470651||95739|
NCT01470664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FST100-AVC-004|FST-100 in the Treatment of Acute Adenoviral Conjunctivitis|A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis||Shire|No|Completed|December 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|176|||Both|18 Years|N/A|No|||August 2014|September 22, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01470664||95738|
NCT01478295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS PI11/02132|Effectiveness of Nursing Intervention on Caregivers|Effectiveness of Nursing Intervention on Quality of Life of Older Caregivers: Clinical Trial Randomised by Clusters|CuidaCare|Gerencia de Atención Primaria, Madrid|Yes|Completed|June 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|266|||Both|65 Years|N/A|No|||February 2016|February 10, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01478295||95154|
NCT01478620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CanUTI2|Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)|An Open-label, Non-randomized, Multicenter, Interventional Study to Investigate the Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)||Bionorica SE||Completed|October 2011|August 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Female|18 Years|65 Years|No|||October 2014|October 10, 2014|November 21, 2011||No||No|August 27, 2014|https://clinicaltrials.gov/show/NCT01478620||95129|
NCT01478906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mzk2010orexin|Difference of Plasma Orexin A Levels Between Elderly and Young Patients at Emergence|To Investigate Difference of Plasma Orexin A Levels Between Elderly and Youth Patients at Emergence From Sevoflurane-fentanyl Anesthesia Undergoing Elective Lumbar Surgery||Xijing Hospital|Yes|Recruiting|July 2011|September 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|plasma|Both|18 Years|80 Years|No|Non-Probability Sample|18 to 80 years old ,undergo Lumbar Surgery|May 2012|May 13, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478906||95107|
NCT01479751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|facilitating RSI|Comparison of Methods to Facilitate Rapid Sequence Intubation|Comparison of Mg, Ketamine, Large Dose Rocuronium, and Priming on Intubating Condition in Rapid Sequence Intubation||Seoul National University Bundang Hospital|Yes|Completed|November 2011|August 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|110|||Both|18 Years|65 Years|No|||August 2012|August 24, 2012|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479751||95043|
NCT01479426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOTTE-MS-EFLA400|A Trial to Evaluate the Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Sexual Function in Men With Erectile Dysfunction|Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Erectile Dysfunction||Chonbuk National University Hospital|Yes|Enrolling by invitation|December 2010|July 2012|Anticipated|March 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||December 2010|November 23, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01479426||95068|
NCT01479725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-247|Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis|A Prospective Trial Comparing the Response to Hyperbaric Oxygen Treatment in Patients With Ulcerative and Non-Ulcerative Interstitial Cystitis||William Beaumont Hospitals|No|Active, not recruiting|March 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 1, 2015|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479725||95045|
NCT01480258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V419-008|Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)|A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months||Sanofi Pasteur MSD|No|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1315|||Both|46 Days|89 Days|Accepts Healthy Volunteers|||October 2013|October 14, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480258||95004|
NCT01480206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCY611-110165|Overlay of 3D Scans on Live Fluoroscopy for Endovascular Procedures in the Hybrid OR|3D Interventional Tools for Endovascular Procedures in the OR||Philips Healthcare|No|Enrolling by invitation|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients with age 18-90, of both genders and all races Patients undergoing elective AAA or        TAA repair or carotid stenting Patients already selected for endovascular treatment by        preoperative CT angiogram Patients with preoperative CT performed within 4 months of        operation|August 2015|August 21, 2015|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01480206||95008|
NCT01480219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1501098|Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g|Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009||Pfizer|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|467|||Both|18 Years|N/A|No|Non-Probability Sample|Patients aged 18 or older who received a lung or heart/lung transplant from January 1,        2002 through December 31, 2009 in the MarketScan database will be initially included in        the study. Patients who are younger than 18 years of age and who are not enrolled for at        least 180 days before and 180 days after the date of transplant will be excluded.|February 2013|February 4, 2013|November 23, 2011||No||No|February 4, 2013|https://clinicaltrials.gov/show/NCT01480219||95007|
NCT01480232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-014|A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence|Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence||Massachusetts General Hospital|Yes|Terminated|December 2011|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|345|||Both|18 Years|65 Years|No|||September 2015|September 18, 2015|November 23, 2011|Yes|Yes|FDA imposed Clinical Hold after a number of patients taking Encenicline (EVP-6124) in    Alzheimer Disease trials reported serious gastrointestinal side effects|No||https://clinicaltrials.gov/show/NCT01480232||95006|
NCT01481012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-1093 PD|The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices|The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices||Icahn School of Medicine at Mount Sinai|Yes|Terminated|January 2006|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|94|Samples Without DNA|Blood for the following markers of thrombin generation and platelet function will be drawn,      spun, aliquoted and stored for later batched analysis: - Thrombo-antithrombin complex (TAT);      - Prothrombin Fragment 1+2 (F1.2); - Thromboelastrograph (TEG) (performed at the clinical      site when available); - Additional markers of coagulation and platelet activation (for      future consideration) - 4ml of plasma frozen in 1ml aliquots.|Both|18 Years|N/A|No|Probability Sample|Patients with underlying systolic ventricular dysfunction who will undergo heart        transplantation, CABG surgery, implantation of a pulsatile LVAD, or implantation of a        continuous flow LVAD (as destination therapy or bridge to transplantation) within 24 hours        of enrollment, are candidates for this study.|November 2011|November 23, 2011|November 7, 2011||No|Slow enrollment - terminated for futility.|No||https://clinicaltrials.gov/show/NCT01481012||94946|
NCT01481272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLRG8 (OMB114361)|Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients|A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant|PLRG8|Polish Lymphoma Research Group|Yes|Recruiting|November 2011|August 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01481272||94926|
NCT01481532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTX01|Open Label Clinical Trial of Intravenous Crotoxin|Open Label Phase I Clinical Trial of Crotoxin in Patients With Advanced Cancer Using an Intravenous Route of Administration||Celtic Biotech Ltd|Yes|Active, not recruiting|September 2011|May 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|75 Years|No|||August 2015|August 17, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01481532||94906|
NCT01481545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRANCH|Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer|Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial|BRANCH|National Cancer Institute, Naples|No|Active, not recruiting|December 2006|March 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01481545||94905|
NCT01478412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHI-001|An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer|A Prospective Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer|Clarity|ProCure Proton Therapy Center|No|Recruiting|December 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Male|N/A|N/A|No|Non-Probability Sample|Members of all races and ethnic groups are eligible for this trial. Since this is a        prostate study, only males will be enrolled.|December 2011|December 6, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478412||95145|
NCT01478425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ-NME-11-01|Efficacy and Tolerability of a Topical Microemulsion in Patients With Allergic Rhinitis Due to Sensitization to Pollen|Study on the Efficacy and Tolerability of a Topical Microemulsion in Patients With Intermittent or Persistent Allergic Rhinitis Due to Sensitization to Birch, Olive Tree or Grass Pollen||Reig Jofre Group|Yes|Completed|March 2011|August 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|No|||November 2011|November 28, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478425||95144|
NCT01478737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDRPOZU1|Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy|A Prospective, Randomized Study on Intravitreal Ozurdex for Preventing Recurrent Vitreous Hemorrhage Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy||St. Erik Eye Hospital|No|Recruiting|November 2011|September 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|12 Years|N/A|No|||September 2014|September 24, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478737||95120|
NCT01478750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL27994.068.09|Oro-gastro-intestinal Digestion of Emulsified Fat|Oro-gastro-intestinal Digestion of Emulsified Fat and How This Digestion Relates to Colloidal Stability and Physiological Responses||Maastricht University Medical Center|No|Completed|December 2009|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01478750||95119|
NCT01483859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0053|Prediction of Intraoperative Blood Loss and Postoperative Recovery by Liver Stiffness Measurement (Fibroscan®) in Right Hepatectomy|Prediction of Intraoperative Blood Loss and Postoperative Recovery by Liver Stiffness Measurement (Fibroscan®) in Right Hepatectomy||Yonsei University|Yes|Completed|September 2011|December 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|20 Years|80 Years|No|||July 2015|July 14, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01483859||94727|
NCT01484405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA|Anterolateral Versus Posterior Approach for Total Hip Arthroplasty After Displaced Femoral Neck Fracture|Anterolateral Versus Posterior Approach for Total Hip Arthroplasty After Displaced Femoral Neck Fracture|THA|Florida Orthopaedic Institute|No|Terminated|June 2010|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|65 Years|N/A|No|||November 2014|November 10, 2014|November 30, 2011||No|Low enrollment.|No||https://clinicaltrials.gov/show/NCT01484405||94685|
NCT01484678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ImagingDMD|Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy|Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy||University of Florida|No|Active, not recruiting|May 2010|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|185|Samples With DNA|Blood and Skin Samples Collected|Male|5 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from across the country as well as locally. The investigators        have established a website (www.imagingDMD.org) and advertise the study nationally through        list serves.The study will also be advertised at the website of non-profit DMD        organizations. General information will be emailed to faculty and colleagues around the        country. Fliers and brochures will be distributed in participating local clinics, MDA        clinics, schools, and local pediatric clinics, and in strategic locations in associated        hospitals. Age-matched healthy boys will be recruited from the families of the local DMD        population as well as the university community. Parents of eligible subjects will be asked        to contact the site clinical coordinator, who will complete a telephone screening        interview to assess eligibility.|April 2015|April 14, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01484678||94664|
NCT01484366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBFA|Forearm Shaft Fractures: Plating of Radius and Ulna Versus Plating of Radius and Nailing of Ulna|Prospective Randomized Trial for Forearm Shaft Fractures: Plating of Radius and Ulna vs. Plating of Radius and Nailing of Ulna||Florida Orthopaedic Institute|No|Terminated|September 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|November 30, 2011||No|Low enrollment. Treament no longer used by researchers.|No||https://clinicaltrials.gov/show/NCT01484366||94688|
NCT01484379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|parathyroid409-11-RMBCTIL|Surgical Approach for Primary Hyperparathyroidism in the Elderly|Surgical Approach for Primary Hyperparathyroidism in the Elderly - a Prospective Study||Rambam Health Care Campus|No|Active, not recruiting|December 2011|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|65 Years|N/A|No|||August 2014|August 6, 2014|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01484379||94687|
NCT01485198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE11-022|Autologous Stem Cells in Osteoarthritis|Clinical Effects of Autologous Bone Marrow Mononuclear Cell Infusion in Knee Osteoarthritis.||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Completed|August 2011|May 2014|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|30 Years|N/A|No|||February 2016|February 29, 2016|November 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485198||94624|
NCT01471002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5062|Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours < 4cm in Patients Who Are Not Candidates for Partial Nephrectomy|Prospective Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours < 4cm in Patients Who Are Not Candidates for Partial Nephrectomy|CRYOREIN|University Hospital, Strasbourg, France|No|Recruiting|November 2011|December 2015|Anticipated|||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2011|September 7, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01471002||95713|
NCT01471314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-089|MRA/fMRI Study of Spontaneous Migraine|Functional MRI and MR Angiography Used in Spontaneous Migraine||Glostrup University Hospital, Copenhagen|Yes|Recruiting||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|||||Both|18 Years|60 Years|No|Probability Sample|Migraine without aura|August 2012|August 28, 2012|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01471314||95689|
NCT01478932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|541-11-EP|Diaphragmatic Breathing Retraining in Heart Failure Patients: Health-Behavior Related Outcomes|Diaphragmatic Breathing Retraining in Heart Failure Patients: Health-Behavior Related Outcomes||University of Nebraska|Yes|Recruiting|December 2011|June 2014|Anticipated|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|50|||Both|19 Years|N/A|No|||January 2014|January 7, 2014|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01478932||95105|
NCT01479439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-3070|Losartan to Reverse Sickle Nephropathy|A Phase II Trial of Losartan to Reverse Sickle Nephropathy||Children's Hospital Medical Center, Cincinnati|Yes|Completed|February 2012|December 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|6 Years|N/A|No|||February 2016|February 1, 2016|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01479439||95067|
NCT01479452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOS-1987|Effects of Bariatric Surgery in Swedish Obese Subjects|Effects of Bariatric Surgery in Swedish Obese Subjects|SOS|Göteborg University|Yes|Completed|January 1987|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4047|||Both|37 Years|60 Years|No|||November 2011|November 23, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479452||95066|
NCT01479738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHQ002|Proximal Interphalangeal Joint Arthroplasty Using a Graft From the Capitate|The Second Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066600, China|PIPPC|The Second Hospital of Qinhuangdao|Yes|Completed|January 2005|October 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|50 Years|No|||November 2011|November 24, 2011|November 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01479738||95044|
NCT01479465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-295-0203|Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.||Gilead Sciences|Yes|Completed|December 2011|February 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|266|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479465||95065|
NCT01479764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07981|Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)|Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry||Merck Sharp & Dohme Corp.|No|Completed|December 2011|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|November 22, 2011|Yes|Yes||No|August 26, 2013|https://clinicaltrials.gov/show/NCT01479764||95042|
NCT01479985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP5-8|Computerized Decision Aid|Randomized Clinical Trial of a Computerized Contraceptive Decision Aid|CDM RCT|Washington University School of Medicine|No|Completed|January 2014|July 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|201|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01479985||95025|
NCT01480271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114450|An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.|A Randomized, Double-blind, Placebo-controlled First Time Into Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Dosing With GSK2245035, a TLR7 Agonist, in Healthy Volunteers and Allergic Rhinitics.||GlaxoSmithKline|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|16||Actual|61|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|March 8, 2012|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480271||95003|
NCT01480284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115409|Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue|A Multi-center, Randomized, Active Controlled, Double-blind, Parallel Group Comparison Study and Subsequent Open-label Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue||GlaxoSmithKline|No|Completed|November 2011|November 2014|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|16 Years|69 Years|No|||April 2015|June 11, 2015|November 23, 2011||No||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01480284||95002|
NCT01480544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031046|Improving Maternal and Child Health in India: Evaluating Demand and Supply Side Strategies (IMATCHINE)|Improving Maternal and Child Health in India: Evaluating Demand and Supply Side Strategies|IMATCHINE|Duke University|No|Completed|August 2012|November 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|14990|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01480544||94982|
NCT01481025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cimicifuga/Herbarium|Efficacy and Safety for Cimicifuga/Hypericum Product|Phase 3 Study - Efficacy and Tolerance for the Mixture of Dry Extracts Black Cohosh and Saint John's Worth Versus Isolated Black Cohosh Extract for the Climacteric Symptoms' Control|CH|Phytopharm Consulting Brazil|Yes|Not yet recruiting|November 2011|August 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|210|||Female|45 Years|60 Years|No|||November 2011|November 28, 2011|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01481025||94945|
NCT01484509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16036|Subjective and Objective Methods of Assessing Walking Limitation Due to Claudication|The Estimation of Ambulation Capacity by History Questionnaire (EACH-Q): An Assessment of Its Validity and Inter-day Reproducibility in Patients With Vascular-type Claudication||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|June 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|37|||Both|18 Years|90 Years|No|Probability Sample|Patients with intermittent claudication recruited from hospital clinics|November 2011|May 14, 2012|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01484509||94677|
NCT01484795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cristina Dias|Noninvasive Ventilation in Acute Myocardial Infarction|Non Invasive Ventilation in Acute Myocardial Infarction||Centro Universitário Augusto Motta|Yes|Completed|January 2011|November 2011|Actual|June 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Both|45 Years|80 Years|No|||November 2011|December 1, 2011|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484795||94655|
NCT01485094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|967165|A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain|Evaluation of the Efficacy, Tolerability, and Safety of 7 Days of Treatment With GRT6010 or Pregabalin in Comparison to Placebo in Subjects With Peripheral Neuropathic Pain.||Grünenthal GmbH|No|Terminated|February 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|114|||Both|18 Years|75 Years|No|||September 2014|September 30, 2014|October 5, 2011||No|The trial was early terminated after it was concluded that there was no added benefit from    exposing further participants after an unblinded interim analysis.|No|September 16, 2014|https://clinicaltrials.gov/show/NCT01485094||94632|
NCT01485328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|labsaude-001-ama|Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics|Phase III - Efficacy Study of AMARGOL - Phytomedicine on Therapeutics|AMARGOL|Laboratorio Saude Ltda.|Yes|Completed|December 2008|September 2009|Actual|April 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 5, 2011|December 16, 2008||No||No||https://clinicaltrials.gov/show/NCT01485328||94614|
NCT01485900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR12446|Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Hemodynamics of Ascending Repeated Oral Doses of SAR407899A in Patients With Moderate Chronic Kidney Disease on Stable Angiotensin Converting Enzyme-inhibitor (ACE-I) Treatment||Sanofi|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|79 Years|No|||August 2012|August 22, 2012|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01485900||94570|
NCT01486160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSO-2011-2012|Respiratory Viral Infection in Nursing Home Slovenia|Etiology, Frequency and Epidemiology of Respiratory Viral Infection in Nursing Home Residents||University Maribor|No|Completed|December 2011|November 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|132|Samples With DNA|whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Nursing home residents and employees of the nursing home|November 2012|November 28, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01486160||94550|
NCT01486121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8667|Sedation Optimisation Strategy (S.O.S.) Ventilation|S.O.S. Ventilation - Sedation Optimisation Strategy For Mechanical Ventilation In Intensive Care Unit Patients||University Hospital, Montpellier|No|Completed|December 2011|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01486121||94553|
NCT01482650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A. 650|Comparison of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients|Comparison of the Effectiveness of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients||University College Hospital Galway|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|92|||Female|16 Years|85 Years|No|||June 2012|June 18, 2012|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01482650||94820|
NCT01486706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLMC10-010|Efficacy and Safety of Gabapentin in Treating Overactive Bladder|A Prospective 12-Week, Randomized, Double-Blind, Double Dummy Placebo-Controlled, Parallel-Group, Clinical Trial to Evaluate The Efficacy And Safety Of Gabapentin In Comparison to Solifenacin Succinate in Patients With Overactive Bladder|OAB|St. Luke's Medical Center, Philippines|Yes|Completed|October 2010|January 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|75 Years|No|||April 2015|April 5, 2015|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01486706||94508|
NCT01482637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0902|Development of Coercion Assessment Scale|Improving Ethics in Research: Development of the Coercion Assessment Scale|CAS|Treatment Research Institute|Yes|Completed|January 2010|December 2013|Actual|December 2013|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|228|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|For Phase 3, a total of 228 clients were drawn from the host study recruiting from a        misdemeanor drug court in New Castle County, Delaware and from Miriam Prison in Rhode        Island. The sample is representative of the combined demographic characteristics of our        host studies with the study participants being 75% male, 75% Caucasian, and 22%        African-American in the Wilmington and Rhode Island sites. Our sample of adolescents is        representative of the host study with 78% African-American, 8% Caucasian and 13% "Other."|July 2014|July 10, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482637||94821|
NCT01483222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101201|Comparison of Inelastic and Elastic Lumbosacral Orthoses on Low Back Pain Prevention in Hospital Nurses|Comparison of Inelastic and Elastic Lumbosacral Orthoses on Low Back Pain Prevention in Hospital Nurses||Central South University|Yes|Completed|November 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|300|||Female|20 Years|25 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|November 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01483222||94776|
NCT01483508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513038|Absorption and Metabolism of Dietary Cocoa Procyanidins in Humans|Contribution of Dietary Cocoa Procyanidins to the Systemic Presence of Flavanols Metabolites in Humans||University of California, Davis|No|Completed|February 2008|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 23, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01483508||94754|
NCT01483651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kw02|Physiologic Response to Glucagon at Varying Insulin Levels|The Hepatic Glucose Response to Glucagon at Varying Insulin Levels: Implications for Closed Loop Glycemic Control.||Legacy Health System|Yes|Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|11|||Both|21 Years|65 Years|No|||May 2015|May 19, 2015|November 29, 2011||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01483651||94743|
NCT01486654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-kaye|Transcranial Direct Current Stimulation and Aphasia Language Therapy|Transcranial Direct Current Stimulation and Aphasia Language Therapy||Rehabilitation Institute of Chicago|No|Active, not recruiting|March 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|12|||Both|21 Years|N/A|No|||March 2016|March 18, 2016|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486654||94512|
NCT01483144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-FAP-310|Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)|Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis||Cancer Prevention Pharmaceuticals, Inc.|Yes|Recruiting|October 2013|June 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|November 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483144||94782|
NCT01483157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vascular occlusion and RA|Vascular Occlusion and Rheumatoid Arthritis|Effects of Strength Training With Vascular Occlusion in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial||University of Sao Paulo|No|Recruiting|November 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|30 Years|70 Years|No|||February 2014|February 27, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483157||94781|
NCT01483118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1377|Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)|The Effects of Oral Cinnamon Extract on Menstrual Cyclicity in PolyCystic Ovary Syndrome||Columbia University|Yes|Active, not recruiting|March 2011|April 2014|Anticipated|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483118||94784|
NCT01483131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vascular occlusion and OA|Vascular Occlusion in Patients With Osteoarthritis|Effects of Strength Training Associated With Vascular Occlusion in Patients With Knee Osteoarthritis||University of Sao Paulo|No|Recruiting|November 2011|December 2014|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483131||94783|
NCT01483404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A10-30|Identification of the Microcirculation of the Caput Femoris After Fracture of the Femoral Neck|Identification of Microcirculation in Fracture of the Femural Neck: How Does the Intracapsular Hematoma Affect the Capillary Bloodflow in the Caput Femoris?|MicroFemNeck|RWTH Aachen University|Yes|Withdrawn|June 2012|November 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with fracture of the femural neck, who are treated in the University Hospital        Aachen|November 2012|November 9, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483404||94762|
NCT01483417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-004|Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy|Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis||Samsung Medical Center|Yes|Recruiting|December 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|20 Years|60 Years|No|||November 2011|February 20, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483417||94761|
NCT01483976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK96|Comparison of Medical Nutritional Supplements|Comparison of Medical Nutritional Supplements With or Without AN777 in Elderly Men||Abbott Nutrition|Yes|Completed|October 2011|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Male|60 Years|90 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01483976||94718|
NCT01484262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3962|Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2|Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2||Novo Nordisk A/S|No|Completed|November 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1334|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients diagnosed with type 2 diabetes mellitus, currently treated with oral        antidiabetics (OADs), who need treatment intensification with insulin or liraglutide due        to inadequate blood glucose control.|January 2015|January 16, 2015|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01484262||94696|
NCT01484522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPAACT P1089|Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth|A Laboratory Study to Assess the Immunogenicity of Three Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-1 Perinatally Infected Children and Youth||International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Yes|Completed|October 2009|September 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|149|||Both|6 Months|25 Years|No|Non-Probability Sample|HIV-1 perinatally infected children and youth 6 months to 25 years of age.        For inclusion into the study, if perinatal acquisition of HIV infection cannot be        confirmed based on the child's medical record, it is acceptable to enroll the child if the        investigator's assessment is that the most likely route of infection was perinatal.|November 2011|November 30, 2011|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484522||94676|
NCT01484808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8DUT115799|The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage|Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage|PSADv|University Urological Associates Inc.|No|Not yet recruiting|January 2012|May 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|6600|||Male|50 Years|74 Years|No|Probability Sample|Men with PSA elevation (>=4), 50-74 years old with negative biopsy of the prostate at        study entry|November 2011|December 1, 2011|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484808||94654|
NCT01485575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILM-AMF2|Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy|Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy||University Hospital, Basel, Switzerland|No|Recruiting|November 2011|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Internal limiting membrane as removed during routine surgery.|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients treated with Chromovitrectomy at 3 tertiary care hospitals.|February 2016|February 4, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01485575||94595|
NCT01485588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT-001|Safety and Tolerability Study for Age-Related Macular Degeneration|A Phase 1 / 2 Trial to Investigate The Safety and Tolerability of Single and Repeated Doses of hI-CON1™ Following Administration by Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD)||Iconic Therapeutics, Inc.|No|Completed|December 2010|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|50 Years|N/A|No|||February 2015|February 4, 2015|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485588||94594|
NCT01485874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN10-149|Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer|A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149||Hoosier Cancer Research Network|Yes|Terminated|November 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|December 2, 2011|No|Yes|Funding withdrawn due to drug unavailability|No||https://clinicaltrials.gov/show/NCT01485874||94572|
NCT01486173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-mars-12551|Early Nutrition and Neurological Development of Very Preterm Infants|Early Nutrition and Neurological Development of Very Preterm Infants|EPINUTRI|Lapillonne, Alexandre, M.D.|Yes|Active, not recruiting|June 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|260|Samples With DNA|whole blood|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subsample of infants born very preterm (before 32 weeks of gestation) otherwise included        in the French national cohort EPIPAGE 2|April 2013|April 16, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486173||94549|
NCT01486459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCC 11.01|A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer|A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer|TULIP|Barwon Health|No|Terminated|November 2012|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||August 2013|March 16, 2015|December 4, 2011||No|Insufficient recruits|No||https://clinicaltrials.gov/show/NCT01486459||94527|
NCT01486134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100138/AOM 10266|Major RF Ablations of Hepatomas Under MR Thermometry Monitoring|Pilot Study of Real Time MR Temperature Monitoring of Multipolar Radiofrequency Ablation of Large Hepatocellular Carcinomas (≥ 5 CM)-ARMTICH STUDY|ARMTICH|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|June 2012|January 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01486134||94552|
NCT01482663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHE-2011-Geh|Chronic Hand Eczema - Self-management and Prognosis|Chronic Hand Eczema - Self-management and Prognosis||University Hospital, Gentofte, Copenhagen|No|Completed|May 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|306|||Both|18 Years|70 Years|No|||December 2014|December 2, 2014|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01482663||94819|
NCT01486719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEN-19750306|Sensory Reconstruction of Finger Pulp Defect Using a Dorsal Digital Island Flap|Sensory Reconstruction of Finger Pulp Defect Using a Dorsal Digital Island Flap||The Second Hospital of Tangshan|Yes|Completed|February 2008|March 2011|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|12|||Both|15 Years|60 Years|No|||December 2011|December 5, 2011|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01486719||94507|
NCT01483495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2010-7521|Assessing Cerebrovascular Reactivity Based on Cerebral Oximetry: a Pilot Study|Assessing Cerebrovascular Reactivity Based on Cerebral Oximetry|DOSI|University of California, Irvine|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|78|||Both|20 Years|N/A|No|Non-Probability Sample|Elective surgery|August 2015|August 5, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01483495||94755|
NCT01483521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02992|Infant Psychiatry Home Visitation Program|Externalizing Behavior in Early Childhood: A Randomized Control Evaluation of a Home Visitation Program||University of British Columbia|No|Completed|April 2009|February 2011|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|N/A|6 Years|No|||November 2011|November 30, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01483521||94753|
NCT01486667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-11-465|Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP|Effect of Thyroxin Treatment in Sub Clinical Hypothyroidism Patients, on the Apnea Hypopnea Index Score, Lipid Profiles and Highly Sensitive CRP : A Randomized Double Blind Controlled Trial||King Saud University|Yes|Recruiting|October 2011|||October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2011|December 6, 2011|December 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01486667||94511|
NCT01482559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIP-FP7-BrePco|Management of Hypotension In the Preterm Infant|Management of Hypotension In Preterm Infants: The HIP Trial Protocol for a Randomized Controlled Trial of Hypotension Management in the Extremely Low Gestational Age Newborn|HIP|University College Cork|Yes|Recruiting|January 2015|January 2018|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|830|||Both|23 Weeks|27 Weeks|No|||January 2015|January 27, 2015|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482559||94827|
NCT01483729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP27945|A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers|||Hoffmann-La Roche||Completed|December 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Masking: Open Label, Primary Purpose: Treatment|6||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01483729||94737|
NCT01483430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_Ginseol Kg1|Effect of Ginseol Kg1 on Blood Pressure Lowering|Effect of Ginseol Kg1 on Blood Pressure Lowering in Prehypertensive or Stage I Hypertensive Patients: Multicenter, Randomized, Placebo-controlled, Double-blind Study||Seoul National University Hospital|No|Recruiting|September 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|N/A|No|||November 2011|November 30, 2011|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483430||94760|
NCT01483716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1481|A Trial of Rehabilitation in Obesity Hypoventilation Syndrome (OHS)|||Guy's and St Thomas' NHS Foundation Trust||Completed|November 2011|August 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||August 2015|August 16, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01483716||94738|
NCT01483989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA-09-49|In Vivo Measurement of Corneal Epithelial Changes in Dry Eye Patients|In Vivo Measurement of Corneal Epithelial Changes in Dry Eye(DE) Patients||Alcon Research|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483989||94717|
NCT01484002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2011-0101|Analysis of Crosslinked and Conventional Polyethylene Explants|Collaborative Analysis of UHMWPE Explants: Conventional UHMWPE With No Radiation and Marathon||Anderson Orthopaedic Research Institute|No|Enrolling by invitation|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Crosslinked and conventional polyethylene liners terminally sterilized without        gamma-irradiation will be used for this study. Specimens will be selected from the implant        retrieval collection maintained by the Anderson Orthopaedic Research Institute.|January 2016|January 6, 2016|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484002||94716|
NCT01484821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/29|Assessment of in Vivo Skeletal Muscle Viscoelasticity (ARFI Imaging) With Aging and Cancer||CAPARFI|University Hospital, Bordeaux|No|Completed|November 2011|October 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01484821||94653|
NCT01485107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-105|Feasibility Study: Evaluation of the Ulthera® System for Treatment of the Décolleté|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Décolleté||Ulthera, Inc|No|Completed|June 2011|May 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485107||94631|
NCT01485341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61-2-9-2011|Gluten Sensitivity in Non-Celiac Patients|Double Blind Randomized Placebo Controlled Multicenter Trial (Gluten vs Placebo) in Gluten Sensitive Subjects|GS|Second University of Naples|Yes|Recruiting|June 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 13, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01485341||94613|
NCT01485601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-GPRT-GL01|Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines|A Randomised, Double-blind, Multi-centre, Phase II, Optimal Dose-finding Study to Determine the Safety and Efficacy of MT10109 (Clostridium Botulinum Toxin Type A) in Subjects With Moderate to Severe Glabellar Lines in Comparison to BOTOX®||Medy-Tox|Yes|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|75 Years|No|||September 2012|September 19, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485601||94593|
NCT01485614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-083|Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)|A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|Yes|Recruiting|February 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|10 Years|17 Years|No|||March 2016|March 22, 2016|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485614||94592|
NCT01486472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-SNUBH-2010-01|S-1-induced Lacrimal Drainage Obstruction|Lacrimal Drainage Obstruction in Gastric Cancer Patients Receiving Adjuvant S-1 Chemotherapy: A Prospective Study||Seoul National University Bundang Hospital|No|Recruiting|November 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Plasma Tears|Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving S-1 as an adjuvant chemotherapy after radial surgery (D2 dissection)        for GC|December 2011|December 6, 2011|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486472||94526|
NCT01486732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP FLT-PET|FLT-PET Activity Change After Allogeneic Umbilical Cord Blood (UCB) Therapy in Cerebral Palsy|FLT(3'-Deoxy-3'-[F-18]Fluorothymidine)-PET Activity Change After Allogeneic Umbilical Cord Blood Cell Therapy in Cerebral Palsy||Bundang CHA Hospital|No|Withdrawn|March 2013|July 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|6 Months|20 Years|No|||November 2013|November 17, 2013|December 4, 2011||No|Difficulty in obtaining specific isotope tracer|No||https://clinicaltrials.gov/show/NCT01486732||94506|
NCT01482676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146/05b|The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction|Investigating the Role of microRNAs in the Regulation of Gene Expression and Organ Remodeling During Lower Urinary Tract Dysfunction, Including Bladder Pain Syndrome/Interstitial Cystitis (BPS), and Overactive Bladder Syndrome (OAB)||University Hospital Inselspital, Berne|No|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|103|Samples With DNA|Frozen cold-cut bladder biopsies preserved in RNAlater buffer or in SDS-PAGE sample buffer;      PFA-fixed tissue, primary cultures of urothelium and smooth muscle|Both|18 Years|N/A|No|Non-Probability Sample|Patients Department of Urology, Inselspital Bern, Switzerland|June 2015|June 1, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01482676||94818|
NCT01482884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2211C00001|Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis|A Phase IIa, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of Tralokinumab (CAT-354), a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), as add-on Therapy, on Clinical Response in Patients With Active, Moderate-to-severe, Ulcerative Colitis||AstraZeneca||Completed|March 2012|June 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|75 Years|No|||April 2014|January 12, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482884||94802|
NCT01482897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 11/4-M|Efficacy of corticoïd Infiltration Via Sacro-coccygien Hiatus in Discal Sciatica|Open Randomized Study on the Efficacy of corticoïd Infiltration Versus Physiological Solution Infiltration Versus Feigning of Infiltration Via Sacro-coccygien Hiatus Versus Natural Evolution in Discal Sciatica|Hiatus|Nantes University Hospital|No|Terminated|December 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|November 29, 2011||No|Enrolment stopped on December 01, 2014 since after 3 years, only 13 patients were included    (instead of 274) (Date of last visit last patient : October 3, 2013).|No||https://clinicaltrials.gov/show/NCT01482897||94801|
NCT01483235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37553|Reduced Cardiac Rehabilitation Program|Design, Implementation and Evaluation of a Reduced Cardiac Rehabilitation Program|rCRP|Simon Fraser University|No|Completed|September 2006|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|118|||Both|30 Years|90 Years|No|||December 2011|December 1, 2011|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01483235||94775|
NCT01482572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-078|Feasibility of Mutational Analysis of Non-Small Cell Lung Cancer (NSCLC) Using Low-volume Lung Aspirates|Feasibility of Gene Expression Profiling Using Low-volume Lung Aspirate||Samsung Medical Center|Yes|Withdrawn|January 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples With DNA|lung tissue|Both|20 Years|N/A|No|Non-Probability Sample|lung cancer patients|October 2015|November 17, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482572||94826|
NCT01482585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2011-09-083|Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy|Prospective Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy||Samsung Medical Center|Yes|Recruiting|October 2011|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|lung tissue, serum|Both|20 Years|N/A|No|Non-Probability Sample|patients with stage I or II lung adenocarcinoma who plans curative operation|November 2011|November 29, 2011|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482585||94825|
NCT01482832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH093342|Interpersonal Therapy-Based Treatment to Prevent Postpartum Depression in Adolescent Mothers|Preventing Postpartum Depression in Adolescent Mothers|REACH 2|Women and Infants Hospital of Rhode Island|Yes|Recruiting|December 2011|April 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|324|||Female|12 Years|19 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01482832||94806|
NCT01483742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP27946|A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis|A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR and RO5024048 in Different Combinations in Null Responder or Treatment Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis||Hoffmann-La Roche||Completed|April 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|No|||September 2015|September 1, 2015|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483742||94736|
NCT01484015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 02110|Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia|Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study||Comprehensive Cancer Center of Wake Forest University|No|Completed|February 2011|October 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||July 2013|July 10, 2013|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01484015||94715|
NCT01484028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005094|Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens|Clinical Validation of Etafilcon A With Print and PVP Contact Lenses for Dark Eyes and Light Eyes||Johnson & Johnson Vision Care, Inc.|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|275|||Female|18 Years|34 Years|No|||May 2015|May 5, 2015|November 30, 2011|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01484028||94714|
NCT01484275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100755|A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma|A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma||Janssen Research & Development, LLC|Yes|Active, not recruiting|March 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484275||94695|
NCT01484288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360025|Baroreflex Activation Therapy in Heart Failure|Baroreflex Activation Therapy in Heart Failure||CVRx, Inc.|Yes|Completed|November 2011|March 2015|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|21 Years|N/A|No|||December 2015|December 23, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484288||94694|
NCT01484535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004187|Aspiration for Pain Relief Following Ankle Fracture|Aspiration for Pain Relief Following Ankle Fracture: A Prospective Double-Blind Randomized Controlled Trial||Mayo Clinic|No|Completed|September 2011|June 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 16, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484535||94675|
NCT01484548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-LVVPX-111|Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects||IDRI|Yes|Completed|January 2012|May 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01484548||94674|
NCT01484834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMetodistaPiracicaba-2011|Comparison of Interventions to Promote Health in Workers|Comparison of Interventions to Promote Health in Workers: A Cluster Randomized Controled Trial||Universidade Metodista de Piracicaba|Yes|Completed|August 2011|November 2011|Actual|November 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|172|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 30, 2011|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01484834||94652|
NCT01484847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1544542/Pan-HER-GT-001|A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma|Pharmacokinetic Assessment of PF-00299804 in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Following Administration Through a Gastrojejunostomy Feeding Tube||University Health Network, Toronto|No|Completed|December 2011|July 2015|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484847||94651|
NCT01485120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118.02-2011-GES-0007|Accuracy Study of a Non-Invasive Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood Pressure|Accuracy Study of a Non-Invasive Forearm Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood Pressure||GE Healthcare|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 28, 2012|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485120||94630|
NCT01485367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD3001|A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura|Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura||Multispecialty Aesthetic Clinical Research Organization|Yes|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|52 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 19, 2012|November 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485367||94611|
NCT01485354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-P-001255|Upper Arm Training With Armeo Spring for Stroke|The Effect of Repetitive Upper Arm Training in a Virtual Environment on Upper Extremity Motor Recovery in Chronic-stroke Survivors|Armeo Stroke|Spaulding Rehabilitation Hospital|No|Active, not recruiting|December 2008|December 2015|Anticipated|October 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01485354||94612|
NCT01485913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDMBRIDGES01|A Randomized Trial of an Intensive Education Intervention Using a Network of Involved Diabetic Patients (Peer Educators) to Improve Glycemic Control of Type 2 Diabetic Patients|A Randomized Trial of an Intensive Education Intervention Using a Network of Involved Diabetic Patients (Peer Educators) to Improve Glycemic Control of Type 2 Diabetic Patients||Sante Diabete Mali|Yes|Active, not recruiting|June 2011|October 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||December 2011|December 2, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01485913||94569|
NCT01486147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11687 (IRB Protocol #)|Effect of a Visual Nutrient Profiling System on Recall of Nutrition Information|||University of Illinois at Urbana-Champaign||Completed|July 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|63|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 5, 2011|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01486147||94551|
NCT01486485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nafamostat01|Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)|Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming||Seoul National University Hospital|Yes|Recruiting|March 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|20 Years|85 Years|No|||February 2013|February 18, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486485||94525|
NCT01486498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SABAL|Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy|Health Economic Analyses of Treatment Strategies for Allergic Respiratory Diseases|SABAL|Aalborg University|No|Completed|November 2005|November 2011|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|571|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The intervention group consisted of 254 patients receiving subcutaneous allergen specific        immunotherapy (SCIT) with grass pollen and/or house dust mite extracts. The control group        consisted of 317 patients with grass pollen and/or house dust mite allergy, who were not        receiving SCIT.|December 2011|December 5, 2011|December 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01486498||94524|
NCT01486745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI-2008|Urine Metabolomics and Colorectal Cancer Screening|Is There a Role for Using NMR Urine Metabolomics as a New Method of Screening for Colorectal Cancer?||University of Alberta|No|Recruiting|April 2008|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|1800|Samples Without DNA|Urine sample|Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing colorectal cancer screening Patients with diagnosis of colorectal        cancer|December 2011|December 3, 2011|December 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01486745||94505|
NCT01473875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CL05|Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102|An Open Label Multicenter Extension Study to Evaluate the Long-term Efficacy and Safety of SBC-102 in Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102||Alexion Pharmaceuticals|No|Terminated|November 2011|January 2015|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2013|January 18, 2013|November 10, 2011|Yes|Yes|Study has been merged with NCT01371825|No||https://clinicaltrials.gov/show/NCT01473875||95493|
NCT01482910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13406|VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)|A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration||Bayer|Yes|Completed|December 2011|August 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|304|||Both|50 Years|N/A|No|||August 2015|August 25, 2015|November 29, 2011|Yes|Yes||No|March 1, 2015|https://clinicaltrials.gov/show/NCT01482910||94800|
NCT01473901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120E2101|A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma||Novartis||Active, not recruiting|December 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473901||95491|
NCT01474200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gambro 1494|Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment|Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF)|AVOID-HF|Gambro Renal Products, Inc.|Yes|Terminated|January 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|November 11, 2011||No|Closed due to patient recruitment challenges. No interim analyses were completed; study    closure was not related to any concerns about safety or futility.|No|July 23, 2015|https://clinicaltrials.gov/show/NCT01474200||95468|Due to patient recruitment challenges, the study was terminated early. At that time, no interim analyses of the data had been completed; therefore the decision to close the study was not related to any underlying concerns about safety or futility.
NCT01474473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT11Q09UPND|Efficacy Of CACIPLIQ20 On Diabetic Ulcers In Patients Wearing An Nonremovable, Windowed, Fiberglass Cast Boot|A Pilot Placebo-Controlled, Randomized and Double Blind Monocenter Study Evaluating CACIPLIQ20 Efficacy On Neuropathic Perforating Foot Ulcer Healing In Diabetic Patients Wearing An Irremovable Windowed Resin Cast|DIAPLIQ|Organ, Tissue, Regeneration, Repair and Replacement|No|Completed|August 2011|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01474473||95447|
NCT01474486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parrington 005|Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure|Feasibility and Effectiveness of a Multi-Micronutrient Intervention as a Palliative Care Therapy in Patients With Congestive Heart Failure(CHF)||Phoenix VA Health Care System|Yes|Active, not recruiting|April 2010|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|89 Years|No|||October 2015|October 19, 2015|January 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474486||95446|
NCT01483170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiFEX003|Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food|Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers.||Drugs for Neglected Diseases||Terminated|September 2011|February 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|November 29, 2011||No|poor tolerability at highest dose|No||https://clinicaltrials.gov/show/NCT01483170||94780|
NCT01483183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|269-11-215|Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation|A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation|CADENCE 215|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Terminated|November 2011|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|85 Years|No|||December 2015|December 11, 2015|November 29, 2011|No|Yes|Enrollment Difficulty|No||https://clinicaltrials.gov/show/NCT01483183||94779|
NCT01483443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2263|Oophorectomy Followed by Chemotherapy Versus Chemotherapy Alone in Colorectal Cancer Patients|Prophylactic Oophorectomy Followed by Chemotherapy Versus Chemotherapy Alone in Colorectal Patients With or Without Ovarian Metastasis||Gachon University Gil Medical Center|Yes|Completed|August 2008|August 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Female|55 Years|80 Years|No|||August 2015|August 28, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483443||94759|
NCT01483456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.666|Impact of Multidisciplinary Program on Falls in Elderly Inpatients|A Multidisciplinary Program for Preventing Falls "Identify, Prevent and Get up": Impact on Falls in Elderly Inpatients|IPR|Hospices Civils de Lyon|No|Active, not recruiting|July 2011|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1852|||Both|65 Years|N/A|No|||September 2014|September 16, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01483456||94758|
NCT01483755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.536/37|Delayed Postconditioning|Delayed Angioplasty Postconditioning in STEMI Patients|PRIME|Hospices Civils de Lyon|No|Completed|July 2009|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01483755||94735|
NCT01483768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 10083|Study of Sleeve Gastrectomy on Iron Intestinal Absorption in Morbidly Obese Patients|Evaluation of the Impact of Bariatric Surgery by Sleeve Gastrectomy on Iron Intestinal Absorption in Morbidly Obese Patients|FORBES|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|83|||Female|18 Years|60 Years|No|||March 2015|March 11, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01483768||94734|
NCT01484041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 2010-535|Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer|A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer||Georgetown University|Yes|Active, not recruiting|April 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||June 2014|June 11, 2014|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484041||94713|
NCT01484054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005128|Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens|Dispensing Evaluation of Lens Comfort and Subjective Vision of an Etafilcon A With Print and PVP Lens for Dark Eyes||Johnson & Johnson Vision Care, Inc.|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Female|18 Years|34 Years|No|||May 2015|May 5, 2015|November 30, 2011|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01484054||94712|
NCT01484301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100408|Impact of Tolerability Issues on Chronic Pain|The Impact of Opioid Tolerability Outcomes on the Management of Chronic Pain||Janssen-Ortho Inc., Canada|No|Completed|February 2010|August 2010|Actual|August 2010|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|165|||Both|18 Years|N/A|No|Probability Sample|Family physician and pain medicine specialist practices|March 2013|March 19, 2013|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01484301||94693|
NCT01484314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-373|Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma|A Phase II Study of Eltrombopag for the Treatment of Thrombocytopenia in Patients Undergoing Therapy for Relapsed Multiple Myeloma||Dana-Farber Cancer Institute|Yes|Completed|April 2012|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484314||94692|
NCT01484561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921152|A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis|A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis||Pfizer|Yes|Completed|April 2012|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|148|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|November 30, 2011|Yes|Yes||No|January 11, 2014|https://clinicaltrials.gov/show/NCT01484561||94673|
NCT01484574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRPL/CLI/10-11/001|A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease|A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease||Stempeutics Research Pvt Ltd|Yes|Recruiting|January 2012|September 2015|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|126|||Both|18 Years|65 Years|No|||February 2012|February 10, 2012|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01484574||94672|
NCT01485133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111103-9|Water Method Colonoscopy in Patients With Prior Surgery|Water Colonoscopy Versus Air Colonoscopy for Unsedated Patients With Prior Abdominal or Pelvic Surgery: a Prospective Randomized, Controlled Trial||Fourth Military Medical University|Yes|Completed|November 2011|November 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|110|||Both|18 Years|80 Years|No|Probability Sample|Patients with prior abdominal or pelvic surgery undergoing unsedated colonoscopy will be        recruited in this study.|November 2012|November 6, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01485133||94629|
NCT01485380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-002333|Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep|Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep||Massachusetts General Hospital|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|November 30, 2011|Yes|Yes||No|September 24, 2014|https://clinicaltrials.gov/show/NCT01485380||94610|
NCT01485627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35388|VOICE: Values and Options in Care Care|Randomized Controlled Trial(RCT)of Patient, Caregiver and Physician Communication Coaching in Advanced Cancer|VOICE|University of Rochester|Yes|Active, not recruiting|April 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|470|||Both|21 Years|N/A|No|||May 2015|May 4, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01485627||94591|
NCT01486186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCM for COPD|Effect of Traditional Chinese Medicine on Outcomes in Patients With Mild/Moderate Chronic Obstructive Pulmonary Disease|Detection and Intervention on Mild/Moderate Chronic Obstructive Pulmonary Disease by Traditional Chinese Medicine Treatment and Application||Henan University of Traditional Chinese Medicine|Yes|Not yet recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|504|||Both|40 Years|80 Years|No|||December 2011|December 2, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01486186||94548|
NCT01477593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMU-124|Circumcision With a Novel Disposable Device in Chinese Children: a Hospital-based Randomized Controlled Trail|||Nanjing Medical University|Yes|Completed|July 2009|June 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Male|3 Years|11 Years|No|||April 2013|April 8, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477593||95208|
NCT01477606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMLSG 16-10|Protocol in Acute Myeloid Leukemia With FLT3-ITD|Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication||University of Ulm|Yes|Recruiting|May 2012|December 2019|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|284|||Both|18 Years|70 Years|No|||June 2015|June 17, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01477606||95207|
NCT01486758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201107151|Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis|Pilot Study: Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis|APW-RSV|Washington University School of Medicine|Yes|Completed|December 2011|May 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Month|18 Months|No|||April 2014|June 3, 2014|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486758||94504|
NCT01486771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPDRS-ED|Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)|A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase||Valley Retina Institute|No|Active, not recruiting|November 2007|February 2014|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486771||94503|
NCT01482923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-173|Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations|Feasibility of Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|"Low-income smokers living with HIV/AIDS being served at community-based organizations."|April 2015|April 28, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482923||94799|
NCT01482936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYI09-CN-101|Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient|A Single Dose PK Study of Oxycodone Hydrochloride Injection 2.5, 5, and 10mg in Chinese Patients With Cancer Pain or Post-operation Patients||Mundipharma (China) Pharmaceutical Co. Ltd|No|Completed|May 2010|||April 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|30 Years|60 Years|No|||August 2015|August 10, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01482936||94798|
NCT01474213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JYMZK-002|Sedation Effect of Dexmedetomidine Versus Remifentanil to Fibreoptic Intubation|Dexmedetomidine Versus Remifentanil Target Controlled Infusion for Sedation During Awake Fibreoptic Nasotracheal Intubation||Shanghai 9th People's Hospital|Yes|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|October 31, 2011|Yes|Yes||No|June 6, 2012|https://clinicaltrials.gov/show/NCT01474213||95467|The sample number is relatively small
NCT01474226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580|Metabolic Availability of Lysine From Rice|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From Cooked Rice Protein in Adult Men||The Hospital for Sick Children|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01474226||95466|
NCT01481454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GQM04|Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults|Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Child/Adolescent and Adult Subjects||Sanofi|No|Completed|March 2012|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1701|||Both|9 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 28, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01481454||94912|
NCT01481987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rodica 01|Microperimetry and Optical Coherence Tomography (OCT) in Idiopathic Epiretinal Membrane|Retinal Sensitivity and Optical Coherence Tomography Findings in Eyes With Idiopathic Epiretinal Membrane||Centre Hospitalier Universitaire Dijon|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|76|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2011|November 29, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01481987||94871|
NCT01483196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 74111|Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery|Feasibility Study of Vascular and Cognitive Assessments During Adjuvant Chemotherapy for Breast Cancer (VASCOG)||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|January 2012|||May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Female|18 Years|N/A|No|||July 2015|July 27, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01483196||94778|
NCT01483469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27890|A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers|Human Proof of Concept Positron Emission Tomography Study to Investigate [11C]-RO5011232 as a Radiotracer for Brain mGlu5 Receptor Occupancy and to Investigate the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-state.||Hoffmann-La Roche||Completed|December 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483469||94757|
NCT01484067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCOWDH0003|Study of a Cold Sore Patch for the Treatment of Herpes Labialis|A Randomized, Clinician-Blind, Clinical Study to Examine the Safety and Performance of Compeed© Total Care™ Cold Sore Patch With Zinc Sulfate for the Treatment of Herpes Labialis||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|472|||Both|18 Years|70 Years|No|||September 2012|September 27, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484067||94711|
NCT01484587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018646|A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single Subcutaneous Administration in Japanese Subjects With Moderate to Severe Plaque Psoriasis||Janssen Pharmaceutical K.K.|Yes|Completed|August 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|65 Years|No|||March 2014|March 15, 2014|September 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01484587||94671|
NCT01484600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-HV-1108|Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers|||Regeneron Pharmaceuticals|Yes|Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|November 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01484600||94670|
NCT01484860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDP-922|Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy|A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy||University Health Network, Toronto|Yes|Terminated|January 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||June 2014|July 3, 2014|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01484860||94650|
NCT01485393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000715|Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep|Pilot Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep||Massachusetts General Hospital|No|Active, not recruiting|January 2015|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485393||94609|
NCT01485406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115373|Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers|Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months||GlaxoSmithKline||Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|61|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||August 2012|August 9, 2012|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485406||94608|
NCT01485640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050298|Lurasidone Extended Use Study|A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study||Sunovion|No|Completed|June 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|N/A|N/A|No|||March 2015|March 12, 2015|December 1, 2011|Yes|Yes||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01485640||94590|
NCT01485926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 10-05|A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.|A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.|TCHL Phase II|ICORG- All Ireland Cooperative Oncology Research Group|No|Active, not recruiting|October 2010|||September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||February 2016|February 26, 2016|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01485926||94568|
NCT01485939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laparo_cholecystectomy_lidotop|Lidocaine Patch for Postoperative Analgesia After Laparoscopic Cholecystectomy|||Seoul National University Hospital||Recruiting|November 2011|May 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 5, 2011|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485939||94567|
NCT01486199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL108929-01|Imaging Airway Liquid Absorption in Cystic Fibrosis|Imaging Airway Liquid Absorption in Cystic Fibrosis||University of Pittsburgh|Yes|Completed|October 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|6 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|November 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486199||94547|
NCT01477619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-1107|Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects|An Open-label, Single Dose, Parallel Group Study to Assess the Effects of Smoking Status, Age and Body Size on the Pharmacokinetics, Safety, and Tolerability of Tasimelteon in Healthy Volunteers||Vanda Pharmaceuticals|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 14, 2014|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01477619||95206|
NCT01477632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD-1640|Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women|Single Dose, Three-way, Cross-over, Relative Bioavailability Study With 3 Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women: 0.5 mg Estradiol + 0.1 mg Norethisterone Acetate, 0.5 mg Estradiol + 0.25 mg Norethisterone Acetate, and 1.0 mg Estradiol + 0.5 mg Norethisterone Acetate||Novo Nordisk A/S|No|Completed|March 2005|June 2005|Actual|June 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|November 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01477632||95205|
NCT01477645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1335|Health Effects Following Use of Lead Free Ammunition Used With HK416|In Norwegian: Helseffekter av Stoff Som Avgis Ved Skyting Med HK416||Oslo University Hospital|No|Completed|November 2011|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Actual|55|Samples Without DNA|Sputum and serum|Male|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Voluntary army soldiers|October 2013|October 13, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477645||95204|
NCT01478204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017509|A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease|An Observational Epidemiological Study on Evaluation of Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease in Clinical Practice||Janssen-Cilag, S.A.|No|Completed|June 2008|July 2009|Actual|June 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|925|||Both|60 Years|N/A|No|Non-Probability Sample|Patients attending the neurology clinic of participating centers throughout Spain who meet        eligibility criteria.|October 2012|October 30, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478204||95161|
NCT01477957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bariatrix|The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism|Assessment of the Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism|Bariatrix|German Diabetes Center|No|Not yet recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|November 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01477957||95180|
NCT01477970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|abcd1234|Double GnRH Antagonist Daily Dose in Hyperresponding IVF/ICSI Cycles May Prevent the OHSS|||Iakentro Fertility Centre|No|Completed|February 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|38|||Female|25 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|PILOT STUDY|November 2011|November 23, 2011|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01477970||95179|
NCT01474187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDRT-003|Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer|Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer||Fudan University|Yes|Recruiting|November 2011|December 2012|Anticipated|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||November 2011|November 15, 2011|November 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01474187||95469|
NCT01478217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vinogradska29|PEEP Recruitment-comparison Between Ultrasonographic Assessment and LIP Assessment|Positive End-expiratory Pressure Induced Lung Recruitment -Comparison Between Ultrasonographic Assessment and Lower Inflection Point Assessment on the Pressure -Volume Loop||Sisters of Mercy University Hospital|No|Completed|October 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control||1|Actual|17|||Both|16 Years|N/A|No|Probability Sample|intensive care patients|November 2011|November 22, 2011|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01478217||95160|
NCT01474850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uppsala 2011 - 190|Thoraco-abdominal Volume Variations During Anesthesia Studied by OEP.|Thoraco-abdominal Volume Variation During Recovery From Total Intravenous Anesthesia Studied by Opto-electronic Plethysmography (OEP).||Uppsala University Hospital|No|Completed|November 2011|November 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|18|||Both|18 Years|80 Years|No|||December 2014|December 5, 2014|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01474850||95418|
NCT01482286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC11016|Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS|Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS|PULSE|Pennington Biomedical Research Center|Yes|Active, not recruiting|May 2012|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|52|||Female|20 Years|40 Years|No|||March 2016|March 24, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482286||94848|
NCT01483209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032002|Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A|Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A||Duke University|Yes|Terminated|March 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|November 29, 2011|Yes|Yes|Low accrual|No|February 16, 2015|https://clinicaltrials.gov/show/NCT01483209||94777|Due to low accrual for this study we were unable to perform any data analysis.
NCT01483482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORH-IB-0001|Treatment of Displaced, Midshaft Clavicle Fractures. Sling or Plate?|Treatment of Displaced, Midshaft Clavicle Fractures. Sling or Plate?||Hvidovre University Hospital|No|Active, not recruiting|April 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|60 Years|No|||March 2016|March 15, 2016|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483482||94756|
NCT01484327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-CAR-EL-02|Carvedilol Vascular Efficacy Trial|Multicentre, Open-label, Non-interventional Observational Clinical Study Lasting 48 Weeks in Patients With Heart Failure or Reduced Left Ventricular Ejection Fraction Following Acute Myocardial Infarction Who Are Treated With Carvedilol|CARVEDIA|Elpen Pharmaceutical Co. Inc.|No|Completed|January 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|415|||Both|18 Years|N/A|No|Probability Sample|Patients with Heart Failure and post-MI LVEF<40%|November 2011|August 30, 2012|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01484327||94691|
NCT01484613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H56|Selected Site Pacing to Avoid Phrenic Nerve Stimulation in Cardiac Resynchronization Patients With Quadripolar Left Ventricular Leads|Effectiveness and Reliability of Selected Site Pacing for Avoidance of Phrenic Nerve Stimulation in CRT Patients With Quadripolar LV Leads|EffaceQ|St. Jude Medical|No|Completed|November 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|337|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are planned for being implanted with a cardiac resynchronization therapy        implantable cardioverter defibrillator (CRT-D) system in the participating centers.|November 2014|November 21, 2014|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484613||94669|
NCT01484873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111185|Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor|Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity||Vanderbilt University|Yes|Completed|June 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|40 Years|No|||April 2015|April 2, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484873||94649|
NCT01485146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETC-1002-004|A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects|A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ETC-1002 at Doses Above 120 mg/Day in Healthy Subjects||Esperion Therapeutics|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|32|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|October 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01485146||94628|
NCT01485419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTI early sex hormone trial|Characterization of the Early Sex Hormone Milieu Post Injury and Relationship With Resuscitation Requirements and Coagulopathy|Characterization of the Early Sex Hormone Milieu Post Injury and Relationship With Resuscitation Requirements and Coagulopathy||University of Pittsburgh|No|Completed|January 2011|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|292|||Both|18 Years|90 Years|No|Non-Probability Sample|Injured patients requiring ICU admission who arrive within 6 hours of injury|February 2014|February 18, 2014|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485419||94607|
NCT01485653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU irb# 0902006824|Dosage of Mepivacaine in Ultrasound Axillary Block|Effective Low Dosage of Mepivacaine in Ultrasound Guided Axillary Block in Patients Undergoing Distal Upper Extremity Surgery||Wayne State University|No|Completed|April 2010|September 2010|Actual|August 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2011|December 7, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01485653||94589|
NCT01485666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC06072011-1|Thoratec's Reduce Driveline Trauma Through Stabilization and Exit Site Management Study|Reduce Driveline Trauma Through Stabilization and Exit Site Management (RESIST) Pilot Study Protocol|RESIST|Thoratec Corporation|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|16 Years|N/A|No|Probability Sample|Ventricular Assist Device clinic|September 2013|September 26, 2013|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485666||94588|
NCT01476722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-149|Lens Wearing Experience and Biocompatibility of a Multi-Purpose Disinfecting Solution (MPDS)|Lens Wearing Experience and Biocompatibility With OPTI-FREE® PureMoist® Multi-Purpose Disinfecting Solution (OFP MPDS) in Silicone Hydrogel and Soft Contact Lens Wearers (US)||Alcon Research|No|Completed|June 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|125|||Both|18 Years|N/A|No|||November 2012|November 16, 2012|November 18, 2011|Yes|Yes||No|October 19, 2012|https://clinicaltrials.gov/show/NCT01476722||95274|
NCT01485952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S015-004|An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196|An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196.|PADDINGTON|Siena Biotech S.p.A.|No|Completed|March 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|18 Years|70 Years|No|||November 2015|November 24, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01485952||94566|
NCT01485965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S015-007|A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease|A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196||Siena Biotech S.p.A.|No|Completed|November 2011|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|25 Years|65 Years|No|||March 2013|March 19, 2013|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01485965||94565|
NCT01477294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS-2010|Effects of Caffeine in Hydration and Energy Metabolism|Effects of Caffeine Ingestion in Total-body Water, Extra and Intracellular Water Distribution, and Energy Metabolism||Technical University of Lisbon|No|Completed|January 2010|March 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||November 2011|November 18, 2011|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01477294||95231|
NCT01477307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-231|Dietary Intervention and Intestinal Microbiota in Non-alcoholic Fatty Liver|Effect of Dietary Intervention on Intestinal Microbiota in Patients With Non-alcoholic Fatty Liver Disease||University Hospital, Geneva|Yes|Recruiting|July 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obesity defined as BMI>30 Abnormal liver function tests defined as ALT > 1.5 times the        upper limit of normal NAFLD present at liver biopsy Age > 18 years, < 60 years|January 2014|January 1, 2014|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01477307||95230|
NCT01477658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq nº 1248/09|Effects of Chronic Right Ventricular Pacing in Children With Advanced Atrioventricular Block|Effects of Chronic Right Ventricular Pacing in Children With Advanced Atrioventricular Block||University of Sao Paulo|Yes|Enrolling by invitation|November 2007|November 2013|Anticipated|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|140|Samples Without DNA|Blood|Both|N/A|N/A|No|Non-Probability Sample|Ambulatory Care|May 2013|May 4, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477658||95203|
NCT01477983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPAFKUHP|Kansai Plus Atrial Fibrillation Trial|Kansai Plus Atrial Fibrillation Trial; UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate Trial; Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation Trial|KPAF|Kyoto University, Graduate School of Medicine|Yes|Active, not recruiting|November 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2000|||Both|21 Years|79 Years|No|||August 2015|August 31, 2015|November 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01477983||95178|
NCT01473654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30397|The Avoiding Diabetes Thru Action Plan Targeting Pilot Randomized Control Trial|Avoiding Diabetes Thru Action Plan Targeting (ADAPT): A Pilot Randomized Control Trial of an Electronic Medical Record Embedded Prediabetes Shared Goal Setting Tool in Primary Care|ADAPT|Boston University|No|Completed|November 2011|April 2014|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|90 Years|No|||August 2014|August 11, 2014|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01473654||95510|
NCT01473667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005969|Superficial Cervical Plexus Block for Pacemaker Insertion|Superficial Cervical Plexus Block for Pacemaker Insertion||Mayo Clinic|No|Terminated|November 2011|December 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|100 Years|No|||November 2015|November 5, 2015|November 14, 2011||No|change in practice occured|No||https://clinicaltrials.gov/show/NCT01473667||95509|
NCT01473888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T89-02-US|A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes|An Open-label, One-sequence, Two Periods, Crossover Trial Study to Evaluate the Effect of T89 on the Pharmacokinetics of Five CYP450 Substrates Cocktail in Healthy Subjects||Tasly Pharmaceuticals, Inc.|Yes|Completed|January 2011|January 2012|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2012|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473888||95492|
NCT01475162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCW-PRO15904|Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease|Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease||Medical College of Wisconsin|Yes|Terminated|August 2011|August 2021|Anticipated|December 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|November 16, 2011||No|While the study did not meet the protocol stopping rules, it was the opinion of the DSMB that    the risks of the study now outweighed the potential benefits.|No||https://clinicaltrials.gov/show/NCT01475162||95394|
NCT01478633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018649|Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil|Evaluation of Efficacy and Safety of Galantamine in Subjects With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil||Janssen Pharmaceutical K.K.|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|40 Years|N/A|No|||March 2014|March 24, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01478633||95128|
NCT01484080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIO-BR-01-2010/GEICAM/2010-10|Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates|Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates||Centro Nacional de Investigaciones Oncologicas CARLOS III|Yes|Completed|October 2011|April 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Female|18 Years|N/A|No|||April 2015|April 15, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01484080||94710|
NCT01484093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-095|Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma|Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma: A Phase I/II Trial||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2011|November 2017|Anticipated|November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|18 Years|70 Years|No|||January 2016|January 29, 2016|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484093||94709|
NCT01484106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-CM-2011|Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis|Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis|COMMIT|Cheetah Medical Inc.|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|65|||Both|18 Years|N/A|No|||September 2012|February 16, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01484106||94708|
NCT01475071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29102|Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses|Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses.|CoMet|Galderma|No|Completed|March 2012|March 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01475071||95401|
NCT01484340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4134401|A Smoking Cessation Trial in HIV-infected Patients in South Africa|A Smoking Cessation Trial in HIV-infected Patients in South Africa|JHU|Johns Hopkins University|Yes|Active, not recruiting|March 2014|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484340||94690|
NCT01484626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203145|Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma|An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma|BVRD|Loyola University|Yes|Recruiting|May 2011|May 2015|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484626||94668|
NCT01484886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38569|Restrictive Versus Liberal Transfusion Protocol in Infants Undergoing Cardiac Surgery|Prospective Randomized Controlled Clinical Trial Comparing a Restrictive Versus Liberal Transfusion Strategy in Neonates and Infants Undergoing Surgery for Congenital Heart Disease||University of Rochester|Yes|Completed|January 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|N/A|7 Months|No|||September 2014|September 4, 2014|November 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01484886||94648|
NCT01484899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACH_1|Smoking: a Risk Factor for Pulmonary Arterial Hypertension?|Smoking: a Risk Factor for Pulmonary Arterial Hypertension? A D-A-CH Pulmonary Hypertension Study (Germany- Austria - Switzerland)|DACH|University of Zurich|No|Completed|September 2011|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|500|||Both|18 Years|N/A|No|Probability Sample|All patients seen at participating DACH -PH centers who have PH defined as mean pulmonary        artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤15mmHg will be        asked to participate upon written informed consent|July 2013|July 4, 2013|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01484899||94647|
NCT01485159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115398|Airflow Limitation in Cardiac Diseases in Europe|Airflow Limitation in Cardiac Diseases in Europe|ALICE|GlaxoSmithKline|No|Completed|October 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|3000|Samples With DNA|In patients that specifically consent, blood samples will be taken for future analysis of      the genetic links between COPD and cardiovascular disease|Both|40 Years|N/A|No|Probability Sample|Patients attending outpatient cardiology clinics with a history of Ischemic Heart Disease|February 2014|February 20, 2014|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01485159||94627|
NCT01476176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2260665|A Pharmacokinetic Study of an Experimental Paracetamol Formulation|A Pivotal Pharmacokinetic Study Investigating the Extent of Absorptions of Paracetamol and Caffeine for Two Different Paracetomol Formulations Containing Caffeine||GlaxoSmithKline|No|Completed|July 2009|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476176||95316|
NCT01476475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT12374|Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients|A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients||Sanofi|Yes|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|November 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476475||95293|
NCT01476488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adva01SNUH|Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients|Conversion of Twice-a-day Tacrolimus to Once-Daily Tacrolimus Extended-Release Formulation in Stable Pediatric Kidney Transplant Recipients||Seoul National University Hospital|No|Completed|July 2011|||March 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|5 Years|15 Years|No|||May 2015|May 24, 2015|July 22, 2011||||No||https://clinicaltrials.gov/show/NCT01476488||95292|
NCT01476735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Individual bowel preparation|Individual Approach for Bowel Preparation Before Colonoscopy|A Prospective, Randomized, Single-blind Study Evaluating Individual Approach on Bowel Preparation Quality for Colonoscopy||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|August 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|266|||Both|18 Years|N/A|No|||November 2011|November 21, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01476735||95273|
NCT01476761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 2011-01|MicroCutter in Surgical Stapling - European Trial I|The Cardica MicroCutter in Surgical Stapling: A Prospective, Open-label, Multi-center Study|MET1|Cardica, Inc|Yes|Completed|November 2011|July 2013|Actual|June 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|N/A|N/A|No|||August 2013|August 7, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01476761||95271|
NCT01477034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW NORC P&F KRATZ|Vitamin D and Adipose Tissue Inflammation|Vitamin D and Adipose Tissue Inflammation||Fred Hutchinson Cancer Research Center|No|Completed|November 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 2, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01477034||95251|
NCT01477320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0170|Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.|Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. Prospective, Double-blind, Randomized, Placebo-controlled Study.||University of Louisville|Yes|Recruiting|August 2013|October 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|198|||Both|18 Years|N/A|No|||September 2014|September 3, 2014|October 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477320||95229|
NCT01477333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-203|Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®|An Evaluation of the Safety and Efficacy of the Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®||United Therapeutics|No|Active, not recruiting|August 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2013|February 5, 2013|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477333||95228|
NCT01477996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-7-CI-2011|Pain After Intravitreal Therapy|||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|51 Years|N/A|Accepts Healthy Volunteers|||November 2011|January 24, 2016|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01477996||95177|
NCT01473680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-139|Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients|Pilot Study of Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients||Memorial Sloan Kettering Cancer Center||Terminated|November 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2|||Female|18 Years|61 Years|Accepts Healthy Volunteers|Non-Probability Sample|MSKCC clinic, The Ralph Lauren Center for Cancer Care and Prevention (RLCCCP)located in        Harlem and Lincoln Hospital located in the Bronx.|September 2012|September 12, 2012|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01473680||95508|
NCT01473693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-145|Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging|Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging||Memorial Sloan Kettering Cancer Center||Terminated|November 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1|||Both|18 Years|80 Years|No|Non-Probability Sample|Thoracic Oncology, Radiation Oncology, Surgery or Ambulatory Care clinic lists|January 2014|January 14, 2014|November 10, 2011||No|Lack of Accrual|No||https://clinicaltrials.gov/show/NCT01473693||95507|
NCT01473940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 10I02|Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery|Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study||Northwestern University|Yes|Active, not recruiting|April 2012|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473940||95488|
NCT01474239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25739|A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma|Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma||Hoffmann-La Roche||Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||September 2015|February 16, 2016|November 8, 2011|No|Yes||No|July 9, 2015|https://clinicaltrials.gov/show/NCT01474239||95465|
NCT01474252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB213|Comparison of Intubation Duration Between Rapid Sequence Intubation (RSI) Technique and Non-RSI Technique|Comparison of Intubation Duration Between Rapid Sequence Intubation Technique and Non- Rapid Sequence Intubation Technique in Siriraj Hospital by Emergency Medicine Residences||Siriraj Hospital|Yes|Completed|July 2006|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|224|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01474252||95464|
NCT01473914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRSV1|Trace Element Replenishment Study in Hemodialysis Patients|Trace Element Replenishment Study in Hemodialysis Patients||University of Alberta|No|Completed|November 2012|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01473914||95490|
NCT01473927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110/06|Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease|Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease||University of Bern|No|Completed|October 2011|June 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Actual|136|Samples With DNA|Serum Stool|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|All CD and UC patients undergoing endoscopy for clinical reasons at one of the involved        clinical centers.|March 2014|March 11, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01473927||95489|
NCT01475708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-DOXY|Doxycycline in Therapy of Erythema Migrans|Doxycycline in Therapy of Erythema Migrans - do the Accompanying Symptoms Influence the Outcome?||University Medical Centre Ljubljana|No|Completed|May 2011|November 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|400|Samples Without DNA|whole blood, serum, cerebrospinal fluid, skin tissue|Both|15 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with erythema migrans reffered to Lyme Borreliosis outpatient clinic of the        University Medical Center Ljubljana, Slovenia, Department of Infectious Diseases.|March 2016|March 23, 2016|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475708||95352|
NCT01476319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-980360|Improving Informed Consent Process for Percutaneous Cholecystostomy in the Emergency Department|||Kaohsiung Medical University Chung-Ho Memorial Hospital||Recruiting|March 2010|||August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|N/A|No|||November 2011|November 17, 2011|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01476319||95305|
NCT01478945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/EM/0331|HI-Light Pilot Trial for Vitiligo: Hand Held NB-UVB for Early or Focal Vitiligo at Home|Pilot Randomised Controlled Trial of Hand Held NB-UVB for the Treatment of Focal or Early Vitiligo at Home|HI-Light|University of Nottingham|No|Completed|February 2012|April 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|29|||Both|5 Years|N/A|No|||August 2013|August 22, 2013|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01478945||95104|
NCT01483794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CondValpo2011|Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile|Genital Warts: Studies for Establishing Epidemiological Profile, Psychosocial Consequences and Costs of Disease in Attendants to the Sexual Health Clinic of the Public Health Service of Valparaiso and San Antonio, Chile.||Universidad de Valparaiso|No|Not yet recruiting|November 2011|April 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients attending the public sexual health clinic of Valparaiso, Chile|November 2011|November 30, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01483794||94732|
NCT01483807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7419-R|Treatments of Acquired Apraxia of Speech|Treatments of Acquired Apraxia of Speech|Apraxia|VA Office of Research and Development|No|Active, not recruiting|August 2011|March 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|24|||Both|21 Years|85 Years|No|||November 2015|November 6, 2015|April 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01483807||94731|
NCT01475084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-0003|Cryobiopsy or Forceps Biopsy During Semirigid Thoracoscopy: a Comparative Study|Cryobiopsy or Forceps Biopsy During Semirigid Thoracoscopy: a Comparative Study||The University Clinic of Pulmonary and Allergic Diseases Golnik|Yes|Completed|November 2011|November 2014|Actual|November 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475084||95400|
NCT01475097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-012-098|Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography|A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography||GE Healthcare|Yes|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|255|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|November 3, 2011|Yes|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT01475097||95399|
NCT01475344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIinTIC|Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)|A Multicenter Double-blind, Placebo Controlled, Randomized, Pilot Trial to Assess the Efficacy of Pre-hospital Administration of Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)||Medical University Innsbruck|Yes|Completed|September 2011|December 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01475344||95380|
NCT01475604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOH-TKA-001|Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty|Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty: A Double-Blind, Randomized, Sham-controlled Trial||Amp Orthopedics, Inc.|No|Terminated|November 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|40 Years|80 Years|No|||July 2012|July 6, 2012|November 17, 2011|No|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01475604||95360|
NCT01475890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008093|Vitamin D Supplementation in HIV|Safe and Effective Vitamin D Supplementation in HIV||Children's Hospital of Philadelphia|No|Active, not recruiting|July 2011|January 2017|Anticipated|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|5 Years|24 Years|No|||March 2016|March 15, 2016|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01475890||95338|
NCT01476189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2750607|A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations|A Repeat Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Sustained Release Paracetamol Formulations||GlaxoSmithKline|No|Completed|November 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476189||95315|
NCT01476202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2111378|Provoked Craving Relief Study by NRT|A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette ® Nicotine Lozenge and Gum|NRT|GlaxoSmithKline|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|July 30, 2013|November 17, 2011|Yes|Yes||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01476202||95314|
NCT01476228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0394-11-HMO-CTIL|EEG Objectification in Neuropsychiatry|EEG Objectification in Neuropsychiatry||Hadassah Medical Organization|No|Not yet recruiting|November 2011|December 2015|Anticipated|November 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|15 Years|90 Years|Accepts Healthy Volunteers|||August 2011|November 17, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01476228||95312|
NCT01476514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131/11|Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing|Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing||University Hospital Inselspital, Berne|No|Terminated|October 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|9|||Both|7 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 3, 2014|November 2, 2011||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT01476514||95290|
NCT01476748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001825|Intraoperative Trocar Slippage Study|A Pilot Study to Determine the Extent of Intraoperative Laparoscopic Trocar Slippage.||Brigham and Women's Hospital|No|Completed|December 2012|September 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|15|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 8, 2014|November 18, 2011||No||No|August 23, 2013|https://clinicaltrials.gov/show/NCT01476748||95272|There were no adverse events encountered during this study
NCT01476774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP08-CN-001|NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain|NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain||Mundipharma (China) Pharmaceutical Co. Ltd|No|Completed|August 2009|||June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|20 Years|80 Years|No|||July 2015|July 7, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01476774||95270|
NCT01477047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-41-6844|Identification of Risk Factors of Prolonged Wound Healing Following Primary Arthroplasty|Identification of Risk Factors of Prolonged Wound Healing Following Total Hip and Knee Arthroplasty||Hvidovre University Hospital|No|Recruiting|January 2012|January 2019|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|||Both|18 Years|90 Years|No|Probability Sample|All patients receiving primary hip or knee arthroplasty at Hvidovre Hospital from january        2012 to january 2014.|March 2015|March 17, 2015|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477047||95250|
NCT01477060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROLT/02|Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer|Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy||Fondazione Michelangelo|No|Terminated|November 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Female|18 Years|N/A|No|||February 2014|February 19, 2014|November 16, 2011||No|The study was stopped due to insufficient accrual|No||https://clinicaltrials.gov/show/NCT01477060||95249|
NCT01477073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEXGP24102|Multiple Dose FSH-GEX(TM) in Healthy Volunteers|A Phase I, Mono-center, Placebo and Comparator Controlled, Single-blind, Randomized, Parallel Group, Clinical Study to Determine Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FSH-GEX(TM) Administered Subcutaneously in Healthy Pituitary-suppressed Female Volunteers||Glycotope GmbH|No|Completed|October 2011|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|57|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|January 2, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01477073||95248|
NCT01477346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19703|Arthritis Research UK Gout Treatment Trial - Phase 2|Arthritis Research UK Gout Treatment Trial. Phase 2: Two Year Randomised Controlled Trial of a Nurse Led Package of Care||University of Nottingham|No|Active, not recruiting|March 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|512|||Both|21 Years|N/A|No|||November 2014|November 3, 2014|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01477346||95227|
NCT01477671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNG10|Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children|Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children in India||Sanofi|No|Completed|September 2011|December 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|667|||Both|5 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants aged between 5 and 10 year-old that are registered in health centers in        India.|April 2014|April 25, 2014|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477671||95202|
NCT01477684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM1|Documentation of In-flight Medical Emergencies With Medical Incident Report Forms.|||Ruhr University of Bochum|Yes|Completed|October 2011|||November 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|10|||Both|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|medical incident report forms|October 2012|October 15, 2012|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477684||95201|
NCT01473706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.01.US.HCN|Validation of a Nutrition Screening Tool|Mini Nutritional Assessment: Consumer Validation||Nestlé|No|Completed|August 2011|June 2012|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|463|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consumers aged 65 or older with or without their caregiver|July 2013|July 16, 2013|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01473706||95506|
NCT01473719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA020509|Emerging Adults Who Use Alcohol and Marijuana|Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana|HEAT|Butler Hospital|Yes|Recruiting|January 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||November 2015|November 10, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01473719||95505|
NCT01473953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9223-3928|Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|31|||Male|18 Years|55 Years|No|||October 2013|October 11, 2013|November 2, 2011|No|Yes||No|June 20, 2013|https://clinicaltrials.gov/show/NCT01473953||95487|
NCT01473966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COFFEE|Coffee Against Obstipation in Intensive Care Treatment|Coffee Against Obstipation in Intensive Care Treatment||University Hospital Heidelberg|No|Enrolling by invitation|November 2011|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|N/A|No|||November 2011|November 14, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01473966||95486|
NCT01474265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102-TR|Sympathovagal Balance in Smoking Cessation|Alterations in the Autonomic Nervous System During Smoking Quit Attempts- Possible Effects of Pharmacological Interventions||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Completed|November 2011|April 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|85|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01474265||95463|
NCT01474564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-141|Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma|Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood|Both|18 Years|N/A|No|Non-Probability Sample|MSKCC clinics|October 2015|October 28, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474564||95440|
NCT01474538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14207|Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy|A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro With the Safety and Efficacy of Insulin Aspart in Subjects With Type 2 Diabetes on CSII Therapy||Eli Lilly and Company|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|85 Years|No|||February 2014|February 4, 2014|November 15, 2011|Yes|Yes||No|February 4, 2014|https://clinicaltrials.gov/show/NCT01474538||95442|
NCT01474551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-091|Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation|A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation||Memorial Sloan Kettering Cancer Center||Terminated|November 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|19 Years|N/A|No|||October 2015|October 20, 2015|November 15, 2011|Yes|Yes|Lack of accrual|No|April 15, 2015|https://clinicaltrials.gov/show/NCT01474551||95441|
NCT01474577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-150|Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging|||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with one or more 82Rb myocardial perfusion stress tests performed at MSKCC,        2008—2011.|November 2015|November 11, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474577||95439|
NCT01486069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUSP - PhD Surg - 01|Mandibular Stability and Dentofacial Deformity|Evaluation of the Perioperative Mandibular Positional Stability in Subjects With Dentofacial Deformity||University of Sao Paulo|Yes|Completed|July 2012|June 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Data will be obtained from subjects to be submitted to orthognathic surgery by the        Department of Oral & Maxillofacial Surgery of the Hospital Geral Universitário of the city        of Cuiabá - Brazil during the period of March 2012 through March 2013. Considering the        local demand, thirty subjects are expected to be included in the research.|June 2013|June 12, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01486069||94557|
NCT01478958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N02044|Dietary Intervention and Vascular Function|The Effects of the Substitution of Dietary SFA With n-6 PUFA or MUFA on Vascular Function|DIVAS|University of Reading|Yes|Completed|May 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|202|||Both|21 Years|60 Years|No|||June 2014|June 12, 2014|November 16, 2011||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01478958||95103|
NCT01483820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC 004|Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma|A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma||Spectrum Health Hospitals|Yes|Terminated|December 2011|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|114|||Both|12 Months|30 Years|No|||January 2016|January 18, 2016|November 28, 2011|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01483820||94730|
NCT01483833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN309-SMPEC-001|Efficacy Study of Iferanserin to Treat Hemorrhoids|Protocol for the Study of the Effects of S-MPEC (Iferanserin) in Patients With Hemorrhoids||Ventrus Biosciences, Inc|No|Completed|September 2001|August 2002|Actual|August 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||November 2011|August 19, 2013|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01483833||94729|
NCT01475110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML0609|Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib|Observational Study in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia (CML) Treated With Nilotinib: Follow-up of the Italian Patients. GIMEMA Study CML0609|CML0609|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|The GIMEMA CML Working Party promotes an observational (retrospective and perspective)        study of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy.        Enrollement will include all patients who started Nilotinib between January 2005 and        December 2012.|April 2015|April 21, 2015|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01475110||95398|
NCT01475357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR 20394|Intestinal Function in Neonates With Complex Congenital Heart Disease|Intestinal Function in Neonates With Complex Congenital Heart Disease||Medical University of South Carolina|Yes|Completed|October 2011|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|37 Weeks|40 Weeks|No|||October 2014|October 14, 2014|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01475357||95379|
NCT01475370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311-10-002|Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)|||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|November 2011|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|60 Years|N/A|No|||October 2015|October 9, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01475370||95378|
NCT01475617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AQV-001|Efficacy of a Novel Multivitamin-Mineral Supplement in Preventing Vitamin Deficiency in Postoperative Bariatric Patients|Efficacy of a Novel Multivitamin-Mineral Supplement in Preventing Vitamin Deficiency in Postoperative Bariatric Patients||Yasoo Health|No|Completed|November 2011|June 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|18 Years|65 Years|No|||January 2015|January 20, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01475617||95359|
NCT01475903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0093|Assessment of Nutritional Consequences of Sleeve Gastrectomy|Assessment of Nutritional Consequences of Sleeve Gastrectomy|ERNEST|University Hospital, Clermont-Ferrand||Not yet recruiting|November 2011|May 2015|Anticipated|November 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|65 Years|No|Non-Probability Sample|defined population|November 2011|November 17, 2011|April 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01475903||95337|
NCT01475916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0105|Quality of Life in Asthmatic Children at School Age|Quality of Life in Asthmatic Children at School Age : Influence of Therapeutic Education||University Hospital, Clermont-Ferrand|No|Not yet recruiting|December 2011|October 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|5 Years|10 Years|No|||November 2011|November 17, 2011|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01475916||95336|
NCT01476215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3950669|A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions|A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions||GlaxoSmithKline|No|Completed|November 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|18|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|November 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476215||95313|
NCT01476501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|diabetes vitamin D 20112012|Vitamin D Supplementation in Diabetic Nephropathy|Vitamin D Supplementation and Bone Health in Adults With Diabetic Nephropathy||University of Alberta|Yes|Active, not recruiting|October 2011|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476501||95291|
NCT01476527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0696-A|Deep Brain Stimulation for the Treatment of Refractory Bipolar Disorder|||University Health Network, Toronto|No|Recruiting|May 2011|||March 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|30 Years|60 Years|No|||November 2011|November 17, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476527||95289|
NCT01476787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-FOL-GELARC-0683C|Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma|A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma|RELEVANCE|Celgene|Yes|Active, not recruiting|December 2011|June 2024|Anticipated|June 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|November 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476787||95269|
NCT01477086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Viamed-Sarco-HF|Prevalence and Pathophysiology of Sarcopenia in the Elderly Patient With Hip Fracture|Prevalence and Pathophysiology of Sarcopenia in the Elderly Patient With Hip Fracture. Prospective, Observational Study on Consecutive Series|PREFISSARC|Hospital Viamed Valvanera, Spain|No|Completed|January 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|198|||Both|65 Years|N/A|No|Probability Sample|Will be included in the study, prospectively, patients with hip fracture admitted to the        Geriatric Rehabilitation Unit, Spain.|February 2016|February 4, 2016|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01477086||95247|
NCT01477099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRUSH-2009|Toothbrushing and Ventilator-associated Pneumonia|Efficacy of Toothbrushing for the Prevention of Ventilator-associated Pneumonia||Hospital Universitario de Canarias|Yes|Completed|August 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|436|||Both|18 Years|N/A|No|||November 2011|November 18, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01477099||95246|
NCT01478009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJRG-INFL-KRG|Efficacy of an Extract of Concentrated Korean Red Ginseng for Preventing Upper Respiratory Tract Infections|A Placebo-Controlled Trial of Korean Red Ginseng Extract to Prevent Acute Respiratory Illness in Healthy Subjects||Chonbuk National University Hospital|Yes|Completed|November 2010|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|November 16, 2011||No||No|July 2, 2012|https://clinicaltrials.gov/show/NCT01478009||95176|
NCT01474603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPEDE-DM2|Impact of n-3 Polyunsaturated Fatty Acids in a Protein-enriched Diet With Low GI in Type 2 Diabetes Patients|IMpact of n-3 Polyunsaturated Fatty Acids With a Protein-Enriched DiEt With Low Glycemic Index on Metabolic and Inflammatory Parameters in Type 2 Diabetic and Obese Patients: an Observational Pilot Study|IMPEDE-DM2|Medical University of Vienna|No|Completed|November 2011|March 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|Samples Without DNA|serum and plasma samples for biochemical analyses|Both|18 Years|75 Years|No|Non-Probability Sample|overweight to obese insulin resistant, prediabetic and diabetic patients|March 2016|March 14, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474603||95437|
NCT01474902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000022022|Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery|A Randomized Controlled Trial of Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery||The Hospital for Sick Children|Yes|Withdrawn|August 2011|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|18 Years|No|||August 2013|August 25, 2013|November 15, 2011||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01474902||95414|
NCT01474876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-768|Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis|Multicountry Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis and Psoriatic Arthritis||AbbVie|No|Completed|November 2011|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|566|||Both|18 Years|N/A|No|Non-Probability Sample|This study is a post-marketing observational study (PMOS) where adalimumab is prescribed        in the usual manner in accordance with the terms of the local marketing authorization with        regards to dose, population and indication. Study population will consist of adult aged        (>18 years) with Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) that can be        administered adalimumab as per locally approved Summary of Product Characteristics (SmPC)        and reimbursement criteria.|June 2015|June 15, 2015|November 16, 2011||No||No|May 18, 2015|https://clinicaltrials.gov/show/NCT01474876||95416|
NCT01475175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AdOPT CRT Sub Study|Adaptive Cardiac Resynchronization Therapy Optimization at Rest and During Exercise (AdOPT CRT)|Adaptive Cardiac Resynchronization Therapy Optimization at Rest and During Exercise (AdOPT CRT)||Medtronic Cardiac Rhythm Disease Management||Terminated|November 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2012|September 12, 2012|November 16, 2011||No|Decision was made to stop the study based on a pre-planned interim analysis that the sample    size would unlikely be sufficient to satisfy the primary objective.|No|September 12, 2012|https://clinicaltrials.gov/show/NCT01475175||95393|A pre-planned interim evaluation of the sample size calculation assumptions was conducted. The variability of the outcome measures was higher than assumed. The study was stopped since the planned sample size would unlikely be sufficient.
NCT01474590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29099|Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne|Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With 200 mg Doxycycline Capsules Versus Vehicle Gel Associated With Isotretinoin Capsules in the Treatment of Severe Acne|POWER|Galderma|No|Completed|November 2011|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|12 Years|35 Years|No|||November 2013|November 22, 2013|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01474590||95438|
NCT01474863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111435|Citrulline in Severe Sepsis|Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous Citrulline to Prevent or Mitigate Acute Lung Injury in Patients With Severe Sepsis||Vanderbilt University|No|Recruiting|August 2012|||December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|75|||Both|13 Years|N/A|No|||December 2015|December 7, 2015|November 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474863||95417|
NCT01475461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621007|Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes|A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate Safety And Efficacy Of PF-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Pfizer|Yes|Completed|November 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|345|||Both|18 Years|55 Years|No|||April 2014|April 21, 2014|September 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01475461||95371|
NCT01486082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP02|Antimicrobial Susceptibility for Helicobacter Pylori Eradication|Usefulness of Antimicrobial Susceptibility in the Eradication of Helicobacter Pylori||Hospital Donostia|No|Recruiting|February 2011|May 2012|Anticipated|November 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1|||Both|18 Years|80 Years|No|Probability Sample|The investigators recruited patients who are diagnosed with helicobacter pylori infection        in our hospital (Hospital Donostia) or in any of the specialist care centres under the        management of the Hospital Donostia.|December 2011|December 11, 2011|November 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01486082||94556|
NCT01479491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116259|Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in Japan|Observational Database Study on the Incidence of Intussusception in Children Aged < 12 Months in Japan||GlaxoSmithKline||Completed|November 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|54|||Both|N/A|12 Months|No|Non-Probability Sample|Children aged <12 months presenting with IS and covered by the JMDC-MDB database from        January 2005 to April 2011.|October 2012|October 18, 2012|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479491||95063|
NCT01479504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GuangxiMU|A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma||Guangxi Medical University|Yes|Recruiting|November 2011|December 2017|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|2|||Both|18 Years|70 Years|No|||October 2011|November 24, 2011|November 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01479504||95062|
NCT01474772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081269|Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)|A Phase 3b Multicenter, Double-blind, Randomized, Placebo-controlled Cross-over Efficacy And Safety Study Of Pregabalin In The Treatment Of Patients With Painful Diabetic Peripheral Neuropathy And Pain On Walking||Pfizer|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|217|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|November 15, 2011|Yes|Yes||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01474772||95424|
NCT01474785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#111237|RYGB and the Gastric Adipose Axis|RYGB Improves Metabolism by Interrupting the Gastric Adipose Tissue Axis||Vanderbilt University|Yes|Enrolling by invitation|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|66|Samples With DNA|Whole blood, plasma, serum, microdialysate, muscle, fat.|Both|18 Years|65 Years|No|Non-Probability Sample|We will study three obese cohorts prior to and within 7-10 days of the following        procedures: RYGB, Vertical Sleeve Gastrectomy (VSG) with caloric restriction equivalent to        the RYGB group, and a Caloric Restriction without surgery.|January 2016|January 21, 2016|November 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01474785||95423|
NCT01475123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-2008-PRECON|Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil|Effects of Nicorandil on Cardiovascular Events in Patients With Coronary Artery Disease Receiving Hemodialysis||Kumamoto University|Yes|Active, not recruiting|June 2008|December 2016|Anticipated|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|268|||Both|N/A|N/A|No|||February 2016|February 25, 2016|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475123||95397|
NCT01475136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12677|A Study of LY2140023 in Hepatic Impaired Participants|A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment||Eli Lilly and Company|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|November 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01475136||95396|
NCT01475383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8801035|Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Of The Safety And Efficacy Of PF-03654746 In Adults With Tourette's Syndrome||Pfizer|No|Terminated|April 2012|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|55 Years|No|||July 2012|July 30, 2012|October 25, 2011|Yes|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01475383||95377|
NCT01475396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exercise_Neuromod|The Effect of Physical Activity on the Brain|Clinical Study on the Effect of Physical Activity on Cognition and Memory in the Elderly||University Hospital Muenster|No|Active, not recruiting|March 2006|December 2012|Anticipated|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|120|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01475396||95376|
NCT01475630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2210|Physical Therapy for Temporomandibular Joint (TMJ) Closed Lock|Randomised Controlled Trial on Physical Therapy PT) for TMJ Closed Lock||Katholieke Universiteit Leuven|No|Completed|June 2003|November 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|N/A|N/A|No|||November 2011|November 21, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01475630||95358|
NCT01475929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS2|Effect of Probiotic Supplement on Bowel Function|Effect of Probiotic Supplement on Bowel Function|IBS2|Danisco|No|Terminated|June 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|149|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|September 20, 2011||No|Protocol violations|No||https://clinicaltrials.gov/show/NCT01475929||95335|
NCT01475942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Turku_elderly|Probiotic Intervention With Elderly Subjects|Randomized Placebo Controlled Study to Assess the Effect of a Probiotic Supplement on the Subclinical Levels of Intestinal C. Difficile Among Elderly||Danisco|No|Completed|January 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|104|||Both|65 Years|N/A|Accepts Healthy Volunteers|||February 2015|January 26, 2016|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01475942||95334|
NCT01476254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESP-1|Respiratory Complications After Laparoscopic Surgery|Respiratory Complications After Laparoscopic Surgery||Herlev Hospital|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Female|45 Years|N/A|No|Probability Sample|Patients scheduled for elective laparoscopic surgery|November 2012|November 19, 2012|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476254||95310|
NCT01476241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG and ENT|Percutaneous Endoscopic Gastrostomy Tube Placement by Otorhinolaryngologist|Percutaneous Endoscopic Gastrostomy Tube Placement by Otorhinolaryngologist: a Single Institution Experience||Helsinki University|No|Completed|September 2005|October 2011|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|292|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that had undergone PEG tube placement in a tertiary care center.|November 2011|November 17, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476241||95311|
NCT01476800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-036|A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers|A Phase 1, Open-Label, Two-Period, One-Sequence Crossover Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Male and Female Adult Volunteers||Astellas Pharma Inc|No|Completed|July 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|November 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476800||95268|
NCT01476813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1106-PR-0066|Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate|A Randomized, Double-blind, Active-controlled, Cross-over Study to Assess Efficacy and Safety of 3 Free Doses of Glycopyrrolate With Beclomethasone/Formoterol pMDI for the Treatment of COPD Patients||Chiesi Farmaceutici S.p.A.|No|Completed|March 2012|July 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|281|||Both|40 Years|80 Years|No|||July 2013|July 26, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01476813||95267|
NCT01476826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP002-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||February 23, 2015|November 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476826||95266|
NCT01477112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIC-HUMNUT-001|Low Dose β-carotene Supplementation Diminishes Oxidative Stress in Type 2 Diabetics and Healthy Individuals|Effect of the Supplementation With β-carotene to Type 2 Diabetic Patients and Healthy Controls on the Iron Status and Antioxidant Capacity of Plasma||Instituto Venezolano de Investigaciones Cientificas|Yes|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|117|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 18, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01477112||95245|
NCT01477359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI-04|Cardiac Sarcoidosis Multi-Center Prospective Cohort|Cardiac Sarcoidosis Multi-Center Prospective Cohort Study|CHASM-CS|Ottawa Heart Institute Research Corporation|No|Recruiting|August 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|99 Years|No|Probability Sample|Electrophysiology Service patients|September 2015|October 1, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01477359||95226|
NCT01474278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27801|A Study of RO5028442 in Adult Male High-Functioning Autistic Patients|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients||Hoffmann-La Roche||Completed|December 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|2||Actual|19|||Male|18 Years|45 Years|No|||March 2016|March 1, 2016|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474278||95462|
NCT01474291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27873|An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)|Evaluation of Factors Influencing Use of RoActemra as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO||Hoffmann-La Roche||Completed|February 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|608|||Both|18 Years|N/A|No|Probability Sample|Moderate to severe rheumatoid arthritis patients treated with RoActemra/Actemra in routine        clinical practice|March 2016|March 1, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474291||95461|
NCT01475188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N 402 057 32/1788|Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy|Regulatory Lymphocytes (Treg) in the Modulation of Allergic Inflammation in Patients Treated With Specific Immunotherapy.||Ministry of Science and Higher Education, Poland|No|Completed|March 2007|December 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|41|||Both|18 Years|65 Years|No|||November 2011|November 18, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475188||95392|
NCT01475201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-MOP-114996|Step Monitoring to Improve ARTERial Health|Step Monitoring to Improve ARTERial Health|SMARTER|McGill University Health Center|No|Active, not recruiting|February 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|364|||Both|18 Years|95 Years|No|||October 2015|October 23, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475201||95391|
NCT01475474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renew Medical - 210CLD|A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage|A Multi-Center, Prospective, Non-Randomized Study of the Renew Insert Efficacy, Safety and Tolerability For the Management of Accidental Bowel Leakage Due to Bowel Incontinence|REST|Renew Medical|No|Completed|December 2009|December 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|November 10, 2011|Yes|Yes||No|July 2, 2013|https://clinicaltrials.gov/show/NCT01475474||95370|
NCT01475695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115243|GSK2251052 Mass Balance in Healthy Adult Subjects|An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2251052 Administered as a Single Intravenous Dose to Healthy Adult Subjects||GlaxoSmithKline|No|Completed|April 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||December 2011|March 8, 2012|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01475695||95353|
NCT01475721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115359|SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.|SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma|AUSTRI|GlaxoSmithKline|Yes|Completed|November 2011|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|11751|||Both|12 Years|N/A|No|||December 2015|December 10, 2015|November 17, 2011|No|Yes||No|December 3, 2015|https://clinicaltrials.gov/show/NCT01475721||95351|
NCT01486680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTY/11/07/082|Silastic Ring Gastric Bypass Versus Sleeve Gastrectomy for Type 2 Diabetes Mellitus in Obese Patients|Prospective Randomised Controlled Trial Comparing the Efficacy of Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy for the Management of Type 2 Diabetes Mellitus in Obese Patients||North Shore Hospital, New Zealand|No|Active, not recruiting|September 2011|October 2019|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|106|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01486680||94510|
NCT01479517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 2-05|Open-Label Study to Evaluate The Efficacy And Recommended Dosing Regimen Of Kovacaine Mist Administered Unilaterally For Anesthetizing Maxillary Teeth|A Phase II, Single-Site, Open-Label Clinical Trial To Evaluate The Efficacy And Recommended Dosing Regimen Of Kovacaine Mist Administered Unilaterally For Anesthetizing Maxillary Teeth In Healthy Dental Patients||St. Renatus, LLC|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 15, 2015|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479517||95061|
NCT01479816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2011-047|Urinary Continence Index for Prediction of Urinary Incontinence in Older Women|Urinary Continence Index for Prediction of Urinary Incontinence in Older Women||William Beaumont Hospitals|No|Completed|September 2011|December 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|702|||Female|55 Years|N/A|No|Non-Probability Sample|Women 55 years and older|January 2016|January 5, 2016|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479816||95038|
NCT01474798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-PT020|Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris|A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Acne Vulgaris||XBiotech, Inc.|No|Completed|February 2012|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|30 Years|No|||June 2014|June 5, 2014|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474798||95422|
NCT01474811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCV-TARGET Study|HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network|HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.||University of North Carolina, Chapel Hill|No|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4500|Samples With DNA|All patients will be invited to participate in the HCV-TARGET Biorepository Specimen Bank      (BSB).      The following will be collected: Blood (Serum and DNA).      All samples will be collected on a voluntary basis and participation in this project will      not affect participation in the main study.      Samples collected will be stored at the University of Florida for up to 15 years after the      end of the study (database closure) at which time they will be destroyed. The implementation      and use of the BSB specimens is governed by the University of Florida Biospecimen Repository      policy to ensure the appropriate use of the deposited samples.|Both|18 Years|N/A|No|Non-Probability Sample|Male and female adult patients: Aged 18 and older with chronic HCV treated with triple        therapy (including protease inhibitors).|June 2015|June 10, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01474811||95421|
NCT01475656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1557|Efficacy of Keppra for Neonatal Seizures|Safety, Tolerability, and Efficacy of Levetiracetam for Neonatal Seizures||Children's Hospital Medical Center, Cincinnati|Yes|Terminated|November 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2|||Both|N/A|30 Days|No|Non-Probability Sample|25 neonates ≥ 35 weeks of gestation and ≤ 30 days of life with        electrographically-confirmed seizures|April 2013|April 17, 2013|November 17, 2011|No|Yes|difficulty with recruitment|No||https://clinicaltrials.gov/show/NCT01475656||95356|
NCT01475409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URomLS01|A Study on Changes in IFN-gamma Levels Following Anti-TNF Treatment in Patients Undergoing Serial QuantiFERON-TB Gold In-Tube|Dynamic Changes in IFN-gamma Plasma Levels Following Anti-TNF Treatment in Patients With Inflammatory Rheumatic Diseases Undergoing Serial QuantiFERON-TB Gold In-Tube Testing: a Prospective Study in a Low Tuberculosis Burden Country||University of Roma La Sapienza|No|Completed|July 2008|February 2011|Actual|February 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|119|||Both|18 Years|N/A|No|||November 2011|November 16, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01475409||95375|
NCT01475643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|670|Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.|Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract||Bausch & Lomb Incorporated|No|Recruiting|July 2013|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|170|||Both|N/A|11 Years|No|||February 2015|February 13, 2015|November 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01475643||95357|
NCT01475955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP0105|Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)|A Phase II Study of Photodynamic Therapy With LEVULAN® Topical Solution + Blue Light Versus LEVULAN® Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face or Scalp||DUSA Pharmaceuticals, Inc.|No|Completed|December 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|235|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|November 15, 2011|Yes|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01475955||95333|
NCT01475968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCON|Physiological Changes in Adults With Metabolic Syndrome Exposed to Ultrafine Air Particles|Physiological Changes in Adults With Metabolic Syndrome Exposed to Concentrated Ultrafine Chapel Hill Air Particles|XCON|Environmental Protection Agency (EPA)|No|Completed|December 2004|October 2013|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|48|||Both|25 Years|70 Years|No|||November 2013|November 5, 2013|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475968||95332|
NCT01476267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP27937|A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers|An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects||Hoffmann-La Roche||Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|6|||Male|45 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01476267||95309|
NCT01476540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0991-A|Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa|Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa||University Health Network, Toronto|No|Recruiting|July 2011|||March 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|20 Years|60 Years|No|||November 2011|November 17, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476540||95288|
NCT01477125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X002|Working Memory Training in Adults With ADHD|Computerised Working Memory Training in Adults With ADHD: A Randomised Controlled Trial||Karolinska Institutet|No|Recruiting|November 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||September 2015|September 29, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01477125||95244|
NCT01477372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240/09|Effect of Physical Exercise Program During Pregnancy on Excessive Weight Gain and Its Consequences|Effect of Physical Exercise Program During Pregnancy on Excessive Weight Gain and Its Consequences||Universidad Politecnica de Madrid|No|Completed|September 2007|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|320|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 10, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01477372||95225|
NCT01477697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Athota-2010-01|Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients|Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients||University of Cincinnati|No|Terminated|June 2011|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||February 2013|February 22, 2013|November 18, 2011||No|Terminated due to slow enrollment and interim analysis showing no difference between treatment    arms.|No||https://clinicaltrials.gov/show/NCT01477697||95200|
NCT01477710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Branson-2010-01|Ability of Caregivers to Provide Ventilation With the SAVe Resuscitator in a Model|Ability of Caregivers to Provide Ventilation With the SAVe Resuscitator in a Model||University of Cincinnati|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|November 18, 2011||No||No|January 23, 2013|https://clinicaltrials.gov/show/NCT01477710||95199|
NCT01474616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPA 108891|Mobility of Vulnerable Elders (MOVE): Translating Knowledge to Health Care Aides in Long-term Care Facilities|Mobility of Vulnerable Elders (MOVE): Translating Knowledge to Health Care Aides in Long-term Care Facilities|MOVE|University of Alberta|No|Completed|August 2011|June 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|113|||Both|N/A|N/A|No|||July 2013|July 18, 2013|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01474616||95436|
NCT01474889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814114|Glucose Counterregulation in Long Standing Type 1 Diabetes|Effect of Real-Time Continuous Glucose Monitoring on Glucose Counterregulation in Long Standing Type 1 Diabetes||University of Pennsylvania|Yes|Active, not recruiting|October 2011|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|36|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474889||95415|
NCT01485042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031123|Dose Escalation Study of Pazopanib Plus TH-302|Phase I Dose Escalation of Pazopanib Plus TH-302 in Advanced Solid Tumors|PATH|Duke University|Yes|Active, not recruiting|December 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|November 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01485042||94636|
NCT01485263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110157|Analysis of Visual-Motor Task Electrophysiological Activity During Deep Brain Stimulation for Treatment-Resistant Movement Disorders|Analysis of Visual-Motor Task Electrophysiological Activity During Deep Brain Stimulation for Treatment-Resistant Movement Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|May 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|15|||Both|18 Years|N/A|No|||April 2015|May 16, 2015|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01485263||94619|
NCT01485783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABPM Hypertensive Children|Improving Outcomes for Hypertensive Children|Improving Outcomes for Hypertensive Children||Arkansas Children's Hospital Research Institute|No|Completed|November 2011|May 2015|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|112|None Retained|none collected|Both|6 Years|17 Years|No|Non-Probability Sample|Approximately 200 children age 6 - <18 years receiving medications for essential HTN will        be recruited from the Pediatric Hypertension Clinic at the time of a routine clinic visit.|September 2015|September 8, 2015|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01485783||94579|
NCT01485796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161101|Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD|Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)||Baxalta US Inc.|No|Completed|December 2011|January 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|2 Years|N/A|No|||January 2013|June 26, 2015|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485796||94578|
NCT01482845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-970|A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors||Abbott|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|20|||Both|55 Years|90 Years|No|||March 2012|May 1, 2012|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01482845||94805|
NCT01480076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218MS403|Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis|An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects With Multiple Sclerosis|ENABLE|Biogen||Completed|February 2013|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|901|||Both|18 Years|75 Years|No|||April 2015|April 2, 2015|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01480076||95018|
NCT01474824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11090|Validation of Nexfin Cardiac Output in Elderly Patients With Hip Fracture|Validation of the Nexfin Non-invasive Cardiac Output Monitor in Patients Undergoing Hip Fracture Repair||University of Nottingham|No|Terminated|January 2013|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|80 Years|N/A|No|Non-Probability Sample|Elderly patients undergoing surgical repair of hip fracture|December 2014|December 3, 2014|October 14, 2011||No|Unable to recruit sufficient participants|No||https://clinicaltrials.gov/show/NCT01474824||95420|
NCT01474837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.E.A.L.T.H|Exercise for Depression in Young People|The H.E.A.L.T.H. Project: Help Enabling Active Lifestyles Toward Health in Young People With Depression.|HEALTH|University of Nottingham|Yes|Completed|October 2011|||November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|14 Years|17 Years|No|||January 2014|January 16, 2014|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01474837||95419|
NCT01476007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024129-20|Oral/Intramuscular B12 to Treat Cobalamin Deficiency|Oral Versus Intramuscular Cobalamin to Treat Cobalamin Deficiency: Noninferiority Randomised Controlled Trial Pragmatic and Multi-center in the Primary Healthcare Setting (OB12 Project)|OB12|Gerencia de Atención Primaria, Madrid|Yes|Recruiting|July 2014|December 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|65 Years|N/A|No|||November 2015|November 12, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476007||95329|
NCT01475981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK853-U-09-001|Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects|Randomized,Double-blind,Placebo-controlled,Ascending Dose Part Evaluating Safety,Tolerability and Pharmacokinetics (PK) of JTK-853 (Fasted/Fed) and Randomized,Open-label,Crossover Part Evaluating Food Effect on PK in Healthy Male Subjects||Akros Pharma Inc.|No|Completed|January 2010|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|11||Actual|70|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2011|November 17, 2011|November 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01475981||95331|
NCT01475994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01 Neurop|Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic Dermatitis|Pilot Study to Assess the Effect of Pollen Challenges in an Environmental Challenge Chamber on Dermal Symptoms in Patients With Atopic Dermatitis|Neurop|Fraunhofer-Institute of Toxicology and Experimental Medicine|No|Completed|November 2011|April 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|65 Years|No|||April 2012|April 4, 2012|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01475994||95330|
NCT01476280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC11MISI0027|Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting|A Randomized Double Blind Study to Evaluate Efficacy of Ramosetron and Palonosetron for Prevention of Postoperative Nausea and Vomiting After Gynaecological Laparoscopic Surgery||Incheon St.Mary's Hospital|Yes|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Female|20 Years|N/A|No|||November 2011|November 17, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476280||95308|
NCT01476293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ivWatch-CT-001|Monitoring the Peripheral Intravenous Infusion Site for Infiltration and Extravasation|Non-invasive Optical Medical Device for Monitoring and Detecting Peripheral Intravenous Infusion Sites for Infiltration and Extravasation in Subjects Receiving Continuous Fluids||ivWatch, LLC|Yes|Completed|August 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|139|||Both|N/A|12 Years|No|Non-Probability Sample|Subjects will be recruited from Cincinnati Children's Hospital Medical Center.|November 2011|February 17, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01476293||95307|
NCT01476553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMM-EIPL|Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in Patients With Gastric Cancer|Elimination of Peritoneal Tumor Cells With "Extensive Intraperitoneal Lavage (EIPL)" During Surgical Treatment of Gastric Adenocarcinoma|EIPL|Universitätsmedizin Mannheim|No|Terminated|February 2011|December 2016|Anticipated|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|November 11, 2011||No|Prematurely halted after interim data analysis|No||https://clinicaltrials.gov/show/NCT01476553||95287|
NCT01476839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08179|Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma|Phase I Study of Yttrium-90 Labeled Anti-CD25 (a-Tac) Monoclonal Antibody Plus BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma, the "a-Tac BEAM Regimen"||City of Hope Medical Center|Yes|Recruiting|November 2012|||January 2021|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|70 Years|No|||November 2015|November 2, 2015|November 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476839||95265|
NCT01477723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK33|Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients|Evaluation of an Oral Nutritional Supplement Containing AN 777 in Older Hospitalized Patients||Abbott Nutrition|Yes|Terminated|October 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|55 Years|N/A|No|||February 2013|February 14, 2013|November 19, 2011||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01477723||95198|
NCT01478022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISOFEN1|To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20|Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses|ISOFEN1|Parent Project, Italy|Yes|Recruiting|October 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|18 Years|27 Years|Accepts Healthy Volunteers|||November 2011|November 22, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01478022||95175|
NCT01473979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SternumStudy-CHUV-CCV-1|Delayed Primary Versus Late Secondary Wound Closure in Sternum Infections|Delayed Primary Versus Late Secondary Wound Closure in the Treatment of Postsurgical Sternum Osteomyelitis||University of Lausanne Hospitals|No|Not yet recruiting|January 2012|July 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||January 2012|January 24, 2012|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01473979||95485|
NCT01473992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6140101200|Comparative Outcomes Assessment of the C-Leg With a New Knee Prosthesis|Comparative Outcomes Assessment of the C-Leg With a New Knee Prosthesis||University of South Florida|Yes|Completed|January 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2014|November 20, 2014|May 31, 2011||No||No|May 6, 2014|https://clinicaltrials.gov/show/NCT01473992||95484|
NCT01485055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCH-IRB11-00659|Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease|Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease||Nationwide Children's Hospital|Yes|Recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|6 Months|75 Years|No|||September 2015|September 23, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485055||94635|
NCT01485276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120012|Combined Deep Brain Stimulation for Parkinson's Disease|Pilot Study of Bilateral Pedunculo-Pontine Nucleus (PPN) Deep Brain Stimulation for Patients With Parkinson Disease (PD) Who Have Persistent Gait Disturbance, Despite Bilateral Subthalamic Nucleus (STN) Deep Brain Stimulation||National Institutes of Health Clinical Center (CC)||Withdrawn|November 2011|July 2014|Actual|||Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|22 Years|N/A|No|||July 2014|July 31, 2014|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01485276||94618|
NCT01484756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FK-RKK-2819|Combined Vitamins and Minerals Decrease Incidence of Upper Respiratory Tract Infections in Older Persons|Combined Vitamins and Minerals Decrease Incidence of Upper Respiratory Tract Infections in Older Persons||Trisakti University|Yes|Completed|August 2008|March 2009|Actual|February 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|270|||Both|60 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 5, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01484756||94658|
NCT01484769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360.05|Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells|Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells|H&N|University of Louisville|No|Recruiting|July 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples With DNA|Tissue samples from patients undergoing elective neck dissection will be collected. Primary      tumors and adjacent normal tissue from unaffected areas will be collected at the time of      surgery. All tissue dissection and removal are part of the standard of care for this type of      surgical procedure. Remaining resected tissue will be used for research.|Both|7 Years|N/A|No|Non-Probability Sample|Adults and minors diagnosed with squamous cell carcinoma of the head and neck that will        undergo elective neck dissection surgery at either Norton Hospital, Kosair Children's        Hospital, or University of Louisville Hospital.|June 2011|April 4, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484769||94657|
NCT01485835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049962|A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma||Emory University|Yes|Completed|January 2012|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01485835||94575|
NCT01485848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT12601|EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer|EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial|ESP2011-002|Esperance Pharmaceuticals Inc|No|Completed|February 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Female|18 Years|N/A|No|||June 2014|June 9, 2014|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485848||94574|
NCT01485822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-01-78|A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution|A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution||Alcon Research|No|Terminated|July 2004|February 2012|Actual|February 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|88|||Both|50 Years|N/A|No|Non-Probability Sample|Patients were identified and enrolled from 9 study centers in the US and 1 in Spain.|May 2013|May 13, 2013|December 1, 2011|No|Yes|Study objectives met|No||https://clinicaltrials.gov/show/NCT01485822||94576|
NCT01486381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1459|Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes|A Multi-national, Multi-centre, Open-labelled Extension Study Assessing the Long-term Safety of Biphasic Insulin Aspart 30 (BIAsp 30) in Young Diabetic Subjects With Type 1 Diabetes Mellitus Previously Treated in BIAsp-1240||Novo Nordisk A/S|No|Completed|March 2002|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|10 Years|17 Years|No|||December 2011|December 2, 2011|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486381||94533|
NCT01482858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCS-003|Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures|A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures||Amorphical Ltd.|No|Not yet recruiting|December 2011|August 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||November 2011|November 30, 2011|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01482858||94804|
NCT01480089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203353|Surgical Pain Control With Ropivacaine by Atomized Delivery|Surgical Pain Control With Ropivacaine by Atomized Delivery|SPRAY|Loyola University|No|Recruiting|November 2011|December 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 10, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480089||95017|
NCT01475422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6266936|Effectiveness of the Self Monitoring of Capillary Blood Glucose at Home|Effectiveness of the Self Monitoring of Capillary Blood Glucose at Home in Metabolic Control of People With Diabetes Mellitus||University of Sao Paulo|Yes|Recruiting|September 2011|March 2012|Anticipated|December 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|91|||Both|18 Years|90 Years|No|||November 2011|November 16, 2011|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01475422||95374|
NCT01477151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16497|Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery|Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial.|RISCCS|Lawson Health Research Institute|Yes|Completed|November 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|464|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01477151||95242|
NCT01476306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00044310|Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study|Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study|TELEMED-PD|Johns Hopkins University|No|Enrolling by invitation|November 2011|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|30 Years|N/A|No|||November 2011|November 17, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476306||95306|
NCT01476566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTV-3|Can Diagnostics and Pharmacological Prescriptions in Patients With Heart Failure be Improved in General Practice?|Can Diagnostics and Pharmacological Prescriptions in Patients With Heart Failure be Improved? A Cluster Randomised Educational Intervention in General Practice. A Study Protocol.||University of Oslo|No|Not yet recruiting|January 2013|January 2016|Anticipated|January 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1940|||Both|N/A|N/A|No|||November 2011|November 17, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01476566||95286|
NCT01476865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1295/09|Articular Sonography: Healthy Subjects Versus Rheumatoid Arthritis Patients|Articular Sonography: Findings in Healthy Subjects Compared With Rheumatoid Arthritis Patients||Federal University of São Paulo|No|Completed|March 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|190|Samples With DNA|serum|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|terciary care clinic (rheumatoid arthritis patients) community sample (healthy people)|November 2011|November 18, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01476865||95264|
NCT01477138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOTEPM|RV Septal Versus Minimized RV Pacing in Sick Sinus Syndrome|Comparison of Right Ventricular Septal Pacing to Minimized Right Ventricular Septal Stimulation in Patients With Sick Sinus Syndrome|VOTE|Klinikum Nürnberg|Yes|Recruiting|July 2011|December 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|126|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with symptomathic sick sinus syndrome|November 2011|November 18, 2011|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01477138||95243|
NCT01477385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDFtrials-01|Treatment of Initial Caries Lesions on Proximal Surfaces of Primary and Permanent Posterior Teeth|Treatment of Initial Caries Lesions on Proximal Surfaces of Primary and Permanent Posterior Teeth: a Randomized Placebo-controlled Study.||University of Sao Paulo|Yes|Recruiting|January 2012|October 2017|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|183|||Both|3 Years|17 Years|No|||June 2015|June 17, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01477385||95224|
NCT01474005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4493|Establishment of an Artificial Larynx After Total Laryngectomy|Establishment of an Artificial Larynx After Total Laryngectomy|LA|University Hospital, Strasbourg, France|No|Recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01474005||95483|
NCT01474018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QR-Bromo|QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes|QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes||University of Texas Southwestern Medical Center|Yes|Completed|November 2011|June 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|November 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01474018||95482|
NCT01474031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s52629|Prospective Study Deltamotion - DAA THA Study|Prospective Study Deltamotion - DAA THA Study||Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|60 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Cohorts: 20 DAA subjects - 20 control subjects|August 2011|November 14, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01474031||95481|
NCT01474304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVAC|Intravenous Acetaminophen for Craniotomy Patients|Intravenous Acetaminophen for Craniotomy Patients: A Single-blinded, Randomized Controlled Trial to Evaluate the Effect of Intravenous Acetaminophen Administered at Induction and Emergence From Craniotomy|IVAC|Swedish Medical Center|No|Recruiting|November 2011|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474304||95460|
NCT01485315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-114|Transfusion-requirements in Septic Shock Trial|Effects of Red Blood Cell Transfusion on Mortality and Morbidity in Patients With Septic Shock|TRISS|Scandinavian Critical Care Trials Group|Yes|Completed|November 2011|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1005|||Both|18 Years|N/A|No|||October 2014|October 2, 2014|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01485315||94615|
NCT01485289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLucey|Stabilimax Investigational Device Exemption (IDE) Clinical Investigation Patient Followup Study|Stabilimax Study Participants Collection of Additional Follow-up Data Clinical Investigation Plan R-001||Rachiotek LLC|No|Recruiting|August 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|25|||Both|21 Years|N/A|No|Non-Probability Sample|Community sample|December 2011|December 1, 2011|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01485289||94617|
NCT01485302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR12399|Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients|A Multi-center, Parallel-group, Double-blind, Placebo-controlled Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability and the Pharmacokinetic Properties of SAR228810 Given as IV Infusion or as SC Injection in Patients With Mild to Moderate Alzheimer's Disease.||Sanofi|No|Completed|January 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|48|||Both|50 Years|85 Years|No|||March 2015|March 24, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01485302||94616|
NCT01486108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|burst spinal cord stimulation|Burst Spinal Cord Stimulation for Neuropathic Pain|Burst, Tonic and Sham Spinal Cord Stimulation. A Verification of the Best Treatment Protocol||University Hospital, Antwerp|No|Completed|January 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|75 Years|No|||December 2011|December 2, 2011|September 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01486108||94554|
NCT01486407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-13|Observational Study of Rapid Sequence Intubation (RSI) Drug Delivery Using Intraosseous (IO) and Intravenous (IV) Access.|An Observational Study of Intubating Conditions Comparing Intraosseous Vascular Access With Peripheral Intravenous Access for Drug Delivery in Rapid Sequence Intubation||Vidacare Corporation|No|Terminated|February 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2|||Both|N/A|N/A|No|Non-Probability Sample|Patients in the emergency department with airway difficulties requiring rapid sequence        intubation.|January 2013|January 31, 2013|December 2, 2011||No|For poor enrollment|No||https://clinicaltrials.gov/show/NCT01486407||94531|
NCT01485523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5103|Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites|Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites||University Hospital, Strasbourg, France|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Blood sample|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|From the allergy clinic patients who have a rhinitis and positive skin test to mite or to        other aeroallergens or negative skin test|March 2013|March 12, 2013|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485523||94599|
NCT01485536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0467|A Study of the HSP90 Inhibitor AUY922|A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma||M.D. Anderson Cancer Center|No|Completed|August 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485536||94598|
NCT01485809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVH-1|Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy|A Phase II Trial of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy|SIIS|Seoul Veterans Hospital|Yes|Recruiting|October 2011|February 2014|Anticipated|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|20 Years|N/A|No|||December 2011|December 5, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01485809||94577|
NCT01486394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-2010074|Sonography in an Unselected Population of Acute Admitted Patients With Respiratory Symptoms|Focused Sonographic Examination of the Heart, Lungs and Deep Veins in an Unselected Population of Acute Admitted Patients With Respiratory Symptoms: a Randomised Clinical Trial||Odense University Hospital|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|315|||Both|18 Years|N/A|No|||August 2013|August 2, 2013|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01486394||94532|
NCT01482871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Focus 2|Safety Study of ALG- 1001 to Treat Diabetic Macular Edema|Safety Study of ALG 1001 to Treat Diabetic Macular Edema||Allegro Ophthalmics, LLC|Yes|Withdrawn|January 2011|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482871||94803|
NCT01484639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRICSII|Transfusion Requirements in Cardiac Surgery|Transfusion Requirements in Cardiac Surgery (TRICS II): A Randomized Controlled Trial|TRICSII|St. Michael's Hospital, Toronto|Yes|Completed|January 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|208|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484639||94667|
NCT01484652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COV15000182|Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension||Mallinckrodt|No|Completed|November 2011|September 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|329|||Both|18 Years|75 Years|No|||June 2014|June 30, 2014|November 28, 2011|Yes|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT01484652||94666|
NCT01475669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI3023_3002|Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery|REPLACE (Randomized Evaluation of Fibrinogen Versus Placebo in Complex Cardiovascular Surgery): a Prospective, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study for the Use of Fibrinogen Concentrate (Human) (FCH) in Complex Cardiovascular Surgery|REPLACE|CSL Behring|Yes|Completed|January 2012|September 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|152|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01475669||95355|
NCT01475682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 10-002|Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea|Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea - Prospective 9 Years Follow-up Study||The University of Hong Kong|Yes|Recruiting|November 2011|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|167|||Male|18 Years|65 Years|No|Non-Probability Sample|167 subjects recruited from our previous "OSA and metabolic syndrome" (OSAMS) cohort from        October 2002 to June 2007 will be invited to be reassessed at this time point.|July 2014|July 16, 2014|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475682||95354|
NCT01476592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0097|A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors|A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors||University of Wisconsin, Madison|Yes|Completed|December 2011|January 2014|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476592||95284|
NCT01477398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36354|Improved Patient Recovery After Anesthesia|Improved Patient Recovery of Spontaneous Respiration After Anesthesia With Hypercapnic Hyperpnoea||University of Utah|Yes|Completed|April 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01477398||95223|
NCT01477736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXITBALM|A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity|A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity||Centro de Reabilitação e Readaptação Dr. Henrique Santillo|Yes|Completed|January 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||November 2011|November 19, 2011|November 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01477736||95197|
NCT01477749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-1|Sipuleucel-T Manufacturing Demonstration Study|An Open-Label Study Study of Sipuleucel-T in European Men With Metastatic, Castrate Resistant Prostate Cancer||Dendreon|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|47|||Male|18 Years|N/A|No|||November 2015|November 4, 2015|November 19, 2011|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01477749||95196|
NCT01478035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFSNC1|Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.|Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial||Hospital Universitari de Bellvitge|Yes|Recruiting|November 2011|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|122|||Both|50 Years|N/A|No|||December 2012|December 19, 2012|November 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478035||95174|
NCT01483664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-180|Communication Skills Intervention to Promote Transition Into Survivorship|Communication Skills Intervention to Promote Transition Into Survivorship||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|November 2011|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|314|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients:        Patients from each site will be recruited from their respective lymphoma services.        Physicians:        Physicians from each site will be recruited from their respective lymphoma services.|February 2016|February 25, 2016|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483664||94742|
NCT01473732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-05-196|Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity|Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity||Montefiore Medical Center|Yes|Active, not recruiting|November 2011|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|N/A|N/A|No|||November 2011|November 16, 2011|November 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01473732||95504|
NCT01473745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-100-1653A3|The Nasal Changes Affected by Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy|The Nasal Changes Affected by 2 Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy--A Randomized Controlled Trial||Chang Gung Memorial Hospital|Yes|Completed|July 2011|January 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2011|October 28, 2014|November 15, 2011||No||No|August 6, 2014|https://clinicaltrials.gov/show/NCT01473745||95503|
NCT01484223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIS PI08/90707|Effectiveness of Cognitive Behavioral Intervention in Patients With Symptoms Somatization in Primary Care|Efectiveness of a Cognitive Behavioral Intervention in Patients With Symptoms Somatization, as Measure Quality of Life, Front the Clinical Practice Usual Action in Primary Health Care. A Controlled Clinical Trial With Parallel Groups||Gerencia de Atención Primaria, Madrid|Yes|Completed|October 2009|August 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|242|||Both|18 Years|65 Years|No|||October 2012|October 10, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484223||94699|
NCT01484483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25502|An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya|Breast Cancer Care (BRECC) Registry - Development of a Breast Cancer Registry to Determine the Magnitude of Breast Cancer and Current Clinical Care Patterns in Kenya||Hoffmann-La Roche||Recruiting|August 2011|October 2020|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|410|||Female|18 Years|N/A|No|Probability Sample|Newly diagnosed breast cancer patients|March 2016|March 1, 2016|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01484483||94679|
NCT01484782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-00047263|Developing Accessible Telehealth Programs for Hypertensive Patients in Latin America|Developing Accessible Telehealth Programs for Hypertensive Patients in Latin America||University of Michigan|No|Completed|May 2011|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|80 Years|No|||April 2015|April 24, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484782||94656|
NCT01485562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.15|Treatment of Postpartum Haemorrhage (PPH) Using Misoprostol in Home Births|Treatment of Postpartum Haemorrhage (PPH) Using Misoprostol in Home Births||Gynuity Health Projects|Yes|Completed|May 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01485562||94596|
NCT01485549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/11|Oligomeric Alpha-synuclein in Multiple System Atrophy|Oligomeric Alpha-synuclein Levels as a Biomarker for Multiple System Atrophy|BIOAMS|University Hospital, Bordeaux|No|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|-  cerebrospinal fluid (CSF)        -  whole blood        -  plasma        -  blood serum        -  urine|Both|30 Years|N/A|No|Non-Probability Sample|Cases will be selected from cohort of 90 MSA patients referenced in Bordeaux University        Hospital.        Controls will be selected from patients requiring spinal tap without being affected by a        neurodegenerative disorder and paired in age and gender with cases.|March 2015|March 4, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01485549||94597|
NCT01486433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OM-EPA-007|The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects|An Open-Label, Randomized, 2-Way Crossover Study to Evaluate the Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects||AstraZeneca|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2015|April 29, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486433||94529|
NCT01486095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH Leuven S53441|COmplex BifuRcation Lesions: a Comparison Between the AXXESS Device and Culotte Stenting: an Optical Coherence Tomography (OCT) Study|Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With a Dedicated Bifurcation Device (Axxess™ Drug Eluting Coronary Bifurcation Stent System + Biomatrix™ Drug Eluting Coronary Stent System Stents in the Distal Branches) Versus the Culotte Technique Using Xience Prime Everolimus-eluting Stents : an Optical Coherence Tomography (OCT) Analysis|COBRA|Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|November 2011|December 2017|Anticipated|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01486095||94555|
NCT01482598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR‐11‐017‐IT‐HF|Clinical Benefits in Optimized Remote HF Patient Management|COR HF - Clinical Benefits in Optimized Remote HF Patient Management|COR-HF|St. Jude Medical|Yes|Active, not recruiting|October 2011|August 2018|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|438|||Both|N/A|N/A|No|||March 2016|March 3, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482598||94824|
NCT01483781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100685|A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Groups Study to Investigate the Effects of JNJ-28431754 (Canagliflozin) on Plasma Volume and Renal Function in Subjects With Type 2 Diabetes Mellitus||Janssen Research & Development, LLC|Yes|Completed|December 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|25 Years|70 Years|No|||August 2014|August 19, 2014|November 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01483781||94733|
NCT01484925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 22211|BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus|Notch Signaling and Novel Biomarkers for Barretts Esophagus||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients with Barretts Esophagus with and without associated dysplasia or cancer and        controls with and without gastro-esophageal reflux.|June 2015|June 15, 2015|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484925||94645|
NCT01476878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRAMELESS SRS|Frameless Stereotactic Radiosurgery for Brain Metastases|Frameless Stereotactic Radiosurgery for Brain Metastases||AHS Cancer Control Alberta|Yes|Recruiting|January 2010|January 2012|Anticipated|January 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||August 2011|November 18, 2011|July 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01476878||95263|
NCT01482546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238499|Comparing Clinical Performance of Novice Trainee Endoscopists Using Conventional Air Insufflation Versus Warm Water Infusion Colonoscopy|Randomized Cross-Over Comparing Clinical Performance of Novice Trainee Endoscopists Using Conventional Air Insufflation Versus Warm Water Infusion Colonoscopy||University of California, Davis|Yes|Recruiting|July 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|First Year Gastroenterology Trainees|November 2011|November 29, 2011|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482546||94828|
NCT01482793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WGT4P|A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures|A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures.||Optimus Clinical Research|Yes|Completed|November 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|120|||Both|60 Years|N/A|No|||July 2015|July 10, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482793||94809|
NCT01476891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eCALM|The eCALM Study - An Online Mindfulness-Based Stress Reduction Program for Individuals Living With Cancer in Alberta|The eCALM Study - eTherapy for Cancer Applying Mindfulness: Online Mindfulness-Based Stress Reduction Program for Underserved Cancer Patients in Alberta: A Randomized Wait-list Controlled Trial.|eCALM|AHS Cancer Control Alberta|Yes|Active, not recruiting|January 2011|||August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|64|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01476891||95262|
NCT01477164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005853|Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults|Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults||Mayo Clinic|No|Active, not recruiting|November 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2015|December 28, 2015|September 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01477164||95241|
NCT01483378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02029|Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital|Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital||New York University School of Medicine|Yes|Completed|January 2012|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|170|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 7, 2013|November 18, 2011||No||No|February 19, 2013|https://clinicaltrials.gov/show/NCT01483378||94764|
NCT01483677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|023-10|Comparison Study of the Nintendo Wii Versus Playstation2 in Enhancing Laparoscopic Skills|Is Nintendo Wii a More Suitable Video Game Platform Than Playstation 2 for Enhancing Laparoscopic Skills?||Beth Israel Medical Center|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|42|||Both|21 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 30, 2011|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01483677||94741|
NCT01483963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-870|AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder|A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder||Endo Pharmaceuticals|No|Completed|November 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01483963||94719|
NCT01483950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CBA-CRE-2011/1|Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values|Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors in Bosnia and Herzegovina||AstraZeneca|Yes|Completed|April 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated by specialist|February 2013|February 4, 2013|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01483950||94720|
NCT01484496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112341|A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)|BLISS-SC|GlaxoSmithKline|Yes|Completed|November 2011|October 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|839|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484496||94678|
NCT01485068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIN1102|Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST)|Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of In-Stent Restenosis Lesions in Native Coronary Arteries.|DEBREST|MINVASYS|Yes|Completed|March 2012|July 2014|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||November 2013|April 7, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01485068||94634|
NCT01485081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIN1101|Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE)|Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of Side Branches of de Novo Bifurcation Lesions in Native Coronary Arteries.|DEBSIDE|MINVASYS|Yes|Completed|May 2012|July 2014|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||November 2013|April 7, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01485081||94633|
NCT01485887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2411264|Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)|A Open-label Long-term Extension Study To Evaluate The Safety And Efficacy Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder||Pfizer|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|N/A|No|||September 2015|September 30, 2015|November 29, 2011||No||No|January 9, 2015|https://clinicaltrials.gov/show/NCT01485887||94571|
NCT01485861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27983|Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy|A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Genentech, Inc.||Active, not recruiting|December 2011|November 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|274|||Male|18 Years|N/A|No|||May 2015|May 28, 2015|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01485861||94573|
NCT01486446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPF-002-202|Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia|Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia||Xenon Pharmaceuticals Inc.|No|Completed|December 2011|May 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|19 Years|80 Years|No|||March 2014|March 10, 2014|December 2, 2011|Yes|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01486446||94528|This was a small trial with many exploratory efficacy measures. There was no primary outcome measure, all measures are "other: pre-specified".Only 8 subjects were enrolled (1 placebo), the actual number of Adverse Events is used, not incidence.
NCT01486420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110157|Open Surgery Versus Corticosteroid Injections in Treatment of Trigger Finger|Open Surgery Versus Ultrasound Guided Local Corticosteroid Injections in Treatment of Trigger Finger - a Randomized Controlled Trial.||Regionshospitalet Silkeborg|No|Completed|January 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|99 Years|No|||October 2015|October 27, 2015|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486420||94530|
NCT01486693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109016RC|Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis|Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis||National Taiwan University Hospital|No|Recruiting|October 2011|September 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|60|||Both|40 Years|80 Years|No|Non-Probability Sample|40 men, 20 women, aged 40-80 years old|December 2011|December 5, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01486693||94509|
NCT01482611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018547|A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382|Phase I, First-in-human, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Increasing Single Oral Doses of JNJ-47910382 in Healthy Caucasian and Japanese Volunteers||Janssen R&D Ireland|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 18, 2013|October 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01482611||94823|
NCT01482624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSK-BE-2011-11|Intra-articular Hyaluronan After Arthroscopic Meniscal Surgery|Intra-articular Hyaluronan After Arthroscopic Meniscal Surgery.||TRB Chemedica AG|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|75 Years|No|||August 2013|August 27, 2013|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482624||94822|
NCT01485458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSCIS|Optimal Treatment for Spinal Cord Injury Associated With Cervical Canal Stenosis (OSCIS) Study|Randomized Trial of Early Versus Delayed Surgery for Acute Traumatic Cervical Spinal Cord Injury Without Bone Injury in Patients With Cervical Canal Stenosis|OSCIS|Tokyo University|Yes|Recruiting|December 2011|||December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|79 Years|No|||November 2015|November 2, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01485458||94604|
NCT01486017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-PK18|A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K|A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Across Three Strengths of a New ASP015K Tablet Formulation in Healthy Volunteers||Astellas Pharma Inc|No|Completed|September 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 2, 2011|December 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486017||94561|
NCT01476332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL11001|Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)|A Single Dose (Part 1) and Multiple Dose (Part 2) Phase I, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers||Laurantis Pharma, Ltd.|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01476332||95304|
NCT01476345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13711|A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants|Bioequivalence Study Comparing the Pharmacokinetics and Pharmacodynamics of LY2963016 With Insulin Glargine in Healthy Volunteers||Eli Lilly and Company|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|October 5, 2011|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01476345||95303|
NCT01482806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH093501|Online Treatments for Mood and Anxiety Disorders in Primary Care|Online Treatments for Mood and Anxiety Disorders in Primary Care||University of Pittsburgh|Yes|Active, not recruiting|February 2012|December 2016|Anticipated|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|700|||Both|18 Years|75 Years|No|||January 2016|January 19, 2016|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01482806||94808|
NCT01482819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005031|Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses|||Johnson & Johnson Vision Care, Inc.|No|Completed|October 2011|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|10||Actual|21|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|November 16, 2011|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01482819||94807|
NCT01483105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6970|DVD-Based Training Program in Self-Hypnosis for Children|DVD-Based Training Program in Self-Hypnosis for Children: A Randomized Clinical Trial|VCUG|Stanford University|Yes|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|56|||Both|4 Years|12 Years|No|||April 2015|April 2, 2015|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01483105||94785|
NCT01483391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH093676|Early Intervention for Youth at Risk for Bipolar Disorder|Early Intervention for Youth at Risk for Bipolar Disorder||University of California, Los Angeles|Yes|Recruiting|October 2011|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|9 Years|17 Years|No|||February 2014|February 17, 2014|November 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01483391||94763|
NCT01483690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2009-003|A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL|A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Terminated|December 2011|||June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|1 Year|21 Years|No|||September 2015|November 20, 2015|November 29, 2011|Yes|Yes|Toxicity|No||https://clinicaltrials.gov/show/NCT01483690||94740|
NCT01483703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2010-8163|Noninvasive Optical Measurement of Critical Care Neonates|Noninvasive Optical Measurement of Critical Care Neonates||University of California, Irvine|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|6|||Both|N/A|6 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Children|August 2015|August 5, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01483703||94739|
NCT01484249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP 001b|Carotid Filtration During Endovascular Aortic Valve Implantation|Carotid Filtration During Endovascular Aortic Valve Implantation||Claret Medical|Yes|Completed|February 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|38|||Both|18 Years|N/A|No|||December 2011|December 2, 2011|November 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01484249||94697|
NCT01484236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERMOP-003|National Lymphangioleiomyomatosis Registry, France|National Lymphangioleiomyomatosis Registry, France|RE-LAM-CE|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lymphangioleiomyomatosis|October 2013|October 16, 2013|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01484236||94698|
NCT01459445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IuliuHatieganuU246|Metformin+ Drospirenone/ethinylestradiol30µg and Flow-mediated Dilation in Polycystic Ovary Syndrome|Metformin Plus EE30µg-drospirenone and Weight Loss- Impact on Endothelial Function and hsCRP Levels in PCOS||Iuliu Hatieganu University of Medicine and Pharmacy|Yes|Active, not recruiting|February 2011|January 2012|Anticipated|June 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Female|15 Years|35 Years|No|||October 2011|October 23, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01459445||96594|
NCT01489826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETS2101-001|A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours|A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumours||e-Therapeutics PLC|Yes|Completed|January 2012|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489826||94268|
NCT01490086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVP-20-001|RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder|REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder|REFRESH|Reviva Pharmaceuticals|Yes|Completed|December 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|234|||Both|18 Years|65 Years|No|||January 2015|January 20, 2015|December 7, 2011|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01490086||94248|
NCT01490099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX1729-1784|Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Cross-over Glucose Clamp Trial to Demonstrate Bioequivalence Between Insulin Detemir Produced by the NN729 Process and Insulin Detemir Produced by the Current Process in Healthy Subjects||Novo Nordisk A/S|No|Completed|August 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|55 Years|No|||February 2016|February 5, 2016|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01490099||94247|
NCT01490658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN4440-1753|Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers|A Randomized, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Volunteers||Novo Nordisk A/S|No|Completed|June 2006|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|45 Years|No|||March 2015|March 23, 2015|December 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01490658||94205|
NCT01490671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-019|Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women|Phase 2 Expanded Safety Study of Tenofovir Gel in Pregnancy||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Withdrawn||||August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Actual|0|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 1, 2015|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490671||94204|
NCT01490983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RexCCWF1|Telemonitoring Study - for Chronic Myeloid Leukemia (CML)|Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy||Rex Cancer Center, Raleigh, NC|No|Active, not recruiting|April 2009|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|48|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490983||94180|
NCT01487122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOjaao|Microwave Diathermy for Treating Nonspecific Chronic Neck Pain|Microwave Diathermy for Treating Nonspecific Chronic Neck Pain. A Randomised Controlled Trial|MOFIS|Health Service of Andalucia|No|Completed|September 2008|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|145|||Both|18 Years|65 Years|No|||December 2011|December 6, 2011|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01487122||94476|
NCT01487135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-012|Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects|A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.|TQT|FORUM Pharmaceuticals Inc|No|Completed|December 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 9, 2014|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487135||94475|
NCT01457820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010CV30|Allopurinol in Acute Coronary Syndrome|Allopurinol as a Possible New Therapy for Acute Coronary Syndromes:The Next Steps|ALLACS|University of Dundee|No|Terminated|April 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|85 Years|No|||May 2015|May 26, 2015|October 17, 2011||No|slow recruitment: stopped early|No||https://clinicaltrials.gov/show/NCT01457820||96719|
NCT01457508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/054|Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately|Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Vaccine Mixed With Hib Vaccine to Healthy Infants at 3, 5 and 11 Months of Age, Compared to Each Vaccine Administered Separately||GlaxoSmithKline||Completed|January 1999|March 2000|Actual|March 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|440|||Both|12 Weeks|16 Weeks|Accepts Healthy Volunteers|||October 2011|October 20, 2011|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457508||96743|
NCT01457521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000|Pain Control In First Trimester Medical Abortion: A Randomized Trial|PAIN CONTROL IN FIRST TRIMESTER MEDICAL ABORTION: A Randomized Trial||Gynuity Health Projects|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Female|N/A|N/A|No|||October 2015|December 10, 2015|October 20, 2011||No||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01457521||96742|
NCT01468909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-03635|Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2011|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||October 2015|March 4, 2016|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01468909||95872|
NCT01468285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S108.4.104|The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow|A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Effect of Betahistine on Cerebral Blood Flow and Gait in Subjects at Risk of Falling|CBF|Abbott|No|Completed|February 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|N/A|No|||May 2013|May 29, 2013|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468285||95919|
NCT01464788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0464|Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke|ARTSS-2: A Pilot, Phase 2b, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke|ARTSS-2|The University of Texas Health Science Center, Houston|Yes|Terminated|October 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|November 1, 2011|Yes|Yes|Begin a new study to test the safety of combining IA with tPA and Argatroban.|No||https://clinicaltrials.gov/show/NCT01464788||96186|
NCT01455805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS2011UK|Minuteman Spinal Fusion Implant Versus Surgical Decompression for Lumbar Spinal Stenosis|Efficacy and Quality of Life Following Treatment of Lumbar Spinal Stenosis, Spondylolisthesis or Degenerative Disc Disease With the Minuteman Interspinous Interlaminar Fusion Implant Versus Surgical Decompression||Spinal Simplicity LLC|Yes|Recruiting|June 2012|December 2020|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01455805||96872|
NCT01455792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-09143c2009/2183|Biopsy Study Comparing MRI and Ultrasound Soft Image Fusion Guided Biopsies and Gold Standard Prostate Biopsies.|MRI and Ultrasound Soft Image Fusion Guided Biopsies Compared to Gold Standard Prostate Biopsies||Oslo University Hospital|Yes|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|200|||Male|N/A|N/A|No|||December 2013|December 27, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01455792||96873|
NCT01456169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491CLD_307|A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone|A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg Monotherapy||Takeda|No|Completed|October 2011|January 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|507|||Both|18 Years|N/A|No|||March 2014|March 21, 2014|October 18, 2011|Yes|Yes||No|December 26, 2013|https://clinicaltrials.gov/show/NCT01456169||96844|
NCT01456793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR-06549-1|Evaluation of the Effectiveness of the Teen Options to Prevent Pregnancy (T.O.P.P.) Program|Evaluation of the Effectiveness of the Teen Options to Prevent Pregnancy (T.O.P.P.) Program||Mathematica Policy Research, Inc.|No|Active, not recruiting|October 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|598|||Female|10 Years|19 Years|No|||April 2015|March 21, 2016|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01456793||96796|
NCT01488734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0899|Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom|Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom||Icahn School of Medicine at Mount Sinai|No|Completed|November 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|47|||Both|30 Years|90 Years|No|||October 2013|October 21, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488734||94352|
NCT01459978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRQ1032|Impact of Monitoring Quality Indicators in Maternity Departments on Mother and Infant Health|Impact of Using Cumulative SUM (CUSUM) Control Chart in Maternity Department on Mother and Infant Health: a Cluster Randomized Trial|MATICUS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2012|November 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|60000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Participating Center        Ten Maternity departments in France will participate to the study (Table1)|July 2015|July 27, 2015|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01459978||96553|
NCT01455649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR17T|Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults|A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium Compared to Patients Who Will Maintain the Use of Calcineurin Inhibitor||Hospital Federal de Bonsucesso|No|Not yet recruiting|November 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||October 2011|October 19, 2011|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455649||96884|
NCT01455636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000014576|Preventing Linear Growth Faltering Among Low Birth Weight Infants in Bangladesh|Preventing Linear Growth Faltering and Reversal of Stunting Among Low Birth Weight Infants in Bangladesh: a Community-based Cluster Randomized Control Trial||The Hospital for Sick Children|No|Completed|June 2010|April 2012|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|467|||Both|N/A|N/A|No|||June 2015|June 30, 2015|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01455636||96885|
NCT01455961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VD-NS-1101|An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder|An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder Treated With Quetiapine XR and/or Quetiapine IR|REED|AstraZeneca|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|16000|||Both|N/A|N/A|No|Non-Probability Sample|All patients who have been hospitalised in Sweden at least once since 1987 with a        diagnosis during hospitalisation of Bipolar Disorder.|August 2014|August 20, 2014|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01455961||96860|
NCT01456299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-11-045|Laryngeal Mask Airway (LMA) Insertion With Sevoflurane and Remifentanil|Target-controlled Infusion of Remifentanil for Laryngeal Mask Airway Insertion During Sevoflurane Induction in Adults||Gachon University Gil Medical Center|Yes|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|102|||Both|18 Years|60 Years|No|||April 2014|April 17, 2014|October 19, 2011|Yes|Yes||No|February 23, 2014|https://clinicaltrials.gov/show/NCT01456299||96834|
NCT01456572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 122/09|Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People|Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People||University Hospital, Basel, Switzerland|No|Completed|January 2007|July 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|65|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2011|October 18, 2011|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01456572||96813|
NCT01456585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 14211|Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma|Phase 1 Study of Preoperative Gemcitabine Plus CP-870,893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patient With Newly Diagnosed Resectable Pancreatic Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456585||96812|
NCT01456858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPS_210_202_01033/01034/01035|Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies|Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies: an Observational Cohort Study in a Refugee Setting in Sierra Leone||The Mentor Initiative|Yes|Completed|December 2003|July 2004|Actual|July 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|222|||Both|4 Months|36 Months|Accepts Healthy Volunteers|||November 2003|October 20, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01456858||96791|
NCT01458431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGR-LB-2010-01|Levobupivacaine to the Surgical Wound Following Cesarean|Efficacy of Continuous Infusion of Levobupivacaine to the Surgical Wound Following Cesarean||Complexo Hospitalario Universitario de A Coruña|Yes|Completed|October 2011|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|45 Years|No|||October 2011|December 20, 2014|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01458431||96672|
NCT01458080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115885|WEUSKOP5410: Observational Study in ENABLE Clinical Trials|WEUSKOP5410: A Retrospective Observational Non-Interventional Nested Case Control Study to Evaluate the Risk for Thromboembolic Events Associated With Surgery and Eltrombopag Exposure in the ENABLE Studies||GlaxoSmithKline|No|Completed|May 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|The study population for this study comprised all patients who participated in both the        open-label phase and the randomization phase of any of ENABLE 1 or ENABLE 2 clinical        trials.|December 2013|December 5, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01458080||96699|
NCT01468636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oral Zinc RTC|A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts|A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts||University of British Columbia|No|Not yet recruiting|November 2011|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|242|||Both|19 Years|N/A|No|||November 2011|November 15, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01468636||95892|
NCT01468922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120009|Pazopanib and ARQ 197 for Advanced Solid Tumors|Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Completed|October 2011|February 2016|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|120 Years|No|||January 2016|February 17, 2016|November 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468922||95871|
NCT01456195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_301|Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes||Takeda|Yes|Completed|November 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|421|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456195||96842|
NCT01456208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999P002189|Genetic Mechanisms in Human Hypertension|Vascular Disease and Hbp: Pai-1, Insulin and Genes (Crc): Hypertension Phenotype||Brigham and Women's Hospital|Yes|Recruiting|October 1999|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1000|||Both|18 Years|65 Years|No|||January 2016|January 11, 2016|September 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456208||96841|
NCT01456221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-2011-785-037|Intervention Study With Omega-3 Fatty Acids for Weight Loss and Insulin Resistance in Adolescents|The Impact of Using omega3 Long-chain Polyunsaturated Fatty Acids in Weight Loss and Insulin Resistance in Obese Adolescents|O3WLIRADOL|Coordinación de Investigación en Salud, Mexico|Yes|Active, not recruiting|July 2012|July 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|366|||Both|12 Years|18 Years|No|||February 2016|February 3, 2016|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01456221||96840|
NCT01456182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFX-2-2010-1|Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia|Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia||Afexa Life Sciences Inc|No|Withdrawn|December 2011|May 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|5||Actual|0|||Both|18 Years|N/A|No|||January 2012|January 23, 2012|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456182||96843|
NCT01456468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012007734|Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis|Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis - A Human Pilot Study||Yale University|No|Active, not recruiting|October 2011|December 2015|Anticipated|June 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||June 2015|June 30, 2015|October 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456468||96821|
NCT01488721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLD-0001|Clinical Evaluation of NeoPlex4 Assay and NeoPlex System|Clinical Evaluation of the xMAP® NeoPlex4™ Assay for Detection of T4, TSH, 17-OHP and IRT Using the NeoPlex System||Luminex Molecular Diagnostics|No|Completed|December 2011|April 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|7462|||Both|N/A|7 Days|Accepts Healthy Volunteers|Probability Sample|Specimens will be derived from prospectively collected neonatal specimens and banked        neonatal specimens originating from hospitals, birthing centers, and/or clinics. Newborn        screening is currently performed on all neonates; there is no selection criterion for        subjects.|August 2012|August 16, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488721||94353|
NCT01488461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 08034|Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias|Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias|ATAXIC|Assistance Publique - Hôpitaux de Paris|No|Completed|January 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Family-Based||1|Actual|165|Samples With DNA|Blood sample|Both|N/A|N/A|No|Non-Probability Sample|All types|June 2015|June 12, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488461||94373|
NCT01488474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI 135|Peripheral Nerve Stimulation in Diabetic Patients|Influence of Diabetic Neuropathy on Current Settings During Peripheral Nerve Stimulation in Regional Anesthesia||Medical University of Graz|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|124|Samples With DNA|-  blood samples        -  any material from surgical resections|Both|18 Years|N/A|No|Probability Sample|Surgical patients scheduled for lower limb surgery and are eligible for a popliteal        sciatic nerve block|January 2015|January 29, 2015|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01488474||94372|
NCT01488487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1032|Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma|Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)||UNC Lineberger Comprehensive Cancer Center|Yes|Completed|December 2011|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||March 2014|March 20, 2015|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488487||94371|
NCT01489046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI467-003|Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive|A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose||Bristol-Myers Squibb|Yes|Terminated|February 2011|July 2014|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|301|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|December 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489046||94328|
NCT01459705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112226|Comparing Virtual Reality Exposure Therapy to Prolonged Exposure|Comparing Virtual Reality Exposure Therapy to Prolonged Exposure in the Treatment of Soldiers With Post Traumatic Stress Disorder (PTSD)|VRPE Extension|National Center for Telehealth and Technology|Yes|Completed|October 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|162|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|October 24, 2011||No||No|October 9, 2015|https://clinicaltrials.gov/show/NCT01459705||96574|
NCT01459718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670AGR02|Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload|A Multicenter Open Label Phase II Study to Evaluate the Safety and Efficacy of Deferasirox in Combination With Deferoxamine Followed by Transitioning to Deferasirox Monotherapy in β-thalassemia Patients With Severe Cardiac Iron Overload|MACS1097|Novartis||Completed|January 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459718||96573|
NCT01459731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT 200-47091|Optical Coherence Tomography (OCT) Data Collection Study|Optical Coherence Tomography Data Collection Study||Optovue|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|No eye disease|May 2012|May 1, 2012|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01459731||96572|
NCT01459991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Walnut Study|The Mediterranean Diet and Lactation Study: A Diet Study in Lactating Women|The Mediterranean Diet and Lactation Study: A Diet Study in Lactating Women||University of Arizona|No|Completed|October 2008|October 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|138|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2011|October 26, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459991||96552|
NCT01455987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5203050|Osteochondritis Dissecans of the Knee|Outcome of the Knee Osteochonditis Dissecans Patiets in Kuopio University Hospital (1990-2009): A Retropective Analysis|KYSOCD|Kuopio University Hospital||Enrolling by invitation|June 2010|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|265|||Both|N/A|N/A|No|Probability Sample|Patients who have been treated in Kuopio University Hospital (KUH) district for        osteochondritis dissecans of the knee between 1.1.1990 and 31.12.2009.|October 2011|October 19, 2011|January 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01455987||96858|
NCT01456325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAM4971g|A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)|A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease||Genentech, Inc.||Active, not recruiting|July 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|499|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456325||96832|
NCT01456338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DA016574_PILOT|Cognitive Behavioral Therapy for Post Traumatic Stress Disorder in Addiction Treatment|Cognitive Behavioral Therapy for PTSD in Addiction Treatment: A Randomized Pilot Trial||Dartmouth-Hitchcock Medical Center|No|Completed|June 2007|August 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||October 2011|October 18, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01456338||96831|
NCT01455974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients|||Capital Medical University||Completed|October 2010|September 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|70 Years|No|||October 2011|October 19, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01455974||96859|
NCT01456312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25588|HBsAg Related Response Guided Therapy|A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B:|S-RGT|Gangnam Severance Hospital|No|Recruiting|September 2012|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|October 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01456312||96833|
NCT01456598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-MDB-11-233|Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer|Prospective Multicenter Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer|KLASS-02-RCT|Ajou University School of Medicine|Yes|Active, not recruiting|October 2011|May 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1050|||Both|20 Years|80 Years|No|||June 2015|June 23, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01456598||96811|
NCT01456611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCL-269|Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium 1% Gel (Anchen Pharmaceuticals, Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee||Anchen Pharmaceuticals, Inc|No|Completed|September 2011|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|749|||Both|35 Years|N/A|No|||July 2012|July 10, 2012|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456611||96810|
NCT01456871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004310|Finger Muscle Reaction After Electrical Stimuli to the Human Finger Pulley System; a Pilot Study|Finger Muscle Reaction After Electrical Stimuli to the Human Finger Pulley System; a Pilot Study||Mayo Clinic|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|6|||Female|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|May 2013|May 8, 2013|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01456871||96790|
NCT01457547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/094|Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course|Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age||GlaxoSmithKline||Completed|October 2003|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|494|||Both|8 Weeks|15 Weeks|Accepts Healthy Volunteers|||October 2011|October 20, 2011|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457547||96740|
NCT01458444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC11-007|BIPAP Vision Versus OPTIFLOW System Comparison in Acute Respiratory Failure After Cardio Thoracic Surgery|Acute Respiratory Failure After Cardio Thoracic Surgery: Non Invasive Ventilation (VNI) by BIPAP Vision Versus OPTIFLOW System, Comparison.|OPTIFLOW|Centre Chirurgical Marie Lannelongue|Yes|Completed|May 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|830|||Both|18 Years|N/A|No|||August 2015|August 30, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01458444||96671|
NCT01458691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM-11-02|Intra-articular Injection of Allogeneic Platelet Rich Plasma (PRP) for Adhesive Capsulitis|Intra-articular Injection of Allogeneic PRP for Adhesive Capsulitis||Seoul National University Hospital|No|Completed|September 2013|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01458691||96652|
NCT01458704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cancer genome analysis|Cancer Genome Analysis|Cancer Genome Analysis||Seoul National University Hospital||Recruiting|August 2011|||April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|fresh frozen tumor tissue|Both|18 Years|N/A|No|Non-Probability Sample|patients with malignant tumor receiving or planning to receive chemotherapy with fresh        frozen tumor tissue with informed consent|October 2011|October 24, 2011|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01458704||96651|
NCT01464814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N21-2011|Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules|A Double Blind Placebo Controlled Crossover Clinical Trial Evaluating The Viability Of KE-99 With Fish Oil In Healthy Adults|Probiomega|Nutrition 21, Inc.|No|Recruiting|October 2011|November 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|15|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||November 2011|November 11, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01464814||96184|
NCT01465048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC049|Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe|A Pilot Study to Optimise Controlled Human Malaria Infections Using Plasmodium Falciparum Sporozoites Administered by Needle and Syringe||University of Oxford|Yes|Completed|October 2011|February 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|October 27, 2011|Yes|Yes||No|April 8, 2013|https://clinicaltrials.gov/show/NCT01465048||96166|
NCT01487655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S271111|Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Glaucoma Patients|Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Primary Open-angle and Normal Tension Glaucoma Patients||Universitaire Ziekenhuizen Leuven|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|primary care clinic|September 2011|February 5, 2013|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01487655||94435|
NCT01487928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29743|Human Milk Cream as a Caloric Supplement in Pre-Term Infants|A Randomized Study of the Use of Human Milk Cream as a Caloric Supplement in a Subset of Very Low Birth Weight Pre-Term Infants||Baylor College of Medicine|No|Completed|December 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|78|||Both|N/A|21 Days|No|||June 2015|June 15, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487928||94414|
NCT01487941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56|Setrox JS Master Study|Efficacy and Safety of the Setrox JS Lead (J=J-shaped, S=Screw)||Biotronik SE & Co. KG|No|Completed|December 2011|October 2014|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|66|||Both|18 Years|N/A|No|Probability Sample|Patients with pacemaker indication|November 2014|November 19, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487941||94413|
NCT01488214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-A01313-54|Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis|Assessment of Neuropsychiatric Involvement in Systemic Sclerosis.|NeuroScS|University Hospital, Lille|No|Recruiting|February 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|108|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01488214||94392|
NCT01488500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOODSMOKE II|Woodsmoke Exposure and Cardiovascular Function|Cardiovascular Effects of Experimental Exposure to Woodsmoke in Man||University of Edinburgh|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 3, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488500||94370|
NCT01488747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC023|Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride|Bioavailability of Fish Oils: Emulsified vs. Capsular Triglyceride||USDA Grand Forks Human Nutrition Research Center|Yes|Active, not recruiting|November 2011|June 2016|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488747||94351|
NCT01488760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRACINI|Abdominal Wall Evaluation in Low Back Pain|Deep Abdominal Wall Muscle Dysfunction During Calm Respiration in Chronic Low Back Pain Patients||University of Sao Paulo General Hospital|No|Completed|December 2009|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|39|||Female|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|December 2011|December 6, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488760||94350|
NCT01489033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-PHL-P1-001|Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense|Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Phleum Pratense.||BIAL Industrial Farmacéutica S.A.|No|Completed|January 2010|May 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|42|||Both|18 Years|60 Years|No|||December 2011|December 8, 2011|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489033||94329|
NCT01489059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA220-007|Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma|A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma||Bristol-Myers Squibb|No|Completed|December 2011|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|42|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|December 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489059||94327|
NCT01489345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2952POU002|Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd|No|Completed|December 2011|||April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|December 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489345||94305|
NCT01455662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10086|Relationship Between Tissue Markes in Patients With Post Cardio Respiratory Syndrome|Relationship Between Lactate and Venous Oxygen Saturation Gradient of Carbon Dioxide in Patients With Post Cardio Respiratory Syndrome||Hospital Nossa Senhora da Conceicao|Yes|Recruiting|January 2010|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Probability Sample|patients hospitalized in the intensive care unit after cardiopulmonary arrest|November 2011|November 2, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01455662||96883|
NCT01455675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PsAer-IgY|Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients|Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients|PsAer-IgY|Mukoviszidose Institut gGmbH|Yes|Active, not recruiting|October 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|164|||Both|5 Years|N/A|No|||August 2015|August 4, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455675||96882|
NCT01456000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25-3002|Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)|Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) or HEARTLIGHT for the Treatment of Symptomatic Atrial Fibrillation|HeartLight|CardioFocus|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|75 Years|No|||July 2015|July 30, 2015|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456000||96857|
NCT01456013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGS001D|Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients|A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory|CIN-RG|PLC Medical Systems, Inc.|Yes|Recruiting|January 2012|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|326|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456013||96856|
NCT01456897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-003|A Long-term Trial of OPC-34712 in Patients With Schizophrenia|||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|October 2011|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|18 Years|N/A|No|||September 2015|September 15, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01456897||96788|
NCT01456624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0686|Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fasting and Fed Condition|A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of DW-ES(B) and Megace® Under Fasting and Fed Conditions in Healthy Male Volunteers||Asan Medical Center|No|Completed|September 2011|||June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|56|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01456624||96809|
NCT01456637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPG-20106524|Online Self-Help Intervention for Insomnia: With or Without Feedback|Online Self-Help Intervention for Insomnia: With or Without Feedback||Utrecht University|Yes|Completed|October 2011|December 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|262|||Both|18 Years|N/A|No|||January 2013|January 7, 2013|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01456637||96808|
NCT01456884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02440|Music Therapy for Pain Modification in Pediatric Palliative Care|Music Therapy as a Pain Modifying Intervention in Children With Life-limiting Neurological Impairments and Metabolic Conditions||University of British Columbia|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Both|12 Months|19 Years|No|||April 2015|April 22, 2015|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01456884||96789|
NCT01457222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/345|Cognition and Health in Adolescents, Mindfulness as Prevention of Stress.|Mindfulness as a Method of Improving Mental Health and Cognitive Results and Decreasing Stress in Secondary School Students; a Prospective Randomised Controlled Single-blinded Pilot Study|CHAMPS|Region Skane|No|Active, not recruiting|October 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Anticipated|150|||Both|15 Years|20 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01457222||96765|
NCT01457534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0671|The Predictors for Continuous Renal Replacement Therapy in Liver Transplant Patient|||Yonsei University|No|Completed|January 2011|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|148|||Both|19 Years|65 Years|No|Non-Probability Sample|the data of 148 liver transplant patients from January 2008 to December 2011 at Severance        Hospital, Yonsei University HealthSystem, in Seoul, Korea. The number of patients treated        with CRRT was 44 (18 patients from living and 26 from deceased donors) and those without        CRRT was 104.|February 2013|February 26, 2013|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01457534||96741|
NCT01457560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/060|Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine|Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Mixed With Hib Vaccine in Healthy Infants, Followed by a Dose of the Same Vaccine Administered Simultaneously With One Dose of Oral Polio Vaccine (OPV)||GlaxoSmithKline||Completed|February 2000|April 2001|Actual|April 2001|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|80|||Both|12 Weeks|16 Weeks|Accepts Healthy Volunteers|||October 2011|October 20, 2011|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457560||96739|
NCT01458093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURV_2011|Large Overuse of Post-polypectomy Surveillance Colonoscopy|Large Overuse of Post-polypectomy Surveillance Colonoscopy: a Prospective Nation-wide Study||Valduce Hospital|No|Completed|July 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|7081|||Both|18 Years|80 Years|No|Non-Probability Sample|All patients referred to one out of 29 endoscopy units in Italy to undergo colonoscopy|October 2011|October 20, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01458093||96698|
NCT01458457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBK|Life Quality and Mental State in Patients With Breast Cancer|Life Quality and Mental State in Patients With Breast Cancer - a Randomized Study|BBK|Charite University, Berlin, Germany|No|Completed|May 2011|July 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|275|||Female|N/A|N/A|No|||February 2015|February 13, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01458457||96670|
NCT01458717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BorderlinePancreas|Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer|Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer||Seoul National University Hospital|Yes|Recruiting|November 2011|December 2017|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|75 Years|No|||January 2014|January 2, 2014|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01458717||96650|
NCT01455818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009600-01H|A Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound|A Multicenter Prospective Cohort Management Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound|SSPE|Ottawa Hospital Research Institute|Yes|Recruiting|March 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with symptomatic, isolated SSPE* (any number), that are newly        diagnosed by computed tomographic pulmonary angiography will be eligible to participate in        the study.|February 2015|February 4, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455818||96871|
NCT01456234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAI-002-11|Time to Oseltamivir Access When Prescribed by Pharmacists Versus Physicians (ACCESS)|Comparison of Time From Symptom Onset to Oseltamivir Access When Oseltamivir is Prescribed by Pharmacists vs. Physicians and the Impact on Symptoms, Oseltamivir Resistance, and Patient Safety|Access|Trial Management Group Inc.|No|Terminated|November 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|48|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|October 18, 2011||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01456234||96839|
NCT01456247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/OCT-302|Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin|A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin||Takeda|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|439|||Both|20 Years|N/A|No|||May 2014|May 7, 2014|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01456247||96838|
NCT01487954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2109|Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy|Alkaline Water Consumption to Reduce Skin Radiation Toxicity in Women With Breast Cancer||Case Comprehensive Cancer Center|Yes|Completed|May 2010|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|45|||Female|18 Years|N/A|No|||June 2015|June 1, 2015|December 5, 2011||No||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01487954||94412|
NCT01487967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008315|Preference and Goal Directed Attention Deficit Hyperactivity Disorder Care- Pilot Study|Preference and Goal-Directed Primary Care to Minimize Disparities and Improve Outcomes in ADHD||Children's Hospital of Philadelphia|No|Active, not recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|12 Years|No|||March 2016|March 15, 2016|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487967||94411|
NCT01488227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR033173|A Prospective Trial on the Effects of Vitamin D Supplementation in Collegiate Swimmers and Divers|A Prospective Trial on the Effects of Vitamin D Supplementation on 25(OH)D, Body Composition and Injury in Collegiate Swimmers and Divers||University of Kentucky|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 22, 2013|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488227||94391|
NCT01488513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTO 101504|ABC294640 in Treating Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors|ABC-101|RedHill Biopharma Limited|Yes|Completed|August 2011|July 2015|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488513||94369|
NCT01488773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|adamusiak-01|Comparison of Two Treatment Regimens in Asthmatic Patients|A Four Year Observational Study Comparing Two Treatment Regimens: Inhaled Glucocorticosteroid + Salmeterol and Inhaled Glucocorticosteroid + Montelukast.||Medical Universtity of Lodz|No|Completed|April 1995|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||2|Actual|132|||Both|N/A|N/A|No|Non-Probability Sample|The study population consisted of 5563 patients continuously treated for bronchial asthma        (28% of all patients) at the Outpatient Asthma and Allergy Treatment Center, Chair of        Clinical Immunology and Microbiology, Medical University of Lodz, Poland in the period        from April 1995 through June 2006.|January 2012|January 10, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488773||94349|
NCT01488786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCB1-010|A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind|A Study to Evaluate the Safety and Efficacy of the BrainPort® Vision Device in Subjects Who Are Blind||Wicab|Yes|Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|75|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488786||94348|
NCT01459198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 275|Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV MEDI ΔM2-2 Lot RSV#002A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, RSV-Seropositive Children 12 to 59 Months of Age, and RSV-Seronegative Infants and Children 6 to 24 Months of Age||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2011|August 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|7||Actual|60|||Both|6 Months|49 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|October 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01459198||96613|
NCT01460004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Winphys01|The Effect of Infrapatellar Strap Treatment on Pain Extent and Athletic Measures in Young Athletes|The Effect of Infra Patellar Strap Treatment on the Extent of Pain and Performance in Young Athletes With Patellar Tendinopathy||Wingate Institute|No|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Male|14 Years|18 Years|No|||July 2015|July 16, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01460004||96551|
NCT01456351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHL 2-2003|Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab|Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas||University of Giessen|No|Completed|September 2003|December 2010|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01456351||96830|
NCT01456364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-DHM A01811|Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing|Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention|ISAR ADAPT PF|Deutsches Herzzentrum Muenchen|Yes|Recruiting|September 2011|May 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||October 2013|October 31, 2013|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01456364||96829|
NCT01456650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNSZ-ABCA1|R230C and C230C Variants of ABCA1 and Glyburide Response|Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|March 2011|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|85|||Both|20 Years|79 Years|No|||January 2014|January 14, 2014|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01456650||96807|
NCT01456663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2123|A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects|A Single-dose, Open-label, Parallel Study to Assess the Pharmacokinetics of AFQ056 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects||Novartis||Completed|May 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|118|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|August 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456663||96806|
NCT01456676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107Y2101|Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy|A Single-arm Dose-finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE225 in Combination With Nilotinib in Chronic or Accelerated Phase of Chronic Myeloid Leukemia Patients Who Have Failed Prior Therapy With Other BCR-ABL Tyrosine-kinase Inhibitors||Novartis||Completed|January 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456676||96805|
NCT01457235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-039|The Effects of Cognitive Remediation on Cognitive Function in Remitted Bipolar Disorder - a Proof of Concept Study|The Effects of Cognitive Remediation on Cognitive Function in Remitted Bipolar Disorder - a Proof of Concept Study (REMEDI)|REMEDI|Rigshospitalet, Denmark|No|Completed|August 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|50 Years|No|||January 2014|January 29, 2014|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01457235||96764|
NCT01457573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 0711-0124|Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms|Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial|LUTS|The Methodist Hospital System|No|Completed|October 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|50 Years|N/A|No|||July 2014|July 16, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457573||96738|
NCT01457586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart surgery hemoderivatives|Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery|Observational Study of Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery||Hospital Pitangueiras|Yes|Recruiting|September 2011|October 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|N/A|N/A|No|||October 2011|October 21, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457586||96737|
NCT01457833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protokoll E1.0-23.05.2011|Implantation of Endobronchial Valves Versus Intrabronchial Valves in Patients With Severe Heterogeneous Emphysema|Endoscopic Lung Volume Reduction by Implantation of Endobronchial Valves (EBV) vs. Intrabronchial Valves (IBV) in Patients With Severe Heterogeneous Emphysema||Heidelberg University||Recruiting|August 2011|May 2012|Anticipated|May 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|N/A|No|||October 2011|October 21, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457833||96718|
NCT01457846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2610C00004|Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients|A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy Versus Paclitaxel in Patients With Advanced Gastric Adenocarcinoma (Inc. Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction)With FGFR2 Polysomy or Gene Amplification.|SHINE|AstraZeneca||Completed|November 2011|February 2015|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|960|||Both|25 Years|N/A|No|||April 2015|April 15, 2015|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01457846||96717|
NCT01457859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0228.CTIL|Effectiveness of Triclosan Coated Sutures in Preventing Leg Wound Infection After Coronary Artery Bypass Surgery|Effectiveness of Triclosan Coated VICRYL\MONOCRYL Sutures in Preventing Leg Wound Infection Compared to POLYSORB\ BIOSYN Sutures in Patients After Coronary Bypass Surgery- a Randomized Controlled Trial||Rambam Health Care Campus|No|Not yet recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|410|||Both|18 Years|N/A|No|||October 2011|October 21, 2011|October 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457859||96716|
NCT01458106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8HA02PED|Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A|An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A|Kids ALONG|Biogen|Yes|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Male|N/A|11 Years|No|||June 2015|June 15, 2015|October 20, 2011|Yes|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01458106||96697|
NCT01458470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01364|A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease|A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study|MITIGATE-HD|University of British Columbia|Yes|Completed|September 2011|November 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|75 Years|No|||March 2014|March 17, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01458470||96669|
NCT01455857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-103|A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes||Intarcia Therapeutics|Yes|Completed|March 2013|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|460|||Both|18 Years|80 Years|No|||July 2015|July 28, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455857||96868|
NCT01455870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-105|A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes||Intarcia Therapeutics|Yes|Completed|May 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|535|||Both|18 Years|80 Years|No|||July 2015|July 29, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455870||96867|
NCT01455883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITCA 650-CLP-106|A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes||Intarcia Therapeutics||Withdrawn|February 2013|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||December 2012|December 21, 2012|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455883||96866|
NCT01455831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221097|Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer|A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer|PERIOP-01|Ottawa Hospital Research Institute|Yes|Recruiting|September 2011|August 2023|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1075|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455831||96870|
NCT01455844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-API-NKPL66-CT-PII|TRIal For Efficacy of Capre on hyperTriglyceridemiA|A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia|TRIFECTA|Acasti Pharma Inc.|No|Completed|September 2011|August 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|387|||Both|18 Years|75 Years|No|||August 2014|August 21, 2014|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01455844||96869|
NCT01456494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16900A|Teaching Use of Respiratory Inhalers (TURI)|Teaching Use of Respiratory Inhalers (TURI)|TURI|University of Chicago|Yes|Completed|July 2009|July 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|50|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01456494||96819|
NCT01456507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531003|Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone|An Open-Label, Single-Dose, Randomized, Three-Way Crossover Study in Healthy Volunteers to Estimate the Effects of Food and of Sprinkling ALO-02 Pellets on Applesauce on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Pellets-in-Capsule Formulation of Oxycodone 40 Mg With Sequestered Naltrexone 4.8 Mg||Pfizer|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456507||96818|
NCT01487980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCC-LBW-SA|Effect of Delayed Cord Clamping on Haematological Status in Low Birth Weight Infants|The Effect of Delayed Cord Clamping on Haematological Status in Low Birth Weight Infants: a Randomised Controlled Trial in South Africa.||Stanger Hospital|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|102|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 15, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487980||94410|
NCT01488240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011: 074|The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars|The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars||University of Manitoba|No|Recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488240||94390|
NCT01489072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM 2012-002|Efficacy of Two Bolus Doses of Remifentanil on the Incidence of Coughing During Emergence of Anesthesia|Comparison of the Efficacy of Two Bolus Doses of Remifentanil on the Incidence of Coughing During Emergence of Anesthesia.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|180|||Both|18 Years|80 Years|No|||October 2012|October 25, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01489072||94326|
NCT01489358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120041|Chikungunya Virus Vaccine Trial in Healthy Adults|VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults||National Institutes of Health Clinical Center (CC)||Completed|December 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2013|October 23, 2014|December 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489358||94304|
NCT01456026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exogene-AGE|Effects of Food Advanced Glycation Endproducts on Vascular Function in Diabetes|Acute Effects of Food Advanced Glycation Endproducts on Macrovascular Function in Subjects With Type 2 Diabetes Mellitus||Profil Institut für Stoffwechselforschung GmbH|No|Completed|June 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|19|||Both|20 Years|70 Years|No|||October 2011|October 18, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01456026||96855|
NCT01456039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROMI-TCL-001|A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)|A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma||Celgene|No|Active, not recruiting|December 2011|June 2018|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|20 Years|N/A|No|||January 2016|January 15, 2016|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456039||96854|
NCT01456052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-204-UC|A Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis|Phase 2 Assessment of the Relationship Between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Preliminary Efficacy of Orally Administered LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis||Lexicon Pharmaceuticals|No|Completed|December 2011|||August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|70 Years|No|||March 2015|March 10, 2015|October 17, 2011|Yes|Yes||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01456052||96853|
NCT01456065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRT-I-L01 Ovar|Safety of Active Immunotherapy in Subjects With Ovarian Cancer|A Phase I, Open, Randomized, Study to Investigate the Safety of Active Immunotherapy With Fully Mature, TERT-mRNA and Survivin - Peptide Double Loaded Dendritic Cells (DCs) in Subjects With Advanced Epithelial Ovarian Cancer, Enrolled in the Study Within Twelve Weeks After Completing Primary Therapy||Life Research Technologies GmbH|Yes|Active, not recruiting|September 2010|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Female|18 Years|75 Years|No|||February 2013|February 28, 2013|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01456065||96852|
NCT01456377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1892/10|The Effectiveness of Oral Corticosteroids in the Treatment of Lumbar Stenosis|A Prospective Controlled Study Randomized Double Blind Study, Evaluate the Effectiveness of Oral Corticosteroids in the Treatment of Stenosis of Lumbar Canal In Symptomatic Patients||Federal University of São Paulo|Yes|Recruiting|July 2011|June 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|75 Years|No|||October 2011|October 19, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01456377||96828|
NCT01456949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOP AF PAS|Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)|Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)|STOP AF PAS|Medtronic Atrial Fibrillation Solutions|Yes|Active, not recruiting|May 2012|January 2020|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456949||96784|
NCT01456910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0018.0.012.000-09|Resistance Training Program, Labor Inclusion, Intellectual Disability|Evaluation and Effects of a Resistance Training Program and Its Relationship With the Labor Inclusion of the Disabled Intellectual||University of Brasilia|No|Completed|June 2009|December 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|40|||Both|14 Years|36 Years|No|||October 2011|October 24, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01456910||96787|
NCT01456923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCRC10|Chemotherapy With DNA Damaging Agents In Colorectal Cancer|Phase 1 Study Of The Efficacy Of Chemotherapy With DNA Damaging Agents Versus Surgery In Colorectal Cancer||Centro Hospitalar Nordeste||Completed||||||Phase 1|Interventional|Primary Purpose: Treatment|2||||||Both|40 Years|90 Years|No|||September 2008|October 20, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01456923||96786|
NCT01457248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMGS-2011-1|Taper-shaped Cuff Endotracheal Tube Against Respiratory Infections|Effect of Endotracheal Tube With Taper-shaped Cuff on Incidence of Postoperative Pneumonia After Aortic Surgery|TETRIS|Groupe Hospitalier Pitie-Salpetriere|Yes|Completed|October 2011|June 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|162|||Both|N/A|N/A|No|||July 2014|July 2, 2014|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01457248||96763|
NCT01457261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBHIPF02|IPF Drug Deposition Study|A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)|TOPICAL-IPF|Royal Brompton & Harefield NHS Foundation Trust|No|Completed|April 2012|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|10|||Both|40 Years|N/A|No|||November 2014|November 4, 2014|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457261||96762|
NCT01457599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-621000-0274-002|Computertomography-guided Wire Marking of the Liver|Computertomography-guided Wire Marking of Colorectal Hepatic Metastases After Complete Response to Neoadjuvant Chemotherapy. A Pilot Study||Medical University of Graz|No|Recruiting|July 2011|April 2016|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Tertiary care clinic|September 2015|September 21, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01457599||96736|
NCT01457612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR2 2011-076|Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)|Effect of 6 Weeks Strawberry Supplementation on Insulin Action and Associated Risk Factors in Insulin Resistant (IR) Subjects (STR2)||Institute for Food Safety and Health, United States|No|Active, not recruiting|October 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457612||96735|
NCT01458119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-041|Open-Label Phase 3 Long-Term Safety Study of Migalastat|An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease|AT1001-041|Amicus Therapeutics|Yes|Completed|October 2011|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|16 Years|N/A|No|||February 2016|February 29, 2016|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458119||96696|
NCT01458756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006_0623|Study of Psychological Defense Mechanisms Used by Liver Transplant Patients|Evaluation of Psychological Defense Mechanisms Used by Liver Transplant Patients on Their Somatic Psychological and Social Outcome. Research for Protective or Vulnerability Factors.|GHEPA|University Hospital, Lille|No|Recruiting|December 2006|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult patients awaiting liver transplantation and registered on the waiting list in the        transplant center of University Hospital of Lille|December 2015|December 1, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01458756||96647|
NCT01456533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMED Study|Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients|Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients|COMED|University Hospital, Basel, Switzerland|No|Completed|October 2011|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|110 Years|No|Probability Sample|hospitalized patients with severe hypo or hypernatremia|November 2015|November 30, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01456533||96816|
NCT01456546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF-380|Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel|Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel||University of Southern Denmark|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|31|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 2, 2013|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01456546||96815|
NCT01456260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/OCT-301|Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)|A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)||Takeda|No|Completed|September 2011|December 2013|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|406|||Both|20 Years|N/A|No|||May 2014|May 7, 2014|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01456260||96837|
NCT01457131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120006|Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Gene Engineered Lymphocytes Cotransduced With Genes Encoding IL-12 and Anti-NY ESO-1 TCR||National Institutes of Health Clinical Center (CC)||Terminated|October 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||August 2013|February 19, 2014|October 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01457131||96771|
NCT01457144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manteau RiBVD|Study of Mantle Cell Lymphoma Treatment by RiBVD|First Line Mantle Cell Lymphoma (MCL) Treatment by RiBVD Schema in Patients Older Than 65 Years or 18 to 65 Years Old Who Cannot or Refuse Receive Conditioning Regimen Followed by Autograft|RIBVD|French Innovative Leukemia Organisation|Yes|Completed|October 2011|March 2016|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|65 Years|85 Years|No|||March 2016|March 15, 2016|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457144||96770|
NCT01457456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM08/2011|Biomarker for Morquio Disease|Biomarker for Morquio Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioMorquio|University of Rostock|Yes|Recruiting|October 2011|November 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml      EDTA blood,sputum tube and a dry blood spot filter card are taken. To proof the correct      Morquio diagnosis in those patients where up to the enrollment in the study no genetic      testing has been done, sequencing of Morquio will be done. The analyses are done in the      Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20,      18055 Rostock (Germany)|Both|12 Months|N/A|No|Probability Sample|Patients with Morquio Disease based upon biochemical and/or genetic criteria|November 2015|November 10, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01457456||96747|
NCT01487993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin 2011-6|Metformin in Obese Children and Adolescents|An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents|MetVoorMin|St. Antonius Hospital|Yes|Active, not recruiting|August 2011|February 2017|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|10 Years|16 Years|No|||September 2015|September 30, 2015|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01487993||94409|
NCT01488253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSBMT2011-01|Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants|Multicenter Trials to Evaluate the Efficacy and Toxicity of Sirolimus/Tacrolimus Combination as a GVHD Prophylaxis After HLA Matched Related PBSCT||The Korean Society of Blood and Marrow Transplantation|Yes|Terminated|January 2012|October 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|3|||Both|20 Years|60 Years|No|||March 2015|March 31, 2015|November 20, 2011||No|We could not receive the support from the national medical insurance owing to the changed    policy of the government for clincal trials.|No||https://clinicaltrials.gov/show/NCT01488253||94389|
NCT01459211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/09/387|Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)|A Pilot Study to Establish the Safety & Efficacy of a Combination of Dexamethasone & Lenalidomide in Patients With Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)|LenD|University College, London|Yes|Active, not recruiting|May 2012|||November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01459211||96612|
NCT01459458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11050458|Family Planning-based Partner Abuse Intervention to Reduce Unintended Pregnancy|Family Planning-based Partner Abuse Intervention to Reduce Unintended Pregnancy||University of Pittsburgh|Yes|Completed|October 2011|September 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3687|||Female|16 Years|29 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01459458||96593|
NCT01459471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEND-11-0905|Staple-line Reinforcement During Laparoscopic Sleeve Gastrectomy Using Three Different Techniques: a Randomized Trial|Staple-line Reinforcement During Laparoscopic Sleeve Gastrectomy Using Three Different Techniques: a Randomized Trial||University of Rome Tor Vergata|Yes|Completed|April 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|28 Years|59 Years|No|||October 2011|October 21, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01459471||96592|
NCT01455701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25737|A Study of RoActemra/Actemra (Tocilizumab) in Patients Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis|A Phase I Pharmacokinetic and Safety Study of Tocilizumab (TCZ) in Patients Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)||Hoffmann-La Roche||Recruiting|October 2012|February 2018|Anticipated|February 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|24 Months|No|||March 2016|March 1, 2016|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01455701||96880|
NCT01456078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2011-000240-16|A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors|A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors|ILUMINET|Lund University Hospital|No|Recruiting|October 2011|October 2018|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||February 2016|February 16, 2016|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01456078||96851|
NCT01456390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-023|Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents|A Prospective Evaluation of Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin||Glaukos Corporation|No|Active, not recruiting|September 2011|April 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01456390||96827|
NCT01456689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLGH447X2101|A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma|A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma||Novartis||Recruiting|April 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|77|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|October 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456689||96804|
NCT01456702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VoMo|Risk Stratification and Goal-directed Volume Therapy|Influence of Pre-operative Risk Stratefiction and Intraoperaitve Monitoring on Perioperative Volume Therapy and Postoperative Outcome||Charite University, Berlin, Germany|No|Not yet recruiting|October 2014|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2013|December 30, 2013|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01456702||96803|
NCT01456936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051123|Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders|A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders|EAGLES|Pfizer|Yes|Completed|November 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|8133|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01456936||96785|
NCT01456962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1265|Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract|Influence of Raltegravir-Containing Antiretroviral Therapy (ART) on Immune Reconstitution and Activation in the Female Genital Tract||University of Colorado, Denver|No|Completed|October 2011|||August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|36|Samples Without DNA|Blood, vaginal fluid samples, cervical biopsies|Female|18 Years|80 Years|No|Non-Probability Sample|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with        raltegravir (RAL) compared to tenofovir (TDF) and emtricitabine (FTC) and ritonavir        (RIT)-boosted atazanavir (ATZ)|December 2014|June 8, 2015|October 6, 2011||No||No|May 18, 2015|https://clinicaltrials.gov/show/NCT01456962||96783|
NCT01457274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.066|"Light" Versus "Deep" Bispectral Index (BIS) Guided Sedation for Colonoscopy|A Randomised Controlled Trial of "Light" Versus "Deep" Sedation for Elective Outpatient Colonoscopy: Recall, Procedural Conditions and Recovery||Melbourne Health|No|Completed|September 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01457274||96761|
NCT01457625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH - 2011 - C - 006|Clinical Study of Serum Fetuin A Level, Insulin Resistance and Hepatic Fat Content in Dialysis Patients|The Association of Serum Fetuin A Level, Insulin Resistance and Hepatic Fat Content and Their Associations With Overall Survival in Maintenance Hemodialysis and Peritoneal Dialysis Patients||Far Eastern Memorial Hospital|Yes|Recruiting|January 2011|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|20 Years|80 Years|No|Probability Sample|Three hundred and fifty ESRD patients undergoing maintenance HD or PD will be recruited        for this prospective investigation.|October 2011|October 20, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457625||96734|
NCT01457872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATRIS|Malmö Treatment Referral and Intervention Study|Malmö Treatment Referral and Intervention Study|MATRIS|Region Skane|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|20 Years|N/A|No|||November 2014|November 24, 2014|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01457872||96715|
NCT01458158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A13749|Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease|The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease|MMACKD|Aristotle University Of Thessaloniki|No|Recruiting|October 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|300|Samples Without DNA|serum and vessels|Both|50 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients from University Hospital AHEPA|February 2015|February 20, 2015|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01458158||96693|
NCT01459315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1733|GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects|Phase I, Open-Label Study in Healthy Male Subjects Describing GSK1349572 Exposure in Blood Plasma, Seminal Fluid and Rectal Mucosal Tissue Following Single and Multiple Dosing||University of North Carolina, Chapel Hill|No|Completed|November 2011|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459315||96604|
NCT01459328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E33034|Resource-Sparing Curative Treatment for Rectal Cancer|Resource-Sparing Curative Treatment for Rectal Cancer||International Atomic Energy Agency|Yes|Recruiting|September 2009|||September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01459328||96603|
NCT01457469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99310|Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer|Adapting Smoking Cessation Interventions for the Outpatient Oncology Setting||Comprehensive Cancer Center of Wake Forest University|No|Completed|January 2011|May 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|6|||Both|18 Years|N/A|No|||July 2015|September 28, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01457469||96746|
NCT01456832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004030|Post Operative Hyponatremia in the Renal Transplant Population|Post Operative Hyponatremia in the Renal Transplant Population||Mayo Clinic|No|Completed|January 2010|October 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|225|||Both|18 Years|N/A|No|Non-Probability Sample|All renal transplant recipients who received a kidney transplant from either a living or        cadaveric donor from 1/1/2010 through 8/19/2011 and subsequently developed post-operative        hyponatremia.|October 2011|October 25, 2011|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01456832||96793|
NCT01458028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14631|Age and Gender Effects on the Pharmacokinetics of BAY85-3934|A Parallel Group, Double-Blind Study to Evaluate the Effects of Age and Gender on the Single-Dose Pharmacokinetics of BAY85-3934, Tablet Formulation||Bayer|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|September 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01458028||96703|
NCT01458041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15439|Iloprost Therapy in Patients With Critical Limb Ischemia|Iloprost Therapy in Patients With Critical Limb Ischemia: Evaluation of Efficacy and Safety||Bayer|No|Completed|August 2011|December 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|126|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients|February 2015|February 27, 2015|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01458041||96702|
NCT01458340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0085|A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)||Theravance Biopharma R & D, Inc.|No|Completed|December 2011|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|285|||Both|18 Years|45 Years|No|||March 2015|March 4, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458340||96679|
NCT01488526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US 174-0174|Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus|Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers||New Discovery LLC|Yes|Active, not recruiting|December 2011|||February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|20 Years|35 Years|No|||June 2015|June 7, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01488526||94368|
NCT01488799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP114909|Motivational Interviewing and Cognitive Behavioural Therapy for Generalized Anxiety Disorder|Adding Motivational Interviewing to Cognitive Behavioural Therapy for Severe Generalized Anxiety Disorder||York University|Yes|Completed|January 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|16 Years|65 Years|No|||December 2015|December 28, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488799||94347|
NCT01488812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2029-32|Waiting Time to Operation for Hip-fracture Patients|Waiting Time to Operation for Hip-fracture Patients||Danderyd Hospital|No|Completed|May 2010|May 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|576|||Both|N/A|N/A|No|Non-Probability Sample|Hip fracture patients admitted to Danderyd Hospital Orthopaedic Department from 1st June        2007 to 1st June 2008|April 2015|April 20, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01488812||94346|
NCT01459484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISG/OS-2|ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma|ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)|ISG/OS-2|Italian Sarcoma Group|Yes|Recruiting|July 2011|February 2020|Anticipated|January 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|N/A|40 Years|No|||March 2016|March 2, 2016|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01459484||96591|
NCT01459744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0618|An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations|An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)|WISDOM|Icahn School of Medicine at Mount Sinai|No|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1200|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01459744||96571|
NCT01456091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR06549-2|Evaluation of the Efficacy of the AIM (Adult Identity Mentoring) 4 Teen Moms Program|Evaluation of the Efficacy of the AIM (Adult Identity Mentoring) 4 Teen Moms Program||Mathematica Policy Research, Inc.|No|Completed|October 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|954|||Female|15 Years|19 Years|No|||March 2016|March 21, 2016|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01456091||96850|
NCT01456403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN-002|Histological Validation Of Carotid Plaque Composition In Preoperative Imaging|Histological Validation Of Carotid Plaque Composition In Preoperative Imaging Of Patients Scheduled For Carotid Endarterectomy||Lawson Health Research Institute|Yes|Recruiting|January 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|Samples Without DNA|Histological sections|Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for carotid endarterectomy|March 2015|March 30, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01456403||96826|
NCT01456715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122.05.01|Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.|Immunogenicity and Safety of Gardasil and Twinrix Vaccines Co-administered or Administered a Month Apart, According to the 0, 6 Months Schedule and the Effect of a Third Dose of Gardasil or Cervarix Administered 42 Months Later.||Laval University|No|Enrolling by invitation|September 2008|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|416|||Female|12 Years|14 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01456715||96802|
NCT01456975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVAPRO|Extravalvular Procedure for Surgical Treatment of Ascending Aorta Aneurism|Reimplantation Procedure for Surgical Treatment of Ascending Aorta Aneurism With Concomitant Aortic Valve Insufficiency|EPSTAAA|Meshalkin Research Institute of Pathology of Circulation|No|Active, not recruiting|January 2007|January 2017|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|September 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01456975||96782|
NCT01457001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUTRI-VITA-D001|Clinical Trial on the Use of 25-OH -D Vitamin in Haemodialysis Patients|Controlled Randomised Interventional Trial on the Use of 25-OH D Vitamin in Haemodialysis Patients.|NUTRIVITA-D001|Consorzio Mario Negri Sud|Yes|Recruiting|November 2012|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|524|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01457001||96781|
NCT01457287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COIT10|A Longitudinal Investigation of Cognitive Function in Colorectal Cancer Patients|Cognitive Function and Fatigue in Cancer Patients After Chemotherapy: A Longitudinal Controlled Study in Patients With Colorectal Cancer||University Health Network, Toronto|No|Completed|October 2003|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients being treated for Colorectal cancer at participating centres|October 2011|October 20, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457287||96760|
NCT01457638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004-20|Inferior Turbinate Surgery in Rhinoseptoplasty: a Randomized Clinical Trial With Quality of Life Outcomes|Inferior Turbinate Surgery in Rhinoseptoplasty: a Randomized Clinical Trial With Quality of Life and Acoustic Rhinometry Outcomes||Hospital de Clinicas de Porto Alegre|No|Recruiting|January 2011|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 20, 2011|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01457638||96733|
NCT01457651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECR-CABG-2010|Comparison of Four Different Recruitment Maneuvers in Patients After Coronary Surgery|Comparison of Different Types of Postoperative Pulmonary Recruitment and Predicting Its Efficacy Following Off-pump Coronary Artery Bypass Grafting|RECR-CABG|Northern State Medical University|No|Completed|March 2010|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|76|||Both|18 Years|75 Years|No|||June 2013|June 24, 2013|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457651||96732|
NCT01457885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.038|Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen|Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen|CloBu4|University of Michigan Cancer Center|Yes|Active, not recruiting|November 2011|March 2017|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|2 Years|65 Years|No|||October 2014|October 14, 2014|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457885||96714|
NCT01458132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115682|Drug Exposure Registry for GSK2248761, an Investigational NNRTI|Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761||ViiV Healthcare|No|Active, not recruiting|July 2011|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Masking: Open Label|2||Actual|1|||Both|N/A|N/A|No|||June 2014|June 26, 2014|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01458132||96695|
NCT01458145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD057947|Minding the Baby Home Visiting: Program Evaluation|Minding the Baby Home Visiting: Program Evaluation||Yale University|Yes|Active, not recruiting|September 2009|December 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|151|||Both|14 Years|25 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01458145||96694|
NCT01458483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACES II|Acute Carotid Sinus Endovascular Stimulation II Study|Acute Carotid Sinus Endovascular Stimulation II Study|ACES II|Medtronic Cardiac Rhythm Disease Management|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|August 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458483||96668|
NCT01458782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1159-3|ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee|A Randomized Trial Comparing Autologous Chondrocyte Implantation Using Collagen Membrane (ACI-C) Versus (Autologous Matrix Induced Chondrogenesis) AMIC for Repair of Cartilage Defects in the Knee||University Hospital of North Norway|No|Active, not recruiting|October 2011|October 2024|Anticipated|October 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||June 2015|June 1, 2015|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01458782||96645|
NCT01459614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11125|Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer|Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With Metastatic Pancreatic Cancer||Sidney Kimmel Comprehensive Cancer Center|No|Active, not recruiting|November 2011|November 2015|Anticipated|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|75 Years|No|||June 2015|June 3, 2015|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459614||96581|
NCT01466114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002055|Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition|A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.||University of California, Los Angeles|No|Recruiting|October 2011|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Female|18 Years|50 Years|No|||February 2016|February 3, 2016|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466114||96085|
NCT01457781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IK-7001-PAH-201|Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)|A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)|PAH|Bellerophon|Yes|Active, not recruiting|April 2012|December 2017|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|78|||Both|16 Years|80 Years|No|||January 2015|January 30, 2015|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457781||96722|
NCT01466712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53020|Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function|Randomized Double-blind Placebo-controlled Crossover Study to Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function in COPD Patients.||Katholieke Universiteit Leuven|Yes|Enrolling by invitation|November 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|N/A|N/A|No|||July 2013|July 29, 2013|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01466712||96039|
NCT01466725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-930-DLE-002|A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus|A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects With Recalcitrant Discoid Lupus Erythematosus (DLE)||Celgene|Yes|Terminated|November 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|5|||Both|18 Years|64 Years|No|||August 2013|August 16, 2013|November 4, 2011|Yes|Yes|The benefit/risk profile does not support continuation of this study.|No||https://clinicaltrials.gov/show/NCT01466725||96038|
NCT01458652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000121|Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation|Effect of Replacement Volume and AST-120 (Kremezin) on Protein-bound Toxins, Oxidative Stress and MicroInflammation in Patients Receiving Online Hemodiafiltration||Tungs’ Taichung Metroharbour Hospital|Yes|Completed|January 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01458652||96655|
NCT01458886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1248.2|Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study Assessing Efficacy and Safety of a 12 Week Treatment With BI 54903 Administered at 90.9 Mcg b.i.d. and 181.8 Mcg q.d. (p.m.Dosing) Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone||Boehringer Ingelheim||Withdrawn|November 2011|||May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|0|||Both|12 Years|65 Years|No|||October 2013|October 30, 2013|October 24, 2011||||No||https://clinicaltrials.gov/show/NCT01458886||96637|
NCT01458899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00025|Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214|Phase I, Open-label, Randomized, Single-dose, Two Treatment (Fed Versus Fasted) Crossover Study to Assess the Effects of Food on the Pharmacokinetics of TC-5214 (S-Mecamylamine) in Healthy Subjects|TC-5214|AstraZeneca||Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|October 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01458899||96636|
NCT01459757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181199|Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib|A Non-Interventional Retrospective Correlation Of Tumor Mutation Status To Clinical Benefit From The SU011248, A6181036 Treatment Protocol Titled: A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate||Pfizer|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|322|||Both|18 Years|N/A|No|Probability Sample|Clinical outcomes data generated from the sunitinib A6181036 study in GIST correlated with        mutational status data previously analyzed for the same patients but not collected as part        of the A6181036 study.|June 2013|June 17, 2013|October 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01459757||96570|
NCT01460017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-11-487|Comparison Between Deep Sclerectomy and Traditional Trabeculotomy & Trabeculectomy in Congenital Glaucoma|Comparison Between The Outcome of Deep Sclerectomy and Traditional Trabeculotomy and Trabeculectomy Surgeries in Congenital Glaucoma||King Saud University|No|Not yet recruiting|November 2011|December 2013|Anticipated|November 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|12 Years|No|||October 2011|October 25, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460017||96550|
NCT01455688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARV-0112|Early Antiviral Therapy for Critically Ill HIV Infected Patients|Early Antiretroviral Therapy for Critically Ill HIV Infected Patients||Hospital Nossa Senhora da Conceicao|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|344|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01455688||96881|
NCT01456104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-229|Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma|Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|N/A|N/A|No|||February 2016|February 11, 2016|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456104||96849|
NCT01456416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAforMS with AutoimmuneComor|Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities|Pilot Study for Evaluation of Glatiramer Acetate in RRMS Patients With Comorbid Autoimmune Conditions||University of Southern California|Yes|Completed|September 2011|April 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|60 Years|No|Non-Probability Sample|All Subjects meeting inclusion/exclusion criteria.|April 2013|April 2, 2013|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01456416||96825|
NCT01456728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34/30.06.2011|Lactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects on Proton Pump Inhibitors|Efficacy of Dietary Supplementation With Lactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects Treated Only With Proton Pump Inhibitors||St Marina University Hospital, Varna, Bulgaria|Yes|Completed|January 2011|September 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|70 Years|No|||September 2013|September 7, 2013|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01456728||96801|
NCT01457677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25712|ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment|A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment (ARTDeCo)||Hoffmann-La Roche||Completed|December 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|357|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457677||96730|
NCT01457300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHC rehab older people|Outcome of Rehabilitation of Older People in Primary Health Care|Outcome of Multi-Disciplinary, Structured Rehabilitation of Older People in an Inpatient District Rehabilitation Centre Versus Standard Primary Health Care Rehabilitation - An Open Comparative Observational Stdy||University of Oslo|Yes|Completed|June 2006|October 2010|Actual|April 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|302|||Both|65 Years|N/A|No|Probability Sample|The Study Populations were Disabled Older People (=>65years), with a need for        Rehabilitation either Post-Acute after Hospitalisation or admitted Directly from their Own        Homes and living within the Geographically small County of Vestfold, Norway.|October 2011|October 24, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01457300||96759|
NCT01457664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25589|A Study of RO4995819 in Healthy Elderly Volunteers|A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of RO4995819 Following Oral Administration in Healthy Elderly Subjects.||Hoffmann-La Roche||Completed|July 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01457664||96731|
NCT01457898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1751/07|Non-invasive Mechanical Ventilation After Cardiac Surgery|Effects of Non-invasive Mechanical Ventilation on Hemodynamics and Gas Exchanges Parameters After Cardiac Surgery in Patients With Relative Hypoxemia||Irmandade Santa Casa de Misericórdia de Porto Alegre|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|42|||Both|20 Years|85 Years|No|||October 2011|October 21, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457898||96713|
NCT01458171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZLB07_001CR|Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)|A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency||CSL Behring||Completed|April 2011|April 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|75 Years|No|||February 2013|February 27, 2013|October 12, 2011|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT01458171||96692|
NCT01458496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243401|Health Coaching to Effect Lifestyle Behaviour Change|Health Coaching to Effect Lifestyle Behaviour Change: A Randomized Trial of Individuals With Pre-disease|HC|Memorial University of Newfoundland|Yes|Completed|October 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|219|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01458496||96667|
NCT01459081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-100|Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China|Randomised, Double-blind, Placebo-controlled Trial of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|65 Years|No|||January 2013|January 15, 2013|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459081||96622|
NCT01459341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0017 CTIL|Near Infrared Spectroscopy and Transcutaneous Oxygen Pressure in Critical Limb Ischemia Before and After Treatment|Comparison of Near Infrared Spectroscopy (NIRS) and Transcutaneous Oxygen Pressure (TCPO2) Measurements in Critical Limb Ischemia (CLI) Patients After Invasive Treatment (Endovascular or Surgery)|NIRS|Carmel Medical Center|Yes|Completed|July 2011|November 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|80 Years|No|Non-Probability Sample|10 patients admitted to the vascular surgical department and undergoing invasive treatment        (surgical or endovacular)|December 2012|December 5, 2012|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01459341||96602|
NCT01459627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAPT-STEMI|Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI|Prospective, Randomized, Open Label Trial of 6 Months vs. 12 Months Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation Myocardial Infarction|DAPT-STEMI|Maasstad Hospital|Yes|Active, not recruiting|December 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1100|||Both|18 Years|85 Years|No|||September 2015|September 9, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01459627||96580|
NCT01465867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sel-01|Selenium Supplementation in Pregnancy|Selenium Supplementation Treatment in Euthyroid Pregnant Women With Autoimmune Thyroid Disease: Effects on Obstetrical Complications|Serena|University of Roma La Sapienza|Yes|Recruiting|April 2012|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|150|||Female|18 Years|38 Years|No|||October 2014|October 25, 2014|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01465867||96104|
NCT01466426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMA projekt K 59 PETVET|The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders (The PETVET Study)|The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders|PETVET|Odense University Hospital|No|Completed|November 2011|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|40|||Both|50 Years|N/A|No|Non-Probability Sample|The study population comprises the following patient groups: 10 patients with a positive        diagnosis of DVT, 10 patients where clinically suspected DVT was ruled out, 10 patients        with a positive diagnosis of PE, and 10 patients where clinically suspected PE was ruled        out.|October 2014|October 26, 2014|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466426||96061|
NCT01466452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S181/211|Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery||ASABYVALV|Centro Cardiologico Monzino|No|Recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|99|||Both|55 Years|80 Years|No|||November 2011|November 7, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01466452||96059|
NCT01458405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-01|Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration|Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction|ALLSTAR|Capricor Inc.|Yes|Recruiting|October 2012|September 2021|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458405||96674|
NCT01458912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1248.3|Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids|A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of a 12-week Treatment With BI 54903 at Doses of 181.8 Mcg b.i.d. and 363.6 Mcg q.d. (p.m. Dosing) Administered Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy||Boehringer Ingelheim||Withdrawn|November 2011|||May 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|0|||Both|12 Years|65 Years|No|||November 2011|November 21, 2011|October 24, 2011||||No||https://clinicaltrials.gov/show/NCT01458912||96635|
NCT01458925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-SY-01-0091|Feasibility of Check-Cap's P1 Capsule System Screening|Feasibility, Multi-center Prospective Study of Check-Cap's P1 Capsule System in Patients Eligible for ColoRectal Cancer [CRC] Screening||Ceck Cap Ltd.|No|Not yet recruiting|November 2011|||November 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2011|October 24, 2011|October 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01458925||96634|
NCT01459224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL10/0271|MELT - MRI Evaluation of Lymphoma Treatment|Whole Body Functional and Anatomical MRI: Accuracy in Staging and Treatment Response Monitoring in Adolescent Hodgkin's Lymphoma Compared to Conventional Multimodality Imaging|MELT|University College, London|Yes|Completed|September 2011|October 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|58|||Both|5 Years|20 Years|No|Non-Probability Sample|Hodgkin's Lymphoma|December 2015|December 1, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01459224||96611|
NCT01459770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DK094016-01|Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD|Medication Intervention in Transitional Care to Optimize Outcomes & Costs in CKD & ESRD|CKD/ESRD-MIT|Providence Medical Research Center|Yes|Recruiting|November 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|120|||Both|21 Years|N/A|No|||August 2013|August 2, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459770||96569|
NCT01460030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN1493-101|An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism|An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism||Kyowa Hakko Kirin Company, Limited||Completed|November 2011|||||Phase 3|Interventional|Primary Purpose: Treatment|1||||||Both|20 Years|N/A|No|||May 2014|May 13, 2014|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460030||96549|
NCT01460043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMP-0032-HR|Trial of Homeopathy on Management of Menorrhagia|Pilot Study of Homeopathy in Dysfunctional Uterine Bleeding Presenting as Menorrhagia||NMP Medical Research Institute|Yes|Completed|June 2008|June 2009|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|25|||Female|35 Years|49 Years|No|||October 2011|November 9, 2011|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01460043||96548|
NCT01456130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/OCT-901|Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes|A Long-Term, Open-Label Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Rapid-Acting Insulin Secretagogues in Subjects With Type 2 Diabetes in Japan||Takeda||Completed|November 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|67|||Both|20 Years|N/A|No|||March 2014|March 17, 2014|October 13, 2011|No|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT01456130||96847|
NCT01456429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aster2-2010|Assessment of Invasive Mediastinal Staging in cN1 Lung Cancer.|Assessment of Surgical Mediastinal sTaging Added to Endoscopic Ultrasound in cN1 Lung canceR.|ASTER2|Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|January 2010|April 2014|Anticipated|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|N/A|No|||January 2010|October 8, 2013|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01456429||96824|
NCT01456741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBNA08091976|The Role of Endobronchial Needle Aspiration With Rapid On-site Evaluation in the Diagnosis of Central Malignant Lesions|Endobronchial Needle Aspiration With Rapid On-Site Evaluation in the Diagnosis of Central Malignant Lesions, a Randomized Controlled Trial||University of Milan|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|134|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01456741||96800|
NCT01457014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDBPM-2011-01|Sleep Disordered Breathing and Chronic Pain|BiPAP Adaptive Servo-Ventilation (AutoSV) Therapy in Patients With Chronic Pain and Sleep Disordered Breathing (SDB)||Philips Respironics|No|Completed|September 2011|September 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|88|||Both|21 Years|70 Years|No|||January 2016|January 22, 2016|September 30, 2011||No||No|October 29, 2015|https://clinicaltrials.gov/show/NCT01457014||96780|
NCT01457313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKA bilat pain|Pain Compared Between the First and the Second Surgery in Staged BTKA|Comparison of Postoperative Pain in the First and Second Knee in Staged Bilateral Total Knee Arthroplasty: Clinical Evidence That Central Sensitization Increases Systemic Pain Sensitivity||Seoul National University Bundang Hospital|No|Recruiting|October 2011|March 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|34|||Both|N/A|85 Years|No|Probability Sample|patients undergoing elective bilateral staged total knee arthroplasty|February 2013|February 4, 2013|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457313||96758|
NCT01457924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112831|Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)|MIRROR|GlaxoSmithKline|Yes|Completed|November 2011|June 2015|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|232|||Both|18 Years|55 Years|No|||October 2015|October 22, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457924||96711|
NCT01458210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11555|A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants|Effect of Dulaglutide (LY2189265) on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects||Eli Lilly and Company|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|October 19, 2011|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01458210||96689|
NCT01457911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11761|Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin|A Multicenter, Randomized, Open-label, 2-arm Parallel Group, 20-week Study Comparing the Efficacy and Safety of Fixed-dose Combination of 1 mg Glimepiride and 250 mg Metformin (AMARYL M 1/250 mg) Versus Glimepiride (AMARYL®) in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin.||Sanofi|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|244|||Both|18 Years|80 Years|No|||May 2014|May 7, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457911||96712|
NCT01458184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27747|Study of PhoneCare System to Treat Patients With Chronic Diseases|A Randomized Trial of the PhoneCare System to Improve Ambulatory Care for Patients With Chronic Diseases|ComplexPt|Boston Medical Center|No|Completed|September 2008|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|264|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 5, 2013|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01458184||96691|
NCT01458769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP405.1003|Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz|Open-labeled, Randomized, Crossover, Single-dose Study in Healthy Male Subjects to Evaluate the Pharmacokinetics, Safety & Tolerability of Stable Isotopologs of Atazanavir (ATV), Administered as Single Agents or as Combinations of Two Isotopologs, With a Pharmacokinetic Comparison to Reyataz®.||Concert Pharmaceuticals|Yes|Completed|December 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|47|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|June 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01458769||96646|
NCT01458795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bask 012|The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins|The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins||Baskent University|Yes|Completed||||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|60|||Both|20 Years|80 Years||||November 2011|November 2, 2011|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01458795||96644|
NCT01459354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-146|The Effects of Bimanual Laryngoscopy on Post-Operative Sore Throat in Adults|||China Medical University Hospital||Recruiting|August 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|490|||Both|20 Years|70 Years|No|Probability Sample|20-70 yrs patient receive elective surgery with general anesthesia without position change        or any influence on sorethroat|October 2011|October 24, 2011|October 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459354||96601|
NCT01459380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2011-01977|Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer||National Cancer Institute (NCI)||Active, not recruiting|October 2011|||August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|October 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01459380||96599|
NCT01490892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11F.438|Quantitative Subharmonic Breast Imaging|Quantitative Subharmonic Breast Imaging||Thomas Jefferson University|Yes|Recruiting|November 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|450|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490892||94187|
NCT01466153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI-551-1019|A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL||MedImmune LLC|Yes|Completed|February 2012|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|183|||Both|18 Years|99 Years|No|||March 2016|March 1, 2016|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01466153||96082|
NCT01466465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProGIT|Vitamin D and Grass Pollen Specific Immunotherapy|||Charite University, Berlin, Germany|No|Completed|October 2011|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|55 Years|No|||June 2015|June 24, 2015|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01466465||96058|
NCT01466127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-002911|The Effect of Oxytocin on Fear Memory Consolidation Novel Intervention to Prevent Posttraumatic Stress Disorder (PTSD)|The Effect of Oxytocin on Fear Memory Consolidation: A Novel Intervention to Prevent PTSD||Massachusetts General Hospital|No|Completed|October 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|80|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|November 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01466127||96084|
NCT01466439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-181|Repetitive Transcranial Magnetic Stimulation (rTMS) and P50 Evoked Potential Component|Evaluation of Effect of Low and High-frequencies of Repetitive Transcranial Magnetic Stimulation (rTMS) by the Suppression of P50 Evoked Potential Component (rTMS-P50)|rTMS-P50|University Hospital, Caen|No|Completed|May 2011|June 2013|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2013|June 7, 2013|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01466439||96060|
NCT01458665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRM-11-01|Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma (PRP) in Medium to Large Rotator Cuff Tears|Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma (PRP) in Medium to Large Rotator Cuff Tears: A Randomized Controlled Trial||Seoul National University Hospital|No|Completed|October 2011|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|N/A|N/A|No|||June 2014|June 16, 2014|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01458665||96654|
NCT01458938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Substance P|This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.|Substance P Neuropeptide Levels in Saliva, Serum and Cerebrospinal Fluid in Patients With Spinal Disease: A Pilot Study|Substance P|Carolina Neurosurgery & Spine Associates|Yes|Terminated|July 2009|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|53|Samples Without DNA|Blood, saliva and cerebrospinal fluid|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|July 2015|July 27, 2015|October 24, 2011||No|Study will need to be redesigned for improved efficacy.|No||https://clinicaltrials.gov/show/NCT01458938||96633|
NCT01459497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052011-093|Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer|Phase III Randomized Study of Standard Versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status||University of Texas Southwestern Medical Center|Yes|Recruiting|October 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|226|||Both|18 Years|N/A|No|||September 2015|September 12, 2015|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459497||96590|
NCT01460056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-11378-001|e-STEPS: Endotoxin-Associated Sterile Peritonitis Observational Study|e-STEPS: Endotoxin-Associated Sterile Peritonitis Observational Study|e-STEPS|Baxter Healthcare Corporation|Yes|Completed|December 2011|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|127|||Both|18 Years|N/A|No|Probability Sample|The study subjects will be incident cases of endotoxin-associated peritonitis (e-SP) and        bacterial peritonitis (BP) and no peritonitis (NoP) who meet all of the study eligibility        criteria during the study eligibility period.|January 2013|January 31, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01460056||96547|
NCT01460069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-000571-13|The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis|The Effect of GLP-1 in Psoriasis||University Hospital, Gentofte, Copenhagen|Yes|Completed|October 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01460069||96546|
NCT01455714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RNN/446/10/KB|Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension|Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension|dysh|Medical Universtity of Lodz|Yes|Not yet recruiting|September 2012|September 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|Samples Without DNA|blood samples|Both|40 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|120 persons (age 40-60 years old) will be included in the study, patients with stage I or        II primary hypertension according to the European Society of Hypertension|October 2011|October 19, 2011|September 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455714||96879|
NCT01455727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100B4022-100MID-08|Pharmaceutical Care of Ambulatory Elderly Diabetes Patients|||Nantou Hospital||Completed|August 2011|||August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|100|||Both|65 Years|90 Years|No|||September 2012|September 13, 2012|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01455727||96878|
NCT01457027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A007|A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season|A Phase IV, Open Label Study to Evaluate the Short and Long Term Immune Response and CROSS-protection After Vaccination With viroSOME Adjuvanted Inflexal V in Elderly Subjects||Crucell Holland BV|No|Completed|October 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|52|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 19, 2013|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01457027||96779|
NCT01457326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34409|Early Standardized Weight Bearing Utilizing Immersion Therapy Following Periarticular Lower Extremity Fractures|Early Standardized Weight Bearing Utilizing Immersion Therapy Following Periarticular Lower Extremity Fractures: Clinical and Radiographic Outcomes||University of Utah|No|Active, not recruiting|June 2009|November 2017|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|This study is a prospective cohort study with a retrospective chart review. Patients who        are treated by the PI, Dr. Erik Kubiak, will participate in an immersion therapy        post-operative protocol. Immersion therapy post-operative protocols have been and are        currently used routinely by Dr. Kubiak.        Patients who are treated by Dr. Dan Horwitz and Dr. Thomas Higgins will undergo a        traditional 10 week non-weight bearing post-operative care per their standard of        procedure. In addition, patients of Dr. Kubiak who are unable to participate in immersion        therapy for logistical reasons will be asked to participate in the traditional 10- week        non-weight bearing post-operative care protocol. These patients will make up the control        cohort.|January 2016|January 4, 2016|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01457326||96757|
NCT01457339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-119|Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia|A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending, Multiple Oral Doses of SPD489 (Lisdexamfetamine Dimesylate) in Clinically Stable Adults With Schizophrenia||Shire|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|31|||Both|18 Years|65 Years|No|||December 2012|March 3, 2015|October 19, 2011|No|Yes||No|December 13, 2012|https://clinicaltrials.gov/show/NCT01457339||96756|
NCT01457690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.634|Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention|Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention|VEDROP|Hospices Civils de Lyon|No|Completed|October 2011|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|6 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01457690||96729|
NCT01458223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17846|The Effect of Prolonged Postoperative Antibiotics Administration on Rate of Infection in Patients Undergoing Posterior Spine Surgery Requiring a Hemovac Drain|The Effect of Prolonged Postoperative Antibiotics Administration on Rate of Infection in Patients Undergoing Posterior Spine Surgery Requiring a Hemovac Drain|PARISS|The London Spine Centre|No|Recruiting|October 2011|October 2018|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1066|||Both|16 Years|N/A|No|||March 2016|March 2, 2016|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01458223||96688|
NCT01458236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS-314d-MR-PAH-301|A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor|A Multinational, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor||Lung Biotechnology PBC|Yes|Withdrawn|November 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||May 2012|May 10, 2012|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458236||96687|
NCT01458197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFN-KD01|A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.|A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.||Kwang Dong Pharmaceutical co., ltd.|No|Completed|September 2011|November 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|235|||Both|20 Years|80 Years|No|||March 2014|March 11, 2014|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01458197||96690|
NCT01458509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-101|Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys|A Comparison of the Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys||Memorial Sloan Kettering Cancer Center||Active, not recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|328|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be screened in colorectal surgery clinics on the 3rd floor of the MSKCC 53rd        Street outpatient clinic buildings or at the Main Hospital at 1275 York Avenue or while        they are an inpatients. Patients will be approached within 1-5 weeks post operatively to        ensure that they can complete the first survey within the 4-6 week window.|September 2015|September 25, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01458509||96666|
NCT01459094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100652|Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers|Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Subjects||Janssen Research & Development, LLC|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 18, 2013|October 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01459094||96621|
NCT01459107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00046418|Human Upper Extremity Allotransplantation|Human Upper Extremity Allotransplantation||Johns Hopkins University|Yes|Recruiting|July 2011|June 2026|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|69 Years|No|||March 2016|March 8, 2016|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01459107||96620|
NCT01490593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-079|Canadian Eye Injury Registry|Canadian Eye Injury Registry|CEIR|Lawson Health Research Institute|Yes|Recruiting|February 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2500|||Both|N/A|N/A|No|Non-Probability Sample|All individuals who have sustained a serious eye injury in Canada.|December 2011|December 9, 2011|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01490593||94210|
NCT01490879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEX-ULC-011|A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)|A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon® in the Treatment of Subjects With a Diabetic Foot Ulcer|DUNE|CoDa Therapeutics Inc.|Yes|Completed|July 2012|April 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|168|||Both|18 Years|N/A|No|||April 2014|April 29, 2014|December 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490879||94188|
NCT01467050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRA_HSR/2010/14|Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients|Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Using STOPP/START Criteria||University College Cork|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|732|||Both|65 Years|N/A|No|||June 2012|June 5, 2012|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01467050||96013|
NCT01467349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Real-Life Study|Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan|Efficacy of Raltegravir in a Large Urban HIV Clinic Population in Milan (Efficacy of Raltegravir in a Large Urban HIV Clinic Setting)|Real-Life|Università Vita-Salute San Raffaele|No|Completed|December 2011|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|400|||Both|18 Years|90 Years|No|Probability Sample|This study will include subjects who received raltegravir and were previously exposed to        NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.        A control group will be used for the evaluation of the primary and secondary objectives in        comparison to patients treated with raltegravir (study patients). The control group will        be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with        the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV        co-infection status yes/no). For control patients, the last antiretroviral regimen        prescribed will be considered.|February 2013|February 8, 2013|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01467349||95990|
NCT01466478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLQ-007|An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris|A Phase I Exploratory Study Evaluating 3 Formulations of LEO 29102 Plus Calcipotriol, Ointment, LEO 29102 Ointment, Calcipotriol Ointment, Daivonex® Ointment and Diprosone® Ointment in the Treatment of Psoriasis||LEO Pharma|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|24|||Both|18 Years|N/A|No|||October 2013|October 24, 2013|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01466478||96057|
NCT01466751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-19338|Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits|Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits||Stanford University|No|Completed|January 2011|December 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|58|||Both|18 Years|65 Years|No|||November 2014|November 17, 2014|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01466751||96036|
NCT01458678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PVI vers OD|Non Invasive Methods to Guide Volume Optimization|Evaluation of Non Invasive Methods for Goal Directed Fluid Therapy During Abdominal Surgery||University Hospital, Linkoeping|No|Completed|November 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01458678||96653|
NCT01459510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100533|A Brief Multimedia Program Affects Parents' Attitudes Toward Physical Punishment|A Brief Multimedia Program Affects Parents' Attitudes Toward Physical Punishment||Vanderbilt University|No|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|260|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2011|October 21, 2011|July 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01459510||96589|
NCT01460082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDAECOPD|Endothelial Dysfunction in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|Endothelial Dysfunction and Systemic Inflammation in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease|EDAECOPD|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|No|Completed|August 2008|September 2010|Actual|September 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|29|Samples Without DNA|Serum, Plasma|Both|40 Years|N/A|No|Non-Probability Sample|Patients with COPD diagnosed according to standard criteria in the state of acute        exacerbation|March 2014|March 10, 2014|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460082||96545|
NCT01455740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0005|A Commitment Device for Medication Adherence Among HIV Patients|A Commitment Device for Medication Adherence Among HIV Patients||National Bureau of Economic Research, Inc.|No|Completed|October 2011|October 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|39|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01455740||96877|
NCT01457352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_09_21|Efficacy and Safety of SPARC0921 in Subjects With Spasticity|||Sun Pharma Advanced Research Company Limited|No|Recruiting|September 2012|January 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457352||96755|
NCT01457365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP-VDCHINA|Vitamin D Deficiency Epidemiological Research in Sichuan, China|Vitamin D Status and Its Correlation to Bone Density, Bone Turnover Markers and Muscle Function in Community-dwelling People in Sichuan Province , P.R. China||West China Hospital||Not yet recruiting|December 2011|December 2012|Anticipated|February 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1500|||Female|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|In total, 1500 female subjects aged more than 30 years old (750 urban and 750 rural        females) will be included|October 2011|October 20, 2011|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01457365||96754|
NCT01457378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU357|Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome|Assessment of Gastrointestinal Symptoms and Health-related Quality of Life in Healthy People and Patients With Irritable Bowel Syndrome||Danone Research|No|Completed|September 2011|June 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2||200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Adult healthy subjects and adult IBS patients (Rome III criteria, all subtype)|June 2012|June 25, 2012|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457378||96753|
NCT01457703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0977|Reproductive Hormonal Alterations in Obesity|Reproductive Hormonal Alterations in Obesity, AIMS #1 & #2||University of Colorado, Denver|No|Completed|June 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|62|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|September 21, 2011|No|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT01457703||96728|
NCT01457937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2011-002459-33|Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)|Boceprevir/Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba) in Difficult-to-Treat Menopausal Women With Chronic Hepatitis C Genotype 1 (Gt 1), Either Deemed Nonresponders to Peginterferon/Ribavirin or Treatment-naives (MEN_BOC)|MEN_BOC|University of Modena and Reggio Emilia|Yes|Recruiting|November 2011|June 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Female|N/A|N/A|No|||September 2012|September 29, 2012|October 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01457937||96710|
NCT01489267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111031SCA|A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation|The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Transplantation in Hereditary Cerebellar Ataxia Patients|SCA|General Hospital of Chinese Armed Police Forces|Yes|Enrolling by invitation|December 2011|July 2014|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||June 2012|June 18, 2012|October 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489267||94311|
NCT01489514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 10-0851|Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects|Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects.|peanut|University of North Carolina, Chapel Hill|No|Completed|December 2011|January 2015|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|22|Samples With DNA|Venipuncture for 30mL of blood taken for measurement of peanut IgE.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Thirty (30) adult subjects with history of peanut allergy, with or without asthma will be        recruited. All participants will be adults ages 18-65. There will no gender or ethnic        restrictions.|May 2015|May 26, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489514||94292|
NCT01458522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033295|Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures|Utility of Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures|TRENdS|Duke University|Yes|Completed|May 2012|July 2015|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458522||96665|
NCT01458535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-998|A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)|An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-267 With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Infection|Navigator|AbbVie|No|Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||May 2014|May 30, 2014|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01458535||96664|
NCT01458548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTLD-1|Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)|Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (Including 1st+2nd Amendment)||Charite University, Berlin, Germany|No|Terminated|December 2002|October 2011|Actual|May 2008|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|16 Years|N/A|No|||October 2011|October 24, 2011|October 18, 2011|Yes|Yes|This study had an major amendment in 12/2006 introducing risk stratified sequential treatment    (RSST). The modified protocol is registered with NCT00590447.|No||https://clinicaltrials.gov/show/NCT01458548||96663|
NCT01458808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|upeclin/HC/FMB-Unesp-55|Dietary and Dialysate Sodium Reduction on Body Fluid Volume and Inflammatory State in Hemodialysis Patients|Effects of Dietary and Dialysate Sodium Reduction on Body Fluid Volume and Inflammatory State in Hemodialysis Patients. A Prospective Randomized Controlled Study||UPECLIN HC FM Botucatu Unesp|Yes|Completed|April 2007|February 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01458808||96643|
NCT01459120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DoDoPi-1|Comparison of Door-to-door Versus Community Gathering to Provide HIV Counseling and Testing Services in Rural Lesotho|Comparing Door-to-door Versus Community Gathering in Providing HIV Counseling and Testing Within an Integrated Primary Health Care Package: a Cluster Randomized Trial in Rural Lesotho|DoDoPi|SolidarMed|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|1800|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 8, 2012|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01459120||96619|
NCT01459367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-003|Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis|A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to AG-1749 (15 mg Once-Daily) in a 24-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE).||Takeda|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|607|||Both|20 Years|N/A|No|||August 2013|August 22, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459367||96600|
NCT01486810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6154|Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence|Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence|Vyvance|New York State Psychiatric Institute|Yes|Recruiting|December 2011|January 2013|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|60 Years|No|||October 2012|October 24, 2012|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486810||94500|
NCT01487083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12666|A Long-Term Study in Schizophrenia|Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients With Schizophrenia||Eli Lilly and Company|No|Terminated|December 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|282|||Both|18 Years|65 Years|No|||November 2012|January 11, 2013|November 30, 2011|Yes|Yes|The decision to stop the trial was based on efficacy results in the overall schizophrenia    participant population.|No||https://clinicaltrials.gov/show/NCT01487083||94479|
NCT01487057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChiricutaIO|Lipid Metabolic Status in Thyroid Carcinoma|"Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution"|LITCA|Prof. Dr. I. Chiricuta Institute of Oncology|No|Completed|February 2011|May 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|52|||Both|18 Years|80 Years|No|Probability Sample|We will prospectively study a group of patients from the evidence of IOCN, with the        histology of differentiated thyroid cancer, radically treated with total thyroidectomy,        radioiodine therapy and undergoing chronic substitutive hormone treatment, levothyroxine.        The evaluation of these patients will be done during the routine oncological control,        after 6-12 months post therapy, while withdrawing the hormone treatment and inducing a        short-term iatrogenic myxedema. We are estimating a total number of 30 patients with 3        successive determinations in 1 year. The ethics committee will evaluate this study and        each patient will be included voluntarily, following clear information of the patient and        an informed consent.|December 2012|December 26, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487057||94481|
NCT01487070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH1005|A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy|A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy||Retina Institute of Hawaii||Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|75 Years|No|||April 2011|December 5, 2011|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487070||94480|
NCT01467362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00034 CR 3 12 1B|Efficacy Emollient on Xerosis in Children With Atopic Dermatitis|Efficacy of the V0034CR01B Emollient on Xerosis in Children With Atopic Dermatitis. Randomised, Vehicle-controlled, Parallel-groups, Double-blind Study With an Open Label Extension.||Pierre Fabre Medicament|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|251|||Both|2 Years|6 Years|No|||February 2013|February 20, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01467362||95989|
NCT01467622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSH-TCH-IIT-2009-1|Effects of Local Protocols on Duration of Chest Tube Therapy Following Thoracic Surgery|Prospective, Non Randomized Investigator Initiated Multi-centre Trial on the Effects of Local Treatment Protocols on the Duration of Chest Tube Therapy Following Thoracic Surgery in Germany||Schillerhoehe Hospital|No|Completed|April 2009|October 2011|Actual|August 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|85 Years|No|Non-Probability Sample|patients undergoing pulmonary resection at one of the four participating thoracic surgery        specialist units|May 2013|May 6, 2013|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01467622||95969|
NCT01459250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178C2104|Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects|An Open Label, Non-randomised, Parallel Group Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of a Single Dose of AGO178C in Subjects With Mild, Moderate, Severe Renal Impairment and End-stage Renal Disease With That in Healthy Matched Control Subjects||Novartis||Completed|March 2011|||August 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|32|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||October 2011|October 21, 2011|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459250||96609|
NCT01459237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120007|Effects of Hormone Stimulation on Brain Scans for Cushing s Disease|Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease||National Institutes of Health Clinical Center (CC)||Recruiting|October 2011|May 2018|Anticipated|May 2018|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|30|||Both|8 Years|N/A|No|||April 2015|March 12, 2016|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459237||96610|
NCT01459783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQ217RC4|Comparative Effectiveness of Dementia Care Strategies in Underserved Communities|Comparative Effectiveness of Dementia Care Strategies in Underserved Communities||RAND|Yes|Completed|March 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|144|||Both|21 Years|N/A|No|||May 2015|May 6, 2015|January 18, 2011||No||No|February 25, 2015|https://clinicaltrials.gov/show/NCT01459783||96568|
NCT01455766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-2011|Volumetric Monitoring in Major Lung Surgery|Pulmonary Edema Following Major Thoracic Resections: a Value of Perioperative Volumetric Monitoring|EVLW-PNEUMO|Northern State Medical University|No|Completed|June 2005|November 2011|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Blood plasma for non-specified additional retrospective tests.|Both|18 Years|80 Years|No|Non-Probability Sample|The study population includes the patients scheduled for extended thoracic resections        (lobar resection and pneumonectomy) due to bronchial cancer or severe destructive        pulmonary infection (abscess and/or pneumonia).|September 2012|September 4, 2012|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01455766||96875|
NCT01455779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-3375|Lyrette: Renewing Continence Objective and Subjective Efficacy Study|Lyrette: Renewing Continence Objective and Subjective Efficacy Study|ROSE|Verathon|No|Active, not recruiting|September 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Female|35 Years|60 Years|Accepts Healthy Volunteers|||November 2013|December 8, 2014|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01455779||96874|
NCT01455753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0006|The Effect of Proximity on Flu-Shot Participation|The Effect of Proximity on Flu-Shot Participation||National Bureau of Economic Research, Inc.|No|Completed|October 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|1912|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 16, 2012|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01455753||96876|
NCT01456117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-4833/TOMM40_102|Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants|A Phase 1, Multiple-Dose, Single-Blind Parallel Design, Single-Center, Dose-Ranging Study to Assess the Effects of Daily Administration of Pioglitazone for 14 Days on the Brain Hemodynamics of Healthy Elderly Subjects||Takeda|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|61|||Both|55 Years|83 Years|Accepts Healthy Volunteers|||August 2012|August 6, 2012|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456117||96848|
NCT01488448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-329|A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis|A Double-Blind, Controlled, Randomized Clinical Trial of Nebulized Hypertonic Saline for Hospitalized Infants With Viral Bronchiolitis||Montefiore Medical Center|Yes|Completed|November 2011|August 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|227|||Both|N/A|12 Months|Accepts Healthy Volunteers|||November 2015|November 20, 2015|December 2, 2011|Yes|Yes||No|August 7, 2014|https://clinicaltrials.gov/show/NCT01488448||94374|
NCT01488695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18478|GlideScope Groove Versus Macintosh Blade for Double-Lumen Endotracheal Tube Intubation|Comparison of GlideScope Groove to Macintosh Blade for Orotracheal Intubation With Double-Lumen Endotracheal Tube: a Randomised Controlled Trial||Lawson Health Research Institute|No|Not yet recruiting|December 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488695||94355|
NCT01488708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13811|On Open-Label Study in Participants With Systemic Lupus Erythematosus|A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)|Illuminate-X|Eli Lilly and Company|Yes|Completed|January 2012|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1518|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488708||94354|
NCT01488981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0014|Feasibility of the Radio-Frequency Microstimulator System to Improve Arm Function Following Traumatic Brain Injury|A Feasibility Study to Assess the Safety and Efficacy of the Radio-Frequency Microstimulator System to Improve Function of the Arm Following Traumatic Brain Injury||The Alfred E. Mann Foundation for Scientific Research|No|Terminated|February 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|December 5, 2011|No|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT01488981||94333|
NCT01490307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA018374|A Family Intervention for Adolescent Problem Behavior (AKA Project Alliance 2)|A Family Intervention for Adolescent Problem Behavior|PAL-2|University of Oregon|Yes|Completed|February 2006|March 2011|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|593|||Both|N/A|N/A|No|||December 2011|December 8, 2011|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01490307||94232|
NCT01490320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 100401|The Effect of Primary Care Interventions on Children's Media Viewing Habits and Exposure to Violence|The Effect of Primary Care Interventions on Children's Media Viewing Habits and Exposure to Violence||Vanderbilt University|No|Completed|June 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|336|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01490320||94231|
NCT01489761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2011-9|LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)|Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents||CardioVascular Research Foundation, Korea|Yes|Recruiting|January 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|19 Years|N/A|No|||August 2015|August 6, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489761||94273|
NCT01490008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 1023|Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers|An Open-label, Single-center Triqal to Evaluate Systemic Exposure of Catechins From Commercially Available, Topically Applied Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers||MediGene|No|Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 18, 2012|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01490008||94254|
NCT01490021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP1P002|Influence of Repetitive Transcranial Magnetic Stimulation (rTMS) Challenge on Cognitive and Functional Magnetic Resonance Imaging Markers in Healthy Subjects|Influence of Repetitive Transcranial Magnetic Stimulation (rTMS) Challenge on Cognitive and Functional Magnetic Resonance Imaging Markers in Healthy Subjects||Qualissima|No|Terminated|December 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|14|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2013|May 14, 2013|November 28, 2011||No|Study stopped for scientific reasons. Another study with a new design is in course of    authorization and implementation|No||https://clinicaltrials.gov/show/NCT01490021||94253|
NCT01490918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACADEMIC|Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients|A Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Acarbose Added on Top of Metformin and Sitagliptin Combination Treatment in Type 2 Diabetes Mellitus Patients||The Catholic University of Korea|Yes|Completed|April 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|165|||Both|20 Years|80 Years|No|||September 2014|September 11, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490918||94185|
NCT01490294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91054|Myocardial Perfusion MRI|Multicenter, Double Blind, Randomized Dose Finding Study in Myocardial Perfusion MRI With Gadavist®1.0||Bayer|No|Completed|March 2004|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|232|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|July 28, 2011|No|Yes||No|December 23, 2011|https://clinicaltrials.gov/show/NCT01490294||94233|Study designed for perfusion imaging, not optimized for delayed enhancement. Routine SPECT selected as standard of reference (SoR) despite known quality limitations.
NCT01486823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-BI-204-02|Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects|An Open-label, Single-dose Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects||BioInvent International AB|Yes|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486823||94499|
NCT01486836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58|Lumax DX / Linox DX Evaluation|Evaluation of the Lumax DX ICD and the Linox DX Lead (ICD=Implantable Cardioverter Defibrillator, DX=Extended Diagnostics)||Biotronik SE & Co. KG|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|38|||Both|18 Years|N/A|No|Probability Sample|Patients with standard ICD indication who are referred to the hospital.|September 2013|September 11, 2013|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01486836||94498|
NCT01487096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR1726D/2001|Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses|A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses||Sanofi|Yes|Completed|April 2001|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|179|||Both|18 Years|65 Years|No|||October 2012|October 3, 2012|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487096||94478|
NCT01467375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1361|Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes|An Open Label, Non Comparative, Multicentre Extension Trial to Assess the Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Who Have Completed BIAsp-1234||Novo Nordisk A/S|No|Completed|January 2001|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||November 2011|November 4, 2011|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01467375||95988|
NCT01467388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLT-Pseudophakic-201|Efficacy of Selective Laser Trabeculoplasty in Pseudophakic Patients|||University of Zurich||Enrolling by invitation|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|glaucoma patients|December 2014|January 5, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01467388||95987|
NCT01467635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011PA002B|EBUS-TBNA Versus EBUS-TBNB|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Endobronchial Ultrasound Transbronchial Needle Biopsy (EBUS-TBNB) in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial||Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|May 2014|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|No|||June 2014|June 2, 2014|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01467635||95968|
NCT01459263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL26327.091.09|Early Outcome of Mechanochemical Endovenous Ablation|Mechanochemical Endovenous Ablation of Great Saphenous Vein Incompetence Using the ClariVeinTM Device: a Prospective Study|ClariVein-2|Rijnstate Hospital|No|Active, not recruiting|November 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Patients with insufficiency of the greater saphenous vein will be included.|January 2015|January 19, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01459263||96608|
NCT01459276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FluvalAB-H-15|A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects|A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccine Containing 6μgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly Subjects||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|No|Completed|October 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1206|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 18, 2012|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01459276||96607|
NCT01459523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21961|Optimizing Catheter Insertion Technique for Ultrasound-guided Continuous Peripheral Nerve Blocks|Optimizing Catheter Insertion Technique for Ultrasound-guided Continuous Peripheral Nerve Blocks||VA Palo Alto Health Care System|No|Active, not recruiting|October 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459523||96588|
NCT01459796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IL1T-GA-1101|Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares|UPSURGE|Regeneron Pharmaceuticals|Yes|Terminated|November 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|219|||Both|18 Years|80 Years|No|||November 2012|September 27, 2013|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01459796||96567|
NCT01456442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2010-0330|Short Protocol Barostat for Assessment of Anorectal Function Versus Standard Protocol Barostat in Healthy Volunteers|Short Protocol Barostat for Assessment of Anorectal Function Versus Standard Protocol Barostat in Healthy Volunteers||University of Zurich|Yes|Completed|January 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|18 Years|65 Years|No|||November 2012|November 13, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01456442||96823|
NCT01456143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-2057|Optical Imaging of Head and Neck Cancer|In Vivo Multimodal Imaging of Upper Aerodigestive Epithelia||Icahn School of Medicine at Mount Sinai|No|Recruiting|December 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|77|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|October 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01456143||96846|
NCT01489527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16685|Preparedness Study - HPV Vaccine|Preparedness Study: Efficacy of HPV Vaccine to Reduce HIV Infection||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|September 2012|December 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|406|||Female|16 Years|24 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|December 8, 2011|No|Yes||No|January 5, 2015|https://clinicaltrials.gov/show/NCT01489527||94291|The EVRI Trial had a short duration with limited follow-up time; therefore, clinical efficacy in reducing HIV acquisition cannot be assessed.
NCT01489774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_HET_101|Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dose, Dose-escalation Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 After Oral Administration in Healthy Male Subjects, Phase I Study||CJ HealthCare Corporation|Yes|Completed|May 2011|June 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|86|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01489774||94272|
NCT01489787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIFU|Study to Evaluate a High Intensity Focused Ultrasound (HIFU) Procedure in Patient With Liver Metastases|A Phase I-II Study to Evaluate, in Patients Operated for a Hepatic Resection of Colorectal Liver Metastases, a High Intensity Focused Ultrasound (HIFU) Procedure: Feasibility, Safety and Accuracy.|HIFU|Centre Leon Berard|No|Recruiting|March 2010|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|38|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01489787||94271|
NCT01490034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK079913-3|Effects of Learning and Food Form on Intake in Humans|Effects of Learning and Food Form on Intake in Humans||Purdue University|No|Completed|September 2011|May 2015|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|120|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01490034||94252|
NCT01489800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0046|The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer|The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer||Columbia University|No|Enrolling by invitation|November 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|164|||Both|18 Years|N/A|No|||July 2015|July 2, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489800||94270|
NCT01490047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2011-001|Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas|Phase I Trial of Intravenous Recombinant Human TNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas||Ludwig Institute for Cancer Research|Yes|Withdrawn|January 2013|||||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490047||94251|
NCT01490606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11191/2011KCTIL|Knee Osteoarthritis (OA) Project Treatment Versus Conventional Physical Therapy in the Treatment of Knee OA Patients|A Comparative, Non Randomized Trial of Knee Osteoarthritis (OA) Project Treatment Versus Conventional Physical Therapy in the Treatment of Knee OA Patients|OA|Meir Medical Center|Yes|Recruiting|January 2012|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|N/A|No|||March 2012|March 2, 2012|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490606||94209|
NCT01490905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0820102|A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain|A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain||Targeted Medical Pharma|Yes|Completed|September 2010|April 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|127|||Both|18 Years|75 Years|No|||December 2011|December 9, 2011|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01490905||94186|
NCT01491191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|213/11|Palmitoylethanolamide for Post-operative Pain Prevention|Perioperative Use of Palmitoylethanolamide for Prevention of Chronic Postsurgical Pain in Patients Undergoing Elective Surgery.|PEAforCPSP|University of Modena and Reggio Emilia|No|Not yet recruiting|January 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2011|December 12, 2011|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01491191||94164|
NCT01491204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OXL-101|Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer|Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer||Hanmi Pharmaceutical Company Limited|No|Completed|August 2006|October 2008|Actual|October 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|19 Years|70 Years|No|||December 2011|December 11, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01491204||94163|
NCT01487473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWA00003852|The Effects of Mindfulness-Based Stress Reduction on Attention and Pain-related Symptoms in Chronic Pain Patients|The Effects of Mindfulness-Based Stress Reduction on Attention and Pain-related Symptoms in Chronic Pain Patients: A Randomized Controlled Trial||York University|No|Completed|December 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|80 Years|No|||February 2014|February 12, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487473||94449|
NCT01487109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP505.2001|A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients|A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy||Concert Pharmaceuticals|No|Completed|January 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||July 2014|March 12, 2015|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487109||94477|
NCT01467414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3763|A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Terminated|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|20 Years|70 Years|No|||November 2013|November 26, 2013|October 31, 2011|No|Yes|This trial was terminated due to low recruitment|No||https://clinicaltrials.gov/show/NCT01467414||95985|
NCT01467648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DORINOS4004|The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia|The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia||Prince of Songkla University|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|12|||Both|20 Years|N/A|No|||November 2011|November 8, 2011|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01467648||95967|
NCT01467661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-309|Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia|A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia||Shire|No|Completed|November 2011|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|20 Years|N/A|No|||May 2015|May 15, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01467661||95966|
NCT01459289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW11-327|Psychosocial Effect of HPV Positivity|The Psychosocial Effect of Testing Positive for HPV on Hong Kong Chinese Women With Normal Cervical Cytology||The University of Hong Kong|No|Recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|200|||Female|30 Years|60 Years||||October 2011|October 21, 2011|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01459289||96606|
NCT01459536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14547|Assessment of Muscle Function and Size in Older Adults With Rotator Cuff Tear|Rotator Cuff Function and Muscle Morphology in Older Adults With Rotator Cuff Tear|ARC|Wake Forest School of Medicine||Active, not recruiting|September 2011|||December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|50|||Both|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|orthopaedic surgery clinic, community sample|July 2013|July 22, 2013|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459536||96587|
NCT01459809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLIME_R_05809|Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients|A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes|RECOMMEND|Sanofi|Yes|Completed|February 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|538|||Both|18 Years|78 Years|No|||January 2015|January 19, 2015|October 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01459809||96566|
NCT01456767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35728.068.11/METC11-2-011|Effects of Administration of L.Plantarum WCFS1, L.Plantarum CIP104448, L.Plantarum CIP104450 on Small Intestinal Mucosa|The Effects of Oral Administration of Lactobacillus Plantarum WCFS1, Lactobacillus Plantarum CIP104448, and Lactobacillus Plantarum CIP104450 on Small Intestinal Mucosa and Barrier Function||Maastricht University Medical Center|Yes|Completed|October 2011|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 18, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01456767||96798|
NCT01456780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-048H|Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis|Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis|ZvL|Massachusetts Eye and Ear Infirmary|No|Active, not recruiting|August 2011|June 2015|Anticipated|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||June 2014|June 12, 2014|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01456780||96797|
NCT01456754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-057|Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning in Impaired Glucose Tolerant (IGT) Men|Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning in Impaired Glucose Tolerant (IGT) Men||Maastricht University Medical Center|No|Completed|December 2010|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|11|||Male|18 Years|70 Years|No|||December 2011|December 14, 2011|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01456754||96799|
NCT01457040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDE-ALL-2011|Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia|A Prospective Study of Intensified Conditioning Regimen With High-Dose-Etoposide for Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia in China||Nanfang Hospital of Southern Medical University|Yes|Completed|October 2011|February 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|14 Years|65 Years|No|||October 2015|October 7, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01457040||96778|
NCT01489007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29640|Iron Absorption in Vegetarian Children|Evaluation of Iron Absorption in Healthy Vegetarian Children 4 to 10 Years of Age||Baylor College of Medicine|No|Active, not recruiting|January 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|36|||Both|4 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|March 2015|March 25, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489007||94331|
NCT01489020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-DPT-P1-001|Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)|Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Dermatophagoides Pteronyssinus.||BIAL Industrial Farmacéutica S.A.|No|Completed|January 2011|August 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|48|||Both|18 Years|60 Years|No|||December 2011|December 7, 2011|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01489020||94330|
NCT01489306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-637-CP-102|A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 Administered to Healthy Volunteers for 10 Days||MicroDose Therapeutx, Inc||Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 10, 2012|December 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489306||94308|
NCT01489319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU-PCOS-0112|Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)|Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome|ELI-ROAS|Indiana University|No|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489319||94307|
NCT01489540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-47|Cost-effectiveness of Laser Doppler Imaging in Burn Care|Cost-effectiveness of Laser Doppler Imaging in Burn Care in the Netherlands||Association of Dutch Burn Centres|No|Completed|December 2011|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|200|||Both|N/A|N/A|No|||December 2011|September 18, 2013|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489540||94290|
NCT01490073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7928|The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women|The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study||Oregon Health and Science University|Yes|Recruiting|December 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|24|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490073||94249|
NCT01490060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0620|Fosaprepitant in Patients Receiving Ifosfamide-based Regimen|Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2012|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||May 2015|May 15, 2015|December 8, 2011||No||No|March 20, 2015|https://clinicaltrials.gov/show/NCT01490060||94250|
NCT01490333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2010-0118|Sunweavers: Supporting Native American Women's Vitamin D Research|Sunweavers: Supporting Native American Women's Vitamin D Research||University of Wisconsin, Madison|Yes|Completed|July 2011|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|99|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||November 2014|November 19, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01490333||94230|
NCT01490619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 DK 090030 01A1|Resilience Promotion in Teens With Type 1 Diabetes: Preventing Negative Outcomes|Resilience Promotion in Teens With Type 1 Diabetes: Preventing Negative Outcomes||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Active, not recruiting|October 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|280|||Both|14 Years|18 Years|No|||July 2014|July 29, 2014|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01490619||94208|
NCT01490931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPRIX IMPLANT 001|Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients|Single-dose and Multi-dose Open-label Pilot Trial of the Analgesic Efficacy and Tolerability of Intranasal Ketorolac Tromethamine (SPRIX®) in Dental Implant Surgery Patients With Postoperative Pain.||Hersh, Elliot V., DMD, MS, PhD|Yes|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|64 Years|No|||April 2014|April 11, 2014|December 11, 2011|Yes|Yes||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01490931||94184|The major weakness of this study was its open-label design and lack of a placebo control and an active comparator drug. The study was also not powered to determine differences between the sites of implant placement and the number of implants placed.
NCT01457183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00037071|Clinical Evaluation of Bedside Pulse Lavage Irrigation Device|Bedside Pulse Lavage Irrigation Project||Northwestern University|No|Completed|October 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 26, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01457183||96768|
NCT01457196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1108|Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions|Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|September 2011|September 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5000|Samples With DNA|Tumor tissue, normal adjacent tissue, blood, cheek (buccal) swab|Both|N/A|N/A|No|Non-Probability Sample|Cancer patients seen at the UNC Cancer Hospital and its clinics|November 2015|November 23, 2015|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01457196||96767|
NCT01487733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000717143|Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301|Analysis of HPV and Other Biomarkers in Specimens From ECOG Studies in Recurrent or Metastatic Head and Neck Cancer (E1395 and E3301)||National Cancer Institute (NCI)||Not yet recruiting|January 2012|||January 2013|Anticipated|N/A|Observational|N/A|||Anticipated|155|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01487733||94429|
NCT01467427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7999-3774|Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B|Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B|paradigm™5|Novo Nordisk A/S|No|Active, not recruiting|May 2012|October 2018|Anticipated|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|N/A|13 Years|No|||January 2016|January 22, 2016|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01467427||95984|
NCT01467687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA32724|Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Synerx Pharma and Verelan PM 300 mg Verapamil HCl Extended Release Capsules Controlled-Onset in Healthy Aduly Volunteers Under Fed Conditions||Synerx Pharma, LLC|Yes|Completed|July 2007|August 2007|Actual|August 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|58|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|November 8, 2011|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01467687||95964|
NCT01467674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1721-D-08|The Effect Of Glycemic Control On Malondialdehyde, Glutathione Peroxidase, Glutathione And Paraoxonase|Malondialdehyde And Antioxidant Levels In Chronic Periodontitis Patients With Type 2 Diabetes Mellitus Under Different Stages Of Metabolic Control||Suleyman Demirel University|No|Completed|January 2008|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|84|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with T2DM were recruited among those attending Suleyman Demirel University (SDU)        Faculty of Medicine, Department of Endocrinology and non-diabetic individuals were        recruited among those attending SDU Faculty of Dentistry, Department of Periodontology.|November 2011|November 8, 2011|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01467674||95965|
NCT01459575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATV 2005|Unboosted Atazanavir as Initial ART Therapy in China|||National Center for AIDS/STD Control and Prevention, China CDC|No|Completed|July 2005|December 2006|Actual|December 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|16 Years|N/A|No|Non-Probability Sample|ART-naïve patients, established HIV infection > 6 months with CD4 count of 100~350        cell/mm3|October 2011|October 24, 2011|October 24, 2011||||No||https://clinicaltrials.gov/show/NCT01459575||96584|
NCT01459549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYYYSOL|Randomized Controlled Trial of Treating Hepatolithiasis (Accompanied With SOL) With Choledochojejunostomy|Randomized Controlled Trial of Treating Hepatolithiasis(Accompanied With Sphincter of Oddi Laxity) With Roux-en-Y Choledochojejunostomy||Zhejiang University||Recruiting|October 2011|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|14 Years|80 Years|No|||October 2011|October 24, 2011|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459549||96586|
NCT01459562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-0501-03|First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy Volunteers|A Randomized Double-blinded Placebo Controlled Single Center Phase I Study of Escalating Single Intravenous Doses of NI-0501 in Healthy Volunteers||NovImmune SA|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|N/A|2||||||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|February 17, 2014|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01459562||96585|
NCT01460095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT07-135|Improving Access to HbA1c in Sub Saharan Africa|Improving Access to HbA1c Measurement in Sub-Saharan Africa|IA3|Yaounde Central Hospital|Yes|Active, not recruiting|March 2009|December 2011|Anticipated|November 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1000|||Both|18 Years|N/A|No|||October 2011|October 24, 2011|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01460095||96544|
NCT01460108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK_11_027_0311|AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation|Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System|CV+|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|No|Recruiting|April 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||October 2011|October 26, 2011|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460108||96543|
NCT01457066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH089719-01A1|Culturally Sensitive Intervention to Improve Retention in HIV Care for Latino MSM|Culturally Sensitive Intervention to Improve Retention in HIV Care for Latino MSM|PODER|University of California, Los Angeles|Yes|Completed|December 2012|September 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|118|||Male|18 Years|N/A|No|||May 2015|May 26, 2015|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457066||96776|
NCT01488188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FM-01 V1|Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route|A Controlled Study to Determine the Immunogenicity and Safety of Cold-adaptive Live Attenuated Influenza Vaccine (Flumist) Administered by the Nasal and Sublingual Route in Healthy Adult Volunteers||International Vaccine Institute|Yes|Completed|December 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|December 4, 2011||No||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01488188||94394|
NCT01457053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11051904|Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics|A Randomized Controlled Pilot Study for Assessment of Coronary Flow Reserve With Cardiac PET Imaging in Acute Decompensated Heart Failure Patients Treated With Diuretics Versus Ultrafiltration||University of Cincinnati|Yes|Terminated|November 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|4|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|October 19, 2011||No|Population not available for enrollment|No|December 19, 2014|https://clinicaltrials.gov/show/NCT01457053||96777|
NCT01488201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4827-001|A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis|A Randomized, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KHK4827 in Healthy Volunteers and Subjects With Moderate to Severe Psoriasis||Kyowa Hakko Kirin Company, Limited|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01488201||94393|
NCT01489332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|163/06/11|Induction Chemotherapy,Radiochemotherapy, Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer|Induction Chemotherapy, Preoperative Radiochemotherapy, Consolidation Chemotherapy, Operation and Adjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer- OIGIT 5-01 Phase II Trial||Institute of Oncology Ljubljana|No|Recruiting|October 2011|April 2018|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01489332||94306|
NCT01489553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 11-008294|Egg Oral Immunotherapy|Egg Oral Immunotherapy||Children's Hospital of Philadelphia|Yes|Completed|January 2012|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|Samples Without DNA|Immunocap testing (bloodwork) will be performed prior to and upon completion of the      desensitization protocol. This testing is considered standard of care in the management of      food allergies.|Both|6 Years|17 Years|No|Non-Probability Sample|outpatient Allergy patients followed at The Children's Hospital of Philadelphia|October 2012|October 21, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489553||94289|
NCT01489813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00050273|Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment|Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy||Emory University|Yes|Not yet recruiting|July 2016|December 2020|Anticipated|July 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489813||94269|
NCT01490372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-207|Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring|Is Gestational Diabetes Mellitus (GDM) an Independent Risk Factor for Cardiometabolic Syndrome in Offspring?|DG3|Université de Sherbrooke|No|Completed|August 2011|May 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|41|||Both|4 Years|12 Years|No|Non-Probability Sample|Offspring born from GDM pregnancies and their siblings born to the same mothers but from        non-GDM pregnancies.|January 2016|January 4, 2016|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01490372||94227|
NCT01490385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-2|The Effect of Light Emitting Diode Phototherapy on the Rate of Orthodontic Tooth Movement - A Clinical Study|The Effect of Light Emitting Diode Phototherapy on the Rate of Orthodontic Tooth Movement - A Clinical Study||University of Toronto|Yes|Completed|July 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|10 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 15, 2013|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01490385||94226|
NCT01490346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712M22448|Tissue Drug Levels of HIV Medications|A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution||University of Minnesota - Clinical and Translational Science Institute|No|Completed|September 2008|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|Samples Without DNA|Blood & lymphatic tissue.|Both|18 Years|N/A|No|Non-Probability Sample|HIV-positive individuals beginning anti-retroviral treatment.|June 2015|June 1, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01490346||94229|
NCT01490359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|806038|Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men|South African Men Health Promotion Project||University of Pennsylvania|No|Completed|November 2007|April 2011|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1181|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01490359||94228|
NCT01490632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14455|A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients With Moderate-to-Severe Plaque Psoriasis||Eli Lilly and Company|Yes|Completed|December 2011|August 2014|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|272|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|December 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490632||94207|
NCT01490645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CDE-XXX-2011/1|A NIS Registry of the Prospective Structured Care In Acute Coronary Syndrome|ProAcor: Prospective Structured Care In Acute Coronary Syndrome Registry|ProAcor|AstraZeneca|No|Completed|December 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1006|||Both|18 Years|N/A|No|Probability Sample|Regional centres / hospitals with a significant number of ACS patients|September 2014|September 4, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490645||94206|
NCT01490970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2081-015|Sarcoma Database at KFSH&RC|Sarcoma Database at KFSH&RC.||King Faisal Specialist Hospital & Research Center|Yes|Recruiting|April 2008|||April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|44|||Both|14 Years|85 Years|No|Non-Probability Sample|Sarcoma Database|January 2016|January 4, 2016|December 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490970||94181|
NCT01490944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNRT/Ph.D/4/2010|Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls|Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls||Indian Council of Medical Research|Yes|Recruiting|January 2012|January 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Female|11 Years|18 Years|Accepts Healthy Volunteers|||January 2012|February 25, 2012|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01490944||94183|
NCT01490957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC# 2071-079|Functional Assessment of Cancer Therapy - Bone Marrow Transplant|Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT)|FACT-BMT|King Faisal Specialist Hospital & Research Center|Yes|Recruiting|March 2008|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|113|||Both|14 Years|85 Years|No|Non-Probability Sample|Lymphoma database|December 2011|December 11, 2011|December 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490957||94182|
NCT01457209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS-AcupIR|Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome|Effect of Acupuncture on Insulin Sensitivity in Women With and Without Polycystic Ovary Syndrome|PCOS-AcupIR|Göteborg University|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||January 2014|January 20, 2014|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01457209||96766|
NCT01457482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|210/422|Art Therapy as Treatment for Fear of Childbirth|Art Therapy as Treatment for Fear of Childbirth:a Randomized Controlled Study||Helsingborgs Hospital|No|Recruiting|May 2011|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Female|N/A|N/A|No|||February 2012|February 13, 2012|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01457482||96745|
NCT01457495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217744/031|Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly|Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites||GlaxoSmithKline||Completed|September 1998|September 1999|Actual|September 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|312|||Both|12 Weeks|16 Weeks|Accepts Healthy Volunteers|||October 2011|October 20, 2011|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01457495||96744|
NCT01467713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375SL_203|Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients||Takeda|No|Terminated|January 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|642|||Both|18 Years|75 Years|No|||December 2015|December 1, 2015|November 4, 2011|Yes|Yes|Business Decision; No Safety Concerns.|No||https://clinicaltrials.gov/show/NCT01467713||95962|
NCT01467726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0048|Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects|A Phase 1, Randomized, Placebo−Controlled, Double−Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects||Theravance Biopharma R & D, Inc.|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|40|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|October 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01467726||95961|
NCT01467700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-375SL_201|Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) in the Treatment of Acute Depressive Episodes Associated With Bipolar I Disorder in Adult Patients Who Are on Lithium and/or Valproate||Takeda|No|Terminated|December 2011|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|312|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 4, 2011|Yes|Yes|Business Decision; No Safety Concerns|No||https://clinicaltrials.gov/show/NCT01467700||95963|
NCT01468025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708101|Effectiveness of Theramine on Chronic Back Pain|A Randomized Double-blind Placebo Study to Determine the Effectiveness of Theramine and a Low Dose Naproxen on the Management of Chronic Back Pain||Targeted Medical Pharma|No|Completed|February 2009|July 2009|Actual|July 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|127|||Both|18 Years|75 Years|No|||November 2011|November 5, 2011|September 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01468025||95939|
NCT01460121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SpotOn Specs 002|Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness|A Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness||Meir Medical Center|No|Active, not recruiting|February 2012|February 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||October 2015|October 11, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01460121||96542|
NCT01459822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301PLAGH-20110824005|MiRNAs Evaluate the Prognosis of Sepsis by Dynamic Study|MiRNAhs in the Evaluation of the Value of Sepsis Prognosis Dynamics Observational Research|METPSDS|Chinese PLA General Hospital|Yes|Recruiting|August 2011|September 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|Samples Without DNA|human serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|within 24 hours after admited in ICU|August 2011|October 25, 2011|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01459822||96565|
NCT01459835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD056506-02|Media Impact on Preschool Behavior|||Seattle Children's Hospital|Yes|Completed|June 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|600|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01459835||96564|
NCT01459848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baby DVD study|Baby Dvd Effects on Cortisol|A Randomized Controlled Trial of Block Play vs Dvd Viewing||Seattle Children's Hospital|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Anticipated|50|||Both|9 Months|12 Months|Accepts Healthy Volunteers|||March 2014|March 24, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01459848||96563|
NCT01456156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-019|Study of Postoperative 3D-CRT/IMRT in Hepatocellular Carcinoma|Phase 2 Study of Postoperative Three-dimensional Conformal Radiation Therapy/Intensive Modulated Radiation Therapy in Hepatocellular Carcinoma: a Single Center Prospective Study||Chinese Academy of Medical Sciences|No|Recruiting|January 2008|||December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|76|||Both|18 Years|75 Years|No|||February 2015|February 4, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01456156||96845|
NCT01456455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGICNS|Gastric Cancer Metastasized to the Central Nervous System (CNS)|Registry of Gastric Cancer and Brain Metastases||University of Zurich|No|Recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|150|||Both|18 Years|N/A|No|Probability Sample|international|May 2014|May 20, 2014|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01456455|2 Years|96822|
NCT01488994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251101|BAX 326 Pediatric Study|BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B||Baxter Healthcare Corporation|Yes|Completed|December 2011|May 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|N/A|12 Years|No|||May 2014|May 29, 2014|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488994||94332|
NCT01489280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26-115-630|Temple Touch Pro (TTP) Non Invasive Continuous Temperature Measurement System|Temple Touch Pro (TTP) Non Invasive Continuous Temperature Measurement System.|TTP|Medisim Ltd|No|Recruiting|May 2012|||February 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|800|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|ages 0 and up, patients subjected to elective surgery.|September 2012|September 9, 2012|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489280||94310|
NCT01489293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC110053CTIL|Inhibitory Receptors in Eosinophils of Atopic Subjects|Characterization of the Expression and Activity of Inhibitory Receptors Such as CLM-1 in Eosinophils of Atopic Subjects||Meir Medical Center|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|40|Samples With DNA|whole blood|Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|allergy clinic|April 2012|March 3, 2013|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489293||94309|
NCT01489566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYS-CN-1.1PUMP III|Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients|A Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Phase III Clinical Trial to Evaluate the Safety and Efficacy of Injectable Tyroserleutide to Treat Hepatocellular Carcinoma||Shenzhen Kangzhe Pharmaceutical Co., Ltd.|No|Enrolling by invitation|July 2011|August 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||December 2011|December 13, 2011|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01489566||94288|
NCT01479322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-11-056|Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome|Correlation Between Hyperghrelinemia and Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome||Samsung Medical Center|Yes|Completed|January 2007|July 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|51|||Both|6 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|The investigators studied twenty-seven children with PWS and 24 normal control subjects.        The groups were adjusted for age, sex, and BMI.|November 2011|November 23, 2011|July 31, 2011||||No||https://clinicaltrials.gov/show/NCT01479322||95075|
NCT01479608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SECA-II|Liver Transplantation and Colorectal Cancer|A Randomized Controlled Clinical Trial to Evaluate the Benefit and Efficacy of Liver Transplantation as Treatment for Selected Patients With Liver Metastases From ColoRectal Carcinoma||Oslo University Hospital|No|Recruiting|November 2011|December 2027|Anticipated|December 2025|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479608||95054|
NCT01479907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNBIOTICSCOLON|Synbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer|||University of Athens|No|Recruiting|November 2010|April 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||November 2011|November 25, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01479907||95031|
NCT01479894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133972|Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer|||University of Arkansas|No|Completed|November 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|44|Samples With DNA|The Oncotype DX Colon Cancer Assay will be utilized to define the gene expression profile of      the tumor tissue.|Both|18 Years|N/A|No|Probability Sample|This is an exploratory study utilizing archived tumor specimens and demographic and        pathologic characteristics derived from the patient's medical charts. As such, all        eligible patients must have a stored tumor specimen which can be accessed for analysis.|February 2015|February 18, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01479894||95032|
NCT01480141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101596|A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)|A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC||Medical University of South Carolina|Yes|Withdrawn|January 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|90 Years|No|||September 2012|March 25, 2013|November 23, 2011|Yes|Yes|PI left MUSC, no patient enrollments|No||https://clinicaltrials.gov/show/NCT01480141||95013|
NCT01480427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PedQLFA1|Assessment of Quality of Life in Food Allergic Children|Assessment of Quality of Life in Food Allergic Children||University of Lausanne Hospitals||Completed|May 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|N/A|12 Years|No|Non-Probability Sample|General population of children 0-12 years old|November 2011|November 25, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480427||94991|
NCT01480401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|82-SH-01|Study of Dietary Intervention Under 100 MMOL in Heart Failure|The Long Term Effects of Dietary Sodium Restriction on Clinical Outcomes in Patients With Heart Failure|SODIUM-HF|University of Alberta|Yes|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480401||94993|
NCT01480648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1313.1|Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 144807 Powder in Bottle (1 to 1200 mg) in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Trial||Boehringer Ingelheim||Completed|November 2011|||February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||Actual|74|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|November 21, 2011||||No||https://clinicaltrials.gov/show/NCT01480648||94974|
NCT01480674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML23001|An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years|A Retrospective Study to Characterize Patients With HER2-positive Metastatic or Locally Advanced Breast Cancer, Treated by Herceptin® as 1st Line-therapy and Without Progression for at Least 3 Years Followed by a 1-year Prospective Study for Patients Still Alive||Hoffmann-La Roche||Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|160|None Retained|unknown|Female|18 Years|N/A|No|Probability Sample|Patients with HER2-positive metastatic breast cancer or locally advanced breast cancer        whose systemic treatment included Herceptin as 1st line therapy, and who were without        progression for at least 3 years after beginning Herceptin|January 2016|January 27, 2016|August 18, 2011||No||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01480674||94972|
NCT01481662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081261|Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome|Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome (RETINOCOCHLEOCEREBRAL Vasculopathy)|CARESS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|100|Samples With DNA|-  serum sample        -  cerebrospinal fluid sample        -  DNA sample        -  RNA sample        -  Peripheral Blood Mononuclear Cell sample|Both|18 Years|N/A|No|Non-Probability Sample|SUSAC's Syndrome (SS) is characterized by the clinical triad of encephalopathy, hearing        loss, and retinal artery branch occlusions. Hundreds of patients with SS, mostly young        women, have been reported.|August 2013|August 13, 2013|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01481662||94896|
NCT01481948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27505|Food, Fun, & Fitness Internet Program for Girls: Outcome Evaluation|Using Technology to Prevent Obesity Among African American Girls|FFFIPG|Baylor College of Medicine|Yes|Completed|January 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|342|||Female|8 Years|10 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01481948||94874|
NCT01481961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALSTIMAG|Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease|Feasibility Study: Cognitive Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)on add-on in Patients With Early Alzheimer's Disease|ALSTIMAG|Centre Hospitalier Universitaire de Besancon|No|Completed|November 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|60 Years|85 Years|No|||February 2015|February 27, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01481961||94873|
NCT01482234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27537|Text Messages and Physical Activity Among Teens|TXT Me: Texting Motivational Messages Encouraging Adolescent Physical Activity||Baylor College of Medicine|No|Completed|February 2012|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|160|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||January 2016|January 18, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482234||94852|
NCT01482247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT008957003|L-Arginine, Vascular Response and Mechanisms|L-Arginine, Vascular Response and Mechanisms||Brigham and Women's Hospital|No|Completed|April 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|25|||Both|70 Years|N/A|No|||October 2014|October 15, 2014|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482247||94851|
NCT01489488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14986|Relative Bioavailability and Food Effect Study|Relative Bioavailability and Food Effect Study of Two Oral Liquid Formulations in Comparison to a 1 mg Tablet of Riociguat to Characterize Its Pharmacokinetic Properties in Healthy Male and Female Adult Subjects in a Randomized, Open Label, 5-fold Crossover Design||Bayer|No|Completed|January 2012|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 29, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489488||94294|
NCT01482143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056B2154|Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)|Sequential, Two-period Study to Assess the Pharmacokinetics, Safety & Tolerability of Single and Multiple Oral Doses of AFQ056 in Patients With FXS (Fragile X Syndrome) Aged 5-11 Years (Cohort 1) and 3-4 Years (Cohort 2)||Novartis||Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|21|||Both|3 Years|11 Years|No|||September 2014|September 29, 2014|November 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482143||94859|
NCT01482156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001X2109|Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors|An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors||Novartis||Completed|January 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01482156||94858|
NCT01482169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012012|Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)|Efficacy of Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve Measurements||Ochsner Health System|Yes|Completed|March 2012|September 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|64|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|November 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01482169||94857|
NCT01478542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL 2009-1|OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine|Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution|OPTIMAL>60|University Hospital, Saarland|Yes|Recruiting|November 2011|October 2019|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|1152|||Both|61 Years|80 Years|No|||October 2015|October 14, 2015|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01478542||95135|
NCT01478555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-101-001|A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease|A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite® Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers|ISV-101|InSite Vision|No|Not yet recruiting|January 2017|January 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|October 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478555||95134|
NCT01478516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-72|Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy|Autologous Intravitreal Plasmin and Fibrinolytic System of Vitreous in Patient With Macular Edema||Hallym University Medical Center|Yes|Recruiting|November 2011|November 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|80 Years|No|||December 2011|December 1, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01478516||95137|
NCT01478529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-033|A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation|A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation||Astellas Pharma Inc|No|Completed|February 2006|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478529||95136|
NCT01478815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-070-3|Contingency Management for Persons With Severe Mental Illness|Contingency Management for Persons With Severe Mental Illness||University of Connecticut Health Center|Yes|Completed|December 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||December 2012|January 15, 2013|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478815||95114|
NCT01479283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHRT01|Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)|Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements|PARITY|McMaster University|Yes|Recruiting|January 2013|December 2019|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|12 Years|N/A|No|||March 2016|March 14, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01479283||95078|
NCT01479296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 085|Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults|A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|December 2011|||May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01479296||95077|
NCT01479309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0354 IIa|Study to Evaluate Sodium Stibogluconate With Interferon Alpha-2b|A Phase IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Withdrawn|September 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2011|November 23, 2011|November 21, 2011|Yes|Yes|Pharmaceutical sponsor terminated study.|No||https://clinicaltrials.gov/show/NCT01479309||95076|
NCT01479348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120014|Imaging Study for FdCyd and THU Cancer Treatment|Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|October 2011|October 2017|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|5|||Both|18 Years|99 Years|No|||April 2015|November 18, 2015|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01479348||95074|
NCT01480154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00084|Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer|A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2011|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01480154||95012|
NCT01480687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FO-1800|Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia|Effects of Fish Oil Supplementation on Vascular Structure and Function in Hypertensive Patients With Hypertriglyceridemia||Hospital Universitario Pedro Ernesto|Yes|Recruiting|May 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|52|||Both|40 Years|65 Years|No|||November 2011|November 23, 2011|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01480687||94971|
NCT01480414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-PVD-002|Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb|Evaluation the Side Effects of Repeated Bone Marrow Derived Mono Nuclear Stem Cells Transplantation in Patients With Lower Limb Ischemic Ulcer||Royan Institute|Yes|Completed|September 2010|May 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|62 Years|No|||July 2010|December 25, 2012|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480414||94992|
NCT01481168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5883|Adenosine Testing to DEtermine the Need for Pacing Therapy|Adenosine Testing to DEtermine the Need for Pacing Therapy With the Additional Use of an Implantable Loop Recorder (ADEPT-ILR Study). The Efficacy of Permanent Pacing in Patients With Syncope and a Positive Intravenous Adenosine Test: a Randomised, Double-blind, Placebo-controlled, Cross-over Trial.|ADEPT-ILR|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|January 2012|October 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|180|||Both|40 Years|N/A|No|||February 2012|February 22, 2012|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01481168||94934|
NCT01487746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0125-11-MMC|Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls|Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls.||Meir Medical Center|No|Not yet recruiting|December 2011|September 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|207|Samples Without DNA|Serum samples of Stroke patients withdrawned within 36 hrs since stroke evoked. Healthy      controls|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|on a bank of 207 stroke patients serum samples, and also on 40 healthy controls. The        samples were collected during the acute phase of the ischemic event.|December 2011|December 6, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487746||94428|
NCT01487759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML4789|Prebiotic Effect on Metabolites in Crohn's Disease|Metabolite Profiling of the Impact of Oligofructose Enriched Inulin in Crohn's Disease Patients||Katholieke Universiteit Leuven|No|Completed|March 2008|July 2009||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|67|||Both|18 Years|N/A|No|||December 2011|December 9, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01487759||94427|
NCT01488019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201-085|Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Dey|No|Active, not recruiting|March 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1071|||Both|40 Years|N/A|No|||April 2015|April 14, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488019||94407|
NCT01488032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 322102010|Differences in Nerve Fiber Layer Between Patients With Normal- and High-Pressure-Glaucoma|Differences in Nerve Fiber Layer Between Patients With Normal- and High-Pressure-Glaucoma With Similar Structural Optic Nerve Damage||Technische Universität Dresden|No|Completed|March 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|18 Years|60 Years|No|Non-Probability Sample|primary care clinic University hospital of Dresden|December 2011|December 8, 2011|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01488032||94406|
NCT01487772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/685-32|Improving Quality of Care for Hip-Fracture Patients: Studies on Fast-track Surgery|Improving Quality of Care for Hip-Fracture Patients: Studies on Fast-track Surgery|Q-HIP|Danderyd Hospital|No|Completed|April 2010|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1307|||Both|N/A|N/A|No|Non-Probability Sample|All hip-fracture patients admitted to the Orthopaedic Department of Danderyd Hospital        during a two-year period.|September 2014|September 18, 2014|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01487772||94426|
NCT01488279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP 39681|Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy|Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy||University of Vermont|No|Not yet recruiting|September 2012|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488279||94387|
NCT01489501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS001-EU01|Multicenter Study of CAOMECS Transplantation to Patients With Total Limbal Stem Cell Deficiency|Multicenter Study of Cultured Autologous Oral Mucosal Epithelial Cell-Sheet (CAOMECS) Transplantation to Patients With Total Limbal Stem Cell Deficiency||CellSeed France S.A.R.L.|No|Withdrawn||||||Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|74 Years|No|||March 2015|March 24, 2015|December 8, 2011||No|Change of strategic priorities in the sponsor's clinical development sector.|No||https://clinicaltrials.gov/show/NCT01489501||94293|
NCT01481883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|486/11|Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?|A Randomised Controlled Trial of Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?||The Alfred|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Male|18 Years|45 Years|No|||January 2016|January 21, 2016|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01481883||94879|
NCT01482182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-05-087|Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy|Prediction of Chemotherapy Response and Patient Prognosis in Non-small Cell Lung Cancer: Dynamic Contrast-enhanced MRI and Diffusion-weighted Imaging Versus Volume-based Parameter of 18F-FDG PET||Samsung Medical Center|Yes|Completed|November 2011|January 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|20 Years|N/A|No|Non-Probability Sample|patients with advanced NSCLC|October 2015|November 17, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01482182||94856|
NCT01479101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0339 NBRST Registry|NBRST: Prospective Neo-adjuvant REGISTRY Trial|Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST) (Pronounced "in Breast")|NBRST|Agendia|No|Active, not recruiting|July 2011|January 2020|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1142|Samples With DNA|As part of routine breast cancer treatment, the doctor will conduct a core needle biopsy and      provide tissue from the tumor to Agendia for testing. After the diagnostic test(s) from the      Agendia Breast Cancer Suite have been performed on the tumor specimen, there might be some      remaining tissue left.|Female|18 Years|90 Years|No|Non-Probability Sample|Women with histologically proven breast cancer, who have started or are scheduled to start        neo-adjuvant chemotherapy therapy or neo-adjuvant hormone therapy.|June 2015|June 22, 2015|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01479101||95092|
NCT01478828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-1153|Pre-Prostatectomy Lovastatin on Prostate Cancer|Pharmacodynamic Trial of Pre-Prostatectomy Lovastatin on MYC (V-myc Myelocytomatosis Viral Oncogene Homolog) Down-Regulation in Localized Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Suspended|March 2012|April 2016|Anticipated|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|18 Years|100 Years|No|||October 2015|October 13, 2015|November 3, 2011|Yes|Yes|The study was stopped due to an unanticipated serious adverse event.|No|January 13, 2015|https://clinicaltrials.gov/show/NCT01478828||95113|
NCT01479088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGG_ev_003|Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)|Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension.||Istituto Giannina Gaslini|Yes|Recruiting|March 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|18 Years|No|||November 2011|November 23, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479088||95093|
NCT01479049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJXZ2009-1010|The Myocardial Protective Effects of a Moderate-potassium Blood Cardioplegia in Pediatric Cardiac Surgery|The Myocardial Protective Effects of a Moderate-potassium Blood Cardioplegia in Pediatric Cardiac Surgery：a Randomized Controlled Trial||Xijing Hospital|Yes|Completed|October 2009|October 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|1 Month|24 Months|No|||November 2011|November 23, 2011|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01479049||95096|
NCT01479062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R44NR012617-01|Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics|Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics (ALIVE-PD)||Berkeley Analytics, Inc.|No|Active, not recruiting|February 2014|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|268|||Both|40 Years|79 Years|No|||February 2015|February 5, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479062||95095|
NCT01479647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631034|A Study To Investigate The Effect Of Food On The Pharmacokinetics Of PH-797804|A Phase 1, Randomized, Open-Label, Single Dose, 2-Cohort Crossover Study To Determine The Effect Of Food On The Pharmacokinetics Of Orally Administered PH-797804 In Healthy Volunteers||Pfizer|No|Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|28|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 25, 2012|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01479647||95051|
NCT01479660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/6095 dated 15/03/2011|Role of Healthy Bacteria in Ulcerative Colitis|Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial||Postgraduate Institute of Medical Education and Research|No|Recruiting|March 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||November 2011|November 23, 2011|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479660||95050|
NCT01480453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU2010-29E|Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty|Prospective Post Market Clinical Follow-up Study of the Zimmer Trabecular Metal Humeral Stem||Zimmer, Inc.|No|Recruiting|January 2011|December 2024|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Each investigator will screen from his/her patients who suffer from Osteoarthritis,        Rheumatoid arthritis, Post-traumatic arthritis, Ununited humeral head fracture,        Irreducible 3- and 4-part proximal humeral fractures, Avascular necrosis who meet the        inclusion/exclusion criteria stated in the protocol.|December 2015|December 18, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480453||94989|
NCT01480466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01HS019789|Use of Electronic Health Records for Addressing Overweight and Obesity in Primary Care|Use of Electronic Health Records for Addressing Overweight and Obesity in Primary Care||Brigham and Women's Hospital|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|65278|||Both|20 Years|N/A|No|||April 2014|April 28, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01480466||94988|
NCT01490684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAMC|Invasive Candidiasis in ICU|Invasive Candidiasis in Critically Ill Patients in Saudi Arabia: A Prospective Cohort Study|ICIP-SA|King Abdulaziz Medical City|No|Recruiting|August 2012|January 2014|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|N/A|No|Non-Probability Sample|All adult patients (> 18 years) admitted to the ICUs of these centers will be evaluated        for the occurrence of Candida infection and followed to discharge or death in ICU. The        duration of the study will be 12 months. Also patients who had invasive candidiasis within        72 hours of ICU admission will be included.|August 2012|August 13, 2012|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01490684||94203|
NCT01490697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000647|Developing Memory Reconsolidation Blockers as Novel Post-traumatic Stress Disorder (PTSD) Treatments|Developing Memory Reconsolidation Blockers as Novel PTSD Treatments||Massachusetts General Hospital|Yes|Completed|March 2009|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|December 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490697||94202|
NCT01480700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00364-37|Consumption of Eggs Rich in Lutein and Omega-3 Fatty Acids on the Macular Pigment|Effect of Consumption of Eggs Rich in Xanthophyll Carotenoids and Omega-3 Fatty Acids on the Macular Pigment in Healthy People|ALGOVUE|Institut Pasteur de Lille|Yes|Completed|October 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|99|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 2, 2013|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01480700||94970|
NCT01480934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01072007|Evaluation of Posterior Capsule Opacification in Eyes With Diabetes Mellitus|A Prospective Evaluation of Posterior Capsule Opacification in Eyes With Diabetes Mellitus -A Case Control Study|DM & PCO|Iladevi Cataract and IOL Research Center|Yes|Completed|June 2005|June 2010|Actual|January 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|150|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients who underwent phacoemulsification for age-related cataract|November 2011|November 28, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480934||94952|
NCT01480440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU2010-28E|Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty|Prospective Post Market Clinical Follow-up Study of the Zimmer Trabecular Metal Reverse Should System||Zimmer, Inc.|No|Recruiting|January 2011|December 2024|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Each investigator will screen from his/her patients who suffer from osteoarthritis,        rheumatoid arthritis, post-traumatic arthritis, ununited humeral head fracture,        irreduciable 3-and 4-part proximal humeral fractures, avascular necrosis, gross rotator        cuff dificiency or failed total shoulder arthroplasty (both glenoid and humeral components        require revision) who meet the inclusion/exclusion criteria stated in the protocol|December 2015|December 18, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480440||94990|
NCT01481441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37231.018.11|Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer|Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer|AMC_2011_190|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|560|||Male|18 Years|N/A|No|||January 2015|January 13, 2015|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01481441||94913|
NCT01487499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCLC|Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)|Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer|SCLC|University of Florida|Yes|Terminated|December 2011|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|N/A|N/A|No|||May 2015|May 15, 2015|December 1, 2011|Yes|Yes|Unable to enroll adequate number of participants|No|March 16, 2015|https://clinicaltrials.gov/show/NCT01487499||94447|
NCT01488305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000076- AT|Action Against Malnutrition Through Agriculture (AAMA) Plus MNP Study|Impact of Micronutrient Powders (MNP)With Homestead Food Production and an Intensive Community Level IYCF-BCC Intervention on Reducing Anemia and Improving Growth in Young Children, Nepal|MNP|Helen Keller International|Yes|Active, not recruiting|October 2010|March 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|3||Actual|334|||Both|6 Months|23 Months|Accepts Healthy Volunteers|||December 2011|December 7, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488305||94385|
NCT01488045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCCS 262|Compare Propofol to Fentanyl and Midazolam for Colonoscopy|Randomized Trial to Compare Propofol to Fentanyl and Midazolam for Colonoscopy.||Saint Joseph Mercy Health System|No|Active, not recruiting|June 2011|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|290|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01488045||94405|
NCT01481870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROSS-J-RCC|Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma|Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma|CROSS-J-RCC|Yamagata University|Yes|Active, not recruiting|January 2010|December 2015|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|80 Years|No|||February 2013|February 21, 2013|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01481870||94880|
NCT01481610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEMEX-805415-00-2|Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia|Comparison of the Effects on Renal Function of Lumiracoxib and Diclofenac in Patients With Chronic Kidney Failure K/DOQI Stage III at the HCSAE PEMEX||Hospital Central Sur de Pemex|No|Terminated|January 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|60 Years|N/A|No|||February 2013|February 11, 2013|November 23, 2011||No|Interim analysis shows harma to one of the study arms.|No||https://clinicaltrials.gov/show/NCT01481610||94900|
NCT01481896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AORI2011-0100|A Five-Year Metal-on-Metal Retrospective Clinical Study|A Five-Year Metal-on-Metal Retrospective Clinical Study||Anderson Orthopaedic Research Institute|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|126|||Both|18 Years|N/A|No|Non-Probability Sample|A consecutive series of patients who had primary total hip arthroplasties performed at the        Anderson Clinic using DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium        alloy femoral heads.|August 2013|August 1, 2013|November 23, 2011|Yes|Yes||No|June 30, 2012|https://clinicaltrials.gov/show/NCT01481896||94878|
NCT01481909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-2010-1|Study on Mastocytosis for Rupatadine Treatment|Study on Mastocytosis for Rupatadine Treatment An Exploratory Phase IV, Randomised, Double-blind, Placebo Controlled Crossover Study to Assess the Efficacy of 20 mg Rupatadine on the Treatment of|SMART|Charite University, Berlin, Germany|Yes|Completed|September 2010|November 2011|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||November 2011|November 28, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01481909||94877|
NCT01482195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0916-P|Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations|Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations||King Khaled Eye Specialist Hospital|Yes|Recruiting|August 2011|August 2023|Anticipated|August 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|14 Years|70 Years|No|||November 2011|November 29, 2011|September 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482195||94855|
NCT01478243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07|Study of Psycho-Social Impact of Keloid|Study of Psycho-Social Impact of Keloid||Tirgan, Michael H., M.D.|No|Terminated|September 2012|July 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All patients with clinical diagnosis of Keloid are invited to particiapate in this study.|December 2013|December 16, 2013|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01478243||95158|
NCT01479127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-925|Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease|An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease||AbbVie|No|Completed|October 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|30 Years|99 Years|No|||February 2016|February 15, 2016|September 26, 2011||No||No|February 15, 2016|https://clinicaltrials.gov/show/NCT01479127||95090|
NCT01479374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-126|Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model|A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model||Alcon Research|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|397|||Both|18 Years|N/A|No|||May 2013|May 28, 2013|November 22, 2011|Yes|Yes||No|March 28, 2013|https://clinicaltrials.gov/show/NCT01479374||95072|
NCT01479387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15043|Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan|Special Drug Use Investigation of Zevalin|ZEVALIN-SDUI|Bayer|No|Completed|August 2008|February 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|72|||Both|N/A|N/A|No|Non-Probability Sample|The target population of this study is 40 patients who received In-111 Zevalin to access        biodistribution of Zevalin.|November 2011|November 22, 2011|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01479387||95071|
NCT01479920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 09-091|A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture|The Identification of Central Neural Network for Antidepressant Effects of Dense Cranial Electroacupuncture Stimulation - a Positron Emission Topographic (PET) Study||The University of Hong Kong|Yes|Completed|June 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|22 Years|65 Years|No|||December 2015|December 4, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01479920||95030|
NCT01479075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Centrin|The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism|The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism|Centrin|German Diabetes Center|No|Recruiting|August 2011|June 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|30|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 23, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479075||95094|
NCT01490398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0865|Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve|Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients|RESERVE|Asan Medical Center|No|Completed|December 2011|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|35 Years|80 Years|No|||May 2014|May 8, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490398||94225|
NCT01490710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/6-H|NAVADYN11 : Hemodynamic Impact of a New Ventilatory Support Mode With Diaphragmatic Synchronization|NAVADYN11 : Hemodynamic Impact of a New Ventilatory Support Mode With Diaphragmatic Synchronization||Nantes University Hospital|No|Terminated|November 2011|||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|||Actual|9|||Both|N/A|N/A|No|||September 2013|September 2, 2013|December 7, 2011||||No||https://clinicaltrials.gov/show/NCT01490710||94201|
NCT01491022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110173|A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease|A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease||University of Miami|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|45 Years|80 Years|No|||January 2016|January 11, 2016|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491022||94177|
NCT01480921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA 5147|Hospital Versus Home Based Exercise in Patients With Chronic Stable Heart Failure|The Effect of Hospital Versus Home-based Exercise on Psychosocial and Physical Outcomes in Patients With Chronic Stable Heart Failure|PEAK-HF|McMaster University|No|Completed|July 2003|November 2007|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||November 2011|November 23, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01480921||94953|
NCT01487486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proteomics of FF in PCOS|Proteomics & Glyco-Proteomic Analysis of Follicular Fluid|Proteomics & Glyco-Proteomic Analysis of Follicular Fluid Derived From Health Patient/Donors and Polycystic Ovary Syndrome Patients||University of Cincinnati|No|Not yet recruiting|December 2011|January 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Follicular Fluid|Female|18 Years|N/A|No|Non-Probability Sample|Women undergoing In Vitro Fertilization who have:          1. male factor only infertility diagnosis or are oocyte donors          2. PCOS|December 2011|December 5, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01487486||94448|
NCT01488058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/055|Cognitive Bias Modification (CBM) and Internet Cognitive Behavioural Therapy (iCBT) for Depression- A Randomised Controlled Trial|A Randomised Controlled Trial Comparing Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder Plus a Cognitive Bias Modification Intervention (OxIGen) vs. Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder vs. a Waitlist Control on Symptoms of Depression and Negative Interpretation Bias.||St Vincent's Hospital, Sydney|Yes|Completed|December 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||September 2012|September 18, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488058||94404|
NCT01488578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121186|Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)|Postmarketing Observational Study of Tolterodine Treatment on Overactive Bladder in Real Life Setting|POTTOR|Pfizer|No|Completed|December 2006|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11157|||Both|N/A|N/A|No|Probability Sample|The subjects whom an investigator involving A6121186 prescribes the Tolterodine tartrate        (Detrusitol Capsule).|May 2012|May 11, 2012|April 27, 2011||No||No|March 8, 2012|https://clinicaltrials.gov/show/NCT01488578||94364|
NCT01488591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-029|Biomarker Research for Personalized Medicine|Biomarker Research for Personalized Medicine in Blood Cancer Patient||Inje University|No|Recruiting|April 2009|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|whole blood|Both|N/A|N/A|No|Probability Sample|healthy volunteers|May 2013|May 30, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488591||94363|
NCT01488344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKM10_0014|Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)|A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy||University Hospital Muenster|Yes|Active, not recruiting|March 2012|||November 2014|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|60 Years|N/A|No|||December 2013|December 10, 2013|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01488344||94382|
NCT01497392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 175610|Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers|Phase I Study of Dovitinib (TKI258) in Combination With Gemcitabine and Capecitabine in Advanced Solid Tumors, Pancreatic Cancer and Biliary Cancers||Roswell Park Cancer Institute|No|Active, not recruiting|March 2012|||October 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|February 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497392||93690|
NCT01498536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22426|Effect of Diet and Exercise in Breast Cancer Survivors|Fit for the Fight: Effect of a Multidisciplinary Diet and Exercise Program on Body Weight, Quality of Life and Inflammation in Survivors of Triple-negative Breast Cancer|F4F tri neg|West Virginia University|No|Completed|July 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|28|||Female|18 Years|80 Years|No|||October 2013|October 29, 2013|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498536||93603|
NCT01481623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081230|Identification and Characterization of Monogenic Diabetes|Identification and Genetic, Clinical and Metabolic Characterization of Monogenic Forms of Insulin-dependent Diabetes|DIAGENE|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|June 1, 2015|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01481623||94899|
NCT01482208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHM-01|Clinical Evaluation of Ultrasonic Hydration Monitor for Infants|Study of Ultrasonic Hydration Monitor for Neonatology and Pediatric Children and Infants and/or Children up to Age 3 Years Old With Diarrhea|IHM-01|Artann Laboratories|No|Completed|November 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|42|||Both|N/A|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|Newborns from 1 to 7 days Small children from 1 month to 3 years old|March 2014|March 28, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482208||94854|
NCT01478581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1111-CA|Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma|A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma||Pharmacyclics|No|Active, not recruiting|March 2012|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|164|||Both|18 Years|N/A|No|||September 2015|January 22, 2016|November 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478581||95132|
NCT01478841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8178|Polyphenols and Insulin Resistance|INFLUENCE OF POLYPHENOLS ON OXIDATIVE STRESS IN HEALTHY INDIVIDUALS WITH HIGH METABOLISM RISK: RELATIONSHIP WITH THE MECHANISMS OF INSULIN RESISTANCE|POLYOXRESIST|University Hospital, Montpellier|Yes|Completed|October 2008|January 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|44|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478841||95112|
NCT01489371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-9928|EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Gynecologic Oncology Group||Recruiting|July 2012|||October 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||August 2014|August 11, 2014|December 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489371||94303|
NCT01489579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-11-1660|Telephone Counseling for Tobacco Cessation|Evaluation of Brief, Structured, Telephone Counseling for Tobacco Cessation as Part of a Cardiovascular Risk Reduction Service||Kaiser Permanente|No|Completed|November 2011|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|192|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489579||94287|
NCT01489839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-174-E|Biomarkers of Periodontal Disease Progression|Biomarkers of Periodontal Disease Progression||The Forsyth Institute|Yes|Active, not recruiting|January 2012|May 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples With DNA|The biological samples listed below will be obtained at baseline, each 2-month assessment      visit for 12 months, and the 6-month post-therapy visit.      Blood. Ten mL of blood will be obtained by venipuncture from the antecubital fossa. Subjects      consenting to have a blood sample drawn for future DNA analysis will have an additional 7 mL      of blood drawn at the baseline visit.      Saliva. Each subject will provide a timed sample of whole saliva by expectorating into a      sterile graduated cylinder.      Gingival crevicular fluid. A GCF sample will be collected from the mesial and distal aspect      of each posterior tooth (excluding third molars) using filter strips (Periopaper®) gently      inserted 1 to 2 mm subgingivally. A total of up to 32 samples will be obtained.      Subgingival plaque samples. Two plaque samples will be taken from the mesial and distal      aspects of each posterior tooth (excluding third molars) for up to 64 samples.|Both|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 500 subjects (375 subjects with periodontal disease and 125 periodontally        healthy subjects) will be enrolled at 4 centers in the US.|August 2015|August 6, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01489839||94267|
NCT01479361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120017|Antiretroviral Drug Interaction Study in Volunteers With HIV|The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers||National Institutes of Health Clinical Center (CC)||Completed|October 2011|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|70 Years|No|||June 2015|July 2, 2015|November 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01479361||95073|
NCT01490411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL0903rB|Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With rBet v1-FV Compared to Placebo in Birch Pollen-Allergic Patients With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis||Allergopharma GmbH & Co. KG|Yes|Completed|October 2010|September 2011|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|37|||Both|18 Years|65 Years|No|||January 2014|January 23, 2014|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01490411||94224|
NCT01490424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111013-009（2）|TREM-1 Gene Polymorphisms|Association Between TREM-1 Gene Polymorphisms and Prognosis in Sepsis Patient||Chinese PLA General Hospital|No|Completed|May 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects were selected from among inpatients who were hospitalized between September        2009 and October 2011 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese        People's Liberation Army (CPLA) General Hospital.|December 2011|December 12, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01490424||94223|
NCT01490723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0393|Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)|Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2013|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||February 2016|February 15, 2016|December 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490723||94200|
NCT01486849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CY 4025|Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)||Cytokinetics|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|N/A|No|||March 2012|September 16, 2013|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486849||94497|
NCT01486862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1673|Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs|NovoMix® 30 (Biphasic Insulin Aspart 70/30) Titrate-to-target: An Observational Study of the Efficacy of NovoMix® 30 in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs||Novo Nordisk A/S|No|Completed|October 2005|July 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2014|November 13, 2014|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486862||94496|
NCT01486875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1721|Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes|NovoMix® Start - A Multicentre, Open Label, Non-randomised, Non-interventional, Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix 30® Treatment|Start|Novo Nordisk A/S|No|Completed|January 2006|January 2008|Actual|January 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1155|||Both|18 Years|68 Years|No|Non-Probability Sample|After the physician has decided to initiate biphasic insulin aspart 30 therapy, any        insulin-naïve patient with type 2 diabetes mellitus in need of improved metabolic control,        as judged by the treating physician, will be able to participate|February 2016|February 18, 2016|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486875||94495|
NCT01481181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSF Zinc Kisumu study|An Efficacy Trial of a Gravity Fed Household Water Treatment Device as a Delivery System for Zinc|An Efficacy Trial of a Gravity Fed Household Water Treatment Device as a Delivery System for Zinc in Zinc Deficient Children and Women From Low Income Settings||Wageningen University|No|Completed|August 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|270|||Both|2 Years|45 Years|No|||February 2014|February 27, 2014|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01481181||94933|
NCT01487174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD019-301|KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy|A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy||Kadmon Corporation, LLC||Terminated|November 2011|May 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|December 2, 2011|Yes|Yes|Kadmon has made a business decision to terminate the study due to slow enrollment. Note the    decision to terminate the study was not related to safety issues|No||https://clinicaltrials.gov/show/NCT01487174||94472|
NCT01488318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-034|Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma|Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6||University of Pittsburgh|Yes|Recruiting|October 2013|May 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488318||94384|
NCT01488331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22973|An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer|A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months||Hoffmann-La Roche||Completed|June 2010|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|217|||Both|18 Years|N/A|No|Probability Sample|Adult patients with non-small cell lung cancer|March 2016|March 1, 2016|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01488331||94383|
NCT01488357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0119|Patient Preferences for Breast Reconstruction After Mastectomy|Patient Preferences for Breast Reconstruction After Mastectomy||UNC Lineberger Comprehensive Cancer Center|No|Active, not recruiting|June 2012|December 2016|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|||Female|21 Years|N/A|No|Non-Probability Sample|Adult women undergoing mastectomy at UNC for treatment of Stage I, II, or III breast        cancer or DCIS, or for prophylaxis|December 2015|December 9, 2015|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01488357||94381|
NCT01504932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06132|Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High-Risk Appalachian Patients Previously Treated With Surgery For Oral Cancer|Pilot Long-Term Oral Dose of Freeze-Dried Black Raspberries in Post-Surgical Appalachian Oral Cancer||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|February 2007|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Both|21 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 15, 2015|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504932||93112|
NCT01504945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000436|Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)|Red Blood Cell Transfusion in Patients With Acute and Chronic Coronary Syndrome||Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|February 2010|June 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|100 Years|No|||November 2015|November 13, 2015|April 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01504945||93111|
NCT01481922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-11-001|What Needle Diameter Should Physician Use When They Perform Lumbar Puncture ? A Randomized Controlled Trial|Should Physicians Use a 24 Gauge Spinal Needle Instead of a 22 Gauge When Performing a Lumbar Puncture ? A Randomized Controlled Trial.||McGill University|No|Completed|November 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|62|||Both|18 Years|N/A|No|||March 2016|March 19, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01481922||94876|
NCT01478594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4130-CL-0201|A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy|A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects||AVEO Pharmaceuticals, Inc.|No|Completed|December 2011|January 2015|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|November 21, 2011|Yes|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01478594||95131|
NCT01478854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-10100|Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide|A Prospective Trial of Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Glioblastoma Multiforme||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|May 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478854||95111|
NCT01478867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELIQK2|Detection of Immunotoxic Gluten Peptides in Feces|Phase 0 Monitoring of Gluten-free Diet Compliance in Celiac Patients by Assessment of Gliadin 33-mer Equivalent Epitopes in Feces|CELIQK2|University of Seville|No|Completed|April 2011|July 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|53|Samples Without DNA|Fecal samples|Both|1 Year|12 Years|No|Non-Probability Sample|Celiac patients, 1-12 years old|November 2011|November 23, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478867||95110|
NCT01479114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MREC 09030|Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates|In Vivo Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on Neutrophilic Expression of CD11b in Septic Neonates||Ain Shams University|No|Completed|April 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|90|||Both|N/A|4 Weeks|Accepts Healthy Volunteers|||November 2011|November 24, 2011|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01479114||95091|
NCT01489384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC-06-2011|Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)|A Canadian Randomized Controlled Trial of DMARD Withdrawal in RA Patients Achieving Therapeutic Response With Cimzia + DMARD Combination Treatment.||Pope Research Corporation|No|Recruiting|December 2011|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|125|||Both|18 Years|N/A|No|Probability Sample|Patients who had not had an adequate response to a DMARD therapy will have Cimzia added to        their existing DMARD therapy at baseline and will be followed.|November 2013|November 14, 2013|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489384||94302|
NCT01489592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-14|Effect of Curcumin on Iron Metabolism in Healthy Volunteer|Effect of Curcumin on Iron Metabolism in Healthy Volunteer|CURHEP|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|October 2011|March 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489592||94286|
NCT01489605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18477|GlideScope Groove vs. Standard GlideScope: A Non-inferiority Study|Comparison of GlideScope Groove to Standard GlideScope for Orotracheal Intubation: A Non-inferiority Study||Lawson Health Research Institute|No|Not yet recruiting|July 2015|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489605||94285|
NCT01489852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2PRETREATMENT|Estrogen Pretreatment Prior to GnRH Antagonist Protocol|Interest of a Steroid Pre-treatment Prior to IVF Protocol With Ovarian Stimulation by Recombinant FSH and With LH Surge Blockage by Daily GnRH Antagonist||Gemer|No|Completed|December 2006|May 2011|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|472|||Female|18 Years|38 Years|No|||December 2011|December 9, 2011|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01489852||94266|
NCT01489865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 2009-608|ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer|A Phase I/II Study of ABT-888 in Combination With 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients With Metastatic Pancreatic Cancer||Georgetown University|Yes|Recruiting|February 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489865||94265|
NCT01480167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-10-005 - PRIORI-T|The PRIORi-T Trial--Prospective Randomized Investigation of Radiofrequency Targeted Vertebral Augmentation|Prospective Randomized Investigation of Radiofrequency Targeted Vertebral Augmentation (The PRIORi-T Trial)|PRIORi-T|DFINE Inc.|No|Suspended|November 2011|||November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|21 Years|90 Years|No|||January 2013|January 24, 2013|November 23, 2011|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01480167||95011|
NCT01490112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1881|Surveillance Study of NovoRapid® for New Drug Re-examination|Regulatory Post Marketing Surveillance Study of NovoRapid for New Drug Re-examination||Novo Nordisk A/S|No|Completed|January 2005|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1239|||Both|N/A|N/A|No|Non-Probability Sample|People with diabetes mellitus (type 1, type 2, or gestational) prescribed with insulin        aspart (NovoRapid®)|December 2011|December 8, 2011|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01490112||94246|
NCT01490437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOSG-AMC-0804|Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma|A Prospective Phase 2 Study of PEmetrexed in Combination With Cisplatin in Patients With Advanced UrotheLIal CAnceR|PECULIAR|Asan Medical Center|No|Completed|July 2008|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|70 Years|No|||September 2014|September 22, 2014|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01490437||94222|
NCT01487187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002554|The Effect of Cord Milking on Hemodynamic Status of Preterm Infants|The Effect of Umbilical Cord Milking on Hemodynamic Status of Preterm Infants: a Randomized Controlled Trial||IWK Health Centre|Yes|Active, not recruiting|November 2011|January 2018|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|73|||Both|24 Weeks|31 Weeks|No|||August 2015|August 31, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01487187||94471|
NCT01487200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX006-2011-002|Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Active Comparator Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects (HPA Axis) of FX006 in Patients With Osteoarthritis of the Knee||Flexion Therapeutics, Inc.|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Both|35 Years|N/A|No|||November 2012|November 16, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487200||94470|
NCT01487148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCARED001|POCARED Diagnostics, LTD, Field Study Protocol|POCARED Diagnostics, LTD, Field Study Protocol||Pocared Diagnostics|No|Not yet recruiting|December 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40000|None Retained|Samples are de-identified leftover samples.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|At least 70 consecutive leftover and de-identified urine samples arriving in the        laboratory each day for culture will be tested.|December 2011|December 6, 2011|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487148||94474|
NCT01487161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FX006-2011-001|Study of FX006 in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee||Flexion Therapeutics, Inc.|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|229|||Both|40 Years|N/A|No|||March 2015|March 16, 2015|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487161||94473|
NCT01487785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225X2103|Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients|A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma||Novartis||Completed|March 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487785||94425|
NCT01488084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|078-2009|Assessing Vein Graft Properties Between Conventional & No-Touch Harvesting Technique - (PATENT SVG)|Comparative Evaluation of Vasomotor Function in Saphenous Veins Harvested Using Pedicled vs Conventional Technique||Sunnybrook Health Sciences Centre|No|Completed|June 2010|November 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|80 Years|No|||December 2012|December 11, 2012|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01488084||94402|
NCT01505231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0352/08|Vasopressin Versus Norepinephrine for the Management of Shock After Cardiac Surgery||VaNCS|University of Sao Paulo|Yes|Recruiting|January 2012|May 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01505231||93089|
NCT01505465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11152|Study of Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery|Effects of Perioperative Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery||Hospital for Special Surgery, New York|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|90 Years|No|||December 2013|December 4, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505465||93071|
NCT01478256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIRB-11-0007|Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis|A Comparative Study in the Clinical and Microbial Efficacy of Topical Besifloxocin Ophthalmic Suspension 0.6% With Erythromycin Ophthalmic Ointment 0.5% BID for the Management of Acute Blepharitis||John, George, M.D.|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|November 21, 2011||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01478256||95157|
NCT01478568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-058|To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together|An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects||Astellas Pharma Inc|No|Completed|October 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|April 8, 2014|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478568||95133|
NCT01488838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2111-096|A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors|||King Faisal Specialist Hospital & Research Center||Completed|November 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||December 2011|February 24, 2016|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01488838||94344|
NCT01488851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2111-094|Study to Assess Incidence of ONJ in Pts With Bone Mets Starting Zoledronic Acid Treatment|Prospective Observational Multi Central Cohort Study to Assess the Incidence of Osteo Necrosis of Jaw in Patients With Bone Metastasis Starting Zoledronic Acid Treatment||King Faisal Specialist Hospital & Research Center|Yes|Completed|January 2012|January 2015|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Bone Metastases|January 2016|January 4, 2016|December 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488851||94343|
NCT01489085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1FRTOU-3|Observational Study Evaluating the Use of Intellivent® for Patients With Respiratory Distress Syndrome|Etude Clinique Observationnelle, Prospective, Ouverte, Monocentrique Sur l'Utilisation d'un Mode Ventilatoire entièrement automatisé Chez Les Patients de réanimation de l'Intubation Jusqu'au Sevrage.|intellivent|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|Yes|Completed|January 2013|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive care Unit intubated Patients|November 2010|July 21, 2014|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01489085||94325|
NCT01489631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKP-37796|Analgesia After Total Knee Replacement Surgery|Comparison of Intra-articular Infiltration and Gabapentin With Epidural Analgesia After Total Knee Replacement Surgery||St. Antonius Hospital|No|Completed|March 2013|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|81|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489631||94283|
NCT01489618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM04-34|"Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency|Randomised, Multicentric, Phase ii Study of the Immunogenicity of a "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency|EVAD|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Terminated|June 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|December 8, 2011||No|End of production|No||https://clinicaltrials.gov/show/NCT01489618||94284|
NCT01489891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005704-15|Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol|Usefulness of Applying Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopies Performed Under Sedation With Propofol- a Randomized Controlled Trial||Hospital Universitario Infanta Cristina|Yes|Completed|December 2011|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 7, 2013|December 3, 2011||No||No|October 29, 2012|https://clinicaltrials.gov/show/NCT01489891||94263|Unicenter study
NCT01489878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081118|Antibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients|Impact of Ambulatory Antibiotics Use on Nasal Carriage of Methicillin-resistant Staphylococci in Community Patients : the StaphMRG Study|StaphMRG|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|571|Samples Without DNA|Three samples of nasal flora should be obtained for each included patient: (i) the first one      before antibiotic exposure (at inclusion, by the patient's GP) (ii) the second and third      ones at the GP's office at the end and 23 to 45 days after the termination of      antibiotherapy, respectively.|Both|18 Years|N/A|No|Non-Probability Sample|community patients receiving antibiotics prescribed by their general practitioner (GP).        Patients older than 18, treated by β-lactams (amoxicillin-clavulanate or penicillins M),        macrolides, synergistins or fluoroquinolones for a minimal expected duration of 5 days        (whatever the indication) Hospitalization within the previous 6 months, antibiotherapy        within the previous 2 months, and second line antbiotherapy after inclusion will        constitute exclusion criterions.|January 2013|January 23, 2013|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01489878||94264|
NCT01490125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2322|The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Multicenter, Randomized, Blinded, Double-dummy, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control|BLAZE|Novartis|No|Completed|October 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|247|||Both|40 Years|N/A|No|||November 2013|November 5, 2013|November 15, 2011|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01490125||94245|
NCT01486940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1374|Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes|A Multi-centre, Multinational, Open-labelled, Randomised, Parallel-Group Comparison of Insulin Detemir Plus Insulin Aspart With NPH Insulin Plus Human Soluble Insulin in Subjects With Type 1 Diabetes on a Basal-Bolus Regimen||Novo Nordisk A/S|No|Completed|March 2002|October 2002|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|598|||Both|18 Years|N/A|No|||December 2011|December 5, 2011|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486940||94490|
NCT01486953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pectus-study|Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum|Phase 4 Study of Desflurane and Sevoflurane That Affect Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum||The Catholic University of Korea|No|Recruiting|November 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|70|||Both|15 Years|N/A|No|||July 2013|July 22, 2013|November 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01486953||94489|
NCT01491035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12708A|Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder|An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder||H. Lundbeck A/S|Yes|Completed|April 2012|June 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|48|||Both|7 Years|17 Years|No|||January 2016|January 29, 2016|November 23, 2011|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT01491035||94176|
NCT01491048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09242|Evaluation of Functional Rehabilitation in Patients Undergoing Physiotherapy After Total Hip Arthroplasty|Evaluation of Functional Rehabilitation Therapy in Patients Undergoing Physiotherapy After Total Hip Arthroplasty|Artrhosis|Hospital de Clinicas de Porto Alegre|Yes|Completed|July 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 9, 2011|October 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01491048||94175|
NCT01487213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WNI1000|Routine Follow-up Versus Self-assessment in Medical Abortion|Routine Follow-up Versus Self-assessment of Complete Abortion Following Medical Abortion, Effect on Its Success and Acceptability: a Randomized Controlled Trial||Karolinska Institutet|Yes|Completed|September 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|929|||Female|18 Years|N/A|No|||August 2013|August 6, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01487213||94469|
NCT01490996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE0225|Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer|A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.|CUFOX|University of Leicester|Yes|Recruiting|February 2012|February 2019|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|51|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01490996||94179|
NCT01491009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-154|Comparison of Remifentanil With Dexmedetomidine or Midazolam in Regards of Sedation Effectivity and Postoperative Cognitive Functions in Cystoscopies|||Gazi University||Completed|May 2006|November 2010|Actual|February 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|70 Years|No|||December 2011|December 12, 2011|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491009||94178|
NCT01486888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX1000-1735|Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Insulin Mixtard® 30 (600 Nmol/ml) and Insulin Mixtard® 30 (1998 Nmol/ml) in Healthy Subjects||Novo Nordisk A/S|No|Completed|May 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|55 Years|No|||March 2015|March 17, 2015|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486888||94494|
NCT01486901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX1000-1736|Bioequivalence of Two Insulatard® Formulations in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Insulatard® (600 Nmol/ml) and Insulatard® (1998 Nmol/ml) in Healthy Subjects||Novo Nordisk A/S|No|Completed|May 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|55 Years|No|||April 2015|April 27, 2015|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486901||94493|
NCT01488071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14178A|A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication|A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment|REVIVE|H. Lundbeck A/S|No|Completed|January 2012|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|495|||Both|18 Years|75 Years|No|||February 2014|February 11, 2014|November 29, 2011||No||No|December 19, 2013|https://clinicaltrials.gov/show/NCT01488071||94403|
NCT01488383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-01|Effect of Stevioside in Postpandrial Glucose in Healthy Adults|Comparison of the Effect on Postpandrial Capillary Blood Glucose Between Oral Stevioside Versus Saccharin in Healthy Adults.||Basque Health Service|No|Withdrawn|September 2013|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 7, 2015|December 7, 2011||No|not i|No||https://clinicaltrials.gov/show/NCT01488383||94379|
NCT01488903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-013GA|A Cohort Research of Genetic Susceptibility for Common Obesity in Women|A Cohort Research of Genetic Susceptibility for Common Obesity in Women (CROWN Study)|CROWN|Taipei Veterans General Hospital, Taiwan|No|Recruiting|September 2011|December 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|1200|Samples With DNA|DNA, fasting blood samples|Female|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The design of the project is a hospital-based case-control study. We will recruit two        study groups: 600 post-menopausal women; 600 premenopausal women.|December 2011|December 12, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488903||94339|
NCT01505491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1297.1|Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects|Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Open-label, Single Dose, Parallel Arm, Active Comparator Clinical Phase I Study||Boehringer Ingelheim||Completed|December 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|193|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|January 4, 2012||||No||https://clinicaltrials.gov/show/NCT01505491||93069|
NCT01505504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRTA-2012|Mirtazapine in Alzheimer-associated Weight Loss|Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study||Brugmann University Hospital|No|Completed|January 2004|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|22|||Both|N/A|N/A|No|Non-Probability Sample|patients with established diagnosis of AD or mixed dementia with reported weight loss|January 2012|January 5, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505504||93068|
NCT01478269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL_ProDLBCL|Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen|Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)|ProDLBCL|Fondazione Italiana Linfomi ONLUS|No|Completed|May 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1927|||Both|18 Years|N/A|No|Non-Probability Sample|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy|November 2011|November 22, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01478269||95156|
NCT01488539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLO0001AGG|Implementation of an Evidence Based Post-Traumatic Stress Disorder (PTSD) Treatment in Public Sector Settings|Implementation of an Evidence Based PTSD Treatment in Public Sector Settings||Palo Alto Veterans Institute for Research|Yes|Active, not recruiting|January 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|352|||Female|18 Years|65 Years|No|||September 2015|September 2, 2015|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01488539||94367|
NCT01488864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LiÖ/AR-2007|Applied Relaxation for Vasomotor Symptoms|Applied Relaxation for Vasomotor Symptoms in Postmenopausal Women - a Randomized, Controlled Trial||Ostergotland County Council, Sweden|No|Terminated|March 2007|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|N/A|N/A|No|||May 2012|May 10, 2012|December 6, 2011||No|Low drop-out rate and slow recruitment rate|No||https://clinicaltrials.gov/show/NCT01488864||94342|
NCT01489098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06.29.INF Addendum|Effect of the Level of Dietary Protein on Body Composition|Effect of the Level of Dietary Protein on Infant Growth and Body Composition in the First Year of Life - Three and Five Year Growth and Body Composition Follow-up||Nestlé|No|Completed|September 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|178|||Both|2 Years|6 Years|No|Non-Probability Sample|Toddlers and Children who have previously participated in an infant formula trial where        various levels of protein were provided and who are now at the age of 3 and 5 years.|October 2014|March 17, 2015|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01489098||94324|
NCT01489111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7088-3860|Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A|Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A|pathfinder™3|Novo Nordisk A/S|No|Recruiting|August 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Male|12 Years|N/A|No|||February 2016|February 8, 2016|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489111||94323|
NCT01489904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021691-28|Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy|Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial.||Hospital Vall d'Hebron|Yes|Active, not recruiting|November 2011|November 2012|Anticipated|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 28, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01489904||94262|
NCT01490177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22871|Single Center Food Allergy Oral Immunotherapy Study|Single Center, Phase I Food Allergy Oral Immunotherapy Study||Stanford University|Yes|Completed|November 2011|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|4 Years|55 Years|No|||November 2015|November 24, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490177||94241|
NCT01490450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM133-004|Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults With Active Psoriatic Arthritis||Alder Biopharmaceuticals, Inc.|Yes|Completed|December 2011|June 2015|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|165|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490450||94221|
NCT01490463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannWGUH_LESUIA|Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms|Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms: Incidence and Influence on Clinical Outcome in a Prospective Study.|LESUIA|Johann Wolfgang Goethe University Hospitals||Completed|August 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with unruptured intracranial aneurysm undergoing endovascular or surgical        treatment|January 2013|January 28, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01490463||94220|
NCT01490138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-test and IFI|Investigation of Clinical Relevance of β-D-Glucan Tests in Patients With Invasive Fungal Infection (IFI)|Investigation of the Clinical Relevance of Serial Concentrations of β-D-Glucan Tests in the Patients With Invasive Fungal Infection||Ruijin Hospital|Yes|Enrolling by invitation|January 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|The patients with compromised immune condition, such as acute leukemia, lymphoma, myeloma,        allogeneic stem cell transplantation or long term immune suppression treatment.|December 2011|December 9, 2011|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490138||94244|
NCT01487265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LUN 214|Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib|Phase II Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib||SCRI Development Innovations, LLC|No|Recruiting|March 2014|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487265||94465|
NCT01487278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.8|Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali|Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin in UnijectTM in Mali||Gynuity Health Projects|Yes|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2014|January 8, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487278||94464|
NCT01487564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017701|Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene|A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetic Profile of OROS Hydromorphone in Healthy Adult Taiwanese Subjects Having Different Genotypes for the UGT2B7 Gene||Janssen Research & Development, LLC|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487564||94442|
NCT01486966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3954|Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes|A 2-week, Randomised, Controlled, Open-label, Two-group Parallel, Multi-centre Trial Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin Both in a Basal Bolus Regimen With or Without Metformin in Chinese Inpatients With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment||Novo Nordisk A/S|No|Terminated|November 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||July 2015|August 26, 2015|December 5, 2011|Yes|Yes|Trial terminated prematurely due to slow recruitment.|No|April 22, 2013|https://clinicaltrials.gov/show/NCT01486966||94488|The size of population analysed in study was smaller than that planned in the protocol. Therefore, the superiority of experimental products to comparator could not be concluded with sufficient statistical power.
NCT01486914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2000-1512|Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process|A Single Centre, Randomized, Balanced Double Blind, Cross-Over Trial Investigating the Bioequivalence of NovoRapid® Produced by the Current Process and Insulin Aspart With the Same Formulation as NovoRapid®, Produced by the NN2000 Process||Novo Nordisk A/S|No|Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|50 Years|No|||December 2011|December 5, 2011|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486914||94492|
NCT01486927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL627_1001|An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A|A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study||CSL Behring||Completed|February 2012|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|175|||Male|12 Years|65 Years|No|||January 2015|December 11, 2015|November 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01486927||94491|
NCT01487525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109738-MOD|Assessment of Efficacy of Low Intensity Resistance Training in Men at Risk for Symptomatic Knee Osteoarthritis|Assessment of Efficacy of Low Intensity Resistance Training in Men at Risk for Symptomatic Knee Osteoarthritis|PBFR3|University of Iowa|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|44|||Male|45 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|December 1, 2011||No||No|June 11, 2015|https://clinicaltrials.gov/show/NCT01487525||94445|
NCT01487512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017692|Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants|A Single-Dose, Open-Label, Randomized, Crossover Dose Proportionality Study to Evaluate the Effect of Dose on the Pharmacokinetics of 8, 16, 32 and 64 mg OROS Hydromorphone Under Fasted Conditions in Healthy Adult Taiwanese Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 15, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487512||94446|
NCT01487824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Early Vascular Study|What is the Impact of Early Life Exposures on the Cardiovascular System in Young Adulthood?|What is the Impact of Early Life Exposures on the Cardiovascular System in Young Adulthood? A 25-Year Follow-up Study of Preterm-born Individuals|EVS|University of Oxford|No|Recruiting|May 2007|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|250|Samples With DNA|whole blood, serum, plasma, immortalised cell lines|Both|20 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Preterm-born Cohort: A cohort of preterm-born young adults who were enrolled, at birth,        from five centres in England between 1982 and 1985 into a randomised trial of milk feeding        regimes to study the influence of early diet on later cognitive function and        cardiovascular disease.        Term-born Cohort: A cohort of controls born at term with normal birthweight now aged        between 20 and 40 years to provide age stratified normal ranges for the outcome measures.|June 2012|December 2, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487824||94422|
NCT01489228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-CH-E1224-001|Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease|Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease||Drugs for Neglected Diseases|Yes|Recruiting|June 2011|December 2013|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|230|||Both|18 Years|50 Years|No|||December 2011|December 19, 2011|November 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489228||94314|
NCT01488955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110512-BG|Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI|Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - a Comparative Effectiveness Study in General Practice (ICUTI)||Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|No|Completed|February 2012|July 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|494|||Female|18 Years|65 Years|No|||August 2014|August 7, 2014|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01488955||94335|
NCT01488630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N44DA-10-5543|Substance Treatment and HIV Testing and Referral System|Substance Treatment Referral System|STaRS|Polaris Health Directions|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|September 15, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01488630||94360|
NCT01506102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEM-A in pregnancy|Thromboelastography During and After Delivery|Determination of Thromboelastography Values in Pregnancy and After Delivery||Città di Roma Hospital|No|Recruiting|November 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|120|||Female|18 Years|40 Years|No|||January 2012|January 6, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01506102||93022|
NCT01488825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMP-0090-YR|Yoga Intervention Study on Episodic Tension Type Headache|Effect of Yoga Intervention on Episodic Tension Type Headache: A Randomized Controlled Trial||NMP Medical Research Institute|Yes|Completed|January 2005|June 2006|Actual|February 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|60 Years|No|||December 2011|December 7, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488825||94345|
NCT01489124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMI-50-372-028|The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia|The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia||Prince of Songkla University|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|9|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01489124||94322|
NCT01489397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP002|Magnified Intelligence Chromoendoscopy Plus Probe-based Confocal Laser Endomicroscopy for Gastric Intestinal Metaplasia Diagnosis|||King Chulalongkorn Memorial Hospital|No|Completed|April 2010|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|45|||Both|18 Years|80 Years|No|||June 2014|June 9, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01489397||94301|
NCT01489917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHARAOH|A-priori Versus Provisional Heparin on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis|Comparison of A-priori Versus Provisional Heparin Therapy on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis|PHARAOH|Laval University|No|Completed|May 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|428|||Both|18 Years|N/A|No|||December 2011|May 7, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01489917||94261|
NCT01490190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07733|Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)|Contraceptive Vaginal Ring Releasing Etonogestrel and Ethinylestradiol (NuvaRing): Cycle Control, Acceptability and Tolerability Study in Indian Women||Merck Sharp & Dohme Corp.|No|Completed|December 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|252|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|November 22, 2011|No|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01490190||94240|
NCT01490476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101202|Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients|A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma|AFINF2|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|January 2012|July 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|15 Years|N/A|No|||April 2015|April 29, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01490476||94219|
NCT01490151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G110143|Medtronic Treat to Range (TTR) Closed-Loop Control|Medtronic Treat to Range (TTR) Closed-Loop Control: Tuning a Treat-to-Range Controller for the Effects of High and Low Glycemic Index Meals||Stanford University|Yes|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|15 Years|30 Years|No|||March 2015|March 5, 2015|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490151||94243|
NCT01490164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120090203|Transfusion Requirements During Spinal Surgery for Severe Scoliosis|An Observational Prospective Study of Transfusion Requirements During Spinal Surgery for Severe Scoliosis||Rutgers, The State University of New Jersey|No|Completed|August 2009|November 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|19 Years|No|Non-Probability Sample|all patients undergoing surgical correction of scoliosis|November 2013|November 12, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490164||94242|
NCT01491074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1971 [REK]|Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction|Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction - a Randomized, Double Blind, Placebo Controlled Study.||Oslo University Hospital|Yes|Completed|August 2011|April 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||May 2014|May 16, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01491074||94173|
NCT01487005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01-4|Cardiovascular Effects of Exposure to Ozone|Multicenter Ozone Study in Elderly Subjects|MOSES|Health Effects Institute|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|Blood|Both|55 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy elderly volunteers living in or around San Francisco, CA, Research Triangle Park,        NC, and Rochester, NY|June 2012|June 8, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01487005||94485|
NCT01486992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N+FOLFIRI-AEC-4|mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus|||Peking University|No|Recruiting|November 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||November 2011|January 11, 2012|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01486992||94486|
NCT01487837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2011-0440|Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.|A Phase IV, Randomized, Single Center, Parallel Group Trial of Human Fibrinogen Concentrate (Haemocomplettan) in the Treatment of Dilutional Coagulopathy During Major Pediatric Surgery||University Children's Hospital, Zurich|Yes|Completed|January 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|57|||Both|6 Months|17 Years|No|||October 2014|October 24, 2014|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487837||94421|
NCT01487850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/2007/55|Wind Instruments' Fungal Contamination|Study of Wind Reed Instruments' Fungal Contamination and Its Immunological and Clinical Consequences for Musicians.||Centre Hospitalier Universitaire de Besancon|No|Completed|May 2007|October 2007|Actual|June 2007|Actual|N/A|Interventional|Primary Purpose: Diagnostic|||||||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 8, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01487850||94420|
NCT01487538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175-09-FB|Weight Maintenance Through Physical Activity and Social Support in Rural Middle-Aged Women|Weight Maintenance Through Physical Activity and Social Support in Rural Middle-Aged Women||University of Nebraska|Yes|Completed|April 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|52|||Female|40 Years|64 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01487538||94444|
NCT01487798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1466|Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes|A Double-blind, Randomised, Crossover Study to Investigate the Difference in Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 Compared to Biphasic Human Insulin 30 in Patients With Well-controlled Type 2 Diabetes|REACH|Novo Nordisk A/S|No|Completed|June 2002|November 2003|Actual|November 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487798||94424|
NCT01487811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1669|Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers|Bioequivalence of Two Biphasic Insulin Aspart 30 (NovoLog® Mix 70/30) Formulations (Current and New Formulation With Glycerol): A Randomized, Double-Blind, Two-Period Crossover Study in Healthy Volunteers||Novo Nordisk A/S|No|Completed|May 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487811||94423|
NCT01488617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOPS 2012|Mainz Outcome Predictor Studies: An Observational Clinical Trial Investigating Predictors for Postoperative Outcome|Mainz Outcome Predictor Studies: An Observational Clinical Trial Investigating Physiological and Psychological Data as Predictors for Postoperative Outcome.|MOPS|Johannes Gutenberg University Mainz|Yes|Completed|January 2012|October 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|616|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients sceduled for elective surgery.|October 2013|October 30, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488617||94361|
NCT01488968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25859|Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients|A Phase II Randomized Control Trial of Conventional Versus Hypofractionated Radiation Regimen in Single Phase Using IMRT Technique and Long Term Androgen Suppression Therapy in High-risk Prostate Cancer Patients.|CHIRP|AHS Cancer Control Alberta|Yes|Recruiting|March 2012|December 2021|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Male|18 Years|N/A|No|||September 2014|September 29, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01488968||94334|
NCT01489475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107008778|Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass|Plasma Angiopoietin Levels in Children Undergoing Modified Ultrafiltration Following Cardiopulmonary Bypass||Yale University|No|Completed|November 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|Samples With DNA|1. Modified ultrafiltration fluid        2. Whole blood which will be spun down to plasma (cells to be discarded)|Both|N/A|18 Years|No|Non-Probability Sample|Patients with congenital heart disease, undergoing surgical intervention requiring        cardiopulmonary bypass and modified ultrafiltration will be recruited.|October 2013|February 24, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01489475||94295|
NCT01506115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-048|Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma|Observational Study for Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma||Samsung Medical Center|Yes|Completed|September 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|19 Years|70 Years|No|||January 2012|November 17, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01506115||93021|
NCT01506128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_GO_001|Human Papillomavirus in Menstrual Blood|Exploration of Optimal Experimental Settings to Detect Human Papillomavirus From Menstrual Blood in Women With High-grade Squamous Intraepithelial Lesion or High-risk Human Papillomavirus Infection||Seoul National University Hospital|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|Samples With DNA|Menstrual blood in pad|Female|N/A|N/A|No|Non-Probability Sample|Premenopausal women with HSIL at Pap test or high-risk HPV|March 2013|March 4, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01506128||93020|
NCT01488552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRT 11-002|Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer|A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer||Pancreatic Cancer Research Team|No|Active, not recruiting|November 2011|October 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|61|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|November 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488552||94366|
NCT01489410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS117|Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma|Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma||Masonic Cancer Center, University of Minnesota|No|Terminated|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|238|||Both|18 Years|N/A|No|||March 2015|April 22, 2015|December 6, 2011|Yes|Yes|Insufficient staff|No||https://clinicaltrials.gov/show/NCT01489410||94300|
NCT01489644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN4440-1779|Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers|A Randomized, Single-Blind, Four-Period Crossover Study Examining the Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet Dosing (NN4440) in Fasting and Fed Healthy Volunteers||Novo Nordisk A/S|No|Completed|June 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|62|||Both|18 Years|45 Years|No|||April 2015|April 13, 2015|December 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489644||94282|
NCT01489657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METPAR1|The Metabolite Profiling of Obese Subjects Before and After Sleeve Gastrectomy|The Impact of Sleeve Gastrectomy Surgery in Obese Subjects on Metabolite Profiling||Wolfson Medical Center|No|Recruiting|July 2011|April 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Serum|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The Bariatric Surgery Clinics|December 2011|December 8, 2011|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489657||94281|
NCT01489943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114671|A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects|A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects||GlaxoSmithKline||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 8, 2011|December 1, 2011||Yes||||https://clinicaltrials.gov/show/NCT01489943||94259|
NCT01490229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|651/2011/D|Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients|Randomized Trial of Ezetimibe Versus nutraCeuticals in Statin-intoLerant patIents Treated With PercutaneouS Coronary Intervention|ECLIPSE|University of Roma La Sapienza|No|Recruiting|January 2013|December 2016|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||March 2013|March 6, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490229||94237|
NCT01490489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-43|EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction|EG-VEGF (Endocrine Gland-derived Vascular Endothelial Growth Factor) in Normal and Pathological Pregnancies: Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction|EGEVE|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|July 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 5, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490489||94218|
NCT01490762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-176|Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler|A Phase 1, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Effect Following Inhalation of Technosphere® Insulin Inhalation Powder at Multiple Doses Using the Gen2C Inhaler||Mannkind Corporation|No|Completed|December 2011|July 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 5, 2012|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01490762||94197|
NCT01491061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|653/2011/D|Ranolazine Loading to Prevent PCI-induced Myocardial Injury|TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention|TWILIGHT|University of Roma La Sapienza|No|Not yet recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||March 2013|March 6, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01491061||94174|
NCT01490736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS ACN-05|Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne|Phase 1/2 Study of Photodynamic Therapy (PDT) With Lemuteporfin Topical Solution (LTS) in Healthy Volunteers and in Subjects With Mild Acne||Dermira, Inc.|No|Completed|December 2011|June 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|129|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 23, 2013|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01490736||94199|
NCT01487603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0109-CE|Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer|Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer||University Health Network, Toronto|No|Recruiting|October 2011|||October 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400||Tissue.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with lung cancer|March 2016|March 17, 2016|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487603||94439|
NCT01487889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PINGU0911DO|Polyunsaturated Fatty Acids in Child Nutrition|Polyunsaturated Fatty Acids in Child Nutrition - A German Multimodal Optimisation Study|PINGU|Research Institute of Child Nutrition, Dortmund|No|Completed|April 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|214|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||November 2014|November 5, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01487889||94417|
NCT01487291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFRiodJaneiro|Prevalence of Clinical and Laboratory Markers of Hypofibrinolysis in Psychotic Patients|Prevalence of Clinical and Laboratory Markers of Hypofibrinolysis in Psychotic Patients||Universidade Federal do Rio de Janeiro|Yes|Completed|January 2013|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|176|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Psychotic patients treated at IPUB-UFRJ, comprising patients with schizophrenia,        schizoaffective disorders, bipolar disorders (mania or depressive episodes, provided that        the patient has shown an acute psychotic episode in the last two years.        Age-matched control group|December 2014|December 15, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487291||94463|
NCT01487304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLIM-1937|Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy|Impact of Professional Societies Recommendations on Practical Use of Hormone Replacement Therapy - Project "WOMAN 2005"||Novo Nordisk A/S|No|Completed|April 2005|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3760|||Female|N/A|N/A|No|Probability Sample|Post-menopausal women suffering from climacteric symptoms who could benefit a switch from        standard therapy to low dose therapy at the discretion of the individual physician|May 2012|May 24, 2012|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487304||94462|
NCT01487226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG1012|Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer|A Phase II Trial of Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in FIGO Stage IA2-IIA Cervical Cancer||Korean Gynecologic Oncology Group|No|Recruiting|January 2008|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Female|20 Years|70 Years|No|||December 2011|December 6, 2011|December 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487226||94468|
NCT01487239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP27915|Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects||Genentech, Inc.||Completed|December 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487239||94467|
NCT01487252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT007104|Circadian Phase Assessments at Home|||Rush University Medical Center|Yes|Completed|December 2011|May 2015|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|73|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01487252||94466|
NCT01487551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11575705|An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)|An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)||Active Biotech AB|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01487551||94443|
NCT01488370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110244|Comparison of 2 Laryngoscopes for Endotracheal Intubation in Children Younger Than 2 Years Old|A Comparison of the Glidescope® Video Laryngoscope and the Storz DCI® Video Laryngoscope for Endotracheal Intubation in Children Younger Than Two Years of Age||Loma Linda University|No|Completed|November 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|169|||Both|N/A|23 Months|No|||January 2016|January 27, 2016|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01488370||94380|
NCT01488110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Migraine2011/1609-31/2|Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine|Undersökning av ny Behandlingsmetod Vid migränanfall (Evaluation of a New Treatment for Migraine Attacks)||Karolinska University Hospital|No|Terminated|January 2012|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|55 Years|No|||June 2013|June 17, 2013|December 2, 2011||No|Too slow recruitment rate. The study has been terminated and will be re-started with an    improved and more suitable study design.|No||https://clinicaltrials.gov/show/NCT01488110||94400|
NCT01488942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00514|Use of Incentives to Retain Drug Users in HIV Therapy|A Randomized Clinical Trial Evaluating the Role of Contingent Reinforcement in the Engagement of and Retention of Drug Users in HAART Programs|Incentives-2|University of British Columbia|Yes|Recruiting|December 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|19 Years|N/A|No|||March 2015|March 31, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488942||94336|
NCT01489241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR2017|Short-term Telehealth Follow up After Hospital Discharge for Chronic Obstructive Pulmonary Disease Exacerbation|Renewing Health RCT in Central Greece for the Evaluation of Short-term Telehealth Follow up After Hospital Discharge for COPD Exacerbation|RHCluster4GR|Regional Health Authority of Sterea & Thessaly|Yes|Completed|March 2011|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|155|||Both|40 Years|N/A|No|||February 2015|February 21, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01489241||94313|
NCT01476046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110951|Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.|A Two-part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of Intravenously Infused GSK1995057 in Healthy Subjects.||GlaxoSmithKline|No|Completed|March 2011|April 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476046||95326|
NCT01476059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113244|Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 Mcg/Dose and Salmeterol 50 Mcg/Dose - ADERE PROJECT|Prospective, Parallel-group, Randomized Study to Evaluate the Compliance to the Treatment of Children Aged Between 6 and 14 Years Old With Persistent Moderate or Severe Asthma, Receiving the Association Fluticasone 250 Mcg/Dose and Salmeterol 50 Mcg/Dose Twice a Day. ADERE PROJECT|ADERE (Ped)|GlaxoSmithKline|No|Completed|May 2004|December 2004|Actual|December 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|472|||Both|6 Years|14 Years|No|||November 2011|November 17, 2011|March 4, 2010||No||No||https://clinicaltrials.gov/show/NCT01476059||95325|
NCT01488877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0171011|A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy|A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria||Pfizer|No|Terminated|January 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|6|||Both|18 Years|65 Years|No|||September 2013|September 24, 2013|December 6, 2011|No|Yes|See termination reason in detailed description.|No|July 18, 2013|https://clinicaltrials.gov/show/NCT01488877||94341|Study was terminated prematurely; this was based on a strategic decision by the sponsor to terminate further development of this compound for proposed indication. The study was not terminated for safety or lack of efficacy reasons.
NCT01489137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_fixation_remifentanil|The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation|The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation in the Patients Undergoing Neurosurgery||Seoul National University Hospital||Completed|November 2011|||February 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Both|20 Years|65 Years|No|||August 2012|August 15, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01489137||94321|
NCT01489423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000718014|Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim|Correlative Analyses of Specimens From Eastern Cooperative Group Study E1608||National Cancer Institute (NCI)||Not yet recruiting|September 2012|||September 2013|Anticipated|N/A|Observational|N/A|||Anticipated|270|||Both|18 Years|N/A|No|||December 2011|December 8, 2011|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489423||94299|
NCT01489670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/032|Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|September 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|387|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with primary open-angle glaucoma or ocular hypertension|February 2014|February 13, 2014|December 1, 2011|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT01489670||94280|
NCT01489683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-CT4-11-073|Intubating Conditions During Propofol-remifentanil Anesthesia With Topical Lidocaine|Effect of Tracheal Lidocaine on Intubating Conditions During Propofol-remifentanil TCI Without Neuromuscular Blockade||Ajou University School of Medicine|No|Completed|May 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|20 Years|60 Years|No|||July 2012|July 13, 2012|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489683||94279|
NCT01490801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHOD12B1|Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma|Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma||Children's Oncology Group|No|Active, not recruiting|December 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|Samples With DNA|Blood and Tissue|Both|N/A|9 Years|No|Non-Probability Sample|Diagnosis of Hodgkin lymphoma.|May 2015|May 8, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490801||94194|
NCT01490502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSS 4407A2/1|Vitamin D Supplementation in Multiple Sclerosis|A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis||Johns Hopkins University|Yes|Recruiting|March 2012|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|172|||Both|18 Years|50 Years|No|||January 2016|January 27, 2016|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490502||94217|
NCT01490749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047026|Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer|Phase I/IIB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy and Dose Escalation of RAD001 in Patients With Esophageal Cancer||Emory University|Yes|Active, not recruiting|February 2012|May 2018|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|October 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490749||94198|
NCT01487616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11072|Prevalence of Congenital Uterine Malformations|Prevalence of Congenital Uterine Malformations in Women With a History of Preterm Delivery or Miscarriage|PUMA|University of Nottingham|No|Recruiting|September 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|246|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Secondary care: Patients from Nottingham University Hospitals NHS Trust|February 2016|February 17, 2016|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487616||94438|
NCT01488123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A112313|Integrative Approaches for Cancer Survivorship|A Whole Systems Approach to the Study of Ayurveda for Cancer Survivorship, Project II|IACS|University of California, San Francisco|No|Active, not recruiting|January 2012|December 2015|Anticipated|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Female|18 Years|N/A|No|||April 2015|April 17, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488123||94399|
NCT01488097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-CL04|Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency|An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01||Alexion Pharmaceuticals|Yes|Active, not recruiting|November 2011|June 2017|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|65 Years|No|||May 2015|May 18, 2015|November 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488097||94401|
NCT01487863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-3|Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)|A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)||Dendreon|No|Active, not recruiting|December 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|69|||Male|18 Years|N/A|No|||March 2016|March 15, 2016|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01487863||94419|
NCT01487876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011005SW0101|Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients|A Randomized Controlled Trial of Dual-plasmid HBV DNA Vaccine Mediated by in Vivo Electroporation in Chronic Hepatitis B Patients Under Lamivudine Chemotherapy||The 458 Hospital of Chinese PLA|Yes|Recruiting|September 2011|December 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||September 2011|December 7, 2011|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01487876||94418|
NCT01488643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5/24-2-2011|Observational Study on Obese Patients During General Anesthesia|Bronchospasm During General Anesthesia in Obese Patients||Larissa University Hospital|No|Recruiting|March 2011|March 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|78 Years|No|Non-Probability Sample|ALL PATIENTS FROM BOTH TEAMS WILL UNDERGO TO LAPAROSCOPIC SURGERIES|December 2011|December 7, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488643||94359|
NCT01489215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-YS-0522-CTIL|Interventions for Sleep Problems in Early Childhood|Interventions for Sleep Problems in Early Childhood:The Role of Child, Parental and Intervention Factors||Tel-Aviv Sourasky Medical Center||Not yet recruiting|February 2012|||February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|180|||Both|9 Months|18 Months|Accepts Healthy Volunteers|||December 2011|December 8, 2011|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01489215||94315|
NCT01481090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS H1007|Electro-acupuncture and Assisted Reproductive Technology|Electro-acupuncture and Assisted Reproductive Technology: Impact of EA on Endometrium During Medicated Frozen Embryo Transfer Uterine Preparation||National University of Health Sciences|Yes|Terminated|November 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Female|21 Years|45 Years|No|||April 2015|April 14, 2015|November 22, 2011||No|IRB violations|No||https://clinicaltrials.gov/show/NCT01481090||94940|
NCT01481337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPERA|Endoscopic Mucosal Colonic Resection and Polypectomy Under Aspirin|Prospective Observatory of Endoscopic Mucosal Colonic Resection and Polypectomy Under Aspirin : the "OPERA" Study|OPERA|Société Française d'Endoscopie Digestive|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|317|||Both|18 Years|N/A|No|Non-Probability Sample|Patient under chronic aspirin therapy (antiplatelet agent) for cardiovascular reason who        underwent colonic polypectomy or endoscopic mucosal resection.|April 2014|April 22, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01481337||94921|
NCT01489254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTR001|Efficacy and Safety of GTR in Comparison to Copaxone®|Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects|GATE|Synthon BV|Yes|Completed|October 2011|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|794|||Both|18 Years|55 Years|No|||June 2014|March 18, 2015|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489254||94312|
NCT01488292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090633|RECAP Multi-Component Intervention Program|Multi-Component Mental Health & Academic Intervention for Student Reintegration||Vanderbilt University||Completed|August 2009|June 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|6 Years|15 Years|No|||December 2014|June 4, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01488292||94386|
NCT01488565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/78|A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia|A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndrome / Acute Myeloid Leukaemia, With Eltrombopag Support for Thrombocytopenia.|Aza-E|Peter MacCallum Cancer Centre, Australia|Yes|Completed|December 2010|May 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01488565||94365|
NCT01489150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EtCO2-NIV|Use of EtCO2 as a PaCO2 Predictor Under Non Invasive Ventilation (NIV) in Cases of Acute Hypercapnic Respiratory Failure|Use of EtCO2 and Prolonged Expiratory Maneuvers as a PaCO2 Predictor in Cases of Acute Hypercapnic Respiratory Failure||University of Lausanne Hospitals|No|Completed|December 2011|December 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive care unit patients equipped with arterial line requiring non invasive        ventilation because of acute hypercapnic respiratory failure|May 2013|May 15, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01489150||94320|
NCT01489163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-03AFerr-02-H|Lifestyle Intervention Program for Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance|Translational Diabetes Prevention in GDM|APPLES|Kaiser Permanente|No|Active, not recruiting|December 2011|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|350|||Female|20 Years|45 Years|No|||December 2015|December 1, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01489163||94319|
NCT01489696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-080|A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin|A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin||Astellas Pharma Inc|No|Completed|August 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|48|||Male|45 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 6, 2013|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489696||94278|
NCT01489449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPCAD NSTEMI|Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction|Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction|PEPCADNSTEMI|University Hospital, Saarland|Yes|Recruiting|December 2012|December 2019|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||May 2014|December 1, 2014|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01489449||94297|
NCT01489930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007689|Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults|Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults||Mayo Clinic|No|Completed|May 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|67|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 9, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01489930||94260|
NCT01490567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC30900485|A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia|Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia||Central South University|Yes|Recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|40 Years|No|||December 2011|December 9, 2011|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490567||94212|
NCT01490814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-123|FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation|A Controlled, Prospective, Non-Inferiority, Parallel-Group, Randomised, Interventional, Open, Blinded Outcome Assessment (PROBE-Design), Multi-centre Trial, Comparing Efficacy and Safety of Isolation of the PVs With a Cryoballoon Catheter vs a Radiofrequency Ablation With a ThermoCool Catheter in Patients With PAF||Medtronic International Trading Sarl|Yes|Completed|December 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|769|||Both|18 Years|75 Years|No|||March 2016|March 16, 2016|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01490814||94193|
NCT01490203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIFE_ISS_2011|Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma|Pre-Surgical Treatment or Radio Frequency Ablation (RFA) Evaluation of Future Remnant Liver Function Using Gd-EOB-DTPA Enhanced MRI in Patients Undergoing Hepatic Resection /RFA for Hepatocellular Carcinoma|LiFE|Seoul National University Hospital|Yes|Active, not recruiting|December 2011|May 2016|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|71|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group 1: Patients who will undergo hepatic resection/RFA for HCC. Group 2: Potential liver        donors with normal hepatic function.|February 2016|February 2, 2016|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01490203||94239|
NCT01490216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3002-11961-00006857|Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence|Open-Label Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence||University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|65 Years|No|||November 2013|November 12, 2013|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490216||94238|
NCT01490515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|metabolomics|Embryo Selection Using Non-invasive Metabolomic Analysis Versus Morphology|Embryo Selection Using Non-invasive Metabolomic Analysis Indicates Improvement in Implantation Rates With Fetal Cardiac Activity||Eugonia|No|Completed|April 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|125|||Female|18 Years|49 Years|Accepts Healthy Volunteers|||December 2011|December 13, 2013|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490515||94216|
NCT01490788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F101|Comparative Bioavailability of TNX-102 and Cyclobenzaprine and Effect of Food on the Pharmacokinetics of TNX-102 in Healthy Adults|A Single-Dose, Open-Label, Randomized, Three-Way Crossover Study of the Comparative Bioavailability of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets and of the Effect of Food on the Pharmacokinetics of TNX-102 in Healthy Adults.||Tonix Pharmaceuticals, Inc.|No|Completed|December 2011|March 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|December 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01490788||94195|
NCT01486979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG-1850|Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis|A Pharmacokinetic Randomized Study With a Parallel Group Design to Assess the Extent of Systemic Absorption of Estradiol During Treatment With a 10 µg or 25 µg Estradiol Vaginal Tablet Administered Once Daily for 2 Weeks Followed by 10 Weeks of Twice-Weekly Maintenance Therapy in Postmenopausal Women With Atrophic Vaginitis||Novo Nordisk A/S|No|Completed|January 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Female|60 Years|70 Years|No|||March 2012|March 19, 2012|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01486979||94487|
NCT01487317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P071244|Rivastigmine in the Management of Delirium|A Randomized, Double-blind, Placebo-controlled Study of an Acetylcholinesterase Inhibitor in the Management of Delirium in Hospitalized Patients Aged 75 Years and Over|confuriv|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|June 2011|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|23|||Both|75 Years|N/A|No|||June 2014|March 20, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487317||94461|
NCT01487330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103|First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System|First In Human Experience and Assessment of the 23mm SJM Transcatheter Aortic Valve Implant and the SJM TAVI Transfemoral Delivery System (SJM TAVI FIH)|SJM TAVI FIH|St. Jude Medical|No|Completed|August 2011|September 2012|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|August 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01487330||94460|
NCT01487343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-194|Patient Factors Impacting Adherence to Oral Chemotherapy|A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|21 Years|N/A|No|Non-Probability Sample|MSKCC clinics|November 2015|November 18, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01487343||94459|
NCT01487629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13368/2010|Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema|Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema|IBERA-DME|University of Sao Paulo|No|Active, not recruiting|April 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|80 Years|No|||December 2011|December 9, 2011|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01487629||94437|
NCT01487642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPH-2066|Comparison of Four Different Smoking Cessation Programmes|Study of the Effect of Two Different Types of Telephone Counselling Respectively and a Web-based Smoking Cessation Programme Among Adult Daily Cigarette Smokers.|Fristart|University of Southern Denmark|Yes|Active, not recruiting|August 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|1600|||Both|16 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 19, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01487642||94436|
NCT01487902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOSG-AMC-0803|The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer|Randomized Phase II Screening Trial of Docetaxel Plus Prednisolone With or Without Androgen Deprivation Treatment in Castrate-Resistant Prostatic Cancer||Asan Medical Center|No|Recruiting|July 2010|||October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Male|18 Years|N/A|No|||December 2011|December 7, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487902||94416|
NCT01487577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHP_BMT_MMF_10|Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention|A Pilot Study of Pharmacokinetics-based Mycophenolate Mofetil Dosing for Graft-Versus-Host-Disease Prophylaxis in Pediatric Blood and Marrow Transplantation||University of Pittsburgh|Yes|Active, not recruiting|June 2010|January 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Months|21 Years|No|||December 2015|December 1, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01487577||94441|
NCT01487590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGS 2006/0404|Cephalic Version by Acupuncture-Moxibustion for Breech Presentation|A Simple Blind Controlled Randomized Trial: Cephalic Version by Acupuncture-moxibustion vs Placebo for Breech Presentation|ACUVERSE|University Hospital, Lille|No|Completed|October 2006|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|328|||Female|18 Years|45 Years|No|||December 2010|January 16, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487590||94440|
NCT01488929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-5619-23-CRD-003|Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia|A Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia||Targacept Inc.|No|Completed|December 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|603|||Both|18 Years|65 Years|No|||December 2013|May 11, 2015|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488929||94337|
NCT01488409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000175|Effects of Acipimox on Mitochondrial Function in Obesity|The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity||Massachusetts General Hospital|Yes|Completed|May 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|55 Years|No|||February 2016|February 2, 2016|December 2, 2011|Yes|Yes||No|January 4, 2016|https://clinicaltrials.gov/show/NCT01488409||94377|
NCT01488656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USU #4001|Effects of Dietary Supplements on Response to Air Pollution|Effect of an Antioxidant and Anti-inflammatory Dietary Supplement Pack on the Adverse Physiological Actions Associated With Acute PM2.5 Exposure||Utah State University|No|Completed|November 2011|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Both|45 Years|80 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488656||94358|
NCT01481597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDZJ1109DT|Deuteporfin Tolerance and Pharmacokinetics in Healthy Volunteers|Tolerance and Pharmacokinetics of Single-dose Intravenous Deuteporfin in Healthy Volunteers||Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01481597||94901|
NCT01481857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0378.0.045.000-10|Influence of Thoracolumbar Proprioceptive Support in the Segmental Stabilization Training|Influence of Thoracolumbar Proprioceptive Support in the Segmental Stabilization Training||Universidade Federal do Piauí|Yes|Completed|February 2011|May 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2011|November 25, 2011|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01481857||94881|
NCT01488890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD51|Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine|Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults.||Sanofi|Yes|Completed|December 2011|April 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|390|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01488890||94340|
NCT01489436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001162|A Comparison of Single Port and Four Port Laparoscopic Gallbladder Removal|Comparative Effectiveness of Novel Minimally Invasive Procedures|CENoMIP|Mayo Clinic|Yes|Completed|July 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01489436||94298|
NCT01489462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR059105|Strength Training for ARthritis Trial|Strength Training for ARthritis Trial|START|Wake Forest School of Medicine|Yes|Recruiting|March 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|372|||Both|50 Years|N/A|No|||December 2015|December 22, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01489462||94296|
NCT01489709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-JC-VC0004|Post Marketing Survey of Vesicare in Japan|Specified Drug Use Results Survey of Vesicare Tablets|SET-Q|Astellas Pharma Inc|No|Completed|June 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1160|||Female|N/A|N/A|No|Non-Probability Sample|Patients who meet the diagnostic criteria for OAB provided in the clinical guidelines for        overactive bladder (patients who have urinary urgency at least once weekly as an essential        symptom and at least one of the other OAB symptoms including daytime frequency, nighttime        frequency, and urgency incontinence)|September 2014|September 4, 2014|December 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489709||94277|
NCT01490281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP2010-15639|Exercise in Women With Fibromyalgia|Land- and Water-Based Exercise Intervention in Women With Fibromyalgia: The Al-Andalus Physical Activity Randomised Control Trial||Universidad de Granada|Yes|Completed|November 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|180|||Female|35 Years|65 Years|No|||January 2015|January 7, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01490281||94234|
NCT01490528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMICADEIBD4008|Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience|||Cedars-Sinai Medical Center|No|Not yet recruiting|January 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|21 Years|No|Non-Probability Sample|All individuals who received at least 2 doses of infliximab before the age of 16 at the        pediatric IBD Center at Cedars Sinai Medical Center for the treatment of Crohn's disease        or ulcerative colitis Able to give consent|December 2011|December 12, 2011|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01490528||94215|
NCT01491113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01373|Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients|Single-Dose Pharmacokinetics of Orally Administered Levetiracetam (LEV) in Japanese Subjects With Normal Renal Function and Various Degrees of Renal Impairment Using a Dosing Regimen Adjusted to Renal Function (250 mg or 500 mg)||UCB Pharma|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|December 9, 2011|Yes|Yes||No|November 21, 2013|https://clinicaltrials.gov/show/NCT01491113||94170|
NCT01487018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gongx31480528|Evaluation of Navigation Assisted Reconstruction of Posttraumatic Zygomatic Deformity|Evaluation of the Application of Point-to-Point Computer-Assisted Navigation for Mirroring-Reconstructing of Unilateral Posttraumatic Zygomatic Deformity: A Randomized Controlled Trial||Peking University|Yes|Completed|December 2011|July 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|16 Years|60 Years|No|||October 2015|October 20, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01487018||94484|
NCT01490775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AUS12T|Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy|Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib)Therapy||Rex Cancer Center, Raleigh, NC|No|Active, not recruiting|April 2009|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|48|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01490775||94196|
NCT01491087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2I60|Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China|Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China||Sanofi|No|Completed|December 2011|December 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|900|||Both|60 Days|74 Days|Accepts Healthy Volunteers|||March 2013|March 28, 2013|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01491087||94172|
NCT01487356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-00312|Factors Associated With Short Withdrawal Time and Polyp Detection Rate During Colonoscopy|Factors Associated With Short Withdrawal Time and Polyp Detection Rate During Colonoscopy||University of British Columbia|No|Completed|May 2008|June 2009|Actual|June 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|802|||Both|N/A|N/A|No|Non-Probability Sample|All adult patients undergoing colonoscopy at St. Paul's Hospital in Vancouver, BC.|December 2011|December 5, 2011|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01487356||94458|
NCT01487369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1946|Special Survey of Production of Insulin Aspart Specific Antibody|Special Survey of Production of Insulin Aspart (IAsp) Specific Antibody||Novo Nordisk A/S|No|Completed|April 2002|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|204|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes requiring insulin therapy and who had a treatment history of        NovoRapid® (insulin aspart)|March 2016|March 3, 2016|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01487369||94457|
NCT01480102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203648|Paravertebral Block for Percutaneous Nephrolithotomy|Paravertebral Block for Percutaneous Nephrolithotomy (PRONE)|PRONE|Loyola University|No|Recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|75 Years|No|||August 2015|August 10, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480102||95016|
NCT01487915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOSG-AMC-1001|Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma|Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin Un-fit Advanced Urothelial Carcinoma: Randomized Phase II Study|COACH|Asan Medical Center|No|Recruiting|October 2010|||June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487915||94415|
NCT01488149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|epidural fentanyl|Intrapartum Epidural Fentanyl and Breast-feeding in the Immediate Postpartum Period: a Prospective Cohort Study|Intrapartum Epidural Fentanyl and Breast-feeding in the Immediate Postpartum Period: a Prospective Cohort Study||University Hospital Case Medical Center|Yes|Recruiting|February 2012|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Female|18 Years|N/A|No|Non-Probability Sample|Parturients who deliver a single live neonate at UHCMC between February 2012 and June 2012|May 2012|May 29, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488149||94397|
NCT01488396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|336/2549|Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye|Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye||Mahidol University|No|Completed|February 2007|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||December 2011|December 6, 2011|November 8, 2010||No||No||https://clinicaltrials.gov/show/NCT01488396||94378|
NCT01488422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT006344|Neural Correlates of Stress Reduction|Structural and Functional Mechanisms of Stress Reduction||Massachusetts General Hospital|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|140|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488422||94376|
NCT01488435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6012|Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age|||Mead Johnson Nutrition|No|Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|310|||Both|36 Months|48 Months|Accepts Healthy Volunteers|||December 2012|December 5, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488435||94375|
NCT01488669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0005|Robot Assisted Supraomohyoid Neck Dissection Via Retroauricular Approach|||Yonsei University||Recruiting|January 2011|September 2013|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|80 Years|No|||December 2011|December 6, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488669||94357|
NCT01488682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0014|The Safety and Efficacy of the Harmonic Scalpel in Neck Dissection|The Safety and Efficacy of the Harmonic Scalpel in Neck Dissection : A Prospective Randomized Study||Yonsei University||Recruiting|January 2010|December 2012|Anticipated|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|59|||Both|18 Years|90 Years|No|||December 2011|December 6, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01488682||94356|
NCT01480895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR452307CTL|Prevention of Diabetes Mellitus Type 2 in Women Post Gestational Diabetes Mellitus Diagnosis|Identification of Risk Factors for DM Type 2 in Women Post GDM Diagnosis and Its Prevention by Changing Life Style|GDM|Soroka University Medical Center|Yes|Completed|March 2007|April 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|180|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||November 2011|November 28, 2011|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01480895||94955|
NCT01481103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS H1009|Integrating Acupuncture Into the Management of Migraines|Integrating Acupuncture Into the Management of Migraines: A Randomized, Comparative Trial||National University of Health Sciences|Yes|Terminated|July 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|65 Years|No|||April 2013|April 2, 2013|November 22, 2011||No|PI cited personal reasons|No||https://clinicaltrials.gov/show/NCT01481103||94939|
NCT01481116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_304|Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination With Metformin in Subjects With Type 2 Diabetes||Takeda|Yes|Terminated|January 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|2610|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|November 25, 2011|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No||https://clinicaltrials.gov/show/NCT01481116||94938|
NCT01481142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ada-UC-08-102|Adacolumn in Refractory UC Patients Trial|Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies|ART|Otsuka Pharmaceutical Europe Ltd|No|Completed|October 2011|July 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|75 Years|No|||October 2015|October 16, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481142||94936|
NCT01481350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0064280|Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery|Phase 2 Use of Sildenafil for the Treatment of Post-capillary Hypertension in Patients Undergoing Cardiac Surgery|SiPaHCS|University of Turin, Italy|No|Completed|February 2012|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2014|December 6, 2014|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01481350||94920|
NCT01481363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOP3203201|The Talking Sense Communication Programme for Dementia Carers|A Feasibility Study of a Psychosocial Intervention - The Talking Sense Communication Programme for Dementia Family Carers||University of Portsmouth|Yes|Completed|March 2012|March 2014|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 18, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01481363||94919|
NCT01488604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCEXP0003|A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold|Efficacy and Safety of an Antiviral Polymeric Nasal Spray: A Randomized, Parallel Group, Double-blind, Placebo-controlled Study in Subjects With Early Symptoms of Common Cold||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488604||94362|
NCT01489189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCR.net Protocol S|Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Protocol S|Diabetic Retinopathy Clinical Research Network|Yes|Active, not recruiting|March 2012|December 2017|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|N/A|No|||January 2015|April 1, 2015|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489189||94317|
NCT01489202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|655/2011/D|Effects of DES Platforms on Markers of Endothelial Damage and Inflammation|Randomized Comparison of the Effects of PLatinum Chromium Everolimus-eluting Stent vs. cobAlT Chromium Everolimus-eluting Stent on inFlammatOry maRkers and Endothelial daMage - The PLATFORM Trial|PLATFORM|University of Roma La Sapienza|No|Not yet recruiting|September 2014|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|N/A|No|||March 2013|March 6, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01489202||94316|
NCT01490255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|654/2011/D|Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity|Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study|ROMAN|University of Roma La Sapienza|No|Recruiting|January 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|N/A|No|||March 2014|March 23, 2014|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490255||94236|
NCT01490541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP003|The Predictive Scores for Gastric Cancer in Gastric Intestinal Metaplasia (GIM) Patient: a Recommendation for Thai Population|||King Chulalongkorn Memorial Hospital|No|Recruiting|October 2011|October 2017|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|280|||Both|N/A|N/A|No|Non-Probability Sample|All GIM patients in KCMH whose diagnosed from 1997 to 2005, at least 280.|June 2012|June 22, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01490541||94214|
NCT01490268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKPDHM-001|Pain Therapy After Elective Cardiac Surgery|Pharmacokinetic-pharmacodynamic Modeling of the Postoperative Pain Sensation During Patient-controlled Analgesia With Target-controlled Infusion of Hydromorphone, Taking Into Account the Interaction With Intraoperatively Administered Sufentanil for Elective Cardiac Surgery|PKPDHM-001|University of Erlangen-Nürnberg Medical School|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|80 Years|No|||December 2014|December 5, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01490268||94235|
NCT01490580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRETTINEO|Premedication Trial for Tracheal Intubation of the NEOnate|Double Blind Randomized Controlled Trial Comparing "Atropine+Propofol" Versus "Atropine+Atracurium+Sufentanil" as a Premedication Prior to Semi-urgent or Elective Endotracheal Intubation of Term and Preterm Newborns|PRETTINEO|Centre Hospitalier Intercommunal Creteil|Yes|Recruiting|May 2012|March 2018|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|28 Days|No|||February 2015|February 2, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01490580||94211|
NCT01491126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8951-DC-CTIL|Single Center Open Prospective Study for the Comparison of Procedural Sequence in Same Day Consecutive Bidirectional Endoscopy|||Sheba Medical Center|No|Not yet recruiting|January 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|170|||Both|18 Years|85 Years|No|Probability Sample|Study population will include sequential examinees undergoing bidirectional endoscopy. The        decision to perform same day sequential bidirectional endoscopy is of the examinee's        caring gastroenterologist, and not part of the study. Only examinees > 18 years will be        eligible.|February 2014|February 24, 2014|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01491126||94169|
NCT01490827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM-01|Argus® II Retinal Prosthesis System Post-Market Surveillance Study|Argus® II Retinal Prosthesis System Post-Market Surveillance Study||Second Sight Medical Products|No|Recruiting|November 2011|May 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|25 Years|N/A|No|Non-Probability Sample|Subjects will be selected from eligible patients who have been implanted with the Argus II        retinal prosthesis at the enrolling center.|March 2015|March 6, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01490827||94192|
NCT01490840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE07|Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis|A 6-month, Multicenter, Randomized, Controlled Parallel Group Study to Evaluate the Effect of Physical Training on Fatigue in Patients With Relapsing-remitting Multiple Sclerosis Treated With Fingolimod, Followed by a 6 Month Optional Extension Phase|PACE|Novartis||Completed|November 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|65 Years|No|||December 2014|December 9, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490840||94191|
NCT01491139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023599-24|Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Study of Olaparib in Addition to Cisplatin Based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)|ORCA|University College, London|Yes|Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 29, 2012|December 9, 2011||No|Study stopped due to issues surrounding development and formulation of olaparib|No||https://clinicaltrials.gov/show/NCT01491139||94168|
NCT01491100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16036|Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis|Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon®|CogniPlus|Bayer|No|Active, not recruiting|April 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1125|||Both|12 Years|70 Years|No|Non-Probability Sample|Community Sample|January 2016|January 15, 2016|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491100||94171|
NCT01479582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120027|Providing Access to Cord Blood Units for Transplants|A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications||National Institutes of Health Clinical Center (CC)||Withdrawn|October 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|N/A|No|||November 2012|June 25, 2014|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479582||95056|
NCT01480388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018814|A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate|A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy||Janssen Research & Development, LLC|Yes|Terminated|November 2011|March 2014|Anticipated|||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|325|||Both|18 Years|80 Years|No|||August 2013|August 16, 2013|November 23, 2011|Yes|Yes|Study was terminated prematurely due to 2 cases of agranulocytosis in a different clinical    trial with this same drug.|No||https://clinicaltrials.gov/show/NCT01480388||94994|
NCT01488136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010DM03|Use of Diazoxide in Acute Hypoglycaemia|Use of Diazoxide in Acute Hypoglycaemia||University of Dundee|Yes|Recruiting|January 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|12|||Both|18 Years|55 Years|No|||June 2012|June 5, 2012|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01488136||94398|
NCT01480869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITACAL|Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients|Randomized Phase III Trial Comparing Conventional Vitamin D Supplementation vs. Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients Treated by Neoadjuvant or Adjuvant Chemotherapy.|VITACAL|Institut du Cancer de Montpellier - Val d'Aurelle|No|Completed|July 2011|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Female|18 Years|N/A|No|||July 2015|July 29, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01480869||94957|
NCT01481129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00081|Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma||National Cancer Institute (NCI)||Completed|December 2011|June 2014|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2015|July 31, 2015|November 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481129||94937|
NCT01481376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVPTAP0161|TAPP Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh|Laparoscopic Transabdominal Preperitoneal (TAPP) Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh: A Retrospective Study With 12 Month Follow-up||Medtronic - MITG|No|Completed|October 2011|April 2013|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|All subjects have undergone Laparoscopic Transabdominal preperitoneal surgical treatment        for inguinal hernia repair with Parietex™ ProGrip™ without additional fixation between        September 2008 and March 2010 (inclusive) with at least 12 months of follow-up. Subjects        must meet the protocol outlined eligibility criteria to be included in the study.|December 2015|December 8, 2015|October 24, 2011||No||No|December 6, 2013|https://clinicaltrials.gov/show/NCT01481376||94918|
NCT01481155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDT vs. CO2|Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses|Prospective, Single-center, Investigator-blinded, Randomized, Half-side, Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses||Ruhr University of Bochum||Active, not recruiting|March 2011|||December 2011|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||December 2011|December 7, 2011|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481155||94935|
NCT01481389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10022V|The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects|The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects||Unilever R&D|No|Completed|December 2010|||January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|152|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 17, 2012|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01481389||94917|
NCT01481415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|p1|Left Atrial Volume and Function in Children Assessed by Echo 3DRT: Reference Values for Normal Children|Left Atrial Volume and Function in Healthy Children Assessed by Three Dimensional Echocardiography||Hospital Israelita Albert Einstein|Yes|Recruiting|November 2011|December 2012|Anticipated|November 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|145|||Both|3 Months|13 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|December 2011|December 3, 2011|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01481415||94915|
NCT01489176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|555-11-FB|Regadenoson Real Time Perfusion Imaging Trial-Optison|Regadenoson Real Time Perfusion Imaging Trial-Optison||University of Nebraska|Yes|Recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|30 Years|N/A|No|||September 2012|September 25, 2012|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489176||94318|
NCT01489956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN047AI|A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)|Pilot Study to Determine the Immunogenicity of Immucothel and Oral Tolerance Induction With Biosyn Native KLH in Healthy Subjects (ITN047AI)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|December 2011|April 2013|Actual|April 2013|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 20, 2013|December 1, 2011|No|Yes|Due to futility, identified after 5 subjects completed treatment in Part B|No||https://clinicaltrials.gov/show/NCT01489956||94258|
NCT01489969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neu-P11-03-PSG|Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients|A Double-blind, Parallel Group, Randomized, Placebo Controlled Sleep Laboratory Study of Efficacy and Safety of Neu-P11 in Insomnia Patients Aged 18-80||Neurim Pharmaceuticals Ltd.|No|Completed|December 2011|January 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|137|||Both|18 Years|80 Years|No|||July 2013|July 15, 2013|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489969||94257|
NCT01489982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-09-10|Treatments for Insomnia in Patients With Parkinson's Disease|Treatments for Insomnia in Patients With Parkinson's Disease: A Pilot Study||McGill University Health Center||Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|N/A|No|||April 2015|April 15, 2015|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01489982||94256|
NCT01490554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP UNIFESP-1787/07|Autologous Fibroblast Grafts in Facial Skin Regeneration|Effectiveness of Autologous Fibroblast Grafts in the Regeneration of Facial Ectoderm||Federal University of São Paulo|Yes|Active, not recruiting|March 2007|December 2012|Anticipated|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 23, 2012|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01490554||94213|
NCT01478789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2010:096|Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans|Naturalis Clinical Trial for a Novel Phytosterol Formulation||University of Manitoba|Yes|Completed|September 2010|October 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|47|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 20, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01478789||95116|
NCT01479036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endostar B-02|Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer|Phase Ⅲ Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy in Patients With Breast Cancer|CBCRT01|Xijing Hospital|Yes|Recruiting|October 2011|February 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|800|||Female|18 Years|70 Years|No|||November 2011|November 21, 2011|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01479036||95097|
NCT01490853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML0509|Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy|Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Remission With Interferon Based Therapy||Università degli Studi di Brescia|Yes|Completed|October 2009|December 2014|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|116|||Both|18 Years|N/A|No|Non-Probability Sample|Adult (>18 years old) patients with CP Ph+/BCR-ABL CML and with CCgR after therapy        including IFN alpha.|December 2014|December 2, 2014|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01490853||94190|
NCT01490866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 154|A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)|A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)||SCRI Development Innovations, LLC|No|Completed|December 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01490866||94189|
NCT01491152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1527|Pilot Study of Whole Body Vibration for Children With Cerebral Palsy (CP) From 12 Months of Age|Side-alternating Whole Body Vibration in Children With Cerebral Palsy (CP) From 12 Months of Age - Pilot Study||University of Cologne|Yes|Completed|January 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|12 Months|24 Months|No|||September 2013|March 6, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01491152||94167|
NCT01487031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE11Z10|Music Therapy on Nausea and Pain for Autologous Stem Cell|Assessment of the Use of Music Therapy on Nausea and Pain During Hospitalization for Autologous Stem Cell Transplantation||Case Comprehensive Cancer Center|Yes|Completed|November 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|108|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01487031||94483|
NCT01479621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FpS-AS-201|A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids|A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fluticasone Propionate DPI Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Persistent Asthma Uncontrolled on Non-steroidal Therapy||Teva Pharmaceutical Industries|No|Completed|January 2012|August 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|622|||Both|12 Years|N/A|No|||March 2015|March 19, 2015|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479621||95053|
NCT01479868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018334|A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1|A Phase III Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of TMC435 Plus PegIFNα-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Subjects Who Are Co-infected With Human Immunodeficiency Virus Type 1 (HIV-1)||Janssen R&D Ireland|No|Completed|October 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|109|||Both|18 Years|70 Years|No|||October 2014|October 28, 2014|October 18, 2011|Yes|Yes||No|August 26, 2014|https://clinicaltrials.gov/show/NCT01479868||95034|
NCT01480115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC11102-11CTLI|A New Tool for Automatic Ovarian Follicle Count and it Abilities to Evaluate Ovarian Reserve|A New Tool for Automatic Ovarian Follicle Count and it Abilities to Evaluate Ovarian Reserve||Meir Medical Center|Yes|Not yet recruiting|April 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Whole blood and serum for FSH, LH, E2, AMH, Prolactin, TSH, Testosterone, Progesterone,      17-OHP, DHEA-S.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study group will include women faced the fertility unit in Meir Medical Center. Each        woman at her first evaluation will invite to volunteer. Also woman during a natural course        treatment will invite to volunteer.|November 2011|March 10, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480115||95015|
NCT01488162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25664|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia|Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera||Hoffmann-La Roche||Active, not recruiting|April 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|327|||Both|18 Years|N/A|No|Probability Sample|Adult patients with relapsing or refractory chronic lymphocytic leukemia (CLL)|March 2016|March 1, 2016|November 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01488162||94396|
NCT01488175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-100|Clinical and Stereoradiological Comparison of the Results After Primary Cemented Total Knee Arthroplasty Inserted With or Without the Use of a Tourniquet|Clinical and Stereoradiological Comparison of the Results After Primary TKA Inserted With or Without the Use of a Tourniquet||Hvidovre University Hospital|Yes|Withdrawn|January 2012|January 2015|Anticipated|January 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||March 2015|March 17, 2015|December 2, 2011||No|Funding problems|No||https://clinicaltrials.gov/show/NCT01488175||94395|
NCT01480882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-11-HPP-001|Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage|"A Prospective, Cross-over Randomized Trial to Assess the Efficacy and Safety of Mechanical Percussor "LEGA" Compared With Conventional Chest Physiotherapy in Adults With Chronic Bronchiectasis or Chronic Obstructive Pulmonary Disease (COPD|LEGA|Penang Hospital, Malaysia|Yes|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01480882||94956|
NCT01480908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSDRBBBB-RV|Right Bundle Branch Block After Surgical Closure of Ventricular Septal Defect|Postoperative Right Bundle Branch Block - Long-term Effect on the Right Ventricle in Children Operated for Ventricular Septal Defect||University of Aarhus|No|Completed|June 2011|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|December 2, 2014|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01480908||94954|
NCT01481402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HerlevH|Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)|Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status|LIHFA|Herlev Hospital|Yes|Completed|July 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|November 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01481402||94916|
NCT01481636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC No: 11/WNo:01/2|Assessing the Symptoms of Obstructive Sleep Apnea|Association of Health Outcomes With Severity of OSA Symptomatology- a Correlation Study.|OSA|Bangor University|No|Completed|November 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|66|Samples Without DNA|Blood serum|Male|18 Years|70 Years|No|Non-Probability Sample|Mild to severe recently diagnosed Obstructive Sleep Apnea patients selected by physician        who have not received any treatment for their condition. Selected from Ysbyty Gwynedd in        North Wales.|June 2014|June 16, 2014|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481636||94898|
NCT01488916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V100C-144-Protocol-1|Vitamin D Inadequacy on Postprandial Glucose in Type 2 Diabetes Mellitus|Impacts of Vitamin D Inadequacy on Postprandial Glucose Excursion in Patients With Type 2 Diabetes||Taipei Veterans General Hospital, Taiwan|No|Recruiting|August 2011|December 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|Samples Without DNA|Serum samples after meal challenge|Both|20 Years|75 Years|No|Non-Probability Sample|In the present study, we propose to screen patients with type 2 DM for vatamin D        inadequacy. Those with different vitamin D status will be invited to participate in a        mixed meal test.|December 2011|December 12, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01488916||94338|
NCT01489735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GRU-XXX-2011/1|The Use of International GerdQ Questionnaire|Observational Non-interventional Study on the Use of International GerdQ Questionnaire for the Diagnosis of Gastroesophageal Reflux Disease in the Russian Practice|GERDq|AstraZeneca|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|CLINICAL PRACTICE|January 2013|January 25, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01489735||94275|
NCT01489995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116050|Migalastat Food Effect Study|A Randomized, Open-Label, 5-Period Crossover Study to Evaluate the Effect of Meal Type and Timing on the Pharmacokinetics of Migalastat Hydrochloride in Healthy Volunteers.||Amicus Therapeutics|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489995||94255|
NCT01482455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FATRAIN|Fat and Transcapillary Insulin Transport|Lipid-induced Insulin Resistance is Not Mediated by Impaired Transcapillary Transport of Insulin and Glucose in Humans|FATRAIN|German Diabetes Center|No|Completed|December 2011|August 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|8|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 7, 2012|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01482455||94835|
NCT01478490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-005|To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol|An Open Label, One-sequence, Parallel Study to Compare the Single Dose Pharmacokinetics of YM178 in Healthy Poor or Extensive Metabolisers for CYP2D6 and to Assess the Effect of Multiple Doses of YM178 on the Metabolism of the Model Substrate Metoprolol||Astellas Pharma Inc|No|Completed|September 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|28|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2011|April 8, 2014|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478490||95139|
NCT01478503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-031|To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females|Double-blind, Randomized, Placebo-controlled, Dose-escalating, Exploratory Study to Investigate the Pharmacokinetics, Safety and Tolerability of Multiple Doses of YM178 OCAS-M in Healthy Young Male and Female Subjects and Healthy Elderly Male and Female Subjects||Astellas Pharma Inc|No|Completed|May 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|96|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|November 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01478503||95138|
NCT01478802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|282-13475|High Frequency Oscillatory Ventilation for Acute Respiratory Distress Syndrome (ARDS)|Effect of Intermittent High Frequency Oscillatory Ventilation on the Pathophysiology and Survival of Patients With the Acute Respiratory Distress Syndrome.||University of Athens|Yes|Terminated|November 2011|November 2013|Actual|November 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|75 Years|No|||April 2015|April 26, 2015|November 21, 2011||No|Low rate of enrollment, in conjunction with inability of continuation of funding|No||https://clinicaltrials.gov/show/NCT01478802||95115|
NCT01487044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH 1006|A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema|A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema|GUARDIAN|Retina Institute of Hawaii||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2011|December 5, 2011|December 5, 2011|Yes|Yes||||https://clinicaltrials.gov/show/NCT01487044||94482|
NCT01479595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQBX258X2201|A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma|A Randomized Double-blind Multiple-dose Placebo-controlled Trial to Establish the Efficacy of QBX258 (Combination of VAK694 and QAX576) in Asthma That is Inadequately Controlled With Inhaled Corticosteroids and Long Acting Beta Agonists||Novartis|No|Completed|January 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|65 Years|No|||January 2016|January 8, 2016|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01479595||95055|
NCT01479634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EARLI|Early HIV Therapy in Patients With High CD4 Cell Counts|Early Antiretroviral Therapy in Resource Limited Settings in Patients With High CD4+ Cell Counts (EARLI)|EARLI|University of California, San Francisco|No|Completed|October 2011|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01479634||95052|
NCT01479881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100686|A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus|A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Effect of TMC435 at Steady-state on the Pharmacokinetics of the Immunosuppressants Cyclosporine and Tacrolimus||Tibotec Pharmaceuticals, Ireland|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 31, 2012|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01479881||95033|
NCT01480128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPA-2011|Multicenter Single-port Colectomy RCT|A Multicenter Prospective Randomized Clinical Trail on the Efficacy of the Single Port Laparoscopic Surgery Compared With Multiport Laparoscopic Surgery|SIMPLE|The Catholic University of Korea|Yes|Enrolling by invitation|July 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|388|||Both|20 Years|85 Years|No|||October 2015|October 5, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01480128||95014|
NCT01480635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV3467|PillCam Colon 2 Capsule Endoscopy (PCCE) After Incomplete Colonoscopy|Evaluation of the PillCam Colon Capsule Endoscopy (PCCE) After Incomplete Colonoscopy|PCCE|Bethesda Krankenhaus|Yes|Recruiting|June 2010|October 2012|Anticipated|July 2012|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|74|||Both|18 Years|N/A|No|Probability Sample|Patients that are indicated for colonoscopy, who are suspected or known to suffer from        colonic diseases and had an incomplete standard colonoscopy|October 2011|November 28, 2011|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01480635||94975|
NCT01480661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2011-77|Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients|Analysis of Airway Responses in Severe COPD Patients to Daxas®, Using CT Based Functional Respiratory Imaging||FLUIDDA nv|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|41|||Both|30 Years|N/A|No|||September 2013|September 18, 2013|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01480661||94973|
NCT01481428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#1002|Reducing High Risk Behavior in Treatment Court|Delivering HIV Risk Reduction Services in Treatment Court||Treatment Research Institute|Yes|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 11, 2015|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01481428||94914|
NCT01481649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1422|Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure|Risk of Hepatitis B Reactivation After Hematopoietic Stem Cell Transplantation in Donors and Recipients With Prior HBV Exposure||The University of Hong Kong|No|Enrolling by invitation|November 2011|February 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Serum and plasma for hepatitis B virus genotypic, virologic and serologic testing|Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for hematopoietic stem cell transplantation (HSCT) in Hong Kong|December 2014|December 29, 2014|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01481649||94897|
NCT01481935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00048554|Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria|Use of an Enhanced Room Cleaning Protocol in the Intensive Care Unit to Reduce Contamination of Disposable Isolation Gowns and Gloves With Methicillin-resistant Staphylococcus Aureus and Multi-drug Resistant Acinetobacter Baumannii||University of Maryland|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|190|||Both|18 Years|N/A|No|||October 2012|October 25, 2012|November 21, 2011||No||No|September 19, 2012|https://clinicaltrials.gov/show/NCT01481935||94875|
NCT01482221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6702C00031|A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients With Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants||AstraZeneca||Completed|December 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|70 Years|No|||September 2013|September 30, 2013|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01482221||94853|
NCT01489722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4510C00001|Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients|A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)||AstraZeneca|No|Terminated|February 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01489722||94276|
NCT01489748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-AVX-11-10239|Canadian Avonex PEN Productivity Study|An Open-Label, Observational, Multicenter Study to Evaluate the Impact of AVONEX PEN Autoinjector Therapy on Work Capacity of Multiple Sclerosis Patients in Canada|CAPPS|Biogen|No|Completed|March 2012|December 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|111|||Both|18 Years|50 Years|No|Non-Probability Sample|Enrollment will consist of approximately 500 participants who have been prescribed AVONEX        PEN in accord with its labeling (Product Monograph). This will include participants who        are naïve to disease modifying therapies (DMTs) as well as those who are being switched        from another injectable DMT.|February 2015|February 18, 2015|December 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01489748||94274|
NCT01482442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101103|SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma|A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma|SARAH|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|December 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|496|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01482442||94836|
NCT01478477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11022|Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole|Prevention of Aromatase Inhibitor-Induced Joint Symptoms With Omega 3 Fatty Acid Supplementation: a Randomized Placebo Controlled Pilot Study||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|October 2011|||January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|6||Anticipated|40|||Female|18 Years|N/A|No|||March 2015|March 23, 2015|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478477||95140|
NCT01478230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICTDP0002|An Exploratory Study Comparing Two Nicotine Inhalers|A Proof of Concept With a New Nicotine Inhaler in Comparison With Nicotine Inhaler 10 mg||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|19 Years|50 Years|No|||July 2012|July 6, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478230||95159|
NCT01498224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-11-002|ReSure Sealant Pivotal Study|ReSure Sealant Pivotal Study||Ocular Therapeutix, Inc.|No|Completed|December 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|488|||Both|22 Years|N/A|No|||February 2016|February 8, 2016|December 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498224||93627|
NCT01498484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-130|Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies|A Phase II Study of The Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies||Atara Biotherapeutics||Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498484||93607|
NCT01496651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeftMain/NOBLE|Coronary Artery Bypass Grafting Vs Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis|Nordic-Baltic-British Left Main Revascularization Study (NOBLE)|LeftMain/NOBLE|Aarhus University Hospital Skejby|Yes|Active, not recruiting|November 2008|December 2018|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|N/A|N/A|No|||January 2015|January 30, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496651||93747|
NCT01499329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-EAZY-05-002|Safety and Performance of the Zeus CC Stent for the Treatment of Iliac Occlusive Disease|Endovascular Treatment of Iliac Artery Occlusions or Stenoses Using the Zeus CC Stent System|EAZY|be Medical|No|Recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients with iliac occlusive disease TASC A, B, C and D lesions.|July 2015|July 15, 2015|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01499329||93542|
NCT01499628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUBG1008|EFFECT:Eccentric Fixation From Enhanced Clinical Training|Eccentric Fixation From Enhanced Clinical Training (EFFECT): A Randomised Clinical Trial for Patients With AMD|EFFECT|Moorfields Eye Hospital NHS Foundation Trust|No|Recruiting|April 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|50 Years|N/A|No|||December 2011|December 22, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499628||93519|
NCT01499914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100201|Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination|Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination in Patients With Cystic Fibrosis and, Where Applicable, the Clinical Expression of Influenza A (H1N1)|MUCOFLU|Assistance Publique - Hôpitaux de Paris|No|Completed|November 2009|December 2012|Actual|January 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|439|||Both|6 Months|N/A|No|||August 2014|August 25, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01499914||93497|
NCT01499927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FZMI-KEK-ZH-Nr. 2010-0457|Early Reassessment of Intravenous Antiinfective Therapy Due to "Antiinfective Reminders" (AIR Study)|Early Reassessment of Intravenous Antiinfective Therapy Due to "Antiinfective Reminders" (AIR Study)|AIR|University of Zurich|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|74766|||Both|N/A|N/A|No|||December 2013|December 18, 2013|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01499927||93496|
NCT01497431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00085|Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants|Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-Cysteine(MSC) and L SeMet in Adult Males||National Cancer Institute (NCI)|Yes|Completed|November 2011|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|66|||Male|40 Years|80 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497431||93687|
NCT01496339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEB-1213-T1DM|Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients|Phase 1/2 Clinical Study of MenSCs Infusion in Type 1 Diabetes||S-Evans Biosciences Co.,Ltd.|Yes|Recruiting|January 2012|May 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|No|||June 2012|June 6, 2012|December 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496339||93771|
NCT01498263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120022|Inherited Diseases, Caregiving, and Social Networks|Inherited Diseases, Caregiving, and Social Networks||National Institutes of Health Clinical Center (CC)||Recruiting|December 2011|||||N/A|Observational|N/A|||Anticipated|2575|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|December 30, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498263||93624|
NCT01498523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38520|The Glycaemic and Insulinaemic Responses of Camel Milk|An Explorative Study to Characterize the Glycaemic and Insulinaemic Responses of Regular Camel Milk and Camel Milk Powder|GLUCAM|Wageningen University|No|Completed|December 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01498523||93604|
NCT01501058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEERSK2011|Parent-supported Social Skills Training for Teens With Autism Spectrum Disorders (PEERS-K)|Parent-Assisted Social Skill Training Program in the Adolescents With Autism Spectrum Disorder||Seoul National University Hospital||Active, not recruiting|December 2011|September 2013|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|11 Years|18 Years|No|||May 2013|May 27, 2013|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01501058||93410|
NCT01502722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IHS/FCNAUP-001|Effect of Ingestion of Sugary Drinks on Thirst Sensation|Effect of Ingestion of Sugary Drinks on Thirst Sensation||Universidade do Porto|Yes|Completed|January 2012|August 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01502722||93282|
NCT01497093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-005|Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) FOR THE COMBINATION OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA||Celgene|No|Active, not recruiting|February 2012|September 2019|Anticipated|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497093||93713|
NCT01497106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006181|Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults|Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults||Mayo Clinic|No|Completed|December 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|29|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|December 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497106||93712|
NCT01500135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-2402-039-SP|Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment in Vascular Surgery|A Randomized, Open Label, Parallel-group, Multi-center Trial to Compare Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery|VASUS|Takeda|No|Active, not recruiting|March 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500135||93480|
NCT01498744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 2010-14118|Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess|Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Skin and Soft Tissue Abscess Undergoing Incision and Drainage||Ann & Robert H Lurie Children's Hospital of Chicago|No|Terminated|February 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|1 Month|17 Years|No|||January 2016|January 27, 2016|December 20, 2011||No|The study was closed due to poor enrollment and lack of interest.|No|November 11, 2015|https://clinicaltrials.gov/show/NCT01498744||93587|Inadequate enrollment numbers leading to early termination of study.
NCT01497964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD12417|Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy|A Phase 2, Multicenter Study of Cabazitaxel Single Agent Administered as a 1-Hour Intravenous Infusion Every 3 Weeks to Evaluate the Safety, Tolerability and Anti-tumor Activity of Cabazitaxel in Patients With Advanced Gastric Adenocarcinoma Who Have Failed Prior Chemotherapy Regimens|GASTANA|Sanofi|No|Completed|December 2011|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497964||93647|
NCT01498211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4961|Normative Data of Intra-epidermal Nerve Fiber Density|Establishement of Normative Intra-epidermal Nerve Fiber Density Using Skin||University Hospital, Strasbourg, France|No|Active, not recruiting|December 2011|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||December 2011|July 4, 2012|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01498211||93628|
NCT01498731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charite-BiC-8|Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS)|The Effect of Integrating the Biomarker Copeptin Into the Process of Managing Patients With Suspected ACS|BiC-8|Charite University, Berlin, Germany|No|Completed|April 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|902|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01498731||93588|
NCT01499043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-06|Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)|A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC)Counts||Plexxikon|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|18 Years|N/A|No|||March 2015|March 23, 2015|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499043||93564|
NCT01496872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100721-001|Newborn Cranial Somatic Dysfunction - An Observational Study|Newborn Cranial Somatic Dysfunction - An Observational Study||A.T. Still University of Health Sciences|No|Completed|August 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|N/A|72 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Infants born at the Northeast Regional Medical Center (NRMC) in Kirksville, MO, between        August 1, 2011, and July 31, 2012. The infants must be greater than 6 but less than 72        hours old to participate in the study.|November 2011|August 11, 2014|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496872||93730|
NCT01497444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1153|Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery|Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC||Alliance for Clinical Trials in Oncology|Yes|Suspended|May 2012|||January 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 20, 2011|Yes|Yes|The current dose cohort (Dose Level +1a) has met its accrual goal in the Phase I portion of    the study.|No||https://clinicaltrials.gov/show/NCT01497444||93686|
NCT01497457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B403201112604|Interest of Saline MR Peritoneography for Pre-operative Assessment of Rectal Cancer|Interest of Saline MR Peritoneography for Pre-operative Assessment of Rectal Cancer||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|December 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01497457||93685|
NCT01497769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB026|Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route|A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intradermal Route in Healthy BCG-vaccinated Adult Subjects||University of Oxford|Yes|Completed|September 2011|April 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497769||93661|
NCT01495819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010007514|Intravenous (IV) Nicotine Self Administration: Dose Ranging and Sex Differences in Smokers|IV Nicotine Self Administration: Dose Ranging and Sex Differences in Smokers||Yale University|Yes|Recruiting|October 2011|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|25 Years|No|||January 2016|January 8, 2016|December 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495819||93811|
NCT01496053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AbM2012-IBD|Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)|Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study||Oslo University Hospital|Yes|Recruiting|December 2011|January 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||December 2011|April 13, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01496053||93793|
NCT01496066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-002-03|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2011|||||N/A|N/A|N/A||||||||||||||August 11, 2015|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496066||93792|
NCT01498016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH-Busulfan|Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia|Pharmacokinetic Study of Intravenous Busulfan as Conditioning Regimen for Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia||Shanghai Jiao Tong University School of Medicine|No|Recruiting|November 2011|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|55 Years|No|||May 2015|May 20, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01498016||93643|
NCT01498276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120023|Family Genetics Health Education and Healthy Behaviors|The Role of the Family Genetics Health Educator in Influencing Health Promoting Behaviors||National Institutes of Health Clinical Center (CC)||Recruiting|December 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|335|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 12, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498276||93623|
NCT01498289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1201|S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer|A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer||Southwest Oncology Group|Yes|Active, not recruiting|February 2012|March 2019|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498289||93622|
NCT01492322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813475|SPECT Imaging of DAT Genotype|Use of SPECT (Single-photon Emission Computed Tomography) to Examine the Role of DAT (Dopamine Transporter) Genotype in Motivated Smoking Behavior|DDAT|University of Pennsylvania|No|Terminated|November 2011|October 2014|Actual|July 2013|Actual|Phase 1|Observational|Observational Model: Cohort||1|Actual|14|||Both|18 Years|60 Years|No|Non-Probability Sample|Subjects will be forty physically-healthy and mentally-stable male and non-pregnant female        subjects between the ages of 18 and 60 who meet the DSM-IV criteria for nicotine        dependence. Subjects will not be excluded based on gender, religion, race, or        socioeconomic status. The subject population of previous smoking studies in our lab was        54% female, 62% Caucasian, and averaged 15 years of education. This is representative of        the urban population in the northeast region of the United States who seek help for        nicotine dependence. We expect our current population to have similar characteristics.|December 2011|October 7, 2015|December 2, 2011|Yes|Yes|UPenn suspended production of the ligand necessary to produce the tracer TRODAT.|No||https://clinicaltrials.gov/show/NCT01492322||94077|
NCT01496846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG#N014189|Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars|Articaine Versus Lidocaine Supplemental Infiltration Efficacy in Irreversible Pulpitis Mandibular Molars After Failed Inferior Alveolar Nerve Block|ARTIC|University of Michigan|No|Completed|September 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|December 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496846||93732|
NCT01497704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK-LSK-AM101|Dose-Escalation and Safety Trial of YN968D1|Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors||LSK BioPartners Inc.|No|Completed|April 2012|May 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|December 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497704||93666|
NCT01498250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|microRNA6|Microarray Analysis of microRNA Expression in Basal Cell Carcinoma|Microarray Analysis of microRNA Expression in Basal Cell Carcinoma||Ruhr University of Bochum|Yes|Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|7|Samples With DNA|basal cell carcinoma and non-lesional skin|Both|1 Year|N/A|No|Non-Probability Sample|Patients with        Basal Cell Carcinoma|October 2012|October 15, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01498250||93625|
NCT01499368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAF-BR-CT-302|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients||Boryung Pharmaceutical Co., Ltd|Yes|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|495|||Both|20 Years|75 Years|No|||January 2013|January 23, 2013|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01499368||93539|
NCT01497366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7977-1231|Phase 3 Study of Sofosbuvir and Ribavirin|A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients With Chronic Genotype 2 or 3 HCV Infection|FISSION|Gilead Sciences|Yes|Completed|December 2011|April 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|527|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|December 19, 2011|Yes|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT01497366||93692|
NCT01497379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1198|Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients|Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Mono- & Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Degenerative Retinal Disease Patients.||Retina Implant AG|Yes|Completed|October 2011|January 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|78 Years|No|||October 2015|October 26, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01497379||93691|
NCT01499654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU53243|Half-Dose Radiopharmaceutical in Wide Beam Reconstruction|Feasibility of Half-Dose Radiopharmaceutical Administration Utilizing Wide-Beam Reconstruction|REGA-1102|Northwestern University|No|Terminated|October 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|64|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 19, 2011|No|Yes|Low enrollment|No|December 18, 2015|https://clinicaltrials.gov/show/NCT01499654||93517|Early termination of study lead to a small numbers of subjects analyzed. Technical problems in WBR processing settings including acquisition matrix sizes and/or number of iterations.
NCT01499667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2324|Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod|A 32-week, Patient- and Rater-blinded, Randomized, Multi-center, Parallel-group Study to Evaluate Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis Transferred From Previous Treatment With Natalizumab to Fingolimod (FTY720)|TOFIINGO|Novartis|No|Terminated|September 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|142|||Both|18 Years|65 Years|No|||August 2014|August 6, 2014|August 18, 2011||No|Based on recent publications, determination of natalizumub washout period was no longer    relevant.|No|November 25, 2013|https://clinicaltrials.gov/show/NCT01499667||93516|Study was terminated due to new data on nataluzimab washout prior to treatment with other disease modifying treatments. The power to detect statistically significant differences between the washout groups based on the (-)binomial is estimated 30-40%.
NCT01495832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2001:084|Impact of Pulse-enriched Foods on Cognitive Function and Cardiometabolic Health in Obese Adults|Impact of Pulse-enriched Foods on Cognitive Function and Cardiometabolic Health in Obese Adults|PULSA-2011|University of Manitoba|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|150|||Both|50 Years|80 Years|No|||September 2014|September 24, 2014|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495832||93810|
NCT01495845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1558|Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy|Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy||University of North Carolina, Chapel Hill|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|48|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495845||93809|
NCT01495858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15881|Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain|A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep|Morpheus/DPH|Bayer|No|Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|267|||Both|12 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 13, 2015|December 16, 2011|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01495858||93808|
NCT01498497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-022|A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021|Six Month Safety Follow-up Study for PR-021 [Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Eosinophilic Esophagitis Subjects]||Forest Laboratories|No|Enrolling by invitation|January 2012|April 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|12 Years|55 Years|No|Non-Probability Sample|Subjects who received study drug and completed the PR-021 study (Safety and Tolerability        Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis)|August 2012|October 31, 2012|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498497||93606|
NCT01496352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA-02-CD-002|DFA-02 in Patients Undergoing Colorectal Surgery|A Randomized, Double-blind, Placebo Controlled, Safety, Tolerability, and Pharmacokinetic Dose Escalation Study of DFA-02 in Patients Undergoing Colorectal Surgery||Dr. Reddy's Laboratories Limited|Yes|Completed|February 2012|June 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|December 15, 2011|Yes|Yes||No|August 15, 2014|https://clinicaltrials.gov/show/NCT01496352||93770|Protocol specified cohorts of 10, 20, 30 or 40 mL to be placed after closure of the fascia and prior to skin closure. Experience with 20 and 30 mL dose levels showed that even largest patients would not accommodate 40 mL so that arm was not done.
NCT01496365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-U201|Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy||Daiichi Sankyo Inc.|Yes|Completed|November 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|452|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496365||93769|
NCT01496391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPDC-HIPP-001|A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function|A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function||Centre for Probe Development and Commercialization|Yes|Completed|September 2012|April 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|6|None Retained|Whole blood (chemistry, hematology) and kidney function (eGRF, eRPF)|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants will be recruited from both healthy subjects (eGFR ≥ 60 mL/minute/1.73m^2)        being assessed as potential renal donors and patients having suspected renal impairment        (eGFR <60 mL/minute/1.73m^2). Severity of disease will be determined based on estimated        glomerular filtration rate (eGFR) derived from serum creatinine concentration.|April 2014|April 8, 2014|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01496391||93767|
NCT01496404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02242|Electrocautery Versus Scalpel for Skin Incisions|A Randomized Controlled Trial Comparing the Cosmetic Outcome of Electrocautery Versus Scalpel for Surgical Skin Incisions||St. Paul's Hospital, Canada|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|19 Years|N/A|No|||July 2014|July 19, 2014|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01496404||93766|
NCT01496625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120042|National Eye Institute Biorepository for Retinal Diseases|NEI Intramural Biorepository for Retinal Diseases||National Institutes of Health Clinical Center (CC)||Recruiting|December 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2300|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|December 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01496625||93749|
NCT01497145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN321-401|A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome|A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Response Study to Evaluate the Efficacy and Safety of KRN321 in Adult Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndrome||Kyowa Hakko Kirin Company, Limited|No|Completed|December 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|45|||Both|20 Years|N/A|No|||March 2015|March 2, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497145||93709|
NCT01497418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102|Long Term Follow-up of the 23mm Portico™ Aortic Valve Implant and the St. Jude Medical Transfemoral Delivery System|Long Term Follow-up of the 23mm Portico™ Aortic Valve Implant and the SJM Transfemoral Delivery System||St. Jude Medical|No|Completed|December 2011|March 2014|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|2|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that are candidate for implantation or have been implanted with the St. Jude        Medical 23mm Portico Transcatheter heart valve.|September 2014|September 18, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01497418||93688|
NCT01501929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bystolic MD52|Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients|Effects of Nebivolol on Microvascular Perfusion in the Skeletal Muscles During Exercise in Hypertensive Patients||University of Texas Southwestern Medical Center|Yes|Completed|August 2010|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01501929||93343|
NCT01501942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIM102-201|Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma|A Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma||AIM Therapeutics Inc.|No|Completed|February 2012|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||February 2014|February 12, 2014|December 26, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01501942||93342|
NCT01497405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA032061-01|WHC+ (Women's Health CoOp PLUS)|Combination Prevention for Vulnerable Women in South Africa||RTI International|Yes|Active, not recruiting|May 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|641|||Female|15 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 8, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01497405||93689|
NCT01498029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CART/ 5 April 2011|Knee Articular Cartilage Repair: Cartilage Autograft Implantation System Versus Conventional Microfracture|A Randomised Clinical Trial Comparing a Novel Single-stage Autologous Cartilage Implantation System to Conventional Microfracture for Repair of Articular Cartilage Defects in the Knee|CAIS|Singapore General Hospital|No|Recruiting|January 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|21 Years|50 Years|No|||December 2011|March 20, 2012|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01498029||93642|
NCT01498302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B5|Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia|Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia||Children's Oncology Group|No|Active, not recruiting|February 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10|Samples With DNA|Bone marrow and/or peripheral blood|Both|N/A|120 Years|No|Non-Probability Sample|Acute myeloid leukemia (AML) enrolled on Children's Oncology Group (COG) studies.|May 2015|September 30, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01498302||93621|
NCT01492335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCP-AG023129|Cognitive Assessment of Elderly Primary Care Patients|Cognitive Assessment of Elderly Primary Care Patients||University of Pittsburgh|Yes|Completed|January 2006|August 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|524|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01492335||94076|
NCT01498003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111211|Tirofiban in Stenting for Long Coronary Lesion|Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent|PETITION|Shanghai Jiao Tong University School of Medicine|Yes|Completed|November 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|748|||Both|18 Years|80 Years|No|||July 2015|July 13, 2015|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01498003||93644|
NCT01499381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRMDA-0001-1011|EMBRACE1: Prostate Biorepository|Evaluation of a Novel Circulating Microvesicle-Based Multi-analyte Assay for the Detection of Prostate Cancer in Men With Elevated Risk for Prostate Cancer; the EMBRACE1 Study||Caris Science, Inc.|No|Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1290|Samples With DNA|Plasma|Male|18 Years|N/A|No|Probability Sample|Men scheduled for routine prostate biopsy|March 2013|March 13, 2013|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01499381||93538|
NCT01498510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WebCBTPain618|Web-based Cognitive-behavior Therapy (CBT) for Opioid-treated, Chronic Pain Patients With Aberrant Behavior|Web-based CBT for Opioid-treated, Chronic Pain Patients With Aberrant Behavior|WebCBTPain|National Development and Research Institutes, Inc.|No|Completed|February 2012|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498510||93605|
NCT01499940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU 11011|Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway|Phase II Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through the Vitamin D Pathway||West Virginia University|Yes|Recruiting|October 2011|October 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|45|||Both|18 Years|90 Years|No|||December 2011|December 22, 2011|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01499940||93495|
NCT01499953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SURPRISE-2011|Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux|Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux||GWT-TUD GmbH|Yes|Recruiting|April 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|506|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01499953||93494|
NCT01499979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_214|Hypothermic Perfusion During Hemihepatectomy|In Situ Hypothermic Perfusion During Right Hemihepatectomy||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|February 2012|August 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499979||93492|
NCT01499966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRahimnajjad|Comparison of Plaster of Paris Against Tubigrip for the Treatment of Lateral Ankle Sprains|Assessment of Tubigrip Versus Plaster of Paris in the Treatment of Grade 1 and 2 Lateral Ankle Sprains|POPTuLAS|Liaquat National Hospital & Medical College|No|Completed|January 2011|September 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|40 Years|No|||December 2011|December 23, 2011|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01499966||93493|
NCT01496079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00051718|Maternal Immunization: Giving Immunity For Tomorrow|The Role of Immunizing Pregnant Women In Protecting Young Infants Against Influenza|MI GIFT|University of Utah|No|Recruiting|December 2011|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|||Female|18 Years|45 Years|No|Non-Probability Sample|Pregnant women and their infants receiving care at University of Utah Health Sciences        (UUHS) will be recruited and followed.|January 2013|January 22, 2013|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01496079||93791|
NCT01496378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HD065180-01A1|Problem Solving Skills Training For Parent Caregivers of Youth With Chronic Pain|Problem Solving Skills Training For Parent Caregivers of Youth With Chronic Pain||Seattle Children's Hospital|Yes|Completed|May 2012|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|10 Years|17 Years|No|||May 2015|May 26, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496378||93768|
NCT01497158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007NT053|Promoting Home Smoking Restrictions: Biomarker Feedback to Smoking and Non-Smoking Adults|Promoting Home Smoking Restrictions: Biomarker Feedback to Cohabitating Smoking and Non-Smoking Adults||University of Minnesota - Clinical and Translational Science Institute|No|Completed|June 2007|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|122|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 21, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497158||93708|
NCT01497171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000247|The ELEGANT Trial: Elevate Transvaginal Mesh vs. Anterior Colporrhaphy|Safety and Efficacy of Transvaginal Mesh Colposuspension for Anterior Vaginal Prolapse: the Elevate vs. Anterior Colporrhaphy Trial||Mayo Clinic|No|Terminated|November 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|5|||Female|21 Years|80 Years|No|||August 2014|August 6, 2014|December 20, 2011|Yes|Yes|Early termination of study due to changes in funding.|No|August 6, 2014|https://clinicaltrials.gov/show/NCT01497171||93707|Early termination of study due to changes in funding.
NCT01498042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813387|Predictors of Outcome in t-PA Treated Stroke.|Ischemic Stroke Treated With iv Thrombolysis Within 4.5 Hours: Predictors of Outcome in a Cohort With a Large Proportion of Patients Above 80 Years||Sorlandet Hospital HF|No|Completed|January 2007|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|162|||Both|18 Years|N/A|No|Probability Sample|Sorlandet hospital is a secondary hospital. The patients will be drawn from thrombolysis        treated patients in its catchement area. A registry of these patients has been ongoing        since before the inclusiondate. All thrombolysed patients at Sorlandet will be included in        the predefined inclusionperiode. In addition we have enrolled 39 patients treated with        thrombolysis from Haukeland hospital; Bergen. These 77 patients over 80 years will be        compared to 85 patients below 80 years treated at SSK in the same defined periode.|December 2011|December 20, 2011|July 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01498042||93641|
NCT01498575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008203|An Evaluation of a Web-based Intervention Program for Parents and Teens to Promote Safe Driving|An Evaluation of a Web-based Intervention Program for Parents and Teens to Promote Safe Driving||Children's Hospital of Philadelphia|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1024|||Both|16 Years|17 Years|Accepts Healthy Volunteers|||March 2015|March 3, 2015|December 20, 2011||No||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01498575||93600|Moderate attrition (although no evidence of selective attrition); limited generalizability of results; and eight teenagers were not administered the highway module and were censored from analysis.
NCT01492998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.501-02|Role of FXR in Hepatitis C Virus Replication|Study of the Role of the Biliary Salts Nuclear Receptor FXR in Hepatitis C Virus Replication|GGST|Hospices Civils de Lyon|No|Terminated|January 2010|||March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|18 Years|60 Years|No|||September 2010|December 14, 2011|September 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01492998||94025|
NCT01493011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMMU|Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer|A Randomized Contrasted Polycentric Clinical Study About Chemotherapy Combined With Whole-body Hyperthermia(WBH)to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|WBH&NSCLC|Xijing Hospital|Yes|Recruiting|November 2011|December 2015|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||May 2012|May 13, 2012|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01493011||94024|
NCT01499082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11628|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin|6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both Plus Mealtime Insulin in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension Period|EDITION I|Sanofi||Completed|December 2011|September 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|807|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|December 16, 2011|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01499082||93561|
NCT01499095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11629|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy|6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension Period|EDITION II|Sanofi|No|Completed|December 2011|November 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|811|||Both|18 Years|N/A|No|||April 2015|April 22, 2015|December 16, 2011|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01499095||93560|
NCT01499394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCBIO-001-0710|Caris Biorepository Research Protocol|The Caris Biorepository Research Protocol||Caris Science, Inc.|No|Active, not recruiting|November 2010|November 2025|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100000|Samples With DNA|Currently plasma with an opportunity to collect other biospecimens|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers as well as those with a known disease state or condition|May 2015|May 18, 2015|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01499394||93537|
NCT01499680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.NV1001|Multimodality Neuromonitoring in XLIF|Multimodality Neuromonitoring In eXtreme Lateral Interbody Fusion (XLIF®)|NV in XLIF®|NuVasive|No|Completed|October 2011|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|323|||Both|18 Years|N/A|No|Probability Sample|Study population will consist of patients from participating site locations.|July 2014|July 14, 2014|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01499680||93515|
NCT01495897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-18|Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study|Adaptation Sensorimotrice, Cervelet et Mouvements Anormaux: Projet d'étude Oculomotrice|MOUVADOC|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|March 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|14|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01495897||93805|
NCT01495884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 10-03|The Myocet/Lapatinib Study. ICORG 10-03, V5|A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes||ICORG- All Ireland Cooperative Oncology Research Group|No|Terminated|March 2011|October 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|18 Years|N/A|No|||October 2015|October 23, 2015|December 16, 2011||No|Slower than anticipated accrual|No||https://clinicaltrials.gov/show/NCT01495884||93806|
NCT01496092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAPD|Study of Keto Acid (KA) on Insulin Resistance in Peritoneal Dialysis (PD) Patients|Effects of Regular Protein Diet Supplemented With Keto Acid on Insulin Resistance In Peritoneal Dialysis Patients||Peking University First Hospital|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||February 2014|February 19, 2014|August 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496092||93790|
NCT01496105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ali elyan 2011|Efficacy Study of Topical Application of Lidacaine Spray Prior to IUD Insertion|||Ain Shams University|Yes|Recruiting|July 2011|January 2012|Anticipated|December 2011|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 20, 2011|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496105||93789|
NCT01496118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI MM 27|Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma|Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma||SCRI Development Innovations, LLC|No|Active, not recruiting|December 2011|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496118||93788|
NCT01496131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 63325-015|Tecemotide (L-BLP25) in Prostate Cancer|A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients||EMD Serono|No|Active, not recruiting|October 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|N/A|No|||September 2015|September 28, 2015|November 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496131||93787|
NCT01496664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100152|Coronary Hybrid Revascularisation Study|Coronary Hybrid Revascularisation Study Registry on Treatment of Significant Coronary Artery Disease by Combined Bypass Operation (CABG) and Catheter Based Treatment (PCI)||Aarhus University Hospital Skejby|Yes|Active, not recruiting|September 2010|October 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|N/A|N/A|No|||August 2015|August 18, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496664||93746|
NCT01496677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-109|Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects|A Phase 1 Open-Label Study With Oral TR-701 Free Acid to Assess Pharmacokinetics, Safety, and Tolerability in Elderly Subjects||Trius Therapeutics LLC|No|Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 17, 2015|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496677||93745|
NCT01501071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Esophageal Calibration During Laparoscopic Fundoplication Reduces Dysphagia|Esophageal Calibration With Soft Orogastric Tube During Laparoscopic Fundoplication Reduces Postoperative Transient Dysphagia||Antalya Training and Research Hospital|No|Completed|January 2009|November 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|N/A|N/A|No|||December 2011|December 28, 2011|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501071||93409|
NCT01496898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|uufpf 43416|Changes in Vaginal, Cervical and Uterine Microflora With Levonorgestrel Intrauterine Device Placement|Vaginal Microflora and Inflammatory Markers Before and After Levonorgestrel Device Insertion||University of Utah|Yes|Completed|January 2011|July 2013|Actual|December 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|13|Samples With DNA|A total of 648 samples will be collected from 12 participants for bacterial species and      human cytokine analysis in 9 collection visits. Specimens will be collected up to one week      prior to IUD insertion and two months after IUD insertion. Vaginal and cervical specimens      will be collected using FLOQSwabs® (Copan) to maximize bacterial DNA sample collection.      Uterine samples will be collected by uterine irrigation with sterile saline using an embryo      replacement catheter.|Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Caucasian woman aged 18 to 45 seeking intrauterine contraception meeting inclusion        criteria.|January 2016|January 11, 2016|August 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01496898||93728|
NCT01497184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0525|Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood|CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2011|||December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|140|||Both|1 Year|65 Years|No|||January 2016|January 11, 2016|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497184||93706|
NCT01497197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200061-506|A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique|A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART)||Merck KGaA|No|Terminated|May 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|174|||Female|36 Years|42 Years|No|||October 2015|October 12, 2015|December 20, 2011||No|Study was terminated as per sponsor's decision|No|June 15, 2015|https://clinicaltrials.gov/show/NCT01497197||93705|Study was terminated as per sponsor's decision.
NCT01501396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202023|Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite|Treatment of Cancer Anorexia-cachexia Syndrome (CACS) With Mirtazapine and Megestrol Acetate||Washington University School of Medicine|No|Withdrawn|September 2013|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01501396||93384|
NCT01501656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092011-047|Epigenetic Testing for Breast Cancer Risk Stratification|Epigenetic Testing for Breast Cancer Risk Stratification||University of Texas Southwestern Medical Center|Yes|Completed|May 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|158|Samples With DNA|benign samples from unselected healthy control populations|Female|30 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Archived tumor tissue, Newly diagnosed primary breast cancer patients and healthy women        who have never been diagnosed with breast cancer|January 2015|January 2, 2015|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01501656||93364|
NCT01501669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-536|Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer|Phase III Multicenter Randomized Open-label Study of Irinotecan Plus Capecitabine Versus Capecitabine in Patients Previously Treated With Anthracycline and Taxane for HER2 Negative Metastatic Breast Cancer[PROCEED]|PROCEED|National Cancer Center, Korea|No|Recruiting|June 2011|February 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|222|||Female|20 Years|N/A|No|||July 2012|July 17, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501669||93363|
NCT01497717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0488-09RMB|Efficacy of Humira in Behcet Patients With Arthritis|Efficacy of Humira in Behcet Patients With Arthritis||Rambam Health Care Campus|No|Recruiting|July 2013|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||June 2015|June 2, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497717||93665|
NCT01497730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003|Multi-center, Non-comparative Study of Primary Total Knee Arthroplasty (TKA) Functional Performance|Multi-center, Non-comparative Study of Primary Total Knee Arthroplasty (TKA) Functional Performance|10003|DePuy Orthopaedics|No|Active, not recruiting|October 2011|December 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|840|||Both|22 Years|80 Years|No|||January 2016|January 19, 2016|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497730||93664|
NCT01498315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0073-CTIL|The Incidence of Pelvic Hematoma Following Hysterectomy|The Incidence of Pelvic Hematoma Following Hysterectomy|Hematoma|Carmel Medical Center|No|Completed|March 2012|May 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|||Female|18 Years|80 Years|No|Non-Probability Sample|Women following hysterectomy|May 2014|May 15, 2014|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498315||93620|
NCT01502839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0219|Role of NSI in Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions|Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions: The Role of The Neurobehavioral Symptom Inventory||VA Eastern Colorado Health Care System|Yes|Terminated|March 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|887|||Both|18 Years|60 Years|No|Non-Probability Sample|Archival data will be collected from all OEF/OIF Veterans who were seen in the VA ECHCS        TBI Clinic by Nancy Cutter, M.D. and her team between January 1, 2009 and December 31,        2010. Electronic Medical Record (EMR) progress note titles "OEF/OIF TBI 2nd Level        Evaluation Consult Report" and "TBI Consult Report" will be used to identify potential        subjects.|December 2012|June 8, 2015|December 9, 2011||No|Unable to complete the data collection for this study.|No||https://clinicaltrials.gov/show/NCT01502839||93273|
NCT01502579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGH201106|An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data|An Observational Study of the Relationship Between Pathological Variants and Clinical Data at Presentation and Follow-up in IgA Nephropathy||Guangdong General Hospital|Yes|Completed|September 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|603|||Both|18 Years|80 Years|No|Probability Sample|The population from which the cohort will be selected is these who have received renal        biopsy in Guangdong General Hospital|August 2013|August 27, 2013|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502579||93293|
NCT01498757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-05-076|Genome-wide Association Study|Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma||Samsung Medical Center|No|Withdrawn|January 2012|||June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Esophageal squamous cell carcinoma Patients treated with Taxane/5-FU/platinum based        chemotherapy.|December 2015|December 28, 2015|December 21, 2011||No|Registration poor|No||https://clinicaltrials.gov/show/NCT01498757||93586|
NCT01498770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08308|An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)|An Observational Drug Utilization Study of SYCREST^® (Asenapine) in the United Kingdom||Merck Sharp & Dohme Corp.|No|Active, not recruiting|April 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||13|Anticipated|3000|||Both|N/A|N/A|No|Non-Probability Sample|The study population is drawn from UK general practitioner practices participating in        CPRD. The database is generally representative of the UK general population.|October 2015|October 22, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498770||93585|
NCT01499108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005344-95|Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes|Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes|Liratime|Steno Diabetes Center|Yes|Completed|August 2012|August 2014|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||July 2013|January 30, 2015|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01499108||93559|
NCT01499407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCTAIL II|Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction|A Randomized Trial to Compare Four Different Intracoronary Modalities to Reduce Thrombus Burden and Improve Microcirculatory Function in Patients With ST-elevation Myocardial Infarction: Rationale and Design of the COCTAIL II Study|COCTAIL II|CLI Foundation|No|Recruiting|December 2011|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|128|||Both|N/A|N/A|No|||January 2012|January 2, 2012|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01499407||93536|
NCT01499992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18466|Rehabilitation of Reconstructed Shoulder Rotator Cuff|Rehabilitation of Reconstructed Shoulder Rotator Cuff : Optimizing Physical Therapy Dosage and Effect of Aquatic Physical Therapy - A Randomized, Factorial Study||Lawson Health Research Institute|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|14|||Both|18 Years|N/A|No|||January 2012|March 18, 2014|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01499992||93491|
NCT01504178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09 303 03|Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease|Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease|DOULOX|University Hospital, Toulouse|No|Recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|36|||Both|30 Years|70 Years|No|||June 2014|June 10, 2015|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01504178||93170|
NCT01496157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1191|Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer|Evaluation of PSMA-based PET as an Imaging Biomarker of Primary Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|December 2011|||January 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Male|18 Years|90 Years|No|||June 2014|June 16, 2014|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496157||93785|
NCT01495871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-276|Amino Acid Supplementation in Recovery From Traumatic Brain Injury|Amino Acid Supplementation in Recovery From Traumatic Brain Injury|TBIS|The University of Texas Medical Branch, Galveston|No|Withdrawn|November 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|0|||Both|18 Years|65 Years|No|||February 2015|February 10, 2015|December 16, 2011||No|PI decided not to pursue this study.|No||https://clinicaltrials.gov/show/NCT01495871||93807|
NCT01500811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-009|Autologous Chondrocyte Intra-articular Implantation in Patients With Severe Hip Osteoarthritis|Evaluation the Side Effects of Autologous Chondrocyte Intra-articular Implantation in Patients With Severe Hip Osteoarthritis||Royan Institute|Yes|Completed|March 2011|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|50 Years|No|||January 2011|April 24, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500811||93429|
NCT01500824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081027|A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer|Phase 2 Open-label Single Arm Study Of The Efficacy And Safety Of Crizotinib In East Asian Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus||Pfizer|Yes|Withdrawn|May 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||February 2013|February 22, 2013|December 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01500824||93428|
NCT01501084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002316|Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women|Effects of the GLP-1 Exenatide on Intrinsic Brain Activity in Lean and Obese Women||University of California, Los Angeles|No|Completed|December 2011|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|34|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01501084||93408|
NCT01496911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-206G/E|Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving|Study to Investigate the Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving at 2 Bar and 4 Bar in Professional Navy Divers||Utrecht Institute for Pharmaceutical Sciences|Yes|Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|24|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496911||93727|
NCT01501409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-2009-0012|Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis|Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis : a Randomised Clinical Trial||Yonsei University|Yes|Completed|January 2010|December 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|90|||Both|N/A|N/A|No|||December 2011|December 28, 2011|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01501409||93383|
NCT01501682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ventralexmesh_KoegeHospital|Long Term Complaints After Elective Repair for Small Umbilical or Epigastric Hernias|Long Term Complaints After Elective Repair for Small Umbilical or Epigastric Hernias||Koege Sygehus|No|Recruiting|February 2011|December 2011|Anticipated|December 2011|Anticipated|N/A|Observational|Time Perspective: Retrospective||3|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|operated for ventral hernia from the year 2004 to the year 2009 at Koege Hospital|December 2011|December 28, 2011|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01501682||93362|
NCT01501968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU 2012-01|Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity|Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity||Mahidol University|No|Not yet recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|54|||Both|18 Years|80 Years|No|||December 2011|December 29, 2011|December 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01501968||93340|
NCT01501981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120211|Impact of Therapy Optimization on the Level of Biomarkers in Patients With Decompensated Heart Failure|Impact of Therapy Optimization on the Level of Biomarkers in Patients With Acute Decompensated and Decompensated Chronic Heart Failure|MOLITOR|Charite University, Berlin, Germany|Yes|Recruiting|February 2011|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|patients with acute decompensated and decompensated chronic heart failure|December 2011|December 29, 2011|March 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01501981||93339|
NCT01497743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KhannaSN0000|Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis|Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis|PRISS|University of Michigan|No|Withdrawn|February 2012|||February 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497743||93663|
NCT01497756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-229|Feasibility Trial of the Circumferential Abdominal Pelvic Pressure Device (CAPP)|Feasibility Trial of the Circumferential Abdominal Pelvic Pressure Device (CAPP)||University of New Mexico|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Female|N/A|N/A|No|||August 2012|August 17, 2012|December 20, 2011||No||No|July 2, 2012|https://clinicaltrials.gov/show/NCT01497756||93662|
NCT01502553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trans 2011004|Clinical Study of Blood Pressure Monitor in Conformance With the ANSI/AAMI SP10|Verify the Functions of BPM LS-802 to Comply With ANSI/AAMI SP10|BPM_S|BTS International|No|Completed|October 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 29, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01502553||93295|
NCT01502566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPEL-PPGO0011|Educational Intervention in Preventing Early Childhood Caries|A Cluster-randomized Trial of the Effectiveness of an Educational Intervention in Preventing Early Childhood Caries||Federal University of Pelotas|No|Completed|June 2010|December 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|500|||Both|N/A|12 Months|Accepts Healthy Volunteers|||July 2013|July 19, 2013|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502566||93294|
NCT01502592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-202|Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer|A Pilot Study of Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer||Memorial Sloan Kettering Cancer Center||Completed|December 2011|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502592||93292|
NCT01498549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103008235|Cognitive Effects of Atomoxetine in Humans: Genetic Moderators|Cognitive Effects of Atomoxetine in Humans: Genetic Moderators||Yale University|Yes|Completed|December 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|21 Years|50 Years|No|||December 2014|December 15, 2014|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498549||93602|
NCT01498783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJREFU|Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma|Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma|SJREFU|St. Jude Children's Research Hospital|No|Completed|December 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|1 Month|21 Years|No|||July 2015|February 1, 2016|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498783||93584|
NCT01498796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002357|KITS Study -Ketorolac In Tonsillectomy Surgery: a Double Blinded, Randomized Clinical Trial|KITS Study -Ketorolac In Tonsillectomy Surgery: a Double Blinded, Randomized Clinical Trial|KITS|University of Alberta|No|Recruiting||||||N/A|Interventional|N/A|2||||||Both|3 Years|15 Years||||December 2011|December 22, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498796||93583|
NCT01499420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-HDL-10-70a|A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients|A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease||CSL Limited||Completed|February 2012|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|45|||Both|18 Years|80 Years|No|||January 2014|January 8, 2014|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499420||93535|
NCT01499693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MX026|Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition|Phase IIIb, Randomized, Triple-blinded and Crossover Study to Evaluate the Effect of Magnesium Pantoprazole 20mg Bid Versus Magnesium Pantoprazole 40mg qd on Intragastric Acid Inhibition Assessed by pHmetry, in Healthy Volunteers||Takeda|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 14, 2012|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01499693||93514|
NCT01504425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-GASTRO-1|Difficult Colon Polypectomies|An Observational Study of Difficult Colonic Polypectomies||Clinical Hospital Colentina||Completed|December 2011|March 2014|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|91|||Both|18 Years|N/A|No|Non-Probability Sample|patients with colonic polyps that are deemed difficult to resect|April 2014|April 6, 2014|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504425||93151|
NCT01504438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031027|Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement|Prospective Randomized Evaluation Of A Two And Three Piece Total Ankle Replacement||Duke University|No|Active, not recruiting|October 2011|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|95 Years|No|||April 2015|April 30, 2015|October 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504438||93150|
NCT01504191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-CARE: Heart|Internet-based Cognitive Behavior Therapy After Myocardial Infarction|A Randomized Controlled Study of the Effects of Internet-based Cognitive Behavior Therapy on Depression and Anxiety in Patients With a Previous Myocardial Infarction|U-CARE: Heart|Uppsala University|No|Recruiting|September 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|N/A|75 Years|No|||January 2016|January 12, 2016|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01504191||93169|
NCT01496144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNS13DPD3-109903|Manual Therapy on the Improvement of Functional Disability in Patients With Chronic Non Specific Low Back Pain|Manual Therapy Followed by Specific Active Exercises Versus a Placebo Followed by Specific Active Exercises on the Improvement of Functional Disability in Patients With Chronic Non Specific Low Back Pain: a Randomized Controlled Trial||University of Applied Sciences of Western Switzerland|No|Completed|December 2005|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|65 Years|No|||December 2011|December 20, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01496144||93786|
NCT01500837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K000000|Treatment of Methicillin-sensitive Staphylococcus Aureus (MSSA)|Treatment of Methicillin-sensitive Staphylococcus Aureus Orthopaedic Infections With Clindamycin in Combination With Rifampin or Levofloxacin: a Randomized Pharmacological and Clinical Study (the CLINDOS Trial)|CLINDOS|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||September 2010|September 17, 2013|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01500837||93427|
NCT01501097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHCBS01|The Impact of Continuous Renal Replacement Therapy on the Outcomes of Burn Patients With Early Phase of Sepsis|A Randomized Controlled Trial on the Impact of Early Application of CRRT on the Outcomes of Burn Patients With Early Phase of Sepsis|CRRT|Southwest Hospital, China|Yes|Active, not recruiting|December 2011|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2011|December 28, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01501097||93407|
NCT01496924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1802/06|Swallowing Rehabilitation of Dysphagic Tracheostomized Patients Under Mechanical Ventilation at ICU|Swallowing Rehabilitation of Dysphagic Tracheostomized Patients Under Mechanical Ventilation at Intensive Care Unit||Federal University of São Paulo|No|Recruiting|January 2008|June 2012|Anticipated|January 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2011|December 19, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01496924||93726|
NCT01496937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0974-CL-101|First-in-Human Exploratory Single Ascending Dose of GLPG0974|Exploratory Double-blind Placebo-controlled Study for the Assessment of Pharmacokinetics (PK), Safety, Tolerability, and Pharmacodynamics (PD) of Single Ascending Oral Doses of GLPG0974 in Healthy Subjects||Galapagos NV|No|Completed|December 2011|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01496937||93725|
NCT01501695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00797953|Phase III Study of 5LGr to Treat Tic Disorder|A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder|5LGr|Tasly Pharmaceuticals, Inc.|Yes|Completed|January 2008|October 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|603|||Both|5 Years|18 Years|No|||December 2012|December 10, 2012|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501695||93361|
NCT01501721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNPq474135/2006-3|Anthropometric Changes Associated With Home-based Exercise Among School Cooks|Anthropometric and Metabolic Changes Associated With a Low-volume Home-based Exercise Program||Rio de Janeiro State University|Yes|Completed|January 2007|March 2008|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|95|||Female|N/A|N/A|Accepts Healthy Volunteers|||December 2011|December 28, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01501721||93359|
NCT01502007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008672|Activity Monitoring and Counseling in a Geriatric Population|Activity Monitoring and Counseling in a Geriatric Population: a Randomized Trial||Mayo Clinic|No|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 5, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502007||93337|
NCT01502020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|094-3152-301|A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses||Actavis Mid-Atlantic LLC|No|Completed|February 2011|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|410|||Both|18 Years|N/A|No|||December 2011|December 29, 2011|December 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502020||93336|
NCT01498055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLiang|Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study|A Randomized Controlled Trail on the Efficacy and Safety of Autologous Cytokine-induced Killer (CIK) Cells Infusion Treatment in Advanced Primary Lung Cancer|CIK|Third Military Medical University|No|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|The one-time folic acid sodium anticoagulation vacuum picks bag, through the venous blood      sampling 60 ml. When blood alcohol on parts of the need blood disinfects processing. After      the department shows will seal in a sterile bag, 16-21 degrees Celsius save, and transported      to a cell biological treatment as soon as possible a follow-up operation center GMP      laboratory.|Both|18 Years|70 Years|No|Non-Probability Sample|Primary lung cancer diagnosis (including small cell lung cancer, lung adenocarcinoma, lung        squamous cell carcinoma and large cell carcinoma) patients|December 2011|March 21, 2012|November 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498055||93640|
NCT01502280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#10BN132|Fluorescence-guided Surgery for Low- and High-grade Gliomas|Barrow 5-ALA Intraoperative Confocal Evaluation Trial|BALANCE|St. Joseph's Hospital and Medical Center, Phoenix|No|Recruiting|November 2010|July 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502280||93316|
NCT01502865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 10-1168|Clinician Access to Soldier Suicide Information (CASSI)|Clinician Access to Soldier Suicide Information (CASSI)|CASSI|VA Eastern Colorado Health Care System|No|Withdrawn|December 2010|December 2012|Anticipated|||N/A|Observational|Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|64 Years|No|Non-Probability Sample|As of December 2009, there were 6,901 non-fatal Department of Defense Suicide Event        Reports(DoDSERs) available for comparison to the VA system. The investigators propose to        analyze up to 8,500 that may be available for analysis by the time the protocol is        approved.|March 2014|March 21, 2014|December 29, 2011||No|Should not have been listed on ClinicalTrials|No||https://clinicaltrials.gov/show/NCT01502865||93271|
NCT01498562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0662|Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer|Randomized Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Patients With Advanced Non-small Cell Lung Cancer: Dual-agent Molecular Targeting of EGFR (DATE)|DATE|Yonsei University|Yes|Completed|December 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|20 Years|N/A|No|||November 2014|November 26, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01498562||93601|
NCT01499121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-042|Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule|A Phase II, Multi-Centre, Study of the Efficacy and Safety of Sunitinib Given on an Individualized Schedule as First-Line Therapy for Metastatic Renal Cell Cancer||Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01499121||93558|
NCT01503853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911133|Discussing Costs in the Doctor-Patient Encounter|Discussing Costs in the Doctor-Patient Encounter||National Institutes of Health Clinical Center (CC)||Completed|April 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|264|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|December 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01503853||93195|
NCT01503866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1003|A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Bardoxolone Methyl Following a Single Oral Dose Administration in Healthy Male Subjects||Reata Pharmaceuticals, Inc.|No|Completed|December 2011|||December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 31, 2011|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503866||93194|
NCT01504165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR062041_016|Pharmacokinetics in Subjects With Renal Impairment|A Phase I, Open-label, Parallel-group, Mono-center Trial to Investigate the Pharmacokinetics of a Single Intravenous Dose of Cilengitide in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Subjects With Normal Renal Function||Merck KGaA|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 3, 2014|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504165||93171|
NCT01503892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StLukeHHN|Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics|Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics|SLHN2011-18|St. Luke's Hospital and Health Network, Pennsylvania|Yes|Recruiting|December 2011|||October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01503892||93192|
NCT01500265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10006 HBVSECURE|Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus|Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus.|HBVSECURE|University Hospital, Limoges|No|Completed|December 2011|December 2015|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|216|Samples With DNA|Plasma and urine samples for determination of TMPi / GFR and FEUA A sample of genomic DNA      will be collected after informed consent of the patient from a saliva sample (Saliva      autocollection kits) in order to investigate genetic polymorphism in transporters      responsible for the renal elimination of TDF and ETV.|Both|18 Years|N/A|No|Non-Probability Sample|Patient with hepatitis B virus|February 2016|February 23, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500265||93470|
NCT01500278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0077|Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate|A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate||UCB Pharma|No|Completed|December 2011|January 2016|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|916|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500278||93469|
NCT01496417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP00048573|Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores|A 12 Month, Single-center, Non-randomized, Open-label Study of Outcomes of Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores in de Novo Renal Transplant Recipients||University of Maryland|Yes|Recruiting|March 2012|April 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||January 2015|January 27, 2015|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496417||93765|
NCT01496430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-491_304|Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes|A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes||Takeda|No|Terminated|January 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|105|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|December 18, 2011|Yes|Yes|Business Decision; No Safety Or Efficacy Concerns. (See below)|No|May 14, 2014|https://clinicaltrials.gov/show/NCT01496430||93764|Because of low enrollment in the study, the sample sizes in the results data do not allow for significant interpretation of the results.
NCT01500850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lantu_L_05720|Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use|Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use.||ikfe-CRO GmbH|No|Recruiting|October 2011|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|No|||December 2011|December 23, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01500850||93426|
NCT01500863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-AB-ERA-2011|Endometrial Receptivity After GnRH Agonist Triggering|Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation|ERAMAD|Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Recruiting|November 2011|||May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Anticipated|35|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2011|December 28, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01500863||93425|
NCT01501110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110061|Effects of N-acetylcysteine on Low T3 Syndrome|Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome||Federal University of Rio Grande do Sul|Yes|Completed|November 2011|November 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|80 Years|No|||March 2015|March 30, 2015|November 25, 2011||No||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01501110||93406|
NCT01501123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCMC 2010-24|Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient|Re-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient|PHASR|Catholic Health East|No|Recruiting|November 2011|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 28, 2011|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501123||93405|
NCT01501422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRU CU-1/2011|Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women|Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women at Menopause Clinic, King Chulalongkorn Memorial Hospital, Double- Blind, Randomized, Placebo-controlled Trial||Chulalongkorn University|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 26, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01501422||93382|
NCT01501994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-007103|Personalized Approach for Promoting Physical Activity in Mayo Clinic Physicians|Personalized Approach for Promoting Physical Activity in Mayo Clinic Physicians||Mayo Clinic|No|Completed|July 2009|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01501994||93338|
NCT01502033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004500|Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens|An Open-Label Eight-Week Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents: Mechanisms of Response||Mayo Clinic|Yes|Completed|December 2011|December 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|13 Years|18 Years|No|||January 2016|January 20, 2016|December 27, 2011|No|Yes||No|August 6, 2015|https://clinicaltrials.gov/show/NCT01502033||93335|Please note that clinical results must be interpreted with caution due to small sample size and study design.
NCT01502046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAT-HD|Neuroprotection by Cannabinoids in Huntington's Disease|A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||January 2013|January 31, 2013|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502046||93334|
NCT01502254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QuIC-3|Patients' Knowledge and Understanding of Cancer Clinical Trials - a Study of Audio Recorded Information|Patients' Knowledge and Understanding of Cancer Clinical Trials - a Randomised Study of Audio Recorded Information||Karolinska University Hospital|No|Completed|October 2008|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|130|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01502254||93318|
NCT01502267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11374|Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant|Phase 2 Study of Desensitization Protocol for Highly Sensitized Wait Listed Patients||Seoul National University Hospital|Yes|Enrolling by invitation|January 2010|January 2016|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|N/A|No|||January 2012|January 5, 2012|December 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01502267||93317|
NCT01502605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1140|Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas|Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|September 2012|||May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|6|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502605||93291|
NCT01503112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11233581|Predicting Response to Incretin Based Agents in Type 2 Diabetes|Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes|PRIBA|Royal Devon and Exeter NHS Foundation Trust|No|Completed|May 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|957|Samples With DNA|Extracted DNA, stored serum/plasma|Both|18 Years|N/A|No|Non-Probability Sample|Patients with type 2 Diabetes commencing DPP-IV inhibitors or GLP-1 agonsists in primary        or secondary care in England|November 2014|November 4, 2014|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503112||93252|
NCT01498809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02823|Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury|Neural and Mechanical Baroreflex Sensitivity and Cerebral Blood Flow||University of British Columbia|Yes|Completed|March 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|49 Years|No|Non-Probability Sample|Individuals with spinal cord injury currently in primary care (less than one year post        injury)|March 2014|March 14, 2014|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498809||93582|
NCT01498822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01367|Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy|A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy|OPTIMAL|UCB Pharma|No|Completed|June 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|353|||Both|16 Years|80 Years|No|||July 2015|July 24, 2015|December 21, 2011|Yes|Yes||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01498822||93581|
NCT01503554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11010702-IRB01|Combined Social Worker and Pharmacist Transitional Care Program|Multidisciplinary Care Transition Intervention - Cardinal Health Grant||Rush University Medical Center|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 30, 2013|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503554||93218|
NCT01503580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200712062M|Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome|Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome||National Taiwan University Hospital|Yes|Completed|August 2008|October 2013|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Female|18 Years|N/A|No|||October 2013|October 30, 2013|September 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01503580||93216|
NCT01503879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARHSG 10 2010 DLCO1|Evaluation of Gas Exchange by the Measurement of Lung Diffusion for Carbon Monoxide During General Anaesthesia|Effects of General Anaesthesia and Invasive Mechanical Ventilation on Alveolo-capillary Membrane: Evaluation of Gas Exchange by the Measurement of Lung Diffusion for Carbon Monoxide (DLCO) and Plasma Dosage of Surfactant Protein-B (SPB).||San Gerardo Hospital|No|Recruiting|October 2011|October 2012|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|surfactant protein B|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing elective surgery lasting more than three hours, requiring general        anaesthesia and invasive mechanical ventilation.|August 2012|August 28, 2012|December 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01503879||93193|
NCT01503905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCSCO001|Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients|Comparison of the Effectiveness of Neoadjuvant Chemotherapy and the Outcomes Associated With Chemo-induced Amenorrhea Between Docetaxel Plus Epirubicin, and Docetaxel Plus Epirubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients.||Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Recruiting|December 2011|December 2021|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Female|18 Years|N/A|No|||December 2011|January 3, 2012|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01503905||93191|
NCT01500044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-#09|Effect of Mobilizations and Exercises Targeting the Opening of Intervertebral Foramens Following Cervical Radiculopathy|Cervical Radiculopathy: A Randomized Clinical Trial Evaluating the Effect of Mobilizations and Exercises Targeting the Opening of Intervertebral Foramens||Laval University|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|No|||July 2013|July 2, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01500044||93487|
NCT01500057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIRB Protocol# 20111638|Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia|An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia||Brooklyn Urology Research Group|No|Active, not recruiting|December 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500057||93486|
NCT01500070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-101020|PREVENT: Promus BTK|PREVENT: a Prospective, Multi-center, Monitored Trial Investigating the Implant of the Promus Everolimus-Eluting Stent System in Critically Ischemic Lesions BTK|PREVENT|Flanders Medical Research Program|Yes|Active, not recruiting|August 2012|March 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01500070||93485|
NCT01504451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAAPITUP 2|Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study: The LAAPITUP 2 Study|Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2|LAAPITUP 2|Eastbourne General Hospital|Yes|Active, not recruiting|April 2012|May 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01504451||93149|
NCT01500564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.635|Functional Interest of Non Invasive Brain Stimulation During Physiotherapy at a Subacute Phase Post Stroke (Anodal Protocol): ReSTIM|Functional Interest of Non Invasive Brain Stimulation During Physiotherapy at a Subacute Phase Post Stroke (Anodal Protocol).|ReSTIM|Hospices Civils de Lyon|Yes|Recruiting|January 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500564||93448|
NCT01500876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-RAD-11-02|A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer|A Feasibility Study Using Four-Dimensional CT Imaging to Evaluate Lung Strain in Patients Treated With External Beam Radiation Therapy for Primary Lung Cancer||James Graham Brown Cancer Center|Yes|Recruiting|January 2012|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01500876||93424|
NCT01501136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hnslblzlzx2011|Treatment of Natural Killer/T Cell Lymphoma-I/II|A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)|CTTNKTL-I/II|Zhengzhou University|Yes|Recruiting|January 2011|May 2019|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|200|||Both|14 Years|70 Years|No|||July 2015|July 15, 2015|November 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01501136||93404|
NCT01501435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_FEN_101|Compare Safety and Pharmacokinetic(PK) Properties of CJ-30039 and Lipidil Supra and To Investigate Food-effect on PK of CJ-30039 in Healthy Male Volunteers|A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra and To Investigate Food-effect on Pharmacokinetics of CJ-30039 in Healthy Male Volunteers||CJ HealthCare Corporation|No|Completed|December 2011|June 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||December 2011|August 1, 2012|December 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01501435||93381|
NCT01501734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0058-11-MMC|Bilevel Positive Pressure Ventilation (BIPAP)in Patients With Sleep Disorders Breathing (SDB)and Congestive Heart Failure (CHF):Comparison of Two Diagnostic Methods|||Meir Medical Center|No|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|90 Years|No|||August 2012|April 12, 2015|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501734||93358|
NCT01502644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P-001047|Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms|Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms||Brigham and Women's Hospital|Yes|Completed|February 2009|||January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|21 Years|75 Years|No|||February 2013|February 25, 2013|December 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502644||93288|
NCT01502657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10-DR-GUINOT|Ultrasound Guided Percutaneous Tracheostomy|Ultrasound Guided Percutaneous Tracheostomy in the ICU||Centre Hospitalier Universitaire, Amiens|No|Completed|September 2010|December 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|40|||Both|18 Years|N/A|No|||December 2011|December 30, 2011|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01502657||93287|
NCT01501955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMETEU.CR.EU88 MHP|The Metaphyseal Hip Prosthesis - Total Hip|Evaluation of the Safety and Efficiency of the Metaphyseal Hip Prosthesis - Total Hip Arthroplasty||Biomet, Inc.|Yes|Suspended|October 2012|December 2023|Anticipated|December 2023|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|55 Years|75 Years|No|||June 2014|June 24, 2015|August 26, 2011||No|First safety criterium not met. Awaiting further follow up data.|No||https://clinicaltrials.gov/show/NCT01501955||93341|
NCT01502878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCHT101060080|Nut Allergy Study: Double-blind Challenge and Oral Desensitization|Nut Allergy Study: Improving Diagnosis And Treatment Of Nut Allergy||Helsinki University Central Hospital|No|Recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|200|||Both|3 Years|18 Years|No|||January 2014|January 8, 2014|May 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01502878||93270|
NCT01503086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL10P1|Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy|Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study||Children's Oncology Group|Yes|Recruiting|November 2013|||November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|71|||Both|6 Years|16 Years|No|||August 2015|August 19, 2015|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503086||93254|
NCT01503294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAT-1|Comparison of Temporal to Pulmonary Artery Temperature Measurement in Patients With Fever|Comparison of Temporal to Pulmonary Artery Temperature Measurement in Patients With Fever||Massachusetts General Hospital|No|Completed|February 2012|June 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|90 Years|No|Non-Probability Sample|ICU patients|June 2014|June 27, 2014|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503294||93238|
NCT01503567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAEM-3971|Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries|Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries|HAEMOcare|Novo Nordisk A/S|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||4|Actual|282|||Male|6 Years|N/A|No|Non-Probability Sample|Male patients at least 6 years old with severe congenital haemophilia A or B (FVIII or FIX        activities below 1% or level below 1U dL^-1) without inhibitor or with inhibitors against        FVIII or FIX|November 2014|November 13, 2014|January 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01503567||93217|
NCT01503593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0326-11-RMB|Using Combination of Synthetic Bone Substitutes During Extractions|Phase 3 Study of Using Combination of Bi Phasic Calcium Phosphate and Bu Phasic Calcium Sulphate During Extractions||Rambam Health Care Campus|No|Not yet recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||May 2012|May 28, 2012|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01503593||93215|
NCT01503606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-07-005|Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane|Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane, Phase III Study.||Samsung Medical Center||Recruiting|October 2011|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|206|||Female|N/A|N/A|No|||November 2015|November 24, 2015|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01503606||93214|
NCT01503931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GS08159|Endophenotyping With Functional Magnetic Resonance Imaging (fMRI)|Endophenotyping With fMRI: Genetic Modulation and Treatment Response|NGFN PLUS TP13|Charite University, Berlin, Germany|Yes|Completed|June 2008|June 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|480|Samples With DNA|whole blood (EDTA)|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic|January 2016|January 27, 2016|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503931||93189|
NCT01504217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912073R|Control of Center of Mass to Predict Balance Ability and Fall Risks in Elderly|Analysis of Muscle Strength and Control of Center of Mass Acceleration Mechanism to Predict Balance Ability and Fall Risks in Elderly||National Taiwan University Hospital|Yes|Recruiting|August 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|community sample|July 2015|July 7, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504217||93167|
NCT01500330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NaSK|Home Use of Cupping Massage in Chronic Neck Pain|Randomised Controlled Study on the Effectiveness of Cupping Massage for Home Use in Chronic Neck Pain [Randomisierte Kontrollierte Studie Zur Wirksamkeit Der Schröpfkopfmassage Als Heimanwendung Bei Chronischen Nackenschmerzen]|NaSK|Universität Duisburg-Essen|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|75 Years|No|||October 2013|October 8, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500330||93465|
NCT01500304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007790|Minimally Invasive Groin Dissection for Melanoma|Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma|SAFE-MILND|Mayo Clinic|Yes|Active, not recruiting|June 2012|March 2016|Anticipated|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||January 2016|March 17, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500304||93467|
NCT01500291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|315/2554(EC3)|A Study Survey of Stress in Anesthesia Personnel|Principal Investigator|stress|Mahidol University|No|Enrolling by invitation|April 2012|April 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|639|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Two hundred and eighty six out of 1,000 anesthesiologists and three hundred and fifty        three out of 3,000 nurse anesthetists are qualified as the final study group.|March 2016|March 14, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500291||93468|
NCT01500577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S222/604|A Prevention Trial in Subjects at High Risk for Breast Cancer|A Randomized Phase II Prevention Trial in Subjects at High Risk for Hormone Non-responsive Breast Cancer||European Institute of Oncology|No|Completed|April 2005|July 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|150|||Female|18 Years|65 Years|No|||June 2014|June 17, 2014|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01500577||93447|
NCT01500889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|anal fissure|Conventional Lateral Internal Sphincterotomy, V-Y Anoplasty and Tailored Lateral Internal Sphincterotomy With V-YF in Treatment of Chronic Anal Fissure(CAF)|Comparative Study of Conventional Lateral Internal Sphincterotomy, V-Y Anoplasty and Tailored Lateral Internal Sphincterotomy With V-Y Anoplasty in Treatment of Chronic Anal Fissure|CAF|Mansoura University|Yes|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|15 Years|80 Years|No|||December 2011|December 23, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01500889||93423|
NCT01501149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hnslblzlzx2011-2|Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ|A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)|CTTNKTL-Ⅲ/Ⅳ|Zhengzhou University|Yes|Recruiting|January 2011|May 2019|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|14 Years|70 Years|No|||July 2015|July 15, 2015|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01501149||93403|
NCT01501448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIMAD-GV-OCPE-2011|Oral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization Patients|||IVI Madrid||Completed|January 2012|February 2013|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|118|||Female|18 Years|38 Years|No|||March 2016|March 20, 2016|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501448||93380|
NCT01501708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH-2011-71|Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection|Phase II Study of Caspofungin Based Combined Anti-fungal Therapy for Patients With Proven or Probable Invasive Fungal Infection After Allogeneic Stem Cell Transplantation From HLA-matched Unrelated or HLA-mismatched Related Donors||Shanghai Jiao Tong University School of Medicine|No|Recruiting|December 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|55 Years|No|||May 2015|May 20, 2015|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501708||93360|
NCT01502072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0813|Respiratory Syncytial Virus - RSV Protocol|An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant||M.D. Anderson Cancer Center|Yes|Active, not recruiting|December 2011|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502072||93332|
NCT01502085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-2580|Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens|A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens|RZD|Hackensack University Medical Center|Yes|Active, not recruiting|December 2011|May 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502085||93331|
NCT01502345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-17088|Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines|Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines, pWRG/HTN-M(x) and pWRG/PUU-M(s2), for Prevention of Hemorrhagic Fever With Renal Syndrome Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device|HTNV/PUUV|U.S. Army Medical Research and Materiel Command|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|31|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|December 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502345||93311|
NCT01502917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-011|Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy|A Phase I Study of Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy||Memorial Sloan Kettering Cancer Center||Recruiting|December 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|3 Years|21 Years|No|||February 2016|February 15, 2016|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502917||93267|
NCT01503151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBM_SP_2012|Cognitive Biases Modification Treatment for Social Anxiety|Cognitive Biases Modification Treatment for Social Anxiety|CBMSP|Tel Aviv University|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|95|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01503151||93249|
NCT01502293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS-I100|Trial of pIL-12 Electroporation Malignant Melanoma|A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma|IL-12MEL|OncoSec Medical Incorporated|Yes|Active, not recruiting|December 2011|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|51|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502293||93315|
NCT01502306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMS NOA # 1B1CMS330882-01-00|A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline|A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline||University of California, San Diego|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3819|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01502306||93314|
NCT01503138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 11-051|Intervention for Abused Chinese Immigrant Women|The Effect of a Purpose-built Intervention on Mental Health in Mainland Chinese Immigrant Women Survivors of Intimate Partner Violence: A Randomized Controlled Trial||The University of Hong Kong|No|Completed|December 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|250|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503138||93250|
NCT01502618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 090|Intervention for HIV-Positive Black Young Men Who Have Sex With Men (YMSM)|Development of a Secondary Prevention Intervention Targeting HIV-Positive Black Young Men Who Have Sex With Men||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Male|16 Years|24 Years|No|||December 2014|October 5, 2015|March 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01502618||93290|
NCT01502631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBI 603|Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury||Daiichi Sankyo Inc.|Yes|Completed|January 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|16 Years|80 Years|No|||October 2015|October 19, 2015|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502631||93289|
NCT01502852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0720|Identifying the Needs of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans and Their Families: TBI and Co-Occurring Behavioral Health Issues|Identifying the Needs of OEF/OIF Veterans and Their Families: TBI and Co-Occurring Behavioral Health Issues||VA Eastern Colorado Health Care System|No|Completed|August 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community||3|Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|OEF/OIF Veterans with a history of TBI, their family members/friends, and community mental        health providers working with these Veterans.|November 2014|November 24, 2014|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502852||93272|
NCT01503099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDS 150|Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease|Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease in Populations of High vs. Low Tuberculosis Endemicity||Lovisenberg Diakonale Hospital|No|Recruiting|October 2009|December 2012|Anticipated|December 2011|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|550|Samples With DNA|Stool samples frozen at -20'C. Blood serum samples frozen at -20'C. Saliva samples stored at      room temperature. Paraffin embedded intestinal biopsies.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive patients from four secondary or tertiary care referral centres in the two        southernmost states in India (Kerala and Tamil Nadu).        Consecutive patients from nine secondary or tertiary care referral centres in South-East        Norway.|December 2011|December 30, 2011|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503099||93253|
NCT01503619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-151111|Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202|Genomics of Small Cell Lung Carcinoma||Alliance for Clinical Trials in Oncology|No|Recruiting|January 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|23|Samples With DNA|Tissue, blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with small cell lung cancer enrolled on the Cancer and Leukemia Group B (CALGB)        140202 study|July 2015|July 23, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01503619||93213|
NCT01503307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 08/160|Parenting After Infant Congenital Heart Defect Diagnosis|Parenting After Infant Congenital Heart Defect Diagnosis||Medical College of Wisconsin|No|Active, not recruiting|January 2009|December 2019|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|||Both|N/A|12 Weeks|No|Non-Probability Sample|In this year-long study, 12 to 16 families (mothers and fathers) will be recruited—6 to 8        of the families from the fetal diagnosis clinic at either Meriter Hospital or Children's        Hospital of Wisconsin and 6 to 8 families whose infant is diagnosed soon after birth with        a complex CHD at either Meriter Hospital or Children's Hospital of Wisconsin.|August 2015|August 19, 2015|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01503307||93237|
NCT01504204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15374|Effect of Samples on Acne Treatment With Epiduo® Gel|Effect of Sample Medication Use and Application Instructions on Adherence to and Efficacy of Treatment of Patients With Mild to Moderate Acne With Epiduo(R) Gel||Wake Forest School of Medicine|No|Completed|December 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|12 Years|N/A|No|||December 2012|December 7, 2012|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01504204||93168|
NCT01500356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL103646|Effect of Exercise and Weight Loss on Cardiovascular Health|Effect of Exercise and Weight Loss on Cardiovascular Health|Heart Health|University of Pittsburgh|Yes|Active, not recruiting|December 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|383|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500356||93463|
NCT01500317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002334|Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans|Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans|tap-oxy|Mayo Clinic|No|Completed|May 2011|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|May 20, 2011|Yes|Yes||No|November 8, 2012|https://clinicaltrials.gov/show/NCT01500317||93466|
NCT01500590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria|Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial|eGFR|Hospital Authority, Hong Kong|No|Recruiting|November 2011|August 2019|Anticipated|August 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1400|||Both|35 Years|80 Years|No|||April 2015|April 17, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01500590||93446|
NCT01503983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUPOCAN-01-11|Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive|Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive.|HerXO|Fundación para el Progreso de la Oncología en Cantabria|Yes|Completed|August 2011|May 2015|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||April 2012|August 26, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01503983||93185|
NCT01501461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-FS-001|Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Intra-venous Implantation of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome||Ageless Regenerative Institute|No|Recruiting|May 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|55 Years|90 Years|No|||October 2013|October 28, 2013|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01501461||93379|
NCT01502670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006621|Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule|A Pilot Study of the Utility of the Novel Amino Acid Radiotracer Anti-[18 F]FACBC for the Noninvasive Imaging of Lung Nodules|SPN|Emory University|Yes|Completed|May 2009|January 2013|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|No|||November 2013|November 18, 2013|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502670||93286|
NCT01502943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009ZX09502-029|Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index|Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index With Stable Angina Pectoris of Coronary Heart Disease as an Example||Liaoning University of Traditional Chinese Medicine|Yes|Completed|May 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|480|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||December 2011|December 30, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01502943||93265|
NCT01502319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 11-0304|Military Suicide Research Consortium|Military Suicide Research Consortium|MSRC|VA Eastern Colorado Health Care System|Yes|Active, not recruiting|September 2010|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|1500|||Both|17 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Given the age range of active duty military, reservists, and veterans, it is expected that        funded Study Principal Investigators will enroll subjects that are young adults (18 to 21        years) to Senior Citizens (over 65 years).|December 2015|December 11, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01502319||93313|
NCT01503684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106068RC|Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome|Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome||National Taiwan University Hospital|No|Recruiting|August 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Exhaled breath condensate|Both|20 Years|N/A|No|Non-Probability Sample|Patients who are admitted to ICU with the diagnosis of sepsis and treated with mechanical        ventilation via an endotracheal tube.|September 2011|January 3, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503684||93208|
NCT01503957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/023411|Nasya in Allergic Rhinitis|Double-blind, Randomized, Placebo-controlled, Crossover Clinical Investigation to Evaluate Safety and Efficacy of Nasya in Reducing Symptoms of Allergic Rhinitis When Applied Before Allergen Challenge||InQpharm Group|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|60 Years|No|||October 2012|October 25, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01503957||93187|
NCT01503346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100610|DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients|Taking Herbal Formula：DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients in Late-stage：A Clinical Control Trial Study|TCM|Changhua Christian Hospital|No|Recruiting|March 2011|March 2012|Anticipated|September 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Anticipated|30|||Both|20 Years|80 Years|No|||January 2012|January 3, 2012|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01503346||93234|
NCT01503320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-GI-2011-05|Efficacy of Enteral Glutamine Supplementation in Patients With Predicted Severe Acute Pancreatitis- A Double-Blinded Randomized Controlled Trial|||Asian Institute of Gastroenterology, India|Yes|Completed|January 2012|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01503320||93236|
NCT01503125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI4500|Giant Axonal Neuropathy Natural History Study|Clinical Study of Giant Axonal Neuropathy||Columbia University|No|Active, not recruiting|December 2011|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|Samples With DNA|Skin Tissue, Blood, Cerebrospinal fluid (CSF)|Both|N/A|N/A|No|Non-Probability Sample|People diagnosed with Giant Axonal Neuropathy|July 2015|July 6, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01503125||93251|
NCT01503918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK4142|Cytomegalovirus Control in Critical Care|Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent Patients in Critical Care|CCCC|University Hospital Birmingham NHS Foundation Trust|Yes|Completed|January 2012|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|124|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503918||93190|
NCT01503632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL1033|Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission|A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL||Children's Oncology Group|Yes|Recruiting|February 2012|||June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|608|||Both|1 Year|21 Years|No|||March 2016|March 2, 2016|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503632||93212|
NCT01500083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14293A|Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia|An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia|BENDACT|Lundbeck Canada Inc.|No|Completed|March 2012|||June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|December 16, 2011||No||No|October 10, 2014|https://clinicaltrials.gov/show/NCT01500083||93484|
NCT01500096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01AT005526-03|American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial|American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Multiple-Dose Escalation Clinical Trial||Johns Hopkins University|Yes|Recruiting|February 2013|July 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||February 2013|February 11, 2013|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500096||93483|
NCT01500109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110257|Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair|Analgesic Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair; a Randomized, Double, Blinded, Placebo Controlled Study||Loma Linda University|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|45|||Both|5 Months|5 Years|No|||April 2015|April 15, 2015|December 19, 2011|Yes|Yes||No|March 23, 2015|https://clinicaltrials.gov/show/NCT01500109||93482|
NCT01500343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFF-Cardiologia-01|A Pilot Study of Probiotic Saccharomyces Boulardii Use in Chronic Heart Failure Patients. Estudo PROICA|A Pilot Study of Probiotic Saccharomyces Boulardii Use in Chronic Heart Failure Patients|PROICA|Universidade Federal Fluminense|Yes|Completed|November 2008|December 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2011|December 27, 2011|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500343||93464|
NCT01500603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100143|Periurethral Pro-ACTTM Balloons vs Retrourethral AdvanceXP(TM) Male Sling for Post-prostatectomy Incontinence|Prospective, Randomized, Multicentric, Comparative Trial of Two Devices in Surgical Treatment of Post-radical Prostatectomy Stress Urinary Incontinence: Periurethral Pro-ACTTM Balloons and AdvanceXP(TM) Retrourethral Male Sling|BALLANCE|Assistance Publique - Hôpitaux de Paris|No|Terminated|March 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Male|18 Years|N/A|No|||October 2014|October 7, 2014|December 23, 2011||No|lack of inclusion in the study|No||https://clinicaltrials.gov/show/NCT01500603||93445|
NCT01500148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101|St. Jude Medical Percutaneous Mitral Valve Repair Study|Clinical Assessment of the St. Jude Medical (SJM) Percutaneous Mitral Valve Repair (PMVr) Device Concept|SJM PMVr|St. Jude Medical|No|Completed|December 2011|August 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01500148||93479|
NCT01501747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC2101105|The Placebo Effect May Involve Modulating Drug Bioavailability|The Placebo Effect May Involve Modulating Drug Bioavailability||King Faisal Specialist Hospital & Research Center|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|162|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501747||93357|
NCT01502098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPI:1780|Effect of Postoperative Immobilization on Healing After Rotator Cuff Arthroscopic Repair|Effect of Postoperative Immobilization on Healing After Rotator Cuff Arthroscopic Repair With Double Row Technique in Small or Medium Ruptures. Prospective, Comparative and Randomized.||Hospital Italiano de Buenos Aires|Yes|Recruiting|January 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|114|||Both|18 Years|90 Years|No|||January 2012|January 9, 2012|December 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01502098||93330|
NCT01501474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP004|Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures|Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures||King Chulalongkorn Memorial Hospital|No|Terminated|January 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|Samples Without DNA|Brush cytology and FISH test|Both|20 Years|N/A|No|Non-Probability Sample|Due to no study in Thai population before, investigator will perform pilot study in 50        malignant biliary stricture patients|July 2014|July 1, 2014|December 27, 2011||No|No suitable case available and many techinical error|No||https://clinicaltrials.gov/show/NCT01501474||93378|
NCT01502059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP UNIFESP 0208/11|Pilates to Treat Low Back Pain|The Effectiveness of Pilates to Treat Low Back Pain: A Randomized Controlled Trial|PTLBP|Federal University of São Paulo|No|Completed|June 2008|June 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|50 Years|No|||December 2011|December 29, 2011|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01502059||93333|
NCT01502332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|InCor-OLA|Intensive Alveolar Recruitment Protocol After Cardiac Surgery|Comparison of Two Protective Mechanical Ventilation Strategies After Cardiac Surgery: Aggressive Versus Moderate Alveolar Recruitment Strategies||University of Sao Paulo|No|Recruiting|December 2011|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|80 Years|No|||December 2011|December 28, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01502332||93312|
NCT01503996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Drinking/Glaucoma|Drinking Habits of Glaucoma Patients and Age Matched Controls|Clinical Study to Evaluate the Drinking Habits of Glaucoma Patients and Age Matched Controls||Technische Universität Dresden|No|Completed|October 2011|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Glaucoma patients who are hospitalized for diurnal intraocular pressure measurements and        glaucoma assessment.        Controls who are hospitalizes because of an other ophthalmic disease and do not suffer        from glaucoma.|November 2015|November 26, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01503996||93184|
NCT01504009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-2011.05|Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS)|Investigating the Effect of Muscle Training in Patients With Amyotrophic Lateral Sclerosis and Looking Into the Mechanisms Behind Development of Muscle Atrophy|ALS-project|University of Southern Denmark|Yes|Enrolling by invitation|May 2011|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||January 2012|January 4, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01504009||93183|
NCT01503970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-04-INR|Autologous Chondrocyte Transplantation For Articular Cartilage Regeneration|Autologous Chondrocyte Transplantation For Articular Cartilage Regeneration. Pilot Study||Instituto Nacional de Rehabilitacion|Yes|Completed|December 2008|December 2012|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|50 Years|No|||March 2015|March 24, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01503970||93186|
NCT01502891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003507|Making Decisions About Depression Medications|Translation of Comparative Effectiveness of Depression Medications Into Practice|iADAPT|Mayo Clinic|Yes|Completed|December 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|301|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01502891||93269|
NCT01503645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9461701139|Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism|Epidemiology of Chinese Herb Nephropathy and Its Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism||National Taiwan University Hospital||Recruiting|May 2006|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|People who use Chinese herb|January 2012|November 12, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503645||93211|
NCT01503944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-133-B03|A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)|Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers||Avid Radiopharmaceuticals|No|Completed|March 2010|July 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|30|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 3, 2012|July 14, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503944||93188|
NCT01503333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL109101|Girls on the Move Intervention to Increase Physical Activity Among Middle School Girls|Girls on the Move Intervention||Michigan State University|Yes|Active, not recruiting|September 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1488|||Female|9 Years|14 Years|Accepts Healthy Volunteers|||March 2016|March 17, 2016|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01503333||93235|
NCT01503723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103016RC|Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors|Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors||National Taiwan University Hospital|No|Recruiting|August 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Exhaled breath condensate|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure        and endotracheally intubated with mechanical ventilation.|September 2011|January 3, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503723||93205|
NCT01504022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37032.029.11|Web Based Interactive Treatment and Self-monitoring in Hypertension|Role of Self Monitoring in Combination With Proactive Web-based Management in the Treatment of Hypertension: a Randomized Controlled Trial.|WISH|VU University Medical Center|No|Recruiting|September 2011|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|80 Years|No|||January 2012|January 2, 2012|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01504022||93182|
NCT01500174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-2007-BDRST-465|Ultraviolet-C Effectiveness in the Management of Pressure Ulcers in People With Spinal Cord Injury|Ultraviolet-C Irradiation in the Management of Pressure Ulcers in People With Spinal Cord Injury: A Randomized, Stratified, Placebo-controlled Trial||Toronto Rehabilitation Institute|No|Completed|November 2007|May 2011|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01500174||93477|
NCT01500187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-011|Fluoride Varnish for Treatment of White Spot Lesions|Fluoride Varnish Application for Treatment of White Spot Lesion After Fixed Orthodontic Treatment. A Pilot Study.||3M|No|Completed|February 2012|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||December 2013|January 15, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500187||93476|
NCT01500629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCEXP0001|Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever|A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of a Topical Nasal Spray in the the Relief of Signs and Symptoms of an Acute Response to a Nasal Allergen Challenge||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|21|||Both|18 Years|55 Years|No|||April 2014|April 9, 2014|December 22, 2011|Yes|Yes||No|December 15, 2013|https://clinicaltrials.gov/show/NCT01500629||93443|
NCT01500902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000047|Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome|The Assessment of Novel Functional Risk Factors for the Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome||Mayo Clinic|No|Completed|September 2011|April 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|101|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500902||93422|
NCT01500915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUSION-001-10-2010|FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration|FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration|FUSION|Institut de la Macula y la Retina|No|Completed|November 2010|July 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|50 Years|N/A|No|||March 2015|March 23, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01500915||93421|
NCT01500616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018787|Telaprevir Open-Label Study in Co-Infected Patients|Multicenter, Open-Label, Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis||Janssen-Cilag International NV|No|Completed|June 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|122|||Both|18 Years|70 Years|No|||August 2015|August 21, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500616||93444|
NCT01500642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130/2011/29/AP|Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy|Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy in Patients With Ragweed Pollinosis: a Phase III Randomized and Controlled Clinical Study||Ospedale L. Sacco – Polo Universitario|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500642||93442|
NCT01500395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-20111126 -2|Hybrid Operation in Thoracic Aortic Dissection|Hybrid Operation in Thoracic Aortic Dissection---Registry of China||Xijing Hospital|Yes|Recruiting|November 2011|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|12 Years|90 Years|No|Probability Sample|Patients with Thoracic Aortic Dissection|December 2015|December 30, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500395|3 Years|93460|
NCT01500408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108HV106|Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers|A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of Interferon Beta-1a Manufactured by Two Different Processes||Biogen|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|110|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 16, 2012|December 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01500408||93459|
NCT01502358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-0007|Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease|A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin®|TVDV|U.S. Army Medical Research and Materiel Command|Yes|Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|December 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502358||93310|
NCT01502371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04223|A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)|A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma (Phase 2; Protocol No. P04223AM3)||Merck Sharp & Dohme Corp.|No|Completed|January 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|583|||Both|5 Years|11 Years|No|||December 2015|December 9, 2015|December 28, 2011|Yes|Yes||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01502371||93309|
NCT01501760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I07034|Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea|Effect of Bevacizumab Subconjunctival Injections on Corneal Newvessels|BECONNEC|University Hospital, Limoges|Yes|Recruiting|January 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501760||93356|
NCT01502124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGH-2124|Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency|Norditropin® and Norditropin® Cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children With Growth Hormone Deficiency||Novo Nordisk A/S|No|Completed|May 2001|March 2003|Actual|March 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|3 Years|17 Years|No|||July 2012|July 11, 2012|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502124||93328|
NCT01503164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00036672|Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism|Sleep, Obesity, and Metabolism in Normal and Overweight Subjects: Effects of CPAP on Glucose Metabolism|SOMNOS|Johns Hopkins University|Yes|Recruiting|September 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|21 Years|75 Years|No|||November 2013|November 6, 2013|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01503164||93248|
NCT01502904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0007|Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents|||Yonsei University|No|Recruiting|July 2010|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Anticipated|120|||Both|20 Years|80 Years|No|||January 2012|January 1, 2012|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502904||93268|
NCT01503359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAR-001|Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia|Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.|PULSAR|Medical Universtity of Lodz|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|60 Years|No|||February 2012|February 1, 2012|December 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503359||93233|
NCT01500161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1127920|Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match|A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood (UCB) Transplant For Patients With Hematologic Malignancies Needing Allogeneic Stem Cell Transplant But Do Not Have A Related HLA-Matched Donor||Texas Oncology Cancer Center|Yes|Terminated|November 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|65 Years|No|||November 2013|November 21, 2013|November 18, 2011||No|Insufficient accruals|No||https://clinicaltrials.gov/show/NCT01500161||93478|
NCT01501526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-190|Unusual Clinical Findings of Herpes Esophagitis|||China Medical University Hospital|Yes|Recruiting|October 2011|March 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1|||Male|50 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|primary care clinic|December 2011|December 28, 2011|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01501526||93374|
NCT01500421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-105|Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)|The Øresund Copenhagen-Malmø Acute Stroke Cooling Trial||Bispebjerg Hospital|Yes|Completed|October 2008|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|31|||Both|18 Years|N/A|No|||December 2011|December 27, 2011|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500421||93458|
NCT01503658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGX_Clopidogrel_001|Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of Clopidogrel|Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions on the Pharmacokinetics/Pharmacodynamics of Clopidogrel in Healthy Volunteers||Seoul National University Hospital|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01503658||93210|
NCT01503671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108035MD|Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients|Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT)|ALEVENT|National Taiwan University Hospital|No|Recruiting|November 2011|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|20 Years|90 Years|No|||August 2015|August 9, 2015|January 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503671||93209|
NCT01500954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|microRNA7|Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma|Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma||Ruhr University of Bochum|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|7|Samples With DNA|cutaneous squamous cell carcinoma (SCC) non.lesional skin|Both|1 Year|N/A|No|Non-Probability Sample|Patients with cutaneous squamous cell carcinoma|October 2012|October 15, 2012|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01500954||93418|
NCT01501214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKUQMHCARE001|Use of Atosiban in in Vitro Fertilization (IVF) Treatment|A Randomized Double Blind Comparison of Atosiban in Patients Undergoing in Vitro Fertilization Treatment||The University of Hong Kong|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|800|||Female|18 Years|43 Years|No|||January 2014|January 6, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01501214||93398|
NCT01504230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104056RB|Multi-joint Coordination Underlies Upright Balance Control in Elderly With Osteoporosis|Multi-joint Coordination Underlies Upright Balance Control in Elderly With Osteoporosis||National Taiwan University Hospital|Yes|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|65 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|community sample|July 2015|July 7, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504230||93166|
NCT01504308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|994045|Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids|Philips Pivotal Clinical Trial for MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|SOFIA|Philips Healthcare|Yes|Active, not recruiting|May 2012|April 2019|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Female|18 Years|50 Years|No|||April 2015|April 23, 2015|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504308||93160|
NCT01501175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108036|Incidence of Superficial Vein Thrombosis|Evaluation of Annual Incidence of Superficial Vein Thrombosis in the Legs|STEPH|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|November 2011|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|848|||Both|18 Years|N/A|No|Non-Probability Sample|patients with suspected SVT inhabitant of the Saint Etienne region|February 2013|February 12, 2013|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501175||93401|
NCT01502111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLA-3104-01/02|Airway Management Study in Physician Manned Helicopter Emergency Medical Services|Improved Knowledge Through Better Data, Implementing and Evaluating a Novel Consensus-based Template for Uniform Reporting of Data From Pre-hospital Airway Management - a Prospective Multicentre Observational Study|AIRPORT|Norwegian Air Ambulance Foundation|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2333|||Both|N/A|N/A|No|Probability Sample|Patients receiving advanced airway management in physician manned helicopter emergency        medical services over a 12-month period.        Data reported according to the Utstein style template for uniform reporting of data from        prehospital advanced airway management|May 2013|May 7, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01502111||93329|
NCT01502384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-NG-0463|A Longitudinal Study in 1st Degree Relatives of Parkinson's Disease (PD) Patients|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2012|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|100|||Both|35 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy 1ST degree realtives of PD patients|December 2011|December 29, 2011|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01502384||93308|
NCT01501162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPALD|Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease|Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease|EPALD|Chuncheon Sacred Heart Hospital|Yes|Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|80 Years|No|||December 2014|March 24, 2015|December 27, 2011||No||No|December 31, 2014|https://clinicaltrials.gov/show/NCT01501162||93402|
NCT01498718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRC 701|Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone|Double-Blind, Randomized Phase 1b Study of 2011/12 Influenza Investigational DNA Vaccine, VRC-FLUDNA061-00-VP, Followed by 2012/13 Trivalent Inactivated Vaccine (TIV) Compared to 2012/13 TIV Alone in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2011|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|131|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 23, 2016|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498718||93589|
NCT01500941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131/2010/77/2009/AP|Probiotics in Adults: do They Improve Atopic Dermatitis?|Evaluation of the Effects of a Combination of Probiotics in the Treatment of Adult Atopic Dermatitis: Randomized Phase III, Double-blind Placebo-controlled||Ospedale L. Sacco – Polo Universitario|No|Completed|April 2010|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 3, 2012|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01500941||93419|
NCT01501188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGR-409|Efficacy Study of Kinesio Taping to Treat Muscular and Joint Problems in Chronic Venous Insufficiency|Study on the Effect of Kinesio Taping on Bioelectrical Activity of Gastrocnemius Muscles and Range of Ankle Motion in Post-menopausal Women With Chronic Venous Insufficiency||Universidad de Granada|No|Completed|September 2008|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|259|||Female|50 Years|75 Years|No|||May 2015|May 28, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01501188||93400|
NCT01501201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_07/1019|Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients|Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients in Terms of Mortality, Glycemic Control, and Cost Effectiveness - Prospective, Multicenter, Randomized Study|DIABSURG|University Hospital, Lille|Yes|Recruiting|February 2011|September 2027|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|490|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01501201||93399|
NCT01502709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVS-TMD-001|Neurostimulation in Temporomandibular Disorders (TMD) Patients|Randomized Blinded Placebo-Controlled Clinical Trial of Caloric Vestibular Neurostimulation in Patients With Chronic TMD|CVS|University of North Carolina, Chapel Hill|No|Enrolling by invitation|December 2011|May 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|65 Years|No|||January 2012|January 3, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01502709||93283|
NCT01503372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaFLO|FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer|Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie|PaFLO|Charite University, Berlin, Germany|Yes|Recruiting|November 2011|May 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01503372||93232|
NCT01503710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105047RC|Early Diagnosis of Postoperative Acute Renal Failure-using Biomarker to Predict Outcome of Cardiac Surgery Associated Acute Kidney Injury|Early Diagnosis of Postoperative Acute Renal Failure - Using Biomarker to Predict the Outcome of Cardiac Surgery Associated Acute Kidney Injury|NSARF|National Taiwan University Hospital|Yes|Recruiting|June 2011|July 2012|Anticipated|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples With DNA|Blood samples are drawn before the first dialysis session after postcardiac sugary      associated severe AKI ( initializing RRT). Blood is drawn into Vacutainer tubes containing      EDTA, and immediately placed on ice and centrifuged within 1 h. All the samples are stored      at -70°C until analysis.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|patients (cases) that developed AKI during the follow-up period of 72 h. AKI was defined        as a 50% or greater increase in SCr from baseline according to the RIFLE-R criteria. For        each of these cases, we then selected 20 controls from patients who also underwent open        heart surgery but did not develop AKI. We matched the cases and controls as closely as        possible for age, sex, baseline estimated GFR, comorbidities, medications, type of surgery        and perioperative complications.|July 2011|January 3, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503710||93206|
NCT01501539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 2011-14460|Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement|Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement: A Randomized Controlled Trial of Hydrocolloid Dressings||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|December 2010|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|171|||Both|1 Month|17 Years|No|||November 2015|November 11, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01501539||93373|
NCT01496599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120031|Imaging Biomarkers in Parkinson s Disease|Imaging Biomarkers in Parkinson Disease||National Institutes of Health Clinical Center (CC)||Recruiting|November 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|December 1, 2015|December 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01496599||93751|
NCT01504347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|730901|Phase 1/2 Lyme Vaccine Study|Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years||Baxalta US Inc.|Yes|Completed|March 2011|February 2014|Actual|August 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|1630|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|June 26, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01504347||93157|
NCT01500499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B2|Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia|The Role of AF1q in Progression of Leukemia||Children's Oncology Group|No|Active, not recruiting|December 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|30 Years|No|Non-Probability Sample|Acute myeloid leukemia.|May 2015|May 8, 2015|December 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01500499||93453|
NCT01504243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111013-009（1）|Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population|Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population||Chinese PLA General Hospital|Yes|Recruiting|May 2010|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects were selected from among inpatients who were hospitalized between September        2009 and October 2011 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese        People's Liberation Army (CPLA) General Hospital.|December 2011|January 4, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01504243||93165|
NCT01504256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-STO-0110|Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas|Explorative Trial to Investigate Catumaxomab (Anti-EpCAM x Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas Prior to Gastrectomy|CatuNeo|AIO-Studien-gGmbH|Yes|Active, not recruiting|October 2011|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504256||93164|
NCT01502137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1630-1559|Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis|An Open, Non-randomized, Single-centre, Parallel Group Trial Investigating the Steady-state Blood Concentration Profile and Effects of Once Daily Subcutaneously Injected Recombinant Human Growth Hormone (Norditropin® SimpleXx®) in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis and in Matched Healthy Subjects||Novo Nordisk A/S|No|Completed|June 2005|November 2005|Actual|November 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502137||93327|
NCT01502436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0214|An Exploration of the Relationship Between Chronic Pain and Suicide Attempt Among Veterans|An Exploration of the Relationship Between Chronic Pain and Suicide Attempt Among Veterans||VA Eastern Colorado Health Care System|No|Completed|June 2008|November 2014|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|230|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Veterans who received care in the VA.|July 2012|January 22, 2016|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01502436||93304|
NCT01500369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unique Protocol ID|Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery|Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial||Baystate Medical Center|Yes|Recruiting|December 2010|June 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|410|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500369||93462|
NCT01500382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4618-004|A Study of the Pharmacokinetics and Pharmacodynamics of MK4618 in Women With Overactive Bladder (MK-4618-004 AM1)|A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder||Merck Sharp & Dohme Corp.|No|Terminated|February 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|4|||Female|40 Years|75 Years|No|||January 2015|January 8, 2015|December 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01500382||93461|
NCT01497353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|funda04|Placental Transfusion and Cord Clamping|Is the Placental Transfusion Volume Influenced by the Position of the New Born at Birth?||Fundacion para la Salud Materno Infantil|Yes|Completed|August 2011|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|400|||Both|N/A|2 Minutes|Accepts Healthy Volunteers|||October 2012|October 17, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497353||93693|
NCT01497678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11050209|Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center|Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury (Coordinating Center Protocol)|MTURR|University of Pittsburgh|Yes|Withdrawn|March 2013|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||January 2016|January 2, 2016|August 9, 2011|Yes|Yes|Funding issues|No||https://clinicaltrials.gov/show/NCT01497678||93668|
NCT01497951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_MuSH|Photodynamic Therapy for Oral Precursor Lesions|A Randomized Controlled Trial: Photodynamic Treatment for the Therapy of Premalignant Mucosal Oral Lesions.|PDT|Medical University of Vienna|No|Recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01497951||93648|
NCT01501487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0334|MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I|MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I|MINT|Agendia|No|Recruiting|October 2011|July 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|226|||Female|18 Years|N/A|No|||January 2016|January 28, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01501487||93377|
NCT01501500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 99-2314-B-182A-020|Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact Insole|Therapeutic Effect of Botulinum Toxin Type A in Addition to Total Contact Insole in Treating Painful Hallux valgus-a Pilot Study||Chang Gung Memorial Hospital|Yes|Completed|August 2010|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||March 2010|September 5, 2013|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01501500||93376|
NCT01502683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046608|Stroke Study: Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery|Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery||Emory University|Yes|Active, not recruiting|December 2011|September 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|136|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01502683||93285|
NCT01502696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-18081|Adjuvant PEG Intron in Ulcerated Melanoma|Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|October 2012|||April 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|70 Years|No|||March 2016|March 21, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01502696||93284|
NCT01499056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-008|Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint|Evaluation the Side Effect of Bone Marrow Derived Mesenchymal Stem Cell in Patients With Osteoarthritis of Hip Joint||Royan Institute|Yes|Completed|June 2010|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|65 Years|No|||January 2010|December 21, 2011|December 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01499056||93563|
NCT01499316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|426/11|Investigating the Effects of Hyperoxia on Fractional Flow Reserve|Investigating the Effects of Hyperoxia on Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease||Bayside Health|No|Not yet recruiting|March 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|90 Years|No|||March 2014|March 6, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01499316||93543|
NCT01501513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI800-440|A Safety Study of 3 Different Bowel Cleansing Preparations|A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel Cleansing Preparations in Adult Subjects, Including the Elderly and Subjects With Hepatic or Renal Insufficiency||Braintree Laboratories|No|Completed|December 2011|||April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|540|||Both|18 Years|N/A|No|||July 2014|July 11, 2014|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01501513||93375|
NCT01502410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00106|Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer|A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma||National Cancer Institute (NCI)|Yes|Completed|January 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|2 Years|30 Years|No|||May 2015|May 14, 2015|December 29, 2011|Yes|Yes||No|April 14, 2015|https://clinicaltrials.gov/show/NCT01502410||93306|
NCT01502423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-964|A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab|A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis||AbbVie|No|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|December 1, 2011||No||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01502423||93305|
NCT01499290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00001|Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections|A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults||AstraZeneca||Completed|March 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|493|||Both|18 Years|90 Years|No|||January 2016|January 29, 2016|December 19, 2011|Yes|Yes||No|November 6, 2015|https://clinicaltrials.gov/show/NCT01499290||93545|This summary describes data collected from two identical CSPs (D4280C00001 and D4280C00005). With agreement from the EMA and the FDA the data have been combined into a single study database.
NCT01499602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-324v|Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women|LNG-IUS or Norethisterone Acetate for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women||Mansoura University|Yes|Completed|May 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|40 Years|50 Years|No|||December 2011|December 22, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499602||93521|
NCT01499615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002709/1; MGH|A Prospective Study of a New Non-Invasive Cardiac Output Monitor in Children Undergoing General Anesthesia|A Prospective Study of a New Non-Invasive Cardiac Output Monitor in Children Undergoing General Anesthesia||Massachusetts General Hospital|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|402|||Both|N/A|18 Years|No|Non-Probability Sample|neonates to teenagers|April 2015|April 7, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499615||93520|
NCT01503385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-L-025|Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer||Chinese Academy of Medical Sciences|Yes|Recruiting|December 2011|December 2016|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|70 Years|No|||January 2012|January 3, 2012|January 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503385||93231|
NCT01503398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|378-11|Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Olanzapine Tablets 5 mg With Zyprexa® Tablets 5 mg in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503398||93230|
NCT01504295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA021128|A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease|A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease||Brown University|Yes|Completed|April 2012|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504295||93161|
NCT01496040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 07/08-K|Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65|Prospective Monocentric Open Label Non Randomized Uncontrolled Phase I/II Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65|RPE65|Nantes University Hospital|Yes|Completed|September 2011|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|6 Years|50 Years|No|||October 2015|October 6, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01496040||93794|
NCT01496612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120033|Buspirone Therapy for Localized Epilepsy|A Phase Two Clinical Trial of Buspirone Therapy in Localization-Related Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|November 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||July 2014|April 2, 2015|December 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01496612||93750|
NCT01500655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001944|Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients|Evaluation of Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients for Reconstructive Surgical Procedures||Massachusetts General Hospital|Yes|Recruiting|April 2008|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|2 Years|21 Years|No|||January 2013|January 30, 2013|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01500655||93441|
NCT01500668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-9023-AH-CTIL|Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis|Botulinum Toxin for Treatment of Catocholamine Induced Finger Necrosis - a Double Blind Randomized Control Prospective Study.||Sheba Medical Center|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2012|January 3, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500668||93440|
NCT01502956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDN 20|Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)|Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)|ROSETTA|NICHD Pelvic Floor Disorders Network|Yes|Active, not recruiting|February 2012|December 2016|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|380|||Female|21 Years|N/A|No|||December 2014|December 5, 2014|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502956||93264|
NCT01500434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2046C|The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Long Lesion Sub-trial|PLATINUM LL|Boston Scientific Corporation|Yes|Active, not recruiting|February 2009|March 2015|Anticipated|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|December 22, 2011|Yes|Yes||No|January 11, 2012|https://clinicaltrials.gov/show/NCT01500434||93457|
NCT01500928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTR-135; VTR-075|Performance Study of the SOLO 2.0 Insulin Pump|||Medingo Ltd|No|Recruiting|July 2011|||July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|16 Years|65 Years|No|||December 2011|December 25, 2011|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01500928||93420|
NCT01497977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|175062|Phytoestrogen Supplementation in Postmenopausal Women|Impact of Phytoestrogens on Serum Lipids in Postmenopausal Women||American Medical Academy, Serbia|Yes|Completed|September 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|74|||Female|40 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 27, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01497977||93646|
NCT01497990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/3-W|Pharmacokinetics Ertapenem Burns|Pharmacokinetics of Ertapenem When Used in Empiric Treatment in Burn Patients. Prospective Open Label Study.||Nantes University Hospital|Yes|Completed|January 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||November 2012|November 2, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01497990||93645|
NCT01498237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102405|Photoacoustic Endoscopy in Endometrial Cancer|A Pilot Study of Photoacoustic Endoscopy in Endometrial Cancer||Washington University School of Medicine|Yes|Withdrawn|January 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Female|18 Years|N/A|No|||July 2013|July 9, 2013|December 12, 2011|Yes|Yes|Need to obtain IDE prior to commencement of study|No||https://clinicaltrials.gov/show/NCT01498237||93626|
NCT01502397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1431|Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study|||The University of Hong Kong|No|Enrolling by invitation|December 2011|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|Serum and plasma for hepatitis B virus genotypic, virologic and serologic testing|Both|18 Years|N/A|No|Non-Probability Sample|Patients with B-cell lymphomas or chronic lymphocytic leukaemia referred to Queen Mary        Hospital for rituximab-containing chemotherapy|December 2014|December 29, 2014|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01502397||93307|
NCT01503697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-EE-262-CTIL|The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer|The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|January 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|75|||Female|18 Years|N/A|No|Non-Probability Sample|Investigating the diagnostic accuracy of NC100692kit in three patient populations:        Arm 1.Patients with unknown breast cancer but unclear lesions in the breast or other        modalities or patients at high risk for breast cancer (BRCA, familial) Arm 2. Staging and        re-staging in patients with breast cancer. Arm 3. Monitoring response to neo-adjuvant        chemotherapy in patients with locally advanced breast cancer|January 2012|January 3, 2012|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01503697||93207|
NCT01496638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080192|The Nordic-Baltic Bifurcation Study IV|How Should Coronary Artery Stenoses With Significant Side Branch be Stented? A Strategy of Stenting Both Main Vessel and Side Branch Compared to a Strategy of Stenting the Main Vessel and Only Stenting the Side Branch if Necessary.|BIF IV|Aarhus University Hospital Skejby|Yes|Active, not recruiting|December 2008|December 2020|Anticipated|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|450|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496638||93748|
NCT01496885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBI 801|Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke|A Multicenter Observational Study to Evaluate the Simplified STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Obtained Between 24 and 48 Hours of a Nonhemorrhagic Ischemic Stroke||Daiichi Sankyo Inc.|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|120|||Both|21 Years|85 Years|No|Non-Probability Sample|Subjects may be selected upon admission to an acute care emergency center, inpatient        facility, or rehabilitation center.|October 2015|October 19, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496885||93729|
NCT01499004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921131|A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers|A Phase 1, Randomized, Open Label, Partial Crossover Study To Evaluate The Pharmacokinetics (PK) And Safety Of Three Modified Release (MR) And One Immediate Release (IR) Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers||Pfizer|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|30|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 11, 2012|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01499004||93567|
NCT01499017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4801001|A Single Dose Study Of PF-06291874 In Healthy Adult Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single Dose Escalating Study To Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of PF-06291874 After Administration Under Fasted And Fed Conditions In Healthy Adult Subjects||Pfizer|No|Terminated|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 27, 2012|November 14, 2011|No|Yes|See termination reason in detailed description.|No||https://clinicaltrials.gov/show/NCT01499017||93566|
NCT01499030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-1147-cNEP-SS|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2011|||||N/A|N/A|N/A||||||||||||||December 21, 2011|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499030||93565|
NCT01499303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4302C00001|Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer|Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)||AstraZeneca||Completed|December 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|December 19, 2011|Yes|Yes||No|June 17, 2014|https://clinicaltrials.gov/show/NCT01499303||93544|
NCT01497132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DvitamininDM2_v1_110815|Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2|Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS|EVIDENS|Karolinska Institutet|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|45 Years|75 Years|No|||September 2014|September 9, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497132||93710|
NCT01499901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091204|Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children|Interest of the Bilateral Cochlear Implantation in the Deep Deaf Children Respect to the Unilateral Implantation - a Randomized Test|Cochleo|Assistance Publique - Hôpitaux de Paris|Yes|Withdrawn|January 2012|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|8 Months|38 Months|No|||November 2012|November 16, 2012|December 6, 2011||No|Recommendations of HAS have changed, the study is now useless|No||https://clinicaltrials.gov/show/NCT01499901||93498|
NCT01496027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04515|Cerebral Tissue Oxygenation Values in Newborns Measured Using Laser and LED NIRS Oximeters|A Comparison of Cerebral Tissue Oxygenation Values in Newborns Measured Simultaneously Using Laser and LED NIRS Oximeters||Poznan University of Medical Sciences|No|Completed|December 2011|April 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|30|||Both|N/A|1 Day|Accepts Healthy Volunteers|Non-Probability Sample|Clinically stable, spontaneously breathing newborns will be included in the study.        Enrolled patients will be divided into two groups: 15 term (≥37 weeks GA) and 15 preterm        (32-37 weeks GA) newborns. NIRS measurements will be performed on the 1st and 3rd day of        life.|September 2013|September 9, 2013|December 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01496027||93795|
NCT01496326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-IBU-CH-001|Osteoarthritis Topical Treatment|A Pilot Study to Compare the Efficacy and Safety of a Novel 10% Ibuprofen Formulation Versus Placebo Alone Applied to the Knee in Patients With Painful Osteoarthritis of the Knee|ANTIPAIN|BioChemics, Inc.|Yes|Completed|February 2011|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|40 Years|N/A|No|||December 2011|December 19, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01496326||93772|
NCT01496859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A.621|Observational Study of Baska Mask, a New Supraglottic Airway Device|Observational Study of Baska Mask, a New Supraglottic Airway Device||University College Hospital Galway|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||March 2012|March 23, 2012|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01496859||93731|
NCT01497119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017455|A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-39758979 in Adult Japanese Subjects With Moderate Atopic Dermatitis||Janssen Pharmaceutical K.K.|No|Terminated|October 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|88|||Both|20 Years|65 Years|No|||November 2015|November 30, 2015|December 20, 2011||No|This study was terminated prematurely due to 2 cases of agranulocytosis.|No||https://clinicaltrials.gov/show/NCT01497119||93711|
NCT01504373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10070341|Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation|Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation||Children's Hospital Boston|Yes|Recruiting|May 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|1 Month|18 Years|No|||January 2016|January 27, 2016|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01504373||93155|
NCT01504386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-HT-2011|Transversus Abdominis Plane Block After Robot-assisted Laparocopic Hysterectomy|Effekt of Transversus Abdominis Plane (TAP) Block After Robot-assisted Laparocopic Hysterectomy|TAP-block|Copenhagen University Hospital at Herlev|Yes|Terminated|December 2011|July 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|18 Years|80 Years|No|||August 2013|August 21, 2013|December 30, 2011||No|Due to local restructering, further recruting was not possible|No||https://clinicaltrials.gov/show/NCT01504386||93154|
NCT01500252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00002794|Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty - A Randomized Clinical Trial|A Randomized Clinical Trial Comparing Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty Using the PROFIX* Total Knee System|PROFIX|University of Alberta|No|Completed|September 1996|December 2009|Actual|June 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|40 Years|75 Years|No|||April 2012|April 5, 2012|December 22, 2011||No||No|January 3, 2012|https://clinicaltrials.gov/show/NCT01500252||93471|
NCT01500525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP 40467|Bronchodilator Response in 4-12 Years Chinese Controller Naive Asthmatic Children|A Prospective Observational Study in a Tertiary Pediatric Hospital in Beijing to Understand the Accuracy of Bronchodilator Response (BDR) in Chinese Controller Naive Asthmatic Children Between the Age of 4~12 Years Old||Capital Institute of Pediatrics, China|Yes|Recruiting|December 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|||Both|4 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|300 asthmatic children and 300 non-asthmatic children will be recruited|February 2013|February 25, 2013|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01500525||93451|
NCT01501773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INVEST|Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke|Phase II Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke||Manipal Acunova Ltd.|Yes|Completed|October 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|70 Years|No|||December 2011|December 26, 2011|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501773||93355|
NCT01503177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1023|Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma|A Phase 1 Trial of Oncolytic Measles Virotherapy in Mesothelioma||Mayo Clinic|Yes|Suspended|November 2011|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|December 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01503177||93247|
NCT01503411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. 11_01|High Resolution Optical Imaging of Barrett's Esophagus Using Nvision Volumetric Laser Endomicroscopy (VLE)|High Resolution Optical Imaging of Barrett's Esophagus Using Nvision Volumetric Laser Endomicroscopy (VLE)||NinePoint Medical|No|Completed|January 2012|||March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Males and females >18 years of age undergoing esophagogastroduodenoscopy (EGD) for        suspected or confirmed Barrett's esophagus (BE)or for non-BE related conditions other than        esophageal varices.|April 2014|April 8, 2014|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503411||93229|
NCT01500122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 5004|Study Evaluating the Pharmacokinetic Profile of Novel Formulations of RHUDEX®|An Open-label, Non Randomized Monocentric Phase I Study Evaluation the Pharmacokinetic Profile of Novel Formulations of RHUDEX®||MediGene|No|Completed|December 2011|June 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01500122||93481|
NCT01497691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111491|Noninvasive Positive Airway Pressure in the Pediatric Emergency Department for the Treatment of Acute Asthma Exacerbations|A Randomized Controlled Trial of Noninvasive Positive Airway Pressure in the Pediatric Emergency Department for the Treatment of Acute Asthma Exacerbations|RCT BiPAP|Vanderbilt University|Yes|Recruiting|January 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|441|||Both|2 Years|18 Years|No|||January 2013|January 1, 2013|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497691||93667|
NCT01499069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-09-036|Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients|Urinary NGF, PGE2 and ATP: Potential Biomarkers for Diagnosis and Prediction of Treatment Efficacy in Overactive Bladder Patients||Samsung Medical Center|No|Recruiting|February 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|197|||Both|18 Years|N/A|No|||January 2014|February 12, 2015|May 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01499069||93562|
NCT01499342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM/BOSS 02-002|Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent in the Superficial Femoral Artery|Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent to Treat Atherosclerotic Lesions in the Superficial Femoral Artery|BOSS|be Medical|No|Completed|November 2009|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Stenosis (> 75%) or occlusion of the superficial femoral artery.|May 2014|May 13, 2014|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01499342||93541|
NCT01499355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211LE201|BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis|A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis|ATLAS|Biogen|Yes|Terminated|July 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|188|||Both|18 Years|75 Years|No|||October 2015|November 12, 2015|November 23, 2011|Yes|Yes|Results from a pre-specified criteria did not demonstrate sufficient efficacy to warrant    continuation of the study.|No||https://clinicaltrials.gov/show/NCT01499355||93540|
NCT01499641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-07-011-RAS|Epidural Steroid Following Discectomy for Herniated Disc Reduces Morbidity|Epidural Steroid Following Discectomy for Herniated Lumbar Disc Reduces Neurological Impairment and Enhances Recovery. A Randomized Study With Two-year Follow-up||Northern Orthopaedic Division, Denmark|No|Completed|May 2001|December 2005|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|66 Years|No|||September 2014|September 12, 2014|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499641||93518|
NCT01502930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICBT_Nightmares|Treatment of Nightmares Via the Internet|MARI - Treatment of Nightmares Via the Internet - a Randomized Controlled Trial|MARI|Karolinska Institutet|No|Completed|January 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|175|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01502930||93266|
NCT01504269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0132|Exercise Stress CMR Comparison Study|Comparison of Exercise MRI and Exercise Nuclear Scintigraphy in Patients With Suspected Coronary Artery Disease.||Ohio State University|Yes|Active, not recruiting|August 2007|||December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|333|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504269||93163|
NCT01504282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8901|Mitomycin-c Application for PRK|Mitomycin-c Application for Photorefractive Keratectomy||hahid Beheshti University of Medical Sciences||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2|||90|||Both|N/A|N/A||||June 2010|January 4, 2012|January 4, 2012||||No||https://clinicaltrials.gov/show/NCT01504282||93162|
NCT01495156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-185|Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania|A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Adjunctive Lithium for the Treatment of Psychotic Mania Followed by an Open Label Long-term Safety Period.||Northwell Health|No|Withdrawn|September 2011|September 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|18 Years|No|||January 2014|January 21, 2014|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495156||93860|
NCT01495442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1260|Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques|Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques|DPI|University of North Carolina, Chapel Hill|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 17, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495442||93839|
NCT01495455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11049|Nottingham Osteoarthritis Biomarker Study 2011|Nottingham Osteoarthritis Biomarker Study 2011||University of Nottingham|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|140|Samples With DNA|Serum, urine and synovial fluid.|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|- Secondary care clinics|January 2013|January 29, 2013|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01495455||93838|
NCT01495468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci-004-CT|Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children|Pegylated Somatropin in the Treatment of Children With Growth Hormone Deficient：A Multicenter, Randomized, Open-label, Controlled Phase Ⅲ Clinical Trial||GeneScience Pharmaceuticals Co., Ltd.|Yes|Completed|March 2007|March 2008|Actual|January 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|343|||Both|8 Years|15 Years|No|||December 2011|December 16, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495468||93837|
NCT01491243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652/2011/D|N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy|Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention|NEW-MOON|University of Roma La Sapienza|No|Not yet recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|N/A|N/A|No|||March 2013|March 6, 2013|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01491243||94160|
NCT01492140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-11-01|Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers|A Randomized, Evaluator-Blind, Bilateral Comparison of an Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers in Patients Seeking Aesthetic Correction of the Nasolabial Folds||TKL Research, Inc.|No|Active, not recruiting|December 2011|February 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 12, 2011|December 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492140||94091|
NCT01492153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPEN3-1886|NovoLet® Surveillance Study on Using Human Insulin System in Indonesia|A Post Marketing Surveillance on the Use of NovoLet® Human Insulin System in Indonesia||Novo Nordisk A/S|No|Completed|February 2003|September 2006|Actual|September 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1981|||Both|N/A|N/A|No|Probability Sample|Patients with type 1 or type 2 diabetes mellitus or other types of diabetes mellitus        (gestational, drug induced or metabolic syndrome-related) who are prescribed NovoLet®        human insulin in the course of their diabetes mellitus management can be enrolled in the        study|April 2012|April 11, 2012|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492153||94090|
NCT01492166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPEN3-1890|Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Mixtard® 30 NovoLet® as Monotherapy, or in Combination With Oral Hypoglycaemic Agent ( OHA ), in Treatment of Subjects With Type 2 Diabetes in Routine Clinical Practice||Novo Nordisk A/S|No|Completed|November 2006|June 2007|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1935|||Both|N/A|N/A|No|Probability Sample|Subjects with type 2 diabetes not achieving adequate control and being prescribed Mixtard®        30 Novolet® either as a single treatment or in combination with oral hypoglycaemic agents        (OHAs).|April 2012|April 11, 2012|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492166||94089|
NCT01491841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030834|IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma|Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma|BRP|Duke University|No|Recruiting|November 2011|November 2021|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491841||94114|
NCT01492127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8671|Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment|Evolution of Plasma Proteasome Levels Following Curative Treatment of Hepatocellular Carcinoma in Cirrhotic Patients||University Hospital, Montpellier|Yes|Active, not recruiting|December 2011|March 2016|Anticipated|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|64|||Both|18 Years|N/A|No|||April 2013|April 22, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492127||94092|
NCT01522911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAA-1|Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage|Interventional Study to Investigate the Effects of Percutaneous Closure of the Left Atrial Appendage on Atrial and Brain Natriuretic Peptide Secretion||University of Leipzig|No|Active, not recruiting|May 2010|January 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01522911||91739|
NCT01523132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2007-0098|Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms|Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms||Rigshospitalet, Denmark|Yes|Completed|November 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|545|Samples With DNA|blood|Female|18 Years|N/A|No|Probability Sample|Breast cancer patients treated in a university hospital|January 2015|January 8, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523132||91722|
NCT01492634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-IIT-01-E|Optimizing Fluid Status|Clinical Investigation Plan Optimizing Fluid Status||Hospital Clinic of Barcelona|No|Completed|November 2011|February 2012|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|56|||Both|18 Years|N/A|No|||December 2011|February 27, 2014|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01492634||94053|
NCT01501045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-001|Effect of Transmagnetic Stimulation on Conditioned Pain Modulation (CPM)|The Effect of Transmagnetic Stimulation on Descending Pain Modulation||Rambam Health Care Campus|No|Recruiting|December 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01501045||93411|
NCT01493219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 369-11-FB|Biomarkers for Prognosis of Glioblastoma (GBM)|MMP-2, MMP-9 and NGAL as Biomarkers for Glioblastoma (GBM) Biomarkers for the Prognosis of Glioblastoma||University of Nebraska|No|Recruiting|September 2011|September 2016|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|Whole Blood, Urine, and Tissue.|Both|19 Years|N/A|No|Non-Probability Sample|Subjects scheduled for a surgical excision or biopsy as ordered by his/her clinic or        inpatient physician for epilepsy OR subjects newly diagnosed with high grade (grade IV)        glioma|December 2011|December 14, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493219||94008|
NCT01493531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-302|Combining Lesinurad With Allopurinol in Inadequate Responders|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol|CLEAR 2|Ardea Biosciences, Inc.|Yes|Completed|December 2011|July 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|612|||Both|18 Years|85 Years|No|||April 2015|April 9, 2015|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493531||93984|
NCT01493804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120011|Noninvasive Study of Brain Connectivity With EEG and NIRS|Non-Invasive Study of Brain Connectivity Using Combined EEG and NIRS||National Institutes of Health Clinical Center (CC)||Completed|November 2011|||||N/A|Observational|Time Perspective: Prospective|||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493804||93963|
NCT01494077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#2011-8161|Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for Carcinoembryonic Antigen (CEA) Measurement|Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for CEA Measurement||University of California, Irvine|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Probability Sample|Patients who are already scheduled for EUS-FNA of a pancreatic cyst at the H.H. Chao        Comprehensive Digestive Disease Center at UC Irvine Medical Center. The procedure will be        performed as usual per standard of care protocol with EUS-FNA of the cyst. Once the fluid        is aspirated, it will be measured and if the fluid volume is 2.25 mL or greater than the        patient will be included in the study.|December 2014|December 10, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01494077||93942|
NCT01494298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1105110|Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes|Preliminary Analysis of Lipoprotein Subclasses, Apoprotein Levels, and Genetic Architecture of African-American Males With Type 2 Diabetes. Lipids in African Americans With Type 2 Diabetes|LAAD|Mercer University|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|111|Samples With DNA|We will retain a sample of serum, plasma and whole blood.|Male|18 Years|79 Years|No|Probability Sample|This is a cross-sectional epidemiologic study in which the lipoprotein subclasses,        apolipoprotein levels, and genetic polymorphisms of African-American men with type 2        diabetes will be compared to African-American men without diabetes.|October 2013|October 23, 2013|December 15, 2011||No||No|June 19, 2013|https://clinicaltrials.gov/show/NCT01494298||93926|
NCT01495169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO522D2402|Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients|A Multicenter, Open-label, Sequential Cohort, Dose-escalation, 14-day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone 12 to 24 mg/Day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/Day) in Adolescent Patients (Aged 12 to 17 Years)||Vanda Pharmaceuticals||Active, not recruiting|October 2011|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|12 Years|17 Years|No|||January 2015|April 8, 2015|August 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495169||93859|
NCT01495182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Effects of Dietary Fiber on Gastrointestinal Function|A Double-blind, Randomized, Crossover Trial to Assess the Gastrointestinal Tolerability of a Dietary Fiber Ingredient in Healthy Men and Women||National Starch LLC|No|Recruiting|December 2011|||July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|26|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||December 2011|December 15, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01495182||93858|
NCT01495195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01406522B|Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior||SDC|Midwest Biomedical Research Foundation|Yes|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|12|||Both|21 Years|50 Years|No|||December 2013|December 17, 2013|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495195||93857|
NCT01491607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS.AVA.006|Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults|Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults||Emergent BioSolutions|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|December 12, 2011|Yes|Yes||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01491607||94132|
NCT01491256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESIST-ACS|Index of Microcirculatory Resistance After Drug-Eluting Stent Implantation With High Dose Atorvastatin Loading|Randomized Comparison Multicenter Trial of High Dose Atorvastatin Pre-treatment on Microcirculatory Dysfunction After Drug-ElutIng Stent Implantation in Patients With Acute Coronary Syndrome|RESIST-ACS|The Korean Society of Circulation|Yes|Recruiting|February 2010|February 2012|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|85 Years|No|||December 2011|December 11, 2011|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01491256||94159|
NCT01492478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39772|Psychobiological Characterization of Depression in Hepatitis C|Psychobiological Characterization of Depression in Hepatitis C||Centro Hospitalar Lisboa Norte|No|Not yet recruiting|January 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients are selected in the context of hospital consultancies (Viral Hepatitis        Consultancies at the Hospital de Santa Maria; Psychiatric Consultancies at the Hospital de        Santa Maria) after informing, requesting voluntary cooperation, confidenciality assurance        and with request of informed consent signature, submitted and approved by the hospital's        ethics committee|December 2011|December 14, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492478||94065|
NCT01492777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 08-019|Pharmacogenetics of Acenocoumarol|Stabilization of Anticoagulation by Acenocoumarol: Role of Genetic Vulnerability and Risk of Drug Interactions||University Hospital, Geneva|No|Completed|November 2008|March 2012|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|115|Samples With DNA|Whole blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Hospitalized patients starting acenocoumarol therapy|June 2013|June 20, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492777||94042|
NCT01493063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/02-Y|LACTACOL 01 - Impact of Breast Milk on the Neurodevelopment of Preterm Newborns|BRD/11/02-Y "LACTACOL 01 - Impact of Breast Milk on the Neurodevelopment of Preterm Newborns".||Nantes University Hospital||Recruiting|September 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|156|||Both|28 Weeks|34 Weeks|No|Non-Probability Sample|Preterm newborn|September 2014|September 9, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493063||94020|
NCT01492790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 11-045 (NAC 11-012)|Cholecystectomy First vs Sequential Common Bile Duct Imaging + Cholecystectomy|An Open Randomized Study Comparing Emergency Cholecystectomy First Versus Sequential Common Bile Duct Imaging/Cholecystectomy for the Management of Gallstone Migration|CCK first|University Hospital, Geneva|No|Completed|June 2011|August 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|16 Years|N/A|No|||August 2013|August 12, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492790||94041|
NCT01493323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8555|Functional Imaging of Psychic Pain|Neuro Anatomic Basis of Psychic Pain in Depression and Suicidal Behaviour||University Hospital, Montpellier|No|Terminated|May 2010|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|123|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|November 10, 2011||No|difficult to patient inclusion|No||https://clinicaltrials.gov/show/NCT01493323||94000|
NCT01493336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27931|A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours|A Randomized, Open-label, Single Dose, Two-way Cross-Over Study to Investigate the Relative Bioavailability of Capecitabine in Rapid Disintegrating Tablets (RDT) Versus the Commercial Xeloda® Tablets Following Oral Administrations in Adult Patients With Solid Tumours||Hoffmann-La Roche||Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493336||93999|
NCT01523353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/H1005/3|Prehabilitation in Liver Surgery|Feasibility Study of Preoperative Exercise Intervention in the Resection of Colorectal Liver Metastasis.||Aintree University Hospitals NHS Foundation Trust|No|Completed|July 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||February 2012|December 16, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523353||91705|
NCT01492647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018673|A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris|A Randomized, Double Blinded, Single Topical Dose Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Subjects With Acne Vulgaris||Janssen Pharmaceutical K.K.|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|20 Years|35 Years|No|||February 2013|February 18, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492647||94052|
NCT01492621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTI|Effect of Antidepressants on White Matter Structure|White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study||Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine|No|Recruiting|November 2011|November 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|40|||Both|18 Years|55 Years|No|||December 2011|December 14, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492621||94054|
NCT01492907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011NTLS016|Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer|Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 21, 2014|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492907||94032|
NCT01493232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190052|Comparing Patient Satisfaction & Stress Distribution on Mandibular Ridge by Three Posterior Occlusal Scheme in Complete Denture|Comparing Patient Satisfaction & Stress Distribution on Mandibular Ridge by Three Posterior Occlusal Scheme in Complete Denture||Isfahan University of Medical Sciences|Yes|Recruiting|October 2011|May 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2011|December 17, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01493232||94007|
NCT01493544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RLA-XXX-2011/1|Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America|Prevalence Study and Regular Practice (Diagnosis and Treatment) Among General Practitioners in Populations at Risk of COPD in Latin America|PUMA PROJECT|AstraZeneca||Completed|February 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1907|||Both|40 Years|N/A|No|Non-Probability Sample|Patients aged 40 or more, smokers or former smokers and/or people exposed to biomass        combustion, who attend primary care consultation.|April 2013|April 25, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01493544||93983|
NCT01493557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.128|A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation|A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa® 150 mg b.i.d., 110 mg b.i.d. or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation (NVAF)||Boehringer Ingelheim||Completed|December 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1067|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|December 12, 2011||||No|July 6, 2015|https://clinicaltrials.gov/show/NCT01493557||93982|The modest sample size,non-specific nature of symptoms,&reliance on patient self-reporting of their symptoms may contributed some bias to the final result.An open-label design may lead to patient/investigator bias in reporting symptoms.
NCT01493817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B1|Biomarkers in Samples From Younger Patients With Wilms Tumor|Observational - Relationships Between Tumor-Associated Macrophages and Clinicopathological Factors in Wilms Tumor||Children's Oncology Group|No|Recruiting|December 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|Wilms tumor patients|November 2015|November 9, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493817||93962|
NCT01493830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL12B4|Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma|Proposed Studies on the Role of Growth Factor Receptor Trafficking in Neuroblastoma Pathogenesis||Children's Oncology Group|No|Active, not recruiting|December 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|5|Samples With DNA|Tumor samples|Both|N/A|120 Years|No|Non-Probability Sample|Patients With Neuroblastoma|May 2015|September 30, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493830||93961|
NCT01494610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114334|Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry Powder Inhaler, in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.||GlaxoSmithKline|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|80 Years|No|||April 2012|April 19, 2012|October 27, 2011||No||No|February 16, 2012|https://clinicaltrials.gov/show/NCT01494610||93902|
NCT01494883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFN 2011-2015|Mindfulness for Lung Cancer Patients and Partners|Mindfulness Based Stress Reduction (MBSR) for Patients With Lung Cancer and Their Partners: a Randomized Controlled Trial.||Radboud University||Completed|February 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|107|||Both|18 Years|N/A|No|||September 2015|September 9, 2015|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01494883||93881|
NCT01494909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113047|Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function|Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function||Texas A&M University|No|Active, not recruiting|January 2011|February 2017|Anticipated|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|31|||Both|10 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494909||93879|
NCT01494922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXC 001-206|Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001|A Phase 2, Open-label Study to Provide Revision of Scars Resulting From Surgery in Prior Studies of EXC 001 (Currently Called PF-06473871)||Pfizer|No|Completed|December 2011|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|N/A|No|||December 2013|November 6, 2014|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494922||93878|
NCT01491269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smartaMB2011|Guided Internet-delivered Cognitive-behavioral Therapy for Former Chronic Pain Patients|Guided Internet-delivered Cognitive-behavioral Therapy for Former Chronic Pain Patients: Randomised Controlled Trial||Linkoeping University|No|Completed|August 2009|June 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||December 2011|December 11, 2011|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01491269||94158|
NCT01491867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4481/2011|Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect|Evaluation of Continuous IOP Measurement and the Influence of Drug Induced IOP Decrease on the Measurement||Semmelweis University|No|Completed|December 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491867||94112|
NCT01491854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP00-402|Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational Age|Long-term Safety Follow-up After Growth Hormone Treatment (rhGH) of Short Children Born Small for Gestational Age (SGA)|SGA|Sandoz|No|Recruiting|November 2009|July 2031|Anticipated|July 2031|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|200|||Both|4 Years|N/A|No|||March 2016|March 22, 2016|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491854||94113|
NCT01492426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-052|Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients|A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C|COMMAND-3|Bristol-Myers Squibb|No|Completed|January 2012|March 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|605|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492426||94069|
NCT01493700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA 2612|Changes of Body Temperature During Shoulder Arthroscopy|Effect of Heated Humidifier on the Body Temperature During Shouler Arthroscopy||Gachon University Gil Medical Center|Yes|Completed|December 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|20 Years|60 Years|No|||June 2013|June 26, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01493700||93971|
NCT01492452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP4555/10|The Anxiety of Parents of Children Undergoing Cardiac Surgery|Standard Guidelines Impact of Nursing Anxiety of Parents of Children Undergoing Cardiac Surgery: Randomized Clinical Trial||Instituto de Cardiologia do Rio Grande do Sul|No|Completed|December 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|44|||Both|18 Years|N/A|No|||December 2011|December 14, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492452||94067|
NCT01492465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100015|Single Ascending Dose Trial in Patients With Type 2 Diabetes|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes||Amgen||Terminated|November 2011|October 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|65 Years|No|||February 2013|February 13, 2013|September 28, 2011|Yes|Yes|Decision by Sponsor|No||https://clinicaltrials.gov/show/NCT01492465||94066|
NCT01493115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD12270|Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus|A Randomized, Double-blind, 3-sequence, 3-period Cross-over, Single-dose Study of a New Formulation of Insulin Glargine Compared to the Marketed Lantus® in Japanese Patients With Type 1 Diabetes Mellitus Using the Euglycemic Clamp Technique||Sanofi|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|20 Years|65 Years|No|||April 2012|April 30, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01493115||94016|
NCT01493362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#5175|Imaging the Dopamine Systems in Bulimia Nervosa|Imaging the Dopamine Systems in Bulimia Nervosa||New York State Psychiatric Institute|No|Completed|January 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|33|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will include people with bulimia nervosa seeking inpatient or        outpatient treatment and people who will act as healthy control participants|November 2011|August 14, 2014|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493362||93997|
NCT01493076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baby-S 2011|Safety and Efficacy of a Newly Developed Baby-sphincterotome for Bile Duct Cannulation|Safety and Efficacy of a New Baby-sphincterotome for Cannulation and Pre-cut in Failed Selective Wire-guided Bile Duct Access||Ruhr University of Bochum|No|Completed|June 2000|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1886|||Both|18 Years|N/A|No|Probability Sample|Use of the baby-sphincterotome for cannulation and pre-cut in cases of failed selective        wire-guided bile duct access.|December 2011|December 14, 2011|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01493076||94019|
NCT01493089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEG-01/2010 (GERD)|Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease|A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated With GERD as on Demand Therapy||Norgine|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|18 Years|75 Years|No|||August 2013|August 12, 2013|December 13, 2011||No||No|December 7, 2012|https://clinicaltrials.gov/show/NCT01493089||94018|
NCT01523145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHCopenHeartRFA|CopenHeartRFA - Integrated Rehabilitation of Patients Treated for Atrial Fibrillation With Radio Frequency Ablation|CopenHeartRFA - A Randomized Clinical Trial Investigating the Effect and Meaning of Integrated Rehabilitation Versus Usual Follow-up of Patients Treated for Atrial Fibrillation With Radio Frequency Ablation||Rigshospitalet, Denmark|Yes|Active, not recruiting|December 2011|January 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523145||91721|
NCT01493258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00040442|Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination|Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination|iADAPT|Johns Hopkins University|No|Active, not recruiting|August 2010|April 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|360|||Both|65 Years|N/A|No|||April 2015|April 1, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01493258||94005|
NCT01492920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0257|Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy|A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer||Gynecologic Oncology Group||Withdrawn|April 2012|||May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|N/A|No|||December 2014|December 29, 2014|December 14, 2011|Yes|Yes|Withdrawn|No||https://clinicaltrials.gov/show/NCT01492920||94031|
NCT01492933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120032|Measuring Effects of Alcohol on Brain Chemistry|Measuring Effects of Acute Ethanol on Human Brain Metabolites Using Magnetic Resonance Spectroscopy||National Institutes of Health Clinical Center (CC)||Terminated|November 2011|February 2015||||Phase 1|Observational|Time Perspective: Cross-Sectional|||Actual|34|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 25, 2015|December 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492933||94030|
NCT01493245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018745|A Study of JNS020QD in Patients With Chronic Pain|A Phase 3 Study of JNS020QD in Patients With Chronic Pain||Janssen Pharmaceutical K.K.|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|20 Years|N/A|No|||March 2014|March 21, 2014|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01493245||94006|
NCT01493570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.3|Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers|Randomised, Double-blind, Placebo-controlled Parallel-group Proof of Mechanism Study to Assess the Pharmacokinetics and to Evaluate the Pharmacodynamic Effect of Different Single Oral Doses of BI 409306 in Healthy Male Volunteers||Boehringer Ingelheim||Completed|December 2011|||February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|20|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|December 12, 2011||||No||https://clinicaltrials.gov/show/NCT01493570||93981|
NCT01494311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1046|Rapydan Topical Anaesthesia for Arterial Cannulation|Lidocaine/Tetracaine Patch (Rapydan) for Topical Anaesthesia Before Arterial Access: A Double-blind, Randomized Trial||Medical University of Vienna|Yes|Completed|March 2011|October 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|90|||Both|18 Years|90 Years|No|||March 2013|March 15, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494311||93925|
NCT01494623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098 / 2006|The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory|Treating Working Memory Deficits in Patients With Schizophrenia Using Repetitive Transcranial Magnetic Stimulation (rTMS)||Centre for Addiction and Mental Health|No|Completed|May 2006|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01494623||93901|
NCT01494896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tyvaso COPD|Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching|An Open-Label Study to Explore the Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching When Used for Treatment of Group 1 Pulmonary Arterial Hypertension in Patients With Concomitant Chronic Obstructive Pulmonary Disease (COPD)||University of Florida|No|Terminated|November 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects initiated on inhaled treprostinil sodium for treatment of PAH who have        concomitant COPD.|August 2013|May 6, 2015|December 15, 2011||No|due to slow enrollment. United Therapeutics and Dr. Bajwa MD decided to terminate study|No||https://clinicaltrials.gov/show/NCT01494896||93880|
NCT01494649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z7871335|Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity|A Pilot Clinical Study Investigating the Efficacy of a Toothpaste in Providing Immediate and Short Term Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|September 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|March 21, 2013|September 1, 2011|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01494649||93899|
NCT01495481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11070129|Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia|Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia||University of Pittsburgh|Yes|Recruiting|January 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|30 Years|No|||February 2012|February 6, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495481||93836|
NCT01495494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3560692|A Multiple Use Tolerability Study of a Breathe Right Nasal Strip Prototype|A Multiple Use Tolerability Study of a Breathe Right Nasal Strip Prototype||GlaxoSmithKline|No|Completed|November 2009|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|November 20, 2014|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495494||93835|
NCT01491633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-142|Dasatinib in Advanced Squamous Cell Lung Cancer|Phase II Trial of Dasatinib in Advanced (Stage IIIB/IV) Squamous Cell Lung Cancer||Dana-Farber Cancer Institute|Yes|Terminated|September 2011|May 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2014|June 14, 2014|October 5, 2011|Yes|Yes|Safety issues/concerns per DF/HCC PI|No|May 14, 2014|https://clinicaltrials.gov/show/NCT01491633||94130|Due to the toxicity of the study agent no subjects were evaluable for response
NCT01491880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH090149|Treatment Study for Rural Latino Youth With Anxiety|Feasible Delivery of CBT for Rural Latino Youth With Anxiety||University of California, San Diego|Yes|Recruiting|November 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|13 Years|No|||January 2012|January 17, 2012|July 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01491880||94111|
NCT01491893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031169|PVSRIPO for Recurrent Glioblastoma (GBM)|Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant Glioma|PVSRIPO|Duke University|Yes|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|December 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491893||94110|
NCT01492179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111212|Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management.|A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study.|PoPuLAR|Örebro University, Sweden|Yes|Completed|November 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Female|30 Years|75 Years|No|||May 2014|May 25, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492179||94088|
NCT01503190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0583.cc|The Immune System's Response to Young Women's Breast Cancer|A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction||University of Colorado, Denver|No|Recruiting|September 2011|July 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|800|Samples With DNA|Tissue, Blood and urine may be collected from subjects who were recently diagnosed. Subjects      who were diagnosed after treatment begins or has ended will only be eligible for tissue      donation section of study|Female|18 Years|49 Years|No|Non-Probability Sample|Women who are between the ages of 18 and 49 who have been diagnosed with breast cancer.        Need not be in active treatment.|March 2016|March 1, 2016|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01503190||93246|
NCT01492803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 097|Trial of Probiotics to Lower Microbial Translocation and Immune Activation in HIV-Infected Adolescents|A Randomized Placebo-Controlled Trial of Probiotics to Lower Microbial Translocation and Immune Activation in HIV-Infected Adolescents||Westat|Yes|Withdrawn|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|13 Years|24 Years|No|||February 2016|February 26, 2016|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01492803||94040|
NCT01493102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-09-007|Discontinuation Order of Vasopressors in Septic Shock|Incidence of Hypotension Based on the Discontinuation Order of Vasopressors in the Management of Septic Shock|DOVSS|Samsung Medical Center|No|Terminated|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|78|||Both|20 Years|N/A|No|||January 2015|January 28, 2015|December 12, 2011||No|Futility by interim analysis|No||https://clinicaltrials.gov/show/NCT01493102||94017|
NCT01493674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP 2448|Folic Acid Supplementation in Eating Disorder|Folic Acid Supplementation for Improving Homocysteine Levels, Cognitive and Depressive Status in Eating Disorders||Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2011|December 14, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493674||93973|
NCT01493284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105|Assessment Of The St. Jude Medical Portico™ Transcatheter Aortic Valve Implant (TAVI) and SJM TAVI Transfemoral Delivery System|Assessment Of The St. Jude Medical Portico™ Transcatheter Aortic Valve Implant (TAVI) And The SJM TAVI Transfemoral Delivery System (Portico TF EU)|Portico TF EU|St. Jude Medical|Yes|Active, not recruiting|December 2011|December 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have severe, symptomatic aortic stenosis|August 2015|March 9, 2016|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01493284||94003|
NCT01493037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 2011-01|PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention|Pressure Controlled Intermittent Coronary Sinus Occlusion in Patients With ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: Safety and Feasibility Study|pRAMSES|Miracor Medical Systems|Yes|Completed|December 2011|||March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493037||94022|
NCT01492946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreopBIA|Impaired Preoperative Nutritional Status as a Risk Factor for Postoperative Clinical Outcome|Impaired Preoperative Nutritional Status as a Risk Factor for Postoperative Clinical Outcome (PreopBIA)|PreopBIA|Charite University, Berlin, Germany|No|Completed|May 2010|July 2012|Actual|November 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|387|||Both|18 Years|N/A|No|Probability Sample|Elective surgical patients|July 2012|July 5, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01492946||94029|
NCT01492959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNOLET-1888|Observational Study With InnoLet® in Daily Clinical Practice|A Prospective, Open, Uncontrolled, Observational Study With Innolet in Daily Clinical Situations According to the Product Labelling, Without Any Study Specific Investigations||Novo Nordisk A/S|No|Completed|March 2004|March 2005|Actual|March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1030|||Both|N/A|N/A|No|Probability Sample|Korean patients with diabetes mellitus in need of insulin treatment|April 2012|April 11, 2012|December 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492959||94028|
NCT01492972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU003-10|Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer|Phase III Study of Mildly Hypo-fractionated Image Guided Proton Beam Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate||Proton Collaborative Group|Yes|Recruiting|January 2012|December 2021|Anticipated|December 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Male|18 Years|N/A|No|||December 2015|December 7, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01492972||94027|
NCT01493843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27912|Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer|A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer||Genentech, Inc.||Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|494|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493843||93960|
NCT01494090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 10-094 STAFF|Statin in Hip Fracture|Efficacy and Safety of Rosuvastatin in the Prevention of Arterial and Venous Vascular Events and Mortality After Hip Fracture: A Multicenter Randomised, Double-blinded, Placebo Controlled Trial.|STAFF|University Hospital, Brest|Yes|Terminated|August 2011|September 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|60 Years|N/A|No|||September 2012|September 19, 2012|December 15, 2011||No|Decision of the Steering Committee. Recruitment more difficult and slower than expected.|No||https://clinicaltrials.gov/show/NCT01494090||93941|
NCT01494324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-122|Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome|Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome||Memorial Sloan Kettering Cancer Center||Recruiting|October 2009|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|56|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01494324||93924|
NCT01494337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-171-SDR|Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP)|Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH||Royal Victoria Hospital, Canada|No|Completed|January 2012|April 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|108|||Male|N/A|N/A|No|||August 2014|August 25, 2014|December 5, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494337||93923|
NCT01494636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115419|The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects|A Two Part Study to Investigate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2339345 in Healthy Subjects. Part A: an Open Label, Dose Escalating, Rinse, Gargle and Spit Study. Part B: a Randomised, Double-blind, Placebo Controlled, Inhaled Dose Escalating Study Using Nebulised Lidocaine for Blinding Purposes.|FTIH|GlaxoSmithKline||Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01494636||93900|
NCT01494662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-344|HKI-272 for HER2-Positive Breast Cancer and Brain Metastases|A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases||Dana-Farber Cancer Institute|Yes|Recruiting|February 2012|September 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494662||93898|
NCT01495208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVER STUDY|Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment|This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg||Vitreous -Retina- Macula Consultants of New York|No|Completed|December 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|50 Years|N/A|No|||August 2013|August 1, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495208||93856|
NCT01491282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-071|Study of the Effect of Vagus Nerve Stimulation on Human Brown Adipose Tissue Activity|Brown Adipose Tissue After Vagus Nerve Stimulation||Maastricht University|No|Recruiting|January 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|65 Years|No|Non-Probability Sample|Postoperative patients treated with vagus nerve stimulation for refractory epilepsy|December 2011|December 11, 2011|November 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01491282||94157|
NCT01491620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-XPC01|Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte|A Single-Center Prospective, Open-Label Study of the Excel V 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte||Cutera Inc.|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|35 Years|65 Years|No|||August 2013|August 5, 2013|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01491620||94131|
NCT01491646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS 2512|Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension|Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension||National Jewish Health|No|Completed|November 2010|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|25|Samples Without DNA|plasma, serum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|specialist clinics community|April 2015|April 14, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491646||94129|
NCT01491659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4141002|A Study to Evaluate the Effect and Safety of Idoform Plus on Bowel Side Effects in Healthy Subjects Treated With Amoxicillin/ Clavulanate|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect and Safety of Idoform Plus on Bowel Side Effects in Healthy Subjects Treated With Amoxicillin/ Clavulanate||Pfizer|No|Withdrawn|January 2013|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01491659||94128|
NCT01493128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABJ01|Ultrastructure of Atrial Myocytes in Patients in Sinus Rhythm and With Atrial Fibrillation|Ultrastructure of Sarcolemma, Immunofluorescence of Calcium Handling Proteins and Mitochondrial Function in Atrial Myocytes of Patients in Sinus Rhythm and With Atrial Fibrillation||Norwegian University of Science and Technology|No|Completed|April 2010|July 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|45|Samples Without DNA|Myocardial tissue from the right and left atrial appendage.|Both|50 Years|85 Years|No|Non-Probability Sample|selected for open heart surgery in St Olavs Hospital, Trondheim University Hospital,        Norway|July 2013|August 6, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493128||94015|
NCT01493375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20100008|Surgical Field Bacterial Contamination in Primary Total Hip (THA) and Knee (TKA) Arthroplasty|Surgical Field Bacterial Contamination in Primary Hip and Knee Replacement Surgery||Northern Orthopaedic Division, Denmark|Yes|Suspended|June 2010|||December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Patients from Northern Orthopaedic Division, Clinic Frederikshavn.|May 2015|May 27, 2015|December 14, 2011||No|Study principal investigator left the organization|No||https://clinicaltrials.gov/show/NCT01493375||93996|
NCT01493388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3914|To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1|Observational, Cross-sectional and Retrospective Study on Diabetes Mellitus Type 1 in Tunisian Children and Adolescents Under 15 Years||Novo Nordisk A/S|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|402|||Both|N/A|15 Years|No|Non-Probability Sample|Patients will be treated according to routine clinical practice at the discretion of the        treating physician.|April 2014|April 29, 2014|December 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01493388||93995|
NCT01493687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18170|Phase 3 Papulopustular Rosacea Study|A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.||Galderma|Yes|Completed|December 2011|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|683|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|December 14, 2011|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01493687||93972|
NCT01503203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSMJ20112|Physical Virtual Training for Older Women|Physical Virtual Training Effectiveness on Nonspecific Chronic Low Back Pain, Body Balance, Functional Autonomy and Mood of Older Women||Universidade Gama Filho|No|Recruiting|November 2011|August 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|39|||Female|65 Years|75 Years|No|||December 2011|December 29, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01503203||93245|
NCT01503216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF 0315668A|Safety and Bioefficacy of Vitamin D2 and Vitamin D3|Safety and Bioefficacy of Vitamin D2 and Vitamin D3: Randomized Trial With Human Volunteers||Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|3||Actual|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 7, 2012|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01503216||93244|
NCT01503424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|379-11|Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Olanzapine Tablets 5 mg With Zyprexa® Tablets 5 mg in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503424||93228|
NCT01503437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-170-OLAN-2006|Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|November 2006|December 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503437||93227|
NCT01503450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-171-OLAN-2006|Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|November 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503450||93226|
NCT01494181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version Nov 14, 2011|Unrecognised Obstructive Sleep Apnea Study|Postoperative Vascular Events in Unrecognised Obstructive Sleep Apnea|OSA|University Health Network, Toronto|No|Recruiting|July 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|400|||Both|45 Years|N/A|No|Non-Probability Sample|Surgical patient|August 2015|August 12, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01494181||93935|
NCT01494194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KQC100140|Study to Evaluate the Potential of Air Structuring Protein to Elicit Allergic Reactions in Mold Sensitized People|Evaluation of the Potential of Air Structuring Protein, a Novel Protein Preparation Derived From Trichoderma Reesei, to Elicit Allergic Reactions in Mold Sensitized People||Unilever SEAC|No|Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|252|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01494194||93934|
NCT01494415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZFH CA11-01|Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer|A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer||First People's Hospital of Hangzhou|Yes|Recruiting|July 2012|June 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|75 Years|No|||December 2015|December 13, 2015|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494415||93917|
NCT01494428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9703|A Pilot Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease||Medtronic Spinal and Biologics|No|Completed|April 1998|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494428||93916|
NCT01494441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9805|Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease|A Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease||Medtronic Spinal and Biologics|No|Completed|May 1999|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494441||93915|
NCT01493271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25466|A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma|An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.||Hoffmann-La Roche||Completed|December 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|21 Years|N/A|No|||March 2016|March 1, 2016|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493271||94004|
NCT01492725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTA1101|Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial|A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection.|EXTEND-IA|Neuroscience Trials Australia|Yes|Terminated|June 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||December 2014|April 20, 2015|November 20, 2011||No|On DSMB advice, trial recruitment has been halted for efficacy. F/U continues|No||https://clinicaltrials.gov/show/NCT01492725||94046|
NCT01493297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETH-FeVZ|Effects of Vitamin A and Carotenoids on Iron Absorption|Effects of Vitamin A and Carotenoids on Iron Absorption||Swiss Federal Institute of Technology|No|Completed|September 2011|July 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|25|||Female|18 Years|52 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01493297||94002|
NCT01493583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG09/033/2B|Central Nervous Processing of Visual Food Stimuli in Severely Obese Subjects|Central Nervous Processing of Visual Food Stimuli in Severely Obese Subjects and After Roux-en Y Gastric Bypass Surgery - a fMRI Study||Cantonal Hospital of St. Gallen|No|Completed|September 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|38|||Female|18 Years|N/A|No|Non-Probability Sample|Severely obese (body mass index; BMI > 35 kg/m2) women and previously severely obese women        who had undergone a Roux-en Y gastric bypass operation were recruited from the        Interdisciplinary Obesity Center, cantonal hospital St. Gallen (Switzerland), and the        adiposity platform of the University of Tübingen.        lean control women were recruited in St. Gallen and in Tübingen|March 2013|March 6, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01493583||93980|
NCT01493596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-115-0001|A Safety, Tolerability and Pharmacokinetic Study of CPP-115|A Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of CPP-115 Solution Administered Orally to Healthy Volunteers||Catalyst Pharmaceuticals, Inc.|Yes|Active, not recruiting|December 2011|July 2012|Anticipated|May 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|48|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|November 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01493596||93979|
NCT01493856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWJ1276002|A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276|A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers||Daewoong Pharmaceutical Co. LTD.|No|Completed|January 2012|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|58|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493856||93959|
NCT01493869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-003|Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects|A Phase I, Open-Label, Parallel-Group, Single-Dose Study to Assess the Pharmacokinetics of XL184 (Cabozantinib) Capsules in Hepatic Impaired Adult Subjects||Exelixis|No|Completed|September 2011|August 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 19, 2014|October 11, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01493869||93958|
NCT01494103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28256-DOTTI|Administration of Donor T Cells With the Caspase-9 Suicide Gene|Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene|DOTTI|Baylor College of Medicine|Yes|Active, not recruiting|November 2011|May 2029|Anticipated|May 2029|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|N/A|N/A|No|||February 2016|February 1, 2016|December 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494103||93940|
NCT01494116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-272|Pediatric Fast Fluid Randomized Controlled Trial|Factors Affecting Pediatric Isotonic Fluid Resuscitation Efficiency: Impact of Syringe Size||McMaster Children's Hospital|No|Completed|October 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Both|N/A|N/A|No|||February 2012|February 26, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01494116||93939|
NCT01494935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005948|"Effect of High Fat and High Glycemic Diets|Effect of High Fat and High Glycemic Diets on Muscle Protein Synthesis in Somali Immigrants and Americans of Northern European Descent||Mayo Clinic||Recruiting|April 2011|August 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01494935||93877|
NCT01495221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOLD STUDY|To Evaluate tHe rOle of Intravitreal Aflibercept Injection (2.0 mg) in the Management of previousLy Treated Patients With Exudative AMD|To Evaluate tHe rOle of Intravitreal Aflibercept Injection (2.0 mg) in the Management of previousLy Treated Patients With Exudative AMD||Vitreous -Retina- Macula Consultants of New York|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|50 Years|N/A|No|||December 2015|December 30, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495221||93855|
NCT01495507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kuj-Germ-1|Validation of Kujala German|Cross-cultural Adaptation and Validation of the German Version of the Kujala Score in Patients With Patellofemoral Instability - a Prospective Multi-centric Study||Medical University Innsbruck||Recruiting|November 2011|||January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|45|||Both|10 Years|70 Years|No|Non-Probability Sample|Patients with patellofemoral instability & scheduled MPFL-reconstruction|April 2015|April 7, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01495507||93834|
NCT01491295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-174-0194|Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients|Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment||Taipei Veterans General Hospital, Taiwan|No|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|N/A|No|||December 2011|November 2, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01491295||94156|
NCT01491308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMAC-11-IM-0449-11-CTIL|Restrictive Versus Liberal Red Cell Transfusion Strategy in Orthopedic-Oncology Patients Undergoing Surgery - a Randomized Controlled Study|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|January 2012|||January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||December 2011|December 12, 2011|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01491308||94155|
NCT01492504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-046|Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial|A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C||Bristol-Myers Squibb|No|Recruiting|February 2012|February 2021|Anticipated|February 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1850|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or        Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C|February 2016|March 11, 2016|November 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492504||94063|
NCT01502735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-10-0003|Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease|A Phase 1 Trial of the Walter Reed Army Institute of Research (WRAIR) Dengue Virus Serotype-1 Purified Inactivated Vaccine (DENV-1 PIV) in Flavivirus Antibody Naïve Adults|DENV-1 PIV|U.S. Army Medical Research and Materiel Command|Yes|Completed|December 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|December 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502735||93281|
NCT01502748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-00311|Endovascular Magnesium Sampling in Acute Stroke|Magnesium Therapy: a Novel Platform for Neuroprotectant Sampling in Acute Stroke||University of Southern California|Yes|Completed|March 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|40 Years|95 Years|No|||February 2013|February 16, 2013|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01502748||93280|
NCT01502969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rotavin-M1-2b|Safety and Immunogenicity Assessment of Rotavin-M1 in Vietnamese Children|A Phase 2b Study of Rotavin-M1 Vaccine in Vietnamese Children|Rotavin-M1|National Institute of Hygiene and Epidemiology, Vietnam|Yes|Completed|May 2010|October 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|799|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2011|December 30, 2011|October 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502969||93263|
NCT01503762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pht-9006|Mirror Therapy and Hand Rehabilitation|Mirror Therapy in Patients With Hand Orthopedic Disorders||Ahvaz Jundishapur University of Medical Sciences|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|65 Years|No|||February 2012|February 27, 2012|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01503762||93202|
NCT01503775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-PMK-0902|TRUfill®'s Line in Intracranial aNeurysm Embolisation|A Prospective, Multicentric Observational Study Evaluating the Long Term Efficacy and Safety of the CODMAN TRUFILL®'s Line of Coils in the Endovascular Treatment of Intracranial Aneurysms|TRULINE|Codman & Shurtleff|Yes|Completed|December 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|171|||Both|18 Years|N/A|No|Non-Probability Sample|Routine clinical practice|February 2016|February 9, 2016|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01503775||93201|
NCT01503463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR2016|Remote Monitoring of Patients With CHF in Central Greece|Renewing Health RCT for the Evaluation of Remote Monitoring of Patients With Congestive Heart Failure (CHF) in Central Greece|RHCluster7GR|Regional Health Authority of Sterea & Thessaly|Yes|Completed|March 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|65 Years|N/A|No|||March 2015|March 19, 2015|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503463||93225|
NCT01503736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNC00301|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease||Panion & BF Biotech Inc.|Yes|Completed|June 2010|||June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|183|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503736||93204|
NCT01504035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORG 001|Analgetic Effectiveness of a Lidocaine Loaded Hemostatic, Bioresorbable Putty|Effectiveness of the Addition of Lidocaine to a Hemostatic, Bioresorbable Putty in the Treatment of Iliac Crest Donor Site Pain||University Hospital, Basel, Switzerland|Yes|Completed|May 2008|November 2008|Actual|July 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|71 Years|No|||February 2012|February 8, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01504035||93181|
NCT01504048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTS-02|Usefulness of Chromoendoscopy in Diagnosing Microscopic Colitis|Prospective Study on the Usefulness of Chromoendoscopy in Detecting Microscopic Colitis in Patients Undergoing Colonoscopy Due to Chronic Watery Diarrhoea||Karolinska University Hospital|No|Recruiting|June 2009|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01504048||93180|
NCT01493024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-002|Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia|Multicenter, Prospective, Randomized, Placebo-Controlled, Double-blind Dose Escalating Study of Safety, Tolerability and Pharmacodynamics of Zirconium Silicate in Chronic Kidney Disease and Moderate Kidney Dysfunction With Mild Hyperkalemia||ZS Pharma, Inc.|Yes|Completed|November 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|90|||Both|18 Years|N/A|No|||June 2013|June 5, 2013|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493024||94023|
NCT01493050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0973|The Effects of Sevelamer Carbonate on Diabetic Nephropathy|Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela®) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy||Icahn School of Medicine at Mount Sinai|Yes|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493050||94021|
NCT01493609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/C/PMLD/03|A Clinical Trial of a New Computer Based Intervention for Children With Autism.|Computer Learning in Children - the Edinburgh Autism Social-attention Trial.|Click-East|University of Edinburgh|Yes|Completed|February 2012|June 2013|Actual|June 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|15 Months|6 Years|No|||November 2013|November 21, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493609||93978|
NCT01493622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU-2010-PSY|The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia|A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia||Central South University|Yes|Completed|June 2010|December 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01493622||93977|
NCT01493882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100710|Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, 2-Part Study of JNJ-39758979 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Withdrawn|March 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|75 Years|No|||May 2012|May 10, 2012|December 15, 2011|Yes|Yes|Study was withdrawn due to 2 cases of agranulocytosis in a different clinical trial with this    same drug.|No||https://clinicaltrials.gov/show/NCT01493882||93957|
NCT01494675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT|Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU|Clinical Impact of Procalcitonin to Shorten Antimicrobial Therapy in Septic Patients With Proven Bacterial Infection in an Intensive Care Setting||Hospital Israelita Albert Einstein|Yes|Completed|March 2008|February 2010|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|1||Actual|81|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|December 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494675||93897|
NCT01495247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235B2101|Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer|A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer||Novartis||Completed|January 2012|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||July 2014|July 22, 2014|September 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495247||93853|
NCT01495520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|671/2011/D|Ranolazine for Improving Symptoms of Palpitations|Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial|RYPPLE|University of Roma La Sapienza|No|Not yet recruiting|January 2014|December 2016|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||March 2013|March 6, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495520||93833|
NCT01492491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-01|Collaborative Research on HFR High Flux|Collaborative Study on Outcome of Antioxidant Vitamines, Microinflammation Parameters and Middle-high Toxins in ESRD Patients Treated With Online HDF, HFR and SUPRA-HFR|SALATO|Azienda Sanitaria Locale di Cagliari|Yes|Completed|September 2011|March 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||July 2015|July 24, 2015|December 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01492491||94064|
NCT01502449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D10-I-AR-J5-786|Delivery of Self Training and Education for Stressful Situations-Telephone Version|Randomized Trial of Telephonic Psychotherapy and Case Management for Combat-Related Posttraumatic Stress Disorder|DESTRESS-T|Uniformed Services University of the Health Sciences|Yes|Not yet recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|91|||Both|18 Years|65 Years|No|||January 2012|January 11, 2012|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01502449||93303|
NCT01502761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-00339|Intra-arterial Magnesium Administration for Acute Stroke|Intra-arterial Magnesium Therapy: A Novel Platorm for Neuroprotectant Delivery in Acute Stroke||University of Southern California|Yes|Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|21 Years|95 Years|No|||December 2015|December 2, 2015|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502761||93279|
NCT01502982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NLG-LBC-04|Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)|CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase II Study|CRY-04|Nordic Lymphoma Group|No|Completed|November 2004|May 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|18 Years|64 Years|No|||September 2014|September 27, 2014|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502982||93262|
NCT01504087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011022RC|ICU Venous Thromboembolism Incidence Study in a Chinese Population|Using Inflammatory Markers to Predict the Development and Outcome of Venous Thromboembolism in an Intensive Care Unit||National Taiwan University Hospital|No|Recruiting|May 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|All patients admitted to ICU with age over 18 y/o are eligible|July 2011|January 4, 2012|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01504087||93177|
NCT01503788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMS-12-HS-0101-11-TLV-CTIL|Bedside Sedation for the Prevention of Post Dural Puncture Headache|Periprocedural Sedation for the Prevention of Post Dural Puncture Headache||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|February 2012|February 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 3, 2012|January 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01503788||93200|
NCT01503749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBMC|Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis|The Role of Peripheral Mononuclear Cells for Treatment of Advanced Liver Cirrhosis||Seoul National University Hospital|No|Completed|January 2012|August 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|20 Years|79 Years|No|||October 2014|December 17, 2014|January 2, 2012||No||No|November 27, 2014|https://clinicaltrials.gov/show/NCT01503749||93203|
NCT01504061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS90025-4007-0|Mederma to Reduce Appearance of Post Surgical Scars|The Comparison of Mederma® N&I to Mederma® Ultra Gel to Reduce the Appearance of Post Surgical Scars||Merz Pharmaceuticals, LLC|No|Completed|January 2012|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|2||Actual|20|||Both|18 Years|70 Years|No|||October 2013|October 23, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01504061||93179|
NCT01504074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071/2009|Morphological and Functional Evaluation of Irvine-Gass Syndrome|||Medical University of Vienna||Completed|November 2011|||July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|100 Years|No|Probability Sample|30 patients suffering on CME secondary to cataract surgery|September 2015|September 23, 2015|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01504074||93178|
NCT01492738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUHS H1011|The Effect of Acupuncture on Anxiety and Working Memory|The Effect of Acupuncture on Anxiety and Working Memory||National University of Health Sciences|Yes|Completed|February 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01492738||94045|
NCT01492751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CaProst 2002|Effectiveness of Localized Prostate Cancer Treatments|Effectiveness of Three Primary Treatments for Localized Prostate Cancer: Radical Prostatectomy, External-beam Radiotherapy, and Prostate Brachytherapy|E-PROSTCaT|Fundacion IMIM|No|Active, not recruiting|April 2003|December 2017|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Male|N/A|N/A|No|Non-Probability Sample|Patients with clinically localized prostate cancer.|February 2016|February 25, 2016|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01492751||94044|
NCT01493908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1727-HMO-CTIL|The Effect of Marketing Variable on Effect of Active Drugs|The Effect of Price and Marketing Variable on the Pain Controlling Effect of Active Drugs in a Clinical Trial.||Hadassah Medical Organization|No|Not yet recruiting|January 2012|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|220|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 15, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493908||93955|
NCT01493310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0546|Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer|A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer||University of Chicago|No|Active, not recruiting|November 2011|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|December 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01493310||94001|
NCT01493895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|becure-CTIL-HMO|Study Assessing Safety and Efficacy of B-cure Laser Treating Diabetic Chronic Wounds|||Hadassah Medical Organization|No|Not yet recruiting||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||||||Both|21 Years|75 Years|No|||March 2013|March 21, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493895||93956|
NCT01494142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADRN-02|Registry for the Atopic Dermatitis Research Network|Registry for the Atopic Dermatitis Research Network (ADRN-02)||National Institute of Allergy and Infectious Diseases (NIAID)|No|Recruiting|August 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|2600|Samples With DNA|Whole blood DNA, whole blood RNA,blood cards, blood clots, serum, skin swabs, and skin swab      isolates will be retained.|Both|8 Months|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|A minimum of 1100 ADEH-Staph+ participants and a minimum of 1100 ADEH-Staph- participants        3-80 years of age will be enrolled. In addition, ADEH+, ADEV+, and Non-atopic participants        8 months to 80 years of age will be enrolled.        It is unknown whether Staph colonization status will change as younger participants get        older. For this reason, the lower age limit for inclusion of ADEH- participants is 3 years        rather than 8 months to ensure that characterization of their Staph+ vs. Staph- state is        more accurate|January 2016|January 27, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01494142||93938|
NCT01494376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-125|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2011|||||N/A|N/A|N/A||||||||||||||March 8, 2012|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494376||93920|
NCT01494350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-10-0006; A-16898.3|WR 279,396 Open Label Treatment Protocol in Tunisia|Open-label Treatment of Non-complicated, Non-severe, Cutaneous Leishmaniasis in Tunisia With WR 279,396 (Paromomycin + Gentamicin Topical Cream) )||U.S. Army Medical Research and Materiel Command|No|Terminated|December 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|November 30, 2011|No|Yes|This study was closed prematurely due study team travel restrictions.|No|December 9, 2014|https://clinicaltrials.gov/show/NCT01494350||93922|This study was closed prematurely due study team and travel restrictions but not due to any safety issues with the study subjects. Only a total of 50 of the 110 planned subjects were enrolled in the study.
NCT01494948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221035-2|Innate Immunity and the Allergic Response|Innate Immunity and the Allergic Response||Medical College of Wisconsin|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 7, 2014|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494948||93876|
NCT01495234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOC#1187b BCP -Mexico|Pilot Study of rhBMP-2/BCP in Patients With Spinal Degeneration With Instability Requiring Surgical Fusion|A Pilot Investigation of Recombinant Human Bone Morphogenetic Protein- 2/Biphasic Calcium Phosphate in Patients With Spinal Degeneration With Instability Requiring Surgical Fusion||Medtronic Spinal and Biologics|No|Completed|October 1996|June 2001|Actual|June 2001|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495234||93854|
NCT01495260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XAMNANTIOXAP2010|A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants|A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E||Onofre, Aurora Pujol, M.D.|No|Completed|September 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|64 Years|No|||May 2012|March 19, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01495260||93852|
NCT01492192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-TSC-663|RGD-PET-CT in Cancer Angiogenesis|Prospective Study of 18F-RGD PET-CT in Assessment of Response to Antiangiogenic Treatment in Patients With Cancer and Comparison With Perfusion CT||Oxford University Hospitals NHS Trust|Yes|Recruiting|May 2013|February 2017|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492192||94087|
NCT01492205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPEN3-1887|NovoLet® Acceptance Study Within the Hospital Practise in Indonesia|A Doctor and Nurse Survey on Using NovoLet® Within the Hospital Practice in Indonesia||Novo Nordisk A/S|No|Completed|September 2005|June 2006|Actual|June 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|203|||Both|18 Years|N/A|No|Probability Sample|Individuals with either type 1 or type 2 diabetes, who were likely to be hospitalised and        require insulin therapy in Indonesia|April 2012|April 11, 2012|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492205||94086|
NCT01502150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR05-0208|Data Collection of Normal Tissue Toxicity for Proton Therapy for Pediatrics|Data Collection of Normal Tissue Toxicity for Proton Therapy for Pediatrics||M.D. Anderson Cancer Center|No|Recruiting|June 2005|||June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric cancer patients receiving proton radiation therapy at MD Anderson Cancer Center        in Houston, Texas|March 2016|March 9, 2016|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01502150||93326|
NCT01502462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Severe_Isol_TR|Prospective Registry of Patients With Isolated Severe Tricuspid Regurgitation|||Asan Medical Center|No|Recruiting|February 2012|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|16 Years|75 Years|No|Probability Sample|Prospective registry for patients with severe isolated tricuspid regurgitation (TR)        without significant left-sided valvular or myocardial diseases.        Aim: To evaluate clinical course and prognostic factors of patients with severe isolated        TR|December 2015|December 28, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502462||93302|
NCT01502995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00583|Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease|Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease||Parkinson's Disease Research, Education, and Clinical Center, Philadelphia|No|Completed|June 2003|April 2005|Actual|April 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|N/A|N/A|No|||December 2011|December 30, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01502995||93261|
NCT01503008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-SBCT2DM|Proteus Sustained Behavior Change Study|Proteus Sustained Behavior Change Study||Proteus Digital Health, Inc.|No|Withdrawn|February 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2013|March 1, 2013|December 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503008||93260|
NCT01503229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7639|Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer||University of Washington||Active, not recruiting|December 2012|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 7, 2015|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503229||93243|
NCT01503476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-40|Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance|RD-40 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance||Given Imaging Ltd.|No|Active, not recruiting|February 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 15, 2015|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01503476||93224|
NCT01503489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWITCH.|Risk Factors for AD-Associated Switch to Mania|Risk for Antidepressant-associated Switch From Depression to Hypomania, Mania, or Mixed Episode During the 8 Weeks After the Introduction of an Antidepressant or After Increasing the Dosage of Baseline Antidepressant.||Hospital Clinic of Barcelona|Yes|Completed|October 2005|July 2011|Actual|January 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|221|||Both|18 Years|80 Years|No|Probability Sample|Bipolar I and II disorder patients.|January 2012|January 3, 2012|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01503489||93223|
NCT01503801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FudanU|Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia|Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia in Preterm Infants|NO-BPD|Fudan University|Yes|Completed|May 2011|December 2012|Actual|September 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|N/A|30 Days|No|||January 2013|January 24, 2013|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503801||93199|
NCT01504360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0328-3maph11|Predictive Study of Radiation Induced Sarcoma|Predictive Study of Radiation Induced Sarcoma From the GSF-GETO Data Base.|SARI|Centre Georges Francois Leclerc|No|Recruiting|December 2011|December 2017|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01504360||93156|
NCT01493986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNorthNorway|Minimum Effective Volume of Ropivacaine 7.5 mg/ml for the Lateral and Sagittal Infraclavicular Brachial Plexus Block|Minimum Effective Volume of Ropivacaine 7.5 mg/ml for the Lateral and Sagittal Infraclavicular Brachial Plexus Block When Using Guidance by Both Ultrasound and Nerve Stimulation.||University Hospital of North Norway|No|Completed|February 2012|July 2012|Actual|June 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|65 Years|No|||September 2012|September 9, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493986||93949|
NCT01493648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP 114917|Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation|Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Completed|December 2011|January 2016|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|78|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01493648||93975|
NCT01493661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPE2011SSQueiroz|Chronic Sleep Restriction|Chronic Sleep Restriction: Neurobehavioral and Physiological Responses|CSR|Federal University of São Paulo|Yes|Completed|December 2011|February 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|20|||Male|20 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|Community sample, residents of Sao Paulo city|February 2016|February 2, 2016|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493661||93974|
NCT01493635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/SS/0079|Two Step Versus the Standard Three Step Approach of the WHO Analgesic Ladder for Cancer Pain Relief.|An International, Multicentre, Open Randomised Parallel Group Trial Comparing a Two Step Approach for Cancer Pain Relief With the Standard Three Step Approach of the WHO Analgesic Ladder in Patients With Cancer Pain Requiring Step 2 Analgesia.|TVT|University of Edinburgh|No|Recruiting|November 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|450|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493635||93976|
NCT01494168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8686|Bariatric Surgery, Arterial Stiffness and Target Organ Damage Study (BASTOD)|Longitudinal Assessment of the Effect of Bariatric Surgery on Arterial Function and Blood Pressure Target Organs Damage|BASTOD|University Hospital, Montpellier|Yes|Recruiting|November 2011|November 2014|Anticipated|April 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|90|||Both|18 Years|60 Years|No|Non-Probability Sample|obese patient candidate for bariatric surgery|December 2011|December 15, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01494168||93936|
NCT01494688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27772|A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors|Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors.||Hoffmann-La Roche||Recruiting|December 2011|April 2018|Anticipated|April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|220|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01494688||93896|
NCT01494961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12127 Prenahtest|Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries|The Public Health Impact of Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries|Prenahtest|French National Agency for Research on AIDS and Viral Hepatitis|No|Completed|February 2009|October 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1943|||Female|15 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 16, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494961||93875|
NCT01494974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0236/11|Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma|Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial.||Federal University of São Paulo|No|Recruiting|December 2011|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|10 Years|No|||April 2014|April 6, 2014|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494974||93874|
NCT01491906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0458|Weight Loss Among Adults in Beijing, China|Weight Loss Among Adults in Beijing, China||Duke University|No|Completed|May 2011|June 2014|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|35 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01491906||94109|
NCT01501786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ketamine in sedation|Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions|The Effect of Small-dose Ketamine on Depression of Respiratory and Cardiac Functions Caused by Propofol in Pediatric Cardiac Catheterization||Ibaraki Children's Hospital|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|150|||Both|6 Months|10 Years|No|||July 2013|July 28, 2013|December 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01501786||93354|
NCT01501799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTA/ADAP/BP/2010|A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris|A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) and Both Active Treatments to Topical Gel Placebo (Actavis Mid-Atlantic Llc) in the Treatment of Mild to Severe Acne Vulgaris||Actavis Mid-Atlantic LLC|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|885|||Both|12 Years|40 Years|No|||December 2011|December 28, 2011|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01501799||93353|
NCT01502176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP Proposal # 38233|A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010|A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010||University Hospital Roskilde|No|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1600|||Both|N/A|N/A|No|Non-Probability Sample|All patients admitted and discharged with a diagnose of atrial fibrillation in 2010 at        Roskilde University Hospital|December 2011|December 29, 2011|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502176||93324|
NCT01502189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROJ07/029|Information to Parents of Children With Cancer. An Exploratory Study|Information to Parents of Children With Cancer. An Exploratory Study||Umeå University|No|Completed|February 2012|August 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|8|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01502189||93323|
NCT01502774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.559|Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients|Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients|CIRCUS|Hospices Civils de Lyon|Yes|Active, not recruiting|April 2011|February 2017|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|972|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01502774||93278|
NCT01503021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMTI-SFP-6|Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis|A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis||Rockwell Medical Technologies, Inc.|No|Completed|November 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|718|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|December 29, 2011|Yes|Yes||No|April 3, 2015|https://clinicaltrials.gov/show/NCT01503021||93259|
NCT01503242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2450.00|90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma||Fred Hutchinson Cancer Research Center|Yes|Recruiting|January 2012|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||January 2016|January 15, 2016|December 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01503242||93242|
NCT01503515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCL1131|Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant|A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)||Children's Oncology Group|Yes|Recruiting|March 2013|||September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|590|||Both|3 Months|20 Years|No|||February 2016|February 22, 2016|January 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503515||93221|
NCT01503528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18448|Outcomes After Total Knee Joint Arthroplasty : A Comparative Study Using 3 Different Analgesic Techniques|Outcomes After Total Knee Joint Arthroplasty : A Comparative Study Using 3 Different Analgesic Techniques||Lawson Health Research Institute|No|Not yet recruiting|December 2015|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|750|||Both|30 Years|80 Years|No|||August 2015|August 31, 2015|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01503528||93220|
NCT01503502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHGV678-201|A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia|Phase II Study of Flumatinib Versus Imatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||Jiangsu HengRui Medicine Co., Ltd.|Yes|Active, not recruiting|August 2011|December 2014|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|75 Years|No|||April 2013|April 9, 2013|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01503502||93222|
NCT01503814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03COE-RA02|Simplified Cardiovascular Management Study|Simplified Cardiovascular Management Study: A Cluster-Randomized Trial to Evaluate the Effects of a Simplified Cardiovascular Management Program in Tibet, China and Haryana, India|SimCard|The George Institute for Global Health, China|No|Active, not recruiting|January 2012|January 2015|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2086|||Both|40 Years|N/A|No|||August 2014|August 25, 2014|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503814||93198|
NCT01504126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0800|Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients|Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2012|||May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|January 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01504126||93174|
NCT01504139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110289|The Luteal Phase After GnRHa Trigger - a Proof of Concept Study|The Luteal Phase After GnRHa Trigger - a Proof of Concept Study||Regionshospitalet Viborg, Skive|Yes|Completed|January 2012|August 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|93|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01504139||93173|
NCT01504100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103111RC|Efficiency of Patellar Taping in Treatment of Patellofemoral Pain Syndrome|The Effects of Distal Femoral Rotation on Patellofemoral Pain Syndrome Treated With Patella Taping||National Taiwan University Hospital|Yes|Completed|May 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|39|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|100 patients|October 2013|October 29, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01504100||93176|
NCT01504113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106079RC|The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis|The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis||National Taiwan University Hospital||Recruiting|July 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples Without DNA|Serum and skin scales|Both|20 Years|90 Years|No|Non-Probability Sample|We include patients with psoriasis who will receive and who are currently on target        therapies,such as TNF-α, TH17,and IL-17 antagonists for psoriasis, in a tertiary referral        centre in northern Taiwan (National Taiwan University Hospital (NTUH)) between 2011 and        2015.|July 2011|January 2, 2012|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01504113||93175|
NCT01493999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECS-002|Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity|Prasugrel Versus Adjusted High-dose Clopidogrel to TREAT High On-clopidogrel Platelet Reactivity in Acute Coronary Syndrome Patients After PCI|TREAT-HPR|University of Pecs|Yes|Completed|September 2011|April 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|74 Years|No|||October 2014|October 6, 2014|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493999||93948|
NCT01493349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2-058|Pathophysiology of Diverticular Disease|The Role of Intestinal Microbiota Composition and Intestinal Permeability in the Development of (Complicated) Diverticular Disease.||Maastricht University Medical Center|No|Not yet recruiting|January 2012|October 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||4|Anticipated|210|Samples Without DNA|-  1 bloodsample (14.5mL)        -  9 Colonic mucosal biopsies        -  1 Intestinal washing sample (at least 15mL)        -  1 Fecal sample|Both|50 Years|75 Years|No|Non-Probability Sample|Patients referred to the hospital by their general practitioner|January 2012|January 4, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493349||93998|
NCT01493947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.40173|CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study|Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.|ATTRACT|Galderma R&D|Yes|Completed|April 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|962|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|December 15, 2011||No||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01493947||93952|
NCT01494402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961SC00001|Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects|A Phase I, Open Label, Randomized, Single Center, 2 Way Crossover Bioequivalence Study Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic Acid 81 mg) With a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects||AstraZeneca||Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|77|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 6, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494402||93918|
NCT01494987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0110|Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus||Gilead Sciences|Yes|Completed|January 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|431|||Both|18 Years|75 Years|No|||November 2014|November 5, 2014|December 15, 2011|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01494987||93873|
NCT01494155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-073|Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton or Photon RT Plus Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer||Massachusetts General Hospital|Yes|Recruiting|December 2011|||July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|July 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494155||93937|
NCT01494363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH01|Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer|Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer||Soon Chun Hyang University|No|Recruiting|October 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|75 Years|No|||December 2011|December 14, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01494363||93921|
NCT01495273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026789|Electrically Guided Needle Insertion: Transtracheal Injection|Adaptation of Nerve Stimulation Technology to Aid Transtracheal Needle Insertion and Injection||University of Alberta|No|Not yet recruiting|May 2016|July 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|August 10, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01495273||93851|
NCT01494389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111013-008|The Changes of CD4+T Lymphocyte Subsets in Septic Patients|The Role of CD4+T Lymphocyte Subsets in Cell Immunity in Patients With Sepsis||Chinese PLA General Hospital|Yes|Active, not recruiting|August 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|||||Both|18 Years|N/A|No|Non-Probability Sample|All subjects were selected from among inpatients who were hospitalized between March 2010        and March 2011 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's        Liberation Army (CPLA) General Hospital.|July 2011|December 16, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01494389||93919|
NCT01494701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 396443 - CS1|An Open-label Safety, Tolerability, and Dose-range Finding Study of ISIS SMNRx in Patients With Spinal Muscular Atrophy|An Open-label, Escalating Dose Study to Assess the Safety, Tolerability and Dose-range Finding of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy|SMNRx|Ionis Pharmaceuticals, Inc.|Yes|Completed|November 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|2 Years|14 Years|No|||April 2013|April 23, 2013|December 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494701||93895|
NCT01491672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001L2404|Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma|An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma|RECORD-4|Novartis|No|Completed|November 2011|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|135|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491672||94127|
NCT01501227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 859.8|Ventilator Associated Pneumonia in Taper Guard Versus Normal Tube in ICU Patients|Comparison of the Incidence of Ventilator Associated Pneumonia in Patients Intubated With the Taper Guard Endotracheal Tube Versus a Normal Endotracheal Tube||University of Malaya|Yes|Not yet recruiting|February 2012|December 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2011|December 28, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01501227||93397|
NCT01501552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECGA259268|Trial Testing the Effect of Strategies on Performance of Brief Intervention Programmes for Harmful Alcohol Consumption|Randomised Controlled Trial Testing the Incremental Effect of Strategies That Raise Awareness, Acceptance and Performance of Identification and Brief Intervention Programmes for Harmful Alcohol Consumption in Primary Health Care|ODHIN_RCT|Fundacion Clinic per a la Recerca Biomédica|No|Enrolling by invitation|January 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|8||Anticipated|120|||Both|N/A|N/A|No|||December 2011|December 27, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01501552||93372|
NCT01501565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP2011/01|Analgesic Efficacy of Ultrasound-guided Transverse-abdominal Plain Blockade in Urological Surgery|Ultrasound-guided Analgesic Transverse Abdominal Plain Blockade in the Multimodal Pain Management for Laparoscopic Urological Surgery. Analgesic Efficacy Assessment.||Fundacio Puigvert|Yes|Completed|December 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|80 Years|No|||November 2012|November 15, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01501565||93371|
NCT01501578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERMOP-004|Pulmonary Fibrosis and Telomerase Mutation Study|Phenotype of Pulmonary Fibrosis Associated With a Mutation of Telomerase||Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|No|Recruiting|December 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|66|Samples With DNA|one blood sample is collected for genetic analysis of telomerase mutation|Both|18 Years|N/A|No|Non-Probability Sample|patients with pulmonary fibrosis with and without telomerase mutation|December 2011|December 27, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01501578||93370|
NCT01502163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/4/11|Efficacy of a Convective Prewarming System in Prevention of Perioperative Hypothermia|Efficacy of a Convective Prewarming System in Prevention of Perioperative Hypothermia||University of Göttingen|No|Completed|October 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|75 Years|No|||March 2012|March 7, 2012|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01502163||93325|
NCT01502475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1086|A Survey of Complementary and Conventional Medicine Use Patterns in the Veteran Population|A Survey of Complementary and Conventional Medicine Use Patterns in the Veteran Population|CACMAS|VA Eastern Colorado Health Care System|No|Completed|November 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|97|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|A range of Veterans eligible to, or seeking care, from a Veterans Affairs healthcare        setting.|July 2012|November 25, 2014|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01502475||93301|
NCT01503034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cancer et grossesse|Pregnant Women With a Breast Cancer Diagnosed Between 2000 and 2014|Study of Tumor Characteristics, Patient Care and Prognosis of Women With Breast Cancer During a Pregnancy Diagnosed Between 2000 and 2014||Centre Oscar Lambret|No|Recruiting|November 2010|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|330|||Female|18 Years|N/A|No|Non-Probability Sample|This study being retrospective, we will include all the subjects that meet our inclusion        criteria over the period analyzed.|May 2015|May 15, 2015|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01503034||93258|
NCT01502813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_48136|Citicoline, Creatine, and Omega-3 Effects in Middle Age Women|||University of Utah|Yes|Completed|February 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|40 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 15, 2015|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01502813||93275|
NCT01503060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000025726|Effectiveness of Parent-Led Interventions in Reducing Infant Hypersensitivity to Pain|Effectiveness of Parent-Led Interventions in Reducing Infant Hypersensitivity to Pain: A Longitudinal Randomized Controlled Trial||The Hospital for Sick Children|No|Recruiting|December 2011|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|352|||Both|2 Months|15 Months|Accepts Healthy Volunteers|||November 2015|November 9, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01503060||93256|
NCT01503255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA020805|A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention|A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention|RAFIKI|Brown University|Yes|Active, not recruiting|July 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|614|||Both|18 Years|100 Years|No|||January 2016|January 29, 2016|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01503255||93241|
NCT01504152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-176|International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center|Survey to Assess International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center||Memorial Sloan Kettering Cancer Center||Completed|December 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|519|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who received HSCT at MSKCC between 2005-2010 and were alive after the first year        after HSCT.|July 2013|July 11, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504152||93172|
NCT01495364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction|A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction.|PreSERVE-AMI|Caladrius Biosciences, Inc.|Yes|Active, not recruiting|December 2011|December 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||November 2014|December 23, 2014|December 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495364||93844|
NCT01503827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZMTG 01-07|Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma|Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma - A Randomised Phase III Trial|WBRTMel|Australia and New Zealand Melanoma Trials Group|Yes|Recruiting|October 2007|June 2021|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01503827||93197|
NCT01500551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921145|Long-Term Safety Study Of CP-690,550 In Patients With Juvenile Idiopathic Arthritis|A Long-term, Open-label Follow-up Study Of Cp-690,550 For Treatment Of Juvenile Idiopathic Arthritis (Jia)||Pfizer|Yes|Recruiting|March 2013|September 2020|Anticipated|September 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|290|||Both|2 Years|17 Years|No|||March 2016|March 2, 2016|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500551||93449|
NCT01500785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCA-2011-1-3|Intracoronary Administration of Levosimendan in Cardiac Surgery Patients|Intracoronary Administration of Levosimendan in Cardiac Surgery Patients||Tampere University Hospital|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||April 2014|April 7, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500785||93431|
NCT01500798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1005|A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes|A Pharmacodynamic Study of Measured Glomerular Filtration Rate Assessed by Tc99m-DTPA in Patients With Chronic Kidney Disease and Type 2 Diabetes||Reata Pharmaceuticals, Inc.||Terminated|January 2012|October 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|December 22, 2011|Yes|Yes|IDMC recommendation for safety concerns|No||https://clinicaltrials.gov/show/NCT01500798||93430|
NCT01494532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111569|A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease|A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease|TANDEM-569|GlaxoSmithKline|No|Completed|April 2012|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|352|||Both|30 Years|N/A|No|||October 2015|November 2, 2015|December 1, 2011|Yes|Yes||No|July 13, 2015|https://clinicaltrials.gov/show/NCT01494532||93908|
NCT01494545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-347-C-016|Performance Evaluation of DAILIES® TOTAL1™ in First Time Contact Lens Wearers|Performance Evaluation of DAILIES® TOTAL1™ in First Time Contact Lens Wearers||Alcon Research|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|44 Years|No|||July 2013|July 12, 2013|December 15, 2011|No|Yes||No|May 1, 2013|https://clinicaltrials.gov/show/NCT01494545||93907|
NCT01493960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSUC-01/10|The Efficacy and Safety of Kappaproct in Chronic Active Treatment Refractory Ulcerative Colitis Patients|A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Kappaproct as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients|COLLECT|InDex Pharmaceuticals|Yes|Completed|December 2011|March 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01493960||93951|
NCT01504321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Human Neuro -PCOS|Polycystic Ovary Syndrome - Improving Outcomes|Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes||Baker IDI Heart and Diabetes Institute||Completed|May 2012|December 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01504321||93159|
NCT01493921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESRTAKA|Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment|A Randomized, Double-Blind, Parallel, Vehicle-Controlled Phase III Trial to Assess the Efficacy and Safety of Topical SR-T100 Gel in the Treatment of Patients With Actinic Keratosis||G&E Herbal Biotechnology Co., LTD|No|Completed|October 2011|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|20 Years|N/A|No|||February 2016|February 17, 2016|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493921||93954|
NCT01493934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C09-07|Development of a Fast Measurement Technique of Insulin Resistance in Human|Development of a Fast Measurement Technique of Insulin Resistance in Human, With 123-6-deoxy-6 Iodo-D-glucose, a New Tracer of Glucose Transport|GLUCIMAG|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|April 2010|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|12|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 28, 2010||No||No||https://clinicaltrials.gov/show/NCT01493934||93953|
NCT01495286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114283|Safety of Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) in Infants|Is the Use of Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) During a Routine Heelstick Safe in Infants?||University of Arkansas|Yes|Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|3 Days|No|||October 2012|October 18, 2012|December 9, 2011|No|Yes||No|September 17, 2012|https://clinicaltrials.gov/show/NCT01495286||93850|This was a small pilot study to determine safety of a TENS unit to deliver NESAP to newborn infants during routine heel sticks. The purpose was not to determine efficacy of NESAP to relieve pain during heel sticks. A large clinical trial will follow.
NCT01495533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM-DCA-01|Paclitaxel-coated or Uncoated AngioSculpt Scoring Balloon Catheter|Treatment of Coronary In-stent Restenosis by a Paclitaxel Coated AngioSculpt Scoring Balloon - a First-in-man Pilot Study||University Hospital, Saarland|Yes|Active, not recruiting|December 2011|July 2014|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01495533||93832|
NCT01491321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2011-006|Bee Venom Acupuncture for the Treatment of Chronic Low Back Pain|Clinical Trial to Evaluate the Efficacy of Bee Venom Acupuncture on Chronic Low Back Pain||Kyunghee University Medical Center||Recruiting|April 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||March 2012|March 20, 2012|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01491321||94154|
NCT01501240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-2011-0797|Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver|Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver: Prospective Pathologic Correlation With Explanted Liver|PriMPa|Asan Medical Center|No|Withdrawn|January 2012|August 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|20 Years|80 Years|No|Probability Sample|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1        month|January 2014|January 26, 2014|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501240||93396|
NCT01502202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-581|Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers|A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers||National Cancer Center, Korea|No|Recruiting|March 2012|February 2015|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||June 2012|June 19, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01502202||93322|
NCT01502501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-CHF-001|Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Non-Ischemic Congestive Heart Failure Patients||Ageless Regenerative Institute|No|Recruiting|May 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||October 2013|October 28, 2013|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01502501||93299|
NCT01502787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bystolic MD19|Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients|Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients||University of Texas Southwestern Medical Center|Yes|Completed|April 2009|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|46|||Both|18 Years|65 Years|No|||December 2014|December 29, 2014|November 1, 2011|Yes|Yes||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01502787||93277|
NCT01503047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULP-2297|Conjugated Linoleic Acid (1:1 Isomer Mixture) Intake in Overweight People|Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tonalin(R)Intake in Overweight People|CLA|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||Completed|March 2008|||March 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|30 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 2, 2012|December 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01503047||93257|
NCT01503840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT-66/11|Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis|Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||Completed|December 2011|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|20|||Both|18 Years|70 Years|No|||April 2014|April 20, 2014|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01503840||93196|
NCT01491529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2223|Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease||Novartis||Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|154|||Both|30 Years|80 Years|No|||January 2014|January 17, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491529||94138|
NCT01491542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-11|INFUSE® Bone Graft and MASTERGRAFT® Granules With CD HORIZON® for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease - Pilot Study|A Pilot Prospective Randomized Clinical Investigation of INFUSE® Bone Graft and MASTERGRAFT® Granules With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease||Medtronic Spinal and Biologics|Yes|Completed|April 2003|March 2007|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491542||94137|
NCT01504399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11BN093|Rhinological Outcomes in Endonasal Pituitary Surgery|Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study||St. Joseph's Hospital and Medical Center, Phoenix|No|Active, not recruiting|October 2011|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with pituitary lesions referred to our investigators for surgical management by        either microscopic or endoscopic transspenoidal surgical resection.|January 2016|January 27, 2016|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504399||93153|
NCT01504412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS5565-A-J202|Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuorpathy|An Asian, Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Pregabalin-controlled, Dose-finding Study of DS-5565 in Patients With Pain Associated With Diabetic Peripheral Neuropathy||Daiichi Sankyo Inc.||Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|450|||Both|20 Years|N/A|No|||December 2013|December 11, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504412||93152|
NCT01491763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL Ph-2008|Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE|||PETHEMA Foundation|Yes|Recruiting|January 2008|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|N/A|55 Years|No|||September 2015|January 16, 2016|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491763||94120|
NCT01492023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS1209|The Effects of Attention Retraining in MS|The Effects of Attention Retraining on Cognitive Performance, QoL and Perceived Cognitive Impairment in MS - a Single Blind, Randomized, Controlled Study|MSattention|Finnish MS Society|No|Completed|November 2010|May 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|97|None Retained|A randomised, controlled, single-blind study|Both|18 Years|58 Years|No|Non-Probability Sample|Patients with MS are collected from community by informing about the study via information        letters send to the members of local MS Associations|March 2013|March 8, 2013|December 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01492023||94100|
NCT01494558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006BAI02A02[1]-03|Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer|Phase 3 Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy in Patients With Unresectable Locally Advanced, Stage III Non-Small Cell Lung Cancer||Chinese Academy of Medical Sciences|Yes|Completed|May 2007|August 2011|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||December 2011|December 16, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01494558||93906|
NCT01504334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAWIN-001|Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for the Safety and Efficacy of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)||Beijing Kawin Technology Share-Holding Co., Ltd.|Yes|Recruiting|January 2012|March 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||February 2012|February 5, 2012|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01504334||93158|
NCT01494714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018670|A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants|A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Subjects||Janssen Pharmaceutical K.K.|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|30|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01494714||93894|
NCT01494727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ_AMV_101|Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volunteers||CJ HealthCare Corporation|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 29, 2012|December 15, 2011||||No||https://clinicaltrials.gov/show/NCT01494727||93893|
NCT01494740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIBP-2009-1|Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants|Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants||Shanghai Institute Of Biological Products|Yes|Completed|December 2009|January 2010|Actual|January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|312|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||October 2009|December 16, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494740||93892|
NCT01495000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114161|A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab|A Six-Month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Indian Postmenopausal Women With Osteoporosis||GlaxoSmithKline|No|Completed|January 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|250|||Female|55 Years|75 Years|No|||December 2013|January 9, 2014|December 15, 2011||No||No|September 12, 2013|https://clinicaltrials.gov/show/NCT01495000||93872|
NCT01495013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115317|A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus|Study ATG115317, a Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|December 2011|September 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|427|||Both|18 Years|N/A|No|||January 2014|March 6, 2014|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495013||93871|
NCT01500707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08235|Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)|A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease||Merck Sharp & Dohme Corp.|No|Withdrawn|January 2013|July 2013|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|30 Years|85 Years|No|||January 2015|January 7, 2015|December 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01500707||93437|
NCT01500720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD12166|Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer|Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy||Sanofi|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|179|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|December 22, 2011|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01500720||93436|
NCT01500681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007339|Maintenance Plasma Exchange for Neuromyelitis Optica|A Prospective Observational Study of Maintenance Plasma Exchange (PLEX) for Neuromyelitis Optica Spectrum Disorders (MultiPLEX Study)|MultiPLEX|Mayo Clinic|No|Active, not recruiting|June 2012|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|14|||Both|18 Years|N/A|No|Non-Probability Sample|Neuromyelitis optica/CNS demyelinating disease specialty clinics|March 2016|March 14, 2016|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01500681||93439|
NCT01500694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD503-318|Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe|A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316||Shire||Completed|March 2012|October 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|249|||Both|6 Years|17 Years|No|||November 2015|November 11, 2015|December 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01500694||93438|
NCT01500967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manual Therapy for Cervicalgia|Shi-style Cervical Manipulations for Cervical Radiculopathy|Shi-style Cervical Manipulations for Cervical Radiculopathy-A Randomized Single Blinded Controlled Trial||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|December 2011|May 2014|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|648|||Both|18 Years|65 Years|No|||January 2012|January 24, 2012|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01500967||93417|
NCT01500980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC-003|Malaria Challenge in Healthy Volunteers|Infection-Treatment-Vaccination for Plasmodium Falciparum|ITV|Seattle Biomedical Research Institute|Yes|Completed|December 2011|November 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|5||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|December 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01500980||93416|
NCT01501851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|placenta and lowbirth weight|Prediction of Low Birth Weight Infants Using Ultrasound Measurement of Placental Diameter and Thickness|Prediction of Low Birth Weight Infants Using Ultrasound Measurement of Placental Diameter and Thickness||Ain Shams Maternity Hospital|Yes|Recruiting|April 2010|May 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|265|||Female|16 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|tertiarty care clinic|December 2011|December 28, 2011|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501851||93349|
NCT01502228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCRO-0279|PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma|PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma||Indiana University|Yes|Terminated|October 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|December 28, 2011|Yes|Yes|No further funding|No||https://clinicaltrials.gov/show/NCT01502228||93320|
NCT01502514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-ME-CHF-002|Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Ischemic Congestive Heart Failure Patients||Ageless Regenerative Institute|No|Recruiting|May 2011|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||October 2013|October 28, 2013|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01502514||93298|
NCT01502527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCS - 001|A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy|An Open Labeled Prospective Study to Investigate the Effect of Femarelle® on Vulvo-vaginal Atrophy Symptoms||Dr. Lila Nachtigall Rapid Medical Research, New York|No|Enrolling by invitation|January 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Female|40 Years|85 Years|Accepts Healthy Volunteers|||December 2010|December 29, 2011|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502527||93297|
NCT01502800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042011-005|Clinical Trial of ARQ 761 in Advanced Solid Tumors|A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors||University of Texas Southwestern Medical Center|Yes|Recruiting|December 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|November 9, 2015|October 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01502800||93276|
NCT01503541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S9031-9333-0106-0112-A|S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin|The Development of Predictive Biomarker Models for Patients Receiving Standard Induction Chemotherapy With and Without Gemtuzumab Ozogamicin||Southwest Oncology Group|Yes|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|365|||Both|18 Years|88 Years|No|Non-Probability Sample|Specimens from patients consenting to future research on S9031, S9333, S0106 and S0112|January 2014|March 5, 2015|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01503541||93219|
NCT01495104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25258|A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers|A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE VALPROATE ON THE PHARMACOKINETICS OF RO4917838 AND VICE VERSA IN HEALTHY MALE VOLUNTEERS||Hoffmann-La Roche||Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|18|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495104||93864|
NCT01492062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09222010-6910|A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery|A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery||Stanford University|Yes|Withdrawn|February 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|45 Years|No|||March 2015|March 31, 2015|January 14, 2011|Yes|Yes|Study halted prior to enrollment of first participant.|No||https://clinicaltrials.gov/show/NCT01492062||94097|
NCT01492075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100101|A Comparison Between Continuous and Intermittent Intraabdominal Analgesia Using Local Anaesthetics|Phase IV Study of Postoperative Pain Management|PoPuLAR|Örebro University, Sweden|Yes|Completed|January 2008|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|65 Years|No|||September 2015|September 26, 2015|October 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01492075||94096|
NCT01492088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25002|Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma|A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma||Millennium Pharmaceuticals, Inc.|No|Recruiting|April 2012|January 2017|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|2 Years|18 Years|No|||January 2016|January 6, 2016|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492088||94095|
NCT01491490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMD09126|Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine|A Randomised, Doubleblind,Placebo Controlled, Parallel Group, Pilot Study of 40:1 Ratio of Formulated GW42003 :GW42004 in the Treatment of Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine Treatment in Subjects With Functional Psychosis|GWMD09126|GW Research Ltd|No|Terminated|October 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|December 5, 2011|Yes|Yes|The Chief Investigator and the Sponsor have concluded that it will not be possible to complete    the enrolment in any meaningful timeframe.|No|August 28, 2013|https://clinicaltrials.gov/show/NCT01491490||94141|Early termination due to low subject recruitment meant only two subjects were randomised; one to active and the other to placebo. Only safety data of these two subjects has been reported.
NCT01491776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND-CSP-2011-01|Evaluation of the IND One Step Strep A Rapid Test vs. Culture|Evaluation of the IND One Step Strep A Rapid Test Versus Culture Using Clinical Throat Swab Samples From Patients With Suspected Strep A Infections, CLIA Waiver Study||IND Diagnostic Inc.|No|Recruiting|December 2011|April 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|315|||Both|3 Years|N/A|No|Non-Probability Sample|Male and female subjects, 3 years of age or older, exhibiting symptoms consistent with        Strep A infection.|March 2012|March 7, 2012|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491776||94119|
NCT01492036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-0676|Long-Term Follow-Up of Recipient of Gene Transfer Research|Long-Term Follow-Up Study of Recipients of Gene Transfer Research Protocols||M.D. Anderson Cancer Center|Yes|Recruiting|December 2011|||December 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Study visits once a year during Years 1-5. Blood (about 2-4 tablespoons each time) drawn for      routine tests. If retroviral gene transfer therapy received, blood (up to 4 tablespoons each      time) drawn every 3 months for first year after gene transfer therapy and once a year after      that. If joining study more than a year after gene transfer therapy, RCR test performed once      a year for all 15 years of the study.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Gene transfer therapy in an M. D. Anderson Cancer Center research study in Houston, Texas|March 2016|March 11, 2016|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492036||94099|
NCT01525992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-04-156-16161|A Community Pharmacy-based Program to Improve Management of Diabetes|A Community Pharmacy-based Intervention on Type 2 Diabetic Patients to Improve Medications Adherence and Disease Outcomes; a Randomized Controlled Trial.||Tehran University of Medical Sciences|No|Completed|March 2012|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|N/A|N/A|No|||April 2014|April 16, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525992||91504|
NCT01500213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-P04833|Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy|A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy|HEC|Tesaro, Inc.|No|Completed|February 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|555|||Both|18 Years|N/A|No|||March 2015|February 2, 2016|December 22, 2011|Yes|Yes||No|October 2, 2015|https://clinicaltrials.gov/show/NCT01500213||93474|
NCT01500200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK5461-202|A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Therapy||Alkermes, Inc.|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|65 Years|No|||November 2013|November 8, 2013|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500200||93475|
NCT01495026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115708|A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia|An Open-label, Randomized, Single Dose, Multi-stage, Cross-over Study to Determine the Relative Bioavailability of Fixed Dose Combination Products Containing a 3-oblong Dutasteride Soft Gel Capsule and Tamsulosin (0.5 mg Dutasteride /0.2 mg Tamsulosin HCl) Pellets Having a Range of Tamsulosin Release Rates Produced by Different Mixtures of Enteric Coated and Uncoated Pellets Relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian Ancestry.||GlaxoSmithKline|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|63|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495026||93870|
NCT01501266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D6997C00008|Faslodex Specific Clinical Experience Investigation|Faslodex Specific Clinical Experience Investigation for Long-term Use||AstraZeneca||Completed|February 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|660|||Female|N/A|N/A|No|Non-Probability Sample|Patients treated with Faslodex for the first time due to postmenopausal breast cancer|January 2016|January 7, 2016|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501266||93394|
NCT01501591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAC 2111001|Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size|Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size||King Faisal Specialist Hospital & Research Center|No|Recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|480|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|September 1, 2015|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01501591||93369|
NCT01501864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIRE-0580|School Support as Structural HIV Prevention for Adolescent Orphans in Kenya|School Support as Structural HIV Prevention for Adolescent Orphans in Kenya||Pacific Institute for Research and Evaluation|No|Active, not recruiting|July 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|835|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 28, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01501864||93348|
NCT01501812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-04-11|Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders|Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders (Schizophrenia, Affective Spectrum and Anxiety Disorders) - an Open, Single Center, Longitudinal Study||Shalvata Mental Health Center|Yes|Recruiting|March 2011|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|180|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Subjects with severe mental disorder in axis one (i.e Schizophrenia, Bipolar, MDD, Anxiety        disorder including Panic or Generalized Disorders, PTSD)and healthy subjects that will be        used as control- Thirty subjects at each of the groups.|December 2011|December 27, 2011|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501812||93352|
NCT01501825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sha-16-11|A Prospective, Comparative Study to Explore the Efficacy and Safety of the Five Channels Multiway Deep Transcranial Magnetic Stimulation (TMS) Device in Subjects With Major Depression Disorder (MDD)|||Shalvata Mental Health Center|Yes|Not yet recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|67 Years|No|||December 2011|July 3, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501825||93351|
NCT01501838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1487|Pulmonary Hypertension Institutional Registry|Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires|RIHP|Hospital Italiano de Buenos Aires|No|Recruiting|December 2010|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100000|||Both|17 Years|N/A|No|Non-Probability Sample|Adults 17 yo or older, Any type of Pulmonary Hypertension except type II|December 2015|December 16, 2015|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01501838||93350|
NCT01502826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJ7CTW-002|Mechanisms of Atherogenesis During Post-prandial Time in Childhood Obesity|Candidate Mechanisms of Atherogenesis During the Post-prandial Period in the Obese Child/Adolescent||Universita di Verona|Yes|Not yet recruiting|February 2012|December 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|Samples With DNA|Whole blood Serum Plasma Urine|Both|6 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Total number: 40 children with a BMI > 90th percentile for sex and age. Selection        criteria: group A, n=20, less insulin resistant: HOMA-insulin resistance index (HOMA-IR) <        1.8; group B, n=20, severely insulin-resistant: HOMA-IR > 2.5.|January 2012|January 18, 2012|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01502826||93274|
NCT01503073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B03920073136|Noninvasive Brain Stimulation for Stroke|Noninvasive Brain Stimulation for Stroke Improvement|NIBSstroke|University Hospital of Mont-Godinne|No|Recruiting|January 2008|December 2030|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01503073||93255|
NCT01503268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTUAL 1.0|Atrial Fibrillation After Catheter Versus Thoracoscopic Ablation Using Patient Activated Implantable Loop Recorders: The ACTUAL Study|Atrial Fibrillation After Catheter Versus Thoracoscopic Ablation Using Patient Activated Implantable Loop Recorders|ACTUAL|Eastbourne General Hospital|Yes|Withdrawn|November 2012|November 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|December 30, 2011||No|Study methodology redesigned|No||https://clinicaltrials.gov/show/NCT01503268||93240|
NCT01503281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-UCH-95|Effects of Group Vs. Home-Based Combined Exercise-Diet Program In Childhood Obesity: A Randomised Controlled Trial|Effects of Group Vs. Home-Based Combined Exercise-Diet Program In Childhood Obesity: A Randomised Controlled Trial||Cardenal Herrera University|No|Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|110|||Both|6 Years|16 Years|Accepts Healthy Volunteers|||January 2011|January 11, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01503281||93239|
NCT01494831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREC23|Randomized Control Trial of Group Intervention With Former War-affected Boys in the Democratic Republic of Congo|Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial.||Queen's University, Belfast|Yes|Completed|May 2011|October 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Male|13 Years|17 Years|Accepts Healthy Volunteers|||January 2012|January 17, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494831||93885|
NCT01494844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X110421003|Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces|Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces||University of Alabama at Birmingham|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494844||93884|
NCT01495377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JS003|Opioid Induced Swallowing Difficulties and Risk for Pulmonary Aspiration|Does Opioid Induced Swallowing Difficulty Lead to Elevated Risk for Pulmonary Aspiration?||University Hospital Orebro|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|25|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01495377||93843|
NCT01491581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VietnamSchoolBar_2011|Efficacy of a Milk-based Nutrient-rich Bar on Nutritional Status and Cognitive Performance of School Children in Vietnam|Efficacy of a Milk-based Nutrient-rich Bar on Nutritional Status and Cognitive Performance of School Children in Vietnam||Institut de Recherche pour le Developpement|No|Completed|December 2011|October 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|415|||Both|6 Years|10 Years|No|||November 2012|November 20, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01491581||94134|
NCT01491815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NORD-STAR|Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction|A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment||Karolinska Institutet|Yes|Recruiting|December 2012|December 2020|Anticipated|December 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|800|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01491815||94116|
NCT01492049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0698|R-21 Colorectal Cancer Screening (CRCS) Pilot Trial|Pilot Trial - Promoting Health Literacy for Colorectal Cancer Screening||M.D. Anderson Cancer Center|No|Recruiting|August 2012|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|180|||Both|49 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492049||94098|
NCT01492660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-495|Echogenic Versus Stimulating Needle and Catheter for Sciatic Blocks|Comparison of Visibility of Echogenic and Standard Non-echogenic Block Needles During Ultrasound Guided Sciatic Blocks. A Randomized Prospective Study|Echostim1|Lawson Health Research Institute|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|80 Years|No|||January 2012|April 19, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01492660||94051|
NCT01492673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-183|Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma|A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma||Memorial Sloan Kettering Cancer Center||Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|N/A|21 Years|No|||January 2016|January 21, 2016|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492673||94050|
NCT01492985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-018198-30|Lipopeptide Immunisation With GTU-multiHIV Trial|Evaluation of a Therapeutic Immunization Strategy Associating a DNA Vaccine (GTU-MultiHIV B) Followed by a Lipopeptide Vaccine (LIPO-5) in the Control of Viral Replication Following Antiretroviral Treatment Interruption in HIV-1 Infected Patients With a CD4 Cell Count ≥ 600/mm3||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|July 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01492985||94026|
NCT01526252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2011803-01H|Reference Population for Speckle Tracking Imaging|Establishing a Reference Population for Normal Left Ventricular Function Parameters to Validate the Use of Two Dimensional Speckle Tracking Imaging Software in the Scar Study|STE Normal|Ottawa Heart Institute Research Corporation|No|Completed|December 2011|January 2015|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|91|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal healthy males and females|March 2016|March 7, 2016|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526252||91484|
NCT01500473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-11-00057|Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome|Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome||Children's Hospital Los Angeles|Yes|Not yet recruiting|February 2012|||December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|8|||Female|16 Years|50 Years|No|||February 2012|February 13, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500473||93455|
NCT01500486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3717|Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™|Observational Study to Assess Ease of Use, Acceptability and Preference of Norditropin NordiFlex® With NordiFlex PenMate™ in Subjects on Prescribed Growth Hormone Therapy||Novo Nordisk A/S|No|Completed|January 2007|March 2009|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|||Both|N/A|N/A|No|Probability Sample|Subjects from secondary care physicians who prescribe growth hormone will be included in        the study. Children who are available for Norditropin® treatment in accordance with the        labelling will be included in the study: Newly-diagnosed subjects who have never received        growth hormone therapy before and subjects in whom physician identifies a need for switch        to another growth hormone preparation|March 2012|June 26, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01500486||93454|
NCT01500447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120049|Inherited Reproductive Disorders|The Molecular Basis of Inherited Reproductive Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|December 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|October 30, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01500447||93456|
NCT01500993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rektum III|Capecitabine in the Perioperative Treatment of Rectal Cancer|5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial|Rektum-III|Universitätsmedizin Mannheim|No|Completed|March 2002|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|401|||Both|18 Years|N/A|No|||December 2011|December 26, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01500993||93415|
NCT01501253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HT11A|CKD-828 S-Amlodipine Non-Responder Trial|Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) vs. S-Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by S-Amlodipine Monotherapy.||Chong Kun Dang Pharmaceutical|No|Completed|August 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|187|||Both|18 Years|N/A|No|||November 2012|November 12, 2012|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501253||93395|
NCT01501604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-211|BKM120 in Cancers With PIK3CA Activating Mutations|An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations||Massachusetts General Hospital|Yes|Withdrawn|January 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|December 27, 2011|Yes|Yes|The study has been closed due to lack of accrual|No||https://clinicaltrials.gov/show/NCT01501604||93368|
NCT01501617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-HIS006-PH|Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia|The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial|HSC Phase I/II|Histogen|Yes|Active, not recruiting|December 2011|December 2012|Anticipated|June 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Male|21 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 13, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01501617||93367|
NCT01501630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090105|Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer|Role of PET/CT With Fluorine-18 Tracers and of Diffusion Weighted Whole-body MRI in the Early Detection of Bone Metastases in Prostate Cancer|FLUPROSTIC|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|112|||Male|18 Years|N/A|No|Non-Probability Sample|Prostate cancer|October 2015|October 13, 2015|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501630||93366|
NCT01502215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002/11|Transfusion Requirements in Surgical Oncologic Patient||TRISOP|University of Sao Paulo||Completed|January 2012|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|N/A|No|||December 2012|December 4, 2012|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502215||93321|
NCT01502488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADI-AT-001|Adipose Derived Stem Cell Therapy for Autism|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Autism||Ageless Regenerative Institute|No|Not yet recruiting|October 2014|January 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|3 Years|12 Years|No|||December 2011|March 19, 2014|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01502488||93300|
NCT01494571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1362|Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System|Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System|PharmaJet|University of Colorado, Denver|No|Completed|December 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||7|Actual|101|||Both|2 Months|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|Up to 400 children, aged 2 months to 14 years|December 2012|March 6, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01494571||93905|
NCT01495117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-563|Study of Chlorhexidine Gluconate as a Preoperative Antisepsis|Comparison of Chlorhexidine Gluconate and Povidone Iodine as a Preoperative Antisepsis in Clean-contaminated Abdominal Surgery : a Randomized Prospective Trial|CHG|National Cancer Center, Korea|Yes|Recruiting|October 2011|April 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|584|||Both|20 Years|85 Years|No|||December 2011|December 15, 2011|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01495117||93863|
NCT01491217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-OXL-201|A Study of Oraxol® in Gastric Cancer Patients|A Phase I-II Clinical Trial to Determine Recommended Dose and to Assess the Efficacy, Safety and Pharmacokinetic Profile of Oral Paclitaxel(Oraxol®) in Patients With Advanced/Metastatic or Recurrent Gastric Cancer||Hanmi Pharmaceutical Company Limited|No|Recruiting|May 2009|December 2012|Anticipated|March 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|19 Years|N/A|No|||December 2011|December 11, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01491217||94162|
NCT01491594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032798|Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia|A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy||Duke University|No|Terminated|April 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1|||Both|18 Years|82 Years|No|||April 2013|April 1, 2014|December 12, 2011|No|Yes|Unable to accrue subjects to the study.|No||https://clinicaltrials.gov/show/NCT01491594||94133|
NCT01495676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETUG V04|A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer|A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer|GETUGV04|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|September 2011|September 2019|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01495676||93822|
NCT01491503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MOLZ-101|A Drug Interaction Study of Montelukast and Levocetirizine|Open Label, Randomized, 6-sequence Crossover Study to Evaluate the Drug-drug Interaction Between Montelukast Sodium and Levocetirizine Dihydrochloride in Health Male Volunteers|MOLZ|Hanmi Pharmaceutical Company Limited|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|20 Years|55 Years|No|||April 2013|April 4, 2013|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01491503||94140|
NCT01491516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-07|TELAMON P™ Implant/INFUSE® Bone Graft/CD HORIZON® Spinal System Pilot Study|A Pilot, Prospective, Non-Randomized Clinical Investigation of TELAMON P™ Implant With INFUSE® Bone Graft and the CD HORIZON® Spinal System for Posterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease||Medtronic Spinal and Biologics|Yes|Completed|July 2003|October 2008|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491516||94139|
NCT01492686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCI186-19|Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis|Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2||Mitsubishi Tanabe Pharma Corporation|Yes|Completed|December 2011|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|20 Years|75 Years|No|||June 2015|June 18, 2015|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01492686||94049|
NCT01492699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-PTSD-NT/001|Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder|Single Site, Open Label Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder.||Nanotherapeutics, Inc.|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|55 Years|No|||September 2014|September 24, 2014|December 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492699||94048|
NCT01522079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dias|Spinal Muscular Atrophy and Cardiac Autonomic Function|Spinal Muscular Atrophy and Cardiac Autonomic Function||Centro Universitário Augusto Motta|Yes|Completed|January 2011|October 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|5 Years|25 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01522079||91803|
NCT01500226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-P04834|Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy|Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy||Tesaro, Inc.|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1369|||Both|18 Years|N/A|No|||July 2014|February 2, 2016|December 22, 2011|Yes|Yes||No|October 2, 2015|https://clinicaltrials.gov/show/NCT01500226||93473|
NCT01500239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00005|A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections|A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults||AstraZeneca||Completed|April 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|577|||Both|18 Years|90 Years|No|||January 2016|January 29, 2016|December 22, 2011|Yes|Yes||No|November 9, 2015|https://clinicaltrials.gov/show/NCT01500239||93472|This summary describes data collected from two identical CSPs (D4280C00005 and D4280C00005). With agreement from the EMA and the FDA the data have been combined into a single study database.
NCT01501006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33086|Social and Behavioral Influence (SBI)|Social and Behavioral Influences on Clinical Care|SBI|University of Rochester|Yes|Enrolling by invitation|October 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|N/A|N/A|No|Non-Probability Sample|Male and Female physicians of all races and ethnicities|May 2015|May 7, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01501006||93414|
NCT01501019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exercise in Autoimmunity|Exercise in Sjogren, Myositis and Takayasu's Arteritis|Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis||University of Sao Paulo|No|Recruiting|October 2011|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||February 2016|February 17, 2016|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01501019||93413|
NCT01501279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diskapi2011|Ultrasound Guided Pudendal Block in Transurethral Prostatectomies|Ultrasound Guided Pudendal Block in Transurethral Prostatectomies||Diskapi Teaching and Research Hospital|Yes|Recruiting|December 2011|June 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Male|50 Years|80 Years|No|||December 2011|December 28, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01501279||93393|
NCT01501292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0095-11-HYMC|Changes in the Distribution of Mitochondria During Oocyte Maturation|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2012|April 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|20|||Female|18 Years|44 Years|No|Probability Sample|Patients undergoing routine in-vitro fertilization with ICSI|December 2011|December 26, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01501292||93392|
NCT01501305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68-2010|Influence of Carob and Probiotics on Acute Diarrhea in Children|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|January 2012|February 2013|Anticipated|January 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|3 Years|18 Years|No|||December 2011|December 28, 2011|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01501305||93391|
NCT01501318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200450|Impact of Personalized Feedback Alone on Substance Use Behaviors|Brief Education to Reduce Health Care Consumers' Risky Substance Use Behaviors: How Brief is Brief?||University of Missouri-Columbia|No|Completed|February 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||January 2013|January 14, 2013|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01501318||93390|
NCT01502241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOA-08|Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly|Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)|Methusalem|Heidelberg University|No|Completed|January 2005|November 2011|Actual|November 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|412|||Both|65 Years|N/A|No|||December 2011|December 29, 2011|December 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01502241||93319|
NCT01501877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA030532|Smoking Cessation Intervention for Diabetic Patients|Smoking Cessation Intervention for Diabetic Patients|SSTOP|Rhode Island Hospital|Yes|Recruiting|December 2011|June 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|21 Years|N/A|No|||October 2015|October 21, 2015|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01501877||93347|
NCT01501890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor003411ctil|Progesterone for First Trimester Vaginal Bleeding|The Impact of Progesterone Treatment on Obstetrical Outcome Among Women With First Trimester Vaginal Bleeding||Soroka University Medical Center|No|Not yet recruiting|January 2012|September 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 29, 2011|September 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01501890||93346|
NCT01494259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00010363|Bupivacaine Pain Pumps to Decrease Mastectomy Post-Operative Pain|Use of Percutaneously-Placed Continuous Flow Bupivacaine Pain Pumps to Decrease Post-operative Pain Following Mastectomy With Immediate Reconstruction: A Prospective, Randomized, Double-Blind Clinical Trial||Johns Hopkins University|No|Withdrawn|January 2016|September 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|100 Years|No|||October 2015|October 9, 2015|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494259||93929|
NCT01494272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110235|Analgesia in Children Using Caudal Epidural Ropivacaine|Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine: A Prospective, Randomized, Double-blinded, Controlled Study||Loma Linda University|No|Completed|June 2012|May 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|90|||Both|2 Months|2 Years|Accepts Healthy Volunteers|Probability Sample|Children under 2 years of age having an elective inguinal herniorrhaphy or orchiopexy.|November 2015|November 23, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494272||93928|
NCT01494857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHK - AD001|Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis|Open-Label, Non-Randomized, Single Patient Group, Multi-Center Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Moderately to Severely Active Ulcerative Colitis||Clalit Health Services|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||October 2012|October 28, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494857||93883|
NCT01495130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4P-10-9|Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery|Mechanically-Manipulated Transrectal Ultrasound (TRUS) During Robotic-Assisted Laparoscopic Prostatectomy (RALP)||University of Southern California|Yes|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Male|18 Years|N/A|No|||January 2014|January 27, 2014|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01495130||93862|
NCT01495390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-ALS-02|A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers|A Multicenter Study for the Discovery and Validation of ALS Biomarkers||Massachusetts General Hospital|Yes|Recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Biological samples will be collected from participants with ALS over time. These biological      samples include blood (plasma, serum, and RNA) and cerebrospinal fluid (CSF). DNA will be      collected at one time point.|Both|18 Years|N/A|No|Non-Probability Sample|Volunteers will be invited to participate in this study by their neurologists either in        clinic or at a regular scheduled appointment visit|September 2015|September 18, 2015|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495390||93842|
NCT01495403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002743|Treatment of Muscle Cramps in Patients With Liver Cirrhosis|A Pilot Study of Hydroxychloroquine for the Treatment of Muscle Cramps in Patients With Cirrhosis||Mayo Clinic|No|Completed|December 2011|April 2015|Actual|April 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|3|||Both|21 Years|N/A|No|||July 2015|July 29, 2015|December 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01495403||93841|
NCT01491802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1426-11|Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD|A 4-week Randomized, Double-blind, Crossover Study to Assess the Effect of a New LABA/LAMA Combination Versus LAMA Alone on Exertional Dyspnea, Exercise Endurance and Neuromechanical Coupling in Patients With GOLD Stage II COPD||Queen's University|Yes|Completed|January 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|40 Years|N/A|No|||November 2014|November 7, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491802||94117|
NCT01492439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143/2011|Effectiveness of Cognitive Remediation in a Supported Education Setting|Examining the Effectiveness of Cognitive Remediation in a Supported Education Setting||Centre for Addiction and Mental Health|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||June 2014|June 10, 2014|December 13, 2011||No||No|January 22, 2014|https://clinicaltrials.gov/show/NCT01492439||94068|
NCT01492764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTFIRM2011|Ablation of Sources for Rapid Heart Rhythms|Ventricular Tachyarrhythmia Focal Impulse and Rotor Modulation Trial|VTFIRM|University of California, San Diego|No|Recruiting|June 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|40|||Both|21 Years|90 Years|No|Probability Sample|Patients with documented rapid heart rhythms involving the bottom chambers of the heart.|December 2013|December 11, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492764||94043|
NCT01491789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00044093|Virtual Sailing Simulator in Individuals With Spinal Cord Injury|Virtual Sailing Simulator in Individuals With Spinal Cord Injury|VSail|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Recruiting|May 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||February 2016|February 22, 2016|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01491789||94118|
NCT01492348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-2-0077|Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial|Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial|STEPS UP|Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Active, not recruiting|January 2012|February 2016|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|666|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|March 31, 2010||No||No||https://clinicaltrials.gov/show/NCT01492348||94075|
NCT01492361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR-01-01-0019|A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.|Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)|REDUCE-IT|Amarin Pharma Inc.|Yes|Recruiting|November 2011|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|8000|||Both|45 Years|N/A|No|||March 2016|March 4, 2016|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492361||94074|
NCT01492387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DURATION|Duration of Antibiotic Therapy in Community - Acquired Pneumonia|Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial.|DURATION|University of Milan|Yes|Recruiting|January 2012|March 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|892|||Both|18 Years|N/A|No|||December 2013|December 31, 2013|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01492387||94072|
NCT01492400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-024|Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema|||Allergan|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|363|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|December 13, 2011|Yes|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT01492400||94071|
NCT01492712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VaSCoM005|Validation Study of Covariates Model (VaSCoM) for Propofol|Validation Study of Covariates Model (VaSCoM) for Propofol|VaSCoM|Golden Jubilee National Hospital|No|Recruiting|January 2011|||November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01492712||94047|
NCT01522092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Escit160710|Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|The Effect of Escitalopram on Exacerbation Rates and Quality of Life in Patients With Anxiety Associated With Severe COPD||Hull and East Yorkshire Hospitals NHS Trust|No|Withdrawn||||||Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|40 Years|80 Years|No|||February 2015|February 19, 2016|January 27, 2012||No|Study was not given ethical approval- a alternative protocol required|No||https://clinicaltrials.gov/show/NCT01522092||91802|
NCT01500538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/111|A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)|A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)|VEIL|Peter MacCallum Cancer Centre, Australia|Yes|Terminated|October 2012|May 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||October 2012|February 12, 2016|December 22, 2011||No|Poor recruitment rate|No||https://clinicaltrials.gov/show/NCT01500538||93450|
NCT01500772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDEB025A2306|Alisporivir With pegIFN/RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C|A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease Inhibitor Treatment Failure Patients With Chronic Hepatitis C Genotype 1||Novartis||Terminated|February 2012|||February 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||May 2012|May 4, 2012|December 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500772||93432|
NCT01500733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120035|PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion||National Institutes of Health Clinical Center (CC)||Active, not recruiting|November 2011|September 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01500733||93435|
NCT01500746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00057288|Evaluation of the Effectiveness of Daily Pulse Lavage Therapy in Chronic Wounds|Bedside Pulse Lavage Irrigation Project|PLI2|Northwestern University|No|Completed|December 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|85 Years|No|||March 2014|March 10, 2014|December 23, 2011||No||No|January 20, 2014|https://clinicaltrials.gov/show/NCT01500746||93434|
NCT01500759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Sleep-Disordered Breathing in Heart Failure - The SchlaHF-Registry|Prevalence, Clinical Characteristics and Type of Sleep-disordered Breathing in Patients With Chronic, Symptomatic, Systolic Heart Failure|SchlaHF|ResMed|No|Completed|November 2007|May 2013|Actual|May 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10775|||Both|18 Years|N/A|No|Probability Sample|Adult patients with Chronic Heart Failure with LVEF ≤ 45% and NYHA III-IV or NYHA class II        with at least one hospitalisation for HF in the last 24 months.|August 2015|August 4, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01500759|4 Weeks|93433|
NCT01501032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006385ctil|Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients With Type 1 Diabetes|Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients|MD-Logic- Cont|Rabin Medical Center|No|Withdrawn|October 2013|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|65 Years|No|||March 2015|March 18, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01501032||93412|
NCT01501903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110907002|Standard Versus Fanning Techniques for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA)|Randomized Trial Comparing the Standard and Fanning Techniques for Fine Needle Aspiration of Pancreatic Mass Lesions at Endoscopic Ultrasound||University of Alabama at Birmingham|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|52|||Both|19 Years|90 Years|No|||February 2012|February 1, 2012|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01501903||93345|
NCT01501916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0315668A|Effect of Vitamin D3 on Cardiovascular Risk Factors|Effect of Vitamin D3 on Cardiovascular Risk Factors: a Randomized Trial in Human||Martin-Luther-Universität Halle-Wittenberg|Yes|Suspended|December 2012|December 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 8, 2013|November 4, 2011||No|technical problems|No||https://clinicaltrials.gov/show/NCT01501916||93344|
NCT01494051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK71869-2|High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders|Fatty Acid Oxidation and Body Weight Regulation in Long-chain Fatty Acid Oxidation Disorders.||Oregon Health and Science University|No|Completed|January 2006|January 2010|Actual|September 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|7 Years|45 Years|No|||December 2011|December 15, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01494051||93944|
NCT01502540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si223/2011|Pain Prevalence After Major Craniotomy|Pain Prevalence After Major Craniotomy in Siriraj Hospital||Mahidol University|No|Completed|October 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|302|||Both|18 Years|N/A|No|Non-Probability Sample|patient undergoing cranitomy|January 2013|January 13, 2013|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01502540||93296|
NCT01494584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113284|Study in Pediatric Subjects With Epilepsy|Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome||GlaxoSmithKline|No|Terminated|July 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|12 Years|17 Years|No|||September 2014|September 25, 2014|December 1, 2011|No|Yes|Terminated after placing the study on hold at the request of the FDA|No|July 10, 2014|https://clinicaltrials.gov/show/NCT01494584||93904|
NCT01495143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-07-012-RAS|Surgical Stress Measured by Microdialysis|Microdialysis of Paraspinal Muscle in Healthy Volunteers and Patients Underwent Posterior Lumbar Fusion Surgery||Northern Orthopaedic Division, Denmark|No|Completed|January 2007|June 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 12, 2014|December 29, 2009||No||No||https://clinicaltrials.gov/show/NCT01495143||93861|
NCT01495429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00050032|Peripherally Inserted Versus Centrally Inserted Central Venous Catheters in the Neurological Intensive Care|A Phase III Study of Peripherally Inserted Versus Centrally Inserted Central Venous Catheters in the Neurological Intensive Care Unit|PICNIC|University of Michigan|Yes|Completed|January 2012|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01495429||93840|
NCT01491555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00001218|Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy|Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy|QED|Children's Hospital Boston|No|Completed|April 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|73|||Male|2 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will involve boys with DMD and healthy male controls.|March 2016|March 23, 2016|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01491555||94136|
NCT01491568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P04-07|rhBMP-2/CRM/CD HORIZON® Spinal System Pilot Study (2-Level)|Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic DDD at Two Adjacent Vertebral Levels||Medtronic Spinal and Biologics|Yes|Completed|July 2005|November 2010|Actual|May 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491568||94135|
NCT01491230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0443-11-TLV|Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation|Neutrophil Extracellular Traps (NETs) Formation Post-hematopoietic Stem Cell Transplantation (HSCT) and Its Relation to Chemotaxis and Creation of Reactive Oxygen Species|NETs post HSCT|Tel-Aviv Sourasky Medical Center|No|Recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|10cc of peripheral venous blood will be collected from each patient at several time points:      Before transplant, at neutrophil engraftment, 6 weeks, 3 months, 4 months, 6 months, 9      months, 1 year, 1.5 years, 2 years, and 3 years post-transplant, or until normalization of      NETs formation in 2 consecutive examinations.|Both|N/A|21 Years|No|Probability Sample|Infants, children and adolescents undergoing autologous and allogeneic HSCT at the        pediatric hemato-oncology departement of Dana children's Hospital, Tel-Aviv Sourasky        Medical Center, Tel-Aviv, Israel.|December 2011|December 12, 2011|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01491230||94161|
NCT01491828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400|Study to Determine Results of Vibratory Stimulus on Subject's Neck|Study to Determine Results of Vibratory Stimulus on Subject's Neck||Kai Medical, Inc.|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2011|March 19, 2012|December 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01491828||94115|
NCT01492101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PIR-11|The BEACON Study (Breast Cancer Outcomes With NKTR-102)|The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine|BEACON|Nektar Therapeutics|Yes|Active, not recruiting|December 2011|||December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|840|||Female|18 Years|N/A|No|||September 2015|September 17, 2015|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492101||94094|
NCT01492114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sbo2011|Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.|Double-blind Cross-over Randomised Controlled Trial on the Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.||University of Turin, Italy|No|Completed|July 2011|March 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492114||94093|
NCT01492374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN167-003|Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease||Bristol-Myers Squibb|Yes|Completed|February 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|50 Years|90 Years|No|||October 2013|July 23, 2014|December 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492374||94073|
NCT01492413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BI-001|Impact of an Online Behavioral Weight Loss Program|Impact of an Online Behavioral Weight Loss Program Provided With or Without a Fortified Diet Beverage||Baylor College of Medicine|No|Completed|October 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|572|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2011|December 14, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492413||94070|
NCT01522612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40085-75083|Colorectal Cancer (CRC) Cetuximab Elderly Frail|Treatment of Patients With KRAS Wild Type Advanced Colorectal Cancer (CRC) With 5-Fluorouracil (5-FU) or 5- FU Plus an Epidermal Growth Factor Receptor (EGFR) Inhibitor (Cetuximab) Based on a Comprehensive Geriatric Assessment (CGA).||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Terminated|April 2013|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|70 Years|N/A|No|||May 2015|May 22, 2015|January 27, 2012||No|poor accrual|No||https://clinicaltrials.gov/show/NCT01522612||91762|
NCT01501357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Effectiveness of Toothbrushing Techniques in Plaque Removal and Caries Lesion Control|Effectiveness of Toothbrushing Techniques in Plaque Removal and Caries Lesion Control in Erupting Primary Permanent Molars - Randomized Clinical Trial Abbreviated Over 24 Months|toothbrushing|University of Sao Paulo|Yes|Recruiting|July 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Both|5 Years|7 Years|Accepts Healthy Volunteers|||August 2012|August 19, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01501357||93387|
NCT01501370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNITO-MM-01|Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy|A Phase II, Multi-center, Open-label, Randomized Study of Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy|ZLd_Ld|University of Turin, Italy|Yes|Withdrawn|January 2012|February 2017|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01501370||93386|
NCT01501383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-765-402|A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy With a 24-Week Open-Label Extension||Vertex Pharmaceuticals Incorporated|Yes|Terminated|December 2011|||August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|55|||Both|18 Years|64 Years|No|||October 2012|January 15, 2014|December 15, 2011|Yes|Yes|Terminated by Sponsor|No||https://clinicaltrials.gov/show/NCT01501383||93385|
NCT01500512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0270|Observation in Patients With Early-Stage Vulvar Cancer Following Surgery and/or Radiation Therapy|Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study||Gynecologic Oncology Group||Recruiting|January 2012|||July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Female|18 Years|N/A|No|Probability Sample|Patients with early stage squamous cell cancer of the vulva|December 2014|December 23, 2014|December 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01500512||93452|
NCT01501331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTVCARDIO2011_01|Multiparametric Heart Failure Evaluation in Internal Cardioverter Defibrillators (ICD) Patients|Multiparametric Evaluation of Heart Failure in Device-implanted Patients.|MULTITUDE-HF|University of Rome Tor Vergata|No|Completed|December 2011|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|85 Years|No|Non-Probability Sample|Consecutive patients implanted with an Energen device or successor using the RRT        diagnostic tool|November 2014|November 16, 2014|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01501331||93389|
NCT01501344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010YogA80|Open-label Study to Evaluate the Effect of MBP-80 on Bone Remodelling|A 12-week, Open-label Study to Evaluate the Effect of MBP-80 (200g of Yogurt With Fortified Calcium Content and MBP 80 mg) on Bone Remodelling as Assessed by Bone Turnover Markers in Early Postmenopausal Women|YogA|Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.|No|Completed|January 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|50|||Female|45 Years|60 Years|Accepts Healthy Volunteers|||December 2011|January 5, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01501344||93388|
NCT01501643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091114|Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease|Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease With Vaso-occlusive Crisis and Morphinic Treatment|VPACS|Assistance Publique - Hôpitaux de Paris|No|Terminated|November 2011|April 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|6|||Both|6 Years|20 Years|No|||April 2015|April 9, 2015|December 26, 2011||No|decision of the promoter|No||https://clinicaltrials.gov/show/NCT01501643||93365|
NCT01493791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120015|CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women|Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Reduce Bleeding in Premenopausal Women With Abnormal Uterine Bleeding: A Pilot Study||National Institutes of Health Clinical Center (CC)||Withdrawn|November 2011|July 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|0|||Both|25 Years|50 Years|No|||July 2013|December 10, 2015|December 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01493791||93964|
NCT01494038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1078|Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women|A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Settings||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|April 2014|||February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|950|||Female|13 Years|N/A|No|||November 2015|November 11, 2015|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494038||93945|
NCT01494064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCPHRI1018/2|Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care|Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care Unit : Standardization of Critical Care Nursing|STANDAREA|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2011|December 2015|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort||2|Actual|224|||Both|18 Years|N/A|No|Probability Sample|ICU patients in Beaujon Hospital as diagnasotic with hepatic encephalopathy and liver        cirrhosis and lice which a treatment plan is formalized|December 2015|December 21, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01494064||93943|
NCT01494285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA1001|Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients|Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, Ambulatory Safety and Efficacy Study of ARK-E021 Topical Foam of 5% and 10% in Subjects With Mild to Moderate Acne Vulgaris.||M. Arkin 1999 Ltd.|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|157|||Both|12 Years|40 Years|No|||December 2013|December 1, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01494285||93927|
NCT01494597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0022|Drug Interaction Study of Isavuconazole and Cyclosporine|Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Cyclosporine: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 16, 2011|December 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494597||93903|
NCT01494870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOKKD-01|Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block|||Samara Regional Cardiology Dispensary|No|Not yet recruiting|January 2012|November 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|75 Years|No|||January 2012|January 7, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01494870||93882|
NCT01474967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin in PCOS|Effect of Dosage of Metformin on Menstruation and Lipid Profile in Women With Polycystic Ovary Syndrome|Effect of Dosage of Metformin on Menstruation and Lipid Profile in Women With Polycystic Ovary Syndrome||Hormozgan University of Medical Sciences|Yes|Completed|February 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|N/A|N/A|No|||November 2011|November 18, 2011|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474967||95409|
NCT01474980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00495-34|Pregnancy Outcomes in Congenital Myasthenie Syndrome|Retrospective Study :Describe the Changes of the Disease in Many Cases Likely to Aggravate.|POCoMS|Institut de Myologie, France|Yes|Completed|January 2010|October 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|25|||Female|18 Years|N/A|No|Non-Probability Sample|Women with Congenital Myasthenie Syndrome|November 2011|November 17, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01474980||95408|
NCT01475552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM-Verifynow|Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus|The Effect of Point-of-care Platelet Function Assay Guided Antiplatelet Therapy on the Periprocedural Increase of Cardiac Enzymes.||Seoul National University Bundang Hospital|Yes|Completed|September 2010|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|80 Years|No|||December 2012|December 12, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475552||95364|
NCT01475851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115912|Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs|A Multi-center, Open-label Study of GSK548470 (Tenofovir Disoproxil Fumarate) in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs||GlaxoSmithKline|No|Completed|December 2011|October 2014|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|16 Years|69 Years|No|||May 2015|June 18, 2015|November 17, 2011||No||No|August 22, 2013|https://clinicaltrials.gov/show/NCT01475851||95341|
NCT01475864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biliary stone|Prospective Evaluation of the Covered Self-expandable Metal Stents (CSEMS) for Incomplete Biliary Stone Clearance|Prospective Evaluation of the Clinical Utility of Endoscopically-placed Self Expandable Stents||University of Florida|No|Withdrawn|November 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Those patients who have a biliary stone that has not been removed by standard medical        care.|June 2013|June 26, 2013|November 16, 2011||No|no subjects were found who met criteria|No||https://clinicaltrials.gov/show/NCT01475864||95340|
NCT01476124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115720|Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine|A Double-Blind, 3-Part Crossover Study to Assess the Pharmacokinetics and Tolerability of Single Doses of Gabapentin Enacarbil and Morphine Administered Alone and in Combination in Healthy Subjects||XenoPort, Inc.|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|July 15, 2013|August 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476124||95320|
NCT01476670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-CO2-TCD|Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor|Cerebral Autoregulation and Carbon Dioxide Reactivity in Patients With Posterior Fossa Tumor||All India Institute of Medical Sciences, New Delhi|No|Not yet recruiting|July 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|60 Years|No|Probability Sample|Due to their anatomic location, posterior fossa tumors result in obstruction of        ventricular outflow, produce hydrocephalus and features of raise intracranial pressure        (ICP). It is possible that lesions in the posterior fossa may affect Cerebral        Autoregulation and Carbon dioxide reactivity. It should also be noted that posterior fossa        surgeries are carried out in positions such as prone, lateral and sitting. Altered        surgical positions themselves affect systemic hemodynamics which may influence cerebral        blood flow; with presence of anesthetics further compromising the blood flow to the brain.        Understanding the homeostatic mechanisms of CA and CO2R may help in deciding proper        positioning of patients and maintenance of intraoperative hemodynamic.|November 2011|November 21, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01476670||95278|
NCT01477008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR09-006|BiPhasic Cartilage Repair Implant (BiCRI) IDE Clinical Trial - Taiwan|A Prospective, Multi-Center, Randomized Clinical Trial Comparing the Biphasic Cartilage Repair Implant to Marrow Stimulation in the Treatment of Focal Chondral and Osteochondral Lesions of the Knee||Exactech Taiwan, Ltd.|Yes|Recruiting|October 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|92|||Both|N/A|54 Years|No|||May 2013|May 9, 2013|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01477008||95253|
NCT01477567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14195|A First-in-Human Study of LY3009385 in Healthy Participants|A Single Ascending Dose (SAD) Study of LY3009385 in Healthy Volunteers||Eli Lilly and Company|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Actual|40|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 2, 2014|November 18, 2011|No|Yes||No|June 13, 2014|https://clinicaltrials.gov/show/NCT01477567||95210|
NCT01477580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V180-001|Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)|A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults||Merck Sharp & Dohme Corp.|Yes|Completed|July 2012|December 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|13||Actual|98|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 16, 2015|November 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01477580||95209|
NCT01477255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIARY1|The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population|The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population: A Pilot Study|DIARY1|St. Jude Children's Research Hospital|No|Recruiting|December 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|174|||Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|All eligible participants will be invited to participate in the research investigation,        including children and parents of both genders and of all races/ethnicities.        St. Jude treats pediatric patients from across the country and around the world, which        results in a culturally diverse pediatric population. Based upon enrollment patterns from        previous investigations, it is anticipated that approximately 19% of enrolled pediatric        participants will be racial/ethnic minority children. Because the control group will be        matched to the pediatric group on variables of gender, age, race/ethnicity, and        socioeconomic status, it is anticipated that the gender and race/ethnicity of the control        group will be commensurate with that of the pediatric group.|December 2015|December 21, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01477255||95234|
NCT01477541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104-6466|Cluster-randomized Trial Measuring Integration of Professional Midwives and Obstetric Nurses in Rural Clinics in Mexico|Incorporation of Alternative Providers for Care During Pregnancy, Delivery and Postpartum in Rural Public Health Clinics.||Instituto Nacional de Salud Publica, Mexico||Completed|November 2007|||March 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|27|||Both|N/A|N/A|No|||November 2011|November 18, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477541||95212|
NCT01477554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-845-6519|PRONTO: Obstetric and Neonatal Emergency Training Program: A Cluster-Randomized Trial to Measure Impact|PRONTO: Obstetric and Neonatal Emergency Training Program: A Cluster-Randomized Trial to Measure Impact|PRONTO|Instituto Nacional de Salud Publica, Mexico|No|Active, not recruiting|September 2009|June 2013|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|24|||Both|N/A|N/A|No|||November 2011|November 18, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477554||95211|
NCT01477476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0814|Anti-IL-1 Treatment in Children DKA at Diagnosis of Type 1 Diabetes|Anti-IL-1 Treatment in Children DKA at Diagnosis of Type 1 Diabetes.||University of Colorado, Denver|Yes|Recruiting|March 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|21|||Both|8 Years|18 Years|No|||January 2016|January 13, 2016|November 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477476||95217|
NCT01477814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSGT-08-148-01-CPPB|Interventions to Improve Colon Cancer Screening in Poor Rural Iowa Counties|Randomized Clinical Trial to Improve Colon Cancer Screening in Poor Rural Iowa Counties||University of Iowa|No|Active, not recruiting|July 2008|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|4||Actual|743|||Both|52 Years|79 Years|Accepts Healthy Volunteers|||November 2011|November 18, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477814||95191|
NCT01477827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bupa Protocol 1|Sunlight Exposure and Vitamin D in Children|Sunlight Exposure and Vitamin D Status of Children in the UK||University of Manchester|No|Completed|June 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|12 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Schoolchildren in Greater Manchester|January 2013|January 14, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477827||95190|
NCT01478113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002148|Stimulant Enhancement of Well-Being Therapy for Depression|Stimulant Enhancement of Well-Being Therapy for Depression||Massachusetts General Hospital|No|Recruiting|February 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||September 2012|September 17, 2012|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01478113||95168|
NCT01478126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOP 05|Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass|Prospective Randomized Study of Glutamin Protective Properties in Cardiac Surgery.||Meshalkin Research Institute of Pathology of Circulation|No|Completed|January 2012|September 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||October 2013|October 30, 2013|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01478126||95167|
NCT01473797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM10182|Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis|Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function|ECLA|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|November 2011|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|55 Years|No|||September 2015|November 30, 2015|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473797||95499|
NCT01474382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHE-11-001|Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients|A Phase 4, Multicenter, Randomized, Double-Blinded, Controlled Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients Undergoing Mandibular and Maxillary Procedures||Novocol Pharmaceutical of Canada, Inc.|Yes|Completed|February 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||August 2014|August 28, 2014|November 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474382||95454|
NCT01474408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/760|Venous Function in Cardiovascular Disease Patients|Venous Function in Cardiovascular Disease Patients; The Neglected Part of Circulatory Regulation||Norwegian University of Science and Technology|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 9, 2013|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01474408||95452|
NCT01474421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAQW051A2209|Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias||Novartis||Completed|September 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|71|||Both|30 Years|85 Years|No|||January 2015|January 12, 2015|October 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474421||95451|
NCT01474694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|063/11|Accuracy Assessment for Computer-assisted Surgical Interventions of the Liver|Accuracy Assessment for Computer-assisted Surgical Interventions of the Liver: A Prospective, Non Randomized Study|CALS|University Hospital Inselspital, Berne|No|Completed|October 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Probability Sample|patients that are still considered unresectable at the time point of presentation|November 2015|November 25, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474694||95430|
NCT01474993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002221|Sulforaphane-rich Broccoli Sprout Extract for Autism|Sulforaphane-rich Broccoli Sprout Extract for Autism||University of Massachusetts, Worcester|Yes|Completed|December 2011|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Male|13 Years|30 Years|No|||November 2014|November 19, 2014|November 8, 2011|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01474993||95407|
NCT01475565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13733|Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome|Insulin Resistance Before and During Pregnancy in Women With PCOS||Virginia Commonwealth University|No|Terminated|May 2013|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2|Samples With DNA|-  blood sample        -  blood sample sample for DNA        -  fasting plasma for insulin, glucose, sex steroids (testosterone, androstenedione,           DHEA-sulfate, estradiol, estrone, progesterone), sex hormone-binding globulin and           estrogen metabolites        -  blood sample for oral glucose tolerance test        -  urine for estrogen metabolites|Female|18 Years|40 Years|No|Non-Probability Sample|Participants will be recruited from clinics in/near Richmond, VA.|December 2015|December 10, 2015|November 8, 2011||No|Only 2 participants were enrolled|No||https://clinicaltrials.gov/show/NCT01475565||95363|
NCT01476462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PdL SMN Study 1|Second Malignant Neoplasms After Childhood ALL Therapy|Second Malignant Neoplasms After Childhood ALL Therapy; An International Ponte di Legno Study|PdL-SMN1|Rigshospitalet, Denmark|No|Completed|January 2009|December 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|642|||Both|N/A|20 Years|No|Non-Probability Sample|The study cohort includes all registered cases of second cancers occurring as the first        event among children diagnosed with acute lymphoblastic leukemia and treated according to        protocol by one of the collaborative groups participating in the present study|May 2012|May 23, 2012|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01476462||95294|
NCT01476683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RACDIR1002|Study to Compare the Pharmacokinetics Profiles of Four Racecadotril Products|An Open-Label, Fasting, Crossover, Single-Dose Pharmacokinetic Study of Four Formulations of Racecadotril||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01476683||95277|
NCT01475825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPO3801011|A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol|FOCUS FH|Sanofi|Yes|Active, not recruiting|December 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|November 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01475825||95343|
NCT01475838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0115|Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients|A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients||Gilead Sciences|No|Completed|November 2011|December 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|438|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|November 17, 2011|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01475838||95342|There were no limitations affecting the analysis or results.
NCT01476137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115829|A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers|An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myeloma||GlaxoSmithKline|Yes|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|20|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476137||95319|
NCT01476436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK195276|Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers|Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers||Oslo University Hospital|No|Recruiting|November 2011|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 10, 2012|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01476436||95296|
NCT01477268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-296|Cognitive Correlates of Antidepressant Treatment Response in Elders|Determining the Impact of Dementia and Executive Impairment on Antidepressant Treatment Response in Older Persons||St. Michael's Hospital, Toronto|No|Completed|June 2007|October 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||May 2011|November 18, 2011|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477268||95233|
NCT01477281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E01-TEU-VEN-08-10|Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon|A Clinical Multicenter, Phase III, Prospective, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon||Laboratório Teuto Brasileiro S/A|Yes|Not yet recruiting|February 2012|August 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|65 Years|No|||November 2011|November 18, 2011|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01477281||95232|
NCT01477944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CES-CRE-2011/1|Pattern of Statins Use in Catalonia|Pattern of Statins Use in Catalonia||AstraZeneca|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|180723|||Both|18 Years|N/A|No|Non-Probability Sample|Hypercolesterolemic patients in treatment with statins.|February 2012|February 20, 2012|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477944||95181|
NCT01478191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL-ProHLRec|Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT|Prognosis of Patients With Relapsed/Refractory Hl Treated With Combination of Ifosfamide, Gemcitabine and Vinorelbine(IGEV) Induction Therapy Before High-dose Chemotherapy (HDCT) With Autologous Hematopoietic Stem Cells Transplantation (AHSCT)|IIL-ProHLRec|Fondazione Italiana Linfomi ONLUS|No|Completed|May 2010|June 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|495|||Both|18 Years|N/A|No|Non-Probability Sample|Cases of relapsed/refractory Hodgkin Limphoma (HL) which received full course IGEV scheme        as induction therapy prior to HDCT with AHSCT from 1997 through 2007. Patients will be        identified from archives of every single Center Registry database.|November 2011|March 5, 2013|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01478191||95162|
NCT01508793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL092910|Enhancing Sleep Duration: Effects on Children's Eating and Activity Behaviors|||The Miriam Hospital|Yes|Recruiting|August 2011|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|104|||Both|8 Years|11 Years|No|||September 2015|September 21, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01508793||92818|
NCT01504659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBRF001|Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder|Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder|IKBP|Juvenile Bipolar Research Foundation|Yes|Suspended|July 2012|July 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|12 Years|No|||September 2015|September 4, 2015|January 3, 2012|Yes|Yes|Protocol Revisions|No||https://clinicaltrials.gov/show/NCT01504659||93133|
NCT01477489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.087|Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer|A Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|January 2012|||October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|19 Years|N/A|No|||March 2016|March 18, 2016|November 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01477489||95216|
NCT01477502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011‐24|Clinical Value of Homeopathic Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury|Clinical Value of Homeopathic Assessment and Treatment for Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury||Swiss Paraplegic Centre Nottwil|No|Active, not recruiting|November 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|46|||Both|18 Years|90 Years|No|||November 2015|November 16, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01477502||95215|
NCT01477840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kermanshah University|Comparative of Effects of Sublingual Misoprostol and Infusion Oxytocin in Reduction of Bleeding at Cesarean|Phase 2-3 Study of Comparative of Effects of Sublingual Misoprostol and Infusion Oxytocin in Reduction of Blood Loss at Cesarean Deliveries||Kermanshah University of Medical Sciences|Yes|Not yet recruiting|August 2012|August 2012|Anticipated|August 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|180|||Female|15 Years|44 Years|Accepts Healthy Volunteers|||December 2011|December 12, 2011|October 31, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477840||95189|
NCT01477853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431E-211|A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|No|Terminated|October 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|166|||Both|18 Years|79 Years|No|||October 2015|October 20, 2015|November 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477853||95188|
NCT01478139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIFTplug-110212|Ligation of Intersphincteric Fistula Tract (LIFT) Versus LIFT-plug Procedure for Anal Fistula Repair|Ligation of Intersphincteric Fistula Tract (LIFT) Versus LIFT-plug Procedure for Anal Fistula Repair: a Multicenter, Randomized, Open-label, Parallel Controlled Trial|LIFT-plug|Beijing Chao Yang Hospital|Yes|Recruiting|February 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01478139||95166|
NCT01473810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-Vacc-4x/L3-2011/1|Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant|Immunotherapy of HIV-infected Patients: A Single-blinded, Randomized, Immunogenicity, Pilot Study of Intranasal Administration of Vacc-4x With Endocine as Adjuvant||Oslo University Hospital|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|70 Years|No|||June 2012|June 19, 2012|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01473810||95498|
NCT01474109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055C301|Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis|DUAL-1|Actelion|Yes|Completed|December 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|289|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|October 31, 2011|Yes|Yes||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01474109||95475|
NCT01474434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908A2213|Efficacy of LCQ908 on Cardiovascular Risk|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of LCQ908 on Cardiovascular Risk|im|Novartis||Terminated|March 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|40 Years|80 Years|No|||May 2015|May 20, 2015|November 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474434||95450|
NCT01474720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRF 11-45|Zostavax in Systemic Lupus Erythematosus|Immunologic Response to Varicella Zoster Vaccination With Zostavax in Patients With Systemic Lupus Erythematosus||Oklahoma Medical Research Foundation|Yes|Completed|November 2011|October 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||November 2011|September 16, 2013|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474720||95428|
NCT01474707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H09-02069|Educational Interventions for Chronic Obstructive Pulmonary Disease (COPD) Self-management in Ethno-cultural Communities|Assessing Chronic Obstructive Pulmonary Disease (COPD) Knowledge, Beliefs, and Health Literacy in Chinese Immigrant Adults With a Diagnosis of COPD|COPD|University of British Columbia|No|Completed|January 2011|January 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|120|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01474707||95429|
NCT01475279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T89-04-US|A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin|An Open-Label, Multiple-Dose, Single-Center, Sequential, Inpatient Study to Determine the Effect of T89 on Steady-State Pharmacodynamics of Warfarin in Healthy Subjects||Tasly Pharmaceuticals, Inc.|Yes|Completed|July 2011|January 2012|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2011|November 7, 2012|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01475279||95385|
NCT01475292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH006|A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Treatment With Repeat Doses of Inhaled RV568 in Patients With COPD||Respivert Ltd|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|40 Years|75 Years|No|||May 2012|May 2, 2012|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475292||95384|
NCT01476163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT1001-188|Physician Initiated Request for Migalastat in Individual Patients With Fabry Disease|Physician Initiated Request for Treatment Use of Migalastat Hydrochloride (AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (AT1001-188)||Amicus Therapeutics|No|Recruiting|December 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|74 Years|No|||June 2015|October 8, 2015|November 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476163||95317|
NCT01507168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP27884|A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma|A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)||Hoffmann-La Roche||Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|186|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507168||92940|
NCT01476150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJFSRI-OP|Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population|Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population||China-Japan Friendship Hospital|Yes|Not yet recruiting|January 2012|March 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||8|Anticipated|10000|Samples Without DNA|complete blood|Both|20 Years|79 Years|No|Probability Sample|The study will comprise 10,000 people aging from 20 to 79 residing in urban Beijing,        China. All of them are members of Beijing Municipal Health Insurance (Beijing is a city        that buy medical insurances for all of its residents).|November 2011|November 22, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01476150||95318|
NCT01476696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12324|A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease|An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease|Crescent|Eli Lilly and Company|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|2 Years|17 Years|No|||January 2014|January 17, 2014|November 17, 2011|Yes|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT01476696||95276|Data for the Primary Outcome Measures 1 and 2 were collected for presentation of results in a scatter plot and were not intended to be summarized due to the limited number of participants per treatment.
NCT01476449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1127228|Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema|Monthly Ranibizumab Versus Treat and Extend Ranibizumab for Diabetic Macular Edema||Retina Vitreous Associates of Florida|Yes|Active, not recruiting|November 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 4, 2014|November 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476449||95295|
NCT01477021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2537.00|Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery|A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma.||Fred Hutchinson Cancer Research Center|Yes|Completed|January 2012|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01477021||95252|
NCT01508065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gluco01|Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device|||GlucoVista|No|Recruiting|September 2012|||March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|65 Years|No|Non-Probability Sample|The patient population will include subjects with controlled type one diabetes mellitus.|February 2014|February 1, 2014|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508065||92872|
NCT01508325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200006-520|Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients|Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients (CREATIVE Study)|CREATIVE|Merck KGaA|No|Completed|December 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|186|||Both|18 Years|70 Years|No|||April 2015|April 28, 2015|January 9, 2012||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01508325||92853|
NCT01508585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0622-BE|Telephone-based Cognitive Behavioral Therapy for Bariatric Surgery Patients: A Pilot Study|Telephone-based Cognitive Behavioral Therapy for Bariatric Surgery Patients: A Pilot Study||University Health Network, Toronto|No|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 14, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01508585||92834|
NCT01505192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Postpartum non invasive Hb|Noninvasive Continuous Measurement of SpHb After Spontaneous Vaginal Delivery|Determination of the Physiological Reference Values of Trend of Hemoglobin in the Post-partum Period After Spontaneous Vaginal Delivery. A Sequential Pilot Study Using the Noninvasive Continuous Technology of SpHb||Città di Roma Hospital|No|Recruiting|December 2011|May 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|120|||Female|18 Years|40 Years|No|||January 2012|January 5, 2012|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01505192||93092|
NCT01477528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-081611|Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)|Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II LVAS (TRACE)|TRACE|Thoratec Europe Ltd|No|Completed|November 2011|August 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|||Both|N/A|N/A|No|Non-Probability Sample|Patients with HeartMate II VAD that are on reduced anticoagulation/antiplatelet regimine|March 2016|March 18, 2016|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01477528||95213|
NCT01477892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFTN-01|Evaluation of Safety and Efficacy of Remifentanil in Pediatric Population|Evaluation of Safety and Efficacy of Remifentanil in Preterm Infant||Seoul National University Hospital|Yes|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|14|||Both|N/A|12 Weeks|No|||September 2013|September 11, 2013|November 10, 2011||No||No|April 12, 2013|https://clinicaltrials.gov/show/NCT01477892||95185|relatively small numbers of subjects
NCT01477866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITOGENEX CRC|Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer|Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer|CITOGENEX PA|University of Palermo|No|Suspended|January 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|250|||Both|40 Years|60 Years|No|||October 2012|October 25, 2012|November 18, 2011||No|because Study Chair and Director have not yet submitted it to Ethic Committee|No||https://clinicaltrials.gov/show/NCT01477866||95187|
NCT01477879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSV1&2|Hsv 1 and 2 Gowey Protocol Versus Placebo|Phase II Clinical Trial of Versabase/Sarracenia Purpurea Versus Placebo||Naturopaths International|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2011|November 19, 2011|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01477879||95186|
NCT01478152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-AN|Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma|A Single Center, Dose Finding, Safety, and Feasibility Study to Investigate the Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma||Bitop AG|No|Completed|September 2009|February 2010|Actual|||Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||November 2011|November 21, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01478152||95165|
NCT01473823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OT-013|Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood|Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood|Omega-Treat|Ostergotland County Council, Sweden|No|Enrolling by invitation|January 2012|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|3 Months|12 Months|No|||March 2012|March 2, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01473823||95497|
NCT01473836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6831005|A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection|A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone||Pfizer|No|Completed|November 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|16 Years|79 Years|No|||December 2013|December 18, 2013|October 11, 2011||No||No|October 10, 2013|https://clinicaltrials.gov/show/NCT01473836||95496|
NCT01474122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055C302|Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis|DUAL-2|Actelion|Yes|Terminated|December 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|265|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|October 31, 2011|Yes|Yes|company decision|No|January 19, 2015|https://clinicaltrials.gov/show/NCT01474122||95474|
NCT01474135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG286-CS201|AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure|A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of Two AR 12286/Travoprost Fixed-dose Combination Products Compared to Travatan® Z in Patients With Elevated Intraocular Pressure||Aerie Pharmaceuticals|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|November 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474135||95473|
NCT01474733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00008039|Effects of a Longitudinal Health Literacy Training Program on Family Medicine Residents|Effects of a Longitudinal Health Literacy Training Program on Family Medicine Residents||Oregon Health and Science University|No|Completed|November 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|12|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474733||95427|
NCT01475006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090505|AMG 595 First-in-Human in Recurrent Gliomas|A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)||Amgen|No|Active, not recruiting|November 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|September 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01475006||95406|
NCT01475019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1732,2011|The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)|The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome||Aristotle University Of Thessaloniki|Yes|Active, not recruiting|January 2004|December 2012|Anticipated|January 2010|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Female|18 Years|39 Years|No|||November 2011|November 18, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475019||95405|
NCT01475318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mifemisolet|Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy|A Pilot Study on the Combined Use of Letrozole, Miferpristone and Misoprostol in Termination of First Trimester Pregnancy up to 63 Days Gestation||The University of Hong Kong||Recruiting|October 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|18 Years|N/A|No|||November 2011|November 16, 2011|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01475318||95382|
NCT01506882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01375|An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy|An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16 Years With Partial Seizures||UCB Pharma|No|Completed|December 2011|April 2015|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|16 Years|N/A|No|||November 2015|November 24, 2015|January 5, 2012|Yes|Yes||No|October 7, 2014|https://clinicaltrials.gov/show/NCT01506882||92962|
NCT01507181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1589|Ketamine For Suicidal Ideation|Investigating Rapid Anti-Suicidal Ideation Effects of Intravenous (IV) Ketamine in Hospitalized Patients||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|No|||November 2014|November 10, 2014|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507181||92939|
NCT01507194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VNK115640|A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)|A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 mg) Dose of the Neurokinin-1 Receptor Antagonist, Vestipitant (GW597599), Compared With a Single 4 mg Intravenous Ondansetron Hydrochloride Dose for the Treatment of Breakthrough Post-Operative Nausea and Vomiting After Failed Prophylaxis With an Ondansetron-Containing Regimen in Patients Undergoing Non-Emergency Surgical Procedures||Accenture||Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|6||Actual|131|||Both|18 Years|75 Years|No|||September 2012|September 30, 2012|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507194||92938|
NCT01507506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08 TETE 01|Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma|Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging|SPECTRO GLIO|Institut Claudius Regaud|No|Recruiting|March 2011|March 2019|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|N/A|No|||September 2014|May 26, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01507506||92915|
NCT01476709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-1-005|Photonic Needle and Sleeve Study|Photonic Needle and Intraforaminal Epidural Injection (Sleeve) - Observational Study in Humans|PhotonicNeedle|Maastricht University Medical Center|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|||Both|18 Years|80 Years|No|Probability Sample|Patients who have radicular pain on lumbar level, caused by disc herniation, and/or        lateral recessus stenosis and/or radiculopathy eci.|April 2012|April 5, 2012|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476709||95275|
NCT01507493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCN9A|The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population|The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population||Huazhong University of Science and Technology|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|N/A||2|Actual|200|Samples With DNA|Heparin anti-coagulated blood (2 ml) was collected from the central venous during the      operation and all blood samples were stored at -80℃. Genomic DNA was extracted from the      blood samples using a guanidinium isothiocyanate method.|Both|20 Years|70 Years|No|Non-Probability Sample|800 Chinese patients receiving elective upper abdominal surgery under general anesthesia|August 2014|August 31, 2014|January 2, 2012||No||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01507493||92916|
NCT01507740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Praemarker AAT 08|Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients|Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients||Medical University Innsbruck|Yes|Terminated|July 2009|October 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|60|Samples With DNA|Consecutive serum and blood probes will be taken and will be examined and correlated with      functional imaging and the clinical course. Following parameters have been selected: soluble      markers in the plasma (VEGF, bFGF, ICAM, sVGFR-2 IL-8, SDF1 and Dickkopf 3) and cellular      parameters like circulating endothelial cells (CEC) and circulating endothelial progenitor      cells (CEPs).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|-  10 NSCLC patients treated with bevacizumab monotherapy (maintenance therapy)          -  10 RCC patients treated either with sorafenib or sunitinib monotherapy          -  10 CRC patients treated with bevacizumab monotherapy          -  10 HCC patients treated with sorafenib monotherapy|April 2015|April 28, 2015|September 18, 2009||No|Study was stopped 04.10.2014 prematurly after recruitment of HCC and RCC patients. NSCLC (2 of    10 patients planned) and CRC patients recruitment was stopped|No||https://clinicaltrials.gov/show/NCT01507740||92897|
NCT01508598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108M02842|Validation of Circulating Endothelial Cells and Microparticles in Youth|Validation of Circulating Endothelial Cells and Microparticles in Youth||University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|February 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|32|Samples Without DNA|10 mL of blood serum and 5 mL of blood plasma will be frozen in long-term storage for future      study analyses and use. 8 mL of urine will be frozen in long-term storage for future study      analyses and use.|Both|8 Years|17 Years|No|Non-Probability Sample|Thirty-two children and adolescents, who are currently scheduled to undergo elective        bariatric surgery.|May 2015|May 26, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01508598||92833|
NCT01508806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1329|Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function|A Single-centre, Open-label, Trial Investigating the Pharmacokinetics and the Tolerability of Liraglutide in Subjects With Normal Renal Function and in Subjects With Impaired Renal Function||Novo Nordisk A/S|No|Completed|August 2005|March 2006|Actual|March 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|75 Years|No|||January 2015|January 22, 2015|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508806||92817|
NCT01508819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K100103|Impact on Mid-term Mortality of Guidelines for ICU Admission of Elderly Patients Arriving in Emergency Departments|Impact on Mid-term Mortality of Guidelines for ICU Admission of Elderly Patients Arriving in Emergency Departments: a Cluster Randomized Controlled Trial|ICECUBII|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|3035|||Both|75 Years|N/A|No|Probability Sample|Patients over 75 visiting the emergency department with a condition potentially warranting        intensive care unit admission|June 2015|June 17, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01508819||92816|
NCT01504685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|banded/unbandedBypassINNSZ|Long-Term Results of a Randomized Trial Comparing Banded-versus-Standard Laparoscopic Roux-en-Y Gastric Bypass|Long-Term Results of a Randomized Trial Comparing Banded-versus-Standard Laparoscopic Roux-en-Y Gastric Bypass||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|May 2003|August 2010|Actual|March 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|65 Years|No|||January 2012|January 25, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01504685||93131|
NCT01477918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetS_1005|Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea|||Asan Medical Center|No|Not yet recruiting|December 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|65 Years|No|Non-Probability Sample|The study will include all patients that met the following criteria:          1. Diagnosis of schizophrenia according to DSM-IV-TR          2. Age between 18-65 years        To obtain the representative results for the prevalence of the MetS in schizophrenic        patients stratified age and gender, we plan to evaluate about one thousand patients in        twenty nationwide centers.          1. 20 centers were selected to provide the representative results of prevalence of the             MetS          2. 50 patients in each center were consecutively enrolled|November 2011|November 22, 2011|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01477918||95183|
NCT01477931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114003|Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features|An Open-Label, 8-week Trial of Bupropion Hydrochloride Extended Release (Wellbutrin XL®) In Patients With Major Depressive Disorder (MDD) With Atypical Features.|WellbutrinXL|The Catholic University of Korea|No|Completed|November 2010|September 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|N/A|No|||November 2011|November 22, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01477931||95182|
NCT01477905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-DEV-DEO-11-005|Impact of Priming the Infusion System on the Performance of Target-controlled Infusion of Remifentanil|Study of Proper Operation of the Syringe Pump Used in Priming of the Syringe||Ajou University School of Medicine|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|48|||Both|20 Years|70 Years|No|||November 2011|November 22, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01477905||95184|
NCT01478165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OC11MISI0090|Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting|Comparative Study of TIVA(Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing PONV(Postoperative Nausea and Vomiting)||Incheon St.Mary's Hospital|Yes|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Female|19 Years|N/A|No|||November 2011|November 22, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01478165||95164|
NCT01473849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHENUS|Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients|Non-interventional, Prospective Study to Evaluate the Impact of CMV Replication Over Hepatitis C Recurrence in Liver Transplant Recipients|VHENUS|Sociedad Española de Trasplante Hepático|No|Active, not recruiting|May 2010|April 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|179|Samples Without DNA|Serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients who underwent liver transplantation after hepatopathy caused by HCV|December 2012|December 19, 2012|May 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01473849||95495|
NCT01474148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#07101-H36|A Neuroprosthesis for Seated Posture and Balance|A Neuroprosthesis for Seated Posture and Balance|Trunk Protocol|Case Western Reserve University|No|Recruiting|July 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|N/A|No|||March 2016|March 17, 2016|November 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01474148||95472|
NCT01474447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-SB-541-CTIL|The Effect of Grinberg Method (GM) Intervention on Low-back Pain (LBP) and Improving the Quality of Life|The Research Protocol: The Effect of Grinberg Method (GM) Intervention on Low-back Pain (LBP) and Improving the Quality of Life||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|18 Years|65 Years|No|||February 2013|February 28, 2013|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01474447||95449|
NCT01475045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20109-HAL-EL-02|ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)|Multicenter, Prospective, Non Interventional Observational Study in Treatments of Asthma and Chronic Obstructive Pulmonary Disease (COPD)|ANASA|Elpen Pharmaceutical Co. Inc.|No|Completed|January 2011|September 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|1160|||Both|18 Years|N/A|No|Probability Sample|Three subgroups of patients who are already in their inhalation treatment (devices:        Discus, Elpenhaler, Turbuhaler) are asked to complete the FSI-10 questionnaire valid in        Greek language. The questionnaire responses indicate their satisfaction by their treatment        devices.|November 2011|November 18, 2011|October 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01475045||95403|
NCT01475032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0807-PR-0024|Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children|A Phase III, 12-week, Multicentre, Multinational, Randomised, Double-blind, Double-dummy, 3 Arm-parallel Group Study to Test the Efficacy of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate (BDP) Plus Formoterol Fumarate (FF)) Versus a Free Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate and Versus a Monotherapy of Beclomethasone Dipropionate in Partly Controlled Asthmatic Children|PAED2/FRESH|Chiesi Farmaceutici S.p.A.|Yes|Completed|September 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|638|||Both|5 Years|11 Years|No|||March 2013|March 27, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01475032||95404|
NCT01475305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ID-MEDI-557-1090|Intra-nasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)|A Phase 1 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of MEDI-557 in Healthy Adults Intranasally Challenged With Respiratory Syncytial Virus (RSV)||MedImmune LLC|No|Completed|November 2011|April 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|7|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 5, 2013|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475305||95383|
NCT01475591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHSAM_NLL_LTU|Individually Tailored Web-based Multimodal Pain Rehabilitation in Primary Health Care|Individually Tailored Web-based Multimodal Pain Rehabilitation in Primary Health Care||Luleå Tekniska Universitet|No|Recruiting|October 2011|June 2015|Anticipated|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|63 Years|No|||September 2014|September 10, 2014|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01475591||95361|
NCT01475877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC-02-11|Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy|Bromday (Bromfenac Ophthalmic Solution)0.09% QD vs Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Control of Pain and Epithelial Healing Post (PRK)||Virdi Eye Clinic|No|Recruiting|May 2011|May 2012|Anticipated|May 2012|Anticipated|Phase 4|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing photorefractive keratectomy in both eyes|November 2011|November 20, 2011|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01475877||95339|
NCT01506895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115403|A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema|A Phase 2, Multi-national, Multi-centre, Double Masked, Randomised, Placebo Controlled, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Darapladib Administered for 3 Months to Adult Subjects With Diabetic Macular Edema With Centre Involvement||GlaxoSmithKline|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||March 2013|March 7, 2013|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01506895||92961|
NCT01506908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S7121359|Provoked Craving Assessment|Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving||GlaxoSmithKline|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|February 6, 2014|December 15, 2011|Yes|Yes||No|December 12, 2013|https://clinicaltrials.gov/show/NCT01506908||92960|
NCT01508091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONDECYT 1110035|Calorie Restriction Retards the Aging Process|Calorie Restriction Retards the Aging Process by Inducing Sirtuins and Uncoupling Protein 3, Thereby Reducing the Production of Reactive Oxygen Species.||University of Chile|No|Recruiting|May 2012|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|48|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 20, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01508091||92870|
NCT01507779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVAC-mH1N1-01|Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine|Evaluation of The Safety and Immunogenicity of an Influenza A/H1N1 Vaccine (IVACFLU), Produced by IVAC, in Healthy Adults in Vietnam||PATH|No|Completed|April 2012|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2013|September 19, 2013|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507779||92894|
NCT01507519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOFIM/MLS/100209|Study Safety,Efficacy of the Biomime Stent in Patients With Single, Discrete, De Novo, Non-Complex Coronary Lesions|The First-In_Man Safety and Performance Evaluation of the Biomime Sirolimus Eluting Stent System for the Treatment of Patients With Single, Discrete, De Novo, Non-Complex Coronary Lesions-The Biomime Pilot FiM Trial.||Meril Life Sciences Pvt. Ltd.|No|Completed|April 2009|March 2011|Actual|October 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 10, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507519||92914|
NCT01507753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0104|Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified|Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Bipolar Disorder- Not Otherwise Specified|OATS|Ohio State University|Yes|Completed|September 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|23|||Both|7 Years|14 Years|No|||March 2016|March 4, 2016|August 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01507753||92896|
NCT01508078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01627|Characterization of Adult Subjects for Asthmatic Research Studies|Characterization of Adult Subjects for Asthmatic Research Studies|CASA|University of California, San Francisco|No|Recruiting|May 2010|July 2018|Anticipated|July 2017|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|2000|Samples With DNA|Samples of induced sputum and blood for DNA and RNA extraction, plasma, and serum will be      banked in the UCSF Airway Tissue Bank.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Asthmatics and healthy control|November 2015|November 10, 2015|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01508078||92871|
NCT01504464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Bone-010|The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis|Evaluation the Effects of Intra-articular Injection of Mesenchymal Stem Cells in Patients With Knee Joint Osteoarthritis, Triple Blind Randomized Clinical Trial||Royan Institute|Yes|Completed|September 2010|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||March 2010|December 25, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504464||93148|
NCT01504698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVKS-20110042|Manipulative Treatment of Children With Neck and Back Pain|Manipulative Treatment of Children With Neck and Back Pain. A Randomised Controlled Trial of 1200 Children From 3rd to 7th Grade||University of Southern Denmark|Yes|Completed|February 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|237|||Both|8 Years|15 Years|No|||May 2015|May 18, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504698||93130|
NCT01504958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000325|Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients|Effects of a Combined TMS and Cognitive Training in Alzheimer Patients: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study||Beth Israel Deaconess Medical Center|No|Active, not recruiting|December 2010|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|55 Years|90 Years|No|||May 2014|May 28, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01504958||93110|
NCT01474499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FE999306 CS01|A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation|A Multi-center, Randomized, Single-blind Clinical Study of the Comparative Safety and Efficacy of Docusate Sodium and Sorbitol Rectal Solution and Glycerine Enemas in Patients With Constipation||Ferring Pharmaceuticals|No|Completed|September 2011|May 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|65 Years|No|||September 2012|September 24, 2012|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01474499||95445|
NCT01474512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12972|A Phase 3 Study in Participants With Moderate to Severe Psoriasis|A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis|UNCOVER-1|Eli Lilly and Company|Yes|Active, not recruiting|November 2011|November 2018|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1296|||Both|18 Years|N/A|No|||March 2015|March 10, 2015|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474512||95444|
NCT01478178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLM-10-001|Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma|Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma||DelMar Pharmaceuticals, Inc.|No|Active, not recruiting|October 2011|December 2016|Anticipated|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|November 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478178||95163|
NCT01474161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-111-7|Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505|Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients||Genfit|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 23, 2012|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474161||95471|
NCT01474460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000493|Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy|Use of Phytonadione to Reduce INR Variability in Patients on Long-term Warfarin Therapy||James A. Haley Veterans Administration Hospital|Yes|Completed|September 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|370|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474460||95448|
NCT01474746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|271070|Trial of Sertraline to Treat Children With Fragile X Syndrome|A Controlled Trial of Sertraline in Young Children With Fragile X Syndrome||University of California, Davis|Yes|Completed|January 2012|September 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|24 Months|68 Months|No|||January 2016|January 26, 2016|November 10, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474746||95426|
NCT01505972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NR13002404_1|Time Schedules for Sending Invitations to Colonoscopy Screening|||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Completed|March 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1600|||Both|55 Years|64 Years|No|||January 2012|January 6, 2012|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01505972||93032|
NCT01475331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 33751|The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts|||Milton S. Hershey Medical Center|Yes|Recruiting|November 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|November 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01475331||95381|
NCT01475578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2001ZL272|Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)|A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)||Sinphar Pharmaceutical Co., Ltd|No|Completed|March 2002|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|45 Years|80 Years|No|||November 2011|November 16, 2011|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475578||95362|
NCT01506622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0536|Comparison Between Propofol and Fentanyl for Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia|||Yonsei University|Yes|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|3||Actual|222|||Both|18 Months|72 Months|No|||July 2015|July 14, 2015|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01506622||92982|
NCT01507766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110-85|The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis|The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis||Nanjing University School of Medicine|Yes|Completed|September 2010|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||November 2012|November 15, 2012|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507766||92895|
NCT01507792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRONCOUGH|Iron Repletion in Chronic Cough and Iron Deficiency|Effect of Iron Repletion in Women With Chronic Cough and Iron Deficiency|CID|University of Turin, Italy|No|Completed|January 2002|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|15 Years|70 Years|No|||January 2012|January 8, 2012|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01507792||92893|
NCT01508611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03|Cost-effectiveness of Silver Diammine Fluoride in Erupting Molars|Cost-effectiveness of Silver Diammine Fluoride to Control Caries Lesions in Erupting Permanent First Molars - Randomized Clinical Trial.||University of Sao Paulo|Yes|Not yet recruiting|June 2014|December 2016|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|4 Years|7 Years|Accepts Healthy Volunteers|||June 2014|June 2, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01508611||92832|
NCT01508364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16091|Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma|NEXTAR - NEXavar® as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma|NEXTAR|Bayer|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|N/A|N/A|No|Non-Probability Sample|The study population will consist of patients with metastatic/advanced RCC (all        histologies), who failed prior cytokine therapy or are not suitable for cytokine therapy        and for whom Nexavar constitutes first targeted therapy.|January 2015|January 19, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01508364||92850|
NCT01504477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-033|Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer|A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer||Georgetown University|Yes|Terminated|December 2011|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||February 2014|July 22, 2015|December 14, 2011|Yes|Yes|Low accrual--unable to meet accrual goals|No||https://clinicaltrials.gov/show/NCT01504477||93147|
NCT01504711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-116|Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy|Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in Gastrointestinal Cancer Patients||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|42|||Both|19 Years|N/A|No|||February 2016|February 11, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01504711||93129|
NCT01504971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111013-001|Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease|Diagnostic Value of Narrow-band Imaging, Autofluorescence Imaging & White-light Imaging on Gastroesophageal Reflux Disease||Chinese PLA General Hospital|Yes|Active, not recruiting|January 2011|December 2016|Anticipated|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|95|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Patients presented with reflux symptoms in outpatient clinic of a general hospital.|August 2015|August 4, 2015|January 4, 2012||No||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01504971||93109|
NCT01474525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFP6075|Managing Diabetes During Pregnancy in the Wireless Age|Managing Diabetes During Pregnancy in the Wireless Age: a RCT of Glucose Telemonitoring||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Recruiting|January 2010|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|50 Years|No|||November 2011|November 17, 2011|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01474525||95443|
NCT01473862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD11-150 ALOSS|Adolescent Loss: The Impact of Loss on Adolescent Oncology Patients|Adolescent Loss: The Impact of Loss on Adolescent Oncology Patients|ALOSS|St. Jude Children's Research Hospital|No|Active, not recruiting|January 2012|June 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|175|||Both|13 Years|21 Years|No|Non-Probability Sample|English-speaking adolescent oncology patients (age 13-21) at St. Jude Children's Research        Hospital who have been on therapy for ≥ 12 months (≥ 6 months if progressive or refractory        disease) OR off therapy for ≤ 3 years.|August 2015|August 4, 2015|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01473862||95494|
NCT01474174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98411|Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors|A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|September 2011|||July 2012|Actual|Phase 0|Observational|Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|patients with primary central nervous system turmors|September 2015|September 22, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01474174||95470|
NCT01474759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PortionSize101|Portion Size Strategies for Management of Body Weight|||Penn State University|Yes|Completed|July 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|186|||Female|20 Years|65 Years|No|||May 2015|May 14, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474759||95425|
NCT01475058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2494.00|CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant|A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant||Fred Hutchinson Cancer Research Center|Yes|Completed|April 2012|||April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||August 2015|August 4, 2015|November 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01475058||95402|
NCT01505699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000720304|Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia|Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities||National Cancer Institute (NCI)||Not yet recruiting|March 2012|||March 2013|Anticipated|N/A|Observational|N/A|||Anticipated|186|||Both|15 Years|65 Years|No|||January 2012|January 4, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505699||93053|
NCT01505985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NES1026CLI|Hip Fracture Surgery and Oral Nutritional Supplements|Effect of a Nutritional Intervention on Hip Fracture Surgery Recovery|HIATUS|Nestlé|No|Terminated|January 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|24|||Both|70 Years|N/A|No|||November 2013|November 22, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01505985||93031|
NCT01505998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5531/06-07|Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions|An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 6, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505998||93030|
NCT01506310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sbo2010|Efficacy of Behavioral Therapy and Exercise in Gestational Diabetes Mellitus (GDM)|Randomized Comparative Trial on the Efficacy of Behavioral Therapy, Exercise and Their Combination in Gestational Diabetes Mellitus (GDM).||University of Turin, Italy|No|Completed|July 2009|June 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01506310||93006|
NCT01506635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8902|Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial|Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After Laser in Situ Keratomileusis: A Randomized Clinical Trial||hahid Beheshti University of Medical Sciences|Yes|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|20 Years|N/A|No|||October 2009|January 9, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01506635||92981|
NCT01506648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSTAPA-FP7-211484|Assessment of Zinc Absorption From a Phytic Acid Rich Complementary Food|Assessment of Zinc Absorption From a Phytic Acid Rich Complementary Food, Consumed by Young Children Immediately After the Addition of the Enzyme Phytase. A Randomized Single Blind Study||Swiss Federal Institute of Technology||Completed|January 2011|October 2012|Actual|April 2012|Actual|N/A|Observational|N/A||1|Actual|40|||Both|12 Months|24 Months|Accepts Healthy Volunteers|Probability Sample|Study not related to a disease. Nutrition study without drug drug administration.        Assessment of zinc absorption from a phytic acid rich complementary food, consumed by        young children immediately after the addition of the enzyme phytase. A randomized single        blind study|June 2013|June 6, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01506648||92980|
NCT01507545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-004-202-CRC|Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)|A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer||Morphotek|Yes|Completed|March 2012|December 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507545||92912|
NCT01508117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCR-2|Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients|A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)||University of Cincinnati|Yes|Recruiting|January 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|70 Years|N/A|No|||January 2012|January 10, 2012|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508117||92868|
NCT01508338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2012-CS01|The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes|The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes||Metabolic Technologies Inc.|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|44|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508338||92852|
NCT01508351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38444|The Hypotensive Effect of Propofol: an Observational Study|The Hypotensive Effect of Propofol: an Observational Study of Hypotension With Anesthetic Induction by Propofol in the General Population Under Standard of Care Anesthesia||Milton S. Hershey Medical Center|No|Completed|May 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Hershey Medical Center patients presenting for surgery.|April 2015|April 28, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508351||92851|
NCT01508624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6045559US|Evaluation of Interventions to Improve Pain Relief, Perceived Anxiety and Recovery in Participants Receiving Office Based Surgery|Evaluation of an Intervention to Increase Pain Relief, Perceived Anxiety and Recovery in Participants Receiving Office Based Surgery||University of Surrey|Yes|Completed|April 2012|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|5||Actual|404|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01508624||92831|
NCT01504490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-345|Phase I Study of CS-7017 and Bexarotene|A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene||Georgetown University|Yes|Terminated|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||September 2015|February 15, 2016|December 14, 2011|Yes|Yes|Drug no longer available|No||https://clinicaltrials.gov/show/NCT01504490||93146|
NCT01504503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|645/09|Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10 mg in Healthy, Adult, Human Subjects Under Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Completed|October 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|January 5, 2012|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504503||93145|
NCT01504724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVB and PRP|Effect of the Adjunctive IVB Before PRP|Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness|IVB|Kyungpook National University|Yes|Completed|August 2011|August 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|N/A|N/A|No|||December 2013|December 24, 2013|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01504724||93128|
NCT01505803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREC 12392|The Effect of a Nutritional Supplement in Individuals With Type 2 Diabetes Mellitus: a Pilot Study|The Effect of a Nutritional Supplement on Cardiometabolic, Inflammatory, and Oxidative Stress Markers in Individuals With Type 2 Diabetes Mellitus: a Pilot Study||University of Sydney|No|Completed|July 2010|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Female|48 Years|N/A|No|||January 2012|January 5, 2012|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01505803||93045|
NCT01475149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 10130|Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)|Effect of Hydroxychloroquine on the Annexin A5 Resistance Assay in Antiphospholipid Antibody-Positive Patients With and Without Systemic Lupus Erythematosus||Hospital for Special Surgery, New York|No|Recruiting|September 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|50|Samples Without DNA|serum, plasma|Both|18 Years|65 Years|No|Non-Probability Sample|For aPL positive groups, subjects must have persistently positive (over at least 12 weeks)        antiphospholipid antibodies in the blood.|February 2013|February 3, 2013|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475149||95395|
NCT01504672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UmU-2011-148-31M|A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia|A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia||Umeå University||Completed|January 2012|August 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|460|||Both|65 Years|N/A|No|||November 2015|November 30, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504672||93132|
NCT01504906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130C00074|Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor|A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine||AstraZeneca||Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|January 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01504906||93114|
NCT01504919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0606|Community Network Program|Reducing Cancer Disparities Among Latinos in Texas||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2012|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 1, 2015|January 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01504919||93113|
NCT01505179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0109|The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction|The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction|RAZE|University of California, San Diego||Enrolling by invitation|February 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505179||93093|
NCT01505413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yun-11349|Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer|Phase 2 Study of GEMOX-T in Previously Untreated Patients With Advanced Pancreatic Cancer|GEMOX-T|Soonchunhyang University Hospital|Yes|Completed|January 2011|March 2014|Actual|December 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||April 2014|April 2, 2014|January 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01505413||93075|
NCT01506375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gpASIT006|Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant|Safety, Clinical Tolerability and Immunogenicity of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Either Alone or in Presence of DnaK Immunoregulating Adjuvant||BioTech Tools S.A.|No|Completed|November 2011|April 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|No|||August 2012|May 23, 2014|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01506375||93001|
NCT01505712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000720334|Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial|Outcome Prediction in Hodgkin Lymphoma by Low-Density Gene Expression Profiling of Formalin Fixed Paraffin Embedded Tissues: A Correlative Study of Inter-Group Trial E2496||National Cancer Institute (NCI)||Active, not recruiting|December 2011|||June 2012|Anticipated|N/A|Observational|N/A|||Anticipated|393|||Both|16 Years|N/A|No|||January 2012|January 7, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505712||93052|
NCT01506674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR CEmet|Metabolomic in Critical Ill Patients|||Università Vita-Salute San Raffaele||Recruiting|January 2015|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|99 Years|No|Non-Probability Sample|Critical ill patients|March 2016|March 9, 2016|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01506674||92978|
NCT01506934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-468|A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1, Open Label, Randomized, Adaptive, Cross-Over Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors||Abbott|No|Terminated|October 2011|January 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|October 11, 2011|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01506934||92958|
NCT01506687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-163|Increasing Colorectal Cancer Screening Uptake With a Patient Navigator|Increasing Colorectal Cancer Screening Uptake With a Patient Navigator - Phase III Trial||Cancer Care Ontario|No|Completed|January 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|750|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||December 2013|December 2, 2013|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01506687||92977|
NCT01506323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLE-003-11S|Mantram Repetition Meditation for Veterans With PTSD|Portable Mantram Meditation for Veterans With Military Related PTSD||VA Office of Research and Development|Yes|Completed|January 2012|June 2015|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|December 19, 2011||No||No|July 8, 2015|https://clinicaltrials.gov/show/NCT01506323||93005|Study was to provide interventions for both conditions (MRP and PCT) in "group" format. Due to poor recruitment and after approval from Data Monitoring Committee, the study protocol was changed to provide both interventions in "individual" format.
NCT01506336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB07001|A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib|A Prospective, Multicenter, Randomized, Open-label, Active Controlled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of Masitinib at 12 mg/kg/Day to Sunitinib at 50 mg/Day in Treatment of Patients With Gastro-intestinal Stromal Tumor Resistant to Imatinib||AB Science|Yes|Active, not recruiting|October 2008|December 2013|Anticipated|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01506336||93004|
NCT01507532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00056702|Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients|Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients||Midwestern University|No|Withdrawn|January 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|N/A|N/A|No|||March 2016|March 16, 2016|January 3, 2012|Yes|Yes|did not enroll a patient|No||https://clinicaltrials.gov/show/NCT01507532||92913|
NCT01507233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B302|A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy|IMPROVE-Open|Pacira Pharmaceuticals, Inc|No|Terminated|May 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|5|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|October 24, 2011|Yes|Yes|Slow enrollment.|No|November 30, 2013|https://clinicaltrials.gov/show/NCT01507233||92935|
NCT01507805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|csyxijing|Electroacupuncture Preconditioning on Geriatric Noncardiac Surgery|Effects of Electroacupuncture Preconditioning on Outcomes of the Geriatric Patients With Coronary Heart Disease Undergoing Non-cardiac Surgery||Xijing Hospital|Yes|Recruiting|February 2011|January 2013|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|65 Years|N/A|No|||February 2011|January 8, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01507805||92892|
NCT01507818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amp-PostOpShoulder-Pain-001|Effectiveness of the Ivivi Torino II, Pulsed Radio Frequency Device, on Narcotic Use, Pain and Quality of Life Following Shoulder Arthroscopic Rotator Cuff Repair.|Impact of Non-thermal Pulsed Radio Frequency (PRF)on Narcotic Use, Pain, and Health-related Quality of Life Following Shoulder Arthroscopic Rotator Cuff Repair: A Double-Blind, Randomized Sham-Controlled Trial||Amp Orthopedics, Inc.|No|Terminated|December 2011|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|37|||Both|40 Years|80 Years|No|||July 2012|July 6, 2012|January 9, 2012|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01507818||92891|
NCT01504516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|646-09|Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10mg in Healthy, Adult, Human Subjects Under Fed Condition.||Dr. Reddy's Laboratories Limited|No|Completed|October 2009|December 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2009|January 5, 2012|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504516||93144|
NCT01508104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235ZUS08T|Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors|A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies||University of Cincinnati|Yes|Recruiting|January 2012|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||January 2012|January 6, 2012|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508104||92869|
NCT01508637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39833-D|Diesel Exhaust and Vascular Function|Effect of Diesel Exhaust Exposures on Vascular Function in Humans: The Role of Sympathetic Activation|CVDTRAP4|University of Washington|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|24|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01508637||92830|
NCT01504984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYO1126|Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers|An Open-label, Randomized, Single Dose, Crossover Phase I Clinical Trial to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab., 4T (400mg) in Healthy Male Volunteers||Samyang Biopharmaceuticals Corporation|Yes|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 10, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01504984||93108|
NCT01505257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR011042|Early Nurse Detection and Management of Delirium|Early Nurse Detection of Delirium Superimposed on Dementia|END-DSD|Penn State University|Yes|Active, not recruiting|April 2010|February 2015|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|390|||Both|65 Years|N/A|No|||October 2014|October 28, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505257||93087|
NCT01505270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-11-HYMC|The Prevalence of Psychological and Medical Comorbidities Among Children Suffering From Autistic Spectrum Disorder and the Differences Between Ethnic Groups in Israel|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|1 Year|18 Years|No|Probability Sample|Community sample|January 2012|January 5, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505270||93086|
NCT01505816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOB05|Visual Outcomes After Implantation of a New Multifocal Intraocular Lens|Visual Outcomes After Implantation of a New Refractive Toric Multifocal Intraocular Lens||Hospital Oftalmologico de Brasilia|Yes|Completed|October 2011|January 2012|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||January 2012|January 6, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01505816||93044|
NCT01475435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMSAL2712|Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients|Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients With Generalized Chronic Periodontitis and Healthy Periodontium||University of Sao Paulo|Yes|Recruiting|August 2011|August 2013|Anticipated|December 2011|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|4||Anticipated|200|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||August 2011|November 16, 2011|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01475435||95373|
NCT01475448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-262790|Long Distance Running Training by Older Adults|Effects of Long Distance Running Training on the Posture and Movement Control of Sedentary Older Adults||University of Sao Paulo|No|Completed|January 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|34|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||November 2011|May 2, 2015|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01475448||95372|
NCT01505426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-2004|A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients|A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone||Astellas Pharma Inc|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|171|||Both|20 Years|N/A|No|||January 2016|January 19, 2016|January 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01505426||93074|
NCT01505439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VENUS-MUI|A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence|A Prospective, Open Label, Single Arm, Multicenter Study to Estimate the Efficacy and Safety of Solifenacin in Female With Clinically Significant Stress Urinary Incontinence and Urgency Urinary Incontinence||Astellas Pharma Inc|No|Recruiting|June 2011|April 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|18 Years|N/A|No|||January 2012|January 4, 2012|January 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01505439||93073|
NCT01505725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999910456|Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms|Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms||National Institutes of Health Clinical Center (CC)||Completed|March 2010|November 2013||||N/A|Observational|N/A|||Anticipated|230|||Both|18 Years|64 Years|No|||November 2013|February 19, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505725||93051|
NCT01506011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5530/06-07|Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fasting Conditions|An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2007|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 5, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506011||93029|
NCT01506349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000354|Assessing Neurocognitive Effects of Gluten Exposure|An Assessment of Neurocognitive Symptoms After Gluten Exposure in Adult Patients With Celiac Disease - a Pilot Study||Beth Israel Deaconess Medical Center|No|Active, not recruiting|June 2015|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|18 Years|50 Years|No|||December 2015|December 7, 2015|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01506349||93003|
NCT01506362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL-7040.01|Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis|An Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis||BioLineRx, Ltd.|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|70 Years|No|||March 2014|July 1, 2014|January 3, 2012||No||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01506362||93002|
NCT01506661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMRF11-53|Zostavax in Rheumatoid Arthritis|Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis||Oklahoma Medical Research Foundation|Yes|Recruiting|January 2012|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01506661||92979|
NCT01506921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 MRI-ASL|Racemic Ketamine Versus S-ketamine With Arterial Spin Labeling (ASL)-MRI in Healthy Volunteers|A Prospective Randomised, Double-blinded Cross-over Study to Investigate the Effects of Racemic and S-ketamine on Cerebral Blood Flow on Healthy Volunteers With MRI-ASL||Lund University|Yes|Completed|May 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01506921||92959|
NCT01506388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12012|A Novel Protocol for Labour Induction|Foley Catheter Plus Vaginal Isosorbide Mononitrate Versus Vaginal Misoprostol for Induction of Labour:a Randomised Controlled Trial||Cairo University|Yes|Completed|February 2012|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2014|January 19, 2014|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506388||93000|
NCT01506947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W12-645|A Prospective Open-Label, Non-randomised, Single-arm, Pilot Clinical Study Evaluating the Effect of PTH Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients|A Prospective Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients||AbbVie|No|Active, not recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01506947||92957|
NCT01506986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11091|Helicobacter Eradication Aspirin Trial|Helicobacter Eradication to Prevent Ulcer Bleeding in Aspirin Users: a Large Simple Randomised Controlled Trial|HEAT|University of Nottingham|Yes|Recruiting|March 2012|April 2017|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|33000|||Both|60 Years|N/A|No|||December 2015|December 1, 2015|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506986||92954|
NCT01507207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 7850|Pediatric Dysphagia Outcomes After Injection Laryngoplasty for Type I Laryngeal Cleft|Pediatric Dysphagia Outcomes After Injection Laryngoplasty for Type I Laryngeal Cleft||Oregon Health and Science University|No|Recruiting|January 2012|June 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|18 Years|No|||January 2012|January 5, 2012|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507207||92937|
NCT01507558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02101|Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization|Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization|DANCE|University of California, San Francisco|Yes|Active, not recruiting|December 2010|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|40 Years|80 Years|No|||October 2015|October 20, 2015|November 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01507558||92911|
NCT01508650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00016973|Rehabilitation and Exercise Training After Hospitalization|Rehabilitation and Exercise Training After Hospitalization: Assessing Benefit in Acute Heart Failure (REHAB-HF) Pilot Study|REHAB-HF|Wake Forest School of Medicine|Yes|Active, not recruiting|October 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|60 Years|N/A|No|||January 2015|January 16, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01508650||92829|
NCT01504529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1018|Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine|Non-Interventional, Retrospective, Multi-center Study to Evaluate Non-Motor Symptoms in Advanced PD Patients Already Treated With Rotigotine|RETO-PD|UCB Pharma|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|391|||Both|30 Years|N/A|No|Non-Probability Sample|As a retrospective Observational Study, the data will be obtained from the medical records        of the patients with advanced PD who have been treated for at least 6 months with        Rotigotine (Neupro®) as prescribed by physicians according to usual clinical practice in        Spain.        The study will approximately include 400 patients from 80 Spanish sites.|April 2013|April 12, 2013|January 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01504529||93143|
NCT01508377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTTV-001|Effects of an Internet-based Intervention for Posttraumatic Stress Disorder|Additive Effect of Cognitive Restructuring in a Web-based Treatment for Traumatized Arab People||Berlin Center for the Treatment of Torture Victims|No|Completed|December 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|293|||Both|18 Years|N/A|No|||January 2016|January 30, 2016|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01508377||92849|
NCT01504997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DaVinci_SCC|Phase II Study for Robot Assisted Distal Gastrectomy|A Phase II Study of Robot Assisted Distal Gastrectomy With Nodal Dissection for Clinical Stage Ia Gastric Cancer|RADGphaseII|Shizuoka Cancer Center|Yes|Active, not recruiting|December 2011|December 2017|Anticipated|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|20 Years|80 Years|No|||January 2013|January 9, 2013|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01504997||93107|
NCT01506141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-HIT-046|Extension of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase (IT)in Conjunction With Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment|An Open Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment||Shire|No|Active, not recruiting|August 2010|November 2021|Anticipated|October 2021|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Male|3 Years|18 Years|No|||November 2015|November 20, 2015|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506141||93019|
NCT01505244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-031|Before-School Physical Activity Intervention in Elementary School Children|Before-School Physical Activity Intervention in Elementary School Children: A Pilot Study||University of Vermont|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|39|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01505244||93088|
NCT01505517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_SBrumagne_DiaphFatigue|Inspiratory Resistive Loading and Diaphragm Fatigue|Inspiratory Resistive Loading and Diaphragm Fatigue in Healthy Individuals and Individuals With Recurrent Low Back Pain||Katholieke Universiteit Leuven|Yes|Completed|January 2011|June 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|young flemish volunteers|July 2012|December 4, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505517||93067|
NCT01476579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/123|Comparison of Low-radiation Dose CT Angiography With Invasive Coronary Angiography in Stable Coronary Disease|Diagnostic Accuracy of New Generation Low-dose CT Coronary Angiography||University Hospital of North Norway|No|Active, not recruiting|January 2012|January 2022|Anticipated|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|769|||Both|30 Years|90 Years|No|||April 2013|April 4, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01476579||95285|
NCT01505205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1606-81160274|Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors|||Guangxi Medical University|Yes|Completed|April 2011|June 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|N/A|N/A|No|Probability Sample|patients with Gist at the Department of Gastrointestinal and Glands Surgery of the First        Affiliated Hospital of Guangxi Medical University in China.|January 2012|January 5, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505205||93091|
NCT01505218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PER 2010/232-31|Propofol Patient-controlled Sedation for Endoscopic Retrograde Cholangiopancreatography|Patient-controlled Propofol Sedation for Endoscopic Retrograde Cholangiopancreatography|PER-projekt|University Hospital, Linkoeping|No|Completed|October 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|281|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01505218||93090|
NCT01505452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOC-OM-Stryker-2009-0019|Study of Surgical Technique With Use of Single-radius Prosthesis in Total Knee Replacement|Translational Error in Flexion-extension Gap Balancing With Singe Radius Total Knee Arthroplasty||Athens Orthopedic Clinic, P.A.|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|43|||Both|18 Years|N/A|No|Non-Probability Sample|Clinic based population (patients undergoing total knee replacement at an orthopedic        surgery clinic).|May 2014|May 5, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505452||93072|
NCT01505738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-Surg-009|Bacterial Growth in Vascular Surgery Wounds|The Effect of Bacterial Growth in Vascular Surgery Wounds to the Incidence of Postoperative Wound Infections||North Karelia Central Hospital|No|Completed|January 2012|November 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|100 patients requiring lower limb vascular surgery due to ischaemic changes and/or lower        limb aneurysms.|December 2012|December 13, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505738||93050|
NCT01505751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100078-E|The Association of G9a Protein and the Outcome of Patients With Cervical Cancer|||Far Eastern Memorial Hospital||Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|70|Samples With DNA|Residual pathology block after pathological exam|Female|20 Years|N/A|No|Non-Probability Sample|Patients with cervical cancer, and underwent primary treatment (surgery, radiotherapy or        chemotherapy) in Far Eastern Memorial Hospital|July 2015|July 4, 2015|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01505751||93049|
NCT01506037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50633|Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition|Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|January 2006|February 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2006|January 10, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506037||93027|
NCT01506024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/450|Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term Results|Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term Results||Norwegian University of Science and Technology|No|Active, not recruiting|September 2011|September 2016|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|N/A|70 Years|No|||July 2015|July 13, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01506024||93028|
NCT01506401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCT94829|The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial|The Oscillation for ARDS Treated Early (OSCILLATE) Trial|OSCILLATE|Canadian Critical Care Trials Group|Yes|Terminated|June 2009|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|548|||Both|16 Years|85 Years|No|||September 2012|August 5, 2015|December 14, 2011||No|Enrolment halted by Steering Committee on advice from Data Monitoring Committee.|No||https://clinicaltrials.gov/show/NCT01506401||92999|
NCT01507246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B303|Adult Patients Undergoing Open Colectomy MA402S23B303|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy|IMPROVE-Open|Pacira Pharmaceuticals, Inc|No|Completed|December 2011|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|42|||Both|18 Years|N/A|No|||May 2013|May 6, 2013|October 23, 2011|Yes|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01507246||92934|
NCT01507571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DignityTherapyDK 01|Implementation and Evaluation of Dignity Therapy in Denmark|Implementation and Evaluation of Dignity Therapy in Denmark|DignityDK|Bispebjerg Hospital|No|Completed|September 2005|September 2007|Actual|September 2007|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|80|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01507571||92910|
NCT01506960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001608|Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque|Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque||Massachusetts General Hospital|No|Terminated|January 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|64|||Both|18 Years|79 Years|No|||October 2013|October 23, 2013|January 3, 2012|Yes|Yes|It was felt that a sufficient number of subjects were enrolled.|No|May 16, 2013|https://clinicaltrials.gov/show/NCT01506960||92956|
NCT01506973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 19211|A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer|A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|January 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01506973||92955|
NCT01507220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B301|A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy|IMPROVE-Open|Pacira Pharmaceuticals, Inc|No|Terminated|March 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|October 24, 2011|Yes|Yes|Slow enrollment|No|November 29, 2013|https://clinicaltrials.gov/show/NCT01507220||92936|
NCT01508390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29665|Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate|Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer||Boston Medical Center|Yes|Recruiting|June 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||January 2015|January 28, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01508390||92848|
NCT01508403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009zx09502-030|A Registry Study on Shuxuetong (a Chinese Medicine Injection) Used in Twenty Hospitals|A Registry Study on Shuxuetong (a Chinese Medicine Injection) Used in Twenty Hospitals|RSCMI-I|China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|all inpatients used or will use Shuxuetong injection in 20 selected hospitals in mainland        China|May 2013|May 13, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01508403||92847|
NCT01508663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0016|The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease|The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study|BRAVE|Yonsei University|Yes|Recruiting|August 2010|||February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1600|||Both|75 Years|84 Years|No|||January 2012|January 9, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01508663||92828|
NCT01505283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/20|Effect of Epidural Analgesia on the Parameter ANI During Childbirth|Effect of Epidural Analgesia on the Parameter ANI During Childbirth|APD-ANI|Hopital Foch|No|Recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Anticipated|360|||Female|18 Years|50 Years|No|||April 2014|April 14, 2015|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505283||93085|
NCT01505296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWI-IIS-0143|Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation|Randomized Comparison of Catheter Ablation Versus Anti-arrhythmic Drug Therapy in Patients With Recently Diagnosed Paroxysmal Atrial Fibrillation as Assessed by a Continuous Implantable Monitor|CABAL|Valley Health System|No|Withdrawn|December 2011|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|N/A|N/A|No|||December 2014|December 13, 2014|December 28, 2011||No|Never initiated|No||https://clinicaltrials.gov/show/NCT01505296||93084|
NCT01504737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RASP|Rehabilitation in Aortic Stenosis Patients|Rehabilitation in the Form of Exercise Training in Aortic Stenosis Patients (RASP)|RASP|Linkoeping University|No|Recruiting|September 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01504737||93127|
NCT01505010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSPiRED, version 4.0|Renal Denervation for Management of Drug-Resistant Hypertension|Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension|INSPiRED|Katholieke Universiteit Leuven|No|Recruiting|April 2014|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|20 Years|69 Years|No|||February 2015|February 17, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01505010||93106|
NCT01505023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEE-001-2004|Partial Meal Replacement and Inulin in Obese Women|Evaluation of the Effectiveness of a Partial Meal Replacement With Inulin on Obesity and Dyslipidemias in Women.||Cindetec|No|Completed|April 2006|February 2007|Actual|November 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|179|||Female|18 Years|50 Years||||January 2012|January 4, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505023||93105|
NCT01475214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2705|Musculoskeletal Effects of Bicarbonate|Musculoskeletal Benefits of Bicarbonate in Older Adults - A Dose-Finding Trial||Tufts University|No|Completed|January 2012|August 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|244|||Both|60 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 18, 2015|November 16, 2011||No||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01475214||95390|
NCT01505530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12552|A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer|A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy||Eli Lilly and Company|No|Completed|December 2011|January 2016|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|125|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505530||93066|
NCT01506453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TINALL|Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)|Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol|TINALL|St. Jude Children's Research Hospital|No|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|1 Year|18 Years|No|||November 2015|November 11, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506453||92995|
NCT01506466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00206-35|Weight Variation During Chemotherapy in Breast Cancer Patients|Weight Variation and Mechanisms Involved, During Chemotherapy in Breast Cancer Patients||Centre Jean Perrin|No|Completed|September 2011|January 2014|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|52|||Female|N/A|70 Years|No|||July 2015|July 23, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01506466||92994|
NCT01505478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000356|Comparing an Automated to a Conventional Sepsis Clinical Prediction Rule|Comparing an Automated to a Conventional Sepsis Clinical Prediction Rule||Beth Israel Deaconess Medical Center|No|Not yet recruiting|July 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted from the Emergency Department with suspected infection.|January 2012|January 10, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505478||93070|
NCT01505790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-020095-32|Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention|Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention||Assistance Publique Hopitaux De Marseille|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|187|||Both|18 Years|N/A|No|||May 2012|May 22, 2012|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01505790||93046|
NCT01505764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-013-08F|The Role of Ghrelin in Cancer Cachexia|The Role of Ghrelin in Cancer Cachexia||VA Office of Research and Development|No|Active, not recruiting|June 2012|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|December 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505764||93048|
NCT01505777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MEMO-201|Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea|Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea: Double Blinded, Randomized, Placebo Drug Controlled, Parallel Designed, Multi-centered, Phase 2 Study||Hanmi Pharmaceutical Company Limited|No|Completed|May 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|280|||Both|18 Years|75 Years|No|||April 2013|April 4, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01505777||93047|
NCT01506050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50632|Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition|Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fasting Conditions||Dr. Reddy's Laboratories Limited|No|Completed|January 2006|February 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2006|January 6, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506050||93026|
NCT01506063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07447/07-08|Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2008|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506063||93025|
NCT01506713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60280|Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions|Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506713||92975|
NCT01506414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-003|Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)|A Multicentre Investigation of Recombinant Human Thrombopoietin (Rh-TPO) Combine With Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)||Shandong University|Yes|Recruiting|June 2009|December 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|200|||Both|16 Years|75 Years|No|||January 2012|January 20, 2012|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01506414||92998|
NCT01506700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DXP 2012-01|Real Time Optical Coherence Tomography (OCT) of Human Tissue|Real Time Optical Coherence Tomography (OCT) of Human Tissue||Diagnostic Photonics, Inc.|No|Active, not recruiting|May 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|N/A|No|Non-Probability Sample|Females with breast cancer|February 2016|February 1, 2016|January 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01506700||92976|
NCT01507831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS11717|Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)|Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study||Sanofi|Yes|Completed|January 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2341|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|January 6, 2012|Yes|Yes||No|November 18, 2015|https://clinicaltrials.gov/show/NCT01507831||92890|Manual reclassification was done by the Sponsor for the "other reasons" of non-completion of study as specified in the electronic case report (eCRF) form.
NCT01507259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN11MT497|Chocolate's Effect on the Cerebral Vasculature|A Randomised Trial of Effect of Chocolate Upon Cerebrovascular Reactivity in Healthy Adult Volunteers||NHS Greater Glasgow and Clyde|No|Completed|February 2012|February 2012|Actual|||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy controls|July 2012|July 26, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507259||92933|
NCT01508130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27900|An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1|Non-Interventional, Prospective Cohort Study of the Effectiveness, Safety and Utilization of Two Approved Pegylated Interferon-Based Direct Acting Antiviral Triple Therapies in the Management of Genotype 1 Chronic Hepatitis C in Routine Clinical Practice in the USA||Hoffmann-La Roche||Completed|January 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|672|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C genotype 1 receiving pegylated interferon-based direct        acting antiviral triple therapies in the US|January 2016|January 25, 2016|January 9, 2012|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01508130||92867|
NCT01508416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108178|Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma|Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study|METRO|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|January 2012|June 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|71|Samples Without DNA|whole blood and serum|Both|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed Multiple Myeloma required chemotherapy|July 2015|July 27, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01508416||92846|
NCT01505036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMARTCARE_DM|Study to Evaluate the Effect of the Smart Care-diabetes Management System on Subjects With Diabetes|Randomized, Multi-center, Open-label, Parallel Group Study to Evaluate the Effect of the Smart Care-diabetes Management System on Subjects With Diabetes|SMARTCARE_DM|SK Telecom Consortium|No|Completed|December 2010|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|554|||Both|N/A|N/A|No|||February 2013|February 5, 2013|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01505036||93104|
NCT01474317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-PRO-2010-009-01|Study of an Investigational Glucose Meter System|Performance of the G3 Blood Glucose Monitoring System With TATSU Strip||Ascensia Diabetes Care|No|Completed|November 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|226|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 16, 2011|Yes|Yes||No|November 30, 2012|https://clinicaltrials.gov/show/NCT01474317||95459|
NCT01474330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-CP-006|A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects|A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) Following Multiple Daily Doses in Healthy Male Subjects||Celgene|No|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|33|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|November 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01474330||95458|
NCT01504750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOAL/HH/014/2009|Healing Patient Rooms|Healing Patient Rooms; The Effect of Lighting on Recovery and Well-being of Patients||Maastricht University Medical Center|Yes|Completed|December 2009|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|196|||Both|18 Years|N/A|No|||January 2012|January 5, 2012|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01504750||93126|
NCT01505829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1598 CCR3694|Diffusion-weighted Imaging Study in Cancer of the Ovary|Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging.|DISCOVAR|Institute of Cancer Research, United Kingdom|No|Recruiting|August 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Tumour samples taken at surgery for histological analysis|Female|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with primary or relapsed ovarian cancer|January 2016|January 19, 2016|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01505829||93043|
NCT01475747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00049314|Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study|Systolic Pressure Intervention Trial (SPRINT)-Factors Affecting Factors Affecting Atherosclerosis Study (FAST)|SPRINTFAST|University of Utah|Yes|Recruiting|September 2011|||September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|Urine, plasma and serum samples.|Both|50 Years|N/A|No|Non-Probability Sample|Clinical characteristics of the SPRINT-FAST population will reflect those of the parent        study. In this ancillary study, one non-CKD participant (control) will be recruited for        each CKD participant (case). SPRINT CKD stratum will likely comprise of those with eGFR        between 20-59 ml/min/1.73 m2.|December 2013|December 9, 2013|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475747||95349|
NCT01475760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD007|A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease|A Multi-Center, Open Label Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease||Denver Nephrologists, P.C.|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|167|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01475760||95348|
NCT01475487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUS-2010|Ultrasound Guided Versus Palpation Guided Cricothyrotomy With Poorly Defined Anatomical Landmarks|A Comparison of Ultrasound Versus Digital Palpation Guided Cricothyrotomy in Subjects With Poorly Defined Anatomical Landmarks||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|April 2011|September 2013|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|47|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2015|June 24, 2015|November 3, 2011||No||No|June 24, 2015|https://clinicaltrials.gov/show/NCT01475487||95369|
NCT01475734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108372|Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes|A Single-site, Randomized, Double-blind, Placebo-controlled, Parallel-group, Stepped Glucose Clamp Study to Assess the Effects of Albiglutide on Counter-regulatory Hormone Responses and Recovery From Hypoglycemia in Subjects With Type 2 Diabetes Mellitus.||GlaxoSmithKline|Yes|Completed|December 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|60 Years|No|||May 2014|May 29, 2014|November 17, 2011|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01475734||95350|
NCT01476020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 08|Is There A LIfe for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel|Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial|ITALICplus|Gilard, Martine|Yes|Not yet recruiting|November 2011|July 2015|Anticipated|July 2012|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1240|||Both|18 Years|N/A|No|Probability Sample|Subjects are selected from the general population needing Percutaneous Coronary        Interventions (PCI).|November 2011|November 17, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01476020||95328|
NCT01476033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-508 ex 10/11|Strong Women Study|Impact of Encapsulated Fruit, Berry and Vegetable Juice Powder Concentrate on Oxidative Stress, Inflammation and Blood Flow Before and Post Exercise in Overweight, Middle-aged, Women.||Green Beat|Yes|Completed|October 2011|December 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|44|||Female|35 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01476033||95327|
NCT01506076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07446/07-08|Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|December 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 6, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506076||93024|
NCT01506089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2011-02|Optimizing the Temperature for Embryo Culture in In Vitro Fertilization|Optimizing the Temperature for Embryo Culture in In Vitro Fertilization: A Randomized Controlled Trial||Reproductive Medicine Associates of New Jersey|No|Completed|January 2012|July 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|55|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01506089||93023|
NCT01506427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX4-201|A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients|A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients||Siemens Molecular Imaging|No|Withdrawn|September 2012|June 2013|Anticipated|April 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|N/A|N/A|No|||December 2012|December 12, 2012|December 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506427||92997|
NCT01506726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033852|Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia|A Randomized, Double-Blind, Placebo Controlled Pilot Trial of Oral Salsalate in the Treatment of the Subset of Unexplained Anemia in Elderly Patients With Elevated Interleukin-6||Duke University|Yes|Terminated|March 2012|November 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|65 Years|N/A|No|||October 2015|October 26, 2015|January 6, 2012|Yes|Yes|Study drug expiration and supply shortage|No|October 26, 2015|https://clinicaltrials.gov/show/NCT01506726||92974|
NCT01506999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENOCOR|Genetic Mapping for Cardiac Risk Assessment|GENOCOR Project-Laboratory of Genetic Mapping for Assessment of Cardiovascular Risk(GENOCOR LAB)|GENOCOR|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|No|Recruiting|July 2006|July 2012||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|2000|Samples With DNA|whole blood|Both|18 Years|75 Years|No|Non-Probability Sample|Patients affected by ischemic heart disease (IHD) with a non-fatal evolution. Patients        with acute coronary syndrome|January 2012|January 5, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01506999||92953|
NCT01507298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1766|Physical Activity and Gastrointestinal Investigations|An Observational Study to Compare the Outcomes of Ambulatory Gastrointestinal Investigations With Physical Activity Using Accelerometry.||Imperial College London|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|30|||Both|18 Years|65 Years|No|Non-Probability Sample|Those who have been advised to undergo 24 hour oesophageal pH monitoring, or capsule        endoscopy (from GI outpatients clinic)|March 2013|December 11, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507298||92930|
NCT01507272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1149|Safety and Tolerability of Liraglutide in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Doses of NNC90-1170 to Assess Tolerability, Pharmacokinetics, Pharmacodynamics and Absolute Bioavailability in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|March 1999|December 1999|Actual|December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Male|18 Years|45 Years|No|||February 2015|February 18, 2015|January 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507272||92932|
NCT01507285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1189|Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Dose-escalation, Parallel-group, Single and Multiple Dosing Trial of NN90-1170 in Healthy Volunteers and Patients With Type 2 Diabetes to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics||Novo Nordisk A/S|No|Completed|August 1999|December 1999|Actual|December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|January 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507285||92931|
NCT01507844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86/09|Continuous Positive Airway Pressure Effect on Air Trapping in Chronic Obstructive Pulmonary Disease Patients|Continuous Positive Airway Pressure Effect on Air Trapping, Endurance Time in Chronic Obstructive Pulmonary Disease Patients|CPAP|Assaf-Harofeh Medical Center|No|Completed|November 2009|June 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|24|||Both|45 Years|75 Years|No|||November 2011|January 8, 2012|November 2, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507844||92889|
NCT01507857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-EV71-3001|An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine|A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines||Sinovac Biotech Co., Ltd|Yes|Completed|January 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|10077|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||March 2013|November 27, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01507857||92888|
NCT01508143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Misoprostol in termination|Comparitive Study of Two Misoprostol Regimen in Early Pregnancy Termination|A Comparative Study of Vaginal Misoprostol Two Dosing Regimen for First Trimester Pregnancy Termination in Patients Admitted at Bandarabbas in Shariati Hospital in 2009||Hormozgan University of Medical Sciences|Yes|Completed|January 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|41|||Female|N/A|N/A|No|||September 2012|September 30, 2012|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508143||92866|
NCT01508156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1894-001|Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)|A Phase I/IIa Study Assessing Single and Multiple Doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-Infected Subjects||Merck Sharp & Dohme Corp.|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508156||92865|
NCT01504763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-004874|Measuring the Effect of Chair Massage on Stress Related Symptoms for Nurses|Measuring the Effect of Chair Massage on Stress Related Symptoms for Nurses: A Pilot Study||Mayo Clinic|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 7, 2012|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01504763||93125|
NCT01474044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CATS-CO-002|To Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis (CAG)|A Phase IV Study to Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis||Xinjiang Biochemical Pharmaceutical Co., Ltd.|No|Completed|August 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|851|||Both|18 Years|70 Years|No|||July 2013|July 6, 2013|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01474044||95480|
NCT01474928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02861|Asthma and Health Literacy in Newcomer Communities in the Greater Vancouver Area|Asthma and Health Literacy in Newcomer Communities in the Greater Vancouver Area (GVA): A Population-based Qualitative Study||University of British Columbia|No|Completed|August 2009|July 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|92|||Both|21 Years|N/A|No|||May 2015|May 27, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01474928||95412|
NCT01505543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_SBrumagne_COPD|Proprioceptive Postural Control and Chronic Obstructive Pulmonary Disease (COPD)|||Katholieke Universiteit Leuven|Yes|Completed|January 2012|September 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|patients from the University Hospital Leuven - Respiratory Disvision|July 2012|December 4, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505543||93065|
NCT01474915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0053|Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting|Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting||Ohio State University|Yes|Completed|June 2007|April 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|122|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|November 8, 2011|Yes|Yes||No|April 30, 2013|https://clinicaltrials.gov/show/NCT01474915||95413|
NCT01476618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0300|Providing Mental Health Services to Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans|Providing Mental Health Services to Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans: Provider Perspectives||VA Eastern Colorado Health Care System|Yes|Completed|July 2011|March 2014|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|13|||Both|18 Years|70 Years|No|Non-Probability Sample|Denver VA Mental Health Providers Up to 30 providers will be interviewed.|June 2015|June 8, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01476618||95282|
NCT01476072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113784|31P MRS Ischaemic Exercise Optimisation and COPD|31P MRS Ischaemic Exercise Optimisation and COPD Myopathy Study||GlaxoSmithKline|No|Completed|April 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01476072||95324|
NCT01476371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPF-0001|Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety|Mindfulness-based Group Treatment of Patients With Depression and Anxiety: Effects on Symptoms and Inflammatory Markers in a Randomized Controlled Multicenter Study in Primary Care||Lund University|No|Completed|January 2012|April 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|20 Years|64 Years|No|||September 2014|September 25, 2014|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01476371||95301|
NCT01486342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105122|PET Imaging in Patients at Risk for Acute Lung Injury|Positron Emission Tomography With [18F]Fluorodeoxyglucose in Patients at Risk for Acute Lung Injury|PET-ALI|Washington University School of Medicine|Yes|Completed|October 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanically ventilated patients without acute lung injury|January 2013|January 3, 2013|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01486342||94536|
NCT01506440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99611|Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy|Feasibility Study of a Cognitive Assessment Tool During Systemic Chemotherapy for Cancer Patients||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|October 2011|||October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|50 Years|N/A|No|Non-Probability Sample|Patients being treated for the first time using standard chemotherapy|December 2015|December 28, 2015|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01506440||92996|
NCT01506739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-033|A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males|A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males||Eisai Inc.||Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|12|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01506739||92973|
NCT01506752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-034|A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males|A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males||Eisai Inc.||Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|20|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||January 2012|June 25, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01506752||92972|
NCT01507012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28AI1|The Effect Of Berry Polyphenols On Human Behaviour|A Double Blind, Placebo Controlled Study Measuring The Effect Of Berry Polyphenols On Mood And Cognition In Healthy Adults||Northumbria University|No|Completed|September 2010|February 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01507012||92952|
NCT01507311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1219|Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes|Effect of NNC90-1170 on Pulsatile Insulin Secretion in Type 2 Diabetic Patients. A Double-blind, Placebo-controlled, Randomised, Single-dose, Cross-over Trial||Novo Nordisk A/S|No|Completed|September 1999|December 1999|Actual|December 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|30 Years|75 Years|No|||March 2015|March 25, 2015|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507311||92929|
NCT01507584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110903|The Effects of the Water Drinking Test on Intraocular Pressure|The Effects of the Water Drinking Test on Intraocular Pressure of Glaucoma Patients Undergoing 24 Hour Continuous Monitoring With the SENSIMED Triggerfish||University of California, San Diego|No|Enrolling by invitation|August 2011|September 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2012|January 6, 2012|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01507584||92909|
NCT01508429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.4.14|Misoprostol for Treatment of Postpartum Haemorrhage (PPH) in Home Births|Misoprostol for the Treatment of Postpartum Haemorrhage (PPH) Following Self- Administration of Misoprostol Prophylaxis in Home Deliveries.||Gynuity Health Projects|Yes|Active, not recruiting|July 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2016|February 24, 2016|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01508429||92845|
NCT01508455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-11-06|Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age|A Phase II/III, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age||Hospira, Inc.|Yes|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|28 Weeks|36 Weeks|No|||September 2015|September 8, 2015|January 5, 2012|Yes|Yes||No|August 2, 2013|https://clinicaltrials.gov/show/NCT01508455||92844|
NCT01508169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNICAMP-REUMATO 01|Foot Orthoses and Elderly Women With Osteoporosis|The Effect of Foot Orthoses on the Balance of Elderly Women With Osteoporosis||University of Campinas, Brazil|No|Completed|April 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|94|||Female|60 Years|N/A|No|||February 2012|March 9, 2012|January 6, 2012||No||No|February 2, 2012|https://clinicaltrials.gov/show/NCT01508169||92864|
NCT01473758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-405-RD|Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Effect of Roflumilast 500 μg Tablets Once Daily at Acute COPD Exacerbations Treated With Standard Therapy of Oral Steroids and Antibiotics. A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial|TREAT|Takeda|No|Terminated|February 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|40 Years|N/A|No|||February 2015|February 20, 2015|October 31, 2011|Yes|Yes|Company decision: No Safety or Efficacy Concerns|No||https://clinicaltrials.gov/show/NCT01473758||95502|
NCT01474642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-09-10|Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma|A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Genexol (XG) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma||Samsung Medical Center|No|Completed|September 2008|May 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01474642||95434|
NCT01475513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13769|Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women|Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women||Virginia Commonwealth University|No|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|47|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|November 8, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01475513||95367|
NCT01475773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7702|Psychological Assessment of Adults Seeking Orthodontic Treatment|Impact of Personality Characteristics and Self-esteem on the Relationship Between Orthodontic Treatment Need and Oral-health Related Quality of Life in Adults.||Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|November 2011|||November 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|adults (starting from age 17) seeking orthodontic treatment on the first consultation of        our clinic (university hospital Leuven)|October 2011|November 18, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01475773||95347|
NCT01474629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-509 ex 10/11|Probiotic Sport Study|Impact of Supplementation With Probiotics on Exercise-induced Oxidative Stress and Endotoxemia in Trained Men||Green Beat|Yes|Completed|October 2011|September 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Male|30 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 9, 2013|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01474629||95435|
NCT01475500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICC THO 1078|Nashville Early Diagnosis Lung Cancer Project|Nashville Early Diagnosis Lung Cancer Project||Vanderbilt-Ingram Cancer Center|Yes|Recruiting|April 2011|November 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|320|Samples With DNA|Sputum, Blood, Urine, Nasal brushings, Buccal cells, Bronchical washings, Bronchioalveolar      lavage brushings, Endobronchial biopsies|Both|50 Years|79 Years|No|Non-Probability Sample|By physician referral, medical professional referral or self-referral|December 2015|December 31, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01475500||95368|
NCT01476930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|n231|Cupping and Serkangabin Versus Conventional Migraine Treatment|Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial||Birjand University of Medical Sciences|Yes|Completed|June 2008|October 2011|Actual|September 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|391|||Both|15 Years|50 Years|No|||November 2014|November 20, 2014|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01476930||95259|
NCT01477203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA103FC001|Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders|Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders|MAN-BIOPSY|Medical University of Vienna|Yes|Recruiting|November 2011|September 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|300|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01477203||95238|
NCT01486355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVurban|Additional Measles Vaccine at 4 Months of Age|A Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality and to Explore the Role of Maternal Measles Antibodies for the Beneficial Non-specific Effects of Measles Vaccine||Bandim Health Project|No|Recruiting|August 2011|||July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Primary Purpose: Prevention|2||||||Both|4 Months|7 Months||||November 2013|November 14, 2013|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01486355||94535|
NCT01486368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I207|A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma|A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma||Canadian Cancer Trials Group|No|Completed|November 2011|February 2015|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01486368||94534|
NCT01507025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Y20110045|The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis|The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis||Wenzhou Medical University||Completed|October 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|400|||Both|18 Years|60 Years|No|Non-Probability Sample|patients were scheduled to undergo LASIK and randomized to different hinge locations|February 2014|February 12, 2014|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01507025||92951|
NCT01507038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14617-201|Safety and Efficacy of YH14617 in Diabetes Mellitus|Phase II Clinical Trial to Investigate the Efficacy, Safety and Pharmacokinetics of YH14617 After Once Weekly or Biweekly Administration in Patients With Type 2 Diabetes Mellitus||Yuhan Corporation|Yes|Completed|December 2011|February 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|84|||Both|20 Years|75 Years|No|||February 2015|February 16, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01507038||92950|
NCT01507337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1327|Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers|An Open Label, Single Dose Trial With Two Groups Comparing the Pharmacokinetics of Liraglutide in Young Versus Elderly Healthy Subjects of Both Sexes||Novo Nordisk A/S|No|Completed|April 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 6, 2012|January 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507337||92928|
NCT01507597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GlukaStase|The Effect of GLP-1 on the Inhibition of Glucagon Secretion|||University Hospital, Gentofte, Copenhagen|No|Completed|December 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 9, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01507597||92908|
NCT01507610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-SUM-1302|Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects|An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX® (Sumatriptan) Nasal Spray, 100 mg IMITREX® (Sumatriptan) Oral Tablet and 6 mg IMITREX® (Sumatriptan) Subcutaneous Injection in Healthy Subjects||Optinose US Inc.|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|February 28, 2012|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507610||92907|
NCT01507870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Primary Onlay|Randomized Controlled Prospective Multicenter Study Primary Onlay- Mesh After Elective Median Laparotomy in Patients With BMI ≥ 27|||Austrian Hernia Study Group||Terminated|January 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 1, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01507870||92887|
NCT01508182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100679|A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (150 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1x300 mg) and Metformin IR Tablets (2x500 mg) in Healthy Fed Subjects||Janssen Research & Development, LLC||Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508182||92863|
NCT01477411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-DDI-004|A Drug-Drug Interaction Study of Digoxin and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Digoxin in Healthy Male and Female Adults||Vifor Inc.|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 17, 2012|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477411||95222|
NCT01477762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051911|Cortisol Supression and Startle Responses in Posttraumatic Stress Disorder (PTSD)|Effects of Cortisol Suppression on Fear-Potentiated Startle in Traumatized Individuals With and Without PTSD|CSS|Emory University|Yes|Completed|November 2011|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|150|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01477762||95195|
NCT01508676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011p000897|Effects of Pennsaid on Clinical Neuropathic Pain|Effects of Pennsaid on Clinical Neuropathic Pain||Massachusetts General Hospital|No|Active, not recruiting|November 2011|December 2015|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|48|||Both|18 Years|80 Years|No|||February 2015|February 24, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508676||92827|
NCT01504542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS110-10-01|Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer|A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)||Heat Biologics|Yes|Withdrawn|December 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|December 20, 2011|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01504542||93142|
NCT01474343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1-SAF-301|Intracerebral Gene Therapy for Sanfilippo Type A Syndrome|An Open-label, Single Arm, Monocentric, Phase I/II Clinical Study of Intracerebral Administration of Adeno-associated Viral Vector Serotype 10 Carrying the Human SGSH and SUMF1 cDNAs for the Treatment of Sanfilippo Type A Syndrome.||LYSOGENE|Yes|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Months|6 Years|No|||May 2014|May 5, 2014|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01474343||95457|
NCT01474941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0961011|A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects|A Phase 1, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multiple-Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of A Modified-Release Formulation Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects||Pfizer|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01474941||95411|
NCT01474954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|652-2-202|Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors|A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus||University of California, San Francisco|Yes|Terminated|September 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Probability Sample|All primary study participants who received at least one dose of study drug and had data        from both a Baseline and at least 1 post-Baseline vis.t|May 2015|May 8, 2015|November 15, 2011|Yes|Yes|Low enrollment|No||https://clinicaltrials.gov/show/NCT01474954||95410|
NCT01475812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0353/03|Daily Activities Are Sufficient to Induce Dynamic Pulmonary Hyperinflation and Dyspnea in Chronic Obstructive Pulmonary Disease Patients||Hyperinflation|Federal University of São Paulo|No|Completed|March 2007|||||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|19|||Both|50 Years|80 Years|No|Probability Sample|The investigators included 19 COPD patients (13 male) with moderate to very severe degree        of airway obstruction, with a mean post bronchodilator forced expiratory volume in the        first second (FEV1) of 48.7 ± 7.1% predicted and mean age of 64.1 ± 5.3.|November 2011|November 18, 2011|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01475812||95344|
NCT01476098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114693|A Study to Investigate the Effect of SB-705498 on Chronic Cough|Two Part Study to Investigate Pharmacokinetics (PK) & Pharamcodynamics (PD) of SB-705498 in Cough. Part A:Open Label Study in Healthy Subjects to Determine Exposure to SB-705498. Part B:Double-blind, Placebo Controlled, Cross Over Study to Investigate Effect of SB-705498 on Capsaicin Induced Cough and 24 Hour Cough Counts in Cough Patients||GlaxoSmithKline|No|Completed|April 2011|January 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|75 Years|No|||January 2012|January 26, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01476098||95322|
NCT01475227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 043|Atazanavir/Ritonavir and Zinc Pharmacokinetic Study|A Randomized Crossover Study of the Effects of Zinc Sulphate Supplementation on Atazanavir/Ritonavir-associated Hyperbilirubinemia|SSAT043|St Stephens Aids Trust|No|Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||March 2012|March 21, 2012|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01475227||95389|
NCT01476085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114238|Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)|An Open-label Study to Evaluate the Utility of the Apoptosis Imaging Biomarker 18F]ML10 to Assess the Response to Chemotherapy in Patients With Non-Hodgkin's Lymphoma(NHL).||GlaxoSmithKline|No|Terminated|July 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|September 1, 2011||No|Study terminated as ongoing analysis suggested objectives not practical to achieve with study    as implemented|No||https://clinicaltrials.gov/show/NCT01476085||95323|
NCT01476384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 10-3-050|Orthogonal Polarisation Study in Young, Elderly and Type 2 Diabetics|Postprandial Insulin Release and the Impact on Muscle Perfusion||Maastricht University Medical Center|No|Completed|October 2010|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|45|||Male|20 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01476384||95300|
NCT01476397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.01.US.INF|Probiotic Formula and Infant Growth|ASSESSMENT OF GROWTH OF INFANTS FED FORMULA WITH PROBIOTICS||Nestlé|No|Completed|December 2011|October 2013|Actual|June 2013|Actual|N/A|Interventional|N/A|2||||||Both|N/A|17 Days|Accepts Healthy Volunteers|||November 2014|November 3, 2014|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01476397||95299|
NCT01476631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105308|Step Down Colon Cancer Risk|Step Down Colon Cancer Risk: A Pilot Intervention for Colon Cancer Risk Reduction||Washington University School of Medicine|No|Terminated|November 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|50 Years|80 Years|No|||August 2013|August 2, 2013|November 9, 2011||No|not enough patients consented during the funding period|No||https://clinicaltrials.gov/show/NCT01476631||95281|
NCT01476943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-077|Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study|Belatacept in Renal Transplantation: Patterns of Use Analysis Using the Collaborative Transplant Study (CTS)|CTS|Bristol-Myers Squibb|No|Active, not recruiting|March 2012|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|4335|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing solid organ transplantation, whose transplant center participates in        CTS and who are treated with Belatacept or a CNI based regimen at the time of        transplantation|January 2016|January 28, 2016|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01476943||95258|
NCT01476956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA BIODAM|Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography|Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis||Canadian Research & Education in Arthritis|No|Recruiting|October 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|Samples Without DNA|-  whole blood/serum        -  urine|Both|18 Years|N/A|No|Non-Probability Sample|RA patients from rheumatologists' clinics|November 2011|September 27, 2012|June 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01476956||95257|
NCT01477216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUSU 182-5|Determination of Glycemic and Insulinemic Indices|The Glycemic and Insulinemic Responses of the Finnish Foods: Measurement and Modification|ELSA|National Institute for Health and Welfare, Finland|No|Active, not recruiting|January 2003|December 2013|Anticipated|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|9||Actual|142|||Both|20 Years|72 Years|Accepts Healthy Volunteers|||November 2011|November 18, 2011|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01477216||95237|
NCT01507051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10849|Switching Study From Warfarin to Rivaroxaban|Randomized, Placebo-controlled, Parallel-group Study in Healthy Male Subjects to Investigate the Pharmacodynamics During the Switching Procedure From Warfarin to Rivaroxaban||Bayer|No|Completed|November 2008|November 2009|Actual|November 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|96|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 26, 2015|December 5, 2011||No||No|January 30, 2012|https://clinicaltrials.gov/show/NCT01507051||92949|
NCT01507350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSR|Effects of Obesity Surgery on Renal Function|Effects of Obesity Surgery on Renal Function||Imperial College London|Yes|Active, not recruiting|June 2011|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|18 Years|65 Years|No|Non-Probability Sample|1. Patients with a BMI of >35kg/m2 approved for obesity surgery based on the NICE             criteria.          2. Patients with a GFR <60 mL/min/1.73 m2|February 2016|February 26, 2016|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507350||92927|
NCT01507623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAPS_CAPNOGRAPHY1|Value of Capnography During Nurse Administered Propofol Sedation (NAPS)|The Role of Capnography in Endoscopy Patients Undergoing Nurse Administered Propofol Sedation (NAPS): A Randomized Study||University Hospital, Gentofte, Copenhagen|No|Completed|September 2010|March 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|591|||Both|N/A|N/A|No|||January 2012|January 10, 2012|November 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01507623||92906|
NCT01477424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-DDI-005|A Drug-Drug Interaction Study of Warfarin and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Warfarin in Healthy Male and Female Adults||Vifor Inc.|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|45|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 14, 2012|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01477424||95221|
NCT01477775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFBU 13-I-PRU|Customized Choice of Oral P2Y12 Receptor Blocker|Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing|PRU-MATRIX|Italian Society of Invasive Cardiology|Yes|Recruiting|January 2012|December 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4000|||Both|18 Years|N/A|No|||September 2014|September 1, 2014|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01477775||95194|
NCT01478061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2007-01|Multi-center Assessment of Grafts in Coronaries: Long-term Evaluation of the C-Port Device|Multi-center Assessment of Grafts in Coronaries: Long-term Evaluation of the C-Port Device||Cardica, Inc|No|Completed|April 2009|July 2015|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|80 Years|No|||July 2015|July 20, 2015|October 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01478061||95172|
NCT01478048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-009|Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma|A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma||Bristol-Myers Squibb|Yes|Active, not recruiting|November 2011|April 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|185|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|November 2, 2011|Yes|Yes||No|December 17, 2015|https://clinicaltrials.gov/show/NCT01478048||95173|
NCT01474655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-07-069|Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal|Assessment of Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal||Samsung Medical Center|No|Completed|September 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||November 2011|November 15, 2011|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01474655||95433|
NCT01474668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP27917|Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14c]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects||Genentech, Inc.||Completed|October 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474668||95432|
NCT01475786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMDN-002|Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy||ViroMed Co., Ltd. dba VM BioPharma|Yes|Completed|August 2012|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01475786||95346|
NCT01475799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP 010|Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis||Direct Flow Medical, Inc.|Yes|Active, not recruiting|November 2011|July 2019|Anticipated|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|70 Years|N/A|No|||November 2015|November 10, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01475799||95345|
NCT01476410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU 11H01|Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma|A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma||Northwestern University|Yes|Recruiting|November 2011|May 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|60 Years|N/A|No|||September 2015|September 18, 2015|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476410||95298|
NCT01476644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#11-128|How Has Glaucoma Affected Your Quality of Life?|A Prospective, Longitudinal, Observational Cohort Study Examining How Glaucoma Affects Quality of Life and Visual Function Over a 4-Year Period||Wills Eye|No|Active, not recruiting|October 2011|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|163|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects for this study will be recruited from the William A. and Anna V. Goldberg        Glaucoma Service and Glaucoma Research Center at Wills Eye Institute in Philadelphia, PA.|February 2016|February 2, 2016|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01476644||95280|
NCT01476969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CentralSouthU|Effect of Remote Ischemic Perconditioning on Acute Kidney Injury in Adult Valve Replace|Effect of Remote Ischemic Perconditioning on Acute Kidney Injury in Adult Valve Replace||Central South University|Yes|Recruiting|September 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|90|||Both|20 Years|70 Years|No|||August 2012|August 11, 2012|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476969||95256|
NCT01477229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoLiRECT|Quality of Life in RECTal Cancer - a Prospective Multicenter Cohort Study|Quality of Life in RECTal Cancer - A Study Within the Scandinavian Surgical Outcomes Research Group|QoLiRECT|Sahlgrenska University Hospital, Sweden|No|Active, not recruiting|February 2012|September 2020|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients presenting at the participating hospitals (both University Hospitals and        Community Hospitals) with newly diagnosed rectal cancer, regardless of stage at diagnosis        and plans for treatment, will be eligible for inclusion.|October 2015|October 3, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01477229||95236|
NCT01476605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2008-0148|Efficacy of Injection Therapy for Lateral Epicondylosis|The Efficacy of Prolotherapy and Platelet Rich Plasma Injections for Lateral Epicondylosis: a Pilot Study||University of Wisconsin, Madison|Yes|Active, not recruiting|June 2009|December 2015|Anticipated|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|October 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476605||95283|
NCT01476917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11449|The ATLAST Long-Term Study|The ATLAST Long-Term Study. A Multicenter, Prospective, Long-Term Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)||ApniCure, Inc.|No|Completed|November 2011|October 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|80 Years|No|||November 2012|November 5, 2012|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476917||95260|
NCT01506765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/03 CE|Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia|Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia: Double-blind and Crossover Study||Centre Hospitalier Universitaire Vaudois|Yes|Completed|August 2003|September 2006|Actual|December 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 17, 2012|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506765||92971|
NCT01476358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC389|Effect of Vitamin A Supplementation on Immune Responses in Human Neonates|A Randomized Controlled Trial in Human Neonates to Determine the Effect of Vitamin A Supplementation on Immune Responses|NNVAS|London School of Hygiene and Tropical Medicine|Yes|Active, not recruiting|November 2011|||June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|200|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||November 2012|November 12, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01476358||95302|
NCT01476904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-E004-CL-C2|Safety Study in Adolescent and Adult Patients With Asthma|A 3-MONTH SAFETY EVALUATION EXTENSION TO THE 12-WEEK E004-C STUDY IN ASTHMA PATIENTS (A Double Blinded, Placebo-Controlled, Parallel, 3-Month Safety Study in Adolescent and Adult Patients With Asthma)||Amphastar Pharmaceuticals, Inc.|No|Completed|November 2011|July 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|208|||Both|12 Years|75 Years|No|||February 2016|February 11, 2016|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476904||95261|
NCT01477177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004237|Polar Wand Carbon Dioxide Cryotherapy for Barrett's Esophagus|Pilot Study of Polar Wand Carbon Dioxide Cryotherapy for Barrett's Esophagus With Low Grade and High Grade Dysplasia||Mayo Clinic||Terminated|August 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|October 24, 2011|No|Yes|enrollment much slower than anticipated, and, funding issues|No||https://clinicaltrials.gov/show/NCT01477177||95240|
NCT01478074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-801-02-08|ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia|A Single-center Open-label Phase I Study of ALT-801 for ex Vivo Maturation and in Vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients With Relapsed/Refractory Acute Myeloid Leukemia||Altor Bioscience Corporation||Withdrawn|November 2011|November 2013|Actual|October 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|2 Years|59 Years|No|||January 2014|January 2, 2014|November 17, 2011|Yes|Yes|The treatment planned was determined to be of low feasibility as no subject was found eligible    and able to enroll after screening over 30 subjects|No||https://clinicaltrials.gov/show/NCT01478074||95171|
NCT01477437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000023483|Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia|Development and Evaluation of an Internet-based Educational Program to Promote Self- Management for Teens With Hemophilia||The Hospital for Sick Children|No|Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|29|||Both|13 Years|18 Years|No|||August 2013|August 19, 2013|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01477437||95220|
NCT01477788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-0083-09|Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass|Prediction of Ovarian Malignancy, in the Presence of Sonographic Pelvic Mass Using Patient History, Sonographic Parameters and Serum Markers||HaEmek Medical Center, Israel|No|Withdrawn|May 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Female|N/A|N/A|No|Non-Probability Sample|Patients referred to the department's sonographic unit with diagnosis of adnexal or pelvic        or ovarian mass|November 2011|June 17, 2015|November 13, 2011||No|The researcher Left the organization|No||https://clinicaltrials.gov/show/NCT01477788||95193|
NCT01473771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0123|Caring Letters for Military Suicide Prevention|Caring Letters for Military Suicide Prevention: A Randomized Controlled Trial||National Center for Telehealth and Technology|No|Active, not recruiting|November 2011|February 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4730|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01473771||95501|
NCT01475266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9EO9201|Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)|Randomized, Placebo-controlled, Double-blinded Study of Single Immediate Instillation of EO9 After TURBT in Patients With NMIBC||Nippon Kayaku Co.,Ltd.|Yes|Terminated|November 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|20 Years|N/A|No|||April 2013|April 15, 2013|November 16, 2011||No|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT01475266||95386|
NCT01475240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 044|The Effect of Hyperbilirubinemia on CV Disease, Neurocog Function and Renal Function|A Cross-sectional Controlled Study to Evaluate the Impact of Hyperbilirubinemia on Markers of Cardiovascular Disease, Neurocognitive Function and Renal Markers in HIV-1 Infected Subjects on Protease Inhibitors|SSAT044|St Stephens Aids Trust|No|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|HIV-infected males/females aged 18 years and above|April 2014|April 10, 2014|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01475240||95388|
NCT01475253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR-100-201|Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis|A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label Extension||Allergan|Yes|Terminated|November 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Female|18 Years|N/A|No|||August 2015|August 19, 2015|November 3, 2011|Yes|Yes|This study was not enrolled completely and was terminated.|No|August 5, 2014|https://clinicaltrials.gov/show/NCT01475253||95387|As per protocol, efficacy analyses were not performed for the Sham Cytoscopic Procedure-Randomized Study Arm/Group. Only safety analyses were completed.
NCT01475526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA140326|The Value of Our Health|El Valor de Nuestra Salud (The Value of Our Health)||San Diego State University|Yes|Completed|October 2011|October 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|370|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475526||95366|
NCT01475539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPV30|Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine|Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone.||Sanofi|No|Completed|November 2011|November 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|456|||Both|2 Months|2 Months|Accepts Healthy Volunteers|||January 2015|January 9, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01475539||95365|
NCT01476111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115400|Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer|A Prospective, Exploratory Observational Study Evaluating Specific Biomarkers in Primary Invasive Breast Cancer and Their Modulation by Standard Neoadjuvant Therapy||GlaxoSmithKline||Terminated|December 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|117|Samples With DNA|Tissue|Both|18 Years|N/A|No|Non-Probability Sample|Patients who provided a pretreatment tumor sample for Wilms' Tumor 1 (WT1) expression        screening in the context of a neoadjuvant interventional study (111172 (WT1-AS15-BRS-001        (NEOADJ)), but who were not included into the active phase of this study.|February 2015|March 6, 2015|November 10, 2011||No|Study termination due to negative Phase III of another study product from same technology    platform.|No||https://clinicaltrials.gov/show/NCT01476111||95321|
NCT01476423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-3521|Observational Registry of the Treatment of Glanzmann's Thrombasthenia|Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry||Novo Nordisk A/S|No|Completed|January 2004|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|N/A|N/A|No|Non-Probability Sample|Patients with GT. There is no limit to the number of bleeding episodes or preventions of        bleeding during invasive procedures/surgery that can be entered for each patient within        the lifetime of the registry. Patients will receive standard care according to local        practice, thus any systemic haemostatic treatment (with or without antifibrinolytic drugs        or other agents) considered useful by the centres for treatment of GT, are included in the        registry.|December 2014|December 19, 2014|October 7, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01476423||95297|
NCT01476657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-02|A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies|A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies||Infinity Pharmaceuticals, Inc.|No|Active, not recruiting|October 2011|December 2016|Anticipated|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|210|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|November 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01476657||95279|
NCT01476995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBMC Triage Study|Prognostic Indicators as Provided by the EPIC ClearView|Prognostic Indicators as Provided by the EPIC ClearView|GBMC|Epic Research & Diagnostics, Inc.|No|Completed|September 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|353|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women ages 18-85 who are inpatients, outpatients, friends/family/staff (controls        only) of Greater Baltimore Medical Center in Baltimore, Maryland. Participants cannot have        an implantable electrical device (such as a pacemaker) on their body, cannot be pregnant,        and cannot be undergoing cancer therapy of any kind.|November 2011|November 18, 2011|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01476995||95254|
NCT01476982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-001|Evaluation of Patients in Chest Pain in the Emergency Room|Evaluation of Patients in Chest Pain in the Emergency Room|EPIC-ER|Epic Research & Diagnostics, Inc.|No|Active, not recruiting|May 2012|||June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|Men and women, ages 18-85, presenting to the Emergency Department with chest pain.|March 2013|March 18, 2013|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01476982||95255|
NCT01477242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1105-114-364|The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department|The Effect of Oral Ondansetron During Intramuscular Ketamine Use in Children||Seoul National University Hospital|No|Recruiting|November 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|266|||Both|3 Months|N/A|Accepts Healthy Volunteers|||January 2012|January 19, 2012|October 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01477242||95235|
NCT01477515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANF-1|Endocannabinoids in End Stage Renal Disease|||Indiana University|No|Completed|February 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Hemodialysis patients healthy control subjects|August 2012|August 21, 2012|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477515||95214|
NCT01477463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0010|Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers|Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers||Stanford University|Yes|Active, not recruiting|September 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Female|18 Years|75 Years|No|||March 2014|March 13, 2014|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01477463||95218|
NCT01477190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-06-023(2)|Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program|Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program||McGill University Health Center|Yes|Completed|October 2010|October 2011|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||November 2011|November 24, 2011|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01477190||95239|
NCT01477450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Branson-2010-02|Comparison of Oxygen Delivery Devices for Reversal of Altitude-Induced Hypoxemia in Normal Subjects|Comparison of Oxygen Delivery Devices for Reversal of Altitude-Induced Hypoxemia in Normal Subjects||University of Cincinnati|No|Completed|October 2011|September 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|November 18, 2011||No||No|January 1, 2014|https://clinicaltrials.gov/show/NCT01477450||95219|
NCT01477801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCV-MO-11-001|Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels|Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels. A Phase 2 Randomized Double Blind Study|ECSPLOIT -D|Azienda Unita' Sanitaria Locale Di Modena|No|Recruiting|November 2011|September 2012|Anticipated|July 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|34|||Both|60 Years|N/A|No|||November 2011|November 18, 2011|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01477801||95192|
NCT01478087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA-2011DCM Pilot Study|Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)|Pilot Study of Immunoadsorption Therapy for Patients With Chronic Non-Ischemic Dilated Cardiomyopathy||Asahi Kasei Medical Co., Ltd.|Yes|Terminated|November 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|November 7, 2011|No|Yes|Sponsor terminated due to business reasons|No|January 8, 2013|https://clinicaltrials.gov/show/NCT01478087||95170|
NCT01478100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1109-106-379|Virtual Coronary Intervention and Non-invasive Fractional Flow Reserve (FFR)|||Seoul National University Hospital|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|From the DISCOVER-FLOW study 20 patients with available post-intervention FFR were        included in this study.|November 2011|November 22, 2011|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01478100||95169|
NCT01473784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07061|Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck|A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|December 2007|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|November 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01473784||95500|
NCT01474096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/90680|Implementation Strategy for a Breastfeeding Guideline in Primary Care|Effectiveness of Implementation Strategy for a Breastfeeding Guideline in Primary Care: Cluster Randomised Trial||Gerencia de Atención Primaria, Madrid|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|208|||Female|N/A|N/A|Accepts Healthy Volunteers|||April 2015|April 8, 2015|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01474096||95476|
NCT01474395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1115-00|N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia|NMDA and Cognitive Remediation in Schizophrenia||Nathan Kline Institute for Psychiatric Research|No|Recruiting|March 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|64 Years|No|||July 2011|October 24, 2012|October 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474395||95453|
NCT01474681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSC835X2201|Safety and Tolerability of HSC835 in Patients With Hematological Malignancies|A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies||Novartis||Recruiting|January 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|10 Years|55 Years|No|||February 2016|February 2, 2016|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474681||95431|
NCT01474057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-07-2-0006|DElivery of Self Training and Education for Stressful Situations-Primary Care Version|Online Early Resilience Intervention for Combat-Related PTSD in Military Primary Healthcare Settings: A Randomized Trial of "DESTRESS-PC"|DESTRESS-PC|Henry M. Jackson Foundation for the Advancement of Military Medicine|Yes|Completed|May 2008|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|133|||Both|N/A|N/A|No|||January 2012|January 11, 2012|March 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01474057||95479|
NCT01474070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAT-DCT-Vergleich|Influence of Discordant Intraocular Eye Pressure Readings Taken by Dynamic Contour Tonometry and Goldmann Applanation Tonometry|||University of Zurich||Active, not recruiting|November 2011|||December 2012|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|102|||Both|18 Years|N/A|No|Non-Probability Sample|glaucoma patients|November 2011|November 14, 2011|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01474070||95478|
NCT01474083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK1-MS-201|A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GK1-399 in Patients With Type 2 Diabetes Mellitus||vTv Therapeutics|Yes|Completed|November 2011|September 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|248|||Both|18 Years|75 Years|No|||September 2013|September 3, 2013|November 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474083||95477|
NCT01474356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTCCU01|Hyperthermia Combined Brachytherapy in CCU|HDR Brachytherapy Combined With Interstitial Hyperthermia 500 kHz in Locally Advanced Cervical Cancer Patients. A Prospective Clinical Trial||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Completed|November 2006|March 2009|Actual|March 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|224|||Female|18 Years|N/A|No|||November 2011|November 15, 2011|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01474356||95456|
NCT01474369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-201|Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease|A Phase 3, Randomized, Double Blind, Placebo Control, Multicenter Study to Evaluate the Efficacy and Safety of TAK- 438 (10 and 20 mg Once-Daily) in Patients With Non-Erosive Gastroesophageal Reflux Disease.||Takeda|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|827|||Both|20 Years|N/A|No|||July 2013|July 2, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01474369||95455|
NCT01505634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7655-003|Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)|A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)||Merck Sharp & Dohme Corp.|No|Completed|May 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|302|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505634||93058|
NCT01505647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-042|Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)|A Phase III Double-Blinded, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Made With an Alternative Manufacturing Process (AMP)||Merck Sharp & Dohme Corp.|No|Completed|April 2012|November 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|498|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 3, 2015|January 4, 2012|Yes|Yes||No|April 10, 2013|https://clinicaltrials.gov/show/NCT01505647||93057|
NCT01506609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-895|The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer|A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer||AbbVie|Yes|Active, not recruiting|January 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|290|||Both|18 Years|99 Years|No|||January 2016|January 13, 2016|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506609||92983|
NCT01506856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOTIC-001/JGOG3019|Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial|A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|iPocc|Gynecologic Oncology Trial & Investigation Consortium|Yes|Recruiting|May 2010|May 2020|Anticipated|November 2019|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|654|||Female|20 Years|N/A|No|||March 2015|March 17, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01506856||92964|
NCT01506544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydroxyurea Pharmacokenetic|Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia|Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia|HU|Children's Mercy Hospital Kansas City|Yes|Completed|December 2011|January 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|39|||Both|2 Years|17 Years|No|||December 2014|December 10, 2014|September 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01506544||92988|
NCT01506557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|763/10|Vitamin D Supplementation of Lactating Mothers|Effect of Vitamin D Supplementation During Lactation on Vitamin D Status, Bone Mineralisation and Body Composition of Mother and Their Exclusively Breastfed Infants.|MAVID|Children's Memorial Health Institute, Poland|No|Completed|March 2011|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|174|||Female|N/A|N/A|Accepts Healthy Volunteers|||July 2013|July 22, 2013|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01506557||92987|
NCT01507467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAEA-HypoX|IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck|IAEA-HypoX. A Randomized Multicenter Study of Accelerated Fractionated Radiotherapy With or Without the Hypoxic Radiosensitizer Nimorazole in the Treatment of Squamous Cell Carcinoma of the Head and Neck|IAEA-HypoX|Danish Head and Neck Cancer Group|Yes|Terminated|March 2012|March 2018|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||November 2014|November 28, 2014|August 14, 2011||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01507467||92918|
NCT01495923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|358308-4|Steroids Versus Gabapentin|Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy||Johns Hopkins University|No|Completed|December 2011|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|145|||Both|17 Years|N/A|No|||January 2015|January 1, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495923||93803|
NCT01521871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214603|Tissue Glue (Cyanoacrylate) Versus Conventional Suture in Kidney Donors|A Prospective, Randomised Study on Tissue Glue (Cyanoacrylate) Versus Conventional Suture for Skin Closure in Laparoscopic Living Donor Nephrectomy|TG-CYANO|Oslo University Hospital|No|Completed|January 2012|February 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|90 Years|No|||November 2014|November 3, 2014|January 12, 2012||No||No|December 13, 2013|https://clinicaltrials.gov/show/NCT01521871||91819|
NCT01517737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 Orth 04S (68-06-11)|Immunology of Failing Metal-on-Metal Hip Replacement|Immune Cell Involvement in the Tissue Response to Metallosis in Patients With Failed Metal-on-metal Hip Replacements||University of East Anglia|Yes|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|N/A||1|Anticipated|105|Samples With DNA|blood from all patients; joint fluid, soft tissue and bone on operated patients|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Ultima TPS patients are all identified and regularly followed up. Other patients will        be identified from planned operating lists and waiting lists. This will be carried out by        the research team.|February 2012|February 8, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517737||92136|
NCT01508572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCG/UMCU_01|VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer|Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A Multicenter Feasibility Study||University Medical Center Groningen|Yes|Completed|October 2011|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||March 2015|March 29, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01508572||92835|
NCT01496456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG#N010508|Radiographic Progression of Infiltrated Caries Lesions In-vivo|Radiographic Progression of Infiltrated Caries Lesions In-vivo|ICON|University of Michigan|No|Completed|May 2010|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|14 Years|35 Years|No|||January 2015|January 30, 2015|December 9, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496456||93762|
NCT01496690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT nr 2010-024488-42|Pregablin for Anxiety-comorbidity in Patients With Schizophrenia|Pregablin for Anxiety-comorbidity in Patients With Schizophrenia - a Double-blinded Randomized Placebo Controlled Study|PACS|University of Aarhus|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496690||93744|
NCT01496963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAH2010|Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia|Observational Multicenter Study Lasting 12 Months to Determine the Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia Major and Intermedia and Verify the Suitability of Common Diagnostic Criteria in This Population|PAH2010|Ente Ospedaliero Ospedali Galliera|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|1500|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Thalassemia Major and Intermedia studied by echocardiography in the six        months prior to the beginning of the study|August 2015|August 3, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01496963||93723|
NCT01497223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290-005|MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis||MethylGene Inc.|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Female|18 Years|N/A|No|||June 2012|April 2, 2013|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497223||93703|
NCT01497236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSF-nutcon03|Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection in Karamoja, Uganda|Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Kaabong, Karamoja, Uganda|MSF-nutcon03|Medecins Sans Frontieres, Spain|Yes|Completed|March 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2202|||Both|6 Months|59 Months|Accepts Healthy Volunteers|||June 2015|June 29, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497236||93702|
NCT01497496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16631|Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497496||93682|
NCT01497210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0205-11-U356|EASH Dressing on Chronic Venous Leg Ulcers|A Prospective, Multi-centre, Non-comparative Study to Evaluate the Safety and Preliminary Performance of the EASH Dressing on Chronic Venous Leg Ulcers||ConvaTec Inc.|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497210||93704|
NCT01505673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000235|Adding Liraglutide to High Dose Insulin: Breaking the Cycle|Adding Liraglutide to High Dose Insulin: Breaking the Cycle||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505673||93055|
NCT01505686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKCH-Surg-008|MRI Findings in Inguinal Hernia|MRI Findings in Inguinal Hernia||North Karelia Central Hospital|No|Completed|May 2012|June 2014|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|22|||Both|18 Years|50 Years|No|||June 2014|June 25, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505686||93054|
NCT01505387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/024511|Litramine in Weight Maintenance|Double-blind, Randomized, Placebo-controlled Clinical Investigation to Evaluate the Safety and Efficacy of Litramine in Maintaining Body Weight Loss in Overweight and Obese Subjects||InQpharm Group|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|January 4, 2012||No||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01505387||93077|
NCT01505946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PredicTGA|Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors|Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic Effectiveness of Factor VIII (FVIII) Concentrates in Patients Affected by Inherited Haemophilia A With FVIII Inhibitors High and Low Anamnestic Response.|PredicTGA|Grifols Italia S.p.A|Yes|Recruiting|March 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|25|Samples Without DNA|plasma samples|Male|N/A|N/A|No|Non-Probability Sample|Patients with moderate or severe hemophilia A with inhibitors divided into two groups:          1. Patients with inhibitors to FVIII and low anamnestic response: Low responders cohort          2. Patients with inhibitors to FVIII and high anamnestic response: High responders             cohort|June 2013|June 14, 2013|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01505946||93034|
NCT01505959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-FFPO-02|Blood Pressure Reduction Induced by CPAP in Sleep Apnea Patients at High Cardiovascular Risk : OPTISAS 2 Study|Blood Pressure Reduction Induced by Continuous Positive Airway Pressure (CPAP) in Sleep Apnea Patients at High Cardiovascular Risk : A Randomized Controlled Trial Comparing Usual CPAP Care Versus a Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform||Fédération Française de Pneumologie|Yes|Recruiting|February 2013|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|936|||Both|18 Years|78 Years|No|||September 2014|September 4, 2014|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01505959||93033|
NCT01506258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-11-011|Autologous Stem Cells in Newborns With Oxygen Deprivation|Effects of the Infusion of Autologous Non-cryopreserved CD34+ Cells in Newborns With Asphyxia||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Recruiting|January 2012|April 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|37 Weeks|42 Weeks|No|||January 2012|January 18, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01506258||93010|
NCT01506271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7655-004|Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)|A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Intra-Abdominal Infection [cIAI]||Merck Sharp & Dohme Corp.|No|Completed|June 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|351|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506271||93009|
NCT01498588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00050068|Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer|Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer||Emory University|Yes|Active, not recruiting|November 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498588||93599|
NCT01506869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD010|Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal Study|A Prospective Cohort Study on the Associations of Diabetes With Cancer Risk in Chinese Men and Women|REACTION|Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|May 2011|June 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200000|Samples With DNA|Blood and urine samples were collected and retained for biomarker analysis|Both|40 Years|75 Years|No|Probability Sample|In phase 1, 200,000-250,000 individuals selected from 20-25 communities stratified        according to geographic regions, degrees of urbanization, and economic development status        In Phase 2, 30,000-40,000 type 2 diabetes, 20,000-30,000 prediabetes, 30,000-40,000 normal        glucose regulation, recruited from the baseline survey|January 2012|January 9, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01506869||92963|
NCT01507142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIA-AIDS-001|Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients|Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients||Gaia Medical Institute|No|Recruiting|October 2011|October 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|100|Samples Without DNA|Saliva|Both|N/A|N/A|No|Non-Probability Sample|HIV-positive, or HIV-negative and Hepatitis-positive adult participants|July 2012|July 16, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507142||92942|
NCT01507480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-650|The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia|The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.|ELLIPSE|Hospices Civils de Lyon|Yes|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||December 2011|May 13, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01507480||92917|
NCT01495689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHRI|Smoking Cessation With the Ottawa Model and SmartCard in Out-patient Respirology Clinic Setting|A Pilot Randomized Control Trial of Smoking Cessation Using The Ottawa Model With the SmartCard in Out-patient Respirology Clinic Setting|Quit&Win|Ottawa Hospital Research Institute|No|Completed|November 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495689||93821|
NCT01495702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0121|Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients|A Phase 3b Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients||Gilead Sciences|No|Completed|December 2011|December 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|439|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 14, 2011|Yes|Yes||No|December 31, 2014|https://clinicaltrials.gov/show/NCT01495702||93820|There were no limitations affecting the analysis or results.
NCT01521884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0881A1-4748|Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy|Longitudinal Changes In Fatigue And Health Status (aims2) In Ra Patients Treated With Sc Anti-tnf-alpha Therapy||Pfizer|No|Completed|November 2010|February 2014|Actual|February 2014|Actual|Phase 4|Observational|Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|No|Probability Sample|patients seen in a rheumatology practice|February 2015|February 3, 2015|August 19, 2011||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01521884||91818|Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.
NCT01521897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0887X1-4447|Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)|Prevenar Special Use-result Surveillance (Multi-center, Prospective Observational Safety Surveillance For Prevenar In Japan)||Pfizer|No|Completed|September 2010|April 2015|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1143|||Both|2 Months|2 Years|No|Probability Sample|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months|December 2015|December 14, 2015|September 14, 2011|No|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01521897||91817|
NCT01517750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH-OSA-TS-2012|Study to Predict the Need for Humidification Use and Comparison of the Effect of ThermoSmart™ and no Humidification on Adherence|||Fisher and Paykel Healthcare|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|70 Years|No|||June 2015|June 21, 2015|January 18, 2012|Yes|Yes||No|March 10, 2015|https://clinicaltrials.gov/show/NCT01517750||92135|
NCT01496170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07820|A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])|A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)]||Merck Sharp & Dohme Corp.|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|32|||Both|50 Years|85 Years|No|||October 2015|October 22, 2015|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01496170||93784|
NCT01496183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCH0320106A|Metabolic Effects of Olanzapine in Healthy Males|Metabolic Effects of Olanzapine in Healthy Males||State University of New York at Buffalo|No|Completed|October 2007|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|December 13, 2011|Yes|Yes||No|November 24, 2014|https://clinicaltrials.gov/show/NCT01496183||93783|The small sample size, the exclusion of obese subjects, and the short olanzapine exposure in the current study may limit the interpretation and generalizability of our findings.
NCT01496443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_118|TAK-875 Glimepiride Drug-Interaction Study|A Phase 1, Single-Blind, Placebo Controlled, Sequential Design Study to Evaluate the Drug Interaction Potential Between Glimepiride and TAK-875 in Subjects With Type 2 Diabetes Mellitus||Takeda|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|28|||Both|18 Years|68 Years|No|||September 2012|September 12, 2012|December 18, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01496443||93763|
NCT01496976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16622|Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496976||93722|
NCT01497249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCHO 2011-086|Assessing Fermentability of a Dietary Fiber|Assessing Fermentability of a Dietary Fiber (FCHO) in Healthy Non-obese Men and Women|FCHO|Institute for Food Safety and Health, United States|No|Active, not recruiting|December 2011|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497249||93701|
NCT01497509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT epidural fentanyl|Intrapartum Epidural Fentanyl and Breastfeeding in the Immediate Postpartum Period: a Randomized, Controlled, Double-blinded Study|Effect of Intrapartum Epidural Fentanyl Upon Breastfeeding in the Immediate Postpartum Period: a Randomized, Controlled, Double-blinded Study||University Hospital Case Medical Center|No|Not yet recruiting|May 2012|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|450|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 28, 2012|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01497509||93681|
NCT01497522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237A1301|Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With LAF237 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy||Novartis||Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|183|||Both|20 Years|N/A|No|||March 2013|March 11, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497522||93680|
NCT01497483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06315|Drug-Drug Interaction Study With Pravastatin and Cyclosporine|The Pharmacokinetic Interaction Between Pravastatin and Cyclosporine in Healthy Volunteers||University of California, San Francisco|Yes|Completed|December 2011|December 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01497483||93683|
NCT01497470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1011-DDI-105|A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen|An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel||Teva Pharmaceutical Industries||Completed|April 2012|October 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|36|||Both|18 Years|N/A|No|||October 2013|October 18, 2013|December 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497470||93684|
NCT01497782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2010-082 FEEDBACK|The FEEDBACK Trial, a Randomized Controlled Trial|Impact of Instructor Feedback on Performance in a Virtual Reality Simulator: A Randomized, Controlled Trial|Feedback|Rigshospitalet, Denmark|No|Enrolling by invitation|April 2011|January 2012|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|99|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2011|December 21, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497782||93660|
NCT01498068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100676|Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C|Open-Label, Bridging Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Treatment- Naïve and Treatment-Experienced Russian Subjects With Genotype 1 Chronic Hepatitis C||Janssen-Cilag International NV|No|Completed|January 2012|March 2013|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|No|||January 2015|January 29, 2015|December 6, 2011||No||No|September 11, 2013|https://clinicaltrials.gov/show/NCT01498068||93639|
NCT01506284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uppsala 2011 - 189|Assessment of Airways Mechanical Properties by FOT and LIR During Anesthesia|Assessment of Airways Mechanical Properties by Forced Oscillatory Technique (FOT) and Laser Interferometry (LIR) During Anesthesia.||Uppsala University Hospital|No|Completed|November 2011|November 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|14|||Both|18 Years|80 Years|No|Probability Sample|Patients ASA classification I-II, scheduled for elective surgery requiring general        anesthesia|January 2012|December 8, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01506284||93008|
NCT01506297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC504|Biologic Assessment of Satiety|Biologic Assessment of Satiety||USDA Grand Forks Human Nutrition Research Center|Yes|Active, not recruiting|July 2012|August 2016|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|blood samples|Both|25 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men and women|November 2015|November 20, 2015|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506297||93007|
NCT01498848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00048757|Effect of Cooking Oils on Whole Blood and Saliva Fatty Acids in Children in Bogota, Colombia|Effect of Cooking Oils on Whole Blood and Saliva Fatty Acids in Children in Bogota, Colombia||University of Michigan|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|10 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 18, 2013|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498848||93579|
NCT01498835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISG 03|Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma|Phase 1 Trial of Concurrent Sunitinib and Radiation Therapy as Preoperative Treatment for Locally Advanced or Recurrent Soft Tissue Sarcoma.|SunRaSe|Heidelberg University|Yes|Completed|February 2012|February 2015|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498835||93580|
NCT01499459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11111111|Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis|Efficacy of Exvivo Expanded Autologous Mesenchymal Stem Cell Transplantation Via Peripheral Vein in Patients With Liver Cirrhosis||Gulhane Military Medical Academy|Yes|Active, not recruiting|June 2008|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||March 2012|March 20, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01499459||93532|
NCT01507155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM-1|An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay|An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay|COM-1|Genomind, LLC|No|Completed|April 2013|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|685|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507155||92941|
NCT01499433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP# 39758|Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease|Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|January 2012|November 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01499433||93534|
NCT01499446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFA20001|A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.|A Randomised, Double-blind, Double Dummy, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening All Administered by Inhalation Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.||GlaxoSmithKline|No|Completed|September 2003|March 2004|Actual|March 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|669|||Both|16 Years|65 Years|No|||July 2012|April 11, 2013|December 8, 2011||||No||https://clinicaltrials.gov/show/NCT01499446||93533|
NCT01495949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si559/2011|The Cortisol Levels During Cardiac Surgery. The Comparison Between Etomidate and Thiopentone|The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone.||Mahidol University|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|60 Years|85 Years|No|||May 2014|May 21, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01495949||93801|
NCT01521910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low Protein Diet|Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy|Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy|LPD|Steno Diabetes Center|No|Completed|April 1995|June 2000|Actual|June 2000|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|60 Years|No|||January 2012|January 30, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01521910||91816|
NCT01518244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-198|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America||Alcon Research|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||February 2014|July 17, 2015|January 23, 2012|No|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01518244||92097|
NCT01518556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-2011-01|Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia|Phase I/II Clinical Study of Idarubicin Dose Intensification for Remission Induction Therapy in Acute Myeloid Leukemia Patients Age of 65 Years or Less|IDAML|Konkuk University Medical Center|Yes|Recruiting|July 2011|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|20 Years|65 Years|No|||September 2015|September 7, 2015|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01518556||92074|
NCT01496703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMFreductionLeuven|Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients|Reasons for Dose Reduction of Mycophenolate Mofetil During the First Post-transplant Year in Renal Transplant Recipients and Its Impact on Graft Outcome: a Single-center Retrospective Analysis||Universitaire Ziekenhuizen Leuven|No|Completed|January 1996|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|749|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who received a single renal transplant at the University Hospitals of Leuven        between April 1996 (when MMF was introduced in the Leuven renal transplant program) and        February 2007 and were treated with MMF (Cellcept®, Roche) as part of their initial        maintenance immunosuppressive regimen were included in this retrospective analysis. If a        patient underwent more than one kidney transplantation in the abovementioned 11-year        period, only the last was considered. No other exclusion criteria were applied.|December 2011|December 20, 2011|December 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01496703||93743|
NCT01496716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA-BMI|Obesity's Impact on the Effect of Hip Arthroplasty|Obesity's Impact on the Clinical Efficacy and Quality of Life 1 Year After Primary Total Hip Arthroplasty||University of Aarhus|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|N/A|No|Probability Sample|All hip total hip replacement patients operated on Hospital Southern Jutland, Denmark.|August 2013|August 12, 2013|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496716||93742|
NCT01496989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAVI B004|Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers|A Phase 1 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Safety and Immunogenicity of a Multiantigen HIV (HIV-MAG) pDNA Vaccine With or Without Human IL-12 pDNA GENEVAX® IL-12) and Ad35-GRIN/ENV Vaccine in HIV-Uninfected, Healthy Volunteers||International AIDS Vaccine Initiative|Yes|Completed|December 2011|||March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Anticipated|75|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 30, 2013|December 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01496989||93721|
NCT01497262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2325|Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis|A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis||Novartis||Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|162|||Both|18 Years|65 Years|No|||March 2015|March 17, 2015|December 5, 2011|Yes|Yes||No|February 26, 2015|https://clinicaltrials.gov/show/NCT01497262||93700|
NCT01497535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1438|Within-subject Variability of Insulin Detemir in Healthy Volunteers|A Single-centre, Parallel-group, Randomised, Double Blind Trial in Healthy Japanese Subjects Comparing the Within-subject Variability of Insulin Detemir and Insulin Glargine With Respect to Pharmacodynamic and Pharmacokinetic Properties||Novo Nordisk A/S|No|Completed|May 2004|October 2004|Actual|October 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497535||93679|
NCT01497548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCG001|Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients|A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care||University of Malaya|No|Recruiting|March 2011|October 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||December 2011|December 21, 2011|February 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01497548||93678|
NCT01497821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090515|AMG 172 First in Human Study in Patients With Kidney Cancer|A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects With Relapsed / Refractory Renal Cell Carcinoma||Amgen||Completed|January 2012|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|December 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497821||93658|
NCT01497834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-026|A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients|A Phase 3 Japanese Study of BMS-790052 Plus BMS-650032 Combination Therapy in Chronic Hepatitis C Genotype 1b Infected Subjects Who Are Non Response to Interferon Plus Ribavirin and Interferon Based Therapy Ineligible Naive/Intolerant||Bristol-Myers Squibb|No|Completed|January 2012|June 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|224|||Both|20 Years|75 Years|No|||September 2015|September 23, 2015|December 2, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497834||93657|
NCT01497808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 06611|RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA|RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|December 2011|||October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497808||93659|
NCT01498081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3060C00003|A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients|A Randomised, Double-blind, Placebo and Active Controlled, Multi-centre, 6 Way Cross-over, Single-dose Phase IIa Study to Investigate the Local and Systemic Effects of 3 Different Doses of Inhaled AZD2115 in Patients With Chronic Obstructive Pulmonary Disease (COPD)||AstraZeneca||Completed|March 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|39|||Both|40 Years|N/A|No|||October 2012|October 25, 2012|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498081||93638|
NCT01498354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEO-TEM-2010-01|Efficiency of Two Dimensional High Definition Versus Three Dimensional Endoscopic Systems in Transanal Endoscopic Surgery|Comparing the Efficiency of Two Dimensional High Definition (TEO) Versus Three Dimensional (TEM) Endoscopic Systems in Transanal Endoscopic Surgery; a Prospective Control Trial||Corporacion Parc Tauli|No|Completed|August 2010|February 2012|Actual|October 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|90 Years|No|||September 2015|September 9, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498354||93617|
NCT01498601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|Improving Oral Care to Reduce Hospital-Acquired Pneumonia (HAP) in the Acute Neurologically Impaired Adult|Improving Oral Care to Reduce Hospital Acquired Pneumonia (HAP) in the Acute, Non-Intubated, Care Dependent, Neurologically Impaired Adult Patient Population||Fraser Health|No|Completed|January 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|19 Years|N/A|No|||December 2011|August 19, 2015|December 13, 2011||No||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01498601||93598|This study was supported by the Fraser Health Point of Care Research Challenge.
NCT01498328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX110-06|A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma|A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma|ReACT|Celldex Therapeutics|No|Active, not recruiting|December 2011|||April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|168|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498328||93619|
NCT01498341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110074|Hypoparathyroidism in Denmark|Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism in Denmark - Epidemiology, Causes, Symptoms and Prognoses|HypoPT|University of Aarhus|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|N/A||1|Actual|1000|None Retained|2 designs: Case-finding; Case-control|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population are persons with hypoparathyroidism, automalt dominant hypocalcaemia        and pseudohypoparathyroidism.        The population is selected via the National Danish Health Registre and the Danish Medical        Registre|January 2013|June 30, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01498341||93618|
NCT01499186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7837|The Effect of 6 Months of Local Vibration Training in Institutionalized Elderly|The Effect of 6 Months of Local Vibration Training of the Thigh and Hip on Muscle Strength, Muscle Mass, Bone Density, Bone Structure and Functionality in Institutionalized Elderly.||Universitaire Ziekenhuizen Leuven|No|Completed|January 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|65 Years|N/A|Accepts Healthy Volunteers|||December 2013|March 17, 2014|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01499186||93553|
NCT01499498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOC_PK|The Boceprevir and Sildenafil Pharmacokinetics Study|A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Boceprevir and Sildenafil When Dosed Separately and Together in Healthy Male Volunteers||Imperial College London|No|Completed|December 2012|May 2014|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2014|November 6, 2014|November 4, 2011||No||No|October 9, 2014|https://clinicaltrials.gov/show/NCT01499498||93529|
NCT01499472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ofer02-HMO-CTIL|Comparing the Expected Benefit of Extra-corporeal-shockwave Therapy (ESWT) Treatment to Standard Care in Treating Diabetic Foot Ulcers|ESWT Treatment of Diabetic Foot VS. Standard Care Trial||Hadassah Medical Organization||Not yet recruiting|January 2012|January 2015|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|No|||August 2011|December 22, 2011|September 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01499472||93531|
NCT01499134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11C.18|Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure|Effect of Nebivolol Compared With Metoprolol in Hypertensive Patients With Peripheral Arterial Disease|ENCOMPASS|Thomas Jefferson University|Yes|Completed|August 2011|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|October 24, 2011|Yes|Yes||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01499134||93557|
NCT01499732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-320|Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects|An Exploratory Trial to Evaluate Premature Endothelial Dysfunction, as Measured by Positron Emission Tomography (PET) Scan With Cold Pressor Test (CPT), in Patients With Early Rheumatoid Arthritis (RA) Compared to Patients With Established RA, and Normal Subjects. Additionally, the Relationship Between the PET Scan Findings and the Inflammatory, Cardiovascular Risk, and Endothelial Dysfunction Biomarkers Will be Analyzed||Orrin M Troum, M.D. and Medical Associates|No|Completed|December 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Five adults (>18 years of age), male or non pregnant, non nursing female with active early        rheumatoid arthritis (<2 years), five adults, male or non-pregnant, non nursing female        with active established rheumatoid arthritis (>2 years), and five healthy adults, male or        non-pregnant, non nursing female without RA are to be enrolled.|May 2013|May 6, 2013|December 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01499732||93511|
NCT01500031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2273|Boston Scientific OffRoad™ Re-entry Catheter System for Subintimal Recanalization of Chronic Total Occlusions in Femoropopliteal Arteries|Boston Scientific OffRoad™ Re-entry Catheter System for Subintimal Recanalization of Chronic Total Occlusions in Femoropopliteal Arteries|Re-ROUTE|Boston Scientific Corporation|Yes|Completed|April 2012|May 2013|Actual|April 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|92|||Both|18 Years|N/A|No|||March 2014|March 10, 2014|December 19, 2011||No||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01500031||93488|
NCT01499758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09-1032|A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.|A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.||Ranbaxy Inc.|No|Completed|October 2009|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2012|July 8, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499758||93509|
NCT01496274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL654_3001|A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B|A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B||CSL Behring|Yes|Completed|February 2012|||July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Male|12 Years|65 Years|No|||October 2014|September 29, 2015|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496274||93776|
NCT01518010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLMAN|Multi-player Online Video Games for Cognitive Rehabilitation|Multi-player Online Video Games for Cognitive Rehabilitation||University of Portsmouth|No|Not yet recruiting|June 2012|January 2014|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01518010||92115|
NCT01519466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-PMR-INX-11012|Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study|Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study||Abbott Diabetes Care|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|55|||Both|18 Years|N/A|No|||November 2012|November 2, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01519466||92004|
NCT01496729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06622|Transversus Abdominis Plane (TAP) Block After Kidney Transplantation|Single Shot Transversus Abdominis Plane (TAP) Block Versus Sham Block for Analgesia in Donors and Recipients Following Kidney Transplantation||University of California, San Francisco|Yes|Withdrawn|January 2012|January 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|80 Years|No|||October 2013|October 8, 2013|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496729||93741|
NCT01496742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27821|A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC||Genentech, Inc.||Active, not recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|258|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496742||93740|
NCT01497002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSHO#069|Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a|Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm. Efficacy of Allogeneic Stem Cell Transplantation in Comparison to a Second Consolidation Chemotherapy in Elderly Patients With Newly Diagnosed AML in the Age Over 60 Years|AML 2004|University of Leipzig|Yes|Recruiting|April 2005|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|730|||Both|18 Years|60 Years|No|||March 2011|December 22, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01497002||93720|
NCT01497561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1538|Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Four-period, Cross-over, Dose Response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2003|June 2003|Actual|June 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497561||93677|
NCT01497574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1633|Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes|A Single-centre, Randomised, Double-blind, Cross-over Trial Comparing the Within-subject Variability of the Pharmacokinetic Profiles of Insulin Detemir and Insulin Glargine in Children and Adolescents With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|May 2005|October 2005|Actual|October 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|6 Years|17 Years|No|||December 2011|December 20, 2011|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497574||93676|
NCT01497587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-3023|Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan|A Single Centre, Open-labelled Trial to Investigate the Pharmacokinetics of Insulin Detemir in Healthy Taiwanese Subjects||Novo Nordisk A/S|No|Completed|August 2005|December 2005|Actual|December 2005|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|55 Years|No|||December 2011|December 20, 2011|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497587||93675|
NCT01497847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S51501|Post-Infectious Irritable Bowel Syndrome (PI-IBS)|Post-Infectious Irritable Bowel Syndrome (PI-IBS)|PI-IBS|Katholieke Universiteit Leuven|No|Completed|March 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|Samples With DNA|whole blood, blood plasma, feces, rectal biopsy|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Travelers to tropical destinations visiting the outpatient clinic for vaccinations in a        tertiary care hospital.|April 2013|April 25, 2013|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01497847||93656|
NCT01498094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03032|Study of High-flow Oxygen Therapy Against Standard Therapy in Bronchiolitis|A Prospective Open Randomized Clinical Trial Comparing High Flow Nasal Cannula Oxygen Therapy Against Standard Therapy for Children Hospitalized With Bronchiolitis|Hi-Flo|University of British Columbia|Yes|Completed|December 2011|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|N/A|18 Months|No|||May 2015|May 8, 2015|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01498094||93637|
NCT01498367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR2015|Life-long Tele-monitoring of Patients With Type 2 Diabetes Mellitus in Central Greece|Renewing Health RCT for the Evaluation of Life-long Tele-monitoring of Patients With Diabetes Mellitus Type 2 in Central Greece|RHCluster2GR|Regional Health Authority of Sterea & Thessaly|Yes|Completed|March 2011|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|154|||Both|18 Years|N/A|No|||February 2015|February 16, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498367||93616|
NCT01498627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112677|Cervarix Long-term Safety Surveillance|Cervarix Long-term Safety Surveillance Using the PGRx Information System (PGRx Study)|PGRx|GlaxoSmithKline||Completed|August 2008|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2945|||Both|14 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects reporting an Autoimmune diseases (AID) in the previous 12 months before        recruitment consultation and those whose AID is reported by physicians in general practice|April 2015|April 2, 2015|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498627||93596|
NCT01498614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FoU-Kronoberg Sweden 4522|Psychological Impact in Diabetes: Intervention With Affect School and Basal Body Awareness|Psychological Impact, Metabolic Control, and Biological Stress Markers in Diabetes: Intervention Study With Affect School and Basal Body Awareness||Lund University|No|Active, not recruiting|March 2009|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|321|||Both|18 Years|59 Years|No|||December 2011|December 22, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498614||93597|
NCT01498861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111855|Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol|A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol When Co-administered With Dolutegravir in Healthy Adult Female Subjects||ViiV Healthcare|No|Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|16|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|May 17, 2012|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498861||93578|
NCT01499199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116070|A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects|A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination With the Abacavir/Lamivudine Fixed Dose Combination Tablet Over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects||ViiV Healthcare|No|Completed|January 2012|May 2014|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|December 15, 2011|Yes|Yes||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01499199||93552|
NCT01499745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCBH116531 CTIL|Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients|Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients||Rabin Medical Center|Yes|Not yet recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|90 Years|No|||December 2011|December 22, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499745||93510|
NCT01495728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jacki2006|Thoracic Manipulation in Patients With Cervical Radiculopathy|Immediate and Short Term Effects of Thoracic Manipulation in Patients With Cervical Radiculopathy||Spine and Sport, Georgia|No|Recruiting|September 2011|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||December 2011|December 19, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495728||93818|
NCT01495741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08307|Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)|An Observational Post-Authorization Safety Surveillance (PASS) Study of Sycrest® (Asenapine) Among Patients Aged 18 and Older Diagnosed With Bipolar Disorder||Merck Sharp & Dohme Corp.|No|Active, not recruiting|July 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|3000|||Both|18 Years|N/A|No|Non-Probability Sample|Participants with Bipolar Disorder codes who are included in the United Kingdom Clinical        Practice Research Datalink (CPRD) and, if required, The Health Improvement Network (THIN)        database.        If pre-specified sample size and exposure criteria are met, secondary objectives will be        conducted in 2 separate study populations: 1. Participants treated with asenapine and        diagnosed with schizophrenia and no prior and/or concomitant diagnosis of bipolar        disorder; 2. Participants treated with asenapine with no prior and/or concomitant        diagnoses of bipolar disorder or schizophrenia, but diagnosed with i) Alzheimer's disease,        ii) other diagnoses - mental disorders or iii) no diagnosis.|November 2015|November 9, 2015|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495741||93817|
NCT01496287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005027|Tympanostomy Tube Placement in Children in the Office (Inova Study)|Tympanostomy Tube Placement in Children in the Office (Inova Study)|Inova|Acclarent|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|6 Months|21 Years|No|||November 2014|November 4, 2014|December 16, 2011|Yes|Yes||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01496287||93775|
NCT01519206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-124|Lifting and Tightening of the Face and Neck Following an Increased Density Treatment|Evaluation of the Efficacy and Safety of the Ulthera® System for Lifting and Tightening of the Face and Neck Following an Increased Density Treatment.||Ulthera, Inc|No|Completed|August 2011|March 2013|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|December 8, 2011|Yes|Yes||No|March 20, 2014|https://clinicaltrials.gov/show/NCT01519206||92024|3-D digital imaging was not completed, thus quantitative measure of submental skin lift was not obtained.
NCT01496482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZagreb Eye 1|Comparison of Evaporimetry With the Established Methods of Tear Film Measurement|Comparison of Evaporimetry With the Established Methods of Tear Film Measurement||University of Zagreb|No|Completed|September 2008|February 2009|Actual|February 2009|Actual|N/A|Observational|N/A||2|Actual|90|||Both|18 Years|61 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients were volunteers who came for a standard ophthalmological exam in Zagreb        University Hospital Eye Clinic, and whose enrollment was based on convenience sampling.|December 2011|December 21, 2011|December 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01496482||93760|
NCT01496508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZ-HFOV|High-frequency Oscillatory Ventilation (HFOV) in Preterm Infants With Severe Respiratory Distress Syndrome (RDS)|Principal Investigator||Zhengzhou Children's Hospital, China|Yes|Completed|June 2007|June 2011|Actual|December 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|360|||Both|N/A|24 Hours|No|||December 2011|December 20, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01496508||93758|
NCT01497600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1439|Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Six-period, Cross-over, Dose-response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects of Blacks or African American, Whites of Hispanic or Latino Origin and Whites Not of Hispanic or Latino Origin With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|February 2004|August 2004|Actual|August 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2011|December 20, 2011|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497600||93674|
NCT01497860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNMC-VRL|Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas|Phase 2 Study of Weekly Vinorelbine in Children With Progressive or Recurrent Low-Grade Gliomas||Children's Research Institute|Yes|Active, not recruiting|July 2011|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|N/A|18 Years|No|||July 2015|July 10, 2015|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497860||93655|
NCT01498107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|609/M/C/791|Technology-enhanced Therapy: the SilverCloud Study|A Pilot Study Evaluating Engagement With a Platform Supporting Online Interventions for Common Mental Health Problems||University of Cambridge|No|Completed|January 2012|October 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01498107||93636|
NCT01498380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03137|The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children|The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children|DexMED|University of British Columbia|Yes|Completed|January 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01498380||93615|
NCT01498640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-862|Retreatment of Recurrent Dupuytren's Contractures|Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX®/XIAPEX®]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe||Endo Pharmaceuticals|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|December 17, 2011|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01498640||93595|
NCT01498874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052120|Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Gevokizumab in Subjects With Moderate to Severe Acne Vulgaris||XOMA (US) LLC|No|Completed|December 2011|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|127|||Both|17 Years|N/A|No|||March 2014|March 3, 2014|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498874||93577|
NCT01499212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0058|Effects of Different I:E Ratio on Intrapulmonary Shunt Fraction and Oxygenation During One Lung Ventilation in the Lateral Decubitus Position|Effects of Different Inspiratory to Expiratory Ratios on Intrapulmonary Shunt Fraction and Oxygenation During One Lung Ventilation in the Lateral Decubitus Position||Yonsei University|Yes|Completed|July 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|58|||Both|40 Years|80 Years|No|||December 2011|December 21, 2011|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01499212||93551|
NCT01499225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14642-201|A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease|A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH14642 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease|YH14642|Yuhan Corporation|No|Completed|December 2011|||July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|162|||Both|20 Years|N/A|No|||July 2014|July 30, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01499225||93550|
NCT01499147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2000-0117|Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies|Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies||University of Illinois at Chicago|Yes|Completed|February 2000|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|152|||Both|10 Years|65 Years|No|||March 2014|March 27, 2014|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499147||93556|
NCT01499160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00040802; GCC 0901|GCC 0901 - Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer|GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer||University of Maryland|Yes|Terminated|May 2012|December 2016|Anticipated|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|December 14, 2011|Yes|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01499160||93555|
NCT01499173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT10624910|A Community Partnership to Treat Stroke|||University of Michigan|No|Active, not recruiting|December 2014|August 2016|Anticipated|August 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|120|||Both|10 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01499173||93554|
NCT01499485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAMA study|Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.|Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial.|TRAMA|Hospital Son Llatzer|No|Completed|November 2011|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499485||93530|
NCT01495754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CofSt3|Effects of Different Coffee Amounts on Energy Intake, Appetite, Glucose Metabolism and Inflammatory Markers|The Effect of Different Amounts of Coffee on Dietary Intake, Appetite-related Feeling, Appetite Hormones, Glucose Metabolism and Inflammatory Markers of Normal Weight and Overweight/Obese Individuals||Harokopio University|No|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2011|December 19, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495754||93816|
NCT01495962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-008404|The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy|The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy: A Pilot Study||Mayo Clinic|No|Active, not recruiting|November 2011|||August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495962||93800|
NCT01519219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2003-081|Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation|Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation|IC-Green|University of Michigan Cancer Center|Yes|Recruiting|January 2003|May 2017|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who take part in this study are required to be scheduled for hepatic irradiation.|November 2015|November 6, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01519219||92023|
NCT01520883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 20646|Evaluation of Decisional Conflict and Needs Assessment in Asthma Management|Decisional Conflict and Needs Assessment in Shared Decision Making in Asthma Management||Laval University|No|Completed|March 2011|December 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Adults with mild to moderate asthma controlled or slightly controlled|May 2013|May 24, 2013|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01520883||91895|
NCT01496495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-614-112|A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes|||Array BioPharma||Completed|January 2012|||December 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|18 Years|N/A|No|||December 2014|December 27, 2014|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496495||93759|
NCT01496768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120412|Effects of Chronic Leucine Supplemetion on Glucose Homeostasis, Body Compositin, Muscle Mass and Strength of Healthy and Young Subjects|Effects of Chronic Leucine Supplemetion on Glucose Homeostasis, Body Compositin, Muscle Mass and Strength of Healthy and Young Subjects: a Randomized, Double-blind, and Placebo Controlled Trial||University of Sao Paulo|Yes|Suspended|January 2012|February 2013|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496768||93738|
NCT01497028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGB|Plicated Laparoscopic Adjustable Gastric Banding (Lap Band)|Prospective Randomized Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding||Jacksonville Surgical Associates|Yes|Terminated|November 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|18 Years|80 Years|No|Probability Sample|Adult patients between the ages of 18-80 years of age who are severly or morbidly obese        and meet NIH and FDA criteria for baratric surgery (BMI>30+ co-morbid disease or BMI>35)        who are undergoing baratric surgery at Jacksonville Surgical Associates, P.A. or Ventura        Advanced Surgical Associates will be returned. All enrolled patients will be assigned to        either the SLAGB (control)group or the PLAGB (study) group.|December 2011|April 2, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01497028||93718|
NCT01497015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64194|Memory Training Intervention for Breast Cancer Survivors|Memory Training Intervention for Breast Cancer Survivors||Indiana University|No|Active, not recruiting|September 2008|December 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Anticipated|91|||Female|40 Years|N/A|No|||March 2012|March 27, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01497015||93719|
NCT01497275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032517|Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma|A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma||Duke University|Yes|Terminated|February 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|December 20, 2011|Yes|Yes|Low accrual due to the approval of new drugs for use in Mantle cell lymphoma.|No|May 20, 2015|https://clinicaltrials.gov/show/NCT01497275||93699|The study was closed to enrollment due to the approval of new drugs for use in Mantle Cell Lymphoma. We were not able to enroll enough subjects to answer our study questions.
NCT01497288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-1301-101-RD|A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects|An Open Label, Randomised, Single-centre, Two Sequence, Cross-over Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects Using a Population PK Approach|PK400 INFS|Takeda||Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|55 Years|No|||September 2012|September 28, 2012|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01497288||93698|
NCT01497301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007909|Efficacy Study of Diabetes Group Visits|Initiating Diabetic Group Visits in Newly Diagnosed Diabetics in an Urban Academic Medical Practice||Oregon Health and Science University|No|Not yet recruiting|February 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2011|December 21, 2011|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01497301||93697|
NCT01497626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-533|Lapatinib and Bortezomib in Patients With Advanced Malignancies|A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies||Georgetown University|Yes|Terminated|September 2011|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2015|February 15, 2016|December 20, 2011|Yes|Yes|Drug support withdrawn|No||https://clinicaltrials.gov/show/NCT01497626||93672|
NCT01497873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SCLC09I|Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients|A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer||Chong Kun Dang Pharmaceutical|Yes|Recruiting|September 2010|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|April 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497873||93654|
NCT01498120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1005|Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome|An Open-Label, Long-Term, Follow-Up Study To Determine The Safety, Tolerability, and Efficacy of Rotigotine Transdermal System As Monotherapy in Adolescents With Restless Legs Syndrome||UCB Pharma|No|Completed|December 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|13 Years|N/A|No|||February 2016|February 9, 2016|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498120||93635|
NCT01498393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-LAMMP-2011-8536|1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis|A Randomized, Placebo-Controlled Study of the 1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis||University of California, Irvine|Yes|Completed|December 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498393||93614|
NCT01498653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113714|Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry|A Randomised, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily Compared to Fluticasone Propionate Delivered Twice Daily in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With High-strength Inhaled Corticosteroids or Mid-strength ICS/LABA Combination Therapy.||GlaxoSmithKline|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|313|||Both|12 Years|N/A|No|||January 2014|February 13, 2014|December 21, 2011||No||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01498653||93594|
NCT01498913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1882|Observational Study of NovoNorm® in Subjects With Diabetes|NovoNorm Post Marketing Surveillance Study||Novo Nordisk A/S|No|Completed|August 2001|March 2005|Actual|March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5841|||Both|N/A|N/A|No|Probability Sample|Korean people with diabetes mellitus|April 2012|April 11, 2012|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498913||93574|
NCT01498887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DES03|Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy|A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.|EARLiMS|Novartis||Recruiting|December 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|434|||Both|18 Years|50 Years|No|||March 2016|March 1, 2016|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01498887||93576|
NCT01498900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1875|An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoNorm® in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice||Novo Nordisk A/S|No|Completed|August 2004|July 2006|Actual|July 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30554|||Both|N/A|N/A|No|Probability Sample|Patients with type 2 diabetes, newly diagnosed or not adequately controlled on their        current therapy, who are treated repaglinide by their physicians in accordance with the        approved labeling|April 2012|April 11, 2012|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498900||93575|
NCT01499238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4|Comparison of Nasal CPAP and Nasal SIMV in Transient Tachypnea of Newborn|Comparison of Nasal CPAP and Nasal SIMV in Transient Tachypnea of Newborn||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Recruiting|December 2011|March 2012|Anticipated|February 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|3 Days|No|||December 2011|December 21, 2011|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499238||93549|
NCT01499251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-055-115|Clinical Studyon the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma|A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide||Actelion|No|Active, not recruiting|January 2012|January 2018|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499251||93548|
NCT01499511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1667|Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study|Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study|ASCOT-10|Imperial College London|No|Not yet recruiting|January 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|5450|Samples Without DNA|Plasma to be stored for future measurement of biochemical markers of cardiovascular disease|Both|18 Years|95 Years|No|Non-Probability Sample|Subjects who participated in the Anglo-Scandinavian Cardiac Outcomes Trial in the UK|December 2011|December 22, 2011|February 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01499511||93528|
NCT01499771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R09-1033|A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions|A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions.||Ranbaxy Inc.|No|Completed|October 2009|December 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Both|18 Years|66 Years|Accepts Healthy Volunteers|||July 2012|July 8, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499771||93508|
NCT01499784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|61418|Urinary Incontinence in an Inpatient Rehab Unit|Can Urinary Incontinence be Treated in an In-patient Rehabilitation Setting?||Rehabilitation Institute of Chicago|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Female|18 Years|99 Years|No|||October 2015|October 26, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499784||93507|
NCT01495715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNT-III-011|Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)|||Santhera Pharmaceuticals||Withdrawn||||||Phase 3|Interventional|N/A|2||Actual|0|||Both|10 Years|65 Years|No|||August 2014|August 21, 2014|December 16, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01495715||93819|
NCT01495767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAC205|Quality of Life in Juvenile Patients With Uveitis|The Impact of Uveitis on Health-related Quality of Life in Adolescents||Hospital Hietzing|No|Completed|January 2006|July 2009|Actual|||N/A|Observational|Observational Model: Cohort||1|Actual|37|||Both|11 Years|18 Years|No|Non-Probability Sample|Patients with uveitis, aged 11-18 years|December 2011|December 22, 2011|November 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01495767||93815|
NCT01495793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1004|Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome|A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome||UCB Pharma|No|Completed|December 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|42|||Both|13 Years|17 Years|No|||June 2015|June 17, 2015|December 16, 2011|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01495793||93813|
NCT01495975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011p-001573|Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control|Impact of a Web-based Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control|DTTK|Massachusetts General Hospital|Yes|Completed|December 2011|January 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 14, 2011||No||No|April 6, 2015|https://clinicaltrials.gov/show/NCT01495975||93799|
NCT01495988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27894|Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma|Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma||Melanoma Research Foundation Breakthrough Consortium|Yes|Terminated|August 2013|June 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|December 9, 2011|Yes|Yes|Slow accrual; toxicity; change in priorities|No||https://clinicaltrials.gov/show/NCT01495988||93798|
NCT01521234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSN-Mansfield-2011|Using Wireless-technology for Feedback of Daily Walking Activity Post-stroke|Using Wireless Technology in Clinical Practice: Does Feedback of Daily Walking Activity Improve Walking Outcomes of Individuals Receiving Rehabilitation Post-stroke?||Toronto Rehabilitation Institute|No|Completed|October 2012|June 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01521234||91868|
NCT01496235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cacao I|Effect of Cocoa Consumption in Cardiovascular and Immune Parameters|Randomized Clinical Trial of the Effect of Cocoa Consumption in Cardiovascular and Immune Parameters in Colombian Patients With Newly Diagnosed Stage 1 Arterial Hypertension||Universidad de Antioquia|Yes|Terminated|July 2009|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|65 Years|No|||December 2011|December 16, 2011|November 24, 2011||No|Difficulties with the patient recruitment|No||https://clinicaltrials.gov/show/NCT01496235||93779|
NCT01496820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPB-HG-COS|A Randomized Trial to Assess the Efficacy and Safety of GO2KA1(Chitosan Oligosaccharide)on Blood Glucose Control|Effect of GO2KA1(Chitosan Oligosaccharide) on Postprandial Blood Glucose in Korean Adults: a Clinical Randomized Trial||Yonsei University|Yes|Completed|July 2011|December 2012|Actual|October 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|20 Years|75 Years|No|||July 2013|July 15, 2013|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01496820||93734|
NCT01497327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2938-0515|Open-Label Hepatic Impairment Study|An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment||Gilead Sciences|No|Completed|July 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|November 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01497327||93695|
NCT01497314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-VA-12-001|Growth and Safety of a Low Lactose Milk-Based Infant Formula|An Open Label Clinical Study to Evaluate Growth and Safety of a Low Lactose Milk-Based Infant Formula in Healthy Term Infants||Perrigo Nutritionals|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|85|||Both|N/A|14 Days|Accepts Healthy Volunteers|||May 2013|May 14, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01497314||93696|
NCT01497613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100482|A Personalized Reminder Information and Social Management System||PRISM|University of Miami|Yes|Completed|February 2011|May 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01497613||93673|
NCT01497912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 04-681/2|Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes|||Karolinska Institutet|Yes|Completed|January 2005|January 2010|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|70 Years|No|||January 2005|December 22, 2011|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01497912||93651|
NCT01498172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URO-68/11|BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients|BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer||University of Lausanne Hospitals|Yes|Completed|January 2012|||February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01498172||93631|
NCT01497886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3455|Effect of Intervention to Improve Stroke Recognition|Randomized Controlled Trial Effect of Novel Intervention to Improve Stroke Symptom Recognition||Columbia University|Yes|Enrolling by invitation|March 2011|||August 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3213|||Both|7 Years|N/A|No|||July 2015|July 27, 2015|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01497886||93653|
NCT01498133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01|Skin-to-skin Contact to Promote Bacterial Decolonization in Preterm Infants|Does Skin-to-skin Contact Promote Bacterial Decolonization in Preterm Infants in Neonatal Intensive Care Unit? A Randomized, Single-blinded Controlled Trial||Universidade Federal do Maranhão|Yes|Active, not recruiting|May 2008|||November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|102|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2011|December 20, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498133||93634|
NCT01498406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051622|Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus|Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus||Emory University|Yes|Terminated|December 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|November 18, 2013|December 21, 2011||No|secondary to funding issues and low enrollment|No||https://clinicaltrials.gov/show/NCT01498406||93613|
NCT01498419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-002-(M-Pa-Z)|Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)|A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear-Positive Pulmonary Tuberculosis||Global Alliance for TB Drug Development|Yes|Active, not recruiting|March 2012|June 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|230|||Both|18 Years|65 Years|No|||March 2013|March 12, 2013|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498419||93612|
NCT01498666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-PRE-0111-CLI-018|Efficacy of Lactobacillus Reuteri Protectis on Functional Abdominal Pain (FAP) in Children 8-14 Years Old|Efficacy of Lactobacillus Reuteri Protectis on Functional Abdominal Pain (FAP) in Children 8-14 Years Old|LactoFAP|BioGaia AB|No|Terminated|December 2011|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|8 Years|14 Years|No|||December 2013|December 2, 2013|December 19, 2011||No|The recruitment rate was too slow according to study protocol and agreement.|No||https://clinicaltrials.gov/show/NCT01498666||93593|
NCT01498926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1685|Comparison of Two Insulin Detemir Formulations in Healthy Volunteers|A Randomised, Single Centre, Two-period, Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Two Insulin Detemir Formulations Containing Mannitol and Glycerol as Isotonic Agents Respectively, in Healthy Subjects||Novo Nordisk A/S|No|Completed|November 2005|February 2006|Actual|February 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|55 Years|No|||January 2015|January 13, 2015|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498926||93573|
NCT01498939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1889|Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects|A Single Centre, Randomised, Double-blind, Three-period Cross-over Trial to Investigate the 24-hour Pharmacokinetics After Single Dose of Insulin Detemir in Healthy Chinese Male Subjects||Novo Nordisk A/S|No|Completed|August 2007|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Male|18 Years|45 Years|No|||December 2011|December 28, 2011|December 21, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498939||93572|
NCT01499563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI-007-005|Study of a Novel Antipsychotic ITI-007 in Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia||Intra-Cellular Therapies, Inc.|No|Completed|December 2011|November 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|335|||Both|18 Years|55 Years|No|||September 2014|September 3, 2014|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499563||93524|
NCT01499524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROHH0280|The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus|A Longitudinal Study of Alterations in Metabolic Markers and Gut Hormones in Pregnant and Non-pregnant Patients With Intrahepatic Cholestasis of Pregnancy, Gestational Diabetes Mellitus and Normal Pregnant and Non-pregnant Controls||Imperial College London|No|Recruiting|November 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|160|Samples Without DNA|Serum, whole blood, plasma.|Female|16 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant and non pregnant women who have had intrahepatic cholestasis of pregnancy and/or        gestational diabetes mellitus matched with parous women who have had uncomplicated        pregnancies|March 2015|June 29, 2015|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01499524||93527|
NCT01499797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/403|The CareWell-programme for Community-dwelling Frail Elderly Persons.|Towards a CARE AND WELFARE STANDARD for Community-dwelling Frail Elderly People With Complex Health Problems|CareWell|Radboud University|No|Completed|January 2011|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|536|||Both|70 Years|N/A|No|||October 2011|June 6, 2013|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499797||93506|
NCT01499810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012|Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension|Study of Efficacy and Safety of Radiofrequency Sympathetic Renal Denervation for Treatment of Drug Resistant Hypertension||Federal State Budgetary Scientific Institution, Research Institute of Cardiology|No|Completed|March 2010|January 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|December 20, 2011||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01499810||93505|
NCT01495806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010|Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood|Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial||Medical University of Warsaw|No|Completed|January 2010|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|8 Years|18 Years|No|||June 2013|June 11, 2013|July 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495806||93812|
NCT01496001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIO-BCS-QoL|Cosmetic and Functional Outcomes After Breast Conserving Surgery|The Effect of Tumor - Breast Volume Ratio on Cosmetic and Functional Outcomes in Breast Conserving Surgery Patients; a Prospective Cohort Study||National Institute of Oncology, Hungary|Yes|Completed|March 2011|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|300|||Female|N/A|70 Years|No|||October 2015|October 5, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01496001||93797|
NCT01496014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-15737.5a|Assessment of Severe Extremity Wound Bioburden at the Time of Definitive Wound Closure or Coverage|Assessment of Severe Extremity Wound Bioburden at the Time of Definitive Wound Closure or Coverage: Correlation With Subsequent Post-Closure Deep Wound Infection: Bioburden Study|Bioburden|Major Extremity Trauma Research Consortium|Yes|Recruiting|September 2011|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Tissue|Both|18 Years|64 Years|No|Non-Probability Sample|Particiapting METRC Trauma Centers across the country.|February 2013|November 10, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01496014||93796|
NCT01517841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00542|Barriers to Peritoneal Dialysis Selection|Barriers to Selection and Initiation of Peritoneal Dialysis in the United States||MetroHealth Medical Center|No|Not yet recruiting|January 2012|April 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with late stage CKD and ESRD patients who        are cared for by nephrologists at MetroHealth Medical Center.|January 2012|January 24, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517841||92128|
NCT01496521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREAT|Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols|Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial.|CREAT|Beijing Friendship Hospital|Yes|Not yet recruiting|January 2012|January 2013|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|600|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||December 2011|December 17, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01496521||93757|
NCT01496755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GV28012|A Study of RG7667 in Healthy Volunteers|A Phase I Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Doses of RG7667 in Healthy Adult Volunteers||Genentech, Inc.||Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|2||Actual|170|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496755||93739|
NCT01496833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-20111126|Total Endovascular Aortic Arch Re-construction Study(TEARS)|Total Endovascular Aortic Arch Re-construction Study(TEARS)------China's Registry||Xijing Hospital|Yes|Recruiting|January 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|50|||Both|12 Years|90 Years|No|||December 2015|December 30, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01496833||93733|
NCT01497041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSWOG 2010-3|A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment|A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment||Korean South West Oncology Group|No|Recruiting|February 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2011|December 19, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01497041||93717|
NCT01497054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3155|Do Elevated BNP Levels Predict Hemodynamically Significant PDAs|Diagnostic Prediction Value of B Type Natriuretic Peptide (BNP) Levels in Hemodynamically Significant Patent Ductus Arteriosus (hsPDA) in Premature Infants.||Albany Medical College|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|109|||Both|N/A|24 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Preterm infants between 24 0/7 weeks gestation and 31 6/7 weeks gestation.|December 2011|July 2, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01497054||93716|
NCT01497067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-043|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2011|||||N/A|N/A|N/A||||||||||||||November 25, 2015|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497067||93715|
NCT01497639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|760906|Comparison of the Efficacy of Double Monopolar Versus Interleaving Stimulation Modes for Pallidal Deep Brain Stimulation|Comparison of the Efficacy of Double Monopolar Versus Interleaving Stimulation Modes for the Deep Brain Stimulation Treatment of Primary Generalized or Segmental Dystonia||University of Pecs|Yes|Recruiting|March 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|7 Years|75 Years|No|||January 2016|January 14, 2016|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01497639||93671|
NCT01497899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-292-0102|Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV-1 Infected, Antiretroviral Treatment-Naive Adults||Gilead Sciences|Yes|Active, not recruiting|December 2011|May 2016|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|279|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|December 14, 2011|Yes|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01497899||93652|There were no limitations affecting the analysis or results.
NCT01497652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-TN-067|A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy|A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy|RECOGNIZE|Georgetown University|No|Completed|January 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|40 Years|N/A|No|||December 2015|December 15, 2015|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497652||93670|
NCT01497665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1005B017|GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)|A Phase II, Multi-center, Open-label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients With Brain Metastases|GRABM-L|Angiochem Inc|Yes|Terminated|November 2011|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|December 20, 2011|Yes|Yes|Slow recruitment|No|May 12, 2015|https://clinicaltrials.gov/show/NCT01497665||93669|
NCT01498185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-072|BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes|A Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Explore the Safety, Pharmacokinetics and Pharmacodynamics of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus||AstraZeneca|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|70|||Both|18 Years|65 Years|No|||March 2015|March 20, 2015|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498185||93630|
NCT01498445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0333|An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)|An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)||M.D. Anderson Cancer Center|Yes|Recruiting|June 2012|||June 2020|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498445||93610|
NCT01498146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-014|Finding Atrial Fibrillation in Patients With Unexplained Stroke Using Longterm Cardiac Monitoring|Stroke Prior to Diagnosis of Atrial Fibrillation Using Longterm Observation With Implantable Cardiac Monitoring Apparatus Reveal(SURPRISE) -the SURPRISE Study|SURPRISE|Bispebjerg Hospital|No|Active, not recruiting|April 2010|October 2014|Anticipated|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Months|N/A|No|Probability Sample|the patients are included from the investigators stroke unit and day clinic|July 2014|July 15, 2014|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01498146||93633|
NCT01498159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0099|Health Promoters and Pharmacists in Diabetes Team Management|Health Promoters and Pharmacists in Diabetes Team Management||University of Illinois at Chicago|No|Active, not recruiting|December 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|300|||Both|21 Years|N/A|No|||May 2015|May 28, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01498159||93632|
NCT01498432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/0339|Physiological Response to Heliox21 and Air O2|Phase 4, Single Centre, Single Blinded,Prospective Randomised Cross Over Comparison on the Physiological Response of Post Extubation Intensive Care Patients to Non-invasive Ventilation Using Either Air O2 or Heliox21||University College, London|Yes|Not yet recruiting|January 2012|April 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|38|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01498432||93611|
NCT01498679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113719|Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With Low to Mid-strength Inhaled Corticosteroid or Low-strength Combination Therapy.||GlaxoSmithKline|No|Completed|January 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|311|||Both|12 Years|N/A|No|||February 2014|February 13, 2014|December 21, 2011||No||No|February 13, 2014|https://clinicaltrials.gov/show/NCT01498679||93592|
NCT01498952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI-573-1028|MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.|A Phase 1b/2, Open-label, Randomized Study of MEDI-573 in Combination With Sorafenib Verses Sorafenib Alone in Adult Subjects With Unresectable or Metastatic Hepatocellular Carcinoma|MEDI-573-1028|MedImmune LLC|No|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|6|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01498952||93571|
NCT01499277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00001|Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections|A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities||AstraZeneca||Completed|May 2012|January 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|802|||Both|18 Years|99 Years|No|||November 2015|November 18, 2015|December 16, 2011|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT01499277||93546|
NCT01499537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APHAGE/IPC 2010-002|Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct|Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct in Patients With Malignant or Post-operative Jaundice After Failure or Impossibility to Perform Endoscopic Retrograde Cholangiography||Institut Paoli-Calmettes|No|Active, not recruiting|January 2011|March 2016|Anticipated|February 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01499537||93526|
NCT01499823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1108-032-372|Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma|Permeability Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma||Seoul National University Hospital|Yes|Enrolling by invitation|December 2011|December 2013|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|74|||Both|18 Years|N/A|No|Probability Sample|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who        receive concurrent chemoradiation (CCRT) with temozolomide|December 2013|December 27, 2013|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01499823||93504|
NCT01506479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1237|Study in Parkinson's Disease of Exercise|Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease|SPARX|University of Colorado, Denver|Yes|Active, not recruiting|April 2012|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|129|||Both|40 Years|80 Years|No|||February 2016|February 3, 2016|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01506479||92993|
NCT01506778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CukurovaU|Tenaculum in Endometrial Sampling Procedure|Using a Tenaculum Which is Actually Necessary for Endometrial Sampling Procedure by Pipelle.|Tenaculum|Cukurova University|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|115|||Female|18 Years|80 Years|No|||January 2012|January 9, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01506778||92970|
NCT01506791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|50631|Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D® 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|No|Completed|April 2006|April 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2006|January 5, 2012|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506791||92969|
NCT01515774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1104-062-358|Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)|An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease||Seoul National University Hospital|No|Recruiting|September 2011|October 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|30 Years|80 Years|No|||January 2012|January 18, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01515774||92287|
NCT01516047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100779|A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function|An Open-Label Pharmacokinetic Study of Abiraterone Acetate Suspension in Subjects With Severe Hepatic Impairment Compared to Matched Control Subjects With Normal Hepatic Function||Janssen Research & Development, LLC|Yes|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Male|35 Years|80 Years|No|||June 2014|June 24, 2014|January 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01516047||92266|
NCT01496781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111219|EndoClot for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection|EndoClotTM Absorbable Polysaccharide Hemostat in Comparison With Metallic Hemoclip for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection: a Prospective, Randomized Trial|EMR|Xijing Hospital of Digestive Diseases|Yes|Completed|April 2010|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|80 Years|No|||April 2012|April 14, 2012|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496781||93737|
NCT01496794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100487|Endophthalmitis Cultures|Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study|PROSPER|Vanderbilt University|No|Recruiting|October 2011|August 2013|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|Vanderbilt Eye Institute|July 2011|December 19, 2011|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496794||93736|
NCT01507636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|042/11|Occupational Therapy in Patients With Multiple Sclerosis|Apraxia-specific Occupational Therapy in Patients With Multiple Sclerosis||University Hospital Inselspital, Berne|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||May 2013|May 14, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01507636||92905|
NCT01497080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18482|Distal Radius Fracture Prospective Database 50-80 Years Old|Distal Radius Fracture Prospective Database 50-80 Years Old Overview: "Identification of Risk of Adverse Activity Transition Following a Distal Radius Fracture".||Lawson Health Research Institute|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|195|||Both|50 Years|80 Years|No|Probability Sample|Participants aged 50-80 years of age who have incurred a wrist fracture|March 2014|March 18, 2014|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01497080||93714|
NCT01497340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|funda03|Position at Birth,Placental Transfusion Volume and Cord Clamping|Is the Placental Transfusion Volume Influenced by the Position of the New Born at Birth? a Pilot Study||Fundacion para la Salud Materno Infantil||Terminated|October 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|27|||Both|N/A|2 Minutes|Accepts Healthy Volunteers|||December 2011|December 21, 2011|December 20, 2011||No|difficulties with the center|No||https://clinicaltrials.gov/show/NCT01497340||93694|
NCT01508195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100684|A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (50 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 500 mg) in Healthy Fed Subjects||Janssen Research & Development, LLC||Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508195||92862|
NCT01497925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2010-001|Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer|Phase 1 Trial of ADI PEG 20 Plus Docetaxel in Advanced Solid Tumors With Emphasis on Castration Resistant Prostate Cancer (CRPC) and Advanced Non-Small Cell Lung Cancer (NSCLC)||Polaris Group|No|Active, not recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01497925||93650|
NCT01497938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 237|Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature|ASPIRE (Automation to Simulate Pancreatic Insulin Response): Pivotal In Home Study to Determine Safety and Efficacy of the LGS Feature in Sensor-augmented Pumps|ASPIRE|Medtronic Diabetes|Yes|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|247|||Both|16 Years|70 Years|No|||January 2014|January 31, 2014|December 18, 2011|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT01497938||93649|
NCT01498458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 62|Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer|Phase I Study to Assess the Optimal Dose for Pazopanib in Combination With Capecitabine in Patients With HER2-negative, Metastatic Breast Cancer (PazoX)|PazoX|German Breast Group|Yes|Completed|October 2010|May 2014|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||September 2014|September 17, 2014|December 21, 2011||No||No|July 4, 2014|https://clinicaltrials.gov/show/NCT01498458||93609|
NCT01498692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2046A|The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Small Vessel Sub-trial|PLATINUM SV|Boston Scientific Corporation|Yes|Active, not recruiting|February 2009|November 2014|Anticipated|December 2010|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|December 20, 2011|Yes|Yes||No|January 10, 2012|https://clinicaltrials.gov/show/NCT01498692||93591|
NCT01498978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5254|Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase II Study of CTLA Blockade by Ipilimumab Plus Androgen Suppression Therapy in Patients With an Incomplete Response to AST Alone for Metastatic Prostate Cancer||OHSU Knight Cancer Institute|Yes|Active, not recruiting|February 2012|April 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Male|18 Years|N/A|No|||February 2016|February 12, 2016|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01498978||93569|
NCT01498965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2185|The Cork BASELINE Birth Cohort Study|BASELINE: Babies After Scope: Evaluating the Longitudinal Impact Using Neurological and Nutritional Endpoints|BASELINE|National Children's Research Centre, Ireland|Yes|Active, not recruiting|August 2008|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2185|Samples With DNA|MAternal DNA, plasma, serum and urine Umbilical serum, plasma, DNA, RNA At 2 years and 5      years: serum, and DNA|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|All infants born to mothers enrolled in the SCOPE pregnancy study (www.scopestudy.net) in        SCOPE Ireland. First time, low risk mothers with singleton pregnancies.|January 2015|January 20, 2015|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01498965||93570|
NCT01505556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_SBrumagne_DiaphParesis|Proprioceptive Postural Control and Diaphragm Paresis|||Katholieke Universiteit Leuven|Yes|Not yet recruiting|January 2014|January 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|patients from the University Hospital Leuven - Respiratory Disvision|January 2012|December 4, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505556||93064|
NCT01505569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011OC057|Auto Transplant for High Risk or Relapsed Solid or CNS Tumors|Alkylator-Intense Conditioning Followed by Autologous Transplantation for Patients With High Risk or Relapsed Solid or CNS Tumors||Masonic Cancer Center, University of Minnesota|No|Recruiting|October 2011|January 2019|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|20|||Both|N/A|70 Years|No|||January 2016|January 22, 2016|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505569||93063|
NCT01499550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nTNI2011|Nocturnal Transnasal Insufflation (nTNI)|Nocturnal Transnasal Insufflation in Patients With COPD and Hypercapnia||Institut für Pneumologie Hagen Ambrock eV|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|70 Years|No|||September 2012|September 24, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01499550||93525|
NCT01499836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110920A|Quality Study of Anesthetic Technique on Breast Cancer Surgery|Effect of Anesthetic Technique on Pain、 Recovery and Satisfaction in Women Undergoing Breast Surgery|PQSAT|Sun Yat-sen University|Yes|Completed|January 2012|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|101|||Female|18 Years|70 Years|No|||January 2014|January 14, 2014|December 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01499836||93503|
NCT01506492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 09-0855-C|Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients|Managing Cancer and Living Meaningfully (CALM): A Randomized Controlled Trial of a Psychotherapeutic Intervention for Patients With Metastatic Cancer|CALM|University Health Network, Toronto|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|604|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01506492||92992|
NCT01506804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-002|Exercise Therapy and Ultrasound Guided Injections in Painful Shoulder|The Efficacy of Exercise Therapy Followed by Ultrasound Guided Injection in Patients With a Painful Shoulder - a Randomised Controlled Study With Blinded Observer||Frederiksberg University Hospital|No|Recruiting|November 2010|July 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2012|January 5, 2012|May 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01506804||92968|
NCT01515787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1048|PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery|A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)||Alliance for Clinical Trials in Oncology|Yes|Recruiting|January 2012|||July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1060|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515787||92286|
NCT01496807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16755|Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma|A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|March 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|16 Years|N/A|No|||October 2015|October 8, 2015|December 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01496807||93735|
NCT01496573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B4|Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma|Observational - CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)||Children's Oncology Group|No|Recruiting|December 2011|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|77|Samples With DNA|tumor tissue|Both|N/A|N/A|No|Non-Probability Sample|Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma|November 2015|November 9, 2015|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01496573||93753|
NCT01507922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEN-401|Comparative Efficacy and Safety of Fenoverine|Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial|FEN-401|Bukwang Pharmaceutical|No|Completed|December 2011|June 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|60 Years|No|||December 2014|December 17, 2014|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01507922||92883|
NCT01507909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EEG CUE study-H-31322|Quantitative EEG Assessment of Cue-Induced Changes in Brain Activity in Alcohol Use Disorders|Quantitative EEG Assessment of Cue-Induced Changes in Brain Activity in Alcohol Use Disorders||Boston University|No|Recruiting|January 2012|January 2015|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Local participants not interested in alcohol treatment.|July 2012|July 25, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01507909||92884|
NCT01507883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHC1|Time-lapse Evaluation of Human Embryo Development in Single Versus Sequential Culture Media - a Sibling Oocyte Study|Time-lapse Evaluation of Human Embryo Development in Single Versus Sequential Culture Media - a Sibling Oocyte Study||Bahceci Health Group|No|Recruiting|March 2011|January 2012|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Human embryos|Female|18 Years|39 Years|No|Probability Sample|Women who had undergone infertility treatment and oocytes subjected to ICSI|January 2012|January 10, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01507883||92886|
NCT01507896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251002|BAX 326 Surgery Study in Hemophilia B Patients|BAX 326 (Recombinant Factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B Undergoing Surgical or Other Invasive Procedures||Baxalta US Inc.|Yes|Completed|December 2011|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|12 Years|65 Years|No|||May 2015|June 26, 2015|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507896||92885|
NCT01508481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitaminD_T2DM|Vitamin D Inadequacy is Associated With Incidence of Type 2 Diabetes|Vitamin D Inadequacy is Associated With Incidence of Type 2 Diabetes||Seoul National University Bundang Hospital|No|Completed|January 2007|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1500|None Retained|Blood sample was collected at the baseline.|Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants, aged over 30 years, are recruited from Korea, between January 2006 and        December 2011. Participants are at high risk for type 2 diabetes, as they are recruited on        the basis of the presence of one or more risk factors for diabetes, including obesity,        hypertension, dislipidemia, and a family history of diabetes. Participants are contacted        every 6 month after the baseline visit to update contact information and collect data on        major health events. Participants are invited to return to the clinic examination centers        after 3 years for follow-up assessments.|October 2012|October 5, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01508481||92842|
NCT01508468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100115|Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy|Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)|GEMRITUX|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|January 2012|July 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01508468||92843|
NCT01498198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:117|Workers Compensation Board: Rotator Cuff Tear Management|A Randomized Study of Non-Operative Management Versus Expedited Surgery Among WCB Patients With Small Rotator Cuff Tears: Affect Upon Time to Claim Closure in 2 Prairie Provinces||University of Manitoba|No|Not yet recruiting|January 2012|||January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||December 2011|December 22, 2011|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01498198||93629|
NCT01498471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UZ/PVB/2011|NICE Guideline 'Red Flags' to Predict Serious Outcome After Transient Loss of Consciousness|NICE Guideline 'Red Flags' to Predict Serious Outcome After Transient Loss of Consciousness: Prospective Validation Study in the Emergency Department.||Universitaire Ziekenhuizen Leuven||Not yet recruiting|January 2012|February 2014|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|490|||Both|16 Years|N/A|No|Probability Sample|Adult patients (>= 16 years) presenting in the ED with a complaint of TLoC|December 2011|December 22, 2011|December 20, 2011||||No||https://clinicaltrials.gov/show/NCT01498471||93608|
NCT01498705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997096|The Natural History of Procalcitonin in Hemorrhagic Stroke|The Natural History of Procalcitonin in Hemorrhagic Stroke||CAMC Health System|No|Withdrawn|December 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|3 mL of blood will be obtained for each PCT sample and will be sent to the Virology lab at      CAMC Memorial hospital where the serum will be frozen until all samples are collected. After      all samples from each of the 30 patients are obtained, the specimens will be analyzed for      the PCT value and then discarded.|Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Neurosurgical ICU with a diagnosis of intraventricular or        intracerebral hemorrhage|January 2014|January 31, 2014|December 20, 2011||No|Anticipated grant was withdrawn and additional funding was unable to be obtained|No||https://clinicaltrials.gov/show/NCT01498705||93590|
NCT01499264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AISLeC-002|Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial|Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial||Associazione Infermieristica per lo studio delle Lesioni Cutanee|Yes|Recruiting|January 2012|October 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01499264||93547|
NCT01499849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-P04832|Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy|Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety & Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)||Tesaro, Inc.|No|Completed|February 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|532|||Both|18 Years|N/A|No|||October 2012|February 2, 2016|December 20, 2011|Yes|Yes||No|October 2, 2015|https://clinicaltrials.gov/show/NCT01499849||93502|
NCT01495780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eRT RHM|eRT Remote Health Monitoring|Feasibility and Cost Effectiveness of Physiological Monitoring at Home in COPD Patients||University of California, Los Angeles|No|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|75|||Both|40 Years|N/A|No|||June 2013|June 28, 2013|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495780||93814|
NCT01507090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mercy TAPE|Validation of the Mercy TAPE|Taking the Guesswork Out of Pediatric Weight Estimation (TAPE): Validation of the Mercy TAPE|TAPE|Children's Mercy Hospital Kansas City|No|Completed|February 2012|April 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|642|||Both|2 Months|16 Years|Accepts Healthy Volunteers|Probability Sample|Normal healthy children|February 2015|February 6, 2015|January 4, 2012||No||No|July 22, 2014|https://clinicaltrials.gov/show/NCT01507090||92946|
NCT01507103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR063325-013|Tecemotide (L-BLP25) in Rectal Cancer|A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy|SPRINT|Merck KGaA|No|Completed|February 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507103||92945|
NCT01515527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0987|Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)|Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Recruiting|February 2012|||February 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|60 Years|N/A|No|||March 2016|March 7, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515527||92306|
NCT01515813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5292|Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation|A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts||AIDS Clinical Trials Group|Yes|Withdrawn|November 2011|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|November 8, 2011|Yes|Yes|On 05/08/12, team working on revising protocol and re-open study under version 2.0|No||https://clinicaltrials.gov/show/NCT01515813||92284|
NCT01516099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53801|A Structural Approach to Implement the Role of 'Physical Activity Counselors' in Sports and Exercise Promotion|Pilot Study: A Structural Approach to Implement the Role of 'Physical Activity Counselors' in Sports and Exercise Promotion in Flanders||Universitaire Ziekenhuizen Leuven|Yes|Completed|April 2012|August 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01516099||92262|
NCT01516411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09162011-8409|Promoting Healthy Lifestyles Using Mobile Phones|Promoting Healthy Lifestyles Using Mobile Phones||Stanford University|No|Completed|October 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|130|||Both|45 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516411||92238|
NCT01496586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120030|Service Member Fatigue and Lack of Motivation Following Concussion|Fatigue and Amotivation Following Mild Traumatic Brain Injury and Their Influence on Service Member Community Reintegration||National Institutes of Health Clinical Center (CC)||Completed|December 2011|August 2015||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|45|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|December 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01496586||93752|
NCT01508247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT010|A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months|A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months||Jiangsu Province Centers for Disease Control and Prevention|Yes|Completed|January 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|10245|||Both|6 Months|35 Months|No|||March 2013|March 27, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01508247||92859|
NCT01508728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00821-40|Efficacy Study of a Sensory Feedback Knee Orthosis in Patients Suffering From Unoperated Severe Knee Sprain||ORTHOSENS|Thuasne||Terminated|March 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|65 Years|No|||September 2014|September 24, 2014|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01508728||92823|
NCT01508221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTC-W1|Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis|A Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophylaxis of Radiation Necrosis||University of Cincinnati|No|Recruiting|June 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|January 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508221||92860|
NCT01508208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2011-07|Comparison of Urine Protein/Creatinine Ratio With 24-hour Urine Protein Excretion in Woman With Hypertensive Disorders|A Comparison of Spot Test (Urine Protein/Creatinine Ratio) With 24 - Hour Urine Protein Excretion in Woman With Hypertensive Disorders of Pregnancy||Saint Thomas Hospital, Panama|No|Recruiting|March 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|420|||Female|N/A|N/A|No|||January 2015|January 1, 2015|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01508208||92861|
NCT01508494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-34|Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment|Evaluation de l'efficacité de la Galantamine Versus Placebo associée à Une Revalidation Neuropsychologique Chez Des Patients présentant un Trouble Cognitif après un Premier Infarctus cérébral : étude en Neuroimagerie Fonctionnelle|COGICRehab|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|July 2011|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|35 Years|75 Years|No|||January 2012|February 14, 2012|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01508494||92841|
NCT01508715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16838|Comparison of Exercise Interventions in Adults With Subacromial Impingement Syndrome|Comparison of an Eccentric Exercise Intervention to a Concentric Exercise Intervention in Adults With Subacromial Impingement Syndrome||Texas Woman's University|No|Completed|February 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01508715||92824|
NCT01508702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-303|Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor|LIGHT|Ardea Biosciences, Inc.|Yes|Completed|January 2012|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|85 Years|No|||July 2015|January 14, 2016|January 10, 2012|Yes|Yes||No|January 14, 2016|https://clinicaltrials.gov/show/NCT01508702||92825|
NCT01508689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16802|Effect of Calcium-fortified Cereal Bars on Dietary Calcium Intake in Women|Effect of Calcium-fortified Cereal Bars on Dietary Calcium Intake in Women||Texas Woman's University|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 17, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508689||92826|
NCT01504555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1810|Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?|Evaluation of the Diagnostic Utility of Serum Dexamethasone Measurements in the Overnight 1mg Dexamethasone Suppression Test in Patients Investigated for Cushing's Syndrome and Incidentalomas|DXM|Haukeland University Hospital|No|Recruiting|October 2011|August 2016|Anticipated|June 2016|Anticipated|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|Blood, saliva, urine|Both|18 Years|N/A|No|Probability Sample|Patients at Haukeland University Hosptial, Bergen, Norway, under routine evaluation for        hypercortisolism.Patients under evaluation for obeity at the overweight clinic, and        Patients treated for alcohol abuse at the clinic for alcohol addicts at Haukeland        University hospital.|February 2016|February 26, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01504555||93141|
NCT01504776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BUS48T|Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)|A Phase I Study of Panobinostat in Combination With Bortezomib in the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma|BUS48T|Georgia Regents University|Yes|Completed|April 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2012|September 18, 2014|August 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504776||93124|
NCT01504789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0201|Part II: Exercise in Hispanic Breast Cancer Survivors|Part II: Exercise in Hispanic Breast Cancer Survivors||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2012|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|180|||Female|21 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 24, 2015|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01504789||93123|
NCT01498991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007762|Spinal Cord Injury Leg Rehabilitation|Rehabilitation of the Lower Extremity With AMES Following Incomplete Spinal Cord Injury (SCI)|AMES|Oregon Health and Science University|Yes|Recruiting|November 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2015|February 23, 2015|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01498991||93568|
NCT01505309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ-20111126 -3|Endovascular Aortic Repair for Aortic Dissection|Endovascular Aortic Repair for Aortic Dissection------XiJing Registry||Xijing Hospital|Yes|Recruiting|January 2008|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|12 Years|90 Years|No|||December 2015|December 30, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01505309||93083|
NCT01505322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH2011-srv01|Persistent Pain to Impair Daily Activities Following Thoracic Surgery|Persistent Pain to Impair Daily Activities Following Thoracic Surgery||Rigshospitalet, Denmark|No|Completed|August 2010|December 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|396|||Both|18 Years|N/A|No|Non-Probability Sample|Patients having thoracic surgery for lung cancer|January 2012|January 5, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505322||93082|
NCT01505582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_SBrumagne_IMT-LBP|Inspiratory Muscle Training and Low Back Pain|||Katholieke Universiteit Leuven|Yes|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|45 Years|No|||January 2012|December 10, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505582||93062|
NCT01499576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-62|Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia|Acetic Acid Chromoendoscopy for Judging Extent of Gastric Intestinal Metaplasia|IM|Konyang University Hospital|Yes|Completed|November 2011|April 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|126|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 20, 2014|December 20, 2011||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01499576||93523|Concomitant comparison with methylene blue chromoendoscopy was not performed.
NCT01499589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si562/2011|Can the Usage of Regional Block Room Save the Time of Anesthesia Team|Can the Usage of Regional Block Room Save the Time of Anesthesia Team in the Main Orthopedic Operating Room?||Mahidol University|Yes|Recruiting|October 2011|July 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|||Both|1 Month|N/A|No|Non-Probability Sample|elective orthopedic surgical patients that require for anesthesia|December 2011|December 22, 2011|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01499589||93522|
NCT01499862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 0003|Mobility Training Using a Bionic Knee Orthosis in Patients Chronic Post-Stroke: A Case Series|Discriminatory Neurosensory Stimulation Neurological H5394-11417-15||Tibion Bionics, Inc.|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|40 Years|60 Years|No|||June 2013|June 30, 2013|December 20, 2011||No||No|June 18, 2012|https://clinicaltrials.gov/show/NCT01499862||93501|These results are from a small group (n of 3) of patients and should not be assumed to be consistent across all populations. Furthermore, the inherent subjective variability of patient response in physical therapy interventions should be considered.
NCT01499875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Penicillin|A Pharmacokinetic and Pharmacodynamic Study of Phenoxymethylpenicillin for Children|A Pharmacokinetic and Pharmacodynamic Study of Phenoxymethylpenicillin for Children||University of Aarhus|No|Completed|January 2012|August 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|10 Years|Accepts Healthy Volunteers|||January 2013|September 30, 2014|August 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499875||93500|
NCT01499888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0096|Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)|Phase I/II Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (SCD)||University of Illinois at Chicago|No|Recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01499888||93499|
NCT01507688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 10-379|Stroke Self-Management|Stroke Self-Management: Effect on Function and Stroke Quality of Life||VA Office of Research and Development|Yes|Recruiting|January 2013|December 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|253|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01507688||92901|
NCT01516112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR-1.0-MEIR|Meir Medical Center Home Monitoring Clinic Registry|Meir Medical Center Home Monitoring Clinic Registry||Meir Hospital, Kfar Saba, Israel|No|Not yet recruiting|February 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with an ICD or CRTD.|July 2011|January 19, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516112||92261|
NCT01520649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS-2010-3|Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects|A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects||Neuralstem Inc.|Yes|Completed|May 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|60 Years|No|||November 2012|April 1, 2014|January 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520649||91913|
NCT01521312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P101105|ACute and Chronic Effects of Saxagliptin|A Randomized, Double Blind, Placebo Controlled, Pilot Study to Evaluate ACute and Chronic Effects of Saxagliptin on Impaired Glucose Tolerance and micro-and Macro-vascular Integrators|ACCES|Assistance Publique - Hôpitaux de Paris|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|70 Years|No|||January 2015|February 2, 2015|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01521312||91862|
NCT01507363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THL-06-11|Analgesic Effect of Gabapentin in Total Knee Arthroplasty (TKA)|Analgesic Effect of Perioperative Gabapentin in Total Knee Arthroplasty: A Randomized, Double-blind, Placebo-controlled, Dose-response Study||Hvidovre University Hospital|Yes|Completed|January 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|50 Years|85 Years|No|||April 2014|April 10, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507363||92926|
NCT01508507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-WC-10|Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine|Effectiveness of a Bivalent, Killed Whole-cell Based Oral Cholera Vaccine(Shanchol®) Delivered Through Community-based Mass Vaccination Campaign in a High-risk Population in India: Matched Case-control Studies||International Vaccine Institute|No|Recruiting|March 2013|March 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|240|Samples Without DNA|Rectal swabs will be collected from all cases that fulfills inclusion criteria. It will be      plated directly into TCBS agar as well as after enrichment in APW for 6 to 20 hours (pH 8.6,      37 degree centrigrade). After this overnight incubation, suspected colonies from TCBS will      be tested biochemically and agglutinated with polyvalent, Ogawa and Inaba antisera.      Biotyping of O1 isolates will be done with chicken erythrocyte agglunitation tests and      determination of polymyxin sensitivity. Non - agglunating strains will be tested with      antiserum to V cholarae O139 strain. V cholarae isolates will be tested for susceptibility      to the following antimicrobials: tetracycline, erythromycin, furazolidin, trimithprim -      sulfame thoxale, ciprofloxacin and norfloxacin.|Both|1 Year|N/A|No|Probability Sample|The same population of Satyabadi block, Puri, Orissa, where Pilot introduction of Oral        Cholera Vaccine (OCV) was conducted during May - June, 2011. During this campaign, the OCV        vaccine was delivered through community based mass vaccination utilizing public health        system.|June 2013|June 4, 2013|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01508507||92840|
NCT01504594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE-2012|Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy|Safeness and Effectiveness of Autologous Hematopoietic Cell Infusion Through Catheterization in Pediatric Patients With Dilated Cardiomyopathy||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Suspended|January 2012|August 2013|Anticipated|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|1 Year|16 Years|No|||August 2013|August 6, 2013|December 15, 2011||No|Suspended because the lack of patients among the time this clinical trial was running.|No||https://clinicaltrials.gov/show/NCT01504594||93138|
NCT01504828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BH111454|Cardiac Energetics and Function in Normal Human Ageing|Cardiac Energetics and Function in Normal Human Ageing||Newcastle-upon-Tyne Hospitals NHS Trust|No|Enrolling by invitation|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|96|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 7, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01504828||93120|
NCT01505088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-004|Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis|A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis||Eyegate Pharmaceuticals, Inc.|No|Completed|December 2011|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|12 Years|85 Years|No|||March 2013|March 28, 2013|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505088||93100|
NCT01504581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-HM10660A-101|Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo- And Active-Controlled Study Of The Pharmacokinetics, Pharmacodynamics And Safety Of Single Ascending Doses Of HM10660A (LAPS-INTERFERON ALPHA-2B) In Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|March 2011|||September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 6, 2014|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01504581||93139|
NCT01505348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QQ-SP751|Effect of Fasting Versus Feeding on the Bone Metabolic Response to Running|Effect of Fasting Versus Feeding on the Bone Metabolic Response to Running||QinetiQ Ltd|No|Completed|July 2007|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 4, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505348||93080|
NCT01504568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134357|The Use of Prophylactic Antibiotics in Isolated Blowout Fractures|The Use of Prophylactic Antibiotics in Isolated Blowout Fractures||University of Arkansas|No|Withdrawn|January 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|5 Years|N/A|No|||November 2012|November 8, 2012|January 3, 2012|Yes|Yes|No subjects enrolled|No||https://clinicaltrials.gov/show/NCT01504568||93140|
NCT01504802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC 167624|Pharmacodynamics of CNP During Growth Hormone Treatment|Pharmacodynamics of C-Type Natriuretic Peptide During Growth Hormone Treatment in Children: A Potential Biomarker of Efficacy||Nemours Children's Clinic|No|Completed|November 2010|September 2014|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|22|Samples Without DNA|Serum, plasma, and urine will be saved for potential future studies.|Both|3 Years|N/A|No|Non-Probability Sample|Children with short stature|September 2014|September 30, 2014|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01504802||93122|
NCT01505062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU13600|Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B|A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected UshStat®, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B||Sanofi|Yes|Recruiting|March 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505062||93102|
NCT01505049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046117|Immune Memory After Papillomavirus Vaccination|Immune Memory After Papillomavirus Vaccination (IMAP-I) Study . DMID 10-0014|IMAP-1|Emory University|Yes|Completed|January 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|203|Samples With DNA|we will retain lymphocyte samples for testing immune function|Female|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|we are seeking healthy female volunteers|July 2015|July 20, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505049||93103|
NCT01505868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0727|Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy|An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2012|||July 2029|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|178|||Male|18 Years|N/A|No|||May 2015|May 13, 2015|December 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505868||93040|
NCT01505881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.138|Follow on Study From RE-ALIGN|Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve||Boehringer Ingelheim||Terminated|December 2011|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|158|||Both|18 Years|75 Years|No|||July 2014|July 10, 2014|January 5, 2012||||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01505881||93039|This study was terminated prematurely due to safety concerns arising during conduct of the trial.
NCT01505894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses|Safety, Tolerability Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 409306 Film-coated Tablets Given Orally q.d. or Bid for 14 Days in Young Healthy and Elderly Healthy Male/Female Volunteers (Randomised, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)||Boehringer Ingelheim||Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|83|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|January 5, 2012||||No||https://clinicaltrials.gov/show/NCT01505894||93038|
NCT01505842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTS-01|Chromoendoscopy for Dysplasia Detection in Chronic Inflammatory Bowel Disease|Randomized Controlled Trial (RCT) to Compare Dysplasia Detection Rate in Colonoscopy Without Chromoendoscopy Versus Colonoscopy With Chromoendoscopy in Detecting Dysplasia in Ulcerative Colitis and Crohn's Colitis Patients.||Karolinska University Hospital|No|Recruiting|February 2011|February 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01505842||93042|
NCT01506154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRX-7EAT-2006|Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Topical Patch in the Treatment of Pain Due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of Shoulder||MEDRx USA, Inc.|No|Completed|December 2011|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|210|||Both|14 Years|N/A|No|||October 2012|October 24, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506154||93018|
NCT01506167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27971|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)|An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma||Hoffmann-La Roche||Active, not recruiting|July 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|719|||Both|18 Years|N/A|No|Probability Sample|Adult patients diagnosed with metastatic colorectal cancer|March 2016|March 1, 2016|January 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01506167||93017|
NCT01507129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM102745|Biomarkers for Noninvasive Assessment of Human Hydration|Biomarkers for Noninvasive Assessment of Human Hydration||Gaia Medical Institute|Yes|Completed|October 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|15|Samples With DNA|Plasma, Serum, Urine, Saliva|Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Aerobically fit individuals|August 2012|August 14, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507129||92943|
NCT01520987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-126|Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects|Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects||Bial - Portela C S.A.|Yes|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 19, 2014|January 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520987||91887|
NCT01521793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET IRD 02|Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)|An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01)||QLT Inc.|Yes|Completed|January 2012|June 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|5 Years|65 Years|No|||July 2014|July 25, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01521793||91825|
NCT01507649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09101031|Effect of a Telephone-based Intervention on Postnatal Depression|The Effect of a Telephone-based Cognitive-behavioral Intervention on Postnatal Depression: a Randomized Controlled Trial||The University of Hong Kong|Yes|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|397|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01507649||92904|
NCT01508520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk6056|a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions|a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions||Shanghai Jiao Tong University School of Medicine|No|Completed|December 2009|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|146|Samples Without DNA|Samples after biopsy or resection are to be retained.|Both|N/A|N/A|No|Non-Probability Sample|patients with gastric lesions suspected of early gastric malignancy|January 2012|January 11, 2012|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01508520||92839|
NCT01508741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS-19719|Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood|Supplement 5-ALA And Sleep And Mood Study||University of Hawaii|Yes|Completed|January 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|85|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508741||92822|
NCT01504607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICIRC-Pedspec|Corneal Endothelial Changes Following Pediatric Cataract Surgery With IOL Implantation|Corneal Endothelial Morphologic Assessment in Pediatric Cataract Surgery With IOL Implantation: Comparison of Preoperative and Early Postoperative Specular Microscopy||Iladevi Cataract and IOL Research Center|Yes|Completed|January 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|106|||Both|4 Years|15 Years|No|Non-Probability Sample|Children older than 4 years undergoing cataract surgery with IOL implantation were        included.|January 2012|January 3, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01504607||93137|
NCT01504841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1090|Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children|A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|March 2012|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|2 Months|6 Years|No|||March 2016|March 14, 2016|December 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01504841||93119|
NCT01504854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-037-RES|Resveratrol for Alzheimer's Disease|Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease||Alzheimer's Disease Cooperative Study (ADCS)|Yes|Completed|May 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|50 Years|N/A|No|||September 2014|September 15, 2014|December 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504854||93118|
NCT01504867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-004856|LIPS-A: Lung Injury Prevention Study With Aspirin|LIPS-A: Lung Injury Prevention Study With Aspirin||Mayo Clinic|Yes|Recruiting|January 2012|August 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01504867||93117|
NCT01505361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROBIOPREG|Study of a Probiotic Strain to Prevent Mastitis and to Eradicate GBS Colonization|Oral Administration of a Probiotic Strain to Pregnant Women: Effects on the Prevention of Lactational Mastitis and on the Eradication of GBS Colonization|PROBIOPREG|Universidad Complutense de Madrid|No|Recruiting|November 2011|June 2012|Anticipated|March 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Female|25 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 11, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505361||93079|
NCT01504815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11ART|Adaptive Radiation Treatment for Head and Neck Cancer|Phase III Randomized Study With Cisplatinum and Conventional or Adaptive High Dose Radiotherapy for Advanced Head and Neck Cancer|ARTFORCE|The Netherlands Cancer Institute|No|Recruiting|March 2012|March 2020|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|268|||Both|18 Years|70 Years|No|||October 2015|October 8, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01504815||93121|
NCT01505075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|043-2011|Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer|Phase II Study of Dose-escalated, Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-Risk Prostate Cancer|pHART8|Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|September 2011|January 2018|Anticipated|January 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||December 2015|December 4, 2015|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01505075||93101|
NCT01506219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NZ-151111-VHDZ|Effect of Geriatric Medical Intervention On Elderly Referred For Rehabilitation|Effect of Geriatric Medical Intervention On Elderly Referred For Rehabilitation|EGMIERR|University of Aarhus|No|Active, not recruiting|November 2012|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Both|65 Years|N/A|No|||August 2013|May 31, 2015|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01506219||93013|
NCT01505335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0460-11-RMB CTIL|The Use of Novel us Device (Jetguide) to Measure the Distance to the Roof of the IAC (Inferior Alveolar Canal)|The Use of Novel us Device (Jetguide) to Measure the Distance to the Roof of the IAC (Inferior Alveolar Canal)||Rambam Health Care Campus|No|Not yet recruiting|January 2012|February 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Probability Sample|Subjects attentding the clinic, requiring dental implant therapy in the posterior part of        the lower jaw.|January 2012|January 5, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505335||93081|
NCT01505595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_SBrumagne_PT-LBP|Proprioceptive Training and Low Back Pain|||Katholieke Universiteit Leuven|Yes|Recruiting|January 2012|December 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|45 Years|No|||January 2012|December 4, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505595||93061|
NCT01505608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC 005|Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma|A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma||Spectrum Health Hospitals|Yes|Terminated|December 2011|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|12 Months|21 Years|No|||January 2016|January 18, 2016|January 4, 2012|Yes|Yes|Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT01505608||93060|
NCT01506817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB-030112|Dynamic Contrast Enhanced (DCE)-MRI in Fibromyalgia|Dynamic Contrast Enhanced MRI of the Hands in Patients With Fibromyalgia. A Pilot Study||Frederiksberg University Hospital||Enrolling by invitation|December 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with fibromyalgia recruited from Department of Rheumatology, Frederiksberg        Hospital. Inclusion in the study will be based on clinical assessment by a specialist in        rheumatology and member of the research team. Patients fulfilling the 1990-ACR criteria        for fibromyalgia and with pain in the hands as a prominent clinical feature will be        referred for DCE-MRI as part of the diagnostic workup.        Healthy controls will be recruited by advertisement at www.forsøgsperson.dk or in the        daily press and included in the project based on written, informed consent.|January 2012|January 5, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01506817||92967|
NCT01505855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD vaccination 1.2|Efficacy Study of Pneumococcal Vaccination in Crohn's Disease|Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study||Kyunghee University Medical Center|Yes|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|197|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01505855||93041|
NCT01506180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGA-GD-2011|In-Hospital Comprehensive Geriatric Assessment in Aged Acute Medical Patients|||University of Aarhus|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|3877|||Both|80 Years|N/A|No|Probability Sample|Acute medical patients aged 80 years or older|January 2012|January 6, 2012|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01506180||93016|
NCT01506193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115555|Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children|Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children||GlaxoSmithKline||Completed|February 2012|March 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|716|||Both|13 Months|15 Months|Accepts Healthy Volunteers|||September 2015|September 21, 2015|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506193||93015|
NCT01507714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0083-11EMC|Anterior Vaginal Wall Repair With Mesh in Combination With TVT-O to Reduce Urinary Stress Incontinence|Anterior Vaginal Wall Repair With Mesh in Combination With TVT-O to Reduce Urinary Stress Incontinence||HaEmek Medical Center, Israel|Yes|Not yet recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|30 Years|N/A|No|||January 2012|January 8, 2012|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01507714||92899|
NCT01521546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0251|Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy|Early Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy|E-SCAR DMD|Ohio State University|Yes|Active, not recruiting|February 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Male|7 Years|N/A|No|||June 2015|June 26, 2015|January 26, 2012|No|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01521546||91844|
NCT01521806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM001|Effects of Dietary Fiber on Insulin Sensitivity|Effects of Dieatry Fiber on Insulin Sensitivity in Pre- and Post-menopausal Women||National Starch LLC|No|Not yet recruiting|January 2012|September 2013|Anticipated|January 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|40|||Female|19 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01521806||91824|
NCT01517698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP27936|A Study of RO4917523 in Patients With Fragile X Syndrome|A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.||Hoffmann-La Roche||Completed|May 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|185|||Both|14 Years|50 Years|No|||September 2015|September 1, 2015|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517698||92139|
NCT01507935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL.1.C/A|Colonisation Resistance Study|Randomised, Controlled, Double-blind Exploratory Study to Investigate the Effect of Specific Prebiotic Oligosaccharides on Gut Microbiota Composition in Healthy Infants|ColoR|Danone Asia Pacific Holdings Pte, Ltd.|No|Withdrawn|January 2012|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|4||Actual|0|||Both|8 Weeks|10 Weeks|Accepts Healthy Volunteers|||September 2012|September 4, 2012|January 5, 2012||No|The study was withdrawn due to change of the study product formulation.|No||https://clinicaltrials.gov/show/NCT01507935||92882|
NCT01507948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10252011-8566|Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD)|The Neurobiology of Psychotherapy: Emotional Reactivity and Regulation in PTSD||Stanford University|Yes|Active, not recruiting|September 2010|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|64|||Both|18 Years|60 Years|No|||July 2015|July 15, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01507948||92881|
NCT01508533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAS/BBIL/07/2008|Epidemiology of Rotavirus Infection in North India Community|Disease Burden Study and Site Preparation for Planning and Implementation of the Phase III Trials for the Oral Rotavirus Vaccine 116E||Society for Applied Studies|No|Completed|July 2009|September 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|N/A|24 Months|Accepts Healthy Volunteers|Non-Probability Sample|This study was conducted in Delhi at Govindpuri-Tigri-Dakshinpuri, Tuglakabad and Sangam        Vihar.|January 2012|January 9, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508533||92838|
NCT01508754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FINEP-01.08.0615.00|Efficacy of CPAP Treatment on Blood Pressure of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome|Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).||Universidade Federal do Rio de Janeiro|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|80 Years|No|||September 2014|September 12, 2014|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01508754||92821|
NCT01504633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUPICO-Indonesia|Nutrigenomics, PUFA, Iron and Cognition Amongst Under-two-year-old Indonesian Children|Can NUtrigenomics / Nutrigenetics Help Explain the Mixed Results on Effect of LCPUFA (DHA) and Iron on Child COgnition?|NUPICO|Indonesia University|No|Active, not recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Anticipated|240|||Both|12 Months|16 Months|Accepts Healthy Volunteers|||February 2014|February 25, 2014|December 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01504633||93135|
NCT01504620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGSTA_C_05445|Performance Evaluation of Blood Glucose Monitoring Systems|Performance Evaluation of BGStar and iBGStar in Terms of Accuracy (Polaris), Intra-assay Precision, and Hematocrit Interference (Helios Substudy) Following ISO15197 and TNO Guidelines|Polaris|IKFE Institute for Clinical Research and Development|No|Completed|January 2011|June 2011|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|106|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2011|January 3, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01504620||93136|
NCT01504880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 09/155|Atrioventricular Valve Regurgitation Vena Contracta; Echo Versus MRI|Evaluation of Mitral and Tricuspid Regurgitation: Cardiovascular Magnetic Resonance Imaging Versus Echocardiographic Doppler Color Flow Mapping of the Vena Contracta||Medical College of Wisconsin|No|Active, not recruiting|June 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|N/A|N/A|No|Non-Probability Sample|Patients scheduled for clinically indicated MRI and have had an echocardiogram in the last        6 months with AV Valve (AVV) Insufficiency.|February 2016|February 10, 2016|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504880||93116|
NCT01505101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA032517-01|Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy|Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy: Exploration of Cognitive, Affective, and Physiological Mechanisms||Florida State University|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505101||93099|
NCT01505114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPTN 069/A5305 (NEXT Prep)|Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women|A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|594|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 22, 2016|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505114||93098|
NCT01505907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXB909-100|Pharmacokinetic Study of CXB909 in Healthy Male Subjects|Phase I, Randomized, Double-Blind, Placebo Controlled, Dose Escalation,Single Dose, Safety, Tolerance, and Pharmacokinetic Study of CXB909 in Healthy Male Volunteers||CeNeRx BioPharma Inc.|Yes|Not yet recruiting|December 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|5||Anticipated|40|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 6, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505907||93037|
NCT01505920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBG-11-08-15A-12|Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial|Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial||Chiang Mai University|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|101|||Female|18 Years|N/A|No|||January 2013|January 13, 2013|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505920||93036|
NCT01506232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P000547|Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study|Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study||Massachusetts General Hospital|No|Terminated|March 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|1|||Both|6 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Youths ages 6-17 diagnosed with ADHD, ASD or BPD, or heathy controls.|October 2013|October 24, 2013|January 5, 2012||No|Due to slow enrollment and lack of funding the study was terminated prior to completion.|No||https://clinicaltrials.gov/show/NCT01506232||93012|
NCT01506518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1509|Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular Dystrophy|Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy||University of North Carolina, Chapel Hill|No|Recruiting|January 2012|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|||Male|5 Years|13 Years|No|Probability Sample|The study population will include patient volunteers with Duchenne muscular dystrophy        (DMD). Thirty volunteers (boys with DMD, enrolling at ages 5 (n=10), 7 (n=10), or 9        (n=10)) having clinical diagnosis of DMD with clinical onset by age 5 will be considered        for enrollment.|October 2015|October 6, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01506518||92990|
NCT01506531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 09-156|Silo Versus Primary Closure for Gastroschisis|Bedside Silo Versus Attempted Operative Closure for Gastroschisis||Children's Mercy Hospital Kansas City|No|Recruiting|January 2012|April 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|2 Days|No|||January 2016|January 27, 2016|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01506531||92989|
NCT01505933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35165|Airway Dimension Study in Children Undergoing MRI Sedated With Propofol and Dexmedetomidine|Comparison of Changes in Upper Airway Dimensions With Dexmedetomidine and Propofol in Children Undergoing MRI||Milton S. Hershey Medical Center|Yes|Not yet recruiting|February 2012|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|2 Years|5 Years|No|||January 2012|January 4, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01505933||93035|
NCT01506830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPEL-PPGO0012|Cervical Restorations Placed Under Two Isolation Methods|Influence of Operatory Field Isolation Techniques on the Clinical Performance of Class V Restorations||Federal University of Pelotas|No|Completed|July 2009|December 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01506830||92966|
NCT01506206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002546|ON/OFF Stimulation and Impulsivity in Patients With Deep Brain Stimulators|ON/OFF Stimulation and Impulsivity in Patients With Deep Brain Stimulators||Massachusetts General Hospital|No|Recruiting|February 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with Deep Brain Stimulators Patients with Major Depressive Disorder or        Obsessive-Compulsive Disorder and no DBS|October 2015|October 23, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01506206||93014|
NCT01506505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2011-001120-38|The Evening Versus Morning Polypill Utilization Study|A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill|TEMPUS|UMC Utrecht|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01506505||92991|
NCT01507415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LF015H|Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?|Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|November 2011|February 2014|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|226|Samples With DNA|Whole blood, plasma and serum.|Both|35 Years|N/A|No|Non-Probability Sample|Any patient hospitalised with an acute exacerbation of COPD. Cohorts will be recruited        from local District General Hospitals with Acute Admissions Units and Accident & Emergency        Departments.|November 2014|November 4, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507415||92922|
NCT01507727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HENGRUI20111231|Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia|A Multicenter, Randomized, Double-blind, Placebo-controlled (Standard Therapy + Placebo) Study to Evaluate the Efficacy and Safety of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia||Jiangsu HengRui Medicine Co., Ltd.|Yes|Recruiting|January 2012|September 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|80 Years|No|||January 2012|January 8, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01507727||92898|
NCT01508039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMP-001-008|Immunological Effects From Intranasal Chitin Micro-Particles|A Randomised, Double-blind,Single-dose,Placebo and Single-blind Active Controlled Cross-over Study in Healthy Volunteers to Access in Effects of Intranasal Chitin Micro-particles on the Release of Cytokines From Nasal Mucosa|INCA|University of Aarhus|Yes|Completed|April 2011|July 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01508039||92874|
NCT01521819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLH006|Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration|A Pilot, Single-center, Interventional Clinical Trial in Which Subjects With Vascularized Pigment Epithelial Detachment (V-PED) Secondary to AMD With Serous Component Superior to 50% of the Lesion Will Receive Low Voltage Stereotactic Radiotherapy (IRay®) Treatment and Lucentis Treatment as Needed.||Oraya Therapeutics, Inc.|Yes|Active, not recruiting|August 2012|August 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|50 Years|N/A|No|||October 2012|October 24, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01521819||91823|
NCT01521832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S015-001|Escalating Dose Study in Healthy Volunteers With SEN0014196|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196||Siena Biotech S.p.A.|No|Completed|October 2009|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|11||Actual|88|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|February 6, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01521832||91822|
NCT01517958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0598|Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates|The Use of Lung Ultrasound to Diagnose RDS vs. TTN in Neonates Greater Than or Equal to 28 Weeks Gestation||Icahn School of Medicine at Mount Sinai|Yes|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Both|28 Weeks|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Neonatal patients admitted to Mount Sinai NICU of gestational age greater than or equal to        28 weeks.|March 2016|March 24, 2016|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517958||92119|
NCT01508000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-40091|Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases|Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS/NRAS Colorectal Cancer|BOS2|European Organisation for Research and Treatment of Cancer - EORTC||Terminated|June 2013|December 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|44|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|January 9, 2012||No|Low or poor accrual|No||https://clinicaltrials.gov/show/NCT01508000||92877|
NCT01508273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0743|Lifestyle Intervention for High Risk Cancer Survivors|Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors||M.D. Anderson Cancer Center|No|Withdrawn|May 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|0|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508273||92857|
NCT01508767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Joyce-2011|Early Post-operative Removal of Urethral Catheter in Patients Undergoing Colorectal Surgery With Epidural Analgesia|Prospective Randomized Controlled Trial of Early Post-operative Removal of Urethral Catheter in Patients Undergoing Colorectal Surgery With Epidural Analgesia||University College Hospital Galway|No|Completed|January 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01508767||92820|
NCT01504893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protectiveOLV|Protective Versus Conventional Ventilation During Thoracic Surgery|Multicenter Randomized Trial on Protective Ventilation Versus Conventional Ventilation During OLV in Patients Undergoing Thoracic Surgery||Azienda Ospedaliera S. Maria della Misericordia|Yes|Recruiting|September 2013|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|18 Years|N/A|No|||February 2015|February 7, 2015|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01504893||93115|
NCT01505153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL 103|Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer|Phase I Trial of Intratumoral Bi-functional shRNA Stathmin 1-knockdown Lipoplex in Patients With Advanced and/or Metastatic Cancer|STMN1-LP|Gradalis, Inc.|Yes|Active, not recruiting|February 2012|March 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||January 2015|March 9, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505153||93095|
NCT01505166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL 107|Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases|Randomized Phase II Trial of Post-operative Adjuvant Chemotherapy ± FANG™ Autologous Tumor Cell Vaccine in Colorectal Carcinoma With Liver Metastases|FANG-CLM|Gradalis, Inc.|Yes|Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01505166||93094|
NCT01505400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-001|Integrated Molecular Profiling in Advanced Cancers Trial|Integrated Molecular Profiling in Advanced Cancers Trial|IMPACT|University Health Network, Toronto|No|Recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1500|Samples With DNA|Archival tumor tissue      1 tube of whole blood|Both|18 Years|N/A|No|Probability Sample|Advanced cancers (breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary        gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and        rare carcinomas) and phase 1 clinical trial candidates|June 2015|June 30, 2015|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505400||93076|
NCT01505127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/CCT-401|Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori|A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the First Line Eradication of H.Pylori||Takeda|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|650|||Both|20 Years|N/A|No|||November 2013|November 2, 2013|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01505127||93097|
NCT01505140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|445246WR77518|Benefits of Walnuts for Male Reproductive Health|Benefits of Walnuts for Male Reproductive Health||University of California, Los Angeles|No|Completed|November 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Male|21 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 3, 2012|December 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01505140||93096|
NCT01505374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11155|Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty|Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty: A Comparative Effectiveness Study in Bilateral Total Knee Arthroplasty Patients||Hospital for Special Surgery, New York|Yes|Completed|March 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|40 Years|80 Years|No|||December 2013|December 4, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505374||93078|
NCT01505660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41128-K|Randomized Controlled Trial Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care|Randomized Controlled Trial Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care||University of Washington|Yes|Active, not recruiting|January 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Supportive Care|2||Anticipated|270|||Both|18 Years|N/A|No|||April 2015|April 11, 2015|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505660||93056|
NCT01505621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004969|Novel Methodology to Measure Protein Accumulation|Novel Methodology to Measure Protein Accumulation||Mayo Clinic|Yes|Completed|December 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|Samples With DNA|On day one of the study (day of the study drink administration): blood samples and skeletal      muscle biopsy (vastus lateralis). Muscle biopsy tissue will be frozen subsequent to      collection.      Week 2 and 3 of the study: blood sample collection Week 4 of the study: blood sample and      skeletal muscle (vastus lateralis) biopsy. Muscle biopsy tissue will be frozen subsequent to      collection.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Two groups of otherwise healthy participants will be recruited: young (18-30 years) and        old (≥65 years). We anticipate screening up to 30 individuals for each group (up to 60        total for study) in order to enroll 12 individuals for each group (24 total for study). A        high ratio of screened to enrolled participants is necessary due to exclusion criteria and        concern about finding healthy older participants and relatively inactive younger        participants. An equal number of participants will be enrolled in each group. We will        attempt to have an equal number of men and women.|April 2014|April 9, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01505621||93059|
NCT01506570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 280|Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-experienced Adult Subjects||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|December 2011|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|58|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|January 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01506570||92986|
NCT01506583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cellex002|Clinical Evaluation of QFlu Combo Test|Clinical Evaluation of QFlu Combo Test|QFlu|Cellex, Inc.|No|Recruiting|November 2010|July 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|1000|Samples Without DNA|Samples were retained in case that the testing needs to be repeated. They are to be      discarded 12 months after the study is completed.|Both|N/A|N/A|No|Non-Probability Sample|There are three population of participants: pediatric (in patient or out patient),        in-patient (any age) and out-patient (any age).|January 2012|January 9, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01506583||92985|
NCT01506596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABLSMLS1101|Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma|A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma||Vector Oncology|No|Active, not recruiting|March 2012|June 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01506596||92984|
NCT01506245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNF 3200B0-120437|Exercise and Behavioral Therapy in Obese Children|Exercise Training and Family-based Behavioural Treatment in Pre-pubertal Obese Children and Their Mother||University Hospital, Geneva|No|Enrolling by invitation|January 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Both|8 Years|11 Years|No|||January 2012|January 4, 2012|December 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01506245||93011|
NCT01507116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3966|Diabetes Attitudes Wishes and Needs|Diabetes Attitudes Wishes and Needs (DAWN) 2 Study: A Multinational, Multi-stakeholder Survey Study of Psychosocial Issues in Diabetes and Patient-centred Diabetes Care|DAWN2|Novo Nordisk A/S|No|Completed|March 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||3|Actual|8985|||Both|18 Years|N/A|No|Non-Probability Sample|The total core study population is intended to comprise 9540 people with diabetes, 2160        family members and 5040 healthcare professionals across the 18 countries participating in        DAWN 2. The study population will be invited to participate by either web based or        telephone recruitment, or if absolutely needed and deemed appropriate, physician        recruitment (i.e. patients recruited by physicians will telephone call centres managed by        the local survey research agency and will be screened by telephone).|January 2015|January 16, 2015|January 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507116||92944|
NCT01507428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00107|Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer|Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)|Yes|Recruiting|February 2012|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507428||92921|
NCT01506843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F3046|Sublingual Immunotherapy in Children With Allergic Rhinitis|Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-allergic Children in a Randomized Double-blind, Placebo-controlled Study in Brazil|SLIT|Federal University of Uberlandia|Yes|Completed|October 2008|April 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|122|||Both|5 Years|15 Years|No|||August 2007|January 9, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01506843||92965|
NCT01499706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUCOM-MI-1|Telephone-delivered Behavioral Interventions to Reduce Risky Sexual Behavior in HIV-positive Late Middle-age and Older Adults|Phase I Clinical Trial of Telephone-delivered Motivational Interviewing to Reduce Sexual Risk Behavior in HIV-positive Persons 45-plus Years of Age|MI|Ohio University College of Osteopathic Medicine|Yes|Completed|November 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|100|||Both|45 Years|N/A|No|||December 2011|December 22, 2011|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01499706||93513|
NCT01499719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|checklist pause|Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery|Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery||Oregon Health and Science University|No|Completed|December 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|100|||Both|18 Years|N/A|No|||April 2013|April 23, 2013|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01499719||93512|
NCT01517711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-Tramadol|Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)|A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD||INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Active, not recruiting|September 2011|July 2015|Anticipated|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|55 Years|No|||January 2015|January 12, 2015|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517711||92138|
NCT01517724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/08/0170|Bortezomib Consolidation Trial|Phase II Study of Bortezomib Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma|BCT|University College, London|Yes|Active, not recruiting|December 2009|December 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|70 Years|No|||December 2014|December 2, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01517724||92137|
NCT01508546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/98|Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer|||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Completed|May 1998|May 2003|Actual|May 2003|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|565|||Female|18 Years|65 Years|No|||January 2012|January 9, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01508546||92837|
NCT01508559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSM Neurocog|Men Who Have Sex With Men (MSM) Neurocog 1&2 Study|Neurocognitive Function in a Central London Cohort of HIV Infected and Uninfected Men Who Have Sex With Men|MSM Neurocog|St Stephens Aids Trust|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|237|||Male|18 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV infected and uninfected MSM 18-50 years old|April 2014|April 10, 2014|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508559||92836|
NCT01508780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000916|Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan|Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan||Massachusetts General Hospital||Withdrawn|May 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|75 Years|No|||February 2014|February 11, 2014|January 3, 2012|Yes|Yes|Due to complex study protocol, no patients have been enrolled in the study.|No||https://clinicaltrials.gov/show/NCT01508780||92819|
NCT01504646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108006205|Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Randomized Controlled Trial of Marine Lipid Fraction PCSO-524™ on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction in Asthma||Indiana University|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|30 Years|No|||April 2013|April 2, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01504646||93134|
NCT01496950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIEP394-07|Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine|Double-blind Randomized Clinical Trial to Evaluate Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in the Preventive Treatment of Chronic Migraine|TMS-CHROMIG|Hospital Israelita Albert Einstein|No|Recruiting|October 2008|February 2012|Anticipated|December 2011|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||December 2011|December 19, 2011|May 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496950||93724|
NCT01521169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU332|Long-term Effectiveness Study on Cholesterol-reducing Activity|Clinical Study for Evaluating the Plasma Cholesterol-reducing Activity of a Plant Sterol-enriched Yoghurt Drink - Effectiveness and Long-term Safety Study||Danone Research|No|Completed|January 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Basic Science|3||||||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521169||91873|
NCT01521182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU356|Effect of the Consumption of a Fermented Dairy Drink on the Immune Function|||Danone Research|No|Active, not recruiting|September 2011|||June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||||||Both|65 Years|80 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521182||91872|
NCT01520077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eprost-20100451|Vytorin in the Treatment of Alopecia Areata|A Pilot Study To Evaluate the Efficacy of Vytorin (Simvastatin +Ezetimibe) In the Treatment of Alopecia Areata||University of Miami|Yes|Completed|July 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520077||91957|
NCT01521988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/089/HP|Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation|Prevention of Atrial Fibrillation by Combined Right Isthmus Ablation and cryoBalloon Pulmonary Vein Isolation in Patients With Typical Atrial Flutter|PAF CRIOBLAF|University Hospital, Rouen|Yes|Active, not recruiting|June 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|75 Years|No|||December 2015|December 4, 2015|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01521988||91810|
NCT01518335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN4157|Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department|A Double-Blind, Randomized, Placebo Controlled Study Evaluating the Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department.|PRP|Albert Einstein Healthcare Network|Yes|Completed|June 2009|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||January 2012|February 11, 2013|December 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518335||92090|
NCT01518881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TKM-EBOV-001|Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion|A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability and Pharmacokinetics of TKM-100201 in Healthy Human Volunteers||Arbutus Biopharma Corporation|Yes|Terminated|January 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|November 8, 2011|Yes|Yes|Corporate decision to reformulate the investigational product.|No||https://clinicaltrials.gov/show/NCT01518881||92049|
NCT01518296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0071-CTIL|Rating Pelvic Organs Prolapse in Women According to the POPQ Method Before and After Emptying the Urinary Bladder|Rating the Degree of Pelvic Organs Prolapse in Women According to the POPQ Method Before and After Emptying the Urinary Bladder||Carmel Medical Center|No|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Female|20 Years|90 Years|No|||March 2013|March 28, 2013|January 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01518296||92093|
NCT01518309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP-103-010|An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients|||ACADIA Pharmaceuticals Inc.||Completed|November 2004|||May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|N/A|N/A|No|||February 2014|February 17, 2014|December 16, 2008|No|Yes||No||https://clinicaltrials.gov/show/NCT01518309||92092|
NCT01520090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2412012|Egyptian Women Knowledge and Use of Different Contraceptive Methods|Egyptian Women Knowledge and Use of Different Contraceptive Methods||Ain Shams University|No|Recruiting|January 2012|April 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|1200|||Female|18 Years|51 Years|Accepts Healthy Volunteers|Non-Probability Sample|egyptian women ,18 -51 years old Using a contraceptive method for at least 6 months        continuously.|January 2012|January 26, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520090||91956|
NCT01520103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-MAM-0110|Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer|Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer|VicTORia|AIO-Studien-gGmbH|No|Active, not recruiting|January 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|139|||Female|18 Years|N/A|No|||March 2016|March 18, 2016|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520103||91955|
NCT01519856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIR-008/K|PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy|Efficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive Function|PIR-008/K|Desitin Arzneimittel GmbH|No|Completed|June 2009|February 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|908|||Both|18 Years|N/A|No|Non-Probability Sample|male and female patients with Morbus Parkinson|July 2015|January 28, 2016|March 12, 2010||No||No||https://clinicaltrials.gov/show/NCT01519856||91974|
NCT01519869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-GYN-098-MCC|Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma|Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Trial Protocol||University of Kentucky|Yes|Active, not recruiting|March 2012|November 2020|Anticipated|November 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519869||91973|
NCT01510756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110574|Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)|A Phase II Translational Study of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia Patients||University of California, San Diego|Yes|Terminated|December 2011|December 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 11, 2012|No|Yes|slow enrollment|No|August 21, 2015|https://clinicaltrials.gov/show/NCT01510756||92669|
NCT01517971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-150807|Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer|Validation of Molecular Prognostic Tests in NSCLC||Alliance for Clinical Trials in Oncology|No|Recruiting|January 2012|||June 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|1060|Samples With DNA|Tissue samples|Both|18 Years|N/A|No|Probability Sample|Patients diagnosed with NSCLC enrolled on the Cancer and Leukemia Group B (CALGB) 140202|July 2015|July 23, 2015|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517971||92118|
NCT01518205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZenti HADIF|HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)|HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F): a RCTrial to Evaluate the Effect of LDL-apheresis on the Recovery of Diabetic Ulcers in Patients With Peripheral Vasculopathy Not Susceptible to Revascularization.|HADIF|Universita di Verona|No|Recruiting|February 2012|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|80 Years|No|||December 2014|December 18, 2014|January 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01518205||92100|
NCT01518491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-DOX-NT/009|Open Label Trial of NanoDOX Hydrogel in Orthopedic Trauma Wounds With and Without Vacuum Assisted Closure Therapy|A Prospective, Randomized, Open Label Trial of NanoDOX™ Hydrogel Plus Vacuum Assisted Closure Therapy Versus Vacuum Assisted Closure Therapy Alone in Orthopedic Trauma Wounds.||Nanotherapeutics, Inc.|No|Withdrawn|April 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518491||92079|
NCT01518504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16286|Effects of Thoracic Mobilization on Shoulder Range of Motion|Effects of Thoracic Mobilization on Shoulder Range of Motion||Creighton University|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 19, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01518504||92078|
NCT01518777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00006818|Reducing Radioisotope Dose: the Half-Dose CZT Study|Reducing Radioisotope Dose in Regadenoson SPECT Myocardial Perfusion Imaging: Comparison of Half-Dose Scans Using a Novel Solid-State-Detector Dedicated Cardiac Camera to Full Dose Scans Acquired On Standard Equipment||The Methodist Hospital System|No|Recruiting|January 2012|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|90 Years|No|||March 2016|March 21, 2016|January 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01518777||92057|
NCT01519128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100750|A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin|A Phase I, Open Label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Effect of Steady-state TMC278 on the Pharmacokinetics of a Single Dose of Digoxin||Janssen R&D Ireland|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|December 27, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01519128||92030|
NCT01519414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00237|Tivantinib in Treating Patients With Metastatic Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of ARQ 197 (Tivantinib) in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer||National Cancer Institute (NCI)||Active, not recruiting|January 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|78|||Male|18 Years|N/A|No|||January 2016|February 19, 2016|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519414||92008|
NCT01519687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRS-TOFS-G201|Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout|Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout||Pharmos|No|Recruiting|January 2012|June 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||January 2012|January 26, 2012|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519687||91987|
NCT01519661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTBM100C2401|Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis|A Single Arm, Open-label, Multicenter, Phase IV Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis||Novartis||Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|157|||Both|6 Years|N/A|No|||February 2015|February 8, 2015|January 24, 2012|Yes|Yes||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01519661||91989|
NCT01519674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3963|Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin|A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin|SIT2MIX|Novo Nordisk A/S|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|582|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|January 24, 2012|Yes|Yes||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01519674||91988|
NCT01520857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTH5535/12/11|Spinal Versus General Anesthesia for Transabdominal Preperitoneal (TAPP) Repair of Inguinal Hernia|A Controlled Randomized Trial Comparing Spinal Versus General Anesthesia for Transabdominal Preperitoneal (TAPP) Repair of Inguinal Hernia||Larissa University Hospital|No|Completed|January 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01520857||91897|
NCT01521936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 201311|Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy|Vitamin D3 Supplementation in Acute Myeloid Leukemia: Pharmacokinetic Study||Roswell Park Cancer Institute|Yes|Terminated|December 2011|June 2015|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|4|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|January 26, 2012|No|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01521936||91814|
NCT01521949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0655.cc|Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA|A Phase 2 Study Acai Juice Product in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising Prostate Specific Antigen (PSA)||University of Colorado, Denver|Yes|Active, not recruiting|November 2011|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|89 Years|No|||December 2015|December 3, 2015|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01521949||91813|
NCT01521962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322/CCT-901|Study of Combination Therapy With SYR-322|A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan||Takeda||Completed|February 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment|2||Actual|67|||Both|20 Years|N/A|No|||November 2013|November 12, 2013|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521962||91812|
NCT01518075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEGLUT|Breathing-swallowing Interaction in Chronic Obstructive Pulmonary Disease Patients - Impact of Non Invasive Ventilation|Breathing-swallowing Interaction in Chronic Obstructive Pulmonary Disease (COPD) Patients Hospitalized in Intensive Care Unit for an Acute Exacerbation: Impact of Non Invasive Ventilation. Physiological Evaluation||University Hospital, Caen|Yes|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 14, 2012|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01518075||92110|
NCT01518894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701004|A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia||Pfizer|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|55 Years|No|||May 2012|May 5, 2012|January 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01518894||92048|
NCT01518907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUX-CC-830|The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)|A Phase 1b, Open-label, Dose-escalation Study of the Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy Commonly Known as Cellulite||Endo Pharmaceuticals|No|Completed|January 2012|February 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|11||Actual|99|||Female|21 Years|60 Years|No|||March 2015|March 17, 2015|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01518907||92047|
NCT01519245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|67452-01|Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery|Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery||University of Saskatchewan|No|Completed|December 2011|June 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 27, 2013|January 17, 2012||No||No|December 6, 2012|https://clinicaltrials.gov/show/NCT01519245||92021|Small sample sizeLow-risk CABG patients enrolled onlyBreak in protocol, with pre-pump TXA not given to 2 participants, and post-pump TXA given to 8 participantsShort study period, with no long-term follow-up data
NCT01519557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6329|Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders|Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders||New York State Psychiatric Institute|Yes|Completed|April 2011|November 2013|Actual|August 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|55 Years|No|||February 2015|March 3, 2015|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519557||91997|
NCT01519570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0290|Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates|Use of an Electronic Medical Record to Improve Standard Practice in the Primary Care Setting: A Randomized-Controlled Study of Herpes Zoster Vaccination Rates||Ohio State University|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2589|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 24, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01519570||91996|
NCT01510496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENDOLCAT|Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy: Analysis of Risk Factors and Association With Genetic Polymorphisms|Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy : Analysis of Risk Factors and Association With Genetic Polymorphisms||Fundacion IMIM|No|Completed|January 2009|July 2014|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|3979|Samples With DNA|Sample collection Five milliliters of venous blood will be extracted from each patient with      chronic pain; control samples will come from a DNA bank. All patients must have given their      written consent to testing and storage.      - Plasma DNA will be extracted with a BioRobot EZ1 Workstation (Qiagen).|Both|18 Years|N/A|No|Non-Probability Sample|All spanish patients who undergo scheduled surgery of one of the following types: inguinal        herniorrhaphy, hysterectomy, toracothomy.|December 2015|December 29, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01510496||92689|
NCT01510769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-304|Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceous Gout|CRYSTAL|Ardea Biosciences, Inc.|Yes|Completed|January 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|330|||Both|18 Years|85 Years|No|||June 2015|June 10, 2015|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510769||92668|
NCT01510782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1293.1|Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.2 mg to 120 mg Administered by Intravenous Infusion and 40 mg to 120 mg Administered by Subcutaneous Injection) of BI 655064 (Buffer Solution for Injection) in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)||Boehringer Ingelheim||Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|72|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|January 12, 2012||||No||https://clinicaltrials.gov/show/NCT01510782||92667|
NCT01517984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-09|Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation|Immune Monitoring and Calcineurin Inhibitor (CNI) Withdrawal in Low Risk Recipients of Kidney Transplantation||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|November 2010|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|January 20, 2012|Yes|Yes|Absence of equipoise on the basis of predetermined stopping rules.|No||https://clinicaltrials.gov/show/NCT01517984||92117|
NCT01518218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOA-002|Effectiveness of Laying-on-of-hands for Sickle Cell Disease|Effectiveness of Laying-on-of-hands for Patients With Sickle Cell Disease in Africa||MOA Health Science Foundation|Yes|Completed|March 2006|December 2009|Actual|March 2007|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|3 Years|40 Years|No|||January 2012|April 9, 2015|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01518218||92099|
NCT01518517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPALL2009-06|GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia|Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia|GRASPIVOTALL|ERYtech Pharma|Yes|Active, not recruiting|December 2009|August 2016|Anticipated|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|1 Year|55 Years|No|||March 2016|March 17, 2016|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01518517||92077|
NCT01518530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0086-11-HYMC|Tailored Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain|||Hillel Yaffe Medical Center|Yes|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||August 2013|August 22, 2013|December 20, 2011||No||No|May 7, 2013|https://clinicaltrials.gov/show/NCT01518530||92076|
NCT01518790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353750|Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children|Evaluation of Short Course, Single-dose Polyethylene Glycol (PEG) 3350 Regimen for Colonoscopy Bowel Preparation in Children||Walter Reed National Military Medical Center|Yes|Completed|September 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|50|||Both|8 Years|18 Years|No|||February 2016|February 9, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518790||92056|
NCT01519141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL095130|Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection|Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases||University of California, San Francisco|No|Recruiting|July 2003|June 2018|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|325 well-characterized HIV-infected individuals and 75 HIV-uninfected individuals.|June 2015|June 3, 2015|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01519141||92029|
NCT01519154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH Nr. 2011-0190|Sedation MRI - Propofol Versus Propofol-Ketamin in Children|Untersuchung Unterschiedlicher Sedationstechniken für Elektive Magnetresonanztomographie (MRT)-Diagnostik Bei Kindern Anhand Klinischer Und MRT-basierter Outcomeparameter (Propofol Versus Propofol-Ketamin)||University Children's Hospital, Zurich|Yes|Completed|March 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|347|||Both|3 Months|10 Years|No|||November 2014|November 26, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01519154||92028|
NCT01519427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00238|Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib|A Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600-Mutant Advanced Melanoma Whose Disease Has Progressed on Prior Therapy With a Selective BRAF Inhibitor (i.e., Vemurafenib, Dabrafenib, LGX818)||National Cancer Institute (NCI)|Yes|Terminated|January 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||January 2014|May 16, 2014|January 25, 2012|Yes|Yes|Study terminated due to slow accrual|No|November 27, 2013|https://clinicaltrials.gov/show/NCT01519427||92007|Because this study terminated early due to slow accrual, data were available for only the two eligible patients that enrolled before study closure.
NCT01519700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP06-302|Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim|A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy|PIONEER|Sandoz|Yes|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|218|||Female|18 Years|N/A|No|||April 2015|April 14, 2015|January 13, 2012||No||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01519700||91986|
NCT01519713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA76 (SFY12080)|Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects|Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects||Sanofi|No|Completed|January 2012|December 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|200|||Both|2 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|January 20, 2012|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01519713||91985|
NCT01521689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLCR lowdoz / IPC 2009-004|Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment|Phase II Study of Tolerance and Efficacy of Subcutanous Low Doses Rituximab Given as Consolidation Treatment to Chronic Lymphocytic Leukaemia (CLL) Patients Responding to Induction Therapy|LLCRlowdoz|Institut Paoli-Calmettes|No|Active, not recruiting|December 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01521689||91833|
NCT01521481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 03 2010|Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery|Analgesic Efficacy of Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery.|U-IFB|Azienda Ospedaliera San Gerardo di Monza|Yes|Completed|April 2011|February 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|87|||Male|18 Years|90 Years|No|||February 2014|February 3, 2014|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01521481||91849|
NCT01521221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-AM-462-CTIL|Assessment of Hand-grip in the Prevention of Postural Orthostatic Hypotension|Assessment of Hand-grip in the Prevention of Postural Orthostatic Hypotension||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|August 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01521221||91869|
NCT01518608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29237403/SMR-1651|Alfentanil and the Elimination of Sympathetic Responses to Tracheal Intubation During Rapid Sequence Induction of Anesthesia: A Probability-based Approach|Alfentanil and the Elimination of Sympathetic Responses to Tracheal Intubation During Rapid Sequence Induction of Anesthesia: A Probability-based Approach||Oslo University Hospital|No|Completed|September 2009|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|84|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01518608||92070|
NCT01519505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05/38|Diabetes in Europe - Prevention Using Lifestyle, Physical Activity and Nutritional Intervention in Catalonia|Diabetes in Europe - Prevention Using Lifestyle, Physical Activity and Nutritional Intervention in Catalonia(DE-PLAN-CAT).|DE-PLAN-CAT|Jordi Gol i Gurina Foundation|No|Active, not recruiting|March 2005|March 2012|Anticipated|March 2006|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2082|||Both|45 Years|74 Years|No|||January 2012|January 26, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519505||92001|
NCT01519804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27820|A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)||Genentech, Inc.||Completed|April 2012|September 2015|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519804||91978|
NCT01510223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NutrientGastEmpt|The Effect of Macronutrients in the Diet on Digestive and Cardiovascular Health|Effect of a 5-day Adaptation and Deadaptation Periods to a High-fat Diet Supplemented With Specific Fatty Acids on Gastrointestinal Transit, Appetite and Substrate Utilisation||University of Limerick|No|Completed|August 2010|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01510223||92709|
NCT01510509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TITANIC-XV|The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients|TITANIC-XV Trial: Prospective, Multicenter and Randomized Trial (Bioactive Bare Metal Titanium Stent Versus Everolimus Drug Eluting Stent)|TITANIC-XV|Hospital Universitario Infanta Cristina|Yes|Active, not recruiting|January 2009|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Both|18 Years|85 Years|No|||December 2008|January 13, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510509||92688|
NCT01510522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200084-508|Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets|Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients, Previously Treated With Metformin Tablets||Merck KGaA|No|Withdrawn|June 2012|||June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01510522||92687|
NCT01510535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HACL010|Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis|An Double-blind, Active-controlled, Parallel-group, Randomized, Multi-center Study to Compare Efficacy and Safety of LBSA0103 Once Versus Hyruan Plus Injection Once Weekly for 3weeks in the Treatment of Patients With Osteoarthritis of the Knee||LG Life Sciences||Completed|December 2011|October 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|287|||Both|40 Years|N/A|No|||January 2013|January 16, 2013|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01510535||92686|
NCT01517997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20884/25-8-11|Infrapopliteal Drug Eluting Angioplasty Versus Stenting|Infrapopliteal Drug Eluting Angioplasty Versus Stenting for the Treatment of Long-segment Arterial Disease: The IDEAS-I Randomized Controlled Trial.|IDEAS-I|University of Patras|No|Completed|August 2011|September 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||October 2013|October 8, 2013|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01517997||92116|
NCT01518231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhejiang Hospital|Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke|Phase 1 Study of Autologous Peripheral Hematopoietic Stem Cell Transplantation in Ischemic Stroke|AHSCTIS|Zhejiang Hospital|No|Recruiting|January 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|70 Years|No|||January 2012|January 24, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01518231||92098|
NCT01519193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKCR2011|Treatment of Aggressive Behavior and Post-Traumatic Stress Disorder|Treatment of Aggressive Behavior and Post-Traumatic Stress Disorder in Former Street Children and Vulnerable Children in Burundi With Narrative Exposure Therapy for Violent Offenders||University of Konstanz|Yes|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Male|12 Years|23 Years|No|||November 2012|November 6, 2012|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01519193||92025|
NCT01518543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECON-EMEA-04|Follow-up of Patient Implanted With the Staple ASTUS®|Follow-up of Patient Implanted With the Staple ASTUS®||Integra LifeSciences Services|No|Terminated|April 2010|January 2013|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|N/A|No|Non-Probability Sample|Patient candidate for an arthrodesis in the following joints (Ankle, 1st MTP, Metatarso -        Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, calcaneum - Cuboid) and whose        surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA can be        enrolled in this study|September 2014|September 10, 2014|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01518543||92075|
NCT01520038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 19811|Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer|Feasibility and Phase 1/II Trial of Adjuvant Radiation Therapy for the Treatment of Urothelial Bladder Cancer Using Proton Therapy or IMRT||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|January 2012|||December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01520038||91960|
NCT01520311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-11015.000 or 297/11 v2.0|The eSVS® Mesh Post-Marketing Trial|Post-market Study to Evaluate Post-implant Patency Rates of the eSVS Mesh in the Treatment of Saphenous Vein Graphs During Coronary Artery Bypass Grafting Versus Saphenous Vein Grafts Without the eSVS Mesh Via Coronary Angiography and Duplex Ultra-Sonography Results||Kips Bay Medical, Inc.|No|Terminated|January 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|21 Years|N/A|No|||February 2015|August 11, 2015|January 3, 2012|Yes|Yes|Company closed|No||https://clinicaltrials.gov/show/NCT01520311||91939|
NCT01519167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX-10-16|Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation|Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation||Hospira, Inc.|No|Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|91|||Both|28 Weeks|16 Years|No|||August 2015|August 7, 2015|January 24, 2012|Yes|Yes||No|May 5, 2015|https://clinicaltrials.gov/show/NCT01519167||92027|
NCT01519180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/148/HP|Antro-pyloro-duodenal Motility in Idiopathic Gastroparesis|Study of the Antro-pyloro-duodenal Motor Dysfunction in Idiopathic Gastroparesis||University Hospital, Rouen|Yes|Completed|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Idiopathic gastroparesis and healthy volunteers|September 2014|September 5, 2014|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01519180||92026|
NCT01520532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-AFS-ERACE|Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)|Evaluate Reduction in Asymptomatic Cerebral Embolism|ERACE|Medtronic Atrial Fibrillation Solutions|No|Completed|March 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|N/A|No|||February 2013|September 10, 2013|January 25, 2012||No||No|December 10, 2012|https://clinicaltrials.gov/show/NCT01520532||91922|
NCT01519726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEMO study|CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug|CYP3A4 Metabolism Before and After Surgery Induced Weight Loss in Morbidly Obese Patients Using Midazolam as a Model Drug|MEMO|St. Antonius Hospital||Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|N/A|1||Anticipated|20|||Both|18 Years|60 Years|No|||January 2012|January 24, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01519726||91984|
NCT01520792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0101|Paracetamol and Pharmacogenetic|Paracétamol and Pharmacogenetic in Healthy Volunteers||University Hospital, Clermont-Ferrand|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|100|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01520792||91902|
NCT01519232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2007-110|A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)|A Pilot Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary SPECT||University of Michigan Cancer Center|Yes|Completed|August 2008|May 2014|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Probability Sample|cancer patients undergoing radiation of the Liver|May 2015|May 14, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01519232||92022|
NCT01514357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001372|Nesiritide in Resistant Hypertension|Natriuretic Peptides and Their Chimerics in Hypertension (Aims 1 and 2)||Mayo Clinic|No|Suspended|April 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|No|||November 2013|November 8, 2013|January 12, 2012|No|Yes|PI has left the institution|No||https://clinicaltrials.gov/show/NCT01514357||92395|
NCT01521715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iOM-605|First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma|A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma|FLIPPER|iOMEDICO AG|No|Recruiting|December 2011|September 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01521715||91831|
NCT01514955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMRT / 25027|An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer|An Initial Feasibility Study to Integrate High-precision, Image Guided, Radiotherapy(MRI Based Brachytherapy and CT/MRI Fused Dynamic IMRT Planning) in the Treatment Planning of 10 Patients With Locally Advanced Carcinoma of the Cervix|IMRT|AHS Cancer Control Alberta|No|Withdrawn|November 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|70 Years|No|||January 2012|February 24, 2016|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01514955||92350|
NCT01515228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2011-11|Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)|Randomized Comparison of Dual Drug-Eluting Cilotax Stent and Everolimus -Eluting Stent Implantation for DE Novo Coronary Artery DisEase in Patients With DIABETES Mellitus||CardioVascular Research Foundation, Korea|Yes|Completed|January 2012|January 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|291|||Both|21 Years|74 Years|No|||January 2015|January 8, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515228||92329|
NCT01520597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 09068|National Study on Listeriosis and Listeria|Multicentric Observational NAtional Study on LISteriosis and ListeriA|MONALISA|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2009|April 2019|Anticipated|October 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1200|Samples With DNA|blood sample|Both|N/A|N/A|No|Non-Probability Sample|Case: patient with culture-proven listeriosis (blood CSF, fetal/placental sample, other…).        Controls: patient above the age of 18 years with medical background and clinical features        compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp >        38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile        symptom leading to empiric amoxicillin prescription.|July 2015|July 7, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01520597||91917|
NCT01520870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEINO 11|Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.|Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of PF299804, a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation||Grupo Español de Investigación en Neurooncología|No|Active, not recruiting|February 2012|October 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||June 2015|August 11, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01520870||91896|
NCT01510236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-CARE: TeenCan|Self-help Program Via Internet for Adolescents With Cancer|A Randomized Controlled Study of the Clinical Efficacy and Cost-effectiveness of a Self-help Program Via Internet on Psychosocial Function Among Adolescents With Cancer|U-CARE:TeenCan|Uppsala University||Withdrawn|January 2013|May 2018|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|13 Years|19 Years|No|||May 2015|May 27, 2015|January 4, 2012||No|a feasibility study showed low recruitment and adherence|No||https://clinicaltrials.gov/show/NCT01510236||92708|
NCT01510249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JKrukowska01|A Comparison of the Analgesic Efficacies of Ultrasound and Shock Wave Therapy in the Patients With Calcaneal Spur|A Comparison of the Analgesic Efficacies of Ultrasound and Shock Wave Therapy in the Patients With Calcaneal Spur||Medical Universtity of Lodz|Yes|Completed|January 2010|June 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|3|||Both|38 Years|86 Years|No|Probability Sample|The study was conducted on a group of 52 patients of both sexes, aged 38-86 years (mean        57.39; SD-11.5) with a plantar calcaneal spur confirmed by X-ray images. Patients were        treated in the Department of Physical Medicine and Rehabilitation Day Unit of the        University Hospital im. WAM - Central Veterans Hospital in Lodz and Municipal Health        Clinic of Andrespol. In order to compare the effectiveness of the two forms of        physiotherapy, ultrasound and radial shock wave therapy, the patients were randomly        assigned (using a simple randomization) into two groups:          -  Group 1 - ultrasound therapy group: 22 patients aged 38-86 years (mean 58.64;             SD-12.99),          -  Group 2 - radial shock wave group: 30 patients aged 40-71 years (mean 56.13;             SD-10.02).|January 2012|January 13, 2012|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01510249||92707|
NCT01510821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049331|Investigation of Endothelium in Saphenous Vein Grafts|A Prospective Trial to Investigate Endothelial Dysfunction in Saphenous Vein Grafts Subjected to the Maquet Vasoshield Pressure Limiting Syringe Versus Non-Regulated Vessel Dilation in Patients Undergoing Coronary Artery Bypass Grafting||Emory University|Yes|Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|21 Years|90 Years|No|||September 2013|September 30, 2013|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01510821||92664|
NCT01511367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLT3506|Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients|A Double-blind, Double Dummy, Randomised, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Flutiform pMDI With Fluticasone pMDI and With Seretide pMDI in Paediatric Subjects Aged 5 to Less Than 12 Years With Moderate to Severe Persistent Reversible Asthma||Mundipharma Research Limited||Completed|March 2012|November 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|498|||Both|5 Years|12 Years|No|||February 2014|February 13, 2014|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01511367||92623|
NCT01518803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGL2011-23810|A Mediterranean-style Breakfast and Postprandial Lipid Disorders in Obese Pre-adolescents and Adults|Influence of a Mediterranean-style Breakfast on Postprandial Lipid Disorders and Inflammatory Processes in Obese Pre-adolescents and Adults||National Research Council, Spain|No|Active, not recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|48|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||October 2015|October 6, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01518803||92055|
NCT01519440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aşıcıoğlu-01|Randomized Comparison of Sharp Versus Blunt Techniques at Cesarean|Unintended Extension of the Lower Segment Uterine Incision at Cesarean Delivery;A Randomized Comparison of Sharp Versus Blunt Techniques||Istanbul Bakirkoy Maternity and Children Diseases Hospital||Completed|March 2011|February 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|1076|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|elective cesarean delivery cases|October 2012|October 21, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519440||92006|
NCT01519453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-107223|Reducing Asthma Morbidity In High Risk Minority Preschool Children|Reducing Asthma Morbidity In High Risk Minority Preschool Children|ABC-HS|Johns Hopkins University|Yes|Recruiting|September 2011|July 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|406|||Both|2 Years|6 Years|No|||September 2015|September 17, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519453||92005|
NCT01519739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-043-EU-MG|Clinical Evaluation of Mediguide System in Cardiac Resynchronization Therapy (CRT) Implants|Clinical Evaluation of Mediguide System in CRT Implants||St. Jude Medical|No|Completed|January 2012|November 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01519739||91983|
NCT01520545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNS-GAB101US|Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump|Study to Assess the Safety of 3 mg/mL Gablofen® (Baclofen Injection) Delivered by Intrathecal Administration Using the Synchromed® II Programmable Infusion System||Mallinckrodt|No|Active, not recruiting|January 2013|October 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|4 Years|N/A|No|||December 2015|December 1, 2015|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01520545||91921|
NCT01520324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-17-01/04|Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy|Intraepithelial Neoplasia Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Patients With Long Standing Ulcerative Colitis Undergoing Colonoscopy.||Cosmo Technologies Ltd|Yes|Completed|January 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|Samples Without DNA|mucosal biopsy|Both|18 Years|N/A|No|Non-Probability Sample|Patients with long standing ulcerative colitis undergoing colonoscopy|January 2014|January 27, 2014|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520324||91938|
NCT01520519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0785|Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients|A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2012|||February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01520519||91923|
NCT01521195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000017147|Oxygen Consumption In Critically Ill Children|A Pilot Study of the Relationship Between Oxygen Delivery and Consumption During Extracorporeal Membrane Oxygenation.||The Hospital for Sick Children|No|Recruiting|October 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|N/A|18 Years|No|||August 2013|August 15, 2013|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01521195||91871|
NCT01521442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01540|Mindful Yoga Therapy as an Adjunctive Treatment for PTSD Among OEF/OIF Veterans|Mindful Yoga Therapy as an Adjunctive Treatment for PTSD Among OEF/OIF Veterans: A Pilot Study||VA Connecticut Healthcare System|No|Withdrawn|April 2013|November 2015|Anticipated|September 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|45 Years|No|||December 2014|December 18, 2014|January 19, 2012||No|Did not have funding or resources to carry out study|No||https://clinicaltrials.gov/show/NCT01521442||91852|
NCT01521156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU312|Effect of the Consumption of a Fermented Dairy Product Enriched With Plant Sterols|Cholesterol Lowering Effects of a Drinkable Low Fat Dairy Product Enriched With Plant Sterols||Danone Research|No|Completed|July 2009|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Basic Science|2||||||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521156||91874|
NCT01521455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-FTOL-101|Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients|A Phase I, Randomized, Open, Multi-center, Cross Over Study to Evaluate the Therapeutic Equivalence of Repeated Dose of HCP0910 250/50 μg to SeretideTM 250 DiskusTM in Asthmatic Patients||Hanmi Pharmaceutical Company Limited|No|Completed|February 2012|July 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|20 Years|75 Years|No|||August 2013|August 22, 2013|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521455||91851|
NCT01519778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-126|A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study|Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients||Trius Therapeutics LLC|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|200|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|January 24, 2012|Yes|Yes||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01519778||91980|
NCT01519791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0055 Period 1|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis|C-early|UCB Pharma|No|Completed|January 2012|September 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|880|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|January 19, 2012|Yes|Yes||No|July 8, 2015|https://clinicaltrials.gov/show/NCT01519791||91979|
NCT01514136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP216|An Investigation of Ostomy Devices|CP216: An Exploratory Investigation of Convex Ostomy Devices||Coloplast A/S|No|Completed|September 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|32|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|January 10, 2012||No||No|January 19, 2015|https://clinicaltrials.gov/show/NCT01514136||92412|This was an exploratory investigation where the participating subjects had to test 8 different test products. A small number of subjects were analysed from two different populations (convex product/flat product users).
NCT01517828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8736|Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room|Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room.||University Hospital, Montpellier|Yes|Active, not recruiting|January 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|N/A|2 Hours|No|||December 2014|December 2, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01517828||92129|
NCT01514669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133719|Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer|Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer||University of Arkansas|No|Active, not recruiting|January 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|75|Samples With DNA|Tear Sample collection; serum sample collection|Male|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be selected from those outpatients followed in the Winthrop P.        Rockefeller Cancer Institute (located at the University of Arkansas for Medical Sciences).|February 2016|February 25, 2016|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514669||92372|
NCT01514682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11T-002|Anti-Inflammatory Treatment of Schizophrenia|Anti-Inflammatory Combination Therapy for the Treatment of Schizophrenia||University of Maryland|Yes|Recruiting|June 2012|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||December 2015|December 15, 2015|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514682||92371|
NCT01514968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP27947|A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers|A Drug-Drug Interaction Study Between Danoprevir/Low-dose Ritonavir and Cyclosporine, a Potent Inhibitor of OATP, in Healthy Subjects||Hoffmann-La Roche||Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514968||92349|
NCT01514981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080451|AMG 761 in Adults With Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 761 in Subjects With Asthma||Amgen|No|Terminated|December 2011|February 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|7|||Both|18 Years|60 Years|No|||April 2014|April 16, 2014|December 19, 2011|No|Yes|Administrative decision|No||https://clinicaltrials.gov/show/NCT01514981||92348|
NCT01515501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH2007p001577|Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)|Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)|EDGE|Massachusetts General Hospital|Yes|Recruiting|October 2007|July 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|10 Years|N/A|No|||September 2015|September 21, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01515501||92308|
NCT01515514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006327|Confocal Endomicroscopy for GI Neoplasia Study|Confocal Endomicroscopy for GI Neoplasia Study||Mayo Clinic|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 40 patients with polyps|May 2013|May 15, 2013|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01515514||92307|
NCT01515761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIIT1A|POsition of Leads in Advanced heaRt Failure: the POLAR Study|POsition of Leads in Advanced heaRt Failure: the POLAR Study - A 6 Month, Observational, Mult-centered, Blinded, Randomized Study to Determine if Lead Positioning in the Lateral Wall of LV in Patients Meeting Criteria for CRT Plays a Role in Determining Myocardial Function and Affect the Severity of Mitral Regurgitation|POLAR|Southern Arizona VA Health Care System|Yes|Recruiting|September 2010|||March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2012|January 23, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01515761||92288|
NCT01509976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVOCET|Triclosan, Triclocarban, and the Microbiota|Triclosan, Triclocarban, and the Microbiota||Stanford University|Yes|Recruiting|July 2011|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 12, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01509976||92728|
NCT01510548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM53|ADALISKIAS: Adalimumab for Acute Disc Prolapse|Adalimumab (Anti TNF Alfa) in the Management of Acute Lumbar Disc Prolapses - a One Year, Randomized, Placebo Controlled, Double Blind, Single Center Trial||Kuopio University Hospital|No|Active, not recruiting|March 2007|July 2014|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|75 Years|No|||October 2013|October 10, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01510548||92685|
NCT01510561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hPAM4-03|A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.|A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.||Immunomedics, Inc.|No|Active, not recruiting|March 2012|September 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2015|February 12, 2015|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510561||92684|
NCT01519752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXZC 1102|A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site, Study Comparing Oxiconazole Nitrate Cream 1% (Taro Pharmaceuticals,Inc) to Oxistat® (Oxiconazole Nitrate Cream) Cream 1% (PharmaDerma) in the Treatment of Tinea Pedis||Taro Pharmaceuticals USA|No|Completed|November 2011|November 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|661|||Both|12 Years|N/A|No|||January 2014|January 19, 2014|January 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01519752||91982|
NCT01520051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MATERIAL|Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations|The Efficacy of Mepolizumab Treatment on Rhinovirus Induced Asthma Exacerbations|MATERIAL|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|January 2012|March 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|48|||Both|18 Years|50 Years|No|||February 2012|February 6, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520051||91959|
NCT01520337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-17-01/05|Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy|Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy||Cosmo Technologies Ltd|Yes|Completed|January 2012|October 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|170|Samples Without DNA|mucosal biopsy|Both|18 Years|N/A|No|Non-Probability Sample|patients scheduled for screening or surveillance colonoscopy.|February 2014|February 10, 2014|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520337||91937|
NCT01520350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARI_1109|Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study|Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study||Douglas Mental Health University Institute|No|Terminated|February 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|No|||July 2014|July 28, 2014|January 25, 2012||No|recruitment issues|No||https://clinicaltrials.gov/show/NCT01520350||91936|
NCT01520558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNDO109-001|CNDO-109-AANK for AML in First Complete Remission (CR1)|A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)||Coronado Biosciences, Inc.|No|Recruiting|December 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|33|||Both|18 Years|N/A|No|||May 2015|May 5, 2015|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01520558||91920|
NCT01520805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-CPI-613-022|Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome|A Phase 2a Open-Label Clinical Trial Evaluating Efficacy & Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents||Cornerstone Pharmaceuticals, Inc.|No|Not yet recruiting|January 2016|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01520805||91901|
NCT01517815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8739|Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients|Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients||University Hospital, Montpellier|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2013|November 5, 2013|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01517815||92130|
NCT01518855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11518|Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension|Clinical Effect and Cost Effectiveness of Ca Antagonist in Combination With AII Receptor Antagonist in Patient With Essential Hypertension (PMS Study)||Bayer|No|Completed|March 2004|April 2005|Actual|April 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|514|||Both|20 Years|79 Years|No|||January 2012|January 24, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01518855||92051|
NCT01518868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|743E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||August 10, 2012|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518868||92050|
NCT01520584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-10|Supplement Intake in Infertile Men;the Effect on Sperm Parameters,Fertilization Rate and Embryo Quality|Vitamins ,Minerals and Amino Acids Supplement Intake in Infertile Men;the Effect on Sperm Parameters,Fertilization Rate and Embryo Quality. A Double Blind Randomized Controlled Trial||Hillel Yaffe Medical Center|No|Not yet recruiting|January 2012|January 2016|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|40|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2012|January 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01520584||91918|
NCT01520844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS CO21 CODEX|the ANRS CO21 " Extreme " Cohort (CODEX)|Multicentric Cohort of HIV Patient With Extrem Profil|CODEX|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|No|Recruiting|February 2012|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|18 Years|85 Years|No|||June 2015|August 10, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01520844||91898|
NCT01514110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAT006|Gastric Cancer RAD001 Study|Phase I/II Study of Paclitaxel / Carboplatin / RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach||Chinese University of Hong Kong|No|Active, not recruiting|January 2008|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01514110||92414|
NCT01514149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DM200-103|Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy||ConjuChem|No|Terminated|August 2011|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|74|||Both|18 Years|70 Years|No|||March 2012|March 8, 2012|October 20, 2011|Yes|Yes|Business decision|No||https://clinicaltrials.gov/show/NCT01514149||92411|
NCT01514656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS- 814676|CPR Training: Video Self-Instruction Kit or Video-Only|Hospital-based CPR Training for At-risk Family Members Using a Video-self Instruction Kit or Video-only||University of Pennsylvania|Yes|Active, not recruiting|November 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|October 7, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01514656||92373|
NCT01514695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.P. 11-3611|Fentanyl Use for Sedation in Esophagogastroduodenoscopy|Fentanyl Use for Sedation in Esophagogastroduodenoscopy (FUSE): a Phase 4, Randomized, Double-blind, Placebo-controlled Trial of Fentanyl Added to Midazolam Compared to Midazolam Alone for Sedation in Routine Upper Endoscopy|FUSE|St. Joseph's Healthcare Hamilton|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|65 Years|No|||January 2013|January 28, 2013|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514695||92370|
NCT01514708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU11T12P|The Safety and Immune Response to Influenza Vaccination in Pregnant Women|The Safety and Immune Response to Influenza Vaccination in Pregnant Women||Adimmune Corporation|No|Completed|November 2011|August 2012|Actual|June 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|46|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 27, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01514708||92369|
NCT01514994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-1486|Valvuloplasty Scoring Balloon Catheter First-in-Man Study|Treatment of Critical Aortic Valve Stenosis Using a Novel Valvuloplasty Scoring Balloon Catheter: a First-in-Man Study||Spectranetics Corporation|No|Active, not recruiting|March 2012|November 2015|Anticipated|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01514994||92347|
NCT01515007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD-3150-1201|Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Time to First Pulmonary Exacerbation, Safety and Efficacy of ARD-3150 (Dual Release Ciprofloxacin for Inhalation-DRCFI) Compared With Placebo in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis|ORBIT-3|Aradigm Corporation|No|Active, not recruiting|April 2014|September 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|255|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515007||92346|
NCT01515241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-001-CLIN-005|Exploratory Study of Plaque Regression|EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia|EXPRESS|Cerenis Therapeutics, SA|No|Completed|January 2012|May 2012|Actual|April 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515241||92328|
NCT01510262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3257547|Repeat Sexually Transmitted Infection (STI) Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk|Repeat STI Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk||University of Wisconsin, Milwaukee|No|Not yet recruiting|April 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01510262||92706|
NCT01510275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-02-2010|Combined Use of Respiratory Devices After Thoracic Surgery|Efficacy on Combined Use of Respiratory Devices RESPILIFT® and RESPIVOL® in Adult Cardio-thoracic Surgery Patients. Randomized-controlled Study||Villa Pineta Hospital|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|80 Years|No|||October 2012|October 25, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01510275||92705|
NCT01511120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/498|The Effect on Fluid Balance After Cardiac Surgery After Use of Two Different Priming Protocols|Ringer`s Acetat Versus Balanced Hydroxyethyl-starch as Primesolution in the Heart-lung Maschine During Cardio-pulmonary-bypass. Postoperatively Fluid Balance and Cardiac Function||Haukeland University Hospital|Yes|Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|80 Years|No|||August 2013|May 11, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01511120||92642|
NCT01511393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3965|An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)|Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry||United BioSource Corporation|Yes|Enrolling by invitation|January 2012|December 2027|Anticipated|December 2027|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6750|||Both|18 Years|N/A|No|Non-Probability Sample|People with medullary thyroid carcinoma invited by either written invitation from the        participating cancer registry or the diagnosing physician to participate in the study.|September 2015|September 1, 2015|November 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01511393||92621|
NCT01520363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FD-004247-01|Placebo Controlled Trial of Dextromethorphan in Rett Syndrome|Placebo Controlled Trial of Dextromethorphan in Rett Syndrome|PCTDMRTT|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Recruiting|March 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|1 Year|10 Years|No|||February 2016|February 24, 2016|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01520363||91935|
NCT01520376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPHA-EPOC|Anxiety and Depression in Patients Hospitalizes for an Acute Exacerbation of COPD|A Prospective Randomized Trial to Asses the Efficacy of an Early Psychiatric Counseling Compared to Usual Care in a Cohort of Patients Hospitalized for an Acute Exacerbation of COPD in Prevention of Re-exacerbation|ADPHA-EPOC|Fundacion Clinic per a la Recerca Biomédica|Yes|Completed|October 2011|April 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|169|||Both|40 Years|90 Years|No|||August 2015|August 11, 2015|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520376||91934|
NCT01522001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHARED REHAB|Shared Care Rehabilitation After Acute Coronary Syndrome|Shared Care Rehabilitation After Acute Coronary Syndrome|SHARED-REHAB|University of Aarhus|No|Completed|October 2011|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|212|||Both|18 Years|79 Years|No|||September 2012|May 28, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522001||91809|
NCT01519258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/20225-1 FAPESP|Mechanical Ventilation With Neurally-Adjusted Ventilatory Assist in Patients With ARDS|Performance of NAVA as Lung Protective Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome||University of Sao Paulo General Hospital|No|Recruiting|October 2012|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|90 Years|No|||September 2013|September 13, 2013|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01519258||92020|
NCT01519817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120056|Cancer Vaccine Targeting Brachyury Protein in Tumors|An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|100 Years|No|||April 2015|February 11, 2016|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01519817||91977|
NCT01520116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATS907-201|Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension|A Phase 1/2a Randomized, Investigator-masked, Placebo- and Active-controlled, Dose-ranging Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension||Altheos, Inc.|No|Active, not recruiting|January 2012|||December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|8||Anticipated|180|||Both|18 Years|N/A|No|||October 2012|October 30, 2012|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01520116||91954|
NCT01521208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEM-HVH-001|LUCAS Chest Compressor Versus Manual Chest Compression in Out-of-hospital Sudden Cardiac Arrest. LUCAT Trial|LUcas Continuous Chest Compressions in Out-of-hospital Cardiac Arrest Treatment. The LUCAT Trial|LUCAT|Sistema d’Emergències Mèdiques|No|Recruiting|January 2012|April 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||February 2012|February 3, 2012|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01521208||91870|
NCT01521468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33941.029.10|Comparison of Cardiac Imaging Techniques for Diagnosing Coronary Artery Disease|Prospective Comparison of Cardiac PET/CT, SPECT/CT Perfusion Imaging and CT Coronary Angiography With Invasive Coronary Angiography|PACIFIC|VU University Medical Center|Yes|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|210|Samples With DNA|Urine and whole blood.|Both|40 Years|N/A|No|Non-Probability Sample|Outpatient clinic of the VU University Medical Center hospital in Amsterdam.|December 2014|December 8, 2014|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01521468||91850|
NCT01518322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AER-040|Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms|An Observational, Multi-Center, Single-Visit Study to Assess the Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms||Aerocrine AB|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|235|||Both|7 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Any person visiting a primary care clinic.|June 2013|June 11, 2013|November 11, 2011||No||No|March 16, 2013|https://clinicaltrials.gov/show/NCT01518322||92091|Physicians were blinded to FeNO results during the study, therefore asthma diagnoses and ICS prescriptions were made without knowledge of FeNO results.
NCT01519492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12520000-010|A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci|A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci||Affinium Pharmaceuticals, Ltd|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|70 Years|No|||August 2012|August 3, 2012|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519492||92002|
NCT01514123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGX-100-1001|Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors|A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors||Circadian Technologies Ltd.|No|Active, not recruiting|January 2012|May 2016|Anticipated|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01514123||92413|
NCT01513824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SongHeart|Stress and Ischemic Heart Disease. The Effect of Bio Feedback Guided Stress Management on Life Quality Including Signs of Depression and Stress|Stress, Ongoing Self Monitoring and Ischemic Heart Disease Rehabilitation, a Randomized Controlled Trial (SongHeart)|SongHeart|Herlev Hospital|Yes|Completed|November 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|216|||Both|19 Years|75 Years|No|||February 2014|February 25, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513824||92434|
NCT01519297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP PE 2012|Preeclampsia: A Marker for Future Cardiovascular Risk in Women|Preeclampsia: A Marker for Future Cardiovascular Risk in Women||Brigham and Women's Hospital|Yes|Recruiting|May 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|150|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519297||92017|
NCT01514370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200136-549|Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a|ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)|CONTAIN|Merck KGaA||Active, not recruiting|April 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|No|||September 2015|September 28, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514370||92394|
NCT01514383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-009|Octylseal Surgical Adhesive in General Surgery|Evaluation of Octylseal as a Topical Surgical Skin Incision Adhesive in General Surgery: A Case Series||Medline Industries|No|Recruiting|January 2012|June 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01514383||92393|
NCT01519882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0919|Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease|A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease.|REFRESH-PD|UCB Pharma|No|Terminated|March 2012|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|January 24, 2012|Yes|Yes|Due to major recruitment issues, a decision was made to terminate this trial|No|December 10, 2013|https://clinicaltrials.gov/show/NCT01519882||91972|Despite many attempts by study sites to recruit subjects, only 1 subject was randomized by Oct 2012. The decision to terminate the study was taken in Nov 2012. The subject completed in Jan 2013.No planned efficacy/safety analyses were performed.
NCT01519895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1336|Effectiveness of Telephone Intervention for Colorectal Cancer Caregivers|Effectiveness of Telephone-based Intervention on Distress, Burden and Quality of Life of Chinese Caregivers of Colorectal Cancer Patients||Hospital Authority, Hong Kong|No|Completed|June 2011|December 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|140|||Both|18 Years|90 Years|No|||April 2015|April 14, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01519895||91971|
NCT01520181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEN5|Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment|||Meir Medical Center||Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|November 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01520181||91949|
NCT01515254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00399|The Feeding Dynamic Intervention: Self Regulation of Intake in Preschoolers|The Feeding Dynamic Intervention Study|FeeDIn|Nationwide Children's Hospital|Yes|Active, not recruiting|February 2012|July 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||July 2014|July 21, 2014|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515254||92327|
NCT01515800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000723653|S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer|S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|May 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|692|||Female|18 Years|120 Years|No|||October 2015|October 23, 2015|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01515800||92285|
NCT01510834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-04/JLS 0002|Computerized Tailored Intervention for Behavioral Sequelae of PTSD in Veterans|Computerized Tailored Intervention for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans|CTI-PTSD|VA Pacific Islands Health Care System|No|Completed|July 2011|October 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 2, 2013|October 7, 2011||No||No|March 5, 2013|https://clinicaltrials.gov/show/NCT01510834||92663|N.A.
NCT01511406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBT2011|Cognitive Behavioral Therapy for Patients With an Early Psychosis|Does Cognitive Behavioral Therapy Improve Depressive Symptoms and Self-Esteem in Patients With a First Episode Psychosis? A Randomized Controlled Study||Oslo University Hospital|No|Completed|January 2011|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|65 Years|No|||October 2014|October 22, 2014|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01511406||92620|
NCT01511419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-H7N3-01|Safety Trial of Live Attenuated Influenza (H7N3) Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine||PATH|Yes|Completed|April 2012|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01511419||92619|
NCT01521494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA1201|PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia|||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Anticipated|150|||Both|20 Years|N/A|No|||January 2012|November 29, 2012|January 26, 2012||||No||https://clinicaltrials.gov/show/NCT01521494||91848|
NCT01521728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00022650|Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)|Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)||Johns Hopkins University|Yes|Active, not recruiting|January 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|60|||Both|18 Years|80 Years|No|||August 2015|August 31, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01521728||91830|
NCT01520129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11110666|Pilot Study of Interpersonal and Social Rhythm Therapy for Subthreshold Bipolar|Pilot Study of Interpersonal and Social Rhythm Therapy for Subthreshold Bipolar||University of Pittsburgh|No|Completed|March 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01520129||91953|
NCT01520389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-151-01-01-01|Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment|A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors||Merrimack Pharmaceuticals||Completed|January 2012|January 2016|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|112|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|January 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520389||91933|
NCT01519518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|923|How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention|A Randomised Controlled Trial to Compare Unfractionated Heparin Versus Bivalirudin in the Treatment of Patients With a Clinical Diagnosis of ST-Segment Elevation Myocardial Infarction Events - For Planned Management With Primary PCI|HEAT-PPCI|Liverpool Heart and Chest Hospital NHS Foundation Trust|Yes|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1829|||Both|18 Years|N/A|No|||April 2015|April 24, 2015|January 24, 2012||No||No|April 7, 2015|https://clinicaltrials.gov/show/NCT01519518||92000|
NCT01520064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C12-001PLV|Post Market Registry Study of the AeriSeal System|Post Market Registry Study of the AeriSeal System||Aeris Therapeutics|No|Terminated|February 2012|November 2013|Actual|November 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|40 Years|N/A|No|Non-Probability Sample|Patients must have been or will be treated with the AeriSeal System|November 2013|November 13, 2013|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520064|2 Years|91958|
NCT01521702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEOPAC / IPC 2011-002|NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer|Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study|NEOPAC|Institut Paoli-Calmettes|No|Completed|December 2011|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01521702||91832|
NCT01521975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBeAg negative Roadmap|A Two-year Study of Telbivudine in HBeAg Negative Hepatitis|A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy|STEN|Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|September 2011|May 2014|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|18 Years|65 Years|No|||January 2012|January 30, 2012|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01521975||91811|
NCT01513811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk0906|Itopride as an Adjuvant for Bowel Preparation in Patients With Chronic Constipation is Effective|High Dose of Itopride: a Valid Adjuvant for Bowel Preparation in Patients With Chronic Constipation||Shanghai Jiao Tong University School of Medicine|No|Completed|February 2010|December 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|115|||Both|18 Years|75 Years|No|||April 2012|April 17, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513811||92435|
NCT01513837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEPARALAT-1010-PII|Rinitis y Sinusitis según la Gravedad Del Asma|PREVALENCIA, GRAVEDAD E IMPACTO DE LA RINITIS Y DE LA SINUSITIS SEGÚN EL NIVEL DE GRAVEDAD Y CONTROL DEL ASMA (PROYECTO IRIS-ASMA)|IRIS-ASMA|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||Completed|March 2011|September 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|450|||Both|18 Years|70 Years|No|Probability Sample|Hospitals in Spain and Latin America|September 2012|September 7, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513837||92433|
NCT01519037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011DR4219|Interaction Between a Calcimimetic Agent and the Renin Angiotensine Aldosterone System|Evaluation of the Interaction Between a Calcimimetic Agent (Cinacalcet) and the Renin Angiotensine Aldosterone System in Healthy Volunteers||Centre Hospitalier Universitaire Vaudois|Yes|Completed|January 2012|June 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519037||92037|
NCT01520194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEMFAM 421|The Psychosocial and Economic Burden of Genital Warts|The Psychosocial and Economic Burden of Genital Warts for Women Attending Six Reproductive Health Clinics in Brazil|GWburden|BEMFAM-Bem Estar Familiar|Yes|Not yet recruiting|January 2012|October 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|220|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Reproductive health clinics|January 2012|January 25, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520194||91948|
NCT01514396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-018|Skin Incision Adhesive in Pediatrics|Evaluation of Surgiseal as a Topical Emergency Department Skin Incision Adhesive in Pediatrics A Case Series||Medline Industries|No|Recruiting|December 2011|September 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514396||92392|
NCT01519583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC11018|WalkMore Walking Interventions for Overweight/Obese Postmenopausal Women|Title: Comparative Effectiveness of Pedometer-Based Walking Interventions: WalkMore||Pennington Biomedical Research Center|No|Active, not recruiting|May 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Female|45 Years|74 Years|No|||May 2015|May 4, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01519583||91995|
NCT01521000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/N-R10-2932B|The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient|The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient|L-Dex|Main Line Health|No|Recruiting|July 2010|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|No|||January 2012|January 25, 2012|February 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01521000||91886|
NCT01521325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-009-006|A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers|A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers||Morphotek|No|Completed|September 2011|November 2013|Actual|August 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|N/A|No|||December 2015|January 8, 2016|January 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01521325||91861|
NCT01520415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEPMU-01|Clinical Trial Examining the Short and Long-term Effect of Myofascial Trigger Points Injection in Low Back Pain Patients|A Prospective, Randomized, Double-blind, Clinical Trial of Trigger Point Injection Therapy for the Treatment of Myofascial Pain Syndrome||McGill University Health Center|No|Completed|January 2012|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||July 2013|July 26, 2013|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01520415||91931|
NCT01510860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URT-15/PBC|Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis|Double-blind, Double-dummy, Randomised, Crossover, Multicentre Phase IV Clinical Study Comparing the Effect of Ursofalk 500 mg Tablets od Versus Ursofalk 250 mg Capsules od on Liver Enzymes in the Treatment of Primary Biliary Cirrhosis||Dr. Falk Pharma GmbH|Yes|Completed|November 2008|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01510860||92661|
NCT01511133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114444|Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™|Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in the Stool of Infants Aged 6 to 12 Weeks Following Administration of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (444563)||GlaxoSmithKline||Completed|April 2010|June 2010|Actual|June 2010|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1|Samples With DNA|Serum and stool samples|Both|6 Weeks|12 Weeks|No|Probability Sample|Infants aged 6 to 12 weeks from 4 previously conducted clinical trials, who received 2 or        3 doses of either Rotarix™ or Placebo|January 2012|January 26, 2012|December 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01511133||92641|
NCT01511692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1589|Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes|A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo||Novo Nordisk A/S|No|Completed|November 2005|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|43|||Both|18 Years|65 Years|No|||January 2015|January 22, 2015|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511692||92598|
NCT01518088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT002|Effects of a Dietary Fiber on Fecal Microbiota and Metabolism|Effects of a Dietary Fiber on Human Gut Microbiota, Bioactive Metabolites and Blood Glucose Control||National Starch LLC|No|Not yet recruiting|February 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|20|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01518088||92109|
NCT01518920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701005|A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-04958242 In Subjects With Age-Related Sensorineural Hearing Loss||Pfizer|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|50 Years|75 Years|No|||April 2013|April 1, 2013|January 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01518920||92046|
NCT01518933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEG-SIL-LTX-02|Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of LEGALON SIL for the Treatment of HCV Recurrence in Stable Liver Transplanted Patients|LEG-SIL-LTX-02|Rottapharm|No|Terminated|August 2011|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|No|||March 2015|March 4, 2015|January 23, 2012||No|when a blind review highlighted that at least 43% of patients had a virological response|No||https://clinicaltrials.gov/show/NCT01518933||92045|
NCT01518946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD426-406|Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension|A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension||Shire|Yes|Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||July 2014|October 10, 2014|January 18, 2012|Yes|Yes||No|July 3, 2014|https://clinicaltrials.gov/show/NCT01518946||92044|
NCT01519765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB#11-002056|Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor|Buccal Versus Vaginal Misoprostol for the Third Trimester Induction of Labor||University of California, Los Angeles|Yes|Terminated|July 2011|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Female|18 Years|50 Years|No|||May 2015|May 26, 2015|January 5, 2012|Yes|Yes|Poor Enrollment|No||https://clinicaltrials.gov/show/NCT01519765||91981|
NCT01520831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1086|Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects|A Randomised, Four-period Cross-over Trial in Healthy Subjects, Investigating the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 50, Biphasic Insulin Aspart 70 and Soluble Insulin Aspart||Novo Nordisk A/S|No|Completed|April 1999|May 2000|Actual|May 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|35|||Both|18 Years|40 Years|No|||June 2014|June 23, 2014|January 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520831||91899|
NCT01517334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-P-5266-M|Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)|Multi-Center Phase 3 Trial of Minocycline HCl 1 mg Microspheres for the Use in Subjects With Peri-Implantitis: Clinical and Microbiological Evaluations||OraPharma|No|Completed|May 2012|November 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|21 Years|N/A|No|||April 2014|August 25, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517334||92167|
NCT01518062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHTUR/BPD/5-13|Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome|Dose Response Trial of Biosynthetic Authentic Human Growth Hormone and Induction of Puberty With 17b Oestradiol in Girls With Turner's Syndrome||Novo Nordisk A/S|No|Completed|November 1989|November 2003|Actual|September 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|65|||Female|2 Years|11 Years|No|||July 2012|July 10, 2012|January 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01518062||92111|
NCT01518582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#0802|GRANVIA®-C Cervical Disc Prosthesis Multicenter European Pilot Study|The GRANVIA®-C Cervical Disc Prosthesis to Treat Symptomatic Degenerative Disc Diseases||Medicrea International|No|Active, not recruiting|August 2012|April 2016|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|21 Years|55 Years|No|Non-Probability Sample|People with Cervicobrachial neuralgia due to symptomatic cervical discopathy|November 2014|November 18, 2014|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01518582||92072|
NCT01518595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Fuhrmann|Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis|Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis - a Prospective Double Blind Randomized Controlled Clinical Study||Medical University of Vienna||Recruiting|October 2011|||October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01518595||92071|
NCT01513551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V114-002|A Study to Compare the Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in Healthy Volunteers (V114-002)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older||Merck Sharp & Dohme Corp.|Yes|Completed|March 2012|February 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|692|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 26, 2015|December 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513551||92455|
NCT01519050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK ZH 2011- 0274|Predictors of Postoperative Left Ventricular Function in Patients Undergoing Mitral Valve Repair for Severe Degenerative Mitral Regurgitation|||University of Zurich||Recruiting|November 2011|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Probability Sample|100 patients with mitral valve proplapse ondergoing mitral valve repair for severe mitral        regurgitation|January 2012|January 25, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519050||92036|
NCT01519908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTMM-COHFAR-MARC|Markers and Response to Cardiac Resynchronization Therapy|Markers and Response to Cardiac Resynchronization Therapy|MARC|University Medical Center Groningen|Yes|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|240|Samples With DNA|Whole blood, serum, plasma|Both|18 Years|N/A|No|Non-Probability Sample|The study group to be recruited will consist of symptomatic heart failure patients (NYHA        II-III), male and female, with a reduced left ventricular ejection fraction and        ventricular dyssynchrony as measured prior to implantation of a cardiac resynchronization        therapy device (CRT-D). Each study subject receives a CRT-Daccording to the current        ESC/AHA guidelines.|November 2015|November 30, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519908||91970|
NCT01520454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000370|Effect of Increased Free Fatty Acids on Leptin Function|Lipotoxicity and Leptin Signaling||Beth Israel Deaconess Medical Center|No|Active, not recruiting|November 2011|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01520454||91928|
NCT01520428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ÖNB13686|Interventions to Prevent Adolescents With Type 1 Diabetes From Long-term Complications|Interventions to Prevent Adolescents With Type 1 Diabetes From Long-term Complications. A Multicenter Randomized Controlled Trial||Medical University of Vienna|Yes|Active, not recruiting|June 2010|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|120|||Both|13 Years|20 Years|No|||September 2012|September 26, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01520428||91930|
NCT01521013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CHSM-11-030|Effectiveness of a Self-care Intervention for Depression in Primary Care Patients With Chronic Physical Illnesses|Effectiveness of a Supported Self-Care Intervention for Depression Compared to an Unsupported Intervention in Older Adults With Chronic Physical Illnesses (DIRECT-sc)|DIRECT-sc|McGill University||Completed|February 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|223|||Both|40 Years|N/A|No|||April 2015|April 7, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01521013||91885|
NCT01521026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NARSAD Young Investigator|Cognitive Training for Patients With Schizophrenia|Cognitive Training for Patients With Schizophrenia||University of California, San Diego|Yes|Completed|September 2003|August 2009|Actual|August 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||November 2013|November 15, 2013|January 22, 2012||No||No|July 1, 2013|https://clinicaltrials.gov/show/NCT01521026||91884|small sample sizerelatively short follow-up periodsignificant dropout ratedid not use an active control condition that matched CCT for therapist time or group involvement
NCT01521559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFTe-RVO-1027|Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)|A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion|VIBRANT|Regeneron Pharmaceuticals|No|Completed|April 2012|March 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|18 Years|N/A|No|||November 2014|November 5, 2014|January 26, 2012|Yes|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01521559||91843|
NCT01521585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S015-002|A Phase II Safety and Tolerability Study With SEN0014196|A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196||Siena Biotech S.p.A.|No|Completed|November 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|144|||Both|30 Years|70 Years|No|||November 2015|November 24, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521585||91841|
NCT01511432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-950-025|A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects|A Two-Part, Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of 3 Novel Oral Formulations of Telaprevir Relative to Incivek 375-mg Tablets When Administered as a Single 1125-mg Dose to Healthy Subjects||Vertex Pharmaceuticals Incorporated|No|Completed|January 2012|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511432||92618|
NCT01511731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|981325|Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions|Open-label, Randomized, 2-way Crossover Study to Compare the Bioavailability of Reddy Cheminor and Merck &Co, Pepcid Famotidine Tablets 40 mg Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|October 1998|October 1998|Actual|October 1998|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511731||92595|
NCT01512004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEES-MIC|Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder|Phase III Study of Propiverine Hydrochloride Extended-Release Capsule in the Treatment of Overactive Bladder (OAB) in Chinese Population With Urgent Micturition, Frequent Micturition and/or Urge Urinary Incontinence||Lee's Pharmaceutical Limited|Yes|Completed|January 2010|August 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|324|||Both|18 Years|65 Years|No|||January 2012|January 24, 2012|November 24, 2010||No||No||https://clinicaltrials.gov/show/NCT01512004||92574|
NCT01518621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RadEr|Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer|Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer|RadEr|Oslo University Hospital|No|Recruiting|May 2012|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|100 Years|No|||December 2015|December 9, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01518621||92069|
NCT01519479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3601-2|Palliative Care for Heart Failure Patients|An Examination of Palliative Care as Standard Practice for Heart Failure Patients||Abbott Northwestern Hospital|No|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|232|||Both|18 Years|N/A|No|||February 2015|March 27, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01519479||92003|
NCT01520571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Computer Assistance TKA|Do We Need Computer Assistance To Improve the Survival of Primary Total Knee Arthroplasty. A Minimum Ten Years Follow-up|||Ewha Womans University|No|Completed|January 2000|December 2011|Actual|December 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|520|||Both|49 Years|88 Years|No|||January 2012|January 25, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01520571||91919|
NCT01520818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1075|Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes|A Multinational, Randomised, Open-labelled, Parallel Group Four Months Comparison of Twice Daily Biphasic Human Insulin 30 and Thrice Daily Biphasic Insulin Aspart 50 and 70 in Subjects With Type 1 or Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 2000|April 2001|Actual|April 2001|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|666|||Both|18 Years|N/A|No|||January 2012|January 27, 2012|January 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520818||91900|
NCT01516879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110109|Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study|A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects|DESCARTES|Amgen|Yes|Completed|January 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|905|||Both|18 Years|80 Years|No|||August 2015|August 28, 2015|January 18, 2012|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01516879||92202|
NCT01517581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLA-Gilsanz-BAT/WAT|Brown Fat Activity and White Fat Accumulation|Study on the Association Between Brown Adipose Tissue Activation and White Adipose Tissue Accumulation in Successfully Treated Pediatric Malignancy||Children's Hospital Los Angeles|No|Completed|October 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|32|||Both|6 Years|18 Years|No|Non-Probability Sample|Pediatric patients with a history of malignancy such that they are required to undergo        PET/CT exams.|January 2012|January 24, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517581||92148|
NCT01517594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000026|Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis|Tolerability of Pentasa® Sachet in Patients With Ulcerative Colitis Under Conditions of Standard Practice in the Czech Republic||Ferring Pharmaceuticals|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|568|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|October 2013|October 18, 2013|January 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517594||92147|
NCT01513538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TherapyGuide|Analysis of the Acceptance and Changes to Parameters Programming Suggested by the TherapyGuide Function|TherapyGuide : Analysis of the Acceptance and Changes to Parameters Programming Suggested by the TherapyGuide Function||Medtronic Bakken Research Center|No|Completed|May 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|700|||Both|18 Years|N/A|No|Non-Probability Sample|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function|December 2013|December 23, 2013|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01513538||92456|
NCT01517607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000027|Mesalazine (PENTASA®) in Ulcerative Colitis|Mesalazine (PENTASA®) in Ulcerative Colitis: Correlation of the Information Level With Patient's Compliance in Everyday Practice|MUKOSA|Ferring Pharmaceuticals|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|506|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care facilities|September 2015|September 30, 2015|January 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517607||92146|
NCT01513564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-07-008-RAS|Multimodal Perioperative Pain Management|Multimodal Perioperative Pain Management of Circumferential Lumbar Fusion Improves Recovery||Northern Orthopaedic Division, Denmark|No|Completed|January 2001|June 2006|Actual|December 2003|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|120|||Both|18 Years|70 Years|No|||May 2015|May 27, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01513564||92454|
NCT01519921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML18495|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.|An Open Label Phase IV Multicenter Study for Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Patients With HBeAg Positive Chronic Hepatitis B||Hoffmann-La Roche||Completed|October 2005|June 2008|Actual|June 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|65 Years|No|||January 2016|January 25, 2016|January 5, 2012||No||No|December 17, 2015|https://clinicaltrials.gov/show/NCT01519921||91969|
NCT01520207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01520207|Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension|Pilot Study of Intravenous Mannitol During Hemodialysis Initiation to Reduce the Occurrence of Intra-dialytic Hypotension.||Brigham and Women's Hospital|No|Active, not recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|70|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520207||91947|
NCT01520688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC#5255|Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth|A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma||West Penn Allegheny Health System|Yes|Recruiting|February 2012|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|60|||Both|6 Years|11 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01520688||91910|
NCT01520701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPAC|Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy|Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy|IPAC|Centre Francois Baclesse|No|Recruiting|February 2012|September 2021|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2012|September 15, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01520701||91909|
NCT01521039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11002|Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease|Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are receiving allogeneic stem cell transplantation at the Ohio State        University are eligible and will be consented for the study.|October 2015|October 7, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01521039||91883|
NCT01521052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-0001-11|Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for Treatment of Major Depressive Episode in the Elderly|||Shalvata Mental Health Center|Yes|Not yet recruiting|January 2012|||December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|68 Years|N/A|No|||January 2012|January 27, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01521052||91882|
NCT01520662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wellness Portal Study|Impact of a Wellness Portal on The Delivery of Patient-Centered Preventive Care|Impact of a Wellness Portal on The Delivery of Patient-Centered Preventive Care||Agency for Healthcare Research and Quality (AHRQ)|Yes|Completed|September 2007|August 2010|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|540|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2012|January 26, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01520662||91912|
NCT01520675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IESC/T-187/2010|Endoscopic Versus Surgical Treatment of Chronic Pancreatitis|Endoscopic Versus Surgical Treatment of Chronic Pancreatitis - A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|July 2010|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|70 Years|No|||July 2013|July 10, 2013|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01520675||91911|
NCT01521845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-1-94-8048|Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)|Phase 3 Study of Poly Unsaturated Fatty Acids of Omega 3 as an Anti Platelet Agent on Biomarkers of Cardiac Necrosis Including CKMB and Troponin I and Inflammation Marker CRP||hahid Beheshti University of Medical Sciences|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|80 Years|No|||December 2012|December 6, 2012|January 19, 2012||No||No|May 31, 2012|https://clinicaltrials.gov/show/NCT01521845||91821|
NCT01521858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B_1111_140_103|THRA_hematologic Variables|Relations Between Hematologic Variables and Postoperative Bleeding in Total Hip Replacement Arthroplasty||Seoul National University Bundang Hospital|No|Completed|January 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|73|||Both|20 Years|80 Years|No|Non-Probability Sample|patients diagosed with avascular necrosis of hip and undergoing total hip replacement        arthroplasty|August 2013|August 28, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01521858||91820|
NCT01511445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amedica 2010-1|Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome|Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome; a Blinded Randomised Trial of Cancellous Structured Ceramic (CSC) Versus PEEK Cages.|CASCADE|Amedica Corporation|Yes|Active, not recruiting|December 2011|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||March 2014|March 27, 2014|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511445||92617|
NCT01511744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hualanbio-influenza IV-001|Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine|A Randomised, Controlled Phase IV Clinical Trial With an Inactivated Influenza Vaccine(Split Virion)||Hualan Biological Engineering, Inc.|Yes|Completed|November 2011|March 2012|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|6000|||Both|3 Years|N/A|Accepts Healthy Volunteers|||March 2012|August 13, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01511744||92594|
NCT01516060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Encore1-NC|The Neurocognitive Sub-study of Encore1|The Neurocognitive Sub Study of Encore1:A Randomised, Double‐Blind, Placebo‐Controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus 2N(t)RTI in Antiretroviral‐naïve HIV‐Infected Individuals Over 96 Weeks A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks||Kirby Institute|Yes|Completed|January 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Actual|71|||Both|16 Years|N/A|No|||September 2013|September 18, 2013|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516060||92265|
NCT01516073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-091|12-Week Study in Adult Subjects With Asthma|A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects With Partly Controlled and Uncontrolled Asthma||Dey|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|629|||Both|18 Years|60 Years|No|||November 2014|November 24, 2014|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516073||92264|
NCT01516385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-8822-ORK-CTIL|Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions.|||Sheba Medical Center|No|Not yet recruiting|January 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|75 Years|No|Non-Probability Sample|All patients attmited for neuro-rehabilitation with spinal cord injury, stroke or        Guillain-Barre syndrome|January 2012|January 26, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516385||92240|
NCT01516658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIBRAIN1119|HYdrogel Coil Versus Bare Platinum Coil in Recanalization Imaging Data Study|Efficacy of Hydrogel Coil on Endovascular Treatment for Intracranial Aneurysms; Multi-center, Prospective, Randomized, Open-label Blind-endpoint Trial|HYBRID|Kobe City General Hospital|Yes|Enrolling by invitation|February 2012|January 2014|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|20 Years|79 Years|No|||September 2012|September 5, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01516658||92219|
NCT01516892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTX-CM-10-001|A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine|||Allergan|No|Completed|December 2011|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|717|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516892||92201|
NCT01516905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO11310|PET/CT Imaging of Malignant Brain Tumors With 124I-NM404|PET/CT Imaging of Malignant Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue 124I-NM404||University of Wisconsin, Madison|Yes|Recruiting|December 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited when seen by oncologists in the UWCCC clinic.|February 2016|February 18, 2016|January 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01516905||92200|
NCT01517087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120060|Studying Motor Neuron Tests|Structural and Functional Brain Imaging Markers of Upper Motor Neuron Function||National Institutes of Health Clinical Center (CC)||Recruiting|January 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|45|||Both|35 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 8, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01517087||92186|
NCT01517347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPH IRB [2012] (09）|Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation|Low Dose of Interleukin-2 Following Allogeneic Unmanipulated Blood and Marrow Transplantation in Treating Patients With Standard Risk Hematologic Malignancy||Peking University People's Hospital|Yes|Suspended|January 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Both|15 Years|65 Years|No|||August 2015|August 4, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01517347||92166|
NCT01517620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|[2011]2-38|Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy|||Sun Yat-sen University|Yes|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|16 Years|65 Years|No|||December 2013|December 12, 2013|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01517620||92145|
NCT01514721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-171|Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy|Assessing the Efficacy and Tolerability of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Prior Prostaglandin Fixed Combination||Alcon Research|No|Terminated|June 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|January 18, 2012|No|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT01514721||92368|
NCT01514734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-191|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Brazil||Alcon Research|No|Terminated|March 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|January 18, 2012|No|Yes|Low recruitment rate|No|August 15, 2013|https://clinicaltrials.gov/show/NCT01514734||92367|
NCT01520220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14539|Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms|A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms||Eli Lilly and Company|No|Active, not recruiting|June 2012|April 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 20, 2015|January 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520220||91946|
NCT01520441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25362|BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)|H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol # 05-09-30-03)||The University of Texas Health Science Center, Houston|Yes|Withdrawn|March 2011|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Male|50 Years|N/A|No|||June 2015|June 1, 2015|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520441||91929|
NCT01520714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-067|Effect of Posture on Left Ventricular (LV) Transvenous Lead Capture Thresholds (EXPECT)|Effect of Posture on LV Transvenous Lead Capture Thresholds (EXPECT)|EXPECT|Baylor Research Institute|No|Terminated|December 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|11|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|February 22, 2010|Yes|Yes|Lower enrollment rate than expected|No|August 9, 2013|https://clinicaltrials.gov/show/NCT01520714||91908|Early termination leading to small numbers of subjects; Non-efficacy of treatment leading to no data summary and analysis.
NCT01521065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS002|An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|A Multicenter, Open-label Study to Evaluate the Clinical and Economic Benefits of Low Voltage Stereotactic Radiotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|ENDEAVOUR|Oraya Therapeutics, Inc.|Yes|Recruiting|September 2012|October 2016|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|50 Years|N/A|No|||April 2013|April 24, 2013|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01521065||91881|
NCT01521078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMH#152/2011|Web-based Personalized Feedback for University Students|Randomized Controlled Trial of a Brief Personalized Feedback Intervention in University Students||Centre for Addiction and Mental Health|No|Completed|January 2012|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|425|||Both|N/A|N/A|No|||May 2012|May 24, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521078||91880|
NCT01521338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F11120200|G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2)|G551D Observational Study (GOAL)-Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2)|GOAL- e2|University of Alabama at Birmingham|No|Recruiting|January 2014|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Blood, Sputum, Urine|Both|6 Years|N/A|No|Probability Sample|Patients with Cystic Fibrosis and the G551D, R117H and non-G551D gating Mutations ages 6        years old and older|February 2016|February 9, 2016|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01521338||91860|
NCT01521351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRcar|Natural History of Carotid Atherosclerosis|A Prospective Natural History Study of Carotid Atherosclerosis||University of Athens|No|Recruiting|January 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|700|||Both|30 Years|80 Years|No|Non-Probability Sample|Patients with coronary artery disease|May 2015|May 26, 2015|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01521351||91859|
NCT01521572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2927/2011|Effect of the Salbutamol on Mechanical Properties of Respiratory System|Effect of the Use of Salbutamol on the Mechanical Properties of the Respiratory System of Healthy Individuals, Smokers and COPD Patients||Rio de Janeiro State University|Yes|Recruiting|June 2011|September 2012|Anticipated|January 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|200|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 31, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521572||91842|
NCT01521598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKL11197C006|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Tolerability of SKL11197 for the Pain of Diabetic Peripheral Neuropathy||SK Life Science|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01521598||91840|
NCT01511458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD007|Non-invasive Chromosomal Examination of Trisomy Study|Non-invasive Chromosomal Examination of Trisomy|NEXT|Ariosa Diagnostics, Inc|Yes|Completed|March 2012|May 2014|Actual|November 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|18955|||Female|18 Years|60 Years|No|Non-Probability Sample|Pregnant women presenting for combined first trimester screening as part of routine        prenatal care|July 2014|July 11, 2014|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511458||92616|
NCT01511718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3874/06-07|Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Ondansetron Hydrochloride Tablets 8 mg With Zofran® (Containing Ondansetron Hydrochloride Dihydrate) Tablets 8 mg in Healthy, Adult, Human Subjects Under Fed Condition.||Dr. Reddy's Laboratories Limited|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2006|January 18, 2012|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511718||92596|
NCT01512043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/2/0285|Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD) Intervention With Device-guided Breathing Control in COPD||Lovisenberg Diakonale Hospital|Yes|Completed|July 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|150|||Both|30 Years|N/A|No|||May 2014|May 5, 2014|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01512043||92571|
NCT01513239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3415A-002|A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)|MODIFY II|Merck Sharp & Dohme Corp.|No|Completed|February 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1203|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513239||92479|
NCT01516086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191-092|A 12-Week Study in Adult Subjects With Asthma|A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects With Partly Controlled and Uncontrolled Asthma||Dey|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|498|||Both|18 Years|60 Years|No|||November 2014|November 24, 2014|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516086||92263|
NCT01516398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPD22044|Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia|Endothelin-1 (ET-1) and Brain Natriuretic Peptide (BNP) Levels as Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia (BPD)||Stanford University||Active, not recruiting|July 2011|June 2016|Anticipated|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|30 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|LPCH premature neonates|May 2015|May 20, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516398||92239|
NCT01516671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU-XX2011|Neuroinflammation and Bispectral Index After Subarachnoid Hemorrhage|Pilot Study on the Role of Neuroinflammation in the Pathophysiology of Subarachnoid Hemorrhage and the Value of the Bilateral Bispectral Index for Early Diagnosis of Cerebral Ischemia After Subarachnoid Hemorrhage.||Ludwig-Maximilians - University of Munich|No|Active, not recruiting|November 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples With DNA|Cerebrospinal fluid Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients after acute SAH admitted to neurosurgical ICU|November 2013|November 11, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01516671||92218|
NCT01517646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA11-003|Pilot Study of CoolTXT for Non-Invasive Fat Reduction|Pilot Study of CoolTXT for Non-Invasive Fat Reduction||Zeltiq Aesthetics|No|Completed|February 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|October 14, 2014|January 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517646||92143|
NCT01517659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA12-002|Non-Invasive Reduction of Fat in the Inner Thighs|Non-Invasive Reduction of Fat in the Inner Thighs With the Zeltiq Coolsculpting System||Zeltiq Aesthetics|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|October 14, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01517659||92142|
NCT01513577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-07-009-RAS|Percutaneous Minimal Invasive Pedicular Screw and Rod Insertion in Circumferential Lumbar Fusion|Percutaneous Minimal Invasive Pedicular Screw and Rod Insertion Reduces Hospital Stay and Morbidity Compared to Open Midline Approach in Circumferential Lumbar Fusion. A Randomized Study With 2 Years Follow-up||Northern Orthopaedic Division, Denmark|No|Completed|January 2003|June 2006|Actual|December 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01513577||92453|
NCT01517100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912018|The Role of Endocannabinoids in Insulin Production and Action|The Roles of Endocannabinoids in Insulin Secretion and Action||National Institutes of Health Clinical Center (CC)||Completed|January 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517100||92185|
NCT01513590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3940|A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes|A 26-week, Randomised, Open-label, Multinational, Treat-to-target Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) and BIAsp 30 BID Both With Metformin in Insulin naïve Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy or Metformin in Combination With One Additional Oral Antidiabetic Drug (OAD)|BOOST™|Novo Nordisk A/S|No|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|394|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|January 16, 2012|Yes|Yes||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01513590||92452|
NCT01517360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Promise # 0041|Pharmacological Approach to Improve the Outcome of Social Cognition Training|Pharmacological Approach to Improve the Outcome of Social Cognition Training||VA Greater Los Angeles Healthcare System|No|Completed|January 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Male|18 Years|55 Years|No|||March 2013|March 27, 2013|January 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517360||92165|
NCT01517633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300165-HMO-CTIL|Study of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine|Study of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine||Hadassah Medical Organization||Active, not recruiting|January 2012|||January 2013|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 24, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01517633||92144|
NCT01519596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97711|Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy|Minimizing Physical Function Decline in Older Adults Receiving Chemotherapy||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|October 2012|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|60 Years|N/A|No|||February 2015|February 24, 2015|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01519596||91994|
NCT01520233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL12B2|Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma|Genome Based Outcome Prediction in High Risk Neuroblastoma||Children's Oncology Group|No|Active, not recruiting|January 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Neuroblastoma patients treated at the University of Chicago, St. Jude Children's Research        Hospital, Children's Memorial Hospital, or Texas Children's Hospital.|May 2015|May 7, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01520233||91945|
NCT01520467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100129|Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome|Efficacy and Tolerance of Treatment With an Aromatase Inhibitor (Anastrozole) to Limit the Progression of Bone Maturation Related to Pathological Adrenarche in Children With Silver-Russell or Prader-Willi Syndrome|ANASILPRA|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|April 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|5 Years|12 Years|No|||January 2016|January 22, 2016|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520467||91927|
NCT01520740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-C11-004PLV|Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema|Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema|CV+/-|Aeris Therapeutics|No|Terminated|February 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|N/A|No|||November 2013|November 13, 2013|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01520740||91906|
NCT01520753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1074|Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes|A Randomised, Double-blind, 4-week, Crossover Trial on Two Treatment Regimens With Biphasic Insulin Aspart 70 and 50 in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|March 1999|June 1999|Actual|June 1999|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||January 2012|January 25, 2012|January 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520753||91905|
NCT01521091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjxhnk01|Comparison of Diagnostic Accuracy for Predicting Histology of Colorectal Lesions|Comparison of Diagnostic Accuracy for Predicting Histology of Colorectal Lesions Using Magnifying Colonoscopy With Narrow Band Imaging, Indigo Carmine, and Acetic Acid Staining||Shanghai Jiao Tong University School of Medicine|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|565|Samples Without DNA|All the lesions will be removed endoscopically or surgically and examine histologically by      an independent gastrointestinal pathologist.      Histological diagnosis is determined according to the World Health Organization (WHO)      criteria. Pedunculated lesions are categorized according to Haggitt's classification.|Both|18 Years|90 Years|No|Non-Probability Sample|consecutive adult patients undergoing colonoscopy and find out more than one lesion ≧ 6mm        from Jan 2009 to Dec 2010.|January 2012|January 27, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01521091||91879|
NCT01521104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjxhnk02|The Value of Narrow Band Imaging in Stratifying Patients for Endoscopic Resection or Surgery|The Value of NBI in Stratifying Patients for Endoscopic Resection or Surgery||Shanghai Jiao Tong University School of Medicine|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|565|Samples Without DNA|All the lesions will be removed endoscopically or surgically and examined histologically by      an independent gastrointestinal pathologist.      Histological diagnosis is determined according to the World Health Organization (WHO)      criteria.Pedunculated lesions are categorized according to Haggitt's classification.|Both|18 Years|90 Years|No|Non-Probability Sample|consecutive adult patients undergo colonoscopy and find out more than one lesion ≧ 6mm        from Jan 2009 to Dec 2010|January 2012|January 27, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01521104||91878|
NCT01521364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35534.042.11|Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients|The Pharmacokinetic Effect of Clarithromycin on the AUC0-12h of Linezolid in Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) Patients||University Medical Center Groningen|No|Completed|December 2011|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||May 2013|May 27, 2013|September 13, 2011||No||No|January 17, 2013|https://clinicaltrials.gov/show/NCT01521364||91858|
NCT01521377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114635|QTc Study GSK573719+GW642444|A Randomised, Placebo-controlled, Incomplete Block, Four Period Crossover , Repeat Dose Study to Evaluate the Effect of the Inhaled GSK573719/Vilanterol Combination and GSK573719 Monotherapy on Electrocardiographic Parameters, With Moxifloxacin as a Positive Control, in Healthy Subjects.||GlaxoSmithKline||Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 23, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521377||91857|
NCT01521624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-01-30-13350|Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients|Comparing Effects of Metformin Plus Life Style Modification Compared With Life Style Modification Alone in Lowering Parameters of Oxidative Stress in Newly Diagnosed Type 2 Diabetes Patients||Tehran University of Medical Sciences|No|Completed|October 2010|September 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|108|||Both|40 Years|N/A|No|||January 2012|January 28, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521624||91838|
NCT01511471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-9|Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis|Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis||University of Patras|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|90 Years|No|||February 2012|February 2, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01511471||92615|
NCT01509352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 01-003|Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication|Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication.||Children's Mercy Hospital Kansas City|No|Completed|February 2010|March 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|N/A|7 Years|No|||January 2016|January 18, 2016|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01509352||92775|
NCT01516684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01211|Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures|A Randomized, Double Blind Trial of Pediatric Lumbar Puncture Under Sedation/Total Intravenous Anesthesia (TIVA) With and Without EMLA Cream||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|January 2012|||February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|N/A|22 Years|No|||February 2016|February 10, 2016|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01516684||92217|
NCT01516918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-222-106|A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis|A Multicenter, Open-Label Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis||Vertex Pharmaceuticals Incorporated|Yes|Completed|February 2012|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|70 Years|No|||October 2014|October 9, 2014|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516918||92199|
NCT01517113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120019|Age-Related Changes in Body Composition|Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors||National Institutes of Health Clinical Center (CC)||Completed|January 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|350|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||November 2015|December 15, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01517113||92184|
NCT01517373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621002|Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate Safety And Efficacy Of PF-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin||Pfizer|Yes|Completed|February 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|305|||Both|18 Years|70 Years|No|||April 2014|April 21, 2014|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517373||92164|
NCT01518439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00879-32|Instrumental and Manual Increase of Couch in Neuromuscular Patients|Instrumental and Manual Increase of Couch in Neuromuscular Patients: Effects of Different Techniques on the Generated Flow|OPTICOUGH|Centre d'Investigation Clinique et Technologique 805|No|Completed|January 2012|July 2013|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||July 2013|July 18, 2013|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01518439||92083|
NCT01513850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hepabulin IV_LT_lll_2011|A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients|A 52-week, Multi-center, Open Label, Single Arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients||SK Chemicals Co.,Ltd.|No|Completed|October 2010|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|87|||Both|18 Years|64 Years|No|||May 2015|May 29, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513850||92432|
NCT01513863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTZG 1101|A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multi-Site Clinical Study to Compare the Bioequivalence of Two Metronidazole 1% Topical Gel Formulations in Patients With Moderate to Severe Rosacea|MTZG|Taro Pharmaceuticals USA|No|Completed|August 2011|September 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|602|||Both|18 Years|N/A|No|||December 2013|December 19, 2013|January 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01513863||92431|
NCT01514162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1003|Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve|Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve||St. Jude Medical|No|Completed|February 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|245|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects implanted with a Trifecta valve.|September 2015|September 9, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514162||92410|
NCT01519063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005006779|Naltrexone and Memantine Effects on Alcohol Drinking Behaviors|Glutamate-opioid Interactions in Alcohol Drinking Behaviors||Yale University|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|86|||Both|21 Years|55 Years|No|||January 2016|January 4, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519063||92035|
NCT01514409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24AQ1|Sub-chronic Effects of 5-hydroxytryptophan on Mood and Emotional Processing in Healthy Volunteers|Sub-chronic Effects of 5-hydroxytryptophan on Mood and Emotional Processing in Healthy Volunteers: A Randomised Trial||Northumbria University|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514409||92391|
NCT01519609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Randers-Moviprep|Trial Comparing Moviprep and Phosphoral as Bowel Prep Before Colonoscopy|Double Blind Randomised Trial Comparing Moviprep and Phosphoral as Bowel Prep Before||Randers Regional Hospital|No|Completed|September 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|400|||Both|18 Years|N/A|No|||November 2012|November 20, 2012|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01519609||91993|
NCT01519934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-120|A Retrospective Study to Evaluate the Effectiveness of the Ulthera System|Retrospective Evaluation of the Ulthera System for Lifting and Tightening of the Face and Neck||Ulthera, Inc|No|Completed|October 2011|August 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|48|||Both|25 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of males and females from the investigator's practice        between 25 and 85 years of age, who have received an Ultherapy™ treatment on or prior to        October 1, 2011, who had pre-treatment baseline photographs taken, and who have chosen to        participate in this clinical trial.|March 2014|March 19, 2014|November 7, 2011|Yes|Yes||No|December 30, 2013|https://clinicaltrials.gov/show/NCT01519934||91968|
NCT01520259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912020|Initial Study of Gallbladder Cancer in Chile|A Pilot Study of Gallbladder Cancer in Chile||National Institutes of Health Clinical Center (CC)||Completed|January 2012|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|446|||Both|18 Years|N/A|No|||August 2015|September 16, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01520259||91943|
NCT01520480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206/02|Pathological Subtrochanteric Fractures in 194 Patients|Pathological Subtrochanteric Fractures in 194 Patients. A Comparison of Outcome After Surgical Treatment of Pathological and Non-pathological Fractures.||Karolinska University Hospital|No|Completed|January 1999|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|281|||Both|15 Years|N/A|No|Non-Probability Sample|Patients with pathological subtrochanteric femur fractures.|January 2012|January 29, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520480||91926|
NCT01520727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-101|A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects|A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects||Bial - Portela C S.A.|No|Completed|October 2007|April 2009|Actual|December 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 29, 2014|January 18, 2012||No||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01520727||91907|
NCT01520766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC3-7.103|Prefabricated Endodontic Posts: Glass Fiber Versus Titanium - A Randomized Controlled Pilot- Trial|||Charite University, Berlin, Germany|No|Completed|January 2003|August 2011|Actual|April 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01520766||91904|
NCT01521117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU-7363|The Effect of Donepezil on Gait and Balance in Parkinson's Disease|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease||Oregon Health and Science University|Yes|Recruiting|December 2011|July 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Both|N/A|N/A|No|||January 2012|January 25, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01521117||91877|
NCT01521390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115487|Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.|Randomized, Double-blind, 5 Period Cross Over Study Assessing Lung Function in Healthy Volunteers Following Single Inhalations of GSK573719 Inhalation Powder From Two Configurations of the Novel Dry Powder Inhaler||GlaxoSmithKline|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|January 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01521390||91856|
NCT01521611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHMCAN0227|Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy|Radiolabelled Anti-CD66 Monoclonal Antibody in the Conditioning Regimen Prior to Haematopoietic Stem Cell Transplantation: Phase I Study in Patients With Poor-risk Disease.||University Hospital Southampton NHS Foundation Trust.|No|Recruiting|March 2002|December 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|75 Years|No|||February 2016|February 1, 2016|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521611||91839|
NCT01521637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMES2012|The Efficacy of Neuromuscular Electrical Stimulation to Attenuate Muscle Loss|The Efficacy of Neuromuscular Electrical Stimulation to Attenuate Skeletal Muscle Loss in ICU Patients||Hasselt University|No|Completed|January 2012|||April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|15|||Male|18 Years|80 Years|No|||August 2015|August 17, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01521637||91837|
NCT01521650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProAnest|Probiotics Against Pathogenic Bacteria in Connection With Anaesthesia|Probiotics for Reduction of Colonisation With Pathogenic Bacteria in the Oropharynx in Connection With Anaesthesia||Region Skane|No|Recruiting|January 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|102|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521650||91836|
NCT01511757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA01514|Bioavailability Study of Fluconazole Tablets 200 mg Under Fed Conditions|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Fluconazole Tablets 200 mg and PFIZER (DIFLUCAN) 200 MG in Healthy Males Under Fed Condition.||Dr. Reddy's Laboratories Limited|No|Completed|June 2002|July 2002|Actual|June 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511757||92593|
NCT01521767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6121196|Pharmacokinetics and Relative Bioavailability Study|A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules||Pfizer|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 26, 2012|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01521767||91827|
NCT01521780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-215|Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)|A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials||Merck Sharp & Dohme Corp.|No|Terminated|April 2012|November 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|December 16, 2011||No||No|August 14, 2013|https://clinicaltrials.gov/show/NCT01521780||91826|The study was terminated early.
NCT01522053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro000027409|Catheter-over-needle: Inpatient Study|Comparison of the Catheter-over-needle and Catheter-through-needle Methods for Continuous Delivery of Local Anesthetic During Peripheral Nerve Blockade||University of Alberta|No|Active, not recruiting|January 2012|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2014|December 17, 2014|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522053||91805|
NCT01517906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR005277|Developing Identity: An Eating Disorder Randomized Clinical Trial|Developing Identity: An Eating Disorder Nursing Therapy||University of Michigan|No|Completed|April 2002|December 2006|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|69|||Female|18 Years|35 Years|No|||January 2012|January 20, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01517906||92123|
NCT01518153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1104|Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)|Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation||M.D. Anderson Cancer Center|No|Terminated|February 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|No|||February 2016|February 18, 2016|January 23, 2012|Yes|Yes|Objectives not met.|No|January 22, 2016|https://clinicaltrials.gov/show/NCT01518153||92104|
NCT01518452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/532|Computerized Working Memory Training in Very-low-birth-weight Children at Preschool Age|Computerized Working Memory Training Evaluated With Clinical Assessments and Quantitative EEG in Very-low-birth-weight (VLBW) Children at Preschool Age||Norwegian University of Science and Technology|No|Completed|April 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|4 Years|6 Years|No|||February 2014|February 27, 2014|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01518452||92082|
NCT01518725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED11189|The Effect of Vitamin D Supplementation on Muscle Power in Elite Cyclist|The Effect of Vitamin D Supplementation on Muscle Power in Elite Cyclist||Oklahoma State University|Yes|Completed|January 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|103|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 27, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01518725||92061|
NCT01518673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/708|Low Dose Effects of X-rays in Pediatric Patients Undergoing a CT Examination.|National Study of Low Dose Effects of X-rays in Pediatric Patients Undergoing a CT Examination.|PedCTBe|University Ghent|No|Recruiting|February 2012|June 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Blood lymphocytes|Both|N/A|12 Years|No|Non-Probability Sample|Pediatric patients undergoing computed tomography are exposed to a relatively high dose of        X-rays.|December 2014|December 4, 2014|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01518673||92065|
NCT01518686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|217/2006 local review board|Age-related Normative Values for the Octopus 900 Perimeter|Normal Values for the Full Visual Field, Corrected for Age- and Reaction Time, Using Semi-automated Kinetic Testing on the Octopus 900 Perimeter|Norm-Oct900|University Hospital Tuebingen|No|Completed|June 2006|September 2008|Actual|March 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|86|||Both|11 Years|79 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01518686||92064|
NCT01518699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ha02-005|Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers|A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Male and Female Adult Subjects, Preceded by a Dose-Escalation Study to Determine the Supratherapeutic Dose of Ha44||Hatchtech Pty Ltd|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|81|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518699||92063|
NCT01519076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI_CS001|A Safety Evaluation of the Use of Magnetic-guided Iron Particles|A Feasibility Study: A Safety Evaluation of the Use of Magnetic-guided Iron Particles Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)||Pulse Therapeutics|Yes|Terminated|June 2012|July 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|80 Years|No|||December 2014|December 8, 2014|January 18, 2012||No|Sponsor Request|No||https://clinicaltrials.gov/show/NCT01519076||92034|
NCT01519310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-988|Gut Flora Dependent Metabolism of Dietary Phosphatidylcholine and Cardiovascular Disease|Gut Flora Dependent Metabolism of Dietary Phosphatidylcholine and Cardiovascular Disease|Glory|The Cleveland Clinic|No|Completed|April 2010|October 2014|Actual|October 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519310||92016|
NCT01519947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25754|A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis|Comparative Study to Assess the Effect of the Altitude on Dose Requirements of Methoxy Polyethylene Glycol-epoetin Beta to Correct Haemoglobin Levels in Chronic Renal Anemia in Pre-dialysis and Dialysis Patients||Hoffmann-La Roche||Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01519947||91967|
NCT01520272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912021|HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda|Immunogenicity of Bivalent HPV Vaccine Among Partially Vaccinated Young Adolescent Girls in Uganda||National Institutes of Health Clinical Center (CC)||Completed|January 2012|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|600|||Female|12 Years|20 Years|Accepts Healthy Volunteers|||August 2015|September 16, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01520272||91942|
NCT01520285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEES_Zanidip_1|Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension|A Multi-center, Randomized, Open-label, Parallel-group Clinical Study to Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for the Treatment of Patients With Mild-to-Moderate Hypertension|Zanidip|Lee's Pharmaceutical Limited|No|Completed|December 2011|August 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|281|||Both|18 Years|75 Years|No|||October 2014|October 14, 2014|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01520285||91941|
NCT01520493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Microcirculation_Local funds|Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension|Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension||Laval University|No|Recruiting|June 2011|December 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2013|April 16, 2013|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520493||91925|
NCT01520779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC recurrence after RFA|Recurrence of Hepatocellular Carcinoma|Risk Factors for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation||Ain Shams University|Yes|Completed|January 2012|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|99|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with hepatocellular carcinoma (HCC) who underwent radiofrequency ablation (RFA)        from 1/2006 till 12/2010in Tropical medicine department and hepatocellular carcinoma        clinic, Ain Shams university|September 2013|September 29, 2013|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01520779||91903|
NCT01521130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS065840-01|Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children|Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children|FIRST|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|144|||Both|5 Years|13 Years|Accepts Healthy Volunteers|||October 2012|February 3, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521130||91876|
NCT01521143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-004|Cvac as Maintenance Treatment in Patients With EOC in Complete Remission Following First-Line Chemotherapy or Second-Line Treatment|CANVAS: A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) in Second Remission|CANVAS|Prima BioMed Ltd|Yes|Terminated|January 2012|April 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|132|||Female|18 Years|N/A|No|||April 2015|April 1, 2015|January 17, 2012|Yes|Yes|Trial terminated per Sponsor direction not due to any safety signal but due to longer than    expected clinical & regulatory approvals & enrolment of patients.|No||https://clinicaltrials.gov/show/NCT01521143||91875|
NCT01521416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116313|Cost of Illness Associated With Influenza in the UK|The Cost of Illness Associated With Influenza in the UK||GlaxoSmithKline||Completed|June 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|||Both|5 Years|65 Years|No|Non-Probability Sample|All patients coded within the relevant database (GPRD and HES) as having acute respiratory        events that could be related to an infection between 2001 and 2009.|August 2013|August 29, 2013|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521416||91854|
NCT01521403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVMV-Blastocystis hominis|Is it Effective to Treat Patients With Blastocystis Hominis Infection?|Is it Effective to Treat Patients With Blastocystis Hominis Infection? A Double-blind Placebo Controlled Randomized Trial||University of Lausanne Hospitals|Yes|Recruiting|November 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01521403||91855|
NCT01521663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPX159-B11-02|Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)|A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of IPX159 in the Treatment of Moderate to Severe Restless Legs Syndrome (RLS)||IMPAX Laboratories, Inc.|No|Completed|November 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|70 Years|No|||September 2015|September 8, 2015|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01521663||91835|
NCT01517763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FPH-SA09-01|Comparison Study of the ICON™ Auto Series With and Without SensAwake™ and ThermoSmart™ and Conventional Continuous Positive Airway Pressure in Obstructive Sleep Apnea Patients|||Fisher and Paykel Healthcare|No|Terminated|January 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|70 Years|No|||September 2014|September 28, 2014|January 17, 2012|Yes|Yes|The site closed down, therefore the study has been terminated.|No||https://clinicaltrials.gov/show/NCT01517763||92134|
NCT01517776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIT-HGG-CilMetro|Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents|Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group -|HGG-CilMetro|Martin-Luther-Universität Halle-Wittenberg|Yes|Terminated|January 2012|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|3 Years|17 Years|No|||June 2015|June 26, 2015|January 11, 2012|Yes|Yes|due to an altered benefit/risk assessment.|No||https://clinicaltrials.gov/show/NCT01517776||92133|
NCT01512602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHP-DiaS-002|Efficacy of Dialectical Behavior Therapy Versus CAMS-informed Supportive Psychotherapy on Self Harming Behavior|Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.|DiaS|Mental Health Services in the Capital Region, Denmark|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|65 Years|No|||April 2015|April 25, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01512602||92528|
NCT01512901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01021104|Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)|A Randomized, Sham Controlled, Multicenter, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion||Santen Pharmaceutical Co., Ltd.||Completed||||||Phase 2/Phase 3|Interventional|N/A|3||||||Both|20 Years|N/A|No|||July 2014|July 17, 2014|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512901||92505|
NCT01509040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WASH CARDIAC|Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest|Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest||University of Washington|Yes|Completed|January 2012|June 2014|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|2|||Both|65 Years|N/A|No|||January 2012|November 6, 2014|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01509040||92799|
NCT01509053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-11-284|Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole|Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting, Europe, Canada and Asia|ARRIVE- EU|Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Terminated|January 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||February 2015|February 12, 2015|December 13, 2011|Yes|Yes||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01509053||92798|
NCT01522066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro000027421|Catheter-over Needle: Outpatient Study|Comparison of the Effectiveness of Single-shot Local Anesthetic Delivery Versus Double-shot Local Anesthetic Delivery Via a Perineural Catheter||University of Alberta|No|Active, not recruiting|January 2012|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|18 Years|80 Years|No|||December 2014|December 17, 2014|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522066||91804|
NCT01517919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRDA 90-0893|Peer-Led Self-Management Support in "Real World" Clinical and Community Settings|Peer-Led Self-Management Support in "Real World" Clinical and Community Settings||University of Michigan|No|Completed|January 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|241|||Both|21 Years|N/A|No|||September 2014|September 8, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01517919||92122|
NCT01518166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1608|Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH|A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential Influence on Intragastric pH||Novo Nordisk A/S|No|Completed|May 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01518166||92103|
NCT01518738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-2011-0123|Attention Training|Attention Training||University of Wisconsin, Madison|No|Completed|February 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|94|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 3, 2014|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01518738||92060|
NCT01519115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16841|Comparison of Outcomes Between Early Physical Therapy Intervention and Usual Care Following Anterior Cervical Fusion Surgery|A Comparison of Clinic Outcomes Between Early Physical Therapy Intervention and Usual Care in Individuals Following Anterior Cervical Fusion|ACF|Texas Woman's University|Yes|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|70 Years|No|||January 2015|January 9, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01519115||92031|
NCT01518712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100681|A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagl||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|December 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01518712||92062|
NCT01519089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921137|A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis|A Phase 3, Multi Site, Randomized, Double Blind Study Of The Long-term Safety, Tolerability And Efficacy Of 2 Oral Doses Of Cp 690,550 In Subjects With Moderate To Severe Plaque Psoriasis And/or Psoriatic Arthritis||Pfizer|Yes|Completed|March 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|20 Years|N/A|No|||August 2015|August 6, 2015|December 22, 2011|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01519089||92033|
NCT01519336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28089|A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers|A Study to Evaluate the Potential Drug-Drug Interaction Between Darunavir and Danoprevir When Administered Together With Low-Dose Ritonavir in Healthy Volunteers||Hoffmann-La Roche||Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519336||92014|
NCT01519349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCH-696110|Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis|Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis.||Nationwide Children's Hospital|Yes|Active, not recruiting|January 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|15|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519349||92013|
NCT01519323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NO25390|BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations|An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations||Hoffmann-La Roche||Recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|12 Years|17 Years|No|||February 2016|February 1, 2016|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519323||92015|
NCT01520246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B2|Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia|Signaling in Tumorigenesis and Immunity||Children's Oncology Group|No|Active, not recruiting|January 2012|||March 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|tissue, blood, and bodily fluids|Both|N/A|120 Years|No|Non-Probability Sample|Patients With T-Cell Acute Lymphoblastic Leukemia|May 2015|September 30, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01520246||91944|
NCT01519973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI Protocol #2008012-01H|Optimization of SPECT Imaging|Optimization of SPECT Cardiac Imaging Through Compensation for Attenuation, Resolution Loss and Scatter - The OSCARS|OSCARS|Ottawa Heart Institute Research Corporation|No|Terminated|August 2008|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|64|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|July 15, 2011||No|Recruitment base changed due to change in clinical acquisition procedures|No||https://clinicaltrials.gov/show/NCT01519973||91965|
NCT01520298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-52|Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients|Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients||Lancaster General Hospital|No|Withdrawn|December 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|65 Years|N/A|No|||September 2014|September 29, 2014|January 23, 2012|Yes|Yes|Difficulty in recruiting subjects for the trial.|No||https://clinicaltrials.gov/show/NCT01520298||91940|
NCT01520506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP 012|Rapid Renal Sympathetic Denervation for Resistant Hypertension|Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot™ Ablation System|RAPID|Medtronic Endovascular|No|Completed|May 2012|June 2014|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|85 Years|No|||August 2015|August 14, 2015|January 25, 2012||No||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01520506||91924|
NCT01518023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lessdiabetes|Long Term Diabetes Improvement After Cancer Gastrectomy and Colectomy|Long Term Diabetes Improvement After Cancer Gastrectomy and Colectomy||University of Sao Paulo|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|240|||Both|18 Years|N/A|No|Non-Probability Sample|Adult males and females submitted to elective curative operations will be enrolled|January 2012|January 24, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01518023||92114|
NCT01518257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-102|Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain|||Allergan|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|40 Years|75 Years|No|||July 2014|July 15, 2014|January 23, 2012|Yes|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01518257||92096|
NCT01518270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LTS-11-003|Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women|||Allergan|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|179|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Females|November 2012|November 9, 2012|January 23, 2012||No||No|November 9, 2012|https://clinicaltrials.gov/show/NCT01518270||92095|
NCT01518283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABASEM-SOGUG|Study of Weekly Cabazitaxel for Advanced Prostate Cancer|Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in "Unfit" Hormone-Refractory Patients Previously Treated With Docetaxel||Spanish Oncology Genito-Urinary Group|No|Active, not recruiting|May 2012|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Male|18 Years|N/A|No|||November 2015|November 16, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01518283||92094|
NCT01521676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-BIO/IPC 2009-005|Predictive Clinical and Biological Parameters in Breast Cancer|Research of Predictive Clinical and Biological Parameters in Breast Cancer|BC-BIO|Institut Paoli-Calmettes|No|Recruiting|December 2010|December 2026|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|750|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01521676||91834|
NCT01521923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0055 Period 2|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis|C-early|UCB Pharma|No|Completed|January 2012|September 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|880|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01521923||91815|
NCT01518816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABDO-0100|Role of Serum Total Antioxidant Level in Preterm Labor|the Role of Serum Total Antioxidant Level in Preterm Labor||Ain Shams Maternity Hospital|Yes|Recruiting|October 2011|May 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|None Retained|serum|Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|pregnant women attending the outpatient obstetric clinic and inpatient of Obstetrics and        Gynecology department or when they will be admitted to the delivary room of Ain Shams        university hospital.|January 2012|January 26, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01518816||92054|
NCT01518829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC and Procalcitonin|Procalcitonin in Hepatocellular Carcinoma|Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment||Ain Shams University|Yes|Completed|April 2012|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|42|Samples Without DNA|Serum|Both|18 Years|70 Years|No|Non-Probability Sample|inpatients in tropical medicine department and hepatocellular carcinoma out patient clinic        ain shams university|September 2013|September 29, 2013|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01518829||92053|
NCT01509378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH KEK-ZH-Nr. 2011-0001/4|4P Study: Predictive Quality With Painfree Therapies|4P Study: A Prospective Study on Predictive Quality Preferring PainFree Therapies|4P|Medtronic Bakken Research Center|Yes|Active, not recruiting|November 2011|March 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|ICD patients primary and secondary prevention according to guidelines|April 2015|April 28, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509378||92773|
NCT01509651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B126201112363|Sugammadex and Heart Failure|Reversal of Rocuronium-induced Neuromuscular Block With Sugammadex in Heart Failure Patients||Onze Lieve Vrouw Hospital|Yes|Completed|January 2012|April 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01509651||92752|
NCT01510184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-ZEV-11-301|Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy|A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy||Spectrum Pharmaceuticals, Inc|Yes|Terminated|April 2012|February 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|60 Years|N/A|No|||August 2014|March 17, 2015|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510184||92712|
NCT01517932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMU-A-201106|Effects of Dexmedetomidine on Stress Response and Postoperative Analgesia|Effects of Dexmedetomidine on Stress Response and Postoperative Analgesia in Patients Undergoing Thoracotomy During Anesthesia Recovery Period||Huazhong University of Science and Technology|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|No|||March 2013|March 18, 2013|January 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01517932||92121|
NCT01517945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-204|Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study|Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study||Memorial Sloan Kettering Cancer Center|Yes|Active, not recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|127|Samples Without DNA|salvia|Female|18 Years|N/A|No|Non-Probability Sample|Breast cancer survivors will be recruited to the study. There are no physical recruitment        sites outside of MSKCC. Participants may be patients who were treated at MSKCC or breast        cancer survivors who were treated elsewhere and learned about the study through an        advertisement. The study summary and research team contact information will be        available/advertised in the community through MSKCC Connections,MSKCC Survivorship Program        and the American Cancer Society website.|February 2016|February 4, 2016|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517945||92120|
NCT01518179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K-11-0131-CTIL|Compression Gloves for Distal Radius Fracture|The Effect of Wearing Made-to-Measure Compression Gloves on Rehabilitation Following DRF.||Clalit Health Services|No|Recruiting|April 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||January 2016|January 19, 2016|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01518179||92102|
NCT01518465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16M-11-1|Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma|A Phase 2 Study of Lenalidomide and Low-dose Dexamethasone in Combination With Dalteparin in Previously Untreated Multiple Myeloma||University of Southern California|Yes|Active, not recruiting|January 2012|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518465||92081|
NCT01519375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RSE-ATC-2011/1|Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)|Cross-sectional, Observational Real Life Study on NSAIDs Treated Patients With Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis: Assessment of Patient Adherence to PPI Treatment|CONVOY|AstraZeneca|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|102|||Both|18 Years|N/A|No|Non-Probability Sample|A total of 100 patients having Osteoarthritis (OA), Rheumatoid Arthritis (RA) and        Ankylosing Spondylitis (AS) selected from medical records at involved clinics. The        investigator will select the patients in order of date by latest visits to the clinic and        backwards. The patients will be selected from 4-6 involved primary care and and specialist        clinics.|May 2012|May 28, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519375||92011|
NCT01519102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS-02|Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting|An Open-label, Randomized Two-way, Cross-over Study to Compare Meal-and-carbohydrate-announcement Strategy Versus Meal-announcement Strategy During Closed-loop Regulation of Glucose Levels in a Morning Meal in Adults With Type-1 Diabetes.|CLASS02|Institut de Recherches Cliniques de Montreal|No|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||12|||Both|18 Years|65 Years|No|||December 2012|December 7, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519102||92032|
NCT01519362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhangduo|A Woman Suffered From Leukocytopenia and Widespread Migration After Polyacrylamide Hydrogel (PAAG) Injection in Epicranial Aponeurosis|||First Hospital of Jilin University|No|Completed|October 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1|||Female|50 Years|50 Years|No|Probability Sample|A 50-year-old lady had PAAG injected into her bilateral temporal epicranial aponeurosis        for augmentation|January 2012|January 25, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519362||92012|
NCT01519648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIFI|A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation|A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation||National Hematological Society, Russia|No|Completed|January 2012|March 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|808|||Both|1 Year|95 Years|No|Probability Sample|This observational study will be implemented in the hematology departments or hematology        centers with or without HSCT located throughout Russia.|July 2014|July 18, 2014|January 23, 2012||No||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01519648||91990|
NCT01519622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K202/2011|Impact of Disease on the Concept of End-of-life Decisions of the Elderly in the Community|||Meir Medical Center|Yes|Not yet recruiting|February 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|88|||Both|65 Years|N/A|No|Probability Sample|Community sample|January 2012|January 26, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01519622||91992|
NCT01519986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VITD_100484|The Effect of Fat on Vitamin D Absorption|The Effect of Fat on Vitamin D Absorption After a Single Oral Dose|VITD_100484|Federal University of Rio Grande do Sul|Yes|Completed|September 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|64|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01519986||91964|
NCT01519999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WISDM-106965|Colorectal Cancer Screening With Improved Shared Decision Making|Colorectal Cancer Screening With Improved Shared Decision Making (CRCS-WISDM)|CRCS-WISDM|Virginia Commonwealth University|No|Active, not recruiting|May 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|5842|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01519999||91963|
NCT01521429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906M68810|Longitudinal Study of Bone Disease in Children With Mucopolysaccharidoses (MPS) I, II, and VI|Longitudinal Study of Bone and Endocrine Disease in Children With MPS I, II, and VI: A Multicenter Study of the Lysosomal Disease Network.||Los Angeles Biomedical Research Institute|No|Recruiting|August 2009|September 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|50|Samples With DNA|Serum, plasma, white cells for DNA extraction, and urine will be retained.|Both|5 Years|35 Years|No|Non-Probability Sample|community sample|March 2016|March 9, 2016|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01521429||91853|
NCT01517789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/09|Advantage of Using Intraoperative Visual Evoked Potentials to Preserve Visual Function During Surgical Procedures Near the Optical Pathways|Advantage of Using Intraoperative Visual Evoked Potentials to Preserve Visual Function During Surgical Procedures Near the Optical Pathways|VISUOPEV|University Hospital, Bordeaux|No|Completed|January 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|13 Years|N/A|No|||March 2015|March 4, 2015|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517789||92132|
NCT01517802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100797|A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate|A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study||Janssen Research & Development, LLC|No|Active, not recruiting|March 2012|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|N/A|No|||March 2016|March 11, 2016|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517802||92131|
NCT01518036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHTUR/BPD/1|Use of Somatropin in Turner Syndrome|The Use of Norditropin® in Turner's Syndrome||Novo Nordisk A/S|No|Completed|September 1987|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Female|2 Years|11 Years|No|||July 2012|July 10, 2012|January 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01518036||92113|
NCT01518049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110029|Clinical Validation of the Rating Scale for Psychotic Depression (RAS-PD)|||Aarhus University Hospital|No|Completed|February 2012|September 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|inpatients or outpatients at Danish Psychiatric Hospitals fulfilling criteria for unipolar        depression with psychotic symptoms.|October 2015|October 12, 2015|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01518049||92112|
NCT01518569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160040|Ulinastatin's Anti-inflammatory Reaction in Cardiac Surgery|Effect of Ulinastatin on Postoperative Systemic Inflammatory Response in Cardiac Surgery|ulistin|Konkuk University Medical Center|Yes|Completed|March 2008|August 2008|Actual|June 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|26|||Both|25 Years|75 Years|No|||January 2012|January 25, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01518569||92073|
NCT01518842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Siqueira Research Center|Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy|Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy|RetinaCell|University of Sao Paulo|Yes|Recruiting|September 2011|January 2014|Anticipated|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||January 2014|January 12, 2014|January 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01518842||92052|
NCT01520142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100754|Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants|A Two-Part, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Subjects Employing the Intravenous Endotoxin-Induced Model of Acute Inflammation||Janssen Research & Development, LLC|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01520142||91952|
NCT01520155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sleffm001|CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)|CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE): Studie Zur Detektion Des kardiovaskulären Risikos in Patienten Mit Systemischem Lupus Erythematodes|CASTLE|Johann Wolfgang Goethe University Hospitals|No|Completed|December 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|90|Samples Without DNA|Every participant will provide 20 ml Serum for further laboratory analysis|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with or without systemic Lupus erythematosus|December 2013|December 20, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01520155||91951|
NCT01520168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UD 069/11|Composix Kugel Mesh Recall Leaves Unresolved Problems of Patient Management|The 2005 Composix Kugel Mesh Recall Leaves Unresolved Problems of Patient Management: Taking Stock After 5-year Follow up||University of Wuerzburg|No|Suspended|October 2003|March 2012|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|21|Samples Without DNA|Explanted meshes|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (>18 years) with the diagnosis of symptomatic incisional hernia.|March 2012|March 12, 2012|January 24, 2012||No|Because of the product recall 2005/2006.|No||https://clinicaltrials.gov/show/NCT01520168||91950|
NCT01518192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EM-DC|Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome|Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome.||University Medical Centre Ljubljana|No|Completed|June 2006|January 2009|Actual|November 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|544|||Both|15 Years|N/A|Accepts Healthy Volunteers|||December 2011|December 18, 2011|June 28, 2010||No||No|June 28, 2010|https://clinicaltrials.gov/show/NCT01518192||92101|Medical explanation besides Lyme disease of the symptoms in patients was based on history and physical examination, therefore some other medical explanations might have been missed. With regard to controls this was even more likely.
NCT01518478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ADRN-03|ADRN Influenza Vaccine Pilot|An Open Label Study in Adults With Atopic Dermatitis to Assess Variability in Immune Response to Fluzone® Intradermal Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|November 2011|March 2012|Actual|February 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|December 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01518478||92080|
NCT01518751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR. 2011-0077|Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease - Evolution|Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease - Evolution A Monocentric Study to Investigate the Development of Symptoms of Autonomic Dysregulation in Parkinson`s Disease||University of Zurich|Yes|Completed|December 2011|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|27|||Both|50 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects included in this trial must fulfil the he following criteria:          -  informed, written & formal consent for participation          -  male / female subjects, aged 50-70 years             18 PD patients          -  9 subjects Hoehn & Yahr stage 1, disease duration <4 years          -  9 subjects Hoehn & Yahr stage 2; disease duration 4-8 years             12 healthy control subjects          -  age- and gender-matched          -  without signs or history of neurological disorders          -  without significant systemic comorbidities (malignant / cardiovascular)|September 2015|September 29, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01518751||92059|
NCT01518764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37147.029.11|The Effects of Red Wine Polyphenols on Microvascular Dysfunction|The Effects of Red Wine Polyphenols on Microvascular Dysfunction||VU University Medical Center||Completed|May 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01518764||92058|
NCT01519388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00771-40|Evaluation of the Impact on Swallowing of Non Invasive Ventilation|Evaluation of Nasal Ventilation on Optimizing Swallowing in Ventilated Neuromuscular Patients|OPTIDEG|Centre d'Investigation Clinique et Technologique 805|No|Completed|February 2012|May 2013|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|N/A|No|||July 2013|July 9, 2013|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519388||92010|
NCT01519635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011DR3137|Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension|Effect of Aliskiren 300mg and Hydrochlorothiazide 25mg on Kidney Oxygenation in Patients With Stage 1 and 2 Hypertension: a BOLD-MRI Study||Centre Hospitalier Universitaire Vaudois|Yes|Recruiting|October 2011|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 27, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01519635||91991|
NCT01519401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000102010|Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.|Clinical Efficacy and Metabolic Impact of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Normal-weight Women With Polycystic Ovary Syndrome: a Randomized Study.||Catholic University of the Sacred Heart||Completed|February 2010|July 2011|Actual|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||||||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 23, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519401||92009|
NCT01519960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YV25718|A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B|A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B||Hoffmann-La Roche||Active, not recruiting|July 2012|August 2022|Anticipated|August 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|165|||Both|3 Years|17 Years|No|||March 2016|March 1, 2016|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519960||91966|
NCT01520012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH4808-102|Food Effect on Pharmacokinetics of YH4808 in Healthy Male Subjects|Clinical Trial to Investigate the Influence of Food on Safety/Tolerability and Pharmacokinetics of YH4808 After Oral Administration in Healthy Male Subjects||Yuhan Corporation|Yes|Completed|February 2012|June 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|44|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||May 2012|July 23, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01520012||91962|
NCT01520025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI Protocol #2011397-01H|Multi-modality Imaging of Ischemia With 18F-FDG PET and CTA|Direct Imaging of Ischemia With 18F-FDG PET Imaging Combined With Coronary Anatomy From CT Coronary Angiography||Ottawa Heart Institute Research Corporation|No|Terminated|December 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|July 15, 2011||No|Continued recruitment of study participants was not feasible|No||https://clinicaltrials.gov/show/NCT01520025||91961|
NCT01509209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-LCT-301|Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis|Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial||Hanmi Pharmaceutical Company Limited|No|Completed|May 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|12 Years|75 Years|No|||May 2013|May 22, 2013|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509209||92786|
NCT01509222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36582.081.11|Changing Dietary Patterns: an Individually Tailored Nutrition Intervention (OKE-study)|Changing Dietary Patterns: an Individually Tailored Nutrition Intervention||Wageningen University|No|Completed|September 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|186|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 24, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509222||92785|
NCT01509534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIMSI-001-2011|Guideline-based Pacing Therapy for Reflex Syncope|Guideline-based Pacing Therapy for Reflex Syncope|SUP2|Gruppo Italiano Multidisciplinare per lo Studio della Sincope|Yes|Completed|January 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|281|||Both|40 Years|N/A|No|Probability Sample|Patients affected by reflex syncopes|July 2015|July 27, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01509534||92761|
NCT01509781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRM-987/2011|Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study|Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study||National Institute of Oncology, Hungary|Yes|Recruiting|September 2011|||January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|400|||Female|N/A|75 Years|No|||October 2015|October 5, 2015|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01509781||92742|
NCT01509755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1310|Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes|Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm||Novo Nordisk A/S|No|Completed|October 2000|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|N/A|7||Anticipated|196|||Both|30 Years|75 Years|No|||March 2015|March 25, 2015|January 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01509755||92744|
NCT01509768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-SNB-088|Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)|An Observational Prospective Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)||Shire|No|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19|Samples With DNA|blood (plasma and serum), cerebrospinal fluid (CSF), urine|Both|1 Year|10 Years|No|Non-Probability Sample|Patients with a documented diagnosis of MPS IIIB and who are currently untreated with        investigational products (drugs/device) for this disease. Patient must also be ≥ 1 year        and < 10 years of age with an age equivalent on the Vineland Adaptive Behavior Scales        (VABS) of ≥ 1 year.|November 2014|November 24, 2014|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509768||92743|
NCT01510002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBN/501/ZKL/1447|Prophylactic Central Neck Dissection for Papillary Thyroid Cancer|Prophylactic Central Neck Dissection for Papillary Thyroid Cancer||Jagiellonian University|Yes|Completed|January 1993|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|640|||Both|18 Years|N/A|No|||January 2012|January 10, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01510002||92726|
NCT01510314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00904-37|Inflammatory Markers After COloRectal Surgery)|Comparison of C-reactive Protein and Procalcitonin to Detect Infectious Complications After Elective Colorectal Surgery|IMACORS|Centre Hospitalier Universitaire Dijon|Yes|Completed||||||N/A|Interventional|N/A|||||||Both|18 Years|N/A|No|||January 2013|June 2, 2014|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01510314||92702|
NCT01510587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4W3685|Family Influences to Prevent Childhood Obesity|Family Influences to Prevent Childhood Obesity: An Integrated Research and Outreach Program for Parents of Montana 4-H Youth|4-Health|Montana State University|No|Completed|July 2010|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|194|||Both|N/A|N/A|No|||January 2015|January 28, 2015|January 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01510587||92682|
NCT01510847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTEST/SCRI|The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)|The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes: OTEST|OTEST|Singapore Clinical Research Institute|Yes|Terminated|October 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|19|||Male|45 Years|75 Years|No|||January 2016|January 5, 2016|January 4, 2012||No|Unable to reach the target recruitment within timeline|No||https://clinicaltrials.gov/show/NCT01510847||92662|
NCT01542671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-32|Tailored Lifestyle Intervention in Obese Adults Within Primary Care Practice - Choose to Lose|Tailored Lifestyle Intervention in Obese Adults Within Primary Care Practice|CTL|Memorial Hospital of Rhode Island|Yes|Active, not recruiting|September 2009|July 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542671||90233|
NCT01542294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-020|SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer|Phase I/II Study of Oral S-1 Plus f Oxaliplatin as an Adjuvant Chemotherapy After Curative Resection of Stage II-IV(M0) Gastric Cancer||Chinese Academy of Medical Sciences|No|Recruiting|June 2011|May 2017|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|20 Years|70 Years|No|||November 2013|November 26, 2013|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01542294||90262|
NCT01542307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000380|Normobaric Oxygen (NBO) Therapy in Acute Migraine|Normobaric Oxygen (NBO) Therapy in Acute Migraine||Massachusetts General Hospital|No|Active, not recruiting|July 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01542307||90261|
NCT01542320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00055040|Effect of Probiotic Supplementation on Immune Function in Healthy Infants|Application of Therapeutic Microbiology to Improve Immunogenicity|ProBoost|Emory University|Yes|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|15|||Both|6 Weeks|32 Weeks|Accepts Healthy Volunteers|||November 2014|March 5, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01542320||90260|
NCT01543217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201116|Respiratory Disease Management|Use of a Respiratory Care Practitioner Disease Management (RCP-DM) Program for Patients Hospitalized With COPD||Barnes-Jewish Hospital|Yes|Recruiting|July 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|428|||Both|18 Years|64 Years|No|||January 2013|January 26, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01543217||90192|
NCT01511055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002980|Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand|Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand||Mayo Clinic|Yes|Terminated|January 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|21|||Female|18 Years|N/A|No|||June 2015|June 3, 2015|January 12, 2012|No|Yes|Accrual temporarily suspended, followed by study closure due to technical problems with    investigational camera.|No||https://clinicaltrials.gov/show/NCT01511055||92647|
NCT01511289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY5511A3001|Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients|A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase||Il-Yang Pharm. Co., Ltd.|Yes|Completed|August 2011|||February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|242|||Both|18 Years|N/A|No|||January 2016|February 22, 2016|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01511289||92629|
NCT01511302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01.1.1.H2|Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma|A Phase I, Single-Blinded, Randomized Study of Nebulized RNS60 in Combination With Budesonide in Adult Subjects With Mild to Moderate Asthma||Revalesio Corporation||Completed|June 2012|May 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|65 Years|No|||July 2014|July 24, 2014|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511302||92628|
NCT01511861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gluco02|Assessing the Reliability of Non-invasive Blood Glucose Monitoring Device|||GlucoVista|No|Recruiting|November 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|18 Years|85 Years|No|Probability Sample|patients with diabetes mellitus type 1 or type 2.|January 2012|January 18, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511861||92585|
NCT01511874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fr-HE530-01|Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer|Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer||HanAll BioPharma Co., Ltd.|No|Completed|January 2011|December 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Male|20 Years|N/A|No|||September 2015|September 21, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511874||92584|
NCT01511601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912048|Apheresis to Obtain Plasma and White Blood Cells in Malies|Apheresis to Obtain Plasma and Leukocytes in Mali for In Vitro Studies||National Institutes of Health Clinical Center (CC)||Not yet recruiting|December 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|55 Years|No|||June 2015|July 14, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511601||92605|
NCT01511614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912474|Nicotine Withdrawal Symptoms and Smoking Relapse|Identifying Neurobiological Mechanisms That Underlie Acute Nicotine Withdrawal and Drive Early Relapse in Smokers||National Institutes of Health Clinical Center (CC)||Recruiting|December 2011|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|462|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|January 29, 2016|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511614||92604|
NCT01511627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT GA + SAB for TAH|Randomized Controlled Trial Comparing Postoperative Pain Following TAH With GA vs. Combined GA + SAB|A Randomized Controlled Trial Comparing Postoperative Pain Following Total Abdominal Hysterectomy With General Anesthetic vs. Combined General and Spinal Anesthetic||University of Saskatchewan|No|Withdrawn|January 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|65 Years|No|||July 2012|July 19, 2012|January 9, 2012||No|Research question was answered by a publication in Acta Anaesthesiol Scand 2012; 56: 102-109.|No||https://clinicaltrials.gov/show/NCT01511627||92603|
NCT01511913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-143|A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma|A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma|IMAGE|Bristol-Myers Squibb|No|Recruiting|April 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1800|||Both|18 Years|N/A|No|Non-Probability Sample|Eligible patients will be selected from approximately 200 medical practice sites (e.g.        community-based, office-based, hospital-based, academic setting) in several European Union        countries, Central America, North America, and South America, as well as Australia and        Israel.|March 2016|March 7, 2016|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01511913||92581|
NCT01512459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|610/06|Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence Two-period, Single Dose Sprinkled on Apple Sauce, Crossover and Relative Bioavailability Study in Healthy Adult, Human Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|May 2006|June 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512459||92539|
NCT01513044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-VIN-182|Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study in Healthy, Adult,Human, Male Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2009|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513044||92494|
NCT01513057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|466-08|Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study in Healthy, Adult,Human, Male Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|January 2009|February 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513057||92493|
NCT01512446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.1.42|Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy||BILANZ|Evangelisches Krankenhaus Lutherhaus gGmbH|Yes|Recruiting|January 2012|March 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|7000|||Both|60 Years|N/A|No|||March 2012|March 21, 2012|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512446||92540|
NCT01512745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HENGRUI 20101208|Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer|A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer||Jiangsu HengRui Medicine Co., Ltd.|Yes|Completed|January 2011|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|70 Years|No|||April 2015|April 2, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01512745||92517|
NCT01509521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-006103-35|The Oxygenation of the Brain During Caesarean Section|The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine|OBDUC|Naestved Hospital|Yes|Completed|February 2012|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 5, 2012|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01509521||92762|
NCT01510028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-MLD-070|Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)|A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy|IDEAMLD|Shire|Yes|Recruiting|August 2012|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|N/A|12 Years|No|||November 2015|November 11, 2015|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510028||92724|
NCT01509794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000906|Psychophysiological Indicators of Performance in Computer-Based Simulation|Psychophysiological Indicators of Performance in Computer-Based Simulation||Massachusetts General Hospital|No|Completed|November 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 27, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509794||92741|
NCT01510015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0503-11-TLV|Evaluation of the Effects of Treatment of Psycho-stimulant and Cannabis-dependent Users in Israel|Evaluation of the Effects of Psychological and Pharmacological Treatment of Psycho-stimulant and Cannabis-dependent Users in Kfar Izun in Israel||Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|January 2012|November 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|45 Years|No|||January 2012|January 10, 2012|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01510015||92725|
NCT01510873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QoL-ITP0411|Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP)|Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP).||Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|424|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients (18 years of age or older) with confirmed diagnosis of pITP in any phase of        the disease|January 2014|January 22, 2014|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01510873||92660|
NCT01511146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA-1023|Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor|Intrahepatic and Systemic Chemotherapy Together With Antibody to Patients With Non-resectable Liver Metastases From Solid Tumors||Copenhagen University Hospital at Herlev|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2012|January 18, 2012|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01511146||92640|
NCT01542684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1123|Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)|Phase II Study of Azacytidine Followed by GM-CSF in Patients With Low- or Intermediate-1- Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Terminated|March 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|February 27, 2012|Yes|Yes|Slow Accrual|No|March 28, 2014|https://clinicaltrials.gov/show/NCT01542684||90232|
NCT01542879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSVAR0017|Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer|Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.||Stanford University|Yes|Recruiting|February 2012|November 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|N/A|40 Years|No|||November 2015|November 18, 2015|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542879||90217|
NCT01543230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09014|CoMplete™ Acetabular Hip System|Ceramic on Metal Total Hip System, CoMplete™ Acetabular Hip System||DePuy Orthopaedics|No|Terminated|February 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|21 Years|N/A|No|||April 2014|April 7, 2014|February 27, 2012|No|Yes|Sponsor withdrew PMA|No||https://clinicaltrials.gov/show/NCT01543230||90191|
NCT01511068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0959_CCHMC_IRB|Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)|Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)|FAMPAP|Children's Hospital Medical Center, Cincinnati|Yes|Completed|August 2012|February 2014|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|8 Years|N/A|No|||January 2013|June 3, 2014|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511068||92646|
NCT01511081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0691|Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)|Randomized Phase II Study Comparing Stereotactic Body Radiotherapy (SBRT) With Stereotactic Body Proton Therapy (SBPT) for Centrally Located Stage I, Selected Stage II and Recurrent Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2012|||August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511081||92645|
NCT01511094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gonio-32|Goniocurettage as First Choice of Surgical Treatment in Chronic Open-Angle Glaucoma: Outcomes and Complications|Goniocurettage as First Choice of Surgical Treatment in Chronic Open-Angle Glaucoma: Outcomes and Complications|GC|Federal University of Minas Gerais|No|Active, not recruiting|June 2009|January 2012|Anticipated|May 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|40 Years|N/A|No|||January 2012|January 17, 2012|October 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01511094||92644|
NCT01511315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stelara QoL|The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment|A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI)||University of California, San Francisco|No|Completed|March 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|January 12, 2012|Yes|Yes||No|December 7, 2015|https://clinicaltrials.gov/show/NCT01511315||92627|
NCT01511328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLL-KI-HPV|Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm|Randomized Implementation of Primary Human Papillomavirus (HPV) Testing in the Organized Screening for Cervical Cancer in Stockholm||Karolinska Institutet|No|Recruiting|January 2012|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|100000|||Female|30 Years|64 Years|No|||February 2016|February 23, 2016|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01511328||92626|
NCT01511640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA036550|Behavioral Effects of Tiagabine and Cannabis|||University of Kentucky|No|Recruiting|January 2012|||June 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|50 Years|No|||February 2016|February 8, 2016|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511640||92602|
NCT01512186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-016675-29|A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)|A Phase II Study Investigating Upfront Pazopanib In Metastatic Clear Cell Renal Cancer (Panther)|Panther|Queen Mary University of London|Yes|Active, not recruiting|July 2010|December 2014|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|95|Samples With DNA|Pre-treatment biopsy and post treatment nephrectomy samples will be obtained|Both|18 Years|N/A|No|Probability Sample|The study population for this trial are patients with confirmed clear cell carcinoma with        measurable metastases on CT/MRI imaging (by RECIST). Only a component of clear cell is        required.|June 2014|June 11, 2014|October 4, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01512186||92560|
NCT01512784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS04/2011|Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults|Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults vs. Healthy Adolescents and Young Adults: Non-randomized Controlled Clinical Trial||University of Milan||Recruiting|October 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|13 Years|27 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01512784||92514|
NCT01512797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAO1107|Treatment of Diabetes After Gastric Bypass With Sitagliptin|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess Efficacy, Safety and Tolerability of Sitagliptin Phosphate 100 mg as Treatment for Recurrent, Persistent or Newly Diagnosed Type 2 Diabetes After Gastric Bypass|LAF33|Columbia University|Yes|Recruiting|July 2012|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|70 Years|No|||October 2015|October 15, 2015|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512797||92513|
NCT01508884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-2012-432|Intradermal Trivalent Influenza Vaccine With Imiquimod|Efficacy and Effectiveness of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod, a Double Blind Randomized Controlled Trial||The University of Hong Kong|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|93|||Both|21 Years|N/A|No|||December 2013|December 8, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508884||92811|
NCT01508858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1330|Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women|A Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide||Novo Nordisk A/S|No|Completed|November 2006|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Female|18 Years|N/A|No|||January 2015|January 16, 2015|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508858||92813|
NCT01508871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0126-A|Electrical Interactions in Heart Disease|||University Health Network, Toronto|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|Ventricular dysfunction|August 2011|January 9, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508871||92812|
NCT01509807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B504|A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of BupiVacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal|IMPROVE-IR|Pacira Pharmaceuticals, Inc|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|33|||Both|18 Years|N/A|No|||March 2014|March 9, 2014|October 24, 2011|Yes|Yes||No|November 30, 2013|https://clinicaltrials.gov/show/NCT01509807||92740|
NCT01510041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBV-123-ER|Effects of Respiratory Muscle Training and Respiratory Exercise in Exercise Tolerance, Performing Daily Life Activities and Quality of Life of Patients With Chronic Obstructive Pulmonary Disease|Effects of Respiratory Muscle Training and Respiratory Exercise in Exercise Tolerance, Performing Daily Life Activities and Quality of Life of Patients With COPD.||Universidade Federal de Sao Carlos|Yes|Recruiting|January 2011|February 2013|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|50 Years|80 Years|No|||January 2012|January 12, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01510041||92723|
NCT01510054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISP 38749|Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA|Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With Gonadotropin Releasing Hormone (GnRH) Antagonists: Focusing on MicroRNA Identification and Expression||Johns Hopkins University|Yes|Withdrawn|July 2002|November 2014|Actual|November 2014|Actual|N/A|Observational|N/A||1|Actual|0|Samples With DNA|endometril tissue|Female|21 Years|31 Years|Accepts Healthy Volunteers|Probability Sample|30 emdometrial biopsy from oocyte donors|April 2015|April 2, 2015|December 22, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01510054||92722|
NCT01510327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2046B|PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Pharmacokinetics Sub-trial|PLATINUM PK|Boston Scientific Corporation|Yes|Active, not recruiting|October 2009|February 2015|Anticipated|February 2010|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|December 21, 2011|Yes|Yes||No|January 16, 2012|https://clinicaltrials.gov/show/NCT01510327||92701|
NCT01510340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 11.184|Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management||HIVMediconline|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|January 2012|December 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|234|||Both|18 Years|N/A|No|||July 2011|January 11, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01510340||92700|
NCT01510600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL12B5|Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma|Alternative Lengthening of Telomeres (ALT) in Neuroblastoma||Children's Oncology Group|No|Active, not recruiting|January 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|99|||Both|N/A|30 Years|No|Non-Probability Sample|Patients diagnosed with neuroblastoma.|May 2015|May 7, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510600||92681|
NCT01510886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NES-XXX-2011/3|Assessment of MDD Management in Andalusia|Assessment of MDD Management Strategies in Andalusia: A Sub-analysis of the PismaEP Study|PismaEP|AstraZeneca|No|Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|5309|||Both|18 Years|N/A|No|Probability Sample|MDD patients treated in Primary Care or Secondary Care in the Region of Granada and        recruited for the PISMA-Ep Study|August 2014|August 12, 2014|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01510886||92659|
NCT01510899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25261|A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838|A Multiple Center, Open-label, Single Dose, Parallel-group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of RO4917838||Hoffmann-La Roche||Completed|October 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01510899||92658|
NCT01511159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1464|Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers|A Single-Centre, Open-Label, Five-Period Crossover Trial In Healthy Male Volunteers Investigating the Relative Bioavailability of NNC 90-1170 By Pulmonary Administration Compared To A Subcutaneous Injection||Novo Nordisk A/S|No|Completed|October 2001|December 2001|Actual|December 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|45 Years|No|||March 2015|March 25, 2015|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511159||92639|
NCT01542697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|698/067/068|Effect of Intraperitoneal Nebulisation of Magnesium Sulphate for Analgesia Following Laparoscopic Cholecystectomy|Phase IV Recruiting||B.P. Koirala Institute of Health Sciences|No|Recruiting|June 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||February 2012|February 27, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542697||90231|
NCT01542710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fixed Glaucoma Medications|Bimatoprost/Timolol Versus Travoprost/Timolol|Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study||Kasr El Aini Hospital|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|N/A|N/A|No|||January 2011|March 1, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01542710||90230|
NCT01542892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.27.CLI|Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study)|Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study)||Tufts University|No|Completed|October 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 14, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542892||90216|
NCT01543243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PhD pilot study 2|Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control|Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control: a Pilot Study||Bern University of Applied Sciences|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|65 Years|N/A|No|||December 2014|December 19, 2014|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01543243||90190|
NCT01510795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHMN1012|Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology|Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft||Clinical Hospital Merkur|No|Enrolling by invitation|January 2012|January 2014|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||January 2012|January 17, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01510795||92666|
NCT01510808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0173-11-HMO-CTIL|The Affect of Orthodontic Treatment on the Periodontal Status of Patients With Aggressive Periodontitis|||Hadassah Medical Organization|No|Recruiting|January 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|25|||Both|13 Years|40 Years|No|Non-Probability Sample|patients with aggressive periodontitis in maintenance that had completed orthodontic        treatment|January 2012|January 15, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510808||92665|
NCT01511354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101653|New Stable Isotope Method to Determine Protein Requirements in Critically Ill Children|Development of New Stable Isotope Method to Determine Protein Requirements in Critically Ill Children||Texas A&M University|No|Completed|February 2008|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Both|N/A|18 Years|No|Non-Probability Sample|Stable critically ill children admitted to the Pediatric Intensive Care Unit or        Cardiovascular Intensive Care Unit of ACH|June 2013|June 12, 2013|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01511354||92624|
NCT01511926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00044|Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns|European Study in Patients With Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis at Gastrointestinal Risk: A Retrospective, Non-interventional Study of Vimovo™ Prescribing Patterns|CHARACTERIZE|AstraZeneca|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid        arthritis (RA) or ankylosing spondylitis (AS), and with gastrointestinal (GI) risk        factors. The patients will be asked to participate by their treating doctors at GP        centres, specialist centres or hospitals across Europe.|March 2015|March 9, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01511926||92580|
NCT01512199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U3-1287-A-U202|Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)|Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)||Daiichi Sankyo Inc.|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|29|||Female|18 Years|N/A|No|||February 2016|February 25, 2016|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01512199||92559|
NCT01512225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232-2011|Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates|Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates|EMPOWER|Sunnybrook Health Sciences Centre|Yes|Terminated|May 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|45 Years|No|||November 2015|November 26, 2015|January 10, 2012||No|Recruitment challenges and their ensuing effects on the feasibility of the trial|No||https://clinicaltrials.gov/show/NCT01512225||92557|
NCT01512472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CURC - FIT-0002|Firmagon (Degarelix) Intermittent Therapy|Randomized, Multicentre Efficacy and Safety Study Comparing 10 Mons vs 4 Mons Degarelix Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy|FIT|Canadian Urology Research Consortium|No|Recruiting|January 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Male|18 Years|85 Years|No|||November 2012|November 30, 2012|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01512472||92538|
NCT01509235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.403|Self Drainage in Pediatric Cystic Fibrosis Patients|Exercise Coupled to Self Drainage in Pediatric Cystic Fibrosis Patients: an Open Label Cross Over Randomised Clinical Trial|GYM-MUCO|Hospices Civils de Lyon|No|Completed|March 2006|March 2008|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|34|||Both|7 Years|17 Years|No|||May 2012|May 7, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509235||92784|
NCT01509248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP-PopPK-Metabol|Population Pharmacokinetics and Metabolomics of Theophylline in Preterm Infants|Population Pharmacokinetics and Metabolomic Analysis of Aminopylline/Theophylline Drug Levels in Preterm Infants With Apnea of Prematurity||Seoul National University Hospital|Yes|Enrolling by invitation|May 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|110|||Both|N/A|37 Weeks|No|Non-Probability Sample|Admitted to Neonatal Intensive Care Unit|February 2012|February 21, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509248||92783|
NCT01508897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1331|Comparison of Two Liraglutide Formulations in Healthy Volunteers|A Randomized, Single-blind, Single-centre, Two-period, Cross-over Trial Investigating the Bioequivalence Between Completed Phase 2 and Planned Phase 3 Formulations of Liraglutide in Healthy Subjects||Novo Nordisk A/S|No|Completed|May 2004|June 2004|Actual|June 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|No|||January 2012|January 9, 2012|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508897||92810|
NCT01508910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|901001|Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina|A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia|RENEW|Baxalta US Inc.|Yes|Completed|April 2012|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|291|||Both|21 Years|80 Years|No|||December 2015|December 11, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508910||92809|
NCT01509833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-013|Efficacy of Low Dose hCG on Oocyte Maturity in Poor Responder Women Undergoing Intracytoplasmic Sperm Injection|Efficacy of Low Dose hCG on Oocyte Maturity for Ovarian Stimulation in Poor Responder Women Undergoing ICSI: a Prospective Randomized Controlled Trial||Royan Institute|Yes|Completed|October 2009|December 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|73|||Female|37 Years|43 Years|Accepts Healthy Volunteers|||August 2009|January 10, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01509833||92739|
NCT01510067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|805758|Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus|Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus||University of Pennsylvania|No|Recruiting|December 2006|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood, Skin Tissue Biopsies|Both|18 Years|N/A|No|Probability Sample|Subjects will be recruited from among the patients seen at the Autoimmune Skin Disease        Clinic at the Hospital of the University of Pennsylvania and other collaborating centers.|July 2012|July 20, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01510067||92721|
NCT01510353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-097|Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization|Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization||North Texas Veterans Healthcare System||Completed|January 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|505|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01510353||92699|
NCT01510613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-007-IT|Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis|An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis.||IRCCS Policlinico S. Matteo|Yes|Active, not recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510613||92680|
NCT01510912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIC3-08-06|Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain|A Multicenter, Open-Label, Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip||Iroko Pharmaceuticals, LLC|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|602|||Both|40 Years|N/A|No|||April 2014|April 8, 2014|January 12, 2012|Yes|Yes||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01510912||92657|
NCT01510938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG-11009|Probiotics in Respiratory Tract Infections in Children|Role of Probiotics in Prevention of Respiratory Tract Infections in Preschool and Primary School Children||Lviv National Medical University|Yes|Completed|January 2012|December 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|242|||Both|3 Years|12 Years|Accepts Healthy Volunteers|||December 2013|December 25, 2013|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01510938||92656|
NCT01511172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1499|Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes|Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Double-dummy, Randomised, Parallel-group, Dose Titration Study With an Open Labelled OHA Arm||Novo Nordisk A/S|No|Completed|August 2002|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|145|||Both|18 Years|70 Years|No|||March 2015|March 25, 2015|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511172||92638|
NCT01542918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112530|Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma|Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma||University of California, San Francisco|Yes|Recruiting|December 2012|June 2017|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|February 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542918||90214|
NCT01542905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG2010|Stress Relief Effect of Korean Red Ginseng|Effects of Korean Red Ginseng on Stress Relief and Cognitive and Mental Function Enhancement Using Neuroimaging: Double-Blind, Randomized, Placebo-Controlled Clinical Trial||Seoul National University Hospital||Completed|May 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 23, 2015|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01542905||90215|
NCT01543503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA27950|An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|A Global Comparative Observational Study In Rheumatoid Arthritis (RA) Patients Who Are Treated With A TNF Inhibitor Or Tocilizumab As The First Biologic Therapy||Hoffmann-La Roche||Completed|February 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1225|||Both|18 Years|N/A|No|Probability Sample|Adult patients with rheumatoid arthritis|January 2016|January 12, 2016|February 28, 2012|No|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT01543503||90170|
NCT01511107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0083|Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance|A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance||University of Pittsburgh|Yes|Terminated|January 2012|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|520|||Both|6 Months|23 Months|No|||February 2016|February 24, 2016|January 10, 2012|Yes|Yes|The primary objective of the study was met.|No||https://clinicaltrials.gov/show/NCT01511107||92643|
NCT01511341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNSF-13DPD6_132135|Impact of a Telenursing Service on Satisfaction and Health Outcomes of Children With Inflammatory Rheumatic Diseases|Impact of a Telenursing Service on Satisfaction and Health Outcomes of Children With Inflammatory Rheumatic Diseases and Their Family: a Crossover Trial||University of Applied Sciences of Western Switzerland|No|Completed|August 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|55|||Both|1 Year|17 Years|No|||February 2015|February 3, 2015|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01511341||92625|
NCT01511952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICU Music Tx Interventions|A Multi-Site Study of Music Therapy Interventions on Vitals, Feeding and Sleep in Premature Infants|A Multi-Site Study of Music Therapy Interventions on Vitals, Feeding and Sleep in Premature Infants||Beth Israel Medical Center|Yes|Completed|January 2007|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|272|||Both|32 Weeks|40 Weeks|No|||March 2015|March 19, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01511952||92578|
NCT01512212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thyroid.iiab|New Thyroid Fine Needle Aspiration Biopsy Apparatus|New Thyroid Fine Needle Biopsy Apparatus|fnab|SB Istanbul Education and Research Hospital|No|Recruiting|January 2012|September 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|17 Years|85 Years|No|||January 2012|January 13, 2012|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512212||92558|
NCT01508923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1332|Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes|Effect of NNC 90-1170 on 24-hour Glucose and Hormonal Profiles, Gastric Emptying, and Fasting Gluconeogenesis in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, Cross-over Trial||Novo Nordisk A/S|No|Completed|May 2001|February 2002|Actual|February 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508923||92808|
NCT01508936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C38072/3084|Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma|A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma||Teva Pharmaceutical Industries||Completed|January 2012|October 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|510|||Both|18 Years|65 Years|No|||May 2014|May 8, 2014|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508936||92807|
NCT01508949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1333|Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes|NNC 90-1170 Mechanism of Action: A Single-centre, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial Evaluating the Effect of NNC 90-1170 on Weight and Appetite in Obese Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|June 2001|March 2002|Actual|March 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508949||92806|
NCT01509547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00014398|Varenicline for Adolescent Smoking Cessation|A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation||Medical University of South Carolina|Yes|Recruiting|August 2012|August 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|166|||Both|14 Years|21 Years|No|||March 2016|March 7, 2016|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01509547||92760|
NCT01509846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC 001|Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults|A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Oral Inactivated Whole Cell Shigella Flexneri 2a Vaccine in Healthy Adult Subjects||PATH|Yes|Completed|March 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|82|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|February 4, 2013|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01509846||92738|
NCT01509859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0333-11-RMC|Comparing Weight Bearing After Intramedullary Fixation Devices for the Proximal Femur Fracture|Prospective Randomized Trial Comparing the Weight Bearing After Fixation of Proximal Femur Fractures With Two Different Proximal Intramedullary Devices||Rabin Medical Center|Yes|Recruiting|December 2011|September 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||January 2012|January 12, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01509859||92737|
NCT01509872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREC73-2011|Psychological and Psychosocial Intervention With War-Affected Children|An RCT Comparing Trauma-Focused Cognitive Behavioral Therapy (a Specific Psychological Intervention) and A Child Friendly Space (a Non-trauma Focused Psychosocial Intervention) in Reducing Psychological Distress Among War-affected Children||Queen's University, Belfast|No|Active, not recruiting|October 2011|April 2012|Anticipated|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01509872||92736|
NCT01510080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WECK-012|Acceptance and Efficacy of Live Supervision|Live Supervision Put to Test - Studies of Acceptance and Efficacy of Computer-assisted Live Supervision||Goethe University|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|42|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01510080||92720|
NCT01510366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMBCAMS-03|The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)|The Phase Ⅲ Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|IPV|Chinese Academy of Medical Sciences|Yes|Completed|January 2012|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1200|||Both|60 Days|90 Days|Accepts Healthy Volunteers|||September 2015|September 13, 2015|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510366||92698|
NCT01510626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22872|Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center|Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center||Stanford University|Yes|Completed|November 2011|December 2015|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|4 Years|55 Years|No|||December 2015|December 9, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510626||92679|
NCT01510951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101147|Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Moderate to Severe Psoriasis||Amgen||Completed|August 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|55 Years|No|||March 2013|March 25, 2013|August 11, 2011||||No||https://clinicaltrials.gov/show/NCT01510951||92655|
NCT01511185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-2063|Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group|NNC 90-1170 Mechanism of Action: A Double-blind, Randomized, Single-center, Placebo Controlled, Crossover Study to Examine Beta-cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|February 2001|October 2001|Actual|October 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|75 Years|No|||November 2014|November 3, 2014|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511185||92637|
NCT01543269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYT1/1001|A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers|A Randomized, Double Blind, Placebo Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYT1, a Selective Thyroid Receptor (TR) ß Agonist, Following the Oral Administrations in Healthy Volunteers.||Cadila Healthcare Limited|Yes|Terminated|February 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 20, 2015|February 21, 2012||No|Safety concerns|No||https://clinicaltrials.gov/show/NCT01543269||90188|
NCT01543256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM00047682|WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study|A Multi-Center, Prospective, Randomized Study Comparing Removable, Self-Expanding Metal Stents to Plastic Stents for the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis||Boston Scientific Corporation|No|Recruiting|September 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|164|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543256||90189|
NCT01511380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA025880|Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth|Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth||Medical University of South Carolina|Yes|Active, not recruiting|September 2008|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|12 Years|17 Years|No|||May 2013|May 30, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01511380||92622|
NCT01512238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO01|Improvement of Intentional and Unintentional Non-adherence in the Elderly|Improvement of Intentional and Unintentional Non-adherence in the Elderly. Importance of Pharmaceutical Care, Generic Substitution, Non-prescription Drugs, Herbal Medicine and Dietary Supplements||University of Aarhus|No|Completed|February 2010|November 2013|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|630|||Both|65 Years|N/A|No|Probability Sample|Persons aged 65 years or older, living in their own homes without assistance to medicine        administration in the Municipality of Aarhus, Denmark and who were in long-term treatment        with > 4 prescription drugs at the beginning of the project|December 2013|September 30, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01512238||92556|
NCT01512498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYS-09-HMO-CTIL|Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menarche|Vulvovaginal Graft Versus Host Disease in Women Who Underwent Transplantation Before and After Menarche||Hadassah Medical Organization|No|Recruiting|December 2012|February 2018|Anticipated|December 2017|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Female|18 Years|70 Years|No|Non-Probability Sample|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at        the time of the study and who are alive .|February 2016|February 20, 2016|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01512498||92536|
NCT01512810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-GYN-130-MCC|Treatment of Endometrial Cancer|Treatment of Endometrial Cancer Utilizing Pathology Intraoperative Consultation to Determine Extent of Surgical Staging||University of Kentucky|Yes|Active, not recruiting|January 2012|January 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512810||92512|
NCT01511653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLNE010|Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma|Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma|GLNE010|University of Michigan|No|Completed|October 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|5230|Samples With DNA|Two 10 ml red top (serum) tubes Two 7 ml purple top (EDTA)tubes 100 ml of urine 2 Fecal      Immunohistochemical Tests (FIT)      1 stool bucket|Both|50 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|6000 asymptomatic subjects aged 50-80 undergoing routine colonoscopic screening for        colorectal cancer from community and major medical center outpatient settings across        multiple centers and consortia will be recruited.|June 2014|June 24, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01511653||92601|
NCT01511939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATCCTCP-1|Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants|Single Center, Open-label Study of Effect of PENNSAID (Diclofenac Sodium Solution Topical) on Coagulation Parameters (PT, PTT, INR and Platelet Function) in Patients With Moderate to Severe Osteoarthritis Pain of the Knee Taking Anticoagulant Medication|ATCCTCP-1|Arthritis Treatment Center, Maryland|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|22|||Both|55 Years|N/A|No|||June 2014|June 24, 2014|January 9, 2012|Yes|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01511939||92579|
NCT01512823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC REF: 259/2006|Randomised Trial of Two Educational Intervention for Improving Evidence-based Practice Knowledge, Atttitudes and Practice|Randomised Trial of the Effectiveness of Two Educational Interventions to Improve Evidence-based Practice Knowledge, Attitudes and Behaviour in Occupational Therapists|OTEBP|University of Cape Town|No|Completed|November 2007|March 2011|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|58|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01512823||92511|
NCT01512264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HD068488|Post-Stroke Aphasia and Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Study|Post-Stroke Aphasia and rTMS Treatment Study|PART|University of Alabama at Birmingham|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|80|||Both|19 Years|N/A|No|||October 2015|October 30, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01512264||92554|
NCT01512511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|u-89140|Comparing Nitrous Oxide and Carbon Dioxide for Laparoscopic Cholecystectomy|Prospective Randomized Trial Comparing Nitrous Oxide and Carbon Dioxide for Laparoscopic Cholecystectomy||Ahvaz Jundishapur University of Medical Sciences|Yes|Completed|November 2010|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|64|||Both|N/A|65 Years|No|||January 2012|January 15, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01512511||92535|
NCT01513070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUXIAOJIUXIN2010|A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis|A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|No|Completed|April 2012|June 2014|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|30 Years|75 Years|No|||August 2014|August 3, 2014|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513070||92492|
NCT01513083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO25499|A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function|A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function||Hoffmann-La Roche||Completed|February 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513083||92491|
NCT01513096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-201201|Efficacy of Prokinetics With Split Dose of PEG in Morning Colonoscopic Bowel Preparation|Efficacy of Prokinetics With Split Dose of PEG in Morning Colonoscopic Bowel Preparation: A Randomized, Controlled Trial|PSPEG|Inje University|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|152|||Both|18 Years|80 Years|No|||January 2012|March 30, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513096||92490|
NCT01513109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BORLEUWT01|Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia|A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT).|ASCI|Jules Bordet Institute|No|Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513109||92489|
NCT01508962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRESS-ALS|PRE-Symptomatic Studies in ALS|PRE-Symptomatic Studies in ALS|PRESS-ALS|University of Miami|Yes|Recruiting|November 2013|||December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|People affected with ALS (either familial or sporadic) and healthy controls|January 2016|January 19, 2016|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508962||92805|
NCT01508975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USARice1|Satiety Response of White and Brown Rice Compared to Glucose Control|Satiety Response of White and Brown Rice Compared to Glucose Control||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508975||92804|
NCT01509261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY-81149-EE03|Efficacy Study of Ilaprazole to Treat Erosive Esophgitis|A Phase Ⅲ Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Ilaprazole (20mg QD) in Adult Patients With Erosive Esophagitis||Il-Yang Pharm. Co., Ltd.|No|Completed|July 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|292|||Both|18 Years|75 Years|No|||January 2012|January 10, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509261||92782|
NCT01509560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ev02 (Everolimus-GvHD)|PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood|PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood||Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|No|Recruiting|November 2011|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01509560||92759|
NCT01510392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00008034-Outreach|CEI Van Outreach Screening Study|Prospective Evaluation of Optical Coherence Tomography Usage in the Screening of Eye Diseases||Oregon Health and Science University|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|This study will be performed enrolling participants from the Casey Eye Institute outreach        van.|August 2014|August 29, 2014|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01510392||92696|
NCT01510379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0236|Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery|Median Nerve Acustimulation Plus Medical Anti-emetic Therapy for Control Post-operative Nausea in Patients Undergoing Foregut Surgery: A Randomized Control Trial|Reletex|Ohio State University|No|Completed|August 2011|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|85 Years|No|||January 2014|February 24, 2014|January 5, 2012||No||No|November 15, 2013|https://clinicaltrials.gov/show/NCT01510379||92697|
NCT01510639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-08.05A/PDGF|The Influence of Growth Factors (PDGF), Applied as Autologous Thrombocyte Concentrate, on Functional Recovery|Results of Subacromial Surgery; The Influence of Growth Factors (PDGF), Applied as Autologous Thrombocyte Concentrate, on Functional Recovery|PRP|St. Antonius Hospital|No|Completed|July 2010|April 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|73|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01510639||92678|
NCT01510652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-006-HF-ID|More Options Available With a Quadripolar LV Lead pRovidE In-clinic Solutions to CRT Challenges|More Options Available With a Quadripolar Left Ventricular (LV) Lead pRovidE In-clinic Solutions to Cardiac Resynchronization Therapy (CRT) Challenges|MORE-CRT|St. Jude Medical|No|Completed|November 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1078|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|November 30, 2011||No||No|August 14, 2015|https://clinicaltrials.gov/show/NCT01510652||92677|Patients were followed for only 6 months, studies with longer follow-up would add to the body of evidence.
NCT01511198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-2072|Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent|NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|February 2001|October 2001|Actual|October 2001|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|223|||Both|18 Years|75 Years|No|||November 2014|November 3, 2014|January 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511198||92636|
NCT01511484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PerceptionLab001|You Are What You Eat: A Randomised Controlled Trial of an Appearance-based Dietary Intervention|||Perception Lab|No|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|73|||Both|18 Years|61 Years|Accepts Healthy Volunteers|||January 2012|January 12, 2012|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01511484||92614|
NCT01511497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B0141008|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers|A Randomized, Placebo Controlled, Double-Blind, Third Party Open, Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Female Adult Volunteers||Pfizer|No|Completed|October 2011|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511497||92613|
NCT01512056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-100-086|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients||National Cheng-Kung University Hospital|No|Recruiting|October 2011|March 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||January 2012|January 13, 2012|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01512056||92570|
NCT01542944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-9090-AN-CTIL|TevaGastrim for Stem Cell Mobilization Sibling Donors|TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)||Sheba Medical Center|No|Active, not recruiting|February 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01542944||90212|
NCT01542957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dilemma2012|Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention|Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention||University of Barcelona|No|Completed|November 2011|May 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|128|||Both|18 Years|70 Years|No|||June 2015|June 1, 2015|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01542957||90211|
NCT01543516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRA-AKAS|Cell Distribution in Induced Sputum in Patients With Asthma|Cell Distribution in Induced Sputum in Healthy Subjects and Patients With Asthma After Different Techniques for Sputum Induction||Johann Wolfgang Goethe University Hospitals|No|Completed|November 2011|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|Samples With DNA|whole blood, serum, and sputum|Both|6 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study is carried out in children, adolescents, and young adults (6 to 25 years of        age). Both the patients (n=20) and the healthy subjects (n=20) are recruited from the        outpatient clinic of the department of Pediatric Allergy and Pulmonology, University        Clinic, Goethe-University, Frankfurt/M, Germany.|June 2012|June 29, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01543516||90169|
NCT01512485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60281|Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions|Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 13, 2012|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512485||92537|
NCT01511991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160037|Sevoflurane's Effect on Mitral Valve Annular Velocity in Cardiac Surgery|Sevoflurane's Effect on Tissue Doppler Profiles of Lateral Mitral Annulus During Cardiac Surgery||Konkuk University Medical Center|Yes|Completed|May 2009|May 2014|Actual|May 2014|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|20|||Both|20 Years|65 Years|No|||February 2015|February 20, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01511991||92575|
NCT01512524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.641|Hormonal Deficiency in the Quality of Life of Patients With Traumatic Brain Injury|Long Term Follow-up of Moderate and Severe Traumatic Bain Injury and Assessment of Involvement of Hormonal Deficiency in the Quality of Life|INSPIRE-TC|Hospices Civils de Lyon|Yes|Recruiting|November 2011|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Both|18 Years|65 Years|No|||March 2014|March 21, 2014|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01512524||92534|
NCT01512537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/687|Alternative Treatments of Vitamin D Deficiency|Comparison of UVB and Vitamin D Supplementation in Treatment of Vitamin D Deficiency||Lund University|No|Completed|February 2010|November 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|32|||Both|15 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 15, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01512537||92533|
NCT01512836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RN-1|A Randomized Controlled Trial to Determine Outcome and Cost Effectiveness of Case Management of Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized Controlled Trial to Determine Outcome and Cost Effectiveness of Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease (COPD) in a Danish Setting||Kronikerenheden Nordjylland|Yes|Completed|July 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|150|||Both|N/A|N/A|No|||March 2015|March 31, 2015|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512836||92510|
NCT01513135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS T-003|A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers|A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers|ISS T-003|Istituto Superiore di Sanità|Yes|Completed|March 2012|July 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|45 Years|No|||March 2016|March 3, 2016|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513135||92487|
NCT01509300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCPHO-SCT0902|HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors|HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3 Depletion for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors After Conditioning of TBI, Fludarabine, Cyclophosphamide and Antithymocyte Globulin||Asan Medical Center||Recruiting|January 2012|March 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|21 Years|No|||January 2012|January 12, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01509300||92779|
NCT01509274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS6000|Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia|Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia - a Prospective, Randomized and Double Blinded Study.||Kolding Sygehus|Yes|Recruiting|August 2011|||June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||January 2012|January 16, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509274||92781|
NCT01509573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPCGA-FSI-15440|Pilot Feasibility Trial of the Family Strengthening Intervention in Rwanda (FSI-R)|Family-Based Prevention of Mental Health Problems in HIV/AIDS-Affected Children (R34MH084679-01A1)||Harvard School of Public Health|Yes|Completed|July 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|82|||Both|5 Years|N/A|No|||August 2014|August 25, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01509573||92758|
NCT01509586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00007428|A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco|A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco||Medical University of South Carolina|No|Completed|November 2011|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1236|||Both|19 Years|N/A|No|||January 2015|March 23, 2016|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01509586||92757|
NCT01510678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8721-B|The Effect of Three Different Dietary Messages on Dietary Intake and Health in Families|The Effect of Three Different Dietary Messages on Dietary Intake and Health in Families||University of Tennessee|Yes|Active, not recruiting|January 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|45|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01510678||92675|
NCT01510665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Magnesium123|Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals|Magnesium Supplementation in the Second Trimester of Pregnancy for Overweight Individuals||University of California, Los Angeles|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01510665||92676|
NCT01510964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA (CE.Prot. 1719)|The Involvement of Breast Cancer Patients During Oncological Consultations|The Involvement of Breast Cancer Patients During Oncological Consultations. A Multi-centre Randomized Controlled Trial. The Study Protocol|INCA|Azienda Ospedaliera Universitaria Integrata Verona|Yes|Completed|June 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|300|||Female|18 Years|75 Years|No|||December 2011|August 9, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01510964||92654|
NCT01511523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVL-001|Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD).||Biovil Research Group, LLC|No|Enrolling by invitation|January 2012|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2012|March 15, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511523||92611|
NCT01511770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA01660|Bioavailability Study of Fluconazole Tablets 200 mg Under Fasting Conditions|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Fluconazole Tablets 200 mg and PFIZER (DIFLUCAN) 200 MG in Healthy Males Under Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Completed|August 2002|September 2002|Actual|August 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511770||92592|
NCT01512329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaceMS|Pacing Activity Self-management for Patients With Multiple Sclerosis|Pacing Activity Self-management for Patients With Multiple Sclerosis: Randomized Controlled Clinical Trial||Vrije Universiteit Brussel|No|Completed|October 2011|October 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||December 2015|December 16, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01512329||92549|
NCT01543295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-SYP-01|Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System|Qualitative Evaluation of the DPP Syphilis Screen and Confirm Rapid Test to Detect the Presence of Antibodies Against Non-Treponemal and Treponema Pallidum Antigens in Fingerstick Whole Blood, Venous Whole Blood, Serum and Plasma Specimens.||Chembio Diagnostic Systems, Inc.|Yes|Withdrawn|July 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Both|13 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from study sites at diverse geographical locations in the        United States. Such sites include primary care clinics, Obstetric/Gynecology clinics,        physician offices, hospitals.|July 2015|July 27, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01543295||90186|
NCT01543282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 11.150|Endoscopic Ultrasonography (EUS) Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles|Randomized Controlled Study Comparing Endoscopic Ultrasonography Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles in Solid Lesions||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Active, not recruiting|December 2011|August 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|240|||Both|18 Years|N/A|No|||February 2013|February 25, 2013|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01543282||90187|
NCT01512290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU_TBS|Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations|Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations; a Placebo-controlled Trail||UMC Utrecht|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01512290||92552|
NCT01511965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-API-01|Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo||Viticell|Centre Hospitalier Universitaire de Nice|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01511965||92577|
NCT01511978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPC 3,4-DAPPER|Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome|Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome|DAPPER|Jacobus Pharmaceutical|No|Active, not recruiting|January 2012|July 2014|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2014|July 1, 2014|December 24, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01511978||92576|
NCT01512862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-CCTO|Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients|Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients||Seoul National University Hospital|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|19 Years|70 Years|No|||April 2012|April 9, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01512862||92508|
NCT01512849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-7284-07|A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment|An Open-Label, Randomized, 2 Way Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment||Mitsubishi Tanabe Pharma Corporation|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|79 Years|No|||May 2014|May 13, 2014|January 13, 2012||No||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01512849||92509|
NCT01513122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2L body comp sub-study|Bone and Body Comp: A Sub Study of the SECOND-LINE Study|||Kirby Institute|Yes|Completed|February 2010|August 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Both|16 Years|N/A|No|||December 2013|December 1, 2013|January 16, 2012||No||No|December 1, 2013|https://clinicaltrials.gov/show/NCT01513122||92488|
NCT01508988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-9054IOU001|Single Dose Escalation Study of ONO-9054 in Healthy Volunteers|A Double-masked Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ONO-9054 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd|No|Completed|January 2012|||April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Actual|48|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01508988||92803|
NCT01509287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009p001589|Metabolic Screening in Patients With Donnai-Barrow Syndrome|Metabolic Screening in Patients With Donnai-Barrow Syndrome||Massachusetts General Hospital|Yes|Recruiting|March 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|70|Samples With DNA|whole blood, saliva, urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Children/infants affected with Donnai-Barrow Syndrome|November 2013|November 7, 2013|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509287||92780|
NCT01509313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPS-MERT-01|A Trial Comparing Morcellation With Electrical Resection for Removal of Uterine Polyps|A Randomised Controlled Trial Comparing Morcellation With Electrical Resection for Removal of Uterine Polyps|MERT|Birmingham Women's NHS Foundation Trust|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|121|||Female|16 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 13, 2013|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01509313||92778|
NCT01509326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112049|Chiropractic and Acupressure for Headaches|A Randomized Clinical Trial of Chiropractic Care for Headaches With and Without an Acupressure Device||Canadian Memorial Chiropractic College|No|Recruiting|January 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|60 Years|No|||January 2012|January 10, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01509326||92777|
NCT01509599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00008711|Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation|Preventing Venous Leg Ulcers With Cryotherapy: A Randomized Clinical Trial||Medical University of South Carolina|Yes|Recruiting|August 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|240|||Both|21 Years|N/A|No|||April 2015|April 7, 2015|August 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01509599||92756|
NCT01510093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1811|Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)|Interactions Between Exogenous Insulin Aspart, Endogenous Insulin and Plasma Glucose in Type 2 Diabetes Mellitus Patients||Aarhus University Hospital|Yes|Completed|May 2012|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|35 Years|75 Years|No|||January 2013|January 28, 2013|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510093||92719|
NCT01512069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCNCS-11-501|Efficacy of a Web-based Tailored Self-management Program|Efficacy of a Web-based Self-management Exercise and Diet Intervention Program With Tailored Motivation and Action Planning for Breast Cancer Survivors: A Randomized Controlled Trial||National Cancer Center, Korea|Yes|Completed|October 2011|August 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|59|||Female|20 Years|N/A|No|||April 2014|April 23, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01512069||92569|
NCT01510977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0733|Second Bowel Preparation for Colonoscopy Failure|The Outcome of a Second Preparation for Colonoscopy After Preparation Failure in the First Procedure: a Prospective Randomized Controlled Study||Asan Medical Center|No|Terminated|November 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 11, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01510977||92653|
NCT01510990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2011-0858|First Line Gefitinib by FDG-PET Metabolic Response|First Line Gefitinib Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) by the FDG-PET Metabolic Response||Asan Medical Center|No|Recruiting|April 2012|November 2015|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|19 Years|N/A|No|||January 2013|January 26, 2013|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01510990||92652|
NCT01511211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMLAMLLDEX|Duration of Leg Nerve Blocks With Dexamethasone Added to Local Anesthetic|Effect of Dexamethasone on Duration of Analgesia After Ultrasound-Guided Femoral, Obturator, and Popliteal Blocks With Ropivacaine in Total Knee Arthroplasty||University of New Mexico||Withdrawn|September 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 11, 2013|January 12, 2012|Yes|Yes|Other researchers have published results on a similar trial|No||https://clinicaltrials.gov/show/NCT01511211||92635|
NCT01511510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701007|Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers|A Phase I, Randomized, Subject And Investigator Blind, Sponsor Open, Multiple Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Healthy Adult Volunteers||Pfizer|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|39|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 17, 2012|July 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01511510||92612|
NCT01512914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR HSG 01-2008|Impact of Intraperitonael Nebulization of Local Anesthetic on Postoperative Pain Associated With Laparoscopic Surgery|Impact of Intraperitonael Nebulization of Local Anesthetic on Postoperative Pain Associated With Laparoscopic Surgery||San Gerardo Hospital|No|Completed|May 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|70 Years|No|||January 2012|January 18, 2012|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512914||92504|
NCT01513252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 231 01|Long-term Effects of Interventional Strategies to Prevent Cognitive Decline in Elderly.|A 2-years Extension Study of MAPT Trial : Evaluation of the Long Term Effects of Interventional Strategies to Prevent the Decline in Cognitive Functioning in Frail Older Adults|MAPT-PLUS|University Hospital, Toulouse|Yes|Recruiting|December 2011|November 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1150|||Both|70 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 18, 2015|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01513252||92478|
NCT01543555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02/15/2012|Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose|Multicenter Randomized Controlled Trial of Loading Dose Statins for the Prevention of Cardiovascular Complications in High-Risk Non-Cardiac Surgery|LOAD|Hospital do Coracao|Yes|Completed|November 2012|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|648|||Both|40 Years|N/A|No|||December 2015|December 30, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543555||90166|
NCT01543542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-204|A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical Tomotherapy for 1-3 Brain Metastases|A Phase II Multi-institutional Study Assessing Simultaneous In-Field Boost Helical Tomotherapy for 1-3 Brain Metastases|TOMOSIBII|Lawson Health Research Institute|Yes|Active, not recruiting|April 2010|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01543542||90167|
NCT01511666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prague OHCA study|Hyperinvasive Approach in Cardiac Arrest|Hyperinvasive Approach to out-of Hospital Cardiac Arrest Using Mechanical Chest Compression Device, Prehospital Intraarrest Cooling, Extracorporeal Life Support and Early Invasive Assessment Compared to Standard of Care. A Randomized Parallel Groups Comparative Study. "Prague OHCA Study"||Charles University, Czech Republic|Yes|Recruiting|March 2013|May 2018|Anticipated|March 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|65 Years|No|||January 2016|January 28, 2016|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511666||92600|
NCT01511679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BANC RFA-AA-12-006|Brain-imaging and Adolescent Neuroscience Consortium|Brain-imaging and Adolescent Neuroscience Consortium|BANC|Children's Hospital Boston|No|Withdrawn|September 2012|September 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|Samples With DNA|Saliva DNA samples for future analyses.|Both|12 Years|21 Years|No|Non-Probability Sample|Male and female adolescents 12-21 years-of-age presenting for care at one of the        participating medical clinics|January 2013|January 2, 2013|January 13, 2012||No|The project was not funded.|No||https://clinicaltrials.gov/show/NCT01511679||92599|
NCT01512303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0641|Complementary and Alternative Interventions for Veterans With Posttraumatic Stress Disorder|Complementary and Alternative Interventions for Veterans With Posttraumatic Stress Disorder: Community Program Evaluation Study||University of Wisconsin, Madison|No|Suspended|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|January 6, 2012||No|Study on hold due to funding issues|No||https://clinicaltrials.gov/show/NCT01512303||92551|
NCT01512251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 11952|BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma|A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)||University of California, San Francisco|Yes|Recruiting|June 2012|July 2015|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512251||92555|
NCT01512277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP97/104|Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis|Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis|Bilhvax1a|University Hospital, Lille|No|Completed|September 1998|September 1999|Actual|March 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|24|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01512277||92553|
NCT01512875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1119|S1119 Peruvian H. Pylori Water Contamination Study|Gastric Cancer and Helicobacter Pylori Infection in Lima, Peru: The Role of Water Contamination||Southwest Oncology Group|No|Completed|December 2011|November 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|107|Samples With DNA|tissue|Both|21 Years|70 Years|No|Non-Probability Sample|Residents of the following districts of Lima, Peru: Brena, Chorrillos, Comas, El Agustino,        La Victoria, Lince, Los Olivos, Miraflores, Puente Piedra, Rimac, San Isidro, San Juan de        Lurigancho, San Luis, San Martin de Porres, Via El Salvador, Villa Maria del Triunfo.|November 2015|November 16, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01512875||92507|
NCT01513174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECP10-03|Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone|Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer|GOAL|Spanish Lung Cancer Group|Yes|Recruiting|August 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01513174||92484|
NCT01513148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-750|Effects of Light Emitting Diode Irradiation on the Conduction Parameters of the Superficial Radial Nerve|The Effect of Light Therapy on Superficial Radial Nerve Conduction Using a Clustered Array of Infrared Super Luminous and Red Light Emitting Diodes||Shenandoah University|No|Completed|June 2006|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|January 9, 2012||No||No|June 11, 2012|https://clinicaltrials.gov/show/NCT01513148||92486|4 subjects were terminated early in the project, two from the light therapy group and two from the sham therapy group. All cases, we were unable to achieve an appropriate baseline temperature of 30 degrees celsius to allow continued participation
NCT01513161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRK-820_PRU_III_2007|Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis|A 14 Day, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose, Phase III Clinical Trial to Assess the Efficacy and Safety of TRK-820 in Treating Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis|TRK-820|SK Chemicals Co.,Ltd.|No|Completed|April 2008|October 2009|Actual|October 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|104|||Both|20 Years|N/A|No|||January 2012|January 19, 2012|November 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01513161||92485|
NCT01509001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILVAMER|Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus|Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes||University of Sao Paulo|No|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|70 Years|No|||January 2012|January 13, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509001||92802|
NCT01510106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-304|Ferric Citrate in Patients With End-Stage Renal Disease on Dialysis|A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis||University of Pennsylvania|Yes|Completed|April 2011|March 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510106||92718|
NCT01510119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 07811|Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma|Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment|||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510119||92717|
NCT01510405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1026|Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer|Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|July 2010|December 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have presumed lung cancer|March 2016|March 23, 2016|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01510405||92695|
NCT01511796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTul Rehab|Examining the Effectiveness of Combined Rehabilitation and Botulinum Toxin Injection on Functional Improvement of the Upper Limb After Stroke|Effectiveness of Botulinum Toxin Combined With Upper Limb Rehabilitation on Arm Function||Toronto Rehabilitation Institute|Yes|Enrolling by invitation|January 2012|April 2014|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|75 Years|No|||January 2012|January 17, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01511796||92590|
NCT01512368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF173|Changes in Serum Fibroblast Growth Factor 21 (FGF21) Levels Correlated With Exercise|Changes in Serum Fibroblast Growth Factor 21 (FGF21) Levels After a Cardiorespiratory Exercise Program||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|March 2010|November 2011|Actual|August 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|82|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 9, 2013|January 11, 2012||No||No|January 20, 2012|https://clinicaltrials.gov/show/NCT01512368||92546|We cannot fully control other potential sources of physical activity. The results may not be applicable to men. We did not register the caloric consumption during the study.
NCT01512342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PacingCFS|Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome|Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome: Randomized Controlled Clinical Trial||Vrije Universiteit Brussel|No|Completed|August 2011|August 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Female|18 Years|65 Years|No|||December 2015|December 16, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01512342||92548|
NCT01512615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHCopenHeartIE|CopenHeart IE - Integrated Rehabilitation of Patients Treated for Infective Endocarditis|CopenHeart IE - A Randomized Clinical Trial Investigating the Effect and Meaning of Integrated Rehabilitation Versus Usual Follow-up of Patients Treated for Infective Endocarditis||Rigshospitalet, Denmark|Yes|Recruiting|December 2011|December 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|18 Years|95 Years|No|||February 2016|February 4, 2016|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01512615||92527|
NCT01512628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1111-140-010|Rotational Thromboelstometry (ROTEM) change_colloid_total Hip Replacement Arthroplasty|Hemostatic Changes After Colloid Fluid Administration During Total Hip Replacement Arthroplasty||Seoul National University Bundang Hospital|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|75|||Both|20 Years|N/A|No|||January 2014|January 26, 2014|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01512628||92526|
NCT01513265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-53664|Rationalisation of Polypharmacy in the Elderly by the RASP Instrument|Rationalisation of Polypharmacy in the Elderly by the RASP Instrument (Rationalisation of Home Medication by an Adjusted STOPP-list in Older Patients): a Prospective, Clinical Trial.|RASP|Universitaire Ziekenhuizen Leuven|No|Completed|December 2011|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|172|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2011|May 21, 2014|December 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01513265||92477|
NCT01509066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HERHealth-KA34|Healthy Eating for Reproductive Health (HERHealth)|Healthy Eating for Reproductive Health (HERHealth)|HERHealth|University of South Carolina|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 18, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509066||92797|
NCT01519843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B039201212957|Post Stroke Motor Learning|Post-stroke Procedural Learning: From Neural Substrates to Therapeutic Modulation by Non-invasive Brain Stimulation||University Hospital of Mont-Godinne|No|Recruiting|September 2010|December 2030|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|95 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01519843||91975|
NCT01543568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TURF-01|Study for Recalcitrant Age Related Macular Degeneration|AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study)|TURF|Greater Houston Retina Research|Yes|Completed|February 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|50 Years|N/A|No|||March 2015|March 25, 2015|February 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01543568||90165|
NCT01543581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110325|Vismodegib for Treatment of Basal Cell Carcinoma|Placebo-controlled, Double Blind Study to Assess Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery (MMS)|Erivedge|Loma Linda University|Yes|Completed|May 2012|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 24, 2014|February 14, 2012|Yes|Yes||No|September 19, 2013|https://clinicaltrials.gov/show/NCT01543581||90164|
NCT01543828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149BUS01|Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Phase IV, Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory, Single-dose Crossover Study With Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease||Novartis||Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|No|||May 2013|May 6, 2013|February 28, 2012|Yes|Yes||No|March 19, 2013|https://clinicaltrials.gov/show/NCT01543828||90145|
NCT01511705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3873/06-07|Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Ondansetron Hydrochloride Tablets 8 mg With Zofran® (Containing Ondansetron Hydrochloride Dihydrate) Tablets 8 mg in Healthy, Adult, Human Subjects Under Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Completed|October 2006|October 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2006|January 18, 2012|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511705||92597|
NCT01512017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZHAOKE-VL2010|Clinical Study on Veloderm for the Treatment of Split-thickness Skin Graft Donor Sites|A Clinical Study to Evaluate the Safety and Efficacy on Veloderm (a Crystalline Cellulose Simple Occlusive Dressing) for the Split-thickness Skin Graft Donor Sites in Burn and Plastic Surgery||Lee's Pharmaceutical Limited|Yes|Completed|June 2008|May 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|96|||Both|18 Years|65 Years|No|||January 2012|January 24, 2012|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01512017||92573|
NCT01512888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVXSCID-ND|Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants|A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells|LVXSCID-ND|St. Jude Children's Research Hospital|Yes|Recruiting|February 2012|February 2029|Anticipated|February 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Male|N/A|12 Months|No|||March 2016|March 10, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512888||92506|
NCT01512550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HipBiomech-SK|Importance of Restoring Biomechanical Correct Hip Anatomy During Total Hip Arthroplasty|Evaluation of the Importance in Restoring Biomechanical Correct Hip Anatomy During THA. A Prospective, Randomized and Controlled Study Evaluated by RSA, CT and Gait Analysis||Region Skane|No|Active, not recruiting|January 2010|December 2016|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|75|||Both|40 Years|75 Years|No|||November 2014|November 24, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01512550||92532|
NCT01512563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRA-cover|Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent|Clinical Trial Comparing Patency and Safety of the Paclitaxel Eluting Covered Metallic Biliary Stent(Niti-S Mira-Cover Biliary Stent ) to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent)|MIRA-cover|Taewoong Medical Co., Ltd.|No|Completed|February 2007|February 2010|Actual|February 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|106|||Both|19 Years|90 Years|No|||January 2012|January 15, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01512563||92531|
NCT01509014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00971412|Community Pharmacy Assisting in Total Cardiovascular Health||CPATCH|University of Saskatchewan|No|Active, not recruiting|March 2010|January 2012|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2250|||Both|N/A|N/A|No|||January 2012|January 11, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509014||92801|
NCT01509027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201112895|Study of the Compliance With Phosphorus Restricted Diet and Phosphate Binder Therapy in Hemodialysis Patients|A Randomized Controlled Trial to Evaluate the Impact of Education on the Knowledge About and Compliance With a Phosphorus Restricted Diet and Phosphate Binder Therapy in Maintenance Dialysis Patients||Universitaire Ziekenhuizen Leuven|No|Recruiting|January 2012|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Anticipated|150|||Both|18 Years|N/A|No|||January 2012|May 29, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509027||92800|
NCT01513187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOGUG-2010-01|Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma|Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma||Spanish Oncology Genito-Urinary Group|No|Completed|September 2010|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01513187||92483|
NCT01513200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRI-155|Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia|A Two Part Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers and the Effects of Bendavia™ and Unfractionated Heparin When Administered Concurrently||Stealth BioTherapeutics Inc.|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 17, 2012|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513200||92482|
NCT01509339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iVCM 1.0|Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis|Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis||Case Western Reserve University|Yes|Active, not recruiting|January 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||January 2013|January 25, 2013|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01509339||92776|
NCT01511003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRGRA-10-04-KOR|A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)|An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs|TREASURE|Astellas Pharma Inc|No|Completed|December 2011|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|20 Years|75 Years|No|||October 2015|October 27, 2015|January 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511003||92651|
NCT01509885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020682|Cyproheptadine and Chlorpromazine Effects on Spasticity|Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury||University of Alberta||Completed|July 2010|November 2012|Actual|November 2012|Actual|N/A|Observational|N/A||2|Actual|20|||Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Spinal Cord Injury Patients|November 2012|November 16, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509885||92735|
NCT01509898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0374-11-RMB|The Use of Water Jet for Initial Treatment FOR Peri-Implant Disease|The Use of Water Jet for Initial Treatment FOR Peri-Implant Disease||Rambam Health Care Campus|No|Recruiting|July 2012|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2012|May 6, 2015|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01509898||92734|
NCT01511536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD12128|Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer|A Phase I/II Study of Cabazitaxel Combined With Abiraterone Acetate and Prednisone in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC) Whose Disease Has Progressed After Docetaxel Chemotherapy||Sanofi|No|Completed|March 2012|December 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Male|18 Years|N/A|No|||November 2015|November 9, 2015|January 4, 2012|Yes|Yes||No|October 2, 2015|https://clinicaltrials.gov/show/NCT01511536||92610|
NCT01511783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-002|Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of E2609 in Healthy Subjects||Eisai Inc.||Completed|December 2011|November 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|January 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511783||92591|
NCT01512082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110021|The Effect of Reducing Soreness in Marathon Runners|The Effect of Pulsed Electromagnetic Field Therapy in Reducing Delayed Onset Muscle Soreness in Marathon Runners. A Double-blind Randomized Placebo-controlled Study.||Northern Orthopaedic Division, Denmark|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512082||92568|
NCT01512355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0466|The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery|||Yonsei University|No|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|N/A|5 Years|No|||July 2015|July 15, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01512355||92547|
NCT01512641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-API-01|Prevalence of Dissociative Disorders in Children|Prevalence of Dissociative Disorders in Children in a Population Supported in the Medico-social and Health Structures in Provence Alpes Cote d'Azur||Centre Hospitalier Universitaire de Nice|No|Completed|December 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|301|||Both|7 Years|18 Years|No|||January 2014|January 31, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01512641||92525|
NCT01512927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112015RIC|Electro Stethoscope in Detect Arteriovenous Fistula (AVF) Stenosis|Electronic Stethoscope and Computer-aided Diagnostic System in Detecting Arteriovenous Fistula (AVF) Stenosis||National Taiwan University Hospital|No|Recruiting|January 2012|December 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|20 Years|90 Years|No|Probability Sample|150|January 2012|January 18, 2012|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512927||92503|
NCT01519544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000017|Comparison of Temazepam and Acetazolamide to Treat Difficulty Sleeping at High Altitude|Treatment of High-altitude Sleep Disturbance: A Double-blind Comparison of Temazepam Versus Acetazolamide.||Massachusetts General Hospital|No|Completed|March 2012|March 2015|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 22, 2015|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01519544||91998|
NCT01519830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010/11|Iron Substitution in Blood Donors|Significance of Iron Deficiency in Transfusion Medicine: Effects of Iron Substitution on Fatigue Und General Well Being in Healthy Blood Donors|ISUB|University Hospital Inselspital, Berne|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|405|||Both|18 Years|70 Years|No|||February 2013|February 27, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01519830||91976|
NCT01509664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-115|Encouraging Healthy Food Shopping and Eating Behaviors by Price Reduction: A Community Supermarket Study|Encouraging Healthy Food Shopping and Eating Behaviors by Price Reduction: A Community Supermarket Study||New York Obesity and Nutrition Research Center|Yes|Completed|August 2006|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|January 3, 2012||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01509664||92751|
NCT01543841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEMs-DC-001|Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in Blood|A Laboratory Evaluation of Tie-2 Expressing Monocytes (TEMs) in Healthy Volunteers and Patients With Advanced Cancer||University Health Network, Toronto|No|Completed|August 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|20|None Retained|One tube of whole blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with advanced cancer attending the Phase I clinic and healthy staff at the        Princess Margaret Hospital|April 2015|April 16, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01543841||90144|
NCT01512030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02|Prevalence of Peripheral Neuropathy in Children and Adolescents With Type I Diabetes Mellitus: a Prospective Study|Prospective Study of Peripherla Neuropathy in Diabetic Type I||Landeskrankenhaus Feldkirch|No|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|8 Years|18 Years|No|Non-Probability Sample|Children and adolescents 8 to 18 years suffering from diabetes mellitus type I for more        than one year.|March 2015|March 31, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01512030||92572|
NCT01509911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLH-206|A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment|||Tiltan Pharma Ltd.||Active, not recruiting|January 2012|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|January 5, 2012||Yes||No||https://clinicaltrials.gov/show/NCT01509911||92733|
NCT01512576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AcuWAD|Does Acupuncture Activate Endogenous Pain Inhibition in Chronic Whiplash?|Does Acupuncture Activate Endogenous Pain Inhibition in Chronic Whiplash Associated Disorders? A Randomized Cross-over Trial||Vrije Universiteit Brussel|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|65 Years|No|||January 2012|January 15, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01512576||92530|
NCT01510418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-343|Socialization of Adult Men With Congenital Hemophilia A or B|Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life|PWBCD|Dana-Farber Cancer Institute|Yes|Recruiting|May 2011|December 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|21 Years|N/A|No|Non-Probability Sample|There are two study populations:        PWCBD: Person with congenital bleeding disorders are adult men with congenital hemophilia        A or B who receive care in Massachusetts or who reside in the New England area or        elsewhere and are willing to travel to the study site may be eligible for recruitment.|January 2012|January 13, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01510418||92694|
NCT01509612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5|Additive Homeopathy in Cancer Patients|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Tumors With or Without "add-on" Homeopathy|HIC|Medical University of Vienna|No|Recruiting|January 2011|January 2019|Anticipated|January 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|600|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|January 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01509612||92755|
NCT01511016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-13372|Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome|The Effect of Leptin Therapy on Abnormal Lipid Kinetics in Subjects With HIV Lipodystrophy Syndrome||Baylor College of Medicine|No|Completed|February 2003|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|17|||Male|18 Years|64 Years|No|||December 2015|December 21, 2015|January 11, 2012|Yes|Yes||No|August 13, 2013|https://clinicaltrials.gov/show/NCT01511016||92650|Relatively small sample size.Early drop-out of 3 subjects (2 in placebo arm, 2 in metreleptin arm).Possible confounders in phenotypic hetereogeneity of HIV lipodystrophy, and differences in antiretroviral drugs.
NCT01511224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTUH-TD-B-111-001|A Prospective Observational Study of Patients With Drug Resistant Acinetobacter Baumannii Bacteremia|A Prospective Observational Study of Patients With Drug Resistant Acinetobacter Baumannii Bacteremia Treated With Antibiotics Therapy|ANTI-AB|National Taiwan University Hospital|No|Recruiting|August 2010|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|200|Samples With DNA|Blood sample will be collected on the day of enrollment (Day 0), Day 1, 2, 3 and 7 for PCR      identification and quantification of Acinetobacter species.|Both|16 Years|N/A|No|Non-Probability Sample|Patients admitted on intensive care units as well as general ward with AB bacteremia        receiving antimicrobial therapy are eligible for this study.|January 2012|January 17, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01511224||92634|
NCT01511809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODAt|Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression|Efficacy of Atazanavir / Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression. Randomized, Open Label Non Inferiority Trial. A Phase 3 Study.||Ospedale San Raffaele|Yes|Completed|September 2010|May 2015|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|90 Years|No|||January 2016|January 8, 2016|January 13, 2012||No||No|November 7, 2014|https://clinicaltrials.gov/show/NCT01511809||92589|
NCT01518114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8081-MA-CTIL|Exercise Training in Patients With Hypertrophic Cardiomyopathy|||Sheba Medical Center|No|Recruiting|December 2011|||January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2012|January 26, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01518114||92107|
NCT01518348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mekos 107P3.2 401|Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents|Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents|PREAII|Allerderm|No|Withdrawn|December 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|6 Years|18 Years|No|||February 2013|February 26, 2013|March 16, 2011|Yes|Yes|Study has been updated with new protocol number|No||https://clinicaltrials.gov/show/NCT01518348||92089|
NCT01518374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A14|Clinical Evaluation of Florbetapir F 18 (18F-AV-45)|Clinical Evaluation of Florbetapir F 18 (18F-AV-45)||Avid Radiopharmaceuticals|No|Recruiting|December 2009|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|1800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518374||92088|
NCT01518387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11878|Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients|Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)||Bayer|No|Completed|January 2006|July 2006|Actual|July 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|20 Years|75 Years|No|||March 2016|March 10, 2016|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01518387||92087|
NCT01518634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004294-87|Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome|Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3)|Stress-3|University of Aarhus|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|20 Years|50 Years|No|||January 2013|January 13, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01518634||92068|
NCT01518959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-HEM|The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases|Phase III, Controlled, Double-blind, Randomized Study of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases|D-HEM|Semmelweis University|No|Recruiting|January 2012|||January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01518959||92043|
NCT01519531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIA-3196-02|Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects|A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects||Madrigal Pharmaceuticals, Inc.|No|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01519531||91999|
NCT01519011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-MDS-004|Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine|A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA||Celgene Corporation|No|Completed|February 2012|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|34|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01519011||92039|
NCT01519024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRACINI_1|Postural Control in Breast Hypertrophy|Poorer Postural Control in Women With Breast Hypertrophy.||University of Sao Paulo General Hospital|No|Completed|April 2010|September 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|28|||Female|24 Years|73 Years|Accepts Healthy Volunteers|Non-Probability Sample|The fourteen women for breast hypertropy group were recruited from the Department of        Plastic Surgery and Department of Gynecology of Clinical Hospital, Faculty of Medicine,        University of São Paulo, and the fourteen women of control group (without breast        hypertrophy)was compound by women dwelling community.|January 2012|January 25, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01519024||92038|
NCT01519271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813803|Mild Cognitive Impairment in Parkinson's Disease|A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease||University of Pennsylvania|No|Completed|December 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|40 Years|85 Years|No|||January 2012|February 24, 2015|January 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01519271||92019|
NCT01519284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-114|Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic|A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects||Bial - Portela C S.A.|No|Completed|November 2009|June 2011|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|82|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 23, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01519284||92018|
NCT01541150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8673|Impaired Decision Making in Pedophilic Offenders|Neuropsychological Approach of Pedophilic Behaviors, a Pilot Study in a Population of Inmates Pedophilic Offenders||University Hospital, Montpellier|No|Recruiting|August 2011|January 2017|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|128|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||February 2012|December 30, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541150||90349|
NCT01541449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV-0061-11|Plaqenil Role in Prevention of Age Related Macular Degeneration|Observational Study Between People That Use Plaquenil and Those Who do Not in Prevention of AMD.||Ziv Hospital|Yes|Recruiting|January 2012|April 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ziv Medical center retina clinic population|January 2012|February 29, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01541449||90326|
NCT01541436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00019284|Remote Ischemic Preconditioning Mechanism Study|Remote Ischemic Preconditioning Effects on Central and Peripheral Sensitization in Healthy Volunteers-A Pilot Study||Wake Forest Baptist Health|No|Recruiting|March 2012|December 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01541436||90327|
NCT01512316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMDCSACQEXT|Exploring Learning and Unlearning of Fear|The Effect of D-cycloserine on Fear Learning and Extinction||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|90|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2011|January 13, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01512316||92550|
NCT01512589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1036|Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial|Phase III Randomized Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for the Treatment of Esophageal Cancer||M.D. Anderson Cancer Center|Yes|Recruiting|April 2012|||April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512589||92529|
NCT01509638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B501|A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal|IMPROVE-IR|Pacira Pharmaceuticals, Inc|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|47|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|October 24, 2011|Yes|Yes||No|November 30, 2013|https://clinicaltrials.gov/show/NCT01509638||92753|
NCT01513213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5119S-11|Correlation of PaCO2 to the Inspired and Expired Oxygen Gradient|Correlation of PaCO2 to the Inspired and Expired Oxygen Gradient|O2 Fraction|Swedish Medical Center|No|Active, not recruiting|October 2011|December 2016|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Adults age 18 to 65 scheduled for a surgical procedure that will last at least two hours        and for whom arterial cannulation and at least two arterial blood gas analyses are planned        during the surgery.|March 2016|March 1, 2016|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01513213||92481|
NCT01513226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-160.7.002.920-3|Cycled Light and Crying of Preterm Infants|Cycled Light Exposure Reduces Fussing and Crying in Very Preterm Infants||University Children's Hospital, Zurich|No|Completed|June 2006|September 2008|Actual|January 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|37|||Both|N/A|N/A|No|||January 2012|January 19, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01513226||92480|
NCT01510132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-012|Travacom Post Marketing Surveillance Study|Post Marketing Surveillance Study to Evaluate the Safety Profile of Travacom (Travoprost/Timolol Fixed Combination) in Patients With Open-Angle Glaucoma or Ocular Hypertension Across India||Alcon Research|No|Withdrawn|January 2012|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 16, 2012|January 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01510132||92716|
NCT01510171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPID|Rapid Activity of Platelet Inhibitor Drugs Study|Rapid Activity of Platelet Inhibitor Drugs Study|RAPID|Careggi Hospital|Yes|Completed|January 2012|January 2013|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510171||92713|
NCT01510691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VE-Oxygen-28062010|Vitrectomy Retinal Oxygenation|The Influence of Retinal Oxygenation on the Clinical Outcomes in Eyes With Different Vitreoretinal Pathologies After a Successful Vitrectomy||Medical University of Vienna||Completed|October 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|7|||Both|18 Years|N/A|No|Non-Probability Sample|Group 1: 20 patients with macular edema following epiretinal membrane Group 2: 20 patients        with persistent diabetic macular edema. Group 3: 20 patients with persistent macular edema        following retinal vein occlusion|April 2015|April 14, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510691||92674|
NCT01522014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000886|Randomized Clinical Trial of Ceramic Bearing Primary Total Hip Arthroplasty|Five-Year Outcome of Ceramic on Ceramic Bearing Versus Ceramic on Crossfire® Highly Cross-Linked Polyethylene Bearing in Primary Total Hip Arthroplasty: A Randomized Trial||University of Alberta|No|Completed|November 1997|June 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|60 Years|No|||February 2012|February 19, 2013|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522014||91808|
NCT01511549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU11333|Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee Osteoarthritis|A Randomized, Double-blind, Placebo-controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SAR113945 (IKK Inhibitor) Following Intra-articular Administration in Japanese Patients With Knee Osteoarthritis||Sanofi|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|40 Years|N/A|No|||September 2012|September 28, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01511549||92609|
NCT01511562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-51101|Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma|A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma||Alliance for Clinical Trials in Oncology|No|Recruiting|September 2012|||October 2026|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511562||92608|
NCT01518101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLMF237ADE03|Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications|A Randomized, Open-label, Cross-over Study to Evaluate Patient Preferences for Eucreas® Versus Victoza® as add-on to Metformin in Type 2 Diabetes Mellitus Patients Who Did Not Have Adequate Glycaemic Control With Metformin.|PREFER|Novartis||Completed|January 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|40 Years|80 Years|No|||August 2013|August 16, 2013|January 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01518101||92108|
NCT01517893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-DERM001|Clinical Trial of Simvastatin to Treat Generalized Vitiligo|A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo||University of Massachusetts, Worcester|Yes|Completed|January 2012|December 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|64 Years|No|||March 2015|March 11, 2015|January 13, 2012|Yes|Yes||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01517893||92124|
NCT01518400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCI-09-00027|LIFE Cancer Survivorship Database for Pediatric Cancer|A Research Database for Survivors of Childhood Cancer||Children's Hospital Los Angeles|No|Recruiting|February 2009|December 2050|Anticipated|January 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|Population diagnosed with cancer at 21 years of age or younger|February 2015|February 5, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01518400||92086|
NCT01518647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110265|Acceptance and Commitment Therapy for Patients With Multi-organ Bodily Distress Syndrome (Stress-4)|Treatment of Multi-organ Bodily Distress Syndrome. A Randomized Controlled Trial of the Effects of Acceptance and Commitment Therapy Given as Group Therapy or Workshop Compared to Standard Treatment (Stress-4)|Stress-4|University of Aarhus|No|Active, not recruiting|January 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|20 Years|50 Years|No|||January 2013|May 23, 2014|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01518647||92067|
NCT01518972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20AA017839|Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder|A Placebo-Controlled Trial of Prazosin in Individuals With Co-occurring Alcohol Dependence and PTSD Seeking Abstinence||Seattle Institute for Biomedical and Clinical Research|Yes|Active, not recruiting|September 2009|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||August 2012|August 13, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01518972||92042|
NCT01518985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRI-120|The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking|A Phase 1, Placebo-Controlled Trial to Evaluate the Impact of Intravenous (IV) Bendavia™ (MTP-131) on Endothelial Reactivity Dysfunction Induced by Cigarette Smoking||Stealth BioTherapeutics Inc.|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 17, 2012|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518985||92041|
NCT01510210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHS2010B233|Risk Profile for Patients With Atrial Fibrillation|Identification of a Risk Profile to Guide Atrial Fibrillation Therapy||University Medical Center Groningen|No|Recruiting|April 2011|June 2021|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with short-lasting symptomatic paroxysmal or persistent AF|July 2015|July 27, 2015|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01510210||92710|
NCT01541709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSTI571BKR24T|Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation|A Phase II Study of Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation||Asan Medical Center|No|Recruiting|March 2012|August 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541709||90306|
NCT01542242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWS.VGH.UBC|Liraglutide Use in Prader-Willi Syndrome|||Vancouver General Hospital||Terminated|February 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|19 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|February 21, 2012||No|Subject withdrew|No||https://clinicaltrials.gov/show/NCT01542242||90266|
NCT01509625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIB-FUL-2011-01|Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)|Assessment of Treatment Response With Faslodex® (500 mg) in Standard Clinical Practice Through a Retrospective Study|EFFICACY|Hospital Clinico Universitario San Cecilio|No|Recruiting|January 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|120|||Female|18 Years|80 Years|No|Non-Probability Sample|Post-menopausal women with Advanced Breast Cancer (ABC) and estrogen receptor positive        (ER+) who were treated with this medicinal product and at said dose after having        progressed with a previous anti-estrogen therapy|August 2013|August 20, 2013|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01509625||92754|
NCT01510717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-016|Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0]|Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2||Alcon Research|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|409|||Both|21 Years|N/A|No|||May 2015|May 8, 2015|January 12, 2012|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01510717||92672|
NCT01510145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-300|Efficacy of Changing to TRAVATAN® From Prior Therapy|Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy||Alcon Research|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|191|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|January 11, 2012||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT01510145||92715|
NCT01510158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-301|Combining Lesinurad With Allopurinol in Inadequate Responders|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol|CLEAR 1|Ardea Biosciences, Inc.|Yes|Completed|January 2012|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|613|||Both|18 Years|85 Years|No|||May 2015|May 18, 2015|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510158||92714|
NCT01521247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJMG-2010|Implementation of a Pediatric-to-adult Asthma Transition Program|||University of Calgary|No|Recruiting|April 2010|July 2015|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|34|||Both|17 Years|19 Years|No|||May 2015|May 26, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01521247||91867|
NCT01521260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27147.042.09|Implant Surface Decontamination in Peri-implantitis Treatment|Microbiological and Clinical Evaluation of Different Implant Surface Decontaminating Procedures in the Surgical Treatment of Peri-implantitis; a Double Blind Placebo Controlled Randomized Clinical Study||University Medical Center Groningen|No|Completed|October 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||June 2013|June 28, 2013|January 18, 2012||No||No|May 3, 2013|https://clinicaltrials.gov/show/NCT01521260||91866|
NCT01510431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD 620|Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease|An Open-label Compassionate Treatment Protocol to Evaluate the Safety and Treatment Outcomes of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease||Mesoblast, Ltd.|No|Completed|May 2009|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|70 Years|No|||May 2014|May 19, 2015|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01510431||92693|
NCT01510704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP10006|Phase II Dose-ranging Study of APD421 in PONV|Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study of APD421 for the Prevention of Post-operative Nausea and Vomiting||Acacia Pharma Ltd|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|215|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|January 12, 2012|Yes|Yes||No|May 15, 2013|https://clinicaltrials.gov/show/NCT01510704||92673|
NCT01517854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RePo1|Revatio Portal-Pulmonary Arterial Hypertension Trial|Revatio Portal-Pulmonary Arterial Hypertension Trial (RePo1 Trial): A Randomized, Double-blinded, Placebo-controlled, Multi-center Study to Evaluate the Effects of Sildenafil Citrate (Revatio) 20 mg TID on Patients With Portal Pulmonary Arterial Hypertension (PPAH)|RePo1|University Health Network, Toronto|Yes|Enrolling by invitation|October 2012|||November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|75 Years|No|||June 2015|June 17, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01517854||92127|
NCT01517867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR012444|Early Parenting Intervention Comparison|Comparing Two Parenting Programs for At-Risk Families|EPIC|Johns Hopkins University|Yes|Recruiting|September 2011|June 2016|Anticipated|October 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|264|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01517867||92126|
NCT01517880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UX001-CL201|A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy|GNE Myopathy|Ultragenyx Pharmaceutical Inc|Yes|Completed|May 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|46|||Both|18 Years|65 Years|No|||January 2014|January 15, 2014|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517880||92125|
NCT01509118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15635|Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery|Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery||Phramongkutklao College of Medicine and Hospital|No|Recruiting|July 2011|September 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|50 Years|N/A|No|Probability Sample|Rivaroxaban safety profile will be observed in 500 patients|January 2012|January 11, 2012|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01509118||92793|
NCT01518127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sao Paulo University|Intravitreal Bone Marrow-Derived Stem Cells in Patients With Macular Degeneration|Intravitreal Bone Marrow-Derived Stem Cells in Patients With Macular Degeneration|AMDCELL|University of Sao Paulo|Yes|Recruiting|August 2011|December 2015|Anticipated|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|80 Years|No|||December 2014|December 3, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01518127||92106|
NCT01518140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0689|BiPAP-Vapotherm RCT|Novel Oxygen Delivery Modalities for Refractory Dyspnea in Patients With Advanced Cancer||M.D. Anderson Cancer Center|Yes|Withdrawn|December 2013|||December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 12, 2013|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518140||92105|
NCT01518413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SorIrin1576|Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors|Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors||Children's Research Institute|Yes|Completed|December 2011|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|2 Years|22 Years|No|||February 2015|February 26, 2015|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01518413||92085|
NCT01518426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00102-39|Evaluation of Evoked Potentials Recording Modalities in Healthy Volunteer Population|Evaluation of Evoked Potentials Recording Modalities in Healthy Volunteer Population.|3Electrods|Centre d'Investigation Clinique et Technologique 805|Yes|Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2014|May 5, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01518426||92084|
NCT01518660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS&PRT_SSAU_TK|Multiple Sclerosis and Progressive Resistance Training|Multiple Sclerosis - Inflammatory, Neurological and Muscular Adaptations to Progressive Resistance Training||University of Aarhus|Yes|Completed|February 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|60 Years|No|||April 2013|December 1, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01518660||92066|
NCT01518998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-FAC-CT-201|A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension|||Boryung Pharmaceutical Co., Ltd|Yes|Recruiting|August 2011|October 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Anticipated|405|||Both|20 Years|75 Years|No|||March 2013|March 26, 2013|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01518998||92040|
NCT01509950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22389|Comparison of Staples Versus Prolene Suture for Skin Closure at Cesarean Delivery|Comparison of Staples Versus Nonabsorbable Subcuticular (Prolene) Suture for Skin Closure in Cesarean Deliveries: A Randomized Study||Stanford University|No|Recruiting|January 2012|January 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Female|18 Years|55 Years|No|||November 2014|November 18, 2014|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01509950||92730|
NCT01509963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 10073|The Memorial Sloan-Kettering Cancer Center (MSKCC|Prospective Evaluation of the Reliability of the Combined Use of Two Models to Predict Non-sentinel Lymph Node Status in Breast Cancer Patients With Metastatic Sentinel Lymph Nodes: the MSKCC Nomogram and the Tenon Score.|NOTEGS|Assistance Publique - Hôpitaux de Paris|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3194|||Female|18 Years|N/A|No|Non-Probability Sample|The study will focus on patients candidates for the SN procedure as recommended by        Saint-Paul de Vence initially in 2005 but modified in 2009.|August 2013|August 2, 2013|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01509963||92729|
NCT01541163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT 11046-6/2010|Heart and Ischemic STrOke Relationship studY|Assessment of Relationship Between Acute Ischemic Stroke and Heart Disease|HISTORY|University Hospital Olomouc|Yes|Recruiting|September 2010|December 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Probability Sample|Consecutive ischemic stroke patients within 12 hours from stroke onset, who will be        admitted at Comprehensive Stroke Center, Department of Neurology, University Hospital        Olomouc from the October 2010 until December 2015.|December 2015|December 14, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541163||90348|
NCT01542255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1010|Metronomic Therapy in Patients With Metastatic Melanoma|Metronomic Therapy in Patients With Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine||Dartmouth-Hitchcock Medical Center|Yes|Terminated|June 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|January 17, 2012|Yes|Yes|Low accrual not allowing to support statistical endpoints|No|August 28, 2014|https://clinicaltrials.gov/show/NCT01542255||90265|terminated early due to difficulty with scheduling three times per week office treatment
NCT01509365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03 PID 11|Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27|Evaluation the Effect of the Double Maintenance Dose of Clopidogrel Versus Single Dose in Patients With Coronary Artery Disease With a BMI ≥ 27 kg.m-2|PLATO-dose|Les Laboratoires des Médicaments Stériles|Yes|Completed|December 2011|May 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|116|||Both|20 Years|N/A|No|||October 2014|May 6, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509365||92774|
NCT01520909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115450|Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.|A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP|PETIT2|GlaxoSmithKline|Yes|Completed|March 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|92|||Both|1 Year|17 Years|No|||February 2015|February 19, 2015|December 21, 2011|Yes|Yes||No|August 21, 2014|https://clinicaltrials.gov/show/NCT01520909||91893|
NCT01520922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115991|Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)|A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)||GlaxoSmithKline|No|Active, not recruiting|March 2012|December 2015|Anticipated|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|99|||Both|18 Years|N/A|No|||April 2015|October 29, 2015|January 19, 2012|Yes|Yes||No|October 10, 2013|https://clinicaltrials.gov/show/NCT01520922||91892|
NCT01520935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116273|Influenza Burden Assessment in the United Kingdom, 1996-2008|Burden of Influenza in the United Kingdom, 1996-2008||GlaxoSmithKline||Completed|September 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|People of any age in the United Kingdom who were registered with an acceptable flag in the        GPRD, or with a potentially influenza-related event in the HES database or the ONS        mortality data.|September 2012|September 6, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01520935||91891|
NCT01509924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tiohundra|Cognitive and Physical Functions in Patients With Transient Ischemic Attack. A Randomized Controlled Trial of Physical Activity on Prescription up to One Year After the Event|Cognitive and Physical Functions in Patients With TIA. A Randomized Controlled Trial of Physical Activity on Prescription up to One Year After the Event||Tiohundra AB|Yes|Active, not recruiting|May 2010|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|100|||Both|N/A|N/A|No|||September 2014|September 15, 2014|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01509924||92732|
NCT01521520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001957|Imaging of Type 1 Diabetes Progression|Ferumoxytol Enhanced Magnetic Resonance Imaging of Type 1 Diabetes Progression||Massachusetts General Hospital|No|Active, not recruiting|January 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will be selected from those already participating in diabetes clinical        trials.|July 2014|July 31, 2014|January 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01521520||91846|
NCT01521507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF-004|Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye|Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye||TearScience, Inc.|No|Completed|January 2012|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|January 26, 2012|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01521507||91847|
NCT01521741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-540|Prospective Analysis of Symptoms and Lymphedema in Patients Following Treatment for Breast Cancer|Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer.||Massachusetts General Hospital|No|Recruiting|August 2009|||August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Female|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed breast cancer patients.|March 2016|March 14, 2016|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01521741||91829|
NCT01521533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXA12C301|NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma|A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bortezomib and Dexamethasone (VD) in Previously Treated Patients With Multiple Myeloma (MM)||NOXXON Pharma AG|Yes|Completed|March 2012|September 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521533||91845|
NCT01522027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro000026880|Electrically Guided Needle Insertion: ICU Study|Use of Nerve Stimulation Technology to Aid in Percutaneous Tracheostomy in Intensive Care Patients.||University of Alberta|No|Active, not recruiting|May 2012|July 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|80 Years|No|||December 2014|December 17, 2014|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522027||91807|
NCT01522040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0641|Pilot Study of Magnesium Infusions in Pediatric Asthma|A Pilot Study of Magnesium Infusions (Drips) for Moderate-to-Severe Pediatric Asthma Exacerbations||University of Louisville|Yes|Recruiting|January 2012|||July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|2 Years|20 Years|No|||June 2012|June 12, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01522040||91806|
NCT01513005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10-PR.-REGIMBEAU|Feasibility of Laparoscopic Sleeve Gastrectomy in Day Case Surgery|Feasibility of Day Case Management by Laparoscopic Sleeve Gastrectomy for Obesity: a Pilot Study|GASTRAMBU|Centre Hospitalier Universitaire, Amiens|No|Completed|May 2011|May 2013|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||February 2014|February 4, 2014|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513005||92497|
NCT01509443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA-2011-015|Breathing & Mild Physical Exercise Therapy for Asthma|Application of Breathing Exercise Program to Improve Asthma in Obese Patients: Effects on Clinico-immunological Parameters||Dasman Diabetes Institute|No|Recruiting|April 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01509443||92768|
NCT01509703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trachea 2.0|Respiratory Physiology Under High Flow Therapy|Respiratory Physiology Measurements Under Transnasal High Flow Therapy in Patients With Tracheostoma After Long Term Ventilation||Institut für Pneumologie Hagen Ambrock eV|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|20 Years|80 Years|No|||March 2015|March 23, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01509703||92748|
NCT01509456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO-2004-068 (MAP)|The Effect of Potassium Bicarbonate on Bone and Several Physiological Systems During Immobilisation|The Effect of Potassium Bicarbonate on Bone and the Immune System During 21 Days of 6° Head- Down- Tilt Bedrest (HDT- Bedrest)|NUC|DLR German Aerospace Center|No|Completed|February 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|8|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 10, 2012|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01509456||92767|
NCT01509469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36916.068.11|The Effect of Different Macronutrients on Ileal Brake Activation|The Effect of Different Macronutrients on Ileal Brake Activation||Maastricht University Medical Center|No|Completed|March 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 28, 2014|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01509469||92766|
NCT01509482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|insulin resistance|Insulin Resistance in Idiopathic Oligospermia and Azoospermia|Insulin Resistance : a New Diagnosis of the Pathogenesis of Idiopathic Oligozoospermia and Non Obstructive Azoospermia||The Egyptian IVF-ET Center|Yes|Completed|January 2012|April 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 23, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01509482||92765|
NCT01509716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Domain E/2011/02008|Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients|Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis CKD Patients||National University, Singapore|No|Recruiting||||||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Predialysis patients with stage 3-5 chronic kidney disease patients seen in outpatient        renal clinic in National University Hospital, Singapore|April 2015|April 14, 2015|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01509716||92747|
NCT01542008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH0933 21-01A1|Treatment Adherence Enhancement in Bipolar Disorder|Treatment Adherence Enhancement in Bipolar Disorder|CAE RCT|Case Western Reserve University|No|Recruiting|April 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01542008||90284|
NCT01542021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-182|Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer|Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|41|||Male|18 Years|N/A|No|||March 2016|March 1, 2016|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542021||90283|
NCT01542034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-11-22|Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|REFINE-1|Kythera Biopharmaceuticals|No|Completed|February 2012|August 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|506|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|February 24, 2012|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01542034||90282|
NCT01541969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11IH006|Evaluation of the CR Neuromodulation Treatment for Tinnitus|Systematic Evaluation of the Acoustic CR ® Neuromodulation Treatment for Tinnitus|RESET2|Nottingham University Hospitals NHS Trust|Yes|Completed|August 2012|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2015|July 14, 2015|February 24, 2012||No||No|April 18, 2015|https://clinicaltrials.gov/show/NCT01541969||90287|Clinical Trial Protocol inadequately specified, particularly (i) device fitting, (ii) tolerance for pitch matching shifts and (iii) monitoring research audiologists after training. Specification of placebo algorithm is not evidenced by published data
NCT01541982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-2 Quality Control|Virtual Autopsy for Quality Control on Intensive Care Medicine|Virtual Autopsy for Quality Control on Intensive Care Medicine||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2012|July 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|160|||Both|18 Years|N/A|No|Non-Probability Sample|patients dying in the icu|June 2015|June 16, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541982||90286|
NCT01541995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA-3 Contrast Medium|Evaluation of Contrast Medium Enhanced Post-mortem CT in Virtual Autopsy|||Universitätsklinikum Hamburg-Eppendorf|No|Completed|April 2012|||August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|Samples Without DNA|Histology|Both|18 Years|N/A|No|Probability Sample|patients dying in the ICU during the study period|September 2013|September 27, 2013|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541995||90285|
NCT01542593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0051-CTIL|Evaluating Ureteral Length Using Computed Tomography (CT)|Evaluation of Ureteral Length Measurement by Computed Tomography (CT) to Actual Ureteral Length Measured by Ureteral Catheterization|URO-Y-2|Carmel Medical Center|No|Completed|February 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|53|||Both|18 Years|75 Years|No|||April 2015|April 29, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01542593||90239|
NCT01542606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F-7-28.6-1|Performance Proof of Product Developed to Detect Abnormal Vaginal pH|Performance Proof of The Norma-Sense Gen 3 - Wearing Study||Common Sense|Yes|Not yet recruiting|March 2012|November 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|256|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||November 2011|March 1, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01542606||90238|
NCT01510457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-MD-23|Milnacipran for Chronic Pain in Knee Osteoarthritis|Milnacipran for the Pain, Sensory Sensitization and Mood Changes in Knee Osteoarthritis|KOA|Rehabilitation Institute of Chicago|No|Completed|November 2010|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|90 Years|No|||May 2015|May 26, 2015|November 29, 2011|Yes|Yes||No|November 5, 2014|https://clinicaltrials.gov/show/NCT01510457||92692|
NCT01520896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00012|Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118|An Open-label, 1-sequence, 3-period, 3-treatment, Crossover Study to Assess the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118 in Healthy Subjects||AstraZeneca||Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|January 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01520896||91894|
NCT01520948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7892W|Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease|Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease|BETTUR PD|Atlanta VA Medical Center|No|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01520948||91890|
NCT01520961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR122011|Functional Recovery After Partial Hip Arthroplasty: Anterior or Posterolateral Approach?|Approach Your Neck Fracture|AYNF|Hospital Ambroise Paré Paris|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|Partial Hip Arthroplasty for Femoral Neck Fracture|February 2015|February 6, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01520961||91889|
NCT01520974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORA.2011.PB3|Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)|ProBiora3 Oral Care Probiotics Usage||Oragenics, Inc.|No|Recruiting|January 2012|||August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|48|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2012|May 1, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01520974||91888|
NCT01521286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114617|Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain|Population Based Surveillance to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain||GlaxoSmithKline||Completed|March 2012|May 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|552|||Both|50 Years|N/A|No|Non-Probability Sample|Adult population, male or female, ≥50 years of age presenting with a HZ episode.|September 2015|September 24, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01521286||91864|
NCT01521299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1049|A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors|A Phase I Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors||Dartmouth-Hitchcock Medical Center|Yes|Withdrawn|March 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 24, 2012|October 31, 2011||No|Insufficient population of eligible patients.|No||https://clinicaltrials.gov/show/NCT01521299||91863|
NCT01512706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV71-KMB17-II-IMB-CAMS|A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants|A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants||Chinese Academy of Medical Sciences|Yes|Completed|July 2011|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|15||Actual|660|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||June 2011|April 26, 2012|January 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512706||92520|
NCT01512966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15657|Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)|An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema|VIVID-Japan|Bayer|Yes|Completed|January 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|January 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01512966||92500|
NCT01521754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.02.9001|Product Surveillance Registry- Deep Brain Stimulation for Epilepsy|Medtronic Registry for Epilepsy (MORE)|MORE|Medtronic International Trading Sarl|Yes|Recruiting|February 2012|August 2020|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Adults diagnosed with refractory epilepsy characterized by partial-onset seizures, with or        without secondary generalization|December 2015|December 3, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01521754||91828|
NCT01512979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.83|Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes|A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patients||Boehringer Ingelheim||Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|January 16, 2012||||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01512979||92499|
NCT01513317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100752|A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome||Janssen Research & Development, LLC|Yes|Terminated|November 2011|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|October 21, 2011|Yes|Yes|The study was stopped after the interim analysis based on lack of sufficient efficacy. There    were no safety concerns.|No|September 24, 2014|https://clinicaltrials.gov/show/NCT01513317||92473|
NCT01513018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEOEC RKEB/IKEB 2976-2009|Effects of High and Low Tidal Volumes on Arterial Oxygenation and Pulmonary Shunt During One-Lung Ventilation|||The Cleveland Clinic||Completed|June 2009|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513018||92496|
NCT01513031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRONE_L_06034|Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation|Pilot Project to Determine Rates and Reasons for Non-Adherence in Patients Receiving Chronic Oral Antiarrhythmic Therapy for Atrial Fibrillation in the State of Nebraska||Creighton University|No|Terminated|January 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|9|||Both|19 Years|N/A|No|||June 2012|June 28, 2012|January 16, 2012||No|Low enrollment|No||https://clinicaltrials.gov/show/NCT01513031||92495|
NCT01513330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP219|Performance Study of Newly Developed Ostomy Products|An Open-labelled, Randomised, Controlled, Crossover Investigation Evaluating Performance of a Newly Developed Ostomy Care Product Compared to Standard Care.||Coloplast A/S|No|Completed|November 2011|August 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|122|||Both|18 Years|N/A|No|||November 2013|November 21, 2013|January 10, 2012||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT01513330||92472|
NCT01509131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMF105BC1/09|Evaluation of a Mixed Bowel Prep (2L PEG + Bisacodyl) Versus PEG With Ascorbate|Low Volume Bowel Preparation for Colonoscopy: a Comparison Between PEG-CS Plus Bisacodyl Versus PEG-ASC||Promefarm S.r.l.|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|408|||Both|18 Years|85 Years|No|||January 2012|January 11, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01509131||92792|
NCT01509144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023693-39|EuroNeut41: Safety & Immunogenicity of Immunisations With HIV Vaccine|Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers||PX'Therapeutics|Yes|Completed|January 2012|October 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|48|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01509144||92791|
NCT01509157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006447ctil|MDRS for Prevention of Nocturnal Hypoglycemia|Prevention of Nocturnal Hypoglycemia in Children and Young Adults With Type 1 Diabetes Using a Remote Safety and Control Diabetes Management System|MDRS|Rabin Medical Center|No|Completed|January 2012|April 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|38|||Both|4 Years|24 Years|No|||July 2013|July 15, 2013|December 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01509157||92790|
NCT01509729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110028|Topical Lidocaine After Major Arthroscopic Knee Surgery|Topical Lidocaine Patch Does Not Have an Analgesic Effect After Major Arthroscopic Knee Surgery. A Double-blind Place-controlled Randomized Study||Northern Orthopaedic Division, Denmark|No|Completed|June 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01509729||92746|
NCT01509742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1224|Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes|Effect of NNC 90-1170 on Hypoglycaemic Counterregulation During Stepwise Hypoglycaemic Clamp in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, 2-period Cross-over Trial||Novo Nordisk A/S|No|Completed|April 2001|November 2001|Actual|November 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|30 Years|75 Years|No|||February 2015|February 18, 2015|January 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01509742||92745|
NCT01509989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Record2012|International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus|International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus|Adherence-SLE|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|January 2013|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|307|Samples With DNA|blood|Both|6 Years|80 Years|No|Probability Sample|Active Systemic Lupus Erythematosus (see eligibility criteria)|October 2015|October 6, 2015|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01509989||92727|
NCT01542047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1015|A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies|A Phase I Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies||New Mexico Cancer Care Alliance|Yes|Terminated|August 2012|July 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|February 6, 2012|No|Yes|Low rate of accrual|No||https://clinicaltrials.gov/show/NCT01542047||90281|
NCT01542060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1892|Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus|A Clinical Experience Programme to Collect Data on the Safety and Efficacy of NovoMix® 30 in the Treatment of Patients With Type 2 Diabetes in Jordan||Novo Nordisk A/S|No|Completed|January 2004|December 2004|Actual|December 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|298|||Both|N/A|N/A|No|Non-Probability Sample|Patients from hospitals or clinics diagnosed with type 2 diabetes mellitus|April 2012|April 11, 2012|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542060||90280|
NCT01542268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-PTX|Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)|Effect of Pentoxifylline on Tight Junctions of Intestinal Mucosa in Patients With Irritable Bowel Syndrome|IBS-PTX|Hospital Universitario de Canarias|Yes|Not yet recruiting|March 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|59|||Both|18 Years|65 Years|No|||March 2012|March 5, 2012|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01542268||90264|
NCT01542619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL689_1001|A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers|A Randomized, Placebo-controlled, Single Center, 5 Cohort Dose Escalation Trial to Investigate Safety and Pharmacokinetics of rVIIa-FP (CSL689) in Comparison to Placebo in Healthy Male Human Volunteers||CSL Behring||Completed|March 2012|July 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2013|May 19, 2014|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01542619||90237|
NCT01542632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-DEN-104|A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers|A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 - 45 Years||Takeda|No|Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|140|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|February 27, 2012|Yes|Yes||No|December 31, 2014|https://clinicaltrials.gov/show/NCT01542632||90236|
NCT01520402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1442|Genetic Response to Warfarin in Healthy Subjects|Quantitative Pharmacogenomics of the Anticoagulant Response to Warfarin in Healthy Subjects||Icahn School of Medicine at Mount Sinai|Yes|Completed|June 2009|May 2011|Actual|May 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|35|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||February 2013|February 6, 2013|January 18, 2012|Yes|Yes||No|October 24, 2012|https://clinicaltrials.gov/show/NCT01520402||91932|Small number of subjects, which prevented detection of modest effects; relied on self-reported race and self-reported adherance to vitamin K restricted diet without objective markers such as ancestry informative markers and serum vitamin k levels.
NCT01521273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rwa3|Iron Absorption From Biofortified Beans With Different Levels of Phytic Acid|A Multiple Meal Study to Evaluate the Role of Phytic Acid From Beans on Human Iron Absorption||Swiss Federal Institute of Technology|No|Completed|March 2012|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|25|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01521273||91865|
NCT01512134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0329|Deep Brain Stimulation for the Treatment of Obesity|Deep Brain Stimulation For Morbid, Treatment-Refractory, Obesity||Ohio State University|No|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|22 Years|60 Years|No|||February 2016|February 19, 2016|January 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01512134||92564|
NCT01512147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007472|Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients|Measuring the Effects of Dexmedetomidine on Somatosensory Evoked and Muscular Evoked Potential During Neurosurgery in Pediatric Patients||Oregon Health and Science University|No|Recruiting|December 2011|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|2 Years|12 Years|No|||October 2015|October 14, 2015|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01512147||92563|
NCT01512407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2011.236-T|RCT on Adjuvant TACE After Hepatectomy for HCC|Randomised Controlled Trial on Adjuvant Transarterial Chemoembolisation After Curative Hepatectomy for Hepatocellular Carcinoma|A-TECH|Chinese University of Hong Kong|No|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|70 Years|No|||February 2015|February 2, 2015|January 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512407||92543|
NCT01512693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-070|Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Subjects With Moderate Hepatic Insufficiency (MK-0822-070)|Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Hepatic Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|January 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01512693||92521|
NCT01512160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1351010|Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain|A Randomized, Double-Blind Third Party Open, Double-Dummy, Parallel Group, Placebo Controlled Study Assessing The Efficacy Of Single Doses Of Pf-04531083 For The Treatment Of Post-Surgical Dental Pain Using Ibuprofen 400 Mg As A Positive Control||Pfizer|Yes|Terminated|October 2011|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|90|||Male|18 Years|55 Years|No|||May 2013|May 23, 2013|August 30, 2011|Yes|Yes|See termination reason in detailed description.|No|March 14, 2013|https://clinicaltrials.gov/show/NCT01512160||92562|Study was terminated for futility based on results of interim analysis.
NCT01512992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH_pilotCAT|Home Telehealth Follow-up After Hospital Discharge for Chronic Obstructive Pulmonary Disease (COPD) Patients|Renewing Health RCT in Catalonia for the Evaluation of Home Telehealth Follow-up After Hospital Discharge for COPD Patients||Catalan Agency for Health Information, Assessment and Quality|Yes|Active, not recruiting|April 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|380|||Both|40 Years|N/A|No|||September 2013|September 4, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01512992||92498|
NCT01512732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HebVerMAV-HMO-CTIL|Validation of the Hebrew Version of the Montreal Affective Voices.|||Hadassah Medical Organization||Not yet recruiting|February 2012|||||N/A|Observational|N/A||3|Anticipated|120|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy group, Parkinson's disease patients, Major depressive disorder patients.|January 2012|January 22, 2012|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512732||92518|
NCT01512758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C14013|A Study of Alisertib (MLN8237) in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas|A Phase 1 Dose Escalation and Pharmacokinetic Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas||Millennium Pharmaceuticals, Inc.|No|Completed|February 2012|November 2013|Actual|October 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|January 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01512758||92516|
NCT01509508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS 12249 TasP|Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence|A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.|TasP|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Recruiting|March 2012|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|22000|||Both|16 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 23, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01509508||92763|
NCT01508832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06121|Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers|Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers||University of California, San Francisco|Yes|Suspended|January 2012|||March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 1, 2014|January 9, 2012||No||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01508832||92815|
NCT01508845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2730|A Pilot Study of the Effect of Dietary Fat Type and Amount on Vitamin D3 Absorption|A Pilot Study of the Effect of Dietary Fat Type and Amount on Vitamin D3 Absorption|MUFA/PUFA|Tufts University|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|61|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 18, 2014|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508845||92814|
NCT01509170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0597-10-HMO|The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia|Observational Cohort Study- The Clinical and Laboratory Characteristics of Recurrent Drug- Related|0597-10-HMO|Hadassah Medical Organization|No|Not yet recruiting|February 2012|January 2017|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|Consequtive patients hospitalized to the internal medicine ward due to hyponatremia|January 2012|January 10, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509170||92789|
NCT01509183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10|Effectiveness of the Asthmapolis Monitoring System|Effectiveness of the Asthmapolis Monitoring System||Reciprocal Labs|No|Recruiting|January 2012|June 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Both|5 Years|90 Years|No|||July 2012|July 23, 2012|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01509183||92788|
NCT01509495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAE00564|Impedance Measurements in Heart Failure Patients|Impedance Measurements in Heart Failure Patients|SIM-HF|Medtronic BRC|No|Terminated|December 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2014|July 3, 2014|December 7, 2011||No|Enrollment rate too low; rate much under estimation of sponsor and investigators|No||https://clinicaltrials.gov/show/NCT01509495||92764|
NCT01510288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-0016|Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer|A Phase 1 Dose Escalation Trial of Ipilimumab in Combination With CG1940 and CG8711 in Patients With Metastatic Hormone-Refractory Prostate Cancer||VU University Medical Center|Yes|Terminated|November 2004|November 2011|Actual|December 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|80 Years|No|||January 2012|January 10, 2012|January 4, 2012||No|The study was terminated because Cell Genesys stopped all activities for GVAX.|No||https://clinicaltrials.gov/show/NCT01510288||92704|
NCT01510301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIHM|Mobile Phone in Hypertension Management|Mastery and Autonomy in Management of Hypertension With a Mobile Self-report System||Göteborg University|Yes|Completed|March 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|51|||Both|30 Years|N/A|No|||June 2014|June 25, 2014|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510301||92703|
NCT01510574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3002|A Study of Self-administered Misoprostol to Prevent Bleeding After Childbirth in the Community (MamaMiso)|||Gynuity Health Projects|Yes|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|749|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01510574||92683|
NCT01542073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM003|68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction|68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Angiogenesis of Myocardial Infarction and the Comparison With Cardiac Perfusion and Metabolism|GRGDMI|Peking Union Medical College Hospital|Yes|Recruiting|February 2012|March 2016|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|30 Years|N/A|No|||November 2014|November 1, 2014|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01542073||90279|
NCT01542281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMA-10-375|Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer|Improving Outcomes in Patients With Hepatobiliary Cancers With a Nutritional and Physical Conditioning Pre-habilitation Program||McGill University Health Center|No|Recruiting|January 2012|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|64|||Both|18 Years|80 Years|No|||February 2012|February 24, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01542281||90263|
NCT01542645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENH10-256|The Effect of Choice of Intraoperative Opioid on Postoperative Pain|The Effect of Choice of Intraoperative Opioid on Postoperative Pain||NorthShore University HealthSystem Research Institute|No|Completed|September 2010|September 2014|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|90 Years|No|||September 2014|September 23, 2014|February 26, 2012||No||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01542645||90235|
NCT01542658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100167-E|Comparison of Robot-assisted Laparoscopic Myomectomy With Traditional Laparoscopic Myomectomy|||Far Eastern Memorial Hospital|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|42|||Female|20 Years|N/A|No|Non-Probability Sample|Patients with uterine myoma, and underwent primary treatment (RALM and TLM) in Far Eastern        Memorial Hospital|February 2012|March 1, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01542658||90234|
NCT01520610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 10018|TAKO-TSUBO Cardiomyopathy and Genetic|Genetic Polymorphisms in Catecholamine Pathway Responsible for the Tako-TSUBO Cardiomyopathy Susceptibly (TAKO-GENE)||Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|November 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|530|Samples With DNA|20 ml of blood sample will be collected from all patients enrolled in order to DNA analysis.|Both|18 Years|N/A|No|Non-Probability Sample|The study population will be consisted of 800 Caucasians subjects: 200 patients with        Tako-Tsubo cardiomyopathy and an age- and sex-matched control group (n = 600) of 400        patients with acute coronary syndrome and 200 patients with stressful event (emergency        postoperative patients) but without Tako-Tsubo cardiomyopathy.|February 2016|February 10, 2016|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01520610||91916|
NCT01511276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-465|The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk (SHAPE-2)|The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk Biomarkers in Postmenopausal Women: the SHAPE-2 Study|SHAPE-2|UMC Utrecht|Yes|Active, not recruiting|February 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|250|||Female|50 Years|69 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01511276||92630|
NCT01520623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC 08025|Complement and Graft-versus-host Disease|Role of Complement System in Human Allogeneic Haematopoietic Stem Cell Transplantation||Assistance Publique - Hôpitaux de Paris|Yes|Completed|April 2010|July 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|70|||Both|18 Years|65 Years|No|||April 2015|April 9, 2015|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01520623||91915|
NCT01520636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100124|Active MOBility Early After Stroke : What Should be the Best Physiotherapy Early After Stroke ?|What Should be the Best Physiotherapy Early After Stroke ?|AMOBES|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|July 2012|December 2015|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01520636||91914|
NCT01511887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ibuprofen in PDA|Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)|Evaluation of the Safety and Efficacy of Oral Ibuprofen in Term 20-28 Days Old Newborns Referred to Bandar Abbass Children Hospital in 2011||Hormozgan University of Medical Sciences|Yes|Completed|January 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|28 Days|No|||January 2012|January 19, 2012|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511887||92583|
NCT01511900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT 1004 102|A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAT-1004 in Patients With Type 2 Diabetes||Catabasis Pharmaceuticals|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|5||Actual|44|||Both|18 Years|65 Years|No|||June 2012|June 7, 2012|January 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511900||92582|
NCT01512173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00400 GL 2 01 1A|Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo|A Randomised, Double Blind, Controlled, Multicentre Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo.||Pierre Fabre Dermatology||Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|35 Days|150 Days|No|||October 2014|October 29, 2014|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01512173||92561|
NCT01512433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 100-2320-B-039-029-MY2|The Clinical Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts|The Clinical Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts: A Randomized Controlled Trial||China Medical University, Taiwan|Yes|Completed|August 2011|January 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|N/A|No|||March 2013|March 21, 2013|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01512433||92541|
NCT01512420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27773|An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)|A Multicenter, Prospective, Observational Study to Identify Different Prognostic Factors Related to Survival in Patients With Previously Treated Advanced NSCLC With Wild-type Epidermal Growth Factor Receptor (EGFR) Gene.||Hoffmann-La Roche||Completed|November 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|355|||Both|18 Years|N/A|No|Probability Sample|Patients with previously treated advanced NSCLC, with wild-type EGFR gene or squamous cell        carcinoma histology|March 2016|March 1, 2016|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01512420||92542|
NCT01512719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040411-HMO-CTIL|POEM- Peroral Endoscopic Myotomy|POEM a Novel Endoscopic Treatment for Achalasia|POEM|Hadassah Medical Organization|Yes|Recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||July 2015|July 2, 2015|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512719||92519|
NCT01512771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00383|The Effect of Nasal Continuous Positive Airway Pressure Treatment on PTSD Symptoms.|The Effect of Nasal Continuous Positive Airway Pressure (Nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms.|PTSD|Northport Veterans Affairs Medical Center|Yes|Completed|March 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|18|||Both|18 Years|80 Years|No|Non-Probability Sample|veterans admitted to PTSD unit at Northport VAMC|September 2014|September 23, 2014|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01512771||92515|
NCT01509196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-FEN-101|A Bioequivalence Study Comparing HIP0901 Capsule With Lipidilsupra Tablet|Open-label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics of Fenofibric Acid Between Lipidilsupra Tablet and HIP0901 Capsule in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|November 2011|February 2012|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01509196||92787|
NCT01491958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11004|Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation|Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Versus Host Disease(GVHD) in Patients With Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|December 2011|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|41|||Both|18 Years|75 Years|No|||March 2015|March 31, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01491958||94105|
NCT01491971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000008|Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer|Open-label, Multi-centre, Parallel Group Dose-Escalation Trial Assessing the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer|IM1|Ferring Pharmaceuticals|Yes|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|76|||Male|18 Years|N/A|No|||November 2013|November 18, 2013|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491971||94104|
NCT01492270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1657|Imaging for Significant Prostate Cancer Risk Evaluation|PICTURE - Prostate Imaging (Multi-parametric MRI and Prostate HistoScanning™) Compared to Transperineal Ultrasound Guided Biopsy for Significant Prostate Cancer Risk Evaluation.|PICTURE|University College London Hospitals|No|Recruiting|December 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|126|||Male|20 Years|N/A|No|||December 2011|December 28, 2011|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01492270||94081|
NCT01492868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT 10785179|Sinusitis in Children and the Nasopharyngeal Microbiome|Sinusitis in Children and the Nasopharyngeal Microbiome||University of Wisconsin, Madison|No|Recruiting|January 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|355|Samples Without DNA|Nasopharyngeal microbiome samples|Both|4 Years|7 Years|No|Non-Probability Sample|Healthy children|July 2015|July 28, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492868||94035|
NCT01493193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UISM-5|Different Endurance Training Protocols in Cardiac Rehabilitation|Effects of Different Endurance Training Protocols on Physical Performance in Cardiac Patients||Paracelsus Medical University|No|Completed|November 2011|May 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|25 Years|85 Years|No|||July 2013|July 31, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493193||94010|
NCT01492855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-02-013-OSi|Evaluation of MRI Diagnosed Meniscal Lesions|The Value of MRI in the Evaluation of Knees Suspected for Meniscal Lesions||Northern Orthopaedic Division, Denmark|No|Completed|January 2008|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|324|||Both|18 Years|N/A|No|||September 2014|September 12, 2014|August 14, 2008||No||No||https://clinicaltrials.gov/show/NCT01492855||94036|
NCT01525108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-04-156-15281|A Home-based Blood Pressure Monitoring Program to Promote Better Management of Hypertension|A Home-based Blood Pressure Measurement Program in Hypertensive Patients to Promote Medications Adherence and Blood Pressure Status.||Tehran University of Medical Sciences|No|Completed|March 2012|March 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525108||91571|
NCT01493778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-3809|Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A|Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A|guardian™4|Novo Nordisk A/S|No|Recruiting|September 2012|June 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|N/A|6 Years|No|||December 2015|December 16, 2015|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493778||93965|
NCT01525693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMR--304-NEW2D|Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China|Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China (NEW2D STUDY) A Study Of China Cardiometabolic Registries (CCMR)|NEW2D|China Cardiometabolic Registries|No|Active, not recruiting|April 2012|January 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|20 Years|N/A|No|Probability Sample|Subjects seen at outpatient clinics of tier 1, 2, and 3 hospitals across the 6 major        geographic regions|February 2012|February 13, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525693||91527|
NCT01507454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAG-1935|Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency|Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency||Novo Nordisk A/S|No|Completed|April 2006|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1613|||Female|N/A|N/A|No|Probability Sample|Women with atrophic vaginitis caused by estrogen deficiency prescribed with Vagifem® by        their treating physician|March 2012|March 19, 2012|January 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507454||92919|
NCT01508013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA134891-01A2|An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk|An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk|iSTART|East Tennessee State University|Yes|Enrolling by invitation|May 2011|December 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|600|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||January 2012|January 9, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508013||92876|
NCT01507701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NorCAPITALps|Pilot Study for the NorCAPITAL Trial|Pilot Study for the NorCAPITAL Trial||Oslo University Hospital|Yes|Completed|January 2010|||March 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|12 Years|19 Years|No|||January 2012|January 12, 2012|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01507701||92900|
NCT01507987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD-619|St.Jude Medical Cardiac Lead Assessment Study|St.Jude Medical Cardiac Lead Assessment Study|CLAS|St. Jude Medical|No|Recruiting|March 2013|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2487|||Both|18 Years|N/A|No|Probability Sample|Patients that have a market released St. Jude Medical Implantable Cardioverter        Defibrillator (ICD) or Cardiac Resynchronization Therapy - Defibrillator (CRT-D) already        implanted and also have at least one market released Riata/ Riata        ST/QuickSite/QuickFlex/Durata already implanted.|May 2015|May 5, 2015|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01507987||92878|
NCT01523119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109_ONDAN_06|Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Ondansetron 8 mg Orally Disintegrating Tablets of Ohm Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals USA) With Zofran 8 mg ODT® Orally Disintegrating Tablets (Containing 8 mg of Ondansetron) Manufactured by Cardinal Health, UK for GlaxoSmithKline USA, in Healthy, Adult, Human, Male Subjects Under Fed Condition.||Ranbaxy Inc.|No|Completed|July 2006|October 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|35|||Male|18 Years|42 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523119||91723|
NCT01523340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MENTOR_2011|A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response|Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib|MENTOR|Chonnam National University Hospital|Yes|Recruiting|December 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|NSCLC tumor tissue for c-MET expression by immuohistochemistry c-MET amplification by silver      in situ hybridization EGFR mutation by realtime PCR|Both|19 Years|80 Years|No|Non-Probability Sample|Patients with histologically or cytologically confirmed stage IV or recurrent NSCLC who        have progressive disease after 1st line chemotherapy who consent for study participation        and meet the study selection criteria|January 2013|January 30, 2013|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01523340||91706|
NCT01523873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGD-55-001|Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)|Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)||Guerbet||Completed|November 2008|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35921|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All consecutive patients scheduled for a Dotarem®-enhanced MRI over a one year period at        each participating radiological site|October 2013|December 14, 2015|January 26, 2012||No||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01523873||91665|
NCT01524432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mic_Clo_Terb|Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis|Phase III Study in Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis||The Hong Kong Polytechnic University|Yes|Completed|January 2012|December 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||March 2013|March 31, 2013|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01524432||91622|
NCT01524679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 27787|Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen|A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys®)180 μg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B|PADD-ON|Johannes Gutenberg University Mainz|No|Recruiting|August 2012|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01524679||91603|
NCT01524978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28072|A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers|An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers||Hoffmann-La Roche||Active, not recruiting|April 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524978||91580|
NCT01525277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110050RB|The Side of Implantable Central Vascular Catheters and Complications|The Side of Implantable Central Vascular Catheters and Complications in Cancer Patients: A Randomization Observational Study||National Taiwan University Hospital|No|Recruiting|March 2012|December 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|246|||Both|20 Years|N/A|No|Non-Probability Sample|Adult cancer patients who required implantable CVCs|April 2014|April 11, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525277||91558|
NCT01525290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WAKE-UP|Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke|Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke: a Randomised, Double-blind, Placebo-controlled Trial|WAKE-UP|Universitätsklinikum Hamburg-Eppendorf|Yes|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525290||91557|
NCT01525303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0044|Effects of Aerobic Exercise Within a Behavioral Treatment Program for Chronic Headaches|Additive Effects of Aerobic Exercise to a Standard Behavioral Self-Management Program for Chronic Headaches||University of Mississippi Medical Center|No|Completed|December 2011|August 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Female|18 Years|64 Years|No|||January 2013|January 14, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525303||91556|
NCT01491919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029537|Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant|Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients|PTN_LISINO|Duke University|Yes|Completed|June 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|26|||Both|2 Years|17 Years|No|||June 2015|June 15, 2015|November 29, 2011|No|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT01491919||94108|
NCT01492218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPEN3-1885|Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction|A Prospective, Open-labelled, Non-controlled Observational Study to Assess Patient Satisfaction, Physician Acceptability and Safety of Mixtard® 30 NovoLet® for the Treatment of Diabetes Mellitus||Novo Nordisk A/S|No|Completed|March 2004|August 2004|Actual|August 2004|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1330|||Both|N/A|N/A|No|Probability Sample|Patients diagnosed with type 1 or type 2 diabetes mellitus and are not presently using        Mixtard® 30 NovoLet®|April 2012|April 11, 2012|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01492218||94085|
NCT01492283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LINK-1-2011|Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes|Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes||University Hospital, Gentofte, Copenhagen|Yes|Completed|December 2011|July 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|48|Samples With DNA|DNA (whole blood) will be kept for 15 years|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with NAFLD and liver cirrhosis confirmed by liver biopsy, and patients with or        without well characterized type 2 diabetes recruited in the the hospitals out patients        clinic|July 2014|July 9, 2014|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01492283||94080|
NCT01492881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1119|Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma|A Multi-Center, Single-Arm, Phase II Study of Vorinostat (V) in Combination With Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) Followed by VB Maintenance in Patients With Relapsed and Relapsed/Refractory Multiple Myeloma||UNC Lineberger Comprehensive Cancer Center|Yes|Withdrawn|April 2012|January 2017|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2012|May 9, 2012|December 12, 2011|Yes|Yes|Doxil is currently unavailable|No||https://clinicaltrials.gov/show/NCT01492881||94034|
NCT01492894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708M13942|Kidney Allograft Dysfunction Without Reversible Causes|A Randomized Controlled Trial of Reducing Calcineruin Inhibitor Target Level by 50% Versus Converting to Rapamycin in Chronic Kidney Dysfunction Without Reversible Causes|KADWORC|University of Minnesota - Clinical and Translational Science Institute|No|Terminated|January 2008|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|August 9, 2010|Yes|Yes|study terminated due to low enrollment|No||https://clinicaltrials.gov/show/NCT01492894||94033|
NCT01493492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111013-007(1)|Urinary Proteomics Analysis for Sepsis and Prognosis|Urinary Proteomics Analysis for Sepsis Identification and Its Prognosis in Sepsis Patient With iTRAQ Labeling and and LC-MS/MS||Chinese PLA General Hospital|Yes|Recruiting|May 2010|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|All subjects were selected from among inpatients who were hospitalized between May 2010        and Jan 2012 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's        Liberation Army (CPLA) General Hospital.|December 2011|December 15, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493492||93987|
NCT01525121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTC_MV|Expiratory Rib Cage Compression in Mechanically Ventilated Patients|Expiratory Rib Cage Compression Does Not Improve Secretion Clearance and Respiratory Mechanics in Mechanically Ventilated Patients||Centro Universitário Augusto Motta|No|Completed|July 2008|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|19 Years|90 Years|No|||February 2012|February 1, 2012|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01525121||91570|
NCT01525719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-53326|Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma|A Phase II Single Arm Study to Evaluate the Safety and Efficacy of RAD001 as Monotherapy in Treatment naïve Advanced Cholangiocarcinoma|CRAD001T|Ratchavithi Hospital|No|Active, not recruiting|January 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||January 2012|February 2, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525719||91525|
NCT01525420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7445|Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy|Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy|TALK|Fred Hutchinson Cancer Research Center|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|January 31, 2012||No||No|March 10, 2014|https://clinicaltrials.gov/show/NCT01525420||91548|
NCT01525680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YEH-09-087|A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure|Improving PTSD Outcomes in OIF/OEF Returnees: A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure Therapy"||Bronx VA Medical Center|No|Recruiting|April 2011|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|89 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525680||91528|
NCT01525706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO18494|Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm|EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm||Lawson Health Research Institute|No|Recruiting|September 2012|June 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||April 2015|April 1, 2015|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525706||91526|
NCT01508026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-MD-01|Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension|A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension||Forest Laboratories|No|Completed|January 2012|May 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|4161|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508026||92875|
NCT01508052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2628|Sequential Compression Device on Body Temperature|The Effects of Sequential Compression Device on Body Temperature During Propofol Anaesthesia: A Comparison With Elastic Stockings||Gachon University Gil Medical Center|Yes|Completed|December 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|20 Years|65 Years|No|||April 2014|April 3, 2014|January 9, 2012||No||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01508052||92873|
NCT01508286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017857|Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects|Multicenter, Open-label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis||Janssen-Cilag International NV|No|No longer available||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|70 Years||||July 2015|July 22, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508286||92856|
NCT01523626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1711020323|A Multicenter, Randomized Study of Early Assessment by CT Scanning in Severely Injured Trauma Patients|Randomized Study of Early Assessment by CT Scanning in Trauma Patients|REACT-2|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|April 2011|December 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1083|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01523626||91684|
NCT01523886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-441|The Muscle Relaxation-study|Optimization of Surgical Conditions During Laparoscopic Cholecystectomy With Deep or Moderate Neuromuscular Blockade||Herlev Hospital|Yes|Completed|March 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Both|18 Years|N/A|No|||March 2014|March 16, 2014|January 19, 2012||No||No|January 16, 2014|https://clinicaltrials.gov/show/NCT01523886||91664|
NCT01524458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010.430|Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders|Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders|POEM|Chinese University of Hong Kong|No|Recruiting|July 2010|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|85 Years|No|||October 2010|February 1, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01524458||91620|
NCT01524692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15627|Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma|A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.|ACC|University of Virginia|Yes|Active, not recruiting|March 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524692||91602|
NCT01524705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42178-E/G|FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)|FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR|FLAT-SUGAR|University of Washington|Yes|Completed|August 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|40 Years|75 Years|No|||September 2014|September 16, 2014|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524705||91601|
NCT01524991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU10-148|First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma|Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148||Hoosier Cancer Research Network|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|January 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524991||91579|
NCT01491685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK1007223|Parturient Microcirculation|An Observational Assessment of the Sublingual Microcirculation of Pregnant and Non-pregnant Women (Parturient Microcirculation - Phase 1)||IWK Health Centre||Completed|August 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant group - women with uncomplicated, singleton, at 36 - 40 weeks gestation,        non-laboring        Non-Pregnant group - healthy nulliparous female volunteers, matched to pregnant patients        for age ± 1 year|January 2012|January 18, 2012|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01491685||94126|
NCT01491698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-070|Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma|A Pilot Randomized Controlled Trial Examining the Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma||Memorial Sloan Kettering Cancer Center||Completed|December 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||August 2013|August 14, 2013|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01491698||94125|
NCT01524029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TomoTrial001|Digital Breast Tomosynthesis Versus Digital Mammography: A National Multicenter Trial|Digital Breast Tomosynthesis vs. Digital Mammography: A National Multicenter Trial||Medical University of Vienna|No|Recruiting|January 2012|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Female|25 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population consists of two groups:        One screening group consisting of asymptomatic women (Age 40+) referred for a screening        mammography examination.        The second group consists of women aged 25+ referred for further examination of a breast        lesion.|January 2012|January 31, 2012|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01524029||91653|
NCT01492582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB-F141204009/UAB-X141204010|Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors|Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial||University of Alabama at Birmingham|Yes|Active, not recruiting|July 2012|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1068|||Both|9 Years|26 Years|No|||March 2016|March 17, 2016|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492582||94057|
NCT01492595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/MBA/2011/TBcontact|Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda|Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda: An Open Cohort of Children <5 Years in Contact With Newly Diagnosed Adult TB Cases in Mbarara Hospital|TBcontact|Epicentre|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|281|||Both|1 Month|5 Years|No|Non-Probability Sample|Children aged 1 month to 5 years living in the same household (a house or cluster of        houses on the same plot) with a newly diagnosed adult case of smear and/or        culture-positive TB will be eligible for the study|February 2016|February 29, 2016|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01492595||94056|
NCT01524276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSR|Product Surveillance Registry|Medtronic Product Surveillance Registry|PSR|Medtronic|No|Recruiting|January 2012|||January 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|Subjects implanted with Medtronic qualifying therapy product.|December 2015|December 15, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524276||91634|
NCT01524536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120026|Steroid Treatment for Hypereosinophilic Syndrome|Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes||National Institutes of Health Clinical Center (CC)||Recruiting|November 2011|January 2030|Anticipated|January 2030|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|7 Years|N/A|No|||June 2015|June 16, 2015|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524536||91614|
NCT01493206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMCC04/16|A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer|A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer||Peter MacCallum Cancer Centre, Australia|Yes|Completed|July 2004|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||December 2011|December 14, 2011|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493206||94009|
NCT01524809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1317|Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes|A Single-Centre, Randomised, Double-Blind, 2- Period Crossover Trial Investigating the Steady State Pharmacokinetics of Biphasic Insulin Aspart 30 and Biphasic Insulin Aspart 70 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|January 2001|June 2001|Actual|June 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524809||91593|
NCT01525732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2010_430|Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Esophageal Motility Disorders|Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders|POEM|Chinese University of Hong Kong||Recruiting|June 2010|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||September 2014|September 5, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525732||91524|
NCT01525459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MNC-Glioma-1-4|Gene Expression, Immunological Status and Metabolome in Glioma Patients|Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients||National Institute of Biology, Slovenia|No|Recruiting|December 2010|December 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|16|Samples With DNA|Whole blood, blood plasma, peripheral blood mononuclear cells, CD4+ T cells, CD56+ NK cells|Both|20 Years|80 Years|No|Probability Sample|Glioma patients treated with surgical resection of the tumor|February 2012|February 6, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01525459||91545|
NCT01525433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IR 7290|Cervical Cancer Screening Among Hispanic Women|Cervical Cancer Screening and Adherence to Follow-up Among Hispanic Women||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|September 2011|July 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|451|||Female|21 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525433||91547|
NCT01526005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015|Brain Nicotine Receptor Density & Response to Nicotine Patch|Brain Nicotine Receptor Density & Response to Nicotine Patch||Brentwood Biomedical Research Institute|No|Completed|March 2012|||January 2014|Actual|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Tobacco dependent cigarette smokers will be recruited through newspaper and internet        advertisements from populations living in the counties surrounding the West Los Angeles        Veterans Affairs Medical Center.|January 2015|January 26, 2015|August 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01526005||91503|
NCT01508299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|crufood1|Skin Prick Test for the Diagnosis of Food Allergy- a Comparison of Different Commercial Extracts and Raw Food|Skin Prick Test for the Diagnosis of Food Allergy- a Comparison of Different Commercial Extracts and Raw Food||Meir Medical Center|Yes|Completed|April 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|1 Month|120 Years|No|||October 2015|October 6, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508299||92855|
NCT01500005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shlomit10|The Effect of Vitamin D Supplementation on Arterial Stiffness in Diabetic Patients|The Effect of Vitamin D Supplementation on Arterial Stiffness, Blood Pressure, Oxidative Stress and Inflammation in Diabetic Patients||Assaf-Harofeh Medical Center|No|Completed|August 2010|April 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|80 Years|No|||December 2011|December 23, 2011|December 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01500005||93490|
NCT01508312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-142|Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma|Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|12 Years|72 Years|No|||February 2016|February 2, 2016|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01508312||92854|
NCT01523366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00012|A Pharmacodynamic Study With Ticagrelor in Hispanic Patients|A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease||AstraZeneca|No|Completed|April 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|January 30, 2012|Yes|Yes||No|May 10, 2014|https://clinicaltrials.gov/show/NCT01523366||91704|Total N for the secondary outcome analysis after multiple doses and for PK measures was not the same for 2 hours, 8 hours and end of dosing. Only the first time point total N can be reported via the form. Row titles indicate N's where they differ.
NCT01523379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COX2009|Efficacy of Parecoxib on Patients With CRPS|Efficiacy of the Selctive COX-2-inhibitor Parecoxibe on the Pathological Low Pressure Pain Threshold (PPT) of Patients With Complex Regional Pain Syndrome (CRPS)||Ruhr University of Bochum||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||April 2012|April 24, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01523379||91703|
NCT01523639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-LUCAS|A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis|A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type, Metastatic Colorectal Cancer|G-LUCAS|Austrian Breast & Colorectal Cancer Study Group|Yes|Terminated|April 2012|May 2014|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|January 26, 2012||No|Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013.    ABCSG guaranteed completed treatment period for ethical reasons.|No||https://clinicaltrials.gov/show/NCT01523639||91683|
NCT01525316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIDISI 57710|Lactoferrin for Prevention of Sepsis in Infants|Lactoferrin for Prevention of Sepsis in Infants|NEOLACTO|Universidad Peruana Cayetano Heredia|Yes|Active, not recruiting|May 2012|December 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|414|||Both|N/A|72 Hours|No|||December 2015|December 10, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525316||91555|
NCT01495546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq0303|Total Hip Arthroplasty (THA): Early Load Versus Load Late|Randomized Comparison of Quality of Life and Functional Patients Undergoing Total Hip Replacement Uncemented. Load Early X Load Late|Latearly|University of Sao Paulo|No|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|45|||Both|30 Years|65 Years|No|||September 2012|September 13, 2012|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495546||93831|
NCT01495572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120045|Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells|Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin||National Institutes of Health Clinical Center (CC)|Yes|Terminated|December 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|December 16, 2011|Yes|Yes|Due to slow accrual, the investigator decided to close the study.|No|May 8, 2014|https://clinicaltrials.gov/show/NCT01495572||93830|Due to slow accrual, the investigator decided to close the study.
NCT01491334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTI-03|Validation of Transvaginal Tactile Imaging|A Clinical Validation Study With Transvaginal Tactile Imaging|VTI-03|Artann Laboratories|No|Completed|December 2011|November 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|158|||Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The patient pool will comprise of 200 female patients.|February 2014|February 24, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491334||94153|
NCT01491347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00452-39|Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal|Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months Following After Alcohol Withdrawal in Alcohol-dependent Subjects in Relation to Abstinence||Centre Hospitalier Esquirol|No|Recruiting|November 2011|April 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|389|Samples Without DNA|serum|Both|18 Years|N/A|No|Non-Probability Sample|Subjects with alcohol dependance diagnosis according to the Diagnostic and Statistical        Manual of Mental Disorders (DSM-IV-TR), and asking for alcohol withdrawal in        hospitalization|July 2015|July 31, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01491347||94152|
NCT01491711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38127|Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate|Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate||Maastricht University Medical Center|No|Recruiting|August 2013|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||January 2014|January 30, 2014|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491711||94124|
NCT01524289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0859-020|Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)|A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia|REALIZE|Merck Sharp & Dohme Corp.|No|Active, not recruiting|February 2012|October 2018|Anticipated|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|306|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|January 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524289||91633|
NCT01524042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0644|Patient Satisfaction With Novel Double Pants Compared to Conventional Single Pants for Outpatient Colonoscopy|Patient Satisfaction With Novel Double Pants Compared to Conventional Single Pants for Outpatient Colonoscopy: Prospective Randomized Study||Yonsei University|Yes|Enrolling by invitation|January 2012|July 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|160|||Both|20 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 29, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01524042||91652|
NCT01524302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEF-MD-02|Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia|Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)||Michigan State University|Yes|Completed|February 2012|April 2015|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524302||91632|
NCT01524549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120061|Blood Vessel Study|The Role of the Functionally Relevant Single Nucleotide Polymorphisms CYP2J2 -50G> T (CYP2J2 7) and EPHX2 9846A> G (EPHX2 K55R) in Human Endothelial Function||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|January 2012|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|118|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|February 23, 2016|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01524549||91613|
NCT01524822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120065|The Effects of Chronic Exposure to Low-Level Blasts|Experienced Breacher Study: Evaluation of the Effects From Chronic Exposure to Low-Level Blast||National Institutes of Health Clinical Center (CC)||Recruiting|January 2012|||||N/A|Observational|N/A|||Anticipated|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2015|December 16, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01524822||91592|
NCT01524835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT RELIVE-05|Live Lung Donor Cross-sectional Cohort Study|Live Lung Donor Cross-sectional Cohort Study||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|August 2010|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|192|||Both|N/A|N/A|No|Non-Probability Sample|Live lung donors who participated in transplantation during 1993 through 2006|June 2013|June 3, 2013|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01524835||91591|
NCT01525472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-18'|Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects|Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects: Involvement in Diseases Associated With Obesity (Viellissement accéléré Des Cellules du Tissu Adipeux viscéral Chez Les obèses Morbides: Implication Dans Les Pathologies associées à l'obésité)|SENAPID|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|February 2012|January 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|225|Samples Without DNA|adipose tissue|Both|18 Years|65 Years|No|Non-Probability Sample|hospital center|February 2015|February 5, 2015|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525472||91544|
NCT01525758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SI000413_OA_Ⅱ|Study of SI000413 in Knee Osteoarthritis Patients|Eight-week, Multi-centre, Dose-response, Double Blind, Placebo-controlled, Randomized, Parallel-group, PhaseⅡ Trial to Evaluate Efficacy and Safety of SI000413 in Patients With Knee Osteoarthritis||Dong-A ST Co., Ltd.|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|152|||Both|35 Years|75 Years|No|||August 2013|August 12, 2013|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525758||91522|
NCT01525745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-294|Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis|Randomized Ph II Study of Stereotactic Body Radiotherapy (SBRT) Versus Conventional Radiation for Spine Metastasis||Beth Israel Deaconess Medical Center|Yes|Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|81|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01525745||91523|
NCT01526018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110921001|The Bottle Study: Infant Weight Gain During Use of Novel Versus Typical Infant Feeding Bottles|||University of Alabama at Birmingham|No|Terminated|January 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|||Both|1 Month|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|Bottle-fed infants aged 1-6 months|August 2014|August 14, 2014|January 31, 2012||No|Inadequate recruitment|No||https://clinicaltrials.gov/show/NCT01526018||91502|
NCT01526031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2009-013|Bee Venom Acupuncture for the Treatment of Frozen Shoulder|Randomized Controlled Double Blind Study of Bee Venom Therapy on Adhesive Capsulitis of the Shoulder||Kyunghee University Medical Center|No|Completed|January 2010|July 2010|Actual|July 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|70 Years|No|||February 2012|February 1, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526031||91501|
NCT01500018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4130C00022|Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214|A Single-center, Single-dose, Double-blind, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of TC-5214 in Healthy Recreational Polydrug Users|TC-5214|AstraZeneca||Withdrawn|January 2012|April 2012|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|14||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 21, 2012|December 6, 2011|No|Yes|Sponsor decision to withdraw.|No||https://clinicaltrials.gov/show/NCT01500018||93489|
NCT01496196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0096-11-MMC|The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis|||Meir Medical Center|No|Recruiting|January 2012|February 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||December 2011|April 12, 2015|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01496196||93782|
NCT01496209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECONSTRUCT|REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts||RECONSTRUCT|Cedars-Sinai Medical Center|No|Withdrawn|July 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 10, 2014|December 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01496209||93781|
NCT01495910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100007|A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency|An Open-Label, Multiple-Dose, Dose-Finding Study of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Yes|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||February 2014|February 27, 2014|November 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01495910||93804|
NCT01524445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018175|Retrospective Survey of Re-treatment With Bortezomib|Retrospective Evaluation of Re-Treatment With Bortezomib in Subjects With First Relapse After Bortezomib First-Line Therapy||Janssen Pharmaceutica N.V., Belgium|No|Completed|March 2011|October 2011|Actual|||Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Clinic; Hospital|June 2012|June 11, 2012|June 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01524445||91621|
NCT01495039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nista 1|Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients|The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients||Policlinico Hospital|Yes|Completed|November 2008|February 2010|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|99|||Both|18 Years|N/A|No|||December 2011|December 16, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495039||93869|
NCT01495299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCAT1|24-hour IOP Fluctuation Profile Recorded With SENSIMED Triggerfish in Primary Open-angle Glaucoma (POAG) Patients After Cataract Surgery|||University of California, San Diego|No|Recruiting|December 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Probability Sample|glaucoma patients scheduled to undergo cataract surgery.|December 2011|December 19, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495299||93849|
NCT01495585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120046|Lonafarnib for Chronic Hepatitis D|Treatment of Chronic Delta Hepatitis With Lonafarnib||National Institutes of Health Clinical Center (CC)||Completed|December 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||April 2015|May 2, 2015|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495585||93829|
NCT01495598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120047|Pomalidomide for Kaposi Sarcoma in People With or Without HIV|A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV||National Institutes of Health Clinical Center (CC)||Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|99 Years|No|||June 2015|December 24, 2015|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495598||93828|
NCT01495611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-1353|Multicenter Perioperative Opioid Pharmacogenetic Study|Predicting Perioperative Opioid Adverse Effects and Personalizing Analgesia in Children: A Multicenter Pharmacogenetic Study||Children's Hospital Medical Center, Cincinnati|Yes|Enrolling by invitation|November 2010|December 2016|Anticipated|January 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|A database/ repository will be constructed for future research, analysis, and recruitment.      De-identified study subjects' genetic information and their responses to pain and pain      medications, side-effects will be included in the database. Blood specimens will be included      in the repository for exploring potentially important SNPs and biomarkers in future. No      patient identifiers will be included in the repository and there will be a confidential      (access limited to investigators only) code or link between the repository/database and      other information about the participant.|Both|6 Years|17 Years|No|Non-Probability Sample|Children undergoing adenotonsillectomy in the United States.|March 2016|March 7, 2016|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495611||93827|
NCT01495624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1048|The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine|||The Cleveland Clinic|No|Terminated|December 2011|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|16|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|December 12, 2011||No|Accrual insufficient to complete study in a feasible time frame|No||https://clinicaltrials.gov/show/NCT01495624||93826|
NCT01491386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9702|Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease||Medtronic Spinal and Biologics|Yes|Completed|August 1998|October 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491386||94149|
NCT01491399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9702 Cornerstone ACDF pilot|INFUSE™ BONE GRAFT/CORNERSTONE-SR™ Allograft Ring/ATLANTIS™ Anterior Cervical Plate- Pilot Study|Study of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the CORNERSTONE-SR™Allograft Ring and ATLANTIS™ Anterior Cervical Plate System in Treatment of Patients With Degenerative Cervical Disc Disease||Medtronic Spinal and Biologics|No|Completed|September 1999|March 2003|Actual|March 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491399||94148|
NCT01491724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP001|The Learning Curve of Probe-based Confocal Laser Endomicroscopy (pCLE) Images Interpretation in Gastric Intestinal Metaplasia (GIM)|The Learning Curve of Probe-based Confocal Laser Endomicroscopy (pCLE) Images Interpretation in Gastric Intestinal Metaplasia(GIM)||King Chulalongkorn Memorial Hospital|No|Recruiting|September 2011|April 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|5|||Both|N/A|N/A|No|Non-Probability Sample|5 beginner endoscopists who never had the experience in pCLE|December 2011|December 14, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01491724||94123|
NCT01491984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWK-4668-2009|Effectiveness and Safety of the Levitan Scope for Laryngoscopy and Tracheal Intubation With a Simulated Difficult Airway|Effectiveness and Safety of the Levitan FPS Scope for Laryngoscopy and Tracheal Intubation With a Simulated Difficult Airway in Surgical Subjects Under General Anesthesia||IWK Health Centre|Yes|Completed|July 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|105|||Female|16 Years|75 Years|No|||February 2015|February 24, 2015|December 12, 2011||No||No|May 22, 2013|https://clinicaltrials.gov/show/NCT01491984||94103|
NCT01523769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EasternVMC|Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants|The Efficacy of Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants Born Between 24 and 28 6/7 Weeks Gestation, a Randomized Controlled Trial.||Eastern Virginia Medical School|Yes|Completed|September 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 30, 2012|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01523769||91673|
NCT01523782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPALL/GRAALLSA2-2008|Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia|An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA®) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-)||ERYtech Pharma|Yes|Completed|April 2009|October 2012|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|55 Years|N/A|No|||March 2013|March 7, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01523782||91672|
NCT01524055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18052011|CO2 Insufflation During Single-Balloon-Enteroscopy|CO2 Insufflation During Single-Balloon-Enteroscopy||University Hospital Muenster||Completed|December 2011|April 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|16 Years|N/A|No|||November 2013|November 25, 2013|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01524055||91651|
NCT01525134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID10-0001|Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis|Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects||Tuberculosis Clinical Diagnostics Research Consortium|No|Active, not recruiting|January 2011|April 2012|Anticipated|February 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|504|||Both|18 Years|N/A|No|||January 2012|February 1, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01525134||91569|
NCT01525147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHB1411-2-101|Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers|A Block-randomized, Double-blind, Placebo-controlled, Single-dose Escalating, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers||Yuhan Corporation|Yes|Completed|December 2011|November 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|49|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2014|July 8, 2014|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01525147||91568|
NCT01525446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-021|Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer|Proton Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable, Peripheral Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Pilot Study||Massachusetts General Hospital|Yes|Terminated|September 2011|December 2015|Actual|December 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|July 19, 2011||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT01525446||91546|
NCT01522404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054397|Effects of Atomoxetine in Mild Cognitive Impairment|A 6 Month, Phase II Randomized, Double-Blind, Placebo Controlled, Flexible Dosing, Crossover Trial of Atomoxetine in Subjects With Mild Cognitive Impairment.|ATX-001|Emory University|Yes|Recruiting|March 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|50 Years|90 Years|No|||December 2015|December 23, 2015|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522404||91778|
NCT01522638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADOA|Advanced Characterization of Autosomal Dominant Optic Atrophy|Cross Sectional Study of Autosomal Dominant Opticus Atrophy||Glostrup University Hospital, Copenhagen|No|Enrolling by invitation|December 2011|June 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|8 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with autosomal dominant optic atrophy in Denmark.|January 2012|January 27, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01522638||91760|
NCT01526057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3281001|A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)|A Randomized, Double-Blind, Study Comparing The Pharmacokinetics And Pharmacodynamics, And Assessing The Safety Of PF-05280586 And Rituximab In Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate Who Have Had An Inadequate Response To One Or More TNF Antagonist Therapies|REFLECTIONS|Pfizer|Yes|Completed|March 2012|May 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|222|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01526057||91499|
NCT01526070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-02012012-9068|Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration|Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Standard Therapy for Exudative Age-Related Macular Degeneration||Stanford University|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|142|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with exudative age-related macular degeneration|November 2014|November 17, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526070||91498|
NCT01526044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33495.100.10|Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients|Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients; a Randomized Controlled Trial (RESCUEII)|RESCUEII|Onze Lieve Vrouwe Gasthuis|No|Completed|December 2010|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|178|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526044||91500|
NCT01496469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67_206|Effect of Febuxostat on Blood Pressure|A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension||Takeda|Yes|Completed|February 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|December 18, 2011|Yes|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01496469||93761|
NCT01496222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|460/2554(EC2)|The Montreal Cognitive Assessment as a Screening Tool for Preoperative Mild Cognitive Impairment in Geriatric Patients|The Montreal Cognitive Assessment as a Screening Tool for Preoperative Mild Cognitive|MoCA|Mahidol University|Yes|Enrolling by invitation|January 2012|April 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|582|||Both|65 Years|N/A|No|Non-Probability Sample|The study enrolls 582 consecutive geriatric patients,322 general and vascular patients        (male 190, female 132) and 260 urological patients (male 220, female 40) who undergoing        general and/or regional anesthesia.|March 2016|March 14, 2016|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01496222||93780|
NCT01523652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRFUnito60_07|Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients|Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche||Azienda Ospedaliera San Giovanni Battista|No|Completed|November 2007|November 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|29|Samples Without DNA|Serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic gynecological patients (benign diseases, oncological diseases)|January 2012|January 30, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01523652||91682|
NCT01523665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-O-H-1102|Blood Glucose Control in Intensive Care Patients Using the Space GlucoseControl System|Evaluation of Blood Glucose Control in Intensive Care Patients Using the Space GlucoseControl System||B. Braun Melsungen AG|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|508|||Both|N/A|N/A|No|Non-Probability Sample|adult patients|November 2013|November 26, 2013|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01523665||91681|
NCT01524185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00022038|FamilyLive Feasibility and Effectiveness Study|FamilyLive Feasibility and Effectiveness Study||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|February 2009|November 2018|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|5 Years|80 Years|No|||September 2013|September 26, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524185||91641|
NCT01524159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR2012|Bromelain and Cardiovascular Risk Factors in Diabetes|Bromelain and Cardiovascular Risk Factors in Diabetes|BRCARDIO|Hebei Yiling Hospital|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|September 20, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524159||91643|
NCT01524172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00021817|Yoga Based Movement Therapy Feasibility and Efficacy Study|Yoga Based Movement Therapy Feasibility and Efficacy Study||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|January 2009|November 2018|Anticipated|November 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|8 Years|12 Years|No|||September 2013|September 26, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524172||91642|
NCT01495052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONOG-0001|Effect of Organic Naked Oat With Whole Germ on Type 2 Diabetes Mellitus|||Peking University|No|Completed|August 2011|||November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|445|||Both|50 Years|65 Years|No|||December 2011|December 15, 2011|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01495052||93868|
NCT01495312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFSLT1|24-hr Intraocular Pressure (IOP) Patterns of Glaucoma Patients After Selective Laser Trabeculoplasty (SLT)|||University of California, San Diego|No|Recruiting|December 2011|||August 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|90 Years|No|||December 2011|December 19, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01495312||93848|
NCT01491360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVG-2013-01|LaserACE® Procedure Restore Visual Function and Range of Accommodation LaserACE® Procedure|Evaluation of the Safety & Efficacy of the LaserACE® Procedure to Restore Visual Function and Range of Accommodation||ACE Vision Group, Inc.|No|Enrolling by invitation|December 2013|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|146|||Both|50 Years|N/A|No|||April 2014|April 25, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01491360||94151|
NCT01491373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9504|Pilot Study of rhBMP-2/ACS/LT-CAGE® for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Feasibility Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease||Medtronic Spinal and Biologics|No|Completed|January 1997|September 1999|Actual|September 1999|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|65 Years|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491373||94150|
NCT01491997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT11-003 - 1 R01 AT007143-01|Mind-Body Medicine and Ulcerative Colitis|Mind-Body Medicine and Ulcerative Colitis||Rush University Medical Center|Yes|Recruiting|August 2011|August 2018|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01491997||94102|
NCT01492296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|safendoscopy|Endoscopy With Short Fasting|Safety, Quality and Comfort of Upper Gastrointestinal Endoscopy With Conscious Sedation After Fasting for Two Hours|safendoscopy|Universidade de Passo Fundo|No|Completed|March 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|115|||Both|18 Years|80 Years|No|||December 2011|December 12, 2011|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01492296||94079|
NCT01523496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11-06|Vitamin D Supplementation in HIV Youth|Vitamin D Supplementation and HIV-related Complications in Children and Young Adults||University Hospital Case Medical Center|Yes|Active, not recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|8 Years|25 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|January 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01523496||91694|
NCT01524315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004080-70|Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery|Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery - a Pilot Study||Medical University of Vienna|No|Active, not recruiting|February 2012|December 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2013|May 14, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524315||91631|
NCT01524848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSG XXI|Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib|Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group|PAGIST|Scandinavian Sarcoma Group|Yes|Active, not recruiting|February 2012|September 2015|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01524848||91590|
NCT01524861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IT 278354|Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy|Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies.||Second University of Naples|Yes|Completed|December 2011|January 2016|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|90|||Both|18 Years|70 Years|No|||January 2016|January 26, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01524861||91589|
NCT01525160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES-54|New Markers to Measure Clotting in Patients With the Obstructive Sleep Apnoea Hypopnoea Syndrome|Novel Biomarkers for Haemostasis in Patients With the Obstructive Sleep Apnoea Hypopnoea Syndrome||Hywel Dda Health Board|No|Completed|October 2011|March 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|66|Samples Without DNA|Frozen aliquots of citrated plasma|Both|18 Years|80 Years|No|Probability Sample|Subjects are recruited prospectively from a specialist sleep-disordered breathing clinic        in Prince Philip Hospital, Hywel Dda Health Board. They are referred from both primary and        secondary care with varying degrees of symptoms suggestive of OSAHS (daytime sleepiness,        snoring and/or nocturnal apneas).|April 2014|April 8, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525160||91567|
NCT01522417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medicure 11002|Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention|A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention|SAVI-PCI|Medicure|No|Recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|675|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522417||91777|
NCT01522105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|046/11|Daptomycin in Pediatric Patients With Bacterial Meningitis|Evaluation of Cerebrospinal Fluid Concentration of Daptomycin (Cubicin¬) in Pediatric Patients With Gram-positive Bacterial Meningitis, Concurrently Receiving Standard Antimicrobial Therapy||University Hospital Inselspital, Berne|No|Recruiting|April 2012|April 2018|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|3 Months|16 Years|No|||December 2015|December 10, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522105||91801|
NCT01524471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE_2010.430|Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders|||Chinese University of Hong Kong||Recruiting|July 2010|||March 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2012|February 1, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01524471||91619|
NCT01523925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 99-2314-B-182-014-MY3|Combined Behavioral Approaches With Functional Electrical Therapy in Stroke Rehabilitation|Combined Behavioral Approaches With Functional Electrical Therapy in Stroke Rehabilitation: Effects on Motor Control, Motor Impairment, Daily Function and Community Reintegration||Chang Gung Memorial Hospital|No|Withdrawn|January 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|N/A|No|||September 2014|February 10, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523925||91661|
NCT01525004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111069 - IRB|Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients|Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine in Pediatric Solid Organ Transplant Patients||Vanderbilt University|Yes|Enrolling by invitation|September 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|2||Anticipated|60|||Both|3 Years|17 Years|No|||January 2012|January 30, 2012|October 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525004||91578|
NCT01525017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-101|A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer|A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma||Immunicum AB|Yes|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01525017||91577|
NCT01495325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-194-31M|Effect of Woodsmoke on Vascular Function|Effect of Woodsmoke on Vascular Function in Healthy Firefighters|FIREWOOD|University of Edinburgh|Yes|Recruiting|September 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01495325||93847|
NCT01495637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIFT Study|GM-CSF for Immunomodulation Following Trauma (GIFT) Study|GM-CSF for Immunomodulation Following Trauma (GIFT) Study|GIFT|Nationwide Children's Hospital|Yes|Recruiting|December 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|1 Year|21 Years|No|||February 2015|February 2, 2015|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495637||93825|
NCT01491412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NME-SER-2011/1|Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia|RECONNECT-S GAMMA : A Non-interventional Study to Observe Real-life Usage of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia||AstraZeneca|No|Completed|December 2011|May 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|503|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects suffering from schizophrenia being discharged from the hospital following        hospitalisation due to acute psychotic episode|November 2012|November 29, 2012|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01491412||94147|
NCT01491425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9803|A Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease||Medtronic Spinal and Biologics|Yes|Completed|November 1998|October 2002|Actual|October 2002|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|134|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491425||94146|
NCT01492608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number 2011-000735-80|Magnesium Sulphate for Preterm Birth (MASP Study)|Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)|MASP|Hvidovre University Hospital|Yes|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|500|||Female|18 Years|50 Years|No|||February 2016|February 22, 2016|December 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01492608||94055|
NCT01523262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100012|Preventing Myocardial Ischemia by Preconditioning in Elective Operation for Abdominal Aortic Aneurysm|The Effect of Preconditioning to Prevent Perioperative Myocardial Ischemia in Elective Operation of Abdominal Aortic Aneurysm||Aarhus University Hospital|No|Recruiting|January 2011|January 2016|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 12, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523262||91712|
NCT01524068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12010444|A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations|A Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations||University of Pittsburgh|Yes|Withdrawn|September 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|90 Years|No|||January 2016|January 4, 2016|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524068||91650|
NCT01524354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Depth-28|Depth of Anesthesia in Cardiac Surgery|Monitoring of Anesthetic Depth During Surgical Correction of Acquired Valvular Disorders||Northern State Medical University|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||September 2012|September 11, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524354||91628|
NCT01524367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0200|Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery|Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery||Yonsei University|No|Completed|October 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|74|||Both|20 Years|60 Years|No|||February 2015|February 4, 2015|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01524367||91627|
NCT01524874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H30-B11|Comparative Effectiveness of Vitamin D and Repletion Strategies|A Comparative Effectiveness Trial of High-quality Vitamin D3 Nutritional Supplements to Replete Serum Vitamin D|CEDARS|Bastyr University|No|Completed|August 2010|November 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 31, 2012|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01524874||91588|
NCT01525173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LUM-11-019|A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension|||Allergan|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||October 2013|October 7, 2013|January 31, 2012|Yes|Yes||No|October 7, 2013|https://clinicaltrials.gov/show/NCT01525173||91566|
NCT01525186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSUIRB 09-451|Observational Study of Parental Feeding Practices to Improve Child's Food Intake and Weight Status|The Relationship of Parental Feeding Control Practices to Food Intake of 3-5Yr Children in Families With Limited Incomes||Michigan State University|Yes|Completed|September 2009|February 2010|Actual|September 2009|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|660|||Both|3 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Low income mother and preschool children participating national school readiness program,        HeadStart.|January 2012|February 1, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525186||91565|
NCT01522950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004M81135|A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function|A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease|EVIDENCE|University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|May 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|80 Years|No|||August 2015|August 11, 2015|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522950||91736|
NCT01522378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006296|Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging|Cardiac Resynchronization and MIBG Imaging||Mayo Clinic|No|Recruiting|February 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|106|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01522378||91780|
NCT01522391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCS-001|A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060|A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060||DermaGen AB||Completed|March 2008|April 2009|Actual|April 2009|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|65 Years|No|||January 2012|January 27, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01522391||91779|
NCT01522625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMRP36100N|Tenofovir in Chronic Hepatitis B With Mild ALT Elevation|Efficacy of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients With High Viral Load But Slight Aminotransferase Elevation||E-DA Hospital|No|Recruiting|January 2012|December 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|160|||Both|25 Years|70 Years|No|||January 2015|January 29, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01522625||91761|
NCT01495936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB 18480|The Effect of Two Airway Interventions, During One Lung Ventilation, on Blood Oxygen Content|The Influence Of Continuous Positive Airway Pressure and Positive End-Expiratory Pressure, With A Recruitment Maneuver, On Oxygenation During One Lung Ventilation Employing A Lung Protective Ventilation Strategy.||Lawson Health Research Institute|No|Not yet recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2011|December 19, 2011|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01495936||93802|
NCT01494207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC Ref 044/2009|Working on Wellness (WOW) Intervention|Working on Wellness (WOW): A Worksite Health Promotion Intervention Programme|WOW|University of Cape Town|No|Active, not recruiting|November 2009|June 2012|Anticipated|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|800|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 24, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01494207||93933|
NCT01494454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9807|Clinical Study of rhBMP-2/BCP With the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease|A Clinical Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With Either the TSRH® Spinal System or the CD Horizon® Spinal System for Posterolateral Lumbar Fusion in Patients With DDD||Medtronic Spinal and Biologics|Yes|Completed|August 1999|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01494454||93914|
NCT01524718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-twoaxis-001.il|Internal Fixation of Hip Fractures Using Intraoperative Simultaneous Two Axis View|||Meir Medical Center|No|Not yet recruiting|September 2012|March 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2012|September 2, 2012|January 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524718||91600|
NCT01494467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR.18171|Phase 3 Papulopustular Rosacea Study|A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.||Galderma|Yes|Completed|December 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|688|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|December 14, 2011|Yes|Yes||No|January 8, 2015|https://clinicaltrials.gov/show/NCT01494467||93913|
NCT01494766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-146|Efficacy of Tyrosine in Restless Legs Syndrome|Pilot Study of the Efficacy of Tyrosine in Restless Legs Syndrome||Seton Healthcare Family|No|Recruiting|January 2012|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494766||93890|
NCT01495650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APAD|Effect of a Tailored Program of Physical Activity and Nutritional Counseling on Fatigue Reduction in Breast Cancer Patients Receiving an Adjuvant Treatment|A Randomized Controlled Trial to Evaluate the Effect of a Tailored Program of Physical Activity and Nutritional Counseling on Fatigue Reduction in Breast Cancer Patients Receiving Adjuvant Treatment.|APAD|Institut du Cancer de Montpellier - Val d'Aurelle|No|Completed|December 2010|December 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|240|||Female|18 Years|76 Years|No|||March 2015|March 2, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01495650||93824|
NCT01491438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULC01|Plasma Rich Growth Factors in Venous Ulcers|Randomized Clinical Trial to Determinate the Effectiveness and Safety of Plasma Rich Growth Factors (PRGF) in Venous Ulcers Treatment||Basque Health Service||Not yet recruiting|November 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|214|||Both|18 Years|N/A|No|||December 2011|February 6, 2013|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01491438||94145|
NCT01491451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9804|A Pilot Study of rhBMP-2/ACS With the INTERFIX™ Device for the AnteriorLumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Pilot Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the INTERFIX™ Device for the Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease||Medtronic Spinal and Biologics|No|Completed|February 1999|January 2003|Actual|January 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491451||94144|
NCT01491737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO27775|A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer|A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.||Hoffmann-La Roche||Recruiting|February 2012|October 2019|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Female|18 Years|N/A|No|||March 2016|March 1, 2016|December 6, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491737||94122|
NCT01523509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU IRB-01|Use of Radiographic Contrast to Detect Dental Caries|The Use of Radiographic Contrast to Differentiate Cavitated From Non-cavitated Dental Caries||Creighton University|No|Active, not recruiting|September 2014|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|96|||Both|19 Years|99 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523509||91693|
NCT01524341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKAE609X2201|Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection|A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection||Novartis||Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|20 Years|60 Years|No|||May 2013|May 9, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524341||91629|
NCT01524094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPS-1|Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis|A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.||Uppsala University|No|Completed|June 2003|January 2012|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|80 Years|No|||January 2012|January 31, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01524094||91648|
NCT01524900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1100.1550|Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice|Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice||Boehringer Ingelheim||Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|398|||Both|18 Years|64 Years|No|Probability Sample|HIV-1 infected patients|June 2015|June 1, 2015|January 17, 2012||||No|May 15, 2015|https://clinicaltrials.gov/show/NCT01524900||91586|
NCT01525199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OAR-XXX-2011/1|Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.|Study of Cases and Controls on Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.|IDENTIFY|AstraZeneca|No|Completed|May 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|450|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be recruited from specialized sites; all the participating investigators        will be oncologists.|April 2014|April 11, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525199||91564|
NCT01524562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912037|HIV Accelerated Liver Disease in Uganda|HIV-Accelerated Liver Disease in Uganda||National Institutes of Health Clinical Center (CC)||Completed|December 2011|||||N/A|Observational|N/A|||Anticipated|1000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 20, 2015|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01524562||91612|
NCT01526083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP0013|Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males|Single-center, Open-label, Randomized 2-way Crossover Study of the Effect of Lacosamide 200 mg Twice Daily on the Single-dose Pharmacokinetics and Pharmacodynamics of Warfarin (25 mg) in Healthy Male Volunteers||UCB Pharma|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526083||91497|
NCT01522118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCa-MRgFUS-I|MR-guided Focused Ultrasound Treatment of Prostate Cancer: Focal Therapy for Locally Non-Advanced Disease|Focal Therapy With Magnetic Resonance Guided Focused Ultrasound Treatment of Locally Non-Advanced Prostate Cancer: Phase 1 Study||University of Roma La Sapienza|No|Completed|January 2011|June 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Male|40 Years|85 Years|No|||February 2013|February 25, 2013|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01522118||91800|
NCT01522651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-291-0102|A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)|A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation||Gilead Sciences|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|134|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522651||91759|
NCT01522664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27935|A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma||Genentech, Inc.||Completed|March 2012|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522664||91758|
NCT01522924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.0026|Tobacco Dependence Treatment Education for Dental Students|Tobacco Dependence Treatment Education for Dental Students Using Standardized Patients||University of Louisville|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|94|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 19, 2013|January 24, 2012||No||No|January 7, 2013|https://clinicaltrials.gov/show/NCT01522924||91738|One participant in the intervention group did not provide gender information. The total number of participants in the intervention group did not equal the number of male and female participants.
NCT01496248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1105721|Efficacy Study of Korean Red Ginseng to Treat Depression|The Effect of Korean Red Ginseng as Adjuvant Treatment for the Residual Symptoms of Depression||Korea University|No|Completed|August 2011|December 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Female|18 Years|55 Years|No|||October 2014|October 6, 2014|December 18, 2011||No||No|September 24, 2014|https://clinicaltrials.gov/show/NCT01496248||93778|
NCT01496261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132HPS11I|Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial|Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||December 2011|December 20, 2011|December 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01496261||93777|
NCT01494220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-5|Validation of the Bispectral Index Monitor During Living Donor Liver Transplantation|Validation of the Bispectral Index Monitor During Living Donor Liver Transplantation||Mansoura University|Yes|Completed|June 2007|February 2011|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|42|||Both|20 Years|50 Years|No|Non-Probability Sample|Mansoura University Liver Transplantation Program|April 2012|April 3, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01494220||93932|
NCT01494753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2345-PII-10/07(IN)|Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension|||Laboratoires Thea||Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2014|December 22, 2014|December 8, 2011||No||No|November 12, 2014|https://clinicaltrials.gov/show/NCT01494753||93891|
NCT01494480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111207ALS|The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis|The Clinical Study on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis||General Hospital of Chinese Armed Police Forces|Yes|Enrolling by invitation|March 2012|April 2015|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|20 Years|65 Years|No|||June 2012|June 18, 2012|December 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494480||93912|
NCT01494779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOMBLA0911|Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A.|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|March 2013|August 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Male|18 Years|32 Years|Accepts Healthy Volunteers|||September 2012|September 21, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01494779||93889|
NCT01495663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCL-10-001|Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned|A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapsed or Refractory Advanced Solid Malignancies||Cellectar Biosciences, Inc.|No|Completed|December 2011|January 2014|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|December 16, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01495663||93823|
NCT01491464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-9806|A Pivotal Study of rhBMP-2/ACS/INTER FIX™ Device for Posterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the INTER FIX™ Device for Posterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease||Medtronic Spinal and Biologics|No|Terminated|March 1999|September 2002|Actual|September 2002|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491464||94143|
NCT01491477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01-04|INFUSE ® Bone Graft/CORNERSTONE-SR® Allograft Ring/ATLANTIS® Anterior Cervical Plate System Pivotal Trial|Study of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the Cornerstone-SR™ Allograft Ring and the ATLANTIS™ Anterior Cervical Plate System in Treatment of Patients With Degenerative Cervical Disc Disease||Medtronic Spinal and Biologics|Yes|Terminated|April 2002|April 2005|Actual|April 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|70 Years|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491477||94142|
NCT01491750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21AT003913-01A2|Guided Imagery Response in Total Knee Replacement|Factors Affecting Guided Imagery Response in Total Knee Replacement||Kent State University|Yes|Completed|June 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||January 2014|January 2, 2014|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01491750||94121|
NCT01492010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEU-10-141|Role of Leucine in the Regulation of Human Myofibrillar Protein Synthesis at Rest and Following Resistance Exercise|Role of Leucine in the Regulation of Human Myofibrillar Protein Synthesis at Rest and Following Resistance Exercise||McMaster University|No|Completed|June 2010|September 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||December 2011|December 12, 2011|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492010||94101|
NCT01492309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|812494|Beat the Blues in Pregnancy Study|Transcranial Magnetic Stimulation in Pregnant Women With Depressive Disorder|TMS|University of Pennsylvania|Yes|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Female|18 Years|39 Years|No|||December 2015|December 7, 2015|December 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01492309||94078|
NCT01523795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1415|PRESENCE 2: Predicting Sedentary Entertainment Choices and Effects|PRESENCE 2: Predicting Sedentary Entertainment Choices and Effects||University of North Carolina, Chapel Hill|No|Completed|October 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|120|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2012|January 31, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523795||91671|
NCT01524107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSURGENT-ELECT-HMO-CTIL|Complications: Urgent C Section VS Elective C Section|Comparison of Maternal and Fetal Complications After Urgent Caesarian Section for Prolapsed Cord Versus Elective Caesarian Section.||Hadassah Medical Organization|No|Recruiting|January 2012|||October 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|240|||Female|20 Years|40 Years|No|Non-Probability Sample|Women undergoing Urgent Caesarian Section for Prolapsed Cord and women undergoing Elective        Caesarian Section at Hadassah Medical Center-Har HaTzofim.|July 2015|July 26, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524107||91647|
NCT01524588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOHP07-DR/VARFSHR|C Terminal Variants of FSH Receptor|C Terminal Peptide Variants of the Fsh Receptor in Women Involved in an Assisted Reproduction Programm : Mechanistic Approach||University Hospital, Tours|No|Completed|April 2008|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|814|||Female|18 Years|N/A|No|Non-Probability Sample|Patients involved in an assisted reproduction programm, once engaged in a stimulation        protocol|October 2012|October 19, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01524588||91610|
NCT01525212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI457-002|Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients|Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1||Bristol-Myers Squibb|No|Withdrawn|April 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|65 Years|No|||June 2013|June 19, 2013|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01525212||91563|
NCT01524575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCH0904|Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1|Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)||University of Hawaii|Yes|Recruiting|January 2012|January 2014|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524575||91611|
NCT01525485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104|Vaginal Electrical Stimulation Versus Neuromodulation|Vaginal Electrical Stimulation Versus Sacral Neuromodulation for the Treatment of Refractory Overactive Bladder: A Pilot Study|Estim|University of Oklahoma|No|Recruiting|March 2011|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Female|21 Years|N/A|No|Probability Sample|The projected sample size is 48 patients. We anticipate the recruitment of 16 patients for        the InterStim arm of this study and 32 patients who will undergo vaginal electrical        stimulation. Participants will be drawn from the University of Oklahoma Urogynecology        clinics. Our catchment area includes OU Physicians clinic (private clinic) and        Presbyterian Professional Building (resident clinic). Our referral area includes all of        Oklahoma as well as the surrounding states. Participants will be recruited by physician        referrals as well as by campus advertisements.|December 2014|December 2, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01525485||91543|
NCT01526096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-551-B|Stem Cell Transplantation for Patients With Multiple Myeloma|Pilot Study T Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Patients With Multiple Myeloma||University of Chicago|No|Active, not recruiting|July 2011|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|21 Years|70 Years|No|||June 2015|June 22, 2015|August 10, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01526096||91496|
NCT01523158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/014/TAR|Mechanisms of Allergen Immunotherapy|An Open Study to Investigate the Effects of Injection Immunotherapy on Allergen-specific T and B Cell Responses in Adult Patients With Seasonal Allergic Rhinitis.||Royal Sussex County Hospital|No|Terminated|April 2012|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|2|||Both|18 Years|N/A|No|||September 2012|September 21, 2012|January 27, 2012||No|R and D approval not forthcoming|No||https://clinicaltrials.gov/show/NCT01523158||91720|
NCT01522677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108643|A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer|A Phase I/II Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer||Holcombe, Randall F., M.D.|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522677||91757|
NCT01522937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2009-053|A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer|A Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|October 2009|November 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01522937||91737|
NCT01496534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0946|Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors|Phase Ib Study of Dovitinib in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Plus Carboplatin in Patients With Advanced Solid Tumors||Icahn School of Medicine at Mount Sinai|No|Terminated|January 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|December 12, 2011|Yes|Yes|toxicity of combination of medications|No||https://clinicaltrials.gov/show/NCT01496534||93756|
NCT01494233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1033.1-201-IBS|A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)||Lexicon Pharmaceuticals|No|Completed|February 2012|||September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|373|||Both|18 Years|70 Years|No|||March 2015|March 3, 2015|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01494233||93931|
NCT01494506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-398-07-03-01|Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer|A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy|NAPOLI-1|Merrimack Pharmaceuticals|Yes|Completed|November 2011|October 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|417|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|December 14, 2011|Yes|Yes||No|November 25, 2015|https://clinicaltrials.gov/show/NCT01494506||93910|
NCT01494493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00-01|Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease||Medtronic Spinal and Biologics|Yes|Terminated|September 2000|February 2004|Actual|February 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||December 2011|August 1, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494493||93911|
NCT01494519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-2-0108|Assessment of Fixation Strategies for Severe Open Tibia Fractures|A Prospective Randomized Trial to Assess Fixation Strategies for Severe Open Tibia Fractures:Modern Ring External Fixators Versus Internal Fixation|FIXIT|Major Extremity Trauma Research Consortium|Yes|Recruiting|July 2011|January 2020|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|624|||Both|18 Years|64 Years|No|||September 2015|September 1, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01494519||93909|
NCT01494792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-0142-02|Sofia Strep A FIA Field Study|Sofia Strep A FIA Field Study||Quidel Corporation|No|Terminated|November 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2090|||Both|3 Years|N/A|No|Non-Probability Sample|Subjects must be three (3) years of age or older and exhibiting symptoms characteristics        of pharyngitis, possibly Group A Streptococcus.|October 2012|October 5, 2012|December 15, 2011|Yes|Yes|Performance did not meet sponsor requirements.|No||https://clinicaltrials.gov/show/NCT01494792||93888|
NCT01495065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116160|A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers|A Two Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK2251052 After Single Ascending Doses and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and a Repeat Dose Study to Evaluate Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers||GlaxoSmithKline||Terminated|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|8|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|December 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01495065||93867|
NCT01495338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-100-0013|A Comparison of the Safety and Comfort of AC-170|||Aciex Therapeutics, Inc.|No|Completed|December 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|N/A|No|||April 2015|June 23, 2015|December 15, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495338||93846|
NCT01522820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 191511|Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors|A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors||Roswell Park Cancer Institute|No|Active, not recruiting|March 2012|||September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|30|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|January 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522820||91746|
NCT01523054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-MET-0027|Metoprolol in Acute Myocardial Infarction. A PK/PD Study|A Pharmacokinetic and Pharmacodynamic Study Comparing Metoprolol IR and Metoprolol CR/XL Subsequent to Initial Treatment With Intravenous and/or Oral Metoprolol in Patients With Suspected Acut Myocardial Infarction||AstraZeneca||Completed|February 2000|April 2002|Actual|April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|27|||Both|N/A|N/A|No|||January 2012|January 30, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523054||91728|
NCT01523275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Laryngotracheal Stenosis|Study of Mitomycin-C Application in Laryngotracheal Stenosis|A Randomized Study of Mitomycin-C Application in the Endoscopic Surgical Treatment of Patients With Laryngotracheal Stenosis||University of California, San Francisco|No|Recruiting|January 2012|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523275||91711|
NCT01524081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNB_ATB|Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures|Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis||The Faculty Hospital Na Bulovce|No|Completed|July 2008|November 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|6||Actual|187|||Both|18 Years|N/A|No|||January 2012|February 7, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524081||91649|
NCT01524328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1683/|Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. A Cross Sectional Study in Norway.|Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. A Cross Sectional Study in Norway.||Oslo University Hospital|No|Completed|October 2009|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|460|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with (>18 years) a verified diagnosis of Crohn`s disease or ulcerative        colitis attending an outpatient clinic in a Norwegian hospital.|January 2012|January 30, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524328||91630|
NCT01524887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161003|Phase 3 IGIV, 10% in Alzheimer´s Disease|A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease||Baxalta US Inc.|Yes|Terminated|January 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|508|||Both|50 Years|89 Years|No|||February 2015|June 26, 2015|January 20, 2012|Yes|Yes|The study was terminated because the first Phase 3 did not demonstrate efficacy on the    co-primary endpoints. The known safety profile remained unchanged.|No|February 3, 2015|https://clinicaltrials.gov/show/NCT01524887||91587|The primary and secondary outcome measures were originally planned to be assessed at 18 months. However, as the study was terminated early, an analysis was completed at 9 months instead, in a subset of subjects who had received 9 months of treatment.
NCT01524913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00018682|A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for TMJ|A Double Blind Randomised Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint Dysfunction||Emory University|Yes|Active, not recruiting|January 2012|April 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|330|||Both|18 Years|90 Years|No|||January 2016|January 9, 2016|January 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524913||91585|
NCT01525810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-016|Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial|A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in Which Peginterferon Lambda-1a (BMS-914143) Was Administered for the Treatment of Chronic Hepatitis C||Bristol-Myers Squibb|No|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who participated in a clinical trial in which BMS-914143 was administered for the        treatment of chronic hepatitis C|March 2015|March 25, 2015|January 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01525810||91518|
NCT01525823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA191-015|Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin|Effects of Metformin on Glucose Homeostasis Following Administration of BMS-754807 in Healthy Volunteer Subjects|NHV|Bristol-Myers Squibb|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01525823||91517|
NCT01525771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-XPID-1|Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer|A Phase I-II Study of Systemic Capecitabine, Cisplatin and Intraperitoneal Docetaxel (XPID) in Patients With Advanced Stomach Cancer With Peritoneal Seeding|XPID|Asan Medical Center|No|Completed|February 2011|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01525771||91521|
NCT01525784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|88\11|Affect of RT-CGMS as Part of Clinical Care in Type 1 Diabetes Mellitus Patients|Prospective Short and Long Term Follow up of Pediatric Diabetes Mellitus Patients Receiving RT-CGMS as Part of National Clinical Care||Assaf-Harofeh Medical Center|No|Not yet recruiting|February 2012|June 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|1 Year|18 Years|No|Probability Sample|All patients recieving CGMS for treatment group and those without RTCGMS but all other        management, for control group.|February 2012|February 1, 2012|November 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01525784||91520|
NCT01525797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002-197|Blood Draw Study for Liver Transplant Patients|Immunomonitoring of Transplant Patients||Baylor Research Institute|No|Active, not recruiting|October 2002|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|200|||Both|17 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Liver Clinic|March 2015|March 13, 2015|May 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01525797||91519|
NCT01523171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD12181|Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib|A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis|JAKARTA2|Sanofi|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|97|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523171||91719|
NCT01523392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00013|A Pharmacodynamic Study With Ticagrelor in African American Patients|A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease||AstraZeneca||Completed|March 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|January 30, 2012|Yes|Yes||No|September 22, 2014|https://clinicaltrials.gov/show/NCT01523392||91702|
NCT01523912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gastric ablation|Radiofrequency Ablation for the Treatment of Gastric Dysplasia|Ablation of Gastric Dysplastic Mucosa by a Novel Endoscopic Radiofrequency Device.||Hospital Sao Joao|No|Completed|January 2011|May 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01523912||91662|
NCT01496547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJH-2011-RefactoryAML-SCT|Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML|Sequential Intensive Chemotherapy Followed by Allogeneic Stem Cell Transplantation With Reduce-intensity Conditioning for Refractory and Relapse Acute Myeloid Leukemia in Adult Patients||Shanghai Jiao Tong University School of Medicine|No|Recruiting|January 2011|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|16 Years|60 Years|No|||December 2014|December 4, 2014|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01496547||93755|
NCT01494805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-135|Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration|A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)|AMD|Lions Eye Institute, Perth, Western Australia|Yes|Active, not recruiting|December 2011|May 2017|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|55 Years|N/A|No|||September 2012|April 9, 2014|December 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01494805||93887|
NCT01495078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Proyecto ICOR|Telemonitoring and Teleintervention of Heart Failure and Decrease of Non-fatal Events.|Telemonitoring and Teleintervention of Heart Failure and Decrease of Non-fatal Events.|ICOR|Parc de Salut Mar|No|Completed|December 2010|December 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|178|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01495078||93866|
NCT01495351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM11-01|Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma|Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma||AHS Cancer Control Alberta|Yes|Recruiting|January 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||December 2011|January 18, 2012|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01495351||93845|
NCT01523067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB1046-PT-CL-0001|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension|Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Adult Subjects With Stage 1 or Stage 2 Essential Hypertension||PhaseBio Pharmaceuticals Inc.|Yes|Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|70 Years|No|||January 2013|January 3, 2013|January 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01523067||91727|
NCT01523288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWS-1051|The Intestinal Function in People With Prader-Willi Syndrome|The Intestinal Function in People With Prader-Willi Syndrome||Aarhus University Hospital|Yes|Completed|February 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with Prader-Willi Syndrome|January 2012|January 31, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523288||91710|
NCT01523522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/067/HP|Autologous Myoblast Intrasphincteric Injection for Fecal Incontinence|Etude de l'efficacité et de la sécurité d'Injections Intra-sphinctériennes de Myoblastes Autologues Chez Des Patients Atteints d'Incontinence Anale sévère Par Insuffisance sphinctérienne|MIAS|University Hospital, Rouen|Yes|Completed|February 2012|October 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|65 Years|No|||October 2015|October 22, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01523522||91692|
NCT01523821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2571.00|Alpha 1 Anti-Trypsin in Treating Patients With Acute Graft-Versus-Host Disease|Treatment of Steroid Non-responsive Acute GVHD With Alpha 1 Antitrypsin (AAT). A Phase I/II Study||Fred Hutchinson Cancer Research Center|Yes|Recruiting|November 2013|||June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|January 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01523821||91669|
NCT01524926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-90101|CREATE: Cross-tumoral Phase 2 With Crizotinib|Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")|CREATE|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|September 2012|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|582|||Both|15 Years|N/A|No|||July 2015|July 16, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01524926||91584|
NCT01526122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G0041(75/100mg)_AS_Ⅰ|Pharmacokinetics & Safety Study of Clopidogrel 75mg and Aspirin 100mg Coadministration|A PhaseⅠ Study to Compare the Pharmacokinetic Characteristics and Safety After Oral Administration of G0041(75/100mg) With Those of Clopidogrel 75mg & Aspirin 100mg Coadministration in Healthy Male Volunteers||Dong-A ST Co., Ltd.|Yes|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 29, 2014|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01526122||91494|
NCT01522157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2011/418-31|A Randomized Cross-over Trial of the Postprandial Effects of Three Different Diets in Patients With Type 2 Diabetes|A Randomized Cross-over Trial of the Postprandial Effects of Three Different Diets in Patients With Type 2 Diabetes||Vårdcentralen Lyckorna||Completed|January 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2013|November 29, 2013|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01522157||91797|
NCT01526109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040.2011|Effect of Strength Training and Whole Body Vibration in Healthy Elderly|Effect of Strength Training and Whole Body Vibration on Cognitive Function, Behavioral and Functional Capacity in Healthy Elderly.||Universidade Gama Filho|Yes|Withdrawn|January 2012|December 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|3||Actual|0|||Both|60 Years|90 Years|Accepts Healthy Volunteers|||February 2012|December 3, 2015|January 31, 2012||No|The study was finished since the University has been closed|No||https://clinicaltrials.gov/show/NCT01526109||91495|
NCT01522430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|140576|Study of Catheter Based Renal Denervation Therapy in Hypertension|DENERVATION OF RENAL SYMPATHETIC ACTIVITY AND HYPERTENSION STUDY|DEPART|Erasme University Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|85 Years|No|||January 2012|January 27, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01522430||91776|
NCT01522963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA029689|Medicinal Nicotine for Preventing Stress Induced Craving and Withdrawal Symptoms|Medicinal Nicotine for Preventing Stress Induced Craving and Withdrawal Symptoms||University of Minnesota - Clinical and Translational Science Institute|No|Completed|December 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|98|||Both|18 Years|65 Years|No|||July 2014|July 30, 2014|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522963||91735|
NCT01522131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-DB-11-0611|Effect of Laser Use on Guided Tissue Regeneration in Treatment of Molar Teeth With Class 2 Furcation Affected by Periodontitis|Treatment of Class II Furcation Defects in the Maxillary and Mandibular Molars With Bioresorbable Collagen Membrane and Laser||The University of Texas Health Science Center, Houston|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|May 13, 2014|January 24, 2012|Yes|Yes||No|January 14, 2014|https://clinicaltrials.gov/show/NCT01522131||91799|
NCT01522144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HS014873|An Electronic Decision Support Tool to Improve Outpatient Asthma Care|EHR Decision Support to Improve Outpatient Asthma Care||Agency for Healthcare Research and Quality (AHRQ)|No|Completed|July 2006|August 2008|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1030|||Both|1 Year|18 Years|No|||January 2012|January 27, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01522144||91798|
NCT01523418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15871|Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)|Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery or Hip or Knee in Indian Patients|XYRIS|Bayer|No|Withdrawn|October 2014|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing elective TKR / THR|February 2016|February 2, 2016|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523418||91700|
NCT01493713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEMCAD-1006|Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer|Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX|AVAMET|Grupo Espanol Multidisciplinario del Cancer Digestivo|No|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|83|||Both|18 Years|N/A|No|||October 2013|October 10, 2013|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01493713||93970|
NCT01523405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIN-XXX-2011/3|A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM|A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)|INSIGHT|AstraZeneca|No|Completed|March 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|4911|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 5,000 adult patients (≥ 18 years) diagnosed with T2DM will be randomly        selected from around 300 hospitals/primary care clinics across India to participate in        this study.|September 2014|September 5, 2014|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523405||91701|
NCT01523951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|367/180-03/04|Topical Local Anaesthesia and Cooling During Capsaicin 8% Patch Application|A Comparison of Topical Local Anaesthesia and Cooling to Reduce the Burning Pain During Capsaicin 8% Patch Application|LACCA|Medical University of Vienna|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|Skin biopsy|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|healthy volunteers|March 2012|March 19, 2012|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01523951||91659|
NCT01496300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1103|Benefit of Orthopedic Navigation in the ARThroplasty of the Hip|Randomised Controlled Double-blind Monocenter Therapy Study Validating the Benefit From Information Provided by Image Free Navigation System on the Precision of the Placement of Acetabular Component in Patients Undergoing Primary THA|BONARTH|Aesculap AG|No|Completed|November 2011|September 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|89|||Both|50 Years|N/A|No|||September 2014|September 2, 2014|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01496300||93774|
NCT01496560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sheba-11-8679-DC-CTIL|Open Prospective Study for Determination of Predictive Measures for Pain During Colonoscopy|Comparison of Procedural Sequence in Same Day Consecutive Bidirectional Endoscopy Using Moderate Sedation: A Prospective Randomized Study||Sheba Medical Center|No|Withdrawn|November 2015|November 2015|Actual|November 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients undergoing screening colonoscopy|November 2015|November 16, 2015|December 19, 2011||No|study terminated due toTechnical issue pre -recruiting|No||https://clinicaltrials.gov/show/NCT01496560|1 Day|93754|
NCT01494818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 10-59 / M-11-02|Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues|Evaluation of the Effects of Clear Care/AOSEPT Plus Hydrogen Peroxide Solution on the Eyelid Tissues - Part II: Comparative Evaluation With RENU MPS Over 3 Months of Wear||Alcon Research|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|79|||Both|18 Years|N/A|No|||July 2013|July 30, 2013|December 15, 2011|Yes|Yes||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01494818||93886|
NCT01495091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1938 (REK)|Markers of Coronary Artery Disease During Exercise Testing|Markers of Coronary Artery Disease During Exercise Testing|CADENCE|Oslo University Hospital|No|Recruiting|December 2011|December 2040|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|600|Samples With DNA|Whole blood, serum.|Both|18 Years|N/A|No|Non-Probability Sample|Participants will be recruited from patients with chest pain/discomfort referred for        exercise stress testing at Oslo University Hospital, including patients with acute chest        pain referred to the emergency department, and referrals to the outpatient clinic.|September 2012|September 11, 2012|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01495091||93865|
NCT01522560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-473|Evaluation of Multiscore Feedback in Professionalism for Anesthesia|||The Cleveland Clinic|No|Recruiting|July 2011|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2012|December 7, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01522560||91766|
NCT01523080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104_ACETA_06|A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fasting Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gel Tabs (Containing Acetaminophen 650 mg) of OHM Laboratories Inc. (Subsidiary of Ranbaxy) With Tylenol 8 Hour Extended Release Gel Tabs (Containing Acetaminophen 650 mg) of McNeil Consumer & Speciality Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fasting Condition||Ranbaxy Inc.|No|Completed|May 2006|July 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|19 Years|39 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523080||91726|
NCT01523301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1041|Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients|Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients||UCB Pharma|No|Completed|April 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|380|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|January 27, 2012|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01523301||91709|
NCT01523535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000365|Repeated Challenge of Insufficient Sleep: Endothelial Effects|Repeated Challenge of Insufficient Sleep: Effects on Endothelial Function||Beth Israel Deaconess Medical Center|No|Active, not recruiting|August 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|52|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523535||91691|
NCT01523808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRASPANC2008-02|Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer|Phase I, Dose Escalation Clinical Trial of GRASPA (Red Blood Cells Encapsulating L-Asparaginase) in Patients With Pancreatic Carcinoma||ERYtech Pharma|Yes|Completed|June 2009|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|70 Years|No|||March 2013|March 7, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01523808||91670|
NCT01524380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sch-FEP-001|Ginkgo Biloba Extract for Schizophrenia|A Double-blind and Randomized Trial of Ginkgo Biloba Extract Added to Risperidone in Treatment-naive First-episode Schizophrenia||Beijing HuiLongGuan Hospital|Yes|Completed|September 2011|August 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 15, 2013|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01524380||91626|
NCT01525498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Foley|Foley Catheterization Following Sacrocolpopexy|Urinary Bladder Catheterization Following Sacrocolpopexy||University of Oklahoma|No|Withdrawn|August 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Female|21 Years|N/A|No|Non-Probability Sample|The projected sample size is 584 participants. Participants will be drawn from the        University of Oklahoma Urogynecology clinics. Our catchment area includes OU Physicians        clinic (private clinic) and Presbyterian Professional Building (resident clinic).|October 2013|October 15, 2013|January 19, 2012||No|No subject accrual|No||https://clinicaltrials.gov/show/NCT01525498||91542|
NCT01522456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10201|Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel|Split-face Tolerability Comparison Between Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Versus Retin-A Micro® (Tretinoin Gel) Microsphere, 0.1% in Subjects With Acne Vulgaris||Galderma Laboratories, L.P.|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|January 23, 2012|Yes|Yes||No|March 11, 2013|https://clinicaltrials.gov/show/NCT01522456||91774|
NCT01522170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-003|aHUS Observational Long Term Follow-Up|An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study|LTFU|Alexion Pharmaceuticals|No|Enrolling by invitation|March 2012|September 2018|Anticipated|December 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Male and female aHUS, including minors, who previously participated in eculizumab clinical        trials.|January 2015|June 2, 2015|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522170|5 Years|91796|
NCT01522976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00242|Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia|A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)||National Cancer Institute (NCI)|Yes|Active, not recruiting|March 2012|||June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|282|||Both|18 Years|N/A|No|||March 2015|February 18, 2016|January 27, 2012|Yes|Yes||No|February 18, 2016|https://clinicaltrials.gov/show/NCT01522976||91734|
NCT01522469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-004|Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations|A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations||Arog Pharmaceuticals, Inc.||Completed|July 2012|November 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|January 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522469||91773|
NCT01522690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCELERIX|Assessment of Accelerometric Measurement Devices for Gait Analysis|Assessment of Accelerometric Measurement Devices for Gait Analysis|ACCELERIX|Institut de Myologie, France|No|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|300|||Both|5 Years|85 Years|Accepts Healthy Volunteers|||January 2012|May 2, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01522690||91756|
NCT01522989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-219|PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies|A Phase I Study of the CDK4/6 Inhibitor PD-0332991, 5-Fluorouracil, and Oxaliplatin in Patients With Advanced Solid Tumor Malignancies||Georgetown University|Yes|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||September 2015|February 15, 2016|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522989||91733|
NCT01493726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK9072-002|A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072 in Subjects With Chronic Stable Schizophrenia||Alkermes, Inc.|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|88|||Both|18 Years|55 Years|No|||August 2013|August 9, 2013|December 12, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01493726||93969|
NCT01523678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BGOG-ov5|Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers|Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers||Belgian Gynaecological Oncology Group||Active, not recruiting|February 2012|January 2019|Anticipated|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|108|||Female|18 Years|N/A|No|||July 2015|July 22, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01523678||91680|
NCT01523938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYPNOC|Influence of Perioperative Hypnotherapy on Postoperative Improvement in Cognitive Performance|Influence of Perioperative Hypnotherapy on Postoperative Improvement in Cognitive Performance. A Randomized-controlled Open Clinical Monocentric Interventional Study.|HYPNOC|Charite University, Berlin, Germany|No|Active, not recruiting|March 2012|June 2016|Anticipated|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523938||91660|
NCT01496313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00097|To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer|An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease||AstraZeneca||Completed|June 2012|March 2015|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|130 Years|No|||October 2015|October 27, 2015|December 2, 2011|Yes|Yes||No|April 1, 2015|https://clinicaltrials.gov/show/NCT01496313||93773|
NCT01526226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2019 REK NORD|Patient Comfort During High Flow Nasal Cannula Versus Nasal Continuous Airway Pressure (CPAP)|Patient Comfort During High Flow Nasal Cannula (HFNC)Versus Nasal Continuous Airway Pressure (CPAP): a Cross Over Randomised Trial||University Hospital of North Norway|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|25 Weeks|34 Weeks|No|||June 2013|June 18, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01526226||91486|
NCT01526239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14225|Reminding Patients of the Important of Colorectal Cancer Screening Results in Patient-Initiated Promoting Colorectal Cancer Screening Via Colonoscopy|Patient-Reminder Results in Patient-Initiated Promoting Colorectal Cancer Screening Via Colonoscopy||University of Oklahoma|Yes|Completed|November 2008|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Screening|2||Actual|274|||Both|45 Years|N/A|Accepts Healthy Volunteers|||January 2012|February 2, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01526239||91485|
NCT01522300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOMOS|Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité Tomos Study- Contribution of Tomosynthesis In Locoregional Pretherapeutic Staging of a Breast Tumor: Multicentricity Search|Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité||Centre Jean Perrin|No|Terminated|January 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|81|||Female|18 Years|N/A|No|||November 2013|November 20, 2013|January 18, 2012||No|No more inclusions since august 2013|No||https://clinicaltrials.gov/show/NCT01522300||91786|
NCT01522313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPHRANEST|Influence of Perioperative Kidney Function on Postoperative Outcome|Retrospective Data Analysis of the Impact of Perioperative Kidney Function on Postoperative Outcome|NEPHRANEST|Charite University, Berlin, Germany|No|Completed|January 2006|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|39369|||Both|N/A|N/A|No|Non-Probability Sample|Retrsospective analysis of electronic charts of all patients that underwent anesthesia        between January 2006 - June 2012 in the Department of Anesthesiology at the Charité -        University Medicine Berlin, Campus Charité Mitte und Campus Virchow Klinikum.|October 2012|October 8, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01522313||91785|
NCT01522833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI OUTCOMES 13|Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer|Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting||SCRI Development Innovations, LLC|No|Completed|October 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|27|Samples With DNA|Tissue-testing will be performed or test results will be reviewed to identify EGFR-wt and      EGFR mutation positive advanced non small cell lung cancer (NSCLC) patient cases with an      erlotinib-treatment duration of six months or longer (as 2nd/3rd line and/or maintenance      single-agent therapy) in a community-based setting.      Biopsy specimens from enrolled patient cases who are EGFR-wt will be evaluated via      exploratory genetic analysis for correlated biomarkers.|Both|N/A|N/A|No|Probability Sample|EGFR-wt and EGFR mutation positive advanced NSCLC patient cases with an        erlotinib-treatment duration of six months or longer (as 2nd/3rd line and/or maintenance        single-agent therapy) in a community-based setting|March 2016|March 4, 2016|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01522833||91745|
NCT01522846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B_1112_069_003|Heparin Solution and INTEM/HEPTEM Analysis|Influence by Heparinized Flush Solution of the Radial Artery Catheter: INTEM and HEPTEM Analysis.||Seoul National University Bundang Hospital|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|20 Years|N/A|No|Non-Probability Sample|Patients requiring continuous invasive arterial pressure monitoring during operation for        anesthetic management.|August 2013|August 28, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01522846||91744|
NCT01523093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108_ONDAN_06|Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Ondansetron 8 mg Orally Disintegrating Tablets of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc,) With Zofran ODT® 8 mg Orally Disintegrating Tablets (Containing 8 mg of Ondansetron) of GlaxoSmithKline in Healthy, Adult, Human, Male Subjects Under Fasting Condition.||Ranbaxy Inc.|No|Completed|July 2006|October 2006|Actual|July 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|32|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523093||91725|
NCT01523314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECEDE|Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema|Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema|DECEDE|King Saud University|Yes|Not yet recruiting|March 2012|February 2013|Anticipated|August 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|70 Years|No|||January 2012|January 31, 2012|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01523314||91708|
NCT01523548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-06425|Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension|Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension|CO in PAH|University of Illinois at Chicago|Yes|Active, not recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523548||91690|
NCT01523561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMO027|Influencing Adolescent Girls´ With Creative Dance Twice Weekly|Influencing Adolescent Girls With Internalizing Problems With Creative Dance Twice Weekly. A Randomised, Controlled Study||Örebro County Council|No|Completed|October 2009|January 2013|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Female|13 Years|18 Years|No|||July 2015|July 14, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01523561||91689|
NCT01524601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RITA-11|The Rosuvastatin In TrAnsplant Recipients Study|The RITA-study -- An Open Study to Evaluate the Blood Lipid Lowering Effect of Rosuvastatin Versus Fluvastatin and the Bilateral Interaction Between Everolimus and Rosuvastatin in Renal Transplant Recipients|RITA|University of Oslo School of Pharmacy|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01524601||91609|
NCT01524614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p002823|Safety Study of Continuous Positive Airway Pressure Via a Nasal Mask|Effect of Continuous Positive Airway Pressure Ventilation Through Nasal Mask on Upper Airway Patency During Induction of Anesthesia||Massachusetts General Hospital|Yes|Completed|October 2011|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Actual|80|||Both|18 Years|65 Years|No|||December 2014|December 1, 2014|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01524614||91608|
NCT01525836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-004|A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）|Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.||Shandong University|Yes|Recruiting|May 2011|December 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|72 Years|No|||May 2013|May 4, 2013|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525836||91516|
NCT01526148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11-01|Gao Bipolar Spectrum Lithium/Quetiapine Study|Comparative Safety, Tolerability, and Effectiveness of Lithium Versus Quetiapine in Patients Across the Spectrum of Bipolar Disorder||University Hospital Case Medical Center|Yes|Terminated|January 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|January 25, 2012|Yes|Yes|Ran out of funding|No|July 30, 2015|https://clinicaltrials.gov/show/NCT01526148||91492|
NCT01522703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00067371|Effects of Whole Sprouts on Upper Airway Allergic Inflammation|Dietary Interventions and Asthma Treatment: A Pilot Study of the Effects of Whole Sprouts on Upper Airway Allergic Inflammation||Johns Hopkins University|Yes|Completed|March 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|50 Years|No|||September 2015|September 5, 2015|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522703||91755|
NCT01522716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSC-cGVH|Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease|Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease||Karolinska Institutet|No|Active, not recruiting|August 2011|January 2017|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01522716||91754|
NCT01523184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YKP10811C003|A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation|A Phase II, Single-Center, Randomized, Parallel Group, Multiple Administration, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation||SK Life Science|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|57|||Both|18 Years|65 Years|No|||July 2014|July 2, 2014|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523184||91718|
NCT01493401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-068|Urinary Urinary Nerve Growth Factor (NGF) as a Biomarker for Mixed Urinary Incontinence|Exploration of the Potential of Urinary Nerve Growth Factor (NGF) as a Biomarker for Diagnosis and Prognosis of Mixed Urinary Incontinence After Midurethral Slings||Samsung Medical Center|No|Recruiting|February 2010|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|121|||Female|18 Years|N/A|No|||January 2014|February 12, 2015|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493401||93994|
NCT01493141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15402|Systemic Effects of Chronic Metal Ion Exposure From Metal-on Metal Hip Resurfacing|Systemic Effects of Chronic Metal Ion Exposure From Metal-on Metal Hip Resurfacing|Metal Ions|Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|November 2009|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|46|Samples With DNA|The following markers will be measured using the blood samples:        1. Serum, erythrocyte, and whole blood cobalt, chromium, and nickel        2. Serum iron stores:           Iron, ferritin, transferrin, and total iron binding capacity.        3. Serum biochemical markers of bone turnover:           Osteoblast activity markers (including PINP, OC, BALP) Osteoclast activity markers           (including NTX-I, CTX-I, ICTP)        4. Hypothalamo-pituitary axis hormones (in the following order of priority):           Prolactin LH/FSH + testosterone/oestradiol Growth hormone + IGF-I TSH + Free T3 ACTH +           cortisol        5. Renal function:           Urea, electrolytes, and creatinine        6. Hepatic function Liver function tests Clotting screen        7. Serum lipid profile, full blood count|Both|18 Years|N/A|No|Non-Probability Sample|All potential subjects will be identified from the clinical records and registered        databases of Mr Wilkinson and Mr Stockley, who are the clinicians who have been directly        responsible for the patients clinical care with respect to their hip arthritis.|December 2012|December 14, 2012|December 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01493141||94014|
NCT01493440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVFAS1103|Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure|Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure||An Sinh Hospital|No|Completed|March 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Female|N/A|N/A|No|||December 2011|December 16, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493440||93991|
NCT01493453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05_DOG05_18|A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy|A Phase I Study of Adoptive Transfer of Autologous Tumour Antigen-Specific T Cells With Pre-conditioning Chemotherapy and Intravenous IL2 in Patients With CD19 Positive Malignancy|CD19|Christie Hospital NHS Foundation Trust|Yes|Recruiting|March 2008|December 2014|Anticipated|May 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493453||93990|
NCT01493973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FA_BBK_8|Efficacy Study of Epoetin Alfa in Friedreich Ataxia|A Double-blind, Randomized, Placebo-controlled, Clinical Trial to Test the Efficacy of Epoetin Alfa on Physical Performance of Friedreich Ataxia Patients.|FRIEMAX|Federico II University|Yes|Completed|January 2013|June 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|12 Years|N/A|No|||August 2015|August 10, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493973||93950|
NCT01493739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBUSTBNA_01|EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy|EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy||Chang Gung Memorial Hospital|Yes|Recruiting|January 2009|January 2012|Anticipated|January 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Patients with mediastinal lymphadenopathy on Chest CT scan with a short-axis > 10mm|December 2011|December 15, 2011|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01493739||93968|
NCT01507064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|epatologia2|Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma|Randomized Controlled Phase II Trial Of Neoadjuvant Sorafenib Therapy Prior to Thermal Ablation for Hepatocellular Carcinoma More Than 4 cm in Size|LANEX|Cardarelli Hospital|No|Recruiting|January 2012|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||February 2015|February 2, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01507064||92948|
NCT01522326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002837|Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness|Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen||Massachusetts General Hospital|No|Recruiting|March 2012|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 22, 2015|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522326||91784|
NCT01522573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111012016|T-EUS for Gastrointestinal Disorders: A Multicenter Registry|Therapeutic Endoscopic Ultrasound (T-EUS) Guided Procedures in the Management of Gastrointestinal Disorders: A Multicenter Registry.|EUSERCPReg|Weill Medical College of Cornell University|No|Recruiting|November 2011|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who has undergone Endoscopic Ultrasound (EUS) guided Endoscopic retrograde        cholangiopancreatography (ERCP) procedure for diagnosis or treatment of a        pancreatico-biliary disorder.        Above 18 years of age.|July 2015|July 31, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522573||91765|
NCT01522859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/NIR01/26|Telehealth Monitoring in Chronic Obstructive Pulmonary Disease|The Efficacy of Telehealth Monitoring in the Management of Patients With Chronic Obstructive Pulmonary Disease||South Eastern Health and Social Care Trust|No|Completed|August 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|110|||Both|N/A|N/A|No|||January 2012|January 27, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01522859||91743|
NCT01522872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-CR-408|Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma|A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma||Threshold Pharmaceuticals||Active, not recruiting|February 2012|September 2017|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|98|||Both|18 Years|N/A|No|||May 2015|January 4, 2016|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522872||91742|
NCT01523574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VE01|Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis|Randomized, Placebo Controlled Study of Vitamin E for Oxaliplatin-induced Neuropathy Prophylaxis||Faculdade de Medicina do ABC|Yes|Completed|August 2009|December 2010|Actual|November 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|N/A|No|||January 2012|January 29, 2012|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01523574||91688|
NCT01523587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.125|LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy|LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy||Boehringer Ingelheim||Active, not recruiting|March 2012|August 2016|Anticipated|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|795|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 30, 2012||||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01523587||91687|
NCT01523834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIL_PanAL10|Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT|A Phase II Study of Oral Panobinostat in Adult Patients With Diffuse Large B-cell Lymphoma Relapsed/Refractory After High-dose Chemotherapy With Autologous Stem Cell Transfusion (ASCT) or Not Eligible for ASCT|FIL_PanAL10|Fondazione Italiana Linfomi ONLUS|Yes|Completed|February 2011|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01523834||91668|
NCT01524120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN-0009|Endoscopy and Endomicroscopy for Assessment of Mucosal Healing in Inflammatory Bowel Disease (IBD)|||University of Erlangen-Nürnberg Medical School|Yes|Not yet recruiting|April 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|96|Samples With DNA|Biopsies were taken from every patient for subsequent histological analysis.|Both|18 Years|85 Years|No|Probability Sample|Patients with Crohn´s disease and ulcerative colitis. Only patients with mucosal healing        are included.|January 2013|January 23, 2013|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01524120||91646|
NCT01524393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2010/267-31/4|Risk of Pulmonary and Venous Thromboembolism in Pregnancies After in Vitro Fertilization|Estimation of the Risk of Pulmonary Embolism and Venous Thromboembolism in Pregnancy After in Vitro Fertilization.||Danderyd Hospital|No|Completed|January 1990|December 2010|Actual|December 2008|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|140458|||Female|N/A|N/A|No|Non-Probability Sample|All mothers who had given birth to a child.|January 2012|February 1, 2012|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01524393||91625|
NCT01525225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-153|Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM|Evaluation of the Pharmacokinetics of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus Following Oral Administration of Saxagliptin and Metformin XR Fixed Dose Combination Tablet and Co-Administration of Saxagliptin and Glucophage® (Metformin) IR Tablets||AstraZeneca|No|Terminated|September 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|4|||Both|10 Years|17 Years|No|||May 2015|May 27, 2015|January 31, 2012|No|Yes|Release of Post Marketing Requirement for this study. Terminated November 2013.|No|August 11, 2014|https://clinicaltrials.gov/show/NCT01525225||91562|Due to the small number of participants (2), the primary endpoints, pharmacokinetic parameters, were not calculated.
NCT01525238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-091|PK Study of Dapagliflozin in Pediatric Subjects With T2DM|A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus||Bristol-Myers Squibb|No|Completed|July 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|24|||Both|10 Years|17 Years|No|||November 2014|February 6, 2015|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01525238||91561|
NCT01522183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-001|Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry|An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With aTypical Hemolytic-Uremic Syndrome (aHUS Registry)||Alexion Pharmaceuticals|No|Recruiting|April 2012|December 2025|Anticipated|December 2023|Anticipated|N/A|Observational|N/A||1|Anticipated|2000|||Both|N/A|N/A|No|Non-Probability Sample|Male or female patients of any age, including minors, who have been diagnosed with aHUS;        clinical diagnosis of aHUS, patients with or without an identified complement regulatory        factor genetic abnormality or anti-complement factor antibody, ADAMTS13 > 5% (if        performed)|April 2015|July 22, 2015|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522183||91795|
NCT01522443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-306|Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer|A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer|COMET-2|Exelixis|Yes|Terminated|March 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|119|||Male|18 Years|N/A|No|||February 2015|February 19, 2015|January 13, 2012|Yes|Yes|Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.|No||https://clinicaltrials.gov/show/NCT01522443||91775|
NCT01492530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL04-DREW-840|Men of African American Legacy Empowering Self|Reducing HIV Risk Behaviors and Psychosocial Stressors Among Bisexual African American Men|MAALES|Charles Drew University of Medicine and Science|Yes|Completed|August 2007|March 2012|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|437|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 10, 2014|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01492530||94061|
NCT01522196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-SCD1122|A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.|A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects.|IMPACTS-2|Anthera Pharmaceuticals|No|Terminated|February 2012|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|2|||Both|5 Years|N/A|No|||January 2014|January 30, 2014|January 18, 2012|Yes|Yes|change in company plans|No||https://clinicaltrials.gov/show/NCT01522196||91794|
NCT01522209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asklepios|Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging|Value of Contrast Enhanced Intraoperative Ultrasound Compared to Preoperative CEUS, CT and MRT in the Treatment of Colorectal Liver Metastases.|CEIOUS-Liver|Asklepios Kliniken Hamburg GmbH|Yes|Completed|December 2011|January 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|59|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01522209||91793|
NCT01493414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424A2401|INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis|An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF)|JUMP|Novartis||No longer available||||||Phase 4|Expanded Access|N/A|||||||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493414||93993|
NCT01493427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-10-298|Efficacy of Changing to TRAVATAN® From Prior Therapy|Multi-Center Study Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (0.004% Travoprost) in Patients Previously on Latanoprost 0.005% or Bimatoprost 0.01% Ophthalmic Solution Monotherapy||Alcon Research|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|December 14, 2011||No||No|February 17, 2014|https://clinicaltrials.gov/show/NCT01493427||93992|
NCT01493180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037E-11-002|Exploratory Study of OPC-12759 Ophthalmic Suspension|Exploratory Study of OPC-12759 Ophthalmic Suspension in Patients With Keratoconjunctiva Epithelial Disorder||Otsuka Pharmaceutical Co., Ltd.|No|Completed|December 2011|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|102|||Both|20 Years|N/A|No|||February 2015|February 19, 2015|December 13, 2011||No||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01493180||94011|
NCT01493154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11129|Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients|A Phase I Clinical Trial Assessing the Safety and Feasibility of Administration of pNGVL4a-CRT/E7(Detox) DNA Vaccine Using the Intramuscular TriGridTM Delivery System in Combination With Cyclophosphamide in HPV-16 Associated Head and Neck Cancer Patients||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|April 2012|||April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|75 Years|No|||September 2014|September 5, 2014|November 21, 2011|Yes|Yes|Study Funding Terminated|No||https://clinicaltrials.gov/show/NCT01493154||94013|
NCT01493167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/13/03/02/2011|Study on Wood-plastic Composite for Circumferential Casting|Study on Circumferential Casting Techniques With WOODCAST|WOODCAST|Onbone Oy|No|Completed|December 2011|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|N/A|90 Years|No|Non-Probability Sample|Healthy patients with fracture in extremity Age range of patients 0-90 years|December 2014|December 3, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493167||94012|
NCT01493752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/0715|Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function and Platelet Reactivity in Hypercholesterolemics.|Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function, Platelet Reactivity in Hypercholesterolemics Without Known Cardiovascular Disease or Atherosclerosis.||Queen Mary University of London|No|Completed|August 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|69|||Both|18 Years|80 Years|No|||April 2014|April 8, 2014|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493752||93967|
NCT01507077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-101|ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity|ZGN-440 (Beloranib for Subcutaneous Injection), A Novel Methionine Aminopeptidase 2 Inhibitor for Treatment of Obesity: A Randomized Double-Blind Placebo Controlled Dose Escalation Phase 1b Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Initial Weight Loss||Zafgen, Inc.|Yes|Completed|December 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 17, 2012|January 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507077||92947|
NCT01507376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-012|Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity|Comparing the Efficacy of Urinary and Recombinant hCG on Oocyte Maturity for Ovulation Induction in Assisted Reproductive Techniques: a Randomized Clinical Trial||Royan Institute|Yes|Completed|October 2010|June 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Female|20 Years|37 Years|Accepts Healthy Volunteers|||October 2010|April 24, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01507376||92925|
NCT01522339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2045|Pilot Study: Safety of a Customized MRI System for Neonatal Imaging|Pilot Study: Safety of a Customized MRI System for Neonatal Imaging|NICU MRI|Children's Hospital Medical Center, Cincinnati|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|N/A|N/A|No|||September 2014|September 23, 2014|November 22, 2011|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01522339||91783|
NCT01522586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWP09031|Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Phase 1 Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031||Daewoong Pharmaceutical Co. LTD.|Yes|Terminated|January 2012|December 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|74|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2012|February 12, 2014|January 27, 2012|No|Yes|change development strategy|No||https://clinicaltrials.gov/show/NCT01522586||91764|
NCT01522885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011375|KatGuide Method Versus Conventional Method at Insertion of Chest Tube|KatGuide-trial. KatGuide Method Versus Conventional Method at Insertion of Chest Tube. A Randomized, Parallel Group, Controlled Trial.|KatGuide|University of Aarhus|No|Completed|April 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||August 2014|August 19, 2014|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01522885||91741|
NCT01523327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ainshamsMH|Study of Association Between Maternal Uric Acid , Maternal and Fetal Outcome in Pregnant Women With Hypertension|Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension||Ain Shams Maternity Hospital|Yes|Recruiting|October 2011|October 2012|Anticipated|November 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|80|||Female|18 Years|40 Years|No|Probability Sample|The study will include 80 pregnant ladies with hypertension admitted to the maternity ward        of the hospital who will be divided into two groups according to their uric acid level.|January 2012|January 31, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01523327||91707|
NCT01523847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL - HD0803|A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)|A Phase II Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)|HD0803|Fondazione Italiana Linfomi ONLUS|No|Completed|November 2010|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01523847||91667|
NCT01523860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIL_FLE09|Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma|Brief Induction Chemoimmunotherapy With Rituximab + Bendamustine + Mitoxantrone Followed by Rituximab in Elderly Patients With Advanced Stage Previously Untreated Follicular Lymphoma|FLE09|Fondazione Italiana Linfomi ONLUS|No|Completed|June 2009|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|65 Years|80 Years|No|||February 2016|February 29, 2016|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01523860||91666|
NCT01524133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROGrESS|PROlonGed ExpoSure Sertraline|Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF).|PROGrESS|VA Ann Arbor Healthcare System|Yes|Recruiting|November 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|441|||Both|N/A|N/A|No|||December 2015|December 15, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01524133||91645|
NCT01524939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIG-SN_KD_P4|Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease|Multicenter, Single-arm, Phase IV Study to Evaluate the Efficacy, Safety of Combined Therapy of Aspirin and High Dose "IVIG-SN" in Pediatric Patients With Kawasaki Disease||Green Cross Corporation|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|6 Months|5 Years|No|||January 2012|September 19, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01524939||91583|
NCT01524952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1273|The Effect of Combined Thermal and Electrical Muscle Stimulation (cTEMS) on Obesity|The Effect of Combined Thermal and Electrical Muscle Stimulation (cTEMS) on Cardiorespiratory Fitness and Adipose Tissue in Obese Individuals||Haukeland University Hospital|No|Completed|December 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|30 Years|70 Years|No|||January 2012|January 31, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01524952||91582|
NCT01525524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1180/12|Treatment of Major Depressive Disorder Post Stroke With Transcranial Direct Current Stimulation|Treatment of Major Depressive Disorder Post Stroke With Transcranial Direct Current Stimulation (TDCS): Randomized, Double-Blind, Clinical Trial||University of Sao Paulo|No|Completed|January 2012|August 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|30 Years|90 Years|No|||September 2014|September 7, 2014|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01525524||91540|
NCT01525862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2091-001|XprESS Maxillary Balloon Dilation Study|XprESS Maxillary Sinus Balloon Dilation Study||Entellus Medical, Inc.|No|Completed|December 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525862||91514|
NCT01525875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1157|Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)|Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)||Icahn School of Medicine at Mount Sinai|Yes|Completed|August 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525875||91513|
NCT01492244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003024|Validation of an Online Knee Pain Map and Questionnaire: A Probabilistic Diagnostic Tool|Alidation of an Online Knee Pain Map and Questionnaire: A Probabilistic Diagnostic Tool||University of California, Los Angeles|Yes|Terminated|December 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients older than 18 years old with knee pain that contains a known diagnosis for their        pain.|March 2012|March 26, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01492244||94083|
NCT01492543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-014|Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer|An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer||Chinese Academy of Medical Sciences|No|Recruiting|December 2011|October 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|75 Years|No|||March 2013|March 14, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492543||94060|
NCT01492556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-BC-015|Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer|A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer||Chinese Academy of Medical Sciences|No|Recruiting|December 2011|June 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|80 Years|No|||March 2013|March 14, 2013|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01492556||94059|
NCT01492816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 105|Enhancement of Connect to Protect® (C2P)|Enhancement of Connect to Protect® (C2P) to Increase Structural Change and Reduce HIV Risk: Phase IV||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|August 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4185|||Both|12 Years|24 Years|No|||December 2014|February 12, 2015|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01492816||94039|
NCT01492829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCC#0016-01-04-01-01|A Community-health Worker Delivered HIV/STI Prevention Intervention for Internally Displaced Women in Leogane, Haiti|Development and Evaluation of a Community Health Worker Delivered HIV/STI Prevention Intervention for Women Living in Internally Displaced Persons Camps in Leogane, Haiti|FASY|Women's College Hospital|No|Completed|January 2012|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 15, 2013|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492829||94038|
NCT01493765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DC011321-01A1|Virtual Temporal Bone Surgery: Defining and Translating Metrics|Virtual Temporal Bone Surgery: Defining and Translating Metrics||Nationwide Children's Hospital|No|Recruiting|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Observational|Time Perspective: Prospective||1|Anticipated|170|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Novice otology surgeons|January 2016|January 26, 2016|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01493765||93966|
NCT01493466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111013-007(2)|Serum Proteomics Analysis for Sepsis|Serum Proteomics Analysis for Dynamic Changes of Differential Proteins in Sepsis Patient With iTRAQ Labeling and LC-MS/MS||Chinese PLA General Hospital|Yes|Recruiting|May 2010|March 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||5|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects were selected from among inpatients who were hospitalized between May 2010        and Mar 2012 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's        Liberation Army (CPLA) General Hospital.|December 2011|December 15, 2011|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01493466||93989|
NCT01493479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06_DOG05_33|Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma|Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin)|FIZZ|Christie Hospital NHS Foundation Trust|Yes|Active, not recruiting|June 2007|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|76|||Both|18 Years|N/A|No|||December 2011|December 15, 2011|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01493479||93988|
NCT01494246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/00817|Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption|Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption (TABATIC). A Randomized Controlled Multicentric Trial|TABATIC|Jordi Gol i Gurina Foundation|Yes|Active, not recruiting|December 2012|December 2014|Anticipated|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|1064|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 18, 2014|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01494246||93930|
NCT01507389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1328|Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function|A Single-centre, Open-label Trial Investigating the Pharmacokinetics and the Safety Profile After a Single Dose of Liraglutide in Subjects With Hepatic Impairment and in Subjects With Normal Hepatic Function||Novo Nordisk A/S|No|Completed|March 2006|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|January 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507389||92924|
NCT01507402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1033-HV-1107|A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)|||Regeneron Pharmaceuticals|Yes|Completed|January 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|76|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2012|November 12, 2012|January 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01507402||92923|
NCT01507961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0229-11-HMO|Comparison of Soft and Hard Tissue Thickness in the Anterior Regions of the Upper and Lower Jaws Taken From CBCT Versus Clinical Measurements|||Hadassah Medical Organization|No|Not yet recruiting|February 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|100 subjects who have done a CT|December 2011|January 10, 2012|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01507961||92880|
NCT01507662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AG033035-01A2|Patient Activation After DXA Result Notification|Patient Activation After DXA Result Notification|PAADRN|University of Iowa|Yes|Completed|February 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|7749|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 22, 2016|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01507662||92903|
NCT01507675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB 11-0948|Burden, Belonging, and Response to Pain in Veterans|Burden, Belonging, and Response to Pain in Veterans||VA Eastern Colorado Health Care System|Yes|Withdrawn|October 2011|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from all individuals eligible to receive care at the Denver        VA Medical Center (DVAMC), regardless of clinic.|March 2014|March 21, 2014|December 9, 2011||No|Study should not have been listed on ClinicalTrials|No||https://clinicaltrials.gov/show/NCT01507675||92902|
NCT01522352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0109|Comparison Between Three Types of Stented Pericardial Aortic Valves|Comparison of Short and Mid-term Hemodynamic Performance Between Three Types of Stented Pericardial Aortic Valves||University Hospital, Clermont-Ferrand||Recruiting|March 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Anticipated|165|||Both|18 Years|85 Years|No|||September 2013|September 2, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01522352||91782|
NCT01522365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF0909-1-272-1x-1|XiVE® CAD/CAM Bridges (Abutment-supported/ Implant-supported)|A Randomized, Prospective, International, Multi-center Clinical Study to Evaluate the Peri-implant Tissue Outcome of Abutment-supported XiVE® CAD/CAM Supra-structures and Directly Implant-supported XiVE® CAD/CAM Supra-structures (Split-mouth) in Partly Edentulous Human Subjects.|XiCC|Dentsply Implants Manufacturing GmbH|No|Active, not recruiting|November 2011|January 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01522365||91781|
NCT01522599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELP-CEI315|Flow-flow ECCO2-R and 4 ml/kg Tidal Volume vs. 6 ml/kg Tidal Volume to Enhance Protection From VILI in Acute Lung Injury|Flow-flow ECCO2-R and 4 ml/kg Tidal Volume vs. 6 ml/kg Tidal Volume to Enhance Protection From Ventilator Induced Lung Injury in Acute Lung Injury (ELP)|ELP|University of Turin, Italy|Yes|Terminated|April 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||June 2014|June 16, 2014|January 26, 2012||No|Financial hardship|No||https://clinicaltrials.gov/show/NCT01522599||91763|
NCT01523600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138,04|Whole Body Vibration Training Among Older People Using Sheltered Housing|Effect of Whole Body Vibration Training on Physical Functioning and Risk of Falling in Older People Using Sheltered Housing|VAREX|UKK Institute|No|Recruiting|October 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 12, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523600||91686|
NCT01523613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N013822|High-strength Glass-ionomer Dental Restorations|Clinical Performance of High-Viscous Glass-Ionomer Restorative Systems In Class II Lesions|ROCK|University of Michigan|No|Completed|November 2011|October 2014|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|63|||Both|7 Years|16 Years|No|||January 2015|January 30, 2015|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523613||91685|
NCT01524406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPP593-103|Safety Study of HPP593 in Subjects During and After Limb Immobilization|A Randomized, Double-blind, Placebo Controlled, Phase I Study to Evaluate the Safety and Tolerability of 28 Day Treatment With HPP593 Capsules in Healthy Volunteers During and After Limb Immobilization||High Point Pharmaceuticals, LLC.|No|Terminated|January 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 14, 2014|January 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524406||91624|
NCT01524419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0004-12-HYMC|Women's Involvement In Decision Making At Labor And Its Effect on Their Perceived Labor Process|Women's Involvement In Decision Making At Labor And Its Effect on Their Perceived Labor Process||Hillel Yaffe Medical Center|No|Not yet recruiting|March 2012|August 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|women after vaginal birth at term with no mechanical or surgical intervention and with no        maternal or fetal complications|January 2012|May 2, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01524419||91623|
NCT01524627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813779|Varenicline and Smoking Behavior|Characterizing a Cue-vulnerable Pharmaco-responsive Endophenotype in Smokers|VSMK|University of Pennsylvania|No|Completed|December 2011|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|60 Years|No|||December 2015|December 23, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524627||91607|
NCT01524640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-WC-09|Bridging Study for Killed Oral Cholera Vaccine in Ethiopia|A Randomized, Double-blind, Controlled Trial to Evaluate the Safety and Immunogenicity of Killed Bivalent (o1 and o139) Whole-cell Based Oral Cholera Vaccine (Shanchol®) in Healthy Individuals in Ethiopia||International Vaccine Institute|Yes|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|216|||Both|1 Year|N/A|Accepts Healthy Volunteers|||May 2015|May 1, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01524640||91606|
NCT01525264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIM-CHI|Breast Cancer Screening Intervention|Korean Immigrants & Mammography—Culture-Specific Health Intervention (KIM-CHI)||University of California, Los Angeles|No|Completed|August 2008|October 2010|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|1||Actual|434|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2012|February 1, 2012|December 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01525264||91559|
NCT01525511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTM1102|Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects|Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects||University of Oxford|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01525511||91541|
NCT01526135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prodige 24 / Accord 24|Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma|Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma||UNICANCER|Yes|Recruiting|January 2012|January 2020|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|490|||Both|18 Years|79 Years|No|||December 2015|December 17, 2015|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526135||91493|
NCT01492231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS#:2008-6258|The Clinical Impact and Outcomes of Interventional Endoscopy Procedures|The Clinical Impact and Outcomes of Interventional Endoscopy Procedures||University of California, Irvine|Yes|Enrolling by invitation|November 2008|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|3500|||Both|18 Years|N/A|No|Probability Sample|Patients with gastrointestinal disease(s) undergoing various interventional endoscopy        procedures performed at H. H. Chao Comprehensive Digestive Disease Center (CDDC).|December 2014|December 10, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01492231||94084|
NCT01492517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E10-025CS|Epigenetic Effects of Diesel Exhaust and Ozone Exposure|Epigenetic Effects of Diesel Exhaust and Ozone Exposure|Lamarck|Environmental Protection Agency (EPA)|No|Completed|May 2010|May 2015|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|January 15, 2016|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01492517||94062|
NCT01492257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSFSDMv1|Shared Decision Making in Patients With Osteoarthritis of the Hip and Knee|Shared Decision Making in Patients With Osteoarthritis of the Hip and Knee|SDM|University of California, San Francisco|No|Completed|July 2011|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|120|||Both|18 Years|N/A|No|||December 2012|December 12, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01492257||94082|
NCT01492569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSVAR0016|Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting|Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting||Stanford University|Yes|Withdrawn|May 2012|||July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|8 Years|21 Years|No|||June 2013|June 11, 2013|December 13, 2011|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01492569||94058|
NCT01492842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATN 114|Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV|Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection||Westat|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|272|||Both|12 Years|24 Years|No|Non-Probability Sample|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive,        who have enrolled in ATN 106.|March 2016|March 1, 2016|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01492842||94037|
NCT01493505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101129|TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers||Amgen||Active, not recruiting|January 2012|July 2020|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1015|||Female|18 Years|N/A|No|||January 2016|January 12, 2016|September 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01493505||93986|
NCT01493518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110105|Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis||Amgen||Terminated|November 2011|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|6|||Both|18 Years|55 Years|No|||November 2013|November 15, 2013|August 18, 2011|||Sponsor decision|No||https://clinicaltrials.gov/show/NCT01493518||93985|
NCT01494012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNOVA0021|Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer|A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer||Stanford University|Yes|Terminated|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Female|18 Years|N/A|No|||October 2013|October 8, 2013|December 13, 2011|No|Yes|low accrual|No||https://clinicaltrials.gov/show/NCT01494012||93947|
NCT01494025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200816512|Identification of Muscle-specific Biomarkers of Fatty Acid Beta-oxidation|Identification of Muscle-specific Biomarkers of Fatty Acid Beta-oxidation|FL-68|USDA, Western Human Nutrition Research Center|No|Completed|October 2009|July 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Female|30 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01494025||93946|
NCT01507974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0068-11-EMC|Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections|The Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections||HaEmek Medical Center, Israel|Yes|Not yet recruiting|January 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Female|16 Years|50 Years|No|||January 2012|January 8, 2012|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01507974||92879|
NCT01507441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B4|Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial|Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia||Children's Oncology Group|No|Active, not recruiting|February 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10|||Both|N/A|3 Years|No|Non-Probability Sample|Down syndrome children diagnosed with acute myeloid leukemia (AML) or myelodysplastic        syndromes (MDS).|May 2015|May 8, 2015|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01507441||92920|
NCT01508260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0475|Ultrafiltration (Aquapheresis) in Patients With Leukemia and Severe Fluid Overload|Ultrafiltration (Aquapheresis) in the Management of Patients With Leukemia and Severe Fluid Overload||M.D. Anderson Cancer Center|Yes|Withdrawn|March 2013|||March 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01508260||92858|
NCT01522898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAH-HREC-Protocol-#111234|Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)|Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation|CAAN-AF|University of Adelaide|Yes|Recruiting|March 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|590|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01522898||91740|
NCT01523106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|carnitine and crohn's disease|L-carnitine to Treat Fatigue Associated With Crohn's Disease|L-carnitine to Treat Fatigue Associated With Crohn's Disease||University of California, San Francisco|No|Withdrawn|August 2013|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||January 2014|January 16, 2014|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523106||91724|
NCT01524146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111012021|Photodynamic Therapy (PDT) Cholangiocarcinoma Registry|To Establish a Multicenter Registry to Evaluate the Impact of Photodynamic Therapy in the Management of Patients With Unresectable Cholangiocarcinoma.|PDTRegistry|Weill Medical College of Cornell University|No|Recruiting|November 2011|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects suffering from unresectable Cholangiocarcinoma who have a blocked bile duct or        biliary stent.|June 2015|June 1, 2015|January 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524146||91644|
NCT01523899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|030927|Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses|||George Washington University|No|Completed|May 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|272|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523899||91663|
NCT01524653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCC 1110|Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)|Impact of Rosuvastatin on Risk Markers of Venous Thromboembolism During Systemic Therapy for Advanced Cancer|DISOLVE|University of Vermont|Yes|Active, not recruiting|March 2012|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 27, 2015|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524653||91605|
NCT01524666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AgS-001|Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy|Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy||JFK Medical Center|No|Recruiting|February 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|Skin Biopsy|Both|18 Years|75 Years|No|Non-Probability Sample|Clinic patients at JFK Med CTR|December 2015|December 1, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01524666||91604|
NCT01524965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUS-272/13/03/02/2010|The Effect of the Timing of Postoperative Mobilisation After Locking Plate Osteosynthesis of Fractures of the Surgical Neck of the Humerus|The Effect of the Timing of Postoperative Mobilisation After Locking Plate Osteosynthesis of Fractures of the Surgical Neck of the Humerus.||Helsinki University|No|Recruiting|May 2011|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|January 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01524965||91581|
NCT01525251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907067R|Nurse Case Manager Model on Neuroblastoma Caregiver's Uncertainty|The Effect of Nurse Case Manager Model on Caregiver's Adaptation of Disease Uncertainty About Their Child With Neuroblastoma|NCMM|National Taiwan University Hospital|No|Recruiting|August 2009|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|N/A|N/A|No|Non-Probability Sample|Caregiver of Neuroblastoma Childern|January 2012|February 1, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525251||91560|
NCT01525537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-134-2|Surgical Pleth Index (SPI) Guided Analgesia During Sevoflurane Anesthesia|Comparison of Surgical Pleth Index Guided Analgesia With Standard Clinical Practise During Balanced Anesthesia||University of Schleswig-Holstein|No|Completed|March 2009|October 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|65 Years|No|||June 2012|June 14, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01525537||91539|
NCT01525849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1984-001|Randomized Evaluation of Maxillary Antrostomy Versus Ostial Dilation Efficacy Through Long-Term Follow-Up||REMODEL|Entellus Medical, Inc.||Completed|December 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525849||91515|
NCT01525550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6181202|A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors|A Single-arm Open-Label International Multi-Center Study Of The Efficacy And Safety Of Sunitinib Malate (SU011248, Sutent (Registered)) In Patients With Progressive Advanced Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors||Pfizer|No|Active, not recruiting|June 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525550||91538|
NCT01491932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAFQ056A2299|Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias||Novartis||Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|129|||Both|N/A|N/A|No|||March 2016|March 22, 2016|December 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01491932||94107|
NCT01491945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0004|Safety and Effectiveness Trial of the Ventana Fenestrated Stent Graft System|Prospective, Multicenter, Single Arm Safety and Effectiveness Trial of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms||Endologix|Yes|Active, not recruiting|March 2012|April 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|122|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01491945||94106|
NCT01523444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASBIRT-PA-11-311|Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings|Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings||Treatment Research Institute|Yes|Withdrawn|September 2013|November 2017|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|January 27, 2012||No|Study not funded.|No||https://clinicaltrials.gov/show/NCT01523444||91698|
NCT01523457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108008901|Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer|Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer|FOLFIRINOX|Yale University|Yes|Active, not recruiting|October 2011|December 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523457||91697|
NCT01523431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCRC-307PLAH-XJM|Individual Dosage Selection of Irinotecan(CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients|Influence of Individual Dosage Selection of Irinotecan(CPT-11)Based on UGT1A1 Genotype on Pharmacokinetics and Clinical Outcome in Chinese Patients With Metastatic Colorectal Cancer||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|No|Active, not recruiting|March 2012|September 2014|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|500|||Both|18 Years|N/A|No|||December 2013|December 26, 2013|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01523431||91699|
NCT01523977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-237|Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL|A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)|CRAD001NUS175T|Dana-Farber Cancer Institute|Yes|Recruiting|November 2011|August 2018|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Months|21 Years|No|||February 2016|February 12, 2016|January 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523977||91657|
NCT01523964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMD-001|DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls|A Phase I, Multi-Center, Controlled, Prospective Correlative Study of Electrical Impedance Myography in Males With Duchenne Muscular Dystrophy and In Healthy Males||Dart Therapeutics. LLC|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|92|||Male|3 Years|12 Years|Accepts Healthy Volunteers|||October 2013|October 16, 2013|January 30, 2012||No||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01523964||91658|
NCT01524198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-MED520-02|The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room|The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room||King Saud University|Yes|Completed|November 2010|April 2012|Actual|April 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|945|||Both|2 Years|12 Years|No|||February 2014|February 12, 2014|January 30, 2012||No||No|November 2, 2013|https://clinicaltrials.gov/show/NCT01524198||91640|
NCT01524484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2011-0421|Quality of Quality Data|Quality of Quality Data - A Retrospective Study on Routine Quality Data Reporting in Anesthesia|QoQ|Klinik Hirslanden, Zurich|No|Completed|November 2011|April 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|255|||Both|N/A|N/A|No|Probability Sample|1. Anesthesia records: a) Pilot study: 50 consecutive cases of the year 2010. b) Main             study: 200 cases of the year 2010, random sample (generated with a random number             generator). All cases are of one hospital, no further restrictions.          2. anesthesia staff interviews: Physicians and nurses entering quality data into             electronic anesthesia record|October 2014|October 21, 2014|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01524484||91618|
NCT01539486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112684|Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy|Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy||University of Arkansas|No|Active, not recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Non-Probability Sample|An estimated 200 patient charts will be reviewed.|January 2016|January 6, 2016|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539486||90476|
NCT01539499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112685|Complications of Endocrine Surgery: Data From the United HealthSystem Consortium|Complications of Endocrine Surgery: Data From the United Health System Consortium||University of Arkansas|No|Active, not recruiting|January 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|90 Years|No|Non-Probability Sample|The study will be conducted through a United HealthSystem Consortium query of endocrine        surgery done as a primary procedure for specific diagnosis.|January 2016|January 6, 2016|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539499||90475|
NCT01538927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC0212-FS|Effect of Fibrin Sealant on Early Wound Healing|Evaluation of Early Wound Healing Following Use of Fibrin Sealant (FS) in Periodontal Surgery. A Controlled Randomized Clinical Trial.|FS|Chhattisgarh Dental College and Research Institute|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|60 Years|No|||December 2012|December 22, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01538927||90519|
NCT01539187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL 03536|Fibroid Ablation Study - Large Fibroids|Symptom Effectiveness Study of VizAblate® Intrauterine Ultrasound-Guided RF Ablation (IUUSgRFA) in the Ablation of Large Uterine Fibroids|FAST-L|Gynesonics|No|Terminated|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|28 Years|N/A|No|||March 2015|March 13, 2015|February 21, 2012|No|Yes|Investigational device changes|No||https://clinicaltrials.gov/show/NCT01539187||90499|
NCT01536080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9612L00150|Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life|Comparison of Risk Factors, GERD Symptoms and PPI Responses in the Reflux Esophagitis, Non-erosive Reflux Disease and Functional Heartburn Using GERD Impact Scale Questionnaire||Seoul National University Bundang Hospital|No|Completed|July 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|207|||Both|16 Years|85 Years|No|Non-Probability Sample|Even the patients complain GERD symptoms such as heartburn and acid regurgitation the        final diagnosis could be reflux esophagitis (RE), non-erosive reflux disease (NERD) and        even functional heartburn (FH).|February 2012|February 15, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01536080||90738|
NCT01516372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114112|A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers|A Randomized, Double-blind, Single Dose Crossover Study to Assess the Effect of Gabapentin Enacarbil on Cardiac Conduction as Compared With Placebo and Moxifloxacin in Healthy Volunteers||XenoPort, Inc.|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|52|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|July 15, 2013|January 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01516372||92241|
NCT01516645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHK2898-001|Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors|Phase 1, Open-Label, Dose Escalation Study of Anti-CD98 Monoclonal Antibody KHK2898 as Monotherapy in Subjects With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy Is Available||Kyowa Hakko Kirin Company, Limited|No|Not yet recruiting|December 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01516645||92220|
NCT01522261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUA 007-2011|The Surgical Benefit and Pt.Tolerability Between Two Different Bowel Cleansing Regimens Performed Prior to Pelvic Reconstructive Surgery. Does One Bowel Cleansing Regimen Improve the Surgeons Visual Field Significantly Better Than the Other.|The Use of Mechanical Bowel Preparation in Pelvic Reconstructive Surgery (MBP)|MBP|Boston Urogynecology Associates|No|Recruiting|January 2012|January 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Anticipated|176|||Female|18 Years|90 Years|No|||April 2015|April 17, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01522261||91789|
NCT01522781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS2010001|10 Year Outcome of Total Knee Replacement (TKR) Using Sigma Prosthesis|10 Year Outcome of Total Knee Replacement (TKR) Using Sigma Prosthesis||NHS Fife|No|Completed|October 1998|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|234|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing total knee replacement in Fife|January 2012|January 27, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01522781||91749|
NCT01522794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXH94C101|Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model|Randomized Double Blind Placebo Controlled PK/PD Study on the Effects of a Single Intravenous Dose of NOX-H94 on Serum Iron During Experimental Human Endotoxemia||NOXXON Pharma AG|Yes|Completed|January 2012|April 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 7, 2014|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522794||91748|
NCT01522807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3301007|A Study Of Three PF-05190457 Formulations In Healthy Volunteers|A Phase I, Cross-Over, Single Dose, Double-Blind Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-05190457 In Healthy Adult Volunteers||Pfizer|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 27, 2012|October 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01522807||91747|
NCT01515020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100110|Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia|A Randomized, Multicenter Trial of Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated Methicillin-resistant Staphylococcus Aureus Bacteremia|DAVASAB|Assistance Publique - Hôpitaux de Paris|No|Terminated|May 2012|July 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 25, 2014|January 18, 2012||No|lack of inclusion|No||https://clinicaltrials.gov/show/NCT01515020||92345|
NCT01515267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA100|Automated Left Ventricular Function Evaluation by LVivoEF|Automated Left Ventricular Function Evaluation by LVivoEF|LVivoEF|Diacardio LTD|Yes|Active, not recruiting|November 2011|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients referred to an echocardiographic examination|January 2012|January 23, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515267||92326|
NCT01515280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11112011|Hull Airway Reflux Questionnaire Scores Following Cough Treatment|Supplementary Study of Hull Airway Reflux Questionnaire Scores Before and After Treatment Study: A Multicentre, Double-Blind, Placebo-Controlled, Pivotal Study of the Efficacy and Safety of Oral Theobromine in the Management of Cough."||Hull and East Yorkshire Hospitals NHS Trust|No|Completed|January 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|57|||Both|18 Years|75 Years|No|Probability Sample|patients attending chronic cough clinics|December 2013|December 11, 2013|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515280||92325|
NCT01515293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUV-APP-MDFB|Single Incision Versus Conventional Laparoscopic Appendectomy|Prospective Randomised Study Comparing Single Incision Transumbilical Versus Conventional Laparoscopic Appendectomy||Hospital Universitario Virgen de la Arrixaca|No|Completed|September 2009|||December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|184|||Both|12 Years|N/A||||May 2011|January 23, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515293||92324|
NCT01523730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMSlab#126/2011|Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia|Effects of Repetitive Transcranial Magnetic Stimulation on Cigarette Smoking and Cognitive Function in Smokers With and Without Schizophrenia|rTMSsmokelab|Centre for Addiction and Mental Health|No|Completed|April 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 8, 2015|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01523730||91676|
NCT01523990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-2349-01|A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients|A Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of Single and Multiple Ascending Oral Doses of TG-2349, and Followed by a Dose-Ranging Study in Hepatitis C Genotype 1 Infected Patients||TaiGen Biotechnology Co., Ltd.|No|Completed|October 2011|July 2013|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|27||Actual|135|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|October 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523990||91656|
NCT01523717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|brahms-moses|Procalcitonin Monitoring Sepsis Study|Procalcitonin Decrease Over 72 Hours and Outcome in Patients With Severe Sepsis or Septic Shock|MOSES|Brahms AG||Completed|December 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|858|Samples Without DNA|EDTA plasma and serum samples|Both|18 Years|N/A|No|Probability Sample|adult patients with severe sepsis or septic shock in the emergency department, medical        floor, ICU|March 2015|March 13, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01523717||91677|
NCT01524003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICAPS|Chinese Cancer Prevention Study(CHICAPS)|Chinese Cancer Prevention Study(CHICAPS) Mass Population Based Cervical Cancer Screening|CHICAPS|Preventive Oncology International, Inc.|No|Completed|November 2011|January 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|8382|||Female|35 Years|59 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01524003||91655|
NCT01524510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_1101|Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients|Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients||University Hospital, Antwerp|No|Recruiting|February 2011|||April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01524510||91616|
NCT01524211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE G110081|Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms|Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms||Lee, W. Anthony, M.D. FACS|No|Recruiting|January 2012|January 2021|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|January 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524211||91639|
NCT01524224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11207|A Dose-Escalation Study in Participants With Advanced Cancer|A Phase 1 Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, in Patients With Advanced Cancer||Eli Lilly and Company|No|Completed|January 2008|January 2016|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|January 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524224||91638|
NCT01524770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14142|A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe|Comparative Pharmacokinetics of Dulaglutide After Administration Via an Auto-injector and a Manual Syringe in Healthy Subjects||Eli Lilly and Company|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 21, 2014|January 31, 2012|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01524770||91596|
NCT01524497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Trazodone_1|A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression|A Clinical Study on Efficacy And Safety of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression A Multicenter, Randomized, Double-Blind, Parallel Controlled Study||Lee's Pharmaceutical Limited|Yes|Completed|November 2011|November 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|382|||Both|18 Years|65 Years|No|||October 2014|October 14, 2014|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01524497||91617|
NCT01524757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL3364409612|Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis|Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis|He-ppi|Maastricht University Medical Center|No|Not yet recruiting|March 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|60 Years|No|||January 2012|February 1, 2012|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524757||91597|
NCT01539824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM-101-007|A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer|A Phase II, Single Arm, Investigative Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Patients With Previously Treated Colorectal Cancer||Immodulon Therapeutics Ltd|Yes|Completed|February 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||January 2014|September 23, 2014|February 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539824||90450|
NCT01539837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICL-11/SC/0101|A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease|A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease|DeferipronPD|Imperial College London|Yes|Recruiting|February 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|50 Years|75 Years|No|||October 2012|October 16, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539837||90449|
NCT01539213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2225|Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg|An Exploratory Study to Investigate the Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid Using Open Flow Microperfusion After a Single Subcutaneous Administration of 300 mg in Healthy Subjects and Psoriatic Patients|OFM ISF|Novartis|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 4, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01539213||90497|
NCT01539226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 027|Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women||International Partnership for Microbicides, Inc.|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|1950|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|February 16, 2016|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539226||90496|
NCT01525576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD_B|Booster as an Adjunct to Internet-based Cognitive Behavior Therapy (CBT)|Efficacy of an Internet-based Booster Program for Obsessive-compulsive Disorder: A Randomized Controlled Trial||Karolinska Institutet|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525576||91536|
NCT01525589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM1183-B-003-11|A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer|A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer||PharmaMar|No|Recruiting|December 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|117|||Female|18 Years|75 Years|No|||September 2015|September 17, 2015|January 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525589||91535|
NCT01522534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|chra-2009-001|Randomized Double Blind Controlled Trial Comparing a Blind Sciatic Nerve Block in the Popliteal Fossa to Intravenous Morphine for Traumatic Severe Acute Pain in the Prehospital Setting||BPOP|Centre Hospitalier de la Région d'Annecy|Yes|Recruiting|January 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||January 2012|January 30, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01522534||91768|
NCT01522547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-SCD-001|Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease|A Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Effect on Induction of Fetal Hemoglobin of CC-4047 In Subjects With Sickle Cell Disease|SCD-001|Celgene|No|Completed|August 2007|December 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|12|||Both|18 Years|60 Years|No|||December 2013|December 24, 2013|January 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522547||91767|
NCT01514747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISMRM_OU|A MRI Study of Visual and Motor Pathways in Premature Infants|||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|October 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|2 Months|5 Months|No|Non-Probability Sample|ELBW infants with birth weight 401-1000 g (gestational age <30 weeks)|January 2015|January 13, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01514747||92366|
NCT01514760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133343|A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans|A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans||Arkansas Children's Hospital Research Institute|Yes|Completed|June 2012|October 2013|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 18, 2012|No|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01514760||92365|There are no limitations/caveats to report.
NCT01515033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117/11|Aerobic Exercise on PETCO2 Response in Coronary Artery Disease Patients|Effect of Continuous and Interval Exercise Training on PETCO2 Response During Graded Exercise Test in Patients With Coronary Artery Disease||Hospital TotalCor|Yes|Completed|September 2010|August 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|40 Years|79 Years|No|||January 2012|January 20, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515033||92344|
NCT01515878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2019|Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS|Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS|HERACLES|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|February 2012|March 2015|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|396|||Both|65 Years|N/A|No|||July 2012|July 4, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01515878||92279|
NCT01516151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-API-NKPL66-CT-PIIB|Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia|A Randomized Open-label Dose-ranging, Multi-center Trial to Assess the Safety and Efficacy of NKPL66(CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia||Acasti Pharma Inc.|No|Completed|December 2011|September 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|289|||Both|18 Years|75 Years|No|||January 2014|January 7, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516151||92258|
NCT01523470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|withdrawalNIV|Withdrawal of Non-invasive Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Acute Hypercapnic Respiratory Failure|A Pilot Randomised Controlled Trial of Withdrawal of Non-invasive Ventilation in COPD Patients With Acute Hypercapnic Respiratory Failure||United Christian Hospital|Yes|Completed|November 2010|October 2011|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2012|January 31, 2012|January 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01523470||91696|
NCT01523483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3-0124|Vaginal Progesterone for Prevention of Preterm Birth After an Episode of Preterm Labor|Vaginal Progesterone for Prevention of Preterm Birth After an Episode of Preterm Labor||University Medical Centre Ljubljana|No|Completed|March 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|48 Years|No|||April 2015|April 21, 2015|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01523483||91695|
NCT01523743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP220|Quality of Life Intermittent Catheter Study|Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters||Coloplast A/S|No|Completed|November 2011|May 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|125|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|January 9, 2012||No||No|August 6, 2013|https://clinicaltrials.gov/show/NCT01523743||91675|
NCT01523756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP226|A Clinical Investigation of New Ostomy Appliances|An Open-labelled Randomized Cross-over and Controlled Exploratory Investigation Comparing Several Variants of a Newly Developed Ostomy Appliance With Regard to Performance in 20 Patients With Ileostomy||Coloplast A/S|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|January 10, 2012||No||No|November 21, 2013|https://clinicaltrials.gov/show/NCT01523756||91674|
NCT01524237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13882|A Study of LY2979165 and LY2140023 in Healthy Volunteers|Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects||Eli Lilly and Company|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|7||Anticipated|52|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 31, 2013|January 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01524237||91637|
NCT01524250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 18804|Optic Neuritis Recovery After Oral or IV Corticosteroids|Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial||London Health Sciences Centre|No|Completed|March 2012|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|64 Years|No|||September 2015|September 1, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01524250||91636|
NCT01524263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR MC-US|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2009|||||N/A|N/A|N/A||||||||||||||January 30, 2012|January 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524263||91635|
NCT01524783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001T2302|Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)|A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin|RADIANT-4|Novartis|Yes|Active, not recruiting|March 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524783||91595|
NCT01525082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NET0012|Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors|A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors||Stanford University|Yes|Recruiting|December 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2015|February 19, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525082||91573|
NCT01538680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15967|Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy|An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy|CONSIGN|Bayer||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2015|December 8, 2015|February 21, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01538680||90538|
NCT01538329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 253 01|Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease|Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)|PREMANDYSK|University Hospital, Toulouse|No|Recruiting|March 2012|June 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|202|||Both|35 Years|N/A|No|||January 2016|January 11, 2016|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538329||90565|
NCT01538342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-API-03|Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis|Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis||Centre Hospitalier Universitaire de Nice|No|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|October 30, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01538342||90564|
NCT01535573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2P50DA009262-16A1|Citalopram for Cocaine Dependence|Clinical Trial of Serotonin Medication Combination in Cocaine Dependence||The University of Texas Health Science Center, Houston|Yes|Recruiting|December 2010|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|125|||Both|18 Years|60 Years|No|||January 2016|January 4, 2016|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01535573||90777|
NCT01539239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-11-001|Safety & Effectiveness Study of the Hydrus Device for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery|The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial||Ivantis, Inc.|Yes|Recruiting|January 2012|January 2018|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1200|||Both|45 Years|N/A|No|||March 2015|March 13, 2015|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539239||90495|
NCT01526187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 11012 (AOR 11101)|Travel in the Tropics and Acquisition of Multidrug-resistant Bacteria (VOYAG-R)|Acquisition of Multidrug-resistant Bacteria After Travel in the Tropics : Prevalence, Determinants and Length of Carriage|VOYAG-R|Assistance Publique - Hôpitaux de Paris|Yes|Completed|February 2012|September 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|750|Samples Without DNA|Stool|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult volunteers in the vaccination center prior to a travel in the tropics.|March 2013|October 13, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526187||91489|
NCT01522274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA155381|Quit Smoking With Nicotine Patch and Exercise/Health Education (Females Only)|Efficacy of Brisk Walking as a Smoking Cessation Treatment Adjunct Among Women|QFH|Brown University|No|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|164|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01522274||91788|
NCT01522287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R43MH090612|Computer Assisted Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Comprehensive Stepped-Care Approach|Computer Assisted CBT for OCD: A Comprehensive Stepped-Care Approach||Center for Psychological Consultation|Yes|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 13, 2014|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01522287||91787|
NCT01514422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0432|Minocycline for Bipolar Depression|Minocycline for Bipolar Disorder||Icahn School of Medicine at Mount Sinai|No|Completed|May 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|68 Years|No|||August 2015|August 4, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514422||92390|
NCT01515046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204737|Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer|Pharmacological Ascorbate for the Control of Metastatic and Node-Positive Pancreatic Cancer (PACMAN): A Phase II Trial|PACMAN-II|University of Iowa|Yes|Terminated|September 2012|July 2016|Anticipated|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|January 18, 2012|Yes|Yes|Standard of care changed to FOLFIRINOX; poor accrual.|No||https://clinicaltrials.gov/show/NCT01515046||92343|
NCT01515306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14432|A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors|A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors||Eli Lilly and Company|No|Active, not recruiting|July 2012|June 2016|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|January 18, 2012|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01515306||92323|
NCT01515579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1693|Comparison of Two Liraglutide Formulations in Healthy Subjects|A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 2 Formulation of Liraglutide at pH 7.7 (Formulation 3) and the Phase 3 Formulation at pH 8.15 (Formulation 4)||Novo Nordisk A/S|No|Completed|April 2006|June 2006|Actual|June 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|No|||January 2015|January 29, 2015|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01515579||92302|
NCT01515865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD426-405|Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension|A Phase 4, Randomized-withdrawal, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension||Shire|Yes|Completed|May 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||October 2014|November 10, 2014|January 18, 2012|Yes|Yes||No|October 16, 2014|https://clinicaltrials.gov/show/NCT01515865||92280|
NCT01516502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-0569B|The Efficacy of Low-level Laser on Cervical Myofascial Pain Syndrome|Is Low-level Laser on Traditional Acupoint as Effective as That on Trigger Point in the Management of Cervical Myofascial Pain Syndrome?||Chang Gung Memorial Hospital|No|Completed|February 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|100|||Both|20 Years|65 Years|No|||January 2012|January 24, 2012|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01516502||92231|
NCT01516515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESRTAKB|Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis|A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)||G&E Herbal Biotechnology Co., LTD|No|Recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01516515||92230|
NCT01515826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-013|VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery|Evaluation of the Safety and Efficacy of VIGADEXA Ophthalmic Gel Compared to VIGADEXA Ophthalmic Solution in Preventing Inflammation and Infection Following Cataract Surgery||Alcon Research|No|Withdrawn|March 2014|October 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|January 19, 2012||No|Management decision|No||https://clinicaltrials.gov/show/NCT01515826||92283|
NCT01524016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM001|68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia|68Ga-DOTATATE PET/CT for Detection and Evaluation of the Causative Tumor of Oncogenic Osteomalacia||Peking Union Medical College Hospital|Yes|Recruiting|December 2011|February 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|70 Years|No|||July 2014|January 13, 2015|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01524016||91654|
NCT01516424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4906011|Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone|A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone||Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|Yes|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|267|||Both|18 Years|64 Years|No|||December 2013|December 2, 2013|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01516424||92237|
NCT01516437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116021|A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD|A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD) Aged Between 45-75 Years||GlaxoSmithKline||Completed|February 2012|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|73|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||February 2013|January 15, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516437||92236|
NCT01524523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120001|Bone Marrow Aspiration Pain Study|Biochemical and Genetic Mechanisms of Acute Clinical Pain During Bone Marrow Aspiration||National Institutes of Health Clinical Center (CC)||Withdrawn|December 2011|June 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|August 20, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01524523||91615|
NCT01524796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0081292|NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark|NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions In Denmark|NEP-TUNE|Pfizer|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|128|||Both|18 Years|N/A|No|Probability Sample|When a subject, independently of the study and before consideration for observation in the        study has been prescribed pregabalin for treatment of peripheral NeP, the subject can        (before first dose of pregabalin is taken) be included in the observational program.|March 2015|March 25, 2015|December 12, 2011||No||No|March 11, 2015|https://clinicaltrials.gov/show/NCT01524796||91594|
NCT01539564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OP-P-5267|Arestin - Use in Subjects With Peri-Implantitis|Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects With Peri-Implantitis||OraPharma|No|Completed|April 2012|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|21 Years|N/A|No|||June 2014|June 25, 2014|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539564||90470|
NCT01539577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-025|A Long-Term Safety Study of OZURDEX® in Clinical Practice|||Allergan|No|Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|875|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with macular oedema due to CRVO or BRVO or non-infectious uveitis|March 2016|March 18, 2016|February 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539577||90469|
NCT01538940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIRD-6181|Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand|Randomized Controlled Trial to Compare the Immunogenicity of Intramuscular Versus Intradermal Trivalent Inactivated Split Virion Influenza Vaccine in HIV-infected Men Who Have Sex With Men in Bangkok, Thailand||Centers for Disease Control and Prevention|No|Recruiting|November 2011|||July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|6||Anticipated|480|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 10, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01538940||90518|
NCT01539551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111015RIB|Investigation of the Role of Brain Natriuretic Peptide and Lactate in Early Goal-directed Therapy for Patients With Severe Sepsis and Septic Shock|Investigation of the Role of Brain Natriuretic Peptide and Lactate in Early Goal-directed Therapy for Patients With Severe Sepsis and Septic Shock||National Taiwan University Hospital|No|Recruiting|February 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|blood(serum/plasma)|Both|18 Years|N/A|No|Probability Sample|Severe sepsis with or without septic shock|March 2012|November 12, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539551||90471|
NCT01526213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09-0788|Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?|Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?||University of North Carolina, Chapel Hill|No|Completed|September 2009|April 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 29, 2012|January 31, 2012|Yes|Yes||No|March 3, 2012|https://clinicaltrials.gov/show/NCT01526213||91487|
NCT01514175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KACW1|A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac|A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac||Culpeper Surgery Center|No|Enrolling by invitation|January 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|1||Actual|50|||Female|18 Years|65 Years|No|||May 2012|May 15, 2012|June 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514175||92409|
NCT01514773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00050147|Patient and Physician Survey Determinants of Appropriate ICD Utilization|Patient and Physician Knowledge and Attitudes Toward Defibrillator Therapy Survey Study||University of Michigan|No|Active, not recruiting|August 2011|December 2016|Anticipated|August 2013|Actual|N/A|Observational|Observational Model: Case Control||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|University of Michigan Health System Ambulatory Heart Failure Registry|March 2016|March 17, 2016|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514773||92364|
NCT01515592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1694|Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers|A Randomised, Double-blind Within Dose Group, Single Centre, Placebo-controlled, Dose Escalation, Multiple s.c. Dose Study to Assess the Safety and Tolerability of Liraglutide 20 ug/kg and 25 ug/kg in Healthy Japanese Male Subjects||Novo Nordisk A/S|No|Completed|January 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Male|20 Years|45 Years|No|||December 2014|December 10, 2014|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515592||92301|
NCT01515891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-103|Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites|An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration||Bial - Portela C S.A.|No|Completed|May 2009|September 2010|Actual|June 2009|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|40 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 30, 2014|January 19, 2012||No||No|December 30, 2014|https://clinicaltrials.gov/show/NCT01515891||92278|
NCT01516177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ITN524ST/CTOT-12|Associating Renal Transplantation With the ITN Signature of Tolerance|An Observational Study to Assess the Prevalence of a Tolerance Signature in Renal Transplant Recipients (ITN524ST/CTOT-12)|ARTIST|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|September 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|Samples With DNA|Whole blood Isolation PBMC isolated RNA specimens|Both|18 Years|65 Years|No|Non-Probability Sample|The study will include 250 participants who are determined to be eligible for further        follow-up based on the eligibility criteria.        Among those eligible for further follow-up          -  at least 25 participants will be renal transplant recipients who received induction             therapy with Campath, and          -  at least 25 participants will be renal transplant recipients who are receiving             sirolimus or everolimus at time of enrollment and who have not received calcineurin             inhibitors for at least 30 days prior to enrollment|May 2014|May 29, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516177||92256|
NCT01516190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-182|The Preoperative Health & Body Study|The Preoperative Health & Body Study|PreHab|Dana-Farber Cancer Institute|Yes|Recruiting|August 2011|||October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Female|18 Years|N/A|No|||April 2014|April 28, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516190||92255|
NCT01516203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0006|Phase 2a EBA Trial of AZD5847|Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|December 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|75|||Both|18 Years|65 Years|No|||April 2014|April 16, 2014|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516203||92254|
NCT01515540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00022968|Brain Imaging of Lidoderm for Chronic Back Pain|Brain Imaging of Lidoderm for Chronic Back Pain||Northwestern University|No|Completed|January 2004|June 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 23, 2013|January 18, 2012|Yes|Yes||No|October 16, 2012|https://clinicaltrials.gov/show/NCT01515540||92305|
NCT01515553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1692|Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers|A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 3a Formulation of Liraglutide (Formulation 4) and the Planned Phase 3b Formulation (Final Formulation 4)||Novo Nordisk A/S|No|Completed|January 2007|April 2007|Actual|April 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|No|||January 2015|January 12, 2015|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01515553||92304|
NCT01515839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCAN 001|Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players|Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study||Amen Clinics, Inc.|Yes|Completed|May 2009|June 2010|Actual|June 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|January 23, 2012|October 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01515839||92282|
NCT01515852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JohannWGUH_GALAXY|General Anesthesia vs. Local Anesthesia in Stereotaxy|General Anesthesia vs. Local Anesthesia in Stereotaxy|GALAXY|Johann Wolfgang Goethe University Hospitals|No|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2013|February 20, 2013|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01515852||92281|
NCT01516125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT|Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing|Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing||Wake Forest Baptist Health|Yes|Recruiting|September 2011|July 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|800|Samples With DNA|A small saliva sample for screening purposes will be collected. If documentation from a      personal physician of blood glucose and lipid levels are unavailable, we will collect a      small tube (10-12 ml) of blood to determine these measurements.|Both|21 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Caucasian or African American adults between 21 and 65 years of age|December 2015|December 17, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01516125||92260|
NCT01516450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116119|Japanese phase1 Study of Belimumab (IV vs SC)|An Open Label, Randomized, Parallel, Single Dose Study to Investigate Safety and Pharmacokinetics Following Intravenous Administration and Subcutaneous Administration of GSK1550188 in Healthy Japanese Males||GlaxoSmithKline|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 5, 2012|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01516450||92235|
NCT01516463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|017-101-09-031|Using Santyl or Bacitracin on Second Degree Burns|Comparison of Collagenase Santyl® Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns||Healthpoint|No|Withdrawn|March 2012|December 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|75 Years|No|||May 2012|May 15, 2012|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516463||92234|
NCT01516697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001449|Non-invasive Cardiac Output Monitoring in Obstetric Patients|Using Thoracic Electrical Bioimpedance to Measure Stroke Volume and Cardiac Output in Patients Under Spinal Anesthesia for Cesarean Section||Massachusetts General Hospital|No|Recruiting|October 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|40|||Female|18 Years|45 Years|No|||August 2012|August 2, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01516697||92216|
NCT01516931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Huaning Wang|Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Depression|A Study to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of the Symptoms of Depression.||Xijing Hospital|Yes|Recruiting|December 2011|February 2015|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|540|||Both|18 Years|60 Years|No|||July 2014|July 17, 2014|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01516931||92198|
NCT01539005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAP005|Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy|Is Tuberculosis Recurrence in Treated Tuberculosis-Human Immunodeficiency Virus (HIV) Co-Infected Patients Relapse or Re-infection?|TRuTH|Centre for the AIDS Programme of Research in South Africa|Yes|Active, not recruiting|November 2009|June 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|402|Samples With DNA|Stored Plasma/Serum/PBMCs: Participants who consent to have additional samples stored for      future testing will have serum, plasma and PBMCs stored . Possible uses of plasma include      assessment of host genetics profiles, including HLA profile, additional viral load      assays.Possible uses of serum include additional safety serology and evaluation of suspected      IRIS on participants where indicated. The PBMCs will be used to test for IRIS/PR when      suspected.      Other potential tests that may be performed on the stored specimens include new generation      assays of immunity.      Stored Sputum Isolates :RFLP testing will be performed from stored bacterial isolates on all      positive cultures in which recurrence is suspected and compared to the initial positive      culture used to diagnose the TB initially.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Men and women > 18 years of age with documented HIV infection and past TB therapy as part        of the SAPIT and START trial will be enrolled.|February 2015|February 3, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01539005||90513|
NCT01539018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESLC1 (SADAT study)|Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE|A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE||Egyptian Society of Liver Cancer|Yes|Terminated|January 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|February 21, 2012||No|After interim results data showed no evidence of a difference between both groups|No||https://clinicaltrials.gov/show/NCT01539018||90512|
NCT01538654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMF2011|Enteroprotein Modified Fast ( EMF )|Enteroprotein Modified Fast ( EMF ) : Clinical Safety and Efficacy. A Six Months Pilot RCT|EMF|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|No|Recruiting|March 2011|May 2012|Anticipated|April 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||February 2012|February 23, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538654||90540|
NCT01538667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11523|Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases|Non-blinded, Single Dose, Single Centre Trial to Assess the Pulmonary Deposition as Well as Pharmacokinetics, Safety and Tolerability of 99mTc Labeled Ciprofloxacin When Delivered as a Single Dose From a Dry Powder Inhaler to Healthy Subjects With and Without Charcoal Block and Patients Suffering From Bronchiectasis and COPD||Bayer|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|February 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538667||90539|
NCT01538953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC3794|Pakistan Flocculent Health Outcome Study|Pakistan Flocculent Health Outcome Study||Centers for Disease Control and Prevention|No|Completed|March 2003|January 2004|Actual|December 2003|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|8949|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 24, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01538953||90517|
NCT01538966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMCIRB 26424|Acromegaly Combination Treatment Study|Comparison of Combination Low-Dose SRL + Daily Pegvisomant Therapy and High-Dose SRL + Weekly Pegvisomant Therapy||Cedars-Sinai Medical Center|Yes|Recruiting|January 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|51|||Both|18 Years|85 Years|No|||February 2015|February 2, 2015|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538966||90516|
NCT01526200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIOUSCLM|Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases|Factors Influencing the Impact of Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases|CEIOUSCLM|University of Milan|No|Completed|October 2007|December 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|127|||Both|29 Years|85 Years|No|Non-Probability Sample|Consecutively enrolled patients with CLM who underwent surgery and during this procedure        received IOUS and CE-IOUS.|January 2012|February 2, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01526200||91488|
NCT01513902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921103|Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)|An Open-label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Cp-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (Jia)||Pfizer|No|Completed|March 2013|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|26|||Both|2 Years|17 Years|No|||February 2016|February 26, 2016|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01513902||92430|
NCT01513915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Parent CBT for Anxiety|A Parent-only Group Cognitive Behavioral Intervention for Children With Anxiety Disorders: a Control Group Study|A Parent-only Group Cognitive Behavioral Intervention for Children With Anxiety Disorders: a Control Waiting List Group Study||Tehran University of Medical Sciences|Yes|Completed|July 2008|July 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|6 Years|18 Years|No|||January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513915||92429|
NCT01514435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRECT-2006-PET|Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)|Clinical Effects of Electroconvulsive Therapy in Severe Depression and Concomitant Changes in Cerebral Glucose Metabolism - an Exploratory Study||Medical University of Graz|No|Completed|May 2006|July 2011|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|85 Years|No|||January 2012|January 17, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01514435||92389|
NCT01515319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QLON/2011/Y242-01|Safety and Pharmacokinetic Study of Y242 in Adult Subjects|A Randomised, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Y242 in Adult Subjects|Y242-01|Imperial College London|Yes|Completed|April 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|68|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01515319||92322|
NCT01515605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MoMoTxRes|Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation|Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation|MoMoTxRes|Odense University Hospital|No|Recruiting|January 2011|December 2023|Anticipated|December 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood, urine, tissue|Both|18 Years|N/A|No|Probability Sample|Kidney transplantation|January 2016|January 12, 2016|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515605||92300|
NCT01515618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1121|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2012|||||N/A|N/A|N/A||||||||||||||August 30, 2012|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515618||92299|
NCT01515904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000025502|Evaluation of the SickKids Team Obesity Management Program|Evaluation of the SickKids Team Obesity Management Program (STOMP)|STOMP|The Hospital for Sick Children|No|Recruiting|April 2011|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|110|||Both|12 Years|18 Years|No|Non-Probability Sample|STOMP Group: 12-17 years of age. Patients in the program have severe complex obesity which        is defined as as children and youth who have a BMI >95th percentile for their age and        gender in addition to any one of the following: at least one significant obesity-related        co-morbidity requiring specialty care (e.g. type 2 diabetes, hypertension), other        co-existing chronic illness impacted by obesity (e.g. CNS tumor, post-organ transplant),        or a BMI ≥99th percentile for their age and gender        Control: Approximately 50% of attendees choose not to book into the program, for reasons        including difficulty attending the frequent appointments due to distance or inability to        leave work early. This population will serve as the control group for the evaluation. In        addition, control participants will be recruited from the community through posters posted        in the hospital.|May 2015|May 20, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515904||92277|
NCT01516775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH Nr. 2011-0034|Gastric pH in Intubated Children|Untersuchung Des Magen-pH in Intubationsanästhesie Bei Kindern||University Children's Hospital, Zurich|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|150|||Both|1 Year|16 Years|No|||September 2012|September 28, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01516775||92210|
NCT01516788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814860|Photoprovocation Testing in Subjects With Cutaneous Lupus|Photoprovocation Testing in Subjects With Cutaneous Lupus||University of Pennsylvania|No|Recruiting|December 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01516788||92209|
NCT01515566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1007|Breakthrough Dyspnea Fentanyl Study in Cancer Patients|Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized Controlled Trial||M.D. Anderson Cancer Center|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|January 13, 2012|Yes|Yes||No|August 7, 2014|https://clinicaltrials.gov/show/NCT01515566||92303|The small sample size means findings are susceptible to random errors and regression to the mean.
NCT01516489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01334|Improving Fecal Occult Blood Test Completion Rates Among Veterans|Improving Fecal Occult Blood Test Completion Rates Among Veterans||Philadelphia Veterans Affairs Medical Center|No|Completed|February 2012|June 2015|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|8||Actual|1549|||Male|N/A|N/A|No|||October 2015|October 23, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516489||92232|
NCT01516138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJcuiqin_2012|Benefits of GIK in Cardiac Surgery Patients|Myocardial Protection of Glucose - Insulin - Potassium in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass||Xijing Hospital|Yes|Active, not recruiting|February 2012|February 2022|Anticipated|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|930|||Both|18 Years|70 Years|No|||July 2014|October 30, 2014|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01516138||92259|
NCT01517152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912040|Testing a Spanish Version of a Patient Toxicity Questionnaire|Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)||National Institutes of Health Clinical Center (CC)||Completed|January 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|18 Years|100 Years|No|||September 2015|October 6, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01517152||92181|
NCT01516710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1285/REK sør-øst B|Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study|Prospective Randomized Study of Laparoscopic Versus Open Liver Resection for Colorectal Metastases|Oslo-CoMet|Oslo University Hospital|No|Recruiting|January 2012|December 2025|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||April 2015|June 18, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01516710||92215|
NCT01516944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTTG030103|Perioperative Chemotherapy for Potentially Resectable Gastric Cancer|Perioperative Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin in Patients With Localized Advanced Gastric Cancer||Hebei Medical University|No|Recruiting|February 2012|December 2018|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|729|||Both|18 Years|75 Years|No|||March 2015|March 5, 2015|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01516944||92197|
NCT01517139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912038|Diet and Nutrition Pilot Study for Chinese Adolescents and Their Mothers|Pilot Study to Test the Methods for the Diet, Nutrition and Physical Activity Feasibility Study of Early Life Determinants of Adult Cancers in a Chinese Cohort of Adolescents and Their Mothers||National Institutes of Health Clinical Center (CC)||Completed|December 2011|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|360|||Both|15 Years|45 Years|No|||July 2015|August 8, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01517139||92182|
NCT01539031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2020-J081-343|Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease|Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease||Eisai Inc.||Completed|March 2012|March 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|351|||Both|50 Years|N/A|No|||September 2015|September 16, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539031||90511|
NCT01539304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITUS_P3|Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis: Double Blinded, Randomized, Placebo Controlled, Parallel Designed, Multi-centered, Phase III Study||SamA Pharmaceutical Co., Ltd||Completed|September 2010|September 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|245|||Both|24 Months|15 Years|No|||February 2012|February 26, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01539304||90490|
NCT01538979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-BM32-003|Phase II Study of Grass Pollen Allergy Vaccine BM32|Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy||Biomay AG|Yes|Completed|March 2012|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|181|||Both|18 Years|60 Years|No|||December 2015|December 17, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01538979||90515|
NCT01539252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDphos1|Examining the Impact of Using Two Dialysers in Parallel on Dialysis Adequacy in Hemodialysis Patients|Examining the Impact of Using Two Dialysers in Parallel on Dialysis Adequacy in Hemodialysis Patients||University of Alberta|No|Completed|January 2013|December 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01539252||90494|
NCT01525966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11174|Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer|Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer||City of Hope Medical Center|Yes|Recruiting|February 2012|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Female|19 Years|N/A|No|||January 2016|January 7, 2016|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525966||91506|
NCT01525979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0832B|Comparative Efficacy Research of Uni- vs Bi-lateral Arm Training Poststroke|Comparative Efficacy Research of Uni- vs Bi-lateral Arm Training Poststroke: Task-Related or Robotic||Chang Gung Memorial Hospital|No|Completed|January 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|42|||Both|40 Years|75 Years|No|||June 2015|June 4, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525979||91505|
NCT01514188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-206-P2-STS-01|Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma|A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma||CytRx|Yes|Active, not recruiting|December 2011|April 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|105|||Both|15 Years|80 Years|No|||September 2013|September 12, 2013|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514188||92408|
NCT01514201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00082|Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas|A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)||National Cancer Institute (NCI)|No|Active, not recruiting|November 2011|||August 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|N/A|21 Years|No|||February 2016|March 15, 2016|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514201||92407|
NCT01515059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/EM/0463|Analysing Differences in Glycaemic Control Immediately Post Obesity SurgEry (The ADIPOSE Study)|A Prospective Pilot Study Investigating the Effects of Bariatric Surgery on Measures of Glycaemic Control and Incretin Levels|ADIPOSE|University of Leicester|No|Terminated|September 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|75 Years|No|Non-Probability Sample|20 successive obese patients who are awaiting either a gastric bypass or sleeve        gastrectomy|December 2015|December 14, 2015|January 18, 2012||No|Slow recruitment and sufficient data available to analyse|No||https://clinicaltrials.gov/show/NCT01515059||92342|
NCT01515345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDEAL-PCI protocol 1.0|Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry|Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry|IDEAL-PCI|Kaiser Franz Josef Hospital|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1008|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|January 18, 2012||No||No|February 3, 2013|https://clinicaltrials.gov/show/NCT01515345||92320|
NCT01516216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-436|Study of Vitamin D in Untreated Metastatic Colorectal Cancer|Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|March 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 10, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516216||92253|
NCT01516255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1644|Effect of Liraglutide on Heart Frequency in Healthy Volunteers|A Thorough QTc Evaluation of the Effect of Liraglutide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Two Period Crossover Study Followed by Open-label Moxifloxacin (Positive Control) Administration||Novo Nordisk A/S|No|Completed|July 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|January 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01516255||92250|
NCT01516268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|886|The Effect of Adding Sufentanyl to Bupivacaine in Transversus Abdominis Plane Block to Reduce the Narcotic Dosage and Pain After Cesarean Delivery|the Effect of Adding Sufentanyl to Bupivacaine in Transversus Abdominis Plane (TAP) Block Under the Guide of Ultrasound to Reduce the Narcotic Dosage, Side Effects and Pain in the First 24 Hours After Cesarean Delivery|TAP|Tehran University of Medical Sciences|Yes|Completed|January 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2013|February 19, 2013|January 19, 2012||No||No|February 19, 2013|https://clinicaltrials.gov/show/NCT01516268||92249|
NCT01516801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0603|A Pragmatic Trial of the Effect of a Mailed Patient Flyer About Prostate Specific Antigen (PSA) Testing Prior to an Annual Exam|A Pragmatic Randomized Trial of the Effect of a Mailed Patient Flyer About PSA Testing Prior to an Annual Exam||University of Colorado, Denver|No|Completed|October 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|303|||Male|50 Years|74 Years|No|||January 2012|January 24, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01516801||92208|
NCT01517009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DoCCS|A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer|A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer|DoCCS|Jeroen Bosch Ziekenhuis|Yes|Completed|June 2008|May 2013|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517009||92192|
NCT01516164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011AN04|A Comparison of the Ease of Tracheal Intubation Using a McGrath MAC Laryngoscope and a Standard MacIntosh Laryngoscope|A Comparison of the Ease of Tracheal Intubation Using a McGrath MAC Laryngoscope and a Standard MacIntosh Laryngoscope||NHS Tayside|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|158|||Both|16 Years|N/A|No|||October 2014|October 3, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516164||92257|
NCT01516476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27804|Study of RO6807952 in Patients With Diabetes Mellitus Type 2|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of RO6807952 in Type 2 Diabetic Patients Inadequately Controlled With Metformin Alone||Hoffmann-La Roche||Terminated|November 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|2|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516476||92233|
NCT01516957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101227|AMG 827 in Subjects With Psoriatic Arthritis|A Randomized, Double-blinded, Placebo-controlled, Multiple-dose Study With an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects With Psoriatic Arthritis.||Amgen|No|Terminated|October 2011|September 2015|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|168|||Both|18 Years|75 Years|No|||February 2016|February 19, 2016|August 18, 2011|Yes|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01516957||92196|
NCT01517165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912469|Pioglitazone to Treat Opioid Withdrawal Symptoms|Pioglitazone as an Aid During Buprenorphine Taper||National Institutes of Health Clinical Center (CC)||Terminated|January 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517165||92180|
NCT01517178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP215OC|Multi-national, Safety and Performance Study of New Ostomy Product Compared to Standard Care|An Open-labelled, Randomised, Controlled, Comparative, Multi-national, Cross-over Study Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared to 2-piece Standard Care Ostomy Products||Coloplast A/S|No|Terminated|May 2011|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|June 24, 2011||No||No|March 3, 2015|https://clinicaltrials.gov/show/NCT01517178||92179|Early termination leading to small number of subjects analyzed.
NCT01517412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12261|Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin|A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin||Sanofi|Yes|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|451|||Both|18 Years|N/A|No|||May 2014|May 6, 2014|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517412||92161|
NCT01513343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA 2011-68001-30009|Promoting The Self-Regulation Of Energy Intake|Promoting The Self-Regulation Of Energy Intake In African American And Latino Preschoolers: A Family Focused Obesity Prevention Program|SEEDs|Baylor College of Medicine|No|Recruiting|August 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|330|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513343||92471|
NCT01539629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELEVATE 3.0|ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0|Evaluation of Left Ventricular Autothreshold|ELEVATE 3|Boston Scientific Corporation|No|Completed|March 2012|November 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be a sample of patients with COGNIS CRT-D devices.|October 2012|December 4, 2012|February 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01539629||90465|
NCT01535391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML0811|Nilotinib in PH+, BCR-, ABL+ CML Patients|The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+, BCR-, ABL+ Chronic Myeloid Leukemia (CML) in Early Chronic Phase: a Phase IIIb, Multicenter Study to Assess the Complete Molecular Response|CML0811|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Active, not recruiting|January 2012|November 2017|Anticipated|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|109|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01535391||90791|
NCT01535651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAH Denver Health|Using Social Media to Enhance the Impact of the Teen Outreach Program|Using Social Media to Enhance the Impact of the Teen Outreach Program|TOP4ME|Colorado School of Public Health|No|Recruiting|September 2011|May 2016|Anticipated|May 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1200|||Both|14 Years|18 Years|Accepts Healthy Volunteers|||May 2014|May 20, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01535651||90771|
NCT01535664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-MS-1008|An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)|An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS||Acorda Therapeutics|No|Completed|January 2012|June 2012|Actual|May 2012|Actual|Phase 2|Observational|Observational Model: Cohort||1|Actual|20|||Both|18 Years|70 Years|No|Non-Probability Sample|MS Population|August 2013|August 8, 2013|February 7, 2012|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01535664||90770|
NCT01539590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001-10|Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack|A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)||Angion Biomedica Corp|Yes|Terminated|July 2012|November 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|21 Years|80 Years|No|||November 2014|November 7, 2014|February 22, 2012|Yes|Yes||No|October 29, 2014|https://clinicaltrials.gov/show/NCT01539590||90468|Five subjects were enrolled into the study; 3 subjects were randomized to BB3 and 2 subjects to placebo. All the 3 subjects randomized to BB3 discontinued the study prematurely. The 2 subjects randomized to placebo completed study treatment.
NCT01513616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-986-06|The Impact of Pulmonary Rehabilitation on Dyspnea in Chronic Obstructive Pulmonary Disease|Mechanisms of Dyspnea Relief Following Exercise Training in COPD||Queen's University|No|Completed|November 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|40 Years|80 Years|No|||December 2012|December 14, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01513616||92450|
NCT01513629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101122|Structural Connectivity as Imaging Endophenotypes of Autism Spectrum Disorders|||National Taiwan University Hospital|Yes|Recruiting|October 2010|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|80|||Male|10 Years|15 Years|Accepts Healthy Volunteers|Probability Sample|High-functioning autism group,family group, and neurotypical group|January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513629||92449|
NCT01514786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00044733|Decision Aid to Technologically Enhance Shared Decision Making|Decision Aid to Technologically Enhance Shared Decision Making|DATES|University of Michigan|Yes|Completed|May 2012|April 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|630|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514786||92363|
NCT01515072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120110125|Remote Ischemic Preconditioning in Neurological Death Organ Donors|Remote Ischemic Preconditioning in Neurological Death Organ Donors|RIPNOD|Rutgers, The State University of New Jersey|No|Completed|July 2011|August 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|324|||Both|6 Years|N/A|No|||August 2014|August 18, 2014|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01515072||92341|
NCT01515332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|131306|Energy Expenditure Methodology|Energy Expenditure Methodology||Arkansas Children's Hospital Research Institute|No|Completed|March 2011|October 2014|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults from the surrounding community|September 2015|September 8, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01515332||92321|
NCT01516229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1941|Special Survey for Long Term Application|Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application||Novo Nordisk A/S|No|Completed|May 1997|March 2007|Actual|March 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|395|||Both|1 Year|15 Years|No|Probability Sample|Patients being treated with somatropin for achondroplasia without epiphyseal line closure|January 2012|June 26, 2012|January 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01516229||92252|
NCT01516242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MS236-1926|Evaluation of Safety and Parameters of Application Technique|Monitoring of Expected Parameters of the Application Technique and Safety of the Therapy||Novo Nordisk A/S|No|Completed|October 2006|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4819|||Both|N/A|N/A|No|Probability Sample|Patients with type 1 diabetes or type 2 diabetes mellitus treated with insulin having        changed administration of inulin from syringe to a Novo Nordisk insulin delivery system|January 2012|January 24, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516242||92251|
NCT01516567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inter B-NHL Ritux 2010 Phase 2|Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation|Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL||Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|December 2011|December 2021|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|6 Months|17 Years|No|||February 2016|February 9, 2016|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516567||92226|
NCT01516580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inter B-NHL Ritux 2010 Phase 3|Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients|Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial||Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|December 2011|December 2021|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|6 Months|17 Years|No|||February 2016|February 9, 2016|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516580||92225|
NCT01516528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115058|Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care|Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care|ACCESS|GlaxoSmithKline|No|Completed|November 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3500|||Both|40 Years|N/A|No|Probability Sample|Primary care outpatients who have a an established clinical history of COPD for a minimum        of 12 months.|July 2015|August 13, 2015|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01516528||92229|
NCT01516541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC25608|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease|A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD).||Hoffmann-La Roche||Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2220|||Both|45 Years|N/A|No|||March 2016|March 1, 2016|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516541||92228|
NCT01517022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKS/Med/NI1161|Intensive Smoking-cessation Versus Basic Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis|Impact of a Package of Intensive Smoking-cessation Interventions Versus Recommended, Basic Smoking-cessation Advice on Outcomes in Smear-positive Patients With Pulmonary Tuberculosis; a Randomised Controlled Trial||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|November 2010|March 2016|Anticipated|August 2015|Anticipated|Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|65 Years|No|Probability Sample|Study participants will be selected from group of sputum smear positive category-I or        Category-II patients who self report to smoke more than 10 cigarette/bidis per day.|June 2015|June 23, 2015|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01517022||92191|
NCT01516749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-08101|Anakinra as a Treatment for Hydradenitis Suppurativa|An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa||University of California, San Francisco|No|Completed|October 2012|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||August 2014|August 15, 2014|December 7, 2011|Yes|Yes||No|July 11, 2014|https://clinicaltrials.gov/show/NCT01516749||92212|Limitations of the study include early termination leading to small numbers of subjects analyzed, and lack of control group.
NCT01516762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15995|Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases|Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases||Bayer||No longer available||||||N/A|Expanded Access|N/A|||||||Male|18 Years|N/A||||July 2014|July 11, 2014|January 20, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01516762||92211|
NCT01516723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2011-02|Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions|Hybrid Sirolimus-eluting Stent With Bioresorbable Polymer Versus Everolimus-eluting Stent With Durable Polymer for Total Coronary Occlusions in Native Coronary Arteries (PRISON-IV)|PRISON-IV|R&D Cardiologie|Yes|Recruiting|February 2012|May 2020|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01516723||92214|
NCT01516736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LA-EP06-302|Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim|Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®|PROTECT2|Sandoz|Yes|Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|308|||Female|18 Years|N/A|No|||September 2015|September 7, 2015|January 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516736||92213|
NCT01516970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018349|Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)|HIV Postexposure Prophylaxis With Darunavir/r (PEPDar)|PEPDar|Janssen-Cilag G.m.b.H|No|Completed|November 2011|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|October 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516970||92195|
NCT01517451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11157|Radiation and Androgen Ablation for Prostate Cancer|Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|May 2013|August 2020|Anticipated|August 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|105|||Male|18 Years|100 Years|No|||January 2016|January 28, 2016|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517451||92158|
NCT01517425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-5676|Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells|Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells|iPSC|Scripps Translational Science Institute|No|Enrolling by invitation|November 2012|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects previously enrolled in the Scripps Genebank or Healthy Elderly Active Longevity        (HEAL) Cohort|October 2015|October 14, 2015|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517425||92160|
NCT01517438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ramosetron|Effects of Serotonin Inhibitors on Patient-controlled Analgesia Related Nausea and Vomiting|||Seoul National University Hospital||Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|21|||Both|2 Years|15 Years|No|||January 2012|January 20, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01517438||92159|
NCT01513356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120XES01T|Pharmacodynamic Study of BKM120 in Breast Cancer|Evaluation of PI3K/AKT/mTOR Signaling Pathway Using BKM120 in Early Breast Cancer||Grupo Hospital de Madrid|No|Completed|October 2012|February 2014|Actual|February 2014|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Female|18 Years|N/A|No|||April 2014|April 1, 2014|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01513356||92470|
NCT01513369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEVER-2011|Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency|Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency|CLEVER|GWT-TUD GmbH|No|Recruiting|August 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01513369||92469|
NCT01539642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP310|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery||AcelRx Pharmaceuticals, Inc.|No|Completed|February 2012|February 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|172|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|February 22, 2012|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT01539642||90464|
NCT01535443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRON0611V1FI|Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.|STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PRO-155 OPHTHALMIC SOLUTION 0.09% IN HEALTHY VOLUNTEERS.|PRO-155|Laboratorios Sophia S.A de C.V.|Yes|Active, not recruiting|September 2011|||February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 24, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535443||90787|
NCT01539278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-12-FB-0266|Effect of Adenotonsillectomy on Quality of Life in Children With Mild Obstructive Sleep Apnea|Effect of Adenotonsillectomy on Quality of Life in Children With Mild Obstructive Sleep Apnea||Eastern Virginia Medical School|No|Completed|February 2011|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|113|||Both|3 Years|16 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01539278||90492|
NCT01539291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0117|Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116|A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539291||90491|
NCT01535417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSB_P3|Efficacy and Safety of Shinbaro Capsule|A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee||Green Cross Corporation|No|Completed|May 2009|December 2009|Actual|December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|198|||Both|35 Years|80 Years|No|||February 2012|February 14, 2012|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01535417||90789|
NCT01535703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007|Comparison of Cardiac Output Measurement Between Transpulmonary Thermodilution and Photoplethysmography|Comparison of Cardiac Output Measurement Between Invasive Method (Transpulmonary Thermodilution) and Non Invasive Method (Photoplethysmography) : an Observational Study|PANEX|University Hospital, Caen|No|Completed|November 2011|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Post cardiac surgery intensive care patients with arterial pressure monitoring and        transpulmonary thermodilution monitoring with indication of fluid challenge.|April 2013|April 3, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01535703||90767|
NCT01513928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1621005|A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects|A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04937319 In Overweight And Obese Otherwise Healthy Subjects||Pfizer|Yes|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01513928||92428|
NCT01514448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001LDE43|Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib|An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib||Novartis|No|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|62|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514448||92388|
NCT01514799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_HG_Aleris_limb_length|Effects of Long Biliopancreatic Limb vs. Long Alimentary Limb in Superobesity, a Randomized Study|Randomized Study Comparing the Effects of Gastric Bypass Using a Long BP-limb vs. a Long Alimentary Limb in Morbid Obesity||Aleris Obesity|No|Recruiting|June 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|55 Years|No|||March 2015|March 16, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01514799||92362|
NCT01514812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-007|A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects|A Double Blind, Randomized, Two Period Crossover Study To Determine The Effect of Multiple Doses of 120 MG Modified Release Formulation of YM150 on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects||Astellas Pharma Inc|No|Completed|February 2006|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 23, 2012|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01514812||92361|
NCT01515917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_53174|Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)|Citicoline and Omega-3 Fatty Acid Effects in Veterans With TBI||University of Utah|Yes|Withdrawn|November 2013|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||January 2015|January 15, 2015|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515917||92276|
NCT01515930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3M's Diabetes Study|Computerized Intervention of Parental Involvement in Diabetes Care of Their Child|Computer-Delivered Motivational Intervention to Improve Teen Diabetes Management||Wayne State University|Yes|Recruiting|April 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|10 Years|13 Years|No|||January 2012|January 23, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515930||92275|
NCT01517256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFM 09-595|A Pilot Study Evaluating a Multidisciplinary Chronic Pain Group Therapy in a Primary Care Setting|Living Everyday Above-and-beyond Pain Research (LEAP): A Pilot Study Evaluating a Multidisciplinary Chronic Pain Group Therapy in a Primary Care Setting|LEAP|McMaster University||Completed|November 2009|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01517256||92173|
NCT01517269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13643|PETS-D (Parent Education Thru Simulation-Diabetes)|PETS-D (Parent Education Thru Simulation-Diabetes)||University of Massachusetts, Worcester|Yes|Completed|April 2010|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|191|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01517269||92172|
NCT01516554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38486|Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients|A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients||Health Sciences Centre, Winnipeg, Manitoba|No|Terminated|February 2012|July 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Male|18 Years|65 Years|No|||July 2014|July 4, 2014|January 19, 2012||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01516554||92227|
NCT01513447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00057039|Intracutaneous Sterile Water Injections|Intracutaneous Sterile Water Injection as an Adjunct to Neuraxial Labor Analgesia: A Randomized Controlled Trial||Northwestern University|No|Terminated|December 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 23, 2015|January 16, 2012||No|low qualified candidate enrollment|No|January 30, 2015|https://clinicaltrials.gov/show/NCT01513447||92463|Early termination leading to small numbers of subjects analyzed; Subjects recruitment unsuccessful because of low number of subjects that were eligible for study inclusion.
NCT01513460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237AAU01|Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease|A Multicenter, Randomized, Blinded, Active-controlled, Parallel-group Study to Compare the Efficacy, Tolerability and Safety of NVA237 Compared to Tiotropium Added on to Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease||Novartis||Completed|April 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|773|||Both|40 Years|N/A|No|||December 2014|December 23, 2014|January 16, 2012||No||No|December 10, 2014|https://clinicaltrials.gov/show/NCT01513460||92462|
NCT01516996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BT-IST-SCCHN-036|Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer|Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx||The Second People's Hospital of Sichuan|Yes|Recruiting|March 2012|March 2018|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||March 2012|March 18, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01516996||92193|
NCT01516983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV04|Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation|A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.||Betta Pharmaceuticals Co.,Ltd.|Yes|Completed|December 2011|December 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|No|||February 2014|February 13, 2014|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01516983||92194|
NCT01517191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOS-VE01|Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults|Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults|SOS-VE01|Dalhousie University|No|Recruiting|November 2011|August 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|2400|Samples Without DNA|Serum and Nasopharyngeal swabs|Both|16 Years|N/A|No|Probability Sample|This observational study is open to adults admitted to hospital with test postitive        influenza or with an influenza like illness who test negative.|January 2012|January 20, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01517191||92178|
NCT01517204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-990305|The Efficacy of Trachway (R) Intubating Stylet in the Insertion of the Double Lumen Endobronchial Tube|The Comparison of Direct Laryngoscope and Trachway (R) Intubating Stylet in the Insertion of the Double Lumen Endobronchial Tube||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|May 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2011|September 16, 2012|November 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01517204||92177|
NCT01513395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000425/2 BIDMC|Focal Myometrial Contractions: Impact on Cervical Assessment and Association With Voiding|Focal Myometrial Contractions: Impact on Cervical Assessment and Association With Voiding. A Randomized Trial||Beth Israel Deaconess Medical Center|No|Recruiting|January 2012|November 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|112|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513395||92467|
NCT01513382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAVUGC-2|Effectiveness of Methylene Blue Guidance in Total Excision of Pilonidal Sinus.|Does Intraoperative Methylene Blue Guidance in Pilonidal Sinus Surgery Really Effective in Total Excision of the Nest ?|BAVUGC-2|Bezmialem Vakif University|Yes|Not yet recruiting|January 2012|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2012|January 19, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513382||92468|
NCT01513694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSM/Fusión/2009|Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease|Clinical Trial Phase I / II Prospective, Open, Non-randomized for Treatment of Lumbar Intervertebral Degenerative Disc Disease With Posterolateral Instrumented and Autologous Mesenchymal Stem Cells.||Red de Terapia Celular|Yes|Active, not recruiting|January 2010|||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||October 2012|October 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513694||92444|
NCT01513980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G. A. 250487-Veneto WP8Cl5|Life-long Monitoring of COPD in Veneto Region|RENEWING HEALTH - Large Scale Pilot in Veneto Region: Life-long Monitoring in COPD||Regione Veneto|Yes|Completed|November 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|750|||Both|18 Years|N/A|No|||January 2012|October 27, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513980||92424|
NCT01535456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO10417|FLT-PET Imaging for MDS|A Pilot Study for Using 18F-FLT PET Imaging To Assess Response In Patients With Myelodysplastic Syndrome (MDS) Being Treated With 5-azacitidine||University of Wisconsin, Madison|Yes|Terminated|July 2012|March 2014|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|February 14, 2012|No|Yes|funding|No||https://clinicaltrials.gov/show/NCT01535456||90786|
NCT01539603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1104/061-001|Comparison of Drug Eluting Balloon and Drug Eluting Stent|Comparison of Drug-Eluting Balloon First and Then Bare Metal Stent With Drug-eluting Stent for Treatment of de Novo Lesions (DEB First): A Randomized Controlled Single Center Clinical Trial|DEBfirst|Seoul National University Bundang Hospital|Yes|Completed|April 2011|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|90 Years|No|||June 2015|June 11, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539603||90467|
NCT01539616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZYH7.10.001.01|A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia|A Multicentric Prospective Randomized Double Blind Parallel Group Active Controlled Study to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia||Cadila Healthcare Limited|Yes|Completed|November 2011|August 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|109|||Both|18 Years|65 Years|No|||October 2013|October 25, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539616||90466|
NCT01535716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01210-41|Effects of a Goal-directed Hemodynamic Therapy Driven by ECOM on Morbidity and Mortality After Cardiac Surgery?|Does Goal-directed Hemodynamic Therapy Driven by Endotracheal Cardiac Output Monitoring System During Surgical Intervention Reduce Hospital Stay and Major Adverse Cardiac Events Following Cardiac Surgery?|ECOMIII|University Hospital, Caen|Yes|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01535716||90766|
NCT01536002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2007.366|Pharmacokinetics of Propofol in Morbidly Obese Patients|Pharmacokinetics (PK) of Propofol in Bariatric (Morbidly Obese) Patients||Oslo University Hospital|No|Recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01536002||90744|
NCT01514461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908B2302|A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome|A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome||Novartis||Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|December 21, 2011|Yes|Yes||No|May 15, 2015|https://clinicaltrials.gov/show/NCT01514461||92387|
NCT01514487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1636|Comparison of Three Liraglutide Formulations in Healthy Volunteers|A Randomised, Double-blind, Single-centre, Three-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Each of the Two New Liraglutide Formulations at pH 7.9 and 8.15 and the Planned Phase 3 Formulation at pH 7.7||Novo Nordisk A/S|No|Completed|January 2005|March 2005|Actual|March 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|50 Years|No|||January 2012|January 20, 2012|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01514487||92386|
NCT01515631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9031|Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review|Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record||Stanford University|No|Recruiting|April 2007|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|25|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Alagille Syndrome. The age range will be from birth through adulthood. There        will be no gender or ethnic limitations to study.|November 2014|November 20, 2014|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515631||92298|
NCT01515644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT.01.2010|Study on the Effect of Inulin in Infant Formula on Gut Health|A Randomized, Double-blind, Controlled Study on the Effect of Inulin on Gut Health of Infants|STAR-IFFO|PT. Sari Husada|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|164|||Both|3 Months|4 Months|Accepts Healthy Volunteers|||April 2013|April 22, 2013|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01515644||92297|
NCT01516281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-DAT-008|Imaging Biomarkers of Delayed Sequelae in Trauma Brain Injury|Imaging Biomarkers of Delayed Sequelae in Mild to Moderate Traumatic Brain Injury||NorthShore University HealthSystem Research Institute|No|Completed|March 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|67|Samples With DNA|Collect blood and extract and store plasma and DNA from 100 mTBI and 100 mTBI- subjects      undergoing clinical assessments and DaTscan studies.|Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|A historical cohort of 7,122 mTBI cases and 7,122 age and gender matched mTBI- controls        was defined from the electronic medical records of NorthShore University HealthSystem.        From survey respondents we are randomly selecting 100 mTBI cases and 100 age and gender        matched mTBI- controls to undergo neurological examinations and DaTscan studies.|January 2016|January 22, 2016|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516281||92248|
NCT01516840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14568|Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients|Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism||Bayer|Yes|Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|60|||Both|20 Years|N/A|No|||January 2014|January 9, 2014|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01516840||92205|
NCT01516814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15960|Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients|Randomized, Open-label, Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism, With or Without Symptomatic Deep Vein Thrombosis||Bayer|Yes|Completed|February 2012|November 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|20 Years|N/A|No|||November 2014|November 27, 2014|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01516814||92207|
NCT01517529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC 11101915|Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations|Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy||University of Cincinnati|No|Completed|January 2012|December 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|Samples With DNA|Blood lymphocytes from enrolled subjects will be retained until all investigations will be      performed and publications are generated. After that remaining samples will be discarded      properly according to the Biosafety instructions.|Both|18 Years|65 Years|No|Non-Probability Sample|Investigators plan to enroll 20 human subjects with chronic hepatitis C virus infection        from the outpatient clinic at the University of Cincinnati College of Medicine.|October 2015|October 20, 2015|January 20, 2012||No||No|August 25, 2015|https://clinicaltrials.gov/show/NCT01517529||92152|
NCT01517542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0014|Evaluation of Effectiveness of Nutritional Counseling in Patients After Stroke|Evaluation on the Effectiveness of Nutritional Counseling on an Adapted DASH Diet in Patients After Stroke: a Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|February 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|128|||Both|18 Years|N/A|No|||August 2014|August 12, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01517542||92151|
NCT01517230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-9-56|Can Mass Media Campaigns Reduce Child Mortality|Can Mass Media Campaigns Reduce Child Mortality||London School of Hygiene and Tropical Medicine|No|Completed|March 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|100000|||Both|N/A|5 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01517230||92175|
NCT01517477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCF-033|One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects|A Prospective, Randomized, Controlled Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted With One, Two, or Three Trabecular Micro-Bypass Stents||Glaukos Corporation|No|Active, not recruiting|January 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|251|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01517477||92156|
NCT01517217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110201KI|Effect of Postoperative Girdle Following Abdominal Surgery on Pulmonary Function, Mobilisation and Postoperative Pain|Randomised Trial Evaluating the Effect of Postoperative Girdle Following Major Abdominal Surgery||Karolinska Institutet|No|Recruiting|April 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2012|January 20, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01517217||92176|
NCT01517464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGT94-01|A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors|A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors|SGT94-01|SynerGene Therapeutics, Inc.|Yes|Recruiting|January 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517464||92157|
NCT01513720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-137|Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition|Single Dose, Two-way, Crossover, Oral Bioequivalence Study of Lamotrigine Tablets 200 mg With Lamictal® Tablets 200 mg in Healthy, Volunteers Under Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Completed|December 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|44 Years|Accepts Healthy Volunteers|||October 2002|January 17, 2012|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513720||92442|
NCT01513733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032421|The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer|The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer|CATCH|Duke University|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|June 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|32|||Male|18 Years|79 Years|No|||January 2016|January 26, 2016|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01513733||92441|
NCT01513707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12-005|The Effects of Pre-transplant Dialysis Modality on Post-transplant Events|The Effects of Pre-transplant Dialysis Modality on Post-transplant Events|PDMP|Samsung Medical Center|No|Recruiting|December 2011|December 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1040|||Both|20 Years|70 Years|No|Probability Sample|primary care clinic|May 2015|May 18, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513707||92443|
NCT01513993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G. A. 250487-Veneto WP8Cl7|Remote Monitoring of Chronic Heart Failure in Veneto Region|RENEWING HEALTH - Large Scale Pilot in Veneto Region: Remote Monitoring of Chronic Heart Failure||Regione Veneto|Yes|Completed|October 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|315|||Both|65 Years|N/A|No|||January 2012|October 27, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513993||92423|
NCT01535469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01GH000517|Operational Research for Cryptococcal Antigen Screening|Operational Research for Cryptococcal Antigen Screening to Improve ART Survival|ORCAS|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|3049|||Both|14 Years|N/A|No|||July 2015|July 28, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01535469||90785|
NCT01535430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|671-11-FB|Assessment of Eloquent Function in Brain Tumor Patients|Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors||University of Nebraska|No|Recruiting|January 2012|December 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|19 Years|N/A|No|Non-Probability Sample|Patient with a brain tumor in or near an area of eloquent brain function (speech, motor,        sensory).|May 2013|May 31, 2013|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01535430||90788|
NCT01536015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1055|Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction|ROADMAP|UCB Pharma|No|Terminated|January 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|30 Years|N/A|No|||July 2014|July 7, 2014|February 15, 2012|Yes|Yes|The study was stopped due to low enrollment.|No|July 7, 2014|https://clinicaltrials.gov/show/NCT01536015||90743|
NCT01536028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1746|Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes|A Double-blind, Randomised, Four-Period Crossover Trial Comparing the Pharmacodynamics and Pharmacokinetics After Single Dose of Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 50, Biphasic Insulin Aspart 70 and Insulin Aspart in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|April 2006|July 2006|Actual|July 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|55 Years|No|||August 2015|August 28, 2015|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536028||90742|
NCT01515358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14340|A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|18|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515358||92319|
NCT01515371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ 60201-2069-1|Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-stage Dose-finding Study to Identify a Safe and Effective Dose of NT 201 for Unilateral Injection Into the Soft Palate for Treatment of Habitual Snoring||Merz Pharmaceuticals GmbH|Yes|Terminated|January 2012|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|No|||June 2013|June 18, 2013|January 18, 2012||No|Due to lack of sufficient eligible subjects, no safety concerns|No||https://clinicaltrials.gov/show/NCT01515371||92318|
NCT01515384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-133-D01|A Trial of 18F-AV-133 Positron Emission Tomography (PET)|A Preliminary Evaluation of the Safety and Pancreas Imaging Properties of 18F-AV-133 in Healthy Volunteers and in Patients With Type 1 or Type 2 Diabetes||Avid Radiopharmaceuticals|No|Suspended|June 2010|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|35|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|February 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515384||92317|
NCT01515956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-007|Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)||BioMarin Pharmaceutical|Yes|Active, not recruiting|October 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|5 Years|No|||September 2014|September 10, 2014|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515956||92273|
NCT01516827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCT-001-ULM|Effectiveness of Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for Children With Post-traumatic Stress Disorder (TreatChildTrauma)|Effectiveness of Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for Children With Post-traumatic Stress Disorder|TCT|University of Ulm|Yes|Active, not recruiting|February 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|7 Years|16 Years|No|||August 2015|August 25, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01516827||92206|
NCT01517035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120028|Improving Blood Stem Cell Collection and Transplant Procedures|Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using Ex Vivo CD3, CD19 Depletion and CD34 Selection||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|2 Years|80 Years|No|||April 2015|June 4, 2015|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517035||92190|
NCT01517295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEMA-HydrocodonePK-001|Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients|Evaluating the Pharmacokinetic Profile of Hydromorphone in Chronic Pain Patients Taking Hydrocodone/APAP||NEMA Research, Inc.|Yes|Completed|February 2012|September 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|75 Years|No|||September 2012|September 30, 2012|January 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517295||92170|
NCT01517516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000069|Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.|A Magnetic Resonance Imaging (MRI) Study to Investigate Differences in the Structure and the Function of the Brain at Rest; Between Persons With Functional Pain Conditions Such as IBS or Vulvodynia, IBD and Healthy Controls|MMI|University of California, Los Angeles|No|Completed|March 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|165|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Subjects will be recruited from clinics, community in and around Los Angeles Area.|January 2016|January 12, 2016|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01517516||92153|
NCT01513499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH1004|Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women|Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Humans||Massachusetts General Hospital|No|Active, not recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|140|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 29, 2016|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513499||92459|
NCT01513512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED-01|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2011|||||N/A|N/A|N/A||||||||||||||December 26, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513512||92458|
NCT01517243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1011|Phase II Study of Alternating Sunitinib and Temsirolimus|Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|June 2010|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01517243||92174|
NCT01517490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Klefter1|Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes|Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes||Glostrup University Hospital, Copenhagen|No|Recruiting|August 2011|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||6|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|30 patients with type 1 diabetes and suboptimal metabolic regulation which is to be        optimized by insulin pump therapy.        30 patients with type 1 diabetes and suboptimal metabolic regulation in whom insulin pump        therapy is not planned.        20 patients with type 2 diabetes and suboptimal metabolic regulation who are enrolled in a        pre-operative weight lowering protocol prior to bariatric surgery.        20 patients with type 2 diabetes and suboptimal metabolic regulation who are not enrolled        in treatment protocols relating to bariatric surgery.        17 patients with type 1 diabetes on insulin pump therapy who were previously followed in        an observational study of retinal function.|March 2015|March 10, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01517490||92155|
NCT01513408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1SLa-01|Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy|Prospective Study of the Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as a New imMUne Prognostic Biomarker in Breast Cancer Treated by NEOadjuvant Chemotherapy|PRIMUNEO|Centre Georges Francois Leclerc|No|Completed|May 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Female|18 Years|80 Years|No|||September 2014|March 20, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513408||92466|
NCT01513746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031840|Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity|Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity||Duke University|Yes|Completed|December 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|83|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|UNC and Duke Endocrine Clinics Community of the Durham, Chapel Hill and Raleigh area|August 2014|August 25, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513746||92440|
NCT01514006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2011-117|Postoperative Anemia and Functional Outcomes After Fast-track Primary Hip Arthroplasty|Postoperative Anemia and Functional Outcomes After Fast-track Primary Hip Arthroplasty - a Prospective Observational Study||Rigshospitalet, Denmark|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|65 Years|N/A|No|Non-Probability Sample|All patients aged 65 or above undergoing primary hip arhtroplasty|March 2015|March 6, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514006||92422|
NCT01514266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-17419|Effect of Curcumin on Lung Inflammation|Effect of Curcumin on Lung Inflammation||Baylor College of Medicine|No|Completed|April 2005|August 2010|Actual|May 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|57|||Both|40 Years|80 Years|No|||January 2012|January 20, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01514266||92402|
NCT01535781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA0001|Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?|Effect of Tranexamic Acid on Blood Loss and Transfusion Need in Patients Operated With a Short Intramedullary Nail, for Pertrochanteric Fractures .||Hvidovre University Hospital|Yes|Terminated|September 2011|August 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|November 23, 2011||No|Recruiting slower than expected.|No||https://clinicaltrials.gov/show/NCT01535781||90761|
NCT01535729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML23023|An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer|Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.||Hoffmann-La Roche||Completed|May 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|465|||Both|65 Years|N/A|No|Probability Sample|Elderly patients with advanced non-small cell lung cancer after first-line platinum-based        chemotherapy|October 2015|October 1, 2015|February 15, 2012||No||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01535729||90765|
NCT01535742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Air-Q versus Ambu-Aura-i|Ambu Aura-i and Air-Q Intubating Laryngeal Airways as a Conduit for Tracheal Intubation in Children|Prospective Randomized Comparison of the Ambu Aura-i and Air-Q Intubating Laryngeal Airways as a Conduit for Tracheal Intubation in Children||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|4||Actual|120|||Both|1 Month|6 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01535742||90764|
NCT01536041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-6950POU006|A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients|A Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Safety and Efficacy of ONO-6950 20 mg and 200 mg QD Versus Placebo and Montelukast (Singulair) in Asthmatic Patients Who Experience Exercise-induced Bronchoconstriction||Ono Pharmaceutical Co. Ltd|No|Completed|March 2012|||November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|60 Years|No|||January 2014|January 21, 2014|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01536041||90741|
NCT01515098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2075|Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline|The Effect of Blueberry Consumption on Cognition and Body Composition in Elderly Who Are Experiencing Mild Cognitive Decline|BERRY|University of North Carolina, Chapel Hill|No|Completed|January 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|123|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||May 2015|May 13, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515098||92339|
NCT01515657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-ASA-004|Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients|A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes||PLx Pharma|No|Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|40|||Both|21 Years|79 Years|No|||February 2016|February 11, 2016|January 13, 2012|Yes|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01515657||92296|
NCT01515943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CITS|Convergence Insufficiency Treatment Study (CITS)|Effectiveness of Home-Based Therapy for Symptomatic Convergence Insufficiency||Jaeb Center for Health Research|Yes|Completed|June 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|204|||Both|9 Years|17 Years|No|||October 2015|October 1, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01515943||92274|
NCT01516307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT-822-001|Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects|A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer||OBI Pharma, Inc|Yes|Active, not recruiting|December 2011|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|349|||Female|21 Years|N/A|No|||January 2016|January 5, 2016|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516307||92246|
NCT01516593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARMEN|Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma|Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma|CARMEN|IRCCS San Raffaele|No|Recruiting|November 2011|August 2015|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|60 Years|No|||January 2012|January 24, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01516593||92224|
NCT01516606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-K|Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma|Phase II Clinical Trial on the Activity of Salvage Therapy With High Dose Oral Clarithromycin in Patients With Relapsed or Refractory Extranodal Marginal Zone Lymphoma|HD-K|IRCCS San Raffaele|No|Recruiting|January 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01516606||92223|
NCT01517282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001064-22|Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis|A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis||MorphoSys AG|Yes|Completed|January 2012|February 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|60 Years|No|||November 2014|November 9, 2014|January 10, 2012||No||No|October 8, 2014|https://clinicaltrials.gov/show/NCT01517282||92171|Key limitations of this trial include its small sample size and limited duration. Efficacy assessments were not made in this study. Larger clinical trials will be required to evaluate the potential of MOR103 in treating patients with MS.
NCT01517568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1699|Metabolism and Excretion of Liraglutide in Healthy Male Volunteers|A Single-Centre, Open Label Trial Investigating the Metabolites in Plasma, Urine and Faeces After a Single Subcutaneous Dose of [3H]-Liraglutide to Healthy Subjects||Novo Nordisk A/S|No|Completed|November 2006|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Male|30 Years|65 Years|No|||January 2015|January 16, 2015|January 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517568||92149|
NCT01513759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKOS 09|A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).|Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy|SEATTLE II|EKOS Corporation|No|Completed|May 2012|April 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513759||92439|
NCT01513473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3561|A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus|A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in Children and Adolescents 1 to Less Than 18 Years With Type 1 Diabetes Mellitus on a Basal-bolus Regimen With Insulin Aspart as Bolus Insulin, Followed by a 26-week Extension Investigating Long Term Safety (BEGIN™: Young 1)|BEGIN™|Novo Nordisk A/S|No|Completed|January 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|350|||Both|1 Year|17 Years|No|||December 2015|December 8, 2015|January 16, 2012|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01513473||92461|
NCT01517503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 10/103|Acceptance and Commitment Therapy Versus Cognitive Therapy for the Treatment of Major Depressive Disorder|Acceptance and Commitment Therapy vs. Cognitive Therapy for the Treatment of Major Depressive Disorder||VU University of Amsterdam|Yes|Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|65 Years|No|||December 2012|December 2, 2012|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01517503||92154|
NCT01513421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281/10|Active Versus Non Active Drainage for the Treatment of Infected Intra-abdominal Collection|Active Versus Non Active Drainage for the Treatment of Infected Intra-abdominal Collection: a Randomized Prospective Trial||Centre Hospitalier Universitaire Vaudois|No|Recruiting|January 2012|January 2014|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|In-hospital patients with infected intra-abdominal collection (primary or secondary to        surgery)|January 2012|January 20, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513421||92465|
NCT01513434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPH2008-004|Femoral Tunnel Position on Conventional MRI After Anterior Cruciate Ligament Reconstruction-Transtibial Technique Versus Transportal Technique|||National Police Hospital|Yes|Completed|July 2008|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Male|17 Years|45 Years|No|||January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513434||92464|
NCT01514019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_Acebutolol|An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese Volunteers|An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese Volunteers||Seoul National University Hospital|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514019||92421|
NCT01514032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP-Stone|Extracorporal Shockwave Lithotripsy Versus Retrograde Intrarenal Surgery for the Treatment of Kidney Stones|TOP-Stone: Treatment of Patients With Small Kidney Stones - Randomized Head-to-head Trial Comparing Extracorporal Shockwave Lithotripsy With Retrograde Intrarenal Surgery||University of Zurich||Recruiting|October 2011|February 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01514032||92420|
NCT01514552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0073|The Use of Functional Confections in Promoting Oral Health|A Pilot Phase I Study of the Use of Functional Confections in Promoting Oral Health in Men and Women||Ohio State University|No|Active, not recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 2, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514552||92381|
NCT01535755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cqykdxfsdyyy2|A Protocol to Wean From Noninvasive Mechanical Ventilation|A Protocol to Wean From Noninvasive Mechanical Ventilation||Chongqing Medical University|Yes|Terminated|July 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|80|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|February 11, 2012|Yes|Yes|Enough patients has been enrolled.|No||https://clinicaltrials.gov/show/NCT01535755||90763|
NCT01536314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0115|Prophylaxis of Neuropathic Pain by mémantine|Preventing the Development of Neuropathic Pain Post-mastectomy/Tumorectomy by Pre-emptive or Post-operative Memantine Administration|MEMANTINE|University Hospital, Clermont-Ferrand||Completed|February 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|43|||Female|18 Years|N/A|No|||June 2014|June 30, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536314||90720|
NCT01536600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1880|Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix 30 as Monotherapy, or in Combination With OHAs, in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice|PRESENT|Novo Nordisk A/S|No|Completed|September 2004|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33010|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes who were not adequately controlled on their current therapy        and who were prescribed biphasic insulin aspart 30 (NovoMix® 30)|February 2016|February 18, 2016|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536600||90698|
NCT01515397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-G-H-0904|Comparison of Two Gelatine Solutions|Efficacy and Safety of a Balanced Gelatine Solution in Combination With a Balanced Electrolyte Solution Versus a Standard Gelatine Solution in Combination With a Non-balanced Electrolyte Solution in Patients Scheduled for Abdominal Surgery||B. Braun Melsungen AG|No|Completed|December 2011|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||November 2013|November 26, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01515397||92316|
NCT01515410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|81-0068|Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations|A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations||Depomed|No|Completed|January 2012|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|30 Years|N/A|No|||November 2012|January 27, 2014|January 11, 2012|Yes|Yes||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01515410||92315|
NCT01515982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60liv02-09B|Physical Exercise as an Additional Treatment for Alzheimer Disease|||Universidade Federal do Rio de Janeiro|Yes|Completed|February 2010|December 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|60 Years|N/A|No|||December 2014|December 1, 2014|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01515982||92271|
NCT01516320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAF34|Mechanisms of Diabetes Relapse After Bariatric Surgery|Mechanisms of Diabetes Relapse After Bariatric Surgery||Columbia University|Yes|Not yet recruiting|July 2015|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|40|Samples With DNA|Serum, Pellet, Urine, Stool, Saliva|Both|18 Years|65 Years|No|Non-Probability Sample|Sample primarily drawn from the community surrounding St. Luke's-Roosevelt Hospital        Center. Post-GBP groups will primarily be drawn from patients of the St. Luke's-Roosevelt        Hospital Center Bariatric Surgery Division.|October 2015|October 15, 2015|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516320||92245|
NCT01517061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120054|Genetics and Phantom Limb Pain|Integrative Genomic Analysis In Phantom Limb Pain||National Institutes of Health Clinical Center (CC)||Withdrawn|January 2012|July 2014||||N/A|Observational|Time Perspective: Retrospective|||Actual|0|||Both|18 Years|60 Years|No|||July 2014|October 9, 2014|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01517061||92188|
NCT01517074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120057|Sirolimus Injections for Autoimmune Scleritis|A Phase I/II Study to Investigate Subconjunctival Sirolimus for the Treatment of Active Autoimmune Non-Necrotizing Anterior Scleritis|ISAS|National Institutes of Health Clinical Center (CC)|No|Completed|January 2012|April 2014|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|January 24, 2012|Yes|Yes||No|May 12, 2014|https://clinicaltrials.gov/show/NCT01517074||92187|
NCT01517555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1698|Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes|A Single Centre, Randomised, Double-blind, Placebo Controlled Trial to Evaluate the Possible Drug-drug Interaction Between Liraglutide and Paracetamol and the Effects of Liraglutide on Postprandial Glucose and Insulin, Gastric Emptying, Appetite Sensations and Energy Intake in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|October 2006|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|70 Years|No|||October 2014|October 29, 2014|January 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517555||92150|
NCT01517308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.E. Federico II 47/11|24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C|24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C, RELAPSERS TO PEG-IFN + RIBAVIRIN TREATMENT. A RANDOMIZED CONTROLLED TRIAL||Federico II University|No|Withdrawn|May 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|January 17, 2012||No|Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week    regimen in this setting. It seems non-ethical to start this trial|No||https://clinicaltrials.gov/show/NCT01517308||92169|
NCT01522729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPINAL-20520|Impact of Muscle Afferent Feedback During Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Impact of Somatosensory Feedback on Peripheral Muscle Fatigue and Exercise Tolerance in Patients With COPD||Laval University|Yes|Completed|October 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|8|||Male|55 Years|75 Years|No|||January 2012|January 27, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01522729||91753|
NCT01513486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-3-073|Electrical Stimulation During Immobilization|The Effects of Daily Neuromuscular Electrical Stimulation on Muscle Mass During Short-term One-legged Knee Immobilization in Healthy Young Men|ESDIM|Maastricht University Medical Center|No|Completed|March 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 20, 2013|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01513486||92460|
NCT01514045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI0005|The Gastric Cancer Foundation: A Gastric Cancer Registry|The Gastric Cancer Foundation: A Gastric Cancer Registry||Stanford University|Yes|Recruiting|April 2011|April 2021|Anticipated|April 2021|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|Blood samples with DNA Paraffin embedded tissue will be stored in the Stanford Tissue Bank      for 100 years.|Both|18 Years|N/A|No|Non-Probability Sample|Participants will be identified for recruitment either by the individual's treating        physician or through information about the registry on the Gastric Cancer Fund website.        Potential participants will be directed to the URL for the gastric cancer registry and        asked to complete a brief registration form which will include eligibility questions.|January 2015|January 30, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514045||92419|
NCT01514058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01711|A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction|A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction||Comprehensive Cancer Center of Wake Forest University|No|Terminated|November 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|8|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|January 12, 2012|No|Yes|new clinical strategies have rendered the question posed by this study less relevant|No||https://clinicaltrials.gov/show/NCT01514058||92418|
NCT01514305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL900830|Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System|Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System||DexCom, Inc.|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects that fit the inclusion criteria will be chosen from the general population|January 2012|January 20, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01514305||92399|
NCT01514279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-1-5U01HL103622-02|Ideas Moving Parents and Adolescents to Change Together (IMPACT)|Targeting Obesity and Blood Pressure in Urban Youth(Consortium Title: Childhood Obesity Prevention and Treatment Research [COPTR] and Site Project Name IMPACT (Ideas Moving Parents and Adolescents to Change Together).|IMPACT|Case Western Reserve University|Yes|Enrolling by invitation|February 2011|December 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|360|||Both|11 Years|15 Years|No|||January 2016|January 26, 2016|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01514279||92401|
NCT01514292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-900590|Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System|PTL-900590 Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System||DexCom, Inc.|No|Completed|December 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||August 2015|September 10, 2015|January 12, 2012|Yes|Yes||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01514292||92400|
NCT01514565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D-574|Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer|Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer.||Thomas Jefferson University|No|Recruiting|December 2011|December 2018|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Female|18 Years|N/A|No|Probability Sample|A maximum of 70 eligible patients will be enrolled. Accrual is expected to be completed in        18-24 months. All patients must have histologically confirmed triple negative breast        cancer and be eligible to receive neoadjuvant chemotherapy.|March 2015|March 17, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514565||92380|
NCT01514578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP130-1001|Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males|A Multi-Part, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TRV130A in Healthy Adult Males||Trevena Inc.|Yes|Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|74|||Male|19 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 23, 2012|January 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01514578||92379|
NCT01514877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH-LCBM-1201|Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer|Phase II Study of Icotinib Combined With Whole Brain Radiotherapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer||Zhejiang Cancer Hospital|Yes|Completed|January 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||July 2014|July 22, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514877||92356|
NCT01535482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH086572-01A2|Cognitive Therapy for Suicidal Older Men|Cognitive Therapy for Suicidal Older Men||University of Pennsylvania|Yes|Recruiting|September 2011|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|122|||Male|50 Years|N/A|No|||July 2015|July 9, 2015|August 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01535482||90784|
NCT01535495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 2011-0475|Propranolol for Diabetic Retinopathy|Propranolol for Diabetic Retinopathy||University of Wisconsin, Madison|No|Completed|February 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535495||90783|
NCT01535508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD11-06899|Open Label Clinical Trial of Vitamin D in Children With Autism|Open Label Clinical Trial of Vitamin D Dosage Tolerability, and Effect on Behavioral Measures in Children With Autism||University of California, San Francisco|Yes|Recruiting|February 2012|December 2015|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|3 Years|8 Years|No|||October 2014|October 20, 2014|February 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01535508||90782|
NCT01535768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PASAGV2012|Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves|Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves||Credit Valley EyeCare|Yes|Recruiting|February 2012|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535768||90762|
NCT01536067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 205011|Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia|A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia||Roswell Park Cancer Institute|Yes|Terminated|April 2012|||April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|February 10, 2012|Yes|Yes|funding was withdrawn|No||https://clinicaltrials.gov/show/NCT01536067||90739|
NCT01515969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUN0044|Phase I Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase I Study of Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer||Stanford University|Yes|Suspended|July 2012|July 2015|Anticipated|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|December 16, 2011|Yes|Yes|Interim analysis of PK and toxicity data|No||https://clinicaltrials.gov/show/NCT01515969||92272|
NCT01516294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLH004|IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD|A Pilot, Single-center, Interventional Clinical Trial in Which Subjects With Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD) Will Receive Low Voltage Stereotactic Radiotherapy (IRay®) Treatment and Lucentis® Treatment as Needed.||Oraya Therapeutics, Inc.|Yes|Active, not recruiting|January 2012|March 2014|Anticipated|March 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|50 Years|N/A|No|||October 2012|October 31, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516294||92247|
NCT01516853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0473|Non-invasive Quantification of Liver Iron With MRI|Non-invasive Quantification of Liver Iron With MRI||University of Wisconsin, Madison||Completed|January 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|10 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 16, 2015|August 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01516853||92204|
NCT01516866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO11811|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy|NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies|NaFl PET/CT|University of Wisconsin, Madison|Yes|Active, not recruiting|November 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|||Male|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|January 2016|January 29, 2016|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01516866||92203|
NCT01517048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120051|Brain-Derived Neurotrophic Factor in Obesity and Brain Function|Brain-Derived Neurotrophic Factor in Obesity and Neurocognitive Function||National Institutes of Health Clinical Center (CC)||Completed|January 2012|December 2014||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|59|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2014|December 13, 2014|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01517048||92189|
NCT01526161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTA 05/503/04|Management of Asthma in School-age Children on Therapy|Management of Asthma in School-age Children on Therapy|MASCOT|University Hospital of North Staffordshire|Yes|Completed|April 2009|January 2011|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|229|||Both|6 Years|14 Years|No|||January 2012|February 2, 2012|August 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01526161||91491|
NCT01522222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEEP|Study to Determine if Using Ventilation During Open Heart Surgery Improves Lung Outcomes|Effect of Continuous Mechanical Ventilation During Cardiopulmonary Bypass on The Lung Mechanics: A Prospective Evaluation|PEEP|Aurora BayCare Medical Center|No|Completed|July 2010|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|N/A|N/A|No|||December 2015|December 28, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01522222||91792|
NCT01517321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-5435-17|MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes|MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes||Ono Pharmaceutical Co. Ltd||Completed||||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||||||Both|20 Years|N/A|No|||July 2013|July 7, 2013|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01517321||92168|
NCT01522482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/31|Apolipoprotein (APO)E Genotype, Meal Fatty Acids, Postprandial Lipaemia|Effects of Meal Fatty Acid Composition on Postprandial Lipaemia in Men According to APOE Genotype||University of Reading|Yes|Completed|March 2009|July 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|31|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||January 2012|January 31, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522482||91772|
NCT01513785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk0904|New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study|New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study||Shanghai Jiao Tong University School of Medicine|No|Completed|April 2011|January 2012|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513785||92437|
NCT01513772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0742|The Effect of Dexmedetomidine on the Emergence Agitation in Nasal Surgery|||Severance Hospital||Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|20 Years|59 Years|No|||August 2012|August 7, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513772||92438|
NCT01514071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103-040|Animated Picture to Improve Provider Adherence to CT Scan for Head Injury Rule|||Children's Hospitals and Clinics of Minnesota||Completed|February 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|746|||Both|N/A|18 Years|No|||July 2013|July 30, 2013|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01514071||92417|
NCT01514318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-805|Encore Revelation Hip Stem|A Long-term Follow Up Study of the Revelation™ Hip Stem||Encore Medical, L.P.|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|The study will include only subjects who received the Revelation Hip Stem prior to 2002        and who voluntarily consent to take part in this study.|October 2012|October 31, 2012|December 22, 2011|Yes|Yes||No|July 18, 2012|https://clinicaltrials.gov/show/NCT01514318||92398|Small patient population to choose from and difficulty in locating people who have not been seen by the doctor in almost 10 years.
NCT01514331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2011-68|Ventilatory Parameters and Inflammatory Responses of Neonates Ventilated by Different Modes of Ventilation|Determination of Ventilatory Parameters and Inflammatory Responses of Neonates Who Are Ventilated by Volume Guarantee Combined With Synchronized Intermittent Mandatory Ventilation or Pressure Support Ventilation||Gazi University|No|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|N/A|24 Hours|No|||November 2013|November 19, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01514331||92397|
NCT01514591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-08162011-8270|Thromboelastography in Non-elective Cesarean Delivery|Thromboelastography to Assess Hemostatic Changes in Laboring Patients Undergoing Non-elective (Intrapartum) Cesarean Delivery||Stanford University|Yes|Completed|August 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|Samples With DNA|Blood samples for TEG analysis.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obstetrical laboring patients who are undergoing non-elective Cesarean delivery with an        'epidural top up' for surgical anesthesia.|June 2013|June 19, 2013|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01514591||92378|
NCT01514604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/NS/0040|Constructing a Learning Curve in Ultrasound Guided Needling|Constructing a Learning Curve in Ultrasound Guided Needling - an Observational Study Using Cumulative Sum (Cusum) Analysis||University of Aberdeen|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|21|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Anaesthetists working within the anaesthetic department of Aberdeen Royal Infirmary /        Woodend hospitals, Aberdeen.|April 2014|April 29, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01514604||92377|
NCT01514890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS CO20|French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin|Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) Included in the French Early Access Program for the Use of Protease Inhibitors in Genotype 1 Patients Who Failed to Eradicate HCV With a Previous Standard PEG-IFN and RBV Combination.|CUPIC|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|February 2011|March 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|675|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C in genotype 1 Who Failed to Eradicate HCV With a        Previous Standard PEG-IFN and RBV Combination|December 2012|December 26, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01514890||92355|
NCT01514903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-SIL-102|Pharmacokinetics of Sildenafil Following Administration of an Chewable Tablet of Sildenafil Relative to Viagra® Conventional Oral Tablet in Healthy Volunteers|||Hanmi Pharmaceutical Company Limited|Yes|Completed|December 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2012|January 20, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01514903||92354|
NCT01515176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00101|Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia|Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL||National Cancer Institute (NCI)|Yes|Active, not recruiting|January 2012|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515176||92333|
NCT01515189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-169|Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab|A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma||Bristol-Myers Squibb|Yes|Active, not recruiting|February 2012|July 2017|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||August 2015|March 14, 2016|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515189||92332|
NCT01515449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS2010002|Predictors of Poor Outcomes in 1038 Sigma Knees|Predictors of Poor Outcomes in 1038 Sigma Knees||NHS Fife|No|Completed|October 1998|October 2008|Actual|October 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1038|||Both|N/A|N/A|No|Non-Probability Sample|All patients undergoing total knee replacement in Fife|January 2012|January 23, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515449||92312|
NCT01535521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SupPos|Sleep Positional Trainer for Positional Sleep Apnea After Mandibular Advancement Device (MAD) Therapy|Evaluation of Sleep Position Trainer for Positional Sleep Apnea Patients After Therapy With Mandibular Advancement Device (MAD)|SupPos|University Hospital, Antwerp||Completed||||February 2013|Actual|N/A|Interventional|N/A|1||||||Both|18 Years|N/A|No|||June 2013|June 19, 2013|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535521||90781|
NCT01535534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-384N-MA|Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis|Evaluation of Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis|MaSep|Universitätsmedizin Mannheim|No|Recruiting|January 2012|July 2016|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|Peripheral blood samples|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients suffering from sepsis|May 2015|May 9, 2015|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535534||90780|
NCT01536054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 199911|Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer||Roswell Park Cancer Institute|No|Active, not recruiting|August 2012|||August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|18 Years|N/A|No|||September 2015|September 11, 2015|December 30, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01536054||90740|
NCT01536301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/PC-02|Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery|Evaluation of Oxycodone Hydrochloride Versus Intravenous Morphine Hydrochloride for Postoperative Analgesia After Hip Prosthetic Surgery||Centre Hospitalier Universitaire de Nīmes|Yes|Recruiting|June 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|80 Years|No|||October 2015|October 21, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536301||90721|
NCT01539200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUD1051|Effects of Daily Nutritional Supplementation in Combination With a Eurhythmics Training (NUDAL)|Effects of 6-months Once Daily Nutritional Supplementation in Combination With a Once Weekly Jacques-Delacroze Eurhythmics Training (NUDAL) on Functionality, Probability of Independence and/or Functional Reserve Among Community-dwelling Seniors|NUDAL|Nestlé|No|Completed|March 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|65 Years|N/A|No|||March 2014|March 25, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01539200||90498|
NCT01515683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA|Behavioral Support Before Anesthesia|Behavioral Support to Cancer Patients Before Anesthesia|STØB|Odense University Hospital|Yes|Completed|December 2008|May 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|350|||Female|N/A|N/A|No|||May 2014|May 5, 2014|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01515683||92294|
NCT01516632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21CA135669|Smoking Cessation Via Text Messaging: Feasibility Testing of Stop My Smoking USA|Smoking Cessation Via Text Messaging: Feasibility Testing of SMS USA|SMS USA|Center for Innovative Public Health Research|No|Completed|June 2009|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||January 2012|January 24, 2012|March 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01516632||92221|
NCT01525888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR21711CTIL|Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy|||Soroka University Medical Center|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||January 2012|June 4, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525888||91512|
NCT01522495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eye vs. Spy Pilot Study|Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging|Pilot Study for: Eye vs. Spy - A Prospective, Randomized Study Evaluating Patient Outcomes With the Use of SPY Imaging During Amputations or Debridements||Georgetown University|Yes|Recruiting|April 2013|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|160|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522495||91771|
NCT01522742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000557|Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study|Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study|MMAPPS|Massachusetts General Hospital|No|Terminated|February 2012|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|29|Samples Without DNA|Plasma, serum.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with moderate-to-severe psoriasis with or without arthritis will be recruited        primarily from dermatology and rheumatology clinics in the eastern Massachusetts area.|March 2016|March 22, 2016|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01522742||91752|
NCT01523197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXZZ11-0711|Auto-trilevel Ventilator for Patients With Overlap Syndrome|Effect of Auto-Trilevel Ventilation on Patients With Overlap Syndrome||Nanjing Medical University|No|Completed|August 2011|November 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|70 Years|No|||November 2012|November 26, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01523197||91717|
NCT01523210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTI_BoNT_distribution|DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle|Influence of Physiotherapy on the Spastic Musculus Biceps Brachii Under Routine Botulinum Toxin Injection. - An Explorative MRI Study||Medical University of Vienna|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|5|||Both|18 Years|80 Years|No|Probability Sample|patients suffering from upper limb spasticity        receiving routine BoNT injection|November 2012|November 12, 2012|January 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01523210||91716|
NCT01513525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1745|Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers|A Randomised, Open-label, Single Centre, Three Period Cross-over Trial in Healthy Subjects Comparing the Pharmacokinetic Profiles After Single Dose Administration of Liraglutide at Three Different Injection Sites||Novo Nordisk A/S|No|Completed|February 2007|May 2007|Actual|May 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|50 Years|No|||January 2015|January 22, 2015|January 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01513525||92457|
NCT01514084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108-081|Cosmetic Outcomes and Patient Satisfaction After Facial Laceration Repair in the Emergency Department|||Children's Hospitals and Clinics of Minnesota||Completed|February 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|160|||Both|N/A|17 Years|No|Non-Probability Sample|Pediatric emergency department|April 2014|April 21, 2014|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01514084||92416|
NCT01514097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112-120|Adequacy of Pain Management for Upper Extremity Fracture After Discharge From a Pediatric Emergency Depart|||Children's Hospitals and Clinics of Minnesota||Recruiting|February 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|300|||Both|N/A|17 Years|No|Non-Probability Sample|Pediatric emergency department|April 2014|July 29, 2015|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01514097||92415|
NCT01514617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53666|Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization|Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization||Universitaire Ziekenhuizen Leuven|No|Active, not recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|100|||Female|N/A|N/A|No|||October 2011|December 1, 2015|October 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01514617||92376|
NCT01514630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60398|Creatine as a Treatment Option for Depression in Methamphetamine Using Females|Creatine as a Treatment Option for Depression in Methamphetamine Using Females||University of Utah|Yes|Completed|January 2013|February 2015|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|13 Years|64 Years|No|||June 2015|June 9, 2015|January 12, 2012|No|Yes||No|May 14, 2015|https://clinicaltrials.gov/show/NCT01514630||92375|
NCT01514916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK VD 64/08|New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease|Evaluation of a Mechanical System (Vascular Join) Facilitating Arterial Anastomoses During Peripheral Vascular Surgery (Bypass).|VJ|Ab Medica Spa|Yes|Recruiting||||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01514916||92353|
NCT01514929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-490-006|A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers|A Randomized, Double-Blind, Placebo and Positive-Controlled, Crossover Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers||Achaogen, Inc.|Yes|Completed|October 2011|March 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|64|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 8, 2012|November 28, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01514929||92352|
NCT01515202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB121-009|Japanese Phase 1 Multiple Ascending Dose Study|A Randomized, Placebo-Controlled, Double-Blinded, Multiple Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-823778 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus||Bristol-Myers Squibb|No|Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|40|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515202||92331|
NCT01537250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-C-3|Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)|A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)||TaiGen Biotechnology Co., Ltd.|No|Completed|August 2009|August 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|18 Years|70 Years|No|||February 2012|February 16, 2012|February 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537250||90648|
NCT01537497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1731013|A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers|Phase 1 Four-Arm Parallel Group, Placebo-Controlled Study To Evaluate The Effects Of Single Doses Of PF- 05175157 At Three Dose Levels On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers||Pfizer|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|February 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537497||90629|
NCT01535794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMSM HPV vaccine acceptability|HPV Vaccine Acceptability Among Young Men Who Have Sex With Men|Exploring the Potential for Social Network Site-delivered Interventions to Increase HPV Vaccine Uptake Among Men Who Have Sex With Men||Indiana University|Yes|Completed|February 2012|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2000|||Male|18 Years|26 Years|No|Non-Probability Sample|This study will be an internet-based, cross-sectional study targeting all US profiles of        two separate online social/sexual networking communities of YMSM. A recruitment email will        be sent internally to all active US profiles for men 18-26 years old.|August 2014|August 7, 2014|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01535794||90760|
NCT01535807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CorMatrix ECM Study|CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM|CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without CorMatrix's Extra Cellular Matrix (ECM)|CorMatrix|Inova Health Care Services|No|Active, not recruiting|January 2012|June 2016|Anticipated|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|February 15, 2012||No||No|November 19, 2015|https://clinicaltrials.gov/show/NCT01535807||90759|
NCT01536730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21MH090892-02|A Self-Guided Intervention to Promote Condom Use Among African American Males|A Self-Guided Intervention to Promote Condom Use Among African American Males||Indiana University|No|Completed|January 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|193|||Male|15 Years|24 Years|Accepts Healthy Volunteers|||March 2015|March 23, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01536730||90688|
NCT01516619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProRom|Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia|Pilot Phase II Trial on Safety and Activity of Secondary Prophylaxis With Romiplostim in Patients With Non-Hodgkin Lymphoma and Chemotherapy-induced Thrombocytopenia|ProRom|IRCCS San Raffaele|No|Recruiting|November 2011|September 2014|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2012|January 24, 2012|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01516619||92222|
NCT01525563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-282|Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study|Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study||Abbott|No|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1000|||Female|18 Years|75 Years|No|Non-Probability Sample|Subjects with irregular menstrual cycle|December 2014|December 17, 2014|February 1, 2012||No||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01525563||91537|
NCT01522235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000397|Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy|A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.||Beth Israel Deaconess Medical Center|Yes|Recruiting|February 2012|December 2014|Anticipated|July 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||July 2013|July 30, 2013|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522235||91791|
NCT01522248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIR 281|Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study|A Pilot Study to Examine the Early Cytokine Responses After Inactivated Influenza Vaccination in Adults 18-50.||Johns Hopkins Bloomberg School of Public Health|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 17, 2015|January 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01522248||91790|
NCT01522755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11|Predictive Factors of a Successful Implant of the CapsureFix MRI Model 5086|Predictive Factors of a Successful Implant of the CapsureFix MRI Model 5086||Medtronic Bakken Research Center|No|Recruiting|May 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Both|18 Years|N/A|No|Non-Probability Sample|Patient implanted with 2 CapsureFix MRI pacing leads model 5086 in the atrium and in the        ventricle|July 2012|July 26, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01522755||91751|
NCT01522768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-166|Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer|A Phase II Study of Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer||Memorial Sloan Kettering Cancer Center||Recruiting|March 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01522768||91750|
NCT01523249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01974|Three-Dimensional Ultrasound (3D US) in Parturients|Three-Dimensional Ultrasound (3D US) for Epidural Needle Insertion in Parturients||University of British Columbia|No|Completed|November 2013|September 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Female|19 Years|N/A|No|Non-Probability Sample|Term pregnant women expecting neuraxial anesthesia or analgesia for cesarean delivery or        labour pain control at BC Women's Hospital.|September 2014|September 26, 2014|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523249||91713|
NCT01523015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGC-0254/87/2011|Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction|Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection||Medical University of Lublin|Yes|Recruiting|January 2012|December 2020|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2013|February 2, 2013|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01523015||91731|
NCT01523028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.12.NRC|Influence of Breakfast Consumption on Chlorogenic Acid Metabolism in Humans|||Nestlé|Yes|Completed|September 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|14|||Both|20 Years|44 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523028||91730|
NCT01523223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT243|Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies|A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation||Stanford University|Yes|Recruiting|January 2012|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||November 2015|November 16, 2015|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523223||91715|
NCT01523236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|70936005|Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Furoate Anhydrous, 50 Mcg/Actuation Nasal Spray (Teva Pharmaceuticals USA) Compared to Nasonex® (Mometasone Furoate Monohydrate) 50 Mcg/Actuation Nasal Spray (Schering) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis||Teva Pharmaceuticals USA|No|Completed|December 2011|January 2012|Actual|January 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|800|||Both|12 Years|N/A|No|||January 2012|January 27, 2012|January 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01523236||91714|
NCT01523002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-014-11|Drug Interaction Study of Pyronaridine-artesunate and Metoprolol and Pyronaridine-artesunate Re-dosing Study in Healthy Volunteers|Open-label, Drug Interaction Study of Pyramax (Pyronaridine:Artesunate) and Metoprolol in Healthy Volunteers and Pyramax Re-dosing Study in Healthy Volunteers||Medicines for Malaria Venture|Yes|Completed|January 2012|October 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|January 25, 2013|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01523002||91732|
NCT01513798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2011-294-31M|Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial|Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial||Umeå University||Completed|January 2012|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|30 Years|65 Years|No|||February 2015|February 25, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513798||92436|
NCT01523691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL105544-01A1 2010P-000399|Repeating Patterns of Sleep Restriction and Recovery|Repeating Patterns of Sleep Restriction and Recovery - do we Get Used to it?||Beth Israel Deaconess Medical Center|No|Active, not recruiting|August 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|14|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01523691||91679|
NCT01523704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|atHome Study|Safety and Efficacy Study of IPG Patient With Home Monitoring|Comparison of the Safety and Efficacy of the Management of Pacemaker Patients Followed-up Via Home Monitoring vs. Conventional In-Office Follow-up||Biotronik Japan, Inc.||Active, not recruiting|January 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1364|||Both|20 Years|N/A|No|||June 2014|June 27, 2014|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01523704||91678|
NCT01514344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRIS|Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma|Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone|IRIS|IRCCS San Raffaele|No|Recruiting|December 2011|October 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2012|January 17, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01514344||92396|
NCT01514643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51134|Inflammatory Response Following Intraarticular Fracture|Inflammatory Response Following Intraarticular Fracture|PTOA|University of Utah|No|Recruiting|October 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Synovial fluid and blood serum|Both|18 Years|60 Years|No|Non-Probability Sample|Patients presenting with tibial plateau or plafond fracture.|December 2015|December 18, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01514643||92374|
NCT01514942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIvsDCI_PCOS/IR|Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters|||AGUNCO Obstetrics and Gynecology Centre||Completed||||||Phase 4|Interventional|N/A|2||||||Female|20 Years|40 Years|No|||January 2012|January 18, 2012|January 13, 2012||||No||https://clinicaltrials.gov/show/NCT01514942||92351|
NCT01515215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040 / 2008|Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder|Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder||Centre for Addiction and Mental Health|No|Active, not recruiting|July 2008|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|85 Years|No|||September 2015|September 28, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515215||92330|
NCT01538641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAM-03-01|Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas|Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma||Auxilio Mutuo Cancer Center|Yes|Completed|October 2003|December 2008|Actual|August 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538641||90541|
NCT01538914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_VATS PVB|Analgesic Effect of Intravenous Patient-Controlled Analgesia (IV PCA) Versus Paravertebral Block After Video Assisted Thoracic Surgery (VATS)|A Comparison Between the Analgesic Effect of Intravenous Patient-controlled Analgesia and of Paravertebral Block After Video Assisted Thoracoscopic Surgery||Seoul National University Hospital||Recruiting|February 2012|||February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|20 Years|70 Years|No|||February 2012|February 23, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01538914||90520|
NCT01537510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18AE000026|Study of Technology to Accelerate Research|Accelerating Adoption of Childhood Obesity Comparative Effectiveness Research|STAR|Harvard Pilgrim Health Care||Completed|December 2010|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|549|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||September 2013|September 25, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01537510||90628|
NCT01535872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSHFCTG34/10|Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients|Dehydroepiandrosterone Treatment for Poor Responders in IVF Patients: A Prospective Randomised Controlled Trial.||KK Women's and Children's Hospital|Yes|Active, not recruiting|February 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|280|||Female|21 Years|42 Years|No|||September 2015|September 3, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01535872||90754|
NCT01516346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01340|Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction|Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction||Philadelphia Veterans Affairs Medical Center|No|Active, not recruiting|January 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516346||92243|
NCT01516359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|intestinal injury|Incidence and Predictive Factors of Intestinal Injury in Patients Undergoing Heart Valve Replacements|Official Title is Required by the WHO and ICMJE||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|October 2011|November 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood samples are retained for the detections of some biomarkers and gene polymorphism.|Both|16 Years|80 Years|No|Probability Sample|Patients undergoing heart valve replacements under cardiopulmonary bypass|January 2012|January 19, 2012|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01516359||92242|
NCT01526174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRI-002|Intratympanic Injection for Autoimmune Inner Ear Disease|Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial|AIED|House Research Institute|No|Terminated|March 2012|April 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|80 Years|No|||October 2013|October 10, 2013|February 1, 2012|Yes|Yes|House Research no longer conducting research.|No||https://clinicaltrials.gov/show/NCT01526174||91490|
NCT01522508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANI-134-1|Evaluation of Analgesia Nociception Index (ANI) During Propofol/Remifentanil and Sevoflurane/Remifentanil Anesthesia|Detection of Nociceptive Stimulation by Analgesia Nociception Index (ANI) During Anesthesia With Propofol or Sevoflurane and Varying Remifentanil Concentrations.||University of Schleswig-Holstein|No|Recruiting|June 2011|October 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|65 Years|No|Probability Sample|Patients scheduled for elective surgery in general anesthesia|June 2012|June 14, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01522508||91770|
NCT01522521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK156 III-1|Study of AK156 in Primary Osteoporosis Patients|Phase 3 Study of AK156 in Primary Osteoporosis Patients||Asahi Kasei Pharma Corporation||Completed|February 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|65 Years|89 Years|No|||October 2015|October 1, 2015|January 27, 2012||||No||https://clinicaltrials.gov/show/NCT01522521||91769|
NCT01523041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1144|Comparison of Two Formulations of Biphasic Insulin Aspart 70|A Randomised, Double Blind, Single Centre, Three Period Crossover Trial Testing the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 and Characterising the Pharmacokinetics of Biphasic Insulin Aspart 50 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|November 1999|November 1999|Actual|November 1999|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Male|18 Years|50 Years|No|||January 2012|January 27, 2012|January 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01523041||91729|
NCT01537302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVI OCT 10005|Chronic Total Occlusion Crossing With the Ocelot System - CONNECT II|A Non-randomized Study of the Avinger Ocelot System Used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries|CONNECTII|Avinger, Inc.|Yes|Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|201|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|February 15, 2012|Yes|Yes||No|March 5, 2015|https://clinicaltrials.gov/show/NCT01537302||90644|
NCT01537549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB1006011088|Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy|An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers||Weill Medical College of Cornell University|No|Active, not recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|40 Years|75 Years|No|||September 2013|September 5, 2013|January 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537549||90625|
NCT01537562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIUC12|Intrauterine Contraception (IUC) After Medical Abortion|Early Versus Delayed Insertion of Intrauterine Contraception After Medical Abortion- a Randomized Controlled Trial||Karolinska Institutet|Yes|Completed|February 2007|October 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|129|||Female|18 Years|45 Years|No|||February 2012|February 22, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01537562||90624|
NCT01537848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUS in surgical collection|Retrospective Study of Endoscopic Ultrasound (EUS) Guided Transmural Drainage of Post-operative Abdominal Collections|Retrospective Study of Endoscopic Ultrasound Guided Transmural Drainage of Post-operative Collections||Erasme University Hospital|No|Completed|January 2002|February 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|43|||Both|15 Years|90 Years|No|Non-Probability Sample|All patients who underwent EUS guided drainage of post-operative collections admitted        between january 2002 and july 2011 for this treatment in the endoscopic department of a        single academic center will be included for analysis.|February 2012|February 23, 2012|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537848||90602|
NCT01537861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204086|Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma|A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma||Washington University School of Medicine|No|Terminated|June 2012|December 2014|Actual|February 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|February 15, 2012|No|Yes|Unexpected toxicity (2 early deaths)|No||https://clinicaltrials.gov/show/NCT01537861||90601|
NCT01538095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00252|Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors|A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors||National Cancer Institute (NCI)|Yes|Active, not recruiting|February 2012|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|2 Years|21 Years|No|||March 2016|March 10, 2016|February 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538095||90583|
NCT01538108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMB AVS P|Study of NMB (Company's Name) Drug Ejecting Balloon for Arteriovenous Fistulae|The Use of NMB Drug Ejecting Balloon for Arteriovenous (AV) Dialysis Fistulae||N.M.B. Medical Applications Ltd||Not yet recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01538108||90582|
NCT01538706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|959584438|Hospital-based Home Care for Children With Cancer|Hospital-based Home Care for Children With Cancer||Rigshospitalet, Denmark|Yes|Completed|August 2008|October 2010|Actual|December 2009|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|75|||Both|1 Month|18 Years|No|||February 2012|February 23, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01538706||90536|
NCT01538719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H31332|IL1-TRAP, Rilonacept, in Systemic Sclerosis|Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial||Boston University|Yes|Recruiting|December 2011|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538719||90535|
NCT01529697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeaumontH|Prospective Study of the Feedback From an Adherence Monitor on Asthma Control|Prospective Study of the Feedback From an Adherence Monitor on Asthma Control|INCA|Beaumont Hospital|No|Completed|February 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|220|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01529697||91222|
NCT01529983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU55341|Fractional Laser vs. Ultrasound for Periorbital Wrinkles|A Comparison of 1550-nm Fractional Photothermolysis Versus Intense Focused Ultrasound for Treatment of Periorbital Wrinkles: A Pilot, Prospective Randomized Control Trial||Northwestern University|No|Active, not recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|35 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01529983||91200|
NCT01530503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002002-70|Second Line Therapy in Advanced Biliary Tract Cancer|A Randomized Phase II Trial of Second Line Therapy in Advanced Biliary Tract Cancer: Capecitabine or Capecitabine Plus Mitomycin C|BIT-2|IRCCS San Raffaele|Yes|Completed|November 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||February 2016|February 24, 2016|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01530503||91160|
NCT01530516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00021423|Crossbow Versus Forsus Springs in Mild to Moderate Class II Malocclusion Cases|3D Changes Comparing the Crossbow Appliance and Later Full Fixed Brackets Against Simultaneous Use of Full Fixed Brackets Plus Forsus Springs Among Mild to Moderate Class II Malocclusion Cases: A Randomized Clinical Trial.||University of Alberta, Graduate Orthodontic Program|No|Recruiting|October 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|11 Years|15 Years|No|||December 2014|December 23, 2014|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01530516||91159|
NCT01526915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBM 2009-01|Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates|Contribution of Platelet Rich Fibrin (PRF) After Tooth Avulsion in the Prevention of Healing Delay and of Jawbone Osteochemonecrosis Induced by Bisphosphonates|OCN/PRF|Centre Hospitalier Régional Metz-Thionville|Yes|Recruiting|January 2012|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|270|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526915||91433|
NCT01526928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-1686-008|Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients|A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral Rociletinib in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)||Clovis Oncology, Inc.|No|Active, not recruiting|March 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|605|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01526928||91432|
NCT01539512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0116|A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Completed|April 2012|April 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|February 12, 2012|Yes|Yes||No|October 9, 2014|https://clinicaltrials.gov/show/NCT01539512||90474|Following a recommendation by an independent Data Monitoring Committee (DMC), the study was stopped early due to highly statistically significant results for the primary efficacy endpoint of progression-free survival.
NCT01539525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005006785|Screening to Augment Referral to Treatment- Project START|Screening to Augment Referral to Treatment- Project START|ProjectSTART|Yale University|No|Active, not recruiting|September 2010|August 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|495|||Female|18 Years|60 Years|No|||February 2016|February 9, 2016|August 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01539525||90473|
NCT01539850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-006|Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102|Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102. A Prospective Multicenter Study||IntraPace, Inc|No|Completed|March 2010|September 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|60 Years|No|||February 2012|February 27, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539850||90448|
NCT01539863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIIMMIIR|Chiropractic Maintenance Care of Persistent or Recurrent Low Back Pain|Chiropractic Maintenance Care of Persistent or Recurrent Low Back Pain. A Randomized Controlled Trial With 1 Year Follow up||Karolinska Institutet|No|Recruiting|March 2012|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|65 Years|No|||February 2016|February 23, 2016|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539863||90447|
NCT01535599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-018|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa||Alcon Research|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|768|||Both|6 Months|N/A|No|||June 2014|June 24, 2014|February 15, 2012|Yes|Yes||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01535599||90775|
NCT01535898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-033|Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers|Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers||Memorial Sloan Kettering Cancer Center||Completed|February 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01535898||90752|
NCT01536145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021001|CP-751,871 Treatment For Patients With Multiple Myeloma|An Open Label Phase I Study Of CP-751,871 In Patients With Multiple Myeloma||Pfizer|No|Completed|December 2003|June 2008|Actual|June 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|February 14, 2012|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT01536145||90733|
NCT01536418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114643|An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease|A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease|SHIELD-4|GlaxoSmithKline|Yes|Terminated|November 2011|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|255|||Both|18 Years|N/A|No|||February 2014|March 6, 2014|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01536418||90712|
NCT01536431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON817-10|Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes|Phase 1b Study of Proinsulin (PI) Peptide Immunotherapy in New-Onset Type 1 Diabetes|MonoPepT1De|Cardiff University|Yes|Completed|January 2012|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|27|||Both|18 Years|40 Years|No|||July 2015|July 27, 2015|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01536431||90711|
NCT01536769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86/2011|Intestinal and Nasal Microbiota of Patients With Idiopathic Parkinson's Disease|Intestinal and Nasal Microbiota of Patients With Idiopathic Parkinson's Disease||Helsinki University Central Hospital|No|Active, not recruiting|November 2011|December 2016|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|150|Samples With DNA|Nasal and oral bacterial swabs and stool samples|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hospital patients in- and outpatient From the community|March 2015|March 18, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536769||90685|
NCT01537042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0934|A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Polysomnography Study to Investigate Safety and Efficacy of the Rotigotine Transdermal Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis||UCB Pharma|No|Completed|April 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|85 Years|No|||October 2014|October 31, 2014|February 16, 2012|Yes|Yes||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01537042||90664|
NCT01537055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110021MD|Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy|Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial||National Taiwan University Hospital|Yes|Recruiting|February 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|20 Years|N/A|No|||January 2015|January 30, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01537055||90663|
NCT01537874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R24MD002772|MassCONECT (Massachusetts Community Networks to Eliminate Cancer Disparities Through Education) 4 Kids: Promoting Smoke-free Homes|MassCONECT 4 Kids: Promoting Smoke-free Homes MassCONECT (Massachusetts Community Networks to Eliminate Cancer Disparities Through Education)||Harvard School of Public Health|No|Completed|May 2010|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|138|||Both|17 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 19, 2014|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537874||90600|
NCT01538121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-01A|Antiphospholipid Antibodies and Early Severe Preeclampsia.|Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study.||Saint Thomas Hospital, Panama|No|Not yet recruiting|June 2015|August 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|310|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant patients admitted for severe preeclampsia between 24-34 weeks pf gestation        (cases) and normal patients in labor at term (controls).|January 2015|January 1, 2015|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538121||90581|
NCT01538134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-01B|Antiphospholipid Antibodies and Fetal Growth Restriction|Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study.||Saint Thomas Hospital, Panama|No|Not yet recruiting|June 2015|March 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|90|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant patients admitted for fetal growth restriction (cases) and normal patients in        labor at term (controls).|January 2015|January 1, 2015|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538134||90580|
NCT01538381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-90111-24111|Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck|Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study.||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Active, not recruiting|July 2012|October 2015|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538381||90561|
NCT01538394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR/01/011|Clinical Trial to Evaluate the Efficacy of Smoking Cessation|Randomized Double-blind Trial of Two Parallel Groups Design to Evaluate the Efficacy of Smoking Cessation With Combined (Varenicline Plus Nicotine Patches) Versus Monotherapy (Varenicline Plus Placebo Patches)|COMBIVAR|Hospital Universitari de Bellvitge|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|322|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 17, 2013|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538394||90560|
NCT01538693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00056144|Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury|Molecular Markers of Neuroplasticity During High-Intensity Exercise in Subjects With Incomplete Spinal Cord Injury||Rehabilitation Institute of Chicago|No|Completed|December 2011|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538693||90537|
NCT01538992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bursa YİEAH|Renal Denervation in Patients With Advanced Heart Failure|Phase 3 Study of Renal Denervation That Improves Symptoms of Heart Failure and Enhances Life Quality in Advanced Heart Failure||Bursa Postgraduate Hospital|No|Withdrawn|April 2013|April 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||July 2013|July 23, 2013|February 16, 2012||No|we could not fined enough patients for the study|No||https://clinicaltrials.gov/show/NCT01538992||90514|
NCT01538732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LISZT-2012|Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin|Single-Center, Prospective, Open Label, Single-arm Pilot Study Investigating the Efficacy and Safety of Alitretinoin in Patients Suffering From Severe Mucosal Lichen Planus.||University of Zurich|Yes|Recruiting|March 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||March 2012|March 19, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538732||90534|
NCT01538745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.2011.173|Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department|Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department||Brooke Army Medical Center|Yes|Recruiting|February 2012|September 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|59 Years|No|||January 2013|January 28, 2013|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538745||90533|
NCT01529710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mirazid2012|Safety and Efficacy of Mirazid for Schistosomiasis Treatment|Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study|PHAR0211|Pharco Pharmaceuticals|Yes|Completed|December 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|15 Years|30 Years|No|||February 2015|February 19, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529710||91221|
NCT01529996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU55489|Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness|Comparison of the Efficacy Between Pulsed Dye Laser (PDL) and the Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness: A Pilot, Prospective Randomized Trial.||Northwestern University|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01529996||91199|
NCT01530230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-74|ST- Depression on Electrocardiogram During Caesarean Section in Regional Anaesthesia in Women With Preeclampsia|Randomised Study on Cardiac Effects of Oxytocin During Caesarean Section in Preeclamptic Women||Uppsala University Hospital||Completed|November 2005|April 2008|Actual|April 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|25|||Female|18 Years|50 Years|No|||February 2012|February 10, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01530230||91181|
NCT01526655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROBOTHYST|Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer|A Randomized Open Controlled Trial Comparing Robot Assisted Laparoscopic Hysterectomy and Abdominal Hysterectomy for Endometrial Cancer in a Fast Track Program||University Hospital, Linkoeping|Yes|Recruiting|January 2012|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|N/A|No|||February 2016|February 20, 2016|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01526655||91453|
NCT01526941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1318|Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes|A Double-blind, Randomised, Two-Period Crossover Trial Comparing the Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Insulin Aspart 70 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|May 2001|July 2001|Actual|July 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|February 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526941||91431|
NCT01526954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-100-0003|Cohera TissuGlu® Surgical Adhesive in the Management of Wound Drainage|A Prospective, Randomized, Controlled, Single-blind, Multicenter Clinical Trial Evaluating the Safety and Efficacy of the Cohera TissuGlu® Surgical Adhesive in the Management of Wound Drainage as Compared to the Standard of Care Closure Techniques Following Abdominoplasty||Cohera Medical, Inc.||Completed|April 2012|November 2013|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2013|December 3, 2013|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01526954||91430|
NCT01539538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP309|A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain|A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain||AcelRx Pharmaceuticals, Inc.|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|357|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|February 22, 2012|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01539538||90472|
NCT01535365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20076955|Heat Versus Ice in the Acute Management of Neck and Back Strain Injuries|Heat Versus Ice in the Acute Management of Neck and Back Strain Injuries||Stony Brook University|No|Completed|March 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|November 5, 2010||No||No|November 5, 2010|https://clinicaltrials.gov/show/NCT01535365||90793|
NCT01539876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNFactor|Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel|Assessing Serial Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neo-adjuvant Taxane Chemotherapy|TNFactor|Lawson Health Research Institute|No|Withdrawn||||||Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|0|||Female|18 Years|N/A|No|||March 2014|March 24, 2014|February 22, 2012||No|Disease Site Team changed research focus unlikely to have sufficient support to complete study|No||https://clinicaltrials.gov/show/NCT01539876||90446|
NCT01536171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|497-2010|Peak Impact Forces and Metabolic Cost During Mid-Forefoot Striking in Shod Versus Barefoot Runners|Peak Impact Forces and Metabolic Cost During Mid-Forefoot Striking in Shod Versus Barefoot Runners: A Pilot Study||University of Florida|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|trained runners (men and women) who run with a FM strike (self-reported and verified in        the laboratory).|March 2014|March 17, 2014|November 2, 2011||No||No|December 13, 2013|https://clinicaltrials.gov/show/NCT01536171||90731|
NCT01536444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-DMG-1|Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer|Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Wounds in Patients After Mohs or Excisional Surgery for Skin Cancer||Momelan Technologies|No|Recruiting|January 2012|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|35 Years|90 Years|No|||February 2012|February 21, 2012|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536444||90710|
NCT01536158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB150212|Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial|Oral Paracetamol Versus Oral Ibuprofen Treatment||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|February 2012|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|N/A|10 Days|No|||December 2012|December 24, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01536158||90732|
NCT01537315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132036|Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study|Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study||University of Arkansas|Yes|Terminated|February 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|80 Years|No|||November 2014|November 18, 2014|February 10, 2012|Yes|Yes|lack of funding|No|October 31, 2014|https://clinicaltrials.gov/show/NCT01537315||90643|
NCT01537575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUDRACT-200700-3559-35|Intravenous Immunoglobulins for Post-Polio Syndrome|||Azienda Ospedaliera Universitaria Integrata Verona|No|Completed|January 2008|||December 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||February 2012|February 23, 2012|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537575||90623|
NCT01537588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|April 2009|Changes in Muscle Morphology Resulting From Anterior Cruciate Ligament Reconstruction|Changes in Muscle Morphology Resulting From ACL Reconstruction: Impact on Strength and Function||Panam Clinic|No|Completed|July 2009|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 9, 2015|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01537588||90622|
NCT01537601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/CHR/01|CIRCumcision and Urinary Tract Infections in Boys With Posterior Urethral Valves|Effect of Circumcision on the Risk of Febrile Urinary Tract Infections in Children With Posterior Urethral Valves.|CIRCUP|Centre Hospitalier Universitaire de la Réunion|No|Recruiting|August 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Male|N/A|28 Days|No|||July 2015|July 28, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537601||90621|
NCT01537887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11947|A Study of LY2484595 on the Electrical Activity of the Heart|A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|February 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537887||90599|
NCT01537900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-010|A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)|A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients||Merck Sharp & Dohme Corp.|No|Completed|October 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|65 Years|No|||December 2015|February 3, 2016|February 17, 2012|No|Yes||No|February 3, 2016|https://clinicaltrials.gov/show/NCT01537900||90598|
NCT01538147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-02|Restless Leg Syndrome and Severe Preeclampsia|Association Between Restless Leg Syndrome and Severe Preeclampsia. A Case Control Study.||Saint Thomas Hospital, Panama|No|Recruiting|August 2014|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|310|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant patients with severe preeclampsia (cases) and normal pregnancies at term        (control).|January 2015|January 1, 2015|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538147||90579|
NCT01538160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8657-OS-CTIL|A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery||rFVIIa|Sheba Medical Center|No|Not yet recruiting|February 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||February 2012|February 22, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538160||90578|
NCT01538407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117.0|Strengthening Exercise and Quadriceps Force During Walking|A Study of Strengthening Exercise on Quadriceps Force During Walking||Frederiksberg University Hospital|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|70 Years|No|||January 2014|January 21, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538407||90559|
NCT01539317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB 7630|Therapy to Prevent Sexual Pain in Breast Cancer Survivors|Therapy to Prevent Sexual Pain in Menopausal Survivors of Breast Cancer||OHSU Knight Cancer Institute|Yes|Completed|December 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|70 Years|No|||July 2015|July 7, 2015|December 21, 2011|Yes|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01539317||90489|
NCT01530529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3441007|A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999|A Phase 1, Cross-Over, Single-Dose, Open-Label Study to Estimate the Relative Bioavailability of a Modified-Release Formulation of PF-05180999 Under Fed and Fasted Conditions in Healthy Adult Subjects||Pfizer|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 29, 2012|February 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01530529||91158|
NCT01530542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K234-10-1001|A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers|Open-Label, Single-Dose, Randomized, 5-Period, 5-Way Crossover Study To Evaluate The Dose Proportionality And The Effects Of Food On The Bioavailability Of Acurox Tablets In Healthy Volunteers||Pfizer|No|Completed|July 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 22, 2012|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01530542||91157|
NCT01526395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00027421|Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital|Decreasing the Use of Unmodified ECT in an Indian Hospital||Johns Hopkins University|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|99|||Both|18 Years|65 Years|No|||April 2013|April 1, 2013|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01526395||91473|
NCT01526668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSTHYSTREC|Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy|A Randomized Study Comparing Four Different Postoperative Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy|POSTHYSTREC|University Hospital, Linkoeping|Yes|Recruiting|October 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|600|||Female|18 Years|60 Years|No|||February 2016|February 20, 2016|January 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526668||91452|
NCT01526681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANG-CP-005|Registry of Avance Nerve Graft Evaluating Utilization and Outcomes for the Reconstruction of Peripheral Nerve Discontinuities|Registry Study: A Multicenter, Retrospective Study of Avance Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair|RANGER|AxoGen, Inc|No|Recruiting|November 2008|December 2020|Anticipated|December 2018|Anticipated|N/A|Observational|N/A||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects treated with Avance Nerve Graft to reconstuct peripheral nerve discontinuities.|January 2016|January 24, 2016|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526681||91451|
NCT01526967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-0509-12-U359|Observational Evaluation of the Peristomal Skin Condition in Ostomates|Observational Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™ Skin Barriers|OSMOSE|ConvaTec Inc.|No|Active, not recruiting|January 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|colostomates, ileostomates, urostomates in acute care settings or community at large.|December 2012|December 14, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526967||91429|
NCT01526980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1319|Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes|A Single-Centre, Randomised, Open-Labelled, Two-Period, Crossover Trial In Subjects With Type 2 Diabetes Comparing the Glycaemic Control of Two Treatment Regimens: A Thrice Daily Regimen With Biphasic Insulin Aspart 70 and - 30 and a Twice Daily Regimen With Biphasic Human Insulin 30||Novo Nordisk A/S|No|Completed|May 2002|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2012|February 1, 2012|February 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526980||91428|
NCT01535378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00838-33|Interest of Behavioural Reeducation in Dysfunctions of Masticatory Apparatus. Relations Between Parafunctions and Dysfunctions of Mastixatory Apparatus|Interest of Behavioural Reeducation in Dysfunctions of Masticatory Apparatus. Relations Between Parafunctions and Dysfunctions of Mastixatory Apparatus|PARADYSAM|Rennes University Hospital||Completed|March 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with temporomandibular disorders|July 2014|July 21, 2014|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535378||90792|
NCT01535612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQR-09001|Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus|A Study Evaluating the Feasibility of Use and Performance of PaQ™ in Patients With Type 2 Diabetes Mellitus Who Are Currently Treated With Basal/Bolus Insulin Therapy||CeQur Corporation|No|Completed|March 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|30 Years|65 Years|No|||March 2015|March 24, 2015|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01535612||90774|
NCT01535625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-MOMO-04-001|Safety and Effectiveness of the Coronary Momo Stent|Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease||be Medical|Yes|Recruiting|February 2012|July 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01535625||90773|
NCT01535638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.26|Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers|Relative Bioavailability of BI 207127 FF Tablets, BI 207127 FF Modified Tablets and BI 207127 TFII Tablets Administered Orally as Three Tablets (Single Dose) to Healthy Male Volunteers, an Open-label, Randomised Three-way Crossover Study||Boehringer Ingelheim||Completed|February 2012|||March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 1, 2013|February 15, 2012||||No||https://clinicaltrials.gov/show/NCT01535638||90772|
NCT01536457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG-LAN-2011|Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only|Data Analysis of a Randomized, Double-Blind, Placebo- Controlled Study of Gastroesophageal Reflux Disease Therapy (Lansoprazole; Solutab™) in the Management of Childhood Asthma||Children's Center for Digestive Health Care|No|Completed|July 2011|January 2013|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|59|||Both|4 Years|11 Years|No|Non-Probability Sample|This is a retrospective study. The study will simply be taking data collected during a        prospective study and analyzing that data. There will be no subjects enrolled in this        retrospective study. The subjects enrolled in the prospective study were children, ages 4        to 11 years of age.|February 2015|February 10, 2015|December 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01536457||90709|
NCT01536795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-9768.2|A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis|Topical Treatment of Old World Cutaneous Leishmaniasis With WR279396 (Paromomycin/Gentamicin Ointment): Efficacy and Tolerance of a Regimen Using an Occlusive Polyurethane Dressing||U.S. Army Medical Research and Materiel Command|Yes|Completed|October 2005|February 2007|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||March 2012|March 15, 2012|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536795||90683|
NCT01536782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-026|Optimal Tube Feeding Method in Head and Neck Cancer Patients|The Optimal Tube Feeding Method in Head and Neck Cancer Patients: A Comparison Between Bolus, Gravity, and Tube Feeding Pump.||Baylor Research Institute|No|Not yet recruiting|July 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01536782||90684|
NCT01537328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1188|Progressive Rehabilitation Following Total Knee Arthroplasty|Progressive Rehabilitation Following Total Knee Arthroplasty|PROG|University of Colorado, Denver|No|Active, not recruiting|July 2011|May 2017|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|162|||Both|50 Years|85 Years|No|||November 2015|November 10, 2015|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01537328||90642|
NCT01537341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF_IOA_Pepper_Nocera|Asymmetric Locomotor Training in the Elderly to Restore Physical Function|Asymmetric Locomotor Training in the Elderly to Restore Physical Function||University of Florida|No|Withdrawn|April 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|65 Years|89 Years|No|||July 2013|July 18, 2013|February 14, 2012||No|Funding was not received for this study.|No||https://clinicaltrials.gov/show/NCT01537341||90641|
NCT01537614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLI-VLM|Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis||COLI-VLM|Poitiers University Hospital||Recruiting||||||Phase 1|Interventional|N/A|2||||||Both|18 Years|N/A||||February 2012|February 23, 2012|February 17, 2012||||No||https://clinicaltrials.gov/show/NCT01537614||90620|
NCT01537913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOUR_Score|FOUR Score in Children With Non-traumatic Impairment of Consciousness|Comparison of the Full Outline of UnResponsiveness (FOUR) Score With Glasgow Coma Scale (GCS) in Children With Non-traumatic Impairment of Consciousness.||All India Institute of Medical Sciences, New Delhi|No|Completed|June 2009|June 2010|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|70|||Both|5 Years|18 Years|No|Probability Sample|Children aged 5-18 years, admitted in PICU or pediatric ward with impaired consciousness        of less than 7 days duration|February 2012|February 22, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01537913||90597|
NCT01538173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR02|Increased Microcirculation for Preventing Postoperative Wound Infections in Patients Undergoing Reduction Mammoplasty|Prospective Study Investigating the Role of Increased Microcirculation for Preventing Postoperative Surgical Side Infections in Patients Undergoing Reduction Mammoplasty||University of Rostock|No|Completed|January 2007|February 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|334|||Female|18 Years|70 Years|No|||November 2015|November 30, 2015|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538173||90577|
NCT01538420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0492-CL-103|GLPG0492 Pharmacodynamics|Assessment of the Muscle Protein Fractional Synthesis Rate Induced by Repeated Administrations of GLPG0492 to Healthy Male Subjects and Assessment of the Safety, Tolerability and Pharmacokinetics of Repeated Administrations of GLPG0492 to Healthy Postmenopausal Women.||Galapagos NV|No|Completed|January 2012|April 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538420||90558|
NCT01538433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGH201107|A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy|A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy: an Observational Study||Guangdong General Hospital|Yes|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|603|||Both|14 Years|80 Years|No|Probability Sample|The consecutive biopsy-proven IgAN patients in Guangdong General Hospital, Guangzhou,China|August 2013|August 17, 2015|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538433||90557|
NCT01539330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP-VOR03|Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy|Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy|VORTarget-site|Martin-Luther-Universität Halle-Wittenberg|No|Completed|February 2009|August 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01539330||90488|
NCT01539343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1019|Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)|Phase II Pilot Study to Estimate the Adverse Events Associated With the Lock Solution When Used to Salvage Central Venous Catheter (CVC) in the Setting of a Central Line Associated Bloodstream Infection (CLABSI)||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2013|||April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539343||90487|
NCT01530555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2081-005|Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia|Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia||King Faisal Specialist Hospital & Research Center||Completed|April 2008|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|16 Years|80 Years|No|||February 2012|February 24, 2016|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530555||91156|
NCT01526408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRI-003|Famvir for Treatment of Hearing in Unilateral Meniere's Disease|Treatment of Hearing Fluctuation in Unilateral Meniere's Disease: A Randomized, Placebo-controlled Clinical Trial of Famciclovir|Famvir|House Research Institute|No|Terminated|December 2011|March 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|90 Years|No|||October 2013|August 27, 2015|January 31, 2012||No|HRI no longer conducting research.|No||https://clinicaltrials.gov/show/NCT01526408||91472|
NCT01526707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10174LH-AS|The Use of FKBP51 in the Identification of Non-adherence to Inhaled Corticosteroids in Difficult Asthma|The Use of FKBP51 in the Identification of Non-adherence to Inhaled Corticosteroids in Difficult Asthma||Belfast Health and Social Care Trust|Yes|Completed|June 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|40|||Both|16 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526707||91449|
NCT01527006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-G000-232|Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs|An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy||Eisai Inc.||Completed|February 2012|April 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|2 Years|11 Years|No|||February 2016|February 10, 2016|November 10, 2011|Yes|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01527006||91427|
NCT01527019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF125|Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)|A Phase III Non-Inferiority Open-label Multicenter Randomized Clinical Trial to Compare CEPHALOSPORIN to NORFLOXACIN in the Treatment of Acute Cystitis|CECI|Eurofarma Laboratorios S.A.|Yes|Withdrawn|October 2012|||October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||February 2012|July 24, 2015|January 31, 2012||No|the company suspended the persecution of this combination|No||https://clinicaltrials.gov/show/NCT01527019||91426|
NCT01536184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:015|Evaluating the Effectiveness of an Attachment-Focused Intervention in Preschool Children With FASD|Evaluating the Effectiveness of an Attachment-Focused Intervention in Preschool Children With Fetal Alcohol Spectrum Disorder (FASD) or At-risk for FASD: A Randomized Controlled Field Trial||University of Manitoba|No|Active, not recruiting|March 2012|December 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|2 Years|5 Years|No|||January 2015|January 26, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01536184||90730|
NCT01536197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0175B|Taste Perception Pre and Post Bariatric Surgery|Effect of Bariatric Surgery-induced Weight Loss on Taste Perception|RBtaste|Washington University School of Medicine|Yes|Completed|September 2009|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|27|Samples With DNA|Tongue tissue|Female|20 Years|70 Years|No|Non-Probability Sample|A total of 27 morbidly obese (BMI>=35 kg/m2)subjects schedule for bariatric surgical        procedures will participate in this study.|July 2014|July 2, 2014|February 9, 2012||No||No|June 2, 2014|https://clinicaltrials.gov/show/NCT01536197||90729|
NCT01536210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YY-162 (b)|Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)|Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks|ADHD|Yuyu Pharma, Inc.|Yes|Recruiting|December 2011|December 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|6 Years|15 Years|No|||October 2011|February 15, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01536210||90728|
NCT01536470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0111|Intraoperative Noradrenaline to Control Arterial Pressure (INPRESS Study)|Effectiveness of Noradrenaline to Control Intraoperative Arterial Pressure in High-risk Surgical Patients: A Multicentre Prospective Randomized Controlled Trial|INPRESS|University Hospital, Clermont-Ferrand|No|Recruiting|March 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|50 Years|N/A|No|||March 2015|March 27, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01536470||90708|
NCT01536483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/4-H|Effects of Recto-colic Enemas of Butyrate on the Digestive Disorders of Very Low Birth Weight Preterms <1250 Grams|Effects of Recto-colic Enemas of Butyrate on the Digestive Disorders of Very Low Birth Weight Preterms <1250 Grams. Clinical Trial Prospective, Monocentric, Randomized in Double-blinded.|NEOTRANS|Nantes University Hospital||Recruiting|February 2012|May 2020|Anticipated|May 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|136|||Both|N/A|5 Days|No|||March 2015|March 25, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536483||90707|
NCT01537068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6457 Pfizer-WS1895577|Desvenlafaxine vs. Placebo Treatment of Chronic Depression|Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression||New York State Psychiatric Institute|No|Recruiting|February 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|65 Years|No|||April 2015|April 13, 2015|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537068||90662|
NCT01537081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-MUC-04|Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections|Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy Mucinex (2400 mg/d) and Immediate-Release Guaifenesin (800 mg/d) in the Treatment of Symptoms of Acute Upper Respiratory Tract Infections For 7 Days||Reckitt Benckiser LLC|No|Completed|September 2011|July 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2810|||Both|12 Years|N/A|No|||October 2013|October 22, 2013|February 16, 2012|Yes|Yes||No|July 3, 2013|https://clinicaltrials.gov/show/NCT01537081||90661|
NCT01537094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-002912|The Effect of Vitamin C on Growth Hormone Secretion|The Effect of Vitamin C on Growth Hormone Secretion||Massachusetts General Hospital|No|Withdrawn|December 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|60 Years|No|||December 2013|December 11, 2013|February 10, 2012||No|Unable to obtain funding to initiate the study. No subjects were enrolled.|No||https://clinicaltrials.gov/show/NCT01537094||90660|
NCT01538186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hetzel01|Treatment Of Coronary Bifurcation Lesions: Stentcovering Of The Side Branch With And Without PCI Of The Side Branch: A Retrospective Analysis Of All Consecutive Patients|Treatment Of Coronary Bifurcation Lesions: Stentcovering Of The Side Branch With And Without PCI Of The Side Branch: A Retrospective Analysis Of All Consecutive Patients||Krankenhaus Hetzelstift|No|Completed|January 2008|February 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|98|||Both|18 Years|95 Years|No|Probability Sample|This retrospective observational study included patients (pts) with PCI of a de novo        coronary bifurcation lesion in one German center between January 2008 - August 2011. We        included all consecutive patients where the side branch was covered with a stent. Patients        with ACS/cardiogenic shock were not excluded.|February 2012|February 23, 2012|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01538186||90576|
NCT01538446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110101|Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel|The ANTARCTIC Study - Assessment of a Normal Versus Tailored Dose of Prasugrel After Stenting in Patients Aged > 75 Years to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications|ANTARCTIC|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|880|||Both|75 Years|N/A|No|||January 2016|January 14, 2016|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538446||90556|
NCT01538758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-03|Ultrasound Guided Needling Versus Ultrasound Guided Corticosteroid Injection Alone, a Randomized Controlled Trial.|Treatment of Calcifying Tendinitis of the Shoulder: Ultrasound Guided Needling With Subacromial Corticosteroid Injection Versus Ultrasound Guided Subacromial Corticosteroid Injection Only, a Randomized Controlled Trial.|BARB-01|Medisch Spectrum Twente|Yes|Recruiting|July 2012|July 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01538758||90532|
NCT01539044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-10-1323-7843|Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal|Phase 4 Study of Optimal Relaxation With Rocuronium Infusion Followed by Rapid Reliable Reversal With Sugammadex: A Comparison With Conventional Practice|ProjectO5Rs|Hospital Sultanah Aminah Johor Bahru|Yes|Completed|February 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|75 Years|No|||August 2015|August 6, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01539044||90510|
NCT01539655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00101|Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib|A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine|Vandetanib|AstraZeneca||Completed|February 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|34|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|February 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01539655||90463|
NCT01539668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|careHPV_2012|Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas|CareHPV - Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas|careHPV|Barretos Cancer Hospital|No|Completed|March 2012|February 2014|Actual|December 2012|Actual|Phase 0|Observational|Time Perspective: Prospective||1|Actual|5079|Samples With DNA|Cervical cell samples (cytology)|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have undegone Pap sampling in a Mobile Unit and Non-Mobile Units.|February 2014|February 25, 2014|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01539668||90462|
NCT01530568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB Xpert ICU|Gene Xpert Diagnosis of TB Using Tracheal Aspirates From Intensive Care Unit (ICU) Patients|A Randomised Control Trial of a Standardised and User-friendly Real-time PCR Assay for the Diagnosis of TB Using Tracheal Aspirates Obtained From Patients in the ICU||University of Cape Town|No|Completed|August 2010|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic|2||Actual|341|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01530568||91155|
NCT01530581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2081-076|Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation|A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies||King Faisal Specialist Hospital & Research Center||Completed|November 2008|June 2014|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|16 Years|65 Years|No|||January 2016|January 4, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01530581||91154|
NCT01530594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2081-113|Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma|Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma||King Faisal Specialist Hospital & Research Center||Completed|January 2009|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|440|||Both|18 Years|80 Years|No|||February 2012|February 24, 2016|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530594||91153|
NCT01526421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00592|Use of Incentives to Engage Drug Users in HIV Therapy|A Randomized Clinical Trial Evaluating the Role of Contingent Reinforcement in the Engagement of and Retention of Drug Users in HAART Programs - Part 1|Incentives-1|University of British Columbia|Yes|Completed|February 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|301|||Both|19 Years|N/A|No|||December 2012|December 18, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526421||91471|
NCT01526694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDT-01-2011|Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs|Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs||Azienda Ospedaliera di Bolzano|No|Recruiting|October 2011|August 2017|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01526694||91450|
NCT01526720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE-955|The Verona Newly Diagnosed Type 2 Diabetes Study|The Verona Newly Diagnosed Type 2 Diabetes Study. Construction of a Biobank of Diabetes Related Genotypes and Phenotypes|VNDS|Universita di Verona|Yes|Recruiting|October 2003|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||2|Anticipated|1500|Samples With DNA|Whole blood Serum Plasma Urine|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Group A: all patients referred to the Division of Endocrinology and Metabolic Diseases of        University of Verona School of Medicine, whose diabetes has been diagnosed in the last six        months, are asked to participate in this research.        Group B: Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes|February 2012|February 3, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01526720||91448|
NCT01526733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Halo-117-401|Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase|A Phase 4, Randomized, Double-Blind, 2-Way Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) With, Compared to Without, Pretreatment With Recombinant Human Hyaluronidase (rHuPH20)||Halozyme Therapeutics|No|Completed|December 2011|September 2013|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|No|||September 2014|September 23, 2014|January 31, 2012|Yes|Yes||No|September 23, 2014|https://clinicaltrials.gov/show/NCT01526733||91447|
NCT01535404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRM-CH-Riv01|Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function Study|Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function (RIVELA) Study|RIVELA|University Hospital, Geneva|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|18 Years|N/A|No|||October 2014|October 19, 2014|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535404||90790|
NCT01535911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-452FS|Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors|Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors|Ketones|Michigan State University|Yes|Recruiting|April 2012|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|90 Years|No|||September 2015|September 18, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01535911||90751|
NCT01535924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11015|Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|February 2012|||December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|59|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535924||90750|
NCT01535937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#6403|The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence|||New York State Psychiatric Institute|Yes|Recruiting|February 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|60 Years|No|||December 2012|January 30, 2015|December 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535937||90749|
NCT01536496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB # 10-0477|Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma|A Prospective, Randomized Comparison Of Rapid Thrombelastography (r-TEG) And Conventional Coagulation Testing For Guiding The Diagnosis And Haemostatic Resuscitation Of Trauma Patients At Risk For Post-Injury Coagulopathy||Denver Health and Hospital Authority|No|Completed|September 2010|July 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|114|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|July 19, 2011|No|Yes||No|June 16, 2015|https://clinicaltrials.gov/show/NCT01536496||90706|
NCT01536821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105005340|PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)|PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study|PROGENI|Indiana University|Yes|Completed|May 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|81|Samples With DNA|DNA, plasma and serum will be obtained and stored from a blood sample. In addition, a whole      blood and urine samples will be obtained and stored.|Both|18 Years|N/A|No|Non-Probability Sample|Participants must provide test results documenting a LRRK2 mutation.|April 2013|December 13, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536821||90681|
NCT01537107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1111|Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery|Phase I Trial of The Combination of Vismodegib and Sirolimus||Mayo Clinic|Yes|Suspended|March 2012|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|February 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537107||90659|
NCT01537354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Curosurf-Survanta-UM13888|Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome|A Comparison of Immediate Changes in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome||University of Michigan|No|Withdrawn|June 2012|||December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|12 Hours|No|||January 2014|January 7, 2014|February 13, 2012||No|Sponsor discontinued clinical trial before enrollment of subjects.|No||https://clinicaltrials.gov/show/NCT01537354||90640|
NCT01536808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.506|Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?|Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?|R2D2|Hospices Civils de Lyon|Yes|Completed|April 2009|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|150|||Both|40 Years|55 Years|No|||August 2010|March 31, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536808||90682|
NCT01537926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALT-HCM|Hypertrophic Regression With N-Acetylcysteine in HCM|Pilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins Mutations|HALT|The University of Texas Health Science Center, Houston|Yes|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01537926||90596|
NCT01538199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002718|Transcranial Laser Therapy for Major Depressive Disorder|Evaluation of LED Therapeutic Effect in Depression (ELATED): a Placebo-Controlled, Parallel Study of Efficacy, Tolerability and Acceptability of a Novel Approach in the Community|ELATED|Massachusetts General Hospital|Yes|Completed|February 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|65 Years|No|||September 2015|September 28, 2015|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538199||90575|
NCT01538459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHCNE.2012.0001|Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block|Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block||Lifespan|No|Withdrawn|November 2012|November 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 17, 2013|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538459||90555|
NCT01538771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMI|Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling|The Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion: Gauging Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction (ICEBERG).||Seoul National University Bundang Hospital|Yes|Completed|November 2009|February 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||June 2015|June 18, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01538771||90531|
NCT01539057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Promotor Code 1553-H-459|The Efficacy of the Administration of Fibrinogen in Liver Transplantation|A Multicenter, Placebo Controlled Study to Evaluate the Efficacy of the Administration of Fibrinogen on Blood Product Requirements in Liver Transplantation|FibstudLT|Hospital Universitari de Bellvitge|Yes|Active, not recruiting|July 2012|January 2015|Anticipated|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|132|||Both|18 Years|70 Years|No|||December 2014|December 3, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01539057||90509|
NCT01539681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16028|Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy|Sorafenib Treatment Modalities for HEpatoceLLular Carcinoma Patients in ItAly|STELLA|Bayer|No|Completed|February 2012|February 2015|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|234|||Both|18 Years|N/A|No|Non-Probability Sample|Hepatocellular Carcinoma Patients treated in Italy|February 2016|February 16, 2016|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01539681||90461|
NCT01539694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|744E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||September 28, 2012|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539694||90460|
NCT01539707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-079|Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder|A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)||Astellas Pharma Inc|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|5 Years|17 Years|No|||October 2012|October 29, 2012|February 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01539707||90459|
NCT01530620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8405010|Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity|Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial||APOGEPHA Arzneimittel GmbH|No|Completed|December 2004|July 2006|Actual|June 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|70 Years|No|||February 2012|February 9, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01530620||91151|
NCT01526434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0053|Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol|An Open-label, Observational 12-week Study to Assess Health-related Quality of Life and Patient-reported Outcomes in Patients With Rheumatoid Arthritis Treated With Certolizumab Pegol|SONAR-12|UCB Pharma|No|Completed|January 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|81|||Both|18 Years|N/A|No|Probability Sample|Patients with RA who begin therapy with CZP will be consecutively included in accordance        with the selection criteria. The choice of medical treatment is made independently by the        physician before evaluating the possible participation of the patient in the study        protocol.        The study will include approximately 105 patients from 20 to 25 sites in Spain.|March 2014|March 18, 2014|February 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526434||91470|
NCT01526759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38515.081.11|Fiber Longer Term Study on Energy Intake|The Effect of 2 Weeks of Supplementation of a High-gelling, High-viscous Dietary Fibre on Energy Intake|FLiTS|Wageningen University|Yes|Completed|December 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01526759||91445|
NCT01535690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDTMLB|Photodynamic Therapy Associated With Full-mouth Ultrasonic Debridement in the Treatment of Severe Chronic Periodontitis|Photodynamic Therapy Associated With Full-mouth Ultrasonic Debridement in the Treatment of Severe Chronic Periodontitis: a Randomized-controlled Clinical Trial Running Title: Photodynamic Therapy Associated With Periodontal Debridement||Escola Bahiana de Medicina e Saude Publica|Yes|Completed|March 2008|July 2010|Actual|October 2009|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|22|||Both|31 Years|62 Years|Accepts Healthy Volunteers|||February 2012|February 17, 2012|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01535690||90768|
NCT01535677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1691C00007|To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately|A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States||AstraZeneca||Completed|April 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|71|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 8, 2015|January 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01535677||90769|
NCT01536223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH13|Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma|Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study|ESNCCT|Zhejiang Cancer Hospital|Yes|Recruiting|April 2012|February 2015|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|70 Years|No|||April 2012|March 3, 2013|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01536223||90727|
NCT01536834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPD396 02|Adult Vettel Pilot Clinical Study|A Pilot Clinical Investigation in Adults to Evaluate the Safety and Performance of a Class IIa Medical Device for the Treatment of Plantar Warts (Verrucas)||Reckitt Benckiser LLC||Not yet recruiting||||||N/A|Interventional|Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536834||90680|
NCT01537120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-258|Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)|Evaluation of Continuous Glucose Monitoring as a Tool to Measure Glucoregulatory Effects of a Twice Daily Oral Insulin Secretagogue||Merck Sharp & Dohme Corp.||Completed|December 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|79 Years|No|||August 2015|August 17, 2015|December 22, 2011|No|Yes||No|September 25, 2013|https://clinicaltrials.gov/show/NCT01537120||90658|
NCT01537367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDCHRSA9272007|Intervention to Retain HIV-positive Patients in Medical Care|Intervention Trials to Retain HIV-positive Patients in Medical Care|Phase II|Centers for Disease Control and Prevention|No|Completed|July 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|3||Actual|1838|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|February 10, 2012||No||No|August 7, 2013|https://clinicaltrials.gov/show/NCT01537367||90639|
NCT01537627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LFIP-001-NAH-1|Long-term Physical Training in Chronic Obstructive Pulmonary Disease|Effects of a Long-term Physical Training Program on Pulmonary and Systemic Aspects in Patients With Chronic Obstructive Pulmonary Disease||Universidade Estadual de Londrina|No|Recruiting|November 2009|July 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|82|||Both|40 Years|N/A|No|||December 2014|December 2, 2014|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01537627||90619|
NCT01537939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUKI2009|ASUKI Step Pedometer Worksite Intervention|ASUKI Step Pedometer Worksite Intervention|ASUKI-Step|Arizona State University|No|Completed|March 2009|December 2009|Actual|September 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|2018|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 22, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01537939||90595|
NCT01538485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADPP 003: GUT|Vitamin D Supplementation and Regulatory FoxP3+ T Cells in the GUT|Pilot Study to Assess the Effects of Vitamin D Supplementation on the Number of Regulatory FoxP3+ T Cells in the Gastrointestinal Mucosa in Healthy Women and Men: Step 3 in the Austrian Diabetes Prevention Programme||Medical University of Graz|Yes|Completed|January 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 9, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01538485||90553|
NCT01538784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-001|Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men|A Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of YF476, a Novel, Potent and Selective Gastrin/Cholecystokinin-B Antagonist, in Healthy Male Volunteers||Trio Medicines Ltd.|No|Completed|May 1996|June 1996|Actual|June 1996|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|15|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538784||90530|
NCT01539070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-785-120|Intervention for the Prevention of Obesity in Preschool|Design and Feasibility of a Clinical-based Intervention to Prevent Obesity in Preschool Children||Coordinación de Investigación en Salud, Mexico|No|Completed|March 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|306|||Both|24 Months|59 Months|No|||March 2014|March 19, 2014|February 14, 2012||No||No|July 1, 2013|https://clinicaltrials.gov/show/NCT01539070||90508|35% of families did not complete follow-up at 3 months, our primary endpoint. To address the resulting bias from missing data we performed multiple imputation of missing information on covariates and behavioral and BMI outcomes.
NCT01539083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018751|Velcade (Bortezomib) Consolidation After Transplant|An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant|VCAT|Janssen Scientific Affairs, LLC|Yes|Active, not recruiting|January 2012|December 2017|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|253|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|November 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539083||90507|
NCT01539356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0154-11-MMC|Hepcidin Levels in Preterm Infants|Hepcidin Levels in Preterm Infants Receiving Blood Transfusion and During Sepsis.||Meir Medical Center|No|Completed|March 2012|August 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|||Both|24 Weeks|37 Weeks|No|Non-Probability Sample|Preterm < 38 weeks gestation Need of blood transfusion according to local Protocol. or        signs and symptoms of sepsis|November 2012|March 15, 2016|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539356||90486|
NCT01539369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/H1305/6|The Leeds Women's Wellbeing (LWW) Study|A Study to Investigate the Short and Long Term Effects of Two 12-week Healthy Eating Interventions on Body Weight, Body Composition, Appetite Control, Biomarkers of Health and Subjective Wellbeing in Overweight Women|LWW|University of Leeds|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|December 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01539369||90485|
NCT01539720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201007|Levonorgestrel Intrauterine System For Emergency Contraception|Levonorgestrel Intrauterine System For Emergency Contraception: a Randomized Control Trial|LIFE|Washington University School of Medicine|Yes|Recruiting|December 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|532|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539720||90458|
NCT01539746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIMPLIFy TAVI Trial|Transcatheter Aortic Valve Implantation Without Predilation|Use of the Self-Expanding Medtronic CoreValve Prosthesis Without Predilation in Patients With Severely IMPaired Left-VentrIcular Ejection Fraction for TAVI Trial - The SIMPLIFy TAVI Trial|SIMPLIFy TAVI|University Hospital, Bonn|No|Recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539746||90456|
NCT01530646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-999|Impact of Whey and Soy Protein Ingestion in Conjunction With Energy Restriction in Overweight/Obese Individuals|Molecular Events Underpinning Changes in Tissue Metabolism With Whey and Soy Ingestion in Energy Restriction in Overweight/Obese Adults||McMaster University|Yes|Completed|February 2012|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|42|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 6, 2015|August 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01530646||91150|
NCT01526447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-4850|Effects of Craniosacral Therapy on Chronic Neck Pain|Effects of Craniosacral Therapy on Chronic Neck Pain: A Randomized Controlled Trial|CranioS|Universität Duisburg-Essen|Yes|Completed|February 2012|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|65 Years|No|||May 2013|May 13, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526447||91469|
NCT01526746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-1106|Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function|An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment With That in Matched Control Subjects With Relatively Normal Renal Function||Vanda Pharmaceuticals|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|32|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|January 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526746||91446|
NCT01557452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSC/11/2357/42|An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis (JIA)|An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Polyarticular Course Juvenile Idiopathic Arthritis (Poly JIA) JIA||Italfarmaco|No|Terminated|December 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|2 Years|18 Years|No|||February 2014|February 26, 2014|March 14, 2012||No|Previous study DSC/08/2357/36 did not show efficacy for Givinostat in JIA. Decision wasn't    related to any tolerability concerns|No||https://clinicaltrials.gov/show/NCT01557452||89104|
NCT01557465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00032758|Mechanical Alternans Study|Study of Mechanical Alternans for Prediction of Ventricular Tachyarrhythmias|MAS|Johns Hopkins University|No|Completed|November 2009|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|134|||Both|18 Years|N/A|No|Probability Sample|Patients with structural heart disease, ischemic or non-ischemic cardiomyopahty|April 2015|April 6, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557465||89103|
NCT01535976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00048723|Ketamine Infusion and Hypoventilation|The Effect of Ketamine in The Prevention of Hypoventilation in Patients With and Without a Positive Berlin Questionnaire Undergoing Deep Sedation||Northwestern University|No|Completed|August 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|54|||Female|18 Years|64 Years|No|||February 2014|February 18, 2014|September 9, 2011|Yes|Yes||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01535976||90746|We did not use depth of anesthesia monitor guided protocol due to controversial effects of ketamine of the correlation of processed EEG monitor and clinical levels of sedation. We did not use opioids as part of the protocol.
NCT01535989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOSI-LND-001|Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma|A Phase I Study of Inotuzumab Ozogamicin (CMC-544) in Combination With Temsirolimus (CCI-779) in Patients With Relapsed or Refractory CD22-positive B-cell Non Hodgkin's Lymphomas|IOSI-LND-001|Oncology Institute of Southern Switzerland|Yes|Recruiting|December 2011|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01535989||90745|
NCT01535950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFG316A2202|Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)|A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration||Novartis||Completed|February 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Both|55 Years|90 Years|No|||January 2015|January 7, 2015|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535950||90748|
NCT01535963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU55818|Patient Satisfaction in Cutaneous Surgery|A Pilot Study of Patient Satisfaction After Cutaneous Surgery||Northwestern University|No|Enrolling by invitation|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing cutaneous surgery|January 2016|January 11, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01535963||90747|
NCT01536509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD067174|Improving Medication Adherence in Pediatric Inflammatory Bowel Disease|Telehealth Enhancement of Adherence to Medication in Pediatric Inflammatory Bowel Disease|TEAM|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yes|Recruiting|February 2012|||July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|194|||Both|11 Years|18 Years|No|||October 2015|October 28, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536509||90705|
NCT01537133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 003|Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment|Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment||Milton S. Hershey Medical Center|Yes|Completed|October 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|84|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537133||90657|
NCT01537146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-04-019-ACL|Local Infiltration Versus Block Against Pains After High Tibial Osteotomy|Examination of the LIA (Local Infiltration) Versus Regional Blockade as Pain Management for Open-wedge High Tibial Osteotomy|HTO_pains|Northern Orthopaedic Division, Denmark|Yes|Completed|April 2010|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01537146||90656|
NCT01537380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD11/6-R|Tissue and Plasma Pharmacokinetics of Cefazolin in Antibiotic Prophylaxis in Bariatric Surgery|Tissue and Plasma Pharmacokinetics of Cefazolin in Antibiotic Prophylaxis in Bariatric Surgery, an Open Label, Prospective, Single Center Trial|Cefasleeve|Nantes University Hospital|No|Completed|March 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|117|||Both|18 Years|70 Years|No|||June 2015|June 16, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537380||90638|
NCT01537653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU12265|Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Subcutaneous Doses of SAR231893/REGN668 in Healthy Japanese Adult Male Subjects||Sanofi||Completed|March 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2012|December 5, 2013|February 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537653||90617|
NCT01537640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKM12350|Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects|A Randomized, Double-Blind, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of Two Different SAR231893 Drug Products After Administration of a Single Subcutaneous Dose to Healthy Subjects||Sanofi|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|December 5, 2013|February 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537640||90618|
NCT01538212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AX-11-009|Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease|Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease|ACT|Accera, Inc.|No|Enrolling by invitation|January 2012|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|50 Years|N/A|No|Non-Probability Sample|The study population will consist of patients with a diagnosis of mild-to-moderate AD who        have been treated with AXONA for ≥ 6 months and whose medical record includes an        evaluation within 3 months prior to initiation of treatment and at least one evaluation        while receiving AXONA.        Potential for intentional inclusion in the study will be determined on the basis of        prescribing data and physicians will be contacted. For Neurology and Psychiatry practices        agreeing to participate, all charts meeting the above criteria and for which        patients/caregivers give consent will be included in the analysis.|February 2012|February 23, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538212||90574|
NCT01538472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID03-0123|Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma|Y Zevalin, BEAM and Rituximab In Autologous Stem Cell Transplantation (ASCT) For Lymphoma||M.D. Anderson Cancer Center|No|Completed|September 2003|November 2011|Actual|November 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||September 2014|September 4, 2014|February 20, 2012|Yes|Yes||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01538472||90554|
NCT01538498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-08-309|Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer|A Clinical Trial to Develop a Peritoneal Carcinomatosis Index (PCI) in Ovarian||National Cancer Center, Korea||Completed|April 2008|February 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|134|||Female|N/A|N/A|No|Non-Probability Sample|-  primary ovarian cancer          -  non-neoadjuvant          -  Debulking operation|March 2013|March 26, 2013|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01538498||90552|
NCT01538511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1638|Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers|A Two-centre, Randomised, Open-labelled, Four-week, Parallel-group Pharmacokinetics Trial in Japanese Type 2 Diabetic Subjects Characterising the Insulin Profile of Thrice Daily Regimen With Biphasic Insulin Aspart 70 (NN2000-Mix70) With Reference to That of Twice Daily Regimen With Biphasic Insulin Aspart 30 (NN-X14Mix30) and Physiological Insulin Profile in Japanese Healthy Volunteers||Novo Nordisk A/S|No|Completed|June 2006|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|59|||Both|20 Years|69 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|February 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538511||90551|
NCT01538797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-016|Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States|YF476: Effects of a Single Dose at 3 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Ranitidine in Healthy Volunteers||Trio Medicines Ltd.|No|Completed|July 1996|August 1996|Actual|August 1996|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|22|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 20, 2012|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538797||90529|
NCT01538810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201061|Biomarker Correlates of Radiologic Imaging|Biomarker Correlates of Radiologic Imaging||Washington University School of Medicine|No|Active, not recruiting|February 2012|February 2016|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|751|||Both|18 Years|N/A|No|Non-Probability Sample|Anyone undergoing an abdominal image, meeting eligibility criteria.|June 2015|June 2, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538810||90528|
NCT01539096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-586|Brain Stimulation-aided Stroke Rehabilitation: Neural Mechanisms of Recovery|||The Cleveland Clinic||Recruiting|July 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01539096||90506|
NCT01539109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-823|Directing Neuroplasticity to Improve Rehabilitative Outcomes of the Upper Limb in Incomplete Quadriplegia|||The Cleveland Clinic|Yes|Recruiting|November 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01539109||90505|
NCT01539382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0891|Measuring and Treating Brain Oxygen Levels in Open Heart Surgery|Optimizing Cerebral Oxygenation in Cardiac Surgery||Icahn School of Medicine at Mount Sinai|Yes|Completed|November 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|140|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539382||90484|
NCT01539759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2477|Immediate Postplacental Insertion of IUDs at Time of Cesarean Delivery: A Randomized Clinical Trial|Immediate Postplacental Insertion of Intrauterine Devices at Time of Cesarean Delivery: A Randomized Clinical Trial|IUD@CSD|University of North Carolina, Chapel Hill|Yes|Completed|March 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|112|||Female|18 Years|45 Years|No|||June 2015|June 16, 2015|February 21, 2012|Yes|Yes||No|June 16, 2015|https://clinicaltrials.gov/show/NCT01539759||90455|
NCT01561157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1102|Longitudinal Study of the Porphyrias|Longitudinal Study of the Porphyrias||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|November 2010|December 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort||9|Anticipated|800|Samples With DNA|whole blood, plasma/serum, red blood cells, white cells, urine, stool, tissue, DNA|Both|N/A|N/A|No|Non-Probability Sample|Subjects will be recruited from the following resources:          1. Patients followed by one of the Investigators          2. The American Porphyria Foundation (APF)          3. The Rare Diseases Clinical Research Network (RDCRN) Contact Registry          4. Non-study Physician referrals          5. Self-referrals, including family members of individuals diagnosed with Porphyria             (proband) and other individuals who may have heard about the study from other             subjects or prospective subjects.          6. Medical Records Review|November 2015|November 25, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01561157||88820|
NCT01561404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTOR-METAB|Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise|Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise.|EXETOR|Hospital Universitari de Bellvitge|No|Terminated|September 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|3|||Both|18 Years|60 Years|No|||April 2015|April 27, 2015|March 20, 2012||No|lack of potential patients|No||https://clinicaltrials.gov/show/NCT01561404||88802|
NCT01527045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2546.00|Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies|Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation||Fred Hutchinson Cancer Research Center|Yes|Recruiting|September 2012|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Both|N/A|N/A|No|||February 2016|February 23, 2016|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527045||91424|
NCT01536249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223HV104|Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)|An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers||Knopp Biosciences||Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536249||90725|
NCT01536262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.22|Japan Long-term Safety for Tiotropium Plus Olodaterol|A Randomised, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed-dose Combination (2.5µg / 5µg, 5µg / 5µg ) and Olodaterol (5 µg) Delivered by the RESPIMAT Inhaler in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)||Boehringer Ingelheim||Completed|February 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|122|||Both|40 Years|N/A|No|||June 2015|June 19, 2015|February 16, 2012||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01536262||90724|
NCT01536236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD_505|Spinal Cord Stimulation for Diabetic Polyneuropathy|A Randomized, Comparison Study of the Safety and Efficacy of Spinal Cord Stimulation Versus Standard of Care Medical Management in the Treatment of Diabetic Polyneuropathy||St. Jude Medical|No|Withdrawn|October 2011|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|October 17, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01536236||90726|
NCT01536522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1049|Asthma Inflammation Research|Asthma Inflammation Research|AIR|The Cleveland Clinic|Yes|Recruiting|October 2011|April 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|February 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536522||90704|
NCT01536847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-09257|Glycaemic Response Testing|Glycaemic Response Testing||Mondelēz International, Inc.|No|Completed|December 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 7, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536847||90679|
NCT01536860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-00794|Glycemic Response Testing|Glycaemic Response Testing||Mondelēz International, Inc.|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 5, 2013|February 16, 2012||No||No|September 11, 2012|https://clinicaltrials.gov/show/NCT01536860||90678|
NCT01537159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8123|MRI Assessment of Leukemia Response to Therapy|Quantitative DCE-MRI as a Predictor of Therapeutic Response in Acute Leukemia||OHSU Knight Cancer Institute|Yes|Recruiting|May 2012|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|8 Years|75 Years|No|Non-Probability Sample|Primary Care Clinic|March 2016|March 21, 2016|February 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537159||90655|
NCT01537393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPTS|Cornea Preservation Time Study|Effect of Corneal Preservation Time on Long-Term Graft Success|CPTS|Case Western Reserve University|Yes|Active, not recruiting|March 2012|August 2017|Anticipated|March 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1330|||Both|30 Years|90 Years|No|||January 2016|January 26, 2016|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537393||90637|
NCT01537666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV005-01|Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics|Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.||Savara Inc.|Yes|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|February 17, 2012||No||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01537666||90616|
NCT01537679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-000270; 09-03-086-01D|Meditation to Reduce Caregiver Stress|Meditation or Relaxation Used to Reduce Stress Response and Improve Cognitive Functioning in Older Family Dementia Caregivers|Meditation|University of California, Los Angeles|Yes|Completed|March 2010|January 2012|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|45 Years|N/A|No|||February 2012|February 17, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01537679||90615|
NCT01537692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-101|Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol|A Randomized, Open-Label, 3-Period Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of BDP HFA Nasal Aerosol in Healthy Volunteers||Teva Pharmaceutical Industries|No|Completed|March 2009|June 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 22, 2012|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537692||90614|
NCT01537952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|230419|Microbiologic Findings of Acute Facial Palsy in Children|Microbiologic Findings of Acute Facial Palsy in Children||Helsinki University|No|Completed|May 2007|August 2009|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Both|N/A|16 Years|No|Non-Probability Sample|Tertiary university Hospital, children 0-16 years old|February 2012|February 22, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01537952||90594|
NCT01538225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M/SATIVX/01|Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity|Neurophysiologic Study on Effects of Sativex® on Spasticity in Progressive Multiple Sclerosis|NS-MSS|Almirall, S.A.|Yes|Completed|April 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||January 2014|January 17, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538225||90573|
NCT01538524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109008RB|Analysis of Patient Seeking Second Opinion Who Are Undergoing Full Mouth Orthodontic Treatment|Analysis of Patient Seeking Second Opinion Who Undergoing Full Mouth Orthodontic Treatment||National Taiwan University Hospital|Yes|Not yet recruiting|February 2012|February 2014|Anticipated|||N/A|Observational|Observational Model: Case-Only||1|Anticipated|30|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients who are not under full mouth fixed orthodontic treatment in National Taiwan        University Hospital|January 2012|February 23, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538524||90550|
NCT01538537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-02|Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer|Phase I Dose Escalation Study of ON 01910.Na by 3-day Continuous Infusion in Patients With Advanced Cancer||Onconova Therapeutics, Inc.|No|Completed|August 2006|January 2012|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2014|July 15, 2014|February 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538537||90549|
NCT01538823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202051|Urine Proteome of Surgical Patients and Healthy Volunteers|Urine Proteome of Surgical Patients and Healthy Volunteers.|UP|Washington University School of Medicine|Yes|Active, not recruiting|February 2012|March 2018|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Anticipated|836|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled to have full or partial kidney removal surgery (possibly because of        kidney cancer).        Patients scheduled to have a procedure because you may have bladder or prostate cancer.        Patients scheduled to have some other type of surgery (non-urological). Healthy volunteers|July 2015|July 14, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538823||90527|
NCT01538836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRPS-201107354|Calorie Restriction, Protein Supplementation and Metabolic Health|Calorie Restriction and Metabolic Health|CRPS|Washington University School of Medicine|Yes|Recruiting|January 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538836||90526|
NCT01539122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMGlenoid H12-00323|Clinical Experience With the Zimmer Trabecular Metal (TM) Glenoid in Total Shoulder Arthroplasty|A Multi-Centre, Randomized Controlled Study on the Zimmer TM Glenoid Component Compared to Cemented Glenoid Component|TMGlenoid|Joint Preservation Centre of BC|No|Active, not recruiting|April 2012|December 2021|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01539122||90504|
NCT01539395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSDX0211|A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis|A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis||MSDx, Inc.|No|Recruiting|January 2012|July 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|65|Samples With DNA|Blood remaining after testing for MSDx Complex-1 will be retained for evaluation for other      MS biomarkers|Both|45 Years|N/A|No|Non-Probability Sample|Patients who currently diagnosed with relapsing remitting multiple sclerosis|February 2012|February 24, 2012|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539395||90483|
NCT01539408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.2.3|Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion in Nigeria|Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion||Gynuity Health Projects|Yes|Completed|August 2009|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|N/A|No|||February 2012|February 21, 2012|February 16, 2012||Yes||No||https://clinicaltrials.gov/show/NCT01539408||90482|
NCT01537003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWM1200|WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test|WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test A Prospective, Multi Centre, Randomised, Clinical Study on Venous Leg Ulcers||Systagenix Wound Management|No|Recruiting|October 2012|January 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|July 4, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01537003||90667|
NCT01537237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00591|Comparison of Rotational Angiography/Electroanatomical Mapping Fusion Versus CT/Electroanatomical Mapping Fusion to Guide AF Ablation|Randomized Comparison of Rotational Angiography/Electroanatomical Mapping Fusion Versus CT/Electroanatomical Mapping Fusion to Guide AF Ablation|3DATGvsCT|Steward St. Elizabeth's Medical Center of Boston, Inc.|Yes|Completed|August 2011|November 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|37|||Both|18 Years|N/A|No|Probability Sample|All patients undergoing a clinically indicated left-sided ablation procedure for atrial        fibrillation who therefore satisfy conventional criteria for catheter ablation.|March 2012|November 24, 2014|January 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537237||90649|
NCT01526460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STATIPLAT|Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention|Prospective, Randomized, Single Center, Open Label Study Designed to Evaluate the Effect on Platelet Reactivity in Response to High Doses of Atorvastatin or Rosuvastatin Administered Before Percutaneous Coronary Intervention (PCI)|STATIPLAT|IRCCS San Raffaele|No|Completed|August 2011|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|146|||Both|18 Years|75 Years|No|||March 2014|March 5, 2014|September 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01526460||91468|
NCT01526772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00018487|A Prospective Study Evaluating The Utility of Transnasal Endoscopy With Roux en Y Gastric Bypass|A Prospective Study Evaluating The Utility of Transnasal Endoscopy With Roux en Y Gastric Bypass Referred for Upper Endoscopy||Wake Forest Baptist Health|No|Recruiting|September 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|This pilot study will attempt to recruit 20 subjects over one year.|February 2012|February 1, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01526772||91444|
NCT01527890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0238|Effect of Intravenous Patient-controlled Analgesia (IV-PCA) With Fentanyl in Adults for Acute Postoperative Pain Control|||Yonsei University||Recruiting|February 2012|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|20 Years|60 Years|No|Non-Probability Sample|Patients with Intravenous Fentanyl Patient-controlled Analgesia for postoperative pain        control|February 2012|February 2, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01527890||91360|
NCT01528189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01|Effect of High Dose Insulin on Infectious Complications Following Major Surgery|Effect of Hyperinsulinemic Normoglycemic Clamp (HINC) on Infectious Complications Following Major Abdominal Surgery. A Randomized Controlled Trial.||McGill University Health Center|Yes|Not yet recruiting|February 2012|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528189||91337|
NCT01536275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPaNIC|Early Versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit|Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Paediatric Critically Ill Patients|PEPaNIC|Katholieke Universiteit Leuven|Yes|Recruiting|June 2012|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1440|||Both|N/A|17 Years|No|||July 2015|July 29, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536275||90723|
NCT01536548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2544|Indicating Direction and Angle for Cannulating of AV-fistula in Hemodialysis Patients|Indicating Direction and Angle for Button-hole Cannulating of AV-fistula in Hemodialysis Patients - a Randomized Controlled Study||Norwegian University of Science and Technology|No|Completed|March 2012|July 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||July 2013|July 31, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536548||90702|
NCT01536535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01DK095745-01|Predicting Response to Standardized Pediatric Colitis Therapy|Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis.|PROTECT|Connecticut Children's Medical Center|Yes|Active, not recruiting|July 2012|June 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|467|||Both|4 Years|17 Years|No|||January 2016|January 27, 2016|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01536535||90703|
NCT01536873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114916|Dolutegravir Expanded Access Study|A GSK1349572 Open Label Protocol for HIV Infected, Adult Patients With Integrase Resistance|DEAP|ViiV Healthcare|No|Available|February 2012|||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||December 2011|February 21, 2012|February 16, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01536873||90677|
NCT01536886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 90100-35|Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris|A Clinical Trial Gathering Insight of Patient Reported Factors That Influence Preference Following Once Daily Topical Treatment With LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris||LEO Pharma|No|Completed|May 2012|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|376|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|February 16, 2012|Yes|Yes||No|November 2, 2015|https://clinicaltrials.gov/show/NCT01536886||90676|
NCT01537172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4053POE002|A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers|A Phase 1, Single Centre, Three-part, Randomised, Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Multiple Ascending Doses of Oral ONO-4053 and the Effects of Food in Healthy Males and Females||Ono Pharmaceutical Co. Ltd|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|December 7, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01537172||90654|
NCT01537406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCABreastIMRT|Long Term Outcomes of Breast Intensity-Modulated Radiation Therapy|Long Term Outcomes of A Multicentre Controlled Clinical Trial of Breast Irradiation Using Intensity-Modulated Radiation Therapy|BIMRT|British Columbia Cancer Agency|Yes|Enrolling by invitation|March 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|314|||Female|18 Years|N/A|No|Probability Sample|Breast cancer subjects treated in Toronto, Ontario, or in Victoria, British Columbia that        participated in The Canadian breast IMRT clinical trial between July 2003 to March 2005.|March 2012|March 7, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01537406||90636|
NCT01537705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012703|A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy|A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy|Neuron012703|Targeted Medical Pharma|No|Not yet recruiting|March 2012|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|75 Years|No|||February 2012|February 17, 2012|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537705||90613|
NCT01537965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 11 03|Evaluation of Innovative Ultrasonic Techniques for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Viral Hepatitis B or C||FIBRECHO|University Hospital, Grenoble|Yes|Completed|January 2012|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|96|||Both|18 Years|N/A|No|||February 2014|February 21, 2014|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01537965||90593|
NCT01538238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01-056|pazopanib_NCRCC,Ph2 STUDY|||Samsung Medical Center|No|Recruiting|December 2012|August 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|19 Years|N/A|No|||March 2014|March 5, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538238||90572|
NCT01538251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST261DM11005|Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis|Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment||sigma-tau i.f.r. S.p.A.|Yes|Terminated|April 2012|December 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|147|||Both|18 Years|75 Years|No|||April 2014|April 9, 2014|February 20, 2012||No|Evidence of very low probability to success. No safety issues.|No||https://clinicaltrials.gov/show/NCT01538251||90571|
NCT01538849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH4808-201|Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis|Randomized, Double-blind, Active-controlled, Multi-center Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis||Yuhan Corporation|No|Completed|December 2012|May 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|154|||Both|20 Years|N/A|No|||July 2014|July 8, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538849||90525|
NCT01538576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1942|Paediatric Subjects - Special Survey|Special Survey for Paediatric Subjects||Novo Nordisk A/S|No|Completed|December 2003|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|N/A|15 Years|No|Non-Probability Sample|Patients under 15 years of age with diabetes requiring insulin therapy with no treatment        history of insulin aspart (NovoRapid®)|March 2016|March 3, 2016|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538576||90546|
NCT01539135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVAIPR0235|The Influence of Endotracheal Tube Design on Fluid Leakage Into the Lungs During Surgery|The Influence of Endotracheal Tube Cuff Design on Intraoperative Microaspiration and Postoperative Respiratory Complications||Medtronic - MITG|No|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|February 6, 2012||No||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01539135||90503|This was a feasibility study and based on the results, we do not believe that a larger, multicenter randomized controlled trial would be appropriate. The study wasn’t powered to find any significant differences.
NCT01539421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-06-007|Use of Wii Home Computer in Patients With Chronic Obstructive Pulmonary Disease: Effects on Quality of Life|The Use of Home Exercise Program Based on Interactive Entertainment Computer System in Patients With Moderate to Severe COPD: Its Feasibility and Effects on Exercise Performance, Physical Activity, Dyspnea, and Quality of Life||Saint Francis Care|No|Completed|June 2010|October 2011|Actual|July 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|40 Years|90 Years|No|||February 2012|February 27, 2012|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539421||90481|
NCT01539733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/225|Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer|Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer||VU University Medical Center|No|Recruiting|March 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539733||90457|
NCT01527058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM002|68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients|Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-BNOTA-PRGD2 in Healthy Volunteers and Lung Cancer Patients|GRGDLC|Peking Union Medical College Hospital|Yes|Recruiting|December 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|30 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 1, 2014|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01527058||91423|
NCT01527370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-025|Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)|A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in India||Merck Sharp & Dohme Corp.|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|250|||Both|50 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|February 2, 2012|No|Yes||No|November 11, 2013|https://clinicaltrials.gov/show/NCT01527370||91400|
NCT01527617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB10178|Effect of Chronic Consumption of a Cranberry Beverage on Inflammation and Oxidative Stress|The Effect of Chronic Consumption of a Cranberry Beverage on Inflammation and Oxidative Stress in Healthy But Overweight/Obese Subjects: A Randomized Clinical Trial||Tufts University||Completed|February 2012|February 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 23, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01527617||91381|
NCT01527903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0311|A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit|Sedation of Surgical Patients in the Intensive Care Unit: A Randomized Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation|ICU|Yonsei University|Yes|Recruiting|September 2011|April 2012|Anticipated|March 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01527903||91359|
NCT01536288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 99-3114-B-182A-002|Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness|Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness.||Chang Gung Memorial Hospital|Yes|Completed|October 2010|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|125|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||November 2011|February 21, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536288||90722|
NCT01536561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104728|Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma|RIT-I-000/RIT-I-000A: Phase I Study of Radiolabeled Monoclonal Antibody Anti B1 for the Treatment of B Cell Lymphomas & RIT-I-000B: Extended Phase I/II Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma||GlaxoSmithKline|Yes|Completed|April 1990|October 2009|Actual|July 1997|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Both|18 Years|N/A|No|||February 2012|March 1, 2012|January 26, 2012|Yes|Yes||No|February 23, 2012|https://clinicaltrials.gov/show/NCT01536561||90701|
NCT01536574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114463|Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528|An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528||GlaxoSmithKline|No|Completed|September 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|295|||Both|30 Years|N/A|No|||October 2012|November 15, 2012|January 19, 2012|Yes|Yes||No|November 15, 2012|https://clinicaltrials.gov/show/NCT01536574||90700|
NCT01536899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC-1|Medical Marijuana Use in HIV+ Patients Prospective Cohort Study|Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients Prospective Cohort Study|MMC-1|Wayne State University|No|Active, not recruiting|February 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|70 Years|No|Non-Probability Sample|HIV positive and marijuana using volunteers|January 2016|January 25, 2016|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536899||90675|
NCT01537419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1304001985|Attachment Based Family Therapy for Suicidal Adolescents|Attachment Based Family Therapy (ABFT) for Suicidal Adolescents||Drexel University|Yes|Recruiting|March 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|12 Years|18 Years|No|||October 2015|October 28, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01537419||90635|
NCT01537718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBSY04|Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker|Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker|DREAM|LivaNova|No|Completed|March 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537718||90612|
NCT01537731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R08031M R09003|Vaginal or Laparoscopic Hysterectomy, Persistent Postsurgical Pain|Chronic Pain After Vaginal or Laparoscopic Hysterectomy for Benign Conditions||Tampere University Hospital|No|Completed|April 2009|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|225|||Female|18 Years|69 Years|No|Probability Sample|Women who undergo vaginal or laparoscopic hysterectomy for benign conditions.|October 2013|October 8, 2013|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01537731||90611|
NCT01537991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/VCC/0080|ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial|A Phase I/II Trial of Isotoxic Accelerated Radiotherapy in the Treatment of Patients With Non-small Cell Lung Cancer|I-START|Wales Cancer Trials Unit|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|121|||Both|16 Years|N/A|No|||February 2012|February 17, 2012|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537991||90591|
NCT01537978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18834|Use of Interactive Gaming for Enhanced Function After Spinal Cord Injury|Use of Interactive Gaming After Spinal Cord Injury||VA Palo Alto Health Care System|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 8, 2014|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537978||90592|
NCT01538550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCpilotNorway|Pilot Study of a National Screening Programme for Bowel Cancer in Norway|Colorectal Cancer Screening in Norway: Pilot Study of a National Screening Programme With Randomised Comparison of Different Screening Strategies to Provide the Best Possible Service to the Population||Norwegian Department of Health and Social Affairs|Yes|Enrolling by invitation|March 2012|December 2030|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|140000|||Both|50 Years|74 Years|No|||April 2015|April 13, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01538550||90548|
NCT01538563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 04-03|Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer|Phase I Dose Escalation Study of ON 01910.Na by 24 Hour Continuous Infusion Per Week in Patients With Advanced Cancer||Onconova Therapeutics, Inc.|No|Completed|June 2006|November 2011|Actual|July 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|February 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538563||90547|
NCT01538589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1943|Special Survey for Patients With Type 1 or Type 2 Diabetes|Special Survey for Type 1 or Type 2 Diabetic Patients||Novo Nordisk A/S|No|Completed|December 2003|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1582|||Both|N/A|N/A|No|Non-Probability Sample|Patients with diabetes requiring insulin therapy with no treatment history of insulin        aspart (NovoRapid®)|March 2016|March 3, 2016|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01538589||90545|
NCT01538602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPV_PCOS|Mean Platelet Volume and TXA2 Levels in Patients With Polycystic Ovary Syndrome (PCOS)|||AGUNCO Obstetrics and Gynecology Centre||Completed||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|||||Female|20 Years|35 Years||Non-Probability Sample|Volunteers|February 2012|February 23, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01538602||90544|
NCT01538862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICCNCPED1210|Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa|Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa||Vanderbilt University|No|Completed|February 2012|November 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|N/A|N/A|No|||December 2014|December 5, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538862||90524|
NCT01538875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-06|Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy|Hydralazine vs. Labetalol for the Management of Hypertensive Crisis in Patients With Hypertensive Disorders of Pregnancy. A Randomized Controlled Trial.||Saint Thomas Hospital, Panama|No|Completed|July 2012|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Female|N/A|N/A|No|||May 2013|May 16, 2013|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01538875||90523|
NCT01539148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.03.0010|A Five-Year Quality of Life Study for Cancer Patients|A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLDSM ) Chemotherapy and Nutrition Therapy in the Treatment of Cancer - The IPTLDSM QoL Broad Study|IPTLD|The Kotsanis Institute|No|Recruiting|March 2010|September 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will be from patients who have been diagnosed with stage 1-4 cancer        that have chosen to use IPTLD and nutritional therapy and have been referred by a        physician, word of mouth or through internet website inquiries.|May 2013|May 1, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01539148||90502|
NCT01539473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-105|A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge|A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge||Trius Therapeutics LLC|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|June 12, 2012|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539473||90477|
NCT01539434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOU-2012-MEKW|Behavioral Intervention to Maintain Physical Capacity and Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Behavioral Medicine Intervention to Maintain Physical Capacity and Level of Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)|COPD|Uppsala University|Yes|Recruiting|September 2010|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|80 Years|No|||February 2012|February 24, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01539434||90480|
NCT01527084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8760PG11|Timing of Surgical Intervention After Percutaneous Catheter Drainage in STEP UP Approach for Severe Acute Pancreatitis|Timing of Surgical Intervention After Percutaneous Catheter Drainage in STEP UP Approach for Severe Acute Pancreatitis: a Randomized Controlled Stud||Postgraduate Institute of Medical Education and Research|No|Completed|July 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|14 Years|85 Years|No|||November 2014|November 8, 2014|January 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01527084||91422|
NCT01527383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V212-009|A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)|A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease||Merck Sharp & Dohme Corp.|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|354|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527383||91399|
NCT01527630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1504|Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects|A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Testing the Bioequivalence of Two Formulations of NN-X14Mix50 in Healthy Japanese Subjects||Novo Nordisk A/S|No|Completed|November 2002|January 2003|Actual|January 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527630||91380|
NCT01528241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABP688A2102|Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)|A Multi-center, Open-label Study in Elderly Healthy Volunteers and Elderly Patients With Major Depressive Disorder to Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)||Novartis||Completed|August 2008|May 2010|Actual|May 2010|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|42|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528241||91333|
NCT01528774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.01.015|Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers|Culture and Characterization of Circulating Tumor Cells (CTC) From Patients With Malignant Melanoma and Other Cancers|CTC|Comprehensive Cancer Centers of Nevada|No|Active, not recruiting|February 2012|December 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|1000|Samples With DNA|Whole blood (up to 40 cc) collected in four 7.5 - 10 ml tubes. Serum samples may be stored      frozen in a coded, de-identified format until DNA or RNA is extracted for assays to allow      for batch processing. Samples will be consumed in the course of the research studies. Viable      tumor cells may be grown as long-term cell lines.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from patients receiving treatment for cancer at        Comprehensive Cancer Centers of Nevada. Healthy volunteers (family members of CCCN        patients or other volunteers) will also be accepted for study control purposes.|July 2015|July 18, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01528774||91293|
NCT01528787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-13324-CS201|Study of AR-13324 in Patients With Elevated Intraocular Pressure|A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of Three Doses of AR-13324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure||Aerie Pharmaceuticals|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|85|||Both|18 Years|N/A|No|||March 2014|March 17, 2014|February 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528787||91292|
NCT01536613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1883|Post Marketing Surveillance Study of Biphasic Insulin Aspart 30|NovoMix® 30 FlexPen, Post Marketing Surveillance Study||Novo Nordisk A/S|No|Completed|September 2004|February 2007|Actual|February 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5346|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with diabetes who did not have indications that are contraindicated in the        product insert|March 2016|March 3, 2016|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536613||90697|
NCT01536626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1925|Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands|SWITCH Mixtard® 30 NovoLet® to NovoMix® 30 FlexPen®. An Observational Study|SWITCH|Novo Nordisk A/S|No|Completed|June 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|211|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes treated with BHI 30 who have been by the physician for some        reason switched to BIAsp 30|February 2012|February 16, 2012|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536626||90696|
NCT01536912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMS-1|Medical Marijuana Use in HIV+ Patients: Probability Survey|Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients: Probability Survey|MMS|Wayne State University|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|218|||Both|18 Years|70 Years|No|Non-Probability Sample|HIV positive|July 2015|July 29, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536912||90674|
NCT01536587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114520|Effects of Salmeterol on Autonomic Nervous System|Effects of Bronchodilatation With Salmeterol on the Autonomic Nervous System|ESAN|GlaxoSmithKline|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|32|||Both|41 Years|79 Years|No|||March 2014|March 13, 2014|February 2, 2012||No||No|July 30, 2013|https://clinicaltrials.gov/show/NCT01536587||90699|
NCT01536925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHO-1|Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects|Biobehavioral Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects|YHO|Wayne State University|Yes|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|16|||Both|18 Years|55 Years|No|Non-Probability Sample|Heroin dependent research volunteers|January 2016|January 25, 2016|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536925||90673|
NCT01537185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC 002|Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults|A Phase 1 Randomized, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (SPWCV+Alum) in Healthy Adults||PATH|Yes|Completed|February 2012|April 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|42|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|May 6, 2014|February 7, 2012|No|Yes||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01537185||90653|
NCT01537198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-203|Surveillance of Synagis in Korean Pediatric Patients|Post-Marketing Surveillance of Synagis in Korean Pediatric Patients Under the "New Drug Re-Examination"||AbbVie|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|618|||Both|N/A|24 Months|No|Probability Sample|General hospital|June 2015|June 18, 2015|December 15, 2011||No||No|June 18, 2015|https://clinicaltrials.gov/show/NCT01537198||90652|
NCT01537432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2223|Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients|Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis||Novartis|No|Completed|January 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||November 2015|December 1, 2015|February 17, 2012|Yes|Yes||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01537432||90634|
NCT01537744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11102|A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma|Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liopsarcoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|February 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|February 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537744||90610|
NCT01537757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08535|A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])|An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535])||Merck Sharp & Dohme Corp.|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|12|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|February 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537757||90609|
NCT01538264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-P-000116|Blood Flow MRI for Monitoring Brain Tumors|Blood Flow MRI for Monitoring of Glioma Angiogenesis|Glioma|Beth Israel Deaconess Medical Center|No|Recruiting|June 2006|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|125|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects will be brain tumor patients recruited through the Brain Tumor Center at the        Beth Israel Deaconess Medical Center.|November 2015|November 13, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538264||90570|
NCT01538277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFC-PVAI|A Pilot Study of a Contact Force Catheter for Pulmonary Vein Antrum Isolation|A Pilot Study of a Contact Force Catheter for Pulmonary Vein Antrum Isolation (CFC-PVAI)|CFC-PVAI|University of Aarhus|No|Active, not recruiting|February 2012|March 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2012|September 11, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538277||90569|
NCT01538290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110166|Validating Non-invasive Measurements of Central Blood Pressure in Type 2 Diabetic Patients|Validating Non-invasive Measurements of Central Blood Pressure in Type 2 Diabetic|IMPRESS|University of Aarhus|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with type 2 diabetes mellitus referred to elective coronary angiography.|June 2012|June 11, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538290||90568|
NCT01537783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED Staph Eradication|Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess|A Randomized Trial to Evaluate a Staphylococcus Eradication Protocol for Patients Who Present to the Emergency Department With Cutaneous Abscess||Tufts Medical Center|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537783||90607|
NCT01538628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGX-11-001-US|SpaceOAR System Pivotal Study|Evaluation of SpaceOAR™ System When Used to Create Space Between the Rectum and Prostate in Men Undergoing IG-IMRT for Localized Stage T1-T2 Prostate Cancer: A Randomized, Multicenter, Parallel Arm Controlled Clinical Study||Augmenix, Inc.|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|222|||Male|18 Years|N/A|No|||November 2014|November 21, 2014|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538628||90542|
NCT01539798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|valente_crossover|Body Composition and Serum Biochemistry After Intravenous Infusion or Oral Intake of Saline in Healthy Volunteers|Changes in Body Composition, Hematological Parameters, and Serum Biochemistry and After Rapid Intravenous Infusion or Oral Intake of 2L of 0.9% Saline Solution in Young Healthy Volunteers. A Randomized Cross-over Study||Federal University of Mato Grosso do Sul|Yes|Completed|August 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|10|||Male|18 Years|26 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01539798||90452|
NCT01535859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNMRCNIG1031|Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers|A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS.||KK Women's and Children's Hospital|Yes|Active, not recruiting|April 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|540|||Female|21 Years|45 Years|No|||September 2015|September 3, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01535859||90755|
NCT01527643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1576|Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects|Single-Centre, Randomised, Balanced, Double- Blind, Cross-Over Trial Investigating the Bioequivalence of Formulation 2 and Formulation 4 of Biphasic Insulin Aspart 50 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|November 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527643||91379|
NCT01527916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-985|Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease||AbbVie|Yes|Completed|February 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|438|||Both|55 Years|90 Years|No|||November 2014|November 6, 2014|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527916||91358|
NCT01527929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP12251|Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment|An Open-label Pharmacokinetic and Safety Study of Cabazitaxel in Patients With Solid Tumors With Moderately and Severely Impaired and With Normal Renal Function||Sanofi|No|Completed|April 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527929||91357|
NCT01528228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENS Study #110518-001|Effects of TENS Therapy Following Arthroscopic Knee Surgery|Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Postoperative Pain and Function Following Arthroscopic Knee Surgery: A Prospective Randomized Clinical Trial Pilot Study|TENS|A.T. Still University of Health Sciences|No|Enrolling by invitation|July 2011|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Both|18 Years|60 Years|No|||July 2011|February 8, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528228||91334|
NCT01528540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-PAN-2012-1|Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a Randomized Control Trial|Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a RCT||Asian Institute of Gastroenterology, India|Yes|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|65 Years|No|||September 2015|September 8, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01528540||91311|
NCT01528553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEK 20080179|Stapling Versus 8plate for Correction of Genu Valgus|Stapling Versus 8plate for Correction of Genu Valgus. A Randomised Clinical Study||University of Aarhus|No|Active, not recruiting|August 2009|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|20|||Both|8 Years|15 Years|No|||February 2012|February 3, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01528553||91310|
NCT01528800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iPACKHD|Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients|Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialyis Patients: iPACKHD Study|iPACKHD|Clinical Evaluation Research Unit at Kingston General Hospital|No|Recruiting|November 2012|November 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2014|October 20, 2014|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01528800||91291|
NCT01536327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMLE11/2011|Biomarker for Metachromatic Leukodystrophy Disease|Biomarker for Metachromatic Leukodystrophy Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|BioMeta|University of Rostock|Yes|Recruiting|September 2011|October 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA      blood, sputum tube and a dry blood spot filter card are taken. To proof the correct      diagnosis in those patients where up to the enrollment in the study no genetic testing has      been done, sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute      for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)|Both|N/A|N/A|No|Probability Sample|Patients with a diagnosis of Metachromatic Leukodystrophy disease or profound suspicion        for Metachromatic Leukodystrophy disease|February 2016|February 26, 2016|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01536327||90719|
NCT01536639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1929|Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes|Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|January 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|454|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with type 2 diabetes in whom at the discretion of the investigator it was decided        to change insulin regimen to biphasic insulin aspart 30|February 2012|February 16, 2012|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536639||90695|
NCT01536938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 90100-7|LEO 90100 in the Treatment of Psoriasis Vulgaris|||LEO Pharma|No|Completed|May 2012|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|303|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|February 16, 2012|Yes|Yes||No|November 2, 2015|https://clinicaltrials.gov/show/NCT01536938||90672|
NCT01536652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1932|Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes|Prandial Oriented NovoMix 30® - the Physiological Insulin Therapy of Diabetes Type 2|ProMix|Novo Nordisk A/S|No|Completed|January 2006|November 2006|Actual|November 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4994|||Both|N/A|N/A|No|Non-Probability Sample|Any patient with diabetes mellitus type 2, using insulin glargine in combination with one        or more OADs, being in inadequate glycaemic control and are indicated to receive biphasic        insulin aspart 30|March 2016|March 3, 2016|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536652||90694|
NCT01536951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14448|A Study of LY3009104 in Healthy Volunteers|A Placebo-Controlled, Single Dose, Dose Escalation (Part A) and a Placebo- and Positive-Controlled Study of the Effect on the Electrocardiographic QT Interval of a Single Dose (Part B) of LY3009104 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|69|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 8, 2013|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536951||90671|
NCT01538303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL-3793806011|Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome|Microvascular Dysfunction in AMI and Its Relation to Outcome||Catharina Ziekenhuis Eindhoven|No|Recruiting|March 2012|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|75 Years|No|Non-Probability Sample|The study population consists of patients with STEMI either in our own hospital either        referred by other hospitals or the ambulance.|July 2012|July 9, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538303||90567|
NCT01539447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48961|Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy|Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy||University of Utah|Yes|Active, not recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|342|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01539447||90479|
NCT01539460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDH0369|A Minimally Invasive Surgery for Axillary Osmidrosis: Combined Liposuction With Subcutaneous Pruning|A Refined Minimally Invasive Procedure for Radical Treatment of Axillary Osmidrosis: Combined Tumescent Liposuction With Subcutaneous Pruning Through a Small Incision||Tang-Du Hospital|No|Enrolling by invitation|February 2012|December 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||November 2015|November 10, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01539460||90478|
NCT01536093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAC-01-ELGAN|Oropharyngeal Administration of Colostrum to Extremely Low Gestational Age Newborns|||Seoul National University Hospital|Yes|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|N/A|96 Hours|Accepts Healthy Volunteers|||August 2014|August 11, 2014|January 6, 2012||No||No|July 17, 2014|https://clinicaltrials.gov/show/NCT01536093||90737|
NCT01538004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0217|Where Should Automated Blood Pressures be Done in Primary Care Offices?|Where Should Automated Blood Pressures be Done? RCT of BpTRU Measurement in Private or Non-private Areas of Primary Care Offices||North Toronto Primary Care Research Network|No|Withdrawn|March 2014|November 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive consenting patients age eighteen or over will be recruited from the waiting        rooms of participating practices in Toronto, Ontario|April 2014|April 2, 2014|February 17, 2012||No|Not funded|No||https://clinicaltrials.gov/show/NCT01538004||90590|
NCT01536977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMT242|Phase II Early Behavioral Intervention in BMT w/ Sleep Disturbance-Assess QOL+Fatigue+Cognitive f(x)|Early Behavioral Intervention in BMT Recipients With Sleep Disturbance: Assessing Its Impact on Quality of Life, Fatigue and Cognitive Function||Stanford University|Yes|Completed|March 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|29|||Both|21 Years|N/A|No|||May 2014|May 29, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536977||90669|
NCT01538316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEM 21 AII|Prostate Cancer Prevention Trial With Quercetin and Genistein|Clinical Trial on the Effectiveness of the Flavonoids Genistein and Quercetin in Men With Rising Prostate-specific Antigen|QUERGEN|University of Hohenheim|No|Recruiting|March 2012|April 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Male|18 Years|65 Years|No|||May 2012|May 13, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538316||90566|
NCT01539174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OER-HM-039|Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma|A Phase II Study of Rituximab Intense Dosing With CHOP-21 (RID-CHOP) in Patients With Previously Untreated High or High-Intermediate Risk IPI (3-5) Diffuse Large B-Cell Lymphoma (DLBCL)||Fox Chase Cancer Center|Yes|Withdrawn||||||Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|February 15, 2012|Yes|Yes|No Funding Source and Competing Trials|No||https://clinicaltrials.gov/show/NCT01539174||90500|
NCT01535560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-019|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa||Alcon Research|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|589|||Both|6 Months|N/A|No|||October 2013|October 18, 2013|February 15, 2012|Yes|Yes||No|October 18, 2013|https://clinicaltrials.gov/show/NCT01535560||90778|
NCT01535846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF 2010-215|Awakening to the Taste of Food Among Restrained Women|Awakening to the Taste of Food: What Are the Effects on Cognitions and Behaviors About Food and Eating Among Restrained Women?|Flaveur|Laval University|No|Completed|January 2011|December 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Female|25 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 24, 2013|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01535846||90756|
NCT01536717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004307-20|Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery|Comparison of Periosteal and Subcutaneous Infusions of Articaine and Bupivacaine in Treatment of Acute Pain After Sternotomy||Helsinki University Central Hospital|No|Recruiting|March 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2015|May 31, 2015|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01536717||90689|
NCT01536990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-002770|Sensitivity to Change of the Lower Extremity Functional Scale in Patients With Stroke|Sensitivity to Change of the Lower Extremity Functional Scale and a Single-Item Functional Assessment Tool in Patients With Neurological Impairments Secondary to Stroke||Mayo Clinic|No|Completed|May 2007|January 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|39|||Both|18 Years|N/A|No|Non-Probability Sample|Medically stable patients receiving inpatient or outpatient physical therapy care for        lower extremity dysfunction due to stroke.|February 2012|February 21, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536990||90668|
NCT01527942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01-003|Intravenous Acetaminophen Use With Bariatric Surgery on Morbidly Obese Patients|Effect of Intravenous Acetaminophen on Postoperative Pain of Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery: A Randomized, Placebo-Controlled Trial||Saint Francis Care|Yes|Terminated|March 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|34|||Both|20 Years|70 Years|No|||March 2014|November 13, 2015|February 2, 2012|Yes|Yes|Study Terminated per Principal Investigator's request|No|March 17, 2015|https://clinicaltrials.gov/show/NCT01527942||91356|
NCT01527955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Project#081197|Kelee® Meditation: A Distinctive and Effective Therapeutic Intervention for Stress, Anxiety, and Depression|Troubleshooting the Mind Through Kelee® Meditation: A Distinctive and Effective Therapeutic Intervention for Stress, Anxiety, and Depression||University of California, San Diego|No|Completed|September 2008|June 2011|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|65 Years|No|||February 2012|February 6, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01527955||91355|
NCT01528254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23156|VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus|A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin & Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus||Novartis||Active, not recruiting|March 2012|April 2019|Anticipated|April 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2005|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528254||91332|
NCT01528566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NR01003|Effect of Tai Chi on Osteoarthritic Knee Pain in Elders With Mild Dementia|Effect of Tai Chi on Osteoarthritic Knee Pain in Elders With Mild Dementia||University of Arkansas|No|Completed|January 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|55|||Both|60 Years|N/A|No|||February 2012|February 3, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01528566||91309|
NCT01529112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-703|A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens||Eisai Inc.|Yes|Active, not recruiting|November 2011|||October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|January 6, 2012|Yes|Yes||No|February 17, 2016|https://clinicaltrials.gov/show/NCT01529112||91267|
NCT01529398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABG MASTER|Sensorimotor Training Versus Resistance Training in Patients With Knee Osteoarthritis|Efficacy of a Sensorimotor Training in Patients With Knee Osteoarthritis: a Randomized Clinical Trial||Federal University of São Paulo|Yes|Completed|March 2008|August 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|96|||Both|50 Years|75 Years|No|||February 2012|February 8, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529398||91245|
NCT01536392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1107|Oral Versus Transdermal Ondansetron for Women With Cervical Cancer Receiving Chemoradiation|Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical Cancer Receiving Chemoradiation||M.D. Anderson Cancer Center|No|Recruiting|March 2012|||March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01536392||90714|
NCT01536405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V221-027|Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)|A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)||Merck Sharp & Dohme Corp.|No|Completed|June 2012|January 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1412|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||May 2015|May 12, 2015|February 16, 2012|Yes|Yes||No|May 30, 2014|https://clinicaltrials.gov/show/NCT01536405||90713|
NCT01537211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00042823|Functional Outcomes in Dysvascular Transfemoral Amputees|Microprocessor Knee Versus Mechanical Knee: Impact on Functional Outcomes in Dysvascular Transfemoral Amputees|CLEG|Rehabilitation Institute of Chicago|No|Active, not recruiting|August 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 7, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01537211||90651|
NCT01539161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reveal Chagas|Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease|Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease||Medtronic Cardiac Rhythm Disease Management|No|Recruiting|July 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|102|||Both|21 Years|N/A|No|||December 2013|December 3, 2013|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01539161||90501|
NCT01535547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0021|Drug Interaction Study of Isavuconazole and Tacrolimus|Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Tacrolimus: A Phase 1, Open Label, Sequential Study in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|December 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01535547||90779|
NCT01536691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROAD|Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone|To Assess the Efficacy and Safety of Ramosetron, Aprepitant and Dexamethasone Therapy vs Ondansetron, Aprepitant and Dexamethasone Therapy for Preventing of Nausea and Vomiting in Highly Emetogenic Chemotherapy (ROAD Study)|ROAD|Hallym University Medical Center|Yes|Recruiting|June 2011|February 2013|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|338|||Both|20 Years|N/A|No|||February 2012|October 2, 2012|October 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01536691||90691|
NCT01537471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028299|The Effects of Antihistamines on Pre-Pulse Inhibition|A Pilot Study of the Effects of Meclizine on Pre-Pulse Inhibition|PPI|Duke University|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|February 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01537471||90631|
NCT01537484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032894|Exploring Massage Benefits for Arthritis of the Knee|Multisite RCT Investigating the Efficacy of Massage in Osteoarthritis|EMBARK|Duke University|Yes|Completed|June 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|222|||Both|35 Years|N/A|No|||August 2015|August 3, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01537484||90630|
NCT01538901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPDTAKOTR/V06/28.12.11|Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients|Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients|AKtransplant|Medical University of Vienna|Yes|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|34|||Both|18 Years|80 Years|No|||September 2012|September 6, 2012|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538901||90521|
NCT01539811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015080|Diabetic Foot Infection Antibiotic Study|Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics||Greenville Health System|No|Terminated|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|February 22, 2012||No|Principal investigator decided to terminate the study.|No|April 13, 2015|https://clinicaltrials.gov/show/NCT01539811||90451|
NCT01536379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114424|A Study of Belimumab in the Prevention of Kidney Transplant Rejection|BEL114424: A Phase 2 Pilot, Multicentered, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in the Prevention of Allograft Rejection in Adult Subjects After Renal Transplantation||GlaxoSmithKline|No|Completed|September 2013|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||February 2016|March 3, 2016|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536379||90715|
NCT01536704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S6491365|Nicotine Lozenge Bioequivalence Study|A Single Dose Bioequivalence Study of 2 Different Doses of Mini Cherry Nicotine Lozenges||GlaxoSmithKline|No|Completed|July 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|50|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|December 15, 2011|No|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT01536704||90690|
NCT01537796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11120127|Comparison of a Technology-based System and an In-person Behavioral Weight Loss Intervention in the Severely Obese|Comparison of a Technology-based System and an In-person Behavioral Weight Loss Intervention in the Severely Obese||University of Pittsburgh|No|Completed|February 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01537796||90606|
NCT01538056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39611-B|Physician Modified Endovascular Grafts|Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysm: An Investigator Initiated Study|PMEG|University of Washington|Yes|Recruiting|March 2011|January 2022|Anticipated|January 2020|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|February 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538056||90586|
NCT01528579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeolssonAWADlong-term|Effects of Different Exercise Programs for People With Chronic Whiplash Associated Disorders|Effects of Different Exercise Programs for People With Chronic Whiplash Associated Disorders: a Prospective Randomized Study||Linkoeping University|Yes|Completed|March 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|63 Years|No|||March 2016|March 6, 2016|January 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01528579||91308|
NCT01528813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUB-UnB OnychoLASER|Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis|AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE||Brasilia University Hospital|No|Recruiting|February 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|19 Years|60 Years|No|||August 2013|August 5, 2013|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01528813||91290|
NCT01529099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT10/01|Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM|A Prospective, Non-comparative, Single Centre Study to Determine the Performance & Survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM.||DePuy International|No|Completed|November 2011|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|21 Years|N/A|No|||June 2015|June 5, 2015|December 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01529099||91268|
NCT01529125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTMAM|Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV|ART Pharmacokinetics, Mitochondrial Integrity, and Antioxidant Capacity in Severely Malnourished HIV-infected Malawian Children|ARMAM|Washington University School of Medicine|No|Completed|July 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|42|||Both|6 Months|59 Months|No|Non-Probability Sample|Children aged 6-59 months with HIV and kwashiorkor and marasmus who are not currently on        HAART will be recruited from the Nutritional Rehabilitation Unit at Queen Elizabeth        Central Hospital in Blantyre, Malawi. Controls will be recruited from the outpatient        cotrimoxazole clinic who are about to start on HAART for a non-nutritional reason.|January 2014|January 22, 2014|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01529125||91266|
NCT01529411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOGUG2011/02|Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer|Randomized Phase II Study of Vinflunine as Maintenance Monotherapy in Patients With Advanced or Metastatic Urothelial Cancer That Obtains Clinical Benefit of the First Line With Cisplatin-gemcitabine Combination|MAJA|Spanish Oncology Genito-Urinary Group|No|Completed|February 2012|December 2014|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|80 Years|No|||February 2012|December 17, 2014|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01529411||91244|
NCT01529658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-767; CIHR MOP 269009|Renal Hypothermia During Partial Nephrectomy|A Randomized Controlled Trial of Renal Hypothermia During Partial Nephrectomy||Ottawa Hospital Research Institute|Yes|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529658||91225|
NCT01536106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPRX/POC/BMSC/AMIRST/1.0|Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients.|Intracoronary Infusion of Concentrated Autologous Bone Marrow Mononuclear Cells in Acute Myocardial Infarction Patients Utilizing a Novel Point-of-Care Device for Rapid-Delivery of Stem Cells (AMIRST)|AMIRST|TotipotentRX Cell Therapy Pvt. Ltd.|Yes|Not yet recruiting|December 2013|March 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|July 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01536106||90736|
NCT01536119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27286|Evaluating a Coparenting Breastfeeding Support Intervention|Evaluating the Effectiveness of a Coparenting Breastfeeding Support Intervention on Exclusive Breastfeeding Rates at 12 Weeks Postpartum|COSI|University of Toronto|No|Completed|February 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|428|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 18, 2013|February 15, 2012||No||No|July 4, 2013|https://clinicaltrials.gov/show/NCT01536119||90735|
NCT01536964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16207|The Effect of Morphine on Prasugrel Absorption in STEMI Patients|||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|April 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|12|||Both|18 Years|75 Years|No|||February 2013|April 2, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536964||90670|
NCT01537770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024050-10|Vertebroplasty Compared With a Sham-procedure for Painful Acute Osteoporotic Vertebral Fractures|Prospective, Randomized Study for Comparison of Percutaneous Vertebroplasty Opposite - Infiltration of the Periost and Vertebral Body With Lidocaine - as Pain Palliative Treatment of Osteoporotic Vertebral Fractures of the Thoracic and Lumbar Spine|VOPE|Sygehus Lillebaelt|Yes|Completed|February 2012|April 2015|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|50 Years|N/A|No|||October 2014|September 10, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01537770||90608|
NCT01538030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHST2012-03|Perinatal Outcome After Premature Rupture of Membranes|Perinatal Outcomes According to Amniotic Fluid Indez After Premature Rupture of Membranes. A Prospective Cohort Study.||Saint Thomas Hospital, Panama|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|80|||Female|N/A|N/A|No|Non-Probability Sample|Pregnant patients between 24-34 weeks of gestation with a confirmed diagnosis of premature        rupture of membranes.|August 2012|August 13, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01538030||90588|
NCT01538615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20521|Healthy Home Offerings Via the Mealtime Environment (HOME) Plus|Healthy Home Offerings Via the Mealtime Environment (HOME) Plus||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|July 2010|June 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|380|||Both|8 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 13, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01538615||90543|
NCT01539772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITT0112|Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping|PITT0112: Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping||Cooperative International Neuromuscular Research Group|Yes|Recruiting|April 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Male|4 Years|N/A|No|Non-Probability Sample|BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.|December 2015|December 16, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539772||90454|
NCT01539785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|138/12|Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence|Surgery Plus Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Versus Surgery Alone in Patients With Platinum-sensitive First Recurrence of Ovarian Cancer: a Prospective Randomized Multicenter Trial.|HORSE|Catholic University of the Sacred Heart|Yes|Recruiting|September 2012|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Anticipated|158|||Female|18 Years|70 Years|No|||August 2014|August 21, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01539785||90453|
NCT01536340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS018694|Identifying Adverse Events After Discharge From a Community Hospital|Identifying Adverse Events After Discharge From a Community Hospital||Florida State University|No|Completed|September 2011|October 2014|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|684|||Both|21 Years|N/A|No|Non-Probability Sample|Our study population includes patients 21 and older living in Florida, who are discharged        home from the TMH hospitalist service. Patients must have a phone number where they can be        reached. They must also speak English or Spanish. Surrogates are permitted to complete an        interview in the event that a patient is unable to complete it.        Rural patients are those who live in counties where the population density is 100 people        per square mile or less. Patients with diminished mental capacity are at increased risk of        adverse events. These patients (or their surrogates) are included in the sample.|May 2015|May 22, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01536340||90718|
NCT01536353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110-AGSAV-P1|Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301|A Single Dose, Randomized, Open-label, 2x2 Crossover Study to Evaluate the Bioavailability and Safety of AGSAV301 Tablet in Healthy Male Volunteers||Ahn-Gook Pharmaceuticals Co.,Ltd||Completed|January 2012|August 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||February 2012|November 24, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01536353||90717|
NCT01536366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-115|Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide|Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|June 2009|January 2011|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 23, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01536366||90716|
NCT01537224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00392-39|Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information|Study of the Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information in Patients With Parkinson's Disease|EMOPHYSIO|Rennes University Hospital||Recruiting|September 2011|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|25|||Both|18 Years|N/A|No|||November 2012|November 30, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01537224||90650|
NCT01538043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAC2010|Spa Therapy in Knee Osteoarthritis: Study on Cost/Effectiveness - Cost/Utility and Possible Mechanisms of Action|Spa Therapy in Knee Osteoarthritis: Study on Cost/Effectiveness - Cost/Utility and Possible Mechanisms of Action||University of Siena|Yes|Completed|December 2010|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|75 Years|No|||July 2014|July 1, 2014|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01538043||90587|
NCT01537523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-001|To Investigate the Effect of Early Community-care Program on Fracture Hip Patient|To Investigate the Effect of Early Community-care Program on Physical and Depressive Aspects for Discharged Hospital Patient Suffered From Hip Fracture.||Hong Kong Healthcare Volunteer Organization|No|Not yet recruiting|February 2012|April 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|N/A|N/A|No|||February 2012|February 17, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01537523||90627|
NCT01537809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103016|Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors [The Daily D Health Study]|The Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors in Schoolchildren||Tufts University|Yes|Completed|June 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|691|||Both|9 Years|14 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01537809||90605|
NCT01538069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1226/11|Heart Failure and Sleep Apnea: Exercise Training and Continuous Positive Airway Pressure|Comparison Between Exercise Training and CPAP Treatment for Patients With Heart Failure and Sleep Apnea.|CPAP|Associação Fundo de Incentivo à Pesquisa|Yes|Recruiting|March 2012|October 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|20 Years|70 Years|No|||August 2013|August 6, 2013|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01538069||90585|
NCT01538355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGEL|A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis|A Randomised Controlled Pilot Study to Compare the Effects of Prolonged Fasting and Ketogenic Low Glycemic Load Treatment on Health Related Quality of Life in Relapsing-remitting Multiple Sclerosis.|IGEL|Charite University, Berlin, Germany|No|Completed|December 2011|January 2015|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|68 Years|No|||February 2015|February 15, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01538355||90563|
NCT01528592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ruby-60029592|PharmacoMRI of Parkinson Disease|A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease||Northwestern University|No|Completed|June 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|18|||Both|30 Years|N/A|No|||November 2013|November 6, 2013|January 31, 2012||No||No|November 6, 2013|https://clinicaltrials.gov/show/NCT01528592||91307|
NCT01528826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVBOX|Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial|A Prospective Phase II Trial of Vinorelbine Plus Oxaliplatin in Pretreated Metastatic Triple-negative Breast Cancer|NVBOX|Fudan University|No|Recruiting|December 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Female|18 Years|70 Years|No|||February 2012|February 7, 2012|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01528826||91289|
NCT01529138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048705|Study of Axitinib and Temsirolimus in Solid Tumors|Phase I Study of Axitinib and Temsirolimus in Solid Tumors||Emory University|Yes|Completed|October 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|November 14, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01529138||91265|
NCT01529151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/IRB/033|Effectiveness of Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT) in Individuals With Vertigo|Effectiveness of Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT) Alone or in Combination on Balance and Visual Function in Individuals With Vertigo and Somatic Dysfunction||Western University of Health Sciences|Yes|Completed|January 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Actual|26|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||June 2015|June 8, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01529151||91264|
NCT01529684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSI-906-104|A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism, and Excretion of 14C-OSI-906 in Subjects With Advanced Solid Tumors With an Optional Treatment Phase||Astellas Pharma Inc|No|Completed|January 2012|February 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|February 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529684||91223|
NCT01529970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-252|Genetic Study in Young Onset Parkinson's Disease|||China Medical University Hospital||Active, not recruiting|January 2012|||||N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|20 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|patients from China Medical University Hospital|February 2012|February 8, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01529970||91201|
NCT01530204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH090333 Sub-Project ID: 8317|RAPID: Reducing Pain; Preventing Depression|RAPID: Reducing Pain; Preventing Depression|RAPID|University of Pittsburgh|Yes|Active, not recruiting|July 2011|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|135|||Both|60 Years|N/A|No|||January 2016|January 5, 2016|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01530204||91183|
NCT01530490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEIC0754|Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention|Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch||Hospital de Cruces|Yes|Completed|August 2007|September 2010|Actual|August 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||February 2012|February 9, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01530490||91161|
NCT01536665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9211-3953|The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes|The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|64 Years|No|||August 2012|August 21, 2012|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01536665||90693|
NCT01536678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116526|Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers|Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers: A Single-dose, Randomized, Open-label, Crossover Study||GlaxoSmithKline|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|February 7, 2013|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01536678||90692|
NCT01538017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110233|Injectable Collagenase and Percutaneous Needle Fasciotomy for Dupuytren's Contracture|Comparing Injectable Collagenase (CI) and Percutaneous Needle Fasciotomy (PNF) for Dupuytren's Contracture (DC) Affecting Proximal Interphalangeal Joints (PIP). A Randomised Controlled Trial||Regionshospitalet Silkeborg|No|Active, not recruiting|February 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|99 Years|No|||October 2015|October 27, 2015|February 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01538017||90589|
NCT01538888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQ1|Effects Whole Body Vibration in Ergospirometrics Parameters and Quality of Life|Effects Whole Body Vibration in Ergospirometrics Parameters, Strength And Quality of Life: A Randomised Controlled Trial|EWBVEPQL|Universidade Federal de Pernambuco|Yes|Completed|February 2011|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|35|||Both|60 Years|74 Years|Accepts Healthy Volunteers|||February 2012|February 18, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01538888||90522|
NCT01535300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S234/2010|Ultrasound and Paediatric Endotracheal Tube Size|Role of Ultrasound Compared to Age-related Formulas for Uncuffed Endotracheal Intubation in a Paediatric Population||Heidelberg University|No|Completed|August 2010|October 2010|Actual|October 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|5 Years|No|Non-Probability Sample|Children <= 5 years of age scheduled for elective surgery|February 2012|February 14, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01535300||90798|
NCT01531166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0461|A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon|An Observational, Multi-Center, Cohort Study Evaluating the Antiviral Efficacy, Safety, and Tolerability in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon-alpha 2a (Pegasys®): TRACES STUDY||Yonsei University|Yes|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|65 Years|No|Probability Sample|HBeAg-positive and HBeAg-negative chronic hepatitis B patients who have completed or are        currently on Pegasys® monotherapy as a first line therapy. In addition, all consecutive        CHB patients who will be initiated on Pegasys® in 2011 will be prospectively enrolled.|February 2012|February 22, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01531166||91110|
NCT01535820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100412|The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women|A Bioequivalence Study to Evaluate the Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 19, 2013|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01535820||90758|
NCT01535833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KP IRB 20111224|Robotic Assisted Sacral Colpopexy : A Prospective Study Assessing Outcomes With Learning Curves|Robotic Assisted Sacral Colpopexy : A Prospective Study Assessing Subjective and Objective Outcomes With Learning Curves in the Development of a New Pelvic Floor Robotics Program||Kaiser Permanente|Yes|Recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01535833||90757|
NCT01531751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-005-IT|High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease|An Open Label Phase II Trial of Free Light Chain Removal by Extended High Cut-Off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End-Stage Renal Disease.|DIACAL|IRCCS Policlinico S. Matteo|Yes|Suspended|February 2015|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Female|18 Years|N/A|No|||September 2015|September 1, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01531751||91066|
NCT01532037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-MS-NHS-1|Self Help for Fatigue in Multiple Sclerosis|A Randomised Controlled Trial of Cognitive Behavioural Therapy Based Self Help for Fatigue in Multiple Sclerosis||University of Edinburgh|Yes|Recruiting|June 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|65 Years|No|||June 2012|June 20, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01532037||91044|
NCT01536743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003234|A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression|A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression||Jonsson Comprehensive Cancer Center|Yes|Recruiting|December 2011|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||February 2016|February 16, 2016|December 1, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01536743||90687|
NCT01537016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWM1215|WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test on DFU|WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test A Prospective, Multi Centre, Randomised, Clinical Study on Diabetic Foot Ulcers||Systagenix Wound Management|No|Recruiting|July 2013|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|July 4, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01537016||90666|
NCT01537263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2371|Ultrasound Perfusion Imaging After Aneurysmal Subarachnoid Hemorrhage|Ultrasound Perfusion Imaging After Aneurysmal Subarachnoid Hemorrhage|PSAB|Asklepios Kliniken Hamburg GmbH|No|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic|April 2012|April 5, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01537263||90647|
NCT01537536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJBNeoEndoTAG-1|Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer|An Open-label Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in Patients With HER2-negative Breast Cancer|EndoTAG-1|Jules Bordet Institute|No|Completed|November 2011|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||February 2012|June 14, 2013|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01537536||90626|
NCT01537822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/679|The Hysteroscopic Morcellator (HM).|The Hysteroscopic Morcellator Versus the Bipolar Resectoscope for Removal of Lager Intrauterine Polyps, Removal of Submucous Myomas and Removal of Residual Placental Tissue: a Randomized Controlled Trial.|HM|University Hospital, Ghent|No|Recruiting|May 2011|September 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|222|||Female|18 Years|N/A|No|||December 2014|December 4, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01537822||90604|
NCT01537835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-5-15504|Bacterial Contamination of Healthcare Worker Uniforms|Bacterial Contamination of Healthcare Worker Uniforms: A Study of Antimicrobial Uniforms on Occupationally Acquired Bacterial Contamination: A Randomized Controlled Trial||Denver Health and Hospital Authority|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|109|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2015|February 9, 2015|February 17, 2012||No||No|December 17, 2014|https://clinicaltrials.gov/show/NCT01537835||90603|
NCT01538082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7Z08/002|Role of the Stress in the Development of the Metabolic Syndrome|Role of Anxiety, Depression, Quality of Life and Stressful Vital Events in the Development of the Metabolic Syndrome. StreX Project.|STREX|Jordi Gol i Gurina Foundation|No|Recruiting|December 2008|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|738|||Both|40 Years|N/A|No|Probability Sample|Aleatory sample of subjects with high risk ( 1 or 2 criteria NCEP-ATPIII ) to develop        Metabolic Syndrome, elderly than 40 years and attended in Primary Care in the last year.        This sample will be provided by the Information's Technology in Primary Care Services.|February 2012|February 19, 2012|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01538082||90584|
NCT01538368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWehrmann|Magnetic Resonance Cholangio-pancreatography (MRCP) for Suspected Bilio-pancreatic Disease|Magnetic Resonance Cholangio-pancreatography (MRCP) for Suspected Bilio-pancreatic Disease: Should the Endoscopist Take a Second Look?||Deutsche Klinik fuer Diagnostik|No|Completed|January 2007|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|155|||Both|18 Years|N/A|No|Non-Probability Sample|During 1/2007 until 12/2009 consecutive patients who were referred for dedicated        endoscopic procedures regarding suspected alterations of the pancreato-biliary ductal        system (nearly exclusively for EUS and/or ERCP) to our unit based on actual MRCP-findings        were enrolled.|February 2012|February 23, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01538368||90562|
NCT01539265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMD3201|A Dose-finding Study of Silodosin in Patients With Urinary Calculi|A Randomized, Double-blind, Placebo-controlled, Phase II Study of Silodosin in Patients With Urinary Calculi||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3|||300|||Both|20 Years|N/A|No|||October 2013|October 29, 2013|February 21, 2012||||No||https://clinicaltrials.gov/show/NCT01539265||90493|
NCT01529164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-023|Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer|Phase II Study of Recombinant Endostatin Combined With Modified FOLFOX6 in Advanced Colorectal Cancer||Chinese Academy of Medical Sciences|No|Recruiting|October 2011|September 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01529164||91263|
NCT01529424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 304801-CS2|Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia||Ionis Pharmaceuticals, Inc.|No|Active, not recruiting|February 2012|March 2014|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|102|||Both|18 Years|N/A|No|||January 2014|January 31, 2014|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529424||91243|
NCT01529671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291011|A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee|An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of Pf-05089771 In Healthy Subjects And In Subjects With Osteoarthritis Of The Knee||Pfizer|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|80|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529671||91224|
NCT01530217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17836/2010|Assessing of Tooth Sensitivity Using Ibuprofen Before in Office-tooth Bleaching|Assessing of Tooth Sensitivity Using Ibuprofen Before in Office-tooth Bleaching: a Randomized, Triple-blind Clinical Trial||Universidade Estadual de Ponta Grossa|Yes|Completed|March 2011|May 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||February 2012|February 8, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01530217||91182|
NCT01526382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZH-01|Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory Distress Syndrome|Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory|PiCCO|Jinhua Central Hospital||Completed|January 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|80 Years|No|||September 2012|April 30, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01526382||91474|
NCT01537445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MERFAP-2012|MR-Evaluation of Renal Function-After-Pancreas-transplantation|MR-Evaluation of Renal Function-After-Pancreas-transplantation|MERFAP|Uppsala University|Yes|Not yet recruiting|February 2012|August 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|15 Years|75 Years|No|Non-Probability Sample|Patients with diabetes mellitus|February 2012|February 22, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01537445||90633|
NCT01537458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Is_TVR_1|Long-term Outcome After Isolated Tricuspid Valve Repair|||Universitaire Ziekenhuizen Leuven|Yes|Not yet recruiting|March 2012|||June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing isolated tricuspid valve repair|February 2012|February 22, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01537458||90632|
NCT01535001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110085|Structured Non-operative Treatment of Knee Osteoarthritis|Structured Non-operative Treatment of Knee Osteoarthritis - a Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up||Northern Orthopaedic Division, Denmark|No|Completed|February 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|February 9, 2012||No||No|December 19, 2015|https://clinicaltrials.gov/show/NCT01535001||90821|
NCT01535313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biopsycontrol|Comparison of a Powered Bone Marrow Biopsy Device With a Manual System|a Prospective Randomized Controlled Trial Comparing a Powered Bone Marrow Biopsy Device With a Manual System||University Hospital, Basel, Switzerland|No|Completed|May 2011|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01535313||90797|
NCT01535586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSR&D I01CX000478|A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder|||The VA Western New York Healthcare System|No|Not yet recruiting|April 2012|||March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01535586||90776|
NCT01535885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTL-11/157|Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus|A Phase I Study Of Using Multi-virus Cytotoxic T-cells Following T-cell Depleted Allogeneic Hematopoietic Progenitor Cell Transplantation For Prophylaxis Against Specific Pathogens- Epstein Barr Virus, Adenovirus, And Cytomegalovirus (ACE TRIAL)|ACE|Medical College of Wisconsin|Yes|Recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|18|||Both|N/A|22 Years|No|||February 2016|February 11, 2016|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535885||90753|
NCT01536132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMIM-LEV-0901|Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients|Multicenter, Double-blind, Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of Intravenous Administration of Intermittent Doses of Levosimendan in Ambulatory Patients With Advanced CHF: the LION-HEART Study|LION-HEART|Parc de Salut Mar|No|Completed|April 2010|November 2015|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||February 2016|February 13, 2016|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01536132||90734|
NCT01531504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ViKY UP IDE|New Use of the ViKY Device for Uterus Positioning|Evaluation of Safety and Effectiveness of ViKY Device for Uterine Positioning||EndoControl|No|Completed|December 2011|September 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|80 Years|No|||December 2012|December 27, 2012|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01531504||91085|
NCT01536756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH-KCH-PSY-RCT|Effectiveness of a Structured Physical Rehabilitation Program for Chinese Patients With Depressive Disorders|A Single Blind Randomized Controlled Study Investigating the Effectiveness of a Structured Physical Rehabilitation Program on the Physical Fitness and Negative Psychological Symptoms for Chinese Patients With Mild to Severe Depressive Disorders||Kowloon Hospital, Hong Kong|No|Recruiting|February 2012|May 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|64 Years|No|||February 2012|February 23, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01536756||90686|
NCT01537029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A11-3691|Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide|Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide||Texas Tech University Health Sciences Center||Recruiting|February 2012|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Female|18 Years|N/A|No|||October 2015|October 6, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01537029||90665|
NCT01537276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|taizhou201101|Improve Hysterosalpingographic Accuracy by Real-time Fluoroscopy|Improve Hysterosalpingographic Accuracy by Real-time Fluoroscopy||Taizhou Hospital|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|263|||Female|18 Years|40 Years|No|||February 2012|February 22, 2012|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01537276||90646|
NCT01537289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0405-03|Pigtail Catheter Versus Chest Tube in the Management of Traumatic Pneumothorax|A Prospective Randomized Study of 14-French (14F) Pigtail Catheters Versus 28F Chest Tubes in Patients With Traumatic Pneumothorax: Impact on Tube-Site Pain and Failure Rate||University of Arizona|No|Recruiting|July 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2012|February 22, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01537289||90645|
NCT01529268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NASH-CyNCh|Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children|Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)|CyNCh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Completed|June 2012|September 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|169|||Both|8 Years|17 Years|No|||October 2015|October 6, 2015|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529268||91255|
NCT01529281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Northumbria_How_BCAA|Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids|Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids||Northumbria University|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01529281||91254|
NCT01529528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-DIANA-301|A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients|A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients|CWP-DIANA-301|JW Pharmaceutical|No|Completed|May 2011|November 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|117|||Both|19 Years|75 Years|No|||January 2013|January 2, 2013|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529528||91235|
NCT01529541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-DIANA-302|Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone|A Multicenter, Randomized, Double-blind, Double Dummy, Active-controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate the Efficacy and Safety of CWP-0403 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DM Insufficiently Controlled With Metformin Alone|CWP-DIANA-302|JW Pharmaceutical|No|Completed|May 2011|October 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|19 Years|75 Years|No|||May 2014|May 12, 2014|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529541||91234|
NCT01529814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3012|Assessment of Integration Success of an Implant System With a Novel Abutment Attachment Design in Early Loaded Cases|A Prospective Randomized-controlled Study of the Integration Success Rate of an Implant System With a Novel Abutment Attachment in Cases Loaded Early|Comet|Biomet, Inc.|No|Active, not recruiting|July 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529814||91213|
NCT01530061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC12001|The Satiating Effect of Eggs in Children|The Satiating Effect of Eggs in Children||Pennington Biomedical Research Center|No|Active, not recruiting|February 2012|April 2013|Anticipated|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|4 Years|17 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01530061||91194|
NCT01530074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QSensory-HMO-CTIL|Quantitative Sensory Testing of the Lower Lip After Inferior Alveolar Nerve Block, and Evaluation of the Role of the Contra-lateral Inferior Alveolar Nerve|||Hadassah Medical Organization|No|Not yet recruiting|March 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01530074||91193|
NCT01530321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT006330|Cervicogenic Headache Dose-Response|Dose-Response of Manipulation for Cervicogenic Headache|CGH D-R|University of Western States|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|256|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01530321||91174|
NCT01560923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS109|Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer|A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|October 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Male|18 Years|N/A|No|||February 2016|February 18, 2016|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560923||88838|
NCT01559558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104016RC|Changes of Pad Weight Results and Urethral Pressure Profiles After Reduction of Cystocele by Vaginal Gauze Packing|||National Taiwan University Hospital|No|Completed|March 2012|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|140|||Female|20 Years|N/A|No|Non-Probability Sample|Patients with >/= stage II cystocle|March 2012|March 19, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01559558||88943|
NCT01559571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDX-01-011|Registry for Severe ROP and Treatment on Visual Outcomes|Study Registry for Severe Retinopathy and Treatment on Visual Outcomes of Premature Neonates||Mednax Center for Research, Education and Quality|No|Active, not recruiting|May 2012|January 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|324|||Both|N/A|7 Days|Accepts Healthy Volunteers|Non-Probability Sample|Neonates who have a diagnosis of Retinopathy of Prematurity Stage 2 or higher|March 2016|March 22, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01559571||88942|
NCT01559805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ3106|Intervention to Improve Engagement in Care Among Newly Diagnosed HIV-positive Men|Efficacy Trial of a Brief Health Enhancement Intervention for Newly Diagnosed Men||Columbia University|Yes|Recruiting|November 2012|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|440|||Male|18 Years|N/A|No|||March 2016|March 23, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01559805||88924|
NCT01552668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109037|Fidaxomicin to Prevent Clostridium Difficile Colonization|The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients||Washington University School of Medicine|No|Withdrawn|September 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 27, 2014|March 8, 2012|Yes|Yes|Study not performed|No||https://clinicaltrials.gov/show/NCT01552668||89470|
NCT01552980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHMO-02|Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma|A Phase II Trial Evaluate a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma|mSOX|Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Recruiting|March 2012|February 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2012|March 27, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552980||89446|
NCT01552993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB2012-02|Registration and Treatment of Pain During Eye Examination of Prematurity|Registration and Treatment of Pain During Eye Examination of Prematurity||St. Olavs Hospital|No|Recruiting|March 2012|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|31 Weeks|37 Weeks|No|||February 2016|February 2, 2016|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01552993||89445|
NCT01553006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTU-EC-PE-5-036/54|Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis|A Comparison of Cefditoren Pivoxil 10 mg/kg/Day and Cefditoren Pivoxil 20 mg/kg/Day in Treatment of Childhood With Acute Rhinosinusitis|RS|Thammasat University|Yes|Recruiting|January 2012|September 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|1 Year|15 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553006||89444|
NCT01527279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Antazoline|Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation|Clinical Efficacy of Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation - a Single Centre, Randomized, Double-blind, Placebo-controlled Study (the AnPAF Study)|AnPAF|Institute of Cardiology, Warsaw, Poland|Yes|Completed|November 2012|March 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01527279||91407|
NCT01527513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-208|Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures|Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial||Bial - Portela C S.A.|No|Completed|August 2010|May 2013|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|6 Years|16 Years|No|||October 2014|October 23, 2014|February 3, 2012||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01527513||91389|
NCT01527773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPDOCS V1.2|Phenotypes and Vascular Damage in Chronic Obstructive Pulmonary Disease (COPD)|The Obstructive Pulmonary Disease Outcomes Cohort of Switzerland (TOP DOCS): Phenotypes and Vascular Damage in COPD|TOPDOCS|University of Zurich|No|Active, not recruiting|May 2011|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|313|Samples Without DNA|Blood samples|Both|40 Years|75 Years|No|Non-Probability Sample|Patients with proven COPD, GOLD stages I-IV|December 2015|December 9, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01527773||91369|
NCT01528072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMU2010-10S|Dynesys Spinal System Post Market 522 Study|Post Market Surveillance for the Dynesys Spinal System, Assessing Safety and Fusion.||Zimmer, Inc.|Yes|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|168|||Both|20 Years|80 Years|No|||February 2016|March 14, 2016|February 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528072||91346|
NCT01528397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSChen3885|Reconstruction of Proper Digital Nerve Defects in the Thumb Using a Pedicled Nerve Graft|||The Second Hospital of Tangshan|Yes|Completed|May 2005|May 2010|Actual|September 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|15 Years|60 Years|No|||January 2012|February 7, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01528397||91321|
NCT01528410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AAR-005|ALFApump System Versus Standard of Care in Ascites Treatment|ALFApump® System Versus Large Volume Paracentesis in the Treatment of Refractory Ascites. A Multicentre Randomised Controlled Study.||Sequana Medical AG|Yes|Active, not recruiting|July 2012|March 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 24, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01528410||91320|
NCT01528657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA098|Ventricular Pace Suppression Versus Intrinsic Rhythm Support Study||VIPERS|Biotronik SE & Co. KG|No|Completed|December 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01528657||91302|
NCT01528930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10-104-001|Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease|Inhaled Amikacin for Treatment of Intractable Nontuberculous Mycobacterial Lung Disease||Samsung Medical Center|No|Withdrawn|February 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|20 Years|N/A|No|||December 2012|December 14, 2012|January 30, 2012||No|Although this study was approved at the Institutional Review Board, Korea Food & Drug    Administration (KFDA) did not approve this study due to safety concern.|No||https://clinicaltrials.gov/show/NCT01528930||91281|
NCT01529294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO522D2401|Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers|Open-label, Single-dose, Parallel-group Study to Compare the PKs of Iloperidone in Subjects With Mild or Moderate Hepatic Impairment With That in Matched Healthy Control Subjects||Novartis||Completed|August 2010|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|90|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|September 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529294||91253|
NCT01560065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI_IVF|Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing In Vitro Fertilization Cycles|||AGUNCO Obstetrics and Gynecology Centre||Completed||||||Phase 4|Interventional|N/A|3||||||Male|18 Years|40 Years||||January 2012|March 21, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560065||88904|
NCT01560351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD/11/6-M|Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study|Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study|STIMJEU|Nantes University Hospital|No|Terminated|March 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||March 2015|March 9, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01560351||88882|
NCT01560364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0106|Bundle Evaluation in Extra Renal Epuration, Incidence of Thrombosis|Bundle Evaluation in Extra Renal Epuration, Incidence of Thrombosis|BEERT|University Hospital, Clermont-Ferrand||Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adults receiving renal replacement therapy|November 2014|November 28, 2014|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01560364||88881|
NCT01560650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXL-CRRT2535|Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Acute Kidney Injury|Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Cardiac Surgery Associated Acute Kidney Injury (CRITERIA STUDY)||Guangdong General Hospital|Yes|Completed|March 2011|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|211|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 17, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560650||88859|
NCT01530100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLTOS|Lower Laser Therapy in Orthognathics Surgery|Lower Laser Therapy in Orthognathics Surgery - Double Blind Study.||Universidade Federal de Goias|No|Completed|February 2012|May 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|community sample|February 2012|December 1, 2014|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01530100||91191|
NCT01560936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.0|Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU|Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU and the Effectiveness of an Antimicrobial Gel in Reducing Transmission to the Hands||Mednax Center for Research, Education and Quality|No|Completed|June 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|13 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Parent's that have a cell phone when visiting their child in the NICU.|May 2013|May 13, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01560936||88837|
NCT01530659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOSLO-CNTF-FFB-01|Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa|Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density||Neurotech Pharmaceuticals|Yes|Recruiting|January 2012|June 2019|Anticipated|June 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|55 Years|No|||November 2015|November 30, 2015|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530659||91149|
NCT01552096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2012082|Tramadol Versus Lidocaine Infiltration for Tonsillectomy|A Comparative Study of the Effects of Pre-incisional Infiltration of Tramadol or Lidocaine on the Inflammatory Response After Tonsillectomy.||Dammam University|Yes|Completed|December 2011|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|2 Years|6 Years|No|||March 2014|March 15, 2014|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01552096||89513|
NCT01552109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10037399DOC|Stable Angina Observational Registry|STable Angina obseRvational Registry|STAR|Medtronic Vascular|No|Completed|January 2012|December 2013|Actual|August 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|2079|||Both|18 Years|N/A|No|Non-Probability Sample|Adult, male or female subjects with symptomatic stable angina visiting non-interventional        consulting physicians for treatment and who meet the study inclusion/exclusion criteria.|October 2014|October 3, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552109||89512|
NCT01552382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006|Vitamin D, Cardiac Surgery and Outcome|Vitamin D and Clinical Outcome in Cardiac Surgical Patients|Vitop|Heart and Diabetes Center North-Rhine Westfalia|No|Completed|March 2012|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4418|||Both|18 Years|N/A|No|Probability Sample|cardiac surgical patients|December 2013|December 12, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01552382||89492|
NCT01552395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000056|A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia|A Prospective Safety Study in 24 Months Treatment of Nocturia With Minirin Melt in Clinical Practice in the Czech Republic||Ferring Pharmaceuticals|No|Active, not recruiting|March 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|4136|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Patients Suffering From Nocturia 1x or More Times a Night|October 2015|October 20, 2015|March 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01552395||89491|
NCT01549171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGAFSH-01|Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)|Pilot Study to Examine Iloprost Can Enhance Human Assisted Reproductive Technology Pregnancy Outcomes.||Fertility Specialists of Houston|No|Recruiting|January 2010|December 2013|Anticipated|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Female|20 Years|39 Years|No|Probability Sample|ART cases with age < 40 and without pre-implantation genetic diagnosis|March 2012|March 8, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549171||89735|
NCT01549418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASAPOL|The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin|The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial|ASAPOL|Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Not yet recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|760|||Both|40 Years|N/A|No|||March 2012|March 8, 2012|March 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01549418||89716|
NCT01527292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-RAD-11-01|Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis|Randomized Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis||James Graham Brown Cancer Center|Yes|Completed|February 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01527292||91406|
NCT01527539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1479|Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes|A Multi-centre, Non-comparative, Open-labelled, Extension Trial to Assess the Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes (Extension to BIAsp-1237)||Novo Nordisk A/S|No|Completed|November 2001|October 2004|Actual|October 2004|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2012|February 2, 2012|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527539||91387|
NCT01527526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/2011/PC|Depot-medroxyprogesterone Acetate (DMPA) Contraceptive Method and Metabolism|Prospective Study for Evaluation of the Insulin Resistance, Lipid Metabolism and Sub Clinical Cardiovascular Disease in Women Who Initiate the Depot-medroxyprogesterone Acetate (DMPA) Contraceptive Method With in Follow-up for Two Years|DMPA|University of Campinas, Brazil|No|Completed|February 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|54|Samples Without DNA|Serum samples for determination of lipid profile, insulin, glucose, coagulation factors,      neuropeptide Y and factors related to bone mineral density.|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Will be included women new-users DMPA, looking for the clinic's family planning        FCM-UNICAMP, from primary care centers in Campinas, São Paulo, Brazil.|June 2015|June 3, 2015|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01527526||91388|
NCT01527786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRISTIQ IOP # 3151A1-44|Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine|A Pilot Study of Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine||BC Women's Hospital & Health Centre|No|Completed|November 2010|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Female|19 Years|45 Years|No|||January 2015|January 26, 2015|October 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01527786||91368|
NCT01528085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWALL-PH-02|Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)||Johann Wolfgang Goethe University Hospitals|Yes|Active, not recruiting|January 2012|November 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|79|||Both|55 Years|N/A|No|||September 2015|September 29, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528085||91345|
NCT01528098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEGPD|Comparison of Bowel Cleansing Methods for Colonoscopy in Hospitalized Patients|Efficacy of Bisacodyl Given as Part of a Polyethylene Glycol-based Bowel Preparation Prior to Colonoscopy in Hospitalized Patients|PEG|Kangbuk Samsung Hospital|Yes|Not yet recruiting|March 2012|October 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Hospitalized patients for colonoscopy in university hospital.|February 2012|February 20, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528098||91344|
NCT01528423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15265|Evaluation of the XtremeCT Device for the Assessment of Bone|Evaluation of the XtremeCT Device for the Assessment of Bone|XtremeCT|Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|May 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||6|Actual|180|Samples Without DNA|Serum samples taken for measurement of PINP, CTX, PTH, calcium, creatinine, albumin,      testosterone, IGF-1, IGFBP-3 and SHBG|Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers|June 2012|June 14, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01528423||91319|
NCT01528670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRANDA|Monitoring of Patients Treated With Particle Therapy Using Positron-Emission-Tomography (PET): The MIRANDA Study|Monitoring of Patients Treated With Particle Therapy Using Positron-Emission-Tomography (PET): The MIRANDA Study.|MIRANDA|University Hospital Heidelberg|No|Recruiting|December 2011|||February 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||8|Anticipated|240|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with Particle Therapy at the Heidelberg Ion Therapy (HIT) Center will be        included and grouped into 8 anatomical regions: Brain, Skull base, Head-and-neck, Upper        GI, Lower GI, Prostate, Pelvic region and other.|February 2013|February 18, 2013|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01528670||91301|
NCT01528683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PANDORA|Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer|Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer|PANDORA|University Hospital Heidelberg|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|December 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01528683||91300|
NCT01528943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET Abdominal|Effect of Prostacyclin on Haemostasis in Abdominal Surgery|The Effect of Prostacyclin on Haemostasis as Evaluated by Thrombelastography and Endothelial Markers in Patients Undergoing Major Abdominal Surgery. A Pilot Study||Rigshospitalet, Denmark|No|Not yet recruiting|March 2012|||March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01528943||91280|
NCT01528956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAR12B1|Studying Genes in Samples From Younger Patients With Adrenocortical Tumor|Using New Approaches for Genomics Studies in Pediatric Adrenocortical Tumors: Whole Genome Sequencing; Deep Sequencing; miRNA; methDNA and SNP 6.0||Children's Oncology Group|No|Active, not recruiting|February 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10|||Both|N/A|21 Years|No|Non-Probability Sample|Patients enrolled on COG-ARAR0332|May 2015|May 7, 2015|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01528956||91279|
NCT01559818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMM-101-008|A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001|An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001||Immodulon Therapeutics Ltd|No|Active, not recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2014|April 29, 2015|March 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01559818||88923|
NCT01529827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 177110|Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation||Roswell Park Cancer Institute|Yes|Active, not recruiting|February 2012|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|3 Years|75 Years|No|||October 2015|October 28, 2015|February 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529827||91212|
NCT01530087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4518-O|Preliminary Evaluation of CASTLE Barrier Prototype UK|Peristomal Skin Irritation: A Preliminary Evaluation of the CASTLE Barrier Prototype for People With Intestinal Stomas||Hollister Incorporated|No|Terminated|January 2012|August 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||September 2015|February 22, 2016|February 7, 2012||No|Inability of site to recruit/enroll target population|No|September 22, 2015|https://clinicaltrials.gov/show/NCT01530087||91192|
NCT01530334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00138|Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment|A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Responded to Gefitinib in 1st Line and Progressed After 2nd Line Chemotherapy|ICARUS|AstraZeneca||Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|130 Years|No|||January 2016|January 26, 2016|January 31, 2012|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01530334||91173|
NCT01526473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00034612|A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901|A Phase I Study To Evaluate The Antitumor Activity And Safety Of DUKE-002-VRP(HUHER2-ECD+TM), An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region, In Patient With Locally Advanced Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer||Duke University|No|Active, not recruiting|February 2012|December 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|January 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526473||91467|
NCT01526785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU09411|A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease|A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale||Sanofi|Yes|Terminated|March 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|1 Year|N/A|No|||November 2015|November 9, 2015|February 2, 2012|Yes|Yes|Terminated due to approved label expansion|No|September 29, 2015|https://clinicaltrials.gov/show/NCT01526785||91443|
NCT01552681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT ASJ02|Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome|A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren's Syndrome (ASJ02)||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Terminated|July 2012|June 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|No|||March 2016|March 22, 2016|March 9, 2012|Yes|Yes|Expired experimental study agent, no additional supply available.|No|February 21, 2016|https://clinicaltrials.gov/show/NCT01552681||89469|Randomization was prematurely stopped in July 2014 due to study product expiration. 52 of the 72 planned subjects were randomized.
NCT01552694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41052|Sitagliptin and HIV|A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia (100 mg/d) for Reducing Inflammation and Increasing Endothelial Progenitor Cell Number in Human Immunodeficiency Virus (HIV) Infected Men and Women With Insulin Resistance and Central Adiposity.||Washington University School of Medicine|No|Completed|October 2012|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||May 2015|May 13, 2015|March 8, 2012|Yes|Yes||No|February 5, 2015|https://clinicaltrials.gov/show/NCT01552694||89468|
NCT01553019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1013-PC03|Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer|A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma|PC03|University of Florida|Yes|Recruiting|October 2011|February 2024|Anticipated|February 2020|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|22|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|October 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553019||89443|
NCT01548937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-2132A|Serotonin Transporter Density in Late-life Depression With and Without Dementia|Serotonin Transporter Density in Late-life Depression With and Without Dementia||Chang Gung Memorial Hospital|Yes|Completed|May 2010|December 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Both|50 Years|N/A|No|||January 2016|January 27, 2016|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01548937||89753|
NCT01557985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH IRB 2010-14308|Single Dose Pharmacokinetics and Pharmacodynamics of Bupivacaine Following Transversus Abdominis Plane (TAP) Block in Neonates|Single Dose Pharmacokinetics and Pharmacodynamics of Bupivacaine Following Transversus Abdominis Plane (TAP) Block in Neonates||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|July 2010|||October 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|13|||Both|N/A|28 Days|No|||March 2013|March 19, 2013|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557985||89064|
NCT01558180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00719|Telephone Care Management to Address Sleep Problems in Young Children With Autism|Telephone Care Management to Address Sleep Problems in Young Children With Autism||Nationwide Children's Hospital|No|Completed|April 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|3 Years|6 Years|No|||February 2015|February 2, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558180||89049|
NCT01558505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo005|Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation|Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study|DEBATE-BTK|Ospedale San Donato|No|Completed|November 2010|||September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||January 2013|January 26, 2013|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01558505||89024|
NCT01558791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 10-221|A Brief Educational Intervention to Improve Traumatic Brain Injury (TBI) Screening Outcomes|A Brief Educational Intervention to Improve TBI Screening Outcomes|TBI|VA Office of Research and Development|No|Completed|September 2011|January 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1236|||Both|18 Years|N/A|No|||August 2014|April 6, 2015|August 10, 2011||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT01558791||89002|
NCT01527305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100739|A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia|An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia|PREVAIL|Johnson & Johnson Pte Ltd|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|212|||Both|18 Years|65 Years|No|||December 2014|December 24, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01527305||91405|
NCT01527552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1488|Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects|A Single-Centre, Randomised, Balanced, Double- Blind, Cross-Over Trial Investigating the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|November 2002|December 2002|Actual|December 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527552||91386|
NCT01527799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-13659|Exercise Capacity in Pediatric Sickle Cell Anemia|The Physiologic Assessment of Exercise Capacity in Pediatric Sickle Cell Anemia||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|June 2009|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|60|Samples Without DNA|Plasma is collected and stored to be analyzed|Both|8 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sickle cell anemia patients followed at Children's Memorial Hospital. Healthy controls        without sickle cell anemia are recruited through flyers posted in Children's Memorial        Hospital.|February 2016|February 3, 2016|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01527799||91367|
NCT01528111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX7101.7-101-OAG|Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|A Phase 1/2a, Randomized, Parallel-group, Double-masked, Vehicle-controlled, Dose-frequency Escalation Study to Evaluate the Safety, Tolerability, and Intraocular Pressure (IOP)-Lowering Efficacy of Topically Administered LX7101 in Subjects Diagnosed With Primary Open-angle Glaucoma (POAG) or Ocular Hypertension (OHT)||Lexicon Pharmaceuticals|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528111||91343|
NCT01528449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNATIFA-10|Babesia Testing in Blood Donors|Blood Donation Screening for Babesia Microti by Real-time Polymerase Chain Reaction (PCR) and by Indirect Flourescent Antibody (IFA) Assays||Imugen|No|Completed|December 2011|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90116|||Both|16 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01528449||91317|
NCT01528696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00037674|Silver Impregnated Dressings to Reduce Wound Complications in Obese Patients at Cesarean Section|Silver Impregnated Dressings to Reduce Wound Complications in Obese Patients at Cesarean Section||University of Michigan|No|Recruiting|February 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 7, 2012|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528696||91299|
NCT01528969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD02/10|Effect of Xylitol on Oral Microbiota in Children|The Effect of the Frequent Xylitol Chewing Gum Use on the Oral Microbiota in Children With High MS Counts||Kuwait University|No|Completed|March 2012|May 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|122|||Male|11 Years|14 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|January 24, 2012||No||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01528969||91278|
NCT01529554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEVER-ACS|Controlled Level EVERolimus in Acute Coronary Syndromes|Phase I-II Randomized Prospective Double-blind Multi-center Trial on the Effects of a Short Course of Oral Everolimus on Infarct Size, Left Ventricular Remodeling and Inflammation in Patients With Acute ST-Elevation Myocardial Infarction|CLEVER-ACS|University of Zurich|Yes|Recruiting|December 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|90 Years|No|||August 2015|August 19, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01529554||91233|
NCT01530347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006631ctil|Non Invasive Breath Based Acetone-meter- Easy Check|Assessing Feasibility of Non-invasive Breath Based Acetone Meter -Easy Check- Relative to Finger Capillary Blood Glucose and Beta Hydroxybutyrate Reference||Rabin Medical Center|No|Suspended|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Male|18 Years|N/A|No|||March 2015|March 11, 2015|February 7, 2012||No|sponsor wish to amend the protocol before proceeding to segment 2 of the study|No||https://clinicaltrials.gov/show/NCT01530347||91172|
NCT01530672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS647|Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test|Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test|MBIO|PATH|No|Completed|January 2012|September 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2900|||Female|N/A|N/A|Accepts Healthy Volunteers|||October 2014|October 27, 2014|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530672||91148|
NCT01526486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00012329|Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer|Videoscopic Versus Open Inguinal Lymphadenectomy for Sentinel Node Positive Cutaneous Malignancies and Genitourinary Staging Procedures||Emory University|No|Completed|June 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||May 2015|May 4, 2015|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01526486||91466|
NCT01557751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09050171|Acute Pain Genomic Study|Preliminary Studies for Whole Genome Association Study (WGAS) in Acute Perioperative Pain||University of Pittsburgh|Yes|Recruiting|February 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|400|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557751||89082|
NCT01557478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIQOL-B|Melatonin as Adjuvant Therapy in Breast Cancer Patients|Melatonin in Improving the Quality of Life of Breast Cancer Patients and Reduction of Postoperative Pain and Chemotherapy Induced Toxicity|MIQOL-B|Khon Kaen University|No|Active, not recruiting|March 2012|||September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Female|18 Years|70 Years|No|||January 2015|January 6, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01557478||89102|
NCT01557738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02-0114|Role of Flavanols in Exercise and Aging|Acute and Long-term Effects of Dietary Flavanols on Local Control of Skeletal Muscle Blood Flow During Exercise in Young and Old Humans||University of Texas at Austin|No|Completed|December 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2014|June 24, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01557738||89083|
NCT01558518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008019|Handheld Echocardiography in Clinical Practice|Handheld Echocardiography in Clinical Practice||Mayo Clinic|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to the Mayo Clinic Echocardiography Laboratory|July 2013|July 9, 2013|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01558518||89023|
NCT01559064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/MED/FIL/017|The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face|A Prospective, Observational Study of the Volumizing Effect of Open-Label Aesthetic Use of VOLUMA® in the Mid-Face Area||Allergan|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|115|||Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Normal, healthy subjects desiring aesthetic improvement|June 2014|October 6, 2014|March 19, 2012|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01559064||88981|
NCT01559090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3461C00002|Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus|A Phase 2, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Intravenous Dose of MEDI-546, a Human Monoclonal Antibody Directed Against Type I Interferon Receptor (IFNAR), in Japanese Subjects With Active Systemic Lupus Erythematosus (SLE)||AstraZeneca|No|Active, not recruiting|April 2012|December 2017|Anticipated|August 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|65 Years|No|||December 2015|December 27, 2015|March 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01559090||88979|
NCT01527318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 11-3-013|The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)|The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)|NLSDM|Maastricht University Medical Center|No|Completed|August 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||May 2013|May 13, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01527318||91404|
NCT01527331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000010|A ProspectiveTrial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer|||Massachusetts General Hospital|No|Recruiting|June 2011|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|150|||Both|21 Years|N/A|No|||April 2012|April 28, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01527331||91403|
NCT01527565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1489|Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects|A Single-Centre, Randomised, Balanced, Double-Blind, Cross-Over Trial Investigating the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 2, 2012|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527565||91385|
NCT01527812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECM 4 (zz) 08/12/09|Optimal Positioning of Local Anaesthetic in Femoral Nerve Block Prior to Hip Surgery|Optimal Positioning of Local Anaesthetic in Femoral Nerve Block Prior to Operative Fixation of Fractured Neck of Femur||Cork University Hospital|No|Completed|December 2009|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|50 Years|N/A|No|||February 2012|March 31, 2012|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527812||91366|
NCT01527825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MatfluHIVpos_3dosingschedule|Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women|Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women: a Randomized Controlled Trial||University of Witwatersrand, South Africa|Yes|Completed|September 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|800|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||January 2015|January 9, 2015|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527825||91365|
NCT01528124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14346|A Study of LY3025876 in Healthy Volunteers|A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3025876 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|63|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|February 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01528124||91342|
NCT01528137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0072|Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer|A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC)||Stanford University|Yes|Terminated|May 2012|July 2013|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2013|January 27, 2014|February 3, 2012|No|Yes|Negative data from another trial led to termination of this trial by sponsor.|No||https://clinicaltrials.gov/show/NCT01528137||91341|
NCT01528436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPUCBRCT|Umbilical Cord Blood Therapy for Cerebral Palsy|Umbilical Cord Blood Therapy for Cerebral Palsy: a Randomized,Double-blind, Placebo-controlled Trial||Bundang CHA Hospital|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|6 Months|20 Years|No|||July 2012|July 17, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528436||91318|
NCT01528709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.02|Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)|Aggressive Cholesterol Therapy to Inhibit Vein Graft Events (ACTIVE Trial): Does High-Dose Postoperative Statin Therapy Improve Graft Patency After Coronary Bypass?|ACTIVE|Boca Raton Regional Hospital|No|Recruiting|March 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528709||91298|
NCT01528982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811S53121|Susceptibility to Pathological Gambling|Susceptibility to Pathological Gambling||University of Chicago|Yes|Recruiting|November 2008|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|600|||Both|18 Years|29 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|August 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01528982||91277|
NCT01528995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011//1300/REKnord|Treatment of Fecal Incontinence After Obstetric Anal Sphincter Injuries|A Blinded Randomized Controlled Clinical Trial Comparing Sacral Nerve Modulation and Anal Bulking Injections as Treatment for Fecal Incontinence After Obstetric Anal Sphincter Injuries (OASIS).|KISS|University Hospital of North Norway|Yes|Completed|February 2012|March 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|65|||Female|18 Years|N/A|No|||March 2015|March 30, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01528995||91276|
NCT01530113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|-0085-11|Childhood Sexual Abuse, Vaginismus and Labor Dystocia|Childhood Sexual Abuse, Vaginismus and Labor Dystocia: Towards a Theoretical Model|CSA-V-LD|Hillel Yaffe Medical Center|No|Not yet recruiting|March 2012|March 2015|Anticipated|March 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|2000|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women in their third trimester|January 2012|February 8, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01530113||91190|
NCT01530360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBP010911|Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants|Safeguarding the Brains of Our Smallest Children - a Pilot Study|SafeBoosC-p|Rigshospitalet, Denmark|No|Completed|September 2011|March 2012|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|N/A|3 Hours|No|||December 2012|December 7, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01530360||91171|
NCT01526265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814761|Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures|Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures||University of Pennsylvania|Yes|Active, not recruiting|February 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|2185|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526265||91483|
NCT01526499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCvsT|Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer|||Fudan University|No|Recruiting|December 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|70 Years|No|||February 2012|February 5, 2012|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01526499||91465|
NCT01526512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|metroCX|Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer|||Fudan University|No|Recruiting|December 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Female|18 Years|80 Years|No|||February 2012|February 5, 2012|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01526512||91464|
NCT01527097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0263 - 11 - RMC|Influence of Atorvastatin on Psoriasis Severity and Endothelial Function|Atorvastatin to Reduce Psoriasis Severity and Improve Endothelial Function in Patients With Severe Psoriasis and Non-Elevated LDL Levels: A Randomized, Double Blind, Placebo-Controlled Study.||Rabin Medical Center|No|Withdrawn|August 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|N/A|No|||November 2015|November 16, 2015|January 15, 2012|Yes|Yes|We strongly feel that the ability to recruit the required number of patients is very low and    thus decided to stop the study.|No||https://clinicaltrials.gov/show/NCT01527097||91421|
NCT01526798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No 1491 CIEPO-PILOT|Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis|Improvement of EPO-resistance in HD Patients With Chronic Inflammation by High Cut-off Hemodialysis - Pilot Study (CIEPO-PILOT)|CIEPO-PILOT|Gambro Dialysatoren GmbH|No|Completed|March 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||January 2013|March 7, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01526798||91442|
NCT01558011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3211|Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study|Using Genetic Polymorphisms of Drug Metabolism and Immunohistochemical Stain to Predict the Efficacy and Toxicity in Patients With Gastric Adenocarcinoma - A Phase II Study||National Health Research Institutes, Taiwan|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|N/A|No|||October 2013|October 28, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01558011||89062|
NCT01558206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390327|Ultrasonography of Chest Versus Pulmonary Artery CT Angiography in Patients With Symptoms and Signs in Favor of PTE|Bedside Ultrasonography of Chest Versus Pulmonary Artery CT Angiography in the Patients Who Came to Emergency Department of Alzahra General Hospital With Respiratory Symptoms and Signs in Favor of Pulmonary Thromboemboli.||Isfahan University of Medical Sciences|Yes|Enrolling by invitation|March 2012|December 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|76|||Both|N/A|N/A|No|Non-Probability Sample|Patients who come to the Emergency Department of Alzahra General Hospital with signs and        symptoms in favor of PTE.|March 2012|March 16, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01558206||89047|
NCT01557998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA032080|Testing and Linkage to Care for Injecting Drug Users in Kenya|Testing and Linkage to Care for IDUs in Kenya|TLCIDU Kenya|New York University|Yes|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|4500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01557998||89063|
NCT01558193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB-0123-DHAVM|The Impact of Supplementation With Multi-vitamins/Minerals, With and Without Fatty Acids, on Impulsivity and Aggression|The Impact of Supplementation With Multi-vitamins/Minerals, With and Without Fatty Acids, on Impulsivity and Aggression||Swansea University|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|202|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01558193||89048|
NCT01558804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0058|GRoup A StrePtococcus|Gene Expression in Isolates of Group A Streptococci Recovered From Patients Who Are Carriers|GRASP|University of Wisconsin, Madison|No|Recruiting|November 2011|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|Samples With DNA|Throat swab specimens|Both|4 Years|16 Years|No|Non-Probability Sample|Children will be eligible for this study if they are ages 4 to 16 years and have been        diagnosed to have acute pharyngitis caused by GAS (with a positive rapid antigen detection        test (RADT) and have not been treated with antibiotics in the last 30 days. Children will        be excluded if they are allergic to beta lactam antibiotics. Children will be enrolled at        either one of two large pediatric practices in Madison, Wisconsin (20 S. Park St or West        Clinic) or at the Pediatric Afterhours Clinic at University Station. They will present        with acute symptoms of sore throat and fever. A RADT will be used for diagnosis.|January 2016|January 20, 2016|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01558804||89001|
NCT01527032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2174|Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis|Risk-adapted Therapy for AL Amyloidosis||FDA Office of Orphan Products Development||Completed|September 2002|September 2005|Actual|||Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||||||||||||July 2011|March 24, 2015|July 28, 2011||||||https://clinicaltrials.gov/show/NCT01527032||91425|
NCT01527591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer-Prevnar13®|Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)|Safety And Long-Term Immunogenicity Of The 13-Valent Pneumococcal Conjugate Vaccine In Children Who Are Solid Organ Transplant Recipients||University of California, Los Angeles|No|Recruiting|February 2012|||December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Both|12 Months|59 Months|No|||November 2015|November 30, 2015|December 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527591||91383|
NCT01527578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simons VIP F-CAP|Simons Variation in Individuals Project, Functional Common Acquisition Protocol|Functional Common Acquisition Protocol Phase of the Simons VIP||University of California, San Francisco|Yes|Completed|September 2011|April 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|7 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy individuals ages 7 through 60.|May 2014|May 8, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01527578||91384|
NCT01558453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXALI_L_04946|Oxaliplatin for Children With Solid Tumors|Phase II Study With Oxaliplatin In Children With Relapsed/Refractory Solid Tumors||Hospital Santa Marcelina|No|Active, not recruiting|March 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|21 Years|No|||March 2013|March 25, 2013|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558453||89028|
NCT01558466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10228/10|Sildenofil in Persistent Pulmonary Hypertension in Newborns|Early Combined Use of Inhaled Nitric Oxide and Oral Sildenafil on the Outcome of Pulmonary Hypertension in New Born Infants|Sildeno|Hamad Medical Corporation|No|Recruiting|November 2011|June 2015|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|36 Weeks|41 Weeks|No|||September 2012|September 23, 2012|March 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01558466||89027|
NCT01528462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|277-2011|Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke|Does Acute Management of Sleep Disorders Improve Outcomes After Non-disabling Cerebrovascular Events?|SMARTIES|Sunnybrook Health Sciences Centre|No|Completed|October 2011|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|97|||Both|N/A|N/A|No|Probability Sample|Please see eligibility criteria below.|November 2014|November 21, 2014|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528462||91316|
NCT01558752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010913-01H|A Clinical Trial of a Metal on Poly Component Versus CORAIL Stem: A Bone Mineral Density Study|A Randomized Clinical Trial of a Modular Cementless Acetabular Metal on Poly Component Versus a Monoblock Cementless Titanium Shell With Ceramic on Ceramic Bearing and CORAIL Stem: A Bone Mineral Density Study||Ottawa Hospital Research Institute|Yes|Recruiting|April 2010|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|74 Years|No|||May 2015|May 6, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558752||89005|
NCT01559025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ABR01T|Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus|Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in Residual β-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.||Federal University of São Paulo|Yes|Recruiting|March 2014|March 2017|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|35 Years|No|||May 2014|May 13, 2014|November 30, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559025||88984|
NCT01559298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARTE|Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial|Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)|ARTE|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|No|Active, not recruiting|March 2012|July 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|155|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559298||88963|
NCT01559311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-10-003-AP-HF|ENHANCE - Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction|Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction|ENHANCE|St. Jude Medical|Yes|Active, not recruiting|February 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|177|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559311||88962|
NCT01559584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Phototoxic UVA in alopecia|Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata|A Clinical and Immunological Study of Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata: A Randomized Controlled Clinical Trial||Cairo University|Yes|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|12 Years|N/A|No|||April 2014|April 5, 2014|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559584||88941|
NCT01530373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132500|Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients|A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy||University of Arkansas|Yes|Recruiting|February 2012|September 2019|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|110|||Female|18 Years|95 Years|No|||December 2015|December 7, 2015|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530373||91170|
NCT01526525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6151/ 22-7-2009|Perioperative Electroacupuncture on Postoperative Analgesia in Prostatectomy|Effect of Perioperative Electroacupuncture With Tramadol and Ketamine on Postoperative Analgesia in Prostatectomy: a Randomized Placebo-controlled Trial||G.Gennimatas General Hospital|No|Completed|July 2009|February 2012|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|70|||Male|50 Years|75 Years|No|||February 2014|February 20, 2014|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01526525||91463|
NCT01526811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P#8888|Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)|Post-market Study on Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms||Medtronic Endovascular|No|Active, not recruiting|March 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects diagnosed with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and        requiring endovascular treatment|January 2016|January 11, 2016|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01526811||91441|
NCT01527110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115215|A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection|An Open-label, Multi-centre, Single Arm Study to Evaluate the Safety and Efficacy of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Confirmed Influenza Infection (NAI115215)||GlaxoSmithKline|No|Completed|January 2012|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|16 Years|N/A|No|||October 2013|January 2, 2014|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01527110||91420|
NCT01527396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG2015|Prospective, Observational Study of Low-risk Criteria for Node Metastasis in Endometrial Cancer|Multi-center Prospective Observational Study for the Validation of Preoperative Low-risk Criteria for Lymph Node Metastasis in Endometrial Cancer|PALME|National Cancer Center, Korea|Yes|Completed|December 2011|August 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|529|||Female|N/A|N/A|No|Non-Probability Sample|Endometrial cancer patients who undergo surgery including systemic lymph node dissection|October 2015|October 27, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01527396||91398|
NCT01558024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2011/APM-03|The Effects of Compression Stockings on Pressure Parameters in Patients With Chronic Venous Insufficiency|The Effects of Compression Stockings on Pressure Parameters in Patients With Chronic Venous Insufficiency|MACIVC|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|July 2014|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Anticipated|111|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted on adult men and women divided into a group of subjects with        chronic venous insufficiency defined by the CEAP classification (Hawaii), stages:          -  C1S (telangiectasias or reticular veins and symptoms of chronic venous             insufficiency),          -  C3 (varicose veins: superficial veins of diameter greater than or equal to 3 mm)          -  And C5 (healed venous ulcer)        and a control group of healthy subjects without venous disease (sedentary, active, and        athletic subjects), matched for age, sex, and body mass index.|December 2015|December 7, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558024||89061|
NCT01558219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003156-39|Second-line Chemotherapy in Castration Resistant Prostate Cancer|Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containing Regimen|ProstyII|Tampere University Hospital|No|Recruiting|November 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|18 Years|N/A|No|||February 2014|February 5, 2014|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01558219||89046|
NCT01558531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo006|Drug Eluting Balloon in Peripheral Intervention for In-Stent Restenosis|Drug Eluting Balloon in peripherAl inTErvention for In-Stent Restenosis: the DEBATE-ISR Study|DEBATE-ISR|Ospedale San Donato|No|Suspended|January 2010|||December 2011|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|18 Years|N/A|No|Probability Sample|Patients referring to our institution for peripheral artery disease|February 2015|February 2, 2015|March 17, 2012||No|slow enrollment|No||https://clinicaltrials.gov/show/NCT01558531||89022|
NCT01558544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901010165|Cryopreservation of Ovarian Tissue|Cryopreservation of Ovarian Tissue for Potential In Vitro Maturation or Autologous Transplantation||Weill Medical College of Cornell University|No|Recruiting|April 1997|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Female|N/A|45 Years|No|||June 2015|June 10, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558544||89021|
NCT01558817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PilotCPR001|Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation With Informed Assent|||University of Vermont|Yes|Completed|February 2012|April 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|29|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01558817||89000|
NCT01557725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH7621|Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty.|Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty|FETA|Rigshospitalet, Denmark|Yes|Completed|February 2010|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4924|||Both|18 Years|N/A|No|Non-Probability Sample|Any patient receiving elective fast-track THR or TKR|December 2015|December 14, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557725||89084|
NCT01527604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB9930|Effects of Avenanthramide-enriched Oats on Inflammation|Effects of Avenanthramide-enriched Oats on Inflammation in Obese Adults With Central Adiposity: A Randomized Clinical Trial||Tufts University||Completed|December 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 18, 2014|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01527604||91382|
NCT01527864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2ES2011-1|Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or With Pegylated Endostatin for Advanced Non-small Cell Lung Cancer||Protgen Ltd|Yes|Recruiting|May 2011|April 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01527864||91362|
NCT01527838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT1050-02|Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit|A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies||Fate Therapeutics|Yes|Completed|January 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||January 2015|January 29, 2015|February 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527838||91364|
NCT01527851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-190|Excess Skin and Physical Activity|Impact of Excess Skin on the Practice of Physical Activity in Women Who Underwent Bariatric Surgery and Exploration of the Benefits of Plastic Surgery||Université de Sherbrooke|No|Active, not recruiting|February 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|30|||Female|18 Years|65 Years|No|Non-Probability Sample|A group of 20 people who underwent bariatric surgery and a group of 10 people who        underwent bariatric surgery and one or several plastic surgery|April 2015|April 9, 2015|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01527851||91363|
NCT01528150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-054-EU-LV|Safety and Efficacy Study of Tendril MRI™ Leads in Standard Bradycardia Pacing Indication|Clinical Investigation to Assess the Safety and Efficacy of the Tendril MRI™ Leads, as a Part of the Accent MRI™ System, in Patients With Standard Bradycardia Pacing Indication.|Tendril MRI™|St. Jude Medical|No|Completed|February 2012|March 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|466|||Both|18 Years|N/A|No|Non-Probability Sample|standard bradycardia indications|April 2015|April 27, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528150||91340|
NCT01528735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.25|This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C|An Open-label, Ascending Dose, Phase II Study to Evaluate Tolerability, Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA in Combination With BI 201335 NA and Ribavirin for 8 Weeks in Treatment-naïve Japanese Patients With Genotype 1chronic Hepatitis C Virus Infection||Boehringer Ingelheim||Completed|February 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|70 Years|No|||April 2014|April 30, 2014|February 6, 2012||||No||https://clinicaltrials.gov/show/NCT01528735||91296|
NCT01528722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute lap chole RCT|Randomized Control Trial of Intraperitoneal Bupivacaine During Cholecystectomy|Double Blind Sham Controlled Randomised Trial of Intraperitoneal Bupivacaine During Acute Laparoscopic Cholecystectomy||University Hospitals Coventry and Warwickshire NHS Trust|No|Completed|January 2009|January 2010|Actual|January 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||February 2012|February 7, 2012|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01528722||91297|
NCT01529008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREOB-ON3|Phase 3 Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head|Phase 3, Pivotal, Multicentre, Randomised, Double-blind Controlled Study to Evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head||Bone Therapeutics S.A|Yes|Recruiting|November 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|70 Years|No|||November 2013|November 4, 2013|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01529008||91275|
NCT01529307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAS266X2101|First in Human Trial of TAS266 in Patients With Advanced Solid Tumors|A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors||Novartis|No|Terminated|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|February 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529307||91252|
NCT01529567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBS-0|Cognitive Behavioral Therapy With Our Without Exposure Therapy for Irritable Bowel Syndrome|||Karolinska Institutet|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|311|||Both|18 Years|N/A|No|||February 2013|February 14, 2013|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529567||91232|
NCT01526824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHP1061010A|Lovaza's Effect on Clopidogrel in a Neuro Population|The Effects of Polyunsaturated Omega-3 Fatty Acids (Lovaza) on Patients Taking Clopidogrel +/- Aspirin Who Have Suffered an Ischemic Stroke/TIA and/or Are Candidates for Neuroendovascular Stenting.||Millard Fillmore Gates Hospital|No|Recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|80 Years|No|||February 2012|February 1, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526824||91440|
NCT01527123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115959|A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris|A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris||GlaxoSmithKline||Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|20 Years|45 Years|No|||June 2012|October 4, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01527123||91419|
NCT01527136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 196111|Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery|A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients With Advanced Cancers||Roswell Park Cancer Institute|Yes|Completed|January 2012|||October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|December 20, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01527136||91418|
NCT01527409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-598|The Efficacy of Health Partnership Program for Cancer Patients|The Efficacy of Health Partnership Program for Cancer Patients||National Cancer Center, Korea|No|Recruiting|February 2012|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|248|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 6, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01527409||91397|
NCT01527656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1577|Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects|Single-Centre, Randomised, Balanced, Double-Blind, Cross-Over Trial Investigating the Bioequivalence of Formulation 2 and Formulation 4 of Biphasic Insulin Aspart 70 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|December 2003|February 2004|Actual|February 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527656||91378|
NCT01558830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0121|Safety of Amiodarone and Ranolazine Together in Patients With Angina|Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina|SARA|Cardiovascular Consultants of Nevada|Yes|Recruiting|January 2012|July 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|35 Years|N/A|No|||March 2012|March 20, 2012|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01558830||88999|
NCT01558843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203034|Sodium Management in Acute Neurological Injury|Sodium Management in Patients With Acute Neurological Injury|SANI|Washington University School of Medicine|No|Recruiting|February 2012|||||N/A|Observational|Observational Model: Cohort||4|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients identified for enrollment will be age ≥ 18 years of age, admitted to an intensive        care unit for more than 48 hours with ICD-9 codes for aneurysmal SAH, TBI, IPH, or        intracranial tumor.|March 2012|March 27, 2012|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01558843||88998|
NCT01558232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP001|A Prospective Study to Evaluate Use of the Tibion Bionic Leg in Sub-Acute Post-stroke Patients|A Prospective, Experimental ABA Study to Evaluate Use of the Tibion Bionic Leg in Subacute Post-stroke Patients Undergoing Physical Therapy|Acute Effects|Tibion Bionics, Inc.|No|Terminated|March 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|40 Years|60 Years|No|||July 2012|July 5, 2012|March 6, 2012||No|Study was terminated base on Sponsor's decision.|No||https://clinicaltrials.gov/show/NCT01558232||89045|
NCT01558557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00041292|Gluten Free Diet in People With Schizophrenia: A Pilot Study|Gluten Free Diet in People With Schizophrenia: A Pilot Study||University of Maryland|No|Completed|June 2008|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|55 Years|No|||January 2014|January 27, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01558557||89020|
NCT01558856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/LW-04|Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder|Prospective Randomized Trial Comparing Unilateral and Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder|HAVIR Bi|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|October 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||October 2015|November 9, 2015|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01558856||88997|
NCT01527344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003775|Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography|Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography as Compared to Intravascular Ultrasound-Virtual Histology|CAV-OCT-IVUS|Mayo Clinic|Yes|Completed|August 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|Heart Transplant Patients|May 2014|May 8, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01527344||91402|
NCT01527357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FC-004|Phase 3 Study of Fibrocaps™ in Surgical Bleeding|A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Hemostasis|FINISH-3|ProFibrix, Inc.|Yes|Completed|May 2012|June 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|719|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527357||91401|
NCT01527877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0828-001|Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck|An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy||Yonsei University|Yes|Recruiting|September 2012|August 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|20 Years|80 Years|No|||October 2012|October 4, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01527877||91361|
NCT01528163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-ONCO 2011-01|Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Therapy.|RACATREX|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|February 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528163||91339|
NCT01528176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00703|Vitamin D Metabolism in Chronic Kidney Disease Patients|Vitamin D Metabolism in Chronic Kidney Disease Patients With Vitamin D Deficiency Treated With Cholecalciferol||Memphis VA Medical Center|Yes|Active, not recruiting|November 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|70|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|February 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01528176||91338|
NCT01529333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G070237|Middle-Ear Implant With MET V Transducer (Aka MET V System)|Middle Ear Implant With MET V for Mixed Hearing Loss||Otologics LLC|No|Not yet recruiting|May 2012|August 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|February 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529333||91250|
NCT01529021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E 23795|Reducing Children's Distress Towards Flu Vaccinations|||University of Calgary|Yes|Completed|October 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|57|||Both|5 Years|9 Years|Accepts Healthy Volunteers|Non-Probability Sample|children in the general public and from hospital ages 5-9 years|February 2012|February 7, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01529021||91274|
NCT01529320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIM-MPA-2011-01|Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers|Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study).||Fundacion IMIM|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 25, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529320||91251|
NCT01529840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHNOO-1658|Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome|Norditropin Treatment in Subjects With Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit||Novo Nordisk A/S|No|Completed|August 2005|September 2005|Actual|September 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|N/A|N/A|No|||April 2014|April 29, 2014|January 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529840||91211|
NCT01530126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005 - PDGF|Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain|Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain||University of Michigan|No|Completed|January 2000|January 2007|Actual|January 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|25 Years|75 Years|No|||January 2016|January 6, 2016|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01530126||91189|
NCT01527422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01297478|Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL|Protocol CCAM 05-02 " Phase I-II Study of Dose Dense of PEG Filgrastim and GM-CSF as Support for Dose Desnse CHOP-R Front Line Therapy for Aggressive Non Hodgkin's Lymphoma"|CHOP-R|Auxilio Mutuo Cancer Center|Yes|Completed|January 2006|March 2011|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2012|February 3, 2012|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527422||91396|
NCT01527669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110011MB|The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects|The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects.||National Taiwan University Hospital|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||February 2012|July 9, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01527669||91377|
NCT01527968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|242119|Epsilon Aminocaproic Acid Vs. Tranexamic Acid Vs. Placebo for Prevention of Blood Loss in Total Knee Arthroplasty|A Prospective, Randomized, Double Blind, Double-Dummy Study Comparing the Safety and Efficacy of Epsilon Aminocaproic Acid (eACA) Versus Tranexamic Acid (TXA) Versus Placebo for Prevention of Blood Loss in Total Knee Arthroplasty||Heekin Orthopedic Research Institute|No|Completed|April 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|54|||Both|21 Years|N/A|No|||March 2015|March 30, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01527968||91354|
NCT01527981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGHBMED2172010|Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes|CBT for Adherence and Depression in Type 1 Diabetes||Massachusetts General Hospital|No|Completed|March 2008|November 2010|Actual|November 2010|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|80 Years|No|||February 2012|February 3, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01527981||91353|
NCT01528267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H0708/100|Bronchoscopic Lung Volume Reduction Using Blood|A Randomised, Double Blind, Sham Controlled Trial of Autologous Blood Lung Volume Reduction||Chelsea and Westminster NHS Foundation Trust|No|Completed|November 2009|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|80 Years|No|||December 2013|December 19, 2013|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528267||91331|
NCT01559129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-SSC-001|Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease|A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease||Celgene Corporation|Yes|Active, not recruiting|August 2012|February 2019|Anticipated|February 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|80 Years|No|||March 2016|March 23, 2016|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559129||88976|
NCT01558258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-001799|A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors|A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors||Jonsson Comprehensive Cancer Center|No|Completed|April 2011|November 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|71|||Female|N/A|50 Years|No|||April 2015|April 8, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01558258||89043|
NCT01559389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203952|Incontinence & Intimate Partners: Assessing the Contribution of Treatment|Incontinence & Intimate Partners: Assessing the Contribution of Treatment|IIMPACT|Loyola University|No|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|200|||Female|18 Years|89 Years|No|||March 2016|March 1, 2016|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559389||88956|
NCT01559415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38099|An Adipocyte-Driven Mechanism For Weight Regain After Weight Loss: The Yo-Yo Effect|An Adipocyte-Driven Mechanism For Weight Regain After Weight Loss: The Yo-Yo Effect|ADIPOSTRESS|Maastricht University Medical Center|No|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Both|20 Years|65 Years|No|||December 2014|December 22, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01559415||88954|
NCT01528202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLS_SUB60|Tart Cherries and Melatonin Content|Effect of Tart Cherry Juice (Prunus Cerasus) on Melatonin Levels and Sleep Quality||Northumbria University|No|Completed|April 2010|June 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|20|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||February 2012|February 3, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528202||91336|
NCT01528215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-PLUS-0001|Multicenter Study Comparing OsseoSpeed TX With OsseoSpeed EV.|An Open, Prospective, Randomized, Multicenter Study Comparing OsseoSpeed™ EV With OsseoSpeed™ TX in Partially Edentulous Maxillae and Mandibles. A 5-year Follow-up Study.||Dentsply Implants||Active, not recruiting|November 2011|||June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||December 2015|December 15, 2015|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528215||91335|
NCT01528475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICE PACS|Initiation of Cooling by EMS to Promote Adoption of In-hospital Hypothermia in Cardiac Arrest Survivors|Initiation of Cooling by Emergency Medical Services to Promote the Adoption of In-hospital Therapeutic Hypothermia in Cardiac Arrest Survivors: the ICE-PACS Trial||Sunnybrook Health Sciences Centre|Yes|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|900|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01528475||91315|
NCT01528488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVOZAC20110210|Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC|A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer||Sun Yat-sen University|No|Completed|December 2011|July 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|118|||Both|N/A|N/A|No|||November 2013|November 4, 2013|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528488||91314|
NCT01528748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15599|Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence|Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence||University of Virginia|No|Recruiting|April 2011|July 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|21 Years|65 Years|No|Non-Probability Sample|Participants will be recruited via a community sample.|May 2014|May 21, 2014|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01528748||91295|
NCT01529034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P261-402|Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters|An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters||Upsher-Smith Laboratories||Recruiting|July 2012|||March 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|165|||Both|12 Years|N/A|No|||January 2016|January 20, 2016|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529034||91273|
NCT01529346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291009|Efficacy Of PF-05089771 In Treating Postoperative Dental Pain|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study Assessing The Efficacy Of Single Doses Of PF-05089771 For The Treatment Of Postoperative Dental Pain Using Ibuprofen 400 mg As Positive Control||Pfizer|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|235|||Both|18 Years|55 Years|No|||August 2012|August 1, 2012|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529346||91249|
NCT01529593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0923|Temsirolimus in Combination With Metformin in Patients With Advanced Cancers|Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers||M.D. Anderson Cancer Center|No|Recruiting|March 2012|||March 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|104|||Both|14 Years|N/A|No|||October 2015|October 28, 2015|February 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529593||91230|
NCT01529580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00049467|School-Age Children With Autism With Limited Expressive Language Skills|School-Age Children With Autism With Limited Expressive Language Skills: An Intervention Study||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|13|||Both|48 Months|95 Months|No|||October 2015|October 13, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529580||91231|
NCT01529853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDR11326|To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)|Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Sanofi|Yes|Completed|January 2012|October 2013|Actual|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529853||91210|
NCT01530399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-MDC-11-01|Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery|A Phase II, Double-blind, Parallel Group, Dose-selection Study to Compare Antifibrinolytic MDCO-2010 vs. Placebo and Tranexamic Acid in Reducing Blood Loss in Patients Undergoing Primary Cardiac Surgery||The Medicines Company|Yes|Terminated|March 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|44|||Both|18 Years|85 Years|No|||November 2015|November 4, 2015|February 7, 2012|Yes|Yes|Safety|No|November 4, 2015|https://clinicaltrials.gov/show/NCT01530399||91168|
NCT01526278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YY_PK_2011|Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women|Pharmacokinetics of a Single Oral Dose of Maxmarvil® in Healthy Postmenopausal Women Without a Previous History of Fractures|YY_PK_2011|Yuyu Pharma, Inc.|Yes|Recruiting|October 2011|September 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|55 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 13, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526278||91482|
NCT01527435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06-0044|Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)|Zeaxanthin as an Adjuvant to Combination Therapy for Treatment of Choroidal Neovascularization (CNV) in Exudative Age Related Macular Degeneration (ARMD)|ARMD|The Retina Center of St. Louis County, PC|No|Active, not recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|200|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1. Male or female at least 50 years of age.          2. Subjects must have age related macular degeneration with a choroidal neovascular             membrane either classic or occult in at least one eye.          3. Preoperative best corrected visual acuity (BCVA) equal to or greater to 19 letters on             the ETDRS diabetic retinopathy study chart (20/400 Snellen).          4. Media clarity, pupillary dilation and subject cooperation sufficient for accurate OCT             and angiographic assessment.          5. Written and informed consent has been obtained.          6. Written authorization for the use and release of the health and research study             information in the United States of America USA.          7. Ability to understand the informed consent and willingness to follow study             instruction and likely to complete all required visits and procedures.|October 2015|October 29, 2015|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01527435||91395|
NCT01527682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-004763-19|Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma|Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor for the Treatment of Pediatric Glaucoma||Azienda Ospedaliera Spedali Civili di Brescia|Yes|Active, not recruiting|July 2009|July 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|N/A|12 Years|No|||August 2015|August 31, 2015|February 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01527682||91376|
NCT01527994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0457|Aprepitant Effects in Intravenous Heroin Dependence|Clinical Laboratory Evaluations of Aprepitant for the Treatment of Opioid Dependence: Inpatient Test||New York University|Yes|Completed|January 2012|February 2015|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|No|||April 2015|April 13, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01527994||91352|
NCT01528280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPE2012FRuiz|Humoral and Cellular Response in Shift Workers|Vaccination Against Hepatitis A Virus in Shift Workers: Evaluation of the Humoral and Cellular Immune Response||Federal University of São Paulo|Yes|Recruiting|January 2013|December 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|75|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01528280||91330|
NCT01558037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU-ViraCor 001|Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients|A Study to Correlate CMV-Specific Cell Mediated Immunity With Risk of CMV Disease and With Clinical Response to Therapy Following Solid Organ Transplantation|ViracorCMI|Northwestern University|No|Completed|April 2010|March 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|113|Samples Without DNA|Blood|Both|18 Years|N/A|No|Probability Sample|The main study will recruit adult solid organ transplant recipients at Northwestern        Memorial Hospital who are CMV donor positive, recipient negative (D+/R-) and SOT        recipients at NMH who are CMV recipient positive, irrespective of donor status (D±/R+). A        sub-study of this study will enroll up to 50 adult SOT recipients who have quantifiable        CMV DNA by PCR and require CMV antiviral therapy, irrespective of their participation in        the main study. Patients will be identified prior to transplantation as part of the        pre-transplant evaluation process and will be consented either pre-transplant or on the        first post-operative day in which they can provide written consent.|April 2013|April 3, 2013|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01558037||89060|
NCT01558271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13990|A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus|A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|March 2012|May 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|492|||Both|20 Years|N/A|No|||May 2015|May 20, 2015|March 12, 2012|Yes|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01558271||89042|
NCT01558583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCRF-CARR2-11-0861|Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making|A Comparison of the Effect of a Conjoint Analysis Based Values Clarification Exercise, Rating and Ranking Exercise, and Balance Sheet for Colorectal Cancer Screening and Prostate Cancer Screening Decision Making|CARR2|University of North Carolina, Chapel Hill|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|1831|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01558583||89018|
NCT01559168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/RdeT-04|Uphold Mesh for the Surgical Treatment of Uterine-predominant Prolapse|Clinical Evaluation of the Uphold Mesh for the Surgical Treatment of Uterine-predominant Prolapse: a Prospective, Multicenter Trial||Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|October 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Female|50 Years|N/A|No|||February 2016|February 5, 2016|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559168||88973|
NCT01529073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTZSPA001|Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection|Phase II Clinical Trial to Evaluate the Antiviral Activity of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in Individuals With Chronic Hepatitis Due to HCV Genotype 4 and Coinfected by HIV||Andaluz Health Service|Yes|Active, not recruiting|February 2012|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|65 Years|No|||January 2015|January 13, 2015|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01529073||91270|
NCT01528501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589BDE03T|Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)|An Open-label, Uncontrolled Phase II Trial of HDAC-Inhibitor LBH589 in Patients With Chemo-refractory Metastatic Gastric Cancer Overexpressing Histone Deacetylases (HDACs) - CLBH589BDE03T|HDAC|Technische Universität München||Terminated|June 2009|||February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|90 Years|No|||December 2012|April 30, 2013|February 1, 2012||No|medical/ethical reasons|No||https://clinicaltrials.gov/show/NCT01528501||91313|
NCT01528514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRG5380258|Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study|The Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study|CUPID|Thailand Research Fund|Yes|Recruiting|September 2009|December 2012|Anticipated|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|N/A|No|||February 2012|February 7, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01528514||91312|
NCT01528761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 R01 HL109429-04|Prosocial Behavior and Volunteerism to Promote Physical Activity in Older Adults|Prosocial Behavior and Volunteerism to Promote Physical Activity in Older Adults||Wake Forest Baptist Health|Yes|Recruiting|February 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|55 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01528761||91294|
NCT01529047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35898-C|Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling|RTC of Web Versus In-Person SUD and Comorbidity Treatment||University of Washington|Yes|Enrolling by invitation|February 2010|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|375|||Both|17 Years|24 Years|No|||December 2013|December 10, 2013|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01529047||91272|
NCT01529060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28463|Phenylbutyrate Therapy for Maple Syrup Urine Disease|A Double-Blind, Randomized, Placebo-Controlled Trial of Phenylbutyrate in the Treatment of Maple Syrup Urine Disease|MSUD|Baylor College of Medicine|Yes|Active, not recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Years|N/A|No|||January 2016|January 25, 2016|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529060||91271|
NCT01530152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-20110006|Method Evaluation Study of Truview Picture Capture Device(PCD) Versus MacIntosh Laryngoscope|Method Evaluation Study of Truview PCD Versus MacIntosh Laryngoscope||Aalborg Universitetshospital|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 18, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01530152||91187|
NCT01529866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3013|Study of the Integration Success of an Implant System With a Novel Abutment Attachment Design in Immediate Loading Cases|A Prospective Randomized-controlled Study of the Integration Success Rate of an Implant System With a Novel Abutment Attachment in Cases Loaded Immediately|Bridge|Biomet, Inc.|No|Active, not recruiting|August 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529866||91209|
NCT01530139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Food4Me-549426|Strategies for Personalised Nutrition|Personalised Nutrition: An Integrative Analysis of Opportunities and Challenges|Food4Me|Newcastle University|No|Completed|August 2012|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|1607|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 25, 2016|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01530139||91188|
NCT01530386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1031|A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects|A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects||UCB Pharma|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530386||91169|
NCT01526538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA029823|Improving Learning-based Treatment of Cocaine Dependence With Medication|Improving Learning-based Treatment of Cocaine Dependence With Medication||Johns Hopkins University|No|Completed|September 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01526538||91462|
NCT01527149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 201611|Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma||Roswell Park Cancer Institute|Yes|Recruiting|December 2011|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|70 Years|No|||October 2015|October 28, 2015|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527149||91417|
NCT01528007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03062010|Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention|Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial||National Institute for Health and Welfare, Finland|No|Completed|January 2011|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|October 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528007||91351|
NCT01528293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ActiVac|ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations|A Prospective, Randomized, Comparative Effectiveness Trial of the ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations||Georgetown University|No|Terminated|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||August 2015|August 25, 2015|January 27, 2012|Yes|Yes|slow recruitment - unable to meet enrollment goals|No|April 14, 2015|https://clinicaltrials.gov/show/NCT01528293||91329|Enrollment was insufficient to support statistical analyses. Three subjects were screened and only one completed the study. The study was terminated due to insufficient enrollment.
NCT01528306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-026|A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa|An Exploratory, Cross-Over Study of the Safety of HP802-247 Applied to Open Wounds of Subjects With Dystrophic Epidermolysis Bullosa||Healthpoint|No|Withdrawn|March 2012|July 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|N/A|No|||May 2012|May 15, 2012|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528306||91328|
NCT01528605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNSFC-30872113|Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration|The Effects of Lutein and Zeaxanthin Supplementations on Early Age-related Macular Degeneration||Peking University|Yes|Completed|June 2010|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|168|||Both|50 Years|N/A|No|||August 2014|August 18, 2014|December 28, 2011|Yes|Yes||No|July 20, 2014|https://clinicaltrials.gov/show/NCT01528605||91306|
NCT01528839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1908Si267|Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression|Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled Study.||Charite University, Berlin, Germany|Yes|Completed|March 2004|August 2008|Actual|May 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|65 Years|No|||February 2012|February 7, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01528839||91288|
NCT01558596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-014-11F|Remote Ischemic Preconditioning Prior to Vascular Surgery|Cardiac Remote Ischemic Preconditioning Prior to Elective Major Vascular Surgery|CRIPES|VA Office of Research and Development|Yes|Active, not recruiting|September 2011|September 2016|Anticipated|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|99 Years|No|||January 2016|January 20, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558596||89017|
NCT01558609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|401|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||March 19, 2012|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558609||89016|
NCT01558869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MONC-HBP24|Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma|An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma||The University of Hong Kong|No|Recruiting|April 2012|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||February 2015|February 20, 2015|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01558869||88996|
NCT01559155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/PS-02|Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid|Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|November 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|130|Samples With DNA|All left over plasma samples will be incorporated into the biological collection at the      Nîmes University Hospital.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is composed of three groups: (1) 50 patients with newly diagnosed        (untreated) bullous pemphigoid, (2) 50 control patients matched for age and sex with the        previous group and (3) 30 patients with other dermatological auto-immune disease (15        pemphigus + 15 cutaneous lupus).|October 2015|November 3, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559155||88974|
NCT01559740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH IRB 2009-13887|Transversus Abdominis Plane Blocks for Infants and Children for Postoperative Pain Control|Transversus Abdominis Plane Blocks for Infants and Children for Postoperative Pain Control: Is it the Concentration or Volume of Local Anesthetic Solution That Improves Analgesia?||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|July 2010|||August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|36|||Both|N/A|8 Years|No|||March 2012|March 19, 2012|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559740||88929|
NCT01529086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDUCE-FOR CAUSE|For Cause Prostate Biopsy in REDUCE Population Trial|Determining the Likelihood of Prostate Cancer Detection in Men Taking Dutasteride When Biopsy is Performed 'for Cause'.||The Cleveland Clinic|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Time Perspective: Retrospective||4|Actual|6729|||Male|50 Years|75 Years|No|Probability Sample|REDUCE trial participants|January 2012|February 7, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01529086||91269|
NCT01529359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PiLeJe-LactiTol-0210|Irritable Bowel Syndrome and Lactibiane Tolerance|Effect of Lactibiane Tolerance on Symptoms Severity of Irritable Bowel Syndrome||Pileje|No|Recruiting|April 2010|December 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|October 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01529359||91248|
NCT01529372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-0020-HT|REnAL denervatIon by ultraSound Transcatheter Emission|REnAL denervatIon by ultraSound Transcatheter Emission|REALISE|ReCor Medical, Inc.|No|Active, not recruiting|May 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||November 2014|November 24, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01529372||91247|
NCT01529606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44DE019041|Cold Plasma for Dental Restoration and Caries Prevention|Development of a Miniature Plasma Brush for Dental Clinical Applications||Nanova, Inc|Yes|Completed|September 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01529606||91229|
NCT01529879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3014|Assessment of the Effect of an Implant System With a Novel Abutment Attachment Design on Crestal Bone Preservation|A Prospective Randomized-Controlled Evaluation of an Implant System With a Novel Abutment Attachment Design for the Preservation of Crestal Bone|Polaris|Biomet, Inc.|No|Active, not recruiting|August 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529879||91208|
NCT01529892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1I|The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine|An Open-Label Study to Evaluate the Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine in Healthy Adults||California Pacific Medical Center Research Institute|Yes|Withdrawn||||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 29, 2013|February 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529892||91207|
NCT01530425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKK-WRWC|Outcome Measures for Pediatric Wheelchairs in Low-resource Settings|Development of a Suite of Outcomes Measures Suitable for Use in Low-resource Settings to Compare Pediatric Wheelchairs Within the Framework of the International Classification of Function, Disability and Health|Wheels|Bethany Relief and Rehabilitation International Inc.|Yes|Recruiting|March 2011|December 2014|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|20|||Both|6 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with disabilities in a primary school in Kenya who would benefit from available        study wheelchairs, and who can provide feedback. Assent provided with parental consent.|February 2012|February 9, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01530425||91166|
NCT01530438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-067|Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis|Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis : Neuropsychological, Imaging and Neuropathological Study|SLAMEM|University Hospital, Caen||Recruiting|April 2009|May 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||March 2014|April 8, 2014|February 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01530438||91165|
NCT01530412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-3-LTE|Long Term Evaluation of Activity Levels Post Pulmonary Rehabilitation|Long Term Evaluation of Activity Levels Post Pulmonary Rehabilitation: 1 Year Follow-up||Beaumont Hospital|No|Completed|June 2007|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Both|35 Years|N/A|No|||February 2012|February 9, 2012|August 18, 2010||No||No||https://clinicaltrials.gov/show/NCT01530412||91167|
NCT01526291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2010.0103|Patient-Reported Outcomes With LASIK:PROWL-1|Patient-Reported Outcomes With LASIK:PROWL-1|PROWL-1|Food and Drug Administration (FDA)|Yes|Completed|August 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|550|||Both|21 Years|84 Years|No|Non-Probability Sample|Active duty service members residing in San Diego, CA and planning to undergo refractive        surgery using LASIK for myopia, hyperopia, or astigmatism|February 2014|February 13, 2014|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526291||91481|
NCT01527162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23HD060764-03B|Orthotics in Ambulatory Cerebral Palsy|Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy|SAFO|Seattle Children's Hospital|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|2 Years|9 Years|No|||February 2016|February 3, 2016|January 30, 2012||No||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01527162||91416|
NCT01527175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNB-KJT-12|Ultrasound-guided Subclavian Venous Catheterization in Children|Comparision of Ultrasound-guided Supraclavicular and Infraclavicular Approach for Central Venous Catheterization in Children|SuCVC|Seoul National University Hospital|No|Completed|November 2011|||February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|98|||Both|N/A|10 Years|No|||March 2012|March 30, 2012|January 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01527175||91415|
NCT01528319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-1|Open-Label Study for Shoulder Dislocation Using MG-1|Open Clinical Trial of Arthroscopic Bankart Repair Using MG-1 for Dislocation of the Shoulder|MG-1|Johnson & Johnson K.K. Medical Company|No|Completed|December 2011|November 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|16 Years|N/A|No|||July 2014|July 14, 2014|January 15, 2012||No||No|January 26, 2014|https://clinicaltrials.gov/show/NCT01528319||91327|
NCT01528618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEM20110714|Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma|A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)||Sun Yat-sen University|Yes|Active, not recruiting|October 2015|June 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|362|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01528618||91305|
NCT01528852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003027|Chlorhexidine Cordcare for Reduction in Neonatal Mortality and Omphalitis|Efficacy of Use of Chlorhexidine to Clean Umbilical Cord of Neonates in First 10 Days for Reduction in Neonatal Mortality and Omphalitis - A Community Based Randomized, Double Masked Controlled Trial in Pemba Tanzania|CHX-Pemba|Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|October 2010|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|28000|||Both|N/A|48 Hours|No|||February 2012|February 7, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528852||91287|
NCT01528865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2010 097|Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma|A Phase I/II Study of Safety and Efficacy of Lamivudine (EPIVIR®) and Tenofovir Disoproxil Fumarate (VIREAD®) Used to Lower the Plasma Level of Viral RNA of HERV-K(HML2) in Patients With Lymphoma||University of Michigan Cancer Center|Yes|Withdrawn|December 2015|||August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|January 12, 2012|Yes|Yes|Funding was removed.|No||https://clinicaltrials.gov/show/NCT01528865||91286|
NCT01529177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|metformin for spermatogenesis|Metformin for the Treatment of Unexplained Oligozspermia|Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia||The Egyptian IVF-ET Center|Yes|Recruiting|February 2012|February 2017|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Male|25 Years|50 Years|No|||August 2015|August 5, 2015|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01529177||91262|
NCT01529437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669|Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies|Phase 1 Single Center, Randomized, Controlled Study Using Sublingual Immunotherapy for Timothy Grass and Dust Mite Allergies|SLIT|Stanford University|Yes|Completed|January 2005|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|5 Years|N/A|No|||November 2015|November 24, 2015|January 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529437||91242|
NCT01558310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSI ScalpPsor 012011|A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis|A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis||Yamauchi, Paul Steven, M.D., Ph.D.|No|Not yet recruiting|August 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558310||89039|
NCT01558323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908B2102|Pharmacokinetics of LCQ908 in Patients With Renal Impairment|An Open-label, Parallel-group, Single Dose Study to Assess the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Renal Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.||Novartis||Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|58|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558323||89038|
NCT01558336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schistosmiasis|Schistosoma Haematobium Infections and Praziquantel|Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel||University of Khartoum|Yes|Completed|August 2008|September 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|520|||Both|6 Years|15 Years|No|||January 2013|January 16, 2013|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558336||89037|
NCT01558622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KVDU 0001 GG|Intraoperative Use of Dexketoprofen Trometamol, Pethidine Hcl, Tramadol Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication|Intraoperative Use of Dexketoprofen Trometamol, Tramadol Hcl, Pethidine Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication||Kavaklıdere Umut Hospital|No|Active, not recruiting|March 2012|||May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|6||Anticipated|72|||Both|18 Years|60 Years|No|||March 2012|March 22, 2012|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558622||89015|
NCT01558635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-CRYO-001|Safety and Efficacy of Cryothermia to Treat Longstanding Persistent Atrial Fibrillation (AF)|Cryo-AF Clinical Study||Medtronic Cardiovascular|No|Active, not recruiting|September 2012|March 2016|Anticipated|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558635||89014|
NCT01558882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/VL-05|Impact of Essure Tubal Sterilization Devices on the Endometrium|Impact of Essure Tubal Sterilization Devices on the Endometrium||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|January 2014|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|All left over samples will be included in the hematology biological collection at the Nîmes      University Hospital.      Endometrial flushing samples will also be included in the Nîmes University Hospital biobank.|Female|35 Years|41 Years|No|Non-Probability Sample|Ten women desiring tubal sterilization via the ESSURE method.|March 2016|March 21, 2016|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01558882||88995|
NCT01560247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU-PRIISM-02|Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry|Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry|PRIISM2|MindFrame, Inc.|No|Active, not recruiting|January 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|The purpose of this registry is to compile data in a "real world setting". All subjects in        whom there is an attempt to use the device will be included in the registry. All subjects        must be recruited according to the Mindframe System "Instructions For Use".|April 2012|April 3, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560247||88890|
NCT01529632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2326|Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Study to Compare the Efficacy and Safety of Once Daily QVA149 Versus the Once Daily Concurrent Administration of QAB149 Plus NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|BEACON|Novartis|No|Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|193|||Both|N/A|N/A|No|||January 2014|January 16, 2014|February 6, 2012|No|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT01529632||91227|
NCT01529645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V113_01|Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years|Phase I, Randomized, Controlled, Observer-Blind, Dose-Ranging Study of Acellular Pertussis and Tetanus-Diptheria-Acellular Pertussis Booster Vaccine in Adults Ages 18 to 40 Years.||Novartis||Completed|March 2012|July 2013|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|10||Actual|420|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|February 6, 2012||No||No|April 30, 2014|https://clinicaltrials.gov/show/NCT01529645||91226|
NCT01529385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORT 112|Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes|Efficacy of a Mild Compression Diabetic Sock Versus A Non- Compression Diabetic Sock in the Control of Lower Extremity Edema in Patients With Diabetes: A Randomized Controlled Trial||Rosalind Franklin University of Medicine and Science|No|Completed|February 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|N/A|No|||November 2014|November 7, 2014|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01529385||91246|
NCT01529619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713D1403|Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors|A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-23) Switched From Cholinesterase Inhibitors (Donepezil, Galantamine)||Novartis||Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|50 Years|85 Years|No|||December 2014|December 9, 2014|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529619||91228|
NCT01529905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-1715|Longitudinal Study of People Presenting for First Treatment of a Mood Disorder|Longitudinal Study of Individuals Presenting With a First Treated Episode of Depression of Mania (First Episode Project)||McMaster University||Recruiting|June 1999|June 2014|Anticipated|September 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|16 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|patients who present to a tertiary care clinic for first treatment of depression or mania|June 2005|February 8, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01529905||91206|
NCT01530165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS10-A5|(Pakistan Diabetes Prevention Program PDPP)|A Translation Randodomized Trial of Culturally Specific and Cost Effective Life Style Intervention for the Prevention of Type 2 Diabetes in Pakistan|PDPP|Aga Khan University|Yes|Active, not recruiting|December 2011|October 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|20000|||Both|30 Years|64 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01530165||91186|
NCT01526317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14755-101|A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers|A Randomized, Open Label, Cross-over Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers||Yuhan Corporation|No|Completed|December 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|36|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526317||91479|
NCT01526304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFS|The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers|A Cross-Sectional Study To Investigate The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers||University of Zurich|No|Recruiting|January 2012|January 2014|Anticipated|||Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples Without DNA|Whole Blood|Both|18 Years|70 Years|No|Non-Probability Sample|All stoneformer patients at the first outpatient stone clinic consultation|January 2012|February 2, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526304||91480|
NCT01526551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCDHD-12-HPV|A Study to Compare the Impact of a School Based HPV Program on Vaccination Uptake and Completion Rates|A Study to Compare the Impact of a School Based HPV Vaccination Program on Vaccination Uptake and Completion Rates Among High School Students in Rural, Southeastern Kentucky||Lake Cumberland District Health Department|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|935|||Both|12 Years|20 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|December 22, 2011||No||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01526551||91461|
NCT01526837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSSNY-B-001|Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence|A Dose-Escalating Phase I Study for Safety and Tolerability of Bevacizumab in Collagen Delivery Vehicle Administered Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence||Brain & Spine Surgeons of New York|No|Recruiting|October 2011|October 2017|Anticipated|October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||February 2015|February 3, 2015|November 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01526837||91439|
NCT01527695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0490C00004|PET Study in Parkinson's Disease Patients|A Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's Disease||AstraZeneca||Completed|April 2012|January 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|45 Years|75 Years|No|||January 2013|January 30, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01527695||91375|
NCT01528631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1AP029010911|The Effects of D-Fagomine on Glycaemic Response to Sucrose in Men|Randomized Controlled Double-blind Nutritional Intervention Trial to Evaluate the Effects of D-fagomine on Glycaemic Response to Sucrose in Men||Bioglane|No|Completed|February 2012|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Male|20 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01528631||91304|
NCT01529216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC CP TAN2011- 014|Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus|An Advanced Configuration (The Third Generation) of the DIAMOND System for the Treatment of T2DM Patients - A Randomized, Double Blind Study|RUBY|Metacure|No|Completed|May 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|21 Years|70 Years|No|||March 2016|March 15, 2016|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01529216||91259|
NCT01528878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 0809|Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases|A Dose-finding, Safety and Preliminary Efficacy Study of Stereotactic Radiosurgery for Hepato-cellular Carcinoma and Metastatic Disease to the Liver.||UNC Lineberger Comprehensive Cancer Center|Yes|Suspended|April 2009|April 2017|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2015|November 23, 2015|January 9, 2012|No|Yes|Data analysis|No||https://clinicaltrials.gov/show/NCT01528878||91285|
NCT01528891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11070498|Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation|Dexmedetomidine as a Rapid Bolus for Treatment and Prophylactic Prevention of Emergence Agitation in Anesthetized Children||Children's Hospital of Pittsburgh|No|Completed|January 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|418|||Both|4 Years|10 Years|No|||February 2012|December 15, 2015|February 6, 2012|Yes|Yes||No|September 16, 2015|https://clinicaltrials.gov/show/NCT01528891||91284|
NCT01529190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pregabalin|Pregabalin on Interleukin-6 Levels in Living Donor Kidney|Effect of Preoperative Pregabalin on Pain Intensity and Interleukin-6 Levels in Living Donor Kidney||Federal University of São Paulo|Yes|Completed|March 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||December 2011|February 7, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01529190||91261|
NCT01529450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0009|Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors|A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothened Inhibitor(s)||Stanford University|Yes|Terminated|February 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|October 11, 2011|No|Yes|Data analysis|No||https://clinicaltrials.gov/show/NCT01529450||91241|
NCT01558895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FS-001|Infrared Ray Heat Treatment in Liver Cirrhosis Patients With Refractory Ascites|Infrared Ray Heat Treatment in Hepatic Area in Liver Cirrhosis Patients With Refractory Ascites||First People's Hospital of Foshan|Yes|Recruiting|March 2012|April 2013|Anticipated|March 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01558895||88994|
NCT01558908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDS-027|Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia|Allogeneic,Unrelated, Menstrual Derived, Mesenchymal Stem Cell-Like, Endometrial Cells; Administered Intramuscular||Medistem Inc.||Not yet recruiting|May 2012|July 2013|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||March 2012|March 18, 2012|March 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558908||88993|
NCT01559181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-41-6044|Study of Offspring of Women With Type 1 Diabetes|Environmental Versus Genetic and Epigenetic Influences on Growth, Metabolism and Cognitive Function in Offspring of Mothers With Type 1 Diabetes|EPICOM|Odense University Hospital|No|Active, not recruiting|April 2012|December 2016|Anticipated|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|584|Samples With DNA|Whole blood, serum and plasma. Tissue biopsies from m. vastus lateralis and subcutaneous      abdominal fat (only selected subgroup of participants)|Both|13 Years|19 Years|No|Probability Sample|Offspring of mothers with type one diabetes.|October 2015|October 13, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559181||88972|
NCT01559441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 11-3-085|Beetroot Juice and Postprandial Vascular Activity|The Effects of Beetroot Juice on Postprandial Vascular Activity After a High-fat Meal in Overweight and Slightly Obese Men||Maastricht University Medical Center|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01559441||88952|
NCT01559454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD0600908A|Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients|A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients||State University of New York at Buffalo|Yes|Completed|February 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||July 2014|July 18, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559454||88951|
NCT01529944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHNOO-3680|Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658|Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial||Novo Nordisk A/S|No|Completed|September 2008|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|N/A|N/A|No|||April 2014|April 29, 2014|January 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01529944||91203|
NCT01529957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-C-2|A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion|A Phase I Clinical Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion||TaiGen Biotechnology Co., Ltd.|No|Completed|September 2008|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|176|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 16, 2012|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529957||91202|
NCT01529918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eDM-1|Detecting Diabetes Sooner With a Risk Survey for the Family Doctor:Comparing Internet and Traditional Methods of Communication for Patients and Doctors|e-Diabetes:Uptake, Patient Preferences and Clinical Outcomes Regarding Self-screening and Clinical Follow-up Using Web-based Technologies in a Large Team-based Primary Care Setting||McMaster University|No|Active, not recruiting|November 2009|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2000|||Both|40 Years|N/A|No|||October 2009|February 8, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01529918||91205|
NCT01529931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-8-FU-1Y|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||November 18, 2014|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529931||91204|
NCT01530178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-246|Sitagliptin Dose Determination Study|Sitagliptin Dose Determination Study in Type 1 Diabetes||Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|November 2011|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|7|||Both|13 Years|30 Years|No|||June 2015|June 22, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01530178||91185|
NCT01530451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOCOSA-001|Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients|Prospective, Randomized, Double-blind Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients||Chinese University of Hong Kong|No|Terminated|March 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||February 2015|February 2, 2015|February 2, 2012||No|Insufficient funding|No||https://clinicaltrials.gov/show/NCT01530451||91164|
NCT01526577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-PYCL001|Study of LC23-1306 in Healthy Male Subjects|A Dose Blocked-randomized, Double-blind, Active and Placebo Controlled, Single and Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect||LG Life Sciences|Yes|Recruiting|March 2012|December 2012|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 9, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01526577||91459|
NCT01526590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS_M11-203|Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions|A Pilot Study of the Effects of Contrast Enhanced Endoscopic Ultrasound on Determining Vascular Involvement in Pancreatic Lesions||University of Vermont|No|Withdrawn|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|January 10, 2012|Yes|Yes|Lack of support|No||https://clinicaltrials.gov/show/NCT01526590||91458|
NCT01526564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZHAOKE-2007L03540|Clinical Study on Acetyl-L-Carnitine|Phase III Study of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablets in Treatment of Peripheral Sensory Neuropathy in Anti-cancer Chemotherapeutics Induce||Lee's Pharmaceutical Limited|Yes|Completed|August 2008|July 2011|Actual|April 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|239|||Both|18 Weeks|75 Years|No|||February 2012|November 7, 2013|September 14, 2010||No||No||https://clinicaltrials.gov/show/NCT01526564||91460|
NCT01526850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D07050701350701|Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease|Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease|MSCsTcGVHD|Chinese Academy of Medical Sciences|Yes|Recruiting|February 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|60 Years|No|||February 2012|August 1, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01526850||91438|
NCT01528020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41565-C|Collaborative Adolescent Research on Emotions and Suicide|Treatment of Suicidal and Self-Injurious Adolescents With Emotional Dysregulation|CARES|University of Washington|Yes|Active, not recruiting|January 2012|May 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|13 Years|17 Years|No|||November 2014|November 6, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01528020||91350|
NCT01529463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01-001-E|Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients|Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients||Saint Francis Care|No|Completed|January 2011|November 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|21|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized with an admitting diagnosis of acute decompensated heart failure.|December 2012|February 28, 2013|January 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01529463||91240|
NCT01529723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSTVS-1|Validity of a New Stroke Dysphagia Screening Tool|Validity of a New Stroke Dysphagia Screening Tool||Rhode Island Hospital|No|Recruiting|February 2012|May 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|||Both|18 Years|N/A|No|Probability Sample|Patients with acute ischemic stroke|March 2012|March 12, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529723||91220|
NCT01529736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3004|Randomized Study of Integration Success of Osseotite Dental Implants Placed Using Different Insertion Procedures|Prospective Randomized-controlled Study of the Integration Success of Osseotite Implants Placed With Different Insertion Procedures|Pegasus|Biomet, Inc.|No|Active, not recruiting|December 2010|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529736||91219|
NCT01530009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00740|The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children|The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children||Nationwide Children's Hospital|Yes|Recruiting|January 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|3 Years|21 Years|No|||February 2012|February 7, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01530009||91198|
NCT01530243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UUNRC 01|The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms|Phase One of Study on Urinary Stent Complications and Treatment||Urmia University of Medical Sciences|Yes|Completed|January 2012|September 2012|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|104|||Both|18 Years|55 Years|No|||February 2015|February 15, 2015|January 18, 2012|No|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT01530243||91180|Applying stents with the same size and length
NCT01559194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEAF|Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk|A Randomized Comparison of a Low Fat or Low Carbohydrate Dietary Pattern for Weight Loss and Impact on Biomarkers Associated With Breast Cancer Risk in Overweight and Obese Premenopausal Women: Lifestyle Eating and Fitness|LEAF|Ohio State University Comprehensive Cancer Center|Yes|Completed|May 2005|December 2007|Actual|December 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|82|||Female|30 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559194||88971|
NCT01559467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37574.068.11 / METC 11-2-077|The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction|The Supplementary Role of Cardiovascular Magnetic Resonance Imaging and Computed Tomography Angiography to Routine Clinical Practice in Suspected Non-ST Elevation Myocardial Infarction - A Randomized Controlled Trial|CARMENTA|Maastricht University Medical Center|No|Recruiting|April 2012|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|300|||Both|18 Years|85 Years|No|||April 2015|September 22, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01559467||88950|
NCT01559987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAH-11-0059|Dental Plaque Removal Study|A Randomized Parallel Method Development Study Comparing Clinical to Subclinical Effects From Oral Cleaning Modalities|PAU2|University of North Carolina, Chapel Hill|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Basic Science|3||Actual|270|||Both|18 Years|75 Years|No|||April 2014|January 20, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01559987||88910|
NCT01559753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUB/GC001|Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment|Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia||Centre Hospitalier Universitaire de Besancon|No|Completed|January 1998|November 2002|Actual|September 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01559753||88928|
NCT01560000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202E10321|Effect of Bran Fiber Type on Subjective and Objective Measures of Appetite|Effect of Bran Fiber Type on Subjective and Objective Measures of Appetite||University of Minnesota - Clinical and Translational Science Institute|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01560000||88909|
NCT01530477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101.02-2011-GES-0005|DXA Precision and Accuracy Comparison Study|DXA Precision and Accuracy Comparison Study|DXA P&A|GE Healthcare|No|Terminated|January 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|82|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The subject population sample will include approximately equal male/female split        volunteers (no gender bias) from clinical practice patients.|November 2015|November 15, 2015|February 6, 2012||No|Early termination due to inability to meet enrollment for >350lb weight class|No|June 26, 2013|https://clinicaltrials.gov/show/NCT01530477||91162|
NCT01530191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shobeiridepression_10.18.11|Factors Affecting Perioperative Outcomes|Factors Affectign Perioperative Outcomes After Surgery for Pelvic Organ Prolapse||University of Oklahoma|No|Withdrawn|September 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Female|21 Years|N/A|No|Non-Probability Sample|Participants will be drawn from the University of Oklahoma Urogynecology clinics. Our        catchment area includes OU Physicians clinic (private clinic) and Presbyterian        Professional Building (resident clinic).|October 2013|October 15, 2013|January 19, 2012||No|No subject accrual|No||https://clinicaltrials.gov/show/NCT01530191||91184|
NCT01530464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028417|The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers|The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers|GQ01|Duke University||Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 28, 2013|February 1, 2012|No|Yes||No|September 1, 2013|https://clinicaltrials.gov/show/NCT01530464||91163|
NCT01526330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14618-201|Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease|A Double-blind, Randomized, Parallel, Placebo Controlled, Phase I/II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH14618 Following Single Intradiscal Injection in Patients With Degenerative Disc Disease||Yuhan Corporation|Yes|Completed|May 2012|July 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|48|||Both|20 Years|N/A|No|||July 2014|May 27, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526330||91478|
NCT01527201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPS1561011B|The ChAMP (Chondral Lesions And Meniscus Procedures) Trial|Design of a Randomized Controlled Trial Examining the Effects of Arthroscopic Debridement on Chondral Lesions in Patients Undergoing Partial Meniscectomy: The ChAMP (Chondral Lesions And Meniscus Procedures) Trial||State University of New York at Buffalo|Yes|Active, not recruiting|January 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|30 Years|N/A|No|||July 2015|July 2, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01527201||91413|
NCT01526863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.53.NRC|Hydrolyzed Egg and Tolerance Induction|Assessment of the Effect of an HA Egg Administration for 6 Months on the Tolerance Induction to Egg in Children Allergic to Egg as Compared to a Placebo||Nestlé|No|Completed|October 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|12 Months|66 Months|No|||January 2015|January 15, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01526863||91437|
NCT01527188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO67.10|Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite (HDM) Tablets in Allergic Rhinitis Environment Exposure Chamber Model|A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase II Study to Assess the Efficacy and Safety of 100IR, 300IR and 500IR Sublingual Tablets of House Dust Mite Allergen for the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber Model||Stallergenes|No|Completed|January 2011|September 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|355|||Both|18 Years|55 Years|No|||August 2013|August 1, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01527188||91414|
NCT01527448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00032|Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II|An Open Label Dose Titration Study of Quetiapine XR in the Treatment of Postpartum Depression in Nonlactating Women Diagnosed With Bipolar Disorder (BD), Type II.||BC Women's Hospital & Health Centre|No|Completed|April 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Female|19 Years|40 Years|No|||February 2012|February 9, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01527448||91394|
NCT01528332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAINCT02|Blue Light Device for Pain Therapy|A Prospective, Randomized, Controlled, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Blue Light Therapy for Relief of Chronic Musculoskeletal Back Pain|PAINCT02|Light and Health Venture|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|171|||Both|18 Years|65 Years|No|||February 2014|February 7, 2014|February 1, 2012||No||No|September 9, 2013|https://clinicaltrials.gov/show/NCT01528332||91326|
NCT01529476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG-873870-C-4|Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP|A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)||TaiGen Biotechnology Co., Ltd.|No|Completed|April 2011|December 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|540|||Both|18 Years|70 Years|No|||June 2013|June 17, 2013|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529476||91239|
NCT01529749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-IMMUNESARTAN|Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated|Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation||Hospital Clinic of Barcelona|No|Completed|February 2012|January 2015|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01529749||91218|
NCT01530022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0998|Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects|A Multicenter, Randomized, Double-blind, Double-dummy, 2-period Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects||UCB Pharma|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530022||91197|
NCT01530256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD518-CLIN-010|Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)|An Exploratory Phase 1/2 Clinical Trial Evaluating ALd518 in Subjects With Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|ALD518-010|Alder Biopharmaceuticals, Inc.|Yes|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530256||91179|
NCT01559207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/SB-02|Reproducibility of Plasma Nucleosomes and Free DNA as Markers for Venous Thromboembolism|Reproducibility of Plasma Nucleosomes and Free DNA as Markers for Venous Thromboembolism||Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2013|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|Samples With DNA|EDTA, CTAD and dry tubes; Biological collection at the Nîmes University Hospital.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population is composed of 15 healthy volunteers with no history of VTE (group        "T") and 100 patients with VTE (group "P"). Fifteen randomly selected members of group P        make up the sub-group "Px".|March 2015|March 25, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559207||88970|
NCT01559220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0362|Deep Brain Stimulation for the Treatment of Alzheimer's Disease|Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease||Ohio State University|No|Recruiting|March 2012|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|45 Years|85 Years|No|||February 2016|February 19, 2016|March 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01559220||88969|
NCT01559480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R015532018|Postoperative Desogestrel for Endometriosis Related Pain|A Prospective Double Blind Randomized Controlled Trial to Study the Effectiveness of a Desogestrel for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis||Mahidol University|No|Completed|January 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|45 Years|No|||April 2015|April 8, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01559480||88949|
NCT01559493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version F 2nd Jan 2012|Fractional Flow Reserve (FFR) Versus Instant Wave-Free Ratio (iFR)|Comparison of Fractional Flow Reserve Versus Instant Wave-Free Ratio for Assessment of Coronary Artery Stenosis Severity in Routine Practice||NHS National Waiting Times Centre Board|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|The aim of the present study is to strengthen the results of retrospective comparisons of        iFR with FFR by conducting a prospective study in 200 consecutive, unselected patients        from 5 different centers.|March 2012|March 19, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01559493||88948|
NCT01559766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.2008BAI58B03|Dietary Vitamin A Requirement in Chinese Children and the New Technology of Dietary Assessment|Estimating Dietary Vitamin A Requirement in Chinese Children by Stable-isotope Dilution Technique||Huazhong University of Science and Technology|Yes|Completed|July 2009|September 2010|Actual|July 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|403|Samples Without DNA|serum|Both|4 Years|9 Years|No|Non-Probability Sample|The study was carried out in a kindergarten and an elementary school in Shiyan city, Hubei        province of China. Initially, 201 kindergarten children (4-6 years old) and 202 grade        children (7-9 years old) were subjected to a questionnaire survey on personal information,        medical history and dietary habits including dietary supplements.ongoing or previous        illnesses, having taken nutritional supplements within 3 months, positive results in the        fat absorption test or parasite test, increased level of CRP (> 8 mg/L), or lower serum        level of retinol (<1.40 umol/L), and higher ratio in relative dosage reaction test(>20%)        .After the screening, 123 children were selected and completed the study, but 60 subjects        were randomly selected for the DRD test to evaluate liver vitamin A storage.|March 2012|March 20, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559766||88927|
NCT01560013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112-10-TLV|The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent Patients|Brain Imaging Study on the Effects of Treatment With Naltrexone on Cue-induced Craving and Brain's Metabolic Changes in Alcohol and Cannabis-dependent Patients||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|22 Years|64 Years|No|||March 2012|March 20, 2012|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01560013||88908|
NCT01526356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0501|Topical Rapamycin to Erase Angiofibromas in TSC|Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy|Treatment|The University of Texas Health Science Center, Houston|Yes|Completed|May 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|177|||Both|N/A|N/A|No|||June 2015|June 9, 2015|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01526356||91476|
NCT01526369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 11-10|A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer|A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer|TH V THL|ICORG- All Ireland Cooperative Oncology Research Group||Terminated|January 2012|||June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|N/A|No|||February 2015|February 20, 2015|February 1, 2012||No|study closure to recruitment as of 2nd February|No||https://clinicaltrials.gov/show/NCT01526369||91475|
NCT01526343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105015|Medtronic Reveal XT Study|A Comparison of Traditional Arrhythmia Assessment With the Use of Continuous Monitoring to Quantify Postoperative Arrhythmia Burden Following Surgical Treatment of Atrial Fibrillation- Medtronic Reveal XT Study||Washington University School of Medicine|Yes|Active, not recruiting|June 2011|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|February 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01526343||91477|
NCT01526616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.31|Spironolactone Plus Metformin in Polycystic Ovary Syndrome|Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study||University Magna Graecia|No|Completed|May 2010|July 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Female|16 Years|35 Years|No|||February 2012|February 3, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01526616||91456|
NCT01526603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011OC072|High Dose Chemotherapy and Autologous Transplant for Neuroblastoma|High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Rescue for Neuroblastoma: Standard of Care Considerations||Masonic Cancer Center, University of Minnesota|No|Recruiting|March 2012|February 2018|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|30 Years|No|||January 2016|January 21, 2016|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01526603||91457|
NCT01526876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF4096|The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients|Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury||Columbia University|No|Withdrawn|November 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 26, 2013|February 2, 2012|Yes|Yes|Terminated by Sponsor|No||https://clinicaltrials.gov/show/NCT01526876||91436|
NCT01527474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1562007|Escitalopram in the Treatment of Postpartum Depression|An Open-label Study of Escitalopram in the Treatment of Postpartum Depression||BC Women's Hospital & Health Centre|No|Completed|April 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|19 Years|40 Years|No|||February 2012|February 9, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01527474||91392|
NCT01527487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI BRE 197|Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer|A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer||SCRI Development Innovations, LLC|Yes|Active, not recruiting|June 2012|March 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01527487||91391|
NCT01527461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-9031-NP-CTIL|Identifying Unique Scent Signature of Lung Cancer Through Body Odor|||Sheba Medical Center|No|Recruiting|February 2012|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|Samples Without DNA|sweat samples|Both|N/A|N/A|No|Non-Probability Sample|The recruitment process will take place at the lung department of Sheba medical center.        The participating physicians will enroll the patients and sing them on the consent form        when they come for their regular appointments.|June 2013|June 2, 2013|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01527461||91393|
NCT01527708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27/27-09-11|Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas|Repeatability, Reliability and Reproducibility of Pentacam-derived Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Cross-linked Corneas||Democritus University of Thrace|Yes|Completed|September 2011|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|129|||Both|18 Years|N/A|No|Probability Sample|Participants were recruited from the Cornea service of the EIT in a        consecutive-if-eligible basis.|January 2012|February 3, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01527708||91374|
NCT01528917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-2-NH01|An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype|An Observational Study of the Clinical Characteristics and Disease Progression of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype||Alexion Pharmaceuticals|No|Active, not recruiting|June 2011|May 2013|Anticipated|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|60|||Both|5 Years|N/A|No|Non-Probability Sample|Patients diagnosed with late onset LAL Deficiency/ Cholesteryl Ester Storage Disease        (CESD).|April 2013|April 30, 2013|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01528917||91282|
NCT01529203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.29097|Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range|Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range|FIRST|Galderma|No|Completed|February 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|60|||Both|18 Years|64 Years|No|||September 2014|September 16, 2014|January 30, 2012||No||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01529203||91260|
NCT01529489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVPS-123|Effect of Two Physical Training Programs on Oxygen Uptake and Heart Rate On-kinetics in Patients COPD|Effect of the Combined (Aerobic/Resisted) and Interval Physical Training on Oxygen Uptake and Heart Rate On-kinetics Responses in Patients With Moderate to Very Severe COPD: Double-blind, Randomized, Controlled Trial|BVPS-123|Universidade Federal de Sao Carlos|No|Completed|January 2008|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|40|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||February 2012|February 6, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01529489||91238|
NCT01529502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Blood Study Overweight|Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting|Effects of Stored Red Blood Cell Transfusion in Overweight Subjects With Endothelial Dysfunction: Influence of Inhaled Nitric Oxide (iNO)||Massachusetts General Hospital|Yes|Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|14|||Both|18 Years|60 Years|No|||January 2014|January 29, 2014|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529502||91237|
NCT01529762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3007|Observational Study of Osseotite Certain Tapered Implants in Immediate Loading Cases|A Prospective, Observational Study of Immediate Loading Cases Using Osseotite Certain Tapered Implants|Carrera|Biomet, Inc.|No|Active, not recruiting|January 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|47|||Both|18 Years|N/A|No|Probability Sample|Patients with partial edentulism needing a minimum of one dental implant restored        immediately (same visit)|March 2016|March 22, 2016|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529762||91217|
NCT01529775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3008|Randomized Study of Osseotite Certain Tapered Prevails vs. Osseotite Certain Tapered|A Prospective Randomized-controlled Evaluation of the Osseotite Certain Tapered Prevail Implant for the Preservation of Crestal Bone|Bolivar|Biomet, Inc.|No|Active, not recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529775||91216|
NCT01530035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-013|Cardiovascular and Muscular Adaptations to Recreational Soccer and Strength Training in Elderly Healthy 65-75-year-old Men|Cardiovascular and Muscular Adaptations to Recreational Soccer and Strength Training in Elderly Healthy 65-75-year-old Men||University of Copenhagen|No|Active, not recruiting|March 2011|November 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|41|||Male|65 Years|75 Years|Accepts Healthy Volunteers|||February 2012|February 8, 2012|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01530035||91196|
NCT01530269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIC-AC-002|C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma|C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma||Phoenix Molecular Imaging|No|Recruiting|April 2012|April 2017|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Male|18 Years|90 Years|No|||March 2015|March 6, 2015|February 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530269||91178|
NCT01559233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP1|Clinical Study to Determine Safety and Efficacy of FPlus for Wrinkle Treatment|Clinical Study to Determine Safety and Efficacy of FPlus for Wrinkle Treatment||Invasix|No|Completed|February 2011|March 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|69|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01559233||88968|
NCT01559506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-003|Air Barrier System Device to Reduce Contamination in Posterior Spine Surgery|ABS to Reduce Contamination in Spine Surgery||Nimbic Systems, LLC|Yes|Completed|November 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|41|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|March 14, 2012|Yes|Yes||No|February 25, 2015|https://clinicaltrials.gov/show/NCT01559506||88947|
NCT01559519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000931-20|Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy|Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt||University of Roma La Sapienza|Yes|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|80 Years|No|||December 2013|December 16, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01559519||88946|
NCT01559779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB-CD-10|Effect of Gastric Bypass Surgery on Pancreatic Islets and Incretin Function|The Effect of Gastric Bypass Surgery on the Beta- and Alpha Cells Secretory Function and the Insulinotropic Effect of the Incretin Hormones|AB-CD-10|Hvidovre University Hospital|No|Completed|November 2010|December 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|11|Samples Without DNA|Plasma and serum specimens are retained|Both|18 Years|65 Years|No|Non-Probability Sample|Subjects are recruited from the population undergoing gastric bypass surgery at Hvidovre        Hospital|June 2014|June 9, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559779||88926|
NCT01559792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BG092011|Band to Bypass - Metabolism Kinetics in Gastric Bypass and Banding|Gastric Banding to Bypass - Metabolism Kinetics in Gastric Bypass and Banding||Hvidovre University Hospital|Yes|Recruiting|December 2011|||December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|18|Samples With DNA|blood|Both|18 Years|65 Years|No|Non-Probability Sample|all with normal glucose tolerance - patients who are undergoing gastric bypass and        patients with a gastric band to are converted to gastric bypass|March 2012|March 20, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559792||88925|
NCT01560026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHG0500|Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma|Study for Elevate the Feasibility of Ovarian Preservation With Endometrial Carcinoma|ECWOP|Taipei Veterans General Hospital, Taiwan|Yes|Recruiting|August 2000|December 2012|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|300|||Female|25 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators retrospectively reviewed the cases of 150 patients who had primary        surgery with early stage endometrial cancer between January 1989 and December 2009|March 2012|March 24, 2012|June 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01560026||88907|
NCT01560039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMS-12-HS-0577-11-TLV-CTIL|Electroencephalography Based Neurofeedback in Chronic Neuropathic Pain|Voluntary Modulation of M1 Motor Cortex Activity Using EEG Neurofeedback for the Treatment of Resistant Chronic Neuropathic Pain - a Clinical and fMRI Study||Tel-Aviv Sourasky Medical Center||Not yet recruiting|April 2012|April 2014|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|65 Years|No|||March 2012|March 19, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01560039||88906|
NCT01526642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/080/HP|Home Non-invasive Ventilation for Chronic Obstructive Pulmonary Disease Patients|Home Non-invasive Ventilation Versus Long-term Oxygen Therapy in COPD Survivors of Acute Hypercapnic Respiratory Failure. A Multicenter Randomized Controlled Trial|NIVOLD|University Hospital, Rouen|Yes|Terminated|December 2011|December 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|85 Years|No|||September 2014|September 5, 2014|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01526642||91454|
NCT01526629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1047|Full Automaticity and Remote Follow-up|Identification of Implantable Cardioverter Defibrillator Patients With Remote Follow up That Requires an Onsite Visit||Medtronic Bakken Research Center|No|Active, not recruiting|May 2011|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|385|||Both|18 Years|N/A|No|Non-Probability Sample|Patient implanted with a sigle- or dual-chamber ICD or a Cardiac        Resynchronization-Defibrillator system (CRT-D) and remotely followed-up|December 2013|December 18, 2013|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01526629||91455|
NCT01526889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFG316A2204|Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,|A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy||Novartis|No|Recruiting|October 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01526889||91435|
NCT01527214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DirectCT|The Effect of Direct Referral for Fast CT Scan in Early Lung Cancer Detection in General Practice|The Effect of Direct Referral for Fast CT Scan in Early Lung Cancer Detection in General Practice. Clinical, Randomised Trial||University of Aarhus|No|Completed|November 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|650|||Both|N/A|N/A|No|||August 2013|August 5, 2013|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01527214||91412|
NCT01527227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|84-11|Parentification Among Children Whose Parents Cope With a Serious Mental Illness|Parentification Among Children Whose Parents Cope With a Serious Mental Illness||Hillel Yaffe Medical Center|No|Recruiting|January 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|130|||Both|9 Years|19 Years|Accepts Healthy Volunteers|Non-Probability Sample|The research group will be recruited by the WHO and ICMJE with sampling method. The        comparison group will be recruited from schools.|January 2012|February 2, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01527227||91411|
NCT01527500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFG316A2203|Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)|A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration||Novartis||Completed|January 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|158|||Both|55 Years|N/A|No|||March 2016|March 16, 2016|February 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527500||91390|
NCT01528059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DongFang|Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes|A Prospective Randomised Study Comparing Billroth II With Roux-en-Y Reconstruction After Radical Distal Subtotal Gastrectomy for Gastric Cancer Comorbid With Type 2 Diabetes||Xiamen University|Yes|Recruiting|February 2012|March 2013|Anticipated|February 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|110|||Both|30 Years|70 Years|No|||February 2012|February 6, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01528059||91347|
NCT01527721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3/2/2012 37|Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus|Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CXL Combined With Photorefractive Keratectomy (PRK) in Keratoconus.||Democritus University of Thrace|No|Completed|September 2010|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||February 2012|February 6, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01527721||91373|
NCT01527734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTX-CINP-201PK|Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers|COMPARISON OF THE PHARMACOKINETICS AND SAFETY OF LIQUID (30 µg) AND LYOPHILIZED TETRODOTOXIN (15 µg AND 30 µg) FOLLOWING SINGLE AND TWICE DAILY SUBCUTANEOUS DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS—DETERMINATIONS IN BLOOD AND URINE||Wex Pharmaceuticals Inc.||Completed|December 2011|||January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 7, 2012|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527734||91372|
NCT01528033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC2010-56|Treatment Study of Vacuum Assisted Closure for Postsurgical Subcutaneous Abdominal Wound Healing Impairments|Treatment of Subcutaneous Abdominal Wound Healing Impairment After Surgery Without Fascial Dehiscence by Vacuum Assisted Closure™(SAWHI-V.A.C.® Study) Versus Standard Conventional Wound Therapy|SAWHI|University of Witten/Herdecke|Yes|Recruiting|August 2011|November 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01528033||91349|
NCT01528046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16962|Metformin in Children With Relapsed or Refractory Solid Tumors|A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors||H. Lee Moffitt Cancer Center and Research Institute|Yes|Recruiting|September 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|1 Year|18 Years|No|||February 2016|February 4, 2016|February 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01528046||91348|
NCT01529229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPREMS1111|Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment|A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Moderate - Severe Persistent Allergic Rhinitis||EMS|Yes|Completed|November 2013|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|210|||Both|2 Years|11 Years|No|||January 2015|January 14, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529229||91258|
NCT01529515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100717|A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia|A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia||Janssen Research & Development, LLC|Yes|Completed|May 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|509|||Both|18 Years|70 Years|No|||June 2015|June 29, 2015|February 6, 2012|Yes|Yes||No|April 7, 2015|https://clinicaltrials.gov/show/NCT01529515||91236|
NCT01529788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medicis-Crow 4|Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study|A Double Blinded Randomized Controlled Trial to Compare the Efficacy, Time to Onset, and Duration of Two Botulinum Type A Exotoxins (Onabotulinum Toxin A and Abobotulinum Toxin A) in the Treatment of "Crow's Feet."||The Maas Clinic|No|Completed|September 2009|September 2014|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 29, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01529788||91215|
NCT01529801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3011|Assessment of the Effect of a Novel Surface Roughness Treatment on Dental Implants on Integration Success|A Prospective Randomized-controlled Study of the Effect of Surface Topographies on Implant Integration Rates and Clinical Success|Luna|Biomet, Inc.|No|Active, not recruiting|February 2011|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|80|||Both|18 Years|N/A|No|||May 2015|May 14, 2015|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01529801||91214|
NCT01530048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDS290-1750|Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)|A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial, Assessing the Bioequivalence Between Insulin Aspart 100 U/mL and Insulin Aspart 200 U/mL in Healthy Individuals||Novo Nordisk A/S|No|Completed|March 2006|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 29, 2012|February 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01530048||91195|
NCT01530282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERNI-0073496|Non-invasive Measurements of Elastance and Resistance|Non-invasive Respiratory Mechanics Assessment During Spontaneous / Assisted Breathing: The ERNI (Elastance, Resistance, Non Invasive Measurements) Study|ERNI|University of Turin, Italy|No|Not yet recruiting|February 2012|November 2012|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|80 Years|No|||February 2012|February 8, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01530282||91177|
NCT01530295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0326|Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer|Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant in Patients With High Risk Locallized Prostate Cancer||Asan Medical Center|Yes|Recruiting|July 2008|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|70|||Male|N/A|N/A|No|||February 2012|February 7, 2012|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01530295||91176|
NCT01530607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2091-013|Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer|Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer||King Faisal Specialist Hospital & Research Center||Completed|November 2009|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|416|||Female|18 Years|50 Years|No|||February 2012|February 24, 2016|January 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530607||91152|
NCT01530308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38027.029.12|Haloperidol Prophylaxis in Older Emergency Department Patients|Early Pharmacological Intervention to Prevent Delirium: Haloperidol Prophylaxis in Older Emergency Department Patients|HARPOON|VU University Medical Center|Yes|Completed|November 2012|October 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|242|||Both|70 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 25, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01530308||91175|
NCT01559246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iRT-001-2012|True Continuous ECG Monitoring (TCEM Study)|Comparison of Short Term Holter Monitoring vs. Long Term Zio(R)Patch True Continuous ECG Monitoring (TCEM Study)|TCEM|iRhythm Technologies, Inc.|No|Active, not recruiting|April 2012|December 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients 18 years of age of greater with suspected arrhythmias.|November 2012|November 5, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01559246||88967|
NCT01559532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|222|Influence of Tourniquet Use and Surgery Duration on the Incidence of Deep Vein Thrombosis in Total Knee Arthroplasty|Influence of Tourniquet Use and Surgery Duration on the Incidence of Deep Vein Thrombosis in Total Knee Arthroplasty||University of Sao Paulo General Hospital|No|Completed|February 2008|September 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|30 Years|90 Years|No|Non-Probability Sample|Seventy-eight consecutive patients from our institution underwent cemented TKA for        degenerative knee disorders and then underwent AV, for which they gave informed consent,        at a point between 7 and 12 days after surgery, after having been discharged from the        hospital.|March 2012|March 19, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01559532||88945|
NCT01559545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFA-03-CD-002|A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis|A Randomized, Open Label, Active Control, Safety, Tolerability and Pharmacokinetics Study of Two Dr. Reddy's Formulations of Metronidazole Versus Immediate Release Metronidazole (Flagyl) in Patients With Mild to Moderate C. Difficile Associated Diarrhea (CDAD)||Dr. Reddy's Laboratories Limited|No|Completed|March 2012|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559545||88944|
NCT01560052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GI-R-01-2011|Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Study)|Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study|TESTING|The George Institute|Yes|Recruiting|April 2012|September 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|750|||Both|14 Years|N/A|No|||July 2015|August 24, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01560052||88905|
NCT01560325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127ASC12A|Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers|Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-516 Inj. Administered on A Twice-Weekly Schedule in Patients With Advanced Solid Cancers Failed to Standard Therapy||Chong Kun Dang Pharmaceutical|No|Completed|June 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|75 Years|No|||August 2015|September 15, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01560325||88884|
NCT01560338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009214|Hypothermia's Impact on Pharmacology|Impact of Hypothermia on Midazolam and Morphine Pharmacokinetics|HIP|Children's Hospital of Philadelphia|No|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|41|Samples With DNA|Whole blood|Both|N/A|18 Years|No|Non-Probability Sample|The study population is the pediatric population equal to or greater than 3 kg and less        than 18 years of age AND have had or currently receiving morphine and/or midazolam AND        receive hypothermia after cardiac arrest administered as part of clinical care.|January 2016|January 29, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560338||88883|
NCT01527266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-3-068|Carbohydrate Mouth-rinse|The Impact of a Sucrose Mouth-rinse in the Fasted and Fed-state on Time Trial Performance|CHO rinse|Maastricht University Medical Center|No|Recruiting|February 2012|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|15|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01527266||91408|
NCT01526902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-12-02A|Proclear 1-D Multifocal Nondispensing Study|Proclear 1-D Multifocal Nondispensing Study||Coopervision, Inc.|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|40 Years|65 Years|No|||March 2014|March 7, 2014|February 2, 2012|No|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01526902||91434|
NCT01527240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.544|Neuroprotection Impact of Cyclosporin A in Cerebral Infarction|Cyclosporin A Combined to Intravenous Thrombolysis. Multicenter Randomized Placebo-controlled|CsAStroke|Hospices Civils de Lyon|Yes|Completed|October 2009|December 2013|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|85 Years|No|||January 2012|May 15, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01527240||91410|
NCT01527253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFC-Food Basket|Effect of a Synergistic Food Basket on Metabolic Syndrome Risk|Effects of a Synergistic Food Basket on Markers of Metabolic Syndrome Risk in Healthy Mature Women||Lund University|No|Completed|September 2011|December 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||May 2014|May 22, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01527253||91409|
NCT01527747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-142|Effects of DPP-4 Inhibition on Triglycerides|Effects of Dipeptidyl Peptidase-4 Inhibition With Saxagliptin on Fasting and Postprandial Triglyceride Concentrations||Oregon Health and Science University|No|Recruiting|January 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|80 Years|No|||October 2015|October 13, 2015|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01527747||91371|
NCT01527760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGUHS2010|Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension|Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension. One Group Pretest Posttest Design||Fr Muller Homoeopathic Medical College|Yes|Completed|February 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|40 Years|N/A|No|||February 2012|February 14, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01527760||91370|
NCT01528371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yoshi0112|Effect of Midazolam on White-coat Hypertensive Dental Patients|The Effect of Low Dose of Midazolam on Blood Pressure and Anxiety Scale in White-coat Hypertensive Dental Patients||Okayama University|No|Completed|October 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|20 Years|64 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01528371||91323|
NCT01528384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2009-002|Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient|A Phase 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient and Have Failed Prior Systemic Therapy||Polaris Group|No|Completed|December 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|4 Years|18 Years|No|||April 2014|April 8, 2014|January 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528384||91322|
NCT01528345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2210|Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer|A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy||Novartis||Completed|April 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|97|||Female|18 Years|N/A|No|||June 2015|June 19, 2015|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01528345||91325|
NCT01528358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11375|Tissue Near InfraRed Spectroscopy (NIRS) in Critically Ill Patients|Tissue NIRS in the Assessment and Management of Critically Ill Patients||Lawson Health Research Institute|No|Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|Samples Without DNA|Blood: inflammatory markers|Both|18 Years|90 Years|No|Non-Probability Sample|Critically ill patients early in clinical course of illness.|March 2015|March 31, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01528358||91324|
NCT01528644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBSRC grant:BB/G0055833/1|Iron & Alginate Study|Study to Measure the Absorption of Iron From Ferrous Gluconate Incorporated Into Alginate Beads.||University of East Anglia|No|Completed|February 2012|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01528644||91303|
NCT01528904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|318/VII-4/3 3186|Maternal Autoimmune Thyroid Disease and Fetal Thyroxin|Fetal Thyroid Hormones Concentration In Hyperthyroid or Hypothyroid Pregnant Women||University of Belgrade|Yes|Completed|January 2001|June 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|83|||Female|23 Years|45 Years|No|Non-Probability Sample|Groups are selected from State tertiary referral centre for Gynecology and Obstetrics|February 2012|February 5, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01528904||91283|
NCT01529242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPUEMS1111|Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment|A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash||EMS|Yes|Recruiting|February 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|2 Years|11 Years|No|||July 2015|July 13, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01529242||91257|
NCT01529255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOH-05|EFFORT Extension Study|A 3-year, Open-label, Multi-center Extension Trial of Telbivudine Therapy for Patients Previously Treated in EFFORT Clinical Trial|EFFORT-Ex|Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|August 2011|December 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|576|||Both|18 Years|65 Years|No|||June 2014|June 17, 2014|September 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01529255||91256|
NCT01541319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|712|Mechanism and Repository Study for the Red Cell Storage Duration Study|Mechanism and Repository Study for the Red Cell Storage Duration Study|MARS|New England Research Institutes|Yes|Active, not recruiting|July 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|300|Samples With DNA|plasma, pRBCs, PBMCs|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There are two study populations for MARS. One study population is adult subjects        undergoing complex cardiac surgery who are participating in the RECESS trial. The other        study population is a set of healthy adult volunteers.|February 2014|March 13, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01541319||90336|
NCT01541839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00028960|Comparison of a Septal Stapler to Suture Closure in Nasal Septoplasty|Randomized, Controlled Trial Comparing an Endoscopic Septal Stapler to Suture Closure in Primary Septoplasty||University of Alberta|No|Active, not recruiting|February 2012|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541839||90297|
NCT01542177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAZA-Pancreas|A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer|The Evaluation of Hypoxia Imaging in Patients With Pancreatic Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)||University Health Network, Toronto|No|Recruiting|February 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|None Retained|2 tubes of whole blood|Both|18 Years|N/A|No|Probability Sample|Pancreatic cancer|September 2015|September 3, 2015|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01542177||90271|
NCT01542489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1927|Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos|An Observational 3 Months Study to Evaluate the Effect of Insulin Levemir® on Glycaemic Control, Weight and Incidence of Hypoglycaemic Events in Insulin Treated Subjects With Type 1 or Type 2 Diabetes||Novo Nordisk A/S|No|Completed|October 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|480|||Both|N/A|N/A|No|Non-Probability Sample|Any subject with type 1 or type 2 diabetes treated with insulin in whom at the discretion        of the participating physicians it was decide to switch insulin treatment to the        long-acting insulin analogue Levemir® in combination with either insulin aspart        (NovoRapid®) or human insulin (Actrapid®)|February 2012|February 24, 2012|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542489||90247|
NCT01543035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETRALL DR3215|Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs|Phase III Prospective Multicentric Trial Evaluating Etravirine for HIV Infected Patients in Need of Lipid Lowering Drugs: the ETRALL Trial|ETRALL|University Hospital, Geneva|No|Completed|December 2011|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|70 Years|No|||December 2013|December 11, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543035||90206|
NCT01543308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-HDL-01|The Alteration of HDL Protein Composition in Patients With Coronary Heart Disease Before and After Statins Treatment|Phase 1 Study of Coronary Heart Disease Proteomics Research||Chinese Academy of Medical Sciences, Fuwai Hospital|No|Active, not recruiting|February 2012|December 2015|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|frozen in -80C|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Clinical indication for coronary heart disease and no lipid-lowering therapy in the past 2        weeks|May 2013|May 16, 2013|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01543308||90185|
NCT01515696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27112001|Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants|Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants- a Phase 4 Study||Medical University of Vienna|Yes|Completed|October 2007|February 2011|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|N/A|24 Hours|No|||June 2014|June 17, 2014|January 10, 2012|No|Yes||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01515696||92293|
NCT01515709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LF001H|Is the Short Physical Performance Battery a Useful Outcome Measure in Chronic Obstructive Pulmonary Disease|Is the Short Physical Performance Battery a Useful Outcome Measure in Patients With Chronic Obstructive Pulmonary Disease ?||Royal Brompton & Harefield NHS Foundation Trust|No|Active, not recruiting|April 2011|September 2016|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|445|||Both|N/A|N/A|No|Non-Probability Sample|Any patient with a diagnosis of COPD.|November 2014|November 4, 2014|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01515709||92292|
NCT01515735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-035|LOXL1 Polymorphism in Pseudoexfoliation Syndrome|Evaluation of LOXL1 Polymorphism in Pseudoexfoliation Syndrome in the Korean Population||Samsung Medical Center|Yes|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Peripheral blood sample|Both|20 Years|70 Years|No|Probability Sample|the groups or cohorts will be recruited from glaucoma clinic in Samsung medical center|January 2012|January 23, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515735||92290|
NCT01515748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCET_R_05153|Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer|A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer|PRODIGY|Sanofi|Yes|Recruiting|January 2012|July 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|530|||Both|20 Years|75 Years|No|||November 2015|November 26, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515748||92289|
NCT01516034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTR-2|The Efficacy of the Cupola Ultrasonic Tattoo Removal Device|The Efficacy of the Cupola Ultrasonic Tattoo Removal Device: A Prospective Single Blinded, Before-After Study Design||Cupola Medical Ltd|No|Terminated|November 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|January 16, 2012||No|Sponsor decided that the results were not significant enough to continue.|No|November 9, 2012|https://clinicaltrials.gov/show/NCT01516034||92267|
NCT01543477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOE-09-11|Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia|Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO II)|PASCO II|Hospira, Inc.|No|Recruiting|July 2010|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4500|Samples Without DNA|Pre-dose serum samples|Both|N/A|N/A|No|Non-Probability Sample|Patients currently under treatment with Retacrit (epoetin zeta) administered        subcutaneously for renal anaemia.|January 2016|January 21, 2016|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01543477||90172|
NCT01543204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101145|Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab|Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab||Amgen|No|Completed|October 2011|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543204||90193|
NCT01543698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2110|A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors|A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors||Array BioPharma|No|Recruiting|May 2012|||January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|179|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543698||90155|
NCT01544036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15591|Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram|Monitoring Renal Blood Flow Using Contrast Enhanced Ultrasound in Predicting Acute Kidney Injury After Exposure to Iodinated Contrast Agent||University of Virginia||Recruiting|February 2012|||February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|February 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01544036||90129|
NCT01539980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRCT-2554-21|Clinical Study on Silk Sericin Wound Dressing for Split-thickness Skin Graft Donor Sites Treatment|Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment||Chulalongkorn University|Yes|Completed|August 2012|April 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|60 Years|No|||April 2015|April 1, 2015|February 17, 2012||No||No|March 10, 2015|https://clinicaltrials.gov/show/NCT01539980||90438|
NCT01539993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00014768|Prospective Liver Study|Prospective Analysis of Liver Cancer Treatment and Interventions||Emory University|No|Completed|November 2008|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients 18 yrs and older with a diagnosis of Hepatocellular carcinoma and elegible for        percutaneous liver treatments|May 2014|May 23, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01539993||90437|
NCT01540227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN PT-011|Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.|Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis. Do Low Serum Penicillin Levels Correlate With Treatment Failure?||Ottawa Hospital Research Institute|No|Enrolling by invitation|September 2011|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Individuals presenting for treatment of primary, secondary or early latent syphilis will        be invited by their attending health care worker to participate in this study. Only        patients presenting for and requiring treatment of infectious syphilis will be asked to        participate.|October 2014|October 14, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01540227||90420|
NCT01540500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-1111|Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine|An Open-label, Single-sequence Study in Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP1A2 Inhibitor, Fluvoxamine||Vanda Pharmaceuticals|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|February 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540500||90399|
NCT01540786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-EC-010|An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics|An Exploratory Study to Evaluate Bladder Contractions in the Storage Phase (Non Voiding Activities) and Related Bladder Sensation in Healthy Females and Untreated Females With Overactive Bladder ("OAB") Using High Resolution and Conventional Urodynamics||Astellas Pharma Inc|Yes|Terminated|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|6|||Female|35 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|February 13, 2012||No|It was decided to discontinue the study due to insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01540786||90377|
NCT01540799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pathway M-1 (CIP-003)|Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache|Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache|Pathway M-1|Autonomic Technologies, Inc.|Yes|Active, not recruiting|February 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540799||90376|
NCT01541332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PO-MM-PI-0049|Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma|A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma||Oncotherapeutics|No|Active, not recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01541332||90335|
NCT01541345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012DR2009|Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2|A Phase III, Randomized, Controlled Clinical Trial of Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2||University of Zurich|No|Active, not recruiting|February 2011|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|20 Years|75 Years|No|||December 2015|December 1, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541345||90334|
NCT01541618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSDX-0411|A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis|A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis||MSDx, Inc.|No|Recruiting|January 2012|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples With DNA|Blood remaining after the biomarker test is completed will be retained for possible      evaluation of additional biomarkers|Both|45 Years|N/A|No|Probability Sample|The study populations for this study is a patient with a diagnosis of relapsing remitting        multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a        relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).|February 2012|February 29, 2012|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01541618||90313|
NCT01541358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0074|Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer|Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer||Stanford University|Yes|Terminated|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|February 23, 2012|No|Yes|Low accrual and no funding|No||https://clinicaltrials.gov/show/NCT01541358||90333|
NCT01541631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|087540|A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes|Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania.||Catholic University of Health and Allied Sciences|No|Not yet recruiting|May 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|2000|||Both|15 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 2, 2012|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01541631||90312|
NCT01541878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSARIM0025|Breast Cancer Registry in Thailand|Pilot Study of Breast Cancer Registry in Thailand||Siriraj Hospital|No|Recruiting|January 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Probability Sample|patients with breast cancer undergoing treatment|February 2012|February 29, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541878||90294|
NCT01541891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COXAVSSY0311FII|Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome|STUDY TO COMPARATIVE THE EFFICACY AND SAFETY OF PRO-148 OPHTHALMIC SOLUTION VS.SYSTANE® IN THE TREATMENT OF MILD-TO-MODERATE DRY EYE SYNDROME|PRO-148|Laboratorios Sophia S.A de C.V.|Yes|Active, not recruiting|September 2011|||February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||February 2012|February 29, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01541891||90293|
NCT01542190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0018014600011|Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery|A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery.||University of Campinas, Brazil|No|Completed|February 2011|August 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|50 Years|N/A|No|||December 2014|December 2, 2014|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01542190||90270|
NCT01509079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03962-10C|Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors|Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors||HealthPartners Institute|Yes|Completed|March 2012|March 2015|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|116|||Female|18 Years|N/A|No|||October 2015|November 30, 2015|December 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01509079||92796|
NCT01509417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 05-101|Different Feeding Methods After Pyloromyotomy|Prospective Randomized Trial Evaluating the Feeding Regimen After Pyloromyotomy.||Children's Mercy Hospital Kansas City|No|Completed|July 2010|February 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|N/A|3 Months|No|||May 2013|May 28, 2013|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01509417||92770|
NCT01543321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11-PR-KRYSTKOWIAK|Xenazine in Late Dyskinetic Syndrome With Neuroleptics|Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial|Xeladys|Centre Hospitalier Universitaire, Amiens|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01543321||90184|
NCT01515462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract 2009-017346-32|Gene Therapy for Wiskott-Aldrich Syndrome|A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome|TIGET-WAS|IRCCS San Raffaele|No|Active, not recruiting|April 2010|April 2023|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Male|N/A|N/A|No|||March 2015|March 5, 2015|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01515462||92311|
NCT01525043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYN-EPI-2011|Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow|Randomized, Parallel-Group, Open Label, Dose Finding Study to Evaluate the Efficacy of Synera Patch Compared to Naproxen Sodium for the Treatment of Lateral and Medial Epicondylitis of the Elbow||International Clinical Research Institute|No|Completed|February 2012|September 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|78|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525043||91576|
NCT01525329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1050|Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease|Combination Therapy With 5-Fluorouracil and Photodynamic Therapy for the Treatment of Post-transplant Premalignant Skin Disease||The Cleveland Clinic|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 2, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525329||91554|
NCT01525355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00013737|EUS Prior to ERCP in the Positive Setting of Positive Intraoperative Cholangiogram (IOC) During Cholecystectomy|A Prospective Study Evaluation the Role of EUS Prior to ERCP in the "Positive" Setting of Positive Intraoperative Cholangiogram (IOC) During Cholecystectomy||Wake Forest Baptist Health|No|Recruiting|October 2010|November 2012|Anticipated|November 2012|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have gone an uncomplicated cholesytectomy and determined to have a "positive        intraoperative cholangiogram" within one month of presentation to Wake Forest Baptist        Health.|February 2012|February 2, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525355||91553|
NCT01543490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-305-001|Comparative Study to Evaluate ISV-305 Compared to Vehicle in Non-Bacterial Blepharitis Subjects|A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (Dexamethasone in DuraSite®) Compared to Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis|ISV-305|InSite Vision||Not yet recruiting|December 2016|January 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543490||90171|
NCT01543711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-41-1530|Long Term Follow-up of Persistent Pain, Sensory Disturbances and Lymphedema After Breast Cancer Treatment|Long Term Follow-up of Persistent Pain, Sensory Disturbances and Lymphedema After Breast Cancer Treatment||Rigshospitalet, Denmark|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|2411|||Female|18 Years|80 Years|No|Non-Probability Sample|Woman treated for breast cancer in Denmark 2005-2006, and participated in the study in        2008|June 2013|June 5, 2013|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543711||90154|
NCT01543724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bpli2008|Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder|A Brain Imaging Study to Investigate Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder: Glycogen Synthase Kinase 3β Polymorphism (-50T/C) and Gray Matter Volume Increase Following Lithium Treatment in Bipolar Disorder||Seoul National University Hospital|Yes|Recruiting|August 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|50|||Both|19 Years|55 Years|No|||February 2012|March 2, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543724||90153|
NCT01544049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41774-G|Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study|Patients Salpingectomy as a Method of Ovarian Cancer Prevention: A Descriptive Study||University of Washington|No|Recruiting|December 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|25|||Female|18 Years|N/A|No|Non-Probability Sample|Women who have had their fallopian tubes removed as a method of ovarian cancer prevention.|April 2014|April 8, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01544049||90128|
NCT01544062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42204-D|IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery|Efficacy of Perioperative Intravenous Acetaminophen as an Adjunct Analgesic in Cardiac Surgery Patients|CarDolMev|University of Washington|Yes|Completed|July 2012|August 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|75 Years|No|||November 2014|November 24, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01544062||90127|
NCT01540253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 186510|PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic|A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors.||Roswell Park Cancer Institute|Yes|Active, not recruiting|May 2012|||June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|November 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540253||90418|
NCT01540266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR13I3_140651|Basel Discharge Communication Project|BACOP - Basel Discharge Communication Project - Study 3|BACOP|University Hospital, Basel, Switzerland|Yes|Completed|July 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|6||Actual|242|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 17, 2015|February 22, 2012||No||No|March 2, 2015|https://clinicaltrials.gov/show/NCT01540266||90417|
NCT01540240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005|Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients|Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients: A Randomized Controlled Trial|AZTlowdose|University Hospital, Geneva|Yes|Recruiting|August 2011|||December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540240||90419|
NCT01540526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO10907|Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib|Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule||University of Wisconsin, Madison|Yes|Completed|March 2012|December 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|February 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540526||90397|
NCT01540812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-AR/2011|Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS|||PETHEMA Foundation|Yes|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|15 Years|60 Years|No|Probability Sample|ALL patients|October 2015|October 12, 2015|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540812||90375|
NCT01540825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314.1|First in Man Trial of BI 113608|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113608 in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|80|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|December 5, 2012|February 13, 2012||||No||https://clinicaltrials.gov/show/NCT01540825||90374|
NCT01541644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00047788|1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma|A Pilot Study to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients||University of Maryland|Yes|Completed|May 2011|December 2014|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|27|||Both|18 Years|N/A|No|||October 2015|February 12, 2016|February 20, 2012|No|Yes||No|April 21, 2015|https://clinicaltrials.gov/show/NCT01541644||90311|TNSc results deemed invalid as original validation of TNSc was performed by 2 neuromuscular trained physicians & the TNSc in our trial was performed by a research nurse. The reliability & validity of research nurse's TNSc not established pre-trial.
NCT01541657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03AR06156101|Sensory-Targeted Ankle Rehabilitation Strategies (STARS)|Sensory-Targeted Ankle Rehabilitation Strategies|STARS|University of Kentucky|Yes|Completed|December 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|80|||Both|18 Years|45 Years|No|||September 2014|September 12, 2014|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01541657||90310|
NCT01542515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-298|Allograft Meniscal Arthroplasty for the Treatment of Basal Joint Arthritis of the Thumb|Allograft Meniscal Arthroplasty for the Treatment of Basal Joint Arthritis of the Thumb||William Beaumont Hospitals|No|Completed|March 2009|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|22|||Both|25 Years|95 Years|No|Non-Probability Sample|Men and women of all ages having the diagnosis of osteoarthritis of the thumb.|July 2014|July 24, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01542515||90245|
NCT01542788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0107|Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 HCV Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon|POSITRON|Gilead Sciences|Yes|Completed|March 2012|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|278|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|February 17, 2012|Yes|Yes||No|January 6, 2014|https://clinicaltrials.gov/show/NCT01542788||90224|
NCT01509430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAHANCA 25B|Progressive Resistance Training as Intervention for Regaining Muscle Mass After Radiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma|Progressive Resistance Training as Intervention for Regaining Muscle Mass After Radiation Therapy in Patients With HNSCC - a Randomized Controlled Trial||Danish Head and Neck Cancer Group|Yes|Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|41|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01509430||92769|
NCT01509391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCVGRZ-IM1|Keyhole Limpet Hemocyanin in Chronic Hepatitis C|Keyhole Limpet Hemocyanin in Chronic Hepatitis C and Compensated Cirrhosis - Pilot Study IM1|IM1|Medical University of Graz|No|Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|80 Years|No|||October 2012|October 16, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01509391||92772|
NCT01509404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00009601|Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection|Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection||Medical University of South Carolina||Completed|November 2011|December 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|N/A|No|||December 2015|February 12, 2016|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01509404||92771|
NCT01515475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTS1|Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation|Glasses Versus Observation for Moderate Hyperopia in Young Children (HTS1)|HTS1|Jaeb Center for Health Research|Yes|Active, not recruiting|February 2012|February 2018|Anticipated|February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|672|||Both|12 Months|71 Months|No|||February 2016|February 22, 2016|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01515475||92310|
NCT01515488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-110|Kiosk-Model Self-Triage System in the Pediatric Emergency Department|Assessing Utility of a "Kiosk Model" Self-Triage System in the Pediatric Emergency Department of A Tertiary Care Teaching Hospital||Maricopa Integrated Health System|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|400|||Both|N/A|18 Years|No|||September 2012|September 13, 2012|January 13, 2012||No||No|August 14, 2012|https://clinicaltrials.gov/show/NCT01515488||92309|
NCT01525927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSLIJ0844|Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity|Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders||Northwell Health|Yes|Terminated|August 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|February 1, 2012|Yes|Yes|Principal Investigator left institution. IRB approval lapsed.|No|August 28, 2015|https://clinicaltrials.gov/show/NCT01525927||91509|Study terminated , PI left the institution, no data analyzed
NCT01525940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCE-CTC|PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy|PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy||Catholic University of the Sacred Heart|No|Completed|November 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01525940||91508|
NCT01525953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCRT-EC|Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis|Predictors of Survival for Complete Clinical Responders to Definite Chemoradiation or Radiation Therapy for Esophageal Cancer|CRCRT-EC|Centre Oscar Lambret|No|Completed|January 2012|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|110|||Both|18 Years|N/A|No|Non-Probability Sample|Patient treated for esophageal cancer in the Northern France Cancer Center from january        1998 to december 2003|February 2012|February 1, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01525953||91507|
NCT01543763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol No. 11955|Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors|Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors||University of California, San Francisco|Yes|Recruiting|May 2012|October 2015|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543763||90150|
NCT01543737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOF EC 01/2010|Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee|Single-blind Randomised Pragmatic Trial Comparing the Effectiveness of Two Hyaluronic Acid Viscosupplements, DUROLANE® (Single Injection) Versus HYALGAN® (Three Injections) for Symptomatic Tibiofemoral Osteoarthritis of the Knee.||Bioventus LLC|No|Terminated|February 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|290|||Both|40 Years|85 Years|No|||February 2016|February 11, 2016|February 20, 2012||No|post transfer of company ownership from Smith & Nephew to Bioventus LLC|No||https://clinicaltrials.gov/show/NCT01543737||90152|
NCT01543750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINCH-EA2|4-Aminopyridine in Episodic Ataxia Type 2|Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2|4AP in EA2|University of California, Los Angeles|Yes|Enrolling by invitation|April 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2014|February 7, 2014|May 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543750||90151|
NCT01540006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UISM-6|Outpatient Cardiac Rehabilitation in Austria|||Paracelsus Medical University|No|Recruiting|January 2009|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|90 Years|No|Non-Probability Sample|Any patients with heart disease willing to participate in an ambulant cardiac        rehabilitation.|October 2015|October 29, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540006||90436|
NCT01540279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Hospital Basel|Clinical Outcome in View of Surgical Site Infection (SSI) With Antibacterial Skin Sutures|Do Antibacterial Skin Sutures Reduce Surgical Site Infections After Open Abdominal Surgery?||University Hospital, Basel, Switzerland||Terminated|July 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|52|||Both|18 Years|N/A|No|Probability Sample|All patients with required open abdominal surgery will be consecutively enrolled.Data of        emergency patients are recorded separately as well as patients with a contaminated or        dirty-infected (class III-IV) operative wound classified according to CDC guidelines on        surgical wound classification1 further Patients with implanted foreign material such as        mesh or vascular prosthesis.|March 2015|March 17, 2015|February 22, 2012||No|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01540279||90416|
NCT01540552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA11-1128|Natural History of Lung Nodules Seen on CT Scans From Participants at High-Risk of Developing Lung Cancer|Evolution of Undetermined Ld-CT Detected Lung Nodules Among a Randomized Phase II Trial With Inhaled Budesonide||M.D. Anderson Cancer Center|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|320|||Both|50 Years|N/A|No|Non-Probability Sample|Participants previously enrolled in two trials: (1) a large scale COSMOS trial and (2) a        subset of the COSMOS trial (MDA05-5-01 Budesonide study and treated for one year). Only        participants enrolled in both trials will be included.|January 2013|January 24, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540552||90395|
NCT01540539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R1154-HV-1116|Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers|||Regeneron Pharmaceuticals|Yes|Completed|March 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|8||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2014|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540539||90396|
NCT01541085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017920|An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART|Ex Vivo Study of Immune-Reconstitution Kinetics in HIV-infected ARV-naive Subjects, With Advanced Disease, Starting a Darunavir/Ritonavir or Efavirenz Based HAART (IMMUNO Study)||Janssen-Cilag S.p.A.|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 4|Observational|Time Perspective: Retrospective||2|Actual|33|||Both|30 Years|50 Years|No|Non-Probability Sample|Antiretroviral treatment-naive patients with advanced HIV infection starting a        Darunavir/Ritonavir - or Efavirenz-based HAART regimen. Patients with advanced HIV        infection are defined by a treatment-naïve CD4+ cell count >50 to <250 cells/mm3.|November 2013|November 25, 2013|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01541085||90354|
NCT01541072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ET2011-010|Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation|Lymphocyte Reconstitution in a Randomized Study After Administration of Pegfilgrastim Versus Filgrastim in Patients With B-cell Non-Hodgkin Lymphoma Treated With High-dose Chemotherapy and Autologous Peripheral Stem Cell Transplantation|PALM2|Centre Leon Berard|No|Terminated|February 2012|September 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|February 17, 2012||No|Number of enrolled patients was insufficient during planned inclusion time.|No||https://clinicaltrials.gov/show/NCT01541072||90355|
NCT01541384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814788|Medication Adherence in Kidney Transplant Recipients Using Automated Reminders and Provider Notification|Medication Adherence in Kidney Transplant Recipients Using Automated Reminders and Provider Notification||University of Pennsylvania|No|Completed|February 2012|September 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|120|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541384||90331|
NCT01542203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 062011-056|Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer|Impact of Body Weight on the Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide in Breast Cancer Patients||University of Texas Southwestern Medical Center|No|Not yet recruiting|March 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18|||Female|18 Years|N/A|No|Non-Probability Sample|primary care clinic|January 2012|February 29, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01542203||90269|
NCT01512940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPN 2011-024|Resolution of Comorbidities, Safety and Efficacy of Greater Curvature Plication in Obese Patients.|Laparoscopic Greater Curvature Plication for Weight Loss and Resolution of Diabetes and Other Comorbidities.|LGCP|Singh, Kuldeep, M.D., P.A.|Yes|Recruiting|October 2011|October 2014|Anticipated|October 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||March 2012|March 11, 2012|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512940||92502|
NCT01513278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APN201-1-01|Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer|Randomized, Double-blind, Split-body, Placebo-controlled Phase Ib Study of APN201 (Liposomal Recombinant Human Cu/Zn-superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer||Apeiron Biologics|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Female|18 Years|N/A|No|||July 2013|July 12, 2013|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01513278||92476|
NCT01513291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096-020|A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)|A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Patients With Episodic Migraine||Merck Sharp & Dohme Corp.|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|237|||Both|18 Years|64 Years|No|||October 2015|October 5, 2015|January 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513291||92475|
NCT01509092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PekingUTH-TMH-2011|Comparative Study Between Early Vitrectomy and Observation for Spontaneous Closure of Traumatic Macular Hole|Traumatic Macular Hole: Six-months Observation Versus Early Surgical Intervention, A Multicenter Clinical Trial||Peking University Third Hospital|Yes|Completed|January 2012|June 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|N/A|N/A|No|||January 2012|October 6, 2014|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01509092||92795|
NCT01540916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|842|Respiratory Alterations of Acid-base Equilibrium: Acute and Chronic Renal Response|Respiratory Alterations of Acid-base Equilibrium: Acute and Chronic Renal Response||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||Active, not recruiting|February 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|16 Years|N/A|No|||November 2015|November 7, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540916||90367|
NCT01509677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO-2455-402-RD|Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease|A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease||Takeda|No|Completed|February 2012|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|80 Years|No|||February 2016|February 18, 2016|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01509677||92750|
NCT01509690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Domain E/2011/1772|Impact of a Multidisciplinary Intensive Management Clinic on Outcomes in Multi-Ethnic Asian Incident Hemodialysis Patients|Impact of a Multidisciplinary Intensive Management Clinic on Clinical, Patient-Reported and Economic Outcomes in Multi-Ethnic Asian Incident Hemodialysis Patients||National University, Singapore|No|Recruiting||||||Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|150|||Both|21 Years|N/A|No|||April 2015|April 14, 2015|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01509690||92749|
NCT01524731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-149-SDR|The Effect of Prophylactic Antiemetic Dexamethasone on Plasma Cortisol Levels|The Effect of Prophylactic Antiemetic Dexamethasone on Plasma Cortisol Levels After Gynecologic Laparotomy||McGill University Health Center|Yes|Completed|May 2012|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|63|||Female|18 Years|80 Years|No|||September 2014|September 2, 2014|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01524731||91599|
NCT01524744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87909|A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus|||Mashhad University of Medical Sciences|Yes|Enrolling by invitation|March 2009|December 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|N/A|No|||January 2012|February 1, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01524744||91598|
NCT01525654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P000795|Patient Rheumatoid Arthritis Social Support Study|Rheumatoid Arthritis Patient-to-Patient Connection Program|PARASS|Brigham and Women's Hospital|No|Enrolling by invitation|March 2009|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 16, 2016|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01525654||91530|
NCT01525667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX-PAD 1301-01|Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty|A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty||Pluristem Ltd.|Yes|Completed|November 2012|June 2015|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|50 Years|75 Years|No|||January 2015|September 7, 2015|January 31, 2012|Yes|Yes||No|January 1, 2015|https://clinicaltrials.gov/show/NCT01525667||91529|
NCT01525901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0929|Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)|A Double-Blind Placebo-Controlled Crossover Trial of Insulin-Like Growth Factor-1 (IGF-1) in Children and Adolescents With 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)||Icahn School of Medicine at Mount Sinai|Yes|Active, not recruiting|February 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|5 Years|12 Years|No|||January 2016|January 26, 2016|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525901||91511|
NCT01525914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRT114918|Response of Patients on Surveillance for Prostate Cancer to Dutasteride|Assessment of Response of Patients on Surveillance for Favorable Risk Prostate Cancer to Dutasteride||Sunnybrook Health Sciences Centre|No|Completed|May 2010|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|100|Samples With DNA|prostate biopsy tissue stored on site|Male|18 Years|N/A|No|Non-Probability Sample|Subjects are a subset of the men with prostate cancer on surveillance for favorable risk        prostate cancer cohort|February 2012|February 2, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01525914||91510|
NCT01544088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-015-11F|Group CBT for PTSD|Group CBT for Chronic PTSD: RCT With Veterans|GCBT|VA Office of Research and Development|Yes|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|196|||Male|18 Years|N/A|No|||January 2016|January 21, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01544088||90125|
NCT01544075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|143201112788|Efficacy of Pain Neurophysiology Education in Combination With Psychologic Inoculation in Chronic Whiplash|Efficacy of Pain Neurophysiology Education in Combination With Psychologic Inoculation in Chronic Whiplash Associated Disorders : a Double-blind Randomised Controlled Trial||Vrije Universiteit Brussel|No|Enrolling by invitation|February 2012|||September 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01544075||90126|
NCT01540292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJT1123|Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders|Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders||University Hospital of Liege|No|Recruiting|March 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||January 2013|January 17, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540292||90415|
NCT01540032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AERD-01|Low Salicylate Diet in Aspirin Exacerbated Respiratory Disease|||Hamilton Health Sciences Corporation|No|Not yet recruiting|February 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01540032||90434|
NCT01540305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|49/09|Efficacy Study of Transcranial Magnetic Stimulation for Treatment of Obsessive-Compulsive Disorder|A Randomized Double-blind Trial of Repetitive Transcranial Magnetic Stimulation in Obsessive -Compulsive Disorder With Three Months Follow-up||University of Brasilia|No|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01540305||90414|
NCT01540838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFU/PARA-BOLU/PLACE|Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis|Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis, Especially of Pneumococcal Meningitis, in Angola.|INFU/PARA|Helsinki University|Yes|Recruiting|February 2012|July 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|2 Months|15 Years|No|||February 2016|February 19, 2016|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540838||90373|
NCT01541371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016165|A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Non Acute Episode Subjects With Schizophrenia||Xian-Janssen Pharmaceutical Ltd.|No|Completed|July 2008|September 2009|Actual|September 2009|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|405|||Both|18 Years|65 Years|No|||July 2013|July 3, 2013|February 23, 2012|Yes|Yes||No|February 28, 2013|https://clinicaltrials.gov/show/NCT01541371||90332|
NCT01541904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVO1209FII|Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis|STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRO-118 OPHTHALMIC SOLUTION IN ALLERGIC CONJUNCTIVITIS|PRO-118|Laboratorios Sophia S.A de C.V.|Yes|Suspended|March 2011|||February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|35|||Both|6 Years|N/A|No|||June 2013|June 3, 2013|February 21, 2012||No|Reformulation|No||https://clinicaltrials.gov/show/NCT01541904||90292|
NCT01512654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8266 3|Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2|Assessment of an Enhanced Version of a Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor-2) for Diabetic Patients Treated by Basal-Bolus Insulin Regimens||University Hospital, Montpellier|Yes|Completed|September 2008|June 2012|Actual|February 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|70 Years|No|||December 2014|December 2, 2014|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01512654||92524|
NCT01512953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-2011-1|Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata|Randomized Comparison of PPI Versus no PPI on Top of Standard Dose Clopidogrel Therapy in Patients Stratified Based on CYC2C19 Activity Via a Genetic Point of Care System.|GENIOUS|Università degli Studi di Ferrara|No|Recruiting|January 2011|August 2013|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|522|||Both|18 Years|N/A|No|||January 2012|January 19, 2012|January 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01512953||92501|
NCT01513304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AECCRCT1|Chiropractic Manual Therapy in Infantile Colic|||Anglo-European College of Chiropractic|No|Completed|September 2007|||May 2011|Actual|N/A|Interventional|Primary Purpose: Treatment|1||||||Both|N/A|8 Weeks||||January 2012|January 19, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513304||92474|
NCT01509105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096A1-4029|Prevenar13 Post Market Surveillance|Post Marketing Surveillance To Observe Safety Of Prevenar 13||Pfizer|No|Recruiting|June 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|||Both|6 Weeks|17 Years|No|Non-Probability Sample|All infants and children meeting the usual prescribing criteria for Prevenar 13 as per the        local product information for usage|February 2016|February 9, 2016|September 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01509105||92794|
NCT01541462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXJ001|Weaning From Prolonged Mechanical Ventilation|Weaning From Prolonged Mechanical Ventilation||RML Specialty Hospital|No|Completed|October 2000|October 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|No|||February 2012|February 23, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01541462||90325|
NCT01525056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRCP01|Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Nodes Using Pet-Ct, CT-Perfusion and 3T MRI|Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Node Metastases Using PET-CT, CT-Perfusion and 3T MRI: A Prospective Feasibility Study||London Health Sciences Centre|No|Completed|March 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01525056||91575|
NCT01525069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111068|Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma|Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma||Washington University School of Medicine|No|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01525069||91574|
NCT01525368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cogT002|Outcome Predictors of a Cognitive Intervention in aMCI|Outcome Predictors of a Complex Cognitive Intervention in Amnestic Mild Cognitive Impairment (aMCI)|OutPreC MCI|Ludwig-Maximilians - University of Munich|No|Completed|September 2010|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|110|||Both|N/A|N/A|No|Probability Sample|Consecutive aMCI patients of an University-based memory clinic|November 2014|November 11, 2014|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01525368||91552|
NCT01525602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX108-07|Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors||Plexxikon|No|Recruiting|May 2012|December 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01525602||91534|
NCT01525615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.15|A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Effect of 12 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg and 5/5 µg) Delivered by the Respimat® Inhaler, on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD)[Torracto (TM)]||Boehringer Ingelheim||Completed|February 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|404|||Both|40 Years|75 Years|No|||August 2015|August 12, 2015|February 1, 2012||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01525615||91533|
NCT01517672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEIN VA MERIT|Imaging Outcomes of Cognitive Behavioral Therapy (CBT) for Battered Women With Posttraumatic Stress Disorder|Neurobiology of Severe Psychological Trauma in Women||University of California, San Diego|No|Completed|January 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|41|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||January 2012|January 21, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01517672||92141|
NCT01513603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L-10,442|Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia|Phase II Trial of CLAG-M in Relapsed ALL||New York Medical College|No|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||January 2012|January 19, 2012|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513603||92451|
NCT01543776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0709|Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer|A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer||University of Chicago|No|Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Male|N/A|N/A|No|||March 2016|March 1, 2016|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543776||90149|
NCT01543789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2012/072|The Flemish Umbilical Nitinol Mesh Trial, a Multicenter Trial|The Flemish Umbilical Nitinol Mesh Trial, a Multicenter Randomized Controlled Trial.|FUN|University Hospital, Ghent|No|Recruiting|March 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01543789||90148|
NCT01543802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GISG-04|Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma|A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma|NOPASS|Heidelberg University|No|Recruiting|April 2013|June 2018|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543802||90147|
NCT01540019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FaculdadeMABC|Paullinia Cupana for Anorexia in Oncologic Patients|Guarana (Paullinia Cupana) for Anorexia Related to Cancer||Faculdade de Medicina do ABC|No|Recruiting|April 2011|July 2013|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2012|February 22, 2012|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01540019||90435|
NCT01540318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|244545-4|Utility of Abdominal Ultrasound in the Evaluation of Children With Blunt Trauma|Utility of Abdominal Ultrasound in the Evaluation of Children With Blunt Trauma||University of California, Davis|Yes|Enrolling by invitation|February 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|916|||Both|N/A|18 Years|No|||February 2012|February 27, 2012|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540318||90413|
NCT01540578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B3|Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia|OBSERVATIONAL: Replication Profiling as a Diagnostic Tool in B-cell Acute Lymphoblastic Leukemia (ALL)||Children's Oncology Group|Yes|Recruiting|February 2012|||January 2100|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|70|Samples With DNA|Fresh and frozen bone marrow cells|Both|N/A|N/A|No|Non-Probability Sample|Patients with B-cell acute lymphoblastic samples banked at the COG Cell Bank|November 2015|November 4, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540578||90393|
NCT01540565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00684|Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP) -1 and -2 Inhibitor Veliparib (ABT-888) (NSC #737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation||National Cancer Institute (NCI)|Yes|Active, not recruiting|April 2012|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|51|||Female|18 Years|N/A|No|||January 2016|March 4, 2016|February 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540565||90394|
NCT01540851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p002597|Adding Value in Knee Arthroplasty Post-total Knee Replacement (TKR) Care Navigator Trial|Adding Value in Knee Arthroplasty Post TKR Care Navigator Trial|AViKA|Brigham and Women's Hospital|No|Active, not recruiting|July 2011|November 2018|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|308|||Both|40 Years|N/A|No|||January 2016|January 22, 2016|February 21, 2012||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01540851||90372|
NCT01540864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPP404-201|A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects|A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects||High Point Pharmaceuticals, LLC.|No|Terminated|May 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|126|||Both|18 Years|65 Years|No|||August 2015|August 19, 2015|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540864||90371|
NCT01541098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-I-LyP-1|A Clinical Study of Lyophilized Plasma in Patients on Warfarin|A Phase II Clinical Study of Lyophilized Plasma in Patients on Warfarin||HemCon Medical Technologies, Inc|Yes|Withdrawn|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01541098||90353|
NCT01541670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|391001|Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis|A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis||Baxalta US Inc.|Yes|Terminated|November 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||May 2015|June 26, 2015|February 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01541670||90309|
NCT01512381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zubarev-vista-17-12|Atrioventricular Node Ablation in Patients With Atrial Fibrillation and Moderate Chronic Heart Failure|Variant of Stimulation in Atrioventricular Node Ablation (VISTA) in Patients With Atrial Fibrillation and Moderate Chronic Heart Failure|VISTA|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|No|Recruiting|December 2010|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||January 2014|August 13, 2015|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01512381||92545|
NCT01512667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-067|Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)|A Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Renal Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|January 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01512667||92523|
NCT01512680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8749|Evaluation of Functional Insulin Therapy in Type 1 Diabetic Patients|Evaluation of Functional Insulin Therapy on Blood Glucose Control in Type 1 Diabetic Patients Treated by Insulin Pumps|IFOPI|University Hospital, Montpellier|No|Recruiting|November 2011|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|70 Years|No|||December 2014|December 2, 2014|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01512680||92522|
NCT01540357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBT-TIN|Mindfulness-based Therapy in Chronic Tinnitus|Mindfulness-based Therapy For the Treatment of Chronic Tinnitus: A Randomized Controlled Pilot Study||University of Regensburg|No|Completed|May 2010|January 2012|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|80 Years|No|||September 2013|September 26, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540357||90410|
NCT01540370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-076|Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)|||Allergan|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|102|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with open-angle glaucoma and/or ocular hypertension|July 2013|July 16, 2013|February 23, 2012||No||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01540370||90409|
NCT01540630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNV1014802/202|A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia|A Phase IIa Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients With Trigeminal Neuralgia||Convergence Pharmaceuticals|Yes|Completed|March 2012|June 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|70 Years|No|||October 2014|October 29, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540630||90389|
NCT01541722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDCRN 5109|Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders|Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders||Children's Research Institute|Yes|Terminated|February 2012|July 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|N/A|N/A|No|Non-Probability Sample|Urea cycle disorders Inherited metabolic disorders N-acetylglutamate synthase (NAGS)        deficiency Carbamyl phosphate synthetase I (CPSI) deficiency Ornithine transcarbamylase        (OTC) deficiency Argininosuccinate synthetase (AS) deficiency (Citrullinemia)        Argininosuccinate lyase (AL) deficiency (argininosuccinic aciduria Arginase (ARG)        deficiency (hyperargininemia) Hyperornithinemia, hyperammonemia and homocitrullinuria        (HHH) syndrome, or mitochondrial ornithine carrier (ORNT) deficiency Citrullinemia type        II, mitochondrial aspartate/glutamate carrier (CITR) deficiency|October 2015|October 1, 2015|February 8, 2012||No|DSMB suggested closure due to low enrollment|No||https://clinicaltrials.gov/show/NCT01541722||90305|
NCT01525381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-221|Strategies to Improve Asthma|Strategies to Improve Diagnosis and Treatment of Asthma in Canadians||Ottawa Hospital Research Institute|No|Recruiting|November 2011|January 2015|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|644|||Both|18 Years|N/A|No|Non-Probability Sample|Canadians diagnosed with Asthma and 18 years of age and older.|May 2012|May 16, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01525381||91551|
NCT01525394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7080-A001-002|A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval|A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval||Eisai Inc.||Completed|December 2010|||August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|52|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|March 3, 2015|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01525394||91550|
NCT01525628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.27|Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients|A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection||Boehringer Ingelheim||Completed|April 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|72|||Both|18 Years|70 Years|No|||February 2015|February 4, 2015|February 1, 2012||||No||https://clinicaltrials.gov/show/NCT01525628||91532|
NCT01525641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|248.680|Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease|Special Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease||Boehringer Ingelheim||Completed|February 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|615|||Both|N/A|N/A|No|Non-Probability Sample|600|July 2015|July 17, 2015|February 1, 2012||||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01525641||91531|
NCT01513642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|oliveira1|Respiratory Physiotherapy After Cardiac Surgery|Inspiratory Volume and Muscle Recruitment During Breath-stacking and Incentive Spirometry Techniques in Postoperative Cardiac Patients||Universidade Federal do Rio de Janeiro|Yes|Completed|March 2009|December 2011|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|50 Years|70 Years|No|||January 2012|January 19, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513642||92448|
NCT01543529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28180|A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers|A Single Center, Randomized, Double-blind, Single-dose, Four Period, Crossover Study to Investigate Pharmacodynamics and Pharmacokinetics of RO4917838 Alone or With Concomitant Administration of Alcohol in Healthy Volunteers||Hoffmann-La Roche||Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543529||90168|
NCT01544114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1120C00037|A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)|A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)||Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|April 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|12 Years|16 Years|No|||February 2016|February 11, 2016|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01544114||90123|
NCT01544101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCCR-ARTH1|A Nutritional Intervention for Arthritis|A Nutritional Intervention for Arthritis||Physicians Committee for Responsible Medicine|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|N/A|No|||October 2012|October 18, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01544101||90124|
NCT01540591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22012|Intralipid for Repeated Implantation Failure|Does Intralipid Infusion Improve the Implantation Rate in Repeated Implantation Failure: a Randomized Controlled Trial|Intralipid|Cairo University|Yes|Completed|February 2012|June 2014|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 24, 2015|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540591||90392|
NCT01540604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardoz-004|CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers|An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD||RSPR Pharma AB||Completed||||||Phase 2|Interventional|N/A|1||||||Both|2 Years|11 Years||||October 2012|October 1, 2012|February 23, 2012||||No||https://clinicaltrials.gov/show/NCT01540604||90391|
NCT01540877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HypCap|A Human Experimental Model for Neuropathic Pain Using Combined Application of Capsaicin and Local Anesthetics|||Ruhr University of Bochum|No|Completed|April 2011|||September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|28|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||February 2012|February 28, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540877||90370|
NCT01540890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Polysom2012|Impairment of Sleep and Pattern of Breathing Before and After Opioid Withdrawal in Comparison to Patients Without Opioid Withdrawal|||Ruhr University of Bochum|No|Completed|November 2011|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|inpatients with chronic pain|March 2014|March 17, 2014|February 23, 2012||||No||https://clinicaltrials.gov/show/NCT01540890||90369|
NCT01541111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP0153/09|Magnesium Associated With Morphine for Cancer Pain Relief|Evaluation of Analgesic Effect of Magnesiun Associated With Morphine for Cancer Pain Relief||Federal University of São Paulo|No|Completed|January 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01541111||90352|
NCT01541397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0119|Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy|Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy||The University of Texas Health Science Center, Houston|No|Terminated|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 11, 2015|July 11, 2011|Yes|Yes||No|June 11, 2015|https://clinicaltrials.gov/show/NCT01541397||90330|
NCT01512095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3958|Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers|A Trial to Examine the Bioequivalence of Norditropin® Versus Nutropin AQ® in Healthy Adult Volunteers||Novo Nordisk A/S|No|Withdrawn|August 2013|November 2013|Anticipated|November 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|40 Years|No|||September 2013|September 13, 2013|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01512095||92567|
NCT01512108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3924|Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone|A 52-week, Multi-centre, Open-labelled, Randomised (2:1), Parallel-group Trial With an Active Control (Two OADs Combination Therapy) to Evaluate the Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Monotherapy||Novo Nordisk A/S|No|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|363|||Both|20 Years|N/A|No|||April 2014|April 25, 2014|January 10, 2012|Yes|Yes||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01512108||92566|
NCT01512394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 09-139|Pre-op Bowel Prep Before Abdominal Surgery|Effects of Preoperative Bowel Preparation Prior to Elective Bowel Resection or Ostomy Closure in the Pediatric Patient Population||Children's Mercy Hospital Kansas City|No|Withdrawn|November 2011|December 2013|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|3 Months|17 Years|No|||January 2016|January 27, 2016|December 13, 2011||No|Study was never started.|No||https://clinicaltrials.gov/show/NCT01512394||92544|
NCT01540136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sun Yat-sen University|Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma|A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Recruiting|February 2012|December 2016|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|372|||Both|18 Years|65 Years|No|||March 2013|September 2, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540136||90427|
NCT01540929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-406-002|Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel|A Phase IV Post-licensure DOD Screening Accuracy Study in Military Personnel||Sanofi|No|Completed|December 2008|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5001|||Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants who had completed the DoD Smallpox Screening Form 600 (2 part format)|April 2014|April 25, 2014|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540929||90366|
NCT01540942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS-1|Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease|A Randomized, Controlled, Open-label Study to Investigate the Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease||Jinling Hospital, China||Completed|November 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|No|||March 2014|March 20, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540942||90365|
NCT01541176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0013|Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation|Impact of the Absence of Steroids on the Evolution of Renal Function and on the Progression of Graft Fibrosis, Quantified by Numerical Method, in Patients With Renal Transplant|Astronef|Nantes University Hospital|Yes|Active, not recruiting|April 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|193|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541176||90347|
NCT01541189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489ACN14|Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.|A 8-week, Multi Center(10),Single Arm, Open-labeled Prospective Study of Valsartan 160 mg in 200 Mild to Moderate Chinese Hypertension Patients Forced Titrated From 2-week Therapy of Valsartan 80 mg.||Novartis|No|Completed|February 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|200|||Both|18 Years|80 Years|No|||November 2013|November 12, 2013|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541189||90346|
NCT01541735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBP1301-93|Pantoprazole on Insulin Secretion in Diabetes|Effect of Pantoprazole on Insulin Secretion in Patients With Type 2 Diabetes|IBP|Coordinación de Investigación en Salud, Mexico|Yes|Completed|January 2012|May 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|30 Years|60 Years|No|||January 2014|January 7, 2014|February 20, 2012|Yes|Yes||No|July 27, 2013|https://clinicaltrials.gov/show/NCT01541735||90304|The intervention time was short to evaluate a total change in the primary outcome variables
NCT01525095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-00030|Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)|Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)-Part 1 (Prospective Collection and Freezing of Whole Blood Specimens)|DIRECT|T2 Biosystems|No|Completed|January 2012|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|700|Samples With DNA|Whole Blood specimens, in addition to bacterial and fungal species isolates|Both|18 Years|95 Years|No|Non-Probability Sample|Adult patients who have undergone a diagnostic blood culture.|June 2014|June 6, 2014|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01525095||91572|
NCT01525407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2545.00|Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation|Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation||Fred Hutchinson Cancer Research Center|Yes|Completed|May 2012|||September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|28|||Both|18 Years|N/A|No|||November 2015|February 26, 2016|January 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01525407||91549|
NCT01514214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-02829|Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction|A Randomized Trial Comparing a Winged Perimeter Stent and Traditional Polyethylene Plastic Stent in the Management of Malignant Distal Biliary Strictures||University of British Columbia|Yes|Recruiting|January 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01514214||92406|
NCT01543815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00289921|Well-Being Therapy by Personalized Mobile Technology Program for Psychological Distress and Promote Healthy Behaviors|Well-Being Therapy for Psychological Distress and Enhancing Healthy Behaviors With Personalized Mobile Technology in Cardiac Patients: a Randomized Controlled-trial Study Protocol|WELL-ME|University of Bergamo|Yes|Completed|January 2006|December 2010|Actual|February 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|400|||Both|N/A|N/A|No|||December 2011|March 4, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543815||90146|
NCT01540071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4202-202-2011|Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer|A Phase II Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer||Io Therapeutics|Yes|Completed|August 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Male|18 Years|N/A|No|||February 2016|February 23, 2016|November 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540071||90431|
NCT01540045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECPCDLC2012|Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer|Effect of Chemotherapy With Paclitaxel and Cisplatin on Development Dysgeusia in Non-small Cell Lung Cancer Patients||Instituto Nacional de Cancerologia de Mexico|Yes|Completed|December 2010|May 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|90 Years|No|Non-Probability Sample|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st        line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study.|March 2015|March 6, 2015|January 13, 2012||No||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01540045||90433|No analysis of serum zinc was performed and a small number of subjects analyzed.
NCT01540058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01202-39|Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP|A Randomised Phase III Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With Carcinoma of an Unknown Primary (CUP)|GEFCAPI04|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Recruiting|March 2012|October 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|223|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01540058||90432|
NCT01511042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1999P001983|Vascular Dysfunction in Diabetes: Genes and Hormones|Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus||Brigham and Women's Hospital|Yes|Active, not recruiting|December 1999|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|500|||Both|18 Years|65 Years|No|||December 2015|December 17, 2015|July 19, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01511042||92648|
NCT01511575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B3|Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder|Analysis of MicroRNA Expression in Down Syndrome Acute Myeloid Leukemia and the Transient Myeloproliferative Disorder||Children's Oncology Group|No|Active, not recruiting|February 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|60|||Both|N/A|3 Years|No|Non-Probability Sample|Patients with Down syndrome (DS) diagnosed with acute myeloid leukemia or transient        myeloproliferative disorder.|May 2015|May 8, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511575||92607|
NCT01511822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dros_Myo2012|Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance|||AGUNCO Obstetrics and Gynecology Centre||Completed||||||Phase 4|Interventional|N/A|3||||||Female|18 Years|35 Years||||January 2012|January 18, 2012|January 11, 2012||||No||https://clinicaltrials.gov/show/NCT01511822||92588|
NCT01512121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0040|Spinal Cord Stimulation and Functional MRI|Investigating the Cortical Correlates of Spinal Cord Stimulation Using Functional Magnetic Resonance Imaging||Ohio State University|No|Active, not recruiting|September 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|55 Years|No|Non-Probability Sample|Patients with implanted spinal cord stimulators|February 2016|February 2, 2016|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01512121||92565|
NCT01544166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91741|Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)|Open-label, Multicenter, Pharmacokinetic, and Safety Study in Children (Term Newborn Infants to 23 Months of Age) Undergoing a Contrast-enhanced MRI With an Intravenous Injection of 0.1 mmol/kg BW Gadobutrol 1.0 M||Bayer|No|Completed|May 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|44|||Both|N/A|2 Years|No|||June 2015|June 3, 2015|February 28, 2012|No|Yes||No|November 18, 2014|https://clinicaltrials.gov/show/NCT01544166||90119|Results for Typical PK parameters were provided by the median value of the population together with the min-max range (individual PK). Typical PK parameter as described in study protocol was reflected by the Median PK parameter in the study report.
NCT01540656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-118|Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence|Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence||Copenhagen University Hospital at Herlev|No|Active, not recruiting|June 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Male|18 Years|N/A|No|||May 2013|May 23, 2013|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540656||90387|
NCT01540669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Q-PRE-0111-CLI-007|Dose-Responsive Effect of Polydextrose on Whole Gut Transit Time|Dose-ranging Efficacy of 2-week Polydextrose Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebocontrolled Trial|PDX-Transit|Danisco|No|Terminated|March 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|February 23, 2012|No|Yes|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01540669||90386|
NCT01541475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112063|Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder|Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder||Ewha Womans University|No|Completed|March 2009|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|20 Years|65 Years|No|||April 2014|April 9, 2014|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01541475||90324|
NCT01541488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310.1|Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1 mg as Drinking Solution, and 5, 20, 60, 150, 300, 500 mg as Tablets) of BI 1021958 in Healthy Male Volunteers (Placebo-controlled, Randomised and Single Blind Within Dose Groups), Including Investigation of the Effect of Food on the Bioavailability of BI 1021958 (Open-label, Randomised, Two-way Cross-over)||Boehringer Ingelheim||Completed|February 2012|||May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|66|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|February 22, 2012||||No||https://clinicaltrials.gov/show/NCT01541488||90323|
NCT01541501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAK-NC|Comparison of Three Different No-contact Pachymetries|Phase 4 Study of Comparison Among 3 Different No-contact Instruments to Valuate Central Corneal Thickness||University of Cantanzaro|No|Recruiting|September 2011|December 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers recruited among subject that underwent a routine ophthalmologic        evaluation or among both students and workers at our clinic|September 2012|September 2, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01541501||90322|
NCT01541527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8844|Non Neutralizing Antibodies: Prevalence and Characterization|Prevalence and Epitope Specificity of Non-neutralizing Antibodies in Haemophilia A Patients Without Inhibitors, Immunogenicity of B Domain: A Prospective Study||University Hospital, Montpellier|No|Withdrawn|February 2012|August 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Male|6 Years|N/A|No|Probability Sample|severe, moderate and mild HA patients (sex: Male and age > 6 years)|February 2012|December 30, 2014|February 17, 2012||No|Promoter's change|No||https://clinicaltrials.gov/show/NCT01541527||90320|
NCT01541748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP009SU|Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study|Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study||Coloplast A/S|No|Recruiting|November 2011|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will be adult female patients with pelvic organ prolapse, POP-Q Stage        ≥ 2 that are clinically indicated for surgical intervention with Axis human tissue in the        anterior, posterior, or combined (anterior and posterior) compartments at the institutions        designated for this study.|September 2015|September 25, 2015|February 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01541748||90303|
NCT01517126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912034|Assessing Suicide Risk in Adolescents With Developmental Delays|Assessing Suicide Risk in Adolescents With Developmental Delays: Development of a Screening Tool||National Institutes of Health Clinical Center (CC)||Recruiting|January 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|12 Years|N/A|No|||September 2015|September 18, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01517126||92183|
NCT01517386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37671.091.11|Photonic Needle and Paravertebral Space Detection|Optical Tissue Stylet (OTS) - Descriptive Observational Study Into Paravertebral Space (PS) Detection in Humans|OTS-PS|Philips Healthcare|No|Completed|January 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients scheduled for elective unilateral thoracic surgery under paravertebral block and        general anesthesia|July 2012|December 3, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01517386||92163|
NCT01514227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPPON 5.0|Nobori Dual Antiplatelet Therapy as Appropriate Duration|Nobori Dual Antiplatelet Therapy as Appropriate Duration.||Associations for Establishment of Evidence in Interventions||Recruiting|December 2011|November 2018|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4598|||Both|20 Years|80 Years|No|||January 2014|January 8, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01514227||92405|
NCT01514825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-026|A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects|YM150 Clinical Pharmacology Study - Repeated Oral Administration to Elderly Subjects||Astellas Pharma Inc|No|Completed|November 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|36|||Both|65 Years|79 Years|Accepts Healthy Volunteers|||January 2012|January 23, 2012|January 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01514825||92360|
NCT01544127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHBA-20-11S|Motivational Interviewing to Prevent Suicide in High Risk Veterans|Motivational Interviewing to Prevent Suicide in High Risk Veterans||VA Office of Research and Development|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|112|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01544127||90122|
NCT01540084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-001|Cocktail Sedation Containing Propofol Versus Conventional Sedation for Endoscopic Retrograde Cholangiopancreatography (ERCP)|Cocktail Sedation Containing Propofol Versus Conventional Sedation for ERCP: a Prospective, Randomized Controlled Study||King Chulalongkorn Memorial Hospital|No|Completed|December 2006|December 2009|Actual|August 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|205|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540084||90430|
NCT01540110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC0907|Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses|Phase 2 Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses||National Cancer Centre, Singapore|Yes|Active, not recruiting|August 2010|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|41|||Both|21 Years|N/A|No|||August 2015|August 18, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01540110||90429|
NCT01540331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNT01|Efficacy And Safety of Pneumatic Trabeculoplasty|Phase 4 Study to Evaluate Efficacy And Safety of Pneumatic Trabeculoplasty (PNT) in Subjects Affected by Primary Open Angle Glaucoma||University of Cantanzaro|No|Completed|June 2009|January 2012|Actual|June 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01540331||90412|
NCT01542814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMSU2011-003A|Collection of FUJIFILM's 3Dimensional Mammograms|Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography|3DM|Fujifilm Medical Systems USA, Inc.|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|600|||Female|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects who are appearing for a routine screening examination or have been referred        for further diagnostic evaluation after a screening examination (within 45 days) or have a        4-view mammogram (within 45 days) due to clinical concerns will be eligible to participate        in the study.|October 2013|October 23, 2013|February 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01542814||90222|
NCT01511237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHPT-5 Second Phase|Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers|PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy|PHPT-5|Institut de Recherche pour le Developpement|Yes|Active, not recruiting|December 2011|June 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1837|||Female|18 Years|N/A|No|||January 2016|January 26, 2016|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01511237||92633|
NCT01511250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV-DEN-203|Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years|A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years||Takeda|Yes|Active, not recruiting|November 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|344|||Both|18 Months|45 Years|Accepts Healthy Volunteers|||May 2015|May 6, 2015|November 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01511250||92632|
NCT01511588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120050|Hormonal Regulation of Puberty and Fertility|Hormonal Regulation of Puberty and Fertility||National Institutes of Health Clinical Center (CC)||Recruiting|December 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|200|||Both|14 Years|N/A|No|||July 2015|October 30, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01511588||92606|
NCT01511835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyoIN_diab|Efficacy of Myo-inositol in Preventing Gestational Diabetes in High-risk Pregnant Women|||AGUNCO Obstetrics and Gynecology Centre||Recruiting||||||Phase 4|Interventional|N/A|3||||||Female|20 Years|45 Years||||January 2012|January 13, 2012|November 16, 2011||||No||https://clinicaltrials.gov/show/NCT01511835||92587|
NCT01511848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AinShamsU|Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload|A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload||Ain Shams University|Yes|Not yet recruiting|February 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|18 Years|No|||February 2012|February 3, 2012|January 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01511848||92586|
NCT01543893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA05|Effect of Personal Versus Video Instruction in Elastic Resistance Exercise on Technical Execution (IRMA05)|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|IRMA05|National Research Centre for the Working Environment, Denmark|No|Completed|March 2012|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38|||Female|18 Years|67 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543893||90140|
NCT01540149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR_TelAviv_sourasky|Tel Aviv Sourasky MC Home Monitoring Clinic Registry|Tel Aviv Sourasky MC Home Monitoring Registry||Tel-Aviv Sourasky Medical Center|Yes|Recruiting|March 2012|October 2014|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Non-Probability Sample|ICD or CRTD implanted patient|February 2012|February 18, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01540149||90426|
NCT01540396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11080682|Gestational Diabetes Diagnostic Methods|GD2M Study:Gestational Diabetes Diagnostic Methods|GD2M|University of Pittsburgh|Yes|Completed|February 2012|December 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Actual|47|||Female|18 Years|50 Years|No|||February 2016|February 2, 2016|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01540396||90407|
NCT01540643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-015|Zenith® Spiral-Z® AAA Iliac Leg Graft Post-market Registry|Zenith® Spiral-Z® AAA Iliac Leg Graft Post-market Registry||Cook||Active, not recruiting|March 2012|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Both|N/A|N/A|No|Non-Probability Sample|Patients implanted with an FDA approved Zenith® Spiral-Z® AAA Iliac Leg Graft|September 2015|September 8, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540643||90388|
NCT01541202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-01-305|Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure||Zensun Sci. & Tech. Co., Ltd.|Yes|Recruiting|February 2012|December 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1600|||Both|18 Years|75 Years|No|||February 2012|February 28, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541202||90345|
NCT01540968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2011-0447|Nutrition and Physical Exercise Study|Influence of a Combined Intervention by Nutritional Support and Physical Exercise on Quality of Life in Cancer Out-patients Treated in Palliative Intention.||Kantonsspital Winterthur KSW|No|Completed|March 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|58|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540968||90363|
NCT01541215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3659|Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes|Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes|Ellipse™|Novo Nordisk A/S|No|Recruiting|November 2012|June 2020|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|10 Years|16 Years|No|||February 2016|February 24, 2016|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01541215||90344|
NCT01541774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP0782|Endovascular Atherectomy Safety and Effectiveness Study|A Prospective, Multicenter Clinical Evaluation of the Safety and Effectiveness of the Phoenix Atherectomy™ System in Atherectomy of the Peripheral Vasculature|EASE|AtheroMed, Inc|Yes|Completed|August 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|128|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|August 4, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01541774||90301|
NCT01542086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1105-050-361|Comparison of the Cost-Effectiveness of Coronary CT Angiography Versus Myocardial SPECT in Patients With Intermediate Risk of Coronary Heart Disease|Comparison of the Cost-Effectiveness of Coronary CT Angiography Versus Myocardial SPECT in Patients With Intermediate Risk of Coronary Heart Disease|CARE-CCTA|Seoul National University Hospital||Recruiting|September 2011|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|1050|||Both|30 Years|80 Years|No|||February 2012|February 24, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01542086||90278|
NCT01541761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USDA 2011-68001-30207|Starting Early Obesity Prevention Program|RCT Testing the Effectiveness of an Early Obesity Prevention Program||New York University School of Medicine|No|Active, not recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|550|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541761||90302|
NCT01517399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ197-A-U158|Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects|A Phase 1, Open-Label, Single-Sequence Crossover Study Assessing the Effect of Tivantinib (ARQ 197) on the Pharmacokinetics of Omeprazole/S-Warfarin/Caffeine/Midazolam and Digoxin in Cancer Subjects||Daiichi Sankyo Inc.|No|Completed|December 2011|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Actual|28|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|January 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01517399||92162|
NCT01517685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111700|Hallelujah Acres Omega 3 Fat Study|Hallelujah Acres Omega 3 Fat Study||Hallelujah Acres|No|Completed|January 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01517685||92140|
NCT01515085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220110114|MRI-Guided Laser Induced Thermal Therapy|MRI-Guided Laser-Induced Thermal Therapy for Cytoreduction of Inoperable Grade III/IV GLiomas Prior to Chemotherapy and Radiation|LITT|Rutgers, The State University of New Jersey|No|Terminated|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with brain tumors receiving MR-guided laser ablation|May 2014|May 20, 2014|October 18, 2011|No|Yes|PI elected to close study|No||https://clinicaltrials.gov/show/NCT01515085||92340|
NCT01544140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00103|Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Dose of 800-mg Vandetanib (CAPRELSA)|Vandetanib|AstraZeneca||Completed|April 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01544140||90121|
NCT01510470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2011028|Clinical and Radiological Outcomes Study on Astra Tech Osseospeed Tx Profile Implant|Clinical and Radiological Outcomes Study on Astra Tech Osseospeed Tx Profile Implant||Hong Kong Brånemark Osseointegration Center|Yes|Enrolling by invitation|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with single missing maxillary or mandibular premolar or molar|January 2012|January 13, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510470||92691|
NCT01510483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA138192|Clinician Promotion of Healthy Diet and Activity to Reduce Obesity Among Adolescents: HEALTHY SMILES|Clinician Promotion of Healthy Diet and Activity to Reduce Obesity Among Adolescents|HS|San Diego State University|Yes|Completed|January 2010|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|693|||Both|8 Years|14 Years|Accepts Healthy Volunteers|||May 2015|May 20, 2015|November 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01510483||92690|
NCT01511029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223HV102|Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)|A Single-Center, Randomized, Blinded, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Dexpramipexole (BIIB050) on the QTc Interval in Healthy Volunteers||Knopp Biosciences|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01511029||92649|
NCT01543360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/JYL-GB-01|Comparison of Axillary Versus Subclavian Vein Strategies for Central Venous Catheterization Under Continuous Ultrasound Guidance|Comparison of Axillary Versus Subclavian Vein Strategies for Central Venous Catheterization Under Continuous Ultrasound Guidance: a Prospective, Randomized, Non-inferiority Study||Centre Hospitalier Universitaire de Nīmes|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|132|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01543360||90181|
NCT01511263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-006-IT|Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis|A Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL)|EpiCardiAL|IRCCS Policlinico S. Matteo|Yes|Recruiting|January 2012|||July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01511263||92631|
NCT01543347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMO-07001|Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae|Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL) Producing and AmpC Hyperproducing Enterobacteriaceae in United Kingdom|TEA|Belpharma s.a.|No|Withdrawn|February 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|21 Years|N/A|No|||January 2013|January 28, 2013|February 22, 2012||No|No patient has been included in 9 months because of strict incl/excl criteria|No||https://clinicaltrials.gov/show/NCT01543347||90182|
NCT01543607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-405|Endoscopic Therapy of Malignant Bile Duct Strictures|Endoscopic Therapy of Malignant Bile Duct Strictures: A Pilot Study||Massachusetts General Hospital|Yes|Terminated|February 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543607||90162|
NCT01540383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/234/11|Effectiveness of Intensive Aphasia Therapy Under Routine Clinical Conditions|From Controlled Experimental Trial to Everyday Communication: How Effective is Intensive Aphasia Therapy Under Routine Clinical Conditions?|FCET2EC|University Hospital Muenster|Yes|Completed|April 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|70 Years|No|||January 2016|January 18, 2016|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01540383||90408|
NCT01540955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003446|Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors|Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors||Jonsson Comprehensive Cancer Center|Yes|Completed|April 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|48|||Both|21 Years|65 Years|No|||April 2015|April 8, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01540955||90364|
NCT01540981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-86034|Deep Tissue Injury Treatment With MIST Therapy Versus Standard Care: REVERSE DTI Study|Multi-Center Study of the Effects of MIST Therapy on the Treatment of Deep Tissue Injury||Celleration, Inc.|Yes|Terminated|February 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|12|||Both|18 Years|90 Years|No|||January 2015|January 6, 2015|February 20, 2012||No|Lack of enrollment|No|October 6, 2014|https://clinicaltrials.gov/show/NCT01540981||90362|Follow-up limited by discharge from hospital.
NCT01540994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101091|Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer|Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate||Sharp HealthCare|Yes|Recruiting|January 2011|||December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|50 Years|90 Years|No|||March 2012|March 9, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540994||90361|
NCT01541241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ayman-1|Study About Patients Using Copper Intrauterine Device|Uterine Haemodynamic Changes in Patients With Copper Intrauterine Device Induced Bleeding|IUD|Egymedicalpedia|Yes|Recruiting|January 2012|May 2012|Anticipated|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|100|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|primary care clinic, hospital out patient clinic|February 2012|February 28, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01541241||90342|
NCT01541514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0172|Evaluating the Patient-Ventilator Synchrony During Mechanical Ventilation in Patients With Acute Lung Injury|||University of Chicago|No|Completed|July 2011|December 2013|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Probability Sample|adult ICU patients receiving mechanical ventilation|December 2014|December 2, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01541514||90321|
NCT01542099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_DLT_remi|The EC50 of Remifentanil Blunting Hemodynamic Response to Double Lumen Tube Intubation|The Effect Site Concentration of Remifentanil Blunting Hemodynamic Responses to Tracheal Intubation: Single Versus Double Lumen Tube||Seoul National University Hospital|Yes|Recruiting|November 2011|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|20 Years|65 Years|No|||July 2013|July 8, 2013|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01542099||90277|
NCT01542112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patient-Centered care|An Innovational Model to Manage Patient Expectations and Improve Patient Satisfaction: An Intervention Study|An Innovational Model to Manage Patient Expectations and Improve Patient Satisfaction: An Intervention Study||University of Aarhus|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|835|||Both|18 Years|N/A|No|||March 2013|March 5, 2013|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01542112||90276|
NCT01542333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B2|Studying Biomarkers in Samples From Younger Patients With Wilms Tumor|Biological Analysis of Ethnic Variations in Wilms Tumor||Children's Oncology Group|No|Active, not recruiting|February 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Diagnosed with Wilms tumor|May 2015|May 7, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01542333||90259|
NCT01542346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 16/11|Subcutaneous Adaption and Cosmetic Outcome Following Caesarean Delivery|||Klinikum Klagenfurt am Wörthersee||Completed|March 2012|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|116|||Female|18 Years|45 Years|No|||July 2013|July 11, 2013|February 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01542346||90258|
NCT01513655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004866-13|Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation|Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation||University Hospital, Gentofte, Copenhagen|Yes|Recruiting|July 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|150|||Both|N/A|N/A|No|||November 2015|November 23, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513655||92447|
NCT01513941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100778|An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)|Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects With Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Type 1 (HCV-1/HIV-1) Coinfection|INSIGHT|Janssen-Cilag International NV|No|Completed|April 2012|June 2014|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|18 Years|70 Years|No|||May 2015|May 22, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513941||92427|
NCT01514838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-2003|A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus|A Phase III, Double-Blind, Randomized, Active Controlled, Monotherapy Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus||Astellas Pharma Inc|No|Terminated|January 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|20 Years|N/A|No|||January 2016|January 19, 2016|January 18, 2012|No|Yes|Discontinued due to company's strategic reason|No||https://clinicaltrials.gov/show/NCT01514838||92359|
NCT01541943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HATLO11III_1|Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia|A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia||HanAll BioPharma Co., Ltd.|No|Completed|March 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|356|||Both|18 Years|80 Years|No|||September 2015|September 21, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541943||90289|
NCT01541956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ACN01|Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)|An Open-labeled, Randomized, Multicenter, Prospective, Parallel Group, Interventional Study to Demonstrate the Effectiveness of 24 Weeks Treatment With Vildagliptin 50mg Bid as Add on to Metformin 500 mg Bid Compared to Metformin up to 1000 mg Bid in Chinese Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy .||Novartis|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3091|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541956||90288|
NCT01510730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20052011|Helicobacter Pylori Eradication After Endoscopic Resection of Gastric Tumors|Effect of Helicobacter Pylori Eradication on the New Tumor Development After Endoscopic Resection of Gastric Tumors||Seoul National University Hospital|No|Completed|January 2005|February 2011|Actual|February 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|855|||Both|20 Years|75 Years|No|||March 2012|March 13, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01510730||92671|
NCT01510743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1112_069_003|Ultrasound Guided Central Vein Catheterization and Complications|Incidence of Complication Depending on the Cannulation Site in US Guided Central Vein Catheterization||Seoul National University Bundang Hospital|No|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1484|||Both|15 Years|N/A|No|Probability Sample|Patients undergoing surgeries requiring central vein catheterizations for anesthetic        management.|July 2015|July 29, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01510743||92670|
NCT01543932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIPLETE RESET|High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients|Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation|TRIPLETE RESET|University of Roma La Sapienza|Yes|Completed|July 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|81|||Both|18 Years|75 Years|No|||December 2013|December 10, 2013|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01543932||90137|
NCT01543945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PONV9268|Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy|||Prince of Songkla University|Yes|Completed|March 2008|||December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|340|||Female|18 Years|45 Years|No|||July 2012|July 29, 2012|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543945||90136|
NCT01543061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG9965-006 ID 11-19|Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints|Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints||Optometric Technology Group Ltd|No|Completed|February 2012|December 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|35|||Both|18 Years|N/A|No|||September 2013|September 26, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01543061||90204|
NCT01543074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA122959|Dietary Histone Deacetylase Inhibitors (HDAC)|Dietary Histone Deacetylase (HDAC) Inhibitors||Texas A&M University|No|Terminated|February 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|23|||Both|20 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 10, 2015|February 17, 2012|Yes|Yes|Poor recruitment|No|June 1, 2015|https://clinicaltrials.gov/show/NCT01543074||90203|Early termination (23/80) due to small numbers of subjects recruited.
NCT01543087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1971033|Duration of Immunity Study|A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086||Pfizer|Yes|Recruiting|September 2012|November 2018|Anticipated|November 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Masking: Open Label|1||Anticipated|800|||Both|10 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|February 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01543087||90202|
NCT01543906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET RP 01|Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)|An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)||QLT Inc.|No|Completed|February 2012|August 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|70 Years|No|||December 2014|December 11, 2014|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01543906||90139|
NCT01543919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631033|Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide|A Phase 2B, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide||Pfizer|Yes|Completed|April 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|730|||Both|40 Years|80 Years|No|||September 2014|October 15, 2014|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543919||90138|
NCT01544179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D791LC00001|A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone|A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progressed on First Line IRESSA|IMPRESS|AstraZeneca|Yes|Completed|March 2012|November 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|287|||Both|18 Years|130 Years|No|||January 2016|January 19, 2016|February 15, 2012|No|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01544179||90118|
NCT01540682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 10311|MLN8237 in Head and Neck Cancer|Phase I Study of MLN8237 in Combination With Cetuximab and Definitive Radiation in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|9|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540682||90385|
NCT01540695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 25911|Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H and E Histology|Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H&E Histology||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|February 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Probability Sample|All patients will be recruited from the Mohs unit of the HUP Department of Dermatology|October 2014|October 10, 2014|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01540695||90384|
NCT01541228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-60|Photodynamic Treatment of Actinic Keratoses With Different Light Doses|Clinical Effect of Photodynamic Treatment When Treating Actinic Keratoses With Different Light Doses||Lithuanian University of Health Sciences|Yes|Completed|April 2010|April 2013|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|50 Years|N/A|No|||September 2013|September 2, 2013|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01541228||90343|
NCT01541254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G110014|Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device|A Feasibility Study of the MicroVention,Inc.(LVIS™) Neurovascular Self-Expanding Retrievable Stent System in the Treatment of Wide-Necked Intracranial Artery Aneurysms|LVIS|Microvention-Terumo, Inc.|Yes|Completed|March 2012|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|80 Years|No|||September 2014|September 6, 2014|February 15, 2012|Yes|Yes||No|September 5, 2014|https://clinicaltrials.gov/show/NCT01541254||90341|
NCT01541540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0580-BE|e-Counseling Promotes Blood Pressure Reduction and Therapeutic Lifestyle Change in Hypertension|Reducing Risk With E-based Support for Adherence to Lifestyle Change in Hypertension|REACH|University Health Network, Toronto|Yes|Recruiting|February 2012|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|528|||Both|35 Years|74 Years|No|||July 2013|July 23, 2013|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01541540||90319|
NCT01541553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-21|A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp|A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp||LEO Pharma|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|288|||Both|18 Years|N/A|No|||February 2014|February 13, 2014|February 17, 2012|Yes|Yes||No|February 13, 2014|https://clinicaltrials.gov/show/NCT01541553||90318|
NCT01542125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0002737|The Effect of Liposomal Lidocaine on Perceived Pain in Children During Percutaneous Interosseous Pin Removal in the Outpatient Setting|The Effect of Liposomal Lidocaine on Perceived Pain in Children During Percutaneous Interosseous Pin Removal in the Outpatient Setting: A Triple Blinded, Randomized Placebo-controlled Clinical Trial||University of Alberta|No|Completed|September 2008|February 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|281|||Both|3 Years|16 Years|No|||February 2012|February 29, 2012|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01542125||90275|
NCT01542359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1SC3GM088049-01A1 REVISED|Effectiveness of Yoga on Ambulatory Blood Pressure in Patients With Pre- and Stage I Hypertension|Effectiveness of Yoga on Ambulatory Blood Pressure in Patients With Pre- and Stage I Hypertension||Long Island University|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|21 Years|74 Years|No|||January 2013|January 8, 2013|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01542359||90257|
NCT01513668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|202_ACETA_06|A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fed Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gel Tabs (Containing Acetaminophen 650 mg) of OHM Laboratories (Subsidiary of Ranbaxy) With Tylenol 8 Hour 650 mg Gel Tabs (Containing Acetaminophen 650 mg) of Mc Neil, Consumer & Speciality Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fed Condition||Ranbaxy Inc.|No|Completed|May 2006|July 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|18 Years|39 Years|Accepts Healthy Volunteers|||January 2012|January 27, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01513668||92446|
NCT01513681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-136|Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition|Single Dose, Two-way, Crossover, Oral Bioequivalence Study of Lamotrigine Tablets 200 mg With Lamictal® Tablets 200 mg in Healthy, Volunteers Under Fed Condition.||Dr. Reddy's Laboratories Limited|No|Completed|November 2002|November 2002|Actual|November 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||October 2002|January 17, 2012|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01513681||92445|
NCT01513954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111821|Examination of Serum Progesterone Levels in an IVF Population Following Two Types of Egg Aspiration|Examination of Serum Progesterone Levels in an IVF Population Following Two Types of Egg Aspiration||Red Rock Fertility Center|Yes|Recruiting|January 2012|June 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|450|||Female|21 Years|37 Years|Accepts Healthy Volunteers|Non-Probability Sample|IUI patients and IVF patients following a long lupron protocol cycle|January 2012|January 17, 2012|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513954||92426|
NCT01513967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN-ADC-001|A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease|A Randomized Single and Multiple Dose Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease||Regenera Pharma Ltd|Yes|Recruiting|January 2012|December 2016|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|14||Anticipated|56|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 14, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01513967||92425|
NCT01515111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRC-006|Guatemala Internal Medicine Physicians' Knowledge of Non-communicable Disease Clinical Preventive Services|Knowledge and Recommendations on Tobacco Cessation and Other Preventive Interventions Among Internal Medicine Staff in Guatemala Teaching Hospitals||Unidad de Cirugía Cardiovascular|No|Completed|April 2011|January 2012|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|394|||Both|18 Years|N/A|No|Non-Probability Sample|Internal medicine interns, residents or attendings of any of the teaching hospitals in        Guatemala.|January 2012|January 18, 2012|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01515111||92338|
NCT01509937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BOCOMO525|Body Composition Monitor(BCM) Guided Fluid Management in Maintenance Hemodialysis (MHD) Patients|A Randomized Controlled Trial of Long Term Effect of BCM Guided Fluid Management in MHD Patients|BOCOMO|Peking University First Hospital|Yes|Completed|January 2013|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|433|||Both|18 Years|80 Years|No|||November 2015|November 22, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01509937||92731|
NCT01510197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarker|Risk Profile for Atrial Fibrillation|Identification of a Risk Profile in Patients With Atrial Fibrillation||University Medical Center Groningen|No|Completed|September 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|503|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with short-lasting symptomatic paroxysmal or persistent AF|July 2015|July 27, 2015|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01510197||92711|
NCT01542229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-306|PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)|Improving PTSD Service Delivery for Veterans With Severe Mental Illness|PTSD/SMI|VA Office of Research and Development|No|Recruiting|May 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|156|||Both|21 Years|N/A|No|||February 2016|February 26, 2016|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01542229||90267|
NCT01543399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T.FR - 245365|Vascular Effect of Tibolone in the Brachial Artery|Vascular Effect of Tibolone Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery|TDILA|Federal University of Minas Gerais|No|Completed|March 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01543399||90178|
NCT01543412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-004637-16|Second Line Chemotherapy for Advanced Pancreatic Cancer|Folfiri as Second-Line Chemotherapy for Advanced Pancreatic Cancer. A GISCAD Phase II Study|SLAP|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente|No|Completed|January 2010|December 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||February 2012|March 2, 2012|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01543412||90177|
NCT01543620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kidney Safety - Aminoglycoside|Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis|Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis||Foundation for the National Institutes of Health|No|Recruiting|February 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|urine and blood|Both|18 Years|N/A|No|Probability Sample|cystic fibrosis patients|July 2014|December 8, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543620||90161|
NCT01540162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS MU 1128 AO|Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement|Open-labelled, Controlled, Parallel Group Study to Assess the Efficacy and Safety of MUTAFLOR in 3 Weeks Treatment for Immunity Improvement in Preterm Infants With 1 Year Follow-up Period|EMSUP|Odessa National Medical University|No|Completed|March 2011|December 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|62|||Both|N/A|24 Hours|Accepts Healthy Volunteers|Non-Probability Sample|Preterm newborns with gestational age of 35-36 weeks|August 2015|August 12, 2015|February 16, 2012||No||No|August 12, 2015|https://clinicaltrials.gov/show/NCT01540162||90425|
NCT01540409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4658-us-202|Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy|Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201||Sarepta Therapeutics|No|Active, not recruiting|February 2012|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|7 Years|13 Years|No|||March 2016|March 11, 2016|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540409||90406|
NCT01540175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD12-013 IROPAST|Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant|Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant|IROPAST|St. Jude Children's Research Hospital|No|Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|31|||Both|N/A|21 Years|No|Non-Probability Sample|Participants will have a diagnosis of solid tumor, brain tumor or lymphoma, be 21 years of        age or younger, and be enrolled on a protocol likely to include autologous stem cell        transplant.|July 2015|July 13, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01540175||90424|
NCT01540708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116409|A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol|An Open-label, Randomised, Cross-over, Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation andROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol.||GlaxoSmithKline|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 11, 2013|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540708||90383|
NCT01540721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2750605|Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend|A Single Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Different Sustained Released Paracetamol Formulations||GlaxoSmithKline|No|Completed|December 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540721||90382|
NCT01541566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TELEBPMET|Blood Pressure Control and Compliance to Treatment in Hypertensive Patients With Metabolic Syndrome: a Study Based on Home Blood Pressure Telemonitoring and Assessment of Psychological Determinants|Blood Pressure Control and Compliance to Treatment in Hypertensive Patients With Metabolic Syndrome: a Study Based on Home Blood Pressure Telemonitoring|TELEBPMET|Italian Institute of Telemedicine|No|Completed|November 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|254|||Both|18 Years|74 Years|No|Probability Sample|Patients referring to 12 Hypertension Centers (Hospitals) and suffering from arterial        hypertension associated to metabolic syndrome|February 2016|February 25, 2016|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01541566||90317|
NCT01541800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-14205|Circulating microRNAs as Disease Markers in Pediatric Cancers|A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|March 2010|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|whole blood and cerebral spinal fluid|Both|3 Years|21 Years|No|Non-Probability Sample|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous        system tumors|February 2016|February 3, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541800||90300|
NCT01542398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREC 06-2012|A Family-based, Resilience-focused Intervention for War-affected Communities in North-eastern Democratic Republic of Congo|Title: Is a Family-based, Life Skills Focused Intervention Effective in Reducing Psychological Distress and Stigma and Improving Inter-personal Relations and Functioning Among Former LRA Abductees and Other War-affected Children in Their Community in Dungu, the Democratic Republic of Congo?||Queen's University, Belfast|No|Enrolling by invitation|March 2012|July 2012|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|7 Years|N/A|Accepts Healthy Volunteers|||February 2012|March 1, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01542398||90254|
NCT01542411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2362|Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment|||Yazd Medical University|Yes|Completed|April 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||3|Actual|520|||Female|19 Years|35 Years|Accepts Healthy Volunteers|Probability Sample|This project evaluated 520 women with unexplained recurrent miscarriage for four years.        They had referred to recurrent abortion clinic of Yazd Reproductive sciences institute.        Women with unexplained recurrent miscarriage included in this study|February 2012|March 1, 2012|February 25, 2012||||No||https://clinicaltrials.gov/show/NCT01542411||90253|
NCT01542372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH094312|Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD|Two Stepped Care Models for PTSD Among Cambodian Refugees With PTSD||Massachusetts General Hospital|Yes|Not yet recruiting|April 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|243|||Both|43 Years|N/A|No|||February 2012|February 25, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01542372||90256|
NCT01542385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIMACY|Primary Reperfusion Secondary Stenting Trial|Immediate vs. Delayed Stenting After Primary Percutaneous Reperfusion in ST Elevation Myocardial Infarction|PRIMACY|Montreal Heart Institute|Yes|Recruiting|April 2014|November 2017|Anticipated|November 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|232|||Both|18 Years|80 Years|No|||September 2015|September 28, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01542385||90255|
NCT01514240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D9423C00001|Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan|A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan||AstraZeneca||Completed|February 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|15 Years|N/A|No|||September 2014|September 16, 2014|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01514240||92404|
NCT01514500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8640-3915|First Human Dose Trial of NNC0195-0092 in Healthy Subjects|First Human Dose Trial of NNC0195-0092 in Healthy Subjects||Novo Nordisk A/S|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|105|||Male|20 Years|45 Years|No|||April 2013|April 11, 2013|January 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01514500||92385|
NCT01514513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LF001-0011|Efficacy and Safety of Licefreee Spray Against Nix 1% Permethrin|A Comparative Study to Demonstrate the Efficacy and Safety of Licefreee Spray Against Nix 1% Permethrin in Head Lice Infested Individuals||South Florida Family Health and Research Centers|Yes|Completed|August 2011|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|4 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 18, 2014|January 11, 2012|No|Yes||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01514513||92384|
NCT01515670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH30-0623|Length of Stay and Complications in High-risk Patients Receiving Fast-track Total Hip (THA) or Knee- Alloplasty (TKA)|Length of Stay and Complications in High-risk Patients Receiving Fast-track Total Hip (THA) or Knee- Alloplasty (TKA).||Rigshospitalet, Denmark|No|Recruiting|February 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|18 Years|N/A|No|Probability Sample|unselected patients receiving THA or TKA|November 2015|November 26, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515670|90 Days|92295|
NCT01541696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1387-PED-ERC-09|Exchangeable Zinc Pool Size and Zn Absorption From Sprinkles and Traditional Foods in Pakistani Infants /Toddlers|Exchangeable Zn Pool Size and Zn Absorption From Sprinkles and Traditional Foods in Pakistani Infants/Toddlers||Aga Khan University|Yes|Active, not recruiting|June 2010|June 2012|Anticipated|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|40|||Both|9 Months|12 Months|Accepts Healthy Volunteers|Probability Sample|Infants between the ages of 9 and 12 months|March 2012|March 6, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01541696||90307|
NCT01542554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKEC-2011-080|Effect of Low Glycaemic Index Diet on Blood Glucose Control in Chinese Type 2 Diabetic Patients|Effect of Low Glycaemic Index Diet on Blood Glucose Control in Chinese Type 2 Diabetic Patients: Randomized Controlled Trial||Hospital Authority, Hong Kong|No|Recruiting|March 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542554||90242|
NCT01542567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0015-CTIL|Efficacy of Diclofenac BCG Irrigations|Efficacy of Diclofenac Suppositories in Prevention of Immediate Side Effects of BCG Bladder Irrigations. A Double Blind Placebo Controlled Randomized Study|DIC-2011|Carmel Medical Center|No|Not yet recruiting|May 2012|||May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|20 Years|80 Years|No|||May 2012|May 20, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01542567||90241|
NCT01542827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA04|Acute Effect of Topical Menthol on Neck Pain|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|IRMA04|National Research Centre for the Working Environment, Denmark|No|Terminated|January 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|February 27, 2012||No|Lack of resources to perform the study|No||https://clinicaltrials.gov/show/NCT01542827||90221|
NCT01543100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/10-02 - PACMoG|Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy|Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy|PACMoG|Rennes University Hospital|No|Completed|November 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|August 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01543100||90201|
NCT01543113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOC/10-16 - KitMel|cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project|cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project|KitMel|Rennes University Hospital|No|Completed|January 2011|February 2014|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|288|||Both|N/A|N/A|No|||February 2014|February 21, 2014|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01543113||90200|
NCT01543386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0113|Effects of Curcumin on Vascular Reactivity|Effects of Curcumin Loading Dose on Vascular Reactivity of Healthy Middle-aged Smokers|CURCUMIN|University Hospital, Clermont-Ferrand||Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|21|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 4, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01543386||90179|
NCT01543984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-154-32028T|Efficacy of "Tailored Physical Activity" in Health Care Workers|Efficacy of "Tailored Physical Activity" on the Number of Sick Days: a Randomized Controlled Trial in Health Care Workers That Have Experienced Pain Related to the Spine or Upper Body||University of Southern Denmark|Yes|Completed|January 2012|April 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|November 19, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543984||90133|
NCT01543997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049003|Clinical Benefits of a Novel Sleep-focused Mind-body Program on Gulf War Illness (GWI) Symptoms|Investigating Clinical Benefits of a Novel Sleep-focused Mind-body Program on Gulf War Illness (GWI) Symptoms: An Exploratory Randomized Controlled Trial||University of Utah|Yes|Active, not recruiting|January 2012|April 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|38 Years|80 Years|No|||November 2015|November 30, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543997||90132|
NCT01539889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The PulmoBind Safety Trial|Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation|Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation||Montreal Heart Institute|Yes|Completed|December 2011|January 2013|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|19 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 30, 2014|February 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01539889||90445|
NCT01543971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2009-003|Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)|Phase I Double-Blinded Comparison Study Using TXA127 and/or Neupogen to Increase Peripheral Blood Stem Cell (CD34+) Counts||US Biotest, Inc.|No|Completed|December 2009|March 2010|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|February 27, 2012|February 10, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01543971||90134|
NCT01539902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT 11-03|Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis|A Randomized, Double Blind, Parallel Group, Placebo Controlled Research of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis|hUC-MSC-SLE|CytoMed & Beike|Yes|Recruiting|February 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|16 Years|65 Years|No|||March 2012|March 5, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539902||90444|
NCT01540734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2750606|Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®|A Single Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Sustained Release Paracetamol Formulations||GlaxoSmithKline|No|Completed|December 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540734||90381|
NCT01541007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004178-27|A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer|A Randomized, Open Label, Multicenter, Phase II Trial Comparing The Conventional 3 Weekly Schedule Of Cabazitaxel With A Weekly Regimen In Patients With Metastatic Castration Resistant Prostate Cancer|ConCab|Karolinska University Hospital|Yes|Completed|April 2012|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Male|18 Years|N/A|No|||October 2015|October 30, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541007||90360|
NCT01541579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cx601-0302|Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease|A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks.|ADMIRE-CD|Cellerix|No|Active, not recruiting|July 2012|May 2017|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|278|||Both|18 Years|N/A|No|||September 2015|November 25, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01541579||90316|
NCT01541813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Afssaps 201O-A00866-33|Rare Iron Overloads Except C282Y Homozygosity : Description and Characterization.|Clinical, Biological, Genetic and Functional Characterization of Rare Iron Overload Phenotypes Associated With Hepcidin Deficiency Except C282Y Homozygosity.|HEPCIDEF|Rennes University Hospital||Terminated|March 2011|December 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a rare iron overloads except C282Y homozygosity.|August 2014|March 9, 2015|February 24, 2012||No|rare overload and low recruitment|No||https://clinicaltrials.gov/show/NCT01541813||90299|
NCT01542736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-1151|Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)|Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET||University of Colorado, Denver|Yes|Active, not recruiting|May 2007|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|3 Years|25 Years|No|||December 2015|December 11, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542736||90228|
NCT01542723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35774.058.11(2)|Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy|Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks|Pot-Kast|Leiden University Medical Center|Yes|Recruiting|May 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542723||90229|
NCT01514253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAOR 006.CTIL|Reduced Infant Response to a Routine Care Procedure After Glucose 25% Analgesia in Comparison to Materna RTF Stage 1|Reduced Infant Response to a Routine Care Procedure After Glucose 25% Analgesia in Comparison to Materna RTF Stage 1|glucose|The Baruch Padeh Medical Center, Poriya|No|Not yet recruiting|February 2012|July 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator)|3||Anticipated|180|||Both|N/A|16 Days|Accepts Healthy Volunteers|||January 2012|January 20, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01514253||92403|
NCT01514526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOGUG2011-03|Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma|Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma||Spanish Oncology Genito-Urinary Group|No|Active, not recruiting|January 2012|December 2015|Anticipated|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01514526||92383|
NCT01514851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11877|Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate|Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis||Bayer|No|Completed|January 2006|May 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|259|||Both|20 Years|N/A|No|||June 2012|June 7, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01514851||92358|
NCT01542580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBMET.CR.G1|A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee|A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee||Biomet, Inc.|No|Enrolling by invitation|March 2012|December 2027|Anticipated|December 2017|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|255|||Both|18 Years|N/A|No|Non-Probability Sample|Patients prescribed the Vanguard 360 Revision Knee System|January 2016|January 6, 2016|February 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542580||90240|
NCT01543126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2011-06|IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer|A Prospective Study Assessing the Correlation Between Disease Prognosis and the Level of IL-6 and IL-8 Level in Blood and Pleural Effusion Before and After Chemotherapy in Patients With Metastatic Breast Cancer||Fudan University|No|Terminated|February 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples With DNA|pleural effusion|Female|18 Years|70 Years|No|Non-Probability Sample|metastatic breast cancer patients with pleural effusion|July 2013|July 24, 2013|February 27, 2012||No|it's too slow to enroll suitable patients into this study|No||https://clinicaltrials.gov/show/NCT01543126||90199|
NCT01543373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21101|Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS|Randomized Comparison Between a DES and a BMS to Assess Neointimal Coverage by OCT Evaluation|DEMONSTRATE|CID - Carbostent & Implantable Devices|No|Recruiting|January 2012|June 2013|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2012|February 27, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01543373||90180|
NCT01543633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005P001549|EEG Studies of Induction and Recovery From Propofol Induced General Anesthesia|Electroencephalogram Studies of Induction and Recovery From Propofol Induced General Anesthesia||Massachusetts General Hospital|Yes|Active, not recruiting|August 2005|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|36 Years|Accepts Healthy Volunteers|||December 2015|December 29, 2015|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543633||90160|
NCT01543139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bpcre2009|Trial of Combined Cytidine and Creatine in the Treatment of the Bipolar Depression|A Double-Blind, Placebo-Controlled Trial of Combined Cytidine and Creatine in the Treatment of the Bipolar Depression: A Magnetic Resonance Spectroscopy Study||Seoul National University Hospital|Yes|Recruiting|October 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|65 Years|No|||June 2012|June 6, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543139||90198|
NCT01543425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0116|Adrenocorticotropic Axis and Neuropathic Pain|Status of the Hypothalamic-pituitary-gonado- Adrenal Axis (HHSG) in Patients With Neuropathic Pain|HORMONES|University Hospital, Clermont-Ferrand||Completed|March 2012|May 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|120|None Retained|Day of inclusion: Blood sample for analysis of several hormones (cortisol, ACTH, SHBG, total      testostérone et S-DHEA, βœstradiol et progestérone for women, LH, FSH).      Day +1: salivary samples (at wake-up, 30 minutes after wake-up, at lunch, at 06:00 pm and      before sleep).      Day +2: salivary samples (at wake-up, 30 minutes after wake-up).|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients older than 18 years,          -  Male or Female with BMI between 18 and 35,          -  Patients with chronic neuropathic pain for more than six months, except to diabetes             or central neuropathic pain          -  Patients receiving systemic therapy for treating chronic neuropathic pain such as             antidepressants, anticonvulsants or opiates for at least 6 months.        Group of healthy volunteers          -  non-painful healthy volunteers matched by age, sex, BMI and menopausal status for             women,          -  Free of analgesics within 8 days before the test,          -  Aged over 18 years,          -  Male or Female,|May 2013|May 13, 2013|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543425||90176|
NCT01543646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIAL MR|Multiparametric MR for Rapid Imaging Assessment of the Liver|Rapid Imaging Assessment of the Liver Using Multiparametric Magnetic Resonance|RIAL|University of Oxford|No|Recruiting|March 2011|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Fresh frozen plasma, frozen serum, and whole blood for DNA analysis|Both|18 Years|N/A|No|Non-Probability Sample|The study aims to recruit 60 patients due to undergo liver biopsy to establish a diagnosis        of liver disease. These patients will be recruited from the Oxford Radcliffe Hospitals        clinics by Dr Jane Collier, consultant hepatologist, and her colleagues. Each patient will        be scheduled for an ultrasound-guided liver biopsy as part of their usual care. We will        ask these patients if they wish to take part in our research study, and offer to arrange        the research scans before the biopsy and a time of their choice.|March 2012|March 2, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01543646||90159|
NCT01543958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5296|Sevelamer for Reducing Endotoxemia and Immune Activation|Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study||AIDS Clinical Trials Group|Yes|Completed|November 2011|November 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|February 29, 2012|Yes|Yes||No|September 23, 2013|https://clinicaltrials.gov/show/NCT01543958||90135|
NCT01540188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA029493|Development of a Family Intervention to Address Drug Use and HIV in Vietnam|Development of a Family Intervention to Address Drug Use and HIV in Vietnam||University of California, Los Angeles|Yes|Completed|July 2010|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|230|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01540188||90423|
NCT01540201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-12-033-002|The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing One-lung Ventilation for Lung Surgery|The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing One-lung Ventilation for Lung Surgery||Samsung Medical Center|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|110|||Both|20 Years|70 Years|No|||December 2013|December 24, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01540201||90422|
NCT01540422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-177|Study to Improve Long Term Vein Graft Patency After Coronary Bypass Surgery by Using a Novel Endoscopic Harvesting Technique|OPTION Trial: Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques||Baylor Research Institute|No|Completed|October 2010|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|93|||Male|18 Years|N/A|No|Non-Probability Sample|Hospital facility|March 2015|March 12, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540422||90405|
NCT01540435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKSH088|Perioperative Treatment of Resectable Liver Metastases|Perioperative FOLFOXIRI and Bevacizumab Compared With Postoperative FOLFOX in Patients With Resectable Liver Metastases From Colorectal Cancer (PERIMAX). A Randomized, Multidisciplinary DGAV(CAO-V/CALGP)/AIO Phase II Trial|PERIMAX|University of Regensburg|Yes|Withdrawn|September 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||May 2013|May 28, 2013|February 16, 2012||No|insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01540435||90404|
NCT01541267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-4/Aliskiren/2011|The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria|The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria in Chronic Non-diabetic Kidney Disease: a Double-blind Cross-over Randomised Controlled Study||Medical University of Gdansk|Yes|Completed|December 2009|November 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|65 Years|No|||February 2012|February 28, 2012|February 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01541267||90340|
NCT01541280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 10/07-H|VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome|Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome|VIDAZA-DLI|Nantes University Hospital||Completed|November 2011|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|70 Years|No|||February 2016|March 17, 2016|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01541280||90339|
NCT01541826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-311|Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers|The Effect of Chokeberry Polyphenols on Biomarkers of Cardiovascular Disease and Antioxidant Defenses in Former Smokers||University of Connecticut|No|Completed|February 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541826||90298|
NCT01542138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIADESAH|Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation|A Double Blind, Randomized Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation||Universidad Autonoma de San Luis Potosí|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 27, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01542138||90274|
NCT01542450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1475|Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes|A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single s.c. Doses of NN304 (Insulin Detemir) and NPH Human Insulin in Japanese Subjects With Type 1 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|August 2002|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|20 Years|N/A|No|||February 2012|February 24, 2012|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542450||90250|
NCT01542463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1893|Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes|Levemir®: the Physiological Basal Insulin. Documentation of Safety Aspects, Glycaemic Control and Weight||Novo Nordisk A/S|No|Completed|September 2004|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4464|||Both|N/A|N/A|No|Non-Probability Sample|Patients with insufficiently controlled type 1 or type 2 diabetes mellitus under their        previous therapy|March 2016|March 2, 2016|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542463||90249|
NCT01542931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPF for resectable OSCC|TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma|Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|January 2008|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|75 Years|No|||February 2012|March 1, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01542931||90213|
NCT01514539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P20RR016474|Hormonal Regulation of Postpartum Weight and Presence of Gut Peptides in Human Milk|Role of Ghrelin and PYY in Postpartum Body Weight Regulation and Presence in Human Milk||University of Wyoming|Yes|Completed|August 2009|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|44|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01514539||92382|
NCT01515124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54CA155850|The Women In Steady Exercise Research (WISER) Survivor Trial|The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and Cost Effectiveness of Alternative Management Strategies||University of Pennsylvania|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|555|||Female|N/A|N/A|Accepts Healthy Volunteers|||January 2012|May 29, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515124||92337|
NCT01515137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-045|Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma|Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac||University of Pittsburgh|Yes|Completed|November 2005|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515137||92336|
NCT01515423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100662|Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia|A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia||Janssen Research & Development, LLC|No|Completed|May 2012|March 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1430|||Both|18 Years|70 Years|No|||July 2015|July 1, 2015|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515423||92314|
NCT01515436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR11247|The Effect of Music Periodicity on Interictal Epileptiform Discharges|A Randomized, Single-Blinded Clinical Trial: The Effect of Music Periodicity on Interictal Epileptiform Discharges||Medical University of South Carolina|No|Completed|February 2004|December 2007|Actual|May 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|5 Years|12 Years|No|||January 2012|January 23, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515436||92313|
NCT01542853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|spondylodiscitis-pilot|The Value of PET/CT in Diagnosing Residual Disease in Patients With Spinal Infection|Preliminary Study. The Value of 18F-FDG PET/CT Compared to MRI in Diagnosing Residual Disease in Patients With Spondylodiscitis||Odense University Hospital||Suspended|March 2012|March 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|10 patients with MRI or PET/CT findings as well as overall clinical assessment compatible        with spondylodiscitis.|February 2013|February 15, 2013|February 27, 2012||No|problems with recruitment and funding|No||https://clinicaltrials.gov/show/NCT01542853||90219|
NCT01543152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-728-1101|Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T|A Phase I, Open-Label Study to Assess the Effect of Escalating Doses of Cyclophosphamide on the Engraftment of SB-728-T in Aviremic HIV-Infected Subjects on HAART||Sangamo Biosciences|Yes|Recruiting|December 2011|September 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|26|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543152||90197|
NCT01543438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R41MD006695-01|Using Point-of-Care Video Prescriptions to Improve Aftercare Following Discharge From a Pediatric Emergency Department|Optimizing Emergency Aftercare With Mobile Video Prescriptions||healthEworks LLC|Yes|Recruiting|January 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention|2||Anticipated|5000|||Both|N/A|18 Years|Accepts Healthy Volunteers|||January 2013|January 2, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01543438||90175|
NCT01543451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIDE-11-10|Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea|Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846)Administered s.c. in the Prevention of Chemotherapy Induced Diarrhea(CID)||Helsinn Healthcare SA|Yes|Completed|February 2012|October 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|138|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543451||90174|
NCT01543672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11VOL|Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously|VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study|VOLUMES|The Netherlands Cancer Institute|Yes|Recruiting|October 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||July 2013|October 8, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01543672||90157|
NCT01539915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCT194A2102|Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients|A Single Center, Open Label Exploratory Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Topically Administered BCT194 in Dermal Interstitial Fluid in Psoriatic Patients Using Open Flow Microperfusion||Novartis||Completed|April 2007|||November 2007|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment|1||Actual|12|||Both|18 Years|75 Years|No|||February 2012|February 27, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539915||90443|
NCT01539928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMA 61 DILUCE|Dual PET/CT Imaging in Lung Cancer|Dual PET/CT Imaging in Lung Cancer (Danish Title: En og Tre Timers FDG-PET/CT Ved Lungecancer)|DILUCE|Odense University Hospital|Yes|Recruiting|March 2012|March 2015|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|216|Samples With DNA|Fresh frozen sample of primary lung cancer tumor|Both|18 Years|N/A|No|Non-Probability Sample|Pt. referred to The Department of Pulmonary Medicine, Odense University Hospital or The        Department of Medicine, Hospital of Southern Denmark, Sønderborg with suspicion of lung        cancer|June 2013|June 24, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01539928||90442|
NCT01540747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mel_FF|Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome|||AGUNCO Obstetrics and Gynecology Centre||Completed||||||Phase 4|Interventional|N/A|2||||||Female|27 Years|38 Years|No|||January 2009|February 23, 2012|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01540747||90380|
NCT01540448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS-005|Role of CT Angiography With Three-dimensional Reconstruction of Mesenteric Vessels in Planning and Performing of Laparoscopic Colorectal Resections||3DCT|University of Roma La Sapienza||Completed|January 2010|February 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||February 2012|February 22, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01540448||90403|
NCT01540461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA182-064|Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)|A Phase 1 Study to Determine the Safety and Pharmacokinetics of Brivanib in Chinese Subjects With Advanced Hepatocellular Carcinoma (HCC)||Bristol-Myers Squibb|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|18 Years|N/A|No|||June 2014|July 4, 2014|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540461||90402|
NCT01541293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1928|Intrauterine Lidocaine for Laminaria|Intrauterine Lidocaine for Pain Control During Laminaria Insertion Prior to Dilation & Evacuation (D&E)||University of North Carolina, Chapel Hill|Yes|Completed|September 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|N/A|No|||October 2013|May 13, 2014|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01541293||90338|
NCT01541306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nemours FL IRB 302926|C-Type Natriuretic Peptide and Achondroplasia|C-Type Natriuretic Peptide and Achondroplasia||Nemours Children's Clinic|No|Completed|February 2012|December 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|91|Samples Without DNA|Plasma and serum samples are stored for potential future research.|Both|3 Months|N/A|No|Non-Probability Sample|Children and adults with achondroplasia or hypochondroplasia|April 2015|April 13, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01541306||90337|
NCT01542151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TimeIOL|Effects of Sleep, Fatigue, and Timing of Post-dates Inductions Among Nulliparas|Effects of Sleep, Fatigue, and Timing of Post-dates Inductions Among Nulliparas||University of California, San Francisco|No|Completed|October 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|72|||Female|14 Years|N/A|No|||March 2015|March 24, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01542151||90273|
NCT01542424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1763|An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia||Novo Nordisk A/S|No|Completed|March 2006|December 2006|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1889|||Both|N/A|N/A|No|Non-Probability Sample|Macedonian people with diabetes mellitus (Type 1 or Type 2)|February 2016|February 18, 2016|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542424||90252|
NCT01542437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBW2992|Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer|Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2|NSCLC|Instituto Nacional de Cancerologia de Mexico|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66|||Both|18 Years|90 Years|No|||July 2015|July 8, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01542437||90251|
NCT01542762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35774.058.11|Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation|Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation: Determining the Balance Between Benefits and Risks|Pot-Cast|Leiden University Medical Center|Yes|Recruiting|March 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|1500|||Both|18 Years|N/A|No|||March 2014|March 6, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542762||90226|
NCT01542502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14079|Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction|Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction||Virginia Commonwealth University||Completed|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||August 2013|August 30, 2013|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01542502||90246|
NCT01542749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAXOR 01|Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer|Pilot Research Study to Asses Total Body Albumin Levels||Daxor Corporation|Yes|Completed|January 2009|January 2012|Actual|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Adult male and female volunteers|February 2012|March 1, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542749||90227|
NCT01542970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FaLr-013|Can Supplementation With Lactobacillus Reuteri and Omega-3 Fatty Acids During Pregnancy and Lactation Reduce the Risk of Allergic Disease in Infancy?|Combined Dietary Supplementation With Lactobacillus Reuteri and Omega-3 PUFA During Pregnancy and Postnatally in Relation to Development of IgE-associated Disease During Infancy|PROOM-3|Ostergotland County Council, Sweden|Yes|Recruiting|February 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|496|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 2, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542970||90210|
NCT01514864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-385|Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation|Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation||Bristol-Myers Squibb|No|Terminated|May 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|January 18, 2012|Yes|Yes|Lack of efficacy and slow accrual|No|July 23, 2015|https://clinicaltrials.gov/show/NCT01514864||92357|The study was terminated due to lack of efficacy and slow enrollment of patients.
NCT01515995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|( STU 072011-043)|Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation|Nebulized Magnesium Sulfate Versus Normal Saline as a Vehicle for Albuterol in Children With Moderate to Severe Asthma Exacerbation: a Randomized Controlled Trial||University of Texas Southwestern Medical Center|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|7 Years|18 Years|No|||January 2014|January 3, 2014|January 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01515995||92270|
NCT01516333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 26026|Replace Glycemic Load and Satiety Study|Response of Energy Peak Levels After Carbohydrates Are Eaten Glycemic Load and Satiety Study - Phase 1||Pennington Biomedical Research Center|No|Completed|February 2007|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|26|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01516333||92244|
NCT01542866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002A2407|A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)|A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab||Novartis|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|160|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|July 1, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01542866||90218|
NCT01543178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFIB3053|Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study|A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)|TARGET3|Valeant Pharmaceuticals International, Inc.|No|Completed|February 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2583|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|February 27, 2012|Yes|Yes||No|June 15, 2015|https://clinicaltrials.gov/show/NCT01543178||90195|
NCT01542840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.200.C|Onset Time of Nerve Block: A Comparison of Two Injection Locations in Patients Having Lower Leg/ Foot Surgery|Onset Time of Ultrasound-Guided Popliteal Sciatic Nerve Block: Comparing Circumferential Injection of Local Anesthetic to Injection That Separates the Nerve in Its Two Components||Ochsner Health System|No|Not yet recruiting|May 2014|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|76|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing lower leg and/or foot surgery at Ochsner Clinic Foundation's Main        Campus.|March 2014|March 20, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01542840||90220|
NCT01543659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-126|Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer|A Phase I/II Study of Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|77|||Male|18 Years|N/A|No|||December 2015|December 21, 2015|February 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01543659||90158|
NCT01539941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA031305-01A1|Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD in Routine Care|Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD in Routine Care||The National Center on Addiction and Substance Abuse at Columbia University|Yes|Completed|August 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|13 Years|17 Years|No|||February 2012|August 3, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01539941||90441|
NCT01539954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JK_NIAAA_02-12|Computerized Alcohol Screening for Children and Adolescents|Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care|cASCA|Children's Hospital Boston|No|Withdrawn|September 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|9 Years|18 Years|No|Non-Probability Sample|Youth 9-18 years old|January 2013|January 2, 2013|February 16, 2012||No|The project was not funded.|No||https://clinicaltrials.gov/show/NCT01539954||90440|
NCT01543685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND3-08-04b|Study of Indomethacin Capsules to Treat Pain Following Bunionectomy|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Indomethacin [Test] Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy||Iroko Pharmaceuticals, LLC|No|Completed|February 2012|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|462|||Both|18 Years|65 Years|No|||January 2014|January 2, 2014|February 28, 2012|Yes|Yes||No|February 27, 2013|https://clinicaltrials.gov/show/NCT01543685||90156|
NCT01544010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA023191-01A1|Optimal TTM Tailoring for Population Cessation|Optimal TTM Tailoring for Population Cessation|STAR|University of Rhode Island|Yes|Completed|February 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Actual|3006|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01544010||90131|
NCT01540474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-17085|Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults|Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults||U.S. Army Medical Research and Materiel Command|No|Completed|February 2012|December 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|February 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540474||90401|
NCT01540487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.5|Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin|Characterisation of Fixed Dose Combination Tablets of Linagliptin 2.5 mg/Metformin 850 mg or Linagliptin 2.5 mg/Metformin 500 mg and Relative Oral Bioavailability Compared With Single Linagliptin 2.5 mg and Metformin 850 mg or 500 mg Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open Label, Randomised, Single-dose, Two-way Crossover, Phase I Study||Boehringer Ingelheim||Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|February 23, 2012||||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01540487||90400|
NCT01540760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA28006|A Study of MCAF5352A in Healthy Volunteers|A Phase Ib, Single-Center, Randomized, Placebo-Controlled, Double-Blind Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers||Genentech, Inc.||Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Investigator)|2||Actual|23|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540760||90379|
NCT01540773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC10043|Supplement Amino Acid|Growth Hormone 120 Minutes Following a Single Low-dose of Amino Acids in Healthy Subjects.||Pennington Biomedical Research Center|No|Completed|October 2011|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|19|||Both|18 Years|70 Years|No|||June 2014|June 6, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540773||90378|
NCT01541020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_SBrumagne_HealthyLBP|Inspiratory Resistive Loading and Proprioceptive Postural Control|Inspiratory Resistive Loading and Proprioceptive Postural Control in Healthy Individuals and Individuals With Recurrent Low Back Pain||Katholieke Universiteit Leuven|Yes|Completed|January 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|young flemish volunteers|January 2012|December 4, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01541020||90359|
NCT01541033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-00206-XP|Biomarker of Children With Familial Autoimmune History|Biomarker Discovery In Children With Autism Plus Familial Autoimmune History||Le Bonheur Children's Hospital|No|Recruiting|November 2009|October 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|Samples With DNA|Blood|Both|4 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children with or without autism|September 2015|September 2, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541033||90358|
NCT01541592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000179|Does Class of Dietary Fat Affect Insulin Resistance?|Insulin Resistance and Dietary Fat||Mayo Clinic|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01541592||90315|
NCT01541605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEMAP1|Methylphenidate for the Treatment of Acute Mania|International Randomised Double-blind Placebo-controlled Study on the Initial Treatment of Acute Mania With Methylphenidate||University of Leipzig|Yes|Recruiting|March 2012|October 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|75 Years|No|||June 2014|June 24, 2014|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01541605||90314|
NCT01541852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A092519|Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.|An Evaluation Of Losmapimod in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Systemic Inflammation Stratified Using Fibrinogen (EVOLUTION)|EVOLUTION|Cambridge University Hospitals NHS Foundation Trust|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|72|||Both|50 Years|85 Years|No|||March 2015|March 15, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01541852||90296|
NCT01541865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR002-020|Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter|Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY|REDUCE-HTN|Boston Scientific Corporation|Yes|Completed|February 2012|June 2015|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|146|||Both|18 Years|75 Years|No|||October 2015|October 23, 2015|February 21, 2012||No||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01541865||90295|
NCT01542164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-B-2009-071|Calcium Intake and Fat Excretion|Calcium Intake and Fat Excretion - an Observational Study|KIFU/B266|University of Copenhagen|No|Active, not recruiting|January 2010|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|160|Samples With DNA|Whole blood, urine and faeces|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Copenhagen and Sjælland|May 2014|May 28, 2014|May 26, 2010||No||No||https://clinicaltrials.gov/show/NCT01542164||90272|
NCT01542476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1924|The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction|An Observational Study in Dutch Type 1 and Type 2 Diabetes Patients: The Impact of Initiation of/Switching to Levemir® on Emotional Well-being, Insulin Perceptions and Treatment Satisfaction - CONFIDENCE (Clinical ObservatioNs oF Levemir® In Dutch ExperieNCE)|CONFIDENCE|Novo Nordisk A/S|No|Completed|August 2006|October 2007|Actual|October 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|299|||Both|N/A|N/A|No|Non-Probability Sample|Any subject with type 1 or type 2 diabetes not optimally controlled in whom at the        discretion of the participating physicians it was decide to either initiate or switch to a        treatment with a long-acting insulin analogue|March 2016|March 2, 2016|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01542476||90248|
NCT01542775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exer(sRAGE)|Effects of Exercise on sRAGE Levels and Cardiometabolic Risk Factors|||Korea University||Completed|January 2010|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2012|March 1, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01542775||90225|
NCT01543009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFI2012WARM|Use of Local Warming in Children Venipuncture|Use of Local Warming in Children to Facilitate Venipuncture. A Randomized Controlled Trial.||University of Florence|Yes|Suspended|March 2012|October 2016|Anticipated|October 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|72|||Both|8 Years|13 Years|No|||October 2015|October 28, 2015|February 27, 2012||No|Difficulty in recruiting|No||https://clinicaltrials.gov/show/NCT01543009||90208|
NCT01542983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120108|Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy|Feasibility of Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy for Breast Cancer||University of California, San Diego|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Female|18 Years|85 Years|No|||February 2013|February 5, 2013|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01542983||90209|
NCT01543022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|184916|Symphony: The Implantable Counter Pulsation Device (CPD) Safety and Feasibility Trial|First in Man Study - a Prospective, Multicenter, Single Arm Trial to Investigate the Safety and Feasibility of the Symphony Device|Symphony|Abiomed Inc.|Yes|Recruiting|November 2011|June 2014|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|19 Years|N/A|No|||May 2013|May 1, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543022||90207|
NCT01515150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-VOD|The Out-patient, Non Antibiotic Management of Patients With Acute Uncomplicated Colonic Diverticulitis|Management of Patients With Uncomplicated Diverticulitis as Out-patient and Without Antibiotics|P-VOD|Uppsala University|Yes|Completed|February 2012|August 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|161|||Both|18 Years|95 Years|No|Probability Sample|Patients with CT- scan varified acute uncomplicated diverticulitis how are abel to        underwent out-patients managment|January 2015|January 23, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01515150||92335|
NCT01515163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lupus and exercise|Exercise and Systemic Lupus Erythematosus|||University of Sao Paulo|No|Active, not recruiting|May 2010|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|90|||Female|7 Years|40 Years|No|||January 2016|January 12, 2016|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01515163||92334|
NCT01515722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-05-106|Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder|Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder : 6-month, Randomized, Open-label, Multi-center Trial||Samsung Medical Center|Yes|Recruiting|December 2010|June 2012|Anticipated|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|692|||Female|18 Years|N/A|No|||January 2012|January 23, 2012|July 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01515722||92291|
NCT01516008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100459|A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy; Bridging Study for Korea||Janssen Research & Development, LLC|No|Completed|January 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|353|||Both|20 Years|80 Years|No|||March 2014|March 28, 2014|January 19, 2012||No||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01516008||92269|
NCT01516021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YOG|How Fat Influences the Brain|Fat Intake Modulates Cerebral Blood Flow in Homeostatic and Gustatory Brain Areas in Humans||University Hospital Tuebingen|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|11|||Male|25 Years|32 Years|Accepts Healthy Volunteers|||January 2012|January 18, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01516021||92268|
NCT01543464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM1120|Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients|Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma||Herlev Hospital|Yes|Terminated|May 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|February 8, 2012||No|Diminished rectruitment|No||https://clinicaltrials.gov/show/NCT01543464||90173|
NCT01543165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1112/141-011|Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic|A Single Center, Prospective Randomized Double-blind Trial: Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic||Seoul National University Hospital||Recruiting|December 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|111|||Both|18 Years|55 Years|No|||December 2012|December 13, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543165||90196|
NCT01543191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-0009|A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis|A Phase 1 Dose-escalation Study TO Evaluate the Safety and Tolerability of PUR118 and Placebo in Subjects With CF||Pulmatrix Inc.|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|55 Years|No|||July 2013|July 18, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543191||90194|
NCT01544023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL001|TiLoop® Bra for Breast Reconstruction|Multicenter Observational Study of Implant Based Breast Reconstruction Using a Titanium-coated Polypropylene Mesh||University of Rostock|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|242|||Female|18 Years|N/A|No|Non-Probability Sample|Patients eligible for immediate or secondary implant based breast reconstruction.|January 2013|January 15, 2013|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01544023||90130|
NCT01539967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09-PR-REGIMBEAU|Impact of the Residual Gastric Volume in Laparoscopic Sleeve Gastrectomy's Failure|Is the Residual Gastric Volume After Sleeve Gastrectomy an Objective Criterion to Adapt the Treatment Strategy After Failure?|GASTROMANCH|Centre Hospitalier Universitaire, Amiens|No|Completed|August 2009|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|90|||Both|18 Years|N/A|No|||April 2012|April 5, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01539967||90439|
NCT01540214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/456|Study of Overactive Bladder in Women With Prolapse|Prevalence of Overactive Bladder (OAB) in Patients With Pelvic Organ Prolapse (POP) and Predictors of Symptoms of OAB After Surgical Correction of POP|SOAP|Radboud University|No|Recruiting|February 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Urine|Female|18 Years|N/A|No|Probability Sample|All women who present with POP at the outpatient clinic of our centre and who will undergo        prolapse repair surgery will be asked informed consent for participation in this study.|December 2012|January 4, 2013|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01540214||90421|
NCT01540513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO11360|PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404|PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404||University of Wisconsin, Madison|Yes|Active, not recruiting|March 2012|||November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01540513||90398|
NCT01541059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/JR/HG-02|Postoperative Analgesia Following Wisdom Teeth Removal: Ropivacaine Versus Placebo|Postoperative Analgesia in Third Molar Surgery Under General Anesthesia: Ropivacaine Versus Placebo|RopiMol|Centre Hospitalier Universitaire de Nīmes|No|Completed|June 2012|August 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|16 Years|65 Years|No|||October 2015|October 21, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01541059||90356|
NCT01541046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000018504|Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic|Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic: A Randomized Double-blind Controlled Trial||The Hospital for Sick Children|Yes|Completed|November 2011|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|N/A|180 Days|No|||November 2014|November 19, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01541046||90357|
NCT01530698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL2009-015737-73|Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients|Single-step Antigen Loading and TLR Activation of Dendritic Cells by mRNA Electroporation for Vaccination in Stage III and IV Melanoma Patients||Radboud University|No|Completed|April 2010|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|70 Years|No|||November 2014|November 4, 2014|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01530698||91146|
NCT01530984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC# 12552|Ipilimumab and GMCSF Immunotherapy for Prostate Cancer|Anti-CTLA4 Blockade Alone or Combined With Systemic GM-CSF for Prostate Cancer Immunotherapy||University of California, San Francisco|Yes|Withdrawn|June 2015|December 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||October 2015|October 1, 2015|February 7, 2012|Yes|Yes|Unable to execute contract|No||https://clinicaltrials.gov/show/NCT01530984||91124|
NCT01530997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1120|De-intensification of Radiation and Chemotherapy for Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma|Phase II Study of De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|November 2011|January 2016|Anticipated|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01530997||91123|
NCT01531582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WEEBER001|Minocycline in the Treatment of Angelman Syndrome|The Efficacy of Minocycline in the Treatment of Angelman Syndrome||University of South Florida|Yes|Active, not recruiting|April 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|4 Years|12 Years|No|||May 2014|May 9, 2014|February 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531582||91079|
NCT01531595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003137-33|Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer|Phase 2 Study of Bevacizumab in Combination With Alternating Xeliri and Xelox as First-line Treatment of Patients With Metastatic Colorectal Cancer||Helsinki University Central Hospital|No|Recruiting|February 2012|December 2025|Anticipated|December 2025|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531595||91078|
NCT01531894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115131|Continuation Study of the Oral AKT Inhibitor GSK2110183|An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies||Novartis|Yes|Recruiting|February 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|80 Years|No|||March 2016|March 22, 2016|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531894||91055|
NCT01532219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-DEPANX2012-APT|Internet-delivered Psychodynamic Therapy for Depression and Anxiety Disorders|Internet-delivered Psychodynamic Therapy for Depression and Anxiety Disorders: A Randomized Controlled Trial|ATLAS|Linkoeping University|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||April 2013|April 23, 2013|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01532219||91030|
NCT01556841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/11/0119|The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer|A Randomised Parallel Group Double-Blind Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|TRIOC|University College, London|Yes|Recruiting|November 2013|October 2018|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|75|||Female|18 Years|N/A|No|||September 2015|September 30, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01556841||89151|
NCT01553188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120079|AMG 386 and Abiraterone for Advanced Prostate Cancer|A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer||National Institutes of Health Clinical Center (CC)||Recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|88|||Male|18 Years|100 Years|No|||August 2015|February 19, 2016|March 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553188||89430|
NCT01553409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89834103|Effect of Blood Donation on Blood Pressure, Iron Metabolism, Oxidative Stress|Prospective Observational Study on the Effects of Blood Donation on Blood Pressure, Iron Metabolism and Oxidative Stress||Charite University, Berlin, Germany|No|Completed|February 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples Without DNA|regular blood donation is done and from blood, that is taken for blood tests by the blood      donation center any there are made blood tests of lipid metabolism, iron metabolism and      antioxidative stress|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|female and male from 18 years to 65 years, who are able and want to donate blood for the        first time or after one year break to the last blood donation|May 2014|May 7, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553409||89413|
NCT01553422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390331|Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava Before and After Fluid Therapy|Assessment of Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava by Emergency Ultrasonography Before and After Fluid Therapy||Isfahan University of Medical Sciences|Yes|Completed|March 2012|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|82|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01553422||89412|
NCT01553162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B4|Studying Dexamethasone and Prednisone Sensitivity in Samples From Younger Patients With High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia|B-precursor Acute Lymphoblastic Leukemia (ALL): Studying the Mechanisms Behind Dexamethasone and Prednisone Sensitivity in High-Risk Patients||Children's Oncology Group|No|Active, not recruiting|March 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|||Both|1 Year|21 Years|No|Non-Probability Sample|Patients diagnosed with high-risk B-cell precursor acute lymphoblastic leukemia|May 2015|May 4, 2015|March 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01553162||89432|
NCT01553643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR98-IRB-281|A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis|||China Medical University Hospital||Recruiting|January 2010|||November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|41 Years|N/A|No|||March 2012|March 13, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01553643||89395|
NCT01533376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVL-SWS-TT4PWM|Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol|Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol||Wills Eye|Yes|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|10|||Both|2 Years|10 Years|No|||December 2015|December 18, 2015|February 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01533376||90942|
NCT01533662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0900103|Prophylactic Phenylephrine Infusion for Preventing Hypotension During Spinal Anesthesia|Phase 2 Study Evaluating the Prophylactic Phenylephrine Infusion for Preventing Hypotension During Spinal Anesthesia for Lower Limb Orthopedic Surgery in the Elderly Patients|PPSA|University Hospital, Toulouse|No|Completed|March 2011|September 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|64|||Both|60 Years|N/A|No|||June 2014|June 20, 2014|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01533662||90920|
NCT01534299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10031728DOC|Global SYMPLICITY Registry|Global ProSpective RegistrY for SyMPathetic RenaL DenervatIon In Selected IndiCatIons Through 3-5 Years Registry||Medtronic Vascular|No|Recruiting|February 2012|July 2021|Anticipated|July 2017|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects undergoing renal denervation procedure to treat the diseases affected by        increased sympathetic activity.|October 2015|October 26, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534299||90872|
NCT01534286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0201302|A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics|A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics||Targeted Medical Pharma|No|Enrolling by invitation|August 2012|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2012|July 24, 2012|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534286||90873|
NCT01534546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG1003-RESOLVE|Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection|A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection||Peking University|Yes|Recruiting|March 2012|September 2019|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1059|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534546||90853|
NCT01534832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIL/2011/INV01|Assessment of a New Surgical Smoke Clearing Technology in Laparoscopic Cholecystectomy|Assessment of a New Surgical Smoke Clearing Technology, "Innervision", in Laparoscopic Cholecystectomy|Innervision|Asalus Medical Instruments Limited|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|80 Years|No|||August 2012|August 14, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01534832||90833|
NCT01535118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7243-021|A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)|National Allergies, Immunotherapy and RhinoConjunctivitis Survey in America|AIRS|Merck Sharp & Dohme Corp.|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|2765|||Both|5 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults and children with ARC in the United States.|February 2015|February 25, 2015|February 14, 2012||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT01535118||90812|
NCT01535079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00498 TA 2 01|Acute Sore Throat Pain Study|Analgesic Profile of 3 New Ibuprofen Lozenges (V0498TA01A 15 mg, 25 mg, 35 mg) After Single Administration in Acute Sore Throat Pain||Pierre Fabre Medicament||Completed|February 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|186|||Both|18 Years|N/A|No|||October 2012|November 9, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01535079||90815|
NCT01535092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEG-SIL-LTX-03|Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients|A Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Legalon SIL for the Treatment of HCV Recurrence of the Graft in Orthotopic Liver Transplant Patients||Rottapharm|No|Terminated|September 2010|November 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|70 Years|No|||February 2012|February 14, 2012|February 7, 2012||No|when realized that the target 60% of patients with SVR was no more achievable|No||https://clinicaltrials.gov/show/NCT01535092||90814|
NCT01535105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gl homeostasis and obesity|Impairment in Glucose Homeostasis Among Obese Adolescents in High Risk Diabetes Prone Population - Jisr Az-Zarqa Village|||Meir Medical Center|No|Recruiting|August 2012|April 2017|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|300|||Both|12 Years|18 Years|No|Non-Probability Sample|Subjects of the study will be selected from a primary care clinic|February 2012|March 13, 2013|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535105||90813|
NCT01530724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISF256/09|Diet and Body Composition|Effect of Weight-loss Diet Strategies and Exercise on Dynamics of Body Fat Depots and Metabolic Rate|CENTRAL|Ben-Gurion University of the Negev|Yes|Completed|October 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|224|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530724||91144|
NCT01530971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10AS00008/044/10|Effect of Maternal and Neonatal Oxygenation|Effects of Neonate and Maternal Oxygenation in Low-dose Oxygen Supplement by Oxygen Cannula or Non- Supplement in Elective Cesarean Section: a Randomized Controlled Trial||Mahidol University|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|325|||Female|19 Years|N/A|Accepts Healthy Volunteers|||June 2013|July 1, 2013|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530971||91125|
NCT01531608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15343|Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma|Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma Independent Of Fixed Gamma Camera Imaging|Mel54|University of Virginia|Yes|Completed|March 2011|||February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with melanoma scheduled to undergo sentinel node biopsy as part of recommended        clinical care, age 18 years or older.|April 2015|April 20, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01531608||91077|
NCT01532492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTME/Z-11.19/WORC|Validation of the Western Ontario Rotator Cuff Index in Patients With Arthroscopic Rotator Cuff Repair|Validation of the Western Ontario Rotator Cuff Index in Patients With Arthroscopic Rotator Cuff Repair|WORC|St. Antonius Hospital|No|Completed|November 2011|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|118|||Both|18 Years|N/A|No|Non-Probability Sample|1. Patients undergoing arthroscopic rotator cuff repair. These patients have a clinical             suspicion of a symptomatic rotator cuff tear and a partial or full thickness lesion             seen on MRI or Ultrasound and confirmed during the arthroscopic repair procedure.          2. Patients diagnosed as having non-Ruptured DRC. They have a clinical suspicion of DRC             and no rupture of the rotator cuff on MRI or Ultrasound.          3. Patients will be diagnosed with shoulder instability|April 2014|April 30, 2014|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01532492||91009|
NCT01556854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011BAI08B02-01|Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke|Comparative Effectiveness of Different Neuroprotectants Among Patients With Acute Ischemic Stroke in Clinical Practice|CER|Ministry of Science and Technology of the People´s Republic of China||Recruiting|July 2011|June 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20000|||Both|18 Years|N/A|No|Probability Sample|The study population will consist of consenting patients who are on neuroprotectant        injection for the treatment of acute IS during hospitalization.|March 2012|March 15, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01556854||89150|
NCT01553435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 09-120|Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients|Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients||King Abdullah International Medical Research Center|Yes|Active, not recruiting|January 2011|||January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|36|||Both|2 Years|14 Years|No|||April 2015|April 12, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01553435||89411|
NCT01553669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009BAI77B03|Reminiscence Therapy on Depression, Self Esteem, Life Satisfaction, and Loneliness of the Elderly|The Effects of Reminiscence Therapy on Depression, Self Esteem, Life Satisfaction, and Loneliness of the Elderly in China||Chinese Academy of Sciences|Yes|Recruiting|October 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|60 Years|N/A|No|||May 2012|May 14, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01553669||89393|
NCT01553396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0165/2008|Muscle Strength and Functional Autonomy of Elderly Women|Muscle Strength and Functional Autonomy of Normo-IGF-1 Elderly Women With Skeletal Muscle Dysfunctions||Euro-American Network of Human Kinetics|No|Completed|January 2009|April 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|35|Samples Without DNA|Whole blood|Female|60 Years|75 Years|No|Non-Probability Sample|The population consists of 123 elderly women residents of São Lucas shelter, located in        Cacimba Velha, Teresina-PI, Brazil. The sample consists of 35 elderly women. The elderly        participants in the study signed a written informed consent.|March 2012|March 13, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01553396||89414|
NCT01553656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-014|Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer|Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors||Exelixis|No|Completed|February 2011|July 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|20 Years|N/A|No|||August 2015|August 19, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01553656||89394|
NCT01553942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-464|Afatinib With CT and RT for EGFR-Mutant NSCLC|Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial||Massachusetts General Hospital|Yes|Recruiting|April 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553942||89373|
NCT01533389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWP-SDS-404|Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones|A 4-week, Double-blind, Randomized, Comparative and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones.|STONE|JW Pharmaceutical|No|Completed|October 2011|August 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|114|||Both|20 Years|N/A|No|||November 2013|November 18, 2013|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01533389||90941|
NCT01533974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR7441|PATH Partnering to Achieve Tobacco-free Health|Acceptance & Commitment Therapy for Smoking Cessation (Aka PATH Study - Partnering to Achieve Tobacco-free Health)|PATH|Fred Hutchinson Cancer Research Center|Yes|Completed|June 2011|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 4, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01533974||90896|
NCT01534858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-O-H-1102|A Prospective, Descriptive Cohort Study With Prontosan® Wound Gel X in Partial and Full Thickness Burns Requiring Split Thickness Skin Grafts|A Prospective, Descriptive Cohort Study With Prontosan® Wound Gel X in Partial and Full Thickness Burns Requiring Split Thickness Skin Grafts||B. Braun Ltd. Centre of Excellence Infection Control|No|Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|51|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01534858||90831|
NCT01535157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOC-2011-001|Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer|Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma||South Plains Oncology Consortium|Yes|Recruiting|February 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||December 2014|December 9, 2014|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535157||90809|
NCT01535170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-076|Bovine Lactoferrin as a Natural Regimen of Selective Decontamination of the Digestive Tract in Patients With Prolonged Mechanical Ventilation|Bovine Lactoferrin as a Natural Regimen of Selective Decontamination of the Digestive Tract in Patients With Prolonged Mechanical Ventilation|LFasSDD|China Medical University Hospital|Yes|Recruiting|September 2010|July 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01535170||90808|
NCT01534845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNOG-1101|Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion|A Randomized Phase 2 Study to Evaluate the Efficacy Between Only Radiotherapy Versus CCRT With Temozolomide in Newly Diagnosed Grade III Gliomas Without 1p/19q Codeletion||Asan Medical Center|Yes|Active, not recruiting|March 2012|February 2017|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|75 Years|No|||July 2015|July 7, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01534845||90832|
NCT01535131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11060248|Furlow Palatoplasty With Tensor Tenopexy|Furlow Palatoplasty With Tensor Tenopexy for Otitis Media||University of Pittsburgh|Yes|Recruiting|February 2012|December 2021|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|15 Months|No|||January 2016|January 18, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01535131||90811|
NCT01530711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMELIORATE|Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response|Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response|AMELIORATE|Hospital Clinic of Barcelona|No|Recruiting|April 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01530711||91145|
NCT01530737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000020202|Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery|Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery||The Hospital for Sick Children|Yes|Completed|November 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|N/A|364 Days|No|||January 2015|January 6, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01530737||91143|
NCT01531296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51477|To Assess Rotation for Femoral Version and Tibial Torsion|Correlation Between MRI and Clinical Measurements of Lower Extremity Rotational Profile: Reliability of MRI to Assess Rotation for Femoral Version and Tibial Torsion||University of Utah|No|Completed|October 2011|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|37|||Both|8 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|The study is aiming to recruit all patients with complaints of patellofemoral        pain/instability associated with rotational malalignment. The two types of rotational        malalignment, fibial version and tibial torsion are most common among the pediatric        population.|January 2016|January 13, 2016|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531296||91101|
NCT01531309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAGO178C2102|Pharmacokinetics of Agomelatine in Patients With Liver Impairment|An Open-label, Parallel-group Study to Compare the Pharmacokinetics, Safety and Tolerability of a Single Sublingual 1 mg Dose of AGO178 in Subjects With Mild and Moderate Hepatic Impairment With That in Matched Healthy Control Subjects||Novartis||Completed|February 2011|September 2011|Actual|September 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531309||91100|
NCT01532245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEOEC RKEB/IKEB 3504-2011|The Use of Constant-flow Technique for Determining the Lower Inflexion Point of Pressure-volume Curve and Intrinsic PEEP During One-lung Ventilation|||The Cleveland Clinic||Recruiting|December 2011|March 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Anticipated|40|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01532245||91028|
NCT01532258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB# 11-475|Effectiveness of an Eight Week Online Mediterranean Based Diet|Effectiveness of an Eight Week Online Mediterranean Based Diet in an Overweight or Obese Outpatient Primary Care Population||The Cleveland Clinic|No|Withdrawn|April 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|0|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|September 23, 2011||No|Online program required re-design|No||https://clinicaltrials.gov/show/NCT01532258||91027|
NCT01557114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSET 2010/1663 -Mel-Ipi-Rx|Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma|A Dose Escalation Phase I Study of Radiotherapy Administered in Combination With Anti-CTLA4 Monoclonal Antibody (Ipilimumab) in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma|Mel-Ipi-Rx|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Terminated|March 2011|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 16, 2011||No|New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab|No||https://clinicaltrials.gov/show/NCT01557114||89130|
NCT01557153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|724|Vascular Augmentation of Late-life Unremitted Depression (VALUeD)|Vascular Augmentation of Late-life Unremitted Depression (VALUeD)|VALUeD|Gateshead Health NHS Foundation Trust|Yes|Not yet recruiting|April 2012|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|50 Years|N/A|No|||March 2012|March 16, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01557153||89127|
NCT01557166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8022-3970|Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea|Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial||Novo Nordisk A/S|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|359|||Both|18 Years|64 Years|No|||February 2015|February 12, 2015|March 15, 2012|Yes|Yes||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01557166||89126|
NCT01553955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ManualPRP|Efficacy of Training in Manual Preparation of Platelet Rich Plasma|Efficacy of Training in Preparation of Platelet Rich Plasma Using a Standard Centrifuge and Manual Pipetting Methods||Peterson, Noel, N.D.|Yes|Completed|January 2012|July 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|28|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||March 2012|July 22, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01553955||89372|
NCT01554189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8325-002|A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C Infected Males||Merck Sharp & Dohme Corp.|No|Terminated|April 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|11||Actual|37|||Male|18 Years|65 Years|No|||July 2015|July 20, 2015|March 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01554189||89354|
NCT01554202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-A00414-49|Multi-modal Neuroimaging in Alzheimer's Disease|Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging|IMAP|University Hospital, Caen|Yes|Active, not recruiting|January 2008|||December 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|9||Anticipated|295|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 5, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01554202||89353|
NCT01553682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00048502|Project N-Liten- HIV Prevention for African American Women|Reducing Alcohol-Related HIV Risk in African American Females||Emory University|No|Completed|December 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|560|||Female|18 Years|24 Years|Accepts Healthy Volunteers|||June 2015|June 24, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01553682||89392|
NCT01533675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# 20100301|A Comparison Study of the Tensile Strength of Sutures Used in Dermatologic Surgery on the Day of Suture Removal, Following Wound Care With Two Different Products|A Comparison Study of the Tensile Strength of Sutures Used in Dermatologic Surgery on the Day of Suture Removal, Following Wound Care With Two Different||University of Miami|No|Completed|May 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 10, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533675||90919|
NCT01533688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2869|Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients|Efficacy and Tolerability of Various Bowel Preparations in Diabetic Patients: A Randomized Controlled Trial||University of Oklahoma|No|Recruiting|October 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Anticipated|244|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01533688||90918|
NCT01534585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YHH-201201|Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma|Phase Ⅰ/Ⅱ Study of Icotinib Hydrochloride Combined With Intensity-modulated Radiotherapy in Nasopharyngeal Cancer||Taizhou Hospital|Yes|Recruiting|February 2012|February 2015|Anticipated|February 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||February 2012|February 16, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534585||90850|
NCT01534559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUB B11/34|Pharmacist-led Medicines Management Outpatient Service|A Pharmacist-led Medicines Management Outpatient Service for Patients at High Risk of Medication Related Problems|MMC|Queen's University, Belfast|No|Recruiting|November 2014|December 2017|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|268|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534559||90852|
NCT01534572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|538/2005|Significance of Synbiotics on Inflammation and Proliferation of Colonic Mucosa|Significance of Synbiotics on Inflammation and Proliferation of Colonic Mucosa||Region Skane|No|Completed|January 2006|February 2012|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534572||90851|
NCT01534871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA_NB_SG-2012|The Effects of Cardiac Rehabilitation on Cardiovascular Disease Risk in Rheumatoid Arthritis Patients|The Effects of a 12-week Cardiovascular Rehabilitation Exercise Program on Inflammatory Markers and Traditional Coronary Artery Disease Risk Factors in Patients With Rheumatoid Arthritis||Nova Scotia Health Authority|No|Recruiting|October 2013|December 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|20 Years|75 Years|No|||July 2015|July 14, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01534871||90830|
NCT01534884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P10 1.1|Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis|Phase 1, Randomized, Controlled, Multicenter, 2-Arm, Parallel-Group, Double-Blind Study to Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis|Triad RA|Celltrion|Yes|Completed|February 2012|February 2014|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|154|||Both|18 Years|75 Years|No|||May 2015|May 20, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01534884||90829|
NCT01530763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-31|Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)|A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization||Forest Laboratories|Yes|Completed|September 2012|July 2014|Actual|April 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|161|||Both|2 Months|18 Years|No|||January 2015|January 12, 2015|February 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530763||91141|
NCT01530776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20227|Healthy4Baby: Preventing Postpartum Weight Retention Among Low-Income, Black Women|Preventing Postpartum Weight Retention Among Low-Income, Black Women||Temple University|No|Active, not recruiting|January 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|88|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01530776||91140|
NCT01530750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37204.060.11|READ-POAF Pilot Studies Postoperative Atrial Fibrillation After Cardiac Surgery|READ-POAF Pilot Study. The Use of the Reveal XT as Device for Postoperative Atrial Fibrillation Detection After Cardiac Surgery||Catharina Ziekenhuis Eindhoven|No|Recruiting|March 2012|February 2014|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|60 Years|90 Years|No|Non-Probability Sample|those patients undergoing cardiac surgery.|August 2012|August 31, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530750||91142|
NCT01535144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|syn09-01|Comparative Study of Osteosynthesis for Chevron Osteotomy of Hallux Valgus Using Degradable Versus Non-degradable Metallic Device|||Syntellix AG|No|Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|40 Years|79 Years|No|||February 2012|February 29, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01535144||90810|
NCT01531010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0808/147-2|Pressure-limited Ventilation Versus Volume-targeted Ventilation in Preterm Newborns|Randomised Controlled Trial of Pressure-limited Ventilation Versus Volume-targeted Ventilation in Prematurely Born Infants||King's College London|No|Completed|July 2010|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|N/A|24 Hours|No|||February 2012|February 8, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531010||91122|
NCT01531621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003158-24|A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland|A Population-based Prospective Study to Evaluate Clinical Behaviour, Resectability and Survival in 1st Line Metastatic Colorectal Cancer (CRC) Patients in Finland|RAXO|Helsinki University Central Hospital|No|Recruiting|February 2012|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic cancer of the colon or rectum|March 2015|March 25, 2015|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531621||91076|
NCT01531634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010-12-HYMC|Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention|Promoting Recovery Processes in Women Diagnosed With Borderline Personality Disorder Using a Dynamic Cognitive Intervention||Hillel Yaffe Medical Center|No|Not yet recruiting||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|45 Years|No|||February 2012|February 8, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01531634||91075|
NCT01531907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16160|Relationships Between GLP-2 and Markers of Bone Turnover Following Feeding|Relationships Between GLP-2 and Markers of Bone Turnover Following Feeding: the Influence of Obesity and Cellular Mechanisms of Action|GLP-2|Sheffield Teaching Hospitals NHS Foundation Trust|No|Enrolling by invitation|September 2011|September 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples Without DNA|On completion of the study, serum and plasma aliquots will be moved to the Human Tissue      Authority (HTA) licensed biorepository housed in the Centre for Biomedical Research.|Female|25 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|The investigators will recruit healthy pre-menopausal, Caucasian female participants 25-40        years and divide them into two groups, obese and lean according to their Body Mass Index.        Participants will be identified and approached from a study group of obese and lean        participants previously recruited for the 'The Effects of Obesity on Bone Structure and        Strength - Fat and Bone Study (FAB)' study (REC ref 10/H1308/61) conducted at the Academic        Unit of Bone Metabolism (AUBM) in Sheffield. Participants from this study have been        selected as some of the scan and neuromuscular function data generated from this study        will be reused as explained below. Body Mass Index ≥30 kg/m2 will be used to define        obesity with BMI for lean participants defined as 18.5-24.9 kg/m2. Thirty participants        will be recruited, 15 obese and 15 lean. Participants will be matched for age, and where        possible height.|December 2012|December 14, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01531907||91054|
NCT01531647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28088|A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers|A Study to Evaluate the Potential Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir When Given With Raltegravir in Healthy Adult Volunteers||Hoffmann-La Roche||Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531647||91074|
NCT01531920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-E044-030|A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel|A Phase 1 Study in Healthy Subjects to Determine the Safety, Tolerability, Psychomotor Function and Cognitive Effects of Perampanel When Administered With Alcohol||Eisai Inc.|No|Completed|May 2010|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|February 10, 2012|February 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01531920||91053|
NCT01532518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIC-04|Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance|A Multicenter, Open Label, Ascending 7 Day-Repeated Dose Study to Investigate Efficacy, Safety and Pharmacokinetics of Nepadutant In Infants With Feeding Intolerance||Menarini Group|No|Completed|August 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|27|||Both|N/A|6 Months|No|||March 2014|March 24, 2014|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532518||91007|
NCT01556880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-560|RCT of SMS for Drivers With Pre-DM|A Randomized Controlled Trial of Short Message Service by Cellular Phone for Professional Drivers With Pre-diabetes||The University of Hong Kong|No|Completed|May 2009|March 2012|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556880||89148|
NCT01557127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16268|Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting|Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma|NEXST|Bayer|No|Active, not recruiting|February 2010|March 2016|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|213|||Both|18 Years|N/A|No|Probability Sample|Adult patients with renal cell carcinoma scheduled to treatment with sorafenib, following        therapy failure with IFN/IL-2|March 2016|March 15, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557127||89129|
NCT01545687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N11C5|CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy|A Phase III, Randomized, Double-Blind Study of Lactobacillus Brevis CD2 Lozenges Versus Placebo in the Prevention of Acute Oral Mucositis (OM) in Patients With Head and Neck Cancer Receiving Concurrent Radiotherapy and Chemotherapy||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|April 2012|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|148|||Both|18 Years|N/A|No|||July 2015|July 9, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545687||90002|
NCT01545973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55R21AT005249-02|Understanding the Physiological Implications of Scanning Kelvin Probe Measurements|Measuring Skin Electrical Potential With the Kelvin Probe: Underlying Physiology||Massachusetts General Hospital|No|Suspended|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|24|Samples With DNA|Whole Blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Volunteers|March 2012|March 2, 2012|March 2, 2012||No|Repair of minor software glitches|No||https://clinicaltrials.gov/show/NCT01545973||89981|
NCT01553201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120083|Botulinum Toxin for Pelvic Pain in Women With Endometriosis|The Effectiveness of Botulinum Toxin on Persistent Pelvic Pain in Women With Endometriosis||National Institutes of Health Clinical Center (CC)||Recruiting|February 2012|December 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|50 Years|No|||March 2016|March 18, 2016|March 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553201||89429|
NCT01553448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL12B6|Studying Gene Expression in Samples From Younger Patients With Neuroblastoma|The Role of Stroma-Derived Soluble TßRIII in Neuroblastoma||Children's Oncology Group|No|Active, not recruiting|March 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|75|||Both|N/A|21 Years|No|Non-Probability Sample|Patients with low-stage (International Neuroblastoma Staging System [INSS] stage 1 or 2)        neuroblastoma (NBL), patients with advanced-stage (INSS stage 3 or 4) NBL, or patients        with stage 4S NBL|May 2015|May 6, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01553448||89410|
NCT01553981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGI/BE/06/2012|A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma|A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma||Sanjay Gandhi Postgraduate Institute of Medical Sciences|No|Completed|March 2012|May 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||April 2015|April 20, 2015|March 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553981||89370|
NCT01544504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-6|Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy|Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy||ProCertus BioPharm, Inc|No|Withdrawn|March 2012|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Female|18 Years|N/A|No|||May 2012|May 25, 2012|February 15, 2012|No|Yes|The principal investigator withdrew from the study. The study was withdrawn because a    qualified replacement was not available.|No||https://clinicaltrials.gov/show/NCT01544504||90093|
NCT01534312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMP in UC|Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)|Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)||University of Aarhus|Yes|Completed|January 2012|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2012|February 4, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534312||90871|
NCT01534325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeckMedical-001|Efficacy Study for SD Device|Efficacy Study of SD Device for Overweight and Obesity Treatment||Beck Medical Ltd.|Yes|Recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||January 2016|January 21, 2016|January 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534325||90870|
NCT01534598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120066|FdCyd and THU for Advanced Solid Tumors|Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors||National Institutes of Health Clinical Center (CC)||Recruiting|January 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||July 2015|August 15, 2015|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01534598||90849|
NCT01534897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-337|Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436|Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436||Massachusetts General Hospital|Yes|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534897||90828|
NCT01535209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAVITY|Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection|Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|Yes|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2012|February 16, 2012|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535209||90805|
NCT01531036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-02|3D Breast Ultrasound Elastography in Patients Under Neoadjuvant Chemotherapy|Imagerie 3D d'élasticité du Sein Par échographie Ultrarapide au Cours d'un Traitement Par chimiothérapie néoadjuvante.||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|December 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Female|18 Years|75 Years|No|||February 2016|February 24, 2016|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531036||91120|
NCT01531322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851046|A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects|A Phase 1 Open-label Study to Assess the Safety and Tolerability of a Single Dose of 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children and Infants||Pfizer|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|72|||Both|42 Days|55 Years|Accepts Healthy Volunteers|||February 2012|February 15, 2012|August 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01531322||91099|
NCT01531023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2214-3|Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice|What is the Outcome of Treatment of Urinary Tract Infections Caused by Bacteria Producing Extended Spectrum Betalactamase in a Primary Care Setting?||University of Oslo|No|Recruiting|April 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Urinesamples|Both|16 Years|N/A|No|Probability Sample|The study population will be selected from all patients ages 16 and over who are diagnosed        with an urinary tract infection where an ESBL producing bacteria (E. coli) is found. The        urinary tract infection must be diagnosed and treated in a primary care setting.|December 2015|December 18, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531023||91121|
NCT01531335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ0079|Hypocaloric Nutrition in Critically Ill Patients|Effectiveness of Hypocaloric Nutrition Compared With Standard Care in Critically Ill Adults Patients, a Randomized Controlled Trial|RuRaL|Lafrancol S.A.|Yes|Completed|August 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|February 7, 2012||No||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01531335||91098|No surgical patients included Wide variety of patients Caloric needs were not estimated with a gold standard
NCT01531348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP-001|Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa|Feasibility and Safety of Adult Human Bone Marrow-Derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa||Mahidol University|Yes|Enrolling by invitation|February 2012|||March 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|65 Years|No|||February 2012|February 8, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01531348||91097|
NCT01531361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1183|Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer|A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 Inhibitor) in Combination With Vemurafenib (BRAF Inhibitor) in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|February 2012|||February 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|183|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01531361||91096|
NCT01531660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|active over 45|Active Over 45: A Step-up Jogging Program in Inactive Female Hospital Staff Aged 45+|Active Over 45: A Step-up Jogging Program in Inactive Female Hospital Staff Aged 45+: Feasability, Role of Motivation and Sustained Benefit||University of Zurich|No|Completed|April 2004|June 2004|Actual|June 2004|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|68|||Female|45 Years|65 Years|No|||March 2012|March 7, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01531660||91073|
NCT01532271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-01|Comparison of Brain Network Activation (BNA™) Analysis, Clinical Symptoms and Neuro-cognitive Performance in Concussed Children and Young Adults|Comparison of Brain Network Activation Analysis (BNA™) Using Evoked Response Potentials, Clinical Symptoms and Neuro-cognitive Performance and Symptoms in Concussed Children, Young Adults and Matched Controls||ElMindA Ltd|No|Completed|February 2012|March 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|146|||Both|14 Years|27 Years|Accepts Healthy Volunteers|Non-Probability Sample|Experimental subjects will include males and females with a recent sports-related        concussion (less than 10 days post-concussion) recruited from approximately 50 high        schools and colleges with UPMC-affiliated certified athletic trainers (ATC) on staff and        from patients at the UPMC Sports Medicine Concussion Program.|April 2014|April 3, 2014|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01532271||91026|
NCT01532284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESHRE-ESTEEM|The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis|The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis|ESTEEM|European Society of Human Reproduction and Embryology|Yes|Recruiting|February 2012|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|600|||Female|36 Years|41 Years|No|||November 2015|November 23, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01532284||91025|
NCT01532531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC98-2|The Effects of Collateral Meridian Therapy for Knee Osteoarthritis Pain Management|||Taichung Armed Forces General Hospital|Yes|Completed|March 2011|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|60 Years|N/A|No|||August 2012|August 14, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01532531||91006|
NCT01532544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THR-PS-03|Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis|Double-blinded, Randomized Trial in Severe Pneumonia Patients With Severe Sepsis Investigating the Safety and Efficacy of Co-administration of Iloprost and Ascending Doses of Eptifibatide Compared to Low-molecular-weight Heparin||Thrombologic ApS|Yes|Suspended|June 2012|March 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01532544||91005|
NCT01557140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carvedilol in Chagas disease|A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy|A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy||Federal University of Minas Gerais|No|Completed|May 2003|December 2006|Actual|March 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01557140||89128|
NCT01546805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R.P. #11-3601|Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm|The Effect of Zinc Supplementation on the Efficacy and Duration of Botulinum Toxin for the Treatment of Oculofacial Spasm Disorders||St. Joseph's Healthcare Hamilton|No|Not yet recruiting|April 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2012|March 1, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01546805||89917|
NCT01546818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAV-CT01|Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients|A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)||Sumagen|No|Completed|March 2012|September 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|33|||Both|18 Years|50 Years|No|||September 2013|September 5, 2013|June 9, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546818||89916|
NCT01546831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-4|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2011|||||N/A|N/A|N/A||||||||||||||July 30, 2015|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546831||89915|
NCT01553461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120064|Transplants With Unlicensed Preserved Cord Blood|A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications||National Institutes of Health Clinical Center (CC)||Recruiting|February 2012|October 2036|Anticipated|October 2036|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|N/A|N/A|No|||July 2015|August 8, 2015|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01553461||89409|
NCT01553695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AOI-01|Adults With Attention Deficit Hyperactivity Disorder (ADHD): Validation of a Clinical Interview and Screening Instruments in French|Validation of a Clinical Interview for a Diagnosis of ADHD in Adults. Cross-validity of Screening Instruments ADHD in Adults. Estimation of Prevalence in France||Centre Hospitalier Universitaire de Nice|No|Completed|March 2012|February 2014|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|110|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2012|July 28, 2014|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01553695||89391|
NCT01534000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2009-053|Cardiac-CT in the Treatment of Acute Chest Pain|Cardiac-CT in the Treatment of Acute Chest Pain|CATCH|Hvidovre University Hospital|No|Completed|January 2010|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|600|||Both|18 Years|N/A|No|||June 2014|June 18, 2014|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01534000||90894|
NCT01534338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH019925|Effect of Mindfulness Training on Sleep and Inflammation Among Older Adults With Sleep Problems|A Randomized Controlled Trial Testing the Effect of Mindfulness Practices Versus Sleep Education on Sleep and Inflammation Among Older Adults With Sleep Problems|MAPS|University of California, Los Angeles|Yes|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 10, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01534338||90869|
NCT01534351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906A-149|Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)|A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia (BPH)||Merck Sharp & Dohme Corp.|Yes|Terminated|August 2013|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1|||Male|50 Years|N/A|No|||January 2016|January 26, 2016|February 13, 2012|Yes|Yes|Business Reasons|No|October 29, 2015|https://clinicaltrials.gov/show/NCT01534351||90868|The trial was terminated for business reasons.
NCT01534624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912476|Stem Cell Study of Genetics and Drug Addiction|Development of Induced Pluripotent Stem Cells Carrying Monoamine Transporter Polymorphisms||National Institutes of Health Clinical Center (CC)||Completed|February 2012|July 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01534624||90848|
NCT01534910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Garlic4|Effect of Aged Garlic Extract on Atherosclerosis|Effect of Aged Garlic Extract on Atherosclerosis|Garlic4|Los Angeles Biomedical Research Institute|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||February 2015|March 19, 2015|February 14, 2012||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01534910||90827|
NCT01535222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC-CU-10-01|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery|A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective CABG Surgery||The Medicines Company|Yes|Completed|November 2010|June 2011|Actual|May 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|32|||Both|18 Years|80 Years|No|||June 2012|June 14, 2012|February 10, 2012|Yes|Yes||No|June 14, 2012|https://clinicaltrials.gov/show/NCT01535222||90804|
NCT01535183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-1201|Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents|Irinotecan, Vincristine, Etoposide, Carboplatin, and Cyclophosphamide for Refractory or Relapsed Brain Tumor in Children and Adolescents||Seoul National University Hospital|No|Recruiting|January 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|N/A|19 Years|No|||July 2014|July 11, 2014|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01535183||90807|
NCT01535196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-heart|Vitamine D Treatment in Chronic Heart Failure|Effects of 25-OH-D3 Vitamin Substitution in Congestive Heart Failure. Controlled, Randomized, Double Blind Trial||Semmelweis University|Yes|Suspended|December 2012|September 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2014|February 18, 2014|January 9, 2012||No|financial reasons|No||https://clinicaltrials.gov/show/NCT01535196||90806|
NCT01530789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00311-40|Paramedical Consultation in Telemedicine|Evaluation of Paramedical Consultation in Type 1 Diabetic Patients in Telemedicine||Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||Terminated|May 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|12 Years|N/A|No|Non-Probability Sample|Diabetic type 1 patients with the electronic pad|October 2012|August 5, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530789||91139|
NCT01530802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA4/07906|Temporary Clipping of the Uterine Arteries During Laparoscopic Myomectomy|Reduction of Intraoperative Blood Loss During Laparoscopic Myomectomy by Temporary Clipping of the Uterine Arteries||Charite University, Berlin, Germany|No|Completed|January 2007|December 2009||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|166|||Female|18 Years|50 Years|No|||June 2010|February 9, 2012|November 1, 2010||No||No||https://clinicaltrials.gov/show/NCT01530802||91138|
NCT01531062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nigella sativa|Effect of Nigella Sativa on Lipid Profiles in Elderly|Effect of Nigella Sativa on Lipid Profiles in Elderly: a Randomized Double-blinded Clinical Trial||Indonesia University|Yes|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|60 Years|N/A|No|||February 2012|February 8, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531062||91118|
NCT01531049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK:99/2011|Smoking Habits and Smoking Cessation in Young Adults|Smoking Cessation in Young Adults in Northern Finland||University of Oulu|No|Active, not recruiting|May 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|300|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||June 2015|June 20, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01531049||91119|
NCT01531374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10037989DOC REV 1C|Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement|Medtronic CoreValve® Continued Access Study||Medtronic Cardiovascular|Yes|Active, not recruiting|February 2012|October 2019|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1690|||Both|N/A|N/A|No|||December 2015|December 15, 2015|February 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531374||91095|
NCT01531673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-661-101|Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation|A Phase 2, Multicenter, Double-Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation||Vertex Pharmaceuticals Incorporated|Yes|Completed|February 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|22||Actual|194|||Both|12 Years|N/A|No|||May 2015|May 5, 2015|February 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531673||91072|
NCT01531933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS3233-0711|Efficacy and Safety of DLBS3233 in Prediabetic Patients|Phase III Clinical Study : DLBS3233 in Primary Prevention of Type 2 Diabetes Mellitus [DIPPER-DM]|DIPPER-DM|Dexa Medica Group|No|Completed|November 2011|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|60 Years|No|||August 2012|August 6, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01531933||91052|
NCT01532297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-CiDi-01-D|Application of Citrate Dialysate in Chronic Haemodialysis|Application of Citrate Dialysate in Chronic Haemodialysis||Fresenius Medical Care Deutschland GmbH|No|Completed|October 2011|August 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|95|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01532297||91024|
NCT01532570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-650-23|Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions|To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650||Mitsubishi Tanabe Pharma Corporation|No|Completed|January 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|16 Years|75 Years|No|||September 2014|September 2, 2014|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01532570||91004|
NCT01556906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP1001|Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor|A Phase II Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Efficacy of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor BMS-201038 in Patients With Homozygous Familial Hypercholeterolemia||Aegerion Pharmaceuticals, Inc.|Yes|Completed|June 2003|February 2004|Actual|February 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|13 Years|N/A|No|||April 2013|April 4, 2013|March 7, 2012|Yes|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT01556906||89146|
NCT01547104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ikfe-Lina-002|Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus|Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus||ikfe-CRO GmbH|No|Recruiting|April 2012|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Both|45 Years|75 Years|No|||April 2012|April 10, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01547104||89894|
NCT01548352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASEL IX|BAsel Syncope EvaLuation (BASEL IX) Study|BAsel Syncope EvaLuation (BASEL IX) Study||University Hospital, Basel, Switzerland|No|Recruiting|April 2010|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|720|Samples Without DNA|EDTA Plasma; Heparin; Serum|Both|40 Years|N/A|No|Probability Sample|Patients presenting to the emergency department with syncope within the last 12 hours.|March 2016|March 3, 2016|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548352||89798|
NCT01534013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1710|Clinical Assessment of a Closed-loop Insulin Delivery System|Clinical Assessment of a Closed-loop Insulin Delivery System||Imperial College London|Yes|Recruiting|August 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01534013||90893|
NCT01534026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01/12|Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study|Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study||The Alfred|No|Completed|March 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01534026||90892|
NCT01534364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery|Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery|CR_KCH|University of Cologne|Yes|Completed|January 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|82|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01534364||90867|
NCT01534637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 02205|Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer|A Feasibility Study to Discern the Tolerability of 5-FU/Gemcitabine Based Chemotherapy Concurrent With Upper Abdominal Radiation and the Utility of Aprepitant/5HT-3 Antagonist (EMEND) for the Prevention of ChemoRadiation-Induced Nausea and Vomiting (CRINV)||Comprehensive Cancer Center of Wake Forest University||Completed|August 2006|August 2012|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|18 Years|N/A|No|||August 2012|September 28, 2012|February 14, 2012|No|Yes||No|August 29, 2012|https://clinicaltrials.gov/show/NCT01534637||90847|
NCT01534923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-017|Doctor-Patient Communication About Colorectal Cancer Screening|Doctor-Patient Communication About Colorectal Cancer Screening||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|225|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Five health centers of the NYC RING will participate in this project. All are located in        underserved urban communities within the Bronx.|February 2016|February 2, 2016|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01534923||90826|
NCT01535248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|238-11-FB|Echo Detection of Endoscopic Retrograde Cholangiopancreatography (ERCP) Air Embolus|Echocardiographic Surveillance of Patients Undergoing Scheduled Endoscopic Retrograde Cholangiopancreatography for the Presence of Intracardiac Air Embolus||University of Nebraska|No|Completed|March 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|17|||Both|19 Years|N/A|No|Non-Probability Sample|The Study Population will be all subjects who are scheduled to undergo ERCP and consent to        participate in the protocol. No exclusions will be made based on gender or race to provide        for a particular distribution, all subjects who would like to participate will be        included.|November 2015|November 30, 2015|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01535248||90802|
NCT01530815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LapHernia_SBCH|Bupivicaine to Reduce Postoperative Pain in Laparoscopic Ventral Hernia Repair|Intraoperative Local Anesthesia for Management of Postoperative Pain Following Laparoscopic Ventral Hernia Repair: a Prospective Double-blind Randomized Trial||Chang, Steve S., M.D.|Yes|Recruiting|August 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2012|February 9, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530815||91137|
NCT01531075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor026511ctil|Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease|Assessment of Hepatitis B Vaccination Efficacy in Patients With Inflammatory Bowel Diseases|HBV VIP|Soroka University Medical Center|No|Recruiting|May 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|75|||Both|18 Years|N/A|No|||June 2012|June 6, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531075||91117|
NCT01531387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29205 SCATE|Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)|Sparing Conversion to Abnormal TCD Elevation (SCATE) - a Phase III Clinical Trial to Compare Standard Care (Observation) With Alternative Therapy (Hydroxyurea) for Reducing the Risk of Converting to an Abnormal TCD Velocity in Children With Sickle Cell Anemia and Conditional Pre-treatment TCD Velocities.|SCATE|Children's Hospital Medical Center, Cincinnati|Yes|Terminated|May 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|38|||Both|2 Years|10 Years|No|||January 2016|January 13, 2016|February 6, 2012|Yes|Yes|inability to reach a satisfactory endpoint with respect to adequate recruitment|No|June 19, 2015|https://clinicaltrials.gov/show/NCT01531387||91094|
NCT01531686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-02|Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route|An Observational Study to Determine the Safety and Effectiveness of Intraosseous Vascular Access for the Delivery of CT Contrast Dye||Vidacare Corporation|No|Enrolling by invitation|March 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients that have received intraosseous vascular access as standard of care and        require CT examination|December 2013|December 12, 2013|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01531686||91071|
NCT01531946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-75|Acute MRI in Transient Ischemic Attack|Acute MRI-techniques for the Detection of Ischemic Lesions After Transient Ischemic Attack||Bispebjerg Hospital|No|Recruiting|January 2012|||December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the stroke ward at Bispebjerg University Hospital with signs of TIA.|July 2014|July 15, 2014|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01531946||91051|
NCT01532310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114256|Belimumab (BENLYSTA®) Pregnancy Registry|Belimumab (BENLYSTA®) Pregnancy Registry (BPR) - Prospective Cohort Study of Pregnancy Outcomes Following Benlysta Exposure Within 4 Months Prior to and/or During Pregnancy||GlaxoSmithKline|No|Recruiting|July 2012|November 2021|Anticipated|November 2021|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Female|N/A|N/A|No|Non-Probability Sample|Women with SLE who have been exposed to commercially supplied belimumab within the 4        months prior to and/or during pregnancy will be eligible to participate in the registry as        well as their infants.|September 2015|September 1, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01532310|9 Years|91023|
NCT01533233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200911022R|Thoracoscopic Lobectomy Using Nonintubated Anesthesia Versus Intubated General Anesthesia for Lung Cancer Patients|Safety and Results of Thoracoscopic Lobectomy Using Nonintubated Anesthesia Versus Intubated General Anesthesia for Lung Cancer Patients.||National Taiwan University Hospital|No|Recruiting|February 2011|December 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|25 Years|80 Years|No|||October 2013|October 27, 2013|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01533233||90953|
NCT01533246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00247|Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer|A Phase 2 Study of OSI-906 in Patients With Asymptomatic or Mildly Symptomatic (Non-Opioid Requiring) Metastatic Castrate Resistant Prostate Cancer (CRPC)||National Cancer Institute (NCI)||Completed|February 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Male|18 Years|N/A|No|||December 2013|March 2, 2015|February 10, 2012|Yes|Yes||No|March 2, 2015|https://clinicaltrials.gov/show/NCT01533246||90952|
NCT01545388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-136|Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)|A Phase III, Randomized, Placebo and Active-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of the Addition of Metformin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Sitagliptin Monotherapy||Merck Sharp & Dohme Corp.|No|Completed|February 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|337|||Both|20 Years|74 Years|No|||April 2015|April 27, 2015|March 1, 2012|Yes|Yes||No|February 10, 2014|https://clinicaltrials.gov/show/NCT01545388||90025|
NCT01545674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSN012B|Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial|Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)|PreNATUS|Natera, Inc.|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Plasma Sample Prepared DNA|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant Women|October 2014|October 28, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545674||90003|
NCT01547832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120084|Mutations Associated With Parkinson s Disease|Metabolic Phenotyping of Subjects With Mutations Associated With Hereditary Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Completed|February 2012|||||N/A|Observational|Time Perspective: Prospective|||Actual|42|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01547832||89838|
NCT01548053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-DATA1|The Primary Care - Dementia Assessment and Treatment Algorithm|A Study Evaluating the Effects of a Primary Care - Dementia Assessment Treatment Algorithm on the Quality of Care Provided to Older Adults With Dementia in Primary Care Settings|PC-DATA|Queen's University|No|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Anticipated|135|||Both|60 Years|N/A|No|||April 2015|April 21, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01548053||89821|
NCT01544829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-SCC-0465|The Acute Effect of 2 Different Serving Regimens of Theobromine on Physiological Effects|The Acute Effect of 2 Different Serving Regimens of Theobromine on Theobromine Concentration in the Blood & Physiological Effects||Unilever R&D|No|Completed|February 2012|June 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|12|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01544829||90068|
NCT01544192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH-Ophthalmol-1|Impact of Oral Versatile Antioxidants on Glaucoma Progression|Impact of Oral Versatile Antioxidants on Glaucoma Progression:Comparative Early Results||Bagcilar Training and Research Hospital|No|Completed|April 2008|February 2012|Actual|November 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|60|||Both|18 Years|67 Years|No|||February 2012|March 2, 2012|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01544192||90117|
NCT01534039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC#001|A Clinical Comparison of Two Marketed Skin Barriers on Healthy Volunteers|Phase 4-A Clinical Comparison of a Marketed Moldable Skin Barrier Versus a Marketed Stretch-to-Fit Skin Barrier in Healthy Volunteers||Independent Nurse Consultants LLC|No|Completed|December 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 23, 2013|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01534039||90891|
NCT01534052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0121|A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100|A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100||Astellas Pharma Inc|No|Active, not recruiting|November 2011|December 2022|Anticipated|December 2022|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Male|18 Years|N/A|No|||January 2016|January 28, 2016|February 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01534052||90890|
NCT01534377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035457|Interpersonal Psychotherapy for Adolescent Girls|Prevention of Depression in Maltreated and Nonmaltreated Adolescents|IPT|University of Rochester|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|350|||Female|13 Years|15 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01534377||90866|
NCT01534949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P10 1.2|Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial|A Phase 1, Multicenter, Open-Label, Single-Arm Study to Evaluate the Initial Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CT-P10 Given in Combination With Dexamethasone, Cytosine Arabinoside, and Cisplatin (DHAP) in Patients With Diffuse Large B-Cell Lymphoma as Second-Line Chemotherapy|Triad-DLBCL|Celltrion|Yes|Terminated|February 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|21 Years|70 Years|No|||July 2014|July 21, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01534949||90824|
NCT01534936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NHU-ATC-2011/1|Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary|Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary.|AFFECT|AstraZeneca|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2153|||Both|18 Years|N/A|No|Probability Sample|Schizophrenic outpatients above 18 years of age with affective symptoms.|December 2012|December 19, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534936||90825|
NCT01535235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-08132|ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study|ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study||University of California, San Francisco|Yes|Completed|February 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01535235||90803|
NCT01530854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-969|Plasma Free Fatty Acids in Risk Assessment of Sepsis in the Emergency Department: A Prospective Pilot Study|Plasma Free Fatty Acids in Risk Assessment of Sepsis in the Emergency Department: A Prospective Pilot Study||The Cleveland Clinic|No|Completed|February 2008|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|74|Samples With DNA|Blood samples (10 cc. total) are to be collected in non-heparinized tubes upon initial      presentation to the ED as well as 3-6hours and 24(+/-3) hours after the initial blood draw.      The 3-6hour and 24-hour blood draw will be optional depending on patient location and the      availability of study personnel. The plasma samples will be aliquoted and frozen at -70°C      for later assays. These samples will be assayed for plasma FFA, plasma glucose, plasma      insulin, and future cytokines including IL-1 and TNF.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a prospective, specimen-procurement pilot study that will enroll adult patients        (aged 18 years or older) who present to the Cleveland Clinic Emergency Department with        suspected infection.|February 2012|February 9, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530854||91134|
NCT01530828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOT IRT|IRT in Infants With Intestinal Perforation|Immunoreactive Trypsinogen in Infants With Intestinal Perforation||Children's Hospitals and Clinics of Minnesota|No|Recruiting|August 2010|August 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|16 Days|Accepts Healthy Volunteers|Probability Sample|Premature infants less than 1000 grams, age 1-16 days|August 2013|August 7, 2013|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530828||91136|
NCT01531088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0015923|Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes|Enhancing the Detection and Management of Adverse Drug Events in the Nursing Home||University of Pittsburgh|Yes|Completed|January 2012|April 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|36|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531088||91116|
NCT01531400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cgmhpmr001|Investigation of Pain and Anxiety During Electrodiagnostic Examination Using Self-selected Music|Investigation of Pain and Anxiety During Electrodiagnostic Examination Using Self-selected Music||Chang Gung Memorial Hospital|No|Completed|December 2002|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|61|||Both|15 Years|N/A|No|||March 2012|March 18, 2012|January 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01531400||91093|
NCT01531413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AppyO2_SBCH|Oxygen Insufflation To Reduce Postoperative Abscess In Laparoscopic Appendectomy|Single-Blind, Randomized, Controlled Trial of Oxygen Insufflation to Reduce Incidence of Postoperative Abscess in Laparoscopic Appendectomy|AppyO2|Chang, Steve S., M.D.|Yes|Completed|March 2006|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|100|||Both|18 Years|N/A|No|||February 2012|February 8, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531413||91092|
NCT01531699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALT005/09CL/11/06|Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers|An Open-label Study to Assess the Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution (ALT005) Compared to Control (Sterile Saline) Following Dermal Administration in Healthy Volunteers||Altacor Ltd.|No|Completed|February 2012|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 10, 2012|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531699||91070|
NCT01531972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP432-102|A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects|A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects||Sunovion|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 6, 2013|February 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01531972||91049|
NCT01531959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002049|Midodrine for the Treatment of Refractory Hypotension|Midodrine for the Treatment of Refractory Hypotension in Patients Otherwise Ready for Discharge From the ICU||Massachusetts General Hospital|No|Recruiting|April 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531959||91050|
NCT01532921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASE TRICUSPID|EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty|EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty||Medtronic Cardiovascular|No|Active, not recruiting|September 2011|July 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|85 Years|No|Non-Probability Sample|The patient population includes all patients indicated for a TV repair procedure        concomitantly to left-sided heart surgery, and for which the surgeon considers the        implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct        the diseased valve. Patients with primary TV are not included, since this is often        characterized by pathological leaflets for which the Contour 3D® Tricuspid Annuloplasty        Ring would not be beneficial.|October 2015|October 29, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532921||90977|
NCT01533571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Juodzbalys|Immediate Implant Placement in the Esthetic Zone|Immediate Implant Placement After Tooth Extraction in the Esthetic Zone: Extraction Socket Morphology-Guided Treatment Modalities and Esthetic Outcome||Lithuanian University of Health Sciences|No|Enrolling by invitation|January 2014|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01533571||90927|
NCT01546480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ImmT|From Acute to Chronic Postoperative Pain in Patients for Elective Cholecystectomy. Immunological Tests|From Acute to Chronic Postoperative Pain in Patients for Elective Cholecystectomy. Immunological Tests||Odense University Hospital|No|Completed|November 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|18|Samples With DNA|Whole blood Serum Plasma Cerebrospinal fluid Saliva|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients in group 1 and 2 previously participated in a study of postcholecystectomy pain.        Patients in group 3 are patients scheduled for elective surgery in spinal anesthesia at        the participating centres.|June 2014|June 16, 2014|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546480||89942|
NCT01555710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM3002|Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)|A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide (PaCE) Chemotherapy Versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer. The MATISSE Study||Ziopharm|Yes|Active, not recruiting|May 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|548|||Both|18 Years|N/A|No|||May 2013|May 20, 2013|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01555710||89237|
NCT01548066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VPA_hair|The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss|The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss||Seoul National University Hospital|No|Completed|September 2011|June 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 5, 2012|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01548066||89820|
NCT01553708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CU0155|Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound|The Clinical Efficacy of Epidermal Growth Factor With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream on Acceleration of Partial Thickness Burn Wound Healing||Chulalongkorn University|Yes|Completed|December 2011|May 2012|Actual|May 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||March 2013|March 19, 2013|February 28, 2012|Yes|Yes||No|July 1, 2012|https://clinicaltrials.gov/show/NCT01553708||89390|Early termination leading to small numbers of subjects analyzed and all samples have 18-60 years of age, this data cannot be applied for pediatrics.
NCT01534065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARD-CP-001|Barricaid EU Post Market Study for Primary Lumbar Disc Herniation|A Multi-center, Post Marketing Surveillance Study to Monitor the Safety and Performance of the Barricaid® ARD in the Treatment of Back and Radicular Pain Caused by Primary Lumbar Disc Herniation||Intrinsic Therapeutics|Yes|Completed|April 2009|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Male|18 Years|75 Years|No|||March 2014|March 5, 2014|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01534065||90889|
NCT01534390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415-E/1442/7-2012|Influence of In-line Microfilters on Systemic Inflammation in Adult Critically Ill Patients|The Influence of In-line Microfilters on Systemic Inflammation in Adult Critically Ill Patients: A Prospective, Randomized, Controlled Trial||University of Salzburg|No|Completed|April 2012|May 2015|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|504|||Both|18 Years|N/A|No|||May 2015|May 31, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01534390||90865|
NCT01534403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL0027|Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects|A Phase 2, Multicenter, Open-label, Long-term, Extension Study to Assess the Safety of Epratuzumab Treatment in Japanese Subjects With Systemic Lupus Erythematosus||UCB Pharma|No|Completed|January 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||March 2015|March 7, 2015|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534403||90864|
NCT01535274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00049747|Ventilation Strategies, Anesthetic Techniques and Cerebral Oxygenation in the Beach Chair Position|The Influence of Basic Ventilation Strategies and Anesthetic Techniques on Cerebral Oxygenation in the Beach Chair Position||University of Michigan|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|85 Years|No|||July 2013|September 19, 2014|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01535274||90800|
NCT01530867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AT005883-02|Physician-Patient Communication Project|Physician-Patient Communication Project||University of California, Los Angeles|Yes|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|456|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care physicians Integrative medicine / complementary and alternative medicine        physicians Patients aged 18 and older of physicians participating in the study|June 2013|June 5, 2013|January 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01530867||91133|
NCT01535261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002E2401|Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion|A 24-month, Phase IIIb, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal|CRYSTAL|Novartis||Completed|February 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|357|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535261||90801|
NCT01531465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31073|High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure|Pulmonary Function Testing in Infants With Respiratory Insufficiency While Receiving High Flow Nasal Cannula (HFNC) Versus Nasal Continuous Positive Airway Pressure (nCPAP)||Christiana Care Health Services|No|Completed|June 2011|January 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|N/A|6 Months|Accepts Healthy Volunteers|||June 2013|June 3, 2013|May 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01531465||91088|
NCT01531478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008102|Long-term Follow-up of Childhood Cancer Survivors in the Rhône-Alpes and Auvergne Regions of France|Long-term Follow-up of Childhood Cancer Survivors in the Rhône-Alpes and Auvergne Regions of France|SALTO|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|May 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|147|||Both|18 Years|N/A|No|Non-Probability Sample|This is a prospective cohort study in non-leukemia cancer survivors diagnosed between 1987        and 1992 in the Rhône-Alpes and Auvergne regions of France, who were younger than 15 years        at the time of diagnosis|March 2015|March 30, 2015|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01531478||91087|
NCT01530841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01306-33|Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy|Prospective Randomized Controlled Single Blind Study of Efficacy and Tolerance of AVAPS Mode Compared to Bilevel Pressure Ventilation un Adult Patients With Myotonic Dystrophy||Centre d'Investigation Clinique et Technologique 805|No|Recruiting|February 2011|November 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01530841||91135|
NCT01531101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sykehuset i Vestfold|First Experimental Study of Transference Work - In Teenagers (FEST-IT)|First Experimental Study of Transference Work - In Teenagers|FEST-IT|Sykehuset i Vestfold HF|No|Recruiting|January 2012|September 2028|Anticipated|September 2020|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|16 Years|18 Years|No|||December 2014|December 5, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531101||91115|
NCT01531426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoCa-01-12|Cerebral Oxygenation in Cardiac Arrest and Hypothermia|Cerebral Oxygen Saturation as Outcome Predictor in Cardiac Arrest Patients Undergoing Mild Therapeutic Hypothermia|CoCaHYp|Charite University, Berlin, Germany|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|||Both|18 Years|N/A|No|Non-Probability Sample|Patients after cardiac arrest|February 2013|February 22, 2013|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01531426||91091|
NCT01531439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 04-059|Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery|Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery||Children's Mercy Hospital Kansas City|No|Active, not recruiting|June 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|10 Years|21 Years|No|||February 2015|January 26, 2016|June 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531439||91090|
NCT01532323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.671|Oral Sphere: Salivary Markers and Food. A Prospective Study in Children Expressing Oral Disorders|Oral Sphere: Salivary Markers and Food. A Prospective Study in Children Expressing Oral Disorders|ORALISENS|Hospices Civils de Lyon|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|44|||Both|2 Years|15 Years|Accepts Healthy Volunteers|||September 2013|September 18, 2013|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01532323||91022|
NCT01532583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13/2005, 15.2.2005|The Outcome of the Transobturator Tape (TOT) Procedure|The Outcome of the Transobturator Tape (TOT) Procedure During the Follow-up of 6.5 Years||Turku University Hospital||Completed|January 2009|October 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|139|||Female|N/A|N/A|No|Non-Probability Sample|191 female patients with genuine or recurrent stress urinary incontinence or mixed        incontinence operated on with the TOT procedure at the mean of 6.5 years ago|December 2012|December 12, 2012|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01532583||91003|
NCT01532908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBL-HCV1-11-03|Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C|A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation|MBL-HCV1|MassBiologics|No|Terminated|May 2012|October 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|February 10, 2012|Yes|Yes|The study was terminated due to funding constraints|No||https://clinicaltrials.gov/show/NCT01532908||90978|
NCT01533272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARAVI-PEP|Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)|Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC||Hospital Clinic of Barcelona|Yes|Completed|February 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01533272||90950|
NCT01533584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOCTURNAL TOD|Evaluation of Nocturnal Hypertension and Correlation With Target-Organ Damage|Evaluation of Nocturnal Hypertension With 24-hour Ambulatory or Home Blood Pressure Measurement: Correlation With Target-Organ Damage||University of Athens|No|Recruiting|March 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|30 Years|N/A|No|Probability Sample|Subjects referred for high Blood Pressure, untreated or, if treated for less than 2 weeks,        4 weeks after withdrwal of treatment.|September 2012|September 9, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01533584||90926|
NCT01547377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROJ-981-199697778|Zinc and Selenium Supplementation in Atherosclerosis|Effect of Zinc and Selenium Supplementation in Patients With Atherosclerosis Treated With Statins||Universidade Federal do Rio Grande do Norte|No|Completed|January 2008|November 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|41 Years|80 Years|No|||March 2012|March 2, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01547377||89873|
NCT01555723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RELATES|Observational Study of Antiretroviral (ARV) Response in a Cohort of African Children Using Viral Load Monitoring|HIV (Human Immunodeficiency Virus) Subtype and ARV Response in African Children|RELATES|University of Wisconsin, Madison|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Plasma obtained fron participants|Both|2 Months|18 Years|No|Non-Probability Sample|Inclusion Criteria: Starting in 2008 children between the ages of 6 weeks and 18 years        having confirmed HIV infection and receiving no ART were consecutively enrolled into this        observational cohort study following consent and/or assent (where applicable).        Exclusion Criteria: Children were excluded from participation if they were enrolled in        another cohort study, or had psychosocial issues precluding participation (no parent or        guardian willing to promote ART adherence or clinic HIV counselor evaluation of non        adherence). The enrollment goal for this study was approximately100 children recruited        over a period of 8 months.|September 2015|September 29, 2015|June 2, 2008||No|New study created.|No||https://clinicaltrials.gov/show/NCT01555723||89236|
NCT01545635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETIC|RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma|RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma||Medical University Innsbruck|Yes|Terminated|March 2012|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|80 Years|No|||March 2016|March 22, 2016|March 1, 2012||No|The Interim analysis (100 patients) revealed a possible harm to patients randomised to the    fresh frozen plasma (FFP) treatment arm.|No||https://clinicaltrials.gov/show/NCT01545635||90006|
NCT01545648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol No. 117527|Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer|Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer||University of California, San Francisco|Yes|Recruiting|November 2012|December 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|February 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545648||90005|
NCT01534416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0021|Effect of Paracervical Block on Post Operative Pain in Laparoscopic Gynecologic Surgery|Use of Paracervical Block in Laparoscopic Gynecologic Surgery: A Randomized Controlled Trial||Icahn School of Medicine at Mount Sinai|No|Completed|September 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|230|||Female|18 Years|N/A|No|||November 2013|November 8, 2013|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534416||90863|
NCT01534650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLNT-001|Movement Disorder Quantification Algorithm Development|||Great Lakes NeuroTechnologies Inc.||Recruiting|February 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Northeastern Ohio with a movement disorder such as Parkinson's disease or        essential tremor.|August 2015|August 10, 2015|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534650||90846|
NCT01534663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE8356|Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure|Effects of Glutamine and Fish Oil on Muscle Function in Heart Failure (GlutFish-HF)|GLUTFISH-HF|Columbia University|No|Completed|November 2011|July 2014|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|35 Years|80 Years|No|||July 2014|July 5, 2014|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01534663||90845|
NCT01535287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201006723|The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia|The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia||University of Iowa|Yes|Recruiting|June 2010|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|1 Year|10 Years|No|||February 2012|February 14, 2012|January 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535287||90799|
NCT01531140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2012|PEG Versus PEG+Bisacodyl Versus Sennosides for Colon Cleansing Before Colonoscopy|High-volume Polyethylene Glycol Solution (PEG) Versus Low-volume PEG Plus Stimulant Laxative Versus Sennosides for Colon Cleansing Before Colonoscopy: a Randomized, Single Blinded Study||Medical University of Warsaw|No|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|240|||Both|10 Years|18 Years|No|||January 2012|February 9, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01531140||91112|
NCT01531153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1007007119|Cognitive Enhancement as a Target for Cocaine Pharmacotherapy|Cognitive Enhancement as a Target for Cocaine Pharmacotherapy||Yale University|Yes|Completed|September 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|60 Years|No|||January 2016|January 8, 2016|December 7, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531153||91111|
NCT01531491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J In 2011-3|Effects of Hypercapnia on Emergence From General Anesthesia Under Propofol|Effects of Hypercapnia on Emergence From General Anesthesia Under Propofol: a Pilot Study||DongGuk University|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|30|||Both|20 Years|60 Years|No|||February 2015|February 12, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01531491||91086|
NCT01531114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESET 2D|PhaRmacodynamic Effect of Therapy With PraSugrel or TicagrElor in Acute Coronary Syndrome paTients With Diabetes Mellitus|PhaRmacodynamic Effect of Therapy With PraSugrel or TicagrElor in Acute Coronary Syndrome paTients With Diabetes Mellitus.RESET 2D Trial|RESET 2D|University of Roma La Sapienza|Yes|Not yet recruiting|May 2013|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|75 Years|No|||April 2013|April 19, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531114||91114|
NCT01531127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0014-12-HYMC|Executive Function in Learning in Children With Attention Deficit Hyperactivity Disorder (ADHD) Receiving Medical Treatment Alone Compared to Children Receiving Additional Treatment to Improve Learning Strategies|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|6 Years|15 Years|No|Probability Sample|Children with ADHD treated in the Institute for Child Development at Hillel Yaffe Medical        Center|February 2012|February 9, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531127||91113|
NCT01531452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-016|The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer|a Phase II Study of Oxaliplatin Plus S-1 (SOX) as First-line Treatment for Patients With Advanced Gastric Cancer||Chinese Academy of Medical Sciences|No|Completed|June 2011|June 2013|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01531452||91089|
NCT01531712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICO-20431|Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable|Phase II Study of Neoadjuvant Treatment With Gemcitabine, Tarceva and Oxaliplatin Followed by Chemotherapy With Tarceva and Gemcitabine in Patients With Pancreas Adenocarcinoma With Borderline Resectability.||Institut Català d'Oncologia|No|Terminated|July 2011|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|No|||July 2012|July 20, 2012|January 11, 2012||No|Due to a low recruitment rate since start of recruitment period.|No||https://clinicaltrials.gov/show/NCT01531712||91069|
NCT01532596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBSR-Older-00001|Mindfulness Meditation in Older Adults|The Effects of Mindfulness Meditation in Older Adults|MIND|University of California, Los Angeles|No|Completed|January 2008|January 2009|Actual|January 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|55 Years|85 Years|Accepts Healthy Volunteers|||February 2012|February 9, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01532596||91002|
NCT01532934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28780|The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention|The Impact of Psychopathic Traits on the Efficacy of a Brief Intervention for Substance Use||University of Rochester|Yes|Recruiting|August 2009|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2012|February 10, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01532934||90976|
NCT01532947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTFP1|Randomized Controlled Trial of Fiber Post Restorations|Survival of Endodontically Treated and Restored Premolars: A Randomized Controlled Trial||University of Siena|No|Completed|January 2003|||June 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|76 Years|No|||February 2012|February 10, 2012|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01532947||90975|
NCT01533259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-236-0123|Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients|A Phase 3B Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF) Single-Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Patients||Gilead Sciences|No|Completed|January 2012|July 2013|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|February 2, 2012|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT01533259||90951|
NCT01533298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-CFO-301|A Safety, Efficacy Study of CombiflexOmega Peri Versus SmofKabiven Peripheral in Patients With Parenteral Nutrition|A Randomized, Open, Multicenter, Compared Phase III Trial to Evaluate the Safety, Efficacy of CombiflexOmega Peri and SmofKabiven Peripheral in Postoperative Patients Requiring Parenteral Nutrition|OMEGA|JW Pharmaceutical||Completed|July 2011|January 2012|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||February 2013|February 15, 2013|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01533298||90948|
NCT01543334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/JYL-03|Antibiotic Concentrations Among Critically Ill Patients|Antibiotic Concentrations Among Critically Ill Patients|DALI|Centre Hospitalier Universitaire de Nīmes|No|Completed|March 2012|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|98|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive care patients with a vein or artery catheter and who are being administered        antibiotics Can be of the following: Amoxicillin-clavulanic acid, ampicillin,        piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin,        cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem;        Vancomycin, teicoplanin.|March 2015|March 25, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01543334||90183|
NCT01555450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10051EE|Study of Patient Navigation to Reduce Social Inequalities|The Patient Navigator to Reduce Social Inequalities. A French Interventional Trial in Public Health|PRADO|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|March 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Screening|2||Actual|28929|||Both|50 Years|74 Years|No|||March 2012|February 23, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555450||89257|
NCT01556022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The ATHENA Trial|Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia|Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.|ATHENA|Cytori Therapeutics|Yes|Active, not recruiting|June 2012|May 2019|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|20 Years|80 Years|No|||October 2015|October 21, 2015|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556022||89213|
NCT01553214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120096|Improving White Blood Cell Collection From Healthy Donors|Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|January 2032|Anticipated|January 2032|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|4||Anticipated|1000|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|March 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01553214||89428|
NCT01553474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120085|Blood and Saliva Sample Collection for AREDS 2|Blood and Saliva Sample Collection and Submission to the Age-Related Eye Disease Study 2 (AREDS2) Genetic Repository||National Institutes of Health Clinical Center (CC)||Completed|February 2012|February 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|56|||Both|55 Years|85 Years|No|||February 2013|August 27, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01553474||89408|
NCT01556243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACOSOG-Z11102|Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer|Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)||Alliance for Clinical Trials in Oncology|Yes|Recruiting|July 2012|||July 2020|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Female|40 Years|N/A|No|||December 2015|December 11, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556243||89196|
NCT01556490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS-103|Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer|A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)|STOP-HCC|BTG International Inc.|Yes|Recruiting|March 2012|October 2019|Anticipated|July 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||January 2016|March 3, 2016|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556490||89178|
NCT01534676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1111|Effects of Transfusion of Older Red Blood Cells on Patients With Hemoglobinopathies|Harmful Effects of Transfusion of Older Stored Red Cells: Iron and Inflammation||Columbia University|No|Terminated|February 2012|||February 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|3|||Both|1 Year|65 Years|Accepts Healthy Volunteers|||May 2015|May 15, 2015|February 14, 2012|No|Yes|Difficulty recruiting donors and recipients, looking for alternative sites|No||https://clinicaltrials.gov/show/NCT01534676||90844|
NCT01534962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAF-01|Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging Phase II Study Assessing Ranolazine in the Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Non-permanent Atrial Fibrillation.|RAFFAELLO|Menarini Group|No|Completed|January 2012|March 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|241|||Both|18 Years|N/A|No|||July 2014|July 29, 2014|February 10, 2012||No||No|July 29, 2014|https://clinicaltrials.gov/show/NCT01534962||90823|Most of the Kaplan-Meier estimates could not be calculated due to the lower than expected number of observed events and the high variability of data.
NCT01540903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSPZC1|Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults|Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites (PfSPZ Challenge)in Tanzanian Adults||Sanaria Inc.|Yes|Completed|February 2012|August 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|30|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01540903||90368|
NCT01530880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1788|Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage|Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage||Columbia University|No|Recruiting|February 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|February 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01530880||91132|
NCT01541410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYBRID-001|Evaluation of the Vascutek Hybrid Graft for Use in the Replacement of the Aortic Arch and Concomitant Treatment of an Aneurysm/Dissection of the Descending Aorta in the Frozen Elephant Trunk Procedure|||Vascutek Ltd.|Yes|Completed|May 2010|||August 2011|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|29 Years|79 Years|No|||July 2013|July 12, 2013|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01541410||90329|
NCT01541423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0624-401|A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema|A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks||Shire|No|Active, not recruiting|March 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|N/A|No|Non-Probability Sample|Patients with HAE in Europe who are receiving CINRYZE in routine clinical practice for        prevention or treatment of angioedema attacks. Approximately 20 sites are planned for        enrollment.|January 2016|January 25, 2016|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01541423||90328|
NCT01531725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C0601|MULTIcentric BElgium/NEtherlands PRO-Kinetic Safety and Efficacy Study|6 Months Evaluation of the BIOTRONIK PRO-Kinetic Coronary Stent System|MULTIBENE|Biotronik AG|Yes|Completed|February 2007|March 2009|Actual|April 2008|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Both|18 Years|N/A|No|||March 2013|March 19, 2013|February 9, 2012||No||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01531725||91068|Limitations:missing comparatorspermission to conduct follow up visits by telephonelimited number of 197 patients allows an insight of the safety and efficacy of the device.
NCT01531985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 10/51; GC 1069|Urine and Serum Biomarkers for Early Detection of Acute Kidney Injury|Urine and Serum Biomarkers for Early Detection of Acute Kidney Injury Following Cardiopulmonary Bypass Surgery for Congenital Heart Disease in Children and Adults: A Pilot Study||Medical College of Wisconsin|No|Completed|April 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Urine samples will be collected after the operation at 6 hours, 12 hours, 24 hours and 72      hours. The urine samples will be collected from your/your child's urinary catheter if one is      in place for your/your child's regular hospital care, or by urine collected in a cup if      you/your child do not have a urinary catheter. This study requires one blood samples of      about 1 teaspoon, before surgery. The blood sample will be collected when other blood      samples are drawn, to avoid extra needle sticks for blood. The extra blood collected,      totaling about 1 teaspoon, is a safe amount for children over 2 years old.|Both|2 Years|N/A|No|Non-Probability Sample|The investigators will enroll a total of 20 patients undergoing pulmonary valve        replacement with CPB. All patients will have a history of a conotruncal anomaly with        previous corrective surgery requiring CPB.|May 2012|May 7, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01531985||91048|
NCT01532336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL1104|Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis|A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis|BAYnovation™|NovaBay Pharmaceuticals, Inc.|No|Completed|May 2012|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|500|||Both|1 Year|N/A|No|||July 2014|May 26, 2015|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532336||91021|
NCT01532609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH083512|Methadone Maintenance and HIV Prevention: A Window of Opportunity in China|Methadone Maintenance and HIV Prevention: A Window of Opportunity in China Version|MMT1|University of California, Los Angeles|Yes|Completed|March 2009|March 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Both|18 Years|N/A|No|||March 2009|February 9, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01532609||91001|
NCT01532622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0218|Impact of Blueberries on Uric Acid and Quality of Life|Impact of Blueberries on Uric Acid and Quality of Life||University of Mississippi Medical Center|No|Completed|January 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|88 Years|Accepts Healthy Volunteers|||October 2013|October 18, 2013|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01532622||91000|
NCT01532960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15881|Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer|A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage I-IV Breast Cancer|Breast 41|University of Virginia|Yes|Suspended|July 2012|||July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|February 8, 2012|No|Yes|Study drug is no longer available. Interim data analysis to evaluate immune responses to the    vaccine is being completed prior to vialing additional study drug.|No||https://clinicaltrials.gov/show/NCT01532960||90974|
NCT01533285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100698|Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients|A 2-way Crossover Study to Explore the Effect of an Inflammatory and Psychosocial Stressor and a Combination Thereof on the Mood and Cytokine Levels in Young and Elderly Healthy Female Subjects and Female Subjects With Major Depressive Disorder||Janssen Pharmaceutica N.V., Belgium|No|Completed|May 2012|November 2013|Actual|November 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|40|||Female|25 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 27, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01533285||90949|
NCT01543048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2010/18|Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization|Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization: Prospective Study With Virological Follow-up on 24 Months (SUIVICOL)|SUIVICOL|University Hospital, Bordeaux|No|Recruiting|March 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Cervical samples|Female|18 Years|N/A|No|Non-Probability Sample|Women with CIN3 treated by conization|November 2014|November 12, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01543048||90205|
NCT01555463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16080|Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea|A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea||Bayer||Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|961|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|March 13, 2012|Yes|Yes||No|December 28, 2014|https://clinicaltrials.gov/show/NCT01555463||89256|
NCT01556295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1586/08|Gesture Behavior and Knowledge on Low Back Pain Among Nurses|Assessment of Gesture Behavior and Knowledge on Low Back Pain Among Nurses||Federal University of São Paulo|Yes|Recruiting|March 2012|April 2013|Anticipated|August 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|100|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Nurses with non-specific low back pain and healthy nurses|March 2012|March 16, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01556295||89193|
NCT01556568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162Y2201|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy|An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy||Array BioPharma|No|Withdrawn|February 2012|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|March 15, 2012|No|Yes|Study was withdrawn due to scientific and business considerations.|No||https://clinicaltrials.gov/show/NCT01556568||89172|
NCT01555996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA10I20015|Early Occupational Therapy for Delirium Prevention in Older Patients Admitted to Critical Care Unit|Early Occupational Therapy (OT) for Delirium Prevention in Older Patients Admitted to Critical Care Unit (CCU)||University of Chile|No|Completed|April 2011|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|126|||Both|60 Years|95 Years|No|||May 2014|May 19, 2014|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01555996||89215|
NCT01556256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANUR1131|Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents|Music Video for AYA-Parent Communication and Resilience||Children's Oncology Group|Yes|Recruiting|April 2012|||October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|198|||Both|11 Years|24 Years|No|||September 2015|September 14, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556256||89195|
NCT01534689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC_TF_001|Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus|An Evaluation of the Effect of the Erchonia FX-405™ on Treating Toenail Onychomycosis Clinical Study||Erchonia Corporation|No|Completed|April 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|18 Years|N/A|No|||November 2015|November 7, 2015|February 14, 2012|Yes|Yes||No|July 13, 2015|https://clinicaltrials.gov/show/NCT01534689||90843|
NCT01534702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-2009-003|Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML|Phase I/II Study on Cytarabine and Idarubicin Combined With Escalating Doses of Clofarabine as Induction Therapy in Patients With Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10)|CIARA|Hannover Medical School|No|Recruiting|January 2012|September 2015|Anticipated|April 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2012|February 17, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01534702||90842|
NCT01534975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Visipaque|Comparison of Contrast Agents During CT Angiography|A Prospective, Single-Center Double-Blind Randomized Study in Subjects Undergoing Coronary Computed Tomography Angiography (CCTA) Examination (VISIPAQUE Randomized Study)|Visipaque|Los Angeles Biomedical Research Institute|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|undergoing CT angiography for diagnostic purposes|January 2013|January 28, 2013|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01534975||90822|
NCT01532973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8742-002|Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002 AM1)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males||Merck Sharp & Dohme Corp.|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|11||Actual|48|||Male|18 Years|60 Years|No|||November 2015|November 2, 2015|February 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01532973||90973|
NCT01541124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1133/07|Morphine as First Drug for Cancer Pain|Morphine as the First Drug for the Treatment of Cancer Pain||Federal University of São Paulo|Yes|Completed|August 2008|November 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||February 2012|February 28, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01541124||90351|
NCT01541137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74555|NSAIDs With Morphine-PCA Compared to Epidural Analgesia in Thoracotomy Pain|NSAID With IV-PCA Morphine is an Alternative to Thoracic Epidural Analgesia in Post-thoracotomy Pain||Helsinki University Central Hospital|No|Completed|March 2004|September 2008|Actual|September 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||February 2012|February 28, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01541137||90350|
NCT01533597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bomnal study|The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)|Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study||Soonchunhyang University Hospital|No|Completed|December 2010|February 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Female|20 Years|70 Years|No|||January 2015|January 24, 2015|February 2, 2012||No||No|January 11, 2015|https://clinicaltrials.gov/show/NCT01533597||90925|small study population
NCT01531738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT|Investigation of the Effects of Bariatric Surgery on Taste Reward in Humans|Investigation of the Effects of Bariatric Surgery on Taste Reward in Humans||Imperial College London|Yes|Recruiting|July 2010|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with obesity attending a specialist obesity clinic and normal weight controls who        are staff at Imperial College London|February 2016|February 26, 2016|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01531738||91067|
NCT01531998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0073|Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)|An Open Label, Single-Arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Lenalidomide, Bortezomib, Dexamethasone and Siltuximab (CNTO 328) in Subjects With Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy||M.D. Anderson Cancer Center|No|Completed|May 2012|May 2014|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|February 9, 2012|Yes|Yes||No|June 2, 2015|https://clinicaltrials.gov/show/NCT01531998||91047|
NCT01532011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0916|Erlotinib in Combination With Pralatrexate in Advanced Malignancies|A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer||M.D. Anderson Cancer Center|No|Recruiting|March 2012|||March 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|74|||Both|12 Years|N/A|No|||November 2015|November 24, 2015|February 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01532011||91046|
NCT01532024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAP|Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs|Phase 1 Exploratory Clinical Study of Microdosing NAP for Optical Molecular Imaging in Human Lungs in Healthy Volunteers and in Patients With Acute Lung Injury in Intensive Care|NAP|University of Edinburgh|Yes|Recruiting|October 2014|||May 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01532024||91045|
NCT01541917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRANT10829275|Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis|WebSMART: Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis|WebSMART|Children's Mercy Hospital Kansas City|Yes|Active, not recruiting|July 2012|January 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|360|||Both|12 Years|18 Years|No|||March 2014|February 2, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01541917||90291|
NCT01532349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00066175|Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease|Cholecalciferol as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease|D-fense|Johns Hopkins University|Yes|Recruiting|May 2012|||May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|1 Year|21 Years|No|||September 2013|September 19, 2013|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01532349||91020|
NCT01542528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YaleHIC11100009142|Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)|Integrated Brain, Body and Social Intervention (IBBS) for Attention Deficit Hyperactivity Disorder (ADHD)|IBBS|Yale University|Yes|Recruiting|March 2012|July 2019|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|5 Years|8 Years|No|||February 2016|February 19, 2016|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01542528||90244|
NCT01542541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000101|A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans|A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans||Beth Israel Deaconess Medical Center|No|Completed|July 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|February 27, 2012|Yes|Yes||No|December 18, 2015|https://clinicaltrials.gov/show/NCT01542541||90243|
NCT01542801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBP_prevention|Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention|Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients||Korea University|Yes|Recruiting|August 2011|October 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|122|||Both|20 Years|75 Years|No|||April 2014|April 8, 2014|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01542801||90223|
NCT01530919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|291.97|Minimally Invasive Radioguided Parathyroidectomy|Minimally Invasive Radioguided Parathyroidectomy|MIRP|University of Louisville|No|Recruiting|September 1998|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|N/A|N/A|No|||February 2012|April 4, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01530919||91129|
NCT01531205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16684|Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA|Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Failure With Biopsy Proven Local Recurrence After Initial Definitive Radiotherapy||H. Lee Moffitt Cancer Center and Research Institute|Yes|Terminated|May 2012|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Male|18 Years|N/A|No|||July 2014|November 4, 2014|February 8, 2012|Yes|Yes|low accrual|No|July 8, 2014|https://clinicaltrials.gov/show/NCT01531205||91107|Study was closed early due to low accrual. Investigators had planned to follow 25 participants from On Study through End of Follow-up, up to 10 years.
NCT01530893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASTCHECK|Flavonoids, Blood Pressure and Blood Vessel Function|Are the Cardiovascular Responses of Individuals at Mild to Moderate Cardiovascular Risk Influenced by Dietary Flavonoid Sub-class and Dietary Form?|FASTCHECK|University of East Anglia|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|64|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01530893||91131|
NCT01530906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8709|Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) in Bulimia|Efficiency of rTMS in Bulimia: a Controlled Randomized Study|rTMS&bulimia|University Hospital, Montpellier|Yes|Recruiting|January 2012|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|40 Years|No|||February 2012|December 2, 2014|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01530906||91130|
NCT01555736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ne0103AV|Comparison of Perennial and Preseasonal Subcutaneous Immunotherapy|A Randomised Double-blind Clinical Trial for Evaluation of Efficacy and Safety of Perennial in Comparison to Preseasonal Grass/Rye Pollen Immunotherapy in Patients Suffering From Seasonal Allergic Rhinitis||Medical Universtity of Lodz|No|Completed|January 2003|September 2006|Actual|July 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|60 Years|No|||March 2012|March 19, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01555736||89235|
NCT01555749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7415-3981|Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects|A Randomised, Double-blind, Placebo-controlled, Single Centre, Single Dose Trial, Assessing the Pharmacokinetics of NNC172-2021, Administered Subcutaneously at Two Different Dose Levels, in Healthy Japanese Subjects||Novo Nordisk A/S|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Male|20 Years|64 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555749||89234|
NCT01553123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1104|Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma|A Randomized, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate in Women With Anemia Associated With Uterine Leiomyomas||Watson Pharmaceuticals|No|Withdrawn|April 2012|December 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|50 Years|No|||February 2013|February 5, 2013|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553123||89435|
NCT01553136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106008598|Varenicline Treatment of Alcohol Dependence in Smokers|1/2-Multi-site Study: Varenicline Treatment of Alcohol Dependent Smokers||Yale University|Yes|Active, not recruiting|September 2012|May 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|70 Years|No|||September 2015|September 29, 2015|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553136||89434|
NCT01556009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-077|Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas|A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas|Vismodegib|Children's Hospital & Research Center Oakland|Yes|Completed|April 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556009||89214|
NCT01556555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|552/03|Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)|Prospective Evaluation of the Clinical Utility of Peroral Cholangiopancreatoscopy With the Spyglass System in Patients With Sclerosing Cholangitis||Karolinska University Hospital|No|Completed|September 2008|October 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Probability Sample|Patients with SC, sclerosing cholangitis, who is undergoing ERCP, (Endoscopic Retrograde        Cholangio and Pancreaticography)|March 2012|March 15, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01556555||89173|
NCT01556763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-6124-005|Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia|A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics||FORUM Pharmaceuticals Inc|No|Completed|April 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|21|||Both|18 Years|55 Years|No|||May 2012|May 21, 2012|March 14, 2012|Yes|Yes||No|April 18, 2012|https://clinicaltrials.gov/show/NCT01556763||89157|
NCT01540344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24/06/2009|Combined Anticancer Treatment of Advanced Colon Cancer|Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.|COMBATAC|University of Regensburg|No|Active, not recruiting|October 2010|October 2017|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|71 Years|No|||December 2014|December 10, 2014|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01540344||90411|
NCT01540617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012_SBrumagne_MRIproprio|The Neural Basis of Lumbosacral Proprioceptive Impairment in Recurrent Low Back Pain|The Neural Basis of Lumbosacral Proprioceptive Impairment in Recurrent Low Back Pain||Katholieke Universiteit Leuven|Yes|Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|36|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Leuven and surrounding area|April 2014|April 11, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01540617||90390|
NCT01533610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#1125|The Efficacy of Stellate Ganglion Block as Post-traumatic Stress Disorder (PTSD) Therapy: A Pilot Study|The Efficacy of Stellate Ganglion Block as PTSD Therapy: A Pilot Study||Southern California Institute for Research and Education|No|Recruiting|February 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|12|||Both|18 Years|90 Years|No|||February 2012|February 14, 2012|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01533610||90924|
NCT01533311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjxhnk03|Prevalence and Characteristics of Nonpolypoid Colorectal Neoplasms - A Chinese Cohort Study|Prevalence and Characteristics of Nonpolypoid Colorectal Neoplasms - A Chinese Cohort Study||Shanghai Jiao Tong University School of Medicine|No|Completed|January 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1342|Samples Without DNA|All the lesions will be removed endoscopically or surgically and examined histologically by      an independent gastrointestinal pathologist.      Histological diagnosis is determined according to the World Health Organization (WHO)      criteria.Pedunculated lesions are categorized according to Haggitt's classification.|Both|18 Years|90 Years|No|Non-Probability Sample|consecutive adult patients undergo colonoscopy by one endoscopist from Jan 2009 to Dec        2010|February 2012|February 14, 2012|February 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01533311||90947|
NCT01533324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC-SL-2W|S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)|Phase II Study of S-1 Combined With Calcium Folinate to Treat Advanced Hepatocellular Carcinoma||Second Military Medical University|Yes|Recruiting|November 2011|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|70 Years|No|||February 2012|February 14, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533324||90946|
NCT01534169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDJP-H200829|Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients|Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients||Nanjing Medical University|Yes|Completed|March 2012|November 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|60 Years|No|||November 2012|November 8, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01534169||90882|
NCT01534182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DRU01|Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)|A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT)|EPOC|Novartis||Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|298|||Both|18 Years|65 Years|No|||August 2014|August 7, 2014|February 8, 2012||No||No|June 11, 2014|https://clinicaltrials.gov/show/NCT01534182||90881|
NCT01541683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM.AS1.28|The Effect of Mentholyptus Drops on the Palatability of PEG-Electrolyte Solution|The Effect of Mentholyptus Drops (Halls®) on the Palatability of PEG-Electrolyte Solution (FORTRANS®) in Colonoscopy Preparation: A Randomized Controlled Trial||American University of Beirut Medical Center|Yes|Completed|January 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|99|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 5, 2013|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01541683||90308|
NCT01541930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDT.07.SPR.27013|An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours|An Open, Uncontrolled Study Investigating the Safety and Efficacy of GK567 in the Deodorization of Malodorous Infected Cutaneous Fungating Neoplastic Tumours, Over 14 Days of Treatment|GK567|Galderma R&D|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|N/A|No|||January 2014|January 7, 2014|February 24, 2012||No||No|November 13, 2013|https://clinicaltrials.gov/show/NCT01541930||90290|
NCT01534143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-151|High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant|A Pilot Study Using High Dose Busulfan and Bortezomib as Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients.||Barbara Ann Karmanos Cancer Institute|Yes|Terminated|February 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|70 Years|No|||December 2015|December 9, 2015|February 13, 2012|Yes|Yes|Data was not collected.|No|October 22, 2013|https://clinicaltrials.gov/show/NCT01534143||90883|Data was not collected.
NCT01542216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17215|Evaluation of Nutrition and Metabolism in Breast Cancer Patients|Evaluation of Nutrition and Metabolism in Breast Cancer Patients||University of Waterloo|No|Withdrawn|February 2012|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Female|18 Years|N/A|No|||November 2015|November 4, 2015|February 20, 2012||No|Recruitment challenges|No||https://clinicaltrials.gov/show/NCT01542216||90268|
NCT01535014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-DI-002|Clinical Trial of Safety and Efficiency of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients|Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficiency of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients||Materia Medica Holding|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|493|||Both|18 Years|65 Years|No|||July 2013|July 24, 2013|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535014||90820|
NCT01535027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vinforce-003|Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis|Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy|Confors|Medical University of Vienna|Yes|Completed|March 2006|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|125|||Female|55 Years|88 Years|No|||December 2012|December 30, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01535027||90819|
NCT01535326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DalinTCGH-hsieh-01|Comparing Water Immersion and Water Exchange Methods During Minimally Sedated Colonoscopy|Comparing Air Insufflation, Water Immersion and Water Exchange Methods During Minimal Sedated Colonoscopy, a Randomized, Controlled Trial||Dalin Tzu Chi General Hospital|No|Completed|February 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|270|||Both|20 Years|80 Years|No|||July 2014|July 28, 2014|February 11, 2012||No||No|March 16, 2014|https://clinicaltrials.gov/show/NCT01535326||90796|Single center; single endoscopist
NCT01530932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-411M-MA|Immune Activation, Hypoxia and Vasoreaction in Sepsis of Pulmonary Versus Abdominal Origin|Immune Activation, Hypoxia and Vasoreaction in Sepsis of Pulmonary Versus Abdominal Origin||Universitätsmedizin Mannheim|Yes|Completed|February 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Blood samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with sepsis of pulmonary or abdominal origin with admission to the ICU in the        first 48 hours of sepsis onset|October 2014|October 20, 2014|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01530932||91128|
NCT01555177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-099|Study of Coronary Plaque Rupture in Heart Attack Following Surgery Using Optical Coherence Tomography (OCT)|OCT Plaque and Thrombus IMaging in Patients Who Underwent Non-cardiac Surgery|OPTIMUS|Hamilton Health Sciences Corporation|Yes|Recruiting|April 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|NSTEMI and peri-operative MI patients will be screened in the catheterisation laboratory.        In addition, peri-operative MI patients will be screened in hospital wards, where patient        referral for cardiac catheterisation will be based on clinical indications.|November 2014|November 3, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01555177||89278|
NCT01555190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000102012|Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone|Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome||Catholic University of the Sacred Heart||Recruiting|January 2012|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||50|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 14, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555190||89277|
NCT01556035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/28|Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma|A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid®) in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) After First Line Treatment by Chemotherapy Plus Rituximab for the French Study Group of Cutaneous Lymphoma (GFELC)|REV-LEG|University Hospital, Bordeaux|Yes|Completed|July 2012|August 2015|Actual|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01556035||89212|
NCT01553370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCT-11-221|Randomized Controlled Trial of Milk Products and Physical Activity on Body Composition and Health in Overweight Young Males|Randomized Controlled Trial of Milk Products and Physical Activity on Body Composition and Health in Overweight Young Males||Brock University|No|Not yet recruiting|April 2012|February 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|54|||Male|18 Years|28 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553370||89416|
NCT01556282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00015167|TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis|A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis||Emory University|No|Completed|March 2009|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01556282||89194|
NCT01557062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibromyalgia_0866/06|Passive Body Heating, Sleep and Fibromyalgia|Passive Body Heating Improves The Sleep Pattern In Women Patients Fibromyalgia||Federal University of São Paulo|Yes|Completed|March 2009|December 2010|Actual|March 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Female|45 Years|70 Years|No|||March 2012|March 15, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01557062||89134|
NCT01532050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWT MRA UZA|PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea|PROMAD : Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea|PROMAD|University Hospital, Antwerp|No|Active, not recruiting|February 2012|||December 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2014|April 1, 2014|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01532050||91043|
NCT01532362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002081|Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer|Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer||Jonsson Comprehensive Cancer Center|Yes|Terminated|November 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1|||Both|18 Years|N/A|No|||June 2013|January 12, 2016|November 30, 2011|Yes|Yes|Drug sponsor stopped drug manufacture due to toxicity issues from other studies|No|January 12, 2016|https://clinicaltrials.gov/show/NCT01532362||91019|Early termination of study when sponsor withdrew drug from market due to toxicities revealed from other studies.
NCT01532635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.570|A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors||Thomas Jefferson University|Yes|Terminated|March 2012|May 2013|Actual|February 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|February 6, 2012|Yes|Yes|Slow accrual|No|November 3, 2014|https://clinicaltrials.gov/show/NCT01532635||90999|Study was terminated due to poor accrual. No reportable data has been collected.
NCT01532648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C2011-0401|Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA).|||Valeant Pharmaceuticals International, Inc.|No|Completed|February 2012|November 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|509|||Both|18 Years|75 Years|No|||December 2013|March 27, 2014|December 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532648||90998|
NCT01532999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLE-004-11S|A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD|A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD||VA Office of Research and Development|Yes|Completed|January 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|254|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|December 8, 2011||No||No|March 6, 2015|https://clinicaltrials.gov/show/NCT01532999||90971|Limitations: PCGT may be more active than originally anticipated and is thus an active control rather than neutral control
NCT01533870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00015|Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118|An Open-label, Fixed-sequence, 3-period, 3-treatment, Crossover Study to Assess the Effects of Rifampin on Pharmacokinetics of NKTR-118 in Healthy Subjects||AstraZeneca||Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|22|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|February 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01533870||90904|
NCT01533623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 11/41/291|The 1 Year Follow-up Objective Oral Appliance Compliance|The 1 Year Follow-up of Objective Measures of Oral Appliance Compliance for Treatment of Sleep-disordered Breathing (SDB): a Clinical Trial||University Hospital, Antwerp|No|Completed||July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|51|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01533623||90923|
NCT01533844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2819-CL-0204|To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis|An Observational, Non-interventional Study to Determine the Role of Clostridium Difficile in the Pathogenesis of Disease Observed in Neonates and to Investigate the Feasibility of a Potential Study to Evaluate Safety, Efficacy and Pharmacokinetics of Fidaxomicin Oral Suspension in Neonates With Clostridium Difficile Associated Disease (CDAD)|DAISY|Astellas Pharma Inc|No|Terminated|March 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1|Samples Without DNA|Stool Sample|Both|N/A|27 Days|No|Non-Probability Sample|Term neonates less than 28 days of age at enrollment, referred to healthcare professionals        due to suspected C Difficile Associated Disease (CDAD).|March 2015|March 3, 2015|February 13, 2012||No|Terminated due to the fact that the required number of trial subjects was not met.|No||https://clinicaltrials.gov/show/NCT01533844||90906|
NCT01533857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-BNH-0379|Pharmacokinetic Behavior of Phenolic Acids Derived From Black Tea|Pharmacokinetic Behavior of Phenolic Acids Derived From Black Tea||Unilever R&D|No|Completed|February 2012|November 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|August 12, 2013|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01533857||90905|
NCT01534741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-IIT-02-E|Comparison FX CorDiax 60 in Relation to the FX 60-Dialyzer|Investigation on the Middle Size Molecule Elimination Characteristics of the FX CorDiax 60 in Relation to the FX 60-Dialyzer||Hospital Clinic of Barcelona|Yes|Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|90 Years|No|||July 2012|April 8, 2014|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01534741||90839|
NCT01535040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99311|Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking|Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors||Wake Forest NCORP Research Base|Yes|Completed|August 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|130|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|February 14, 2012||No||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01535040||90818|
NCT01535339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-03|Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion|Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion||ElMindA Ltd|No|Active, not recruiting|February 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|||Both|14 Years|26 Years|Accepts Healthy Volunteers|Non-Probability Sample|Phase 1: gender-balanced groups of 30 healthy high school (14-17 years old) and 30 healthy        college aged (18-26 years old) individuals who participate in non-contact sports Phase 2a:        30 high school and/or collegiate athletes aged 14-26 years with concussion and 30 matched        control athletes.        Phase 2b: at least 30 high school and/or collegiate contact sport athletes aged 14-26        years whose head impacts are monitored during games and practices.|April 2014|April 8, 2015|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01535339||90795|
NCT01535352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH091199-02|Depressed Mothers in Rural Areas: Web-Facilitated Cognitive Behavioral Treatment|Depressed Mothers in Rural Areas: Web-Facilitated Cognitive Behavioral Treatment|Mom-NetRCT|Oregon Research Institute|Yes|Recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|N/A|N/A|No|||October 2015|October 15, 2015|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535352||90794|
NCT01535066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1200|S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer|Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer||Southwest Oncology Group|Yes|Recruiting|March 2012|October 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Anticipated|228|||Female|18 Years|N/A|No|||September 2015|September 25, 2015|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01535066||90816|
NCT01555489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.365|Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca|Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer||Thomas Jefferson University|Yes|Active, not recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|February 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01555489||89254|
NCT01555762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27829|An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)|Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin ® Regimen for Metastatic Colorectal Cancer.||Hoffmann-La Roche||Active, not recruiting|March 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|403|||Both|75 Years|N/A|No|Probability Sample|Elderly patients with metastatic colorectal cancer initiating first-line treatment with        Avastin|March 2016|March 1, 2016|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555762||89233|
NCT01557075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2010-0298|Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation|Effects of High-dose Statin Treatments on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Drug-eluting Stents Implantation: a Randomized Controlled Study|statin|Yonsei University|Yes|Recruiting|July 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|2000|||Both|20 Years|N/A|No|||March 2012|March 16, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01557075||89133|
NCT01556776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLLM1 Protocol of the GCLLSG|A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy|CLLM1-Protocol of the German CLL-Study Group (GCLLSG) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for High-risk Patients With Chronic Lymphocytic Leukemia Following First-line Therapy|CLLM1|German CLL Study Group|Yes|Recruiting|July 2012|July 2018|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01556776||89156|
NCT01553578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97511|Healing Touch or Guided Imagery In Treating Pain, Fatigue, Nausea, and Anxiety in Patients Undergoing Chemotherapy|The Efficacy of Healing Touch Versus Guided Imagery on Pain, Fatigue, Nausea, and Anxiety in Patients' Receiving Outpatient Chemotherapy||Comprehensive Cancer Center of Wake Forest University|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|244|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01553578||89400|
NCT01553591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27018966IBS3001|Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)|A Randomized, Double-blind, Placebo-controled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome||Furiex Pharmaceuticals, Inc|No|Completed|May 2012|July 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1282|||Both|18 Years|80 Years|No|||April 2015|April 26, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553591||89399|
NCT01532986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 11-126|Randomized Trial to Test the "Coordinated Care for Health Promotion and Activities in Parkinson's Disease" Intervention in the Veterans Administration|Improving Quality of Care in Parkinson's Disease: A Randomized Controlled Trial|CHAPS|VA Office of Research and Development|Yes|Enrolling by invitation|July 2012|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01532986||90972|
NCT01533337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tschen3886|Use of the Free Dorsal Digital Flap Including Both Dorsal Branches of the Proper Digital Nerves for Reconstruction of Volar Soft Tissue Defect of Digits|||The Second Hospital of Tangshan|Yes|Completed|May 2007|October 2011|Actual|May 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|15 Years|60 Years|No|||February 2012|February 14, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533337||90945|
NCT01532687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7943|Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma|A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma||OHSU Knight Cancer Institute|Yes|Recruiting|March 2012|||March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532687||90995|
NCT01532700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMH-GSK2110183-CLL001|An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)|||University Health Network, Toronto|Yes|Recruiting|February 2012|April 2019|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01532700||90994|
NCT01533909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54035|Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients|Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients||Universitaire Ziekenhuizen Leuven|No|Completed|March 2012|September 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|56|Samples Without DNA|The blood sample that will be collected is part of the routine hospital assessment. The      biomarkers that will be measured are albumine, creatine, CRP, hemoglobin and Lactate      dehydrogenase (LDH).|Both|18 Years|95 Years|No|Non-Probability Sample|The population from which the groups or cohorts will be selected (e.g., primary care        clinic, community sample, residents of a certain town). (Limit: 1000 characters)|March 2012|December 2, 2014|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533909||90901|
NCT01533922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.13|Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients|A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 1]||Boehringer Ingelheim||Completed|March 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|295|||Both|40 Years|75 Years|No|||August 2015|August 12, 2015|February 13, 2012||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01533922||90900|
NCT01533350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201002089|Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase|Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase of Infertile Women With Natural Cycles||Shen-Zhen City Maternity and Child Healthcare Hospital|Yes|Completed|September 2010|January 2012|Actual|January 2012|Actual|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|28|Samples Without DNA|The specimen was divided into three parts after washing with sterilized saline, and one was      ﬁxed by 2.5% glutaraldehyde solution immediately ，then coated with palladium gold for      electron microscopic examination;one was fixed by 2.5% glutaraldehyde arsenate ,then      embedded in Epon for transmission electron microscopy ; one was ﬁxed by 4% formalin, then      embedded in parafﬁn for immunohistochemical analysis.|Female|26 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|The mean age of the women were 31.9±3.7 years ( range, 26-39 years). The mean body mass        index was 20.96±2.46 kg/m2 (range, 17.58-26.04 kg/m2).With a regular menstral cycle        (25-35days) and 2-11 years infertile history, all subjects had signed the proper consent        forms.|February 2012|February 15, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01533350||90944|
NCT01534221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPERNICOS|The COOPerative Establishment for Necessary Investigation in Clinical Outcome After Stenting|Randomized Comparison of Outcome of Stenting in Unselected Patients in Everyday Clinical Practice|COPERNICOS|Roskilde County Hospital|No|Not yet recruiting|March 2012|March 2021|Anticipated|March 2020|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|5100|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01534221||90878|
NCT01534520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFP-RBR001|Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women|Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women: a Randomized Controlled Trial|LIVIIN|University of Pittsburgh|Yes|Active, not recruiting|June 2012|May 2013|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Female|14 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534520||90855|
NCT01533883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB1-1|Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair|Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair||Valtech Cardio Ltd|Yes|Recruiting|September 2011|May 2018|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patient is a candidate for mitral valve repair: moderate to severe mitral regurgitation,        symptomatic or asymptomatic with evidence of left ventricular dysfunction (AHA/ACC        criteria)|January 2016|January 31, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01533883||90903|
NCT01533896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|grownicely|Can a Brief Primary Care Intervention Affect Healthy Weight Habits|Can a Brief Primary Care Intervention Affect Healthy Weight Habits||Vanderbilt University|No|Completed|June 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|N/A|N/A|Accepts Healthy Volunteers|||February 2012|February 14, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533896||90902|
NCT01534481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD-NRN-0047|Donor Milk vs. Formula in Extremely Low Birth Weight (ELBW) Infants|Neurodevelopmental Effects of Donor Human Milk vs. Preterm Formula in Extremely Low Birth Weight (ELBW) Infants||NICHD Neonatal Research Network|Yes|Recruiting|August 2012|June 2018|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|670|||Both|N/A|21 Days|No|||July 2015|July 21, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534481||90858|
NCT01534494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heffter-UNM-HSC-15671|Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence|Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence||University of New Mexico|Yes|Active, not recruiting|January 2012|March 2014|Anticipated|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|25 Years|65 Years|No|||February 2014|February 6, 2014|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534494||90857|
NCT01534754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-00064322-25|Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon|Mesalazine and/or Lactobacillus Casei in Maintaining Remission of Symptomatic Uncomplicated Diverticular Disease of the Colon: a Double-blind, Double-dummy, Placebo-controlled Study||Hospital Cristo Re|No|Completed|January 2009|December 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|250|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01534754||90838|
NCT01534780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KIR-001-HRH|3 Fixation Devices in Laparoscopic Ventral Herniotomy|A Controlled Randomized Study of Protack, Securestrap and Glubran Glue as Fixation Devices in Laparoscopic Ventral Herniotomy|FS|Horsens Hospital|Yes|Recruiting|April 2013|April 2020|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534780||90837|
NCT01534793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K070301 / IC0709|QUAPELLA (QUAlity of Prostate Enucleation by LUMENIS - Laser)|Observational Study Evaluating the Quality of Laser Enucleation of the Prostate Using a LUMENIS Laser Device|QUAPELLA|Assistance Publique - Hôpitaux de Paris|No|Completed|February 2012|July 2014|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Male|50 Years|N/A|No|Non-Probability Sample|Patient presenting low urinary tract symptoms due to benign prostatic hyperplasia|February 2015|February 24, 2015|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01534793||90836|
NCT01535053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0275|Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia|A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia||Gynecologic Oncology Group|Yes|Recruiting|June 2012|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|384|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01535053||90817|
NCT01530685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PILEJE-Glyca-0910|Gycabiane and Glycemic Control of Prediabetic Subjects|Effect of Glycabiane, a Dietary Supplement, on Glycemic Control of Prediabetic Subjects||Pileje||Recruiting|November 2011|August 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 9, 2012|December 5, 2011||||No||https://clinicaltrials.gov/show/NCT01530685||91147|
NCT01531257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 25946|Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients|Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients|"Mini-Kidney"|Northwestern University|No|Recruiting|April 2010|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Urine Collection: Approximately one cup of urine (200 mL) will be taken for research tests      on the day of a routine care biopsy, if possible.      Blood Draws: About 1.5 tablespoons of blood (20.5 mL) will be taken for research tests      before the biopsy.      Kidney Biopsy: A kidney biopsy is a procedure to remove and examine a small piece of kidney      tissue. For this study, one biopsy will be taken from the new kidney and used specifically      for research. The biopsy will be done at the same time as the biopsies done for routine      care. If there are any complications during the routine care biopsies, the tissue for this      research study will not be taken.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who present for routine care kidney transplant biopsies to the Comprehensive        Transplant Center and who satisfy all of the eligibility criteria are approached for this        research study.|January 2016|January 6, 2016|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531257||91103|
NCT01531283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-07-19-04|Deacylated Ghrelin and Beta Cell Function|Impact of Unacylated Ghrelin on Beta-cell Function in Humans|UAG|University of Cincinnati|Yes|Active, not recruiting|February 2011|||April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 13, 2012|February 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531283||91102|
NCT01555775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFRH/BD/75276/2010|Compared Effect of a Fruit Milk Shake With a Protein-Carbohydrate Supplement on Recovery After Resistance Exercise|Compared Effect of a Fruit Milk Shake With a Protein-Carbohydrate Supplement on Muscle Damage, Inflammation, Oxidative Stress and Functional Recovery, After Resistance Exercise||Universidade do Porto|No|Completed|March 2012|May 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|13|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 15, 2013|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01555775||89232|
NCT01556789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONT-10-001|Phase 1 Study of ONT-10 in Patients With Solid Tumors|Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors||Oncothyreon Inc.|Yes|Completed|March 2013|September 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|70 Years|No|||September 2015|September 15, 2015|March 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556789||89155|
NCT01553149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00703|Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma|A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas||National Cancer Institute (NCI)|Yes|Recruiting|March 2012|||March 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|21 Years|No|||December 2015|March 24, 2016|March 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553149||89433|
NCT01557088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-008161|Lp-PLA2 and Coronary Atherosclerosis in Humans|Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans|AIM 1 and II|Mayo Clinic|Yes|Completed|February 2009|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|166|||Both|18 Years|85 Years|No|||September 2015|September 22, 2015|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01557088||89132|
NCT01553357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CROB0108/1 -- RV-PCL-PI-350|Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia|A Pilot Study of Lenalidomide and Dexamethasone in Patients With Primary Plasma Cell Leukemia||IRCCS Centro di Riferimento Oncologico della Basilicata|Yes|Completed|March 2009|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2012|March 13, 2012|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01553357||89417|
NCT01553877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10066|Development and Acceptability Testing of Ready-to-use-complementary Food Supplement (RUCFS) for Children in Bangladesh|Development and Acceptability Testing of Ready-to-use-complementary Food Supplement (RUCFS) for Children in Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|No|Completed|January 2012|May 2012|Actual|February 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|3||Actual|90|||Both|6 Months|18 Months|Accepts Healthy Volunteers|||March 2012|January 1, 2013|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01553877||89378|
NCT01553890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vitamin D and Scleroderma|Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples|Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at SSc Patients Compared Healthy Peoples|SSc|Meir Medical Center|Yes|Not yet recruiting|March 2012|March 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2012|March 13, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01553890||89377|
NCT01532388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/308-31/5D|Randomized Controlled Trial of eScreen for Problematic Drug Use|Randomized Controlled Trial of eScreen for Problematic Drug Use||Karolinska Institutet|No|Completed|September 2009|May 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|202|||Both|15 Years|N/A|No|||June 2013|June 13, 2013|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01532388||91017|
NCT01533636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-04834|Preventing Fucose-dependent Binding of Aspergillus and Pseudomonas to Lung Mucin|Preventing Fucose-dependent Binding of Aspergillus and Pseudomonas to Lung Mucin|CADET|University of California, San Francisco|No|Recruiting|July 2012|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|Samples With DNA|Samples of induced and expectorated sputum and blood for DNA and RNA extraction, plasma, and      serum will be banked in the UCSF Airway Tissue Bank.|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cystic Fibrosis and Healthy Controls|November 2015|November 10, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533636||90922|
NCT01533948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 197811|Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery|Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma||Roswell Park Cancer Institute|Yes|Completed|January 2012|||July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01533948||90898|
NCT01534247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00012|A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately|A Phase I, Open-Label, 3-way Crossover, Pharmacokinetic and Drug-Drug Interaction Study of Ceftazidime Avibactam (CAZ-AVI) and Metronidazole When Administered Alone and in Combination in Healthy Subjects||AstraZeneca||Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|28|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|February 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01534247||90876|
NCT01534234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITSY06 - RESPOND CRT|Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D|Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D|RESPOND CRT|LivaNova|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1039|||Both|18 Years|N/A|No|||November 2014|November 10, 2014|September 27, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534234||90877|
NCT01534260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110007281; IUCRO-0327|Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype|Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype||Indiana University|Yes|Recruiting|February 2012|||September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534260||90875|
NCT01534533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNSFC-30972472|Effects of Lutein Supplementation on Subclinical Atherosclerosis|The Effects of Lutein Supplementation on Subclinical Atherosclerosis||Peking University|Yes|Completed|June 2010|June 2012|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|192|||Both|45 Years|68 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|February 13, 2012|Yes|Yes||No|July 26, 2012|https://clinicaltrials.gov/show/NCT01534533||90854|
NCT01534806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110808|Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department|A Randomized Double Blinded Study Comparing Use of Prochlorperazine Versus Prochlorperazine and Ketorolac in the Treatment of Pediatric Migraine in the Emergency Department||Akron Children's Hospital|Yes|Withdrawn|January 2012|||January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|18 Years|No|||June 2014|June 23, 2014|November 8, 2011|Yes|Yes|Drug is backordered;|No||https://clinicaltrials.gov/show/NCT01534806||90835|
NCT01534819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anchor Post Market Registry|ANCHOR (Aneurysm Treatment Using the Heli-FX Aortic Securement System Global Registry)|Aneurysm Treatment Using the Heli-FX Aortic Securement System Global Registry|ANCHOR|Medtronic Endovascular|No|Recruiting|April 2012|March 2021|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|Subjects undergoing primary placement of an approved endograft to treat an abdominal        aortic aneurysm or subjects undergoing revision of a previously placed abdominal aortic        endograft.|January 2016|January 29, 2016|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01534819||90834|
NCT01534195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-270-0001|Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model|A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model||ORA, Inc.|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|9|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01534195||90880|
NCT01534208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-300|Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism|An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism||Repros Therapeutics Inc.|No|Completed|May 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|499|||Male|18 Years|65 Years|No|||June 2014|June 27, 2014|February 9, 2012|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01534208||90879|
NCT01534507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11038|Small and Large Bowel Transit Tests Using MRI (Study 1)|Optimising Measurement of Small and Large Bowel Transit During MRI Scanning and Characterising IBS Subtypes and Their Response to Stress Using MRI (Study 1)||University of Nottingham|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Prospective||5|Actual|108|Samples Without DNA|Study 1: no samples Study 2: no samples|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers will be selected via poster advertisement Participants with Irritable        Bowel Syndrome will be selected from the gastroenterology clinics /poster advertisement|August 2014|August 12, 2014|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534507||90856|
NCT01530945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR013359|Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease|Mapping Multidimensional Illness Trajectories of Patients With ESKD||University of North Carolina, Chapel Hill||Completed|March 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|227|||Both|18 Years|N/A|No|Non-Probability Sample|ESKD patients who have been on dialysis|September 2015|September 2, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01530945||91127|
NCT01530958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07399|Kidney Awareness Registry and Education|The Kidney Awareness Registry and Education Study|KARE|University of California, San Francisco|Yes|Active, not recruiting|April 2013|October 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 26, 2014|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01530958||91126|
NCT01531556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-1101|A Study of How Tutin and Hyenanchin, Two Toxins Found in Honey, Are Absorbed and Processed by the Body|An Open-label, Non-randomised Study to Investigate the Pharmacokinetics of Tutin and Hyenanchin, Following Single Dose Administration of Honey Containing Tutin and Hyenanchin to Healthy Male Subjects.||Food Standards Australia New Zealand||Recruiting|January 2012|July 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01531556||91081|
NCT01531881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 66805|Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression|Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression||Roswell Park Cancer Institute|Yes|Active, not recruiting|March 2006|March 2016|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|240|Samples With DNA|saliva, oral mucosal and tongue brushings.|Both|21 Years|99 Years|No|Probability Sample|Dental clinic patients|March 2016|March 1, 2016|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01531881||91056|
NCT01556802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38212050|Use of Minocicline in Patients With Stroke|Effect of Minocicline Use in Less Neurologic Sequels in Patients With Stroke||Hospital Universitario Hernando Moncaleano Perdomo|Yes|Recruiting|October 2011|January 2013|Anticipated|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|85 Years|No|||March 2012|March 15, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01556802||89154|
NCT01556828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMNHL0091|Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing|Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing||Stanford University|Yes|Recruiting|June 2011|April 2015|Anticipated|April 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|whole blood tissue|Both|18 Years|N/A|No|Non-Probability Sample|Eligible subjects will be identified and recruited by referral from that individual's        treating physician, mainly Stanford-affiliated dermatologists, oncologists, and        hematologists.|February 2014|February 19, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01556828||89152|
NCT01557101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEC_cribado_CCR|Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population|Effectiveness of Colon Capsule Endoscopy as Colorectal Cancer Method of Screening in The Familiar-Risk Population|CRIBADO|Hospital Universitario de Canarias|No|Completed|April 2012|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01557101||89131|
NCT01553175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B5|Studying Gene Expression in Samples From Patients With Rhabdoid Tumors|Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors||Children's Oncology Group|No|Active, not recruiting|March 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|25|||Both|N/A|120 Years|No|Non-Probability Sample|Patients diagnosed with rhabdoid tumors|May 2015|September 30, 2015|March 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01553175||89431|
NCT01553604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Micro02|Dressing Wear Time After Breast Augmentation With Prosthesis|Influence of Dressing Wear Time on Skin Colonization After Breast Augmentation With Prosthesis: a Randomized Controlled Trial||Federal University of São Paulo|No|Completed|July 2013|September 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|80|||Female|18 Months|60 Years|Accepts Healthy Volunteers|||February 2016|February 10, 2016|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553604||89398|
NCT01553617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLU-010-C P4|VolulyteTM in Cardiac Surgery|Efficacy and Safety of Perioperative Infusion of 6 % Hydroxyethyl Starch 130/0.4 in an Isotonic Electrolyte Solution (VolulyteTM) vs. 5% HSA as Volume Replacement Therapy During Cardiac Surgery for Adult Patients||Fresenius Kabi|No|Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01553617||89397|
NCT01553383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREC2012.037|Comparison of Nasal Positive End Expiratory Pressure Valve to Dental Device as an Alternative Treatment for Obstructive Sleep Apnea|Comparison of Nasal Positive End Expiratory Pressure Valve to Dental Device as an Alternative Treatment for OSA||Chinese University of Hong Kong|No|Completed|February 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01553383||89415|
NCT01533363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1612|Study About Patient Comfort and Long-term Outcome After Stapled Hemorrhoidopexy|Patient Comfort After Stapled Hemorrhoidopexy Long Term Results of a Randomized Controlled Trial||Universitätsklinikum Hamburg-Eppendorf|No|Completed|July 2000|September 2007|Actual|September 2007|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Both|N/A|N/A|No|||February 2012|February 11, 2012|February 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01533363||90943|
NCT01533649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHOENICS-01|Personalizing Health Outcome in Epilepsy Now - An Introduction to Clinical Services|Pilot Trial: Personalizing Health Outcome in Epilepsy Now - An Introduction to Clinical Services|PHOENICS|University Health Network, Toronto|Yes|Not yet recruiting|April 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|40 Years|No|||February 2012|February 10, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01533649||90921|
NCT01533935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.14|Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.|A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 2]||Boehringer Ingelheim||Completed|February 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|291|||Both|40 Years|75 Years|No|||August 2015|August 12, 2015|February 13, 2012||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01533935||90899|
NCT01533961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDiOXA001|Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158|Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers||Drugs for Neglected Diseases|No|Completed|February 2012|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|136|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2012|September 17, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01533961||90897|
NCT01534273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14464|A Study of LY2886721 in Healthy Participants|Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects||Eli Lilly and Company|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|39|||Both|20 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 9, 2012|February 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01534273||90874|
NCT01547364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SweetCaudal|Caudal Epidural Injection of Dextrose For Low Back Pain|Blinded Analgesic Effect and 1 Year Outcome of Caudal D5W Injection in All-Comers With Chronic Low Back Pain and Either Buttock or Leg Pain||Smigel, Liza, M.D.|Yes|Completed|February 2012|November 2015|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547364||89874|
NCT01547637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Not Assigned yet|Preventing the Obturator Nerve Reflex|Preventing the Obturator Nerve Reflex: A Comparison of Ultrasound Guided Obturator Nerve Block and Classic Anatomic Block Technique.||Milton S. Hershey Medical Center|No|Recruiting|May 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|35 Years|N/A|No|||September 2015|September 30, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01547637||89853|
NCT01555216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00037311|Continuous Tibial Nerve Block Versus Single Shot Tibial Nerve Block|A Randomized Comparison of a Continuous Posterior Tibial Nerve Block and Single Injection Posterior Tibial Nerve Block in Patients Undergoing Forefoot Surgery||Northwestern University|No|Withdrawn|October 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||March 2015|March 26, 2015|October 20, 2011||No|No participants enrolled.|No||https://clinicaltrials.gov/show/NCT01555216||89275|
NCT01555476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IBUPAI1002|Study to Test the Blood to See if a New Medicine is Likely to Provide Pain Relief Similar to a Product Already Sold in Stores|Bioequivalence Between an Ibuprofen Suspension and a Reference Formulation. A Study in Healthy Volunteers.||Johnson & Johnson Consumer and Personal Products Worldwide|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555476||89255|
NCT01544920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07755|Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)|A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects||Merck Sharp & Dohme Corp.|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|737|||Both|18 Years|N/A|No|||June 2015|June 18, 2015|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01544920||90061|
NCT01544933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rtisot01|The Influence of the Ribs on the Gravity of Burst Thoracic Spine Fractures|The Influence of the Ribs on the Gravity of Burst Thoracic Spine Fractures||Universidade de Passo Fundo|Yes|Completed|February 2011|September 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|2|||Both|17 Years|79 Years|No|Non-Probability Sample|patients with burst fractures of the thoracic spine treated by the Hospital Ortopedico de        Passo Fundo|August 2011|March 5, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01544933||90060|
NCT01545479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4111/08|Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition|Renal Oxygen Content is Increased in Healthy Subjects After Angiotensin Converting Enzyme Inhibition||Instituto de Cardiologia do Rio Grande do Sul|No|Completed|January 2010|December 2010|Actual|October 2010|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|5|||Female|45 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 1, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01545479||90018|
NCT01545492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-00882CHIPS-Child|Testing the Developmental Origins Hypothesis|CHIPS-Child:Testing the Developmental Origins Hypothesis|CHIPS-Child|Children's & Women's Health Centre of British Columbia|Yes|Recruiting|January 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|626|Samples With DNA|1. ~150 strands of hair        2. Four buccal swabs|Both|N/A|N/A|No|Non-Probability Sample|Only women participating in the CHIPS RCT and their children born after recruitment are        eligible to participate in CHIPS-Child.|March 2012|March 1, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01545492||90017|
NCT01545193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH11-045|The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade|The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade||NorthShore University HealthSystem Research Institute|No|Completed|June 2011|September 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|300|||Both|18 Years|90 Years|No|Probability Sample|Patients undergoing general anesthesia and surgery|April 2015|April 3, 2015|March 1, 2012||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01545193||90040|
NCT01545440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB27862|A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication||Genentech, Inc.||Completed|March 2012|July 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|258|||Both|18 Years|75 Years|No|||March 2015|March 3, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545440||90021|
NCT01545739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|57|Evia/Entovis HF-T Master Study|Master Study of the Evia/Entovis HF-T Pacemaker||Biotronik SE & Co. KG|No|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|122|||Both|18 Years|N/A|No|Probability Sample|Patients with indication for CRT therapy|October 2014|October 15, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545739||89998|
NCT01545752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-based education|Comparing Interactive and Non-interactive CD-based Method|Comparing Interactive and Non-interactive CD-based Method in Teaching Medical Terminology||Mashhad University of Medical Sciences|No|Terminated|October 2009|June 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|180|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2012|July 11, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01545752||89997|
NCT01546064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTUDIOKEHR|Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity|Prospective and Randomized Trial on the Usefulness of T-Tube in the Bile Duct Anastomosis in Liver Transplantation Procedure.||Hospital Universitario La Fe|No|Completed|May 2008|July 2011|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|67 Years|No|||March 2012|March 1, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01546064||89974|
NCT01546077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLOCSTIM1|Placement of Perineural Catheters in the Popliteal Region|Comparison of Techniques for Placement of Perineural Catheters in the Popliteal Region||Attikon Hospital||Recruiting|January 2012|||March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||November 2012|November 9, 2012|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01546077||89973|
NCT01546298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGU-0757|Immune Reactions in Contact Dermatitis Affected Skin|Analysis of Immune Reactions Occurring Upon Administration of Patch Tests and Contact Dermatitis Affected Skin||Rockefeller University|No|Recruiting|January 2012|November 2026|Anticipated|November 2026|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Patch tests of skin|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Allergic Contact Dermatitis|August 2015|August 11, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546298||89956|
NCT01546311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IST1387 PADSII|Evaluation of a Pro-Active Dynamic Accommodating Socket||PADS|Infoscitex Corporation||Recruiting|January 2012|December 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|5|||Both|18 Years|80 Years|No|Non-Probability Sample|Persons with transfemoral or transtibial amputation who have been using a prosthesis for        at least one month will be recruited for this study.|March 2012|March 2, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546311||89955|
NCT01554488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-20-11S|Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease|Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease|InFLOW|VA Office of Research and Development|Yes|Terminated|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|58|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|February 29, 2012||No|Low subject accrual|No||https://clinicaltrials.gov/show/NCT01554488||89331|
NCT01554215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mom Power|Mom Power is an Attachment Based Parenting Program for Families and Their Children|Phase 1 of Mom Power: Attachment Based Parenting and Self-Care Skills Program|MP|University of Michigan|Yes|Recruiting|October 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|15 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554215||89352|
NCT01554228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obes_Sur_Cog|Change in Cognitive Function in Obese Patients After Bariatric Surgery - an Observational Study|Change in Cognitive Function in Obese Patients After Bariatric Surgery - an Observational Study|Obesity|Charite University, Berlin, Germany|No|Recruiting|August 2011|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|64|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients from the surgery department of the Charite Universtiy Berlin|March 2016|March 15, 2016|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01554228||89351|
NCT01554501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0710003159|The Role of Stress in Self-Control, Coping, and Emotion Regulation|The Role of Stress in Self-Control, Coping and Emotion Regulation||Yale University|Yes|Active, not recruiting|November 2007|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|2500|Samples With DNA|Blood taken for understanding genetic factors.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|July 2015|July 28, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01554501||89330|
NCT01555047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJU127|Correlation Among Sperm DNA Fragmentation, Genitourinary Infection by Mycoplasma in Male and the Pregnancy Outcomes After IUI in Their Partner|||Nanjing Medical University|Yes|Active, not recruiting|September 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|200|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01555047||89288|
NCT01554813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hualanbio-influenza III-001|Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)|A Single - Blind, Randomized, - Controlled Clinical Trial With Inactivated Influenza Vaccine (Split Virion) (0.5ml Formulation)||Hualan Biological Engineering, Inc.|Yes|Completed|May 2006|October 2006|Actual|July 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|900|||Both|6 Months|N/A|Accepts Healthy Volunteers|||March 2012|September 4, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554813||89306|
NCT01554826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hualanbio-influenza III-002|Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)|A Double - Blind, Randomized, - Controlled Clinical Trial With Inactivated Influenza Vaccine (Split Virion)(0.25ml Formulation for Pediatric Use)||Hualan Biological Engineering, Inc.|Yes|Completed|March 2009|February 2010|Actual|May 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|810|||Both|6 Months|36 Months|Accepts Healthy Volunteers|||April 2012|September 4, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554826||89305|
NCT01545089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/LD-02|Use of a Fabric Mattress Cover for Patient Comfort|Use of a Fabric Mattress Cover for Patient Comfort||Centre Hospitalier Universitaire de Nīmes|No|Completed|July 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|174|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545089||90048|
NCT01545362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-004|Effect of Preop Nutritional Status on Outcomes of Staged Bilateral Total Knee Arthroplasty|The Effect of Preop Nutritional Status on Outcomes of Staged Bilateral Total Knee Replacements Performed Within One Week||Heekin Orthopedic Research Institute|No|Active, not recruiting|November 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|21 Years|N/A|No|Non-Probability Sample|Cohort selected from patients in orthopaedic clinic|March 2015|March 30, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545362||90027|
NCT01545375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115597|Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children|Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants||GlaxoSmithKline|Yes|Active, not recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1800|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545375||90026|
NCT01545960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R21AT005249-03|Evaluating Acupuncture Points With Scanning Kelvin Probe|Scanning Kelvin Probe Measurements of Acupuncture Point||Massachusetts General Hospital|No|Suspended|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|24|Samples With DNA|Whole Blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy volunteers|March 2012|March 2, 2012|March 2, 2012||No|Adjusting minor software glitches|No||https://clinicaltrials.gov/show/NCT01545960||89982|
NCT01547091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alliancells-1|Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis|Clinical Trial of Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation for Rheumatoid Arthritis-Phase I/II|RA|Alliancells Bioscience Corporation Limited|No|Recruiting|April 2013|December 2014|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|200|||Both|18 Years|70 Years|No|||March 2013|June 26, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01547091||89895|
NCT01548339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252/08 CHV|Laparoscopic Cholecystectomy for Acute Cholecystitis After 72 Hours of Symptoms|Laparoscopic Cholecystectomy for Acute Cholecystitis: is the Rule of 72 Hours Still Actual?||University of Lausanne Hospitals|No|Terminated|February 2009|October 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|86|||Both|16 Years|N/A|No|||December 2015|December 29, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548339||89799|
NCT01548599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shamba Maisha|Shamba Maisha: Pilot Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya|Shamba Maisha: Pilot Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya|Shamba|University of California, San Francisco|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|140|||Both|18 Years|49 Years|No|||August 2014|August 19, 2014|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548599||89779|
NCT01554033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0902-023-271|Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN)|Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN).||Seoul National University Hospital|Yes|Recruiting|May 2009|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples With DNA|serum-60ml urine-60ml Formation study of Lymphoblast and diagnosis of a Huntington gene|Both|1 Year|80 Years|Accepts Healthy Volunteers|Probability Sample|primary care clinic|March 2012|March 16, 2012|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01554033||89366|
NCT01554371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol Number11996|Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies|A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies||University of California, San Francisco|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|80 Years|No|||March 2015|March 4, 2015|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554371||89340|
NCT01555502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRQOL VATS lobectomy|Health Related Quality of Life After Video Assisted Thoracoscopic Lobectomy for Lung Cancer|||University of Alberta|Yes|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with operable early stage NSCLC by the VATS approach who are referred to the        Thoracic surgery Center in Edmonton, Alberta, Canada.|May 2015|May 26, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01555502||89253|
NCT01555515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-001-03|Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant|Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in End Stage Renal Disease (ESRD) Dialysis Patients Using EPODURE Biopump||Medgenics Medical Israel Ltd.|No|Terminated|March 2012|April 2014|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|75 Years|No|||October 2015|October 20, 2015|March 13, 2012||No|New protocol to start with improved product|No||https://clinicaltrials.gov/show/NCT01555515||89252|
NCT01544946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sucrose3415|Trial of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Nasopharyngeal Aspiration|A Randomized Double-blind Trial Comparing the Effect on Pain of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Nasopharyngeal Aspiration||St. Justine's Hospital|No|Completed|February 2012|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|1 Month|3 Months|Accepts Healthy Volunteers|||December 2015|December 21, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01544946||90059|
NCT01545466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001654|Non-drug Interventions for Migraines|Mindfulness Based Stress Reduction for Adults With Migraines: A Pilot Study||Brigham and Women's Hospital|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01545466||90019|
NCT01545453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB27864|A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication||Genentech, Inc.||Completed|March 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|205|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545453||90020|
NCT01545765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR29103|Anesthetic Effect Duration Assessment|Anesthetic Effect Duration Produced by Lidocaine 7% + Tetracaine 7% Cream on 2 Different Body Areas||Galderma|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 25, 2013|February 24, 2012|Yes|Yes||No|June 25, 2013|https://clinicaltrials.gov/show/NCT01545765||89996|No limitation or caveat on this study
NCT01546610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1348/09|Rheumatoid Foot Insole|Effect of Rheumatoid Foot Insole||Federal University of São Paulo|Yes|Recruiting|November 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|65 Years|No|||March 2012|March 8, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546610||89932|
NCT01546623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-144-SR(6M)IP/CPH-002|A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy|A Phase 3, Multi-center, Randomized, Open-label, Parallel-group, Comparative Study of TAP-144-SR (3M) to Evaluate Hormone Dynamics, Pharmacokinetics, Safety and Efficacy of TAP-144-SR (6M) 22.5 mg Subcutaneous Injection for 48 Weeks in Prostate Cancer Patients Previously Treated With Hormonal Therapy||Takeda|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Male|20 Years|85 Years|No|||June 2015|June 24, 2015|February 28, 2012||No||No|April 2, 2015|https://clinicaltrials.gov/show/NCT01546623||89931|
NCT01546909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVX01C|Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE|Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE||Sanofi Pasteur MSD|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|278|||Both|11 Years|13 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546909||89909|
NCT01553968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2-069|Effects of Acute Exercise on Acetylcarnitine Concentration in Endurance Trained and Untrained Subjects|Effects of Acute Exercise on Acetylcarnitine Concentration in Endurance Trained and Untrained Subjects||Maastricht University Medical Center|No|Recruiting|April 2012|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|13|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01553968||89371|
NCT01554527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F029661-00|Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children|Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children||University of Michigan|Yes|Recruiting|March 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|5 Years|12 Years|No|||December 2015|December 2, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554527||89328|
NCT01554514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LDrituximab|Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura|Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency||Washington University School of Medicine|No|Recruiting|August 2012|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||December 2014|October 1, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554514||89329|
NCT01555073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00004604|Preemptive Analgesia Following Uterine Artery Embolization|A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization||Northwestern University|No|Terminated|October 2011|October 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|23|||Female|18 Years|65 Years|No|||September 2014|September 11, 2014|October 14, 2011||No|Subjects did not meet inclusion criteria|No|September 11, 2014|https://clinicaltrials.gov/show/NCT01555073||89286|Early termination due to lost of follow-up for primary outcome at 3 months
NCT01545661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SINET study|Utility of Sputum Induction and Novel Technologies to Improve TB Diagnosis in a High HIV Prevalence Primary Care Setting|A Randomised Control Trial of Sputum Induction, and New and Emerging Technologies in a High HIV Prevalence Primary Care Setting|SINET|University of Cape Town|Yes|Completed|August 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|517|||Both|18 Years|N/A|No|||December 2012|December 21, 2012|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01545661||90004|
NCT01553760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0163-11-MMC|The Use of an Anterior Chamber Maintainer as a Sole Fluid Source in Micro Incision Cataract Surgery as Compared to a Standard Phacoemulsification Procedure|||Meir Medical Center|No|Not yet recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01553760||89386|
NCT01554345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-04-30-11624|Effect of Vitamin E+Selenium on Kidney Function in Controlled Hypotension|Assessment of Preventive Effect of Vitamin E +Selenium on Acute Kidney Injury Through NGAL in Patients Undergoing Controlled Hypotension During Neurosurgery Operations||Tehran University of Medical Sciences|Yes|Recruiting|June 2011|||August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01554345||89342|
NCT01554358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TWCHC09-01|Tianjin Gestational Diabetes Prevention Program (TGDPP)|Lifestyle and Genetic Factors on Diabetes Risk in Women With GDM After Delivery: Tianjin Gestational Diabetes Prevention Program (TGDPP)|GDM|Tianjin Women and Children's Health Center|Yes|Recruiting|August 2009|||July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|1180|||Female|20 Years|49 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01554358||89341|
NCT01554579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-004|A Four-Week Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Subjects With Osteoarthritis of the Knee|||Afferent Pharmaceuticals, Inc.|Yes|Completed|March 2012|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|190|||Both|40 Years|80 Years|No|||January 2014|January 6, 2014|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554579||89324|
NCT01554592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-02/12|Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study|Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study.||The Alfred|No|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01554592||89323|
NCT01554930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907001-3|Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease|A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease||Jiangxi Qingfeng Pharmaceutical Co. Ltd.|Yes|Completed|May 2010|December 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|230|||Both|1 Year|13 Years|No|||March 2012|March 14, 2012|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01554930||89297|
NCT01555203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R44HL074485-04|A Multiple Health Behavior Change Internet Program for College Students|A Multiple Health Behavior Change Internet Program for College Students||Pro-Change Behavior Systems|No|Completed|November 2009|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|1877|||Both|17 Years|25 Years|No|||April 2015|April 27, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01555203||89276|
NCT01556308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AOI-02|Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara|Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara||Centre Hospitalier Universitaire de Nice|No|Completed|March 2012|October 2013|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|1 Year|N/A|No|||March 2012|July 28, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556308||89192|
NCT01545518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052646|IVIG Treatment for Refractory Immune-Related Adult Epilepsy|IVIG Treatment for Refractory Immune-Related Adult Epilepsy||Emory University|No|Terminated|November 2011|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|50 Years|No|||August 2014|August 21, 2014|November 30, 2011|Yes|Yes|Futility criteria, unable for Phase 2 of study, & phase 1 was terminated.|No|August 21, 2014|https://clinicaltrials.gov/show/NCT01545518||90015|Study was terminated early. Subject eligibility for phase 2 not available.
NCT01545804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105063MB|Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma|Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial||National Taiwan University Hospital|No|Active, not recruiting|August 2011|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|20 Years|N/A|No|||October 2015|October 14, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545804||89993|
NCT01545791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1952|Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes|A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Patients Using Insulin Detemir for the Treatment of Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study - Predictable Results and Experience in Diabetes Through Intensification and Control to Target: An International Variability Evaluation|PREDICTIVE™|Novo Nordisk A/S|No|Completed|May 2006|February 2008|Actual|February 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1037|||Both|N/A|N/A|No|Non-Probability Sample|Any patient with type 1 or type 2 diabetes mellitus was eligible for the study, including        newly diagnosed patients who had never received insulin or an insulin analogue before|March 2012|March 6, 2012|March 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01545791||89994|
NCT01546090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|390553|Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block|Effect of Preoperative Alprazolam on the Success of Inferior Alveolar Nerve Block for Teeth With Irreversible Pulpitis||Isfahan University of Medical Sciences|Yes|Completed|March 2011|February 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 6, 2012|March 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01546090||89972|
NCT01545778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100822|Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)|Risk of Shopping Behavior of Tapentadol IR Immediate-Release (IR) Compared to Oxycodone IR Immediate-Release (IR)||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|February 2010|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|646620|||Both|18 Years|N/A|No|Non-Probability Sample|Opioid naive patients exposed to tapentadol IR or oxycodone IR from July 2009 to December        2010 who did not fill any other opioid prescription within 4 days on or after the index        date. The index date is the date of the first prescription for tapentadol IR or oxycodone        IR after June 30, 2009. A naive patient is a patient who has not received an opioid of any        type in the 3 months before the index date.|October 2012|October 26, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01545778||89995|
NCT01546636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH10-184|The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position|The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position||NorthShore University HealthSystem Research Institute|No|Completed|November 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|90 Years|No|||March 2015|March 11, 2015|March 2, 2012||No||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01546636||89930|There were no technical limitations to the trial
NCT01546649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-144-SR(6M)IP/CPH-202|A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer|||Takeda||Completed|April 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|167|||Female|20 Years|N/A|No|||October 2015|October 22, 2015|February 28, 2012||No||No|October 22, 2015|https://clinicaltrials.gov/show/NCT01546649||89929|
NCT01546922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 35668.042.11|Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)|A Randomized Double Blind Cross-over Study of the Effects of Low Dose and High Dose Hydrocortisone Replacement Therapy on Cognition, Quality of Life, Metabolic Profile and Somatosensation in Patients With Secondary Adrenal Insufficiency|SUPREME CORT|University Medical Center Groningen|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|75 Years|No|||June 2014|June 10, 2014|February 7, 2012||No||No|April 25, 2014|https://clinicaltrials.gov/show/NCT01546922||89908|
NCT01554241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DinNH2012|Optimizing Vitamin D in the Elderly|Optimizing Vitamin D in the Elderly||University of California, San Francisco|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|86|||Both|65 Years|N/A|No|||February 2015|February 13, 2015|March 12, 2012||No||No|January 23, 2015|https://clinicaltrials.gov/show/NCT01554241||89350|
NCT01546766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA IRB#11-002987|Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)|Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy.||University of California, Los Angeles|No|Recruiting|February 2007|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|315|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|145 normal adults 270 adults with diabetic retinopathy 50 adults with retinal conditions|December 2014|December 15, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546766||89920|
NCT01546779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5583-OE-CTIL|The Use of Visual Feedback in Airway Clearance|The Immediate Effect of Resistive Expiration Via "Volumetric Incentive Spirometer" on Lung Function in Patients With Cystic Fibrosis.||Sheba Medical Center|No|Completed|December 2008|July 2009|Actual|June 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|5 Years|65 Years|No|||March 2012|March 1, 2012|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01546779||89919|
NCT01554839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB#01165|The Family of Heroes: an Evaluation of an Online Educational Tool|The Family of Heroes Program for Veterans and Their Families: An Evaluation of an Online Educational Tool for Helping Veterans.||Department of Veterans Affairs, New Jersey|No|Completed|October 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|N/A|No|||June 2013|February 9, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01554839||89304|
NCT01554852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2009-010956-93|Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients|Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance|Myeloma XI|University of Leeds|Yes|Recruiting|May 2010|||September 2017|Anticipated|Phase 3|Interventional|N/A|2||Anticipated|1970|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01554852||89303|
NCT01548586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-52|Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex|Modulation de l'excitabilité Des Aires Corticales Motrices Primaires Correspondant Aux hémi Diaphragmes à l'Aide de la tDCS (Transcranial Direct Current Stimulation)||Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|January 2012|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|October 5, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01548586||89780|
NCT01553513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMU|PET/CT for the Quantification of Atherosclerotic Plaque Inflammation|PET/CT for the Quantification of Atherosclerotic Plaque Inflammation in Patients With Coronary Heart Disease: The QAEK Trial|QAEK|Ludwig-Maximilians - University of Munich|No|Not yet recruiting|June 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|140|Samples With DNA|A 20 ml blood sample will be obtained from each patient. The following biomarkers will be      assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol,      triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP,      resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin,      fetuin, FGF21.      ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum      markers.|Both|50 Years|N/A|No|Probability Sample|Patients with stable coronary artery disease or with acute coronary syndrome|March 2012|March 13, 2012|March 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01553513||89405|
NCT01553526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1101|BIOFLOW-III All-comers Orsiro Safety and Performance Registry|BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III|BIOFLOW-III|Biotronik AG|No|Active, not recruiting|August 2011|June 2017|Anticipated|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1356|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers patient population with all subjects requiring coronary revascularization with        a Drug Eluting Stent (DES)|March 2015|March 23, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01553526||89404|
NCT01553773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESPMP#1|Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment|Hyaluronic Acid Concentration in Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment: Double-blind and Randomized Clinical Trial of Efficacy||Federal University of São Paulo|Yes|Completed|July 2004|March 2005|Actual|March 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Female|45 Years|55 Years|No|||March 2012|March 13, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01553773||89385|
NCT01554631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16025|A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg|Randomized, Non-blinded, 3-fold Crossover Study to Investigate the Bioequivalence Between Glucobay ODT 100 mg Taken Without and With Water and the Glucobay Standard Tablet 100 mg Following Single Oral Dosing in Healthy Male Subjects||Bayer|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|34|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01554631||89320|
NCT01554644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPM-I-H-0910|Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients|A Randomized, Double-Blind Exploratory Pilot Study Comparing Prontosan(TM) Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients||B. Braun Medical Inc.|No|Withdrawn|March 2012|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 15, 2013|March 6, 2012||No|Lack of Enrollment|No||https://clinicaltrials.gov/show/NCT01554644||89319|
NCT01555229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00912-37|Effect of Intermittent Versus Continuous Subglottic Secretion Drainage on Tracheal Mucosa Damages|Randomized, Single Blind Study Comparing the Effect of Intermittent Versus Continuous Subglottic Secretion Drainage on Tracheal Mucosa Damages in Intensive Care Patients Requiring Prolonged Mechanical Ventilation|ASPIRE|Rennes University Hospital|No|Terminated|August 2011|September 2015|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|No|||April 2015|September 16, 2015|July 1, 2011||No|Enrolment difficulties|No||https://clinicaltrials.gov/show/NCT01555229||89274|
NCT01545817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114907|Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma|Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment|CATChEz|Novartis|No|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01545817||89992|
NCT01546103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008075|Vitamin D3 Supplementation Pilot Study|Pilot Study of Vitamin D3 Supplementation and Outcomes in Vitamin D Deficient Obese, African American Adolescents||Children's Hospital of Philadelphia|No|Completed|August 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||January 2013|January 22, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01546103||89971|
NCT01546324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVF013|Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing|Prenatal Diagnosis of Fetal DNA Isolated From Maternal Plasma||Natera, Inc.|No|Completed|February 2012|August 2013|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|16|Samples With DNA|Blood|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women 18 years of age or older who used Natera (formerly Gene Security Network)'s        Preimplantation Genetic testing (PGS/PGD) to achieve their current pregnancy.|August 2013|August 8, 2013|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01546324||89954|
NCT01546948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH11-232|Intraoperative Opioids and Postoperative Recovery After Hepatobiliary or Foregut Surgery|Intraoperative Opioids and Postoperative Recovery After Hepatobiliary or Foregut Surgery||NorthShore University HealthSystem Research Institute|No|Active, not recruiting|August 2011|December 2015|Anticipated|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|80 Years|No|||March 2015|March 11, 2015|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01546948||89906|
NCT01547234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0081-CTIL|Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis|Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis||Carmel Medical Center|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|47|||Both|18 Years|70 Years|No|Non-Probability Sample|MS patients visiting the Multiple Sclerosis Clinic at the Carmel Medical Center, Haifa|February 2015|February 3, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01547234||89884|
NCT01547221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKH24-01-2555|Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients|Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients: a Randomized Controlled Trial||Khon Kaen Hospital|Yes|Completed|March 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|7 Years|N/A|No|||April 2015|April 27, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01547221||89885|
NCT01554254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA127-2010-002|Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation|Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation||US Biotest, Inc.||Withdrawn|March 2012|||December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|6 Months|20 Years|No|||December 2013|December 18, 2013|March 12, 2012|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01554254||89349|
NCT01554267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|127891|The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability|The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction|ICG|Stony Brook University|No|Recruiting|January 2014|May 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|45|||Female|18 Years|N/A|No|||May 2014|May 12, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554267||89348|
NCT01547351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QSC02-ARMS-01|Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire|Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire - A Phase 4 Pilot Study|ARMS|Mallinckrodt||Completed|December 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|103|||Both|18 Years|N/A|No|Non-Probability Sample|Clinical practice setting, including academic medical centers and private practices in the        US|October 2015|October 21, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01547351||89875|
NCT01547624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ultrasound on neck muscles WAD|Neck Muscle Activation in Patients With Long Standing Problems After a Whiplash Trauma Registered With Ultrasound With Speckle Tracking|||Linkoeping University|Yes|Completed|February 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Anticipated|60|||Both|18 Years|63 Years|Accepts Healthy Volunteers|||March 2016|March 6, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01547624||89854|
NCT01544777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOF-1|Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study|Visual Quality Following Aspheric and Monovision Lens Implantation - a Comparative Clinical Study|751|Hoya Surgical Optics, Inc.|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|40 Years|N/A|No|||August 2012|March 23, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01544777||90072|
NCT01544790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35048.041.11|Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy|Robot-assisted Minimally Invasive Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer. The ROBOT-trial: a Monocenter Randomized Controlled Trial.|ROBOT|UMC Utrecht|Yes|Recruiting|January 2012|January 2021|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|75 Years|No|||October 2014|October 7, 2014|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01544790||90071|
NCT01553292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:016|Early CPAP And Large Volume Minimally Invasive Surfactant (ECALMIST) in Preterm Infants With RDS|Feasibility of Using Early CPAP (Continuous Positive Airway Pressure) And Large Volume Minimal Invasive Surfactant Therapy (ECALMIST) in Preterm Infants With Respiratory Distress Syndrome (RDS)|ECALMIST|University of Manitoba|Yes|Completed|April 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|N/A|24 Hours|No|||June 2013|June 18, 2013|March 6, 2012||No||No|October 5, 2012|https://clinicaltrials.gov/show/NCT01553292||89422|This is non randomized interventional feasibility trial, small sample size and in one center
NCT01553799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UST12|Use of Ultrasound Technology to Check Proper Placement of Tracheal and Endobronchial Tubes|||King Saud University||Not yet recruiting|April 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|50 Years|No|Probability Sample|all adult of both sexes|March 2012|March 12, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553799||89383|
NCT01554046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-8292-DG-CTIL|The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)|The Effect of Methylphenidate (Ritalin IR) Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)||Sheba Medical Center|No|Recruiting|October 2011|December 2022|Anticipated|March 2022|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|6 Years|65 Years|No|||March 2012|March 11, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01554046||89365|
NCT01554059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHMO-03|Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients|Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma|New Beat|Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Completed|March 2012|August 2014|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|70 Years|No|||November 2014|November 7, 2014|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01554059||89364|
NCT01554384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBNEATXpertRCT|Trial of Point-of-treatment Xpert MTB/RIF Assay|Multicentre Randomised Control Trial of Point-of-treatment (Clinic-based) Xpert MTB/RIF Assay|TBNEATXpert|University of Cape Town|Yes|Completed|October 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1472|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|July 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01554384||89339|
NCT01554943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE1740|Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients|Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years)||Jules Bordet Institute|No|Completed|July 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|73|||Female|18 Years|90 Years|No|||August 2013|August 29, 2013|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01554943||89296|
NCT01556048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA08/09-07|Pilot Study of Behavioral Activation for Prolonged Grief|||University of Nevada, Las Vegas|No|Completed|February 2009|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|21 Years|N/A|No|||December 2014|December 1, 2014|March 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556048||89211|
NCT01556581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|363397|Comparative Effectiveness of Early Physical Therapy Versus Usual Care for Low Back Pain|Effectiveness and Subsequent Healthcare Use Associated With Early Physical Therapy Access Compared With a Stepped Usual Care Approach for Treatment of Low Back Pain.|COMPETE|Madigan Army Medical Center|No|Active, not recruiting|September 2013|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|60 Years|No|||February 2016|February 2, 2016|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01556581||89171|
NCT01556815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongCHI-001|Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma|Phase II Trail of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma||Shandong Cancer Hospital and Institute|No|Not yet recruiting|May 2012|May 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||April 2012|April 24, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01556815||89153|
NCT01546116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTER_114093|Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)|Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance|ALTER|Korea University|Yes|Completed|February 2010|February 2014|Actual|February 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|December 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546116||89970|
NCT01546129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOCS001|Effect of Dianatal Obstetric Gel (Cross-linked Polyacrylic Acid) on Outcomes in Vaginal Delivery|Effect of Dianatal Obstetric Gel (Cross-linked Polyacrylic Acid) on Outcomes in Vaginal Delivery||Rabin Medical Center||Not yet recruiting|April 2012|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|180|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2012|March 6, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546129||89969|
NCT01546363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYNCVX0002|Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer|Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer||Stanford University|Yes|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|Samples With DNA|Blood Tissue|Both|18 Years|N/A|No|Non-Probability Sample|Recruitment of patients for participation in this study will occur at Stanford Medical        Center. All facilities are adequately equipped to meet all study requirements. Patients of        this disease type are regularly treated at Stanford Cancer Center. Estimated accrual rates        are based on normal patient flow.|March 2015|March 30, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546363||89951|
NCT01546350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reprogenetics study 389|Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH|Comparison of Standard ART Practice vs. Trophectoderm Biopsy, Array CGH Analysis, and Day-6 Replacement of a Single Euploid Embryo||Reprogenetics|Yes|Suspended|March 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|200|||Female|32 Years|42 Years|No|||May 2013|August 20, 2013|March 2, 2012||No|not enough patients recruited on time|No||https://clinicaltrials.gov/show/NCT01546350||89952|
NCT01546337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCTIRS908111|Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome|Search for Predictive Markers of Efficacy of Epoetin Beta (NEORECORMON) in the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Chemotherapy or Myelodysplastic Syndrome|EPO|Rennes University Hospital|No|Terminated|May 2008|November 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Non-myeloid haemopathy or Myelodysplastic Syndromes patients with anemia, who needs ESAs        treatment|March 2012|March 6, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546337||89953|
NCT01546662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EB-RH-02-11|A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.|A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.|EB-RH-02-11|Enovate Biolife Pvt Ltd|No|Recruiting|October 2011|June 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|54|||Both|18 Years|60 Years|No|||March 2012|March 2, 2012|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546662||89928|
NCT01547247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 03|Cap-assisted Water Immersion Versus Water Immersion Colonoscopy|Cap-assisted Water Immersion Versus Water Immersion Minimal Sedation Colonoscopy - a Prospective, Randomized, Single-center Trial||Vitkovice Hospital|No|Completed|January 2012|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|208|||Both|18 Years|N/A|No|||October 2015|October 4, 2015|February 26, 2012||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT01547247||89883|There were no complications recorded in the study.
NCT01544517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2010-02464415|5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection|Five-day Concomitant Versus 10-day Sequential Therapy for Eradication of Helicobacter Pylori Infection: a Randomized Trial of Levofloxacin-based Regimens||Second University of Naples|Yes|Completed|January 2011|December 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|80 Years|No|||February 2012|March 5, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01544517||90092|
NCT01546207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0045|Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia|Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia|STRATUM VT|Icahn School of Medicine at Mount Sinai|Yes|Terminated|September 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|18 Years|90 Years|No|||March 2014|March 24, 2014|February 13, 2012||No|low enrollment|No|August 20, 2013|https://clinicaltrials.gov/show/NCT01546207||89963|Early termination due to poor enrollment. Data analysis not done - there is not enough data for meaningful analysis.
NCT01547819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120082|Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder|Imaging the GABAergic System Using 11C-flumazenil PET to Assess the Role of Mild Traumatic Brain Injury in the Development of Post Traumatic Stress Disorder||National Institutes of Health Clinical Center (CC)||Withdrawn|February 2012|December 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|February 19, 2014|March 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01547819||89839|
NCT01556958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iS-2012-Wz|WheezoMeter® Correlation Study|Prospective Comparative Study of WheezeRATE™ (Wz%) Readings With Spirometry, Symptoms, and Auscultatory Findings in Children With Wheezing.||iSonea||Terminated|March 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|19|||Both|N/A|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pediatric Specialty Clinic|August 2013|August 16, 2013|March 15, 2012||No|Device revised|No||https://clinicaltrials.gov/show/NCT01556958||89142|
NCT01548027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|752/2554|Surgical Transversus Abdominis Plane Block in Pediatric Patients|Efficacy of Surgical Transversus Abdominis Plane Block for Postoperative Pain Relief Following Abdominal Surgery in Pediatric Patients.|TAP|Mahidol University|Yes|Completed|July 2012|July 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|N/A|15 Years|Accepts Healthy Volunteers|||July 2014|July 30, 2014|March 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01548027||89823|
NCT01553279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI01C|Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines|A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine||Sanofi Pasteur MSD|No|Completed|March 2012|March 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|284|||Both|46 Days|74 Days|Accepts Healthy Volunteers|||March 2014|March 18, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01553279||89423|
NCT01553045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMURF|Reasons for Variations in Health Related Quality of Life and Symptom Burden in Patients With Atrial Fibrillation|Observational Study of the Variation in Health-related Quality of Life and Symptom Burden in Patients Accepted for Catheter Ablation of Atrial Fibrillation in Relation to Biomarkers, Intracardiac Pressures and Echocardiography.|SMURF|University Hospital, Linkoeping|Yes|Active, not recruiting|November 2011|June 2015|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood samples will be drawn from femoral vein, CS and LA (baseline sampling).      Concerning sub-study: After the induction of AF and after the patient has maintained AF in      30 minutes blood samples will be drawn in the exact same way as before the induction in the      intervention group.      Patients who are going to be randomized to control group after the baseline blood sampling,      are going to be monitored in about 30 minutes to examine whether they maintain sinus rhythm      (SR) under that time. No intervention, clinical or experimental is going to be made during      that time. After those 30 minutes, blood samples are going to be drawn in the exact same way      as before.      Blood to be analyzed for biomarkers will be froozen to -70 degress and analyzed when the      study is completed.|Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for catheter ablation of atrial fibrillation for the first time.|December 2014|December 2, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01553045||89441|
NCT01553539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 71108|Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery|A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas||Comprehensive Cancer Center of Wake Forest University|No|Completed|October 2009|||January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|March 9, 2012|Yes|Yes||No|November 15, 2013|https://clinicaltrials.gov/show/NCT01553539||89403|
NCT01553786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVAIL|Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)|STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)||The Lymphoma Academic Research Organisation|No|Recruiting|November 2011|March 2020|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|60 Years|80 Years|No|||November 2015|November 12, 2015|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01553786||89384|
NCT01554397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTERTECC|Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer|Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma||University of California, San Diego|Yes|Recruiting|September 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|425|||Female|18 Years|N/A|No|||December 2014|December 1, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01554397||89338|
NCT01554657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108280|Five Versus Seven Day Antibiotic Course for the Treatment of Pneumonia in the Intensive Care Unit|||Washington University School of Medicine|Yes|Completed|January 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01554657||89318|
NCT01555788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8829|DiaPort Closed-Loop Artificial Pancreas|Closed Loop Artificial Pancreas Using Intraperitoneal (IP) Insulin Via DiaPort®||University Hospital, Montpellier|No|Completed|February 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||December 2014|December 2, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01555788||89231|
NCT01556334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEACE Trial-1011004323|Erythromycin Versus Azithromycin in Preterm Premature Rupture of Membranes|Preterm Premature Rupture of Membranes: Erythromycin Versus Azithromycin a Randomized Trial Comparing Their Efficacy to Prolong Latency (PEACE Trial)|PEACE|Indiana University|Yes|Withdrawn|April 2010|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|No|||March 2014|March 4, 2014|March 14, 2012||No|Terminated before starting due to need for IND determined by FDA.|No||https://clinicaltrials.gov/show/NCT01556334||89190|
NCT01556594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMG102|Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia|Phase II Study to Investigate the Safety and Efficacy of 2 Dose Levels of a Novel Glucagon Formulation Compared to Commercially Available Glucagon in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia|AMG102|Locemia Solutions ULC|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|55 Years|No|||August 2014|August 9, 2014|March 15, 2012|Yes|Yes||No|March 18, 2013|https://clinicaltrials.gov/show/NCT01556594||89170|
NCT01546142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-11-23|Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area||Kythera Biopharmaceuticals|No|Completed|March 2012|August 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|516|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|February 24, 2012|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01546142||89968|
NCT01546155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P0022171|The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials|The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials||Massachusetts General Hospital|No|Active, not recruiting|December 2011|December 2015|Anticipated|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|10|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||April 2015|April 6, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01546155||89967|
NCT01546376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THAIHIV001|Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients|Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients||Rajavithi Hospital|No|Recruiting|August 2009|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|HIV positive cancer patients Curative RT treatment|January 2009|March 6, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546376||89950|
NCT01546389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0027|Sanaria™ PfSPZ Challenge Vaccine|A Phase I, Randomized Malaria Challenge Study of Intradermally-Administered Infectious (Replication-intact), Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) in Malaria-Naïve Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2013|September 12, 2013|December 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01546389||89949|
NCT01546675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9227-P|Interface Kinematics of Transhumeral Prosthetic Sockets Using XROMM|Interface Kinematics of Transhumeral Prosthetic Sockets Using XROMM||VA Office of Research and Development|No|Completed|January 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|February 27, 2012||No||No|October 17, 2014|https://clinicaltrials.gov/show/NCT01546675||89927|These results cannot be generalized outside of this small sample and may have been different if the intervention socket had been optimized. Additional research is needed to expand our understanding of the impact of prosthetic socket designs.
NCT01546935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEA022|Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One|SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study.||University of Oxford|Yes|Withdrawn|December 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|12 Months|No|||July 2013|July 26, 2013|March 1, 2012||No|Study drugs (Oseltamivir suspension from Roche) were unavailable|No||https://clinicaltrials.gov/show/NCT01546935||89907|
NCT01547559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5010-2007005|Research for Prevention and Treatment of NSAIDs Related Gastrointestinal Side Effects|Evaluation of Preventive and Treatment Effects of Hp Eradication and Teprenone in Patients Taking NSAIDs||Sun Yat-sen University|Yes|Active, not recruiting|June 2007|||November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|7||Actual|369|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2014|October 20, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01547559||89859|
NCT01553994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|condylomaeffect001|Effectiveness Study of Gardasil on Condyloma|Gardasil® Population-Based Condyloma Effectiveness Study In Swedish Women Including Condyloma Incidence Estimations For Swedish Men And Women||Karolinska Institutet|No|Completed|June 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|500000|||Both|13 Years|25 Years|Accepts Healthy Volunteers|Probability Sample|Historically prospective study of population-based nationwide cohorts.|March 2013|March 15, 2013|August 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01553994||89369|
NCT01547065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120110047|Use of Transesophageal Echocardiography to Measure Intraoperative Renal Resistive Index and Predict Acute Renal Injury|Use of Transesophageal Echocardiography to Measure Intraoperative Renal Resistive Index and Predict Acute Renal Injury||Rutgers, The State University of New Jersey|No|Terminated|August 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|89 Years|No|Non-Probability Sample|potential subjects are those undergoing cardiac or major abdominal or vascular surgery        where TEE is standard of care|April 2015|April 23, 2015|March 2, 2012||No|Enrollment lower than anticipated|No||https://clinicaltrials.gov/show/NCT01547065||89897|
NCT01547078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-I-LyP-2|Clinical Study of Lyophilized Plasma in Patients With Liver Disease|A Phase 2 Clinical Study of Lyophilized Plasma in Patients With Acquired Coagulopathy Due to Liver Disease||HemCon Medical Technologies, Inc|Yes|Withdrawn|January 2015|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547078||89896|
NCT01556971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Botox 5515|Efficacy Study of Botox for Depression|A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD)||Capital Clinical Research Associates, LLC|No|Active, not recruiting|February 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2012|March 15, 2012|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556971||89141|
NCT01553305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AarhusUH-TS|A Study of the Effect of Supervised Exercise Programme in Patients With Rheumatoid Arthritis|The Effect of 6-weeks Supervised Exercise Programme Followed by 6-weeks Unsupervised Exercise Programme Versus 12 Weeks Unsupervised Exercise Programme in Patients With Rheumatoid Arthritis.||Aarhus University Hospital|No|Completed|January 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01553305||89421|
NCT01554072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|384767|Home-based in Chronic Obstructive Pulmonary Disease|Home-based Pulmonary Rehabilitation in COPD|HBCOPD|University of Nove de Julho|Yes|Completed|January 2012|December 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|N/A|No|||June 2013|June 24, 2013|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01554072||89363|
NCT01555242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMN54-101|A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas|A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas||Omnitura Therapeutics, Inc.|No|Completed|August 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555242||89273|
NCT01555528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104_535|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Mexico|Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment in Mexico|ECOS MEX|Merck KGaA|No|Active, not recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|193|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555528||89251|
NCT01556321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38773|Long-term Effects of Green Tea on Gut Flora, Fat Absorption, Body Composition and Resting Energy Expenditure|Long-term Effects of Green Tea on Gut Flora, Fat Absorption, Body Composition and Resting Energy Expenditure||Maastricht University Medical Center|Yes|Completed|June 2012|April 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|70|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|March 17, 2016|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01556321||89191|
NCT01556347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND110875|Multi-Drug Desensitization Protocol for Heart Transplant Candidates|Multi-Drug Desensitization Protocol for Heart Transplant Candidates||Providence Health & Services|Yes|Recruiting|July 2012|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|67 Years|No|||January 2016|January 20, 2016|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556347||89189|
NCT01556360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A000386-47|Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study|Bone Status on Patients With Genetic Hemochromatosis : a 3 Years Descriptive and Evolutionary Study.|FEROS|Rennes University Hospital|No|Completed|July 2008|||August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|-  serum        -  urine        -  DNA|Both|18 Years|80 Years|No|Non-Probability Sample|Patient with genetic hemochromatosis diagnosed in western France hospitals|May 2015|May 26, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01556360||89188|
NCT01556607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-637-CP-103|A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma|A Double-Blind, Randomized, 3 Period Crossover, Single Ascending Dose Study to Assess the Safety, and Tolerability of Inhaled MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma||MicroDose Therapeutx, Inc||Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|50 Years|No|||May 2012|May 21, 2012|March 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556607||89169|
NCT01556620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCSSA|Is NIRS Able to Detect Ischemia Following Brain Insult|The New 4 Wavelengths EQUANOX NIRS Sensor: Correlation and Detection of Ischemic Episodes. An Observational Comparative Study Versus PtiO2|NIRS|Direction Centrale du Service de Santé des Armées|No|Completed|November 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Brain injury (head trauma, SAH, ICH)|March 2012|March 15, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556620||89168|
NCT01556633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV25655|A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance|An Open Label, Prospective, Single Oral Dose Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Oseltamivir in Adult Subjects on Peritoneal Dialysis (PD) Using a Rapid Cycle Regimen to Simulate APD and in Adult Subjects With Creatinine Clearance From 10 to 30 mL/Min Not on Dialysis||Hoffmann-La Roche||Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|19 Years|90 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556633||89167|
NCT01545843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH077690|Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression|Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression||University of Michigan|Yes|Completed|March 2009|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|65 Years|No|||January 2015|January 19, 2015|January 12, 2012||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01545843||89990|Sample is largely young, healthy adults
NCT01547780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120063|Translocator Protein and Inflammation After Traumatic Brain Injury|PET Imaging of Translocator Protein in Subjects With Traumatic Brain Injury||National Institutes of Health Clinical Center (CC)||Recruiting|January 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|March 8, 2016|March 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01547780||89842|
NCT01546688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E044-402|A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures|A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures||Eisai Inc.||Terminated|November 2008|August 2011|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|65 Years|N/A|No|||November 2015|January 6, 2016|March 2, 2012||No||No|November 12, 2012|https://clinicaltrials.gov/show/NCT01546688||89926|
NCT01546701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130-1848|Buprenorphine in Acute Renal Colic Pain Management|||Tehran University of Medical Sciences|Yes|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|55 Years|No|||December 2012|December 6, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546701||89925|
NCT01546961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU1003|Chloroquine Population Pharmacokinetics in Pre and Post-partum Women|The Population Pharmacokinetics of Chloroquine for the Treatment of Uncomplicated P.Vivax Malaria in Pre- and Post-partum Women.||University of Oxford|No|Recruiting|June 2011|December 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|160|||Both|18 Years|50 Years|No|||February 2016|February 12, 2016|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546961||89905|
NCT01546974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hsd2012|Ventilator-associated Pneumonia (VAP) and Humidification System|Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification||Hospital Sao Domingos|Yes|Recruiting|November 2011|February 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|306|||Both|18 Years|N/A|No|||January 2012|March 6, 2012|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01546974||89904|
NCT01548534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN11-PB|A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer|A Phase III Randomized, Multicenter, Two Arms Double-blind Trial Versus Placebo, Evaluating the Interest of a Dietary Supplementation With Docosahexaenoic Acid (DHA) During Chemotherapy for Metastatic Breast Cancer|DHALYA|University Hospital, Tours|No|Terminated|February 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|65|||Female|18 Years|80 Years|No|||July 2015|July 28, 2015|February 27, 2012||No|Judicial liquidation of the society providing dietary supplementation.|No||https://clinicaltrials.gov/show/NCT01548534||89784|
NCT01545921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-435|Cancer End Of Life Evaluation|Evaluation and Validation of Quality Of Life Scales in Palliative Advanced Cancer|CEOLE|ICO Paul Papin|No|Recruiting|December 2010|April 2014|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|402|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|March 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01545921||89985|
NCT01545934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01 HL114377A|Preventing Excessive Gestational Weight Gain in Obese Women|Preventing Excessive Gestational Weight Gain in Obese Women||California Polytechnic State University-San Luis Obispo|Yes|Active, not recruiting|November 2012|June 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|350|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01545934||89984|
NCT01545947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-223-NSCL-001|Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer|A Phase 1b, Multi-Center, Open-Label Study of the mTOR Kinase Inhibitor CC-223 in Combination With Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer||Celgene|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|76|||Both|18 Years|N/A|No|||August 2015|August 14, 2015|March 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01545947||89983|
NCT01556477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMDSG10B|The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).|A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q)||Nordic MDS Group|Yes|Recruiting|March 2012|November 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||March 2012|March 14, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01556477||89179|
NCT01548300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIRCMD|Environmental Triggers Of Cardiometabolic Disease|Environmental Triggers Of Cardiometabolic Disease|AIRCMD|Ohio State University|No|Enrolling by invitation|February 2011|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|50|||Both|35 Years|65 Years|No|Non-Probability Sample|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The        participants will be nonsmokers with cardiometabolic disease, that are not taking        anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter        baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS        is not allowed.|March 2012|March 7, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548300||89802|
NCT01548313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J4 3606 BF-UL My milk|The Role of Human Milk in Development of Breast Fed Child's Intestinal Microbiota|The Role of Human Milk in Development of Breast Fed Child's Intestinal Microbiota|MYMILK|University of Ljubljana|No|Active, not recruiting|May 2010|May 2015|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|300|Samples With DNA|colostrum, meconium, milk, child's faeces, urine, venous blood|Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Slovenian, otherwise healthy pregnant women, plan to fully breastfeed their baby for at        least 6 weeks, willingness to write a 7-day weighted dietary protocol (7DP) twice: during        pregnancy and again at 4 weeks post partum.|January 2015|January 30, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548313||89801|
NCT01548326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|behdasht-90-6-16|Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine|Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine||Baqiyatallah Medical Sciences University|Yes|Enrolling by invitation|September 2011|July 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|52|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 6, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01548326||89800|
NCT01553812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KW/EX-12-030 (48-15)|The Assessment of Airway Resistance and Airtrapping in Elderly COPD Patients by Forced Oscillation Technique (FOT)|The Assessment of Airway Resistance and Airtrapping in Elderly COPD Patients by Forced Oscillation Technique (FOT)||Kwong Wah Hospital|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|158|||Both|60 Years|90 Years|No|Non-Probability Sample|COPD patients from both 'in-patient' and 'outpatient clinic' in Kwong Wah Hospital, Hong        Kong, China|March 2012|March 12, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553812||89382|
NCT01554670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|radio-frequency micro-tenotomy|Radio-frequency (RF)-Based Plasma Micro-tenotomy for the Treatment of Shoulder Impingement Syndrome|A Prospective Randomized Controlled Study of Radio-frequency Treatment for Shoulder Impingement Syndrome|RF|Beijing Hospital|No|Completed|January 2009|February 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|26 Years|74 Years|No|||March 2012|March 18, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01554670||89317|
NCT01554956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB046|Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients|A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis||Kedrion S.p.A.|No|Recruiting|September 2012|January 2015|Anticipated|October 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|N/A|No|||May 2013|May 15, 2013|December 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554956||89295|
NCT01555801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112273|Endoscopic Ultrasound Plus Submucosal Injection for Early Esophageal Cancer|Efficacy Study of Endoscopic Ultrasound Combining With Submucosal Saline Injection for Pretreatment Staging of T1a and T1b in Patients With Early Esophageal Cancer||Sun Yat-sen University|Yes|Recruiting|February 2012|September 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|18 Years|65 Years|No|||March 2012|March 14, 2012|February 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555801||89230|
NCT01556061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0573|Comparison of Storz C-MAC and D-MAC Orotracheal Intubation Systems in Morbidly Obese Patients|Comparison of Storz C-MAC and D-MAC Orotracheal Intubation Systems in Morbidly Obese Patients - A Prospective Randomized Crossover Trial||The University of Texas Health Science Center, Houston|Yes|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|March 1, 2012||No||No|July 27, 2013|https://clinicaltrials.gov/show/NCT01556061||89210|
NCT01556074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000263|Evaluation of Yoga for Sleep Disturbances in Post Traumatic Stress Disorder (PTSD)|Evaluation of Yoga for Sleep Disturbances in Insomnia and Posttraumatic Stress Disorder||Brigham and Women's Hospital|Yes|Completed|June 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01556074||89209|
NCT01556087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA032767|Distress Tolerance and Buprenorphine|Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients|TRUST|Butler Hospital|Yes|Completed|March 2012|August 2015|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|59|||Both|18 Years|75 Years|No|||September 2015|September 9, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01556087||89208|
NCT01556100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-3989A|Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression|Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression||Chang Gung Memorial Hospital|Yes|Completed|November 2011|December 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Both|20 Years|N/A|No|||December 2015|January 27, 2016|March 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556100||89207|
NCT01556126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21102|Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population|Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients|PARTICIPATE|CID - Carbostent & Implantable Devices|No|Recruiting|February 2012|February 2018|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|18 Years|N/A|No|||March 2012|March 15, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01556126||89205|
NCT01556646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bajaj 01720|Effect of Tolvaptan on Cognitive Function in Cirrhosis|Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial||Hunter Holmes Mcguire Veteran Affairs Medical Center|No|Completed|April 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|75 Years|No|||February 2014|February 6, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556646||89166|
NCT01556867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/06-U|Evaluation of Two Strategies for Umbilical Cord Care : Dry Cord Care Versus Antiseptic on the Incidence of Omphalitis in Healthy Term Newborn|Evaluation of Two Strategies for Umbilical Cord Care : Dry Cord Care Versus Antiseptic on the Incidence of Omphalitis in Healthy Term Newborn|NEOCORD|Nantes University Hospital||Terminated|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|8698|||Both|N/A|24 Hours|No|||January 2013|January 30, 2013|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01556867||89149|
NCT01547572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IhediohaU|Psychological Preparation for Colorectal Surgery: Impact of Video Education|Psychological Preparation for Colorectal Surgery: Impact of Video Education. A Randomised Trial||Ihedioha, Ugo, M.D.|Yes|Completed|September 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 7, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547572||89858|
NCT01547286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P002386|Imaging Study of the Lungs During an Allergic Asthma Attack|Redistribution of Pulmonary Perfusion During Bronchoconstriction in Asthma||Massachusetts General Hospital|Yes|Completed|May 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|18 Years|65 Years|No|||October 2013|October 25, 2013|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547286||89880|
NCT01547299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-07|Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer|A Randomized, Open-Label, Phase 2 Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer||Medivation, Inc.|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Male|18 Years|N/A|No|||April 2015|April 21, 2015|February 27, 2012|Yes|Yes||No|March 30, 2015|https://clinicaltrials.gov/show/NCT01547299||89879|
NCT01547975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201004004R|Retrospective Analysis of Surgical Outcomes After Corneal Transplantation|Retrospective Analysis of Surgical Outcomes After Corneal Transplantation||National Taiwan University Hospital|Yes|Completed|April 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|1000|||Both|N/A|90 Years|Accepts Healthy Volunteers|Probability Sample|The patients who received corneal transplantation within full chart records.|March 2012|April 1, 2012|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01547975||89827|
NCT01546987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1115|Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer|Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer||Radiation Therapy Oncology Group|Yes|Active, not recruiting|May 2012|||June 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|900|||Male|18 Years|N/A|No|||November 2015|November 14, 2015|March 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546987||89903|
NCT01547260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LENAGEM-PANC|Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer|Phase I/II Study of Lenalidomide and Gemcitabine as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer|LENAGEM|Karolinska University Hospital|Yes|Completed|October 2009|November 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|19 Years|N/A|No|||November 2014|November 26, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01547260||89882|
NCT01547546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28070|A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma|An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma||Genentech, Inc.||Completed|April 2012|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547546||89860|
NCT01547988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRF 2001-056|Training Improves Balance Control|Improving Balance Control and Self-Reported Lower Extremity Function in Community Dwelling Older Adults - A Randomized Control Study||Boston University|No|Completed|October 2001|August 2003|Actual|February 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 5, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01547988||89826|
NCT01548274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGU-65|Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells|Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells||Aichi Gakuin University|Yes|Recruiting|October 2010|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|N/A|No|||March 2012|March 5, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548274||89804|
NCT01556230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE1260|Prospective Study of Clinically Nonfunctioning Pituitary Adenomas|Prospective Study of Clinically Nonfunctioning Pituitary Adenomas|PAPS|Columbia University|No|Recruiting|November 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|350|Samples Without DNA|Blood Serum and Plasma samples|Both|18 Years|N/A|No|Non-Probability Sample|Any persons diagnosed with a non-functioning pituitary adenoma that is willing to travel        to our study center at Columbia University in New York, NY for all study visits.|May 2015|May 13, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01556230||89197|
NCT01556737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37475.081.11|Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women|Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women|ISOII|Wageningen University|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|72|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 30, 2012|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01556737||89159|
NCT01556750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-026|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2012|||||N/A|N/A|N/A||||||||||||||February 27, 2013|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556750||89158|
NCT01556724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09090339|A Comparison of Postoperative Analgesic Nerve Block Ropivacaine Concentrations|A Comparison of 0.1 and 0.2% Ropivacaine in Lumbar Plexus Catheters After Primary Total Hip Arthroplasty: a Comparison of Postoperative Analgesia and Motor Function.||University of Pittsburgh|No|Active, not recruiting|January 2010|December 2014|Anticipated|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|75 Years|No|||July 2013|July 21, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01556724||89160|
NCT01556984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wz2010007|Changes of Endothelial Function Before and After DSA in Patients With Diabetes|Changes of Endothelial Function Before and After DSA in Patients With Diabetes||Wuhan General Hospital of Guangzhou Military Command||Completed|October 2012|October 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|We will select 200 patients with diabetes. DSA will be taken for this group. Endothelial        function will be measured before and after DSA. In the meantime, 100 healthy subjects will        be selected as controls.|June 2015|June 12, 2015|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556984||89140|
NCT01553032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniHD-2010-11-40-1001|Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)|Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux®|HICARE|University of Heidelberg Medical Center|Yes|Recruiting|May 2011|October 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|May 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01553032||89442|
NCT01554410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD 100597|Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma|A Phase I Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Escalating Gemcitabine for Locally Advanced Cervical Carcinoma||University of California, San Diego|Yes|Recruiting|August 2010|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Female|18 Years|N/A|No|||December 2014|December 1, 2014|March 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01554410||89337|
NCT01555541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112525|Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma|A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma||University of California, San Francisco|Yes|Recruiting|June 2012|June 2019|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01555541||89250|
NCT01555554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-10-2-0078|Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)|Effect of Prophylactic, Perioperative Propranolol on Peri- and Postoperative Complications in Patients With Post Traumatic Stress Disorder||University of California, San Francisco|No|Recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|40 Years|N/A|No|||December 2015|December 9, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01555554||89249|
NCT01555814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2010-142|Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen|Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes||University of Copenhagen|Yes|Recruiting|May 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|180|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2015|December 15, 2015|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01555814||89229|
NCT01556113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112009408|Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease|The Genetic Effect on Omega 3 Fatty Acid Supplementation for the Treatment of Non Alcoholic Fatty Liver Disease in Obese Children and Adolescents||Yale University|Yes|Recruiting|March 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|10 Years|19 Years|No|||March 2015|March 3, 2015|March 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556113||89206|
NCT01556386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-1202|Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia|Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia||Seoul National University Hospital|No|Completed|June 2006|May 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|1. Candidate genes exhibit polymorphisms and encodes proteins that are involved in the           pharmacokinetics and pharmacodynamics of antileukemic agents             -  Priority was given to polymorphism that were demonstrated to be associated with                phenotypes in both clinical and preclinical studies.             -  Candidate genes : CYP3A4*1B, CYPA5*3, GSTM1 deletion, GSTP1 313, GSTT1 deletion,                MDR exon 21, MDR exon 26, MTHFR 677, MTHFR 1298, NR3C1 1088, RFC 80, TPMT-1 238,                TPMT-1 460, TPMT-1 719, VDR intron 8, VDR FokI, ITPA        2. Blood sample at complete remission→DNA extraction        3. Total-Plex (multiplex) PCR amplification        4. Luminex system analysis|Both|N/A|21 Years|No|Non-Probability Sample|All the patients with acute lymphoblastic leukemia who was diagnosed and treated in SNUCH.|December 2013|July 11, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01556386||89186|
NCT01547013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-20|The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients|Phase II The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients|NIRS|U.S. Army Medical Research and Materiel Command|No|Active, not recruiting|February 2012|May 2017|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Anticipated|130|||Both|18 Years|60 Years|No|Non-Probability Sample|Adults who have sustained major blunt and penetrating trauma, who present to Grady        Memorial Hospital, Atlanta Medical Center, or Athens Regional Medical Center for treatment        meeting the inclusion and exclusion|December 2015|December 31, 2015|March 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01547013||89901|
NCT01547026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKonstanzMichaelOdenwald2012-1|Self-regulation Strategies to Improve Exercise Behavior Among Schizophrenic Patients|Self-regulation Strategies to Improve Exercise Behavior: A Randomized Clinical Trial in Persons With Schizophrenia Spectrum Disorders||University of Konstanz|No|Completed|April 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|60 Years|No|||February 2013|February 12, 2013|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01547026||89900|
NCT01547039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33061.051.10|Platelet Reactivity and MES During CEA|Platelet Reactivity Testing in Association With Perioperative Microembolic Signals During Carotid Endarterectomy||UMC Utrecht|No|Not yet recruiting|June 2012|July 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Plasma|Both|18 Years|90 Years|No|Probability Sample|patients undergoing elective carotid endarterectomy in University Medical Centre Utrecht|March 2012|March 8, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01547039||89899|
NCT01547806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120074|Collection of Transplant Stem Cells for Plasma Cell Myeloma|Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM)||National Institutes of Health Clinical Center (CC)||Recruiting|February 2012|April 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|75 Years|No|||September 2015|October 6, 2015|March 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547806||89840|
NCT01547585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOY-CVD-2012|A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy|A Randomized Controlled Trial to Determine the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Whole Soy: a Dose Response Study|SOY-LDL|Guelph Food Research Centre|No|Completed|May 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|243|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 10, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01547585||89857|
NCT01548248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1928|Efficacy and Safety of Levemir® Used as Basal Insulin|An Observational 3-months Study to Evaluate Efficacy and Safety of Insulin Levemir® Used as Basal Insulin on the Glycaemic Control, Weight and Incidence of Hypoglycaemic Events in Insulin Treated Subjects With Type 1 or Type 2 Diabetes||Novo Nordisk A/S|No|Completed|January 2006|October 2006|Actual|October 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|631|||Both|N/A|N/A|No|Non-Probability Sample|Any subject with type 1 or type 2 diabetes treated with human insulin NPH in whom at the        discretion of the participating physicians it was decided to switch insulin treatment to        the long-acting insulin analogue insulin detemir in combination with insulin aspart. The        selection of the subjects was at the discretion of the participating physicians.|March 2016|March 2, 2016|March 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01548248||89806|
NCT01548261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110051RB|Donating Oral Mucosal Cells for the Study of ex Vivo Culture of Cells Sheets|||National Taiwan University Hospital|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|1|Samples With DNA|Donating oral mucosal cells for the study of ex vivo culture of cells sheets.|Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Health people.|March 2012|March 7, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548261||89805|
NCT01544439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTN: U111-1128-3875|Occlusal Splint and Counseling to Temporomandibular Disorder|The Efficacy of Occlusal Stabilization Appliance Associated to Counseling in the Management of Myofascial Pain Chronic and in the Improvement of the Quality of Life of Patients With Temporomandibular Disorders||Federal University of Juiz de Fora|Yes|Recruiting|March 2012|July 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|20 Years|55 Years|No|||March 2012|May 15, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01544439||90098|
NCT01556503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00006939|Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis|Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis||OHSU Knight Cancer Institute|No|Active, not recruiting|April 2011|||August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|12 Years|N/A|No|Non-Probability Sample|Primary care clinic|November 2014|November 17, 2014|March 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556503||89177|
NCT01556516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-CFCT-02|Pregnancy and Birth Outcome in Women With Pompe Disease|Pregnancy and Birth Outcome in Women With Pompe Disease||O & O Alpan LLC|No|Active, not recruiting|February 2012|February 2017|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|N/A|No|Non-Probability Sample|20 female subjects (18 and above) who meet eligibility criteria.|May 2015|May 6, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01556516||89176|
NCT01553097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12321|Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty|Neurocognitive Impairment in Women With Early Stage Breast Cancer||Virginia Commonwealth University|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|51|Samples Without DNA|3 cc of blood in a BD Vacutainer® tube preserved with 5.4mg K2 EDTA for the cytokine assay|Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants in the two BC groups will be recruited from the Massey Cancer Center (MCC)        clinical sites in Richmond, VA. Healthy volunteers will be recruited throughout the VCU        Health System and through women's groups throughout the greater Richmond, VA area. The PI        will provide physicians and clinical nurses an overview of the research and work with them        to identify potential project participants. Participants will be provided oral and written        information about the research and given an opportunity to ask questions or discuss the        project with family or significant others.|December 2014|December 12, 2014|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01553097||89437|
NCT01557010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWP05195-P003|Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia|The Clinical Trial for Evaluation of Efficacy and Safety of DWP05195 in Postherpetic Neuralgia: Double-blind, Placebo-controlled, Randomized, Multi-center, Exploratory Clinical Trial||Daewoong Pharmaceutical Co. LTD.||Completed|March 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|140|||Both|20 Years|80 Years|No|||February 2014|February 19, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01557010||89138|
NCT01557023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 124 NINA|Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol|||Eurofarma Laboratorios S.A.|Yes|Withdrawn||||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|0|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|July 24, 2015|March 8, 2012||No|Change Company strategy|No||https://clinicaltrials.gov/show/NCT01557023||89137|
NCT01557036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED002|Aneurysm Study of Pipeline in an Observational Registry|Aneurysm Study of Pipeline in an Observational Registry|ASPIRE|ev3|Yes|Terminated|May 2012|||May 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|Patients with an intracranial aneurysm meeting the labeled indication for the relevant        geography.|January 2015|January 19, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01557036||89136|
NCT01556997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X985400|Perindopril Amlodipine for the Treatment of Hypertension|Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension|PATH|Symplmed Pharmaceuticals LLC|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|837|||Both|18 Years|75 Years|No|||August 2015|September 8, 2015|March 15, 2012|Yes|Yes||No|July 28, 2015|https://clinicaltrials.gov/show/NCT01556997||89139|
NCT01554969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054181|Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer|Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer||Emory University|Yes|Completed|May 2012|June 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01554969||89294|
NCT01555294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO 2003/174|Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification|Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification: a Study in a Population-based Cohort and Familial Combined Hyperlipidemia|NIMA|Radboud University|No|Completed|May 2005|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1960|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants recruited from a population-based survey aged 50-70 years. Participants from        families with Familial Combined Hyperlipidemia.|March 2012|March 14, 2012|September 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01555294||89269|
NCT01555827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2011/19|Retinal Neurodegenerative Signs in Alzheimer's Diseases|Retinal Neurodegenerative Signs in Alzheimer's Diseases|SIGNAL|University Hospital, Bordeaux|Yes|Recruiting|April 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Both|50 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 12, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555827||89228|
NCT01555840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01442-37(AFSSAPS)|Comparative Study of the Magnetically Guided Capsule Endoscopy Versus High Definition Gastroscopy|"EVALUATION CLINIQUE D'UNE CAPSULE A GUIDAGE MAGNETIQUE POUR L'EXPLORATION GASTRIQUE "Capsule Dirigée Versus Gastroscopie à Haute Définition""||Universitätsklinikum Hamburg-Eppendorf|No|Completed|November 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|189|||Both|18 Years|75 Years|No|||December 2013|December 17, 2013|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01555840||89227|
NCT01555853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204071|Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma|A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma||Washington University School of Medicine|No|Active, not recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|54|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01555853||89226|
NCT01555866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0018|Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.|A Phase 1 Open Label, 2 Part, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole||Astellas Pharma Inc|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|6||Actual|49|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|March 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555866||89225|
NCT01556373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00612-37|Effects of Acute Systemic Inflammation on Arterial Stiffness and Microcirculation.|Effects of Acute Systemic Inflammation on Arterial Stiffness and Microcirculation.|IRIGA|Rennes University Hospital|No|Recruiting|February 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|Samples Without DNA|serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|20 patients with severe sepsis. 20 controls matched on age, sex and cardiovascular risk        factors .|September 2015|September 11, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01556373||89187|
NCT01556893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-004f|Creating LASIK Flaps With the LenSx Femtosecond Laser|Prospective, Single-center Clinical Trial of Subjects Scheduled to Undergo LASIK Surgery Requiring an Initial Corneal Flap.||Alcon LenSx, Inc.|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 23, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556893||89147|
NCT01547598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LUM-11-020|Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction|||Allergan|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||July 2014|July 28, 2014|February 10, 2012|Yes|Yes||No|July 28, 2014|https://clinicaltrials.gov/show/NCT01547598||89856|
NCT01547611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rehab. after cervical surgery|Outcome of Physiotherapy After Surgery for Cervical Disc Disease: a Prospective Multi-Centre Trial|Outcome of Physiotherapy After Surgery for Cervical Disc Disease: a Prospective Randomised Multi-Centre Trial||Linkoeping University|Yes|Active, not recruiting|January 2009|December 2017|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||March 2016|March 6, 2016|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547611||89855|
NCT01578044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 11-424|Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation|Pilot Intervention to Improve Adherence to Dabigatran for Patients With Atrial Fibillation||VA Office of Research and Development|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|12|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|April 3, 2012||No||No|April 27, 2015|https://clinicaltrials.gov/show/NCT01578044||87528|
NCT01578603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-2010|Effects of Two Sugar Substituted Chewing Gums on Caries and Gingivitis Variables|Effects of Two Sugar Substituted Chewing Gums Plus Tooth Brushing on Different Caries and Gingivitis Related Variables: a Double Blind, Randomized Controlled Clinical Trial||Universidad de Antioquia|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|130|||Both|16 Years|34 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01578603||87485|
NCT01548001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-106|Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Active, not recruiting|May 2012|January 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|910|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548001||89825|
NCT01548014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-11-046|The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease|Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study||Samsung Medical Center|Yes|Recruiting|January 2010|January 2016|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|1|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01548014||89824|
NCT01547793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120069|Carbon Monoxide Levels and Sickle Cell Disease Severity|End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|January 2012|November 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|106|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 5, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01547793||89841|
NCT01575054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-116|BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity|||Allergan|No|Completed|May 2012|July 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|468|||Both|18 Years|85 Years|No|||December 2015|December 29, 2015|April 9, 2012|Yes|Yes||No|October 1, 2015|https://clinicaltrials.gov/show/NCT01575054||87757|
NCT01575067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth5|Blood Pressure Monitor Clinical Test (Cuff Range: 22 Cm-42cm)|||Andon Health Co., Ltd|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|85|||Both|30 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|resident of a community|April 2012|April 10, 2012|April 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575067||87756|
NCT01556529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDRM 92/07/56|CDRM Study: Computer-assisted Diabetes Risk Management-for Secondary and Tertiary Prevention of T2DM Complications|CDRM Study: Computer-assisted Diabetes Risk Management-evaluation of a Medical Care Approach to Support Secondary and Tertiary Prevention of Type 2 Diabetes Mellitus and Its Complications|CDRM_DMP|Philipps University Marburg Medical Center|Yes|Completed|June 2007|June 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|405|||Both|40 Years|68 Years|No|||March 2012|March 20, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01556529||89175|
NCT01556542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo004|Drug Eluting Balloon in peripherAl inTErvention SFA|Drug Eluting Balloon in peripherAl inTErvention: the DEBATE SFA Study|DEBATE SFA|Ospedale San Donato|No|Completed|November 2010|||September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||January 2013|January 26, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01556542||89174|
NCT01553344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR -7|Serum Sclerostin Level & Treatment of Vitamin D Deficiency|Serum Sclerostin Level in Patients With Vitamin D Deficiency|OMSOST|Bagcilar Training and Research Hospital|No|Completed|March 2012|November 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|||Female|20 Years|50 Years|No|Non-Probability Sample|Patients with vitamin D deficiency|December 2014|December 22, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553344||89418|
NCT01553318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106005839 (1106-01)|Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study|Novel Use of Ketotifen (Mast Cell Stabilizer) in Fibromyalgia: A Pilot Study|KetoforFMS|Indiana University|Yes|Active, not recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Anticipated|46|||Both|18 Years|65 Years|No|||March 2012|October 11, 2012|March 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01553318||89420|
NCT01553331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSHPB10208|Day Case Laparoscopic Cholecystectomy: Fundus First With Ultrasonic Dissection or Conventional Diathermy Hook|Day Case Laparoscopic Cholecystectomy: Comparison of Fundus First With Ultrasonic Dissection or Conventional Diathermy Hook, Randomized Trial||Central Finland Hospital District|Yes|Completed|March 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|169|||Both|18 Years|65 Years|No|||December 2014|December 10, 2014|March 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01553331||89419|
NCT01553058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814278|Vascular Inflammation in Psoriasis Trial (The VIP Trial)|A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease|VIP|University of Pennsylvania|Yes|Active, not recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|96|||Both|18 Years|N/A|No|||June 2015|September 9, 2015|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553058||89440|
NCT01553071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPOC-2010-002|Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies|Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|March 2012|||March 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|18 Years|N/A|No|||August 2011|March 9, 2012|March 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01553071||89439|
NCT01554735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12200233|Effects of Lifestyle-modification Induced Weight Loss on Sexual and Urinary Function, and Quality of Life in Obese Men|The Effects of Lifestyle-modification Induced Weight Loss on Metabolic and Inflammatory Profile, Endothelial, Sexual and Urinary Function, and Quality of Life in Obese Men||Changi General Hospital|No|Completed|July 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01554735||89312|
NCT01555255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC390|Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria|Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria||Foundation for Innovative New Diagnostics, Switzerland|No|Active, not recruiting|November 2010|December 2012|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1205|Samples With DNA|Red cell pellets, dried whole blood on filter paper, and fixed blood and placental tissue|Female|16 Years|44 Years|No|Non-Probability Sample|Women presenting for routine antenatal care in the second and third trimesters of        pregnancy, at antenatal clinics at ≥2 sites of varied malaria transmission intensity in        Africa|October 2012|April 22, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555255||89272|
NCT01555268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 186010|Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia|A Phase lb Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients||Roswell Park Cancer Institute|No|Active, not recruiting|October 2011|||November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555268||89271|
NCT01555281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 39/10|Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma|Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy - A Single Arm Phase I/II Trial||Swiss Group for Clinical Cancer Research|Yes|Recruiting|April 2012|December 2019|Anticipated|December 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01555281||89270|
NCT01555879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-322|Real-world Clinical Efficacy of Abatacept in the T3 Data Registry|Abatacept in T3: A Characterization of Abatacept's Efficacy and Outcomes From a Real-Word Clinical Practice Information Hub on Novel Patient Sub-Groups||Arthritis Northwest PLLC|No|Active, not recruiting|March 2012|April 2012|Anticipated|March 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|All rheumatoid arthritis patients from a single site who have been on Abatacept for        greater than 3 months.|March 2012|March 16, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01555879||89224|
NCT01556165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13485A|Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China||H. Lundbeck A/S|No|Completed|April 2012|||December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|35 Years|N/A|No|||December 2014|December 22, 2014|March 13, 2012||No||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01556165||89202|
NCT01556659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004265-32|LV Thrombus After Acute AMI: A Randomized Controlled Trial|Left Ventricular Thrombus Formation After Acute Myocardial Infarction - a Randomized Multi-center Trial Comparing Two Different Anti-thrombotic Regimens||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|March 2012|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01556659||89165|
NCT01556672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6021|Adalimumab-psoriasis and Small Bowel Lesions|Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab||Innovaderm Research Inc.|No|Active, not recruiting|April 2012|March 2016|Anticipated|January 2016|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|80 Years|No|||February 2016|February 23, 2016|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556672||89164|
NCT01577771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCV13-Immunogenicity-Bobo|Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso|Immunogenicity and Reactogenicity of 13-valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers and Children in Bobo-Dioulasso, Burkina Faso: a Phase 4 Randomized Trial|PCV13-Bobo|Agence de Médecine Préventive, France|No|Completed|February 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|663|||Both|N/A|4 Years|Accepts Healthy Volunteers|||January 2015|January 19, 2015|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577771||87549|
NCT01578031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH P02 HL094307-01|The Effects of Treating Obese and Lean Patients With Sleep Apnea|Responses to CPAP Treatment in Obese and Lean Sleep Apnea Patients|PISA|University of Pennsylvania|Yes|Active, not recruiting|March 2009|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|172|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578031||87529|
NCT01578863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc009-12CTIL|Predictors of Success in an Intervention Program for the Treatment of Childhood Obesity|Predictors of Success in a Multidisciplinary Intervention Program for Obese Children and Adolescence||Meir Medical Center|No|Completed|June 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|176|||Both|8 Years|18 Years|Accepts Healthy Volunteers|||May 2014|April 13, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01578863||87465|
NCT01548573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202818|Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment|Tandem Autotransplantation for Multiple Myeloma in Participants With Less Than 12 Months of Preceding Therapy, Incorporating Velcade (Bortezomib) With the Transplant Chemotherapy and During Maintenance||University of Iowa|Yes|Terminated|May 2012|March 2014|Anticipated|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||November 2013|November 26, 2013|February 29, 2012|Yes|Yes|Met study stopping rules|No||https://clinicaltrials.gov/show/NCT01548573||89781|
NCT01575080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R&D-2011-2012-0.20|Performance Evaluation of Blood Glucose Monitoring System Using ISO Study Design|Performance Evaluation of the Contour TS BGMS Using ISO/DIS 15197:2011 Section 8 Study Design and Performance Criteria||Ascensia Diabetes Care|No|Completed|April 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|April 9, 2012|Yes|Yes||No|April 26, 2013|https://clinicaltrials.gov/show/NCT01575080||87755|
NCT01557049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1324/07|Global Postural Reeducation in Chronic Low Back Pain|Global Postural Reeducation in Chronic Low Back Pain: an Randomized Controlled Trial|GPR|Federal University of São Paulo|No|Completed|June 2008|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2010|March 15, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01557049||89135|
NCT01553084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL109031-01|A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers|A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers|NHLBI-RO1|University of Wisconsin, Madison|Yes|Active, not recruiting|May 2012|January 2019|Anticipated|January 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|1500|||Both|18 Years|99 Years|No|||October 2015|October 5, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01553084||89438|
NCT01554098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16220|A Comparison of Two Colonoscopic Withdrawal Techniques|A Comparison of Two Colonoscopic Withdrawal Techniques on Colonic Polyp Detection: an Open, Randomised, Cross Over Trial||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|130|||Both|40 Years|80 Years|No|||March 2014|March 27, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01554098||89361|
NCT01553565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cold vs.hot|Prospective Comparison of Cold Polypectomy and Conventional Polypectomy for Small Colorectal Polyps in Patients Taking Antithrombotic Agents|||Showa Inan General Hospital|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|20 Years|90 Years|No|||August 2014|August 13, 2014|March 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01553565||89401|
NCT01553825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0075|Assessment of Patient Experience During Treatment for Cancer|Assessment of Patient Experience During Treatment for Cancer||Stanford University|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Pathologically diagnosed carcinoma patients at Stanford cancer center who signed the        informed consent form.|May 2013|May 31, 2013|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553825||89381|
NCT01553552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPLS11-MS|Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal|Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status|SchistoVAN|Biomedical Research Center EPLS|Yes|Completed|October 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|99|Samples Without DNA|Whole blood Sera Urine Stool|Both|6 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of 3 villages from the Senegal Valley River, belonging to the Podor District in        Saint-Louis Region in Northern Senegal: Agniam Towguel, Fanaye Diery and Niandane.        Subcohort of a previous study "AnoPalAnoVac" (ClinicalTrials.gov ID: NCT01545115)|March 2012|March 13, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01553552||89402|
NCT01553838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|A Prospective Study to Evaluate MRI Guided Biopsy Compared With Transrectal Ultrasound Guided Biopsy of the Prostate in Men With Increased PSA Values|A Prospective Study to Evaluate MRI Guided Biopsy Compared With Transrectal Ultrasound Guided Biopsy of the Prostate in Men With Increased PSA Values||Heinrich-Heine University, Duesseldorf|No|Completed|January 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|185|||Male|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|August 18, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01553838||89380|
NCT01555021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001921|Pharmacogenomics for Antidepressant Guidance and Education|Pharmacogenomics for Antidepressant Guidance and Education||Massachusetts General Hospital|No|Recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||July 2014|July 24, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01555021||89290|
NCT01554995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCB01-0371-11-1-01|A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCB01-0371 in Healthy Male Subjects||LegoChem Biosciences, Inc|Yes|Completed|March 2012|February 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2013|November 13, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01554995||89292|
NCT01555008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX4211.1-107-DM|Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment||Lexicon Pharmaceuticals|No|Completed|March 2012|||August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|80 Years|No|||September 2013|September 6, 2013|March 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555008||89291|
NCT01556152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC 17536-201|A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)|A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Neuropathy||Glenmark Pharmaceuticals Ltd. India|Yes|Withdrawn||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|75 Years|No|||November 2012|November 9, 2012|March 15, 2012||No|Due to new scientific evidence assessment, the study design was revised before the study    started recruitment|No||https://clinicaltrials.gov/show/NCT01556152||89203|
NCT01555567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACLNMES|Electrical Stimulation and Eccentric Exercise for Anterior Cruciate Ligament (ACL) Injury|Quadriceps Inhibition After ACL Injury: Neuromuscular and Functional Consequences||University of Michigan|No|Completed|August 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|43|||Both|14 Years|35 Years|No|||May 2015|May 13, 2015|March 6, 2012||No||No|April 26, 2015|https://clinicaltrials.gov/show/NCT01555567||89248|
NCT01555580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDA 2011 MG GM-CSF|A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis|A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Symptomatic Autoimmune Generalized Myasthenia Gravis||Muscular Dystrophy Association|No|Not yet recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|80 Years|No|||March 2012|March 14, 2012|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555580||89247|
NCT01556685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVX-MEX-09-17|MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia|Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia|MATRIX|Biogen|No|Completed|March 2011|||October 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|2||Actual|180|||Both|N/A|N/A|No|||March 2012|September 12, 2013|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01556685||89163|
NCT01556412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ti-EUS|Endoscopic Ultrasound as an Early Diagnostic Tool for Primary Sclerosing Cholangitis|Pilot Study of Endoscopic Ultrasound as an Early Diagnostic Tool for Evaluation of Suspected Primary Sclerosing Cholangitis||Tischendorf, Jens, M.D.|No|Completed|March 2009|November 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to a single tertiary clinic center with chronic cholestatic hepatopathy|October 2014|October 19, 2014|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01556412||89184|
NCT01556425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052254|The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence|The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence||Johns Hopkins University|Yes|Recruiting|May 2012|January 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|124|||Both|18 Years|65 Years|No|||April 2015|April 1, 2015|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556425||89183|
NCT01557179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEES_Hyalofemme_1|Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness|Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness. A Multicenter, Randomized, Controlled, Open-label, Parallel-group, Clinical Trial||Lee's Pharmaceutical Limited|No|Completed|May 2009|May 2010|Actual|November 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|144|||Female|25 Years|70 Years|No|||March 2012|March 16, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01557179||89125|
NCT01574521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tz2008032|Seroepidemiologic Study of Spermatozoal Transmission of Hepatitis B Virus (HBV)|A Fetal Seroepidemiologic Study in Hepatitis B Virus Transmitted Via Male Germ Line||Taizhou Hospital|No|Completed|January 2008|December 2011|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|407|Samples With DNA|whole blood, serum,amniotic fluid|Female|16 Years|45 Years|No|Non-Probability Sample|The research consisted of the pregnant women who visited for prenatal diagnosis during the        January 2008 and June 2010.|April 2012|April 9, 2012|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01574521||87798|
NCT01575106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000663|The Neurobiology of Expectancy and Pain Perception|||Massachusetts General Hospital|Yes|Active, not recruiting|June 2012|June 2016|Anticipated|June 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|40|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01575106||87753|
NCT01578317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120103|Immune Responses to H5N1 Vaccine With and Without MF59 Adjuvant|Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine||National Institutes of Health Clinical Center (CC)||Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|1||Actual|49|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2015|November 3, 2015|April 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578317||87507|
NCT01578330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DTR01|A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720|A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine||Novartis||Completed|October 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|42|||Both|18 Years|65 Years|No|||March 2016|March 1, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01578330||87506|
NCT01578616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHI OCT study|Endothelial Dysfunction and Plaque Vulnerability|Association of Endothelial Function With Plaque Vulnerability Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome||Yokohama City University Medical Center|No|Completed|July 2010|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|||Both|20 Years|90 Years|No|Probability Sample|Yokohama City University Medical Center|August 2015|August 5, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578616||87484|
NCT01578876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSWT IN CHINA|Extracorporeal Cardiac Shock Wave Therapy (CSWT) for Treatment of Coronary Artery Disease|To Prove up the Effect of CSWT in Vivo and to Evaluate the Feasibility and Efficiency of CSWT for Treatment of CAD and to Establish the Inclusion and Exclusion Criteria and Summarize the Methodological Outlines of CSWT in China.||Kunming Medical University|Yes|Completed|December 2008|January 2012|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|35 Years|81 Years|No|||April 2012|April 17, 2012|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01578876||87464|
NCT01574781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSN012|Non-invasive Prenatal Diagnostic Validation Study|Development of Non-invasive Prenatal Diagnostic Test Based on Fetal DNA Isolated From Maternal Blood|NIPD|Natera, Inc.|No|Completed|September 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Time Perspective: Prospective||6|Actual|1781|Samples With DNA|Maternal blood, paternal blood or cheek swab, paternal relative blood or cheek swab, fetal      blood or tissue, POC tissue, and child cord blood or saliva.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy non-pregnant women, pregnant women, male relatives, women undergoing miscarriage,        and children born to participating women|June 2013|June 28, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01574781||87778|
NCT01576484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1032|Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia|A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia||Regeneron Pharmaceuticals|Yes|Active, not recruiting|March 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|58|||Both|18 Years|75 Years|No|||June 2015|June 30, 2015|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576484||87647|
NCT01553110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14200|An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms|An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms in Acute Rhinosinusitis.||Virginia Commonwealth University|Yes|Recruiting|March 2012|November 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|62|Samples With DNA|Nasal Secretions|Both|12 Years|100 Years|No|Non-Probability Sample|Primary Care Clinics and Community|November 2015|November 3, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01553110||89436|
NCT01554436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8269|Neuropsychological Prognosis Factors of Smoking Cessation|Neuropsychological and Psychopathological Prognosis Factors of Smoking Cessation||University Hospital, Montpellier|No|Completed|December 2008|November 2011|Actual|May 2011|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|135|||Both|18 Years|60 Years|No|||March 2012|December 30, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01554436||89335|
NCT01554423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA029894|Four-Arm Randomized Control Trial of Brief MI Versus Couples-Based HIV/STI Prevention in South Africa|Four-Arm RCT of Brief MI vs. Couples-Based HIV/STI Prevention in South Africa|SA R01|The City College of New York|Yes|Recruiting|July 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|720|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01554423||89336|
NCT01554709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0009|Safety and Performance Study of the CardioGard Cannula|A Study to Collect Additional Information Related to the Safety and Performance of the CardioGard Cannula||CardioGard Medical Ltd.|No|Completed|March 2012|May 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|50 Years|85 Years|No|||September 2014|September 23, 2014|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01554709||89314|
NCT01554085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-2158-201|First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002158 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection||Alios Biopharma Inc.|No|Terminated|December 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|March 12, 2012||No|ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical    development.|No||https://clinicaltrials.gov/show/NCT01554085||89362|
NCT01554683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000303|Seizure Activity in Alzheimer's Disease|Seizure-like Hippocampal Activity in Alzheimer's Disease Neurodegeneration||Beth Israel Deaconess Medical Center|Yes|Recruiting|February 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|20|||Both|50 Years|N/A|No|||November 2015|November 13, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01554683||89316|
NCT01555320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201007001-02|Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure|Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure (CACT-IHF) A Randomized, Double-blind, Multicenter, Placebo-controlled Trial|CACT-IHF|State Administration of Traditional Chinese Medicine of the People's Republic of China|Yes|Recruiting|March 2012|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Both|40 Years|79 Years|No|||March 2013|March 19, 2013|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01555320||89267|
NCT01555307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-06-461|Effectiveness of Exercise Programs Following Total Hip and Knee Joint Arthroplasty|Effectiveness of Exercise Programs Following Total Hip and Knee Joint Arthroplasty||Lawson Health Research Institute|No|Completed|June 2007|April 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|55 Years|N/A|No|||January 2012|March 14, 2012|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01555307||89268|
NCT01555619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60030283|Quadripolar Pacing Post Approval Study|Quadripolar Pacing Post Approval Study|Quad PAS|St. Jude Medical|No|Active, not recruiting|February 2012|April 2020|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1971|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated for cardiac resynchronization therapy.|April 2015|April 23, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555619||89244|
NCT01556139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spirotiger|Effectiveness of Respiratory Muscle Training by Spirotiger in Chronic Patients|Evaluation of the Effectiveness of Respiratory Muscle Training by the Technique of Hypocapnia Hyperpnea (Spirotiger) in COPD and CHF Patients||Fondazione Salvatore Maugeri|Yes|Active, not recruiting|June 2011|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01556139||89204|
NCT01548040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012744|Compare the Effects of a Standard Therapy Protocol With a 12-week Peri-Operative Program of Kneehab XP Neuromuscular Electrical Stimulation Compared to a Control Treatment in Patients Undergoing Total Knee Replacement|A Randomised Controlled Study To Compare the Effects of a Standard Therapy Protocol With a 12-week Peri-Operative Program of Kneehab XP Neuromuscular Electrical Stimulation Compared to a Control Treatment in Patients Undergoing Total Knee Replacement||Bio-Medical Research, Ltd.|No|Active, not recruiting|March 2012|January 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Both|40 Years|N/A|No|||January 2016|January 21, 2016|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01548040||89822|
NCT01556919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120126|Esophageal Monitoring Device for Assessing Mucosal Impedance|Development of an Esophageal Monitoring Device for the Assessment of Esophageal Epithelium Integrity With Mucosal Impedance||Vanderbilt University|No|Recruiting|March 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|January 19, 2016|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556919||89145|
NCT01544491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001A2314|Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients|||Novartis|Yes|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|1 Year|18 Years|No|||October 2015|October 16, 2015|June 9, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01544491||90094|
NCT01575119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-009150|Decision Aid for Cigarette Smokers Undergoing Surgery|Decision Aid Development for Cigarette Smokers Undergoing Surgery: Specific Aim 2||Mayo Clinic|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|4||Actual|130|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01575119||87752|
NCT01544205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON927-11|Neurofeedback as a Treatment Tool for Depression|fMRI Based Neurofeedback as a Treatment Method for Depression|NFD|Cardiff University||Completed|March 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|65 Years|No|||August 2015|August 19, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01544205||90116|
NCT01574807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endo-Lam2012|The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections|A Prospective, Randomized, Double-blind Study of the Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Inferior Alveolar Nerve Blocks.||Ohio State University|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01574807||87776|
NCT01575093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-112|Safety Evaluation of Bowel Cleansing Regimen for PillCam® COLON 2 Capsule Endoscopy|||Given Imaging Ltd.|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 4, 2012|March 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575093||87754|
NCT01574794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIC-CAPES-001|Exercise Intervention and Running Biomechanics in Older Adults|Changes in Running Gait Biomechanics Following an Intervention Program in Older Runners||University of Calgary|No|Completed|April 2012|September 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|105|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574794||87777|
NCT01576198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN11B3|Studying Biomarkers in Samples From Younger Patients With Wilms Tumor|Validation of Copy Number Changes by MLPA as Predictors of Relapse in Wilms Tumor||Children's Oncology Group|No|Active, not recruiting|April 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2227|||Both|N/A|120 Years|No|Non-Probability Sample|Patients With Wilms Tumor|May 2015|September 30, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01576198||87669|
NCT01545115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPLS08-JBS|Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal|Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal|AnoPalAnoVac|Biomedical Research Center EPLS|Yes|Completed|October 2008|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|410|Samples Without DNA|Sera, culture supernatants|Both|1 Year|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of 5 villages from the Senegal Valley River, belonging to the Podor District in        Saint-Louis Region in Northern Senegal.        Agniam (16°32'N-14°48'W; total population (TP): 989; several temporary ponds, traditional        housing, irrigated crops) Fanaye Diery (16°32'N-15°13'W; TP: 6781; animal husbandry,        irrigated crops, some urbanized habitat) Niandane (16°35'N-14°59'W; TP: 5100; Rice and        banana farming, irrigated crops, some urbanized habitat) Ndiayène Pendao (16°30'N-        15°03'W; TP: 2734; animal husbandry, Savannah surroundings) Guédé Village        (16°33'N-14°48'W; TP:3005; Traditional housing, irrigated crops)|March 2012|March 12, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545115||90046|
NCT01553851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205124|GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer|A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer||Washington University School of Medicine|No|Completed|February 2013|December 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553851||89379|
NCT01554111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1429-11|Comparing Bowel Preparation Regimens for Flexible Sigmoidoscopy|A Randomized Controlled Study Comparing PicoSalax, Versus PicoSalax and Fleet Enema Versus Fleet Enema Alone for Sigmoidoscopy||Queen's University|Yes|Completed|March 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554111||89360|
NCT01553903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 SEIN 09|Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not|Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not|OXYTAM|Institut Claudius Regaud|No|Completed|December 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|29|||Female|18 Years|N/A|No|||June 2013|June 3, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01553903||89376|
NCT01554722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R6345|Needle Nerve Contact in Ultrasound Guided Femoral Block|Incidence of Intraneural Needle Insertion in Ultrasound Guided Femoral Block: Out of Plane Versus in Plane Approach||Hospital Clinic of Barcelona|Yes|Recruiting|November 2011|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 13, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01554722||89313|
NCT01554696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-RA21|A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate|A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate||Astellas Pharma Inc|Yes|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|379|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554696||89315|
NCT01554982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRX-0502-307|A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis|A Long-Term Safety Extension Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis||Keryx Biopharmaceuticals|Yes|Completed|August 2012|August 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554982||89293|
NCT01555606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100687|An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis|A Multicenter, Observational, Noninterventional, Narrative Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis||Janssen Biotech, Inc.|No|Completed|June 2011|July 2012|Actual|July 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|N/A|No|Non-Probability Sample|Study population includes adult patients with moderate-to-severe plaque psoriasis who are        candidates for phototherapy or systemic therapy|July 2015|July 20, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555606||89245|
NCT01555593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630CEC|Effect of Prolonged Decubitus on Nitric Oxide Concentration in Chronic Obstructive Pulmonary Disease|Effect of Prolonged Decubitus on Bronchial Inflammation in COPD Patients Evaluated by Expired NO Concentration Assessment||University of Milan|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|50 Years|85 Years|No|||October 2014|October 28, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01555593||89246|
NCT01556178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-14612|Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research|Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5|Samples Without DNA|whole blood and cerebrospinal fluid|Both|1 Year|21 Years|No|Non-Probability Sample|All children without central nervous system tumors between the ages of 1 year and 21 years        who are undergoing a neurosurgical procedure to address hydrocephalus during which CSF        will be obtained will be considered|February 2016|February 3, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01556178||89201|
NCT01556191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-1003|Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR|Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer|LADIE|Intergroupe Francophone de Cancerologie Thoracique|No|Recruiting|May 2012|December 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|394|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01556191||89200|
NCT01556399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LST-UGIM|Endoscopic Characteristics of Duodenal and Ampullary Lesions|A Correlation of the Endoscopic Characteristics of Duodenal and Ampullary Laterally Spreading Tumours With Their Somatic or Germline Mutations.|DUO/AMP-LST|Western Sydney Local Health District|Yes|Recruiting|November 2011|November 2021|Anticipated|November 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|Adenoma tissue sample and control "regular" tissue sample|Both|18 Years|85 Years|No|Non-Probability Sample|Patients with Duodenal and/or ampullary adenomas or cancers.|December 2015|December 15, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01556399||89185|
NCT01548612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNPSCZ001|Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia|Randomised Double Blind Placebo Controlled Study of Sodium Nitroprusside Added to Treatment as Usual in Patients With Schizophrenia||University of Sao Paulo|Yes|Completed|February 2006|December 2010|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|45 Years|No|||March 2012|March 7, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01548612||89778|
NCT01544478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-110|V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)|A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women||Merck Sharp & Dohme Corp.|No|Active, not recruiting|November 2011|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|1000|||Female|16 Years|26 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|February 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01544478||90095|
NCT01546233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RajavithiMultidisciplinary01|Multidisciplinary Education in Lung Cancer Patients Who Receiving Chemotherapy Treatment|Outcome of Multidisciplinary Education Programme in Self-care in Fatigue Lung Cancer Patients Who Receiving Chemotherapy Treatment||Rajavithi Hospital|No|Not yet recruiting|March 2012|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|45 Years|65 Years|No|Non-Probability Sample|Fatigue Lung Cancer Patients|March 2012|March 6, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546233||89961|
NCT01545102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TN11-26|Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure|Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure||Eastbourne General Hospital|No|Not yet recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|21|||Both|18 Years|N/A|No|Probability Sample|21 CHF patients from Heart Failure clinic at Eastbourne District General Hospital|March 2012|March 6, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545102||90047|
NCT01544218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SL_NIAAARFA_0212|Validating NIAAA Screen Guide in YCMC|Validating NIAAA's Brief Screening Guide in Youth With Chronic Medical Conditions||Children's Hospital Boston|No|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|460|||Both|9 Years|18 Years|No|Non-Probability Sample|9-18 year old youth with one of four chronic conditions - asthma, diabetes, rheumatic or        gastroenterologic conditions|January 2013|January 2, 2013|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01544218||90115|
NCT01544868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P001559|Total Energy Expenditure, Protein Kinetics, and Body Composition in Recovering Burn Children.|Total Energy Expenditure, Protein Kinetics and Body Composition During Recovery From Severe Burn Injury in Children.|TEE|Shriners Hospitals for Children|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Both|2 Years|18 Years|No|||August 2014|August 19, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01544868||90065|
NCT01544530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORID - 335|Cooling to Optimize Organ Life in Donor Study|Feasibility of Mild-to-moderate Therapeutic Hypothermia as an In-vivo Organ Preservation Strategy in Brain-dead Donors|COOLDonor|University of Pittsburgh|Yes|Terminated|March 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|November 21, 2011||No|Lack of funding and other logistic reasons|No||https://clinicaltrials.gov/show/NCT01544530||90091|
NCT01544543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VES0109|Validation of HealthCare Standards in Chronic Obstructive Pulmonary Disease|Validation of HealthCare Standards in COPD|VESALIO|Sociedad Española de Neumología y Cirugía Torácica|No|Completed|February 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|600|||Both|40 Years|N/A|No|Non-Probability Sample|COPD patients hospitalized for an exacerbation of COPD|February 2012|March 5, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01544543||90090|
NCT01575392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Krabbe_trial|Quality Assessment Creatinines in Plasma and Urine|Quality Assessment of Creatinines in Plasma and Urine||Medical Research Foundation, The Netherlands|No|Completed|June 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|181|Samples Without DNA|All patients presenting at the laboratory facility for a 24-hour creatinine clearance and      patients in the dialysis population of the Isala Clinics who came for their periodical KT/V      control, were informed about the study and asked to participate. From the 24-hour urine (and      for peritoneal dialysis population also from the 24-hour peritoneal dialysate fluid) 4      samples of 4 ml were collected. Moreover, extra blood samples (16 ml in total) were drawn on      top of the samples that were necessary for the (routine) 24-hour creatinine clearance.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All patients presenting at the laboratory facility for a 24-hour creatinine clearance and        patients in the dialysis population of the Isala Clinics who came for their periodical        KT/V control, were informed about the study and asked to participate. Moreover, 20        'healthy' volunteers (including the investigators of this study and staff working at the        clinical chemistry department of the Isala clinics) participated in this study.|April 2012|April 10, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01575392||87731|
NCT01545141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-131|Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer|Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer||University of Pittsburgh|Yes|Recruiting|October 2012|August 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|February 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545141||90044|
NCT01545154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMS M12-073|The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer|Phase II Study of The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer||University of Vermont Medical Center||Completed|February 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Male|18 Years|N/A|No|Non-Probability Sample|Males with prostate cancer, 18+|March 2014|March 27, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545154||90043|
NCT01545167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK 061451|The North American Pancreatitis Study|The North American Pancreatitis Study|NAPS|University of Pittsburgh|Yes|Recruiting|September 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|4800|Samples With DNA|Blood samples and extracted biomarkers and genetic material.|Both|14 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|people with and without pancreatitis|February 2012|February 29, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545167||90042|
NCT01545414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICBT Parkinson|Internet-CBT (Cognitive Behavioral Therapy) for Depression and Anxiety in Parkinsons Disease|Internet-based CBT for Depression and Anxiety in Parkinson's Disease: a Pilot Study and Randomized Controlled Trial||Karolinska Institutet|No|Completed|February 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|N/A|N/A|No|||February 2015|February 12, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545414||90023|
NCT01553630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reamed Locked Plating|Reamed Locked Plating - Metaphyseal Fractures of the Distal Femur and Tibia|Reamed Locked Plating - Metaphyseal Fractures of the Distal Femur and Tibia||Florida Orthopaedic Institute|No|Terminated|May 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|6|||Both|18 Years|90 Years|No|||November 2014|November 10, 2014|March 8, 2012||No|Low enrollment.|No||https://clinicaltrials.gov/show/NCT01553630||89396|
NCT01553916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202073|Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain|Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)||Washington University School of Medicine|No|Recruiting|April 2012|April 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|26|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553916||89375|
NCT01554137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8571|Interests of Strengthening Isokinetic Upper Extremity Hemiparetic Sequelae in Patients|Interests of Strengthening Isokinetic Upper Extremity Hemiparetic Sequelae in Patients||University Hospital, Montpellier|Yes|Active, not recruiting|October 2010|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554137||89358|
NCT01554150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/NW/0736|Randomised Controlled Trial of Method of Levels Cognitive Therapy|A Randomised Controlled Trial Comparing Method of Levels Cognitive Therapy With a Contact Service for Improving Outcomes in Primary Care||University of Manchester|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|16 Years|N/A|No|||July 2014|July 18, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554150||89357|
NCT01554124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001521-25|Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis|Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Probable and Confirmed Meningitis: A European Multicenter Phase I-II Trial|NeoMero-2|PENTA Foundation|Yes|Completed|February 2013|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|N/A|90 Days|No|||February 2015|February 12, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01554124||89359|
NCT01554449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8642|Upper Arm Reahabilitation After Stroke and Video Game|Effect of Early Upper Arm Rehabilitation After Stroke Using Adaptative Video Games|MARGAUT|University Hospital, Montpellier|No|Recruiting|September 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01554449||89334|
NCT01554748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01|Improvement of Implant Survival in Total Joint Arthroplasty of the Trapeziometacarpal Joint|Improvement of Implant Survival in Total Joint Arthroplasty of the Trapeziometacarpal Joint||Regional Hospital Holstebro|Yes|Recruiting|January 2008|January 2019|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||August 2015|August 18, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554748||89311|
NCT01555060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|714|Hemoglobin and Iron Recovery Study|Hemoglobin and Iron Recovery Study|HEIRS|National Heart, Lung, and Blood Institute (NHLBI)|Yes|Completed|March 2012|June 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|215|||Both|18 Years|N/A|No|||January 2014|January 22, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01555060||89287|
NCT01555892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29617-GRALE|Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE|Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma|GRALE|Baylor College of Medicine|Yes|Recruiting|January 2013|July 2022|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|N/A|N/A|No|||November 2015|November 11, 2015|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555892||89223|
NCT01555905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF-IRB 147-2011|Respiratory Muscle Strength in Patients With NMD|Respiratory Muscle Strength and Function in Patients With Neuromuscular Disease||University of Florida|No|Recruiting|April 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|12 Months|65 Years|No|||October 2015|October 14, 2015|March 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555905||89222|
NCT01546220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120216-5|Water Method in Elder Patients With Unsedated Colonoscopy|Water Method With Water Exchange Versus Air Insufflation in Elder Patients Undergoing Unsedated Colonoscopy: a Prospective Randomized, Controlled Trial||Fourth Military Medical University|Yes|Withdrawn|November 2011|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|0|||Both|70 Years|80 Years|No|||March 2016|March 24, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01546220||89962|
NCT01555918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0038|A Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers|A Phase I, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers||Astellas Pharma Inc|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|March 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555918||89221|
NCT01555931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1786|Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding|Immediate vs. 4-8 Week Postpartum Levonorgestrel-releasing Intrauterine System Placement: A Randomized Clinical Trial (Short Title: PPIUD1)|PPIUD1|University of North Carolina, Chapel Hill|Yes|Completed|March 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Female|18 Years|45 Years|No|||June 2013|August 21, 2014|March 14, 2012|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01555931||89220|
NCT01544803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/308-31/5A|Randomized Controlled Trial of eScreen for Problematic Alcohol Use|Randomized Controlled Trial of eScreen for Problematic Alcohol Use||Karolinska Institutet|No|Completed|September 2009|October 2011|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|633|||Both|15 Years|N/A|No|||February 2012|March 5, 2012|October 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01544803||90070|
NCT01544816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFG-123X-01|Evaluating the Effects of Snack Products on Energy|||Mondelēz International, Inc.|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|49|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01544816||90069|
NCT01555138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAB149B2401|Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)|A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez® Breezhaler® 150 mcg o.d.) With Salmeterol/Fluticasone Propionate (Seretide® Accuhaler® 50 mcg/500 mcg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease|INSTEAD|Novartis||Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|581|||Both|40 Years|N/A|No|||April 2015|April 8, 2015|March 13, 2012||No||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01555138||89281|
NCT01555151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149E2201|Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma|A Randomized, Double-blind, Double-dummy, 4-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of Two Doses of Mometasone Furoate Delivered Via Concept1 or Twisthaler® in Adult and Adolescent Patients With Persistent Asthma||Novartis|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|739|||Both|12 Years|N/A|No|||April 2015|April 10, 2015|March 13, 2012||No||No|July 6, 2014|https://clinicaltrials.gov/show/NCT01555151||89280|
NCT01555164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0147|A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus||Gilead Sciences|Yes|Completed|June 2012|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|442|||Both|18 Years|75 Years|No|||September 2014|September 17, 2014|March 13, 2012|Yes|Yes||No|September 17, 2014|https://clinicaltrials.gov/show/NCT01555164||89279|
NCT01544556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prineo 1|Use of PrineoTM (Dermabond Protape) Skin Adhesive for Wound Closure Following Abdominoplasty|Use of PrineoTM (Dermabond Protape) Skin Adhesive for Wound Closure Following Abdominoplasty: An Open, Prospective, Controlled, Randomized Clinical Study||Medical University of Graz||Completed|July 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|1|||Both|18 Years|65 Years|No|Probability Sample|Fifty-two women and 8 men aged between 21 and 65 years scheduled for abdominoplasty were        included in the study.|February 2012|March 5, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01544556||90089|
NCT01544881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKC-TI-177|Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes|A Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Study in Subjects With Type 1 Diabetes Comparing Insulin Exposure & Response Following Inhalation of Technosphere Insulin Inhalation Powder Using the Gen2C Inhaler Vs Subcutaneous Rapid-Acting Analog||Mannkind Corporation|No|Completed|March 2012|January 2013|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|60 Years|No|||January 2013|January 24, 2013|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01544881||90064|
NCT01545427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-214|Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma|A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma||Lawson Health Research Institute|Yes|Terminated|April 2008|December 2008|Actual|December 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2012|March 6, 2012|March 1, 2012|Yes|Yes|Frequent adverse events occurred early in treatment with poor tolerability.|No||https://clinicaltrials.gov/show/NCT01545427||90022|
NCT01575405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHARM-01|A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally|A Randomized, Double Blind Phase 1 Safety, Acceptability, and Pharmacokinetic Study Comparing Three Formulations of Tenofovir 1% Gel Administered Rectally to HIV-1 Seronegative Adults||University of Pittsburgh|Yes|Completed|March 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|13|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 6, 2013|February 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575405||87730|
NCT01546038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1371003|A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase 1b/2 Study To Evaluate The Safety And Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose ARA-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome||Pfizer|Yes|Recruiting|June 2012|October 2019|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|255|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546038||89976|
NCT01546272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0147|Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device|Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device|S2CARA|Nantes University Hospital|No|Completed|March 2012|November 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|664|||Both|18 Years|75 Years|No|||March 2016|March 7, 2016|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01546272||89958|
NCT01553929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AOI-03|Physical Training and Cognitive Activity on the Mild Cognitive Impairment (MCI) Patient|Physical Trainig and Cognitive Activity on the MCI Patient|EPAC-M|Centre Hospitalier Universitaire de Nice|No|Terminated|March 2012|January 2015|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|5|||Both|40 Years|75 Years|No|||August 2015|August 13, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01553929||89374|
NCT01554163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-112|Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis|A Phase III, 12-Week, Randomized, Active-Comparator-Controlled, Parallel-Group, Double Blind Study in Korea to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis||Merck Sharp & Dohme Corp.|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|239|||Both|40 Years|N/A|No|||October 2015|October 8, 2015|March 12, 2012|Yes|Yes||No|September 25, 2013|https://clinicaltrials.gov/show/NCT01554163||89356|
NCT01554475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1705(REK)|Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction|Use of Alternative Medicine Among Patients With Dementia and Mild Cognitive Dysfunction||University Hospital of North Norway|No|Completed|March 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|151|||Both|N/A|N/A|No|Non-Probability Sample|patients diagnosed with dementia, under follow-up at Kløveråsen out-patient clinic|February 2015|February 16, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01554475||89332|
NCT01554462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08033V|The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD|The Effects of Eicosapentaenoic Acid (EPA)/ Docosahexaenoic Acid (DHA) Supplementation on Cognitive Control in Children With Attention Deficit Hyperactivity Disorder (ADHD)||Unilever R&D|No|Completed|January 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|79|||Male|8 Years|12 Years|Accepts Healthy Volunteers|||December 2013|December 10, 2013|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01554462||89333|
NCT01554761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia|Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia||China Medical University, China|Yes|Recruiting|February 2012|||May 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||March 2012|March 13, 2012|February 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554761||89310|
NCT01555034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|016111CTIL|Movement Therapy and Childhood Obesity|The Effect of Movement Therapy on the Success in a Multidisciplinary Intervention for the Treatment of Childhood Obesity||Meir Medical Center|No|Completed|April 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||March 2014|April 13, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01555034||89289|
NCT01555372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U2032001|Treatment of Unstable Distal Clavicular Fractures (Neer 2b): Hook Plate vs Locking Plate|Treatment of Unstable Distal Clavicular Fractures (Neer 2b): Hook Plate vs Locking Plate||Shanghai Jiao Tong University School of Medicine|Yes|Not yet recruiting|May 2012|May 2014|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2012|March 14, 2012|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01555372||89263|
NCT01555359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCT-TEL-001|Telomerase Activity as a Marker For Mobilization Quality|Telomerase Activity Of CD34+ Cells - Marker For Mobilization Quality And Predictor For Engraftment After Autologous Hematopoietic Cell Transplantation||Rabin Medical Center|No|Recruiting|February 2012|February 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Whole blood|Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing stem cell mobilization and collection|January 2012|March 14, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555359||89264|
NCT01556438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14459|Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma|A Phase 1 Study of LY2127399 in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed or Refractory Multiple Myeloma||Eli Lilly and Company|No|Completed|July 2012|August 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|20 Years|N/A|No|||February 2016|February 9, 2016|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556438||89182|
NCT01556451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-034|ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)|An Open-label, Single-arm, Multi-center, Phase IV Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in Korea||Merck Sharp & Dohme Corp.|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|180|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 11, 2015|February 17, 2012|No|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01556451||89181|
NCT01554904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 0102011|Study Will Test the Theory That Training With the Facial-Flex Exercise Device Will Improve Snoring in Patients|Facial-Flex as a Treatment for Snoring||Facial Concepts, Inc.|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 29, 2013|February 28, 2012|Yes|Yes||No|February 24, 2013|https://clinicaltrials.gov/show/NCT01554904||89299|This was not a sham controlled trial. The number of participants was somewhat limited.
NCT01554605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-NV-648-CTIL|Gait Disturbances and Hips Bone Mineral Density|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|March 2012|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|40|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|subjects will be recruited from the bone clinic|March 2012|March 14, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01554605||89322|
NCT01554618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5551C00002|Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes|A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes||AstraZeneca|Yes|Recruiting|November 2011|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|10 Years|17 Years|No|||February 2016|February 17, 2016|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554618||89321|
NCT01554917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-109|A Study of Iguratimod in Patients With Active Rheumatoid Arthritis|A Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA)||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|May 2012|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1759|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554917||89298|
NCT01544894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sr-ral-postmOTP|Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis|Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis||University of Valencia|No|Completed|September 2009|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||August 2012|August 31, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01544894||90063|
NCT01544907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBAPTA|Prospective Randomized Trial Comparing DEB Versus Conventional PTA for the Treatment of Hemodialysis AVF or AVG Stenoses|Prospective Randomized Trial Comparing Drug Eluting Balloon Angioplasty Versus Conventional Percutaneous Transluminal Angioplasty Balloon for the Treatment of Hemodialysis Arterio-Venous Fistula or Arterio-Venous Graft Stenoses|DEBAPTA|Singapore General Hospital|Yes|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|21 Years|N/A|No|||March 2014|March 4, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01544907||90062|
NCT01545206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100046-E|Dose Reducing Door-to-balloon Time in ST-elevation Myocardial Infarction Cause Less Cost?|Better Quality With Less Cost? A Single Hospital Experience on Reducing Door-to-balloon Time in ST-elevation Myocardial Infarction||Far Eastern Memorial Hospital|Yes|Completed|February 1997|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|215|||Both|18 Years|N/A|No|Non-Probability Sample|Patient presented between Feb. 1, 2007 and Jul. 31, 2009 at Far Eastern Memory Hospital        for acute STEMI and unwent primary PCI.|March 2012|March 5, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545206||90039|
NCT01545180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11415|Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure|Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure.|PH-HF|French Cardiology Society|No|Recruiting|February 2012|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|520|Samples With DNA|-  3 tubes of 6 blood for analysis of biomarkers        -  2 tubes of 6 mL blood for DNA analysis|Both|18 Years|N/A|No|Non-Probability Sample|Inclusion of consecutive patients recruted from cardiology departments for all        participating centres. Participation in the study is offered to all French institutions        (academic hospitals, general hospitals, army hospitals and private clinics) with        cardiology units. A physician is responsible for study recruitment at each centre.|February 2015|February 12, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545180||90041|
NCT01544842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Takrolimuusi123|Tacrolimus Ointment in Oral Lichen Planus|Comparison of Topical Tacrolimus, Triamcinolone and Placebo in the Treatment of Symptomatic Oral Lichen Planus||University of Oulu|No|Terminated|August 2004|July 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|28|||Both|18 Years|N/A|No|||December 2014|July 15, 2015|January 4, 2012||No|Lack of resources|No||https://clinicaltrials.gov/show/NCT01544842||90067|
NCT01544855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Centrum|Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype?|Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype?||Université de Sherbrooke|Yes|Completed|February 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|80|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 27, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01544855||90066|
NCT01545128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/H0311/87|Impact of Pulmonary Rehabilitation on Direct Healthcare Costs in Chronic Obstructive Pulmonary Disease (COPD)|A Retrospective Case-control Study Comparing the Direrct Healthcare Costs of Conventionally Managed COPD Patients With Those Who Have Completed a Pulmonary Rehabilitation Programme||East and North Hertfordshire NHS Trust|No|Completed|January 2009|January 2010|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|70|||Both|40 Years|N/A|No|Non-Probability Sample|copd|March 2012|March 5, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545128||90045|
NCT01546051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCI-632-CL-002|A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Food Effect of BCI-838; and, An Open-Label Minidose Bioavailability Study to Compare Several BCI-632 Pro-drug Candidates in Healthy Male Subjects||BrainCells Inc.|No|Completed|October 2011|February 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|31|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01546051||89975|
NCT01546285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118.04-2011-GES-0002|B40 Non-Invasive Blood Pressure Equivalency Study|B40 Non-Invasive Blood Pressure Equivalency Study||GE Healthcare|No|Completed|March 2012|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|3 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 2, 2013|February 28, 2012||No||No|January 16, 2013|https://clinicaltrials.gov/show/NCT01546285||89957|
NCT01554176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096-022|Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)|A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder||Merck Sharp & Dohme Corp.|No|Terminated|May 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|129|||Both|21 Years|64 Years|No|||September 2015|September 16, 2015|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554176||89355|
NCT01554800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP 501-01|Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease|An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease||Alphacore Pharma, LLC|No|Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|30 Years|85 Years|No|||January 2013|January 10, 2013|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01554800||89307|
NCT01554774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVVV-CBM-01|Non-invasive Assessment of Pulmonary Vascular Resistance in Elderly Patients With Chronic Obstructive Pulmonary Disease|Observational Study of Comparison of Echocardiographic Markers of Right Ventricular Function and Electrocardiographic Signs of Chronic Cor Pulmonale in Elderly Patient With COPD|PVR-COPD|Hospital Viamed Valvanera, Spain|Yes|Completed|March 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Actual|60|||Both|50 Years|90 Years|No|Non-Probability Sample|Consecutive series of patients with a diagnosis of COPD who were treated in the consulting        rooms of the department of respiratory physiopathology.|February 2015|February 6, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01554774||89309|
NCT01554787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-251|Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue|||China Medical University Hospital||Recruiting|January 2012|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|40 Years|80 Years|No|||March 2012|March 13, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01554787||89308|
NCT01555333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|209FX303|An Open Label Extension Study in Subjects With Fragile X Syndrome|An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome|209FX303|Seaside Therapeutics, Inc.|Yes|Terminated|November 2011|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|357|||Both|5 Years|50 Years|No|||July 2013|July 30, 2013|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01555333||89266|
NCT01555346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-T21-304|Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies|A Clinical Study to Evaluate the Clinical Performance of the SEQureDx Trisomy 21 Test in the Detection of the Relative Quantity of Chromosome 21 in Circulating Cell-Free DNA Extracted From a Maternal Blood Sample Obtained From Pregnant Women With One or More High Risk Indicators for Fetal Chromosome 21 Aneuploidy||Sequenom, Inc.|No|Active, not recruiting|March 2012|December 2015|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|3062|Samples With DNA|Whole blood specimens will be collected and processed to plasma. DNA will be extracted from      the plasma.|Female|18 Years|60 Years|No|Non-Probability Sample|Pregnant women between 10 and 22 weeks of gestation inclusive who have one or more high        risk indicators for fetal chromosome 21 aneuploidy.|August 2014|December 9, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01555346||89265|
NCT01544452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2009-094|Total Preoperative MR Diagnostic Evaluation Versus Standard Diagnostic Evaluation in Patients With Rectal Cancer|Prospective Randomized Study of Total Preoperative MR Diagnostic Evaluation Versus Standard Diagnostic Evaluation in Patients With Rectal Cancer||Herlev Hospital|No|Terminated|August 2010|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|75|||Both|18 Years|N/A|No|||November 2014|November 26, 2014|November 7, 2011||No|Lack of MR scanning capacity|No||https://clinicaltrials.gov/show/NCT01544452||90097|
NCT01544465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00045490|Structured Physical Activity for Sleep Quality and Daytime Sleepiness in Patients With Parkinson's Disease|Effect of a Structured Physical Activity Program on Sleep Quality and Sleepiness in Parkinson's Disease||Northwestern University|No|Terminated|August 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|50 Years|N/A|No|||March 2014|March 20, 2014|February 22, 2012||No|Difficulty recruiting, funding lapsed|No||https://clinicaltrials.gov/show/NCT01544465||90096|
NCT01555632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|429-11|Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy|A Pilot Study of Atorvastatin on Prevention of Metabolic Syndrome in Subjects With Prostate Cancer on Long Term Androgen-deprivation Therapy||University of Nebraska|Yes|Withdrawn|March 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|0|||Male|19 Years|N/A|No|||June 2013|June 17, 2013|February 9, 2012|No|Yes|Other more favorable treatments are now available.|No||https://clinicaltrials.gov/show/NCT01555632||89243|
NCT01546454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB8023|Relationship Between the Menstrual Cycle and Heart Disease in Women|Identification of the Menstrual Cycle-Associated Factors That Modulate Circulating Lipid Levels in Premenopausal Women||Oregon Health and Science University|No|Completed|February 2012|January 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|5|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 17, 2014|February 22, 2012|No|Yes||No|April 11, 2014|https://clinicaltrials.gov/show/NCT01546454||89944|
NCT01546467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/1788 (REK)|Cognitive Remediation in Early Phase Psychosis|Cognitive Remediation in Early Phase Psychosis||Oslo University Hospital|No|Recruiting|September 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|40 Years|No|||March 2012|March 1, 2012|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01546467||89943|
NCT01546792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15488|Lifestyle Intervention in Obstructive Sleep Apnoea|Effects of a Lifestyle Intervention on Quality of Life, Weight Loss and Cardiovascular Risk in Patients With Obstructive Sleep Apnoea Established on Continuous Positive Airway Pressure||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|85 Years|No|||March 2012|March 1, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01546792||89918|
NCT01545011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 11.083 (EMI)|Effects of Inspiratory Muscle Training on Dyspnea in Subjects With Chronic Obstructive Pulmonary Disease|Effects of Inspiratory Muscle Training Combined With a Pulmonary Rehabilitation Program Versus a Program of Pulmonary Rehabilitation Alone on Dyspnea: a Randomized Trial|IMT|University Hospital, Brest|No|Completed|October 2011|September 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|38|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545011||90054|
NCT01546402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aniruddha9|Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema|Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema||Postgraduate Institute of Medical Education and Research|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 17, 2014|March 2, 2012||No||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01546402||89948|
NCT01546415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ACN01|Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia|A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia||Novartis||Completed|October 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01546415||89947|
NCT01546428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X1101|A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors|A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors||Novartis|No|Active, not recruiting|November 2004|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01546428||89946|
NCT01546727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK091251|Behavioral Treatment for Obese Preschoolers|Clinic and Home Family Based Behavioral Treatment for Obese Preschoolers|LAUNCH|Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|March 2012|November 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|168|||Both|2 Years|5 Years|No|||January 2016|January 26, 2016|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546727||89923|
NCT01576107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT-PA8|MOTIVACTION - Study|Motivational Intervention Enhancing Physical Activity In Oncology Patients (MOTIVACTION)||German Cancer Research Center||Completed|April 2012|May 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|76|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01576107||87676|
NCT01576120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-207|Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients|Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study|RD-207|Given Imaging Ltd.|No|Completed|March 2012|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Both|18 Years|75 Years|No|||October 2014|October 5, 2014|April 5, 2012|No|Yes||No|October 5, 2014|https://clinicaltrials.gov/show/NCT01576120||87675|
NCT01568580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC8AIII|Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A|Open-label, Non-comparative, Multicenter, Phase III for Evaluation of Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Previously Treated Patients With Hemophilia A||Green Cross Corporation|No|Completed|December 2004|September 2006|Actual|September 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|71|||Both|12 Years|N/A|No|||March 2012|March 29, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01568580||88253|
NCT01568866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003|Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients|A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma|ENDEAVOR|Onyx Pharmaceuticals|Yes|Active, not recruiting|June 2012|December 2018|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|929|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|March 28, 2012|Yes|Yes||No|November 6, 2015|https://clinicaltrials.gov/show/NCT01568866||88231|
NCT01576653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-343|Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL|Prospective Clinical Evaluation of Bata-D-Glucan Assay for Diagnosis of Invasive Fungal Infection in Blood and Bronchoalveolar Lavage||Medical University of Graz|No|Recruiting|June 2011|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|95 Years|No|||March 2016|March 18, 2016|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576653||87634|
NCT01576666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDE225X2114|Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors|A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors||Novartis|No|Completed|July 2012|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|April 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01576666||87633|
NCT01576913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9340-GDR-CTIL|Music Pacing in Pediatric Exercise Testing|Music Pacing in Pediatric Exercise Testing||Sheba Medical Center|No|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator)|2||Actual|20|||Male|8 Years|12 Years|Accepts Healthy Volunteers|||November 2014|November 22, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01576913||87614|
NCT01576926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116/08|Evolution of Swallowing in Patients Undergoing Lateral Pharyngoplasty With Preservation Stylopharyngeal Muscle|Evolution of Swallowing in Patients Undergoing Lateral Pharyngoplasty With Preservation Stylopharyngeal Muscle||Hospital do Servidor Publico Estadual|Yes|Completed|March 2009|February 2012|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with obstructive sleep apnea, indicating the lateral pharyngeal|April 2012|April 11, 2012|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01576926||87613|
NCT01576939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-21777|Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer|A Feasibility Study of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer Patients||Stanford University|Yes|Active, not recruiting|August 2011|May 2015|Anticipated|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|September 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01576939||87612|
NCT01577498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR 11118|Age Estimation of Adolescents for Legal Purposes|Age Estimation of Adolescents for Legal Purposes: Determining the Medical Response|AGE-ADO|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|May 2012|March 2014|Anticipated|April 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|||Male|10 Years|30 Years|No|Non-Probability Sample|Adolescents or young adult addressed by the judicial police officer,for age determination        in one of the participating centers|January 2012|February 13, 2013|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01577498||87569|
NCT01546571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103A-301|Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients|A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence|MAVIS|Polynoma LLC|No|Recruiting|April 2012|October 2018|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|1059|||Both|18 Years|80 Years|No|||December 2015|December 8, 2015|February 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546571||89935|
NCT01546584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-1|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2011|||||N/A|N/A|N/A||||||||||||||July 30, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546584||89934|
NCT01546597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0137|Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine|A Phase 1, Open-Label, Single Cohort, Four-period Sequential Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine in Subjects With Type 2 Diabetes Mellitus||Gilead Sciences|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|30 Years|65 Years|No|||July 2012|July 9, 2012|February 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01546597||89933|
NCT01547468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.198.C|A Comparison of Two Pain Control Techniques on Deliruim in Hip Fracture Patients|Does Femoral Nerve Catheterization Reduce the Incidence of Post-Operative Delirium in Patients Presenting for Hip Fracture Repair?||Ochsner Health System|No|Recruiting|March 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|270|||Both|50 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 14, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547468||89866|
NCT01547169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39683-A|Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days|Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days|SNIFF-LONG 21|University of Washington|Yes|Completed|March 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|50 Years|89 Years|No|||December 2012|December 17, 2012|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547169||89889|
NCT01547182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R18HL076441-06|Cooperative Lifestyle Programs (CLIP-II)|Cooperative Lifestyle Programs (CLIP-II)|CLIP-II|Wake Forest School of Medicine|Yes|Active, not recruiting|March 2012|March 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|273|||Both|60 Years|79 Years|No|||December 2015|December 7, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01547182||89888|
NCT01548209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0415|Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery|Effects of a Single Dose Dexmedetomidine on Postoperative Nausea and Vomiting (PONV) and Quality of Recovery 40 (QoR 40) in Breast Cancer Surgery||Yonsei University|Yes|Completed|September 2011|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|97|||Female|20 Years|70 Years|No|||January 2015|January 30, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01548209||89809|
NCT01544712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ref 2004/08 st 3|Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow|Treatment of Stage 3 Osteonecrosis of the Femoral Head by Autologous Transplantation of Bone Marrow Cells: a Randomized, Controlled Double Blind Study||University Hospital of Liege|No|Completed|August 2004|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||February 2012|March 5, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01544712||90077|
NCT01548495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDS-2011|Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients|Investigating Recombinant Human Erythropoietin (rHuEPO) Treatment Efficacy Depending on the Presence of Erythropoietin Autoantibodies in Myelodysplatic Syndrome (MDS) Patients|MDS|Meir Medical Center|No|Not yet recruiting|May 2012|September 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|MDS patient from meir health care center|March 2012|March 8, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01548495||89787|
NCT01548508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0730502|Evaluation of Functionnal ElectromyoStimulation on Leg In Advanced Chronic Heart Failure After Hospitalisation for Acute Decompensation|Evaluation of Functionnal ElectromyoStimulation on Leg In Advanced Chronic Heart Failure After Hospitalisation for Acute Decompensation|EMSICA|University Hospital, Toulouse|Yes|Completed|July 2008|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||August 2015|August 21, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01548508||89786|
NCT01544673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951164|Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males|An Open-label, Placebo-controlled Phase 1 Study to Evaluate the Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Male Subjects||Pfizer|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|February 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01544673||90080|
NCT01544348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-MEDI4212-1085|A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL|A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE >= 30 IU/mL||MedImmune LLC|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|295|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|January 31, 2012|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01544348||90105|
NCT01546714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASTDA WSHP|Sexually Transmitted Infections Among African American Women Who Have Sex With Women|Sexually Transmitted Infections Among African American Women Who Have Sex With Women|WSHP|University of Alabama at Birmingham|No|Completed|August 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|165|Samples With DNA|One vaginal swab and one endocervical swab to be stored for future studies.|Female|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|African American women, aged 16 years or older, living in Birmingham, Alabama|October 2015|October 2, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546714||89924|
NCT01546753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113364|Walnut Oral Immunotherapy for Tree Nut Allergy|Walnut Oral Immunotherapy for Tree Nut Allergy|WOIT|University of Arkansas|Yes|Active, not recruiting|April 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|6 Years|45 Years|No|||November 2015|November 30, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546753||89921|
NCT01547052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012007764|Adapting Dialectical Behavior Therapy for Children in Residential Care|Adapting Dialectical Behavior Therapy for Children in Residential Care: Pilot Randomized Clinical Trial With Children With Severe Emotional and Behavioral Dysregulation|DBT-C res|Weill Medical College of Cornell University|Yes|Active, not recruiting|April 2011|September 2016|Anticipated|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Male|6 Years|12 Years|No|||December 2015|December 27, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01547052||89898|
NCT01547312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5172-022|Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)|A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-5172 in Participants With Chronic Hepatitis C||Merck Sharp & Dohme Corp.||Withdrawn|May 2012|November 2012|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Actual|0|||Both|18 Years|65 Years|No|||October 2015|October 13, 2015|February 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01547312||89878|
NCT01547325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-DOX-NT/005|Study of NanoDOX Hydrogel vs Placebo for Dehisced Surgical Wounds|Double-Blind, Single-Site, Pilot Study of NanoDOX Hydrogel Versus Placebo Hydrogel for Dehisced Surgical Wounds.||Nanotherapeutics, Inc.|No|Withdrawn|May 2012|||October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01547325||89877|
NCT01547338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12SU052|Photography or Video in Assessing Breast Reconstruction?|Comparison of Static Photography and Real Time Digital Video in the Assessment of Aesthetic Outcomes Following Breast Reconstruction||NHS Greater Glasgow and Clyde|No|Completed|June 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|35|||Female|18 Years|N/A|No|Non-Probability Sample|Breast reconstruction patients attending for Nipple Areola Complex Tattoing|April 2015|April 13, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547338||89876|
NCT01568268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11-112|Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting|A Randomized, Double Blind, Multicenter Phase III Trial to Evaluate the Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting||Samsung Medical Center|Yes|Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|384|||Both|19 Years|70 Years|No|||December 2013|December 24, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568268||88277|
NCT01569672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPNRP|Ohio Patient Navigator Research Program|Ohio Patient Navigation Research Program|OPNRP|Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|November 2006|||December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|941|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01569672||88169|
NCT01569685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTF3|The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy|The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study|PTF3|Psychiatric Center Ballerup|Yes|Completed|April 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|207|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01569685||88168|
NCT01576679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000029136|Safety and Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-Abdominal Collections in Children - A Prospective Study|A Double Blind, Randomized Controlled Trial Examining the Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-abdominal Collections in Children - a Prospective Study||The Hospital for Sick Children|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|18 Years|No|||November 2015|November 16, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576679||87632|
NCT01569386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMIN000007598|Low Intensity Physical Activity Leads to Improvement in Brachial-ankle Pulse Wave Velocity of Hemiplegics|Low Intensity Physical Activity Leads to Improvement in Brachial-ankle Pulse Wave Velocity in the Affected Leg of Hemiplegics|LIPA|Gunma PAZ College|Yes|Completed|June 2004|February 2012|Actual|February 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Male|65 Years|90 Years|No|||April 2012|April 2, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01569386||88191|
NCT01570166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC16|Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma|Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma||Sun Yat-sen University|Yes|Recruiting|November 2011|June 2015|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||March 2012|April 3, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570166||88131|
NCT01566084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5114|Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults|Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults||University of Colorado, Boulder|Yes|Completed|February 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|March 23, 2012|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT01566084||88444|Due to the complexity, burden, and, in some cases, invasiveness of the study design and procedures, only a limited number of subjects could be studied.
NCT01547195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0360/10|Effects of Swimming in the Treatment of Fibromyalgia|Assessment of the Effects of Swimming in the Treatment of Patients With Fibromyalgia.|ESTF|Federal University of São Paulo|Yes|Recruiting|January 2012|December 2012|Anticipated|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Female|18 Years|60 Years|No|||March 2012|March 28, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01547195||89887|
NCT01547481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fMRI - Skidmore|MRI Study of Brain Activity in Healthy Adults and Individuals With Parkinsonism and Rapid Eye Movement Disorder.|Statistical Mapping of the Brain in Progressive Supranuclear Palsy, Essential Tremor, Parkinson Disease, Parkinsonism, and REM Behavior Disorder||University of Alabama at Birmingham|No|Recruiting|December 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|150|||Both|19 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with PD, MSA-P, ET, or PSP will be recruited based on clinical criteria from the        UAB Comprehensive Parkinson Disease and Movement Disorder Clinic located at The Kirklin        Clinic at UAB. This center sees over 3,500 patients annually. Individuals with RBD will be        recruited from the UAB University Hospital and UAB Highlands Sleep Disorders Center and        will be identified through patient contact with a UAB Department of Neurology physician.|September 2015|September 9, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01547481||89865|
NCT01547494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCCR-MIG1|A Nutritional Intervention for Migraines|A Nutritional Intervention for Migraines||Physicians Committee for Responsible Medicine|Yes|Completed|September 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Both|18 Years|N/A|No|||May 2013|May 13, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547494||89864|
NCT01547728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004125|Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery|Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery||Mayo Clinic|No|Terminated|February 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|90 Years|No|||July 2015|July 13, 2015|February 7, 2012|Yes|Yes|Too many barriers to enroll participants.|No|April 21, 2015|https://clinicaltrials.gov/show/NCT01547728||89846|The study was terminated because there were too many barriers to enroll participants.
NCT01545583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14352|A Study of LY3016859 in Healthy Volunteers|Study of the Safety, Tolerability and Pharmacokinetics of LY3016859 After Single Intravenous and Subcutaneous Dosing in Healthy Volunteers||Eli Lilly and Company|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Anticipated|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 18, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545583||90010|
NCT01545596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-0111|Will a Real Time Advisory for Double Low State Change Clinical Behavior and Impact Outcomes|A Randomized Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Double and Triple Low Combination of Mean Arterial Pressure, and Either End-tidal Anesthetic Concentration or Bispectral Index.||Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2011|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20237|||Both|18 Years|N/A|No|||May 2014|May 23, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545596||90009|
NCT01545024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-Kamoi|Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus|Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus||Nagaoka Red Cross Hospital|No|Recruiting|September 2011|January 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|20 Years|95 Years|No|Probability Sample|Type 1 and 2 diabetic patients who have AND determined by C.V. R-R, outpatients regularly        visiting hospital and more than 20 years old (gender is disregarded). Type 1 diabetic        patients are treated with Epalrestat 50 mg. 150 mg t.i.d., while type 2 diabetic patients        are treated with DPP-IV inhibitors.|February 2012|March 13, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01545024||90053|
NCT01544361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-MEDI7814-1027|A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers|A Phase 1, Randomized, Placebo-controlled, Single-dose Study to Evaluate the Safety of MEDI7814 in Adult Volunteers||MedImmune LLC|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|125|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|February 15, 2012|Yes|Yes||No|June 23, 2014|https://clinicaltrials.gov/show/NCT01544361||90104|Analyses of PK parameters and immunogenicity were not performed as the clinical development of MEDI7814 had been discontinued because the indication was no longer being pursued.
NCT01545284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6022|Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis|Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis||Innovaderm Research Inc.|No|Completed|March 2012|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545284||90033|
NCT01546168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0909|Deviating the Esophagus in Atrial Fibrillation Ablation|Esophageal Deviation in Atrial Fibrillation Ablation: A Randomized Control Trial||Icahn School of Medicine at Mount Sinai|Yes|Terminated|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|88|||Both|18 Years|80 Years|No|||February 2015|February 23, 2015|February 13, 2012|Yes|Yes|Interim analysis: no statistically significant difference in the 2 study arms.|No||https://clinicaltrials.gov/show/NCT01546168||89966|
NCT01546181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-03|Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases|Observational, Follow-up Study of Adaptive Optics Retinal Imaging in Controls and During Retinal or General Diseases|iPhot|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|October 2010|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||8|Anticipated|300|||Both|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|controls and patients with any kind of retinal alteration|February 2016|February 23, 2016|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546181||89965|
NCT01576952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-303-003|Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects|A Randomized Double-Masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects|ISV-303|InSite Vision||Completed|July 2012|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|268|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576952||87611|
NCT01577225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT10/02|OPSITE Post-Op Visible Wound Dressings in Treatment of Surgical Incisions|A Prospective, Open, Randomised Controlled Trial to Compare OPSITE Post-Op Visible Wound Dressings With Standard Therapy in the Treatment of Surgical Incisions.|OPOV|Smith & Nephew Medical (Shanghai) Ltd|No|Completed|November 2011|August 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|90 Years|No|||April 2013|April 2, 2013|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577225||87590|
NCT01577511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/JFB-01|Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer|Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer: Molecular Characterization and Implications for Therapeutic Strategies||Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|June 2012|October 2017|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|Peroperative blood sample plus primary and metastatic tumor biopsies.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at        the Nîmes University Hospital.|November 2015|November 3, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577511||87568|
NCT01569399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-21|Efficacity of rTMS in Alcohol Dependance|Evaluation de l'efficacité thérapeutique de la Stimulation magnétique transcrânienne répétée Sur le Traitement du Craving à l'Alcool et la prévention de la Rechute Alcoolique à 6 Mois Chez Les Sujets dépendants et Des Facteurs génétiques déterminant la réponse thérapeutique||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2011|||February 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|65 Years|No|||February 2015|February 5, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01569399||88190|
NCT01569698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00670-39|Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury|Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury|EPURE|Rennes University Hospital|No|Recruiting|June 2012|October 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|600|||Both|N/A|18 Years|No|Non-Probability Sample|Children with an acute renal failure|May 2015|May 26, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01569698||88167|
NCT01569126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14638|A Study of LY110140 in Healthy Japanese Male Participants|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY110140 in Healthy Japanese Male Subjects||Eli Lilly and Company|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|56|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 14, 2014|March 30, 2012|No|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01569126||88211|
NCT01569373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001493|Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)|Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD).||Mayo Clinic|No|Enrolling by invitation|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have undergone an allogeneic stem cell transplant being followed for post        transplant care.|May 2014|May 26, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01569373||88192|
NCT01565876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|963-2010-CLIL|Auxiliary Device to Alleviate Soldiers' Backload|Auxiliary Device to Alleviate Soldiers' Backload|minkal|Medical Corps, Israel Defense Force||Not yet recruiting|December 2012|January 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|12|||Male|21 Years|28 Years|Accepts Healthy Volunteers|||March 2012|March 28, 2012|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01565876||88460|
NCT01566097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1202-032-397|Intervention Trial of Culturally-Appropriate Decision Aids for Smoking Cessation|Development and Application of Culturally-Appropriate Decision Aids for Smoking Cessation in Korea: a Single Arm Intervention Trial With Historical Control||Seoul National University Hospital|No|Active, not recruiting|April 2012|July 2015|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 25, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566097||88443|
NCT01566331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|unipd|Safe Delivery Using a New Device Namely a Belt on the Belly of Pregnant Woman|Safe Natural Delivery by Using a New Inflatable Ergonomic Three Chambers Belt|SDB|University of Padua|Yes|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|80|||Female|23 Years|42 Years|Accepts Healthy Volunteers|||March 2012|March 26, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01566331||88425|
NCT01566578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGFR-Study|A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF|A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF|EGFR|Ennar Pharmaceuticals AF|No|Recruiting|April 2012|November 2012|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Male|18 Years|60 Years|No|||August 2012|August 2, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01566578||88406|
NCT01547208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARTITA|Does Timing of VT Ablation Affect Prognosis in Patients With an Implantable Cardioverter-defibrillator?||PARTITA|IRCCS San Raffaele|No|Recruiting|September 2012|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|590|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01547208||89886|
NCT01547936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-270-0002|Effect of Controlled Adverse Environment (CAE) on Tear Film Stability|A Single-Center Study Evaluating the Effect of the Controlled Adverse Environment (CAE) on Tear Film Stability Using the OPI 2.0 System, Ocular Protection Index (OPI), Tear Film Break-Up Time (TFBUT) and Mean Break up Area by Region (MBA) in Patients Diagnosed With Dry Eye Evaluated During Their Natural Blink Pattern||ORA, Inc.|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|33|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed with dry eye disease|March 2012|March 5, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01547936||89830|
NCT01547741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSABP-B-49|Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer|A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer||NSABP Foundation Inc|Yes|Active, not recruiting|April 2012|May 2019|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1871|||Female|18 Years|N/A|No|||October 2015|October 21, 2015|March 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547741||89845|
NCT01545609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1385|A Trial Assessing the Effectiveness of Text Messages in Improving Continuation of Birth Control|A Text Message Support System for Effective Continuation of a Birth Control Method in Female Adolescents: 'BC 2U'|BC 2U|Icahn School of Medicine at Mount Sinai|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Female|15 Years|19 Years|Accepts Healthy Volunteers|||December 2013|December 20, 2013|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01545609||90008|
NCT01545869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fractional CO2 in freckles|Efficacy and Safety of Fractional Carbon Dioxide Laser for Treatment of Facial Freckles.|Efficacy and Safety of Fractional Carbon Dioxide Laser for Treatment of Facial Freckles||Cairo University|Yes|Completed|March 2012|October 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|10 Years|N/A|No|||April 2014|April 4, 2014|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545869||89988|
NCT01545557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.CIP.29090|Pan Facial Volume Restoration|Pan Facial Volume Restoration With a New Hyaluronic Acid Dermal Filler||Galderma|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2014|March 24, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01545557||90012|
NCT01546441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123|IMPACT Plus: The Integrated Complex Care Clinic|IMPACT Plus: The Integrated Complex Care Clinic||Sunnybrook Health Sciences Centre|No|Not yet recruiting|April 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|350|||Both|65 Years|N/A|No|||March 2012|March 6, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546441||89945|
NCT01546740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIV-0060-11|Prevalence of Glaucoma in the Israeli Arab Population|Glaucoma Prevalence in the Israeli Arab Population||Ziv Hospital|Yes|Recruiting|January 2012|May 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|15000|||Both|20 Years|N/A|No|Non-Probability Sample|primary care clinics from 1 Arab city in the center of Israel|March 2012|March 6, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01546740||89922|
NCT01577524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-1350|The Use of Diluted Povidone Iodine Irrigation in Spine Surgery|The Use of Diluted Povidone Iodine Irrigation in Spine Surgery||Attabib, Najmedden, M.D.|No|Recruiting|January 2012|June 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|430|||Both|18 Years|75 Years|No|||April 2012|April 12, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01577524||87567|
NCT01577784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APRO02-2011|Pazopanib in Second-line Therapy in Renal Cell Carcinoma|A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor||Associació per a la Recerca Oncologica, Spain|No|Active, not recruiting|April 2012|October 2015|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Both|18 Years|N/A|No|||March 2014|March 11, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01577784||87548|
NCT01578057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-1108|Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol|A Randomized, Double-mask, Four-period Crossover Study in Healthy Subjects to Evaluate the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol||Vanda Pharmaceuticals|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|28|||Female|19 Years|79 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|April 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578057||87527|
NCT01578070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSG-2011-101|Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine|A Single-centre Study Evaluating the Safety of ViscoGel® and Its Safety and Efficacy as an Adjuvant in Act-HIB® Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design|VSG-2011-101|Viscogel AB|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Actual|130|||Both|22 Years|50 Years|Accepts Healthy Volunteers|||August 2013|August 29, 2013|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578070||87526|
NCT01569412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERTUSO|Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors|Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Expressing (1+/SISH Positive, 2+ and 3+) Solid Tumors Progressing After Standard Therapy||Krankenhaus Nordwest||Active, not recruiting|March 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01569412||88189|
NCT01569711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00234-51|Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder|Preliminary Study Evaluating Deep Brain Stimulation of Nucleus Accumbens in Patients Suffering From Chronic and Resistant Major Depressive Disorder|PRESTHYM|Rennes University Hospital|No|Completed|February 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|6|||Both|30 Years|60 Years|No|Non-Probability Sample|Patients with a chronic and resistant major depressive disorder.|May 2015|May 26, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01569711||88166|
NCT01569971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD12-025 TRANSCD|Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program|Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program||St. Jude Children's Research Hospital|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|55|||Both|12 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Adolescents with SCD (all genotypes) ages ≥ 12 years old and ≤ 18 years old and             currently receiving services through the SJCRH Sickle Cell Disease Transition Program          2. Caregiver of an adolescent with SCD who has resided with the adolescent for at least             2 years prior          3. Young adults with SCD (all genotypes) ages ≥ 18 years old and ≤ 30 years old who have             transitioned to adult care|June 2014|June 23, 2014|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569971||88146|
NCT01565889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7977-1910|Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.|Part A: Drug Interaction Study Between GS-7977 and Antiretroviral Therapy (ARV) Combinations of Efavirenz, Tenofovir and Emtricitabine; Efavirenz, Zidovudine and Lamivudine; Atazanavir/Ritonavir, Tenofovir and Emtricitabine; Darunavir/Ritonavir, Tenofovir and Emtricitabine; Raltegravir, Tenofovir and Emtricitabine in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve HIV/HCV Co-infected Patients.||Gilead Sciences|No|Completed|March 2012|November 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|52|||Both|21 Years|N/A|No|||September 2014|September 25, 2014|March 27, 2012|Yes|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT01565889||88459|
NCT01565902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312A2122|Pharmacokinetics of BAF312 in Patients With Hepatic Impairment|A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects.||Novartis|No|Completed|October 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|March 26, 2012||No||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01565902||88458|
NCT01566110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000030346|Celiac Disease and Diabetes- Dietary Intervention and Evaluation Trial|A Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Gluten-Free Diet in Patients With Asymptomatic Celiac Disease and Type 1 Diabetes, Celiac Disease and Diabetes - Dietary Intervention and Evaluation Trial (CD-DIET)|CD-DIET|The Hospital for Sick Children|No|Recruiting|March 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|8 Years|35 Years|No|||August 2013|August 6, 2013|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566110||88442|
NCT01566344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37355.068.11|Reversal of Cardiomyopathy by Suppression of Frequent Premature Ventricular Complexes|Reversal of Cardiomyopathy by Suppression of Frequent Premature Ventricular Complexes - A Prospective Randomized Clinical Trial||Maastricht University Medical Center|No|Recruiting|May 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566344||88424|
NCT01547507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biovo-12-CTIL|Performance Evaluation of AirWay Medix Closed Suction System Compared With a Standard Closed Suction System|Performance Evaluation of AirWay Medix Closed Suction System Compared With a Standard Closed Suction System||Biovo Technologies Ltd|No|Recruiting|March 2012|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|80 Years|No|||May 2012|May 29, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01547507||89863|
NCT01548196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004138|Standard Percutaneous Nephrolithotomy Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL|A Prospective, Randomized Controlled Pilot Study Of Standard Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL||Duke University|Yes|Completed|February 2008|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|N/A|No|||March 2012|March 12, 2015|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01548196||89810|
NCT01575873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101217|A Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids|A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals|GIOP|Amgen|No|Active, not recruiting|March 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|795|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575873||87694|
NCT01545882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-059|A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer|A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer|OTT 10-06|Ottawa Hospital Research Institute|No|Terminated|May 2011|July 2013|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||July 2013|July 22, 2013|March 1, 2012||No|Negative study; Principal Investigator chose to prematurely terminate the study.|No||https://clinicaltrials.gov/show/NCT01545882||89987|
NCT01545908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB # 11-600|Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis|A Randomized Controlled Trial of Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis||Hamilton Health Sciences Corporation|No|Completed|March 2012|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|February 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545908||89986|
NCT01546194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH09-533|A Survey of Patient's Attitudes Towards Consent For Clinical Research In Anesthesiology|A Survey of Patient's Attitudes Towards Consent For Clinical Research In Anesthesiology||NorthShore University HealthSystem Research Institute|No|Completed|September 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|200|||Both|18 Years|90 Years|No|Probability Sample|Patients participating in approved, minimal risk clinical research projects in the        Department of Anesthesiology at NorthShore University HealthSystem will be approached by        the study investigators.|August 2015|August 26, 2015|February 28, 2012||No||No|August 26, 2015|https://clinicaltrials.gov/show/NCT01546194||89964|
NCT01576692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GD2NK|Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma|A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma||St. Jude Children's Research Hospital|No|Active, not recruiting|April 2012|September 2019|Anticipated|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|N/A|21 Years|No|||February 2016|February 1, 2016|April 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01576692||87631|
NCT01577251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 11908|Registry and Biosample Repository|Registry and Biosample Repository||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|June 2008|||June 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|89 Years|No|Probability Sample|Donors will be between the ages of 18 and 89 with pathologically confirmed neoplasia that        are selected for definitive photodynamic therapy, proton, photon radiotherapy        -Pediatric patients with pathologically confirmed neoplasia that have been selected for        definitive radiotherapy may elect to participate in a pediatric arm of quality of life,        provided that the proper processes of parental permission and assent have occurred.|December 2015|December 8, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577251||87588|
NCT01577550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1311.1|Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis|Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)||Boehringer Ingelheim||Completed|April 2012|May 2014|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|39|||Both|18 Years|75 Years|No|||October 2015|October 26, 2015|April 10, 2012||||No||https://clinicaltrials.gov/show/NCT01577550||87565|
NCT01577797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1|A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence|A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence||New Leaf Treatment Center|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01577797||87547|
NCT01578083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203045|Chemotherapy-Induced Cognitive Impairment|The Neurobiology of Chemotherapy-Induced Cognitive Impairment|CICI|Washington University School of Medicine|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|28|||Female|35 Years|70 Years|No|Non-Probability Sample|Breast cancer surviviors from Washington University's Siteman Cancer Center and from        community at large.|April 2012|February 25, 2013|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578083||87525|
NCT01578629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0242|NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event|Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA|NUTRITION|Ohio State University|No|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Anticipated|210|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01578629||87483|
NCT01569425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0048-12-WOMC|Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome|Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome|M-PCOS|Tel Aviv University|Yes|Active, not recruiting|March 2012|June 2015|Anticipated|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|45 Years|No|||April 2015|April 7, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569425||88188|
NCT01570010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Norwegian Foods Study|Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors|Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors|NFS|University of Oslo|Yes|Recruiting|March 2012|March 2040|Anticipated|March 2040|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|500|||Both|50 Years|75 Years|No|||December 2015|December 4, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01570010||88143|
NCT01565915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1400-05|Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit|||Medicis Global Service Corporation||Active, not recruiting|March 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|221|||Both|18 Years|65 Years|No|||August 2013|August 20, 2013|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565915||88457|
NCT01569984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OZM-032|Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis|An Open Label, Single-Centre, Phase II Study for Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy (SBRT) for Colorectal Liver Metastasis (SBRT Avastin)|SBRT-Avastin|Sunnybrook Health Sciences Centre|No|Completed|March 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569984||88145|
NCT01566123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RETROWTS|Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)|Clinical Phase I/II Trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in Patients With Retroperitoneal Soft Tissue Sarcoma||University Hospital Heidelberg|Yes|Recruiting|March 2007|February 2020|Anticipated|January 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01566123||88441|
NCT01547520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DalinTCGH-hsieh-02|Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy|Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy, a Double-blind, Randomized Controlled Study||Dalin Tzu Chi General Hospital|No|Completed|June 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|140|||Both|20 Years|65 Years|No|||March 2012|March 7, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01547520||89862|
NCT01547533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LACT-BENZNIDAZOLE|Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease|Study of Benznidazole Transfer Into Breastmilk in Lactating Women Treated for Chagas Disease|LACTBENZ|Hospital de Niños R. Gutierrez de Buenos Aires|Yes|Completed|August 2011|December 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|Samples Without DNA|breastmilk; plasma|Female|18 Years|40 Years|No|Non-Probability Sample|population of young women with Chagas disease referred to our center for evaluation and        treatment|March 2015|March 17, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01547533||89861|
NCT01548222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM2012|CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target|CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target||Diabetes Care Center|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the Diabetes Care Center clinic|August 2013|August 23, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01548222||89808|
NCT01548235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1812|Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment|A Multicentre, Open Label, Non-randomised, Non-interventional, Observational Safety Study in Subjects With Type 2 Diabetes Mellitus, Starting or Switching to NovoMix® 30 Treatment||Novo Nordisk A/S|No|Completed|February 2006|April 2007|Actual|April 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|423|||Both|N/A|N/A|No|Non-Probability Sample|Patients who started insulin therapy with biphasic insulin aspart 30 and subjects who        switched from other insulin regimens to biphasic insulin aspart 30 by prescription of        their physician as part of routine clinical practice in order to improve glycemic control.        The selection of patients was at the discretion of the treating physician.|March 2012|March 5, 2012|March 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01548235||89807|
NCT01547754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120059|Mild Neurocognitive Disorder in HIV Infection of the Brain|Inflammation and Function of P-gp in HIV Infection of Brain||National Institutes of Health Clinical Center (CC)||Terminated|January 2012|August 2014||||N/A|Observational|Time Perspective: Prospective|||Actual|8|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|March 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01547754||89844|
NCT01547949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e7220|Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults|Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults||Oregon Health and Science University|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01547949||89829|
NCT01576445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIS1|Functional Outcome in Two Types of Total Knee Replacement Surgery for People With Osteoarthritis|Randomised Controlled Trial to Compare the Speed of Recovery and Functional Outcome Following Total Knee Replacement (TKR) Using a Quadriceps Sparing Approach to the Knee Against a Standard Medial Parapatellar Surgical Exposure||Queen Margaret University|No|Completed|March 2010|February 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||April 2012|April 10, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576445||87650|
NCT01576133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00031539|Reducing Disability Via a Bundled Bio-Behavioral-Environmental Approach|Reducing Disability Via a Bundled Bio-Behavioral-Environmental Approach|CAPABLE|Johns Hopkins University|Yes|Recruiting|April 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 24, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01576133||87674|
NCT01576146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAI-4169-005-01 (aka 20120334)|Open-label Study to Assess the Long-term Safety and Efficacy of AMG 416 (Also Known as KAI-4169) in Patients With Secondary Hyperparathyroidism|A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF KAI-4169 (ALSO KNOWN AS AMG 416)IN THE TREATMENT OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM||KAI Pharmaceuticals|No|Terminated|March 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|April 5, 2012|Yes|Yes|Study was terminated early to allow subjects to roll over to study NCT02102204.|No||https://clinicaltrials.gov/show/NCT01576146||87673|
NCT01576419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG201-P3|Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients|Double Blinded, Randomized, Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients||PMG Pharm Co., Ltd|Yes|Completed|January 2010|September 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|309|||Both|40 Years|80 Years|No|||April 2012|April 10, 2012|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576419||87652|
NCT01576432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|260 271110|Non-pharmacological Analgesia During Heel Prick|Non-pharmacological Analgesia During Heel Prick: A Randomized, Controlled Trial||Puerta de Hierro University Hospital|No|Terminated|January 2011|April 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Actual|136|||Both|37 Weeks|41 Weeks|Accepts Healthy Volunteers|||April 2012|April 10, 2012|April 2, 2012||No|The data showed that pain was higher for our standardized method of sampling|No||https://clinicaltrials.gov/show/NCT01576432||87651|
NCT01577264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0091|Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)|Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring||UCB Pharma|No|Terminated|August 2011|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|199|||Both|18 Years|N/A|No|Non-Probability Sample|Patients from previous UCB sponsored studies and all patients for whom the treating        physician prescribed Cimzia.|November 2015|November 9, 2015|April 11, 2012||No|Study is replaced by some Risk Manag. Activities covering the whole Russian Federation.    Primary objectives could not be met due to critical missing information.|No||https://clinicaltrials.gov/show/NCT01577264||87587|
NCT01577537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-016|A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis||Starpharma Pty Ltd|Yes|Completed|March 2012|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|251|||Female|12 Years|N/A|No|||October 2013|October 27, 2013|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577537||87566|
NCT01578642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS004|Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease|A Feasibility Study: An Evaluation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD)||EndoStim Inc.|No|Completed|September 2010|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|21 Years|65 Years|No|||January 2013|February 11, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578642||87482|
NCT01574534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BASKET-SMALL2|Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions|A Prospective, Randomized, Controlled, Open Label, Multicenter Trial to Test the Non-inferiority of Drug Eluting Balloon vs. Drug Eluting Stent Treatment in de Novo Stenoses of Small Native Vessels Regarding Efficacy and Safety|BASKET-SMALL2|University Hospital, Basel, Switzerland|No|Recruiting|April 2012|October 2019|Anticipated|October 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|758|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01574534||87797|
NCT01574820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCKUH HR95-10|Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease|Role of Rosiglitazone Treatment and Secondary Prevention of Cardiovascular Events in Patients With Pre-Diabetes Mellitus and Coronary Artery Disease||National Cheng-Kung University Hospital|No|Completed|November 2006|July 2011|Actual|August 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|105|||Both|18 Years|80 Years|No|||April 2012|April 10, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01574820||87775|
NCT01574833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QYK10147|Early Application of Pulsed Electromagnetic Field in the Treatment of Postoperative Delayed Union|Phase 4 Study of Early Applied Pulsed Electromagnetic Field in the Treatment of Postoperative Delayed Union of Long-bone Fractures||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Completed|March 2007|January 2012|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|80 Years|No|||April 2012|April 9, 2012|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01574833||87774|
NCT01569724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A23465-21|Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma|Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study|TgBEX|Rennes University Hospital|No|Recruiting|January 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|15|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01569724||88165|
NCT01575132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-106-12|Deep Brain Stimulation Follow-up After 10 Years|STN-DBS Retrospective/Prospective Study With a Follow-up Time of Minimum 10 Years||University of Aarhus|No|Enrolling by invitation|November 2012|September 2015|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|15|||Both|N/A|N/A|No|Non-Probability Sample|All Parkinson-patients treated with Deep Brain Stimulation at Aarhus University Hospital        in the years 1998-2002.|November 2012|December 10, 2013|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575132||87751|
NCT01569997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910701|Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units|Interest of Systematic Tracking of Dementia Cases in Nursing Homes: Analysing the Contribution of MultiDisciplinary Team Meeting (MDTM) in Alzheimer's Disease and Related Diseases|IDEM|University Hospital, Toulouse|No|Completed|May 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1428|||Both|60 Years|N/A|No|||August 2015|August 21, 2015|July 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01569997||88144|
NCT01565928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-06|Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer|A Phase 1b, Open-label, Safety and Tolerability Study of Oral MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer||Medivation, Inc.|No|Active, not recruiting|February 2012|December 2015|Anticipated|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Male|18 Years|N/A|No|||June 2015|June 1, 2015|February 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565928||88456|
NCT01575639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREDIS|Prednisolone in Infantile Spasms- High Dose Versus Usual Dose|Randomized Trial of High Dose (4mg/kg) Versus Usual Dose (2mg/kg) Oral Prednisolone in the Treatment of Infantile Spasms.||Lady Hardinge Medical College||Completed|February 2012|March 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|3 Months|24 Months|No|||April 2013|April 7, 2013|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01575639||87712|
NCT01575938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH094323|HIV Prevention Intervention for Young Transgender Women|HIV Prevention Intervention for Young Transgender Women|LifeSkills|Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Active, not recruiting|March 2012|October 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|300|||Female|16 Years|29 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01575938||87689|
NCT01575613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDHOT_OPP1024438|Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission|Reducing the Burden of Malaria by Targeting Hotspots of Transmission and Improving Malaria Control Measures in the Highlands of Western Kenya: Simultaneous Rollout of Four Malaria Control Interventions and Evaluation by Cross-sectional Surveys|REDHOT|Radboud University|No|Completed|April 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17506|||Both|6 Months|N/A|Accepts Healthy Volunteers|||November 2012|November 26, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01575613||87714|
NCT01576224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-275|Early Mobilization After Volar Plate Osteosynthesis of Distal Radius Fractures|Early Mobilization After Volar Plate Osteosynthesis of Distal Radius Fractures. A Prospective Randomized Study.|E-MOB|Koege Sygehus|Yes|Completed|January 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|50 Years|N/A|No|||September 2015|September 6, 2015|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01576224||87667|
NCT01547767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120062|Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy|Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy||National Institutes of Health Clinical Center (CC)||Active, not recruiting|January 2012|||||N/A|Observational|N/A|||Actual|2|||Both|18 Years|80 Years|No|||June 2015|July 23, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01547767||89843|
NCT01547962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-PER-001|A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva|A Pilot Clinical Trial to Assess the Safety and Efficacy of Gintuit (TM) (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen) in Establishing a Functional Zone of Attached Gingiva||Organogenesis|No|Completed|September 2005|May 2006|Actual|May 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|70 Years|No|||April 2012|April 6, 2012|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547962||89828|
NCT01544725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-16|Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults|Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults : a Blinded, Randomized Controlled Trial||Centre Hospitalier Universitaire de Nice|No|Recruiting|April 2012|November 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01544725||90076|
NCT01544738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMNB-01|Sensory Stimulation Effect on Movement Speed in Patients With Parkinson Disease|Aponeurotic Stimulation Effect on Parkinson Bradykinesia||Université Libre de Bruxelles||Completed|November 2008|||May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|N/A|N/A|No|||February 2012|March 5, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01544738||90075|
NCT01548521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 152 02|Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies|Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies and Effect on Suck and Food Intake.|OTBB|University Hospital, Toulouse|No|Completed|July 2011|April 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|N/A|5 Months|No|||June 2013|June 20, 2013|December 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01548521||89785|
NCT01544374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1155|Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities|Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities||Icahn School of Medicine at Mount Sinai|No|Active, not recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|198|||Female|21 Years|N/A|No|||December 2015|December 23, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01544374||90103|
NCT01544387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-0352|Preterm Premature Rupture of Membranes (PPROM): Bed Rest Versus Activity Trial|PPROM: Bed Rest Versus Activity Trial (BRAT)|BRAT|Icahn School of Medicine at Mount Sinai|No|Completed|July 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Female|18 Years|55 Years|No|||February 2014|February 26, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01544387||90102|
NCT01544699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B039201212957(2)|Impact of Non-invasive Brain Stimulation on Motor Recuperation|Impact of Non-invasive Brain Stimulation on Motor Recuperation||University Hospital of Mont-Godinne|No|Recruiting|January 2012|January 2030|Anticipated|January 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01544699||90078|
NCT01576471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNDO 201-003|Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo|A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease|TRUST-I|Coronado Biosciences, Inc.|Yes|Active, not recruiting|July 2012|October 2014|Anticipated|November 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|65 Years|No|||February 2013|May 17, 2013|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576471||87648|
NCT01576731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-003799-35|Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)|Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir|RAL-PEP|Hospital Clinic of Barcelona|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 31, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01576731||87628|
NCT01576705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJL-AFHT-TH10|Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children|Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children|ACTHYF|Institut Jerome Lejeune|Yes|Recruiting|April 2012|February 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|175|||Both|6 Months|18 Months|No|||January 2016|January 29, 2016|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01576705||87630|
NCT01576718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FpS-AS-202|A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications|A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High Dose Inhaled Corticosteroid Therapy||Teva Pharmaceutical Industries||Completed|May 2012|August 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|622|||Both|12 Years|N/A|No|||March 2015|March 19, 2015|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576718||87629|
NCT01576965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1602|Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial|Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial||University of North Carolina, Chapel Hill|No|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|160|||Female|18 Years|N/A|No|||September 2013|September 6, 2013|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01576965||87610|
NCT01577238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPL7013-015|A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis||Starpharma Pty Ltd|Yes|Completed|March 2012|||December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Female|12 Years|N/A|No|||October 2013|October 27, 2013|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577238||87589|
NCT01547845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912039|Cancer Symptom Data From Multiple Treatment Centers|The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study||National Institutes of Health Clinical Center (CC)||Completed|February 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|2550|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01547845||89837|
NCT01548079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDCAINBS|Ursodeoxycholic Acid in Bariatric Surgery|Effects of Ursodeoxycholic Acid on Hepatobiliary Detoxification/Elimination Mechanisms and Hepatic Fatty Acid/Triglyceride Metabolism in Morbidly Obese Patients.||Sahlgrenska University Hospital, Sweden|No|Completed|October 2008|May 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Both|25 Years|60 Years|No|||December 2013|December 2, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01548079||89819|
NCT01548365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITNE01|Impact of an Infusion Therapy Nursing Expert Service on Length of Stay and Clinical Results of Venous Access Devices|Impact of an Infusion Therapy Nursing Expert Service on Length of Stay, Clinical Results of Venous Access Devices and Satisfaction on Patients With Long Intravenous Therapy Prescription.|ETI|Basque Health Service|No|Completed|March 2012|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|82|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548365||89797|
NCT01548378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL003CLI-II|Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia|NL003CLI-II|Beijing Northland Biotech. Co., Ltd.|Yes|Completed|March 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|200|||Both|30 Years|80 Years|No|||March 2015|March 23, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548378||89796|
NCT01574547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dig-3|Risk Factors of Cat Scratch Colon Developing.|Risk Factors of Cat Scratch Colon Developing.|CSC|University Hospital of the Nuestra Señora de Candelaria|Yes|Completed|September 2007|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10715|||Both|N/A|N/A|No|Non-Probability Sample|All of the ambulatory colonoscopies performed at our Hospital|April 2012|April 9, 2012|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01574547||87796|
NCT01574846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THE VANTAS STUDY|Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer|Prospective, Multicentre, Non-interventional (Observational) Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer.|Vantas|Orion Corporation, Orion Pharma|No|Completed|January 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|142|||Male|18 Years|N/A|No|Probability Sample|• Male patients for whom hormone treatment for advanced prostate cancer is indicated|October 2014|October 15, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01574846||87773|
NCT01575652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-11-00212R1|Effects of Aceis on Peritoneal Protein Loss and Solute Transport in pd Patients|Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients||Turkish Nephrology Association|No|Completed|June 2008|January 2009|Actual|January 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|43|||Both|18 Years|55 Years|No|||April 2012|April 10, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01575652||87711|
NCT01575665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8313-86|Normalizing CO2 in Chronic Hyperventilation by a Novel Breathing Mask: A Pilot Study|CO2 Rebreathing by a Partial Rebreathing Mask as a Treatment of Chronic Idiopathic Hyperventilation - a Pilot Study|HVMASKE|University of Aarhus|Yes|Completed|February 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||April 2012|April 10, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575665||87710|
NCT01575418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHARM-02|An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations|An Exploratory, Double-Blinded, Randomized, Pharmacokinetic and Safety Study of Three Rectally-Applied Tenofovir 1% Microbicide Gel Formulations||University of Pittsburgh|Yes|Completed|March 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|9|||Male|18 Years|N/A|Accepts Healthy Volunteers|||May 2014|May 6, 2014|March 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575418||87729|
NCT01575626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-IM-0011-CTIL|The Effect of Different Sevoflurane Concentrations on Intraocular Pressure in Patients Undergoing Ocular Surgery Under General Anesthesia|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|May 2012|||May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|30|||Both|18 Years|N/A|No|||April 2012|April 10, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01575626||87713|
NCT01576237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DGTI-AGHV_01|Multinational Haemapheresis Vigilance Study|Open Prospective Multi-national Long-term Study to Register Adverse Events Related to Hemaphereses by Means of an Internet-based Haemapheresis Vigilance Questionnaire||DGTI - Haemapheresis Vigilance Working Party|Yes|Active, not recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|all blood donors having an Adverse Event during preparative cell aphereses|April 2012|February 24, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576237||87666|
NCT01576536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111760|Genetic Variation in Platelet Aggregation|Genetic Variation in Platelet Aggregation||Vanderbilt University|No|Recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Blood samples for DNA and plasma/serum for subsequent biomarker analysis if required.|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy subjects will be recruited by advertisement and word-of-mouth.|June 2015|June 16, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576536||87643|
NCT01544400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/03-V|Description and Evaluation of Eating Disorders in Elite Athletes (TCA SHN)|Description and Evaluation of Eating Disorders in Elite Athletes|TCA SHN|Nantes University Hospital||Terminated|June 2010|January 2013|Actual|January 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|386|||Both|12 Years|N/A|No|Non-Probability Sample|Athletes registered on the high level sportsmen list or in access to high level sport|March 2013|March 22, 2013|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01544400||90101|
NCT01544413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENORITA-2012|Quality Control Study of Laparoscopic Sentinel Node Biopsy in Early Gastric Cancer|Quality Control Study for Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy and Stomach Preserving Surgery in Early Gastric Cancer||National Cancer Center, Korea|Yes|Completed|February 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|112|||Both|20 Years|80 Years|No|||December 2014|December 14, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01544413||90100|
NCT01544426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42012|Office Hysteroscopy and Endometrial Snip Improve Intrauterine Insemination Outcome|Does Office Hysteroscopy and Endometrial Snip Improve IUI Outcome? : a Randomized Controlled Trial||Cairo University|Yes|Completed|February 2012|October 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|332|||Female|18 Years|38 Years|No|||December 2014|December 27, 2014|February 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01544426||90099|
NCT01544751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.42|Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin|Metformin Versus Atorvastatin in Nonalcoholic Hepatic Steatosis: a Randomized Study||University Magna Graecia|No|Recruiting|September 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|55 Years|No|||May 2014|May 27, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01544751||90074|
NCT01545037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111005-SCN-BIO-IBS-RA|Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome|Effect of Lactobacillus Acidophilus CL1285 and Lactobacillus Casei LBC80R on Symptoms of Irritable Bowel Syndrome: a Double-blind, Randomized, Placebo-controlled Study||Bio-K Plus International Inc.|No|Completed|July 2012|January 2015|Actual|January 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|117|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|December 11, 2015|March 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01545037||90052|
NCT01545050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM133-005|Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease|A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease||Alder Biopharmaceuticals, Inc.|Yes|Terminated|June 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|72|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545050||90051|
NCT01545297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0607-A|Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery|Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery: a Randomized Controlled Trial||University Health Network, Toronto|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2015|January 26, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545297||90032|
NCT01577810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHNX-NIRS-12-024|Near Infrared Spectroscopy (NIRS) for Heart Failure Assessment.|Near Infrared Spectroscopy (NIRS) for Heart Failure Assessment in the Outpatient Setting||Phoenix Children's Hospital|No|Recruiting|June 2013|August 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|N/A|18 Years|No|||June 2013|June 6, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01577810||87546|
NCT01577823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIJPARU2011|Utility of Indwelling Catheter in Orthopaedic Patients Receiving Spinal Anesthesia|||Rothman Institute Orthopaedics|No|Completed||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A||||April 2013|April 8, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01577823||87545|
NCT01576744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHE4-2010|Serum Biomarker HE4 During IVF Treatment|Serum Concentration of HE4, a New Marker for Ovarian Cancer, Changes Little Throughout IVF Stimulation|FHE4|Turku University Hospital|No|Active, not recruiting|March 2010|||June 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Repeated serum samples|Female|27 Years|39 Years|No|Non-Probability Sample|Finnish caucasian women being treated for infertility by in vitro-fertilization|June 2012|June 1, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576744||87627|
NCT01576978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|w7tgp7jt|Hatha Yoga Exercises in Pelvic and Lumbar Back Pain in Pregnant Woman|Hatha Yoga Exercises in Pelvic and Lumbar Back Pain in Pregnant Woman||University of Campinas, Brazil|Yes|Completed|June 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|45 Years|No|||April 2012|April 11, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01576978||87609|
NCT01578343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC2011-11-102-001|Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma|A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma|ZOLINZA|Samsung Medical Center|No|Not yet recruiting|January 2013|September 2016|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|20 Years|75 Years|No|||December 2012|December 30, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01578343||87505|
NCT01578356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/122|Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery|Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery||University Hospital, Ghent|No|Recruiting|February 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Male|18 Years|N/A|No|Non-Probability Sample|Men who were surgically treated or who are being surgically treated for prostate cancer.|December 2014|December 4, 2014|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578356||87504|
NCT01547663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIRB 461/2554|A Comparison of Pain Scales in Patients With Disorder of Consciousness Following Craniotomy|A Comparison of Pain Scales in Patients With Disorder of Consciousness Following Craniotomy||Mahidol University|No|Not yet recruiting|March 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|patients with disorder of consciousness within 48 hours following craniotomy|March 2012|March 7, 2012|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01547663||89851|
NCT01548092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC10-343|Stromal Vascular Fraction (SVF) for Treatment of Recto-vaginal Fistula|A Phase II Clinical Trial to Study the Feasibility and Safety of Stromal Vascular Derived From Adipose Tissue for the Treatment of Recto-vaginal Fistula|HULPCIR|Instituto de Investigación Hospital Universitario La Paz|No|Recruiting|December 2011|December 2013|Anticipated|July 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01548092||89818|
NCT01548391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0070|A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects|||Biotoxtech Co., Ltd|Yes|Not yet recruiting|March 2012|||||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|9||Anticipated|66|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|March 5, 2012||||No||https://clinicaltrials.gov/show/NCT01548391||89795|
NCT01548404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1117|Study of REGN668/SAR231893 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis||Regeneron Pharmaceuticals|Yes|Completed|April 2012|June 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01548404||89794|
NCT01544231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2011/SP-03|Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis|Plasma Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels During Emergency Management of Rhabdomyolysis: Predicting Renal Failure||Centre Hospitalier Universitaire de Nīmes|No|Completed|August 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|197|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with suspected rhabdomyolysis admitted to the participating University        Hospital emergency rooms (see inclusion/exclusion criteria).|December 2015|December 11, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01544231||90114|
NCT01575431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199/2012/D|Progenitor Cells Role in Restenosis and Atherosclerosis|PROgenitor Cells Role in Restenosis and Progression of Coronary ATherosclerosis After Percutaneous Coronary Intervention (PROCREATION) Study|PROCREATION|University of Roma La Sapienza|No|Recruiting|April 2012|December 2017|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|consecutive patient sampling|March 2013|March 6, 2013|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01575431||87728|
NCT01575964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51053|Biomechanical Assessment of Femoroacetabular Impingement|Biomechanical Assessment of Femoroacetabular Impingement|FAI|University of Utah|No|Enrolling by invitation|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|36|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal subjects and subjects with femoroacetabular impingement.|February 2016|February 22, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01575964||87687|
NCT01575977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43600|Stress Analysis of Hip Dysplasia|Stress Analysis of Hip Dysplasia After Corrective Surgery||University of Utah|No|Enrolling by invitation|February 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|40 Years|No|Non-Probability Sample|18-40 years old|February 2016|February 22, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01575977||87686|
NCT01575951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI38583|Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection|Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection||University of Utah|Yes|Active, not recruiting|February 2010|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|16|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01575951||87688|
NCT01576809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147-A-302|Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)|An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection||Novartis|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|51|||Both|12 Years|N/A|No|||October 2013|October 18, 2013|March 29, 2012||No||No|April 17, 2013|https://clinicaltrials.gov/show/NCT01576809||87622|
NCT01577082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1005-PR-0040|Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients|A 12-week, Multinational, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of CHF 1535 200/6µg Versus Beclomethasone Dipropionate in Adult Asthmatic Patients Not Adequately Controlled on High Dose of Inhaled Corticosteroids or on Medium Dose of Inhaled Corticosteroids Plus Long-acting β2 Agonists||Chiesi Farmaceutici S.p.A.|No|Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|542|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01577082||87601|
NCT01548287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3030C00005|A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment|A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study||AstraZeneca||Completed|April 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|81|||Both|50 Years|85 Years|No|||February 2013|February 21, 2013|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01548287||89803|
NCT01548547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE0924|Patient Outcomes in Simulation Education (POISE) Intravenous (IV) and Lumbar Puncture (LP) Multi-institution Protocol|Patient Outcomes in Simulation Education (POISE) Intravenous (IV) and Lumbar Puncture (LP) Multi-institution Protocol|POISE|Columbia University|No|Completed|June 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|2||Actual|210|||Both|N/A|N/A|No|||March 2012|March 7, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548547||89783|
NCT01548560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAME 02|Assessing the Safety of Dapivirine Gel and Film Formulations|||International Partnership for Microbicides, Inc.||Completed|August 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|60|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|December 8, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01548560||89782|
NCT01545076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgPro20_3003|Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)|Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study||CSL Behring|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|350|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545076||90049|
NCT01545063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54137|CAre of Patients With PArenteral Nutrition At Home|Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate the Quality of Care for Adult Patients on Home Parenteral Nutrition (HPN)|CAPANAH|Katholieke Universiteit Leuven|Yes|Recruiting|May 2012|December 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Probability Sample|Adult HPN patients with peritoneal carcinomatosis with intestinal occlusion or with        crohn's disease, radiation enteritis, chronic diarrhea, intestinal lymphomas.|May 2012|May 25, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545063||90050|
NCT01545323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10MI30|Gene Therapy for Netherton Syndrome|Phase I Study of Ex-vivo Lentiviral Gene Therapy for the Inherited Skin Disease Netherton Syndrome||Great Ormond Street Hospital for Children NHS Foundation Trust|Yes|Recruiting|April 2014|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|N/A|No|||September 2015|September 11, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545323||90030|
NCT01545310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-700|A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia|An Open-Label, Positron Emission Tomography (PET) Study to Evaluate the Brain 5 HT6 Receptor Occupancy by Single Doses of SLV354 in Healthy Male Subjects and Subjects With Stable Schizophrenia||Abbott|No|Completed|May 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|December 15, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01545310||90031|
NCT01547117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111261|Dietary Salt in Postural Tachycardia Syndrome|Dietary Salt in Postural Tachycardia Syndrome||Vanderbilt University|No|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01547117||89893|
NCT01578096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD005879|Stress Management Among Latinos With Type 2 Diabetes|Stress Management Among Latinos With Type 2 Diabetes Mellitus|CALMS-D|Yale University||Completed|May 2012|June 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578096||87524|
NCT01578109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00727|Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia|A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance||National Cancer Institute (NCI)|No|Recruiting|January 2012|||December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|19 Years|N/A|No|||November 2015|March 23, 2016|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578109||87523|
NCT01547130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHMC-2008-35|Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation|A Single Blind, Parallel Group, Randomized Controlled Trial Comparing Solution PEG Based Colon Preparation (HalfLytely) Versus Bolus Luke Warm Saline (Shudh) and Yoga Exercise for Large Bowel Cleansing Prior to Colonoscopy||Arya, Vijaypal, M.D., P.C.|Yes|Completed|May 2008|January 2011|Actual|December 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|133|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||February 2015|February 17, 2015|February 26, 2012||No||No|January 17, 2015|https://clinicaltrials.gov/show/NCT01547130||89892|Shudh Colon Cleanse (SCC) is suitable to only 30% of patients who are undergoing colonoscopy. A multi-center study is warranted to confirm these results.
NCT01544244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRIP/2011/DR-03|The Global Shoulder Concept (GSC) Method Versus Classic Physical Therapy for Shoulder Tendinitis|Comparison of the Global Shoulder Concept (GSC) Method Versus Classic Physical Therapy for Shoulder Tendinitis: a Prospective, Randomized Study||Centre Hospitalier Universitaire de Nīmes|No|Terminated|October 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||March 2016|March 21, 2016|February 23, 2012||No|Inclusion curve too slow.|No||https://clinicaltrials.gov/show/NCT01544244||90113|
NCT01544569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B3|Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors|Endogenous DNA Transposition in Rhabdoid Tumors||Children's Oncology Group|No|Active, not recruiting|March 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|1 Year|No|Non-Probability Sample|rhabdoid tumors|May 2015|May 7, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01544569||90088|
NCT01544582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08518|Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)|An Observational Post-Authorization Safety Study (PASS) of Victrelis™ (Boceprevir) Among Chronic Hepatitis C Patients||Merck Sharp & Dohme Corp.|No|Completed|May 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|719|||Both|18 Years|N/A|No|Non-Probability Sample|Adults 18 years or older.|June 2015|June 30, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01544582||90087|
NCT01575145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002207|Helping Hospitalized Patients Quit Smoking|Helping Hospitalized Patients Quit Smoking||Mayo Clinic|No|Completed|May 2012|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|600|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01575145||87750|
NCT01575158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUAG-5|Citalopram vs Clomipramine vs Placebo in Recurrent Depression|||University of Aarhus|No|Completed|October 1997|September 2007|Actual|September 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|59|||Both|18 Years|70 Years|No|||April 2012|April 10, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575158||87749|
NCT01575678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EnuMel-11|The Effect of Melatonin on Nocturnal Enuresis|The Effect of Melatonin on Nocturnal Enuresis||University of Aarhus|Yes|Recruiting|January 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|14 Years|No|||November 2012|November 1, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01575678||87709|
NCT01575691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-0799 Phase I|Phase I 5-Azacytidine Plus VPA Plus ATRA|Phase I Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia||M.D. Anderson Cancer Center|No|Completed|July 2005|December 2007|Actual|July 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|3 Years|N/A|No|||April 2012|April 10, 2012|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01575691||87708|
NCT01576549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14319|A Study of LY2127399 in Rheumatoid Arthritis|An Exploratory Open-Label Biomarker Study of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Synovial Biopsies||Eli Lilly and Company|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576549||87642|
NCT01576822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H35B11|Sauna Detoxification Study: Pilot Feasibility|Complementary and Alternative Medicine Detoxification: Safety and Efficacy||Bastyr University|Yes|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|10|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01576822||87621|
NCT01577095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR94-IRB-139|Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy|A Randomized Controlled Trial Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy on Patients With Type 2 Diabetes Mellitus||China Medical University Hospital|Yes|Completed|April 2006|May 2007|Actual|May 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|49|||Both|20 Years|65 Years|No|||April 2012|April 12, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01577095||87600|
NCT01544764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-3|Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina|Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX)|AFIX|University of North Carolina, Chapel Hill|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|91|||Both|N/A|N/A|No|||December 2013|December 16, 2013|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01544764||90073|
NCT01575587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100737|A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Male Subjects||Janssen Research & Development, LLC|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|51|||Male|25 Years|35 Years|Accepts Healthy Volunteers|||January 2014|January 9, 2014|January 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575587||87716|
NCT01545336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815035|Anastrozole in Patients With Pulmonary Arterial Hypertension|A Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial Hypertension|AIPH|University of Pennsylvania|Yes|Completed|October 2012|September 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|February 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01545336||90029|
NCT01545349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011 P 002849|Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine|Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine|LAIV|Massachusetts General Hospital|Yes|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|30|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|February 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01545349||90028|
NCT01545622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104675|Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease|Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease||University of Arkansas|No|Active, not recruiting|March 2008|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|61|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of 30 surgeons and 30 nuclear radiologists.|April 2015|April 29, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01545622||90007|
NCT01575860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 11411|Maintenance Lenalidomide in Lymphoma|Maintenance Lenalidomide in Lymphoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|28|||Both|18 Years|N/A|No|||April 2015|April 23, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575860||87695|
NCT01547390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112007|Early Prevention of Preeclampsia Study|Early Prediction and Aspirin for Prevention of Preeclampsia|EPAPP|Washington University School of Medicine|Yes|Active, not recruiting|March 2012|September 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|684|||Female|N/A|N/A|Accepts Healthy Volunteers|||June 2014|June 9, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01547390||89872|
NCT01548105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smoking and prolapse|Systemic Markers of Collagen Metabolism and Vitamin C in Smokers and Non-Smokers With Pelvic Organ Prolapse|Systemic Markers of Collagen Metabolism and Vitamin C in Smokers and Non-Smokers With Pelvic Organ Prolapse||TriHealth Inc.|No|Completed|March 2012|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|96|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with pelvic organ prolapse and without prolapse will be identified based on a        manual review of patients in a tertiary care referral-based Urogynecology practice|February 2014|October 15, 2014|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01548105||89817|
NCT01547650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-Kamoi|Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium|Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium||Nagaoka Red Cross Hospital|No|Active, not recruiting|February 2012|February 2023|Anticipated|February 2022|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|42|None Retained|There is no biospeciment.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients with disorders of fluid with sodium including cerebral salt wasting syndrome        (CSWS), syndrome of inappropriate antidiuretic hormone secretion (SIADH), primary        polydipsia (PP), central diabetes insipidus (CDI) and others          -  Patients more than 18 years old (gender is disregarded)          -  Healthy subjects more than 18 years old (gender is disregarded)|March 2012|March 13, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01547650||89852|
NCT01544257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEO-01|Effect of Osteopathic Manipulative Treatment on Length of Stay in Preterms|Effect of OMT on Length of Stay in a Population of Preterm Infants: RCT Study||European Institute for Evidence Based Osteopathic Medicine|Yes|Completed|August 2008|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|29 Weeks|37 Weeks|Accepts Healthy Volunteers|||February 2012|February 28, 2012|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01544257||90112|
NCT01544270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH-SHOK-002|The Effects of Dietary Factors on Physiological Subjective Stress Responses|The Effects of Dietary Factors on Physiological Subjective Stress Responses in Cronically Stressed Subjects: a Randomised Clinical Trial|AivoPro2|Helsinki University|No|Completed|September 2011|September 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|101|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 24, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01544270||90111|
NCT01544595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2302E1|Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab|A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 2 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab||Novartis|Yes|Active, not recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1150|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01544595||90086|
NCT01575444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010NTLS097|Cervical Cancer Screening Project Part C|Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative||Masonic Cancer Center, University of Minnesota|No|Recruiting|June 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Home based or clinic based HPV test (Pap) collection|Female|25 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Somali female - Participants may speak Somali or English as their primary language.|May 2014|May 15, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575444||87727|
NCT01575704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BISON01042011|Physical Exercise Therapy in Pediatric Stem Cell Transplantation|Physical Exercise Therapy in Pediatric Stem Cell Transplantation (BISON- Bewegungstherapie in Der Pädiatrischen Stammzelltransplantation)|BISON|Johann Wolfgang Goethe University Hospitals|No|Completed|January 2011|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|68|||Both|5 Years|25 Years|No|||March 2015|March 31, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01575704||87707|
NCT01576003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-2706|Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants|Efficacy of Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants||Children's Hospital Medical Center, Cincinnati|Yes|Completed|April 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|6 Weeks|12 Months|Accepts Healthy Volunteers|||July 2015|July 28, 2015|April 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01576003||87684|
NCT01576250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38795.068.11/METC 11-3-074|The Effect of Lowered Physical Activity on Insulin Sensitivity and Lipid and Glucose Metabolism|The Effect of Lowered Physical Activity (Induced by Lower Limb Suspension (ULLS)) on Insulin Sensitivity and Lipid and Glucose Metabolism||Maastricht University Medical Center|No|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576250||87665|
NCT01576263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20090061|Autologous Blood Transfusion After Local Infiltration|Autologous Blood Transfusion After Local Infiltration Analgesia With Ropivacaine in Total Knee and Hip Arthroplasty||Northern Orthopaedic Division, Denmark|No|Completed|March 2010|June 2010|Actual|April 2010|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|52|Samples Without DNA|Venous blood to collect an analysis of total ropivacaine concentrations.|Both|18 Years|N/A|No|Probability Sample|Primary care clinic.|April 2015|April 9, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01576263||87664|
NCT01576562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13674|Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) Implantation|Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) Implantation||Virginia Commonwealth University|No|Enrolling by invitation|May 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Patients with wireless ICDs undergoing VAD implantation (study group) or other        cardiothoracic surgery (control group) will be included.|March 2016|March 9, 2016|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576562||87641|
NCT01576575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104146|Buprenorphine Disposition and Clinical Effects|Influence of CYP3A Modulation on Buprenorphine Disposition and Clinical Effects|BUP|Washington University School of Medicine|Yes|Recruiting|June 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|7||Anticipated|25|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576575||87640|
NCT01576835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACT2012|Renal Artery Contrast-Free Trial|Comparison of Non-contrast Renal Artery Magnetic Resonance Angiography With Contrast-enhanced CT Angiography|REACT|Central Coast Cardiovascular Research|Yes|Completed|February 2012|December 2012|Actual|November 2012|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients who have had an abdominal CT for any reason will be considered for the REACT        study. They may be referred from private practice or imaging center.|August 2015|August 24, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576835||87620|
NCT01577108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-309|Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women|Oral Probiotics Lactobacillus Rhamnosus GR-1 and Lactobacillus Reuteri RC-14 Reduce Group B Streptococci Colonization in Pregnant Women||China Medical University Hospital|Yes|Recruiting|April 2011|November 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|July 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577108||87599|
NCT01575340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20.179/2010-0|Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer|Markers of the Inflammatory Response (IL-1β, IL-10, IL-17A and TNF-α) in Patients With Colorectal Cancer in Chemotherapy Supplemented With Fish Oil||Universidade Federal de Santa Catarina|No|Completed|July 2011|July 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|11|||Both|19 Years|N/A|No|||September 2012|September 5, 2012|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01575340||87735|
NCT01575353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1399/10|Nasal High-flow Versus Venturi Mask Oxygen Therapy in the Post-extubation Period|Nasal High-flow Oxygen Therapy vs Standard Oxygen Therapy Via Venturi Mask in the Post-extubation Period||Catholic University of the Sacred Heart|No|Completed|December 2010|November 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|105|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|December 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01575353||87734|
NCT01575600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-095|Effect of Intravenous Fluid Therapy on Postoperative Vomiting in Children Undergoing Otorhinolaryngological Surgery|Effect of Intravenous Fluid Therapy on Postoperative Vomiting in Children Undergoing Otorhinolaryngological Surgery||Pontificia Universidad Catolica de Chile|No|Completed|July 2010|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|100|||Both|1 Year|12 Years|No|||May 2012|May 8, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575600||87715|
NCT01575886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA105292_ETM|Enhancing Teachable Moment Communication for Smoking Cessation and Weight Management|Enhancing Teachable Moment Communication for Smoking Cessation and Weight||Case Western Reserve University|No|Enrolling by invitation|July 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|1152|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2012|April 10, 2012|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01575886||87693|
NCT01576159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAPK06K07K03K00K17|Serum Cartilage Oligomeric Matrix Protein Levels After 12 Weeks of Different Exercises|The Effect of Mechanical Loading During Sports Exercises on Degradation of Human Articular Cartilage||Middle East Technical University|Yes|Completed|January 2008|September 2008|Actual|June 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Actual|48|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||June 2015|June 9, 2015|April 9, 2012||No||No|May 2, 2012|https://clinicaltrials.gov/show/NCT01576159||87672|
NCT01576172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01149|Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|March 2012|||December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Male|18 Years|N/A|No|||December 2015|December 21, 2015|April 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576172||87671|
NCT01576185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B8|Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia|Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents||Children's Oncology Group|No|Recruiting|April 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|tissue|Both|N/A|N/A|No|Non-Probability Sample|Cryopreserved human AML samples FLT3-ITD samples with high allelic ratios|November 2015|November 5, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01576185||87670|
NCT01546493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2009-537|Hip Impingement - Understanding Cartilage Damage|Femoroacetabular Impingement: Correlating Hip Morphology to Changes in Cartilage and Subchondral Bone||Ottawa Hospital Research Institute|No|Active, not recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|75|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01546493||89941|
NCT01546506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.654/58|Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells|Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells|FLUMED|Hospices Civils de Lyon|Yes|Completed|February 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|79|||Both|18 Years|65 Years|No|||January 2015|January 7, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546506||89940|
NCT01546519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP27839|A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function|A Phase Ib Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function||Genentech, Inc.||Completed|March 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|31|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 1, 2015|March 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01546519||89939|
NCT01546857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011001012|Effect of Gabapentin on Orthopedic Pain|The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial||Rutgers, The State University of New Jersey|No|Terminated|March 2012|August 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|70 Years|No|||January 2016|January 28, 2016|March 1, 2012||No|No longer able to recruit subjects due to unavailability of orthopedic surgeon.|No||https://clinicaltrials.gov/show/NCT01546857||89913|
NCT01548118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|311-HPV-1001|Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females|A Blind, Randomized and Placebo-controlled Clinical Trial With Recombinant HumanPapillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Health Women-Phase I||Shanghai Zerun Biotechnology Co.,Ltd|No|Enrolling by invitation|February 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|8||Actual|160|||Female|9 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01548118||89816|
NCT01548131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|228/2006|A Randomized Longitudinal Trial About Treatment for Severe Fear of Childbirth|A Randomized Longitudinal Trial About Treatment for Severe Fear of Childbirth|LINNEA|Helsinki University Central Hospital|Yes|Completed|November 2007|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|370|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01548131||89815|
NCT01548144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1142|Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer|A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2012|||April 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|364|||Both|N/A|N/A|No|||January 2016|January 25, 2016|March 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01548144||89814|
NCT01547403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2719|Customer Support Response Study|Evaluation of Customer Support Issues, Questions, or Alleged Complaints Regarding Use of Approved Commercially Distributed Scout DS Product in the Field|CUSTOM|VeraLight, Inc.|No|Withdrawn|August 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Up to 500 volunteers age 18 and above, of either sex and of any ethnic background, will be        recruited at one site.|January 2013|January 14, 2013|February 27, 2012||No|Protocol no longer meeting sponsor objectives|No||https://clinicaltrials.gov/show/NCT01547403||89871|
NCT01544283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS001|Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome|Heated Lidocaine Patch Compared to Subacromial Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome, A Pilot||Injury Care Medical Center|No|Recruiting|March 2012|March 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01544283||90110|
NCT01544608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NME-XXX-2011/1|Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia|A Non- Interventional Study to Observe Real Life Usage of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia.|RECONNECT-S|AstraZeneca||Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1076|||Both|18 Years|N/A|No|Non-Probability Sample|Psychiatric Institutes|June 2013|June 19, 2013|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01544608||90085|
NCT01544621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051150|Escape Smoke Project: Non-Intervention Non-Drug Multicenter Study on the Real-life Effectiveness of Smoking Cessation in General Practice in Denmark|Escape Smoke Project: Non-Intervention Multicenter Study On the Real-Life Effectiveness of Smoking Cessation in General Practice in Denmark|ESCAPE SMOKE|Pfizer|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|544|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Active smokers who wish to quit|May 2013|May 20, 2013|February 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01544621||90084|
NCT01575990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1638|Elders Preferences in Care Decisions|Improving Appropriate Colorectal Cancer Screening in Elderly Patients|EPIC-D|University of North Carolina, Chapel Hill|No|Completed|March 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|424|||Both|70 Years|84 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01575990||87685|
NCT01576601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00051171|The Management of Postoperative Craniotomy Pain in Pediatric Patients|The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study||Johns Hopkins University|No|Enrolling by invitation|August 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|200|||Both|N/A|18 Years|No|Non-Probability Sample|200 patients who are scheduled for craniotomy surgery under general anesthesia at 3 major        children's hospitals will be eligible. Potential patients include those undergoing brain        surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive        surgery. Following surgery, patients will receive routine postoperative management and        treated for pain based on institutional routine. We will follow patients for the first 5        post-operative days or until discharge, whichever comes first.        Once daily, a study investigator will make an independent pain assessment using an age        appropriate, validated tool (FLACC, Pain Face Scale-Revised, self report on a 0-10 scale).        The study investigator will also assess overall quality of life and patient/parent        satisfaction using a subset of the NRC Picker satisfaction tool and in adolescents a        modified QoR-40 (see below).|April 2012|April 11, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576601||87638|
NCT01576276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000358|A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects|A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects||Massachusetts General Hospital|Yes|Recruiting|April 2012|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|60|||Both|21 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 20, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01576276||87663|
NCT01576289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Reflux_Multicenter_1|Analysis of Biopsies From the Upper Gastrointestinal Tract|Clinical Evaluation and Histological Analysis of Biopsies From the Upper Gastrointestinal Tract of Patients With and Without Symptoms of Reflux Disease (histoGERD Trial)|histoGERD|Medical University of Graz|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Biopsy specimens (formalin fixed and paraffin embedded) which are routinely obtained during      the endoscopic procedure are retained according to legal requirements.|Both|8 Years|N/A|No|Non-Probability Sample|Patients who routinely undergo upper endoscopy (for different, not selected reasons)|July 2012|July 23, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01576289||87662|
NCT01576588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT-CLL-2s|Rituximab in Pretreated Elderly or Unfit B-CLL Patients|Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients With Chronic B Lymphocytic Leukemia||Vilnius University|No|Active, not recruiting|October 2011|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 9, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01576588||87639|
NCT01577420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA104883-05|Reflexology: An Intervention for Advanced Breast Cancer|Reflexology: An Intervention for Advanced Breast Cancer||Michigan State University|Yes|Completed|August 2005|August 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|451|||Female|21 Years|N/A|No|||April 2012|April 12, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577420||87575|
NCT01575366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Movement Velocity Effect|Movement Velocity Effect on Cortical Reorganization and Finger Function in Stroke|Movement Velocity Effect on Cortical Reorganization and Finger Function in Stroke||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|February 2010|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||August 2013|August 16, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01575366||87733|
NCT01575379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF 17-2012-377|A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes|A Pilot Study of Allopurinol to Prevent GFR Loss in Type 1 Diabetes.|PERL|Joslin Diabetes Center|Yes|Terminated|September 2012|June 2019|Anticipated|June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|60 Years|No|||February 2016|February 22, 2016|April 9, 2012|Yes|Yes|The pivotal trial was funded by NIH. Participants were transferred to that study    (NCT02017171)..|No||https://clinicaltrials.gov/show/NCT01575379||87732|
NCT01576991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108093|Telomeres and Reproduction in Women|Telomeres and Reproduction in Women||University of South Florida|Yes|Completed|June 2009|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|145|Samples With DNA|Blood, Follicle cells, and or polar body of eggs|Female|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|InVItro Fertilization patients undergoing therapy|August 2013|August 9, 2013|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576991||87608|
NCT01575899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB096-28|Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori|Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori.||Buddhist Tzu Chi General Hospital|Yes|Terminated|December 2007|December 2009|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|20 Years|95 Years|No|||July 2012|July 28, 2012|April 10, 2012||No|Early termination due to efficacy|No|April 19, 2012|https://clinicaltrials.gov/show/NCT01575899||87692|The limitation of this study is the local primary resistance of Hp to levofloxacin and to amoxicillin/clavulanate is unknown. We are currently engaged in an on-going investigation of the influence of CYP2C19 genotypes on this new regimen.
NCT01576458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73/180/2011|Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy|Randomised Placebo-controlled Study of Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy||Turku University Hospital|Yes|Completed|January 1998|December 1998|Actual|December 1998|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Female|N/A|N/A|No|||April 2012|April 11, 2012|February 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01576458||87649|
NCT01577563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-PLA-XXX-2011/1|Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).|Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis Receiving Treatment With Non- Steroidal Anti- Inflammatory Drugs.|RATIONAL|AstraZeneca||Completed|May 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|5383|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients over 21 years old, diagnosed with OA, RA or AS who are receiving at least        one dose of NSAIDs for at least 2 weeks (15 days) before study visit, who attend to        primary care centres, specialists offices, hospitals, private centres, urban or rural.|May 2013|May 13, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01577563||87564|
NCT01547689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|307-CTC-MSC-001|Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease|Open-Label, Single-Center, Self Control, Phase Ⅰ/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of UC-MSC in Patients With Alzheimer's Disease|SEMAD|Affiliated Hospital to Academy of Military Medical Sciences|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|85 Years|No|||February 2016|February 18, 2016|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01547689||89849|
NCT01548157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ROMA-101|Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule|A Randomized, Open Label, Single Dose, 2X2 Cross-over Study to Compare Pharmacokinetics Between Rosuvastatin 10mg and Omega-3 1g Co-administration and HCP1007 in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|Yes|Completed|March 2012|December 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2013|June 3, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01548157||89813|
NCT01548417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA012602-11A1|Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists|Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists||The Scripps Research Institute|No|Completed|March 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|56|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01548417||89793|
NCT01544972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB170212|Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants|Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|February 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|80|||Both|N/A|10 Days|No|||December 2012|December 13, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01544972||90057|
NCT01575717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1149|The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List|The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List||Icahn School of Medicine at Mount Sinai|No|Recruiting|January 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|N/A|No|||October 2012|October 22, 2012|April 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575717||87706|
NCT01576614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-071|The Role of Off-shift Robotic Telerounding Between Physicians and Nurses in the Surgical Intensive Care Unit|A Prospective Randomized Study on the Role of Off-shift Robotic Telerounding on the Collaboration Between Physicians and Nurses in the Surgical Intensive Care Unit||Lahey Clinic|No|Completed|August 2011|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|35|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Full time Nursing and Physician Staff providing rounding services in the Surgical        Intensive Care Unit|September 2013|September 24, 2013|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576614||87637|
NCT01576848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 11-3-040|Impact of Carbohydrate Co-ingestion on the Post-prandial Anabolic Response of Protein in Young and Elderly Men|Impact of Carbohydrate Co-ingestion on the Post-prandial Anabolic Response of Protein in Young and Elderly Men|PRO-CARB|Maastricht University Medical Center|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|48|||Male|18 Years|85 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01576848||87619|
NCT01577121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INDOGEST|Evaluation of the Use of Indomethacin as Co-treatment in Women With Preterm Labor and High Risk of Intraamniotic Inflammation|Evaluation of the Utility of Indomethacin as Support Treatment in Women With Preterm Labor With Intact Membranes and High Risk of Intraamniotic Inflammation|INDOGEST|Fundacion Clinic per a la Recerca Biomédica|No|Completed|April 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|N/A|No|||October 2014|October 20, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01577121||87598|
NCT01577134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01ET1001B|Personal Resources of Elderly People With Multimorbidity|Personal Resources of Elderly People With Multimorbidity: Fortification of Effective Health Behaviour|PREFER|German Centre of Gerontology|Yes|Completed|April 2012|December 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|310|||Both|64 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 26, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01577134||87597|
NCT01577433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC11282011|Driveline Silicone Skin Interface Registry|Driveline Silicone Skin Interface (SSI) Registry|SSI|Thoratec Corporation|No|Active, not recruiting|May 2012|December 2018|Anticipated|July 2018|Anticipated|N/A|Observational|N/A||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who are implanted/have been implanted with the commercially available HeartMate        II LVAD for approved indications|March 2016|March 18, 2016|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577433||87574|
NCT01577394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 09158|Oculomotor Testing in the Differential Diagnosis of Dementia|Oculomotor Recording in the Contribution to the Early Differential Diagnosis of Dementia With Lewy Bodies and Alzheimer's Disease|OculoMacl|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2011|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|65 Years|N/A|No|||April 2015|April 23, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01577394||87577|
NCT01577407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 110103|Non Opioid Treatment for Experimental Dyspnea|Non Opioid Treatment for Experimental Dyspnea|Nefopel|Assistance Publique - Hôpitaux de Paris|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||October 2011|December 10, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01577407||87576|
NCT01576757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL-11.0146|Harvest, Isolation and Culture of Cardiac Stem Cells From Endomyocardial Biopsies|Harvest, Isolation and Culture of Cardiac Stem Cells From Endomyocardial Biopsies||University of Louisville|No|Enrolling by invitation|April 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Biopsy samples are taken at the time of right heart catheterization. They are frozen in a      GMP facility at the University of Louisville. The tissue is shipped either to the Institue      of Molecular Caridology, Louisville, KY or shipped overnight to the Brigham and Women's      Hospital in Boston, MA. The tissue is enzymatically dissociated, and cardiac stem cells are      isolated and maintained in culture for 6-8 passages (point of clinical utility). During that      time period, experimentation is carried out to charcterize the biological attributes of      these cell populations. After this experimentation is complete, the cultures are destroyed      in accordance with the biohazard handling policies of the individual institution.|Both|18 Years|75 Years|No|Non-Probability Sample|Patients with heart failure undergoing evaluation for medical management at the University        of Louisville or Jewish Hospital in Louisville, KY will be considered for participation        based on the evaluation of enrollment criteria.|December 2014|December 2, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576757||87626|
NCT01545986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-04|A Comparative Analysis of Two Types of Exercise on Outcomes Following Total Knee Arthroplasty|A Comparative Analysis of High Velocity and Standard Low Velocity Exercise Training on Rehabilitation Outcomes Following Total Knee Arthroplasty||Helen Hayes Hospital|No|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Both|60 Years|89 Years|No|||March 2012|March 1, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01545986||89980|
NCT01545999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#165/2009-04|Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: a Combined Transcranial Magnetic Stimulation and Electroencephalography Study Across the Life Span|Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: a Combined Transcranial Magnetic Stimulation and Electroencephalography Study Across the Life Span||Centre for Addiction and Mental Health|No|Recruiting|March 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01545999||89979|
NCT01577277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D208 baseline|OPUS School Meal Study - Cross Sectional Analyses From Baseline Investigations|OPUS(Optimal Well-being, Development and Health for Danish Children Through a Healthy New Nordic Diet) School Meal Study - - Cross Sectional Analyses From Baseline Investigations||University of Copenhagen|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|834|Samples With DNA|serum and white cells|Both|8 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|School children participating in OPUS School Meal Study (registered as an intervention        study with protocol number: NCT01457794)|August 2014|August 4, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577277||87586|
NCT01546844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Care4Life Grant|Mobile Health Technology as an Intervention for Diabetes Self-Management|Use of Mobile Health Technology as an Intervention for Type II Diabetes Self-Management|Care4Life|HealthInsight|No|Enrolling by invitation|March 2012|February 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|500|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01546844||89914|
NCT01547676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4K-10-2|Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer|Prospective Randomized Comparison of Clamped Versus Unclamped Partial Nephrectomy||University of Southern California|Yes|Terminated|December 2011|September 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|28|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|February 10, 2012|Yes|Yes|P.I. decided to terminate study due to multiple unresolved issues|No||https://clinicaltrials.gov/show/NCT01547676||89850|
NCT01547702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSHRF-44576|Classroom-based Distance Intervention for Teachers of Children With Attention Deficit Hyperactivity Disorder|Randomized-controlled Trial of a Classroom-based Distance Intervention for Teachers of Elementary School-aged Children With ADHD||Dalhousie University|Yes|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|116|||Both|6 Years|12 Years|No|||March 2014|March 27, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547702||89848|
NCT01547715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_43|Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India|A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 75 Years of Age in India.||Novartis|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|180|||Both|2 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 18, 2014|February 23, 2012||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01547715||89847|
NCT01547858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912055|Studying Blood Toxicity in Workers Exposed to Formaldehyde|A Cross-Sectional Study of Hematotoxicity in Workers Exposed to Formaldehyde||National Institutes of Health Clinical Center (CC)||Completed|February 2012|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|720|||Both|18 Years|60 Years|No|||November 2015|March 9, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01547858||89836|
NCT01547871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912067|Infants With Spinal Muscular Atrophy Type I|A Pilot Study of the Natural History of Infants With Spinal Muscular Atrophy (SMA) Type 1||National Institutes of Health Clinical Center (CC)||Recruiting|February 2012|||||N/A|Observational|N/A|||Anticipated|50|||Both|1 Year|6 Years|No|||November 2012|November 11, 2014|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01547871||89835|
NCT01544634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011RC16|Beta Blocker Therapy in Mild to Moderate Asthmatics|Evaluation of Any Steroid Sparing Effect of Beta Blocker Therapy on Airway Hyper-responsiveness in Stable, Mild to Moderate Asthmatics|ANDA1|University of Dundee|No|Recruiting|March 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|65 Years|No|||June 2012|June 11, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01544634||90083|
NCT01548430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP4000-101|A Safety Study of TTP4000 in Subjects With Alzheimer's Disease|A Double-blind, Randomized, Placebo-controlled, Phase 1 Study of 2 Escalating, Single Subcutaneous Doses to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of TTP4000 in Subjects With Alzheimer's Disease With Mild Cognitive Impairment||vTv Therapeutics|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|8|||Both|50 Years|85 Years|No|||February 2015|February 11, 2015|February 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01548430||89792|
NCT01545830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPA ID 3607|Metabolic Syndrome and Insulin Resistance at Allina|Randomized, Controlled Trial of Vitamin D Replenishment in Metabolic Syndrome|MISURA|Allina Health System|No|Recruiting|March 2012|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 6, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01545830||89991|
NCT01545219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/38|A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers|A Double-blind, Placebo-controlled, Randomized Crossover Study to Determine the Effects of Xylooligosaccharides (XOS), B. Lactis (BI07) and XOS + BI07 Upon the Gut Microbiota and Immune Response of Healthy Volunteers|XOS|University of Reading|No|Completed|September 2008|January 2010|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|44|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545219||90038|
NCT01545505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AOI-09|Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse|Early Diagnosis of Risk of Post-Traumatic Stress Disorder (PTSD) Relapse in Children and Their Families||Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2012|July 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|120|||Both|9 Years|18 Years|No|||February 2013|February 20, 2013|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01545505||90016|
NCT01576302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008528|Comparison of Diaphragmatic Breathing and Muscle Relaxation for Rumination|Diaphragmatic Breathing and Progressive Muscle Relaxation: Behavioral Interventions for Gastrointestinal Rumination||Mayo Clinic|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01576302||87661|
NCT01576861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Long-Term GH in CHF|Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure|||Federico II University||Completed|January 2007|December 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||October 2012|October 17, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01576861||87618|
NCT01577147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0400|Early Pregnancy Sample Collection Study|Generic Protocol for the Collection of Early Pregnancy Urines|EPS|SPD Development Company Limited|No|Active, not recruiting|January 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4025|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577147||87596|
NCT01577459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-114|A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response|A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response to Pseudoephedrine Concurrent With Placebo or TR 701 FA||Trius Therapeutics LLC|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|June 6, 2012|April 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577459||87572|
NCT01577654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-003|Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer|A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC|TARGET|Endocyte|Yes|Completed|March 2011|August 2015|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|203|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|April 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577654||87558|
NCT01577680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114637|A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers|An Open-label, Non-randomized, Pharmacokinetic and Safety Study of Single Dose GSK573719 + GW643444 (VI) Combination and Repeat Doses of GSK573719 in Healthy Subjects and in Subjects With Moderate Hepatic Impairment||GlaxoSmithKline|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01577680||87556|
NCT01545401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRR-11-250-8769|Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)|Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)||Ministry of Health, Malaysia|Yes|Completed|January 2012|June 2014|Actual|June 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|1545|||Both|18 Years|N/A|No|||September 2014|September 18, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545401||90024|
NCT01545700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH08-413|Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery|Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery||NorthShore University HealthSystem Research Institute|No|Completed|September 2009|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|200|||Female|18 Years|90 Years|No|||January 2013|January 15, 2013|February 27, 2012||No||No|November 9, 2012|https://clinicaltrials.gov/show/NCT01545700||90001|
NCT01546012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT1550-PIV-CE-10/11|Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials|||Laboratoires Thea|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|March 2, 2012||No|Too difficult to select patient according to the investigator|No||https://clinicaltrials.gov/show/NCT01546012||89978|
NCT01546025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA016000|Brief Alcohol Intervention for School-to-Work Transitions|Brief Alcohol Intervention for School-to-Work Transitions||Brown University||Completed|June 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|163|||Both|17 Years|20 Years|Accepts Healthy Volunteers|||March 2012|March 2, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01546025||89977|
NCT01546246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120216-6|Water Method in Patients With Incomplete Colonoscopy|Water Method With Water Exchange Versus Air Insufflation in Patients With Incomplete Colonoscopy: a Prospective Randomized, Controlled Trial||Fourth Military Medical University|Yes|Withdrawn|November 2011|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|0|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01546246||89960|
NCT01547429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Artisan Adult Aphakia|Artisan Aphakia Lens for the Correction of Aphakia (Secondary) in Adults|Artisan Aphakia Lens for the Correction of Aphakia in Adults||Ophtec USA|No|Recruiting|January 2012|December 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|22 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 31, 2016|February 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547429||89869|
NCT01548456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF 23346|Nails Versus Plates for Femur Fractures in Dar es Salaam, Tanzania|Intramedullary Nailing Versus Plates for Femoral Shaft Fractures in Dar es Salaam, Tanzania With Minimum 1-Year Follow-up||University of California, San Francisco|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|332|||Both|18 Years|65 Years|No|Non-Probability Sample|All patients with diaphyseal fractures of the femur presenting to Muhimbili Orthopaedic        Institute in Dar es Salaam, Tanzania will be considered eligible for enrollment.|May 2015|May 16, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01548456||89790|
NCT01547884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912073|Effect of Filarial Infection on Immune Responses in Latent Tuberculosis|Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis||National Institutes of Health Clinical Center (CC)||Recruiting|February 2012|||||N/A|Observational|Time Perspective: Cross-Sectional|||Anticipated|4000|||Both|18 Years|65 Years|No|||October 2015|January 22, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01547884||89834|
NCT01548469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRUS_DENTAL|Study to Evaluate Clinical Efficacy and Safety of Bio Mineral Toothpaste in Patients With Mild Periodontitis|Single Blind, Randomized, Active-controlled Comparative Clinical Trial to Evaluate Clinical Efficacy and Safety Following the Application for 4 Weeks of Bio Mineral Toothpaste in Patients With Mild Periodontitis||Seoul St. Mary's Hospital|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|63 Years|No|||February 2013|February 5, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548469||89789|
NCT01544322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME-344-001|Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors|Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors|ME-344-001|MEI Pharma, Inc.|Yes|Completed|May 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2014|June 17, 2015|February 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01544322||90107|
NCT01548443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP-MH-D01|Study to Evaluate Clinical Efficacy and Safety of "Medifoam H" in Wound Healing|The Wound Healing Efficacy and Safety of Medifoam H in Patients With Minor, Acute Trauma: a Single-center, Randomized, Active-controlled, Open-label, Phase IV|Medifoam H|Seoul St. Mary's Hospital|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|N/A|N/A|No|||February 2013|February 5, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548443||89791|
NCT01545258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI101.03|Exercise and Pain Sensitivity in Knee Osteoarthritis|Exercise and Changes in Pain Sensitivity in Patients With Knee Osteoarthritis||Frederiksberg University Hospital||Completed|March 2012|||March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|60|||Both|40 Years|N/A|No|||June 2013|June 24, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545258||90035|
NCT01545271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/2011/3799|Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth|Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth: A Randomised Pilot Study|CoolXenon2|University Hospitals Bristol NHS Foundation Trust|Yes|Active, not recruiting|May 2012|October 2015|Anticipated|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|N/A|N/A|No|||October 2014|October 30, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545271||90034|
NCT01545232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-GEN-11-0174|Pragmatic, Randomized Optimal Platelet and Plasma Ratios|Pragmatic, Randomized Optimal Platelet and Plasma Ratios|PROPPR|The University of Texas Health Science Center, Houston|Yes|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|680|||Both|15 Years|N/A|No|||May 2015|May 29, 2015|February 29, 2012|Yes|Yes||No|April 22, 2015|https://clinicaltrials.gov/show/NCT01545232||90037|
NCT01576042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033180|Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator|Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL|CALYPSO|Duke University|Yes|Terminated|May 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||September 2014|October 6, 2014|April 3, 2012|Yes|Yes|Main objectives of the study were met; consensus among investigators that continuing the study    would not add new information beyond that already learned.|No|September 18, 2014|https://clinicaltrials.gov/show/NCT01576042||87681|
NCT01576055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCE 09-02|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2012|||||N/A|N/A|N/A||||||||||||||December 9, 2015|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576055||87680|
NCT01576315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005799-41|ATCF (Azole Therapy in Cystic Fibrosis)|Efficacy of Itraconazole and of Voriconazole in Patients With Cystic Fibrosis and Presenting With Persistent Positive Sputums for Aspergillus.|ATCF|Rennes University Hospital|No|Recruiting|June 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|12 Years|N/A|No|||May 2015|May 26, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01576315||87660|
NCT01576328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSB-DM003|Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes|A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin||Mesoblast, Ltd.|Yes|Active, not recruiting|April 2012|October 2015|Anticipated|October 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|61|||Both|18 Years|80 Years|No|||October 2014|October 20, 2014|April 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576328||87659|
NCT01576341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX575-308|HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)|Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of HX575 Epoetin Alfa in the Treatment of Anemia Associated With Chronic Kidney Disease in Pre-dialysis and Dialysis Patients|SENSE|Sandoz|No|Completed|April 2012|June 2015|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|417|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01576341||87658|
NCT01576627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNL/CTC11-12|Zinc Absorption From Zinc Citrate, Zinc Gluconate and Zinc Oxide|Zinc Absorption From Zinc Supplements Comparing Zinc Citrate to Zinc Gluconate and Zinc Oxide in Young Adults||Swiss Federal Institute of Technology|No|Completed|March 2012|November 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01576627||87636|
NCT01577160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015664|A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia|An Open Label, Prospective, Non-Comparative Study to Evaluate Flexible Dose of Paliperidone ER and Clinical Response in the Treatment of Subjects With Schizophrenia||Johnson & Johnson Taiwan Ltd|No|Completed|May 2008|April 2009|Actual|April 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|353|||Both|18 Years|65 Years|No|||November 2013|November 25, 2013|April 12, 2012|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01577160||87595|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.
NCT01577199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112012095|Randomized Clinical Trial of Low-dose Clomiphene Based Antagonist Protocol vs. High Dose Gonadotropin/Antagonist Protocol for IVF Poor Responders|Randomized Prospective Controlled Non-inferiority Trial of Low-dose Clomiphene Based Antagonist Protocol vs. High Dose Gonadotropin/Antagonist Protocol for IVF Poor Responders|CLOVANT|Weill Medical College of Cornell University|No|Suspended|April 2012|December 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Female|18 Years|42 Years|No|||December 2012|December 13, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577199||87592|
NCT01577693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115148|Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects|An Open-label, Single Dose, Randomized, Two-period Crossover Study to Investigate the Bioavailability of a Novel Dosage Form of Dutasteride in Healthy Male Subjects|ARI115148|GlaxoSmithKline|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 12, 2012|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577693||87555|
NCT01577979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1209|Adolescent Vaccination in the Medical Home: Established and Innovative Strategies|Adolescent Vaccination in the Medical Home: Established and Innovative Strategies||University of Colorado, Denver|No|Completed|August 2012|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|34581|||Both|11 Years|17 Years|No|||February 2015|February 24, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577979||87533|
NCT01545713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM-One AbSorber|Correlation of Donor-specific Anti-endothelial Cells|A Phase II, Prospective, Single-center Study: Correlation of Donor-specific Anti-precursor Endothelial Cells With Transplant Outcome for Recipients of Living-donor Kidney Transplants, Are Auto-antibodies Important.||Northwestern University|No|Active, not recruiting|June 2011|April 2016|Anticipated|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|Samples Without DNA|A total of 40 cc/3 tablespoons of blood will be drawn once.|Both|18 Years|N/A|No|Probability Sample|Living-Donor kidney transplant recipients at Northwestern Memorial Hospital 18 year of age        or older.|January 2016|January 6, 2016|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545713||90000|
NCT01545726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQAW039A2208|Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma|A Double-blind, Placebo-controlled Study Examining the Effect of Orally Administered QAW039 on Sputum Eosinophil Levels and Other Efficacy Outcomes in Patients With Sputum Eosinophilia and Persistent Asthma||Novartis||Completed|February 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||October 2013|October 8, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01545726||89999|
NCT01546870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArkansasChRI|Coronary Artery Study in Pediatric Heart Transplantation||CAS-POHT|Arkansas Children's Hospital Research Institute|No|Not yet recruiting|April 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|7 Years|21 Years|No|Non-Probability Sample|Pediatric heart transplant recipients|March 2012|March 6, 2012|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01546870||89912|
NCT01547143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-H-72|Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis|Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis (HLH) in Adult Patients|HELA2012|Asan Medical Center|No|Recruiting|March 2012|February 2019|Anticipated|February 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||July 2015|July 1, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01547143||89891|
NCT01546259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120216-7|Water Method in Low-body Mass Index (BMI) Female Patients With Unsedated Colonoscopy|Water Method With Water Exchange Versus Air Insufflation in Low-BMI Female Patients Undergoing Unsedated Colonoscopy: a Prospective Randomized, Controlled Trial||Fourth Military Medical University|Yes|Withdrawn|November 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|0|||Female|18 Years|80 Years|No|||March 2016|March 24, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01546259||89959|
NCT01547442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Artisan Pediatric Aphakia|Artisan Aphakia Lens for the Correction of Aphakia in Children|Artisan Aphakia Lens for the Correction of Aphakia in Children||Ophtec USA|No|Recruiting|January 2012|December 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|2 Years|21 Years|Accepts Healthy Volunteers|||January 2016|January 31, 2016|February 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547442||89868|
NCT01547455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1002-007|Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery|Anti-inflammatory and Renoprotective Effect of Pretreatment Loading Dose Atorvastatin in CABG||Peking Union Medical College|Yes|Completed|April 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|96|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01547455||89867|
NCT01547897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXE36C301|NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria|A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer® NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria||NOXXON Pharma AG|No|Completed|March 2012|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||September 2013|February 21, 2014|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547897||89833|
NCT01547910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildrensMHIPoland|Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children|Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children - a Randomized, Double Blind, Placebo Controlled, Multicenter Study||Children's Memorial Health Institute, Poland|Yes|Completed|August 2007|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|6 Years|19 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01547910||89832|
NCT01544985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sucrose3456|Trial of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Bladder Catheterization|A Randomized Double-blind Trial Comparing the Effect on Pain of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Bladder Catheterization||St. Justine's Hospital|No|Completed|April 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|1 Month|3 Months|Accepts Healthy Volunteers|||December 2015|December 21, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01544985||90056|
NCT01544998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004257|Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure|To Define the Role of PDEV in Mediating the Decreased GFR and Attenuated Renal Sodium and cGMP Excretory Response to Acute Saline Volume Expansion in PSD and PDD With Renal Dysfunction.||Mayo Clinic|Yes|Completed|February 2012|August 2014|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|43|||Both|21 Years|90 Years|No|||October 2015|October 1, 2015|January 24, 2012|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01544998||90055|
NCT01544959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-09-174|Postoperative Analgesia Impact of Narcotic Free Anesthesia|The Impact on Postoperative Pain of Substituting Opioids by Beta Blockers for Peroperative Hemodynamic Control in Patients Undergoing Mastectomy|PAINFree|Université de Sherbrooke|No|Active, not recruiting|January 2010|January 2018|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|84|||Female|18 Years|65 Years|No|||May 2015|May 27, 2015|September 9, 2010||No||No||https://clinicaltrials.gov/show/NCT01544959||90058|
NCT01547000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1004006635|Guanfacine in Children With Tic Disorders|Guanfacine in Children With Tic Disorders: A Multi-site Study||Yale University|Yes|Active, not recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|6 Years|17 Years|No|||June 2015|June 30, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547000||89902|
NCT01545544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANRS HC13 Lympho C|Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)|Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) in Patients With Hepatitis C Virus|Lympho C|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|November 2006|November 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Actual|138|Samples With DNA|whole blood and bone marrow|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with HCV infection with positive viral load and a B-cell NHL.|June 2013|February 6, 2014|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01545544||90013|
NCT01576640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2008-04|Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia|An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia||Massachusetts General Hospital|No|Terminated|December 2005|October 2007|Actual|October 2007|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||May 2015|May 19, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576640||87635|
NCT01576367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885D2307E1|Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease|An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS)||Novartis|Yes|Recruiting|January 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|15|||Both|N/A|4 Years|No|||January 2015|January 15, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01576367||87656|
NCT01576380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A1201|A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients|A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments||Novartis|No|Completed|June 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|20 Years|N/A|No|||June 2014|June 4, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01576380||87655|
NCT01577186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR015667|Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)|Symptomatic Remission and Social Function in Patients Treated With Paliperidone ER||Johnson & Johnson Taiwan Ltd|No|Completed|July 2008|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|480|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|April 12, 2012|Yes|Yes||No|December 2, 2013|https://clinicaltrials.gov/show/NCT01577186||87593|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.
NCT01577446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM-002|Narrow QRS Ischemic Patients Treated With Cardiac Resynchronization Therapy (NARROW CRT)|Narrow QRS Ischemic Patients Treated With Cardiac Resynchronization Therapy|NARROW CRT|Ospedale Santa Maria di Loreto Mare||Active, not recruiting|January 2008|||August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||April 2012|April 12, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577446||87573|
NCT01577212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMO 2011/345|Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy|Individualized Dose Escalation for Non-small Cell Lung Cancer (NSCLC) Using Volumetric Modulated Arc Therapy (VMAT)|IDEAL-VMAT|Radboud University|Yes|Terminated|March 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|85 Years|No|||November 2015|November 6, 2015|March 16, 2012||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01577212||87591|
NCT01578252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/126|Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Ondansetron Tablets USP 8 mg With Zofran® 8 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.||IPCA Laboratories Ltd.|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578252||87512|
NCT01546532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2202|Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Renal Hemodynamic Effects of RLX030 and Placebo Infused for 24 Hours in Subjects With Chronic Heart Failure (CHF)||Novartis||Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||February 2013|May 20, 2015|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01546532||89938|
NCT01546883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB # 43119|Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation|Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation|DEPAF|University of Utah|Yes|Terminated|February 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|February 15, 2012||No|Not enough patients in time period allotted for study|No|August 11, 2015|https://clinicaltrials.gov/show/NCT01546883||89911|
NCT01547416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0344|The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function|The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function After Robot-assisted Prostatectomy||Yonsei University|No|Completed|November 2011|May 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|N/A|No|||July 2013|July 9, 2013|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01547416||89870|
NCT01548170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-ONCOFARMA-01|To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib|A Phase I, Pilot, Dose Finding Clinical Trial to Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib for National Health System||Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|No|Completed|April 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 5, 2012|December 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01548170||89812|
NCT01547923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-380|Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines|The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study|DPD côlon|ICO Paul Papin|Yes|Recruiting|June 2008|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2296|||Both|18 Years|N/A|No|||March 2012|March 5, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01547923||89831|
NCT01544296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6188-004|A Comparative Study of KHK6188|Phase II Study of KHK6188 (A Placebo-controlled, Double Blind, Crossover Study of KHK6188 in Postherpetic Neuralgia)||Kyowa Hakko Kirin Company, Limited|No|Completed|February 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|42|||Both|20 Years|N/A|No|||October 2013|October 8, 2013|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01544296||90109|
NCT01544309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0059|LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts|Study on Effect of Highly Potent Statins on Lipid Lowering Effect and Glucose Metabolism in Hypercholesterolemia Patients With Diabetes Mellitus|LISTEN|Listen Trial Group||Completed|March 2012|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1049|||Both|20 Years|N/A|No|||March 2015|March 4, 2015|February 23, 2012||No||No|November 10, 2014|https://clinicaltrials.gov/show/NCT01544309||90108|
NCT01544686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRKS00003368|Antimicrobial Catheter Securement Dressings for the Prevention of Cvc-related Bloodstream Infections in Cancer Patients|Chlorhexidine Containing Iv-securement Dressings for the Prevention of Central Venous Catheter-related Blood Stream Infections in Neutropenic Patients: a Randomized Trial|COAT|University of Cologne|Yes|Completed|February 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|630|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01544686||90079|
NCT01545570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114403|A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers|A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2374697 in Healthy Volunteers||GlaxoSmithKline|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|November 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01545570||90011|
NCT01544647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01319-32|Spa Therapy in Knee Osteoarthritis (OA): Nancy-thermal|Comparison of 2 Spa Therapy Protocols in Symptomatic Knee Osteoarthritis : a Randomised Trial|Nancythermal|Central Hospital, Nancy, France|Yes|Completed|February 2012|January 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|283|||Both|18 Years|N/A|No|||August 2014|August 13, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01544647||90082|
NCT01547273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110339|The Effect of Bone Grafts on Facial Gingival Profile in Maxillary Anterior Single Tooth Replacement|The Effect of Bone and Connective Tissue Grafts on Facial Gingival Profile in Single Maxillary Anterior Immediate Implant Placement and Provisionalization: A 1-Year Prospective Study||Loma Linda University|No|Active, not recruiting|March 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 21, 2015|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01547273||89881|
NCT01576094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MilevoNeo|Two Inodilators Postsurgery in Neonates|Phase I Study of Two Inodilators in Neonates Undergoing Cardiovascular Surgery||Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|Yes|Completed|November 2009|November 2010|Actual|November 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|40 Days|No|||April 2012|April 11, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01576094||87677|
NCT01576393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006B0269|Adolescent Involvement in Parental Substance Abuse Treatment|Adolescent Involvement in Parental Substance Abuse Treatment: Evaluation of EBFT||Ohio State University|No|Completed|August 2009|April 2015|Actual|May 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|183|||Both|8 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 20, 2015|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01576393||87654|
NCT01576406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081012|Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients|A Phase I Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Crizotinib In Advanced Cancer Patients||Pfizer|No|Recruiting|July 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576406||87653|
NCT01576874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016931|The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking|The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking|SCOR-III|Medical University of South Carolina|Yes|Recruiting|June 2012|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|45 Years|No|||March 2016|March 7, 2016|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576874||87617|
NCT01576887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1201|A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis|||Reata Pharmaceuticals, Inc.||Withdrawn|July 2012|October 2013|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|March 30, 2012|Yes|Yes|IDMC recommendation for safety concerns|No||https://clinicaltrials.gov/show/NCT01576887||87616|
NCT01577173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28076|A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck|A Phase II, Open-Label, Randomized Study of MEDH7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Progressed During or Following Platinum-based Chemotherapy||Genentech, Inc.||Completed|July 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01577173||87594|
NCT01576900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nocturia-SBMP|The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia|||Seoul National University Hospital|Yes|Completed|April 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|124|||Both|20 Years|80 Years|No|Non-Probability Sample|Korean patients with nocturia regardless of age and gender|November 2014|November 19, 2014|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576900||87615|
NCT01569646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-021|Monocytosis and Culprit Vessel in STEMI Patients|Significance of Monocytosis and Culprit Vessel in Patients With Acute ST Elevation Myocardial Infarction||Northwell Health|Yes|Completed|April 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|226|||Both|N/A|N/A|No|Non-Probability Sample|STEMI patients,|March 2012|March 30, 2012|June 2, 2010||No||No||https://clinicaltrials.gov/show/NCT01569646||88171|
NCT01569659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sunovion Pharmaceuticals|High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia|High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia|HDL|Northwestern University|No|Completed|October 2011|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|60 Years|No|||December 2015|December 8, 2015|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569659||88170|
NCT01577472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CANTAPOR_2012|Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol|Prospective Randomized Phase IV Study Comparing the Effect of Adding Clomiphencitrate Versus Placebo to a High Dose Versus a Minimal Dose GnRH Antagonist Protocol on the Number of Oocytes Collected From Women That Are Poor Responders|CANTAPOR|University Hospital, Basel, Switzerland|Yes|Recruiting|August 2013|April 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|120|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01577472||87571|
NCT01577485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETMK:22/180/2012|LGG/BB12-pastille Study|LGG/BB12-pastille Study||University of Turku|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|60|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577485||87570|
NCT01546545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC11021|Insulin Variance Throughout the Day|Testing Whether Insulin Resistance Varies Throughout a Day A Pilot Study||Pennington Biomedical Research Center|No|Recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|IV Blood sample|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants with blood sugar between normal and diabetes.|December 2012|December 12, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01546545||89937|
NCT01546558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0143|Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg|A Phase 1, Open-label, Single Cohort, Two-Period Fixed Sequence Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg Twice Daily in Subjects With Type 2 Diabetes Mellitus||Gilead Sciences|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|30 Years|65 Years|No|||July 2012|July 9, 2012|February 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01546558||89936|
NCT01546896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bsp2010|Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder|||Seoul National University Hospital|Yes|Withdrawn|March 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01546896||89910|
NCT01547156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MobileSipoo|Mobile Sipoo - Telemonitoring With Combined With Active Assistance Technology|Mobile Sipoo a Randomized Controlled Trial||VTT Technical Research Centre of Finland|No|Completed|May 2011|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|30 Years|70 Years|No|||March 2016|March 9, 2016|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01547156||89890|
NCT01548482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02848|Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor||National Cancer Institute (NCI)||Completed|March 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||May 2015|October 5, 2015|February 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01548482||89788|
NCT01544335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-325|Evaluation of BIS for Quantification of Lymphedema|Evaluation of the Validity of BIS as a Tool for Quantification of Lymphedema Through Comparison With Perometry and Self-Report||Massachusetts General Hospital|Yes|Recruiting|December 2011|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects with histologically or cytologically confirmed breast cancer who will be        returning routinely for follow-up at Massachusetts General Hospital|March 2016|March 14, 2016|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01544335||90106|
NCT01548183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10100400|Text-message Program to Reduce Risky Sexual Behavior in Young Adult Female Emergency Department (ED) Patients|Mobile Phone Text-message Program to Reduce Risky Sexual Behavior in Young Females Discharged From the Emergency Department|StARSS|University of Pittsburgh|Yes|Completed|August 2011|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|52|||Female|18 Years|25 Years|No|||May 2015|May 26, 2015|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01548183||89811|
NCT01544660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH-Multicenter Interscanner|Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research|Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research|Interscanner|University of California, San Francisco|No|Completed|April 2012|March 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Both|65 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy men and women aged 65-80|April 2014|April 15, 2014|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01544660||90081|
NCT01545856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116493|Cardiovascular Events in Parkinson's Disease Patients|Background Incidence of Cardiovascular Ischaemic Events in Treated Parkinson's Disease Patients in the Impact Database||GlaxoSmithKline|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|20 Years|N/A|No|Non-Probability Sample|The study cohorts of interest will be identified from the most recent datacut of the IHCIS        database. Individuals with one or more prescriptions of levodopa between 1st July 2004 and        30th June 2010 will be included. The date of the first prescription of levodopa in the        study time period is defined as the INDEX DATE. All individuals must be on the database        with medical and pharmacy benefit for at least 6 months prior to the INDEX DATE. All        individuals must have one or more diagnosis codes for Parkinson's disease within the 6        months prior or 6 months post INDEX DATE. Individuals will be excluded if age is <20 years        on the INDEX date. Individuals will also be excluded if they have a previous levodopa        prescription prior to the INDEX date as only new users of levodopa are of interest.|February 2012|March 1, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01545856||89989|
NCT01545245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCELIA study|Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants|Cohort Study to Evaluate Effects of Prophylactic Treatment for Respiratory Syncytial (RS) Virus Infection in Respiratory Tract During Infancy on Subsequent Atopic Asthma in Preterm Infants||Tokai University|No|Completed|July 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|343|Samples Without DNA|The serum samples|Both|3 Years|3 Years|No|Non-Probability Sample|The children who are participating in another on-going study, "Effect of Palivizumab on        Later Recurrent Wheezing in Preterm Infants (ClinicalTrials.gov Identifier: NCT01072552)"        and whose parents or legal guardian provide informed consent in writing for continuing        participation in the study.|December 2014|December 5, 2014|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01545245||90036|
NCT01545531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6726|Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance|||University of Washington|No|Completed|September 2008|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Both|2 Years|N/A|No|||March 2016|March 1, 2016|September 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01545531||90014|
NCT01561209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMIT-CNP|Low Doses Amitriptyline & Chronic Neck Pain|Prospective Randomized & Controlled Study of the Role of Low Doses Amitriptyline in the Management of Chronic Neck Pain||St Joseph University, Beirut, Lebanon|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|20 Years|60 Years|No|||June 2014|June 9, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01561209||88816|
NCT01561222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zhangxu2012|Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2|||Taixing People's Hospital||Not yet recruiting|July 2015|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|80 Years|No|||June 2015|June 5, 2015|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561222||88815|
NCT01557244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221047|A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition|A 24-week Randomized, Open-label, Study To Evaluate The Safety And Efficacy Of Fesoterodine In Subjects Aged 6 To 17 Years With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity)||Pfizer|Yes|Recruiting|July 2012|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|187|||Both|6 Years|17 Years|No|||March 2016|March 23, 2016|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557244||89120|
NCT01557257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531006|Pharmacokinetics Study of ALO-02 and OxyContin|An Open-label, Single-dose and Multiple-dose, Randomized, Crossover Study to Evaluate Pharmacokinetics, Safety and Tolerability After Administration of ALO-02 40 Mg Twice Daily Compared to ALO-02 80 Mg Once Daily and to Oxycontin 40 Mg Twice Daily in Healthy Volunteers||Pfizer|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01557257||89119|
NCT01557504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431A-296|A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)|A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets||Merck Sharp & Dohme Corp.|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|10 Years|17 Years|No|||January 2016|January 21, 2016|March 16, 2012|No|Yes||No|April 6, 2015|https://clinicaltrials.gov/show/NCT01557504||89100|
NCT01557517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120068|Clobetasol for Oral Graft-Versus-Host Disease|A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host-Disease||National Institutes of Health Clinical Center (CC)||Recruiting|January 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|99 Years|No|||September 2015|March 19, 2016|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557517||89099|
NCT01557764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206025|Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer|A Phase II Study of Lapatinib in Combination With Trastuzumab in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer||Washington University School of Medicine|No|Withdrawn|September 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 2, 2013|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557764||89081|
NCT01557777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-641|Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)|An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)||AbbVie|No|Completed|June 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 2, 2014|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557777||89080|
NCT01531842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#11-110|A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye|Bacterial Resistance and Alterations in Conjunctival Flora Following Serial Intravitreal Injections||Mid Atlantic Retina|No|Recruiting|August 2011|August 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|N/A|N/A|No|||February 2012|February 8, 2012|October 13, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01531842||91059|
NCT01531855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|west-walker1|Post-exercise Insulin Reductions in Type 1 Diabetes|The Metabolic and Glycaemic Responses to Reductions in Rapid-acting Insulin Dose After Running Exercise in People With Type 1 Diabetes Mellitus.||Northumbria University|Yes|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|13|||Male|18 Years|50 Years|No|||August 2014|August 1, 2014|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531855||91058|
NCT01531868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPFACS-1|Alternative Sensory Presentation Formats in Asymptomatic Carotid Stenosis|A Randomized Trial of Alternative Sensory Presentation Formats in Asymptomatic Carotid Stenosis||Rhode Island Hospital|No|Recruiting|February 2012|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|6||Anticipated|450|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 12, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01531868||91057|
NCT01532167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-755|Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis|Impact and Utility of Positron Emission Tomography (PET) for the Assessment of Inflammatory Activity Arteritis Versus Clinical Score and Laboratory Values in Takayasu Arteritis: a Cohort Study||Instituto Nacional de Cardiologia Ignacio Chavez|No|Completed|February 2010|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|26|||Both|N/A|N/A|No|Probability Sample|Patients treated for TA at our institution's immunology outpatient clinic were included        between.|March 2012|March 23, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01532167||91034|
NCT01532180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMT 2009-01/02/03|Safety and Efficacy of a Hypoglossal Nerve Implant for the Treatment of Obstructive Sleep Apnea (OSA)|A Pilot Study and Follow Up of the Use of a Hypoglossal Nerve Implant for Treatment of Obstructive Sleep Apnea||ImThera Medical, Inc.|No|Completed|November 2009|December 2011|Actual|December 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|25 Years|70 Years|No|||February 2012|February 9, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01532180||91033|
NCT01532427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-AAR-004|ALFApump System Post Marketing Surveillance Registry|ALFApump System Post Marketing Surveillance Registry, In Support of the Following Indication: Automated Removal of Excess Peritoneal Fluid Into the Urinary Bladder in Patients With Cirrhosis or Malignancy, With Persistent or Refractory Ascites|2011-AAR-004|Sequana Medical AG|No|Enrolling by invitation|June 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|The Registry will include 200 patients implanted after market approval at up to 25        centres, in patients with liver cirrhosis or malignancy, with persistent or refractory        ascites.|June 2015|June 24, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01532427|2 Years|91014|
NCT01532440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR5-Face|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|January 2012|||||N/A|N/A|N/A||||||||||||||July 31, 2013|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532440||91013|
NCT01532453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP 488/2009|Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients|Open, Multicentre, Randomised, Comparative, Prospective Trial With MD-3511356 Versus Standard Sun Protection Measures in Immunosuppressed Solid Organ Transplanted Patients for Prevention of UV-induced Carcinogenic Skin Alterations||Spirig Pharma Ltd.|Yes|Terminated|November 2010|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|244|||Both|40 Years|N/A|No|||December 2015|December 3, 2015|February 9, 2012||No|For futility reasons and potential "loss of chance" for MD 3511356 group|No|July 16, 2015|https://clinicaltrials.gov/show/NCT01532453||91012|Trial was terminated early for futility reasons (outcome would not be changed, if trial pursued up completion) and potential “loss of chance” (which could neither be confirmed nor rejected at the time) for patients included in the MD 3511356 group.
NCT01532739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS/2012-227|Making Memory Better for Seniors With Mild Cognitive Impairment|Neuropsychological Intervention for a Seniors Mental Health Population With Mild Cognitive Impairment||Nova Scotia Health Authority|No|Recruiting|April 2012|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||April 2015|April 30, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532739||90991|
NCT01532752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR2-1Y|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|December 2011|||||N/A|N/A|N/A||||||||||||||July 31, 2013|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532752||90990|
NCT01533051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quit Anti-viral therapy|Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B|Phase IV Study of Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B||Yonsei University|Yes|Recruiting|February 2012|March 2016|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples Without DNA|Initially, 30ml of heparinized peripheral blood will be obtained from each subjects. After      then, 10ml of heparinized peripheral blood will be additionaly obtained at every 3 months      follow-up visit.|Both|20 Years|75 Years|No|Probability Sample|Chronic Hepatitis B patients under anti-viral therapy|May 2012|May 7, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01533051||90967|
NCT01548911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 22311|Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia|Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)||Comprehensive Cancer Center of Wake Forest University|No|Withdrawn|May 2012|||March 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2013|September 23, 2013|February 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01548911||89755|
NCT01548924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIO-BR-01-2011|Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors|Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus Priming With BIBF 1120 BIBF 1120 Followed by Plus Paclitaxel in Breast Cancer With HER-2 Negative Correlative Proteomic Studies. and Dynamic Image||Centro Nacional de Investigaciones Oncologicas CARLOS III|Yes|Terminated|April 2012|August 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|76 Years|No|||January 2014|January 7, 2014|February 15, 2012||No|Drug toxicity|No||https://clinicaltrials.gov/show/NCT01548924||89754|
NCT01549158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-110875-01|Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure|Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure (CHF).||Ferrer Internacional S.A.|No|Terminated|February 2012|December 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|18 Years|75 Years|No|||April 2013|April 24, 2013|March 6, 2012||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01549158||89736|
NCT01549405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diskapi|Ultrasound-Guided Intercostal Nerve Block for Postoperative Pain Relief in Percutaneous Nephrolitotomy|||Diskapi Teaching and Research Hospital|Yes|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|40|||Both|18 Years|65 Years|No|||April 2013|April 1, 2013|March 7, 2012|Yes|Yes||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01549405||89717|
NCT01549678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1349/09|Plantar Fasciitis Foot Insole|Effect of Plantar Fasciitis Foot Insole||Federal University of São Paulo|Yes|Recruiting|August 2010|August 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||November 2010|March 7, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01549678||89696|
NCT01549691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2011-20|Reassessment of Premedication in Surgery|Assessment of Two Modes of Premedication in Surgery - PREMED Study|PREMED|University Hospital, Angers|Yes|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|455|||Both|18 Years|65 Years|No|||September 2013|September 24, 2013|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01549691||89695|
NCT01549990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0012|A Comparison of Kidney Function After Nephrectomy in Living Donors Under Sevoflurane and Desflurane Anesthesia|||Yonsei University|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|236|||Both|20 Years|70 Years|No|Non-Probability Sample|From January 2006 through December 2011, donors who went through nephrectomy for kidney        donation|January 2015|January 26, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549990||89673|
NCT01560416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-477|Fulvestrant With or Without Ganetespib in HR+ Breast Cancer|Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|May 2012|||February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|71|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|February 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560416||88877|
NCT01560429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANAE-147-08|Efficacy of Patient Controlled Epidural Anesthesia Versus Continuous Epidural Analgesia for Post-thoracotomy Pain|Efficacy of Patient Controlled Epidural Anesthesia (PCEA) Versus Continuous Epidural Analgesia (CEA) for Post-thoracotomy Pain.||Queen's University|No|Completed|June 2009|July 2010|Actual|July 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|75 Years|No|||March 2012|March 21, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01560429||88876|
NCT01560078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T-18012/2/2005-TB/CCD|Efficacy Study of Thrice Weekly Directly Observed Treatment Short-Course Regimen in Tubercular Pleural Effusion|Evaluation of Efficacy of Thrice Weekly DOTS Regimen in Tubercular Pleural Effusion at 6 Months||All India Institute of Medical Sciences, New Delhi|No|Completed|September 2006|December 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|360|||Both|15 Years|65 Years|No|Non-Probability Sample|1042 patients presenting with unilateral tubercular pleural effusion who attended DOTS        Centres/Chest clinics at the respective Study sites between the ages 15 and 65 years were        screened for the study.351 were enrolled after 691 were excluded due to various reasons.|July 2013|July 11, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560078||88903|
NCT01560091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4378|Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy|Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL||Albert Einstein Healthcare Network|Yes|Not yet recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 21, 2012|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560091||88902|
NCT01560390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0108|Use of Ketamine Associate With an Opioid for Sedation in ICU|Use of Ketamine Associate With an Opioid for Sedation in ICU : a Randomized Controlled Double Blind Study|KetaRea|University Hospital, Clermont-Ferrand||Completed|October 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01560390||88879|
NCT01560403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED-C11-001|A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021|A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021|STEPS3|Shire|Yes|Completed|May 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||December 2014|November 10, 2015|March 13, 2012|Yes|Yes||No|December 16, 2014|https://clinicaltrials.gov/show/NCT01560403||88878|This study provided further long-term safety and efficacy data on the 14 US subjects who enrolled in the CL0600-020 and the CL0600-021 study. Given the small number of subjects in this study, only descriptive statistics were employed and presented.
NCT01561235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B243|Protein Dose-repsonse Effect on GLP-1, PYY and Appetite in Male Subjects|The Contribution of Gastrointestinal Appetite Hormones to Protein-induced|Protein|University of Copenhagen|No|Completed|February 2008|July 2008|Actual|July 2008|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|25|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01561235||88814|
NCT01557270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GernerDex001|Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery|The Efficacy and Safety of Dexmedetomidine as an Additive to Ropivacaine for Interscalene Brachial Plexus Blocks for Shoulder Surgery||Paracelsus Medical University|Yes|Completed|March 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|75 Years|No|||December 2012|December 3, 2012|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01557270||89118|
NCT01557283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801314|An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria|An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria - Beflex Study|BEFLEX|Pfizer|No|Completed|September 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|140|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects enrolled should meet the usual prescribing criteria for Enbrel as per local        reimbursement criteria and should be entered into the study at the investigator's        discretion. It is requested to include patients in a consecutive manner as much as        possible.|May 2014|May 28, 2014|September 30, 2011||No||No|May 28, 2014|https://clinicaltrials.gov/show/NCT01557283||89117|
NCT01557543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120078|Stem Cell Injection to Treat Heart Damage During Open Heart Surgery|Preliminary Assessment of Direct Intra-Myocardial Injection of Autologous Bone Marrow-derived Stromal Cells on Patients Undergoing Revascularization for CAD With Depressed Left Ventricular Function||National Institutes of Health Clinical Center (CC)||Suspended|February 2012|December 2020|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|85 Years|No|||November 2015|January 12, 2016|March 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01557543||89098|
NCT01557556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912471|Pexacerfont to Reduce Stress-induced Tobacco Craving|Pexacerfont for Reduction of Stress-induced Tobacco Craving, Nicotine Reinforcement, and Brain Activation in Humans||National Institutes of Health Clinical Center (CC)||Withdrawn|February 2012|December 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|18 Years|55 Years|No|||December 2013|July 3, 2015|March 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01557556||89097|
NCT01557790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 17811|Proton Radiotherapy for Stage I, IIA, and IIB Seminoma|A Phase II Study of Adjuvant Proton Radiation Therapy for the Treatment of Stage I, IIA and IIB Seminoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|March 2012|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Primary Purpose: Treatment|||Anticipated|56|||Male|18 Years|N/A|No|||October 2015|October 16, 2015|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557790||89079|
NCT01558570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00049310|Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin|Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin||University of Maryland|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|Samples With DNA|Laboratory Measures:      Zonulin and gliadin antibodies will be sent to the lab of Dr. Alessio Fasano for assay.      Genetic and Biochemical analysis will be sent for analysis and storage of blood sample at      the Maryland Psychiatric Research Center Neurogenetics laboratory under the direction of Dr.      Ikwunga Wonodi. Analysis will include kynurenic acid metabolites, inflammatory markers from      Peripheral Blood Mononuclear Cells (PBMC) and future genetic analysis including but not      limited to human leukocyte antigen (HLA) haplotypes (DQ2 and DQ8).      Cytokines will be analyzed by the Cytokine Core Laboratory at the University of Maryland      using Luminex Technology.      Other standard laboratories will be done by Lab Corp or other contract laboratory.|Both|18 Years|75 Years|No|Probability Sample|Patients with schizophrenia will be recruited by MPRC through their patient recruiting        network including the Treatment Research Program and the Outpatient Research Program and        affiliated sites. Patient with schizophrenia may also be recruited through the NIDA        screening protocol process. (UMB approved IRB protocol HP-00043664)|March 2012|March 17, 2012|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01558570||89019|
NCT01531816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008|Early Rehabilitation in Critically Ill Children Pilot Study|Early Rehabilitation in Critically Ill Children, a Pilot Study|WeeHab in PCCU|McMaster University|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|3 Years|17 Years|No|||November 2013|November 4, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531816||91061|
NCT01531829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCYH1893|Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD|Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized，Multi-Center，Controlled Trial||Beijing Chao Yang Hospital|Yes|Recruiting|July 2009|December 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|75 Years|No|||February 2012|February 11, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01531829||91060|
NCT01532466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC100-5|The Effect of Priming Intravenous Rocuronium on Fentanyl-Induced Coughing|||Taichung Armed Forces General Hospital|Yes|Completed|March 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|260|||Both|18 Years|80 Years|No|||December 2011|February 9, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01532466||91011|
NCT01532765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|422-2010|Randomized Trial Comparing Epiretinal Membrane Surgery With and Without Internal Limiting Membrane Removal|A Multicentre Randomized Clinical Trial Comparing Epiretinal Membrane Surgery With and Without Internal Limiting Membrane Peeling||Sunnybrook Health Sciences Centre|No|Recruiting|September 2011|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01532765||90989|
NCT01532778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01225-34|Saliva Modification Related to Fat Perception in Human|Perception Ortho-nasale du Gras Chez l'Homme Sain : Relations Entre Typages olfactométriques, Sensoriels et Composition de la Salive.|SensInFat|Centre des Sciences du Goût et de l'Alimentation|No|Recruiting|January 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Male, healthy|February 2012|February 13, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532778||90988|
NCT01533077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-117|Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa|Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects||Bial - Portela C S.A.|No|Completed|March 2009|February 2010|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|January 24, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01533077||90965|
NCT01533090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMF 105|Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy|Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy|LowVolumePEG|Catholic University of the Sacred Heart|Yes|Completed|April 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|162|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2010|February 11, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01533090||90964|
NCT01533103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRC.2012.0004|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2012|||||N/A|N/A|N/A||||||||||||||August 20, 2013|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01533103||90963|
NCT01533064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCH 8 2012|Response of Psychiatric Outpatients to the Great East Japan Earthquake|Response of Psychiatric Outpatients to the Great East Japan Earthquake||Ashikaga Red Cross Hospital|Yes|Completed|March 2011|May 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|328|||Both|11 Years|90 Years|No|Probability Sample|a total of 328 psychiatric outpatients of Ashikaga Red Cross Hospital|February 2012|February 14, 2012|February 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01533064||90966|
NCT01557972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5|Long-term of 10 Years Results of a Prospective Longitudinal Study|Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients : Long-term (10 Years) Results of a Prospective Longitudinal Study||Nagaoka Red Cross Hospital|No|Active, not recruiting|November 1999|March 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|20 Years|95 Years|No|Probability Sample|400 patients|March 2012|March 16, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01557972||89065|
NCT01558167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLL2P|A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomid in Patients With Chronic Lymphocytic Leukemia|A phaseI/II Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomid (BRL) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|CLL2P|German CLL Study Group|No|Terminated|February 2011|June 2015|Anticipated|October 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|May 19, 2011||No|delayed recruitment|No||https://clinicaltrials.gov/show/NCT01558167||89050|
NCT01558479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW IRB 36777-A|The Parkinson's Genetic Research Study|The Parkinson's Genetic Research Study (PaGeR)|PaGeR|University of Washington|No|Recruiting|September 2009|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||3|Anticipated|5000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Families in which two or more people have been diagnosed with Parkinson's disease.|March 2012|March 16, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558479||89026|
NCT01558492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008011188|Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer|A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel||Weill Medical College of Cornell University|Yes|Recruiting|March 2011|December 2015|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Male|18 Years|N/A|No|||June 2013|June 17, 2013|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558492||89025|
NCT01558765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHCopenHeartVR|CopenHeartVR - Integrated Rehabilitation of Patients After Heart Valve Surgery|CopenHeartVR - A Randomized Clinical Trial Investigating the Effect of Integrated Rehabilitation Versus Usual Care Without Physical Exercise After Heart Valve Surgery.|CopenHeartVR|Rigshospitalet, Denmark|Yes|Completed|March 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|147|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558765||89004|
NCT01561001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1113|IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant|24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Primary Open Angle Glaucoma Before and After Deep Sclerectomy With Collagen Implant||Sensimed AG|No|Terminated|April 2012|March 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|N/A|No|||May 2015|May 19, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561001||88832|
NCT01560715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rubens Siqueira|Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa|Phase 2 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa|RETICELL|University of Sao Paulo|Yes|Completed|June 2011|June 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||January 2014|January 12, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01560715||88854|
NCT01560975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF-1108|IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure|A Prospective, Explorative, Open Label Study to Assess the 24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Moderate to Severe Obstructive Sleep Apnea Syndrome Using Continuous Positive Airway Pressure With or Without Primary Open Angle Glaucoma||Sensimed AG|No|Completed|March 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|99 Years|No|||December 2015|December 21, 2015|March 20, 2012||No||No|November 18, 2014|https://clinicaltrials.gov/show/NCT01560975||88834|
NCT01557569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133414|Clinical Efficacy of Atomoxetine for Methamphetamine Dependence||ATM|University of Arkansas|Yes|Completed|April 2012|July 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||July 2015|July 22, 2015|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557569||89096|
NCT01557582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011052|Assessmet of Patients With PAH Right Ventricular Volume|Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension||VentriPoint Diagnostics Ltd.|No|Completed|April 2012|December 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|103|||Both|12 Years|N/A|Accepts Healthy Volunteers|||October 2012|March 25, 2015|August 30, 2011|No|Yes||No|March 25, 2015|https://clinicaltrials.gov/show/NCT01557582||89095|
NCT01557803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRU-HAS 006/2012|Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome|Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome in Lambaréné, Gabon|IRIS|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Completed|January 2012|January 2015|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|Samples Without DNA|Plasma, Paxgene RNA tubes and urine|Both|18 Years|N/A|No|Non-Probability Sample|Adult HIV patients starting anti retroviral therapy for the first time|January 2015|January 13, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557803||89078|
NCT01557595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X110825016|Blue Wavelength Light-blocking Glasses in ADHD-Insomnia|Evening Use of Polarized Glasses Designed to Filter Out Blue Light in Attention Deficit Hyperactivity Disorder - Delayed Circadian Rhythm Disorder Patients|ADHD|University of Alabama at Birmingham|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|19 Years|N/A|No|||September 2014|September 5, 2014|February 16, 2012||No||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01557595||89094|
NCT01558245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KPRASS|Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis|Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis||Jinling Hospital, China|Yes|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|99|||Both|30 Years|N/A|No|||September 2013|September 11, 2013|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558245||89044|
NCT01558284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STO-010|The Effect of Neu-P11 on Symptoms in Patients With D-IBS|Clinical Study on the Effect of Neu-P11 on Symptoms in Patients With Diarrhea- Irritable Bowel Syndrome (D-IBS)|Neu-P11|Ludwig-Maximilians - University of Munich|Yes|Completed|February 2012|February 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|40|||Both|18 Years|79 Years|No|Non-Probability Sample|Patients with diarrhea-praedominant Irritated Bowel Syndroms|February 2014|February 4, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01558284||89041|
NCT01558297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106008713|Internet Treatment for Weight Loss in Primary Care|Internet Treatment for Weight Loss in Primary Care||Yale University|Yes|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|89|||Both|18 Years|65 Years|No|||June 2015|June 3, 2015|March 15, 2012||No||No|May 19, 2015|https://clinicaltrials.gov/show/NCT01558297||89040|Treatment as Usual (TAU) was subsequently referred to as Usual Care (UC) when the study results were disseminated because the literature evolved regarding treatment terms. UC more accurately reflect the condition.
NCT01531569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHPD - 174041|Single Oral Dose of BeneFlax to Healthy Young and Older Adults|Community Alliance for Quality of Life in Long Term Care: Single Oral Dose of BeneFlax to Healthy Young and Older Adults|SOD|University of Saskatchewan|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01531569||91080|
NCT01532479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHTGN-001|Saliva, Hyperbaric Oxygen Therapy, & Gland Function: A Prospective Study|Saliva, Hyperbaric Oxygen Therapy, & Gland Function: A Prospective Study|SHOTGUN|Loma Linda University|No|Withdrawn|August 2015|January 2022|Anticipated|August 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Both|18 Years|N/A|No|Probability Sample|Patients in the Loma Linda University Healthcare System|October 2014|October 13, 2014|February 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532479||91010|
NCT01532791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAB1425|Natural History Study - Mitochondrial Disease|Mitochondrial Encephalomyopathies and Mental Retardation: Investigations of Clinical Syndromes Associated With MtDNA Point Mutations||Columbia University|No|Recruiting|July 2004|January 2022|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|300|None Retained|skin fibroblast blood urine buccal cells hair samples|Both|4 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Carriers of the m.3243A>G mitochondrial DNA point mutation, and their maternal relatives        (carrier status documentation not required) will be enrolled. Paternal relatives will        participate as controls. Mitochondrial DNA mutations are genetically determined and        transmitted through the maternal lineage. Therefore, this study will focus on family        clusters and concentrate on the maternal relatives including the mother and all siblings.        All patients suspected of having an mtDNA point mutation regardless of age, health status,        gender, race, or ethnicity will be evaluated. The minimal age of entry into the study will        be 4 years or older. We will also evaluate controls, or people do do not carry a        mitochondrial mutation and are generally family members, not maternally related to a mtDNA        mutation carrier|December 2015|December 21, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532791||90987|
NCT01533116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-118|Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide|Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects||Bial - Portela C S.A.|No|Completed|March 2009|March 2010|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|52|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|January 24, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01533116||90962|
NCT01533129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSM-022011|The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism|Phase 4 Study That Evaluates the Effects of Two Different Testosterone Replacement Regiments on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism.||Gulhane School of Medicine|No|Completed|August 2008|||April 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Male|18 Years|26 Years|No|||February 2012|February 14, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01533129||90961|
NCT01533428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E05-CL-3004|A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)|A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of QUTENZA® in Subjects With Painful Diabetic Peripheral Neuropathy|STEP|Astellas Pharma Inc|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|369|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|February 12, 2012|Yes|Yes||No|February 6, 2015|https://clinicaltrials.gov/show/NCT01533428||90938|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.
NCT01533402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2027-31/5|Internet-delivered Cognitive Behavior Therapy (CBT) for Children Age 8-12 Years With Anxiety Disorders|Internet-delivered Cognitive Behavior Therapy (CBT) Treatment for Anxiety Disorders in Children Age 8-12 Years - a Randomised Controlled Trial||Karolinska Institutet|No|Completed|February 2012|April 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|8 Years|12 Years|No|||September 2014|September 8, 2014|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01533402||90940|
NCT01533415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.020712|Use of Alpha-Stim Cranial-electrotherapy Stimulation (CES) in the Treatment of Anxiety|The Efficacy of Cranial-electrotherapy Stimulation (CES) Using Alpha-Stim Technology in The Treatment of Anxiety Disorders||Wyndhurst Counseling Center|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|65 Years|No|||April 2013|April 5, 2013|February 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01533415||90939|
NCT01533701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UASKK2012|Scalp Sampling for Fetal Surveillance|Biosampling for Markers of Hypoxia in Fetal Blood Scalp Sampling During Labor|FBS|Uppsala University Hospital|No|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|60|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||February 2012|February 10, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01533701||90917|
NCT01558778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 190510|Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant|Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss||Roswell Park Cancer Institute|Yes|Withdrawn|May 2012|||June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|March 16, 2012||No|device not available|No||https://clinicaltrials.gov/show/NCT01558778||89003|
NCT01559051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMR-EPOC-001|Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Intra-venous Implantation of Autologous Adipose-Derived Stem Cells in Patients With Chronic Obstructive Pulmonary Disease||Ageless Regenerative Institute|No|Recruiting|March 2014|December 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|80 Years|No|||July 2014|July 10, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559051||88982|
NCT01559337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHEN-19750471|Nerve Transfer for Finger Sensory Reconstruction With Dorsal Branch of the Digital Nerve|||The Second Hospital of Tangshan|Yes|Completed|May 2007|January 2012|Actual|June 2009|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|15 Years|50 Years|No|||March 2012|March 20, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559337||88960|
NCT01559636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-458-GID-037|Diarrhea and Bivalent Oral Polio Vaccine Immunity|Effect of Diarrheal Disease on Bivalent Oral Polio Vaccine (bOPV) Immune Response in Infants in Nepal||Centers for Disease Control and Prevention|Yes|Completed|August 2012|October 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|699|||Both|6 Weeks|11 Months|Accepts Healthy Volunteers|||October 2015|October 13, 2015|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01559636||88937|
NCT01559844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7977-2025|Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant|An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant||Gilead Sciences|Yes|Completed|March 2012|October 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|March 5, 2012|Yes|Yes||No|May 12, 2015|https://clinicaltrials.gov/show/NCT01559844||88921|
NCT01560728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH095210-01|Bringing What Works to Youth in Corrections: A Trauma Intervention|Bringing What Works to Youth in Prison: An Evidence-Based Trauma Intervention||University of Texas at Austin|Yes|Completed|November 2012|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|13 Years|18 Years|No|||March 2016|March 15, 2016|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01560728||88853|
NCT01560988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010p002041|Borage and Echium Seed Oils for Asthma|Treatment of Bronchial Asthma With Borage and Echium Seed Oils|Borage|Brigham and Women's Hospital|No|Completed|February 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560988||88833|
NCT01557309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAstudy2|Clinical and Structural Outcome After Early Repair of the Traumatic Rotator Cuff Tear|Arthroscopic Repair of Traumatic Rotator Cuff Tears. A Prospective Trial||Helsingborgs Hospital||Recruiting|November 2010|January 2015|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|Peroperatively retained rotator cuff biopsy.|Both|18 Years|75 Years|No|Probability Sample|A prospective trial analysing the results after early arthroscopic repair of the traumatic        rotator cuff tear. Every consecutive patient between Nov 2010 and Oct 2013 who fulfill the        inclusion criteria are asked to participate after oral and written information. With a        population of 250.000 we approximate an enrollment of 60 participants.|March 2012|March 16, 2012|January 27, 2012||||No||https://clinicaltrials.gov/show/NCT01557309||89115|
NCT01557829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Amedica 2011-9|Valeo OL Interbody Fusion Devices for Posterior Lumbar Interbody Fusion SNAP Trial|Clinical Study of the Amedica Corporation Valeo OL Interbody Fusion Devices for Posterior Lumbar Interbody Fusion|SNAP|Amedica Corporation|Yes|Active, not recruiting|February 2012|March 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||January 2015|January 20, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557829||89076|
NCT01557842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASPIRE|Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators|Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators|ASPIRE|Biosense Webster, Inc.|No|Terminated|June 2012|September 2017|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||December 2014|December 19, 2014|March 16, 2012||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01557842||89075|Please note that this study was terminated early and only 15 subjects were enrolled. As a result the reported results might be unreliable (unmonitored) and limited.
NCT01557816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALPMF-006-2010|Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee|A Randomized, Double-Blind, Placebo-controlled Cross-over, Exploratory Trial of Naproxen to Evaluate Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee||Analgesic Solutions|Yes|Recruiting|December 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|21 Years|N/A|No|||February 2012|March 21, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01557816||89077|
NCT01558050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RR001|the Effect of a Red Rice Nutrition Supplement on Cholesterol Levels|The Effect of a Commercially Available Red Rice Nutrition Supplement on Serum Lipids||Universiteit Antwerpen|Yes|Completed|March 2012|September 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558050||89059|
NCT01558076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-14565|Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia|Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|90|||Both|8 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Sickle cell anemia patients followed at Children's Memorial Hospital. Healthy controls        without sickle cell anemia or sickle cell trait are recruited through flyers posted in        Children's Memorial Hospital.|September 2015|September 21, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01558076||89057|
NCT01532193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903-C-059-MJ|The Effect of Embryo Culture Under Low Oxygen Tension on Pregnancy Rates|A Randomized Controlled Trial Evaluation the Effect of Low Oxygen Tension on the Pregnancy Rate After Day 3 Embryo Transfer in an Egg Donation Programme.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|November 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|380|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01532193||91032|
NCT01532206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00069912|IL-10 Levels and Remote Ischemic Preconditioning in Acute Myocardial Infarction|Interleukin-10 Levels and Remote Ischemic Preconditioning in Acute Myocardial Infarction.||Johns Hopkins University|No|Terminated|March 2013|May 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||March 2013|March 24, 2016|February 9, 2012||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01532206||91031|
NCT01533142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/3287|Bariatric Surgery on the West Coast of Norway (Vestlandet)|Bariatric Surgery on the West Coast of Norway (Vestlandet): Prospective Study of Overweight People Undergoing Bariatric Surgery|FatWest|Helse Fonna|No|Recruiting|February 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|Plasma, serum, urine and biopsi from fat|Both|18 Years|60 Years|No|Probability Sample|Both sexes 18-60 years old Patients with morbid obesity that is applied to the bariatric        surgery. Signed informed consent|February 2016|February 17, 2016|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01533142||90960|
NCT01533155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00011|Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118|A Randomized, 2-Part, Crossover, Single Center Study to Evaluate Effect of Quinidine on the Pharmacokinetics of NKTR-118 and the Concomitant Effect of Quinidine and NKTR-118 on Morphine-induced Miosis||AstraZeneca||Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|214|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|February 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01533155||90959|
NCT01533441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFE K study|Vitamin K2 Intervention in Patients With Vitamin K Antagonists|Study of the Effect of Food Vitamin K2 Intake in Association With a Fermented Dairy Product on Patients Treated With Vitamin K Antagonist (VKA)|SAFEK|Danisco|No|Completed|February 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|50|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01533441||90937|
NCT01533714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0089|The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis|Multi-center, Open-label, Follow-up Study to Assess the Long-term Safety and Efficacy of CDP6038 Administered Subcutaneously to Asian Subjects With Active Rheumatoid Arthritis Who Completed Study RA0083||UCB Pharma|No|Completed|January 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|20 Years|N/A|No|||August 2014|August 27, 2014|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01533714||90916|
NCT01533987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-06|Effects of Juice Plus+® Supplementation on Endothelial Function in Overweight Men|Effects of Juice Plus+® Supplementation on Endothelial Function in Overweight Men: A Randomized, Controlled Trial||Griffin Hospital|No|Completed|July 2009|August 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||August 2011|February 15, 2012|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01533987||90895|
NCT01559077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR02-001|Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects|A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Healthy Volunteers||Alnylam Pharmaceuticals|No|Completed|March 2012|November 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559077||88980|
NCT01559350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-11-065|Graft Patency Analysis of the Right Coronary Artery System|Graft Patency of the Right Coronary Artery System in OPCAB: Saphenous Vein Graft Versus Right Gastroepiploic Artery||Samsung Medical Center|Yes|Recruiting|January 2012|December 2022|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|224|||Both|20 Years|75 Years|No|Probability Sample|Patients who undergo OPCAB for triple vessel disease at Samsung Medical Center are        enrolled.|March 2012|October 28, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559350||88959|
NCT01559649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7242-R|Stroke Swallowing Screening Tool Validation|Development and Validation of a VA Stroke Swallowing Screening Tool|SSST|VA Office of Research and Development|No|Active, not recruiting|October 2012|December 2015|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|305|None Retained|no samples will be collected|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Veterans admitted with stroke symptoms Nurses working on the stroke ward Nurse        practitioners with advanced practice skills in stroke|October 2015|October 19, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559649||88936|
NCT01559857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH093948-01A1|Pioglitazone in Patients With Mood Disorders|Pioglitazone Treatment for Insulin Resistant Patients With Mood Disorders||Stanford University|No|Recruiting|November 2011|June 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|65 Years|No|||March 2012|March 19, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01559857||88920|
NCT01560741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TeleMotiNIV2012|Telemedicine and Ventilator Titration in Chronic Respiratory Patients Initiating Non-invasive Ventilation|Randomized Trial Comparing Telemedicine Monitoring and Titration in Patients Initiating Non-invasive Ventilation With Usual Care (TELEMOTINIV Study)|TeleMotiNIV|Hospital Sao Joao|No|Recruiting|July 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|128|||Both|15 Years|80 Years|No|||October 2012|October 3, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560741||88852|
NCT01560754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KKS-135|Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease|A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA|NIC-PD|University of Vermont|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|160|||Both|30 Years|N/A|No|||September 2015|September 28, 2015|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560754||88851|
NCT01561248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHEC-2011-PEG|Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis|Repetitive Intestinal Lavage Using Polyethylene Glycol Solution in Patients With EHEC O104:H4 Infection During the German 2011 Outbreak for Prevention of Severe Thrombocytopenia With Subsequently Following Therapeutic Plasmapheresis|EHEC-PEG|Universitätsklinikum Hamburg-Eppendorf|No|Completed|May 2011|February 2012|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|33|||Both|N/A|N/A|No|||March 2012|March 21, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01561248||88813|
NCT01557296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#EMS-5115#|Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis|Comparing Treatment With Food of Small Particle Size and Food of Large Particle Size in Subjects With Diabetic Gastroparesis. Evaluation of Diagnostic Methods. Determination of the Motility of Gastric Emptying After Intervention||Göteborg University|No|Recruiting|September 2007|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||January 2016|January 7, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557296||89116|
NCT01557322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801345|Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)|Evaluation of the Clinical Characteristics, Real-world Treatment Pathways, and Outcomes of Patients With Moderate Rheumatoid Arthritis||Pfizer|No|Completed|October 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1754|||Both|18 Years|N/A|No|Non-Probability Sample|The BSR Biologics Register tracks the progress of patients with severe rheumatoid        arthritis and other rheumatic conditions who are taking biologic therapy and those who are        biologic naive.|August 2013|August 26, 2013|February 8, 2012||No||No|August 26, 2013|https://clinicaltrials.gov/show/NCT01557322||89114|Since this study was a retrospective registry analysis of de-identified participants’ data, only SAEs pre specified in analysis were reported with preferred terms and all other SAEs were reported under the preferred term Other Serious Event.
NCT01558063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6460|Ketamine in the Treatment of Depression|The Antidepressant Action of Ketamine: Brain Chemistry||Columbia University|Yes|Active, not recruiting|February 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Anticipated|76|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 4, 2015|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558063||89058|
NCT01558648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003|Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer|Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|265|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the Thoracic Surgery clinics.|October 2015|October 14, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558648||89013|
NCT01558661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004|Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558661||89012|
NCT01532232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-136|Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)|Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)||Memorial Sloan Kettering Cancer Center||Terminated|February 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|7|Samples Without DNA|saliva samples|Both|18 Years|N/A|No|Probability Sample|MSK breast clinic|December 2015|December 22, 2015|February 9, 2012|No|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01532232||91029|
NCT01532804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEVATOMOX|2nd-line Treatment of Metastatic Colorectal Cancer|A Multicenter Randomized Phase 2 Trial to Evaluate the Triplet Combination of Raltitrexed, Oxaliplatin and Bevacizumab Versus FOLFOX6 Plus Bevacizumab in Second-line Treatment of Metastatic Colorectal Cancer|BEVATOMOX|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Recruiting|July 2011|December 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532804||90986|
NCT01532856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBRAM0002|Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years|Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maintenance Therapy With Thalidomide + Prednisone Versus Thalidomide Alone in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65years.||Grupo de Estudos Multicentricos em Onco-Hematologia|Yes|Active, not recruiting|January 2007|June 2012|Anticipated|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|N/A|No|||February 2012|February 14, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532856||90982|
NCT01533168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B1|Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia|Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region to Identify Previously Undetectable Minimal Residual Disease in Children With Acute Lymphoblastic Leukemia With Prognostic Significance||Children's Oncology Group|No|Active, not recruiting|February 2012|||March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|12|Samples With DNA|cell samples|Both|1 Year|30 Years|No|Non-Probability Sample|Patients With Acute Lymphoblastic Leukemia|May 2015|May 4, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01533168||90958|
NCT01533181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00245|Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer|Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)||National Cancer Institute (NCI)|No|Completed|February 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||August 2015|December 10, 2015|February 11, 2012|Yes|Yes||No|December 10, 2015|https://clinicaltrials.gov/show/NCT01533181||90957|
NCT01533727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010014|CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)|A Phase 2,Open-label Study of Autologous Cytokine-Induced Killer Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer||Sun Yat-sen University|Yes|Withdrawn|August 2011|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||February 2012|December 5, 2013|February 12, 2012||No|Few patients would like to participate ,since CIK cell transfusion was a new treatment and its    efficacy was doubted.|No||https://clinicaltrials.gov/show/NCT01533727||90915|
NCT01559103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4430C00001|Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients|A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (Anti-IL-6)||AstraZeneca||Terminated|May 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|39|||Both|20 Years|75 Years|No|||February 2015|February 19, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559103||88978|
NCT01559116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1237.20|Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease|Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg, 5/5 µg), Tiotropium (2.5 µg, 5 µg) and Olodaterol (5 µg) (Oral Inhalation, Delivered by the Respimat® Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM]||Boehringer Ingelheim||Completed|March 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|6||Actual|219|||Both|40 Years|N/A|No|||June 2015|June 19, 2015|March 19, 2012||||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01559116||88977|
NCT01559363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD019-101|A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease||Kadmon Corporation, LLC|No|Active, not recruiting|September 2012|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|75|||Both|18 Years|55 Years|No|||January 2016|January 15, 2016|March 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01559363||88958|
NCT01559662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMCGumStudy|Effect of Sugared Chewing Gum on Gastrointestinal Recovery After Major Colorectal Surgery|A Prospective Randomized Controlled Trial of Sugared Chewing Gum on Gastrointestinal Recovery After Major Colorectal Surgery in Patients Managed With Early Enteral Feeding||Cedars-Sinai Medical Center|No|Completed|August 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|18 Years|85 Years|No|||August 2012|August 14, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01559662||88935|
NCT01559870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE541122|Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac Surgery|Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac Surgery With Cardiopulmonary Bypass||Khon Kaen University|No|Completed|August 2011|August 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|164|Samples Without DNA|whole blood taken from arterial line|Both|18 Years|80 Years|No|Non-Probability Sample|adult patients who had undergone elective cardiac surgery with CPB|March 2012|November 10, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01559870||88919|
NCT01559883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE-Thrombose-NIS-2012|Study on Thrombosis Therapy in German Cancer Patients|Study on Thrombosis Therapy in German Cancer Patients||LEO Pharma|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|76|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patient with acute deep vein throbosis/ pulmonary embolism in ambulatory oncology        care/practice|November 2013|August 14, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01559883||88918|
NCT01560117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_NHL 9|Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma|Multicenter Study to Evaluate the Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy Und Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Completed|January 2004|July 2010|Actual|July 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Actual|29|||Both|18 Years|N/A|No|||March 2012|March 20, 2012|March 16, 2012||||No||https://clinicaltrials.gov/show/NCT01560117||88900|
NCT01560442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0117|Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine|Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine.|PUPIDOL|University Hospital, Clermont-Ferrand||Recruiting|February 2012|October 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|18 Years|65 Years|No|Non-Probability Sample|Opiate dependent patients|January 2013|January 11, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560442||88875|
NCT01560182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudract 2009-017349-77|Gene Therapy for Metachromatic Leukodystrophy|A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Treatment of Metachromatic Leukodystrophy|TIGET-MLD|IRCCS San Raffaele|No|Active, not recruiting|April 2010|April 2023|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|N/A|No|||April 2015|April 20, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01560182||88895|
NCT01560468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSM 12-00045|Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection|Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection||Schiano, Thomas D., MD|Yes|Active, not recruiting|March 2012|October 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|18 Years|72 Years|No|||November 2014|November 17, 2014|February 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01560468||88873|
NCT01561014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 60106|Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase I Study of Preoperative Chemoradiation With Oxaliplatin, 5-Fluorouracil, Erlotinib and Radiation Followed by Resection and Consolidative Erlotinib for Patients With Locally Advanced Cancer of the Esophagus and Gastroesophageal Junction||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|April 2007|||August 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561014||88831|
NCT01561261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00004105|Predicting Acute Compartment Syndrome (PACS)|Predicting Acute Compartment Syndrome (PACS) Using Optimized Clinical Assessment, Continuous Pressure Monitoring, and Continuous Tissue Oximetry|PACS|Major Extremity Trauma Research Consortium|Yes|Recruiting|October 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|60 Years|No|||April 2015|April 16, 2015|March 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561261||88812|
NCT01557868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOSSM 51H|Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis|Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis||American Orthopaedic Society for Sports Medicine|No|Completed|October 2008|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)|2||Actual|198|||Both|18 Years|65 Years|No|||February 2014|February 19, 2014|March 12, 2012|Yes|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01557868||89073|
NCT01557608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA151692|Characterization and Treatment of Chemotherapy Neuropathy|Characterization of and Treatment for Chemotherapy-Induced Neuropathy|CIN|University of California, San Francisco|Yes|Recruiting|April 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|142|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557608||89093|
NCT01558089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801138|Good EULAR Response in Patients With Early Rheumatoid Arthritis|Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece|EARLY RA|Pfizer|No|Completed|March 2013|May 2015|Actual|May 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|||Both|18 Years|N/A|No|Non-Probability Sample|patients with rheumatoid arthritis who fulfill the inclusion/exclusion criteria|June 2015|June 18, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01558089||89056|
NCT01557855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX_000013|Investigation of a Novel Gene Expression Test for Diagnosis of Obstructive Coronary Artery Disease|Coronary Obstruction Detection by Molecular Personalized Gene Expression||CardioDx|No|Completed|April 2012|May 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|342|||Both|21 Years|N/A|No|Probability Sample|Subjects will be enrolled at multiple qualified participating study centers that have        incorporated CORUS CAD for the diagnosis of obstructive CAD into their routine practice.|November 2014|November 25, 2014|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557855||89074|
NCT01558921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36315.042.11|Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial|Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.|RAPIDO|University Medical Center Groningen|Yes|Recruiting|June 2011|June 2019|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|920|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558921||88992|
NCT01532817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC-US-06|Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device|Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore™ Device, for the Relief of Acute Bronchoconstriction Due to Asthma||ElectroCore LLC||Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|65 Years|No|||May 2012|May 25, 2012|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532817||90985|
NCT01532830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-US-01|Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine|Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine||ElectroCore LLC||Completed|February 2012|||July 2012|Actual|N/A|Interventional|Primary Purpose: Treatment|||Actual|30|||Both|18 Years|55 Years|No|||August 2014|August 4, 2014|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532830||90984|
NCT01533194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00248|Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1 Study of Reolysin Alone in Patients With Relapsed or Refractory Multiple Myeloma||National Cancer Institute (NCI)||Completed|April 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2014|April 14, 2015|February 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01533194||90956|
NCT01533493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000301|Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study|Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study||Massachusetts General Hospital|No|Completed|May 2012|August 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|50 Years|No|||March 2014|March 10, 2014|February 8, 2012|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01533493||90933|
NCT01559376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDO2012|Long Term Follow-up of Open Versus Endoscopic Radial Artery Harvest With CT Angiography|Long Term Follow-up of Open Versus Endoscopic Radial Artery Harvest With CT Angiography||Lawson Health Research Institute|No|Enrolling by invitation|February 2012|February 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|118|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The patient population consists of patients that have previously participated in our RCT        from 2005-2007 with an open or endoscopically harvested radial artery graft used as a        bypass conduit. We are following them for 5-year follow up.|March 2012|March 19, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01559376||88957|
NCT01559896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36690.068.11|Egg Protein Hydrolysate and Vascular Function|The Effect of Egg Protein Hydrolysate on Arterial Stiffness in Overweight or Moderately Obese Subjects With Impaired Glucose Tolerance or Diabetes Type 2||Maastricht University Medical Center|No|Completed|September 2011|November 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Actual|40|||Both|18 Years|70 Years|No|||August 2014|August 4, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559896||88917|
NCT01560130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211699-7|State-wide Health Approach to Increase Reach and Effectiveness: Study 2|Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies|SHARE|The Miriam Hospital|No|Completed|January 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|300|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2013|April 23, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560130||88899|
NCT01560780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-007-11F|Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis|Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis||VA Office of Research and Development|Yes|Recruiting|February 2013|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01560780||88849|
NCT01561040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-2011|Oral Nutrition Impact on Tear Film|Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy|ONIT|Eye and Vision Technologies and Research Institute|No|Recruiting|March 2012|December 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|October 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01561040||88829|
NCT01560767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAKA/PROTOCOL/V002|Perioperative Analgesia for Knee Arthroplasty (PAKA)|Can Periarticular Knee Injection of Multimodal Agents Levobupivicaine, Morphine, Ketorolac and Adrenaline Improve Postoperative Pain and Function Following Primary Total Knee Arthroplasty?|PAKA|University of Warwick|No|Completed|October 2010|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|46|||Both|N/A|N/A|No|||March 2012|March 20, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01560767||88850|
NCT01561027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNV1014802/201|Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy|A Randomized, Double Blind, Cross-over Study to Evaluate the Safety and Efficacy of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy||Convergence Pharmaceuticals|No|Completed|April 2011|August 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|65 Years|No|||August 2012|August 2, 2012|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561027||88830|
NCT01561274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-134-SDR|ET 50 for Post Caesarean Section Spinal Hypotension|The Time Required to Remain Sitting After Spinal Anesthesia for 50% of Patients to Not Experience Hypotension|ET-50|McGill University Health Center|Yes|Completed|March 2012|May 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|45 Years|No|||June 2014|June 20, 2014|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561274||88811|
NCT01557881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE15Z11|Positron Emission Tomography/Magnetic Resonance Imaging in Patients|Evaluating Attenuation Correction Methods Applied to PET/MRI||Case Comprehensive Cancer Center|Yes|Terminated|February 2012|||April 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|98|||Both|N/A|N/A|No|||August 2015|August 12, 2015|March 16, 2012|Yes|Yes|Funding unavailable|No||https://clinicaltrials.gov/show/NCT01557881||89072|
NCT01558102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PED001|International Retrospective Study of Pipeline Embolization Device|International Retrospective Study of Pipeline Embolization Device|IntrePED|ev3|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|793|||Both|N/A|N/A|No|Non-Probability Sample|Patients with brain aneurysms who were treated with the Pipeline Embolization Device|November 2013|November 20, 2013|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01558102||89055|
NCT01558349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/LM-05|Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques|Circulating Tumor Cells and Melanoma: Comparing the EPISPOT (EPithelial ImmunoSPOT) and CellSearch Techniques||Centre Hospitalier Universitaire de Nīmes|No|Recruiting|June 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|82|||Both|18 Years|N/A|No|Non-Probability Sample|The two cohorts in this study are composed of (1) patients suffering from metastatic        melanome and (2) hospitalized patients with no history of cancer.|March 2016|March 4, 2016|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01558349||89036|
NCT01558934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1005-1|Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients|A Pilot, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects||US WorldMeds LLC|No|Completed|February 2012|April 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|60 Years|No|||April 2012|April 16, 2012|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558934||88991|
NCT01558947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC-AGC-01|Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer|Peri-operative Chemotherapy With ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the Treatment of Advanced Gastric Cancer: a Randomized, Multicenter, Parallel Control||Zhejiang Cancer Hospital|Yes|Recruiting|January 2011|June 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|2|||Both|18 Years|70 Years|No|||March 2012|March 18, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01558947||88990|
NCT01532505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18511|Effect of Vasopressin on Tissue Oxygen Saturation in Cardiac Surgery Patients During Cardiopulmonary Bypass|A Randomized Study Comparing Low Dose Vasopressin Infusion or Placebo on Near Infrared Spectroscopy Tissue Oxygen Saturation and the Vascular Occlusion Test in Cardiac Surgery Patients During Cardiopulmonary Bypass: A Pilot Study||London Health Sciences Centre|Yes|Not yet recruiting|February 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Stable patients coming from home for elective cardiac surgery are eligible to participate|February 2012|February 13, 2012|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01532505||91008|
NCT01532843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV 11-02|Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B|Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B (PEGON-study)|PEGON|Foundation for Liver Research|No|Completed|June 2012|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|18 Years|70 Years|No|||January 2016|January 22, 2016|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532843||90983|
NCT01533207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0277|Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery|A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma||Gynecologic Oncology Group|Yes|Recruiting|June 2012|||February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|216|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|February 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01533207||90955|
NCT01533519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-1487|A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)|A Dose Escalation Study of Intranasal Neuropeptide Y in PTSD||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|December 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|24|||Both|18 Years|60 Years|No|||September 2015|September 21, 2015|January 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01533519||90931|
NCT01533532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLH1202|A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)|A Multicenter, Randomized, Placebo-controlled, Double-blind Phase II Study of KLH-2109 in Patients With Endometriosis(2)||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4|||100|||Female|20 Years|N/A|No|||May 2014|May 29, 2014|February 12, 2012||||No||https://clinicaltrials.gov/show/NCT01533532||90930|
NCT01533545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-154|Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients|Effect of Epinephrine on Systemic Absorption of Mepivacaine Administered for Brachial Plexus Block in Patients With Chronic Renal Insufficiency||Rigshospitalet, Denmark|Yes|Terminated|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||April 2014|April 15, 2014|February 8, 2012||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01533545||90929|
NCT01533454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0742_001|A Randomized Incentive-Based Weight Loss Trial in Singapore|A Randomized Incentive-Based Weight Loss Trial in Singapore||Duke-NUS Graduate Medical School|No|Completed|September 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research|2||Actual|161|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 3, 2016|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01533454||90936|
NCT01533467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH-HBG-12|A Device Designed to Protect the Perineum During Labor|Study of Perineal Protection Device||Helsingborgs Hospital|No|Completed|November 2010|November 2011|Actual|November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1200|||Female|18 Years|45 Years|No|||February 2012|February 12, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01533467||90935|
NCT01533480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADV-GAN-10-2011|A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis|A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis||Lifelong Vision Foundation|No|Recruiting|January 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|14 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01533480||90934|
NCT01533740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONCOPTV-01-2012|Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients|Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy||University of Rome Tor Vergata|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|Samples With DNA|whole blood sample|Both|N/A|N/A|No|Non-Probability Sample|Hospital setting, single-center study, metastatic colorectal cancer patients treated with        standard first line chemotherapy|February 2014|February 1, 2014|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533740||90914|
NCT01559675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSMCSteroidStudy|Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery|Randomized Controlled Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery||Cedars-Sinai Medical Center|Yes|Completed|September 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|121|||Both|18 Years|75 Years|No|||August 2014|August 18, 2014|March 16, 2012||No||No|August 18, 2014|https://clinicaltrials.gov/show/NCT01559675||88934|
NCT01559688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TATRC-01|Accelerated Resolution Therapy (ART) for Psychological Trauma|||University of South Florida|No|Completed|July 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||October 2013|October 29, 2013|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01559688||88933|
NCT01559909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197622|Effect of Socket Wall Height With Vacuum Suspension for Above Knee Amputees|Effect of Brim Height Using Vacuum Assisted Technology With Transfemoral Amputees||Stony Brook University|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|21 Years|75 Years|No|||May 2014|May 8, 2014|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01559909||88916|
NCT01559922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUN-11-001|Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction|A Phase 3 Randomized Placebo-Controlled Double-Blind Study of the Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction||Suneva Medical, Inc.|No|Active, not recruiting|February 2012|||April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|177|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559922||88915|
NCT01560143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007|Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects|Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects||Albany College of Pharmacy and Health Sciences|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|July 19, 2012|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560143||88898|
NCT01560156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-035|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2012|||||N/A|N/A|N/A||||||||||||||January 10, 2014|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560156||88897|
NCT01560455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBC TWO|European Bifurcation Club Trial - Two-stent Versus One-stent Technique for Large Bifurcation Lesions|The European Bifurcation Coronary Study; A Randomised Comparison Of Provisional T-Stenting Versus A Systematic Two Stent Strategy In Large Calibre True Bifurcations|EBC TWO|Royal Sussex County Hospital|Yes|Completed|May 2011|||September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|September 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01560455||88874|
NCT01560793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX161-01B|Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years|Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years||VaxInnate Corporation|Yes|Completed|June 2012|November 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|1||Actual|224|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||September 2014|September 22, 2014|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560793||88848|
NCT01561053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1002|A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease|A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD|AMBAR|Grifols Biologicals Inc.|No|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|350|||Both|55 Years|85 Years|No|||June 2015|June 15, 2015|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561053||88828|
NCT01561300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDS-BEV-0284|Efficacy of Brooke Bond Black Tea Extract on Flow Mediated Dilation in Indian Males|Efficacy of Standardized Brooke Bond Black Tea Extract on Flow-Mediated Dilation After an Acute Dose as Well as After One Week of Consumption in Healthy Adult Indian Males||Unilever R&D|No|Completed|March 2012|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|30|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||May 2012|August 12, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561300||88809|
NCT01561287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0595-F2L|A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction|A Comparison of Dermal Autograft to Commercially Available Dermal Allograft in Breast Reconstruction||University of Kentucky|No|Active, not recruiting|July 2011|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|50|||Female|N/A|N/A|No|||December 2014|December 2, 2014|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561287||88810|
NCT01557335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA32540-111|A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540|A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers||POZEN|No|Completed|November 2010|February 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 15, 2012|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557335||89113|
NCT01557348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA22401|An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor|A Global Multi-centre Observational Study in RA Patients Who Are Non Responders or Intolerant to a Single TNF Inhibitor.||Hoffmann-La Roche||Completed|April 2009|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1219|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients who are non-responders or intolerant to a single        TNF-inhibitor|March 2013|March 4, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01557348||89112|
NCT01558362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120080-01H|A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers|A Phase 1 Study of Safety, Tolerance, Pharmacokinetics and Nuclear Medicine Imaging of 123I-CMICE-013 Administered Intravenously in Healthy Adult Volunteers|CMICE|Ottawa Heart Institute Research Corporation|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01558362||89035|
NCT01558674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7145-011|A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)|A Two Part, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7145 in Patients With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II)||Merck Sharp & Dohme Corp.|Yes|Terminated|May 2014|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|12|||Both|18 Years|75 Years|No|||April 2015|April 9, 2015|March 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01558674||89011|
NCT01558960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-001-HMO-CTIL|Intravitreal Injections of Melphalan for Retinoblastoma|Intravitreal Injections of Melphalan for Retinoblastoma||Hadassah Medical Organization|No|Terminated|March 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|20 Years|No|||March 2012|August 19, 2015|March 1, 2012||No|Sufficient findings to draw conclusions|No||https://clinicaltrials.gov/show/NCT01558960||88989|
NCT01558973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0405026787|FMRI of Stress and Addictive Disorders|Functional Magnetic Resonance Imaging of Stress and Addictive Disorders||Yale University|Yes|Active, not recruiting|August 2005|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|370|||Both|13 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Cocaine dependent individuals, opioid dependent individuals, alcohol dependent        individuals, healthy controls, adolescent subjects, pathological gamblers|July 2015|July 28, 2015|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01558973||88988|
NCT01532869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA27788|A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis|A PHASE II/III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS||Hoffmann-La Roche||Completed|March 2012|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|February 10, 2012|Yes|Yes||No|October 8, 2015|https://clinicaltrials.gov/show/NCT01532869||90981|
NCT01533220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMPEMS1011|Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal|A Randomized, Double-blind, Prospective, Monocentric, Superior Efficacy and Safety of Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal Due to Colds or Other Upper Respiratory Allergies||EMS|Yes|Active, not recruiting|June 2013|December 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|212|||Both|12 Years|N/A|No|||September 2013|September 24, 2013|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01533220||90954|
NCT01533506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000690|Stiripentol in Dravet Syndrome|Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome||Mayo Clinic|No|No longer available|February 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 4|Expanded Access|N/A|||||||Female|11 Years|N/A|No|||February 2013|February 26, 2013|February 9, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01533506||90932|
NCT01533753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO11813|Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer|Randomized, Open-Label Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer||University of Wisconsin, Madison||Terminated|February 2012|May 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Male|18 Years|N/A|No|||September 2014|September 10, 2014|February 10, 2012|Yes|Yes|Slow accrual|No|August 25, 2014|https://clinicaltrials.gov/show/NCT01533753||90913|The study was terminated due to slow accrual. The data was uninterpretable due to the small numbers of subjects analyzed.
NCT01559142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP CZD 2008-01-14|Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease|Efficacy and Safety of Induction Therapy With Three Doses of Infliximab in Patients With Crohn Disease Aged 7-17 Years-multicenter Open Study. Efficacy and Safety of Two Regimens of Maintenance Therapy in Patients With Crohn Disease Aged 7-17 Years-multicenter Randomized Study||Children's Memorial Health Institute, Poland|No|Active, not recruiting|November 2008|December 2012|Anticipated|April 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|7 Years|17 Years|No|||April 2012|April 2, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559142||88975|
NCT01559402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2011 / 462|Oxygenation Test During General Anesthesia|Application of Protective Ventilation Improves Oxygenation During and After Anesthesia. Is it Possible That a Special Procedure, an Oxygenation Test, Can Replace Arterial Blood Gases When Evaluating Oxygenation?||Landstinget Västmanland|Yes|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|50 Years|No|||August 2014|August 31, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01559402||88955|
NCT01559701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTI-821-CM|Long-term Safety of PF-00345439 (Oxycodone)|A Long-Term, Open-Label, Safety Study Of PTI-821 In Patients With Moderate To Severe Chronic Low Back Pain Or With Moderate To Severe Chronic Pain Due To Osteoarthritis Of The Hip Or Knee||Pain Therapeutics|No|Completed|April 2006|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|823|||Both|18 Years|75 Years|No|||August 2015|August 28, 2015|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559701||88932|
NCT01559935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108011903|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma|A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma||Weill Medical College of Cornell University|Yes|Recruiting|March 2012|March 2015|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Both|18 Years|N/A|No|||June 2013|June 17, 2013|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559935||88914|
NCT01560169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALV003-1121|Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients|Clinical Evaluation of Three Celiac Disease-Specific Patient Reported Outcome Instruments in Established and Newly Diagnosed Celiac Disease Patients||Alvine Pharmaceuticals Inc.|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|110|||Both|18 Years|70 Years|No|Non-Probability Sample|Biopsy proven celiac disease patients|October 2013|October 9, 2013|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560169||88896|
NCT01561066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRA2011232-1|Autologous Fibrin Glues for Fistulas Closure|Adjuvant Use of Autologous Platelet-rich Fibrin Glue in the Treatment of Fistulas and Anastomotic Leakages of the Digestive Tract||Jinling Hospital, China|Yes|Completed|January 2008|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|75 Years|No|||February 2013|February 23, 2013|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561066||88827|
NCT01561313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-783|Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.|A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis.||AbbVie|No|Completed|March 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|March 21, 2012||No||No|November 8, 2013|https://clinicaltrials.gov/show/NCT01561313||88808|
NCT01557361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR MOP 111116|Standard Versus Accelerated Initiation of Dialysis in Acute Kidney Injury|STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI)|STARRT-AKI|St. Michael's Hospital, Toronto|Yes|Completed|May 2012|October 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||August 2013|September 11, 2014|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01557361||89111|
NCT01557621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1480|Comparative Effectiveness Trial of Two Reminder/Recall Methods to Increase Immunization Rates in Young Children|Center for Research in Implementation Science and Prevention (CRISP): Project 1: Comparative Effectiveness Trial of Two Reminder/Recall Methods to Increase Immunization Rates in Young Children||University of Colorado, Denver|No|Completed|September 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|68000|||Both|19 Months|5 Years|No|||December 2015|December 15, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557621||89092|
NCT01558115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2568|Denosumab in Primary Hyperparathyroidism|Denosumab in Primary Hyperparathyroidism||Columbia University|Yes|Completed|January 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Female|40 Years|N/A|No|||April 2015|April 7, 2015|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558115||89054|
NCT01558375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIDRA03|Anakinra in Hidradenitis Suppurativa|A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa||University of Athens|Yes|Completed|March 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01558375||89034|
NCT01558687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR062041-017|Cilengitide Imaging Trial in Glioblastoma|A Multi-center, Open-label, Randomized, Controlled Phase I Trial to Investigate the Effects of Cilengitide (EMD 121974) Using Dynamic MR and FET-PET Imaging as a Pharmacodynamic Measure of Response in Subjects With Newly Diagnosed Glioblastoma||Merck KGaA|No|Terminated|August 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|1|||Both|18 Years|70 Years|No|||February 2014|February 3, 2014|March 16, 2012|Yes|Yes|Discontinuation of development program|No||https://clinicaltrials.gov/show/NCT01558687||89010|
NCT01558700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00039556|Duloxetine in Osteoarthritis (OA) Pain|Brain Morphometries in OA Patients Treated With Duloxetine||Northwestern University|No|Completed|March 2012|August 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|March 16, 2012|Yes|Yes||No|December 5, 2014|https://clinicaltrials.gov/show/NCT01558700||89009|
NCT01558986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 2007-07-10-02|Routine Preoperative Antibiotic Prophylaxis in Modified Radical Mastectomy|A Randomized, Double Blinded Placebo-Controlled Trial on the Routine Use of Preoperative Antibiotic Prophylaxis in Modified Radical Mastectomy||University of the Philippines|Yes|Completed|December 2007|September 2011|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|254|||Female|18 Years|80 Years|No|||March 2012|March 19, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01558986||88987|
NCT01558999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|614/1121|A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye|||Seikagaku Corporation||Completed|March 2012|||July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|March 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01558999||88986|
NCT01532882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIO401-10|Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs|Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups|EDEN|Laboratoire Innotech International|No|Completed|January 2012|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|378|||Both|18 Years|N/A|No|||April 2013|April 26, 2013|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532882||90980|
NCT01533779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0592-11-TLV|Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy and Their Role in Antitumor Activity|Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy for Pediatric Hematological and Solid Tumors, and Its Relation to Other Neutrophil Functions and the Role of NETs in Antitumor Activity||Tel-Aviv Sourasky Medical Center|No|Recruiting|February 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|21 Years|Accepts Healthy Volunteers|Probability Sample|All pediatric patients from birth to 21 years, male and female, undergoing chemotherapy        treatment for solid and hematological malignancies.|February 2012|February 14, 2012|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01533779||90911|
NCT01534078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-462|Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma|Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma||Massachusetts General Hospital|Yes|Active, not recruiting|March 2012|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|February 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534078||90888|
NCT01534091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MeirMc02711CTIL|Enhancing the Amount of Physical Activity Carried Out by Overweight Children at Leisure Time|Enhancing the Amount of Physical Activity Carried Out by Overweight Children at Leisure Time||Meir Medical Center|No|Terminated|May 2012|December 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|5 Years|18 Years|No|||October 2013|April 13, 2015|January 18, 2012||No|Lack of cooperation by the participants|No||https://clinicaltrials.gov/show/NCT01534091||90887|
NCT01533766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-CFO-302|A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition|A Randomized, Open, Multicenter, Compared Phase III Trial to Evaluate the Safety, Efficacy of CombiflexOmega and SmofKabiven in Postoperative Patients Requiring Parenteral Nutrition|OMEGA|JW Pharmaceutical||Completed|August 2011|February 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|N/A|No|||February 2013|February 15, 2013|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01533766||90912|
NCT01559714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37776.091.11|A Biomarker and MRI Study on Troponin Release After Exercise in Hypertrophic Cardiomyopathy|BE STRONG HCM: Biomarkers, Exercise Stress Testing, and mRi to Obtain New insiGhts in Hypertrophic CardioMyopathy Study|BE STRONG HCM|Heartcenter, University Medical Center St. Radboud|No|Recruiting|April 2012|||December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|The study population will consist of clinical or pre-clinical HCM patients that are        registered in the HCM database of the HCM outpatient clinic of University Medical Center        St. Radboud. This database will be screened for eligible patients according to the in- and        exclusion criteria described below.|March 2015|March 17, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559714||88931|
NCT01559948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16931|Effectiveness of the Compression Belt for Patients With Sacroiliac Joint Pain|A Randomized Clinical Trial of the Effectiveness of the Compression Belt for Patients With Sacroiliac Joint Pain||Texas Woman's University|No|Completed|January 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||February 2014|February 10, 2014|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01559948||88913|
NCT01560195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHPG-19K -III-02|A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy|A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) on the Incidence of Neutropenia in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Myelosuppressive Chemotherapy||Jiangsu HengRui Medicine Co., Ltd.|No|Recruiting|April 2012|||January 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|70 Years|No|||November 2012|November 4, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01560195||88894|
NCT01560481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTC00940472|Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers|Open Crossover Randomized Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic-pharmacodynamic Profile of Metformin Glycinate 620 mg,1240 mg, 2480 mg and Metformin Chlorhydrate 1000 mg After Administration of One Single Dose, Multiple Dose and After Food Intake in Healthy Volunteers|NTC00940472|Laboratorios Silanes S.A. de C.V.|No|Completed|December 2011|March 2013|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|7||Actual|49|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2014|February 12, 2014|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01560481||88872|
NCT01557387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091017|Real-time Diagnosis of Pseudopolyps During Colonoscopy|Real-time Diagnosis of Pseudopolyps During Colonoscopy Using Noninvasive Advanced Endoscopic Techniques - a Prospective Study||University of Miami|No|Completed|September 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|||Both|18 Years|75 Years|No|Non-Probability Sample|Approximately 100 patients with inflammatory bowel disease (IBD) will be enrolled in the        study. They will be identified from a population of patients undergoing colonoscopy for        diagnostic purposes with IBD.|December 2014|December 27, 2014|August 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01557387||89109|
NCT01557660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIN-PH-303|Inhaled Treprostinil for PAH: Open-label Extension|Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study|INTREPID - OL|United Therapeutics|Yes|Withdrawn|June 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2012|March 23, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557660||89089|
NCT01557673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H062011|Effects of Bolus and Continuous Nasogastric Feeding on Small Bowel Water Content and Blood Flow|Effects of Bolus and Continuous Nasogastric Feeding on Small Bowel Water Content and Blood Flow||University of Nottingham|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01557673||89088|
NCT01557374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 11061|TOward the Lowest Effective DOse of Abatacept or Tocilizumab|Tapering Abatacept or Tocilizumab in Rheumatoid Arthritis in Remission. An Evaluation of Disease Activity, Relapse Risk, Structural Progression and the Economic Impact of a Tapering Strategy|TOLEDO|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2012|April 2018|Anticipated|April 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|232|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557374||89110|
NCT01557634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APCam10|Closing the Loop in Young Children With Type 1 Diabetes|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of Overnight Closed-loop Insulin Delivery Using Diluted Insulin in Comparison With Closed-loop With Non-diluted Insulin in Children With Type 1 Diabetes Aged 2 to 6 Years||University of Cambridge|No|Recruiting|December 2012|||December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|2 Years|6 Years|No|||March 2012|April 1, 2013|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01557634||89091|
NCT01557647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIN-PH-302|Safety and Efficacy of Inhaled Treprostinil in Patients With PAH|Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil.|INTREPID|United Therapeutics|Yes|Withdrawn|June 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||March 2012|March 23, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557647||89090|
NCT01558128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105011705|Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery|Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery||Weill Medical College of Cornell University|No|Recruiting|March 2012|||March 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01558128||89053|
NCT01558388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spedali Civili 926|Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy|Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy||Università degli Studi di Brescia|No|Recruiting|September 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|45 Years|No|||March 2012|March 16, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01558388||89033|
NCT01558401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ethics Committe UFSCar Nº104/4|Efficiency of Physical Activity on the Physical Condition of Elderly Women|Effects of an Adapted Physical Activity Program on the Physical Condition of Elderly Women: an Analysis of Efficiency||Universidade Federal de Sao Carlos|Yes|Completed|April 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|120|||Female|60 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 19, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01558401||89032|
NCT01558713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1312010-25|Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections|Assessment of Sensory and Motor Block After Intrathecal Administration of Bupivacaine, Ropivacaine and Levo-bupivacaine Combined With Small Doses of Fentanyl, Followed by Administration of Normal Saline Epidurally:a Clinical Trial in Parturients Scheduled for C-section||University of Patras|No|Recruiting|January 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|6||Anticipated|120|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01558713||89008|
NCT01559259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5061001|Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain|Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain||Pfizer|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|394|||Both|16 Years|40 Years|No|||July 2014|July 25, 2014|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01559259||88966|
NCT01559272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012652|A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia||Janssen Research & Development, LLC|No|Completed|February 2008|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|328|||Both|18 Years|65 Years|No|||May 2015|May 8, 2015|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01559272||88965|
NCT01559285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNU05-2011-054|Effects of Epidurally Administered Ropivacaine Concentration on the Hemodynamic Parameters|Effects of Epidurally Administered Ropivacaine Concentration on the Hemodynamic Parameters|PNU|Pusan National University Hospital|No|Recruiting|November 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|120|||Both|18 Years|65 Years|No|||January 2013|January 24, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559285||88964|
NCT01532895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100741|Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid|Clinical Usefulness and Quality of Life of OROS Hydromorphone in Strong Opioid-Naïve Cancer Pain Patients; Multicenter, Prospective, Open-Label and Observational Study||Janssen Korea, Ltd., Korea|No|Completed|September 2011|October 2012|Actual|September 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|20 Years|N/A|No|Non-Probability Sample|Korean cancer patients having cancer pain who visit or are hospitalized at the research        centers during the study.|March 2014|March 15, 2014|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532895||90979|
NCT01533792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFMA-2011-DANI|Effect of Non-surgical Periodontal Treatment|Effect of Non-surgical Periodontal Treatment on Pregnant Women With Periodontitis: a Randomized Clinical Trial|EONSPT|Universidade Federal do Maranhão|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Female|15 Years|43 Years|No|||February 2012|February 15, 2012|January 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01533792||90910|
NCT01533805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0119031200011|Effects of Different Techniques of the Method Pilates in Chronic Low Back Pain|Effects of Different Techniques of the Method Pilates in Chronic Low Back Pain in Women 46 to 60 Years||Universidade Gama Filho|Yes|Not yet recruiting|February 2012|December 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Female|45 Years|60 Years|No|||February 2012|February 14, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01533805||90909|
NCT01534104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008|MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning|Using Functional MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning||Memorial Sloan Kettering Cancer Center||Recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01534104||90886|
NCT01534117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASA/Plavix/Platelets_SBCH|Platelet Function Analysis in Head Trauma: ASA/Plavix|Platelet Function Analysis in Head Trauma: ASA/CLOPIDOGREL|ASA/Plavix|Chang, Steve S., M.D.|Yes|Completed|October 2009|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|97|||Both|18 Years|N/A|No|||February 2012|February 15, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01534117||90885|
NCT01534429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000180|Quantitative Sensory Testing and Analysis of Post Inguinal Hernia Surgery Pain|Quantitative Sensory Testing and Neurophysiologic Analysis of Post-Herniorraphy Pain in Patients Undergoing Selective Neurectomy and Mesh Removal||University of California, Los Angeles|No|Recruiting|February 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic pain occuring after groin hernia repair who are surgical candidates        for mesh removal and triple neurectomy.|February 2012|February 13, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534429||90862|
NCT01559428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 09-3-088|Phytosterols and Oxyphytosterol Concentrations|The Effects of Plant Sterol and Stanol Esters on Serum Oxyphytosterol Concentrations in Healthy Human Subjects||Maastricht University Medical Center|No|Active, not recruiting|May 2010|||April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2012|March 19, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01559428||88953|
NCT01559727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-2011-29|Dose-comparison Study of Prednisone in Heart Failure|Randomized Dose-comparison Study of Prednisone in Patients With Symptomatic Heart Failure||Hebei Medical University|Yes|Completed|March 2012|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|75 Years|No|||August 2013|August 27, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559727||88930|
NCT01559961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTI-IC-0111-SAD|Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome|A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome||Trillium Therapeutics Inc.|Yes|Completed|March 2012|June 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|65 Years|No|||June 2013|June 24, 2013|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01559961||88912|
NCT01560208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACSIKS|The Asia Cornea Society Infectious Keratitis Study|The Asia Cornea Society Infectious Keratitis Study|ACSIKS|Asia Cornea Society|No|Recruiting|April 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|6750|Samples Without DNA|Positive bacterial and fungal growth obtained from the cornea samples of ACSIKS patients      will be retained and stored.|Both|N/A|N/A|No|Probability Sample|ACSIKS will recruit all patients with infectious keratitis from 11 Study Centres in eight        different countries (India, China, Japan, South Korea, Taiwan, Thailand, the Philippines        and Singapore), each evaluating all cases of infectious keratitis presenting over a 12        month period.        There will be a total of 11 Study Centres¸ with India, China and Japan each having 2        separate study centres. Some Study Centres will also be responsible for coordinating cases        accrued from affiliated hospitals ("Participating Institutions").|December 2012|December 18, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560208||88893|
NCT01560494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAC|Validation of a Curriculum (STAC) for Technical Skill Acquisition in Minimally Invasive Surgery|Validation of a Structured Training and Assessment Curriculum (STAC) for Technical Skill Acquisition in Minimally Invasive Surgery. A Randomized Controlled Study||St. Michael's Hospital, Toronto|No|Completed|July 2008|July 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 20, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01560494||88871|
NCT01561352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-2080|Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis|An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven®) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy||Novo Nordisk A/S|No|Completed|September 2001|November 2003|Actual|November 2003|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|65 Years|No|||October 2013|October 23, 2013|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561352||88806|
NCT01557400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTC124-GD-019-DMD|Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada|An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy||PTC Therapeutics|No|Enrolling by invitation|May 2012|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Male|N/A|N/A|No|||November 2013|November 12, 2013|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01557400||89108|
NCT01557894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTudor|Internet Treatment for Social Phobia in Romania|Internet Treatment for Social Phobia in Romania: A Randomized Controlled Trial|iSOFIE-Ro|Babes-Bolyai University|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|March 15, 2012||No||No|October 9, 2013|https://clinicaltrials.gov/show/NCT01557894||89071|1) An active control condition matched for clients’ expectations, time, and therapist involvement was not included, 2)Due to personnel constrains, post-intervention SCID interviews were not blinded regarding the study conditions etc.
NCT01557920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002472|The Effects of General Anesthetics on Upper Airway Collapsibility in Healthy Subjects|The Effects of Sevoflurane, Propofol, and Carbon Dioxide 'Reversal' on Upper Airway Collapsibility in Healthy, Adult Subjects||Massachusetts General Hospital|No|Recruiting|January 2013|March 2014|Anticipated|November 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557920||89069|
NCT01557933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000693|Effects of Electroconvulsive Therapy (ECT) in Bipolar Depression|A Study of the Acute and Chronic Effects of Electroconvulsive Therapy on Glutamatergic Neurotransmission in Bipolar Depression||Mclean Hospital|No|Withdrawn|April 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|55 Years|No|Non-Probability Sample|Twelve study participants between the ages of 18-55 with will be recruited from inpatient        units at McLean Hospital.|November 2012|November 28, 2012|March 9, 2012||No|Due to a lack of participants, this study has been closed.|No||https://clinicaltrials.gov/show/NCT01557933||89068|
NCT01558141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108011882|Follicular Flushing|Follicular Flushing on Cycle Outcomes in Poor Responders||Weill Medical College of Cornell University|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Female|18 Years|45 Years|No|||June 2015|June 10, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01558141||89052|
NCT01558414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Llatzer-FSIS|Single Incision Laparoscopic Surgery vs Flexible Single Incision Surgery for Cholecystectomy|Prospective Randomized Clinical Trial Comparing Single Incision Laparoscopic Surgery vs Flexible Single Incision Surgery on Cholecystectomy||Hospital Son Llatzer|No|Completed|April 2011|November 2012|Actual|October 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|65 Years|No|||March 2013|March 11, 2013|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01558414||89031|
NCT01558726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0176|Case Management for Crack Users Who Seek Treatment in CAPSad in Brazil|Effectiveness of Case Management for Crack Users Who Seek Treatment in CAPSad in Six Brazilian Capitals||Federal University of Rio Grande do Sul|No|Recruiting|October 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||March 2012|March 17, 2012|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01558726||89007|
NCT01558739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC424AGB02|Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)|A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)|MACS2030|Novartis|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||March 2015|March 1, 2015|March 16, 2012||No||No|January 26, 2015|https://clinicaltrials.gov/show/NCT01558739||89006|
NCT01551875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIN-XXX-2011/2|A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors|A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors in Asymptomatic Nationwide Indian Population (SCORE India)|Score-India|AstraZeneca|Yes|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1200|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Asymptomatic subjects with or without risk factors but not suffering from any established        cardiovascular event.|July 2013|July 8, 2013|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01551875||89530|
NCT01533558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKF UMCN 11.02|Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates|Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates|CASCADE|Radboud University|No|Completed|January 2012|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Plasma samples for determination of caspofungin|Both|18 Years|N/A|No|Probability Sample|intensive care patients with invasive fungal infection|August 2013|August 28, 2013|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01533558||90928|
NCT01534130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30801488|Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome|Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome||Chengdu University of Traditional Chinese Medicine|No|Recruiting|April 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 6, 2012|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01534130||90884|
NCT01543867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1930|Safety and Efficacy of Long-term Somatropin Treatment in Children|Non-interventional Study of the Safety and Efficacy of Long-term Somatropin Treatment in Children (GrowthWIN II / GrowthWIN II SGA)|GrowthWIN II|Novo Nordisk A/S|No|Completed|January 2001|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|5442|||Both|N/A|18 Years|No|Probability Sample|Children treated with somatropin|March 2015|March 27, 2015|February 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01543867||90142|
NCT01534468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URMC 11-001|Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults|Evaluation of Priming by Pandemic Live Attenuated Influenza Vaccine (LAIV) on the Subsequent Response to Inactivated H7N7 Vaccine in Healthy Adults: A Non-Randomized, Open Label Study||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|February 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01534468||90859|
NCT01534442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Atropin clamp|Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response|The Significances of Atropin Administration for the GLP-1 Potentiation of Glucose Induced Insulin Secretion and the Cephalic Insulin Response||University Hospital, Gentofte, Copenhagen|No|Recruiting|September 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|10|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 6, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01534442||90861|
NCT01534455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 64|Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)|A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab Pre-treated Patients With HER2-positive Metastatic Breast Cancer (E-VITA)||German Breast Group|Yes|Terminated|February 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|February 8, 2012||No|very slow patient recruitment and concerns about the actuality of the study design|No||https://clinicaltrials.gov/show/NCT01534455||90860|
NCT01559974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P Vit D 23032011 v2|Vitamin D and Walking Ability in Patients With Peripheral Artery Occlusive Disease|Phase 4 Study of 25-hydroxy-vitamin D in Patients With Peripheral Artery Occlusive Disease and Walking Ability||University Hospital, Basel, Switzerland|Yes|Terminated|November 2011|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|4|||Both|N/A|N/A|No|||March 2013|March 8, 2013|December 1, 2011||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01559974||88911|
NCT01560221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA033141|Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution|Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution||Johns Hopkins University|Yes|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|65 Years|No|||December 2014|December 10, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01560221||88892|
NCT01560234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0542C00001|AZD8848 Single Ascending Dose Study|A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects||AstraZeneca||Completed|April 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|55|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560234||88891|
NCT01560507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032605|Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants|Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants|LiveForLife2|Duke University|Yes|Terminated|May 2012|July 2013|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|65 Years|No|||November 2014|December 5, 2014|March 20, 2012|Yes|Yes|Low Recruitment|No|September 9, 2013|https://clinicaltrials.gov/show/NCT01560507||88870|Early termination of the study because of recruitment difficulties lead to insufficient data collection and analysis of primary and secondary outcome measures.
NCT01560520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30704|Physical Activity Immediately After Acute Cerebral Ischemia|Physical Activity Immediately After Acute Cerebral Ischemia: Too Little or Too Much?||Hillerod Hospital, Denmark|No|Completed|November 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|Interleukin (IL)-6, IL-1beta, Tumor Nekrosis Factor(TNF)-alpha, C-Reactive Proteine (CRP),      IL-1ra, IL-10, fasting-insuline, fasting-glucose|Both|18 Years|N/A|No|Probability Sample|Patients with stroke admitted acutely to a hospital|October 2012|October 17, 2012|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01560520||88869|
NCT01560806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VNHI-07-001|Intervention Study on Hypertension Management Combined With Health Promotion at Commune Level|Quasi-experimental Intervention Study on Hypertension Management Combined With Comprehensive Healthy Lifestyle Promotion at Commune Level||Vietnam National Heart Institute|Yes|Completed|December 2006|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|2400|||Both|25 Years|N/A|No|||March 2012|March 20, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01560806||88847|
NCT01561365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ottawarules|Applicability of the Ottawa Ankle Rules|Applicability of the Ottawa Ankle Rules to Exclude Fractures of the Ankle and Midfoot - Comparison to Orthopedic Residents Routine.||Hadassah Medical Organization|No|Completed|October 2003|May 2004|Actual|May 2004|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|92|||Both|15 Years|N/A|No|||March 2012|March 21, 2012|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01561365||88805|
NCT01557413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOO269-32|Randomised Study Between Intramedullary Locking Nails and Locking Plates for Treatment of Proximal Humerus Fractures|Randomised Study Between Intramedullary Locking Nails and Locking Plates for Treatment of Proximal Humerus Fractures in Patients After 40-year-old|HUMERUS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|February 2012|August 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|40 Years|85 Years|No|||March 2015|March 11, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01557413||89107|
NCT01557686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2010-046 Pilot|Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study|Patient Activation Through Counseling and Exercise - Acute Leukemia - Pilot Trial|PACE-AL|Universitetshospitalernes Center for Sygepleje|Yes|Completed|May 2010|February 2011|Actual|February 2011|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557686||89087|
NCT01557907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDT-11-ADC001|Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion|Multi-day (3) In-patient Evaluation of Intradermal vs Subcutaneous Basal/Bolus Insulin Infusion||Becton, Dickinson and Company|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|55 Years|No|||July 2012|July 25, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01557907||89070|
NCT01557946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001192|Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression|Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression||Mclean Hospital|No|Active, not recruiting|March 2012|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557946||89067|
NCT01558154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011DFA30960|Comparison of Treatment Effect of Chinese Medicine and Western Medicine on Depression in China and America|Comparison of Treatment Effect of Chinese Medicine and Western Medicine on Depression in China and America||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Not yet recruiting|March 2012|July 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|160|||Both|16 Years|70 Years|No|||March 2012|March 16, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01558154||89051|
NCT01558427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/156|Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer|Salvage Treatment or Active Clinical Surveillance for Oligometastatic Prostate Cancer: a Randomized Phase II Trial||University Hospital, Ghent|No|Recruiting|May 2012|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Male|18 Years|80 Years|No|||December 2014|December 4, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01558427||89030|
NCT01558440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10039|Rehabilitation of Malnourished Infants With F-100 or Diluted F-100|Rehabilitation of Severely Malnourished Infants Aged <6months: a Randomised, Controlled Comparison of Three Recovery Diets (Infant Formula, F-100 and Diluted F-100)||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|January 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|132|||Both|N/A|6 Months|No|||June 2015|July 26, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01558440||89029|
NCT01559012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Registro CE 409 det. 163/2012|Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum|The CLONEMESI Study: a Randomized Placebo-controlled Study With Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum.|CLONEMESI|Azienda Ospedaliera Città della Salute e della Scienza di Torino|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Female|N/A|N/A|No|||March 2014|March 31, 2014|March 12, 2012||No||No|February 12, 2014|https://clinicaltrials.gov/show/NCT01559012||88985|Efficacy and safety issues are represented by maternal exposure in a critical period for organogenesis and hypotensive effect of the drug.Findings based on a very limited number of women limit the reliability of results
NCT01552408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27954|Efficacy and Safety Trial of Intravitreal Injections Combined With PRP for the Treatment of CSME Secondary to Diabetes Mellitus (DAVE)|A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE|DAVE|Greater Houston Retina Research|Yes|Active, not recruiting|March 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01552408||89490|
NCT01533818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1979-CHS-ERC-11|Community Based Management of Fast Breathing in Infants Aged < 60 Days in Low-income Settlements of Karachi|Community Based Management of Fast Breathing in Infants Aged < 60 Days: A Double-Blind, Randomized Placebo-Controlled Trial in Low-income Settlements of Karachi|MAT-YI|Aga Khan University|Yes|Terminated|May 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|963|||Both|N/A|59 Days|No|||June 2014|June 2, 2014|February 13, 2012||No|The study was stopped by DSMB based on high treatment failure rate in placebo compared to    active drug.|No||https://clinicaltrials.gov/show/NCT01533818||90908|
NCT01533831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-09-076|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|February 2012|||||N/A|N/A|N/A||||||||||||||February 12, 2013|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01533831||90907|
NCT01543880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-1931|Safety and Efficacy of Long-term Somatropin Treatment in Adults|Non-interventional Study of Safety and Efficacy of Long-term Somatropin Treatment in Adults|NordiWIN|Novo Nordisk A/S|No|Completed|July 2003|June 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|752|||Both|20 Years|N/A|No|Probability Sample|Adults in need of somatropin or current users|April 2015|April 28, 2015|February 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01543880||90141|
NCT01532063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8819|Risk Factors of Difficult Intubation and Related Complications in Adults in Intensive Care Units: FRIDA-Rea|Risk Factors of Difficult Intubation and Related Complications in Adults in Intensive Care Units(ICU)|FRIDA-Rea|University Hospital, Montpellier|No|Completed|October 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|1400|||Both|18 Years|N/A|No|||March 2013|March 14, 2013|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01532063||91042|
NCT01544153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA155489|Improving Adherence to Web-Based Cessation Programs: A Social Network Approach|Improving Adherence to Web-Based Cessation Programs: A Social Network Approach||Truth Initiative|No|Active, not recruiting|February 2012|April 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|5292|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01544153||90120|
NCT01534715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN0301|IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia|A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia||ImmunoGen, Inc.|No|Active, not recruiting|January 2012|||April 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||December 2015|January 28, 2016|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01534715||90841|
NCT01534728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-33|Identification of Hepatitis C Virus (HCV) Specific T Cells|Identification of HCV Specific T Cells Using Tetramer Technology - TETRA Study|TETRA|Institut National de la Santé Et de la Recherche Médicale, France|No|Completed|February 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|Samples Without DNA|PBMCs|Both|18 Years|60 Years|No|Non-Probability Sample|Chronic HCV Patients|March 2014|January 12, 2015|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01534728||90840|
NCT01560533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.640|Representation of the Body for Patients With Cancer|Representation of the Body and Treatment of Peritoneal Cancer by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - A Collaborative Approach Between Professionals of Health / Patients / Researchers|CORCAN|Hospices Civils de Lyon|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|N/A|No|||January 2014|January 29, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01560533||88868|
NCT01560819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-233|Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases|Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases|GMT|Spectrum Health Hospitals|Yes|Completed|March 2012|June 2013|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|7 Years|21 Years|No|||December 2013|December 4, 2013|March 20, 2012|Yes|Yes||No|July 15, 2013|https://clinicaltrials.gov/show/NCT01560819||88846|This short-term pilot study is limited by its small sample size; therefore, studies with a larger sample size and longer follow-up period will be required to determine true efficacy of GMT in patients with ulcerative colitis (UC).
NCT01561079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00051600|Fetal and Infant Effects of Maternal Buprenorphine Treatment|Fetal and Infant Effects of Maternal Buprenorphine Treatment||Johns Hopkins University|Yes|Recruiting|February 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|120|||Female|18 Years|40 Years|No|||February 2016|February 29, 2016|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561079||88826|
NCT01561326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB04802|Facilitating Follow-Up Adherence for Abnormal Pap Smears|Facilitating Follow-Up Adherence for Abnormal Pap Smears|TC3|Fox Chase Cancer Center|Yes|Completed|May 2005|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|211|||Female|18 Years|N/A|No|||March 2012|March 21, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561326||88807|
NCT01561378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-538|Cardiac Surgery Neuroprotection Study in Elders|Intranasal Insulin for Neuroprotection in Elderly Cardiac Surgery Patients|CNS-Elders|Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|August 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|22|||Both|65 Years|N/A|No|||January 2015|January 13, 2015|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561378||88804|
NCT01557426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|304321|Soft Tissue Ultrasound of Infections|Soft Tissue Ultrasound of Infections||Rhode Island Hospital|No|Completed|March 2012|March 2015|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|N/A|No|||March 2012|April 28, 2015|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557426||89106|
NCT01557699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMV-001|A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices|An Open-Label, Randomized, Phase I Study in Healthy Male Adults to Evaluate the Safety of a Measles Vaccine (Dry Powder)Administered by Two Devices|PMV-001|Serum Institute of India Limited|No|Completed|March 2012|September 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|60|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 29, 2014|March 16, 2012||No||No|June 14, 2014|https://clinicaltrials.gov/show/NCT01557699||89086|
NCT01557959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 62107|Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer||Comprehensive Cancer Center of Wake Forest University|Yes|Completed|July 2007|||February 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|February 14, 2012|Yes|Yes||No|May 1, 2013|https://clinicaltrials.gov/show/NCT01557959||89066|
NCT01551030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-060|Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium|Phase II Study of Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium||Memorial Sloan Kettering Cancer Center||Active, not recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551030||89595|
NCT01551303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000387|Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety|Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety||Massachusetts General Hospital|No|Completed|February 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|May 29, 2014|February 21, 2012|Yes|Yes||No|March 26, 2014|https://clinicaltrials.gov/show/NCT01551303||89574|
NCT01551316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN-221-CL-012|Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase Ib Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Repeated Administration, Intravenous MN-221 in Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients||MediciNova||Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|40 Years|75 Years|No|||May 2012|May 17, 2012|February 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01551316||89573|
NCT01551602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK159 I-1|Clinical Study of AK159 in Healthy Postmenopausal Women|||Asahi Kasei Pharma Corporation||Recruiting|March 2012|||September 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|11||Anticipated|132|||Female|45 Years|N/A|Accepts Healthy Volunteers|||January 2012|March 12, 2012|March 1, 2012||||No||https://clinicaltrials.gov/show/NCT01551602||89551|
NCT01561417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1007-1744|Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects|A Single-centre, Randomised, Double-blind, Two-way Cross-over Trial Investigating the Bio-equivalence in Healthy Male Subjects of NovoSeven (CP-rFVIIa) and a Formulation of NovoSeven Stable at 25°C (VII25)||Novo Nordisk A/S|No|Completed|April 2006|September 2006|Actual|September 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Male|18 Years|45 Years|No|||June 2012|June 28, 2012|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561417||88801|
NCT01561430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13735|Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease|Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease||Eli Lilly and Company|No|Terminated|March 2012|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Anticipated|128|||Both|55 Years|N/A|No|||January 2014|January 7, 2014|March 21, 2012|Yes|Yes|Study terminated due to abnormal liver biochemical tests in some participants.|No||https://clinicaltrials.gov/show/NCT01561430||88800|
NCT01543594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG-624|Italian Registry of Arthritis on Biologic Therapy|Study of Efficacy and Safety of Biologic Drugs in the Therapy of Rheumatoid Arthritis and Spondyloarthritis|GISEA|Gruppo Italiano Studio Early Arthritis|Yes|Recruiting|January 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|14 Years|80 Years|No|Non-Probability Sample|Patients affected by active polyarthritis beginning conventional biologic drugs|February 2012|March 2, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543594||90163|
NCT01543854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2201|Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure|A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Hemodynamic Responses to Intravenous RLX030 Infusion in Subjects With Acute Heart Failure||Novartis||Completed|March 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|87 Years|No|||August 2014|August 4, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01543854||90143|
NCT01532375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH_2008_AT_4|Kochujang, a Fermented Soybean-based Red Pepper Paste, Decreases Visceral Fat and Improves Blood Lipid Profiles in Overweight Adults|Kochujang Decreases Visceral Fat and Improves Lipids Profiles||Chonbuk National University Hospital|Yes|Completed|October 2009|March 2010|Actual|March 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||February 2012|February 13, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532375||91018|
NCT01531803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB058|Study to Evaluate the Safety of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients|A Prospective, Randomized, Multi-Center, Controlled, Open-Label Study to Evaluate the Safety of Kedbumin 25% Compared to Normal Saline Solution in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients Undergoing Major Elective Surgery.||Kedrion S.p.A.|Yes|Terminated|September 2012|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|N/A|12 Years|No|||October 2015|October 22, 2015|February 1, 2012|No|Yes|Per FDA CBER letter dated July 15, 2015, Kedrion SpA was released from the PMC to perform the    study with Kedbumin 25 % in pediatric patients|No||https://clinicaltrials.gov/show/NCT01531803||91062|
NCT01540123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28AI3|The Time Effects of a Berry Extract Upon Cerebral Blood Flow.|The Time Effects of a Berry Extract Upon Cerebral Blood Flow.||Northumbria University|Yes|Recruiting|February 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 23, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01540123||90428|
NCT01560260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00708|Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors|A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors||National Cancer Institute (NCI)||Completed|March 2012|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560260||88889|
NCT01560546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002102-73|Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)|Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) - a Randomised, Doubleblinded and Placebocontrolled Trial of Men With Subnormal Testosterone Levels and T2DM.||Odense University Hospital|Yes|Completed|March 2012|November 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Male|50 Years|70 Years|No|||November 2013|November 13, 2013|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560546||88867|
NCT01560559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.696|Peroral Endoscopic Myotomy for Primary Esophageal Achalasia|Peroral Endoscopic Myotomy for Primary Esophageal Achalasia|TAMEO|Hospices Civils de Lyon|Yes|Completed|March 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2012|May 22, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01560559||88866|
NCT01560832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0382|Descriptive Epidemiology of Clostridium Difficile Infection in Hospitalized Adult Patients in the Asia Pacific Region|||Yonsei University|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|188|||Both|20 Years|N/A|No|Non-Probability Sample|patient who has experienced the passage of 3 or more unformed or loose stools [diarrhea]        conforming to the shape of a container within a 24-hour period and has a positive        laboratory test result confirmed by PCR.|March 2014|March 4, 2014|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01560832||88845|
NCT01561092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|397-2011|Escitalopram Treatment In Acute Stroke|Efficacy of Escitalopram Treatment in Acute Stroke and the Role of SERT Genotype in Stroke|ESTIAS|University of Aarhus|Yes|Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|March 20, 2012||No|Study medication could not be supplied. An alternative project will be conducted|No||https://clinicaltrials.gov/show/NCT01561092||88825|
NCT01549977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67_207|Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina|A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Exercise Tolerance in Subjects With Chronic Stable Angina||Takeda|Yes|Terminated|July 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|85 Years|No|||October 2013|October 30, 2013|March 6, 2012|Yes|Yes|Business Decision (please see below)|No|October 30, 2013|https://clinicaltrials.gov/show/NCT01549977||89674|
NCT01550250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACREC-25845|Night-time Compression Systems for Breast Cancer Related Lymphedema|Feasibility of Night-time Compression Systems for Breast Cancer Related Lymphedema: a Pilot Study||University of Alberta|Yes|Completed|April 2012|December 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Female|18 Years|N/A|No|||July 2012|July 16, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550250||89653|
NCT01557712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1129|Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks|Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks.|KETADEP|University Hospital, Grenoble|Yes|Recruiting|March 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557712||89085|
NCT01550744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100708|A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis|A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis|PSTELLAR|Janssen Biotech, Inc.|Yes|Completed|March 2012|July 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|480|||Both|18 Years|80 Years|No|||December 2015|December 9, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550744||89616|
NCT01551615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00102|A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an OCT2 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Oral Dose of Vandetanib (CAPRELSA) 800 mg|Vandetanib|AstraZeneca||Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|March 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01551615||89550|
NCT01551888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-PK-01|Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 µg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 µg Via Foradil® Aerolizer® In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease||Forest Laboratories|No|Completed|January 2012|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|40 Years|N/A|No|||October 2015|October 28, 2015|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551888||89529|
NCT01551901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEN 007|Luna Interbody System for Fusion Trial|LIFT: Luna Interbody System for Fusion Trial|LIFT|Benvenue Medical, Inc.|No|Active, not recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|65 Years|No|||September 2014|September 18, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01551901||89528|
NCT01552122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-050|Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)|A Phase III Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density, Tolerability, and Safety in the Treatment of Postmenopausal Women With Osteoporosis Previously Treated With Alendronate||Merck Sharp & Dohme Corp.|Yes|Withdrawn|May 2012|February 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|60 Years|N/A|No|||August 2015|August 26, 2015|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01552122||89511|
NCT01557491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8080808|Hair Regrowth After Bicoronal Incision|A Randomized Blinded Comparison of Hair Growth Following Either Bevelled or Standard Bi-coronal Scalp Incisions.||Sunnybrook Health Sciences Centre||Not yet recruiting|May 2012|||November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|26|||Both|18 Years|N/A|No|||March 2012|March 16, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557491||89101|
NCT01531179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB6303|Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants|Role Of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis in Very Low Birth Weight Infants||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Completed|February 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|400|||Both|N/A|6 Months|No|||February 2013|May 8, 2013|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01531179||91109|
NCT01531764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.137|BIBW 2992 (Afatinib) and Vinorelbine|Single-arm, Open-label, Multicentre Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) in Combination With Vinorelbine for the Treatment of Patients With Metastatic Breast Cancer With Intermediate HER2 Expression (HER2 2+ by Immunohistochemistry, Fluorescence In-situ Hybridisation (FISH) Negative) After Failure of First-line Therapy in the Metastatic Setting and Having Been Pre-treated With Anthracyclines||University of Magdeburg|No|Terminated|July 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Female|18 Years|N/A|No|||February 2012|October 17, 2013|February 9, 2012||No|The recruitment was discontinued because of failure to meet expected enrolment goals|No||https://clinicaltrials.gov/show/NCT01531764||91065|
NCT01531777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APTN-II-CRC|Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer|A Random, Open, Dose Finding and Pharmacokinetics/Pharmacodynamics(PK/PD) Phase II Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer||Jiangsu HengRui Medicine Co., Ltd.|Yes|Completed|April 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||February 2012|April 2, 2015|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531777||91064|
NCT01531517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pedyphar2012|Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers|Study of the Efficacy of Topical Application of Royal Jelly and Panthenol (PedyPhar® Ointment) on the Diabetic Foot Ulcers, An Open Label, Randomized, Non-placebo-controlled Study|PED111|European Egyptian Pharmaceutical Industries|Yes|Terminated|July 2011|July 2013|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|70 Years|No|||February 2012|February 19, 2015|February 6, 2012|Yes|Yes|inability to recruit patients|No||https://clinicaltrials.gov/show/NCT01531517||91084|
NCT01531530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00049727|Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP|Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP||University of Maryland|Yes|Completed|July 2011|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|October 26, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01531530||91083|
NCT01531790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-93|A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients|A Phase I Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced NSCLC Patients||Jiangsu Simcere Pharmaceutical Co., Ltd.|No|Completed|September 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|70 Years|No|||January 2013|January 15, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531790||91063|
NCT01532076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|348/10|Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts|Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts Versus Acellular Bone Graft Substitutes for Augmentation in the Treatment of Proximal Humeral Fractures as Model for Fractures of Osteoporotic Bone - a Prospective Randomized First in Men Proof of Principle Trial|ROBUST|University Hospital, Basel, Switzerland|No|Terminated|June 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|50 Years|N/A|No|||September 2014|September 16, 2014|January 5, 2012||No|Slow recruitment|No||https://clinicaltrials.gov/show/NCT01532076||91041|
NCT01532401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLADSEL 2010-023410-31|Oral Sodium Blood Pressure in Normal Weight, Overweight and Obese Volunteers|Simplification of the Test of Sensibility in the Salt: Preliminary Study at the Child and the Adult|PLADSEL|Poitiers University Hospital||Recruiting||||||Phase 2|Interventional|N/A|2||||||Both|6 Years|45 Years|No|||February 2012|February 13, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01532401||91016|
NCT01532661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 07 20|National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology|National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology|NOVO7|University Hospital, Grenoble|Yes|Completed|April 2008|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|114|||Both|18 Years|N/A|No|Probability Sample|All patients admitted in ICU after massive bleeding trauma and received rFVIIa|November 2014|November 17, 2014|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01532661||90997|
NCT01532674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UV1|Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy|Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy||University of Valencia|Yes|Recruiting|November 2011|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2012|February 16, 2012|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01532674||90996|
NCT01560273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP-11-002|Aspen Spinous Process Fixation System for Use in PLF in Patients With Spondylolisthesis|A Multi-Center Prospective Study Evaluation Aspen Spinous Process Fixation System for Use in Posterolateral Fusion (PLF) in Patients With Spondylolisthesis||Biomet, Inc.|No|Terminated|February 2012|September 2015|Actual|September 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|50 Years|80 Years|No|Non-Probability Sample|Patients 50 years and older with spondylolisthesis requiring a single level posterolateral        decompression and posterolateral fusion|September 2015|March 14, 2016|March 15, 2012|Yes|Yes|Will answer study question through other research means.|No||https://clinicaltrials.gov/show/NCT01560273||88888|
NCT01560286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|165-205|A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks|A Phase II, Multi-center, Open-label, Dose-finding Study to Evaluate Safety, Efficacy and Tolerability of Subcutaneously (SC) Administered rAvPAL-PEG in Patients With PKU for 24 Weeks||BioMarin Pharmaceutical|Yes|Completed|May 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|16 Years|70 Years|No|||July 2015|July 23, 2015|March 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01560286||88887|
NCT01560572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allegro|Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen|Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen|Allegro|University Medical Center Groningen|Yes|Active, not recruiting|April 2011|April 2016|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Both|18 Years|80 Years|No|||December 2014|December 31, 2014|December 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01560572||88865|
NCT01560845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZMC1-10-1|ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis|Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study||Wenzhou Medical University|No|Recruiting|June 2010|June 2014|Anticipated|June 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|No|||March 2012|March 21, 2012|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01560845||88844|
NCT01560858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-92-52014-196|Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State|A Retrospective Observational Study to Describe Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State, in Routine Clinical Practice in Spain.||Ipsen|No|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|407|||Male|18 Years|N/A|No|Non-Probability Sample|Community sample|June 2013|June 19, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560858||88843|
NCT01561105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAHF 98297|Improving Depression Care for Elders: Coordinating Center|This Was a Five-year Seven-site Trial to Study the Cost-effectiveness of a Population Based Disease Management Program for Late Life Depression in Primary Care.|IMPACT|University of California, Los Angeles|Yes|Completed|January 1999|June 2004|Actual|June 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1801|||Both|60 Years|N/A||||March 2012|March 26, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561105||88824|
NCT01550263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48948|Psychological Distress and Outcomes in Hip Preservation Patients|Pre-Operative Psychological Distress and Post-Operative Outcomes in Hip Preservation Patients|Hip|University of Utah|No|Active, not recruiting|January 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients are selected by Dr. Aoki|January 2016|January 13, 2016|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01550263||89652|
NCT01550484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-133-B04|A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders|An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis||Avid Radiopharmaceuticals|No|Active, not recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|150|||Both|40 Years|N/A|No|||January 2016|January 7, 2016|March 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550484||89635|
NCT01550471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC#5401|Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis|A Study Evaluating the Effect of Omnaris Nasal Spray 200 mcg QD & Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 mcg BID & QVAR Inhalation Aerosol 40 mcg BID vs Placebo Nasal Spray QD & Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma & Allergic Rhinitis||West Penn Allegheny Health System|Yes|Recruiting|March 2012|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|60|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|February 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01550471||89636|
NCT01551329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP0037|Ketamine for Depression and Alcohol Dependence|A Randomized Controlled Trial of the N-methyl-D-aspartate (NMDA) Receptor Antagonist Ketamine in Comorbid Depression and Alcohol Dependence.|KetamineDep|Yale University|Yes|Completed|March 2012|November 2015|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|65 Years|No|||December 2015|December 1, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01551329||89572|
NCT01560377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1|Perfusion Assessment in Laparoscopic Left Anterior Resection|Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures|PILLAR II|Novadaq Technologies Inc.|No|Completed|May 2012|November 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|147|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|March 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01560377||88880|
NCT01560663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOMHGUGM022011|Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer|Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer||Hospital General Universitario Gregorio Marañon|No|Recruiting|January 2012|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|185|||Female|18 Years|75 Years|No|Non-Probability Sample|Female patients with triple negative primary tumors|February 2016|February 18, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560663||88858|
NCT01560676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008007228|Reducing Obesity and Type 2 Diabetes in High Risk Youth|A School-based Internet Obesity Prevention Program for Adolescents|HEALTH[e]TEEN|Yale University|No|Completed|September 2009|August 2011|Actual|June 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|384|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||March 2012|March 20, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560676||88857|
NCT01560949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1208|Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas|A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2012|||June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560949||88836|
NCT01561170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20110052|Electromagnetic Field Therapy to Improve Healing of Chronically Venous Ulcer|The Effect of Electromagnetic Field Therapy to Improve Healing of Chronically Venous Ulcer in Lower Extremities||Northern Orthopaedic Division, Denmark|No|Active, not recruiting|October 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|36|||Both|18 Years|90 Years|No|Probability Sample|Primary care clinic|April 2015|April 9, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01561170||88819|
NCT01531192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZTB630301|Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants|Zekai Tahir Burak Maternity Teaching Hospital, Ankara/Turkey||Zekai Tahir Burak Women's Health Research and Education Hospital|Yes|Completed|June 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|300|||Both|N/A|6 Months|No|||February 2012|July 13, 2013|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01531192||91108|
NCT01531218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT number: 2011-000808-18|Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea|Randomized, Double-Blind, Placebo-Controlled Trial Of Azithromycin In Campylobacter Concisus Positive Patients With Diarrhea|Concisus2012|University of Aarhus|Yes|Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2014|July 3, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531218||91106|
NCT01531543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BuloVAC|Prospective Comparison of Primary Abdominal Closure and Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis|Phase 4 Study of Primary Use of the Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis||The Faculty Hospital Na Bulovce|No|Completed|July 2008|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|80 Years|No|||February 2012|February 10, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01531543||91082|
NCT01532141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-113|Effect of Rasagiline on BIA 9-1067 Pharmacokinetics|Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects||Bial - Portela C S.A.|No|Completed|November 2009|August 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 23, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01532141||91036|
NCT01532102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP611074.CT3|Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts|A Double-blind, Placebo Controlled, Randomized, Phase IIa Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Repeated Topical Applications Over 42 Days of AP611074 5% Gel in Condyloma Patients||Biota Scientific Management Pty Ltd|No|Completed|February 2012|||May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|No|||January 2016|January 22, 2016|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01532102||91039|
NCT01532115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-111|Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women|A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women||Bial - Portela C S.A.|No|Completed|May 2010|May 2011|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01532115||91038|
NCT01532128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-112|Effect of BIA 9-1067 on Rasagiline Pharmacokinetics|Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects||Bial - Portela C S.A.|No|Completed|November 2009|July 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|January 23, 2012||No||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01532128||91037|
NCT01532713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0358|The Effect of Oxygen Administration on Regional Cerebral Oxygen Saturation (rSO2) in the Non-block Side After Stellate Ganglion Block|||Yonsei University|No|Completed|January 2012|March 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|38|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 4, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01532713||90993|
NCT01532089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1126|Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations|A Randomized Phase II Trial of Erlotinib Alone or In Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations||Academic and Community Cancer Research United|Yes|Recruiting|March 2012|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|February 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01532089||91040|
NCT01533012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0619|Initial Positioning of Left Sided Double Lumen Endobronchial Tubes Using Peak Inspiratory Pressures Difference Between Two Lungs|Initial Positioning of Left Sided Double Lumen Endobronchial Tubes Using Peak Inspiratory Pressures Difference Between Two Lungs||Yonsei University|Yes|Recruiting|November 2011|||April 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|100|||Both|20 Years|80 Years|No|||February 2012|February 14, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01533012||90970|
NCT01560299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metiodine|Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients|||Mashhad University of Medical Sciences|No|Completed|February 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|150|||Both|18 Years|65 Years|No|||March 2012|March 20, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01560299||88886|
NCT01560312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Charles University|Renal Denervation in Refractory Hypertension|Renal Denervation - Hope for Patients With Refractory Hypertension?|PRAGUE-15|Charles University, Czech Republic|No|Terminated|October 2011|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|March 19, 2012||No|Based on analysis of our data after the Symplicity-3 trial announcement, decision for study    termination was done.|No||https://clinicaltrials.gov/show/NCT01560312||88885|
NCT01560585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISOTRT-01|Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease|Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease||University Hospital Case Medical Center|No|Terminated|April 2012|August 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|50 Years|90 Years|No|||August 2014|August 27, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01560585||88864|
NCT01560598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gerdadipokine|Adipokines and the Risk of Reflux Esophagitis|Adipokines and the Risk of Reflux Esophagitis : Prospective Case-control Study||Seoul National University Hospital|Yes|Not yet recruiting|June 2012|||June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples Without DNA|serum|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy adults who visit healthcare system for routine checkup|March 2012|March 21, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560598||88863|
NCT01560611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5162|A New Non-invasive Marker to Detect Silent Hypoxia in Patients Undergoing Cardiac Surgery|The Somatic-to-cerebral Oxygen Saturation Gradient as a Non-invasive Index of Anaerobic Threshold in High-risk Cardiac Surgical Patient||University Hospital, Strasbourg, France|No|Not yet recruiting|March 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing cardiac surgical procedures under cardiopulmonary bypass in Strasbourg        University Hospital|March 2012|March 21, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560611||88862|
NCT01560871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16969|Effects of a Walking Program and Inspiratory Muscle Training on Individuals With Chronic Heart Failure|Effects of a Walking Program and Inspiratory Muscle Training on Individuals With Chronic Heart Failure - A Pilot Study||Texas Woman's University|Yes|Recruiting|March 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||November 2015|November 17, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560871||88842|
NCT01560884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-RZB-11-101|Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb|A Double Blind, Dose-Ranging, Phase 1 Study In Healthy Volunteers to Assess Safety and the Phosphate Binding Capacity of Lanthanum Dioxycarbonate (SPI-014, Renazorb)|SPI-014|Spectrum Pharmaceuticals, Inc|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 6, 2013|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560884||88841|
NCT01560897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pilot Study|Investigating Project of the Functional C13 Test "Pilot Study"|Investigating Project of the Functional C13 Test|PIL001|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|January 2012|||December 2012|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|2 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560897||88840|
NCT01561118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1137|DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis|DiaSport - Ausdauerorientiertes Trainingsprogramm Mit Kindern Und Jugendlichen an Der Dialyse (DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis)|DiaSport|University of Cologne|Yes|Not yet recruiting|April 2012|September 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|66|||Both|6 Years|19 Years|No|||March 2012|March 23, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561118||88823|
NCT01559038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-666|Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis|Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete‐ PsA)|Complete-PsA|AbbVie|No|Recruiting|March 2012|May 2020|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|670|||Both|18 Years|99 Years|No|Non-Probability Sample|Offices of community rheumatologists & dermatologists|January 2016|January 20, 2016|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559038||88983|
NCT01560104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-898|A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer|Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)||AbbVie|Yes|Completed|February 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|99 Years|No|||September 2015|September 30, 2015|February 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560104||88901|
NCT01559324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6.2009.06 2011/02/0009|Electroconvulsive Therapy (ECT) for Elderly Patients With Major Depression|Randomized Controlled Comparison of Bifrontal and Right Unilateral ECT as to Effects on Depression, Global Cognitive Function and Biomarkers.||Diakonhjemmet Hospital|No|Completed|August 2009|November 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|60 Years|85 Years|No|||July 2015|July 8, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559324||88961|
NCT01550757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDR 11-230|Aligning Resources to Care for Homeless Veterans|Aligning Resources to Care for Homeless Veterans (ARCH)|ARCH|VA Office of Research and Development|No|Active, not recruiting|March 2012|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Anticipated|600|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|September 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01550757||89615|
NCT01559831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC51-319|Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination|Immune Responses to Revaccination After Potentially Insufficient Priming With the Japanese Encephalitis Vaccine IXIARO Batch JEV09L37||Valneva Austria GmbH|No|Withdrawn|June 2012|March 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 7, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559831||88922|
NCT01560962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|blepharitis|Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis|Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis||Southern California Institute for Research and Education||Terminated|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|N/A|4||||||Both|18 Years|N/A||||May 2013|May 28, 2013|March 20, 2012||No|research staffs unable to continue.|No||https://clinicaltrials.gov/show/NCT01560962||88835|
NCT01561183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IKHDC: 01-11-1390|Vital Pulp Therapy (VPT) Using Calcium Enriched Mixture (CEM) to Treat Irreversible Pulpitis|Vital Pulp Therapy for Management of Irreversible Pulpitis in Human Permanent Teeth: A Randomized Clinical Trial.||hahid Beheshti University of Medical Sciences|Yes|Enrolling by invitation|March 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|50|||Both|10 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 21, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01561183||88818|
NCT01561196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sloth1|Conventional Verses Ultrasound Guided Arteria Cannulation, With and Without Local Anesthesia|Conventional vs. Ultrasound Guided Arteria Cannulation, With and Without Local Anesthesia||Aarhus University Hospital Skejby|Yes|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|20|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01561196||88817|
NCT01557231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00059872|Epidemiology of Osteoarthritis (OA) Pain|Epidemiology of OA Pain||Northwestern University|No|Active, not recruiting|March 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|40 Years|N/A|No|Non-Probability Sample|Individuals with OA|October 2015|October 14, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01557231||89121|
NCT01531231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1 HL103692-01 A1|Typical Daily Experiences, Ischemia and Repolarization in Coronary Artery Disease|Typical Daily Emotions, Ischemia and Repolarization in Coronary Artery Disease||University of Arizona|No|Recruiting|January 2012|February 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|||Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|University of Arizona Medical Center (overhead TV monitors); Cardiology Clinics; Community        Centers; Primary Care Clinics; Pima Heart; Desert Cardiology; Referrals from study        participants, Craig's List|July 2013|July 23, 2013|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531231||91105|
NCT01531244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-X335|Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma|A Phase I/II Study of Isolated Limb Infusion and Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma||Washington University School of Medicine|Yes|Withdrawn|December 2014|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2014|July 17, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01531244||91104|
NCT01532154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218MS402|Fampridine Pregnancy Exposure Registry|Fampridine Pregnancy Exposure Registry||Biogen|No|Terminated|August 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|375|||Female|N/A|N/A|No|Non-Probability Sample|The study population will be pregnant female participants with multiple sclerosis who have        been exposed to prolonged release fampridine since the first day of the last menstrual        period or at any time during pregnancy. This information will be from ongoing fampridine        clinical studies or the post-marketing setting. The outcome of the pregnancy must not be        known at the time of report.|October 2015|November 30, 2015|December 15, 2011|No|Yes|Due to low enrollment, registration closed in agreement with the Regulatory Agency|No||https://clinicaltrials.gov/show/NCT01532154|12 Weeks|91035|
NCT01532414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-301|Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism|A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration||Repros Therapeutics Inc.|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|151|||Male|18 Years|60 Years|No|||May 2015|May 7, 2015|February 9, 2012|Yes|Yes||No|June 13, 2014|https://clinicaltrials.gov/show/NCT01532414||91015|
NCT01532726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-403|Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)|A Non-Interventional, Prospective Study to Assess Seizure Control and Tolerability of Eslicarbazepine Acetate as Adjunctive Therapy to One Baseline Antiepileptic Drug, in Adults With Partial-Onset Seizures With or Without Secondary Generalization||Bial - Portela C S.A.|No|Active, not recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Adults with Partial-Onset Seizures With or Without Secondary Generalization|July 2015|January 4, 2016|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01532726||90992|
NCT01533025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPH2008-007|Single Bundle Anterior Cruciate Ligament Reconstruction in Active Young Men|Single Bundle Anterior Cruciate Ligament Reconstruction in Active Young Men: Free Tendon Achilles Allograft vs. Bone-tendon Achilles Allograft||National Police Hospital|Yes|Completed|August 2008|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|72|||Male|19 Years|45 Years|No|||February 2012|February 14, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01533025||90969|
NCT01533038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP12317|BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia|BPH-6: A UroLift® System Post Market Multi-Center Randomized Study|BPH-6|NeoTract, Inc.|No|Completed|February 2012|January 2016|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Male|50 Years|N/A|No|||February 2016|February 18, 2016|February 10, 2012||No||No|October 22, 2015|https://clinicaltrials.gov/show/NCT01533038||90968|
NCT01560624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-310|Trial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial Hypertension|A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy|FREEDOM-Ev|United Therapeutics|Yes|Recruiting|July 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|610|||Both|18 Years|75 Years|No|||September 2015|September 2, 2015|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560624||88861|
NCT01560637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-311|An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension|Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310||United Therapeutics|Yes|Recruiting|May 2012|August 2021|Anticipated|May 2021|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|610|||Both|18 Years|75 Years|No|||September 2015|September 2, 2015|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01560637||88860|
NCT01560910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSNEXI0018|Detection of Minimal Change Esophagitis by I-scan|||Maharaj Nakorn Chiang Mai Hospital|No|Completed|January 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|||Both|18 Years|80 Years||Non-Probability Sample|The patients with or without GERD symptoms presenting to gastrointestinal clinic of        Maharaj Nakorn Chiangmai Hospital from November 2009 to November 2010 were invited to        participate in this study. All patients completed 2 validated questionnaires (RDQ: reflux        diagnostic questionnaire and HRQL: Health-related quality-of-life GERD questionnaire)        after giving written informed consent. Patients were enrolled if they were 18 to 80 years        of age and had ability to provide written informed consent.        Patients who have heartburn or regurgitation more than 2 times/week for at least 1 month        were defined as having GERD and patient without any reflux symptoms served as controls.The        exclusion criteria were 1) pregnancy, 2) cirrhosis or presence of gastroesophageal        varices, 3) gastrointestinal hemorrhage, 4) angina pectoris, 5) allergy to PPI, 6) high        risk or contraindication for endoscopy, 7) chronic cough, laryngitis, asthma.|March 2012|March 21, 2012|March 20, 2012||||No||https://clinicaltrials.gov/show/NCT01560910||88839|
NCT01561131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B288|The Effect of Protein and Calcium on Weight Change and Blood Lipid Profile|The Effect of Protein and Calcium on Weight Change and Blood Lipid Profile|PROKA|University of Copenhagen|No|Active, not recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Anticipated|200|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 28, 2014|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561131||88822|
NCT01561144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMBRELLA|UMBRELLA - Incidence of Arrhythmias in Spanish Population With a Medtronic Implantable Cardiac Defibrillator Implant|UMBRELLA - Incidence of Arrhythmias in Spanish Population With a Medtronic ICD Implant|UMBRELLA|Medtronic Bakken Research Center||Recruiting|August 2011|||August 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10000|||Both|13 Years|N/A|No|Non-Probability Sample|Patients inplanted with an Implantable Cardiac Defibrillator (ICD) according to        guidelines.|April 2014|April 8, 2014|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01561144||88821|
NCT01561391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM/USA/4/USA|Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery|An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery||Novo Nordisk A/S|No|Completed|April 1998|May 2004|Actual|May 2004|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|5 Years|N/A|No|||December 2012|December 5, 2012|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561391||88803|
NCT01557439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/058|Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal® 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fasting Condition||IPCA Laboratories Ltd.|Yes|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01557439||89105|
NCT01559597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre/CTC-TT/2012|Comparative Study of Two Tetanus Toxoid Vaccination Strategies: Cold Chain Versus Controlled Temperature Chain|Etude Comparative de Deux stratégies de Vaccination antitétanique en Situation réelle: Vaccin conservé en chaîne de Froid Versus en chaîne de température contrôlée.||Epicentre||Completed|November 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|2129|||Female|14 Years|49 Years|Accepts Healthy Volunteers|||February 2013|May 1, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559597||88940|
NCT01559610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP 4150/08|Preoperatively Orientation in Cardiac Surgery: Nurses Intervention on Patients Recovery|Preoperatively Orientation in Cardiac Surgery: Nurses Intervention on Patients Recovery||Instituto de Cardiologia do Rio Grande do Sul|Yes|Completed|August 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|180|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01559610||88939|
NCT01559623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OAB2012|Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract Symptoms|||University of Zurich||Completed|January 2009|February 2013|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|766|||Female|16 Years|N/A|No|Non-Probability Sample|clinic for urogynecology|December 2014|December 15, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01559623||88938|
NCT01560689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2|Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation|Open-labeled Trial to Evaluate the Therapeutic Effects of Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation|alloforb|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2008|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|16 Years|N/A|No|||September 2012|September 6, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560689||88856|
NCT01560702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#:278/12-3-2012|Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers|Endoscopic Injection of Autologous Blood Versus Diluted Epinephrine for Control of Actively Bleeding Gastroduodenal Ulcers||Zagazig University|Yes|Completed|March 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|16 Years|60 Years|No|||September 2013|September 24, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01560702||88855|
NCT01549665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-008|Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease|Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease|GVHD-MSC|Samsung Medical Center|No|Recruiting|January 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|30 Years|No|||March 2012|March 14, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01549665||89697|
NCT01552421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOTES02|The Effect of Transvaginal vs. Conventional Laparoscopic Cholecystectomy on the Postoperative Course|The Effect of Transvaginal vs. Conventional Laparoscopic Cholecystectomy on the Postoperative Course|TRAVAKOL|Herlev Hospital|Yes|Terminated|September 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 23, 2013|March 7, 2012||No|For logistic reasons in the department and due to very low inclusion rates.|No||https://clinicaltrials.gov/show/NCT01552421||89489|
NCT01552434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0061|Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab|A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy||M.D. Anderson Cancer Center|No|Recruiting|March 2012|||March 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|216|||Both|N/A|N/A|No|||October 2015|October 26, 2015|March 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01552434||89488|
NCT01548625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DE pilot|Cardiovascular Effects of Incremental Diesel Exhaust Inhalation in Middle-Aged Healthy GSTM1 Null Human Volunteers|||Environmental Protection Agency (EPA)|No|Completed|July 2007|||November 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|50 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy 50-75 year-old male and female subjects with GSTM1 null genotype.|March 2012|March 7, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548625||89777|
NCT01561781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00100|Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With a Single Dose of Vandetanib (CAPRELSA) 300 mg|Vandetanib|AstraZeneca||Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561781||88773|
NCT01562067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125-11CTIL|Sonographic Characteristics of Tumor Indices in Patients With Cervical Cancer During Chemo-radiotherpy|Sonographic Characteristics of Tumor Indices in Patients With Cervical Cancer During Chemo-radiotherpy||Rambam Health Care Campus|No|Not yet recruiting|March 2012|April 2014|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|Samples Without DNA|pap smear|Female|18 Years|70 Years|No|Non-Probability Sample|women with cervical cancer during radiotherapy|March 2011|March 22, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562067||88751|
NCT01562327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28142|A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|||Hoffmann-La Roche||Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients treated with tocilizumab|March 2016|March 1, 2016|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562327||88731|
NCT01574352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S20120015|The Odense Overweight Intervention Study|The Odense Overweight Intervention Study (OOIS): A Randomized Controlled Trial on Overweight Prevention in Children.|OOIS|University of Southern Denmark|No|Active, not recruiting|April 2012|July 2017|Anticipated|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Both|10 Years|13 Years|No|||July 2014|July 2, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01574352||87811|
NCT01570309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHA Award #0885041N|Vitamin D Repletion in Coronary Artery Disease|The Effects of Vitamin D Repletion on Endothelial Function and Inflammation in Patients With Coronary Artery Disease||New York City Health and Hospitals Corporation|No|Completed|August 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|March 26, 2012||No||No|September 23, 2012|https://clinicaltrials.gov/show/NCT01570309||88120|
NCT01571167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26875|Varenicline as a Treatment for Methamphetamine Dependence|A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline in Methamphetamine-Dependent Volunteers Receiving Methamphetamine|Varenicline|Baylor College of Medicine|Yes|Completed|January 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|17|||Both|18 Years|55 Years|No|||June 2013|June 12, 2013|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571167||88055|
NCT01570829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMH-DI-003|Clinical Trial of Safety and Efficiency of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients|Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficiency of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients||Materia Medica Holding|No|Completed|December 2011|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|65 Years|No|||July 2013|July 24, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570829||88080|
NCT01570842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005468|Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury|The Role of Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury||Mayo Clinic|No|Completed|October 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570842||88079|
NCT01552083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Etude SAS|A Community Pharmacist-led Intervention to Improve Screening of Sleep Apnea in Primary Care|A Community Pharmacist-led Intervention to Improve Screening of Sleep Apnea in Primary Care||Institut National de la Santé Et de la Recherche Médicale, France||Recruiting|January 2012|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|400|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 12, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01552083||89514|
NCT01552044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-21|Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis|Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|January 2012|February 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|60 Years|No|||February 2016|February 24, 2016|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01552044||89517|
NCT01552057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14377|A Study of Duloxetine in Fibromyalgia|A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia||Eli Lilly and Company|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|393|||Both|20 Years|74 Years|No|||January 2015|January 7, 2015|March 9, 2012|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01552057||89516|
NCT01552356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00690|Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors|Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: A Phase I Study||National Cancer Institute (NCI)||Active, not recruiting|March 2012|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|March 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01552356||89494|
NCT01552954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1112/142-008|Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan|Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial|ESPECIAL|Seoul National University Bundang Hospital|No|Completed|February 2012|October 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|269|||Both|19 Years|75 Years|No|||December 2014|December 10, 2014|February 24, 2012||No||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01552954||89448|The major limitation of this study is that we used a 24-hour volume urine collected at a single time point for each follow-up visit. Urine excretion can be influenced by the sodium intake of individual patients at certain point.
NCT01552967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHMO-01|Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma|A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma|mXELOX|Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Recruiting|March 2012|February 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2012|March 27, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01552967||89447|
NCT01551342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZT-CL-04B|Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology|Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology||Zetiq Technologies|No|Recruiting|January 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|urine samples|Both|18 Years|N/A|No|Non-Probability Sample|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer        undergoing routine cystoscopic surveillance, TURT or Cystectomy.|August 2013|March 20, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01551342||89571|
NCT01549132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKHT RETINAL RESEARCH UNIT|Retinal Oximtery Following Treatment for Diabetic Maculopathy|Non-invasive Retinal Oximetry Using Oxymap in Patients With Diabetic Maculopathy Receiving Laser/Intravitreal Anti-VEGF Therapy||East Kent Hospitals University NHS Foundation Trust|No|Not yet recruiting|April 2012|March 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|N/A|N/A|No|Non-Probability Sample|• Patients will be selected from the Ophthalmology clinics with all sites at East Kent        Hospitals University Foundation NHS Trust. These patients will be selected non−randomly by        the ophthalmology clinician involved in their care based whether their clinical diagnosis        fulfils the inclusion criteria. The ophthalmologists who are seeing patients in the        ophthalmology clinics will identify the patients fulfilling the inclusion criteria for        this study.|March 2012|March 8, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549132||89738|
NCT01549145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EST-01-IL|Sub-chronic Neurostimulation Delivered in the Middle Ear for Tinnitus Suppression|||EstimME Ltd.|No|Completed|June 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549145||89737|
NCT01549119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVVAC-3S/P1|Phase I/IIa Dose-escalation Clinical Study of VAC-3S|Multicentre, Randomized, Placebo-controlled, Double-blind, Phase I/IIa Dose-escalation Clinical Study of a Therapeutic Vaccine (VAC-3S) Intended to Confer Protection Against Immunopathological Effects of HIV-1 in Infected Patients||InnaVirVax|Yes|Completed|February 2012|December 2014|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|33|||Both|18 Years|55 Years|No|||January 2015|January 30, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01549119||89739|
NCT01554007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCDC 2011-088|Clinical Course of Korean Crohn's Disease Cohort|Clinical Course of Crohn's Disease: a Prospective Multicenter Long-term Follow-up Study in Korea||Kyunghee University Medical Center|Yes|Enrolling by invitation|December 2012|May 2018|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Whole blood and faeces will be retained for central biobank|Both|16 Years|N/A|No|Non-Probability Sample|About 500 patients diagnosed with Crohn's disease in the period of January 2009 to        December 2013 in academic teaching hospitals in Korea.|March 2015|March 31, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554007||89368|
NCT01548638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814947|Effect of Galantamine on Smoking Abstinence|The Effect of the Acetylcholinesterase Inhibitor, Galantamine, on Short-term Abstinence||University of Pennsylvania|No|Completed|February 2012|October 2013|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|60 Years|No|||June 2014|July 1, 2014|March 5, 2012|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01548638||89776|
NCT01548651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29171|Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation|Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients With Impaired Glucose Tolerance||Baylor College of Medicine|No|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|30 Years|70 Years|No|||February 2016|February 17, 2016|February 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01548651||89775|
NCT01573312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0074|H5N1 Vaccination With and Without AS03: Systems Biology Analysis|A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered With and Without AS03 Adjuvant: Standard & Systems Biology Analyses||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|June 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||July 2013|January 9, 2014|April 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01573312||87890|
NCT01573559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPIC-003|ClearView Predicate Comparison Testing|ClearView Predicate Comparison Testing||Epic Research & Diagnostics, Inc.|No|Completed|September 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|31|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Men and women ages 18-85.|April 2012|April 5, 2012|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01573559||87872|
NCT01562600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00012|Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation for Long-term Use Concerning Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer With NSAIDs||AstraZeneca||Completed|April 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1634|||Both|N/A|N/A|No|Non-Probability Sample|Patients who are given NSAIDs for long terms to control pain due to disease such as        rheumatoid arthritis and osteoarthritis, and given Nexium to suppress recurrence of        gastric ulcer or duodenal ulcer.        (Patients who have previous experience of Nexium given in the treatment for gastric ulcer        or duodenal ulcer can be registered to this S-CEI.)|September 2015|September 17, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562600||88710|
NCT01573572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOP 1024|Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium|A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.||Valeant Pharmaceuticals International, Inc.|No|Recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|125|||Both|50 Years|N/A|No|||June 2015|June 1, 2015|February 4, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573572||87871|
NCT01574365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-003|A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus|A Phase 2 Study of RTA 402 in CKD Patients With Type 2 Diabetes Mellitus||Kyowa Hakko Kirin Company, Limited|No|Terminated|February 2012|||November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|40|||Both|20 Years|79 Years|No|||April 2014|April 27, 2014|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01574365||87810|
NCT01574378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vl12345|Effectiveness of Wound Closure Using V-Loc™ 90 Sutures in Lipoabdominoplasty Patients|Cost Effectiveness and Clinical Outcomes of Wound Closure Using V-Loc™ 90 Sutures.||Grigoryants Medical Corporation|No|Active, not recruiting|August 2010|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|32 Years|75 Years|No|||April 2012|April 8, 2012|November 28, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574378||87809|
NCT01574391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMHEPI-12|A Comparison Study Of Two Different Techniques For Identifying The Epidural Space In Parturients In Labour|A COMPARISON STUDY OF TWO DIFFERENT TECHNIQUES FOR IDENTIFYING THE EPIDURAL SPACE IN PARTURIENTS IN LABOUR: A PILOT PROSPECTIVE RANDOMIZED STUDY.||National Maternity Hospital, Ireland|Yes|Completed|March 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 13, 2015|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01574391||87808|
NCT01570608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 06-233-0107|Lucentis KAV Study|Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy (Verteporfin) in Patients With Subfoveal Choroidal Neovascularisation Due to Age-Related Macular Degeneration - a Pilot Study||The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|No|Completed|March 2007|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|50 Years|N/A|No|||April 2012|April 3, 2012|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01570608||88097|
NCT01570855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|246601-1|Chemotherapy Resistance and Sensitivity Testing in Lung Tumors|Chemotherapy Resistance and Sensitivity Testing in Lung Tumors||Marshall University|No|Suspended|October 2011|June 2015|Anticipated|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have a suspected or confirmed diagnosis of lung cancer, and who are scheduled        to have a diagnostic fine needle aspiration, core needle biopsy, or excisional biopsy of        the lung lesion.|June 2015|June 1, 2015|March 19, 2012||No|lung cancer study was rolled into a broader "human subject tissue" study including lung    cancer.|No||https://clinicaltrials.gov/show/NCT01570855||88078|
NCT01571440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Camp Calcium 11-Tate and Lyle|Soluble Corn Fiber and Calcium Utilization in Adolescents|The Effect of Soluble Corn Fiber on Calcium Utilization and Retention and Gut Microflora in Adolescents||Purdue University|No|Completed|February 2010|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|January 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01571440||88034|
NCT01556204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-173|Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a Prospective Randomized Controlled Trial|Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a Prospective Randomized Controlled Trial|LAROSE|The Cleveland Clinic|No|Completed|March 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01556204||89199|
NCT01556698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC001|Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris|||Novan, Inc.||Completed|July 2011|||December 2011|Actual|Phase 1/Phase 2|Interventional|N/A|2||||||Both|12 Years|40 Years|No|||March 2012|March 15, 2012|March 14, 2012||||No||https://clinicaltrials.gov/show/NCT01556698||89162|
NCT01552070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-0362A3|Recruitment on Extravascular Lung Water in Acute Respiratory Distress Syndrome (ARDS)|Impact of Alveolar Recruitment Maneuver on Extravascular Lung Water of Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome.||Chang Gung Memorial Hospital|Yes|Completed|September 2010|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|20 Years|N/A|No|||September 2013|September 13, 2013|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01552070||89515|
NCT01552655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREAC-AUT|Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT|Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT|BREAC-AUT|Odense University Hospital|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|101|||Female|18 Years|N/A|No|||April 2015|April 20, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01552655||89471|
NCT01553253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACTS1|From ACute To Chronic Postoperative Pain in Patients for Elective Cholecystectomy|From Acute To Chronic Postoperative Pain in Patients for Elective Cholecystectomy: The Significance of Components of Pain|FACTS1|Odense University Hospital|No|Completed|April 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples With DNA|Whole Blood|Both|18 Years|N/A|No|Non-Probability Sample|Consecutive Patients for elective cholecystectomy|June 2014|June 16, 2014|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01553253||89425|
NCT01553266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 2010-282|Mobile Diabetes Education Teams in Primary Care|Mobile Diabetes Education Teams in Primary Care||Ryerson University|No|Active, not recruiting|March 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01553266||89424|
NCT01551927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr667-10|Patients Expectations for Future Examination and Treatment|What Are the Expectations for Future Examination and Treatment in Patients Undergoing Evaluation and Treatment of Coronary Heart Disease?|TAPE|Göteborg University|No|Completed|March 2011|February 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|754|Samples Without DNA|Blood samples NtProBNP|Both|18 Years|N/A|No|Probability Sample|Patients planned for elective coronary angiography|February 2014|February 17, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01551927||89526|
NCT01553487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEAH FTR-6|Effects Of Unilateral Forearm Vibration On The Loss Of Muscle And Bone Of Contralateral Forearm|Effects Of Unilateral Forearm Vibration On The Loss Of Muscle Strength And Bone Of The Contralateral Forearm Due to Forearm/Elbow Fracture|Vib-Frx|Bagcilar Training and Research Hospital|No|Withdrawn|September 2013|March 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|50 Years|No|||August 2013|August 13, 2013|March 5, 2012||No|We did not found voluntary subjects|No||https://clinicaltrials.gov/show/NCT01553487||89407|
NCT01549392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRCP02|Imaging Study of Glioblastomas Treated With Avastin|Feasibility Study of Magnetic Resonance Spectroscopy and Dynamic Enhanced Cat Scan Imaging in Glioblastomas Treated With and Without Avastin||London Health Sciences Centre|No|Terminated|February 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|3|||Both|18 Years|90 Years|No|||September 2014|September 11, 2014|February 17, 2012||No|insufficient accrual|No|April 2, 2014|https://clinicaltrials.gov/show/NCT01549392||89718|
NCT01552135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2567B|Pilot Study - Putative Penetration of Nanoparticles in Sunscreen in Intact or Sunburned Skin|Pilot Study - Does Nanoparticles in Sunscreen Penetrate Intact or Sunburned Skin?||Oslo University Hospital|No|Active, not recruiting|January 2012|December 2012|Anticipated|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|2|||Male|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|2 healthy males older than 50 years|May 2012|May 29, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01552135||89510|
NCT01552473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 032011-191|Brain Training to Enhance Frontal Lobe Reasoning|Brain Training to Enhance Frontal Lobe Reasoning in Soldiers and Civilian Adults With TBI||The University of Texas at Dallas|Yes|Recruiting|March 2012|October 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|19 Years|65 Years|No|||January 2013|January 14, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552473||89485|
NCT01552707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCEL-MT-10-02|Safety Study of Mesenchymal Stem Cells and Spinal Fusion|"Ex Vivo" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue for Spinal Fusion in Spine Degenerative Disease||Banc de Sang i Teixits|No|Recruiting|June 2012|June 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|85 Years|No|||November 2015|November 13, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01552707||89467|
NCT01552720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJHEART2012|Clinical Characteristics, Management and Outcomes of Chinese Patients With Acute Aortic Dissection|Clinical Investigation of Chinese Patients With Aortic Dissection|CCMOCPAAD|Xijing Hospital|Yes|Recruiting|January 2011|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|5000|||Both|18 Years|80 Years|No|Probability Sample|Chinese patients suffering acute aortic dissection|March 2012|March 12, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01552720||89466|
NCT01573013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IZ70Z0_123902|Iron Fortification Trail Using NaFeEDTA in Iron Deficient Lead-exposed Children|Interactions of Lead Intoxication and Iron Deficiency in Morocco: The Effects of Iron Fortification With and Without NaEDTA on Lead Burden, Iron Status and Cognition in Children||Swiss Federal Institute of Technology|Yes|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|4||Actual|457|||Both|3 Years|13 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|November 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01573013||87913|
NCT01573026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD-CR 02|Five Year Survival Study Evaluating the Genesis Dental Implant System|Clinical Analysis of a Biomimetic Implant System: Five Year Survival Rates, Marginal Bone-level Changes, and Soft Tissue Aesthetics.|Genesis Dental|Keystone Dental, Inc.|No|Active, not recruiting|August 2011|July 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects between the ages of 18 and 85 who require dental implants|April 2012|April 5, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01573026||87912|
NCT01573325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00060397|HRQoL in the Low MELD Pre-tx Population|Health-Related Quality of Life in the Low Model for End-Stage Liver Disease (MELD) Pre Transplant Patient Candidate: A Pilot Study|LowMELD|Northwestern University|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|N/A||1|Actual|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Adults who are a candidate for a liver transplant at Northwester Memorial Hospital with        MELD score </=15|February 2014|February 27, 2014|April 5, 2012||No||No|December 26, 2012|https://clinicaltrials.gov/show/NCT01573325||87889|The small sample size and convenience sampling were limitations of this study. Additionally, since subjects were recruited from only one site, generalizability of findings is limited.
NCT01573585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00837|Fast Muscle Activation and Stepping Training (FAST) Post-stroke|Effectiveness of Fast Muscle Activation and Stepping Training (FAST) on Balance and Mobility Post-stroke|FAST|University of British Columbia|No|Recruiting|November 2012|June 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|19 Years|N/A|No|||September 2015|September 1, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573585||87870|
NCT01574092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSJD-GLIOMAS-IC|Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas|Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas||Hospital Sant Joan de Deu|No|Completed|November 2009|March 2015|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|6 Months|18 Years|No|||August 2015|August 21, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01574092||87831|
NCT01570335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101010-E|The SBAR Effect on Safety Attitudes in the Perinatal Department|||Far Eastern Memorial Hospital||Completed|April 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|40|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All Physicians and Nurses in the Perinatal Department|March 2013|December 1, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570335||88118|
NCT01570595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3358936|Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV|A Pilot Study of Positively Smoke Free on the Web (PSFW) for HIV-infected Smokers|PSFW|Georgetown University||Completed|September 2011|September 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|138|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01570595||88098|
NCT01571193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002413|Twelve-Month Study of Pomegranate Extract in Normal Aging|Twelve-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract in Normal Aging||POM Wonderful LLC|Yes|Recruiting|November 2011|December 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|212|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 4, 2012|April 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571193||88053|
NCT01571726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120106|Imaging Studies and the Development of Multiple Myeloma|Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||April 2014|November 1, 2014|April 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01571726||88012|
NCT01571739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912036|Determining Risk in Latent Tuberculosis|Risk Stratification in Latent Tuberculosis: PET/CT Findings in TB Contacts||National Institutes of Health Clinical Center (CC)||Terminated|January 2012|May 2014||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1200|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2014|October 23, 2014|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01571739||88011|
NCT01571752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912472|Health Outcomes by Neighborhood Baltimore|Health Outcomes by Neighborhood - HON Study Baltimore||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|||||N/A|Observational|N/A|||Anticipated|1250|||Both|18 Years|75 Years|No|||June 2015|January 20, 2016|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01571752||88010|
NCT01552369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 11-0073|Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients|Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients|CAPSIL|University of Pittsburgh|Yes|Recruiting|October 2012|February 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|80 Years|No|||November 2015|November 30, 2015|March 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01552369||89493|
NCT01557192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001097|Low Field Magnetic Stimulation (LFMS) in Mood Disorders: 6 Treatments|Low Field Magnetic Stimulation in Mood Disorders in Six Visits|LFMS6tx|Mclean Hospital|No|Suspended|May 2010|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|55 Years|No|||October 2012|October 22, 2012|March 14, 2012||No|on hold indefinitely due to lack of funding|No||https://clinicaltrials.gov/show/NCT01557192||89124|
NCT01554020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120216-SUS-NWC-BSS-GP|Blood Sugar Take Care and Glucose Metabolism|Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study||NewChapter, Inc.|No|Withdrawn|June 2012|November 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 11, 2013|March 7, 2012||No|Change of CRO|No||https://clinicaltrials.gov/show/NCT01554020||89367|
NCT01554306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38851.091.11|Measuring the Effects of Continuous Dopaminergic Stimulation on Nocturnal Movements in Parkinson's Disease|Observational Study on the Effecst of Continuous Dopaminergic Stimulation on Nocturnal Hypokinesia in Parkinson's Disease||Sleep Medicine Centre Kempenhaeghe|Yes|Recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Parkinson's disease with nocturnal hypokinesia based on the clinical        interview who are going to start with rotigotine|March 2012|March 12, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01554306||89345|
NCT01554319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB010/02/2011|Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects|Phase-I Study in Healthy Male Subjects to Investigate Safety, Tolerability and Pharmacokinetics of Orally Inhaled Multiple Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation||Sterna Biologicals GmbH & Co. KG|Yes|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01554319||89344|
NCT01553721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA8159_PAH_II|Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)|A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)||Dong-A ST Co., Ltd.|Yes|Completed|August 2011|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|January 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01553721||89389|
NCT01553734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-130-11|Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia?|Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia?||HaEmek Medical Center, Israel|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized with severe community aquired pneumonia treated with azithromycin|June 2015|June 14, 2015|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01553734||89388|
NCT01552746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FACTS2|From ACute To Chronic Postoperative Shoulder Pain in Patients for Elective Lobectomy|From Acute to Chronic Postoperative Shoulder Pain in Patients for Elective Lobectomy|FACTS2|Odense University Hospital|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients, scheduled for elective lobectomy of the lung at Odense University        Hospital|June 2014|June 16, 2014|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01552746||89464|
NCT01552733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12MT023|Robotic Therapy Early After Stroke Events|Robotic Therapy Early After Stroke Events|R-TEASE|NHS Greater Glasgow and Clyde|No|Not yet recruiting|March 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||March 2012|March 19, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552733||89465|
NCT01573598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-02|Safety and Efficacy of Vilazodone in Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder||Forest Laboratories|No|Completed|April 2012|January 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1219|||Both|18 Years|70 Years|No|||May 2015|May 15, 2015|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573598||87869|
NCT01573845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HD065888-01|The GREEN Project Lunch Box Study|The GREEN (Growing Right: Eating Eco-Friendly & Nutritious) Project Lunch Box Study||Tufts University|No|Completed|September 2011|July 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|979|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2015|March 23, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01573845||87850|
NCT01574105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-37|Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients|Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients||University of Saskatchewan|No|Completed|May 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|66|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|On the date of surgery, the patient would be brought to the operating room. The first        blood sample would be drawn prior to heparinization. This would include analysis for        Activated Clotting Time, Heparin Concentration/Heparin Dose Response, antithrombin and        Thrombelastograph. During this first sampling interval, the patient's Heparin Sensitivity        or Resistance is determined by Heparin Dose Response (slope). The following values would        determine which one of the two study groups the patient would be assigned:          -  Sensitive to heparin: at or above 90 seconds/unit/millilitre          -  Resistant to heparin: below 89 seconds/unit/millilitre|July 2014|July 3, 2014|March 6, 2012||No||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01574105||87830|
NCT01571453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13926A|Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries|Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries||H. Lundbeck A/S|No|Completed|May 2012|||October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|65 Years|No|||October 2014|October 6, 2014|March 28, 2012||No||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01571453||88033|
NCT01571466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RisVac 03|A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART|A Double-blind Phase I Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART|2009-016578-34|Hospital Clinic of Barcelona|Yes|Completed|September 2011|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01571466||88032|
NCT01571206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 1.3|An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1|An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1||Celltrion|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|174|||Both|18 Years|75 Years|No|||July 2013|July 30, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01571206||88052|
NCT01571778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00051378|Hand Hygiene Before Non-sterile Glove Use|The Utility of Hand Hygiene Before Non-sterile Glove Use||University of Maryland||Completed|April 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|230|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01571778||88008|
NCT01571479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-026|The Feasibility and Safety of a Three-Port Laparoscopic Cholecystectomy Using a 2-mm Mini-Instrument|The Feasibility and Safety of a Three-Port Laparoscopic Cholecystectomy Using a 2-mm Mini-Instrument||Inje University|No|Completed|April 2010|March 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|133|||Both|N/A|N/A|No|||April 2012|April 3, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01571479||88031|
NCT01571765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIDA S-065346|MNCH Programming in Southwest Uganda Maternal and Child Health In Bushenyi and Rubirizi Districts, UGANDA|Scaling Up Maternal and Child Health In Bushenyi and Rubirizi Districts, UGANDA|HCUM|University of Calgary|Yes|Completed|April 2012|March 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|10985|||Both|15 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 4, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01571765||88009|
NCT01556464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00676|Initiation of Auto-adjusting CPAP for Newly Diagnosed OSA in Hospitalized Patients|Initiation of Auto-adjusting Continuous Positive Airway Pressure (CPAP) for Management of Newly Diagnosed Obstructive Sleep Apnea (OSA) in Hospitalized Patients: A Pilot Study||MetroHealth Medical Center|No|Terminated|February 2012|January 2013|Actual|January 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|65 Years|No|||November 2014|November 20, 2014|March 12, 2012|Yes|Yes|Difficulty with enrollment. Study stopped after first 5 patients.|No||https://clinicaltrials.gov/show/NCT01556464||89180|
NCT01556711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-AHEAD II Trial|Assessment of Head Injury in the Emergency Department Using BrainScope® Ahead® Technology|Assessment of Head Injury in the Emergency Department: Clinical Validation of the BrainScope® Ahead™ Technology|B-AHEAD II|BrainScope Company, Inc.|No|Completed|August 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|816|||Both|18 Years|80 Years|No|Probability Sample|Patients who enter the ED at hospitals that are participating as clinical sites for this        study|December 2013|December 7, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01556711||89161|
NCT01556932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14141|Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea|A Randomized Trial of the Effectiveness of Topical "ABH Gel" (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) Versus Placebo in Patients With Nausea||Virginia Commonwealth University|Yes|Completed|March 2012|May 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|22|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|March 13, 2012|Yes|Yes||No|March 3, 2015|https://clinicaltrials.gov/show/NCT01556932||89144|
NCT01557205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202019RIC|Research and System Development on Functional 3D Optical Tomography for Skin Cell Imaging|Research and System Development on Functional 3D Optical Tomography for Skin Cell Imaging||National Taiwan University Hospital|No|Not yet recruiting|March 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|30|None Retained|No biospecimen to be retained.|Both|20 Years|N/A|No|Non-Probability Sample|Aged between 20 to 100. People who received benign skin tumor removal in dermatological        surgical unit. OR people who received skin grafts (full thickness or split thickness) for        reconstruction of surgical wounds after removing malignant skin cancer.|March 2012|March 16, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557205||89123|
NCT01557218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChildFood101|Increasing the Variety of Vegetables and Fruits Served to Preschool Children at a Snack|||Penn State University|No|Completed|January 2011|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|8||Actual|61|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01557218||89122|
NCT01551043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 01410|Allo CART-19 Protocol|Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|September 2010|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|10|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|March 8, 2012|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01551043||89594|
NCT01551056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-100-0012|A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)|||Aciex Therapeutics, Inc.|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|10 Years|N/A|No|||April 2015|April 30, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551056||89593|
NCT01551355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-0702|Promoting Heart Health in Preschool Children|Evaluation of an Intervention to Promote Healthy Heart Habits in Pre-School Children||Icahn School of Medicine at Mount Sinai|No|Completed|July 2009|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|1216|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||March 2012|March 7, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01551355||89570|
NCT01551641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZEY-THA-001|Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer|A Phase II Clinical Trial on VEGF Expression Interfered by Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer||Changzhou No.2 People's Hospital|Yes|Recruiting|January 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|180|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 14, 2016|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01551641||89548|
NCT01551654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.546-T|Electrical Stimulation Over Acupuncture Points in Reduction of Rectal Discomfort Distension|Non-invasive Acu-point Stimulation (Acu-TENS) in Reduction of Discomfort Associated With Barostat-induced Rectal Distension - a Randomized Controlled Study||Chinese University of Hong Kong|No|Completed|September 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 19, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01551654||89547|
NCT01551628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT-100-003|A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma|A Pilot Study of the Safety and Preliminary Efficacy of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma||Bio-Cancer Treatment International Limited|Yes|Terminated|April 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|1 Year|17 Years|No|||March 2014|March 13, 2014|February 29, 2012||No|slow patient recruitment|No||https://clinicaltrials.gov/show/NCT01551628||89549|
NCT01554332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-13|Motor Cortex Stimulation for Chronic Neuropathic Pain|A Clinical Evaluation for the Management of Patients With Chronic Neuropathic Pain With Cortical Stimulation||St. Jude Medical|No|Recruiting|October 2012|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|21 Years|70 Years|No|||November 2015|November 17, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01554332||89343|
NCT01551914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0148|Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy|Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy|FOThyr|Nantes University Hospital||Active, not recruiting|March 2012|March 2015|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1350|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01551914||89527|
NCT01548703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCI-632-CL-003|A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of BCI 838 in Healthy Adult Subjects||BrainCells Inc.|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 7, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01548703||89771|
NCT01548690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALFSG-OCR-002|Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure|A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure|STOP-ALF|University of Texas Southwestern Medical Center|Yes|Recruiting|June 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|February 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01548690||89772|
NCT01573611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11002966|Impact of Grape Consumption on Brain Metabolism and Cognitive Function|Examining the Impact of Grape Consumption on Brain Metabolism and Cognitive Function in Patients With Mild Cognitive Impairment||University of California, Los Angeles|Yes|Completed|April 2012|November 2014|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|12|||Both|65 Years|N/A|No|||December 2014|December 2, 2014|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573611||87868|
NCT01573858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOSAct|Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome|Effect of Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial (PCOSAct)|PCOSAct|Heilongjiang University of Chinese Medicine|Yes|Recruiting|April 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|1000|||Female|20 Years|40 Years|No|||February 2013|February 1, 2013|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573858||87849|
NCT01573871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK94|Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula|Tolerance and Compliance of Infants Fed an Extensively Hydrolyzed Infant Formula||Abbott Nutrition|Yes|Completed|February 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|180 Days|No|||February 2013|February 14, 2013|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01573871||87848|
NCT01574404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0911010734|Polar Body Biopsy for Preimplantation Genetic Screening|Polar Body Biopsy (PB) for Preimplantation Genetic Screening|Polar Body|Weill Medical College of Cornell University|No|Completed|September 2011|December 2014|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01574404||87807|
NCT01570322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REIMS-PHRCNAT2009-N11-01|Determinants of Quality of Life Related to Health in Alzheimer Disease|||CHU de Reims|No|Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|75 Years|N/A|No|Non-Probability Sample|-  Patients with Alzheimer disease (DSM IV - Diagnostic and Statistical Manual of Mental             Disorders - and NINCDS/ADRDA - National Institute of Neurological and Communicative             Disorders and Stroke/Alzheimer's Disease and Related Disorders Association)          -  Patients with MMSE (Mini Mental State Examination) > or = 10|April 2012|April 4, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570322||88119|
NCT01570881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Okamasui3130|Association of Plasma Melatonin Levels With Delirium|Association of Plasma Melatonin Levels With Delirium After Sevoflurane Anesthesia||Okayama University|No|Completed|April 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|20 Years|N/A|No|Non-Probability Sample|Okayama University Hospital with 22 beds in ICU.|April 2012|April 3, 2012|March 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01570881||88076|
NCT01572038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28047|A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)|A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer||Hoffmann-La Roche||Active, not recruiting|June 2012|September 2019|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1432|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01572038||87988|
NCT01550302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42272-D|Superficial Cervical Plexus Block for Shoulder Pain After Lung Surgery|The Effect of Superficial Cervical Plexus Block on Post-Thoracotomy/Scopy Ipsilateral Shoulder Pain|SCPB|University of Washington|Yes|Terminated|October 2013|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|75 Years|No|||November 2015|November 30, 2015|March 1, 2012||No|Unable to continue enrollment due to lack of resources (research coordinator no longer    available).|No||https://clinicaltrials.gov/show/NCT01550302||89649|
NCT01550510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11D.459|Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA|Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer||Thomas Jefferson University|Yes|Terminated|December 2011|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|February 23, 2012|Yes|Yes|Study closed due to low enrollment. There are many other treatment options available for    patients with colorectal cancer.|No||https://clinicaltrials.gov/show/NCT01550510||89633|
NCT01550497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092011-073|Spinal Stabilization Exercises for Low Back Pain in Adolescents With Idiopathic Scoliosis|Effectiveness of Spinal Stabilization Exercises for Low Back Pain in Adolescents With Idiopathic Scoliosis|LBPAIS|Texas Scottish Rite Hospital for Children|Yes|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|10 Years|17 Years|No|||December 2013|December 17, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01550497||89634|
NCT01556945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR #849|Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S|Phase I/IIa Safety, Immunogenicity, and Preliminary Efficacy of an Administration Schedule of FMP1 and SmithKlineBeecham Biologicals' Candidate Malaria Vaccine RTS,S Each Adjuvanted With SBAS2, Given Concomitantly in Separate Injections|MAL019|U.S. Army Medical Research and Materiel Command|No|Completed|April 2001|||February 2002|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|72|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2014|May 1, 2014|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01556945||89143|
NCT01551069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12368|Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion|A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion||Sanofi|No|Completed|March 2012|April 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||May 2014|May 12, 2014|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551069||89592|
NCT01551667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2011/JPL-02|Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds|Observational and Comparative Study on the Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds (Localized Infections Versus Bacteremia)|ORISA|Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|November 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|76|Samples Without DNA|Left over blood/serum/plasma specimens will be incorporated into the biobank at the      Bacteriology Laboratory of the Nîmes University Hospital|Both|18 Years|N/A|No|Non-Probability Sample|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases        of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle        ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed).        This infection must involve S. aureus in a mono-or polymicrobial setting.|November 2015|November 27, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01551667||89546|
NCT01551953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000412|BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)|BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease|BEAM COPD|Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|February 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|100|||Both|40 Years|N/A|No|||January 2016|January 15, 2016|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01551953||89524|
NCT01552187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86/19/11|COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial)|COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial).|COPPS-2|Maria Vittoria Hospital|Yes|Active, not recruiting|March 2012|July 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|360|||Both|18 Years|90 Years|No|||June 2014|June 29, 2014|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552187||89506|
NCT01552148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5504/2012LD|Transversus Abdominis Plane Block for Laparoscopic Hysterectomy|Randomized, Controlled, Observer-blinded Study on the Efficacy of TAP Block With 0.375% Levobupivacaine in Terms of PCA Morphine Postoperative Consumption in Patients Undergoing Laparoscopic Hysterectomy||Istituti Ospitalieri di Cremona||Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|52|||Female|18 Years|70 Years|No|||February 2014|February 14, 2014|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552148||89509|
NCT01552447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFVLU001|Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers|A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers.||MiMedx Group, Inc.|No|Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|98|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552447||89487|
NCT01552460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000375|Brain Genomics Superstruct Project|Brain Genomics Superstruct Project||Massachusetts General Hospital|No|Completed|April 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|61|Samples With DNA|Saliva|Both|13 Years|N/A|No|Non-Probability Sample|Adults with Autism Spectrum Disorders ages 13 and older.|April 2015|April 2, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01552460||89486|
NCT01552772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-11-289|Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole|An Open-label, Safety and Tolerability Trial of Aripiprazole IM Depot Treatment Initiation in Adult Subjects With Schizophrenia Stabilized on Atypical Oral Antipsychotics Other Than Aripiprazole||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|64 Years|No|||October 2014|October 8, 2014|February 13, 2012|Yes|Yes||No|September 2, 2014|https://clinicaltrials.gov/show/NCT01552772||89462|
NCT01552785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF010312|A Comparison of Measurements of Peripheral Tissue Oxygenation by NONIN EQUANOX 7600, INVOS 5100c, and FORE-SIGHT|||Rigshospitalet, Denmark|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Citizens of Copenhagen|June 2012|June 21, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552785||89461|
NCT01552798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15771|Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache|A Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single Dose of Fast Release Aspirin 1000 mg and Acetaminophen 1000 mg in Tension Type Headache Pain|Tarot Headache|Bayer|No|Terminated|March 2012|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|9|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|March 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01552798||89460|
NCT01549015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD09|Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function|Open, Prospective, Diagnostic, Multicentre Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD), and Carriers of UCD Mutations, to Evaluate in Vivo Ureagenesis Measured After a Single Application of Sodium [1,2-13C]-Acetate||Cytonet GmbH & Co. KG|No|Completed|January 2012|March 2013|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|37|||Both|N/A|65 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01549015||89747|
NCT01573884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK97|Ex Vivo Exploratory Analysis in Healthy Full-term Infants|Ex Vivo Exploratory Analysis in Healthy Full-term Infants||Abbott Nutrition|No|Completed|September 2011|February 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|54|||Both|N/A|17 Days|Accepts Healthy Volunteers|Non-Probability Sample|infant and mother pairs|April 2012|April 6, 2012|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01573884||87847|
NCT01574118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02-0100|Enhancing Exposure Therapy for Post-traumatic Stress Disorder|Enhancing Exposure Therapy for PTSD: An Investigation of Non-Pharmacological Augmentation Strategies||University of Texas at Austin|No|Recruiting|April 2012|March 2018|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01574118||87829|
NCT01571180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s53782|Influence of Obesity and Gastric Bypass on Medication Absorption|Influence of Obesity and Gastric Bypass on Medication Absorption: Prospective Follow-up of Patients|INOGMA|Katholieke Universiteit Leuven|Yes|Recruiting|April 2012|September 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients who have scheduled a gastric bypass|February 2016|February 2, 2016|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01571180||88054|
NCT01570894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUET-T25-PVFD-2|Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|July 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570894||88075|
NCT01570907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUET-T25-PVFS-2|Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|June 2007|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570907||88074|
NCT01571492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09010511|Continuous L2 Paravertebral Block Versus Continuous Lumbar Plexus Block for Postoperative Analgesia|Continuous L2 Paravertebral Block Versus Continuous Lumbar Plexus Block for Postoperative Analgesia After Total Hip Arthroplasty||University of Pittsburgh|No|Active, not recruiting|June 2009|June 2013|Anticipated|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||June 2012|June 12, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01571492||88030|
NCT01571505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLIO ROTA-02|Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)|Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA||International Vaccine Institute|No|Active, not recruiting|March 2012|September 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|372|||Both|42 Days|49 Days|Accepts Healthy Volunteers|||May 2015|May 1, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01571505||88029|
NCT01571791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/41|Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery|A Randomized Study of the Effects of Perioperative i.v. Ketorolac-lidocaine on the Hemodynamic Response in the Patients With Valvular Heart Diseases During Cesarean Delivery||Mansoura University|Yes|Recruiting|June 2012|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Female|18 Years|45 Years|No|||March 2015|March 15, 2015|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01571791||88007|
NCT01550536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD GCRC 1910/6766|Physical Activity and Basal Metabolic Rate in Postmenopausal Women|Aging and Basal Metabolic Rate in Postmenopausal Women: Effects of Long-Term and Short-Term Physical Activity||University of California, San Diego|No|Completed|January 2008|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|49|||Female|40 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 9, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01550536||89631|
NCT01550523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWA-11G.532|Pilot Immunotherapy Trial for Recurrent Malignant Gliomas|Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurrent Malignant Glioma||Thomas Jefferson University|Yes|Completed|January 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||December 2013|December 2, 2013|February 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550523||89632|
NCT01550770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10-0005|Exploratory Study of Propofol and Fentanyl Pharmacodynamics|An Open Label, Exploratory Study of Propofol and Fentanyl Pharmacodynamics||Ethicon Endo-Surgery||Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 20, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01550770||89614|
NCT01551368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0175-A|Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients|Using Nimodipine, a Calcium Channel Blocker, to Prevent the LH Surge and Ovulation in Women Undergoing Assisted Reproduction|nimodipine|Mount Sinai Hospital, Canada|No|Active, not recruiting|December 2012|July 2015|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|25 Years|40 Years|No|||April 2015|April 7, 2015|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01551368||89569|
NCT01551394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001515-31|Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis|Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Clinical or Confirmed Late-onset Sepsis : a European Multicenter Randomised Phase III Trial|NeoMero-1|PENTA Foundation|Yes|Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|272|||Both|N/A|90 Days|No|||February 2015|February 12, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01551394||89567|
NCT01551680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPIBE|A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases|A Phase I Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib (BSI-201) in Multiple Non Operable Brain Metastases|RAPIBE|Institut du Cancer de Montpellier - Val d'Aurelle|Yes|Terminated|September 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|February 10, 2012||No|end of study of this product|No||https://clinicaltrials.gov/show/NCT01551680||89545|
NCT01551940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.607/11|Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea|Evaluation of Efficacy of Botulinum Toxin Type A in the Treatment of Sialorrhea in the Patient Affected by Amyotrophic Lateral Sclerosis (ALS)|ALS-TOX|Hospices Civils de Lyon|Yes|Completed|February 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01551940||89525|
NCT01552161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN402374938|Prevalence of Allergic Diseases and Atopy in Subjects With Coronary Artery Disease|Prevalence of Allergic Diseases and Atopy in Patients With Angiographically Confirmed Coronary Artery Disease||Medical Universtity of Lodz|No|Completed|April 2010|June 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|Samples With DNA|Blood samples for total IgE, specific IgE and markers of inflammation.|Both|30 Years|N/A|No|Probability Sample|Patients who underwent coronary angiography are eligible for the study.|January 2014|January 26, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552161||89508|
NCT01552174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEIBUM survey|Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice||MEIBUM|Laboratoires Thea|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|185|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be eligible for inclusion if all these criteria are respected:          -  Outpatients of either sex, aged at least 18 years, seen in general ophthalmological             consultation          -  Patients informed of the objectives of the survey and agreeing to participate.          -  Patient attending to the ophthalmological consultation for any reasons: regular             check-up of chronic disease, acute symptoms, or for surgery preparation or follow up.|August 2015|August 31, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552174||89507|
NCT01552811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS Dnr2011/439|Studies of Pancreatic Islet Mass by Positron Emission Tomography (PET)|Open Study to Investigate Pancreatic Islet Mass by Positron Emission Tomography Using the Tracer [11C]5-hydroxytryptophane||Uppsala University Hospital||Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Adult, type 1 diabetic patients Healthy controls|February 2014|February 4, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552811||89459|
NCT01549054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E5501-G000-012|A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501|A Single-center, Randomized, Open-label, Two-part Study to Evaluate Bioavailability of Prototype Third-generation Formulations of E5501 Relative to Second-generation Tablet Formulation in Healthy Subjects||Eisai Inc.|No|Completed|January 2012|August 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|28|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01549054||89744|
NCT01548716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11318|A Study of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients|A Cross-sectional Analysis of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients||Winthrop University Hospital|No|Completed|September 2011|February 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|85 Years|No|Non-Probability Sample|ESRD patients on hemodialysis|March 2012|March 5, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01548716||89770|
NCT01548729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4790|Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis|Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis : a Pilot Study|PIM|University Hospital, Strasbourg, France|Yes|Recruiting|March 2012|March 2018|Anticipated|March 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||March 2016|March 16, 2016|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01548729||89769|
NCT01570348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2551.00|Crohn's Allogeneic Transplant Study|Allogeneic Hematopoietic Cell Transplantation for Patients With Treatment-Refractory Crohn's Disease: A Phase 2 Study|CATS|Fred Hutchinson Cancer Research Center|Yes|Suspended|July 2012|||July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|60 Years|No|||December 2015|December 29, 2015|April 2, 2012|No|Yes|Temporarily closed to enrollment|No||https://clinicaltrials.gov/show/NCT01570348||88117|
NCT01570361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATTEST|Atrial Fibrillation Progression Trial|Atrial Fibrillation Progression Trial|ATTEST|Biosense Webster, Inc.|No|Recruiting|February 2012|June 2018|Anticipated|June 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|60 Years|N/A|No|||November 2015|November 12, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570361||88116|
NCT01570621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DrumTower206-01|Personalized Peroral Endoscopic Myotomy for Achalasia|Personalized Peroral Endoscopic Myotomy for Achalasia|POEM|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Active, not recruiting|March 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||April 2012|April 3, 2012|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01570621||88096|
NCT01570868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0074|Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)|Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase||M.D. Anderson Cancer Center|No|Active, not recruiting|April 2012|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|April 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570868||88077|
NCT01570634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAL-2011-01PCL-01|Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection|Proof-of-Concept, CASAD for Treatment of Clostridium Difficile Infection||Salient Pharmaceuticals Incorporated|Yes|Terminated|March 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2013|February 3, 2013|April 1, 2012|Yes|Yes|Study was stopped for slow enrollment - only 2 patients, no evaluable results|No|December 29, 2012|https://clinicaltrials.gov/show/NCT01570634||88095|This study was terminated early for slow enrollment. Only 2 patients were enrolled during the open period. One of the two took less than 50% of the prescribed study drug. The results are not meaningful.
NCT01562769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01360-41|Interest of Contact Precautions for Preventing Micro-organisms Acquisition in Patients Hospitalized in Infectious Disease Unit of University-affiliated Hospital in Rennes|Interest of Contact Precautions for Preventing Micro-organisms Acquisition in Patients Hospitalized in Infectious Disease Unit of University-affiliated Hospital in Rennes|ISOL/STAND|Rennes University Hospital||Terminated|March 2012|June 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients hospitalized in Infectious Disease Unit of university-affiliated hospital in        Rennes|May 2015|August 20, 2015|March 22, 2012||No|enrollment difficulties|No||https://clinicaltrials.gov/show/NCT01562769||88697|
NCT01563003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AASD-2012|Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism|Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism||University of South Florida|No|Completed|June 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|11 Years|16 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|March 22, 2012||No||No|April 1, 2015|https://clinicaltrials.gov/show/NCT01563003||88679|
NCT01563250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMR-001|Improving the Management of Acute Coronary Syndromes in the Emergency Department|Improving the Management of Acute Coronary Syndromes in the Emergency Department Using a Rapid Acute Cardiac Evaluation Pathway|RACE|Integrated Medical Research LLC|No|Completed|June 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|705|||Both|35 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 3, 2013|June 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01563250||88660|
NCT01563848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAF-712|Cryoablation in Patients With Atrial Flutter|Cryoablation in Patients With Atrial Flutter|CIAFL|Meshalkin Research Institute of Pathology of Circulation|Yes|Recruiting|September 2011|September 2015|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563848||88616|
NCT01550328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2721|Bias Source of Signal in SCOUT DS|Bias Source of Signal in SCOUT DS|BSOS|VeraLight, Inc.|No|Terminated|April 2012|January 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects must be 18 years of age or greater.|January 2013|January 14, 2013|March 1, 2012|No|Yes|Protocol no longer meets sponsor objectives|No||https://clinicaltrials.gov/show/NCT01550328||89647|
NCT01550822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114|HEALS (Healthy Eating And Lifestyle After Stroke)|HEALS (Healthy Eating And Lifestyle After Stroke): A Pilot Trial of a Multidisciplinary Lifestyle Intervention Program||Los Amigos Research and Education Institute|No|Enrolling by invitation|April 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01550822||89610|
NCT01550835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV-10322|Impact of Aspiration Thrombectomy During Carotid Stenting|Impact of Aspiration Thrombectomy During Carotid Stenting on New Ischemic Lesions Identified by Diffusion-Weighted Magnetic Resonance Imaging||Fogarty Clinical Research Inc.|No|Recruiting|February 2012|||February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|N/A|No|||April 2015|April 17, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01550835||89609|
NCT01550783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7489|Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening|Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS||University of Washington|Yes|Active, not recruiting|March 2012|||May 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|2000|||Female|21 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 28, 2016|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01550783||89613|
NCT01550796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110105|Treatment of Chronic Bothersome Tinnitus Using Cognitive Training and D-cycloserine|Treatment of Chronic Bothersome Tinnitus Using Cognitive Training and D-cycloserine||Washington University School of Medicine|No|Completed|January 2012|June 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|37|||Both|35 Years|65 Years|No|||May 2013|May 21, 2013|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01550796||89612|
NCT01550809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP7-PEOPLE-2009-IEF #252085|New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy|New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy: Feasibility of Insulin Dosing Based on Information From Continuous Glucose Monitoring||Fundación para la Investigación del Hospital Clínico de Valencia|No|Completed|February 2010|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|60 Years|No|||August 2012|August 20, 2012|February 28, 2012||No||No|June 5, 2012|https://clinicaltrials.gov/show/NCT01550809||89611|
NCT01551381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV077/C005|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects|Double-blind, Controlled Study in Healthy and Type 2 Diabetic Subjects to Assess Safety, Tolerability and Pharmacokinetics of 28 Days EV-077 Treatment, and the Effects on Platelet Function, Vascular Inflammation and Oxidative Stress.||Evolva SA|Yes|Terminated|January 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|No|||June 2013|June 14, 2013|March 8, 2012|Yes|Yes|Interim review indicated that the dose selected was too high for diabetics|No||https://clinicaltrials.gov/show/NCT01551381||89568|
NCT01551121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11 004|Assessment of an Automated Telesurveillance System on the Incidence of Serious Falls in Nursing Homes|Assessment of an Automated Telesurveillance System on the Incidence of Serious Falls in Nursing Homes|TELEHPAD|University Hospital, Limoges|No|Recruiting|March 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|216|||Both|75 Years|N/A|No|Probability Sample|old subject|March 2012|October 31, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01551121||89588|
NCT01551719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52/11|Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation|Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation||Federico II University|No|Withdrawn|March 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 28, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01551719||89542|
NCT01552005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-148|Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France|Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France|DIAPAZON|AstraZeneca|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|The study will be proposed by GPs and diabetologists in France to ambulatory patients|September 2015|September 23, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552005||89520|
NCT01552200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G-Eye 15501|Performance Evaluation of the NaviAid™ G-Eye System|Performance Evaluation of the NaviAid™ G-Eye System||Smart Medical Systems Ltd.|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|126|||Both|40 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 6, 2014|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552200||89505|
NCT01552213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23445|Early Screening and Treatment of Women With Prediabetes in Pregnancy|A Randomized Controlled Trial of Early Screening and Treatment of Women With Prediabetes in Pregnancy||Stanford University|No|Active, not recruiting|March 2012|September 2015|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|55 Years|No|||March 2015|March 30, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552213||89504|
NCT01552486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21AT006773-01A1|Chiropractic Spinal Manipulative Therapy for Acute Sciatica Secondary to Lumbar Disc Herniation|Biology and Clinical Outcomes of Chiropractic Spinal Manipulative Therapy in the Treatment of Patients With Acute Inflammatory Radiculopathy Secondary to Lumbar Disc Herniation: a Pilot Study||Vancouver General Hospital|Yes|Not yet recruiting|June 2012|September 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|30|||Both|19 Years|60 Years|No|||February 2012|March 8, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01552486||89484|
NCT01552499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFDFU001|Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Parallel Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers||MiMedx Group, Inc.||Completed|March 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|25|||Both|18 Years|N/A||||August 2015|August 13, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552499||89483|
NCT01549899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-10-1-0828|Comparing Internet and In-Person Brief Cognitive Behavioral Therapy of Insomnia|Comparing Internet and In-Person Brief Cognitive Behavioral Therapy of Insomnia||University of North Texas, Denton, TX|Yes|Active, not recruiting|March 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|189|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 24, 2015|February 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01549899||89680|
NCT01548742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLE-012-11S|Meditation Interventions for Treatment of PTSD in Veterans|Meditation Interventions for Treatment of PTSD in Veterans|VMP|VA Office of Research and Development|Yes|Completed|March 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|March 5, 2012||No||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01548742||89768|Initial analyses did not account for clustering effects. However, when we re-analyzed data using a multilevel model including a random effect for therapy group, we found that the results were essentially unchanged.
NCT01570374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oroshjalpen|Internet-based Treatment of Generalized Anxiety Disorder|Internet-based Treatment of Generalized Anxiety Disorder||Umeå University|No|Recruiting|January 2012|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||March 2012|April 3, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01570374||88115|
NCT01570387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31082|A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis|A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis||Boston Medical Center|Yes|Active, not recruiting|June 2012|February 2030|Anticipated|October 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|February 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570387||88114|
NCT01570647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44AT004379|Automated Connective Tissue Torque Sensor|Automated Connective Tissue Torque Sensor|StromaTorque|Stromatec, Inc.|Yes|Completed|February 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||5|Actual|165|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|community sample|October 2013|October 8, 2013|April 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01570647||88094|
NCT01570660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|026/2002|Phielix et al.: Hepatic Fat Content and Adipokines|Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients||German Diabetes Center|No|Completed|February 2002|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570660||88093|
NCT01563263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC43-202|Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43|A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients||Valneva Austria GmbH|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|August 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|80 Years|No|||September 2015|September 25, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01563263||88659|
NCT01563562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1002|Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function|A Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function||Reata Pharmaceuticals, Inc.||Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2012|April 9, 2013|March 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01563562||88637|
NCT01563536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-386|Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects|An Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects||AbbVie|No|Completed|February 2012|June 2013|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|70 Years|No|||December 2014|December 29, 2014|January 27, 2012|Yes|Yes||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01563536||88638|
NCT01564134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDCWJ201102|Dose of Hepatitis B Vaccines in Non/Low-response Populations|Effect of Dose of Hepatitis B Vaccines in Non/Low-response Populations||Centers for Disease Control and Prevention, China|Yes|Completed|August 2011|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|537|||Both|1 Year|65 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564134||88594|
NCT01550874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 12-035|STEP: Enhanced Physical Activity in Children and Youth With Epilepsy|STEP: Enhanced Physical Activity in Children and Youth With Epilepsy: Developing Evidence of Impacts on Health, Functioning, Psychological Wellbeing, and Quality of Life|STEP|McMaster University|No|Recruiting|April 2012|March 2018|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|200|||Both|8 Years|14 Years|No|||September 2015|September 22, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01550874||89606|
NCT01550848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2011-07|A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer|A Phase II Study of Abraxane Combined With Gemcitabine in the Patients With Metastatic Breast Cancer||Fudan University|No|Completed|January 2012|June 2015|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Female|18 Years|70 Years|No|||September 2015|September 8, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01550848||89608|
NCT01551082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM Chest tube study|Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes|Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes||Alliance of Cardiothoracic and Vascular Surgeons|Yes|Enrolling by invitation|March 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients undergoing thoracic resection by one surgeon with post operative air leak being        discharged home with chest tube and portable drainage device.|March 2012|March 9, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551082||89591|
NCT01551095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00048369|Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J)|Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J): A Pilot Study||Johns Hopkins University|Yes|Terminated|January 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|7|||Both|18 Years|90 Years|No|||June 2013|June 28, 2013|February 29, 2012||No|Proof of principle was achieved after inclusion of 7 patients|No||https://clinicaltrials.gov/show/NCT01551095||89590|
NCT01551134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-03082|Is Laparoscopic Fundoplication Better Than Open Fundoplication in Children ?|IS Laparoscopic Fundoplication Superior to Open Fundoplication in Children - a Randomized Study||Oslo University Hospital|No|Terminated|January 2003|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|N/A|15 Years|No|||March 2012|March 9, 2012|March 8, 2012||No|Fewer patients than anticipated were referred|No||https://clinicaltrials.gov/show/NCT01551134||89587|
NCT01551706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11OAHE|Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status|A Randomized, Double-blind, Placebo-controlled, Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status||Ethical Naturals, Inc.|Yes|Completed|February 2012|June 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|26|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01551706||89543|
NCT01552265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIAD1109|Shanghai Mild Cognitive Impairment Cohort Study|Shanghai Cohort Study on Mild Cognitive Impairment for Early Detection of Alzheimer's Disease||Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Active, not recruiting|February 2012|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|N/A|90 Years|No|Probability Sample|Subjects|September 2015|September 17, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01552265||89500|
NCT01552564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1625|The Microcirculation in Acute Myocardial Infarction (Micro-AMI)|The Microcirculation in Acute Myocardial Infarction (Micro-AMI)|Micro-AMI|University of Bristol|Yes|Completed|March 2012|||January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|STEMI attending Bristol Heart Institute via the primary PCI service|October 2014|October 27, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552564||89478|
NCT01551966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.644/48|Esophageal Capsule Endoscopy in Children|Evaluation of Wireless Capsule Endoscopy for the Detection and the Control of the Esophageal Varices in Children|PREVOCAP|Hospices Civils de Lyon|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|100|||Both|7 Years|18 Years|No|||July 2013|July 26, 2013|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551966||89523|
NCT01551979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000373|Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia|Therapeutic Efficacy of Cerebellar Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia||Beth Israel Deaconess Medical Center|No|Active, not recruiting|February 2012|||November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|November 12, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551979||89522|
NCT01552512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSM-001|Nutributter Programming to Prevent Undernutrition: an Evaluation|Randomized Control Trial of Complementary Food to Prevent Undernutrition Among At-Risk Infants in Fort San Michel, Haiti|NPPU|Washington University School of Medicine|Yes|Active, not recruiting|June 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|612|||Both|6 Months|12 Months|No|||March 2012|March 8, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01552512||89482|
NCT01552759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-163|Appetite Hormones in Binge Eating Disorder|Appetite Hormones in Binge Eating Disorder||New York Obesity and Nutrition Research Center|Yes|Completed|May 2007|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 8, 2013|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552759||89463|
NCT01549912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54314|Results of Rotator Cuff Repair|Results of Rotator Cuff Repair Following Acute Shoulder Dislocation||University of Utah|No|Completed|February 2012|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|2|||Both|35 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study population will include patients age 35 years and older who have sustained an acute        rotator cuff tear following shoulder dislocation who underwent a rotator cuff repair        either by open or arthroscopic techniques between January 1, 2001 and June 1, 2011.|August 2015|August 5, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549912||89679|
NCT01549301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FILBLA1211I|Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Indústria e Comércio Ltda. Compared to Granulokine Produced by Produtos Roche Químicos e Farmacêuticos S/A.|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|August 2012|November 2012|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|128|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549301||89725|
NCT01549561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEEP2020172|Preventing Behavior and Health Problems in Foster Teens|Preventing Behavior and Health Problems in Foster Teens|KEEP2|Oregon Social Learning Center|No|Completed|November 2006|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|259|||Both|12 Years|16 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549561||89705|
NCT01574417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-005|Plant Stanols and Gene Expression Profile|The Effects of Plant Stanol Esters on Intestinal Mucosal Gene Expression Profiles and Microbiota Composition in Healthy Human Subjects||Maastricht University Medical Center|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01574417||87806|
NCT01574430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDTCSC-CHINA|Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)|A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy||Peking University People's Hospital|No|Recruiting|December 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|50 Years|No|||April 2012|April 9, 2012|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01574430||87805|
NCT01574443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106011763|Brain Dynamics in Different Stages of Arousal and Anesthesia|Brain Dynamics in Different Stages of Arousal and Anesthesia|ECOG|Weill Medical College of Cornell University|No|Recruiting|August 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|15 Years|65 Years|No|Non-Probability Sample|Patients undergoing epilepsy resection surgery|June 2013|June 13, 2013|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01574443||87804|
NCT01571219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-P13 3.2|An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1|An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-Administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab(Remicade or CP-P13) in Study CT-P13 3.1||Celltrion|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|302|||Both|18 Years|75 Years|No|||July 2013|July 30, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01571219||88051|
NCT01571518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-91|Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy|Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase||Sunchonhang University|Yes|Not yet recruiting|April 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Female|20 Years|70 Years|No|||April 2012|April 3, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01571518||88028|
NCT01563575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WHOHPHRP|WHO-HPH Recognition Project on Fast-Track Implementation of Clinical Health Promotion|WHO-HPH Recognition Project on Fast-Track Implementation of Clinical Health Promotion - a Multi-Centre RCT|RP|Bispebjerg Hospital|Yes|Suspended|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|88|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|March 22, 2012||No|Updating of core tools by WHO Europe in 2016|No||https://clinicaltrials.gov/show/NCT01563575||88636|
NCT01563354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230DIC03|3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial|Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial|LUNA|Novartis|Yes|Active, not recruiting|August 2013|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01563354||88652|
NCT01563861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000729157|S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma|Determining the Cell of Origin and Prognostic Gene Signatures in SWOG Trials of Diffuse Large B-Cell Lymphoma||Southwest Oncology Group|No|Active, not recruiting|February 2012|||March 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|220|||Both|18 Years|N/A|No|Non-Probability Sample|Patients registering to S9704-S0014-S0313 consenting to banking|September 2015|September 15, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563861||88615|
NCT01563874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999909155|Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins|Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins||National Institutes of Health Clinical Center (CC)||Completed|May 2009|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|300|||Both|18 Years|N/A|No|||July 2015|August 5, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563874||88614|
NCT01550601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8643|Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity|Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity: a Prospective,Controlled, Randomized, Multicentrique Study.|QUALISLEEVE|University Hospital, Montpellier|No|Recruiting|September 2011|October 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|346|||Both|18 Years|65 Years|No|||March 2012|March 9, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01550601||89626|
NCT01550614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-3-002|Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease|A Randomized, Controlled, Parallel Group, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Ad5FGF-4 Using SPECT Myocardial Perfusion Imaging in Patients With Stable Angina Pectoris|ASPIRE|Cardium Therapeutics|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|75 Years|No|||January 2016|January 26, 2016|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01550614||89625|
NCT01551108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC11022|Parent-targeted Mobile Phone Based Intervention to Increase Physical Activity in Children (P-Mobile)|Parent-targeted Mobile Phone Based Intervention to Increase Physical Activity in Children (P-Mobile)||Pennington Biomedical Research Center|No|Completed|March 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551108||89589|
NCT01551420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9226-R|Home Study of an Advanced Upper Limb Prosthesis|Home Study of an Advanced Upper Limb Prosthesis||VA Office of Research and Development|No|Recruiting|April 2012|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|Males and females with single or bilateral upper limb amputation|January 2016|January 20, 2016|February 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01551420||89565|
NCT01548794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiskapiTRHDYAZICIOGLU|Recovery of Bupivacaine or Bupivacaine-Lidocaine Spinal Anesthesia and Infiltration Anesthesia in Herniorrhaphy|A Comparison of the Recovery Profiles of Bupivacaine or Bupivacaine Mixed With Lidocaine Spinal Anesthesia and Local Infiltration Anesthesia for Outpatient Herniorrhaphy||Diskapi Teaching and Research Hospital|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|93|||Both|19 Years|80 Years|No|||December 2012|April 21, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01548794||89764|
NCT01548807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 06810|Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy|Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|September 2010|||September 2017|Anticipated|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|33|||Male|18 Years|N/A|No|||January 2016|January 25, 2016|March 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01548807||89763|
NCT01551992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quill LSC|Affixing Polypropylene Mesh Using Barbed Suture (Quill™ Srs) During Laparoscopic Sacrocolpopexy Randomized Controlled Trial (Quill Lsc)|Affixing Polypropylene Mesh Using Barbed Suture (Quill™ Srs) During Laparoscopic Sacrocolpopexy Randomized Controlled Trial|QUILL-LSC|Kaiser Permanente|No|Completed|November 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 15, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01551992||89521|
NCT01552226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCNM 114|Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery|Prospective Randomized Clinical Trial to Compare Continuous Preperitoneal Analgesia to Continuous Epidural Analgesia for Pain Control After Colon and Rectal Surgery||Saint Joseph Mercy Health System|No|Active, not recruiting|January 2010|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|137|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01552226||89503|
NCT01552525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91/10|L-Arginine, Symmetrical and Asymmetrical Dimethylarginine (SDMA/ADMA) in Acute Kidney Injury (AKI)|Regulation of L-Arginine Und Its Derivatives of Asymmetrical and Symmetrical Dimethylarginine and L-NG Monomethylarginine (ADMA/SDMA/L-NMMA) in Acute Kidney Injury and Correlation to Cardiac, Renal and Vascular Function and Mortality||Wuerzburg University Hospital|No|Completed|January 2011|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood and urine samples will be centrifuged. One ml aliquots of plasma, serum, urine and a      whole blood sample will be stored at -80°C.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with acute kidney injury in the University Hospital of Wuerzburg will be        recruited on the wards and in the emergency unit when nephrologists are consulted.|March 2012|March 2, 2016|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01552525||89481|
NCT01549925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI41380|Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand|A Prospective Randomized Surgical Trial Comparing the Efficacy of LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Standard Surgical Resection in Women With Stage IIIC or Stage IVA Epithelial Ovarian Cancer||University of Utah|Yes|Completed|January 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|March 6, 2012|Yes|Yes||No|October 2, 2015|https://clinicaltrials.gov/show/NCT01549925||89678|
NCT01550159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1081/04|Correlation Between Markers of Neuronal Injury and Cognitive Dysfunction After Coronary Artery Bypass Surgery|Study of Correlation Between Serum Levels of Markers of Neuronal Injury and Cognitive Dysfunction After Coronary Artery Bypass Graft Surgery||University of Sao Paulo|Yes|Recruiting|April 2009|April 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|88|||Both|40 Years|90 Years|No|Probability Sample|Patients underwent for coronary artery bypass graft surgery.|March 2012|March 6, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01550159||89660|
NCT01550172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6201111800|Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers|Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers||University of South Florida|Yes|Recruiting|April 2012|December 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|21 Years|N/A|No|||August 2015|August 24, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01550172||89659|
NCT01570673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-089|Group Versus Individual Urotherapy for Children|Group Versus Individual Urotehrapy in Children With Non-neurogenic Lower Urinary Tract Dysfunction||Hamilton Health Sciences Corporation|No|Completed|May 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|6 Years|10 Years|No|||June 2015|June 11, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570673||88092|
NCT01570686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2413|8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension|An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension||Novartis||Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|589|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|April 2, 2012|Yes|Yes||No|November 10, 2013|https://clinicaltrials.gov/show/NCT01570686||88091|
NCT01570400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOFIE13a|Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT|Reduction of Social Phobia Symptoms With Combined Internet-Based Cognitive Bias Modification and Cognitive Behavioral Therapy|SOFIE13a|Umeå University|No|Active, not recruiting|September 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||January 2013|January 15, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01570400||88113|
NCT01563016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|selfcontrolvsglucose|Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia|Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia: A Randomized Controlled Study||The University of Hong Kong|No|Not yet recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|15 Years|N/A|No|||March 2012|March 23, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563016||88678|
NCT01563029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106855|A Dose-ranging Study of Fluticasone Furoate (FF)|A Dose-ranging Study of Fluticasone Furoate (FF) Inhalation Powder in Children Aged 5-11 Years With Asthma||GlaxoSmithKline|No|Completed|March 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|597|||Both|5 Years|11 Years|No|||April 2015|June 25, 2015|March 15, 2012|Yes|Yes||No|April 9, 2015|https://clinicaltrials.gov/show/NCT01563029||88677|
NCT01563653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/RdeT-01|Development and Evaluation of a New Diagnostic Test in Female Urinary Stress Incontinence|Development and Evaluation of a New Diagnostic Test in Female Urinary Stress Incontinence|IEUF|Centre Hospitalier Universitaire de Nīmes|Yes|Terminated|February 2014|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Female|18 Years|N/A|No|||March 2016|March 21, 2016|March 16, 2012||No|Not enough inclusions.|No||https://clinicaltrials.gov/show/NCT01563653||88630|
NCT01563939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02|Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour|Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour: is Demand Bolus Required for Optimal Analgesia||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Terminated|February 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|2|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|March 23, 2012||No|Difficult recruitment.|No||https://clinicaltrials.gov/show/NCT01563939||88609|
NCT01564745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Extu-Cough|Cough Determinants in Mechanically Ventilated Patients|Cough Determinants in Mechanically Ventilated Patients: a Physiological Study|Extu-Cough|University Hospital, Caen|Yes|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|180|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01564745||88547|
NCT01564758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951090|Post Marketing Surveillance Study on Linezolid|Post Marketing Surveillance on the Efficacy, Safety and Tolerability of Linezolid (Zyvox) in the Treatment of Gram Positive Infections|A5951090|Pfizer|No|Completed|February 2004|March 2005|Actual|March 2005|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|||Both|18 Years|N/A|No|Non-Probability Sample|Adult, Filipino patients diagnosed with gram positive infection|June 2012|June 27, 2012|March 26, 2012||No||No|June 27, 2012|https://clinicaltrials.gov/show/NCT01564758||88546|Protocol did not indicate primary or secondary endpoints and all determination of primary or secondary endpoints were arbitrary.
NCT01550900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1100|Prospective Trial of Metformin - Chemoprevention Role|A Prospective Placebo-control Double-blind Randomized Trial of Metformin in Chemoprevention of Metachronous Colonic Neoplastic Polyps||M.D. Anderson Cancer Center|Yes|Withdrawn|July 2013|||July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|40 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|March 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01550900||89604|
NCT01550549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-PT01|Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans|Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans||Avid Radiopharmaceuticals|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|151|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 3, 2012|March 6, 2012|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01550549||89630|
NCT01550562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7002|Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation|Precision™ High-Rate Sub-perception Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain||Boston Scientific Corporation|No|Terminated|February 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|N/A|No|||May 2013|May 8, 2013|February 15, 2012||No|In >9 months only 1 patient enrolled. Study stopped because design was too cumbersome and    subjects not willing to participate|No||https://clinicaltrials.gov/show/NCT01550562||89629|
NCT01550575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7005|Precision Retrospective Outcomes|Precision Retrospective Outcomes|PRO|Boston Scientific Corporation|No|Recruiting|March 2012|December 2016|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects who have previously been implanted with , or who are candidates for implantation        with a spinal cord stimulation system.|December 2015|December 3, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01550575||89628|
NCT01550861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1201012117|In Vitro Maturation (IVM) of Human Oocytes|IN VITRO MATURATION (IVM) OF HUMAN OOCYTES|IVM|Weill Medical College of Cornell University|No|Active, not recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|25 Years|42 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01550861||89607|
NCT01551732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00000440|Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger|Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger||Gonzalez-Heydrich, Joseph, M.D.|No|Active, not recruiting|July 2011|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|10 Years|17 Years|No|||February 2016|February 8, 2016|August 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01551732||89541|
NCT01548820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV resistance|Resistance to Lamivudine in HBV Egyptian Patients|Pretreatment and On-treatment Indicators of Virologic Breakthrough in Chronic HBV Egyptian Patients Receiving Lamivudine Therapy||Ain Shams University|Yes|Completed|June 2010|January 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|230|Samples With DNA|blood samples +/- tissue biopsy|Both|18 Years|65 Years|No|Non-Probability Sample|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National        Hepatology & Tropical Medicine Research Institute in Egypt in the period from 2007- 2011.|September 2013|September 8, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01548820||89762|
NCT01552902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-406|Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder|A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)||Shire|No|Completed|April 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|549|||Both|13 Years|17 Years|No|||June 2014|March 4, 2015|March 6, 2012|Yes|Yes||No|March 4, 2015|https://clinicaltrials.gov/show/NCT01552902||89452|
NCT01552915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-405|Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder|A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)||Shire|No|Completed|April 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|464|||Both|13 Years|17 Years|No|||December 2014|December 10, 2014|March 6, 2012|Yes|Yes||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01552915||89451|
NCT01552551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U48DP002657-RCT|Assessment and Referral Versus Exercise in Primary Prevention of Falls: PA Healthy Steps Program|Assessment and Referral Versus Exercise in Primary Prevention of Falls: PA Healthy Steps Program||University of Pittsburgh|Yes|Completed|May 2012|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|189|||Both|50 Years|100 Years|No|||December 2015|December 29, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01552551||89479|
NCT01552239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRE-1205-ROE-0050-I|Preoperative Radiotherapy for Sarcomas of the Extremities With Intensity-Modulation, Image-Guidance and Small Safety-margins|Phase II Study of Preoperative Radiotherapy for Sarcomas of the Extremities With Intensity-Modulation, Image-Guidance, Small Safety-margins and Brachytherapy Conditioned by Resection Margin|PREMISS|Technische Universität München||Recruiting|August 2011|October 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01552239||89502|
NCT01552252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POs-Ca02|Evaluation of an Apple Juice Drink With POs-Ca|Development and Evaluation of a Low Erosive Apple Juice Drink With Phosphoryl Oligosaccharides of Calcium (POs-Ca)||Tokyo Medical and Dental University||Completed|March 2010|March 2012|Actual|March 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|5||Actual|30|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01552252||89501|
NCT01552538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPM-006|Long Term Extension Study For SPM-005 Participants|Long Term Observational Study of the Safety and Efficacy of an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid Arthritis||SetPoint Medical Corporation|No|Active, not recruiting|January 2012|October 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||May 2015|May 18, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552538||89480|
NCT01549639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rrk4342|Blood Propofol Measurement During Anaesthesia Using Propofol Target Controlled Infusion|Use of a Novel Point of Care Device to Measure Blood Propofol Levels During Propofol Based General Anesthesia by Target Controlled Infusion Using the Marsh Model in Effect Site Mode||University Hospital Birmingham NHS Foundation Trust|No|Completed|January 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|16 Years|N/A|No|Non-Probability Sample|Patients treated in the Operating Theatre undergoing propofol intravenous anaesthesia who        require an arterial line to be inserted as standard care.|July 2012|July 18, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01549639||89699|
NCT01550185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 206111|Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia|Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia||Roswell Park Cancer Institute|No|Active, not recruiting|May 2012|||December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|March 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01550185||89658|
NCT01550198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Edscini Study 1.0|Early Detection of Neonatal Shock|Early Detection of Shock in Critically Ill Newborn Infants. The Impact of Advanced Hemodynamic Monitoring|Edscini|Radboud University|Yes|Recruiting|May 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|N/A|N/A|No|Non-Probability Sample|Neonates admitted to a neonatal intensive care unit|December 2015|December 9, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550198||89657|
NCT01570933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIP2011|Feasibility Study Over the NAVA Mode in Noninvasive Ventilation After Cardiac Surgery in Infants.|Feasibility Study Over the Neurally Adjusted Ventilatory Assist (NAVA) Mode in Noninvasive Ventilation After Cardiac Surgery in Infants.|NIVNAVA|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|N/A|12 Months|No|||December 2013|December 6, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01570933||88072|
NCT01570946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/1/MRC-ICMR/09/NCD-II_018|Use of Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK|A Pragmatic and Scalable Strategy Using Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK||India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals|Yes|Completed|May 2012|December 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1171|||Both|35 Years|55 Years|No|||December 2015|December 29, 2015|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01570946||88071|
NCT01570920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/04JUIL/193|Effects of Regular Brisk Walking in Chronic Stroke Patients|Effects of Regular Brisk Walking in Chronic Stroke Patients||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Yes|Completed|September 2009|March 2011|Actual|December 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|1||Actual|34|||Both|18 Years|80 Years|No|||April 2012|April 2, 2012|March 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01570920||88073|
NCT01563276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007924|Postural Instability in Progressive Supranuclear Palsy|Postural Instability in Progressive Supranuclear Palsy: Why do Patients With PSP Fall?||Oregon Health and Science University||Recruiting|December 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|40|||Both|40 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|OHSU Movement Disorders Clinic Volunteers from the community (Portland, Oregon and        surrounding areas)|March 2012|March 23, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563276||88658|
NCT01563289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028021|Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries|A Randomised, Multicentre, Two-arm, Parallel Group, Double-blind, Placebo-controlled, Comparative Efficacy and Safety Clinical Study of Ibuprofen in Patients With Pain Related to Uncomplicated Ankle Injuries||Orion Corporation, Orion Pharma|No|Completed|February 2012|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|45 Years|No|||September 2012|May 7, 2013|March 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01563289||88657|
NCT01563302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 481464-CS1|Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers|A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers||Ionis Pharmaceuticals, Inc.|No|Active, not recruiting|February 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||December 2015|December 31, 2015|February 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563302||88656|
NCT01563588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACThe|Support and Rehabilitation Protocol for Non Metastatic Breast Cancer Patients in Complete Remission After Chemotherapy|Post Therapeutic Support and Rehabilitation Protocol in Hydrothermal Centers for Breast Cancer Patients in Complete Remission: a Multicenter Prospective Randomized Trial Testing the Intervention Versus Best Supportive Care||Centre Jean Perrin|No|Terminated|December 2008|October 2013|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|251|||Female|18 Years|70 Years|No|||December 2015|December 23, 2015|February 22, 2012||No|Enrollment lasted longer than expected and expected number of patients could not be matched in    time.|No||https://clinicaltrials.gov/show/NCT01563588||88635|
NCT01563601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C41601/3099|Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer||Teva Pharmaceutical Industries|Yes|Withdrawn|August 2012|January 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|March 15, 2012|Yes|Yes|Business Decision|No||https://clinicaltrials.gov/show/NCT01563601||88634|
NCT01565304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPR-06549-03|Evaluation of the Effectiveness of the POWER Through Choices Program|Evaluation of the Effectiveness of the POWER Through Choices Program||Mathematica Policy Research, Inc.|No|Completed|January 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1039|||Both|13 Years|18 Years|No|||September 2015|September 22, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01565304||88504|
NCT01551485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-022|Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement|Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement||Rigshospitalet, Denmark|Yes|Active, not recruiting|February 2012|October 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Both|60 Years|N/A|No|||August 2012|August 7, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01551485||89560|
NCT01551745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-PTL 112|Salvage Ovarian FANG™ Vaccine + Bevacizumab|Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105||Gradalis, Inc.|Yes|Active, not recruiting|March 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551745||89540|
NCT01551147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-6950POU005|A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma|A Double-blind, Placebo-controlled, Three-way Crossover Study to Compare the Safety and Efficacy of 8 Days of Therapy With ONO-6950 Versus Placebo and Montelukast (Singulair®) on Asthmatic Responses and Airway Hypersensitivity Following Allergen Challenge in Patients With Asthma||Ono Pharmaceutical Co. Ltd|No|Completed|June 2012|||April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|25|||Both|18 Years|60 Years|No|||April 2013|April 29, 2013|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551147||89586|
NCT01551407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC B202/11|Detection of Bladder Tumors After 30 Min Instillation of Hexvix|Open Prospective Within Patient, Phase IIa Study of Hexvix Flexible Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer After 30 Minutes Instillation of Hexvix in Patients With Known or Suspicion of Bladder Cancer||Photocure|No|Terminated|December 2011|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|38|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|March 2, 2012||No|slow inclusion rate|No||https://clinicaltrials.gov/show/NCT01551407||89566|
NCT01551693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-039|STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma|A Phase II Study of the HSP90 Inhibitor STA-9090 in Patients With Unresectable Stage III or Stage IV Melanoma Who Received Prior Tyrosine Kinase Inhibitor Treatment||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2011|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|April 29, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551693||89544|
NCT01552291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|170/11|The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies|The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study|Glutaminprojec|University Hospital Inselspital, Berne|No|Recruiting|May 2012|May 2017|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|N/A|N/A|No|||November 2015|November 12, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01552291||89499|
NCT01552928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD422-111|Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, 4-Period Crossover Trial to Assess the Effect of Anagrelide Hydrochloride on QT/QTc Interval in Healthy Men and Women.||Shire|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|March 6, 2012|No|Yes||No|September 20, 2013|https://clinicaltrials.gov/show/NCT01552928||89450|
NCT01552941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPM-005|Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis|Pilot Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid Arthritis||SetPoint Medical Corporation|No|Completed|July 2011|May 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|75 Years|No|||June 2014|June 3, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01552941||89449|
NCT01548768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1026|RHYTHM (Formerly Escape II Myocardium)|RHYTHM (RHeumatoid Arthritis studY of THe Myocardium): How Rheumatoid Arthritis (RA) and Tumor Necrosis Factor (TNF) Inhibitors Affect the Myocardial Structure and Function.|RHYTHM|Columbia University|Yes|Recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01548768||89766|
NCT01548781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133G110245|The Effect of Resistance to Participant-Supported Reaching on Workspace of the Hand in Severe Chronic Stroke|The Effect of Resistance to Participant-Supported Reaching on Workspace of the Hand in Severe Chronic Stroke||Northwestern University|No|Completed|March 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|38|||Both|21 Years|85 Years|No|||October 2015|October 5, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01548781||89765|
NCT01552824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0853/11|Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions|Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions|CYSTUO|University of Sao Paulo General Hospital|Yes|Not yet recruiting|June 2015|June 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|N/A|N/A|No|||May 2015|May 9, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552824||89458|
NCT01548755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMR_Naharia|The Western Galilee Hospital in Nahariya Home Monitoring Registry|Workload Assessment of a Home Monitoring Based Follow up for Biotronik ICD and CRTD Patients.||Western Galilee Hospital-Nahariya|Yes|Not yet recruiting|April 2012|January 2015|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|85 Years|No|Probability Sample|ICD or CRTD implanted patient|March 2012|March 12, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548755||89767|
NCT01549652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5HT3 19821|5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence|5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence||Stanford University||Active, not recruiting|April 2011|December 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|60 Years|No|||February 2016|February 8, 2016|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01549652||89698|
NCT01549938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIPRIS|Cholecalciferol Intervention to Prevent Respiratory Infections Study|Cholecalciferol Intervention to Prevent Respiratory Infections Study: a Double-blind Randomised Controlled Trial to Evaluate the Efficacy of 20,000 IU/wk Cholecalciferol in Reducing Respiratory Tract Infection in a Cohort of Healthy Young Adults|CIPRIS|Menzies Institute for Medical Research|Yes|Completed|May 2012|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 17, 2012|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01549938||89677|
NCT01562509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMW 171103002|PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care|Improvement of Hospital Care for Patients With Non-Hodgkin's Lymphoma||Radboud University|No|Active, not recruiting|October 2012|December 2014|Anticipated|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|418|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01562509||88717|
NCT01562795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xzhou|Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease|Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease||Wenzhou Medical University|Yes|Completed|March 2012|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|48|||Both|18 Years|70 Years|No|||January 2014|January 2, 2014|March 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562795||88695|
NCT01571232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIT-406|Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema|Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.||Retina Macula Institute|No|Recruiting|April 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2013|January 13, 2013|April 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571232||88050|
NCT01561508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB-GABA|Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children|Double Blinded, Placebo Controlled Trial on the Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children|GABA|University of Alabama at Birmingham|No|Withdrawn|June 2012|||April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|18 Years|No|||December 2012|December 21, 2012|March 16, 2012|No|Yes|Unable to obtain IND currently|No||https://clinicaltrials.gov/show/NCT01561508||88794|
NCT01564147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/02-J|More Added Value of Therapeutic Education in the Management of Patients With Rheumatoid Arthritis (ETP-PR)|More Added Value of Therapeutic Education in the Management of Patients With Rheumatoid Arthritis|ETP-PR|Nantes University Hospital|No|Terminated|September 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|62|||Both|18 Years|N/A|No|||June 2013|June 11, 2013|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01564147||88593|
NCT01564160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0202|Assessment of PCSO-524 Relative to a Comparator Product|Assessment of the Acute and Chronic Bioavailability of Marine Lipid Fraction PCSO-524 Relative to a Comparator Product.||Nutrasource Diagnostics Inc.|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564160||88592|
NCT01564420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Santos 2012|Morphine Postoperative Analgesia and Pharmacokinetic/Pharmacodynamic Modeling|Pharmacokinetic/Pharmacodynamic Modeling of Morphine for Postoperative Analgesia Through a Patient Controlled Device After Coronary Artery Bypass Grafting. Intrathecal Morphine Significantly Reduces Drug Consumption||University of Sao Paulo|No|Completed|January 2003|||December 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|36|Samples Without DNA|For pharmacokinetic analysis, a serial of blood samples of patients was collected      postoperatively after the extubation from a venous catheter (5mL each) into an EDTA tube      (BD, Sao Paulo/Brazil) in the periods as follows: 0, 0.08, 0.25, 0.5, 1, 3, 6, 12, 18, 24      and 36 hrs. Blood samples were centrifuged at 2800 g for 20 minutes, plasma was transferred      to labeled polyethylene vials and frozen at -80ºC until drug plasma assay.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with coronary artery disease, eligible to cardiopulmonary artery bypass grafting        surgery|March 2012|March 23, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564420||88572|
NCT01574287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051415|Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas|Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC||Emory University|Yes|Recruiting|August 2012|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|12|||Both|18 Years|99 Years|No|||October 2015|October 14, 2015|March 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574287||87816|
NCT01570231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009|Feasibility, Safety and Efficacy of Remote Ischemic Preconditioning for Symptomatic Intracranial Arterial Stenosis in Octogenarians|Feasibility, Safety and Efficacy of RIPC for Symptomatic Intracranial Arterial Stenosis in Octogenarians||Capital Medical University||Completed|January 2008|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|58|||Both|80 Years|95 Years|No|||July 2012|July 26, 2012|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01570231||88126|
NCT01570244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.56|Drug-drug Interaction of BI 201335 and Microgynon|An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of 240 mg BI 201335 QD on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers||Boehringer Ingelheim||Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|April 2, 2012||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01570244||88125|
NCT01552304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol version May 30, 2011|Oxygen Supplementation Study in Obstructive Sleep Apnea (OSA) Patients|The Benefit and Risk of Oxygen Supplementation in Perioperative Management of Obstructive Sleep Apnea||University Health Network, Toronto|No|Active, not recruiting|February 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|156|||Both|18 Years|80 Years|No|||May 2015|May 27, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552304||89498|
NCT01550887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANNA2011|Evaluation of Impulsivity on Cocaine and Crack Addicts|Evaluation of Impulsivity on Cocaine and Crack Addicts||Federal University of São Paulo|Yes|Completed|April 2012|May 2015|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Male|18 Years|50 Years|No|||August 2015|August 10, 2015|December 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01550887||89605|
NCT01551160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC1001|Impact of Non-technical Skills Training on Performance and Effectiveness of a Medical Emergency Team|Impact of Non-technical Skills Training on Performance and Effectiveness of a Medical Emergency Team|IMPACT|Lyell McEwin Hospital|Yes|Recruiting|July 2014|August 2019|Anticipated|August 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|600|||Both|16 Years|N/A|No|||September 2015|September 2, 2015|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01551160||89585|
NCT01551433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-192|Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy|A Prospective Trial to Evaluate Whether Variations in Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy||Memorial Sloan Kettering Cancer Center||Active, not recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|111|||Both|21 Years|N/A|No|Non-Probability Sample|The Thoracic Surgery clinics|March 2016|March 1, 2016|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01551433||89564|
NCT01551446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1103|Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes|Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes||Reata Pharmaceuticals, Inc.||Withdrawn|April 2012|October 2013|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2012|November 1, 2012|March 5, 2012|Yes|Yes|IDMC recommendation for safety concerns|No||https://clinicaltrials.gov/show/NCT01551446||89563|
NCT01548872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA/11-152|Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery|||Baskent University|Yes|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|1 Month|6 Years|No|||March 2012|March 6, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01548872||89758|
NCT01548885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-PRO-2012-001-01|Comparison Evaluation of Blood Glucose Meter Systems|Evaluation of Blood Glucose Meter Systems - NACT Study||Ascensia Diabetes Care|No|Completed|March 2012|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|146|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 29, 2016|March 6, 2012|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01548885||89757|
NCT01548898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nd-YAG laser in AKN|The Efficacy of Laser Assisted Hair Removal in the Treatment of Acne Keloidalis Nuchae; a Pilot Study|||Cairo University|Yes|Completed|January 2008|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|N/A|N/A|No|||March 2012|March 6, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01548898||89756|
NCT01549080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011001P02/June 3rd, 2011|Study of Effects of YisuiShengxueGranules on Thalassemia|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study of the Safety and Effects of YisuiShengxueGranules on Thalassemia Presenting the Syndrome of Deficiency of Liver/Kidney-yin, and Asthenia of Essence/Blood.|thalessemia|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Completed|July 2011|January 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2|Samples With DNA|Peripheral blood and bone marrow cells|Both|3 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|The type of severe β-Thalassemia：Hb <60g/L, microcytic hypochromic anemia; more than 10%        target erythrocyte and erythrocyte fragments; increased number of reticulocyte; more        erythroblast in peripheral blood; extremely proliferative in marrow; HbF>30%～90%.        The type of intermedia β-Thalassemia：Hb 60g/L～100g/L; the shape of mature erythrocyte is        similar to severe type; more reticulocyte; erythroblast may be found; HbF>3.5%.        The type of intermedia α-Thalassemia： The patients have mild or moderate anemia        (Hemoglobin in a few patients is less than 60g/L or more than 100g/L)，probably have        hepatosplenomegaly, jaundice, and Mediterranean anemia features.        The Diagnosing Criteria for the Deficiency Syndrome of Liver-yin and Kidney-yin, and        Asthenia of Essence and Blood in Chinese Medicine|June 2011|March 7, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01549080||89742|
NCT01549067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sprit|The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey|The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey|Sprit|Chinese Medical Doctor Association|Yes|Recruiting|September 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|3700|||Both|N/A|N/A|No|Non-Probability Sample|Advanced Colorectal Cancer|March 2012|March 13, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549067||89743|
NCT01549314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH 2012P000269|Cystic Fibrosis Related Bone Disease: the Role of CFTR|Cystic Fibrosis Related Bone Disease: the Role of CFTR||Massachusetts General Hospital|No|Recruiting|April 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|90|Samples Without DNA|Plasma and urine|Both|6 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with CF will be recruited from the Cystic Fibrosis Centers at Children's Hospital        Boston and Massachusetts General Hospital. Healthy subjects will be a community sample        recruited from nearby communities.|October 2015|October 19, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01549314||89724|
NCT01549587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011001|Oral Hygiene and Maternity Outcomes Multicenter Study (OHMOM)|A Randomized Controlled Clinical Trial to Evaluate Late First to Mid-Second Trimester Introduction of Advanced Daily Oral Hygiene on Gingivitis and Maternity Outcomes|OHMOM|Procter and Gamble|Yes|Completed|February 2012|April 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|746|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 18, 2015|February 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01549587||89703|
NCT01549600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011063|Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose|A Randomized, Controlled Study To Compare the Effects of 2 Types of Dietary Fiber, Psyllium and Microcrystalline Cellulose, on Glycemic Measures in Subjects With Pre-type 2 Diabetes||Procter and Gamble|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|18|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|October 27, 2014|March 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01549600||89702|
NCT01549964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_302|Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes||Takeda|Yes|Terminated|May 2012|May 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|916|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|March 6, 2012|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No||https://clinicaltrials.gov/show/NCT01549964||89675|
NCT01554280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBE-001-SEOS|Fully Coated, Removable, Self-expanding Oesophageal Stents for Preventing Strictures Following Complete Barretts Excision.|Fully, Coated, Removable, Self-expanding Oesophageal Stents for the Prevention of Oesophageal Stricture Following Endoscopic Mucosal Resection of Short Segment Barrett's With High Grade Dysplasia and Early Cancer.|CBE-001-SEOS|Western Sydney Local Health District|No|Completed|January 2012|January 2014|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|75 Years|No|||December 2014|December 3, 2014|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01554280||89347|
NCT01549951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21012|Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer||Millennium Pharmaceuticals, Inc.|No|Completed|May 2012|March 2013|Actual|December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|18 Years|N/A|No|||July 2013|July 1, 2013|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01549951||89676|
NCT01550224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMAML0017|Phase II Temozolomide + Vorinostat in Patients (>60) w/ Newly Diagnosed or Relapse/Refractory AML|A Phase 2 Study of Temozolomide Plus Vorinostat for Elderly Patients (>60) With Newly Diagnosed Acute Myeloid Leukemia (AML) or Relapse/Refractory AML||Stanford University|Yes|Recruiting|May 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550224||89655|
NCT01562808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A070001|Change in Brain Metabolism and Cognitive Function by Aripiprazole|The Relationship Between D2 Occupancy and Change in Frontal Metabolism and Working Memory Induced by Aripiprazole||Seoul National University Hospital|No|Completed|January 2009|January 2012|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|15|||Male|19 Years|30 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562808||88694|
NCT01562535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMBE-ITESM-2|A Clinical Trial of Pronation Versus Supination Maneuvers for the Reduction of the Pulled Elbow|A Randomized Clinical Trial of Pronation Versus Supination Maneuvers for the Reduction of the Pulled Elbow||Instituto Tecnologico y de Estudios Superiores de Monterey|Yes|Not yet recruiting|June 2012|September 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|6 Months|6 Years|No|||March 2012|March 23, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562535||88715|
NCT01562782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110011995|Change of Fructose to Fat in South Asians|Fructose-induced Hepatic De Novo Lipogenesis in South Asians||The Rogosin Institute|No|Active, not recruiting|March 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|36|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562782||88696|
NCT01564199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3106006|Phase I Pharmacokinetic Study (SALBLOCK)|Effect of Charcoal on Gastrointestinal Absorption of Salmeterol and Fluticasone Propionate.|SALBLOCK|Orion Corporation, Orion Pharma|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|June 25, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01564199||88589|
NCT01564212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-217|Quantitative Heat Loss With Laminar Air Flow|||The Cleveland Clinic|No|Active, not recruiting|March 2012|September 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564212||88588|
NCT01574300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THO 09110|Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network|Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network|CASTLE|Vanderbilt-Ingram Cancer Center|No|Recruiting|November 2010|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Advanced stage lung cancer patients|October 2012|October 18, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01574300||87815|
NCT01574313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGB09804-003|Effect of Stellate Ganglion Block on Meniere's Disease|Effect of Stellate Ganglion Block on Meniere's Disease||Chi Mei Medical Hospital|Yes|Completed|April 2010|March 2012|Actual|April 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|30 Years|65 Years|No|||April 2012|April 10, 2012|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01574313||87814|
NCT01574326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCARB07609|An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease|A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease||Sanofi|Yes|Completed|May 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|101|||Both|N/A|18 Years|No|||June 2015|June 19, 2015|April 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574326||87813|
NCT01551173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXUO320BCN01|Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD||Novartis||Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|436|||Both|18 Years|N/A|No|||August 2015|August 10, 2015|March 8, 2012||No||No|May 13, 2014|https://clinicaltrials.gov/show/NCT01551173||89584|
NCT01551459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-008794-55|A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma|A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma|SUAVE|The Clatterbridge Cancer Centre NHS Foundation Trust|Yes|Active, not recruiting|October 2010|August 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551459||89562|
NCT01552837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1449L00030|Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology|Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology||RWTH Aachen University|No|Completed|December 2007|December 2010|Actual|February 2010|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 9, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01552837||89457|
NCT01552850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501010|Pharmacokinetics And Relative Bioavailability Study Of Oxycodone|An Open-Label, Single-Dose, Randomized, Crossover Pharmacokinetics And Relative Bioavailability Study Of Three Modified 40 Mg Oxycodone Formulations Compared With 40 Mg Pf-00345439 Capsule Formulation In Healthy Volunteers||Pain Therapeutics|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|18|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|March 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01552850||89456|
NCT01552863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4501018|A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers|Open-Label, Single-Dose, Randomized, Crossover Study To Evaluate The Pharmacokinetics Of Oxycodone Following Oral Administration Of PF-00345439 Under Fed Conditions In Healthy Volunteers||Pain Therapeutics|No|Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|March 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01552863||89455|
NCT01552876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-4582|Comparative Clinical Evaluation of Soft Toric Lens Designs|Comparative Clinical Evaluation of Soft Toric Lens Designs||Johnson & Johnson Vision Care, Inc.|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|March 9, 2012|Yes|Yes||No|October 30, 2013|https://clinicaltrials.gov/show/NCT01552876||89454|
NCT01549093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HunanPTH022|Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)|A Randomized, Open Label, Controlled Study About Endostar Continued Pumping or Injecting Into Vein Combining With Gemcitabine-Carboplatin Versus Gemcitabine-Carboplatin Alone to Treat Non-Small Cell Lung Cancer (NSCLC)||Hunan Province Tumor Hospital|Yes|Recruiting|August 2011|October 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||March 2015|March 22, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01549093||89741|
NCT01549327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEN-C|The Effect of a Virtual Navigator on Colorectal Cancer Patient Empowerment|A Web-Based Person-Centred Navigation Tool for Newly Diagnosed Colorectal Cancer Patients: A Randomized Clinical Trial (RCT) to Assess Effects on Empowerment and Cost-Effectiveness (The TEN-C Study: Together to Enhance Navigation in Cancer)||McGill University|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|129|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01549327||89723|
NCT01549613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-11-03-06|Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections|Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections||University of Cincinnati|Yes|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||July 2014|July 7, 2014|February 8, 2012||No||No|July 7, 2014|https://clinicaltrials.gov/show/NCT01549613||89701|
NCT01554293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBL/CR/2011/05/CT|Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Phase I Study To Determine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers||Panacea Biotec Ltd|Yes|Recruiting|July 2012|September 2013|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554293||89346|
NCT01554540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC TIPPS 11 18|Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study|Pharmacodynamic and Pharmacokinetic Assessment of Treprostinil Iontophoresis on the Forearm and the Fingers|TIPPS|University Hospital, Grenoble|No|Active, not recruiting|February 2012|February 2014|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 17, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01554540||89327|
NCT01562548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3940666|Exploratory Efficacy Study of Guaifenesin in Upper Back Pain|A Proof of Principle Study to Explore the Utility of Guaifenesin in Upper Back Pain||GlaxoSmithKline|No|Completed|February 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|78|||Both|18 Years|65 Years|No|||March 2014|May 1, 2014|March 22, 2012|No|Yes||No|March 6, 2014|https://clinicaltrials.gov/show/NCT01562548||88714|
NCT01564186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|643|Characterization of Cardiac Hemodynamics During MultiSite Pacing|Characterization of Cardiac Hemodynamics by Pressure-Volume Loop Analysis During MultiPoint Pacing||St. Jude Medical|Yes|Completed|April 2012|December 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|44|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated for standard CRT-D therapy.|April 2014|April 8, 2014|March 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01564186||88590|
NCT01563042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114594|A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunteers|An Exploratory First Time in Human (FTIH) Study Investigating the Pharmacokinetics (PK), Immunogenicity, Safety and Tolerability of GSK2434735 Administered as a Single Low Dose in Healthy Male Subjects||GlaxoSmithKline||Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|5|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01563042||88676|
NCT01564459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6096-021|Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)|A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 in Patients With Painful Diabetic Neuropathy||Merck Sharp & Dohme Corp.||Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|18 Years|75 Years|No|||July 2015|July 31, 2015|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01564459||88569|
NCT01563094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12441|Bone Accrual and Hormones in Response to Lactation|Bone Accrual and Hormones in Response to Lactation||University of Virginia|No|Active, not recruiting|January 2003|December 2016|Anticipated|August 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|141|Samples Without DNA|Blood samples.|Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Postpartum women from outpatient obstetrical/gynecology clinics.|May 2015|May 14, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563094||88672|
NCT01573806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEPS-SCH-001|Pharmacology of Exenatide in Pediatric Sepsis|Phase 1-2 Study of the Pharmacology of Exenatide in Pediatric Sepsis|PEPS|Seattle Children's Hospital|Yes|Withdrawn|October 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|1 Month|18 Years|No|||May 2013|May 24, 2013|March 28, 2012|Yes|Yes|No funding|No||https://clinicaltrials.gov/show/NCT01573806||87853|
NCT01573819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115719|A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278|A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278||GlaxoSmithKline||Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|February 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01573819||87852|
NCT01574053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Enroll -HD|Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort|Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort||CHDI Foundation, Inc.|Yes|Recruiting|July 2012|||||N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Anticipated|15000|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with HD and their family members will be recruited from specialty clinics (Human        Genetics, Neurology, Psychiatry) that advise and treat people affected by HD. In addition,        in some areas community clinics and neurologists who see HD patients will recruit        participants for this study.Participants may also receive information about the study        through a website, clinical practices, support groups, advocacy newsletters, etc. and        place a direct request to be considered for participation in the study. Community controls        will be identified, using advertisements, flyers and newsletters, by study site staff with        the support of the Enroll-HD operational staff.|June 2015|June 1, 2015|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574053|1 Year|87834|
NCT01570283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-29966 ARMS|ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus|ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant|ARMS|Baylor College of Medicine|Yes|Recruiting|September 2012|January 2020|Anticipated|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|N/A|N/A|No|||January 2016|January 21, 2016|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570283||88122|
NCT01570556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193/11|Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients|Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients||Assaf-Harofeh Medical Center||Recruiting|December 2011|||December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||March 2012|April 3, 2012|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570556||88101|
NCT01552031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-FOT-MON1|Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device|Monitoring COPD Patients at Home by a Forced Oscillation Technique Device||Politecnico di Milano|No|Recruiting|November 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|40 Years|80 Years|No|Probability Sample|80 COPD patients, with the characteristics of frequent exacerbators (> 2 exacerbations in        the past year), will be enrolled in the study.|December 2013|June 2, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01552031||89518|
NCT01551758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115151|A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)|A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) Compared With the Existing COPD Maintenance Therapy Alone in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|Yes|Completed|January 2012|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2802|||Both|40 Years|N/A|No|||February 2016|February 25, 2016|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551758||89539|
NCT01552018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/773b (REK)|Saxagliptin and Atherosclerosis|Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.|SAXATH|Oslo University Hospital|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|80 Years|No|||June 2014|June 17, 2014|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01552018||89519|
NCT01552889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105510|Depression Outpatient Cardiology Screening Study|Randomized Controlled Trial of Screening for Depression in Cardiac Outpatients|DOCS|Washington University School of Medicine|Yes|Active, not recruiting|January 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|21 Years|N/A|No|||March 2016|March 3, 2016|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01552889||89453|
NCT01553227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXZZ11-0726|Treatment for Obstructive Sleep Apnea Hypopnea Syndrome and Obesity Hypoventilation Syndrome (OHS)|Effect of Auto-trilevel Ventilator on Patients With Obstructive Sleep Apnea Hypopnea Syndrome and Obesity||Nanjing Medical University|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|70 Years|No|||November 2012|November 26, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01553227||89427|
NCT01553240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5438|Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies|Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies||New York State Psychiatric Institute|Yes|Terminated|June 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 6, 2013|July 19, 2011||No|Principal Investigator (Dr. Sporn) left the sponsoring institution.|No||https://clinicaltrials.gov/show/NCT01553240||89426|
NCT01548833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00924|Pre-Lens Tear Film Performance of Silicone Hydrogel Daily Disposable Contact Lenses|Randomized Cross-Over Evaluation of Silicone Hydrogel Daily Disposable Soft Contact Lenses||Alcon Research|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|39|||Both|18 Years|N/A|No|||June 2013|June 6, 2013|March 6, 2012|No|Yes||No|April 22, 2013|https://clinicaltrials.gov/show/NCT01548833||89761|
NCT01549340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7243-022|Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)|Evaluation of Patient Initiation and Persistence With Advised Allergen Immunotherapy||Merck Sharp & Dohme Corp.|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|8790|||Both|N/A|N/A|No|Non-Probability Sample|Patients who were managed by physicians in a large allergy practice, recommended for AIT        between 2005 and 2011 and identified by their electronic health records.|June 2015|June 8, 2015|March 6, 2012||No||No|January 23, 2014|https://clinicaltrials.gov/show/NCT01549340||89722|
NCT01549353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 02/10|Gum Chewing After Gynecologic Laparoscopy|Does Gum Chewing After Gynecologic Laparoscopy Stimulate Earlier Return of Bowel Motility?||Klinikum Klagenfurt am Wörthersee|No|Completed|July 2011|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|1||Anticipated|200|||Female|18 Years|80 Years|No|||December 2012|December 1, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01549353||89721|
NCT01549626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|w831102m|Effects of Flaxseed Flour in Appetite Sensations, Lipid Profile and Pressure Levels Among Overweighed and Obese Women|Effects of Flaxseed Flour - Whole Brown Flaxseed Flour, Brown Defatted Flaxseed Flour and Golden Flaxseed Flour in Appetite Sensations Satiety, Lipid Profile, Pressure Levels and Associated Costs Among Overweighed and Obese Women||Universidade Federal do Rio de Janeiro|Yes|Completed|March 2009|March 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|54|||Female|N/A|N/A|Accepts Healthy Volunteers|||March 2012|March 8, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01549626||89700|
NCT01549366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASP-11-001|Comparison of the Aspen Device Versus Pedicle Screws for Supplemental Posterior Fixation in Lumbar Interbody Fusion|A Multi-Center Prospective Randomized Study Comparing Supplemental Posterior Instrumentation, Aspen™ Spinous Process System Versus Pedicle Screw Fixation, in Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)||Biomet, Inc.|No|Recruiting|February 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|75 Years|No|||February 2016|March 15, 2016|February 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01549366||89720|
NCT01554878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESREFO08|Observational Study on the Treatment of Knee Osteochondral Lesions of Grade III-IV|Observational Studies, Prospective, Multicenter, to Evaluate the Effect of Treatment of Knee Osteochondral Lesions of Outerbridge Grade III-IV|LOGIC|Ettore Sansavini Health Science Foundation|No|Active, not recruiting|March 2012|December 2014|Anticipated|November 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|30 Years|60 Years|No|Probability Sample|patients referred to the participating centers for the treatment of symptomatic        degenerative lesions of the knee, which meet the following inclusion criteria|May 2014|May 18, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01554878||89301|
NCT01555099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2340C00011|Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol|A Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group,Multi-centre Study to Assess the Efficacy and Safety of Two Staggered Dose Levels of Inhaled Once Daily AZD5423 or Twice Daily Budesonide for 12 Weeks in COPD Patients on a Background Therapy of Formoterol.||AstraZeneca||Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|353|||Both|40 Years|N/A|No|||June 2013|June 14, 2013|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01555099||89284|
NCT01564446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2580|Interactive Medication Reconciliation By Secure Messaging|Interactive Medication Reconciliation by Secure Messaging|SMMRT|VA Boston Healthcare System|Yes|Active, not recruiting|April 2011|July 2014|Anticipated|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|152|||Both|18 Years|N/A|No|||March 2014|March 26, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01564446||88570|
NCT01565083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO27782|A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer|A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.||Hoffmann-La Roche||Completed|April 2012|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|214|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565083||88521|
NCT01564472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dx-1152-SWGVAL-SS|Validation of Sleepware G3 Autoscoring Algorithm|Validation of Sleepware G3 Autoscoring Algorithm||Philips Respironics|No|Not yet recruiting|February 2013|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Any retrospective, de-identified adult polysomnogram collected using American Society of        Sleep Medicine (AASM) criteria.|November 2012|November 30, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01564472||88568|
NCT01564784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1931022|A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia|An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)||Pfizer|Yes|Active, not recruiting|August 2012|February 2017|Anticipated|March 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|325|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01564784||88544|
NCT01562821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7LIVER-1313|Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Safety and Efficacy of A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Cirrhotic Patients Scheduled to Undergo Partial Hepatectomy Due to Liver Cancer or Benign Tumours||Novo Nordisk A/S|No|Completed|July 2001|December 2002|Actual|December 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|235|||Both|21 Years|70 Years|No|||October 2013|October 28, 2013|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562821||88693|
NCT01563055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115601|A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia|A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia||GlaxoSmithKline|No|Completed|April 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||July 2015|July 16, 2015|March 15, 2012||No||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01563055||88675|
NCT01574066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM10014|Chest CT-scan for the Diagnosis of Community-acquired Pneumonia|Chest CT-scan for the Diagnosis of Community-acquired Pneumonia in Patients Visiting the Emergency Department|PACSCAN|Assistance Publique - Hôpitaux de Paris|Yes|Completed|November 2011|July 2013|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|339|||Both|18 Years|N/A|No|||July 2013|August 1, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01574066||87833|
NCT01574079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0244|Effect of Mirror Therapy on Lower Extremity Motor Control and Gait in Patients With Stroke|Effect of Mirror Therapy on Lower Extremity Motor Control and Gait in Patients With Stroke||University of Mississippi Medical Center|No|Completed|November 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|January 30, 2012||No||No|June 25, 2013|https://clinicaltrials.gov/show/NCT01574079||87832|
NCT01574339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS005|Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD|An Investigation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD)||EndoStim Inc.|Yes|Active, not recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|21 Years|70 Years|No|||March 2015|March 17, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01574339||87812|
NCT01570270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASU|Cheese Intake and Hypercholesterolemia|||Azienda Ospedaliera Brotzu|No|Completed|May 2009|April 2010|Actual|December 2009|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|42|||Both|30 Years|60 Years|No|||April 2012|April 3, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01570270||88123|
NCT01551810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMBCAMS-04|The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)|The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)|IVV|Chinese Academy of Medical Sciences|Yes|Recruiting|March 2012|August 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1200|||Both|36 Months|N/A|Accepts Healthy Volunteers|||March 2012|March 13, 2012|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551810||89535|
NCT01552577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R072LP-SS3|The RETINA Project: Reliable Eye Tracking in Neurocognitive Assessment of Traumatic Brain Injury|Eye Tracking Indicators of Neurocognitive Status After Traumatic Brain Injury|RETINA|Uniformed Services University of the Health Sciences|Yes|Terminated|October 2010|October 2017|Anticipated|August 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|183|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The population to be studied will include civilians and military personnel with and        without a history of traumatic brain injury / concussion.|March 2016|March 10, 2016|March 8, 2012||No|Expiration of funding|No||https://clinicaltrials.gov/show/NCT01552577||89477|
NCT01552590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-KOB-1101i|Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites|Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites|ECF|Korea Otsuka Pharmaceutical Co.,Ltd.|No|Recruiting|April 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|74|||Both|20 Years|N/A|No|||January 2013|January 3, 2013|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01552590||89476|
NCT01552603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.11|Artificial Pancreas Control System in an Inpatient Setting|Sensor-controlled Insulin- and Glucagon Delivery in Subjects With Type 1 Diabetes: Testing of an Automated System in a Supervised Inpatient Setting||Legacy Health System|Yes|Completed|March 2012|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|21 Years|65 Years|No|||September 2014|September 15, 2014|February 22, 2012|Yes|Yes||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01552603||89475|
NCT01552616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMSA|Safety and Performance of Muscle Activation for Critical Care Patients|Evaluation of Thermal-aided Muscle Activation in Intensive Care Unit (ICU) Patients - A PILOT Study||Niveus Medical, Inc.|No|Terminated|February 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|5|||Both|18 Years|N/A|No|||April 2013|April 5, 2013|February 20, 2012|Yes|Yes|Enrollment|No||https://clinicaltrials.gov/show/NCT01552616||89474|
NCT01552629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031X2201|A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis||Novartis||Completed|January 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|22|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01552629||89473|
NCT01553500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPBG_GLUCO_2010|Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease|Study of the Efficacy and Tolerability of Glucomannan on Children Affected by NAFLD|GC-NASH|Bambino Gesù Hospital and Research Institute||Completed|June 2011|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|4 Years|16 Years|No|||March 2012|April 1, 2014|October 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553500||89406|
NCT01553747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27018966IBS3002|Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome||Furiex Pharmaceuticals, Inc|No|Completed|May 2012|February 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1150|||Both|18 Years|80 Years|No|||April 2015|April 26, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01553747||89387|
NCT01548846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOQUAL|Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract|Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract|TOQUAL|Centre Francois Baclesse|No|Terminated|May 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|No|||March 2014|March 12, 2015|March 6, 2012||No|lack of recrutment|No||https://clinicaltrials.gov/show/NCT01548846||89760|
NCT01548859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA 11/60|Comparison of the Effects of Sevoflurane and Midazolam Used for the Maintenance of Anaesthesia on the Levels of Postoperative Cardiac Troponin I in Pediatric Cardiac Surgery|||Baskent University|Yes|Active, not recruiting|July 2011|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|1 Month|6 Years|No|||March 2012|March 6, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01548859||89759|
NCT01549106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-145-01|IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food and Ketoconazole on the Pharmacokinetics of IPI-145 When Administered to Healthy Adult Subjects||Infinity Pharmaceuticals, Inc.|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|106|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 6, 2012|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01549106||89740|
NCT01549379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO18826|Dynamic Contrast Enhanced Computed Tomography (CT) for Head and Neck Cancer|Dynamic Contrast Enhanced Computed Tomography (DCE-CT) to Assess Lymph Node Metastases in Head and Neck Cancer: A Prospective Study||Lawson Health Research Institute|No|Terminated|July 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|1|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|February 24, 2012||No|Poor Accrual|No||https://clinicaltrials.gov/show/NCT01549379||89719|
NCT01554553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0605|Longitudinal Sleeve Gastrectomy Study Comparing Posterior Crural Repair Versus No Repair|A Prospective Randomized Clinical Trial Comparing Patients Who Have Had Longitudinal Sleeve Gastrectomy With Posterior Crural Repair Versus Without Posterior Crural Repair||The University of Texas Health Science Center, Houston|No|Enrolling by invitation|January 2012|January 2018|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|100|||Both|21 Years|65 Years|No|||June 2015|June 11, 2015|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01554553||89326|
NCT01554566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|honey1010|Metabolic Effects of Honey in Type 1 Diabetes Mellitus|Metabolic Effects of Honey in Type 1 Diabetes Mellitus: a Cross Over Randomised Controlled Pilot Study||Ain Shams University|Yes|Completed|January 2010|October 2011|Actual|June 2011|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|4 Years|18 Years|No|||March 2012|March 14, 2012|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01554566||89325|
NCT01554891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-SAFE-TBI|INTRuST Structured Assessment For Evaluation of TBI (SAFE-TBI)|Reliability and Initial Validation of the INTRuST Structured Assessment For Evaluation of TBI (SAFE-TBI)|SAFE-TBI|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Completed|February 2012|March 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|305|||Both|18 Years|60 Years|No|Non-Probability Sample|Cohort 1: Active duty OEF/OIF/OND military personnel ages 18-60 who have recently screened        positive for TBI following deployment.        Cohort 2: OEF/OIF/OND veterans ages 18-60 who have recently screened positive for TBI.        Cohort 3: Participants ages 18-60 in the INTRuST Consortium Brain Indices Study at WRNMMC        or FBCH.|March 2016|March 2, 2016|March 12, 2012||No||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01554891||89300|
NCT01565343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A04|A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers|Test-retest Reproducibility of 18F-AV-45 for Brain Imaging of Amyloid in Healthy Volunteers and Alzheimer's Disease Patients||Avid Radiopharmaceuticals|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|3||Actual|25|||Both|35 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 8, 2012|March 26, 2012|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01565343||88501|
NCT01565356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A06|Evaluation of PET Scan Timing Relative to AV-45 Injection Time|Comparison of PET Images Acquired at 30 Min and 50 Min Post Injection of 18F-AV-45 in Healthy Volunteers and Alzheimer's Disease Patients||Avid Radiopharmaceuticals|No|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|41|||Both|35 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 3, 2012|March 26, 2012|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01565356||88500|
NCT01565629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCAL-2012|Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders|Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders|CCAL|University of South Florida|No|Active, not recruiting|February 2012|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565629||88479|
NCT01565642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0699|Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia|Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia|GOC|University of North Carolina, Chapel Hill|Yes|Completed|May 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|302|||Both|65 Years|N/A|No|||March 2016|March 1, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565642||88478|
NCT01573832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-289c|Integrated Client Care Project Trial: Wound Care Evaluation|Integrated Client Care Project Randomized Control Trial: Wound Care Evaluation|ICCP-WC|Sunnybrook Health Sciences Centre|No|Completed|June 2012|January 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|13999|||Both|18 Years|N/A|No|Probability Sample|Patients who receive wound care from participating Ontario Community Care Access Centres.|May 2015|May 25, 2015|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01573832||87851|
NCT01570296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-11-03|A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR|A Phase Ib Trial of Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa™) in Combination With BKM120, an Oral Pan-class I PI3K Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR|BKM120|National Cancer Centre, Singapore|No|Active, not recruiting|October 2011|December 2016|Anticipated|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|21 Years|N/A|No|||March 2016|March 21, 2016|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01570296||88121|
NCT01570569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-152|Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human|Development of High-throughput Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human||Inje University|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|5||Actual|26|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 1, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01570569||88100|
NCT01570582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG3017|A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|A Phase II Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer||Korean Gynecologic Oncology Group|No|Active, not recruiting|March 2010|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|314|||Female|18 Years|70 Years|No|||April 2012|April 3, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570582||88099|
NCT01570803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENS-FP|Efficacy Between Different Two Self-Expanding Nitinol Stents For The Atherosclerotic Femoro-Popliteal Arterial Disease|Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)|SENS-FP|Korea University Guro Hospital|Yes|Recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|346|||Both|20 Years|90 Years|No|||September 2015|September 6, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570803||88082|
NCT01570816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12004-H02|Improving Ambulatory Community Access After Paralysis|Improving Ambulatory Community Access After Paralysis||Louis Stokes VA Medical Center|Yes|Active, not recruiting|April 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|75 Years|No|||March 2016|March 17, 2016|April 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01570816||88081|
NCT01551823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMBCAMS-05|The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）|The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)（Children Forms of Drug）||Chinese Academy of Medical Sciences|Yes|Recruiting|March 2012|August 2012|Anticipated|May 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1200|||Both|6 Months|35 Months|Accepts Healthy Volunteers|||March 2012|March 13, 2012|March 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551823||89534|
NCT01552317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OxCKD1|OxCKD1 -Empowering Healthy Lifestyle Choices in Chronic Kidney Disease|OxCKD1 - a Randomised Controlled Trial of the OxSalt1 Care Bundle to Help Renal Patients Learn How to Lower the Salt Content of Their Diets.|OxCKD1|University of Oxford|No|Completed|April 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|201|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01552317||89497|
NCT01552330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-016-11|Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects|Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Pyronaridine-Artesunate in Healthy Adult Subjects||University of Oxford|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01552330||89496|
NCT01552343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000034|Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary|A Double-blind, Randomized, Placebo-controlled Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary|IMPACT|Ferring Pharmaceuticals|No|Completed|March 2012|June 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01552343||89495|
NCT01552642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD068783|An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children|An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children||University of Wisconsin, Madison|No|Completed|February 2013|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|N/A|N/A|No|||July 2015|July 27, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01552642||89472|
NCT01573052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UU40574|Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal|Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment||VA Salt Lake City Health Care System|Yes|Completed|March 2004|September 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|80 Years|No|||June 2012|June 20, 2012|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573052||87910|
NCT01573065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906005270|HIV Testing and Brief Alcohol Intervention for Young Drinkers in the Emergency Department|Addressing HIV Risk in Young Unhealthy Alcohol Drinkers in the Emergency Department With Rapid HIV Testing and Brief Intervention||Yale University|No|Completed|March 2010|August 2011|Actual|May 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|85|||Both|18 Years|40 Years|No|||August 2012|August 9, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01573065||87909|
NCT01573078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02479|Psychology of Crohn's Disease|Will The Real Psychology Of Crohn's Disease Please Stand Up?||University of British Columbia||Active, not recruiting|May 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|19 Years|N/A|No|Non-Probability Sample|Crohn's Disease Patients|September 2014|September 29, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01573078||87908|
NCT01573351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-029|Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)|A Phase 3, Open-Label Study With Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin With Chronic Hepatitis C Genotypes 1 or 4 Infection|Hallmark QUAD|Bristol-Myers Squibb|No|Completed|May 2012|December 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|398|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573351||87887|
NCT01561664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8685|Inflammation Regulation in Obese Patients|Relations Between Obesity and Insulin Resistance: Role of Inflammation Regulatory Mechanisms in Obese Patients Without Associated Comorbidity||University Hospital, Montpellier|No|Completed|November 2011|December 2013|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|30|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||March 2012|September 17, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01561664||88782|
NCT01561924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1675|Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography|An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors||Novo Nordisk A/S|No|Completed|November 2005|May 2006|Actual|May 2006|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Male|16 Years|N/A|No|||March 2012|June 15, 2012|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561924||88762|
NCT01562184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC11515|Investigating tDCS as a Treatment for Unipolar and Bipolar Depression|A Controlled Trial of Transcranial Direct Current Stimulation as a Treatment for Unipolar and Bipolar Depression||The University of New South Wales|Yes|Completed|June 2012|October 2015|Actual|October 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562184||88742|
NCT01593020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0167|Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2|A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2012|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Female|18 Years|N/A|No|||June 2015|June 2, 2015|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593020||86390|
NCT01593293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC 2011-0857|Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer|A Randomized, Open-label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|ACE|Asan Medical Center|No|Recruiting|March 2012|November 2015|Anticipated|November 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|266|||Both|70 Years|N/A|No|||May 2012|May 5, 2012|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01593293||86369|
NCT01593800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLI ver3|The Effect of Probiotics on Lactose Intolerance|The Effect of Probiotics on Lactose Intolerance|PLI|Rabin Medical Center|Yes|Not yet recruiting|May 2012|April 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|60|||Both|18 Years|80 Years|No|||February 2012|May 6, 2012|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01593800||86330|
NCT01593553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Strokestop|Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden|Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden.||Karolinska University Hospital||Active, not recruiting|March 2012|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|6500|||Both|75 Years|76 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593553||86349|
NCT01571089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLL-189011|Anxiety Treatment Inspired by Dialectical Behavior Therapy (DBT)|Anxiety Treatment Inspired by Dialectical Behavior Therapy (DBT) - An Alternative for Patients Who Previously Received Exposure-based Treatment for Anxiety Without Sustained Improvements.||Örebro County Council|No|Completed|March 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|64 Years|No|||May 2015|May 19, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01571089||88060|
NCT01571102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/161|Impact of Physiotherapy on Short-term Outcome After Meniscectomy|Study of Impact of Physiotherapy on Short-term Outcome After Meniscectomy.||University Hospital, Ghent|No|Recruiting|February 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01571102||88059|
NCT01571115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0147/11|Effects of Resistance Physical Exercise in Patients With Chronic Primary Insomnia|Effects of Resistance Physical Exercise in Patients With Chronic Primary|IER|Federal University of São Paulo|Yes|Completed|January 2012|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Both|30 Years|55 Years|No|||August 2014|August 12, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01571115||88058|
NCT01572272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D007157|Comparison of Open Versus Masked Distal EtCO2 Monitoring of Neonates Ventilated With Conventional Ventilation|Comparison of Open Versus Masked Distal EtCO2 Monitoring of Neonates Ventilated With Conventional Ventilation. A Randomized, Multi-Center Study||Oridion|No|Completed|August 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|66|||Both|N/A|N/A|No|Non-Probability Sample|Intubated neonates that require conventional ventilation|February 2015|February 25, 2015|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01572272||87970|
NCT01571934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046800|Inhibitor Development in Patients With Hemophilia A Undergoing Surgery|Inhibitor Development in Patients With Hemophilia A Undergoing Surgery|PASs|Emory University|No|Recruiting|November 2011|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|140|Samples With DNA|Blood drawn during study includes 15 ml within 7 days prior to surgery and 15 ml drawn on      post-operative days 1, 14 and 90.      Samples for DNA storage will be generated from blood draw study samples.|Male|N/A|N/A|No|Non-Probability Sample|In addition to Emory University, subjects will be recruited at one of 8 following sites:        University of Pittsburgh, University of North Carolina, Oregon Health and Science        University, University of Colorado, University of Texas Health Science Center at Houston,        University of Minnesota, and Indiana Hemophilia Treatment Center.|January 2016|January 9, 2016|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01571934||87996|
NCT01572545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PolyzosAnastasilakis|Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass|Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial|DenoZol|Aristotle University Of Thessaloniki|Yes|Completed|April 2012|January 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|91|||Female|40 Years|N/A|No|||January 2013|January 15, 2013|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572545||87949|
NCT01572506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912109|Mechanisms Accounting for Unexplained Anemia in the Elderly|Assessing Mechanisms Accounting for Unexplained Anemia in the Elderly||National Institutes of Health Clinical Center (CC)||Completed|March 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|4||Anticipated|128|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|August 5, 2015|April 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01572506||87952|
NCT01572519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100813|A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma|An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma||Janssen Research & Development, LLC|Yes|Completed|June 2012|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01572519||87951|
NCT01573091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/0043537|Cardiac Resynchronization Therapy Modular Registry|Cardiac Resynchronization Therapy Modular Registry|CRT MORE|University of Florence||Active, not recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients eligible for CRT device implanted according to current guidelines|October 2014|October 27, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01573091||87907|
NCT01573364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQFST5213|Prevalence and Reversibility of Lung Hyperinflation in Asthma|Evaluation of the Prevalence and the Reversibility of the Lung Hyperinflation in Uncontrolled Persistent Asthmatic Patients With Dyspnea|Dist'air2|Chiesi Farmaceutici S.p.A.|No|Completed|February 2011|January 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Both|18 Years|90 Years|No|Non-Probability Sample|Adults|April 2012|April 5, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573364||87886|
NCT01573624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115938|Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma|A Multi-center, Randomized, Double-blind, Dose-ranging Study to Evaluate GSK573719 in Combination With Fluticasone Furoate, Fluticasone Furoate Alone, and an Active Control of Fluticasone Furoate/Vilanterol Combination in Subjects With Asthma|ILA115938|GlaxoSmithKline|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|3||Actual|421|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573624||87867|
NCT01561937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1825|Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment|Use of Recombinant FVIIa to Mitigate Warfarin Anticoagulation Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial||Novo Nordisk A/S|No|Completed|January 2007|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|127|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561937||88761|
NCT01561950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1955|Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding|Use of Recombinant FVIIa to Mitigate Clopidogrel Anti-platelet Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial||Novo Nordisk A/S|No|Terminated|May 2008|January 2009|Actual|January 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|91|||Male|18 Years|45 Years|No|||March 2012|March 22, 2012|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561950||88760|
NCT01562197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AxiGII|A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma|A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma|AxiGII|Universitair Ziekenhuis Brussel|No|Active, not recruiting|April 2014|May 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||July 2015|July 1, 2015|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562197||88741|
NCT01562210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35195.031.11|Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC|Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma|olaparib|The Netherlands Cancer Institute|No|Recruiting|April 2012|March 2020|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562210||88740|
NCT01562223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000728901|Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer|Repeatability Assessment of Quantitative DCE-MRI and DWI: A Multicenter Study of Functional Imaging Standardization in the Prostate|A6701 QIBA|American College of Radiology Imaging Network|Yes|Recruiting|August 2012|||January 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Male|18 Years|N/A|No|||January 2013|January 25, 2013|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562223||88739|
NCT01562496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38116.091.11|The ParkCycle Study: Aerobic Exercise in PD|The ParkCycle Study: Effects of Aerobic Exercise on Cognitive and Adaptive Plasticity in Parkinson's Disease||Radboud University|No|Completed|January 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|30 Years|75 Years|No|||November 2014|November 12, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01562496||88718|
NCT01562756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRiSM Pilot|Patient Response to Spinal Manipulation - Pilot Study|Pilot for Patient Response to Spinal Manipulation (PRiSM)|PRiSM|Palmer College of Chiropractic|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||March 2012|August 2, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562756||88698|
NCT01593306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pragyat1805|Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix|||Indira Gandhi Medical College|Yes|Recruiting|July 2011|February 2013|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|65 Years|No|||May 2012|May 7, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01593306||86368|
NCT01593579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120390|Autonomic Phenotype Before and After Akt Inhibition|Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study||Vanderbilt University|No|Withdrawn|May 2012|May 2016|Anticipated|May 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|18 Years|80 Years|No|Probability Sample|Patients will have a diagnosis of Melanoma and be participating in a clinical trial with        an arm using oral Akt therapy. Patients will be recruited from the Vanderbilt Ingram        Cancer Center.|December 2014|December 18, 2014|May 4, 2012||No|Planned parent study never enrolled|No||https://clinicaltrials.gov/show/NCT01593579||86347|
NCT01593826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103010|Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler|Pharmacokinetic Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 320/9 Microg/Inhalation and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects||Orion Corporation, Orion Pharma|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2012|November 21, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593826||86328|
NCT01593566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mahidol University|Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction|Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction|FNB for ACLR|Mahidol University|No|Completed|April 2011|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||April 2015|April 8, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593566||86348|
NCT01593839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182006/V50|Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism|Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism||Oslo University Hospital|Yes|Recruiting|May 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|6|Samples Without DNA|Interstitial|Both|30 Years|50 Years|No|Non-Probability Sample|Persons referred to Hospital of rehabilitation due to chronic non-specific low back pain|May 2012|May 7, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593839||86327|
NCT01594411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-PCP|Primary Care Providers Use of a Gene Expression Test in Coronary Artery Disease Diagnosis|Investigation of a Molecular Personalized Coronary Gene Expression Test on Primary Care Practice Pattern|IMPACT-PCP|CardioDx|No|Completed|April 2012|February 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|251|Samples Without DNA|One 2.5 mL PAXgene (PreAnalytiXTM) (for RNA preservation) tube will be filled with      approximately 7.5 ml of blood and sent to CardioDx, Inc. for analysis.|Both|21 Years|N/A|No|Probability Sample|This is a prospective, multi-center study examining the clinical impact of the Corus® CAD        assay in approximately 250 evaluable subjects with no history of obstructive coronary        artery disease who now present with chest pain or anginal-equivalent symptoms to a primary        care physician (PCP) for evaluation.|November 2014|November 19, 2014|April 20, 2012||No||No|September 3, 2013|https://clinicaltrials.gov/show/NCT01594411||86283|Prospective design may have influenced the diagnostic strategy; but historical controls had a similar diagnostic strategy.Possible Selection bias; we believe these pts are typical of each practice. Appropriateness of care not evaluated
NCT01594424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Actemra + IVIG|A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation|A Phase I/II Trial of Tocilizumab + Intravenous Immunoglobulin (IVIG) as Agents to Reduce Donor-Specific Anti-HLA Antibodies (DSA) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Kidney Transplantation||Cedars-Sinai Medical Center|Yes|Completed|June 2012|May 2015|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|65 Years|No|||July 2015|July 8, 2015|May 4, 2012|Yes|Yes||No|July 8, 2015|https://clinicaltrials.gov/show/NCT01594424||86282|
NCT01594437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCN-202-001|Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody|Phase 1 Study of TCN-202 (Human Anti-Cytomegalovirus Monoclonal Antibody) in Healthy Adult Volunteers||Theraclone Sciences, Inc.|Yes|Completed|May 2012|March 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 19, 2014|May 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01594437||86281|
NCT01571128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AI094607-1|Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)|Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)|MP3-Youth|New York University|No|Active, not recruiting|November 2014|August 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|1215|||Both|15 Years|24 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01571128||88057|
NCT01571141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHMB_HPV|Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection|||AGUNCO Obstetrics and Gynecology Centre|No|Completed||||||Phase 4|Interventional|N/A|2||||||Female|30 Years|45 Years|No|||June 2011|April 18, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01571141||88056|
NCT01571947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A003.11|Acute Effects of Dietary Fats and Carbohydrate in Subjects With Metabolic Syndrome|Acute Effects of Dietary Fats and Carbohydrate on Insulinaemia, Lipaemia, Inflammatory Responses and Gastrointestinal Peptide Secretion in Subjects With Metabolic Syndrome||Malaysia Palm Oil Board|Yes|Completed|November 2011|July 2014|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|30|||Both|20 Years|60 Years|No|||July 2014|July 22, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571947||87995|
NCT01571960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 094|Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults|A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|April 2012|||August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|6||Actual|48|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01571960||87994|
NCT01571973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPPsicobio1Lu|Evaluation of Pharmaceutical Care in Depressed Outpatients|EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL CARE (DÁDER PROGRAM) IN DEPRESSED OUTPATIENTS TREATED WITH PSYCHOTROPIC|depression|Federal University of São Paulo|Yes|Active, not recruiting|March 2010|May 2012|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Female|18 Years|65 Years|No|||June 2011|April 4, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571973||87993|
NCT01571986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP/50/ER/mm|Improving Non-invasive Ventilation|Improving Non Invasive Ventilation|Improving NIV|Università Vita-Salute San Raffaele|No|Recruiting|February 2012|||February 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|99 Years|No|Probability Sample|All patients with acute respiratory failure treated with non-invasive ventilation who give        informed consent about treatment of their clinical data|March 2016|March 9, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01571986||87992|
NCT01572571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLG-182/2011|Ultrasound in Undifferentiated Hypotension|Focused Multiorgan Ultrasound in the Emergency Evaluation of Undifferentiated Hypotension|US-UHP|San Luigi Gonzaga Hospital|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|16 Years|N/A|No|Probability Sample|Patients presenting to the Emergency Department with undifferentiated hypotension|December 2013|December 18, 2013|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572571||87947|
NCT01572584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLG-181/2011|Lung Ultrasound in the Evaluation of Pneumothorax Size|Accuracy of Lung Ultrasound in the Prediction of Pneumothorax Volume Assessed by CT Scan|LUS-PNXsize|San Luigi Gonzaga Hospital|No|Completed|December 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|115|||Both|16 Years|90 Years|No|Probability Sample|Patients from the Emergency Department Patients admitted to the Hospital Outpatients from        the Radiology Department who undergo invasive thoracic procedures|December 2013|December 18, 2013|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572584||87946|
NCT01572259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001688-34|Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism|Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism||Assistance Publique Hopitaux De Marseille|No|Recruiting|September 2011|March 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|70 Years|No|||August 2015|November 16, 2015|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01572259||87971|
NCT01573104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RID-001|Evaluating Novel Biomarkers in Acute Kidney Injury|Evaluating the Utility of Urinary Proteomics and Novel Biomarkers in Acute Kidney Injury||University of Glasgow|No|Completed|November 2012|January 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|87|||Both|18 Years|90 Years|No|||May 2015|May 26, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01573104||87906|
NCT01572532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003063|Maternal Genitourinary Infections and Adverse Perinatal Outcomes|Maternal Genitourinary Infections and Adverse Perinatal Outcomes in Sylhet District, Bangladesh||Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|August 2010|May 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|9000|||Both|N/A|47 Years|Accepts Healthy Volunteers|||December 2011|August 18, 2014|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01572532||87950|
NCT01573637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSJD-RAL-2010|Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women|Six Month, Double Blind, Placebo-controlled Trial of the Efficacy of Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women||Fundació Sant Joan de Déu|No|Completed|July 2011|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|78|||Female|45 Years|N/A|No|||August 2015|August 21, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573637||87866|
NCT01573897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AGIR-01|Impact of Sleep Apnea on Diabetic Foot Wound|Influence of Sleep Apnea Syndrome and Its Treatment by Positive Airway Pressure Therapy on Transcutaneous Oxygen Tension (PtcO2)in Patients With Foot Wound or at Risk for Foot Wound|SAS-FOOT|AGIR à Dom|No|Recruiting|May 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|Consecutives diabetic patients referred to our tertiary diabetes unit (Grenoble University        Hopsital, France) for diabetic foot wound|January 2016|January 7, 2016|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01573897||87846|
NCT01574131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-106|Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients|Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients||The University of Texas Medical Branch, Galveston|Yes|Terminated|May 2012|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|3|||Both|4 Years|20 Years|No|||February 2016|February 9, 2016|March 22, 2012|No|Yes|lost funding|No||https://clinicaltrials.gov/show/NCT01574131||87828|
NCT01592214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0007|Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73|A Two-Part Phase I Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XF-73 for Decolonization of Staphylococcus Aureus: A Previously Investigated 0.5 mg/g Viscosified Gel Formulation Versus a Modified Formulation||National Institute of Allergy and Infectious Diseases (NIAID)||Recruiting|August 2012|August 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|December 4, 2014|May 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01592214||86451|
NCT01592227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6480791|A Study to Compare Two Paracetamol Formulations.|A Pharmacokinetic Study Investigating the Rate and Extent of Absorption of Paracetamol and an Adjuvant From Two Different Paracetamol Formulations.||GlaxoSmithKline|No|Completed|December 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01592227||86450|
NCT01592474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SET|Evaluation of Brain Atrophy in CIS Patients on Avonex|Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNβ-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy)||University at Buffalo|No|Completed|October 2005|June 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|18 Years|55 Years|No|Non-Probability Sample|Multiple sclerosis patients being treated with Avonex after first clinical attack.|July 2014|July 8, 2014|May 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01592474||86431|
NCT01592773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-69|Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)|An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)||Forest Laboratories|No|Terminated|October 2012|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|747|||Both|6 Years|12 Years|No|||January 2015|January 30, 2015|May 3, 2012|No|Yes|Terminated because primary efficacy parameter failed to demonstrate statistically significant    difference between memantine and placebo in controlled trials|No|January 30, 2015|https://clinicaltrials.gov/show/NCT01592773||86409|
NCT01593059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1106|BIOFLOW-III Romania Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Romania||Biotronik Vertriebs-GmbH|No|Terminated|August 2012|November 2013|Actual|October 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers patient population with all subjects requiring coronary revascularization with        a Drug Eluting Stent (DES)|August 2012|April 25, 2014|May 4, 2012||No|low enrollment|No||https://clinicaltrials.gov/show/NCT01593059||86387|
NCT01593319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAROP11|Is Regional Anesthesia of the Hip Preferable Over Traditional Analgesia in the Acute Stage of the Management of Patients With a Fracture of the Hip|||Landstinget i Värmland|Yes|Terminated|January 2012|April 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|37|||Both|65 Years|N/A|No|||April 2015|April 17, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01593319||86367|
NCT01593332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87549|Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis|||Mashhad University of Medical Sciences|Yes|Completed|July 2010|October 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|19 Years|75 Years|No|||May 2012|May 5, 2012|January 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593332||86366|
NCT01593592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#:395/29-4-2012|Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients|Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients: a Double Blind Placebo Controlled Randomized Clinical Trial||Zagazig University|Yes|Completed|June 2012|||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|60 Years|No|||July 2015|July 19, 2015|May 5, 2012||No||No|March 7, 2015|https://clinicaltrials.gov/show/NCT01593592||86346|no limitations
NCT01594463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/090/HP|Routine Ultrasound Screening in the Third Trimester|Third Trimester Routine Ultrasound in Low-risk Pregnancies : Comparison of Two Timing Periods Procedure for Screening Intrauterine Growth Restriction|RECRET|University Hospital, Rouen|No|Active, not recruiting|May 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|3760|||Female|18 Years|50 Years|No|||January 2016|January 22, 2016|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01594463||86279|
NCT01594723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13861|A Study of LY2784544 in Participants With Myeloproliferative Neoplasms|A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms||Eli Lilly and Company|No|Active, not recruiting|May 2012|August 2016|Anticipated|March 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|May 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594723||86259|
NCT01565096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ikfe-Vilda-001|Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy|Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy||ikfe-CRO GmbH|No|Recruiting|November 2011|||November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|30 Years|80 Years|No|||March 2012|March 26, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01565096||88520|
NCT01571999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114636|Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment|A Single-blind, Non-randomized Pharmacokinetic and Safety Study of Single Dose of GSK573719 and GSK573719 + GW642444 Combination in Healthy Subjects and in Subjects With Severe Renal Impairment||GlaxoSmithKline|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|17|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571999||87991|
NCT01572012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HALO-102-102|Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers|Phase 1 Open-Label Randomized 4 Period Crossover Study Comparing Safety, Tolerability and PK of Ondansetron Given Subcutaneously With Hylenex Recombinant and Given Alone Intramuscularly, Intravenously and Orally in Healthy Volunteers||Halozyme Therapeutics|No|Completed|February 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 22, 2014|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572012||87990|
NCT01572285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0530/09|Transforaminal Epidural Steroid Injection to Treat Hemiplegic Shoulder Pain|Transforaminal Epidural Steroid Injection to Treat Hemiplegic Shoulder Pain : A Randomized, Sham-Controlled, Proof of Principle Trial||University of Sao Paulo General Hospital|Yes|Recruiting|October 2011|November 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|65 Years|No|||March 2012|April 5, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572285||87969|
NCT01572597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB100-26|Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy|Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy.||Buddhist Tzu Chi General Hospital|Yes|Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|80 Years|No|||April 2012|April 5, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572597||87945|
NCT01572558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2011/4:8|Conservative Treatment of Acute Appendicitis in Children|Conservative Treatment of Acute Appendicitis in Children Pilot Trial|CONSAPP Pilot|Karolinska University Hospital|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|5 Years|15 Years|No|||October 2012|October 15, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01572558||87948|
NCT01572831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB 2011-089|PCT and Clinical Algorithm for Determination of Duration of Antibiotics|A Pilot Study to Evaluate a Procalcitonin-Based Algorithm for Duration of Antibiotic Therapy in Critically Ill Patients||Fraser Health|No|Completed|May 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|19 Years|N/A|No|||April 2012|May 22, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572831||87927|
NCT01573117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCOOL 1|A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill (iCOOL 1)|iCOOL 1 (Induction of COOLing 1): A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill|iCOOL 1|University Hospital Heidelberg|No|Completed|September 2010|||November 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01573117||87905|
NCT01572818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-A00636-49|Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients|Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients|SAINPOS|Rennes University Hospital|Yes|Recruiting|October 2010|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|70 Years|No|||May 2015|May 26, 2015|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01572818||87928|
NCT01573663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-AMBLE-101|A Drug-Drug Interaction Study of Ambroxol and Levodropropizine|Open Label, Randomized, 3-sequence Crossover Study to Evaluate the Drug-drug Interaction Between Ambroxol HCl and Levodropropizine in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||April 2012|July 18, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573663||87864|
NCT01573910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-051|An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients|An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients||Alcon Research|Yes|Completed|May 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|985|||Both|1 Year|N/A|No|||April 2015|April 27, 2015|April 6, 2012|Yes|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT01573910||87845|
NCT01574144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|READMIT-HF|REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)|Observational Study of Reducing 30-day Admissions in Post-discharge Subjects|READMIT-HF|Medtronic Cardiac Rhythm Disease Management|No|Completed|March 2012|July 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|N/A|No|Non-Probability Sample|Heart failure patients who are admitted to the hospital.|July 2013|July 22, 2013|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01574144||87827|
NCT01574157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-002-11F|Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.|Investigations of the Optimum Serum Bicarbonate Level in Renal Disease||VA Office of Research and Development|Yes|Recruiting|November 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01574157||87826|
NCT01592487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114663|Effects of a Breakfast and Snack on Cognitive Function in Preadolescents|||University of Arkansas|Yes|Withdrawn|December 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|9 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy 4th and 5th graders|February 2014|February 11, 2014|May 3, 2012|No|Yes|Study never started, and there are no plans to initiate.|No||https://clinicaltrials.gov/show/NCT01592487||86430|
NCT01592500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-4-004|Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children|Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children||Opko Biologics|Yes|Completed|February 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|53|||Both|3 Years|11 Years|No|||July 2015|November 10, 2015|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592500||86429|
NCT01592786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-91|An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)|An Open-Label Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)||Forest Laboratories|No|Completed|June 2012|August 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|906|||Both|6 Years|12 Years|No|||July 2014|July 15, 2014|May 3, 2012|No|Yes||No|July 15, 2014|https://clinicaltrials.gov/show/NCT01592786||86408|
NCT01593033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJM - Fish Oil|Effectiveness of Micronutrient Supplementation and Fish Oil + Micronutrient Supplementation in the Treatment of Environmental Enteropathy|Randomized, Double-blind, Placebo-controlled Trial Evaluating the Impact of Micronutrient Supplementation and Fish Oil + Micronutrient Supplementation in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children||Washington University School of Medicine||Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|1 Year|3 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01593033||86389|
NCT01593046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115428|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects|A Randomized, Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects||ViiV Healthcare|No|Completed|May 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|43|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||January 2014|February 6, 2014|May 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01593046||86388|
NCT01593345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2476|Self-management of Chronic Mobility Limitations in MUHC Seniors|Promotion of Self-management of Chronic Mobility Limitations Among Vulnerable Seniors at the MUHC: Training the New Generation of Canadian Physiotherapists for This Role. Addendum: Planning Physiotherapy Services for Persons Treated at the MUHC for Cancer: A Needs Assessment||McGill University|No|Completed|February 2013|December 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|70 Years|N/A|No|||December 2015|December 18, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01593345||86365|
NCT01593865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CathUni001|The Catholic University BIMA Grafting Study|Observational, Case-Control, Propensity-Matched Study of Bilateral Versus Monolateral Internal Mammary Artery Grafting for Severe Coronary Artery Disease. Assessment of Feasibility of Systematic Bilateral Mammary Artery Grafting and Early/Late Clinical Outcomes|CATHEXIS|Catholic University, Italy||Recruiting|April 2012|||June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|||Both|18 Years|85 Years|No|Probability Sample|The target study population consists of 1,000 patients undergoing isolated coronary        surgery for multivessel disease within a Cardiac Surgery University Department.|August 2012|August 17, 2012|May 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01593865||86325|
NCT01593878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Distracted Homework|Media Background and Test Performance|||Seattle Children's Hospital||Withdrawn|June 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|0|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||March 2014|March 24, 2014|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593878||86324|
NCT01593891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESEARCH_REGISTRY_2|Radiographic and Intravascular (IVUS) Evaluation of Venous Morphology During CCSVI Treatment|Radiographic and Intravascular (IVUS) Evaluation of Venous Morphology During CCSVI Treatment|Resrch_Reg_2|Synergy Health Concepts, Inc.|Yes|Active, not recruiting|August 2011|September 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|45|||Both|20 Years|60 Years|No|Non-Probability Sample|Many questions remain about how and when CCSVI might play a role in nervous system damage        and whether venous angioplasty is helpful in treating the symptoms of CCSVI. Utilizing        intravascular ultrasound (IVUS,) this pilot study will provide data that will allow        researchers to evaluate venous morphology pre- and post- percutaneous angioplasty and        sub-classify valve morphology as related to treatment success by distinguishing vessels        which are more responsive to treatment. In addition, this study will validate the safety        of valvuloplasty in various neurodegenerative disorders that involve venous obstruction.|May 2012|May 6, 2012|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01593891||86323|
NCT01594138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-1421|Linguistic Characteristics of Suicidal Patients in the Emergency Department|Linguistic Characteristics of Suicidal Patients in the ED (Emergency Department)||Children's Hospital Medical Center, Cincinnati|No|Completed|September 2009|July 2014|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|13 Years|17 Years|No|Non-Probability Sample|CCHMC suicidal and non-suicidal adolescents|July 2014|February 26, 2016|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01594138||86304|
NCT01565109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NESC|NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma|Phase II Multicenter Study in the Preoperative Treatment of Gastric Adenocarcinoma Consisting of Chemotherapy Using Docetaxel-cisplatin-5FU + Lenograstim Followed by Chemoradiation Based 5FU and Oxaliplatin||Institut Sainte Catherine|Yes|Recruiting|March 2009|March 2018|Anticipated|March 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|65 Years|No|||December 2012|December 20, 2012|October 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01565109||88519|
NCT01572025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11054|Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging|Efficacy of Dehydroepiandrosterone to Overcome the Effect of Ovarian Aging - A Pilot Double Blinded Randomised Controlled Trial|DITTO|University of Nottingham|Yes|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|23 Years|48 Years|No|||December 2015|December 8, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01572025||87989|
NCT01572298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20120108H|A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts|A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts.||The University of Texas Health Science Center at San Antonio|Yes|Completed|April 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|April 3, 2012||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01572298||87968|
NCT01573143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.0 /06.09.11|Statin Therapy In Cardiac Surgery|Statin Therapy In Cardiac Surgery|STICS|University of Oxford|Yes|Completed|September 2011|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1922|||Both|18 Years|80 Years|No|||September 2014|September 16, 2014|February 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01573143||87903|
NCT01572844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121131|Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis|Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis||George Washington University|Yes|Recruiting|August 2012|December 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|65 Years|No|||April 2014|December 15, 2014|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572844||87926|
NCT01573130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Progredi|Treating Depression With Physical Exercise|An Internet-administered, Therapist-supported Physical Exercise Program for the Treatment of Depression||Umeå University|No|Recruiting|March 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||April 2012|April 4, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01573130||87904|
NCT01573377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS-Qifu Li|Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial|Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial||Chongqing Medical University|Yes|Completed|February 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|35 Years|No|||December 2013|December 26, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573377||87885|
NCT01573676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0048-11-HYMC|The Influence of Bariatric Surgery on Patients With Obstructive Sleep Apnea (OSA)|The Influence of Bariatric Surgery on Patients With Obstructive Sleep Apnea (OSA)|OSA|Hillel Yaffe Medical Center|No|Not yet recruiting|May 2012|December 2013|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|80 Years|No|Non-Probability Sample|both males and females|April 2012|April 6, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573676||87863|
NCT01573689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLeblanc - bereaved children|Bereaving, But Not Alone : the Development and Actualization of a Mutual Aid Group for Children Who Have Lost a Parent.|Bereaving, But Not Alone : the Development and Actualization of a Mutual Aid Group for Children Who Have Lost a Parent.||Université de Montréal|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Both|8 Years|12 Years|No|||May 2013|May 7, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573689||87862|
NCT01573923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Alliancells-2012-1|Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis|Clinical Trial of Umbilical Mesenchymal Stem Cells Transplantation for Liver Cirrhosis-Phase I/II|LC|Alliancells Bioscience Corporation Limited|No|Recruiting|July 2014|October 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|30 Years|60 Years|No|||April 2012|April 12, 2015|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01573923||87844|
NCT01573936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yoshihara_AACD2011|Quality of Life in Adult Neurological Patients|The Influence of Rehabilitation on Quality of Life in Adult Patients With Neurological Disorders||Associação de Assistência a Criança Deficiente|Yes|Completed|January 2008|December 2011|Actual|September 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|19 Years|74 Years|No|||April 2012|April 6, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01573936||87843|
NCT01570413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31421|Pelvic Examination in Pregnancy|Utility of Pelvic Examination in the Evaluation of Threatened Abortion|PEP|Boston Medical Center|Yes|Completed|February 2012|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|270|||Female|18 Years|65 Years|No|||February 2016|February 14, 2016|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01570413||88112|
NCT01592279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|597-11|GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients|||Hadassah Medical Organization|No|Not yet recruiting|June 2012|||June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|65 Years|No|||April 2012|May 3, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01592279||86446|
NCT01592513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc116633CTIL|Effect of BIS Monitoring on Propofol Usage During Elective Bronchoscopy|Effect of BIS Monitoring on Propofol Usage During Elective Bronchoscopy||Rabin Medical Center|No|Recruiting|April 2012|October 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|N/A|No|||May 2012|May 3, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01592513||86428|
NCT01592799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114004|Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in Spain|Burden of Influenza-related Hospitalizations and ER Visits in Children in Spain||GlaxoSmithKline||Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|501|||Both|N/A|15 Years|No|||May 2012|May 3, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592799||86407|
NCT01593072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7537-us-101|A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers||Sarepta Therapeutics|Yes|Withdrawn|August 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|May 3, 2012|No|Yes|Terminated for convenience of the Government due to funding constraits|No||https://clinicaltrials.gov/show/NCT01593072||86386|
NCT01593631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120506000|Acid Lactase in Combination With Yoghurt Bacteria for Improvement of Lactose Digestion in Lactose Malabsorbers|A Combination of Yoghurt Bacteria and Acid Lactase From Aspergillus Oryzae Improves Lactose Digestion in Lactose Malabsorbers More Reliably Than Preparations Containing Acid Lactase or Yoghurt Bacteria Alone||Vitacare Gmbh & Co. KG||Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 7, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593631||86343|
NCT01593917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1104|Long Term Follow Up Study of the St. Jude Medical Trifecta Valve|Long Term Follow Up Study of the St. Jude Medical Trifecta™ Valve||St. Jude Medical|Yes|Enrolling by invitation|June 2012|April 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|650|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects previously implanted with a Trifecta prosthetic valve|September 2015|September 9, 2015|May 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01593917||86321|
NCT01594151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2010-59|Modelling of the Upper Airway in Children With Controlled Asthma|Modelling of the Upper Airway in Children With Controlled Asthma||FLUIDDA nv|No|Completed|March 2011|May 2011|Actual|May 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|6 Years|12 Years|No|||October 2012|October 19, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594151||86303|
NCT01564810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03|Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer|Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer||Fudan University|Yes|Recruiting|September 2006|September 2015|Anticipated|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|75 Years|No|||October 2012|October 23, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01564810||88542|
NCT01572311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAE-1234|Dual Task Aerobic Exercise for Older Adults With Cognitive Impairment (HM2)|Study of Community Based Dual Task and Aerobic Exercise Intervention on Cognition and Mobility in Older Adults Without Dementia|HM2|Parkwood Hospital, London, Ontario|No|Completed|June 2012|May 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|44|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||October 2014|October 24, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572311||87967|
NCT01572324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCH12031308|Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas|Phase II Study of Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil in Patients With Unresectable Biliary Tract Carcinomas||Peking University|Yes|Recruiting|March 2012|February 2016|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572324||87966|
NCT01572610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA 402-004|A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus|A Phase 2 GFR Measuring Study of RTA 402 in CKD Patients With Type 2 Diabetes Mellitus||Kyowa Hakko Kirin Company, Limited|No|Terminated|February 2012|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|79 Years|No|||April 2014|April 27, 2014|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572610||87944|
NCT01572623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005330-18|Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting|Efficacy of Two Different Pre-Intervention Therapeutic Strategies With Clopidogrel and Atorvastatin for the Prevention of Cerebral Damage During Carotid Artery Stenting. Armyda-Caro Randomized Trial.|ARMYDA-CARO|Campus Bio-Medico University|No|Recruiting|July 2011|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|150|||Both|50 Years|90 Years|No|||April 2012|April 5, 2012|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572623||87943|
NCT01572870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|450-10 CTIL|Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients|Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients||Rambam Health Care Campus||Completed|December 2010|September 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|40|||Both|3 Years|50 Years|No|Non-Probability Sample|40 Cystic Fibrosis patients: Group 1: 22 CF patients who had neither ABPA nor Aspergillus        infection in the past.        Group 2: 12 CF patients with persistent Aspergillus infection, without ABPA. Group 3: 6 CF        patients with current or past ABPA|April 2012|April 5, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572870||87924|
NCT01573156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN1102 KCM201|Vascular Targeted Photodynamic Therapy T1a Renal Tumours|Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial|KCM201|University of Oxford|Yes|Recruiting|May 2013|June 2015|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|60 Years|90 Years|No|||July 2013|July 1, 2013|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01573156||87902|
NCT01573169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREVENTIHS|PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients|PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients|PREVENTIHS|University Of Perugia|Yes|Suspended|May 2012|||August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|406|||Both|18 Years|N/A|No|||July 2014|July 20, 2014|March 31, 2012||No|The trial has been momentarily suspended after the randomization of 38 patients due to a lack    of funding.|No||https://clinicaltrials.gov/show/NCT01573169||87901|
NCT01572857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201O-AOI354-35|Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma|Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma.|RCP-MM|Rennes University Hospital|No|Recruiting|April 2012|April 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|-  Proteinuria        -  Albuminuria        -  Urinary FLC (Freelite ™)        -  Urine creatinine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with multiple myeloma.|May 2015|May 26, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01572857||87925|
NCT01573702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1123|Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)|Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|January 2012|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573702||87861|
NCT01573390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010H0017|Non Invasive and Non-Contact Dual-modal Imaging Of Tissue Oxygenation and Vascular Reactivity Dynamic Imaging Of Tissue Metabolism and Vascular Function.|Non Invasive and Non-Contact Dual-modal Imaging Of Tissue Oxygenation and Vascular Reactivity Dynamic Imaging Of Tissue Metabolism and Vascular Function.||Ohio State University|No|Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|None Retained|there is no biospecimen collection require in this protocol.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Interested healthy volunteers|March 2016|March 16, 2016|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573390||87884|
NCT01573650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2, 01/04/2012|Optimization of Peripheral Nerve Reconstruction: A Non-inferiority Trial|Optimization of Peripheral Nerve Reconstruction: A Non-inferiority Trial||University Hospital, Basel, Switzerland|Yes|Recruiting|March 2015|June 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Patients with traumatic peripheral nerve injury of the finger(s) who are to be treated        with peripheral nerve repair at the Department of Plastic, Reconstructive and Aesthetic        Surgery, Handsurgery, University Hospital of Basel Written informed consent|March 2016|March 14, 2016|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573650||87865|
NCT01574170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 SEIN 07|Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival|Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival|METAL3|Institut Claudius Regaud|No|Recruiting|May 2012|June 2019|Anticipated|June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|270|||Female|18 Years|N/A|No|||September 2014|May 26, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01574170||87825|
NCT01574456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36156.068.11|Blood-brain Barrier Permeability in Alzheimer's Disease|||Maastricht University Medical Center||Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|39|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Three groups of participants have been included: 7 patients diagnosed with dementia of the        Alzheimer's type; 13 patients with mild cognitive impairment due to AD, which represents a        preclinical stage of AD in which patients already have memory impairment and at least one        AD biomarker (i.e. hippocampal atrophy or abnormal amyloid and tau protein content in the        cerebrospinal fluid); and 19 healthy controls. Patients have been recruited from the        memory clinics of the Maastricht University Medical Center and the Leiden University        Medical Center.|December 2013|December 9, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01574456||87803|
NCT01574469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU114|Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (France)|Effect of Low-fat, Fermented Milk Enriched With Plant Sterols on Serum Lipid Profile in Moderate Hypercholesterolemia||Danone Research|No|Completed|September 2004|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind|2||Actual|242|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 7, 2012|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01574469||87802|
NCT01570699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC10 073|Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients|COMT Val158Met Polymorphism in Opiate-using Subjects Without Lifetime Opiate Dependence|COM-ON|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|December 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples With DNA|We will compare polymorphism COMT between COM-ON patients and METHADOSE patients. Samples      may be blood sample or salivary sample.|Both|35 Years|N/A|No|Non-Probability Sample|subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine)        more than 10 times in their life, without ever having the DSM-IV criteria for opiate        dependence or abuse|March 2015|March 26, 2015|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570699||88090|
NCT01561976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116519|Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers|The Effect of Food on the Pharmacokinetics of Metformin Given Either as Metformin Hydrochloride SR 1000mg Tablet or as a Fixed Dose Combination of Metformin Hydrochloride SR 1000mg/Glimepiride 2mg Tablet in Healthy Indian Volunteers.||GlaxoSmithKline|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01561976||88758|
NCT01592552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAN-ND-01|A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery|A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies||Sanguine Biosciences|No|Completed|November 2011|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|20|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|A diagnosis of Multiple Sclerosis, Alzheimer's, Huntington's, or Parkinson's Disease.|March 2016|March 1, 2016|November 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01592552||86425|
NCT01592812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01546-35|Arterial Inflow and Muscle Ischemia During Calf Stimulation With the Veinoplus Device|Investigation of the Arterial Effects of the Veinoplus(r) Stimlator Device.||University Hospital, Angers|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2013|March 15, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592812||86406|
NCT01593085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DECAPAL|Evaluation of States in Major Depressive Patients With Cancer, Hospitalized in a Hospital Palliative|Evaluation of States in Major Depressive Patients With Cancer, Hospitalized in a Hospital Palliative|DECAPAL|Centre Francois Baclesse|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Probability Sample|Patients with cancer in palliative cares|April 2012|February 5, 2013|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01593085||86385|
NCT01593358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESEARCH_REGISTRY|Venous Obstruction in Neurodegenerative Disorders Research Registry|Venous Obstruction in Neurodegenerative Disorders Research Registry||Synergy Health Concepts, Inc.|Yes|Recruiting|August 2011|January 2014|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|18 Years|90 Years|No|Non-Probability Sample|Human subjects will be approached for participation in this registry that are receiving or        seeking medical care at Synergy Health Concepts, Inc.No individuals shall be excluded from        participation in the Research Registry based on race, ethnicity, or gender.|May 2012|May 5, 2012|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01593358||86364|
NCT01594164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2010-61|Clinical Study to Assess Change in Upper Airway Geometry Between Upright and Supine Position|Clinical Study to Assess Change in Upper Airway Geometry Between Upright and Supine Position||FLUIDDA nv|No|Completed|March 2011|April 2011|Actual|April 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 19, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594164||86302|
NCT01593605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNIS-NCI|Resveratrol-Leucine Metabolite Synergy in Pre-diabetes|Resveratrol-Leucine Metabolite Synergy in Pre-diabetes||Vanderbilt University|Yes|Completed|February 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|No|||September 2013|September 18, 2013|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01593605||86345|
NCT01593618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007NT078|Empowering Cancer Survivors Through Information Technology|Empowering Cancer Survivors Through Information Technology||Masonic Cancer Center, University of Minnesota|No|Completed|August 2007|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|53|||Both|15 Years|28 Years|No|||January 2016|January 22, 2016|May 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01593618||86344|
NCT01564823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APPRECIA|Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease|Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease|APPRECIA|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa|No|Completed|June 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|N/A|No|||March 2015|March 15, 2015|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01564823||88541|
NCT01565382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A09|Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)|Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Evaluation of Inter-reader Reliability Using Images From Subjects With a Clinical Presentation of AD or MCI||Avid Radiopharmaceuticals|No|Completed|February 2011|February 2011|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|40|||Both|50 Years|N/A|No|||May 2012|May 23, 2012|March 26, 2012|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01565382||88498|
NCT01572051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P.A.R.Q.V.E.|Project Osteoarthritis: Recovering Quality of Life Through Education|Project Osteoarthritis: Recovering Quality of Life Through Education|PARQVE|University of Sao Paulo General Hospital|No|Completed|October 2011|October 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|8||Actual|228|||Both|N/A|N/A|No|||October 2013|January 14, 2015|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01572051||87987|
NCT01572337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP/96/ER/mm|Early Non-invasive Ventilation Outside the Intensive Care Unit|Reducing the Need for Intensive Care Unit in Hospitalized Patients With Early Respiratory Failure Using the Non-invasive Ventilation Technique. A Multicentre Randomized Study.|e-NIV|Università Vita-Salute San Raffaele||Recruiting|April 2012|||April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|520|||Both|18 Years|99 Years|No|||March 2016|March 9, 2016|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01572337||87965|
NCT01572350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALBA09|Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema|Randomized Multicenter Clinical Trial of Three Parallel Groups to Estimate the Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema.|ALBA|Hospital Universitario de Canarias||Recruiting|October 2010|||October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|105|||Both|18 Years|N/A|No|||April 2011|April 4, 2012|April 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01572350||87964|
NCT01572636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011OC140|Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome|MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).||Masonic Cancer Center, University of Minnesota|No|Recruiting|April 2012|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Probability Sample|Diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) and being considered        as a candidate for first transplant according to a University of Minnesota myeloablative        hematopoietic stem cell transplant (HSCT) protocol|January 2016|January 21, 2016|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572636||87942|
NCT01572649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKD11475|Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes||Sanofi|No|Completed|May 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|10 Years|65 Years|No|||May 2014|May 22, 2014|April 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01572649||87941|
NCT01572883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eHER2-TM|Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer|Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer||Institute of Oncology Ljubljana|No|Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|175|||Female|18 Years|N/A|No|Probability Sample|breast cancer patients treated in Institut of Oncology Ljubljana,slovenia since year 2005.|October 2014|October 15, 2014|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572883||87923|
NCT01564355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24336|Postoperative Systemic Corticosteroids When Utilizing a Steroid-Eluting Spacer Following Endoscopic Sinus Surgery|The Role of Postoperative Systemic Corticosteroids When Utilizing a Steroid-Eluting Middle Meatal Spacer Following Endoscopic Sinus Surgery: A Randomized, Double-Blind, Placebo Controlled Trial||University of Calgary||Completed|April 2012|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564355||88577|
NCT01573416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEDAUC-11-205|"Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care."|"Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care."||Pontificia Universidad Catolica de Chile|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|October 8, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573416||87882|
NCT01573429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120089|Bisphenol A Controlled Exposure Study|Bisphenol A (BPA) Pharmacokinetic (PK): Controlled Exposure Study||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|25 Years|45 Years|No|||May 2015|February 12, 2016|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01573429||87881|
NCT01573715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005720-18|Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS)|Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS||Assistance Publique Hopitaux De Marseille|No|Recruiting|April 2012|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573715||87860|
NCT01573403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS2411-0111|Efficacy and Safety of DLBS2411 in Healthy Volunteers|Effect of DLBS2411 on Gastric pH Regulation in Healthy Volunteers : Comparison With Placebo||Dexa Medica Group|No|Completed|April 2012|January 2013|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 12, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573403||87883|
NCT01574482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU216|Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Italy)|Effects of the Consumption of a Plant Sterols-enriched Dairy Fermented Product on Hypercholesterolemia Management in Hypercholesterolemic Adults||Danone Research|No|Completed|January 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|116|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 7, 2012|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01574482||87801|
NCT01565837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS CA184-168|Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma|Phase II Evaluation of Concurrent Ipilimumab Therapy and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Malignant Melanoma|SART|Comprehensive Cancer Centers of Nevada|Yes|Recruiting|August 2012|November 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565837||88463|
NCT01570426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0195-07|Brain Imaging and Computer Games in Children With Either Bipolar Disorder, ADHD, Anxiety or Healthy Controls|Brain/Behavior Alterations in Pediatric Psychopathology|BBPP|Bradley Hospital|No|Recruiting|July 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|240|Samples With DNA|Spit samples are collected for DNA/RNA extraction.Genetic tests will be performed at the      Brown University affiliated Molecular Genetics Laboratory located at the Providence VA      Medical Center. For privacy purposes, all genetic samples will be assigned a study code      number to ensure that there is no identifiable information with them. After this study is      over, genetic samples will be disposed.|Both|7 Years|17 Years|Accepts Healthy Volunteers|Probability Sample|Participants will be recruited from in and around the Providence. Rhode Island area|January 2016|January 11, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01570426||88111|
NCT01562236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gender148|Gender-specific aEEGs and Outcome in Preterms|Gender-related Differences in Early Amplitude-integrated Electroencephalography in Newborns < 30 Weeks' Gestational Age and Their Correlation With Neurodevelopment Outcome at Three Years Corrected Age||Medical University of Vienna|Yes|Completed|January 2000|October 2011|Actual|December 2002|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|148|||Both|24 Weeks|30 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|preterms born < 30 weeks gestational age who had aEEG measurements within the first 2        weeks of life who had assessment of outcome at 3 years corrected age|March 2012|March 22, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562236||88738|
NCT01592825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN_Halle_01|PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors|PiA Trial: a Cross-sectional, Multicenter, Consecutive Cohort Evaluating the Distribution of uPA/PAI-1 Versus St. Gallen Algorithm in >1000 Prospectively Included Patients|PiA|Martin-Luther-Universität Halle-Wittenberg|No|Active, not recruiting|September 2009|September 2012|Anticipated|May 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Tumor specimen frozen Tumor specimen formalin fixed|Female|18 Years|N/A|No|Non-Probability Sample|Patients with newly diagnosed, operable breast cancer without metastasis.|June 2012|June 28, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592825||86405|
NCT01593098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN study|A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)|A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)|AN|Chinese University of Hong Kong|No|Recruiting|May 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|600|Samples With DNA|colonic biopsies, blood, stool|Both|40 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|residence of Hong Kong siblings with colonoscopy done Siblings of Patients with Advanced        Neoplasm (case) siblings of patients with normal colonoscopy (control)|October 2015|October 5, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01593098||86384|
NCT01593111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3904|Comparative Effectiveness of Environmental Intervention and Standard Care in Ability to Reduce Pharmacologic Therapy for Asthma|Comparative Effectiveness of Environmental Intervention and Standard Care in Ability to Reduce Pharmacologic Therapy for Asthma|ERA|Columbia University|Yes|Completed|April 2011|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|243|||Both|6 Years|N/A|No|||February 2015|February 2, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01593111||86383|
NCT01593124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11-119|Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation|Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation|Biomarkers|CONRAD|No|Completed|May 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Female|21 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 30, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01593124||86382|
NCT01593371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-D-130-655|Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients|Comparing Effects of Metformin and Pioglitazone on Regulation of Serum Adipokines in Newly Diagnosed Type 2 Diabetes Patients||Tehran University of Medical Sciences|No|Completed|July 2011|January 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|98|||Both|40 Years|N/A|No|||May 2012|May 8, 2012|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01593371||86363|
NCT01564511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT&SM-01|Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis|Effects of Electromechanical Gait Trainer on Endurance, Fatigue and Daily Life Autonomy in Patients With Multiple Sclerosis: a Randomized Control Trial||Universita di Verona|Yes|Completed|November 2011|December 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|60 Years|No|||January 2013|January 3, 2013|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01564511||88565|
NCT01564836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC10ENME0465|Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib|A Multi-center Study of the Discontinuation of Imatinib in Adult Patients With Ph+ CML in CP Who Have a Complete Molecular Response to Imatinib||Seoul St. Mary's Hospital|Yes|Recruiting|June 2010|||June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01564836||88540|
NCT01593904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VERIFYMS|Venous Irregularities, Flow and Perfusion in MS Study|Venous Irregularities, Flow and Perfusion in MS Study|VERIFYMS|Synergy Health Concepts, Inc.|Yes|Recruiting|January 2012|January 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|400|||Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Human subjects will be approached for participation in this study that are receiving or        seeking medical care at Synergy Health Concepts Inc.|May 2012|May 6, 2012|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01593904||86322|
NCT01561560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-347-C-019|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses||Alcon Research|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|March 21, 2012|No|Yes||No|November 19, 2013|https://clinicaltrials.gov/show/NCT01561560||88790|
NCT01561573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPH-POCUS-2012|Ultrasound Assisted Distal Radius Fracture Reduction|Ultrasound Assisted Distal Radius Fracture Reduction||University of British Columbia|No|Recruiting|April 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|136|||Both|19 Years|N/A|No|||April 2012|April 21, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01561573||88789|
NCT01563835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-03|Analgesia for 2nd Trimester Termination of Pregnancy|Analgesia for 2nd Trimester Termination of Pregnancy: a Randomized Controlled Trial of Intravenous Versus Epidural Patient Controlled Analgesia||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Terminated|March 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Female|16 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 9, 2014|March 23, 2012||No|Recruitment difficulty|No||https://clinicaltrials.gov/show/NCT01563835||88617|
NCT01564108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OKHN1005|The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema|An Exploratory Study of Ranibizumab (Lucentis) for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema Which Has Proven Refractory or Ineligible to Standard Treatment.||Moorfields Eye Hospital NHS Foundation Trust|Yes|Recruiting|February 2012|February 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||March 2012|March 23, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01564108||88596|
NCT01564693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FRFLAV|Cancer Anorexia and the Central Nervous System|Neuroimaging of Hypothalamic Activity During Cancer Anorexia||University of Roma La Sapienza|Yes|Completed|April 2010|April 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|15|Samples Without DNA|serum|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|Lung cancer patients with confirmed cancer diagnosis before the initiation of any        anti-cancer treatments will be enrolled. Nine anorexic cancer patients, 4 non-anorexic        cancer patients and 2 healthy individuals will be studied.|July 2015|July 28, 2015|March 14, 2012||No||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01564693||88551|
NCT01573442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A221102|Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment|Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias||Alliance for Clinical Trials in Oncology|Yes|Recruiting|August 2013|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|224|||Female|18 Years|N/A|No|||November 2015|November 3, 2015|April 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573442||87880|
NCT01573468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOG301|Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer|A Randomized, Double-blind Study of Capecitabine Plus Tesetaxel Versus Capecitabine Plus Placebo as Second-line Therapy in Subjects With Gastric Cancer|TESEGAST|Genta Incorporated|Yes|Recruiting|April 2012|August 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|580|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573468||87879|
NCT01565265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBCH001|Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression|Prospective Randomized Study Comparing Ovarian Stimulation With Pergoveris Supported by a GnRH Agonist in a Long Protocol Versus Multidose GnRH Antagonist Regimen in Young Infertile Women Treated With ICS|Pergoveris|University of Basel|Yes|Not yet recruiting|April 2012|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|165|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||March 2012|March 25, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01565265||88507|
NCT01573949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002909|A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)|A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)||University of California, Los Angeles|No|Completed|December 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|90 Years|No|||June 2013|June 20, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01573949||87842|
NCT01565850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-299-0102|Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults||Gilead Sciences|Yes|Completed|April 2012|February 2014|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565850||88462|
NCT01561690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-502-201|A Study of ARRY-502 in Patients With Persistent Asthma|||Array BioPharma|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|184|||Both|18 Years|70 Years|No|||June 2013|June 6, 2013|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561690||88780|
NCT01561703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200310|Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use|Postoperative Healthcare Utilization in Adenotonsillectomy Patients With Postoperative Antibiotic Administration Compared to Patients Without Antibiotic Administration||University of Missouri-Columbia|No|Recruiting|March 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|58|||Both|N/A|17 Years|No|||March 2012|March 21, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01561703||88779|
NCT01561963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-CP-025|A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast|A Phase 1, Open-label, Three-period, Fixed-sequence Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects||Celgene|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01561963||88759|
NCT01562249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORTHOGSURG01|Rehabilitative Management of Mastication|Rehabilitative Management of Mastication After Orthognathic Surgery: A Randomized Controlled Trial||University of Sao Paulo General Hospital|Yes|Completed|March 2009|October 2011|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|17|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 21, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562249||88737|
NCT01562522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-95-52014-192|Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.|Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.|EXPEDIENT|Ipsen|No|Terminated|March 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|6|||Male|N/A|N/A|No|||March 2016|March 22, 2016|March 21, 2012||No|Poor enrolment; only 6 subjects enrolled and they were all screen failures.|No||https://clinicaltrials.gov/show/NCT01562522||88716|
NCT01592578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSY-CJ-2012|The Research of the Evaluation of Clinical Procedures in Gastroesophageal Varices in Patients With Liver Cirrhosis|A Randomized Controlled Trial of Ligation Versus Ligation Plus Sclerotherapy in Addition to Cyanoacrylate in Patients With Gastroesophageal Varices||Shanghai Zhongshan Hospital|No|Recruiting|March 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|72 Years|No|||May 2012|April 25, 2013|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01592578||86423|
NCT01592838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116721|Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccination Introduction in Belgium|Feasibility Pilot Study Assessing the Impact on the Quality of Hospital Care After the Introduction of Rotavirus Vaccination in Belgium||GlaxoSmithKline||Completed|December 2013|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|15 Years|No|Non-Probability Sample|Children ≤15 years old hospitalised for any reason between June 2004 and May 2010.|March 2015|March 30, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592838||86404|
NCT01592851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01324|Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Short Term Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2014|May 1, 2014|May 3, 2012|Yes|Yes||No|April 5, 2013|https://clinicaltrials.gov/show/NCT01592851||86403|
NCT01592864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01325|The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|February 6, 2014|May 3, 2012|Yes|Yes||No|May 16, 2013|https://clinicaltrials.gov/show/NCT01592864||86402|
NCT01593644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADEN-Ph2-2011-1|Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler|Phase 2, Monocentric, Single Blind Study, Comparing the Efficacy and Tolerance of a Dipyridamole/Adenosine Combination Given Intravenously, as a Slow Bolus and at Low Doses to Adenosine Alone for Coronary Flow Reserve Assessment (in Patients With Stable Ischemic Heart Disease) Using Transthoracic Echodoppler||Adenobio N.V|No|Recruiting|June 2011|||March 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Anticipated|75|||Both|18 Years|N/A|No|||September 2012|September 6, 2012|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01593644||86342|
NCT01565395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000304|Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)|Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)|Xeomin 2012|Beth Israel Deaconess Medical Center||Withdrawn|March 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|80 Years|No|||January 2016|January 12, 2016|March 26, 2012|Yes|Yes|Could not recruit ALS participants, hence ALS arm discontinued|No||https://clinicaltrials.gov/show/NCT01565395||88497|
NCT01564485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20086170|Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome|Role of Cardiac CT in Risk Factor Control in Asymptomatic Patients With Diabetes|CTRAD|University of California, Irvine|Yes|Active, not recruiting|July 2008|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01564485||88567|
NCT01564498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012MeckPurpleVeg|Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors|A Pilot Study of the Effects of Replacing Orange Carrots and White Potatoes With Purple Varieties, on Risk Factors for Cardiovascular Disease||University of Guelph|No|Recruiting|April 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Both|18 Years|65 Years|No|||June 2013|June 12, 2013|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564498||88566|
NCT01562119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDLL-2012109|Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn|Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn|ADM|Tang-Du Hospital|Yes|Active, not recruiting|January 2011|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|30|Samples With DNA|The skin with ADM inplant and the nomal skin as control group|Both|3 Years|52 Years|No|Non-Probability Sample|Thirty burn patients, treated by composite graft of ADM with autologous split-thickness        skin from January 2007 to December 2009, were enrolled in this study.|April 2013|April 17, 2013|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562119||88747|
NCT01563510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHZSG001|Research of the Key Technology and Standardization of Minimal Invasive Treatment for Hepatolithiasis|Comparison of Laparoscopic Versus Open Operation for Hepatolithiasis||Southwest Hospital, China|Yes|Enrolling by invitation|January 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2012|October 8, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01563510||88640|
NCT01563523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7TRAUMA-2159|Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ Niastase®) in the Treatment of Bleeding in Severely Injured Trauma Subjects||Novo Nordisk A/S|No|Completed|March 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|283|||Both|16 Years|65 Years|No|||March 2012|March 27, 2012|March 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563523||88639|
NCT01564368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000729174|DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy|Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis)|ACRIN 6698|American College of Radiology Imaging Network|Yes|Recruiting|August 2012|||February 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|304|||Female|18 Years|N/A|No|||May 2014|May 1, 2014|March 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01564368||88576|
NCT01564381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|270881|Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women|Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women||University of California, Davis|No|Recruiting|March 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|80|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||September 2014|September 12, 2014|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564381||88575|
NCT01562834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHDADULT/F/1/F|Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients|Randomized Cross Over Double Blind Versus Placebo Trial Followed by an Open Phase Studying Effect of Norditropin® on Left Ventricular Mass of Growth Hormone Deficient Adult Patients||Novo Nordisk A/S|No|Completed|October 1998|December 2002|Actual|December 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|50 Years|No|||June 2012|June 28, 2012|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562834||88692|
NCT01562847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AKR05T|Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib|Dynamics of ABL Mutations in Imatinib Failed Ph Positive or Bcr-Abl Positive CML CP or AP Patients Who Treated With Nilotinib as Second-line TKI Therapy (AMICAN-Prospective)in Asia|AMICAN|Seoul St. Mary's Hospital|Yes|Active, not recruiting|July 2011|June 2015|Anticipated|June 2014|Anticipated|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|125|Samples Without DNA|RNA analysis for mutation and Bcr-Abl gene quantification using mainly peripheral blood|Both|18 Years|N/A|No|Non-Probability Sample|Korean Adult CML patients|January 2014|January 10, 2014|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01562847||88691|
NCT01564706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A02|A Study of 18F-AV-45 in Healthy Volunteers|Positron Emission Tomography Whole Body Biodistribution Using 18F-AV-45||Avid Radiopharmaceuticals|No|Completed|October 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 11, 2012|March 25, 2012|No|Yes||No|April 3, 2012|https://clinicaltrials.gov/show/NCT01564706||88550|
NCT01564719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORC-1447SP|Study of a Holistic Health Program for United Methodist Clergy|A Randomized Multiple Baseline Intervention Study of Metabolic Syndrome, Mental Health, and Spiritual Well-Being of United Methodist Clergy in North Carolina|SpiritedLife|Duke Clergy Health Initiative|No|Active, not recruiting|October 2010|August 2016|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1167|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 19, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01564719||88549|
NCT01564992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 071240|Drug Interaction With Genes in Parkinson's Disease|Drug Interaction With Genes in Parkinson's Disease|DIGPD|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2009|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|Men and women adults with a Parkinson Disease according to UKPDSBB criteria, diagnosed < 6        years|April 2015|April 23, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564992||88528|
NCT01565551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC2NS069409|Transforming Research and Clinical Knowledge in TBI Pilot|Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot||University of California, San Francisco|No|Completed|April 2010|December 2013|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|650|Samples With DNA|Whole blood for genetic analysis. Plasma for proteomic analysis.|Both|N/A|N/A|No|Non-Probability Sample|This is a population-based TBI study. All patients presenting to the acute sites with        traumatic brain injury and receive a head CT scan as part of standard care within 24 hours        of injury date and time are initially eligible. As most six-month Common Date Elements        (CDE) outcome measures are normed and validated only in English, study participants must        be English-speaking. There are no other restrictions to eligibility.|January 2014|January 3, 2014|March 24, 2012||No||No|January 3, 2014|https://clinicaltrials.gov/show/NCT01565551||88485|Enrolling patients representative of the TBI population created challenges for follow-up (e.g. homelessness, substance abuse); limited access to research MRI scanner; lack of validated outcome measures for non-English-speaking and pediatric patients.
NCT01573962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Topaz|A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury|A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury||Astute Medical, Inc.|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|420|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients at risk of AKI.|September 2013|October 13, 2014|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01573962||87841|
NCT01561716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR024160/5-23087|An Evaluation of the Energy Expenditure From Wii Fit Games|Is the Wii Fit / Wii Fit Plus Good Enough? A Comparison of the Energy Expenditure From Interactive Physical Activity Promoting Technology to Walking and Running||University of Rochester|No|Completed|September 2009|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|March 14, 2012||No||No|March 29, 2012|https://clinicaltrials.gov/show/NCT01561716||88778|The lab staffs that administrated the tests were not blinded to the order of the randomization, nor were they blinded to the results of the test. Thus, our study is subjected to observer and measurement biases.
NCT01561989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 203111|Cholecalciferol and Flu Vaccine in Treating Healthy Participants|Immune Responses to Influenza Vaccine Among Healthy Employees Working at Roswell Park Cancer Institute and the Relationship to Vitamin D Status||Roswell Park Cancer Institute|Yes|Terminated|October 2011|June 2015|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|211|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||August 2015|August 11, 2015|March 16, 2012||No|low accrual|No||https://clinicaltrials.gov/show/NCT01561989||88757|
NCT01562002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOBA-05-2010|Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome|Advanced Therapy for Ocular Surface Reconstruction. Allogenic Limbus Epithelial Stem-cell Transplant vs Bone Marrow Mesenchymal Stem-cell Transplant in Limbus Insufficiency Syndrome. Double-masked Randomized Trial||Instituto Universitario de Oftalmobiología Aplicada||Completed|March 2012|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562002||88756|
NCT01562262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP1122/11|Comparison of RT in Patients With Sleep Apnea With and Without Complaints of Daytime Sleepiness|Behavior of Psychomotor Vigilance Task Performance in Subjects With Obstructive Sleep Apnea With and Without Complaints of Daytime Sleepiness||Federal University of São Paulo|Yes|Recruiting|October 2011|March 2013|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Man, ages between 20 and 45 years with and without drowsiness and no sleep disturbances        checked before the study|March 2012|March 24, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562262||88736|
NCT01563913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-006-11S|Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids|Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids|RLID-PD|VA Office of Research and Development|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|40|||Both|21 Years|99 Years|No|||January 2016|January 27, 2016|March 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563913||88611|
NCT01593137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFC-0001|A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes|A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes|ADELANTE|Fundación Fernández-Cruz|No|Withdrawn|May 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|75 Years|No|||July 2013|July 1, 2013|May 3, 2012||No|Lack of patients with the criteria established in the protocol.|No||https://clinicaltrials.gov/show/NCT01593137||86381|
NCT01593384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2112|Prospective Chart-Review: Impact of Combination - Digital Breast Tomosynthesis + Digital Mammography|To Determine the Clinical Impact of the Combination of Digital Breast Tomosynthesis and Digital Mammography on Screening for Breast Cancer||Case Comprehensive Cancer Center|No|Withdrawn|April 2012|||February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Subjects from routine clinical patient population at our medical facility. There will be        inclusion of employees and students in the study. A number of UHCMC employees and a few        CWRU students are in our routine clinical patient population.|February 2016|February 15, 2016|May 4, 2012||No|Funding unavailable|No||https://clinicaltrials.gov/show/NCT01593384||86362|
NCT01564225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-004|A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200|A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200, an Ectodysplasin-A1 Replacement Molecule, in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Adults||Edimer Pharmaceuticals|Yes|Completed|May 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|40 Years|No|||November 2013|November 25, 2013|March 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01564225||88587|
NCT01565148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-007-03-DME|A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)|A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)|iDEAL|Johns Hopkins University|Yes|Active, not recruiting|February 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|208|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565148||88516|
NCT01565733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-4017|Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes|Multicenter, Open Label, Non-randomized, Non-interventional Observational Study of Safety of Treatment Initiation With a Biphasic Insulin Aspart (NovoMix® 30) in Hospitalized Patients With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|January 2007|July 2007|Actual|July 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2223|||Both|N/A|N/A|No|Non-Probability Sample|Patients with type 2 diabetes requiring treatment with NovoMix® 30 insulin on admission        who before hospitalisation had been treated with oral antidiabetics and/or human insulin|March 2012|March 29, 2012|March 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565733||88471|
NCT01561586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG 1027/THAI 2012|Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer|Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer|TACO|Korea Cancer Center Hospital|Yes|Recruiting|March 2012|March 2020|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|590|||Female|18 Years|75 Years|No|||February 2016|February 24, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561586||88788|
NCT01565122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28207|An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)|An Observational, Non-interventional, Multi-national Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|51|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients initiated on RoActemra/Actemra treatment|March 2016|March 1, 2016|March 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565122||88518|
NCT01565135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1149|Immunization Delivery in Obstetrics and Gynecology Settings|Immunization Delivery in Obstetrics and Gynecology Settings||University of Colorado, Denver|No|Active, not recruiting|September 2012|September 2017|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|225000|||Female|15 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565135||88517|
NCT01562132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21NS077858-01|Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection|An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone|SToP-Crypto|Yale University|Yes|Terminated|September 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|March 21, 2012||No|Stopped in accordance with pre-specified stopping rules for poor recruitment.|No|July 31, 2015|https://clinicaltrials.gov/show/NCT01562132||88746|
NCT01564121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04/10-E|Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa|Phase 2 Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone|Zometa|Nantes University Hospital|No|Terminated|January 2006|January 2011|Actual|January 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||August 2013|August 29, 2013|June 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01564121||88595|
NCT01564732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033638|Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding|Multicenter Prospective Randomized Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding||Duke University|Yes|Active, not recruiting|September 2013|April 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|60 Years|No|||March 2016|March 16, 2016|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01564732||88548|
NCT01563315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK:S-06266a|Community-acquired Pneumonia in Buskerud County in Norway|Community-acquired Pneumonia: A Prospective Observational Study to Explore Etiology, Risk Factors and Potential Predictors for re- Admittance to Hospital and All-cause Mortality||Vestre Viken Hospital Trust|Yes|Completed|January 2008|January 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|270|Samples With DNA|whole blood, serum, plasma, blood culture, airways specimens, urine|Both|18 Years|N/A|No|Probability Sample|All adult patients with CAP admittet to Vestre Viken HF-Buskerud Hospital (VVHF-BH)        between January 2008 og January 2011, were evaluated for inclusion in the study.|March 2012|March 23, 2012|March 22, 2012||||No||https://clinicaltrials.gov/show/NCT01563315||88655|
NCT01565278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0298-B|Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition|Effect of n-3 Polyunsaturated Fatty Acid Lipid Emulsion on Parenteral Nutrition Associated Liver Disease||University Health Network, Toronto|No|Recruiting|February 2012|July 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 24, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565278||88506|
NCT01565564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02|Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes|A Randomized Translational Study to Examine the Effects of Shared Care Versus Usual Care in Management of Gestational Diabetes in a Three-tier Prenatal Care Network in Tianjin, China||Tianjin Women and Children's Health Center|Yes|Completed|September 2010|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|948|||Female|18 Years|50 Years|No|||June 2015|June 9, 2015|March 21, 2012||No||No|May 21, 2015|https://clinicaltrials.gov/show/NCT01565564||88484|Exclusion of 242 women with GDM diagnosed from 10 Nov 2011 to 31 Jul 2012 due to potential contaminations due to logistic reasons.
NCT01565577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/199/HP|Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)|Phase 3, Vaccinal Activity Assessment of MenBVac Against Nesseiria Menigitidis B:14,P1.7,16 Strain in Child Vaccinated With MenBVac®|Exten MenbVac|University Hospital, Rouen|No|Completed|April 2012|September 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|117|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||September 2014|September 5, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565577||88483|
NCT01565538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wsy001|Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma|A Randomized Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma||Sun Yat-sen University|No|Completed|December 2008|May 2013|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|75 Years|No|||September 2014|September 11, 2014|March 22, 2012||No||No|September 3, 2014|https://clinicaltrials.gov/show/NCT01565538||88486|
NCT01561729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004691|Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity|Evaluation of RightBio Metrics', RightSpot pH Indicator, for Rapid Bedside Verification of Proper Nasogastric/ Orogastric Tube Placement in Emergency Department & Intensive Care Unit Patients||RightBio Metrics|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01561729||88777|
NCT01562015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9090-09|A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)|A Single Arm, Phase 2 Study of Ganetespib in Subjects With Advanced Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)|CHIARA|Synta Pharmaceuticals Corp.|No|Completed|April 2012|November 2014|Actual|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562015||88755|
NCT01563081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116455|Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics|A Multi-Center, Open-labelled Study to Evaluate the Safety of Levocetirizine Hydrochloride Oral Solution in Children Aged 6 Months to 2 Years With Allergic Rhinitis or Pruritus Associated With the Skin Diseases.||GlaxoSmithKline|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|6 Months|23 Months|No|||April 2013|June 12, 2013|March 15, 2012||No||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01563081||88673|
NCT01563926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHLIQUID-1315|Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency|An Open, Multi-Centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin Simplexx™ in Children With GH Deficiency||Novo Nordisk A/S|No|Completed|October 2000|October 2002|Actual|October 2002|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|168|||Both|N/A|N/A|No|||June 2012|June 28, 2012|March 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563926||88610|
NCT01563679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054905|Analysis of Percutaneous Ablations for Cancer Treatment|Prospective Analysis of Percutaneous Ablations for Cancer Treatment||Emory University|Yes|Completed|February 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who undergo ablative therapy procedures, in the Interventional Radiology        department as part of a clinical treatment for cancer.|May 2014|May 23, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01563679||88629|
NCT01563692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/08|Immune Response to Respiratory Syncytial Virus (RSV) in Health Care Workers|Analysis of the Immune Response to Respiratory Syncytial Virus (RSV) Infection in Health Care Personnel||University of Oxford|No|Completed|March 2012|||August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|Samples With DNA|The humoral and cellular immune response to RSV exposure. To characterise these further some      analysis of HLA typing my occur.|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy health care personnel working in a pediatric ward and healthy volunteers from        non-NHS staff|November 2015|November 6, 2015|December 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01563692||88628|
NCT01563952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0023|Impact of Intravascular Ultrasound(IVUS)-Guided Chronic Total Occlusion Intervention With Drug-eluting Stents|Impact of IVUS-guided Chronic Total Occlusion InterVention With DrUg-eluting Stents on Mid-term Angiographic and Clinical Outcomes (CTO-IVUS Study)|CTO|Yonsei University|Yes|Recruiting|October 2010|October 2013|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|400|||Both|20 Years|80 Years|No|||March 2012|March 26, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01563952||88608|
NCT01565161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U48 DP001946-5033375|Healthy Habits, Happy Homes: An Intervention to Improve Household Routines for Obesity Prevention|Healthy Habits, Happy Homes: An Intervention to Improve Household Routines for Obesity Prevention|HH|Harvard Pilgrim Health Care|No|Active, not recruiting|September 2009|September 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|117|||Both|2 Years|5 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565161||88515|
NCT01565408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8828-3841|Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis|Safety and Tolerability of NNC0114-0006 Following Multiple s.c. Dosing at Escalating Dose Levels in Subjects With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||October 2013|October 9, 2013|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565408||88496|
NCT01561599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|004-09|Study on Delayed Graft Function Using Paired Kidneys|Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death||Angion Biomedica Corp|Yes|Active, not recruiting|August 2011|May 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01561599||88787|
NCT01561612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190250|Promotion of Breastfeeding Intervention Trial|Breastfeeding Promotion RCT and Child Metabolic Syndrome|PROBIT|Harvard Pilgrim Health Care|No|Completed|June 1996|||December 1998|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17046|||Both|N/A|N/A|No|||October 2013|October 9, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561612||88786|
NCT01565707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-076|A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug|A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in Pediatric Subjects From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)|LION|Astellas Pharma Inc|Yes|Completed|June 2012|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|189|||Both|5 Years|17 Years|No|||June 2015|June 12, 2015|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565707||88473|
NCT01562418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|757-2008-IDF-CTIL|Multi Dimensional System for Evaluating a Preventive Program for Upper Extremity Disorders Among Computer Operators|Multi Dimensional System for Evaluating a Preventive Program for Upper Extremity Disorders Among Computer Operators||Medical Corps, Israel Defense Force|No|Recruiting|September 2009|February 2013|Anticipated|March 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|108|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 22, 2012|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01562418||88724|
NCT01562431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11SIG|The Signal-Trial: Evaluation of a Screening Tool for Psychosocial Problems in Cancer Genetics|The Signal-Trial: Evaluation of a Screening Tool for Psychosocial Problems in Cancer Genetics||The Netherlands Cancer Institute|No|Completed|October 2011|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|246|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01562431||88723|
NCT01562444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V48P7E2|Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules|A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules||Novartis|No|Active, not recruiting|March 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|206|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 8, 2016|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01562444||88722|
NCT01564394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U of Utah COA Pilot Grant|Body Mind Training Project|Effects of Qigong on Fatigue & Quality of Life in Elderly Prostate Cancer Survivors||University of Utah|Yes|Completed|October 2011|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|60|||Both|55 Years|99 Years|No|||November 2015|November 9, 2015|March 22, 2012||No||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01564394||88574|
NCT01564407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10110342|A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures|A Phase I/II Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures||University of Pittsburgh|Yes|Terminated|January 2011|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 31, 2015|December 20, 2011|Yes|Yes|Study Terminated due to lack of Funding|No||https://clinicaltrials.gov/show/NCT01564407||88573|
NCT01561469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5951168|Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin|Multicenter, Retrospective, Observational Study to Evaluate Clinical and Economic Outcomes of Patients With MRSA Hospital-Acquired Pneumonia Treated With Linezolid Or Vancomycin||Pfizer|No|Completed|November 2008|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|188|||Both|18 Years|N/A|No|Non-Probability Sample|This non-interventional study will retrospectively evaluate patients with documented MRSA        hospital-acquired including ventilator-associated pneumonia treated with linezolid or        vancomycin with incorporation of 100 patients in the vancomycin arm and 100 patients in        the linezolid arm.|June 2014|June 9, 2014|March 21, 2012|No|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01561469||88797|Prioritization of endpoints as primary or secondary was not specified in protocol and was based on study team's inputs.
NCT01562561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1272|Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes|Multi-centre, Multinational, Open-labelled, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled on Repaglinide, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime NPH Insulin Versus Twice Daily NPH Insulin||Novo Nordisk A/S|No|Completed|June 2001|December 2002|Actual|December 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|213|||Both|18 Years|N/A|No|||March 2012|March 23, 2012|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562561||88713|
NCT01563887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15360|Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)|Identifying Driving Risk Factors in T1DM and Their Reduction Via Behavioral Intervention||University of Virginia|No|Completed|February 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|568|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01563887||88613|
NCT01563900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00052358|Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea||Northwestern University|No|Withdrawn|February 2012|February 2016|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||April 2013|April 16, 2013|March 23, 2012||No|Was unable to recruit subjects|No||https://clinicaltrials.gov/show/NCT01563900||88612|
NCT01565005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100128|Microcephaly Genetic Deficiency in Neural Progenitors|Microcephaly Genetic Deficiency in Neural Progenitors: Genotyping, Phenotyping and Functional Neuro-anatomy and Neurobiology Comparative Primitive Microcephaly (MCPH) and the Fanconi Anemia (FA)|MICROFANC|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|135|||Both|3 Years|N/A|No|Non-Probability Sample|Group1:          -  Primary microcephaly without gross malformation within or extra nervous central             system          -  OFC < -2SD at birth and < -3 SD after age 6months          -  Mutation in one MCPH gene        Group2:        Proven Fanconi Anemia with:          -  Positive chromosome breakage blood test          -  One of the 3 following elements:        FANCD2 positive test Fibroblast sensitivity to mitomycine Mutation in one FANC gene|February 2016|February 24, 2016|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01565005||88527|
NCT01565018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD0002|Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects|Single-site, Open-label, Randomized, Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations||UCB Pharma|No|Completed|March 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|55|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|March 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565018||88526|
NCT01565291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A01|A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers|A Preliminary Evaluation of the Amyloid Binding Properties, Pharmacokinetics and Safety of 18F-AV-45 in Healthy Elderly Volunteers and Patients With Alzheimer's Disease||Avid Radiopharmaceuticals|No|Completed|June 2007|January 2008|Actual|January 2008|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|32|||Both|50 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 11, 2012|March 25, 2012|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01565291||88505|
NCT01565317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS #2011-16|Evaluating the Effect of Diabetes Control Through Intensive Lifestyle Modifications on Diabetic Peripheral Neuropathy|Evaluation of the Effect of Intensive Diabetes Control Through Non-Surgical Intensive Lifestyle Modifications and Weight Reduction on Diabetic Peripheral Neuropathy||Joslin Diabetes Center|No|Completed|April 2012|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|50|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565317||88503|
NCT01565330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A03|A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers|An Open Label, Parallel Group, Dose Comparison of Safety and Imaging Characteristics of 111 and 370 MBq (3 and 10 mCi) of 18F-AV-45 for Brain Imaging of Amyloid in Healthy Volunteers and Patients With Alzheimer's Disease (AD)||Avid Radiopharmaceuticals|No|Completed|March 2008|August 2008|Actual|August 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|4||Actual|20|||Both|35 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 14, 2012|March 26, 2012|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01565330||88502|
NCT01565863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGAP for Vets 1166.01.410.10|Progressive Goal Attainment Program for Veterans|The Progressive Goal Attainment Program for Veterans Project|PGAP for Vets|MDRC|No|Recruiting|February 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01565863||88461|
NCT01563328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115697|A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).|A Phase I, Open Label, Randomized, Two Cohort, Two Period, Oneway Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697)||ViiV Healthcare|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563328||88654|
NCT01564238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Camp Calcium 5-6|Effect of Sodium Intake on Calcium Retention in Girls|Effect of Sodium Intake on Calcium Retention in Black and White Adolescent Girls.||Purdue University|No|Completed|June 1999|August 2000|Actual|August 2000|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|67|||Female|11 Years|15 Years|Accepts Healthy Volunteers|||April 2012|April 3, 2012|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01564238||88586|
NCT01564524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10100293|Effect of Concentrating Endogenous Stromal Cells in the Fat Graft|Structural Fat Grafting for Craniofacial Trauma: Effect of Concentrating Endogenous Stromal Cells in the Fat Graft||University of Pittsburgh|Yes|Suspended|April 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Civilian or military|December 2014|December 2, 2014|March 21, 2012||No|Suspending while a funding source is identified|No||https://clinicaltrials.gov/show/NCT01564524||88564|
NCT01564849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-2011|The Clinical Efficacy of Topical Nasal Pomegranate Fruit Extract for Patients With Chronic Rhinosinusitis|The Clinical Efficacy of Topical Nasal Pomegranate Fruit Extract (PFE) for Patients With Chronic Rhinitis, Chronic Sinusitis With or Without Nasal Polyps||Hillel Yaffe Medical Center|No|Not yet recruiting|April 2012|December 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||6|Anticipated|198|||Both|18 Years|80 Years|No|Non-Probability Sample|Adults suffering from chronic rhinitis, sinusitis and nasal polyps|March 2012|March 27, 2012|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01564849||88539|
NCT01564862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LuAA21004_202|Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)||Takeda|No|Completed|April 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|602|||Both|18 Years|65 Years|No|||February 2015|February 4, 2015|March 26, 2012|Yes|Yes||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01564862||88538|
NCT01565720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0017|Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization|A Phase 1, Randomized, Double Blind, Placebo and Active Controlled, Parallel Study to Evaluate the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|161|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|March 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565720||88472|
NCT01561885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC 10/134/J|Collaborative Healthcare Professionals Approach in Monitoring of Patient Centered Outcomes Through Pathways|A Pragmatic Randomized Controlled Trial of Patient-Centered Integrated Clinical Pathways Based Versus Usual Care in an Academic Center: National Guard Health Affairs Western Region Experience|CHAMP-Path|King Abdullah International Medical Research Center|Yes|Active, not recruiting|March 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|341|||Both|14 Years|N/A|No|||February 2016|February 1, 2016|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01561885||88765|
NCT01561846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOBROTZUCMDA|Cheese Intake,CLA and Hypercholesterolemia|Randomized, Double Blind, Controlled, Cross Over Clinical Trial on Intake of CLA Enriched Cheese in Hypercholesterolemic Patients|CASU|Azienda Ospedaliera Brotzu|No|Completed|June 2008|March 2009|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|42|||Both|30 Years|60 Years|No|||March 2012|March 22, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01561846||88768|
NCT01561859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000267/1|Brain Imaging, Cognitive Enhancement and Early Schizophrenia|Brain Imaging, Cognitive Enhancement and Early Schizophrenia|BICEPS|Beth Israel Deaconess Medical Center|No|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|102|||Both|18 Years|35 Years|No|||March 2014|March 5, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01561859||88767|
NCT01562964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P40285|Hypnotherapy in Patients With Chest Pain & Unobstructed Coronaries|The Impact of Hypnotherapy on Symptoms, Psychological Morbidity and Quality of Life in Postmenopausal Women With Chest Pain and Unobstructed Coronary Arteries||Imperial College London|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|September 8, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562964||88682|
NCT01565031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULA|Prediction of Future Risk in Patients With Controlled Asthma|A Simple Prognostic Score for Future Risk Assessment in Patients With Controlled Asthma Who Undergo a Step-down Guidelines-based Strategy||Hospital Universitario Lucus Augusti|No|Not yet recruiting|May 2012|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|338|||Both|18 Years|80 Years|No|Non-Probability Sample|Well-controlled asthmatics who are regularly under the care of Allergy or Pneumology        specialists.|March 2012|March 27, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565031||88525|
NCT01562574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7CPB-3343|Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease|A Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombi-nant Factor VIIa (rFVIIa/ NovoSeven®) With Standard Haemostatic Replacement Therapy, and Standard Haemostatic Replacement Ther-apy Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease||Novo Nordisk A/S|No|Completed|January 2002|August 2004|Actual|August 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|N/A|1 Year|No|||March 2012|March 22, 2012|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562574||88712|
NCT01571336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS 01|Photodynamic Therapy of Actinic Keratoses With Alacare®|Non-interventional Observational Study on Photodynamic Therapy of Actinic Keratoses With Alacare®||photonamic GmbH & Co. KG|Yes|Active, not recruiting|April 2012|March 2016|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|420|||Both|18 Years|N/A|No|Probability Sample|Community sample|April 2015|April 28, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571336||88042|
NCT01571349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02--85-001|Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura|Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura||Samsung Medical Center|Yes|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|20|||Both|20 Years|70 Years|No|Probability Sample|Those who visits the outpatients clinic of Samsung Medical Center with a diagnosis of        idiopathic (immune) thrombocytopenic purpura between March, 2012 and February, 2013.|December 2013|December 24, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01571349||88041|
NCT01563614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DepoRaCe|A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain|Safety and Efficacy of Liposomal Cytarabine in Combination With Radiotherapy (RT) and Lomustine for the Treatment of Leptomeningeal Metastasis From Malignant Melanoma||University Hospital, Bonn|No|Recruiting|March 2012|March 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01563614||88633|
NCT01564433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCI-GT-2|Effects of Electromechanical Gait Trainer in Patients With Cerebral Palsy|The Effects of an Electromechanical Gait Trainer in Gait Impairments and Endurance in Patients With Cerebral Palsy: a Randomized Control Trial||Universita di Verona|Yes|Completed|November 2011|January 2012|Actual|December 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|10 Years|16 Years|No|||June 2012|June 13, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01564433||88571|
NCT01561482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28936|Study of Metformin With Simvastatin for Men With Prostate Carcinoma|Open-Label Study Of Metformin In Combination With Simvastatin For Men With Prostate Carcinoma And A Rising Serum Prostate-Specific Antigen Level After Radical Prostatectomy And/Or Radiation Therapy||Baylor College of Medicine|Yes|Withdrawn|January 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|18 Years|N/A|No|||July 2015|July 20, 2015|March 20, 2012|Yes|Yes|Study closed due to slow/low enrollment; no subjects were enrolled.|No||https://clinicaltrials.gov/show/NCT01561482||88796|
NCT01561495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 09510|Proton Radiotherapy for Extremity Soft Tissue Sarcoma|Proton Radiotherapy for Extremity Soft Tissue Sarcoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|June 2010|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561495||88795|
NCT01561443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-ORU-XXX-2011/1|LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer|LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer|LINE|AstraZeneca|No|Completed|May 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|153|||Female|N/A|N/A|No|Non-Probability Sample|hormone positive, postmenopausal breast cancer|January 2016|January 8, 2016|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01561443||88799|
NCT01561456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXL-003|Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung|Phase II, Randomized, Open-label Study of the IGF-1R Inhibitor AXL1717 Compared to Docetaxel in Patients With Previously Treated, Locally Advanced, or Metastatic Squamous Cell Carcinoma or Adenocarcinoma of the Lung||Axelar AB|Yes|Completed|December 2011|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01561456||88798|
NCT01562028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOP 2-11 / MO27911|BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)|An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations|BELIEF|European Thoracic Oncology Platform|Yes|Active, not recruiting|June 2012|October 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562028||88754|
NCT01562041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPJMR0032105|Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease|Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease||Novartis|No|Terminated|March 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|40 Years|75 Years|No|||September 2014|September 16, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562041||88753|
NCT01562054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS-DIMS-2|Evaluation of a Rating Tool for Measuring General Surgeons' Non-technical Performance in the Operating Room|Evaluation of a Rating Tool for Measuring General Surgeons' Non-technical Performance in the Operating Room||Herlev Hospital|No|Completed|February 2012|April 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|General surgeons from eight hospitals in Denmark will be recruited to participate as        raters. We wish to recruit consultant surgeons (n=10) and senior residents in surgery        (n=10) who have an interest in education and supervision. Once recruited background        information such as age, gender, position, years of surgical experience and prior        experience with assessment of others will be collected.|August 2012|August 8, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01562054||88752|
NCT01563627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8668|Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy|Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy: New Targets for Diagnosis and Prediction of Drug Resistance||University Hospital, Montpellier|Yes|Recruiting|October 2011|April 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|18 Years|75 Years|No|||April 2015|April 13, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01563627||88632|
NCT01563640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|282589-T|Insecticidal School Uniforms for Dengue Prevention in Thailand|Can Insecticide-treated School Uniforms Reduce Dengue Infections in School-aged Children in Thailand|DengueTools|Umeå University|Yes|Terminated|March 2012|December 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1825|||Both|7 Years|15 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|March 16, 2012||No|Insecticidal treatment of school uniforms did not last through a dengue season|No||https://clinicaltrials.gov/show/NCT01563640||88631|
NCT01564537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16010|A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma||Millennium Pharmaceuticals, Inc.|Yes|Active, not recruiting|August 2012|December 2020|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|722|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|March 22, 2012|Yes|Yes||No|December 19, 2015|https://clinicaltrials.gov/show/NCT01564537||88563|
NCT01564875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-SIM4|Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia|Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4)|HM-SIM4|Hanmi Pharmaceutical Company Limited|No|Active, not recruiting|December 2010|May 2012|Anticipated|May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|122|||Both|20 Years|75 Years|No|||March 2012|March 26, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564875||88537|
NCT01564888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL/IMRC/TCC/TP/10/2010|Prevention of Radial Artery Occlusion: Prophylactic Hyperperfusion Evaluation Trial|Prevention of Radial Artery Occlusion: Prophylactic Hyperperfusion Evaluation Trial|PROPHET-II|Total Cardiovascular Solutions|No|Completed|January 2011|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3000|||Both|18 Years|99 Years|No|||February 2016|February 16, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01564888||88536|
NCT01565174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0541-11-HMO-CTIL|The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis|The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis||Hadassah Medical Organization|No|Not yet recruiting|October 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|100|Samples With DNA|Samples of DNA will be taken from saliva of participants|Male|18 Years|26 Years|No|Non-Probability Sample|100 current users of cannabis|April 2012|April 1, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565174||88514|
NCT01565746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15354|Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients|Uncontrolled, Open-label, Non-randomized Phase I Study to Investigate Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics of a Single Dose of BAY88-8223 in Japanese Patients With Castration-resistant Prostate Cancer and Bone Metastases||Bayer|No|Active, not recruiting|March 2012|April 2016|Anticipated|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|19|||Male|20 Years|N/A|No|||March 2016|March 1, 2016|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01565746||88470|
NCT01562158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7BMT-1360|Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation|A Multi-centre, Randomised, Double-blind, Parallel Groups, Placebocontrolled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Treatment of Bleeding in Patients Following Stem Cell Transplantation (SCT)||Novo Nordisk A/S|No|Completed|April 2001|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|12 Years|N/A|No|||December 2012|December 10, 2012|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562158||88744|
NCT01562457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1731-1668|Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State|A Randomised, Open-label, Multi-centre Trial Investigating the Intra-subject Variability of ROTEM® and TEG® Parameters Following Two Intravenous Administrations of the Same Dose of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Haemophilia Patients in a Non-bleeding State||Novo Nordisk A/S|No|Completed|November 2005|April 2006|Actual|April 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|16 Years|N/A|No|||July 2012|July 9, 2012|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562457||88721|
NCT01561872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11 005|Assessment of an Automated Telesurveillance System on Serious Falls Prevention in an Elderly Suffering From Dementia Specialized Care Unit: the URCC|Assessment of an Automated Telesurveillance System on Serious Falls Prevention in an Elderly Suffering From Dementia Specialized Care Unit: the URCC. GET-BETTER Study (Geriatric Environmental Telecare - Behavioral Engineering Technology To Enhance Rehabilitation)|GET-BETTER|University Hospital, Limoges|No|Completed|April 2012|February 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|350|||Both|65 Years|N/A|No|Probability Sample|demented old subjects|February 2015|February 12, 2015|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01561872||88766|
NCT01562990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-R-GEMOX|Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse|A Multi-center, Phase IB/II, Open Label, Single Arm Study of Inotuzumab Ozogamicin Plus Rituximab (R-CMC544) Alternating With Gemcitabine-oxaliplatin Plus Rituximab(R-GEMOX)in Patients Aged From 18 to 80 Years With CD20 and CD22 Positive Diffuse Large B-cell Lymphoma (DLBCL) in Relapse After/Refractory to 1ST or 2ND Line Treatment, Who Are no Candidates for Autologous Transplant.||The Lymphoma Academic Research Organisation|Yes|Active, not recruiting|December 2012|April 2016|Anticipated|August 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|80 Years|No|||January 2016|January 13, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01562990||88680|
NCT01565590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-11-22-01|Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage|Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage||University of Cincinnati|Yes|Terminated|February 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|March 23, 2012||No|Slow enrollment along with new competing studies, investigators decided to stop study|No||https://clinicaltrials.gov/show/NCT01565590||88482|
NCT01565603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCB 2011-A00071-40|Sleep and Cerebral Responses to High Altitude|Intolerance Mechanisms and Exercise Performance Limitation During a High Altitude Stay: Investigation of Sleep and Cerebral Responses|VALLOT 2011|University Hospital, Grenoble|No|Active, not recruiting|July 2011|October 2012|Anticipated|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|12|Samples Without DNA|Venous blood|Male|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy young subjects|March 2012|March 29, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565603||88481|
NCT01563068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115750|To Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Calcipotriene 0.005%, Applied Under Maximal Use Conditions in 12-16 Year Olds With Plaque Psoriasis|A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) With Plaque Psoriasis||GlaxoSmithKline|No|Recruiting|April 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|12 Years|16 Years|No|||April 2015|August 27, 2015|March 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01563068||88674|
NCT01564173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|644|Dependence of LV Hemodynamics on Pacing Site|Characterization of LV Hemodynamics During Epicardial and Endocardial Pacing||St. Jude Medical|Yes|Completed|June 2012|March 2016|Actual|March 2016|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated for epicardial mapping and ablation of arrhythmia(s) utilizing a        transcutaneous subxiphoid approach|March 2016|March 23, 2016|March 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01564173||88591|
NCT01565044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.675|Automatic Versus Intentional Movement Exercises to Enhance Arm Functions After Stroke|Automatic Versus Intentional Movement Exercises to Enhance Arm Functions After Stroke|AUTOTAB|Hospices Civils de Lyon|No|Recruiting|March 2012|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|80 Years|No|||April 2014|April 30, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565044||88524|
NCT01565057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFR07/2010|Gastric Layering Study|A Study on the Effect of Gastric Layering and Emptying Induced by a Food Emulsion||Institute of Food Research|Yes|Completed|August 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 4, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01565057||88523|
NCT01562288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCTG-N9831D-NCCTG-ICSC|Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab|Adjuvant Chemotherapy Combined With Trastuzumab in the Randomized Phase III Trial N9831 Actively Immunizes Patients Against Tumor Antigens||Alliance for Clinical Trials in Oncology||Withdrawn|February 2012|||February 2013|Anticipated|N/A|Observational|N/A|||Actual|0|||Female|18 Years|N/A|No|||July 2013|July 18, 2013|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562288||88734|
NCT01562301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0147|Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of the Combination of Carboplatin, Docetaxel, and Increasing Doses of Sublingual Anvirzel (Nerium Oleander) in Advance Non-Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Withdrawn|June 2014|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|March 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562301||88733|
NCT01562314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWID10160|A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)|A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis.|GWID10160|GW Research Ltd|No|Completed|February 2012|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||June 2015|July 17, 2015|March 21, 2012||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01562314||88732|
NCT01562587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1503|Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State|Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non-Bleeding State||Novo Nordisk A/S|No|Completed|September 2002|May 2003|Actual|May 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Male|3 Years|55 Years|No|||May 2012|May 24, 2012|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562587||88711|
NCT01562860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.0039|Influence of Pronator Teres Release on Treatment of Median Nerve Compression Neuropathy|The Influence of Pronator Teres Release in the Treatment of Median Nerve Compression Neuropathy: A Randomized Prospective Study||Christine M. Kleinert Institute for Hand and Microsurgery|No|Recruiting|July 2010|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2013|July 9, 2013|August 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01562860||88690|
NCT01564797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR6194|Partnership for a Hispanic Diabetes Prevention Program|Partnership for a Hispanic Diabetes Prevention Program||Fred Hutchinson Cancer Research Center|No|Completed|July 2008|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|430|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 4, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564797||88543|
NCT01565070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOFREEZE OSTEOARTHRITIS|Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic|Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic||University of Chile|Yes|Withdrawn|April 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|60 Years|80 Years|No|||March 2012|July 9, 2014|March 26, 2012||No|The local authorities did not authorize the use of biofreeze in Chile.|No||https://clinicaltrials.gov/show/NCT01565070||88522|
NCT01564550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33046|The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism|The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism||University of Aarhus|Yes|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|Samples With DNA|Blood samples|Male|35 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The type 2 diabetic men will be recruited from the endocrinology ambulatory of Aarhus        University hospital. The healthy subjects will be recruited by local advertisement in the        city of Aarhus and by national website advertisement.|November 2012|December 5, 2014|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564550||88562|
NCT01564901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27904|An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids|A Prospective Observational Study to Assess the Impact of RoActemra® on the Use of Glucocorticoids in Patients With Rheumatoid Arthritis Treated With the Standard of Care.||Hoffmann-La Roche||Completed|January 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Probability Sample|Patients with moderate to severe rheumatoid arthritis and concomitant treatment with        glucocorticoids|March 2016|March 1, 2016|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01564901||88535|
NCT01565187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001131|Development of a Psychosocial Assessment Database for Reconstructive Hand Transplantation|Development of a Psychosocial Assessment Database for Reconstructive Hand Transplantation||Mayo Clinic|No|Enrolling by invitation|February 2012|March 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|None Retained|No biospecimens to be gathered and used for this study.|Both|18 Years|N/A|No|Non-Probability Sample|Candidate who will be receiving a hand transplant at Mayo Clinic.|April 2015|April 6, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01565187||88513|
NCT01565421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID OVAR0801|Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients|A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression.||Cerulean Pharma Inc.|Yes|Withdrawn|September 2008|May 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|78 Years|No|||April 2012|September 15, 2014|March 26, 2012|Yes|Yes|By previous sponsor|No||https://clinicaltrials.gov/show/NCT01565421||88495|
NCT01565434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REIMS-AOL2011-01|Erythrocyte Complement Receptor 1 and Alzheimer Disease|||CHU de Reims|No|Recruiting|February 2012|||||N/A|Interventional|Primary Purpose: Screening|||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 27, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565434||88494|
NCT01561625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIM-COPD-20458|Signaling Pathway Activation After Exercise in Patients With Chronic Obstructive Pulmonary Disease|Signaling Pathway Activation in the Quadriceps of Patients With COPD After an Acute Bout of Resistance|SIM|Laval University|Yes|Completed|October 2009|April 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Male|50 Years|75 Years|Accepts Healthy Volunteers|||May 2013|May 3, 2013|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561625||88785|
NCT01562977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEL-TAMO/R-GemOx-08-04/v2|Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL|Prospective, Open-label, Multicentric, ph. II Study of R-GemOx and Dexametasone in Patients With Agressive Lymphomas Refractory or Relapsed to Previous Treatment and Non Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplanted|RGemOx|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||Recruiting|April 2011|April 2017|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|129|||Both|18 Years|N/A|No|||August 2013|August 22, 2013|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01562977||88681|
NCT01562145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HannaBjornssonstud3|Elevated Plasma Levels of TIMP-1 in Patients With Rotator Cuff Tear|Elevated Plasma Levels of TIMP-1 in Patients With Rotator Cuff Tear||University Hospital, Linkoeping|No|Completed|January 2009|February 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|34|Samples With DNA|Blood samples|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with ultrasound verified rotator cuff tears and healthy age and gender matched        controls|March 2012|March 23, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562145||88745|
NCT01594060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0042-12-EMC|Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards|A Randomized, Comparative Study of Basal-bolus Insulin Versus Conventional Sliding-scale Regular Insulin Therapy in Management of Non-critically Ill Patients Hospitalized in the Medical Ward.||HaEmek Medical Center, Israel||Not yet recruiting||||||Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|18 Years|N/A|No|||May 2012|May 7, 2012|May 7, 2012||Yes||No||https://clinicaltrials.gov/show/NCT01594060||86310|
NCT01562275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE28079|A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors||Genentech, Inc.||Completed|April 2012|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562275||88735|
NCT01571037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195-11-FB|Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study|Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study||University of Nebraska|Yes|Completed|April 2012|February 2014|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|N/A|No|||February 2014|February 28, 2014|May 6, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01571037||88064|
NCT01570777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110127|Renal Denervation in Hypertension|Renal Denervation in Patients With Resistant Hypertension|DENER-HTN|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|April 2012|April 2018|Anticipated|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|75 Years|No|||October 2015|November 3, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570777||88084|
NCT01570790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FBO-206|Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration|An Open Label, Pilot (Phase I/II), Dose-Escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration.||Johns Hopkins University|No|Completed|May 2003|June 2005|Actual|June 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|50 Years|N/A|No|||April 2012|April 3, 2012|April 2, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01570790||88083|
NCT01564771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851065|Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.|Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.|B1851065|Pfizer|No|Completed|January 2011|April 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|320|Samples Without DNA|Urine Samples|Both|18 Years|N/A|No|Non-Probability Sample|Adults ≥18 years of age with chest X-ray confirmed CAP|August 2014|August 20, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01564771||88545|
NCT01565616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00068287|Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease|A Phase II Study of Hematopoietic Stem Cell Therapy for Young Adults With Severe Sickle Cell Disease|STRIDE|Emory University|Yes|Active, not recruiting|March 2012|August 2018|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|16 Years|40 Years|No|||January 2016|January 27, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565616||88480|
NCT01561742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0201|Minocycline Augmentation in Schizophrenia|Minocycline Augmentation in Early-Course Schizophrenia||The University of Texas Health Science Center, Houston|Yes|Recruiting|February 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|35 Years|No|||March 2012|March 22, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01561742||88776|
NCT01561755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 10-1108|A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy|A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy||Icahn School of Medicine at Mount Sinai|No|Recruiting|February 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561755||88775|
NCT01561768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX 778.S205|A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults|A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-64) Adults||Novavax|No|Completed|March 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|500|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2013|July 16, 2013|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561768||88774|
NCT01572467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARAR12B2|Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors|DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood||Children's Oncology Group|No|Active, not recruiting|April 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|120 Years|No|Non-Probability Sample|Patients With Ovarian or Testicular Sex Cord Stromal Tumors|May 2015|September 30, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01572467||87955|
NCT01572480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120107|Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma|Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study||National Institutes of Health Clinical Center (CC)||Active, not recruiting|March 2012|September 2018|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|99 Years|No|||October 2015|November 17, 2015|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572480||87954|
NCT01572493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120113|Continuous Infusion of rhIL-15 for Adults With Advanced Cancer|A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers||National Institutes of Health Clinical Center (CC)||Suspended|April 2012|April 2019|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|99 Years|No|||February 2016|February 23, 2016|April 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01572493||87953|
NCT01563341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007086|Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation|Tandem DBS for Parkinson&Apos;s Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation||Mayo Clinic|No|Enrolling by invitation|April 2012|January 2015|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|40 Years|80 Years|No|||April 2013|April 24, 2013|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01563341||88653|
NCT01572987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0058|Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus|Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus|ERADICATE|Midwest Biomedical Research Foundation|Yes|Terminated|September 2011|June 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|April 4, 2012||No|Recruitment goals not being met|No||https://clinicaltrials.gov/show/NCT01572987||87915|
NCT01573000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104515|A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)|Phase II a Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)||GlaxoSmithKline|Yes|Completed|September 1998|April 2010|Actual|April 1999|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|N/A|No|||April 2012|September 6, 2012|March 8, 2012|Yes|Yes||No|April 12, 2012|https://clinicaltrials.gov/show/NCT01573000||87914|
NCT01564914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105GM201/Case 1312|A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab|A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab|105GM201|Tracon Pharmaceuticals Inc.|No|Active, not recruiting|May 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||May 2014|July 16, 2014|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01564914||88534|
NCT01565200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IJBMNTDM1|HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1|Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1|ZEPHIR|Jules Bordet Institute|No|Recruiting|April 2012|November 2017|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|105|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01565200||88512|
NCT01565447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OregonHSU|Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study|Temporal and Spatial Gait Parameters of Children Undergoing Treatment for and Surviving Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma||Oregon Health and Science University|Yes|Enrolling by invitation|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|2 Years|27 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children diagnosed with ALL or LL and are currently undergoing treatment for or have        survived treatment and are no more than 10 years post completion of treatment|October 2014|October 14, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01565447||88493|
NCT01565759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-RS-2012-317|In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects|Investigation of the Effects of in Vivo Lithium Treatment on Gene Expression Levels Using Lymphoblastoid Cell Lines From Human Healthy Subjects||Nova Scotia Health Authority|No|Recruiting|May 2012|July 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|March 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565759||88469|
NCT01561898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR012628|A Long-Term Study of JNS007ER in Patients With Schizophrenia|A Long-Term Study of JNS007ER in Patients With Schizophrenia||Janssen Pharmaceutical K.K.|No|Completed|June 2006|October 2008|Actual|October 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|228|||Both|20 Years|N/A|No|||September 2012|September 14, 2012|March 22, 2012||No||No|August 8, 2012|https://clinicaltrials.gov/show/NCT01561898||88764|
NCT01562691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH-09706-001|Effect of Airway Integrated Nasal Packing With Different Material|Comparison of Nasal Packing Methods:Nasal Packing Was Done With Nasopore@, Airway-integrated Nasopore@ and Airway-integrated Vaseline Gauze||Chi Mei Medical Hospital|Yes|Completed|June 2009|December 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Both|20 Years|55 Years|No|||March 2012|March 23, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562691||88703|
NCT01593813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PQ repair|Repair or Not Repair Pronator Quadratus in the Volar Plating of Distal Radial Fracture Are Functional Outcomes Differ ?|Repair or Not Repair Pronator Quadratus in the Volar Plating of Distal Radial Fracture-Are Functional Outcomes Differ ?|PQ|National Taiwan University Hospital|Yes|Active, not recruiting|May 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|80 Years|No|Probability Sample|patient with distal radius fracture|May 2012|May 7, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593813||86329|
NCT01570530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROFACE|Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery|Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery|PROFACE|Fundación General Universidad de Valladolid|No|Terminated|January 2011|September 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|March 1, 2012||No|End of finantial support|No||https://clinicaltrials.gov/show/NCT01570530||88103|
NCT01571687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/071|Pik Lenin High Altitude Research Expedition 2009|Pik Lenin High Altitude Research Expedition 2009, a Follow-up Project of the Muztagh Ata High Altitude Research Expedition 2005|PLHARE|University Hospital Inselspital, Berne|No|Completed|April 2009|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 3, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01571687||88015|
NCT01571921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|896.128|Gamma-delta Tocotrienol as Potential Maintenance Treatment in Women With Metastatic Breast Cancer|Phase 1a: A Randomized, 2-period Cross-over Study to Compare the Bioavailability of Gamma-Delta Tocotrienol (GDT) With That of Tocotrienol Rich Fraction (TRF) in Twelve Healthy Subjects|GEMM1a|Malaysia Palm Oil Board||Completed|January 2013|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571921||87997|
NCT01571648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-MDS-005|A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes|A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Subjects With Myelodysplastic Syndromes||Celgene|No|Completed|April 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|20 Years|N/A|No|||June 2013|June 14, 2013|April 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01571648||88018|
NCT01571661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG219017|A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|A Double Blind, Randomized, Placebo Controlled, Single-dose Escalation, First-time-in-human Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus||GlaxoSmithKline|No|Completed|September 2004|January 2005|Actual|January 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|8||Actual|16|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 3, 2012|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01571661||88017|
NCT01571895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEX0111|Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid|A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.||Dompé Farmaceutici S.p.A|Yes|Terminated|July 2011|||July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|April 4, 2012||No|Limited efficacy response observed at 1/3 enrollment at investigated dosage.|No||https://clinicaltrials.gov/show/NCT01571895||87999|
NCT01572181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/6-N|Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens|Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens|FB4-PEDIA|Nantes University Hospital|No|Recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|12 Months|25 Years|No|||December 2015|December 23, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01572181||87977|
NCT01572194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0215_01|Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation (MUCO-IRC)|Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation.|MUCO-IRC|Nantes University Hospital|No|Recruiting|April 2012|June 2019|Anticipated|June 2019|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|95|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01572194||87976|
NCT01571908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER 11-235|Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study|Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study|MagInRoc|University Hospital, Geneva|Yes|Completed|September 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|65 Years|No|||May 2015|July 17, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571908||87998|
NCT01572766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osteo Prevention|Effect of Assessing Risk for Osteoporosis on Physician and Patient Behaviors|Impact of the FRAX Assessment on Physician and Patient Treatment Behavior||Duquesne University|No|Completed|February 2010|February 2011|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|90|||Female|45 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 5, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572766||87932|
NCT01572779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProA-BSM-001|A Study to Investigate the Effect of a New Postural Bio-feedback Device on Low Back Pain|A Multicentre, Cluster Randomised, Placebo-controlled, Open-label Pilot Study of Back Strain Monitor (BSM) With Feedback Compared With the BSM Without Feedback in Subjects With Moderate Lower Back Pain.||Pro-Active Medical Pty Ltd|Yes|Completed|November 2009|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|65 Years|No|||March 2015|March 23, 2015|June 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01572779||87931|
NCT01565460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-976|Bile and Bile Duct/Pancreatic Duct Brushings Database for Patients With Pancreato-biliary Stricture|Bile and Bile Duct/Pancreatic Duct Brushings Database for Patients With Pancreato-biliary Stricture||The Cleveland Clinic|No|Recruiting|February 2012|December 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Bile and bile duct/pancreatic duct brushings|Both|19 Years|N/A|No|Non-Probability Sample|All patients with pancreatic or biliary duct stricture who present for evaluation and        intervention of their stricture|February 2013|February 12, 2013|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565460||88492|
NCT01565473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01NS015655|PET Study of Non-Motor Symptoms of Parkinson Disease|PET Study of Biochemistry and Metabolism of the CNS: Parkinson Disease||University of Michigan|No|Completed|September 2008|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|242|Samples With DNA|Whole blood Saliva|Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Movement Disorders Clinic, Hospital, Primary Care, Community|December 2014|December 1, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565473||88491|
NCT01565772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-253|Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer|A Phase I Trial of Hypofractionated Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer||Massachusetts General Hospital|Yes|Terminated|March 2012|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|March 26, 2012||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT01565772||88468|
NCT01561638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anesth_MUH_6/2011|Pulsed Radiofrequency Versus Pulsed Dose for Shoulder Pain|Pulsed Radiofrequency Versus New Technique "Pulsed Dose" in Treatment of Chronic Shoulder Pain||Mansoura University|Yes|Completed|June 2013|April 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|38|||Both|18 Years|75 Years|No|||March 2015|March 15, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561638||88784|
NCT01562704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0110|Visualisation of the Central Analgesic Effect of Paracetamol in Functional MRI|Visualisation of the Central Analgesic Effect of Paracetamol in Functional MRI|IRMf|University Hospital, Clermont-Ferrand||Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|21|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01562704||88702|
NCT01562717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028022|Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries|A Randomised, Multicentre, Two-arm, Parallel Group, Double-blind, Placebo-controlled, Comparative Efficacy and Safety Clinical Study of Ibuprofen in Patients With Pain Related to Uncomplicated Ankle Injuries||Orion Corporation, Orion Pharma|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|45 Years|No|||October 2012|May 7, 2013|March 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562717||88701|
NCT01562470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-104-002|Clinical Trial to Assess the Efficacy and Safety of a Novel Cellulite Cream|Clinical Trial to Assess the Efficacy and Safety of a Novel Cellulite Cream in Reducing the Appearance of Cellulite in Human Subjects||Nutrasource Diagnostics Inc.|No|Completed|June 2011|December 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 23, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01562470||88720|
NCT01562483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEEL-2011-03|The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain|The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain; a Randomized, Double Blinded, Placebo-controlled, Experiment||Radboud University|No|Completed|October 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01562483||88719|
NCT01563224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAA/001/2011|GABA-B Receptor Function in Healthy Volunteers|GABA-B Receptor Function in Healthy Volunteers: a Pilot, Double Blind Crossover Study of the Effects of 2 Doses of Baclofen and Placebo on Objective and Subjective Measurements of Brain Function||Imperial College London|No|Completed|July 2013|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|8|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||September 2014|June 3, 2015|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01563224||88662|
NCT01594086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT201201|Effects of Green Tea Consumption on Homocysteine Metabolism and Cognitive Dysfunction|Effects of Green Tea Consumption on Homocysteine Metabolism and Cognitive Dysfunction in Elderly: An Exploratory Clinical Study||University of Shizuoka|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|50 Years|95 Years|No|||July 2013|July 14, 2013|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01594086||86308|
NCT01570257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 03.1073|A Trial of High and Low Pressure Level Settings on a Programmable Ventriculoperitoneal Shunt Valve for Idiopathic Normal Pressure Hydrocephalus|A Randomized Trial of High and Low Pressure Level Settings on a Programmable Ventriculoperitoneal Shunt Valve for Idiopathic Normal Pressure Hydrocephalus. Results of the Dutch Evaluation Program Strata Shunt (DEPSS) Trial||Erasmus Medical Center|Yes|Completed|September 2003|October 2007|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|N/A|85 Years|No|||March 2012|April 3, 2012|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01570257||88124|
NCT01570543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-2011-GES-0029|MRI Scanning of People With MR Safe Orthopedic Implants That Are Made of Metal|Development of MR Systems, Accessories, and Software for Imaging Subjects With Metallic Orthopedic Implants.|MRI|GE Healthcare|No|Withdrawn|March 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|0|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample from Waukesha, Wisconsin area.|October 2012|September 27, 2013|March 13, 2012|Yes|Yes|After over a year no subjects were identified|No||https://clinicaltrials.gov/show/NCT01570543||88102|
NCT01571401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRACKS Trial for Kidney Cancer|Trying Activity in Kidney Cancer Survivors (TRACKS) Trial|Trying Activity in Kidney Cancer Survivors (TRACKS) Trial: A Randomized Controlled Trial Comparing the Effects of Supervised Physical Activity Versus Supervised Physical Activity Plus Behavioural Counselling|TRACKS|University of Alberta|Yes|Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2012|June 17, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01571401||88037|
NCT01571700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS6901|Investigation of Dysynchrony in Patients With Pulmonary Hypertension|Investigation of Dysynchrony in Patients With Pulmonary Hypertension||Stanford University|Yes|Recruiting|September 2006|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|100|||Both|5 Years|N/A|No|Non-Probability Sample|Patients will be approached during their routine pulmonary hypertension clinic visit.|November 2015|November 17, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571700||88014|
NCT01571050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOPFBioavailability2011|Systemic Fluoride Bioavailability From Toothpastes Containing Calcium Carbonate or Silica as Abrasives|||University of Campinas, Brazil|No|Completed|January 2011|December 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|5||Actual|20|||Both|19 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01571050||88063|
NCT01571063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SASL 34|Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D|||University of Zurich||Active, not recruiting|January 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||June 2015|June 8, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01571063||88062|
NCT01571362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531002|A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain|A Multicenter, 12-Week, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Determine the Efficacy and Safety Of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) Extended-Release Capsules in Subjects With Moderate to Severe Chronic Low Back Pain||Pfizer|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571362||88040|
NCT01571375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10037|The Effect of Different Emergency Medical Systems on the Prognosis of Traumatic Brain Injury - a Prospective Study|The Differences Between Out-of-hospital Severe Traumatic Brain Injury (TBI) Treatment in a Physician-staffed Versus Paramedic-staffed Emergency Medical Service (EMS) Unit and Its Effect on Patient Prognosis||Tampere University Hospital|No|Active, not recruiting|June 2012|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Primary Care Clinic|November 2014|November 30, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01571375||88039|
NCT01571674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0040|Validation of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation: A Randomized Clinical Trial|Validation of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation: A Randomized Clinical Trial||University of Colorado, Denver|Yes|Enrolling by invitation|June 2015|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||January 2016|January 27, 2016|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01571674||88016|
NCT01572792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-MD-36|Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)||Forest Laboratories|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|909|||Both|40 Years|N/A|No|||February 2015|February 27, 2015|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572792||87930|
NCT01572207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-531|Promoting Physical Activity Behavior in Persons With Multiple Sclerosis|Using Targeted Print-material to Promote Physical Activity Behavior in Adults With Multiple Sclerosis||Case Western Reserve University|No|Completed|July 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|65 Years|No|||January 2015|January 22, 2015|March 28, 2012||No||No|August 7, 2013|https://clinicaltrials.gov/show/NCT01572207||87975|
NCT01573338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14858|Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Smal Cell Lung Cancer)|Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer||Bayer|No|Active, not recruiting|February 2013|April 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|April 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01573338||87888|
NCT01561651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAAOSIII-2012|Left Atrial Appendage Occlusion Study III|Left Atrial Appendage Occlusion Study III|LAAOS III|McMaster University|Yes|Recruiting|July 2012|August 2020|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|4700|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01561651||88783|
NCT01561911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH1/103|A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment|A Phase I Clinical Research Study Evaluating the Safety, Tolerability and Biological Effects of the Chimeric Anti-CD40 Monoclonal Antibody Chi Lob 7/4 Given Intravenously, Weekly for Four Weeks in the Treatment of Patients With Advanced Malignancies Refractory to Conventional Anti-cancer Treatment.||Cancer Research UK||Completed|July 2007|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label|||Actual|29|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01561911||88763|
NCT01562171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:010|Lentils as a Functional Food to Improve Glucose and Decrease Cardiovascular Risk|Lentils as a Functional Food to Improve Glucose Tolerance and Decrease Cardiovascular Disease Risk in Hypercholesterolemic Overweight Individuals|LEN-0-2012|University of Manitoba|No|Completed|March 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|102|||Both|30 Years|75 Years|No|||December 2014|December 11, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562171||88743|
NCT01593280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0308.01|TAP Catheters Versus Intrathecal Morphine for Cesarean Section|Quality of Recovery Following Administration of Transverse Abdominus Plane (TAP) Catheter as Compared to Intrathecal Morphine After Cesarean Delivery Under Spinal Anesthesia: a Prospective, Randomized Trial||Stamford Anesthesiology Services, PC|Yes|Recruiting|May 2012|||February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|45 Years|No|||May 2012|May 7, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01593280||86370|
NCT01593527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885H2402|Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease|A Randomized Double-blind Active-controlled Trial of Canakinumab Versus Triamcinolone Acetonide on Reducing the Proportion of Patients With Any New Gouty Arthritis Flare(s) in Patients With Chronic Kidney Disease||Novartis||Withdrawn|September 2012|||September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||August 2013|August 14, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01593527||86351|
NCT01593540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|woel-01|Clinical Examination of Metal Free Interdental Brushes|Clinical Efficacy and Patient Acceptance of Metal and Metal-Free Interdental Brushes: A Controlled Prospective Randomized Study||University of Freiburg|No|Completed|September 2010|September 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|39|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 7, 2012|April 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01593540||86350|
NCT01562730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTL-01-11|Myovista iECG for Detecting Ischemic Heart Disease: Comparison With Computed Tomography Coronary Angiography|Incremental Value of Signal Processed Surface Electrocardiography (IECG) for Detecting Ischemic Heart Disease: Comparison With Computed Tomography Coronary Angiography (CTCA)||Cardiocentro Ticino|No|Recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive individuals undergoing a clinically indicated Computed Tomography Coronary        Angiography|April 2012|April 30, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562730||88700|
NCT01562743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-07-004|A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome|An Open-label Long-term Extension Trial From Late Phase II of SPM 962 (243-07-003) in Patients With Restless Legs Syndrome|RLS|Otsuka Pharmaceutical Co., Ltd.|No|Completed|August 2008|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|20 Years|79 Years|No|||March 2014|March 26, 2014|March 22, 2012||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01562743||88699|
NCT01593852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39479.060.012|X-ray Dose Reduction in Electrophysiology|X-ray Dose Reduction in Electrophysiology||Philips Healthcare|No|Completed|April 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|136|||Both|18 Years|N/A|No|||February 2014|February 17, 2014|March 27, 2012||No||No|December 9, 2013|https://clinicaltrials.gov/show/NCT01593852||86326|
NCT01571076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112-C-091-CR|Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor|Prospective and Randomized Study of the Use of Comparative Genomic Hybridization (CGH) Arrays to Study Embryo Aneuploidies in Female Advanced Age and Male Factor In Vitro Fertilization (IVF) Patients.||Igenomix|No|Recruiting|June 2012|February 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|240|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||November 2013|July 10, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01571076||88061|
NCT01571388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7471018|A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment|A Phase 1 Study To Evaluate The Single Dose Pharmacokinetics Of Dacomitinib (PF-00299804) In Subjects With Impaired Hepatic Function||Pfizer|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|25|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|April 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01571388||88038|
NCT01571414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5306|Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin|A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|52|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|March 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01571414||88036|
NCT01571427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|socialengagementR01|Conversations as a Means to Delay the Onset of Alzheimer's Disease|Conversational Engagement as a Means to Delay Alzheimer's Disease Onset|conversation|Oregon Health and Science University|No|Completed|February 2012|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|96|||Both|70 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 21, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01571427||88035|
NCT01571713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHSE22242|Side Effects of Pulmonary Hypertension Medications|Patient Reported Side Effects of Pulmonary Hypertension (PH) Medications||Stanford University|Yes|Recruiting|August 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|18 Years|No|Non-Probability Sample|Pediatric patients with pulmonary hypertension seen in the pulmonary hypertension clinic        at Stanford Lucile Packard Children's Hospital|November 2015|November 17, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571713||88013|
NCT01572220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0009|Stress Echo Ultrasound Contrast in an Urban Safety Net Hospital to Refine Ischemia Evaluation|Stress Echo Ultrasound Contrast in an Urban Safety Net Hospital to Refine Ischemia Evaluation|SECURE|Denver Health and Hospital Authority|No|Active, not recruiting|April 2012|August 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|240|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572220||87974|
NCT01572233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103086RC|Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection|Effects of Personalized Physical Activity and Psycho-Education Program on Patients With Chronic Hepatitis C Infection||National Taiwan University Hospital|Yes|Recruiting|December 2011|June 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|300|||Both|20 Years|70 Years|No|||November 2012|December 26, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572233||87973|
NCT01572246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISROTH20028|Effects of Monopolar Electrocautery Use During Surgery on Implanted Cardiac Defibrillators|Effects of Surgical Monopolar Electrocautery and Optimal Electrosurgery Unit Return Pad Placement on Implantable Cardioverter Defibrillators Protocol||Oregon Health and Science University|No|Recruiting|May 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with ICDs (including cardiac resynchronization therapy system-defibrillators)        scheduled for surgery involving ME.|February 2016|February 9, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01572246||87972|
NCT01572805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12612000117819|Evaluation of Melatonin's Effect on Pain and Blood Loss After Cesarean Section|||Qazvin University Of Medical Sciences|Yes|Completed|February 2012|October 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|120|||Female|18 Years|42 Years|No|||October 2012|October 10, 2012|April 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01572805||87929|
NCT01573039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0045/11|Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients|Definition of Cut Off for PCR - Quantitative and Antigenemia in the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients||University of Sao Paulo General Hospital|Yes|Completed|November 2011|July 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|14 Years|75 Years|No|Non-Probability Sample|Kidney transplant recipients|January 2013|April 3, 2014|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01573039||87911|
NCT01592006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0156|Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients|A Pilot Study on the Efficicay and Safety of Pegylated Interferon, Ribavirin and Telaprevir in Recurrent Hepatitis C Virus (HCV) Infection in Orthotopic Liver Transplant (OLT) Recipients.||University of Chicago|No|Terminated|April 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||January 2015|January 5, 2015|April 27, 2012|Yes|Yes|Low accrual|No|January 5, 2015|https://clinicaltrials.gov/show/NCT01592006||86467|
NCT01592019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-223-00277-01|Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products|Use of Dermal Microdialysis to Evaluate the Effect of Skin Properties and Application Site on the Topical Bioequivalence of Diclofenac: The Main Study||University of Florida||Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|6|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|December 12, 2012|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592019||86466|
NCT01563367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-CABG-01|A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof|A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute CABG, Valve Replacement or a Combination Thereof|CABG-01|Pharmacosmos A/S|Yes|Completed|January 2012|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01563367||88651|
NCT01563380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|adi_agg_tka_prp-2012|Role of Autologous Platelet Rich Plasma in Total Knee Arthroplasty|Efficacy of Autologous Platelet Rich Plasma on Blood Loss, Pain, Wound Healing and Functional Outcome After Total Knee Arthroplasty by a Single Surgeon A Randomized, Prospective, Controlled, Double-blinded Study|PRPTKA2012|Postgraduate Institute of Medical Education and Research|Yes|Completed|January 2010|December 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|30 Years|N/A|No|||March 2012|March 26, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01563380||88650|
NCT01593670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS124|Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes|Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS)||Masonic Cancer Center, University of Minnesota|Yes|Active, not recruiting|March 2013|July 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|75 Years|No|||January 2016|January 22, 2016|May 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593670||86340|
NCT01593696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120112|Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma|Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies||National Institutes of Health Clinical Center (CC)||Recruiting|April 2012|December 2025|Anticipated|January 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|1 Year|30 Years|No|||November 2015|December 19, 2015|May 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01593696||86338|
NCT01593943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD061115|Gender Equity-Focused, Male-Centered Family Planning for Rural India|Gender Equity-Focused, Male-Centered Family Planning for Rural India|CHARM|University of California, San Diego|Yes|Completed|March 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2162|||Both|15 Years|30 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593943||86319|
NCT01594190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30704 part 2|Physical Activity Immediately After Acute Cerebral Ischemia|Physical Activity Immediately After Acute Cerebral Ischemia: Too Little or Too Much - a Randomized Controlled Study||Hillerod Hospital, Denmark|No|Not yet recruiting|September 2012|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01594190||86300|
NCT01594203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0103-12-HMO|Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma|||Hadassah Medical Organization||Not yet recruiting|May 2012|May 2013|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|patients with advanced Soft Tissue Sarcoma prior to pazopanib therapy|April 2012|May 7, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01594203||86299|
NCT01594502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0670|Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies|R01 CA155301: Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies||University of Illinois at Chicago|No|Active, not recruiting|September 2011|July 2021|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||6|Anticipated|300|Samples Without DNA|Biopsy tissue (Year 2 and Year 4) already collected in REDUCE trial|Male|50 Years|75 Years|No|Probability Sample|Probability Sample|December 2015|December 1, 2015|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594502||86276|
NCT01594515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1305.1|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers (a Partially Randomised, Partially Single-blind, Placebo-controlled Phase I Study)||Boehringer Ingelheim||Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|10||Actual|70|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 11, 2015|May 7, 2012||||No|November 11, 2015|https://clinicaltrials.gov/show/NCT01594515||86275|BI 1015550 high dose 24mg was originally planned as 26 mg but reduced due to PK interim analysis results of previous dose group.
NCT01595100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 29023|Anthropometric Assessment of Abdominal Obesity and Health Risk in Children and Adolescents|Anthropometric Assessment of Abdominal Obesity and Health Risk in Children and Adolescents|Waist|Pennington Biomedical Research Center|No|Completed|January 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|423|Samples Without DNA|Serum|Both|5 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample from the Baton Rouge, Louisiana, metropolitan region|February 2016|February 4, 2016|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595100||86230|
NCT01595113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC-BD-CT-P-001|Safety Study of Clinical Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction|A Follow-up Observational Study of Safety of Clinical Trial Conducted With Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction||Pharmicell Co., Ltd.|Yes|Completed|May 2012|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Non-Probability Sample|Subjects agreed to participate in this follow-up observational study among the subjects        (80 patients:40-test group, 40-control group) who participated in the previously conducted        clinical trial.|November 2013|November 13, 2013|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595113||86229|
NCT01595334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB/LH-M2/OM/2011|Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity|Is it Possible to Obtain Higher Yield of Mature M2 Oocytes by Establishing Appropriate Levels of LH During Controlled Ovarian Hyperstimulation (COH) in Antagonist Cycles for In-vitro Fertilization-embryo Transfer (IVF-ET)/ Intracytoplasmic Sperm Injection (ICSI)?|LH/M2-Oocyte|Southern Cross Fertility Centre|Yes|Recruiting|April 2012|November 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 24, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01595334||86212|
NCT01595919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mixed Meal Milk Study|A Comparison of Beverages Consumed Within a Meal to Satiation on Meal-time Food Intake and Post-meal Appetite and Glycemic Response in Healthy Young Adults|||University of Toronto|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|26|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595919||86167|
NCT01596218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-094|Brentuximab Vedotin for Steroid Refractory GvHD|Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft vs. Host Disease (GvHD)||Massachusetts General Hospital|Yes|Recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596218||86144|
NCT01596231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001099|Kudzu Treatment for Alcohol Abuse|Isoflavone (Kudzu) Extract Effects on Alcohol Drinking: Single Dose Pretreatment Study|KUDZU|Mclean Hospital|No|Completed|May 2010|July 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|May 9, 2012||No||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01596231||86143|
NCT01594099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCR-02|Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women|Weekly Cisplatin or Weekly Liposome Paclitaxel Concurrent Radiation Therapy in Treating Elderly People With Cervical Cancer||Xi’an Jiaotong University College of Medicine|Yes|Active, not recruiting|April 2012|March 2014|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Female|65 Years|80 Years|No|||May 2012|May 6, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01594099||86307|
NCT01594658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUT-3F|Venous Ulcer Treatment With Foam Versus Conservative Treatment|Prospective Random Study for Handling Venous Ulcer With Conservative Treatment (Dressings Alone) and Foam Sclerotherapy Versus Conservative Treatment|VUTEF|Hospital Occidente de Kennedy|No|Completed|July 2011|September 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with C6 by CEAP Clasification|September 2012|September 30, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01594658||86264|
NCT01594996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00057|European Drug Utilization Study|A Multinational, Multicenter, Retrospective, Observational Drug Utilisation Study of Seroquel Extended Release (XR) Prescribed by Psychiatrists as Treatment for Major Depressive Disorder (MDD) in Selected Countries in the European Union (EU)|EUDUS|AstraZeneca||Completed|April 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1008|||Both|18 Years|N/A|No|Non-Probability Sample|500-2000 patients that are broadly representative of the overall Major Depressive Disorder        population in Europe. Patients are distributed at medical healthcare centres, private        practice, as well as university and community hospitals in five European countries.|May 2015|May 26, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01594996||86238|
NCT01595477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-CMBM-001|Mind-Body Skills Groups for the Treatment of War-Related Trauma in Children in Gaza|A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Children in Gaza||The Center for Mind-Body Medicine|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|114|||Both|8 Months|13 Years|No|||January 2014|January 27, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595477||86201|
NCT01595490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GT-CMBM-001|Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza|A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza||The Center for Mind-Body Medicine|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|121|||Both|14 Years|17 Years|No|||January 2014|January 27, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595490||86200|
NCT01595503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00046254|Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia|Functional Targeting of Transcranial Magnetic Stimulation for the Treatment of Refractory Auditory Hallucinations in Schizophrenia||University of Michigan|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|60 Years|No|||July 2013|July 15, 2013|May 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01595503||86199|
NCT01595763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-TVP-2011-13|Diagnostic Approach of Deep Vein Thrombosis in Primary Care|Orientación Diagnóstica de la Trombosis Venosa Profunda en la Atención Primaria. Estudio de Coste Efectividad||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|November 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|blood to calculate the value of Dimer D|Both|18 Years|N/A|No|Non-Probability Sample|Patients referred by physicians with clinical suspicions of a first episode of deep vein        thrombosis visited in emergency department of Hospital Santa Creu i Sant Pau|April 2011|May 8, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595763||86179|
NCT01595776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHVAS-01-08|Autologous Endothelial Progenitor Cells (EPCs) From Peripheral Blood in the Treatment of Critical Limb Ischemia|Autologous Immunomagnetic Selected cd133+ Cells in the Treatment of No-option Critical Limb Ischemia: Clinical and Ceus Assessed Results.||IRCCS Policlinico S. Matteo|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|70 Years|No|||June 2012|June 13, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01595776||86178|
NCT01595789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBHAH-2011430|The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes|Adding Liraglutide to the Backbone Therapy of Biguanide in Patients With Coronary Artery Disease and Newly Diagnosed Type-2 Diabetes|AddHope2|Haugaard, Steen Bendix, M.D., DMSc|Yes|Completed|May 2012|July 2015|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|85 Years|No|||July 2015|July 29, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595789||86177|
NCT01592032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAS110775|Concentration of Antimicrobials in Catheter-lock Solutions|Concentration and Antibiotic Activity in Antibiotic Lock Solutions|CONAN|Clinica Universidad de Navarra, Universidad de Navarra|Yes|Active, not recruiting|May 2012|December 2015|Anticipated|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|N/A|No|||February 2015|February 18, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01592032||86465|
NCT01592331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP27959|A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Single Dose, Placebo-Controlled, Parallel Group Study to Investigate the Pharmacodynamic and Pharmacokinetic Behavior of RO5508887 in Plasma and Cerebral Spinal Fluid Following Oral Administration in Healthy Volunteers||Hoffmann-La Roche||Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator)|2||Actual|42|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592331||86442|
NCT01563718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH VIVITROL -01|Pre-Release VIVITROL for Opioid Dependent Inmates|VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison||Rhode Island Hospital|Yes|Completed|March 2012|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|60 Years|No|||October 2015|October 21, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563718||88626|
NCT01563965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pexe_aguilar|Carbohydrates and Proteins 3h Before Surgery|Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations||Federal University of Mato Grosso do Sul|Yes|Completed|March 2010|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||March 2012|March 26, 2012|March 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01563965||88607|
NCT01593956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/021/12|Influence of Transcranial Direct Current Stimulation on Cortical Plasticity in Concussed Athletes|Influence of Anodal Transcranial Direct Current Stimulation on Cortical Plasticity in Concussed Athletes and Healthy Volunteers||Charite University, Berlin, Germany|No|Recruiting|March 2012|||July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 22, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01593956||86318|
NCT01594229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-630|A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma||AbbVie|No|Active, not recruiting|June 2012|March 2017|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|99 Years|No|||January 2016|January 23, 2016|April 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594229||86297|
NCT01594528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00048-35|Behavior During Experimentally Induced Pain|Behavior During Experimentally Induced Pain||Centre Hospitalier Esquirol|No|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 13, 2014|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01594528||86274|
NCT01594827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMEP|Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)|Persistent MRSA Eradication Protocol (PMEP)|PMEP|Johns Hopkins University|Yes|Recruiting|October 2012|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|N/A|No|||January 2016|January 16, 2016|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594827||86251|
NCT01594840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Changing chat|Changing Chat: Diaper Tips to Improve Language Development|Changing Chat: Diaper Tips to Improve Language Development||Seattle Children's Hospital|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|16 Months|18 Months|Accepts Healthy Volunteers|||March 2014|March 24, 2014|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594840||86250|
NCT01595360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021882-57|Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction|A Phase 1, Randomized, Open, Controlled, Comparative Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction||Thrombotargets Europe S.L|Yes|Completed|April 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 13, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01595360||86210|
NCT01595373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-28512|Local Metabolic Effects of Ghrelin in Skeletal Muscle and Adipose Tissue|Local Metabolic Effects of Ghrelin: A Clinical Microdialysis Study||University of Aarhus|No|Completed|June 2012|January 2013|Actual|September 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595373||86209|
NCT01595347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSM-SAS-2012-1|Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care|Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care.A Cluster Randomized Clinical Trial.|PrevenUP|Andaluz Health Service|No|Enrolling by invitation|January 2012|January 2014|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|410|||Both|18 Years|N/A|No|||January 2012|May 8, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01595347||86211|
NCT01595646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00023230|Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)|Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)|SL120|Wake Forest School of Medicine|Yes|Active, not recruiting|November 2011|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|36|||Both|50 Years|89 Years|No|||June 2015|June 1, 2015|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595646||86188|
NCT01595958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.571|Cyclosporine A in Cardiac Arrest|CYclosporine A in Non-shockable Out-of-hospital Cardiac Arrest ResUScitation|CYRUS|Hospices Civils de Lyon|Yes|Completed|June 2010|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|796|||Both|18 Years|80 Years|No|||April 2014|April 30, 2014|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01595958||86164|
NCT01595932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|α-galactosidase|Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children|Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children. A Randomized, Double-blind, Placebo-controlled Trial||Azienda Policlinico Umberto I|Yes|Completed|June 2009|May 2010|Actual|May 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|4 Years|18 Years|No|||May 2012|May 9, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595932||86166|
NCT01595945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCKBHS-01|Effect of Caloric Restriction and Gastric Bypass on Resting Metabolic Rate|Effect of Caloric Restriction and Gastric Bypass on Resting Metabolic Rate in Obese Subjects||KiloCoach e.U.|No|Terminated|April 2012|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|75|||Both|18 Years|60 Years|No|||February 2015|February 4, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595945||86165|
NCT01594671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-ATR-2010-23|Tranexamic Acid for Unilateral Total Knee Arthroplasty|Prevention of Postoperative Blood Loss: Randomised Multicentre Parallel Clinical Trial That Assess the Topical and Intravenous Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.|TRANEXTOP|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|February 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|150|||Both|18 Years|N/A|No|||December 2012|December 18, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594671||86263|
NCT01595009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001K24133E1|Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors|Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors||Novartis|No|Active, not recruiting|June 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||December 2015|December 19, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595009||86237|
NCT01595243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200908011R|Effects of Telephone Consultations on Discharged Liver Cancer|Effects of Telephone Follow- up Consultations on Discharged Liver Cancer Following Non-surgical Treatment||National Taiwan University Hospital|Yes|Recruiting|October 2009|February 2013|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|254|||Both|18 Years|N/A|No|||November 2012|December 26, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01595243||86219|
NCT01595022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13830|FR01 and FR20 IUS (Intrauterine System) Wearing Study|A Multi-center, Single-blinded, Randomized, Controlled, Parallel-group Study to Evaluate the Wearing Comfort of Two Different Placebo Intrauterine Systems FR01 and FR20 Compared to a Placebo T-frame Intrauterine System for 3 Cycles in Healthy Women Aged 18-40 Years||Bayer|No|Completed|January 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|90|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595022||86236|
NCT01595256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109041RB|Exploration the Effect of Walking Program in Patients With Colorectal Cancer|Exploration the Effect of Individualized Home-based Walking Program on Muscle Strength and Fatigue in Patients With Colorectal Cancer Both During and After Treatment||National Taiwan University Hospital|Yes|Completed|October 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|237|||Both|18 Years|65 Years|No|||October 2014|October 13, 2014|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01595256||86218|
NCT01595516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYS-MD-72|Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)|Nebivolol and Endothelial Regulation of Fibrinolysis||University of Colorado, Boulder|Yes|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Anticipated|54|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|March 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595516||86198|
NCT01596101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-07-21-03|Circadian Rhythm of Melatonin in Burns|Role of Circadian Rhythm of Melatonin on Sleep-related Disturbances Postburn|Sleep4|Shriners Hospitals for Children|Yes|Completed|April 2009|August 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|86|||Both|5 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|pediatric burn patients|August 2014|August 10, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01596101||86153|
NCT01596114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELN-001|European Stop Tyrosine Kinase Inhibitor Study|Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukemia After Stopping TKI|EURO-SKI|European LeukemiaNet|Yes|Active, not recruiting|June 2012|June 2018|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|800|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596114||86152|
NCT01563107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VUMC 111633|Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome|Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome||Vanderbilt University|No|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|40|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563107||88671|
NCT01593423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00451|Food Security and Nutrition in Rural Cambodia|Integration of Small-scale Aquaculture With Homestead Food Production for Improved Household Food Security and Nutrition in Rural Cambodia||University of British Columbia|No|Active, not recruiting|June 2012|June 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|900|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2015|May 14, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01593423||86359|
NCT01593683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH 2011-P-002799|Waitlist-controlled Trial of a Psychological Education Program for Nurses|Waitlist-controlled Trial of a Psychological Education Program for Nurses||Massachusetts General Hospital|No|Active, not recruiting|March 2012|September 2013|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 9, 2013|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593683||86339|
NCT01594242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 05411|Autophagy Induction After Bortezomib for Myeloma|A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2012|||April 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|15|||Both|18 Years|N/A|No|||December 2015|December 15, 2015|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594242||86296|
NCT01594541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC-004|A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients|Hyperhomocysteinemia in a Mild Cognitive Impairment and Dementia Population: the Effect of Treatment With Cerefolin NAC® in a Naturalistic Community-based Dementia Practice||Pamlab, Inc.|No|Active, not recruiting|January 2013|April 2014|Anticipated|August 2013|Actual|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|700|||Both|55 Years|89 Years|No|Non-Probability Sample|Medical charts of 700 de-identified elderly patients who underwent evaluation and        treatment for cognitive loss.|March 2014|March 21, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594541||86273|
NCT01594853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00045673|Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy|Exercise Study of Function and Pathology for Women With X-ALD||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|May 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Female|21 Years|70 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594853||86249|
NCT01595139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-14927|MicroRNAs in Patients With Neurofibromatosis Type 1|MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|February 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|9|||Both|2 Years|21 Years|No|Non-Probability Sample|Participation in the study will be offered to patient's ages 2 years to 21 years seen for        a routine visit in the Neurofibromatosis Clinic at Children's Memorial Hospital and Lurie        Children's Hospital in Chicago.|February 2016|February 3, 2016|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595139||86227|
NCT01595633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0937|Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy|Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance||Yonsei University|Yes|Recruiting|March 2012|February 2014|Anticipated|February 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|20 Years|N/A|No|||May 2012|May 9, 2012|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01595633||86189|
NCT01595971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED/FNS 774/08|Distance Education Versus Usual Care Qualification in Asthma Care|Distance Education Versus Usual Care in the Qualification of Asthma Care: A Cluster Randomized Clinical Trial - RESPIRANET|RESPIRANET|Hospital de Clinicas de Porto Alegre|No|Active, not recruiting|August 2010|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|467|||Both|5 Years|45 Years|No|||August 2010|May 9, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595971||86163|
NCT01596257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-016|Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation|Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Active, not recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|N/A|75 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596257||86141|
NCT01592188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054782|Cognitively-Based Compassion Training and Mindfulness Attention Training Program|Cognitively-Based Compassion Training and Mindfulness Attention Training for Elementary School Students||Emory University|Yes|Completed|January 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|53|||Both|7 Years|12 Years|Accepts Healthy Volunteers|||November 2013|November 13, 2013|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01592188||86453|
NCT01594450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_56|Biological Meshes in Infected Fields: a Randomized Controlled Trial|Use of Biological Mesh Versus Standard Wound Care in Infected Incisional Ventral Hernias: a Multicenter Randomized Controlled Trial, the SIMBIOSE Study|SIMBIOSE|University Hospital, Lille|Yes|Recruiting|May 2012|December 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01594450||86280|
NCT01594684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 11108|Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries|Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study||Klinikum Rosenheim|No|Recruiting|January 2012|June 2016|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|112|||Both|18 Years|N/A|No|||June 2012|June 16, 2012|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594684||86262|
NCT01594697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000082011|Metformin in Pregnancy in Women With Polycystic Ovary Syndrome|||Catholic University of the Sacred Heart||Completed||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Female|18 Years|40 Years||||May 2012|May 10, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594697||86261|
NCT01594710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreaHealth_MS|Risk Factor Analysis for Developing Metabolic Syndrome in Korean Adults|||Korea University|Yes|Completed|February 2012|May 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1800|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Apparently healthy people who underwent medical routine check up in Korea University        Helath Promotion Center.|April 2014|October 12, 2015|April 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01594710||86260|
NCT01595529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008186|The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children|Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"|SCOUT|Children's Hospital of Philadelphia|Yes|Recruiting|May 2012|April 2018|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|746|||Both|2 Months|10 Years|No|||December 2015|December 23, 2015|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595529||86197|
NCT01595542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1041|A School Health Center Intervention to Increase Adolescent Vaccination|A School Health Center Intervention to Increase Adolescent Vaccination||University of North Carolina, Chapel Hill|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|3417|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2014|March 12, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595542||86196|
NCT01595802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC1B-01|Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm|A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler as an Aid to Diagnosing Vasospasm||Jan Medical, Inc.|No|Completed|January 2012|July 2015|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|72|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01595802||86176|
NCT01595815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GJHS120509DK|Successful Pregnancy and Delivery After AOA|Successful Pregnancy and Delivery After AOA in Couples With Repeated Complete Fertilization Failure or Low Fertilization Rates||Maria Fertility Hospital|Yes|Active, not recruiting|May 2007|April 2016|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|20 Years|45 Years|No|||January 2014|January 6, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595815||86175|
NCT01562873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-024|Ruxolitinib in Patients With Breast Cancer|Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer||Dana-Farber Cancer Institute|Yes|Terminated|June 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||November 2015|November 25, 2015|March 20, 2012|Yes|Yes|Not enough responses to continue treatment.|No||https://clinicaltrials.gov/show/NCT01562873||88689|
NCT01563120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0002-11-EMC|A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus|||HaEmek Medical Center, Israel||Enrolling by invitation|January 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Female|18 Years|45 Years|No|||March 2012|March 23, 2012|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01563120||88670|
NCT01563393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC12-6634|Validation of a STAMP in Hospitalized Children and the Effect of Its Use on the Awareness of the Medical Staff|Validation of a Nutritional Risk Screening Tool- STAMP in Hospitalized Children and the Effect of Its Use on the Awareness of the Medical Staff|STAMP|Rabin Medical Center|Yes|Not yet recruiting|May 2012|||March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|350|||Both|1 Year|17 Years|No|||March 2012|March 28, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563393||88649|
NCT01563705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00615-34|Prospective Follow-up of Patients With Glycogen Storage Disease Type III|Prospective Follow-up of Patients With Glycogen Storage Disease Type III|PRO GSDIII|Institut de Myologie, France|No|Recruiting|February 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|10 Years|N/A|No|||December 2012|December 19, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01563705||88627|
NCT01593969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSC 2157|A Trial of n-3 PUFA-Enriched Ready to Use Therapeutic Food for Childhood Severe Malnutrition|A Randomised Controlled Trial of n-3 Polyunsaturated Fatty Acid-Enriched Therapeutic Food for Childhood Severe Malnutrition|Njugu Plus|University of Oxford|No|Completed|May 2012|June 2014|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|6 Months|5 Years|No|||August 2014|August 15, 2014|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593969||86317|
NCT01594216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02112|Ruxolitinib in Estrogen Receptor Positive Breast Cancer|A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer)||Abramson Cancer Center of the University of Pennsylvania|Yes|Recruiting|April 2012|||October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|January 14, 2016|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594216||86298|
NCT01594268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AKR10|A Prospective, Open Label Study of CERtican in KIdney Transplantation|A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients|CERKI|Novartis||Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|54|||Both|18 Years|60 Years|No|||January 2015|January 5, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01594268||86294|
NCT01594554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452018 ST|A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.|A 5-year Observational Follow-up Study to Describe Treatment Patterns and Outcomes in Real World Clinical Practice for Patients of Newly Confirmed HCV Infection in China (2012-2016)||Peking University People's Hospital|No|Recruiting|April 2012|September 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Samples with HCV RNA|Both|18 Years|N/A|No|Non-Probability Sample|600|May 2012|May 8, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01594554||86272|
NCT01594866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AYM-LEADERS|Lexapro®'s Efficacy After Dose Escalation in Remission Study|A Double-blinded 6-week Prospective Study to Evaluate the Remission Rate According to Dose of Escitalopram (Lexapro®) in Patients With Major Depressive Disorder: a Preliminary Study|LEADERS|Seoul National University Hospital|Yes|Recruiting|May 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594866||86248|
NCT01595126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-14877|Longitudinal Study of Biomarkers|A Longitudinal Study of Biomarkers in Pediatric Patients With Central Nervous System Tumors||Ann & Robert H Lurie Children's Hospital of Chicago|No|Recruiting|December 2011|||December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|21 Years|No|Non-Probability Sample|Newly diagnosed patients with central nervous system tumors|February 2016|February 3, 2016|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595126||86228|
NCT01595399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R500458|Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation|Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation||University of Manitoba|No|Recruiting|April 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|N/A|2 Months|No|||May 2012|September 23, 2013|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595399||86207|
NCT01595386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Postop Steroids after CPB|Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass|Effect of Postoperative Hydrocortisone on Cardiovascular and Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass||University of Alabama at Birmingham|Yes|Completed|April 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|28 Days|No|||October 2015|October 12, 2015|March 16, 2012|Yes|Yes||No|January 28, 2015|https://clinicaltrials.gov/show/NCT01595386||86208|small, single-center trial; included subjects from more than one surgeon; all patients received preoperative and rescue steroids; definition of low cardiac output syndrome although appropriate must ultimately be arbitrary.
NCT01592201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100782|A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug|An Open-label, Prospective, Randomized and Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug||Janssen Korea, Ltd., Korea|No|Terminated|July 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|20 Years|65 Years|No|||June 2014|June 24, 2014|February 10, 2012||No|This study was early terminated due to insufficient enrollment required for hypothesis    testing.|No||https://clinicaltrials.gov/show/NCT01592201||86452|
NCT01584856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1267|Small Dense Low-density Lipoprotein in Patients With Prediabetes and Type 2 Diabetes|||University of Zurich||Active, not recruiting|May 2006|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Male|20 Years|90 Years|No|Non-Probability Sample|Prediabetes / Type 2 Diabetes|April 2012|April 25, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584856||87010|
NCT01584869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23042012|Emergency Capsule Endoscopy in Severe GI-bleeding|Emergency Capsule Endoscopy in Severe GI-bleeding||Technische Universität München|No|Completed|December 2011|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584869||87009|
NCT01594112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS056|Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.|Inappropriate Therapies and Home Monitoring® in Implantable Cardioverter Defibrillators (ICD)|THORN|Biotronik SE & Co. KG|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1750|||Both|18 Years|N/A|No|Probability Sample|Population implanted of ICD with Biotronik Home Monitoring® system. 510 patients will be        selected by investigators in 50 centers in France.|January 2015|January 28, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594112||86306|
NCT01594125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.120|Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma|An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma.||Boehringer Ingelheim||Completed|May 2012|January 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|N/A|No|||January 2016|January 11, 2016|May 2, 2012||||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01594125||86305|
NCT01595035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1984|A Clinical Trial of a Psycho-educational Intervention to Improve Pain Management After Day Surgery|A Randomized Clinical Trial of a Psycho-educational Intervention to Improve Pain Management After Day Surgery||Oslo and Akershus University College of Applied Sciences|No|Active, not recruiting|May 2012|December 2018|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|200|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595035||86235|
NCT01565655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-RA22|A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis|A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects||Astellas Pharma Inc|Yes|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|289|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565655||88477|
NCT01595269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAWSON-686|The Clinical and Economic Impacts of e-Heath on Diabetes|The Clinical and Economic Impacts of e-Heath on Diabetes|eHealthDM|Pacaud, Danièle, M.D.|No|Completed|April 2007|December 2009|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|79|||Both|18 Years|N/A|No|||May 2012|May 8, 2012|March 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01595269||86217|
NCT01561807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-787-101|A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus|A Phase 2a, Randomized, Double-Blind,Placebo-Controlled Study to Investigate the Effects of VX-787 Administered to Adult Volunteers Experimentally Inoculated With Live Influenza Virus||Vertex Pharmaceuticals Incorporated|No|Completed|March 2012|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|140|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|January 8, 2014|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561807||88771|
NCT01562080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARM-PLUS-LDL|Combined Effects of Bioactive Compounds in Lipid Profile|Combined Effects of Bioactive Compounds (ARMOLIPID PLUS ®) on Lipid Profile and Clinical Criteria of Metabolic Syndrome in Patients With Serum Elevated LDL-C|ARM-PLUS-LDL|Rottapharm Spain|No|Completed|January 2012|October 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|118|||Both|18 Years|N/A|No|||February 2013|February 27, 2013|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562080||88750|
NCT01562340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41986-D|Pomegranate and Hemodialysis Pilot Trial|A Pilot Trial Assessing the Effect of Pomegranate Juice and Extract on Biomarkers of Oxidative Stress, Systemic Inflammation, and Monocyte Function in Hemodialysis Patients|POM Pilot|University of Washington|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Both|18 Years|85 Years|No|||May 2015|May 26, 2015|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562340||88730|
NCT01562613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-165|A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan|Stroke Estimation (According to Framingham Profile ParameterS) in Patients Under medicAtion Due to Essential Hypertension. (NASA)||Abbott|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|533|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with eprosartan according to routine medical practice from hospitals and        private physicians.|August 2014|August 8, 2014|March 16, 2012||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01562613||88709|No important limitations apply. Missing data and drop-out rate was very low; but some factors required for patient CV (cardiovascular) risk classification were unknown and may have resulted in CV risk underestimation in a limited number of patients.
NCT01562626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APS001F-001|Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors|A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors||Anaeropharma Science, Inc.||Recruiting|September 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562626||88708|
NCT01562886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|278_CSF|The Rilpivirine Cerebrospinal-fluid (CSF) Study|A Phase I Pharmacokinetic Study to Assess the Cerebrospinal-fluid (CSF) Exposure of Rilpivirine in HIV-infected Subjects Switching From TDF/FTC/Nevirapine to TDF/FTC/Rilpivirine||Imperial College London|No|Completed|March 2012|February 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|N/A|No|||May 2014|May 19, 2014|March 22, 2012||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01562886||88688|
NCT01564251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28153|A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma|An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma||Genentech, Inc.||Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|March 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01564251||88585|
NCT01593982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0181/08|Repetitive Transcranial Magnetic Stimulation in Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts|Effect of Repetitive Transcranial Magnetic Stimulation on Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts|rTMSinADHD|University of Sao Paulo General Hospital|No|Recruiting|March 2010|March 2013|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|40 Years|No|||May 2012|May 22, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593982||86316|
NCT01594281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002DDE21|Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)|Multicenter Randomized Open-label Three-arms Controlled 12 Months Clinical Proof of Concept Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy|PRIDE|Novartis||Recruiting|December 2012|January 2018|Anticipated|January 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594281||86293|
NCT01594294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-11-09|An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues|EVALUATION OF THE EFFECTS OF CLEAR CARE® / AOSEPT® PLUS HYDROGEN PEROXIDE SOLUTION ON THE EYELID TISSUES - Part III: COMPARATIVE EVALUATION WITH RENU® MPS OVER 3 MONTH OF WEAR - CONTROL EVALUATION WITH AIR OPTIX® AQUA and ACUVUE® 2®|ID11-56|Alcon Research|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|100|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|May 7, 2012|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01594294||86292|
NCT01594567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-KRS-2011-263052|Meta-analyses of Dietary Pulses and Cardiometabolic Risk|Effect of Dietary Pulses on Cardiometabolic Risk in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development||University of Toronto|No|Active, not recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Probability Sample|Varied|July 2015|September 21, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01594567||86271|
NCT01594879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG2009|Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer|Treatment With Medroxyprogesterone Acetate(MPA) Plus Levonorgestrel-releasing Intrauterine System(LNG-IUS) in Young Women With Early Stage Endometrial Cancer: Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2009)||Korean Gynecologic Oncology Group|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Female|N/A|40 Years|No|||May 2012|May 8, 2012|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594879||86247|
NCT01596270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED12471|A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma|A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma||Sanofi|No|Completed|June 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|49|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01596270||86140|
NCT01584245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6009|Evaluation of the Efficacy of an Amino Acid Based Formula in Infants|Evaluation of the Efficacy of an Amino Acid Based Formula in Infants||Mead Johnson Nutrition|No|Terminated|February 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment|||Actual|32|||Both|1 Month|12 Months|No|||September 2014|September 15, 2014|April 23, 2012||No|Enough participants enrolled to provide adequate statistical power|No||https://clinicaltrials.gov/show/NCT01584245||87056|
NCT01595659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-111034|Influence of Alcohol and Peer Passengers on Risky Driving Behavior in Young Adults|Influence of Alcohol and Peer Passengers on Risky Driving Behavior in Young Adults||Centre Hospitalier Universitaire de Sherbrooke|No|Recruiting|May 2012|||April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|200|||Both|18 Years|19 Years|Accepts Healthy Volunteers|||May 2012|May 8, 2012|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01595659||86187|
NCT01595672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAP-CVVH-XHDD-002|Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis|Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis: Single-center, Randomized, Controlled Trial|EHVCVVHSAP|Fourth Military Medical University|Yes|Recruiting|April 2012|March 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|80 Years|No|||May 2012|May 8, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01595672||86186|
NCT01584544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-024|Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer|Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients||Chinese Academy of Medical Sciences|Yes|Completed|January 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|24|||Both|75 Years|N/A|No|||April 2015|April 17, 2015|April 20, 2012||No||No|April 7, 2015|https://clinicaltrials.gov/show/NCT01584544||87034|
NCT01565694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-047|A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Patients 5 to 18 Years of Age With Neurogenic Detrusor Overactivity|A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)||Astellas Pharma Inc|Yes|Active, not recruiting|September 2012|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|5 Years|17 Years|No|||October 2015|October 23, 2015|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565694||88474|
NCT01594736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJ-MRI-ORSIRO_OCT-V3.1|Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography|Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography|ORSIRO OCT|Deutsches Herzzentrum Muenchen|No|Recruiting|April 2012|January 2015|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594736||86258|
NCT01565668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2689-CL-2004|Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)||Daiichi Sankyo Inc.|No|Completed|April 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01565668||88476|
NCT01565681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7163-CL-0101|Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects|A Phase 1 Single Ascending Dose Study of ASKP1240 in Healthy Male and Female Volunteers||Astellas Pharma Inc|No|Completed|January 2009|December 2009|Actual|December 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|13||Actual|109|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 7, 2012|March 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01565681||88475|
NCT01561521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-100-0008|An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis|||Akorn, Inc.|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|10 Years|N/A|No|||May 2012|July 16, 2013|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561521||88793|
NCT01561534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0104|Vascularized Free Fibula Flap and Computer-guided Implant Surgery|Long-term Results of Mandibular/Maxillary Reconstruction With Vascularized Free Fibula Flap and Computer-guided Implant Surgery||University of Bari|Yes|Recruiting|February 2012|March 2014|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5|||Both|N/A|N/A|No|Non-Probability Sample|patients with free fibula flaps for maxillary and mandibular reconstruction|March 2012|March 21, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01561534||88792|
NCT01561794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15992|A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia|A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and TID) in Hospitalized Patients With Bacterial Pneumonia or Secondary Infection of Chronic Respiratory Disease With Severe Disease or a Poor Response to Other Antimicrobials||Bayer|No|Completed|May 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|44|||Both|20 Years|N/A|No|||April 2015|April 24, 2015|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01561794||88772|
NCT01562353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPH.CSA.0005|Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction|A Pilot Study to Determine the Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction in Patients Treated for Pain Using a Comparative Transcriptomic Analysis of Gene Expression in Peripheral Blood Cells||Analgesic Solutions|No|Recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|30|Samples With DNA|One tube (2.5-5.0 mL) of blood will be drawn from each subject during the visit for mRNA      testing|Both|18 Years|N/A|No|Non-Probability Sample|A sample of 15 subjects per group will be sought. Cases and Controls will be selected by a        community-based advertising program supplemented by referrals from clinicians.|September 2013|September 13, 2013|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562353||88729|
NCT01563406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54CK000161-01W1|Hub Cleansing to Prevent Hub Infection|Hub Cleansing to Prevent Hub Infection|HUC-PHIN|Rush University Medical Center|No|Completed|March 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|509|||Both|16 Years|N/A|No|||June 2013|April 2, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01563406||88648|
NCT01563731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAI27F201_2012|Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives|European Society of Hypertension and Chinese Hypertension League Stroke in Hypertension Optimal Treatment Trial|ESH-CHL-SHOT|Istituto Auxologico Italiano|Yes|Recruiting|April 2013|November 2018|Anticipated|September 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Anticipated|7500|||Both|65 Years|N/A|No|||February 2016|February 23, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01563731||88625|
NCT01563978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00033|Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis|OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis|Oskira ABPM|AstraZeneca|Yes|Completed|April 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||April 2014|April 23, 2014|March 23, 2012|Yes|Yes||No|November 8, 2013|https://clinicaltrials.gov/show/NCT01563978||88606|
NCT01564264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNEndometrialCa|Sentinel Node Biopsy in Endometrial Cancer|Prospective Cohort Study Evaluating Identification Rate of Sentinel Node in the Management of Endometrial Cancer Utilizing a Combined Method of Cervical and Myometrial Injections||Hamilton Health Sciences Corporation|No|Recruiting|November 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Female|18 Years|N/A|No|||August 2014|August 29, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564264||88584|
NCT01564563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7SCT-1485|Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation|A Multi-center, Randomized, Double-blind, Parallel Groups, Placebo-controlled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation (HSCT)||Novo Nordisk A/S|No|Terminated|June 2002|October 2003|Actual|October 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|11|||Both|12 Years|N/A|No|||December 2012|December 10, 2012|March 23, 2012|No|Yes|Trial enrollment was prematurely terminated due to excessively slow patient recruitment|No||https://clinicaltrials.gov/show/NCT01564563||88561|
NCT01593995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAU-12-01(ML25441)|EGF Ointment for Erlotinib Skin Lesion|Phase II Trial of Epidermal Growth Factor Ointment for Patients With Erlotinib Related Skin Effects||Dong-A University Hospital|Yes|Completed|May 2012|October 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|20 Years|N/A|No|||November 2014|November 2, 2014|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01593995||86315|
NCT01594255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAEB071A2115|CAEB071 Thorough QTc Study in Healthy Volunteers|A Randomized, Partially Blinded, 4-period, Crossover Study to Assess the Effects of Single-dose AEB071 Administration (300 and 900 mg) on Electrocardiographic QT Intervals Compared to Placebo in Healthy Volunteers||Novartis||Completed|July 2009|||September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 7, 2012|May 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01594255||86295|
NCT01594333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000857|Cardiovascular Inflammation Reduction Trial|A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome|CIRT|Brigham and Women's Hospital|Yes|Recruiting|April 2013|December 2019|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|7000|||Both|18 Years|N/A|No|||November 2015|March 15, 2016|May 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594333||86289|
NCT01594580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00051506|Contamination of Hospital Scrubs|A Novel Agent to Decrease Contamination of Hospital Scrubs||University of Maryland|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|111|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594580||86270|
NCT01594892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOSIS|Fractionated Radiosurgery for Painful Spinal Metastases|Dose-intensified Image-Guided Fractionated Radiosurgery for Spinal Metastases (DOSIS)|DOSIS|Wuerzburg University Hospital|Yes|Active, not recruiting|April 2012|||January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|N/A|No|||August 2015|August 6, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594892||86246|
NCT01595152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMB-0096-12|Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms|Solifenacin Succinate vs. Fesoterodine A Comparison Trial for the Treatment of Bothersome Urgency Symptoms||Rambam Health Care Campus|No|Recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|80 Years|No|||May 2012|May 14, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595152||86226|
NCT01584258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACCP003|Prostate Advances in Comparative Evidence|International Randomised Study of Laparoscopic Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Early Stage Organ-Confined Prostate Cancer|PACE|Royal Marsden NHS Foundation Trust|Yes|Recruiting|April 2012|September 2026|Anticipated|September 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1716|||Male|18 Years|N/A|No|||April 2015|April 24, 2015|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01584258||87055|
NCT01584557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCSF-2011-001|Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management|A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management|Secret of CHF|Cardiovascular Clinical Science Foundation|Yes|Recruiting|June 2012|October 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||July 2014|February 5, 2015|April 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01584557||87033|
NCT01584570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0791|The Effects of Dexmedetomidine and Tracheal Intubation on Heart Rate Variability and QTc Interval|||Yonsei University|No|Recruiting|January 2012|December 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|66|||Both|20 Years|60 Years|No|||July 2014|July 13, 2014|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01584570||87032|
NCT01584583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth6|Blood Pressure Monitor Clinical Test (Cuff Range: 22 Cm-36cm)|||Andon Health Co., Ltd|No|Completed|February 2012|April 2012|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|85|||Both|24 Years|81 Years|Accepts Healthy Volunteers|Non-Probability Sample|resident of a community|April 2012|April 24, 2012|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584583||87031|
NCT01584882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-062|Computer-Assisted Tobacco Interventions in Dental Offices|Computer-Assisted Guidance for Tobacco Dependence Interventions in Dental Offices|CATI|HealthPartners Institute|No|Completed|October 2009|July 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|548|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 15, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584882||87008|
NCT01561833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0901004690|A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients|A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients||Yale University|Yes|Completed|October 2009|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01561833||88769|
NCT01565369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-A08|Evaluation of Physician Training Methods to Read Florbetapir-PET Scans|Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Validation of Binary Image Rating Methodology Using Amyloid Histopathology at Autopsy as the Reference Standard.||Avid Radiopharmaceuticals|No|Completed|January 2011|January 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|35|||Both|18 Years|N/A|No|||May 2012|May 3, 2012|March 26, 2012|No|Yes||No|April 6, 2012|https://clinicaltrials.gov/show/NCT01565369||88499|
NCT01561820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFUBH-18495|Mild Cognitive Impairment, Buddy Supported Exercise/ My Buddy Study|Community-based, Buddy-supported Exercise in Patients With MCI: a Pilot Trial||Wake Forest School of Medicine|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|15|||Both|60 Years|N/A|No|||June 2015|June 2, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01561820||88770|
NCT01562093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/158|Effect of Intranasal Corticosteroids on Pulmonary Symptoms in Asthmatics With Nasal Congestion|Effect of Intranasal Corticosteroids on Pulmonary Symptoms in Asthmatics With Nasal Congestion, a Randomized Controlled Trial||St. Olavs Hospital|No|Recruiting|January 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01562093||88749|
NCT01562899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEK162X2111|A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors|A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors||Array BioPharma||Completed|August 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|77|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01562899||88687|
NCT01563419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|magnifier|Clinical Usefulness of a Magnifier for Insulin Pen|||Seoul National University Hospital||Completed|October 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|60 Years|N/A|No|||March 2012|March 26, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01563419||88647|
NCT01563432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMX-67_BE_I_2011|Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Febuxostat Between TMX-67 40mg 2 Tablets and Feburic® 80mg 1 Tablet in Healthy Male Volunteers||SK Chemicals Co.,Ltd.|Yes|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2012|March 26, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01563432||88646|
NCT01563744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGD-assisted 2012|EGD-assisted Bowel Preparation for Colonoscopy|EGD-assisted Bowel Preparation for Colonoscopy||Rockford Gastroenterology Associates|No|Completed|August 2009|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|N/A|N/A|No|||April 2012|April 10, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563744||88624|
NCT01564004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/11|Clinical Hypnosis Before External Cephalic Version (ECV)|Clinical Hypnosis Versus Neuro-linguistic Programming Before External Cephalic Version (ECV) - a Prospective Off-centre Randomised Controlled Trial||Johann Wolfgang Goethe University Hospitals|No|Recruiting|February 2011|September 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|716|||Female|18 Years|N/A|No|||March 2012|March 26, 2012|March 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01564004||88604|
NCT01563991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-016|Impact of Perioperative Intravenous Fluid Utilization on Postoperative Outcomes|Impact of Perioperative Intravenous Fluid Utilization on Postoperative Outcomes Following Elective Open Colorectal Surgery||The Cleveland Clinic|No|Active, not recruiting|February 2007|||June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|186|||Both|18 Years|N/A|No|||February 2013|February 12, 2013|March 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01563991||88605|
NCT01564576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9237-HB-CTIL|Neuromuscular Blockade and Surgical Conditions|The Influence of the Magnitude of Neuromuscular Blockade on the Surgical Conditions During Laparoscopic Sleeve Gastrectomy|Sugamadex|Sheba Medical Center|No|Not yet recruiting|April 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|65 Years|No|||March 2012|March 27, 2012|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01564576||88560|
NCT01564589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4-0212|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2012|||||N/A|N/A|N/A||||||||||||||August 25, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01564589||88559|
NCT01594008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|250305-3|The Effects of Antioxidants in Blueberry Powder on Inflammation Induced by a Single High Fat Meal.|Does Blueberry Intake Alleviate Postprandial Lipemia-induced Inflammation?|FL89|USDA, Western Human Nutrition Research Center|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|43|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|March 20, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01594008||86314|
NCT01595165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|schbcanesthesia|Transversus Abdominis Plane Block and Postoperative Pain After Laparoscopic Cholecystectomy|Effect of Subcostal Transversus Abdominis Plane Block on Early Postoperative Pain in Laparoscopic Cholecystectomy: Randomized, Controlled Trial||Soonchunhyang University Hospital|Yes|Recruiting|July 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|65 Years|No|||July 2012|July 5, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595165||86225|
NCT01583478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITGR-2012|Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids|An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids||The Maas Clinic|No|Recruiting|September 2014|December 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 27, 2014|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583478||87113|
NCT01595685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC2012-0201|Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B|A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment|TERESA|Asan Medical Center|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|80 Years|No|||June 2015|June 24, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595685||86185|
NCT01595984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10 - Pr. CHOUKROUN|Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)|Randomized, Multicenter, Open-label, Comparative Study of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI), Associating Myfortic ® and Neoral ® Compared to a CNI-free Treatment, Combining Myfortic ® and Certican ® , in Adult Patients With de Novo Renal Transplant|CIME|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|May 2012|December 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|134|||Both|18 Years|70 Years|No|||July 2015|July 28, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595984||86162|
NCT01595997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLX105-003-001-001|Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris|A Multi-center, Double-blinded, Randomized, Placebo-controlled, Intra-individual Comparison, Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris|2011-00500-15|Delenex Therapeutics AG|Yes|Completed|February 2012|October 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|75 Years|No|||January 2013|January 7, 2013|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595997||86161|
NCT01584596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 11028|Steps Ahead, Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population|Steps Ahead, Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population||Pennington Biomedical Research Center|No|Completed|March 2012|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|35 Years|64 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584596||87030|
NCT01584895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hfhs-pc-RehabVAD|Cardiac Rehabilitation in Patients With Continuous Flow Left Ventricular Assist Devices:Rehab VAD Trial|Cardiac Rehabilitation in Patients With Continuous Flow Left Ventricular Assist Devices:Rehab VAD Trial|RehabVAD|Henry Ford Health System|No|Completed|May 2011|January 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584895||87007|
NCT01585246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Application ID 213|Saw Palmetto: Symptom Management for Men During Radiation Therapy|Saw Palmetto Use During Radiation Therapy for Symptom Management Among Prostate Cancer Patients||Michigan State University|Yes|Active, not recruiting|October 2011|||April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|60|||Male|21 Years|N/A|No|||September 2015|September 18, 2015|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585246||86981|
NCT01562379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003703|Complementary Food Supplements for Reducing Childhood Undernutrition|Evaluation of Complementary Food Supplements For Reducing Childhood Undernutrition: The JiVitA-4 Study||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|September 2012|November 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|5449|||Both|6 Months|8 Months|Accepts Healthy Volunteers|||April 2015|April 23, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01562379||88727|
NCT01562392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2010/457,2011/510|Effects of Berries and Vegetables on Cardiometabolic Risk Markers and Cognitive Functions|Effects of 5 w Daily Intake of Berries and Vegetables on Cardiometabolic Risk Markers and Cognitive Functions||Lund University||Completed|September 2011|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01562392||88726|
NCT01561547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAKC|Trial of Repeated Analgesia With Kangaroo Care|Maternal Analgesia for Procedural Pain in Preterm Neonates: Does It Remain Efficacious?|TRAKC|IWK Health Centre|No|Not yet recruiting|June 2012|||December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|285|||Both|N/A|N/A|No|||March 2012|March 22, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01561547||88791|
NCT01562366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM-2012-01|Research Study to Compare the Addition of Topaz Micro Debridement to the Standard of Care Surgery|A Randomised, Controlled, Double-blind Clinical Investigation on the Efficacy and Safety of Radiofrequency Micro Debridement, Topaz, in Recalcitrant Greater Trochanteric Pain Syndrome (GTPS) vs. Standard of Care||Smith & Nephew, Inc.|No|Recruiting|April 2012|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|66|||Both|40 Years|70 Years|No|||March 2016|March 2, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562366||88728|
NCT01562639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961HC00013|Nexium Capsules RE Maintenance Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis||AstraZeneca||Completed|April 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|647|||Both|N/A|N/A|No|Non-Probability Sample|Patients with repeatedly recurring/relapsing reflux oesophagitis who will be given Nexium        for the first time as a maintenance therapy.        (Patients who had been given Nexium for the initial treatment for reflux oesophagitis can        be enrolled to this investigation).|October 2014|October 30, 2014|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562639||88707|
NCT01563757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 12/28, GC 1479|Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology|An Investigation Into The Potential Roles Of Vasoactive Intestinal Peptide And Substance P In The Pathophysiology Of Plastic Bronchitis And Protein Losing Enteropathy In Children With Palliated Single Ventricle Physiology||Medical College of Wisconsin|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|20|||Both|6 Months|N/A|No|Probability Sample|Children's Hospital of Wisconsin Catheterization Lab|October 2013|October 28, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563757||88623|
NCT01563770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QPHT-35|Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)|A Double Blind, Randomized Placebo-controlled Cross-over Study on the Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen) in Patients With Hypertension and Hyperlipidemia.||Radboud University|Yes|Recruiting|April 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|40 Years|70 Years|No|||January 2012|May 23, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563770||88622|
NCT01564017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA--DPT-P2-001|Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract|Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Dermatophagoides Pteronyssinus.||BIAL Industrial Farmacéutica S.A.|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|150|||Both|18 Years|60 Years|No|||May 2015|May 29, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564017||88603|
NCT01564615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01/2012|AgION Catheter for Preventing Catheter-Related Bloodstream Infections|Reduction of Catheter-Related Bloodstream Infections in Preterm Infants by the Use of Catheters With the AgION Antimicrobial System||University of Florence|Yes|Completed|July 2007|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|86|||Both|N/A|7 Days|No|||March 2012|March 27, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01564615||88557|
NCT01564927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20110510001|Physiological Changes Associated With Deqi During Electroacupuncture to Right LI4 and LI11|Physiological Changes Associated With Deqi During Electroacupuncture to Right LI4 and LI11||The Hong Kong Polytechnic University|Yes|Recruiting|March 2012|December 2012|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01564927||88533|
NCT01564277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 197711|Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies|Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed by Allopurinol in Adult Patients With Malignancy||Roswell Park Cancer Institute|Yes|Terminated|September 2011|||May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|March 2, 2012||No|low accrual|No||https://clinicaltrials.gov/show/NCT01564277||88583|
NCT01565213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LS 0506-1010|Transdiagnostic Group Treatments for Patients With Common Mental Disorders in Primary Health Care|Transdiagnostic Group Treatments for Patients With Common Mental Disorders in Primary Health Care: A Randomized Controlled Trial||Karolinska Institutet|No|Completed|January 2006|September 2010|Actual|September 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|245|||Both|18 Years|65 Years|No|||March 2012|March 26, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01565213||88511|
NCT01594021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/13|Efficacy of Preemptive Volume Loading to Prevent Arterial Hypotension During Induction of General Anesthesia|Efficacy of Preemptive Volume Loading to Prevent Arterial Hypotension During Induction of General Anesthesia|NICOM-MAP|Hopital Foch|No|Terminated|July 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|N/A|No|||October 2014|October 9, 2014|May 5, 2012||No|Difficulty of realization of the study|No||https://clinicaltrials.gov/show/NCT01594021||86313|
NCT01594307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth7|Blood Pressure Monitor Clinical Test (Cuff Range: 13.5 Cm-22cm)|||Andon Health Co., Ltd|No|Completed|February 2012|April 2012|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|85|||Both|23 Years|28 Years|Accepts Healthy Volunteers|Non-Probability Sample|resident of a community|April 2012|May 8, 2012|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594307||86291|
NCT01594320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX778.P101|A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1|A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 1.||Novavax|Yes|Completed|April 2012|August 2013|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|333|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|May 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01594320||86290|
NCT01583491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|900093|Evaluation of Platelet Rich Fibrin on Reduction of Periodontal Problems After Surgical Removal of Mandibular Third Molar|Evaluation of Platelet Rich Fibrin Efficacy on Reduction of Periodontal Problems||Mashhad University of Medical Sciences|Yes|Active, not recruiting|December 2011|May 2012|Anticipated|April 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|December 7, 2011||Yes||No||https://clinicaltrials.gov/show/NCT01583491||87112|
NCT01583777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-BEL-12-103|Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer|A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Belinostat in Patients With Advanced Cancer||Spectrum Pharmaceuticals, Inc|No|Active, not recruiting|September 2013|December 2015|Anticipated|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583777||87091|
NCT01584011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN1|Taste Disorders in Middle Ear Disease and After Middle Ear Surgery|Taste Disorders in Middle Ear Disease and After Middle Ear Surgery||Uppsala University|Yes|Recruiting|January 2010|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|310|Samples Without DNA|Samples of nerve tissue|Both|N/A|N/A|No|Non-Probability Sample|Patients planned for primary middle ear surgery due to chronic otitis media, cholesteatoma        and otosclerosis|April 2012|May 7, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01584011||87073|
NCT01584908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofA - AdVEnTR|Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients|Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients(AdVEnTR)||University of Alberta|No|Completed|August 2012|November 2014|Actual|April 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|68|||Both|18 Years|75 Years|No|Probability Sample|adult kidney tranplant recipients|December 2014|December 31, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584908||87006|
NCT01585259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lees_Anfibatide_Phase2|Anfibatide Phase Ib-IIa Clinical Trial|A Multi-center, Randomized, Double-blind, Multi-dose Group, Parallel Group and Placebo Controlled Phase Ib-IIa Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin for Injection for the Treatment of Patients With Non-ST Segment Elevation Myocardial Infarction (NSTEMI).||Lee's Pharmaceutical Limited|Yes|Active, not recruiting|July 2012|July 2015|Anticipated|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||July 2015|July 15, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585259||86980|
NCT01585272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713DTW04|Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia|A 52-week, Prospective, Multi-center, Open-label Study to Assess the Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Patients With Alzheimer's Dementia in a Controlled Titration Schedule||Novartis|No|Completed|July 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|113|||Both|50 Years|85 Years|No|||October 2015|October 8, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585272||86979|
NCT01585532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCBorstel002|Alere Mycobacterium Tuberculosis Urine Study|Evaluation of Various Methods for the Detection of Mycobacterium Tuberculosis Nucleic Acid||Research Center Borstel|No|Completed|January 2012|December 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|60|Samples Without DNA|Urine Sputum Blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients with suspected or confirmed tuberculosis|November 2015|November 3, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01585532||86960|
NCT01585545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03-068|Radiogenomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers|Radiogenomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers||Samsung Medical Center|Yes|Recruiting|October 2013|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|lung cance tissue|Both|20 Years|N/A|No|Non-Probability Sample|The patients with non-small cell lung cancer|November 2015|November 16, 2015|April 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01585545||86959|
NCT01562405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-318|ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma|Phase 1, Multicenter, Open-label, Dose-escalation Study of ACE-011 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma||Massachusetts General Hospital|Yes|Recruiting|May 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||August 2015|August 23, 2015|January 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562405||88725|
NCT01562106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IR 5197|Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery|A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment||Swedish Medical Center|No|Active, not recruiting|February 2012|December 2016|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|130|||Female|18 Years|N/A|No|||November 2015|November 11, 2015|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562106||88748|
NCT01562912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NERG-01|Efficiency Study Evaluating the Use of the PVAC Catheter Technology for Performing Ablation in Patients With Atrial Fibrillation|The Prospective, Multicenter Canadian Atrial Fibrillation PVAC Cohort Study|CAPCOST|Newmarket Electrophysiology Research Group Inc|No|Recruiting|February 2012|August 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|N/A|No|||January 2016|January 3, 2016|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01562912||88686|
NCT01563172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3158587|Effect of Dentifrice Usage Regime on Efficacy of Fluoride in Situ|A Study to Measure the Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride Using an In Situ Caries Model||GlaxoSmithKline|No|Completed|January 2009|June 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|65|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01563172||88666|
NCT01563133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MKT-2012-nCLE-02|Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas|Clinical Evaluation Of NCLE in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas|CONTACT|Mauna Kea Technologies|No|Recruiting|June 2012|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563133||88669|
NCT01563146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116311|Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007|Assessing the Number of Rotavirus Related Hospitalizations in 11 Hospitals in Belgium - Season 2006-2007||GlaxoSmithKline||Not yet recruiting|February 2016|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|1|||Both|N/A|5 Years|No|Non-Probability Sample|Children aged ≤5 years undergoing a RV detection test across 11 participating hospitals.|January 2016|January 11, 2016|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01563146||88668|
NCT01563159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116312|Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011|Assessing the Rotavirus Positive Test Results in 11 Hospitals in Belgium From 2005 to 2013: the RotaBIS Study (Rotavirus Belgian Impact Study)||GlaxoSmithKline||Active, not recruiting|March 2015|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|1|||Both|N/A|5 Years|No|Non-Probability Sample|Children aged ≤5 years undergoing a RV detection test across 11 participating hospitals.|November 2015|November 19, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01563159||88667|
NCT01564290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protprobiot2010|Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children|Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children: A Randomized Double-blind Trial||Centro Pediatrico Albina de Patino|No|Completed|February 2011|February 2012|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|10 Months|36 Months|No|||March 2012|March 26, 2012|October 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01564290||88582|
NCT01564602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH2011-03-011IA|To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy|Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy||Taipei Veterans General Hospital, Taiwan|No|Recruiting|January 2011|December 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|200|||Female|N/A|N/A|No|||March 2012|March 28, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01564602||88558|
NCT01565226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D007171|Capnography in Neonates Ventilated With High Frequency Ventilation: Prospective, Observational Multi-Center Study|Capnography in Neonates Ventilated With High Frequency Ventilation: Prospective, Observational Multi-Center Study||Oridion|No|Completed|August 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|N/A|N/A|No|Non-Probability Sample|Neonates|February 2015|February 25, 2015|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01565226||88510|
NCT01564940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ib2C-11-015|Human Factors Usability Study of Ib2C Conception System|Human Factors Usability Study of Abbreviated Functional Use of the Intimate Bridge 2 Conception, Inc. Conception System||Rinovum Women's Health, Inc.|Yes|Completed|September 2011|September 2011|Actual|September 2011|Actual|N/A|Observational|N/A||1|Actual|15|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Females between the ages of 20 and 45.|March 2012|March 27, 2012|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01564940||88532|
NCT01565785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|259192-1|Evaluating a New Way to Prepare Parents of Hospitalized Children for Discharge and Management of Child at Home|Self-Management Guided Discharge Teaching for Parents of Hospitalized Children: A Pilot Study||Medical College of Wisconsin|No|Completed|February 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565785||88467|
NCT01565798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOD W81XWH-07-C-0053|Efficacy Of Copper To Reduce Acquisition Of Microbes and Healthcare-acquired Infections|Copper Antimicrobial Research Program: Environmental and Patient Sampling For Indicator Organisms To Determine The Efficacy Of Copper To Reduce Acquisition Of Microbes From The Patient Care Environment||Medical University of South Carolina|Yes|Completed|July 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|614|||Both|18 Years|N/A|No|||December 2011|March 23, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565798||88466|
NCT01594905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-273|Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection|A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection||Yonsei University|Yes|Active, not recruiting|August 2012|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|20 Years|N/A|No|||January 2014|January 30, 2014|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594905||86245|
NCT01594918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol No. 11951|Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer|A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy||University of California, San Francisco|Yes|Active, not recruiting|June 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Male|18 Years|N/A|No|||March 2016|March 22, 2016|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594918||86244|
NCT01583790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-001-12|Factors Influencing the Positive Outcome of Bariatric Surgery for Morbidly Obese Patients|A Prospective Trial for Laparoscopic Adjustable Gastric Banding in Morbidly Obese Patients: Report on Weight Loss, Metabolic Changes and Quality of Life||Assuta Hospital Systems|No|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|2000|||Both|14 Years|65 Years|No|Non-Probability Sample|The study includes about 1500 patients, 70% female and 30% male. All patients that had        bariatric surgery and were in the follow-up group for longer than one month will take part        in the study. A special emphasis will be given to special population groups such as        adolescents, old patients, patients undergoing revision surgery, and patients that        required a additional type of surgery in conjunction with the bariatric surgery (e.g.,        gallbladder removal).|March 2012|April 13, 2015|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583790||87090|
NCT01584024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N010508-S3|Resin Infiltration to Arrest Early Tooth Decay|Radiographic Progression of Early Caries Lesions After Resin Infiltration||University of Michigan|No|Active, not recruiting|March 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|24 Years|No|||February 2016|February 13, 2016|April 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584024||87072|
NCT01584271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011058|Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)|Phase II 3 Arm Double Blinded Clinical Study Evaluating the Pain Killing and Healing Time of Botanical Ear Drops, Ear Comfort(TM), in Severe External Ear Infection (AOE) Patients, Compared to Dex-Otic(R) and Otidin(R)||Assuta Hospital Systems|Yes|Recruiting|July 2011|December 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|70 Years|No|||April 2012|July 7, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01584271||87054|
NCT01584310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC206-2011KCTIL|Validation of the STAMP Screening Tool|Validation of the STAMP Screening Tool For Pediatric Nutritional Risk To Be Used in the Ambulatory Setting.|STAMP2|Rabin Medical Center|No|Not yet recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|250|||Both|1 Year|6 Years|No|||April 2012|April 22, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01584310||87051|
NCT01584323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0231-11-RMB|Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes|Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes||Rambam Health Care Campus|Yes|Recruiting|April 2012|May 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|17 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 22, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01584323||87050|
NCT01584635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005252|The Role That Peroral Endoscopic Myotomy (POEM) Could Play in the Treatment of Achalasia|Peroral Endoscopic Myotomy (POEM) for Treatment of Achalasia|POEM|Mayo Clinic|No|Enrolling by invitation|January 2012|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||August 2015|August 17, 2015|January 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01584635||87027|
NCT01584921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-068|Renal Effects of Erythropoietin in Humans|Renal Effects of Erythropoietin in Humans|EPO 2012|University of Copenhagen|Yes|Completed|March 2012|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|16|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||November 2013|November 4, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584921||87005|
NCT01562678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P000280|Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI|Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI||Beth Israel Deaconess Medical Center|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|No|||January 2015|January 12, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562678||88704|
NCT01562652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Apos_Sing_01|AposTherapy for Singaporean Patients With Knee Osteoarthritis (OA)|||Apos Medical and Sports Technology Ltd.||Completed||||||N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|50 Years|70 Years|No|||March 2012|March 23, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562652||88706|
NCT01562925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenPro-WINE|Effect of Red Wine, White Wine and Beer on Contrast-Medium Induced Acute Kidney Injury|Randomized Controlled Study for Evaluation of the Impact of Red Wine, White Wine and Beer Intake on Contrast-Medium Induced Acute Kidney Injury|RenPro-II-WINE|University of Cologne|Yes|Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|260|||Both|18 Years|N/A|No|||July 2013|July 4, 2013|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562925||88685|
NCT01563471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7LIVER-1465|Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers|Single-centre, Randomised, Placebo-controlled, Double-blind, Dose Escalation Trial Investigating Pharmacokinetics, Pharmacodynamics and Tolerability of Three Different Single Intravenous Doses of Activated Recombinant Factor VIIa (rFVIIa/NovoSeven®) in Healthy Caucasian and Japanese Subjects||Novo Nordisk A/S|No|Completed|October 2001|July 2002|Actual|July 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|39|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2012|June 26, 2012|March 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563471||88643|
NCT01563783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0015|Post Market TRUST Study|The Trust (Treatment Results of Uterine Sparing Technologies) Study|TRUST|Halt Medical, Inc|Yes|Recruiting|December 2012|December 2020|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Female|18 Years|N/A|No|||February 2016|February 16, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563783||88621|
NCT01563445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7ICH-2073|Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage|Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven®) for Preventing Early Hematoma Growth in Acute Intracerebral Hemorrhage (ICH)||Novo Nordisk A/S|No|Completed|November 2001|March 2003|Actual|March 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2012|March 23, 2012|March 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563445||88645|
NCT01563458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7LIVER-1256|Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Dose Exploratory Trial Evaluating the Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Reduction of Bleeding in Subjects Undergoing Orthotopic Liver Transplantation||Novo Nordisk A/S|No|Completed|August 2001|September 2003|Actual|September 2003|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|208|||Both|18 Years|N/A|No|||June 2014|June 23, 2014|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01563458||88644|
NCT01564953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110280|Vitamin D, Magnesium and Calcium in Chronic Obstructive Pulmonary Disease (COPD)|Vitamin D, Magnesium And Calcium In Chronic Obstructive Pulmonary Disease (COPD)||University of Aarhus|No|Completed|February 2012|January 2013|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|143|Samples Without DNA|Blood samples:      p-creatinine p-potassium p-sodium p-albumine p-phosphate p-magnesium p-calcium-ion      p-parathyrine p-25-hydroxy-vitamin D2 + D3|Both|40 Years|N/A|No|Non-Probability Sample|Outpatients from the Department Of Resoiratory Diseases, Aarhus University Hospital|January 2013|January 16, 2013|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01564953||88531|
NCT01565239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Landspitali-1|Fiix-prothrombin Time for Monitoring Warfarin|Clinical Outcome During Warfarin Anticoagulation Monitored With "Fiix-INR" Compared to Standard Monitoring With INR.A Prospective Randomized Double-blinded Trial.|Fiix|Landspitali University Hospital|Yes|Completed|March 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1156|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01565239||88509|
NCT01565486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC11DISI0534|Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated With the Harmonic ACE® Scalpel and LigaSure Precise™ Instrument During Conventional Thyroidectomy: A Single-blind Prospective Randomized Controlled Trial|UCBEST|Seoul St. Mary's Hospital|Yes|Active, not recruiting|August 2011|August 2017|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|304|||Both|20 Years|80 Years|No|||December 2012|December 4, 2012|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01565486||88490|
NCT01565811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|girba2291|Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis|Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis|LN|Gachon University Gil Medical Center|Yes|Completed|August 2010|December 2013|Actual|March 2012|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Biopsy confirmed colorectal cancer with liver metastasis|August 2015|August 28, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01565811||88465|
NCT01587534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-570|Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)|Phase 2 Study of Randomized Controlled Trial of Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer||National Cancer Center, Korea|No|Completed|October 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01587534||86808|
NCT01584037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DR-501-401|Adenovirus Vaccine Pregnancy Registry|Adenovirus Vaccine Pregnancy Registry||Teva Pharmaceutical Industries|Yes|Withdrawn|December 2011|April 2014|Actual|April 2014|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|0|||Female|17 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of:          1. Women previously or currently enrolled in the U.S. Military who received Adenovirus             Type 4 and Type 7 Vaccine, Live, Oral while pregnant or who conceived within 6 weeks             of vaccine administration, and          2. Infants born to females with confirmed exposure to Adenovirus Type 4 and Type 7             Vaccine, Live, Oral, followed through one year post delivery.|April 2014|April 17, 2014|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01584037|12 Months|87071|
NCT01584284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL-ONC1-005|Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer|Phase I Trial Of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiotherapy in Patients With Locoregionally Advanced Head and Neck Carcinoma||Genelux Corporation|Yes|Completed|April 2012|July 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|April 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01584284||87053|
NCT01584297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETHI 2011-03|Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary|Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.|GreKo|Grupo Español de Tumores Huérfanos e Infrecuentes|No|Terminated|October 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||January 2015|January 19, 2015|April 22, 2012||No|Insufficient recruitment rate|No||https://clinicaltrials.gov/show/NCT01584297||87052|
NCT01584609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 4853|A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke|A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke||Penumbra Inc.|Yes|Active, not recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|85 Years|No|||March 2016|March 14, 2016|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584609||87029|
NCT01584622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUM1040-001|Clinical Evaluation of the CADenceTM System in Detection of Coronary Artery Diseases|Clinical Evaluation of the CADence System in Detection of Coronary Artery Diseases|CADENCE|AUM Cardiovascular, Inc.|No|Withdrawn|July 2012|February 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01584622||87028|
NCT01584648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115306|A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma|A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma||GlaxoSmithKline|Yes|Active, not recruiting|May 2012|January 2018|Anticipated|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|423|||Both|18 Years|N/A|No|||October 2014|November 6, 2014|April 23, 2012|No|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01584648||87026|
NCT01584934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/197|Sodium Oxybate in Patients With Chronic Fatigue Syndrome.|The Effect of Sodium Oxybate in Patients With Chronic Fatigue Syndrome.||University Hospital, Ghent|No|Recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|65|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584934||87004|
NCT01584947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-006196-19|Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain|Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Oral Mucosal Pain in Burning Mouth Syndrome, Sjögrens Syndrome and Lichen Planus.||Hvidovre University Hospital|Yes|Terminated|April 2012|August 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||February 2016|February 17, 2016|April 23, 2012||No|Because of a very slow patient recruitment.|No||https://clinicaltrials.gov/show/NCT01584947||87003|
NCT01585298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE17|STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)|A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis|START|Novartis|Yes|Recruiting|June 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7000|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585298||86977|
NCT01585857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8606|ADIPOA - Clinical Study|A Phase I, Prospective, Bi-centric,Single -Arm, Open-label, Dose-escalating Clinical Trial to Evaluate the Safety of a Single Injection of Autologous Adipose Derived Mesenchymal Stromal Cells in the Treatment of Severe Osteoarthritis of the Knee Joint||University Hospital, Montpellier|Yes|Completed|April 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|50 Years|75 Years|No|||December 2014|December 3, 2014|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01585857||86936|
NCT01563211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72393/271478/14/611|Predictive Model of Therapy Outcomes in Breast Cancer Patients|Predictive Modelling of Short Term Outcomes Following Systemic Neo-adjuvant and Adjuvant Therapy in Breast Cancer Patients||Imperial College London|No|Completed|February 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|70|Samples With DNA|plasma/serum urine buffy coat - for purposes of DNA extraction|Female|18 Years|N/A|No|Non-Probability Sample|Patients who have newly diagnosed primary breast cancer who will be receiving chemotherapy        (FEC and FEC-D regimes only) or endocrine treatment (anastrozole, letrozole or tamoxifen        only).        All new patients with Breast Cancer are discussed at the multidisciplinary team meeting        (MDT) where they will be identified for the study. Patients will be identified by the        oncologist and the multidisciplinary team (i.e the existing clinical care team).|March 2012|March 25, 2015|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01563211||88663|
NCT01562665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-OAE-XXX-2011/1|Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf|Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA|Lung-EPICLIN/G|AstraZeneca|No|Completed|August 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|25|||Both|N/A|N/A|No|Probability Sample|Oncology Institutes|February 2016|February 8, 2016|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01562665||88705|
NCT01562938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ID-MEDI-557-1092|MEDI-557 Adult Dosing|A Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of MEDI-557, a Humanized Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus (RSV), Administered to Healthy Adults|CD-1092|MedImmune LLC|No|Completed|March 2012|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 4, 2013|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01562938||88684|
NCT01563185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HZ-CA-402|Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis|A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis||Horizon Pharma Ireland, Ltd., Dublin Ireland|No|Completed|April 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|10 Years|16 Years|No|||November 2015|November 19, 2015|March 20, 2012|Yes|Yes||No|July 17, 2015|https://clinicaltrials.gov/show/NCT01563185||88665|
NCT01563198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43AT0062696|Reduction of Claustrophobia and Patient Motion After Training of MRI Personnel in Comfort TalkTM|Amelioration of Claustrophobia and Disruptive Patient Motion in MR Imaging||Hypnalgesics, LLC|No|Active, not recruiting|August 2011|August 2016|Anticipated|August 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|3|||Both|N/A|N/A|No|||August 2015|August 18, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01563198||88664|
NCT01564303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nazh7343ctil|Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)|Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study||The Nazareth Hospital, Israel|Yes|Not yet recruiting|May 2012|February 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|80|||Both|18 Years|85 Years|No|||March 2012|March 24, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564303||88581|
NCT01564030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01|Gastric Ultrasound in Pregnant Women at Term|Qualitative Ultrasound Assessment of the Gastric Content of Pregnant Women at Term||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|32|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564030||88602|
NCT01564043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VABHS2328|Internet Walking Program and Pedometer in Chronic Obstructive Pulmonary Disease|||VA Boston Healthcare System|No|Completed|February 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|40 Years|90 Years|No|||March 2012|March 26, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564043||88601|
NCT01564966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120209|Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation|Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation||Istanbul University|Yes|Completed|April 2008|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|70 Years|No|Probability Sample|Living kidney donors in Istanbul Faculty of Medicine|March 2012|March 28, 2012|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01564966||88530|
NCT01565525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD50944|Anticipatory Guidance to Prevent Childhood Obesity|Can Changing How Moms Eat Prevent Obesity in Toddlers?|MOMS|Nationwide Children's Hospital|No|Completed|June 2005|July 2007|Actual|July 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|306|||Both|N/A|2 Months|Accepts Healthy Volunteers|||March 2012|March 27, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01565525||88487|
NCT01565499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2011-02|Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer|Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer||Spanish Breast Cancer Research Group|No|Active, not recruiting|June 2013|August 2019|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Female|18 Years|N/A|No|||November 2012|June 7, 2013|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01565499||88489|
NCT01565512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI5060|Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort|Randomized Trial to Determine the Effect of Dorsal Penile Block on Post-Robotic Prostatectomy Foley Discomfort||Columbia University|Yes|Withdrawn|November 2011|July 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Male|40 Years|80 Years|No|||March 2015|March 3, 2015|March 26, 2012|Yes|Yes|Lack of funding, PI left the institution, poor enrollment|No||https://clinicaltrials.gov/show/NCT01565512||88488|
NCT01561677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8670|Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP)|Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP)||University Hospital, Montpellier|No|Recruiting|September 2011|||March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|5||Anticipated|300|||Both|18 Years|85 Years|No|||March 2012|March 21, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01561677||88781|
NCT01583504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/YH/0376|High Volume Saline Injections for Achilles Tendinopathy|A Double Blind, Randomised Controlled Trial of High Volume Saline Injections for Chronic Midportion Achilles Tendinopathy||Leeds Comunity Healthcare NHS Trust|No|Recruiting|March 2012|March 2014|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583504||87111|
NCT01583803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0108|Sex Differences in Oral Bacteria|Investigation of the Sex Differences in Oral Microbiota and Their Effect on Circulating Nitrite Levels||Queen Mary University of London|No|Active, not recruiting|June 2012|June 2017|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|24|Samples Without DNA|Urine, saliva and plasma|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|November 2015|November 3, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583803||87089|
NCT01583530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1006-C1105|Study of Belimumab Administered Subcutaneously to Healthy Subjects|A Randomized, Parallel-Group, Open-Label Study to Evaluate the Absolute Bioavailability, Pharmacokinetics, Tolerability and Safety of a High Concentration Formulation of Belimumab (HGS1006), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Healthy Subjects||Human Genome Sciences Inc.|No|Completed|February 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|118|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 1, 2013|April 20, 2012|No|Yes||No|May 22, 2012|https://clinicaltrials.gov/show/NCT01583530||87109|
NCT01583816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP848-AK-1101|Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions|Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions||Spirig Pharma Ltd.|No|Completed|May 2012|June 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|218|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01583816||87088|
NCT01584050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-03426|Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate|Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate||University of British Columbia|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|150|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01584050||87070|
NCT01585311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA5384|Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)|Impact of Prolonged Tachycardia on Cardiovascular Morbidity and Outcome After Subarachnoid Hemorrhage (SAH)||Columbia University|No|Enrolling by invitation|April 2012|April 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Columbia Neurocritical Care Unit with a diagnosis of subarachnoid        hemorrhage established by computed tomography (CT scan) or xanthochromia of the        cerebrospinal fluid if the CT is negative.|April 2012|April 24, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585311||86976|
NCT01585584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP #39897|Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment|Triple-Therapy With PegInterferon α-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon α + Ribavirin|LeeG3|University of Calgary|Yes|Completed|May 2012|July 2015|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|65 Years|No|||August 2015|August 22, 2015|April 18, 2012|Yes|Yes||No|August 22, 2015|https://clinicaltrials.gov/show/NCT01585584||86956|Small sample size (n=11)
NCT01586104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lung IMRT|Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases|Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|February 2011|September 2015||September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|1 Year|29 Years|No|||September 2013|September 23, 2013|April 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01586104||86918|
NCT01563484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|320982198703092517|Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media|Comparison of Liver and Renal Function After TACE for PHC With Iso-osmolar and Low-osmolar Contrast Media||Southeast University, China|Yes|Active, not recruiting|March 2012|September 2012|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|75 Years|No|Probability Sample|This test chooses the patients with unresectable PHC. Then divide them into two groups.In        one group,patients underwent a transarterial infusion of ioversol injection(a kind of        low-osmolar contrast media).In the other group,patients underwent a transarterial infusion        of iodixanol injection(a kind of iso-osmolar contrast media).|March 2012|March 30, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01563484||88642|
NCT01562951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A12-771|Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants|cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants|ADACAL|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa|No|Terminated|October 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|75 Years|No|||November 2013|March 15, 2015|March 13, 2012||No|Not enough patient population according to selection criteria to complete the study|No||https://clinicaltrials.gov/show/NCT01562951||88683|
NCT01563796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONC04|Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer|A Multi-Center Study to Evaluate the Safety and Efficacy of a Urine DEK ELISA in Diagnosis of Subjects With Bladder Cancer||Medical Diagnostic Laboratories, LLC|No|Active, not recruiting|March 2012|December 2016|Anticipated|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1000|None Retained|urine|Both|25 Years|N/A|No|Non-Probability Sample|patients visiting urologist (primary care, referral, community, university or hospital).|September 2015|September 22, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563796||88620|
NCT01564069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P000874|Intrathecal Therapy for Chronic Non-Cancer Pain: An Analysis of Its Efficacy|Intrathecal Therapy for Chronic Non-Cancer Pain: An Analysis of Its Efficacy||Brigham and Women's Hospital|No|Recruiting|July 2009|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|Males or females greater than 18 years of age History of chronic pain greater than 6        months Patient in the BWH Pain Center for greater than 6 months|March 2013|March 5, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564069||88599|
NCT01564316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-0505-148-016|Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients|Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients||Seoul National University Hospital|Yes|Recruiting|May 2005|May 2013|Anticipated|May 2008|Actual|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|500|Samples With DNA|serum:10ml      WHO: neurodegeneration patients and control group include dementia patients visited the part      of neurology.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|neurodegeneration patients group include dementia patients visited the part of neurology.        (almost after diagnosis)|March 2012|March 23, 2012|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01564316||88580|
NCT01564329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sim-endo-201201|The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar|The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar||Simcere Pharmaceutical Co., Ltd|Yes|Recruiting|March 2012|July 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|70 Years|No|||March 2012|March 23, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01564329||88579|
NCT01564628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC003-SH|Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm|Data Acquisition for Optimization of Coronary Artery Disease Algorithm||Coloplast A/S|No|Enrolling by invitation|March 2012|December 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred to examination for Coronary Artery Disease|March 2012|March 26, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01564628||88556|
NCT01564641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001|Study With the ConforMIS iDuo(R) G2|A Prospective, Multicenter Study of the ConforMIS iDuo(R) G2 Bicompartmental Knee Repair System||ConforMIS, Inc.|No|Active, not recruiting|May 2012|March 2025|Anticipated|August 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting this specific form of osteoarthritis at participating sites with IRB        approval.|May 2015|May 29, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01564641||88555|
NCT01565252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6445|Assessment of the Effect of n-3(Omega 3) Fortified Egg in Healthy Subjects|Assessment of the Effect of n-3(Omega 3) Fortified Egg Compared to Omega-6 Israeli Regular Egg on Metabolic, Inflammation and Other Physiologic Parameters Prospective, Crossover, Compared Study in Healthy Subjects|PisNShMiGSL-01|Rabin Medical Center|Yes|Not yet recruiting|April 2014|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|November 21, 2013|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01565252||88508|
NCT01595698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESQ-001|Schizophrenia and Physical Exercise|Schizophrenia and Physical Exercise: Effect of 20 Weeks of Training in Symptoms and Concentration in Serum IGF-1 and BDNF||Federal University of São Paulo|Yes|Completed|February 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|11|||Male|18 Years|50 Years|No|||June 2012|June 8, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01595698||86184|
NCT01565824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODIAB-web|Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web)|Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web)|MODIAB-web|Göteborg University|Yes|Recruiting|November 2011|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Female|18 Years|N/A|No|||March 2016|March 3, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01565824||88464|
NCT01596283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-056|Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection|A Prospective Randomized Controlled Clinical Trial of Standard Compared to Goal-directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|270|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01596283||86139|
NCT01583231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|302192-1|Efficacy of the Brushless Scrub|Efficacy of the Brushless Scrub||Winthrop University Hospital|No|Completed|May 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|19 Years|62 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01583231||87132|
NCT01583829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8926|Study of Computer Attention Training Programs in Schools for Children With Attention Deficit/Hyperactivity Disorder|Randomized Control Trial of Two Computer-Based Attention Training Programs in Schools for Children With Attention Deficit/Hyperactivity Disorder (ADHD)|CATS|Tufts Medical Center|Yes|Active, not recruiting|May 2009|November 2013|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|104|||Both|6 Years|12 Years|Accepts Healthy Volunteers|||June 2013|June 13, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01583829||87087|
NCT01584063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOMS-2002|Healthy Mothers on the Move||Healthy MOMs|University of Michigan|No|Completed|February 2004|November 2006|Actual|November 2006|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|276|||Female|18 Years|N/A||||April 2012|April 23, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01584063||87069|
NCT01584336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLASS-03|Laparoscopy-assisted Total Gastrectomy for Clinical Stage I Gastric Cancer (KLASS-03)|Prospective Multi-center Study of Laparoscopy-assisted Total Gastrectomy for Clinical Stage I Gastric Cancer (KLASS-03)|KLASS-03|Soonchunhyang University Hospital|Yes|Recruiting|October 2012|March 2014|Anticipated|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|168|||Both|20 Years|80 Years|No|||February 2014|February 5, 2014|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01584336||87049|
NCT01585597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056889|Reperfusion With Cooling in Cerebral Acute Ischemia|Phase 1 Study of Mild Induced Hypothermia After Endovascular Revascularization in Acute Ischemic Stroke of the Anterior Circulation|ReCCLAIM|Emory University|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|85 Years|No|||July 2014|July 7, 2014|April 22, 2012|Yes|Yes||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01585597||86955|
NCT01594749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-031|Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy||Merck Sharp & Dohme Corp.|No|Completed|September 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1015|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|April 24, 2012|Yes|Yes||No|August 26, 2015|https://clinicaltrials.gov/show/NCT01594749||86257|
NCT01586117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-GI-022|A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity|A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity||Chinese Academy of Medical Sciences|Yes|Recruiting|February 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|75 Years|No|||August 2013|August 14, 2013|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01586117||86917|
NCT01586351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP02|Rotator Cuff Reconstruction With Xenologous Dermis-patch Augmentation and ACP® - Injection|Arthroscopic Rotator Cuff Reconstruction With Xenologous Dermis-patch Augmentation and ACP® - Injection in Patients Over 60 Years (ACP = Autologous Conditioned Plasma)||Schulthess Klinik|No|Active, not recruiting|October 2012|January 2016|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|60 Years|N/A|No|Probability Sample|The potential patients will be recruited from the operation list due to the inclusion and        exclusion criteria.|December 2015|December 18, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586351||86899|
NCT01563497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291007|A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State|A Phase 1, Open-Label, Single Dose, Bioavailability Study In Healthy Volunteers Comparing PF-05089771 TS Tablet To PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And The Fed State||Pfizer|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 23, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01563497||88641|
NCT01564056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERICO11/PACS10|Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment|Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial|ASTER 70s|UNICANCER|No|Recruiting|March 2012|March 2026|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Female|70 Years|N/A|No|||August 2015|August 31, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01564056||88600|
NCT01563809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0711-E-39-EB|Basal Androgens and LH Needing for Ovarian Stimulation for in Vitro Fertilization|The Relationship Between Basal Androgen Levels and the Needing of LH for Controlled Ovarian Stimulation for in Vitro Fertilization||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|December 2008|December 2010|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|400|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01563809||88619|
NCT01564082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18855|Comparison of Early Endotracheal Tube Insertion With GlideScope Use|Comparison of Early Endotracheal Tube Insertion With GlideScope Use||Lawson Health Research Institute|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01564082||88598|
NCT01564342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M1272|Tap Water Versus Normal Saline for Wound Irrigation|A Prospective Double-Blind Randomized Clinical Trial Comparing Tap Water Irrigation With Normal Saline for Wound Management||Stanford University|No|Completed|June 1994|June 1996|Actual|June 1996|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|660|||Both|12 Months|N/A||||March 2012|March 23, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01564342||88578|
NCT01564654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCP 11-002|A Retrospective Study of the iTotal CR Knee Replacement System|A Retrospective, Multi-Center Study to Evaluate the ConforMIS iTotal® CR (Cruciate Retaining) Total Knee Replacement System||ConforMIS, Inc.|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|106|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have received an iTotal Knee replacement|April 2013|April 17, 2013|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01564654||88554|
NCT01564667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16311|Attention Bias Modification Treatment for Warzone-Related Posttraumatic Stress Disorder (PTSD)|Attention Bias Modification Treatment for Warzone-Related PTSD: A Randomized Clinical Trial Magnetoencephalography Study||Creighton University|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01564667||88553|
NCT01595711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/37|Prediction of Chronic Pain by the Pain Monitor|Prediction of the Occurrence of Chronic Pain After Thoracotomy by Measuring Preoperative Skin Conductance (Pain Monitor Device)|D3C|Hopital Foch|No|Recruiting|April 2012|September 2016|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Blood samples|Both|18 Years|75 Years|No|Non-Probability Sample|Patients scheduled to undergo a lung surgical procedure (thoracotomized patients)|March 2015|March 25, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01595711||86183|
NCT01595724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16108|Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life|Study to Characterize Patients Treated With Visanne for Their Endometriosis Under Real-life Practice Conditions and Evaluate Their Quality of Life at Baseline and After 6 Months of Treatment With Visanne.|DIVA|Bayer|No|Completed|May 2012|May 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3006|||Female|18 Years|N/A|No|Probability Sample|Gynecological patients|July 2015|July 9, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595724||86182|
NCT01596010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI-1915|Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women|Single Dose, Double-blind, Two-way Cross-over Bioequivalence Trial With 2 Different Oral Formulations of Estradiol and Norethisterone||Novo Nordisk A/S|No|Completed|October 2007|November 2007|Actual|November 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Female|50 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 17, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596010||86160|
NCT01592240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1481015|Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin|A Phase 2B Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose-Ranging Study To Assess The Efficacy, Safety And Tolerability Of PF-04950615 (RN316) Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin||Pfizer|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|356|||Both|18 Years|N/A|No|||October 2014|October 14, 2014|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592240||86449|
NCT01592253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAPA CONVERT TRIAL|Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient|Investigation of the Safety and Immunologic Biomarker After Conversion From Calcineurin Inhibitor to Rapamune in Stable Renal Transplant Recipient||Seoul St. Mary's Hospital|No|Recruiting|May 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|N/A|N/A|No|||June 2012|June 22, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592253||86448|
NCT01583543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-470|Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma|Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy||Massachusetts General Hospital|Yes|Completed|May 2012|November 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583543||87108|
NCT01584362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXFEND-02, IND 113,628|Single Ascending Dose Safety Study of Oxfendazole|Phase I Study of Oxfendazole (Toward the Treatment of Neurocysticercosis)|OXFEND-02|Johns Hopkins Bloomberg School of Public Health|No|Not yet recruiting|December 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|70|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|April 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01584362||87048|
NCT01584661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABB-1-2012|The Continuity of Nutritional Care Among Elderly Patients|The Continuity of Nutritional Care From the Hospital to the Community and Its Impact on Health and Functional Indicators Among Elderly Patients||Bait Balev Hospital|Yes|Not yet recruiting|July 2012|||August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|65 Years|95 Years|No|Non-Probability Sample|Study population Patients over the age of 65 who are members of Maccabi Health Care        Services will be recruited for the current study. The Inclusion criteria comprise patients        who were treated nutritionally with food enrichment supplements during their        hospitalization in "Bait Balev" and were discharged to their homes with dietary        recommendations. Participants who are willing to participate will sign an informed consent        form. For patients with cognitive impairment or dementia, as reported in their medical        records, their formal primary caregiver or proxy will sign the informed consent form.|April 2012|April 24, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584661||87025|
NCT01584674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-K1005-P001|A Clinical Trial Evaluating the Safety and Efficacy of the KLOX Biophotonic System in Moderate to Severe Acne|A Prospective Clinical Trial Evaluating the Efficacy of the KLOX Biophotonic System (KLOX KLGA0105-01 and KLOX THERA LAMP) On Moderate to Severe Acne||KLOX Technologies Inc.|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|98|||Both|16 Years|30 Years|No|||May 2013|May 15, 2013|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01584674||87024|
NCT01584960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-D-2008-015|The Effect of Endurance Training in Patients With Prostate Cancer|The Effect of Endurance Training on PSA Doubling Time, Body Composition, Insulin Sensitivity and Inflammation in Patients With Prostate Cancer||Rigshospitalet, Denmark|Yes|Completed|April 2008|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Male|18 Years|N/A|No|||November 2013|November 29, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584960||87002|
NCT01584973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201108032RC|Changes in Inter-joint Coordination and Muscle Activation After Cruciate Ligament Injury of the Knee Joint|Changes in Inter-joint Coordination and Muscle Activation After Cruciate Ligament Injury of the Knee Joint||National Taiwan University Hospital|Yes|Recruiting|April 2012|||||N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|unilateral cruciate ligament injury or unilateral cruciate ligament reconstructed after 3        month|April 2012|April 24, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584973||87001|
NCT01594762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPX-306|Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers|A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers|OneStep-2|Dipexium Pharmaceuticals, Inc.|Yes|Recruiting|June 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594762||86256|
NCT01594775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR: 2009-0063|Oxytocin, Couple Interaction and Wound Healing|||University of Zurich||Completed|October 2011|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|160|||Both|21 Years|45 Years|No|||February 2014|February 24, 2014|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594775||86255|
NCT01595048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANHL1131|Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia|Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients||Children's Oncology Group|Yes|Active, not recruiting|June 2012|December 2020|Anticipated|December 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|640|||Both|6 Months|17 Years|No|||October 2015|October 20, 2015|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595048||86234|
NCT01594801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-PP-003|Testing the Effect of the InsuPad Device in Daily Life Conditions|Testing the Effect of the InsuPad Device in Daily Life Conditions - The InsuPad in Daily Life Study||Insuline Medical Ltd.|No|Completed|May 2012|March 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|75 Years|No|||March 2013|March 12, 2013|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01594801||86253|
NCT01595282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-p-000259|Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage|Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage: a Randomized Clinical Trial.||Planned Parenthood League of Massachusetts|No|Completed|June 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 30, 2014|May 19, 2011||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT01595282||86216|
NCT01563237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INN004|Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant|Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) to Relieve Glaucoma Symptoms||InnFocus Inc.|No|Recruiting|June 2011|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|85 Years|No|||June 2014|May 4, 2015|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01563237||88661|
NCT01563822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|132012|Does Flushing the Uterine Cavity With Follicular Fluid After Ovum Pick-up Improve Implantation Rates in ICSI Cycles?|Phase I Study of the Effect of Flushing the Uterine Cavity With Follicular Fluid After Ovum Pick-up on Implantation Rates in ICSI Cycles||Kasr El Aini Hospital|Yes|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Female|20 Years|38 Years|No|||October 2012|October 6, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01563822||88618|
NCT01564095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOP-Study|TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion|TOP-Study (Tacrolimus Organ Perfusion): A Prospective Multicenter Trial for Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion|TOP|Ludwig-Maximilians - University of Munich|Yes|Recruiting|October 2011|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||March 2014|March 16, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01564095||88597|
NCT01595178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1065276 R10701 SAEM|Combination SBIRT for Emergency Department Patients Who Drink and Smoke|Development of a Combined Screening and Intervention Program for Emergency Department Patients Who Both Drink and Smoke||Yale University|No|Not yet recruiting|June 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 7, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595178||86224|
NCT01594944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC110046CTIL|Fetal Orbital Measurements by 3D Ultrasound|||Meir Medical Center|No|Not yet recruiting|May 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Female|18 Years|45 Years|No|Probability Sample|pregnant women 13-37w|May 2012|May 8, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594944||86242|
NCT01564680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#201021|Lornoxicam vs. Paracetamol After Lower Abdominal Surgery|Intravenous Lornoxicam is More Effective Than Paracetamol as a Supplemental Analgesic After Lower Abdominal Surgery; A Randomized Controlled Trial||Dammam University|Yes|Completed|March 2009|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|69 Years|No|||March 2012|March 27, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01564680||88552|
NCT01564979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTS-001-BTX|Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm|Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm||Khon Kaen University|Yes|Not yet recruiting|April 2012|December 2012|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|20 Years|70 Years|No|||March 2012|March 27, 2012|March 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01564979||88529|
NCT01595412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTR2743|An International Double Cohort Study to Compare Laparoscopic Ventral Rectopexy With Laparoscopic Resection Rectopexy|Laparoscopic Rectal Prolapse Surgery Study. An International, Double Cohort Study to Determine the Optimal Treatment for Rectal Prolapse.|LaProS|Cleveland Clinic Florida|Yes|Recruiting|April 2010|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2014|July 21, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595412||86206|
NCT01596036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS 6649|Readiness for Behavior Change After a Heart Attack|Stages of Change Through the Cardiac Rehabilitation Experience After a Recent Hospitalization|ENROLL|Henry Ford Health System|No|Completed|February 2011|November 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|150|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596036||86158|
NCT01596023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0033|Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients|Evaluation of Effect of Breathe Ventilation System on Work of Breathing in COPD Patients||Breathe Technologies, Inc.|No|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Actual|14|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596023||86159|
NCT01596296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCB_PG_parous women|Foley Catheter Versus Dinoprostone Vaginal Insert for Induction of Labor in Parous Women at Term: A Randomized Trial|||Seoul National University Hospital|No|Recruiting|May 2012|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|154|||Female|N/A|N/A|No|||December 2013|May 19, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596296||86138|
NCT01592266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0112-12-HMO|F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)|F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML|AML F18-FLT|Hadassah Medical Organization||Not yet recruiting|October 2012|||October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|N/A|No|Non-Probability Sample|patients with new diagnosis of AML|April 2012|May 3, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01592266||86447|
NCT01592526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-011|Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers|Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers||Rigshospitalet, Denmark|Yes|Completed|June 2012|December 2015|Actual|January 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|23|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01592526||86427|
NCT01592539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton11|Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls|Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls||Creighton University|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|78|||Both|19 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Type 1 DM|February 2015|February 25, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592539||86426|
NCT01584076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00002887|Treatment of Residual Amblyopia With Donepezil|Recovery From Amblyopia With Cholinesterase Inhibitors||Children's Hospital Boston|No|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|8 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 31, 2015|April 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01584076||87068|
NCT01584687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025ABR03T|mRNA Expression as a Biomarker of Omalizumab Response|mRNA Expression as a Biomarker of Xolair (Omalizumab) Response||Instituto de Investigação em Imunologia|Yes|Not yet recruiting|June 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|6|||Both|12 Years|60 Years|No|||April 2012|April 24, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01584687||87023|
NCT01584986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACP_CLI_P01|Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease|Autologous Stem Cell Therapy for the Treatment of Patients With Peripheral Artery Disease||Salus Ltd.|No|Completed|May 2008|July 2009|Actual|April 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|N/A|N/A|No|||April 2012|April 24, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584986||87000|
NCT01584999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot 210163|Effects on Septic Patient's Microcirculation of the Transfusion of Different Types of Concentrated RBCs.|Effects on the Septic Patient's Microcirculation of the Transfusion of Three Different Types of Concentrated Red Blood Cells.||Università Politecnica delle Marche|No|Completed|February 2011|||February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584999||86999|
NCT01585324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25186|A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)|Open, Multicenter Phase IV Study, Evaluating Drop of Hemoglobin in Association to the Rate of Sustained Virological Response in Chronic Hepatitis C Patients Treated With Ribavirin (Copegus®) in Combination With Standard Treatment (ANECO)||Hoffmann-La Roche||Completed|January 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||June 2015|June 25, 2015|April 24, 2012||No||No|June 25, 2015|https://clinicaltrials.gov/show/NCT01585324||86975|
NCT01595321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1179|Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas|Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated With Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|76 Years|No|||July 2015|July 27, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595321||86213|
NCT01595061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0279|Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva|A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva||Gynecologic Oncology Group|Yes|Suspended|July 2012|||September 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Female|18 Years|N/A|No|||March 2016|March 16, 2016|May 8, 2012|Yes|Yes|Scheduled Interim Monitoring|No||https://clinicaltrials.gov/show/NCT01595061||86233|
NCT01594372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VM-2012-01|Comparison of Laparoscopic to Vaginal Surgical Repair for Uterine Prolapse|Randomized Trial Comparing Vaginal Hysterectomy to Laparoscopic Supracervical Hysterectomy With Vault Suspension for Symptomatic Uterine Prolapse||Brigham and Women's Hospital|No|Terminated|January 2013|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Female|18 Years|N/A|No|||May 2015|May 7, 2015|May 4, 2012||No|Laproscopic procedure not offered at this time; will not be offered for the foreseeable, thus    we are unable to randomize participants between the two arms.|No||https://clinicaltrials.gov/show/NCT01594372||86286|
NCT01594606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD070621|Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth|RCT of an Animal-Assisted Intervention With Adjudicated Youth||Wayne State University|No|Completed|May 2012|June 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01594606||86268|
NCT01594931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-C-002-05|Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria|A Randomised, Multi-Centre, Phase II, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria||Medicines for Malaria Venture|Yes|Completed|July 2005|April 2006|Actual|March 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|477|||Both|15 Years|60 Years|No|||May 2012|May 8, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594931||86243|
NCT01594957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908B2101|Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment|An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.||Novartis||Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|53|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2013|May 23, 2013|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594957||86241|
NCT01595191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-346 TLV|Bach Music in Preterm Infants: No "Mozart Effect" on Resting Energy Expenditure|Bach Music in Preterm Infants: No "Mozart Effect" on Resting Energy Expenditure||Tel-Aviv Sourasky Medical Center|No|Completed|July 2010|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|N/A|59 Days|Accepts Healthy Volunteers|||May 2012|May 8, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595191||86223|
NCT01595425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961TC00001|Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects|A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Bioequivalence Study Comparing a Pellets Based Sachet Formulation of D961H 20 mg and a Commercial HPMC Capsule of D961H 20 mg After Repeated Oral Administration in Japanese Healthy Male Subjects||AstraZeneca||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|71|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 11, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595425||86205|
NCT01595737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACA-SPAI-2008-20|Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery|Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|February 2011|November 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|85 Years|No|||May 2012|March 11, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595737||86181|
NCT01596049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hernia313-11-RMBCTIL|The Efficacy of a Self-fixating Mesh in Unilateral Open Inguinal Hernia Repair|The Efficacy of a Self-fixating Mesh in Unilateral Open Inguinal Hernia Repair, in Comparison to the Standard Treatment in the Literature||Rambam Health Care Campus|No|Recruiting|May 2012|June 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Male|18 Years|90 Years|No|Non-Probability Sample|patients who are undergoing Inguinal Hernia Repair Surgery.|August 2014|August 12, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596049||86157|
NCT01591967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM001|Measure the Effects of Specific Thoracic Chiropractic Adjustments on Blood Pressure and Pulse Rate|A Randomized Controlled Trial to Measure the Effects of Specific Thoracic Chiropractic Adjustments on Blood Pressure and Pulse Rate||Spinal Missions, Inc., LLC|Yes|Completed|January 2010|March 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|290|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01591967||86470|
NCT01592565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007H0132 JD|Exercise Cardiac Magnetic Resonance Imaging Accuracy for Cardiovascular Stress Testing|An In-state Multi-center Evaluation of Treadmill Exercise Stress Cardiac Magnetic Resonance|EXACT|Ohio State University|Yes|Active, not recruiting|August 2010|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|227|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01592565||86424|
NCT01592318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28136|A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers|An Up to Two-Part Relative Bioavailability Study of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets as Compared to the Reference Phase 2 Ad Hoc Combination Tablets in Healthy Adult Volunteers||Hoffmann-La Roche||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592318||86443|
NCT01584375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE11/022|The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions|The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions in Preterm Infant Less Than 30 Weeks of Gestation: a Multicenter Randomized Control Trial||King Abdul Aziz General Hospital|No|Terminated|April 2012|April 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|71|||Both|N/A|2 Hours|No|||November 2013|October 30, 2014|April 21, 2012||No|Due to low patient recruitment|No||https://clinicaltrials.gov/show/NCT01584375||87047|
NCT01585337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109033RC|Trunk Forward Ability in Patients With Lumbar Fusion|Joint Coordination Changes During Functional Activities After Lumbar Fusion||National Taiwan University Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|30 Years|80 Years|No|Non-Probability Sample|All subjects will be recruited from Far Eastern Memorial Hospital. The study is approved        by the Institutional Medical Research Ethics Committees in both National Taiwan University        Hospital and Far Eastern Memorial Hospital. The consent form is as . We will recruit        patients aged between 30 to 60 years old.|July 2015|July 7, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585337||86974|
NCT01585610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA137616-01|Motivating Smokers With Mobility Impairments to Quit Smoking|Motivating Smokers With Mobility Impairments to Quit Smoking|ABLE|The Miriam Hospital|No|Active, not recruiting|September 2012|May 2016|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01585610||86954|
NCT01585623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT12497|Drug Interaction Study of SAR302503 in Patients With Solid Tumor|An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors||Sanofi|No|Completed|June 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585623||86953|
NCT01594814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPRA|Patients' Perspective on Radiofrequency Catheter Ablation of AVRT and AVNRT|Patients' Perspective on Radiofrequency Catheter Ablation of AVRT and AVNRT - a Quality of Life, Utility and Willingness to Pay Study (PPRA Study)|PPRA|Institute of Cardiology, Warsaw, Poland|Yes|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|82|||Both|18 Years|N/A|No|Non-Probability Sample|All patients scheduled for ablation of AVNRT, AVRT or SVT will be eligible for the study.|December 2014|December 12, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01594814||86252|
NCT01594476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8120|Early Postpartum Intrauterine Device (IUD) Placement|Early Versus Standard Interval Postpartum Intrauterine Device (IUD) Placement at 3 Weeks or 6 Weeks Following Delivery: A Prospective Randomized Trial||Oregon Health and Science University|Yes|Terminated|March 2012|July 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|201|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||October 2014|October 14, 2014|March 9, 2012|No|Yes|Incomplete study enrollment prior to depletion of funding|No||https://clinicaltrials.gov/show/NCT01594476||86278|
NCT01594489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prato0704|Aminophylline and Contrast Induced Nephropathy in Acute Myocardial Infarction|Effect of Aminophylline on Contrast Induced Acute Kidney Injury in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty||Ospedale Misericordia e Dolce|Yes|Completed|January 2009|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|250|||Both|18 Years|N/A|No|||October 2012|October 26, 2012|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01594489||86277|
NCT01594788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-NGL-2011-04|Neutrophil Gelatinase-associated Lipocalin as a New Biomarker to Detect Acute Kidney Injury in Postoperative Cardiac Surgery|NGAL as a Marker of Acute Kidney Injury After Cardiac Surgery. Observational Study||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Recruiting|April 2011|December 2012||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1||340|||Both|18 Years|N/A|No|Non-Probability Sample|Hospitalised patients|January 2012|May 8, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594788||86254|
NCT01595594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAPESP|Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics|Effect of a PDT Protocol With Multiple Applications as an Adjuvant on the Non Surgical Treatment of Periodontal Disease in Patients With Type 2 Diabetes. A Clinical and Laboratorial Study in Humans||University of Sao Paulo||Completed|March 2010|October 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|35 Years|70 Years|No|||July 2014|July 15, 2014|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01595594||86192|
NCT01595607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS39|The Effect of Avocado Consumption on Vascular Health|The Influence of Daily Consumption of Avocado on Biomarkers of Vascular Health||USDA Beltsville Human Nutrition Research Center|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|28 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595607||86191|
NCT01595581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-11-00649|Testosterone Administration and ACL Reconstruction in Men|The Effects of Acute Testosterone Administration in Men on Muscle Mass, Strength, and Physical Function Following ACL Reconstructive Surgery|TACL|University of Southern California|No|Recruiting|April 2012|||April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|14|||Male|18 Years|50 Years|No|||December 2013|December 3, 2013|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595581||86193|
NCT01595867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALO-01-10-4004|Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo|A Randomized, Double-Blind, Placebo-Controlled, 3 Way Crossover Study Evaluating The Relative Abuse Potential Of Crushed Embeda Compared To Morphine Sulfate Controlled Release Tablets (Crushed) And Placebo In Non-Dependent, Recreational Opioid Users Following Intranasal Administration||Pfizer|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|May 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01595867||86171|
NCT01594073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOMARKER-ICD|Evaluation of Novel Biomarkers to Improve Risk Stratification and Patient Selection in Implantable Cardioverter-defibrillator (ICD) Therapy|Evaluation of Novel Biomarkers to Improve Risk Stratification and Patient Selection in ICD Therapy|BIOMARKERICD|Hannover Medical School|No|Active, not recruiting|April 2012|December 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Serum, plasma (EDTA, heparin), monocytes, DNA|Both|18 Years|N/A|No|Probability Sample|Patients reveicing or having received an implantable cardioverster-defibrillator in the        Dept. of Cardiovascular Medicine of the Hanover Medical School.|March 2015|March 17, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01594073||86309|
NCT01594385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009H0311|Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients|Seprafilm in Open Abdomens: a Prospective Evaluation of Wound and Adhesion Characteristics in Trauma Damage Control (OASIT)|OASIT|Ohio State University|Yes|Completed|April 2010|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|89 Years|No|||January 2014|January 27, 2014|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594385||86285|
NCT01594632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10242|Safety,Effectiveness and Acceptability of Sino-implant II in DR|A Study to Evaluate the Contraceptive Effectiveness, Safety and Acceptability of Sino-implant II||FHI 360|Yes|Active, not recruiting|January 2011|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|500|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01594632||86266|
NCT01594619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00032|Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol|An Open-label, Sequential, 3-period Study to Assess the Effects of Diltiazem on the Pharmacokinetics of Naloxegol in Healthy Subjects||AstraZeneca||Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|May 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01594619||86267|
NCT01594970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APMA-001211|A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)|||Allergan|No|Completed|March 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|800|||Both|20 Years|N/A|No|||January 2014|January 27, 2014|May 8, 2012|Yes|Yes||No|January 27, 2014|https://clinicaltrials.gov/show/NCT01594970||86240|
NCT01595204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/758/CE/2009|Validation of a Laparoscopic Score to Predict the Chance of Optimal Cytoreduction in Advanced Ovarian Cancer Patients|Olympia-MITO13-validation of a Laparoscopic Score to Predict the Chance of Optimal Cytoreduction in Advanced Ovarian Cancer Patients: an Open-label Prospective Multicentric-trial.|MITO13|Catholic University of the Sacred Heart|Yes|Completed|March 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Female|18 Years|N/A|No|||May 2012|May 20, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595204||86222|
NCT01595438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00002|Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)|A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults||AstraZeneca||Completed|October 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|598|||Both|18 Years|90 Years|No|||March 2016|March 8, 2016|April 27, 2012|Yes|Yes||No|October 28, 2015|https://clinicaltrials.gov/show/NCT01595438||86204|
NCT01595750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIB-ROF-2011-01|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease|REVASC|Spanish Research Center for Respiratory Diseases|No|Not yet recruiting|May 2012|August 2012|Anticipated|July 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|55 Years|75 Years|No|||May 2012|May 9, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595750||86180|
NCT01591993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SenSk12|Determination of Sensitive Skin and Its Biophysical Response in a Latin-American Population|Determination of Sensitive Skin in a Mexican Population by Lactic Acid Testing and Its Analysis Through Biophysical Measures||Universidad Autonoma de San Luis Potosí|No|Completed|October 2011|August 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|260|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01591993||86468|
NCT01591980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB-10-388|Effects of Perioperative Pregabalin for Post-Craniotomy Pain|Effects of Perioperative Low-dose Pregabalin on Post-craniotomy Pain: A Two-centre Randomized Controlled Trial||St. Michael's Hospital, Toronto|Yes|Withdrawn|August 2013|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|65 Years|No|||February 2014|February 18, 2014|December 9, 2011|Yes|Yes|Pfizer Canada and the SMH ORA could not come into an agreement on responsibility to be the    Importer of Record for the trial.|No||https://clinicaltrials.gov/show/NCT01591980||86469|
NCT01592292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27923|An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy|A Non-interventional Study for Relative Efficacy Outcome of Rituximab Treatment in RA Patients Who Have Inadequate Response or Have Been Intolerant to a First Anti-TNF Agent||Hoffmann-La Roche||Completed|November 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|20 Years|N/A|No|Probability Sample|Adult patients with rheumatoid arthritis who have inadequate response or have been        intolerant to a first anti-TNF alpha therapy|March 2016|March 1, 2016|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01592292||86445|
NCT01592604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH 15761|An Optimal Treatment for Avulsion Fractures of the Base of Fith Metatarsal Bone|An Optimal Treatment for Avulsion Fractures of the Base of Fith Metatarsal Bone. A Level I Prospective Randomised Control Trial||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|November 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|15 Years|N/A|No|||August 2013|August 23, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01592604||86422|
NCT01592877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Holux_SKH01|A Comparative Study of the Performance of a New Type Non-contact Patient Monitor|Clinical Test of Ultra-Wideband Non-contact Heart Rate and Breath Rate Monitor||Holux Technology, Inc.|Yes|Recruiting|December 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult, >18 years old.|July 2012|July 30, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01592877||86401|
NCT01585012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-045|Usability Study of the Focus Touch™ Conception System: Semen Collection|Phase 2 Human Factors Usability Study of the Focus Touch™ Conception System: Semen Collection|Ib2C|Rinovum Women's Health, Inc.|Yes|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|30|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 4, 2015|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585012||86998|
NCT01585025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1909|Obeticholic Acid in Bile Acid Diarrhoea|Obeticholic Acid Treatment in Patients With Bile Acid Diarrhoea: an Open-label, Pilot Study of Mechanisms, Safety and Symptom Response.|OBADIAH1|Imperial College London|Yes|Completed|April 2012|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|80 Years|No|||June 2014|September 5, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585025||86997|
NCT01593930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Articaine pulpal anesthesia|Evaluation of the Success Rate of Pulpal Anesthesia in Mandibular First Molar Following Infiltration of 4% Articaine Alone and as Supplemental Injection After Inferior Alveolar Nerve Block|||Zahedan University of Medical Sciences|No|Completed|May 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593930||86320|
NCT01594177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 70|Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy|Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy|DAFNE|German Breast Group|Yes|Completed|May 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|65|||Female|18 Years|N/A|No|||March 2014|March 12, 2014|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594177||86301|
NCT01595087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODX-001|A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)|A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)||DexTech Medical AB|Yes|Completed|January 2012|September 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Male|18 Years|N/A|No|||November 2014|November 12, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595087||86231|
NCT01595074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01965|Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy|The Identification, Validation and Implemention of Prognostic and/or Predictive Biomarkers for Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer (NSCLC)||National Cancer Institute (NCI)||Not yet recruiting|May 2012|||January 2100|Anticipated|N/A|Observational|N/A||1|Anticipated|950|||Both|18 Years|N/A|No|Probability Sample||August 2013|September 19, 2013|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595074||86232|
NCT01595620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1005006859|Cannabinoid Modulation of Pain|Cannabinoid Modulation of Pain||Yale University|Yes|Recruiting|December 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|April 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01595620||86190|
NCT01595906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1037-2011-IDF-CTIL|The Affect of a Ventilated Helmet on Physiological Load|The Affect of a Ventilated Helmet System on Human Physiological Load||Medical Corps, Israel Defense Force|No|Not yet recruiting|September 2012|February 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|12|||Male|21 Years|28 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01595906||86168|
NCT01596192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC-PETGVHD-001|PETCT for Diagnosing and Monitoring Acute GVHD|The Sensitivity and Specificity of 18F-Fluorodeoxyglucose Positron Emission Tomography -Computed Tomography for the Diagnosis and Monitoring of Acute Graft vs. Host Disease|PETGVHD-001|Rabin Medical Center|No|Not yet recruiting|May 2012|June 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Levels of HGF, IL8, IL2R and TNFR1 will be measured at the onset of GVHD and prior to the      second PET-CT. Five cc blood will be drawn twice from each patient and will be collected in      an EDTA containing tube.|Both|18 Years|80 Years|No|Non-Probability Sample|Patients admitted to the BMT unit, Beilinson Hospital with the diagsnosis of acute GVHD|February 2012|May 9, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01596192||86146|
NCT01594398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNDX-275-0110|Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer|A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer|ENCORE110|Syndax Pharmaceuticals|No|Active, not recruiting|May 2012|May 2014|Anticipated|April 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|18 Years|90 Years|No|||September 2013|September 9, 2013|May 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594398||86284|
NCT01594645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013612- HMO-CTIL|The Clinical Impact of Selecting Acrosome Reacted Spermatozoa for ICSI|The Impact of Selecting Acrosome Reacted Spermatozoa for ICSI- a Prospective RCT||Hadassah Medical Organization|No|Withdrawn|September 2012|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|38 Years|No|||May 2012|August 19, 2015|May 3, 2012||No|PI moved from Hadassah|No||https://clinicaltrials.gov/show/NCT01594645||86265|
NCT01594983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908C2201|A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia|A Multicenter, Randomized, Active Comparator, Placebo Controlled, Double-blind Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia||Novartis|No|Completed|June 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|58|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594983||86239|
NCT01595217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XYang|The Diagnosis of Biliary Tract Neoplasm by Diffusion Weighted Imaging and Magnetic Resonance Cholangiopancreatography|The Application of Combining Diffusion Weighted Imaging(DWI) and Magnetic Resonance Cholangiopancreatography(MRCP) at 3.0T MRI in the Diagnosis of Biliary Tract Neoplasm||China Medical University, China|Yes|Recruiting|March 2012|March 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|60|||Both|16 Years|N/A|No|||August 2012|August 9, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595217||86221|
NCT01595230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-284|Internal Hernias After Gastric Bypass Can be Prevented Safely With Primary Closure of All Mesenteric Defects With Clips|Randomized Controlled Trial: Internal Hernias After Gastric Bypass Can be Prevented Safely With Primary Closure of All Mesenteric Defects With Clips||Region Zealand|No|Recruiting|May 2012|December 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|85 Years|No|||October 2015|October 27, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01595230||86220|
NCT01595451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000757|Brain Mechanisms of Acupuncture Treatment in Chronic Low Back Pain|Brain Mechanisms of Acupuncture Treatment in Chronic Low Back Pain||Brigham and Women's Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|60 Years|No|||March 2015|March 18, 2015|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595451||86203|
NCT01595464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-CMBM-001|Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza|A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza||The Center for Mind-Body Medicine|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595464||86202|
NCT01596062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHI621AFR05|Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)|Prospective, Multicenter, Randomized, Open-label, Phase 2, Lasting 12 Weeks, Evaluating the Pharmacodynamics, Efficacy and Safety of Basiliximab in de Novo Adult Renal Transplant Patients at Low Risk Receiving Either a Cumulative Dose of Basiliximab of 40 or 80 mg in Combination With Cyclosporine Microemulsion, or a Cumulative Dose of 80 mg of Basiliximab Without Calcineurin Inhibitor, With Additional Follow-up of 12 Weeks|IDEALE|Novartis|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|16|||Both|18 Years|65 Years|No|||June 2014|June 26, 2014|September 29, 2011||No||No|March 17, 2014|https://clinicaltrials.gov/show/NCT01596062||86156|
NCT01596075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0388-11-RMC|Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation|Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation||Rabin Medical Center|No|Recruiting|July 2012|||July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2012|September 9, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596075||86155|
NCT01596088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KDX1101|A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents|A Multicenter, Open Label, Single-arm Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents||Kissei Pharmaceutical Co., Ltd.|No|Completed||||January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|20 Years|N/A||||March 2015|March 18, 2015|May 8, 2012||||No|February 27, 2015|https://clinicaltrials.gov/show/NCT01596088||86154|
NCT01592305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28104|A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir|A Study to Evaluate the Potential Drug-Drug Interaction Between Danoprevir When Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir in Healthy Adult Volunteers||Hoffmann-La Roche||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592305||86444|
NCT01575327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AGIR-01|Closed-loop System for Oxygen Delivery and Exercise in Chronic Obstructive Pulmonary Disease|Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Exercise Tolerance During Walk in Patients With COPD, Oxygen Therapy and Hypercapnia|FreeO2-rehab|AGIR à Dom|Yes|Recruiting|July 2012|December 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|40 Years|N/A|No|||June 2015|June 9, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01575327||87736|
NCT01567657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEE 2012|Safety Study of Two Regimen for Sedation for Transesophageal Echocardiography|Phase II Study of Comparison of Two Sedation Regimen for Transesophageal Echocardiography in Point of View of Blood Pressure Response, Safety and Patient Comfort||Kantonsspital Münsterlingen|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|200|||Both|18 Years|90 Years|No|||January 2013|January 25, 2013|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01567657||88324|
NCT01567930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1‐2247|Temsirolimus as Second-line Therapy in HCC|A Phase II Study of Temsirolimus as Second-line Therapy in Patients With Advanced, Unresectable Hepatocellular Carcinoma||University of Tennessee Cancer Institute|Yes|Recruiting|February 2010|March 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||March 2012|December 13, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01567930||88303|
NCT01569139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Validation of CALIBER linkage|Comparison of Information Recorded in MINAP, GPRD and HES: a CALIBER Study|Comparison of the Information Recorded in the Myocardial Ischaemia National Audit Project, the General Practice Research Database and Hospital Episode Statistics: a CALIBER Study||London School of Hygiene and Tropical Medicine|Yes|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|21000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of "acceptable" patients registered at those GPRD        practices that agreed to the linkage with MINAP and HES, whose practices are "up to        standard" according to GPRD criteria. Practices taking part in the GPRD are chosen to be        representative of UK practices, and 98% of people in the UK are registered with a GP.        Therefore the GPRD should be a representative sample of the UK population.|October 2015|October 1, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569139||88210|
NCT01550211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-0001-12|Changes in Brain Synchronization During Perceptual and Linguistic Tasks in Schizophrenic Patients|||Shalvata Mental Health Center|Yes|Not yet recruiting|March 2012|||March 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|150|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Chronic patients - Up to 30 chronic schizophrenic patients.          2. Naive patients - Up to 30 unmedicated first episode schizophrenic patients.          3. Patients' relatives - Up to 60 family members (parents or siblings) of the             participants - control group 1.          4. Students - Up to 30 students from Bar-Ilan University - control group 2.|March 2012|March 7, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550211||89656|
NCT01550445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-CRO-08-067|Steroid Withdrawal Immunosuppression After Renal Transplantation|Prospective Controlled Protocol for 3 Months Steroid Withdrawal With Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients||Ajou University School of Medicine|No|Recruiting|May 2008|July 2012|Anticipated|October 2009|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|13 Years|N/A|No|||March 2012|March 7, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01550445||89638|
NCT01550666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20110149H|Treatment Development Targeting Severe and Persistent Negative Symptoms|Treatment Development Targeting Severe and Persistent Negative Symptoms|MOVE|The University of Texas Health Science Center at San Antonio|Yes|Completed|January 2011|January 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|96|||Both|18 Years|60 Years|No|||January 2016|January 8, 2016|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01550666||89621|
NCT01550679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHSCRT114338|Early Detection of COPD Patients in GOLD 0 (Smokers) Population|Early Detection of COPD Patients in GOLD 0 (Smokers) Population|MARKO|Children's Hospital Srebrnjak|Yes|Recruiting|October 2010|December 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|whole blood, serum, plasma|Both|40 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Primary care clinic|January 2016|January 26, 2016|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01550679||89620|
NCT01550978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HST-AG-04|Evaluation of the Safety and Efficacy of the AnapnoGuard 100 System|The Safety of Using the AnapnoGuard 100 System in Intubated Critical Care Patients||Hospitech Respiration|No|Completed|February 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|60|||Both|21 Years|N/A|No|||February 2016|February 17, 2016|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01550978||89598|
NCT01551251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-0522B|Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer|Tumor-Associated Macrophages Correlate With Response and Outcomes in Advanced Non-Small Cell Lung Cancer After First Line Treatment.||Chang Gung Memorial Hospital|Yes|Completed|January 2006|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|107|Samples With DNA|All specimens were fixed in 10% buffered formalin and embedded in paraffin according to      standard procedures. All of the tissues were fixed immediately after biopsy, with time from      tissue acquisition to fixation as short as possible. Serial sections (4 μm thickness) placed      on positively charged slides (Menzel-Glasser, German) were used for immuno-histochemistry.|Both|20 Years|N/A|No|Non-Probability Sample|All patients with advanced non-small cell lung cancer (stage IIIb and IV NSCLC) who had        been treated at the Linkou Branch of Chang Gung Memorial Hospital between 2006 and 2009        were included.|April 2011|July 27, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551251||89578|
NCT01551264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110158|Duration of Brace Wear in Clubfoot Treatment - A Prospective Randomized Trial|Duration of Brace Wear in Clubfoot Treatment - A Prospective Randomized Trail|FAB24|Washington University School of Medicine|Yes|Active, not recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|N/A|1 Year|No|||December 2015|December 21, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01551264||89577|
NCT01551836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E3870651|At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations|A Randomised, Two Way Crossover Study to Determine the Time at Which Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations||GlaxoSmithKline|No|Completed|June 2009|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01551836||89533|
NCT01551849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00470|Echocardiographic Assessment of Function During ECMO Support|Echocardiographic Assessment of Function During ECMO Support||Nationwide Children's Hospital|No|Recruiting|January 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|N/A|N/A|No|Non-Probability Sample|Critically ill patients supported by VA-ECMO in the NICU, PICU, or CTICU.|February 2015|February 12, 2015|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01551849||89532|
NCT01551862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PlastSurg01|Complications in Lower Body Lifts|Prospective Study on Complications Following a Lower Body Lift After Massive Weight Loss||Medical University of Vienna|No|Completed|January 2007|September 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients which are referred to Department of Plastic Surgery for body contouring surgery|March 2012|March 12, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01551862||89531|
NCT01578005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10 047 08|IVUS Assessment of Atheroma Burden After Acute Coronary Syndrome|Intravascular Ultrasound (IVUS) Assessment of the Atherosclerotic Plaque Causing an Acute Coronary Syndrome: One-year Changes Under Optimal Secondary Prevention Drug Treatment|OPTIVUS|University Hospital, Toulouse|No|Recruiting|March 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|bioanalysis on DNA, searching genes involving coronary disease|Both|18 Years|N/A|No|Probability Sample|female and male aged more than 18 years hospitalized for acute coronary syndrom|August 2015|August 18, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01578005||87531|
NCT01578291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00034999|Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram|Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram||Johns Hopkins University|No|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|100|||Both|2 Years|10 Years|No|||April 2012|April 13, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01578291||87509|
NCT01578538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|herni|Safety of Mesh Used Repairs in Emergency Abdominal Wall Hernias. Prospective Randomized Multicenter Trial|Mesh Used Repairs in Emergency Abdominal Wall Hernias|hernia|SB Istanbul Education and Research Hospital|No|Recruiting|February 2012|June 2016|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|N/A|No|||April 2012|April 16, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578538||87490|
NCT01578551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1188|A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.|A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma|NA_00052073|Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|April 2012|August 2015|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578551||87489|
NCT01578564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR-C13 01|Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel|Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel||Soricimed Biopharma Inc|Yes|Recruiting|July 2012|September 2015|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578564||87488|
NCT01578850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801315|Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening|A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s)||Pfizer|No|Completed|July 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|491|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578850||87466|
NCT01567943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01AA020248-01A1|Contingency Management of Alcohol Abuse in the Severely Mentally ILL|Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill|CM ETG|University of Washington|Yes|Active, not recruiting|March 2012|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||June 2015|June 17, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567943||88302|
NCT01567072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018543-34|Non Steroidal Antiinflammatory Drugs Influence on Heal of Distal Radius Fracture|Non Steroidal Antiinflammatory Drugs Influence on Heal of Distal Radius Fracture|CHIP|Aalborg Universitetshospital|Yes|Active, not recruiting|April 2012|June 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|192|||Both|50 Years|80 Years|No|||December 2015|December 30, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01567072||88368|
NCT01567410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/471|Evaluation of an E-learning Program for Assessing Pressure Ulcer Risk and Pressure Ulcer Classification - a Pilot Study|Randomized Controlled Trial to Evaluate the Effect of E-learning on Nurses Ability to Assess Patient Risk for Pressure Ulcers and Pressure Ulcer Classification||Oslo University Hospital|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Actual|68|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01567410||88343|
NCT01568879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN-11RGold-02-H|Evaluating the Effectiveness of a Chronic Disease Management Program for Gout|Evaluating the Effectiveness of a Chronic Disease Management Program for Gout||Kaiser Permanente|Yes|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|21 Years|80 Years|No|||March 2015|March 4, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01568879||88230|
NCT01569152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08683|Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (MK-8457-008)|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial With a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy||Merck Sharp & Dohme Corp.|No|Terminated|May 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|9||Actual|82|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569152||88209|
NCT01550237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/710|Curative Image Guided Radiotherapy for Prostate Cancer|A Randomised, Two Centre Trial on Daily Cone-beam vs Standard Weekly Orthogonal Image Guided Radiotherapy (IGRT) for Prostate Cancer|RIC|St. Olavs Hospital|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|260|||Male|18 Years|80 Years|No|||February 2016|February 2, 2016|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550237||89654|
NCT01550458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAU-2011-01|Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers|A Study of the Pharmacokinetic and Safety Profile of QID Dosing of Mibefradil in Normal Human Volunteers||Cavion LLC|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 11, 2012|February 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01550458||89637|
NCT01550731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-110|Preparing Older Veterans With Serious and Chronic Illness for Decision Making|Preparing Older Veterans With Serious and Chronic Illness for Decision Making|PREPARE|VA Office of Research and Development|No|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|410|||Both|60 Years|N/A|No|||February 2016|February 3, 2016|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01550731||89617|
NCT01550705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTINH|Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria|Quantification of the Effects of Isoniazid Treatment on Erythrocyte and Plasma Protoporphyrin IX Concentration and Plasma Aminolevulinic Acid in Patients With Erythropoietic Protoporphyria|INHEPP|University of Utah|Yes|Withdrawn|March 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 5, 2012|Yes|Yes|The interim analysis indicated that the treatment was not effective in decreasing the levels    of protoporphyrin in plasma.|No||https://clinicaltrials.gov/show/NCT01550705||89619|
NCT01550718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|41577-G|Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial|Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial||University of Washington|No|Completed|February 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|152|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01550718||89618|
NCT01551004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0008|Phase I Trial of a Single Dose of CRS3123|Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|May 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|October 2, 2014|March 8, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01551004||89597|
NCT01551576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROS0046|Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study|Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study||Stanford University|Yes|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Male|18 Years|80 Years|No|Non-Probability Sample|Medical oncologists with appropriate patient populations will be informed of the study and        the inclusion and exclusion criteria. Potential participants will be recruited from the        Stanford Urologic Oncology Clinic. A study investigator will follow-up with participants        who are interested in participating in this study. Study information will be posted on the        Stanford Cancer Center website as well.|October 2015|October 23, 2015|March 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01551576||89553|
NCT01551589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSWOG0001|Elective or Prophylactic Nodal Irradiation for Esophageal Cancer|Multicenter Prospective Randomized Phase III Trial Comparing Elective to Prophylactic Regional Lymph Node Irradiation for Thoracic Esophageal Cancer|ENI or PNI|The Second People's Hospital of Sichuan|Yes|Active, not recruiting|March 2012|September 2015|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|80 Years|No|||March 2012|March 8, 2012|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01551589||89552|
NCT01569958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDCS2011-01|Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis|Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis||Università degli Studi 'G. d'Annunzio' Chieti e Pescara|Yes|Recruiting|July 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|85 Years|No|||October 2012|October 8, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01569958||88147|
NCT01566071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REIMS-PHRCNAT2011-N11-02|Ability to Drive of Early Stage Alzheimer Disease||DRIVE COG|CHU de Reims|No|Not yet recruiting||||||N/A|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Diagnostic|||Anticipated|60|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 28, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566071||88445|
NCT01578018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16249|Tumor Markers in Lung Cancer: DCAMLK-1LK-1|Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study||University of Oklahoma|No|Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|49|||Both|45 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 8, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578018||87530|
NCT01578304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-IFCL002|Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder|Phase IV Study to Evaluate the Efficacy and Safety Imidafenacin Versus Fesoterodine in Patients With Overactive Bladder||LG Life Sciences|No|Completed|December 2010|October 2011|Actual|October 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|207|||Both|20 Years|N/A|No|||April 2012|April 13, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578304||87508|
NCT01578577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medication Therapy Management|Northwestern University and Access Community Health Network Medication Education Study|EHR-based Health Literacy Strategy to Promote Medication Therapy Management|NAMES|Northwestern University|Yes|Active, not recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1680|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578577||87487|
NCT01578590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 11-3-088|Post-exercise Recovery After Dietary Protein Ingestion in Healthy Young Men (Meat-Milk Study)|Post-exercise Recovery After Dietary Protein Ingestion in Healthy Young Men|Meat-Milk|Maastricht University Medical Center|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01578590||87486|
NCT01567423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epicentre-MSF-OCBA|Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria|Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008||Epicentre|No|Completed|April 2008|April 2009|Actual|April 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|301|||Both|6 Months|59 Months|No|||March 2012|March 28, 2012|January 27, 2009||No||No||https://clinicaltrials.gov/show/NCT01567423||88342|
NCT01567670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72925|Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray|Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration|BED|Lightlake Sinclair Ltd.|Yes|Active, not recruiting|August 2011|||June 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 29, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01567670||88323|
NCT01567696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-000135/11007|Clinical, Radiographic and Laboratory Analysis of Failures of Joint Replacements|Defining the Inflammatory Cytokines in Patients With Adverse Reactions to Metal-on-Metal Hip Replacements||University of California, San Diego|No|Recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients ≥18 years of age, that present with a failed joint replacement.|March 2012|March 29, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567696||88321|
NCT01567956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST261DM11006|Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study|Phase III Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment||sigma-tau i.f.r. S.p.A.|Yes|Terminated|April 2012|January 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||April 2014|April 9, 2014|March 28, 2012||No|Evidence of very low probability to success. No safety issues|No||https://clinicaltrials.gov/show/NCT01567956||88301|
NCT01568281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D539EC00001|Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects|A Randomised, Open Label, Single Centre, 2 Way Crossover Bioequivalence Study Comparing Arimidex Tablet 1 mg and Anastrozole Orally Rapid Disintegration Film Formula 1 mg After Single Oral Administration in Japanese Healthy Male Subjects||AstraZeneca||Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|58|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 22, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01568281||88276|
NCT01568294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-004|Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma|A Phase 1, Multicenter, Open-label, Dose-escalation Study in Japan to Determine the Tolerated Dose and to Evaluate the Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination With Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma||Celgene|No|Completed|April 2012|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||August 2015|August 19, 2015|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01568294||88275|
NCT01568307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|74/12|Major Depressive Disorder - Understanding The Link Between The Brain And The Heart|Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart|MDD|Baker IDI Heart and Diabetes Institute|No|Recruiting|May 2012|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|70 Years|No|||December 2013|December 16, 2013|March 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568307||88274|
NCT01568593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LT2750-PIII-10/11|Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome|Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome||Laboratoires Thea|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|March 29, 2012||No||No|October 7, 2014|https://clinicaltrials.gov/show/NCT01568593||88252|
NCT01568619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AESCULON|Validation of Electrical Cardiometry Versus Fick Method in Cardiac Output Measurement|Validation of Electrical Cardiometry Versus Fick Method to Measure Stroke Volume and Cardiac Output in Patients With or Suspected of Having Heart Failure||Massachusetts General Hospital|No|Active, not recruiting|March 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients of 18 years or older who undergo cardiopulmonary exercise testing (CPET)        with invasive hemodynamic monitoring for their routine care.|December 2014|December 1, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568619||88250|
NCT01568892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116529|Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir|A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo Over 7 Days in HIV-1-infected Subjects With RAL/ELV Resistance, Followed by an Open-label Phase With an Optimized Background Regimen|VIKING-4|ViiV Healthcare|No|Active, not recruiting|April 2012|June 2015|Anticipated|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|N/A|No|||December 2013|January 2, 2014|March 29, 2012|Yes|Yes||Yes|August 15, 2013|https://clinicaltrials.gov/show/NCT01568892||88229|
NCT01569165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89629|Effect of Water Rinsing After Topical Fluoride Application on Dental Plaque pH|Effect of Water Rinsing After APF Application on Dental Plaque Acidogenicity||Mashhad University of Medical Sciences|No|Completed|February 2011|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|25|||Both|21 Years|29 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01569165||88208|
NCT01569178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAMI-01|BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction|The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction.|BAMI|Queen Mary University of London|Yes|Recruiting|September 2013|May 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|3000|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569178||88207|
NCT01554865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010075D|Effects of Diet-induced Weight Loss in Obese Men|The Effects of Diet-induced Weight Loss on Metabolic and Inflammatory Profile, Endothelial, Sexual and Urinary Function, and Quality of Life in Obese Men||Changi General Hospital|No|Completed|December 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01554865||89302|
NCT01555086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP 55/09|Prospective Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy|Prospective Randomized Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy|SEAL|Association of Urogenital Oncology (AUO)|Yes|Recruiting|August 2011|||August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Male|18 Years|75 Years|No|||November 2015|November 3, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555086||89285|
NCT01551017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARP24-214|Fast Track Recovery Knee Arthroplasty Project|Postoperative Cryotherapy: Fast Track Recovery Knee Arthroplasty Project|FARP|Medical University of Graz|No|Recruiting|December 2011|December 2016|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|90 Years|No|Probability Sample|Patients receiving a total knee endoprosthesis at the Department of Orthopaedics Surgery        Graz|April 2015|April 21, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551017||89596|
NCT01551277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jaqueline 01|Use of Breath Stacking Technique on Regional Ventilation in Box Chest in Women With Morbid Obesity|Use of Breath Stacking Technique on Regional Ventilation in Box Chest in Women With Morbid Obesity: Clinical Trial Controlled and Randominzado||Universidade Federal de Pernambuco|Yes|Completed|March 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|32|||Female|19 Years|60 Years|No|||March 2012|March 9, 2012|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551277||89576|
NCT01551290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018769|A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis||Xian-Janssen Pharmaceutical Ltd.|No|Completed|April 2012|October 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|65 Years|No|||October 2015|October 28, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01551290||89575|
NCT01556217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017404|A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers|A Double-blind, Placebo-controlled, Single Dose, Pharmacokinetic Study to Characterize the Central Brain Penetrance of JNJ-39393406 Using Cerebrospinal Fluid in Healthy Male and Female Subjects||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||Completed|September 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|12|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01556217||89198|
NCT01555944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyCard|Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines|Screening and Management of Cardiovascular Risk in Belgian Women Aged > or = 65 Years With Metastatic Breast Cancer Before and After Anthracycline Treatment||Teva Pharma|No|Recruiting|February 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|65 Years|N/A|No|Probability Sample|Belgian women aged > or = 65 years with metastatic breast cancer before and after        anthracycline treatment.        Patients will be included in 24 centers specialized in the treatment of breast cancer, in        Belgium.|November 2014|November 24, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555944||89219|
NCT01555957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URochester|Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis|Effect of Lipid Intake on Direct Hyperbilirubinemia in Late Preterm and Term Infants With Gastrointestinal Surgical Problems.||University of Rochester|No|Recruiting|February 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|72 Hours|No|||December 2015|December 21, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555957||89218|
NCT01566318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30MH090333-PRC1|Depression Agency-Based Collaboration|Depression Agency-Based Collaborative (Depression ABC)||University of Pittsburgh|Yes|Active, not recruiting|March 2012|June 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|104|||Both|60 Years|N/A|No|||December 2015|December 29, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566318||88426|
NCT01566305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL33461.068.10|Effects of Buttermilk on Serum LDL Cholesterol Concentrations|The Effects of Buttermilk With or Without Lutein-enriched Egg Yolk on the Serum LDL Cholesterol Concentration of Slightly Hypercholesterolaemic Volunteers||Maastricht University Medical Center|No|Active, not recruiting|October 2010|||July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|108|||Both|18 Years|70 Years|No|||March 2012|March 27, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566305||88427|
NCT01566552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHU001/2012|Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis|Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India.||Banaras Hindu University|Yes|Not yet recruiting|June 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1300|||Both|5 Years|65 Years|No|||March 2012|January 21, 2014|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566552||88408|
NCT01566825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVDT|The Influence of Amitriptyline on Learning in a Visual Discrimination Task|The Influence of Amitriptyline (Amitriptylin-CT 25 mg®) on Learning in a Visual Discrimination Task (Karni-Sagi-paradigm)||Charite University, Berlin, Germany|Yes|Completed|August 2008|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|32|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566825||88387|
NCT01567085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-002|Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor|An Open-Label, Single-Arm, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Sensitized Recipients of a Kidney Transplant From a Deceased Donor.||Alexion Pharmaceuticals|Yes|Active, not recruiting|May 2012|June 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01567085||88367|
NCT01567436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10728|A Prospective Field Study: Introducing the Shang Ring in Routine Clinical Settings|A Prospective Study of Male Circumcision Using the Shang Ring in Routine Clinical Settings in Kenya & Zambia||FHI 360|No|Completed|February 2012|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1200|||Male|18 Years|54 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567436||88341|
NCT01567969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1102008073|Family Health and Development Project|Family Health and Development Project: Intensive In-home Child and Adolescent Psychiatric Service (IICAPS) vs. Home-based Child Treatment Coordination (Home-based CTC) for Seriously Emotionally Disturbed Children|FHDP|Yale University|Yes|Active, not recruiting|May 2011|February 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|110|||Both|6 Years|16 Years|No|||January 2016|February 8, 2016|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01567969||88300|
NCT01567982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008007212|Effects of Transcranial Direct Current Stimulation on Tobacco Withdrawal Symptoms|Phase 1 Study of Effects of tDCS on Tobacco Withdrawal Symptoms|tDCSsmokers|Yale University|No|Completed|March 2011|July 2015|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567982||88299|
NCT01568320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007|Zenith® Dissection Clinical Trial|Use of the Zenith® Dissection Endovascular System in the Treatment of Patients With Acute, Complicated Type B Aortic Dissection||Cook||Active, not recruiting|August 2012|April 2020|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568320||88273|
NCT01568606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCLA M-IRB1 # 10-001055|Safety of Body Composition Analysis in Heart Failure Patients With Implantable Cardioverter Defibrillators (ICDs)|Safety of Body Composition Analysis Using Bioimpedance in Heart Failure Patients With Implantable Cardioverter Defibrillators (ICDs)||University of California, Los Angeles|No|Completed|January 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|18 Years|N/A|No|||March 2012|March 30, 2012|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01568606||88251|
NCT01568632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120091|Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma|A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2012|October 2012|Actual|||Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|1 Year|21 Years|No|||November 2012|November 20, 2012|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568632||88249|
NCT01568645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120093|Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease|A Pilot Study of Treatment of Adults With Sickle Cell Disease Associated Pulmonary Hypertension Based on Hemodynamic Stratification: Safety and Tolerability Study of Imatinib and Carvedilol||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2012|June 24, 2015|March 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01568645||88248|
NCT01568905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011NTLS004|Palatability of Experimental Cigarettes|Palatability of Experimental Cigarettes||Masonic Cancer Center, University of Minnesota|No|Recruiting|February 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2013|July 25, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01568905||88228|
NCT01569438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF219-005|The Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome|||Afferent Pharmaceuticals, Inc.||Completed|March 2012|June 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Female|18 Years|80 Years|No|||January 2014|June 12, 2014|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569438||88187|
NCT01569451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1143|Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy for MS|A Double Blinded, Placebo Controlled, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis|GATEWAY II|University of Colorado, Denver|Yes|Completed|February 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|55 Years|No|||June 2015|June 3, 2015|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569451||88186|
NCT01555112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AS101-IL#001|Safety and Efficacy Study to Test Topical AS101 for External Genital Warts|A Phase I/II, Open Labeled, Uncontrolled, Single Center Study of Topical AS101 for External Genital Warts||BioMAS Ltd|Yes|Completed|March 2012|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|18 Years|N/A|No|||August 2013|August 14, 2013|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01555112||89283|
NCT01555411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1475 C|Akershus Cardiac Examination (ACE) 1950 Study|Akershus Cardiac Examination 1950 Study - a Cohort Study on Cardio- and Cerebrovascular Disease in 62-65-year-old Subjects|ACE1950|Vestre Viken Hospital Trust|Yes|Active, not recruiting|September 2012|December 2050|Anticipated|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|Samples With DNA|Blood samples, including for genetic testing, and urine.|Both|62 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents of Akershus County, Norway, born in 1950.|June 2015|June 15, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555411||89260|
NCT01555424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M2327|Vitamin D Fortified Cheese and Well-being in the Institutionalized Elderly|Bioavailability of Casein-bound Vitamin D From Fortified Cheese and Its Effects on the Well-being of the Institutionalized Elderly||University of Toronto|No|Active, not recruiting|February 2012|April 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|28|||Both|70 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 14, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555424||89259|
NCT01555385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UH-SHOK-001|The Effects of Breakfast on Mental Workload|The Effects of Nutritive and Non-nutritive Breakfast on Subjective Mental Workload During Multitasking - a Pilot Study in Healthy Volunteers|AivoPro1|Helsinki University|No|Completed|September 2011|March 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|13|||Both|22 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 5, 2013|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555385||89262|
NCT01555398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-FEN-102|Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of HIP0901 Capsule|Open-label, Randomized Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Fenofibric Acid for HIP0901 Capsule in Healthy Male Subjects||Hanmi Pharmaceutical Company Limited|No|Completed|February 2012|May 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 5, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555398||89261|
NCT01555645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K2010-70X-21412-01-3|Stress Management in Breast Cancer Patients|How Can Health Care Help Female Breastcancer Patients Reduce Their Stress Symptoms? A Randomized Intervention Study With Stepped-care||Uppsala University|Yes|Completed|May 2009|September 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|466|||Female|18 Years|N/A|No|||December 2015|December 3, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01555645||89242|
NCT01555658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BILLION|Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial|Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial|BILLION|University of Roma La Sapienza|Yes|Not yet recruiting|April 2012|October 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|204|||Both|18 Years|N/A|No|||March 2012|March 13, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01555658||89241|
NCT01549704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-UG-11|Effect of Adductor-Canal-Blockade on High Pain Responders After Total Knee Arthroplasty|Effect of Adductor-Canal-Blockade on High Pain Responders the 1. or 2. Postoperative Day After Total Knee Arthroplasty||University Hospital, Gentofte, Copenhagen|Yes|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|30 Years|85 Years|No|||January 2013|January 7, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01549704||89694|
NCT01550003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RA0043|Pediatric Arthritis Study of Certolizumab Pegol|A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)|PASCAL|UCB Pharma|Yes|Active, not recruiting|March 2012|May 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|2 Years|17 Years|No|||January 2016|January 5, 2016|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550003||89672|
NCT01550276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVT001|Treatment of Tension-type Headache With Articulatory and Suboccipital Soft Tissue Therapy|Treatment of Tension-type Headache With Articulatory and Suboccipital Soft Tissue Therapy: a Double-blind, Randomized, Placebo-controlled Clinical Trial||University of Valencia|Yes|Completed|January 2010|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|65 Years|No|||March 2012|March 8, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01550276||89651|
NCT01550289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYD47|Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India|Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India.||Sanofi|Yes|Completed|March 2012|February 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|189|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550289||89650|
NCT01566591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR-BIP-03|Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression|A Prospective, Double Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Conjunction With Mood Stabilizers in Subjects With Bipolar Depression||Brainsway|Yes|Recruiting|May 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|22 Years|68 Years|No|||July 2015|July 26, 2015|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566591||88405|
NCT01566604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2309|Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease|A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease|GLOW7|Novartis||Completed|March 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|460|||Both|40 Years|N/A|No|||July 2014|July 16, 2014|March 27, 2012||No||No|June 3, 2014|https://clinicaltrials.gov/show/NCT01566604||88404|
NCT01566565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Strand|The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension|The Safety Evaluation of Theophylline and Bambuterol When Administered Orally Alone and in Combination to Healthy Volunteers||Norwegian Armed Forces Medical Service|Yes|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566565||88407|
NCT01566838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120104onq|Continuous Subpleural Infusion of Bupivacaine|A Randomized Controlled Trial of Continuous Subpleural Infusion of Bupivacaine After Thoracoscopy||Inova Health Care Services|No|Active, not recruiting|October 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01566838||88386|
NCT01567098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC/KE-12-0051|Single Incision Versus Conventional 3-Port Laparoscopic Appendectomy|Single Incision Versus Conventional 3-Port Laparoscopic Appendectomy: A Single Center Prospective Randomized Trial||Hospital Authority, Hong Kong|No|Not yet recruiting|June 2012|June 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||May 2012|May 28, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01567098||88366|
NCT01567111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T79/2011|11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism|Functional Imaging With 11C-Metomidate Positron Emission Tomography Versus Adrenal Vein Sampling in Differential Diagnosis of Unilateral and Bilateral Aldosterone Secretion in Primary Aldosteronism|MIA|Helsinki University Central Hospital|No|Active, not recruiting|February 2012|December 2019|Anticipated|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|20 Years|65 Years|No|||August 2015|August 17, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567111||88365|
NCT01567709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00715|Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma|Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies||National Cancer Institute (NCI)||Active, not recruiting|April 2012|||December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|February 11, 2016|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01567709||88320|
NCT01568346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-330|Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy|Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy||Dana-Farber Cancer Institute|Yes|Terminated|February 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|348|||Female|18 Years|N/A|No|||March 2013|March 29, 2013|March 29, 2012||No|Slow Accural|No||https://clinicaltrials.gov/show/NCT01568346||88271|
NCT01568333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-Low-dose Decitabine|A Multi-center Study of Low-dose Decitabine for the Treatment of Refractory Immune Thrombocytopenia|A Multi-center Study of Low-dose Decitabine for the Treatment of Refractory Immune Thrombocytopenia||Shandong University|Yes|Recruiting|June 2015|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||September 2015|November 5, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568333||88272|
NCT01568918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006704|Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery|The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery||Mayo Clinic|No|Recruiting|May 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|350|||Both|35 Years|N/A|No|||January 2016|January 7, 2016|March 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568918||88227|
NCT01569191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allergy12|Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis|Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis||Aston University|No|Completed|March 2012|February 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|N/A|No|||June 2013|June 3, 2013|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01569191||88206|
NCT01569204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Targeted BEACOPP|Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma|||University of Cologne|Yes|Active, not recruiting|October 2012|December 2015|Anticipated|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||December 2014|December 16, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01569204||88205|
NCT01578655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OGX-011-12|Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer|A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)|AFFINITY|OncoGenex Technologies|Yes|Active, not recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|630|||Male|N/A|N/A|No|||January 2016|January 14, 2016|April 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578655||87481|
NCT01555125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2308|First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis|FEATURE|Novartis|Yes|Active, not recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|177|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|March 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01555125||89282|
NCT01555437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjyyxhk0306|Assessment of Capsule Endoscopy Scoring Index (CESI), Harvey-Bradshaw Index (HBI) and Biological Markers in Small Bowel Crohn's Disease (SBCD)|Assessment of Capsule Endoscopy Scoring Index, Clinical Disease Activity and Biological Markers in Small Bowel Crohn's Disease||Shanghai Jiao Tong University School of Medicine|No|Completed|October 2008|February 2011|Actual|February 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|58|Samples Without DNA|serum of small bowel Crohn's disease patients|Both|17 Years|80 Years|No|Probability Sample|All patients underwent CE examination (described below), and only those patients for whom        complete CE examination (in which the capsule reached the cecum within the CE test time)        was achieved were retained for study.|November 2013|November 18, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555437||89258|
NCT01555671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-11-11-Rev-1|Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women|Is There Any Effect of Meperidine on the Length of Duration of Labor? A Prospective Randomized Controlled Trial.||Kanuni Sultan Suleyman Training and Research Hospital|Yes|Recruiting|January 2012|January 2013|Anticipated|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|440|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01555671||89240|
NCT01555970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACTOC|Efficacy Study of add-on Therapy With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder|Serotonin Reuptake Inhibitor Augmentation With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder: a Double-blind, Randomized and Controlled Study|NACTOC|University of Sao Paulo|No|Completed|March 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|65 Years|No|||October 2014|October 23, 2014|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01555970||89217|
NCT01550016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|281803 (EU FP7-HEALTH-2011)|International Research Consortium on Dengue Risk Assessment, Management, and Surveillance|Clinical Evaluation of Dengue and Identification of Risk Factors for Severe Disease (WP1)|IDAMS|University of Heidelberg Medical Center|No|Recruiting|October 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7500|Samples With DNA|Blood samples|Both|5 Years|N/A|No|Non-Probability Sample|Febrile patients presenting to outpatient clinic|December 2015|December 1, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550016||89671|
NCT01576523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL830_2001|A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route|An Open-label, Cross-over, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of the Subcutaneous Administration of a Human Plasma-derived C1-esterase Inhibitor in Subjects With Hereditary Angioedema||CSL Behring||Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|18|||Both|18 Years|N/A|No|||June 2014|October 5, 2015|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576523||87644|
NCT01566617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chagas2303|Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease|Impact of The Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial|ChagasCare|Evandro Chagas Institute of Clinical Research|No|Recruiting|October 2012|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Anticipated|88|||Both|18 Years|76 Years|No|||January 2016|January 20, 2016|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01566617||88403|
NCT01566851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01|Application of EULAR Recommendations for Cardiovascular Risk Management in Patients With Rheumatoid Arthritis|Application of EULAR Recommendations for Cardiovascular Risk Management in Patients With Rheumatoid Arthritis in France in the Entire Population of the RSI (Other Branches of the Universal Healthcare Insurance Agency)||Centre Hospitalier Universitaire de Nice|No|Not yet recruiting|May 2012|November 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|7000|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis|March 2012|March 28, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566851||88385|
NCT01567124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|108/12|Alleviating the Metabolic Side Effects of Antipsychotic Medications|A Randomised Trial Examining the Effectiveness of Sympathetic Nervous Inhibition in Alleviating the Metabolic Side Effects of Antipsychotic Medications in Patients With Schizophrenia||Baker IDI Heart and Diabetes Institute|No|Recruiting|May 2012|December 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|65 Years|No|||December 2013|December 16, 2013|March 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567124||88364|
NCT01567137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 2995 07/H0806/85|MR Characterisation/Localisation of Breast Cancer|Using Magnetic Resonance Techniques to Improve the Characterisation and Localisation of Breast Cancer||Institute of Cancer Research, United Kingdom|No|Active, not recruiting|November 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|16|||Female|18 Years|80 Years|No|Probability Sample|Women with confirmed breast cancer|January 2016|January 19, 2016|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567137||88363|
NCT01567449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110011|Risk Factors for Aneurysm Rebleeding|Risk Factors in Predicting Spontaneous Intracranial Aneurysm Rebleeding During Hospitalization||Fujian Medical University|Yes|Recruiting|September 2011|April 2012|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|66|||Both|N/A|N/A|No|Non-Probability Sample|A total of 66 SAH patients were enrolled in this study|March 2012|March 28, 2012|March 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567449||88340|
NCT01567462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00053735|PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors|PK Button Vaporization Electrode for Treatment of Bladder Tumors|PK Button|Emory University|Yes|Recruiting|December 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|160|||Both|18 Years|89 Years|No|||November 2015|November 16, 2015|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567462||88339|
NCT01567995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111187|Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety|Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate Cream in Patients With Eczema for Two Weeks to Evaluate the Efficacy and Safety||GlaxoSmithKline|No|Completed|February 2008|January 2009|Actual|January 2009|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|12 Years|65 Years|No|||March 2012|December 17, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01567995||88298|
NCT01568008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/031|Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|||Allergan|No|Completed|October 2011|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|933|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with POAG or OHT|July 2013|July 18, 2013|March 29, 2012|Yes|Yes||No|July 18, 2013|https://clinicaltrials.gov/show/NCT01568008||88297|
NCT01568021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/RET/007|Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)|||Allergan|No|Completed|October 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with BRVO and CRVO prescribed OZURDEX®|January 2015|January 27, 2015|March 29, 2012|No|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01568021||88296|
NCT01577290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMA|An Internet-administered, Mindfulness Training Program for the Treatment of Anxiety|An Internet-administered, Mindfulness Training Program for the Treatment of Anxiety||Umeå University|No|Recruiting|March 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||April 2012|April 11, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577290||87585|
NCT01577303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Attention training|Treatment of Social Phobia With Cognitive Bias Modification|Reduction of Social Phobia Symptoms With Internet-Based Cognitive Bias Modification||Umeå University|No|Active, not recruiting|April 2012|October 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|128|||Both|18 Years|N/A|No|||January 2013|January 18, 2013|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577303||87584|
NCT01568658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120095|Genetic and Physical Study of Childhood Nerve and Muscle Disorders|Clinical and Molecular Manifestations of Neuromuscular and Neurogenetic Disorders of Childhood||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|5570|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|September 15, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01568658||88247|
NCT01568671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120097|Energy Expenditure Responses to Different Temperatures|Energy Expenditure Responses to Different Temperatures||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01568671||88246|
NCT01568684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120099|Brain Imaging, Genetics and Treatment for Major Depression|Pharmacogenetics and Neuroimaging in Major Depressive Disorder (PAN-D)||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|25 Years|55 Years|No|||December 2012|March 11, 2014|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01568684||88245|
NCT01578122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVE301-10 (Themas) : DCIC/1028|Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome|Evaluation of the Efficacy of Elastic Compression in Preventing Post-thrombotic Syndrome. Randomised Non-inferiority Study for Ankle Pressure Targeted at 25 mm Hg Versus 35 mm Hg|CELEST|Laboratoires Innothera|Yes|Recruiting|June 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||August 2015|September 4, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578122||87522|
NCT01578135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHSGA-1757|French National Registry of Children Born Small for Gestational Age Treated With Somatropin|French National Longitudinal Prospective Follow-up of Children Born Small for Gestational Age and Treated With Norditropin SimpleXx (French Health Authorities Commitment)||Novo Nordisk A/S|No|Active, not recruiting|April 2005|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|N/A|N/A|No|Non-Probability Sample|Phase I: All patients born SGA treated with Norditropin® SimpleXx® (somatropin) whether        they were previously treated with another growth hormone for this indication or not from        the 29th of April 2005 until 29th of April 2010.        Phase II: Sub-population randomly selected (every 5th patient being included in registry        in study phase I).|December 2015|January 22, 2016|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578135||87521|
NCT01578369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240/09B|Effect of Pelvic Floor Muscle Training Included in General Fitness Classes During Pregnacy|Pelvic Floor Muscle Training Included in General Fitness Classes is Effective in Primary Prevention of Urinary Incontince in Pregnancy. A Randomized Controlled Trial||Universidad Politecnica de Madrid|No|Completed|September 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|169|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578369||87503|
NCT01574859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T4-CVR-12|Central Hypothyroidism and Cardiovascular Risk|Central Hypothyroidism and Cardiovascular Risk Factors||Rigshospitalet, Denmark|No|Completed|April 2012|March 2013|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|all patients at Rigshospitalet treated for pituitary hypothyroidism in the years 1993 to        2008|March 2013|March 30, 2013|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01574859||87772|
NCT01574872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEROSAL1|Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis|Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis||Tecno Sun SRL|Yes|Withdrawn|March 2012|April 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||November 2014|November 17, 2014|April 6, 2012||No|Changes in the sponsorship, design and locations of the study|No||https://clinicaltrials.gov/show/NCT01574872||87771|
NCT01548950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0502/11|Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension|Combined Clinical and Surgical Approaches to Congenital Heart Disease Associated With Pulmonary Arterial Hypertension (PAH-CHD)||University of Sao Paulo General Hospital|Yes|Recruiting|September 2011|December 2016|Anticipated|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Months|N/A|No|||June 2015|June 17, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548950||89752|
NCT01549184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCQITP|Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia|Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia Among 40 Patients|HCQITP|Henri Mondor University Hospital|No|Completed|December 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|40 patients with an immune thrombopenia with or without a definite SLE have been        retrospectively studied. All the patients should have an ITP according to the ASH        guidelines 2011 and have positive antinuclear antibodies (title >1/160e on Hep2 cells).|March 2012|March 20, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549184||89734|
NCT01555684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPREC#501|Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients|The Effect of Percutaneous Venoplasty on Muscular Function, Mobility and Fatigue of Multiple Sclerosis (MS) Patients With Chronic Cerebrospinal Venous Insufficiency (CCSVI).||University of Stirling|Yes|Withdrawn|April 2012|December 2012|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||December 2015|December 1, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01555684||89239|
NCT01555697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIMH-R34-MH093453-NS|Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia|Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia|Swerdlow-R34|University of California, San Diego|Yes|Recruiting|July 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|60|||Both|18 Years|45 Years|No|||March 2012|March 14, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01555697||89238|
NCT01555983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|256412-3|Vaporized Cannabis and Spinal Cord Injury Pain|The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury||University of California, Davis|No|Completed|July 2012|August 2014|Actual|August 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|February 9, 2012|Yes|Yes||No|December 3, 2015|https://clinicaltrials.gov/show/NCT01555983||89216|
NCT01550315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111577|Effect of Dietary Sodium Intake on Vascular Endothelium|A Pilot Study of the Effect of Dietary Sodium Intake on Assessments of Vascular Endothelium||Vanderbilt University|No|Recruiting|April 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01550315||89648|
NCT01576796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB11-01|Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer|Phase II Study of the Efficacy and Safety of a Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Identified by F-miso PET/CT in Patients With Stage III Non-small-cell Lung Cancer (NSCLC) Not Amenable to Curative Surgical Resection Who Are Candidate for Curative Radio-chemotherapy|RTEP-5|Centre Henri Becquerel|No|Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||October 2013|June 9, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01576796||87623|
NCT01566864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50HL0105187|Multi-Method Health System Quality Improvement Intervention to Reduce Hypertension Disparities|Multi-Method Health System QI Intervention to Reduce Hypertension Disparities||Johns Hopkins University|Yes|Active, not recruiting|April 2011|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|66570|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01566864||88384|
NCT01566877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7288-us-101|A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers||Sarepta Therapeutics|Yes|Completed|May 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566877||88383|
NCT01567150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5064-W|Wound Fluid Protease Levels During Use of Novel Wound Dressing|Wound Fluid Protease Levels During Use of Novel Wound Dressing||Hollister Incorporated|No|Completed|February 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01567150||88362|
NCT01567163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14434|A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors|A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors||Eli Lilly and Company|No|Completed|July 2012|March 2014|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|March 28, 2012|Yes|Yes||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01567163||88361|
NCT01567475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAD001-R|The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas|A Phase I/II Study Investigating the Combination of RAD001 and Rituximab in Patients With Non-Hodgkin's Lymphomas|(RAD001-R)|The Lymphoma Academic Research Organisation|No|Completed|December 2011|December 2015|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01567475||88338|
NCT01577004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFMNet-1|Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?|Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?||Université de Sherbrooke|Yes|Completed|July 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|50 Years|90 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01577004||87607|
NCT01577017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCOS- Letrozole vs Clomid|The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)|Study On The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)||University of Science Malaysia|Yes|Completed|May 2008|March 2012|Actual|May 2009|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Female|19 Years|39 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01577017||87606|
NCT01578148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT-01-2012|Noxipoint Therapy Versus Standard Physical Therapy Using Electrical Stimulation for Chronic Pain|Noxipoint Therapy vs. Standard Physical Therapy Using Electrical Stimulation for Chronic Pain||Pain Cure Center, California|Yes|Completed|April 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|64 Years|No|||April 2013|April 23, 2013|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578148||87520|
NCT01577836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOI/2011/SD-03|Medico-economic Comparison of Robot-assisted Radical Prostatectomy Versus Radical Prostatectomy Via Laparotomy|Medico-economic Comparison of Robot-assisted Radical Prostatectomy Using the da Vinci System Versus Radical Prostatectomy Via Laparotomy|RoboProstate|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|November 2012|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|90|||Male|45 Years|75 Years|No|Non-Probability Sample|Men between the ages of 45 and 75 and who have been diagnosed with localised prostate        cancer. The treatment option retained is radical prostatectomy.|October 2015|October 30, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01577836||87544|
NCT01578668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZTO1201|Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases|Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases||Guangzhou Medical University|Yes|Completed|January 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|N/A|No|||January 2015|January 23, 2015|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578668||87480|
NCT01574560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009NTLS058|P60 Program Project Grant-Outreach for Smoke-Free Homes|Community Outreach and Biomarker Feedback for Smoke-Free Homes||University of Minnesota - Clinical and Translational Science Institute|No|Completed|January 2011|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|212|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 5, 2014|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01574560||87795|
NCT01548963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eMPC_long|Perioperative Versus Postoperative Glycemia Control in Cardiac Surgery Patients|Perioperative Versus Postoperative Glycemia Control in Cardiac Surgery Patients||Charles University, Czech Republic|No|Completed|January 2007|June 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2384|||Both|18 Years|90 Years|No|||May 2015|May 15, 2015|February 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01548963||89751|
NCT01549197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM10104|Quality of Dying in the Intensive Care Unit: Validation of the CAESAR Scale|End-of-life in French Intensive Care Units: Perception of the Quality of Dying and Experience of Physicians, Nurses and Relatives. Validation of the CAESAR Scale|CAESAR|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|475|||Both|18 Years|N/A|No|Non-Probability Sample|Physicians and nurses in charged of ICU deceased patients Bereaved relatives of ICU        patients|November 2012|November 19, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549197||89733|
NCT01549210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIR-2011\OSS001|Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of Life|Multicentre Prospective Observational Study for Identification of Determinants of Disability and Quality of Life in Patients With Gout.|KING|Italian Society for Rheumatology|Yes|Completed|April 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Both|18 Years|N/A|No|Probability Sample|Patients referring to rheumatologic clinics|March 2013|March 9, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549210||89732|
NCT01549444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Renin HIT study-01|Renin and Aldosterone Levels in the Preterm Neonate At Risk for Hypertension|Renin and Aldosterone Levels in the Preterm Neonate At Risk for Hypertension (RENAL HIT Study)||Ottawa Hospital Research Institute|No|Completed|March 2012|October 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|76|Samples Without DNA|Serum samples for Renin and Alsosterone, to be discarded when study is complete.|Both|26 Weeks|34 Weeks|No|Non-Probability Sample|Babies born between 26 and 34 weeks gestation|October 2015|October 21, 2015|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01549444||89714|
NCT01549431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00049368|Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma|A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma||Emory University|Yes|Active, not recruiting|January 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|March 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01549431||89715|
NCT01549717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0526|Feasibility And Efficacy Of Continuous In-Hospital Patient Monitoring|Feasibility And Efficacy Of Continuous In-Hospital Patient Monitoring|LISTEN|Guy's and St Thomas' NHS Foundation Trust|No|Completed|December 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|300|||Both|18 Years|N/A|No|||February 2014|February 11, 2014|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01549717||89693|
NCT01550055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMAB009mCRCⅡ/Ⅲ|Study of Cetuximab to Treat KRAS Wild Type Metastatic Colorectal Cancer|Phase II/III Trial of Cetuximab Plus Irinotecan Synchronously/Subsequently in Patients With KRAS Wild-type Metastatic Colorectal Cancer: an Randomized, Open-label, Multicenter, Prospective Study|CRC009|Shanghai Zhangjiang Biotechnology Limited Company|Yes|Completed|March 2009|December 2015|Actual|December 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|512|||Both|18 Years|70 Years|No|||December 2015|December 20, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550055||89668|
NCT01577368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PiperTazo|Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa|Efficacy and Safety of Piperacillin-Tazobactam Continuous Infusion vs Intermittent Infusion for Complicated or Nosocomial Pseudomonas Aeruginosa Infection or Suspected Infection|PiperTazo|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Completed|May 2011|August 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||September 2014|September 19, 2014|May 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577368||87579|
NCT01575912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00047-36|Past Pain Experience and Perception of Experimental Pain|Past Pain Experience and Perception of Experimental Pain||Centre Hospitalier Esquirol|No|Completed|March 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects hospitalized in the Esquirol Hospital center with schizophrenia or major        depression according to the DSM-IV-TR criteria.        Subjects without without known psychiatric history. Recruited persons will be matched        according to age classes.|May 2014|May 13, 2014|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01575912||87691|
NCT01575925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-008|Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiply Myeloma and Impaired Renal Function (POM Renal)|A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function|POM Renal|Celgene|No|Recruiting|June 2012|June 2020|Anticipated|June 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|April 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575925||87690|
NCT01576211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B6|Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor|Investigating the Frequency of Loss of Imprinting Across a Birth Cohort and the Link DNA Methylation Plays||Children's Oncology Group|No|Active, not recruiting|April 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|40|Samples With DNA|blood and tissue|Both|N/A|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients registered on Children's Oncology Group Wilms tumor protocols|May 2015|May 6, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01576211||87668|
NCT01576497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0018|Optimal Number of To-and-fro Motion in EUS-guided Fine Needle Aspiration for Pancreatic Masses|Optimal Number of To-and-fro Motion in EUS-guided Fine Needle Aspiration for Pancreatic Masses in Terms of Suction or Without Suction: Prospective Randomized Single Blinded Trial||Asan Medical Center|No|Completed|April 2012|March 2013|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|193|||Both|18 Years|85 Years|No|||April 2012|May 28, 2014|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01576497||87646|
NCT01576510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01MH072833-04A2|fMRI Predictors of Treatment Response in Posttraumatic Stress Disorder (PTSD)|Brain Circuitry and Psychosocial Predictors of PTSD||Research Foundation for Mental Hygiene, Inc.|No|Completed|August 2010|June 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|95|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2014|June 23, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576510||87645|
NCT01576770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0042|In Children, Does Using a Synera Patch Decrease Pain When Injecting Propofol at Anesthesia Induction?|In Children, Does the Use of Synera Patch for Local Analgesia Before Vascular Access Reduce Pain Associated With Propofol Injection for Anesthesia Induction?|Synera patch|The University of Texas Health Science Center, Houston|No|Recruiting|April 2012|January 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|6 Years|17 Years|No|||April 2012|April 11, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01576770||87625|
NCT01578395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR: 2010-0352|Impact of Antioxidant Agents on the Number of DNA Double-strand Breaks After Radiation-based Cardiac Examinations|Randomized, Double-blinded, Placebo-controlled, Single Center, and Prospective Phase II Clinical Trial to Analyze the Effects of Antioxidant Agents on DNA Double-strand Breaks in Patients After Radiation-based Cardiac Examinations||University of Zurich|Yes|Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|102|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 5, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578395||87501|
NCT01578382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR2010-0433/0|Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)|Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU): A Comparison of Martorell HYTILU, Calciphylaxis and Venous Ulcer (Control)||University of Zurich|No|Recruiting|September 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|50|Samples With DNA|Blood serum (2 tubes); blood plasma in citrate (2 tubes); blood plasma in heparin (2 tubes)      Diseased skin tissue in formalin for paraffin embedded H-E histology; Diseased skin tissue      snap frozen Diseased skin tissue in "RNA later" tube (1 tube)|Both|20 Years|90 Years|No|Probability Sample|n=20: Having Martorell hypertensive ischemic leg ulcer (as defined above) or n=10: Having        Calciphylaxis (calcific uremic arteriolopathy (as defined above) or n=20: Having a venous        ulcer (as defined above) (controls)|December 2015|December 1, 2015|May 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01578382||87502|
NCT01574885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEROSAL3|Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases|Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases||Tecno Sun SRL|Yes|Terminated|February 2012|April 2013|Anticipated|February 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|4 Years|12 Years|No|||November 2012|November 7, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01574885||87770|
NCT01574898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00474 PC 1 01|Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations|Pilot Pharmacokinetic Study of Three New Nicotine Lozenge Formulations (V0474) Versus Two Reference Formulations (V0018 B mg and Niquitin® Fresh Mint, 4mg) After Single Oral Administration in Healthy Male Smokers.||Pierre Fabre Medicament||Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|13|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 6, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01574898||87769|
NCT01575171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01287|Using Nudges to Implement Comparative Effectiveness|Using Nudges to Implement Comparative Effectiveness: Behavioral Economics and Statins||New York University School of Medicine|Yes|Completed|September 2010|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|19|||Both|18 Years|N/A|No|Non-Probability Sample|Doctors in a large multi-specialty private practice|July 2015|July 31, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01575171||87748|
NCT01548664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-02|The Utilization of Nintendo Wii™ in Outpatient Rehabilitation Following Total Knee Replacement|The Utilization of Nintendo Wii™ in Outpatient Rehabilitation Following Total Knee Replacement||St. John's Rehab Hospital|No|Completed|May 2009|September 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|16 Years|90 Years|No|||February 2014|February 25, 2014|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548664||89774|
NCT01548677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-90091-10093|Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer|TRastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("TREAT CTC" Trial)|TREAT-CTC|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|April 2013|December 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2175|||Female|18 Years|N/A|No|||November 2015|November 6, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01548677||89773|
NCT01548976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/BF-01|Validation of a French Version of the PISQ-R|Validation of a French Version of the PISQ-R: a Tool for Evaluating the Sexuality of Patients With Urinary Incontinence or Pelvic Organ Prolapse||Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Female|18 Years|N/A|No|Non-Probability Sample|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal        incontinence.|March 2015|March 25, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01548976||89750|
NCT01548989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/BF-02|Validation of a New Sexuality Questionnaire for Patients With Urinary Incontinence or Pelvic Organ Prolapse|Validation of a New Sexuality Questionnaire: a Tool for Evaluating the Sexuality of Patients With Urinary Incontinence or Pelvic Organ Prolapse||Centre Hospitalier Universitaire de Nīmes|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|||Female|18 Years|N/A|No|Non-Probability Sample|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal        incontinence.|March 2015|March 25, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01548989||89749|
NCT01549223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002284|Oxytocin And Uterotonic Agent Use For Cesarean Delivery|A Randomized Controlled Trial of Standardized Versus Conventional Oxytocin and Uterotonic Agent Use for Cesarean Delivery||Brigham and Women's Hospital|No|Completed|April 2011|January 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|50 Years|No|||January 2015|January 2, 2015|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01549223||89731|
NCT01549730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 11-0026-C|Cervix Hypoxia FAZA|A Feasibility Study of Hypoxia Imaging in Patients With Cervix Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)||University Health Network, Toronto|Yes|Recruiting|May 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01549730||89692|
NCT01549743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-CER-101|The Pharmacokinetic Interaction Between Celecoxib and Rebamipide|Clinical Trial to Assess the Pharmacokinetic Interaction Between Celecoxib and Rebamipide in Healthy Male Volunteers||Hanlim Pharm. Co., Ltd.||Not yet recruiting|May 2012|August 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2012|March 8, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01549743||89691|
NCT01550029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-09-14-02|Targeted Intervention for Bipolar Smokers|Targeted Intervention for Bipolar Smokers||University of Cincinnati|Yes|Active, not recruiting|July 2010|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2014|January 3, 2014|April 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01550029||89670|
NCT01550042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL36491.044.11|Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients|Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients|SCARF|Medisch Spectrum Twente|Yes|Recruiting|September 2011|September 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted with a ischemic stroke of undetermined etiology|April 2012|April 20, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550042||89669|
NCT01550341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011007631|HIV, Buprenorphine, and the Criminal Justice System|HIV, Buprenorphine, and the Criminal Justice System|STRIDE|Yale University|Yes|Active, not recruiting|April 2012|June 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550341||89646|
NCT01577381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1181003|Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration|A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration||Pfizer|Yes|Terminated|August 2012|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|60 Years|90 Years|No|||February 2016|February 16, 2016|April 11, 2012|Yes|Yes|See termination reason in detailed description.|No|December 9, 2015|https://clinicaltrials.gov/show/NCT01577381||87578|The study was terminated early due to an organizational decision, which was not based on safety or efficacy concerns. As only 10 participants enrolled at the time of termination, there were not enough subjects or data to perform meaningful analyses.
NCT01576783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|183210|Omega Tots: A Pilot Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes|Omega Tots: A Pilot Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes||Nationwide Children's Hospital|No|Enrolling by invitation|April 2012|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|232|||Both|10 Months|16 Months|No|||March 2015|March 11, 2015|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576783||87624|
NCT01577030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LH002|Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness|Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness||University of Texas at Austin|No|Completed|January 2012|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|35 Years|80 Years|No|||February 2014|February 10, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01577030||87605|
NCT01577043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protracec2011|Efficacy of Racecadotril in Acute Watery Diarrhea in Children|Efficacy of Racecadotril in the Management of Acute Watery Diarrhea in Children||Centro Pediatrico Albina de Patino|No|Completed|September 2011|April 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|6 Months|59 Months|No|||June 2011|April 12, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577043||87604|
NCT01577316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI 1059_1170|Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women|Clinical Trial to Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women|VACINFL2011|Instituto Nacional de Salud Publica, Mexico|Yes|Not yet recruiting|April 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Female|18 Years|39 Years|No|||April 2012|April 12, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577316||87583|
NCT01577329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|um-nursing-meditation|Mindfulness Mediation Intervention in Chronic Obstructive Pulmonary Disease (COPD)|Mindfulness Mediation Intervention in COPD||University of Michigan|No|Recruiting|October 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|56|||Both|40 Years|N/A|No|||April 2012|April 12, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577329||87582|
NCT01577862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM7X9F8K|Colistin and Rifampicin for MDR-Acinetobacter|Randomised, Open-Label Clinical Trial on The Efficacy of Colistin Plus Rifampicin Treatment Versus Colistin Alone for Severe Infections Due to Multidrug-Resistant Acinetobacter Baumannii|CoRAb|Second University of Naples|Yes|Completed|November 2008|October 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Both|18 Years|N/A|No|||April 2012|April 12, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01577862||87542|
NCT01577875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI_Zoom_CVS_01|Comparison of Narrow Band Imaging With or Without Magnifying Colonoscopy|A Prospective Clinical Study to Evaluate Narrow Band Imaging and Magnifying Colonoscopy for the Histologic Prediction of Colorectal Polyps||Seoul National University Hospital|Yes|Completed|April 2012|March 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|122|||Both|18 Years|N/A|No|||April 2012|November 18, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01577875||87541|
NCT01577576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/APM-01|Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes|Morphological, Biomechanical and Functional Properties of the Arterial Wall of Athletes: Impact and Consequences of Mechanical Stress on the Cardiovascular Adaptations of Peripheral Arterial Calcifications|MediaSport|Centre Hospitalier Universitaire de Nīmes|No|Terminated|September 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|56|Samples Without DNA|A non-fasting venous blood sample is required for the following cofactors:        -  serum protein        -  serum calcium        -  phosphorus        -  PTH        -  Vitamin D2 and D3      Left-over serum will be stored in the Nîmes University Hospital "Sérotheque" (serum      collection).|Both|25 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study population is composed of three groups of healthy volunteers: (1) high impact        lower-limb sports (marathon or trail); (2) low-impact lower-limb sports and (3) sedentary        volunteers. All volunteers are between the ages of 25 and 40.        The groups will be matched by age and sex. Athletic groups will be matched according to        years of intensive practice and hours of training.|November 2015|November 27, 2015|April 12, 2012||No|Inclusion curve too slow.|No||https://clinicaltrials.gov/show/NCT01577576||87563|
NCT01577849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR206-02|Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers|Randomized, Open-label Crossover Study to Evaluate Comparative Pharmacokinetics of Vitamin D3 Between DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 Tablet) and a 24,000 IU Vitamin D3 in Healthy Adult Volunteers||Alvogen Korea|No|Enrolling by invitation|March 2012|October 2012|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|36|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01577849||87543|
NCT01578681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/10|ELTGOL and Bronchiectasis. Respiratory Therapy|Multicenter Randomized Placebo-controlled Trial to Evaluate the Efficacy of the ELTGOL Technique in the Drainage of Secretions in Patients With Bronchiectasis|ELTGOLBQ|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|No|Active, not recruiting|September 2011|December 2016|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|95 Years|No|||September 2015|September 21, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578681||87479|
NCT01575184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMC 2011-04-004-001|Effect of Shoulder Traction on Size and Relative Position of Internal Jugular Vein to Carotid Artery|Effect of Shoulder Position and Head Rotation on Size and Relative Position of Internal Jugular Vein to Carotid Artery in Infants and Children||Samsung Medical Center|Yes|Recruiting|August 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|25|||Both|1 Month|12 Months|No|||April 2012|April 12, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575184||87747|
NCT01575457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00017226|Harriet Lane Healthy Futures Program|The Harriet Lane Clinic Healthy Futures Program is to Increase Academic or Workforce Development Success Among Adolescents and Young Adults|HF|Johns Hopkins University|No|Completed|June 2009|December 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|202|||Both|14 Years|21 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01575457||87726|
NCT01549002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI0699|Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children|Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children||Columbia University|Yes|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|4 Years|18 Years|No|||August 2015|August 20, 2015|February 2, 2012||No||No|February 2, 2015|https://clinicaltrials.gov/show/NCT01549002||89748|
NCT01549236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNDi-CD-PEDBZ-001|Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease|Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease|Pop PK Chagas|Drugs for Neglected Diseases|No|Active, not recruiting|May 2011|October 2012|Anticipated|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|12 Years|No|||August 2012|August 27, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01549236||89730|
NCT01549470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 156|Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed||March 2006|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|31|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2012|March 12, 2012|March 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01549470||89712|
NCT01549457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02216|TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment|The Effect of Weekly Text-message Communication on Treatment Completion Among Patients With Latent Tuberculosis Infection: a Randomised Controlled Trial (WelTel LTBI)||University of British Columbia|No|Active, not recruiting|April 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|350|||Both|19 Years|N/A|No|||October 2015|October 7, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549457||89713|
NCT01549756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|facpsc1001|Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers|Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers||Find A Cure Panel|No|Recruiting|March 2012|||April 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|30|||Both|22 Years|N/A|No|Non-Probability Sample|stage 4 stomach cancer patients and caregivers|March 2012|March 8, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01549756||89690|
NCT01549769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1102|Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes|A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes||Reata Pharmaceuticals, Inc.||Terminated|April 2012|October 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2014|April 28, 2014|March 6, 2012|Yes|Yes|IDMC recommendation for safety concerns|No||https://clinicaltrials.gov/show/NCT01549769||89689|
NCT01550081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2632|Target Heart Rate and Aerobic Interval Training|Exercise Intensity and Target Heart Rate During Aerobic Interval Training in Cardiac Rehabilitation||Norwegian University of Science and Technology|No|Completed|March 2012|June 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|10|||Both|18 Years|85 Years|No|||November 2013|November 27, 2013|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550081||89666|
NCT01550354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0824|Comparison Among Propofol, Alfentanil and Rocuronium as Adjunct to Sevoflurane Anesthesia for Endotracheal Intubation in Children With Frenectomy|||Yonsei University|Yes|Completed|February 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|3||Actual|114|||Both|1 Year|9 Years|No|||February 2014|February 4, 2014|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01550354||89645|
NCT01550588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0553|Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO)|Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO||CardioVascular Research Foundation, Korea|Yes|Recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|210|||Both|18 Years|80 Years|No|||August 2012|August 8, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01550588||89627|
NCT01577628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRP11005|Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis|Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis||Cosmetique Active International|No|Terminated|June 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2|||Female|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 10, 2012||No|Sponsor Decision|No|February 23, 2016|https://clinicaltrials.gov/show/NCT01577628||87559|
NCT01577056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1028883|Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils|Effect of Fish Oil Supplementation on Postprandial Lipid Metabolism in Familial Hypercholesterolaemia|FIFH|The University of Western Australia|No|Not yet recruiting|April 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|70 Years|No|||April 2012|April 11, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01577056||87603|
NCT01577069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDPS-100211|Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir|Predictive Factors of the Treatment Failure in HCV Mono-infected Patients Treated With Pegylated-interferon/Ribavirin/Telaprevir.|GENUPI|Association HGE CHU Bordeaux Sud|No|Completed|February 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|73|||Both|18 Years|N/A|No|Non-Probability Sample|HCV mono-infected patients treated in the Hepatology Unit of Pr Victor de Lédinghen        (Hôpital du Haut-Lévêque, Pessac)|July 2015|July 29, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577069||87602|
NCT01577342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-10-458|Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora|Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora||Lawson Health Research Institute|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|56|||Both|60 Years|N/A|No|||April 2012|April 12, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577342||87581|
NCT01577355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14484|A Study of LY2784544 in Healthy Male Subjects|Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects||Eli Lilly and Company|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01577355||87580|
NCT01577589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00015|A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects|A Phase I, Single-center, 2-part, Randomized, 2-way Crossover Study to Assess the Local Tolerability and Safety (Multiple-dose) and to Assess the Pharmacokinetics, Safety, and Tolerability (Single-dose) of Ceftaroline in Healthy Subjects When Ceftaroline Fosamil is Diluted in Various Infusion Volume||AstraZeneca||Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|6||Actual|34|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 9, 2014|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01577589||87562|
NCT01578694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007231-01H|Characterization of Proteoglycan Depletion in Femoroacetabular Impingement With T1ρ Magnetic Resonance Imaging (MRI)|Characterization of Proteoglycan Depletion in Femoroacetabular Impingement With T1ρ MRI||Ottawa Hospital Research Institute|No|Completed|July 2007|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|26|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2014|February 7, 2014|August 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01578694||87478|
NCT01578161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_01|The Effect of Dexmedetomidine on Emergence Agitation in Children Undergoing a Surgery Under Desflurane Anesthesia|The Effect of Dexmedetomidine on Emergence Agitation in Children Undergoing a Surgery Under Desflurane Anesthesia||Seoul National University Hospital|No|Recruiting|January 2012|April 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|116|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578161||87519|
NCT01578174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0928|The Effect of Dexmedetomidine in the Management of Pain After Uterine Artery Embolization|||Severance Hospital|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|66|||Female|20 Years|N/A|No|||October 2012|October 31, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578174||87518|
NCT01574573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0054|Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study|Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study||Midwest Biomedical Research Foundation|No|Terminated|June 2009|December 2018|Anticipated|September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|April 6, 2012||No|Closed due to lack of recruitment|No||https://clinicaltrials.gov/show/NCT01574573||87794|
NCT01574911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8834|Validation of a New Method of Limb Volumetry|Development and Validation of a Limb Volumetry Technique Applicable in Daily Clinical Practice Using Self Positioning 3D Laser Scanning:Reproductibility and Comparison to the Reference Method||University Hospital, Montpellier|Yes|Recruiting|April 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|90|None Retained|Validation study an innovative non-invasive diagnostic technique. Biomedical research      conducted with the help of Montpellier University Hospital Clinical Investigation Center      (CIC) for the recruitment of healthy controls, and vascular Medicine clinics for the      recruitment of patients with chronic venous insufficiency or lymphedema|Both|10 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Recruitment of healthy controls and vascular Medicine clinics for the recruitment of        patients with chronic venous insufficiency or lymphedema|April 2012|April 19, 2012|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574911||87768|
NCT01575197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHANA-HRV-01|Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana|Immunogenicity of the Human Rotavirus Vaccine (Rotarix™) at Varying Schedules, Doses, and Ages in Rural Ghana||PATH||Completed|September 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|456|||Both|42 Days|55 Days|Accepts Healthy Volunteers|||April 2015|May 13, 2015|April 6, 2012||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01575197||87746|
NCT01575210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA210212|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2012|||||N/A|N/A|N/A||||||||||||||November 25, 2013|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575210||87745|
NCT01575470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0477|Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells|Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells||The University of Texas Health Science Center, Houston|Yes|Completed|March 2012|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|55 Years|No|||December 2015|December 9, 2015|April 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575470||87725|
NCT01575483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-171|Korean Post-marketing Surveillance for Onglyza®|Korean Post-marketing Surveillance for Onglyza®||Bristol-Myers Squibb|No|Recruiting|March 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|3900|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diagnosis of type 2 diabetes mellitus initiating Onglyza® treatment within        the approved indications will be enrolled|November 2015|November 19, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575483||87724|
NCT01576016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60028820|Safety and Efficacy of the Accent Magnetic Resonance Imaging™ (MRI) Pacemaker and Tendril MRI™ Lead|Accent Magnetic Resonance Imaging Pacemaker and Tendril Magnetic Resonance Imaging™ Lead Investigational Device Exemption Study||St. Jude Medical|No|Active, not recruiting|March 2012|June 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|N/A|N/A|No|||March 2015|March 23, 2015|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01576016||87683|
NCT01549249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KyorinEye007|Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery|Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery||Kyorin University|No|Completed|June 2008|November 2011|Actual|November 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|333|||Both|40 Years|90 Years|No|||November 2012|November 12, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549249||89729|
NCT01549262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1009-C-088-IR|Clinical Validation of Embryo Cinematography|Clinical Validation of Embryo Culture and Selection by Morphokinetic Analysis; a Randomized Controlled Trial by Time-lapse System||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|February 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|843|||Female|18 Years|38 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01549262||89728|
NCT01549483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABHR001|Small Airways Disease in Asymptomatic and Symptomatic Subjects With Airway Hyperresponsiveness (AHR)|Differences in Small Airways Disease Between Asymptomatic and Symptomatic Subjects With Airway Hyperresponsiveness|ABHR|University Medical Center Groningen|No|Completed|May 2012|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|Samples With DNA|Nasal epithelium brushes for mRNA expression|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Out-patient clinic|January 2015|January 15, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549483||89711|
NCT01549496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHRI-BCP-CCB-2012|A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers|A Drug Interaction Study Investigating the Effect of Boceprevir on the Pharmacokinetics of the Calcium Channel Blockers Amlodipine and Diltiazem and Vice Versa in Healthy Volunteers||Ottawa Hospital Research Institute|No|Withdrawn|May 2012|||September 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 7, 2015|March 1, 2012||No|Investigator left this hospital|No||https://clinicaltrials.gov/show/NCT01549496||89710|
NCT01549795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2372P|Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy|Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante||Azienda Ospedaliera di Padova|Yes|Recruiting|January 2012|||July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|65 Years|No|||July 2012|July 17, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01549795||89687|
NCT01549782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prebiotic2005|Mixture of Prebiotics on Intestinal Microbiota of Patients Receiving Abdominal Radiotherapy.|Effect of a Mixture of Inulin and Fructo-oligosaccharide on Lactobacillus and Bifidobacterium Intestinal Microbiota of Patients Receiving Radiotherapy: a Randomised, Double-blind, Placebo-controlled Trial.||Hospital General Universitario Gregorio Marañon|No|Completed|June 2005|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|40|||Female|18 Years|N/A|No|||March 2012|March 8, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01549782||89688|
NCT01550068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|018/12|Rheumatic Heart Disease School Project|A Population-Based Study of Prevalence of Rheumatic Heart Disease and Cardiovascular Outcomes Among Schoolchildren in Nepal||University Hospital Inselspital, Berne|No|Active, not recruiting|December 2012|March 2019|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|5476|||Both|5 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Schoolchildren aged 5-15 years from public and private school in urban and rural areas in        Southeast Nepal|September 2015|September 29, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550068||89667|
NCT01550367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCI 11-080|Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)|Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study||University of Pittsburgh|Yes|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||May 2015|October 2, 2015|February 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550367||89644|
NCT01550380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI47841|BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers|A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers|BKM120|University of Utah|Yes|Withdrawn|May 2014|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||July 2014|July 28, 2014|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550380||89643|
NCT01577667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Intellivent RCT1|Intellivent Versus Conventional Ventilation|Comparative Monocenter RCT Comparing Safety and Efficacy of an Automated Closed-loop Oxygenation and Ventilation(IntelliVent® System - HAMILTON MEDICAL AG) With Non-automated Conventional Ventilation and Oxygenation|Intellivent|Hamilton Medical AG|Yes|Completed|February 2011|June 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|80|||Both|18 Years|90 Years|No|||December 2012|December 5, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577667||87557|
NCT01577940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM1-PLP-11|Method Study: Bilateral TAP Block With 24 Hours Infusion|Method Study of Bilateral Transversus Abdominis Plane (TAP) Block With 24 Hours Infusion. Extent of Sensory Block, Analgetic Effect and Lung Function in Healthy Volunteers||Glostrup University Hospital, Copenhagen|Yes|Completed|January 2011|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01577940||87536|
NCT01577602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-667|Standard Medication Reconciliation Protocol in the Primary Care Office-based Setting|Standard Medication Reconciliation Protocol in the Primary Care Office-based Setting: A Focused Investigation of Two Interventions||The Cleveland Clinic|No|Completed|October 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|424|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 13, 2013|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01577602||87561|
NCT01577888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD-0047|Safety and Feasibility Study of the Shockwave Lithoplasty System|Safety and Feasibility Study of the Shockwave Lithoplasty System||Shockwave Medical, Inc.|Yes|Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||August 2014|August 6, 2014|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01577888||87540|
NCT01578187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR6-LCU|Hair2Go Label Comprehension and Usability Study|Evaluating Label Comprehension and Usability of the Hair2Go System|OHR6-LCU|Syneron Medical|Yes|Completed|March 2012|June 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|63|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 27, 2013|April 13, 2012|Yes|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01578187||87517|
NCT01578408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Corail-SP Study|Cemented Versus Uncemented Stems in Total Hip Arthroplasty in Patients With Femoral Neck Fractures|Corail-SP Study - A Prospective Randomized Comparison Between Cemented and Uncemented Hydroxyapatite Coated Prosthesis Stems in Total Hip Arthroplasty in Patients With Femoral Neck Fractures||Sahlgrenska University Hospital, Sweden|No|Recruiting|May 2010|December 2023|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|85 Years|No|||May 2015|May 28, 2015|April 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578408||87500|
NCT01578421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD-FX-01-CH|Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser|Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser||Kantonsspital Aarau|No|Completed|February 2012|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||August 2013|August 6, 2013|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578421||87499|
NCT01578707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCYC-1112-CA|A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|RESONATE™|Pharmacyclics|Yes|Active, not recruiting|June 2012|December 2017|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|391|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|April 11, 2012|Yes|Yes||No|June 23, 2015|https://clinicaltrials.gov/show/NCT01578707||87477|
NCT01578720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB-001|Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome|Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)||Retina Research Institute, LLC|No|Active, not recruiting|June 2012|December 2015|Anticipated|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|21 Years|N/A|No|||July 2015|July 24, 2015|April 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578720||87476|
NCT01574586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEGIN12|Bifurcation Stenting Using 2 Link Stent Nobori Versus 3 Link Stent Xience|A Multicenter, Randomized Trial to Compare 2 Link Nobori and 3 Link Xience Stents in Bifurcation Stenting|BEGIN|Kurashiki Central Hospital||Active, not recruiting|April 2012|June 2015|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|20 Years|N/A|No|||April 2015|April 6, 2015|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574586||87793|
NCT01574924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERINT-01|Personality Change During Medical Residency|Personality Change During Medical Residency Across Different Medical Specialties||University of Coimbra|Yes|Not yet recruiting|April 2012|||October 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|600|||Both|23 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|All portuguese medical (first year) residents will be invited to participate in the study        (target population).        Targeted enrollment stategies will be used to recruit participants (individual invitation        emails). Also, the study will be disclosed in some social networks. The research team has        created a proper email account (personalidade.internato@gmail.com) to answer any questions        and to change email with the participants of the study.        To those who accepted and consent to participate (study population), it will be send the        online link to create a confidential account and access (and to give answers to the        questionnaires).|April 2012|April 12, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01574924||87767|
NCT01575730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/237|Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis|Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer||University Hospital, Ghent|Yes|Recruiting|June 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|24|||Both|18 Years|75 Years|No|||December 2014|December 4, 2014|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01575730||87705|
NCT01575743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Burnout_1|Effects of Aerobic Exercise on Occupational Burnout|Effects of Aerobic Exercise on Occupational Burnout||University Hospital, Basel, Switzerland|No|Completed|March 2008|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 10, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01575743||87704|
NCT01576029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAZ_L_05933|Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer|Phase II Randomized Study of Continuing Treatment With Docetaxel Versus Switching to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in the First Line Treatment of Patients With Castration-Resistant Metastatic Prostate Cancer.|SWITCH|Sanofi|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Male|18 Years|N/A|No|||December 2013|December 23, 2013|March 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01576029||87682|
NCT01575509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAVI|A Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects|A Clinical, Randomized, Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects||Clinical Life Sciences Ltd.|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|14|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|June 14, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575509||87722|
NCT01549028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-2225A3|Osteoporosis in Chronic Obstructive Pulmonary Disease (COPD)|The Prevalence, Correlations and Effectiveness of Intervention of Osteoporosis in COPD Patients||Chang Gung Memorial Hospital|No|Recruiting|September 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|90 Years|No|||March 2012|March 7, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549028||89746|
NCT01549275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|990043|Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration|Kaohsiung Medical University Hospital||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|April 2010|July 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|105|Samples With DNA|cancer cells and cancer-associated fibroblasts|Both|20 Years|90 Years|No|Non-Probability Sample|patients with hepatic tumor measuring larger than or equal to 3 cm underwent fine-needle        aspiration of tumor for diagnosis.|July 2013|September 7, 2015|February 7, 2012||No||No|July 15, 2013|https://clinicaltrials.gov/show/NCT01549275||89727|
NCT01549509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV 156A|Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP Administered Alone or Administered as a Boost to a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|April 2007|October 2009|Actual|April 2008|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|18|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|March 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01549509||89709|
NCT01549522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|facplc1001|Qualitative Research for Stage 4 Liver Cancer Patients and Their Caregivers|Phase 1 0 Qualitative Research for Stage 4 Liver Cancer Patients and Their Caregivers.||Find A Cure Panel|No|Recruiting|March 2012|||April 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|30|||Both|22 Years|N/A|No|Non-Probability Sample|liver cancer stage 4 patients and caregivers|March 2012|March 8, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01549522||89708|
NCT01550094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.191.B|A Comparison of Two Injection Locations in Obese Patients Having Lower Leg/Foot Surgery|Evaluation of Ultrasound-Guided Popliteal Sciatic Nerve Blockade in the Severely and Morbidly Obese Populations||Ochsner Health System|No|Completed|March 2012|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Severely and morbidly obese patients scheduled for foot or ankle surgery.|October 2015|October 13, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550094||89665|
NCT01550107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEO006|Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'|A Prospective Study to Evaluate the Effect of Allopurinol on Muscle Energetics in Primary Sarcopenia||University of Dundee|No|Enrolling by invitation|December 2014|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|65 Years|N/A|No|||December 2015|December 1, 2015|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01550107||89664|
NCT01550627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2127-10/09|Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy|Study of Possible Effects of Intravenous Fluid Supplementation on Serum Bilirubin Levels and Cardiorespiratory Parameters in Preterm Infants During Phototherapy||University of Jena|Yes|Completed|November 2007|June 2009|Actual|June 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|N/A|1 Week|No|||March 2012|March 9, 2012|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550627||89624|
NCT01551186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201106182|The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria|The Use of the Probiotic, Lactobacillus Rhamnosus GG to Evaluate Colonization With Antimicrobial Resistant Bacteria in High Risk Patients||Washington University School of Medicine|No|Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|104|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01551186||89583|
NCT01577953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB010/03/2011|Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma|Phase-Ib Study in Male Patients With Stable Allergic Asthma With Airway Hyperresponsiveness to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation - A Randomised, Double-blind, Placebo-controlled, Parallel-group (Per Dose Level) Dose-escalation Study in Asthmatic Patients||Sterna Biologicals GmbH & Co. KG|Yes|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|45 Years|No|||November 2012|April 28, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577953||87535|
NCT01577966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB 1108|Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma|A Pilot Study to Determine the Effect of Sulfasalazine on Glutamate Levels Detected by Magnetic Resonance Spectroscopy(MRS) in Patients With Glioma||University of Alabama at Birmingham|Yes|Completed|January 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|19 Years|N/A|No|||February 2016|March 19, 2016|April 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577966||87534|
NCT01577615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NR012307-02|Patterned Experience for Preterm Infants|Patterned Experience for Preterm Infants|PEPI|Children's Hospital Medical Center, Cincinnati|Yes|Completed|February 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|N/A|32 Weeks|No|||November 2015|November 10, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577615||87560|
NCT01577901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL-0425|Consumer in Stream and Container Collected Study|Consumer in Stream and Container Collected Study||SPD Development Company Limited|No|Completed|March 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|168|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|August 14, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577901||87539|
NCT01578200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGU1111|Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study|Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate on Cardiovascular Mortality and Morbidity in Patients With Chronic Kidney Disease on Hemodialysis (CKD5D)|LANDMARK|Translational Research Informatics Center, Kobe, Hyogo, Japan||Active, not recruiting|December 2011|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2309|||Both|N/A|N/A|No|||September 2015|September 9, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578200||87516|
NCT01578733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580-A|Determination of Protein Requirement in Elderly Female Subjects 65-75 Yrs Old|Use of Indicator Amino Acid Oxidation Technique to Determine Protein Requirement of Elderly Female Subjects 65-75 Yrs Old||The Hospital for Sick Children|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|14|||Female|65 Years|75 Years|Accepts Healthy Volunteers|||August 2013|August 16, 2013|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01578733||87475|
NCT01574625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOSAIC|Post-Approval Study for the MOSAIC® Bioprostheses|Post-Approval Study for the MOSAIC® Bioprostheses: A Long Term Follow Up Study.||Medtronic Cardiovascular|No|Active, not recruiting|April 2001|June 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|225|||Both|N/A|N/A|No|Non-Probability Sample|The subject population for this study includes all patients who were enrolled and        implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany)        during the previous Mosaic PMA study and who are still available for follow-up.|October 2015|October 6, 2015|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574625||87790|
NCT01574638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5311|Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults|Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|April 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01574638||87789|
NCT01574599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005596|Use of Repetitive Facilitative Exercise Program in Established Stroke|A Randomized Controlled Evaluation of a Repetitive Facilitative Exercise Program for Adults With an Established Stroke and Upper Extremity Impairment||Mayo Clinic|No|Recruiting|April 2012|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 1, 2016|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574599||87792|
NCT01574612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP 800|Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old|An Open Label Multi Center Phase III Subject/Caregiver Initiated Safety Study of Xerese(Acyclovir and Hydrocortisone)Cream 5%/1% in the Treatment of Recurrent Herpes Labialis in Children||Meda Pharmaceuticals|No|Completed|March 2012|February 2013|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|6 Years|11 Years|No|||April 2014|April 28, 2014|April 5, 2012|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01574612||87791|
NCT01575496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV-12-02-004761|Transcranial Direct Current Stimulation (tDCS) for the Treatment of Tinnitus|Transcranial Direct Current Stimulation (tDCS) for the Treatment of Chronic Subjective Tinnitus||Centre Hospitalier Universitaire Vaudois||Enrolling by invitation|April 2012|||January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2012|August 1, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575496||87723|
NCT01575249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The ENIGMAS trial|Identification of Parameters in rapId-proGression Subgroup Patients With Moderate Aortic Stenosis|Prospective Study Focused on idEntification of cliNical, Biological and Imagistic Parameters in rapId-proGression Subgroup Patients With Moderate Aortic Stenosis|ENIGMAS|Carol Davila University of Medicine and Pharmacy|Yes|Not yet recruiting|July 2012|June 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|standard blood count, c-reactive protein, urea, creatinin, hepatic standard biology, serum      calcium, cholesterol and tryglicerides.|Both|50 Years|90 Years|No|Probability Sample|The enrollment will be done by echo screening of the population (of the 3rd Arrondissement        in Bucharest, Romania) with age >50 years until target patients reached and also by        screening out-patients arriving at "Bagdasar-Arseni" Emergency Hospital (Bucharest) with        other cardiovascular diseases other than specified in the exclusion criteria.|April 2012|April 10, 2012|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01575249||87742|
NCT01575756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORMA-01|Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap|A Prospective, Controlled, Randomised, Cross-over Study Investigating the Pharmacokinetic Properties, Surrogate Efficacy and Safety of Octafibrin Compared to Haemocomplettan.Riastap in Subjects With Congenital Fibrinogen Deficiency||Octapharma|No|Completed|May 2013|September 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|12 Years|N/A|No|||October 2015|October 14, 2015|April 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575756||87703|
NCT01549041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00029068|Once-Daily Asenapine for Schizophrenia|A Randomized Comparison of Twice-Daily Versus Once-Daily Asenapine for Schizophrenia||Duke University|No|Completed|April 2012|November 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|No|||November 2013|April 23, 2014|October 14, 2011|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01549041||89745|Small sample size Open label design
NCT01549288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADIS|Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy|Evaluation of the Modified Atkins Diet in Children With Infantile Spasms Refractory to Hormonal Therapy: a Randomized Controlled Trial||Lady Hardinge Medical College||Withdrawn|February 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|9 Months|36 Months|No|||April 2013|April 7, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549288||89726|
NCT01549535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-1158|Polyp Detection With The Peerscope System™|Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study||PeerMedical Ltd.||Recruiting|February 2012|October 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Anticipated|196|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||November 2012|November 4, 2012|February 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01549535||89707|
NCT01549548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008238|Compassionate Use Ponatinib|Treatment Plan for the Compassionate Use of Ponatinib (AP24534) in Patients With Imatinib-, Dasatinib-, and Nilotinib- Resistant/Intolerant Philadelphia Chromosome Positive Leukemias.||OHSU Knight Cancer Institute||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||March 2013|March 13, 2013|March 6, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01549548||89706|
NCT01549808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIT ITA SLS 4141RH|Early Mobilization in Intensive Therapy|Early Mobilisation in Intensive Therapy|MIT|Region Zealand|No|Recruiting|February 2011|April 2014|Anticipated|January 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2012|March 8, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01549808||89686|
NCT01549834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-793|Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors||AbbVie|Yes|Completed|March 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|434|||Both|55 Years|90 Years|No|||October 2014|October 24, 2014|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01549834||89685|
NCT01549847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAR-PIR.11.01|A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome|A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Therapeutic Effect of the Association of L-carnitine and Piracetam as an Adjuvant Therapy in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome||Biolab Sanus Farmaceutica|No|Withdrawn||||February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||November 2015|November 16, 2015|March 7, 2012||No|Study was not approved by Health Surveillance Agency|No||https://clinicaltrials.gov/show/NCT01549847||89684|
NCT01550120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-027|Free Fatty Acids: Threshold Repeatability Study|Free Fatty Acids: Threshold Repeatability Study||Purdue University|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants between the ages of 18 and 55 years of age from any ethnic background who are        in good health and are available for the next three months will be recruited.        Additionally, equal numbers of lean and overweight participants will be sought.|March 2013|November 21, 2013|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550120||89663|
NCT01550393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B4|Biomarkers in Urine Samples From Patients With Wilms Tumor|Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics||Children's Oncology Group|No|Active, not recruiting|March 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|Samples With DNA|Urine|Both|N/A|120 Years|No|Non-Probability Sample|Patients with stage II-III Wilms tumors|May 2015|September 30, 2015|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01550393||89642|
NCT01551472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-706|Post Market Study of the 3DKnee™ With E-plus Insert|Prospective Multicenter Open Label Study Examining the Mid- and Long-term Safety and Efficacy of the 3DKnee™ System With Vitamin E UHMWPE Tibial Inserts (3DKnee™ With E-plus Insert)|e-plus|Encore Medical, L.P.|No|Recruiting|April 2012|June 2024|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|40 Years|75 Years|No|Non-Probability Sample|Subjects must be diagnosed with either osteoarthritis or traumatic arthritis and be        candidates for a primary total knee arthroplasty. They must also meet the indications for        use for the 3DKnee system with the vitamin E tibial insert.|January 2016|January 19, 2016|March 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01551472||89561|
NCT01578265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/127|Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Ondansetron Tablets USP 8 mg With Zofran® 8 mg in Normal, Healthy, Adult, Human Subjects Under Fed Condition.||IPCA Laboratories Ltd.|Yes|Completed|May 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 13, 2012|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578265||87511|
NCT01577914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/203|Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Carvedilol Tablets USP 12.5 mg With Coreg® 12.5 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.||IPCA Laboratories Ltd.|Yes|Completed|July 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577914||87538|
NCT01578213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISAV|Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients|Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV)|ISAV|University of Milano Bicocca|No|Active, not recruiting|November 2011|November 2018|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578213||87515|
NCT01578434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rickets 1|Role of Calcium And Vitamin D In Nutritional Rickets And It's Management|Role of Calcium And Vitamin D In Nutritional Rickets And It's Management|ROCAVINR|Lady Hardinge Medical College|No|Completed|November 2007|April 2009|Actual|February 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|67|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||April 2012|April 17, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578434||87498|
NCT01578746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811398|Comparison Between Anterior and Direct Lateral Approach in Total Hip Arthroplasty|Comparison Between Minimally Invasive Anterior Approach and Direct Lateral Approach in Total Hip Arthroplasty - A Prospective Randomized Trial||Sorlandet Hospital HF|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|80 Years|No|||June 2013|June 13, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578746||87474|
NCT01578759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0440|Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function|Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function||University of North Carolina, Chapel Hill|No|Completed|April 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|45 Years|No|||October 2014|October 11, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578759||87473|
NCT01574651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149ADE01|The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment, Multicenter, Randomized, Parallel Group, Blinded Study to Assess the Efficacy and Safety of QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Using Tiotropium Plus Formoterol as Control|QUANTIFY|Novartis|No|Completed|May 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|934|||Both|40 Years|N/A|No|||May 2014|May 19, 2014|April 6, 2012||No||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01574651||87788|
NCT01574664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S10-001|Evaluation of RFID Localization System for Marking and Retrieving Breast Lesions|A Prospective, Single-Arm, Multicenter Clinical Study to Evaluate the Safety and Performance of the Health Beacons Radiofrequency Identification (RFID) Localization System for Marking and Retrieving Non-Palpable Breast Lesions||Health Beacons|No|Active, not recruiting|September 2012|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|18 Years|50 Years|No|Non-Probability Sample|Female patients|December 2014|December 10, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01574664||87787|
NCT01575223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVSI-001|Saline Irrigation After Surgery in Patients With Chronic Sinusitis|The HVSI STUDY: High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial|HVSI|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|86|||Both|18 Years|65 Years|No|||April 2014|April 22, 2014|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01575223||87744|
NCT01575236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Schulthess_Anä_3|A Randomized Non Crossover Study of the GuardianTM Versus SupremeTM Laryngeal Mask Airway|A Randomized Non Crossover Study of the GuardianTM Versus SupremeTM Laryngeal Mask Airway||Schulthess Klinik|Yes|Completed|March 2012|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|120|||Female|18 Years|75 Years|No|||August 2012|August 6, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01575236||87743|
NCT01575769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27783|An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis|Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From Poland and Russia Who Completed the Global, Multinational Trial (WA19977).||Hoffmann-La Roche||Terminated|March 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|2 Years|N/A|No|||December 2015|December 3, 2015|April 10, 2012|No|Yes||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01575769||87702|The study was terminated prior to the planned final on-treatment efficacy assessments due to commercial availability of tocilizumab in Russia and Poland.
NCT01575782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHLOROQUINE I-III|Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer|Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer (SCLC) Patients: a Phase I Trial.|Chloroquine|Maastricht Radiation Oncology|No|Recruiting|May 2014|October 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 22, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01575782||87701|
NCT01576068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/3128/I|Chronic Obstructive Pulmonary Disease Case Finding in Community-pharmacies by Spirometry|Efficiency of COPD Case Finding Program by Spirometry in High-risk Customers of Urban Community Pharmacies|FARMAEPOC|Col·legi de Farmacèutics de la Província de Barcelona|No|Active, not recruiting|October 2010|June 2013|Anticipated|July 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|3600|||Both|40 Years|N/A|No|||April 2012|April 11, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01576068||87679|
NCT01549574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081035|Drug Drug Interaction Study Of Crizotinib With Esomeprazole.|A Phase 1, Open Label, Single Dose, Randomized, Cross-Over Study To Estimate The Effect Of Esomeprazole On The Pharmacokinetics Of Crizotinib In Healthy Volunteers||Pfizer|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|February 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01549574||89704|
NCT01549886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-MGD-11-201|Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma|A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma||Spectrum Pharmaceuticals, Inc|No|Terminated|November 2011|December 2015|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|March 6, 2012|Yes|Yes|Due to business reasons.|No||https://clinicaltrials.gov/show/NCT01549886||89681|
NCT01550406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PFDP-2011|Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy|Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study||Seoul National University Hospital|Yes|Active, not recruiting|November 2011|December 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|150|||Both|20 Years|84 Years|No|||April 2014|April 8, 2014|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01550406||89641|
NCT01549860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-BALANCE VLU|Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers|IN-BALANCE VLU Inflammation, Bacteria, & Angiogenesis Effects in Launching Venous Leg Ulcer Healing||Celleration, Inc.|Yes|Completed|April 2012|April 2015|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|156|||Both|18 Years|90 Years|No|||July 2015|July 2, 2015|March 7, 2012|No|Yes||No|April 27, 2015|https://clinicaltrials.gov/show/NCT01549860||89683|
NCT01549873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00727|Anesthesia During Neurophysiologic Monitoring in Scoliosis Patients|Anesthesia During Neurophysiologic Monitoring in Scoliosis Patients: Volatile Agents Versus Total Intravenous Anesthesia||Nationwide Children's Hospital|No|Completed|January 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|N/A|N/A|No|||February 2015|February 24, 2015|March 7, 2012|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01549873||89682|
NCT01550913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34DA030428-01A1|Sober Network IPT for Perinatal Women With Comorbid Substance Use and Depression|Sober Network IPT for Perinatal Women With Comorbid Substance Use and Depression||Women and Infants Hospital of Rhode Island|Yes|Active, not recruiting|July 2011|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|50 Years|No|||December 2014|December 9, 2014|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01550913||89603|
NCT01550926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W3680604|A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms|A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms||GlaxoSmithKline|No|Completed|February 2009|March 2009|Actual|March 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|48|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2012|January 24, 2013|November 17, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01550926||89602|
NCT01551771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115802|GW824575 First Time in Human|A Single-centre, Masked, Placebo-controlled Four Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of the CC-chemokine Receptor 3 (CCR3) Antagonist, GW824575, Coadministered With or Without Food in Healthy Male Subjects||GlaxoSmithKline|No|Terminated|February 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|16|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01551771||89538|
NCT01551784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CSE-CRE-2011/1|An Observational Study of Statin Treatment Induced HDL Changes|An Observational Study of Statin Treatment Induced HDL Changes - Effect on Cardiovascular Disease|SIRIUS|AstraZeneca|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|120000||Cholesterol values (HDL-C, LDL-C, TC)|Both|18 Years|86 Years|No|Non-Probability Sample|Patients who received a first prescription of a statin (ATC code C10AA) between 1st of        January 2004 and 31st of December 2010. Swedish data will be extracted from medical        records and national registers and for UK and the Netherlands from central registers.|October 2013|October 14, 2013|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01551784||89537|
NCT01577927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UTIR|Feasibility Study of a Home Rehabilitative Network to Treat Prolonged Weaned Patients|Feasibility and Efficacy of a Home Rehabilitative Network for Prolonged Weaned Patients Discharged From a Weaning Unit|UTIR|Fondazione Salvatore Maugeri|Yes|Completed|July 2011|July 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01577927||87537|
NCT01578226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCTCIRR|Procalcitonin in Cirrhotic Patients at High Risk for Sepsis|Role of Procalcitonin (PCT) for the Diagnosis of Sepsis in Ascitic Cirrhotic Patients||University of Modena and Reggio Emilia|No|Completed|October 2009|September 2011|Actual|September 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|75|Samples Without DNA|Serum|Both|18 Years|80 Years|No|Non-Probability Sample|All ascitic cirrhotic patients admitted to our third level Liver Unit.|April 2012|April 13, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578226||87514|
NCT01578447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00003213|Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda|Acceptability of Depo-subQ Provera 104 in Uniject Versus Intramuscular Depo-Provera Among HIV-positive Women and Family Planning Providers in Rakai, Uganda||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|April 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|356|||Female|18 Years|45 Years|No|||September 2014|September 16, 2014|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01578447||87497|
NCT01578772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|miFMD|A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease|Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease||University of California, Los Angeles|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|50 Years|N/A|No|||December 2014|December 2, 2014|February 1, 2012||No||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01578772||87472|Given the limited size of the study population, the study was underpowered.
NCT01574677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Septin 9 Colorectal Biomarker|Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test|Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test||Epigenomics, Inc|Yes|Withdrawn|June 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|49 Years|80 Years|No|Non-Probability Sample|Eligible subjects will be identified at Kaiser Permanente Northwest (KPNW) and Kaiser        Permanente Georgia (KPGA). KPNW is a nonprofit group-model HMO with membership of about        485,000 in SW Washington and NW Oregon. KPNW includes 797 physician s and 395 allied        clinicians (265 primary care providers). The member population base is similar to the        local insured community in terms of age, gender, race, and ethnicity. About 19% of members        are racial and ethnic minorities. Membership of KPGA has a racial and socioeconomic        distribution similar to metropolitan Atlanta: ~ 50% Caucasian, 45% African American, 4%        Hispanic, and 1% other races. 90 percent of the KPGA membership receives primary care at        12 medical offices owned and operated by KPGA and through contracts with 125 community        practices.|August 2014|August 1, 2014|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01574677||87786|
NCT01574963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GORF 2.0|Graz Osteoprotegerin as a Risk Factor (GORF) Study|Graz Osteoprotegerin as a Risk Factor (GORF) Study: THE ROLE of OSTEOPROTEGERIN (OPG) and the RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-Kb LIGAND (RANKL) IN PATIENTS REQUIRING SURGERY FOR CORONARY HEART DISEASE||Medical University of Graz|Yes|Recruiting|July 2010|September 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Male|40 Years|90 Years|No|Non-Probability Sample|Male patients above 40 years of age presenting with symptomatic CAD and scheduled for a        coronary artery bypass graft (CABG) are eligible for the study. The control group includes        male patients scheduled for elective surgery other than cardiac procedures.|April 2012|April 9, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01574963||87764|
NCT01574976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37/12|Effect of Feedback and Practice on Probabilistic Decision Making in Attention Deficit and Hyperactivity Disorder|Effect of Feedback and Practice on Probabilistic Decision Making in Attention Deficit and Hyperactivity Disorder||Shaare Zedek Medical Center|No|Completed|May 2015|November 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|80|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01574976||87763|
NCT01574989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-p-001461|Effects of rTMS and tDCS on Motor Function in Stroke|Effects of Repetitive Transcranial Magnetic Stimulation and Transcranial DC Stimulation on Motor Function in Stroke Patients||Spaulding Rehabilitation Hospital|No|Active, not recruiting|May 2011|||May 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|5||Anticipated|26|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01574989||87762|
NCT01575262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAL-v1|The Physical Activity Loyalty Card Scheme|The Physical Activity Loyalty Card Scheme: A Randomised Controlled Trial to Encourage Physical Activity|PAL|Queen's University, Belfast|Yes|Completed|March 2011|October 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|406|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 10, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575262||87741|
NCT01575275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1311|Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme|A Phase 2 Comparative Study of 5-Aminolevulinic Acid (5-ALA) and Intraoperative MRI (iMRI) to Enhance Completeness of Resection of Glioblastoma||Case Comprehensive Cancer Center|Yes|Terminated|May 2012|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|April 9, 2012|Yes|Yes|Drugs unavailable|No||https://clinicaltrials.gov/show/NCT01575275||87740|
NCT01574937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-441|XL-184+Abiraterone in Post-Chemo CRPC|A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer||Dana-Farber Cancer Institute|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|27|||Male|18 Years|N/A|No|||March 2016|March 17, 2016|April 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574937||87766|
NCT01574950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00051796|Impact of Impaired Cerebral Autoregulation on Postoperative Delirium in Elderly Patients Undergoing Spine Surgery|The Impact of Impaired Cerebral Autoregulation on the Development of Postoperative Delirium in Elderly Patients Undergoing Spine Surgery||Johns Hopkins University|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|Samples Without DNA|Blood samples|Both|70 Years|N/A|No|Probability Sample|The study population is male and female subjects age 70 years and older that are having        spine surgery.|October 2015|October 23, 2015|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01574950||87765|
NCT01576081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLR|The Novel Unloading Device "HEPHAISTOS" and Its Effects Upon Bone, Muscle and Vasculature|The Effects of a 56day Unilateral Muscular Unloading Intervention With a Novel Device That Allows Normal Ambulation While Reducing Muscle Activation Drastically, on Muscles, Bones and Vessels.|HEP|DLR German Aerospace Center|Yes|Completed|April 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|11|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 15, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01576081||87678|
NCT01576354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAMPKIN|Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis|A Phase IIb, Double-blind, Randomized, Mono-center, Placebo-controlled Study With Crossover Design Characterizing the Effects of Prolonged-release Fampridine Treatment on Ambulatory Function in Patients With Multiple Sclerosis Using Detailed Gait Analysis Based on Kinematic and Kinetic Parameters|FAMPKIN|University of Zurich||Active, not recruiting|March 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||December 2015|December 3, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01576354||87657|
NCT01550653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ott-NN-001|Liraglutide Effects on Memory in Healthy Subjects|Liraglutide Effects on Memory in Healthy Subjects||University of Luebeck|Yes|Completed|May 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 26, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01550653||89622|
NCT01550939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS1 Time Study 2|Time Study for Biometry Measurements With the Lenstar and IntraOcularLens (IOL) Master 500|A Single-Center, Open-Label, Randomized Clinical Study Measuring Time Needed for Testing Between the Haag-Streit Lenstar 900 Version i4 and the Carl Zeiss IOL Master 500 Instruments||Haag Streit USA|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|61|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 31, 2012|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01550939||89601|
NCT01550640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|remifentanil|Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia|Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia||Charles University, Czech Republic|No|Completed|March 2011|August 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|149|||Female|18 Years|45 Years|No|||November 2014|November 14, 2014|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01550640||89623|
NCT01551498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-007|Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Potential Effects of the Dietary Supplement Anatabloc on Antithyroid Autoantibodies and Thyroid Function in Autoimmune Thyroiditis|ASAP|Rock Creek Pharmaceuticals, Inc.|No|Completed|March 2012|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|70 Years|No|||October 2015|October 29, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01551498||89559|
NCT01551511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEEL-2011-02|Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain|Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design||Radboud University|No|Completed|October 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|N/A|No|||October 2014|October 27, 2014|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01551511||89558|
NCT01551797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2750894|A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.|A Proof of Principal Study to Investigate the Pharmacokinetic Profiles of Sustained Release and Standard Paracetamol Formulations||GlaxoSmithKline|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|December 6, 2012|February 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01551797||89536|
NCT01577706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000197|Spectroscopic Imaging at 4T: A Drug Challenge Study|Spectroscopic Imaging of GABA and Glutamate/Glutamine in Healthy Volunteers at 4T: A Double Blind, Crossover Drug Challenge Study|CEBRA2|Mclean Hospital|No|Completed|June 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Anticipated|30|||Male|21 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|April 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577706||87554|
NCT01577719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHARA-Pilot|South Asian HeArt Risk Assessment Project - Pilot|South Asian HeArt Risk Assessment Project - Pilot|SAHARA-Pilot|McMaster University|No|Active, not recruiting|June 2009|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|30 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 12, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01577719||87553|
NCT01578239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAA-III-01|A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours|A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours|NETTER-1|Advanced Accelerator Applications|Yes|Active, not recruiting|September 2012|February 2021|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|359|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578239||87513|
NCT01578460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-223|Healthy Moms, Healthy Babies|Healthy Moms, Healthy Babies: A Strategy to Improve the Care and OUtcome of Diabetes in Pregnancy in On-Reserve First Nations Women|HMHB|Lawson Health Research Institute|No|Not yet recruiting|May 2012|September 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 13, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01578460||87496|
NCT01578473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD Plus Study|Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease|An Open-Label, Nine-Month Randomized Controlled Study of Testosterone (Testopel) Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease|PD+|Men's Health Boston|Yes|Active, not recruiting|April 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|75|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 8, 2015|April 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578473||87495|
NCT01578785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-MS-302|An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection|GLOW|Teva Pharmaceutical Industries|Yes|Terminated|March 2012|November 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|55 Years|No|||February 2014|February 19, 2014|March 13, 2012|Yes|Yes||No|February 19, 2014|https://clinicaltrials.gov/show/NCT01578785||87471|
NCT01575002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-p-001902|Effects of Transcranial Direct Current Stimulation (tDCS) in Chronic Corneal Pain|Neural Correlates of Pain-related Cognitive Processing in Chronic Pain of the Cornea: an ERP and Electrical Stimulation Study.||Spaulding Rehabilitation Hospital|No|Recruiting|January 2012|||January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 4, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01575002||87761|
NCT01575288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B6310|Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults|Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults||University of Colorado, Boulder|Yes|Completed|May 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|50 Years|79 Years|Accepts Healthy Volunteers|||December 2015|December 9, 2015|April 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575288||87739|
NCT01575301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011DIRECT01 (GLP)|DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists|DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists|DIRECTGLP|University of Dundee|No|Recruiting|March 2011|December 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|800|||Both|18 Years|80 Years|No|||April 2012|April 11, 2012|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575301||87738|
NCT01574703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3051148|Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.|A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders|CATS|Pfizer|Yes|Completed|May 2012|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment|4||Actual|4599|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|April 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574703||87784|
NCT01575535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S0106B|S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia|S0106B, Stem Cell Origin in AML: Prognostic and Therapeutic Implications||Southwest Oncology Group|Yes|Completed|April 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|100|||Female|18 Years|N/A|No|Non-Probability Sample|Repository specimens|March 2015|March 5, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01575535||87720|
NCT01575548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00723|Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery|Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy||National Cancer Institute (NCI)|Yes|Recruiting|August 2012|||August 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||October 2015|March 24, 2016|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575548||87719|
NCT01575522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00722|Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer|A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer||National Cancer Institute (NCI)||Completed|March 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||October 2015|February 23, 2016|April 10, 2012|Yes|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT01575522||87721|
NCT01575561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050308|This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296|A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder|PERSISTExt|Sunovion|No|Completed|June 2012|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|377|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|March 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575561||87718|
NCT01575821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hermanhoney|The Effect of Honey on Nocturnal Cough and Sleep Quality|The Effect of Honey on Nocturnal Cough and Sleep Quality: a Double-blind, Randomized,Placebo-controlled Study||Meir Medical Center|No|Completed|January 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|300|||Both|1 Year|5 Years|No|||April 2012|April 11, 2012|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01575821||87698|
NCT01575834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070337|Registrational Study With AMG 785 to Treat Postmenopausal Osteoporosis|A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of AMG 785 Treatment in Postmenopausal Women With Osteoporosis|FRAME|Amgen|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7180|||Both|55 Years|90 Years|No|||February 2016|February 19, 2016|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01575834||87697|
NCT01550133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK079913-4|Effects of Food Form on Cephalic Phase Responses|Effects of Nutritive and Non-Nutritive Food Form and Learning on Cephalic Phase Responses||Purdue University|No|Active, not recruiting|September 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|8||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 14, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550133||89662|
NCT01550146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14640820|Single Dose of Dexamethasone in Femur Fractures|Effects of a Single Dose of Dexamethasone in Patients Undergoing Operative Fixation of Proximal Femur Fracture||Cork University Hospital|No|Recruiting|July 2009|July 2012|Anticipated|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2012|March 8, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01550146||89661|
NCT01550952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002|Interscalene Dynamometer Pilot Study|Interscalene Dynamometer Pilot Study||Hospital for Special Surgery, New York||Completed|December 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients 18-80 years old who are undergoing primary total shoulder arthroplasty.|September 2012|September 24, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01550952||89600|
NCT01551199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDA2-012-09F-1|Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1)|Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1)||VA Office of Research and Development|Yes|Completed|March 2012|June 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|64 Years|No|||January 2015|January 27, 2015|March 2, 2012||No||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01551199||89582|
NCT01551524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZPO2-CLT-001|Phase I Study of mPEG-R-Crisantaspase Given IV|A Dose Escalation Phase I Study of Asparec®(mPEG-R-Crisantaspase) Administered as Intravenous (IV) Infusion in Patients With Relapsed or Refractory Hematological Malignancies||Jazz Pharmaceuticals|No|Completed|March 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|50 Years|No|||February 2015|May 5, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551524||89557|
NCT01551537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113763|Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka|Post-marketing Surveillance (PMS) of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) -16/18 Vaccine, Cervarix™ When Administered to Healthy Females According to the Prescribing Information in Sri Lanka||GlaxoSmithKline||Withdrawn|April 2013|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|10 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy females aged 10 years and above who will receive Cervarix as a part of routine        practice as per the PI in Sri Lanka.|September 2013|September 5, 2013|March 8, 2012|No|Yes|Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it    was concluded GSK will submit local PSURs|No||https://clinicaltrials.gov/show/NCT01551537||89556|
NCT01577732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115389|Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers|Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers||GlaxoSmithKline||Completed|December 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|321|||Both|12 Months|24 Months|Accepts Healthy Volunteers|||April 2014|April 3, 2014|April 5, 2012|Yes|Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01577732||87552|
NCT01577745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI0639-1078|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors|A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects With Advanced Solid Tumors||MedImmune LLC|No|Recruiting|April 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|99 Years|No|||November 2015|November 12, 2015|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01577745||87551|
NCT01578486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-000798|Salsalate as an Adjunctive Treatment for Patients With Schizophrenia|Salsalate as an Adjunctive Treatment for Patients With Schizophrenia||University of Massachusetts, Worcester|No|Completed|June 2011|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01578486||87494|
NCT01578798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22678|Detection of Immune Changes as a Result of Surgical Trauma in Human Subject|Detection of Immune Changes as a Result of Surgical Trauma in Human Subject||Stanford University|No|Completed|March 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|Samples With DNA|Whole blood|Both|18 Years|90 Years|No|Non-Probability Sample|Patients undergoing primary hip replacement.|October 2013|October 29, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01578798||87470|
NCT01578811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK-MS10_GID_II_2010|Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis|||SK Chemicals Co.,Ltd.|Yes|Completed|August 2011|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|102|||Both|19 Years|75 Years|No|||December 2010|March 14, 2013|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578811||87469|
NCT01574690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLS STP-9000008|Correlation of Physical Exam Versus Non-invasive Assessment Versus Invasive Assessment of Central Venous Pressure|Correlation of Physical Exam Versus Non-invasive Near-infrared Spectroscopy Versus Invasive Hemodynamic Assessment of Central Venous Pressure||Mespere Lifesciences Inc.|No|Completed|April 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with heart failure (HF)|February 2013|February 7, 2013|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574690||87785|
NCT01578824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vit D and asthma in VDRR CTIL|Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients|Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients||Rambam Health Care Campus|Yes|Completed|March 2011|December 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|26|||Both|3 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|November 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01578824||87468|
NCT01574716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MORAb-004-203-STS|Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE)|A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma|SOURCE|Morphotek||Active, not recruiting|May 2012|March 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|209|||Both|18 Years|N/A|No|||March 2016|March 21, 2016|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574716||87783|
NCT01574742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0007-12-SHA|Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression|A Single Center, Open Label Study Assessing the Feasibility, Safety and Therapeutic Effect of Minocycline in Adult Patients With Diagnosis of Unipolar Depression.||Shalvata Mental Health Center|Yes|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|68 Years|No|||April 2012|July 3, 2012|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01574742||87781|
NCT01574755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHAT-FU-1|Long Term Outcome of Argon Plasma Coagulation of Cervical Heterotopic Gastric Mucosa as an Alternative Treatment for Globus Sensations|Long Term Outcome of Argon Plasma Coagulation of Cervical Heterotopic Gastric Mucosa as an Alternative Treatment for Globus Sensations|ACHAT FU|Technische Universität München|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|49|Samples Without DNA|biopsy of gastric inlet patches|Both|18 Years|80 Years|No|Non-Probability Sample|outpatient clinic of a university hospital|June 2013|June 29, 2013|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574755||87780|
NCT01575015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOFAPro00026047|Intraoperative Dialysis in Liver Transplantation|Intra-Operative Continuous Renal Replacement Therapy in Liver Transplantation: A Phase II Randomized Controlled Trial (INCEPTION)|INCEPTION|University of Alberta|No|Recruiting|May 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01575015||87760|
NCT01575795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-10|Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI): a Multi-center Randomized Parallel Pharmacodynamic Study.||University of Patras|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|95 Years|No|||April 2013|April 9, 2013|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01575795||87700|
NCT01575808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VJH 11-01|Multi-center Study for Stent Graft System for Peripheral Artery|The Utility of GP1101 Relative to Surgical Bypass in the Treatment of Femoral / Popliteal Arterial Symptomatic Peripheral Arterial Disease|VJH 11-01|W.L.Gore & Associates|Yes|Active, not recruiting|April 2012|August 2018|Anticipated|August 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|142|||Both|20 Years|N/A|No|||June 2015|June 9, 2015|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01575808||87699|
NCT01575574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIGA|Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis|Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis|PRIGA|Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01575574||87717|
NCT01575847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acetaminophen Adduct Dipstick|Adduct Dipstick for Diagnosis of Acetaminophen Toxicity|Adduct Dipstick for Diagnosis of Acetaminophen Toxicity||Arkansas Children's Hospital Research Institute|No|Active, not recruiting|August 2011|||||N/A|Observational|Time Perspective: Prospective||2|Anticipated|120|Samples Without DNA|Acetaminophen Adduct Samples|Both|12 Years|N/A|No|Non-Probability Sample|Part 1 - Arkansas Children's Hospital ER        Part 2 - adults presenting to hepatology centers participating in the Acute Liver Failure        Study Group (ALFSG).|April 2015|April 8, 2015|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01575847||87696|
NCT01550432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-03252010-5442|Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation|Effects of GSH and N-Acetylcysteine on Inflammatory Markers Among Adults With CVD Risk||Stanford University|Yes|Completed|June 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|78|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 7, 2012|June 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01550432||89639|
NCT01550419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHC Hospital 01|Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke|Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke||Shanghai Minhang Central Hospital|Yes|Recruiting|March 2012|February 2014|Anticipated|February 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|80 Years|No|||February 2013|February 24, 2013|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01550419||89640|
NCT01551212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001HDE13|Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients|A 12-month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate Efficacy/Safety and Evolution of Renal Function of Everolimus in Co-exposure With Tacrolimus in de Novo Liver Transplant Recipients|HEPHAISTOS|Novartis|No|Recruiting|January 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Both|18 Years|65 Years|No|||January 2016|January 6, 2016|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551212||89581|
NCT01551225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102051|Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder|Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder||Maastricht University Medical Center|Yes|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||May 2015|May 4, 2015|November 3, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01551225||89580|
NCT01550965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-045|A Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting|An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting|InspirAda|AbbVie|No|Completed|May 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|463|||Both|18 Years|75 Years|No|||April 2015|April 7, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01550965||89599|
NCT01551238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39152|Energy Expenditure, Sleep and Macronutrients|Energy Expenditure and Sleep in Response to Protein/Carbohydrate and Fat Ratio||Maastricht University Medical Center|No|Recruiting|March 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 2, 2013|December 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01551238||89579|
NCT01551550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P010-2, Version 4|Shunt Tube Exposure Prevention Study|Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial|STEPS|Tissue Tech Inc.|Yes|Recruiting|June 2013|August 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|96|||Both|21 Years|N/A|No|||November 2015|November 5, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01551550||89555|
NCT01551563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUSI_1|Stavanger University Hospital Inflammatory Bowel Disease Trial|Management of Inflammatory Bowel Disease in the Stavanger Area - a Prospective Evaluation of Standardized Treatment Regimens on Disease Outcome With Focus on Mucosal Healing and Associations to Fatigue|SUSI|Helse Stavanger HF|No|Recruiting|April 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Plasma and mucosal biopsies|Both|16 Years|80 Years|No|Non-Probability Sample|All newly diagnosed IBD patients (Crohns and Ulcerative colitis) within Stavanger Univ        Hospital catchment area|December 2013|December 4, 2013|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01551563||89554|
NCT01577758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C26001|Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C|An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C||Millennium Pharmaceuticals, Inc.|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|April 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01577758||87550|
NCT01577992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0931403|Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy|Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy|MSA-DOUL|University Hospital, Toulouse|No|Completed|December 2011|November 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01577992||87532|
NCT01578278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00186|Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis|||Bausch & Lomb Incorporated|No|Completed|December 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|606|||Both|12 Years|N/A|No|||April 2014|April 4, 2014|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578278||87510|
NCT01578499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C25001|A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma|A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma||Millennium Pharmaceuticals, Inc.|Yes|Active, not recruiting|August 2012|July 2018|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578499||87493|
NCT01578512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK083440|SPARK a Healthy and Fit Lifestyle|SPARK a Healthy and Fit Lifestyle|SPARK|The Miriam Hospital|No|Recruiting|February 2012|November 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|25 Years|No|||March 2012|April 16, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578512||87492|
NCT01578525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-192|Medication Safety of Elderly Patients in Hospital and Ambulatory Setting|Medication Safety of Elderly Patients in Hospital and Ambulatory Setting Considering the Transitions of Care for Home-cared Patients and Nursing Home Residents||RWTH Aachen University||Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|61|||Both|65 Years|N/A|No|||May 2012|October 29, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01578525||87491|
NCT01578837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OG-2-09-2920-VV|Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes|Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes|R-KAT|St. Michael's Hospital, Toronto|No|Recruiting|April 2012|June 2015|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|40 Years|75 Years|No|||February 2014|February 18, 2014|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578837||87467|
NCT01574729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-p53NSCLC|Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma|Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma|rAd-p53|Shenzhen SiBiono GeneTech Co.,Ltd|No|Not yet recruiting|August 2012|October 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574729||87782|
NCT01574768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|135/11|LATERAL PHARYNGOPLASTY OUTCOMES IN THE TREATMENT OF SNORE AND OBSTRUCTIVE SLEEP APNEA|LATERAL PHARYNGOPLASTY OUTCOMES IN THE TREATMENT OF SNORE AND OBSTRUCTIVE SLEEP APNEA||Hospital do Servidor Publico Estadual|No|Active, not recruiting|November 2011|September 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|65 Years|No|||April 2012|April 7, 2012|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01574768||87779|
NCT01567683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMTOP-II|A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects||Limsafe|Moberg Derma AB||Completed||||||Phase 1|Interventional|N/A|1||||||Both|18 Years|N/A||||May 2012|May 25, 2012|March 29, 2012||||No||https://clinicaltrials.gov/show/NCT01567683||88322|
NCT01575028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00140|Transversus Abdominis Plane (TAP) Versus Local Anesthetic for Lap Appendectomies|A Prospective, Double Blinded, Randomized Comparison of Transversus Abdominis Plane Block Versus Local Anesthetic Infiltration for Laparoscopic Appendectomy in the Pediatric Population||Nationwide Children's Hospital|Yes|Terminated|October 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|N/A|N/A|No|||July 2015|July 29, 2015|April 5, 2012|Yes|Yes|The study was allowed to expire due to changes in standard care for the patient population    within the NCH institution.|No|May 14, 2015|https://clinicaltrials.gov/show/NCT01575028||87759|
NCT01575041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KaNa-trial|The Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function|Study on the Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function in Untreated (Pre)Hypertensive Subjects|KaNa|Wageningen University|No|Completed|January 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|40|||Both|40 Years|90 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01575041||87758|
NCT01575314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUR-11-09-26A-13-X|Cost-consequence Analysis of Parenchymal Stapling Device Versus Hand-sewing for Pulmonary Lobectomy in Lung Disease|Cost-consequence Analysis of Parenchymal Stapling Device Versus Hand-sewing for Pulmonary Lobectomy in Lung Disease: A Randomized Controlled Trial||Chiang Mai University|Yes|Completed|November 2011|July 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|15 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|April 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01575314||87737|
NCT01572376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCentralAsturias|Autologous Bone Marrow Stem Cells in Pressure Ulcer Treatment|Treatment of Pressure Ulcers With Autologous Bone Marrow Stem Cells in Spinal Cord Injury Patients.Phase I/II Study.||Hospital Universitario Central de Asturias|No|Completed|November 2007|December 2010|Actual|December 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||August 2015|August 24, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01572376||87962|
NCT01572389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 10-135|Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression|Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression||VA Office of Research and Development|Yes|Active, not recruiting|November 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|242|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01572389||87961|
NCT01581398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TB1203IFN|Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients|A Phase 3, Randomized, Multi-center, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Combination With Ribavirin in Chinese Chronic Hepatitis C Patients||Xiamen Amoytop Biotech Co., Ltd.|Yes|Completed|April 2012|June 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|770|||Both|18 Years|65 Years|No|||April 2012|October 6, 2014|February 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581398||87273|
NCT01581164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol No. 112526|Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation|Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation||University of California, San Francisco|Yes|Completed|December 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|Samples With DNA|Serum will be collected and stored for immunologic analysis after vaccination. Samples will      be cryopreserved. No cell lines will be created using samples procured on this protocol.|Both|5 Years|70 Years|No|Non-Probability Sample|Patients who have been treated with HSCT|May 2015|May 7, 2015|April 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581164||87290|
NCT01581177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-A006-CL-B2|Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation|A Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Crossover Dose-ranging Study of A006 in Adult Asthma Patients||Amphastar Pharmaceuticals, Inc.|No|Completed|April 2012|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|28|||Both|18 Years|55 Years|No|||July 2013|July 9, 2013|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581177||87289|
NCT01581957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.10.CLI|Pilot Study on Gastro-intestinal (GI) Enteral Nutrition (EN) Tolerance in Intensive Care Unit Patients|A Pilot Study to Evaluate the Effect of a Specific Enteral Formulation Designed to Improve Gastrointestinal Tolerance in the Critically Ill Patient|SPIRIT|Nestlé|No|Completed|December 2012|April 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|90|||Both|18 Years|N/A|No|||June 2014|June 26, 2014|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01581957||87230|
NCT01581970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS002|Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer|Potentiation of Cetuximab by Tregs Depletion With Metronomic Cyclophosphamide in Metastatic Squamous Cell Cancers of Head and Neck||Masonic Cancer Center, University of Minnesota|No|Completed|June 2012|July 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581970||87229|
NCT01582269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13849|A Study in Recurrent Glioblastoma (GB)|A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma||Eli Lilly and Company|No|Active, not recruiting|April 2012|June 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|180|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582269||87206|
NCT01582529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|319498|SVRII Family Factors Study|The Impact of Family Factors on Developmental and Psychosocial Outcomes in Children With Hypoplastic Left Heart Syndrome (HLHS) at 6 Years of Age - Pediatric Heart Network Single Ventricle Reconstruction Extension (SVR II) Ancillary Study||Medical College of Wisconsin|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|60 Years|No|Non-Probability Sample|Parents of subjects that are enrolled in the "Single Ventricle Reconstructive Extension        Study" (SVR) or the SVR II study sponsored by the Pediatric Heart Network.|February 2016|February 1, 2016|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582529||87186|
NCT01582243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ATW03|Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients|A Prospective, Open-label, Interventional Study to Assess the HbA1c Change an 24-hr Glucose Fluctuation After Vildagliptin Plus Metformain (SPC) Treatment in Metformin Monotherapy Uncontrolled Type 2 Diabetes Mellitus Patients||Novartis||Completed|April 2013|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|20 Years|N/A|No|||November 2015|November 5, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582243||87208|
NCT01582997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116056|A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors|An Open-label, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of GSK2118436 in Japanese Subjects With BRAF V600 Mutation Positive Solid Tumors.||GlaxoSmithKline|No|Completed|May 2012|April 2015|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||November 2015|November 12, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01582997||87150|
NCT01578941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Treximet-UAB-Glaxo|An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine|||University of Alabama at Birmingham|No|Completed|January 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|12|||Female|19 Years|N/A|No|||October 2012|October 31, 2012|January 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01578941||87459|
NCT01581112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/256|Microbial Community Transplantation on the Armpit/Foot|Microbial Community Transplantation on the Armpit/Foot in Order to Reduce the Malodour Generation on Armpit/Foot||University Ghent|No|Completed|September 2012|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01581112||87294|
NCT01574183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16488|Vilazodone Treatment for Marijuana Dependence|Vilazodone Treatment for Marijuana Dependence||Medical University of South Carolina|No|Active, not recruiting|August 2012|March 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|65 Years|No|||December 2015|December 10, 2015|April 5, 2012|Yes|Yes||No|September 21, 2015|https://clinicaltrials.gov/show/NCT01574183||87824|Limitations included small sample size, significant attrition, and difficulty with UCT (urine cannabinoid test) interpretation due to long excretion half-life of cannabis in urine.
NCT01574196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108162|Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood|Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood. Ancillary Study of the "Long-term Follow-up of Childhood Cancer Survivors in the Rhône-Alpes and Auvergne Regions of France" Study|SALTO-SNA|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|83|||Both|18 Years|N/A|No|Non-Probability Sample|This is a prospective cohort study in non-leukemia cancer survivors diagnosed between 1987        and 1992 in the Rhône-Alpes and Auvergne regions of France, who were younger than 15 years        at the time of diagnosis|March 2015|March 30, 2015|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01574196||87823|
NCT01570738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carmel-001|Validation of Home Sleep Testing (WP200) Compared to an Overnight Sleep Testing in the Sleep Laboratory|Validation of Home Sleep Testing (WP200) Compared to an Overnight Sleep Testing in the Sleep Laboratory||Itamar-Medical, Israel|No|Recruiting|July 2012|||August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|5 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults and children with and without sleep disorders, referred to Carmel Medical Center        clinical sleep laboratory for an overnight sleep study|April 2014|February 24, 2016|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570738||88087|
NCT01570998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117515|Targeted Intraoperative Radiotherapy United States (TARGIT-US) Registry Trial|Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery|TARGIT-US|University of California, San Francisco|Yes|Recruiting|May 2012|||June 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|755|||Female|45 Years|N/A|No|||March 2016|March 14, 2016|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570998||88067|
NCT01571271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-168|Electrohydraulic Versus Laser Lithotripsy for Treatment of Difficult to Remove Biliary Stones|Electrohydraulic Versus Laser Lithotripsy for Treatment of Difficult to Remove Biliary Stones|EHLvlaser|The Cleveland Clinic|No|Recruiting|January 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|December 23, 2009||No||No||https://clinicaltrials.gov/show/NCT01571271||88047|
NCT01571245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252121|Predicting Treatment Response Using Psychophysiologic Reactivity Measures|Predicting Treatment Response Using Psychophysiologic Reactivity Measures||Central Arkansas Veterans Healthcare System|No|Completed|April 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|60 Years|No|Non-Probability Sample|Veterans receiving or seeking treatment at the Central Arkansas Veterans Healthcare        Administration Mental Health Clinics.|December 2015|December 14, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01571245||88049|
NCT01571258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4R44CA138011|Text4Diet: A Text Messaging Program for Weight Loss|Text4Diet: A Text Messaging Program for Weight Loss|Text4Diet|Santech, Inc|No|Completed|September 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|170|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571258||88048|
NCT01571570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100787|A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.|A Phase I, Open-Label, Randomized, 3-Panel, 3-way Crossover Trial in Healthy Adult Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of 2 Liquid Formulations or 2 Different Capsule Concept Formulations Compared ot the Phase III 150 mg Capsule, and to Assess the Effect of Food on the Bioavailability of TMC435 Following Administration of the Liquid Formulations.||Janssen R&D Ireland|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Actual|72|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|January 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01571570||88024|
NCT01571856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protzinc2012|Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants|Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Under Six Months.||Centro Pediatrico Albina de Patino|No|Completed|July 2011|May 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|1 Month|6 Months|No|||May 2013|May 5, 2013|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571856||88002|
NCT01571609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-113-12|Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders|Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders||University of Aarhus|Yes|Completed|August 2012|November 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Male|18 Years|70 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571609||88021|
NCT01571830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 11/181, GC 1404|Improving Nutrient Intake and Growth in Children With Multiple Food Allergies|Improving Nutrient Intake and Growth in Children With Multiple Food Allergies||Medical College of Wisconsin|No|Completed|December 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|43|||Both|6 Months|6 Years|No|Non-Probability Sample|New patients to the Allergy & Immunology outpatient clinic at Children's Hospital of        Wisconsin (CHW).|August 2015|August 5, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571830||88004|
NCT01581983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008355|Mindfulness Meditation Format Pilot Study|Mindfulness Meditation Format Pilot Study||Oregon Health and Science University||Completed|April 2012|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|25 Years|65 Years|No|||July 2015|July 9, 2015|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01581983||87228|
NCT01581996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20266-01|Fosrenol and Phosphorus Balance - Lanthanum Carbonate|Effect of Lanthanum Carbonate (Fosrenol) on Fecal Phosphorus Excretion and Phosphorus Balance||Los Angeles Biomedical Research Institute|Yes|Recruiting|March 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|30 Years|65 Years|No|||October 2013|October 8, 2013|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01581996||87227|
NCT01582802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSP 64155|Determinants of Neonatal Anemia in Women Carrying Multiples|Determinants of Neonatal Iron Homeostasis in Women Carrying Multiples||Cornell University|No|Active, not recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|350|Samples With DNA|maternal and cord blood, placental tissue and RNA|Female|19 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women (n = 100-125) carrying multiples (twins, triplets and quadruplets)|January 2016|January 21, 2016|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01582802||87165|
NCT01582815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100851|A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms|A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults With Major Depressive Disorder With Anxiety Symptoms||Janssen Research & Development, LLC|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|64 Years|No|||June 2015|June 15, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582815||87164|
NCT01578954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1111|Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction|LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|60 Years|N/A|No|||October 2015|October 7, 2015|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578954||87458|
NCT01582516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL24958.000.08|Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma|A Phase I/II Trial of a Conditionally Replication-competent Adenovirus (Delta-24-rgd) Administered by Convection Enhanced Delivery in Patients With Recurrent Glioblastoma||Erasmus Medical Center|Yes|Completed|June 2010|December 2014|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||March 2015|March 6, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582516||87187|
NCT01582737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15798|Xarelto [SPAF] Post-marketing Surveillance in Japan|Special Drug Use Investigation of Xarelto [SPAF]||Bayer|No|Active, not recruiting|May 2012|March 2019|Anticipated|March 2019|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|11311|||Both|N/A|N/A|No|Non-Probability Sample|Patients with non-valvular arterial fibrillation necessary for the treatment for        prevention of ischemic stroke and systemic embolism|March 2016|March 4, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582737||87170|
NCT01583010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK572/2011|Improvement of Needle Visibility in Ultrasound Guided Regional Anaesthesia|Improvement of Needle Visibility in In-line Regional Anaesthesia by "Advanced Needle Visualization Technology ®"||Medical University of Vienna|No|Recruiting|December 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583010||87149|
NCT01583023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTMS-BD-1|Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression|Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression||McGill University Health Center|No|Not yet recruiting|April 2014|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|45|||Both|18 Years|70 Years|No|||March 2014|March 31, 2014|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583023||87148|
NCT01581125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01 HL114088-01|Sleep Duration Required to Restore Performance During Chronic Sleep Restriction|Sleep Duration Required to Restore Performance During Chronic Sleep Restriction||Brigham and Women's Hospital|No|Recruiting|April 2012|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01581125||87293|
NCT01581684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1308.1|Safety Tolerability and Pharmacokinetic of BI 411034|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 411034 (PIB) in Healthy Male Volunteers (Randomised, Single-blind, Placebocontrolled Within Dose Groups, Phase I Study)||Boehringer Ingelheim||Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment|4||Actual|62|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 13, 2014|April 19, 2012||||No|March 13, 2014|https://clinicaltrials.gov/show/NCT01581684||87251|
NCT01581697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|up 4100/07|Impact of Consumption of Oats in Lipid Profile of Children and Adolescents With Dyslipidemia|Impact of Consumption of Oats in Lipid Profile of Children and Adolescents With Dyslipidemia at the Outpatient Clinic of Reference in Preventive Pediatric Cardiology at the Institute of Cardiology of Rio Grande do Sul||Instituto de Cardiologia do Rio Grande do Sul||Recruiting||||||Phase 1/Phase 2|Interventional|N/A|1||||||Both|5 Years|16 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 17, 2012||||No||https://clinicaltrials.gov/show/NCT01581697||87250|
NCT01570725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR01|Virtual Reality to Reduce Anxiety in Ambulatory Surgical Operations|A Portable Virtual Reality System as an Alternative Medical Treatment to Reduce Anxiety in Ambulatory Surgical Operations: a Randomized Controlled Study|VRSurg|Istituto Auxologico Italiano|Yes|Withdrawn|October 2008|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|February 22, 2009||No|Difficulty in recruiting the selected subjects|No||https://clinicaltrials.gov/show/NCT01570725||88088|
NCT01570491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1171|A Real-Time Ultrasound Guided Approach For Spinal Anesthesia|||The Cleveland Clinic|No|Active, not recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|55 Years|N/A|No|||August 2015|August 19, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01570491||88106|
NCT01570504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD1-2012|Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis|Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis|STRONGTREAT|Centro per le Malattie Tropicali|Yes|Recruiting|March 2013|||December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|6 Years|N/A|No|||December 2015|December 11, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01570504||88105|
NCT01570751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3943|A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin|A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin||Novo Nordisk A/S|No|Completed|April 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|145|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|April 2, 2012|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01570751||88086|
NCT01571284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFLIBC06097|Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen|A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen||Sanofi|No|Active, not recruiting|May 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|900|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571284||88046|
NCT01571297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-004|Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis||Rhythm Pharmaceuticals, Inc.|No|Completed|April 2012|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|75 Years|No|||November 2014|November 6, 2014|April 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571297||88045|
NCT01571583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018721|An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation|Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects|REPLACE|Janssen-Cilag International NV|Yes|Completed|December 2011|July 2014|Actual|April 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|70 Years|No|||July 2015|July 14, 2015|December 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01571583||88023|
NCT01571869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU142|Pilot Study in the Cholesterol Absorption Reduction After Consumption of Low-fat, Drinkable Fermented Milk Enriched With Plant Sterols|Influence of a Meal on the Efficacy of Plant Sterol Given at Different Times of the Day in Management of Hypercholesterolemia||Danone Research|No|Completed|May 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind|2||Actual|30|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571869||88001|
NCT01572116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRCT201110137790N1|Effect of Sufentanil on the Rate of Anesthesia|Comparison the Effect of Lidocaine (With Epinephrine) With and Without Sufentanil on the Rate of Anesthesia of Intra-ligamentary Injection in Teeth With Irreversible Pulpitis||Islamic Azad University, Tehran|Yes|Completed|January 2010|October 2011|Actual|June 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|March 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572116||87982|
NCT01572090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OBECUN-WL-01|Comparison of Weight Loss Induced by Bariatric Surgery vs Conventional Treatment|Comparison of Weight Loss Induced by Bariatric Surgery vs Conventional Treatment on Body Composition, Adipokines, Gastro-intestinal Hormones and Cardiometabolic Risk Factors||Clinica Universidad de Navarra, Universidad de Navarra|No|Enrolling by invitation|January 2006|December 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|600|||Both|21 Years|65 Years|No|||April 2012|April 3, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01572090||87984|
NCT01572103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIC|Coffee Effect in HCV-related Hepatitis|Coffee Consumption and Oxidative DNA Damage, Apoptosis and Collagen Synthesis in HCV-related Liver Disease: a Prospective Randomized Trial.||Azienda Ospedaliera di Padova|No|Completed|January 2010|June 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|80 Years|No|||April 2012|April 4, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01572103||87983|
NCT01572402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5206|Postprandial Insulin Secretion, Oxidative Stress and Gastrointestinal Peptides in Patients With Type 2 Diabetes Versus Healthy Subjects|||Institute for Clinical and Experimental Medicine|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|100|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572402||87960|
NCT01579474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.54|Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial|Safety, Efficacy and Pharmacokinetics of BI 201335 NA in Patient With Genotype 1 Chronic Hepatitis C Virus Infection in Combination With Pegylated Interferon Alfa-2b and Ribavirin - Cohort 1 for Treatment-naive Patients: Randomised, Double-blind Part of BI 201335 NA for 12 or 24 Weeks - Cohort 2 for Treatment-experienced Patients: Open-label Part of BI 201335 NA for 24 Weeks||Boehringer Ingelheim||Completed|April 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|131|||Both|20 Years|70 Years|No|||July 2015|July 3, 2015|April 12, 2012||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01579474||87418|
NCT01579487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA10-001.A1-EXT|Extended Follow-Up Study for Subjects Who Participated in 2010 Study|Non-Invasive Reduction of Abdominal Fat Utilizing the JUNO Applicator|JUNO|Zeltiq Aesthetics|No|Completed|March 2012|February 2013|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2012|February 4, 2013|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01579487||87417|
NCT01581710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA-121|Bronchoprotection Effect of Montelukast in Children With Persistent Allergic Rhinitis|A Double-blind, Randomized, Cross-over Design Study to Compare the Bronchoprotection Effect of Montelukast Versus Placebo in Preschool Children With Persistent Allergic Rhinitis Without Overt Asthma Symptoms Using Bronchial Challenge Test||CHA University|No|Completed|May 2012|December 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|28|||Both|3 Years|7 Years|No|||January 2016|January 26, 2016|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01581710||87249|
NCT01581723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUHK_TURB_2012|Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor|Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial||Chinese University of Hong Kong|No|Recruiting|May 2012|September 2015|Anticipated|June 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01581723||87248|
NCT01581736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004005|Molecular Regulation of Muscle Glucose Metabolism|Molecular Regulation of Muscle Glucose Metabolism||Mayo Clinic|No|Recruiting|April 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|60|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01581736||87247|
NCT01582542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0366-11-RMC|Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction|Usage of Desmopressin fo Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Orthotopic Bladder Reconstruction||Rabin Medical Center|Yes|Active, not recruiting|April 2012|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582542||87185|
NCT01582295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005|XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease|Dose Finding Pilot Study of Cabozantinib (XL184) Administered Orally as Monotherapy for the Treatment of Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With Bone Disease||Massachusetts General Hospital|Yes|Active, not recruiting|June 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||August 2015|August 23, 2015|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582295||87204|
NCT01582308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-142|A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)|A Study to Assess and Compare the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Actual|22|||Both|18 Years|65 Years|No|||April 2015|April 1, 2015|April 19, 2012|No|Yes||No|December 4, 2013|https://clinicaltrials.gov/show/NCT01582308||87203|
NCT01579981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-A-2008-080-31742|The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects|||Hvidovre University Hospital|No|Recruiting|April 2012|||November 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|10|||Both|25 Years|N/A|No|||April 2012|April 17, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01579981||87379|
NCT01579994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-015|Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers|A Phase I Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579994||87378|
NCT01582750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH-RO-GI-eus|Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy|Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy||Chinese Academy of Medical Sciences|No|Recruiting|October 2010|December 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|75 Years|No|Non-Probability Sample|Local advanced rectal cancer|September 2013|September 17, 2013|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582750||87169|
NCT01580865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-LN-11-01|Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis|Comparison Between Tacrolimus and Mycophenolate Mofetil for Induction of Remission in Lupus Nephritis||Ramathibodi Hospital|Yes|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|N/A|N/A|No|||November 2015|November 2, 2015|April 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01580865||87313|
NCT01590550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120017|Observational Study of Citrate Based Dialysis in Pediatric Patients Receiving Hemodialysis|A Prospective Study of Citrate Based Dialysate in Pediatric Patients Receiving Intermittent Hemodialysis||Loma Linda University|No|Completed|May 2012|August 2015|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|18|||Both|N/A|21 Years|No|Non-Probability Sample|Admitted pediatric patients|February 2016|February 2, 2016|April 29, 2012||No||No|February 2, 2016|https://clinicaltrials.gov/show/NCT01590550||86579|No control group
NCT01590004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lumbar01|Technical Description of Cooled Radiofrequency Ablation of Lumbar Medial Branches for the Treatment of Lumbar Facet Pain|Technical Description of Cooled Radiofrequency Ablation of Lumbar Medial Branches for the Treatment of Lumbar Facet Pain||MAPS Applied Research Center|Yes|Recruiting|August 2012|||March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|75 Years|No|Probability Sample|Patients of Medical Advanced Pain Specialists, PA (MAPS)|May 2015|May 18, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590004||86621|
NCT01570465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML1411|Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients|Prospective Survey on Severe Infections During a Multicenter Study of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia.|AML1411|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|237|||Both|18 Years|60 Years|No|Non-Probability Sample|All patients receiving induction, consolidation and salvage chemotherapy, and autologous        or allogeneic stem cell transplantation according to a strategy defined in the GIMEMA        AML1310 protocol will be prospectively monitored for SI (bacteremia, invasive mycoses,        other microbiologically documented bacterial infections, pneumonia, other invasive tissue        infections and viral diseases) during each chemotherapy and transplant and the impact of        these infections on survival will be evaluated until 24 months from the diagnosis of AML.|February 2015|February 23, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570465||88108|
NCT01570478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/15009/001/11|A Study in Patients With Asthma|A 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® NEXThaler® (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Inhalations b.i.d., Versus Seretide® Accuhaler® (Fluticasone 250 µg Plus Salmeterol 50 µg/Actuation), 1 Inhalation b.i.d., on Small Airway Derived Parameters in Patients With Asthma|NELSON|Chiesi Farmaceutici S.p.A.|No|Completed|July 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|108|||Both|18 Years|N/A|No|||January 2015|January 19, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570478||88107|
NCT01571024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1036|BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer|A Phase I Study of BKM120 With mFOLFOX6 in Patients With Advanced Solid Tumors With Expansion Cohort in Metastatic Pancreatic Cancers.||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|May 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|January 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571024||88065|
NCT01571323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTRN12612000095864|Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section|||Qazvin University Of Medical Sciences|Yes|Completed|February 2012|September 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Female|18 Years|42 Years|No|||October 2012|October 10, 2012|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571323||88043|
NCT01571011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJF 68177|Chicago Urban Resiliency Building (CURB)|Chicago Urban Resiliency Building (CURB): Phase 3 Clinical Trial in Primary Care to Engage Adolescents With a Web-based Depression Prevention Intervention|CURB|University of Illinois at Chicago|No|Completed|March 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|10|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||July 2015|July 31, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01571011||88066|
NCT01571310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCCCBI 017-2007-112|Effect of Breakfast or Omission of Breakfast in T2D|Effect of Breakfast Omission on Postprandial Glycemia After Lunch and Dinner in T2D|OB-B|Tel Aviv University|Yes|Active, not recruiting|July 2012|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Female|30 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01571310||88044|
NCT01571596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRN23-INT-002|An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia|An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|February 2012|June 2014|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|February 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571596||88022|
NCT01572168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-14423|Acupuncture for the Treatment of Cancer Related Fatigue|A Phase II Study of Acupuncture for the Treatment of Cancer Related Fatigue in Children and Adolescents With Central Nervous System Tumors||Ann & Robert H Lurie Children's Hospital of Chicago|No|Terminated|September 2011|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|7|||Both|8 Years|21 Years|No|||February 2016|February 3, 2016|February 24, 2012||No|slow accrual|No||https://clinicaltrials.gov/show/NCT01572168||87978|
NCT01568931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|197/2012/D|Local Thrombolytics Before Thrombectomy in STEMI|Local Delivery of thrombolytIcs Before Thrombectomy in patientS With ST-elevatiOn myocardiaL Infarction Undergoing Primary percuTaneous Coronary interventION - The DISSOLUTION Randomized Trial|DISSOLUTION|University of Roma La Sapienza|No|Not yet recruiting|January 2014|March 2017|Anticipated|March 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568931||88226|
NCT01572142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01N5070856|Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease|Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PD|OLF|University of Michigan|No|Active, not recruiting|August 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|75|Samples With DNA|saliva|Both|50 Years|N/A|No|Non-Probability Sample|Movement Disorders Clinic, Hospital, Primary Care, Community|July 2015|July 27, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572142||87980|
NCT01572129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005449-11|Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy|Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial.||Campus Bio-Medico University|No|Recruiting|November 2011|||May 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|90 Years|No|||April 2012|April 4, 2012|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572129||87981|
NCT01572441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0909005677|Parent-Adolescent Interactions and Adolescent Development|Responses During Parent-child Interactions and Alcohol Use Behavior in Adolescents.|PAIT|George Mason University|Yes|Active, not recruiting|September 2009|July 2018|Anticipated|July 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Retain saliva sample.|Both|12 Years|14 Years|Accepts Healthy Volunteers|Non-Probability Sample|12-14 year olds and their primary caregivers.|August 2015|August 11, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572441||87957|
NCT01580904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEParaiba|Impact of Pharmaceutical Care in Diabetics Patients|Popular Pharmacy of Brazil: Impact of Pharmaceutical Care in Diabetics Patients|IPCD|Universidade Estadual da Paraiba|Yes|Completed|September 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|101|||Both|30 Years|80 Years|No|||April 2012|April 17, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01580904||87310|
NCT01580917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUSPM-JF-01|Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study|Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control|ILH|Temple University|No|Completed|November 2007|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|18|||Both|40 Years|75 Years|No|Non-Probability Sample|A community sample|November 2015|November 3, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580917||87309|
NCT01582035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100735|Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir|A Phase I, Open Label Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC647055 Given in Combination With Telaprevir||Janssen R&D Ireland|No|Completed|April 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|60 Years|No|||February 2014|February 14, 2014|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582035||87224|
NCT01582048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E:531/2011|Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning|Multicenter Phase II Study of Peritransplantation Immunosuppression Using ATG, Rituximab, Sirolimus and Mycophenolate Mofetil in Patient Receiving Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning With Fludarabine and Treosulfan||University Hospital Tuebingen|Yes|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||December 2014|December 3, 2014|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01582048||87223|
NCT01588561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-p-001656|Effects of IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones, and Subjective Ratings of Stimulant Drug Effect|Effects of IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones, and Subjective Ratings of Stimulant Drug Effect||Mclean Hospital|No|Completed|October 2005|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|145|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|April 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588561||86729|
NCT01588574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-GPRT-CD01|Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia|||Medy-Tox|Yes|Completed|August 2012|December 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||February 2013|September 5, 2014|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01588574||86728|
NCT01582581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VHS 85350-02|Study of Technology-assisted Treatment of Adolescent Depression|Information Technology Enabled Treatment of Adolescent Depression|iTAD|iHope Network, Inc.|Yes|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|45|||Both|12 Years|17 Years|No|||April 2015|April 29, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582581||87182|
NCT01589718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No-Crunch 01|A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy|A Phase III Randomized 1:1, Masked, Study of the Safety, Tolerability, and Efficacy of Intravitreal Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Adjuvant Management of TRD and Vit Hem Associated With PDR|No-Crunch01|Greater Houston Retina Research|Yes|Withdrawn|April 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|April 27, 2012|No|Yes|No patients were enrolled|No||https://clinicaltrials.gov/show/NCT01589718||86642|
NCT01579448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-WC-11|Evaluation of a Boosting Regimen With Oral Cholera Vaccine|A Open Labeled Controlled Trial to Evaluate the Immune Response of a Boosting Regimen With Shanchol™, a Killed Whole Cell Oral Cholera Vaccine (WC-OCV), in Previously Immunized Adults and Children in Eastern Kolkata, India|Boost|International Vaccine Institute|Yes|Completed|December 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|426|||Both|6 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 24, 2013|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01579448||87420|
NCT01581424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0811M54283|Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study|Natural History and Structural Functional Relationships in Fabry Renal Disease Natural History, Structural Functional Relationships and Determinants of Renal Structural Responses (Changes) With Enzyme Replacement Therapy in Fabry Disease|LDN6702|University of Minnesota - Clinical and Translational Science Institute|No|Recruiting|October 2010|September 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum and Plasma samples as well as urine samples from an overnight collection.|Both|1 Year|75 Years|No|Non-Probability Sample|50-60 male and female adults and children with Fabry disease who either have or have not        been initiated on enzyme replacement therapy, and whose physicians have determined that a        kidney biopsy and renal functional studies are clinically indicated before initiation of        enzyme replacement therapy and as follow-up for this therapy or who have completed        clinical trials of ERT, have baseline or baseline and and follow biopsies, and have        consented to allow their tissues to be examined for research purposes. We are expecting to        recruit patients from many different centers.|December 2015|December 1, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01581424||87271|
NCT01581671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005160|Non-Invasive EndoPAT Increases Diagnostic Yield of CAD by Coronary Angiography|Non-Invasive Peripheral Arterial Tonometry (EndoPAT) Increases Diagnostic Yield of Coronary Artery Disease by Coronary Angiography||Mayo Clinic|No|Completed|September 2010|June 2014|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|201|||Both|18 Years|N/A|No|Probability Sample|Patients coming to the Cardiac Cath Lab to determine if they have coronary artery disease|June 2014|June 24, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01581671||87252|
NCT01590017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-081|Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer|Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer||AIDS Malignancy Consortium|No|Active, not recruiting|April 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|120 Years|No|||November 2015|March 22, 2016|May 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590017||86620|
NCT01590030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mesial Dermoid Incision|Ovarian Mesial Incision: a New Safe and Fertility-sparing Technique|Mesial Incision for Laparoscopic Dermoid Cystectomy: a New Safe and Fertility-sparing Technique||University Magna Graecia|No|Completed|September 2004|January 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Female|18 Years|45 Years|No|||May 2012|May 2, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590030||86619|
NCT01570192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0060|Clinical Trials to Reduce the Risk of Antimicrobial Resistance|Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation||University of Florida|Yes|Terminated|January 2013|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|March 22, 2012|Yes|Yes|NIAID terminated the study due to low subject enrollment|No||https://clinicaltrials.gov/show/NCT01570192||88129|
NCT01568034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-201|A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067|A Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 on the Levodopa Pharmacokinetics, Motor Response, and Erythrocyte Soluble Catechol-O-methyltransferase Activity in Parkinson's Disease Patients Concomitantly Treated With Levodopa/Dopa-decarboxylase Inhibitor||Bial - Portela C S.A.|No|Completed|April 2009|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|10|||Both|30 Years|75 Years|No|||December 2014|December 19, 2014|March 29, 2012||No||No|February 5, 2014|https://clinicaltrials.gov/show/NCT01568034||88295|
NCT01568047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-202|Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients|Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations ("Wearing-off" Phenomenon)||Bial - Portela C S.A.|No|Completed|February 2010|June 2010|Actual|June 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|30 Years|N/A|No|||November 2015|November 23, 2015|March 29, 2012||No||No|February 5, 2014|https://clinicaltrials.gov/show/NCT01568047||88294|
NCT01571622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0175-11-WOMC|Whey Protein on Posprandial Glucose, Insulin GLP-1, GIP and DPP4 in Type 2 Diabetes|Effect of Whey Protein Concentrate on Postprandial Glycemic Insulin, Active and Intact GLP-1and GIP, and DPP-4 Response in Type 2 Diabetic Patients|WheyGLP-1|Tel Aviv University|Yes|Completed|April 2012|September 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|40 Years|70 Years|No|||March 2014|March 27, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571622||88020|
NCT01571635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-011-B-THAL-001|Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.|A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA.||Celgene|No|Active, not recruiting|October 2012|November 2019|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|46|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571635||88019|
NCT01571882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU235|Effects of Fermented Milk Product Enriched With Plant Sterols and Policosanols in Mild Hypercholesterolaemic Adults|Effects of the Consumption of a no Added Sugar Fermented Milk Product Enriched With Plant Sterols and Policosanols on Hypercholesterolaemia Management in Moderately Hypercholesterolaemic Adults||Danone Research|No|Completed|June 2007|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|3||Actual|72|||Both|20 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 4, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571882||88000|
NCT01572155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53497|Pilot Study: Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve|Pilot Study: Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve: Potential New Therapeutic Intervention to Shorten Postoperative Ileus||Katholieke Universiteit Leuven|No|Completed|March 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|70 Years|No|||December 2015|December 3, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01572155||87979|
NCT01569477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0198|Striving to Quit-Wisconsin Tobacco Quit Line|Striving to Quit: Wisconsin Tobacco Quit Line Tobacco Cessation Research||University of Wisconsin, Madison|No|Withdrawn|September 2012|March 2013|Actual|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 7, 2013|March 30, 2012||No|Not able to recruit participants|No||https://clinicaltrials.gov/show/NCT01569477||88184|
NCT01572454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02-012-001|Comparison of Dexmedetomidine and Remifentanil Infusion During CABG|The Comparison of Serum Potassium Concentration, Antiarrhythmic Effect, and Myocardial Protective Effect Between Dexmedetomidine and Remifentanil Infusion in Patients Undergoing Coronary Artery Bypass Surgery||Samsung Medical Center|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|77|||Both|20 Years|70 Years|No|||December 2013|December 24, 2013|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572454||87956|
NCT01572740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3925|Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes|A 36-week, Randomised, Multi-centre, Double-blind, Parallel Group Trial to Investigate the Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus||Novo Nordisk A/S|No|Completed|April 2012|March 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|257|||Both|20 Years|N/A|No|||June 2014|June 11, 2014|April 4, 2012|Yes|Yes||No|March 27, 2014|https://clinicaltrials.gov/show/NCT01572740||87934|
NCT01572753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-3794|Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects|A Single Centre, Multiple Dose, Open Label Randomised Trial to Evaluate the Effect of Post Dose Meal Timings and the Effect of Volume of Water With Dosing on the Pharmacokinetic Properties of Oral Semaglutide in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|161|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|April 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01572753||87933|
NCT01588249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZMCS-6441|A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection|A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection||Zarbee's Inc.||Terminated|April 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|12 Months|No|||October 2012|October 9, 2012|April 26, 2012||No|Revisiting product options|No||https://clinicaltrials.gov/show/NCT01588249||86753|
NCT01588535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR01.004|Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis Media|Phase 2, Multicenter, Placebo-controlled, Double-masked, Randomized Study to Demonstrate Reliability and Validity of FAECC Scale (Modified FLACC) to Evaluate Relief of Pain in Subjects With Acute Otitis Media Aged >/=2 Months to <5 Years||Arbor Pharmaceuticals, Inc.|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|38|||Both|2 Months|4 Years|No|||March 2015|April 13, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588535||86731|
NCT01588548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4510C00005|Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma||AstraZeneca|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|130 Years|No|||October 2015|October 6, 2015|April 27, 2012|No|Yes||No|July 24, 2015|https://clinicaltrials.gov/show/NCT01588548||86730|
NCT01589471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 11.088|The Value of Botox-A for Management of Low Anterior Resection Syndrome|The Value of Botox-A Administered as a Single Intra-rectal Injection for the Management of Low Anterior Resection Syndrome: A Phase II Study||Centre hospitalier de l'Université de Montréal (CHUM)|No|Active, not recruiting|May 2012|November 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|80 Years|No|||May 2015|May 7, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589471||86661|
NCT01582763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC-2011-477|International Guillain-Barré Syndrome Outcome Study|International GBS Outcome Study (IGOS): A Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).|IGOS|Erasmus Medical Center||Recruiting|May 2012|January 2019|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|4000|Samples With DNA|serum, cerebrospinal fluid, samples with DNA|Both|N/A|N/A|No|Non-Probability Sample|All patients with Guillain-Barré syndrome (GBS) or variants of GBS, including the Miller        Fisher syndrome (MFS) and overlap syndromes.|March 2015|March 2, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582763||87168|
NCT01583036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116216|An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed|An Interaction Study to Assess the Effect of the Ezogabine/Retigabine and the Main Metabolite NAMR on the Pharmacokinetics of Digoxin in Healthy Volunteers||GlaxoSmithKline|No|Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01583036||87147|
NCT01589133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD-201108|Surgiscreen Registration|A Multi-center Clinical Study for Assessment of the Consistency of the Results of Human Irregular Antibody Screening With Surgiscreen and Serascan Diana 3||Johnson & Johnson Medical, China|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|3109|Samples Without DNA|Plasma or Serum left after routine clinical testing.|Both|N/A|N/A|No|Non-Probability Sample|Patients who need transfusion therapy in investigator sites.|April 2012|May 29, 2013|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589133||86687|
NCT01589146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unipg-CRU-01-2012|ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.|ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.|PRO-LAPS I|University Of Perugia|No|Recruiting|September 2010|||December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||April 2012|April 28, 2012|April 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01589146||86686|
NCT01580293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13024|A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A|A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A|PROTECT-VIII|Bayer|Yes|Active, not recruiting|April 2012|February 2017|Anticipated|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|141|||Male|12 Years|65 Years|No|||December 2015|December 16, 2015|March 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01580293||87356|
NCT01590277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-026-11F|Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans|Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans||VA Office of Research and Development|No|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|4||Anticipated|49|||Both|21 Years|35 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|April 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590277||86600|
NCT01590290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16033|Randomized Controlled Cluster Trial of Resident Pay for Performance and Cardiovascular Outcomes|Randomized Controlled Cluster Trial of Resident Pay for Performance and Cardiovascular Outcomes||University of Virginia|No|Recruiting|April 2012|||April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|N/A|No|||April 2012|May 1, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590290||86599|
NCT01567488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GETNE 1003|Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET|A Phase II Study on Everolimus, an mTOR Inhibitor (Oral Formulation), With Octreotide LAR® in Adult Patients With Advanced, Non-functioning, Well-differentiated Gastrointestinal Neuroendocrine Tumours (GI NET)|EVERLAR|Grupo Espanol de Tumores Neuroendocrinos|Yes|Active, not recruiting|June 2011|April 2018|Anticipated|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567488||88337|
NCT01570764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081241|Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease|Intravenous Cyclophosphamide for the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease|SCLEROCYC|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|January 2013|March 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570764||88085|
NCT01567722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-083|Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies|Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies||AIDS Malignancy Consortium|No|Recruiting|July 2012|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Fresh-frozen tissue, Peripheral blood mononuclear cells|Both|18 Years|N/A|No|Non-Probability Sample|HIV-infected males and females age 18 and older with one of the three malignancy types        studied with available diagnostic biopsy material|October 2015|February 22, 2016|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01567722||88319|
NCT01567735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100695|A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients|An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Subjects|RESTORE|Janssen R&D Ireland|Yes|Completed|March 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Both|18 Years|70 Years|No|||April 2015|April 13, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01567735||88318|
NCT01567748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00021889|In-human Validation of a Technique for Measuring Central Aortic Hemodynamics With Peripheral Arterial Waveforms|In-human Validation of a Technique for Measuring Central Aortic Hemodynamics With Peripheral Arterial Waveforms||University of Alberta|Yes|Completed|January 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|40|||Both|18 Years|80 Years|No|Non-Probability Sample|This study is looking at those individuals undergoing Coronary Artery Bypass surgery        requiring CPB, between the age of 18-80, with a BMI < 35.|December 2014|December 3, 2014|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01567748||88317|
NCT01568398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/OCT-304|A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy|||Takeda||Completed|May 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||Actual|27|||Both|20 Years|N/A||||February 2014|February 7, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568398||88267|
NCT01568710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120101|Blood Flow and Pain Crises in People With Sickle Cell Disease|Measurement of the Reactive Hyperemia Index in Sickle Cell Patients During Pain Crisis and After Recovery||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|120|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01568710||88243|
NCT01568359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00046786|Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors|Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.||Emory University|No|Completed|December 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|49|Samples Without DNA|Blood and urine samples obtained from subjects.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with uncontrolled acromegaly and nonfunctioning pituitary adenomas presenting to        the Emory University Pituitary Center for medical or surgical treatment.|December 2014|December 4, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568359||88270|
NCT01568372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tonsils|Efficacy of a Nurse Telephone Follow-up on Pain Intensity After Removal of Tonsils in Children|Efficacy of a Nurse Telephone Follow-up on Post-tonsillectomy Pain Management and Complications in Children: A Randomized Clinical Trial||St. Justine's Hospital|No|Completed|May 2010|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|52|||Both|4 Years|12 Years|Accepts Healthy Volunteers|||March 2012|March 30, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01568372||88269|
NCT01568697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120100|Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)|Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|7 Years|N/A|Accepts Healthy Volunteers|||July 2015|March 4, 2016|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01568697||88244|
NCT01569776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.55.PED|Elemental Formula Hypoallergenicity|Evaluation of Hypoallergenicity of an Amino Acid-Based Infant Formula||Nestlé|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|37|||Both|2 Months|12 Years|No|||June 2013|June 24, 2013|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569776||88161|
NCT01569217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 003-CCP Ile de France XI|Regional Distribution of Ventilation to Assess Respiratory Muscle Dysfunction|Construction of a Database to Identify Early Indicators of Respiratory Muscle Dysfunction in Neuromuscular Patients From the Optoelectronic Plethysmography Assessment of the Thoracoabdominal Motion||Centre d'Investigation Clinique et Technologique 805|Yes|Enrolling by invitation|June 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Neuromuscular patients|July 2015|July 27, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01569217||88204|
NCT01569464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RL0003|Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)|A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome|RESTORE|UCB Pharma|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|75 Years|No|||August 2014|August 13, 2014|March 30, 2012|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01569464||88185|
NCT01569737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914-012|Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella|Prospective Multicenter Observational Study to Assess Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella|ellipse II|HRA Pharma|Yes|Recruiting|January 2012|April 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Pregnant women who have been exposed to ella during the menstrual cycle in which the        pregnancy started or at any time during pregnancy will be enrolled in the study.|January 2014|September 18, 2014|March 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01569737||88164|
NCT01569750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100844|A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma|A Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With CD20-Positive B-Cell Non Hodgkin Lymphoma (NHL)||Janssen Research & Development, LLC|Yes|Completed|June 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|March 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01569750||88163|
NCT01587963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220100048|High Dose Vitamin C in the Critically Ill Patient|The Efficacy of High Dose Vitamin C in the Critically Ill Patient Population|VitC|Rutgers, The State University of New Jersey|Yes|Terminated|February 2013|April 2015|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|8|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|April 26, 2012|No|Yes|PI's additional responsibilities and time commitments prevent him from completing this    clinical trial so he decided to close the study prematurely|No||https://clinicaltrials.gov/show/NCT01587963||86775|
NCT01588262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REKnr 2010/1911|Early Rehabilitation of Cancer Patients|Early Rehabilitation of Cancer Patients||Haukeland University Hospital|Yes|Completed|May 2011|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|300|||Both|18 Years|81 Years|No|||October 2015|October 12, 2015|January 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01588262||86752|
NCT01588275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL34138.042.10|MRA Therapy Versus CPAP Therapy in Moderate OSAS|Cost-effectiveness of obstRuctivE Sleep Apnea Therapy (REST Study): Comparison of MRA Therapy Versus CPAP Therapy in Moderate OSAS|REST|University Medical Center Groningen|No|Recruiting|March 2012|July 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01588275||86751|
NCT01579695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200147-501|Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®|A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®||Theratechnologies|Yes|Recruiting|February 2013|January 2025|Anticipated|December 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3190|||Both|18 Years|N/A|No|Probability Sample|Study population will be representative of the HIV-injected population affected by        abdominal lipohypertrophy|July 2015|August 11, 2015|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579695||87401|
NCT01579968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7-1948|Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery|Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery||Novo Nordisk A/S|No|Completed|March 1999|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|86|||Both|N/A|N/A|No|Non-Probability Sample|Patients with haemophilia A and B with inhibitors who received NovoSeven® (eptacog alpha)        as treatment when undergoing the surgery|August 2014|August 8, 2014|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579968||87380|
NCT01589172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120296|Evaluating the Use of Thromboelastography to Diagnose Coagulopathy After Traumatic Brain Injury|Evaluating the Use of Thromboelastography to Diagnose and Monitor Coagulopathy Associated With Pediatric Traumatic Brain Injury||University of California, San Diego|No|Recruiting|May 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|15 Years|No|Non-Probability Sample|Trauma patients admitted to the Rady Children's Hospital Pediatric Intensivse Care Unit|May 2015|May 28, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589172||86684|
NCT01589445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-67/2008-09|Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects|Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.|T2DMCT|University of Dhaka|Yes|Completed|November 2008|June 2010|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|40 Years|50 Years|No|||February 2014|February 26, 2014|April 29, 2012|Yes|Yes||No|May 5, 2012|https://clinicaltrials.gov/show/NCT01589445||86663|The sample size was relatively small for more detailed analysis, treatment period was also short and there was a possibility of confounding by the use of non-study medication.
NCT01589731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEC-2008|Polymerized Beta-lactoglobulin Comparative Immunoreactivity|Study of the Immunoreactivity of Native and Polymerized Beta-lactoglobulin in Children and Adults With Cow's Milk Allergy and/or Intolerance|ImmuneBLG|University of Campinas, Brazil|No|Completed|July 2010|July 2011|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|114|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with convincing clinical histories of reproducible adverse reactions to bovine        milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.|April 2012|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589731||86641|
NCT01589991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOPBioq002|Anticaries Potential and Fluorosis Risk From Different Fluoride Toothpastes|Anticaries Potential and Fluorosis Risk From Different Fluoride Toothpastes||University of Campinas, Brazil|No|Completed|January 2011|July 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|4||Actual|24|||Both|3 Years|4 Years|Accepts Healthy Volunteers|||October 2013|October 25, 2013|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01589991||86622|
NCT01567761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3111|The Effect of Two Different Artificial Respiration Methods on the Intraocular Pressure During Surgery Under General Anesthesia|A Prospective, Randomized and Double Blind Study on The Effect of Two Different Artificial Respiration Methods on the Intraocular Pressure During Surgery Under General Anesthesia||Western Galilee Hospital-Nahariya|No|Not yet recruiting|May 2012|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Patients aged 18 - 40, candidates to elective orthopedic surgery in the limbs. These        patients do not suffer from general diseases that restrict their daily functioning.|March 2012|March 29, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01567761||88316|
NCT01568073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-91067-301|Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon|Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study||Bial - Portela C S.A.|No|Completed|March 2011|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|600|||Both|30 Years|83 Years|No|||September 2015|September 1, 2015|March 29, 2012||No||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01568073||88292|
NCT01568060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114917|Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea|Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus Vaccine, Infanrix-IPV When Administered According to the Approved Prescribing Information in Korea||GlaxoSmithKline||Recruiting|May 2012|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|456|||Both|2 Months|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infants and children who receive at least one dose of Infanrix-IPV as a part of routine        practice at a private clinic or hospital.|July 2015|July 20, 2015|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01568060||88293|
NCT01568385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/OCT-303|A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy|||Takeda||Completed|April 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|N/A||||February 2014|February 7, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568385||88268|
NCT01568411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0089|A Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211|A Phase 1, Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211||Theravance Biopharma R & D, Inc.|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|March 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568411||88266|
NCT01568424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC10152008|CentriMag RVAS U.S. Post-approval Study Protocol|CentriMag RVAS U.S. Post-approval Study Protocol||Thoratec Corporation|No|Completed|September 2009|June 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|N/A|No|||July 2014|July 29, 2014|March 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568424||88265|
NCT01568723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006510|Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation|Stem Cells And The Origins Of Barrett's Esophagus:Identification Of Novel Biomarkers And Gene Signatures In Barrett's Esophagus|BetrnetRF|Mayo Clinic|No|Recruiting|January 2012|August 2020|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|biopsy samples, serum, plasma, buffycoat, cytology brushings|Both|18 Years|N/A|No|Non-Probability Sample|Participants must have biopsy proven Barret's esophgus with evidence of specialized        intestinal epithelium with high grade dysplasia or early intramucosal carcinoma (mEAC) on        histology (confirmed by two pathologists). Patients must have a BE length ≥ 2 cm and ≤ 8        cm.|January 2016|January 4, 2016|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568723||88242|
NCT01568957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SDG7270001|Training Dual-Task Walking After Stroke|Training Dual-Task Walking After Stroke: Effects on Attentional and Locomotor Control||University of North Carolina, Chapel Hill|No|Recruiting|September 2011|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01568957||88224|
NCT01568944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DE020916|Role of Infected Blood Dendritic Cells in Heart Disease Risk|Peripheral Blood Dendritic Cells and Periodontitis||Georgia Regents University|Yes|Completed|March 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|19|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01568944||88225|
NCT01569243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-002708/1; MGH|Text to Move (TTM)Study|Using Activity Monitoring and Text Messaging For Behavior Change in a Diabetes Self-Management Program|TTM|Massachusetts General Hospital|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|126|||Both|18 Years|N/A|No|||February 2014|February 4, 2014|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01569243||88202|
NCT01569230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B080017-KCT0000385|Efficacy and Safety Study of Individualized and Standardized Acupuncture Treatment for Knee Osteoarthritis|Clinical Trial to Evaluate and Compare the Efficacy and Safety of Individualized and Standardized Acupuncture for Knee Osteoarthritis Patients: Randomized, Single-blind, Controlled Study||DongGuk University|Yes|Recruiting|October 2010|December 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|250|||Both|20 Years|80 Years|No|||April 2012|April 2, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01569230||88203|
NCT01565967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AutoLog|Registry AutoLog Lipid Removal and Blood Component Characterization|Registry AutoLog Lipid Removal and Blood Component Characterization||Medtronic Cardiovascular|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|199|Samples With DNA|Whole blood and washed blood will be collected from each patient|Both|N/A|N/A|No|Non-Probability Sample|The subject population includes all subjects with an indication for cardiac surgery,        orthopedic surgery etc. in which the hospital treatment protocol requires the routine use        of an autotransfusion system, and who meet the inclusion and exclusion criteria.|October 2015|October 28, 2015|June 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01565967||88453|
NCT01569763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP0005|Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation|Minerva Pivotal Study||Minerva Surgical, Inc.|Yes|Active, not recruiting|March 2012|April 2017|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|153|||Female|25 Years|50 Years|No|||March 2016|March 14, 2016|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569763||88162|
NCT01570049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGB-NHL|Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma|A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma||Shandong Lanjin Pharmaceuticals Co.,Ltd|Yes|Recruiting|April 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|75 Years|No|||August 2012|August 1, 2012|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570049||88140|
NCT01587703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115521|A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers|A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers||GlaxoSmithKline||Recruiting|March 2012|May 2020|Anticipated|May 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|225|||Both|16 Years|N/A|No|||March 2016|March 10, 2016|April 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01587703||86795|
NCT01588587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7-Kamoi|DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients|Effect of DPP-IV Inhibitors on Occurence of Cancers and the Mechanism Using AGE and RAGE in Patients With Type 2 Diabetes||Nagaoka Red Cross Hospital|No|Not yet recruiting|October 2012|December 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|20 Years|95 Years|No|Probability Sample|500 patients|April 2012|October 17, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588587||86727|
NCT01588860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099084-F|Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma|Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma||Far Eastern Memorial Hospital|Yes|Active, not recruiting|January 2011|||December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|Samples Without DNA|Fixed tissue in the paraffin embedded blocks|Both|20 Years|N/A|No|Non-Probability Sample|The patients diagnosed as biliary tact adenocarcinoma.|December 2010|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588860||86708|
NCT01588912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDT600AKR07T|Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir|A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients|TETRA|Pusan National University Yangsan Hospital|No|Recruiting|April 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588912||86704|
NCT01589185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBSA301-001|Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of KBSA301 in Severe Pneumonia (S. Aureus)||Aridis Pharmaceuticals, Inc.|Yes|Recruiting|April 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|52|||Both|18 Years|80 Years|No|||December 2015|December 28, 2015|April 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01589185||86683|
NCT01589198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJH HS-2639|Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma|Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma||National Jewish Health|No|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|110|Samples Without DNA|Blood and lung samples will be retained for RNA purposes.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|We are looking for mild non-smoking asthmatic adults who are well-controlled with their        asthma therapy (non-refractory asthmatics).|March 2016|March 23, 2016|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589198||86682|
NCT01590342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000247-27|Diclofenac for Submassive PE|Efficacy of Diclofenac for Patients With Acute Submassive Pulmonary Embolism: a Randomized Clinical Trial|AINEP-1|Ministry of Health, Spain|Yes|Recruiting|May 2012|January 2016|Anticipated|September 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2014|September 4, 2014|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590342||86595|
NCT01580579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCANOGAR2012-JA2|Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer Treated With Chemoradiation|Clinical, Biochemical, Dosimetric and Functional Respiratory Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer (Stages IIIa and IIIb) Treated With Chemotherapy and Radiotherapy||Instituto Nacional de Cancerologia de Mexico|No|Recruiting|July 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with locally advanced lung cancer candidates to receive treatment with        chemoradiation that will receive treatment in the National Cancer Institute in Mexico        City.|February 2016|February 22, 2016|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580579||87335|
NCT01580592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025EDE14T|Cold Urticaria Treatment With Xolair|A Two-center, Double Blind, Placebo-controlled Study in Parallel Design to Assess the Efficacy and Safety of 150 and 300 mg Omalizumab in Subjects With Antihistamine-resistant Cold Contact Urticaria (CCU)|CUTEX|Charite University, Berlin, Germany|No|Completed|April 2012|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|April 18, 2012||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT01580592||87334|
NCT01580605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHDA-1755|French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin|Prospective, Longitudinal and National Follow-up Program of Adult Patients With Somatotropic Hormone Deficiency for Whom Substituting Treatment by Norditropin SimpleXx Was Started||Novo Nordisk A/S|No|Completed|July 2003|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|331|||Both|N/A|N/A|No|Non-Probability Sample|All adult patients with growth hormone deficiency and treated with Norditropin® SimpleXx        (somatropin) for whom Norditropin® SimpleXx® has been initiated either before or during        the registry inclusion period|April 2014|April 29, 2014|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01580605||87333|
NCT01589744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 11 24|Proof of Concept Study of a Sucker Hemostatic Intra Uterine in Postpartum Hemorrhage After Abruptio Placenta Assisted|Vacuum Device for Hemostasis in Obstetrics and Gynecology: Proof of Concept Study in the Post Partum Hemorrhage||University Hospital, Grenoble|Yes|Terminated|July 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|15|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|April 25, 2012||No|Non adequation between the medical device and the study population|No||https://clinicaltrials.gov/show/NCT01589744||86640|
NCT01568086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF005B|Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A|Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A||Affiris AG|Yes|Terminated|December 2011|October 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|16|Samples Without DNA|Serum|Both|50 Years|80 Years|No|Non-Probability Sample|Patients with mild to moderate Alzheimer's disease (MMSE 16 to 26)that have participated        in AFF005A|November 2013|November 5, 2013|December 16, 2011||No|The study could not be performed as planned for organizational reasons.|No||https://clinicaltrials.gov/show/NCT01568086||88291|
NCT01568463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0806-A|Distance for Interscalene Block|What is the Maximal Effective Distance for Interscalene Block?||University Health Network, Toronto||Recruiting|February 2012|February 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients undergoing shoulder surgery (shoulder arthroscopy or open shoulder surgery)|March 2012|March 30, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01568463||88262|
NCT01568437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0869-B|Transversus Abdominis Plane (TAP) Block in Laparoscopic Gastric-bypass Surgery|Is the Analgesic Effect of the Transversus Abdominis Plane (TAP) Block in Laparoscopic Gastric-bypass Surgery Useful?||University Health Network, Toronto|No|Completed|January 2012|March 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|70 Years|No|||December 2015|December 7, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568437||88264|
NCT01568450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GL2907-101|A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Crossover Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers|GL2907-101|GL Pharm Tech Corporation|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01568450||88263|
NCT01568970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2404|Multidisciplinary Return-to-work Rehabilitation and Return-to Work Follow-up|Multidisciplinary Return-to-work Rehabilitation and Return-to-work Follow-up, a Randomized Study of Patients With Complex Symptom Disorders||Norwegian University of Science and Technology|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|59 Years|No|||January 2015|January 14, 2015|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01568970||88223|
NCT01568983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optijuice|The Effects of Polyphenol-rich Berry Juice on Blood Pressure in Hypertensive Subjects|The Effects of Polyphenol-rich Berry Juice on Blood Pressure and Additional CVD Related Parameters in Pre-hypertensive Subjects||University of Oslo|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|153|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 29, 2012|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01568983||88222|
NCT01569256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESG1|Ovarian Hyperstimulation Syndrome and Cabergoline|The Effect Of Cabergoline On Follicular Microenvironment Profile In Patients With High Risk Of Ohss||Etlik Zubeyde Hanim Womens' Health and Teaching Hospital|Yes|Completed|March 2008|March 2009|Actual|March 2009|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|40|||Female|23 Years|35 Years|Accepts Healthy Volunteers|||April 2012|April 3, 2012|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569256||88201|
NCT01569542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|John Daniel Uelk|Crossed Leg Sign and it's Correlation With Significant Pathology|Crossed Leg Sign and it's Correlation With Significant Pathology||Uelk, J. Daniel, D.O.|Yes|Not yet recruiting|May 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|This study should include all comers. To exclude a patient population would add a        selection bias.|March 2012|March 30, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569542||88179|
NCT01569503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC11/12|Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease|The Anti-inflammatory Effect of Vagus Nerve Stimulation (VNS): a New Approach in the Treatment of Crohn's Disease|VNS|University Hospital, Grenoble|Yes|Recruiting|March 2012|September 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|65 Years|No|||January 2016|February 9, 2016|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569503||88182|
NCT01569516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHY2010L00161-HPAD2|Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease|A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease||Changchun Huayang High-tech Co., Ltd|Yes|Recruiting|June 2011|October 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|288|||Both|50 Years|85 Years|No|||May 2011|April 6, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569516||88181|
NCT01569490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0136|Striving to Quit: First Breath|Striving to Quit: First Breath Tobacco Cessation Research|STQ FB|University of Wisconsin, Madison|No|Active, not recruiting|September 2012|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|3100|||Female|18 Years|N/A|No|||February 2016|February 1, 2016|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569490||88183|
NCT01570062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Allen,R-MOP111042|Cardiovascular Effects of Aerosols in Residences Study|Subclinical Cardiovascular Health Benefits of Interventions to Reduce Exposure to Combustion-Derived Particulate Air Pollution|CLEAR|Simon Fraser University|Yes|Completed|November 2011|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|83|||Both|19 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 10, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01570062||88139|
NCT01588288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/042/HP|Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter|Diagnosis Interest of Galectin 3 Dosage in Nodular and Multinodular Goiter Pretreatment|Galectins|University Hospital, Rouen|Yes|Active, not recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|193|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01588288||86750|
NCT01588301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA08-KH / APACHE-2|Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention|Attitudes to Different Strategies Among Women Not Attending Cervical Cancer Screening: Further Invitation by Mail or Kit for Self-collected Vaginal Sample|APACHE-2|University Hospital, Tours|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|3||Actual|5998|||Female|30 Years|65 Years|No|||July 2014|September 11, 2014|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01588301||86749|
NCT01588873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/2011|Contraceptive Pill and Hormonal Vaginal Ring in Women With Polycystic Ovary Syndrome|The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).||University of Oulu|No|Recruiting|April 2012|December 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01588873||86707|
NCT01588925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0297/11|Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation|Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation||University of Sao Paulo General Hospital|No|Completed|November 2011|January 2014|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|70 Years|No|||March 2013|October 2, 2014|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01588925||86703|
NCT01588821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-091|Cabozantinib in Advanced Solid Malignancies|Phase II Trial of Cabozantinib (XL184) in Patients With Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases||Massachusetts General Hospital|Yes|Recruiting|June 2012|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588821||86711|
NCT01588834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000458|Histology of Functional Density in Premenopausal Breast|Pilot Study to Examine Histological Characteristics of Mammographic Density With Molecular Breast Imaging: Part 2 - Premenopausal Women||Mayo Clinic|Yes|Enrolling by invitation|April 2012|October 2017|Anticipated|April 2016|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|core biopsy samples from mammographically dense breast tissue|Female|40 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with mammographically dense breasts who demonstrate either photopenic or marked        background parenchymal uptake on MBI|May 2015|May 8, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588834||86710|
NCT01589978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2066|PROMUS Element Plus US Post-Approval Study|A U.S. Post-Approval Study of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System||Boston Scientific Corporation|No|Active, not recruiting|May 2012|September 2018|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2689|||Both|N/A|N/A|No|||February 2014|February 20, 2014|May 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589978||86623|
NCT01568762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQBX258X2101|To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma|A Randomized, Double-blind, Placebo Controlled Study to Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 (Sequential Administration of a Fixed Dose of VAK694 and Single Ascending Doses of QAX576) in Patients With Well-controlled Mild to Moderate Asthma||Novartis||Completed|October 2010|||July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|50|||Both|18 Years|60 Years|No|||March 2012|March 30, 2012|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568762||88239|
NCT01568775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPP100A2262|Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects|An Open-label, Parallel Group, Single-sequence Study to Evaluate Pharmacokinetics, Safety, and Tolerability of a Single Dose Administration of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects||Novartis||Completed|June 2010|September 2010|Actual|September 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01568775||88238|
NCT01568736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAIR 7003|B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency|B7 Coreceptor Molecules as Clinically-Relevant Surrogate Biomarkers in the Hyper IgD Syndrome (HIDS) Form of Mevalonate Kinase Deficiency (MKD)|HIDS-MKD|Michigan Technological University|Yes|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|Blood Urine|Both|18 Years|89 Years|No|Non-Probability Sample|Subjects with Hyper IgD Syndrome (HIDS)|March 2012|March 30, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568736||88241|
NCT01568749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2750596|A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations|A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations||GlaxoSmithKline|No|Completed|December 2008|August 2009|Actual|August 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|14|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|November 20, 2014|June 23, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01568749||88240|
NCT01569269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6870|Effects of Reiki, Yoga, Meditation, on the Physical and Psychological Symptoms of Chemotherapy-Induced Peripheral Neuropathy|A Randomized, Four-Arm Study Comparing Reiki, Yoga, Meditation, or Patient Education Group for Addressing Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)||George Mason University|No|Completed|May 2010|March 2012|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|4||Actual|36|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2012|April 2, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01569269||88200|
NCT01569529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-06778|Young Adult Smoker's Treatment Demand|Increasing Young Adult Smoker's Demand for Internet-based Cessation Treatment||University of Illinois at Chicago|Yes|Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|3070|||Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young adult Internet users|April 2014|April 11, 2014|March 30, 2012||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01569529||88180|
NCT01569815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2204|Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function|An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Mild and Moderate Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function||Novartis||Completed|February 2009|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|March 30, 2012|No|Yes||No|July 30, 2015|https://clinicaltrials.gov/show/NCT01569815||88158|
NCT01569828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2205|Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function|An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function||Novartis||Completed|March 2009|September 2009|Actual|September 2009|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|March 30, 2012|Yes|Yes||No|July 30, 2015|https://clinicaltrials.gov/show/NCT01569828||88157|
NCT01569555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7286|Significant Pathology Associated With Crossed Leg Sign|Crossed Leg Sign and it's Correlation With Significant Pathology||Uelk, J. Daniel, D.O.|Yes|Not yet recruiting|May 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|This study should include all comers. To exclude a patient population would add a        selection bias.|March 2012|March 30, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569555||88178|
NCT01569841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3874|A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes|A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|75 Years|No|||January 2016|January 21, 2016|March 30, 2012|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01569841||88156|
NCT01569867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 2011H0402|Genetic Influence on Statin Pharmacokinetics|An Observational Study Investigating Genetic Influences on Statin Plasma Concentrations in Adults Taking Atorvastatin, Simvastatin, or Lovastatin||Ohio State University|No|Recruiting|March 2012|March 2022|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|Frozen plasma and frozen nuclear pellet|Both|18 Years|N/A|No|Non-Probability Sample|Individuals will be recruited from various hospitals, ancillary clinics, and primary-care        offices affiliated with the Ohio State University Medical Center (OSUMC).|January 2016|January 15, 2016|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569867||88154|
NCT01569789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vagus-1|Effects of Auricular Vagus Nerve Stimulation on the Pro-inflammatory Cytokine Response in Healthy Adults|Effects of Auricular Vagus Nerve Stimulation on the Pro-inflammatory Cytokine Response in Healthy Adults||Northwell Health|Yes|Completed|January 2012|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 14, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569789||88160|
NCT01569802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02|A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population|A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population||Rose Imaging Specialists, P.A.|No|Recruiting|January 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|10000|||Female|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|radiology clinic screening population|March 2012|March 30, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01569802||88159|
NCT01570075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC17|Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria|Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria||Sun Yat-sen University|Yes|Recruiting|November 2011|July 2015|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|65 Years|85 Years|No|||March 2012|March 30, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570075||88138|
NCT01566175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neovasc Reducer|Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization|Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Angina Class 3-4 Who Are Not Candidates for Revascularization|Reducer|Tel-Aviv Sourasky Medical Center|No|Recruiting|August 2011|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 28, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566175||88437|
NCT01588600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL001|Effects of Fiber on Satiety|Effects of Fiber on Satiety and Food Intake in Men and Women||National Starch LLC|No|Recruiting|April 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 27, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01588600||86726|
NCT01588626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5133C00001|Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers|A Phase I, Single Centre, Open Study to Assess the Pharmacokinetics of Oral AZD6140 After Single Dose in Healthy Japanese Male Volunteers||AstraZeneca||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588626||86725|
NCT01589211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS899101|Brief Intervention Study for Quitting Smoking||BISQUITS|Heidelberg University|No|Enrolling by invitation|December 2011|December 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|800|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589211||86681|
NCT01588938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0174, A-15214.1b|External Immobilization Compared to Limited Immobilization Using a Novel Real-time Localization System of the Prostate|||U.S. Army Medical Research Acquisition Activity|Yes|Active, not recruiting|December 2009|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will include patients with prostate cancer for whom definitive radiation        therapy is planned to the prostate. Patients will be referred from Urology and Radiation        Oncology.|September 2015|September 9, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588938||86702|
NCT01589484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00795812.8.0000.0068|Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones|Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones: Results From a Prospective Multifactorial Analysis||University of Sao Paulo|No|Completed|April 2012|December 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|18 Years|N/A|No|||December 2014|December 17, 2014|April 29, 2012||No||No|December 5, 2014|https://clinicaltrials.gov/show/NCT01589484||86660|
NCT01589497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5307|Essentiality of INH in TB Therapy|Essentiality of Isoniazid in Tuberculosis Therapy||AIDS Clinical Trials Group|Yes|Active, not recruiting|June 2015|February 2016|Anticipated|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|69|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589497||86659|
NCT01589510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/034|A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|||Allergan|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|419|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with POAG and OHT|May 2014|May 15, 2014|April 30, 2012|Yes|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01589510||86658|
NCT01588847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02-AnIt-11|Anesthesia and Cancer Recurrence im Malignant Melanoma|Long-term Outcome After Radical Lymph Node Dissection of Malignant Melanoma. Comparison Between Regional Versus General Anesthesia With Respect to Impact of Perioperative Immunoediting and Validation of New Potential Predictive Biomarkers||University Hospital Muenster|No|Recruiting|March 2012|March 2019|Anticipated|March 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01588847||86709|
NCT01589159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCP09|A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes|A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes||Peking University|Yes|Recruiting|January 2013|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Female|18 Years|80 Years|No|||June 2015|June 9, 2015|April 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01589159||86685|
NCT01589757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UofTORE26937|MAIN STUDY: Low Glycaemic Index (GI) Diet in the Management of GDM SUB-STUDY: The Breast Milk Sub-Study|The Effect of a Low GI Diet on Maternal and Neonatal Markers of Glycaemic Control and Postpartum Diabetes Risk SUBSTUDY The Effect of a Low GI Diet on Postpartum Markers of Oxidation in Breast Milk of Women With Gestational Hyperglycaemia|GIinGDM|University of Toronto|No|Recruiting|October 2011|June 2015|Anticipated|October 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|N/A|No|||June 2014|June 4, 2014|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01589757||86639|
NCT01590082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1165|Doxycycline, Temozolomide and Ipilimumab in Melanoma|Phase I / II Study of the Combination of Doxycycline With Temozolomide and Ipilimumab in Patients With Metastatic Melanoma||M.D. Anderson Cancer Center|No|Terminated|November 2012|July 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|April 30, 2012|Yes|Yes|Accrual slow due to alternate trials and treatment options.|No||https://clinicaltrials.gov/show/NCT01590082||86615|
NCT01589432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-383|A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy|A Randomized, Double-blind, Placebo and Active-controlled Study of the Electrophysiological Effects of ABT-639 on Spontaneous Activity in C-Nociceptors in Patients With Painful Diabetic Peripheral Neuropathy||AbbVie|No|Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|39|||Both|18 Years|75 Years|No|||January 2013|January 2, 2013|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01589432||86664|
NCT01589458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOPBioq003|Fluoride Availability in Saliva After Use of Sodium Fluoride or Monofluorophosphate Toothpastes|Fluoride Availability in Saliva After Use of NaF or MFP Toothpastes||University of Campinas, Brazil|No|Completed|August 2011|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|12|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||April 2012|May 1, 2012|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01589458||86662|
NCT01590589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGISTRY 3.0|REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)|REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)|REGISTRY|European Huntington's Disease Network|No|Recruiting|June 2004|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|10000|Samples With DNA|-  DNA from whole blood        -  DNA        -  Lymphoblastoid cell lines        -  Urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with manifest HD, unaffected individuals known to carry the HD mutation or at        risk of carrying the HD mutation, and control research participants (e.g., spouses,        siblings or offspring of HD mutation carriers known not to carry the HD mutation)|February 2015|February 18, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01590589||86576|
NCT01590888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBT2-203|Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease|Reach2HD|Prana Biotechnology Limited|Yes|Completed|April 2012|February 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|109|||Both|25 Years|N/A|No|||February 2014|February 9, 2014|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590888||86553|
NCT01568502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00837006|Dobutamine Stress Cardiac Magnetic Resonance Versus Echocardiography for the Assessment of Outcome. Are the Two Imaging Modalities Comparable?|||University Hospital Heidelberg|No|Completed|January 2001|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5008|||Both|18 Years|N/A|No|Probability Sample|Consecutive patients referred to our institution for clinically indicated dobutamine        stress testing (either DSCMR or DSE) due to suspected or known CAD(with/without prior        revascularization and with/without history of previous myocardial infarction).|March 2012|March 30, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568502||88259|
NCT01568996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-114|Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions|A Pilot Study Evaluation of Sulforaphane in Atypical Nevi--Precursor Lesions: Assessment of STAT1 and STAT3 Risk Markers of Melanoma||University of Pittsburgh|Yes|Recruiting|August 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01568996||88221|
NCT01569282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Double bypass vs Stent|Double Bypass Versus Stent-treatment in Irresectable Pancreatic Cancer|Double Bypass vs Stent Strategy in Peroperatively Diagnosed Irresectable Pancreatic Cancer - A Prospective Randomized Multicenter Study||Göteborg University|No|Withdrawn|October 2011|October 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||April 2015|April 20, 2015|March 16, 2012||No|Difficulties to recruit patients|No||https://clinicaltrials.gov/show/NCT01569282||88199|
NCT01569295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0115|A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Active, not recruiting|June 2012|December 2017|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|390|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569295||88198|
NCT01569854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 2011H0261|Genetic Influence on Statin Pharmacodynamics|An Observational Study Investigating Genetic Influences on Clinical Outcomes and Change in Carotid Intimal Thickness in Adults Taking Atorvastatin, Simvastatin, or Lovastatin||Ohio State University|No|Withdrawn|March 2012|March 2022|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|nuclear pellet|Both|18 Years|N/A|No|Non-Probability Sample|Individuals will be recruited from various hospitals, ancillary clinics, and primary-care        offices affiliated with the Ohio State University Medical Center (OSUMC).|January 2016|January 15, 2016|March 30, 2012||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01569854||88155|
NCT01569880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CF-HAST-OUS|Pre-flight Evaluation of Adult Patients With Cystic Fibrosis|Pre-flight Evaluation of Adult Patients With Cystic Fibrosis||Oslo University Hospital|No|Completed|January 2006|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|17 Years|80 Years|No|Non-Probability Sample|Adult patients with cystic fibrosis|March 2012|March 30, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569880||88153|
NCT01570088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00339|Bioavailability of Folic Acid Fortified Bread|Bioavailability of Folic Acid and L-5-methyltetrahydrofolic Acid in Fortified Bread: a Randomized Placebo-controlled Trial||University of British Columbia|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|45|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01570088||88137|
NCT01565993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EQCLIPS|The Use of Prophylactic Hemoclips in the Endoscopic Resection of Large Pedunculated Polyps|Is the Use of Prophylactic Hemoclips in the Endoscopic Resection of Large Pedunculated Polyps Useful? A Prospective and Randomized Study||Hospital Severo Ochoa|No|Terminated|July 2007|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|108|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|March 27, 2012||No|The unexpected increase in morbidity of the hemoclip group|No|March 28, 2012|https://clinicaltrials.gov/show/NCT01565993||88451|Not to reach the sample size established previously in the initial design, implies bias and decreases the strength of the study.
NCT01565980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSI grant|Mindfulness Therapy for Individuals With Lung Cancer|A Mindfulness Intervention for Symptom Management in Lung Cancer||Michigan State University|Yes|Completed|March 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|21 Years|N/A|No|||November 2014|November 14, 2014|March 22, 2012||No||No|July 13, 2014|https://clinicaltrials.gov/show/NCT01565980||88452|
NCT01588899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|907764|China Clinical Trial for Therapeutic MR-HIFU Ablation of Uterine Fibroids|China Clinical Trial for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids||Philips Healthcare|Yes|Completed|May 2012|May 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|107|||Female|18 Years|55 Years|No|||October 2015|October 21, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588899||86705|
NCT01588353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK160-III-1|Collagenase Option for Reduction of Dupuytren's Contracture in Japan|Phase III Study of AK160 in Patients With Dupuytren's Contracture|CORD-J|Asahi Kasei Pharma Corporation||Completed|May 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|69|||Both|20 Years|N/A|No|||June 2014|June 30, 2014|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588353||86745|
NCT01588665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1203002861|Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy|Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy||Cornell University|No|Active, not recruiting|April 2012|December 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|23|Samples With DNA|-  A total of 45 mL maternal blood sample is collected at five study visits during           pregnancy        -  At delivery, an additional 10 mL maternal blood sample, a 30 mL cord blood, and the           placenta are collected|Female|15 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women and pregnant adolescents from Rochester, NY (n=24)|January 2016|January 21, 2016|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588665||86723|
NCT01580514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHMC-2012001|Myocardial Protection of Exenatide in AMI|Cardioprotective Effects of Exenatide in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention ; Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study|EMPIRE|Kyunghee University Medical Center|Yes|Completed|September 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|127|||Both|20 Years|79 Years|No|||April 2012|April 18, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01580514||87340|
NCT01589224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreaHealth_MDCT|Risk Factor Analysis for Coronary Atherosclerosis Measured by MDCT|||Korea University|Yes|Completed|May 2012|||August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Apparently healthy people who underwent medical routine check up in Korea Helath Promotion        Center.|April 2012|October 12, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01589224||86680|
NCT01580176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ContAssGlu|Continuous GlucoseMonitor for Measurement of Blood Glucose Level|A Prospective Clinical Trial on Agreement to Evaluate the GlucoseMonitor, a Novel Device for Continuous Assessment of Blood Glucose Levels, in Comparison With the RAPIDLab® 1265 Blood Gas Analyser (ContAssGlu)|ContAssGlu|University Hospital Heidelberg|No|Completed|March 2012|March 2013|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|18 Years|80 Years|No|||December 2013|December 19, 2013|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580176||87365|
NCT01590043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSA002-HMO-CTIL|Identifying Saliva Markers in Inflammatory Bowel Disease|||Hadassah Medical Organization||Recruiting|May 2012|||May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|160|Samples With DNA|Whole saliva|Both|3 Years|18 Years|No|Probability Sample|Patients identified with infalmmatory bowel disease|July 2012|September 6, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590043||86618|
NCT01590095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11063|WASH Benefits Bangladesh|WASH Benefits Bangladesh: A Cluster Randomized Controlled Trial of the Benefits of Water, Sanitation, Hygiene Plus Nutrition Interventions on Child Growth||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|May 2012|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|7||Anticipated|5040|||Both|N/A|63 Years|Accepts Healthy Volunteers|||June 2015|July 26, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590095||86614|
NCT01589796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0308.03|Medial Versus Traditional Approach to US-guided TAP Blocks for Open Inguinal Hernia Repair|Effect of Medial vs Traditional Approach to US-guided Transverse Abdominis Plane (TAP) Blocks on Analgesia After Open Inguinal Hernia Repair||Stamford Anesthesiology Services, PC|Yes|Recruiting|April 2012|||February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||April 2012|April 30, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589796||86636|
NCT01590056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STN_Cog_HMO-CTIL|Emotional and Cognitive Subthalamic Nucleus in Deep Brain Stimulation Treated Parkinson Patients|Mapping and Manipulating the Motor, Emotional and Cognitive Territories of the Subthalamic Area in Deep Brain Stimulation Treated Parkinson Patients||Hadassah Medical Organization|No|Recruiting|March 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|40 Years|75 Years|No|Non-Probability Sample|PD patients that are treated or are candidates for treatment with STN DBS will be followed        for 12 months (n=20). These patients will represent a consecutive sample of community        based PD patients who will be enrolled in a prospective, open label, clinical trial.|May 2012|May 1, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590056||86617|
NCT01590069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0700|Aerosol IL-2 for Pulmonary Metastases|Phase I/II Study of Aerosol Interleukin-2 for Pulmonary Metastases||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2012|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|12 Years|50 Years|No|||December 2015|December 1, 2015|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590069||86616|
NCT01590355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORATOR|A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)|A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)|ORATOR|Lawson Health Research Institute|Yes|Recruiting|June 2012|June 2021|Anticipated|June 2021|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590355||86594|
NCT01568801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/381/A|Evaluation of the Singapura Program of All Inclusive Care for the Elderly (SingaPACE) Demonstration Project|Evaluation of the Singapura Program of All Inclusive Care for the Elderly|SingaPACE|National University, Singapore|No|Completed|August 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|80|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568801||88236|
NCT01568788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hualanbio-influenza-IV-002|Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine|Post-marketing Clinical Observation of Hualan's Inactivated Influenza Vaccine: A Single Center, Parallelled, Controlled, Randomised Clinical Trial||Hualan Biological Engineering, Inc.|Yes|Completed|December 2008|March 2009|Actual|January 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|600|||Both|3 Years|N/A|Accepts Healthy Volunteers|||April 2012|June 18, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01568788||88237|
NCT01569308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-109|Pulse Pressure Variation Helps to Predict Fluid Responsiveness in Patients Ventilated With Low Tidal Volumes|Pulse Pressure Variation Helps to Predict Fluid Responsiveness in Patients Ventilated With Low Tidal Volumes||Hospital de Clinicas de Porto Alegre|Yes|Completed|May 2006|October 2009|Actual|October 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|38|||Both|16 Years|N/A|No|Probability Sample|Patients age ≥ 16 years, from both genders, admitted to the HCPA ICU, receiving invasive        mechanical ventilation, with hemodynamic instability defined as need for norepinephrine        infusion and/or intravascular fluid administration to maintain systolic arterial blood        pressure > 90 mm Hg; with arterial line in place (radial or femoral) and pulmonary        arterial catheter in place.|March 2012|April 2, 2012|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01569308||88197|
NCT01569568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCRDC 5107|Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI|Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI||Children's Research Institute|Yes|Terminated|September 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|68|||Both|7 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|Males and females, ages 7-60 years with ornithine transcarbamylase deficiency Males and        females, ages 7-60 years who are healthy controls without ornithine transcarbamylase        deficiency|September 2014|September 22, 2014|March 30, 2012||No|Not enough enrollment|No||https://clinicaltrials.gov/show/NCT01569568||88177|
NCT01569893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G. A. 250487 - Veneto WP8Cl2|Life-Long Monitoring of Diabetes Mellitus in Veneto Region|RENEWING HEALTH - Large Scale Pilot in Veneto Region: Life-long Monitoring of Diabetes Mellitus||Regione Veneto|Yes|Completed|March 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|598|||Both|18 Years|N/A|No|||January 2014|October 27, 2015|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569893||88152|
NCT01570101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-10763-01|European Sapheon™ Closure System Observational ProspectivE (eSCOPE) Study|Post Market Study - "European Observational Study of the Sapheon™ Closure System for the Definitive Treatment of Incompetent Great Saphenous Veins: A Prospective Single Arm Multicenter Clinical Observational Study"|eSCOPE|Sapheon, Inc.|No|Completed|December 2011|September 2015|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|70 Years|No|Probability Sample|Subjects presenting at primary care clinics/doctors clinics who meet the eligibility        criteria will be enrolled sequentially.|October 2015|October 8, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01570101||88136|
NCT01566214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910778-MVW|Vet-Harts Pilot Intervention for Veterans With Coronary Heart Disease|Representational Telehealth Nursing Intervention for Veterans With CHD|VHPI|University of Iowa|No|Completed|April 2012|October 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01566214||88434|
NCT01588366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13107|The Effects of LY2409021 on the Liver|Effects of LY2409021 on Hepatic Metabolism in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|April 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|36|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2013|September 10, 2013|April 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01588366||86744|
NCT01588678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DS3078-A-U101|A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas|A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas||Daiichi Sankyo Inc.|No|Completed|April 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588678||86722|
NCT01588691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRD-517|Traumatic Brain Injury Peripheral Nerve Study|A Feasibility Study to Examine the Efficacy of C2-C3 Dermatomal Peripheral Nerve Stimulation in Cognitive Improvements Following Persistent Impairment After Traumatic Brain Injury|TBI|St. Jude Medical|No|Completed|December 2011|November 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|65 Years|No|||March 2015|March 20, 2015|February 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588691||86721|
NCT01580527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.627|Postoperative Artificial Nutrition After Pancreaticoduodenectomy|A Prospective, Multicentric, Randomized Trial Comparing Early Enteral Nutrition Versus Parenteral Nutrition After Pancreaticoduodenectomy|Nutri-DPC|Hospices Civils de Lyon|No|Recruiting|March 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|220|||Both|18 Years|N/A|No|||April 2012|April 17, 2012|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01580527||87339|
NCT01580189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:068|Whole Milk Versus Whey Protein Supplement and Resistance Exercise|Effects of Whole Milk Versus Whey Protein Supplementation With Resistance Exercise on Body Composition, Muscle Hypertrophy and Strength Changes in Healthy Individuals||University of Manitoba|Yes|Completed|October 2011|December 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|32|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580189||87364|
NCT01589770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120314|Inflammation and the Heart|Inflammation and the Heart||Vanderbilt University|No|Active, not recruiting|August 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|345|Samples With DNA|serum plasma DNA RNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|people with rheumatoid arthritis and people without rheumatoid arthritis or other        inflammatory disease|June 2015|June 16, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01589770||86638|
NCT01589783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitDand Preg-HMO-CTIL|Vitamin D During Pregnancy|Evaluation of the Influence of Education, Knowledge and Existing Guidelines on the Consumption of Vitamin D During Pregnancy.||Hadassah Medical Organization|No|Completed|May 2012|June 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|764|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|We are recruiting either pregnant women or those who just gave birth (and still        hospitalized) and a group of both family practice physicians and obstertricians.|July 2015|July 26, 2015|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01589783||86637|
NCT01589809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR01849|Effect of Nicotinamide in Friedreich's Ataxia|Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in Friedreich's Ataxia||Imperial College London|No|Active, not recruiting|June 2012|September 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01589809||86635|
NCT01580735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-007|ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer|A Phase 2, Multicenter, Open-label, Single-arm Study of ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer||Kyowa Hakko Kirin Company, Limited|No|Completed|May 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|N/A|No|||August 2015|August 16, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580735||87323|
NCT01590368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM-1015-12-U365|A Comparative Wear Test of Two Adhesives on the Unilect ™ Biotab Short Term Monitoring Electrode|A Comparative Wear Test of Two Adhesives on the Unilect ™ Biotab Short Term Monitoring Electrode||ConvaTec Inc.|No|Not yet recruiting|June 2012|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2012|May 2, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590368||86593|
NCT01590381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDF 1047-2011|Assessment of HBV Vaccine Immunity After 18 Years|Assessment of the Immune Status of New Health Care Workers in the Israel Defense Forces (IDF) Vaccinated in Infancy Against Hepatitis B Virus (HBV), Before and After a Booster Dose.||Medical Corps, Israel Defense Force|No|Recruiting|December 2011|April 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||10|Anticipated|545|Samples Without DNA|blood samples from study subjects vaccinated at infancy, before and after booster dose.|Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|The study population will consist of both males and females who were born after January        1st 1992, who are in medical training at the Medical Corps Training Base.|May 2012|May 1, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590381||86592|
NCT01569321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01673-38|Diagosis of Breast Carcinoma: Characterization of Breast Lesions With CLEARPEMSONIC : Feasibility Study|Diagosis of Breast Carcinoma: Characterization of Breast Lesions With CLEARPEMSONIC : Feasibility Study||Assistance Publique Hopitaux De Marseille|No|Terminated|March 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|10|||Female|18 Years|N/A|No|||April 2015|April 20, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01569321||88196|
NCT01569581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV71-KMB17-III-IMB-CAMS|A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children|A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children||Chinese Academy of Medical Sciences|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Actual|12000|||Both|6 Months|71 Months|Accepts Healthy Volunteers|||March 2012|March 10, 2013|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569581||88176|
NCT01569906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4795|Narrowband UVB for Children With Moderate to Severe Atopic Eczema|Narrowband Ultraviolet B Phototherapy in Children With Moderate to Severe Atopic Eczema- an Observational Prospective Controlled Study||Royal Victoria Infirmary|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|58|Samples With DNA|saliva|Both|3 Years|16 Years|No|Non-Probability Sample|Children aged 3-16 years|April 2012|April 3, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569906||88151|
NCT01569009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0085|Physical Activity in Bronchiectasis|Patterns of Physical Activity Levels in Patients With Bronchiectasis: Cross Sectional Study Using Quantitative Methodology|PhAB|University of Ulster|Yes|Completed|June 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|63|||Both|18 Years|N/A|No|Probability Sample|Patients with bronchiecatsis|July 2013|July 24, 2013|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01569009||88220|
NCT01569022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-005-11F|A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder|A Randomized Cross Over Trial of Two Treatments for OSA in Veterans With PTSD||VA Office of Research and Development|No|Active, not recruiting|November 2012|March 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||March 2016|March 17, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01569022||88219|
NCT01569035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wuoh|Warfarine in Unexplained Oligohydramnios|a Randomized Clinical Trial Using Oral Anti Coagulant in the Management of Unexplained Oligohydramnios||Woman's Health University Hospital, Egypt|Yes|Completed|January 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|200|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|March 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569035||88218|
NCT01566019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00841-40|Molecular Screening for Cancer Treatment Optimization|Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment|MOSCATO 02|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|October 2011|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|1050|||Both|6 Months|N/A|No|||February 2016|February 9, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566019||88449|
NCT01566240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 11/0034|Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer|A Phase III Multicentre Trial of Weekly Induction Chemotherapy Followed by Standard Chemoradiation Versus Standard Chemoradiation Alone in Patients With Locally Advanced Cervical Cancer|INTERLACE|University College, London|No|Recruiting|September 2012|September 2021|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|770|||Female|18 Years|N/A|No|||August 2015|August 21, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566240||88432|
NCT01566461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10031540DOC|IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)|Randomized Trial of IN.PACT (Paclitaxel) Admiral Drug-Coated Balloon (DCB) vs. Standard Percutaneous Transluminal Angioplasty (PTA) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)|INPACT SFA II|Medtronic Endovascular|Yes|Active, not recruiting|March 2012|June 2018|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|331|||Both|18 Years|85 Years|No|||January 2016|January 25, 2016|March 27, 2012|Yes|Yes||No|February 18, 2015|https://clinicaltrials.gov/show/NCT01566461||88415|
NCT01566773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT001003|PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD|A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (14 Days), Four Period, Eight Treatment, Placebo-Controlled, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Six Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide, Open Label) as An Active Control||Pearl Therapeutics, Inc.|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|140|||Both|40 Years|80 Years|No|||November 2013|November 14, 2013|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566773||88391|
NCT01567020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C7755-I|Central Auditory Processing Deficits Associated With Blast Exposure|Central Auditory Processing Deficits Associated With Blast Exposure|CAPD Blast|VA Office of Research and Development|No|Active, not recruiting|May 2012|September 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|None Retained|None collected.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|January 2016|January 28, 2016|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01567020||88372|
NCT01566006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nazh8827ctil|Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration|Mycophenolate Mofetil (MMF) ,Carnitine and Phosphodiesterase Type 5 Inhibitor, Three Potential Treatments for Resistant Proteinuria and for Slowing the Deterioration of Diabetic Nephropathy in Patients With Type II Diabetes Mellitus|Myridian|The Nazareth Hospital, Israel|Yes|Not yet recruiting|April 2012|August 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|80|||Both|30 Years|80 Years|No|||March 2012|March 28, 2012|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01566006||88450|
NCT01588379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0804|Mothers and Girls Dancing Together Trial|Effects of an Afro-centric Dance Program for African-American Daughters and Mothers|MAGNET|University of Massachusetts, Amherst|No|Active, not recruiting|January 2013|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|99|||Female|7 Years|11 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01588379||86743|
NCT01580202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-246|Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine|A Randomized, Open Labeled, Multicenter Study Comparing Entecavir Versus Lamivudine as Antiviral Prophylaxis for Patients With Hepatitis B Infection Undergoing Cytotoxic Chemotherapy for Malignant Tumors||Seoul National University Hospital|Yes|Recruiting|April 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01580202||87363|
NCT01581047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/078|Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units|Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units|AMOCEF|University Hospital, Ghent|No|Recruiting|March 2012|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|8 serum samples will be taken per patient.|Both|18 Years|N/A|No|Non-Probability Sample|Patients on the intensive care unit, with an infection (which requires        amoxicillin/clavulanic acid or cefuroxime).|December 2014|December 4, 2014|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01581047||87299|
NCT01580761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007272|Sleep Restriction and Obesity|Sleep Restriction and Obesity||Mayo Clinic|No|Recruiting|July 2012|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 21, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580761||87321|
NCT01589523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0780|GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis|Conjugated Cholic Acid for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-Chain Conjugation||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|February 2006|December 2020|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|N/A|85 Years|No|||July 2014|July 3, 2014|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589523||86657|
NCT01580748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1109-066-002|Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients|||Seoul National University Bundang Hospital||Not yet recruiting|May 2012|January 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|80 Years|No|||April 2012|April 18, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580748||87322|
NCT01590108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/2063|The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects|The Apelin-APJ System in Idiopathic Pulmonary Arterial Hypertension and Healthy Volunteers; Tissue Location and Cardiopulmonary Response.|EXAP|Imperial College London|No|Completed|March 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|12|||Male|18 Years|90 Years|Accepts Healthy Volunteers|||April 2012|February 15, 2016|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590108||86613|
NCT01581554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110151|Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B|Withdrawal of Therapy After Long-Term Oral Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B||National Institutes of Health Clinical Center (CC)||Recruiting|April 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|50|||Both|18 Years|N/A|No|||May 2015|June 5, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01581554||87261|
NCT01569594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PR-1021|CorMatrix ECM for Carotid Repair Following Endarterectomy Registry|CorMatrix® ECM® for Carotid Repair Following Endarterectomy Registry||CorMatrix Cardiovascular, Inc.|No|Active, not recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|230|||Both|N/A|N/A|No|Non-Probability Sample|Up to 230 subjects may be enrolled from up to ten U.S. clinical sites|May 2014|May 6, 2014|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569594||88175|
NCT01569607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052053|Structurally Reorganizing Motor Cortex in Stroke Patients Through Hebbian-type Stimulation|Structurally Reorganizing Motor Cortex in Stroke Patients Through Hebbian-type Stimulation||Emory University|No|Recruiting|September 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|85 Years|No|||November 2015|November 16, 2015|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569607||88174|
NCT01569919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/VCC/0049|A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma|A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma|SKOPOS|Wales Cancer Trials Unit|Yes|Recruiting|December 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||March 2013|March 11, 2013|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01569919||88150|
NCT01570114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FCSEMS|Covered Metallic Stent and Benign Colonic Strictures|EFFICACY OF A SELF EXPANDABLE FULLY COVERED METALLIC STENT IN THE TREATMENT OF BENIGN COLONIC STRICTURES||Société Française d'Endoscopie Digestive|No|Completed|January 2011|October 2011|Actual|September 2011|Actual|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|43|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in universitary tertiary care center benefited from a fully covered metallic        colonic stent for treatment of benign stricture|March 2012|March 30, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01570114||88135|
NCT01566032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011619-01H|Digital Versus Analog Pleural Drainage in Patients With Pulmonary Air Leak|Digital Versus Analog Pleural Drainage in Patients With Pulmonary Air Leak|DiVA|Ottawa Hospital Research Institute|No|Completed|January 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|A target of 30 patients at the Ottawa Hospital who experienced pulmonary air leak        following pulmonary resection will be recruited.|March 2014|March 17, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01566032||88448|
NCT01566253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8832|Oral Self Medication Versus IV Administration of Pain Killers After Caesarian Delivery|Comparison of a Patient Controlled Oral Administration (PCOA) of Analgesic Protocol With an IV Administration After Planned Caesarian Section : Monocentric, Randomised and Controlled Study||University Hospital, Montpellier|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|64 Years|No|||April 2013|April 3, 2013|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566253||88431|
NCT01567384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00047570|A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies|A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies||Emory University|Yes|Withdrawn|May 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||November 2013|November 19, 2013|December 20, 2011||No|The sponsor withdrew support for the study before any patients were enrolled.|No||https://clinicaltrials.gov/show/NCT01567384||88345|
NCT01566474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICS10/0273|Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study|Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study||Aragon Institute of Health Sciences|Yes|Recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|80 Years|No|||January 2013|January 23, 2013|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01566474||88414|
NCT01566786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7ICH-1389|Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage|Randomised, Double-Blind, Placebo-Controlled, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage||Novo Nordisk A/S|No|Completed|August 2001|October 2002|Actual|October 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||March 2012|March 29, 2012|March 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01566786||88390|
NCT01567033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201103147|Healthy Eating and Active Living Taught at Home|Translating a Weight Loss Intervention Through a National Home Visiting Program|HEALTH|Washington University School of Medicine|Yes|Active, not recruiting|July 2011|July 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|512|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01567033||88371|
NCT01567345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP-401|Intrathecal Morphine Administration Using Implantable Pump With Continuous or Programmable Flow|Comparison of Two Types of Intrathecal Morphine Administration by Pump for Analgesia in Cancer Patients With Failure of Conventional Analgesic Therapy.|PITAC|ICO Paul Papin|Yes|Completed|January 2009|October 2010|Actual|October 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01567345||88348|
NCT01579864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/05|Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia|Interventional Rigid Bronchoscopy Under General Anesthesia: Influence of the Muscle Relaxant, Succinylcholine or Rocuronium, on the Quality of the Surgical Procedure|Broncho-SR|Hopital Foch|No|Terminated|January 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||June 2015|June 17, 2015|January 4, 2012||No|recent publication (Ghezel-Ahmadi. Thorac Cardiovasc Surg. 2014 Nov 21)|No||https://clinicaltrials.gov/show/NCT01579864||87388|
NCT01580215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|630-0013|Long Term Follow up Investigation of Endobronchial Valves in Emphysema|Long Term Follow up Investigation of Endobronchial Valves in Emphysema|LIVE|Pulmonx, Inc.|Yes|Active, not recruiting|July 2012|December 2020|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Patient participation is entirely voluntary. Patients must meet the inclusion/exlusion        criteria to be eligible for the study.|October 2015|October 20, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580215||87362|
NCT01580774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSHCANADA-CSCB|Effect of Post-discharge Phone Calls on Patient Outcomes|Effect of Post-discharge Phone Calls on Patient Outcomes for General Internal Medicine Patients Discharged From a Teaching Hospital.||Mount Sinai Hospital, Canada|No|Completed|July 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|334|||Both|18 Years|N/A|No|Probability Sample|Study population is patients admitted to a general internal medicine ward.|April 2012|June 20, 2013|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580774||87320|
NCT01581359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOFIV-010|The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis|A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment|ENDOFIV|Instituto de Investigacion Sanitaria La Fe|Yes|Completed|March 2012|May 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|40 Years|No|||April 2014|October 21, 2015|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581359||87276|
NCT01580488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLQ-008|A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris|A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris||LEO Pharma|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|24|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|April 16, 2012||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01580488||87342|This was an exploratory study in which each of the 24 subjects received all 6 treatments on 2 cm diameter dermal test sites. Regarding Adverse Events, only local dermal reactions could be potentially attributed to a specific treatment.
NCT01580501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO 27521|PDE Inhibitors in DMD Study (Acute Dosing Study)|Functional Muscle Ischemia and PDE5 Inhibition in Duchenne Muscular Dystrophy: Acute Dosing Study||Cedars-Sinai Medical Center|No|Completed|March 2012|||March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|7 Years|15 Years|Accepts Healthy Volunteers|||January 2014|January 27, 2014|April 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01580501||87341|
NCT01581307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16764|Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets|A Phase II Clinical Trial Evaluating Overall Survival With Therasphere® In Conjunction With 2nd-Line FOLFOX In Patients With Gemcitabine-Refractory Pancreatic Carcinoma With Liver Metastases||H. Lee Moffitt Cancer Center and Research Institute|Yes|Completed|April 2012|March 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581307||87280|
NCT01581320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DP-CTR206-03|Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis|A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R206 and Bonviva for the Improvement of Vitamin D in Postmenopausal Women With Osteoporosis|DIOS|Alvogen Korea|No|Recruiting|January 2012|||July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|204|||Female|40 Years|N/A|No|||April 2012|April 18, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01581320||87279|
NCT01581567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110210|Neuroimmunology Branch Repository|NIB Repository Protocol||National Institutes of Health Clinical Center (CC)||Completed|July 2011|||||N/A|Observational|N/A|||Anticipated|500|||Both|N/A|N/A|No|||December 2015|January 7, 2016|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01581567||87260|
NCT01581580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110211|Deep Brain Stimulation Surgery for Movement Disorders|Deep Brain Stimulation Surgery for Movement Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|July 2011|March 2021|Anticipated|March 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 9, 2016|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01581580||87259|
NCT01581866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40349|Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|November 2004|January 2005|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581866||87237|
NCT01570140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSD|Large Scale Demonstrator, Webportal Diabetes|Large Scale Demonstrator, Webportal Diabetes|LSD|Medical Research Foundation, The Netherlands|No|Recruiting|May 2012|October 2015|Anticipated|February 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|N/A|No|Non-Probability Sample|The study consists of people known with type 2 diabetes mellitus who are being guided and        treated in primary health care in the Drenthe region of the Netherlands.|November 2013|November 29, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01570140||88133|
NCT01566266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-011|Gut Flora and Lipid Metabolism|||Maastricht University Medical Center|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|77|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||May 2013|May 13, 2013|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566266||88430|
NCT01566487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353-09|Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition|Randomized, Open-Label, Balanced, Two-treatment, Two-period, Two-sequence, Crossover, Multicentric Experimental Bioequivalence Study of Quetiapine Fumarate Film-coated Tablets 300 mg (Test)and Seroquel Film-coated Tablets 300 mg (Reference) Under Fasting Condition||Dr. Reddy's Laboratories Limited|No|Completed|June 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2010|March 28, 2012|March 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566487||88413|
NCT01570127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOMCIRB-02-20101130-02|Efficacy and Safety Study of Individualized and Standardized Acupuncture Treatment for Low Back Pain|Clinical Trial to Evaluate and Compare the Efficacy and Safety of Individualized and Standardized Acupuncture for Low Back Pain Patients: Randomized, Double-blind, Controlled Study||Kyunghee University Medical Center|Yes|Recruiting|October 2010|December 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|276|||Both|N/A|N/A|No|||April 2012|April 5, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01570127||88134|
NCT01566500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1597|Medication Adherence in Individuals With Epilepsy|Best Practices and Challenges in Medication Adherence for Individuals With Epilepsy||Columbia University|Yes|Completed|September 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|140|||Both|18 Years|65 Years|No|Non-Probability Sample|A total of 140 participants between 18 and 65 years old will be recruited with the        condition that all participants have been diagnosed with epilepsy. The participants will        be of diverse ethnic background. It is estimated that the participant population will also        include individuals from a disadvantaged socioeconomic and/or educational background.|July 2015|July 29, 2015|March 28, 2012||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01566500||88412|
NCT01567046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B5|Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas|Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)||Children's Oncology Group|No|Recruiting|March 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|70|Samples With DNA|Tissue|Both|N/A|30 Years|No|Non-Probability Sample|Non-rhabdomyosarcoma soft tissue sarcoma|November 2015|November 6, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01567046||88370|
NCT01567397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReDuCTO ID 7090|Registry of Dupuytren's Contracture Treatment Outcomes|Registry of Dupuytren's Contracture Treatment Outcomes|ReDuCTO|Technische Universität Dresden|No|Completed|December 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|87|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Dupuytren's Disease|November 2013|November 7, 2013|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567397||88344|
NCT01571531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMSCI|European Multicentre Study of Human Spinal Cord Injury|European Multicentre Study of Human SCI||University of Zurich|Yes|Recruiting|April 2004|||August 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|2300|||Both|18 Years|N/A|No|Probability Sample|primary care clinic|January 2016|January 6, 2016|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01571531||88027|
NCT01567358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI071C1(ACT12719)|Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade® in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate||Nichi-Iko Pharmaceutical Co.,Ltd.|No|Completed|February 2012|April 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|75 Years|No|||June 2013|June 18, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01567358||88347|
NCT01567371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00096|LiDCO Monitor Study|Use of the LiDCORapid Monitor in Patients During Graded Phlebotomy and the Removal of Autologous Blood||Nationwide Children's Hospital|No|Completed|March 2012|March 2015|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|N/A|N/A|No|||May 2015|May 14, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567371||88346|
NCT01579877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOMCIRB2011-28/KHNMC-OH-IRB20|Treatment of Xerostomia by Herbal Preparation|Efficacy of Yukmijihwang-tang on Xerostomia in the Elderly: A Randomized,Double-blind, Placebo-controlled, Two-center Trial||Korea Health Industry Development Institute|No|Recruiting|April 2012|November 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|96|||Both|60 Years|80 Years|No|||May 2013|May 12, 2013|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579877||87387|
NCT01580787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|saocamilo-sp|Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment|Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment||Sao Camilo University Center|Yes|Completed|August 2009|April 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|65 Years|85 Years|No|||April 2012|April 18, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580787||87319|
NCT01581619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-351|External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks|A Phase I Study of Once-Daily External-Beam Partial-Breast Irradiation (PBI) for Selected Patients With Early Invasive N0 or Non-Invasive Breast Cancer||Massachusetts General Hospital|Yes|Active, not recruiting|May 2012|||May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|No|||March 2016|March 14, 2016|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01581619||87256|
NCT01581372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00020054|A Community Based Approach to Dyslipidemia Management: Pharmacist Prescribing to Achieve Cholesterol Targets|A Community Based Approach to Dyslipidemia Management: Pharmacist Prescribing to Achieve Cholesterol Targets (RxACT Study)|RxACT|University of Alberta|No|Completed|December 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|N/A|No|||April 2015|April 25, 2015|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01581372||87275|
NCT01581034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146/11|Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery Disease|A Randomized, Placebo-controlled, Double-blinded Trial on the Effect of PADMA 28 on Endothelial Function, Biomarkers and the Autonomic Nervous System in Patients With Coronary Artery Disease|PADMA 28|University Hospital Inselspital, Berne|Yes|Completed|April 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|80|||Male|N/A|N/A|No|||July 2013|July 31, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01581034||87300|
NCT01581008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 11-239|Improving Symptoms and Quality of Life in Chronic Heart Failure: Pilot Study|Implementing Collaborative Care to Alleviate Symptoms and Adjust to Heart Failure: A Pilot Study|CASA|VA Office of Research and Development|No|Completed|October 2011|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|31|||Both|18 Years|N/A|No|||April 2015|April 27, 2015|October 31, 2011||No||No|November 3, 2014|https://clinicaltrials.gov/show/NCT01581008||87302|
NCT01581333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005152-34|Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia|Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia|HOWLONG|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|No|Recruiting|April 2012|January 2017|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01581333||87278|
NCT01582230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237A23155|Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus|A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus||Novartis||Completed|April 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|293|||Both|18 Years|80 Years|No|||August 2013|August 29, 2013|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582230||87209|
NCT01566279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 37128.031.11|A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)|A Two Parts, Biomarker Study to Identify Genetic Aberrations Predictive for Response on Everolimus in Solid Tumors Without Regular Treatment Options (CPCT-03)|CPCT-03|UMC Utrecht|No|Recruiting|August 2012|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2014|February 23, 2014|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566279||88429|
NCT01566292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268/08|Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy|Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy: a Randomised, Double-blind, Controlled Trial Using Subjective and Objective Outcomes||Catholic University of the Sacred Heart|Yes|Completed|September 2009|||September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|33|||Male|50 Years|80 Years|No|||March 2012|March 27, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01566292||88428|
NCT01566799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MET-INCAN-1|Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer|Clinical Phase II, Randomized, Double Blind Trial, to Evaluate the Efficacy of Metformin and Chemotherapy Versus Placebo Nad Chemotherapy in Neoadjuvant Setting for Locally Advanced Breast Cancer||Instituto Nacional de Cancerologia de Mexico|Yes|Not yet recruiting|April 2012|April 2014|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|70 Years|No|||March 2012|March 29, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01566799||88389|
NCT01566812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRAVO_trial|Effect of Breastfeeding Optimization on Early Vascular Development|BReast Feeding Attitude and Volume Optimization (BRAVO) Trial: A Randomized Breast Feeding Optimization Experiment|BRAVO|Indonesia University|No|Recruiting|June 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2015|August 24, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566812||88388|
NCT01567059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2566.00|Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS||Fred Hutchinson Cancer Research Center|No|Completed|May 2012|||June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|March 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01567059||88369|
NCT01571544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12038|The Use of Thermal Suits as Preventing Hypothermia During Surgery|The Use of Thermal Suits as Preventing Hypothermia During Surgery||Tampere University Hospital|Yes|Completed|November 2012|November 2014|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Male|18 Years|90 Years|No|||December 2014|December 12, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01571544||88026|
NCT01571557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/RET/011|A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)|||Allergan|No|Completed|April 2012|June 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|573|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with macular oedema due to retinal vein occlusion|June 2015|June 22, 2015|April 3, 2012|Yes|Yes||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01571557||88025|
NCT01567631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWHZSG002|Classical Procedure Versus Intrahepatic Glisson's Approach|Laparoscopic Anatomical Hepatectomy With Intrahepatic Glisson's Approach Versus Laparoscopic Anatomical Hepatectomy With Classical Procedure|LAHIGA|Southwest Hospital, China|Yes|Recruiting|January 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|70 Years|No|||January 2016|January 29, 2016|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567631||88326|
NCT01567644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR-NRW-DE|Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris|Clinical Trial Evaluating the Treatment of Patients With Refractory Chronic Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device||Medispec|No|Active, not recruiting|January 2008|September 2012|Anticipated|April 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2012|April 1, 2012|November 15, 2010||No||No||https://clinicaltrials.gov/show/NCT01567644||88325|
NCT01567904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKM11204|Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line|An Open-label, Pharmacokinetic, Pharmacodynamic, and Tolerability Study of AVE5026 Administered at Weight-adjusted Doses to Patients Less Than 18 Years of Age With a Central Venous Line (CVL)||Sanofi|Yes|Terminated|May 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|2|||Both|N/A|17 Years|No|||January 2013|January 14, 2013|March 28, 2012|Yes|Yes|due to the decision from sanofi to withdraw on a worldwide basis the Marketing Authorisation    Applications for semuloparin in the adult indication|No||https://clinicaltrials.gov/show/NCT01567904||88305|
NCT01567917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-SNUBH-2012-01|Incidence of Venous Thromboembolism Following Surgery in Patients With Colorectal Cancer|Incidence of Venous Thromboembolism Following Surgery in Korean Patients With Colorectal Cancer; a Prospective Study||Seoul National University Bundang Hospital|No|Recruiting|June 2011|December 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|600|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with CRC receiving curative or palliative surgery|March 2012|March 29, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567917||88304|
NCT01580228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07714|A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)|A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia||Merck Sharp & Dohme Corp.|Yes|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01580228||87361|
NCT01581385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-1049|Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive, Diagnostic Atherosclerosis Imaging|Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive, Diagnostic Atherosclerosis Imaging; Independent Scientist: ARFI and RWI Ultrasound for Improved Atherosclerosis Imaging||University of North Carolina, Chapel Hill|No|Active, not recruiting|April 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|25|Samples Without DNA|Plaque specimens extracted during clinically indicated carotid endarterectomy surgery will      be sectioned and histochemically processed.|Both|18 Years|N/A|No|Non-Probability Sample|Adult (18 years or older) male and female patients scheduled to undergo clinically        indicated carotid endarterectomy surgery.|February 2016|February 12, 2016|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01581385||87274|
NCT01581632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-007004|Assessment of Coronary Plaque Composition|Assessment of Coronary Plaque Composition Using Near Infrared Spectroscopy During Inhibition of LpPLA2 Activity||Mayo Clinic|Yes|Completed|January 2010|May 2015|Actual|May 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Both|18 Years|85 Years|No|||September 2015|September 22, 2015|March 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01581632||87255|
NCT01581606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18045E|Evaluation of TeleOphthalmology in AMD-TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes|Evaluation of TeleOphthalmology in Age-related Macular Degeneration (AMD) - TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes.||Lawson Health Research Institute|No|Recruiting|November 2011|November 2013|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|212|||Both|55 Years|N/A|No|Probability Sample|Group 1: Patients will be collected from all referrals with a provisional diagnosis of        possible Wet-AMD to any of the physician investigators.        Group 2: Subjects will be collected from patients previously treated at this institution        for wet-AMD within the practices of the physician investigators.|April 2012|April 18, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01581606||87257|
NCT01581021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-0110|Pedicle Screw Usage in Conventional Fixation Pattern Constructs Compared to Thoracic Hook Constructs in Scoliosis|Pedicle Screw Usage in Conventional Fixation Pattern Constructs Compared to Thoracic Hook Constructs in Adolescent Idiopathic Scoliosis Patients and Neuromuscular Ambulators||University of Mississippi Medical Center|No|Completed|August 2005|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|7 Years|21 Years|No|||December 2013|December 13, 2013|April 13, 2012|Yes|Yes||No|April 14, 2013|https://clinicaltrials.gov/show/NCT01581021||87301|The design of this study is a computer-generated randomized trial. Initially, the first 3 participants were not computer-randomized and therefore, these subjects had to be removed from the study.
NCT01581593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB052|Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)|Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).||Kedrion S.p.A.|Yes|Active, not recruiting|November 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|70 Years|No|||September 2013|September 12, 2013|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01581593||87258|
NCT01581905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38824|Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution|A Randomized Controlled Trial Comparing Conventional Laparoscopic Hysterectomy With Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution||Milton S. Hershey Medical Center|No|Recruiting|March 2012|June 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01581905||87234|
NCT01582724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKUD-12|Effectiveness of Additional Self-care Acupressure for Women With Menstrual Pain Compared to Usual Care Alone|Randomized Pragmatic Trial for Women With Menstrual Pain Comparing Additional Self-care Acupressure to Usual Care Alone|AKUD|Charite University, Berlin, Germany|No|Completed|December 2012|March 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Female|18 Years|25 Years|No|||August 2015|August 3, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582724||87171|
NCT01566045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02072012|MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer|MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer. A Phase III Study||Philips Healthcare|Yes|Recruiting|May 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|980|||Male|18 Years|N/A|No|||May 2013|May 28, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01566045||88447|
NCT01566058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/FBC-01|Impact of the BB Box System on Postpartum Maternal Anxiety, Post Traumatic Stress and Mother-child Relationships|Pilot Study Evaluating the Impact of the BB Box System on Postpartum Maternal Anxiety, Post Traumatic Stress and the Establishment of a Mother-child Relationship in the Context of a Premature Birth|BBBox|Centre Hospitalier Universitaire de Nīmes|No|Completed|January 2013|April 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|59|||Female|18 Years|N/A|No|||April 2015|April 29, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566058||88446|
NCT01574495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133E0700 13|Evaluating Error Augmentation for Neurorehabilitation|Evaluating Error Augmentation for Neurorehabilitation|VREA|Rehabilitation Institute of Chicago|No|Completed|January 2008|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 23, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01574495||87800|
NCT01566513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010007542|Effectiveness and Cost Effectiveness of Peer Mentors in Reducing Hospital Use|Effectiveness and Cost Effectiveness of Peer Mentors in Reducing Hospital Use|Project PEP|Yale University|Yes|Completed|August 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|285|||Both|18 Years|N/A|No|||January 2015|January 22, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01566513||88411|
NCT01566526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/RET/012|Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion|||Allergan|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion        (CRVO) who received OZURDEX® as part of the Belgium Medical Needs Program.|March 2013|March 27, 2013|March 27, 2012|Yes|Yes||No|March 27, 2013|https://clinicaltrials.gov/show/NCT01566526||88410|
NCT01566539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007905|Biological Basis of Individual Variation in Social Cooperation|The Biological Basis of Individual Variation in Social Cooperation||Emory University|Yes|Enrolling by invitation|April 2008|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|6||Anticipated|750|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||February 2016|February 26, 2016|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566539||88409|
NCT01570712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00668-33|Evaluation of the "Housing First Program" in Patients With Severe Mental Disorders in France|Evaluation of the "Housing First Program" in Patients With Severe Mental Disorders in France: a Multicentric Randomized Controlled Study||Assistance Publique Hopitaux De Marseille|No|Recruiting|August 2011|February 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|600|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570712||88089|
NCT01570959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUET-T300-PVSS|Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions|A Two Period, Two Treatment, Two Way, Steady State Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Fasting Conditions||Roxane Laboratories|No|Completed|April 2007|November 2007|Actual|November 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|55 Years|No|||April 2012|April 2, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01570959||88070|
NCT01570972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U. Az IRB 09-1113-02|Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis|Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis||University of Arizona|No|Recruiting|February 2010|February 2020|Anticipated|February 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|35 Years|No|||November 2015|November 30, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01570972||88069|
NCT01571843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAE6548|Radius Loading in Primary Hyperparathyroidism|Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism||Columbia University|No|Completed|February 2010|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Female|45 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01571843||88003|
NCT01571804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/49|Pregabalin Reduce the Sevoflurane Requirement|Does Pregabalin Reduce the Sevoflurane Requirement During Laparoscopic Cholecystectomy? Mansoura University Hospitals Experience.||Mansoura University|Yes|Completed|December 2011|March 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|42|||Male|25 Years|55 Years|No|||May 2012|May 4, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01571804||88006|
NCT01571817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Islet-Tx-Sub-DERC|Pancreatic Islet Transplantation Into the Gastric Submucosa|Treatment of Type I Diabetes by Pancreatic Islet Transplantation Into The Gastric Submucosa||University of California, San Francisco|No|Enrolling by invitation|April 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|4|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||August 2013|August 7, 2013|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01571817||88005|
NCT01572064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0403/1|Magnetic Resonance Imaging in the Evaluation of Liver Fibrosis|Magnetic Resonance Imaging in the Evaluation of Hepatic Fibrosis: Search for MRI Biomarker|Mrker|University of Nottingham|No|Completed|May 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|134|||Both|18 Years|80 Years|No|||September 2012|September 17, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572064||87986|
NCT01572077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010539-01H|Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension|Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension|RVMET|Ottawa Heart Institute Research Corporation|No|Active, not recruiting|January 2011|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 4, 2016|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01572077||87985|
NCT01580813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1393|Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes|Effects of Serum Fatty Acid Lowering on Insulin Sensitivity, Cardiovascular Function, And Exercise Capacity in Non-Insulin Dependent Diabetes|AcT2|University of Colorado, Denver|Yes|Recruiting|June 2011|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|60 Years|No|||September 2015|September 30, 2015|May 24, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01580813||87317|
NCT01581060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WX/80-003|Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours|A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours||Wilex|No|Terminated|March 2012|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|March 28, 2012||No|Study terminated for business reasons|No||https://clinicaltrials.gov/show/NCT01581060||87298|
NCT01579721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILS rectal cancer|Prospective Randomized Study of SILS Versus CLS for Rectal Cancer|Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer||Hvidovre University Hospital|No|Completed|September 2011|October 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 3, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01579721||87399|
NCT01580020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002EDE20|Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO|An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18)||Novartis|No|Completed|May 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|175|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580020||87376|
NCT01581450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-000966-37|Hyperalgesia and Pain|Evaluation of Antihyperalgesic and Analgesic Effects of 35% Nitrous Oxide in a Human Model of Electrically Evoked Hyperalgesia and Pain||Air Liquide Santé International||Completed|January 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01581450||87269|
NCT01581918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thaiana123|Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting|PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF CARBAMAZEPINE FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.||Faculdade de Medicina do ABC|Yes|Recruiting|December 2011|||March 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|43|||Female|18 Years|70 Years|No|||April 2012|April 23, 2012|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581918||87233|
NCT01581931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1288.20|Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets|Bioequivalence of Metformin Under Fed Conditions After Administration of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Male and Female Volunteers, (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial)||Boehringer Ingelheim||Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 14, 2013|April 19, 2012||||No|June 14, 2013|https://clinicaltrials.gov/show/NCT01581931||87232|
NCT01581944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MtHopeMaternity0075|Gonadotropin-releasing Hormone Agonist Prior to Myomectomy|Phase 3 Study of Experience With a Gonadotropin-releasing Hormone Agonist Prior to Myomectomy - Comparison of 2 Versus 3 Monthly Doses.||Mt. Hope Maternity Hospital|Yes|Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Actual|68|||Female|20 Years|45 Years|No|||April 2012|April 18, 2012|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01581944||87231|
NCT01582256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201006RIB|Behavior, Neuropsychology, Neuroimage and Electrophysiology in Autistic Individuals With and Without CNVs|Behavior, Neuropsychology, Neuroimage and Electrophysiology in Autistic Individuals With and Without Copy Number Variation and Their Unaffected Siblings||National Taiwan University Hospital|Yes|Not yet recruiting|August 2012|July 2015|Anticipated|||N/A|Observational|N/A||6|Anticipated|132|Samples With DNA|The subjects will receive blood withdrawal. The blood sample will be used for establishing      lymphoblastoid cell lines, which will be used for molecular genetic experiments.|Both|10 Years|25 Years|No|Non-Probability Sample|The sample (6 groups) consists of 44 individuals with clinical diagnosis of ASD confirmed        by the ADI-R and ADOS assessments (22 with CNVs and 22 without CNVs), their unaffected        siblings (n=22 for each group) and age-, sex-, handedness-, and IQ-matched school        comparison groups (22 for each group).|April 2012|April 19, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582256||87207|
NCT01581346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSITIVE_II|Exercise Study in Patients With Lung Cancer|Pilot Study to Establish an Exercise Intervention in Patients With Lung Cancer|POSITIVE|German Cancer Research Center|No|Completed|March 2011|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01581346||87277|
NCT01582503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GB27980|A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Dosing Regimens of MEMP1972A in Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA)||Genentech, Inc.||Completed|April 2012|November 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|578|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582503||87188|
NCT01578915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|High Risk Women|A Case Control Study of Women With Multiple Sexual Partners|A Case Control Study of Women With Multiple Sexual Partners Attending the Jefferson County Department of Health Sexually Transmitted Diseases Clinic||University of Alabama at Birmingham|No|Completed|May 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|213|||Female|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women presenting to the Jefferson County Department of Health Sexually Transmitted        Diseases Clinic|October 2015|October 2, 2015|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01578915||87461|
NCT01578928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2126|A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers|A Phase I, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous (s.c.) Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to a Matched Control Group of Healthy Volunteers||Novartis|No|Completed|May 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01578928||87460|
NCT01570985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSS-2010-SKB|Treatment Study of Frozen Shoulder: Corticosteroid Injection in Joint Versus Wait and See Policy|Outcome in Shoulder Capsulitis (Frozen Shoulder) Between Corticosteroid and Corticosteroid With Distension Compared to Wait and See Policy, a Randomised Controlled Trial|FSS|University of Bergen|Yes|Active, not recruiting|February 2010|December 2015|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01570985||88068|
NCT01570439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KK001|To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore|||National University Hospital, Singapore|Yes|Recruiting|January 2012|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|22 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Anonymous donors at blood donation center in NUH.|December 2013|December 10, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01570439||88110|
NCT01582854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-2500-301-RD|Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)|A 12-month, International, Parallel Group, Randomised, Multi-centre, Double-blind, Placebo-controlled Trial to Examine the Effect of Actovegin® Treatment Given First Intravenously and Subsequently Orally Over 6 Months, in Subjects With Post-stroke Cognitive Impairment (PSCI).|ARTEMIDA|Takeda|No|Completed|June 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|503|||Both|60 Years|N/A|No|||January 2016|January 23, 2016|April 20, 2012||No||No|January 23, 2016|https://clinicaltrials.gov/show/NCT01582854||87161|
NCT01582867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1495|HemoControl System Activated in Hemodiafiltration Treatments|Studio Cross-Over Controllato Randomizzato Sul Dispositivo ArTis Con Hemocontrol in Emodiafiltrazione - SOCRATHE|SOCRATHE|Gambro Dasco S.p.A.|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01582867||87160|
NCT01583127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H.33.02.03.07.A|Examining Variation in the Impact of School-Wide Positive Behavioral Interventions and Supports (PBIS)|Examining Variation in the Impact of School-Wide Positive Behavioral Interventions and Supports (PBIS)||Johns Hopkins Bloomberg School of Public Health|No|Completed|September 2002|June 2007|Actual|June 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32986|||Both|5 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583127||87140|
NCT01579071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIRBA2681-2012|Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor|A Randomized, Controlled, Double-blind Trial of the Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor||Gachon University Gil Medical Center|Yes|Completed|April 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|110|||Both|19 Years|85 Years|Accepts Healthy Volunteers|||February 2015|February 8, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01579071||87449|
NCT01579084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-001|Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea|||Allergan|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|64|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|April 13, 2012|Yes|Yes||No|September 12, 2013|https://clinicaltrials.gov/show/NCT01579084||87448|
NCT01579539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-120312|The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy|The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy||Medical University of Vienna|Yes|Recruiting|June 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579539||87413|
NCT01579292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107481|A Mobile Based Diabetes Prevention Program|mDPP Pilot RCT of a Motivational Mobile Diabetes Prevention Program (mDPP)||University of California, San Francisco|Yes|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|61|||Both|35 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 16, 2014|April 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01579292||87432|
NCT01579305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S15L-003|Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-L® for Lip Volume Enhancement|||Allergan||Completed|April 2012|January 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|285|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 30, 2015|April 16, 2012|Yes|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01579305||87431|
NCT01580150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|247032|Effects of Berries on Post-meal Blood Sugar|Effects of Berries on Postprandial Glycemic Responses to Sucrose and Starch|SOMA|University of Eastern Finland|No|Completed|November 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|25 Years|69 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580150||87367|
NCT01580462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPK 510-13-55|The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes|The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes. Prospective Study|ADHERENCE|Institution of Mother and Child, Warsaw, Poland||Recruiting|April 2012|October 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|18 Years|No|Probability Sample|Participants will be recruited from the Outpatient Diabetes Clinic in the Institute of        Mother and Child. Patient should be treated by intensive insulinotherapy using Continous        Subcutaneus Infusion Set (CSII). Number of participants: 200.|April 2012|April 18, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580462||87344|
NCT01579799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-NR. 2012-0005|The Effect of L-lysine on Human Gastrointestinal Secretion: A Dose-finding Study Applying Magnetic Resonance Imaging (MRI)|||University of Zurich||Completed|April 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01579799||87393|
NCT01580475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPEAEK - PYTHAGORAS II|Training, Detraining, Retraining and Glycemic Control in Patients With Type 2 Diabetes|Training, Detraining and Retraining Effects on Glycemic Control and Physical Fitness in Patients With Type 2 Diabetes||Democritus University of Thrace|No|Completed|September 2008|June 2010|Actual|September 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|13|||Female|45 Years|65 Years|No|||April 2012|April 18, 2012|March 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580475||87343|
NCT01580137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diary number 235/2011|Acute Upper Respiratory Tract Infection - When is Bacteria Involved?|Acute Upper Respiratory Tract Infection - When is Bacteria Involved?||Oulu University Hospital|No|Active, not recruiting|February 2012|April 2014|Anticipated|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|48|||Both|18 Years|28 Years|No|Non-Probability Sample|Finnish conscripts from the prigade of Kainuu who suffer from acute common cold with nasal        symptoms. Consecutive sample. Subjects with known allergies, nasal polyps and prior sinus        surgery are excluded.|October 2013|October 29, 2013|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580137||87368|
NCT01610739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHSobeid2012|Carpal Tunnel Release Effects on Median Nerve Perfusion|Effect of Carpal Tunnel Release on Median Nerve Perfusion Using SPY Scope Imaging||Henry Ford Health System|No|Not yet recruiting|July 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2012|July 17, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610739||85028|
NCT01610752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 11024|Personalized Management of Body Weight During Pregnancy|Expecting Success: Personalized Management of Body Weight During Pregnancy||Pennington Biomedical Research Center|Yes|Completed|December 2012|October 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|54|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610752||85027|
NCT01583049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVX01E|Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish Children|Observational Post Authorisation Safety Study to Describe the Safety Profile of the Diphtheria, Tetanus, Acellular Pertussis Combination Vaccine, Reduced Antigen Content (Triaxis) as a 5th Dose in 4-6 Year Old Spanish Children||Sanofi Pasteur MSD|No|Completed|March 2012|August 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|556|||Both|4 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children between 4-6 years of age who attend the investigator's office to receive a 5th        dose of tetanus, diphtheria and pertussis Triaxis vaccine as part of the routine        vaccination schedule, as described in the Spanish version of the EU SmPC and local        vaccination calendar|August 2012|August 3, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583049||87146|
NCT01579227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0286|Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound|Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound.|TOP/OTOP|Ohio State University|No|Recruiting|January 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|101|Samples With DNA|Tissue biopsy will be collected twice in the study period.|Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|We plan to recruit 27 healthy adult subjects for the TOP group, 34 healthy adult subjects        for the OTOP group,10 healthy adult subjects for the TAM group and 30 healthy subjects for        Normal Skin.|March 2016|March 16, 2016|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579227||87437|
NCT01579240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBIR51 Sr. Exercise|Internet Intervention Promotes Physical Activity in Sedentary Older Adults|Internet Intervention Promotes Physical Activity||Oregon Center for Applied Science, Inc.|No|Completed|February 2006|October 2006|Actual|October 2006|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|368|||Both|55 Years|N/A|Accepts Healthy Volunteers|||December 2006|April 16, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579240||87436|
NCT01580007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09068|Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)|Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis in Bangladesh: a Pilot Study||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|December 2010|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|288|||Both|18 Years|60 Years|No|||January 2014|February 12, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580007||87377|
NCT01581437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM13720|Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps|Recording for Potential AF Drivers and Patient Specific Atrial Anatomy and Atrial Electrogram Maps Using an FDA Approved 64-Pole Basket Catheter (CONFIRM)|CONFIRM|Virginia Commonwealth University|Yes|Completed|October 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|78|||Both|21 Years|N/A|No|||March 2016|March 9, 2016|April 6, 2012||No||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01581437||87270|
NCT01583062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|235/04|Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures|Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures (Mandibular Fractures, Zygomaticoorbital Fractures, Isolated Orbital Blow-out Fractures and LeFort I/II/III Fractures): 1 Day vs. 5 Days: a Prospective, Randomized, Double Blind and Placebo Controlled Study (Phase IV)||University Hospital Inselspital, Berne|Yes|Terminated|January 2006|December 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|217|||Both|16 Years|N/A|No|||July 2013|July 12, 2013|April 20, 2012||No|Limited number of patients|No||https://clinicaltrials.gov/show/NCT01583062||87145|
NCT01591824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pold-LBP|Study of Effectiveness of Pold in Chronic Nonspecific Low Back Pain|Effectiveness of Resonant Oscillation, According to the Pold Concept in Chronic Nonspecific Low Back Pain|Pold-LBP|Omphis Foundation|No|Completed|May 2012|September 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|25 Years|70 Years|No|||February 2016|February 6, 2016|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01591824||86481|
NCT01582880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03-020|Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis|The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis||Massachusetts Eye and Ear Infirmary|No|Recruiting|March 2012|June 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2013|March 20, 2013|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582880||87159|
NCT01583140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALUDABLES-2009|Seamos Saludables - Physical Activity Intervention Study for Latinas|Culturally and Linguistically Adapted Physical Activity Intervention for Latinas (Seamos Saludables)||University of California, San Diego|No|Completed|October 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|312|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 24, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01583140||87139|
NCT01579097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSPIVTCHN001|Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation|A Randomized, Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-Chamber Parenteral Nutrition Formulation (Oliclinomel N4)||Baxter Healthcare Corporation|No|Completed|December 2011|January 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|458|||Both|18 Years|80 Years|No|||January 2013|January 31, 2013|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579097||87447|
NCT01579578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00006|Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer|A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE)||AstraZeneca||Terminated|April 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|April 13, 2012|Yes|Yes|AstraZeneca sponsored trials of AZD8931 have been halted|No|March 20, 2014|https://clinicaltrials.gov/show/NCT01579578||87410|
NCT01579812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.037|Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients|A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer||University of Michigan Cancer Center|Yes|Recruiting|October 2011|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|104|||Female|19 Years|79 Years|No|||November 2015|November 16, 2015|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579812||87392|
NCT01579838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD59-Mevorach-1|An Open Label Study of the Effects of Eculizumab in CD59 Deficiency|An Open Label Study of the Effects of Eculizumab in CD59 Deficiency||Hadassah Medical Organization|No|Recruiting|February 2012|March 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|2 Months|70 Years|No|||April 2012|April 17, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01579838||87390|
NCT01609946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-004|Realtime-Elastography (RTE) and Thyroid Nodules|Evaluation of Realtime-Elastography for Differentiation of Thyroid Nodules: a Multicenter Study||Johann Wolfgang Goethe University Hospitals|No|Recruiting|June 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|593|||Both|18 Years|N/A|No|||May 2012|July 13, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01609946||85089|
NCT01580709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10895519|Endoscopic Retrograde Cholangiopancreatography (ERCP) Based Sampling of Indeterminate Bile Duct Strictures|Optimizing the Role of ERCP in Evaluating Indeterminate Bile Duct Strictures||Medical University of South Carolina|Yes|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580709||87325|
NCT01580722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASD-1213-100|Comparison of Early Versus Delay Reconstruction in Anterior Cruciate Ligament Tearing|Study of Surgical Methods for Anterior Cruciate Ligament Tearing||Isfahan University of Medical Sciences|Yes|Completed|March 2012|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|36 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580722||87324|
NCT01611038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220100243|Methylselenocysteine Effects on Circadian Rhythm|Chemoprevention of Breast and Prostate Cancers in Shift Workers by Dietary Methylselenocysteine: Effects on Circadian Rhythm and Estrogen Receptor-B Cycling||Rutgers, The State University of New Jersey|No|Completed|October 2011|June 2015|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|100|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01611038||85005|
NCT01582282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX-105|Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects|A Clinical Study to Determine the Ability of Metamucil to Reduce Fasting Blood Glucose and HbA1c Levels in Type II NIDDM||Procter and Gamble|No|Terminated|May 1988|January 1990|Actual|January 1990|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|37|||Both|36 Years|80 Years|No|||November 2012|November 8, 2012|April 18, 2012||No|due to slow enrollment|No|October 3, 2012|https://clinicaltrials.gov/show/NCT01582282||87205|
NCT01582776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALEN|Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma|A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma||The Lymphoma Academic Research Organisation|Yes|Recruiting|October 2012|December 2020|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582776||87167|
NCT01591122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100011|Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer||Janssen Research & Development, LLC|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|313|||Male|18 Years|N/A|No|||March 2016|March 11, 2016|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591122||86535|
NCT01591356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0216|EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery|EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial||M.D. Anderson Cancer Center|No|Recruiting|July 2015|||July 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|May 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01591356||86517|
NCT01591369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-1700-04|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2012|||||N/A|N/A|N/A||||||||||||||August 13, 2013|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591369||86516|
NCT01579708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Preschool_PSI!|Evaluation of the Program SI! for Preschool Education: A School-Based Randomized Controlled Trial|Evaluation of the Program SI! for Preschool Education: A School-Based Randomized Controlled Trial|Preschool_PSI!|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III||Active, not recruiting|September 2011|June 2014|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|2060|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||April 2012|April 17, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01579708||87400|
NCT01591382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001126|Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients|Hydromorphone PCA or Hydromorphone PCA With Ketamine for Acute Postoperative Pain Relief in Opioid-Dependent Chronic Pain Patients||Brigham and Women's Hospital|No|Active, not recruiting|September 2008|June 2012|Anticipated|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|May 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591382||86515|
NCT01580618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HI-07HYoon-02|Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy|TNK for Loculated Pleural Effusions in Patients With Malignancy||Kaiser Permanente|No|Terminated|January 2008|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|September 17, 2010|No|Yes|Unable to accrue patients at a reasonable rate|No|June 24, 2013|https://clinicaltrials.gov/show/NCT01580618||87332|Results are limited due to the small numbers of patients enrolled
NCT01587690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220060134|Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells|Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells||Rutgers, The State University of New Jersey|No|Completed|November 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|24|Samples With DNA|peripheral blood|Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|human subjects will be enrolled in New Brunswick, NJ|November 2013|November 19, 2013|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587690||86796|
NCT01591616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP73|Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel|A Phase 4 Pediatric Study to Assess the Pharmacokinetics and Safety of Oraqix Gel in Healthy Children and Adolescent Volunteers Following Tooth Extraction||Dentsply International|No|Completed|April 2010|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|1||Actual|16|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|June 24, 2011|Yes|Yes||No|February 20, 2014|https://clinicaltrials.gov/show/NCT01591616||86497|
NCT01587976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/570|Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases|Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases A Prospective Multicenter Study|HQOL|Haukeland University Hospital|No|Recruiting|June 2011|December 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients with resectable colorectal liver metastases treated at Haukeland and Stavanger        University hospital, Norway.|September 2013|March 27, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01587976||86774|
NCT01583153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIHO-1042554|The HIHO Study: Hospital Inpatient vs Home Rehabilitation After Total Knee Replacement|Randomised Controlled Trial Comparing Hospital Inpatient vs Home Rehabilitation After Total Knee|HIHO|South West Sydney Local Health District|Yes|Active, not recruiting|June 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|N/A|N/A|No|||March 2015|March 2, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01583153||87138|
NCT01579110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZXMZ2012|Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.|Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.||Institute of Hematology & Blood Diseases Hospital|Yes|Active, not recruiting|April 2012|April 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579110||87446|
NCT01579318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS-I120|Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma|A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma|CTCL|OncoSec Medical Incorporated|Yes|Completed|July 2012|||March 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|April 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579318||87430|
NCT01579331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCT01|Reliability of Dynamic Contour Tonometry (DCT)|Study of Test-retest Reliability of Dynamic Contour Tonometry and Its Correlation With Goldmann Applanation Tonometry|DCT|University of Cantanzaro|No|Completed|July 2011|September 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|102|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 25, 2012|April 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01579331||87429|
NCT01579591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A.1459/2011|VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer|A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in Increasing the Pathological Major Response Rate in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy||Catholic University of the Sacred Heart|No|Recruiting|March 2012|June 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||April 2012|April 17, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01579591||87409|
NCT01579604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-02475|Nerve Transfer Reconstruction in the Tetraplegic Upper Extremity|Early Nerve Reconstruction Approach in Tetraplegic Patients With Dysfunctional Upper Extremity: a Randomized Controlled Trial.||University of British Columbia|No|Recruiting|June 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01579604||87408|
NCT01579825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00003717|Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh|Evaluation of the Effect of Buffer on the Immune Response to Oral Poliovirus Vaccine in Bangladesh: a Randomized Controlled Trial||Johns Hopkins Bloomberg School of Public Health|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|300|||Both|N/A|8 Weeks|Accepts Healthy Volunteers|||April 2012|April 24, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01579825||87391|
NCT01609959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-Ken-001|New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering|Effects of the New Angiotensin II Receptor Blocker Azilsartan Versus Valsartan on Blood Pressure in Japanese Patients With Hypertension|NARA|Nara Medical University|Yes|Completed|June 2012|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|N/A|N/A|No|||October 2013|October 28, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01609959||85088|
NCT01580163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZhao-002|Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After Detoxification|Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After Detoxification||Shanghai Mental Health Center|No|Completed|September 2009|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|554|||Both|18 Years|65 Years|No|||November 2015|November 16, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580163||87366|
NCT01610219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807106|Lifestyle Modification for Type 2 Diabetes Prevention in Overweight Youth|Lifestyle Modification for Type 2 Diabetes Prevention in Overweight Youth||University of Pennsylvania|No|Completed|August 2008|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610219||85068|
NCT01610726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2079|Economic and Clinical Evaluation of Enhanced Recovery in Colorectal Surgery|Economic and Clinical Evaluation of Enhanced Recovery in Colorectal Surgery||Haukeland University Hospital|Yes|Recruiting|February 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|320|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610726||85029|
NCT01611051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHPG-19K -III-01|A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy|||Jiangsu HengRui Medicine Co., Ltd.|No|Completed|March 2012|||January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|330|||Both|18 Years|70 Years|No|||January 2013|January 5, 2013|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611051||85004|
NCT01582789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-MKTG-37|Comparative Study of Two Marketed Spherical Soft Contact Lenses|Comparative Study of Two Marketed Spherical Soft Contact Lenses||Coopervision, Inc.|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|38 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582789||87166|
NCT01590836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-1979|A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|65 Years|No|||November 2013|November 26, 2013|April 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590836||86557|
NCT01590563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOS-C1000-02|A Study to Evaluate the Safety and Initial Efficacy of a Novel Intrauterine Device|A Study to Evaluate the Safety and Initial Efficacy of a Spherical Copper Intrauterine Contraceptive Device the IUB(tm)||Ocon Medical Ltd.|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|15|||Female|25 Years|42 Years|Accepts Healthy Volunteers|||October 2015|October 12, 2015|April 20, 2012|No|Yes||No|November 5, 2013|https://clinicaltrials.gov/show/NCT01590563||86578|
NCT01590576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101019-E|Population-based Estimates of Medical Comorbidities in Women With Lower Urinary Tract Symptoms or Pelvic Organ Prolapse|||Far Eastern Memorial Hospital||Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|2500|||Female|20 Years|99 Years|No|Non-Probability Sample|Patients with low urinary tract symptoms|February 2016|February 22, 2016|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590576||86577|
NCT01591603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120382|Comparison of Perineural Catheter Depth for the Continuous Popliteal Nerve Block Using Ultrasound Guidance and Dermabond|Comparison of Perineural Catheter Depth for the Continuous Popliteal Nerve Block Using Ultrasound Guidance and Dermabond||Vanderbilt University|Yes|Completed|May 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01591603||86498|
NCT01591135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESO-Shanghai1|A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma|A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma||Fudan University|Yes|Active, not recruiting|April 2012|July 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|436|||Both|18 Years|75 Years|No|||January 2016|January 5, 2016|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01591135||86534|
NCT01591811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-01299|Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost|Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost||New York University School of Medicine|Yes|Active, not recruiting|April 2012|April 2020|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|433|||Female|18 Years|N/A|No|||December 2015|December 14, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01591811||86482|
NCT01587677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCBorstel001|Evaluation of a LAM FLISA for the Diagnosis of Tuberculosis|Diagnostic Evaluation of a Urine and Plasma Based LAM FLISA for the Diagnosis of Infection With Mycobacterium Tuberculosis|LAM FLISA|Research Center Borstel|No|Suspended|February 2012|February 2013|Anticipated|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|130|Samples Without DNA|Urine and EDTA plasma|Both|N/A|N/A|No|Probability Sample|Patients with confirmed or suspected tuberculosis. Patients with NTM infection or        bronchial carcinoma serve as control|December 2012|December 7, 2012|April 23, 2012||No|Interim analysis shows poor sensitivity and specificity for the diagnosis of TB.|No||https://clinicaltrials.gov/show/NCT01587677||86797|
NCT01591629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108008940|The Effects of ∆-9-THC and Naloxone in Humans|Assessment of Cannabinoid-opiate Interactions in Humans With a Cannabis Use Disorder and Healthy Subjects||Yale University|Yes|Recruiting|July 2011|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|56|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591629||86496|
NCT01587716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115658|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.|A Randomised, Double-blind, Placebo Controlled, Inhaled Single Escalating and Repeat Dose Study Using an Aqueous Droplet Inhaler to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.||GlaxoSmithKline||Completed|April 2012|August 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 11, 2013|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01587716||86794|
NCT01588314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112M07943|Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease|Placebo Controlled Trial Evaluating Gabapentin for the Treatment of Small Fiber Neuropathic Pain in Patients With Fabry Disease||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn|April 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|April 26, 2012||No|No patients were enrolled. No data & no study results to report.|No||https://clinicaltrials.gov/show/NCT01588314||86748|
NCT01582906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCR 3664|A Survivorship Care Plan for Gynaecological Cancer Patients|Does a Post Treatment Survivorship Care Plan Improve Gynaecological Cancer Patient's Quality of Life and Self Efficacy? A Mixed Methods Pilot Study.||Royal Marsden NHS Foundation Trust|No|Recruiting|August 2011|||August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Probability Sample|We aim to capture patients with gynaecological cancers at Stage I or II. Overall there        were approximately 500 referrals of patients with Stage I or II gynaecological cancer to        the Royal Marsden NHS Foundation Trust (RM) in the year April 2009 to April 2010. There        were 729 gynaecological referrals of all stages of cancer. Of these, 333 were referred to        the surgical team and 396 to the medical teams. Of those 729 patients, 378 were referred        to the Rehabilitation Department, the majority of whom were referred post-surgery and seen        as inpatients, leaving 48% of patients with gynaecological cancer never seen by a        rehabilitation professional at RM.|April 2012|April 20, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582906||87157|
NCT01583166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14197|Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial|Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial|URINE&ME|University of Massachusetts, Worcester|Yes|Recruiting|March 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|160|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01583166||87137|
NCT01583179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0781|Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution|Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution||University of Wisconsin, Madison|No|Terminated|April 2012|December 2015|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|79 Years|No|||January 2016|January 6, 2016|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01583179||87136|
NCT01579123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|012-010|Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia|Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease||Baylor Research Institute|Yes|Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2015|June 19, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579123||87445|
NCT01579136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201147|Do Home Monitors Improve Blood Pressure Control?|||Exempla Saint Joseph Hospital|No|Terminated|December 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|N/A|No|||December 2012|December 20, 2012|April 12, 2012||No|Lack of subjects|No||https://clinicaltrials.gov/show/NCT01579136||87444|
NCT01613781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-051|Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery|Determination of Target of Adequate Partial Neuromuscular Blockade With Sevoflurane Anesthesia for Electrophysiologic Monitoring During Microvascular Decompression Surgery||Samsung Medical Center|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|61|||Both|20 Years|70 Years|No|||December 2013|December 24, 2013|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613781||84794|
NCT01609985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart Sounds During CRT|Cutaneous Heart Sounds Data Collection During Cardiac Resynchronization Therapy (CRT) Optimization Study|Cutaneous Heart Sounds Data Collection During CRT Optimization Study||Medtronic Cardiac Rhythm Disease Management|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|52|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with an implanted Medtronic market approved CRT-D device.|June 2013|June 28, 2013|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01609985||85086|
NCT01610245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM08-3002|Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza||Romark Laboratories L.C.|No|Completed|March 2013|||March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|1941|||Both|13 Years|65 Years|No|||March 2015|March 18, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610245||85066|
NCT01610232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98142708|Infrared-LED During Physical Training for Rehabilitation, Physical Performance and Body Aesthetics|Effects of Infrared-LED Illumination Applied During Treadmill Training in Postmenopausal Women||University of Sao Paulo|Yes|Completed|December 2009|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|45|||Female|50 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610232||85067|
NCT01610453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2011/731|Prediction of Delivery With Transperineal Ultrasound in Women With Prolonged Labour. Multicentre Study|Prediction of Mode of Delivery With Transperineal Ultrasound in Women With Prolonged First Stage of Labour. A Multicentre Study||Helse Stavanger HF|Yes|Completed|January 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Female|15 Years|48 Years|Accepts Healthy Volunteers|Probability Sample|primiparous women in labor|June 2013|June 13, 2013|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01610453||85050|
NCT01590849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nisenbaum1|Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone|Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone||Instituto do Coracao|Yes|Active, not recruiting|January 2011|||May 2012|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|69|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 2, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590849||86556|
NCT01590303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UWO HSREB #18803|Outcome Following Vitamin C Administration in Sepsis|A Pilot Study Examining the Efficacy of Vitamin C Administration in Septic Patients.||Lawson Health Research Institute|No|Not yet recruiting|May 2012|September 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590303||86598|
NCT01591148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stanford-16509|A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects|A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects||Stanford University|Yes|Active, not recruiting|January 2011|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|40|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|May 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591148||86533|
NCT01591161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|790|Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery||Bausch & Lomb Incorporated|No|Completed|July 2012|July 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|369|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591161||86532|
NCT01590862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002821|ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators|ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators||Massachusetts General Hospital|No|Recruiting|June 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients with Deep Brain Stimulation AND Patients with Major Depressive Disorder or        Obsessive-Compulsive Disorder and no DBS|October 2015|October 27, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01590862||86555|
NCT01591642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-099087-E|Physical Activity, Functional Fitness and Quality of Life After Coronary Artery Bypass Grafting|||Far Eastern Memorial Hospital|Yes|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|315|||Both|20 Years|N/A|No|Probability Sample|. All patients who underwent CABG at the Department of Cardiovascular Center at        Far-Eastern Memorial Hospital since January 2000 were selected for recruitment to this        study.|October 2010|May 2, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01591642||86495|
NCT01591395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-IRB-003-X|Prospective Randomized Trial Comparing Three-port and Single-port TEP Repair in Adults|Prospective Randomized Trial Comparing the Short-term and Long-term Outcomes of Three-port and Single-port TEP Repair in Adults||Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|Yes|Recruiting|August 2010|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|85 Years|No|||May 2012|May 4, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591395||86514|
NCT01587989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27837|A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate|A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) Versus Tocilizumab Monotherapy in Patients With Mild to Moderate Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 < 4,5 and >2,6)||Hoffmann-La Roche||Completed|February 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|March 12, 2012||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01587989||86773|
NCT01588327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1693|A Prospective Pharmacodynamic Study of Dabigatran|A Prospective Pharmacodynamic Study of Dabigatran Using Peak and Trough Coagulation Test Results in Patients on Therapeutic Doses of Dabigatran||University of North Carolina, Chapel Hill|No|Completed|October 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|65|Samples Without DNA|Blood plasma|Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients taking FDA-approved doses of dabigatran and control subjects not taking an        anticoagulant or antiplatelet were eligible for inclusion.|April 2012|April 27, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588327||86747|
NCT01588639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16372|To Evaluate Clinical Outcome and Injection Compliance of Scilin|A Prospective Multi-centre, Non-randomized, Open-label, Non-interventional Study to Evaluate the Safety, Efficacy and Injection Compliance of Scilin N, Scilin R or Scilin M30 in Chinese Type 2 Diabetes Mellitus (T2DM)|SEAS|Bayer|No|Completed|August 2012|January 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2683|||Both|N/A|N/A|No|Non-Probability Sample|Primary care clinic|January 2015|January 11, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588639||86724|
NCT01588886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101013-E|Proton Pump Inhibitor Use is Associated With High Risk of Pneumonia in Chronic Kidney Disease Patients|Institute of Emergency and Critical Care Medicine , School of Yang-Ming University||Far Eastern Memorial Hospital|Yes|Suspended|March 2012|November 2013|Anticipated|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|9000|||Both|N/A|N/A|No|Non-Probability Sample|Investiators use the longitudinal health insurance database 2008 (LHID 2008) released by        the Taiwan National Health Research Institutes (NHRI) in 2009. Taiwan implemented its        National Health Insurance (NHI) program in 1995 to provide affordable health care for all        the island's residents.|November 2013|November 6, 2013|April 27, 2012||No|review|No||https://clinicaltrials.gov/show/NCT01588886||86706|
NCT01613157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-PK1|Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression|||Canadian Immunodeficiency Research Collaborative||Completed|January 2006|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|||Female|18 Years|N/A|No|Non-Probability Sample|HIV positive patients|June 2012|June 4, 2012|November 5, 2009||No||No||https://clinicaltrials.gov/show/NCT01613157||84842|
NCT01613456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEC11010|Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome|Effect of S.Cerevisiae vs Placebo on the Improvement of Gastrointestinal Disorders,Especially During Irritable Bowel Syndrome. Randomized, Double-blind Study||Lesaffre International||Completed|December 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|364|||Both|18 Years|75 Years|No|||May 2015|May 13, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613456||84819|
NCT01613755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Met-Dipy001|Metformin-Dipyridamole Interaction Trial|The Effect of Dipyridamole on the Pharmacokinetics of Metformin|MetDipy|Radboud University|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2012|April 26, 2013|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01613755||84796|
NCT01613768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7674|Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer|Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers||University of Washington|No|Active, not recruiting|May 2012|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|June 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613768||84795|
NCT01609686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0165-B|Pharmacokinetics of Tranexamic Acid in Patients With Varying Renal Function Undergoing High-risk Cardiac Surgery With the Use of Cardiopulmonary Bypass|Pharmacokinetics of Tranexamic Acid in Patients With Varying Renal Function Undergoing High-risk Cardiac Surgery With the Use of Cardiopulmonary Bypass||University Health Network, Toronto|No|Recruiting|January 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|Samples Without DNA|Plasma|Both|18 Years|N/A|No|Probability Sample|HIgh risk cardiac surgical patients|November 2015|November 30, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609686||85109|
NCT01609647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAISE-HPR|Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention|Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention|PRAISE-HPR|Dong-A University|Yes|Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|76|||Both|20 Years|80 Years|No|||December 2014|December 21, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609647||85112|
NCT01609660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDS - APQ-01005-11|Impact of Probiotics on the Intestinal Microbiota and Its Association With Postoperative Outcome After Colorectal Surgery|Impact of Probiotics on the Intestinal Microbiota and Its Association With Postoperative Outcome After Colorectal Surgery||Federal University of Minas Gerais|No|Completed|March 2010|March 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|33|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01609660||85111|
NCT01610258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARDOU-PHRC-2011|Maternal Plasmatic Regulatory T Cells and Th17 as Possible Diagnosis Markers of Acute Chorioamnionitis|Contribution of the Study of Maternal Plasmatic Regulator T Cells and Th17 for the Diagnosis of Acute Chorioanmionitis Among Women Hospitalized for Premature Rupture of Fetal Membranes (PPROM) Between 24 and 34 Gestation Weeks|ICAR|Centre Hospitalier Universitaire Dijon|No|Recruiting|March 2013|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|December 3, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610258||85065|
NCT01610466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH 11-202|Design and Validation of a Simulation-based Training Curriculum for Laparoscopic Bariatric Surgery|Design and Validation of a Simulation-based Training Curriculum for Laparoscopic Bariatric Surgery||St. Michael's Hospital, Toronto|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|24|||Both|N/A|N/A|No|||November 2015|November 16, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610466||85049|
NCT01610765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 11-0068|A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)|A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)||University of Alabama at Birmingham|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|32|||Both|N/A|98 Days|No|||November 2015|November 30, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610765||85026|
NCT01610778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eki-541|Effects of 5-Aminolevulinic Acid on Glucose Metabolism|A Randomized, Double-blind, Cross-over Study to Assess Efficacy of 5-Aminolevulinic Acid in Type 2 Diabetic Patients on Medication.||Hiroshima University|No|Completed|May 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|35|||Both|35 Years|70 Years|No|||December 2013|December 17, 2013|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610778||85025|
NCT01590329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMT-LSS-1|Use of Epidermal Expansion System for Epidermal Grafting on Hypopigmented Skin and Surgical Wounds|A Proof of Concept Cases Series on the Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Hypopigmented Skin and Surgical Wounds||Momelan Technologies|No|Recruiting|March 2012|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||May 2012|May 1, 2012|May 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590329||86596|
NCT01590316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB010512|SafeBoosC - a Phase II Trial|SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants|SafeBoosC|Rigshospitalet, Denmark|Yes|Active, not recruiting|June 2012|April 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|165|||Both|N/A|3 Hours|No|||May 2015|May 18, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590316||86597|
NCT01590875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCWPRO00016186|Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation|Validation of the Durability of the Adenosine Effect in Verification of Pulmonary Vein Isolation||Medical College of Wisconsin|No|Completed|May 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|15|||Both|18 Years|75 Years|No|||July 2015|July 23, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590875||86554|
NCT01591421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I208|P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.|Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.||Canadian Cancer Trials Group|No|Active, not recruiting|May 2012|September 2016|Anticipated|September 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591421||86512|
NCT01591408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0042|EEG Biofeedback Therapy as an Adjunct Treatment for PTSD|Placebo-controlled Study of EEG Biofeedback Therapy as an Adjunct Treatment for PTSD, Evaluating Symptoms and EEG Dynamics||United States Naval Medical Center, San Diego|Yes|Completed|May 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|68|||Male|18 Years|40 Years|No|||March 2014|March 21, 2014|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591408||86513|
NCT01591850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27852|A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers|A Randomized, Single-center, Open-label, One-sequence, Two-period Crossover Study in 3 Parts to Investigate the Effects of Multiple Doses of Ketoconazole (Part 1), Rifampicin (Part 2), and Ritonavir-boosted Atazanavir (Part 3) on the PK of a Single Dose of RO5093151 in Healthy Female & Male Subjects||Hoffmann-La Roche||Completed|September 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Open Label|3||Actual|51|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591850||86479|
NCT01591837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-ASU-12-76|A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2012/2013 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)||CSL Limited||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 25, 2013|May 3, 2012|Yes|Yes||No|June 6, 2013|https://clinicaltrials.gov/show/NCT01591837||86480|
NCT01587729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115734|IMI PROTECT(WP2): Antidepressants & Fractures|IMI PROTECT (Work Package 2): Use of Antidepressants and Risk of Hip and/or Hip/Femur Fracture||GlaxoSmithKline|No|Completed|November 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of all patients included in the period of valid data        collection for each of the databases. The study period will be defined from January 1,        2001 to December 31, 2009. Information on the use of antidepressants and occurrence of        hip/femur fracture will be obtained from individual databases comprising of medical        records of general practitioners and/or claims data where prescription and diagnosis data        are recorded.|March 2015|March 26, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587729||86793|
NCT01588340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00055762|MRI Hydronephrosis Study|Comparison of Rapid Protocol Noncontrast MRI vs. Ultrasound in the Evaluation of Pediatric Hydronephrosis||University of Michigan|Yes|Withdrawn|February 2012|January 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|0|||Both|N/A|2 Years|No|||May 2015|May 29, 2015|April 26, 2012||No|PI leaving institution|No||https://clinicaltrials.gov/show/NCT01588340||86746|
NCT01587768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115738|WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics|WEUKBRE5555: IMI PROTECT (Work Package 2): The Risk of Acute Liver Injury Associated With the Use of Antibiotics||GlaxoSmithKline||Completed|November 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|The primary source population will be comprised of patients of all ages with an active or        died registration status during the study period of January 1, 2004 to December 31, 2009.        Patients must have attained one year of enrolment with the general practioner (GP) and one        year of computerized prescription history.        From the aforementioned source population, two study cohorts will be selected.        The first cohort will include all patients who received at least one antibiotic        prescription during the study period. For this cohort, the date of first prescription of        an antibiotic after meeting the eligibility criteria (entry date) defines the start of        follow-up (start date), for the exposed cohort.        The second cohort will be selected from the same source population among patients who have        not received an antibiotic prescription during the study period and in the year before the        entry date (date when the patient meet the eligibility criteria and enter in the study).|December 2014|December 8, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587768||86790|
NCT01588015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12022|Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant|A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant||City of Hope Medical Center|Yes|Active, not recruiting|August 2012|||November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|36|||Both|18 Years|75 Years|No|||November 2015|November 27, 2015|April 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01588015||86771|
NCT01588028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF002JG|A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer|A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer||Hoffmann-La Roche||Active, not recruiting|April 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||October 2014|October 16, 2014|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588028||86770|
NCT01612936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000705|T Cell Effector and Regulatory Mechanisms in Asthma|T Cell Effector and Regulatory Mechanisms in Asthma|MGH-001|Massachusetts General Hospital|Yes|Recruiting|September 2012|August 2020|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|180|||Both|18 Years|50 Years|No|||September 2015|September 14, 2015|June 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01612936||84859|
NCT01613170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11074|Premarin Versus Toviaz for Treatment of Overactive Bladder|A Combined Treatment Program for the Symptoms of Urinary Urgency and Frequency With Toviaz and Premarin Vaginal Cream||Cleveland Clinic Florida|Yes|Recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Female|30 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 4, 2012|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613170||84841|
NCT01613183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJZX-001|Exploratory Study of Effective Core Formula of Chinese Medicine to Treat Primary Insomnia|||China Academy of Chinese Medical Sciences|No|Recruiting|May 2012|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2|||2|||Both|18 Years|65 Years|No|||June 2012|June 4, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01613183||84840|
NCT01613469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-3092L|Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer|Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer||Marks, John, M.D.|No|Recruiting|August 2011|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613469||84818|
NCT01610271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28131|Air Barrier System for the Prevention of Surgical Site Infection|Air Barrier System to Reduce Contamination of Wounds During Surgery|ABS|Nimbic Systems, LLC|Yes|Completed|January 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|N/A|No|||April 2015|April 16, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01610271||85064|
NCT01609673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR22T|Study of Everolimus in de Novo Renal Transplant Recipients|Evaluation of the Early Conversion From a Calcineurin Inhibitor-based Immunosuppressive Regimen to Everolimus in de Novo Renal Transplant Recipients, a Multicenter Experience||Fundação Instituto Mineiro de Estudo Pesquisa Em Nefrologi|Yes|Terminated|March 2013|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|85 Years|No|||June 2013|June 11, 2013|May 24, 2012||No|The inclusion of proposed sample turned to be infeasible due to Ethical Non-approval of 2    research sites and another site no transplant activity since 2012.|No||https://clinicaltrials.gov/show/NCT01609673||85110|
NCT01609972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA2011 US|Comparison of Senza to Commercial Spinal Cord Stimulation for the Treatment of Chronic Pain|Multi-Center, Prospective, Randomized, Controlled Clinical Trial to Demonstrate Non-Inferiority of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Pain as Compared to Commercially Available SCS Devices|SENZA-RCT|Nevro Corp|Yes|Active, not recruiting|June 2012|June 2015|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|356|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609972||85087|
NCT01610817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D50802|Impact of a Procedure for the Information and Active Participation of the Patient in the Primary Care Prescription of Antihypertensives|Impact of a Procedure for the Information and Active Participation of the Patient in the Primary Care Prescription of Antihypertensives : InPAct Study (Information for Participating Actively in Cardiovascular Treatment)|InPAct|Hospices Civils de Lyon|No|Completed|May 2012|June 2014|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|1100|||Both|18 Years|N/A|No|Non-Probability Sample|Hypertensive patients on anti-hypertensive medication. Patients of 85 general        practitioners selected in Rhone-Alps/Auvergne and Paris region in France.|January 2015|January 22, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610817||85022|
NCT01610479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Taiho10050020|A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors|A Phase 1 Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors||Taiho Pharmaceutical Co., Ltd.|No|Active, not recruiting|June 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|N/A|No|||February 2016|February 23, 2016|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01610479||85048|
NCT01610492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116472|A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy|BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy||GlaxoSmithKline||Active, not recruiting|July 2012|August 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|75 Years|No|||May 2015|February 4, 2016|May 31, 2012||No||No|May 11, 2015|https://clinicaltrials.gov/show/NCT01610492||85047|
NCT01610791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22638|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)|A Single Arm, Open Label Study to Assess the Safety, Tolerability and Efficacy of Tocilizumab in Active Rheumatoid Arthritis Patients With Inadequate Response to the DMARDs (REMISSION Study)||Hoffmann-La Roche||Completed|March 2010|August 2011|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|121|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|May 31, 2012|No|Yes||No|May 7, 2014|https://clinicaltrials.gov/show/NCT01610791||85024|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.
NCT01610804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSCR2011|Choroidal Thickness Measurements During Central Serous Chorioretinopathy (CSCR) Treatment|Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology||University Hospital Regensburg|No|Completed|April 2011|May 2012|Actual|November 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients with reduction of vision due to Central Serous Chorioretinopathy|May 2012|June 1, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610804||85023|
NCT01590901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|009-11-803-01|Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects|The Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects||Otsuka Beijing Research Institute|Yes|Completed|February 2012|January 2013|Actual|April 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|12|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01590901||86552|
NCT01590914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-174|Brain Activation in Response to Appetitive Cues Pre- and Post- Bariatric Surgery|Brain Activation in Response to Appetite Cues Pre- and Post- Bariatric Surgery||New York Obesity and Nutrition Research Center|No|Enrolling by invitation|January 2008|||January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 8, 2013|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590914||86551|
NCT01591174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ghrelin 12010078|Ghrelin and Gastric Emptying in Children With Functional Dyspepsia|Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia|GHR|Children's Mercy Hospital Kansas City|No|Active, not recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|Samples Without DNA|breath specimen blood plasma|Both|8 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|All FD patients will be recruited from the Section of Gastroenterology at the Children's        Mercy Hospital and Clinics. The control group will be recruited by advertisement within        Children's Mercy Hospital.|February 2015|February 2, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591174||86531|
NCT01591434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-0209-11-U361|Study to Evaluate the Performance of AQUACEL® Extra™ in Venous Leg Ulcers|An Open Randomised Comparative Study to Evaluate the Performance of AQUACEL® Extra™ in Venous Leg Ulcers||ConvaTec Inc.|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||July 2013|July 29, 2013|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591434||86511|
NCT01591655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|793|Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.||Bausch & Lomb Incorporated|No|Completed|July 2012|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|363|||Both|18 Years|N/A|No|||November 2013|November 22, 2013|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591655||86494|
NCT01591876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WS/0129|Exercise and Vascular Function in Haemodialysis Patients|The Effect of an Intra-dialytic Aerobic Exercise Intervention on Vascular Function in People Undergoing Maintenance Haemodialysis Therapy for Chronic Kidney Disease Stage 5. An Exploratory Study||Queen Margaret University|No|Recruiting|November 2012|February 2014|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01591876||86477|
NCT01587755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-006|Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)|Optimising Outpatient Care in Mild to Moderate Psoriasis by a Newly Developed 'Topical Treatment Optimising Programme' - an International Study Using Daivobet®/Dovobet® Gel|PSO-TOP|Reich, Kristian, M.D.|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1852|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01587755||86791|
NCT01587742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115736|IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer|IMI PROTECT (Work Package 2): Calcium Channel Blocker Treatments and Cancer Risk||GlaxoSmithKline|No|Completed|November 2011|August 2014|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Retrospective||5|Actual|1|||Both|18 Years|79 Years|No|Non-Probability Sample|The study population will consist of CCB first-time users and non-users from January 1,        1996 to December 31, 2009, aged 18 to 79 years enrolled in the GPRD, THIN or Danish        National database|December 2014|December 18, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587742||86792|
NCT01587781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1824|Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery|Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery||Children's Research Institute|Yes|Recruiting|November 2011|June 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|12 Years|20 Years|No|Probability Sample|A total of 12 patients will be enrolled. The population for this study will include both        male and female adolescent patients from all ethnic backgrounds with BMI greater than or        equal to 95 percentile. Each patient will receive enoxaparin SC q 12 hours. The blood        samples for the study would be taken prior to the second dose.|January 2016|January 11, 2016|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587781||86789|
NCT01588041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00016827|Intraoperative OCT Guidance of Intraocular Surgery|Intraoperative OCT Guidance of Intraocular Surgery|MIOCT|Duke University|Yes|Enrolling by invitation|September 2009|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|802|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|A total of 722 subjects identified and recruited from the clinics of Duke Eye Center and        Cole Eye Institute. Of those, there will be 500 retina subjects and 222 anterior segment        subjects. Control subjects may include employees and students of both institutions.|October 2015|October 20, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588041||86769|
NCT01588054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2107-01|Prospective Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity|Prospective Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study|PCD|International Spine Study Group Foundation|No|Enrolling by invitation|April 2012|December 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|spine surgeon clinic|March 2015|March 23, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01588054||86768|
NCT01613196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 11080|Positron Emission Tomography in Extrapulmonary Tuberculosis|Evaluation of Positron Emission Tomography in Extrapulmonary Tuberculosis|TUBOGTEP|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|May 2012|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|55|||Both|18 Years|N/A|No|||February 2016|March 16, 2016|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01613196||84839|
NCT01613482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSARINE 0602|TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention|Interest of the Prophylactic Cerebral Radiotherapy in the Metastatic Breast Cancer Expressing HER2/NEU Treated by Trastuzumab|TSARINE|Centre Oscar Lambret|No|Terminated|October 2007|October 2012|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Female|18 Years|70 Years|No|||June 2012|June 6, 2012|June 1, 2012||No|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01613482||84817|
NCT01613495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eIRB #1265|Ghrelin Suppression by Octreotide in Prader-Willi|Ghrelin Suppression by Sandostatin LAR® Depot (Octreotide Acetate for Injectable Suspension) in Patients With Prader-Willi Syndrome||Oregon Health and Science University|No|Completed|August 2005|November 2010|Actual|March 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 4, 2012|April 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613495||84816|
NCT01609452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-ITP3321|MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP|MONICA-SC: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With Immune Thrombocytopenic Purpura (ITP)||Anthera Pharmaceuticals||Withdrawn|December 2015|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||July 2015|July 28, 2015|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609452||85127|
NCT01610518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UT25964|The Glycemic Response Elicited by Beta-glucans of Different Physical Properties and Form|The Glycemic Response Elicited by Beta-glucans of Different Physical Properties and Form||Guelph Food Research Centre|No|Completed|February 2011|April 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2012|June 1, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610518||85045|
NCT01609998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRC 702|Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents|Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Completed|June 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|75|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||October 2013|October 15, 2013|May 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01609998||85085|
NCT01611077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sevicontrol-2|Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg|Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial|Sevicontrol-2|Institut für Pharmakologie und Präventive Medizin|Yes|Completed|January 2012|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01611077||85002|
NCT01611064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ReTAP Study|A Study Investigating Ways to Make Local Anaesthetic Hand Surgery Less Painful - Reducing Tourniquet Associated Pain|A Randomised Controlled Trial to Investigate Whether Oxygen Supplementation Can Extend the Time Tolerated or Reduce the Pain Associated With an Upper Limb Tourniquet for Hand Surgery Under Local Anaesthetic|ReTAP|University of Oxford|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 27, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01611064||85003|
NCT01611623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-5422-CLN1-004|Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies|A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma||Esanex Inc.|No|Completed|May 2012|March 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||March 2013|March 29, 2013|May 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611623||84960|
NCT01611636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100165-E|Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study|Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study||Far Eastern Memorial Hospital|No|Recruiting|January 2012|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200000|||Both|N/A|N/A|No|Non-Probability Sample|National Health Insurance Research Database Far Eastern Memorial Hospital clinical        database|August 2015|August 17, 2015|May 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01611636||84959|
NCT01591187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD12-026 SMTEXT|The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease|The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease||St. Jude Children's Research Hospital|No|Completed|May 2012|November 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|77|||Both|10 Years|17 Years|No|Non-Probability Sample|For the purposes of this protocol, the notation of the term "parent" will be used to        include biological parents, step-parents, and legal guardians. The primary study        population will consist of patients and parents with the characteristics noted under        eligibility criteria.|March 2015|March 4, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01591187||86530|
NCT01591200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRPL/LC/09-10/001|Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis|A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis||Stempeutics Research Pvt Ltd|Yes|Recruiting|June 2012|May 2015|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|65 Years|No|||July 2013|July 5, 2013|April 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01591200||86529|
NCT01591668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-243-0102|A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C|A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection||Gilead Sciences|Yes|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|51|||Both|18 Years|65 Years|No|||August 2013|August 12, 2013|March 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591668||86493|
NCT01591863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5119-010|Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)||Merck Sharp & Dohme Corp.|Yes|Completed|June 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|6 Months|18 Years|No|||March 2015|April 27, 2015|April 27, 2012|Yes|Yes||No|March 5, 2015|https://clinicaltrials.gov/show/NCT01591863||86478|
NCT01591681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSO3|Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study|Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension: An Outpatient Pilot Feasibility and Efficacy Study||In Home Closed Loop Study Group|Yes|Completed|November 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|49|||Both|15 Years|45 Years|No|||June 2015|June 24, 2015|April 30, 2012|Yes|Yes||No|March 11, 2014|https://clinicaltrials.gov/show/NCT01591681||86492|
NCT01591889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TINI-T500-PVFD-1|Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|September 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 17, 2014|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01591889||86476|
NCT01588002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28103|A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers|A Study to Evaluate the Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir When Administered Together in Healthy Adult Volunteers||Hoffmann-La Roche||Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|3||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588002||86772|
NCT01579344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0528/11|Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma|Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma||University of Sao Paulo|Yes|Enrolling by invitation|January 2012|||March 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|N/A|No|||April 2012|April 16, 2012|April 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01579344||87428|
NCT01579617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261904-1|e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls|e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls|eSiHLE|Tulane University Health Sciences Center|No|Active, not recruiting|August 2012|December 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|700|||Female|18 Years|19 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01579617||87407|
NCT01579851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/58|Recovery After Sugammadex(Propofol vs Sevoflurane)|Recovery After Sugammadex(TIVA Using Propofol vs Inhalation Anesthesia Using Sevoflurane)|Sugammadex2|Hopital Foch|No|Recruiting|January 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|January 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01579851||87389|
NCT01609465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER 10-13|Prognostic Models for People With Stable Coronary Artery Disease|Prognostic Models for People With Stable Coronary Artery Disease||University College, London|Yes|Active, not recruiting|January 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300000|||Both|18 Years|N/A|No|Non-Probability Sample|To define incident cases we will exclude patients who have not been observed during the        year prior to their CAD diagnosis date. For prevalent cases we will remove this condition.        Our startpoint population is defined as patients aged 18 years or over diagnosed with CAD,        under which we include:          1. patients diagnosed with stable angina          2. patients with ACS (STEMI, NSTEMI & unstable angina) who survived > 4 weeks. Patients             with a CAD diagnosis who received revascularization during follow-up will enter the             cohort after the procedure (given post-procedure survival >4 weeks).|May 2012|May 29, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01609465||85126|
NCT01609699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-RB-CY1|Effectiveness Study of the UltraShape® Contour I-Y for Non-Invasive Reduction in Abdominal Circumference|A Baseline Controlled Study to Evaluate the Effectiveness of the UltraShape® Contour I - Y System for Non-Invasive Reduction in Abdominal Circumference||UltraShape|No|Not yet recruiting|August 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609699||85108|
NCT01609712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-O-P-LF-01|Osteoporotic Vertebral Compression Fractures: Can Kyphoplasty Improve Lung Function? A Prospective Evaluation|Osteoporotic Vertebral Compression Fractures: Can Kyphoplasty Improve Lung Function? A Prospective Evaluation||University Hospital, Bonn|No|Recruiting|May 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with osteoporotic compression fractures, mostly elderly females|June 2012|June 3, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609712||85107|
NCT01610011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001576|Acute Glycine Pharmacodynamic Study|Acute Glycine Pharmacodynamic Study||Mclean Hospital|No|Completed|July 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 25, 2015|May 28, 2012||No||No|May 11, 2015|https://clinicaltrials.gov/show/NCT01610011||85084|This trial was limited by small sample sizes, especially in the GLDC mutation group, since this is a rare genetic mutation.
NCT01610024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDF001|Northern Board Beet Breathlessness Trial|||Northern Health and Social Care Trust|No|Recruiting|August 2012|November 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator)|1||Anticipated|8|||Both|18 Years|80 Years|No|||June 2013|June 25, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610024||85083|
NCT01610843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200907757|Worldwide Sarcoidosis Research Study|Worldwide Sarcoidosis Research Study|WISE|University of Iowa|No|Recruiting|December 2011|||January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Saliva samples will be collected and processed at the University of Iowa.|Both|18 Years|N/A|No|Non-Probability Sample|Individuals diagnosed with sarcoidosis who have a computer with Internet access.|May 2015|May 27, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610843||85020|
NCT01611090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100840|A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Janssen Research & Development, LLC|Yes|Active, not recruiting|September 2012|January 2019|Anticipated|January 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|580|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611090||85001|
NCT01610505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KINE-1101|A Study of the KineSpring System Versus High Tibial Osteotomy Surgery for Medial Compartment Knee Osteoarthritis Treatment|Global, Prospective, Multi-Center, Non-randomized, Controlled Non-inferiority Trial to Evaluate Symptom Relief in Patients With Medial Knee Osteoarthritis Treated With the KineSpring® Knee Implant for Load Reduction Compared to HTO|GOAL|Moximed|No|Active, not recruiting|May 2012|May 2019|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|225|||Both|25 Years|80 Years|No|||January 2016|January 14, 2016|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610505||85046|
NCT01610830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSPRONOSTIC|Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura|Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura||Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|April 2010|July 2014|Anticipated|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|120|Samples With DNA|Blood and urine analysis - Skin and kidney biopsies|Both|N/A|N/A|No|Probability Sample|Children or adults, suffering from biopsy-proven HSP.2 groups:          1. Skin involvement +/- an extra renal disease (arthritis, digestive and/or other),             without renal disease. Absence of renal disease is defined by: absence of             hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults),             absence of hematuria (<5 RBCs /mm3 or < 5000 RBCs/ ml), absence of proteinuria             (proteinuria <0.1 g/d) and absence of renal dysfunction (MDRD> 80 ml / min)          2. Renal impairment, defined by the presence of renal dysfunction (calculated clearance             <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or             hematuria.|July 2012|April 22, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610830||85021|
NCT01611649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRD-2012-REBECA|Effect of a Mix of Dairy Lipids and Plant Oils in Infant Formula on Omega-3 Fatty Acid in Red Blood Cells|Profilo Degli Acidi Grassi Omega-3 Dei Globuli Rossi in Neonati Sani Alimentati Con Una Formula Per l'Infanzia Contenente Una Miscela di Grassi Del Latte e Oli Vegetali|REBECA|Lactalis|Yes|Completed|March 2012|||September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|117|||Both|N/A|21 Days|Accepts Healthy Volunteers|||April 2015|April 20, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01611649||84958|
NCT01611662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERP-GU-052|Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer|Phase II Trial of Neoadjuvant Dose Dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer||Fox Chase Cancer Center|Yes|Active, not recruiting|May 2012|December 2018|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|47|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611662||84957|
NCT01611324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EASE|Painless Local Infiltration Anesthesia|Efficacy of Alkalinised 2% Mepivacaine for Local Infiltration Anesthesia, in Ambulatory Phlebectomy|EASE|Campus Bio-Medico University|Yes|Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||December 2012|December 9, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01611324||84983|
NCT01612169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK1709|Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users|NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users|CTN0049|Columbia University|Yes|Completed|July 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|801|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612169||84918|
NCT01612182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESBL 2012-1|The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy|||Inje University||Completed|March 2012|May 2012|Actual|||N/A|Observational|Time Perspective: Retrospective||2|Actual|1289|||Both|18 Years|79 Years|No|Non-Probability Sample|The patients had admitted in single center|June 2012|June 4, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01612182||84917|
NCT01590602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGISTRY-JHD|REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN)|REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN)|JHD|European Huntington's Disease Network|No|Recruiting|November 2011|December 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|HD patients of all ages with an age of onset below 26|February 2015|February 18, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01590602||86575|
NCT01590615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-US-174-0172|Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy|Observational, Post-marketing Renal Safety Surveillance Registry in Subjects With Chronic Hepatitis B (HBV) Infection With Decompensated Liver Disease Receiving Nucleotide/Side Therapy||Gilead Sciences|No|Enrolling by invitation|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Adult participants with chronic HBV infection receiving or anticipated to receive anti-HBV        nucleoside/nucleotide therapy and with decompensated liver disease at time of consent.|January 2016|January 12, 2016|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01590615|1 Year|86574|
NCT01590628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC P#02.01.020|Pilot Study Evaluating Safety & Efficacy of a DCBT: NiCord® & UNM CBU to SCD Patients After Myeloablative Therapy|Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hemoglobinopathies||Gamida Cell ltd|Yes|Recruiting|April 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|2 Years|21 Years|No|||August 2015|August 16, 2015|April 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590628||86573|
NCT01590927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MScPTHM|Reliability and Validation of 3-D Electromagnetic Tracking During Pelvic Floor Muscle (PFM) Activation - a Pilot Study|Reliability and Validation of 3-D Electromagnetic Tracking During Pelvic Floor Muscle (PFM) Activation - a Pilot Study||Moser, Helene|No|Not yet recruiting|August 2012|May 2013|Anticipated|February 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|20|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy women, students of the University of Applied Sciences Health|May 2012|May 2, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01590927||86550|
NCT01591213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD12-040 SJCECP2|St. Jude Cancer Education for Children Program: The Feasibility of Teacher Delivery (Pilot Study)|St. Jude Cancer Education for Children Program: The Feasibility of Teacher Delivery (Pilot Study)||St. Jude Children's Research Hospital|No|Completed|November 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|426|||Both|8 Years|11 Years|Accepts Healthy Volunteers|Non-Probability Sample|Fourth grade students enrolled in Memphis-area schools.|January 2015|January 12, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01591213||86528|
NCT01591447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE01-202|Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea|An Open-Label Study to Evaluate the Efficacy and Safety of a Single-Dose of Oral CEM-101 in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea||Cempra Inc|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|N/A|No|||February 2014|February 6, 2014|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591447||86510|
NCT01591694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00047384|National Child Traumatic Stress Network (NCTSN) Quality Improvement Initiative Database|National Child Traumatic Stress Network (NCTSN) Quality Improvement Initiative Database||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|April 2012|September 2018|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|500|||Both|2 Years|89 Years|No|Non-Probability Sample|Children enrolled in treatment at the Family Center and their caregivers|September 2013|September 26, 2013|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01591694||86491|
NCT01591902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200147-500|Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®|A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes||Theratechnologies|Yes|Recruiting|June 2012|July 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|648|||Both|18 Years|N/A|No|||August 2015|August 11, 2015|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591902||86475|
NCT01591915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|499-09|A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer|A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer||Skaraborg Hospital|No|Recruiting|January 2010|December 2020|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|150|||Female|N/A|N/A|No|||May 2012|May 3, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591915||86474|
NCT01579162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HepQuant-001|Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation|Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation|Repro|HepQuant, LLC|No|Active, not recruiting|January 2012|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|40|||Both|22 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|February 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579162||87442|
NCT01579357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT-Capecet_PK|Pharmacokinetics and Metabolic Activation of Capecitabine|Pharmacokinetics and Metabolic Activation of Capecitabine When Given Concomitantly With Oxaliplatin and the Monoclonal Antibody Cetuximab||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Completed|February 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01579357||87427|
NCT01579370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032718|Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)|A Four-arm Prospective, Multicenter Study to Assess the Efficacy, Effectiveness, and Feasibility of Enhanced Terminal Room Disinfection With Chlorine and UV Light Using Clinical and Microbiologic Outcomes||Duke University|No|Completed|April 2012|August 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|21395|||Both|N/A|N/A|No|||November 2015|November 15, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01579370||87426|
NCT01579383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALD403-CLIN-001|Safety Tolerability and Pharmacokinetics of ALD403|A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection||Alder Biopharmaceuticals, Inc.|No|Completed|April 2012|April 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 25, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01579383||87425|
NCT01609478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149E2203|Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma|A Multicenter, Randomized, Double-blind, Placebo-controlled, 12-week Treatment, Parallel-group Study to Assess the Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate (75 and 150 µg o.d.) in Patients With Persistent Asthma||Novartis|No|Completed|August 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|335|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|April 23, 2012||No||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01609478||85125|
NCT01609725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA110146|Periodontal Therapy in Coronary Artery Patients|Impact of Periodontal Therapy in Flow-mediated Dilation and Serum Levels of Cardiovascular Risk Biomarkers in Coronary Artery Disease Patients: 12 Months Randomized Controlled Trial|PerioCardio|Federal University of Rio Grande do Sul|No|Recruiting|January 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|35 Years|70 Years|No|||June 2015|June 8, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609725||85106|
NCT01610037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2339|Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation|A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation||Novartis|Yes|Recruiting|October 2012|January 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|1224|||Both|40 Years|N/A|No|||September 2014|October 21, 2014|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610037||85082|
NCT01610284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120F2302|Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor|A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment|BELLE-2|Novartis|Yes|Active, not recruiting|August 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1147|||Female|18 Years|N/A|No|||March 2016|March 4, 2016|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610284||85063|
NCT01611103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15657-O|Cognitive Effects of Transcranial Direct Current Stimulation in Older Adults|Cognitive Effects of Transcranial Direct Current Stimulation in Older Adults||Johns Hopkins University|Yes|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|43|||Both|55 Years|79 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611103||85000|
NCT01611337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00155-38|Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry|Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry||Centre Hospitalier Esquirol|No|Recruiting|June 2012|January 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|250|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01611337||84982|
NCT01611350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRA001|Testing New Marketing Models for Improved Cookstoves - Uganda|Behavior Change Interventions to Improve the Acquisition and Correct Use of Improved Cookstoves||University of California, Berkeley|Yes|Recruiting|February 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Anticipated|3500|||Female|18 Years|N/A|No|||June 2012|June 2, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01611350||84981|
NCT01611675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-088|Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma|A Phase I/II Trial of Leflunomide in Combination With Vemurafenib in Patients With V600 Mutant Metastatic Melanoma||Massachusetts General Hospital|Yes|Suspended|July 2012|December 2015|Anticipated|July 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||December 2013|December 24, 2013|May 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611675||84956|
NCT01611922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/365/11/L|Optimization of Assessment and Grading for Lid Wiper Epitheliopathy|Optimization of Assessment and Grading for Lid Wiper Epitheliopathy|BURNABY|Alcon Research|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|57|||Both|17 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be identified and screened by the University of Waterloo in Ontario,        Canada.|June 2012|June 4, 2012|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611922||84937|
NCT01611909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Citriodiol®&Impetigo-001|Citriodiol® and Impetigo|A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo.||Royal North Shore Hospital|No|Not yet recruiting|July 2012|March 2013|Anticipated|January 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|12 Months|12 Years|No|||June 2012|June 18, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01611909||84938|
NCT01612429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000775|Carbamylation in Renal Disease-modulation With Amino Acid Therapy|Amino Acid Therapy to Modify Protein Carbamylation in End Stage Renal Disease|CarRAAT|Massachusetts General Hospital|No|Active, not recruiting|January 2013|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||May 2015|May 22, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01612429||84898|
NCT01612442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|290-0310|Integrated Education Intervention to Improve Infant and Young Child Nutrition and Growth in Ghana|||McGill University|No|Completed|June 2010|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|367|||Both|6 Months|11 Months|Accepts Healthy Volunteers|||June 2012|June 3, 2012|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01612442||84897|
NCT01590641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-283-0106|A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B|A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection||Gilead Sciences|Yes|Completed|April 2012|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|49|||Both|18 Years|65 Years|No|||November 2013|November 13, 2013|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590641||86572|
NCT01590940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODSC001|Use of Parietex Plug and Patch Hernia System in Open Inguinal Hernia Repair|Use of Parietex Plug-and-patch Hernia Mesh in Elective Open Inguinal Hernia Repair: A Pilot Investigation||Owen Drive Surgical Clinic of Fayetteville||Recruiting|April 2012|||April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|n=50 males and females age 18 and up|May 2012|May 3, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01590940||86549|
NCT01582464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-012|Addressing Attitudes to Improve Use of Protective Headwear in Older Adults|Effect of Social Marketing on Attitudes Towards Protective Headwear in Older Adults to Reduce Traumatic Brain Injury|AAIU-PHOA|University of California, Los Angeles|No|Not yet recruiting|May 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|80|||Both|65 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The population is English speaking male or female > 65 years of age who are competent to        give informed consent.|April 2012|April 19, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582464||87191|
NCT01591460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MV28073|A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C|An International, Multicenter, Open-Label Study Evaluating Sustained Virological Response and Safety With Boceprevir in Triple Combination Therapy With Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-Naïve Patients With Genotype 1 Chronic Hepatitis C||Hoffmann-La Roche||Completed|August 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 2, 2012|No|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT01591460||86509|
NCT01582919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/15|Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study|STUDY OF IMAGING MARKERS IN THE VERY EARLY STAGES OF DEMENTIA AMONG RETIRED RURAL FARM IN THE GIRONDE AND PARTICIPATING IN THE AMI COHORT EPIDEMIOLOGY: A LONGITUDINAL STUDY.|AMIMAGE 2|University Hospital, Bordeaux|No|Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Both|65 Years|N/A|No|||January 2015|January 12, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582919||87156|
NCT01591928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-LR-01|Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study|Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study||University of Alberta|No|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|6 Months|No|Non-Probability Sample|All infants with heteterotaxy syndrome whose families provide written informed consent.|March 2016|March 14, 2016|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591928||86473|
NCT01579890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105-95|Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis|A Non-blinded, Non-placebo Controlled, Compassionate Use, Open Treatment, Open-ended Program of the Safety of Pennsaid Topical Lotion (Diclofenac) in the Treatment of Osteo or Rheumatoid Arthritis||Mallinckrodt||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||April 2012|April 17, 2012|April 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579890||87386|
NCT01579903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1831077|Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)|An Open-Label, Randomized, Two-period Crossover Study To Compare Relative Bioavailability of Two Formulations of Moroctocog Alfa (Af-cc) In Subjects With Moderately Severe Or Severe Hemophilia A (FVIII:C </=2%)||Pfizer|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Male|18 Years|N/A|No|||February 2013|February 7, 2013|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579903||87385|
NCT01609738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37648.068.11|Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum|Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum - Feasibility, Long-term Lead Stability and Safety||Maastricht University Medical Center|Yes|Recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|12|||Both|18 Years|75 Years|No|Non-Probability Sample|Study subjects are recruited from patients referred to the out-patient pacemaker/ICD        clinic of our hospital.|April 2015|April 9, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01609738||85105|
NCT01610050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFA102X1101|A Phase I Study of LFA102 in Japanese Patients|A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Japanese Patients With Castration-resistant Prostate Cancer or Advanced Breast Cancer||Novartis|Yes|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||November 2014|November 9, 2014|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610050||85081|
NCT01610297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CICL670ATR04|Post Hematopoietic Stem Cell Transplantation|A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation.||Novartis|No|Completed|September 2013|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|2 Years|N/A|No|||February 2016|February 3, 2016|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610297||85062|
NCT01610531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/11-N|COPARIME: Pilot Study of a Target Detection of Malignant Melanoma|COPARIME: Pilot Study of a Target Detection of Malignant Melanoma||Nantes University Hospital|Yes|Recruiting|April 2011|May 2020|Anticipated|May 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|7700|||Both|18 Years|N/A|No|||September 2013|September 18, 2013|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610531||85044|
NCT01611688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8210-3926|First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis|First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|75 Years|No|||November 2013|November 14, 2013|June 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611688||84955|
NCT01611701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFA-655-CA|Cryoballoon Ablation of Pulmonary Veins After Failed RF Ablation in Patients With Paroxysmal AF|Cryoballoon Ablation of Pulmonary Veins After Failed Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation||Meshalkin Research Institute of Pathology of Circulation|Yes|Completed|October 2009|February 2012|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|65 Years|No|||June 2012|June 1, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01611701||84954|
NCT01611363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0050|A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin|An Exploratory Study to Investigate the Effects of Ipragliflozin (ASP1941) on Glucose Homeostasis and Urinary Glucose Excretion in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)||Astellas Pharma Inc|No|Completed|October 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|44|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611363||84980|
NCT01611376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICG-01-Choe|Impedance Cardiography During Major Abdominal Surgery|Comparison of Cardiac Output Derived From Flotrac/Vigileo and Impedance Cardiography During Major Abdominal Surgery||Inje University|No|Completed|September 2012|February 2013|Actual|January 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|11|||Both|20 Years|80 Years|No|||May 2012|August 16, 2013|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611376||84979|
NCT01612208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|51842|MotionLoc Study, Femur Fractures|Healing of Distal Femur Fractures Stabilized With a Flexible Plating Construct Using MotionLoc Screws||University of Utah|No|Completed|April 2011|January 2013|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2|||Both|17 Years|N/A|No|Non-Probability Sample|Distal femur fractures (AO/OTA Type 33A and 33C)|May 2014|May 21, 2014|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01612208||84915|
NCT01612455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032082|Linking Infectious and Narcology Care in Russia|Linking Russian Narcology & HIV Care to Enhance Treatment, Retention, & Outcomes|LINC|Boston Medical Center|No|Active, not recruiting|July 2012|April 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|349|||Both|18 Years|70 Years|No|||January 2016|January 13, 2016|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612455||84896|
NCT01612195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFP-2|Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula|Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula||University Hospital, Basel, Switzerland|No|Completed|January 2007|January 2012|Actual|March 2009|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|June 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01612195||84916|
NCT01613612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGH_201112_Ortho_1|Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH)|Control Study of Implantation of Enriched Bone Marrow Cells for the Treatment of Avascular Necrosis of Femoral Head||Guangdong General Hospital|No|Enrolling by invitation|March 2009|December 2012|Anticipated|August 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|55 Years|No|||August 2012|August 12, 2012|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01613612||84807|
NCT01613625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00950-39|Interest Of Renal Elastography In Children As A Diagnostic Tool Of Renal Fibrosis: Confrontation To Histological Features Of Renal Biopsies|Interest Of Renal Elastography In Children As A Diagnostic Tool Of Renal Fibrosis: Confrontation To Histological Features Of Renal Biopsies||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|January 2011|December 2014|Anticipated|July 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|5 Years|18 Years|No|||August 2014|August 28, 2014|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01613625||84806|
NCT01581840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFCD 0904|Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus|Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus||Federation Francophone de Cancerologie Digestive|Yes|Recruiting|June 2012|June 2020|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||April 2012|August 30, 2012|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01581840||87239|
NCT01581853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMON|Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily|Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily||Hospital Universitari de Bellvitge|No|Recruiting|May 2012|October 2014|Anticipated|October 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2013|April 19, 2013|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01581853||87238|
NCT01582204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-134|Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma|Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma||Memorial Sloan Kettering Cancer Center||Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|April 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01582204||87211|
NCT01582451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14703|A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus|A Comparison of LY2605541 Versus Insulin Glargine Alone or in Combination With Pre-study Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin: An Open-Label, Randomized Study The IMAGINE 5 Study|IMAGINE 5|Eli Lilly and Company|Yes|Completed|April 2012|December 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|426|||Both|18 Years|N/A|No|||January 2014|April 14, 2014|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582451||87192|
NCT01582477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B701|TAP-patients With Robotic Assisted Lap Prostatectomy|Evaluation of the Safety and Efficacy of EXPAREL When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) for Prolonged Postsurgical Analgesia in Subjects Undergoing Robot-assisted Laparoscopic Prostatectomy|TAP|Pacira Pharmaceuticals, Inc|No|Completed|March 2012|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|75 Years|No|||May 2013|May 5, 2013|April 19, 2012|Yes|Yes||No|February 26, 2013|https://clinicaltrials.gov/show/NCT01582477||87190|
NCT01582685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0121|Exercise in Breast Cancer Survivors|Exercise in Breast Cancer Survivors: Analysis of Angiogenic Profile||University of Mississippi Medical Center|No|Withdrawn|April 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|0|||Female|18 Years|N/A|No|||December 2014|December 1, 2014|April 2, 2012||No|no patients enrolled|No||https://clinicaltrials.gov/show/NCT01582685||87174|
NCT01582945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002800|Ketamine Infusion for Treatment-resistant Major Depressive Disorder|N-methyl-D-aspartate Antagonist (Ketamine) Infusion for Treatment-resistant Major Depressive Disorder With Suicidal Ideation||Massachusetts General Hospital|Yes|Completed|April 2012|December 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|65 Years|No|||April 2015|April 6, 2015|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582945||87154|
NCT01583192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mbshadid|Chloridehexidine Versus Povidine Jodine Both Soluted in Alcohol in Forefoot Surgery|Prospective Study of Chloridehexidine/Alcohol Versus Jodine/Povidine in Forefoot Surgery||St. Antonius Hospital|No|Completed|March 2013|June 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01583192||87135|
NCT01579149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOZ24211|A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent|A Phase 1, Randomized, Single-center, Single-dose, Double-blind, Placebo-controlled Pharmacokinetic, Safety, and Pharmacodynamic Study of Subcutaneous Injection of 160 μg/kg, 240 μg/kg, and 400 μg/kg Plerixafor in Healthy Adult Volunteers of Japanese Descent||Sanofi|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|24|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579149||87443|
NCT01579630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7913L00077|Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy|An Open Label, Randomized, Multicenter, Phase II Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Advanced (Stage IV) EGFR Mutation Negative or T790M Single Mutation Nonsquamous NSCLC Who Respond to 4 Cycles of Pemetrexed/ Platinum as First-line Therapy||Taipei Veterans General Hospital, Taiwan|No|Active, not recruiting|March 2011|June 2014|Anticipated|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|20 Years|N/A|No|||April 2014|April 3, 2014|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01579630||87406|
NCT01579643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00006612 LALAK Child|OCT-guided LALAK in Children|Randomized Clinical Trial of OCT-guided Laser-assisted Lamellar Anterior Keratoplasty in Children|LALAK|Oregon Health and Science University|Yes|Recruiting|January 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|1 Month|18 Years|No|||April 2015|April 21, 2015|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01579643||87405|
NCT01610310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105HV103|Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers|A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of Peginterferon Beta-1a (BIIB017) Delivered by Pre-filled Syringe (PFS) or Autoinjector in Healthy Volunteers||Biogen|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|55|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01610310||85061|
NCT01610544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120130|18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma|A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors||National Institutes of Health Clinical Center (CC)||Withdrawn|May 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|99 Years|No|||December 2012|November 18, 2015|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610544||85043|
NCT01610856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21972|Single Dose Versus Split Dose Polyethylene Glycol-based Colonic Lavage for Colonoscopy|A Randomized Prospective Trial Comparing Single Dose Polyethylene Glycol-based Lavage Versus Split Dose Polyethylene Glycol-based Lavage in the Preparation of Patients Undergoing Colonoscopy||University of Calgary|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)|2||Actual|250|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||May 2012|June 1, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610856||85019|
NCT01610869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/10/0470|Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer|Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer|METRO-BIBF|University College, London|Yes|Recruiting|August 2014|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|124|||Female|18 Years|N/A|No|||August 2015|August 19, 2015|November 25, 2011||No||No||https://clinicaltrials.gov/show/NCT01610869||85018|
NCT01612468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lira1|Liraglutide in Type 1 Diabetes|Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients||Steno Diabetes Center|Yes|Completed|June 2012|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01612468||84895|
NCT01611935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811293|AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock|AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock|AVERT Shock|University of Pennsylvania|Yes|Recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||January 2013|August 19, 2014|June 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611935||84936|
NCT01613040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP21705|A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers|A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects.||Hoffmann-La Roche||Completed|January 2009|July 2009|Actual|July 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|169|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613040||84851|
NCT01612741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13925|Diabetes Treatment With Glucobay in Combination With Metformin|Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Metformin Under Daily Life Treatment Conditions||Bayer|No|Completed|April 2008|January 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|19509|||Both|18 Years|N/A|No|Probability Sample|Type 2 diabetes|July 2014|July 7, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612741||84874|
NCT01613027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27998|An Observational Study of MabThera/Rituxan in Patients With Severe Active Rheumatoid Arthritis (Positive Trial)|An Observational Study on the Efficacy and Safety of MabThera (Rituximab) in seroPOSITIVE TNF IR Patients With Severe Active Rheumatoid Arthritis in Routine Clinical Practice (POSITIVE TRIAL)||Hoffmann-La Roche||Completed|February 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|135|||Both|18 Years|N/A|No|Probability Sample|Patients with severe active rheumatoid arthritis who have an inadequate response or        intolerance to TNF-inhibitors therapy|March 2016|March 1, 2016|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01613027||84852|
NCT01580033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT009|Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine|Immunogenicity and Safety Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Aged 3-5 Months: A Phase 3 Clinical Trial||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|April 2012|November 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|900|||Both|3 Months|5 Months|No|||May 2013|May 7, 2013|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580033||87375|
NCT01580046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XNK201201|Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction|Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial|RIPE|Peking University First Hospital|No|Recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|75 Years|No|||October 2013|October 14, 2013|April 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01580046||87374|
NCT01581879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40350|Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|November 2004|January 2005|Actual|November 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581879||87236|
NCT01581892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUCA|Use of Adult Bone Marrow Mononuclear Cells in Patients With Long Bone Nonunion|Treatment of Long Bone Nonunion With Autologous Bone Marrow Stem Cells. Phase I/II Study||Hospital Universitario Central de Asturias|No|Completed|December 2011|January 2013|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01581892||87235|
NCT01582217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0028|Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition|TRIAGE: Patients Undergoing Percutaneous Coronary Interventions to Improve Clinical Outcomes Through Optimal Platelet Inhibition|TRIAGE|Icahn School of Medicine at Mount Sinai|Yes|Completed|March 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|318|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects in any of the participating sites who are on chronic clopidogrel treatment and        return for PCI will be considered for this study.|December 2015|December 22, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582217||87210|
NCT01582958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122470|The Effect of OMT on Patients With COPD: Correlating Pulmonary Function Tests With Biochemical Alterations|The Effect of Osteopathic Manipulative Treatment on Patients With Chronic Obstructive Pulmonary Disease:Correlating Pulmonary Function Tests With Biochemical Alterations||Michigan State University|No|Completed|April 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|45|||Both|49 Years|80 Years|No|||October 2015|October 6, 2015|April 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01582958||87153|
NCT01582698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|691101|TBE Seropersistence up to 10 Years After First Booster in Adults|Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults||Baxter Healthcare Corporation|Yes|Completed|April 2012|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|243|||Both|25 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 23, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582698||87173|
NCT01582932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115469|To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis|A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis||GlaxoSmithKline|No|Recruiting|April 2013|April 2019|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|2 Years|11 Years|No|||August 2015|October 15, 2015|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582932||87155|
NCT01579396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1486|High Cut Off Dialysis in Systemic Inflammatory Response Syndrome Patients After Cardiac Surgery|The Effects of High-cutoff (HCO) Hemofiltration in the Immediate Postoperative Period on Systemic Inflammatory Response Syndrome (SIRS) and Renal Recovery in Cardiac Surgery Patients With a High Risk for Renal Failure. (HICOSIRS)|HICOSIRS|Gambro Dialysatoren GmbH|No|Withdrawn|April 2012|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 8, 2013|January 18, 2012||No|Study halted prematurely, prior to enrollment of first patient, due to recruiting problems.|No||https://clinicaltrials.gov/show/NCT01579396||87424|
NCT01583205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6514|Coping Effectiveness Training for ALS|Coping Effectiveness Training for Recently Diagnosed ALS Patients and Care Partners||Research Foundation for Mental Hygiene, Inc.|No|Withdrawn|April 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||November 2014|November 7, 2014|April 5, 2012||No|The study was not funded.|No||https://clinicaltrials.gov/show/NCT01583205||87134|
NCT01580826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML 3398|Pasteurization of Mother's Own Milk for Preterm Infants|Pasteurization of Mother's Own Milk for Preterm Infants : a Randomized Trial.||Universitaire Ziekenhuizen Leuven|Yes|Completed|March 2006|April 2012|Actual|February 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|303|||Both|N/A|2 Days|No|||April 2012|April 18, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580826||87316|
NCT01580839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTA0903|EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)|Extending the Time for Thrombolysis in Emergency Neurological Deficits|EXTEND|Neuroscience Trials Australia|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2014|April 15, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580839||87315|
NCT01580540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epigenomics-SPR 0022|Head to Head Study Epi proColon and FIT|Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population||Epigenomics, Inc|No|Completed|March 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|336|Samples With DNA|Plasma|Both|50 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited from gastroenterology clinics and surgical centers in the United        States.|July 2014|August 3, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580540||87338|
NCT01580553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeesPharm_LC-HF|The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure|The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure —A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study||Lee's Pharmaceutical Limited|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|268|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01580553||87337|
NCT01580800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10042011-8529|National Breast Cancer and Lymphedema Registry|National Breast Cancer and Lymphedema Registry||Stanford University|Yes|Recruiting|September 2011|December 2025|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Breast cancer survivors|December 2015|December 16, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01580800||87318|
NCT01610882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01273|Panda: Evaluation of a Smartphone-based Perioperative Pain Assessment Tool|Panda: Evaluation of a Smartphone-based Perioperative Pain Assessment Tool|Panda|University of British Columbia|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|144|||Both|4 Years|18 Years|No|||January 2015|January 16, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01610882||85017|
NCT01610895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24206|Split Dose Polyethylene Glycol (PEG) + Clear Fluids Versus Split Dose PEG + Low-Residue Diet|A Randomized Prospective Trial Comparing Split Dose Polyethylene Glycol-Based Lavage With Clear Fluids Versus Split Dose Polyethylene Glycol-Based Lavage With a Low-Residue Diet in Preparation of Patients for Colonoscopy.|BP|University of Calgary|No|Recruiting|December 2011|October 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|345|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||May 2012|June 1, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610895||85016|
NCT01611116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3066K1-1165|Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia|A Double-blind, Placebo-controlled, Randomized, Multicenter Phase II Trial to Assess the Efficacy of Temsirolimus Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML|TOR-AML|Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|May 2012|December 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|224|||Both|61 Years|N/A|No|||September 2015|September 3, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01611116||84999|
NCT01611129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS-IT-03|Internet-based Pre-fitting Counseling of Persons With Hearing Impairment|Use of the 'Patient Journey' Model in the Internet-based Pre-fitting Counseling of a Person With Hearing Impairment: A Randomized Controlled Trial||Linkoeping University|Yes|Completed|November 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||April 2013|April 16, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01611129||84998|
NCT01611389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|83562|Minimizing Ventricular Pacing|Minimizing Right Ventricular Pacing in Dual-chamber Pacemaker Patients With Sinus Node Disease and First Degree Atrioventricular Block.||Military Institute of Medicine, Poland|No|Recruiting|September 2010|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|N/A|No|||May 2012|June 4, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611389||84978|
NCT01611402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120142|Gene Expression in HIV and Tuberculosis Co-infection|Transcriptional Signature of HIV And TB Co-Infection||National Institutes of Health Clinical Center (CC)||Completed|May 2012|||||N/A|Observational|Time Perspective: Cross-Sectional|||Actual|20|||Both|18 Years|N/A|No|||January 2016|February 3, 2016|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01611402||84977|
NCT01612481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASSANDRE - 1108|Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma|Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma: Chest Radiograph Versus Chest CT||Centre Oscar Lambret|No|Active, not recruiting|April 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|18 Years|70 Years|No|||August 2012|March 6, 2014|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612481||84894|
NCT01612494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HTS-100423|Hypertonic Saline as Therapy for Pediatric Concussion|Hypertonic Saline as Therapy for Pediatric Concussion: A Randomized Controlled Trial in the Emergency Department||University of California, San Diego|Yes|Completed|March 2010|April 2012|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|44|||Both|4 Years|17 Years|Accepts Healthy Volunteers|||February 2014|February 20, 2014|May 29, 2012||No||No|June 17, 2013|https://clinicaltrials.gov/show/NCT01612494||84893|
NCT01612754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA 02|Prospective Trial on Noise Reduction in Surgical Operating Theaters|Noise Reduction Programme by Work Rules and Technical Devices (i.e.SoundEar-TM)for Surgical Theathres||Hannover Medical School|Yes|Completed|September 2010|April 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|16|||Both|N/A|16 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612754||84873|
NCT01612767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G110147|BIOHELIX-I Bare Metal Stent Study|The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent|BIOHELIX-I|Biotronik, Inc.|Yes|Active, not recruiting|November 2012|November 2017|Anticipated|September 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|329|||Both|18 Years|N/A|No|||September 2015|October 20, 2015|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612767||84872|
NCT01579019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV22877|A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment|||Hoffmann-La Roche||Withdrawn|July 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579019||87453|
NCT01579500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC12MIMV0005|Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients|The Effect of Botulinum Toxin A in Post Spinal Cord Injury Neuropathic Pain||Catholic University of Korea Saint Paul's Hospital|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|N/A|No|||April 2013|April 23, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01579500||87416|
NCT01613339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AF-1-2011|Body Awareness Therapy for People With Stroke|Body Awareness Therapy for People With Stroke||Örebro County Council|No|Completed|October 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|April 16, 2012||No||No|June 7, 2013|https://clinicaltrials.gov/show/NCT01613339||84828|
NCT01613352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|329 / E6 / 07|Feasibility of Ambulatory Surgery for Early Breast Cancer|Same Day Discharge After Surgery for Early Breast Cancer - a Feasible Option||Helsinki University Central Hospital|No|Completed|March 2008|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|100|||Female|18 Years|90 Years|No|||June 2012|June 5, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613352||84827|
NCT01579747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNMLAM_USvsNSobese|Does Ultrasound Improve Procedural Time in the Lateral Popliteal Approach to the Sciatic Nerve in Obese Patients|Does Ultrasound Improve Procedural Time in the Lateral Popliteal Approach to the Sciatic Nerve in Obese Patients||University of New Mexico|No|Completed|July 2012|March 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|April 16, 2012||No||No|August 19, 2013|https://clinicaltrials.gov/show/NCT01579747||87397|We attempted to minimize performance bias by only involving staff anesthesiologists with years of experience in peripheral nerve blockade using both guidance modalities.
NCT01579760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aflibercept2012|Intravitreal Aflibercept Injection for Radiation Retinopathy|Treatment of Radiation Retinopathy With Intravitreal Aflibercept Injection 2.0mg||Washington University School of Medicine|Yes|Active, not recruiting|November 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579760||87396|
NCT01582490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA402S23B901|Study of EXPAREL in Patients Undergoing Breast Augmentation|Evaluation of the Safety and Efficacy of EXPAREL® (Bupivacaine Liposome Injectable Suspension) When Administered Via Infiltration Versus Instillation in Subjects Undergoing Bilateral Augmentation Mammoplasty||Pacira Pharmaceuticals, Inc|No|Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Female|18 Years|75 Years|No|||May 2014|May 31, 2014|April 19, 2012|Yes|Yes||No|April 29, 2014|https://clinicaltrials.gov/show/NCT01582490||87189|
NCT01582711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCHHSTP 6222|Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT|TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.|iAdhere|Centers for Disease Control and Prevention|Yes|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1002|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|February 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582711||87172|
NCT01579188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KG 1/2012|Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer|A Double-blind, Multicenter, Randomized Phase III Study of the Telomerase Vaccine, GV1001 Administered After Curative Intent Chemo-radiotherapy in Patients With Inoperable Stage III Non-small Cell Lung Cancer Compared to Best Supportive Care|LucaVax|Kael-GemVax Co., Ltd.|Yes|Not yet recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|N/A|No|||April 2012|April 18, 2012|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579188||87440|
NCT01578889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HVTN 087|Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults|A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an IL-12 pDNA Enhanced HIV-1 Multiantigen pDNA Vaccine Delivered Intramuscularly With Electroporation, With an HIV-1 rVSV Vaccine Boost, in Healthy HIV-Uninfected Adult Participants||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|May 2012|||September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|8||Actual|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2016|March 15, 2016|April 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01578889||87463|
NCT01579175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00036423|The Effect of Gum Chewing on Postoperative Ileus After Gynecologic Surgery|The Effect of Gum Chewing on Postoperative Ileus After Gynecologic Surgery.|GumGyn|Johns Hopkins University|No|Completed|January 2010|February 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|294|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 13, 2013|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579175||87441|
NCT01579656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLUSEED-2|Effect of Flax, Poppy, Sesame & Salba on Postprandial Blood Glucose Response, Vascular, Appetite & Sensory Parameters|The Effects of Four Commonly Consumed Seeds (Flax, Poppy, Sesame & Salba) on Postprandial Blood Glucose Response, Vascular, Appetite and Sensory Parameters in Healthy Individuals||St. Michael's Hospital, Toronto|No|Completed|February 2011|August 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|21|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01579656||87404|
NCT01579916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-VA-FluMist-1114|A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults||MedImmune LLC|No|Completed|May 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|303|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2013|December 16, 2013|April 16, 2012|Yes|Yes||No|December 16, 2013|https://clinicaltrials.gov/show/NCT01579916||87384|
NCT01580241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2606|Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer|Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma||University of Oklahoma|No|Active, not recruiting|October 2010|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We        will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy        only, surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a        change in DCAMKl-1 expression.|December 2014|December 2, 2014|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580241||87360|
NCT01581411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRVO-IAT1|Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion|Phase 1 Trial of Intra-Ophthalmic Artery Thrombolysis for Treating Recent Severe Central Retinal Vein Occlusion||Weill Medical College of Cornell University||Recruiting|January 2012|January 2015|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|90 Years|No|||April 2012|April 18, 2012|April 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01581411||87272|
NCT01581073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIGU1115|PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease|Prevention of End Stage Kidney Disease by Darbepoetin Alfa In CKD Patients With Non-diabetic Kidney Disease|PREDICT|Translational Research Informatics Center, Kobe, Hyogo, Japan||Active, not recruiting|December 2011|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|476|||Both|20 Years|85 Years|No|||September 2015|September 7, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01581073||87297|
NCT01611714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 02-0515(3)|Equity in Diagnostic Imaging Trial|Equity in Diagnostic Imaging Trial (EDIT)|EDIT|Icahn School of Medicine at Mount Sinai|No|Completed|July 2010|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|181|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01611714||84953|
NCT01611948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA030988|Treatment for Cannabis Withdrawal and Dependence|Pharmacological Treatment of Cannabis Withdrawal and Dependence||The Scripps Research Institute|No|Recruiting|May 2011|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||October 2015|October 15, 2015|June 3, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611948||84935|
NCT01612221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI50308|Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo|A Phase II Placebo-controlled Intervention Trial of Oral N-acetylcysteine (NAC) for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo||University of Utah|Yes|Completed|September 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|141|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 23, 2015|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612221||84914|
NCT01579032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2863|PULSE WAVE ANALYSIS AND VELOCITY IN PATIENTS WITH CHRONIC RENAL FAILURE|PULSE WAVE ANALYSIS AND VELOCITY IN PATIENTS WITH CHRONIC RENAL FAILURE: A CROSS-SECTIONAL OBSERVATIONAL STUDY TO ASSESS ASSOCIATION WITH LEFT VENTRICULAR HYPERTROPY, UREMIC TOXINS AND INFLAMMATION.||Universitaire Ziekenhuizen Leuven|No|Completed|January 2004|||January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|90|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|CKD patients|February 2012|April 16, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579032||87452|
NCT01579045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005141|Effect of Head and Gaze Position on Soft Toric Contact Lens Performance|Effect of Head and Gaze Position on Soft Toric Contact Lens Performance||Johnson & Johnson Vision Care, Inc.|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|12||Actual|24|||Both|18 Years|55 Years|No|||May 2015|May 5, 2015|April 13, 2012|No|Yes||No|August 28, 2014|https://clinicaltrials.gov/show/NCT01579045||87451|
NCT01583075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STXS 10-005|Pulmonary Vein Ablation of Atrial Fibrillation Using Magnetic Navigation: Single Ring Versus Circumferential Techniques|Pulmonary Vein Ablation With Magnetic Navigation in Patients With Therapy-refractory Symptomatic Atrial Fibrillation: Comparison of "Single Ring" and Circumferential Ablation Techniques||University Medical Center Goettingen|No|Completed|December 2009|||March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|30 Years|80 Years|No|||April 2012|April 23, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583075||87144|
NCT01579006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28164|Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|A Multi National, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (Actemra)||Hoffmann-La Roche||Completed|May 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|184|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients treated with tocilizumab|February 2016|February 4, 2016|April 16, 2012|No|Yes||No|December 8, 2015|https://clinicaltrials.gov/show/NCT01579006||87454|
NCT01579734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IEO S51/200|Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users|The HOT Study: Hormone Replacement Therapy Opposed by Low Dose Tamoxifen. A Phase III Trial of Breast Cancer Prevention With Low Dose Tamoxifen in HRT Users.|HOT|European Institute of Oncology|Yes|Active, not recruiting|March 2002|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|1884|||Female|18 Years|80 Years|No|||October 2015|October 8, 2015|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01579734||87398|
NCT01580670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-650-20|Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease|Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease||Mitsubishi Tanabe Pharma Corporation|No|Completed|March 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|6 Years|17 Years|No|||April 2015|April 9, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01580670||87328|
NCT01580969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI55264|Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma|A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in Patients With Recurrent gliOma (RAMBO)|RAMBO|University of Utah|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01580969||87305|
NCT01582971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA157459-01|Home-Based Symptom Management Via Reflexology for Breast Cancer Patients|Home-Based Symptom Management Via Reflexology for Breast Cancer Patients||Michigan State University|Yes|Active, not recruiting|May 2011|April 2017|Anticipated|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|255|||Female|21 Years|N/A|No|||March 2016|March 15, 2016|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01582971||87152|
NCT01582984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSPVA-124|Patient Understanding and Satisfaction in Informed Consent for Total Knee Arthroplasty|Patient Understanding and Satisfaction in Informed Consent for Total Knee Arthroplasty||Minneapolis Veterans Affairs Medical Center|No|Completed|February 2008|August 2009|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|176|||Both|N/A|N/A|No|||April 2012|April 21, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582984||87151|
NCT01578902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-2006|Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer|Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer (pHART 3)|pHART3|Sunnybrook Health Sciences Centre|Yes|Completed|October 2006|April 2013|Actual|April 2008|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Male|18 Years|N/A|No|||December 2014|December 19, 2014|October 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01578902||87462|
NCT01579669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH092503|Partnering With Autistic Adults to Improve Healthcare|Partnering With Autistic Adults to Develop Tools to Improve Primary Healthcare||Oregon Health and Science University|No|Completed|September 2013|August 2014|Actual|August 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|237|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|April 13, 2012||No||No|August 18, 2015|https://clinicaltrials.gov/show/NCT01579669||87403|This study was designed as a single-arm trial to assess feasibility and acceptability and to explore potential mechanisms of action. As such, there was no control group. PCPs are not a separate arm, but were included to assess acceptability.
NCT01579409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-20|The Impact of the French PNNS Guidelines on Vascular Function Following a Standardised Breakfast.|The Impact of the French National Program for Nutrition and Health Guidelines on Vascular Function Following a Standardised Breakfast:The Nutri-Vasc Study|NUTRIVASC|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Enrolling by invitation|November 2011|December 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|94|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 16, 2012|April 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01579409||87423|
NCT01580254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GENERIC-LATANOPROST|Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma|Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma|LATANOPROST|University of Cantanzaro|No|Recruiting|June 2011|July 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|80 Years|No|||April 2012|April 17, 2012|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580254||87359|
NCT01580566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-03/11|Renal Acute MI Study|Renal Structural, Functional and Cytokine Responses to Acute Myocardial Injury in Man||Monash University|No|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|160|Samples With DNA|Blood samples to measure bio-markers|Both|18 Years|N/A|No|Probability Sample|Patients who have presented to the Emergency Department with chest pain caused by a        possible myocardial infarction.|June 2015|June 2, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01580566||87336|
NCT01582568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-26958|EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment|EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment|EUS|Baylor College of Medicine|Yes|Terminated|June 2011|March 2014|Actual|March 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|70 Years|No|Non-Probability Sample|Crohn's disease patients with peri-anal or peri-rectal fistulizing disease. Moderate to        severe Crohn's disease patients between the ages of 18 and 70 years with active peri-anal        or peri-rectal fistula.|February 2016|February 17, 2016|April 19, 2012||No|Not enough subjects to reach accrual goals.|No||https://clinicaltrials.gov/show/NCT01582568||87183|
NCT01578980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16130|Outpatient Control-to-Range: System and Monitoring Testing|Outpatient Control-to-Range: System and Monitoring Testing||University of Virginia|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|65 Years|No|||August 2014|September 5, 2014|April 13, 2012|No|Yes||No|August 8, 2014|https://clinicaltrials.gov/show/NCT01578980||87456|
NCT01581645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-002978|Mobilaser Study to Help With People Who Are Having Problems With Their Gait|Increasing Mobility in Parkinsonian Patients With Freezing of Gait and Gait Hypokinesia With an Adjustable, Attachable Laser (Mobilaser)||Mayo Clinic|No|Completed|May 2012|December 2013|Actual|December 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|30 Years|99 Years|No|||April 2015|December 30, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01581645||87254|
NCT01581658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.53|Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes|A Phase I, Open-label, Parallel-group Study to Investigate Pharmacokinetics, Pharmacodynamics and Safety of a Single 25 mg Dose of Empagliflozin in Japanese Type 2 Diabetes Patients With Different Degrees of Renal Impairment in Comparison to Type 2 Diabetes Patients With Normal Renal Function||Boehringer Ingelheim||Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|20 Years|75 Years|No|||May 2014|May 16, 2014|April 17, 2012||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01581658||87253|
NCT01611727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN-001/83/07|Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients|Phase II Open-Label, Non-Randomized Trial of Cisplatin Chemotherapy in Patients With BRCA1-Positive Metastatic Breast Cancer|Cisplatin|Pomeranian Medical University Szczecin|No|Completed|July 2007|April 2009|Actual|January 2009|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|N/A|No|||July 2012|July 10, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611727||84952|
NCT01611961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYPHU-DT-LM-01|Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients|A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Docetaxel Lipid Microsphere for Injection in Cancer Patients Receiving Chemotherapy||Shenyang Pharmaceutical University|Yes|Recruiting|August 2012|December 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|65 Years|No|||September 2014|September 27, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01611961||84934|
NCT01611974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1263-202|Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients|A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients||Shire|Yes|Completed|July 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|120|||Both|12 Years|N/A|No|||December 2014|November 13, 2015|June 1, 2012|Yes|Yes||No|November 13, 2015|https://clinicaltrials.gov/show/NCT01611974||84933|
NCT01612234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK082803|Saturated Fat Versus Monounsaturated Fat and Insulin Action|Palmitate Metabolism and Insulin Resistance||University of Vermont|No|Completed|April 2010|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|70|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01612234||84913|
NCT01612247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V1010|Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy|Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy||University of Vermont|Yes|Recruiting|February 2011|February 2014|Anticipated|February 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|13|||Female|18 Years|N/A|No|||May 2012|June 4, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01612247||84912|
NCT01579279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-210|A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain||AbbVie|Yes|Terminated|April 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|1|||Both|18 Years|75 Years|No|||August 2013|September 24, 2013|April 16, 2012|No|Yes|Study Stopped|No||https://clinicaltrials.gov/show/NCT01579279||87433|
NCT01579526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Clin01-001|A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers|A Randomized, Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers||Cerecor Inc|No|Completed|April 2012|May 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|April 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579526||87414|
NCT01579773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80158|Comparison of Body Composition & Weight Change in Users of Progestin-only Contraception During the First Year of Use|Comparison of Body Composition & Weight Change in Users of Progestin-only Contraception During the First Year of Use|DEXA|Washington University School of Medicine|No|Completed|April 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|345|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who are starting an IUD or implant through their provider could be eligible.|December 2014|December 8, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01579773||87395|
NCT01580098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D250487|Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus|Regions of Europe Working Together for Health (Renewing Health)|RenewingHealth|Landeskrankenanstalten-Betriebsgesellschaft|Yes|Completed|February 2010|February 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|193|||Both|N/A|N/A|No|||April 2015|August 21, 2015|April 17, 2012||No||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01580098||87371|
NCT01579266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120104|Validating a New Writer s Cramp Scale|Validating a New Writer's Cramp Scale||National Institutes of Health Clinical Center (CC)||Completed|March 2012|||||N/A|Observational|Time Perspective: Prospective|||Actual|16|||Both|18 Years|99 Years|No|||November 2015|December 2, 2015|April 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01579266||87434|
NCT01579513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro16545|Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass|Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass||Medical University of South Carolina|Yes|Recruiting|June 2012|June 2018|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|190|||Both|N/A|30 Days|No|||March 2016|March 15, 2016|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01579513||87415|
NCT01580982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1621.cc|Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer|Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers||University of Colorado, Denver|No|Recruiting|December 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|175|Samples With DNA|Tumor tissue will be acquired from either archival or de novo biopsy material|Both|18 Years|85 Years|No|Probability Sample|Patients considered for this study would be undergoing a standard care procedure|December 2015|December 3, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580982||87304|
NCT01579201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LoubertHMR2012/01|ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery|ED90 Determination of Carbetocin for the Prevention of Postpartum Uterine Atony in Women Undergoing an Elective Cesarean Delivery||Maisonneuve-Rosemont Hospital|No|Recruiting|March 2012|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|40|||Female|N/A|N/A|No|||February 2013|February 12, 2013|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579201||87439|
NCT01579422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008007225|Social Cognitive Training for Psychosis: Treatment Development|Social Cognitive Training for Psychosis: Phase I Treatment Development||Yale University|No|Completed|May 2012|December 2015|Actual|August 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|77|||Both|18 Years|55 Years|No|||January 2016|January 11, 2016|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01579422||87422|
NCT01579682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPO 49694|Adaptive Family Treatment for Adolescent Anorexia Nervosa|Adaptive Family Treatment for Adolescent Anorexia Nervosa||Stanford University|Yes|Active, not recruiting|September 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|12 Years|18 Years|No|||December 2015|December 10, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01579682||87402|
NCT01579942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000200|Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression|Potential Use Of Brain Network Activation Analysis Using Evoked Response Potentials to Diagnose Major Depression and Assess Response to Antidepressant Treatment||Massachusetts General Hospital|No|Active, not recruiting|April 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|For Patients with Major Depressive Disorder        • Subjects meeting full criteria for the diagnosis of current Major Depressive Disorder        (MDD) without psychotic features, as determined by clinical evaluation and Mood Module of        structured diagnostic interview (SCID), completed by the study clinician.        For Healthy controls          -  Males and females, aged 18-55 years          -  Subjects who do not meet full criteria for any of the major psychiatric diagnosis             including MDD, bipolar disorder, schizophrenia, substance abuse/dependence, as             determined by clinical evaluation and structured diagnostic interview, completed by             the study clinician.|July 2014|July 16, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01579942||87382|
NCT01579929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-206|Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)|A Phase I Trial of the Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579929||87383|
NCT01579955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7-1947|Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice|Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice||Novo Nordisk A/S|No|Completed|March 1999|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|321|||Both|N/A|N/A|No|Non-Probability Sample|Patients with haemophilia A and B with inhibitors who received NovoSeven® (eptacog alpha)|August 2014|August 8, 2014|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579955||87381|
NCT01580280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/01-006|Manual Therapy and Exercise in Patients With Cervicogenic Headache|Effect of Upper Cervical and Upper Thoracic Thrust Manipulation Versus Mobilization and Exercise in Patients With Cervicogenic Headache||Alabama Physical Therapy & Acupuncture|Yes|Completed|April 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|18 Years|65 Years|No|||November 2014|November 12, 2014|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580280||87357|
NCT01580852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor008412clit|The Effects of Immersion in Dead Sea Water on Glucose Levels in Type 2 Diabetes Mellitus Patients|The Effects of Immersion in Dead Sea Water on Glucose Levels in Type 2 Diabetes Mellitus Patients||Soroka University Medical Center|No|Not yet recruiting|July 2012|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||April 2012|April 18, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580852||87314|
NCT01581086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAST11060550|Vascular Subphenotypes of Lung Disease in HIV & COPD|Identify and Characterize Populations at Risk for Developing Pulmonary Arterial Hypertension (PAH)|VAST|University of Pittsburgh|Yes|Recruiting|January 2012|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|140|Samples With DNA|Whole Blood|Both|18 Years|80 Years|No|Non-Probability Sample|Pitt mens Study(MACS).        University of Pittsburgh HIV Clinic(PACT).        Emphysema COPD Research Center Research Registry(ECRC).        University of Pittsburgh Medical center pulmonary hypertension clinic|December 2015|December 2, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01581086||87296|
NCT01581099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP - 0355/11|Effect of Bariatric Surgery "Digestive Adaptations III" on Cardiovascular Risk|Effect of Bariatric Surgery "Digestive Adaptations III" on Clinical, Laboratory and Cardiovascular Risk Factors|ADIII|University of Sao Paulo|No|Active, not recruiting|April 2013|May 2017|Anticipated|March 2016|Anticipated|Phase 2|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|30|Samples Without DNA|Whole blood samples will be retained for future exams.|Male|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population will be selected in a primary care clinic.|December 2015|December 3, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01581099||87295|
NCT01578993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-PICC 2012-01|Observational Study of Complications Related to Use of Peripherally Inserted Central Catheters|A Phase IV, Prospective Clinical Evaluation of Complications Related to the Use of Peripherally Inserted Central Catheters (PICC) - An Observational Baseline Multicenter Study.|PRISM-1|Teleflex|No|Completed|August 2012|October 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|101|||Both|18 Years|N/A|No|Probability Sample|Adult patients necessitating insertion of a PICC for fluid, nutritional, chemotherapy or        antibiotic treatment for a minimum of 14 days.|May 2014|February 18, 2016|April 12, 2012||No||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01578993||87455|Further comparative studies standarizing the management of PICC line flushing solutions and type if PICC line required to provide comparative and evidence based clinical practice recommendations.
NCT01579253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|361-11|Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients|Untersuchungen Zur Verlaufskontrolle Bei Re-Bestrahlung Von Glioblastompatienten Mittels Kombinierter [18F]FET-PET-Kernspintomographie||Ludwig-Maximilians - University of Munich|No|Recruiting|April 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with recurrent glioblastoma who are planned to receive a re-irradiation|December 2012|December 17, 2012|April 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01579253||87435|
NCT01582594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCD-200902|A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection|A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection||Johnson & Johnson Medical, China|No|Terminated|February 2012|January 2013|Actual|August 2012|Actual|Phase 3|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|795|Samples With DNA|A minimum of 1000 qualified specimens shall be collected, including at least 350 anti-HCV      seropositive specimens.      To further evaluate RIBA test specificity in HAV IgG positive, HBsAg positive, HEV IgG      positive and anti-HIV positive specimens, approximately 30 specimens of each viral infection      will be included in the study.      A minimum of 60 matched plasma and serum specimens will be collected to evaluate the      applicability of the investigational product on different types of samples, including at      least 30% of anti-HCV seropositive specimens.|Both|1 Year|90 Years|Accepts Healthy Volunteers|Probability Sample|The specimens used for this study will be pre-tested by licensed anti-HCV screening        methods and / or Nucleic acid test (NAT) in combination with the past history and will be        classified as either seronegative or seropositive.|May 2012|June 27, 2013|April 19, 2012||No|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT01582594||87181|
NCT01582828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHAFT-01|Serial Hybrid Atrial Fibrillation Ablation|Serial Hybrid Atrial Fibrillation Ablation|SHAFT|Medisch Spectrum Twente|No|Not yet recruiting|August 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||April 2012|April 20, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01582828||87163|
NCT01582841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1CA140377-01A2|Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting|Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting|HNPCC|Kaiser Permanente|No|Active, not recruiting|February 2012|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|247|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01582841||87162|
NCT01583088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM11046|Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation|Can Diaphragm Pacing Delay Non Invasive Ventilation in Amyotrophic Lateral Sclerosis ? a Randomized Controlled Study|RespiStimALS|Assistance Publique - Hôpitaux de Paris|Yes|Terminated|September 2012|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|74|||Both|18 Years|N/A|No|||April 2015|December 21, 2015|April 20, 2012||No|in the absence of benefits and because of a statistically significant excess mortality in the    group of patients receiving active stimulation.|No||https://clinicaltrials.gov/show/NCT01583088||87143|
NCT01579786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|university of padova|Treatment of Post Operative Pain in Thyroid Surgery Patients: Perspective Study Acupuncture Versus Drugs|The Treatment of Post Operative Pain in Thyroid Surgery Patients: Perspective Study Acupuncture Versus Pharmacological Treatment||University of Padova|Yes|Active, not recruiting|May 2011|February 2014|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|80 Years|No|||February 2014|February 19, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01579786||87394|
NCT01580124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV3572|CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study|CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study.|CHASE-AF|Universitätsklinikum Hamburg-Eppendorf|No|Completed|November 2010|February 2015|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|80 Years|No|||January 2016|January 26, 2016|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580124||87369|
NCT01579552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-104|Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer|EMPOWER Study: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|360|||Female|25 Years|49 Years|No|||September 2015|September 9, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01579552||87412|
NCT01580111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-001|Effect of Blood Storage Age on the Resolution of Lactic Acidosis in Children With Severe Malarial Anemia at Mulago Hospital|Effect of Blood Storage Age on the Resolution of Lactic Acidosis in Children With Severe Malarial Anemia at Mulago Hospital||Makerere University|Yes|Completed|December 2010|November 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|74|||Both|6 Months|59 Months|No|||April 2012|April 17, 2012|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580111||87370|
NCT01580384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25612|A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome|||Hoffmann-La Roche||Completed|February 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|12 Years|30 Years|No|Probability Sample|Individuals with Down Syndrome|March 2015|March 2, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01580384||87349|
NCT01580397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INNO-206-P2-PDA-01|Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer|A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy||CytRx|No|Completed|May 2012|June 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||June 2013|June 27, 2013|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01580397||87348|
NCT01580423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS23276|The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing|The Role of Substance P on Perception of Breathlessness|SP-RLB|Dartmouth-Hitchcock Medical Center|Yes|Completed|April 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|50 Years|N/A|No|||May 2013|May 24, 2013|April 16, 2012||No||No|May 24, 2013|https://clinicaltrials.gov/show/NCT01580423||87346|single dose of aprepitant usedclinical diagnosis of chronic bronchitis phenotype of chronic obstructive pulmonary disease
NCT01580436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVP Study|Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery|Prospective, Randomized Evaluation of Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery||Hasselt University|Yes|Recruiting|August 2011|||December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|October 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01580436||87345|
NCT01579214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-002|Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda|Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda||Massachusetts General Hospital|No|Completed|July 2012|April 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|540|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01579214||87438|
NCT01579435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-37|Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation|Thérapeutique expérimentale du Tremblement Essentiel Par la Stimulation Trans-crânienne Par Courant Direct (tDCS) du Cortex cérébelleux et du Cortex Moteur. Etude Exploratoire.|ELECTRE|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|50 Years|No|||April 2013|April 10, 2013|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01579435||87421|
NCT01578967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1115|Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma|LCCC 1115: A Pilot Feasibility Trial of Induction Chemotherapy With ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients With Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)||UNC Lineberger Comprehensive Cancer Center|Yes|Suspended|April 2012|January 2018|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|60 Years|No|||February 2016|February 3, 2016|April 13, 2012|No|Yes|Determining evaluable subjects|No||https://clinicaltrials.gov/show/NCT01578967||87457|
NCT01580267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00053750|Hepcidin and Anemia in Trauma|Hepcidin and Anemia in Trauma||University of Michigan|No|Completed|June 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|74|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|Trauma patients, 18 years of age or older, admitted to a University of Michigan ICU|April 2014|April 24, 2014|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580267||87358|
NCT01580306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.58|Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment|Pharmacokinetics, Safety and Tolerability of BI 201335 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase I Trial||Boehringer Ingelheim||Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|April 12, 2012||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01580306||87355|
NCT01580319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2994/01|Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity|Outpatient Strategy of Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity||Instituto de Cardiologia do Rio Grande do Sul|No|Terminated|April 2009|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|6 Years|17 Years|Accepts Healthy Volunteers|||May 2012|May 7, 2012|June 30, 2011||No|Difficulty in selecting the sample and follow-up lost.|No||https://clinicaltrials.gov/show/NCT01580319||87354|
NCT01580878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTNF 1104|Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis|A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.||Taro Pharmaceuticals USA|No|Completed|January 2012|December 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|707|||Both|18 Years|N/A|No|||January 2014|January 19, 2014|April 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01580878||87312|
NCT01581138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-222-108|VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C|A Multicenter, Randomized, Open-label, Phase 2b Study to Evaluate the Efficacy and Safety of Two Regimens of All-oral Triple Therapy (VX-222 in Combination With Telaprevir [Incivek™] and Ribavirin [Copegus®]) in Treatment-Naïve Subjects With Genotype 1a Chronic Hepatitis C||Vertex Pharmaceuticals Incorporated|No|Completed|July 2012|December 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|70 Years|No|||July 2014|July 2, 2014|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581138||87292|
NCT01581151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WE IRB# 11-122|Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion|Dexamethasone Implant With Rescue Ranibizumab for Treating Macular Edema Secondary to Retinal Vein Occlusion||Wills Eye|No|Recruiting|September 2011|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|90 Years|No|||February 2015|February 19, 2015|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581151||87291|
NCT01580332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRUSAL01|Non-Invasive Biomarkers For Early Detection Of Lung Cancers|NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF LUNG CANCERS: ELEMENT 1: NON-RANDOMIZED PHASE II EVALUATION AND VALIDATION IN NEWLY DIAGNOSED LUNG CANCER PATIENTS|ISRUSAL01|Baptist Cancer Institute|No|Completed|January 2012|July 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|serum; sputum|Both|18 Years|N/A|No|Non-Probability Sample|any patient with newly diagnosed lung cancer (any histology, any stage) who has not yet        begun definitive treatment, and who has no prior history of cancer of any type|April 2012|July 22, 2014|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01580332||87353|
NCT01582334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200104-532|To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina|Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using "Easypod™" Electromechanical Device for Growth Hormone Treatment in Argentina|ECOS ARG|Merck KGaA|No|Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|67|||Both|2 Years|18 Years|No|Non-Probability Sample|Paediatric subjects (aged 2-18) who are taking SAIZEN® for registered indications using        the easypod™ electromechanical device.|March 2015|March 3, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582334||87201|
NCT01582607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3089|Subarachnoid Administration of Levobupivacaine for Cesarean Section|Intrathecal Plain Bupivacaine, Ropivacaine and Levo-bupivacaine With or Without Fentanyl for Elective c Section.||University of Patras|Yes|Recruiting|January 2010|May 2012|Anticipated|April 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|6||Anticipated|130|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01582607||87180|
NCT01583114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-44|PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors|Preventive Effect of ACE Inhibitor Perindopril)on the Onset or Progression of Left Ventricular Dysfoction in Subjects at a Preclinical Stage From Families With Dilated Cardiomyopathy|PRECARDIA|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Terminated|December 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|60 Years|No|||February 2016|February 23, 2016|April 11, 2012||No|recruitement problem|No||https://clinicaltrials.gov/show/NCT01583114||87141|
NCT01583101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHICA_Highlight_Study|Child Health Improvement Through Computer Automation (CHICA) Highlighting Study|Increasing Prompt Response Rates in the CHICA System||Indiana University|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|2237|||Both|N/A|N/A|Accepts Healthy Volunteers|||November 2012|November 13, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01583101||87142|
NCT01579058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0884|Effect of Bisoprolol on Progression of Aortic Stenosis|A Randomized Trial of Beta-blocker Therapy in Aortic Stenosis|BLAST|Asan Medical Center|Yes|Terminated|July 2012|July 2018|Anticipated|July 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|20 Years|70 Years|No|||May 2014|May 8, 2014|April 14, 2012||No|The sponsor discontinued to support the study.|No||https://clinicaltrials.gov/show/NCT01579058||87450|
NCT01579565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMS302-ILR-004|Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Pharmacokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|OMS302-ILR-004|Omeros Corporation|No|Completed|April 2012|January 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|416|||Both|18 Years|N/A|No|||August 2014|August 5, 2014|April 13, 2012|Yes|Yes||No|July 2, 2014|https://clinicaltrials.gov/show/NCT01579565||87411|
NCT01580410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 59109|Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix|A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After HIPEC With Oxaliplatin or Mitomycin C in Patients With Appendiceal Tumors||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|May 2009|November 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01580410||87347|
NCT01580683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WU0811SB|Vitamin C and Atrial Fibrillation After Cardiac Surgery|Effect of Ascorbic Acid on the Incidence of Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery||Regional Hospital of Scranton|Yes|Withdrawn|July 2012|August 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|50 Years|N/A|No|||May 2015|May 11, 2015|April 13, 2012|Yes|Yes|No funding obtained to support patient recruitment|No||https://clinicaltrials.gov/show/NCT01580683||87327|
NCT01611012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIR2012|The Development of a Clinical Test to Assess the Inflammatory Phenotype of Asthma|The Development of a Clinical Test to Assess the Inflammatory Phenotype of Asthma|AIR|UMC Utrecht|No|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|115|Samples Without DNA|Leukocytes in peripheral blood, serum samples for protein profiling and sputum samples.|Both|18 Years|75 Years|No|Non-Probability Sample|Asthma patients between the age of 18 and 75, visiting outpatient respiratory clinic of        the University Medical Centre in Utrecht, The Neterlands.|July 2014|July 2, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01611012||85007|
NCT01582009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I146308|Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate|A Phase I/II Study of the HDAC Inhibitor LBH-589 in Combination With the mTOR Inhibitor Everolimus (RAD001) in Metastatic Renal Cell Carcinoma||Roswell Park Cancer Institute|Yes|Active, not recruiting|March 2010|||June 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 15, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582009||87226|
NCT01582555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-AA-0089-CTIL|Postoperative Nasal Irrigation Using Mucolytic Agents|Postoperative Nasal Irrigation Using Mucolytic Agents in Patients Undergoing Endoscopic Sinus Surgery||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01582555||87184|
NCT01579461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-039|A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects|An Open Label Single Dose Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of YM178 Compared With Healthy Subjects||Astellas Pharma Inc|No|Completed|November 2008|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01579461||87419|
NCT01580891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTFC 1105.0|Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis|Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design Study to Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis.||Taro Pharmaceuticals USA|No|Completed|May 2012|July 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1053|||Both|18 Years|N/A|No|||May 2014|May 5, 2014|April 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01580891||87311|
NCT01582022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-12-598|Evaluation of The Effect of Bupivacaine (Marcaine) in Reducing Early Post Tonsillectomy Pain|The Effect of Bupivacaine (Marcaine) in Reducing Early Post Tonsillectomy Pain||King Saud University|Yes|Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||||||Both|N/A|N/A|No|||April 2012|April 19, 2012|April 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01582022||87225|
NCT01587937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|416-2009|Hospital Wide Roll-Out of Antimicrobial Stewardship|Hospital Wide Roll-Out of Antimicrobial Stewardship: A Stepped Wedge Randomized Controlled Trial||Sunnybrook Health Sciences Centre|No|Completed|April 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|19220|||Both|N/A|N/A|No|||November 2014|November 17, 2014|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01587937||86777|
NCT01587950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z3770631|The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity|An Exploratory Study Investigating the Effects of a Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|February 2009|April 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|65 Years|No|||March 2013|April 9, 2015|November 17, 2011|Yes|Yes||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01587950||86776|
NCT01601223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAS VEGAS|Local Assessment of Ventilatory Management During General Anesthesia for Surgery|Local Assessment of Ventilatory Management During General Anesthesia for Surgery - a Prospective Observational Multi-center Cohort Study|LAS VEGAS|European Society of Anaesthesiology|No|Completed|January 2013|November 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10690|||Both|18 Years|N/A|No|Non-Probability Sample|Mechanically ventilated patients undergoing general anesthesia for surgery during a period        of one week|October 2015|October 13, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01601223||85759|
NCT01601496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR7000856|Evaluation of FUSION™ Vascular Graft for Above Knee Targets|Study of PERipheral Bypass GraFting: ProspECTive Evaluation of FUSION™ Vascular Graft for Above Knee Targets(PERFECTION)|PERFECTION|Maquet Cardiovascular|No|Completed|September 2009|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|117|||Both|18 Years|85 Years|No|||January 2014|January 15, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01601496||85738|
NCT01602536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA030538-01A1|Twitter-enabled Mobile Messaging for Smoking Relapse Prevention|Twitter-enabled Mobile Messaging for Smoking Relapse Prevention||University of California, Irvine|No|Completed|January 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|280|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602536||85658|
NCT01602783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-464|11C Acetate Imaging Post Prostatectomy|Use of 11C Acetate Imaging for Improved Prediction of the Effectiveness of Salvage Pelvic Radiation Post Prostatectomy: A Pilot Study||Massachusetts General Hospital|Yes|Terminated|December 2011|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|2|||Male|18 Years|N/A|No|||March 2014|March 17, 2014|May 17, 2012||No|Slow accrual; no further funding|No||https://clinicaltrials.gov/show/NCT01602783||85639|
NCT01603017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06/S0802/131|Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis|Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis: A Double Blind Ranomised Controlled Trial||NHS Grampian|Yes|Completed|September 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||May 2012|May 17, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01603017||85621|
NCT01603030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAMOXPRE01/10|Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation|Efficacy of Moxifloxacin 0.5%/Prednisolone 1% Fixed Combination Compared With Individual Administration of Moxifloxacin 0.5% and Prednisolone 1% in the Prevention of Post Operative Inflammation in Patients Having Lasik Surgery||Adapt Produtos Oftalmológicos Ltda.|Yes|Not yet recruiting|June 2012|September 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|50 Years|No|||May 2012|May 21, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01603030||85620|
NCT01603329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Increasing Medication Adherence Through Physician Incentives and Messaging|Increasing Medication Adherence Through Physician Incentives and Messaging||National Bureau of Economic Research, Inc.|No|Completed|June 2012|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|11||Actual|734|||Both|65 Years|N/A|No|||October 2015|October 22, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01603329||85597|
NCT01603316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-099|Food: A Three-Arm Study Examining Food Insecurity Interventions|Food: A Three-Arm Randomized Controlled Study Examining Food Insecurity Interventions||Memorial Sloan Kettering Cancer Center||Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|120|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01603316||85598|
NCT01604148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06-082|Retrospective Review a Comprehensive Case Database of HoLEP Procedure Performed by a Single Surgeon|Retrospective Review of a Comprehensive Case Database of HoLEP (Holmium Laser Enucleation of Prostate) Procedure Performed by a Single Surgeon||Samsung Medical Center|No|Completed|July 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|||Male|50 Years|80 Years|No|Probability Sample|Patients underwent Holmium Laser Enucleation of the Prostate by a single surgeon|May 2012|May 22, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604148||85534|
NCT01603589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AHEPA_CTS_04|Comparison of Minimal Versus Conventional Extracorporeal Circulation in Coronary Surgery|Research on Remote End-organ Protection, Clinical Outcome and Quality of Life With Implementation of the Novel Minimal Extracorporeal Circulation Circuit in Open Heart Surgery||AHEPA University Hospital|No|Recruiting|January 2009|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|80 Years|No|||November 2013|November 27, 2013|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01603589||85577|
NCT01603862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThinkingFit 1|ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI)|Piloting a Complex Intervention Involving Physical Exercise, Cognitive Training and Socialising to Delay the Onset of Dementia in Mild Cognitive Impairment|ThinkingFit|North Essex Partnership NHS Foundation Trust|Yes|Completed|January 2010|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|128|||Both|40 Years|N/A|No|||April 2014|April 25, 2014|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603862||85556|
NCT01604473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02538|Endothelial Function and Arterio-Venous Fistula Maturation|Endothelial Function and Arterio-Venous Fistula Maturation|EFAVF|University of California, San Francisco|No|Recruiting|October 2010|October 2018|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Non-Probability Sample|Vascular surgery clinic|December 2015|December 1, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604473||85509|
NCT01604707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEDYOG 1|Medical Yoga for Patients With Stress-related Symptoms and Diagnoses|Medical Yoga for Patients With Stress-related Symptoms and Diagnoses in Primary Health Care - a Randomized Controlled Trial||University Hospital Orebro|No|Completed|March 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01604707||85491|
NCT01580995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-001C-10F|Herpes Simplex Type 1 Suppression in Hepatitis C|HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2|HSV1/HCV|VA Office of Research and Development|No|Completed|April 2012|March 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 12, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01580995||87303|
NCT01611246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPR005031|Earset Healthy Volunteer Study|Performance of the Acclarent Iontophoresis System With Earset (IPSES) in Healthy Volunteers||Acclarent|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|12 Months|N/A|Accepts Healthy Volunteers|||November 2013|March 14, 2014|May 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611246||84989|
NCT01611259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_MALT2|Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue|Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type||Arbeitsgemeinschaft medikamentoese Tumortherapie|Yes|Completed|May 2012|February 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||March 2015|March 11, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01611259||84988|
NCT01611545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIHG-1410-Clopidogrel|Pharmacogenomics and Effective Treatment With Clopidogrel|Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.||Avera McKennan Hospital & University Health Center|Yes|Completed|June 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|130|Samples With DNA|blood or buccal samples|Both|18 Years|N/A|No|Non-Probability Sample|Patients of either the Avera Heart Hospital of South Dakota or North Central Heart        Institute who have been precribed Clopidogrel or are being considered for treatment with        Clopidogrel.|June 2015|June 9, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611545||84966|
NCT01611558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-201|Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Patients|A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects With Residual Measurable Disease||Bristol-Myers Squibb|No|Active, not recruiting|August 2012|December 2016|Anticipated|August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||September 2014|May 6, 2015|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611558||84965|
NCT01611818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI10/01083|Low Intensity Versus Self-guided Internet-delivered Psychotherapy for Major Depression|Low Intensity Versus Self-guided Internet-delivered Psychotherapy for Major Depression: a Multicenter, Controlled, Randomised Study||Hospital Miguel Servet|No|Active, not recruiting|September 2012|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|450|||Both|18 Years|65 Years|No|||February 2016|February 15, 2016|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01611818||84945|
NCT01611831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/024|Efficacy of Acceptance and Commitment Therapy (ACT) in Group in Fibromyalgia|Efficacy of Acceptance and Commitment Therapy (ACT) in Group in Fibromyalgia: a Randomized, Controlled Study.|ACTGROUP|Hospital Miguel Servet|No|Active, not recruiting|January 2012|January 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||May 2012|June 4, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01611831||84944|
NCT01612052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997028|Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)|Double Blinded Prospective Randomized Controlled Trial Comparing Cefazolin Plus Vancomycin Versus Cefazolin Plus Daptomycin for Vascular Surgery Prophylaxis||CAMC Health System|No|Recruiting|May 2011|October 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2013|February 18, 2013|September 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01612052||84927|
NCT01612065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2752012|Optimum Misoprostol Dose Prior to Office Hysteroscopy|The Optimum Dose of Vaginal Misoprostol Prior to Office Hysteroscopy: Double Blind Randomized Controlled Trial||Cairo University||Completed|June 2012|April 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 10, 2013|May 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612065||84926|
NCT01612078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHDX1101|Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients|A Double-blind, Randomized and Placebo-controlled Study to Evaluate the Efficacy and Safety of L-threo-3,4-dihydroxyphenylserine (Droxidopa) on Orthostatic Hypotension Treatment in Hemodialysis Patients|OH|TSH Biopharm Corporation Limited|Yes|Terminated|June 2012|||February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|20 Years|80 Years|No|||March 2013|March 11, 2013|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612078||84925|
NCT01612338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5U48DP001901-03|Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives|Interventions to Increase Screening Utilization by Breast Cancer Survivors and Their High Risk Female Relatives: Using Cancer Surveillance and the Michigan Genomics Academic-Practice Partnership||University of Michigan|Yes|Completed|July 2012|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|1290|||Female|20 Years|64 Years|No|||October 2014|July 31, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612338||84905|
NCT01612949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#9929|Facial Analysis to Classify Difficult Intubation|Comparison of a Computerized Image Analysis to Conventional Airway Examination Techniques to Predict Difficult Endotracheal Intubation||Tufts Medical Center|No|Recruiting|May 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|310|||Both|18 Years|64 Years|No|Non-Probability Sample|Patients undergoing surgical procedures requiring general anesthesia with endotracheal        intubation; patients from all ethnic groups|March 2015|March 13, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612949||84858|
NCT01601912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFWG-22|Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders|Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders: a Randomized Controlled Clinical Trial for the Treatment of Central Sensitization||Vrije Universiteit Brussel|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|59|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|WAD patients: primary care clinic & community sample Healthy people: community sample|January 2014|January 13, 2014|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601912||85706|
NCT01603628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-111|BOTOX® Treatment in Pediatric Lower Limb Spasticity|||Allergan|Yes|Recruiting|July 2012|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|412|||Both|2 Years|16 Years|No|||March 2016|March 14, 2016|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603628||85574|
NCT01603641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-112|BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity|||Allergan|Yes|Recruiting|August 2012|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|2 Years|16 Years|No|||March 2016|March 10, 2016|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603641||85573|
NCT01602796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-01|Effectiveness of Intervention on Reducing the Prevalence of Smoking Among Adolescents|Effectiveness of a Complex Intervention on Reducing the Prevalence of Smoking Among Adolescents: a Cluster Randomized Control Trial|ITACA|Fundació d'investigació Sanitària de les Illes Balears|No|Recruiting|September 2011|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2226|||Both|11 Years|14 Years|No|||May 2012|May 18, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01602796||85638|
NCT01603043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-020|A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)|A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-of-Concept Study of Intravitreal AL-78898A in Patients With Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)||Alcon Research|Yes|Terminated|June 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|55 Years|N/A|No|||December 2013|December 3, 2013|May 18, 2012|Yes|Yes|Management Decision|No|December 3, 2013|https://clinicaltrials.gov/show/NCT01603043||85619|
NCT01603342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7HAEM-1954|A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers|A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers||Novo Nordisk A/S|No|Completed|December 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01603342||85596|
NCT01603602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-101|BOTOX® Treatment in Pediatric Upper Limb Spasticity|||Allergan|Yes|Recruiting|July 2012|May 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|412|||Both|2 Years|16 Years|No|||March 2016|March 10, 2016|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603602||85576|
NCT01603615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-105|BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity|||Allergan|Yes|Recruiting|August 2012|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|350|||Both|2 Years|16 Years|No|||March 2016|March 10, 2016|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603615||85575|
NCT01604460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 010|Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part V|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part V||University of Alabama at Birmingham|Yes|Completed|June 2012|November 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|275|||Both|N/A|72 Hours|No|||February 2013|February 8, 2013|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604460||85510|
NCT01604161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH-3910|Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome|A Multicentre, Open Label, Non-interventional Study to Evaluate on Long-term Safety and Efficacy of Norditropin® Formulation in Child Patients With GHD or Turner Short Stature Without Closure of Epiphyseal Discs.|NordiPAD|Novo Nordisk A/S|No|Completed|May 2005|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2016|||Both|N/A|N/A|No|Non-Probability Sample|Patients from normal practice who have been deemed appropriate to receive somatropin (        Norditropin®) as part of routine out-patient care by the prescribing physician.|July 2015|July 2, 2015|May 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01604161||85533|
NCT01604720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOLecco002|Sample Size Definition in Cochrane Hepato-Biliary Trials|Review: Analysis of the Sample Size Definitions in the Randomized Clinical Trials Included in Systematic Reviews of the Hepato-biliary Group of the Cochrane Collaboration||Azienda Ospedaliera di Lecco|No|Recruiting|July 2012|April 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|250|||Both|N/A|N/A|No|Non-Probability Sample|Randomized clinical trials included in systematic reviews of the hepato-biliary Group of        the Cochrane Collaboration|January 2015|January 13, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01604720||85490|
NCT01604759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01313|Polarized Reflectance Spectroscopy for Oral Lesions|Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions|PolProbe|British Columbia Cancer Agency|No|Recruiting|December 2011|May 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||August 2015|September 1, 2015|November 3, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01604759||85487|
NCT01600794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-TMU-IVF-201107012|To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization|To Evaluate The Androgens and Ovary Function Impact on The Pregnancy Outcome in In Vitro Fertilization||Taipei Medical University WanFang Hospital|No|Suspended|October 2011|October 2012|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Female|20 Years|45 Years|No|Probability Sample|This study include the patients who are evaluated by the doctors and are sure to process        the IVF cycle.|May 2012|May 16, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600794||85792|
NCT01611025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP39134|Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time|The Impact on the Hospital's Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic, Using Antibiotic Utilization and Hospital Susceptibility Data Over Time||Taipei Veterans General Hospital, Taiwan|No|Active, not recruiting|June 2011|December 2013|Anticipated|||N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|selected bacterial isolates, such as but not limited to Pseudomonas aeruginosa,        Acinetobacter Baumannii and Enterobacteriaceae species|May 2012|June 1, 2012|October 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01611025||85006|
NCT01611272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00019|A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta|A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta||AstraZeneca||Recruiting|April 2013|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|||Both|19 Years|130 Years|No|Probability Sample|Patients who take Brilinta according to the local approval condition|March 2016|March 7, 2016|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01611272||84987|
NCT01611571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAA4304|Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis|Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis|RPM|Columbia University|No|Completed|December 2003|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|31|||Male|30 Years|85 Years|No|||January 2014|January 15, 2014|May 29, 2012||No||No|August 20, 2013|https://clinicaltrials.gov/show/NCT01611571||84964|
NCT01612104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RKBU62|Psychological First Aid With Children in a High Risk Group - a Repeated Single Case Design|Psychological First Aid With Children in a High Risk Group - a Repeated Single Case Design||Uni Research|No|Completed|March 2012|August 2015|Actual|July 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|11 Years|16 Years|No|||December 2015|December 4, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01612104||84923|
NCT01612091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01270|The Monitoring Messenger: Mobile Patient Monitoring for the Pediatric Intensive Care Unit|The Monitoring Messenger: Mobile Patient Monitoring for the Pediatric Intensive Care Unit||University of British Columbia|No|Enrolling by invitation|November 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 29, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612091||84924|
NCT01612351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1125|Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery|Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|June 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612351||84904|
NCT01612624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP1|Prospective Study on Changes in Acromegaly|FACIAL AND HAND ANALYSIS, SLEEP APNEA AND SPEECH IN PATIENTS WITH ACROMEGALY: A PROSPECTIVE STUDY TO INVESTIGATE CHANGES IN CRANIOFACIAL AND HAND CHARACTERISTICS, SLEEP APNEA AND SPEECH DURING TREATMENT AND AFTER REMISSION||Radboud University|No|Recruiting|May 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Acromegaly patients and healthy controls|May 2012|June 5, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612624||84883|
NCT01613508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001341|A Randomized Study of Approaches in Total Hip Arthroplasty|A Randomized Clinical Trial of Direct Anterior Approach and Mini-Posterior Approach Total Hip Arthroplasty||Mayo Clinic|No|Enrolling by invitation|January 2013|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|20 Years|N/A|No|||July 2015|July 28, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613508||84815|
NCT01602224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14199|A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma||Eli Lilly and Company|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|181|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602224||85682|
NCT01602237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2449|Preventing Respiratory Health Problems in Bakery Employees|Preventing Respiratory Health Problems in Bakery Employees.|Baker2012|Haukeland University Hospital|No|Active, not recruiting|February 2012|December 2015|Anticipated|December 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|253|Samples Without DNA|Serum, Nasal lavage fluid (without cells)|Both|18 Years|80 Years|No|Probability Sample|1. All the employees in 5 bakeries investigated in 1999-2002 (one of the original 6             bakeries has fused with one of the others)          2. All the employees in additional 2 bakeries located in the same Hordaland county,             Norway, as the other 5 bakeries|January 2014|January 5, 2014|March 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01602237||85681|
NCT01602497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-01-30-13200|Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder|A Sham-controlled Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Patients||Tehran University of Medical Sciences|Yes|Enrolling by invitation|February 2012|December 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||May 2012|May 18, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602497||85661|
NCT01603082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D5130L00014|Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients|A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention||AstraZeneca|No|Completed|July 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|343|||Both|18 Years|130 Years|No|||November 2015|November 9, 2015|May 18, 2012|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01603082||85616|
NCT01603095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMN 111-901|A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia|A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia||BioMarin Pharmaceutical|No|Enrolling by invitation|April 2012|November 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|13 Years|No|Probability Sample|200 boys and girls with achondroplasia aged 0-13.5 will be enrolled|July 2015|July 28, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01603095||85615|
NCT01603875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC5506|Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV|Immune Response in Adults to Pre-exposure Rabies Vaccination and Simulated Post-exposure Rabies Booster Vaccination With a New Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA®) : a Randomized Controlled Trial With Purified Vero-cell Rabies Vaccine (PVRV)||Queen Saovabha Memorial Institute|Yes|Completed|July 2012|October 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|105|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||January 2014|January 3, 2014|May 16, 2012||No||No|January 3, 2014|https://clinicaltrials.gov/show/NCT01603875||85555|
NCT01604174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REHABITIC|Interactive Virtual Telerehabilitation After Total Knee Arthroplasty|Effectiveness of an Interactive Virtual Telerehabilitation System in Patients After Total Knee Arthroplasty. A Randomized Controlled Trial|REHABITIC|Parc de Salut Mar|No|Completed|November 2008|December 2010|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||May 2012|May 23, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604174||85532|
NCT01603914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11/01121|Central Venous Catheter Replacement Strategies in Adult Patients With Major Burn Injury|Comparison of Three Strategies for Changing of Central Venous Catheters in Patients With Serious Burns for the Prevention of Catheter-associated Bacteremia: Randomized Clinical Trial|CARB|Hospital Universitario Getafe|Yes|Recruiting|May 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|1120|||Both|18 Years|N/A|No|||May 2012|August 28, 2012|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01603914||85552|
NCT01603927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DISCARD2|Detect InSpect ChAracterise Resect and Discard 2|Detect InSpect ChAracterise Resect and Discard 2|DISCARD2|South Tyneside NHS Foundation Trust|Yes|Not yet recruiting|June 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients attending for routine diagnostic or screening colonoscopy.|May 2012|May 22, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603927||85551|
NCT01604733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-EG-CRE-2010/01|Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|CEPHEUS|AstraZeneca|No|Completed|October 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1000|None Retained|blood sample|Both|18 Years|N/A|No|Non-Probability Sample|Community patients|May 2012|May 23, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604733||85489|
NCT01604187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Abstral|Procedural Pain Treatment With Transmucosal Sublingual Fentanyl Tablet in Colonoscopy Patients|Procedural Pain Treatment With Transmucosal Sublingual Fentanyl Tablet in Colonoscopy Patients|Abstral|Turku University Hospital|No|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|85 Years|No|||November 2015|November 21, 2015|May 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01604187||85531|
NCT01604772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01966|Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma|A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma||National Cancer Institute (NCI)||Active, not recruiting|July 2012|||October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||July 2014|June 4, 2015|May 22, 2012|Yes|Yes||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01604772||85486|
NCT01604785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meckler01|Low-dose Propofol for Pediatric Migraine|Low-dose Propofol for Abortive Therapy of Pediatric Migraine in the Emergency Department||Oregon Health and Science University|Yes|Recruiting|November 2012|January 2016|Anticipated|November 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|74|||Both|7 Years|18 Years|No|||September 2015|September 19, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01604785||85485|
NCT01604746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|881201|Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801|Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801)||Nanotherapeutics, Inc.|Yes|Completed|July 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1146|||Both|16 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 7, 2015|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01604746||85488|
NCT01600560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1551|Facilitating Completion of HPV Vaccination|Facilitating the Completion of the 3-Dose Series of HPV Vaccination in Males and Females||University of North Carolina, Chapel Hill|No|Not yet recruiting|May 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|11 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescent males and females age 11-21 at a Pediatric clinic|April 2012|May 16, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600560||85810|
NCT01600573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PazTo_2010|Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)|A Phase I/II Study of Pazopanib and Weekly Topotecan in Patients With Platinum-resistant or Intermediate-sensitive Recurrent Ovarian Cancer||Charite University, Berlin, Germany|No|Recruiting|May 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Female|18 Years|N/A|No|||February 2015|February 17, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01600573||85809|
NCT01611285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-04-002|Uphold Versus Robotic Surgery for Pelvic Prolapse Repair: A Decision Analytic Approach|Uphold Versus Robotic Surgery for Pelvic Prolapse Repair: A Decision Analytic Approach||Atlantic Health System|No|Completed|November 2010|August 2011|Actual|July 2011|Actual|N/A|Observational|N/A||2|Actual|20|||Female|18 Years|90 Years|No|Non-Probability Sample|20 patients who underwent either robotic surgery or the UPHOLD procedure to treat pelvic        organ prolapse from 2009-2010|May 2012|May 31, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01611285||84986|
NCT01611584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1046|A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer|A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer||Dartmouth-Hitchcock Medical Center|Yes|Withdrawn|June 2010|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||November 2014|November 11, 2014|April 10, 2012|Yes|Yes|PI left institution|No||https://clinicaltrials.gov/show/NCT01611584||84963|
NCT01611844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.591|Optimization of Tuberculosis Intradermal Skin Test|Optimization of Tuberculosis Intradermal Skin Test: TB Dermatest WP 3.1|TB Dermatest|Hospices Civils de Lyon|No|Completed|September 2011|April 2013|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 30, 2013|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01611844||84943|
NCT01612364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5138 - 1805142/1|RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb|Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb||University of Sao Paulo|Yes|Recruiting|January 2010|November 2013|Anticipated|November 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01612364||84903|
NCT01612637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2011-072|Can Pelvic Floor Muscle Training Reduce my Prolapse|Can Pelvic Floor Muscle Training Reduce my Prolapse? A Randomised Controlled Trial Comparing the Effect of Pelvic Floor Muscle Training and Lifestyle Advice on Pelvic Organ Prolapse||Copenhagen University Hospital at Herlev|Yes|Completed|August 2012|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|108|||Female|18 Years|N/A|No|||July 2014|February 2, 2016|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612637||84882|
NCT01612611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCMI-Ⅵ|Safety Study of Shenmai(a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Shenmai (a Chinese Medicine Injection) Used in China||China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|all inpatients used Shenmai injection in 30 selected hospitals in mainland China|June 2012|June 5, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01612611||84884|
NCT01612650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOMOSEIN-1104|Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis|Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis|TOMOSEIN|Centre Oscar Lambret|No|Recruiting|February 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Anticipated|1172|||Female|40 Years|N/A|No|||June 2014|June 20, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612650||84881|
NCT01613209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sevicontrol-1|Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine|Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial|Sevicontrol1|Institut für Pharmakologie und Präventive Medizin|Yes|Completed|December 2011|October 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|83|||Both|18 Years|N/A|No|||June 2013|June 24, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01613209||84838|
NCT01613521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-174|Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer|Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer||Memorial Sloan Kettering Cancer Center||Terminated|June 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Female|18 Years|N/A|No|||March 2014|March 12, 2014|June 5, 2012||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01613521||84814|
NCT01602250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100501|Local Anaesthetics Toxicity and Intralipid®|Prevention of Systemic Toxicity Induced by Levobupivacaine and Ropivacaine by Intralipid®|TOXALIP|Assistance Publique - Hôpitaux de Paris|Yes|Completed|January 2011|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2012|November 13, 2013|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01602250||85680|
NCT01603355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|e8343|Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis|An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression||Oregon Health and Science University||Recruiting|November 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|2 Years|17 Years|No|||January 2015|January 8, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603355||85595|
NCT01602809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120124|Microvessels and Heart Problems in Sickle Cell Disease|Microvascular and Cardiac Dysfunction in Sickle Cell Disease||National Institutes of Health Clinical Center (CC)||Completed|April 2012|||||N/A|Observational|Time Perspective: Prospective|||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 31, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01602809||85637|
NCT01603394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A9001464|Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia|A Phase 4 Multicenter, Open-Label, Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia||Pfizer|No|Terminated|October 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|April 16, 2012|Yes|Yes|See termination reason in detailed description.|No|June 6, 2014|https://clinicaltrials.gov/show/NCT01603394||85592|Outcome measure PCS was removed in protocol amendment1. Study stopped due to low enrolment and not safety. Efficacy analyses were not performed; safety results are described. Overall risk-benefit of pregabalin has not changed due to trial termination
NCT01603680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ArAL 11.1|Distribution Circumferential Versus Non Circumferential of Mepivacaine in the Median and Ulnar Nerves|Circumferential Versus Not Circumferential Distribution of Mepivacaine Around the Median and Ulnar Nerves in the Carpal Tunnel Surgery. Randomized Clinical Trial, Double Blinded.||Complexo Hospitalario Universitario de A Coruña|Yes|Completed|January 2012|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01603680||85570|
NCT01603888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bnp1-HMO-CTIL|Molecular Forms of Plasma and Urinary B-type Natriuretic Peptide and Its N-terminal Prohormone in Health and Disease in Pediatric Cardiology|||Hadassah Medical Organization||Recruiting|January 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|40|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Normal newborn infants and premature babies. Infants and children with significant heart        disease.|September 2013|September 15, 2013|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01603888||85554|
NCT01603901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYMC-2012-31|Regulated Negative Pressure-Assisted Wound Therapy Device|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|June 2012|May 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|16 Years|N/A|No|||May 2012|May 22, 2012|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01603901||85553|
NCT01603654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low volume preparations|Sodium Picosulphate/Magnesium Citrate and Low-volume PEG -Ascorbic Acid as Preparation for Colonoscopy|A Randomized Controlled Trial Comparing the Efficacy and Acceptability of Sodium Picosulphate/Magnesium Citrate With Low-volume PEG -Ascorbic Acid as Preparation for Colonoscopy.||Ospedale L. Sacco – Polo Universitario|No|Completed|January 2011|September 2011|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|85 Years|No|||May 2012|May 21, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603654||85572|
NCT01603667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR100-IRB-185|PG2 Injection 500 mg in Acute Stroke Study (Pass)|PG2 Injection 500 mg in Acute Stroke Study (Pass): A Randomized, Double-Blind, Placebo-Controlled Study of PG2 Injection 500 mg in Patients With Treatment Started Within 3-6 Hrs of the Onset of Acute Ischemic Stroke|Pass|China Medical University Hospital|Yes|Active, not recruiting|June 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|20 Years|N/A|No|||July 2015|July 19, 2015|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01603667||85571|
NCT01604213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9455-RK-CTIL|Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease|Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease|VAAST|Sheba Medical Center|No|Recruiting|September 2012|February 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||November 2014|November 17, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604213||85529|
NCT01604200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|292-2011|Dental PROBE (Dental Practice suRvey of Office Blood Pressure mEasurement)|A Mixed Methods Study to Assess How to Engage Dentists in Blood Pressure Screening|Dental-PROBE|Sunnybrook Health Sciences Centre|No|Withdrawn||||||N/A|Observational|Time Perspective: Prospective||1|Actual|0|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Canadian dental faculties and regulators. Canadian dentists. Canadian dental patients.        Canadian dental experts|August 2013|August 26, 2013|May 21, 2012||No|Funding unsuccessful|No||https://clinicaltrials.gov/show/NCT01604200||85530|
NCT01600833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-TMU-PCOS-201111006|The Association of Ferrtin and Homocysteine Etc. With RI and MS in Polycystic Ovary Syndrome (PCOS)|To Association of Serum Ferrtin and Homocysteine Levels With Insulin Resistence and Metabolic Syndrome in Women With Polycystic Ovary Syndrome||Taipei Medical University WanFang Hospital|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|539|||Female|18 Years|45 Years|No|Non-Probability Sample|Female patients who had been performed with fully PCOS-related survey Who visited the        Reproductive Endocrinology Clinic at the Wan Fang Medical Center at Taipei Medical        University from Jan 1, 2008, to November 30, 2011.|November 2013|November 6, 2013|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600833||85789|
NCT01611597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pre-Acti|Continuous Measurement of the Activity for Clinical Evaluation at Home, for Non-ambulant Neuromuscular Patients|Continuous Measurement of the Activity for Clinical Evaluation at Home, for Non-ambulant Neuromuscular Patients|Pre-Acti|Institut de Myologie, France|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|10 Years|80 Years|No|||April 2013|April 18, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01611597||84962|
NCT01611857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI GI 157|Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach|A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)||SCRI Development Innovations, LLC|No|Completed|July 2012|August 2015|Actual|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|47|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|June 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611857||84942|
NCT01611870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1119-AVAPSAECOPD-SS|AVAPS-AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD)Patients|Engineering Validation of the AVAPS-AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD)Patients|AVAPS-AE COPD|Philips Respironics|No|Recruiting|May 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||May 2012|June 4, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01611870||84941|
NCT01612117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013-REP-CER-FR|Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in Invasive Cardiology|Is Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) the "Renal Troponin" in Invasive Cardiology?||University of Freiburg|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|244|Samples Without DNA|urinary samples|Both|18 Years|90 Years|No|Probability Sample|all consecutive patients|May 2014|May 27, 2014|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01612117||84922|
NCT01612130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|098/2002|Valerian for Conscious Sedation in Patients Submitted to Impacted Lower Third Molars Surgery|Valeriana Officinalis L. for Conscious Sedation in Patients Submitted to Impacted Lower Third Molars Surgery: A Randomized, Double-Blind, Placebo-Controlled Crossover Study||Federal University of the Valleys of Jequitinhonha and Mucuri|No|Completed|March 2003|August 2003|Actual|August 2003|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A||||June 2012|June 5, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612130||84921|
NCT01612377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z102-009|Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis|A Phase II, Double-blind, Controlled, Multi-center, Randomized, Long Term Safety Trial of z102 and Prednisone (5 mg or 7.5 mg) in Patients With Moderate to Severe Rheumatoid Arthritis||Zalicus|No|Terminated|March 2012|September 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||September 2012|September 10, 2012|February 22, 2012|Yes|Yes|missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg|No||https://clinicaltrials.gov/show/NCT01612377||84902|
NCT01612390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hit 1234|Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor|Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor||Ain Shams University|Yes|Not yet recruiting|August 2012|December 2013|Anticipated|August 2013|Anticipated|Phase 0|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|180|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will include (180)randomly allocated|June 2012|June 4, 2012|June 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01612390||84901|
NCT01612962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-316|Diagnostic Tests to Help Determine Osteomyelitis|Diagnostic Tests to Help Determine Osteomyelitis: an Analysis and Comparison of Clinical Signs, Microbiology, Pathology and Radiology.||Georgetown University|No|Terminated|May 2011|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|196|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that underwent a bony debridement or amputation in the operating room at        Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger|February 2014|February 5, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01612962||84857|
NCT01613222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118.02-2011-GES-0012|SpO2 System Accuracy Testing|SpO2 System Accuracy Testing||GE Healthcare|No|Recruiting|June 2012|||||N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment|1||Anticipated|100|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 8, 2012|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613222||84837|
NCT01613235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/157|Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage|Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage|HIMALAIA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Terminated|August 2010|January 2016|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|June 1, 2012||No|As advised by the DSMB the study was stopped due to slow recruitment.|No||https://clinicaltrials.gov/show/NCT01613235||84836|
NCT01609491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PheNor-001|Phenylephrine Versus Norepinephrine in Ophthalmic Surgery|Comparison of the Effects of Phenylephrine and Norepinephrine on Hemodynamics and Tissue Oxygenation in Patients Undergoing Ophthalmic Surgery||University Medical Center Groningen|No|Completed|January 2012|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|55 Years|No|||December 2015|December 9, 2015|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01609491||85124|
NCT01609504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URBINO-LEZ-1995|ELRR by TEM Versus Laparoscopic TME in iT2N0M0 SMALL LOW RECTAL CANCER|Randomized Controlled Clinical Trial: Endoluminal Loco-regional Resection (ELRR) by Transanal Endoscopic Microsurgery (TEM) Versus Laparoscopic Total Mesorectal Excision (LTME) in it2n0m0 Small Low Rectal Cancer|ELRRvsLTME|University of Roma La Sapienza|No|Completed|April 1997|April 2004|Actual|April 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|283|||Both|N/A|N/A|No|||May 2012|May 29, 2012|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01609504||85123|
NCT01603368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2012/28-31|Prophylactic Probiotics to Extremely Low Birth Weight Prematures|Prophylactic Probiotics to Extremely Low Birth Weight Prematures|PROPEL|Ostergotland County Council, Sweden|Yes|Recruiting|June 2012|May 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|134|||Both|N/A|3 Days|Accepts Healthy Volunteers|||July 2012|July 4, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603368||85594|
NCT01603108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI4155|Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant|Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients With Chronic Hepatitis C Virus Infection|Rifaximin|Columbia University|No|Recruiting|March 2012|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||October 2015|October 6, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603108||85614|
NCT01603407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01NS061799|Finding the Optimum Regimen for Duchenne Muscular Dystrophy|Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen|FOR-DMD|University of Rochester|Yes|Recruiting|January 2013|August 2019|Anticipated|August 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|225|||Male|4 Years|7 Years|No|||October 2015|October 22, 2015|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603407||85591|
NCT01603706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9349-MG-CTIL|Radial Strain ECHO-Guided Implantation of Cardiac Resynchronization Therapy|Radial Strain Imaging-Guided Lead Placement for Improving Response to Cardiac Resynchronization Therapy in Patients With Ischemic Cardiomyopathy: A Randomized Clinical Trial|RAISE-CRT|Sheba Medical Center|No|Recruiting|May 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01603706||85568|
NCT01603381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01257|The Effect of Family History on Insomnia During Sobriety in Alcoholics|The Effect of Family History on Insomnia During Sobriety in Alcoholics||Philadelphia Veterans Affairs Medical Center|No|Active, not recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|24|||Male|18 Years|65 Years|No|||September 2015|September 21, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01603381||85593|
NCT01603940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONTROL STUDY|Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine|Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.|CONTROL|Hospital Universitario Pedro Ernesto|No|Completed|May 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|70 Years|No|||December 2015|December 29, 2015|May 20, 2012||No||No|August 18, 2015|https://clinicaltrials.gov/show/NCT01603940||85550|
NCT01604226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-04-094|Predicting Bispectral Index Values by Estimated Effect-site Concentration of Propofol and Remifentanil Displayed on the Target-centered Infusion Pump|Predicting Bispectral Index Values by Estimated Effect-site Concentration of Propofol and Remifentanil Displayed on the Target-centered Infusion Pump||Samsung Medical Center|Yes|Recruiting|April 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|100|||Both|20 Years|80 Years|No|Non-Probability Sample|Those undergoing gynecologic or urologic surgery with general anesthesia with total        intravenous anesthesia|July 2014|July 8, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604226||85528|
NCT01604486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH CALIBER IP|Natural Ischaemic Preconditioning Before First Myocardial Infarction|Natural Ischaemic Preconditioning Before First Myocardial Infarction: an Analysis of Prospectively Collected UK Electronic Primary Care Records Linked to the National Registry of Acute Coronary Syndromes||London School of Hygiene and Tropical Medicine|Yes|Completed|September 2009|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Retrospective||4|Actual|16000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of patients with a first myocardial infarction who are        registered at those GPRD practices that agreed to the linkage with the MINAP database, and        whose practices are "up to standard" according to GPRD criteria. Practices taking part in        the GPRD are chosen to be representative of all UK practices, and 98% of people in the UK        are registered with a GP. Therefore the GPRD should be a representative sample of the UK        population.|October 2015|October 1, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604486||85508|
NCT01600586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VKC 4-30-100-9622|A Clinical Trial of A Pacifier-Activated Music Player|A Pacifier-Activated Music Player With Mother's Voice Improves Oral Feeding in Preterm Infants|NICU PAL|Vanderbilt University|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|34 Weeks|36 Weeks|No|||December 2013|December 23, 2013|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01600586||85808|
NCT01600599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180880|Reducing Post Operative Bleeding Following Cabg|Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial|LATA|University of Malaya|No|Completed|January 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||May 2012|May 17, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01600599||85807|
NCT01611298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-21942-TAR|Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR|Transfer of Donor-Derived Humoral Immunity Following Allogeneic Hematopoietic Stem Cell Transplantation|TAR|Baylor College of Medicine|Yes|Completed|March 2008|July 2013|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|14|||Both|3 Years|70 Years|Accepts Healthy Volunteers|||April 2014|April 1, 2014|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611298||84985|
NCT01611610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMA Europe|Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe)|Clinical Assessment of Spinal Muscular Atrophy Type II and III||Institut de Myologie, France|No|Completed|May 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|4|||Both|30 Months|18 Years|No|||March 2014|March 4, 2014|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01611610||84961|
NCT01611883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06541|A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)|Examination of the Effect of Ezetimibe on Glucose Metabolism - Randomized, Double-blind, Placebo-controlled Study in Type 2 Diabetes Mellitus Patients With Hypercholesterolemia - Phase 4, Protocol No. 367 (Also Known as SCH 58235, P06541)||Merck Sharp & Dohme Corp.|No|Completed|July 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|152|||Both|20 Years|75 Years|No|||June 2015|June 3, 2015|June 1, 2012|No|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01611883||84940|
NCT01612689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-30-S|3-Dimensional Accelerometer Sub-Study|3-Dimensional Accelerometer Sub-Study for Patients Participating in the E-30 Study: Heart Rate Changes in Subjects With Epilepsy During an Epilepsy Monitoring Unit Admission||Cyberonics, Inc.|No|Completed|May 2012|July 2014|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Both|6 Years|N/A|No|||August 2014|August 6, 2014|June 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01612689||84878|
NCT01612143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28327|A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers|A Randomized, Open-label, Single Dose, Cross-over Study to Investigate the Relative Bioavailability of Setrobuvir (STV) Tablet Formulation Versus the Reference Setrobuvir Capsule Formulation Following Oral Administration With or Without a High Fat Meal in Healthy Subjects||Hoffmann-La Roche||Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|40|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612143||84920|
NCT01613287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-2010-224|Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension|A Clinical Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension||Miltenyi Biotec GmbH|Yes|Completed|June 2012|November 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|80 Years|No|||December 2013|December 6, 2013|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01613287||84832|
NCT01612663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007212-HNO-CTIL|Effect of Distal Needling on Knee Pain Using Acupuncture Techniques|Comparison of Different Acupuncture Methods on Knee Pain||Hadassah Medical Organization|Yes|Not yet recruiting|June 2012|June 2015|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|80|||Both|18 Years|85 Years|No|||May 2012|June 5, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01612663||84880|
NCT01613534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|501-2-1-09-14/03|Combined Therapy in Radiation Proctopathy|Argon Plasma Coagulation Plus Placebo or Oral Sucralfate for Chronic Radiation Proctopathy: a Randomized Placebo Controlled Trial||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Completed|June 2003|June 2007|Actual|June 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|N/A|N/A|No|||June 2012|June 5, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613534||84813|
NCT01610063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-005610|A Pilot Study for the Evaluation of the Clinic-wide Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting|A Pilot Study for the Evaluation of the Clinic-wide Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting||Mayo Clinic|No|Completed|January 2009|May 2013|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|227|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01610063||85080|
NCT01602835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPLATFRM2201|Human Urine Sample Collection for Alport Nephropathy Biomarker Studies|Human Urine Sample Collection for Alport Nephropathy Biomarker Studies||Novartis|Yes|Terminated|September 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|80|None Retained|urine|Both|5 Years|N/A|No|Non-Probability Sample|Individuals with Alport syndrome identified by the Alport Syndrome Treatments and Outcome        Registry (ASTOR)|February 2014|February 10, 2014|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602835||85635|
NCT01603121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DL-001|Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus|A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (9 mg/kg) Administration in Subjects With Type 1 Diabetes Mellitus||Eastern Virginia Medical School|Yes|Terminated|February 2012|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|1|||Both|18 Years|45 Years|No|||January 2015|January 25, 2015|May 18, 2012|Yes|Yes|Unable to enroll sufficient number of subjects|No||https://clinicaltrials.gov/show/NCT01603121||85613|
NCT01603979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-203-12-101|A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors|A Phase 1 Open-label, Multiple Dose, Dose Escalation Study of Monoclonal Antibody AV-203 Administered in Subjects With Metastatic or Advanced Solid Tumors||AVEO Pharmaceuticals, Inc.|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|24|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01603979||85547|
NCT01603693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BioOss-BondBone-HMO-CTIL|Bone Quality and Quantity Following Guided Bone Regeneration Prior to Dental Implant Placement|Bone Quality and Quantity Following Guided Bone Regeneration With Bio-Oss Alone or Combined With BondBone, Prior to Dental Implant Placement||Hadassah Medical Organization|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2012|September 8, 2013|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603693||85569|
NCT01603719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EWK-001|Efficacy and Safety of an Infant Formula With Milkfat and Prebiotics|Safety and Efficacy of an Infant Starter Formula With Prebiotics (GOS) and a Higher Content of Beta-palmitate on Stool Characteristics, Food Tolerance, Calcium Uptake, and Incidence of Infectious Disease in the First Year of Life||Waldkrankenhaus Protestant Hospital, Spandau|No|Active, not recruiting|August 2011|May 2016|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|102|||Both|N/A|10 Days|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01603719||85567|
NCT01603953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gas-549-09-12-1|Bioelectrical Impedance Vector Analysis in Cirrhotic Patients|Malnutrition Assessed Through Bioelectrical Impedance Vector Analysis is Related to Poor Prognosis in Cirrhosis|BIVA|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|January 2009|May 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|65 Years|No|Non-Probability Sample|The participants will be recruited from the Gastroenterology Department of a tertiary care        setting.|November 2014|November 17, 2014|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01603953||85549|
NCT01603966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Val-030|Low Dose Aspirin Studied With the AggreGuide|Low Dose Aspirin Study With the AggreGuide||Aggredyne, Inc.|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|13|None Retained|whole blood|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|July 2012|July 14, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01603966||85548|
NCT01604798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSCG-001|Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer|Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer||Fudan University|Yes|Completed|January 2007|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|547|Samples Without DNA|All fasting blood samples were prepared without anticoagulant and left to clot at room      temperature for 1.5 h. The serum was then isolated by centrifugation at 3000 g for 10 min at      room temperature and stored at -80℃. All samples were subjected to one freeze-thaw cycle.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|All of the CRC serum samples were obtained from patients with histologically confirmed        colorectal cancer in the Department of General Surgery, Zhongshan Hospital, Fudan        University, China. The control samples were collected from healthy volunteers.|May 2012|May 22, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01604798||85484|
NCT01604811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P00048 GP 4 03|Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)|Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study|PERMIN|Pierre Fabre Medicament||Completed|June 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|206|||Male|45 Years|85 Years|No|||July 2013|January 14, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01604811||85483|
NCT01604499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011D004784|Building on a Point-of-purchase Intervention to Encourage Healthy Food Choices|Building on a Point-of-purchase Intervention to Encourage Healthy Food Choices||Massachusetts General Hospital|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2672|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 2, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604499||85507|
NCT01604512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-067|A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression|Enhancing Brain Lesions After Radiation Therapy: A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression||Memorial Sloan Kettering Cancer Center||Recruiting|May 2012|May 2018|Anticipated|May 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|140|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604512||85506|
NCT01609842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 12-179|Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence|Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence||VA Office of Research and Development|No|Recruiting|January 2014|October 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|2500|||Both|18 Years|91 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01609842||85097|
NCT01611311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1289.17|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Young and Elderly Healthy Male/Female Volunteers (Randomized, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)||Boehringer Ingelheim||Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|40|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|May 22, 2012||||No||https://clinicaltrials.gov/show/NCT01611311||84984|
NCT01611896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-026|Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism|GRAves Selenium Supplementation Trial (GRASS) - an Investigator-initiated Randomised, Blinded, Multicentre Clinical Trial of Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism|GRASS|Rigshospitalet, Denmark|Yes|Recruiting|October 2012|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|492|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01611896||84939|
NCT01612403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|babil-1|Study the Effect of Oral Zinc Supplementation on High Molecular Weight Zinc Binding Protein in Semen|Study the Effect of Oral Zinc Supplementation on High Molecular Weight Zinc Binding Protein in Semen|supplement|Babylon University|Yes|Completed|July 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|37|||Male|27 Years|35 Years|No|Non-Probability Sample|This study includes 37 subfertile male partners from couples who had consulted the        infertility clinic of the Babil hospital of maternity (Hilla city/ IRAQ).|June 2012|June 5, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612403||84900|
NCT01612676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000025|Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock|An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.||Ferring Pharmaceuticals|Yes|Completed|June 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612676||84879|
NCT01613001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FWH20120036H|Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force Readiness|||Mike O'Callaghan Federal Hospital|No|Completed|March 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|67904|||Both|18 Years|N/A|No|Non-Probability Sample|DoD Beneficiaries|July 2013|October 15, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613001||84854|
NCT01613300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GELTAMO-O-CRT-2011|Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients|Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation||Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|No|Active, not recruiting|May 2012|June 2020|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|65 Years|No|||February 2016|February 16, 2016|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613300||84831|
NCT01612975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHHNaproxenRCT|The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection|The Effect of Perioperative Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection||McMaster University|No|Recruiting|April 2014|December 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|100 Years|No|||September 2015|September 22, 2015|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612975||84856|
NCT01612988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICLL01 BOMP|Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL|Phase II Salvage Treatment With Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in Relapsed B-cell Chronic Lymphocytic Leukemia (B-CLL)|BOMP|French Innovative Leukemia Organisation|Yes|Terminated|July 2012|September 2019|Anticipated|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|74|||Both|18 Years|80 Years|No|||December 2015|March 15, 2016|May 30, 2012||No|Other drugs others studies|No||https://clinicaltrials.gov/show/NCT01612988||84855|
NCT01613248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1602-006|A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine||Merck Sharp & Dohme Corp.|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|834|||Both|18 Years|65 Years|No|||January 2015|January 23, 2015|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613248||84835|
NCT01613261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C20002|Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies||Millennium Pharmaceuticals, Inc.|No|Withdrawn|August 2013|November 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2013|October 31, 2013|June 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613261||84834|
NCT01613274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCBM|The Effect of Gum Chewing on Bowel Motility in Post-operative Colon Resection Patients|The Effect of Gum Chewing on Bowel Motility in Post-operative Colon Resection Patients||Allina Health System|No|Completed|June 2012|April 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01613274||84833|
NCT01609751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPCRU2|Prevention of Diverticulitis by Taking a Daily Probiotic|Does a Daily Dose of the Probiotic Lactobacillus Casei Shirota Prevent Acute Episodes of Diverticulitis (LACTOPRoD) - a Pilot Study|LACTOPRoD|University of Surrey|Yes|Completed|April 2013|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|50 Years|75 Years|No|||March 2016|March 1, 2016|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609751||85104|
NCT01610570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120135|Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma|Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II)||National Institutes of Health Clinical Center (CC)|No|Terminated|May 2012|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|8|||Both|1 Year|N/A|No|||February 2016|February 18, 2016|May 31, 2012|Yes|Yes|Study was closed to enrollment before dose level one was completed.|No|November 25, 2015|https://clinicaltrials.gov/show/NCT01610570||85041|
NCT01602848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-08-243-05-G|A Patient Centered Intervention to Improve Health and Reduce Medicaid Costs|A Patient Centered Intervention to Improve Health and Reduce Medicaid Costs||New York City Health and Hospitals Corporation|No|Active, not recruiting|August 2009|December 2012|Anticipated|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1000|||Both|18 Years|N/A|No|||June 2011|May 18, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602848||85634|
NCT01603732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102410|Association Between a Mother's Exposure to "Strep Throat" and Her Baby's Developing Heart Disease|Evaluation of Maternal B-hemolytic Streptococcal Pharyngeal Exposure in Pregnancies Affected by Congenital Heart Disease(CHD)||Washington University School of Medicine|No|Recruiting|January 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|505|Samples With DNA|Confirmation of maternal ß-hemolytic streptococcal & enterovirus infection(s) will be      determined from nose and rectal swabs & blood samples assayed for standard marker antibodies      to ß-hemolytic streptococcal & enterovirus exposure.|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Random Healthy Controls and Moms with fetal care/echos during pregnancy.|December 2015|December 7, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603732||85566|
NCT01603745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zoely1984|Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome|||Catholic University of the Sacred Heart||Recruiting|April 2012|October 2012|Anticipated|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603745||85565|
NCT01604239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCSB_P4|To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis|A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of 'Shinbaro Capsule' Compared With Historical Data of 'Celebrex Capsule' in Patients With Osteoarthritis||Green Cross Corporation|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|761|||Both|19 Years|N/A|No|||November 2013|November 11, 2013|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604239||85527|
NCT01604525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL089491|Tailored Web and Peer Email Cessation Counseling for College Smokers|RealU: Tailored Web and Peer Email Cessation Counseling for College Smokers|RealU|University of Michigan|Yes|Completed|May 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1699|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604525||85505|
NCT01612780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2233-001|Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study|Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study||Entellus Medical, Inc.|No|Completed|April 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|81|||Both|18 Years|N/A|No|||May 2014|May 20, 2014|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612780||84871|
NCT01613066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Emato68|Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies|Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies||Ospedale Santa Croce-Carle Cuneo|No|Recruiting|November 2008|May 2013|Anticipated|November 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||June 2012|June 5, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613066||84849|
NCT01613365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004536-63|Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections|Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections: a Multicentric, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial|CHLORHEX|Assistance Publique Hopitaux De Marseille|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|474|||Both|18 Years|N/A|No|||August 2015|August 6, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613365||84826|
NCT01613638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC/10-02 - PENEW|Pregnancy Environment and Newborn Malformations|Congenital Malformations and Intrauterine Pollutants Exposure (Alcohol, Solvents and Pesticides) in Brittany. Population Based Case-control Study Short Title : Malformations and Environment Acronym : PENEW for "Pregnancy Environment and Newborn Malformations"|PENEW|Rennes University Hospital|No|Recruiting|October 2012|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|5000|||Both|N/A|12 Months|Accepts Healthy Volunteers|||December 2015|December 17, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01613638||84805|
NCT01609569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09/12|Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.|Utility of Pro-calcitonin as an Indicator of Ischemia in Patients Undergoing Percutaneous Coronary Intervention With Subsequent Coronary Complications.||Saint Michael's Medical Center|No|Active, not recruiting|May 2012|May 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Community sample|February 2013|February 20, 2013|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609569||85118|
NCT01612156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS- 11- 00573|Lubricant Versus Lidocaine Gel for Pain Control During Urodynamics|Use of 2% Lidocaine Gel Versus Water Based Lubrication: Is There a Difference in Pain During and After Multi-channel Urodynamics?||University of Southern California|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Female|18 Years|N/A|No|||January 2015|January 16, 2015|May 31, 2012||No||No|January 7, 2015|https://clinicaltrials.gov/show/NCT01612156||84919|Our patient population represented a predominantly Latina/Hispanic population, and our results might not be generalizable to other populations.
NCT01612702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1102/121-006|Efficacy and Safety of Single, Low-dose Dexamethasone in Patients After Total Knee Arthroplasty|The Use of a Single, Low-dose Dexamethasone in Total Knee Arthroplasty||Seoul National University Hospital|Yes|Completed|April 2011|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|291|||Both|18 Years|90 Years|No|||May 2013|May 21, 2013|June 3, 2012||No||No|June 6, 2012|https://clinicaltrials.gov/show/NCT01612702||84877|
NCT01613573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenSci-004 Clinical Trial|Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children|A Phase 1, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Pegylated Somatropin(PEG Somatropin) in GHD Children|Phase 1|GeneScience Pharmaceuticals Co., Ltd.|Yes|Completed|March 2010|November 2010|Actual|October 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|4 Years|10 Years|No|||October 2010|June 13, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01613573||84810|
NCT01609530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR 11-1215|Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy|Randomized Double Blind Study Comparing Liquid Nitrogen Cryotherapy With Nd:YAG in the Treatment of Verruca Vulgaris||Saint Joseph Mercy Health System|Yes|Completed|January 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||May 2014|May 13, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609530||85121|
NCT01613547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI/NIGER/821242|The Effect of Routine Antibiotic Use in the Outpatient Treatment of Severely Malnourished Children Without Complications|The Effect of Routine Antibiotic Use in the Outpatient Treatment of Severely Malnourished Children Without Complications: Maradi, Niger||Epicentre|No|Completed|October 2012|May 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2412|||Both|6 Months|59 Months|No|||May 2014|May 20, 2014|May 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01613547||84812|
NCT01613560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCP08|Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy|Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy||Peking University|Yes|Recruiting|June 2012|December 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|404|||Female|N/A|75 Years|No|||June 2015|June 9, 2015|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01613560||84811|
NCT01609517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-04-089-001|The Influence of Body-mass Index on the Outcome of Spinal Anesthesia for Total Knee Replacement Arthroplasty|The Influence of Body-mass Index on the Outcome of Spinal Anesthesia for Total Knee Replacement Arthroplasty||Samsung Medical Center|No|Completed|May 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|209|||Both|20 Years|80 Years|No|Non-Probability Sample|Patients who are undergoing spinal anesthesia in Samsung Medical Center during study        period|October 2014|October 29, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609517||85122|
NCT01610076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-003628|Code Status Video in the Intensive Care Unit: Video Assisted Patient Education|Pilot Study to Determine Effectiveness and Acceptance of a Code Status Video in the ICU||Mayo Clinic|No|Completed|November 2010|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|208|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610076||85079|
NCT01610323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC11-05-021-21|Fitness Improvement in Obese, Pregnant Women: an Intervention Trial|Fitness Improvement in Obese, Pregnant Women: an Intervention Trial (InterGOFIT)|InterGOFIT|Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Completed|October 2011|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 25, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610323||85060|
NCT01610557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120134|Ranibizumab and Bevacizumab for Diabetic Macular Edema|A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)||National Institutes of Health Clinical Center (CC)||Active, not recruiting|May 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||July 2014|October 10, 2014|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610557||85042|
NCT01611415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0054|Drug to Drug Interaction Study With Ipragliflozin and Furosemide|A Clinical Pharmacological Study to Assess Pharmacodynamic and Pharmacokinetic Interactions Between Furosemide and Ipragliflozin in Healthy Subjects||Astellas Pharma Inc|No|Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611415||84976|
NCT01611428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0057|Absolute Bioavailability Study With Ipragliflozin|A Single Dose, Open-label, Randomized Two-period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Ipragliflozin||Astellas Pharma Inc|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611428||84975|
NCT01603433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-10669-01|The Sapheon Closure System Feasibility Study|The Sapheon Closure System Feasibility Study||Sapheon, Inc.|Yes|Completed|July 2011|July 2014|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|21 Years|76 Years|No|Probability Sample|All patients with venous leg insufficiency presenting themselves at the hospital vein        clinic and or physicians office will be evaluated to inclusion.|September 2014|September 24, 2014|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603433||85589|
NCT01603147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IXT TOA62936|Safety Study of Ch-mAb7F9 for Methamphetamine Abuse|A Phase Ia, Double-blind, Randomized, Placebo-controlled, Ascending IV Single-dose Study to Evaluate the Safety and Pharmacokinetics of ch mAb7F9 in Healthy Subjects||InterveXion Therapeutics, LLC|Yes|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|May 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01603147||85611|
NCT01603446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000023405|L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome|Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome.||The Hospital for Sick Children|No|Completed|May 2012|December 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|17 Years|23 Years|Accepts Healthy Volunteers|||December 2013|December 13, 2013|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603446||85588|
NCT01613651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11113|Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer|A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients With Prostate Cancer||City of Hope Medical Center|Yes|Recruiting|August 2012|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|312|||Male|18 Years|N/A|No|||November 2015|November 4, 2015|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613651||84804|
NCT01603992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999906408|Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms|Quitting Marijuana Use: Self-Report Study of Quitting Strategies and Withdrawal Symptoms||National Institutes of Health Clinical Center (CC)||Completed|November 2005|May 2012||||N/A|Observational|N/A|||Anticipated|1230|||Both|18 Years|N/A|No|||May 2012|February 19, 2014|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01603992||85546|
NCT01612793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD-CA-01|Vagus Nerve Stimulation for Management of Bronchoconstriction in Patients Hospitalized With COPD Exacerbations|Non-Invasive Vagus Nerve Stimulation With the AlphaCore Device for Management of Bronchoconstriction in Patients Hospitalized With COPD||ElectroCore LLC|Yes|Terminated|October 2012|April 2013|Actual|April 2013|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|Samples Without DNA|Complete CBC and blood gases will be drawn at different time points to establish the medical      condition of the subjects.|Both|35 Years|N/A|No|Probability Sample|Potential study subjects will be provided a study information sheet (informed consent        form) to review. Those who are interested in participating will provide signed informed        consent and then be screened for eligibility (inclusion/exclusion criteria). Subjects        meeting the inclusion/exclusion criteria will be assigned a study ID number, randomized        and enrolled in the study.|January 2013|March 11, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01612793||84870|
NCT01613053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107DCN03|Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination|Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination|MACS2226|Novartis|No|No longer available||||||Phase 4|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||April 2015|April 23, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613053||84850|
NCT01610141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSFC-30971259|Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients|Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients||Chinese PLA General Hospital|Yes|Recruiting|June 2012|June 2015|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|80 Years|No|||October 2013|October 7, 2013|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610141||85074|
NCT01610154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIFuwaiHospital-MISP39889|Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics― the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics|||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Recruiting|May 2012|March 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|140|Samples Without DNA|serum|Both|25 Years|60 Years|No|Non-Probability Sample|primary care clinic|May 2012|May 31, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610154||85073|
NCT01610167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-001|NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r)Sensitivity Relief Study|NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r) for the Treatment of Dentin Hypersensitivity.||Dentsply International|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|151|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 8, 2013|May 30, 2012|Yes|Yes||No|February 20, 2013|https://clinicaltrials.gov/show/NCT01610167||85072|
NCT01610180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VI-Plt-01|Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)|Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)||Fondazione Progetto Ematologia|Yes|Recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610180||85071|
NCT01610700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS0001 Part A|An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients|Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension||GW Pharmaceuticals Ltd.|No|Completed|May 2001|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 31, 2012||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT01610700||85031|
NCT01610375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEACUP|Telephone Follow-up After Treatment for Endometrial Cancer|Telephone Follow-up After Treatment for Endometrial Cancer.|TEACUP|Queensland Centre for Gynaecological Cancer|No|Active, not recruiting|June 2012|November 2014|Anticipated|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|280|||Female|N/A|N/A|No|||September 2014|September 7, 2014|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01610375||85056|
NCT01610388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113376|A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects||GlaxoSmithKline|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|7||Actual|61|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01610388||85055|
NCT01612416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTM 021|Spectral Domain Optical Coherence Tomography Analysis for Glaucoma|Comparison of Ganglion Cell and Retinal Nerve Fiber Layer Thickness in Primary Open Angle Glaucoma and Normal Tension Glaucoma With Spectral Domain OCT||Inonu University|No|Completed|November 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|169|||Both|28 Years|72 Years|Accepts Healthy Volunteers|||June 2012|June 3, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01612416||84899|
NCT01613014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCIG-004|ABT-436 for Alcohol Dependence|A Phase 2, Double-Blind, Randomized, Placebo Controlled Trial to Assess the Efficacy of ABT-436 for Alcohol Dependence||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Yes|Completed|March 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|148|||Both|21 Years|65 Years|No|||April 2015|March 8, 2016|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613014||84853|
NCT01609543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27880|A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations|Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations||Hoffmann-La Roche||Completed|May 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|62|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|May 30, 2012||No||No|December 29, 2015|https://clinicaltrials.gov/show/NCT01609543||85120|
NCT01609790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01969|Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors|Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma||National Cancer Institute (NCI)|Yes|Active, not recruiting|June 2012|||July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||May 2015|July 31, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609790||85101|
NCT01609803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B7|Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma|Tissue Microarray Studies of the 12q13-q14 Amplicon in Alveolar Rhabdomyosarcoma||Children's Oncology Group|No|Recruiting|June 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|99|Samples With DNA|tissue samples|Both|N/A|21 Years|No|Non-Probability Sample|Tissue samples from younger patients with rhabdomyosarcoma from 2006|November 2015|November 16, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01609803||85100|
NCT01609764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40040.068.12|Physical Activity, Sleep and Age|Physical Activity and Movement Efficiency and Quality Sleep With Increasing Age||Maastricht University Medical Center|No|Completed|January 2013|October 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|45|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||April 2015|March 15, 2016|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01609764||85103|
NCT01609777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HandSAFE|HandSAFE - Development and Evaluation of a Handover Tool for Doctors and Nurses|HandSAFE - Development and Evaluation of a Handover Tool for Doctors and Nurses|HandSAFE|University of Zurich|No|Not yet recruiting|June 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|68 Years|No|||May 2012|May 29, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01609777||85102|
NCT01610583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912144|Testing Spanish-language Genetic Literacy|Development of a Tool to Assess Spanish-Language Genetic Literacy||National Institutes of Health Clinical Center (CC)||Completed|May 2012|February 2015||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Both|18 Years|75 Years|No|||February 2015|February 24, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610583||85040|
NCT01610908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00043397|Multicenter Schroth Exercise Trial for Scoliosis|A Multicenter Randomized Controlled Trial to Compare the Effect of Schroth Exercises to Standard Care on Curve Characteristics, Posture, and Quality Of Life in Adolescents With Idiopathic Scoliosis|MultiSETS|University of Alberta|No|Recruiting|April 2011|January 2017|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|258|||Female|10 Years|16 Years|No|||May 2015|May 26, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01610908||85015|
NCT01611142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL 0761-007|Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)|Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)||Kyowa Hakko Kirin Pharma, Inc.|No|Completed|April 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01611142||84997|
NCT01611441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2285M00029|Investigation of Specific Protein/Markers in Patients With Osteoarthritis of the Knee Having a Total Knee Replacement|Investigation of Biomarkers in an Exploratory Study in Patients With Osteoarthritis of the Knee Undergoing Total Knee Replacement Surgery||AstraZeneca|No|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|Samples With DNA|Whole blood, plasma, serum, urine, synovial fluid, synovial membrane, cartilage|Both|40 Years|N/A|No|Non-Probability Sample|Primary and secondary care clinics|June 2012|June 26, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611441||84974|
NCT01613079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIFRA|Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis|Evaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.|TRIFRA|Peking Union Medical College Hospital|Yes|Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|65 Years|No|||August 2013|August 2, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613079||84848|
NCT01613378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28121|A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|February 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiating treatment with RoActemra/Actemra|December 2015|December 1, 2015|June 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613378||84825|
NCT01613391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU-BS-2012-RAV|Effect of Roux-en-Y Gastric Bypass Versus Laparoscopic Adjustable Gastric Band Operations on Resistin, Apelin and Visfatin Peptides|Effect of Roux-en-Y Gastric Bypass Versus Laparoscopic Adjustable Gastric Band Operations on Resistin, Apelin and Visfatin Peptides||Istanbul University||Completed|July 2011|||February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|N/A|N/A|No|Probability Sample|Morbidly obese 15 patients underwent LAGB and 15 patients underwent RYGBP|June 2012|June 8, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613391||84824|
NCT01613404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016009|An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis|A Prospective, Observational, Randomized Comparative Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis|PROSTARRT|Janssen Inc.|Yes|Completed|February 2012|December 2014|Actual|November 2014|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|248|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic kidney disease|January 2016|January 20, 2016|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613404||84823|
NCT01609582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_306|Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and With Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events||Takeda|Yes|Terminated|June 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3207|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|May 29, 2012|Yes|Yes|Due to potential concerns about liver safety (See Detailed Description)|No|July 24, 2015|https://clinicaltrials.gov/show/NCT01609582||85117|
NCT01609855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBB-1|Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate?|Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study||Valduce Hospital|No|Recruiting|January 2012|June 2012|Anticipated|June 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01609855||85096|
NCT01609868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-16432|The Effect of a Liquid Protein Modular on Growth and Outcomes in the NICU|The Effect of a Liquid Protein Modular on Growth and Outcomes in the NICU||University of Nebraska|No|Not yet recruiting|June 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|N/A|40 Weeks|No|||May 2012|May 31, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01609868||85095|
NCT01609881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12022|The Role of Prostaglandins in the Progression of Diabetic Retinopathy|The Role of Prostaglandins in the Progression of Diabetic Retinopathy and the Therapeutic Efficacy of Topical Ketorolac (Acuvail)|Prostaglandin|Vanderbilt University|No|Recruiting|March 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|90 Years|No|||December 2015|December 7, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01609881||85094|
NCT01610986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251/11|Effects of Glucose-fructose Drinks During Training on Lactate Transport|Effects of Glucose-fructose Drinks During Training on Lactate Transport and Oxidation and on Endurance Performance|LactEx|University of Lausanne|No|Completed|May 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|17|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01610986||85009|
NCT01610401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metformin-FMD 001|The Metformin-FMD Trial|Can Metformin Prevent Endothelial Ischemia and Reperfusion Injury? The Metformin-FMD Trial|MetFMD|Radboud University|No|Completed|May 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|26|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||February 2012|May 17, 2013|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01610401||85054|
NCT01610414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115523|Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A|Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A||GlaxoSmithKline||Active, not recruiting|July 2012|January 2017|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1846|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610414||85053|
NCT01612715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHS-12-197|Analysis of Fel d 1-specific T Cells After Airway Allergen Challenge in Asthma|Analysis of Fel d 1-specific T Cells After Airway Allergen Challenge in Asthma:Frequency and Phenotype and Trafficking of Cat Allergen-specific T-cells in Blood, Bone Marrow and Bronchoalveolar Lavage Fluid (BALF) Following Segmental Allergen Challenge in Allergic Asthma.||Hamilton Health Sciences Corporation|No|Recruiting|January 2014|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|48|||Both|18 Years|65 Years|No|Probability Sample|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the        study.|March 2015|March 19, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612715||84876|
NCT01612728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIA-001|Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer|Aromatase Inhibitor-Induced Arthralgia: A Proposed Management Algorithm|AIA|Baylor Breast Care Center|No|Withdrawn|October 2013|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||February 2013|February 11, 2013|June 4, 2012||No|The grant application for this project was rejected.|No||https://clinicaltrials.gov/show/NCT01612728||84875|
NCT01613586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3652-CL-0018|A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Subjects With Bladder Pain Syndrome / Interstitial Cystitis|AMARANTH|Astellas Pharma Inc|Yes|Completed|May 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|287|||Female|18 Years|N/A|No|||March 2014|March 26, 2014|June 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613586||84809|
NCT01613599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WA27893|An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis|Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab||Genentech, Inc.||Active, not recruiting|June 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Patients with granulomatosis with polyangiitis or microscopic polyangiitis treated with        MabThera/Rituxan|March 2016|March 1, 2016|June 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613599||84808|
NCT01580930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kozey-Keadle|Changes in Habitual Physical Activity and Inactivity|Changes in Physical Activity and Inactivity During a 12-week Exercise Training and/or Sedentary Time Intervention|START|University of Massachusetts, Amherst|No|Completed|March 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|57|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01580930||87308|
NCT01610336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CINC280X2202|A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment|A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment||Novartis|No|Active, not recruiting|April 2012|March 2017|Anticipated|||Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|161|||Both|18 Years|N/A|No|||March 2016|March 20, 2016|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01610336||85059|
NCT01610349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-1000-0043|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2012|||||N/A|N/A|N/A||||||||||||||March 11, 2013|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610349||85058|
NCT01610921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 37702.042.12|Determining the Optimal Adenosine Provocation Test|Determining the Optimal Dry Powder Adenosine Provocation Test to Assess Small Airways Disease|impact|University Medical Center Groningen|No|Completed|February 2012|May 2014|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Actual|11|||Both|18 Years|65 Years|No|||July 2014|July 10, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01610921||85014|
NCT01611155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC11C4|Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy|A Pilot Randomized, Placebo-controlled, Double Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy||Mayo Clinic|Yes|Active, not recruiting|February 2012|||September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2015|January 7, 2016|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611155||84996|
NCT01582061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230B2406|An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.|An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).||Novartis||Active, not recruiting|August 2011|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|103|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|April 12, 2012|No|Yes||Yes||https://clinicaltrials.gov/show/NCT01582061||87222|
NCT01582321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/2038|Investigation of the Influence of Gender on Cardiovascular Function|Investigation of the Influence of Gender on Cardiovascular Function and Inflammation||Queen Mary University of London|No|Recruiting|March 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|56|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582321||87202|
NCT01612832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-WAA-016512-TLV|Pregabalin for Post-craniotomy Pain Control|Peri-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Elective Neurosurgical Patients: A Randomized, Comparative, Placebo-controlled, Double Blind Study||Tel-Aviv Sourasky Medical Center||Not yet recruiting|June 2012|||June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||June 2012|June 5, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612832||84867|
NCT01613092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADIT Cluster Crossover Pilot|Prevention of Arrhythmia Device Infection Trial (PADIT)|Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study||Population Health Research Institute|Yes|Completed|May 2011|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|241|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 9, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613092||84847|
NCT01609608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|091004|Whole-Body Vibration for Functional Constipation|Whole-Body Vibration for Functional Constipation: A Single-Center, Single-Blinded, Randomized, Controlled Trial||Changhua Christian Hospital|Yes|Completed|October 2009|November 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|20 Years|60 Years|No|||May 2012|May 30, 2012|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01609608||85115|
NCT01609621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008|Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions|Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions||Cook||Completed|May 2012|August 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|199|||Both|N/A|N/A|No|Non-Probability Sample|Patients will be selected among those presenting with symptoms of peripheral arterial        ischemic disease of the lower extremities and for whom endovascular intervention is deemed        appropriate.|September 2013|September 30, 2013|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01609621||85114|
NCT01613664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11-PR REGIMBEAU-2|Efficiency of TISSEEL for Sleeve Gastrectomy Complications|Randomized Prospective Clinical Study Evaluating the Usefulness of Fibrin Glue (TISSEEL® KIT) to Prevent Gastric Fistula, Intra Abdominal Haemorrhage and Intra Abdominal Loco Regional Collections After Laparoscopic Sleeve Gastrectomy|TISSEEL|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|February 2014|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|60 Years|No|||July 2015|July 28, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613664||84803|
NCT01609595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST20-P2T|Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand|An Open Label Academic Phase 2 Study of SDMB in Subjects in Thailand With Beta Thalassemia Intermedia|ST20-P2T|Boston University|Yes|Completed|March 2012|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|55 Years|No|||March 2013|March 12, 2013|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01609595||85116|
NCT01610427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116329|Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects|Optimizing the Quality of Samples for CMI in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects||GlaxoSmithKline||Completed|June 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|22|||Both|18 Years|55 Years|No|||October 2014|October 9, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610427||85052|
NCT01610674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diabetesperiop2008|Developing and Testing an Implementation Strategy to Improve Perioperative Diabetes Care|Perioperative Diabetes Care: Developing and Testing an Implementation Strategy in Terms of Effectiveness, Experiences and Costs||Radboud University|No|Enrolling by invitation|January 2009|May 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|800|||Both|18 Years|N/A|No|||May 2012|June 1, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610674||85033|
NCT01610687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS0001 EXT|A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis|A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension||GW Pharmaceuticals Ltd.|No|Completed|July 2001|February 2005|Actual|February 2005|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|137|||Both|18 Years|N/A|No|||June 2013|June 18, 2013|May 31, 2012||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT01610687||85032|
NCT01610999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Plerixafor|Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation|Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation||Tufts Medical Center|Yes|Terminated|July 2013|September 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|7|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 16, 2012|Yes|Yes|Unavailability of study article|No||https://clinicaltrials.gov/show/NCT01610999||85008|
NCT01611220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USL22#03/12-CEP329|Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa|Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa: A Randomized Control Trial|RePAN|Villa Garda Hospital|Yes|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Female|13 Years|65 Years|No|||December 2015|December 7, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01611220||84991|
NCT01609829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCOMtrain|iCOMtrain, Development and Evaluation of a Combined Training of Technical and Non-Technical Skills During the Management of Simulated Incidents in Intensive Care|||University of Zurich||Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|200|||Both|18 Years|68 Years|No|Non-Probability Sample|Doctors and nurses working on the surcical ICU.|May 2012|May 31, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609829||85098|
NCT01610089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27226|Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)|RDCRN 5110, Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)(Version 24Feb12, NIH Approved 4/5/2012)|NOASSD|Baylor College of Medicine|Yes|Completed|December 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|6|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610089||85078|
NCT01610102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1104|PROGRESS-AMS 1.0 Clinical Long Term Follow-Up|Clinical Performance and Angiographic Results of Coronary Stenting With Absorbable Metal Stents, Clinical Long Term Follow-Up||Biotronik AG|No|Completed|July 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|55|||Both|N/A|N/A|No|Non-Probability Sample|63 eligible patints previously enrolled in the PROGRESS AMS-1 study|February 2015|February 4, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610102||85077|
NCT01610362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC5504|Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response|Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response||Queen Saovabha Memorial Institute|No|Recruiting|June 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01610362||85057|
NCT01610596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000-0551-207|A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis|A Double-blind, Randomized, Multicenter, Vehicle-Controlled Parallel Group Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment||Therapeutics, Inc.|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|N/A|No|||June 2013|June 4, 2013|January 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610596||85039|
NCT01581749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-3104L|Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer|Prospective Evaluation of Truebeam STX Stereotactic Body Radiosurgery for Low and Intermediate Risk Prostate Cancer||Main Line Health|No|Recruiting|October 2011|December 2022|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|21 Years|N/A|No|||March 2016|March 22, 2016|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581749||87246|
NCT01582074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911199|The Ultrasound Study of Tamoxifen|The Ultrasound Study of Tamoxifen||National Institutes of Health Clinical Center (CC)||Active, not recruiting|July 2011|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|300|||Female|30 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 24, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582074||87221|
NCT01582087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-030|Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure|Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure||The University of Texas Medical Branch, Galveston|Yes|Active, not recruiting|February 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|Samples Without DNA|Samples previously collected for diagnostic use which could include blood, urine, bile,      cerebral spinal fluid, feces, liver tissue, brain tissue.|Both|18 Years|N/A|No|Probability Sample|GI clinic hospital inpatient stay|July 2015|August 24, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01582087||87220|
NCT01582100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56024|Reletex for Nausea in GERD Patients|Reletex ™ Band as an Adjunct to Standard Therapy in Patients With GERD, Nausea With or Without Vomiting- A Pilot Study||Northwestern University|No|Terminated|March 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||July 2014|November 5, 2014|April 19, 2012||No|study was terminated by investigator due to low enrollment|No|November 5, 2014|https://clinicaltrials.gov/show/NCT01582100||87219|The study was terminated due to low enrollment. One subject withdrew due to minor wrist discomfort and the other withdrew after determining the study schedule was undesirable.
NCT01613118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RET-D-001|Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis|Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study|DUET|Retrophin, Inc.|Yes|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Both|8 Years|75 Years|No|||December 2015|December 10, 2015|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613118||84845|
NCT01613417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-107|Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain|Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH)|TRUTH|Bracco Diagnostics, Inc|No|Completed|August 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|229|||Both|18 Years|N/A|No|||June 2015|June 4, 2015|June 4, 2012|Yes|Yes||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01613417||84822|Histologic confirmation of disease available for only 139/198 patients in the PP analysis. Of these, 128 patients had confirmed brain tumors and were available for the analyses of diagnostic performance (tumor detection and tumor characterization).
NCT01613677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120ZBR01|Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer|Phase II, Open Label, Non-randomized, Trial of BKM120 as Palliative Treatment for Metastatic or Locally Advanced Cervical Cancer After Failure to Platinum Based Regimen||Novartis|Yes|Withdrawn|November 2015|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2016|February 3, 2016|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613677||84802|
NCT01613690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2105|Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment|An Open Label, Non-randomized, Parallel-group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of a Single Dose of NVA237 in Subjects With Mild, Moderate, Severe and End-stage Renal Impairment With That in Matched Healthy Control Subjects||Novartis||Completed|June 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|5||Actual|48|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613690||84801|
NCT01609920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-2-032|Nodal Staging in Breast Cancer With MRL|Non-invasive Nodal Staging in Breast Cancer With Magnetic Resonance Imaging Lymphography Using Gadofosveset||Maastricht University Medical Center|No|Recruiting|May 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Female|18 Years|N/A|No|||May 2013|May 13, 2013|May 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01609920||85091|
NCT01609933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-101|A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study|An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination With Peginterferon α-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study||AbbVie|No|Active, not recruiting|December 2012|May 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|93|||Both|18 Years|71 Years|No|||January 2016|January 18, 2016|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609933||85090|
NCT01609894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205IFO|Individualized Fortification of Breast Milk|Individualized Fortification of Breast Milk With Fat, Carbohydrate and Protein for Preterm Infants|IFO|McMaster Children's Hospital|Yes|Recruiting|August 2013|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|112|||Both|N/A|32 Weeks|No|||October 2015|October 1, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01609894||85093|
NCT01609907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14700-101|Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan in Healthy Male Volunteer||Yuhan Corporation|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|30|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||January 2012|May 31, 2012|January 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01609907||85092|
NCT01610193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSP_Appendix|The Value of Pancreatic Stone Protein in Predicting Acute Appendicitis|The Value of Pancreatic Stone Protein in Predicting Acute Appendicitis in Patients Presenting at the Emergency Department With Abdominal Pain||University of Zurich|Yes|Recruiting|June 2012|January 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|245|Samples Without DNA|Whole blood and serum or plasma of 245 patients.|Both|18 Years|N/A|No|Probability Sample|All patients that will present at the emergency department with abdominal pain and a        clinical suspicion of acute appendicitis.|August 2013|August 22, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610193||85070|
NCT01610713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS0001 Part B|An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis|Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension||GW Pharmaceuticals Ltd.|No|Completed|May 2001|July 2002|Actual|July 2002|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|154|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 31, 2012||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT01610713||85030|
NCT01603810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTW001|Evaluating In Vivo OCT Imaging for Periocular Basal Cell Carcinoma|An Investigation of the Correlation Between OCT and Histology in Defining the Margins of Periocular Basal Cell Carcinoma||Maidstone & Tunbridge Wells NHS Trust||Not yet recruiting||||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Non-Probability Sample|Adults with periocular basal cell carcinoma|May 2012|May 21, 2012|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01603810||85560|
NCT01603537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 2007/264|The Impact of Prehospital Trauma Life Support (PHTLS) on Outcome of Traffic Injury|Impact of Prehospital Trauma Life Support (PHTLS) Training of Ambulance Caregivers on Outcome of Traffic Injury Victims||Uppsala University Hospital|No|Active, not recruiting|January 2011|September 2012|Anticipated|May 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||2|Anticipated|40000|||Both|N/A|N/A|No|Non-Probability Sample|Study Population: Motor vehicle traffic crashes were selected using the causes of injury        matrix developed by the National Center for Health Statistics, Centers for Disease Control        and Prevention, USA.|May 2012|May 18, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01603537||85581|
NCT01611233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000554|Massachusetts General Hospital Evaluation of DePuy ASR Hip System|Clinical Follow-up of ASR Patients Post-Recall||Massachusetts General Hospital|No|Recruiting|September 2012|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients with DePuy ASR or ASR-XL hip implants|April 2015|April 14, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01611233||84990|
NCT01613313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lipoma DE/01|A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma|A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma||Gerut, Zachary, M.D.|No|Completed|May 2012|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|14|||Both|18 Years|75 Years|No|||February 2016|February 10, 2016|June 5, 2012|Yes|Yes||No|February 10, 2016|https://clinicaltrials.gov/show/NCT01613313||84830|
NCT01613326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2314|Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Randomized, Blinded, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of NVA237 (50 µg o.d.) Compared to Tiotropium (18 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|GLOW5|Novartis|No|Completed|June 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|657|||Both|40 Years|N/A|No|||April 2014|April 22, 2014|February 17, 2012||No||No|January 10, 2014|https://clinicaltrials.gov/show/NCT01613326||84829|
NCT01580631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0059|Narrow Band Imaging Project on Barrett's Esophagus|Assessment of a Consensus Driven Narrow Band Imaging (NBI) Pattern Classification System in Barrett's Esophagus (BE)||Midwest Biomedical Research Foundation|No|Recruiting|October 2012|December 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Eligible subjects at the participating institution who meet the inclusion criteria for        this study will be offered the opportunity to participate in this clinical trial.|October 2015|October 19, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01580631||87331|
NCT01580345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERC/LS-451/2011|Effect of Docosa-hexaenoic Acid (DHA) Supplementation During Pregnancy on Newborn Outcome in India|Effect of Docosa-hexaenoic Acid (DHA) Supplementation During Pregnancy on Newborn Outcomes in India - the DHANI Randomized Controlled Trial.|DHANI_RCT|Centre for Chronic Disease Control, India|Yes|Not yet recruiting|December 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|1000|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580345||87352|
NCT01580358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMP98 -CT-203|Therapeutic Effects of Traditional Chinese Medicine, Shen-Mai San in Cancer Patient Undergoing Chemotherapy or Radiotherapy|Changhua Christian Hospital||Changhua Christian Hospital|Yes|Recruiting|October 2009|September 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|90 Years|No|||June 2012|June 19, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580358||87351|
NCT01580371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|133HL/NHL11L|Safety and Pharmacokinetic Profile of CKD-581|Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-581 in Patients With Lymphoma or Multiple Myeloma Failed to Standard Therapy|CKD-581|Chong Kun Dang Pharmaceutical|No|Recruiting|May 2012|October 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|N/A|No|||July 2015|July 30, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580371||87350|
NCT01581190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0082|Bananas as an Energy Source During Exercise: a Metabolomics Approach|Comparison of Bananas and Gatorade on Performance and Exercise-induced Inflammation, Oxidative Stress, and Changes in Immune Function in Endurance Athletes||Appalachian State University|No|Completed|September 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 18, 2012|April 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01581190||87288|
NCT01580644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0187-CL-104|Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers|Bioavailability Study of Two Formulations of the Isopropyl Malonate Prodrug of GLPG0187 in Healthy Male Subjects||Galapagos NV|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580644||87330|
NCT01581463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCT303|A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects|Phase 1 Single-Dose Study of the Pharmacokinetics of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects||Ipe, LLC|Yes|Completed|April 2012|||August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 3, 2012|April 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01581463||87268|
NCT01581203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI447-028|Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)|A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection|Hallmark DUAL|Bristol-Myers Squibb|No|Completed|May 2012|September 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|748|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581203||87287|
NCT01581476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP06|Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial|Randomised, Double Blind, Placebo Controlled Trial of Angiotensin Converting Enzyme Inhibitors and Statins in the Prevention of Long Term Complications in Young People With Type 1 Diabetes|AdDIT|Cambridge University Hospitals NHS Foundation Trust|Yes|Active, not recruiting|January 2009|September 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Anticipated|500|||Both|10 Years|16 Years|No|||June 2015|June 23, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01581476||87267|
NCT01612533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCMI-IV|Safety Study of Shenfu (a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Shenfu (a Chinese Medicine Injection) Used in China||China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 20000. Patients using        Shenmai injection from 2012 to 2014 in 15 hospitals.|June 2012|June 5, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01612533||84890|
NCT01613430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54CA153710|Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors|Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors (COACH)|COACH|Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|1106|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||August 2015|August 25, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613430||84821|
NCT01613703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-2952POU003|ONO-2952 Single-dose PET Study in Healthy Adult Subjects|Open-Label, Single-Center, Single Dose Positron Emission Topography (PET) Using [11C]PBR28 to Evaluate Brain Translocator Protein 18KDa (TSPO) Occupancy of ONO-2952 in Healthy Adult Subjects||Ono Pharmaceutical Co. Ltd||Completed|August 2012|||March 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 31, 2013|June 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613703||84800|
NCT01613716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115200|Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)|Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)|OPERA|The Cleveland Clinic|Yes|Active, not recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|85 Years|No|||March 2016|March 14, 2016|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613716||84799|
NCT01609634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPI.2.C/A|New Infant Formula Trial in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety|A Randomised, Controlled, Double-blind Trial to Investigate the Effects of a New Infant Formula in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety.|Venus|Danone Asia Pacific Holdings Pte, Ltd.|Yes|Active, not recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|541|||Both|N/A|28 Days|Accepts Healthy Volunteers|||October 2015|October 19, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609634||85113|
NCT01602965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0008363|Effectiveness Between Nutritional Counseling Monthly Phone Call Versus Self Help Informative Booklet|Personalized Nutritional Program Plus a Nutritional Counseling Monthly Phone Call Versus a Personalized Nutritional Program With Self Help Informative Booklet||Istituto Ortopedico Rizzoli|No|Recruiting|September 2012|September 2016|Anticipated|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|75 Years|No|||August 2015|December 10, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01602965||85625|
NCT01610206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16153|A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer|A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma||University of Virginia|Yes|Recruiting|September 2012|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|142|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01610206||85069|
NCT01610440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKCR-DMD-1(Ⅰ)|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy|Phase I/II Study of Stem Cell Therapy in Patients With Duchenne Muscular Dystrophy||Shenzhen Beike Bio-Technology Co., Ltd.|No|Recruiting|October 2011|October 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|5 Years|12 Years|No|||November 2012|November 28, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01610440||85051|
NCT01603277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB003-04|Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids|A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids|KB003-04|KaloBios Pharmaceuticals|Yes|Completed|July 2012|January 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|160|||Both|16 Years|75 Years|No|||January 2015|January 30, 2015|May 16, 2012|Yes|Yes||No|January 12, 2015|https://clinicaltrials.gov/show/NCT01603277||85601|
NCT01603550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-09|Brain Energy and Cognition|Brain Energy and Cognition||United States Army Research Institute of Environmental Medicine|No|Recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|52|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||May 2015|May 29, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603550||85580|
NCT01609556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMGN853-0401|First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors|IMGN-0401|ImmunoGen, Inc.|No|Recruiting|May 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|205|||Both|18 Years|N/A|No|||September 2015|October 5, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609556||85119|
NCT01609816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-203|Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma|Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.||Barbara Ann Karmanos Cancer Institute|Yes|Active, not recruiting|May 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609816||85099|
NCT01580657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00005529|Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics|Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics||Medical College of Wisconsin|No|Completed|September 2006|October 2010|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|6||Actual|1728|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 17, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01580657||87329|
NCT01580943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMDUP101351003|Efficacy of Two Commercially Available Chlorhexidine Mouthrinses Non-alcohol Base|Efficacy of Two Commercially Available Chlorhexidine Mouthrinses Non-alcohol Base - a Randomized Clinical Trial||Universidade do Porto|Yes|Completed|October 2011|March 2012|Actual|October 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 20, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580943||87307|
NCT01582113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_49504|Cognizin Citicoline Dosing in a Healthy Adolescent Male Population|||University of Utah|Yes|Completed|June 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|84|||Male|13 Years|18 Years|Accepts Healthy Volunteers|||January 2015|November 30, 2015|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582113||87218|
NCT01580956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8897|"VARIABLE-PSV" Study|Evaluation a New Ventilatory Modes: VARIABLE-PSV: a Randomized Controlled Cross-over Study: the " VARIABLE-PSV" Study||University Hospital, Montpellier|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2012|May 28, 2013|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01580956||87306|
NCT01582620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2277(REK)|Telestroke in Nordland Hospital. A Study of a Telemedicine Network in Rural Hospitals|Telestroke in Nordland Hospital: Improved Treatment of Cerebral Stroke in Small Hospitals|Telestroke|University Hospital of North Norway|No|Recruiting|August 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|50|||Both|18 Years|N/A|No|||April 2012|April 19, 2012|May 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01582620||87179|
NCT01582633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0015/2010|Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine|Assessment of Dose-sparing of Pandemic A/California/7/2009 H1N1 Influenza Vaccine Administered Intradermally by Needle-free Disposable-syringe Jet Injector (DSJI)||University of Sao Paulo General Hospital|No|Not yet recruiting|July 2012|September 2012|Anticipated|August 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|300|||Both|42 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582633||87178|
NCT01612845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-523|Effect of Platelet-rich Fibrin on Rotator Cuff Repair|Platelet-Rich Fibrin for Arthroscopically Repaired Massive Rotator Cuff Tears: A Prospective Randomized Pilot Clinical Trial|PRP-Fibrin|Hospital Universitario La Paz|No|Completed|May 2007|June 2011|Actual|May 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|N/A|N/A|No|||June 2012|June 5, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612845||84866|
NCT01613105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13927|Diabetes Treatment With Glucobay in Combination With Sulfonylurea|Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Sulfonylurea Under Daily Life Treatment Conditions||Bayer|No|Completed|April 2008|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4564|||Both|18 Years|N/A|No|Probability Sample|Type 2 diabetes|June 2013|June 24, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613105||84846|
NCT01602172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRI 11-339|Health Behavior Change for Hospitalized Veterans|Trial of Nurse-delivered Alcohol Brief Intervention for Hospitalized Veterans||VA Office of Research and Development|No|Active, not recruiting|November 2012|December 2015|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|426|||Both|21 Years|N/A|No|||July 2015|July 15, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602172||85686|
NCT01602445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSFO-000524|Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism|Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study|REMARK|Ottawa Hospital Research Institute|No|Active, not recruiting|July 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|Serum specimens Optional DNA banking|Both|18 Years|N/A|No|Non-Probability Sample|Referrals of cancer patients to the Thrombosis clinic at each participating center at the        time that an acute episode of VTE has been confirmed ( within 0 +/- 1 day) from the start        of anticoagulation treatment. Our centers provide VTE treatment for all the cancer        patients in our regions given the design of the Ontario Cancer Program, ensuring a        generalizable patient population.|April 2015|April 21, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602445||85665|
NCT01603238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL008|Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444|An Open Label, Single-Dose, Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444||LG Life Sciences||Completed|May 2011|July 2011|Actual|May 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|35 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603238||85604|
NCT01603251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTIVE|Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission|A Double Blind Randomized Controlled Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission|ACTIVE|London School of Hygiene and Tropical Medicine|Yes|Completed|January 2013|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|15 Years|25 Years|Accepts Healthy Volunteers|||April 2013|April 17, 2013|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01603251||85603|
NCT01603264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3271001|A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-05280014 And Trastuzumab Sourced From US And EU Administered To Healthy Male Volunteers||Pfizer|No|Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|105|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 15, 2012|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603264||85602|
NCT01603524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011583-01H|Integrating the "Ottawa Model" for Smoking Cessation Into Primary Care Practice|Integrating the "Ottawa Model" for Smoking Cessation Into Routine Primary Care Practice: A Cluster Randomized Controlled Trial|RCT-OMSC-PC|Ottawa Heart Institute Research Corporation|No|Completed|March 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603524||85582|
NCT01602991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-3647|Clinic-based Nasopharyngoesophagogastroscopy Following Bariatric Surgery|Sensitivity, Specificity, and Positive and Negative Predictive Values of Clinic-based Nasopharyngoesophagogastroscopy Following Bariatric Surgery|EGScan|McMaster University|No|Withdrawn|May 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 22, 2015|May 7, 2012||No|difficulty obtaining funding|No||https://clinicaltrials.gov/show/NCT01602991||85623|
NCT01603290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111066RIC|Change of Fatigue and Physical Fitness in Hospitalized Hematology Patients|Change of Fatigue and Physical Fitness and Their Related Factors in Hospitalized Hematology Patients||National Taiwan University Hospital|Yes|Enrolling by invitation|December 2011|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|20 Years|N/A|No|Non-Probability Sample|Acute leukemia inpatients|May 2012|May 18, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603290||85600|
NCT01604122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461036|Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers|Cross-sectional, Non-interventional Burden Of Disease (Bod) Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (Ttr-fap) Or Transthyretin Cardiomyopathy (ttr-cm) And Caregivers||Pfizer|No|Completed|February 2013|July 2015|Actual|July 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|90|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults (ages 18-85 years inclusive) diagnosed with TTR-FAP or TTR-CM and experiencing        symptoms or currently providing care for a patient with TTR-FAP or TTR-CM|October 2015|October 6, 2015|May 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01604122||85536|
NCT01604070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nextremity_2011|Study to Evaluate Safety, of NextraTM in Surgery to Fuse the Proximal-interphalangeal- Joints|Randomized Multi-Center Post Market Clinical Study to Evaluate the Safety and Performance of NextraTM for Use in Foot Surgery to Fuse the Proximal-interphalangeal- Joints||eMedtrain Inc.|Yes|Completed|May 2012|June 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|98|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|This is a post market study and will consist of patients meeting the inclusion and        exclusion criteria. The investigator recruits subjects if they meet the        Inclusion/Exclusion requirements and are willing to sign an Informed Consent. Since the        product is commercially available, randomization will occur at the time of surgery.        Randomization will be according to a randomization table provided to the site        investigators. The Surgeon will be unblended, and the subject will be blinded as to his/        her group (Treated-implant or Control-pin fixation).|July 2014|July 2, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604070||85540|
NCT01603823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10082007|Angiographie and OCT in Macula and Retinal Diseases|||Medical University of Vienna|Yes|Completed|August 2008|September 2011|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Twenty eyes of 20 patients with previous 23-gauge PPV and ILM peeling (PPV group) and 15        consecutive eyes with senile cataract with a healthy macula (control group) were included.|May 2012|May 21, 2012|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01603823||85559|
NCT01580072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C250487|Telemonitoring of Patients With COPD in Carinthia|REgions of Europe WorkiNg toGether for HEALTH (Renewing Health)|RenewingHealth|Landeskrankenanstalten-Betriebsgesellschaft||Completed|February 2010|February 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|65|||Both|N/A|N/A|No|||April 2015|July 1, 2015|April 17, 2012||No||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01580072||87373|
NCT01580085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gantep gogus 1|Obstructive Sleep Apnea in Pulmonary Embolism|Obstructive Sleep Apnea is Prevalent in Patients With Pulmonary Embolism||University of Gaziantep|No|Completed|November 2009|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|75|||Both|18 Years|N/A|No|Probability Sample|All subjects admitted to Department of Pulmonary Medicine of Gaziantep University who were        diagnosed to have PE were included in the study group. Control group consisted of age and        sex matched subjects without a clinic consistent with PE referred to the Sleep Clinic. PE        was diagnosed when one or more of the following was present: compatible physical        examination findings and multislice CT angiography or presence of deep venous thrombus        (DVT) in addition to high risk with Wells criteria [5]. Subjects with any        restrictive/obstructive lung pathology or younger than 18 years old were excluded.|April 2012|April 17, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01580085||87372|
NCT01581216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fatigue-hcb-01|Fatigue Before and After Exercise in Patients With Advanced Cancer Stage|The Use of Physical Activity to Control Fatigue and Improve the Quality of Life in Patients With Advanced Cancer Stage||Barretos Cancer Hospital|No|Recruiting|December 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|90 Years|No|||August 2015|August 10, 2015|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01581216||87286|
NCT01581229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012BAI05B00|Early Use of Noninvasive Positive Pressure Ventilation for Intro-pulmonary Acute Lung Injury|||Beijing Hospital|No|Recruiting|June 2012|||June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2012|July 5, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01581229||87285|
NCT01581762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChineseUHK|EUS-FNA With 22G Procore Needles vs 22G Conventional Needles|Prospective Comparative Study on Endoscopic Ultrasonography (EUS) - Guided Fine-Needle Aspiration (FNA) Using the 22G Conventional Needles or Procore Needles Without Immediate On-site Cytopathologic Examination||Chinese University of Hong Kong|Yes|Active, not recruiting|April 2012|October 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|80 Years|No|||January 2014|January 19, 2014|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01581762||87245|
NCT01581775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-VIN-122|Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions|Open Label, Balanced, Randomized, Single-dose, Crossover Oral Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's and Depakote ER 500 mg Tablets of Abbott Laboratories, in Healthy Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2011|March 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581775||87244|
NCT01581788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-vin-123|Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions|Open Label, Balanced, Randomized, Single-dose, Crossover Oral Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's and Depakote ER 500 mg Tablets of Abbott Laboratories, in Healthy Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2011|March 2011|Actual|February 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581788||87243|
NCT01582126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ö-1-12|Group Balance Training for People With Multiple Sclerosis|Group Balance Training for People With Multiple Sclerosis||Örebro County Council|No|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01582126||87217|
NCT01582347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB-UK-11-0017|Transfer of Subjects From Subutex/Suboxone to RBP-6300|A Randomized, Double-blind, Double-dummy, Active-drug-controlled, Parallel-group, Multicentre Acceptability and Safety Study of the Transfer From Subutex/Suboxone to RBP-6300 in Opioid-dependent Subjects||Indivior Inc.|Yes|Completed|March 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|65 Years|No|||May 2015|August 7, 2015|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582347||87200|
NCT01582152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0705|Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma|Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2012|||July 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582152||87215|
NCT01582360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/10076|2012_PharmacoCRRT-study:Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT)|Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT) or Without CRRT|PharmacoCRRT|Oslo University Hospital|Yes|Recruiting|May 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Anticipated|640|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients admitted to the ICU at Oslo University Hospital, in need of        treatment with antiinfectives.|October 2015|October 14, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582360||87199|
NCT01582646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4705|Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain|Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain|Bêtapain|University Hospital, Strasbourg, France|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||April 2012|September 17, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01582646||87177|
NCT01582893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1492|Permeability Enhancement to Reduce Chronic Inflammation|Permeability Enhancement to Reduce Chronic Inflammation|PERCI|Gambro Dialysatoren GmbH|No|Completed|April 2012|July 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01582893||87158|
NCT01613131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1711|Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression|Effectiveness of Perimenopausal Hormone Therapy in Suppression of Ovulation, Stabilization of Reproductive Hormones and Symptom Control||University of Colorado, Denver|Yes|Completed|April 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Female|40 Years|52 Years|No|||October 2015|October 29, 2015|June 4, 2012|Yes|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01613131||84844|The main limitation was the sample size, which is consistent with a pilot study, and which can only inform the design of future research.
NCT01613742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6651|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2012|||||N/A|N/A|N/A||||||||||||||November 21, 2013|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613742||84797|
NCT01601509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOA-123|Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and|Randomized Placebo-controlled Cross-over Trial of the Effect of Nasal Tramazoline With Dexamethasone in Obstructive Sleep Apnoea Patients|NTD|University of Athens|No|Completed|April 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|80 Years|No|||May 2012|May 17, 2012|March 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01601509||85737|
NCT01601886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 092010-201|Delivery Room Practice Change Following the Initiation of the NICHD SUPPORT Trial|Delivery Room Practice Change Following the Initiation of the NICHD SUPPORT Trial||University of Texas Southwestern Medical Center|No|Completed|April 2008|April 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|3843|||Both|24 Weeks|35 Weeks|No|Non-Probability Sample|All babies born at Parkland Memorial Hospital with gestational age at least 24 weeks and        less than 35 weeks between 01/2003 and 06/2010|May 2012|May 17, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601886||85708|
NCT01602718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00053828|Physical Activity and Functioning in Home Dialysis Patients|Physical Activity and Functioning in Home Dialysis Patients||University of Utah|No|Enrolling by invitation|June 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|90 Years|No|||June 2014|June 2, 2014|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602718||85644|
NCT01602731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 12-198|Targeted Intervention to Improve Medication Adherence in Cognitively Impaired Patients With HF (TARGET)|Targeted Intervention to Improve Medication Adherence in Cognitively Impaired Patients With Heart Failure|TARGET|VA Office of Research and Development|No|Completed|October 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|45|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|May 17, 2012||No||No|April 22, 2015|https://clinicaltrials.gov/show/NCT01602731||85643|Low enrollment in the study reflects the fact that many patients with HF do not admit the need for assistance with their medications. Patients should first be tested for the presence of cognitive impairment and baseline medication adherence problems.
NCT01602458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-10-134|A Randomized Control Trial for Preventative Scar Management|The Use of Pressure and Silicone in Children With Skin Grafts After Traumatic Skin Injury: A Randomized Control Trial for Preventative Scar Management||Seton Healthcare Family|Yes|Completed|May 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|1 Year|18 Years|No|||May 2014|May 13, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01602458||85664|
NCT01602744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0036-12 WOMC|The Use of STOPP/START Criteria for Medication Intervention Among Elderly Population Living in a Geriatric Hospital|The Use of STOPP/START Criteria for Medication Intervention and the Risk of Falls, Hospitalization, Functioning and Quality of Life Among Elderly Population Living in a Geriatric Hospital in Israel and Comparison to Beers|STOPP|Wolfson Medical Center|No|Completed|April 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|382|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2014|March 23, 2014|May 1, 2012||No||No|November 24, 2013|https://clinicaltrials.gov/show/NCT01602744||85642|The limitations of the study were that it was conducted in a single geriatric center. This precludes the possibility of generalizing its findings to other older segments of the community.
NCT01602978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5100032|Comparison of Pulse Hemoglobin and Pleth Variability Index|Comparison of Pulse Hemoglobin and Pleth Variability Index to Standard Methods of Guiding Intraoperative Fluid and Transfusion Management During Major Surgical Procedures.|Pleth|Loma Linda University|No|Recruiting|February 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|240|||Both|18 Years|N/A|No|Probability Sample|The study population will be adults more than 18 years old that are scheduled for a major        surgical procedure.|January 2016|January 19, 2016|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01602978||85624|
NCT01603849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pciAdenoINCAN|Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis|Randomized Phase II Trial of Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma Clinical Stage IIIB and IV With High Risk of Brain Metastasis|PCI|Instituto Nacional de Cancerologia de Mexico|Yes|Active, not recruiting|May 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|60 Years|No|||February 2016|February 22, 2016|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603849||85557|
NCT01604135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DNR-949-11|Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial|Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial|CXL-RCT|Sahlgrenska University Hospital, Sweden|Yes|Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|30 Years|No|||November 2014|November 28, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604135||85535|
NCT01603836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLFBMC|Study Confirms or Refutes the Hypothesis That the Autologous Bone Marrow Concentrate Together With the Allograft is a Better Alternative for the Posterolateral Fusion in Spine Surgery Than the Allograft Alone|Allograft Alone Versus Allograft With Bone Marrow Concentrate for the Healing of the Instrumented Posterolateral Lumbar Fusion||Hospital Znojmo|No|Completed|February 2009|March 2012|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|80|||Both|45 Years|89 Years|No|||May 2012|May 20, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01603836||85558|
NCT01581489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NATIBAR1213|Early Versus Delayed Cord Clamping at Term: Neurodevelopmental Outcomes in Swedish Infants at 4 Years of Age|Early Versus Delayed Cord Clamping at Term: Neurodevelopmental Outcomes in Swedish Infants at 4 Years of Age||Uppsala University|No|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|263|||Both|48 Months|51 Months|No|Non-Probability Sample|The eligble population consists of a group of 382 children who were included in a trial        (NCT01245296) and randomized to either early or delayed cord clamping. The parents will be        asked for consent for their child to participate in the current follow up study.|June 2015|June 11, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01581489||87266|
NCT01581502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|samurai2011|SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)|Stroke Acute Management With Urgent Risk-factor Assessment and Improvement (SAMURAI) Study on Anticoagulant Therapy in Nonvalvular Atrial Fibrillation (NVAF)|SAMURAI-NVAF|Ministry of Health, Labour and Welfare, Japan|No|Active, not recruiting|September 2011|December 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|inpatients|August 2015|August 31, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01581502||87265|
NCT01581242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BKP-1003|A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Three-sequence, Three-period, Three-treatment Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects|BKP-1003-101|Bukwang Pharmaceutical|No|Completed|April 2012|||June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|42|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 16, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01581242||87284|
NCT01581255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSCILLATE Biomarkers Study|The Effect of High Frequency Oscillation on Biological Markers of Lung Injury|The Effect of High Frequency Oscillation on Biological Markers of Lung Injury||Canadian Critical Care Trials Group|No|Terminated|February 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|2|Samples Without DNA|Blood samples will be drawn to measure the following biomarkers of ventilator-induced lung      injury: IL-1β, IL-6, IL-8, IL-10, IFN-γ, TGF-β, TNF-α, VEGF, sICAM-1, surfactant protein D      (SP-D), Krebs von den Lungen protein (KL-6), Clara cell 16 kD protein (CC16),      Angiopoietin-1, Angiopoietin-2, and vWF.|Both|16 Years|85 Years|No|Non-Probability Sample|Critically-ill patients with the acute respiratory distress syndrome enrolled in the        OSCILLATE trial (NCT01506401).|September 2012|September 10, 2012|April 17, 2012||No|Parent study (OSCILLATE) stopped by the Data Monitoring Committee|No||https://clinicaltrials.gov/show/NCT01581255||87283|
NCT01581515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0080|Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation|2-phased Randomized Comparison Between PromusTMElementTM Versus Xience PRIME® Stent|ANCHOR|Yonsei University|Yes|Recruiting|January 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|80 Years|No|||April 2012|April 17, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01581515||87264|
NCT01581801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSC-2012-V01|Bariatric Surgery and Reactive Hypoglycemia|RANDOMIZED CLINICAL STUDY COMPARING THE EFFECT OF ROUX-en-Y GASTRIC BYPASS AND SLEEVE GASTRECTOMY ON REACTIVE HYPOGLYCEMIA||Catholic University of the Sacred Heart|Yes|Active, not recruiting|October 2012|March 2016|Anticipated|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|25 Years|65 Years|No|||March 2015|March 31, 2015|April 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01581801||87242|
NCT01582139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15970|Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker|Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker||University of Virginia|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|21 Years|65 Years|No|||July 2014|July 28, 2014|April 18, 2012|No|Yes||No|June 27, 2014|https://clinicaltrials.gov/show/NCT01582139||87216|
NCT01582165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3tcAZ|Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance|Microvascular Resistance in Women With Chest Pain and no or Minimal Coronary Artery Disease||Oslo University Hospital|No|Recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Female|30 Years|70 Years|No|||October 2015|October 14, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01582165||87214|
NCT01582373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBCT-01|Pilot Study to Assess the Efficacy of Cognitive-behavioral Couple Therapy for Provoked Vestibulodynia|Pilot Study to Assess the Efficacy of an Experimental 12-week Cognitive-behavioral Couple Therapy in the Treatment of Provoked Vestibulodynia||Université de Montréal|No|Completed|May 2012|December 2014|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|45 Years|No|||December 2014|December 1, 2014|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01582373||87198|
NCT01582386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REX-OUS-2012-002|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2012|||||N/A|N/A|N/A||||||||||||||April 28, 2014|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582386||87197|
NCT01582399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7163-CL-0106|Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240|A Phase 1 Single-Dose, Parallel Group, Randomized, Open-Label Study to Determine the Absolute Bioavailability of ASKP1240 After Intravenous and Subcutaneous Administration in Healthy Subjects||Astellas Pharma Inc|No|Completed|February 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 7, 2012|April 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01582399||87196|
NCT01582659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OutCon|Outpatient Treatment of Constipation in Children|Outpatient Treatment of Constipation in Children - a Randomized Interventions Study||Vejle Hospital|No|Completed|June 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|239|||Both|2 Years|16 Years|No|||December 2014|December 4, 2014|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01582659||87176|
NCT01582672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-003-007|Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)|An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)|ADAPT|Argos Therapeutics|Yes|Active, not recruiting|November 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01582672||87175|
NCT01602146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208048|Problems Associated With Ultramarathon|Acute and Chronic Problems Associated With the Practice of Mountain Ultramarathon|CHAMONIX2|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|ultramarathon runner|November 2012|November 9, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01602146||85688|
NCT01602159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROBUST|Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)|Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)|ROBUST|Johns Hopkins University|Yes|Recruiting|July 2009|||June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602159||85687|
NCT01602198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG022304|Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients|24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients||The Cleveland Clinic|No|Terminated|June 2011|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|1|||Both|55 Years|85 Years|No|||February 2014|February 21, 2014|June 13, 2011|Yes|Yes|Study has been revised to use a different study medication and patient population.|No||https://clinicaltrials.gov/show/NCT01602198||85684|
NCT01602211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2605.00|INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant|INSPIRE for Survivorship After Transplant: A Multicenter Randomized Controlled Trial of an Internet and Social-Media Program for Long-Term Hematopoietic Cell Transplantation Survivors|INSPIRE|Fred Hutchinson Cancer Research Center|Yes|Active, not recruiting|May 2013|||December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|1600|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01602211||85683|
NCT01602510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113783|Lamotrigine Phase III Study in Bipolar I Disorder|A Fixed-Dose Study of Lamotrigine Versus Placebo in the Long Term Prevention of Relapse and/or Recurrence of a Manic, Hypomanic, Mixed or Depressive Episode in Adult Subjects With Bipolar I Disorder||GlaxoSmithKline||Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602510||85660|
NCT01601899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRU01|Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients|Molecular, Biochemical and Clinical Differences Between Stavudine and Tenofovir, Each Combined With Lamivudine and Efavirenz in South African HIV-infected Patients|CHRU01|University of Witwatersrand, South Africa|Yes|Terminated|October 2008|December 2010|Actual|October 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|May 14, 2012||No|DSMB decision to begin closeout process in view of April 2010 SA HAART guideline|No||https://clinicaltrials.gov/show/NCT01601899||85707|
NCT01602185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0112|Study of NMDA Antagonists and Neuropathic Pain|Antagonists NMDA in Relay to Ketamine in Neuropathic Pain|NMDA|University Hospital, Clermont-Ferrand||Recruiting|May 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||October 2012|October 8, 2012|January 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01602185||85685|
NCT01602471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K5-C200|[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis|An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis||Siemens Molecular Imaging|No|Terminated|May 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|5|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|September 14, 2011|Yes|Yes|Sponsor decided to develop the product in collaboration|No|July 26, 2013|https://clinicaltrials.gov/show/NCT01602471||85663|
NCT01602757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SC-101|Pharmacokinetic Study of Synera in Healthy Volunteers|An Open-Label Pharmacokinetic Study of the Synera Patch Applied for 2-, 4-, and 12-hours and a Lidocaine/Tetracaine Patch Without Heat Applied for 4 Hours in Healthy Adult Volunteers||ZARS Pharma Inc.|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 15, 2012|May 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01602757||85641|
NCT01604447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 009|Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part IV||University of Alabama at Birmingham|Yes|Completed|June 2012|February 2015|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|118|||Both|N/A|72 Hours|No|||February 2015|February 23, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604447||85511|
NCT01604421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 007|Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part II|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part II||University of Alabama at Birmingham|Yes|Recruiting|February 2013|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|182|||Both|N/A|120 Days|No|||January 2016|January 12, 2016|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604421||85513|
NCT01580696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-20025/20288|Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer|Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients||San Antonio Military Medical Center|No|Active, not recruiting|April 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||November 2015|November 16, 2015|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01580696||87326|
NCT01581281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIN-001|The Childhood and Adolescent Migraine Prevention Study|Amitriptyline and Topiramate in the Prevention of Childhood Migraine|CHAMP|Children's Hospital Medical Center, Cincinnati|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|675|||Both|8 Years|17 Years|No|||February 2015|February 16, 2015|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581281||87282|
NCT01581528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B5|Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia|Metabolic Pathways in T-Cell Acute Lymphoblastic Leukemia (T-ALL)||Children's Oncology Group|No|Active, not recruiting|April 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|15|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|patients diagnosed with T-ALL|May 2015|May 4, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01581528||87263|
NCT01581814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|disfunzionale14|Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome|||Catholic University of the Sacred Heart|Yes|Completed|October 2008|March 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|99|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2012|April 19, 2012|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01581814||87241|
NCT01582178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDC VN 04|Warm Water Versus Room Temperature Water Immersion Colonoscopy|Warm Water Versus Room Temperature Water Immersion Colonoscopy - a Prospective, Randomized, Double-blind, Single-center Trial||Vitkovice Hospital|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|212|||Both|18 Years|N/A|No|||September 2013|September 19, 2013|April 18, 2012||No||No|June 2, 2013|https://clinicaltrials.gov/show/NCT01582178||87213|
NCT01582191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0953|A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer|A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer||M.D. Anderson Cancer Center|No|Recruiting|May 2012|||May 2026|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|174|||Both|N/A|N/A|No|||February 2016|February 9, 2016|April 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01582191||87212|
NCT01582412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0025|Drug Interaction Study of Isavuconazole and Digoxin|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Digoxin in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|April 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01582412||87195|
NCT01582425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0027|Drug Interaction Study of Isavuconazole and Methadone|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Methadone in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 28, 2012|April 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01582425||87194|
NCT01582438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481304|An Open Label Access Study For Subjects Who Completed A1481156|A Local, Multicentre, Open Label Access Study, To Provide Sildenafil Therapy For Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil For Subjects In India||Pfizer|No|Temporarily not available|November 2012|August 2014|Actual|August 2014|Actual|Phase 3|Expanded Access|N/A|||||||Both|12 Years|30 Years|No|||June 2015|June 1, 2015|April 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01582438||87193|
NCT01612897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HS018453|Study of the Effectiveness of a Computer Decision Support System to Improve Physicians' Screening for Autism|Computer Assisted Autism Care (CAAC)|CAAC|Indiana University|No|Completed|September 2009|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|368|||Both|17 Months|4 Years|No|||March 2015|March 23, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612897||84862|
NCT01612910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-111|Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery|A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive, Invasive Breast Cancer, Who Have Residual Disease Following Surgical Resection After Neoadjuvant Chemotherapy||Barbara Ann Karmanos Cancer Institute|Yes|Withdrawn|June 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||February 2014|February 10, 2014|June 4, 2012|Yes|Yes|Research cancelled.|No||https://clinicaltrials.gov/show/NCT01612910||84861|
NCT01602523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13383|Effect of Symbicort on Sleep Quality in Patients With Emphysema|Effect of Symbicort on Sleep Quality in Patients With Emphysema||Temple University|No|Active, not recruiting|March 2011|August 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|80 Years|No|||December 2012|December 6, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01602523||85659|
NCT01602484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002091|Application Time of Plaster-of-Paris Splint Packs Compared to Bulk Supplies Following Standard Orthopaedic Procedure|Application Time of Plaster-of-Paris Splint Packs Compared to Bulk Supplies Following Standard Orthopaedic Procedure||Brigham and Women's Hospital|Yes|Recruiting|October 2011|July 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|18 Years|N/A|No|Probability Sample|Post-operative patients undergoing standard splint application|May 2012|May 17, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602484||85662|
NCT01602770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16233|Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy|Prospective, Non-interventional, 2-year Post-authorization Safety Study for QLAIRA®||Bayer|No|Recruiting|July 2015|July 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Female|18 Years|40 Years|No|Non-Probability Sample|Cohort of healthy women of reproductive age currently Qlaira users from selected        obstetrics and gynecology (Ob/Gyn) primary care clinics|March 2016|March 15, 2016|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01602770||85640|
NCT01603004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-058|Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors|A Pilot Study to Identify Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Potential research patients will be identified by doctors from the Gastrointestinal        Oncology Service in the Department of Medicine.|February 2016|February 8, 2016|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01603004||85622|
NCT01603303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0125|Preventing Sexual Dysfunction With Aromatase Inhibitors|Preventing Sexual Dysfunction in Women on Aromatase Inhibitors||M.D. Anderson Cancer Center|No|Active, not recruiting|December 2012|||December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|472|||Female|18 Years|N/A|No|||March 2016|March 11, 2016|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603303||85599|
NCT01603563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH092373-01A1|Stepped Care for Young Children After Trauma|Stepped Care for Young Children After Trauma||University of South Florida|No|Completed|July 2011|November 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|3 Years|7 Years|No|||April 2015|April 23, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01603563||85579|
NCT01603576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVA_0001|Pilot Study of a Suprachoroidal Retinal Prosthesis|Safety and Feasibility Study of a Prototype Suprachoroidal Retinal Prosthesis for Vision Restoration||Center for Eye Research Australia||Completed|May 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|80 Years|No|||August 2014|August 29, 2014|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603576||85578|
NCT01600534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0810|GooDMoMS: A Multimodel Pregnancy and Postpartum Intervention for Gestational Diabetics|GooDMomS: A Multimodel Pregnancy and Postpartum Intervention for Gestational Diabetics||University of North Carolina, Chapel Hill|No|Completed|May 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Female|21 Years|35 Years|No|||September 2014|September 10, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600534||85812|
NCT01604434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 008|Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part III|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part III||University of Alabama at Birmingham|Yes|Recruiting|June 2012|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|118|||Both|N/A|72 Hours|No|||January 2016|January 12, 2016|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604434||85512|
NCT01581294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIA 2011-1|The Norwegian Antirheumatic Drug Register|Long-term Safety and Effectiveness of Disease Modifying Therapies in Inflammatory Arthropathies: a Multicentre, Phase IV, Longitudinal Observational Study|NOR-DMARD|Diakonhjemmet Hospital|Yes|Recruiting|April 2012|December 2050|Anticipated|December 2050|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15000|Samples With DNA|Samples (including serum, plasma and full blood) for biomarker or DNA/RNA discovery and      validation will be collected and stored in a freezer at -70 C at visits at baseline and at      the 3-month assessment.|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with inflammatory arthropathies starting a new treatment with a biological        disease modifying anti-rheumatic drug|February 2014|February 4, 2014|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01581294||87281|
NCT01581541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110150|PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment|Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma||National Institutes of Health Clinical Center (CC)||Completed|April 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|120 Years|No|||November 2015|November 17, 2015|April 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01581541||87262|
NCT01581827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|52/09|SCREEN-HFL (SCReening Evaluation of the Evolution of New Heart Failure) - a Longitudinal Study|SCREEN-HFL (SCReening Evaluation of the Evolution of New Heart Failure) - a Longitudinal Study|SHF-L|Monash University|No|Enrolling by invitation|January 2009|December 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|Samples Without DNA|Blood samples to measure BNP and NT-proBNP|Both|60 Years|N/A|No|Non-Probability Sample|People at high risk of heart failure|June 2015|June 2, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01581827||87240|
NCT01612325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU-11-538|Radioactive Holmium Microspheres for the Treatment of Unresectable Liver Metastases|Radioactive Holmium Microspheres for the Treatment of Patients With Unresectable Liver Metastases; a Single Center, Interventional, Non-randomized, Phase II (HEPAR II) Trial|HEPAR-2|UMC Utrecht|Yes|Completed|May 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|56|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612325||84906|
NCT01612585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCMI-Ⅴ|Safety Study of Dengzhanxixin (a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Dengzhanxixin (a Chinese Medicine Injection) Used in China||China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|April 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 30000. Patients using        Kudiezi injection from 2012 to 2014 in more than 30 hospitals|June 2012|June 7, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01612585||84886|
NCT01612598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12123|Palliative Care Intervention in Patients With Solid Tumors Participating in Phase I Clinical Trials|Feasibility of a Palliative Care Intervention for Patients on Phase 1 Clinical Trials||City of Hope Medical Center|Yes|Completed|July 2012|January 2014|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|16|||Both|21 Years|N/A|No|||January 2014|January 29, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612598||84885|
NCT01612923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W2010U|Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians|Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians||Karolinska Institutet|Yes|Completed|April 2011|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1180|||Female|18 Years|45 Years|No|||June 2012|August 25, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612923||84860|
NCT01601860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR444841|The Maternal and Perinatal Outcomes Associated With the Use of Non-pharmacological in Labor|Evaluation of Maternal and Perinatal Outcomes Associated With the Use of Non-pharmacological in Parturients in Active Phase of Labor||University of Sao Paulo|Yes|Recruiting|January 2012|July 2014|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|15 Years|30 Years|Accepts Healthy Volunteers|||June 2013|June 4, 2013|September 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01601860||85710|
NCT01601873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTVS-KC01|Propaten Randomized Investigation on Cost-benefit and Efficacy|A Randomized Controlled Comparative Study on Efficacy and Cost-effectiveness of Heparin-bonded Versus Non-heparin-bonded Polytetrafluroethylene Hemodialysis Access Grafts.|PRICE|The University of Texas Health Science Center, Houston|Yes|Recruiting|November 2012|December 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601873||85709|
NCT01593761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CG400549-2-01|Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus|Phase 2a, Repeated-dose, Open-label, Single-arm Study of CG400549 for the Treatment of Complicated Acute Bacterial Skin and Skin Structure Infection (cABSSSI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)|CG400549|CrystalGenomics, Inc.|No|Completed|June 2012|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||December 2012|December 27, 2012|May 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593761||86333|
NCT01566188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/010 HP|Vascular Impact of Omega-3 in Metabolic Syndrome|Cardiovascular Impact of Omega-3 Dietary Supplement From Vegetal Origin in Hypertension Associated With Metabolic Syndrome|CARDIOMEGA|University Hospital, Rouen|Yes|Completed|January 2011|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|95|||Both|18 Years|70 Years|No|||September 2014|September 1, 2014|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01566188||88436|
NCT01566201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCT-RACAD-ATTIKON-01|Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease|The Effect of Inhibition of Interleukin-1 Activity on Vascular and Left Ventricular Function in Patients With Coronary Artery Disease and Coexistent Rheumatoid Arthritis||University of Athens|Yes|Completed|March 2011|June 2013|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566201||88435|
NCT01566448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU041011|Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash|Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash||West Virginia University|Yes|Completed|February 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 11, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566448||88416|
NCT01566994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA022291|Comparing Population Cessation Services|Comparing Population Cessation Services With Emphasis on Unmotivated Smokers||University of Rhode Island|Yes|Completed|March 2010|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|2500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 16, 2013|January 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01566994||88374|
NCT01567332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/04-P|Evaluation of Walking After Repetitive Transcranial Magnetic Stimulation (rTMS) Inhibitory 1Hz in Vascular Hemiplegia|Evaluation of Walking After Repetitive Transcranial Magnetic Stimulation (rTMS) Inhibitory 1Hz in Vascular Hemiplegia.|rTMS|Nantes University Hospital|No|Terminated|September 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|10|||Both|18 Years|80 Years|No|||January 2013|January 30, 2013|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567332||88349|
NCT01568190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002017-11|An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy|An Open Trial to Asses the Tolerability of AVANZ Mite Mix Immunotherapy|AV-M-01|ALK-Abelló A/S|No|Completed|December 2011|July 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|102|||Both|18 Years|65 Years|No|||January 2015|January 5, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568190||88283|
NCT01569360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091121|Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord Injury|Randomised Open Study of the Efficiency and Tolerance of the Use of a Corset on the Respiratory Function of Spinal Cord Injury Patients|Garchoise|Assistance Publique - Hôpitaux de Paris|Yes|Withdrawn|March 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2012|December 18, 2013|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01569360||88193|
NCT01569100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REASTAT01|Atorvastatin After Aneurysmal Subarachnoid Hemorrhage|Atorvastatin Effect in Incidence and Ischemic Complications of Vasospasm After Subarachnoid Aneurysmal Hemorrhage: a Cohort Study||Groupe Hospitalier Pitie-Salpetriere|No|Completed|December 2005|December 2007|Actual|December 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|278|||Both|16 Years|80 Years|No|Non-Probability Sample|All patients admitted between April 20, 2004, and October 1, 2007, to the Pitie-        Salpetriere Teaching Hospital in Paris with aneurysmal SAH and treated by endovascular        coiling or surgery within 96 hrs after SAH onset were considered for inclusion.|March 2012|March 30, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569100||88213|
NCT01569347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI10027 / AOM 10165|Clinical and Genetic Factors Associated With Psychotic Symptoms Among Cocaine Abusers|Multicentric Descriptive Cross-sectional Study Evaluating Cocaine Users in Treatment Center|PSYCHOCOKE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|April 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|400|Samples With DNA|-  Hair sampling: cocain and metabolit dosage (last 3 months)        -  Blood sampling : plasmatic DBH activity, polymorphisms of several genes (DBH,D2R, DAT,           COMT)|Both|18 Years|N/A|No|Non-Probability Sample|Lifetime cocaine users|December 2014|December 13, 2014|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01569347||88194|
NCT01569620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-1159|Improving Colorectal Cancer Screening for Diverse Hispanics in Urban Primary Care|Improving Colorectal Cancer (CRC) Screening for Diverse Hispanics in an Urban Primary Care Setting||Icahn School of Medicine at Mount Sinai|No|Completed|April 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|386|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01569620||88173|
NCT01569932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105082|Cognitive Changes in Adult Cancer Survivors|Cognitive and Functional Changes With Chemotherapy in Adult Cancer|CFCC|Washington University School of Medicine|No|Completed|February 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|40 Years|N/A|No|Non-Probability Sample|The final study population will include sixteen adults over the age of 40 years with        newly-diagnosed locally-advanced breast, head and neck, ovarian, primary peritoneal,        bladder , and urethral cancer although up to 25 patients will be approached for enrollment        to account for losses to attrition.|February 2013|February 25, 2013|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01569932||88149|
NCT01569945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML2436 - 1|Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur|||University Hospital, Gasthuisberg|No|Completed|September 2004|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|371|||Female|18 Years|42 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01569945||88148|
NCT01595893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Graz 24-220 ex 11/12|Vitamin D Supplementation in Polymorphic Light Eruption|Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial|VitD-PLE_2012|Medical University of Graz|No|Recruiting|April 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|75 Years|No|||July 2014|July 22, 2014|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01595893||86169|
NCT01592136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-12-901|Expanded Access Program of Ponatinib|Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia||Ariad Pharmaceuticals||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||January 2013|March 12, 2013|May 3, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01592136||86457|
NCT01592162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/34|Comparison of Different Propofol Formulations With or Without Remifentanil|Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Remifentanil|PropofolRemi|Hopital Foch|No|Recruiting|May 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Anticipated|360|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01592162||86455|
NCT01592175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-49|Magnetoencephalography (MEG), Attention and Conscience|Spatio-temporal Dynamic of the Relationship Between Spatial Attention and Visual Awareness||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|March 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|8|||Both|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Young adults living in Paris or around fulfilling the eligibility criteria|May 2012|May 3, 2012|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01592175||86454|
NCT01592110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZX003-1101|A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia|A Pilot, Open-Label, Non-Randomized, Single Ascending Dose, Safety and Pharmacokinetic Trial With Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder||Zogenix, Inc.|Yes|Completed|July 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|N/A|No|||July 2013|July 23, 2013|May 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01592110||86459|
NCT01592123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MG-ATA-001|Effects of Nasal Septal Surgery on Sleep Quality, Daytime and Dream Anxiety|Evaluation of Benefits of Nasal Septal Surgery on Subjective Sleep Quality, Daytime and Dream Anxiety||Ataturk Training and Research Hospital|No|Completed|October 2010|April 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|68|||Both|18 Years|65 Years|No|Probability Sample|Otorhinolaryngology outpatient clinic|May 2012|May 3, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01592123||86458|
NCT01592695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N32-FY12Q1-S1-P00005|Tailored Tobacco Quitline for Rural Veterans|Tailored Tobacco Cessation Program for Rural Veterans With Comorbid Depression, Alcoholism or Obesity||University of Iowa|No|Enrolling by invitation|June 2012|March 2013|Anticipated|September 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 12, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01592695||86415|
NCT01592708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0622|Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery|A Prospective Evaluation of an Anesthesia Protocol to Reduce Post-operative and Post-discharge Nausea and Vomiting in a High Risk Orthognathic Surgery Population||University of North Carolina, Chapel Hill|No|Completed|June 2012|April 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|233|||Both|15 Years|N/A|No|||June 2014|August 15, 2014|April 16, 2012|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01592708||86414|
NCT01592721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 11-47|Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma|Safety and Efficacy of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma||The University of Texas Health Science Center at San Antonio|Yes|Active, not recruiting|April 2013|November 2024|Anticipated|January 2024|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592721||86413|
NCT01592994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21MH085312|Enhancing HIV Risk Reduction Among Indian Women With Risky Husbands|Enhancing HIV Risk Reduction Among Indian Women With Risky Husbands|RHANI Wives|University of California, San Diego|No|Completed|July 2010|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|220|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592994||86392|
NCT01593228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTS12674|Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial|International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study||Sanofi|No|Active, not recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593228||86374|
NCT01593241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAKK 01/10|Therapy De-escalation in Seminoma Stage IIA/B|Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma||Swiss Group for Clinical Cancer Research|No|Recruiting|May 2012|June 2037|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|115|||Male|18 Years|N/A|No|||October 2015|October 8, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01593241||86373|
NCT01593254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-399|Open Label, Randomized Phase 2b Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who do Not Have Favorable Imatinib Response (DASCERN)|An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib||Bristol-Myers Squibb|Yes|Recruiting|September 2012|January 2022|Anticipated|January 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|258|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|May 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593254||86372|
NCT01594047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|metadone|Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone|Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|No|Recruiting|December 2009|August 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|75 Years|No|||May 2012|May 15, 2012|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01594047||86311|
NCT01594346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT00056329|Multicenter Vitamin E Trial in Aging Persons With Down Syndrome|||New York State Institute for Basic Research|Yes|Completed|September 2000|April 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|349|||Both|50 Years|N/A|No|||May 2012|May 8, 2012|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01594346||86288|
NCT01593774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUMS-9277|Melatonin for Prevention of Metabolic Side Effects of Olanzapine|Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.||Guilan University of Medical Sciences|Yes|Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|36|||Both|18 Years|65 Years|No|||April 2013|April 8, 2013|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01593774||86332|
NCT01594359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project #8209|Nutrition Study of Effect of High Iron Beans on Iron Status|Efficacy of Iron Biofortified Beans in Improving the Iron Status of Rwandan Adolescent Girls: A Randomized Control Trial||Swiss Federal Institute of Technology|No|Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|300|||Female|12 Years|N/A|No|||November 2015|November 30, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01594359||86287|
NCT01566435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202113|Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer|Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)||Washington University School of Medicine|No|Active, not recruiting|August 2012|October 2023|Anticipated|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|March 27, 2012|Yes|Yes||No|September 8, 2015|https://clinicaltrials.gov/show/NCT01566435||88417|
NCT01566734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1128-4677|Effect of Cefazolin and Normal Saline Irrigation on Surgical Site Infections (SSIs)|Comparison of the Effect of Cefazolin and Normal Saline Irrigation With no Irrigation on the Incidence of Surgical Site Infections||Hormozgan University of Medical Sciences|Yes|Completed|December 2010|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|200|||Female|N/A|N/A|No|||October 2012|October 12, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01566734||88394|
NCT01566760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0221069|A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers|Open-Label, Single-Dose, Randomized, Crossover Study To Estimate The Effects Of Food On The Pharmacokinetics Of Two Fesoterodine Sustained-Release Beads-In-Capsule Formulations And To Estimate The Relative Bioavailability Of One Or Both Formulations Compared To Commercial Tablet Formulation In Healthy Adult Volunteers||Pfizer|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|24|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 24, 2012|March 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01566760||88392|
NCT01567007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WOMENPED|Change in Physical Activity Levels in Women at Working Place|Impact of Different Interventions in Physical Activity Level and Co-morbidities in Women: Randomized, Controlled Study||University of Sao Paulo General Hospital|Yes|Active, not recruiting|March 2011|August 2012|Anticipated|April 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|195|||Female|40 Years|50 Years|Accepts Healthy Volunteers|||March 2012|March 27, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01567007||88373|
NCT01568203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101275|First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia|Phase I, Randomized, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 579 in Healthy Adult Subjects and Patients With Stable Schizophrenia or Schizoaffective Disorder||Amgen|No|Terminated|September 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|50|||Both|18 Years|60 Years|No|||October 2012|October 5, 2012|February 27, 2012|No|Yes|Amgen decision (business)|No||https://clinicaltrials.gov/show/NCT01568203||88282|
NCT01573481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI11 - Dr ANDREJAK Mlle|Comparison of Two Ventilator Mode During the Night: New Strategy of Mechanical Ventilation Weaning|Pressure Controlled Ventilation Versus Pressure Support Ventilation During the Night: New Strategy of Mechanical Ventilation Weaning?||Centre Hospitalier Universitaire, Amiens|No|Recruiting|January 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2011|April 5, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01573481||87878|
NCT01569633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ft2011ep|Use of Prokinetics in Early Enteral Feeding in Preterm Infants|Pilot Study for Use of Prokinetics in Early Enteral Feeding of Preterm Infants ; Double Blind; Cross Over Study Comparing Eryththromycin, Metoclopramide and Placebo||East Tennessee State University|Yes|Terminated|October 2011|December 2015|Anticipated|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|3|||Both|N/A|14 Days|No|||February 2015|February 13, 2015|March 30, 2012||No|very poor enrollment|No||https://clinicaltrials.gov/show/NCT01569633||88172|
NCT01570153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000312|Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial|Biomarkers Plus Bioimpedance Vector Analysis to Predict Cardiorenal Syndrome Onset and Prognosis in Patients With Acutely Decompensated Heart Failure: Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial|BIONICS-HF|Massachusetts General Hospital|Yes|Completed|March 2012|November 2013|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|10 ml sample of blood will be draw into a tube containing ethylenediaminetetraacetic acid,      spun for 15 minutes, and aliquoted to freezer tubes for biomarker measurement following the      completition of the trial|Both|18 Years|N/A|No|Probability Sample|Patients presenting to the Emergency Department of the Massachusetts General Hospital with        complaints compatible with Acute Decompensated Heart Failure (ADHF)|March 2014|March 21, 2014|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01570153||88132|
NCT01570452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|andreapolistena1|Matrilysin Expression in Different Stages of Colorectal Tumors|Matrilysin Expression in Different Stages of Colorectal Tumors|MMP7|University of Roma La Sapienza|No|Completed|September 2005|February 2012|Actual|September 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|38|Samples With DNA|normal mucosa, cancer tissue, lymph nodes and serum from cancer patients serum from healty      volunteers|Both|40 Years|83 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients affected by colorectal neoplasm admitted to our department of surgery|March 2012|April 3, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01570452||88109|
NCT01570179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005504-14|Sugammadex-dosing in Bariatric Patients|Sugammadex in Patients Undergoing Bariatric Surgery: An Equivalence Trial Comparing Real and Ideal Body Weight-based Dosing|SugReBaCh-1|Central Hospital, Nancy, France|Yes|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|34|||Both|18 Years|N/A|No|||January 2013|January 23, 2013|March 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01570179||88130|
NCT01592149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16235|Survey of Prevalence of Loss of Appetite in Subject With Health Disorders|Survey of Prevalence of Loss of Appetite in Subject With Health Disorders.|SPLASH|Bayer|No|Completed|May 2012|January 2015|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|16629|||Both|18 Years|N/A|No|Probability Sample|Patient with various health related disoder|February 2015|February 10, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01592149||86456|
NCT01592760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0805|Air-Q® SP Versus Air-Q® and I-gel|Comparison of the Air-Q® Self-Pressurizing (SP) Intubating Laryngeal Airway With the Air-Q® Intubating Laryngeal Airway and I-gel for Airway Maintenance in Adults Under General Anesthesia||University of Wisconsin, Madison|No|Completed|May 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|225|||Both|18 Years|N/A|No|||December 2014|September 30, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01592760||86410|
NCT01592435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8H9323|Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol|Carestream Digital Radiography Long Length Imaging Manual Stitch Editor Software Data Collection|LLI-MSE|Carestream Health, Inc.|No|Completed|April 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|75|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prospective enrollment from the diagnostic schedule|March 2013|March 25, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592435||86434|
NCT01592448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|McNeil-7247|Investigation of Efficacy of Improved Acetaminophen Labeling|Consumer Understanding and Use of Non-Prescription Analgesics, Investigation of Efficacy of Improved Acetaminophen Labeling||Northwestern University|Yes|Completed|October 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|662|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Two types of practices - an academic general medicine clinic and the other a community        health center - will serve as performance sites.|November 2014|November 17, 2014|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01592448||86433|
NCT01592734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEG-P1|Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children|Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children. A Controlled Double Blind Randomized Study vs a Standard PEG-EL Laxative||Azienda Policlinico Umberto I|Yes|Completed|May 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|2 Years|16 Years|No|||May 2012|May 4, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01592734||86412|
NCT01592747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEM-MD-68|Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine|A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine||Forest Laboratories|No|Completed|September 2012|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|480|||Both|6 Years|12 Years|No|||October 2013|October 31, 2013|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592747||86411|
NCT01593501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC #2011-0547|How Does Magnesium Status Influence Calcium Homeostasis?|How Does Magnesium Status Influence Calcium Homeostasis?||University of Wisconsin, Madison|Yes|Active, not recruiting|May 2012|April 2016|Anticipated|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Female|30 Years|75 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01593501||86353|
NCT01593514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVG 2012/02|Understanding the Immune Response to Two Different Meningitis Vaccines|A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine||University of Oxford|No|Completed|December 2012|||April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|20|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 6, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01593514||86352|
NCT01593787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A1304|Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction|A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction||Novartis|Yes|Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|20 Years|N/A|No|||August 2015|August 7, 2015|April 30, 2012||No||No|July 8, 2015|https://clinicaltrials.gov/show/NCT01593787||86331|
NCT01594034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-2009-0176-H|Effects of Hemoperitoneum Driven Carbon Monoxide on Post-Traumatic Stability and Platelet Aggregation|Effects of Hemoperitoneum Driven Carbon Monoxide on Post-Traumatic Stability||The University of Texas Health Science Center at San Antonio|No|Completed|November 2009|May 2011|Actual|May 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|9|||Female|18 Years|N/A|No|Probability Sample|patients in the ICU on a ventilator|May 2012|May 11, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01594034||86312|
NCT01587001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22219201|The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis|The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis||National Jewish Health|Yes|Completed|November 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|January 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587001||86849|
NCT01594593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110353|Acceptance-Based Treatment for Prostate Cancer Distress|Pilot Study of an Acceptance and Commitment Therapy Workshop for Distress and Decision Making in Early Stage Prostate Cancer in Veterans||Veterans Medical Research Foundation|No|Completed|March 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|24|||Male|18 Years|80 Years|No|||November 2012|November 16, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01594593||86269|
NCT01587248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1519-Sur-ERC-10|Use of Harmonic in Breast Surgery|Harmonic Scalpel vs. Electrocautery Dissection in Modified Radical Mastectomy: A Randomized Controlled Trial|HMRM|Aga Khan University|No|Completed|March 2010|August 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|152|||Female|16 Years|80 Years|No|||April 2012|April 26, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01587248||86830|
NCT01566227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:012|Within-subject Comparison of Mandibular Overdentures Retained by 1,2,or 3 Implants|Within-subject Comparison of Mandibular Overdentures Retained by 1,2,or 3 Implants||University of Manitoba|No|Recruiting|February 2012|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Both|25 Years|N/A|No|||March 2012|March 26, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01566227||88433|
NCT01567605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011s0593|Bowel Care and Cardiovascular Function After Spinal Cord Injury|Bowel Care and Cardiovascular Function After Spinal Cord Injury||Simon Fraser University|No|Recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|13|||Both|19 Years|80 Years|No|||June 2015|June 12, 2015|March 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567605||88328|
NCT01567618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAHMO-04|Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer|A Phase II Trial Evaluating Biweekly Docetaxel and DeGramont Regimen in First-Line Treatment of Unresectable or Metastatic Gastric Adenocarcinoma (DaeMon)|DaeMon|Sixth Affiliated Hospital, Sun Yat-sen University|Yes|Completed|March 2012|April 2014|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|80 Years|No|||November 2014|November 6, 2014|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01567618||88327|
NCT01568216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101299|20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms|"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"||Amgen|No|Terminated|May 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|121|||Both|18 Years|60 Years|No|||July 2015|July 8, 2015|February 27, 2012|Yes|Yes|Toxic Epidermal Necrolysis|No||https://clinicaltrials.gov/show/NCT01568216||88281|
NCT01567878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1649/09|Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects|Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects||University of Sao Paulo|No|Completed|May 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|N/A||2|Actual|80|Samples With DNA|Blood sample|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with ankylosing spondylitis healthy subjects|December 2014|December 1, 2014|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567878||88307|
NCT01568177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22264|Cardiac Autonomic Function in Women With Microvascular Coronary Dysfunction|Cardiac Autonomic Function in Women With Microvascular Coronary Dysfunction||Cedars-Sinai Medical Center|No|Recruiting|February 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|60|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568177||88284|
NCT01573988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010.612/16|Satiety, Meal Frequency and Nutritional Aspects|Behavioural and Metabolic Consequences of Increasing Eating Frequency|SAFRAN|Hospices Civils de Lyon|No|Terminated|August 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|37|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|April 4, 2012||No|Difficulties in recruiting of volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2|No||https://clinicaltrials.gov/show/NCT01573988||87839|
NCT01573507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|237/10|Lactate Therapy After Traumatic Brain Injury|Neuroprotective Role of Lactate Therapy in Humans With Traumatic Brain Injury|LS_TCC|Centre Hospitalier Universitaire Vaudois|Yes|Recruiting|March 2012|March 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01573507||87876|
NCT01573728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111007450|Role of Exercise in Depression in Middle Aged and Older Adults|Role of Exercise in Depression Among Middle Aged and Older Adults|RED|Indiana University|Yes|Enrolling by invitation|May 2012|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|60|||Both|46 Years|N/A|No|||March 2015|March 23, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573728||87859|
NCT01573975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB097-76|Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori|Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori||Buddhist Tzu Chi General Hospital|Yes|Completed|January 2009|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|345|||Both|20 Years|95 Years|No|||April 2012|April 9, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01573975||87840|
NCT01574248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000626|Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema|Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial||Vanderbilt University|Yes|Terminated|August 2011|December 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|80 Years|No|||December 2015|December 16, 2015|December 14, 2011|Yes|Yes|DSMC recommended discontinuation for futility and feasibility|No||https://clinicaltrials.gov/show/NCT01574248||87819|
NCT01596244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WDF07-231|Jordan Diabetes Microclinic Project|Pilot and Expansion Project for the Jordan Diabetes Microclinic Project||Microclinic International|No|Completed|April 2008|August 2012|Actual|April 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 7, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596244||86142|
NCT01585493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Change|CHANGE -it is About Life|CHANGE.A Randomized Clinical Trial of Health Promoting Programme Versus Standard Treatment for Patients With Schizophrenia||Mental Health Services in the Capital Region, Denmark|No|Active, not recruiting|December 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|430|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01585493||86963|
NCT01593007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tese02|Inspiratory Muscular Training|REGIONAL LUNG VENTILATION DISTRIBUTION AMONG INDIVIDUALS WITH CHRONIC HEART FAILURE AFTER AN INSPIRATORY MUSCLE TRAINING PROGRAMM: A RANDOMIZED CONTROLLED CLINICAL TRIAL||Universidade Federal de Pernambuco|Yes|Completed|June 2010|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|21 Years|65 Years|No|||October 2011|June 12, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01593007||86391|
NCT01593267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02BN090|Barrow Ruptured Aneurysm Trial|Barrow Ruptured Aneurysm Study|BRAT|St. Joseph's Hospital and Medical Center, Phoenix|No|Active, not recruiting|November 2002|March 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|80 Years|No|||October 2015|October 8, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01593267||86371|
NCT01586000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCN012|A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women|A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women||Health Decisions||Completed|March 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|197|||Female|18 Years|39 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586000||86925|
NCT01586247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07/47|The Effect of a Prebiotic, Probiotic and Synbiotic on the Gut Microbiota and Immune Response of Older Volunteers (GOS)|A Double-blind, Placebo-controlled, Randomized Crossover Study of a Prebiotic (Galacto-oligosaccharides, GOS), Probiotic (B.Lactis, BI07) and Synbiotic (GOS + BI07) on the Gut Microbiota and Immune Response of Older Volunteers||University of Reading|No|Completed|March 2008|October 2009|Actual|October 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|40|||Both|60 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 26, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01586247||86907|
NCT01586741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/227-31/3/PE/96|A Study to Evaluate Two Different Surgical Methods for Treatment for Abdominal Wall Diastasis|A Prospective Randomized Study to Evaluate Two Different Surgical Methods for Treatment for Abdominal Wall Diastasis||Karolinska Institutet|No|Active, not recruiting|December 2009|December 2012|Anticipated|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|96|||Both|18 Years|65 Years|No|||April 2012|April 25, 2012|November 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01586741||86869|
NCT01587014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-001|Safety and Feasibility of Prima-Temp Thermometer Patch|Safety and Feasibility of Prima-Temp Thermometer Patch in Determining Baseline Temperatures of Research Subjects in a Hospital Intensive Care Unit (ICU)|Prima-Temp|Poudre Valley Health System|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in hospital intensive care unit (ICU).|February 2014|March 17, 2014|March 1, 2012|Yes|Yes||No|March 17, 2014|https://clinicaltrials.gov/show/NCT01587014||86848|
NCT01587547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK005|Amino Acid Profiling of Spent Culture Medium|Amino Acid Profiling of Spent Culture Medium to Retrospectively Determine Individual Embryo Selection Criteria for Improved Clinical IVF Outcome|EmbryoSure|Origio A/S|Yes|Terminated|April 2012|April 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|10|Samples Without DNA|Spent culture medium from the individual embryos|Female|18 Years|40 Years|No|Non-Probability Sample|Subjects will be recruited from couples and single women attending the IVF clinic for        IVF/ICSI treatment.|May 2013|May 7, 2013|April 26, 2012||No|ORIGIO a/s acquired by Cooper Surgical Inc. who decided to withdraw from the project|No||https://clinicaltrials.gov/show/NCT01587547||86807|
NCT01567891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADP-0011-001|CT Antigen TCR-redirected T Cells for Ovarian Cancer.|A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.||Adaptimmune|Yes|Recruiting|June 2013|January 2019|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||February 2016|February 29, 2016|March 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567891||88306|
NCT01568229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110165|20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms||Amgen|No|Terminated|May 2012|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|111|||Both|18 Years|60 Years|No|||September 2014|September 19, 2014|February 28, 2012|Yes|Yes|Toxic Epidermal Necrolysis|No||https://clinicaltrials.gov/show/NCT01568229||88280|
NCT01568242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APEC-VitTemp|Changes in Vitreous Temperature During Phacoemulsification|Changes in Vitreous Temperature During Phacoemulsification||Asociación para Evitar la Ceguera en México|Yes|Recruiting|February 2012|March 2012|Anticipated|March 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|N/A|N/A|No|||March 2012|March 29, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01568242||88279|
NCT01568853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK2010-017-1|A Prospective Study of The Complement Depletion in Patients With Severe Abdominal Sepsis|The Complement C3 Depletion in Patients With Severe Abdominal Sepsis: Risk Prediction and the Association With Down-regulated Adaptive Immunity||Jinling Hospital, China|Yes|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|75|||Both|18 Years|60 Years|No|||April 2012|April 5, 2012|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568853||88232|
NCT01568554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC7204|Clinical Diagnosis of Acute Porphyria|Clinical Diagnosis of Acute Porphyria||University of California, San Francisco|Yes|Recruiting|December 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|600|||Both|15 Years|N/A|No|Non-Probability Sample|Group 1:        Individuals who are first-degree relatives of a patient with one of the acute porphyrias        (AIP, HCP, VP). They will complete questionnaires and laboratory tests, including genetic        testing for porphyria. The data will be used to develop a clinical profile for the risk        factors associated with the genetic carrier state.        Group 2:        Subjects who possibly have acute porphyria, but do not have a confirmed diagnosis based on        genetic testing. They will serve to test the validity of the clinical index derived from        Group 1.        Group 3:        Patients who have been seen by one of the Porphyria Consortium physicians/investigators 10        or more years ago, but were not given a diagnosis of porphyria. They will complete a        questionnaire to determine whether they received a porphyria diagnosis, or another        diagnosis that might explain the initial presentation.|September 2013|September 23, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01568554||88255|
NCT01569113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2914-015|Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.|A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo.||HRA Pharma|No|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|76|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01569113||88212|
NCT01573754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDA-2604|Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda|A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435||The University of Texas Medical Branch, Galveston|Yes|Recruiting|April 2003|August 2020|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|100 Years|No|||February 2016|February 5, 2016|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573754||87857|
NCT01574209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD5X1000|Gut Peptides and Intestinal Permeability in Celiac Disease and Irritable Bowel Syndrome|Gut Peptides and Intestinal Permeability in Celiac Patients, Healthy Subjects and IBS Patients: a Comparative Study|PPCD|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|No|Completed|April 2012|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Outpatients recruited in IRCCS "S. de Bellis"|November 2012|November 8, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01574209||87822|
NCT01574508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD012|Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy||CAMACS|Shanghai Jiao Tong University School of Medicine||Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|25 Years|65 Years|No|||May 2013|May 3, 2013|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01574508||87799|
NCT01570218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGM-02|Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy|Randomized Clinical Trial Testing Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy.||Universidade Federal de Goias|No|Completed|February 2010|February 2011|Actual|December 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|164|||Both|20 Years|80 Years|No|||April 2012|April 1, 2012|March 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01570218||88127|
NCT01570517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-01|Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System|Evaluation of the DC Devices IASD System in the Treatment of Patients With Heart Failure With Preserved Ejection Fraction||Corvia Medical|No|Completed|May 2012|December 2014|Actual|October 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|85 Years|No|||December 2014|December 9, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01570517||88104|
NCT01592461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-0050|START Follow-up Study|START Follow-up Study (NIDA CTN Protocol 0050)||University of California, Los Angeles|No|Enrolling by invitation|September 2010|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1269|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will include the 1,269 study participants from the original START Study        (CTN-0027) that was conducted from 2006 to 2010 at eight community treatment programs        (CTPs).|December 2014|December 1, 2014|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592461||86432|
NCT01585194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0919|Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma|Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma||M.D. Anderson Cancer Center|No|Recruiting|November 2012|||November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585194||86985|
NCT01586026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAS-11-001|Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters|A Retrospective Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters|DISTAL|C. R. Bard|No|Enrolling by invitation|May 2012|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|100|||Both|21 Years|N/A|No|Non-Probability Sample|All subjects with an implanted Bard port with a distally valved catheter|April 2012|April 27, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586026||86923|
NCT01586260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMTRC 003|Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission|A Phase II Preventative Trial of DFMO as a Single Agent in Patients With High Risk Neuroblastoma in Remission||Spectrum Health Hospitals|Yes|Recruiting|June 2012|June 2020|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|160|||Both|N/A|21 Years|No|||November 2015|November 8, 2015|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586260||86906|
NCT01585766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-IA-MEDI-551-1102|Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis|A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis||MedImmune LLC|Yes|Active, not recruiting|April 2012|July 2016|Anticipated|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|56|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|April 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585766||86943|
NCT01586013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSepulveda_ke0age|the Effect Site Equilibration Time of Propofol is Age Dependant|Importance of Age as Covariable in the Requirements to Determine the Drug Plasma -Site Effect Equilibration Time for TCI Propofol Pharmacokinetic Models|ke0agedep|Universidad del Desarrollo|Yes|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 25, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01586013||86924|
NCT01586754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|34|Subclinical Organ Damage in Overweight and Obese Patients: Does Presence of Metabolic Syndrome Matter?|||Goztepe Training and Research Hospital|No|Active, not recruiting|October 2011|May 2012|Anticipated|April 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|100|Samples Without DNA|Blood will be drawn from patients for routine biochemical analyses for glucose, urea,      creatinine, liver function tests, thyroid function tests, electrolytes and homocysteine and      also glucose tolerance test. Spot urine samples will be drawn for assessment of      microalbuminuria.|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese or overweight patients, aged between 18-80 who are non-smokers, with a GFR > 60        ml/min and without any history of diabetes (insulin dependent or non-insulin dependent),        coronary artery disease or peripheral arterial disease, attending to hyperlipidemia and        obesity outpatient clinic.|April 2012|April 26, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586754||86868|
NCT01583218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-019|Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)|(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients|APEX|Portola Pharmaceuticals|Yes|Active, not recruiting|March 2012|January 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|7500|||Both|40 Years|N/A|No|||October 2015|November 3, 2015|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01583218||87133|
NCT01587053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF8745|Anti Vitamin K Therapeutic Education|Anti Vitamin K Therapeutic Education With INR Self Measure Device Within Children From 0 to 18 Years||University Hospital, Montpellier|Yes|Recruiting|April 2012|April 2016|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|N/A|18 Years|No|Non-Probability Sample|children from 0 to 18 years having AVK prescription|April 2014|April 14, 2014|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01587053||86845|
NCT01583517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011003897|ERCP in Idiopathic Recurrent Acute Pancreatitis|Defining the Role of ERCP in the Evaluation and Treatment of Idiopathic Recurrent Acute Pancreatitis||Indiana University|No|Completed|September 1997|October 2014|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|89|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583517||87110|
NCT01568255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23187|Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms|Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms||Cedars-Sinai Medical Center|No|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 5, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568255||88278|
NCT01568567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP U-11-008|Study to Demonstrate the Safety of a Novel Powder Formulation of Lactobacilli in Adults|To Demonstrate That a Novel Powder Formulation of Lactobacillus Reuteri DSM 17938 is Safe in Adults, a Randomized, Placebo Controlled Double-blind Study|BSSII|Good Food Practice, Sweden|No|Completed|March 2012|June 2012|Actual|June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|32|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01568567||88254|
NCT01572896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000028028|An Internet-based Self-management Program for Adolescents With Arthritis|An Internet-based Self-management Program for Adolescents With Arthritis: A Randomized Controlled Trial||The Hospital for Sick Children|Yes|Recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|294|||Both|12 Years|18 Years|No|||November 2015|November 16, 2015|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572896||87922|
NCT01573182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VADOVAR|Herpes Zoster Vaccine for Bone Marrow Transplant Donors|A Phase II Clinical Trial of Vaccination of Stem Cell Donors With Zostavax to Reduce the Incidence of Herpes Zoster in Transplant Recipients - A Pilot Study|VZV-Zostavax|University of Sydney|No|Recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|10|||Both|50 Years|N/A|No|||December 2015|December 6, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01573182||87900|
NCT01573520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268/09|Treatment Adhesion in Dialysis Patients Treated With Cinacalcet|A Randomized Trial Comparing an Integrated Care Approach Using Electronic Cinacalcet Adherence Data Versus Usual Care to Improve Secondary Hyperparathyroidism in Hemodialysis Patients|MEMS-cinac|Centre Hospitalier Universitaire Vaudois|No|Completed|January 2010|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01573520||87875|
NCT01574001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPIN-01|Smoking Cessation Interventions in Stroke Patients|Comparison of Smoking Cessation Interventions of Different Intensities in Patients With First Ever Ischemic Stroke.||Institute of Psychiatry and Neurology, Warsaw|Yes|Recruiting|April 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|240|||Both|18 Years|80 Years|No|||April 2012|May 14, 2013|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01574001||87838|
NCT01574222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-004-09F|A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer|Intratumoral Genetic Therapy for Lung Cancer|VTNSCLC|VA Office of Research and Development|No|Active, not recruiting|October 2011|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|21 Years|N/A|No|||November 2015|November 18, 2015|March 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01574222||87821|
NCT01574235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEXT|Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents|Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice||Hospira, Inc.|No|Completed|October 2011|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2114|||Both|18 Years|N/A|No|Non-Probability Sample|Patients receiving chemotherapy and treated with Nivestim® to prevent or reduce        chemotherapy-induced febrile neutropenia.|July 2015|July 27, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01574235||87820|
NCT01585233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7163-CL-0107|A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis||Astellas Pharma Inc|No|Completed|April 2012|January 2015|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|75 Years|No|||January 2015|January 19, 2015|April 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585233||86982|
NCT01585506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-4018|Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues|Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues||Novo Nordisk A/S|No|Completed|September 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3618|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians who switched therapy from biphasic human insulins to a biphasic insulin        analogue providing questionnaires for completion to patients whose therapy was switched        from biphasic human insulins to biphasic insulin analogues|April 2012|April 23, 2012|March 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585506||86962|
NCT01585207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0964|Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder|Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder||Icahn School of Medicine at Mount Sinai|Yes|Completed|July 2012|March 2015|Actual|March 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|35 Years|No|||September 2015|September 22, 2015|April 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585207||86984|
NCT01585220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT_PRT_NLF01|Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold|A Randomized, Multi-center, Double Masked, Matched Pairs, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Injection With Neuramis as Compared to Restylane® in Correction of Nasolabial Fold||Medy-Tox|No|Recruiting|February 2012|October 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|69|||Both|30 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585220||86983|
NCT01586533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-201|Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis|A Phase II Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa™ Rectal Gel (Mesalamine Plus N-acetylcysteine) in Subjects With Left-sided Ulcerative Colitis||Altheus Therapeutics, Inc.|Yes|Active, not recruiting|June 2012|||April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|64 Years|No|||January 2014|January 7, 2014|April 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01586533||86885|
NCT01586546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBM 5538|A Pilot Study To Assess Guidance in and Subsequent Use of Mind-Body Techniques on the Quality of Life of Cancer Patients|Quality of Life Outcomes Following Mind-body Skills Training for Cancer Patients That Are Facilitated Either Face-to-face or Online: A Pilot Study||Absenger Cancer Education Foundation|No|Not yet recruiting|May 2012|June 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|32|||Both|18 Years|N/A|No|||April 2012|April 26, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586546||86884|
NCT01586273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|906273|Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases|Magnetic Resonance-guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study||Philips Healthcare|Yes|Recruiting|September 2012|November 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586273||86905|
NCT01586767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-308|Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy|A Phase II Study of Intensity-Modulated or Proton Radiation Therapy for Locally Advanced Sinonasal Malignancy||Massachusetts General Hospital|Yes|Recruiting|July 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|October 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01586767||86867|
NCT01587040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED12414|Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen|International, Multicenter, Open-label, Treatment-extension Study for Subjects Who Completed a Phase 1 or Phase 2 Parental Study to Continue Receiving Treatment With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen||Sanofi|No|Active, not recruiting|July 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|N/A|N/A|No|||October 2015|October 7, 2015|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587040||86846|
NCT01586507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014017|A Study of ULTRAM ER at Two Dose Levels in Adolescents With Pain|A Single Dose Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER at Two Dose Levels in Adolescents Twelve to Seventeen Years Old, Inclusive, With Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2007|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|12 Years|17 Years|No|||August 2012|August 28, 2012|April 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01586507||86887|
NCT01586520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5559|Diagnosing Thyroid Cancer Using a Blood Test|Diagnosing Thyroid Cancer Using a Blood Test||Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Recruiting|April 2011|December 2016|Anticipated|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|400|Samples With DNA|serum, DNA and RNA|Both|18 Years|N/A|No|Non-Probability Sample|400 patients attending the regional thyroid cancer clinic (Northern Centre for Cancer        Care) over 24 months will be recruited.|October 2015|October 7, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586520||86886|
NCT01587066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443L00059|Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression|||Naju National Hospital|No|Withdrawn|August 2010|September 2011|Anticipated|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587066||86844|
NCT01587287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YNKT201101|A Comprehensive Assessment of Anterior Corneal Power by Different Devices|A Comprehensive Assessment of the Precision and Agreement of Anterior Corneal Power Measurements Obtained Using Different Devices||Wenzhou Medical University|Yes|Completed|April 2011|July 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|The present study's definitions of reproducibility, repeatability and agreement were based        on those adopted by the British Standards Institute and the International Organization for        Standardization.        Corneal curvature measurement provides crucial information for calculating intraocular        lens power,screening and managing corneal refractive surgeries and corneal disease.        Volunteers with healthy corneas will be measured by different instruments to detect their        anterior corneal power.Only the right eye of each subject was selected.Measurements were        repeated in the second session scheduled 1 to 2 weeks later, at almost the same time as        the first session, by the same examiner using the same protocol.|January 2011|April 28, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587287||86827|
NCT01572363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML6721|Fontan Patients: Comprehensive Evaluation of Pulmonary Circulation and Ventricular Function|Fontan Patients: Comprehensive Evaluation of the Pulmonary Circulation to Identify Pulmonary Vascular Disease and Its Influence on Ventricular Hemodynamics.||Universitaire Ziekenhuizen Leuven|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|14 Years|N/A|No|||March 2014|March 4, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572363||87963|
NCT01572675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0663-148|A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)|Pharmacoepidemiological Study on the Use of Arcoxia® Under Actual Conditions of Use in France||Merck Sharp & Dohme Corp.|No|Completed|June 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|544|||Both|N/A|N/A|No|Non-Probability Sample|Participants spontaneously consulting a general practitioner or rheumatologist and having        agreed to take part in this study.|April 2015|April 24, 2015|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572675||87939|
NCT01572662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0958|Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning|Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation||M.D. Anderson Cancer Center|Yes|Active, not recruiting|April 2012|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|5 Years|75 Years|No|||December 2015|December 18, 2015|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572662||87940|
NCT01573494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-AOI-04|Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma|Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma.||Centre Hospitalier Universitaire de Nice|No|Completed|May 2012|June 2014|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01573494||87877|
NCT01573741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nju-030614|Study of Ketamine as an Antidepressant in Major Depressive Disorder|Department of AnesthesiologyJinling Hospital, Nanjing University School of Medicine, Nanjing, China||Jinling Hospital, China|Yes|Recruiting|February 2012|February 2013|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|65 Years|No|||April 2012|May 2, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01573741||87858|
NCT01573780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 210811|Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors|A Phase I Study of TL32711 In Combination With Gemcitabine in Patients With Advanced Solid Tumors||Roswell Park Cancer Institute|No|Terminated|April 2012|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|March 13, 2012|No|Yes|Sponsor did not have funds to continue study|No||https://clinicaltrials.gov/show/NCT01573780||87855|
NCT01573793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13852|Promoting Optimal Parenting (Bright Start)|Promoting Optimal Parenting||Seattle Children's Hospital|Yes|Recruiting|April 2012|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|500|||Female|18 Years|23 Years|No|||March 2014|March 24, 2014|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01573793||87854|
NCT01573767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106853|Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children|A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy||GlaxoSmithKline|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|463|||Both|5 Years|11 Years|No|||March 2015|April 2, 2015|March 8, 2012|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01573767||87856|
NCT01574014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|161/07|Glucocorticoid Treatment for Social Phobia|Glucocorticoid Treatment for Social Phobia||University Hospital Inselspital, Berne|No|Terminated|July 2009|April 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|66|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|March 14, 2012||No|Recruiting problems|No||https://clinicaltrials.gov/show/NCT01574014||87837|
NCT01574261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|disfunzionale12|Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial|||Catholic University of the Sacred Heart|Yes|Recruiting|March 2012|||August 2012|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||April 2012|April 9, 2012|April 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574261||87818|
NCT01585519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.22v5|A Study Examining Effects of Apples/ Apple Products on Heart Disease Risk|Effect of Increased Whole Apple Consumption, Apple Extract and Freeze-dried Apple Products on Biomarkers of Cardiovascular Disease Risk: a Randomised Intervention in Participants at Increased Risk of Cardiovascular Disease|APPS|Queen's University, Belfast|Yes|Active, not recruiting|April 2012|December 2016|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 15, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01585519||86961|
NCT01585779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10030481DOC|Contour 3D®/Tri-Ad® Tricuspid Annuloplasty Ring Post-Market Clinical Trial|Contour 3D®/Tri-Ad® Tricuspid Annuloplasty Ring Post-Market Clinical Trial|Contour 3D|Medtronic Cardiovascular|No|Active, not recruiting|May 2012|January 2017|Anticipated|August 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|85 Years|No|Non-Probability Sample|The subject population includes patients indicated for a TV repair procedure concomitant        to left-sided heart surgery, and for which the surgeon considers the implantation of a        Contour 3D® or Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients        with primary TV regurgitation will not be included in this study. Implantation with the        Contour 3D® or Tri-Ad® ring will occur in conjunction with another concomitant surgical        repair procedure|October 2015|October 26, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01585779||86942|
NCT01587027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GQ01 DARPA|Safety Evaluation of Aminophylline and Methazolamide|The Safety Evaluation of Aminophylline and Methazolamide When Administered Orally Alone and in Combination to Healthy Volunteers||Poudre Valley Health System|Yes|Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||May 2014|May 12, 2014|April 16, 2012|Yes|Yes||No|August 7, 2013|https://clinicaltrials.gov/show/NCT01587027||86847|
NCT01586559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IGANT11 392-6/2010-1|Evaluation of the Long-term Stability of Sheath Plication Using Absorbable Sutures in Patients With Diastasis of the Recti Muscles: an Ultrasonography Study|Evaluation of the Long-term Stability of Sheath Plication Using Absorbable Sutures in Patients With Diastasis of the Recti Muscles: an Ultrasonography Study||Bulovka Hospital||Completed|October 2010|April 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|65|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Patients with interval after rectus sheath plication|April 2012|April 26, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586559||86883|
NCT01587261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRA2012|Vitamin C for Severe Thermal Injuries|Prospective Placebo-Controlled Double-Blinded Trial for High-Dose Vitamin C Administration During the Acute Resuscitative Phase of Severe Thermal Injuries||University of Texas Southwestern Medical Center|Yes|Not yet recruiting|June 2017|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|65 Years|No|||January 2016|January 12, 2016|April 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01587261||86829|
NCT01587274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low Back Pain RCT|A Randomized Study of Three Medication Regimens for Acute Low Back Pain|A Randomized Three-armed Comparative Effectiveness Study of Various Medications for Musculoskeletal Low Back Pain: Defining the Added Benefit of Muscle Relaxants and Opioids.||Montefiore Medical Center|Yes|Active, not recruiting|April 2012|January 2015|Anticipated|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|323|||Both|21 Years|64 Years|No|||October 2014|October 9, 2014|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587274||86828|
NCT01587300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2004-05|Neuroblastoma Biology Study|N2004-05: Neuroblastoma Biology Study||New Approaches to Neuroblastoma Therapy Consortium|Yes|Recruiting|July 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|The biospecimen includes blood and bone marrow and their derivatives (e.g., DNA, RNA,      plasma, lymphocytes) as well as tumors.|Both|N/A|99 Years|No|Non-Probability Sample|Neuroblastoma patients from various NANT sites.|December 2015|December 11, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587300||86826|
NCT01583244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-300|Korean Post-marketing Surveillance for Orencia®|Korean Post-marketing Surveillance for Orencia®||Bristol-Myers Squibb|No|Completed|March 2010|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|701|||Both|N/A|N/A|No|Non-Probability Sample|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis|March 2016|March 8, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583244||87131|
NCT01572688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG0276|Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma|A Multicenter, Single Arm, Open Label Study of Autologous Stem Cell Transplantation With High Dose Melphalan in Patients With Multiple Myeloma|MM|Shandong Lanjin Pharmaceuticals Co.,Ltd|Yes|Recruiting|November 2011|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|65 Years|No|||April 2012|August 1, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572688||87938|
NCT01572909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPIRI-201|Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction|EMBRACE|Stealth BioTherapeutics Inc.|Yes|Completed|April 2012|February 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|300|||Both|18 Years|85 Years|No|||November 2015|November 11, 2015|March 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572909||87921|
NCT01572415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-MK01|Evaluation of SCOUT DS Device in the Diagnosis of Diabetes Mellitus|Evaluation of SCOUT DS Device in the Diagnosis of Diabetes Mellitus||VeraLight, Inc.|No|Completed|September 2011|March 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|409|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects must be 18 years of age or greater.|December 2012|December 3, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01572415||87959|
NCT01573195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0168 (MSN141105)|Merck IISP Stewardship Grant for Antibiotic Best Practices|Implementation of Antimicrobial Stewardship and Decision Support Into the EPIC Electronic Medical Record||University of Wisconsin, Madison|No|Completed|March 2011|April 2012|Actual|April 2012|Actual|Phase 4|Observational|Time Perspective: Retrospective||1|Actual|1285|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|1285 consecutive patients issued BPA for de-escalation of antibiotics in EPIC|December 2014|December 16, 2014|May 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01573195||87899|
NCT01573208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HO 278/10|Custom Guides for Total Knee Arthroplasty (TKA)|Prospective Cohort of FIRST TKA With Custom Guides||University of Lausanne Hospitals||Recruiting|February 2011|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||June 2015|June 3, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01573208||87898|
NCT01573221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GiroudPHRCN2010|Stroke and PMSI (Medicalisation Information Systems Programm)|Stroke and PMSI Evaluation of the Sensitivity and Specificity||Centre Hospitalier Universitaire Dijon|No|Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A|No|Probability Sample|hospitalized stroke|January 2013|January 4, 2013|April 4, 2012||||No||https://clinicaltrials.gov/show/NCT01573221||87897|
NCT01572922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDAS|Massive Iron Deposit Assessment|Massive Iron Deposit Assessment||St. Jude Children's Research Hospital|No|Recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|235|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2016|January 13, 2016|April 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572922||87920|
NCT01573234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AISLeC-003|Efficacy of MySkin Patch for the Healing of Cut Injuries and Abrasions|Efficacy of MySkin Patch for the Healing of Cut Injuries and Abrasions: a Randomised Controlled Trial||Associazione Infermieristica per lo studio delle Lesioni Cutanee|Yes|Completed|April 2012|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01573234||87896|
NCT01573247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKN001|Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia|A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients With Acute Myelogenous Leukemia (AML)||Akinion Pharmaceuticals AB|Yes|Terminated|December 2011|March 2016|Actual|March 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|March 28, 2012||No|During the study two patients have experienced serious liver events related to AKN-028. The    risk-benefit balance was judged to be negative.|No||https://clinicaltrials.gov/show/NCT01573247||87895|
NCT01566357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029/UZS|Impact of Milk on Erosion/Abrasion of Enamel and Dentin - an in Situ Study|Impact of Milk and Casein Phosphopeptide-amorphous Calcium Phosphate on Erosion/Abrasion of Enamel and Dentin - an in Situ Study||University of Zurich|No|Completed|January 2012|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|7||Actual|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 17, 2013|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566357||88423|
NCT01574027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01CA122299|Efficacy of Vitamin D in Colorectal Cancer Chemoprevention|||University of Illinois at Chicago||Completed|April 2008|October 2011|Actual|October 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|55|||Both|50 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 5, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01574027||87836|
NCT01566630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030A2205|Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia|An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia||Novartis||Terminated|May 2013|August 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|40 Years|No|||October 2015|October 12, 2015|March 27, 2012|Yes|Yes|Novartis terminated this study due to internal, strategic decisions.|No|August 6, 2015|https://clinicaltrials.gov/show/NCT01566630||88402|
NCT01574274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001|SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma|Randomized Study of Intravenous Calaspargase Pegol (SC-PEG Asparaginase) and Intravenous Oncaspar in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|April 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|365 Days|21 Years|No|||February 2016|February 12, 2016|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01574274||87817|
NCT01570205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDD-1002-024|Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers|The Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Male Volunteers in a Randomized, Double Blind, Placebo Controlled, Dose Escalating Phase I Study||Xigen SA|No|Completed|July 2011|February 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|24|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 3, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01570205||88128|
NCT01585818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SICS-10/1/2/002|Dietary Intervention in Diabetes Mellitus (DIDM)- Intermediate and Acute Effects|Nutrition Studies and Dietary Intervention in Individuals With Type 2 Diabetes Mellitus of Chinese, Malay and Indian Ethnicity|DIDM|National University Hospital, Singapore|No|Recruiting|August 2011|August 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|45 Years|64 Years|No|||January 2014|January 15, 2014|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01585818||86939|
NCT01585792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875/CPH-030|Double Blind Comparative Study of TAK-875|||Takeda||Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Primary Purpose: Treatment|4||Actual|80|||Both|20 Years|N/A||||April 2013|April 15, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585792||86941|
NCT01585805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00864|Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)||National Cancer Institute (NCI)|Yes|Recruiting|April 2012|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|107|||Both|19 Years|N/A|No|||January 2016|January 27, 2016|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585805||86940|
NCT01586039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-002834|Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep|Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep.||Brigham and Women's Hospital|No|Completed|August 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|36|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||August 2014|August 8, 2014|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586039||86922|
NCT01586052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPEPOPhase1|Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1|A Phase 1 Clinical Research of Erythropoietin Therapy for Children With Cerebral Palsy: Safety and Efficacy||Bundang CHA Hospital|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|6 Months|3 Years|No|||April 2014|April 7, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586052||86921|
NCT01586312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TerCel004|Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells|Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Mesenchymal Stromal Cells From Valladolid|MSV_allo|Red de Terapia Celular|Yes|Completed|April 2012|June 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||September 2015|September 26, 2015|April 23, 2012||No||No|September 24, 2014|https://clinicaltrials.gov/show/NCT01586312||86902|
NCT01586286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111573|A Study Examining the Use of Vaginal Nifedipine With Pelvic Floor Physical Therapy for Levator Myalgia and Pelvic Pain|Does Adjunctive Treatment With Vaginal Nifedipine Result in Symptomatic Improvement in Patients With Levator Myalgia and Pelvic Floor Pain Who Are Undergoing Pelvic Floor Physical Therapy?||Vanderbilt University|No|Withdrawn|July 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||May 2014|May 21, 2014|April 20, 2012|Yes|Yes|No patients were recruited over a 12 month period|No||https://clinicaltrials.gov/show/NCT01586286||86904|
NCT01586299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-11-RMC|NSAIDs Treatment in Children With Pleuropneumonia|The Role of Non Steroidal Anti Inflammatory Drugs in the Treatment of Pleuropneumonia in Children. a Randomized Controlled Trial||Rabin Medical Center|No|Recruiting|March 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|18 Years|No|||January 2012|November 13, 2014|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586299||86903|
NCT01586793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rTMS-ERB12/05-2012|Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar Depression|A Randomized Trial Comparing the Effectiveness and Tolerability of High and Low Frequency Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar Depression: An Exploratory Study||Douglas Mental Health University Institute|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|70 Years|No|||May 2015|May 26, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586793||86865|
NCT01586780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 1.556/2008|Metabolic Effects of a Pre-meal Protein Drink With or Without Added Amino Acids at a Subsequent Composite Meal|Effects of Pre-meal Drinks With Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite Meal||Lund University|No|Completed|August 2009|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|7||Actual|14|||Both|20 Years|28 Years|Accepts Healthy Volunteers|||April 2012|April 25, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586780||86866|
NCT01587313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR06.004|A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers|A Four-arm, Single Dose, Two-Period, Pharmacokinetic Study of BiDil SR and IR Capsules and Commercial BiDil Tablets||Arbor Pharmaceuticals, Inc.|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|36|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|April 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01587313||86825|
NCT01587326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAFH-101-05|The Effects of Escitalopram on Cytokines|The Effects of Escitalopram on Cytokines in Depressive Patients|BAFH|Beitou Armed Forces Hospital, Taipei, Taiwan|Yes|Recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|20 Years|65 Years|No|||May 2012|May 13, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587326||86824|
NCT01583257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDHA-AVG2012|Pilot Study: Active Video Gaming to Facilitate Physical Activity and Quality of Life in Kidney Transplant Recipients|Pilot Study: Active Video Gaming to Facilitate Physical Activity and Quality of Life in Kidney Transplant Recipients||Nova Scotia Health Authority|No|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment|1||Anticipated|10|||Both|N/A|N/A|No|||May 2015|May 14, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583257||87130|
NCT01572428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1012-17|Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon|Randomized Controlled Trial Comparing the Use of Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon||Indiana University|No|Active, not recruiting|April 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|950|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|July 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01572428||87958|
NCT01572701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-TcTx-P104|Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection|A Phase 1 Pilot Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection (PLND)||Molecular Insight Pharmaceuticals, Inc.|No|Completed|January 2012|||June 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|8|||Male|21 Years|N/A|No|||November 2015|November 23, 2015|December 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572701||87937|
NCT01572935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2011-N-50|Body Weight Assessment in Swiss Primary School Children: Trend Analysis Over 10 Years|Body Weight Assessment in Swiss Primary School Children: Trend Analysis Over 10 Years||Swiss Federal Institute of Technology|No|Completed|February 2012|September 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|2979|||Both|6 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|3 classrooms each from 60 randomly selected schools|September 2012|September 18, 2012|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01572935||87919|
NCT01573260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEN-11-261|Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease.|Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease: A Randomized Control Study.||McGill University Health Center|Yes|Completed|April 2012|April 2014|Actual|April 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|April 5, 2012||No||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01573260||87894|This was a relatively small study, and many of our negative results could be related to inadequate power. The higher baseline activity rate in the controls may have affected responsiveness to change.
NCT01566903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01258-33|Neurovascular Non Contrast-Enhanced MR Angiography at 3T|Morphological and Dynamic Non Contrast-enhanced MR Angiography in the Exploration of Neurovascular Diseases|NCE MRA|Rennes University Hospital||Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with neurovascular diseases|October 2015|October 29, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01566903||88381|
NCT01566643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCRD100-16|Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections|Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections||Buddhist Tzu Chi General Hospital|Yes|Recruiting|January 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|231|||Both|20 Years|85 Years|No|||April 2012|April 4, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566643||88401|
NCT01566890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DD2011101|Microvascular Blood Flow in Sickle Cell Anemia|Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia||Blood Center of Wisconsin|Yes|Recruiting|July 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|March 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566890||88382|
NCT01567176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.674|Circulating SIRT6 Expression, Effect on Aging Quality|Circulating Expression Measurement of a Sirtuin Protein Isoform, Sirt6, as an Early Marker of Aging Quality|Sirt6|Hospices Civils de Lyon|No|Completed|March 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|60|||Both|60 Years|N/A|Accepts Healthy Volunteers|||February 2012|January 17, 2013|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01567176||88360|
NCT01585285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUM-11-233|Coronary Artery Bypass Grafting Strategies for the Anterolateral Territory: a Prospective Randomized Clinical Trial|Composite Arterial and Venous Grafting Strategy Versus Conventional Coronary Artery Bypass Grafting for the Anterolateral Territory: a Prospective Randomized Clinical Trial|AMI-PONT|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Recruiting|July 2012|June 2028|Anticipated|June 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585285||86978|
NCT01585558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-50310X|Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus|Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310.||Shionogi Inc.||Completed|May 2006|September 2008|Actual|||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Female|40 Years|80 Years|No|||March 2013|May 21, 2013|April 18, 2012|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01585558||86958|
NCT01585831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0874|Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome|Psychological and Motor Effects of Testosterone Therapy in Adolescents With XXY/Klinefelter Syndrome|TestoXXY/KS|University of Colorado, Denver|Yes|Recruiting|March 2012|February 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Male|8 Years|18 Years|No|||December 2015|December 9, 2015|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585831||86938|
NCT01586065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R03HD067329-01A1|Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes|Use of CGM in Adolescents With Poorly-controlled Type 1 Diabetes||Nemours Children's Clinic|No|Completed|February 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|26|||Both|12 Years|18 Years|No|||September 2014|September 25, 2014|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586065||86920|
NCT01586325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100718|A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients|A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens||Janssen R&D Ireland|No|Recruiting|May 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|70 Years|No|||July 2014|July 10, 2014|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586325||86901|
NCT01586572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1891-Ped-ERC-11|Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3|Comparison of Immunogenicity of Type 1 mOPV Administered at Short Intervals With Type 1 mOPV1 and Type 1 & 3 bOPV Oral Polio Vaccine Given at Standard Intervals in Pakistan:A Randomized Trial|SIAD|Aga Khan University|No|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|1000|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||June 2015|June 26, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01586572||86882|
NCT01586806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #2012-002|Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction|Postoperative Analgesia Comparing Subsartorial Saphenous Nerve Block With and Without Dexamethasone in ACL Reconstruction||Hospital for Special Surgery, New York|Yes|Completed|July 2012|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|195|||Both|16 Years|65 Years|No|||December 2014|December 19, 2014|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586806||86864|
NCT01587079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT003005|Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double Blind, (Test Products), Chronic Dosing (7 Days), Four Period, Eight Treatment , Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Five Doses of PT003, One Dose of PT001 and One Dose of PT005 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide 18 µg, Open Label) as Active Control||Pearl Therapeutics, Inc.|No|Completed|April 2012|October 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|159|||Both|40 Years|80 Years|No|||October 2013|October 22, 2013|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587079||86843|
NCT01584102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VTech-2012-1|Randomized Controlled Trial Targeting Obesity-related Behaviors|Better Together Healthy Caswell County: Randomized Controlled Trial Targeting Obesity-related Behaviors||Virginia Polytechnic Institute and State University|No|Completed|January 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2012|April 23, 2012|April 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584102||87067|
NCT01572727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120F2202|A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation|A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.|BELLE-4|Novartis|Yes|Completed|August 2012|June 2015|Actual|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|416|||Female|18 Years|N/A|No|||January 2016|January 11, 2016|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572727||87935|
NCT01572961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-10|Microvascular Function Assessment in Healthy Subjects|Amélioration Des Techniques d'étude de la Micro-cirulation cutanée Chez Des Sujets Sains|MICROTEC|University Hospital, Angers|Yes|Completed|November 2010|May 2013|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01572961||87917|
NCT01572714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-14-19|Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis|Examining the Effects of Physical Activity Promotion, Fatigue Management Education, and Social Support Using a Telehealth Intervention Approach Among Adults With Multiple Sclerosis||Case Western Reserve University|No|Recruiting|July 2011|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Anticipated|215|||Both|18 Years|65 Years|No|||January 2015|January 22, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01572714||87936|
NCT01573273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00016890|Oxytocin in Cocaine Dependence|||Medical University of South Carolina|Yes|Recruiting|October 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|152|||Both|18 Years|65 Years|No|||February 2016|February 5, 2016|April 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01573273||87893|
NCT01573286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLP-2-01|Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure|Phase 1-2 Trial of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure|GLP-2-01|Alberta Children's Hospital|Yes|Terminated|January 2012|August 2015|Anticipated|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|N/A|18 Years|No|||December 2014|December 19, 2014|April 5, 2012||No|GLP-2 Drug product stability concerns|No||https://clinicaltrials.gov/show/NCT01573286||87892|
NCT01573533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005640|A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS|A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin||Mayo Clinic|Yes|Active, not recruiting|October 2013|November 2018|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|6 Years|80 Years|No|||January 2016|January 12, 2016|April 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01573533||87874|
NCT01567215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201|Treatment of Granuloma Umbilical in Newborn Babies|Treatment of Granuloma Umbilical in Newborn Babies - Comparison of Treatment With Silver Nitrate Versus Alcohol Swaps Versus Steroid Creme Group IV||Hvidovre University Hospital|Yes|Completed|May 2012|June 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|N/A|6 Months|Accepts Healthy Volunteers|||June 2014|June 30, 2014|March 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567215||88357|
NCT01567228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01LM010923-01|Delivering Geospatial Intelligence to Health Care Providers|Delivering Geospatial Intelligence to Health Care Providers|CHICA GIS|Indiana University|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1076|||Both|1 Year|21 Years|No|||September 2015|September 14, 2015|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01567228||88356|
NCT01567189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERC1|Cost-effectiveness of Outpatient Versus Hospital Cardiac Rehabilitation|Outpatient Cardiac Rehabilitation Versus Hospital. Cost-effectiveness Study|CERC1|Basque Health Service|No|Not yet recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||March 2012|March 28, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01567189||88359|
NCT01567202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC81001115|Study of DC Vaccination Against Glioblastoma|A Triple-blind Randomized Clinical Study of Vaccination With Dendritic Cells Loaded With Glioma Stem-like Cells Associated Antigens Against Brain Glioblastoma Multiform||Huashan Hospital|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|No|||May 2015|May 19, 2015|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567202||88358|
NCT01567501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/059|Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal® 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fed Condition||IPCA Laboratories Ltd.|Yes|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 30, 2012|March 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567501||88336|
NCT01567514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU-IRB 2008/269.3110|Postoperative Pulpal Complications in Posterior Resin Composite Restorations Without Glass-ionomer Cement Lining|A 2-year Clinical Study on Postoperative Pulpal Complications Arising From the Absence of a Glass-ionomer Lining in Deep Occlusal Resin Composite Restorations||Mahidol University|Yes|Completed|March 2008|March 2011|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567514||88335|
NCT01585571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD069769|Balance and Posture in Adults With Cerebral Palsy|Observational Study of Balance and Posture in Adults With Cerebral Palsy||Temple University|No|Recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|15 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The proposed investigation will be a cross-sectional study conducted with adolescents and        young adults with typical development, and adolescents and young adults classified as        having spastic diplegic or spastic quadriplegic CP between 15 and 30 years of age.|March 2016|March 20, 2016|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01585571||86957|
NCT01585844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWJ64323|Sleep Apnea in Pregnancy Screening Study|Obstructive Sleep Apnea in Pregnancy:Epidemiology and Maternal/ Neonatal Morbidity|SAPSS|MetroHealth Medical Center|No|Completed|August 2008|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|182|Samples With DNA|urine serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Obstetric care clinic at a tertiary care hospital|April 2012|April 25, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585844||86937|
NCT01586091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022747-38|Safety Study of Levocetirizine and Fexofenadine|Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response|LAWAF|Charite University, Berlin, Germany|Yes|Completed|February 2011|February 2012|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|April 24, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586091||86919|
NCT01583270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-biofuncarb second meal|Effect of Arabinoxylan and Rye Kernels on Second Meal Responses|Effect of Arabinoxylan and Rye Kernels on Second Meal Responses in Subjects With the Metabolic Syndrome||Aarhus University Hospital|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01583270||87129|
NCT01583283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACE-MM-101|Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma|A Phase I/II, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma||Acetylon Pharmaceuticals Incorporated|No|Enrolling by invitation|April 2012|October 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|148|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01583283||87128|
NCT01586585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0021-CTIL|Back to Functional Life Following Cardiac Surgery|Patient Rehabilitation Post Cardiac Surgery Based on Their Pre-op Status|BTFL2012|Carmel Medical Center|No|Withdrawn|May 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|50 Years|90 Years|No|Non-Probability Sample|Cardiac surgery patients|October 2013|October 23, 2013|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01586585||86881|
NCT01583556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000632|Optional Follow-up Visits for Common, Low-risk Arm Fractures|Optional Follow-up Visits for Common, Low-risk Arm Fractures||Massachusetts General Hospital|Yes|Completed|July 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|120|None Retained|n.a.|Both|18 Years|N/A|No|Non-Probability Sample|All adult, English-speaking patients presenting to our outpatient clinic, that meet the        inclusion criteria for this study will be invited to enroll at the time of the first visit        at the outpatient clinic.|April 2015|April 6, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01583556||87107|
NCT01587092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC12015|Workstation Pilot Study|WorkStation Pilot Study||Pennington Biomedical Research Center|No|Completed|August 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2013|November 14, 2013|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01587092||86842|
NCT01583842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12088|124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study|124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study||University of California, San Francisco|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|3 Years|N/A|No|||January 2015|January 9, 2015|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583842||87086|
NCT01583855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0260|Manual vs Amigo SmartTouch Atrial Fibrillation Study|Manual vs Amigo SmartTouch Atrial Fibrillation Study|MAST-AF|University of Leicester|Yes|Active, not recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01583855||87085|
NCT01583868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|755E|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|April 2012|||||N/A|N/A|N/A||||||||||||||August 10, 2012|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583868||87084|
NCT01584401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0295-11-RMC|Temperature Measurement Using a Non Invasive Device|||Medisim Ltd|No|Not yet recruiting|May 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Non-blinded, randomized study format. Study population includes 500 patients at all ages        and from both genders.|April 2012|April 24, 2012|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01584401||87045|
NCT01593410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-021|Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma|A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma||Celgene|No|Completed|August 2010|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|194|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|May 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01593410||86360|
NCT01572974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS0056|Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease|Quality of Life in Barrett's Esophagus and GERD:GERD Symptoms, Perception of Cancer Risk, and Actual Cancer Risk||Midwest Biomedical Research Foundation|No|Terminated|January 2010|December 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||4|Anticipated|384|||Both|18 Years|N/A|No|Probability Sample|The study population is a Veteran population presenting to a VA Hospital with GERD symptom        or Barrett's esophagus|October 2015|October 19, 2015|April 4, 2012||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01572974||87916|
NCT01572948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAL-MD-01|A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)|A Placebo-controlled Trial of Roflumilast (Daliresp) on Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD)||University of Alabama at Birmingham|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|40 Years|N/A|No|||September 2015|September 28, 2015|April 4, 2012|Yes|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01572948||87918|small sample size and limited follow-up
NCT01573546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031464|ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement|Lifestyle, CVD Risk, and Cognitive Impairment|ENLIGHTEN|Duke University|Yes|Recruiting|December 2011|January 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|160|||Both|55 Years|N/A|No|||November 2015|November 11, 2015|December 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01573546||87873|
NCT01574040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasc-UMCU-14B|The Lifestyle moDIfCation Study|A Before-and-after Study to Evaluate Effects of Low-cost Interventions for Promoting Healthy Lifestyle Modifications|LUDIC|UMC Utrecht|No|Active, not recruiting|February 2012|||April 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|11000|||Both|N/A|N/A|Accepts Healthy Volunteers|||April 2012|April 5, 2012|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01574040||87835|
NCT01567540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10-54|A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients|A Pilot Study to Evaluate the Clinical and Biological Tolerance of Sitagliptin With Pegylated Interferon alfa2a Plus Ribavirin Combination Therapy in Chronic Hepatitis C Patients||Institut National de la Santé Et de la Recherche Médicale, France|Yes|Terminated|March 2013|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|70 Years|No|||January 2014|January 17, 2014|March 2, 2012||No|New treatments available, which prevents additional recruitment.|No||https://clinicaltrials.gov/show/NCT01567540||88333|
NCT01567527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-08-250|Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients|52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Active, not recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|731|||Both|18 Years|65 Years|No|||February 2016|February 2, 2016|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567527||88334|
NCT01567774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|198/2012/D|Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity|Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy|PEARL|University of Roma La Sapienza|No|Recruiting|April 2012|June 2015|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2013|May 3, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01567774||88315|
NCT01586338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNVIL06244|A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)|A Multicenter, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Synvisc® (Hylan G-F 20) in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)||Sanofi|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|237|||Both|30 Years|N/A|No|||January 2016|January 27, 2016|April 23, 2012|Yes|Yes||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01586338||86900|
NCT01586598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-IRB-100-2302A3|Sensory Retraining Facilitates Sensory Recovery After Mandibular Nerve Injury|Sensory Retraining Exercise Facilitates Sensory Recovery After Bilateral Sagittal Split Osteotomy - a Randomized Controlled Trial||Chang Gung Memorial Hospital|Yes|Active, not recruiting|April 2012|September 2015|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|40 Years|No|||April 2012|April 25, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01586598||86880|
NCT01587105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCMS|Improving Care for Children With Complex Needs|Improving Care for Children With Complex Needs (I3CN) Study|I3CN|Seattle Children's Hospital|Yes|Active, not recruiting|October 2010|||September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|277|||Both|3 Months|18 Years|No|||November 2014|November 18, 2014|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01587105||86841|
NCT01587118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00156|An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder|An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder||Tuscaloosa Research & Education Advancement Corporation|No|Recruiting|June 2012|August 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|19 Years|65 Years|No|||November 2014|November 25, 2014|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587118||86840|
NCT01587339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115049|Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy|Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy||GlaxoSmithKline|No|Completed|September 2010|July 2011|Actual|March 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|6498|||Both|N/A|N/A|No|Non-Probability Sample|We included published papers on studies that had recruited drug-resistant (or refractory)        partial epilepsy of all types|September 2013|September 12, 2013|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587339||86823|
NCT01587352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00860|Vorinostat in Treating Patients With Metastatic Melanoma of the Eye|A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma||National Cancer Institute (NCI)|Yes|Recruiting|April 2012|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|February 26, 2016|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587352||86822|
NCT01587131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:131|DNA-based Influenza Vaccine in the Elderly|Phase I, Open Label Study of a DNA Vaccine's Ability to Increase the Immune Response to the Trivalent Seasonal Influenza Vaccine in the Elderly||University of Manitoba|Yes|Completed|June 2012|March 2015|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|50|||Both|65 Years|N/A|Accepts Healthy Volunteers|||January 2013|April 16, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01587131||86839|
NCT01587365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV206-001|Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins|Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-962476 in Healthy Subjects and in Patients With Hypercholesterolemia on Statin Therapy||Bristol-Myers Squibb|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|66|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 2, 2013|April 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01587365||86821|
NCT01592045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIV-NB-201|ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma|A Comparative Pharmacokinetic and Safety Study of Chimeric Monoclonal Antibody ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2 (IL-2) and Isotretinoin in High Risk Neuroblastoma Patients Following Myeloablative Therapy||United Therapeutics|Yes|Completed|August 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|N/A|8 Years|No|||August 2015|August 20, 2015|April 30, 2012|Yes|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT01592045||86464|
NCT01587378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1434|Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome|A Prospective, Randomized, Double-blind, Multi-centre Study, Where the Possible Effect of Metformin to Prevent Late Miscarriage and Preterm Delivery is Studied in Women With Polycystic Ovary Syndrome (PCOS)|PregMet2|Norwegian University of Science and Technology|No|Recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Female|18 Years|45 Years|No|||January 2016|January 5, 2016|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587378||86820|
NCT01583296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-223|LUCHAR - Latinos Using Counseling for Help With Asthma and Anxiety Reduction|Adaptation of a Behavioral Treatment for Latinos With Panic Disorder and Asthma|LUCHAR|Albert Einstein College of Medicine of Yeshiva University|Yes|Completed|July 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||January 2015|January 12, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01583296||87127|
NCT01583309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONVESTUDY|Effects of Convective Therapies in Dialysis Patients|Effects of Convective Therapies in Dialysis Patients|ECTDP|A. Manzoni Hospital|No|Completed|November 2003|February 2008|Actual|February 2008|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|146|||Both|18 Years|80 Years|No|||April 2012|April 23, 2012|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01583309||87126|
NCT01583881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-046|Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction|Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction|DIASTOLE|UMC Utrecht|No|Active, not recruiting|April 2012|July 2016|Anticipated|June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01583881||87083|
NCT01584115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6889|Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)|Phase I Clinical Trial of a Therapeutic Vaccine for Malignancies, Comprising the Tumor Antigen NY-ESO-1 in Combination With the Adjuvant MPLA of Bordetella Pertussis. Evaluation of Toxicity and Immunogenicity||Instituto de Investigação em Imunologia|Yes|Not yet recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|60 Years|No|||April 2012|April 24, 2012|April 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01584115||87066|
NCT01584388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011p002414|Rituximab in IgG4-related Disease: A Phase 1-2 Trial|Rituximab in IgG4-Related Disease: A Phase 1-2 Trial||Massachusetts General Hospital|Yes|Completed|April 2012|January 2015|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|April 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584388||87046|
NCT01593657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 01112|Mindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery|||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|May 2012|||March 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Female|18 Years|N/A|No|||September 2015|September 22, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01593657||86341|
NCT01570023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0518|Study of Tongue Strengthening for Swallowing Problems|Comparison Between Isometric Lingual Strengthening Exercises and Standard Clinical Care for the Treatment of Dysphagia||University of Wisconsin, Madison|No|Completed|April 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|21 Years|95 Years|No|||October 2015|October 9, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01570023||88142|
NCT01570036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|368255|Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax|Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence||Cancer Insight, LLC|Yes|Recruiting|January 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|N/A|No|||December 2015|December 1, 2015|March 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01570036||88141|
NCT01573299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/4-C|Ischemic Stroke and Early Vertical Positioning (SEVEL)|Ischemic Stroke and Early Vertical Positioning, the SEVEL Study: a Randomised Controlled Trial Comparing the 3 Months Rankin Score Outcome in Ischemic Stroke Patients; in Whom Early or Delayed Mobilization is Performed|SEVEL|Nantes University Hospital|Yes|Terminated|November 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|167|||Both|18 Years|N/A|No|||December 2014|December 16, 2014|April 5, 2012||No|The required number of patients was not reached. The sites were not able to include more    patients.Despite several actions the stop of the study has been decided|No||https://clinicaltrials.gov/show/NCT01573299||87891|
NCT01566370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZNS-BP|Zonisamide for Heavy Drinkers With Bipolar Disorder|Zonisamide for Heavy Drinkers With Bipolar Disorder|ZNSBP|VA Connecticut Healthcare System|Yes|Terminated|May 2012|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|65 Years|No|||January 2016|January 4, 2016|December 15, 2011|Yes|Yes|recruitment infeasible|No||https://clinicaltrials.gov/show/NCT01566370||88422|
NCT01566656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/6-L|Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies|Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies|TLI-ATG|Nantes University Hospital|Yes|Recruiting|March 2012|March 2019|Anticipated|March 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|66 Years|No|||February 2016|February 29, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566656||88400|
NCT01566916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIFJPAR 12-01|Medium Term Survivorship of Cementless THA Performed Using the Bone Preservation Tri-Lock Femoral Stem|||Rothman Institute Orthopaedics||Not yet recruiting||||||N/A|Interventional|Primary Purpose: Treatment|2||||||Both|21 Years|N/A|No|||February 2014|February 10, 2014|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01566916||88380|
NCT01567800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHN REB 11-0953-C|Prostate Hypoxia FAZA|A Feasibility Study of Hypoxia Imaging in Patients With Prostate Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)||University Health Network, Toronto||Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||January 2016|January 26, 2016|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01567800||88313|
NCT01567787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPTI 1101-NF01|Proton Radiation Therapy for Spinal Tumors|Spinal Tumor Proton Protocol|NF01|University of Florida|Yes|Withdrawn|June 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|March 13, 2012|Yes|Yes|Feasibility issues|No||https://clinicaltrials.gov/show/NCT01567787||88314|
NCT01568099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFF008|Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease|A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's Disease||Affiris AG|Yes|Completed|February 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|32|||Both|40 Years|65 Years|No|||August 2015|August 14, 2015|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01568099||88290|
NCT01586611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Panc001|A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer|A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing.|Panc001|AHS Cancer Control Alberta|No|Recruiting|June 2012|June 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586611||86879|
NCT01595828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NK-104-4.03EU|Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome|An Open Label Study of the Chronic and Acute Effects of Pitavastatin on Monocyte Phenotype, Endothelial Dysfunction and HDL Atheroprotective Function in Subjects With Metabolic Syndrome (CAPITAIN)|CAPITAIN|Kowa Research Europe|No|Completed|October 2010|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Male|30 Years|65 Years|No|||July 2013|July 19, 2013|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01595828||86174|
NCT01592058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102211|Weight Change Among Users of Three Progestin-Only Methods of Contraception Over a 12-Month Time Period|Weight Change Among Users of Three Progestin-Only Methods of Contraception Over a 12-Month Time Period|BMI|Washington University School of Medicine|No|Completed|June 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|427|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants already enrolled in the Contraceptive CHOICE Project will be offered        participation during their 12-month follow up window if they had originally selected one        of the four methods being studied during CHOICE enrollment.|July 2012|July 30, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01592058||86463|
NCT01592344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-STMR11-001|Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy|Prospective, Multi-Center, Randomized, Double-Blinded, Study to Assess Safety and Efficacy of the Bioness® StimRouter™ Neuromodulation System in Patients With Chronic Pain of Peripheral Nerve Origin||Bioness Inc|No|Completed|April 2012|July 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|94|||Both|22 Years|N/A|No|||February 2016|February 15, 2016|May 3, 2012|Yes|Yes||No|January 16, 2016|https://clinicaltrials.gov/show/NCT01592344||86441|The device was designed for treatment of mononeuritis excluding the face. For this reason, mononeuropathies of the face were excluded.
NCT01592617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S488410LP|Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer|Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer||Shiga University|Yes|Active, not recruiting|May 2012|September 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|20 Years|79 Years|No|||August 2015|August 11, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01592617||86421|
NCT01592890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP27854|A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers|Single-centre, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Dose of 14C-labeled RO4917523 and an Intravenous Tracer Dose of 13C-labeled RO4917523 in Healthy Male Volunteers||Hoffmann-La Roche||Completed|April 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|6|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01592890||86400|
NCT01593150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|project nr.: S-20110075|Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation|Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation.||Odense University Hospital||Completed|November 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|141|||Both|18 Years|85 Years|No|||February 2015|February 2, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01593150||86380|
NCT01593397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1K23GM100273-01|Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity|Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity||Stanford University|Yes|Recruiting|November 2011|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593397||86361|
NCT01593163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IbuEchoG|Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus|Randomised Controlled Clinical Trial of Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus: a Pilot Study||Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|Yes|Completed|May 2009|March 2010|Actual|March 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|N/A|1 Month|No|||May 2012|May 4, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01593163||86379|
NCT01566149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08212|Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)|An Open-Label Study to Assess the Safety and Tolerability of Zenhale® (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects With Persistent Asthma (Protocol No. 206-00 [P08212])||Merck Sharp & Dohme Corp.|No|Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|12 Years|N/A|No|||June 2015|June 23, 2015|March 27, 2012|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01566149||88439|
NCT01566136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR DPA-93049|An Inpatient Rehabilitation Model of Care Targeting Patients With Cognitive Impairment|An Inpatient Rehabilitation Model of Care Targeting Patients With Cognitive||University Health Network, Toronto|No|Completed|August 2009|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|198|||Both|65 Years|N/A|No|||April 2014|April 23, 2014|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01566136||88440|
NCT01566669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCEA|Efficacy and Safety of Parecoxib on Morphine Patient-controlled Epidural Analgesia (PCEA) After Gynecologic Surgery|A Multicenter, Randomised, Double-blinded, Placebo-controlled Trial Comparing the Efficacy and Safety of Intravenous Parecoxib Sodium on Morphine Patient-controlled Epidural Analgesia After Gynecologic Surgery|PCEA|First Affiliated Hospital, Sun Yat-Sen University|No|Completed|June 2009|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|294|||Female|18 Years|65 Years|No|||September 2012|September 20, 2012|March 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566669||88399|
NCT01566929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Obesity/IVF|Weight Management Intervention for Obese Women and the Live Birth Outcome of in Vitro Fertilization (IVF)|Weight Management Interventions for Obese Women and the Live Birth Outcome of in Vitro Fertilization (IVF): a Randomized Controlled Trial||Sahlgrenska University Hospital, Sweden|Yes|Recruiting|October 2010|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|334|||Female|18 Years|37 Years|No|||November 2014|November 20, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01566929||88379|
NCT01567254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54/11|The Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control|Subject: A Blinded Randomized Trial: the Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control||Assaf-Harofeh Medical Center|No|Completed|April 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|13|||Both|7 Years|16 Years|No|||January 2015|January 1, 2015|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01567254||88354|
NCT01567566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIC-WCB-001|An Efficacy Study of Exercise Rehabilitation on Pain and Disability for Patients With Non-specific Low Back Pain|The Effect of Hip Stabilizer Muscle Strengthening on Pain and Disability for Patients With Non-specific Low Back Pain: an Outcome-based Randomized Controlled Trial|LBP-RCT|Running Injury Clinic|No|Recruiting|June 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||March 2012|March 28, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01567566||88331|
NCT01568112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV321|A Study in Healthy Volunteers to Evaluate Effects of Pre-Medication or Slow Dose Titration on Flushing and Gastrointestinal Events|A Randomized, Double-Blind, Phase 3b Study to Evaluate Effects of Aspirin or Slow Dose Titration on Flushing and Gastrointestinal Events Following Oral Administration of BG00012 Dosed at 240 mg BID||Biogen|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|173|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 3, 2014|March 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01568112||88289|
NCT01568476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0059-A|Does Interneural Local Anesthetic Spread at the Site of Sciatic Nerve Bifurcation Shorten Block Onset Time?|Does Interneural Local Anesthetic Spread at the Site of Sciatic Nerve Bifurcation Shorten Block Onset Time?||University Health Network, Toronto||Recruiting|July 2011|December 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|88|||Both|18 Years|85 Years|No|||March 2012|March 29, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01568476||88261|
NCT01568489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-009-ADP2-US-01|Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis|A Randomized, Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of HL-009 Liposomal Gel in Adult Patients With Mild to Moderate Atopic Dermatitis||HanAll BioPharma Co., Ltd.|No|Completed|March 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|120|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568489||88260|
NCT01595555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-278|Effectiveness of Stress Free Now: an Internet-based Mindfulness Program for Stress Management|Effectiveness of an Internet-based Mindfulness Program for Stress Management||The Cleveland Clinic|No|Completed|September 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|684|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 7, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595555||86195|
NCT01595568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER CHU Ste-Justine 3435|Prevention and Reduction of Alcohol and Drug Problems in a Clinical Psychiatric Youth Population|||St. Justine's Hospital|No|Recruiting|February 2012|||July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|60|||Both|14 Years|17 Years|No|||July 2012|July 18, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01595568||86194|
NCT01586819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203555|Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A|Treatment of Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: A Split-face, Rater-blinded Randomized Control Trial||Loyola University|No|Recruiting|September 2011|September 2013|Anticipated|September 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|30 Years|75 Years|No|||October 2012|October 29, 2012|November 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586819||86863|
NCT01586832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-20080104|Stocking of a Busy Emergency Department|Stocking of a Busy Emergency Department||Lehigh Valley Hospital|No|Completed|January 2008|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|565|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will include the nurses in the emergency department who will be observed        during their shift.|June 2014|June 14, 2014|July 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01586832||86862|
NCT01596153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSH 10-006|Probiotics in Hospitalized Patients Study|Randomized Double-blind, Placebo-Controlled Trial Comparing the the Effect of Enhance Probiotic (EP, Go Live Rx,) Versus Placebo (Pl) on the Incidence of Clostridium Difficile Associated Diarrhea (CDAD) or Antibiotic-Associated Diarrhea (AAD)in Hospitalized Patients Initiated on Antibiotics||South Shore Hospital|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 17, 2014|May 8, 2012||No|The study was not initiated|No||https://clinicaltrials.gov/show/NCT01596153||86149|
NCT01596166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDMIGR-004-01|Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department|Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department|EDMigraine-4|University of Alberta|No|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|6 Years|17 Years|No|||January 2015|January 21, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01596166||86148|
NCT01592071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20080670|IgG-mediated Food Test for Weight Loss|Eliminating IgG-mediated Reactive Foods From the Diet and Its Effect on Body Composition and Quality of Life in Overweight Persons||University of Miami|No|Completed|October 2008|October 2010|Actual|October 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 14, 2014|May 1, 2012||No||No|August 23, 2012|https://clinicaltrials.gov/show/NCT01592071||86462|
NCT01592357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA7343|The Effects of Tai Chi in Older Patients With Cardiovascular Disease|The Effects of Tai Chi in Older Patients With Cardiovascular Disease||McMaster University|No|Active, not recruiting|November 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|60 Years|N/A|No|||March 2013|March 18, 2013|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01592357||86440|
NCT01592630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1017.01|Effectiveness of Transverse Abdominus Plane Catheter Blocks to Patient-controlled Analgesia in Laparoscopic Colon Resections|Effectiveness of Adding Transverse Abdominus Plane (TAP) Catheter Blocks to Patient-controlled Analgesia (PCA) in Laparoscopic Colon Resections: a Prospective, Randomized Controlled Study||Stamford Hospital|Yes|Recruiting|May 2012|||May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2012|May 3, 2012|May 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592630||86420|
NCT01592903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006-C-072-CS-F|Somatic Stem Cells in Leiomyomas?|Identification and Characterization of Putative Leiomyoma Stem Cells.||Igenomix|No|Active, not recruiting|April 2012|September 2018|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|PHASE 1:SAMPLE COLLECTION Duration: From the first month to 36th month approximately. PHASE      2: CELL PREPARATION PROTOCOL Duration: From the first month to 12th month PHASE 3: ISOLATION      OF PUTATIVE SOMATIC STEM CELLS Duration: From the third month (March 2010) to 12th month      PHASE 4: CELL CULTURE Duration: From the sixth month to 18th month PHASE 5: ENDOCRINE      CHARACTERIZATION Duration:From the 18th month to 36th month Biospecimen Retention Samples      With DNA - samples retained, with potential for extraction of DNA from at least one of the      types of samples retained (e.g., frozen tissue, whole blood) Biospecimen Description Samples      of human leiomyomas obtained from patients with symptomatic uterine fibroids.|Female|20 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|Female patients from 20 years and older undergoing laparoscopic myomectomy for symptomatic        uterine fibroids.|April 2015|April 7, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592903||86399|
NCT01566162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050307|A Twelve Week, Open Label Extension Study in Patients With Schizophrenia|A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia||Sunovion|No|Completed|April 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|191|||Both|18 Years|N/A|No|||November 2014|November 12, 2014|March 27, 2012|Yes|Yes||No|October 21, 2014|https://clinicaltrials.gov/show/NCT01566162||88438|
NCT01566396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC210117_F, rev. 01|Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles|Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles||Pollogen|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||May 2012|October 18, 2012|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566396||88420|
NCT01566383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120288|Assessing Normal Multichannel Intraluminal Impedance (MII)-pH Parameters for Today's Population|Assessing Normal Multichannel Intraluminal Impedance (MII)-pH Parameters for Today's Population||Vanderbilt University|No|Active, not recruiting|March 2012|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|33 Years|65 Years|Accepts Healthy Volunteers|||September 2015|January 19, 2016|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566383||88421|
NCT01566942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-170|FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer|FOLFIRI or mFOLFOX6 as Adjuvant Chemotherapy Regiment After Neo-adjuvant Chemotherapy With FOLFIRI in Patients With Advanced Colorectal Cancer: a Randomized, Multicenter Clinical Trial||Sun Yat-sen University|Yes|Not yet recruiting|June 2012|June 2017|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||March 2012|March 27, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01566942||88378|
NCT01567241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|329/11|Clinical Hypnosis During Insemination or Embryotransfer|Prospective Off-center Randomised Trial of Clinical Hypnosis Versus Relaxation Music||Johann Wolfgang Goethe University Hospitals|No|Recruiting|March 2012|March 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|282|||Female|18 Years|N/A|No|||March 2012|March 30, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01567241||88355|
NCT01567267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EbM@Bio-01|Evaluation of Educational Intervention to Teach Principles of Evidence-based Medicine (EbM) in Biology Classes|Phase II Study of a Short Term Educational Intervention for Upcoming Biology Teachers to Teach Principles of Evidence-based Medicine (EbM) in Biology Classes at High-school||Goethe University|No|Active, not recruiting|February 2010|May 2018|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|87|||Both|N/A|N/A|No|||September 2015|September 19, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01567267||88353|
NCT01567553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-005363-10|The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.|Early Neuroinflammatory Changes as a Prognostic Marker in Clinically Isolated Syndromes Patients.|USPIO-CIS|Rennes University Hospital|No|Terminated|April 2009|June 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|37|||Both|18 Years|45 Years|No|Non-Probability Sample|CIS at presentation (clinically isolated syndromes) will be recruited with MRI evidence of        at least two asymptomatic brain MRI lesions. The group will compromise 50 CIS patients.        These CIS patients will be included within three months after first clinical presentation.|January 2015|October 27, 2015|February 24, 2012||No|terminated ( Halted prematurely,expiration of investigationnal product)|No||https://clinicaltrials.gov/show/NCT01567553||88332|
NCT01567839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4% dental local anesthetics|Testing the Anesthetic Effectiveness of Three Different Dental Local Anesthetics Injected Next to a Lower First Molar|Anesthetic Efficacy of 4% Articaine With 1:100,000 Epinephrine, 4% Prilocaine With 1:200,000 Epinephrine, and 4% Lidocaine With 1:100,000 Epinephrine as a Primary Buccal Infiltration in the Mandibular First Molar.||Ohio State University|No|Completed|May 2012|May 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|3||Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 7, 2013|March 28, 2012||No||No|June 24, 2013|https://clinicaltrials.gov/show/NCT01567839||88310|No adverse events.
NCT01567813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V501-070|Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)|Post-Licensure Observational Study of the Safety of GARDASIL™ in Males||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|June 2011|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|44000|||Male|9 Years|26 Years|Accepts Healthy Volunteers|Probability Sample|Males who are members of a large geographically diverse US health plan.|March 2016|March 22, 2016|March 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01567813||88312|
NCT01567826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1294|Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy|Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy. (YELLOW Trial)|YELLOW|Icahn School of Medicine at Mount Sinai|Yes|Completed|May 2010|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|March 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01567826||88311|
NCT01568125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6|Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus|Effect of Incretin-related Drugs on Energy and Contents of Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus||Nagaoka Red Cross Hospital|No|Active, not recruiting|January 2010|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|20 Years|95 Years|No|Probability Sample|100 patients|March 2012|March 30, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568125||88288|
NCT01568138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20032-P|Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy|This Study is a Multi-center, Prospective, Single-armed, Study Designed to Evaluate the Safety and Feasibility of the BioVentrix PliCath HF System for Left Ventricular (LV) Volume and Radius Reduction Through Scar Exclusion in Patients Whose Systolic HF is Due to Ischemic Cardiomyopathy.|CONFIGURE-HF|BioVentrix|Yes|Active, not recruiting|August 2010|March 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|80 Years|No|||April 2012|April 2, 2012|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568138||88287|
NCT01595295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGMT_Vidaza Register|VIDAZA® in Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia|Patient Registry: VIDAZA® in Patients With MDS, CMML or AML||Arbeitsgemeinschaft medikamentoese Tumortherapie|No|Recruiting|February 2009|||December 2017|Anticipated|N/A|Observational|N/A||1|Anticipated|400|Samples With DNA|Biospecimen are collected prospectively on d1 of each cycle and in some cases also between      the azacitidine cycles, after written informed consent has been provided. The aim is to      establish a biobank of patient samples from patients treated with azacitidine, in order to      have a meeningfull set of samples for future analysis of methylationstatus or mutationstatus      of relevant genes, as well as to study potential changes in certain cellular subsets during      and after treatment with azacitidine.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with MDS, CMML, and AML, who begin with or already have received treatment with        VIDAZA|June 2015|June 3, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01595295||86215|
NCT01595308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-002|A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers|A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers||POM Wonderful LLC|No|Completed|April 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|April 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595308||86214|
NCT01596179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC2011-001|Technology Enhanced Nurse Navigator Trial (TENN Trial)|Technology Enhanced Nurse Navigator Trial (TENN Trial) Phase III Randomized Controlled Trial|TENN|Mercy Medical Center|No|Completed|February 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|101|||Female|N/A|N/A|No|||January 2015|April 16, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01596179||86147|
NCT01596127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0844|Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System|Safety and Efficacy of Intrathecal Rituximab in Patients With Lymphoid Malignancies Involving the Central Nervous System||M.D. Anderson Cancer Center|No|Recruiting|January 2013|||January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|3 Years|N/A|No|||November 2015|November 25, 2015|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596127||86151|
NCT01596140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0153|Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer|A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination With an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects With Advanced Cancer||M.D. Anderson Cancer Center|No|Recruiting|December 2012|||December 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|114|||Both|N/A|N/A|No|||February 2016|February 18, 2016|May 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01596140||86150|
NCT01592383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0032|Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma|Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations||University of Chicago|No|Active, not recruiting|June 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592383||86438|
NCT01592643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22760|Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain|Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain|Nexis-CS0032|Stanford University|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 2, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01592643||86419|
NCT01592656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2010-68|Long-term Effects of Non-invasive Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients|Long-term Effects of Non-invasive Ventilation in Hypercapnic COPD Patients.||FLUIDDA nv|No|Terminated|February 2011|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|N/A|No|||October 2012|January 15, 2014|May 3, 2012||No|Lack of budget|No||https://clinicaltrials.gov/show/NCT01592656||86418|
NCT01592916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU-143-12|Acute Effects of Exercise in Women With Fibromyalgia (FM)|Acute Effects of Exercise in Women With FM||Göteborg University|No|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Blood serum|Female|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants are recruited from previous studies.|January 2016|January 7, 2016|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01592916||86398|
NCT01593176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001012|Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures|Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures|RSA|Massachusetts General Hospital|No|Recruiting|May 2012|June 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|All potential subjects will be in the inpatient setting of Massachusetts General Hospital        or Brigham & Women's Hospital at the time of recruitment awaiting surgery on their distal        femur fracture|May 2015|May 4, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01593176||86378|
NCT01593436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0708/11|Polysomnography Evaluation of a Practice of Mindfulness in Menopausal Patients With Insomnia|Polysomnography and Sleep Quality Evaluation Before and After a Practice of Mindfulness in Menopausal Patients With Insomnia||University of Sao Paulo|Yes|Completed|July 2011|July 2015|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|54|||Female|50 Years|66 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01593436||86358|
NCT01565941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-P00002310|Heart And Lung Failure - Pediatric INsulin Titration Trial|Heart And Lung Failure - Pediatric INsulin Titration Trial (HALF-PINT)|HALF-PINT|Children's Hospital Boston|Yes|Recruiting|March 2012|October 2018|Anticipated|July 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1414|||Both|N/A|17 Years|No|||January 2016|January 5, 2016|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01565941||88455|
NCT01566708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMTR-TA-01|Neuro-Music Therapy for Recent Onset Tinnitus: Evaluation of a Therapy Concept|Diagnostic and Interventional Study of Neuro-Music Therapy for Recent Onset Tinnitus: Evaluation of a Therapy Concept Using Psychological Assessment and Functional Neuroimaging||German Center for Music Therapy Research|No|Active, not recruiting|January 2012|September 2013|Anticipated|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 24, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01566708||88396|
NCT01566682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-208|A Multi-Center Trial of the ProLung Test™|A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients With Pulmonary Lesions Suspicious for Lung Cancer||Fresh Medical Laboratories|Yes|Recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Subjects with pulmonary lesions suspicious for lung cancer|October 2015|October 20, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566682||88398|
NCT01566695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-MDS-003|The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)|A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.||Celgene|No|Recruiting|April 2013|March 2020|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|386|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|March 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01566695||88397|
NCT01567280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFIDM-1101|International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)|International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)|LIAISON|Chiesi Farmaceutici S.p.A.|Yes|Completed|May 2012|October 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|8111|||Both|18 Years|N/A|No|Probability Sample|Asthmatic patients (in treatment with the same antiasthmatic therapy for at least 4 weeks)        visiting the centre.|January 2015|January 19, 2015|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01567280||88352|
NCT01567306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-PHL-P2-001|Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense|Phase II, Multicenter, Randomized, Double Blind Study, With Subcutaneous Immunotherapy At Different Doses, in Parallel Groups and Placebo-Controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Phleum Pratense||BIAL Industrial Farmacéutica S.A.|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|151|||Both|18 Years|60 Years|No|||February 2013|May 29, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01567306||88351|
NCT01567579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHW 09/98, GC 896|An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease|An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease||Medical College of Wisconsin|No|Recruiting|January 2009|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|6 Months|18 Years|No|Non-Probability Sample|Children who have had congenital heart surgery, before the age of 1.|February 2016|February 1, 2016|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567579||88330|
NCT01568164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-0015|Safety and Efficacy Study of the BioVentrix PliCath HF System|Phase II Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy|CONFIGURE-HF|BioVentrix|Yes|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|80 Years|No|||November 2013|November 14, 2013|March 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01568164||88285|
NCT01568151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIME|Testing Interventions to Motivate and Educate|Testing Interventions to Motivate and Educate|TIME|Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|April 2009|December 2015|Anticipated|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Actual|551|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||February 2015|February 5, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01568151||88286|
NCT01568515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP-39631|Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students|A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase HPV Vaccine Utilization and Adherence Among College Students in Eastern North Carolina.||East Carolina University|No|Completed|October 2011|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|283|||Both|18 Years|26 Years|Accepts Healthy Volunteers|||October 2014|October 31, 2014|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01568515||88258|
NCT01568528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052127|Oxytocin as Adjunctive Treatment of Schizophrenia|Oxytocin as Adjunctive Treatment of Schizophrenia||Emory University|Yes|Recruiting|March 2013|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|55 Years|No|||December 2015|December 2, 2015|March 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01568528||88257|
NCT01595880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DMCL001|BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone in Healthy Male Volunteers||LG Life Sciences|No|Completed|December 2014|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01595880||86170|
NCT01592396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-CAT-354-1054|A Trial to Investigate the Pharmacokinetics of Tralokinumab in Adolescents, a Product Under Investigation for the Treatment of Asthma|A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of Tralokinumab in Adolescents With Asthma|CAT354-1054|MedImmune LLC|No|Completed|July 2012|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|22|||Both|N/A|N/A|No|||May 2013|May 22, 2013|April 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01592396||86437|
NCT01595841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-774|Sirolimus Use in Angioplasty for Vascular Access Extension|A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy|SAVE|Lawson Health Research Institute|No|Recruiting|December 2011|August 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01595841||86173|
NCT01595854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.141|Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran|Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor (Part 1 and 2, Open, Non-randomised, 2 Parallel Groups) and Assessment of Ticagrelor Interaction Potential With Dabigatran (Part 3, Open, Randomised, Two-period Cross-over) in Healthy Male Subjects||Boehringer Ingelheim||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|May 9, 2012||||No|June 18, 2013|https://clinicaltrials.gov/show/NCT01595854||86172|
NCT01592929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUI-2011-80|Evaluation With Scans and Pharyngometry of the Possible Changes in Upper Airway Geometry Induced by Using Different Mouthpieces.|Assessment of the Effect of the Shape of an Inhaler's Mouthpiece on Upper Airway Geometry, Using Functional Respiratory Imaging and Pharyngometry.||FLUIDDA nv|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Male|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 20, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01592929||86397|
NCT01593189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R324A080026|Efficacy Trial of the Kids in Transition to School (KITS) Program for Children With Developmental Disabilities and Behavioral Problems|A Randomized Efficacy Trial of the Kids in Transition to School (KITS) Program for Children With Developmental Disabilities and Behavioral Problems||Oregon Social Learning Center|No|Completed|April 2008|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|209|||Both|4 Years|6 Years|No|||October 2015|October 13, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01593189||86377|
NCT01592942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH5200627|Mesh Fixation in Lichtenstein Hernioplasty|A Randomized Multi-center Study of Tissue Glue Fixation of Optilene™ Mesh With Histoacryl™ or Self-gripping Parietex ProGrip™ Compared to Conventional Non-absorbable Suture Fixation of Ultrapro™ Mesh||Kuopio University Hospital|No|Recruiting|August 2012|December 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|650|||Both|18 Years|80 Years|No|||August 2015|March 20, 2016|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592942||86396|
NCT01593449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 5 UL1RR031982-02|A Community-based Social Networking Intervention to Increase Walking in Dog Owners|A Community-based Social Networking Intervention to Increase Walking in Dog Owners||University of Massachusetts, Worcester|Yes|Completed|January 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|107|||Both|21 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 11, 2013|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01593449||86357|
NCT01593462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00046580|Comparative Effectiveness of MR Enterography|Comparative Effectiveness of MR Enterography, Enteric Ultrasound, and Ultrasound Elastography Imaging in the Evaluation of Pediatric Small Bowel Crohn Disease||University of Michigan|Yes|Active, not recruiting|May 2011|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|1 Month|18 Years|No|||December 2015|December 7, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01593462||86356|
NCT01565954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110102|Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children: Hydroxycarbamide Effect on Isolated Hypoxemia|Systematic Evaluation of Sleep Respiratory Disorders During Sleep in Children With Sickle Cell Disease : Effect of Hydroxycarbamide Therapy on Isolated Hypoxemia - Multicenter Randomized Clinical Trial, Against Placebo, Double-blind|SOMMEDREP|Assistance Publique - Hôpitaux de Paris|No|Recruiting|January 2014|March 2017|Anticipated|March 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|280|||Both|2 Years|6 Years|No|||February 2016|February 24, 2016|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01565954||88454|
NCT01566422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vanc-1510|Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients|Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients||Vanderbilt University|No|Recruiting|June 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|March 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01566422||88418|
NCT01566955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMM-Mannheim|Feasability Study of Removing the Ovaries and Fallopian Tubes|Feasability of Transgastric Adnexectomy|TG-Adnex|Heidelberg University|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01566955||88377|
NCT01566968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEAT Version 2, 18/03/11|Novel Endpoints in Cough Challenge Testing|Novel Endpoints in Cough Challenge Testing.|NEAT|University Hospital of South Manchester NHS Foundation Trust|No|Completed|January 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|98|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Selected from secondary care.|April 2012|April 5, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01566968||88376|
NCT01566981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHDI|E-health Care Process Support for Diabetes Type II Patients|E-support for Healthcare Processes - DIABETES|EHDI|University of Primorska|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|18 Years|75 Years|No|||October 2014|October 28, 2014|February 12, 2012||No||No|July 27, 2014|https://clinicaltrials.gov/show/NCT01566981||88375|
NCT01567592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESMR-KMH-Canada|Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris|Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device||Medispec|No|Suspended|March 2009|December 2012|Anticipated|June 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||April 2012|April 1, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567592||88329|
NCT01567852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRRC#: 11-236|Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time|The Use of Ketamine Versus Methohexital for Electroconvulsive Therapy: A Cross-Over Comparative Study on Patient Recovery and Re-Orientation Time||University of New Mexico|Yes|Completed|August 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|N/A|N/A|No|||June 2014|December 15, 2014|March 28, 2012||No||No|May 21, 2014|https://clinicaltrials.gov/show/NCT01567852||88309|
NCT01568814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0-A2012|Low Volume PEG With Low Residue Test Meals Versus High Volume Split-dose PEG Bowel Preparation|Efficacy and Tolerability of Morning (AM) Only Low Volume (2L) PEG With Low Residue Test Meals Versus High Volume (4L) Split-dose (PM/AM) PEG Bowel Preparation With Standard Meals: A Prospective Randomized, Investigator Blinded Trial|LOWPEG|Inje University|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|188|||Both|18 Years|85 Years|No|||January 2012|March 30, 2012|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01568814||88235|
NCT01569048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0023|Randomized Controlled Trial to Evaluate of Dexmedetomidine for the Effect on Operative Visibility in Patients Undergoing Endoscopic Sinus Surgery|||Yonsei University|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|66|||Both|20 Years|70 Years|No|||March 2014|March 4, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01569048||88217|
NCT01569061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-179|Painless Laser Therapy for Overactive Bladder|A Double-blind, Randomized, Sham-controlled, Multicenter Clinical Trial to Assess the Effectiveness of Therapeutic Class IV Laser LCT-1000TM Treatment for Overactive Bladder Syndrome.|PLTOAB|Zipper Urogynecology Associates|No|Recruiting|February 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|N/A|No|||March 2012|March 29, 2012|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01569061||88216|
NCT01592097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DUS04T|Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Relapsing Remitting Hispanic Multiple Sclerosis Forms|A Non-randomized, Exploratory, Study to Assess Clinical Response to Gilenya® (Fingolimod) in a Cohort of Relapsing Remitting Hispanic MS Forms||University of Southern California|No|Recruiting|June 2012|October 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|DNA will be extracted from isolated cells; the remaining cells will be cryopreserved for any      duplicate analyses.|Both|18 Years|65 Years|No|Non-Probability Sample|We will recruit 50 individuals with MS who self identify Hispanic descent and are served        at USC clinics. Hispanic patients with clinically definite MS, defined by the newly        revised McDonald criteria, will be offered the opportunity to participate in this study        and asked to give informed consent.|June 2012|June 29, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01592097||86460|
NCT01596205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-04-080|The Efficacy of Robot Assisted Group Cognitive Training in Elderly Adults Without Cognitive Impairment|The Efficacy of Robot Assisted Group Cognitive Training in Elderly Adults Without Cognitive Impairment||Samsung Medical Center|No|Completed|June 2011|May 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|85|||Both|60 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 9, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596205||86145|
NCT01592084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB(2)0609-0087|Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis|Cohort Study of the Relationship of Hyperlipidemia and Statin Therapy on Survival and Disease Progresssion in Amyotrophic Lateral Sclerosis||The Methodist Hospital System|No|Completed|April 2008|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|267|Samples Without DNA|serum|Both|18 Years|N/A|No|Probability Sample|the Methodist Neurological Institute|May 2012|May 3, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01592084||86461|
NCT01592370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-039|Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma|A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (Nivolumab, BMS936558) and the Combination of Nivolumab and Ipilimumab or Nivolumab and Lirilumab in Subjects With Relapsed or Refractory Hematologic Malignancy||Bristol-Myers Squibb|No|Recruiting|June 2012|August 2018|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|315|||Both|18 Years|N/A|No|||January 2016|March 11, 2016|May 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01592370||86439|
NCT01592409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|125/2011|Cannabis Effects on Driving-related Skills of Young Drivers|Acute and Residual Effects of Cannabis on Young Drivers' Performance of Driving-related Skills||Centre for Addiction and Mental Health|No|Recruiting|July 2012|August 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|142|||Both|19 Years|25 Years|Accepts Healthy Volunteers|||December 2015|December 11, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592409||86436|
NCT01592955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EYEMUST-2|Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU)|Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound With the EyeOP1 Medical Device.||EyeTechCare|Yes|Completed|May 2012|March 2015|Actual|March 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||March 2013|June 15, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01592955||86395|
NCT01592968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0884|A Prospective Phase III Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy|A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases||M.D. Anderson Cancer Center|Yes|Recruiting|August 2012|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 28, 2015|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592968||86394|
NCT01593202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ES4894|Long Term Efficacy of DBT-A in Adolescents With Repetitive Self-harming and Suicidal Behaviours|Long Term Efficacy of Dialectical Behaviour Therapy vs Enhanced Usual Care for Adolescents With Self-Harming and Suicidal Behaviours||Oslo University Hospital|No|Active, not recruiting|January 2012|September 2022|Anticipated|September 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|13 Years|20 Years|No|||April 2015|April 28, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01593202||86376|
NCT01593475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-11-567|Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma|A Phase II Study of Induction Chemotherapy With Gemcitabine and Cisplatin Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Pancreatic Carcinoma||National Cancer Center, Korea|No|Active, not recruiting|March 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01593475||86355|
NCT01593709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120121|Volunteer Screening for Vaccine and Antivirals Clinical Trials|Screening of Volunteers for Clinical Trials of Investigational and Licensed Vaccines, Antiviral Products, or Live Virus Challenge Studies||National Institutes of Health Clinical Center (CC)||Recruiting|April 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|18 Years|99 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01593709||86337|
NCT01593722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912117|Post-Treatment Side Effects of Ivermectin or DEC for Loa Loa Infection|Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection||National Institutes of Health Clinical Center (CC)||Completed|April 2012|January 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|300|||Both|20 Years|60 Years|No|||January 2014|March 14, 2014|May 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593722||86336|
NCT01593735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2748-002|A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2748 in Hepatitis C-Infected Participants||Merck Sharp & Dohme Corp.|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|30|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|May 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01593735||86335|
NCT01566409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MainCon|Maintenance Treatment for Children With Constipation|Maintenance Treatment With Polyethylene Glycol 3350 for Children With Constipation. A Randomized, Placebocontrolled Intervention Study||Vejle Hospital|No|Completed|September 2013|September 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|115|||Both|2 Years|16 Years|No|||September 2015|September 24, 2015|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01566409||88419|
NCT01566747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICORG 10-01|Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. ICORG 10-01, V5|A Phase II Study of Pazopanib in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC) Who Have Failed Prior Sunitinib Therapy||ICORG- All Ireland Cooperative Oncology Research Group||Active, not recruiting|March 2011|||October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01566747||88393|
NCT01566721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28048|A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)|A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study]||Hoffmann-La Roche||Active, not recruiting|May 2012|March 2020|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2578|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|March 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01566721||88395|
NCT01567319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-STD-002|Biological Standardization of D. Glomerata, L. Perenne, S. Cereale and O. Europaea Pollen Extracts|Biological Standardization of D. Glomerata, L. Perenne, S. Cereale and O. Europaea Pollen Extracts in Patients Sensitized to Them.||BIAL Industrial Farmacéutica S.A.|No|Completed|February 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|177|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 14, 2013|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01567319||88350|
NCT01567865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEV05 (VAC004)|Lot-to-lot Consistency Trial of JE Live Attenuated SA 14-14-2 Vaccine|A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Manufactured in a New Good Manufacturing Practices Facility and Non-inferiority With Respect to an Earlier Product.||PATH||Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|N/A|1||||||Both|10 Months|12 Months|Accepts Healthy Volunteers|||March 2012|August 2, 2013|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01567865||88308|
NCT01568840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192/10|Global Postural Reeducation and Segmental Exercises in Patients With Scapular Dyskinesis and Cervicalgia|Effectiveness of Global Postural Reeducation and Segmental Exercises on Function, Pain, and Quality of Life of Patients With Scapular Dyskinesis and Cervicalgia: A Randomized Clinical Study||Irmandade da Santa Casa de Misericordia de Sao Paulo|Yes|Completed|July 2010|February 2011||January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2012|March 29, 2012|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01568840||88233|
NCT01568541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT17591320|Fluoride Intake From Toothbrushig With Children's or Regular Toothpastes|Fluoride Intake From Tooth Brushing With Children's and Regular Toothpastes: a Study With Preschooler Children|F|Federal University of Minas Gerais|Yes|Completed|October 2007|March 2009|Actual|July 2008|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|208|||Both|6 Months|48 Months|Accepts Healthy Volunteers|||September 2012|September 14, 2012|March 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01568541||88256|
NCT01568827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 2011H0394|Inflammation, Polyphenols, and Genetics|Inflammation, Polyphenols, and Genetics: A Pilot Study in Overweight and Obese Adult Males to Determine Whether Black-Raspberry Consumption Affects Markers of Inflammation in Study Participants Fed a High-Fat, High-Calorie Challenge Meal||Ohio State University|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Male|55 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 17, 2016|March 29, 2012||No||No|September 25, 2015|https://clinicaltrials.gov/show/NCT01568827||88234|
NCT01569074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00008|Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis|(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy|OSKIRA-Asia-1|AstraZeneca|Yes|Terminated|April 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|163|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|March 30, 2012|Yes|Yes|AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to    Rigel Pharmaceuticals.|No|November 21, 2013|https://clinicaltrials.gov/show/NCT01569074||88215|
NCT01569087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCD-017-2|Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients|Randomized Multicenter Open-label Phase II Clinical Study Comparing the Efficacy and Safety of the Single Dose of Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy||Biocad|No|Completed|May 2012|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|60|||Female|18 Years|70 Years|No|||December 2013|January 10, 2014|March 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01569087||88214|
NCT01569334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01145-34|Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasculopathy|Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasculopathy||Assistance Publique Hopitaux De Marseille|No|Active, not recruiting|February 2011|November 2014|Anticipated|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|170|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|February 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01569334||88195|
NCT01592422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIKSCLC-2012|Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer|Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer||People's Hospital of Guangxi|Yes|Recruiting|July 2012|September 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||July 2012|July 2, 2012|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01592422||86435|
NCT01592669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSGH-C101-105|Passive Leg Raising Attenuates and Delays Tourniquet Deflation-induced Hypotension and Tachycardia|The Effect of Passive Leg Raising or Experimental Clinical Practices on the Prevention of Hypotension Following Tourniquet Release in Total Knee Arthroplasty Patients||Tri-Service General Hospital|Yes|Completed|September 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|35|||Both|60 Years|90 Years|No|||May 2012|May 4, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01592669||86417|
NCT01592682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261778|Creating Smokefree Living Together for Chinese Household Pairs|"Creating Smokefree Living Together": Smokefree Counseling Intervention for Chinese Smokers and Household Nonsmokers||University of California, Davis|No|Completed|April 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|410|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01592682||86416|
NCT01592981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/11/0353|Randomised Trial in Waldenstrom's Macroglobulinaemia|Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstrőm's Macroglobulinaemia (WM): a Randomized Phase II Trial|R2W|University College, London|Yes|Active, not recruiting|January 2013|July 2021|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01592981||86393|
NCT01593215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018604-85|Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant|Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant|YOH1|Region Skane|Yes|Completed|May 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|No|||January 2015|January 7, 2015|May 3, 2012||No||No|October 31, 2014|https://clinicaltrials.gov/show/NCT01593215||86375|
NCT01593488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILI|Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children|Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement|CILI|National Cancer Institute, Naples|No|Recruiting|March 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01593488||86354|
NCT01593748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUSC 101644|A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma|A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma||Medical University of South Carolina|Yes|Recruiting|May 2012|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|May 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01593748||86334|
NCT01607047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU FDF 10/B/13|French West Indies Leptospirosis Study|Utility of Quantitative Polymerase Chain Reaction to Predict Clinical Outcome of Leptospirosis in French West Indies|LEPTO|Centre Hospitalier Universitaire de Fort-de-France|No|Recruiting|December 2010|December 2016|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|whole blood, serum, white cells, plasma, DNA|Both|18 Years|120 Years|No|Non-Probability Sample|Adults with a leptospirosis diagnosis confirmed by qPCR|February 2016|February 29, 2016|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607047||85311|
NCT01607333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115737|WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide|WEUKBRE5557: IMI PROTECT (Work Package 2): Use of Antiepileptics and Risk of Suicidality||GlaxoSmithKline|No|Completed|December 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Retrospective||3|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|For the descriptive studies that compare six European databases: All patients with at        least one prescription of an AED between January 1, 2000 and December 31, 2009 from the        following databases: National Databases (Denmark), General Practice Research Database        [GPRD] (UK), Health Improvement Network [THIN] (UK), the Mondriaan database (Netherlands),        BIFAP [Base de Datos para la Investigación Farmacoepidemiologica en Atencion Primaria]        (Spain), and the Bavarian health-insurance database (Germany).        Additional descriptive and analytic studies comparing the study populations from GPRD and        Danish data sources: study cohorts consisting of patients who have received a first        prescription to at least one AED on July 1, 1996 or later to December 31, 2009.|March 2015|March 26, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01607333||85289|
NCT01607619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI-11-01|Effect of Anatabine on Elevated Blood Levels of C-reactive Protein|A 12-week Multi-site Trial of the Dietary Supplement Anatabine (RCP006) to Determine the Effects on Peripheral Markers of Inflammation in Patients With Elevated Levels of C-reactive Protein (CRP)||Roskamp Institute Inc.|Yes|Completed|May 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|1||Actual|117|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 24, 2013|February 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01607619||85268|
NCT01607892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-001|Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer|A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 in Patients With Advanced Hematological Malignancies||Karyopharm Therapeutics, Inc|No|Active, not recruiting|June 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|284|||Both|18 Years|N/A|No|||February 2016|February 22, 2016|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607892||85247|
NCT01607905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCP-330-002|Safety Study of KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer|A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Advanced or Metastatic Solid Tumor Malignancies||Karyopharm Therapeutics, Inc|No|Active, not recruiting|June 2012|June 2016|Anticipated|March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|189|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607905||85246|
NCT01608191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCC-LCD-PV|Obesity Treatment With LCD in Primary Health Care|Obesity Treatment With LCD(Low Calorie Diet) in Primary Health Care - Long Term Effects With or Without Internet Based CBT (Cognitive Behavioral Therapy) , for Weight Stability|LCD-KBT|Örebro County Council|No|Active, not recruiting|March 2012|October 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|60 Years|No|||February 2016|February 1, 2016|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608191||85224|
NCT01608490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLN0009|Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study|Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study|RENEW|PneumRx, Inc.|Yes|Active, not recruiting|October 2012|March 2020|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|315|||Both|35 Years|N/A|No|||October 2015|October 21, 2015|May 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01608490||85201|
NCT01608503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SVCLungDown|Lung Deflation in Pediatric Subclavian Vein Catheterization|The Effect of Lung Deflation on the Position of the Pleura in Mechanically Ventilated Infants During Subclavian Vein Cannulation: an Ultrasound Study|SCVLD|Seoul National University Hospital|Yes|Completed|May 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|1||Actual|41|||Both|N/A|1 Year|No|||April 2013|April 20, 2013|May 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01608503||85200|
NCT01608854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYUHJD08139|Comparison of Antibiotic Protocols in Spine Patients With Postoperative Drains|Prospective, Randomized Study of the Utilization of Antibiotics and Drains in Spinal Surgery||New York University School of Medicine|No|Completed|November 2008|April 2012|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|539|||Both|18 Years|N/A|No|Probability Sample|Surgical spine patients of a single urban institution from 2008-2011|June 2012|June 5, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01608854||85173|
NCT01608867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54F28-001|A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors||OncoMed Pharmaceuticals, Inc.|No|Active, not recruiting|June 2012|July 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|90 Years|No|||May 2014|April 13, 2015|May 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01608867||85172|
NCT01600170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB Protocol # 815512|Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)|Statin Modulation of Monocyte/Macrophage Activation for HAND Treatment||University of Pennsylvania|Yes|Recruiting|January 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|60 Years|No|||July 2015|July 14, 2015|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01600170||85840|
NCT01600183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNFO-12-SOR-CTIL|Safety and Efficacy of the Universal Neonatal Foot Orthosis in the Treatment of Metatarsus Adductus (MTA)|Safety and Efficacy of the Universal Neonatal Foot Orthosis in the Treatment of Metatarsus Adductus (MTA)||Unfo Ltd.|No|Not yet recruiting|August 2012|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Month|4 Months|No|||May 2012|May 15, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600183||85839|
NCT01600131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-343|RESCUE Stroke Caregiver Website to Enhance Discharge Planning|Utilizing the RESCUE Stroke Caregiver Website to Enhance Discharge Planning|RESCUE|VA Office of Research and Development|Yes|Recruiting|June 2015|July 2018|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600131||85843|
NCT01600144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s53792|Data Collection for CAD Evaluation|||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|March 2012|||August 2014||N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|women|March 2012|August 6, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600144||85842|
NCT01600157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-267|Ambulant Laparoscopic Nephrectomy; Are There Limiting Factors|Ambulant Laparoscopic Nephrectomy||University Hospital Roskilde|Yes|Completed|April 2013|February 2015|Actual|February 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|62|||Both|30 Years|70 Years|No|||November 2015|November 15, 2015|May 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01600157||85841|
NCT01596569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCST|Combined Transcranial Magnetic Stimulation and Cognitive Treatment in Blast Traumatic Brain Injury|Combining Cognitive Treatment With Noninvasive Brain Stimulation in Blast TBI|COST-TBI|Boston Medical Center|No|Recruiting|May 2012|December 2017|Anticipated|May 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|21 Years|50 Years|No|||August 2014|July 21, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01596569||86117|
NCT01583348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45/12|Technical Feasibility of Routine Intraoperative Cholangiography During Elective Rigid-hybrid Transvaginal Natural Orifice Transluminal Endoscopic Cholecystectomy|An Open Case Series About Technical Feasibility of Routine Intraoperative Cholangiography (IOC) During Elective Rigid-hybrid Transvaginal Natural Orifice Transluminal Endoscopic Cholecystectomy (tvNCC)||Cantonal Hosptal, Baselland|No|Completed|April 2012|April 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Female|18 Years|N/A|No|Non-Probability Sample|Women with symptomatic gallstone disease with an indication for elective cholecystectomy|April 2013|April 28, 2013|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583348||87123|
NCT01583361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCHEN-PLAGH|SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer|Phase III, Randomized, Multicenter, Controlled Evaluation of S‐1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients|RESONANCE|Chinese PLA General Hospital|Yes|Recruiting|March 2012|January 2017|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|772|||Both|20 Years|75 Years|No|||April 2012|April 23, 2012|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01583361||87122|
NCT01583959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-124|Study of Different Doses of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis|Randomized Trial of 10 mg Versus 30 mg Per Week of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis|FOLVARI|Postgraduate Institute of Medical Education and Research|No|Completed|April 2012|December 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|75 Years|No|||February 2014|February 5, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01583959||87077|
NCT01584167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCOOL 2|A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Flex.Pads (iCOOL 2)|iCOOL 2 (Induction of COOLing 2): A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Flex.Pads|iCOOL 2|University Hospital Heidelberg|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|April 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01584167||87062|
NCT01584492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-0903-PR-0060|Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children|Double Blind, Double Dummy, Cross-over Study to Compare the Bronchodilator Effect of CHF1535 pMDI (Fixed Combination of Beclometasone 50 µg + Formoterol 6 µg) Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children|PAED3|Chiesi Farmaceutici S.p.A.|Yes|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|59|||Both|5 Years|11 Years|No|||November 2014|November 20, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584492||87038|
NCT01584505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1107-PR-0067|Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD|Randomized, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study To Evaluate The Cardiac Safety Of Two Doses Of CHF5993 BID Delivered Via HFA PMDI Both Combined With CHF1535 BID Delivered Via HFA PMDI Versus CHF1535 BID Delivered Via HFA PMDI In Patients With Moderate To Severe COPD|CARSAF|Chiesi Farmaceutici S.p.A.|No|Completed|April 2012|January 2013|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|191|||Both|40 Years|80 Years|No|||October 2014|October 13, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584505||87037|
NCT01584830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15808|Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy|A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy|CONCUR|Bayer|Yes|Completed|April 2012|January 2016|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584830||87012|
NCT01584791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOPIDO STENT|Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting|||Seoul National University Hospital||Completed|October 2010|||February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|20 Years|85 Years|No|||April 2012|April 24, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584791||87015|
NCT01584804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2003L03253|Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma|Randomised, Double-blinded, Placebo-Controlled Study of Therapeutic Effect of Su-Huang Antitussive Capsule on Cough Variant Asthma(CVA)||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|June 2012|August 2013|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||November 2012|November 15, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584804||87014|
NCT01584752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSSHP1U/2011|Gore-BioA Fistula Plug to Treat Transsphincteric Fistulas|Clinical Multicenter Study of the Efficacy of Gore-BioA Fistula Plug in High Transsphincteric Perianal Fistulas||Central Finland Hospital District|No|Terminated|November 2011|November 2015|Anticipated|December 2014|Anticipated|Phase 3|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|70 Years|No|Probability Sample|Inhabitants of Finland|April 2012|November 21, 2014|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584752|12 Months|87018|
NCT01585064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A06-216|Optimization of Treatment With Adalimumab (Humira)|Optimization of Treatment With Adalimumab (HUMIRA): A Multi-center, Randomized, Single Blind, Controlled Clinical Trial||Lawson Health Research Institute|Yes|Completed|August 2006|February 2010|Actual|December 2009|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|309|||Both|18 Years|N/A|No|Probability Sample|Patients will be recruited from approximately 40 sites across Canada. The study sample        selection will be stratified in order to ensure adequate representation from all Canadian        regions.|April 2012|April 24, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585064||86994|
NCT01606774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNC2.0|A Modernized Approach to Prenatal Care in Low Risk Women|A Modernized Approach to Prenatal Care in Low Risk Women||Massachusetts General Hospital|No|Not yet recruiting|July 2012|December 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Female|N/A|35 Years|Accepts Healthy Volunteers|||May 2012|May 25, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606774||85332|
NCT01606787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-079|Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes|Phase 3 Trial of Intravenous Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes||Memorial Sloan Kettering Cancer Center||Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606787||85331|
NCT01598415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT12505|Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II|A Two Part Protocol to Assess, Using Double Blind Placebo Control, the Safety, Tolerability, and Pharmacokinetics of Ascending Single Doses of a New Intra-articular Administration Formulation of SAR113945 (IKK Inhibitor) Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose in Patients With Knee Osteoarthritis.||Sanofi|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|40 Years|N/A|No|||October 2014|October 16, 2014|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598415||85975|
NCT01598649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSEP H52-12|Intervention With Lupin Protein-enriched Foods in Hypercholesterolemic Subjects|Influence of Intervention With Lupin Protein-enriched Foods on Cardiovascular Risk Factors in Hypercholesterolemic Subjects||University of Jena|Yes|Completed|June 2012|October 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|72|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 28, 2013|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01598649||85957|
NCT01607632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00173|Loving-kindness Meditation for Posttraumatic Stress Disorder (PTSD)|An Open Pilot Study of Loving-Kindness Meditation for PTSD||Seattle Institute for Biomedical and Clinical Research|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||May 2012|May 24, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607632||85267|
NCT01607645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2588.00|Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes|Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML.||Fred Hutchinson Cancer Research Center|No|Completed|July 2012|September 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|N/A|No|||October 2013|October 9, 2013|May 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607645||85266|
NCT01607918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110019MD|Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy|Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial|THC|National Taiwan University Hospital|Yes|Recruiting|February 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1300|||Both|20 Years|N/A|No|||October 2013|October 27, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01607918||85245|
NCT01608217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER001-02-02|Delta-THC in Dementia|Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia||Radboud University|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|40 Years|N/A|No|||June 2014|June 26, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608217||85222|
NCT01599377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3921141|Tofacitinib Bioequivalence Study Comparing Tablets And Capsules|Phase 1, Open-Label, Randomized, Single-Dose, Cross-Over, Bioequivalence Study Comparing Tablets (5 And 10 Mg) And Capsules (5 And 10 Mg) Of Tofacitinib Under Fasted Conditions In Healthy Volunteers||Pfizer|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|50|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 8, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599377||85901|
NCT01599390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116730|Influenza Burden Assessment in the United States, July1997 - up to April 2009|Burden of Influenza in the United States, July 1997 up to April 2009||GlaxoSmithKline|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|All records of people in the US in the Nationwide Inpatient Sample (NIS) hospitalization        data or in the US mortality data will be included in this study.|February 2013|February 21, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599390||85900|
NCT01599611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pkv|Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study|Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study||University of Aarhus|No|Completed|March 2010|January 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|128|||Both|5 Years|10 Years|No|Non-Probability Sample|All children born in Denmark in the period 01.01.2000 - 31.12.2005 with a gestational age        >= 35 weeks and a total serum bilirubin > 450 umol/L and a matched control group of        children|May 2012|May 15, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599611||85883|
NCT01599624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0032|Stress Resilience Training System|Stress Resilience Training System|SRTS|United States Naval Medical Center, San Diego|Yes|Not yet recruiting|October 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 29, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01599624||85882|
NCT01600196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCC2005009|Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus|Surgical Resection Versus Best Supportive Care for Resectable Hepatocellular Carcinoma Invading the First Branch of Portal Vein||Sun Yat-sen University|Yes|Completed|January 2006|July 2011|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|126|||Both|18 Years|75 Years|No|||May 2012|May 15, 2012|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01600196||85838|
NCT01600209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Exact Sciences 2011-N|Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing|Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing||Exact Sciences Corporation|No|Completed|October 2011|September 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|674|Samples With DNA|Provide anonymous, clinically characterized specimens for bio-repository for future      colorectal cancer-related test development.|Both|50 Years|84 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients are at average risk of developing colorectal cancer at the time of their        colonoscopy and the colonoscopy resulted in normal findings.|May 2015|May 12, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01600209||85837|
NCT01600456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Optimizing1|Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline|Optimizing PTSD Treatment: PE Versus PE Plus Sertraline|OPT|Case Western Reserve University|Yes|Active, not recruiting|March 2011|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Actual|150|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01600456||85818|
NCT01596582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-CA131197|Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening|Impact of Risk Stratification on Shared Decision-Making for Colorectal Cancer Screening||Boston Medical Center|No|Active, not recruiting|April 2012|January 2016|Anticipated|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|440|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||August 2014|July 27, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01596582||86116|
NCT01583647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0524A-158|A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)|A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia||Merck Sharp & Dohme Corp.|No|Terminated|June 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|10 Years|16 Years|No|||November 2015|November 2, 2015|April 20, 2012|No|Yes|In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a    significant increase in incidence of some types of non-fatal SAEs.|No|October 7, 2013|https://clinicaltrials.gov/show/NCT01583647||87100|
NCT01583972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N3-TSA-003|Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function|Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function||USDA, Western Human Nutrition Research Center|Yes|Completed|January 2012|August 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|N/A|48 Hours|Accepts Healthy Volunteers|||August 2014|August 22, 2014|April 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01583972||87076|
NCT01584180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCOOL 3|A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Brain.Pad (iCOOL 3)|iCOOL 3 (Induction of COOLing 3): A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Brain.Pad|iCOOL 3|University Hospital Heidelberg|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|April 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01584180||87061|
NCT01584843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116246|Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus|A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus||GlaxoSmithKline|No|Completed|May 2012|June 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|6||Actual|41|||Both|12 Years|N/A|No|||March 2015|July 2, 2015|April 23, 2012||No||No|June 26, 2014|https://clinicaltrials.gov/show/NCT01584843||87011|
NCT01588951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1227|Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior|Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior||Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|August 2013|June 2017|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|100 Years|No|||November 2015|November 17, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588951||86701|
NCT01588964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prot.lf.P.177(A.200)/C.E./2005|IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer|Surgery and Intraperitoneal Hyperthermic Chemotherapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer .|IPHC|Catholic University of the Sacred Heart|Yes|Completed|March 2005|December 2011|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Female|18 Years|65 Years|No|||April 2012|April 28, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01588964||86700|
NCT01584817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120405-6|A Repeated Instruction by Telephone on the Day Before Colonoscopy to Patients Undergoing Colonoscopy|A Repeated Instruction by Telephone on the Day Before Colonoscopy Improves the Quality of Bowel Preparation and Colonoscopy Procedure : a Prospective Randomized, Controlled Trial||Fourth Military Medical University|Yes|Completed|February 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Screening|2||Actual|605|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2013|December 1, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584817||87013|
NCT01585090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89094|Effect of Ankle Position and Pelvic Floor Muscle Force With Relaxation of Pelvic Floor Muscles Syndrome|||Mashhad University of Medical Sciences|Yes|Withdrawn||||||Phase 2/Phase 3|Interventional|Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|0|||Female|25 Years|55 Years||||April 2012|April 24, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585090||86992|
NCT01585103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006429|Cytosponge Protocol IRB 11-006429|Cytosponge Protocol||Mayo Clinic|No|Recruiting|December 2012|September 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|120|||Both|18 Years|65 Years|No|||December 2015|December 16, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585103||86991|
NCT01598129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oncos-C1|ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers|Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours||Oncos Therapeutics|Yes|Completed|April 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||September 2014|October 1, 2014|April 19, 2012||No||No|June 11, 2014|https://clinicaltrials.gov/show/NCT01598129||85997|
NCT01598142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YLS2011-105|Single-operator Wire-guided Endoscopic Retrograde Cholangiopancreatography Cannulation Technique|Single-operator Wire-guided ERCP Cannulation Technique: a Single-center Randomized Controlled Study||Zhejiang University|Yes|Completed|October 2007|February 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|465|||Both|14 Years|N/A|No|||May 2012|May 14, 2012|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01598142||85996|
NCT01598428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YGao|Anterior Capsule Polishing Effect on Effective Lens Position|Effect of Anterior Capsule Polishing on Effective Lens Position After Cataract Surgery||Shandong University|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|20|||Both|N/A|N/A|No|||January 2015|January 14, 2015|May 8, 2012||No||No|June 17, 2014|https://clinicaltrials.gov/show/NCT01598428||85974|
NCT01598896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-002262|Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia|Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia|DCCS|Mclean Hospital|No|Recruiting|May 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|45 Years|No|||October 2015|October 26, 2015|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598896||85938|
NCT01598870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOLecco001|Diagnosis of Spontaneous Bacterial Peritonitis|Redefinition of Diagnostic Criteria for Spontaneous Bacterial Peritonitis: Assessment of Accuracy of Available Tests and of Reference Standard|ARSDIASP|Azienda Ospedaliera di Lecco|No|Recruiting|May 2012|October 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Blood and ascitic fluid samples stored at -80°C|Both|18 Years|N/A|No|Non-Probability Sample|Patients with cirrhosis and ascites requiring paracentesis.|January 2015|January 13, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598870||85940|
NCT01598883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Altered Heparin Responsiveness|Understanding "Heparin Resistance" in Cardiac Surgery|Understanding "Heparin Resistance" in Cardiac Surgery: Altered Heparin Responsiveness and Its Association With Acute Inflammatory Reactions||Massachusetts General Hospital|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|504|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 7, 2015|April 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598883||85939|
NCT01599104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A1306|Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension||Novartis|Yes|Completed|June 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1161|||Both|20 Years|N/A|No|||September 2015|September 25, 2015|May 13, 2012||No||No|July 11, 2015|https://clinicaltrials.gov/show/NCT01599104||85922|
NCT01599117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1202-006-396|A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]|Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial]||Seoul National University Hospital|Yes|Recruiting|October 2012|May 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||January 2013|January 30, 2013|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01599117||85921|
NCT01599637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIGE025E2201|Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment|A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Determine the Mode of Action of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)||Novartis||Completed|April 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|75 Years|No|||October 2014|March 11, 2015|January 25, 2012||No||No|September 10, 2014|https://clinicaltrials.gov/show/NCT01599637||85881|
NCT01599871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1559-F-447|Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease|Multicenter 52 Weeks Double Blind Placebo-controlled Trial for the Assessment of Theophylline on Top of Combination Therapy in Severe COPD|ASSET|Hospital Son Espases|No|Active, not recruiting|January 2011|March 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|128|||Both|45 Years|90 Years|No|||August 2015|August 31, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599871||85863|
NCT01600222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LEO 90100-30|Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris|A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris||LEO Pharma|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||July 2015|July 17, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01600222||85836|
NCT01596309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNAV-006/2012|Cocoa Extract-enriched Meals and Cardiovascular Risk in Older Population|Study of the Effect of Ready-cooked Meals Containing Cocoa Extract, as a Potential Functional Ingredient, on Cardiovascular Risk Markers in Older Population||Clinica Universidad de Navarra, Universidad de Navarra|No|Completed|January 2012|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||September 2012|June 17, 2013|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596309||86137|
NCT01596595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSS of 4-SITE|Longitudinal Surveillance Study of the 4-SITE Lead/Header System|Longitudinal Surveillance Study of the 4-SITE Lead/Header System|LSS of 4-SITE|Boston Scientific Corporation|No|Active, not recruiting|April 2013|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|1820|||Both|N/A|N/A|No|Non-Probability Sample|From Physicians patient population|February 2016|March 2, 2016|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596595||86115|
NCT01583660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC-KS-2011-026|Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture|Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture||Beijing Army General Hospital|Yes|Recruiting|January 2012|December 2015|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples Without DNA|Peripheral blood serum|Both|60 Years|N/A|No|Probability Sample|Elderly patients(age > 60 years old)with hip fracture(intertrochanteric fractures and        femoral neck fractures)adimited into Beijing Army General Hospital|April 2012|April 21, 2012|February 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01583660||87099|
NCT01584219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0016-12HYMC|The Role of Placental Myeloid Cells During Gestation, Labor and Disease|The Role of Placental Myeloid Cells During Gestation, Labor and Disease||Hillel Yaffe Medical Center|No|Not yet recruiting|April 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|100|||Female|18 Years|45 Years|No|Non-Probability Sample|pregnant women|April 2012|May 7, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584219||87058|
NCT01584193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHV 46/11|Ultrasound-guided Subclavian Vein Puncture Versus Cephalic Vein Dissection for Venous Access Port Implantation|Ultrasound-guided Subclavian Vein Puncture Versus Cephalic Vein Dissection for Totally Implantable Venous Access Port Implementation: a Single-center Controlled Randomized Superiority Trial||University of Lausanne Hospitals|No|Withdrawn|June 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2015|June 23, 2015|April 21, 2012||No|Logistical reasons (institutional reorganization of ambulatory surgery)|No||https://clinicaltrials.gov/show/NCT01584193||87060|
NCT01584206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011:051|Sitosterolemia Metabolism|Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe|STAIR7002|University of Manitoba|Yes|Active, not recruiting|April 2012|December 2016|Anticipated|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|16 Years|99 Years|Accepts Healthy Volunteers|||December 2015|March 9, 2016|April 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584206||87059|
NCT01588977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APR042012|Subchondral Microfracture of Tibia After Arthroscopic Anterior Cruciate Ligament Surgery Reconstruction|Subchondral Microfracture of Tibia After Arthroscopic Anterior Cruciate Ligament Surgery Reconstruction With Two Different Drilling Techniques. Correlation With Postoperative Pain||Hospital Ambroise Paré Paris|No|Completed|April 2012|August 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|43|||Both|18 Years|N/A|No|Non-Probability Sample|Primary arthroscopic reconstruction surgery of an Anterior Cruciate Ligament tear|February 2015|February 6, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588977||86699|
NCT01589250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBL-03|Risk Scoring Systems in Upper GI-haemorrhage|Risk Scoring Systems in Upper GI-haemorrhage||Odense University Hospital|No|Completed|August 2009|April 2012|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|831|||Both|18 Years|N/A|No|Non-Probability Sample|Data were collected from consecutive patients admitted with UGIH at Odense University        Hospital between August 2009 and August 2011. UGIH was defined as history of haematemesis,        coffee-ground vomit, or melaena.|April 2012|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589250||86678|
NCT01585168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106008650|Functional Neuroimaging of Alcoholism Vulnerability (PIT)|Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity and Pavlovian-to-Instrumental Transfer (PIT)|CTNA|Yale University|Yes|Recruiting|December 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|84|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585168||86987|
NCT01585181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PXVX-VC-0200-002|Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200|A Phase 1 Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the LIve Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae Serotype 01 Inaba CVD 103-HgR Vaccine Strain||PaxVax, Inc.|No|Completed|April 2012|January 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|April 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585181||86986|
NCT01585129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0704|Treatment Utility of Postpartum Antibiotics in Chorioamnionitis|Treatment Utility of Postpartum Antibiotics in Chorioamnionitis|TUPAC|Washington University School of Medicine|Yes|Terminated|September 2010|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Female|14 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|April 23, 2012||No|The trial was stopped for futility in patient enrollment following a planned interim analysis    after 80 patients were randomized.|No||https://clinicaltrials.gov/show/NCT01585129||86990|
NCT01585142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.18.INF|Growth of Infants Fed With BabyNes System|Assessment of Growth of Infants Fed With BabyNes System (Single-serve Formulas, Adaptative System)||Nestlé|No|Completed|April 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|33|||Both|N/A|14 Days|Accepts Healthy Volunteers|||January 2015|January 15, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585142||86989|
NCT01598155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGomes 01|Effect of Supragingival Control Versus Supra- and Subgingival Control in the Periodontal Health During the Maintenance|The Effect of Supragingival Biofilm Control, and the Combination of Supra and Subgingival Biofilm Control in Periodontal Health of Patients Participating in a Periodontal Preventive Maintenance Program - A Randomized Clinical Trial.||Federal University of Rio Grande do Sul|No|Active, not recruiting|May 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|35 Years|N/A|No|||December 2014|December 7, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01598155||85995|
NCT01598675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1240|Error Based Learning for Restoring Gait Symmetry Post-Stroke|Error Based Learning for Restoring Gait Symmetry Post-Stroke||University of North Carolina, Chapel Hill|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|54|||Both|21 Years|N/A|No|||September 2015|September 9, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01598675||85955|
NCT01599130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Zhangyufeng|Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss|The Efficacy of Peg-interferon α-2a in HBeAg (+) Chronic Hepatitis B Patients Who Have Been Treated by Entecavir for 48 Weeks But Without HBeAg Loss||Sun Yat-sen University|No|Not yet recruiting|July 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|No|||May 2012|May 14, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01599130||85920|
NCT01599143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYGH REB # 09-0041|Identifying Therapeutic Factors in an 8-Week (30 Hour) Mindfulness-Based Stress Reduction (MBSR) Program|Identifying Therapeutic Factors in an 8-Week (30 Hour) Mindfulness-Based Stress Reduction (MBSR) Program|mbsr|North York General Hospital|No|Completed|January 2009|April 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|135|||Both|18 Years|N/A|No|||May 2012|May 13, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01599143||85919|
NCT01599403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002702 Frendl|Thoracic Blocks Versus Thoracic Epidural and Patient Controlled Anesthesia in Traumatic Rib Fracture Patients|Comparative Effectiveness of Continuous Thoracic Paravertebral Blocks Versus Thoracic Epidural and Continuous Intercostal Blocks Versus Patient-Controlled Anesthesia in Traumatic Rib Fracture Patients||Brigham and Women's Hospital|No|Recruiting|April 2012|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|70|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|February 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599403||85899|
NCT01599650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRFB002E2402|Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion|A 24-month, Phase IIIb, Open-label, Randomized, Active Controlled, 3-arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy or With Adjunctive Laser Photocoagulation in Comparison to Laser Photocoagulation in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion|BRIGHTER|Novartis|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|455|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01599650||85880|
NCT01599884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVMREF-001|N-Acetylcysteine for Patients With COPD and ChronicBronchitis|Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-1||Minnesota Veterans Research Institute|No|Not yet recruiting|June 2012|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|65|||Both|40 Years|85 Years|No|||May 2012|May 15, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01599884||85862|
NCT01599897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-TBVPX-113|Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults||IDRI|Yes|Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|6||Actual|60|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|May 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01599897||85861|
NCT01599910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ed-scribe|Scribes in the Emergency Department|The Effect of Scribes in the Emergency Department||Beth Israel Deaconess Medical Center|No|Not yet recruiting|October 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult emergency department patients|May 2012|May 15, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01599910||85860|
NCT01600235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01-023|Safety and Efficacy of Therapeutic INduced HYPERTENSION in Acute Non-cardioembolic Ischemic Stroke (SETIN-HYPERTENSION)|Safety and Efficacy of Therapeutic Induced Hypertension in Patients With Acute Non-cardioembolic Ischemic Stroke: A Multicenter, Randomized, Open Label, Prospective, Phase 3 Study||Samsung Medical Center|Yes|Recruiting|June 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|N/A|N/A|No|||May 2014|May 8, 2014|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01600235||85835|
NCT01596322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARTO, R01 MH054907|International HIV Antiretroviral Adherence, Resistance and Survival|Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Uganda|UARTO|Massachusetts General Hospital|No|Recruiting|September 2004|September 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|775|Samples With DNA|plasma, buffy coat, saliva|Both|18 Years|N/A|No|Probability Sample|HIV positive adults 18 years and older, who are ART naive and initiating ART at either        Mbarara HIV clinic or Mulago HIV clinic in Uganda|April 2015|April 6, 2015|April 22, 2010||No||No||https://clinicaltrials.gov/show/NCT01596322||86136|
NCT01597401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aes-103-002|A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease|A Phase 1, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating, Single Oral Doses of Aes-103 in Subjects With Stable Sickle Cell Disease||Baxalta US Inc.|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|65 Years|No|||August 2015|August 6, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597401||86053|
NCT01597414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-75111-10114|Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1|Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group||European Organisation for Research and Treatment of Cancer - EORTC|Yes|Recruiting|June 2013|July 2018|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|60 Years|N/A|No|||November 2015|November 6, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01597414||86052|
NCT01583673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09.56.PED|Growth of Infants Fed an Amino Acid Infant Formula|Assessment of Growth of Infants Fed an Amino Acid Based Formula||Nestlé|Yes|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|225|||Both|N/A|17 Days|Accepts Healthy Volunteers|||June 2014|October 20, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583673||87098|
NCT01583686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120111|CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer|Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes||National Institutes of Health Clinical Center (CC)||Recruiting|March 2012|December 2019|Anticipated|December 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|136|||Both|18 Years|70 Years|No|||October 2015|November 3, 2015|April 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583686||87097|
NCT01583699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 111/2011|Endomicroscopy and Gastric MALT-lymphoma|Confocal Laser Endomicroscopy as Diagnostic Tool for Gastrointestinal MALT-lymphoma||Medical University of Vienna|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||July 2015|July 19, 2015|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01583699||87096|
NCT01584232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14359|A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus|A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide||Eli Lilly and Company|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|361|||Both|20 Years|N/A|No|||October 2014|October 14, 2014|April 23, 2012|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01584232||87057|
NCT01584518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-16126|B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading|B-type Natriuretic Peptide (BNP) as a Surrogate Marker Guiding Post-operative Fluid Off-loading||Creighton University|Yes|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|N/A|No|||June 2013|June 27, 2013|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01584518||87036|
NCT01589263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-023-11F|Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With Benign Prostatic Hyperplasia and Lower Urinary Track Symptoms (BPH)|OnabotulinumtoxinA (onaBoNT-A) vs Oral Tamsulosin for BPH & LUTS (#02-10-10-05)||VA Office of Research and Development|No|Recruiting|June 2012|July 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Male|50 Years|N/A|No|||January 2016|January 13, 2016|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589263||86677|
NCT01589874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|328/2007|Anemia of Inflammation: Investigation on Impaired Iron Regulation in Acutely Ill Patients and Their Clinical Outcome|Anemia of Inflammation: Investigation on Impaired Iron Regulation in Acutely Ill Patients and Their Clinical Outcome||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Yes|Recruiting|January 2008|December 2014|Anticipated|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|serum, buffy coat|Both|18 Years|90 Years|No|Probability Sample|all consecutive patients admitted to Internal Medicine ward because of acute inflammatory        illness|April 2012|April 30, 2012|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01589874||86630|
NCT01589237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCQ908B2305|Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.|An Open Label, 52-week, Safety and Tolerability Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.||Novartis|No|Completed|February 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|April 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01589237||86679|
NCT01585155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-650-21|Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis|Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Ulcerative Colitis.||Mitsubishi Tanabe Pharma Corporation|No|Completed|February 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|6 Years|17 Years|No|||May 2015|May 10, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585155||86988|
NCT01598441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMCIRB-201127|Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)|Multi-centre, Randomized Study of Iloprost Inhaled in Preventing and Treating Reactive Pulmonary Hypertension (RPH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Diseases (CHD)||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|June 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|800|||Both|N/A|18 Years|No|||December 2012|December 28, 2012|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01598441||85973|
NCT01598688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSADOC|Cyclosporine (CSA) Level in Blood Samples Collected From Different Lines|Monitoring of Cyclosporine Serum Levels in Hematopoietic Stem Cell Transplantation||University of Sao Paulo|Yes|Completed|February 2012|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01598688||85954|
NCT01598662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUD Study B090743|Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement|Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement: A Randomized, Controlled Trial|IUD|University of Louisville|Yes|Active, not recruiting|July 2009|March 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598662||85956|
NCT01598909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARINE Study|Efficacy of Arnica D1 Ointment After Upper Blepharoplasty|Efficacy of Arnica D1 Ointment After Upper Blepharoplasty: a Randomized, Double-blind Placebo-controlled Study|ARINE|Isala|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|136|||Both|18 Years|N/A|No|||August 2015|August 21, 2015|May 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598909||85937|
NCT01599156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF11|Reflexology for Chronic Constipation|Reflexology for Patients Suffering From Chronic Constipation- a Phase II B, Single Armed, Open Label Study.||Shaare Zedek Medical Center|No|Recruiting|July 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|January 14, 2013|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01599156||85918|
NCT01599416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGMH-O&G-201101TF01|Influence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative|Randomized, Double-blind, Placebo-controlled Study ,Oral U-relax in the Influence of the Vaginal Environment Health Promotion, and the HPV DNA Test Index Change From Positive to Negative on the HPV Infection Women||Chang Gung Memorial Hospital|Yes|Recruiting|June 2011|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Anticipated|80|||Female|30 Years|65 Years|No|||April 2012|May 15, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01599416||85898|
NCT01599663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project number 3234|Pain Management of Intensive Care Unit Patients|Pain Management of Intensive Care Unit (ICU) Patients. An Intervention Study to Evaluate the Effect of Systematic Pain Management of Various Groups of ICU Patients.||Ostfold Hospital Trust|Yes|Active, not recruiting|May 2012|October 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|720|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01599663||85879|
NCT01599923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-02/05|Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation|Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation||Instituto Bioclon S.A. de C.V.|No|Completed|May 2005|August 2006|Actual|June 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|6 Months|18 Years|No|||May 2012|May 14, 2012|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599923||85859|
NCT01596335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-650-22|Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease|To Evaluate the Efficacy and Safety of TA-650 in Comparison With a Control Drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in Patients With Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin (IVIG).||Mitsubishi Tanabe Pharma Corporation|No|Completed|May 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|1 Year|10 Years|No|||April 2015|April 9, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596335||86135|
NCT01596348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR_Ex|Exercise Perceptions and Preferences Among Rheumatoid Arthritis Patients|Perceived Exercise Benefits, Barriers and Preferences Among Swiss Rheumatoid Arthritis Patients||University of Lausanne|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|120|||Both|30 Years|80 Years|No|Probability Sample|Patients will be selected in the Rheumatology Department of the Centre Hospitalier        universitaire Vaudois in Lausanne.|May 2012|May 10, 2012|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01596348||86134|
NCT01583426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 69|Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)|A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)|GeparSepto|German Breast Group|Yes|Active, not recruiting|July 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01583426||87117|
NCT01583439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHP041|The Mochudi Prevention Project ART Protocol|An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 ≥ 250 Cells/mm3 and HIV Virus Load ≥ 50,000 cp/mL||Harvard School of Public Health|Yes|Terminated|September 2012|September 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|16 Years|64 Years|No|||March 2015|March 18, 2015|April 11, 2012||No|Low Accrual.|No||https://clinicaltrials.gov/show/NCT01583439||87116|
NCT01583985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-125|Strategies for Prescribing Analgesics Comparative Effectiveness Trial|Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) Trial|SPACE|VA Office of Research and Development|Yes|Active, not recruiting|June 2013|May 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583985||87075|
NCT01588704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GASTO1001|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma|A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma||Sun Yat-sen University|No|Completed|April 2012|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588704||86720|
NCT01584531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onconova 09-05|Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome|A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification|ONTARGET|Onconova Therapeutics, Inc.|No|Active, not recruiting|May 2012|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584531||87035|
NCT01590160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/12/0158|Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma|A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma|MESO-02|University College, London|Yes|Recruiting|August 2013|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|March 8, 2016|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590160||86609|
NCT01589614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A6631036|A Study To Investigate The Effect Of Erythromycin On The Pharmacokinetics Of PH-797804|A Phase 1, Randomised, Open Label, Two Sequence, Two Treatment, Two Way Crossover Study to Estimate the Steady-state Effect of Erythromycin on the Single Dose Pharmacokinetics of Ph-797804 in Healthy Subjects||Pfizer|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 16, 2012|April 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01589614||86650|
NCT01589562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-ES 1201|Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fed Condition|A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of DW-ES(B) and Megace® Under Fed Conditions in Healthy Male Volunteers||Daewon Pharmaceutical Co., Ltd.|Yes|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|28|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 21, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01589562||86654|
NCT01590134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS/2012/1|The Efficacy and Safety of Iron Supplementation|Pilot Studies on the Efficacy and Safety of Dietary Iron Supplementation||Imperial College London|No|Active, not recruiting|March 2012|December 2015|Anticipated|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||April 2012|February 3, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590134||86611|
NCT01585480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002S78225|Preventing Obesity in the Worksite: A Multi-Message, Multi-"Step" Approach|Preventing Obesity in the Worksite: A Multi-Message, Multi-"Step" Approach|Go!|University of Minnesota - Clinical and Translational Science Institute|No|Completed|November 2010|December 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|499|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2013|October 17, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585480||86964|
NCT01598454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-RACO-1-2-09|Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides|Phase 1 Study on the Use of Racotumomab Anti-idiotype Antibody in Patients With Pediatric Malignancies That Express N-glycolylated Gangliosides and Are Resistant to Conventional Treatment.||Laboratorio Elea S.A.C.I.F. y A.|No|Completed|February 2011|June 2015|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|1 Year|10 Years|No|||July 2015|July 27, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01598454||85972|
NCT01599689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P01629|Pilot and Feasibility Study of a Mirrors Intervention for Reducing Delirium in Older Cardiac Surgical Patients|Can an Evidence-based Mirrors Intervention Reduce Postoperative Delirium in Older Cardiac Surgical Patients? A Pilot and Feasibility Cluster Randomised Controlled Trial||Papworth Hospital NHS Foundation Trust|No|Completed|October 2012|September 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|223|||Both|70 Years|N/A|No|||June 2013|April 21, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01599689||85877|
NCT01598922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-12-1-0109|Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function|Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function|iCBT|Mclean Hospital|No|Active, not recruiting|October 2012|December 2017|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 14, 2016|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598922||85936|
NCT01599169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID-RCB : 2012 - A00096 - 37|Evaluation of the Efficacy and Tolerance of B-Back® on the Burnout Syndrome|Evaluation of the Efficacy and Tolerance of B-Back® on the Burnout Syndrome. Double-blind, Randomized, Monocentric Trial With Two Parallel Groups (B-Back® Verum Versus B-Back® Placebo)||Université Victor Segalen Bordeaux 2|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|87|||Both|30 Years|65 Years|No|||April 2013|April 21, 2013|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01599169||85917|
NCT01599429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMS-2011-01|Study of the Predictive Marker FLT in Patients Suffering From AML|Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy|TEP-FLT-LMA|Centre Hospitalier Universitaire de Sherbrooke|Yes|Recruiting|October 2011|October 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|N/A|No|Probability Sample|Patients newly diagnosed with acute myeloid, between October 2011 and October 2013, at the        Centre Hospitalier Universitaire de Sherbrooke (CHUS).|September 2014|September 24, 2014|November 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01599429||85897|
NCT01599676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 09008|Citrulline, Exercise Training and Muscle Strength in the Elderly|"Effect of Citrulline Supplementation on Muscle Strength in Elderly Institutionalized Subjects Undergoing an Exercise Training Programme. "|CITREX|Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|91|||Both|75 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 6, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599676||85878|
NCT01599936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-02/06|Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting Envenomation|Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation||Instituto Bioclon S.A. de C.V.|No|Completed|April 2004|June 2007|Actual|October 2006|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|6 Months|18 Years|No|||March 2016|March 18, 2016|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599936||85858|
NCT01596881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB #00008179-MS|Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis|Using OCT to Capture Retinal Microvascular Changes Associated With MS|OCT in MS|Oregon Health and Science University||Active, not recruiting|April 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will enroll both males and females and include all ethnic and racial groups        through clinical practices. The study will enroll subjects from 18 to 70 years of age.        Participants older than 70 years are excluded as cooperation with tests may be difficult.        For similar reasons, participants who have MS and vision worse than 20/200 are excluded.        The study also excludes those with any eye disease that would interfere with of assessment        of MS. Otherwise people with any health status are eligible for enrollment. Two groups of        participants are recruited: people with healthy, normal eyes and people with any type of        MS.|August 2014|August 29, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596881||86093|
NCT01596894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0035-12-WOMC|Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease|A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone.||Wolfson Medical Center|No|Completed|October 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|73|||Both|5 Years|17 Years|No|||December 2015|December 6, 2015|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596894||86092|
NCT01597128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0080-P6A|Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or Contaminated Cases|Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or Contaminated Cases|Flex HD|University of Kentucky|Yes|Active, not recruiting|March 2011|June 2016|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|85 Years|No|||December 2014|December 23, 2014|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597128||86074|
NCT01583712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 787/2010|Endomicroscopy and Graft-versus-host Disease|Diagnosis of Acute Gastrointestinal Graft-versus-Host Disease by Early Endomicroscopic Features of the Small Intestine||Medical University of Vienna|No|Recruiting|April 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 19, 2015|January 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01583712||87095|
NCT01583998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03MH092509-01|Electronic-Measurement Based Care for Major Depressive Disorder|Electronic-Measurement Based Care (e-MBC) for Major Depressive Disorder (MDD)|e-MBC|University of Texas Southwestern Medical Center|Yes|Active, not recruiting|June 2011|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||April 2012|May 21, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01583998||87074|
NCT01589289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP2-01-NEU|Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC|Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo|Nidiag-Neuro|Institute of Tropical Medicine, Belgium|No|Completed|September 2012|May 2015|Actual|January 2015|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|352|||Both|5 Years|N/A|No|||January 2016|January 15, 2016|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589289||86675|
NCT01588990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25753|A Translational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ASCENT)|An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin) [ASCENT]||Hoffmann-La Roche||Active, not recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|128|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588990||86698|
NCT01589627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009.003|Wrist Extension Dynasplint (WED) Distal Radius Fracture|Contracture Reduction Following Distal Radius Fracture||Dynasplint Systems, Inc.||Not yet recruiting||December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||April 2012|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589627||86649|
NCT01589536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10001|Social Medical Progression of Coronary Heart Disease With Associated Psychosocial Comorbidity -Interval Rehabilitation.|Improvement of the Social Medical Progression of Coronary Heart Disease With Associated Psychosocial Comorbidity by the Use of Interval Rehabilitation.|SINKO|Clinic Roderbirken|Yes|Recruiting|October 2011|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|480|||Both|18 Years|58 Years|No|||April 2012|May 1, 2012|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01589536||86656|
NCT01589549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/128|Mesenchymal Stromal Cells for Acute Graft Versus Host Disease|A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation||Royal Perth Hospital|Yes|Recruiting|April 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|55 Years|No|||June 2015|June 8, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589549||86655|
NCT01598467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PARSEC-1|Prospective Assessment of Robotic Sacrocolpopexy: a European Multicentric Cohort (PARSEC)|Prospective Interventional Study on Robotic Sacrocolpopexy: a European Multicentric Cohort (PARSEC)|PARSEC|Cork University Hospital|No|Recruiting|August 2011|August 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|18 Years|N/A|No|||May 2012|May 14, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01598467||85971|
NCT01598480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201004DSA|To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Superficial Dermal Burn|To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Superficial Dermal Burn||Bio-medical Carbon Technology Co., Ltd.|No|Completed|May 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|80 Years|No|||November 2014|November 4, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01598480||85970|
NCT01599468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA-1|Can Tranexamic Acid Reduce Bleeding After Post Partum Hemorrhage in Cesarean Section Delivery|Effects of Tranexamic Acid on Post Partum Hemorrhage by Uterine Atony After Cesarean Section Delivery: a Randomized, Placebo Controlled Trial.||Hédi Chaker Hospital|No|Completed|July 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Female|20 Years|40 Years|No|||May 2012|May 21, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599468||85894|
NCT01599702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-Monofer-IBD-02|Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease|A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE)|IBD-02|Pharmacosmos A/S|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|21|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01599702||85876|
NCT01598935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.44.NRC|Post-exercise Protein Intake for Active Children|Double Blind Controlled Trial of Protein in Active Children||McMaster University|No|Active, not recruiting|October 2011|April 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Anticipated|36|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||June 2013|June 12, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01598935||85935|
NCT01599182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17074|Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer|Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer||University of Waterloo|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|9|Samples Without DNA|Measurements related to glucose, lipid and immune metabolism will be measured.|Male|18 Years|N/A|No|Probability Sample|Intermediate and high risk prostate cancer patients with >T2a or Gleason > 6 or PSA >10        would be offered participation in this study.|June 2015|June 22, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01599182||85916|
NCT01599442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|August-1|Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia|Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia|August-1|GWT-TUD GmbH|No|Terminated|June 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|123|||Both|18 Years|N/A|No|Non-Probability Sample|outpatients from hospitals with a department specializing in the treatment of diabetic        foot syndrome|April 2014|April 4, 2014|May 14, 2012||No|recrution number was not reached|No||https://clinicaltrials.gov/show/NCT01599442||85896|
NCT01596608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|145-2010|Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder|Efficacy and Tolerability of Magnetic Seizure Therapy (MST) as an Alternative to Electroconvulsive Therapy (ECT) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder||Centre for Addiction and Mental Health|Yes|Recruiting|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|85 Years|No|||March 2016|March 7, 2016|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01596608||86114|
NCT01596920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Osiris 302|Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers|A Multicenter, Adaptive Design, Randomized, Single-Blind Study With an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Grafix® for the Treatment of Chronic Diabetic Foot Ulcers|DFU|Osiris Therapeutics|No|Completed|April 2012|March 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|80 Years|No|||April 2014|April 7, 2014|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596920||86090|
NCT01597141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH065367-01A1|Psychosis: Early Detection, Intervention and Prevention|Psychosis: Early Detection, Intervention and Prevention|EDIP|Maine Medical Center|Yes|Completed|May 2003|December 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|12 Years|35 Years|No|||January 2016|January 7, 2016|May 9, 2012||No||No|October 22, 2015|https://clinicaltrials.gov/show/NCT01597141||86073|
NCT01597427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNIFESP-02|Reduction of Pulmonary Artery Pressure in Patients Subjected to Cardiac Surgery|Intravenous Clonidine Does Not Reduce Pulmonary Artery Pressure in Patients Subjected to Cardiac||Federal University of São Paulo|No|Completed|March 2009|March 2012|Actual|April 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|18 Years|80 Years|No|||May 2012|May 10, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01597427||86051|
NCT01583738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V0251 IV 202 4A|Effect of V0251 in Acute Vertigo|||Pierre Fabre Medicament|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|70 Years|No|||October 2014|October 29, 2014|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01583738||87093|
NCT01583751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pilonidal1|Videoendoscopic Pilonidal Sinus Surgery|Videoendoscopic Pilonidal Sinus Surgery. A New Technique|videosinus|SB Istanbul Education and Research Hospital|No|Recruiting|March 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|60 Years|No|||April 2012|April 23, 2012|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01583751||87092|
NCT01588392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0817|Short bouTs of Exercise for Preschool-age Children|Effects of Short Bouts of Physical Activity in Low-income Preschool-age Children|STEP|University of Massachusetts, Amherst|No|Completed|November 2011|September 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|323|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||July 2014|July 22, 2014|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01588392||86742|
NCT01589302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11133|PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia|A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|May 2012|||December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|78|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589302||86674|
NCT01589315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEAST for depression|Focal Electroconvulsive Therapy for Depression|Focal Electrical Administered Seizure Therapy (FEAST) for Major Depression|FEAST|Medical University of South Carolina|No|Recruiting|January 2007|January 2015|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|90 Years|No|||April 2012|April 29, 2012|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589315||86673|
NCT01589575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/CR-03|Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives|Evaluation of the Impact of Symptoms of Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives|StressRéa|Centre Hospitalier Universitaire de Nīmes|No|Completed|September 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|208|||Both|18 Years|N/A|No|Non-Probability Sample|The study population includes relatives of patients admitted to intensive care (over the        age of 16 years and intubated and ventilated for at least 48 hours). The study population        mainly inclused spouses, parents, children, and siblings of patients in intensive care.|March 2015|March 30, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01589575||86653|
NCT01590212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WS/0024|Mellow Bumps RCT - Antenatal Intervention for Vulnerable Women|Antenatal Parenting Support for Women Vulnerable in Pregnancy: an Exploratory Randomised Controlled Trial of Mellow Bumps||University of Glasgow|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|3||Actual|35|||Female|16 Years|N/A|No|||March 2014|March 5, 2014|April 30, 2012||No||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01590212||86605|Participants lived in one health board area and one community health care partnership (CHCP) in the west of Scotland. Midwives may have approached only those potential participants who were thought to be likely to take part in the group programmes.
NCT01589848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador|Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador|VWD|Universidad del Azuay|Yes|Completed|March 2013|June 2013|Actual|June 2013|Actual|N/A|Observational|N/A||1|Actual|81|Samples Without DNA|Blood samples|Female|18 Years|50 Years|No|Non-Probability Sample|Target population: all women from Cuenca district with a hemorrhage history.        Accessible population: Those women referred from professionals with an initial hemorrhage        history, who comply with the inclusion criteria and who sign the informed consert form.        Sample population: First comers referred with a hemorrhage history until fulfilling the        projected sample size. This non-probabilistic purposive sample will be used because it has        been reported that it could represent the target population.        *2010 Ecuadorian census: 131.163 women ages 18 to 50 years, at Cuenca district.|July 2013|July 2, 2013|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01589848||86632|
NCT01589861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIKHER2/IPC 2011-001|Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer|A Phase Ib/II Open-label Study Evaluating Safety and Efficacy of Oral BKM120 in Combination With Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Locally Advanced, Recurrent and Metastatic Breast Cancer. PIKHER2/IPC 2011-001|PIKHER2|Institut Paoli-Calmettes|Yes|Suspended|December 2011|January 2018|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|106|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|March 28, 2012||No|Data analysis|No||https://clinicaltrials.gov/show/NCT01589861||86631|
NCT01590420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cost-utility of OSAS|Cost-utility Study of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome Patients|Cost-utility Study of CPAP Treatment in Obstructive Sleep Apnea Patients||Associação Fundo de Incentivo à Pesquisa|Yes|Recruiting|March 2011|March 2014|Anticipated|March 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Both|30 Years|70 Years|No|||May 2012|May 2, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590420||86589|
NCT01599455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHC-SCI-CV|Baseline Cardiovascular Measurements in Pediatric Spinal Cord Injury|Cardiovascular Measurements at Baseline and During Cystometry in Pediatric Spinal Cord Injury||Shriners Hospitals for Children|No|Recruiting|May 2012|May 2022|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|315|||Both|N/A|18 Years|No|Non-Probability Sample|Children and adolescents with spinal cord injury who are admitted for spinal cord injury        rehabilitation program, visiting outpatient clinics, or undergoing scheduled urodynamic        study|May 2015|May 18, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599455||85895|
NCT01599988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APC032|Study to Compare Milk Protein Isolate (MPI) With Caseinate in Terms of Protein Utilization|A Randomised, Double-blinded Study to Compare Milk Protein Isolate (MPI)With Caseinate in Terms of Protein Utilization in Healthy Elderly Subjects||University College Cork|No|Completed|October 2011|April 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|65 Years|75 Years|Accepts Healthy Volunteers|||January 2013|January 15, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01599988||85854|
NCT01600001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KWA1201|A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)|A Randomized, Double-blind, Placebo-controlled, Phase II Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Anticipated|75|||Both|20 Years|N/A|No|||October 2013|October 29, 2013|May 14, 2012||||No||https://clinicaltrials.gov/show/NCT01600001||85853|
NCT01600014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0041-22|Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp|Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp||LEO Pharma|No|Completed|May 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|463|||Both|18 Years|N/A|No|||May 2015|May 6, 2015|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01600014||85852|
NCT01599949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100847|A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy|A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy||Janssen Research & Development, LLC|No|Completed|August 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|May 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01599949||85857|
NCT01600248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:078|Online Chronic Pain Therapy for Adults|Online Chronic Pain Therapy for Adults||University of Manitoba|Yes|Completed|June 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01600248||85834|
NCT01600261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200-47425|iCam Clinical Validation Study|iCam Clinical Validation Study||Optovue|No|Completed|April 2012|June 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|131|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects shall be recruited from the practice of the principal investigator (PI).|June 2012|June 27, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600261||85833|
NCT01596361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/01711|Verification of a Pharmacogenetic Approach to Customizing Chemotherapy to Asians|||National University Hospital, Singapore|Yes|Recruiting|August 2011|||August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|750|||Both|21 Years|N/A|No|Probability Sample|Samples will be obtained from the Tissue Repository, National University Hospital, St.        John of God Hospital, Perth, Australia and Kanazawa University, Japan.|December 2013|December 10, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01596361||86133|
NCT01596374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/01714|Clinical Relevance of ROS (V-ros UR2 Sarcoma Virus Oncogene Homolog) Aberrations in Solid Tumours|||National University Hospital, Singapore|Yes|Recruiting|August 2011|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|21 Years|N/A|No|Probability Sample|Department of Pathology, NUH Tissue Repository, The samples collected for the study are        leftover clinical samples and the patients have consented for their samples to be used for        research.|December 2013|December 10, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01596374||86132|
NCT01596387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-142-Fondecyt-UC-2012|Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients|Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients||Pontificia Universidad Catolica de Chile|Yes|Completed|March 2012|May 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01596387||86131|
NCT01596621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C18083/3076|Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment|An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment||Teva Pharmaceutical Industries|Yes|Active, not recruiting|July 2012|September 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596621||86113|
NCT01596907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115183|Treatment of Low Metabolic Rate Following Bariatric Surgery|Treatment of Low Metabolic Rate and Low Weight Loss Rate Following Bariatric Surgery||Oregon Weight Loss Surgery, LLC|No|Completed|May 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|218|||Both|18 Years|70 Years|No|||September 2015|September 22, 2015|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596907||86091|
NCT01597154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:023|Lifestyle Therapy for Youth With Type 2 Diabetes|Beating Diabetes Together: A Randomized Controlled Trial for Intensive Lifestyle Therapy for Youth With Type 2 Diabetes|BDT|University of Manitoba||Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|15|||Both|10 Years|20 Years|No|||July 2014|July 28, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597154||86072|
NCT01597713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1954-3936|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects||Novo Nordisk A/S|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2015|May 28, 2015|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597713||86029|
NCT01598012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R015535011|The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea|The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea||Mahidol University|No|Completed|December 2011|August 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 26, 2013|April 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598012||86006|
NCT01598272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PHX-03-NU-01|Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women|A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Center Study on the Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women.|Pharmanex|Pharmanex|Yes|Completed|July 2011|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|95|||Female|35 Years|73 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01598272||85986|
NCT01588067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-10-1488|Effectiveness of Medical Therapy, Endovascular Therapy, and Surgery for Peripheral Arterial Disease|Effectiveness of Medical Therapy, Endovascular Therapy, and Surgery for Peripheral Arterial Disease.|PAD|Kaiser Permanente|No|Completed|May 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|271|||Both|18 Years|N/A|No|Non-Probability Sample|The study population includes patients with PAD|July 2015|July 6, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01588067||86767|
NCT01588730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dyna-PF 2011|Dynamic and Static Splinting as a Treatment for Plantar Faciiopathy|Dynamic and Static Splinting as a Treatment for Plantar Faciiopathy||Dynasplint Systems, Inc.|Yes|Terminated|June 2011|||June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||August 2013|August 8, 2013|July 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01588730||86718|
NCT01589003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acute01|The Impact of Milk-products Differing in Their Glycaemic Properties on the Behaviour of Infants|An Intervention Study to Consider the Impact of Milk-products Differing in Their Glycaemic Properties on the Behaviour of Infants.||International Medical University|Yes|Recruiting|April 2012|February 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Anticipated|70|||Both|15 Months|21 Months|Accepts Healthy Volunteers|||April 2012|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589003||86697|
NCT01589276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH08|Risk Factors and Results of Emergency Ventral Hernia Repair|Risk Factors and Results of Emergency Ventral Hernia Repair||University Hospital Koge|No|Completed|January 2007|February 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10976|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hernia repairs registered in the Danish Ventral Hernia Database during the study period|April 2012|April 28, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589276||86676|
NCT01589029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885MCH01T|A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)|A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)|ILARIS|Triemli Hospital|Yes|Terminated|April 2012|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|April 27, 2012||No|The results of the interim analysis showed that the primary endpoint was not met|No||https://clinicaltrials.gov/show/NCT01589029||86695|
NCT01589042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP782|Chocolate Balloon Angioplasty Registry|Chocolate Balloon Angioplasty Registry|Chocolate BAR|TriReme Medical, LLC|No|Active, not recruiting|May 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Peripheral Arterial Disease appropriate for treatment with balloon        angioplasty|December 2014|May 11, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589042||86694|
NCT01589588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-163|Administration of Oxygen to Cluster Headache Patients|||Danish Headache Center||Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|57|||Both|18 Years|65 Years|No|||October 2015|October 9, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589588||86652|
NCT01589601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032443|Palliative Care in Heart Failure|Palliative Care in Heart Failure (PAL-HF)|PAL-HF|Duke University|Yes|Active, not recruiting|August 2012|July 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|19 Years|N/A|No|||March 2016|March 15, 2016|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01589601||86651|
NCT01590784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY-11-09-09-12|Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS)|The Reliability and Validity of the Thai Version of Calgary Depression Scale for Schizophrenia (CDSS)||Chiang Mai University|No|Recruiting|January 2012|November 2012|Anticipated|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Pariticipants diagnosed with schizophrenia according to DSM-IV-TR.|September 2012|September 22, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01590784||86561|
NCT01590797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-254|A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy, Alone or in Combination With Metformin||Merck Sharp & Dohme Corp.|No|Completed|July 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|467|||Both|18 Years|79 Years|No|||April 2015|April 29, 2015|May 1, 2012|Yes|Yes||No|January 16, 2015|https://clinicaltrials.gov/show/NCT01590797||86560|
NCT01590173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123123|Addition of Prednisolone and Heparin in Patients Undergoing Controlled Ovarian Hyperstimulation (COH) for In Vitro Fertilization (IVF) With Failed IVF Cycles|||National and Kapodistrian University of Athens||Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|200|||Female|25 Years|45 Years|No|||September 2015|September 8, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590173||86608|
NCT01590186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-02-003-OSi|Examination and Treatment of Pain in Front Foot|Examination and Treatment of Pain in Front Foot||Northern Orthopaedic Division, Denmark|No|Completed|October 2002|January 2004|Actual|April 2003|Actual|N/A|Observational|N/A||1|Actual|40|||Both|18 Years|68 Years|No|Non-Probability Sample|Examination and treatment of pain in front foot|March 2014|March 28, 2014|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01590186||86607|
NCT01590147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98211|Supportive Intervention Programs Study|Supportive Intervention Programs to Lessen Treatment Related Symptoms|SIPS|Wake Forest School of Medicine|No|Completed|June 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|15|||Both|18 Years|N/A|No|||July 2013|July 26, 2013|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590147||86610|
NCT01599208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-MEMORY-1|Facilitating Associative Memory Via Deep Transcranial Magnetic Stimulation to the Medial Temporal Lobe|Facilitating Associative Memory Via Deep Transcranial Magnetic Stimulation to the Medial Temporal Lobe||Brainsway|Yes|Suspended|August 2012|October 2015|Anticipated|August 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Anticipated|80|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2014|September 15, 2014|May 7, 2012||No|no IRB|No||https://clinicaltrials.gov/show/NCT01599208||85914|
NCT01600339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISGUOG1101.CTIL|A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)|A Single Arm, Multicenter, Open-label Phase II Trial of Cabazitaxel as Second Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Carcinoma||Rambam Health Care Campus|Yes|Completed|May 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||May 2015|May 10, 2015|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01600339||85827|
NCT01599715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The TULIP Project|Translating Unique Learning for Incontinence Prevention|Translating Unique Learning for Incontinence Prevention for Women Over the Age of 55|TULIP|University of Michigan|Yes|Active, not recruiting|September 2010|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|600|||Female|55 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 14, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599715||85875|
NCT01599962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012DR2027|Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects|Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects|Mira-Basel|University of Basel|Yes|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01599962||85856|
NCT01600300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESMAC-2002.2|Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration|A Double-Blind, Placebo-Controlled Feasibility Study to Evaluate the Efficacy of TESMAC™ (Transcutaneous Electrical Stimulation of the Macula)||Acuity Medical International, Inc.||Completed|August 2002|April 2004|Actual|April 2004|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|N/A|No|||May 2012|May 15, 2012|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01600300||85830|
NCT01599975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Concerta HIV Study|A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV|Phase III, Placebo-Controlled, Double-Blind Crossover Study of Slow-Release Methylphenidate (Concerta ™) for Treatment of HIV Associated Neurocognitive Disorder||University of California, Los Angeles|Yes|Recruiting|May 2012|September 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|64 Years|No|||May 2012|May 14, 2012|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599975||85855|
NCT01600274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1229ed09ct|Bioavailability Study With Oral Single Dose Administration of Ethinylestradiol and Dienogest|Characterisation of Relative Bioavailability and Assessment of Bioequivalence of a Newly Developed Ethinylestradiol/Dienogest IR Formulation in Comparison With a Marketed Reference Product (Valette®)||Pharbil Waltrop GmbH|Yes|Completed|January 2010|February 2010|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 15, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01600274||85832|
NCT01600287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8450/PG-2Trg/2010/|Closed Loop Propofol Administration in Pediatric Cardiac Surgery|Evaluation of Closed Loop Anaesthesia Delivery System for Propofol Anaesthesia in Pediatric Cardiac Surgery||Postgraduate Institute of Medical Education and Research|No|Completed|January 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Both|5 Years|18 Years|No|||July 2013|July 10, 2013|May 11, 2012||No||No|December 22, 2012|https://clinicaltrials.gov/show/NCT01600287||85831|anesthesiologist could get visual impression of his performance.
NCT01596400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/44/C|Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years|An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)||Prostrakan Pharmaceuticals||Active, not recruiting|May 2012|||May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|13 Years|17 Years|No|||December 2015|December 16, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596400||86130|
NCT01596413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/46/C|Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years|An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)||Prostrakan Pharmaceuticals||Not yet recruiting|May 2014|||May 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|6 Years|12 Years|No|||January 2014|January 23, 2014|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596413||86129|
NCT01596933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NKP_CA_04|Effect of Omega-3 Supplements on the Prevention of Cachexia in Head and Neck Cancer Treated With Radio(Chemo)Therapy|Multi-centric, Placebo-controlled Trial of Omega-3 Fatty Acid Supplementation in Weight Maintenance and Preservation of Lean Body Mass, in (Pre)Cachectic Head and Neck Cancer Patients, Undergoing Curative Radio(Chemo)Therapy|NUTRIOM|General Hospital Groeninge|Yes|Completed|April 2012|February 2014|Actual|February 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|91|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01596933||86089|
NCT01597752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|107-PR-PRI-185|Biological Standardization of Blomia Tropicalis Allergen Extract|Biological Standardization of Blomia Tropicalis Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units||Laboratorios Leti, S.L.|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|50 Years|No|||May 2012|November 29, 2012|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597752||86026|
NCT01598051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16296|Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan|Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)||Bayer|No|Recruiting|May 2012|January 2020|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|725|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with non-valvular atrial fibrillation necessary for the treatment for prevention        of ischemic stroke and systemic embolism|March 2016|March 9, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01598051||86003|
NCT01597726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|32020|Cervical Priming Before Dilation & Evacuation|Cervical Priming Before Dilation & Evacuation: a Randomized Controlled Trial||Ibis Reproductive Health|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|159|||Female|18 Years|N/A|No|||November 2013|November 6, 2013|May 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597726||86028|
NCT01598025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-053|Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor|Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor||Memorial Sloan Kettering Cancer Center||Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|21|||Both|N/A|19 Years|No|||January 2016|January 21, 2016|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598025||86005|
NCT01588743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prof. Li Guangwei|Effects of Short-term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes Patients|Effects of Short-term Intensive Insulin Therapy on Insulin Resistance and Insulin Secretion in Newly Diagnosed Lean and Obese Type 2 Diabetes Patients||China-Japan Friendship Hospital||Active, not recruiting|October 2008|||December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|130|||Both|25 Years|60 Years|No|||April 2012|April 30, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588743||86717|
NCT01588145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EMSI-101|Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 (BI 1482694) in NSCLC Patients|Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 (BI 1482694) in NSCLC Patients With EGFR Mutation||Hanmi Pharmaceutical Company Limited|No|Recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|20 Years|N/A|No|||February 2016|February 1, 2016|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588145||86761|
NCT01589016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0711-C-033-JG|Activin A and Inhibin A in Predicting Outcome of Pregnancies of Unknown Location After Assisted Reproductive Technology|Single Determination of Serum Activin A and Inhibin A in Predicting the Outcome of Pregnancies of Unknown Location (PUL) After IVF and Oocyte Donation.||Instituto Valenciano de Infertilidad, IVI VALENCIA|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|96|None Retained|Blood samples are to be taken at the time of the first ultrasound examination and stored at      -20ºC. Inhibin A and activin A to be determined by ELISA. β-hCG and P were also determined      using Microparticle Enzyme Inmunoassay (MEIA).|Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|In the first control, made 22-27 days after oocyte retrieval, all women underwent a        transvaginal ultrasound (TVS) examination using a 6.5-MHz transducer (Voluson 730 Pro V;        General Electric, Madrid, Spain). They were diagnosed with an ectopic pregnancy (EP) or an        intrauterine pregnancy (IUP) on the basis of this examination and where there was no clear        ultrasound evidence of pregnancy were classified as pregnancy of unknown location (PUL).        Women were followed up until the final pregnancy outcome was known.|September 2013|September 18, 2013|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01589016||86696|
NCT01589341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANBL12B7|Studying Chromosomes in Samples From Younger Patients With Neuroblastoma|Prognostic Impact of Segmental Chromosome Aberrations in Non MYCN Amplified Neuroblastomas in Different Age Groups||Children's Oncology Group|No|Active, not recruiting|April 2012|||August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|300|Samples With DNA|tumor tissue|Both|N/A|18 Years|No|Non-Probability Sample|Neuroblastoma patient samples|May 2015|May 5, 2015|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01589341||86671|
NCT01589640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDD-BLNK-12-001|Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance|Phase 4 Study Accessing Patient Satisfaction and Tear Osmolarity While Using Blink Tears, Blink Gel Tears and Systane Balance||Ophthalmic Consultants of Connecticut|No|Not yet recruiting|May 2012|October 2012|Anticipated|September 2012|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|greater then age 18|April 2012|May 1, 2012|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589640||86648|
NCT01589328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-12-605|Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB|Randomized Controlled Trials for the Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB|EPADE-PB|National Cancer Center, Korea|No|Recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|288|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01589328||86672|
NCT01589653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3968|Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients|A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin||Novo Nordisk A/S|No|Completed|May 2012|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|155|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589653||86647|
NCT01589666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSX-102|Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers|Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers||Entegrion, Inc.|Yes|Recruiting|November 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 12, 2015|August 2, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01589666||86646|
NCT01591083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ER-100-008|The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers|The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses|DDE|National Cheng-Kung University Hospital|Yes|Completed|August 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|474|||Both|18 Years|95 Years|No|||October 2015|October 11, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591083||86538|
NCT01591096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS065818|Thrombolysis in Pediatric Stroke (TIPS)|Thrombolysis in Pediatric Stroke (TIPS)|TIPS|Seattle Children's Hospital|Yes|Terminated|October 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|2 Years|17 Years|No|||February 2014|February 10, 2014|May 1, 2012|Yes|Yes|Lack of patient accrual|No||https://clinicaltrials.gov/show/NCT01591096||86537|
NCT01589900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU|Identification the Expression of Sox2 in Colorectal Cancer Tissues|The Role of Sox2 in Tumor Genesis and Migration in Colorectal Cancer||Sun Yat-sen University|Yes|Completed|January 2005|March 2012|Actual|December 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|136|||Both|24 Years|79 Years|No|Probability Sample|All rchived 136 tissues were obtained and pathologically confirmed from patients who        underwent surgical resections between 2005 and 2006 at the Cancer Center of Sun Yat-sen        University (Guangzhou, Guangdong, P. R. China)). The patients from whom the samples were        derived underwent curative resection between 2005 and 2006. Tumor differentiation was        characterized according to WHO classification, while the surgical pathologic stage was        analyzed according to the TNM classification system of the International Union against        Cancer. All samples were anonymously coded in accordance with local ethical guidelines.|May 2012|May 2, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01589900||86629|
NCT01589913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKW-CHFC-G2|REmote Web Assisted Care for Heart Failure Patients With Implantable Cardioverter Defibrillators|Remote Care for Reducing Cardiac Fear, Fear of Dying, Depression, and Increasing Quality of Life in ICD‐Patients With Cardiac Insufficiency/at Risk for Fatal Cardiac Arrhythmia.|REACH-ICD|Wuerzburg University Hospital|Yes|Active, not recruiting|May 2012|November 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|119|||Both|18 Years|75 Years|No|||March 2016|March 4, 2016|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01589913||86628|
NCT01590459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-509-102|24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate|A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension||Vertex Pharmaceuticals Incorporated|Yes|Completed|April 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|359|||Both|18 Years|80 Years|No|||October 2015|October 23, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590459||86586|
NCT01590199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001KDE47|Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs|Extension Study to the "Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study"|MACS2002|Novartis|No|Active, not recruiting|May 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|N/A|No|||April 2015|April 11, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01590199||86606|
NCT01599728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UcnHFP2|Effect of Urocortins in Patients With Heart Failure|Urocortins 2 & 3-Effects on Forearm Arterial Blood Flow in Patients With Heart Failure||University of Edinburgh|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599728||85874|
NCT01597791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00005516|Combined Spinal Epidural Urinary Retention|Do Women Receiving Low Dose Combined Spinal Epidural for Labor Analgesia Exhibit Less Bacteriuria Using a Urinary Retention Protocol Versus Routine Urinary Catheter Placement?||Northwestern University|No|Recruiting|May 2012|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Female|18 Years|N/A|No|||October 2015|October 29, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597791||86023|
NCT01600313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QUMS-2225|Effect of Low Calorie Diet With Rice Bran Oil on Cardiovascular Risk Factors in Hyperlipidemic Patients|Effect of Low Calorie Diet With Rice Bran Oil on Cardiovascular Risk Factors in Hyperlipidemic Patients||Qazvin University Of Medical Sciences|Yes|Active, not recruiting|June 2008|June 2012|Anticipated|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|50|||Both|25 Years|65 Years|No|||May 2012|May 16, 2012|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01600313||85829|
NCT01600326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00039445|A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection|A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection Versus Tenotomy for Treatment of Gluteus Minimus and Medius Tendinosis||University of Michigan|Yes|Active, not recruiting|July 2010|July 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01600326||85828|
NCT01596426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|392MD/47/C|Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years|An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 2 to 5 Years)||Prostrakan Pharmaceuticals||Not yet recruiting|July 2014|||October 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|16|||Both|2 Years|5 Years|No|||January 2014|January 23, 2014|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596426||86128|
NCT01596634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 98112|Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy|A Pilot Study of Bovine Lactoferrin in Patients With Colorectal Carcinoma Receiving Oxaliplatin-Based Chemotherapy and Self-Reported Taste Disturbances||Comprehensive Cancer Center of Wake Forest University|No|Active, not recruiting|January 2013|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|49|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596634||86112|
NCT01597167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110168|Magnesium Sulfate Versus 5% Dextrose With Treatment Resistant Depression|A Double-blinded Randomized Study of IV Infusion of Magnesium Sulfate Versus 5% Dextrose in a Crossover Design in Male and Female Volunteers With Treatment Resistant Depression||University of Miami|No|Completed|October 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|21|||Both|21 Years|70 Years|No|||January 2016|January 19, 2016|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597167||86071|
NCT01598571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00027|Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose|A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib With Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers||AstraZeneca||Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|37|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|April 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598571||85963|
NCT01597440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCGC 0007|Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia|Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia||Children's Research Institute|Yes|Terminated|September 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|N/A|4 Weeks|No|||December 2015|December 8, 2015|May 10, 2012|Yes|Yes|insufficient enrollment|No||https://clinicaltrials.gov/show/NCT01597440||86050|
NCT01597453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/74|NOR-SYS: The Norwegian Stroke in the Young Study|NOR-SYS: The Norwegian Stroke in the Young Study Young Ischemic Stroke and Family Risk Factors|NOR-SYS|Haukeland University Hospital|No|Active, not recruiting|September 2010|December 2035|Anticipated|December 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1062|||Both|15 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01597453||86049|
NCT01597466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/01|Epidrum for Thoracic Epidural Analgesia|A Comparison Study of Two Different Techniques for Identifying the Epidural Space in Patients Requiring Thoracic Epidural Analgesia: a Prospective Multicentric Randomized Study|Epidrum-Tho|Hopital Foch|No|Recruiting|April 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||November 2013|November 9, 2013|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01597466||86048|
NCT01600378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/245/Cilddatabase|Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases|Prospective Data Collection of Clinical, Pulmonary Function, Radiological, Bronchoscopic and Fibered Confocal Fluorescence Microscopy Imaging, and Pathological Characteristics in Patients With Diffuse Parenchymal Lung Diseases||Singapore General Hospital|No|Recruiting|May 2012|April 2022|Anticipated|April 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|21 Years|90 Years|No|Non-Probability Sample|Patients evaluated for diffuse parenchymal lung diseases|November 2015|November 26, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600378||85824|
NCT01596673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C33237/1085|A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Abuse Potential of the Hydrocodone Bitartrate Extended-Release Tablet in Healthy, Nondependent, Recreational Opioid Users||Teva Pharmaceutical Industries|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|March 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01596673||86109|
NCT01596686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COL-GASTRO-2|Comparison of Preparation Regimens for Colonoscopy|||Clinical Hospital Colentina|Yes|Completed|May 2012|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|184|||Both|18 Years|80 Years|No|||December 2013|December 23, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01596686||86108|
NCT01588431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 11-36|Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer|A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer (CTRC# 11-36)||The University of Texas Health Science Center at San Antonio|Yes|Active, not recruiting|December 2011|March 2022|Anticipated|December 2021|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01588431||86739|
NCT01588444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20110039H|Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft|Histological Comparison of Healing Following Tooth Extraction With Ridge Preservation Using Cortical Versus Cancellous Freeze Dried Bone Allograft||The University of Texas Health Science Center at San Antonio|No|Completed|October 2010|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|99 Years|No|||October 2015|October 1, 2015|March 16, 2012||No||No|October 1, 2014|https://clinicaltrials.gov/show/NCT01588444||86738|
NCT01588756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM08193|Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)|Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)|AcSDKP-NH2|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2010|May 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01588756||86716|
NCT01589926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01532001|Bi-Level Positive Airway Ventilation for Acute Chest Syndrome|Early Bi-Level Positive Airway Pressure (BLPAP) Ventilation for Acute Chest Syndrome (ACS) - a Double-Blind Randomized Controlled Pilot Study||Albert Einstein College of Medicine of Yeshiva University|Yes|Not yet recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|4 Years|21 Years|No|||May 2012|May 1, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01589926||86627|
NCT01590498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCA0608|Radiotherapy vs Observation for CRPC|Salvage Radiotherapy vs Observation for Castration Resistant Prostate Cancer in Central China||Zhengzhou University|No|Recruiting|May 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|Samples Without DNA|the biopsy specimens of prostate tissue|Male|N/A|N/A|No|Probability Sample|inpatients with CRPC in 9 hospitals|May 2012|May 3, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01590498||86583|
NCT01591109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-1|A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy|A Reversal in the Vascularity of Metastatic Liver Tumors in Patients With Colorectal Cancer After the Cessation of Anti-VEGF Therapy: A Study Using Contrast-enhanced Ultrasonography and Histological Techniques.||NHO - Matsumoto Medical Center|Yes|Completed|January 2010|April 2012|Actual|April 2012|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|20|Samples Without DNA|formalin fixed oarafin embedded block of liver specimen|Both|N/A|N/A|No|Non-Probability Sample|Residents cared by the institution this study was perfomed.|May 2012|May 2, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591109||86536|
NCT01590485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pain control by saffron|Evaluation of the Effect of Saffron (Crocus Sativus) on Pain Control After Root Canal Therapy in Teeth With Vital Pulps|||Zahedan University of Medical Sciences|No|Completed|May 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01590485||86584|
NCT01590745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/NEURO/04/EKHT|Ultrasound Therapy for Carpal Tunnel Syndrome (CTS)|A Randomised Controlled Double Blind Trial Of Therapeutic Ultrasound in Carpal Tunnel Syndrome (CTS)|CTS|East Kent Hospitals University NHS Foundation Trust|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|90 Years|No|||February 2013|February 13, 2013|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01590745||86564|
NCT01590758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPX-305|Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers|A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers|OneStep-1|Dipexium Pharmaceuticals, Inc.|Yes|Recruiting|June 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590758||86563|
NCT01590771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431-253|A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy, Alone or in Combination With Metformin||Merck Sharp & Dohme Corp.|No|Completed|July 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|498|||Both|18 Years|79 Years|No|||February 2016|February 4, 2016|May 1, 2012|Yes|Yes||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01590771||86562|
NCT01599741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCY607-100093|X-ray Dose Reduction Study for Endovascular Interventional Radiology|Clinical Validation and Evaluation of X-ray Image Processing for Endovascular Digital Subtraction Angiography and Intervention||Philips Healthcare|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|May 8, 2012||No||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01599741||85873|
NCT01599754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP311736|Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients|Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC|ATLAS|SFJ Pharmaceuticals, Inc.|Yes|Recruiting|April 2012|May 2019|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|700|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01599754||85872|
NCT01598805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FZMI-KEK-ZH-Nr. 2010-0458|Increased Rate of Prophylaxis Against Venous Thromboembolism Due to eAlerts|Increased Rate of Prophylaxis Against Venous Thromboembolism Due to eAlerts||University of Zurich|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|1||Actual|10000|||Both|16 Years|N/A|No|||November 2012|November 15, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598805||85945|
NCT01596439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 01|A Prospective Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive Function of Breast Cancer Patients|||National University Hospital, Singapore|Yes|Recruiting|June 2013|||May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|21 Years|64 Years|Accepts Healthy Volunteers|Probability Sample|Patients being treated with breast cancer at National University Hospital (Singapore)and        healthy women would be used consisting of a friend or relative of the patient.|December 2013|December 10, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01596439||86127|
NCT01596452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1|Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology|||National University Hospital, Singapore||Recruiting|June 2012|||May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|31|||Both|18 Years|N/A|No|Probability Sample|Patients being treated for cancer at the National University Hospital (NUH), Singapore|December 2013|December 8, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01596452||86126|
NCT01596647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258A2119|Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors|A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of TKI258 on the Pharmacokinetics of Caffeine, Diclofenac, Omeprazole and Midazolam Administered as a Four-drug Cocktail in Patients With Advanced Solid Tumors, Excluding Breast Cancer||Novartis|No|Completed|May 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|March 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01596647||86111|
NCT01596946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Forss8743, LiO 201 261|Home-sampling in Partner Notification of Chlamydia|Home-sampling as a Tool in a Chlamydia Trachomatis Partner Notification Context. A Multi-centre Cluster-randomized Controlled Trial.||Ostergotland County Council, Sweden|No|Completed|November 2006|November 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|633|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2012|May 10, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596946||86088|
NCT01596998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-026|Plasma Concentrations of Levobupivacaine With and Without Epinephrine in Transversus Abdominis Plane Blocks|Comparison of Plasma Concentrations of Levobupivacaine With and Without Epinephrine for Transversus Abdominis Plane Block Under Ultrasound.||Pontificia Universidad Catolica de Chile|No|Completed|December 2011|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|11|||Male|N/A|N/A|Accepts Healthy Volunteers|||May 2012|May 10, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596998||86084|
NCT01596660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-JMejia|Transversus Abdominis Bilateral Plane Block in Total Laparoscopic Hysterectomy : A Randomized Controlled Trial|Transversus Abdominis Bilateral Plane Block in Total Laparoscopic Hysterectomy : A Randomized Controlled Trial|TAPBLOCK|CES University|Yes|Recruiting|August 2011|May 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Female|30 Years|70 Years|No|||May 2012|May 9, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01596660||86110|
NCT01599286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCGC0008|Short-term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia|Short-term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia||Children's Research Institute|Yes|Recruiting|September 2012|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Both|N/A|99 Years|No|||January 2016|January 26, 2016|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599286||85908|
NCT01598779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Genital Warts|Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population|Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population||University of Buenos Aires|Yes|Completed|June 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|Samples With DNA|Biopsy specimens will be held in a formol 10% solution and will be sent to the pathologist.      A portion of each sample will be processed for histological analysis, which will be      performed by one pathologist. The remainder of each specimen will be saved to extract DNA      for PCR analysis|Female|15 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with genital warts|December 2015|December 18, 2015|May 11, 2012||No||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01598779||85947|
NCT01596699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol No. 110819|Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation|A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation||University of California, San Francisco|Yes|Suspended|July 2012|June 2019|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|31|||Both|3 Months|30 Years|No|||August 2014|August 14, 2014|May 7, 2012|Yes|Yes|Triggering of futility rule, requires study modification|No||https://clinicaltrials.gov/show/NCT01596699||86107|
NCT01597193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-08|Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer|A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide (Formerly MDV3100) in Patients With Incurable Breast Cancer||Medivation, Inc.|No|Active, not recruiting|April 2012|December 2016|Anticipated|December 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|101|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597193||86069|
NCT01588769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV003|A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients|A Phase I Study to Investigate Tolerability and Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-cells (ALECSAT) Administered to Patients With Glioblastoma Multiforme (GBM)|ALECSAT-GBM|CytoVac A/S|No|Completed|August 2011|April 2013|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01588769||86715|
NCT01589679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DYN1-12-047|Contracture Reduction Following Bunionectomy: a Longitudinal, Controlled Trial|Contracture Reduction Following Bunionectomy: a Longitudinal, Controlled Trial|Bunionectomy|Dynasplint Systems, Inc.|No|Terminated|April 2012|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|90 Years|No|||August 2013|August 8, 2013|April 30, 2012|No|Yes|Unrelated to Trial|No||https://clinicaltrials.gov/show/NCT01589679||86645|
NCT01589055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-p-001057|IV Nicotine Induced Changes in Hormone Function, Mood States and Behavior|IV Nicotine Induced Changes in Hormone Function, Mood States and Behavior||Mclean Hospital|No|Suspended|April 2005|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|180|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589055||86693|
NCT01590251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111009292|Yoga for Pain and Opioid Dependence|Yoga for Pain and Opioid Dependence|Yoga|Yale University|No|Completed|April 2012|November 2014|Actual|November 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|65 Years|No|||September 2015|September 23, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590251||86602|
NCT01590225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08034|Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)|A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1||Merck Sharp & Dohme Corp.|Yes|Withdrawn|January 2013|August 2021|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|3 Years|17 Years|No|||February 2015|February 20, 2015|May 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590225||86604|
NCT01590238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1|Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)|Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)||The New York Eye & Ear Infirmary|No|Completed|May 2012|November 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01590238||86603|
NCT01590810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8150-001|A Single Rising Dose Study of MK-8150 (MK-8150-001)|A Single Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150||Merck Sharp & Dohme Corp.|No|Completed|May 2012|February 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|34|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||January 2015|January 29, 2015|May 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590810||86559|
NCT01591070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUHDM|Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis|Phase 4 Study of Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis||Pusan National University Hospital|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|104|||Both|18 Years|N/A|No|||August 2012|August 7, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01591070||86539|
NCT01591330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12857|A Study of LY2140023 in Healthy Males and Females|A Particle Size Study of 3 Different Particle Size Test Tablet Formulations Compared to the Reference Tablet Formulation in Healthy Subjects||Eli Lilly and Company|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|35|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|May 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01591330||86519|
NCT01591304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULT-116|Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne|Feasibility Study: Evaluation of the Safety and Effectiveness of the Ulthera® System for the Treatment of Moderate to Severe Facial Acne||Ulthera, Inc|No|Completed|August 2011|July 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591304||86521|
NCT01591317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11990|Study of Prasugrel in Korean Healthy Male Volunteers|Single and Multiple Dose Pharmacokinetics and Pharmacodynamics of Prasugrel (LY640315) in Korean Healthy Male Subjects||Eli Lilly and Company|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|May 2, 2012|No|Yes||No|September 4, 2012|https://clinicaltrials.gov/show/NCT01591317||86520|
NCT01597518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPN-12-001|Riluzole in Spinal Cord Injury Study|A Multi-Center, Randomized, Placebo Controlled, Double-Blinded, Trial of Efficacy and Safety of Riluzole in Acute Spinal Cord Injury|RISCIS|AOSpine North America Research Network|Yes|Recruiting|August 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|351|||Both|18 Years|75 Years|No|||January 2016|January 22, 2016|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597518||86044|
NCT01599312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39915.060.12|Forces on Teeth During Videolaryngoscopy|Forces Exerted on Upper and Lower Teeth During Intubation: a Randomized, Cross-over Trial Comparing Indirect Videolaryngoscopy to Direct Videolaryngoscopy.||Catharina Ziekenhuis Eindhoven|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|100|||Both|18 Years|N/A|No|||February 2015|February 8, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599312||85906|
NCT01599325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZA-MDS-002|Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome|A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Chinese Subjects With Higher-Risk Myelodysplastic Syndromes||Celgene|No|Active, not recruiting|May 2012|February 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 14, 2012|No|Yes||No|January 29, 2016|https://clinicaltrials.gov/show/NCT01599325||85905|
NCT01597219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/10/0411|Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers|A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies|UK-Haplo|University College, London|Yes|Recruiting|March 2013|||March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|16 Years|70 Years|No|||December 2015|December 7, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597219||86067|
NCT01596465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRHMC-049-010|Study of Two Teaching Techniques to Teach Cardiac Auscultation to Physicians|Self-Directed Study Using MP3 Players Versus Multimedia Lecture to Improve Auscultation Proficiency of Physicians: A Randomized, Controlled Trial.||The Reading Hospital and Medical Center|Yes|Completed|January 2011|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|83|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2012|May 10, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01596465||86125|
NCT01597479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-LEV-2011-21|Ultrasound Guided Distal Peripheral Nerve Blocks and Postoperative Pain.|Effectiveness of Distal Peripheral Nerve Blocks on Postoperative Pain Management After Ambulatory Thumb Resection Arthroplasty.||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||January 2016|February 19, 2016|May 7, 2012||No||No|May 6, 2015|https://clinicaltrials.gov/show/NCT01597479||86047|We could included another group: distal blocks with 0,125% levobupivacaine+ 4mg dexamethasone; register patient satisfaction with anesthetic technique or patient risks factors for nausea and vomiting.
NCT01597739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100801|A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy|A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy||Janssen Research & Development, LLC|Yes|Completed|July 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|80 Years|No|||April 2014|April 7, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597739||86027|
NCT01608438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00057856|Motor Learning in a Customized Body-Machine Interface|Motor Learning in a Customized Body-Machine Interface for Persons With Paralysis|BMI|Rehabilitation Institute of Chicago|No|Recruiting|February 2013|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|65 Years|No|||September 2015|September 9, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01608438||85205|
NCT01608451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D3/377/TMH|Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer|Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer.||Tata Memorial Hospital|Yes|Recruiting|September 2007|December 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|800|||Female|18 Years|70 Years|No|||June 2014|June 23, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01608451||85204|
NCT01599780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18354|Language Development in Preterm Children|On- and Off-line Measures of Language Development in Preterm Children||Stanford University|No|Active, not recruiting|January 2010|||February 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|18 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children born <33 weeks gestation (preterm)|December 2014|December 4, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01599780||85870|
NCT01600365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADA-GAN-02/10|Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus|"Prospective, Interventional, Randomized, Double-masked With the Use of Ganciclovir Gel 0.3% for Treatment of Conjunctivitis Caused by Adenovirus."||Adapt Produtos Oftalmológicos Ltda.|Yes|Not yet recruiting|May 2012|June 2012|Anticipated|June 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|22|||Both|18 Years|65 Years|No|||May 2012|May 15, 2012|March 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01600365||85825|
NCT01609075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27907|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)|Use of Bevacizumab in the Treatment of Metastatic Colorectal Cancer (mCRC) in Italy: an Observational Cohort Study||Hoffmann-La Roche||Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|437|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic colorectal cancer having initiated first-line treatment with        fluoropyrimidine-based chemotherapy and Avastin|March 2016|March 1, 2016|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609075||85156|
NCT01609088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31447|Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus||Boston University|No|Completed|May 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|24|||Both|35 Years|65 Years|No|||July 2013|July 23, 2013|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01609088||85155|
NCT01589692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AR062066-01A1|A Clinical Trial for the Surgical Treatment of Elderly Distal Radius Fractures|A Clinical Trial for the Surgical Treatment of Elderly Distal Radius Fractures. The Wrist and Radius Injury Surgical Trial (WRIST)|WRIST|University of Michigan|Yes|Recruiting|April 2012|April 2019|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|623|||Both|60 Years|N/A|No|||February 2016|February 4, 2016|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01589692||86644|
NCT01590264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204069|rTMS Bimodal Treatment For Tinnitus: A Pilot Study|rTMS Bimodal Treatment For Patients With Subjective Idiopathic Tinnitus: A Pilot Study||Washington University School of Medicine|Yes|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|60 Years|No|||September 2012|February 25, 2013|April 30, 2012|No|Yes||No|September 17, 2012|https://clinicaltrials.gov/show/NCT01590264||86601|
NCT01587391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1291.1|Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX|A Randomised, Double-blind, Placebo-controlled Trial in Healthy Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 2.5 mg to 160 mg of BI 163538 XX||Boehringer Ingelheim||Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|48|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|April 26, 2012||||No||https://clinicaltrials.gov/show/NCT01587391||86819|
NCT01590511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/XB-02|Echocardiographic Prediction of Fluid Responsiveness After a Mini-fluid Challenge in Non-ventilated Patients With Shock|Echocardiographic Prediction of Fluid Responsiveness After a Mini-fluid Challenge in Non-ventilated Patients With Shock|IVT NonVent|Centre Hospitalier Universitaire de Nīmes|No|Completed|January 2013|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the emergency room or intensive care in acute circulatory failure without        ventilatory support.|December 2015|December 3, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590511||86582|
NCT01590823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dabigatran Hemodialysis 2012|An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients|Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients||Nova Scotia Health Authority|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|October 31, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01590823||86558|
NCT01583569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3273723|Complex Dynamic Systems in Mood Disorders|Complex Dynamic Systems in Mood Disorders||Massachusetts General Hospital|No|Completed|November 2011|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|The sample will consist of subjects with Major Depressive Disorder(n=5), Bipolar Disorder        (n=5), as well as healthy controls (n=5)|October 2015|October 5, 2015|March 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583569||87106|
NCT01583582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARE-050312|Antihypertensive Effect and Safety of Peptides Derived From Coldwater Shrimp|Assessment on Antihypertensive Effect and Safety of Bioactive Peptides Derived From Coldwater Shrimp (Pandalus Borealis) in Healthy Subjects With Mild or Moderate Hypertension|MARE|Marealis AS|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|74|||Both|30 Years|75 Years|No|||January 2013|January 30, 2013|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583582||87105|
NCT01583595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008157|Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease|Determining the Relationships Between Self-efficacy for Walking Ability, Gate Speed and Physical Activity in Patients With Chronic Lung Disease||Mayo Clinic|No|Completed|December 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|40 Years|N/A|No|Non-Probability Sample|Adults with chronic lung disease|March 2013|April 1, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01583595||87104|
NCT01591577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000493|Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme|Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme||Jonsson Comprehensive Cancer Center|Yes|Recruiting|December 2012|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591577||86500|
NCT01591798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCC-CTS603|Efficacy Study of Robotic Surgery for Rectal Cancer|Clinical Assessment of Laparoscopic and Robotic Surgery for Rectal Cancer - Randomized Phase II Trial||National Cancer Center, Korea||Recruiting|March 2012|December 2017|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|146|||Both|18 Years|80 Years|No|||May 2012|May 3, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01591798||86483|
NCT01598597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28289|An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)|An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin||Genentech, Inc.||Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|276|Samples With DNA|saliva, optional blood|Both|18 Years|N/A|No|Probability Sample|Participants with history of metastatic or locally recurrent breast cancer treated with        Avastin|May 2015|May 7, 2015|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598597||85961|
NCT01599793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1031|Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib on Bone Metastases in Patients With Castrate Resistant Prostate Cancer|A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184||University of Chicago|No|Active, not recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|25|||Male|N/A|N/A|No|||July 2015|July 10, 2015|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599793||85869|
NCT01599806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00004|Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)|A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults||AstraZeneca||Completed|October 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|641|||Both|18 Years|90 Years|No|||February 2016|February 3, 2016|May 15, 2012|Yes|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01599806||85868|
NCT01597232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCPTS120508|Clinic Trial for West China Perioperative Transfusion Score (WCPTS)|Effect of West China Perioperative Transfusion Score (WCPTS) on Red Blood Cells Transfusion in Patients Undergoing Major Surgery: a Prospective, Multicenter, Randomized Controlled Trial|WCPTS|West China Hospital|Yes|Enrolling by invitation|June 2012|December 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|3000|||Both|14 Years|99 Years|No|||January 2016|January 11, 2016|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597232||86066|
NCT01600391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VCTpilot|Visual Cues for Gait Training Post-stroke|Visual Cue Training to Improve Walking and Turning After Stroke: a Pilot Study|VCTpilot|University of Salford|Yes|Completed|May 2012|March 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01600391||85823|
NCT01596738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fuwai2008|Tranexamic Acid in On-pump CABG With Premature Clopidogrel Cessation|Tranexamic Acid in Patients Receiving Primary and Isolated On-pump CABG With Premature Clopidogrel Cessation to Reduce Postoperative Bleeding and Transfusion||Chinese Academy of Medical Sciences, Fuwai Hospital|Yes|Completed|October 2008|March 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|85 Years|No|||May 2012|May 9, 2012|May 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01596738||86104|
NCT01597180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0832|Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir|Pharmacokinetics, Pharmacodynamics and Genital Tract Viral Shedding in HIV+ Women Using Combined Oral Contraceptives and Raltegravir||University of North Carolina, Chapel Hill|No|Withdrawn|July 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|20 Years|40 Years|No|Non-Probability Sample|Women recruited from an infectious diseases clinic in Chapel Hill, NC.|March 2014|March 4, 2014|May 9, 2012||No|Could not find subjects who met all the enrollment criteria so the study was stopped.|No||https://clinicaltrials.gov/show/NCT01597180||86070|
NCT01598324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS2058787|Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder|Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder||Mclean Hospital|No|Terminated|July 2012|||April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1|||Both|18 Years|65 Years|No|Non-Probability Sample|Participants in a clinical trial for treatment-resistant depression who agree to have        magnetic resonance scans|August 2013|August 10, 2013|May 9, 2012||No|Clinical trial from which subjects were recruited closed to enrollment|No||https://clinicaltrials.gov/show/NCT01598324||85982|
NCT01608802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6594/3200|Outcomes for Antiretroviral Therapy Patients Receiving Palliative Care|Phase 3 Trial of Palliative Care for HIV Patients on Antiretroviral Therapy|TOPCare|King's College London|Yes|Completed|May 2011|August 2013|Actual|May 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|240|||Both|18 Years|N/A|No|||June 2014|June 9, 2014|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608802||85177|
NCT01608815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TYP31 (SFY12079)|Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects|Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects||Sanofi|No|Completed|May 2012|December 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|200|||Both|2 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 15, 2014|May 28, 2012||No||No|March 7, 2014|https://clinicaltrials.gov/show/NCT01608815||85176|
NCT01596478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSU-#080211M1F|Effectiveness of Therapy Treatment|Effectiveness of Cognitive-Motivational Behaviour Therapy in Community||National Institute on Drug Abuse (NIDA)|Yes|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|80 Years|No|||May 2012|May 9, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01596478||86124|
NCT01609348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIADs-3|Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)|Venlafaxine for Depression in Alzheimer's Disease|DIADs-3|Johns Hopkins University|No|Recruiting|April 2012|January 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|N/A|N/A|No|||March 2016|March 7, 2016|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609348||85135|
NCT01609361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111006|Benefit of Rehabilitation Program in Colorectal Surgery|Benefit of Rehabilitation Program in Colorectal Laparoscopic Surgery|REHAB|Assistance Publique - Hôpitaux de Paris|No|Recruiting|November 2012|May 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|270|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01609361||85134|
NCT01587404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007856 BLT|Catheter Contact Force and Electrograms|Relationship Between Catheter Contact Force and Electrogram Characteristics in Fibrillating Human Atrial Myocardium||Barts & The London NHS Trust||Recruiting|April 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|55|||Both|18 Years|N/A|No|||July 2015|August 18, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587404||86818|
NCT01587417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1307.1|Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL|A Randomised, Double-blind, Placebo-controlled Trial in Healthy Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 2.5 mg to 360 mg of BI 187004 CL||Boehringer Ingelheim||Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|72|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|April 26, 2012||||No||https://clinicaltrials.gov/show/NCT01587417||86817|
NCT01590524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-GIPMRL-87|Feasibility Study on the Effect of Complementary Methods as Supportive Interventions for Parents of Children With Cancer|Randomized Control Trial for the Effect of Guided Imagery and Progressive Muscle Relaxation in Reducing Anxiety for Parents of Hospitalized Children With Cancer||Cyprus University of Technology|Yes|Completed|April 2012|October 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|52|||Both|N/A|N/A|No|||October 2014|October 7, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01590524||86581|
NCT01590537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15508|Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction|Prospective Multicentre Non-interventional Comparative Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction|Mirabel|Bayer|No|Completed|September 2011|October 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|2348|||Female|20 Years|40 Years|No|Non-Probability Sample|Females who plan long-term contraception and meet criteria of inclusion and exclusion.|October 2015|October 15, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01590537||86580|
NCT01583608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BVS 12|ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease|ABSORB: Initial Clinical Experience With the Everolimus-eluting Bioresorbable Vascular Scaffold (BVS) System in the Treatment of de Novo Native Coronary Artery Lesions - a Surveillance Registry|ASSURE|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|Yes|Active, not recruiting|April 2012|March 2016|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|18 Years|75 Years|No|Probability Sample|Patients with cardiovascular disease|March 2013|March 20, 2013|April 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01583608||87103|
NCT01583621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pro#00000051|Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)|Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)|D-SUNNY|Georgia Regents University||Active, not recruiting|November 2011|October 2014|Anticipated|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research|4||Anticipated|96|||Both|13 Years|45 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01583621||87102|
NCT01583920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clinicaltrials_hchu_042012|Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer|Pilot Study of Focal Salvage HDR Prostate Brachytherapy||Sunnybrook Health Sciences Centre|No|Active, not recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||May 2015|May 19, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583920||87080|
NCT01591343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-PG-PSC-186|Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma.|Prospective Study to Evaluate the Safety of a 4-month Treatment With Depigoid® Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml) in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Mild Persistent or Intermittent Asthma.||Laboratorios Leti, S.L.|Yes|Terminated|June 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|8|||Both|18 Years|55 Years|No|||March 2013|November 8, 2013|May 2, 2012||No|Study halted by Sponsor|No||https://clinicaltrials.gov/show/NCT01591343||86518|
NCT01591590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORIOLAN|Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer|Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer|CORIOLAN|Jules Bordet Institute|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|53|||Both|18 Years|N/A|No|||December 2015|January 11, 2016|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591590||86499|
NCT01587651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS747s-B-U4003|Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease|A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents|SWAP-2|Daiichi Sankyo Inc.|No|Completed|March 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|110|||Both|18 Years|74 Years|No|||March 2014|March 26, 2014|April 26, 2012|Yes|Yes||No|February 11, 2014|https://clinicaltrials.gov/show/NCT01587651||86799|
NCT01599546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-22233|Reading in Preterm and Full-term Children: Neural Basis and Prediction|||Stanford University|No|Recruiting|January 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|57 Months|78 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children born <35 weeks (preterm) as compared to >36 weeks (full-term)|May 2012|May 15, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599546||85888|
NCT01607034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223HV106|Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects|An Open-Label, Randomized, Crossover Study to Assess the Bioavailability of Dexpramipexole Administered in Soft Food and Water, and in Intact Tablet Form in the Fasted and Fed States in Healthy Volunteers||Knopp Biosciences|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|May 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607034||85312|
NCT01600079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V211-024|ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)|Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™||Merck Sharp & Dohme Corp.|Yes|Active, not recruiting|May 2012|October 2023|Anticipated|October 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|30000|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Members of Kaiser Permanente Northern California (KPNC)|March 2016|March 21, 2016|May 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01600079||85847|
NCT01600352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/245/Cautoantibodies|Specific Autoantibody Testing in Patients With Interstitial Lung Disease|To Evaluate the Clinical Utility of Specific Autoantibody Testing in Patients With Interstitial Lung Disease||Singapore General Hospital|No|Recruiting|May 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples Without DNA|Blood|Both|21 Years|90 Years|No|Non-Probability Sample|Patients with weak positive ANA (1:400 titre) and no overt connective tissue disease        manifestations OR borderline/negative ANA with some clinical suggestion of connective        tissue disease.|November 2014|November 26, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600352||85826|
NCT01607866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R/89|Quadrant Versus Superficial Parotidectomy|Quadrant Parotidectomy Versus Superficial Parotidectomy for Treatment of Pleomorphic Adenoma||Mansoura University|No|Recruiting|June 2014|December 2017|Anticipated|July 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|116|||Both|20 Years|70 Years|No|||August 2015|August 27, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607866||85249|
NCT01608152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0362|Using Game Mechanics to Improve Outcomes Among Stem Cell Transplant Survivors|Using Game Mechanics to Improve Outcomes Among Stem Cell Transplant Survivors||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2013|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|30|||Both|15 Years|29 Years|No|Non-Probability Sample|Hematopoietic stem cell transplantation (HSCTs) patients in recovery in the Houston, Texas        area.|December 2015|December 16, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608152||85227|
NCT01608165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUK/11/036|A Feasibility Study for a Multicentre Randomised Controlled Trial to Compare Surgery With Needle Ablation Techniques in People With Small Renal Masses (4cm)|CONSERVE: a Feasibility Study for a Multicentre Randomised Controlled Trial to Compare Surgery (Partial Nephrectomy) With Needle Ablation Techniques (Radiofrequency Ablation/Cryotherapy) for the Treatment of People With Small Renal Masses (4cm)|CONSERVE|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|June 2012|January 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|17|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608165||85226|
NCT01608828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/350/A|Assessing the Functional and Psychosocial Impact of Strabismus in Asian Children Using the AS-20 and IXTQ Questionnaires|Assessing the Functional and Psychosocial Impact of Strabismus in Asian Children Using the AS-20 and IXTQ Questionnaires||Singapore National Eye Centre|No|Recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|5 Years|16 Years|Accepts Healthy Volunteers|Probability Sample|Children with strabismus|May 2012|May 31, 2012|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608828||85175|
NCT01608841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-01-34A|The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib|The Role of Epidermal Growth Factor Receptor (EGFR) Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib||Taipei Veterans General Hospital, Taiwan|No|Recruiting|July 2005|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||February 2015|February 14, 2015|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608841||85174|
NCT01608750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B.30.2.BAV.0.05.05/331|The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia|The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia: Randomised, Double-blind, Placebo-controlled Trial.||Bezmialem Vakif University|Yes|Not yet recruiting|June 2012|June 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|45 Years|No|||May 2012|May 30, 2012|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608750||85181|
NCT01608763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001/2012|What is the Active Ingredient in Personalized Feedback Interventions for Problem Drinkers? A Randomized Controlled Trial|What is the Active Ingredient in Personalized Feedback Interventions for Problem Drinkers? A Randomized Controlled Trial||Centre for Addiction and Mental Health|No|Completed|May 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|804|||Both|19 Years|N/A|No|||December 2014|December 5, 2014|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608763||85180|
NCT01608776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-86036|RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs|Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs||Celleration, Inc.|Yes|Terminated|May 2012|March 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|90 Years|No|||October 2014|October 6, 2014|May 29, 2012|Yes|Yes|Enrollment delays, business re-allocation of resources|No||https://clinicaltrials.gov/show/NCT01608776||85179|
NCT01609374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-C002|Restore CLINICAL TRIAL|Prospective, Concurrently Controlled, Multi-Center Study to Evaluate the Safety and Effectiveness of the Spinal Kinetics™ M6-C Artificial Cervical Disc Compared to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Symptomatic Cervical Radiculopathy||Spinal Kinetics|Yes|Recruiting|April 2014|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|243|||Both|18 Years|75 Years|No|||June 2015|June 24, 2015|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609374||85133|
NCT01609387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LTC 745|Postoperative Vitamin Supplementation in Morbidly Obese Patient (VITAAL Study)|Postoperative Vitamin Supplementation in Morbidly Obese Patient||Rijnstate Hospital|No|Active, not recruiting|July 2011|December 2015|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Anticipated|450|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|September 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01609387||85132|
NCT01589939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0174, A-15214.1a|Reduced Planning Target Volume (PTV) Margins for the Treatment of Prostate Cancer Using the Calypso 4D Localization System|Reduced PTV Margins for the Treatment of Prostate Cancer With IMRT Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study|PTV|U.S. Army Medical Research Acquisition Activity|Yes|Active, not recruiting|March 2009|August 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Male|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with localized prostate cancer for whom definitive radiation therapy is planned        to the prostate only or prostate and seminal vesicle only, without ajuvant or neoadjuvant        hormornal therpy will be referred by the radiation oncololgists and urologists.|September 2015|September 9, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589939||86626|
NCT01589952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BB1|Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)|Pilot Study of First Line Combination Treatment With Low Dose Pegylated Interferon and Entecavir in Treatment-naïve Patients With Chronic Hepatitis B.|Bangabandhu|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|No|Recruiting|March 2012|March 2013|Anticipated|February 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|65 Years|No|||May 2012|May 1, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01589952||86625|
NCT01589965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100|The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence in Lesotho|The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence Among Youth: Evidence From a Randomized Controlled Field Trial in Lesotho||Bocconi University|Yes|Active, not recruiting|February 2010|June 2012|Anticipated|February 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|5000|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 1, 2012|April 19, 2010||No||No||https://clinicaltrials.gov/show/NCT01589965||86624|
NCT01587430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML-01.10|3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia|Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance||National Research Center for Hematology, Russia|Yes|Active, not recruiting|January 2010|January 2015|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|245|||Both|15 Years|60 Years|No|||April 2014|April 4, 2014|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587430||86816|
NCT01583322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GINECO-OV119|Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer|Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum|CHIVA|ARCAGY/ GINECO GROUP|Yes|Completed|June 2012|March 2016|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|188|||Female|18 Years|N/A|No|||March 2016|March 15, 2016|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01583322||87125|
NCT01584154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101|Comparative Study Between Cryoablation and Radiofrequency Ablation in the Treatment of Supraventricular Tachycardia|CRYOthermy and Radiofrequency ABLation For AVNRT TrEatment|CRYOABLATE|Princess Margaret Hospital, Hong Kong|No|Recruiting|March 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|520|||Both|18 Years|80 Years|No|||September 2015|September 3, 2015|April 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584154||87063|
NCT01584440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-AVR-131|Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients|A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.||Avanir Pharmaceuticals|Yes|Completed|June 2012|September 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|50 Years|90 Years|No|||September 2014|September 18, 2014|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584440||87042|
NCT01583894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7003|Multiple Areas of Pain (MAP)|Multiple Areas of Pain (MAP): Epidemiology of Multisite Pain in the Chronic Pain Population|MAP|Boston Scientific Corporation|No|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|828|||Both|18 Years|N/A|No|Non-Probability Sample|Chronic pain patients resident in a US pain management practice.|November 2013|March 9, 2015|April 23, 2012||No||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01583894||87082|
NCT01583907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBC-100789|Nutrition in Children With Food Allergy|||Federico II University|No|Recruiting|March 2012|March 2014|Anticipated|March 2013|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|Samples Without DNA|blood sampling to measure laboratory parameters useful to asses nutritional status|Both|6 Months|36 Months|No|Probability Sample|children with a sure diagnosis of food allergy|April 2012|April 24, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01583907||87081|
NCT01584128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38775EP|Oxidized Regenerated Cellulose to Decrease Vaginal Cuff Complications|Use of Structured Non-woven Absorbable Hemostat (or Oxidized Regenerated Cellulose) to Decrease Vaginal Cuff Dehiscence Rate in Laparoscopic Hysterectomy||Milton S. Hershey Medical Center|Yes|Recruiting|April 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Female|20 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|women, age 20-80, undergoing laparoscopic hysterectomy|April 2012|April 23, 2012|April 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01584128||87065|
NCT01606761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100864|A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy||Janssen Research & Development, LLC|Yes|Completed|August 2012|January 2016|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|878|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606761||85333|
NCT01600027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R 54|Dexmedetomidine Addition to Fascia Iliaca Compartment Block|Effects of Dexmedetomidine Addition to Bupivacaine on the Quality of Fascia Iliaca Compartment Block (FICB) in Children Undergoing Femur Fracture Surgery||Mansoura University|Yes|Completed|January 2012|May 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|28|||Both|2 Years|6 Years|No|||March 2015|March 15, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600027||85851|
NCT01607580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPH IRB [2012] (26)|Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)|Risk Stratification-directed Low-dose Glucocorticoid Prophylaxis for Acute GVHD After Unmanipulated Haploidentical Blood and Marrow Transplantation——a Randomized, Controlled, Clinical Trial||Peking University People's Hospital|Yes|Active, not recruiting|June 2012|February 2014|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|145|||Both|N/A|60 Years|No|||January 2014|January 3, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607580||85271|
NCT01596959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|79426/244082/1/568|The Contact-CTI Study: Use of Tissue Contact Data to Guide Atrial Flutter Ablation|The Contact-CTI Study - Does Assessment of Tissue Contact During Ablation of Atrial Flutter Improve Outcomes?||Oxford University Hospitals NHS Trust|No|Recruiting|January 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2012|May 10, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01596959||86087|
NCT01608178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120123|Taurine Therapy for SSADH Deficiency|Succinic Semialdehyde Dehydrogenase Deficiency: Physiological Markers of Taurine Therapy||National Institutes of Health Clinical Center (CC)||Completed|April 2012|December 2013||||N/A|Observational|Time Perspective: Prospective|||Actual|7|||Both|12 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 17, 2013|May 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01608178||85225|
NCT01608464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2111-104|Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer|A Trial Comparing Pre-operative Chemo-radiotherapy With Cisplatin and Fluorouracil Versus Chemotherapy With Docetaxel and Irinotecan in PET Non Responders Resectable Cancer Esophagus: a Multicenter Study||King Faisal Specialist Hospital & Research Center|Yes|Completed|May 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|170|||Both|14 Years|75 Years|No|||February 2016|February 24, 2016|May 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01608464||85203|
NCT01608789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU012|Virtue® European Study|Virtue® Male Sling European Study||Coloplast A/S|No|Active, not recruiting|August 2012|February 2018|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Male|18 Years|N/A|No|||April 2015|April 22, 2015|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608789||85178|
NCT01609127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOB206|Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer|A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer||Genta Incorporated|No|Recruiting|May 2012|July 2014|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|213|||Female|18 Years|N/A|No|||May 2012|May 31, 2012|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609127||85152|
NCT01609101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-1210|Oropharyngeal Space in Videolaryngoscopy|Oropharyngeal Space in Videolaryngoscopy: a Randomised Crossover Trial Measuring Remaining Space Adjacent to the Videolaryngoscope Blade||Catharina Ziekenhuis Eindhoven|Yes|Completed|May 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|7||Actual|489|||Both|18 Years|N/A|No|||April 2014|April 3, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01609101||85154|
NCT01600443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOF-0022|Comparison of Microtrauma in Urethra After Usage of Different Catheters|A Randomized Cross-over Study on Urethral Microtrauma After Intermittent Catheterization.||Wellspect HealthCare||Terminated|April 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|21|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 31, 2014|April 24, 2012||No|Planned interim analysis showed study was underpowered|No||https://clinicaltrials.gov/show/NCT01600443||85819|
NCT01587144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-LUC-11-01|Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)|An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme||Spectrum Pharmaceuticals, Inc|Yes|Terminated|March 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||October 2013|October 30, 2013|April 11, 2012|Yes|Yes|Sponsor's decision|No||https://clinicaltrials.gov/show/NCT01587144||86838|
NCT01583634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLS STP-9100001|Accuracy of Oximeters With Hypoxia and Methemoglobin or Carboxyhemoglobin|Accuracy of Oximeters With Hypoxia and Methemoglobin or Carboxyhemoglobin||Mespere Lifesciences Inc.|No|Completed|September 2014|October 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples With DNA|Whole blood|Both|21 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers between the ages of 21 and 49 years of either gender, and a range of        skin tones|October 2014|October 2, 2014|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583634||87101|
NCT01583335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tryg-7984-07|The Healthy Start Project: Primary Prevention of Overweight in Preschool Children Predisposed to Future Overweight|Prevention of Weight Gain Among Normal Weight, High Risk, Pre-school Children - a Randomized Controlled Interventions Study.||Bispebjerg Hospital|No|Active, not recruiting|May 2009|December 2020|Anticipated|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|1100|||Both|2 Years|6 Years|Accepts Healthy Volunteers|||January 2015|January 27, 2015|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01583335||87124|
NCT01584453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1500|Safety and Effectiveness of Intra-coronary Nitrite in Acute Myocardial Infarction|A Randomised, Double-blind, Placebo-controlled Trial Assessing the Safety and Efficacy of Intracoronary Nitrite Infusion During Acute Myocardial Infarction|NITRITE-AMI|Barts & The London NHS Trust|Yes|Active, not recruiting|April 2012|November 2015|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|80 Years|No|||July 2015|August 18, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01584453||87041|
NCT01584765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115983|Rechallenge, Potential Drug Induced Liver Injury (Kaiser)|Rechallenge Analysis: Detection of Potential Drug-Induced Liver Injury Using Kaiser California Database||GlaxoSmithKline||Completed|February 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|The population was defined as patients 1) 18 years or older at the start of the drug        exposure, 2) with 12 months or more of continuous membership plus drug benefit immediately        prior to the drug start date, and 3) filling at least one prescription for fourteen drugs        associated with hepatotoxicity (Chalasani 2008) anytime between Jan. 1, 2003 to June 30,        2009. Overall, 1,064,722 patients fulfill these criteria as derived from the total study        population of the descriptive analysis. To be included in this analysis, patients had to        be rechallenged with the same suspect drug and had at least one ALT measured at first        exposure and during the rechallenge event. Study observations started in 2002 to allow for        a year of pre-study observation in all exposures at risk. Applying all inclusion and        exclusion criteria, the total study population comprises of 846 subjects.|July 2014|July 3, 2014|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01584765||87017|
NCT01584778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TF.00.U.32.|Behçet's Disease and Eosinophil Cationic Protein|The Serum Eosinophil Cationic Protein Levels in Behçet's Disease and Its Relation to the Clinical Activity||Cukurova University|No|Completed|January 2002|December 2002|Actual|December 2002|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|47|||Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive Behçet patients of the outpatient clinic of the Rheumatology-Immunology        Department of University Hospital|April 2012|April 25, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01584778||87016|
NCT01584141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999911206|Study of Lymphoma in Asia|A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph)||National Institutes of Health Clinical Center (CC)||Recruiting|July 2011|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|10400|||Both|18 Years|79 Years|No|||June 2015|July 15, 2015|April 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01584141||87064|
NCT01584427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERN-ButCoIns|ButCoIns - Metabolic Effects of Resistent Starch and Arabinoxylans in Subjects With Metabolic Syndrome|ButCoIns - Metabolic Effects of Resistent Starch and Arabinoxylans in Subjects With Metabolic Syndrome|ButCoIns|Aarhus University Hospital|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|22|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01584427||87043|
NCT01607307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JAPAN-PD|Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After Pancreaticoduodenectomy|Effect of Daikenchuto (TJ-100) on Intestinal Dysmotility and For the Prevention of Postoperative Paralytic Ileus in Patients Undergoing Pancreaticoduodenectomy: A Multicenter, Randomized, Placebo-Controlled Phase II Trial|JAPAN-PD|Wakayama Medical University|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|220|||Both|20 Years|N/A|No|||August 2012|December 17, 2013|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607307||85291|
NCT01607320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9469|Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome|Effect of Raloxifene on Ovulation in Women With Polycystic Ovarian Syndrome.|PCOS|Greenville Health System|Yes|Terminated|June 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|3|||Female|18 Years|36 Years|No|||May 2015|May 12, 2015|February 15, 2012|Yes|Yes|Over budget, slow recruitment, and personnel change|No|April 14, 2015|https://clinicaltrials.gov/show/NCT01607320||85290|
NCT01607593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0501099|A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients|A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients||Pfizer|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|123|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with PTSD|December 2013|December 11, 2013|May 21, 2012||No||No|September 26, 2013|https://clinicaltrials.gov/show/NCT01607593||85270|
NCT01607606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PerMIT II|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2012|||||N/A|N/A|N/A||||||||||||||May 29, 2012|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607606||85269|
NCT01607879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00016781|Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation|Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy||Medical College of Wisconsin|Yes|Recruiting|March 2014|October 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Male|60 Years|N/A|No|||October 2015|October 23, 2015|April 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607879||85248|
NCT01608204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU/MEAdultPK/PGx1|Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation|||Rambam Health Care Campus|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|63|Samples With DNA|Peripheral Blood was used for DNA extraction|Both|18 Years|67 Years|No|Non-Probability Sample|Adults suffering from AML who were selected to be treated by Hematological Stem Cell        Transplantation|May 2012|June 10, 2013|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608204||85223|
NCT01608230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-5270|Human Tumor Sequencing Project|Human Tumor Sequencing Project|HuTS|Scripps Translational Science Institute|No|Completed|April 2010|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer|November 2014|November 17, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608230||85221|
NCT01608477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRIGHT|Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation|Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation|BRIGHT|University of Basel|No|Recruiting|April 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1800|||Both|18 Years|N/A|No|Probability Sample|Adult heart transplant recipients|May 2012|May 28, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01608477||85202|
NCT01599858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|96-018|Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers|YF476: Effects of Repeated Dosing at 2 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Omeprazole in Healthy Volunteers||Trio Medicines Ltd.|No|Completed|August 1996|October 1996|Actual|October 1996|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|49|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 14, 2012|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01599858||85864|
NCT01609114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH No.:100163-F|Irradiation Modulates the Pharmacokinetics of Anticancer Drugs for Head and Neck Cancer|Irradiation Modulates the Pharmacokinetics of Anticancer Drugs for Head and Neck Cancer||Far Eastern Memorial Hospital|Yes|Active, not recruiting|April 2012|||July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|20 Years|80 Years|No|Probability Sample|Chemotherapy-naive patients with histologically confirmed, locally advanced head and neck,        nasopharyngeal cancers, who prepares for concurrent chemoradiation therapy as definitive        or adjuvant setting, are consecutively enrolled in this study|May 2013|May 8, 2013|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01609114||85153|
NCT01609400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31GB1103|An Extension of CTN 31GB0607 to Evaluate Long Term Safety of NASHA Treatment in the Breast|||Q-Med AB|No|Completed|December 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|11|||Female|25 Years|50 Years|No|Non-Probability Sample|Subjects treated in study 31GB0607|February 2015|February 26, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01609400||85131|
NCT01596556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8767-AD-CTIL|The Effect of Smoking on Thermoregulation|The Effect of Smoking on Thermoregulation||Sheba Medical Center|No|Completed|June 2012|May 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01596556||86118|
NCT01586871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202M09721|Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network|Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|March 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|3 Years|18 Years|No|Non-Probability Sample|This is an observational study of 60 individuals with MPS I, II and VI between the ages of        3 and 18. Those participating in this study will be seen for a onetime, one-hour study        visit. Participants will be enrolled at the University of Minnesota, Minneapolis,        Minnesota and Children's Hospital of Orange County, Orange, California.|September 2014|September 4, 2014|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586871||86859|
NCT01587157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20042012|Capnography During Percutaneous Transhepatic Cholangiodrainage (PTCD) (HepaBreath)|||Technische Universität München|No|Completed|August 2010|August 2011|Actual|June 2011|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Prevention|1||Actual|20|||Both|18 Years|N/A||||April 2012|April 25, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587157||86837|
NCT01583946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11070243|Temporally-Oriented Subjective Well-being Across Transitions—Resources & Outcomes|Temporally-Oriented Subjective Well-being Across Transitions—Resources & Outcomes|LIFT|University of Pittsburgh|Yes|Active, not recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Observational|Observational Model: Cohort||8|Anticipated|1560|||Both|50 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Males and females 50 and older|December 2015|December 1, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01583946||87078|
NCT01583933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFHA-02|Essix Retainer vs Hawley Retainer|PHASE 3 STUDY OF THE EFFECTIVITY OF TWO RETAINERS IN THE DENTAL AND OCCLUSAL STABILITY|retainer|CES University|No|Recruiting|September 2011|May 2012|Anticipated|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|16 Years|40 Years|No|||April 2012|April 26, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01583933||87079|
NCT01584466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00052194|Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study|Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study||University of Maryland|No|Withdrawn|January 2014|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|64 Years|No|||January 2014|January 27, 2014|March 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584466||87040|
NCT01584479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00037624|Periodontal Disease Prevention Study|Periodontal Disease Prevention Study:A Retrospective Cohort Study to Assess the Effect of Genetics and Dental Preventive Care on Periodontal Disease||University of Michigan|No|Completed|December 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|5117|Samples With DNA|buccal swabs|Both|34 Years|55 Years|Accepts Healthy Volunteers|Probability Sample|Study may include all participants who are 34-55 years old in 1992 (48-68 years old in        2010) and who have at least a 15-year dental claim history with Delta Dental.|June 2015|June 17, 2015|April 12, 2012||No||No|June 13, 2014|https://clinicaltrials.gov/show/NCT01584479||87039|
NCT01628250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-MIS|Laparoscopic Complete Mesocolic Excision on Colon Cancer|Clinical Research on the Efficacy and Feasibility of Laparoscopic Complete Mesocolic Excision on Colon Cancer: A Randomized Controlled Study|LCME|Ruijin Hospital|Yes|Recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|79 Years|No|||July 2013|July 16, 2013|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01628250||83687|
NCT01628588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/026|Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|||Allergan|No|Completed|March 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|854|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary open angle glaucoma or ocular hypertension|August 2012|August 21, 2012|June 25, 2012|Yes|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT01628588||83661|
NCT01628601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/027|GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy|||Allergan|No|Completed|May 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|392|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary open angle glaucoma or ocular hypertension prescribed GANfort®        (fixed combination 0.3 mg bimatoprost and 5 mg timolol) by the physician prior to study        entry|August 2012|August 21, 2012|June 25, 2012|Yes|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT01628601||83660|
NCT01628614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/028|A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|||Allergan|No|Completed|November 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4812|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary open angle glaucoma or ocular hypertension|August 2012|August 2, 2012|June 25, 2012||No||No|August 2, 2012|https://clinicaltrials.gov/show/NCT01628614||83659|
NCT01628887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12175|Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors|Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors||City of Hope Medical Center|Yes|Terminated|August 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|4|||Female|21 Years|N/A|No|||July 2013|July 12, 2013|June 25, 2012||No|Proposal will not be submitted and low accrual.|No||https://clinicaltrials.gov/show/NCT01628887||83638|
NCT01629420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLH1203|A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis|A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2|||20|||Female|20 Years|N/A|No|||May 2014|May 29, 2014|June 25, 2012||||No||https://clinicaltrials.gov/show/NCT01629420||83597|
NCT01630031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Contact Force Sensing and Pulmonary Vein Isolation|Pulmonary Vein Isolation: Interest of Real-Time Contact Force Sensing During Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation||Clinique Pasteur|No|Active, not recruiting|November 2010|November 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population included patients with paroxysmal atrial fibrillation who undergo a first        catheter ablation procedure (pulmonary vein isolation).|June 2012|June 26, 2012|June 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01630031||83550|
NCT01597804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 189910|Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery|A "Bathing Bundle" Regimen to Reduce the Risk of Gynecological Surgical Site Infection||Roswell Park Cancer Institute||Active, not recruiting|April 2011|||February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|429|||Female|19 Years|N/A|No|||September 2015|September 29, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597804||86022|
NCT01630551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1136|Omega 3 Supplementation and Ocular Surface Disease in Glaucoma|Omega-3 Fatty Acid Nutritional Supplementation in the Treatment of Ocular Surface Disease Associated With Intraocular Pressure-Lowering Medications||University of Illinois at Chicago|No|Recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2013|August 7, 2013|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01630551||83510|
NCT01598376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBH Suture Study|A Prospective Double-blind Interventional Study of Tissue Reaction to Polyglycolic Acid Sutures in Human Skin|A Prospective Double-blind Interventional Study of Tissue Reaction to Polyglycolic Acid Sutures in Human Skin||The Royal Bournemouth Hospital|No|Completed|June 2010|March 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|42|||Both|18 Years|N/A|No|||May 2012|May 14, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598376||85978|
NCT01631149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bliss s|Effect of Deep BLock on Intraoperative Surgical Conditions|Effect of Deep BLock on Intraoperative Surgical Conditions, Perioperative Hemodynamic Status and Respiratory Parameters Following Reversal With Sugammadex in Patients Undergoing Laparoscopic Renal and Prostate Surgery.|BLISS|Leiden University Medical Center|No|Recruiting|June 2012|December 2014|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2012|June 27, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01631149||83464|
NCT01598389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01DK078601|Eating Behaviors Among Weight-Discordant Siblings|Eating Behaviors Among Weight-Discordant Siblings||University of Pennsylvania|No|Completed|October 2008|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|94|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01598389||85977|
NCT01596829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAD-EU2012|Effect of Probiotic Formula on Reducing the Risk for Antibiotic-associated Diarrhoea|Effect of Probiotic Formula on Reducing the Risk for Antibiotic-associated Diarrhoea||Danisco|No|Terminated|December 2012|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|258|||Both|18 Years|65 Years|No|||December 2014|January 21, 2016|May 8, 2012||No|low incidence|No||https://clinicaltrials.gov/show/NCT01596829||86097|
NCT01597063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-T21-303|Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies|A Clinical Study to Evaluate the Relative Clinical Specificity Performance of the SEQureDx Trisomy Test in Pregnant Women at Low Risk for Fetal Chromosomal Aneuploidy||Sequenom, Inc.|No|Active, not recruiting|July 2012|December 2015|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3333|Samples With DNA|Whole blood specimens will be collected and processed to plasma. DNA will be extracted from      the plasma.|Female|18 Years|34 Years|No|Probability Sample|Pregnant with low risk for fetal chromosome 21 aneuploidy|December 2014|December 9, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597063||86079|
NCT01597375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002961|Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)|Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)|Aspirin|Brigham and Women's Hospital|Yes|Recruiting|August 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|115|||Both|18 Years|65 Years|No|||September 2015|September 21, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01597375||86055|
NCT01597674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-010|Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers|A Double-blind, Placebo-controlled, Parallel-group Study of the Effect of 5, 10 and 25 mg Daily of YF476 for 14 Days on 24-hour Ambulatory Gastric pH and Plasma Gastrin Concentrations in Healthy Volunteers||Trio Medicines Ltd.|No|Completed|April 1997|June 1997|Actual|June 1997|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 11, 2012|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597674||86032|
NCT01597960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0597|Yoga And Cardiovascular Health Trial|Yoga And Cardiovascular Health Trial|YACHT|Imperial College London|Yes|Not yet recruiting|June 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|80|||Both|35 Years|80 Years|No|||June 2012|June 14, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01597960||86010|
NCT01598207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201003768|The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain|||University of Iowa||Completed|February 2011|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|75 Years|No|||December 2014|December 4, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01598207||85991|
NCT01597908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116513|Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma|A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma|COMBI-v|GlaxoSmithKline|Yes|Active, not recruiting|June 2012|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|704|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|May 10, 2012|No|Yes||No|December 1, 2014|https://clinicaltrials.gov/show/NCT01597908||86014|
NCT01598194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0907|Comparison of a Novel 22-gauge Core Biopsy Needle|Prospective Comparison of a Novel 22-gauge Core Biopsy Needle With Reverse Bevel Design to a Standard Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) Needle for Diagnosis of Solid Pancreatic Mass Lesions||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2012|||January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||August 2015|August 13, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598194||85992|
NCT01627951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP3|Comparison of Three Plasmodium Falciparum Isolates in a Controlled Human Malaria Infection|Comparison of NF54, NF135 and NF166 Strains of Plasmodium Falciparum in a Controlled Human Malaria Infection (TIP3)|TIP3|Radboud University|Yes|Completed|August 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|15|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||November 2012|November 26, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01627951||83710|
NCT01628263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CH/2011/3827|Does a Follow-up Appointment Help Parents of Children on PICU?|Does Screening Parents Allow Targeting of a Paediatric Intensive Care Follow-up Clinic? A Feasibility Study|PICUfu|University Hospitals Bristol NHS Foundation Trust|No|Recruiting|December 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|150|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2012|June 25, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01628263||83686|
NCT01628900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 10103|Prospective Study in the Emergency|New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency|PROPA|Assistance Publique - Hôpitaux de Paris|No|Terminated|May 2012|July 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|23|||Both|18 Years|N/A|No|||June 2011|October 7, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01628900||83637|
NCT01628913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235Z2401|Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors|Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors|MACS1938|Novartis|No|Completed|October 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628913||83636|
NCT01629199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-EGF011P|Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus|The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF(Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.||Daewoong Pharmaceutical Co. LTD.||Completed|October 2010|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|N/A|No|||August 2014|August 1, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629199||83614|
NCT01629173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97-11-12A|The Analysis and Applications of Dynamic Impression Insole|The Effect of Dynamic Impression Insoles on Plantar Pressure and Pain in Persons With Metatarsal Pain||Taipei Veterans General Hospital, Taiwan|Yes|Completed|April 2011|June 2012|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|50|||Both|18 Years|90 Years|No|||June 2012|June 24, 2012|October 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01629173||83616|
NCT01597531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECDOI-D71|Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding|LIRAGLUTIDE AND ORLISTAT TREATMENT FOR PERSISTENT TYPE 2 DIABETES AFTER GASTRIC BANDING: A PILOT STUDY||East Carolina University|No|Recruiting|June 2012|June 2014|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|9|||Both|25 Years|70 Years|No|||June 2012|June 13, 2012|May 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597531||86043|
NCT01597245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12973|A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis|UNCOVER-2|Eli Lilly and Company|Yes|Active, not recruiting|May 2012|July 2019|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|1225|||Both|18 Years|N/A|No|||May 2015|May 7, 2015|May 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597245||86065|
NCT01598090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-020|Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir|A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin|PEDESTAL|Bristol-Myers Squibb|Yes|Active, not recruiting|June 2012|January 2016|Anticipated|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|636|||Both|18 Years|70 Years|No|||February 2015|January 26, 2016|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598090||86000|
NCT01597817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UP-AD-2012|Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis|A Randomized Controlled Trial of the Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis|2ndDermisII|Universidade do Porto|No|Completed|November 2011|December 2012|Actual|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|12 Years|N/A|No|||December 2014|December 8, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597817||86021|
NCT01598610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2012-002-01|Performance Evaluation of an Investigational Blood Glucose Monitoring System|Performance of the CONTOUR® PLUS Blood Glucose Monitoring System With CONTOUR® PLUS Strip||Ascensia Diabetes Care|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|220|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 13, 2012|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01598610||85960|
NCT01598103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAF312A2202|Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions|A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy||Novartis|No|Terminated|January 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|65 Years|No|||March 2013|March 18, 2013|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01598103||85999|
NCT01599364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATLAS 2|Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression|Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression|ATLAS|Catholic University of the Sacred Heart|Yes|Active, not recruiting|July 2011|November 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|80 Years|No|||July 2014|July 31, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599364||85902|
NCT01596842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAU-12-073|Effect of Omega-3 Fatty Acid on Vitamin D Activation|Effect of Omega-3 Fatty Acid on Vitamin D Activation in Hemodialysis Patients||Dong-A University|Yes|Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|17|||Both|20 Years|80 Years|No|||March 2015|March 8, 2015|May 8, 2012||No||No|February 20, 2015|https://clinicaltrials.gov/show/NCT01596842||86096|
NCT01596855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-048|Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China|A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)||FibroGen|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|75 Years|No|||January 2013|January 31, 2013|April 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01596855||86095|
NCT01597076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111118-SUS-NON-AGE-GP|Effect of an Iridoid Enriched Beverage on Skin Autofluorescence|||Tahitian Noni International, Inc.|Yes|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|34|||Both|25 Years|60 Years|Accepts Healthy Volunteers|||August 2012|December 2, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597076||86078|
NCT01597947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACHN-975-001|A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers|A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) ACHN-975 in Normal Healthy Volunteers||Achaogen, Inc.||Completed|May 2012|December 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|May 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597947||86011|
NCT01598506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054701|Intrathecal Hydromorphone for Labor Analgesia|Determination of the ED50 of Intrathecal Hydromorphone in Laboring Women Using the Up-and-down Sequential Allocation Method||Emory University|Yes|Completed|September 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|May 10, 2012|Yes|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01598506||85968|
NCT01597921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23267384|A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer|Phase II, Double Blinded, Randomized Study of R1 and R2 (Waterjel) Verses Aloe Vera Jell for the Prevention and Treatment of Radiation Induced Dermatitis in Breast Cancer Patients||Water-Jel|No|Terminated|May 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|50|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|75|August 2012|August 8, 2012|May 10, 2012||No|The study was stopped due to unbalanced side effects|No||https://clinicaltrials.gov/show/NCT01597921||86013|
NCT01597934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI463-274|Antiviral Efficacy of Switching to ETV Plus TDF|A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation||Yonsei University|Yes|Active, not recruiting|August 2012|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|104|||Both|20 Years|N/A|No|||January 2014|January 30, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01597934||86012|
NCT01598948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICA|Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis|Effect of Mipomersen on LDL-Cholesterol Levels in Patients With Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis|MICA|Ludwig-Maximilians - University of Munich|No|Completed|August 2012|June 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|May 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598948||85934|
NCT01599195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4209|Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis|Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis||Albert Einstein Healthcare Network|No|Recruiting|April 2010|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|||Both|19 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|any person age 19 through 90 years who have been clinically determined to require        evaluation of carotid or femoral arteries for suspected stenosis|May 2012|May 14, 2012|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599195||85915|
NCT01627977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUT-RET|Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy|A Descriptive Study to Evaluate the Effectiveness of the Dye Compound of the Combination of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy||Federal University of São Paulo|Yes|Completed|October 2012|March 2014|Actual|January 2014|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|18|||Both|18 Years|90 Years|No|||March 2016|March 15, 2016|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01627977||83708|
NCT01628224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pritts-2010-01|Enhanced Critical Care Air Transport Team Training for Mitigation of Task Saturation|Enhanced Critical Care Air Transport Team Training for Mitigation of Task Saturation||University of Cincinnati|No|Completed|October 2011|January 2013|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|48|||Both|18 Years|60 Years|No|Non-Probability Sample|The population for the first task will consist of 4 CCATT teams (of 3 members each)|March 2013|March 4, 2013|November 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01628224||83689|
NCT01628237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A011695-36|Effectiveness and Cost Management of Multicolumn Spinal Cord Stimulation in Neuropathic Pain Patients With Failed Back Surgery Syndrome||ESTIMET|Poitiers University Hospital||Completed|May 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|115|||Both|18 Years|80 Years|No|||March 2014|February 13, 2015|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01628237||83688|
NCT01628627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EuropeanFREMS|Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy|Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy||Lorenz Biotech S.p.A.|No|Completed|May 2006|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|18 Years|75 Years|No|||June 2012|June 26, 2012|June 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01628627||83658|
NCT01628640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1148|Viral Therapy in Treating Patient With Liver Cancer|Phase I Trial of Intratumoral Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta in Patients With Sorafenib Refractory/Intolerant Hepatocellular Carcinoma||Mayo Clinic||Recruiting|August 2012|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|June 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01628640||83657|
NCT01629719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK 002-001|Study Phase III Comparison of Superiority, Open With Blind Appraiser, to Evaluate the Efficacy and Safety of Barium Sulphate 66.7% With V (OPTI-BAR) Compared to Proceedings in Inert Radiological Examinations for the Diagnosis of Diseases for Image the Tratogastrointstinal|STUDY PHASE III COMPARISON OF SUPERIORITY, OPEN WITH BLIND APPRAISER, TO EVALUATE THE EFFICACY AND SAFETY OF BARIUM SULPHATE 66.7% W / V (OPTI-BAR) COMPARED TO PROCEEDINGS IN INERT RADIOLOGICAL EXAMINATIONS FOR THE DIAGNOSIS OF DISEASES FOR IMAGE THE TRATOGASTROINTSTINAL.||Alko Do Brasil Industria e Comercio Ltda|No|Not yet recruiting|June 2012|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|73|||Both|18 Years|N/A|No|Probability Sample|Men and women over 18 years.|June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629719||83574|
NCT01629732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI472-007|Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C|Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C||Bristol-Myers Squibb|No|Withdrawn|March 2013|June 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|7||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629732||83573|
NCT01630044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037089|Neurostimulation Device for Treatment of Migraine Headache|Clinical Pilot Study to Evaluate a Non-Invasive, Neurostimulation Device for Treatment of Migraine Headache||Duke University|No|Completed|May 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|N/A|No|||June 2015|July 15, 2015|June 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01630044||83549|
NCT01597011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS12-000733|Long-term Follow-up After Laparoscopic Inguinal Hernia Repair Using Tisseel for Mesh Fixation|Long-term Follow-up After Laparoscopic Inguinal Hernia Repair Using Tisseel for Mesh Fixation||Herlev Hospital|No|Completed|July 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2340|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be enrolled based on their registration in the Danish Hernia Database. All        patients in the database who have undergone laparoscopic inguinal hernia repair from        January 2009 to September 2012 will be included.|March 2015|March 17, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597011||86083|
NCT01597830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L07041071|The Effects of Specialized Footwear in Osteoarthritis|The Effects of Specialized Footwear in Osteoarthritis||Rush University Medical Center|No|Active, not recruiting|July 2007|||June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|130|||Both|N/A|N/A|No|||March 2013|March 11, 2013|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597830||86020|
NCT01598116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-00482|A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas|A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas.||Ohio State University|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|serum and urine|Both|N/A|5 Months|Accepts Healthy Volunteers|Non-Probability Sample|Children with hemangiomas and children without hemangiomas will be enrolled from        Hemangioma and Vascular Malformation Clinic and Ambulatory Pediatric Clinics.|March 2016|March 21, 2016|January 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01598116||85998|
NCT01597544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241110|Post-operative Voiding Dysfunction: the Preferred Method for Catheterization|Post-operative Voiding Dysfunction: the Preferred Method for Catheterization||St. Michael's Hospital, Toronto|Yes|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597544||86042|
NCT01598857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN-VAS3321|BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis|BIANCA-SC|Anthera Pharmaceuticals||Withdrawn|December 2014|||June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||July 2015|July 28, 2015|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598857||85941|
NCT01599091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GF-PDLF-0148-12-HMO-CTIL|Characterizing Gingival and Periodontal Ligament Fibroblasts Reaction to Infection With the Bacteria Porphyromonas Gingivalis|Characterizing Gingival and Periodontal Ligament Fibroblasts Reaction to Infection With the Perio- Pathogenic Bacteria Porphyromonas Gingivalis||Hadassah Medical Organization|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|100|Samples With DNA|Anyway extracted teeth and gingiva. Patients undergoing tooth extraction will be asked      permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for      further basic research.|Both|18 Years|N/A|No|Non-Probability Sample|Healty over 18 years of age eligible for signing patients that go through tooth extraction        for reasons not related to the study.|September 2013|September 8, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01599091||85923|
NCT01629511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0249|Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)|Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)||M.D. Anderson Cancer Center|No|Recruiting|November 2012|||November 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629511||83590|
NCT01596868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mshi|GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China|A Randomized, Phase II Trial Comparing Induction Chemotherapy Gemcitabine Plus Cisplatin With Docetaxel Plus Cisplatin Followed by Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma in Northwest China||Fourth Military Medical University|Yes|Completed|May 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|69 Years|No|||October 2013|October 29, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01596868||86094|
NCT01597089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120125|Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples|Detection of Respiratory Viruses in Upper and Lower Respiratory Tract Specimens Using a Rapid Multiplex PCR||National Institutes of Health Clinical Center (CC)||Recruiting|April 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|100|||Both|12 Years|99 Years|No|||January 2016|January 16, 2016|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597089||86077|
NCT01598220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACR-2012-MT|Computer Assisted Cognitive Remediation Program in Schizophrenia|Efficacy Study of a Computer Cognitive Remediation Program in Patients With Schizophrenia|CACREPS|Consorci Sanitari de Terrassa|Yes|Completed|September 2002|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|55 Years|No|||May 2012|May 17, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01598220||85990|
NCT01598233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3056-CEP/HUPE|Effects of Intragastric Balloon on Bone, Metabolic and Respiratory Parameters|Effects of Intragastric Balloon on Bone, Metabolic and Respiratory Parameters||Universidade Federal do Rio de Janeiro|No|Completed|March 2011|August 2012|Actual|January 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|20 Years|50 Years|No|||December 2014|December 16, 2014|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01598233||85989|
NCT01598727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16019|Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics|A Phase I Feasibility Study of Intra-operative Near Infra-red Fluorescent Imaging in Thyroid/Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|July 2012|April 2013|Actual|January 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01598727||85951|
NCT01598974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001364|Back Pain Response to Different Acupuncture Methods|Brain Plasticity Underlying Back Pain Response to Different Acupuncture Methods|LBP|Brigham and Women's Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|129|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598974||85932|
NCT01598493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201003DSA|To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Deep Dermal Burn|To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Deep Dermal Burn||Bio-medical Carbon Technology Co., Ltd.|No|Completed|May 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|20 Years|80 Years|No|||November 2014|November 4, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01598493||85969|
NCT01598701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0055|Intravenous Acetaminophen in Craniotomy|The Opioid-Sparing and Analgesic Effects of IV Acetaminophen in Craniotomy: A Prospective, Randomized, Placebo-Controlled, Double-Blind Study||The University of Texas Health Science Center, Houston|No|Recruiting|June 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598701||85953|
NCT01598961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03-089-001|Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery|Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery||Samsung Medical Center|Yes|Completed|May 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|150|||Both|20 Years|70 Years|No|||December 2013|December 24, 2013|May 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01598961||85933|
NCT01627990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VENICE|Nivestim™ in Treatment of Malignant Diseases|The Compatibility of Nivestim™ Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases||Hospira, Inc.|No|Completed|June 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|386|Samples With DNA|-  CD34+ cell count in peripheral blood (low/high at Visit 1)        -  Concentrations of haemoglobin, thrombocytes, leukocytes, neutrophil and CRP are           represented across time (v1, 2 and 3)|Both|N/A|N/A|No|Non-Probability Sample|Children and adult patients with a solid tumour or a malignant haematological tumour|July 2015|July 23, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01627990||83707|
NCT01628276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSRC-AE-DCM-1|Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study|||Sina Hospital, Iran|Yes|Completed|July 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)|3||Actual|45|||Both|18 Years|54 Years|Accepts Healthy Volunteers|||September 2014|September 11, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01628276||83685|
NCT01628939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FacetJointEdema2009|Association Between Clinical Signs and MRI Findings of the Lumbar Facet Joints|Association Between Clinical Signs Assessed by Manual Segmental Examination and Findings of the Lumbar Facet Joints in Magnetic-resonance Scans in Subjects With and Without Current Low Back - a Prospective Single-blinded Study||Ruhr University of Bochum|No|Completed|June 2009|November 2009|Actual|November 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|pain clinic, sports clubs and fitness centers|June 2012|June 24, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01628939||83634|
NCT01629186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGH-94-269C|Nose-close and Abdomen-compression in Pediatric Flexible Bronchoscopy|Nasopharyngeal Oxygen With Nose-close and Abdomen-compression in Pediatric Flexible Bronchoscopy|NPO-NC-AC|Taipei Veterans General Hospital, Taiwan|Yes|Completed|January 2007|December 2010|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|156|||Both|N/A|20 Years|No|||June 2012|June 24, 2012|September 12, 2011||No||No||https://clinicaltrials.gov/show/NCT01629186||83615|
NCT01629745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B6|Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial|Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus||Children's Oncology Group|No|Active, not recruiting|June 2012|||August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|99|||Both|N/A|30 Years|No|Non-Probability Sample|Samples from patients registered on the Children Oncology Group (COG - AALL08B1)|May 2015|May 4, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629745||83572|
NCT01629758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA220-008|Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors|A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors||Bristol-Myers Squibb|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|No|||February 2015|March 5, 2015|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01629758||83571|
NCT01596764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOP-MNTX-2011|Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.|Effects of Extended Release Methylnaltrexone Bromide (150 mg b.i.d.) in Comparison to Extended Release Naloxone Hydrochloride (20 mg b.i.d.) on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time in Healthy Subjects.||University Medicine Greifswald|No|Completed|May 2011|January 2012|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01596764||86102|
NCT01596777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOP-MNTX-2009|Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects|Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects|LOP-MNTX-2009|University Medicine Greifswald|No|Completed|January 2010|May 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|5||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 9, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01596777||86101|
NCT01597843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 11-408|Veterans Service Organizations and My HealtheVet (MHV)|Working With Veterans Organizations to Encourage Use of My HealtheVet||VA Office of Research and Development|No|Completed|June 2012|January 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|282|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|April 6, 2015|May 10, 2012||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01597843||86019|Response rates on surveys were lower than expected. One of the first round intervention posts almost certainly did not deliver anything resembling the planned educational intervention at any point.
NCT01628393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-201 (Part A)|Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study)|A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients||Celgene|Yes|Active, not recruiting|July 2012|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|55 Years|No|||January 2014|June 2, 2015|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628393||83676|
NCT01628406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122|A Patient Registry at the Neurosurgery Department|A Patient Registry at the Neurosurgery Department.||University of Zurich||Enrolling by invitation|June 2012|August 2022|Anticipated|August 2022|Anticipated|Phase 1|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|12000|||Both|N/A|N/A|No|Non-Probability Sample|All patients treated at the Neurosurgery Department|December 2014|December 19, 2014|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01628406||83675|
NCT01598402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCNONCO201007|Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia|Efficacy and Cost Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Locally Advanced Head and Neck Cancer to Prevent Aspiration Pneumonia. A Randomized Phase II-III Study|PANTAP|Radboud University|No|Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01598402||85976|
NCT01598636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/324|The Lateral Tibial Tunnel in ACL Surgery|The Lateral Tibial Tunnel in Anterior Cruciate Ligament Surgery. A Clinical and Ct-graphic Study.to Evaluate the Concept|LTT-HVDB|University Hospital, Ghent|No|Recruiting|February 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||December 2014|December 4, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01598636||85958|
NCT01629004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|308-2010|Increasing Uptake of Colorectal Cancer Screening in Ontario|Increasing Uptake of Colorectal Cancer Screening in Ontario||Sunnybrook Health Sciences Centre|No|Completed|April 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|5155|||Both|50 Years|74 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629004||83629|
NCT01629264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CER-11-180|The Influence of Hormonal Changes During Pregnancy on Corneal Biomechanics in Humans|Influence of Pregnancy-related Hormonal Fluctuations on Corneal Biomechanics in Humans||University Hospital, Geneva|Yes|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women at the Dept. of Gynecology and Obstetrics of the University Hospital of        Geneva|March 2016|March 14, 2016|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01629264||83609|
NCT01629277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN03|Closing the Loop in Adolescents During Non-compliance Behaviours|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of 24-hour Closed-loop Glucose Control in Comparison With Conventional Subcutaneous Insulin Pump Treatment Simulating Non-compliant Behaviours in Adolescents With Type 1 Diabetes||University of Cambridge|No|Completed|July 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|12 Years|18 Years|No|||June 2012|June 26, 2012|April 4, 2011||No||No||https://clinicaltrials.gov/show/NCT01629277||83608|
NCT01629810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110957|Use of Whole-Body Periodic Acceleration Therapy To Aches and Pains|An Unblinded Crossover Study of The Use of Whole-Body Periodic Acceleration Therapy To Treat Pain, Stiffness, Abnormal Gait and Balance|Exer-Rest|Center for Translational Medicine|No|Recruiting|August 2011|||August 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629810||83567|
NCT01597102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|837.041.10 III|Cerebrovascular Autoregulation During and After Liver Transplantation|Cerebrovascular Autoregulation During and After Liver Transplantation|dARICULtx|Johannes Gutenberg University Mainz|No|Active, not recruiting|January 2012|March 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients with and stage liver failure and transplantation|January 2013|January 9, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01597102||86076|
NCT01597115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DUPLEX-IV-02-12|ENhancing Maturation of Autogenous Arteriovenous Hemodialysis Access by Aggressive surveillaNCe With Duplex and Endovascular Treatment|ENhancing Maturation of Autogenous Arteriovenous Hemodialysis Access by Aggressive surveillaNCe With Duplex and Endovascular Treatment|ENHANCE|Seoul National University Hospital|No|Completed|May 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|70 Years|No|||May 2014|May 25, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597115||86075|
NCT01597388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2270C00005|AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer|A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer||AstraZeneca||Active, not recruiting|May 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|122|||Female|18 Years|100 Years|No|||January 2016|January 26, 2016|March 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597388||86054|
NCT01598519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007BAI17B03|School-based Comprehensive Suicide Intervention in Shanghai, China|||Shanghai Mental Health Center|Yes|Recruiting|February 2011|December 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|3000|||Both|12 Years|19 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01598519||85967|
NCT01599234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWCL0403|A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis|A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis.||GW Pharmaceuticals Ltd.|No|Completed|March 2005|December 2005|Actual|December 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|337|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 10, 2012||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT01599234||85912|
NCT01599247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P002851|Natural History of Hopelessness, Suicidality, and Optimism in Psychiatric Inpatients Following Discharge|Natural History of Hopelessness, Suicidality, and Optimism in Psychiatric Inpatients Following Discharge||Massachusetts General Hospital|No|Completed|July 2011|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to the Inpatient Psychiatric Unit at Massachusetts General Hospital|August 2014|August 7, 2014|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01599247||85911|
NCT01598714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15909|Comparison of Patient Satisfaction Between 3 Types Dressing Shoes|A Comparison of Patient Satisfaction Between Darco, Podalux and Standard Dressing Shoes Following Forefoot Surgery||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|July 2012|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 23, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01598714||85952|
NCT01599221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBA2|Observational Retrospective and Prospective Study on the Treatment of Femoral Fractures With EBA2|Observational Retrospective and Prospective Study on the Treatment of Lateral Proximal Femoral Fractures With Medical Device EBA2||Citieffe S.r.l|No|Active, not recruiting|March 2012|October 2012|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Anticipated|40|||Both|60 Years|N/A|No|Non-Probability Sample|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral        fracture in the period 01.08.2011 - 31.01.2012 followed by each study sites|May 2012|September 10, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01599221||85913|
NCT01628289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UW 08-134|The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong|The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong||The University of Hong Kong|Yes|Completed|February 2009|August 2010|Actual|August 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|4644|||Both|N/A|N/A|No|||June 2012|June 21, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01628289||83684|
NCT01628653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2011-084|Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training|Feasibility and Efficacy of the Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (U-SMART) on Mild Cognitive Impairment|U-SMART|Seoul National University Bundang Hospital|Yes|Completed|June 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|55 Years|90 Years|No|||June 2012|June 23, 2012|June 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01628653||83656|
NCT01597557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED7441011B|Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial|Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial|MICA|State University of New York at Buffalo|Yes|Completed|April 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597557||86041|
NCT01628419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIN12345|Health Promotion Intervention Program at the Workplace|Health Promotion Intervention Program at the Workplace||Wingate Institute|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01628419||83674|
NCT01628367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00050746|Guided Bone Regeneration Around Immediate Implants|The Effectiveness of the Cytoplast Technique in Preventing Bone Loss Around Immediate Implant Placement in the Esthetic Zone. A Randomized Clinical Trial.||University of Michigan|Yes|Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 29, 2014|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01628367||83678|
NCT01628380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHORINE 2012-002616-22|Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer|Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel.|CHORINE|A.O. Ospedale Papa Giovanni XXIII|Yes|Recruiting|June 2012|July 2018|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Female|18 Years|70 Years|No|||August 2014|August 27, 2014|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01628380||83677|
NCT01628718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100322|Adaptive Disclosure|Adaptive Disclosure: A Combat-Specific PTSD Treatment||Veterans Medical Research Foundation|Yes|Active, not recruiting|March 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|266|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01628718||83651|
NCT01629290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00062943|In Vivo Comparison of Salivary Fluoride Levels Following the Application of Different 5% NaF Varnishes|In Vivo Comparison of Salivary Fluoride Levels Following the Application of Different 5% NaF Varnishes||University of Michigan|No|Completed|June 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01629290||83607|
NCT01629524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-08|Influence of Tumor Associated Immunity on the Number of Lymph Node Retrieved After Colorectal Cancer Surgery (Preliminary Study)|||Yonsei University|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|25|Samples Without DNA|Serum and postoperative specimen|Both|20 Years|80 Years|No|Non-Probability Sample|Colorectal cancer patients diagnosed with clinically TNM I, II, or III stage|January 2013|January 28, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629524||83589|
NCT01629537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2010.0157|A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder|A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder||United States Naval Medical Center, San Diego|Yes|Active, not recruiting|June 2011|December 2014|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|41|||Both|18 Years|N/A|No|||June 2014|June 27, 2014|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629537||83588|
NCT01597700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116051|Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.|A RANDOMIZED, BALANCED, OPEN LABEL, CROSSOVER, TWO PERIOD, TWO TREATMENT, TWO SEQUENCE, SINGLE DOSE, BIOEQUIVALENCE STUDY OF ACOTRAL® EZETIMIBE 10 MG TABLETS CONTAINING EZETIMIBE MANUFACTURED BY LABORATORIOS PHOENIX S.A.I.C.F, ARGENTINA AND ZETIA® EZETIMIBE 10 MG TABLETS OF MERCK/SCHERING - PLOUGH PHARMACEUTICALS, USA IN HEALTHY ADULT HUMAN MALE SUBJECTS UNDER FASTING CONDITION||GlaxoSmithKline|No|Completed|January 2012|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|52|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01597700||86030|
NCT01597687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115741|Pertussis Infection in Adolescents and Adults With Prolonged Cough|Bordetella Pertussis Infection Among Adolescents and Adults With Prolonged Cough||GlaxoSmithKline||Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|337|||Both|13 Years|N/A|No|||November 2013|November 7, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01597687||86031|
NCT01597973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 10-0065|Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli|Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli||Kaye, Keith, M.D., M.P.H.|Yes|Recruiting|October 2012|September 2017|Anticipated|August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|444|||Both|18 Years|95 Years|No|||January 2016|January 8, 2016|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597973||86009|
NCT01597986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0031|Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone|A Phase 1, Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone||Astellas Pharma Inc|No|Completed|April 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|May 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597986||86008|
NCT01599000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRAC.09.13|Artemether-Lumefantrine Clinical Effectiveness Study|Artemether-Lumefantrine Clinical Effectiveness Study||Papua New Guinea Institute of Medical Research|No|Completed|March 2011|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|159|||Both|6 Months|10 Years|No|||August 2012|August 14, 2012|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01599000||85930|
NCT01599260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00069415|Resistance Exercise in Rheumatic Disease|Resistance Exercise in Rheumatic Disease||Johns Hopkins University|No|Recruiting|May 2012|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|45 Years|85 Years|No|||December 2015|December 22, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01599260||85910|
NCT01599273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0164|Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections|||Yonsei University|No|Completed|May 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|19 Years|75 Years|No|||January 2015|January 26, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01599273||85909|
NCT01598987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001H2305|Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.|A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.||Novartis|Yes|Recruiting|October 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|1 Month|17 Years|No|||January 2015|January 5, 2015|March 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598987||85931|
NCT01628926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-08-001|A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients|A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa||Otsuka Pharmaceutical Co., Ltd.|No|Completed|June 2009|May 2011|Actual|May 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|420|||Both|30 Years|79 Years|No|||April 2014|April 23, 2014|June 24, 2012||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01628926||83635|
NCT01629433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|onabotulinumatoxin and NGF|Onabotulinumtoxina Intradetrusorial Injections and NGF Expression|PHASE IV STUDY ON THE EFFECTS OF ONABOTULINUMTOXINA INTRADETRUSORIAL INJECTIONS ON BLADDER EXPRESSION OF NGF, TRKA, P75 AND TRPV1 IN PATIENTS WITH DETRUSOR OVERACTIVITY|Onab/A-NGF|University Of Perugia|Yes|Completed|January 2009|March 2012|Actual|June 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|Samples With DNA|Bladder biopsy specimens obtained from the postero-lateral wall of the bladder with cold cup      resection. Deep bladder wall biopsy including urothelium and smooth muscle were performed.      No biopsies were taken from the bladder neck or the trigone.|Both|18 Years|80 Years|No|Non-Probability Sample|We consecutively enrolled 18 patients with neurogenic DO (8 patients with spinal cord        injury: 7 men and 1 women, mean age: 46±2 yrs, disease duration 6.25±1 yrs; 10 patients        with suprapontine bilateral lesions: 4 men and 6 women, mean age: 55±4 yrs, disease        duration 6.6±1.49 yrs ) and 7 with idiopathic DO (3 men and 4 female, mean age: 53±5 yrs,        disease duration 7.1±1.53 yrs). All the patients had overactive bladder (OAB) symptoms and        DO refractory to conventional anticholinergics (at least 3 antimuscarinic agents --        tolterodine, oxybutynin and solifenacin -- each taken for at least 1 month).        Anticholinergics were discontinued one month before entry into the study.|June 2012|June 25, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01629433||83596|
NCT01629446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1003-1|Lofexidine Mass Balance in Volunteers|A Single-Center, Open-Label, Single-Period, Single-Treatment Study to Determine the Mass Balance of a Single Oral Dose of 14C Labeled Lofexidine||US WorldMeds LLC|No|Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2015|June 5, 2015|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629446||83595|
NCT01596504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY12625|Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin|An Open-label, Randomized, Three-parallel-group Study on Pharmacodynamic Effects of 8-week QD Treatment With Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin||Sanofi|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|142|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596504||86122|
NCT01596751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol No. 12751|Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer|Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer||University of California, San Francisco|Yes|Recruiting|July 2012|December 2016|Anticipated|January 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||March 2015|March 3, 2015|May 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01596751||86103|
NCT01597570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FASTSEAL® VCD|Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System|Clinical Evaluation of Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable Vascular Access Closure System and Perclose® ProGlide Suture-Mediated Closure System; Randomized, Comparative Study||Taewoong Medical Co., Ltd.|No|Terminated|May 2012|||November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|116|||Both|20 Years|85 Years|No|||November 2012|November 20, 2012|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597570||86040|
NCT01628731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FUROCRYNIC trial-1|Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease|Phase III Study of Furosemide Continuous Infusion Versus Ethacrynic Acid Continuous Infusion in Children Undergoing Cardiac Surgery: Randomized Double Blind Controlled Clinical Trial||Bambino Gesù Hospital and Research Institute|Yes|Completed|October 2012|November 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|74|||Both|N/A|10 Years|No|||July 2014|July 23, 2014|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01628731||83650|
NCT01628744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR-99-IRB-075-1|Autoantibodies Against Specific Cytokines in Adults With Severe Mycobacterial Infection|||China Medical University Hospital|No|Recruiting|January 2011|December 2014|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Pateitns with Mycobacterium, Particular to the non Tuberculosis mycobacterium infection,        in Taiwan|June 2012|June 26, 2012|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01628744||83649|
NCT01629017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSBMT179|Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation|Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation||Stanford University||Recruiting|January 1995|January 2099|Anticipated|January 2099|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|blood, saliva|Both|N/A|18 Years|No|Non-Probability Sample|Stanford Blood and Marrow Transplant clinic.|October 2013|October 11, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629017||83628|
NCT01628757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM2011-07-01|Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer|Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer||Huazhong University of Science and Technology|Yes|Recruiting|July 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Female|18 Years|70 Years|No|Probability Sample|Patients with histologically confirmed Ib~ IIIb cervical carcinoma underwent Neoadjuvant        Chemotherapy|June 2012|June 26, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01628757||83648|
NCT01629030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-067-001|Risk Factors of Sternal Wound Infection After Coronary Artery Bypass Graft|Risk Factors of Sternal Wound Infection After Coronary Artery Bypass Graft||Samsung Medical Center|No|Recruiting|June 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1850|||Both|20 Years|90 Years|No|Non-Probability Sample|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung        Medical Center during the period of January 2008 and December 2011.|July 2014|July 8, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629030||83627|
NCT01629875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWP450001|Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line|Efficacy and Safety of DWP450 Compared With Botox in Patients With Moderate to Severe Glabellar Line: Active Controlled, Double-blind, Randomized, Multi-center, Phase I/III Clinical Trial||Daewoong Pharmaceutical Co. LTD.||Completed|March 2012|November 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|268|||Both|20 Years|65 Years|No|||November 2012|November 5, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629875||83562|
NCT01629303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/23|Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation|Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation|CONSTIMOD|University Hospital, Bordeaux|Yes|Completed|June 2012|January 2015|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01629303||83606|
NCT01598285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEICAM/2011-07|A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer|A Combined Genome-Wide Association Study (GWAS) and microRNA (miRNA) Profiling Approach for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer||Spanish Breast Cancer Research Group|No|Active, not recruiting|May 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|Whole blood|Female|18 Years|N/A|No|Probability Sample|Patients suffering from metastatic (disseminated at the time of diagnosis) breast cancer,        treated with bevacizumab.|June 2013|June 7, 2013|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01598285||85985|
NCT01597999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15262|Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer|Accuracy of Magnetic Resonance Imaging (MRI) in Predicting Aggressiveness of Early Breast Cancer According to Molecular Subtypes Identified by ER PR and HER-2 Status||Mahidol University|No|Recruiting|February 2011|December 2013|Anticipated|July 2012|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2013|January 21, 2013|May 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01597999||86007|
NCT01598246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-02-051E|Study to Evaluate Causes of Failure to Extubate|Prospective Observational Study on Factors Influencing Re-Intubation Following a Planned Extubation (RIPE) in a Pediatric Intensive Care Unit: Identifying Targets for a Quality Improvement Initiative|RIPE|Montefiore Medical Center|No|Recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|500|||Both|N/A|18 Years|No|Non-Probability Sample|Children aged 0 to 18 years, admitted in pediatric intensive care unit and required        intubation and mechanical ventilation.|May 2012|May 14, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598246||85988|
NCT01598259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1613|Randomized Controlled Trial to Assess Efficacy of Melatonin for Children During Burn Rehabilitation|Randomized Controlled Trial to Assess Efficacy of Melatonin for Children During Burn Rehabilitation|Sleep6|Shriners Hospitals for Children|Yes|Active, not recruiting|May 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|5 Years|22 Years|No|||January 2016|January 17, 2016|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598259||85987|
NCT01598740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTST-25|Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease|A Phase 1, Open-label, Randomized, Crossover Study to Assess the Safety, Tolerability, and Efficacy of CLP With and Without Spironolactone in Adults With Heart Failure||Sorbent Therapeutics|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||July 2013|July 12, 2013|May 11, 2012|Yes|Yes||No|March 22, 2013|https://clinicaltrials.gov/show/NCT01598740||85950|
NCT01599013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L00070 IN 213 P1|JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin|Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium|JASINT1|Pierre Fabre Medicament|Yes|Completed|February 2011|April 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|79 Years|No|||December 2015|December 7, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01599013||85929|
NCT01599026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dhvf 7531|Cardiac Septal Hypertrophy in the Fetus of Diabetic Mother and Its Effect on Postnatal Cardiac Function|Cardiac Septal Hypertrophy in the Fetus of Diabetic Mother and Its Effect on Postnatal Cardiac Function||Ain Shams Maternity Hospital||Enrolling by invitation|April 2012|March 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|120|||Female|20 Years|45 Years|No|Probability Sample|diabetic pregnant ladies gestational age more than 35 weeks|May 2012|May 14, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599026||85928|
NCT01599520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16956|Stress Management Training for Latinas Receiving Chemotherapy|Stress Management Training for Latinas Receiving Chemotherapy||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|April 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|375|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01599520||85890|
NCT01599481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLAM-ICM-1011|Career Management to Improve Education, Employment and Retention for People With Anxiety and Depression|Effectiveness and Cost Effectiveness of Individual Career Management for People With Anxiety and Depression: A Randomised Controlled Trial|CAREER|South London and Maudsley NHS Foundation Trust|No|Completed|October 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Health Services Research|2||Actual|261|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 19, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599481||85893|
NCT01599494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07056|An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)|A Multi-center, Open-label, Randomized Trial in India to Investigate the Efficacy and Safety of a Single Injection of MK-8962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as a Reference (Phase III, Protocol No. MK-8962-029-00 [Also Known as SCH900962, P07056])||Merck Sharp & Dohme Corp.|No|Withdrawn|March 2014|June 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|42 Years|No|||October 2015|October 30, 2015|May 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01599494||85892|
NCT01599507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-047|Study of FG-4592 in Subjects With Chronic Kidney Disease in China|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia||FibroGen|No|Completed|December 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|75 Years|No|||February 2014|February 27, 2014|May 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01599507||85891|
NCT01600404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011‐25|Effects of Antimuscarinics on Cognition in Spinal Cord Injury|Effects of Antimuscarinic Drugs on the Cognition of Patients With Acute Spinal Cord Injury||Swiss Paraplegic Centre Nottwil|No|Completed|December 2011|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|32|||Both|18 Years|65 Years|No|Non-Probability Sample|patients with acute (4-8 week post-injury) traumatic spinal cord injury during first        rehabilitation|November 2015|November 16, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01600404||85822|
NCT01597024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Full4Health|Full4Health: Understanding Food-gut-brain Axis Across the Lifecourse|Full4Health: Neuro-gut Interactions in Humans Across the Lifecourse|F4H|University of Aberdeen|No|Recruiting|May 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|348|||Both|8 Years|75 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01597024||86082|
NCT01597258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081031|Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Xalkori For NSCLC (Regulatory Post Marketing Commitment Plan)||Pfizer|No|Active, not recruiting|May 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Probability Sample|The patients whom an investigator involving A8081031 prescribes the Crizotinib (XALKORI).|February 2016|February 3, 2016|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597258||86064|
NCT01597271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-040|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2012|||||N/A|N/A|N/A||||||||||||||June 22, 2012|May 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597271||86063|
NCT01597284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COG-OBS|Oral Therapies in Oncology: Cognitive Function and Compliance|Oral Therapies in Oncology: Cognitive Function and Compliance||Centre Francois Baclesse|No|Terminated|February 2012|December 2016|Anticipated|March 2016|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|129|||Both|18 Years|N/A|No|Probability Sample|Patient treated for cancer by a first prescription of exclusive oral therapy (chemotherapy        and / or targeted therapy)|March 2016|March 14, 2016|May 10, 2012||No|Loss of recruitment|No||https://clinicaltrials.gov/show/NCT01597284||86062|
NCT01627821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G100124|Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study|Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study||Jarvik Heart, Inc.|Yes|Recruiting|February 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|75 Years|No|||February 2016|February 22, 2016|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627821||83720|
NCT01628133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|`20969|Packed Red Blood Cell Transfusion and Intestinal Blood Flow in Preterm Neonates|Packed Red Blood Cell Transfusion and Intestinal Blood Flow in Preterm Infants||St. Louis University|Yes|Completed|December 2011|January 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|25|||Both|N/A|3 Months|No|Non-Probability Sample|Preterm neonates (≤1500 grams of birth weight) of singleton and multiple births who are        admitted to the NICU at Cardinal Glennon Children's Hospital and who are tolerating ≥ 20        ml/kg/day of feeding volume run over 30 minutes or less; both males and females of all        ethnic groups.        Very Low Birth Weight (VLBW) neonates will be studied since morbidities such as        transfusion related acute gastrointestinal injury and/or necrotizing enterocolitis, PDA        and feeding intolerance most frequently occur in this group.        Because the need to ensure parental comprehension prior to consent documentation, parents        who, in the judgement of the attending physician and/or research team members, do not have        an adequate command of the English language will not be invited to participate in the        study.|June 2014|June 18, 2014|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01628133||83696|
NCT01628445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1126-3937|Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin|Phase 3 Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin|SAIL|University of Manitoba|No|Terminated|August 2012|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|June 21, 2012||No|Error made by local pharmacy caused mixed randomization of 20 participants|No||https://clinicaltrials.gov/show/NCT01628445||83672|
NCT01628432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN11/LO/SALPINGOVA|Effect of Salpingectomy During Conservative Hysterectomy|Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial|SALPINGOVA|University Hospital, Tours|No|Recruiting|July 2012|October 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|350|||Female|18 Years|52 Years|No|||January 2016|January 5, 2016|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01628432||83673|
NCT01629563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL11-006|PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata|A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids|PEARLIV|PregLem SA|Yes|Completed|June 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|451|||Female|18 Years|50 Years|No|||December 2015|December 7, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01629563||83586|
NCT01629576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010902|Obesity and Financial Incentives|Finanzielle Anreize Zur Reduktion Von Übergewicht|Obesity|Rhine-Westphalia Institute for Economic Research||Active, not recruiting|March 2010|October 2014|Anticipated|October 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|700|||Both|18 Years|75 Years|No|||June 2012|June 25, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01629576||83585|
NCT01629888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU336|A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink|A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink||Danone Research||Completed|February 2010|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|48|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629888||83561|
NCT01630122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 97112|Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates|Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|90|||Both|18 Years|N/A|No|Non-Probability Sample|primary care clinic|July 2015|July 27, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01630122||83543|
NCT01598038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEVERENAL|Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma|Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma||Centre Francois Baclesse|Yes|Terminated|April 2012|December 2015|Anticipated|March 2015|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01598038||86004|
NCT01598298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S1202|S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy|A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer||Southwest Oncology Group|Yes|Active, not recruiting|May 2013|September 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|294|||Female|N/A|120 Years|No|||October 2015|October 15, 2015|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598298||85984|
NCT01598532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-001552|Effects of LEDs on Memory in TBI Patients|Treatment of Cognitive Dysfunction in Mild TBI With Transcranial Light Emitting Diodes- An Open Protocol, Pilot Study|LED|Spaulding Rehabilitation Hospital|No|Completed|September 2009|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|65 Years|No|||July 2015|July 23, 2015|May 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598532||85966|
NCT01598545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00058097|Hydromorphone and C-section|Determination of the ED50 of Intrathecal Hydromorphone for Post-cesarean Section Pain Relief||Emory University|Yes|Completed|February 2013|September 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 9, 2014|May 10, 2012|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01598545||85965|
NCT01598753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42444-D|Combined Behavioral and Analgesic Trial for Fibromyalgia|Phase 3 Double Blind Randomized Study Comparing Drug Treatment (Tramadol Versus Placebo) and Behavioral Health Treatments (Cognitive Behavior Therapy Versus Health Education)for Patients With Fibromyalgia|COMBAT-FM|University of Washington|Yes|Recruiting|May 2012|||June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|250|||Both|21 Years|70 Years|No|||December 2015|December 1, 2015|May 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598753||85949|
NCT01598766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05069|General Investigative MRI Protocol|General Investigational Protocol for EXCELART VANTAGE ZGV/XGV/AGV/ ATLAS/XGV/ZGV TITAN/XGV VANTAGE TITAN 3T||Toshiba America Medical Systems, Inc.||Recruiting|May 2012|May 2020|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|May 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598766||85948|
NCT01599039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NS3NL|Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema|Prospective Controlled Study Comparing the Effectiveness and Specificity of Inverse Water Volumetry Versus Bio-impedance Spectroscopy in the Assessment of Early Recognition of Breast Cancer Related Lymphoedema.||Nij Smellinghe Hosptial|No|Active, not recruiting|May 2012|January 2016|Anticipated|January 2014|Actual|N/A|Observational|Time Perspective: Prospective||3|Anticipated|75|||Both|18 Years|N/A|No|Non-Probability Sample|There study population consists of breast cancer patients treated with either sentinel        node biopsy either axillary dissection. As a control group we use colorectal cancer        patients|November 2015|November 1, 2015|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01599039||85927|
NCT01599533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00042-41|Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm|Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm : Prevalence, Description of the Different Thoracic Aortic Phenotypes by Aortic Volumetric Numerized Imaging and Their Relationship With Epidemiologic, Clinical, Biological and Genetic Factors||Assistance Publique Hopitaux De Marseille|No|Recruiting|June 2012|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01599533||85889|
NCT01596491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Capsaicin2011|Study of Possible Changes in QST After Application of Capsaicin on Patients With Peripheral Neuropathic Pain|Kind and Duration of Possible Changes of the Sensory Profiles After the Topical Application of Capsaicin (8%) in Patients With Peripheral Neuropathic Pain||Ruhr University of Bochum|No|Completed|April 2011|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|proved peripheral neuropathy (e.g. peripheral nerve lesion, postherpetic neuralgia)|December 2012|December 19, 2012|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01596491||86123|
NCT01599767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-p-002353|Spaulding-Harvard Model System: Effects of Transcranial Direct Current Stimulation (tDCS) on Chronic Pain in Spinal Cord Injury|Spaulding-Harvard Spinal Cord Injury (SH-SCI) Study: Effects of tDCS on Chronic Pain in Spinal Cord Injury.||Spaulding Rehabilitation Hospital|No|Recruiting|December 2011|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||July 2015|July 24, 2015|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01599767||85871|
NCT01596790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8748|COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer|Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment||University Hospital, Montpellier|No|Recruiting|April 2012|April 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|168|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01596790||86100|
NCT01597037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DC011754|Aphasia Rehabilitation: Modulating Cues, Feedback & Practice|Aphasia Rehabilitation: Modulating Cues, Feedback & Practice||Rehabilitation Institute of Chicago|No|Recruiting|June 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|16|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597037||86081|
NCT01627509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-7894-JI-CTIL|Comparison of Two Insulin Regimens in Optimally-controlled Patients With DM2.|Comparison of Modern Premixed Insulin and Basal-Bolus Regimens on Blood Glucose Control Using CGMS Device in Optimally-controlled Subjects With DM2.||Sheba Medical Center|No|Recruiting|May 2012|August 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|80 Years|No|Probability Sample|40 Subjects with 1 year and more of T2DM history , with two consistent HbA1C values of 7%        or less - according to the blood tests within last six months.|June 2012|June 21, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627509||83744|
NCT01627522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-01-01-2395|Evaluation of Finastride Effect in Different Dosage on the Amount of Perioperative Bleeding in Transurthral Resection of Prostate||TURP|Shiraz University of Medical Sciences|Yes|Active, not recruiting|January 2012|June 2013|Anticipated|March 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|60|||Male|50 Years|N/A|No|||June 2012|June 23, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627522||83743|
NCT01628146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1162|Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism|PHASE IV STUDY # 1162. Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism||Technolas Perfect Vision GmbH|No|Active, not recruiting|September 2012|October 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01628146||83695|
NCT01628159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL0002-09|LEVANT 2 Continued Access Registry|A Prospective, Multicenter, LEVANT 2 Continuation Registry of the Moxy™ Drug Coated Balloon for Treatment of Femoropopliteal Arteries||C. R. Bard|Yes|Active, not recruiting|June 2012|September 2018|Anticipated|September 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|675|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628159||83694|
NCT01628770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7865|Use of Iron Isomaltoside 1000 (Monofer) in Postpartum Anemia|Iron Isomaltoside 1000 (Monofer)||Dow University of Health Sciences|Yes|Recruiting|May 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Female|18 Years|45 Years|No|||June 2012|June 26, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01628770||83647|
NCT01629043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPF-QII|National Parkinson Foundation Quality Improvement Initiative|National Parkinson Foundation Quality Improvement Initiative|NPF-QII|National Parkinson Foundation|No|Recruiting|July 2009|||||N/A|Observational|Time Perspective: Prospective||1|Anticipated|10000|||Both|N/A|N/A|No|Probability Sample|Any person who receives medical care for the diagnosis of idiopathic Parkinson's disease        at any of the participating Centers is eligible to participate in the Registry. There are        no limitations for participation based on age, disease severity or presence of cognitive        impairments.|May 2013|September 3, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629043||83626|
NCT01629914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037192|Executive Functioning and Mindfulness in Adults With Attention Deficit/Hyperactivity Disorder Imaging|Executive Functioning and Mindfulness in Adults With ADHD Imaging|EFMImaging|Duke University|No|Withdrawn|June 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 28, 2013|June 26, 2012||No|study close-out|No||https://clinicaltrials.gov/show/NCT01629914||83559|
NCT01630148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMU|Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries|Bemiparin as a Thromboprophylaxis After Benign Gynaecological Surgeries:A Randomized Clinical Trial||Hawler Medical University|Yes|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|774|||Female|15 Years|90 Years|No|||October 2014|October 3, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630148||83541|
NCT01596972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000576|The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location|The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location: A Pilot Randomized Controlled Trial||Planned Parenthood League of Massachusetts|No|Completed|June 2012|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|51|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 27, 2014|May 8, 2012||No||No|May 15, 2014|https://clinicaltrials.gov/show/NCT01596972||86086|
NCT01598311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4261-006|A Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea|A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea||Cubist Pharmaceuticals LLC|No|Completed|May 2012|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|608|||Both|18 Years|90 Years|No|||September 2015|September 2, 2015|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598311||85983|
NCT01598558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYMIMG0002|Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT|Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT||Stanford University|Yes|Withdrawn|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|February 10, 2012|No|Yes|Accrual issues - Low Accrual|No||https://clinicaltrials.gov/show/NCT01598558||85964|
NCT01598584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJ20111123|Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer|A Phase II/III Prospective Randomized Placebo-control Trail Compare Mirtazapine Plus Gemcitabine With Gemcitabine in Metastasis Pancreatic Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Withdrawn|June 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|0|||Both|N/A|N/A|No|||December 2012|September 24, 2015|May 5, 2012||No|Gemcitabine is not the first choice for most pancreatic cancer patients nowdays|No||https://clinicaltrials.gov/show/NCT01598584||85962|
NCT01599052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.02.20-2010/0042|Social Cognition in Children Treated for a Brain Tumour|Social Cognition in Children Treated for a Brain Tumour: A Prospective Longitudinal Multi-Centre Study||University Medical Center Groningen|No|Active, not recruiting|March 2011|September 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|113|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Brain tumour (BT) patients will be recruited at paediatric oncology centres in Groningen        (UMCG), Nijmegen (UMC St.Radboud) and Leuven (UZL).        Cystic Fibrosis (CF) patients will be recruited at the department of paediatric lung        diseases in Groningen (UMCG) and Nijmegen (UMC St. Radboud).|March 2015|March 19, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01599052||85926|
NCT01596985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P.S.PJ.6.10.GYN|Ovarian Endometrioma Ablation Using Plasma Energy Versus Cystectomy|Prospective, Monocentric Study Comparing Cystectomy to PlasmaJet Ablation in the Surgical Management of Ovarian Endometriomas||Plasma Surgical Inc|No|Recruiting|November 2010|May 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Female|18 Years|45 Years|No|||May 2012|May 11, 2012|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01596985||86085|
NCT01598077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLJM716X2101|A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer|A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer||Novartis|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Both|18 Years|N/A|No|||April 2014|April 21, 2014|May 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01598077||86001|
NCT01597206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDA Clinical Trial|Interventions for Patients With a Shortened Dental Arch|Outcomes of Interventions for Patients With a Reduced Posterior Dental Arch: A Randomized Controlled Trial|SDA-RCT|University of the Western Cape|Yes|Recruiting|January 2014|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|55 Years|No|||January 2016|January 19, 2016|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597206||86068|
NCT01596803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8426|Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD)|Effects of Antioxidants Supplementation on Muscular Function of Patients Affected by Facioscapulohumeral Dystrophy (FSHD)|FSHD|University Hospital, Montpellier|Yes|Recruiting|June 2010|December 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|54|||Both|18 Years|60 Years|No|||May 2012|May 9, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01596803||86099|
NCT01627236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zssywzb01|Efficacy of Short-term Immunosuppressive Therapy and Anti-allergenic Therapy in Severe Acute Exacerbation of Chronic Hepatitis B|||Third Affiliated Hospital, Sun Yat-Sen University|No|Recruiting|December 2012|November 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|60 Years|No|||August 2013|October 9, 2013|June 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627236||83765|
NCT01627249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRCR.net Protocol T|Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema|A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema|Protocol T|Diabetic Retinopathy Clinical Research Network|Yes|Completed|August 2012|October 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|660|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|June 21, 2012|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01627249||83764|
NCT01627834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|034-09|Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited, India With REQUIP@ XL (Ropinirole) 2 mg ER Tablets of Glaxosmithkline, USA, in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.||Dr. Reddy's Laboratories Limited|No|Completed|October 2009|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|September 27, 2012|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627834||83719|
NCT01627847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|035-09|Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited, India With REQUIP@ XL (Ropinirole Hydrochloride Extended Release) 2 mg Tablets of Glaxosmithkline, USA, in Normal, Healthy, Adult, Human Subjects Under Fed Condition.||Dr. Reddy's Laboratories Limited|No|Completed|October 2009|November 2009|Actual|October 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2010|September 27, 2012|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627847||83718|
NCT01628783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002476-14|Sequence Towards Remission in Depression|Sequence Towards Remission in Depression|STRIDE|Helsinki University|No|Recruiting|June 2012|October 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|60 Years|No|||June 2012|June 26, 2012|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01628783||83646|
NCT01628796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-2012.CTIL|Ultrasound Examination and Guided Injection Into the Acromio-clavicular Joint|Ultrasound Measurement of the Acromio-clavicular Joint and Injection of Standard Contrast Material Into the Joint Under Ultrasonic Control||The Baruch Padeh Medical Center, Poriya|Yes|Not yet recruiting|July 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 26, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01628796||83645|
NCT01629056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|77431/244334/1/228|The Contact PVI Study: Use of Tissue Contact Data to Guide Atrial Fibrillation Ablation|The Contact-PVI Study - Does Assessment of Tissue Contact During RF Ablation Using the St. Jude Medical™ Ensite™ Contact™ System Increase Rates of Long-term Pulmonary Vein Isolation? A Prospective Randomised Study||Oxford University Hospitals NHS Trust|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|156|||Both|18 Years|N/A|No|||June 2012|June 26, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629056||83625|
NCT01629329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4258|Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine|A Randomized, Double-blind Comparison of Single Dose Prochlorperazine Versus Acetaminophen, Aspirin and Caffeine for the Treatment of Acute Migraine in the Emergency Department.|Migraine|Albert Einstein Healthcare Network|No|Terminated|November 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|65 Years|No|||June 2014|June 24, 2014|June 25, 2012||No|no difference found between two groups in a preliminary analysis|No||https://clinicaltrials.gov/show/NCT01629329||83604|
NCT01629316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CID 1007 - UNC IRB 10-1183|Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX|CID 1007 - Randomized Controlled Trial of an Augmented Test, Treat, Link & Retain Model for NC and TX Prisoners (imPACT Study)|imPACT|University of North Carolina, Chapel Hill|Yes|Completed|March 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|381|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01629316||83605|
NCT01629589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td551|Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents|Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents||Sanofi|No|Completed|June 2012|June 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|423|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 22, 2012|Yes|Yes||No|August 16, 2013|https://clinicaltrials.gov/show/NCT01629589||83584|
NCT01629927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-012|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)|ECP-012|Edimer Pharmaceuticals|No|Completed|March 2012|June 2012|Actual|April 2012|Actual|N/A|Observational|N/A||2|Actual|30|||Male|1 Year|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study is being conducted among family members attending the 2012 Spanish Association        for those Affected by Ectodermal Dysplasia Annual Reunion, March 30-April 1, 2012, at the        Center for Rare Diseases in Burgos, Spain.|June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629927||83558|
NCT01630135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116364|Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis|Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis||GlaxoSmithKline||Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|261|||Both|6 Years|14 Years|No|||May 2013|May 9, 2013|June 26, 2012|Yes|Yes||No|March 14, 2013|https://clinicaltrials.gov/show/NCT01630135||83542|
NCT01630460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHC03-008CMD|Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD)|Identification of Mutations That Lead to Craniometaphyseal Dysplasia in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms|CMD|University of Connecticut Health Center|No|Recruiting|April 2009|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Saliva, blood, bone tissue|Both|N/A|N/A|No|Non-Probability Sample|Individuals with diagnosed CMD|December 2015|December 2, 2015|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01630460||83517|
NCT01630798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00062875|A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract|A Phase 1B In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract|NTR 1B|University of Michigan|Yes|Completed|July 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|100 Years|No|||October 2015|October 7, 2015|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01630798||83491|
NCT01597492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115470|A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)||GlaxoSmithKline|No|Completed|May 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597492||86046|
NCT01597505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4261-005|Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea|A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea||Cubist Pharmaceuticals LLC|No|Completed|May 2012|March 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|608|||Both|18 Years|90 Years|No|||October 2015|October 27, 2015|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597505||86045|
NCT01597765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si 063/2009|Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients|Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients||Mahidol University|Yes|Completed|June 2009|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 13, 2012|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597765||86025|
NCT01597778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMTCTN1101|Double Cord Versus Haploidentical (BMT CTN 1101)|A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101)||Medical College of Wisconsin|Yes|Recruiting|June 2012|June 2019|Anticipated|June 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|410|||Both|18 Years|70 Years|No|||February 2016|February 5, 2016|May 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597778||86024|
NCT01599299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.2.2012|Comparison of the Right and Left Internal Jugular Vein Using Ultrasound|Comparison of the Diameter, Cross-sectional Area and Position of the Left and Right Internal Jugular Vein in Adults Using Ultrasound||Catharina Ziekenhuis Eindhoven|Yes|Completed|March 2012|July 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|100|||Both|18 Years|N/A|No|Probability Sample|All patients who will need a central venous access (into the right jugular vein)        preoperative are included|March 2014|March 5, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599299||85907|
NCT01605903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-054H|Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy|Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy||Massachusetts Eye and Ear Infirmary|Yes|Recruiting|September 2011|June 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|722|||Both|2 Years|18 Years|No|||October 2015|October 20, 2015|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605903||85399|
NCT01600040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-269|Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix|Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix With Metastases to Regional Lymph Nodes||Massachusetts General Hospital|Yes|Recruiting|May 2013|||May 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600040||85850|
NCT01600053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101955|Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia|A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)||University of California, San Diego|Yes|Terminated|November 2011|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||October 2014|October 1, 2014|May 9, 2012|Yes|Yes|interim analysis showed that the trial will not meet the interim endpoint.|No||https://clinicaltrials.gov/show/NCT01600053||85849|
NCT01600066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERSAN-1|Erectile Dysfunction in Severe Obstructive Sleep Apnea: Effects of CPAP Therapy|Erectile Dysfunction in Severe Obstructive Sleep Apnea : Effects of CPAP Therapy||University of Giessen|Yes|Completed|May 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|Samples Without DNA|blood specimens for the determination of lipids and glucose|Male|18 Years|80 Years|No|Non-Probability Sample|male patients with untreated severe sleep apnea (apnea-hypopnea-index > 30/h)|December 2015|December 2, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01600066||85848|
NCT01598363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1104|An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers|||Reata Pharmaceuticals, Inc.||Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 1, 2012|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598363||85979|
NCT01606475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108M03061|Islet Transplant for Type 1 or Surgical Diabetes|Human Alloislet Transplant for Type 1 or Surgical Diabetes Mellitus With Complications|EXAX|University of Minnesota - Clinical and Translational Science Institute||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|70 Years||||December 2015|December 1, 2015|May 23, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01606475||85355|
NCT01596517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC2003-0059|Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C|Efficacy and Effectiveness of Combination Therapy With Pegylated Interferon Alfa-2a and Ribavirin in Korean Patients With Chronic Hepatitis C||Asan Medical Center|No|Completed|June 2003|May 2012|Actual|December 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|272|||Both|18 Years|70 Years|No|||May 2012|May 12, 2012|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01596517||86121|
NCT01631513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100757|An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)|An Open-label, Multi-center, Single-arm, Phase IV Clinical Trial Assessing Conversion From Hydrocodone, Oxycodone CR or Morphine SR to Tapentadol ER in Subjects With Moderate to Severe Chronic Low Back or OA Pain of the Hip or Knee||Janssen Scientific Affairs, LLC|No|Terminated|August 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|74 Years|No|||March 2013|March 4, 2013|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631513||83436|
NCT01627262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAG-20/DIV|Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study|Double-blind, Randomised, Placebo-controlled, Parallel-group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Pellets vs. Placebo in Diverticular Disease||Dr. Falk Pharma GmbH|No|Completed|May 2002|April 2006|Actual|August 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|123|||Both|45 Years|80 Years|No|||January 2016|January 20, 2016|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627262||83763|
NCT01627535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11320|Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain Tumors|Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain Tumors||City of Hope Medical Center|Yes|Completed|May 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01627535||83742|
NCT01627860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017248|First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients|Topiramate in the Treatment of Epilepsy: 1st Add-on vs. Mono-therapy Study in Neuro-Surgical Patients|TEAMS|Johnson & Johnson Taiwan Ltd|No|Completed|February 2010|January 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|65 Years|No|||September 2013|September 24, 2013|May 31, 2012|Yes|Yes||No|September 6, 2012|https://clinicaltrials.gov/show/NCT01627860||83717|No limitations were reported in this study.
NCT01628484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SkinPrep|Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation|Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure||University of Zurich|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|65 Years|No|||November 2012|November 6, 2012|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01628484||83669|
NCT01628497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fil-01|Exhaled NO Testing in Filariasis|Exhaled NO Testing in Filariasis||Vanderbilt University|No|Recruiting|May 2012|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|180|||Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects:          -  recruited from patients with a chief complaint of wheezing, asthma or cough.          -  assessed by a physician prior to consideration for enrollment into the study          -  screened by the study investigator after evaluation by the physician        Control subjects:        Controls will be matched with cases by gender, age and region of residence. They will have        non-emergent complaints without respiratory symptoms.|June 2012|June 22, 2012|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01628497||83668|
NCT01629069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004988|A Transplant or Cancer Resilience Intervention|A Resilience Intervention Involving Mindfulness Training for Transplant and Cancer Patients and Their Caregivers||Mayo Clinic|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|60|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01629069||83624|
NCT01629082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120146|Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia|Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia||National Institutes of Health Clinical Center (CC)||Completed|June 2012|October 2015|Actual|October 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|99 Years|No|||February 2016|February 25, 2016|June 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01629082||83623|
NCT01629342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-001|Standardized Physical Activities Measured by Accelerometers|||Hillerod Hospital, Denmark|Yes|Recruiting|June 2012|December 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients just prior discharge from Stoke Unit, Neurologic Department, Hillerød Hospital|June 2012|June 27, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629342||83603|
NCT01629901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035775|Caloric Stimulation on Cerebral Blood Flow|The Effect of Vestibular Stimulation on Cerebral Blood Flow||Duke University|No|Completed|June 2012|April 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01629901||83560|
NCT01629602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSChen4112|Treatment of Soft Tissue Loss With Nerve Defect in the Finger Using the Boomerang Nerve Flap|||The Second Hospital of Tangshan|No|Completed|July 2008|June 2011|Actual|May 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|49|||Both|16 Years|50 Years|No|||May 2011|June 26, 2012|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01629602||83583|
NCT01630161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16458|Smoking Relapse-Prevention Intervention for Cancer Patients|Smoking Relapse-Prevention Intervention for Cancer Patients||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|441|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630161||83540|
NCT01630174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|phase 1 pem IMRT|IMRT/Pemetrexed/Cisplatin in Esophageal Cancer|Phase I Study of Concurrent Selective Lymph Node Late Course Accelerated Hyper-fractionated Radiotherapy and Pemetrexed, Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma||Shandong Cancer Hospital and Institute|Yes|Recruiting|October 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|No|Probability Sample|esophagus cancer patients|June 2012|June 27, 2012|June 27, 2012||||No||https://clinicaltrials.gov/show/NCT01630174||83539|
NCT01630187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARB-011|Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony, During Elective Cesarean Section|Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony During Elective Cesarean Section: a Randomized Controlled Trial||Laval University|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Female|18 Years|N/A|No|||May 2013|May 27, 2013|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01630187||83538|
NCT01630850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0684|Islet Transplantation in Patients With "Brittle" Type I Diabetes|Islet Transplantation in Patients With "Brittle" Type I Diabetes||University of Chicago|No|Recruiting|May 2012|June 2019|Anticipated|May 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|70 Years|No|||October 2015|October 13, 2015|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630850||83487|
NCT01598064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK#10|Probiotics for Liver Cirrhosis With Portal Hypertension|Clinical Trial of Probiotics in Preventing Complication Related to Portal Hypertension in Cirrhotic Patients||National Cheng-Kung University Hospital|No|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Both|20 Years|N/A|No|||July 2014|September 9, 2014|May 8, 2012||No||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01598064||86002|
NCT01598337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSCC002CT|The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency|The Effect Of Antiplatelets Therapy, Tirafiban, Prasugrel, And Aspirin On Saphenous Vein Coronary Artery Bypass Graft Patency||Prince Sultan Cardiac Center, Adult Cardiology Department.|Yes|Recruiting|April 2011|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||May 2012|May 14, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01598337||85981|
NCT01598350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0910-003|Gait in Children With Down Syndrome While Wearing Orthoses|Using Anthropometric Measurements to Predict Orthotic Influence on Gait Parameters in Children With Down Syndrome||University of Puget Sound|No|Completed|January 2010|June 2011|Actual|June 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|10 Years|No|||November 2013|November 12, 2013|January 20, 2010||No||No|November 12, 2013|https://clinicaltrials.gov/show/NCT01598350||85980|small number of subject recruited.
NCT01605344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1127|Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI|A Prospective, Randomized, Crossover Evaluation of the Effect of Atorvastatin on the Pharmacokinetics of Irinotecan in Colorectal Cancer Patients Receiving FOLFIRI||UNC Lineberger Comprehensive Cancer Center|Yes|Withdrawn|April 2012|July 2014|Anticipated|July 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 26, 2014|May 22, 2012|No|Yes|Study was withdrawn due to lack of patient enrollment.|No||https://clinicaltrials.gov/show/NCT01605344||85442|
NCT01605617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004589|Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate|Prospective Randomized Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate||Mayo Clinic|No|Terminated|June 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|4|||Female|18 Years|N/A|No|||December 2013|December 16, 2013|May 3, 2012|Yes|Yes|Low recruitment rate, and study patients were removed prior to completion|No|September 24, 2013|https://clinicaltrials.gov/show/NCT01605617||85421|The study was terminated due to a low recruitment rate prior to subjects completing treatment.
NCT01605916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00067|Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer|A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)||AstraZeneca||Completed|June 2012|May 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|20 Years|N/A|No|||June 2015|June 3, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01605916||85398|
NCT01596712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031A1101|Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Following Subcutaneous Injections of QGE031 in Japanese Atopic Male Subjects||Novartis||Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|209|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 20, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01596712||86106|
NCT01596725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NVX778.P102|A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2|A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 2.||Novavax|Yes|Completed|May 2012|August 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|333|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01596725||86105|
NCT01606488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110506|Effects of Brain Beta-Amyloid on Postoperative Cognition|Effects of Brain Beta Amyloid on Postoperative Cognition and 18F-AV-45-A14: Clinical Evaluation of Florbetapir F 18 (18F-AV-45)||University of California, San Francisco|Yes|Recruiting|May 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|100|||Both|65 Years|N/A|No|||December 2015|December 9, 2015|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606488||85354|
NCT01606748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14473|A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin|An Open-Label, Non-controlled, Non-randomized Sequential Design, Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin in Patients With Advanced Solid Cancers||Eli Lilly and Company|No|Active, not recruiting|August 2012|October 2015|Anticipated|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606748||85334|
NCT01596530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0102C00019|Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment|A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status|CHIVE|AstraZeneca||Terminated|June 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|3|||Female|18 Years|N/A|No|||December 2012|December 13, 2012|April 27, 2012||No|All AstraZeneca sponsored clinical trials of AZD8931 have been halted|No||https://clinicaltrials.gov/show/NCT01596530||86120|
NCT01631214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110142|Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis|A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis||Amgen|Yes|Active, not recruiting|May 2012|February 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4094|||Female|55 Years|90 Years|No|||February 2016|February 19, 2016|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631214||83459|
NCT01631526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC12-053|Vitamin D Loading Dose in Advanced Lung Cancer|Open Clinical Trial to Validate a Short-term Vitamin D Loading and Maintenance Dose Protocol in People With Advanced Lung Cancer||Jewish General Hospital|No|Completed|June 2012|February 2016|Actual|November 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631526||83435|
NCT01631539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018384-42|Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC|Chemoembolisation With Irinotecan Loaded DC Bead (DEBIRI) in Combination With Cetuximab and 5FU/LV in the First Line Treatment of Patients With KRAS Wildtype Metastatic Colorectal Cancer (mCRC)||Universitaire Ziekenhuizen Leuven|No|Withdrawn|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|September 14, 2011||No|No patients enrolled|No||https://clinicaltrials.gov/show/NCT01631539||83434|
NCT01627548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003109|UCLA Couples Counseling for Combat Veterans|UCLA Welcome Back Veterans Family Resilience Center Couples Counseling for Combat Veterans|CCCV|University of California, Los Angeles|No|Recruiting|January 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627548||83741|
NCT01627561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115887|Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine in Healthy Female Children|Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old||GlaxoSmithKline||Active, not recruiting|October 2012|November 2016|Anticipated|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|149|||Female|4 Years|25 Years|Accepts Healthy Volunteers|||January 2016|February 4, 2016|June 14, 2012|Yes|Yes||No|April 23, 2015|https://clinicaltrials.gov/show/NCT01627561||83740|
NCT01628458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-018|Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer|Phase II Study: Radiofrequency Ablation of Locally Advanced Pancreatic Cancer|RFA of LAPC|UMC Utrecht|Yes|Completed|September 2012|November 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|No|||January 2015|January 29, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01628458||83671|
NCT01628471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMAN-10-01|MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer|A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects||Uman Pharma|Yes|Completed|November 2012|September 2015|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|75 Years|No|||September 2015|September 21, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01628471||83670|
NCT01629095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120147|Genetic Studies of Non-Alcoholic Fatty Liver Disease|Genetic Studies of Non-Alcoholic Fatty Liver Disease||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|1000|||Both|N/A|99 Years|No|||December 2015|January 7, 2016|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01629095||83622|
NCT01629641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17008|Reliability and Validity of Goniometric iPhone Applications|Reliability and Validity of Goniometric iPhone Applications for the Assessment of Active Shoulder External Rotation||Texas Woman's University|No|Completed|January 2012|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|94|||Both|20 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Texas Woman's University students from the School of Physical Therapy - Houston campus        will be recruited to participate in this study.|June 2012|June 26, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01629641||83580|
NCT01629615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120ZES02T/SOLTI-1103|A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer|A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer||SOLTI Breast Cancer Research Group|Yes|Active, not recruiting|June 2012|June 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||July 2015|July 15, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01629615||83582|
NCT01629628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-10-ES-0446-TLV-CTIL|Adalimumab for the Management of Post-operative Crohn's Disease (CD)|An Investigator Initiated Prospective, Single Center, Randomized, Open Label Study to Assess the Efficacy of Adalimumab for the Maintenance of Remission in Post-operative CD Patients|POPART|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|70 Years|No|||June 2012|June 25, 2012|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629628||83581|
NCT01630863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YUH-12-007-D4|The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy|The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy||Yeungnam University College of Medicine||Recruiting|June 2012|March 2015|Anticipated|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|45|||Both|20 Years|70 Years|No|||February 2015|February 13, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630863||83486|
NCT01609335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006972|Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults|Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults (30-49yo)||Mayo Clinic|Yes|Completed|July 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|41|||Both|30 Years|49 Years|Accepts Healthy Volunteers|||August 2014|August 7, 2014|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01609335||85136|
NCT01598792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN47069182|Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer|REALISTIC: A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Genotype 16 Target Antigens (ADXS11-001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma|REALISTIC:|University of Liverpool|Yes|Recruiting|February 2012|October 2014|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598792||85946|
NCT01605630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004328|Family Cancer Literacy to Promote Mammography Screening Among Navajo Women|Family Cancer Literacy to Promote Mammography Screening Among Navajo Women||Mayo Clinic|No|Active, not recruiting|March 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01605630||85420|
NCT01606241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1015|Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer||Mayo Clinic|Yes|Active, not recruiting|July 2012|||June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Female|18 Years|N/A|No|||June 2015|January 7, 2016|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606241||85373|
NCT01606202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWSC0101|A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury|A Randomised, Double Blind, Placebo Controlled, Parallel Group Comparative Study of the Efficacy, Safety and Tolerability of Sublingual Cannabis Based Medicine Extracts and Placebo in Patients With Intractable Neuropathic Pain Associated With Spinal Cord Injury||GW Pharmaceuticals Ltd.|No|Completed|July 2002|January 2005|Actual|January 2005|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|May 21, 2012||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT01606202||85376|
NCT01606215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1959|Stem Cells in Rapidly Evolving Active Multiple Sclerosis|Stem Cells in Rapidly Evolving Active Multiple Sclerosis|STREAMS|Imperial College London|No|Active, not recruiting|January 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|50 Years|No|||July 2015|August 4, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01606215||85375|
NCT01606501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-09-2-0108-OUT|Outcomes Following Severe Distal Tibia, Ankle and/or Foot Trauma: Comparison of Limb Salvage Versus Transtibial Amputation Protocol|Outcomes Following Severe Distal Tibia, Ankle and/or Foot Trauma: Comparison of Limb Salvage Versus Transtibial Amputation Protocol (OUTLET Study)|OUTLET|Major Extremity Trauma Research Consortium|Yes|Recruiting|May 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|464|||Both|18 Years|60 Years|No|Probability Sample|The study population will be patients aged 18-60 with severe open or crushed distal tibia,        ankle and/or foot injury that go on to limb salvage or receive a below the knee        amputation.|December 2015|December 1, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01606501||85353|
NCT01631227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-385|Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension|A Prospective, Randomized Double-blind Parallel Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects With Mild to Moderate Essential Hypertension||Abbott|No|Completed|June 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|665|||Both|18 Years|N/A|No|||July 2014|July 18, 2014|June 27, 2012||No||No|April 28, 2014|https://clinicaltrials.gov/show/NCT01631227||83458|
NCT01631253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPA001|The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation|The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation||CHA University|No|Recruiting|October 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Female|21 Years|45 Years|No|||June 2012|June 30, 2012|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631253||83456|
NCT01627275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003975|Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant|Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation||Duke University|Yes|Recruiting|June 2012|June 2018|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|June 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01627275||83762|
NCT01627873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A/575/2009|Effect of Remifentanil on Postoperative Cognition Function in Patients Undergoing Major Abdominal Surgery|Effect of Remifentanil on Postoperative Cognitive Function in Patients Undergoing Major Abdominal Surgery||Catholic University of the Sacred Heart|Yes|Completed|August 2009|December 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|2||Actual|622|||Both|60 Years|90 Years|No|||June 2012|June 22, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627873||83716|
NCT01628809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS-2011|Mindfulness-Based Meditation to Treat Stress in Unemployed Community Adults|Stress Reduction and Healthy Living in Pittsburgh||Carnegie Mellon University|No|Completed|January 2011|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|35|||Both|24 Years|52 Years|No|||July 2015|July 27, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01628809||83644|
NCT01628822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOL11-Dr SERRA|Efficacy Study of Relaxation to 12 Weeks Against Placebo in the Overall Care Chronic Pain in Patients With Fibromyalgia|Pilot Study, Prospective, Single Center,Randomized, Single Blind, Evaluating the Efficacy of Relaxation to 12 Weeks Against Placebo, in the Overall Care Chronic Pain in Patients With Fibromyalgia|Sophrodol-1|Centre Hospitalier Universitaire, Amiens|No|Completed|January 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01628822||83643|
NCT01629368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28256|A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers|A Single-Center, Open-Label, One-Sequence, Crossover Study to Investigate the Effects of Multiple Doses of Carbamazepine on the Pharmacokinetics of a Single Dose RO4917523 in Healthy Subjects||Hoffmann-La Roche||Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629368||83601|
NCT01629953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D7635-R|Assessing Supported Employment With Veterans With Felony Convictions and Mental Illness or Substance Abuse|Assessing Supported Employment With Veterans With Felony Convictions and MI or SA||North Texas Veterans Healthcare System|No|Active, not recruiting|October 2011|November 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|196|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629953||83556|
NCT01630200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELASTIC2011|Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)|Effects of ROFLUMILAST on Markers of Subclinical Atherosclerosis In Stable COPD; the ELASTIC-trial|ELASTIC|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|Yes|Active, not recruiting|May 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|80 Years|No|||September 2015|September 21, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01630200||83537|
NCT01629940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECP-013|Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status|Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status|ECP-013|Edimer Pharmaceuticals|No|Completed|June 2012|October 2012|Actual|July 2012|Actual|N/A|Observational|N/A||2|Actual|36|Samples With DNA|Whole blood|Male|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study is being conducted among family members attending the 2012 National Foundation        for Ectodermal Dysplasia (NFED) Family Conference, July 19-21, 2012, in Orlando, FL.|December 2012|December 17, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629940||83557|
NCT01630213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-001217|Impact of Vitamin D Supplementation on Cardiac Structure and Function|Vitamin D and Omega-3 Trial: Ancillary Study (VITAL-Echo) on the Impact of Vitamin D Supplementation on Cardiac Structure and Function|VITAL-Echo|Massachusetts General Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 11, 2016|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01630213||83536|
NCT01605071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0788|Timing Estrogen After MenoPaUSe|Time Past Menopause, Duration of Estrogen Deficiency, and Insulin Action|TEMPUS|University of Colorado, Denver|Yes|Active, not recruiting|September 2011|August 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Anticipated|60|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605071||85463|
NCT01605084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-493|Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone|An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone|SUPPRESS|Bristol-Myers Squibb|No|Withdrawn|June 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2012|December 3, 2012|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605084||85462|
NCT01605058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRI 1.1|Visual Performance With a Trifocal Intraocular Lens|Visual Performance Adn Quality of Vision Evaluation After Implantation of a Trifocal Intraocular Lens||BMI Southend Hospital|Yes|Not yet recruiting|June 2012|August 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|30|||Both|40 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients from a private ophthalmology clinic|May 2012|May 25, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605058||85464|
NCT01605331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-SHCL007|Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)|||LG Life Sciences||Completed|December 2009|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|132|||Both|20 Years|N/A|No|||October 2012|October 3, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605331||85443|
NCT01605929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000874|Clinical Evaluation of the Ultrasound-Guided Retroclavicular Brachial Plexus Block|Clinical Evaluation of the Ultrasound-Guided Retroclavicular Brachial Plexus Block||Brigham and Women's Hospital|No|Withdrawn|July 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|100 Years|No|||December 2015|December 4, 2015|May 16, 2012|Yes|Yes|withdrawn before IRB approval|No||https://clinicaltrials.gov/show/NCT01605929||85397|
NCT01605942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|206207-027|A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery|||Allergan|No|Terminated|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|May 23, 2012|Yes|Yes|Study terminated due to corporate decision.|No|June 11, 2015|https://clinicaltrials.gov/show/NCT01605942||85396|
NCT01606254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013612|A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia|A Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia||Janssen Pharmaceutical K.K.|No|Completed|January 2007|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|56|||Both|20 Years|65 Years|No|||May 2013|May 28, 2013|May 15, 2012|Yes|Yes||No|March 4, 2013|https://clinicaltrials.gov/show/NCT01606254||85372|
NCT01606228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014452|A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia|An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly-Dosed Paliperidone ER Among Treatment-Naïve and Newly Diagnosed Patients With Schizophrenia||Janssen Pharmaceutica|No|Completed|December 2007|December 2008|Actual|December 2008|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|188|||Both|18 Years|65 Years|No|||September 2012|September 19, 2012|May 16, 2012|Yes|Yes||No|August 3, 2012|https://clinicaltrials.gov/show/NCT01606228||85374|
NCT01606800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8908B-059|Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)|Randomized Open Label Study to Assess the Efficacy and Safety of Short Course Therapy (24 Weeks) With Peginterferon Alpha-2b and Ribavirin for Chronic Hepatitis C (Genotype 4) Patients Who Achieve a Rapid Virological Response (HCV -RNA Undetectable at Week 4 of Treatment)|START 4|Merck Sharp & Dohme Corp.|No|Terminated|January 2013|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|May 24, 2012|Yes|Yes|The trial was terminated due to change in new standard of therapy during the study period.|No|January 26, 2016|https://clinicaltrials.gov/show/NCT01606800||85330|This Trial was prematurely terminated due to the availability of more promising treatment for HCV participants and the change in treatment guidelines, which will offer the patient a better treatment opportunity.
NCT01626963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUR-089|Single-port Versus Conventional Laparoscopic Colorectal Surgery|Randomised-controlled Trial on the Immune Response to Single-port Access Versus Conventional Laparoscopic Colorectal Surgery||North Tees and Hartlepool NHS Foundation Trust|Yes|Recruiting|January 2014|December 2016|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01626963||83786|
NCT01627288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033820|Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)|Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)|IDEAL|Duke University|No|Recruiting|June 2012|June 2020|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Female|18 Years|N/A|No|||March 2016|March 9, 2016|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627288||83761|
NCT01627574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD065942|Contraceptive Awareness and Reproductive Education|Contraceptive Awareness and Reproductive Education||University of Rhode Island|Yes|Recruiting|August 2012|October 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Female|13 Years|18 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01627574||83739|
NCT01628523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205165|Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study|Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study||Washington University School of Medicine|No|Completed|July 2012|March 2014|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|259|||Both|N/A|N/A|No|Non-Probability Sample|Patients presenting to the emergency department requiring invasive mechanical ventilation.|March 2014|March 28, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01628523||83666|
NCT01628536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH0524BlackCohosh|A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ|A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ||Yale University|Yes|Active, not recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Female|18 Years|90 Years|No|||February 2016|February 10, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01628536||83665|
NCT01628172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0965|Renal Sympathetic Denervation for the Management of Chronic Hypertension|Renal Sympathetic Denervation for the Management of Chronic Hypertension|RELIEF|Icahn School of Medicine at Mount Sinai|Yes|Completed|January 2011|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|85 Years|No|||September 2015|September 15, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01628172||83693|
NCT01629108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120152|Normal Values in Hearing and Balance Testing|Normative Values in Audiovestibular Testing||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|500|||Both|5 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 15, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01629108||83621|
NCT01629355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2149 (REK)|Auditory Brainstem Response as a Diagnostic Tool in Schizophrenia and Bipolar Disorder|Auditory Brainstem Response as a Diagnostic Tool in Schizophrenia and Bipolar Disorder||University Hospital of North Norway|No|Completed|July 2012|August 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|66|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients recruited from the University Hospital of North Norway and the General Practice        Clinic in Balsfjord, Troms, Norway. Healthy controls from North Norway.|August 2015|August 31, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01629355||83602|
NCT01629654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEA2011|Poststroke Fatigue - Developing and Testing a Program to Reduce and Cope With Fatigue|Poststroke Fatigue - Developing and Testing a Program to Reduce and Cope With Fatigue||University of Aarhus|No|Completed|March 2011|June 2012|Actual|March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|41|||Both|18 Years|N/A|No|||June 2012|June 25, 2012|January 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01629654||83579|
NCT01629667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-RI-CAT-354-1066|A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis|A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis||MedImmune LLC|Yes|Terminated|October 2012|January 2016|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|409|||Both|50 Years|79 Years|No|||February 2016|February 29, 2016|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629667||83578|
NCT01630486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNOW-CKD|KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease : A 10-year Longitudinal Cohort Study of the Chronic Kidney Disease|KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease|KNOW-CKD|Seoul National University Hospital|No|Recruiting|March 2011|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|2550|Samples With DNA|A biobank is also established for the DNA, serum and urine taken at regular interval.|Both|20 Years|75 Years|No|Non-Probability Sample|CKD stage 1 through 5 Ages below 75|May 2015|May 21, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630486||83515|
NCT01630499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MyLIFE2012|My Lifestyle Intervention of Food and Exercise|Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.|MyLIFE|University of Florida|No|Active, not recruiting|October 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Female|21 Years|65 Years|No|||October 2015|October 8, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01630499||83514|
NCT01630525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/22|" The Eyes Have it " : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease||LYLO|University Hospital, Bordeaux|No|Completed|December 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|83|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Group A : 30 Prodromal Alzheimer Disease, Group B : 30 typical Alzheimer Disease, Group C        : 30 controls age-matched ± 5 years to Group A (to Group A) Total of 90 subjects.|January 2016|January 22, 2016|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01630525||83512|
NCT01605383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XCEL-MT-10-01|Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head|A Pilot Clinical Trial of "ex Vivo" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue (XCEL-MT-OSTEO- ALPHA) in Osteonecrosis of the Femoral Head||Banc de Sang i Teixits|No|Recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|50 Years|No|||November 2015|December 10, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605383||85439|
NCT01605357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGH-HH5|Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury|A Randomized, Open Label Clinical Trial of Sustained Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury||Massachusetts General Hospital|Yes|Not yet recruiting|July 2012|August 2013|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||May 2012|May 23, 2012|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605357||85441|
NCT01605370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007035|Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?|Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?|Inapprop|Mayo Clinic|No|Terminated|June 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|1|||Both|30 Years|70 Years|No|||May 2014|May 8, 2014|May 22, 2012|Yes|Yes|Difficulty in identifying subjects satisfying the inclusion criteria.|No|April 4, 2014|https://clinicaltrials.gov/show/NCT01605370||85440|The study was terminated early due to the difficulty in identifying subjects satisfying the inclusion criteria. Only 1 subject was enrolled.
NCT01605955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AndonHealth8|Fingertip Pulse Oximeter Clinical Test|||Andon Health Co., Ltd||Completed|November 2011|December 2011|Actual|||N/A|Observational|Time Perspective: Prospective||2|Actual|10|||Both|25 Years|32 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers who consent to induced hypoxia and arterial blood sampling as part of        the experimental procedure|April 2012|May 23, 2012|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605955||85395|
NCT01597297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218MS205|Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis|MOBILE|Biogen|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|70 Years|No|||July 2014|July 17, 2014|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597297||86061|
NCT01606514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH081056-01A1|Web-based Intervention for Disaster-Affected Youth and Families|Web-based Intervention for Disaster-Affected Youth and Families||Medical University of South Carolina|Yes|Completed|December 2010|June 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|2000|||Both|12 Years|N/A|Accepts Healthy Volunteers|||August 2012|October 3, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01606514||85352|
NCT01597583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00051021|MobileMedMinder: A Networked Aide for Medication Compliances|MobileMedMinder: A Networked Aide for Medication Compliances||University of Maryland|Yes|Completed|November 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|50|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597583||86039|
NCT01597856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-091|Evaluation and Treatment of Substance Abuse in Veterans With PTSD Disability Claims|Evaluation and Treatment of Substance Use in Veterans With PTSD Disability Claims|SBIRT-PTSD|VA Office of Research and Development|Yes|Recruiting|March 2013|December 2017|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|640|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597856||86018|
NCT01627301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00054697|Sympathetic Overactivity in Post-traumatic Stress Disorder|Mechanisms of Sympathetic Overactivity in Post-traumatic Stress Disorder|SO-PTSD|Emory University|No|Recruiting|July 2012|||June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01627301||83760|
NCT01627587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115893|A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole|A Two Cohort, Open-label Study to Evaluate the Pharmacokinetics of GSK2847065, the Metabolite of Retosiban (GSK221149) After Single and Repeat Oral Doses, the Pharmacokinetics of GSK221149 Coadministered With a High Fat Meal, and the Pharmacokinetics of GSK221149 Coadministered With an Inhibitor of CYP3A4 (Ketoconazole)||GlaxoSmithKline|No|Completed|December 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|46|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01627587||83738|
NCT01627899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3091611|One Touch VerioIQ US Clinical Outcomes Study|One Touch VerioIQ US Clinical Outcomes Study||LifeScan|No|Terminated|October 2012|July 2013|Actual|May 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||January 2014|January 29, 2014|June 22, 2012|Yes|Yes|Business decision to terminate trial|No||https://clinicaltrials.gov/show/NCT01627899||83714|
NCT01628185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0691|Pain Assessment in the Intensive Care Unit|Pain Assessment in the Intensive Care Unit||University of Chicago|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|100 Years|No|Probability Sample|Intensive Care Unit patients|December 2015|December 16, 2015|February 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01628185||83692|
NCT01628549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-10411|Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of P005672 in Treatment of Facial Acne Vulgaris|A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of P005672 Compared to Placebo in the Treatment of Facial Acne Vulgaris||Warner Chilcott|No|Completed|June 2012|January 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|285|||Both|12 Years|45 Years|No|||April 2015|April 9, 2015|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628549||83664|
NCT01628835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version1.0|Low Glycemic Index (GI) Diet Management for Pregnant Woman With Overweight|Low Glycemic Index Diet Intervention on Insulin Resistance of Overweight Pregnant Women.||Fudan University|Yes|Recruiting|June 2012|February 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|400|||Female|18 Years|45 Years|No|||December 2014|December 15, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01628835||83642|
NCT01629121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHSF11085|Prevention of Traumatic Brain Injury in Youth and Adolescents|Prevention of Traumatic Brain Injury in Youth and Adolescents||Georgia Regents University|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01629121||83620|
NCT01629134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/MED/FIL/019|Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the Lips|||Allergan|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|62|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers desiring lip augmentation|October 2014|October 3, 2014|June 25, 2012||No||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01629134||83619|
NCT01629394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|952/21-3-12|Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients|Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Weight Loss Surgery.Use of Acceleromyography Monitoring in Adductor Pollicis and Corrugator Supercilii.||University of Patras|Yes|Recruiting|January 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Anticipated|120|||Both|18 Years|60 Years|No|||June 2012|June 25, 2012|April 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01629394||83599|
NCT01629381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024338-43|Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy|Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study)|ERIKA|University of Padua|Yes|Recruiting|May 2012|March 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||July 2013|July 3, 2013|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01629381||83600|
NCT01629992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|preopcounseling|Preoperative Counseling in Cholecystectomy|Preoperative Counseling in Cholecystectomy. A Randomized Trial||Federal University of Mato Grosso do Sul|Yes|Completed|January 2009|December 2011|Actual|November 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|119|||Both|18 Years|65 Years|No|||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01629992||83553|
NCT01630005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00905-34|Talk Therapy After Stroke|Talk Therapy After Stroke. PS-POST AVC|PS-POST AVC|Centre Hospitalier Universitaire de Nice|No|Terminated|February 2011|March 2013|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|85 Years|No|||December 2010|October 30, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01630005||83552|
NCT01629966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLZ-MD-05|Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder|A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.|VLZ-MD-05|Forest Laboratories|No|Completed|June 2012|March 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|680|||Both|18 Years|70 Years|No|||February 2015|February 27, 2015|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629966||83555|
NCT01629979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-018886-52|Epidermal Cell Transplantation in Vitiligo Skin|Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo|VITICELL|Centre Hospitalier Universitaire de Nice|No|Completed|May 2011|November 2012|Actual|November 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|85 Years|No|||May 2013|May 29, 2013|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01629979||83554|
NCT01630915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-044|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Clopidogrel Tablets Under Fed Condition|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Single-Dose Bioequivalence Study of Clopidogrel Tablets USP 75mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Plavix® (Clopidogrel Bisulfate Tablets) 75mg [Reference Formulation, Bristol-Myers Squibb/Sanofi Pharmaceuticals, USA], in Healthy Human Volunteers Under Fed Condition||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|55 Years||||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630915||83482|
NCT01631136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFCT-GFPC-1101|Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer|Phase III Study Evaluating Two Strategies of Maintenance, One With Pemetrexed in Continuous Strategy and One According to the Response of Induction Chemotherapy, in Non Squamous Non Small Cell Lung Cancer of Advanced Stage||Intergroupe Francophone de Cancerologie Thoracique|Yes|Recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|932|||Both|18 Years|70 Years|No|||March 2016|March 9, 2016|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01631136||83465|
NCT01605643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001144|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women: Phase 1|MAW|Mayo Clinic|Yes|Active, not recruiting|March 2012|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples With DNA|urine and serum specimen samples collected from mother and infant pairs|Both|N/A|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women will be recruited through prenatal care|January 2016|January 12, 2016|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01605643||85419|
NCT01605656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0240|A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women|A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women||M.D. Anderson Cancer Center|No|Completed|July 2012|||April 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|188|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV-positive women seeking care at Thomas Street Health Center (TSHC) of the Harris County        Hospital District (HCHD).|April 2015|April 10, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01605656||85418|
NCT01597050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-932333-002|Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions|SKINDLE|Rigel Pharmaceuticals|No|Completed|August 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|75 Years|No|||September 2013|September 27, 2013|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597050||86080|
NCT01597622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114333|BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115|BEL114333, a Multicenter, Continuation Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase III Study BEL113750 in Northeast Asia or Completed the Open-label Extension of HGS1006-C1115 in Japan||GlaxoSmithKline|No|Recruiting|June 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|420|||Both|18 Years|N/A|No|||May 2015|July 9, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597622||86036|
NCT01597596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGLU07510|A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease|A Phase 3/4, Prospective, Multinational, Open-label, Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease||Sanofi|Yes|Terminated|August 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|N/A|12 Months|No|||December 2015|December 14, 2015|May 10, 2012|Yes|Yes|Study was stopped due to approved label expansion of alglucosidase alfa.|No|September 25, 2015|https://clinicaltrials.gov/show/NCT01597596||86038|
NCT01597869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02-009|Safety of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration : A Prospective Study|Safety of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration : A Prospective Study||Samsung Medical Center|Yes|Recruiting|April 2012|||January 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Patients admmitted to the tertiary hospital|January 2013|January 1, 2013|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597869||86017|
NCT01597882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8550|Improving Monitoring of Patients Receiving Case Management|Improved Targeting of Admission Avoidance Interventions in Older People With Long-term Conditions:An Observational,Longitudinal Study Exploring the Feasibility of Measures of Strength as a Monitoring Aid in Patients Receiving Case Management||University of Southampton|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|114|||Both|65 Years|N/A|No|Non-Probability Sample|Patients receiving cmmunity health case management.|February 2014|February 16, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597882||86016|
NCT01627886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA0859144-01|Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition|Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's Laboratories Limited, India and 'BONIVA®' 150 mg (Ibandronate Sodium) Tablets Of Roche Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|September 2008|October 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|19 Years|64 Years|Accepts Healthy Volunteers|||November 2008|June 27, 2012|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627886||83715|
NCT01628510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201111170|The Developmental Effects of NICU Positioning|Randomized Clinical Trial Investigating the Developmental Effects of Two Different Methods of Neonatal Positioning in the NICU||Washington University School of Medicine|Yes|Completed|January 2011|December 2014|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|7 Days|No|||April 2015|April 10, 2015|June 19, 2012||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01628510||83667|
NCT01627938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RUB001CarMS|Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination|A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)|MSCardioPro|Ruhr University of Bochum|Yes|Active, not recruiting|April 2012|April 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|55 Years|No|||November 2014|November 4, 2014|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01627938||83711|
NCT01628562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dilek Esmolol|A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol in Intracranial Surgery|A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol: a Double Blind Randomized Controlled Study||Diskapi Teaching and Research Hospital|No|Completed|June 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|19 Years|80 Years|No|||December 2012|February 14, 2015|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01628562||83663|
NCT01628848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-05-001|A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients|A Placebo-controlled Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa||Otsuka Pharmaceutical Co., Ltd.|No|Completed|August 2006|April 2008|Actual|April 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|174|||Both|30 Years|79 Years|No|||February 2014|February 3, 2014|June 24, 2012||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01628848||83641|
NCT01628861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200813897|Point-of-Choice Prompts to Reduce Prolonged Sitting Time at Work|Point-of-Choice Prompts to Reduce Prolonged Sitting Time at Work: A Randomised Trial||Glasgow Caledonian University|No|Completed|March 2010|June 2010|Actual|June 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01628861||83640|
NCT01629147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8960-BW-CTIL|Treatment of Chronic Constipation in Children With Lactobacillus Reuteri|Treatment of Chronic Constipation in Children With Lactobacillus Reuteri (Biogaia): A Prospective Placebo-controlled Trial||Sheba Medical Center|No|Not yet recruiting|July 2014|September 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|4 Years|10 Years|No|||May 2014|May 21, 2014|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01629147||83618|
NCT01629706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-373-C-105|Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers|Determination of Cell Population in SICS and Symptomatic Versus Asymptomatic Lens Wearers|ABBOTSFORD|Alcon Research|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|92|||Both|17 Years|N/A|No|||January 2015|February 12, 2015|June 26, 2012|Yes|Yes||No|January 29, 2015|https://clinicaltrials.gov/show/NCT01629706||83575|
NCT01629680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-080210|A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects|A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects||Medical University of Vienna|Yes|Completed|October 2010|June 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01629680||83577|
NCT01629693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00973|Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses|Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses||Alcon Research|No|Completed|July 2013|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|398|||Both|18 Years|N/A|No|||October 2014|November 3, 2014|June 26, 2012|Yes|Yes||No|November 3, 2014|https://clinicaltrials.gov/show/NCT01629693||83576|
NCT01630239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-000864|MR-Guided Laser Ablation of Hepatic Tumors|Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors||Mayo Clinic|No|Completed|June 2012|March 2015|Actual|March 2015|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||May 2015|May 1, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01630239||83534|
NCT01630226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BN-001/83/07-B|Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland|Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland||Pomeranian Medical University Szczecin|No|Recruiting|June 2007|||December 2013|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Female|20 Years|70 Years|No|||July 2012|July 10, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630226||83535|
NCT01631448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrin-2012-01|Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplantation|Application of the Biological Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplant||Instituto Mexicano del Seguro Social|Yes|Completed|May 2010|March 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|152|||Both|16 Years|60 Years|No|||March 2015|March 23, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631448||83441|
NCT01627158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103011|Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte|Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Double-dummy, Single Centre, Single Dose, Crossover Study in Healthy Subjects|ADECO|Orion Corporation, Orion Pharma|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 12, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627158||83771|
NCT01605097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00557|High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule|High Dose Rate Prostate (HDR) Brachytherapy Dose Escalation to Dominant Intra-prostatic Nodule for Patients With Intermediate and High Risk Prostate Cancer|Dosepainting|British Columbia Cancer Agency|No|Active, not recruiting|May 2012|December 2016|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Male|40 Years|80 Years|No|||August 2015|February 19, 2016|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605097||85461|
NCT01605396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8669-064|A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)|A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients||Merck Sharp & Dohme Corp.|No|Active, not recruiting|July 2012|June 2016|Anticipated|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Female|18 Years|N/A|No|||January 2016|February 3, 2016|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605396||85438|
NCT01605669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2011.0123|Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography|Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography|Cassette|United States Naval Medical Center, San Diego|No|Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Aortic Stenosis seen in the internal medicine clinic at NMCSD|November 2013|November 1, 2013|May 17, 2012||No||No|May 17, 2013|https://clinicaltrials.gov/show/NCT01605669||85417|Patients with significant concomitant valvular disease were not evaluated. The software does not provide immediate feedback on the severity of the stenosis. Multiple early recordings had artifact noise rquiring modificaiton of recording techniques.
NCT01597310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223HV105|Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study|An Open-Label Study to Assess the Effect of Dexpramipexole (BIIB050) on the Pharmacokinetics of Warfarin in Healthy Volunteers||Knopp Biosciences|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 24, 2014|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597310||86060|
NCT01597323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC84611|Safety & Efficacy Evaluation of a Radiofrequency & Laser/Light System for Improvement of Skin Texture|Safety and Efficacy Evaluation of the eTWO System for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction||Candela Corporation|No|Recruiting|October 2011|December 2017|Anticipated|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Optional biopsy, for consenting subjects, of facial skin tissue from areas directly in front      of ear (Pre-Auricular)|Both|35 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial        photodamage (sun damage) and presence of mild to moderate facial wrinkling|September 2015|October 29, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01597323||86059|
NCT01597635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114622|The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury|A Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2586881 in Patients With Acute Lung Injury||GlaxoSmithKline|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|80 Years|No|||July 2015|October 29, 2015|January 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597635||86035|
NCT01597648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115325|A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™|A Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ Administered Concurrently in Healthy Adult Subjects||GlaxoSmithKline||Completed|November 2011|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01597648||86034|
NCT01597609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110739|A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects|A Single-blind, Randomised, Placebo-controlled, Parallel Group, Incomplete Block Design, Benchmark Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects||GlaxoSmithKline|No|Completed|May 2008|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Actual|60|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 10, 2012|April 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597609||86037|
NCT01598168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02-09|Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia|Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia||McMaster University|Yes|Terminated|January 2013|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|May 11, 2012|Yes|Yes|slow recruitment|No||https://clinicaltrials.gov/show/NCT01598168||85994|
NCT01627912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUABIO01|Acute Effects of Wine Consumption on Healthy Volunteers|Acute Effects of Wine Consumption on Platelet Aggregation, and on Inflammatory / Oxidative Stress Markers|winepost|Harokopio University|No|Active, not recruiting|April 2011|October 2012|Anticipated|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|||Actual|10|||Male|26 Years|39 Years|Accepts Healthy Volunteers|||June 2012|June 22, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01627912||83713|
NCT01628198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0740|Impact of Renal SympAthetic DenerVation on Chronic HypErtension|Impact of Renal SympAthetic DenerVation on Chronic HypErtension|SAVE|Icahn School of Medicine at Mount Sinai|Yes|Terminated|May 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|85 Years|No|||September 2015|September 15, 2015|June 12, 2012|Yes|Yes|recommendation by the study's DSMB due to insufficient data to determine efficacy.|No||https://clinicaltrials.gov/show/NCT01628198||83691|
NCT01628575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMO-0626-11|Periodontally Accelerated Orthodontics - A Novel Technique For a Shortened Orthodontic Treatment With a Stable Result. A Clinical and Computerized Tomography Analysis|||Hadassah Medical Organization|No|Recruiting|May 2012|April 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|13 Years|85 Years|No|Probability Sample|patients from the department of orthodontics Hadassah medical center|June 2012|June 26, 2012|June 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01628575||83662|
NCT01628874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0542|Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children|A Double-Blind, Randomized Controlled Trial of Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children|JTIP|University of Colorado, Denver|No|Enrolling by invitation|September 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|387|||Both|N/A|18 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01628874||83639|
NCT01629160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|642|Ventricular Wall Motion Characterization|Characterization of Normal and Abnormal Ventricular Wall Motion||St. Jude Medical|Yes|Completed|July 2012|||January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Atrial Fibrillation or Ventricular Tachycardia|January 2014|January 13, 2014|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01629160||83617|
NCT01629407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/015|A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years|||Allergan|No|Completed|June 2009|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|315|||Both|N/A|N/A|No|Non-Probability Sample|Patients with primary open angle glaucoma in one or both eyes|June 2013|June 19, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629407||83598|
NCT01630252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL11-021|PGL5001 Proof of Concept Study in Inflammatory Endometriosis|A Phase IIa Efficacy and Safety Study of PGL5001 Versus Placebo Administered for up to 5 Months With Concomitant Administration of Depot Medroxyprogesterone Acetate for the Treatment of Peritoneal and/or Ovarian Endometriosis With an Inflammatory Component.|JADE|PregLem SA|Yes|Completed|June 2012|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|24|||Female|18 Years|N/A|No|||June 2014|June 2, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630252||83533|
NCT01630018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11AOC09J|Efficacy and Safety of Belotecan or Topotecan in Patients With Recurrent or Refractory Ovarian Cancer|A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Recurrent or Refractory Ovarian Cancer|AOC|Chong Kun Dang Pharmaceutical|Yes|Recruiting|January 2011|December 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|N/A|No|||September 2013|September 3, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01630018||83551|
NCT01630928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1296 (REK)|Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors|Renal Sympathetic Denervation for Treatment Resistant Hypertension and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors (The Re-Shape CV-Risk Study)|Re-Shape|University Hospital of North Norway|Yes|Active, not recruiting|March 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||June 2015|June 2, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630928||83481|
NCT01630538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMCT-01|Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants|Phase II Pilot Study of Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection in Kidney Transplantation||University of Manitoba|Yes|Recruiting|June 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630538||83511|
NCT01598818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|553-11-FB|First-Sight Refractive Error Correction in the Developing World|First-Sight Refractive Error Correction in the Developing World||University of Nebraska|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|150|||Both|7 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Population with refractive error between -4.50 to +4.50 diopter spherical error and        astigmatism up to 1.50 diopters.|May 2012|July 3, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598818||85944|
NCT01596543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8728-AD-CTIL|The Effect of Partial and Complete Sleep Deprivation on Heat Tolerance|Thr Effect of Partial and Complete Sleep Deprivation on Heat Tolerance||Sheba Medical Center|No|Completed|November 2012|May 2014|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2014|May 8, 2014|May 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01596543||86119|
NCT01596816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CKNO-PRO-0901|Hypofractionated Stereotactic Boost in Prostate Cancer|Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study|CKNO-PRO|Centre Oscar Lambret|Yes|Active, not recruiting|August 2010|September 2016|Anticipated|September 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Male|18 Years|N/A|No|||June 2014|June 20, 2014|June 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01596816||86098|
NCT01597336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11120126|Treatment of Abdominal Abscesses With or Without Fibrinolysis|Treatment of Abdominal Abscesses With or Without Fibrinolysis||Children's Mercy Hospital Kansas City|No|Completed|June 2009|May 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|N/A|17 Years|No|||February 2015|February 3, 2015|May 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597336||86058|
NCT01597349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN01-002-A|Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection|An Exploratory, Randomized, Placebo Controlled, Double Blind, Parallel Arm Dose Ranging Study to Determine the Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection||Cerecor Inc|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|208|||Both|18 Years|65 Years|No|||January 2014|January 27, 2014|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01597349||86057|
NCT01597362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRC-01|Three Laparoscopic Access Techniques|||Campus Bio-Medico University|No|Completed|February 2006|September 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|608|||Female|18 Years|70 Years|No|||May 2012|May 11, 2012|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01597362||86056|
NCT01597661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115433|Bupropion & Cardio Birth Defect (Slone)|Bupropion and Cardiac Birth Defects (Slone Epidemiology Center)||GlaxoSmithKline|No|Completed|September 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|The primary focus of the Slone Epidemiology Center Birth Defects Study (BDS) case-control        surveillance is to identify the risks and safety of marketed drugs taken by pregnant        women. Infants with any of a wide range of malformations are identified at tertiary care        and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using        approaches that include reviewing lists of discharge diagnoses available in medical        records; contacting newborn nursery and/or labor and delivery rooms; reviewing        admission/discharge lists; and reviewing clinic and surgical logs. Information gathered on        each subject includes name, address, telephone number, diagnostic information, and date of        birth. Beginning in 1992, the BDS also included mothers of non-malformed infants:        initially these infants were identified exclusively at study hospitals, but in 1998, they        expanded their normal newborn capability by obtaining a population-based random sample of        newborns in Massachusetts.|July 2014|July 3, 2014|February 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01597661||86033|
NCT01597895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4001108|Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects|Open-Label, Randomized, Fixed-Sequence, Crossover Study to Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects||ViiV Healthcare|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 18, 2012|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01597895||86015|
NCT01598181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/2256/REK n|Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia|Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia||University Hospital of North Norway|No|Active, not recruiting|December 2011|October 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01598181||85993|
NCT01627639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM09109|Effectiveness of Acetazolamide for Reversal of Metabolic Alkalosis in Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients|A Randomized Trial to Evaluate Effectiveness of Acetazolamide in COPD Patients Developing Metabolic Alkalosis During Invasive Mechanical Ventilation|DIABOLO|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2011|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|380|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01627639||83734|
NCT01627925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000054|Safety Study of Positive Airway Pressure Via a Nasal Mask in Obese Patients|Safety Study of Positive Airway Pressure Via a Nasal Mask on Upper Airway Patency During Induction of Anesthesia in Obese Patients||Massachusetts General Hospital|Yes|Recruiting|June 2012|June 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|32|||Both|18 Years|65 Years|No|||July 2012|July 3, 2012|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01627925||83712|
NCT01628211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPEC|Second Look Laparoscopy in Colorectal Cancer|Randomized Phase 2 Study Comparing Second Look Laparoscopy to Standard Follow up in Patients With no Radiologic Evidence of Disease at 6 Months After Complete Resection of Colorectal Mucinous Carcinoma|HIPEC|National Cancer Institute, Naples|No|Recruiting|April 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|65 Years|No|||November 2015|November 27, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01628211||83690|
NCT01630330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CI002B|Contact Force Sensing Use in Atrial Fibrillation Ablation|The Role of Contact Force Sensing in Electrical Pulmonary Vein Isolation When Conducting Atrial Fibrillation Ablation||Royal Brompton & Harefield NHS Foundation Trust|No|Recruiting|May 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||June 2012|June 26, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630330||83527|
NCT01622244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StMichael|Coordinated Access to Care From Hospital Emergency Departments|Coordinated Access to Care From Hospital Emergency Departments - Assessing Effectiveness and Cost-Effectiveness|CATCH-ED|St. Michael's Hospital, Toronto|No|Completed|November 2012|September 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|166|||Both|N/A|N/A|No|||June 2012|October 29, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01622244||84146|
NCT01622556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15954 UCB-2011|Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies|Phase II Trial of Reduced Intensity Conditioning (RIC) and Allogeneic Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies||University of Virginia|Yes|Terminated|January 2012|January 2017|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|70 Years|No|||February 2014|February 10, 2014|June 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01622556||84122|
NCT01630967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCCA_Deg01|Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)|A Phase II Single Arm Study of Degarelix in Men With Castrate Resistant Prostate Cancer With a Rising Prostate-Specific Antigen (PSA) Despite LHRH Agonist Therapy.||British Columbia Cancer Agency|No|Not yet recruiting|August 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|18 Years|N/A|No|||June 2012|June 27, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01630967||83478|
NCT01618955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-11-002|Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device|Phase 2, Multi-Center, Open-Label, Single-Dose, Single Arm, In-Clinic Study to Evaluate the Actual Human Use of Methotrexate Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device in Adult Patients With Rheumatoid Arthritis.||Antares Pharma Inc.|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|101|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|June 4, 2012|Yes|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT01618955||84398|
NCT01618968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTX-11-003|Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device|Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis||Antares Pharma Inc.|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|49|||Both|18 Years|N/A|No|||May 2014|May 8, 2014|June 4, 2012|Yes|Yes||No|February 27, 2014|https://clinicaltrials.gov/show/NCT01618968||84397|
NCT01619241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC12EISI0104|Pilot Study for Evaluating the Role of F-18 FLT PET/CT in Therapeutic Decision Making in Non-small Cell Lung Cancer|The Role of F-18 FLT PET/CT for Selecting the Patients Who Need Maintenance Treatment After First-line Chemotherapy in Advanced Non-small Cell Lung Cancers||The Catholic University of Korea|No|Not yet recruiting|June 2012|August 2015|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|N/A|No|Non-Probability Sample|advanced non-small cell lung cancer|June 2012|June 12, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01619241||84376|
NCT01619514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/00106|Uncovering Potential Breast Cancer Biomarkers Amp; Possible Drug Targets Using Advanced Quantitative Mass Spectrometry|||National University Hospital, Singapore|Yes|Recruiting|March 2012|||March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Female|N/A|N/A|No|Probability Sample|Tumor specimens that have been stored in the NUHS tissue repository will be retrieved|December 2013|December 10, 2013|April 2, 2012||||No||https://clinicaltrials.gov/show/NCT01619514||84355|
NCT01620372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-25|French Childhood Cancer Survivor Study|Constitution d'Une Cohorte Nationale rétrospective de Survivants d'un Cancer Solide de l'Enfant diagnostiqué Avant 2000|FCCSS|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|November 2011|November 2031|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Anticipated|18000|Samples With DNA|saliva and blood samples (under another protocol)|Both|N/A|18 Years|No|Non-Probability Sample|The study population includes all types of solid childhood cancer cases (with the        exception of leukemia) treated in, or before the end of, 1999.        The study population is based on the French clinical trials, registries, cohorts and        department of paediatric oncology.|October 2012|October 8, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620372||84289|
NCT01620385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ciPDA0001|Cochlear Implant PDA Based Research Platform|Multi Center Clinical Study to Assess the Safety of the UTD Cochlear Implant PDA (ciPDA) REsearch Platform|ciPDA|The University of Texas at Dallas|No|Recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 12, 2012|September 8, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620385||84288|
NCT01621282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Education|Running Successful Journal Club|Effect of Education on Running Successful Journal Club||Mashhad University of Medical Sciences|No|Terminated|November 2011|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2012|July 11, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621282||84220|
NCT01599585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0118|A Randomized Controlled Trial of In-Home Tele-Behavioral Health Care Utilizing Behavioral Activation for Depression|A Randomized Controlled Trial of In-Home Tele-behavioral Health Care Utilizing Behavioral Activation for Depression||National Center for Telehealth and Technology|Yes|Active, not recruiting|May 2012|May 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|18 Years|65 Years|No|||March 2016|March 21, 2016|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01599585||85885|
NCT01599598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2011.0130|Coherence Training for Military Personnel|Coherence Training for Military Personnel||United States Naval Medical Center, San Diego||Active, not recruiting|April 2012|October 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|106|||Both|N/A|N/A|No|||September 2013|September 3, 2013|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01599598||85884|
NCT01599078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCRF-001-EJD|Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention|Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention (PacTAP Study): A Double Blind, Randomized Control Study|PacTAP|Midwest Cardiovascular Research Foundation|Yes|Recruiting|January 2012|January 2014|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2012|May 13, 2012|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01599078||85924|
NCT01599351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA-E-RAD001|Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography Between Prone and Left Lateral Decubitus|Different Radiation Exposures to Patient and Endoscopists Between Performing ERCP in Patients Lying Prone and Left Lateral Decubitus||Chulalongkorn University|No|Completed|July 2009|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|40|||Both|18 Years|80 Years|No|||May 2012|May 15, 2012|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599351||85903|
NCT01599572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8541|Effect of Zinc Supplementation on Serum Zinc Level in Nursing Home Elderly|Zinc Intervention in Nursing Home Elderly||Tufts University|No|Completed|July 2009|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|31|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 19, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599572||85886|
NCT01599819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|261101|BAX 855 Dose-Escalation Safety Study|BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A||Baxalta US Inc.|Yes|Completed|September 2011|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Male|18 Years|65 Years|No|||September 2012|June 26, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01599819||85867|
NCT01600092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V260-035|A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)|A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™||Merck Sharp & Dohme Corp.|No|Completed|April 2013|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1020|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||April 2015|April 13, 2015|May 14, 2012|Yes|Yes||No|March 9, 2015|https://clinicaltrials.gov/show/NCT01600092||85846|
NCT01618916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14354|A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Japanese and Non-Japanese Subjects With Elevated LDL-C||Eli Lilly and Company|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Anticipated|48|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2013|February 26, 2013|June 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01618916||84401|
NCT01622257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU6-2011|Cavitation Ultrasound in Treatment of Patients With PCOS|Comparison of Cavitation Ultrasound, Metformin or the Combination of Both in Obese Women With Polycystic Ovary Syndrome||Ain Shams University|Yes|Completed|June 2011|June 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|198|||Female|18 Years|40 Years|No|||December 2012|December 26, 2012|June 18, 2012||No||No|October 14, 2012|https://clinicaltrials.gov/show/NCT01622257||84145|
NCT01622270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-NV-533-CTIL|Energy Expenditure in Patients With Crohn's Disease|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|June 2012|||June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|30|||Both|18 Years|60 Years|No|Non-Probability Sample|Patients with Crohn's disease|January 2012|June 14, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01622270||84144|
NCT01622283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116459|Pharmacokinetic Study of Levocetirizine Oral Solution|Pharmacokinetic Study of Levocetirizine Oral Solution -An Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, the Safety and Tolerability of Levocetirizine Oral Solution (5 mg) and Cetirizine Dry Syrup (10 mg), Following a Single Dose in Japanese Healthy Male Subjects-||GlaxoSmithKline|No|Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|20|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||June 2012|July 19, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01622283||84143|
NCT01622569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-FLU-NP-3101|Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety|A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety||Optinose US Inc.|No|Completed|October 2013|December 2015|Actual|October 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|323|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01622569||84121|
NCT01622582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UARK 2008-30|Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma|Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma||University of Arkansas|No|Completed|January 2006|March 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|796|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Multiple Myeloma, developing engraftment syndrome|March 2015|March 2, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622582||84120|
NCT01622595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112265|UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients|A Non-interventional Observational Study of Infectious Complications in Cancer Patients||University of Arkansas|No|Withdrawn|November 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|cancer patients with Infections|October 2015|October 26, 2015|June 15, 2012||No|Principal Investigator has left the institution.|No||https://clinicaltrials.gov/show/NCT01622595||84119|
NCT01618435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F12-04|The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation in the Elderly With Spinal Stenosis Due to Degenerative Spondylolisthesis|The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation|IVANOS|Sygehus Lillebaelt|No|Active, not recruiting|March 2012|March 2016|Anticipated|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|108|||Both|60 Years|N/A|No|||January 2016|January 23, 2016|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618435||84438|
NCT01618448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-TWA-1101|Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure|A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure||Taiwan Otsuka Pharm. Co., Ltd|No|Completed|July 2012|December 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|20 Years|85 Years|No|||January 2013|June 1, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01618448||84437|
NCT01619254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AECID|Impact of Hand Hygiene Activities on the Prevention of Intestinal Parasitic Infections and Anaemia Among School Children|Hand Hygiene Promotion Activities: Effect on Intestinal Parasitic Infections and Anaemia Among School-aged Children in Eastern Tigray, Ethiopia: a Factorial Randomised Controlled Trial||Mekelle University|Yes|Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|365|||Both|6 Years|15 Years|Accepts Healthy Volunteers|||January 2015|January 31, 2015|June 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01619254||84375|
NCT01619267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GER-EP-008|Role of New Diagnostic Tool in Device (ICD / PM) Associated Infections|Device Associated Infections - Role of New Diagnostic Tools|DIRT|Deutsches Herzzentrum Muenchen|No|Completed|January 2012|April 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|103|Samples Without DNA|new inflammatory biomarkers such as procalcitonine|Both|N/A|N/A|No|Probability Sample|Consecutive patients presenting with device associated infections|July 2013|July 3, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01619267||84374|
NCT01618981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAURENT PHRC N 2011|LEft Atrial Pacing in Diastolic Heart Failure|LEft Atrial Pacing in Diastolic Heart Failure|LEAD|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|September 2012|||||N/A|Interventional|N/A|2||||||Both|65 Years|N/A|No|||January 2014|January 6, 2014|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01618981||84396|
NCT01618994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-01-018|Validation Study for Robotic Surgery Simulator|Validation Study for Robotic Surgery Simulator||Atlantic Health System|Yes|Completed|April 2011|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|14|||Both|N/A|N/A|No|Non-Probability Sample|Gynecologic surgeons with no robotic experience|June 2012|June 12, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618994||84395|
NCT01619007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15915|Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy|Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE)|XALIA|Bayer|No|Completed|June 2012|July 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|5145|||Both|18 Years|N/A|No|Probability Sample|In- and outpatients in sites participating in the study|July 2015|July 9, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01619007||84394|
NCT01619527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100699|A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions|A Single-Dose, Open-Label, 3-Panel, Randomized, Pivotal Crossover Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat as Either a Fixed Dose Combination Tablet (G006) or as Single Agents Under Fed and Fasted Conditions in Healthy Subjects||Janssen R&D Ireland|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|133|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|June 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01619527||84354|
NCT01619800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02-333-05|The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise|The impAct of Blended Sensor Optimization on resoLVing Chronotropic Incompetence: ABSOLVE CI|ABSOLVE CI|Icahn School of Medicine at Mount Sinai|Yes|Terminated|March 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|2|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|June 12, 2012|Yes|Yes|The study was terminated due to poor enrollment.|No|February 17, 2015|https://clinicaltrials.gov/show/NCT01619800||84333|2 subjects enrolled, unable to meet goal of 38 enrollments. Data not analyzed.
NCT01620424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1356|Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Investigating the Pharmacokinetics and Pharmacodynamics of NN-X14Mix30 and NN-X14Mix50 in Type 2 Diabetic Patients||Novo Nordisk A/S|No|Completed|February 2001|April 2001|Actual|April 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|N/A|No|||June 2012|June 13, 2012|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620424||84285|
NCT01620450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2000-1612|Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese|A Single-centre, Randomised, Double Blind, Cross-over Trial Demonstrating the Bioequivalence Between NN2000-Mix30 and NN-X14Mix30 (NovoRapid® 30 Mix) in Healthy Japanese Subjects||Novo Nordisk A/S|No|Completed|November 2004|February 2005|Actual|February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|34|||Male|20 Years|50 Years|No|||November 2013|November 21, 2013|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620450||84283|
NCT01621295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006682|Assessing the Patient Experience in Cancer Care|Assessing the Patient Experience in Cancer Care: An Observational Communication Study||Mayo Clinic|Yes|Completed|May 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|N/A||1|Actual|408|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients age 18 or over receiving care from clinicians who have also consented to        participate in this study at Mayo Clinic Rochester, University of Southern        California-Norris, or LA County Hospital.|January 2016|January 18, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621295||84219|
NCT01629797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU64905|Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne|Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne||Northwestern University|Yes|Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|100|||Both|18 Years|N/A|No|||April 2013|April 29, 2013|June 26, 2012||No||No|April 29, 2013|https://clinicaltrials.gov/show/NCT01629797||83568|
NCT01599845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-YS-0107-CTIL|The Differential Pattern of Deposition of Nano Particles in the Airways of Exposed Workers|The Differential Pattern of Deposition of Nano Particles in the Airways of Exposed Workers (Nanoexposure)|Nanoexposure|Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|May 2012|May 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|60|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients|May 2012|May 14, 2012|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01599845||85865|
NCT01630343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QEHHIPPAIN|Pain Management in Geriatric Hip Fracture|The Efficacy of Pain Management Protocol for Elderly Hip Fracture Patients After Surgery: A Prospective Cohort Study||Queen Elizabeth Hospital, Hong Kong|No|Completed|January 2010|April 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|400|||Both|65 Years|N/A|No|||June 2012|June 29, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01630343||83526|
NCT01630356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 00002501|Controlled Trial to Reduce Secondhand Smoke Exposure at Homes in Armenia|Monitoring Secondhand Smoke Exposure in Buildings in Armenia: Controlled Trial||Johns Hopkins Bloomberg School of Public Health|No|Completed|April 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|250|||Both|2 Years|N/A|No|||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630356||83525|
NCT01630655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|426-09|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting Condition|An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (Reference, Mylan Pharmaceuticals Inc., USA) in Healthy Human Volunteers Under Fasting Condition||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630655||83502|
NCT01599832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0121|Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer|DCE-MRI as Pazopanib Biomarker in Metastatic Renal Cancer||University of Chicago|No|Active, not recruiting|June 2012|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|65|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01599832||85866|
NCT01600417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA-001|Investigation of Lumbo-sacral Instability Using Custom Made Table - a Pilot Study|Radiologic Presentation of Lumbo-sacral Instability Using a Custom Made Table - a Pilot Study||Swiss Paraplegic Centre Nottwil|No|Terminated|May 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|||Both|20 Years|60 Years|No|Non-Probability Sample|Patients suffering from chronic low back pain and clinical suspicion of lumbar        instability.|March 2015|March 17, 2015|May 8, 2012||No|principal investigator has left the institution|No||https://clinicaltrials.gov/show/NCT01600417||85821|
NCT01629485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005712|Part vs Whole Task Mastery Training for Laparoscopic Hernia Repair|Part vs Whole Task Mastery Simulation Training for Laparoscopic Hernia Repair: A Randomized Trial||Mayo Clinic|No|Completed|September 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629485||83592|
NCT01629238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU333|Characteristics of Plant Sterols Consumers in France|||Danone Research|No|Completed|October 2010|||||N/A|Observational|N/A||2|Actual|780|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|adults followed by general practitionners|June 2012|June 26, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01629238||83611|
NCT01629459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205024|Resistance Exercise in Barth Syndrome|Effects of Resistance Exercise Training on Cardiac, Metabolic and Muscle Function and Quality of Life in Barth Syndrome||Washington University School of Medicine|Yes|Recruiting|June 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Male|15 Years|30 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01629459||83594|
NCT01622296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107214|Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients|Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients. A Prospective, Double-blind, Randomized, Crossover Study|BufferDent|University of California, San Francisco|Yes|Completed|April 2012|July 2013|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care|2||Actual|20|||Both|9 Years|12 Years|Accepts Healthy Volunteers|||February 2014|February 10, 2014|June 11, 2012||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01622296||84142|The variation of VAS scores was found to be larger than that used in the sample size calculation; thus, the study was underpowered to reach statistical significance.
NCT01618734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPO-r switch|Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.|Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP).||Henri Mondor University Hospital|No|Completed|January 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with primary Immune Thrombopenia receiving romiplostim and eltrombopag        alternatively.|June 2012|June 12, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618734||84415|
NCT01618747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25550|An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse|A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma||Hoffmann-La Roche||Not yet recruiting|May 2013|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients with previously treated glioblastoma multiforme in first or second relapse|March 2013|March 18, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618747||84414|
NCT01618461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3R43MD004048-02S1|PictureRx: An Intervention to Reduce Latino Health Disparities (Supplement: Medical Icons)|PictureRx: An Intervention to Reduce Latino Health Disparities (Supplement: Medical Icons)||PictureRx, LLC|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|4||Actual|200|||Both|18 Years|N/A|No|||June 2012|June 11, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618461||84436|
NCT01618708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNV04910|A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip|A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip||Sanofi|No|Completed|September 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|35 Years|N/A|No|||August 2015|August 3, 2015|June 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618708||84417|
NCT01619540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valsalva|Valsalva Manœuvre in the Diagnosis of Left Ventricular Failure in Chronic Obstructive Pulmonary Disease Exacerbation|Study of the Valsalva Manœuvre in the Diagnosis of Left Ventricular Failure During Acute Exacerbation of Chronic Obstructive Pulmonary Disease||University of Monastir|Yes|Completed|May 2011|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 23, 2013|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619540||84353|
NCT01619813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I209|Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer|A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer||Canadian Cancer Trials Group|Yes|Active, not recruiting|July 2012|September 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|85|||Male|18 Years|N/A|No|||April 2015|March 22, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619813||84332|
NCT01619826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD069381|Enhancing Children's Cognitive and Brain Health Through Physical Activity Training (FITKids2)|Enhancing Children's Cognitive and Brain Health Through Physical Activity Training|FITKids2|University of Illinois at Urbana-Champaign|Yes|Recruiting|April 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Anticipated|240|||Both|8 Years|9 Years|Accepts Healthy Volunteers|||August 2014|August 25, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619826||84331|
NCT01619839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-181-04|A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain|A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee||Nektar Therapeutics|No|Completed|June 2012|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|213|||Both|18 Years|N/A|No|||August 2014|August 14, 2014|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619839||84330|
NCT01620112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090/2002|The Effects of Different Clonidine Concentrations on Axillary Brachial Plexus Block With 1,5% Lidocaine|The Effects of Different Clonidine Concentrations on Axillary Brachial Plexus Block With 1,5% Lidocaine for Upper Limb Surgery: a Prospective Randomized Study||Universidade Federal do Rio de Janeiro|Yes|Completed|February 2009|July 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|4||Actual|60|||Both|18 Years|65 Years|No|||June 2012|June 14, 2012|June 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01620112||84309|
NCT01621555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSOASS1|Pain Sensitivity and Outcome in Arthroscopic Shoulder Surgery|Pain Sensitivity and Outcome in Arthroscopic Shoulder Surgery|PSOASS|NHS Fife|No|Not yet recruiting|August 2012|November 2014|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting for elective arthroscopic shoulder surgery|June 2012|June 14, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621555||84199|
NCT01630096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRMC 12 0008|Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe|COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe|COLITIS|Genesys Regional Medical Center|Yes|Recruiting|June 2012|||June 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01630096||83545|
NCT01629849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310.2|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 Tablets in Otherwise Healthy Controlled Asthmatic Subjects (Phase I, Randomised, Placebo-controlled, Double-blind Within Dose Groups)||Boehringer Ingelheim||Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|55 Years|No|||May 2013|May 15, 2013|June 21, 2012||||No||https://clinicaltrials.gov/show/NCT01629849||83564|
NCT01630083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-IMAB-001-03|Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer|A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX Regimen as First-Line Treatment of Patients With CLDN18.2-positive Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction.|FAST|Ganymed Pharmaceuticals AG|Yes|Active, not recruiting|June 2012|December 2018|Anticipated|September 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|210|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01630083||83546|
NCT01630668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-12LCHM|Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule|||Micropharma Limited|No|Completed|August 2012|June 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|20 Years|75 Years|No|||June 2014|June 25, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630668||83501|
NCT01630681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-CARE AdultCan|Internet Based Screening and Stepped Care for Cancer Patients With Anxiety and Depression Symptoms|Uppsala University Psychosocial Care Programme: Internet Based Screening and Stepped Care for Adult Cancer Patients With Anxiety and Depression Symptoms - A Randomized Controlled Trial|AdultCan|Uppsala University|No|Recruiting|April 2013|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01630681||83500|
NCT01600105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 09-1187|Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)|Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests||Icahn School of Medicine at Mount Sinai|No|Recruiting|May 2010|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 23, 2016|May 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01600105||85845|
NCT01600430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 006|Vitamin D Supplementation for Extremely Preterm Infants|Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial||University of Alabama at Birmingham|Yes|Completed|June 2012|December 2014|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|100|||Both|N/A|7 Days|No|||December 2014|December 1, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600430||85820|
NCT01629498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1058|Intensity-Modulated Scanning Beam Proton Therapy (IMPT) With Simultaneous Integrated Boost (SIB)|Phase I/II Trial of Image-Guided, Intensity-Modulated Photon (IMRT) or Scanning Beam Proton Therapy (IMPT) Both With Simultaneous Integrated Boost (SIB) Dose Escalation to the Gross Tumor Volume (GTV) With Concurrent Chemotherapy for Stage II/III Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Recruiting|September 2012|||September 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629498||83591|
NCT01629784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU65095|Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus|Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus||Northwestern University|Yes|Completed|May 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|31|||Both|18 Years|N/A|No|||April 2013|April 15, 2013|June 26, 2012||No||No|April 15, 2013|https://clinicaltrials.gov/show/NCT01629784||83569|
NCT01630070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMRP-110629|Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK Arteries|A Prospective, Multi-center, Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent in the Treatment of Atherosclerotic Tibial-peroneal Arteries|PES-BTK-70|Flanders Medical Research Program|Yes|Completed|January 2012|October 2014|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||March 2015|March 6, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01630070||83547|
NCT01618474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-HDZ-201205001|Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients|A Phase II Randomized Controlled Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients (IIIb-IIIc)||Tianjin Medical University Cancer Institute and Hospital|Yes|Enrolling by invitation|May 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2012|December 21, 2015|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01618474||84435|
NCT01618487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0565|Comparison of Surgical Interventions for Lateral Epicondylitis: A Prospective Study|Comparison of Surgical Interventions for Lateral Epicondylitis: A Randomized, Prospective Study||Christine M. Kleinert Institute for Hand and Microsurgery|No|Recruiting|February 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|65 Years|No|||January 2013|July 9, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618487||84434|
NCT01618760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL-12/127|Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Risperidone Tablet 1 mg With Risperdal® 1 mg in Normal, Healthy, Adult, Human Subjects Under Fed Condition||IPCA Laboratories Ltd.|Yes|Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|June 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618760||84413|
NCT01619891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MR/J00281X/1|VitamIN D Treating patIents With Chronic heArT failurE|VitamIN D Treating patIents With Chronic heArT failurE|VINDICATE|University of Leeds|Yes|Active, not recruiting|August 2012|January 2016|Anticipated|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619891||84326|
NCT01619904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAK 14|GDT Vs ST for Pancreas Transplant Surgery|Effects of Goal-Directed Therapy on Inflammatory Mediators and Postoperative Outcome in Pancreas Transplant: a Prospective Randomised Clinical Trial||University of Manchester|No|Completed|November 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|99 Years|No|||December 2015|December 1, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619904||84325|
NCT01619020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHCRC IR 7532|FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health|Gut Microbiota and Colonic Gene Expression: A Lignan Trial in Humans|FlaxFx|Fred Hutchinson Cancer Research Center|No|Recruiting|October 2012|August 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|80|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 21, 2016|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01619020||84393|
NCT01619553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHC03-007|Genetic Analysis of Keloids|Identification of Genetic Variants That Contribute to Keloid Formation in Families and Isolated Cases.||University of Connecticut Health Center|No|Recruiting|April 2009|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|4000|Samples With DNA|Saliva, blood, scar tissue|Both|N/A|N/A|No|Non-Probability Sample|Individuals with diagnosed keloids.|December 2015|December 2, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619553||84352|
NCT01619852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00061676|Lidocaine and Prevention of Chronic Pain|The Effect of Lidocaine to Prevent the Development of Chronic Post-Surgical Pain: a Functional and Morphological Brain Imaging Study||Northwestern University|No|Completed|June 2012|January 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Female|18 Years|64 Years|No|||April 2015|April 29, 2015|June 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01619852||84329|
NCT01619865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110718|Safety and Efficacy of 68Ga-DOTA-tyr3-Octreotide|Safety and Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging and Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.|GA-68|University of Iowa|Yes|Active, not recruiting|February 2012|||March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|2 Years|N/A|No|||November 2015|November 20, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619865||84328|
NCT01620125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lactobacillus reuteri pilot|Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients|Metabolic Control of Type 2 Diabetes Patients Before and After Dietary Supplementation With the Probiotic Lactobacillus Reuteri DSM 17938 - a Pilot Study||Vastra Gotaland Region|No|Recruiting|May 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|50 Years|80 Years|No|||June 2012|June 14, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01620125||84308|
NCT01620398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCDT|Brazilian Cardioprotective Nutritional Program Trial|The Brazilian Cardioprotective Nutritional Program to Reduce Events and Risk Factors in Secondary Prevention for Cardiovascular Disease|BALANCE|Hospital do Coracao|No|Active, not recruiting|February 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2100|||Both|45 Years|N/A|No|||September 2015|September 2, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620398||84287|
NCT01620411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120565|War Wounded, a Comparison of Two Pain Management Approaches|Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty. Comparison of Spinal Cord Stimulation and Comprehensive Medical Management.||University of California, San Diego|Yes|Withdrawn|June 2012|||June 2016||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||June 2013|June 17, 2013|June 13, 2012|No|Yes|Site was never activated by sponsor|No||https://clinicaltrials.gov/show/NCT01620411||84286|
NCT01620970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT01/12|PF-03446962 in Relapsed or Refractory Urothelial Cancer|Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment.||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Not yet recruiting|July 2012|October 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||June 2012|June 13, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01620970||84244|
NCT01621568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120118|Sunitinib for Advanced Thymus Cancer Following Earlier Treatment|A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy||National Institutes of Health Clinical Center (CC)||Recruiting|April 2012|April 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|100 Years|No|||November 2015|March 8, 2016|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621568||84198|
NCT01621581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120137|AAV2-GDNF for Advanced Parkinson s Disease|A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease||National Institutes of Health Clinical Center (CC)||Recruiting|May 2012|January 2018|Anticipated|January 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|December 15, 2015|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01621581||84197|
NCT01629862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8354706|Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea|Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea.||Brigham and Women's Hospital|Yes|Recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629862||83563|
NCT01630382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1203-088-402|Cerebrospinal Fluid Congestion in Spinal Stenosis Patients|||Seoul National University Hospital|No|Not yet recruiting|June 2012|December 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|30|||Both|30 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|study group : spinal stenosis patient control group : matched sex, age|June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630382||83523|
NCT01630369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUBIN_L_05574|Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes|Multicenter, Open, Non-randomized 6 Months Study to Evaluate Efficacy and Safety Insuman® Basal, Insuman® Comb 25, Insuman® Rapid in Insulin-naÏve Patients With T2DM Who Received Baseline Education Course in the Diabetes School.|SPIRIT|Sanofi|Yes|Completed|February 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|552|||Both|18 Years|N/A|No|||May 2014|May 16, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630369||83524|
NCT01630694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB case number: 00032136|Three-dimensional Craniofacial Phenotyping of Patients With Difficult Airway|Three -Dimensional (3-D) Craniofacial Phenotyping of Patients With Difficult Airway||University of Rochester|No|Terminated|July 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|28|||Both|18 Years|70 Years|No|||December 2015|December 14, 2015|August 16, 2011||No|study stopped due to not meeting enrollment goal.|No|November 2, 2015|https://clinicaltrials.gov/show/NCT01630694||83499|
NCT01630707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE G120029|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2012|||||N/A|N/A|N/A||||||||||||||March 19, 2013|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630707||83498|
NCT01600118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESWT1|Effect of Shock Waves on Dental Parameters|Effect of Low-energy Extracorporeal Shock Waves on Periodontal and Endodontic Parameters||Medical University of Vienna|Yes|Completed|September 2011|December 2013|Actual|October 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01600118||85844|
NCT01630629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12050600|Longitudinal Lactation Bone Density Study|"Bone Density and Calcitropic Hormones During Lactation in African-American and Caucasian Women"||University of Pittsburgh|No|Completed|August 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|77|Samples Without DNA|Blood and breast milk|Female|21 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|New mothers will be recruited from UPMC hospital population, primarily Magee Womens        Hospital. As this is a study which aims to describe racial differences in bone metabolism        during lactation in African-Americans and Caucasians, subjects must identify themselves as        belonging to one of these groups.|January 2016|January 15, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01630629||83504|
NCT01630980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INC 2012 KRS|Meta-analyses of the Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome|Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome: A Systematic Review and Meta-analysis of Controlled Dietary Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development||University of Toronto|No|Completed|May 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1|||Both|N/A|N/A|No|Probability Sample|Varied|May 2015|May 26, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01630980||83477|
NCT01621919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TITAP|Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1|Concentration of S-1 Metabolites in Tear and Plasma and Correlation With Its Side Effects in Patients Receiving S-1 Adjuvant Chemotherapy||Seoul National University Bundang Hospital|No|Recruiting|December 2010|May 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|plasma tears|Both|18 Years|80 Years|No|Probability Sample|Patients who receiving S-1 as an adjuvant chemotherapy after radial surgery for gastric        cancer|June 2012|June 14, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621919||84171|
NCT01619033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-13 / BF2.649|Pharmacokinetics of BF2.649 in Renal Impairment|Pharmacokinetics of 20 mg BF2.649 in Single Dose, in Subjects With Normal Renal Function Compared to Subject With Impaired Renal Function||Bioprojet|No|Completed|July 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2013|April 11, 2013|July 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01619033||84392|
NCT01619046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GreenGeneF_P3|Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A|Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A||Green Cross Corporation|No|Recruiting|March 2013|September 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|124|||Both|12 Years|N/A|No|||July 2014|July 2, 2014|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619046||84391|
NCT01619306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/00752|Knowledge and Attitudes of Patients and Healthcare Professionals on a Spectrum of Genetic Tests Relevant to Breast Cancer Patients|||National University Hospital, Singapore|Yes|Recruiting|January 2011|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|850|||Female|21 Years|N/A|No|Probability Sample|Questionnaires will be handed out to agreeable participants on the following occasions. 1.        Patients- National University Health System Cancer Centre Level 3 amp; 4 waiting areas 2.        Medical students - before or after lectures, or at personal contact 3. Cancer researchers        - before or after lectures, or at personal contact 4. Healthcare professionals - before or        after NUHS breast tumour board, or at personal contact Due caution will be exercised to        ensure that the questionnaire is only handed out to subjects who are aged 21 years and        above.|December 2013|December 10, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01619306||84371|
NCT01619618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000734898|Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1302 Trial|Evaluation of Polymorphisms and Mutations in Genes Postulated to Alter the Efficacy of Gefitinib in Samples From E1302||National Cancer Institute (NCI)||Not yet recruiting|May 2012|||June 2012|Anticipated|N/A|Observational|N/A|||Anticipated|183|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619618||84347|
NCT01619579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110973|Investigation of AVACEN Thermal Exchange System for Fibromyalgia Pain|Effects of a 4 Week AVACEN Treatment on Pain Perception in Fibromyalgia - An Open Label Study|AVACEN: TES|Avacen, Inc.|Yes|Completed|June 2011|May 2013|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|99 Years|No|||November 2015|November 30, 2015|June 12, 2012|Yes|Yes||No|July 30, 2015|https://clinicaltrials.gov/show/NCT01619579||84350|
NCT01619878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCOA566B2306|Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg|An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight||Novartis||Completed|October 2012|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||June 2015|June 1, 2015|June 12, 2012|No|Yes||No|May 11, 2015|https://clinicaltrials.gov/show/NCT01619878||84327|
NCT01620138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230BBR01T|Expression Profile of Somatostatin Receptors and Dopamine Receptor 2 in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vivo Response to Pasireotide and Cabergoline|Quantitative Analysis of All Somatostatin Receptors and Dopamine Receptor Subtype 2 mRNA and Protein Expression Study in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist||Universidade Federal do Rio de Janeiro|No|Recruiting|March 2010|June 2012|Anticipated|June 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|September 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01620138||84307|
NCT01620437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1581|Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects|A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Testing the Bioequivalence of Two Formulations of NN-X14Mix50 in Healthy Japanese Subjects||Novo Nordisk A/S|No|Completed|November 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620437||84284|
NCT01620983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1UM1AR062800-01|Knee Arthroplasty Pain Coping Skills Training (KASTPain): A Randomized Trial|Knee Arthroplasty Pain Coping Skills Training (KASTPain): A Randomized Trial|KASTPain|Virginia Commonwealth University|Yes|Recruiting|December 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|402|||Both|45 Years|N/A|No|||December 2015|December 4, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620983||84243|
NCT01629550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00090-43|Prospective Randomized Controlled Multicenter Trial of 4 Antiseptic Strategies for Prevention of Catheter Infection in Intensive Care Unit for Adults Patients||CLEAN|Poitiers University Hospital||Completed|October 2012|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4|||2400|||Both|18 Years|N/A|No|||March 2014|March 7, 2014|June 20, 2012||||No||https://clinicaltrials.gov/show/NCT01629550||83587|
NCT01629823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALA-ACRC-13|Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)|Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma|CPAP|American Lung Association Asthma Clinical Research Centers|Yes|Active, not recruiting|July 2012|||October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|200|||Both|15 Years|60 Years|No|||August 2015|August 17, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629823||83566|
NCT01629836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-0005|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2012|||||N/A|N/A|N/A||||||||||||||May 5, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01629836||83565|
NCT01630408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVID-LAVI|The Effects of Active VItamin D on Left Atrial Volume Index|A Pilot Study of the Effects of Active VItamin D on Left Atrial Volume Index in Patients With Heart Failure and Preserved Ejection Fraction|AVID-LAVI|Massachusetts General Hospital|No|Withdrawn|March 2014|June 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 15, 2013|June 26, 2012||No|Investigator decided not to pursue.|No||https://clinicaltrials.gov/show/NCT01630408||83521|
NCT01630395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_recruitment maneuver|The Effect of Recruitment Maneuver With Protective Ventilation During Thoracic Surgery|The Effect of Recruitment Maneuver With Protective Ventilation on the Pulmonary and Systemic Inflammatory Response to One-lung Ventilation||Seoul National University Hospital||Recruiting|June 2012|August 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|60|||Both|20 Years|80 Years|No|||June 2012|June 26, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01630395||83522|
NCT01630720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-041|Vitamin Therapy in JGH Patients|Vitamin Therapy in JGH Patients||Jewish General Hospital|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|June 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01630720||83497|
NCT01631032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMRPD1B0081|Effect of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis|Phase 3 Study of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis||Chang Gung Memorial Hospital|Yes|Completed|July 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|112|||Both|20 Years|50 Years|No|||August 2015|August 5, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01631032||83473|
NCT01631279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR610-1001|A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors|A Phase I/II, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR610 Given Weekly in Subjects With Solid Tumors||Proacta, Incorporated|No|Terminated|August 2012|August 2015|Anticipated|March 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|N/A|No|||June 2014|June 13, 2014|June 7, 2012|Yes|Yes|Study was prematurely discontinued due to unacceptable toxicity.|No||https://clinicaltrials.gov/show/NCT01631279||83454|
NCT01630642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-043|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Clopidogrel Tablets Under Fasting Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Single-Dose Bioequivalence Study of Clopidogrel Tablets USP 75mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Plavix® (Clopidogrel Bisulfate Tablets) 75mg [Reference Formulation, Bristol-Myers Squibb/Sanofi Pharmaceuticals, USA], in Healthy Human Volunteers Under Fasting Condition.||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630642||83503|
NCT01630993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HU0708-113M|Milking the Umbilical Cord at Term Cesarean Birth|Milking the Umbilical Cord at Term Cesarean Birth: Effect on Hemoglobin Levels in the First 48 Hours of Life||University of Rhode Island|Yes|Completed|May 2008|December 2009|Actual|April 2009|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Female|18 Years|44 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630993||83476|
NCT01631240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-10|NHANES Urinary Sodium Calibration Study|National Health and Nutrition Examination Survey (NHANES), Urinary Sodium Calibration Study||Centers for Disease Control and Prevention|No|Completed|June 2011|August 2011|Actual|August 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|441|Samples Without DNA|urine specimens|Both|18 Years|39 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will be conducted with 400 adult volunteer participants living in the Washington        DC, Maryland areas. who meet the following criteria:|June 2012|June 27, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01631240||83457|
NCT01621646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly|The Effect of Consumption of 2 Eggs or 4 oz of Egg Substitute Daily for 6 Months on Cognitive Function in Older Adults.||Tufts University|No|Recruiting|July 2012|August 2014|Anticipated|July 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 3, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01621646||84192|
NCT01621932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101105A|Anterior Capsulectomy vs. Repair in Direct Anterior THA|Anterior Capsulectomy vs. Repair in Direct Anterior THA||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|March 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621932||84170|
NCT01621945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/198/HP|Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)|Phase 3, Vaccinal Activity Assessment of MenBVac Against Neisseria Meningitidis B:14,P1.7,16 Strain in Child|Exten Effivac|University Hospital, Rouen|No|Completed|April 2012|September 2013|Actual|April 2013|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|4 Years|8 Years|Accepts Healthy Volunteers|Probability Sample|Children aged 4 to 8 years old and living in neufchatel en bray area|September 2014|September 5, 2014|March 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01621945||84169|
NCT01618175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOR0013-12CTIL|Home Oxygen Treatment of Childhood Acute Bronchiolitis|||Soroka University Medical Center||Not yet recruiting|October 2012|August 2014|Anticipated|June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|85|||Both|2 Months|24 Months|No|||May 2012|June 12, 2012|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01618175||84458|
NCT01618188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1218-3978|A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes||Novo Nordisk A/S|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|52|||Both|18 Years|64 Years|No|||February 2015|February 20, 2015|June 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01618188||84457|
NCT01619592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/321|Web-based Education for Diabetes Patients on Adaptable Insulin Schedules|The Belgian Quality of Life and Costs Study on Web-based Education for Diabetes Patients on Adaptable Insulin Schedules|Telediabetes|University Hospital, Ghent|No|Recruiting|June 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619592||84349|
NCT01619605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|669/2551(EC4)|The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis|The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis||Mahidol University|Yes|Completed|June 2006|June 2008|Actual|May 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||June 2012|June 14, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619605||84348|
NCT01619631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001313|Tai Chi Intervention for Chinese Americans With Depression|Tai Chi Intervention for Chinese Americans With Depression||Massachusetts General Hospital|Yes|Active, not recruiting|February 2012|||June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|80 Years|No|||April 2015|April 21, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619631||84346|
NCT01619280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0102-A|Safety Study of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury|A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury||Mount Sinai Hospital, Canada|No|Recruiting|May 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01619280||84373|
NCT01619566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111654|Cymbalta for Fibromyalgia Pain|Duloxetine (Cymbalta): for Fibromyalgia: An Open Label Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therpeutic Responsiveness to Duloxetine.||University of California, San Diego|Yes|Recruiting|June 2012|||||Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619566||84351|
NCT01620463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1326|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers|A Randomised, Double-blind, Single-centre, Placebo-controlled, Ascending Single s.c. Dose, Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 90-1170 in Healthy Japanese Male Subjects||Novo Nordisk A/S|No|Completed|December 2002|March 2003|Actual|March 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620463||84282|
NCT01620697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAT-40-GVA|Visceral Obesity and Colorectal Surgery|Value of Perirenal Fat Surface as a Risk Factor for Morbidity After Elective Colorectal Surgery||University Hospital, Geneva||Completed|January 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|224|||Both|18 Years|N/A|No|Non-Probability Sample|We included all elective colorectal resections for benign, malignant and inflammatory        diseases, admitted to the Geneva university hospital, Geneva, Switzerland|June 2012|June 15, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620697||84264|
NCT01620476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1551|Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers|A Randomised, Double-blind, Single-centre, Placebo-controlled, 21-day Multiple s.c. Doses, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide (NNC 90-1170) in Healthy Japanese Male Subjects||Novo Nordisk A/S|No|Completed|September 2003|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620476||84281|
NCT01620710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRIAMOS|Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes|Hypofractionated Helical Intensity-Modulated Radiotherapy of the Prostate Bed After Prostatectomy With or Without the Pelvic Lymph Nodes - the PRIAMOS Trial|PRIAMOS|Heidelberg University|No|Active, not recruiting|February 2012|September 2017|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Male|18 Years|80 Years|No|||December 2014|December 5, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620710||84263|
NCT01620996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-2005-267|A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR)|A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR): A Primary Prevention Initiative Examining The Impact Of Global Risk Factor Assessment & Management On Health Care In Nova Scotia|ANCHOR|Nova Scotia Health Authority|Yes|Completed|March 2006|September 2010|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1708|||Both|30 Years|N/A|Accepts Healthy Volunteers|||June 2008|June 14, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620996||84242|
NCT01621009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998-369|Bupropion SR Plus Counseling for Smoking Cessation|A Randomized Controlled Clinical Trial of Bupropion SR and Individual Smoking Cessation Counseling||University of Wisconsin, Madison|No|Completed|January 2001|October 2003|Actual|October 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|463|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 16, 2015|June 13, 2012|Yes|Yes||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01621009||84241|Lack of a no-treatment control condition; limited ability to generalize to broader population
NCT01630759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0016|Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study|Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study for a Randomised Controlled Trial|Tele-Mum|University of Ulster|Yes|Completed|January 2012|May 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Female|N/A|N/A|No|||January 2014|January 24, 2014|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01630759||83494|
NCT01630733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TV1011-LC-303|A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer|A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer||OncoGenex Technologies|Yes|Recruiting|September 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630733||83496|
NCT01630746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-438/OCT-002|A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis|||Takeda||Completed|July 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Primary Purpose: Treatment|2||Actual|19|||Both|20 Years|N/A|No|||February 2014|February 7, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630746||83495|
NCT01631305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPS-01|Levothyroxine for Children With Euthyroid Sick Syndrome|Efficacy and Safety of Levothyroxine in Critical Children With Euthyroid Sick Syndrome in a Pediatric Intensive Care Unit.||Sinaloa Pediatric Hospital|No|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|1 Month|17 Years|No|||March 2014|March 4, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01631305||83452|
NCT01631318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP0043|3D Dynamic Contrast-Enhanced Ultrasound Imaging in Predicting Treatment Response in Patients With Liver Metastases From Colon Cancer|Pilot Feasibility Study on 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Patients With Liver Metastases||Stanford University||Recruiting|November 2012|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01631318||83451|
NCT01631006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDC 325209/003|Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy|Acute Hemodynamic Effects of Continous Positive Airway Pressure (CPAP) in Patients With Hypertrophic Cardiomyopathy|CPAPandHCM|University of Sao Paulo|Yes|Completed|January 2012|April 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|65 Years|No|||December 2014|December 18, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01631006||83475|
NCT01631266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESEC-06|Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI|A Phase III Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI||Statens Serum Institut|Yes|Completed|July 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|979|||Both|6 Weeks|65 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01631266||83455|
NCT01621659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TITAN 102|Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study)|Multidisciplinary Team IntervenTion in CArdio-ONcology|TITAN|University of Alberta|No|Recruiting|May 2014|May 2018|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|282|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01621659||84191|
NCT01621672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110468|UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma|Myeloma Cure Project: Prospective, Randomized Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Who Have Completed 3 Years of VTD/TD or VTD or VRD Maintenance on Total Therapy 3 (TT3) Trials 2003-33 and 2006-66||University of Arkansas|Yes|Completed|April 2010|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||September 2015|September 29, 2015|May 31, 2012|Yes|Yes||No|August 12, 2015|https://clinicaltrials.gov/show/NCT01621672||84190|
NCT01622322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/1539|Effect Nitrous Oxide On Acute Postoperative Pain and Opioid Consumption and Chronic Pain After Inguinal Hernia Repair Surgery|||The Cleveland Clinic|No|Recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|65 Years|No|||February 2015|February 12, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622322||84140|
NCT01618500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-47-31M|Computerised Testing of Cognitive Response to Cerebrospinal Fluid Shunting in Idiopathic Normal Pressure Hydrocephalus|Computerised Testing of Cognitive Response to Cerebrospinal Fluid Shunting in Idiopathic Normal Pressure Hydrocephalus||Umeå University|No|Recruiting|January 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|60 Years|N/A|No|Non-Probability Sample|Eighty INPH-patients. Consecutively included.|June 2012|June 11, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618500||84433|
NCT01618773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELANG|Long-term Study of Epiduo in Patients With Moderate to Severe Acne|Epiduo in the Long-term Treatment of Moderate to Severe Acne With or Without Concomitant Medication|ELANG|Galderma Laboratorium GmbH|Yes|Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6036|||Both|N/A|N/A|No|Probability Sample|About 6,650 patients with moderate to severe acne (Leeds grade 4-12)|February 2016|February 15, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01618773||84412|
NCT01619059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-168|Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin||AstraZeneca|No|Completed|June 2012|January 2015|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|317|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|June 12, 2012|Yes|Yes||No|February 18, 2016|https://clinicaltrials.gov/show/NCT01619059||84390|
NCT01619072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3001|Misoprostol for Treatment of Postpartum Hemorrhage at Community-level Births in Egypt|A Randomized Controlled Community Study of the Effectiveness of Misoprostol for PPH Treatment at the Community Level (Home Births Attended by Primary Care Unit Staff) in Etay El Barood and Kafr El Dawar Districts (El Beheira Governorate), Egypt||Gynuity Health Projects|Yes|Completed|November 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 21, 2013|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619072||84389|
NCT01619943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Head injury|The Value of the Canadian CT Head Rule and the New Orleans Criteria in Minor Head Trauma|Prediction Value of the Canadian CT Head Rule and the New Orleans Criteria for Positive Head CT Scan and Acute Neurosurgical Procedures in Minor Head Trauma: a Multicenter External Validation Study||University of Monastir|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1600|||Both|10 Years|N/A|No|Probability Sample|Patients with MHI defined as a blunt trauma to the head within 24 hours with a Glasgow        Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of        consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic        seizure, vomiting, headache, external evidence of injury above the clavicles, confusion,        and neurologic deficit.|June 2012|June 13, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619943||84322|
NCT01620151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTECS001|Open Thyroid Surgery With Pillow Versus no Pillow for Better Post-operative Outcomes|A Randomized Controlled Trial Comparing Post-operative Pain & Outcomes of Open Thyroidectomy; Extended Neck vs No Extended Neck||The University of Hong Kong|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||December 2013|December 18, 2013|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01620151||84306|
NCT01620164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1015102|Assessment of Three-dimensional Vision Alteration in Parkinson Disease|Assessment of Three-dimensional Vision Alteration in Parkinson Disease.|3Dparks|University Hospital, Toulouse|No|Completed|November 2011|June 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|36|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||June 2014|June 11, 2014|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01620164||84305|
NCT01620489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3916|Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment|Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial||Novo Nordisk A/S|No|Completed|June 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|80 Years|No|||October 2014|October 23, 2014|June 13, 2012|Yes|Yes||No|August 20, 2014|https://clinicaltrials.gov/show/NCT01620489||84280|
NCT01620723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7111442|Evaluation of Breastfeeding Support After Short Time Hospitalization|Effect Evaluation of a Theory and Evidence Based Programme for Establishing Effective Breastfeeding After Short Time Hospitalization Post Partum||Danish Committee for Health Education|No|Active, not recruiting|May 2013|December 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|1500|||Female|N/A|N/A|No|||February 2015|February 9, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01620723||84262|
NCT01620736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WashU201109171|Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load|Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load||Washington University School of Medicine|Yes|Active, not recruiting|January 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620736||84261|
NCT01621308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPvsSC|Intraperitoneal vs Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus|Intraperitoneal Insulin Administration as Alternative for Intensive Subcutaneous Insulin Therapy in Patients With Type 1 Diabetes Mellitus.|IPvsSC|Medical Research Foundation, The Netherlands|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|190|||Both|18 Years|N/A|No|Non-Probability Sample|The study sample consists of the subjects on CIPII, who participated in the crossover        study performed by Logtenberg et al. (Diabetes Care 32:1372-1377, 2009) or subjects who        already used CIPII at that moment (so, for a minimum of 4 years), and matched controls on        SC insulin treatment .        The inclusion and exclusion criteria of the previous study are described in detail in        (Diabetes Care 32:1372-1377, 2009). In brief, it consisted of patients with T1DM, low        fasting c-peptide concentrations (<0.20 nmol/L), aged 18 to 70 years, treated with MDI or        CSII and intermediate or poor glycaemic control; defined as glycated haemoglobin (HbA1c)        ≥7.5% (58 mmol/mol) and/or ≥5 incidents of hypoglycaemia (< 4.0mmol/L) per week.        If subjects are on SC insulin, they must be able to 'function' as matched control for        CIPII patients. The matching procedure, based on age and gender, will take place after        patients are being included in the current study.|March 2014|March 18, 2014|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621308||84218|
NCT01630109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRMC120006|Study of Metoclopramide in Small Bowel Capsule Endoscopy|Metoclopramide As An Adjunct To Small Bowel Capsule Endoscopy: Rate of Complete Evaluation And Affect on Transit Times||Genesys Regional Medical Center||Completed|December 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|5|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|June 26, 2012||No||No|August 23, 2013|https://clinicaltrials.gov/show/NCT01630109||83544|The main limitation of this study was that there was a lower number of capsule studies performed at the study center than anticipated so it was difficult to find patients to enroll.
NCT01630421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHC03-008ACC|Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)|Identification of Mutations That Lead to Aplasia Cutis Congenita in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms|ACC|University of Connecticut Health Center|No|Recruiting|April 2009|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Saliva, blood, bone tissue, skin|Both|N/A|N/A|No|Non-Probability Sample|Individuals with diagnosed ACC|December 2015|December 2, 2015|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01630421||83520|
NCT01630772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6500|Physical Therapy in Pregnant Women With Preeclampsia|Influence of a Physical Therapy Protocol in Maternal and Fetal Hemodynamics in Pregnant Women With Preeclampsia|FPE|University of Sao Paulo|No|Recruiting|June 2012|February 2013|Anticipated|January 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Anticipated|60|||Female|N/A|N/A|No|||June 2012|June 27, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01630772||83493|
NCT01630785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|121|Observation of Neurosurgical Interventions With Intraoperative Neurophysiological Monitoring IONM|Observation of Neurosurgical Interventions With Intraoperative Neurophysiological Monitoring IONM||University of Zurich||Enrolling by invitation|January 2012|December 2023|Anticipated|December 2022|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|All patients whose surgery involved intraoperative neurophysiological monitoring|December 2014|December 19, 2014|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01630785||83492|
NCT01631045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38022|The Effect of a Meal on Brain Activation in Reward Pathways|The Effect of a Meal on Brain Activation in Reward Pathways|Satiety|University of Washington|Yes|Completed|April 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||7|Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|We will enroll 21 healthy subjects. Participants will be recruited by flyers posted at the        University and by newspaper advertisements.|July 2013|July 2, 2013|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01631045||83472|
NCT01627002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA401/01|A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401|A Phase 1, FIH, Double-blind, Randomised Placebo-controlled Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of PA401, and the Effects of PA401 Following LPS Challenge, in Healthy Subjects||ProtAffin Biotechnologie AG|No|Terminated|May 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|June 12, 2012||No||No|July 18, 2013|https://clinicaltrials.gov/show/NCT01627002||83783|Part B of the study was terminated early which led to a small number of subjects analyzed. Pharmacokinetic parameters were not calculated for Part A 0.3mg and 10 mg PA401
NCT01627015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114-12|Safety, Acceptance and Metabolic Effects in Infants Receiving a Novel Low Glycaemic Index follow-on Formula|Safety, Acceptance and Metabolic Effects in Infants Receiving a Novel Low Glycaemic Index follow-on Formula||Ludwig-Maximilians - University of Munich|No|Completed|June 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|50|||Both|4 Months|6 Months|Accepts Healthy Volunteers|||March 2015|March 6, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627015||83782|
NCT01631019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|95-1401B|Mobile-phone-based Home Exercise in Chronic Obstructive Pulmonary Disease|Influence of Long-term Cell-phone Based Home Exercise on Biomarkers, Skeletal Muscle and Mortality in Patients With COPD||Chang Gung Memorial Hospital|Yes|Completed|January 2007|May 2009|Actual|December 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|26|||Both|40 Years|80 Years|No|||June 2012|July 4, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01631019||83474|
NCT01631292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBGP201095157|Vitamin D Supplementation in Obesity and Weight Loss (3DD Study)|A Pilot Dose Response Study to Vitamin D in Obesity and Weight Loss: Effect on Bone||Rutgers University|No|Recruiting|January 2010|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research|3||Anticipated|48|||Female|50 Years|72 Years|Accepts Healthy Volunteers|||June 2012|July 12, 2014|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01631292||83453|
NCT01626976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5211001|A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single Dose Escalating Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects||Pfizer|No|Completed|June 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 12, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01626976||83785|
NCT01621958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-02052|Motor Training for Fall Prevention|Motor Training for Fall Prevention: Adaptation and Retention in Older Adults||University of Illinois at Chicago|No|Completed|September 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|212|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 24, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01621958||84168|
NCT01622309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|062/10-CEP|Effect of Balanced Hypocaloric Diet Associated With Supplementation of Eggplant Meal in the Remission of Cardiovascular Risk Factors|Effect of Balanced Hypocaloric Diet Associated With Supplementation of Eggplant Meal in the Remission of Cardiovascular Risk Factors||Universidade Federal do Rio de Janeiro|No|Completed|March 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|363|||Both|20 Years|N/A|No|||December 2014|December 2, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01622309||84141|
NCT01618786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPS-001|Flooring for Injury Prevention Trial|Randomized Controlled Trial of Compliant Flooring to Reduce Injuries Due to Falls in Older Adults in a Long-Term Care Facility|FLIP|Simon Fraser University|Yes|Active, not recruiting|September 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|151|||Both|N/A|N/A|No|||January 2015|January 8, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618786||84411|
NCT01619293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wolf-5|The Neuromarker S-100B in Patients With Different Types of Intracranial Injury|The Neuromarker S-100B in Patients With Subarachnoidal, Epidural, Subdural, and Intracerebral Hematoma, Edema Cerebri, and Concussion||Medical University of Vienna|No|Completed|May 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|1800|Samples Without DNA|7ml of blood drawed from peripheral vein|Both|18 Years|N/A|No|Non-Probability Sample|Patients from Level 1 trauma center|November 2013|November 20, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01619293||84372|
NCT01619319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cognitive Remediation in CHR|Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis|Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis||University of Calgary|Yes|Completed|July 2010|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|32|||Both|12 Years|35 Years|No|||September 2014|September 3, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619319||84370|
NCT01619956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|663-2009|Osteotome Sinus Floor Elevation With or Without Grafting|Osteotome Sinus Floor Elevation With or Without Grafting: a Randomized Controlled Study||Shanghai 9th People's Hospital|Yes|Completed|January 2010|March 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|June 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01619956||84321|
NCT01620203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120065|Observational Study in Preterm Infants With Intracranial Hemorrhage|Observational Study in Preterm Infants With and Without Intracranial Hemorrhage: Longitudinal Assessment of Cerebral Oxygenation, Perfusion and Function||University of Miami|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|40|||Both|N/A|7 Days|No|Non-Probability Sample|Preterm infants admitted to the newborn intensive care unit at Holtz Children's Hospital        of the Jackson Memorial Hospital/University of Miami Medical Center.|November 2015|November 18, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01620203||84302|
NCT01619917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2011: 075|The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars|The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars||University of Manitoba|No|Recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|60 Years|No|||November 2015|November 30, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619917||84324|
NCT01620177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109850|Effects of Inhaled Cannabis on Driving Performance|Effects of Inhaled Cannabis on Driving Performance||University of Iowa|Yes|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|6||Actual|99|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|June 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620177||84304|
NCT01620502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC98-2628-B-039-020-MY3|N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression|N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression||National Science Council, Taiwan|Yes|Completed|July 2009|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|230|||Both|18 Years|75 Years|No|||October 2013|October 26, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620502||84279|
NCT01621035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7732|Objective Assessment of Physical Activity in Older Adults|||Universitaire Ziekenhuizen Leuven||Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|70 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Older adults (> 70 years)|June 2012|June 26, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01621035||84239|
NCT01621048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s54403|Evaluation of Treatment Related Toxicity After Radiotherapy for Head and Neck Cancer|Evaluation of Treatment Related Toxicity After Radiotherapy for Head and Neck Cancer and Correlation With Dose to Organs at Risk||Universitaire Ziekenhuizen Leuven|No|Recruiting|June 2012|||December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|Patients treated with primary (chemo-)radiotherapy for head and neck squamous cell        carcinoma up to 70-72 Gy.|March 2013|March 11, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01621048||84238|
NCT01621321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABPA/003|Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis|A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis||Postgraduate Institute of Medical Education and Research|Yes|Active, not recruiting|June 2013|April 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|15 Years|65 Years|No|||October 2015|October 21, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01621321||84217|
NCT01630434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCS-LUN-03-2010|International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation|Prospective, International, Multi-Center, Randomized Clinical Investigation of TransMedics Organ Care System (OCS LUNG) for Lung Preservation and Transplantation|INSPIRE|TransMedics|Yes|Completed|November 2011|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630434||83519|
NCT01630837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHB0186.0.243.000-10|Frequency of Oral Hygiene|Frequency of Oral Hygiene in the Maintenance of Gingival Health||Universidade Federal de Santa Maria|Yes|Completed|May 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|4||Actual|52|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630837||83488|
NCT01631331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKIN0012|Vismodegib in Treating Patients With Basal Cell Carcinoma|A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCC)||Stanford University|Yes|Active, not recruiting|June 2012|November 2017|Anticipated|November 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01631331||83450|
NCT01631344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008036|Effectiveness of Lifestyle Counseling Versus Physical Therapy on Chronic Low Back Pain|Intervention Study to Examine the Effectiveness of Lifestyle Counseling Using the "Stage of Change" Model Versus Conventional Physical Therapy on Chronic Low Back Pain||Assuta Hospital Systems|No|Active, not recruiting|February 2011|July 2017|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|25 Years|55 Years|No|||July 2015|July 21, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01631344||83449|
NCT01631357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-RXB-201205001|Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer|Phase II/III Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy in Stage IIIb-IV Squamous Non-Small-Cell Lung Cancer|CIK|Tianjin Medical University Cancer Institute and Hospital|Yes|Not yet recruiting|November 2016|December 2016|Anticipated|November 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|200|||Both|18 Years|80 Years|No|||February 2013|December 21, 2015|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631357||83448|
NCT01627028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ID 10-53-28|Thai Traditional Massage Increases Biochemical Marker of Bone Formation in Postmenopausal Women|Thai Traditional Massage Increases Biochemical Marker of Bone Formation in Postmenopausal Women: a Randomized Crossover Trial||Mahidol University|No|Completed|March 2011|March 2012|Actual|March 2011|Actual|Phase 3|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|48|||Female|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|community sampling|June 2012|June 21, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627028||83781|
NCT01627041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01959|Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia|Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)||National Cancer Institute (NCI)||Active, not recruiting|September 2011|||October 2022|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|65 Years|No|||February 2016|March 11, 2016|June 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627041||83780|
NCT01626989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ST-1007-ASV4-MS|Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders|Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With||Philips Respironics|No|Completed|June 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|21 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|May 19, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626989||83784|
NCT01627314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT1050-03|The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.|A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.||Fate Therapeutics|Yes|Recruiting|July 2012|December 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|65 Years|No|||October 2015|October 23, 2015|June 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627314||83759|
NCT01627327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115805|Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease|A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease||GlaxoSmithKline|No|Completed|April 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|623|||Both|40 Years|N/A|No|||December 2013|December 5, 2013|June 21, 2012|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01627327||83758|
NCT01622348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3100-202|Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis||Idera Pharmaceuticals, Inc.|Yes|Completed|May 2012|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|44|||Both|18 Years|70 Years|No|||March 2013|March 26, 2013|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01622348||84138|
NCT01618201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-AM-521-CTIL|Inflammatory Markers Identification in Migraine Patients|Inflammatory Markers Identification in Migraine Patients||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|The patient group will consist of 150 subjects with various headache types treated at the        headache clinic at the Sourasky Medical Center, Tel-Aviv, ISRAEL, and 50 healthy controls.|September 2009|June 12, 2012|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01618201||84456|
NCT01618526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V02062012|ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome|ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome||University of Aarhus|Yes|Completed|April 2012|May 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|22|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||August 2013|May 28, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01618526||84431|
NCT01618799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/BA/1264033|Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Lamotrigine Tablets 25 mg (2 × 25 mg Tablets) and 'LAMICTAL®' (Lamotrigine) Tablets 25 mg (2 × 25 mg Tablets) in Healthy Adult Human Subjects Under Fasting Conditions.||IPCA Laboratories Ltd.|Yes|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|June 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618799||84410|
NCT01618812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090162|Calcaneal Neck Lengthening Osteotomy in Children With Artificial Bone Graft|Calcaneal Neck Lengthening Osteotomy - Allogen Bone Graft Material Versus a Hydroxyapatite / β- Tricalcium Phosphate Bone Substitute||University of Aarhus|No|Active, not recruiting|September 2010|April 2013|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|10|||Both|8 Years|20 Years|No|Non-Probability Sample|• children with planovalgus deformity referred to Dept. of Children's Orthopaedics, Dept        of Orthopaedic Surgery E, Aarhus University Hospital from June 2009 until January 2012.|June 2012|June 12, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618812||84409|
NCT01619644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/20|Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial|Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial|RUBIVAL|University Hospital, Bordeaux|Yes|Completed|April 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|6 Years|21 Years|No|||March 2015|March 17, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619644||84345|
NCT01619969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/025/E|Celgosivir as a Treatment Against Dengue|Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever|CELADEN|Singapore General Hospital|Yes|Completed|July 2012|July 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|21 Years|60 Years|No|||November 2013|November 28, 2013|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01619969||84320|
NCT01619930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAS-FYS|The Effects of Behavioral Activation and Physical Exercise on Depression|The Effects on Depression of Internet-administered Behavioural Activation and Physical Exercise With Relapse Prevention, Motivational Interviewing and Treatment Rationale||Umeå University|No|Not yet recruiting|August 2012|May 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|9||Anticipated|500|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619930||84323|
NCT01620515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NX03-0040|Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer|Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer||Nymox Corporation|Yes|Active, not recruiting|June 2012|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Male|45 Years|85 Years|No|||April 2014|April 1, 2014|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620515||84278|
NCT01620749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/11|Of 18F MEL050 Using PET/CT in Metastatic Melanoma|A Phase 0 Exploratory Microdosing Study of 6-18fluoro-N-[2-(Diethylamino)Ethyl]Pyridine-3-carboxamide (18F MEL050) Using PET/CT in Patients With Metastatic Melanoma|MEL050|Cooperative Research Centre for Biomedical Imaging Development|Yes|Active, not recruiting|June 2010|December 2012|Anticipated|March 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Both|18 Years|N/A|No|||June 2012|June 14, 2012|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01620749||84260|
NCT01621022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB S-01-07|Bupropion Alone or Combined With Nicotine Gum|Efficacy of Bupropion Alone and in Combination With Nicotine Gum||University of Wisconsin, Madison|Yes|Completed|January 2001|October 2002|Actual|October 2002|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|608|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|September 30, 2015|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621022||84240|
NCT01621061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-7/219|Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders|Sleep Apnea and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders||University of Zurich|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|125|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Highlanders with high altitude pumonary hypertension living at an altitude of 2500-4000 m;        healthy highlanders living at an altitude of 2500-4000 m; healthy lowlanders living at an        altitude of <1000 m.|May 2014|May 14, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01621061||84237|
NCT01621334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37863-C|The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use|Stage 1B Study Motivating Substance Abusing Batterers to Seek Treatment.|MDACU|University of Washington|No|Completed|September 2009|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 13, 2012|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01621334||84216|
NCT01630447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCHC03-008CBM|Genetic and Functional Analysis of Cherubism|Identification of Mutations That Lead to Cherubism in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms|CBM|University of Connecticut Health Center|No|Recruiting|April 2009|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|600|Samples With DNA|Saliva, blood, bone tissue|Both|N/A|N/A|No|Non-Probability Sample|Individuals with clinically diagnosed cherubism|December 2015|December 2, 2015|June 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01630447||83518|
NCT01627067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1239|Exemestane-RAD001-Metformin|Circulating FGF21 Levels and Efficacy of Exemestane, Everolimus and Metformin in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer and BMI >/= 25||M.D. Anderson Cancer Center|No|Active, not recruiting|September 2012|||September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|June 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627067||83778|
NCT01627340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115918|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus|An Open-label Study to Assess the Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix™-B (103860) in Adults With or Without Type 2 Diabetes Mellitus||GlaxoSmithKline||Completed|July 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|667|||Both|20 Years|N/A|Accepts Healthy Volunteers|||December 2014|January 5, 2015|June 21, 2012|Yes|Yes||No|December 15, 2014|https://clinicaltrials.gov/show/NCT01627340||83757|
NCT01627353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-23700|Post Hysterectomy Pain Prevention: Pre-op Wound Infiltration With Anesthetic Protocol Versus Standard of Care|Post Hysterectomy Pain Prevention: Randomized Clinical Trial of High Volume Preoperative Wound Infiltration and Pain Specific Anesthetic Protocol Versus Standard of Care (no Wound Infiltration and Routine Anesthetic Protocol)||University of Calgary|No|Terminated|January 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|16|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|June 19, 2012||No|Funding withdrawn|No||https://clinicaltrials.gov/show/NCT01627353||83756|
NCT01627054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I193|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia||Canadian Cancer Trials Group|No|Completed|August 2012|February 2015|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Months|N/A|No|||February 2015|February 13, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627054||83779|
NCT01627600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAP-001-2012|Door-to-door Survey of Cardiovascular Health, Stroke and Ischemic Heart Disease in Atahualpa|The Atahualpa Project, a 3-phase Epidemiologic Survey|TAP|Hospital Clínica Kennedy|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|Phase 1|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|642|||Both|40 Years|N/A|Accepts Healthy Volunteers|Probability Sample|CVH status will be evaluated in all Atahualpa residents aged ≥ 40 years who did not have        history of stroke or ischemic heart disease.        Certified neurologists and cardiologists will evaluate all individuals who screened as        suspected cases of stroke and ischemic heart disease during Phase I of the study, as well        as a 2% sample of age- and gender-matched negative individuals.        All patients with diagnosis of stroke and ischemic heart disease will be invited to        undergo complementary exams to achieve more specific diagnosis.|October 2012|October 2, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01627600||83737|
NCT01618214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-3984|Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes|A 20-week, Randomised, Open-label, 2-armed, Parallel Group Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes Inadequately Controlled With Premixed Human Insulin||Novo Nordisk A/S|No|Completed|June 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|344|||Both|18 Years|65 Years|No|||April 2014|April 7, 2014|June 11, 2012|Yes|Yes||No|January 30, 2014|https://clinicaltrials.gov/show/NCT01618214||84455|
NCT01618513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOM-2012-01|Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target|Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target||University of Aarhus|No|Active, not recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|75|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618513||84432|
NCT01618825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/BA/1264034|Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Lamotrigine Tablets 25 mg (2 × 25 mg Tablets) and 'LAMICTAL®' (Lamotrigine) Tablets 25 mg (2 × 25 mg Tablets) in Healthy Adult Human Subjects Under Fed Conditions.||IPCA Laboratories Ltd.|Yes|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|June 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618825||84408|
NCT01619098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS020628|Evaluating Sequential Strategies to Reduce Readmission in a Diverse Population|Evaluating Sequential Strategies to Reduce Readmission in a Diverse Population||Harvard Pilgrim Health Care|No|Completed|October 2011|November 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|1510|||Both|18 Years|N/A|No|||January 2014|January 21, 2014|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01619098||84387|
NCT01619085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.33|Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis|An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Boehringer Ingelheim||Active, not recruiting|June 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|759|||Both|40 Years|N/A|No|||January 2016|January 12, 2016|June 6, 2012||||No||https://clinicaltrials.gov/show/NCT01619085||84388|
NCT01619670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 235/11|A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa|A Prospective Single Center Within Subject Controlled Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa||University Hospital, Basel, Switzerland|No|Terminated|June 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|2 Years|65 Years|No|||March 2015|March 9, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619670||84343|
NCT01620255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7281009|A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis|A Double-blind, Randomized, Placebo-controlled, Parallel, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Moderate To Severe Ulcerative Colitis (Turandot)|TURANDOT|Pfizer|Yes|Active, not recruiting|November 2012|January 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Anticipated|300|||Both|18 Years|65 Years|No|||November 2015|November 5, 2015|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620255||84298|
NCT01620268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CK2012-001|An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria|An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection||Changzheng-Cinkate|Yes|Recruiting|July 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|N/A|75 Years|No|||May 2015|May 20, 2015|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620268||84297|
NCT01620190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7755|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer|A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors||University of Washington|No|Recruiting|November 2012|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620190||84303|
NCT01620216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7195|Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients|A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies.||OHSU Knight Cancer Institute|Yes|Recruiting|June 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|21 Years|70 Years|No|||October 2015|October 14, 2015|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620216||84301|
NCT01620528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-665|A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain||AbbVie|Yes|Completed|May 2012|September 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|872|||Female|18 Years|49 Years|No|||November 2015|November 13, 2015|May 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620528||84277|
NCT01620762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP007|Phase III Cat-PAD Study|A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects||Circassia Limited|Yes|Active, not recruiting|October 2012|||April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1182|||Both|12 Years|65 Years|No|||March 2016|March 22, 2016|May 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620762||84259|
NCT01621347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/12|Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women|Retrospective Study: Evaluation of Antiretroviral Adherence During Pregnancy and Postpartum Using Electronic Monitoring Data||Policlinique Médicale Universitaire|No|Completed|March 2012|September 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|26|||Female|18 Years|N/A|No|Non-Probability Sample|Pregnant and Postpartum Women enrolledin the HIV adherence program at the pharmacy of        Department of Ambulatory Care and Community Medicine in Lausanne|December 2015|December 21, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01621347||84215|
NCT01621854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-001|NUC-1031 in Patients With Advanced Solid Tumours|A Two-part, Phase I Open Label Dose-escalation Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-1031, a Nucleotide Analogue, in Patients With Advanced Solid Tumours.|ProGem1|Imperial College London|Yes|Completed|October 2012|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|68|||Both|18 Years|N/A|No|||August 2015|August 26, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621854||84176|
NCT01630811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHKI-Nued0911|Nuedexta for the Treatment of Adults With Autism|Nuedexta for Neurobehavioral Symptoms of Adults With Autism Spectrum Disorder|Nuedexta|Sutter Health|Yes|Active, not recruiting|June 2012|January 2016|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|60 Years|No|||April 2015|April 2, 2015|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630811||83490|
NCT01631084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2012.199-T|Comparing the Effect of Structured Care Versus Usual Care in Type 2 Diabetes Patients Across the Asia Pacific Region|A Multicentre Randomized Program to Compare the Effect of the Joint Asia Diabetes Evaluation (JADE, Structured Care) Versus the DIAbetes MONitoring Database (DIAMOND, Usual Care) Programs in Type 2 Diabetes in the Asia Pacific Region|AP-JD|Asia Diabetes Foundation|Yes|Active, not recruiting|April 2012|December 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50000|||Both|18 Years|N/A|No|||June 2015|December 28, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631084||83469|
NCT01631097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-12-118|A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function|A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function||AVEO Pharmaceuticals, Inc.|No|Completed|May 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|44|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|June 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01631097||83468|
NCT01631058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26423|Renal Transplantation in the Elderly - nEverOld Study|Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study||University of Sao Paulo General Hospital|Yes|Recruiting|July 2012|June 2019|Anticipated|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|60 Years|N/A|No|||January 2013|December 3, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01631058||83471|
NCT01631071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADD-V-A003|Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2012/2013-Season Virosomal Subunit Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations||Crucell Holland BV|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|December 19, 2013|June 25, 2012||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01631071||83470|
NCT01627080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0004|Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation|Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation||M.D. Anderson Cancer Center|No|Withdrawn|April 2014|||April 2024|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood draws include troponin I, NT-proBNP, and BNP.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with histologically proven esophageal cancer to be treated with radiation therapy        with concurrent chemotherapy to a final dose of >/=40 Gy included in this study at UT MD        Anderson Cancer Center in Houston, Texas.|July 2014|July 25, 2014|June 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01627080||83777|
NCT01627366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA140481|Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors|Survivorship Plans and Outcomes in Underserved Breast Cancer Survivors RCT||University of California, Los Angeles|Yes|Completed|August 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|500|||Female|21 Years|N/A|No|||November 2015|November 30, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01627366||83755|
NCT01627379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POWER / AIO-STO-0309|Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer|An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer|POWER|AIO-Studien-gGmbH|Yes|Active, not recruiting|May 2012|September 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01627379||83754|
NCT01627613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP301-II-001|Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury|Proof of Concept Study in Male and Female Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury||Apeptico Forschung und Entwicklung GmbH|Yes|Completed|July 2012|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01627613||83736|
NCT01627626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-2011-0032|Effect of 0.1% Pilocarpine Mouthwash on Xerostomia|Effect of 0.1% Pilocarpine Mouthwash on Xerostomia : Double-blind, Randomized Controlled Trial||Yonsei University|No|Completed|August 2011|March 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|60|||Both|20 Years|N/A|No|||June 2012|June 21, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01627626||83735|
NCT01618240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001919A|Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients|Determining Predictors of Adequate Upper Airway Function in Long-term Ventilated Patients||Massachusetts General Hospital|Yes|Completed|January 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples With DNA|Whole Blood|Both|18 Years|N/A|No|Non-Probability Sample|Long term ventilated and tracheostomized patients in the Respiratory Acute and Surgical        Intensive Care Unit|May 2013|October 2, 2014|June 6, 2012||No||No|May 21, 2013|https://clinicaltrials.gov/show/NCT01618240||84453|
NCT01619111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETECT III|DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs|DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells|DETECT III|University of Ulm|Yes|Recruiting|February 2012|March 2018|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|N/A|No|||January 2015|January 7, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01619111||84386|
NCT01619332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEZ763X2201|Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Following Single and Multiple Ascending Doses in Healthy Subjects and Patients With Type 2 Diabetes||Novartis|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|220|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 2, 2014|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619332||84369|
NCT01619345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-3957|Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects|Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|June 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01619345||84368|
NCT01619358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/00058|Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma|||National University Hospital, Singapore|Yes|Recruiting|March 2012|||February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|21 Years|N/A|No|Probability Sample|Patients being treated with Multiple Myeloma at National University Hospital (Singapore)|December 2013|December 10, 2013|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01619358||84367|
NCT01619371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2614|Engorgement Study With a Double Electric Breast Pump|Engorgement Study With the Simplisse Double Electric Breast Pump||Foundation for Maternal Infant and Lactation Knowledge|Yes|Completed|March 2011|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|21|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|First 20 women arriving at the Newborn Care Center clinic in Reno, Nevada during their        first week postpartum seeking lactation management assistance for engorgement.|June 2012|June 13, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619371||84366|
NCT01619683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA-303|Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism|A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism||Repros Therapeutics Inc.|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|300|||Male|18 Years|60 Years|No|||September 2014|September 29, 2014|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619683||84342|
NCT01619696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0932103|Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas|Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas.||University Hospital, Toulouse|No|Terminated|March 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|3|||Both|18 Years|80 Years|No|||January 2013|January 22, 2013|June 12, 2012||No|Insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01619696||84341|
NCT01620281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBP-1|The Efficacy of the no!no!Back for Chronic Low Back Pain|The no!no!Back Continuous Passive Motion Device for the Treatment of Chronic Low Back Pain: A Randomized Controlled Pilot Study|LBP-1|Radiancy|No|Completed|June 2012|February 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|85 Years|No|||August 2013|August 4, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620281||84296|
NCT01620229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2560.00|Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies||Fred Hutchinson Cancer Research Center|Yes|Withdrawn|June 2013|||April 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|12 Years|75 Years|No|||April 2014|April 17, 2014|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620229||84300|
NCT01620242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC-0130/1106|A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes|A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.|ORL03|UNICANCER|Yes|Active, not recruiting|April 2012|April 2015|Anticipated|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01620242||84299|
NCT01620541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB223|Comparing Ankle Fusion to Ankle Replacement|Comparing Ankle Arthrodesis to Ankle Arthroplasty||Seattle Institute for Biomedical and Clinical Research|Yes|Active, not recruiting|May 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|516|||Both|21 Years|89 Years|No|Non-Probability Sample|Subjects are recruited from surgical foot and ankle orthopedic clinics at the        participating study sites.|May 2015|May 19, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01620541||84276|
NCT01620775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00055261|MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain|MR (Magnetic Resonance) Imaging of the Excitatory and Inhibitory Neurotransmitters in Chronic Pain||University of Michigan|Yes|Recruiting|September 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|170|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 5, 2014|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620775||84258|
NCT01621360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC-2011-01|Hip Arthroscopy Versus Conservative Management of Femoroacetabular Impingement|A Randomized Controlled Trial Comparing Arthroscopic Surgery to Conservative Management of Femoroacetabular Impingement||University of Western Ontario, Canada|No|Recruiting|May 2011|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||February 2013|February 6, 2013|December 19, 2011||No||No||https://clinicaltrials.gov/show/NCT01621360||84214|
NCT01627197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012009|Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer|Adjuvant Intraarterial Chemotherapy Following Surgery in Treating Patients With Locally Advanced Bladder Cancer||Sun Yat-sen University|Yes|Enrolling by invitation|June 2012|December 2021|Anticipated|April 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627197||83768|
NCT01627210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL900920|Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System|Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System - GLYCOAIM Study|GLYCOAIM|DexCom, Inc.|No|Completed|May 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Non-Probability Sample|Adults diagnosed with diabetes mellitus|February 2013|February 11, 2013|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627210||83767|
NCT01630473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CORT2011|Effect of Corticotomy on the Orthodontic Tooth Movement|Clinical Comparison Between the Corticotomy-assisted Orthodontics and Conventional Orthodontics||Universidad de Antioquia|Yes|Completed|August 2011|August 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 13, 2014|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01630473||83516|
NCT01630824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTXEdu2012|Development and Effects of a Structural Education Program in Adult Kidney Transplant Recipients|Development an Effects of a Structural Education Programm in Adult Kidney Transplant Recipients||University of Jena|No|Recruiting|June 2012|||June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|180|||Both|18 Years|90 Years|No|||May 2013|May 21, 2013|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630824||83489|
NCT01630876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YUH-12-0309-M2|Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane|Anatomic and Functional Outcomes of 23-gauge Vitrectomy Combined With Posterior Subtenon Triamcinolone Injection for the Treatment of Idiopathic Epiretinal Membrane||Yeungnam University College of Medicine|No|Recruiting|January 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|80 Years|No|||October 2012|October 1, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630876||83485|
NCT01631370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKOM20110071|The Effects of Renal Denervation on Insulin Sensitivity|The Effects of Renal Sympathetic Denervation on Insulin Sensitivity in Patients With Resistant Essential Hypertension||University of Aarhus|Yes|Enrolling by invitation|June 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|30 Years|70 Years|No|||December 2013|December 23, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01631370||83447|
NCT01631396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-002-12|Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery|Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery||Assuta Hospital Systems|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|20 Years|65 Years|No|Probability Sample|Subjects for the study will be recruited from patients within the community who have        sought treatment for morbid obesity by bariatric surgery, are qualified for the surgery        and meet all of the eligibility criteria listed below.|March 2012|June 24, 2014|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01631396||83445|
NCT01627093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA11-0803|Proton Therapy for Head and Neck Malignancies|Prospective Data Collection of Patients Treated With Proton Therapy for Head and Neck Malignancies||M.D. Anderson Cancer Center|Yes|Recruiting|January 2012|||January 2018|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|375|||Both|18 Years|N/A|No|Probability Sample|Patients with diagnosis of head and neck cancer, treated with proton therapy from January        1, 2008 to December 31, 2014 at UT MD Anderson Cancer Center in Houston, Texas.|February 2016|February 26, 2016|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627093||83776|
NCT01627392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08635|Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence|Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence|NMR|University of California, San Francisco|No|Completed|July 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|305|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01627392||83753|
NCT01627405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-00-0102|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2012|||||N/A|N/A|N/A||||||||||||||September 29, 2012|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627405||83752|
NCT01627652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 2011-N-51|Human Adaptation to High Altitude|Human Adaptation to High Altitude||Zurich Center for Integrative Human Physiology|No|Recruiting|April 2012|September 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|8|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2012|June 21, 2012|May 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627652||83733|
NCT01627665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081208|Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban|New Oral Anticoagulant Drugs Dabigatran Etexilate and Rivaroxaban: Influence of Genetic Factors in Healthy Volunteers|DRIVING|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2011|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|64|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2011|October 8, 2014|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01627665||83732|
NCT01627691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP3687|REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance|REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance||Boston Scientific Corporation|Yes|Active, not recruiting|October 2012|March 2018|Anticipated|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|70 Years|N/A|No|||January 2014|January 14, 2014|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01627691||83730|
NCT01618539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011001109|Correlation of Bispectral Index Score and Total Intravenous Anesthesia (TIVA)|A Prospective Study to Establish a Correlation Between Infusion Rate of Propofol and Bispectral Index (BIS) in Patients Receiving Total Intravenous Anesthesia (TIVA)||Rutgers, The State University of New Jersey|No|Active, not recruiting|June 2012|December 2015|Anticipated|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|65 Years|No|Non-Probability Sample|male and female|June 2015|June 9, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01618539||84430|
NCT01618552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012336397-1|Training Doctors to Support Patient Self-Care of Depression|Physician Training to Support Patient Self-Efficacy for Depression Care Behaviors||University of California, Davis|Yes|Completed|April 2013|May 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01618552||84429|
NCT01619124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DKS 2011.11|Osteonecroses in Pediatric Patients With ALL|Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL|OPAL|Heinrich-Heine University, Duesseldorf|No|Recruiting|March 2012|March 2020|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|whole blood, serum|Both|10 Years|18 Years|No|Non-Probability Sample|Pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, aged >= 10        and < 18 years|March 2014|March 4, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01619124||84385|
NCT01619657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKH-PIHSNC-1|Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis|Randomized, Double-blind, Controlled Pilot Study on Safety of Hypertonic Saline as Preventive Inhalation Therapy in Newborns and Infants With Cystic Fibrosis|PRESIS|Heidelberg University|Yes|Active, not recruiting|June 2012|March 2017|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|N/A|4 Months|No|||December 2015|December 17, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619657||84344|
NCT01619384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB# 00044|Mindfulness-Based Stress Reduction and the Microbiome|Pyrosequencing to Identify Alterations in Intestinal Microbiota Following a Stress Reduction Course||Seattle Institute for Biomedical and Clinical Research|No|Completed|July 2010|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|N/A|No|||November 2014|November 17, 2014|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01619384||84365|
NCT01619709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11 223 02|Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage|Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage|COGHIC-AV45|University Hospital, Toulouse|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|70|||Both|40 Years|90 Years|No|||August 2015|August 18, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619709||84340|
NCT01630265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-03-173|Caregivers' Knowledge of Emergency Department Discharge Instructions Improves With the Use of Video|||Georgia Regents University|No|Completed|April 2010|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|436|||Both|N/A|N/A|No|||June 2012|June 27, 2012|June 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01630265||83532|
NCT01630278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/6-O|Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)|Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)|TRIOCAPI|Nantes University Hospital|Yes|Recruiting|March 2012|March 2019|Anticipated|March 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|385|||Both|N/A|28 Weeks|No|||March 2016|March 7, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01630278||83531|
NCT01620554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-16 / BF2.649|Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)|Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo||Bioprojet|Yes|Completed|October 2010|December 2011|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|110|||Both|21 Years|90 Years|No|||June 2012|June 13, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01620554||84275|
NCT01620788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIEMS1111|Comparison of Losartan Associated With Indapamide Versus Indapamide for Treatment of Hypertension|Randomized, Phase 3, Multicenter, Double-blind, Double Dummy, Evaluating the Effect of Combined Treatment of Indapamide 1.5mg/Losartan 50mg and Indapamide 1.5mg/Losartan 100mg, Compared With 1.5 mg Indapamide Monotherapy in the Treatment of Hypertension||EMS|Yes|Not yet recruiting|January 2014|February 2015|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|255|||Both|18 Years|N/A|No|||August 2013|August 20, 2013|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01620788||84257|
NCT01621074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nbc|Influence of Sodium Bicarbonate on Time-to-exhaustion at Critical Power in Endurance Athletes|||University of Zurich|No|Completed|October 2011|January 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|12|||Male|18 Years|45 Years|No|||April 2013|April 11, 2013|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01621074||84236|
NCT01627171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP 12-3657|Colonoscopy Preparation Optimization for INpatients- COIN Study|A Randomized Control Trial Comparing 4L PEGlyte to Regular Dose Pico-Salax and Split Dose Pico-Salax for Colonoscopy Bowel Preparation in Hospitalized Patients|COIN|St. Joseph's Healthcare Hamilton|No|Recruiting|September 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|126|||Both|18 Years|N/A|No|||January 2013|January 28, 2013|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627171||83770|
NCT01627184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTL-900905|Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus|Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus|LUCID|DexCom, Inc.|No|Completed|May 2012|June 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|N/A|No|Non-Probability Sample|Adult athletes with diabetes mellitus|February 2015|February 10, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627184||83769|
NCT01620047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGH-007 IRB # Pro00002055|Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study|Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study||University of South Florida|No|Completed|March 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 12, 2013|June 12, 2012||No||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01620047||84314|
NCT01620073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42561|Home-Based Versus Partner-Friendly Clinic Testing to Enhance Male Partner HIV-1 Testing During Pregnancy|Home-Based Versus Partner-Friendly Clinic Testing to Enhance Male Partner HIV-1 Testing During Pregnancy: A Randomized Clinical Trial||University of Washington|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Actual|488|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2013|August 27, 2013|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01620073||84312|
NCT01630512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METIS|Mindfulness-Based Cognitive Therapy (MBCT) and Cognitive Behavioral Therapy (CBT) for Depression in Diabetes Patients|Mindfulness-Based Cognitive Therapy (MBCT) and Cognitive Behavioral Therapy (CBT) for Depression in Patients With Diabetes: a Randomized Controlled Trial||University Medical Center Groningen|No|Completed|May 2011|||May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|94|||Both|18 Years|70 Years|No|||September 2014|September 10, 2014|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01630512||83513|
NCT01631123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF NUGAT 0315424|NUtriGenomic Analysis in Twins|Genetic Determinants of Metabolic Responses to Isocaloric Carbohydrate and Fat Diet Strategies|NUGAT|German Institute of Human Nutrition|No|Completed|September 2009|September 2012|Actual|January 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01631123||83466|
NCT01631383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00051290|Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use|Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use||University of Maryland|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|50 Years|No|||December 2015|December 3, 2015|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631383||83446|
NCT01627106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6621-055|A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)|A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation||Cardiome Pharma|Yes|Withdrawn|September 2012|March 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 23, 2013|June 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627106||83775|
NCT01627119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200906054R|The Functional and Clinicopathological Roles and Therapeutic Implication of Connective Tissue Growth Factor in Peritoneal Metastasis of Gastric Cancer|The Functional and Clinicopathological Roles and Therapeutic Implication of Connective Tissue Growth Factor in Peritoneal Metastasis of Gastric Cancer|CTGF|National Taiwan University Hospital|Yes|Recruiting|July 2009|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|120|Samples With DNA|Cancer tissue and adjacent normal tissue Urine Blood serum and blood plasma|Both|25 Years|90 Years|No|Probability Sample|Gastric cancer patients Age 25-90|June 2012|June 22, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627119||83774|
NCT01627418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC08/072AR|Warm Homes for Elder New Zealanders|Warm Homes for Elder New Zealanders: a Community Trial of People With COPD|WHEZ|University of Otago|No|Completed|April 2009|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|522|||Both|55 Years|N/A|No|||June 2015|June 15, 2015|August 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01627418||83751|
NCT01627678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-BI-Vacc-C5-2011/1|Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART|Immunotherapy of HIV-infected Patients An Open, Dose-escalating Assessment of Vacc-C5 With Either GM-CSF or Alhydrogel as Adjuvant in HIV-1-infected Subjects on Antiretroviral Therapy (ART)||Bionor Immuno AS|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|55 Years|No|||January 2014|January 13, 2014|June 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01627678||83731|
NCT01627964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-IRB-100070-E|Motion Analysis and Assessment of Cardiac Function for Cardiac Images|Motion Analysis and Assessment of Cardiac Function for Cardiac Images||Far Eastern Memorial Hospital|No|Completed|August 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Actual|20|||Both|N/A|N/A|No|Probability Sample|randomly selected patients|June 2012|June 25, 2012|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01627964||83709|
NCT01618838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2009-474|Endoscopic Evaluation of Late Rectal Injury Following CyberKnife Radiosurgery for Prostate Cancer|Prospective Endoscopic Safety Evaluation of Late Rectal Mucosal Injury Following CyberKnife Radiosurgery for Clinically Localized Prostate Cancer||Georgetown University|Yes|Terminated|February 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Male|18 Years|N/A|No|||March 2014|March 21, 2014|June 12, 2012||No|The study only accrued 4 patients in 2 years, far below target (40). It was closed with no    subject reached the primary endpoint, thus no results to publish.|No|March 21, 2014|https://clinicaltrials.gov/show/NCT01618838||84407|
NCT01619137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|soap in ununion wound|Soap Versus Normal Salin Plus Povidone-iodine in Ununion Wound|Comparison of the Effect of Water and Soap Irrigation With With Povidone-iodine And Normal Salin Treatment of Patients With Ununion Laparatomy or Episiotomy Wound ( a Pilot Study)||Hormozgan University of Medical Sciences|Yes|Recruiting|August 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Female|10 Years|60 Years|No|||October 2012|October 5, 2012|January 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619137||84384|
NCT01619397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPD 684_03|Evaluation of Tolerance and Acceptability of a Coated Condom|Clinical Investigation Report for the Clinical Investigation to Evaluate In-use Genital Tolerance and User Acceptability of a Xanthan Gum Coating on a Standard Natural Rubber Latex (NRL) Condom in Healthy Volunteer Mutually Monogamous Adult Couples||Reckitt Benckiser LLC|No|Completed|September 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 12, 2013|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01619397||84364|
NCT01619410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0550|Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections|Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial||University of Chicago|No|Recruiting|January 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|152|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619410||84363|
NCT01630291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCU-002|The Effect of Electrical Stimulation on Tear Production|A Non-Randomized, Open-Label Study to Determine the Effect of Electrical Stimulation on Tear Production||Oculeve, Inc.|No|Completed|July 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2014|December 8, 2014|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01630291||83530|
NCT01630304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00563|WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS|WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS||University of British Columbia|Yes|Active, not recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|700|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01630304||83529|
NCT01620567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|002|Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults|The Effect of Consumption of Potatoes, Avocados and Chickpeas Daily for 6 Months on Cognitive Function in Older Adults||Tufts University|No|Recruiting|August 2012|May 2014|Anticipated|February 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|44|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 16, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620567||84274|
NCT01620801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAV8-hFIX19-101|Hemophilia B Gene Therapy - Spark|A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX||Spark Therapeutics|Yes|Active, not recruiting|October 2012|October 2029|Anticipated|October 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|15|||Male|18 Years|N/A|No|||May 2015|May 18, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620801||84256|
NCT01620814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-31|Intravaginal Misoprostol Versus Dinoprostone Before Diagnostik Hysteroscopy|Comparison of Intravaginal Misoprostol and Dinoprostol for the Purpose of Cervical Ripening Before Diagnostic Hysteroscopy in the Women at the Reproductive Age:RANDOMİSED,CONTROLLED PROSPECTİVE TRİAL||Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|July 2012|September 2012|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|30|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 6, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01620814||84255|
NCT01621087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIHCC-E5744|Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: an RCT|Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: a Randomized Controlled Dietary Trial||National Institutes of Health Clinical Center (CC)|No|Completed|February 1966|||June 1973|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|458|||Male|30 Years|59 Years|No|||June 2012|June 15, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01621087||84235|
NCT01631487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100890|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants|A Double-Blind, Randomized, Placebo-Controlled, Sequential Group, Single Ascending and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Subjects||Janssen Research & Development, LLC||Completed|July 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|9||Actual|86|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 24, 2013|June 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01631487||83438|
NCT01620086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134662|Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia|Effect of Repetitive Transcranial Magnetic Stimulation (RTMS) on Resting State Brain Activity in Schizophrenia||University of Arkansas|No|Completed|June 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|26|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 27, 2015|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620086||84311|
NCT01620359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC006|Study of ExAblate Focused Ultrasound Ablation of Breast Cancer|Study of ExAblate Focused Ultrasound Ablation of Breast Cancer Under MR Guidance (MRgFUS) and MRI Evaluation of Ablation||InSightec|No|Recruiting|June 2011|August 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|N/A|No|||March 2016|March 7, 2016|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620359||84290|
NCT01630889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FGCL-4592-059|Open Label Extension Study for the Long-term Efficacy and Safety of FG-4592 in Dialysis and Non-dialysis Chronic Kidney Disease Patients|||FibroGen|Yes|Enrolling by invitation|May 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Chronic Kidney Disease on dialysis and non-dialysis.|June 2012|June 27, 2012|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630889||83484|
NCT01630902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-09-183|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed Condition|An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (Reference, Mylan Pharmaceuticals Inc., USA) in Healthy Human Volunteers Under Fed Condition||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 27, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630902||83483|
NCT01627132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHSG-01|Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial|Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial||Shimousa Hematology Study Group|Yes|Recruiting|February 2012|January 2019|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|15 Years|N/A|No|||June 2012|June 22, 2012|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01627132||83773|
NCT01627145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012024RC|Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug|Post-treatment Normallized Urodynamic Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Correlations With Voiding Diary, King＇s Health Questionnaire, and Overactive Bladder Sympto||National Taiwan University Hospital||Recruiting|August 2012|July 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 14, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627145||83772|
NCT01631110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A010|Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2012/2013-Season Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations||Crucell Holland BV|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|December 19, 2013|June 25, 2012||No||No|October 25, 2013|https://clinicaltrials.gov/show/NCT01631110||83467|
NCT01627431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAPIENZA-PAD|Residual Platelet Activity In Advanced Peripheral Artery Disease|Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management.|TRAIANO|University of Roma La Sapienza|Yes|Recruiting|July 2012|July 2015|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|410|||Both|40 Years|80 Years|No|||November 2012|November 27, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01627431||83750|
NCT01627444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acupuncture_doctorate|Acupuncture in Mothers of Very Low Birth Weight Infants|Ear Acupuncture for Anxiety in Mothers of Very Low Birth Weight Infants||University of Sao Paulo||Recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 22, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01627444||83749|
NCT01627704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110113|Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer|16α-[18F]-Fluoro-œstradiol PET: an in Vivo Biomarker Predicting Response to Hormone Treatment of Metastatic Breast Cancer?|ESTROTEPREDIC|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Female|18 Years|N/A|No|||October 2015|October 13, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01627704||83729|
NCT01627717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVC.1201|The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers|The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers||Centre hospitalier de l'Université de Montréal (CHUM)|No|Recruiting|June 2012|February 2014|Anticipated|November 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|11|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627717||83728|
NCT01618851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 2009-599|Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer|Phase II Study to Evaluate the Efficacy of Intensity Modulated Radiation Therapy With Hypofractionated Radiosurgical Boosts in the Treatment of Clinically Localized Prostate Cancer||Georgetown University|Yes|Active, not recruiting|November 2009|||February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Male|18 Years|N/A|No|||July 2015|July 23, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01618851||84406|
NCT01619150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSKNEEPA02|A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain|A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.||C4Pain|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|39|||Both|40 Years|75 Years|No|||July 2013|July 22, 2013|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01619150||84383|
NCT01619163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed11662452|Prednisolone for Pain Reduction in Knee OA|Phase 4 Study of Low Dose Prednisolone for Knee Osteoarthritis||Faculty of Medicine, University of Alexandria|Yes|Completed|November 2011|January 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|125|||Both|65 Years|N/A|No|||June 2012|June 13, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619163||84382|
NCT01619462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCV1103|Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children|A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children|PCV1103|Papua New Guinea Institute of Medical Research|Yes|Recruiting|November 2011|November 2016|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|35 Days|Accepts Healthy Volunteers|||September 2012|March 20, 2014|May 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619462||84359|
NCT01619982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-11112011-8670|Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients|Effect of Pre-operative Prophylaxis With Vancomycin on Rate of Cefazolin Non-susceptible Gram Positive Surgical Site Infections in Cardiovascular Surgery Patients||Stanford University|No|Completed|February 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|32|||Both|N/A|18 Years|No|||September 2014|February 4, 2016|March 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01619982||84319|
NCT01619995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10020240|Brain Imaging Plus Urodynamics to Investigate the Brain's Control of the Bladder|Brain Imaging Plus Urodynamics to Investigate the Brain's Control of the Bladder|NIRS/fBFB|University of Pittsburgh|Yes|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Female|60 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|women over 60 years|May 2015|May 27, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619995||84318|
NCT01631188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220110241|Use of Transvenous Pacing Wire During Minimally Invasive Port Access Aortic Valve Surgery|Use of Transvenous Pacing Wire During Minimally Invasive Port Access Aortic Valve Surgery||Rutgers, The State University of New Jersey|Yes|Enrolling by invitation|December 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2013|November 13, 2013|March 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631188||83461|
NCT01631201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APL-1648-027|Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women|A Phase 2b, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Safety and Efficacy of Rifalazil (25 Milligram) Compared With Azithromycin (1 Gram) for the Treatment of Uncomplicated Genital Chlamydia Trachomatis Infection in Women||ActivBiotics Pharma, LLC|No|Completed|July 2012|April 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|82|||Female|19 Years|N/A|No|||April 2013|April 25, 2013|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631201||83460|
NCT01630564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1178|Phase I Study of Cord Blood Lymphocyte Infusion|Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2013|||March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|6 Months|N/A|No|||August 2015|August 31, 2015|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01630564||83509|
NCT01630941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-001481-18|Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty|Uncemented Total Hip Implant and Subcutaneous Injections of Denosumab for Patients With Osteoarthritis of the Hip. A Randomized Double Blind Placebo Controlled Study on the Effects on Bone Evaluated With DXA, PET/CT and Biochemical Markers||Uppsala University Hospital|No|Active, not recruiting|March 2012|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|64|||Both|35 Years|65 Years|No|||May 2015|May 25, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01630941||83480|
NCT01631162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0052-CTIL|The Identification of Different Lung Diseases by Analysis of Volatile Organic Compounds in Breath Samples|Application of Nanotechnology and Chemical Sensors for Lung Diseases by Respiratory Samples|PHNOSE|Carmel Medical Center|No|Recruiting|May 2012|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 28, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01631162||83463|
NCT01631461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PainBreastfeed|Painful Breastfeeding and Bacterial or Yeast Infection|The Prevalence of Yeast and Bacteria in Women With Painful Breastfeeding and the Diagnostic Value of Signs and Symptoms||Göteborg University|No|Completed|December 2006|December 2009|Actual|December 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|136|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Group 1 and 2: Selected from the breastfeeding receptions (n=2) at Sahlgrenska University        hospital and Skövde hospital Group 3, controls: Selected from Primary health care clinics|June 2012|June 28, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01631461||83440|
NCT01631474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171-7151-201|A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris|A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris||Intrepid Therapeutics, Inc.|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|363|||Both|12 Years|N/A|No|||March 2015|March 27, 2015|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631474||83439|
NCT01619761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0493|Natural Killer (NK) Cells in Cord Blood Transplantation|Natural Killer Cells In Allogeneic Cord Blood Transplantation||M.D. Anderson Cancer Center|No|Recruiting|May 2013|||May 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|13|||Both|18 Years|75 Years|No|||December 2015|December 28, 2015|June 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01619761||84336|
NCT01619774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0579|An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor|An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor||M.D. Anderson Cancer Center|No|Completed|September 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|16 Years|N/A|No|||November 2015|November 10, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619774||84335|
NCT01620658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTECT|Radioprotective Light-weight Caps in the Interventional Cardiology Setting|Radioprotective Light-weight Caps in the Interventional Cardiology Setting: a Randomized Controlled Trial|PROTECT|Baptist Health South Florida|No|Completed|August 2012|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor)|3||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01620658||84267|
NCT01631435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA-206|PillCam® Platform With the PillCam Crohn's Disease Capsule|Evaluation of the PillCam® Platform With the PillCam Crohn's Disease Capsule in Visualization of Lesions in the Small Bowel and Colon That May Indicate Crohn's Disease||Given Imaging Ltd.|No|Completed|June 2012|February 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|75|||Both|18 Years|75 Years|No|||March 2015|March 11, 2015|June 28, 2012|No|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01631435||83442|
NCT01628055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IVIG/AIS-IFH-MB-CSL|IVIG in Acute Ischemic Stroke: A Pilot Study|IVIG in Acute Ischemic Stroke: A Pilot Study|IVIG/AIS|Inova Health Care Services|No|Withdrawn|March 2013|September 2013|Actual|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|45 Years|75 Years|No|||November 2013|November 7, 2013|June 14, 2012|Yes|Yes|difficult recruitment and new black box warning for IVIG|No||https://clinicaltrials.gov/show/NCT01628055||83702|
NCT01631409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSWT City Hosp No 40, SPB, Ru|Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy|Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital|CSWTSPB40|City Hospital No 40, Saint Petersburg, Russia|Yes|Withdrawn|September 2013|September 2021|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||7|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|There are 55 thousand adults live within the zone of responsibility of the hospital. From        those there are approximately 2 thousand patients with CHD.|April 2014|April 7, 2014|June 24, 2012||No|The study has been withdrawn due to organizational problems|No||https://clinicaltrials.gov/show/NCT01631409||83444|
NCT01631422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28235|A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers|Single-Center, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Radio-labeled RO4602522 in Healthy Male Volunteers||Hoffmann-La Roche||Completed|June 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|6|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01631422||83443|
NCT01627457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-094|Heart Cycle Prestudy|Heart Cycle Prestudy Guided Exercise (GEx) for Coronary Artery Disease Patients (CAD) "GEx Home Application Testing"|PreGEx|RWTH Aachen University|No|Completed|September 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01627457||83748|
NCT01627756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2894-2008|Continued Ventilation During Cardiopulmonary Bypass|Continued Mechanical Ventilation During CABG Operation Attenuates Systemic Immune Modulation||Medical University of Vienna|No|Completed|April 2009|August 2010|Actual|August 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|30|||Both|40 Years|80 Years|No|||June 2012|June 25, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01627756||83725|
NCT01627730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|029/2554(EC1)|Computer-Assisted Instruction: Arterial Blood Gases|Development and Assessment of On-line Computer-Assisted Instruction: Arterial Blood Gases|CAI|Mahidol University|No|Enrolling by invitation|June 2011|April 2016|Anticipated|October 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1000|||Both|N/A|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01627730||83727|
NCT01627743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RRO-ATC-2012/1|CorRELation Between PatIent PErception and Findings on Clinical Examination|CorRELation Between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients|RELIEF|AstraZeneca||Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|505|||Both|40 Years|N/A|No|Non-Probability Sample|COPD patients, group C and D according to GOLD guidelines 2011, being treated for at least        1 month with combination ICS/LABA treatment|February 2013|February 20, 2013|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01627743||83726|
NCT01628003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7297-AS-CTIL|Study of Reserves After Traumatic Brain Injury|Study of Reserves After Traumatic Brain Injury:Influence of Brain, Cognitive, and Emotional Reserves on Long-Term Consequences of Traumatic Brain Injury||Sheba Medical Center|No|Active, not recruiting|August 2009|||January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|240|||Both|19 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 25, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01628003||83706|
NCT01628016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJK011AXL002|The Effect of Attention Bias Modification Training on Reducing Depressive Symptoms|A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy of Attentional Bias Modification Training in the Treatment of Depressive Symptoms||Hunan Normal University|No|Enrolling by invitation|September 2011|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|99|||Both|16 Years|N/A|No|||June 2012|June 25, 2012|June 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01628016||83705|
NCT01618877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01362B|A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers|A Monocenter, Open-label, Two-way Randomized Cross-over Study to Evaluate the Bioequivalence of Levetiracetam Administered as a 45 Minutes Intravenous Infusion and Same Dosage Levetiracetam Oral Tablet (Part A); and a Randomized, Double-blind, Placebo-controlled, Parallel Study on the Safety, Tolerability and Pharmacokinetics of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of b.i.d. Dosing (Part B), in Chinese Healthy Volunteers||UCB Pharma|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 2, 2012|June 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01618877||84404|
NCT01619722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRN10/FM-ECOPHEN|Study of a National Cohort of Adult Patients With Phenylketonuria|Study of a National Cohort of Adult Patients With Phenylketonuria|ECOPHEN|University Hospital, Tours|Yes|Recruiting|February 2012|February 2019|Anticipated|February 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|220|Samples Without DNA|Plasma an serum at the beginning of study and at 5 years|Both|18 Years|N/A|No|Non-Probability Sample|All adult patients with PKU during a consultation in Hospital care centers.|July 2014|July 29, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619722||84339|
NCT01629771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU63944|Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India|Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India||Northwestern University|Yes|Completed|May 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|72|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This study will be conducted in the Kasaragod district of Kerala, India. Subjects with a        clinical diagnosis of lymphatic filariasis of a single body part or more will be recruited        from the Institute of Applied Dermatology, and age-matched controls|February 2014|February 24, 2014|June 26, 2012||No||No|June 3, 2013|https://clinicaltrials.gov/show/NCT01629771||83570|
NCT01630590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0252|Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer|An Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer||M.D. Anderson Cancer Center|No|Active, not recruiting|January 2014|||January 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|N/A|N/A|No|||February 2016|February 5, 2016|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01630590||83507|
NCT01619735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002553|"Dusting" Versus "Basketing" - Treatment Of Intrarenal Stones|Ureteroscopic Treatment of Intrarenal Stones - A Comparative Analysis of "Dusting" Versus "Basketing" With Holmium Laser Lithotripsy||Mayo Clinic|No|Recruiting|April 2013|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients will be identified at clinic visit or hospital admission|December 2015|December 30, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619735||84338|
NCT01618682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0616|Cortical Organization in Allogeneic Transplants or Heterotopic Hand Replants|Cortical Organization in Allogeneic Transplants or Heterotopic Hand Replants||Christine M. Kleinert Institute for Hand and Microsurgery|No|Recruiting|March 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||2|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Subjects will be patients who have undergone hand transplant or replant procedures at        Kleinert Kutz and Associates or who are on the hand transplant registry.|January 2013|July 9, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618682||84419|
NCT01618695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-J000-335|A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures|A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures||Eisai Inc.||Active, not recruiting|May 2012|September 2016|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|680|||Both|12 Years|N/A|No|||February 2016|February 4, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618695||84418|
NCT01630577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVPChallenge|Central Venous Pressure Change With Volume Challenge|Early Change of Central Venous Pressure With Volume Challenge as Predictor of Fluid Responsiveness in Patients With Hemodynamic Instability||University of Monastir|Yes|Completed|January 2012|December 2014|Actual|November 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|70|||Both|20 Years|N/A|No|||March 2016|March 7, 2016|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01630577||83508|
NCT01630954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-Chaudhuri|A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole|A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform||Nilratan Sircar Medical College|Yes|Recruiting|June 2012|June 2019|Anticipated|December 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Female|15 Years|45 Years|No|||March 2016|March 22, 2016|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01630954||83479|
NCT01631175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lenze-2011|Indication-based Identification and Psychosocial Treatment of Orthopedic Cancer Patients|Establishment of an Indication-based Identification and Psychosocial Treatment of Orthopedic Cancer Patients Suffering From Psychosocial Stress||Technische Universität München|Yes|Completed|January 2011|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01631175||83462|
NCT01619787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1090209-1-55244|Price Changes and Hypothetical Food Purchases in Adult Grocery Shoppers|Experimental Analysis of Price Changes and Food Purchases in Obese and Lean Mothers|Grocery|State University of New York at Buffalo|No|Completed|January 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|217|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Lean and overweight Low and high socioeconimic status primary grocery shopper|February 2016|February 11, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01619787||84334|
NCT01620060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1050300|Lurasidone Pediatric Pharmacokinetics Study|A Phase 1 Open-Label, Multicenter, Single and Multiple Ascending Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Lurasidone in Subjects 6 to 17 Years Old With Schizophrenia Spectrum, Bipolar Spectrum, Autistic Spectrum Disorder, or Other Psychiatric Disorders||Sunovion|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|105|||Both|6 Years|17 Years|No|||August 2014|August 21, 2014|May 23, 2012|Yes|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01620060||84313|
NCT01620671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTS-240310|Fast-track Surgery for Perforated Peptic Ulcers|The Feasibility of Fast-track Surgery for Perforated Peptic Ulcers. A Prospective Randomized Clinical Trial||Bakirkoy Dr. Sadi Konuk Research and Training Hospital|Yes|Completed|May 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||January 2013|January 22, 2013|June 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620671||84266|
NCT01627769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-12-0050-CTIL|Evaluation and Comparison of Keloids and Second Degree Burns Blisters Fluid|Comparison of the Blister Fluid Components of Second Degree Burned Patients With the Blister Fluid Components Following Intralesional Cryosurgery of Keloid Scars - A Feasibility Study.||Carmel Medical Center|Yes|Recruiting|July 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|20|Samples With DNA|blister fluid of kryosurgery and second degree burns|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with second degree burns patients status post cryosurgery treatment for keloid        scars with post treatment blisters|February 2013|February 14, 2013|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01627769||83724|
NCT01628315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASA|Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study|Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study|ASA|University at Buffalo|No|Completed|March 2009|December 2014|Actual|March 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|159|||Both|18 Years|55 Years|No|Non-Probability Sample|-  Multiple Sclerosis, relapsing-remitting          -  Enrolled into the 2-year, double-blind, placebo-controlled ASA study|February 2016|February 11, 2016|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01628315||83682|
NCT01628328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|colonstent|Colonic Stent and Tumor Cell Dissemination|Impact of Metallic Stent Insertion for Obstructing Colorectal Cancer on Circulating Tumor Cell Dissemination||The University of Hong Kong|No|Completed|July 2010|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|40|||Both|18 Years|N/A|No|Non-Probability Sample|The study plan to recruit 20-30 patients in the stenting group and about 10-20 patients in        the control groups.        There is no previous study on this topic and hence, no information availabe for        statistical analysis of sample size required to show a difference.|June 2012|June 21, 2012|June 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01628328||83681|
NCT01628666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PADIT Cluster Crossover Study|Prevention of Arrhythmia Device Infection Trial (PADIT)|Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study||Population Health Research Institute|Yes|Recruiting|December 2012|March 2018|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|10800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 16, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01628666||83655|
NCT01628029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0120|Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Advanced Cancer|Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Advanced Cancer||M.D. Anderson Cancer Center|Yes|Recruiting|January 2014|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Anticipated|64|||Both|18 Years|N/A|No|||January 2016|January 8, 2016|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628029||83704|
NCT01628042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4618-014|A Single Dose Study of the Pharmacokinetics of MK-4618 in Participants With Renal Insufficiency (MK-4618-014 AM1)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency||Merck Sharp & Dohme Corp.|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2015|January 8, 2015|June 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01628042||83703|
NCT01628302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HT-Salt|Effect of Salt Restriction on Renin Activation|Investigation of Salt Restriction Effect on Renin Activation||Turkish Society of Hypertension and Renal Diseases|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|28|||Both|50 Years|N/A|Accepts Healthy Volunteers|||August 2011|June 22, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01628302||83683|
NCT01618890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUMC-40226|Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding|A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy|Porthos|Leiden University Medical Center|Yes|Recruiting|September 2012|April 2019|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618890||84403|
NCT01619202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009288|Comparing Driving Performance Among Trained and Untrained Drivers Using a Driving Simulator|Comparison of Driving Performance Among Trained and Untrained Novice Drivers: Validation of a Multidimensional Simulated Driving Assessment||Children's Hospital of Philadelphia|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|16 Years|18 Years|Accepts Healthy Volunteers|||January 2015|January 23, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01619202||84379|
NCT01619449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #11-0626|Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant|Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant: A Randomized Trial||University of Chicago|Yes|Withdrawn|April 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 26, 2015|June 12, 2012||No|Research never begun and no subjects enrolled. Protocol term with IRB in Dec 2014|No||https://clinicaltrials.gov/show/NCT01619449||84360|
NCT01630603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC14-12|Maternal Vitamin D Status and Neonatal Bone Strength|Maternal Vitamin D Status and Neonatal Bone Strength|Vitamin D|Meir Medical Center|No|Recruiting|July 2012|||July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Inborn mother infants pairs|June 2012|February 11, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01630603||83506|
NCT01630616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0822-066|A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)|A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated With Glucocorticoids||Merck Sharp & Dohme Corp.|No|Recruiting|March 2013|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|24|||Both|12 Years|25 Years|No|||March 2016|March 18, 2016|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01630616||83505|
NCT01630057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2090-E039-401|Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug|An Open-label, Randomized, Multi-centre, Superiority Study to Compare, in Patients With Partial Onset Seizures, the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug||Eisai Inc.|Yes|Completed|September 2009|July 2012|Actual|June 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|75 Years|No|||July 2014|July 11, 2014|November 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01630057||83548|
NCT01618721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOP10|Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)|Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)||Echosense Ltd.||Terminated|December 2011|||October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients are referred to the outpatient pulmonary clinics or PFT lab for further        workup|August 2011|June 23, 2014|June 12, 2012||No|Low recruiting rate and fulfill requirements|No||https://clinicaltrials.gov/show/NCT01618721||84416|
NCT01631500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Gothenburg|Effects of an Integrative Treatment Model to Reduce Anxiety and Depression in Minor Mental Health Problems and Medically Unexplained Symptoms|||Göteborg University|Yes|Completed|January 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|120|||Both|20 Years|55 Years|No|||June 2012|August 29, 2012|December 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01631500||83437|
NCT01627223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUC115132|Comparison Between Lamivudine and Entecavir Treatment in Patients|Comparison Between Lamivudine and Entecavir Treatment in Patients With Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B.|NUC115132|Taichung Veterans General Hospital|No|Recruiting|July 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|20 Years|N/A|No|||February 2013|February 18, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01627223||83766|
NCT01619501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/00117|Dysregulation of the C/EBPa Pathway in Human Lung Cancer and Search for New Biomarkers and/or Therapeutic Targets|||National University Hospital, Singapore||Recruiting|April 2012|||March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|||||Both|N/A|N/A|No|Probability Sample|Archived samples from the Department of Pathology (for IHC, FISH) and the Tissue        Repository (for fresh tumor samples) at NUHS|December 2013|December 10, 2013|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01619501||84356|
NCT01620099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAISA01|Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study|Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study||Università degli Studi di Ferrara|No|Completed|November 2011|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|50 Years|No|||May 2014|May 5, 2014|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01620099||84310|
NCT01620346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sapi2012_1|Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) Benefits in the Presence of Advanced Maternal Age: a Prospective Randomized Study|IMSIAMA|Sapientiae Institute|No|Completed|November 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|66|||Female|37 Years|N/A|No|||January 2013|January 7, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620346||84291|
NCT01620684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Metyrapone|Cortisol and Nutritional Sympathetic Responsiveness|The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome||Baker Heart Research Institute|No|Recruiting|February 2013|||December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|24|||Both|45 Years|65 Years|No|||September 2014|September 8, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01620684||84265|
NCT01598623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9103-MW-CTIL|Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients|A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder|OXY-S-01|Sheba Medical Center|No|Not yet recruiting|May 2012|September 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|18 Years|65 Years|No|||November 2013|November 22, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01598623||85959|
NCT01598831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-001|Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.||Asahi Kasei Pharma America Corporation|Yes|Recruiting|August 2012|September 2018|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||January 2016|January 21, 2016|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01598831||85943|
NCT01599065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-2011|Comparison of a MAGNET Protocol Versus "off-on" Protocol for Patients With Implantable Cardioverter Defibrillators|Comparison of a MAGNET Protocol Versus "off-on" Protocol for Patients With Implantable Cardioverter Defibrillators Undergoing Procedures Requiring Electrocautery|MAGNET|Midwest Heart Foundation|No|Completed|December 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|80|||Both|19 Years|N/A|No|Probability Sample|Patients who have an ICD and are patients at Edward Hospital or Advocate Good Samaritan        undergoing surgical, endoscopic and interventional radiologic procedures will be        considered for the study. Hospital and cardiology practice staff will identify potential        subjects by reviewing surgical, endoscopic and interventional radiologic procedure        schedules. When patients with an ICD are identified research staff will be notified. Any        scheduled adult patient with a past medical history of an ICD will be considered for        participation. If electrocautery is anticipated for the procedure this patient will be        screened for the study.|May 2012|October 18, 2013|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01599065||85925|
NCT01598844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JV03PMS|Longterm Safety and Performance of the JenaValve|"The JenaValve" EvalUation of Long Term Performance and Safety In PaTients With SEvere AoRtic Stenosis|JUPITER|JenaValve Technology GmbH|No|Recruiting|May 2012|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|230|||Both|N/A|N/A|No|Non-Probability Sample|Patients with severe aortic stenosis or with severe aortic insufficiency and an increased        risk for an open aortic valve replacement surgery|December 2014|December 29, 2014|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01598844||85942|
NCT01599338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A100991-10|Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients|Influence du Victoza (Liraglutide,Analogue GLP-1) Sur Les Performances Gustatives, le Rassasiement Sensoriel spécifique, le Liking et le Wanting Chez Les Patients diabétiques de Type 2.||Centre Hospitalier Universitaire Dijon|No|Completed|January 2011|September 2011|Actual|January 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|30|||Both|18 Years|80 Years|No|||May 2012|May 31, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01599338||85904|
NCT01599559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IELSG37|This Trial is a Randomized, Open-label Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma|IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)||International Extranodal Lymphoma Study Group (IELSG)||Recruiting|November 2011|May 2025|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|752|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01599559||85887|
NCT01628952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2012_843_0007|Comparison of the Bilateral TAP Block Versus Curare in Muscle Relaxation of the Abdominal Wall During Laparoscopic Digestive Surgery: Prospective Randomized Study|Comparison of the Bilateral Transversus Abdominis Plane (TAP) Block Versus Curare in Muscle Relaxation of the Abdominal Wall During Laparoscopic Digestive Surgery: Prospective Randomized Study||Centre Hospitalier Universitaire, Amiens|No|Completed|June 2012|||January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||June 2012|March 19, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01628952||83633|
NCT01628965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-07-002|A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients|An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2008|October 2010|Actual|October 2010|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|143|||Both|N/A|N/A|No|||February 2014|February 3, 2014|June 25, 2012||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01628965||83632|
NCT01629212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW-TRP001|Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome|Comparative and Analytical Study for Effectiveness and Safety of Tiropramide HCl and Octylonium Bromide in the Treatment of Irritable Bowel Syndrome: Mullticenter, Randomized, Double Blind, Active Controlled Study||Daewoong Pharmaceutical Co. LTD.||Recruiting|December 2011|February 2013|Anticipated|February 2013|Anticipated|Phase 4|Interventional|Primary Purpose: Treatment|2||||||Both|20 Years|75 Years|No|||June 2012|June 26, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01629212||83613|
NCT01629225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThirdMMU|GRK4 Polymorphisms Blood Pressure Response to Candesartan|||Third Military Medical University|Yes|Recruiting|July 2013|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|500|||Both|30 Years|75 Years|No|||June 2013|November 17, 2014|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01629225||83612|
NCT01619423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PP095, (PLIANT)|A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer|A Double Blinded Randomised Three Armed Phase II Trial of PledOx in Two Different Doses in Combination With FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Advanced Metastatic Colorectal (Stage IV) Cancer|PLIANT|PledPharma AB|Yes|Active, not recruiting|September 2012|November 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|165|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619423||84362|
NCT01619436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0279/03.05.2010|The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass|The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass.||Federal University of Juiz de Fora|Yes|Completed|January 2011|May 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|45 Years|80 Years|No|||June 2012|June 13, 2012|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619436||84361|
NCT01629472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7162336|Protection From Gender-based Violence in Cote d'Ivoire|Protection From Gender-based Violence in Cote d'Ivoire||Yale University|No|Completed|October 2010|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|981|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 15, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01629472||83593|
NCT01630317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULISES|Slow Continuous Ultrafiltration Using Central vs Peripheral Line: Feasibility of Implementation, Safety and Efficacy in Acute Heart Failure Syndromes.|Slow Continuous Ultrafiltration Using Central vs Peripheral Line: Feasibility of Implementation, Safety and Efficacy in Acute Heart Failure Syndromes.||Parc de Salut Mar|No|Recruiting|November 2011|October 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||November 2013|November 20, 2013|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01630317||83528|
NCT01591564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00046454|Interpersonal Psychotherapy in Youth With Severe Mood Dysregulation-Pilot|Interpersonal Psychotherapy in Youth With Severe Mood Dysregulation-Pilot||Johns Hopkins University|Yes|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|13 Years|17 Years|No|||March 2015|March 30, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591564||86501|
NCT01591785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0038|Treatment of Staphylococcus Aureus Colonization in Hand Eczema|An Investigator-Initiated Study: Treatment of Staphylococcus Aureus Colonization in Hand Eczema Decreases Severity of Disease||Icahn School of Medicine at Mount Sinai|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||July 2015|July 8, 2015|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591785||86484|
NCT01589120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000341|Using Videos to Facilitate Advance Care Planning for Patients With Heart Failure|Using Videos to Facilitate Advance Care Planning for Patients With Heart Failure|VIDEO-HF|Massachusetts General Hospital|Yes|Recruiting|April 2012|||April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|248|||Both|65 Years|N/A|No|||May 2012|May 1, 2012|April 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01589120||86688|
NCT01587885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18131|Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)|Protocol PT 11-29: Randomized, Open-label, Cross-over Pilot Study to Evaluate and Compare Two Omeprazole Containing Products for Relief of Frequent Heartburn||Bayer|No|Completed|January 2012|May 2012|Actual|April 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 20, 2015|April 4, 2012|No|Yes||No|April 4, 2013|https://clinicaltrials.gov/show/NCT01587885||86781|
NCT01587898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116581|4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis|A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis||GlaxoSmithKline|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|74|||Both|18 Years|N/A|No|||February 2014|April 27, 2015|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587898||86780|
NCT01588483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATACT-study|Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis|Prospective Study for the Follow-up of Aortic Diameter in Patients With Arteritis Temporalis / Giant Cell Arteritis.|ATACT|Universitaire Ziekenhuizen Leuven|Yes|Recruiting|March 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|50 Years|N/A|No|Non-Probability Sample|Proven Giant Cell Arteritis|December 2014|December 2, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01588483||86735|
NCT01589393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-2009|OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Study)|OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Study)|OPTTTICH|McMaster University|No|Active, not recruiting|September 2010|September 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|16 Years|N/A|No|||April 2012|May 8, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01589393||86667|
NCT01586624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/11/001|A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)|A Cancer Research UK Phase I Dose Escalation Trial of Oral VEGFR and EGFR Inhibitor, Vandetanib in Combination With the Oral MEK Inhibitor, Selumetinib (VanSel-1) in Solid Tumours (Dose Escalation) and NSCLC (Expansion Cohort).||Cancer Research UK||Recruiting|December 2011|||September 2017|Anticipated|Phase 1|Interventional|Masking: Open Label, Primary Purpose: Treatment|||Anticipated|48|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586624||86878|
NCT01586637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0206/10|Art Therapy to Treat Women With Fibromyalgia|Assessment of Art Therapy Program for Women With Fibromyalgia: Randomized, Controlled, Blinded Study||Federal University of São Paulo|Yes|Completed|January 2011|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Female|18 Years|65 Years|No|||April 2012|April 25, 2012|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01586637||86877|
NCT01587443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB Domain E/2011/02160|Comparison of Outcomes Between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population|A Comparison of Patient-Reported, Economic and Clinical Outcomes Between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population||National University, Singapore|No|Active, not recruiting|January 2012|||April 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Anticipated|200|||Both|21 Years|N/A|No|Non-Probability Sample|Stage 5 chronic kidney disease hemodialysis peritoneal dialysis|April 2015|April 14, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587443||86815|
NCT01601054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-003|Supplemental Anterior Lumbar Interbody Fusion (ALIF) in Spinal Deformity|Supplemental Anterior Lumbar Interbody Fusion in Posterior Instrumented Fusion in Surgical Treatment of Spinal Deformities. A Randomized Study|SALIF|Rigshospitalet, Denmark|No|Recruiting|May 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2012|May 15, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01601054||85772|
NCT01601288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/845/Cpftdatabase|Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital|Prospective Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital||Singapore General Hospital|No|Recruiting|May 2012|January 2022|Anticipated|January 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25000|||Both|12 Years|N/A|No|Non-Probability Sample|Prospective data collection of all patients who have undergone pulmonary function testing        at Singapore General Hospital|November 2014|November 26, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601288||85754|
NCT01601301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0035|Post-Market Study of the Ellipse PRECICE Intramedullary Limb Lengthening System|A Post-Market Prospective Evaluation of the Performance and Safety of the Ellipse PRECICE Intramedullary Limb Lengthening System|PINS|Ellipse Technologies, Inc.|No|Active, not recruiting|July 2012|December 2017|Anticipated|September 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|N/A|N/A|No|||January 2016|January 19, 2016|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01601301||85753|
NCT01601626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5290|Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV|A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifampin-Based Tuberculosis Treatment Versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifabutin-Based Tuberculosis Treatment With or Without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIV||AIDS Clinical Trials Group|Yes|Recruiting|April 2013|November 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|471|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601626||85728|
NCT01601353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED1001|Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction|Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction||Tissue Genesis, Inc.|Yes|Recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Male|40 Years|70 Years|No|||November 2015|November 2, 2015|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601353||85749|
NCT01601366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNG-IUS-dysmenorrhea|LNG-IUS for Treatment of Dysmenorrhea|Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial|LNGIUSAD|Assiut University|Yes|Active, not recruiting|April 2012|April 2014|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Female|20 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601366||85748|
NCT01601314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAGNA|Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients|Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients|MAGNA|Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|October 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|90 Years|No|||August 2015|August 17, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01601314||85752|
NCT01601327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01052012|Effects of Medications in Patients With Hypogonadism|Effects of Three Different Medications on Metabolic Parameters and Testicular Volume in Patients With Hypogonadotropic Hypogonadism-Last Three Years Experience||Gulhane School of Medicine|Yes|Completed|January 2008|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|119|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01601327||85751|
NCT01602276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|47863|The Effect of tDCS on Subcortical Brain Functioning|The Effect of Transcranial Direct Current Stimulation on Subcortical Brain Functioning||Johns Hopkins University|Yes|Enrolling by invitation|February 2012|December 2020|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01602276||85678|
NCT01602861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Eudra CT: 2011-002243-98|The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity|The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity|SPIREN|Odense University Hospital|Yes|Enrolling by invitation|February 2013|September 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|170|||Both|18 Years|N/A|No|||January 2014|January 23, 2014|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602861||85633|
NCT01603134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/US/07/030|Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition|A Randomized, Open Label, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Comparative Bioequivalence Study of Allopurinol 300 mg Tablets USP With Zyloprim® 300 mg in Normal, Healthy, Adult, Human Male Subjects Under Fasting Condition.||IPCA Laboratories Ltd.|Yes|Completed|November 2007|April 2008|Actual|April 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603134||85612|
NCT01603420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU004-11|External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer|Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate||Proton Collaborative Group|Yes|Terminated|July 2012|May 2014|Actual|May 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Male|18 Years|75 Years|No|||February 2016|February 11, 2016|May 18, 2012||No|enrollment goals not met|No|July 31, 2015|https://clinicaltrials.gov/show/NCT01603420||85590|
NCT01587638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111198|Use of Beta-blockers and Risk of New Onset Diabetes|Use of Beta-blockers and Risk of New Onset Diabetes||GlaxoSmithKline||Completed|April 2009|December 2009|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|12336|||Both|18 Years|N/A|No|Non-Probability Sample|This retrospective database study identified patients aged ≥18 years with at least one        pharmacy claim for a beta-blocker of interest (carvedilol immediate-release        [IR]/controlled-release [CR], atenolol, metoprolol succinate, or metoprolol tartrate)        identified in the IMS LifeLink Health Plan Claims Database. Index date was the first        chronologically occurring prescription for any beta-blocker during the enrollment period        (July 1, 2000-December 31, 2007). Patients were identified if they were continuously        eligible to receive healthcare services 6 months prior to and 3 months after the index        date and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time        frame.|April 2012|April 26, 2012|April 14, 2011||No||No||https://clinicaltrials.gov/show/NCT01587638||86800|
NCT01587911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614016|Casinomacropeptide and Satiety|Characterization of the Physiological and Subjective Satiety Response to Preloads Varying in Bioactive Dairy Proteins|CMP2|University of California, Davis|No|Active, not recruiting|May 2008|September 2015|Anticipated|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|20|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||May 2015|May 12, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587911||86779|
NCT01588496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110233|Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities|2-part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part A - Open-label, Single-arm, Multicenter Pilot Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part B - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia|TESLA|Amgen|Yes|Completed|April 2012|January 2014|Actual|January 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|58|||Both|12 Years|80 Years|No|||November 2015|November 19, 2015|February 27, 2012|Yes|Yes||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01588496||86734|
NCT01589406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|538-10CTIL|Quality of Life and Sexuality in Women With Gynaecological Cancer|Quality of Life and Sexuality in Women With Gynaecological Cancer||Rambam Health Care Campus|No|Not yet recruiting|June 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Female|18 Years|70 Years|No|Non-Probability Sample|women with Gynaecological cancer|April 2012|May 1, 2012|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01589406||86666|
NCT01585870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15977|Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination|A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors||Bayer|No|Completed|July 2012|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01585870||86935|
NCT01585883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Breathlessness Pilot|Self-Management Intervention for Breathlessness in Lung Cancer|A Pilot Trial of a Self-Management Intervention for Breathlessness in Lung Cancer||University Health Network, Toronto|No|Active, not recruiting|May 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|56|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01585883||86934|
NCT01589107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001731|A Randomized Controlled Trial of a Video Decision Making Aid to Obtain Informed Consent in the Surgical Intensive Care Unit|A Randomized Controlled Trial of a Video Decision Making Aid to Obtain Informed Consent in the Surgical Intensive Care Unit||Massachusetts General Hospital|No|Recruiting|December 2011|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|52|||Both|21 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 1, 2012|April 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01589107||86689|
NCT01589380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT16453143|A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)|Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis|ALFA|Seoul National University Hospital|Yes|Recruiting|April 2012|December 2014|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|20 Years|75 Years|No|||April 2012|April 30, 2012|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01589380||86668|
NCT01586364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15-50312|Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus|Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310||Shionogi Inc.||Completed|May 2006|||||Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|301|||Female|40 Years|80 Years|No|||March 2013|May 21, 2013|April 18, 2012|Yes|Yes||No|March 20, 2013|https://clinicaltrials.gov/show/NCT01586364||86898|
NCT01586377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-382|Near-infrared Spectroscopic Measurement in Complex Regional Pain Syndrome|Near-infrared Spectroscopic Measurement of Tissue Oxygen Saturation and the Vascular Occlusion Test in Complex Regional Pain Syndrome||Lawson Health Research Institute|Yes|Completed|August 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with CRPS Type 1 will be selected from a tertiary care chronic pain clinic.        Healthy volunteers will be selected from a community sample|July 2013|July 2, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586377||86897|
NCT01586390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAPvsMOK|Functional Treatment for Acute Ankle Sprains: Softcast Wrap Versus MOKcast|Functional Treatment for Acute Ankle Sprains: Softcast Wrap Versus MOKcast. A Prospective Randomized Single-centre Trial||Spaarne Ziekenhuis|No|Completed|June 2009|December 2010|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|70 Years|No|||April 2012|April 24, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586390||86896|
NCT01586403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|203732|Transfer of Genetically Engineered Lymphocytes in Melanoma Patients|Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study||Loyola University|Yes|Recruiting|July 2012|September 2028|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|15|||Both|18 Years|N/A|No|||July 2012|July 24, 2012|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586403||86895|
NCT01586416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03CA157200-01A1|Intervention to Increase Chemotherapy Tolerance in Elderly Cancer Patients|Intervention to Increase Chemotherapy Tolerance in Elderly Cancer Patients||Massachusetts General Hospital|No|Active, not recruiting|December 2012|December 2015|Anticipated|September 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|60 Years|N/A|No|||September 2015|September 21, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586416||86894|
NCT01587456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00453-38|Arteos II Study: Relationship Between Osteoporosis and Arterial Rigidity Within Fractured Patients Cohort|Relationship Between Osteoporosis and Arterial Rigidity Within Fractured Patients Cohort.|ARTEOS2|Central Hospital, Nancy, France|Yes|Recruiting|April 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Serum, Plasma and DNA|Both|60 Years|N/A|No|Probability Sample|Women and men > 60 years of age with medical history of low energy fracture andradiologic        osteoporosis with DXA Tscore at -2,5 DS.|April 2012|April 27, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587456||86814|
NCT01600547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s20110162|Odense Fallers and Osteoporosis Study|Odense Fallers and Osteoporosis Study|OFOS|University of Southern Denmark|Yes|Completed|May 2012|December 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|322|||Female|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive patients attending the Odense University hospital falls clinic will be        recruited to the study Two control groups will be recruited. A questionnaire will be sent        to randomly selected community aged matched female controls.|December 2014|December 5, 2014|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01600547||85811|
NCT01600807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-148|OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas|Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas||Dana-Farber Cancer Institute|Yes|Withdrawn||||||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 25, 2013|August 8, 2011|Yes|Yes|Study was pending major changes and was on hold, pending activation; administratively    withdrawn; will be submitted as a new protocol if study is revised.|No||https://clinicaltrials.gov/show/NCT01600807||85791|
NCT01601691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|241/2011|Protection of Rectum From High Radiation Doses|Protection of Rectum From High Radiation Doses||University of Oulu|No|Completed|April 2012|March 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Male|50 Years|76 Years|No|||November 2014|November 13, 2014|May 14, 2012|No|Yes||No|November 4, 2014|https://clinicaltrials.gov/show/NCT01601691||85723|
NCT01601704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-CVOT|Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR||Takeda|Yes|Active, not recruiting|June 2012|July 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10400|||Both|45 Years|N/A|No|||March 2016|March 7, 2016|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601704||85722|
NCT01601678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POEM rcpmt|Endoscopic Versus Laparoscopic Myotomy for Treatment of Idiopathic Achalasia: A Randomized, Controlled Trial|Endoscopic Versus Laparoscopic Myotomy for Treatment of Idiopathic Achalasia: A Randomized, Controlled Trial|POEM rcpmt|Universitätsklinikum Hamburg-Eppendorf|Yes|Active, not recruiting|December 2013|December 2019|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||September 2015|January 7, 2016|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601678||85724|
NCT01601652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCD#225576-3|Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis|Open Label, Compassionate Use Protocol of an Intravenous Fish Oil Emulsion in Infants With Cholestasis||University of California, Davis|Yes|Enrolling by invitation|November 2011|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|N/A|1 Year|No|||March 2015|March 19, 2015|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601652||85726|
NCT01601665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-11-020|Post Approval Study of the AcrySof® IQ Toric Intraocular Lens (IOL) Models SN6AT6-SN6AT9|Post Approval Study of the AcrySof® IQ Toric High Cylinder Power IOL Models SN6AT6-SN6AT9||Alcon Research|No|Completed|February 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|477|||Both|21 Years|N/A|No|Non-Probability Sample|Population will be selected from up to 80 clinical investigative sites.|July 2015|August 3, 2015|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601665||85725|
NCT01602653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTJ-2011-0252.R1|Extracorporeal Shock-wave Therapy for Supraspinatus Calcifying Tendonitis: a Randomized Clinical Trial Comparing Two Different Energy Levels|Extracorporeal Shock-wave Therapy for Supraspinatus Calcifying Tendonitis: a Randomized Clinical Trial Comparing Two Different Energy Levels||University of Roma La Sapienza|No|Completed|November 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 18, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01602653||85649|
NCT01602666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACNS1123|Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors|Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)||Children's Oncology Group|Yes|Recruiting|May 2012|||January 2024|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|220|||Both|3 Years|21 Years|No|||October 2015|October 20, 2015|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602666||85648|
NCT01602874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3074K4-3340|Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia|Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years||Pfizer|Yes|Withdrawn|January 2011|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|8 Years|17 Years|No|||February 2013|February 21, 2013|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602874||85632|
NCT01602887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5481009|Relative Bioavailability Study|A Single Dose Open-Label Relative Bioavailability Study Comparing Two Capsule And A Solution Formulation Of PD-0332991 To The PD-0332991 Isethionate Capsule In Healthy Volunteers||Pfizer|No|Completed|May 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|May 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01602887||85631|
NCT01587664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIL-02-PEC-1-A|NewBreez Safety and Efficacy Evaluation|Safety and Efficacy Evaluation of the NewBreez Intra-laryngeal Prosthesis||ProTiP Medical|No|Terminated|May 2012|December 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|April 26, 2012||No|A joint decision was made between sponsor and the study sites to terminate the study due to    lack of recruitment and loss of the French principal investigator.|No||https://clinicaltrials.gov/show/NCT01587664||86798|
NCT01587924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116582|4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease|A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease||GlaxoSmithKline|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|86|||Both|18 Years|N/A|No|||February 2014|April 27, 2015|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587924||86778|
NCT01588236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GF-2011-001|Effect of KYG0395 on Primary Dysmenorrhea|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Further Assess the Efficacy, Safety and Dose Response of KYG0395 in the Treatment of Primary Dysmenorrhea||Jiangsu Kanion Pharmaceutical Co., Ltd|No|Completed|May 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|280|||Female|18 Years|35 Years|No|||October 2015|October 5, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588236||86754|
NCT01588509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110253|Transition From Alendronate to AMG 785|An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate||Amgen|No|Completed|March 2012|January 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Female|55 Years|85 Years|No|||October 2013|October 10, 2013|April 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01588509||86733|
NCT01584700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JROSM0135|Renal Artery Denervation in Chronic Heart Failure|Renal Artery Denervation in Chronic Heart Failure- Pilot|REACH-Pilot|Imperial College London|Yes|Completed|January 2011|July 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|September 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01584700||87022|
NCT01589419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-950|A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer|An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)||AbbVie|No|Completed|June 2012|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589419||86665|
NCT01585038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMC278HIV4002|Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress|A Randomized Controlled Trial Comparing Efavirenz With Rilpivirine on Changes in Endothelial Function, Inflammatory Markers, and Oxidative Stress in HIV-uninfected Healthy Volunteers||Indiana University|Yes|Completed|July 2012|November 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|April 23, 2012||No||No|June 11, 2015|https://clinicaltrials.gov/show/NCT01585038||86996|
NCT01585376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B3|Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma|Study Recurrency Testing of Mutations Identified in WGS of Pediatric Rhabdomyosarcoma||Children's Oncology Group|No|Active, not recruiting|April 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|58|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with rhabdomyosarcoma|May 2015|May 6, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585376||86972|
NCT01585636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQ109-CP001|Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers|A Phase Ia, Randomized, Placebo-Controlled, Single-Dose, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of SQ109 in Normal, Healthy Male and Female Volunteers||Sequella, Inc.|No|Completed|September 2006|February 2007|Actual|February 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|8||Actual|62|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 16, 2013|April 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585636||86952|
NCT01585649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM22-07|PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma|Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma||Teva Pharmaceutical Industries||Completed|July 2012|July 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|21|||Both|2 Years|17 Years|No|||July 2014|July 29, 2014|April 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585649||86951|
NCT01586130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0114|Assessing the Impact of Isokinetic Muscular Strengthening in Eccentric Mode in the Medical Treatment of Knee Osteoarthritis|Assessing the Impact of Isokinetic Muscular Strengthening in Eccentric Mode in the Medical Treatment of Knee Osteoarthritis.|ISOGO|University Hospital, Clermont-Ferrand||Recruiting|February 2012|December 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|80|||Both|40 Years|70 Years|No|||January 2013|January 11, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01586130||86916|
NCT01586143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0118|Clinical Study Comparing the Efficacy of Transbuccal Paracetamol 125 mg Versus Paracetamol Injection 1g in Slow Infusion IV in Patients With Acute Pain|Clinical Study Comparing the Efficacy of Transbuccal Paracetamol 125 mg Versus Paracetamol Injection 1g in Slow Infusion IV in Patients With Acute Pain|PARAJUG|University Hospital, Clermont-Ferrand||Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|60 Years|No|||July 2014|July 4, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01586143||86915|
NCT01587170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00019967|Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury|Phase 2: Effects of Zolmitriptan on Sensory Afferent Transmission After Spinal Cord Injury||University of Alberta||Completed|January 2012|November 2012|Actual|May 2012|Actual|N/A|Observational|N/A||2|Actual|13|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Spinal cord injury subjects|November 2012|November 30, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587170||86836|
NCT01583374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-AS-001|Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis|A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS|POSTURE|Celgene|Yes|Active, not recruiting|May 2012|October 2018|Anticipated|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|491|||Both|18 Years|N/A|No|||January 2016|January 28, 2016|April 20, 2012|Yes|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01583374||87121|
NCT01583387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU340|Effect of Water Intake on the DNA Adducts Formation|Proof of Concept of the Effect of Water Intake on the DNA Adducts Formation||Danone Research||Completed||||||N/A|Interventional|Primary Purpose: Basic Science|2||||||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2012|April 23, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583387||87120|
NCT01600820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU146|Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Spain)|A Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Study on the Effects of a Fermented Dairy Product Enriched With Phytosterols Over Blood Cholesterol Levels of Hypercholesterolemic Adult Subjects||Danone Research|No|Completed|February 2005|||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind|3||Actual|126|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600820||85790|
NCT01601080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200077-516|An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device|REbiSmart™ Retrospective ADherencE Review (READER) An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device|READER|Merck KGaA|No|Completed|April 2012|||October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|230|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with Relapsing Multiple Sclerosis who have been prescribed Rebif® (22mcg or        44mcg)|February 2014|February 3, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601080||85770|
NCT01601093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008L03354|Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection|CAZ-SBT|Xiangbei Welman Pharmaceutical Co., Ltd|Yes|Recruiting|November 2011|November 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|288|||Both|18 Years|70 Years|No|||April 2012|June 3, 2013|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01601093||85769|
NCT01611454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PREFER II|New Fabric Attenuation Device in Endovascular Interventional Radiology II (PREFER II)|Prospective Randomized Evaluation of a New Fabric Attenuation Device in Endovascular Interventional Radiology II (PREFER II)|PREFER-II|Baptist Health South Florida|No|Completed|May 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 23, 2014|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01611454||84973|
NCT01602328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC 6071103|A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects|ACT-AKI|AlloCure Inc.|Yes|Terminated|June 2012|August 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|156|||Both|21 Years|N/A|No|||August 2014|August 5, 2014|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602328||85674|
NCT01602341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-AD-204|Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Four-Week, Bilateral Study of the Safety and Efficacy of Two Concentrations of AN2728 Ointment Administered Once or Twice a Day in Adolescents With Atopic Dermatitis||Anacor Pharmaceuticals, Inc.|No|Completed|August 2012|||January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|12 Years|17 Years|No|||June 2013|June 21, 2013|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602341||85673|
NCT01602003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL006|Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes|A Multicenter, Multinational, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone||LG Life Sciences||Completed|December 2009|May 2012|Actual|June 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|425|||Both|18 Years|75 Years|No|||May 2012|May 17, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01602003||85699|
NCT01602016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|136002|A Folinic Acid Intervention for Autism Spectrum Disorders|A Folinic Acid Intervention for ASD: Links to Folate Receptor-alpha Autoimmunity & Redox Metabolism||University of Arkansas|No|Terminated|May 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|99|||Both|3 Years|14 Years|No|||March 2016|March 23, 2016|May 15, 2012|Yes|Yes|Non-compliance|No||https://clinicaltrials.gov/show/NCT01602016||85698|
NCT01612507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00010|A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects|A Phase I, Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ceftaroline After Different Intravenous Dose Regimens of Ceftaroline Fosamil to Healthy Subjects||AstraZeneca||Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|4||Actual|41|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612507||84892|
NCT01612806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEI-006|A Multi-center, Prospective, Randomized Study With PriMatrix and PriMatrix Ag for the Treatment of Venous Leg Ulcers|A Multi-center, Prospective, Randomized Study With PriMatrix Dermal Repair Scaffold, PriMatrix Ag Antimicrobial Dermal Repair Scaffold, and Standard of Care for the Treatment of Venous Leg Ulcers||Integra LifeSciences Corporation|No|Suspended|June 2011|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|31|||Both|18 Years|N/A|No|||February 2013|May 11, 2015|June 4, 2012|Yes|Yes|Site selection|No||https://clinicaltrials.gov/show/NCT01612806||84869|
NCT01612819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVRF2012-01|DXR Stent(Previous Cilotax) Implantation Registry|Evaluation of Effectiveness and Safety of DXR(Previous Cilotax) Stent in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study (IRIS-CILOTAX)||CardioVascular Research Foundation, Korea|No|Recruiting|April 2012|December 2020|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|20 Years|N/A|No|Non-Probability Sample|patients with coronary artery disease requiring drug eluting stents|September 2015|September 14, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01612819||84868|
NCT01584414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZT-CL-01A|Evaluation of the Zetiq Histological and Cytological Staining Technique for the Detection Cervical Cancer|Evaluation of the Zetiq Histological and Cytological Staining Technique for the Detection Cervical Cancer||Meir Medical Center||Completed|October 2007|April 2010|Actual|||Phase 1|Observational|Time Perspective: Prospective||2|Actual|210|||Female|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|60 archival cervical biopsy cases with the following diagnoses: normal, 22 cases; CIN-2/3,        18 cases; squamous cell carcinoma, 20 cases.|April 2012|April 24, 2012|April 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01584414||87044|
NCT01585389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABTR12B3|Studying Gene Expression and Location in Samples From Patients With Brain Tumors|Expression and Subcellular Localization of NEIL3 in Tumors||Children's Oncology Group|No|Active, not recruiting|April 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with brain tumors|May 2015|May 6, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585389||86971|
NCT01585402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120110|Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)|An Open-label, Non-Randomized, Single-Arm Pilot Study to Evaluate the Effectiveness of Etidronate Treatment for Arterial Calcifications Due to Deficiency in CD73 (ACDC)||National Institutes of Health Clinical Center (CC)||Recruiting|April 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 23, 2016|April 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585402||86970|
NCT01584713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC10-345|Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)|A Phase II Clinical Trial to Study the Feasibility and Safety of Stromal Vascular Derived From Adipose Tissue for the Treatment of Enterocutaneous Fistula|HULPUTC|Instituto de Investigación Hospital Universitario La Paz|No|Recruiting|December 2011|December 2013|Anticipated|July 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2012|April 23, 2012|February 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01584713||87021|
NCT01585350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15781|A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients|A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients, With Evaluation of the Injection Site Microenvironment|MEL58|University of Virginia|Yes|Active, not recruiting|October 2012|||July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|51|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|April 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585350||86973|
NCT01585922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120418BIRM|Noninvasive Positive Pressure Ventilation in Moderate Acute Respiratory Distress Syndrome|||Beijing Hospital||Recruiting|July 2012|||July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||September 2012|September 10, 2012|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01585922||86931|
NCT01586156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1198|PAHTCH (Carvedilol)|Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure||The Cleveland Clinic|Yes|Recruiting|December 2012|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|68|||Both|18 Years|65 Years|No|||September 2015|September 10, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586156||86914|
NCT01586429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-12-589|Ultrasound Guided Femoral Nerve Block Catheter Analgesia Compared With Epidural Analgesia for Patients With Knee OA (Osteoarthritis) Who Underwent Unilateral Total Knee Replacement|||King Saud University||Recruiting||||||Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|||||Both|30 Years|N/A||Probability Sample|for patients with knee OA (osteoarthritis) who underwent unilateral total knee        replacement.|February 2011|April 25, 2012|April 25, 2012||||No||https://clinicaltrials.gov/show/NCT01586429||86893|
NCT01585896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111146|Self-Help Group for the Treatment of Hoarding Disorder|Self-Help Group for the Treatment of Hoarding Disorder||University of Miami|No|Recruiting|April 2012|June 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||October 2015|October 30, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585896||86933|
NCT01585909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBM_septic_shock|Evaluation of Intestinal Brush Border Enzyme Function in Critically Ill Patients|Evaluation of Intestinal Brush Border Enzyme Function in Patients With SIRS and Septic Shock Compared to Control Patients||Medical University of Vienna|No|Recruiting|July 2011|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|45|||Both|18 Years|80 Years|No|||February 2014|February 4, 2014|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01585909||86932|
NCT01586884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-3-LGH|Study to Determine the Safety and Feasibility of Utilizing the CD Leycom Pressure/Conductance Catheter to Determine Optimal LV Pacing Site|Study to Determine the Safety and Feasibility of Utilizing the CD Leycom Pressure/Conductance Catheter to Determine Optimal LV Pacing Site||Lancaster General Hospital|Yes|Withdrawn|April 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 8, 2014|April 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01586884||86858|
NCT01587469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5295|Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects|Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects||Cepheid||Recruiting|April 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1634|Samples With DNA|Samples of sputum may be retained|Both|18 Years|N/A|No|Non-Probability Sample|HIV-1-infected and -uninfected men and women, 18 years and older, pulmonary TB suspects        who have either a) smear positive sputum or b) clinical suspicion of pulmonary TB        including one or more self-reported symptoms of cough, night sweats, weight loss, or        fever. Within the 180 days prior to collection of the initial sputum sample, participants        will have received none or fewer than 48 hours of TB treatment and, in those 48 hours,        fewer than three doses of TB treatment.|April 2012|April 30, 2012|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01587469||86813|
NCT01583400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPHS#22616, W&P-PCMH-01|Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial|Development and Evaluation of Enhanced Digital Health Coaching Program for Depressive Symptoms to Support Collaborative Depression Treatment in Primary Care: The RESPECT-D-E (Enhanced) Trial||Dartmouth-Hitchcock Medical Center|Yes|Completed|September 2011|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01583400||87119|
NCT01583413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH000410A-2|CDC Prevention Epicenters Wake Up and Breathe Collaborative|CDC Prevention Epicenters Wake Up and Breathe Collaborative||Harvard Pilgrim Health Care|No|Completed|May 2012|October 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3342|||Both|N/A|N/A|No|||October 2013|October 10, 2013|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01583413||87118|
NCT01601106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37190.018.11|Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease|A Phase I/II, Single-Center, Randomized, Placebo-Controlled Study Evaluating the Therapeutic Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) in Subjects With Severe Inflamed Carotid or Aortic Atherosclerosis Plaques|SILENCE|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||Recruiting|September 2011|||May 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||May 2012|May 18, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01601106||85768|
NCT01601119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR200136_550|Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients|The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients||Merck KGaA|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|545|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the UK newly diagnosed with RMS (and naive to previous DMT) and receiving a        DMT that can be self-administered|May 2015|May 28, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601119||85767|
NCT01601379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016519|Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.|Symptoms of Gastroesophageal Reflux Disease (GERD): Classification of Adult Subjects Suffering From Typical GERD Symptoms and Description of the Most Frequent Symptom Profiles and Characteristics - European Observational Study|PROFILE|Janssen-Cilag International NV|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|7964|||Both|18 Years|N/A|No|Probability Sample|Patients suffering from GERD and presenting at least 1 of the typical GERD symptoms (i.e.,        heartburn and/or regurgitation), at least once a week, in the week prior to the first (and        only) study visit are candidates for documentation in this study.|June 2015|June 10, 2015|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01601379||85747|
NCT01602614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F21116007|Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection|Evaluation of the Pharmacokinetics and Pharmacodynamics of Ganciclovir in Premature Infants Receiving Treatment for Cytomegalovirus Infection|Gan Premie|University of Alabama at Birmingham|Yes|Recruiting|April 2013|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||4|Anticipated|32|Samples Without DNA|Remnant blood will be retained for future CMV studies if subjects/subject families consent      to future use. IRB approval for any future studies of remnant specimens will be required.|Both|N/A|180 Days|No|Non-Probability Sample|Premature infants who receive intravenous ganciclovir as part of clinical care|November 2015|November 30, 2015|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602614||85652|
NCT01602627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE3Y10|Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies|A Phase I Dose Escalation, Single Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients 75 Years of Age or Older With Advanced Solid Malignancies||Case Comprehensive Cancer Center|Yes|Terminated|September 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|75 Years|N/A|No|||February 2013|February 6, 2013|May 16, 2012|No|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01602627||85651|
NCT01602640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDES001|Comparison of Morphine and Fentanyl/Midazolam in Intensive Care Unit|Sedation and Analgesia in Intensive Care: Comparison of Morphine and Fentanyl/Midazolam||Clínica de Los Andes IPS|No|Completed|January 2009|March 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|90|||Both|18 Years|80 Years|No|||May 2012|May 17, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01602640||85650|
NCT01612546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11276|Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery|Pilot Trial of CRLX101 in the Treatment of Patients With Advanced Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma||City of Hope Medical Center|Yes|Completed|November 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 3, 2015|June 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01612546||84889|
NCT01585051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|x335/08|Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D|Effect of Administration of 25(OH) Vitamin on Mean 24 Hour Blood Pressure and HBA1c Levels in Patients With Stable Type 2 Diabetes Mellitus||Kantonsspital Baselland Bruderholz|No|Completed|January 2009|June 2010|Actual|June 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||April 2012|April 24, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585051||86995|
NCT01585675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-0688|Specimen Banking From Patients With Lung Cancer|Specimen Banking From Patients With Lung Cancer||University of Colorado, Denver|Yes|Recruiting|November 2005|May 2020|Anticipated|May 2018|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Tissue, blood, urine, and sputum, breath|Both|18 Years|85 Years|No|Probability Sample|Subjects who are undergoing further testing for the diagnosis or treatment of lung cancer.|December 2015|December 9, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01585675||86949|
NCT01585688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-hLL1-DOX-02|Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL|A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)||Immunomedics, Inc.|No|Active, not recruiting|August 2012|February 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|April 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585688||86948|
NCT01585662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111|Prospective Random Comparing Study on EUS-guided Pseudocyst Drainage by Naso-pancreatic Tube and Stents|Random Comparing Study on Two Different EUS-guided Pseudocyst Drainage Methods--Modified Naso-pancreatic Tube Drainage and Stents Drainage||Fourth Military Medical University|No|Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|85 Years|No|||April 2012|April 24, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01585662||86950|
NCT01586455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC 550|Human Placental-Derived Stem Cell Transplantation|A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders|HPDSC|New York Medical College|Yes|Recruiting|April 2013|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|N/A|55 Years|No|||April 2015|April 29, 2015|April 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01586455||86891|
NCT01586663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 1070/09|Serial Night Time Position Splint on Systemic Sclerosis|Evaluation of Serial Night Time Position Splint on Range of Motion for Patients With Systemic Sclerosis||Federal University of São Paulo|No|Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586663||86875|
NCT01586676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DESPR DA023230|Effectiveness of Motivational Interviewing Supervision in Community Programs|Effectiveness of Motivational Interviewing Supervision in Community Programs||National Institute on Drug Abuse (NIDA)|Yes|Completed|January 2009|May 2014|Actual|September 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Actual|450|||Both|18 Years|100 Years|No|||October 2015|October 5, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586676||86874|
NCT01586442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1911307|Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes|A Comparison of the Effects of Selective and Non Selective Mineralocorticoid Antagonism on Glucose Homeostasis and Lipid Profile of Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes.|SNOW|Montreal Heart Institute|Yes|Active, not recruiting|March 2012|July 2016|Anticipated|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586442||86892|
NCT01586650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1325/08|Effects of Aerobic Training in Patients With Ankylosing Spondylitis|||Federal University of São Paulo|Yes|Completed|July 2011|February 2013|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|60 Years|No|||March 2014|March 31, 2014|April 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01586650||86876|
NCT01587183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08425|Running Against Prehypertension Trial (RAPT): A Pilot Trial|Running Against Prehypertension Trial (RAPT): A Pilot Randomized Controlled Trial|RAPT|University of California, San Francisco|No|Completed|March 2012|June 2013|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|22|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 20, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01587183||86835|
NCT01587482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROG/11/79|PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis|PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis|PLAISIR|Nantes University Hospital|No|Recruiting|December 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|From December 2011 to December 2012 at 13 hospitals in France, we will include patients        with symptomatic atherosclerotic lesions related to superficial femoral artery in-stent        restenosis to undergo endovascular repair by paclitaxel drug eluting balloon. 100 patients        will be included.|November 2012|November 16, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01587482||86812|
NCT01600846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031122|Pharmacogenetic Testing in Primary Care|Delivery of Pharmacogenetic Testing in a Primary Care Setting||Duke University|Yes|Completed|December 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physician population will be physicians practicing at the two clinics part of Duke        University Medical Center Patient population will be patients who receive primary care at        one of the two participating clinics.|August 2014|July 16, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600846||85788|
NCT01600859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2609-A001-101|Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease||Eisai Inc.||Completed|May 2012|October 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|50 Years|85 Years|No|||November 2015|November 2, 2015|May 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01600859||85787|
NCT01601132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPC-004-11-4001|Drug Interaction Study of Colchicine and Theophylline|An Open-Label, One Sequence, Pharmacokinetic Drug Interaction Study of Colchicine and Theophylline in Healthy Subjects||Takeda|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 18, 2013|May 15, 2012|Yes|Yes||No|March 7, 2013|https://clinicaltrials.gov/show/NCT01601132||85766|
NCT01601392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|tDCS in stroke recovery|Anodal and Cathodal Transcranial Direct Current Stimulation in Stroke Recovery|Effect of Anodal Versus Cathodal Transcranial Direct Current Stimulation on Stroke Recovery: a Pilot Randomized Controlled Trial|tDCS|Assiut University||Active, not recruiting|January 2011|June 2012|Anticipated|May 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|40 Years|70 Years|No|||May 2012|May 16, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01601392||85746|
NCT01601717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25186|RTI-336 as a Treatment for Methamphetamine Dependence|RTI-336 for Methamphetamine Dependence||Baylor College of Medicine|Yes|Withdrawn|January 2010|January 2012|Actual|January 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|0|||Both|18 Years|55 Years|No|||May 2012|May 16, 2012|December 10, 2009|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01601717||85721|
NCT01601730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-25669|Modafinil - Escitalopram Study for Cocaine Dependence|Combination Therapy With Modafinil and Escitalopram for the Treatment of Cocaine Dependence||Baylor College of Medicine|Yes|Completed|August 2010|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|68|||Both|18 Years|55 Years|No|||May 2012|May 16, 2012|December 10, 2009|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601730||85720|
NCT01611168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08040023|REMEDIES4D: REdesigning MEDication Intensification Effectiveness Study for Diabetes|Redesigning Medication Intensification Effectiveness Study for Diabetes|Remedies4D|University of Pittsburgh|No|Active, not recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|370|||Both|18 Years|N/A|No|||December 2014|December 3, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01611168||84995|
NCT01611181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VN 2004/30|Iron Substitution After Total Knee Arthroplasty|Iron Substitution After Total Knee Arthroplasty - a Randomized Study||Northern Orthopaedic Division, Denmark|No|Completed|May 2006|June 2007|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||March 2014|March 28, 2014|May 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611181||84994|
NCT01602029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|roses_pill|Randomized Double Blind Placebo Control Study in Patients With Schizophrenia|Randomized Double Blind Placebo Controlled Study of Ondansetron and Simvastatis Added to Treatment as Usual in Patients With Schizophrenia|ROSES|Pakistan Institute of Learning and Living|Yes|Completed|August 2010|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|303|||Both|18 Years|65 Years|No|||May 2012|November 8, 2014|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602029||85697|
NCT01602042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R44AG034708-02A1|Adaptive Portable Essential Tremor Monitor|Phase II Study: Adaptive Portable Essential Tremor Monitor||Great Lakes NeuroTechnologies Inc.||Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Essential tremor|December 2012|December 3, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602042||85696|
NCT01602354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAA G- SEP|Endotoxin in Gram-negative Septic Shock|Endotoxin Activity Assay as a Prognostic Factor in Gram-negative Septic Shock||Azienda Ospedaliero, Universitaria Pisana|No|Recruiting|April 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|Patients admitted to Intensive Care Unit with a diagnosis of severe sepsis or septic shock|June 2012|June 27, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602354||85672|
NCT01612858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAMP-K23|Metabolic Abnormalities in HIV-infected Persons|Metabolic Abnormalities in HIV-infected Persons||Tufts Medical Center|Yes|Active, not recruiting|June 2011|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2015|April 28, 2015|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612858||84865|
NCT01612260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yl-yxb06-lcsyfa-201201|Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat|Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial||Wuhan University|Yes|Recruiting|September 2012|December 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|460|||Both|18 Years|75 Years|No|||January 2013|January 7, 2013|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01612260||84911|
NCT01612273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0018|The Effect of Triflusal on Peripheral Microcirculation Dysfunction|The Effect of Triflusal on Peripheral Microcirculation Dysfunction: A Double-Blind, Randomized, Controlled, Crossover Study.||Yonsei University|Yes|Completed|April 2011|June 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|40 Years|70 Years|No|||March 2014|March 4, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01612273||84910|
NCT01612520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53665|Telecoaching of People With Type 2 Diabetes in Primary Care|||Katholieke Universiteit Leuven|Yes|Completed|April 2012|January 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|574|||Both|18 Years|75 Years|No|||February 2015|February 2, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612520||84891|
NCT01585415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120114|Vemurafenib and White Blood Cell Therapy for Advanced Melanoma|A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|April 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|66 Years|No|||November 2015|February 20, 2016|April 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01585415||86969|
NCT01585428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120116|Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers|A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers||National Institutes of Health Clinical Center (CC)||Recruiting|April 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|73|||Both|18 Years|70 Years|No|||January 2016|February 10, 2016|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01585428||86968|
NCT01585948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOICAD2010|Study of the Effect of Diabetes on the Incidence and the Extent of Coronary Artery Disease|The Role of Newer and Traditional Risk Factors in the Development, Extent and Manifestation of Coronary Artery Disease||University of Ioannina|No|Active, not recruiting|November 2009|December 2015|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|1000|Samples With DNA|Includes retaining blood samples for DNA analyses and biochemical markers.|Both|18 Years|90 Years|No|Probability Sample|Diabetics and non-diabetics with or without known CV disease who are admitted in the        Department of Cardiology in the University Hospital of Ioannina and undergo coronary        angiography for clinical purposes will be studied. The study will include subjects who 1)        have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and        2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic        angiography (with or without previous history of CAD). Patients revascularized in the        past, with either coronary artery bypass grafting or percutaneous coronary intervention,        will be excluded from the study since it is not possible to describe the extent of CAD in        these patients.        We plan to recruit about 1,000 patients in about 2 years in order for valid conclusions to        be drawn from the studies associating CV risk factors to the presence and extent of CAD as        well as for the gene polymorphisms studies.|December 2014|December 13, 2014|August 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01585948||86929|
NCT01586169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNAM/AZIVAL/01|Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination|A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali|AZIVAL|Centre d'Appui à la lutte contre la Maladie|Yes|Completed|February 2010|February 2010|Actual|February 2010|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3000|||Both|5 Years|65 Years|No|||April 2012|April 24, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586169||86913|
NCT01586182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-037|Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma|Stereotactic Boost for Poor-Prognosis Oropharyngeal Squamous Cell Carcinoma||Dana-Farber Cancer Institute|Yes|Withdrawn|November 2011|September 2015|Actual|April 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||September 2015|September 2, 2015|April 24, 2012|Yes|Yes|Local IRB closed the study due to poor accural.|No||https://clinicaltrials.gov/show/NCT01586182||86912|
NCT01586468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WF10-07-002|PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS|A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS||Nuvo Research GmbH|No|Completed|March 2010|November 2010|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||February 2010|April 25, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586468||86890|
NCT01586689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHEO1|Evaluating Alternative Aftercare Models for Ex-offenders|Evaluating Alternative Aftercare Models for Ex-offenders||National Institute on Drug Abuse (NIDA)|Yes|Completed|September 2006|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|270|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586689||86873|
NCT01586897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS018648|The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care|The Medication Metronome Project||Massachusetts General Hospital|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|April 25, 2012||No||No|July 8, 2015|https://clinicaltrials.gov/show/NCT01586897||86857|Study participants did not embrace this method of non-visit based care, with only 660 medication prescriptions using the Medication Metronome ordering option (21% of possible orders).
NCT01586910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDE #G120169|Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).|Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)|SURTAVI|Medtronic Cardiovascular|Yes|Recruiting|March 2012|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2500|||Both|N/A|N/A|No|||December 2015|December 15, 2015|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586910||86856|
NCT01587196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813953|CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery|CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery - Prescription Opiates/Medication|fMRI CURE|University of Pennsylvania|Yes|Recruiting|January 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|60 Years|No|||April 2012|April 25, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01587196||86834|
NCT01587495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030565|Pharmacokinetics and Safety of Ertapenem in the Postpartum Period|Pharmacokinetics and Safety of Ertapenem in the Postpartum Period||Duke University|No|Terminated|March 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Female|18 Years|65 Years|No|||May 2015|May 19, 2015|April 5, 2012|No|Yes|study terminated due to low subject accrual|No||https://clinicaltrials.gov/show/NCT01587495||86811|
NCT01610115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV-P-01|HBV DNA Levels During Pregnancy in Chronic Hepatitis B|Serial HBV DNA Levels During Pregnancy in Patients With Chronic Hepatitis B: a Prospective Observational Follow-up Study||Chang Gung Memorial Hospital|No|Recruiting|January 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Female|20 Years|50 Years|No|Non-Probability Sample|1. Documented chronic hepatitis B defined by clinical history compatible with chronic             hepatitis B and detectable serum HBsAg          2. Female 20 years of age with confirmed pregnancy|May 2012|May 30, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610115||85076|
NCT01610128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCT-D|Development of an Urticaria Control Test|UCT - Development of an Instrument to Assess Disease Control in Patients With Chronic Urticaria (Urticaria Control Test)|UCT-D|Charite University, Berlin, Germany|No|Recruiting|October 2011|August 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|12 Years|N/A|No|Non-Probability Sample|all patients suffering from chronic forms of urticaria|February 2013|February 14, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01610128||85075|
NCT01610609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1P01HS021141-01-Project 2|Reducing Disparities in Primary Prevention of Cardiovascular Disease|Center for Advancing Equity in Clinical Preventive Services Project 2: Reducing Disparities in Primary Prevention of Cardiovascular Disease||Northwestern University|Yes|Completed|June 2012|July 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|646|||Both|35 Years|N/A|No|||September 2014|September 26, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610609||85038|
NCT01610934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MODY-TREAT|The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)|Phase 2 Study: A Double-blind, Randomised, Clinical Cross-over Trial to Investigate the Treatment Potential of Liraglutide Compared to Glimepiride in MODY Patients||University Hospital, Gentofte, Copenhagen|Yes|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||September 2013|September 4, 2013|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01610934||85013|
NCT01611194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-17|mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms|Brain Injury and Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms After Mild Traumatic Brain Injury (BIMA) Protocol|BIMA|U.S. Army Medical Research and Materiel Command|Yes|Active, not recruiting|September 2012|January 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|72|||Both|18 Years|65 Years|No|||October 2015|October 30, 2015|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01611194||84993|
NCT01611493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|implantes3i|Osseotite Certain Prevail for the Preservation of Crestal Bone|A Prospective, Randomized-Controlled Evaluation of the Osseotite CP4 Certain Prevail Tapered Implant for the Preservation of Crestal Bone|OCPTI|CES University|No|Recruiting|March 2011|September 2013|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2012|June 1, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01611493||84970|
NCT01611740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00324-37|Contribution of Real Time Analyses of CARdio-RESpiratory Signals to the Diagnosis of Infection in PREterM Infants|Contribution of Computerized Real Time Analyses of Cardio-respiratory Signals to the Diagnosis of Infection in Preterm Infants|CARESS_PREMI|Rennes University Hospital|No|Recruiting|May 2012|January 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|24 Weeks|32 Weeks|No|Non-Probability Sample|Preterm birth before < 32wks and > 24wks|October 2015|October 5, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01611740||84951|
NCT01611987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR258309|The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis|The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis|MStep|McGill University|No|Active, not recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|19 Years|65 Years|No|||October 2015|October 6, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01611987||84932|
NCT01612000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSC25|Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults|Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years|PSC25|Protein Sciences Corporation|No|Completed|May 2012|December 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|341|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|May 7, 2012|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01612000||84931|
NCT01613443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POCT-NOAC|Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices|Time-dependent ex Vivo Influence of Rivaroxaban on Point-of-care Devices||Johann Wolfgang Goethe University Hospitals|No|Completed|June 2012|||||N/A|Observational|Time Perspective: Retrospective||4|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients indicated for NOAC-therapy|November 2012|November 1, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613443||84820|
NCT01613729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|corestin/bd/2012-16|Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin|An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin|Cor16|D16 Pharma & Biotec Ltd.|Yes|Enrolling by invitation|July 2012|December 2013|Anticipated|July 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|45 Years|75 Years|No|||September 2012|September 22, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613729||84798|
NCT01584726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#12095/12|Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma|Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)||Hamad Medical Corporation|Yes|Recruiting|December 2012|December 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|2 Years|14 Years|No|||January 2014|January 27, 2014|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01584726||87020|
NCT01584739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1883C00002|AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase I, Single Centre, Double-Blind, Randomised, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD8683 in Healthy Volunteers and COPD Patients||AstraZeneca||Terminated|June 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2012|November 30, 2012|April 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01584739||87019|
NCT01585701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRUKD/12/001|Phase I Study of AT13148, a Novel AGC Kinase Inhibitor|A Cancer Research UK Phase I First in Man Study of the Novel AGC Kinase Inhibitor AT13148 Given Orally in Patients With Advanced Solid Tumours.||Cancer Research UK|No|Recruiting|May 2012|||February 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01585701||86947|
NCT01585961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ThermoCool SF Phase IV|NAVISTAR® THERMOCOOL® SF Catheter: Observational Study|NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population|SFAF|Biosense Webster, Inc.|No|Completed|April 2012|July 2014|Actual|July 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|511|||Both|18 Years|N/A|No|Non-Probability Sample|Older and younger patients with drug refractory, symptomatic paroxysmal atrial        fibrillation.|January 2015|January 20, 2015|March 14, 2012||No||No|January 13, 2015|https://clinicaltrials.gov/show/NCT01585961||86928|
NCT01586208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU-2009-01|Refractory Status Epilepticus Treatment Study|Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility||Hospital Universitari de Bellvitge|Yes|Completed|January 2010|October 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|N/A|N/A|No|||March 2013|March 10, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01586208||86910|
NCT01586481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090501|Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers|Effectiveness and Safety of an Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers of the Fore Foot: a Prospective Randomised Pilot Study|SANIBA|Assistance Publique - Hôpitaux de Paris|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||May 2013|November 13, 2013|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586481||86889|
NCT01586702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA2/084/11|Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients|Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients (INSPiRE-TMS) A Randomized Trial Comparing a Patient Centered Support Program Versus Conventional Car|INSPiRE-TMS|Charite University, Berlin, Germany|Yes|Recruiting|September 2011|June 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2082|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586702||86872|
NCT01586923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21|RBC Transfusion in Severe Anemia With Lactic Acidosis|A Prospective Study of RBC Transfusion in Children With Severe Anemia|TOTAL|Massachusetts General Hospital|Yes|Active, not recruiting|February 2013|April 2016|Anticipated|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|6 Months|5 Years|No|||June 2015|June 1, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586923||86855|
NCT01586936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7-1949|Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors|Special Survey of Production of Antibody Against Coagulation||Novo Nordisk A/S|No|Completed|March 1999|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|9|Samples Without DNA|Serum|Both|N/A|N/A|No|Non-Probability Sample|Patients from general practice setting who have been deemed appropriate to receive        NovoSeven® (eptacog alpha) as new treatment and as part of routine out-patient care by the        prescribing physician|August 2014|August 8, 2014|April 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01586936||86854|
NCT01586949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-EFF-2012|Effectiveness of a Well-being Web-based Intervention|A Randomized Controlled Trial of the Effectiveness of the Web-based Well-being Intervention Daily Challenge||MeYou Health, LLC|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1503|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586949||86853|
NCT01587209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814139|Microparticles in Scuba Divers With Decompression Sickness|Phase 1 Study Investigating Alterations of Circulating Microparticles in Scuba Divers With Decompression Sickness||University of Pennsylvania|No|Recruiting|August 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|SCUBA divers over age 21 that present for evaluation of suspected decompression sickness|July 2015|July 10, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587209||86833|
NCT01583452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGoMaRIPO|Chewing Gum Use to Reduce Post-operative Ileus in Pediatric Patients|Use of Chewing Gum to Reduce Postoperative Ileus in Pediatric Patients After Gastrointestinal Surgery||Instituto Tecnologico y de Estudios Superiores de Monterey|Yes|Completed|April 2012|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|41|||Both|5 Years|18 Years|No|||June 2015|June 27, 2015|April 3, 2012||No||No|March 19, 2015|https://clinicaltrials.gov/show/NCT01583452||87115|We had a small number of participants because of time limitations. We included only patients with diagnosis of appendicitis and post-op appendectomy.
NCT01610622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-C-COSTATUS-4A-H|Estimation of Cardiac Output in Neonatal ICU Using an Ultrasound Dilution Technique|Estimation of Cardiac Output in Neonatal ICU Using an Ultrasound Dilution Technique|CH|Transonic Systems Inc.||Recruiting|March 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|25|||Both|N/A|1 Month|No|Non-Probability Sample|Patients from Neonatal Intensive Care Unit|June 2012|June 4, 2012|May 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01610622||85037|
NCT01610635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01-GEN|INTERVAL Study: To Determine Whether the Interval Between Blood Donations in England Can be Safely and Acceptably Decreased|A Randomised Trial to Determine Whether the Interval Between Blood Donations in England Can be Safely and Acceptably Decreased|INTERVAL|University of Cambridge|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|6||Anticipated|50000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 9, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01610635||85036|
NCT01610947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8785|Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity|Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity: a Randomized Controlled Trial|SPACING|University Hospital, Montpellier|No|Recruiting|May 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|398|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01610947||85012|
NCT01611207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-2012|Evaluate the Efficacy of the Treatment of Iatrogenic Subcutaneous Abdominal Wounds (ISAW) After Surgery by Application of Negative Pressure Wound Therapy (NPWT) in Comparison to Standard Conventional Wound Therapy (SCWT) of the Clinical Routine|Randomised Controlled Study to Evaluate the Efficacy of the Treatment of Iatrogenic Subcutaneous Abdominal Wounds (ISAW) After Surgery by Application of Negative Pressure Wound Therapy (NPWT) in Comparison to Standard Conventional Wound Therapy (SCWT) of the Clinical Routine.|ISAW|University of Witten/Herdecke|Yes|Terminated|June 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|N/A|No|||May 2013|May 17, 2013|March 28, 2012||No|The patient recruitment was behind target, no successful completion of the planned patient    numbers within trial period could be expected|No||https://clinicaltrials.gov/show/NCT01611207||84992|
NCT01611467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-223-CP-002|A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects|A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects|AME/FE|Celgene|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 23, 2012|May 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01611467||84972|
NCT01611480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIMTOP-I|Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head|||Moberg Derma AB||Completed||||January 2013|Actual|Phase 2|Interventional|N/A|||||||Both|18 Years|N/A||||June 2013|June 25, 2013|June 1, 2012||||No||https://clinicaltrials.gov/show/NCT01611480||84971|
NCT01611753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1177/04|Red Blood Cell Transfusion Improves Perfusion Parameters in Septic Shock Patients With Hypoperfusion|Red Blood Cell Transfusion Improves Perfusion Parameters in Septic Shock Patients With Hypoperfusion: a Prospective Randomized Study||Federal University of São Paulo|No|Completed|April 2004|August 2008|Actual|August 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|N/A|No|||May 2012|May 31, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01611753||84950|
NCT01611766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V02_2010_10|Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?|Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial||Shanghai Gynecologic Oncology Group|Yes|Recruiting|January 2011|December 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|420|||Female|18 Years|80 Years|No|||October 2015|October 30, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01611766||84949|
NCT01612013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPM1FU311281|Intravenous High Dose NAC and Sodium Bicarbonate for the Prevention of Contrast-induced Acute Injury|Intravenous High Dose of N-acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-induced Acute Injury: a Randomized Controlled Trial||Federal University of São Paulo|No|Completed|May 2005|December 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 4, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01612013||84930|
NCT01585077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIV - 08 - 102010|Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge|Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites.|ChallengeIII|Malaria Vaccine and Drug Development Center|No|Completed|October 2012|November 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 13, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01585077||86993|
NCT01585441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120119|Finasteride for Chronic Central Serous Chorioretinopathy|Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy||National Institutes of Health Clinical Center (CC)|Yes|Terminated|April 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||November 2014|November 25, 2014|April 24, 2012|Yes|Yes|This study was terminated early due to lack of enrollment.|No|October 29, 2014|https://clinicaltrials.gov/show/NCT01585441||86967|This study was terminated early due to lack of enrollment.
NCT01585727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-012|Intraoperative Monitoring of the Pelvic Autonomic Nerves|Continuous Intraoperative Monitoring of the Pelvic Autonomic Nerves During Total Mesorectal Excision (TME) for the Prevention of Urogenital and Anorectal Dysfunction in Patients With Rectal Cancer.|NEUROS|Johannes Gutenberg University Mainz|Yes|Recruiting|June 2012|December 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|188|||Both|18 Years|90 Years|No|||February 2016|February 23, 2016|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01585727||86946|
NCT01586234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHSU IRB#00006612 DSAEK|OCT-guided DSAEK Graft Shaping and Smoothing|Randomized Clinical Trial of OCT-guided DSAEK Graft Shaping and Smoothing|DSAEK|Oregon Health and Science University|Yes|Suspended|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|62|||Both|18 Years|N/A|No|||May 2013|May 16, 2013|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01586234||86908|
NCT01585935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUV-Neo2|Preventing Cholestasis Using SMOFLipid®|Preventing Cholestasis in Premature Infants Using SMOFLipid®||Medical University of Vienna|No|Active, not recruiting|June 2012|December 2017|Anticipated|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|200|||Both|N/A|5 Days|No|||July 2015|July 14, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01585935||86930|
NCT01586715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HULPCIR-2010-01|Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)|A Phase IIa Clinical Trial to Study the Treatment of the Extremely Complex and Conventional Treatment Resistant Perianal Fistulae With Autologous Stem Cells From Lipoaspirate||Instituto de Investigación Hospital Universitario La Paz|No|Recruiting|March 2012|December 2013|Anticipated|May 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||April 2012|April 25, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01586715||86871|
NCT01586975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aspirin Resistance and Stroke|Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events|Multiphase Study to Determine if Platelet Function Analysis Results Correlate With Ischemic Events and Bleeding Complications||Northwestern University|No|Completed|July 2007|December 2011|Actual|April 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|93|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|August 3, 2011|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01586975||86851|
NCT01586962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|147-A-301|Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI|An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection||Novartis|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|56|||Both|12 Years|N/A|No|||April 2013|August 6, 2013|April 23, 2012||No||No|April 25, 2013|https://clinicaltrials.gov/show/NCT01586962||86852|
NCT01587508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF 127|Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago|A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago||Eurofarma Laboratorios S.A.|No|Not yet recruiting|February 2016|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|471|||Both|18 Years|75 Years|No|||April 2012|July 24, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01587508||86810|
NCT01583465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091312|Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty|Open Label, Randomized, Blinded Study to Evaluate the Efficacy of Aquamantys System for Reducing the Transfusion Requirements Associated With the Anterior-Supine Intermuscular (ASI) Approach for Total Hip Arthroplasty (THA)|Aquamantys|Joint Implant Surgeons, Inc.|Yes|Completed|October 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|N/A|N/A|No|||April 2012|April 23, 2012|April 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01583465||87114|
NCT01583725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-101|fMRI and Appetite-Related Hormones Pre and Post Obesity Surgery|Functional Brain Imaging and Appetite-Related Hormones Pre and Post Obesity Surgery||New York Obesity and Nutrition Research Center|Yes|Enrolling by invitation|July 2010|July 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01583725||87094|
NCT01610648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#10391|Improving the STOP-Bang Screening Questionnaire for Patients With Sleep Apnea|Improving the Sensitivity and Specificity of the STOP-Bang Screening Questionnaire for Patients With Obstructive Sleep Apnea||Tufts Medical Center|No|Active, not recruiting|June 2012|May 2016|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Non-Probability Sample|All patients presenting for a sleep study to Tufts Medical Center|March 2015|March 20, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01610648||85035|
NCT01610661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2735|Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators|Dietary Carbohydrate Type and CVD Risk Indicators||Tufts University|No|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|10|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 1, 2015|November 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01610661||85034|
NCT01610960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8937|Comparison of Three Noninvasive Ventilation Modes: a Physiological Study in Healthy Volunteers|Comparison of Helmet NEXT, Helmet Standard and Facemask for Noninvasive Ventilation: a Physiological Study in Healthy Volunteers||University Hospital, Montpellier|No|Completed|April 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|13|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 30, 2013|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01610960||85011|
NCT01610973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/084/HP|Comparison of Two Techniques in Achieving Corneal Graft|Comparison of Manual and Automated Techniques in Achieving Posterior Lamellar Transplantation of the Cornea||University Hospital, Rouen|No|Active, not recruiting|June 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2015|September 28, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01610973||85010|
NCT01612312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070-11-07032011|Thrombus Aspiration in ThrOmbus Containing culpRiT Lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI)|Thrombus Aspiration in ThrOmbus Containing culpRiT Lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI)||University of Leipzig|Yes|Recruiting|March 2011|October 2013|Anticipated|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|90 Years|No|||August 2013|August 19, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01612312||84907|
NCT01612026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1997155|Ultrasound Versus Fluoroscopically-guided Arterial Access in Non-cardiac Vascular Patients|Ultrasound Versus Fluoroscopically-guided Arterial Access in Non-cardiac Vascular Patients||CAMC Health System|No|Active, not recruiting|May 2012|December 2013|Anticipated|May 2013|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1052|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Subjects referred to the West Virginia University Department of Surgery: Division of        Vascular and Endovascular Surgery with accepted indications to undergo a catheter-based        diagnostic or interventional procedure requiring arterial cannulation.Procedures include        peripheral, renal, mesenteric and carotid.|June 2012|June 4, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01612026||84929|
NCT01612039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3291-CL-0004|Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis|A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis||Telsar Pharma Inc.|Yes|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|65 Years|No|||June 2014|December 22, 2014|June 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612039||84928|
NCT01611779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011|FAST as a Treatment for Obstructive Sleep Apnea|Functional Advancement and Suspension of the Tongue (FAST) as a Treatment for Obstructive Sleep Apnea|FAST|Siesta Medical, Inc.|No|Recruiting|May 2012|August 2013|Anticipated|August 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|20 Years|65 Years|No|||June 2012|June 4, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01611779||84948|
NCT01612286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejaingCH-npc-02|Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma|A Phase II Clinical Study of Endostar Combination With Chemotherapy in the Metastatic Nasopharyngeal Carcinoma||Zhejiang Cancer Hospital|Yes|Active, not recruiting|May 2012|May 2014|Anticipated|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||April 2013|February 16, 2014|May 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612286||84909|
NCT01600976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100872|A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment|A Phase I Study to Assess the Safety and Pharmacokinetics of Telaprevir (VX-950) in Subjects With Moderate and Severe Hepatic Impairment||Janssen Infectious Diseases BVBA|No|Completed|June 2012|November 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|May 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01600976||85778|
NCT01600989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015/10|Mitochondrial Function of Immune Cells in Sepsis|Mitochondrial Function of Immune Cells in Severe Sepsis and Septic Shock - a Prospective Observational Cohort Study|MitoSepsis|University Hospital Inselspital, Berne|No|Completed|May 2012|November 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|Samples With DNA|Serum, isolated B-cells, T-cells, Monocytes|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|30 patients with severe sepsis or septic shock at ICU admission|April 2014|April 24, 2014|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01600989||85777|
NCT01601522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 07-348|Peanut Allergy Oral Immunotherapy Desensitization|Peanut Allergy Oral Immunotherapy Desensitization||McMaster University|No|Active, not recruiting|February 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|5 Years|10 Years|Accepts Healthy Volunteers|||April 2015|April 13, 2015|July 27, 2011||No||No||https://clinicaltrials.gov/show/NCT01601522||85736|
NCT01585454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912108|Healthy Lifestyle in Pregnancy|Healthy Lifestyle in Pregnancy||National Institutes of Health Clinical Center (CC)||Withdrawn|March 2012|January 2016||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 21, 2016|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585454||86966|
NCT01585740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FluidObs-1|Ringer's Lactate Versus Normal Saline in Caesarean Section|Effect of Ringer's Lactate on Maternal and Neonatal pH in Caesarean Section at Mulago Hospital, a Randomized Trial||Makerere University|Yes|Completed|September 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Female|N/A|N/A|No|||June 2012|June 13, 2012|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01585740||86945|
NCT01590394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003154|Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.|Prospective Evaluation of Luminal Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.||Mayo Clinic|No|Active, not recruiting|September 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|85 Years|No|||March 2016|March 16, 2016|April 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590394||86591|
NCT01590407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALS-2200-101|First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002200 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection||Alios Biopharma Inc.|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2015|January 22, 2015|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01590407||86590|
NCT01586195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27763|Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E|An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E||Genentech, Inc.||Terminated|October 2011|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|16 Years|N/A|No|||March 2016|March 1, 2016|April 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586195||86911|
NCT01586988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH086329|A Parenting and Self-Care Intervention for HIV Infected Mothers|A Parenting Intervention for HIV+ Moms: The IMAGE Program|IMAGE|University of California, Los Angeles|Yes|Completed|February 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|124|||Both|6 Years|65 Years|No|||December 2013|December 9, 2013|July 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01586988||86850|
NCT01587222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAFRI-II|Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure|||Fundacion Clinic per a la Recerca Biomédica|No|Recruiting|July 2013|August 2016|Anticipated|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|80 Years|No|||September 2015|September 10, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01587222||86832|
NCT01587521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSY-11-07-26A-12|Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia|Prevalence of and Factors Associated With Metabolic Syndrome in Patients With Schizophrenia||Chiang Mai University|No|Recruiting|January 2012|November 2012|Anticipated|||N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Participants diagnosed with schizophrenia|September 2012|September 22, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587521||86809|
NCT01587794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-3-31|Topographic Changes of Retinal Layers After Resolution of Acute Retinal Detachment|Topographic Changes of Retinal Layers After Resolution of Acute Retinal||Samsung Medical Center|No|Completed|April 2010|April 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|21|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients who were diagnosed with unilateral RRD involving only the superior or inferior        half of the retina and who underwent successful scleral buckling procedure or vitrectomy        by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study        sample.|April 2012|April 26, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01587794||86788|
NCT01611506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV-CePO-B354re (gastric)|Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer|Integration of Cetuximab, in Combination With Local Radiotherapy, in Perioperative Chemotherapy of Resectable and Locally Advanced Gastric Cancer. A Pilot Phase Ib-trial||Centre Hospitalier Universitaire Vaudois|Yes|Terminated|February 2012|December 2012|Actual|December 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||January 2013|January 8, 2013|May 15, 2012||No|Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in    advanced gastric cancer in the overall patient population)|No||https://clinicaltrials.gov/show/NCT01611506||84969|
NCT01611519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006618|Early or Late Foley Removal After Thoracotomy|Optimal Timing of Foley Catheter Removal in Patients Undergoing Thoracic Surgery With Epidural Analgesia: A Randomized, Controlled Trial||Mayo Clinic|No|Completed|December 2011|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|375|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients undergoing thoracic surgery at the Mayo Clinic|January 2016|January 12, 2016|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01611519||84968|
NCT01611792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH/NCMRR/R01-HD040909|Effects and Mechanisms of Specific Trunk Exercises in Low Back Pain|Effects and Mechanisms of Specific Trunk Exercises in Low Back Pain||University of Vermont|No|Completed|March 2003|June 2008|Actual|June 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Actual|58|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||June 2012|June 6, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01611792||84947|
NCT01604889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 24360-201|A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma|A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma||Incyte Corporation|No|Active, not recruiting|March 2012|October 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|136|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01604889||85477|
NCT01612572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCMI-Ⅲ|A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals|A Registry Study on Safety Surveillance of Xiyanping (a Chinese Medicine Injection) Used in China||China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20000|||Both|N/A|N/A|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 20000. Patients using        Xiyanping injection from 2012 to 2014 in more than 50 hospitals|June 2012|June 5, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01612572||84887|
NCT01612871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11SEIN12|Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer|Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer? Pilot Study.|MIRHO|Institut Claudius Regaud|No|Active, not recruiting|June 2012|September 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Female|18 Years|N/A|No|||September 2014|September 8, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01612871||84864|
NCT01612299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3048108907|Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients|Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients||University of Kentucky|Yes|Recruiting|May 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|N/A|N/A|No|||August 2013|August 30, 2013|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612299||84908|
NCT01612559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSCMI-Ⅱ|Safety Study of Kudiezi (a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Kudiezi (a Chinese Medicine Injection) Used in China|RSCMI-Ⅱ|China Academy of Chinese Medical Sciences|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30000|||Both|N/A|N/A|No|Non-Probability Sample|An anticipated sample size was caculated in this study, about 30000. Patients using        Kudiezi injection from 2012 to 2014 in more than 20 hospitals.|June 2012|June 3, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01612559||84888|
NCT01601535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N2009-03|Study of MLN8237 in Combination With Irinotecan and Temozolomide|Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma||New Approaches to Neuroblastoma Therapy Consortium|Yes|Active, not recruiting|May 2012|June 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|12 Months|30 Years|No|||March 2016|March 23, 2016|May 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601535||85735|
NCT01601925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2011-0231|Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block|Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block||Yonsei University|No|Recruiting|January 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|20 Years|N/A|No|||January 2013|January 23, 2013|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01601925||85705|
NCT01585467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02102010|Anterior Shoulder Dislocation|Selective Radiography in Anterior Shoulder Dislocation: Prospective Validation Rule of Decision Rules Derived in Fresno and Quebec||University of California, San Francisco|No|Completed|February 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|300|||Both|18 Years|N/A|No|Probability Sample|Community sample|May 2015|May 5, 2015|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01585467||86965|
NCT01585974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16263|Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma|Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma|TURCOS|Bayer|No|Completed|November 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|151|||Both|18 Years|N/A|No|Non-Probability Sample|Patients diagnosed as metastatic renal cell carcinoma and could not tolerate previous        cytokine therapy within the first month of treatment|October 2015|October 26, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01585974||86927|
NCT01585987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-162|An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy|A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer||Bristol-Myers Squibb|No|Completed|July 2012|April 2015|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|143|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|April 25, 2012|Yes|Yes||No|July 15, 2015|https://clinicaltrials.gov/show/NCT01585987||86926|
NCT01591239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P50DA027841|Home-Based Program to Help Parents of Drug Abusing Adolescents|Parents as Interventionists for Moderate Drug Abusing Adolescents||Treatment Research Institute|Yes|Active, not recruiting|September 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Both|12 Years|19 Years|Accepts Healthy Volunteers|||May 2015|May 11, 2015|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01591239||86526|
NCT01586221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-02284|Music Therapy/Physical Therapy Intervention to Enhance Well-being and Functional Recovery Post-stroke|A Collaborative Music Therapy/Physical Therapy Intervention to Enhance Well-being and Functional Recovery Post-stroke|MT/PT|New York University School of Medicine|Yes|Active, not recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|75 Years|No|||March 2016|March 9, 2016|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01586221||86909|
NCT01586494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR014014|A Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER in Children With Pain|A Single Dose Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER at Two Dose Levels in Children Seven to Eleven Years Old, Inclusive, With Pain||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No|Completed|October 2007|June 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|7 Years|11 Years|No|||August 2012|August 28, 2012|April 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01586494||86888|
NCT01586728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100801|Oxygen Therapy in Cystic Fibrosis|Indication and Benefits of Nocturnal Oxygen Therapy in Cystic Fibrosis|MUCOXY|Assistance Publique - Hôpitaux de Paris|No|Terminated|October 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|6 Years|N/A|No|||June 2015|June 12, 2015|January 18, 2012||No|lack of inclusion in the study|No||https://clinicaltrials.gov/show/NCT01586728||86870|
NCT01590966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/279|Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis|Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis|SCINTRA|University Hospital, Ghent|No|Recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||December 2014|December 4, 2014|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590966||86547|
NCT01591473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMP-600|Safety Study of FluMist With and Without Ampligen|A Phase I/II, Two-Staged, Single-Center, Randomized, Double-Blind, Antibody Titer Study to Assess Immunogenicity and Safety of FluMist® Intranasal Influenza Vaccine Administered With and Without a TLR-3 Agonist, Ampligen®.||Hemispherx Biopharma|Yes|Active, not recruiting|April 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Anticipated|72|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|May 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01591473||86508|
NCT01587235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0653A-406|A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)|A Multicenter, Open-label, 6 Week Study to Evaluate the Efficacy and Safety of Algorithm Based Intensive Treatment With Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Patients.|VYCTORY|Merck Sharp & Dohme Corp.|No|Withdrawn|March 2013|May 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|79 Years|No|||December 2014|December 29, 2014|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587235||86831|
NCT01591941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCM06-0007|Effectiveness of a Novel Warm-up in Decreasing Risk Factors for ACL Injury in Female Youth Soccer Players|The Effectiveness of a Novel Warm-up in Decreasing Risk Factors for Anterior Cruciate Ligament Injury in Female Youth Soccer Players||University of British Columbia|No|Completed|June 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Female|14 Years|17 Years|Accepts Healthy Volunteers|||May 2012|May 3, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591941||86472|
NCT01588405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDE-PH-205|Remodulin® to Oral Treprostinil Transition|A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension||United Therapeutics|No|Completed|April 2012|December 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|15 Years|80 Years|No|||March 2015|March 20, 2015|January 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588405||86741|
NCT01588717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIDES-G|Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)|A Pilot Study to Measure and Treat Antidepressant-Induced Excessive Sweating With Glycopyrrolate (AIDES-G)|AIDES-G|Thomas Jefferson University|No|Recruiting|April 2012|April 2018|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588717||86719|
NCT01611532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/WS/0040|An Observational Study of the Role of Intra-abdominal Pressure Monitoring in Patients With Acute Pancreatitis|An Observational Study of the Role of Intra-abdominal Pressure Monitoring in Patients With Acute Pancreatitis||NHS Greater Glasgow and Clyde|No|Completed|November 2010|December 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|18 Years|N/A|No|Probability Sample|All adult patients with a diagnosis of acute pancreatitis|June 2012|June 1, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01611532||84967|
NCT01611805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114472|Japanese Phase I of GSK1605786|A Placebo-Controlled, Four-Period Crossover, Single Ascending Oral Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of the CCR9 Receptor Antagonist GSK1605786 in Japanese Healthy Male Subject||GlaxoSmithKline|No|Completed|July 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|5||Actual|30|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01611805||84946|
NCT01604642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTICA|Role of Activin A (ActA) in the Human Cancer Cachexia|Role of Activin A (ActA) in the Human Cancer Cachexia||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Active, not recruiting|May 2012|||March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|80|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01604642||85496|
NCT01600690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2616P|Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients|Evaluation of the Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients. A Controlled Randomized Study|SStatin-EPC|University of Padova|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|34|||Both|35 Years|80 Years|No|||August 2013|August 12, 2013|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600690||85800|
NCT01612884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106005745|Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)|Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)||Indiana University||Recruiting|August 2011|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|21 Years|75 Years|No|||March 2015|March 24, 2015|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01612884||84863|
NCT01601210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00055231|Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder|Placebo-Controlled Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study||University of Utah|Yes|Completed|June 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|32|||Female|13 Years|21 Years|No|||December 2014|December 19, 2014|April 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601210||85760|
NCT01613144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC-000784|OsseoScrew Versus Fenestrated Pedicle Screws Augmented With Polymethylmethacrylate|Expandable Pedicle Screws Versus Fenestrated Pedicle Screws Augmented With Polymethylmethacrylate (PMMA): Complications and Clinical Outcomes in Patients With Osteoporosis or Poor Bone Quality|EVOLVE|Alphatec Spine, Inc.|No|Active, not recruiting|May 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|90|||Both|18 Years|N/A|No|Probability Sample|150 skeletally mature study subjects with spinal instability and osteopenia will be        enrolled in the study. Subjects will be randomized 1:1 to the OsseoScrew or the control        group.|January 2016|January 15, 2016|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01613144||84843|
NCT01601483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MacuCLEAR MC-1101-001|Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration|Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration||MacuCLEAR, Inc.|No|Terminated|October 2012|March 2013|Actual|March 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|50 Years|85 Years|No|||April 2014|April 24, 2014|May 15, 2012|Yes|Yes|Unmasked without Sponsor's prior knowledge or authorization by the PI.|No||https://clinicaltrials.gov/show/NCT01601483||85739|
NCT01601938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHEM-SEREAL-12-0001|Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients|Effects of Selenium Replacement on Prognosis of Severe Sepsis and Septic Shock Patients and Their Initial Serum Selenium Level: a Randomized, Double-blind Placebo Controlled Phase 2 Study|SEREAL|Seoul National University Hospital|Yes|Withdrawn|September 2012|May 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|May 15, 2012||No|We failed to obtain study drugs from the company|No||https://clinicaltrials.gov/show/NCT01601938||85704|
NCT01585753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARCH-Kirby VE substudy|MARCH Vascular Endothelium Substudy|Maraviroc Switch Vascular Endothelium (VE) Substudy: a Substudy of MARCH|MARCH VE|Kirby Institute|Yes|Completed|June 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|34|||Both|18 Years|N/A|No|Probability Sample|Participants in MARCH|January 2016|January 18, 2016|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01585753||86944|
NCT01590121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS/20|Hereditary Haemorrhagic Telangiectasia Flight Safety Study|A Questionnaire Based Study to Evaluate the Safety of Flying in Hereditary Haemorrhagic Telangiectasia (HHT)|Flying and HHT|Imperial College London|No|Completed|January 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|145|||Both|16 Years|N/A|No|Non-Probability Sample|HHT patients previously assesses at Hammersmith Hospital, England|April 2012|May 28, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01590121||86612|
NCT01590992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT1_135328_A|Treatment of Globus Sensations With Psychotherapy|Psychotherapy and Psychobiology of Somatoform Disorders (Globus Sensations): A Randomized Controlled Trial||University Hospital, Basel, Switzerland|No|Active, not recruiting|May 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|175|||Both|18 Years|85 Years|No|||August 2015|August 10, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01590992||86545|
NCT01591005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT11386-5/2010|SONOlysis in Prevention of Brain Infarctions dUring Carotid Stenting and caroTid EndaRterectomy|Risk Reduction of Symptomatic and Silent Brain Infarctions During Carotid Endarterectomy and Carotid Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring|SONOBUSTER|University Hospital Ostrava|Yes|Completed|October 2010|June 2015|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|242|||Both|40 Years|80 Years|No|||August 2015|August 29, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01591005||86544|
NCT01590654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-283-0102|A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection|A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection||Gilead Sciences|Yes|Completed|April 2012|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|51|||Both|18 Years|65 Years|No|||December 2013|December 18, 2013|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590654||86571|
NCT01590953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.049.a|A Study of the Effects of an Employee Wellness Program|||Ochsner Health System|No|Recruiting|May 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|90 Years|No|Non-Probability Sample|Ochsner employees with a BMI greater than or equal to 30|May 2012|May 2, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590953||86548|
NCT01591226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JF_001|Caffeine and Sodium Citrate Ingestion|Effects of Caffeine and Sodium Citrate Ingestion in 1500m Wheelchair Racing Athletes||Swiss Paraplegic Centre Nottwil|No|Completed|February 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 10, 2013|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01591226||86527|
NCT01591720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-VR-DEP-2|Tailored Internet-delivered Cognitive Behaviour Therapy in Primary Care|Effectiveness Testing of a Tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Symptoms of Depression, Anxiety and Comorbid Problems|TAYLOR2|Linkoeping University|No|Completed|September 2010|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||May 2012|May 2, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01591720||86489|
NCT01591954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11101|A Feasibility Study of a Modular Video Augmentation System for Image-Guided Skull Base Surgery|A Feasibility/Pilot Study of a Modular Video Augmentation System for Image-Guided Endoscopic Skull Base Surgery||Sidney Kimmel Comprehensive Cancer Center|Yes|Terminated|January 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|15|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 12, 2015|May 1, 2012||No|3rd party proprietary software issue|No||https://clinicaltrials.gov/show/NCT01591954||86471|
NCT01591707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00073501|Development of an Intervention for Preschoolers With Autism|Development of a Social and Communication Intervention for Preschoolers With Autism||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Enrolling by invitation|July 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|3 Years|6 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01591707||86490|
NCT01588080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVA|Comparison Between Infant Flow SiPAP and Noninvasive NAVA in the Neonatal Intensive Care Unit|A Pilot Study Comparing Infant Flow SiPAP to Noninvasive NAVA||Fraser Health|No|Completed|July 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|28 Weeks|32 Weeks|No|||May 2015|May 25, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588080||86766|
NCT01588418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|233-GAS-08|Effect of Exenatide on Brain, Adipose Tissue, Pancreas, and Liver Function|Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|July 2010|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|15|||Male|18 Years|65 Years|No|||December 2014|December 1, 2014|March 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01588418||86740|
NCT01604356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00050691|Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa|Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa||Johns Hopkins University|No|Completed|April 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|10 Years|N/A|No|||March 2014|March 3, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604356||85518|
NCT01604629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDES-TNF/2012|Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF|Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial.|REDES-TNF|Spanish Clinical Pharmacology Society|Yes|Completed|July 2012|September 2015|Actual|April 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01604629||85497|
NCT01604668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000524C|Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring|Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring.||University of California, San Francisco|Yes|Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing spine surgery|August 2013|August 19, 2013|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01604668||85494|
NCT01600469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-2452A3|NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease|NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease||Chang Gung Memorial Hospital|No|Completed|January 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Both|50 Years|90 Years|No|||April 2011|June 3, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01600469||85817|
NCT01604902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-218/2-86|miRNAs and mRNAs in Psoriasis|miRNAs and mRNAs in Psoriasis During Treatment With Biological Drugs.||University of Aarhus|Yes|Recruiting|March 2011|January 2016|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples With DNA|tissue: 4mm skin pinch biopsies for mRNA and miRNA extration.|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients included are adults (> 18 years) with psoriasis vulgaris who are going to be        treated with biological drugs independent of this project.|January 2013|August 22, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01604902||85476|
NCT01604915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0149|Comparison of Dexamethasone Added to Ropivacaine and Ropivacaine Alone in Caudal Analgesia in Children Undergoing Orchiopexy|Comparison of Analgesic Effect of Dexamethasone Added to Ropivacaine and Ropivacaine Alone in Caudal Analgesia on Postoperative Pain Control in Pediatric Patients Undergoing Orchiopexy||Yonsei University|Yes|Completed|May 2012|February 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Male|6 Months|5 Years|No|||July 2013|July 5, 2013|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01604915||85475|
NCT01601470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2225|Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension|An Open Label, Three-period, Single Sequence Study to Evaluate the Pharmacokinetic Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension||Novartis|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|28|||Male|18 Years|65 Years|No|||October 2015|October 6, 2015|May 16, 2012||No||No|July 11, 2015|https://clinicaltrials.gov/show/NCT01601470||85740|
NCT01601236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QSC01-DN-01|Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.||Mallinckrodt||Active, not recruiting|May 2012|||January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 23, 2015|May 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601236||85758|
NCT01601951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-01|Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee Osteoarthritis|Autologous Bone Marrow Concentrate Database Outcomes Research Project||Regenerative Pain Center, Illinois|No|Completed|April 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|12|||Both|18 Years|85 Years|No|Non-Probability Sample|Orthopedic clinic, those with a diagnosis of hip or knee osteoarthritis, scheduled for an        Autologous Bone Marrow injection|March 2014|March 14, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01601951||85703|
NCT01589822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-11-002|The EVICEL® Gastrointestinal Study|A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques||Ethicon, Inc.|Yes|Completed|June 2012|September 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|214|||Both|18 Years|N/A|No|||February 2015|February 24, 2015|April 30, 2012|Yes|Yes||No|July 16, 2014|https://clinicaltrials.gov/show/NCT01589822||86634|
NCT01589835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01330|Preventing Diabetes in Those at Risk by Having a Facilitator and Family Doctor Encourage Healthy Activity and Eating Habits|Preventing Diabetes With Facilitated Lifestyle Intervention Prescriptions.Phase 2: Pilot Study|FLIP|University of British Columbia|No|Completed|July 2012|||October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|59|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01589835||86633|
NCT01590979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bekheit-Ranolazine|Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation|Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation Rates in Post-Operative Cardiac Surgery Patients||Northwell Health|Yes|Completed|April 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|54|||Both|18 Years|N/A|No|||August 2015|August 18, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01590979||86546|
NCT01591265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011DE02|SIXES; Should I eXtract Every Six?|SIXES; Should I eXtract Every Six?|SIXES|University of Dundee|Yes|Terminated|May 2014|May 2019|Anticipated|May 2019|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Both|7 Years|11 Years|No|||June 2015|June 29, 2015|April 30, 2012||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01591265||86524|
NCT01591486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2NA3NANC|Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding|A Long-term Prospective Cohort Study of Testing for Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding With Low-dose Aspirin|2NA3NANC|Chinese University of Hong Kong|No|Completed|January 1995|March 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|904|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive users of ASA presented with upper gastrointestinal bleeding to the Endoscopy        Centre of the Prince of Wales Hospital will be screened for eligibility. The Prince of        Wales Hospital serves a local population of 1.5 million people in Hong Kong. All patients        undergo endoscopy within 24 hours of hospitalisation to identify the source of bleeding,        to secure haemostasis, and to determine their Hp status.|November 2014|August 10, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01591486||86507|
NCT01591499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00886-35|Clinical Evaluation of Biofinity Multifocal Compared With Air Optix Aqua Multifocal and With PureVision Multifocal|Clinical Evaluation of the Biofinity Multifocal Lens Compared With the Air Optix Aqua Multifocal Lens and With PureVision Multifocal Lens (INNOVATION PRESBYOPIA Study)|INNOVATION|Coopervision, Inc.|No|Completed|September 2011|September 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|142|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|March 19, 2012||No||No|December 30, 2013|https://clinicaltrials.gov/show/NCT01591499||86506|
NCT01587560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PyroTITAN DS|A Comparison Between a Pyrocarbon and a CoCr Shoulder Resurfacing Implant|||Danderyd Hospital|Yes|Active, not recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|75 Years|No|||April 2015|April 20, 2015|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01587560||86806|
NCT01587820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROB-SCI 12-001|Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer|A Pilot/ Feasibility Study Comparing Response Rates of Intra-arterial and Intravenous Cisplatin Chemotherapy, Combined With Radiation, in Patients With Locally Advanced Carcinoma of the Oral Cavity and Oropharynx||Southern Illinois University|Yes|Terminated|June 2012|August 2014|Actual|August 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||July 2014|December 4, 2014|March 19, 2012|Yes|Yes|lack of enrollment|No||https://clinicaltrials.gov/show/NCT01587820||86786|
NCT01587807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116236|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057|A Two-part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057 in Healthy Subjects||GlaxoSmithKline||Completed|March 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|6||Actual|53|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|May 9, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01587807||86787|
NCT01588106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWT-2011-1|Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients|Evaluation of the Impact of the CONTOUR® USB Blood Glucose Monitoring System With Integrated Data Management on Glycaemic Control in Insulin-treated Diabetic Patients|CONGO|GWT-TUD GmbH|No|Completed|June 2012|January 2016|Actual|October 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|154|||Both|18 Years|N/A|No|Probability Sample|patients of assorted practices|January 2016|January 21, 2016|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588106||86764|
NCT01587846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LR-2012-KL|Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children|Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children - Randomized, Double Blind, Placebo Controlled Study||Sisters of Mercy University Hospital|No|Recruiting|October 2012|October 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|300|||Both|2 Years|18 Years|No|||October 2012|October 2, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587846||86784|
NCT01588119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAC|Register for New Oral Anticoagulants|Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants|NOAC|GWT-TUD GmbH|No|Recruiting|November 2011|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|patients in clinical routine|January 2016|January 21, 2016|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588119||86763|
NCT01588132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LeesPharm_Anfibatide_Phase1|Anfibatide Phase 1 Clinical Trial in Healthy Volunteers|First Assessment of the Glycoprotein Ib-IV-V Complex Antagonist Anfibatide in Healthy Human Volunteers||Lee's Pharmaceutical Limited|No|Completed|September 2010|March 2011|Actual|March 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|11||Actual|94|||Both|18 Years|28 Years|Accepts Healthy Volunteers|||April 2012|April 26, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01588132||86762|
NCT01604083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETPOS|European Transfusion Practice and Outcome Study|European Transfusion Practice and Outcome Study A Multi-central Evaluation of Standard of Transfusion Care and Clinical Outcome for Elective Surgical Patients. Observational Study.|ETPOS|European Society of Anaesthesiology|No|Completed|April 2013|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6066|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing a non cardiothoracic, non emergency-trauma surgical procedure of        participating hospital will be included, if they receive at least one pRBC. There are no        further specific inclusion criteria. The only exclusion criteria will be age < 18 years        and cardiothoracic and emergency trauma patients.|March 2014|March 11, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604083||85539|
NCT01604096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM8FKC3H|Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy|Doctors and Local Media: a Synergy for Public Health Information? A Controlled Trial to Evaluate the Effects of a Multifaceted Campaign on Antibiotic Prescribing|LOCAAL|Regional Health and Social Care Agency, Italy|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||||||Both|N/A|N/A||||May 2012|May 22, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01604096||85538|
NCT01604369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS1|Cryoablation as Standard Treatment of Atrial Flutter|Cryoablation as Standard Treatment of Atrial Flutter - Long Term Efficacy and Patient Content|CASTAF|Karolinska University Hospital|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604369||85517|
NCT01604382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLM-2012-CPH|Early Mobilization After Total Knee Arthroplasty|A Randomized Study of Whether General or Regional Anesthesia for Patients Undergoing Elective Total Knee Arthroplasty Could Effect Length of Hospital Stay||Region Skane|Yes|Completed|September 2008|June 2010|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|85 Years|No|||May 2012|May 22, 2012|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01604382||85516|
NCT01600742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110052MB|Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis|Vorinostat and Concomitant Whole Brain Radiation Therapy in Patients With Brain Metastases: A Randomized, Double-blind, Placebo-controlled, Phase II Study||National Taiwan University Hospital|Yes|Terminated|August 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|20 Years|N/A|No|||January 2014|January 7, 2014|April 23, 2012||No|Sponsor stops to provide the study drug.|No||https://clinicaltrials.gov/show/NCT01600742||85796|
NCT01600482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIP-TS-003|Clinical Investigation for Safety and Efficacy Study of CELT ACD Arterial Closure Device|Clinical Investigation Plan for Safety and Efficacy Study of Arterial Closure Device (CELT ACD). Clinical Investigation Plan No.: CIP-TS-003||Vasorum Ltd|Yes|Recruiting|May 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|207|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01600482||85816|
NCT01600716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-117|Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)|||Allergan|No|Completed|June 2012|March 2015|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|144|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|May 15, 2012|Yes|Yes||No|February 17, 2016|https://clinicaltrials.gov/show/NCT01600716||85798|
NCT01600729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-119|Reliability of the Facial Wrinkle Scale in Japanese Subjects|||Allergan|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|66|||Both|20 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with facial lines|September 2013|September 27, 2013|May 15, 2012||No||No|July 12, 2013|https://clinicaltrials.gov/show/NCT01600729||85797|
NCT01600703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sitagliptin-REB-09-0428-B|Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans|Sitagliptin (®Januvia) Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans||University Health Network, Toronto|No|Completed|July 2012|August 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|15|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|April 2, 2014|May 15, 2012||No||No|March 24, 2014|https://clinicaltrials.gov/show/NCT01600703||85799|
NCT01601548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012NTLS014|Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy|Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy||Masonic Cancer Center, University of Minnesota|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|45|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|April 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601548||85734|
NCT01601561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-105-SDR|The Effect of Insulin on Protein Metabolism After Cardiac Surgery|The Effect of Insulin on Protein Metabolism After Cardiac Surgery||McGill University Health Center|No|Recruiting|June 2010|||December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|90 Years|No|||May 2012|May 17, 2012|March 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01601561||85733|
NCT01603056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS-M-01|Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis|A Randomised, Double-blind, Placebo-controlled Phase III Multicentre Clinical Trial Investigating the Efficacy and Safety of Pangramin SLIT HDM-mix in Chinese Population With House Dust Mite Induced Rhinitis With or Without Asthma.||ALK-Abelló A/S|No|Completed|October 2009|February 2012|Actual|February 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|617|||Both|5 Years|55 Years|No|||January 2015|January 19, 2015|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01603056||85618|
NCT01603069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D0490C00005|A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease|A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease||AstraZeneca||Completed|October 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|51|||Both|30 Years|80 Years|No|||July 2013|July 18, 2013|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603069||85617|
NCT01590667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/028711|Effect of Litramine on Fat Excretion|Double-blind, Randomized, Placebo-controlled, Crossover Clinical Investigation to Evaluate the Effect of Litramine on Fecal Fat Excretion in Healthy Subjects||InQpharm Group|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590667||86570|
NCT01590680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDI2007-01|Expanded Access Protocol Using I131-MIBG|An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma||Jubilant DraxImage Inc.||Available||||||N/A|Expanded Access|N/A|||||||Both|12 Months|N/A||||February 2016|February 24, 2016|May 1, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01590680||86569|
NCT01590693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S4|Botulinum Toxin A for Idiopathic Toe-walking|Botulinum Toxin A Does Not Improve Cast Treatment for Idiopathic Toe-walking- a Prospective Randomized Trial.||Karolinska Institutet|No|Completed|November 2005|April 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|52|||Both|5 Years|15 Years|No|||May 2012|May 2, 2012|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590693||86568|
NCT01591044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-940343-004|A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients With Mild to Moderate Allergic Asthma|SITAR|Rigel Pharmaceuticals|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|300|||Both|18 Years|70 Years|No|||August 2013|August 12, 2013|April 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591044||86541|
NCT01591278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-ODP-1|MTA and Biodentine in Pulpotomized Primary Molars|Clinical and Radiographic Outcomes of MTA and Biodentine in Pulpotomized Primary Molars. A Randomized Clinical Trial||Universitat Internacional de Catalunya|No|Active, not recruiting|March 2012|November 2014|Anticipated|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|4 Years|9 Years|No|||November 2014|November 11, 2014|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01591278||86523|
NCT01591252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVBone_K12|Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)|Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)||University of Alabama at Birmingham|Yes|Completed|April 2012|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|19 Years|N/A|No|Non-Probability Sample|For primary outcomes: 1917 Clinic cohort. For secondary outcomes: Medicare sample.|January 2015|January 26, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01591252||86525|
NCT01591746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-001687|Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction|Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial||Mayo Clinic|No|Recruiting|August 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|128|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 5, 2016|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591746||86487|
NCT01591759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCL 2011-P-002028|A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI)|A Pilot Trial of Citicoline in Individuals With mTBI||Mclean Hospital|No|Withdrawn|April 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|35 Years|No|||April 2014|April 22, 2014|February 29, 2012|Yes|Yes|Our citicoline supply expired and the exact product has discontinued.|No||https://clinicaltrials.gov/show/NCT01591759||86486|
NCT01587833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116440|WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture|WEUKBRE5559: IMI PROTECT (Work Package 2): Use of Benzodiazepines and Risk of Hip/Femur Fracture||GlaxoSmithKline|No|Completed|November 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of all patients included in the period of valid data        collection from the following data bases: Bavarian, Mondriaan, National Databases        (Denmark), GPRD, BIFAP and THIN. The study period will be defined from January 1, 2001 to        December 31, 2009.|July 2014|July 3, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01587833||86785|
NCT01588093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDIGF-1|IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations|Insulin-like Growth Factor (IGF-I) Induced Muscle Glucose Uptake and Interstitial IGF-1 Concentrations.||Karolinska University Hospital|Yes|Completed|April 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|8|||Both|18 Years|23 Years|No|||April 2012|April 27, 2012|April 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01588093||86765|
NCT01588158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001670|Patient Satisfaction With Pain Relief After Ambulatory Hand Surgery|Satisfaction With Pain Relief After Carpal Tunnel Release Surgery||Massachusetts General Hospital|No|Enrolling by invitation|July 2012|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588158||86760|
NCT01588457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC20110361H|Sequential Multiple Assignment Treatment for Bipolar Disorder|Sequential Multiple Assignment Randomized Treatment (SMART)for Bipolar Disorder|SMART|The University of Texas Health Science Center at San Antonio|Yes|Active, not recruiting|June 2011|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|200|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01588457||86737|
NCT01604109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TU-Dent-01|Effect of CPP-ACP Paste on Dental Caries in Primary Teeth|Effect of CPP-ACP Paste on Dental Caries in Primary Teeth: A Randomized Trial||Thammasat University|No|Completed|July 2010|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|296|||Both|30 Months|42 Months|Accepts Healthy Volunteers|||June 2013|June 10, 2013|May 19, 2012||No||No|June 10, 2013|https://clinicaltrials.gov/show/NCT01604109||85537|This one year study was performed on high caries risk pre-school children who enrolled in government nursery schools in central part of Thailand.
NCT01604395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-HGOS001|Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA and ISS in Children|An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. / Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA and ISS in Children|LGS|LG Life Sciences|Yes|Recruiting|January 2012|January 2022|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2000|||Both|2 Years|N/A|No|Non-Probability Sample|children with GHD, TS, CRF, SGA and ISS|March 2016|March 21, 2016|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604395||85515|
NCT01604408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14499|A Study in Older Participants Who Have Fallen and Have Muscle Weakness|A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness||Eli Lilly and Company|Yes|Completed|May 2012|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|172|||Both|75 Years|N/A|No|||December 2013|April 14, 2014|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01604408||85514|
NCT01604655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-307|ProspEctive First Evaluation in Chest Pain Trial|ProspEctive Randomized First Evaluation in Chest Pain Trial|PERFECT|St. Luke's-Roosevelt Hospital Center|No|Completed|September 2011|December 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|411|||Both|45 Years|N/A|No|||March 2016|March 7, 2016|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01604655||85495|
NCT01600755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-025|Autologous Cell Therapy for Treatment of Fecal Incontinence|A Prospective Nonrandomized Study of Autologous Muscle Derived Cell (AMDC) Transplantation for Treatment of Fecal Incontinence||Cook||Recruiting|May 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 26, 2015|May 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01600755||85795|
NCT01600768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200912104M|Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients|||National Taiwan University Hospital||Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||February 2012|May 16, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01600768||85794|
NCT01601015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UVT002|Effectiveness of the Treatment of Tension-type Headache With Manual and Manipulative Therapy|Effectiveness of the Treatment of Tension-type Headache With Manual and Manipulative Therapy in the Perception of Pain and Cervical Motion: a Double-blind, Randomized, Placebo-controlled Clinical Trial.||University of Valencia|Yes|Completed|January 2010|December 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|84|||Both|18 Years|65 Years|No|||May 2012|May 16, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01601015||85775|
NCT01601002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSREB-102574|LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression|Does LEPR Polymorphism Predict Variability in Weight Gain Induced by Mirtazapine in the Treatment of Late Life Depression?||Lawson Health Research Institute|No|Recruiting|June 2012|June 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|70|||Both|50 Years|90 Years|No|||October 2014|October 29, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601002||85776|
NCT01601587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4.2009.77.2009/1980 ( part 2)|Introduction Seminar About Patient Participation and Treatment Options Decisional Preferences|Introduction Seminar About Patient Participation, Treatment Options and Decisional Preferences for Psychiatric Outpatients on Waiting List||Norwegian University of Science and Technology|No|Completed|May 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|70 Years|No|||December 2015|December 21, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01601587||85731|
NCT01590433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000310|Weight Loss With Exenatide Treatment|A Prospective Study of Patterns, Predictors, and Mechanisms of Weight Loss With Exenatide Treatment in Overweight and Obese Women Without Diabetes||Beth Israel Deaconess Medical Center|Yes|Recruiting|March 2012|September 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|70 Years|Accepts Healthy Volunteers|||November 2015|November 13, 2015|February 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590433||86588|
NCT01590446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111-101|A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers|A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers||BioMarin Pharmaceutical|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|74|||Male|22 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|March 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590446||86587|
NCT01591018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT13498-4/2012|SONOlysis in Risk REduction of Symptomatic and Silent Brain infarCtions dUring Cardiac surgEry|Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring|SONORESCUE|University Hospital Ostrava|Yes|Completed|September 2012|July 2015|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|120|||Both|40 Years|90 Years|No|||August 2015|August 29, 2015|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01591018||86543|
NCT01591551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US-TYS-11-10221|NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness|NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness||Cornerstone Health Care, PA|No|Completed|March 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|37|||Both|18 Years|65 Years|No|||January 2014|January 28, 2014|April 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01591551||86502|
NCT01591772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-075|Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer|Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|36|||Female|21 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be identified and recruited by physicians in the Gynecologic Medical        Oncology Clinic at MSKCC.|October 2015|October 5, 2015|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01591772||86485|
NCT01591512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDI-36|A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer|A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell||Fujirebio Diagnostics, Inc.||Terminated|May 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4|Samples Without DNA|Collection of whole blood and urine.|Both|18 Years|N/A|No|Non-Probability Sample|Small cell lung cancer patients undergoing treatment.|March 2015|March 4, 2015|May 2, 2012||No|Decision was made by Sponsor to stop the trial.|No||https://clinicaltrials.gov/show/NCT01591512||86505|
NCT01591525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EADCEC-001|Diabetes Mellitus Community Based Screening in Minority Populations|Diabetes Mellitus Community Based Screening in Minority Populations||Ethnicity and Disease Community Empowerment Center||Not yet recruiting|June 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||4|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents in Boston Public Housing|May 2012|May 3, 2012|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591525||86504|
NCT01587872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSK_DBC|Double-balloon Colonoscopy to Increase Colonoscopy Completion Rate|Double-balloon Colonoscopy to Increase Cecal Intubation Rate in Technically Difficult Colonoscopies||Sorlandet Hospital HF|No|Terminated|October 2011|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|62|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||April 2012|April 11, 2014|January 12, 2012||No|Slow patient recruitment, not enough patients willing to participate within the prespecified    time frame.|No||https://clinicaltrials.gov/show/NCT01587872||86782|
NCT01591733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-328|FOLFIRINOX + RT for Pancreatic Cancer|Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer||Massachusetts General Hospital|Yes|Recruiting|May 2012|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|April 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591733||86488|
NCT01587573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PeriRx-1|Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer|Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma||PeriRx|Yes|Recruiting|April 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|370|Samples With DNA|cell free saliva|Both|18 Years|N/A|No|Non-Probability Sample|patients with oral lesions suspicious for squamous cell cancer and scheduled for        clinically driven biopsy|August 2015|December 19, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587573||86805|
NCT01588782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100650|A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone (JNJ-589485) Following Administration of Abiraterone Acetate (JNJ-212082) Tablets in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 23, 2012|January 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01588782||86714|
NCT01589068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-p-001985|Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs|||Mclean Hospital|No|Suspended|January 2007|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|300|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|April 27, 2012|Yes|Yes|Clinical studies stopped, pending funding.|No||https://clinicaltrials.gov/show/NCT01589068||86692|
NCT01589354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/S0801/74|Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery|Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery||NHS Grampian|No|Not yet recruiting|May 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||April 2012|April 30, 2012|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01589354||86670|
NCT01604681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|171/2011|Supplementation With Flaxseed Oil in the State of Rio de Janeiro|The Effect of Flaxseed Oil Supplementation on Biomarkers, Quality of Life and Cognitive Function in Hypertensive and Dyslipidemic Subjects With or Without the C677T and A1298C Polymorphisms in MTHFR Gene in Different Municipalities of Rio de Janeiro||Universidade Federal do Rio de Janeiro|Yes|Recruiting|January 2011|December 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|200|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||December 2010|May 23, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01604681||85493|
NCT01600495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR259137|Transcutaneous Electrical Nerve Stimulation for Pain Relief During the Active Phase of Labor|Effects of Transcutaneous Nerve Electrical Stimulation for Pain Relief in Nulliparous Women in Active Phase of Labor||University of Sao Paulo|Yes|Completed|September 2011|January 2013|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|46|||Female|15 Years|30 Years|Accepts Healthy Volunteers|||September 2015|September 18, 2015|September 19, 2011||No||No|May 16, 2012|https://clinicaltrials.gov/show/NCT01600495||85815|
NCT01601041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP-003|Role of Residual Urine and Asymptomatic Prostatitis in the Development of Urinary Tract Infections in Spinal Cord Injury|Role of Residual Urine and Asymptomatic Prostatitis in the Development of Lower Urinary Tract Infections in Spinal Cord Injury Patients - a Prospective Study||Swiss Paraplegic Centre Nottwil|No|Completed|December 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|60|||Male|18 Years|70 Years|No|Non-Probability Sample|Male patients with chronic (> 1 year) spinal cord injury who perform intermittent        catheterization due to neurogenic bladder dysfunction|February 2013|February 11, 2013|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01601041||85773|
NCT01601028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hydroxychloroquine|Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome|Phase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome||Seoul National University Hospital|Yes|Completed|July 2011|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|39|||Both|19 Years|N/A|No|||October 2013|October 16, 2013|April 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01601028||85774|
NCT01601249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|008212- HMO-CTIL|Improving IVF Embryo Quality Grading Using Polarized Light|A Prospective Comparison Between Conventional IVF Embryo Grading and Polscope Based Grading||Hadassah Medical Organization|No|Withdrawn|September 2012|August 2015|Actual|August 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Female|18 Years|38 Years|No|||May 2012|August 19, 2015|May 3, 2012||No|PI moved from Hadassah|No||https://clinicaltrials.gov/show/NCT01601249||85757|
NCT01602263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15657|Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing|Transcranial Direct Current Stimulation (tDCS)and Cognitive Processing||Johns Hopkins University|Yes|Recruiting|January 2009|December 2030|Anticipated|January 2025|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|300|||Both|18 Years|79 Years|Accepts Healthy Volunteers|Non-Probability Sample|You must also belong to one of three groups to join this study:          1. Healthy adults with no known deficits in cognition          2. Adults with acquired language problems (i.e., stroke, mental illness)          3. Adults with developmental language delays|August 2015|August 31, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01602263||85679|
NCT01602549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115816|A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying||GlaxoSmithKline|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|58|||Both|40 Years|80 Years|No|||February 2015|February 5, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602549||85657|
NCT01602562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116100|Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients|A Multicenter, Open-label Study to Evaluate Preventive Efficacy for Herpes Simplex Virus Infection and Safety of 256U87 (Valaciclovir Hydrochloride) in Adult and Pediatric Hematopoietic Stem Cell Transplantation Patients||GlaxoSmithKline|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|40|||Both|1 Year|64 Years|No|||January 2014|February 27, 2014|May 17, 2012||No||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01602562||85656|
NCT01602575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO1AT007137|Neuroimaging and Biomarkers in Chronic Visceral Pain|Neuroimaging Biomarkers of Mind-Body Treatment Response in Chronic Visceral Pain||University of California, Los Angeles|Yes|Recruiting|January 2013|May 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|18 Years|50 Years|No|||May 2014|May 20, 2014|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602575||85655|
NCT01590706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC1101|A Study of Characterizing Cognitive Decline and Functional Cardiac Senescence in Healthy Korean Volunteers|An Association Study of Characterizing Cognitive Decline and Functional Cardiac Senescence Profile Through the Association of Biomarkers and Clinical Outcomes in Healthy Middle Aged and Elderly Korean Volunteers||Korea Institute of Oriental Medicine|Yes|Completed|November 2011|March 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|116|Samples With DNA|Samples for single nucleotide polymorphism, and for cardiac enzyme level detection|Both|45 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy middle aged (45-64 age) and elderly (over 65 age) person|April 2014|April 1, 2014|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01590706||86567|
NCT01590719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO28252|A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative Gastroesophageal Cancer||Hoffmann-La Roche||Completed|July 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|123|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01590719||86566|
NCT01590732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0183|Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma|Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma||M.D. Anderson Cancer Center|No|Recruiting|October 2012|||October 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|May 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01590732||86565|
NCT01591031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2011 124|Laryngeal Injuries After Anesthesia Induction With Sevoflurane and After Anesthesia Induction With Rocuronium|Laryngeal Injuries After Anesthesia Induction With Sevoflurane and After Anesthesia Induction With Rocuronium. A Randomized, Prospective, Controlled Trial||University of Rostock|No|Completed|April 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|80 Years|No|||February 2013|February 13, 2013|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01591031||86542|
NCT01587612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON-02-005-OSi|Study of Quantification of Hyperpronation|Study of Quantification of Hyperpronation||Northern Orthopaedic Division, Denmark|No|Completed|August 2003|March 2004|Actual|December 2003|Actual|N/A|Observational|N/A||1|Actual|80|||Both|18 Years|68 Years|No|Non-Probability Sample|Hyperpronation of foot|March 2014|March 28, 2014|January 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01587612||86802|
NCT01587625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxytocin high low dose|High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour|High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour|OxyHighLow|Göteborg University|Yes|Recruiting|August 2013|December 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1376|||Female|18 Years|60 Years|No|||March 2016|March 3, 2016|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01587625||86801|
NCT01591538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAV148-EPI-01|Multi-Antibiotic Resistance Carriage in Gut Flora|Prevalence Study Evaluating the Acquisition of Carriage of Resistant Bacteria in the Gut Flora in Volunteers From French Armed Forces Coming Back From External Operations|MARC|Da Volterra|No|Completed|March 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|272|Samples Without DNA|Stool|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Volunteers from French Armed Forces|May 2014|May 28, 2014|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01591538||86503|
NCT01588184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO25757|An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study|An Open Label Multicentre Extension Study of Bevacizumab Administered as Single Agent or in Combination With Other Anticancer Therapies in Patients on Study Treatment With Bevacizumab at the End of a F. Hoffmann-La Roche and/or Genentech Sponsored Study||Hoffmann-La Roche||Recruiting|July 2012|May 2024|Anticipated|May 2024|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|April 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01588184||86758|
NCT01588197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR # 20270|Real-Time fMRI Feedback Effects on Pain Perception|Real-Time fMRI Feedback Effects on Pain Perception||Medical University of South Carolina||Active, not recruiting|November 2010|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|October 1, 2015|February 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01588197||86757|
NCT01587586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A11-201|Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With HCV Genotype 1 Infection|An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection||PharmaEssentia|No|Recruiting|October 2011|||December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|208|||Both|18 Years|N/A|No|||April 2012|April 27, 2012|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01587586||86804|
NCT01587859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniboDipTrap|Short Esophagus in Type II-IV Hiatus Hernia|Frequency of True Short Esophagus in Type II-IV Hiatus Hernia|SEHH|University of Bologna|No|Completed|January 1995|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|Patients consecutively operated upon with minimally invasive surgery for type II-IV hiatus        hernia in the period January 1995 - December 2010.|April 2012|April 27, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01587859||86783|
NCT01589081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-p-000454|Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect|Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect||Mclean Hospital|No|Suspended|September 2008|||December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|45|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|April 27, 2012|Yes|Yes|Clinical studies are stopped, pending funding.|No||https://clinicaltrials.gov/show/NCT01589081||86691|
NCT01589094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-071|Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer|Phase II Study of Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01589094||86690|
NCT01589367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG 013|Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer|Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer||Seoul National University Hospital|Yes|Recruiting|May 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|208|||Female|18 Years|80 Years|No|||June 2015|November 18, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01589367||86669|
NCT01604694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/10|Ultrasound-guided Transversus Abdominis Plane Block for Analgesia After Abdominoplasty|Ultrasound-guided Transversus Abdominis Plane Block for Analgesia After Abdominoplasty: Randomized- Controlled- Trial Double Blind Monocentric Study, Against Placebo|TAPlastie|University Hospital, Bordeaux|No|Completed|June 2012|October 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|52|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01604694||85492|
NCT01600508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/1432a (REK)|Videoconference Stoma Consultation|Videoconference in Stoma Out-patient Clinic. A Randomized Controlled Trial||University Hospital of North Norway|No|Enrolling by invitation|September 2011|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01600508||85814|
NCT01601639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030955|Endoscopic Band Ligation Versus Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial|Endoscopic Band Ligation vs Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial||University of Alberta|Yes|Completed|September 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|90 Years|No|||July 2013|July 5, 2013|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601639||85727|
NCT01601275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005/060/CTBdatabase|Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection|Prospective Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection Treated at Singapore General Hospital||Singapore General Hospital|No|Recruiting|May 2012|May 2022|Anticipated|May 2022|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|4000|||Both|21 Years|N/A|No|Non-Probability Sample|All patients with microbiologically proven mycobacteria tuberculosis infection treated at        the Singapore General Hospital.|November 2014|November 26, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601275||85755|
NCT01601600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338X2201|A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults|A Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults With Mobility Limitations||Novartis|Yes|Completed|January 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|N/A|No|||February 2015|February 4, 2015|February 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601600||85730|
NCT01601262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0179-12-RMB|Efficacy & Safety of a 2nd Series of Low Intensity Shock Waves for ED on Partial Responders to First Treatment|Efficacy and Safety of a Second Series of Low Intensity Extracorporeal Shock Wave Therapy (LI-ESWT) Treatment for Erectile Dysfunction Patients Who Were Partial Responders to the Initial Treatment.||Rambam Health Care Campus|No|Not yet recruiting|July 2012|January 2015|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Male|18 Years|80 Years|No|||July 2012|July 25, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601262||85756|
NCT01601574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WW-MUSC-1201|Weight Loss Study for People With Type 2 Diabetes|Effects on Glycemic Control and Weight of a Modified Commercial Weight Control Program for People With Type 2 Diabetes|T2D|Medical University of South Carolina|No|Completed|May 2012|September 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|563|||Both|18 Years|70 Years|No|||March 2012|October 14, 2014|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01601574||85732|
NCT01601990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DPCL005|Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes|A Multicenter, Multinational, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes||LG Life Sciences||Completed|December 2009|November 2011|Actual|March 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|189|||Both|18 Years|75 Years|No|||May 2012|May 17, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601990||85700|
NCT01602289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14637|A Study of LY2875358 in Japanese Participants With Advanced Cancer|A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies||Eli Lilly and Company|No|Completed|June 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|17|||Both|20 Years|N/A|No|||June 2015|June 4, 2015|May 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01602289||85677|
NCT01602588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL11/0404|A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)|A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)|HCQ|University College, London|Yes|Recruiting|May 2013|May 2017|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|57|||Both|70 Years|100 Years|No|||December 2015|December 7, 2015|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01602588||85654|
NCT01602822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS PEP|Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV|A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for Non-occupational Prophylaxis Following Potential Exposure to HIV-1|BMS PEP|Fenway Community Health|No|Terminated|February 2012|May 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 6, 2013|February 8, 2012|Yes|Yes|Grade 3 elevation in liver function tests|No||https://clinicaltrials.gov/show/NCT01602822||85636|
NCT01590472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GTS 36076 MARF|Do Your Genes Put You at a Higher Risk of Developing Mesothelioma|Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma||Wake Forest School of Medicine|No|Recruiting|June 2011|December 2015|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|1000|Samples With DNA|whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the clinics and in patient wards of the academic medical        centers noted as collaborators.|July 2014|July 9, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01590472||86585|
NCT01591291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G15991|Pharmacogenetic Treatments for Alcoholism|1/2 - Pharmacogenetic Treatments for Alcoholism||University of Virginia|Yes|Not yet recruiting|June 2012|February 2018|Anticipated|December 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|256|||Both|18 Years|65 Years|No|||May 2012|May 2, 2012|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01591291||86522|
NCT01588210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120-01|Fluoride Concentration in Inter-proximal Fluid From Dental Sealants|Fluoride Concentration in Inter-proximal Fluid From Dental Sealants.||Università degli Studi di Sassari|No|Completed|January 2008|June 2010|Actual|March 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2776|||Both|6 Years|7 Years|No|||May 2012|May 17, 2012|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588210||86756|
NCT01588223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-C-069-OB|Non Invasive Diagnostic of Endometrial Receptivity|A Non Invasive Diagnostic of Endometrial Receptivity Based on Lipidomic Profile on Endometrial Fluid.||Igenomix|No|Completed|January 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588223||86755|
NCT01588522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTL0211|Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease|Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease||Berg, LLC|Yes|Recruiting|July 2012|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588522||86732|
NCT01587599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI_CLIN_PHARM_EMAU_01|Pharmaceutical Care of Patients With Impaired Mobility in a Model-region of Decreasing Supply of Medical Services|Pharmaceutical Care of Elderly Diabetes-patients With Impaired Mobility in a Model-region of Decreasing Supply of Medical Services in North-eastern Germany||Foerderinitiative Pharmazeutische Betreuung e.V.|No|Active, not recruiting|June 2010|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|54|||Both|65 Years|N/A|No|||April 2012|April 27, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01587599||86803|
NCT01588808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 12-3-012|Immobilization and Protein Supplementation (IM-PRO)|The Impact of Dietary Protein Supplementation and Age on Muscle Mass Loss During Short Term One-legged Knee Immobilization|IM-PRO|Maastricht University Medical Center|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|35|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588808||86712|
NCT01588171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hawler Medical University|Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum|Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial||Hawler Medical University|No|Completed|May 2012|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|7020|||Female|15 Years|48 Years|No|||March 2015|March 17, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01588171||86759|
NCT01588470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM20060280|Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)|Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) - Role of Intramyocellular Lipid Content and Mitochondrial Dysfunction in Myocardial Insulin Resistance and Their Correction With Pioglitazone||The University of Texas Health Science Center at San Antonio|No|Completed|June 2006|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2012|April 30, 2012|March 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01588470||86736|
NCT01588795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110122|Renal Denervation in Diabetic Nephropathy|Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria|DERENEDIAB|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|April 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|75 Years|No|||June 2013|April 2, 2015|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01588795||86713|
NCT01589705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erciyes 2011/273|The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease|Endothelial Dysfunction in Patients With Polycystic Kidney Disease||TC Erciyes University|No|Terminated|January 2012|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|150|||Both|20 Years|60 Years|No|Non-Probability Sample|Patients with early stage(preserved renal function) Autosomal dominant polycystic kidney        disease (n = 91) from two academic medical center.We also excluded the patients with a        previous diagnosis of hypertension, gout, diabetes, current use of oral antidiabetic        medication, insulin, thiazide, allopurinol or uricosuric, or a fasting glucose level 126        mg/dl. In addition, the subjects with a history of smoking or current use of any        anti-hypertensive medication and statins were excluded|July 2012|July 29, 2012|April 30, 2012||No|Patients recruitment and analysis were terminated|No||https://clinicaltrials.gov/show/NCT01589705||86643|
NCT01586845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISA10-12|Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation|A Phase III, Randomized, Multicentre, Open-Label, Concentration-Controlled, Safety and Efficacy Study of Voclosporin and Tacrolimus in Renal Transplantation|INSPIRE|Aurinia Pharmaceuticals Inc.|Yes|Withdrawn|March 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|65 Years|No|||January 2014|January 16, 2014|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01586845||86861|
NCT01586858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27815|Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study|Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study|RAVELOS|Johns Hopkins University|No|Enrolling by invitation|May 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|||Both|12 Years|N/A|No|Non-Probability Sample|RAVE study participants|April 2012|April 25, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01586858||86860|
NCT01600521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205E14290|A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications|A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|November 2004|March 2012|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1748|||Both|18 Years|N/A|No|||April 2015|April 7, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01600521||85813|
NCT01600781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHE-ALL001|Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic Leukemia|Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed on the Nutritional Status, Gut Microbiota and Quality of Life of Children With Acute Lymphocytic Leukemia: an Egyptian Pilot Study||Children's Cancer Hospital Egypt 57357|Yes|Completed|December 2011|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|120|||Both|2 Years|12 Years|No|||February 2015|February 8, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600781||85793|
NCT01601067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-011-11F|Integrated Alcohol Disorder and PTSD Treatment|Integrated Alcohol Disorder and PTSD Treatment||VA Office of Research and Development|Yes|Recruiting|January 2013|September 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|118|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|February 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01601067||85771|
NCT01601340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQP 1001-SCD-007|Effects of HQK-1001 in Patients With Sickle Cell Disease|A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease||HemaQuest Pharmaceuticals Inc.|Yes|Terminated|July 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|77|||Both|12 Years|60 Years|No|||March 2015|March 17, 2015|May 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601340||85750|
NCT01601977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVAPS AE in COPD|Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients|Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease: A Non-randomised Pilot Study|AVAPS AE|Guy's and St Thomas' NHS Foundation Trust|No|Recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|21 Years|90 Years|No|||May 2012|May 22, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01601977||85701|
NCT01601613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7-3015|Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever||Novo Nordisk A/S|No|Completed|July 2001|November 2002|Actual|November 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|28|||Both|N/A|18 Years|No|||May 2012|May 22, 2012|May 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601613||85729|
NCT01601964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEH GynObs-1|Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy|Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy|VEGF|Bagcilar Training and Research Hospital|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|30|||Female|18 Years|46 Years|No|Probability Sample|The patients with ectopic pregnancy|August 2015|August 6, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01601964||85702|
NCT01602302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-5; V2|Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis|Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis|RA-BioStop|Medical University of Graz|Yes|Recruiting|June 2012|September 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Anticipated|110|||Both|18 Years|90 Years|No|||February 2016|February 24, 2016|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602302||85676|
NCT01602315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719X2104|A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma||Novartis||Active, not recruiting|November 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|177|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602315||85675|
NCT01602601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116406|A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723|A Study to Test the Possibility of Cross Reaction of the Antibodies Induced by the ELAPRASE (R) to GSK2788723ELAPRASE is a Trade Mark Owned by a Third Party||GlaxoSmithKline|No|Completed|April 2012|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|10|Samples With DNA|blood samples will be collected and serum will be analyzed and retained|Both|N/A|N/A|No|Probability Sample|Approximately 11 subjects will be enrolled in the study.|October 2012|May 9, 2013|May 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01602601||85653|
NCT01591057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/07|Effect of Fruit and Vegetable Intake on Markers of Fruit and Vegetable Consumption|Effect of Increased Fruit and Vegetable Intake on Biomarkers of Fruit and Vegetable Consumption|BIOFAV|Queen's University, Belfast|Yes|Completed|June 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2012|November 22, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01591057||86540|
NCT01615835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067.3|EnSite NavX-Guided Coronary Sinus Mapping During CRT Implant|Mapping in the Coronary Sinus During Implant of a Bi-Ventricular Implantable Cardioverter Defibrillator Utilizing the NavX Mapping System|Bi-VNavX|St. Jude Medical|No|Completed|April 2007|October 2007|Actual|October 2007|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|75 Years|No|||January 2008|June 6, 2012|December 21, 2007||No||No||https://clinicaltrials.gov/show/NCT01615835||84637|
NCT01615679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6520-0660-02|Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder|Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder (ADHD)|IDEA|Medice Arzneimittel Pütter GmbH & Co KG|No|Completed|August 2012|August 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|468|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult patients with newly diagnosed ADHD who shall be treated with Medikinet(R) adult.|April 2015|April 14, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615679||84649|
NCT01616199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PX-866-007|Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma|Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma||Oncothyreon Inc.|Yes|Terminated|August 2012|March 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|June 6, 2012|Yes|Yes|slow accrual|No||https://clinicaltrials.gov/show/NCT01616199||84609|
NCT01617499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109022|Physical Activity for Campus Employees|Physical Activity for Campus Employees|PACE|Washington University School of Medicine|No|Completed|January 2012|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|141|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study population will consist of employees of Washington University in St. Louis. A        convenience sample of staff employees located on the Danforth campus will be enrolled.|May 2015|May 19, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01617499||84510|
NCT01617512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 1116|Study Accelerometer Signals to Measure Daily Activities (SASMDA)|Study Accelerometer Signals to Measure Daily Activities: a Pilot Study||University Hospital, Grenoble|Yes|Completed|February 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|30|||Male|18 Years|N/A|No|||April 2014|April 10, 2014|December 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01617512||84509|
NCT01613963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12DEV0010|Causes of Visual Loss in Retinal Disease|Observational Study of Visual Outcomes in Retinal Disease||Royal Surrey County Hospital|No|Enrolling by invitation|May 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2000|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with ocular inflammation|June 2012|June 5, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01613963||84780|
NCT01615081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B287|The Acute Effect of Malt Extract Versus Sucrose on the Response of Glucose and Insulin, Subjective Appetite Sensations and ad Libitum Energy Intake||Harboe|University of Copenhagen|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2012|October 4, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615081||84694|
NCT01615380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA021729|Exercise to Enhance Smoking Cessation for Women at the YMCA|Using a YMCA Exercise Program to Enhance Nicotine Dependence Treatment for Women||The Miriam Hospital|No|Completed|September 2006|April 2012|Actual|September 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|408|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 6, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01615380||84672|
NCT01616784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15295|The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial|The Relative Effectiveness of Pumps Over Multiple Dose Injections and Structured Education Trial|REPOSE|Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Completed|November 2011|November 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|267|||Both|18 Years|N/A|No|||November 2014|November 20, 2015|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01616784||84565|
NCT01617525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Korean Diet Study|A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles|A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles||USDA Beltsville Human Nutrition Research Center|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|29|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 11, 2012|March 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01617525||84508|
NCT01626326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCapp-1|San Francisco Stop Smoking App - Pilot Study|Evaluation of a Stop Smoking iPhone App|TCapp-1|University of California, San Francisco|No|Recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12000|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adults who use iPhone stop smoking apps|May 2015|May 21, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626326||83835|
NCT01606410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRI-IPC-aging|The Impact of Age and Fitness on Reperfusion Injury and Ischemic Preconditioning to Prevent This Injury|The Impact of Age and Fitness on Endothelial Reperfusion Injury and the Ability of Ischemic Preconditioning to Prevent This Injury||Radboud University|No|Completed|April 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||4|Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study population: Young sedentary volunteers (n=23, age 18-30), young active volunteers        (n=23, age 18-30), older sedentary subjects (n=23, >55 years) and older physically active        subjects (n=23, >55 years).|November 2013|November 19, 2013|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606410||85360|
NCT01605539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21 DA027781(2)|Acute and Short-term Effects of Cannabidiol Administration on Cue-induced Craving in Drug-abstinent Heroin Dependent Subjects|Cannabidiol as Treatment Intervention for Opioid Relapse||Hurd,Yasmin, Ph.D.|Yes|Active, not recruiting|May 2012|April 2016|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|10|||Both|21 Years|65 Years|No|||March 2015|March 17, 2015|May 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605539||85427|
NCT01605825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALF-PS-1003|A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke|A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke||Acorda Therapeutics|Yes|Completed|May 2012|March 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|85 Years|No|||December 2015|December 18, 2015|May 21, 2012|Yes|Yes||No|January 28, 2014|https://clinicaltrials.gov/show/NCT01605825||85405|
NCT01605838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABM-TBI-0001|Noninvasive Monitoring of Cerebral Blood Flow Autoregulation in Patients With Traumatic Brain Injury (TBI)|Pilot (Feasibility) Study of New Portable Monitor for Continuous Assessment of Cerebral Blood Flow (CBF) Autoregulation in Patients With Moderate to Severe Traumatic Brain Injury (TBI)|REG01|Advanced Brain Monitoring, Inc.|No|Withdrawn|August 2012|May 2014|Actual|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|65 Years|No|Non-Probability Sample|Adult patients (18 - 65 years) hospitalized in the surgical intensive care unit (ICU)        because of moderate to severe traumatic brain injury|January 2015|January 12, 2015|May 22, 2012||No|A series of administrative delays on all sides involved, combined with funding problems.|No||https://clinicaltrials.gov/show/NCT01605838||85404|
NCT01607229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-D2O-TBW|Multi-frequency Bioelectrical Impedance for Estimating Total Body Water by Deuterium Dilution|Utility of Multi-frequency Bioelectrical Impedance Compared to Deuterium Dilution for Assessment of Total Body Water||University of Southern California|Yes|Completed|January 2010|May 2010|Actual|May 2010|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|25|||Both|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|community sample|May 2012|May 24, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01607229||85297|
NCT01607242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|thyro25|Impact of Total Thyroidectomy on Voice and Swallowing|Study of Total Thyroidectomy Effect on Voice and Swallowing Function||University of Thessaly|Yes|Recruiting|March 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients undergoing total thyroidectomy|May 2012|May 24, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01607242||85296|
NCT01606085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00026671|Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes|Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes|QUALITYHF-DM|Emory University|No|Completed|September 2009|April 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|141|||Both|21 Years|80 Years|No|||September 2013|April 22, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01606085||85385|
NCT01606397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11071|A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes|The Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Doses of LY2409021 in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|March 2008|November 2008|Actual|November 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Actual|50|||Both|21 Years|70 Years|No|||May 2012|May 23, 2012|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606397||85361|
NCT01616446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLINICS-D-12-00179R1|Pharmacokinetics of Cyclosporin in Nephrotic Syndrome|PHARMACOKINETICS OF CYCLOSPORIN - A MICROEMULSION IN CHILDREN WITH IDIOPATHIC NEPHROTIC SYNDROME||University of Sao Paulo|No|Completed|February 2007|February 2010|Actual|August 2009|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|10|Samples Without DNA|Whole blood|Both|1 Year|18 Years|No|Non-Probability Sample|Children with Iidiopathic nephrotic syndrome followed in the Pediatric Nephrology Unit of        Instituto da Criança-HCFMUSP|May 2012|June 8, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616446||84590|
NCT01615848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC12043-20kCTIL|Comparison Between Mediterranean Diet and High Protein Diet in Women With Polycystic Ovary Syndrome (PCOS)|Comparison Between Mediterranean Diet and High Protein Diet in Women With Pcos: Randomized Controlled Trial||Meir Medical Center|Yes|Not yet recruiting|April 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|35 Years|No|||February 2013|February 19, 2013|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01615848||84636|
NCT01616121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0037-12-HYMC|Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|June 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01616121||84615|
NCT01616134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRG-0912|Effect of Korean Red Ginseng on Insulin Sensitivity in Non Diabetic Overweight Korean Adults||KRGIS|The Korean Society of Ginseng||Completed|August 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01616134||84614|
NCT01615939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00058306|A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block|A Randomized Controlled Trial Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block||Northwestern University|No|Terminated|June 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|20|||Both|18 Years|80 Years|No|||October 2015|October 1, 2015|June 7, 2012||No|The study has been terminiated due to minimal subject recruitment|No||https://clinicaltrials.gov/show/NCT01615939||84629|
NCT01617239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INF-V-A017|Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine|A Phase I, Open Label, Randomized Study in Healthy Adults to Compare Safety and Immunogenicity of Different Administration Schedules of Virosomal Influenza Vaccine||Crucell Holland BV|No|Completed|June 2012|December 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|84|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01617239||84530|
NCT01617252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/9-H|High Flow Nasal Oxygen Therapy for Hypoxemy After Cardiac Surgery|High Flow Nasal Oxygen Therapy for Hypoxemy After Cardiac Surgery|Optiflow|Nantes University Hospital|No|Completed|June 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|90|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617252||84529|
NCT01614535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0356|Comparison of the Effect Site Concentration of Remifentanil for Preventing Cough During Emergence Between Male and Female Patients With Thyroidectomy|||Yonsei University|Yes|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|46|||Both|25 Years|46 Years|No|||June 2012|June 7, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01614535||84736|
NCT01614548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZU2012|Management of Prostate Cancer in Central China|Comparisons of Management and Outcome of Prostate Cancer in Central China Between 2003 and 2008: A Multi-institutional Report||Zhengzhou University|No|Completed|January 2003|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|789|||Male|N/A|N/A|No|Probability Sample|all inpatients with prostate cancer in 14 hospitals|June 2012|June 5, 2012|June 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01614548||84735|
NCT01625312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSGY-201202025-5|China PEACE-Prospective 3-vessel Disease Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Revascularization in Patients With Three-vessel Coronary Heart Disease||China National Center for Cardiovascular Diseases|Yes|Completed|December 2012|December 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2339|Samples With DNA|A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for      biomarker analysis and storage for future genetic studies;      A urine samples of 40mL will be collected at 1-month visit and 12-month visit for biomarker      analysis and storage.|Both|18 Years|N/A|No|Non-Probability Sample|In 25 tertiary hospitals with capability of Percutaneous Coronary Intervention and CABG in        China, 1500 hospitalized patients diagnosed as three-vessel coronary heart disease        following elective coronary angiograghy will be enrolled consecutively.|September 2014|May 3, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01625312||83913|
NCT01625559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA_CTP_0903|Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)|A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)||CHABiotech CO., Ltd|Yes|Active, not recruiting|September 2012|June 2015|Anticipated|March 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|3|||Both|20 Years|N/A|No|||August 2012|February 16, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01625559||83894|
NCT01625819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL096784-01A2|Exploring Behavioral Interventions to Improve Heart Failure|Exploring Tai Chi as a Behavioral Intervention for Heart Failure Patients||University of California, San Diego|Yes|Completed|August 2010|August 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|135|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01625819||83874|
NCT01626079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-512|COAPT Clinical Trial|Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation|COAPT|Evalve|Yes|Recruiting|August 2012|August 2020|Anticipated|January 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|430|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626079||83854|
NCT01616849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PF-N-UMNPC|Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma|Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Completed|May 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|70 Years|No|||September 2015|September 19, 2015|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01616849||84560|
NCT01616862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274342|The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis|The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis||State University of New York - Upstate Medical University|No|Completed|February 2012|August 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|53|||Both|5 Years|19 Years|No|Non-Probability Sample|Biological parents of children with cystic fibrosis who are treated at Upstate Medical        University. Children's age is more than 5 yrs and less than 20 yrs.|May 2015|May 29, 2015|January 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01616862||84559|
NCT01606683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLA-LENI-09 - SUBSTUDY 1|Impact of Infant Feeding on Newborn Metabolomic Profile|Impact of Infant Feeding on Newborn Metabolomic Profile||Heinz Italia SpA|No|Completed|April 2012|December 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|N/A|21 Days|No|||February 2015|February 2, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606683||85339|
NCT01606956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2012-0012|The Comparison of Two Different Methods of Partial Inflation of Cuff for Facile Insertion of Laryngeal Mask Airway in Adult Patients|The Comparison of Two Different Methods of Partial Inflation of Cuff for Facile Insertion of Laryngeal Mask Airway in Adult Patients||Yonsei University|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator)|2||Actual|80|||Both|20 Years|70 Years|No|||March 2014|March 4, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01606956||85318|
NCT01606969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0062|Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution|Randomized Controlled Trial to Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution for the Effect on Hemodynamic Response Due to Scalp Infiltration in Patients Undergoing Craniotomy||Yonsei University|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|20 Years|70 Years|No|||March 2014|March 4, 2014|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01606969||85317|
NCT01606423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11165|The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants|The Effect of LY2409021 on Blood Glucose Concentrations During Hyperglucagonaemia in Healthy Male Subjects||Eli Lilly and Company|No|Completed|November 2007|March 2008|Actual|March 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|21|||Male|21 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606423||85359|
NCT01606436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12676|A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia|A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia||Eli Lilly and Company|No|Completed|June 2012|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|60|||Both|18 Years|65 Years|No|||September 2012|September 28, 2012|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606436||85358|
NCT01607502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-408 ex 10/11|Database for Clinical and Anamnestic Data in Pulmonary Hypertension|Database for Clinical and Anamnestic Data in Pulmonary Hypertension||Medical University of Graz|No|Recruiting|July 2010|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|900|Samples With DNA|Blood samples are collected and stored anonymously in our biobank if patients give their      informed consent containing the option of DNA analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who come to our outpatient clinic with pulmonary haypertension, symptoms that may        be caused by pulmonary hypertension and patients at risk for pulmonary hypertension|September 2015|September 7, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01607502||85276|
NCT01617538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WS1788891-22-CT25|Application of Contrast Enhance Ultrasound to Evaluate Hemodynamics Change in MCA With Moderate to Severe Stenosis|Application of Contrast Enhance Ultrasound to Evaluate Hemodynamics Change in MCA With Moderate to Severe Stenosis After 24-week Atorvastatin Treatment||Capital Medical University|No|Recruiting|January 2012|September 2013|Anticipated|March 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|40 Years|90 Years|No|||June 2012|June 11, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01617538||84507|
NCT01616433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IU48DP09-0014918-01|Arthritis Foundation Exercise Program & "10 Keys" to Healthy Aging--Prevention Research Center|Arthritis Foundation Exercise Program & "10 Keys" to Healthy Aging|AFEP+10 Keys|University of Pittsburgh|Yes|Completed|March 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|462|||Both|50 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 17, 2014|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616433||84591|
NCT01616732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04495|Testosterone and Weight Loss|Effect of Testosterone and Diet on Weight||Austin Health|No|Completed|May 2012|December 2015|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|100|||Male|18 Years|80 Years|No|||January 2015|December 28, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01616732||84569|
NCT01616745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1103-057-355|Phenotypic Clinical, and Genetic Characteristics of Patients With Nontuberculosis Mycobacteria|Characteristics of Patients With Nontuberculosis Mycobacteria in Korean Population|Korean NTM|Seoul National University Hospital|No|Recruiting|July 2011|February 2021|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|N/A|No|Non-Probability Sample|persons met diagnostic criteria of NTM lung disease by ATS/IDSA on 2007|June 2012|June 11, 2012|March 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01616745||84568|
NCT01616758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200801|Phase II Study of GTx024 in Women With Metastatic Breast Cancer|Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy||GTx|No|Active, not recruiting|April 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|18 Years|N/A|No|||February 2016|February 5, 2016|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616758||84567|
NCT01616485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-04|Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo|A Double-blind, Randomized, Crossover Evaluation of the Hemodynamic Response to Sublingual Glyceryl Trinitrate in Patients Receiving TA-1790, Sildenafil, and Placebo||VIVUS, Inc.|Yes|Completed|March 2004|May 2004|Actual|May 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|106|||Male|30 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 12, 2012|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616485||84587|
NCT01617031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LRB-10-023|Aspirin Twice Daily in Diabetic Patients With Coronary Artery Disease|Biological Efficacy of Twice Daily Aspirin in Type 2 Diabetic Patients With Coronary Artery Disease||Hopital Lariboisière|No|Completed|September 2010|May 2012|Actual|March 2011|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|92|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive stable DM patients presenting to the Department of Cardiology, Lariboisiere        Hospital. Patients are eligible if they have DM and documented CAD and are treated for at        least 7 days with a non-enteric-coated aspirin.|June 2012|June 11, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01617031||84546|
NCT01618084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC10-1-068|RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem|A Prospective Randomised Rontgen Stereophotogrammatic Analysis (RSA) Study Using the Uncemented Trident Tritanium Acetabular Component and the Uncemented HA Coated Symax Hip Stem in a Single Centre: Assessment of Implant Migration, Bone Remodeling and Clinical Function|RSA|Maastricht University Medical Center|Yes|Recruiting|November 2011|December 2014|Anticipated|November 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|35 Years|70 Years|No|||June 2012|June 11, 2012|May 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01618084||84465|
NCT01624714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPI-004|Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects|Phase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects With Refractory Multiple Sclerosis||Advanced Neurosciences Institute|No|Active, not recruiting|September 2012|September 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||March 2014|March 8, 2014|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624714||83959|
NCT01624727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006P-000175|Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids|Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)|HEARTS|Beth Israel Deaconess Medical Center|Yes|Active, not recruiting|June 2009|May 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|338|||Both|21 Years|80 Years|No|||November 2015|November 13, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01624727||83958|
NCT01615692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-102610|The 36-month Extension to Follow up Sub Study|The Extension to Follow up Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX Trial)||Sir Mortimer B. Davis - Jewish General Hospital|Yes|Active, not recruiting|June 2004|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects previously enrolled in the SOX Trial (ClinicalTrials.gov Identifier NCT00143598)        who did not develop PTS by 2 years follow up.|April 2014|April 14, 2014|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01615692||84648|
NCT01615952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00058413|Patient Positioning on Supraclavicular Nerve Block|||Northwestern University|No|Terminated|January 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|6|||Both|18 Years|65 Years|No|Probability Sample|Patients 18 y/o to 65 y/o, who are scheduled to receive a ultrasound-guided        supraclavicular nerve block as part of their postoperative pain management.|March 2015|March 27, 2015|June 7, 2012||No|Lack of recruitment|No||https://clinicaltrials.gov/show/NCT01615952||84628|
NCT01616212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-12-033|Early Intervention for Minors in Possession of Alcohol/Drugs: A Feasibility Study|Early Intervention for Minors in Possession of Alcohol/Drugs: A Feasibility Study|MAST1|Oregon Research Institute|No|Completed|July 2011|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|239|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01616212||84608|
NCT01616511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-005|Pathway CH-1 Long-Term Follow-Up|Long-Term Follow-Up for the Pathway CH-1 Trial: Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache||Autonomic Technologies, Inc.|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|33|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who have been implanted with an ATI Neurostimulator as a part of the Pathway CH-1        trial, who have completed the Pathway CH-1 trial, and who remain implanted with an ATI        Neurostimulator.|March 2016|March 8, 2016|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616511||84585|
NCT01616524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI452-017|Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3|A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects|PRINCIPAL|Bristol-Myers Squibb|No|Completed|July 2012|September 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|880|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616524||84584|
NCT01616875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ON/2011/3775|Bristol Bladder Trial|A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder||University Hospitals Bristol NHS Foundation Trust|No|Recruiting|May 2012|May 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01616875||84558|
NCT01616888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KTT2|Paclitaxel Eluting Balloon for SFA In-stent Restenosis|Rug Eluting Balloon With Paclitaxel for Treatment of In-stent Restenosis in Femoropopliteal Arteries||University Health Network, Toronto|No|Active, not recruiting|June 2012|August 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616888||84557|
NCT01605552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105005448|Beating the Blues for Your Heart|Computer-Based Depression Treatment to Reduce Coronary Artery Disease Risk|BtB-Heart|Indiana University|Yes|Completed|July 2011|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|29|||Both|40 Years|N/A|No|||January 2016|January 27, 2016|May 9, 2012||No||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01605552||85426|Missing data precluded analysis of one secondary outcome variables: Tumor Necrosis Factor-Alpha (TNF-a).Due to the very small sample of randomized patients, conclusions should not be drawn from the results of this pilot trial.
NCT01605877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J-11-037|AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0] in Japan|Clinical Investigation of AcrySof® IQ ReSTOR® Multifocal Intraocular Lens Model SN6AD2||Alcon Research|No|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|20 Years|N/A|No|||June 2015|June 8, 2015|May 22, 2012|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01605877||85401|
NCT01605864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3216|Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia|Ceftaroline Fosamil Versus Standard of Care for Community Acquired Bacterial Pneumonia (CABP): Clinical Outcomes Among Hospitalized Adults at a Single United States Hospital|CAP|Albany Medical College|No|Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||May 2012|March 20, 2014|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605864||85402|
NCT01606111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVE-CN-0610|The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery|A Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury|CAPTAIN|Ever Neuro Pharma GmbH|Yes|Active, not recruiting|September 2013|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|60 Years|No|||February 2015|February 9, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01606111||85383|
NCT01606124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC084C|Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer|Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia||Mayo Clinic|Yes|Active, not recruiting|June 2012|||January 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|N/A|No|||January 2016|January 7, 2016|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606124||85382|
NCT01606709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-168-1|Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation|A Prospective Comparison of Transcriptional Profiling of Luteal Phase Endometrial Biopsies After Induction of Oocyte Maturation With a Gonadotropin Releasing Hormone (GnRH) Agonist or Human Chorionic Gonadotropins (hCG)||University of Connecticut Health Center|Yes|Enrolling by invitation|April 2012|July 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|20|||Female|21 Years|33 Years|Accepts Healthy Volunteers|||May 2012|May 25, 2012|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01606709||85337|
NCT01606696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS-PC-HIIT|Higher Intensity Interval Training in Cardiac Rehabilitation|Practical Use of Higher Intensity Interval Exercise in Cardiac Rehabilitation to Improve Aerobic Fitness|HIIT|Henry Ford Health System|No|Completed|August 2011|January 2014|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|49|||Both|18 Years|75 Years|No|||July 2015|July 15, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606696||85338|
NCT01606982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0401|Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Astellas Pharma Inc||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Male|N/A|N/A||||June 2015|June 5, 2015|May 24, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01606982||85316|
NCT01614288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC 2010 - 2|High Tibial Osteotomy (HTO) With or Without Arthroscopy of the Knee Joint|A Randomized Clinical Trial to Compare the Effectiveness of High Tibial Osteotomy (HTO) With or Without Arthroscopy of the Knee Joint on Quality of Life, Function, Pain and Swelling for Patients With Medical Compartment Osteoarthritis of the Knee||University of Western Ontario, Canada|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01614288||84755|
NCT01614301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEL001|Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma|A Prospective Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial of Temsirolimus in Combination With Pioglitazone, Etoricoxib and Metronomic Low-dose Trofosfamide Versus Dacarbazine (DTIC) in Patients With Advanced Melanoma||University of Regensburg|Yes|Recruiting|May 2012|May 2016|Anticipated|May 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Both|18 Years|N/A|No|||June 2012|June 5, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614301||84754|
NCT01617837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-281-31M|The Efficacy of P6 Acupressure in Reducing Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy|The Efficacy of P6 Acupressure in Reducing Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy. - a Randomized, Double-blinded, Placebo Controlled Study.||Umeå University|No|Completed|November 2011|August 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|80|||Both|18 Years|N/A|No|||September 2013|September 17, 2013|June 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01617837||84484|
NCT01618110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-12-0012|Transcranial Magnetic Stimulation in Treatment of Attention Deficit/Hyperactivity Disorders|Transcranial Magnetic Stimulation of the Pre-Frontal Cortex in the Treatment of Attention Deficit/Hyperactivity Disorders: A Randomized, Controlled, Double Blind Study.||Shalvata Mental Health Center|No|Not yet recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|50 Years|No|||June 2012|June 18, 2012|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01618110||84463|
NCT01616498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00019632|Lean Muscle Function|Obesity and Muscle Function Pilot Study|LEAN|Wake Forest School of Medicine|Yes|Completed|June 2012|November 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|24|Samples Without DNA|serum and plasma to be retained|Both|65 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|20 sedentary, normal-weight (BMI= 18-24 kg/m2) older (65-75 yrs) men and women (n=10 each)|November 2013|November 15, 2013|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616498||84586|
NCT01616771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1111-037-385|GlideScope®Video Laryngoscope for Difficult Intubation: Implication of the Size of Blade|GlideScope®Video Laryngoscope for Difficult Intubation: Implication of the Size of Blade||Seoul National University Hospital|No|Completed|February 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|23|||Both|N/A|N/A|No|||November 2014|November 3, 2014|April 30, 2012||No||No|November 21, 2013|https://clinicaltrials.gov/show/NCT01616771||84566|
NCT01617798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00007857|Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis|Stop Hypernatremia, Use Metolazone for Aggressive, Controlled, Effective Diuresis|SHUM|Oregon Health and Science University|Yes|Recruiting|June 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|N/A|N/A|No|||June 2012|June 26, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01617798||84487|
NCT01617811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120530|Effect of Epidural Anesthesia and Analgesia on Patients' Outcomes After Liver Resection|Effects of Epidural Anesthesia and Analgesia on Postoperative Metabolic, Immune Function and Hemodynamic Changes of Open Liver Resection||Sir Run Run Shaw Hospital|Yes|Completed|August 2007|December 2008|Actual|December 2008|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|26|||Both|18 Years|60 Years|No|||June 2012|June 9, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01617811||84486|
NCT01624428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108008929|Varenicline on Reward Responses and Cognition in Adolescent Smokers|Examining the Effects of Varenicline on Reward Responses,Cognition, and Tobacco Cues in Adolescent Smokers|GRAND|Yale University|Yes|Completed|June 2012|December 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|16 Years|19 Years|No|||January 2014|January 30, 2014|June 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01624428||83981|
NCT01615419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28259|An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|May 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiating treatment with RoActemra/Actemra|March 2016|March 1, 2016|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01615419||84669|
NCT01615432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Synchro_Non invasive vent|Comparison of Synchrony Between 4 NIV Ventilators|Comparison of Four Different Ventilators for Noninvasive Ventilation in Terms of Patient-ventilator Synchrony and Comfort||University of Lausanne Hospitals|No|Completed|June 2012|April 2013|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||May 2013|May 15, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615432||84668|
NCT01615705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-89349/NA-5629|Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial|The Etiologic Role of Inflammation, Thrombophilia and Fibrinolysis in the Post-thrombotic Syndrome: The Bio-SOX Sub Study|Bio-SOX|Sir Mortimer B. Davis - Jewish General Hospital|Yes|Completed|June 2004|February 2012|Actual|September 2010|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|803|Samples With DNA|Blood samples collected and processed by centrifuge to obtain serum, peripheral blood      leukocytes and platelet-poor plasma. Samples then aliquoted into 2.0ml microcentrifuge tubes      for storage at -80°C until further analysis.|Both|18 Years|N/A|No|Non-Probability Sample|Subjects previously enrolled in the SOX Trial (ClinicalTrials.gov Identifier NCT00143598)|June 2012|June 6, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01615705||84647|
NCT01615965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2607/09|Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer|Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer||Technische Universität München|No|Active, not recruiting|February 2010|December 2021|Anticipated|December 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|160|||Male|18 Years|80 Years|No|||July 2015|July 27, 2015|February 27, 2010||No||No||https://clinicaltrials.gov/show/NCT01615965||84627|
NCT01615978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-1591|Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes|A Randomised, Double-blind Within Dose Group, Single-centre, Placebo-controlled, Parallel 2-different Dose Group, 14-day Multiple s.c. Doses Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Liraglutide (NNC 90-1170) in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|December 2003|March 2004|Actual|March 2004|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|20 Years|64 Years|No|||June 2012|June 7, 2012|June 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01615978||84626|
NCT01616225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRM-001|Growth Hormone in Poor Responders to IVF Trial|Adjuvant Growth Hormone in Infertile Women With Prior Poor IVF Response: a Randomized, Controlled, Open-label Study||Pacific Centre for Reproductive Medicine|No|Terminated|June 2012|August 2015|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|44 Years|No|||July 2014|July 22, 2014|April 10, 2012|Yes|Yes|Insufficient/slow patient recruitment|No||https://clinicaltrials.gov/show/NCT01616225||84607|
NCT01616537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01063-38|Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter|Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter: Confirmatory Validation of QASICC Questionnaire|QASICC-EVA|Centre Antoine Lacassagne|Yes|Terminated|November 2011|December 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|990|||Both|18 Years|N/A|No|||February 2013|November 13, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616537||84583|
NCT01617122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACH 03-0120|Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)|To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency|Bacteriophage|University of South Florida|No|Recruiting|October 1995|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|2 Years|85 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617122||84539|
NCT01606137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWEXT0102|A Study of the Long-term Safety of Sativex Use|A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.||GW Pharmaceuticals Ltd.|No|Completed|February 2002|December 2004|Actual|December 2004|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|507|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 21, 2012||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT01606137||85381|
NCT01605591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20110172|Comparison of Different Bending Mode for Double-lumen Endotracheal Tube Intubation|Comparison of Different Bending Mode for Double-lumen Endotracheal Tube Intubation||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|August 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2014|September 4, 2014|October 16, 2011||No||No||https://clinicaltrials.gov/show/NCT01605591||85423|
NCT01606150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MGUHNICULP|Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain|Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain||Georgetown University|Yes|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|5|||Both|N/A|8 Days|Accepts Healthy Volunteers|||February 2015|February 9, 2015|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606150||85380|
NCT01606449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UniBoDipTrap2|Follow-up of Patients Operated Upon for Type II-IV Hiatal Hernia|Thirty-year Follow-up of a Case Series of Patients Operated Upon for Type II-IV Hiatal Hernia||University of Bologna|No|Completed|January 1980|January 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients consecutively operated upon for type II-IV hiatal hernia in the period January        1980-December 2010.|January 2012|May 24, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606449||85357|
NCT01606462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXT-071/10|Oxytocin and Social Cognition|Double-blind, Placebo-controlled, Randomized Study: Oxytocin and OXTR-genotypes Influence Behavioral and Neural Social Reactions||University Hospital, Bonn|No|Completed|June 2011|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|153|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606462||85356|
NCT01607008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11143|MRI for Assessing Prostate Cancer Response|Multiparametric MRI for Assessing Radiotherapy Treatment Response of Prostate Cancer|NA_00067284|Sidney Kimmel Comprehensive Cancer Center|No|Recruiting|September 2012|May 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Male|18 Years|N/A|No|||November 2015|November 18, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607008||85314|
NCT01606722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LLC-DAR-2010-01|Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy|Relation Between Darunavir Levels and Virological Efficacy, Integrated Proviral ADN and Resistance Mutations in HIV-infected Patients on Treatment With Darunavir/Ritonavir Monotherapy|MonDar|Hospitales Universitarios Virgen del Rocío|Yes|Completed|January 2010|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|Samples Without DNA|Blood samples (plasma and PBMC)|Both|18 Years|65 Years|No|Non-Probability Sample|HIV-infected patients who started an antiretroviral regimen based on darunavir-ritonavir        (800/100 mg) once daily monotherapy between June 2010 and September 2010|July 2013|July 10, 2013|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606722||85336|
NCT01614574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGT-GCB-087|Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease|A Multicenter, Open-Label Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease||Shire|No|Completed|March 2012|August 2013|Actual|May 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|2 Years|N/A|No|||July 2014|July 8, 2014|June 6, 2012|Yes|Yes||No|March 25, 2014|https://clinicaltrials.gov/show/NCT01614574||84733|All 6 enrolled patients received previous long-term treatment with the enzyme replacement therapy (ERT), imiglucerase. Key therapeutic parameters were expected to indicate stability after switching from imiglucerase.
NCT01623934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DG2A1|Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development|Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development|Gen3G|Université de Sherbrooke|Yes|Active, not recruiting|January 2010|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|1086|Samples With DNA|plasma, whole cord blood, serum cord blood, white cells, sample of placenta|Female|18 Years|N/A|No|Non-Probability Sample|Pregnant women when they come for their first prenatal visit at the Clinique de        Prélèvements et de Recherche en Grossesse.|December 2015|December 1, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623934||84018|
NCT01623947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03-0043|Effects of Sustamine(TM) on Cycling Time Trial Performance|Effects of Sustamine(TM) on Cycling Time Trial Performance Following Prolonged Cycling||University of Texas at Austin|Yes|Active, not recruiting|June 2012|May 2013|Anticipated|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|14|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 18, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623947||84017|
NCT01614873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A0030043|Comparison of Breathing Pattern During Neurally Adjusted Ventilatory Assist Ventilation and Pressure Support Ventilation|Comparison of Breathing Pattern During PSV and NAVA||Centre d'Investigation Clinique et Technologique 805|Yes|Completed|May 2012|August 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 11, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614873||84710|
NCT01614886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CENA713D1303|Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)|A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)||Novartis|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|216|||Both|50 Years|85 Years|No|||June 2015|June 3, 2015|June 6, 2012||No||No|April 16, 2015|https://clinicaltrials.gov/show/NCT01614886||84709|
NCT01615445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008540-01H|Resveratrol Supplementation on Exercise in Healthy Sedentary Adults|A Pilot Randomized Controlled Clinical Trial of Resveratrol Supplementation on Exercise in Healthy Sedentary Adults||Ottawa Hospital Research Institute|No|Completed|February 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 20, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01615445||84667|
NCT01615458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G009567|Disseminating Evidence-based Mood Disorder Chronic Care Models|||University of Michigan|No|Completed|July 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|1||Actual|60|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615458||84666|
NCT01615991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIMS-2012-01|Multicentre Canadian Study to Measure the Safety and Efficacy of Radiosynoviorthesis|Multicentre Canadian Study to Measure the Safety and Efficacy of Synoviorthesis Performed With Yttrium-90 or Rhenium-186 Sulfide|RSO|Centre Hospitalier Universitaire de Sherbrooke|Yes|Recruiting|May 2012|December 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1500|||Both|N/A|N/A|No|||September 2014|September 24, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01615991||84625|
NCT01616238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/11/0532|A Study for Older Adults With Acute Lymphoblastic Leukaemia|A Phase 2 Study for Older Adults With Acute Lymphoblastic Leukaemia|UKALL60+|University College, London|Yes|Recruiting|December 2012|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|148|Samples Without DNA|Bone marrow aspirate, peripheral blood samples and buccal swabs for constitutional DNA      analysis|Both|55 Years|N/A|No|Non-Probability Sample|Patients over the age of 60 with acute lymphoblastic leukaemia (or over 55 and unsuitable        for the UKALL14 trial)|December 2015|December 7, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616238||84606|
NCT01616550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DB 2012-001|Quality of Postoperative Pain Management Following Thoracic Surgery|Quality of Postoperative Pain Management Following Thoracic Surgery: a Prospective Observational Study.||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|18 Years|80 Years|No|Probability Sample|Patients undergoing elective thoracotomy or thoracoscopy in a teaching hospital over a one        year period will be considered for this study|September 2013|September 12, 2013|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616550||84582|
NCT01616563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHANGE|Canadian Health Advanced By Nutrition and Graded Exercise|Canadian Health Advanced By Nutrition and Graded Exercise: CHANGE Health Paradigm|CHANGE|Clinical Evaluation Research Unit at Kingston General Hospital|No|Recruiting|June 2012|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|307|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616563||84581|
NCT01616901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8923|Wean Obese Study : Determination of the Optimal Spontaneous Breathing Trial for Obese Patient|Wean Obese Study : Determination of the Optimal Spontaneous Breathing Trial for Obese Patient||University Hospital, Montpellier|Yes|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|31|||Both|18 Years|N/A|No|||June 2012|May 30, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01616901||84556|
NCT01601769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENDOCOLP|Tissue Sparing Therapy of Female Precancerous Genital Lesions With VITOM|Development of a Tissue Sparing Procedure for the Diagnosis and Therapy of Female Precancerous Genital Lesions Combining Endoscopic and Ultrasound Technics.|VITOM|Charite University, Berlin, Germany||Active, not recruiting|April 2011|July 2012|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|N/A|N/A|No|||May 2012|May 16, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01601769||85717|
NCT01601782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00030780|Impact of Volume Imaging Using Diagnostic Ultrasound|Impact of Volume Imaging With Ultrasound||University of Michigan|No|Terminated|August 2009|May 2010|Actual|March 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|16|||Both|18 Years|N/A|No|||August 2014|August 18, 2014|May 1, 2012||No|It was determined that the volume imaging was not working.|No|December 10, 2013|https://clinicaltrials.gov/show/NCT01601782||85716|16 patients were studied as part of a pilot project to determine if 3D ultrasound offers any benefit over routine standard ultrasound imaging of the extremity. The study was terminated after evaluating 16 subjects.
NCT01605604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si496-2010|Effectiveness of Buddhist Intergrated Group Intervention on Minefulness in Adolescents|Department of Orthopedic Surgery, Faculty of Medicine Siriraj Hospital||Mahidol University|No|Completed|October 2011|July 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Female|10 Years|15 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01605604||85422|
NCT01601743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27380|Exercise as a Behavioral Treatment for Cocaine Dependence|Exercise as a Behavioral Treatment for Cocaine Dependence||Baylor College of Medicine|Yes|Completed|September 2011|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|21 Years|55 Years|No|||May 2012|January 26, 2015|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01601743||85719|
NCT01605890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005038-20|Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients|ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients|VIH-2|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Yes|Active, not recruiting|July 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2015|May 11, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605890||85400|
NCT01606163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1102|Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose Escalation Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male Adults||Green Cross Corporation|No|Completed|August 2012|December 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2014|January 1, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606163||85379|
NCT01606176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWPS0105|A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin|A Multi Centre Randomised, Double Blind, Placebo Controlled, Parallel Group Comparison of the Effects of Cannabis Based Medicine Standardised Extracts Over 4 Weeks, in Patients With Chronic Refractory Pain Due to Multiple Sclerosis or Other Defects of Neurological Function.||GW Pharmaceuticals Ltd.|No|Completed|March 2002|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||August 2012|August 28, 2012|May 21, 2012||No||No|July 19, 2012|https://clinicaltrials.gov/show/NCT01606176||85378|
NCT01606189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWBP0101|A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain|A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury.||GW Pharmaceuticals Ltd.|No|Completed|December 2001|September 2002|Actual|September 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|18 Years|N/A|No|||June 2013|February 18, 2014|May 23, 2012||No||No|July 12, 2012|https://clinicaltrials.gov/show/NCT01606189||85377|
NCT01602679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16085|Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)|Acute Effects of Progesterone on LH Pulses During the Follicular Phase||University of Virginia|Yes|Active, not recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|36|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||June 2015|June 22, 2015|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602679||85647|
NCT01606735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-01|Efficacy and Safety of IBI-10090 in Ocular Surgery Patients|A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Ocular Surgery||ICON Bioscience Inc|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|172|||Both|40 Years|N/A|No|||September 2014|September 17, 2014|May 24, 2012|Yes|Yes||No|September 2, 2014|https://clinicaltrials.gov/show/NCT01606735||85335|
NCT01602900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116038|Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)||GlaxoSmithKline|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Male|22 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|December 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01602900||85630|
NCT01614847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSUOCO-2012-11|Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears|Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears||Northeastern State University|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 18, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614847||84712|
NCT01615107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0013-12-HYMC|Premature Rupture of Mambrane and Unfavourable Cervix|Comparison Between the Use of Standard Oxytocin Induction Protocol and the Double-balloon Catheter Device With Concurrent Oxytocin||Hillel Yaffe Medical Center|No|Not yet recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Female|16 Years|50 Years|Accepts Healthy Volunteers|||April 2012|June 6, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01615107||84692|
NCT01614600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00849|Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers|Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers||Alcon Research|Yes|Completed|June 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|18 Years|N/A|No|||September 2013|September 27, 2013|June 6, 2012|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01614600||84731|
NCT01614912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1001057|Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia|Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>||Sumitomo Dainippon Pharma Co., Ltd.|No|Completed|August 2012|||May 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|284|||Both|18 Years|74 Years|No|||June 2015|June 30, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614912||84707|
NCT01614925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR 02/11|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|November 2012|||||N/A|N/A|N/A||||||||||||||May 21, 2015|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614925||84706|
NCT01615185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSPH-2008-13|A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia|||Kaohsiung Kai-Suan Psychiatric Hospital|Yes|Terminated|January 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|18 Years|55 Years|No|||February 2016|February 27, 2016|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01615185||84687|
NCT01615146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHREB 2011500|Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot|Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot|OPTIMAL|Ottawa Hospital Research Institute|Yes|Terminated|June 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|June 6, 2012||No|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01615146||84690|
NCT01615159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHSPH4135|Maintenance of Recommended Sodium Intake|Maintenance of Recommended Sodium Intake|SPICE|Johns Hopkins Bloomberg School of Public Health|No|Active, not recruiting|June 2012|February 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 10, 2013|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01615159||84689|
NCT01615718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-p-001120|Non-invasive Neurostimulation in Parkinson's Disease|Effects of Non-invasive Neurostimulation Methods on Motor Function in Parkinson's Disease Patients.||Spaulding Rehabilitation Hospital|No|Recruiting|September 2013|||August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|48|||Both|40 Years|N/A|No|||May 2015|May 14, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01615718||84646|
NCT01616004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-SB-340-CTIL|Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject|Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject|N2O|Tel-Aviv Sourasky Medical Center|Yes|Not yet recruiting|October 2014|August 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|September 21, 2014|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01616004||84624|
NCT01616251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B294|Acute Effect of Animal and Vegetable Protein Rich Meals With Comparable Dietary Fibers Content on Appetite Sensation and Energy Intake|Acute Effect of Animal and Vegetable Protein Rich Meals With Comparable Dietary Fibers Content on Appetite Sensation and Energy Intake|PAVA-II|University of Copenhagen|No|Not yet recruiting|August 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|33|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616251||84605|
NCT01616576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR0611|Evaluation of a HiRes™ Optima Sound Processing Strategy for the HiResolution™ Bionic Ear|||Advanced Bionics|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|N/A|No|||August 2014|August 28, 2014|June 1, 2012|Yes|Yes||No|February 26, 2014|https://clinicaltrials.gov/show/NCT01616576||84580|
NCT01616914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZZH-2|Subclinical Delirium and Clinical Outcome|Delirium and Clinical Outcome|ZZH-2|Jinhua Central Hospital|Yes|Completed|January 2010|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|250|||Both|18 Years|80 Years|No|Probability Sample|patients enter ICU GCS > 10 RASS > -2 No dementia|June 2012|April 1, 2013|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616914||84555|
NCT01617135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVT-301-002|Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes|A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations ("Off Episodes")||Acorda Therapeutics|No|Completed|May 2012|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|25|||Both|30 Years|N/A|No|||May 2015|May 4, 2015|May 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01617135||84538|
NCT01617356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Buenos Aires 1969|Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection|Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection: A Randomised Clinical Trial of Efficacy||Frusso, Ricardo, M.D.|Yes|Enrolling by invitation|June 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|19 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 8, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01617356||84521|
NCT01602107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REH-503-11|The Effect of Pre-operative Pelvic Floor Muscle Exercise on Surgical Outcomes in Women With Stress Urinary Incontinence|Optimizing Treatment Outcomes for Women With Stress Urinary Incontinence Through the Identification of Factors Contributing to Successful Interventions|SUIPT|Queen's University|Yes|Recruiting|November 2011|||November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Female|18 Years|N/A|No|||October 2015|October 1, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602107||85691|
NCT01602133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01570-41|Assessment of Ultrasound-guided Inserted Peripheral Intravenous Catheter|A Clinical Assessment of an Ultrasound-guided Inserted Peripheral Intravenous Catheter|ECLIPSE|Prodimed SAS|Yes|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|29|||Both|18 Years|N/A|No|||October 2012|October 24, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602133||85689|
NCT01601756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-I-H-0917|Joint Line Reconstruction in Navigated Total Knee Arthroplasty Revision|Joint Line Reconstruction in Navigated Total Knee Arthroplasty Revision|NavRevKnie|Charite University, Berlin, Germany|Yes|Recruiting|September 2011|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 16, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01601756||85718|
NCT01602081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-012|Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula|Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula|LIFT+Graft|Cook||Completed|January 2013|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Both|18 Years|N/A|No|Non-Probability Sample|Regional and Community Hospitals|February 2015|February 10, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602081||85693|
NCT01602055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XXI/32/CL/2009|A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects|||PT Novell Pharmaceutical Laboratories|Yes|Completed|October 2010|November 2010|Actual|November 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01602055||85695|
NCT01602068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGP-437-005|Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens|A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens||Eyegate Pharmaceuticals, Inc.|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|N/A|No|||July 2012|March 28, 2013|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602068||85694|
NCT01602367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB121-008|Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects With Inadequately Controlled Hypertension||Bristol-Myers Squibb|No|Terminated|July 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|7|||Both|18 Years|80 Years|No|||September 2015|September 23, 2015|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602367||85671|
NCT01602380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D699BC00001|A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.|A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.|FALCON|AstraZeneca||Active, not recruiting|October 2012|July 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|450|||Female|18 Years|130 Years|No|||December 2015|January 6, 2016|May 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602380||85670|
NCT01602913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116554|Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine|Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine||GlaxoSmithKline|No|Completed|December 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Data will be ascertained from the Thomson-Reuters Marketscan database, which contains        administrative healthcare data among an insured population in the US between 2000 and        2009. The MarketScan® Databases capture person-specific clinical utilization,        expenditures, and enrollment across inpatient, outpatient, and prescription drug from a        selection of large employers, health plans, and government and public organizations        (MarketScan Users manual). The MarketScan Databases link paid claims and encounter data to        detailed patient information across sites and types of providers, and over time. The        annual medical databases include private sector health data from approximately 100 payers.        Historically, more than 500 million claim records are available in the MarketScan        Databases. These data represent the medical experience of insured employees and their        dependents for active employees, early retirees, COBRA continues and Medicare-eligible        retirees with employer-provided Medicare supplemental|June 2014|June 30, 2014|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01602913||85629|
NCT01603186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/257|Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fed Condition|A Randomized, Open Label, Two-Treatment, Two-Period, Two-Sequence, Crossover, Single Dose, Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg With Seroquel® 25 mg in Normal, Healthy, Adult, Human Subjects, Under Fed Condition||IPCA Laboratories Ltd.|Yes|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603186||85608|
NCT01618149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204035RIB|Use Quantitative Microradiography to Predict the Periprosthetic Bone Loss in Distal Femur After Total Knee Arthroplasty|Use Dual-energy X-ray Absorptiometry and Quantitative Microradiography to Predict the Periprosthetic Bone Loss in Distal Femur After Total Knee Arthroplasty||National Taiwan University Hospital|Yes|Not yet recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|A 2X1X0.5cm bone fragment harvested during the chamfer cut of total knee arthroplasty|Female|50 Years|70 Years|No|Non-Probability Sample|the patients who are indicated for total knee arthroplasty and are post menopausal women.        The patients who had history of immune disease , fracture of the femur and end stage of        renal disease will be excluded|June 2012|June 12, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618149||84460|
NCT01623349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-159|Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer|Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|September 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2015|January 9, 2015|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623349||84063|
NCT01623362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOWF-UFPB|Evaluation of a Low Fluoride Dentifrice for Caries Control|Low-fluoride Acidic Liquid Dentifrice in Non-fluoridated Communities: a Randomized Clinical Trial||Federal University of Paraíba|No|Completed|September 2010|February 2012|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|212|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||May 2012|June 15, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623362||84062|
NCT01615406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-1404-P105|A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer|A Phase 1 Pilot Comparison Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging to Histology in Men With Prostate Cancer||Molecular Insight Pharmaceuticals, Inc.|No|Completed|April 2012|||November 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|9|||Male|21 Years|N/A|No|||November 2015|November 23, 2015|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615406||84670|
NCT01614626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AA020780|Alcohol's Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort|Alcohol & Zinc Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort||Boston Medical Center|Yes|Active, not recruiting|November 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|375|Samples With DNA|We are storing serum and plasma for future use, as well as dried blood spots for PEth      testing.|Both|18 Years|70 Years|No|Non-Probability Sample|This is a study of HIV-infected adults who are ART naive at enrollment. Subjects will be        recruited from a recently completed NIAAA trial (HERMITAGE; NCT00483483) and from HIV and        addiction care sites.|July 2015|July 8, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01614626||84729|
NCT01614899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1001056|A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia|Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>||Sumitomo Dainippon Pharma Co., Ltd.|No|Completed|June 2012|||November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|457|||Both|18 Years|74 Years|No|||June 2015|June 30, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614899||84708|
NCT01615484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNC-002 Vitrolife|Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability|Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability||University of North Carolina, Chapel Hill|Yes|Recruiting|September 2013|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|15 Years|N/A|No|||July 2015|July 21, 2015|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01615484||84664|
NCT01615172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXI-001|Cannulation of the Artery Axiliaris for Extracorporeal Circulation|Cannulation of the Artery Axiliaris for Extracorporeal Circulation||Johann Wolfgang Goethe University Hospitals|No|Recruiting|January 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|85 Years|No|||August 2014|August 5, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01615172||84688|
NCT01615471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNNC2012|Lose Now North Carolina Community Weight Loss Program|Lose-Now-NC: Feasibility of a Large Group Format Community Weight Loss Program Coupled With Internet Support|Lose Now NC|University of North Carolina, Chapel Hill|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|225|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 17, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615471||84665|
NCT01616017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-COstatus-11A-H|Comparison of Cardiac Output Measured by Ultrasound Dilution Method and Pulmonary Artery Thermodilution Technique|Comparison of Cardiac Output Measured by Ultrasound Dilution Method and Pulmonary Artery Thermodilution Technique||Transonic Systems Inc.||Recruiting|May 2012|October 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|35|||Both|18 Years|N/A|No|Probability Sample|Age ≥ 18 years of age Presence of arterial catheter plus central venous pressure monitor        and pulmonary artery catheter for hemodynamic monitoring.|June 2012|June 6, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01616017||84623|
NCT01616927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIPAK1|Study of Lanreotide to Treat Polycystic Kidney Disease|The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD|DIPAK1|University Medical Center Groningen|Yes|Active, not recruiting|June 2012|December 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|60 Years|No|||May 2015|May 27, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01616927||84554|
NCT01617148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFTe-AMD-1211|Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept|A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative AMD Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)||The Cleveland Clinic|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|50 Years|N/A|No|Probability Sample|Subjects will be recruited through clinics at the Cole Eye Institute, Cleveland, OH.|March 2015|March 12, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617148||84537|
NCT01616602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVAMC-10-098|Prone Versus Left-sided Colonoscopy in Obese Patients|||Dallas VA Medical Center||Completed||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind|2|||100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|June 11, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01616602||84578|
NCT01617369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1932|Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects|A Study to Characterize the Durability of Hypertonic Saline for the Enhancement of Mucociliary Clearance in Healthy Subjects||University of North Carolina, Chapel Hill|No|Completed|June 2012|March 2013|Actual|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|June 17, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01617369||84520|
NCT01617382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-54350|Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed|Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed|HIPEC|Universitaire Ziekenhuizen Leuven|No|Recruiting|May 2012|June 2019|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|125|||Both|N/A|N/A|No|Non-Probability Sample|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma        peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to        undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy.|July 2015|July 3, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617382||84519|
NCT01602432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120209-01H|Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients|Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients||Ottawa Hospital Research Institute|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|143|||Both|18 Years|N/A|No|Non-Probability Sample|Because of their higher thrombogenic potential, we will aim to identify high-risk cases        for VTE within the group of cancer patients whose primary malignancy is located in the        brain, bladder, lung, testicle, pancreas, stomach and lymphomas.|September 2014|September 8, 2014|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602432||85666|
NCT01602094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAI5501|Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors|Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors||Queen Saovabha Memorial Institute|No|Not yet recruiting|July 2012|March 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|550|Samples Without DNA|Each participant will be taken blood sample approximately 8 ml. The blood sample will be      centrifuged and kept as serum. The serum will be kept under - 20 degree Celsius. Then, all      serum will be tested by ELISA.|Both|18 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Health Thai participant age 18-30 years old.|May 2012|May 17, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602094||85692|
NCT01602393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1014-PR-0053 POLEP|Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase|A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment|CT04 POLEP|Chiesi Pharmaceuticals Inc.|No|Completed|May 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|51|||Both|18 Years|79 Years|No|||January 2014|January 7, 2014|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602393||85669|
NCT01602692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0543|A Comparison of Tumescence in Breast Reduction Surgery|A Comparison of Tumescence in Breast Reduction Surgery||University of Wisconsin, Madison|No|Active, not recruiting|August 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Female|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 6, 2015|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01602692||85646|
NCT01602926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2012-Minibunion|Prospective Trial of Minimally Invasive Surgery Versus Standard Surgery for Correction of Hallux Valgus|Randomized Prospective Trial of Minimally Invasive Surgery Versus Standard Surgery for Correction of Hallux Valgus.|Minibunion|Henry DeGroot, M.D.|No|Recruiting|August 2012|September 2018|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 24, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01602926||85628|
NCT01603199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-460-11/12-1|High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis|Impact of a High-protein High-fiber Diet on the Nutritional Status of Patients With Primary Biliary Cirrhosis||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Active, not recruiting|September 2011|February 2016|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|70 Years|No|||September 2015|September 29, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603199||85607|
NCT01618162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9068-3951|The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy|The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy|DUAL™IV|Novo Nordisk A/S|No|Completed|August 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|435|||Both|18 Years|N/A|No|||December 2013|December 3, 2013|June 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618162||84459|
NCT01614028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP2012-01|Total Hip Arthroplasty Using Small Direct Anterior Incision: The Role of Short Femoral Stem|||Rothman Institute Orthopaedics||Recruiting||||||N/A|Interventional|N/A|2||||||Both|18 Years|N/A|No|||April 2013|April 8, 2013|June 4, 2012||||No||https://clinicaltrials.gov/show/NCT01614028||84775|
NCT01614015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA029406|Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial|Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial|BOOST|Oregon Research Institute|Yes|Active, not recruiting|September 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|636|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 29, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01614015||84776|
NCT01623674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Herlev-12345|Laparoscopic Skills and Cognitive Function Are Not Affected by Night Shifts in Surgeons|Laparoscopic Skills and Cognitive Function Are Not Affected by Night Shifts in Surgeons||Herlev Hospital|No|Completed|December 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|30|Samples Without DNA|Urin (melatonine) Saliva (cortisol)|Both|22 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Surgeons at a surgical unit of gastroenterology in Denmark.|May 2013|May 19, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623674||84038|
NCT01615198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2316|Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension|A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension||Novartis||Completed|August 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|588|||Both|65 Years|N/A|No|||October 2015|October 1, 2015|June 6, 2012||No||No|July 20, 2015|https://clinicaltrials.gov/show/NCT01615198||84686|
NCT01616030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HH-S-1|Early Strength Training After Hip Fracture Surgery|Feasibility of Progressive Strength Training in the Early Post Surgical Rehabilitation Period After Hip Fracture Surgery||Copenhagen University Hospital, Hvidovre|Yes|Completed|June 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|60 Years|N/A|No|||May 2014|May 14, 2014|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01616030||84622|
NCT01615731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-05302012-10088|Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks|Value of Mifepristone in Eliminating the Need for a Second Set of Osmotic Dilators Prior to Dilation and Evacuation Between 19-24 Weeks: A Randomized Trial||Stanford University|No|Completed|May 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Female|18 Years|N/A|No|||January 2015|January 26, 2015|May 30, 2012||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01615731||84645|Failure of randomization with respect to assigning similar numbers of nulliparous women to both groups; inaccurate method for measurement of pre-operative cervical dilation; small size of cohort.
NCT01615744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CalcanealfxRCT|Surgical vs Conservative Treatment of Displaced Intra-articular Calcaneal Fractures: A Prospective RCT|Surgical vs. Conservative Treatment of Displaced Intra-articular Calcaneal Fractures: A Prospective, Randomized, Controlled Multicenter Trial||Agren, Per-Henrik, M.D.|No|Completed|December 1993|December 1998|Actual|January 1994|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|82|||Both|18 Years|78 Years|No|Probability Sample|Between 1994 and 1998. Patients presenting at 5 hospitals in Stockholm after trauma        resulting in a fracture with > 2mm Dislocated Intraarticular Calcaneal Fractures (DIACFs)        verified by axial and coronal computerized tomography (CT) scan were considered for        inclusion|June 2012|June 7, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01615744||84644|
NCT01616589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGFX0001|Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay|Acquisition of Saliva Samples for Validation as a Specimen Type in the Esoterix Genetic Laboratories Fragile X Assay||Esoterix Genetic Laboratories, LLC|No|Not yet recruiting|July 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|100|Samples With DNA|In some cases, the de-identified, residual saliva specimen may be used in quality assurance;      it may be used in clinical testing as a control; it may be used for future research studies.|Both|N/A|N/A|No|Non-Probability Sample|Fragile X full mutations (affecteds), fragile X premutations (carriers), and fragile X        intermediates who previously had fragile X testing through Esoterix Genetic Laboratories.        Subject population will be in the US.|June 2012|June 7, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616589||84579|
NCT01616303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QPT-ORE-002|A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer|Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma||Quest PharmaTech Inc.|No|Active, not recruiting|June 2012|June 2016|Anticipated|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|18 Years|75 Years|No|||October 2015|October 13, 2015|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616303||84601|
NCT01616316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-08-058|Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients|Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study||Samsung Medical Center|Yes|Completed|March 2010|February 2012|Actual|January 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|86|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01616316||84600|
NCT01616615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASAP|Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation|Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation|ASAP|Fundacion Clinic per a la Recerca Biomédica|No|Completed|September 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|190|||Female|18 Years|N/A|No|||June 2015|August 17, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01616615||84577|
NCT01616940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U69HA23262|Minority AIDS Initiative Retention and Re-Engagement Project|Minority AIDS Initiative Retention and Re-Engagement Project: Peer Re-Engagement Project||Boston University|No|Enrolling by invitation|September 2011|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|375|||Both|18 Years|N/A|No|||June 2012|June 8, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616940||84553|
NCT01617395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120122|Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility|Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility||National Institutes of Health Clinical Center (CC)||Recruiting|April 2012|||||N/A|Observational|N/A|||Anticipated|2050|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|February 20, 2016|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617395||84518|
NCT01617681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVAL489K2306|Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD|A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Without Chronic Kidney Disease, Followed by a 20 Week Open-label Titration Phase||Novartis|No|Recruiting|October 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|130|||Both|1 Year|5 Years|No|||March 2016|March 7, 2016|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617681||84496|
NCT01607359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007088|Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation|Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation||William Beaumont Hospitals|No|Active, not recruiting|May 2012|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|404|||Both|18 Years|N/A|No|Probability Sample|All patients undergoing catheter ablation for atrial fibrillation|May 2012|May 24, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607359||85287|
NCT01607658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBS-2-AMB-2012-01|Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder|A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Efficacy and Safety of TBS-2 Intranasal Testosterone Gel in Women With Acquired Female Orgasmic Disorder||Trimel Biopharma SRL|No|Completed|May 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|253|||Female|18 Years|N/A|No|||September 2014|September 16, 2014|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607658||85265|
NCT01602406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLJM716X2102|Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer|A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer||Novartis||Active, not recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|May 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01602406||85668|
NCT01602419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wil-20|Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease|Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease||Octapharma|No|Recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum Samples|Both|N/A|N/A|No|Non-Probability Sample|VWD patients of any gender, age, or VWD type|October 2015|October 23, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01602419||85667|
NCT01602705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010PS06|Effective Feedback to Improve Primary Care Prescribing Safety|Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS): a Randomised Controlled Trial Using ePrescribing Data|EFIPPS|University of Dundee|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|262|||Both|N/A|N/A|No|||October 2014|October 5, 2014|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01602705||85645|
NCT01602939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC11-187|Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis|Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.||Hospital Virgen de la Salud|No|Recruiting|May 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||May 2012|May 19, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01602939||85627|
NCT01603797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|smartaSIAMB_GA|Guided Internet-delivered Acceptance and Commitment Therapy for Chronic Pain Patients|Guided Internet-delivered Acceptance and Commitment Therapy for Chronic Pain Patients: a Randomized Controlled Trial||Linkoeping University|No|Completed|February 2010|December 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01603797||85561|
NCT01604330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110112|Baclofen for the Treatment of Alcohol Drinkers|Alcohol Treatment: Pragmatic Therapeutic Trial Randomized, Double-blind for a Year in Ambulatory Care of Baclofen Versus Placebo.|BACLOVILLE|Assistance Publique - Hôpitaux de Paris|Yes|Completed|May 2012|October 2015|Actual|September 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|323|||Both|18 Years|65 Years|No|||October 2015|December 21, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604330||85520|
NCT01614054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01080|Nicotine Replacement Provided at a Tertiary Care Hospital|A Patient-centered Approach to Behavioral Modification in a Tertiary-care University-affiliated Hospital and the Incidence of Smoking Cessation|N-PATCH|University of British Columbia|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01614054||84773|
NCT01614041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSPC-SED-1101|Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder|Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial|TACGAD|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|Yes|Recruiting|November 2011|October 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|65 Years|No|||November 2015|November 19, 2015|November 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01614041||84774|
NCT01614353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI-12-001|Medication-taking Preferences & Practices of Patients With Chronic Conditions|Medication-taking Preferences & Practices of Patients With Chronic Conditions||Washington State University|No|Recruiting|October 2012|November 2013|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|60 Years|N/A|No|Non-Probability Sample|Persons seen at the Providence Kidney Disease and Hypertension Clinic, aged 60 years or        older, with 3 chronic conditions, taking 5 or more medications, and who receive a        prescription for a NEW medication will be invited to participate in the 30 day study.|December 2012|December 19, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01614353||84750|
NCT01614340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HS020648-01A1|Treating Pain to Reduce Disability Among Older Home Health Patients|Treating Pain to Reduce Disability Among Older Home Health Patients||Visiting Nurse Service of New York|Yes|Completed|October 2012|December 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|658|||Both|55 Years|N/A|No|||March 2016|March 14, 2016|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01614340||84751|
NCT01615757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AML HIDAC, AIIMS|Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation|Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study|Ara-c|All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|August 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|N/A|N/A|No|||September 2012|September 13, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01615757||84643|
NCT01615510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TapCapMentho01|Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models|Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models of: 1) Cold and Mechanical Hyperalgesia Evoked by Topical High-concentration Menthol , 2) Heat and Mechanical Hyperalgesia by Capsaicin.||University of Schleswig-Holstein|Yes|Terminated|October 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 25, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615510||84662|
NCT01615523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EF_MRI_EEG|Executive Function in Preterm Born Children: An Integrative Approach From Genetics to Brain Function|||University of Zurich|No|Not yet recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|60|||Both|10 Years|16 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and adolescents born preterm with their peers as controls|June 2012|June 7, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615523||84661|
NCT01616264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JUL 200456|Reproducibility of Computed Tomography|Evaluation of the Reproducibility of Computed Tomography for the Measurement of Tuberculosis Pleural Effusion||Universidade Federal do Rio de Janeiro|Yes|Completed|January 2006|December 2009|Actual|October 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|20 Years|70 Years|No|Non-Probability Sample|Patients age 18 years or older with a confirmed diagnosis of pleural TB effusion|June 2012|June 8, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616264||84604|
NCT01616277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5161001|A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects||Pfizer|No|Completed|June 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|7||Anticipated|86|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|May 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01616277||84603|
NCT01616043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/363|Glyaderm Clinical Evaluation Multicenter Study|Clinical Application of GLYADERM. A Multicentre, Prospective, Randomized Controlled, Comparative Trial of Glyaderm and Split Thickness Skin Graft Versus Split Thickness Skin Graft Alone in Full Thickness Skin Defects||Euro Tissue Bank|No|Terminated|February 2011|November 2014|Anticipated|September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2010|June 6, 2014|May 29, 2012||No|delay in recruitment, lack of additional funding|No||https://clinicaltrials.gov/show/NCT01616043||84621|
NCT01616290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRT-201-103|Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)|Open-Label, Dose-Escalation, Pilot Study of PRT-201 Administered Following Angioplasty in Patients With Peripheral Artery Disease in the Lower Extremity||Proteon Therapeutics|Yes|Completed|October 2012|July 2015|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01616290||84602|
NCT01616966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 2010 29|Laryngeal Injuries After Removal of the Tracheal Tube: A Comparison Between Sevoflurane and Propofol|Laryngeal Injuries After Removal of the Tracheal Tube: A Comparison Between Anesthesia With Sevoflurane and Intravenous Anesthesia With Propofol A Randomized, Prospective, Controlled Trial||University of Rostock|No|Completed|August 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|65|||Both|18 Years|80 Years|No|||June 2012|June 29, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616966||84551|
NCT01617174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-110|Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer|Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer||Memorial Sloan Kettering Cancer Center||Withdrawn|June 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Male|18 Years|N/A|No|Non-Probability Sample|Eligible patients will be recruited from 3 different collaborating sites: MSKCC, John        Hopkins, and OHSU. MSKCC will enroll approximately 200 patients, and John Hopkins and OHSU        will each enroll approximately 100 patients; 400 participants will be enrolled in total.        MSKCC is the coordinating site for this study.|November 2013|November 6, 2013|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617174||84535|
NCT01617707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0181|Safe and Effective Sedation in Chronic Alcoholic Patients Underwent Diagnostic Endoscopic Procedures: Study Comparing Midazolam and Propofol With Midazolam|Safe and Effective Sedation in Chronic Alcoholic Patients Underwent Diagnostic Endoscopic Procedures: a Prospective, Randomized Study Comparing Midazolam and Propofol With Midazolam||Yonsei University|No|Recruiting|June 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|56|||Both|20 Years|N/A|No|||March 2014|March 4, 2014|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01617707||84494|
NCT01617720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VC1-2|MITRAFIT- Cardinal Adjustable Mitral Repair Follow-up International Postmarketing Surveillance (PMS)|MITRAFIT Cardinal Adjustable Mitral Repair Follow-up International Postmarketing Surveillance (PMS)|MITRAFIT|Valtech Cardio Ltd|Yes|Active, not recruiting|May 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients who are candidate for mitral valve repair, with our without concomitant        procedures.|December 2015|December 20, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01617720||84493|
NCT01607671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAION-001|Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%|Can Urgent Reduction of Intraocular Pressure With Ophthalmic Timolol Improve Recovery From Non-arteritic Anterior Ischemic Optic Neuropathy (NAION): a Randomized Study.||Fraser Health|No|Withdrawn|June 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|41 Years|N/A|No|||May 2012|May 22, 2015|May 25, 2012||No|Unable to recruit participants from recruiting sites.|No||https://clinicaltrials.gov/show/NCT01607671||85264|
NCT01602952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IY5511A1201|Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI|A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)||Il-Yang Pharm. Co., Ltd.|No|Active, not recruiting|July 2008|December 2016|Anticipated|October 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|N/A|No|||March 2015|February 23, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01602952||85626|
NCT01603212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0847|Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor|Systemic Therapy of Metastatic Melanoma With Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor||M.D. Anderson Cancer Center|No|Active, not recruiting|July 2013|||July 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|65 Years|No|||March 2016|March 17, 2016|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603212||85606|
NCT01603225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42345|Transcranial Direct Current Stimulation and Low-Functioning Autism|The Use of Transcranial Direct Current Stimulation (tDCS) to Improve Communicative Efforts, Speech, Language and Related Cognitive Functions in Individuals With Autism||Johns Hopkins University|Yes|Not yet recruiting|October 2015|December 2025|Anticipated|October 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|79 Years|No|Non-Probability Sample|The experimental group will consist of adults with autism (n=40). Participants will be        18-79 years of age, diagnosed with autism by independent clinicians and confirmed by        formal assessment (e.g., CDI, ADOS, Bayley, Sensory Profile), and with receptive and        expressive vocabulary levels of ≥ 3 years age-equivalent, as assessed by standardized        measures. Additionally, the Autism Diagnostic Interview will be administered to caregivers        in order to appropriately identify specific areas (regarding speech, language and        cognition) in which participants are experiencing the most difficulty.|August 2015|August 31, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603225||85605|
NCT01603498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|053/10|Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery|Preemptive Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery: a Split-mouth Randomized Triple-blind Clinical Trial||Federal University of the Valleys of Jequitinhonha and Mucuri|Yes|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01603498||85584|
NCT01603511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:024|Effectiveness of Heat Donation Through the Head or Torso on Mild Hypothermic Rewarming|Effectiveness of Heat Donation Through the Head or Torso on Mild Hypothermic Rewarming||University of Manitoba|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|April 4, 2013|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603511||85583|
NCT01608880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01161|Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis|Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis||University of British Columbia|Yes|Completed|August 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|154|||Female|21 Years|65 Years|No|||September 2014|September 8, 2014|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608880||85171|
NCT01614951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4141|The Pulmonary Protection Trial|Pulmonary Dysfunction After Open Heart Surgery: Randomized Clinical Trial With Focus on Lung-protective Interventions||Rigshospitalet, Denmark|Yes|Completed|July 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|90|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614951||84704|
NCT01615211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W300TL|Randomized Study of Letrozole and Trilostane for Medical Abortion|A Randomized Pilot Study of Two New Drug Combinations Fot the Termination fo Early Pregnancy||Karolinska Institutet|Yes|Terminated|May 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|36|||Female|18 Years|45 Years|No|||May 2015|May 15, 2015|June 4, 2012||No|No access to study drug Trilostan. Company closed down|No||https://clinicaltrials.gov/show/NCT01615211||84685|
NCT01614639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000748|Brain Imaging Study of Acupuncture in Chronic Low Back Pain|A Physiological fMRI Study of Acupuncture and Perceptions of Pain in Chronic Low Back Pain Patients.||Brigham and Women's Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|138|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614639||84728|
NCT01614652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VA0956|A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System|Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease|PARACHUTE IV|CardioKinetix, Inc|Yes|Recruiting|December 2012|July 2023|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|560|||Both|18 Years|79 Years|No|||March 2016|March 17, 2016|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614652||84727|
NCT01615224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMA11|Repeated Doses of Misoprostol for Medical Treatment of Missed Miscarriage|Repeated Doses of Misoprostol for Treatment of Missed Abortion||Karolinska Institutet|Yes|Suspended|May 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|55 Years|No|||October 2015|October 23, 2015|June 4, 2012||No|No funding|No||https://clinicaltrials.gov/show/NCT01615224||84684|
NCT01614366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSHDM1101|DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension|A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension||TSH Biopharm Corporation Limited|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|111|||Both|50 Years|75 Years|No|||November 2015|November 11, 2015|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01614366||84749|
NCT01614613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD-2010-009-02|Comparison Evaluation of Blood Glucose Meter Systems in a Clinical Setting|Clinical Evaluation of Bayer G3 / Tatsu System and BGMs From Other Companies||Ascensia Diabetes Care|No|Completed|May 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|146|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|May 13, 2012|Yes|Yes||No|June 30, 2013|https://clinicaltrials.gov/show/NCT01614613||84730|
NCT01615237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA162035-01A1|Dentistry United to Extinguish Tobacco|Implementing Tobacco Use Treatment Guidelines in Dental Public Health Clinics|DUET|New York University School of Medicine|No|Enrolling by invitation|February 2013|September 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|3420|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615237||84683|
NCT01616056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2617.00|Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease|A Single Center Phase II Study of Bandage Lenses for Ocular Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation||Fred Hutchinson Cancer Research Center|No|Completed|June 2012|||October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01616056||84620|
NCT01615770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09282010-6951|Behavioral Maintenance Treatment for Smoking Cessation|Behavioral Maintenance Treatment for Smoking Cessation||Stanford University|No|Completed|February 2004|June 2009|Actual|March 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|October 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01615770||84642|
NCT01616641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Orofacial|Orofacial Evaluation in Women With Rheumatoid Arthritis|Orofacial Evaluation in Women With Rheumatoid Arthritis||Federal University of São Paulo|Yes|Completed|June 2011|June 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|150|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|150 individuals, half of them, 75 were rheumatoid arthritis and the others 75 consisted        the group control|June 2012|June 11, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01616641||84575|
NCT01616953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00060042|Cell Therapy for Craniofacial Bone Defects|Cell Therapy for Craniofacial Bone Defects||University of Michigan|No|Completed|August 2012|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 15, 2016|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616953||84552|
NCT01616979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH-1160037|Saline Bag and TEE During Cardiac Displacement|Placing a Saline Bag Underneath the Heart Enhances Transgastric Transoesophageal Echocardiographic Imaging During Cardiac Displacement for Off-pump Coronary Artery Bypass Surgery||Konkuk University Medical Center|Yes|Completed|March 2008|March 2012|Actual|February 2012|Actual|Phase 0|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|20 Years|65 Years|No|Non-Probability Sample|elective OPCAB surgery patients|August 2012|August 16, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616979||84550|
NCT01617187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05688|A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)|A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia||Merck Sharp & Dohme Corp.|No|Completed|December 2012|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|360|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|June 8, 2012|Yes|Yes||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01617187||84534|
NCT01617161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-497|Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer|Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Intermediate Risk Prostate Cancer|PARTIQoL|Massachusetts General Hospital|Yes|Recruiting|July 2012|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Male|18 Years|N/A|No|||January 2016|January 6, 2016|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617161||84536|
NCT01617733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH15164|Pasireotide Therapy in Patients With Nelson's Syndrome|An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (som230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients With Nelson's Syndrome||Sheffield Teaching Hospitals NHS Foundation Trust|Yes|Terminated|March 2011|December 2015|Anticipated|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|80 Years|No|||November 2014|November 20, 2015|June 8, 2012||No|Inadequate patient recruitment|No||https://clinicaltrials.gov/show/NCT01617733||84492|
NCT01607957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPU-TAS-102-301|Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies|Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies|RECOURSE|Taiho Oncology, Inc.|Yes|Active, not recruiting|June 2012|April 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607957||85242|
NCT01607931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFSD-2012|Exercise, Glucose Kinetics, and the Incretin Effect|The Effects of Acute Exercise on Glucose Kinetics, Beta-cell Function and the Incretin Effect in Subjects Representative of the Whole Glucose Tolerance Continuum||Rigshospitalet, Denmark|No|Recruiting|January 2013|||December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607931||85244|
NCT01608243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VO71.11|Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts|Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma||Stallergenes|No|Completed|May 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|94|||Both|18 Years|50 Years|No|||June 2014|June 30, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608243||85220|
NCT01608516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|80/10|Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque|Multimodal Assessment of the Inflammatory Atheromatous Plaque : Comparison Between 68Ga-NODAGA-RGD PET/CT, 18F-FDG PET/CT, MRI AND US||University of Lausanne Hospitals|No|Recruiting|April 2012|January 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|20|||Both|18 Years|85 Years|No|||January 2016|January 24, 2016|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01608516||85199|
NCT01608893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carvedilol for PAF|Carvedilol for Prevention of Paroxysmal Atrial Fibrillation|Carvedilol for Prevention of Paroxysmal Atrial Fibrillation||University of Calgary|Yes|Recruiting|May 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||December 2015|December 7, 2015|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608893||85170|
NCT01614977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6570|Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled Study|Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled Study||Rabin Medical Center|No|Withdrawn|October 2011|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|3 Months|20 Years|No|||August 2011|November 26, 2014|June 6, 2012||No|Technical problems.|No||https://clinicaltrials.gov/show/NCT01614977||84702|
NCT01614990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27747|Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia|Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia||Garcia, Jose M., MD, PhD|Yes|Recruiting|May 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|26|||Both|N/A|N/A|No|||March 2015|March 9, 2015|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614990||84701|
NCT01614938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN201002|Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer|Phase II Trial of Docetaxel-Cisplatin Neoadjuvant Chemotherapy Followed by Concurrent Radiotherapy With Cetuximab or Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma||Fudan University|Yes|Active, not recruiting|August 2010|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|70 Years|No|||June 2012|June 6, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614938||84705|
NCT01615783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113900|Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population|Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population||GlaxoSmithKline|No|Completed|November 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|40884|||Both|40 Years|N/A|No|Non-Probability Sample|Medicaid recipients (aged >=40 years) diagnosed with COPD (International Classification of        Disease, Ninth Revision, Clinical Modification (ICD-9 CM) codes: 491.xx, 492.x, 496.xx)        and newly initiated on Chronic Obstructive Pulmonary Disease (COPD) maintenance medication        (maintenance therapies include ipratropium alone/combination ipratropium-albuterol (IPR),        tiotropium (TIO), inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and        combination product of inhaled corticosteroid and long-acting beta-agonist (ICS/LABA))        will be identified and matched in a 1 to 3 ratio to non-COPD Medicaid recipients on age        (exact), gender, race, index year, Medicare dual eligibility, pre-index long-term care        use. Index date was defined as the date of the first chronologically-occurring COPD        maintenance medication during an identification period (01/01/2004 to 12/31/2006) for COPD        patients, and as the date of the first medical or prescription claim during the index year        of the corresponding matche|June 2012|June 21, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01615783||84641|
NCT01616082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIMDFH 266040|Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)|Effect of Caloric Restriction on Metabolic Biomarkers and Fat Oxidation in Obese Men and Women (Magellan II)|Magellan II|Translational Research Institute for Metabolism and Diabetes, Florida|Yes|Completed|September 2011|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|45|||Both|18 Years|55 Years|No|||December 2012|December 5, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01616082||84618|
NCT01616329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPOC-08-006|R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions|R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions|R-FACT|Sanquin Research & Blood Bank Divisions|No|Recruiting|January 2009|January 2013|Anticipated|August 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1500|Samples With DNA|Blood samples from consenting participants collected and retained: plasma,serum and buffy      coat|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Study Design and study population We will perform a retrospective matched case- cohort        study at hospitals nationwide from a period January 2005 to December 2011. Large red blood        cell using hospitals will be selected as study bases. The study cohort will comprise of        consecutive red blood cell transfused patients at the study center.        Cases are defined as first time ever irregular red blood cell antibody formers, with no        prior history of red blood cell transfusions and alloimmunization before the study period.        Controls will be all consecutive transfused patients who had received their first and        subsequent red blood transfusions at the study center with no prior history of red blood        cell transfusions and alloimmunization.|June 2012|June 7, 2012|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01616329||84599|
NCT01616628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|68246|The Use of Incentives to Promote Healthier Eating in Low-income Communities|The Use of Incentives to Promote Healthier Eating in Low-income Communities||Albert Einstein Healthcare Network|No|Completed|November 2010|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|58|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 8, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616628||84576|
NCT01616654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06.SPR18223|Dose Range Study of CD5789 in Acne Vulgaris|A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris||Galderma|No|Completed|June 2012|September 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|304|||Both|12 Years|35 Years|No|||January 2014|January 14, 2014|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616654||84574|
NCT01616992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK083538|Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic Characteristics (ICEPAC) Study|Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic|ICEPAC|Case Western Reserve University|Yes|Completed|September 2009|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Actual|200|||Female|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The patient population will be composed of four subject groups:        Group I: This group will consist of female IC/PBS patients (n = 76) Group II: This group        will consist of female siblings of patients (n = 38) Group III: This group will consist of        female MPP patients (n = 76) Group IV: This group will consist of healthy female control        subjects (n = 38) Female subjects ages 18-80 will be recruited.|February 2015|February 2, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01616992||84549|
NCT01617746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR012|Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma|Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma||University of Glasgow|No|Not yet recruiting|November 2012|December 2015|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|18|||Both|18 Years|60 Years|No|||June 2012|June 10, 2012|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617746||84491|
NCT01617759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Asp-PCR-CSF|Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis|Diagnostic Study on the Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis||Heidelberg University|No|Enrolling by invitation|September 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|Samples With DNA|fungal DNA from CSF samples|Both|N/A|N/A|No|Probability Sample|Immunocompromised individuals|December 2015|December 8, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617759||84490|
NCT01617408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120128|Brain Stimulation and Vision Testing|TMS Investigations of the Human Visual System||National Institutes of Health Clinical Center (CC)||Recruiting|May 2012|||||Phase 1|Observational|Time Perspective: Prospective|||Anticipated|320|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2015|December 30, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617408||84517|
NCT01613911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5146S-11|Study of Human Sensory Perception|A Combined fMRI and Electrophysiological Study of Human Sensory Perception||Swedish Medical Center|No|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|6|||Both|10 Years|65 Years|No|Non-Probability Sample|People between 10 and 65 years old diagnosed with epilepsy who will have invasive        eletrophysioloigcal monitoring as part of a clinical evaluation for epilepsy treatment.|September 2014|December 4, 2014|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613911||84784|
NCT01607970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXT-168/11|Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making|Double-blind, Placebo-controlled, Randomized Study: Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making||University Hospital, Bonn|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|80|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 25, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607970||85241|
NCT01607983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-06070|Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients|The Effect of Selective Pulmonary Vasodilation on Ventricular Afterload and Ventricular-arterial Coupling in Patients With Fontan Physiology and Validation of Echocardiographic Measures of Systolic and Diastolic Function.||University of California, San Francisco|No|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|60 Years|No|||April 2015|April 16, 2015|May 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607983||85240|
NCT01607944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNF2012|Incretins and Metabolism|The Extrapancreatic Metabolic Effects of Incretin Hormones||Rigshospitalet, Denmark|No|Completed|April 2012|December 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Male|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Local community volunteers|December 2014|December 2, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607944||85243|
NCT01608256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ק0012012|Driving Ability Among People With Mild Cognitive Impairment|Assessing the Effect of MCI on Driving Ability by Using on Road Driving Test. The Relationship Between Their Driving Outcome and Their Cognitive Decline Will be Examined|MCI|Tel Aviv University|No|Not yet recruiting|June 2012|June 2014|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|50 Years|70 Years|No|Probability Sample|primary care clinic|May 2012|May 29, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608256||85219|
NCT01608269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-002|Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy|Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy|EPZSwitch|Therapeutic Concepts|No|Recruiting|November 2010|October 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||May 2012|May 29, 2012|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01608269||85218|
NCT01608529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC26392|Feel Breathe, Restriction Device Ventilatory Nasal|Phase 1: Effects of a Restriction Device Ventilatory Nasal Flow on Pulmonary Ventilation and Gas Exchange During Exercise|FB|University of Cadiz|No|Completed|January 2011|December 2011|Actual|July 2011|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|25 Years|35 Years|No|||May 2013|May 16, 2013|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01608529||85198|
NCT01609166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIB-ALO-2010-02|Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome|Placebo-controlled Trial to Determine the Effectiveness of a 3% Allopurinol-base Topical Agent for Prevention of Capecitabine-induced Hand-foot Syndrome||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Yes|Completed|July 2011|December 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|N/A|No|||May 2014|May 22, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01609166||85149|
NCT01614431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cystinosis and NAC|N Acetyl Cysteine for Cystinosis Patients|N Acetyl Cysteine Can Decrease the Progression of Renal Disease in Cystinosis Patients||University of Sao Paulo||Completed|March 2011|May 2012|Actual|January 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|1 Year|18 Years|No|||June 2012|June 19, 2012|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01614431||84744|
NCT01614717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-11-030-EU-HF|Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients - TRICHAMPION STUDY|Triple Chamber Pacing in HOCM Patients - TRICHAMPION STUDY|TRICHAMPION|St. Jude Medical|No|Recruiting|July 2014|July 2018|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614717||84722|
NCT01614665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMR-EC-1207|A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time|A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated With an Advagraf® or Prograf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up||Astellas Pharma Inc|Yes|Recruiting|March 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|64|||Both|N/A|15 Years|No|||February 2016|February 5, 2016|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01614665||84726|
NCT01614678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-383-C-005/C-12-026|A Comparison of Manufacturing Processes for AIR OPTIX® COLORS Contact Lens|AIR OPTIX® COLORS: Automated vs Semi-automated Manufacturing Processes||Alcon Research|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|49|||Both|18 Years|N/A|No|||February 2014|February 20, 2014|June 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01614678||84725|
NCT01615497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204010157|Web-based CBT4CBT for Alcohol|Computer Based Training in Cognitive Behavioral Therapy Web-based Delivery of CBT4CBT for Alcohol|CBT4CBT Etoh|Yale University|Yes|Completed|November 2012|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|68|||Both|18 Years|70 Years|No|||July 2015|July 15, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615497||84663|
NCT01615796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115198|Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses|A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.||GlaxoSmithKline||Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|12||Actual|86|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2014|May 29, 2014|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01615796||84640|
NCT01616069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0362/14-12-2011|Assessment of Hemodynamic Response in Cardiopulmonary Bypass Graft After Cardiopulmonary Bypass Using Transesophegeal Echocardiography|Assessment and Hemodynamic Response in CABG After Cardiopulmonary Bypass Using Intraoperative Transesophegeal Echocardiography||Federal University of Juiz de Fora|Yes|Completed|February 2012|December 2013|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|45 Years|65 Years|No|||May 2015|May 29, 2015|April 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616069||84619|
NCT01616095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GH GIIR - 2011|Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype|The Effect of a Long-Term Growth Hormone Supplementation on the Whole-Body Metabolic Characteristics and Adipose Tissue Phenotype in Growth Hormone Deficient Adults: the 5-yr Follow-up|GHAT|Slovak Academy of Sciences|Yes|Active, not recruiting|June 2011|August 2013|Anticipated|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|44|Samples With DNA|plasma 2.5 ml, serum 5 ml, adipose tissue 300 mg taken by the percutaneous biopsy of      abdominal subcutaneous adipose tissue, in local anaesthesia.|Both|21 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|Twenty growth hormone deficient adults, receiving supplementation with rhGH for 5 years        (extensively examined in 2005-2006, prior to the start of rhGH therapy) and 20 age-,        gender- and BMI- matched controls will enter the study. Both, GHD patients and controls        will undergo an extensive clinical protocol, identical to that performed in 2005 (Ukropec        et al., 2008a).        The possibility of drop-out of patients needs to be taken into consideration. Possible        lowering of the numbers of participants due to drop-out of individuals tested in the        Baseline Study will be resolved by either (i) using biological material obtained in the        Baseline Study which was originally not subjected to an extensive molecular genetic        testing due to the limited capacity and high cost of these analyses and/or by (ii)        recruiting necessary amount of new patients with history of 5 years rhGH therapy (initial        examination is missing).|July 2013|July 18, 2013|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616095||84617|
NCT01616342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29SEPT2011|Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty|Investigator Initiated Trial- Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty. Comparison of Spinal Cord Stimulation and Comprehensive Medical Management|War Wounded|Sceptor Pain Foundation|Yes|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 7, 2012|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01616342||84598|
NCT01616667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120009|Comparing the Clinical Effects of Posterior Approach Versus Lateral Approach in Osteoarthritis Patients With a THA|Posterior Approach Versus Lateral Approach in Osteoarthritis Patients, With Primary Total Hip Arthroplasty. The Effect on Early Physical Function, Pain, Patient Reported Outcome Measures, Gait and Muscle Weakness A Randomized Clinical Trial|COMPALA|Odense University Hospital|No|Completed|May 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 3, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01616667||84573|
NCT01617434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN2211-3917|The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes|The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|451|||Both|18 Years|80 Years|No|||October 2014|October 31, 2014|June 8, 2012|Yes|Yes||No|October 22, 2014|https://clinicaltrials.gov/show/NCT01617434||84515|
NCT01618058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPM 007|Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials|A Long-Term Observational Cohort Study of HIV Infection in Participants Who Seroconvert After Enrolment in Dapivirine Vaginal Ring Trials||International Partnership for Microbicides, Inc.|Yes|Enrolling by invitation|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|68|||Female|18 Years|45 Years|No|Non-Probability Sample|Both microbicide and placebo recipients in IPM 027 who have become HIV infected (HIV-1 or        HIV-2) while participating in IPM 027 will be offered enrolment in IPM 007 at the exit        visit of IPM 027, i.e. approximately 6 weeks after identification of HIV seroconversion.        This study includes all active IPM clinical research centres that enrol participants for        IPM microbicide trials.|August 2012|August 20, 2012|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618058||84467|
NCT01617421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120145|Yoga as Self-Care for Arthritis in Minority Communities|Pilot Study of Yoga as Self-Care for Arthritis in Minority Communities||National Institutes of Health Clinical Center (CC)||Recruiting|May 2012|March 2020|Anticipated|March 2020|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617421||84516|
NCT01614223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSCM 2010 -1|Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis|A Randomized Double-Blind Clinical Trial to Investigate the Use of Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis||University of Western Ontario, Canada|No|Recruiting|September 2010|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||April 2014|April 24, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01614223||84760|
NCT01608932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G.A. 250487 - Veneto WP8Cl10|Life-long Monitoring of Frail Patients With Chronic Diseases|RENEWING HEALTH - Telemonitoring of Elderly and Frail Patients With Multiple Chronic Diseases in Veneto Region||Regione Veneto|Yes|Completed|April 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|152|||Both|65 Years|N/A|No|||May 2012|October 27, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01608932||85167|
NCT01608282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00493|Internet Intervention to Improve Physical Activity in Early Knee Osteoarthritis|Capitalizing on the Teachable Moment: the OPEN (Osteoarthritis Physical Activity & Exercise Net) for Improving Physical Activity in Early Knee Osteoarthritis|OPEN|University of British Columbia|No|Recruiting|October 2012|February 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|252|||Both|50 Years|75 Years|No|||October 2012|October 11, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608282||85217|
NCT01608542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00032|A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects|A Phase I, Open-label Study to Assess the Pharmacokinetics of Oral Fostamatinib in Healthy Japanese Subjects After Single and Multiple Doses||AstraZeneca||Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|May 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01608542||85197|
NCT01608555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP2|Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis|Tobramycin 300 mg o.d. Aerosol in in Adult Patients With Cystic Fibrosis: Pilot Study on Antimicrobial Activity||University of Milan|Yes|Completed|January 2012|July 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|45 Years|No|||July 2012|July 23, 2012|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608555||85196|
NCT01608906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0854|Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery|Efficacy of Low Dose Intravenous Heparin in Preventing Thromboembolism in the SICU.||University of Colorado, Denver|Yes|Completed|May 2007|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|113|||Both|18 Years|80 Years|No|||May 2014|May 19, 2014|May 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01608906||85169|
NCT01609179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI-926-09|IPI-926 Extension Protocol for Continuation of Treatment With IPI-926|IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol||Infinity Pharmaceuticals, Inc.|No|Completed|March 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|May 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609179||85148|
NCT01604967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110597-600-602-603|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|May 2012|||||N/A|N/A|N/A||||||||||||||May 11, 2015|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01604967||85471|
NCT01615016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-12295|MISurf Versus InSurE. A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants|Feasibility Study of A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants|MIsurf|Hamilton Health Sciences Corporation|Yes|Recruiting|July 2012|December 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|36 Hours|No|||March 2015|March 19, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01615016||84699|
NCT01615250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCIC-2012|Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy|Phase I Study to Evaluate the Efficacy and Safety of Intramyocardial Implantation of Peripheral Mononuclear Cells With CD34+ Stem Cells in Patient With Ischemic Cardiomyopathy After Preparatory Course of Shock - Wave Therapy|ISCIC|Odessa National Medical University||Recruiting|January 2012|January 2016|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|20 Years|75 Years|No|||June 2012|June 8, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615250||84682|
NCT01615263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IUCPQ 20784|Lung Collapse With Bronchial Blocker|Isolated Lung Collapse in Two Stages With Bronchial Blocker: Comparison With Double Lumen Tube||Laval University|No|Completed|April 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)|2||Actual|40|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|May 25, 2012||No||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01615263||84681|
NCT01614964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2149|Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)|Phase 2 Proof of Concept Study of a Candidate Aminoquinoline Antimalarial (AQ-13)||Tulane University Health Sciences Center|Yes|Active, not recruiting|August 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|66|||Male|18 Years|N/A|No|||December 2015|December 13, 2015|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614964||84703|
NCT01615809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSJD-ABELNEB-2010|Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia|A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia||Fundació Sant Joan de Déu|No|Completed|October 2011|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|3 Years|17 Years|No|||November 2015|November 4, 2015|June 4, 2012||No||No|August 28, 2015|https://clinicaltrials.gov/show/NCT01615809||84639|
NCT01615822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMV_OZ439_12_001|Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers|A Phase I Healthy Volunteer Study Investigating the Safety, Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 and Mefloquine||Medicines for Malaria Venture|Yes|Terminated|August 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2015|March 27, 2015|June 7, 2012|No|Yes|Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single    dose cure due to low probability of success|No|March 17, 2015|https://clinicaltrials.gov/show/NCT01615822||84638|
NCT01616381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS2011DIKE01|Sildenafil Versus Placebo in Chronic Heart Failure|Sildenafil in Heart Failure (SilHF); An Investigator Initiated Multinational Randomized Controlled Clinical Trial.|SilHF|Helse Stavanger HF|Yes|Recruiting|March 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|85 Years|No|||December 2014|December 16, 2014|June 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616381||84595|
NCT01616394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/07/DEC/460|Postoperative Troponin in Children With Congenital Heart Disease|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|February 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|180|||Both|N/A|10 Years|No|Probability Sample|children with congenital heart disease admitted for surgery|September 2013|November 18, 2014|February 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01616394||84594|
NCT01616407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 382/11|Effects of MDMA and Methylphenidate on Social Cognition|Effects of MDMA (Ecstasy) and Methylphenidate (Ritalin) on Social Cognition||University Hospital, Basel, Switzerland|Yes|Completed|August 2012|April 2013|Actual|December 2012|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616407||84593|
NCT01616355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|068/2008|Evaluation of Sodium Hypochlorite as a Denture Cleanser|Denture Condition: Influence on Masticatory Performance, Volatile Sulfur Compounds and Presence of Biofilm||University of Campinas, Brazil|No|Completed|August 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|15|||Both|N/A|N/A|Accepts Healthy Volunteers|||June 2012|June 8, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616355||84597|
NCT01616368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIRB 00458|The Effects of Mindfulness Training on Eating Behaviors and Food Intake|The Effects of Mindfulness Training on Eating Behaviors and Food Intake||Seattle Institute for Biomedical and Clinical Research|No|Completed|January 2012|January 2013|Actual|January 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01616368||84596|
NCT01617005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25699|An Observational Study of RoActemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Non-Biological DMARDs|Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD||Hoffmann-La Roche||Completed|May 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis and an inadequate response to DMARDs|March 2016|March 1, 2016|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617005||84548|
NCT01617200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05689|Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)|A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine Using Olanzapine as an Active Control in Subjects Diagnosed With Schizophrenia Who Completed Protocol P05688||Forest Laboratories|No|Completed|December 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|105|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617200||84533|
NCT01617772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDRI/90.10|Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis|Comparison the Effectiveness of L-Carnitine With Atorvastatin in Non-Alcoholic Steatohepatitis (NASH)|NALCAT|Tehran University of Medical Sciences|Yes|Recruiting|January 2013|April 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|440|||Both|40 Years|60 Years|No|||November 2015|November 3, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617772||84489|
NCT01618071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRINC 11-LO-0116|Vascular Effects of Triglyceride-rich Lipoproteins|Unravelling the Mechanisms of Vascular Protection by n3-PUFAs to Optimise and Support Their Use as Bioactives by the Food Industry||King's College London|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Anticipated|16|||Male|35 Years|70 Years|Accepts Healthy Volunteers|||October 2012|October 10, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01618071||84466|
NCT01618045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120293|Nutritional Regulation of Wound Inflammation: Part II|Nutritional Regulation Of Wound Inflammation: Part II|FPPT2DM-II|Ohio State University|No|Active, not recruiting|May 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|25|Samples Without DNA|Blood will be drawn for the study.|Both|30 Years|80 Years|No|Probability Sample|The subject population in this study will be patients with type 2 diabetes with the        following parameters.          -  Age 30 to 80 years old          -  HbA1c ≤ 9. 0          -  BMI between 22-42|September 2015|September 8, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618045||84468|
NCT01614236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-WAA-024811-TLV|Pre- Versus Post-Incisional Pregabalin for Postoperative Pain Control|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2012|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||June 2012|June 6, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01614236||84759|
NCT01609205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ClinTrid-US-1201|Doppler Evaluation in RA Patients After Adalimumab.|Doppler Quantitative Evaluation and Follow-up Over 12 Months in RA Patients With Moderate and High Disease Activity Who Are Candidates for Biologic add-on Therapy With Adalimumab|Muscara|Karolinska Institutet|Yes|Recruiting|October 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609205||85146|
NCT01609218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12858|A Study of LY2140023 in Healthy Participants|A Study to Evaluate the Impact of Activated Charcoal on the Absorption of LY2140023 in Healthy Subjects||Eli Lilly and Company|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||October 2012|October 4, 2012|May 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01609218||85145|
NCT01608295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VII-IT-02|Vilazodone for Treatment of Geriatric Depression|A Pilot Study of Double-blind Comparison of Vilazodone to Paroxetine in Geriatric Depression||University of California, Los Angeles|Yes|Completed|July 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|65|||Both|60 Years|N/A|No|||November 2015|November 30, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608295||85216|
NCT01608568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Robotic Sacrocolpopexy Quill|Affixing Polypropylene Mesh Using Barbed Suture (Quill™ SRS) During Robotic Assisted Laparoscopic Sacrocolpopexy|AFFIXING POLYPROPYLENE MESH USING BARBED SUTURE (QUILL™ SRS) DURING ROBOTIC ASSISTED LAPAROSCOPIC SACROCOLPOPEXY RANDOMIZED CONTROLLED TRIAL|Quill RALSC|University of California, San Diego|No|Recruiting|November 2010|August 2013|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|32|||Female|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 31, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01608568||85195|
NCT01608919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1295|Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection|Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection.||University of Colorado, Denver|No|Terminated|November 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|80 Years|No|||August 2015|August 7, 2015|May 29, 2012||No|Sara Cheng, MD has left the University of Colorado and we have closed this study.|No||https://clinicaltrials.gov/show/NCT01608919||85168|
NCT01605188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nviazis2|Predictors of Non-response and Loss of Response in IBD Patients Treated With Anti-TNF|Predictors of Non-response and Loss of Response in IBD Patients Treated With Anti-TNF.||Evangelismos Hospital|Yes|Completed|May 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|132|Samples With DNA|Whole blood Serum Bowel mucosal tissue|Both|N/A|N/A|No|Non-Probability Sample|IBD patients treated with anti-TNF that need dose escalation.|January 2016|January 27, 2016|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605188||85454|
NCT01605487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAFCUTIII|Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria|Double-blind, Three-way Cross-over, Placebo-controlled Study to Assess the Efficacy, Safety and Mechanisms of Treatment With Rupatadine 20 mg and 40 mg in Cold Contact Urticaria (CCU)|PAFCUTIII|Charite University, Berlin, Germany|No|Completed|June 2012|October 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|N/A|No|||April 2014|October 14, 2014|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01605487||85431|
NCT01605773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-2137|Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes|Repaglinide Versus Glyburide: Comparitive Effect on Postprandial Lipemia: An Open-labeled, Randomized, Parallel Group Study in Patients With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|November 2001|March 2003|Actual|March 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||August 2012|August 30, 2012|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01605773||85409|
NCT01615302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 10-1-082|Is the Use of Blood Platelets Effective in the Treatment of Difficult Fistulas Related to the Anal Sphincter?|Use of Platelet Rich Plasma (PRP) as an Adjunct in the Treatment of High Peri-anal Fistulas.||Maastricht University Medical Center|Yes|Recruiting|March 2012|April 2016|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||August 2012|August 21, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01615302||84678|
NCT01615315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH-URO-2012-01|Aspirin and the Risk of Microscopic Hematuria in Asymptomatic Screened Population|||Seoul National University Hospital|No|Completed|August 2012|||August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|60048|||Both|20 Years|89 Years|No|Non-Probability Sample|Asymptomatic general population who underwent general health screening program|August 2012|August 27, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615315||84677|
NCT01614730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-12-1002|User Evaluation in Healthy Volunteers to Verify no Pelvic Floor Contraction is Stimulated When the Modified Neurotech Vital Device is Used Compared to the Neurotech Vital Device|User Evaluation Trial in Healthy Volunteers : Modified Neurotech Vital Device|BMR-12-1002|Bio-Medical Research, Ltd.|No|Completed|June 2012|July 2012|Actual|June 2012|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|10|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|July 5, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614730||84721|
NCT01615003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NNSF81173116|The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease|The Analysis of Blood Stasis Syndromeand of Coronary Heart Disease Related MicroRNA Genomics and Target Gene Regulatory Networks||Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Yes|Recruiting|May 2012|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|30 Years|75 Years|No|||January 2014|January 12, 2014|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01615003||84700|
NCT01615536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0211-A|The Role of Canine Fossa Trephination in the Severely Diseased Maxillary Sinus|The Role of Canine Fossa Trephination in the Severely Diseased Maxillary Sinus|CFT|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Withdrawn|December 2010|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||January 2014|January 8, 2014|June 5, 2012||No|Inability to recruit subjects|No||https://clinicaltrials.gov/show/NCT01615536||84660|
NCT01616108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPX-STRAB|Bupivacaine Injection of Eye Muscles to Treat Strabismus|Bupivacaine Injection of Eye Muscles to Treat Strabismus||Smith-Kettlewell Eye Research Institute|No|Recruiting|April 2012|September 2020|Anticipated|September 2019|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|8 Years|95 Years|No|||November 2015|November 20, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616108||84616|
NCT01616693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC ZP 2012; PATH HS-658|Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines|Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants||PATH|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|620|||Both|5 Weeks|16 Weeks|Accepts Healthy Volunteers|||August 2013|August 28, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01616693||84571|
NCT01616719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMT002|Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease|Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease||Providence Medical Technology, Inc.||Enrolling by invitation|May 2012|February 2015|Anticipated|February 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|35 Years|80 Years|No|||January 2013|January 13, 2013|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616719||84570|
NCT01616680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2589.00|Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease|Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients With Steroid-Resistant Acute GVHD||Fred Hutchinson Cancer Research Center|Yes|Withdrawn|September 2012|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|0|||Both|12 Years|N/A|No|||June 2013|June 25, 2013|June 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01616680||84572|
NCT01617460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-11-003|A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder|A Long-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|September 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||||||Both|6 Years|17 Years|No|||November 2015|November 4, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617460||84513|
NCT01617473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUPH IRB [2012] (27)|Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant|Randomized Trial of Unmanipulated Mobilized Blood/Marrow Versus Blood Haploidentical Transplant With Standard-risk Leukemia||Peking University People's Hospital||Not yet recruiting|October 2015|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|320|||Both|2 Years|60 Years|No|||April 2015|April 27, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617473||84512|
NCT01617785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|fuwai201112|PEACE Prospective Study of Patients With Three-vessel Disease|Patient-centered Evaluative Assessment of Cardiac Events (PEACE): Prospective Study of Patients With Three-vessel Coronary Heart Disease|PEACE3VD|China National Center for Cardiovascular Diseases|Yes|Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|4500|||Both|18 Years|N/A|No|Non-Probability Sample|elective patients for coronary angiogram.|June 2012|August 13, 2013|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617785||84488|
NCT01615653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005037|EUS Guided Celiac Neurolysis|Prospective Randomized Trial of EUS Guided Celiac Ganglia Neurolysis (CGN) Versus EUS Guided Celiac Plexus Neurolysis (CPN) for Pancreatic Cancer Pain||Mayo Clinic|No|Active, not recruiting|September 2009|September 2016|Anticipated|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|N/A|No|||August 2015|August 18, 2015|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01615653||84651|
NCT01613924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00792|Efficacy of Handheld Acne Heat Device|Efficacy of a Handheld Heat Based Device for the Spot Treatment of Mild to Moderate Acne Vulgaris: A Controlled Study to Determine Time to Resolution of Individual Inflammatory Lesions Using an Over-the-counter Acne Heat Device.||University of British Columbia|No|Withdrawn|July 2013|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|64 Years|Accepts Healthy Volunteers|||December 2015|December 2, 2015|May 30, 2012||No|Lack of funding and resources|No||https://clinicaltrials.gov/show/NCT01613924||84783|
NCT01617265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRLF-TG-1-AWARE|Study of a Strategy to Prevent Oversedation in Intensive Care Patients Under Mechanical Ventilation|Prevention of Oversedation in Intensive Care Patients Under Mechanical Ventilation : the AWARE Multicentric Randomized Trial|AWARE|French Society for Intensive Care|Yes|Completed|June 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1180|||Both|18 Years|N/A|No|||August 2015|August 25, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01617265||84528|
NCT01605240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:092|Ibuprofen Versus Codeine. Is One Better for Post-operative Pain Relief Following Reduction of Paediatric Forearm Fractures?|Ibuprofen vs. Codeine. Is One Better for Post-operative Pain Relief Following Reduction of Paediatric Forearm Fractures?||University of Manitoba|Yes|Recruiting|July 2012|August 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|3 Years|16 Years|No|||July 2013|July 24, 2013|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605240||85450|
NCT01609192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 081227|Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated|Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated.|HYDREP|Assistance Publique - Hôpitaux de Paris|No|Completed|April 2010|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Male|18 Years|60 Years|No|||August 2013|August 6, 2013|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01609192||85147|
NCT01604980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0019850580-B|Determination of Protein Requirements in Elderly Female Subjects >75 Yrs Old|Use of Indicator Amino Acid Oxidation Technique to Determine Protein Requirement of Elderly Female Subjects >75 Years Old||The Hospital for Sick Children|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Female|76 Years|90 Years|Accepts Healthy Volunteers|||August 2013|August 16, 2013|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01604980||85470|
NCT01605201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|92/11|Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage|Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage in the Knee After Traumatic Injury - a Phase I Clinical Trial-|Nose2Knee|University Hospital, Basel, Switzerland|Yes|Recruiting|May 2012|August 2018|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|55 Years|No|||March 2016|March 14, 2016|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605201||85453|
NCT01605799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 12-237|IOK Treatment Study|A Novel PTSD Treatment for Veterans Who Killed in War||VA Office of Research and Development|No|Completed|October 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|70 Years|No|||January 2016|January 22, 2016|May 18, 2012||No||No|November 13, 2015|https://clinicaltrials.gov/show/NCT01605799||85407|
NCT01615601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR018595|An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients|PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naïve to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial|POISE|Janssen Inc.|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|77|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients infected with human immunodeficiency virus type 1 who have experienced        tolerability issues on their current or prior ccombination antiretroviral therapy regimen        and for whom a regimen including darunavir and/or etravirine is clinically indicated.|May 2014|May 20, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615601||84655|
NCT01615289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKBB 32/09|Neural Effects of Green Tea Extract on Dorsolateral Prefrontal Cortex|||University Hospital, Basel, Switzerland|No|Completed|July 2010|January 2012|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|12|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01615289||84679|
NCT01615276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 12-3-020|Neuromuscular Electrical Stimulation (NMES) and Muscle Protein Accretion (ES-PRO)|The Effect of Neuromuscular Electrical Stimulation on Post-prandial Muscle Protein Accretion in Healthy Elderly Men|ES-PRO|Maastricht University Medical Center|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|10|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01615276||84680|
NCT01615549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Simbionix 20120507|Efficacy of Proficiency-based Versus Free Laparoscopic Training in Cholecystectomy on a Virtual Reality Simulator|Proficiency-based Versus Free Laparoscopic Training in Cholecystectomy Using the Simbionix LAP Mentor™. A Randomized Controlled Trial||University of Zurich|Yes|Recruiting|April 2004|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|64|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2013|August 22, 2013|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01615549||84659|
NCT01616420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43628-J|Assisted Partner Notification to Augment HIV Treatment and Prevention in Kenya|Assisted Partner Notification to Augment HIV Treatment and Prevention in Kenya|APS|University of Washington|Yes|Recruiting|June 2012|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|3240|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 2, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616420||84592|
NCT01617213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16043|Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma|Autologous Peripheral Blood Stem Cell Transplantation and Maintenance Lenalidomide After High-dose Melphalan for Multiple Myeloma|AMM-2011|University of Virginia|Yes|Terminated|April 2012|||April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|75 Years|No|||June 2013|June 20, 2013|June 8, 2012||No|Study is no longer needed as recent data have answered the primary hypotheses for this study.|No||https://clinicaltrials.gov/show/NCT01617213||84532|
NCT01617447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-11-002|A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder|A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder||Otsuka Pharmaceutical Co., Ltd.|No|Active, not recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||||||Both|6 Years|17 Years|No|||November 2015|November 4, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617447||84514|
NCT01617486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105325|Achieving Energy Balance in Post Partum Teens|Achieving Energy Balance in Overweight Post Partum Teens|BALANCE|Washington University School of Medicine|No|Completed|January 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1325|||Female|12 Years|20 Years|Accepts Healthy Volunteers|||June 2012|June 8, 2012|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01617486||84511|
NCT01613937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SWDI Dulce Mothers|Community Approach to Reduce the Risks of Diabetes After Gestational Diabetes Mellitus|Dulce Mothers: A Community Approach to Reduce the Risks of Developing Diabetes After Gestational Diabetes||Scripps Whittier Diabetes Institute|Yes|Completed|December 2009|September 2013|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|67|||Female|18 Years|45 Years|No|||November 2014|November 17, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613937||84782|
NCT01613950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYL719X2103|PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer|A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2||Novartis||Completed|December 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613950||84781|
NCT01617824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2588P|Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes|Rapid Effects of the DPP-4 Inhibitor Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetic Patients With and Without Chronic Renal Failure. A Randomized Cross-over Trial Versus Placebo||University of Padova|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|45|||Both|35 Years|75 Years|No|||December 2014|December 18, 2014|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01617824||84485|
NCT01604993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11216|Acute Effect of Nitrate From Natural Dietary Sources on Arterial Stiffness and Blood Pressures in Healthy Individuals|Acute Effect of Nitrate Supplementation From Natural Dietary Sources on Arterial Stiffness and Aortic and Brachial Blood Pressures: a Double-blind, Placebo-controlled, Randomized, Crossover Clinical Trial in Healthy Adults|DNAB|St. Michael's Hospital, Toronto|No|Completed|October 2011|October 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|31|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 7, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01604993||85469|
NCT01605214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UHNEVLW-1|Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung Transplant|Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung Transplant||University Health Network, Toronto|No|Recruiting|October 2015|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|All patients undergoing bilateral lung transplant for any indication will be considered to        be enrolled in this study.|November 2015|November 13, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605214||85452|
NCT01605227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XL184-307|Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100|A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100|COMET-1|Exelixis|Yes|Completed|June 2012|March 2015|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1028|||Male|18 Years|N/A|No|||April 2015|April 13, 2015|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605227||85451|
NCT01605500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-12-445|Utility of the Audible Alert in Current Generation Medtronic Implantable Cardioverter-defibrillators|Investigation of the Utility of the Audible Alert in Current Generation Medtronic ICDs||Englewood Hospital and Medical Center|No|Completed|June 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|patients who have a Generation 2 Medtronic implantable cardioverter-defibrillator (ICD)|February 2016|February 18, 2016|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01605500||85430|
NCT01605513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011L0901|Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease|Phase I Clinical Trial of PEG-IFN-SA in HCV Disease: Evidence for Drug Safety, Tolerance, and Antiviral Activity|PEG-IFN-SA|First Hospital of Jilin University|Yes|Completed|June 2011|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|80|||Both|20 Years|65 Years|No|||January 2016|January 23, 2016|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01605513||85429|
NCT01615861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|714|Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens|Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens||Bausch & Lomb Incorporated|No|Active, not recruiting|November 2012|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|103|||Both|40 Years|N/A|No|||March 2014|March 27, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01615861||84635|
NCT01615874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05574|Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)|A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclomethasone Dipropionate (BDP HFA) on the HPA Axis in Asthmatic Children 5 to 11 Years of Age (Protocol No. P05574/PN158)||Merck Sharp & Dohme Corp.|No|Withdrawn|January 2013|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|5||Actual|0|||Both|5 Years|11 Years|No|||September 2015|September 25, 2015|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615874||84634|
NCT01616147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01DK094463|LIFT: Lifestyle Interventions For Two|LIFT: Lifestyle Interventions For Two (Member of the LIFE Moms Consortium)|LIFT|St. Luke's-Roosevelt Hospital Center|Yes|Recruiting|October 2012|August 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|210|||Female|18 Years|N/A|No|||March 2014|April 13, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616147||84613|
NCT01615575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|URomLS1|Transanal Haemorrhoidal Dearterialisation Versus Stapler Haemorrhoidopexy|Transanal Haemorrhoidal Dearterialisation Versus Stapler Haemorrhoidopexy. A Randomized Trial With Long-term Follow-up||University of Roma La Sapienza|No|Completed|October 2008|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|124|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01615575||84657|
NCT01615588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Manuka GI Study|The Glycaemic Index of Manuka Honey|The Glycaemic Index of Manuka Honey||Waiariki Institute of Technology|Yes|Completed|April 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|June 7, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615588||84656|
NCT01615562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54HD034449- Wickham Pilot|Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome|Endothelial Dysfunction in Adolescents and Women With Polycystic Ovary Syndrome (PCOS)||Virginia Commonwealth University|Yes|Terminated|December 2011|July 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|18|Samples Without DNA|serum and plasma for analysis of hormones|Female|14 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Specifically the study will enroll: 15 treatment-naïve adolescents with PCOS; 15 age- and        BMI Z-score matched adolescent controls without PCOS; 15 adult treatment-naïve women with        PCOS; and 15 age- and BMI-matched adult women without PCOS. Subject race/ethnicity is not        a specific inclusion/exclusion criterion for this study.|December 2015|December 10, 2015|June 6, 2012||No|Difficulty in enrolling suitable subjects|No||https://clinicaltrials.gov/show/NCT01615562||84658|
NCT01615666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2R01AG020279-06A2|A Composite MR Neuroimaging Marker for Alzheimer's Disease|A Composite MR Neuroimaging Marker for Alzheimer's Disease||Medical College of Wisconsin|No|Withdrawn|March 2009|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|0|Samples With DNA|Buccal (cheek) swab|Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  Alzheimer's, non-Alzheimer's dementia, and mild cognitive impairment (MCI)             participants recruited from the Medical College of Wisconsin/Froedtert Hospital             Memory Disorders Clinic          -  MCI and healthy volunteers recruited from the community|January 2016|January 13, 2016|June 6, 2012||No|This was never a clinical trial and should never have been approved.|No||https://clinicaltrials.gov/show/NCT01615666||84650|
NCT01617018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM09195|Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis|French Multicentric Prospective Observational Cohort of Patients Receiving Systemic Treatment for Cutaneous Psoriasis|PSOBIOTEQ|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2012|July 2020|Anticipated|July 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2636|||Both|18 Years|N/A|No|Non-Probability Sample|Patient consulting or being hospitalized for cutaneous psoriasis (clinical diagnosis),        justifying the prescription of a major systemic therapy (methotrexate or cyclosporine, or        biotherapy) and for whom cutaneous psoriasis is the main reason for systemic treatment|November 2015|November 11, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617018||84547|
NCT01617226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG_11-187|Randomised Study of Azacitidine Versus Azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes|Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy|RAvVA|University of Birmingham|Yes|Recruiting|September 2012|September 2016|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|No|||July 2013|July 16, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01617226||84531|
NCT01614249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ODR-2011/2012|Omega-3 Supplementation and Depression Clinical Trial|Role of Omega-3 Fish Oil Fatty Acids on Depression Among HIV-seropositive Pregnant Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial||University of Nairobi|Yes|Completed|June 2012|January 2014|Actual|July 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|216|||Female|15 Years|49 Years|No|||February 2016|February 9, 2016|June 5, 2012|Yes|Yes||No|November 25, 2015|https://clinicaltrials.gov/show/NCT01614249||84758|Omega-3 intake value based on international database due to absence in local food composition database. Cellular level EPA/DHA not reported due to technical problems with collected samples.
NCT01614821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-015|Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia|Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia||Dana-Farber Cancer Institute|Yes|Active, not recruiting|May 2012|November 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||November 2015|November 11, 2015|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614821||84714|
NCT01614834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCT-V|Validation of an Urticaria Control Test|Development (and Validation) of an Instrument to Assess Disease Control in Patients With Urticaria (Urticaria Control Test)|UCT-V|Charite University, Berlin, Germany|No|Recruiting|July 2012|September 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|100|||Both|12 Years|N/A|No|Non-Probability Sample|all patients suffering from chronic forms of urticaria|February 2013|February 14, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614834||84713|
NCT01616160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000387|An Open-label Study to Identify Molecular Markers of Steroid Resistance|An Open-label Study to Identify Molecular Markers of Steroid Resistance in Nasal Polyposis Before and Following Treatment With Mometasone Furoate (MFNS) 2 Sprays/Nostril (100 Mcg/Nostril) Twice Daily for 4 Weeks.|MERK2|Massachusetts General Hospital|Yes|Recruiting|July 2013|July 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|24|||Both|21 Years|70 Years|No|||January 2014|January 17, 2014|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616160||84612|
NCT01616173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00058849|Analgesic Benefits of Perineural Versus Intravenous Dexamethasone in Patients Receiving Sciatic Nerve Block|The Effects of Perineural Versus Intravenous Dexamethasone on Sciatic Nerve Blockade Outcomes||Northwestern University|No|Completed|June 2012|June 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Actual|80|||Both|18 Years|70 Years|No|||November 2014|November 12, 2014|June 6, 2012|Yes|Yes||No|September 18, 2014|https://clinicaltrials.gov/show/NCT01616173||84611|We enrolled a very specific surgical patient population and all surgical procedures required a saphenous nerve block and the pain in the saphenous nerve distribution could have affected some of our results.
NCT01616459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116485|Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants|Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants||GlaxoSmithKline|No|Completed|July 2012|January 2014|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|953|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||July 2015|December 10, 2015|June 7, 2012|Yes|Yes||No|April 10, 2014|https://clinicaltrials.gov/show/NCT01616459||84589|
NCT01617044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotics_Iron Defieciency|Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome|Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome-A Double-blind, Randomized Controlled Study||Children's Hospitals and Clinics of Minnesota|No|Completed|May 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|5 Years|18 Years|No|||January 2016|January 19, 2016|March 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617044||84545|
NCT01613976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLBH589H1101|A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (Vidaza®) in Adult Japanese Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)||Novartis|No|Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|20 Years|N/A|No|||January 2015|January 13, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01613976||84779|
NCT01605006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN 20-0009-0020|Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis|HDE Post-Approval Study (PAS) of NeuRx DPS for ALS||Synapse Biomedical|No|Recruiting|July 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|21 Years|N/A|No|||May 2014|May 30, 2014|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605006||85468|
NCT01605253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH091338-01A1|Eszopiclone for the Treatment of Posttraumatic Stress Disorder|Eszopiclone for the Treatment of PTSD||Rush University Medical Center|Yes|Recruiting|March 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||May 2015|May 11, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01605253||85449|
NCT01605526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28021|A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma|A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma||Hoffmann-La Roche||Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|May 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605526||85428|
NCT01605812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZYXY-ZYY-OCT|Evaluate Capsular Apposition to Intraocular Lens|Phase 1 Evaluate Capsular Apposition to Intraocular Lens in Subjects With High Myopia by Ultra-long Scan Depth Optical Coherence Tomography; Phase 2 Evaluate Capsular Apposition to Different Types of Intraocular Lens in Subjects||Wenzhou Medical University|Yes|Recruiting|April 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|150|||Both|N/A|N/A|No|Probability Sample|This prospective study consisted consecutive patients with high axial myopia (myopia        group) and age-matched patients with normal axial length (control group). All eyes        underwent uncomplicated phacoemulsification with a single-piece IOL (AcrySof, Alcon)        implantation for cataract treatment.|January 2015|January 7, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01605812||85406|
NCT01606384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY5467|Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder|A Double-blind, Placebo-controlled Study Evaluating the Pharmacodynamic Effects of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) on Hypothalamic-pituitary-adrenal Axis Function in Outpatients With Major Depressive Disorder|NAPA|Sanofi||Completed|December 2006|August 2007|Actual|August 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|64 Years|No|||May 2012|May 24, 2012|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606384||85362|
NCT01649011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC-ODI-12-2012|Validation of a Translation Into Spanish of the Oswestry Disability Index|Validation of a Translation Into Spanish of the Oswestry Disability Index||American British Cowdray Medical Center|No|Recruiting|July 2012|||March 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with low back pain|July 2012|July 25, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01649011||82143|
NCT01649297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.10|A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy|A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control||Boehringer Ingelheim||Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|983|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|July 23, 2012||||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01649297||82122|
NCT01646294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-030|A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions|An Exploratory Open Label, Three-way Crossover Study to Compare the Pharmacokinetic Profiles of Three Different YM178 Modified Release (OCAS) Formulations Under Fasted and Fed Conditions With YM178 Immediate Release (IR) Formulation Under Fasted Conditions in Healthy Subjects||Astellas Pharma Inc|No|Completed|January 2005|May 2005|Actual|May 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|34|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 1, 2013|July 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01646294||82323|
NCT01645982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120943|Comparative Analysis of Cerebral Oximetry and Mean Arterial Pressures at the Cerebral Level in the Beach Chair Position|||Holy Cross Hospital, Florida|No|Completed|July 2012|March 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|N/A|No|Probability Sample|Primary Care Clinic; Patients undergoing elective shoulder surgery|February 2016|February 9, 2016|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645982||82347|
NCT01646268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP0914|Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease||UCB Pharma|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|249|||Both|30 Years|N/A|No|||July 2015|July 14, 2015|July 18, 2012||No||No|May 20, 2015|https://clinicaltrials.gov/show/NCT01646268||82325|
NCT01647152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120168|Ustekinumab for Active Sight-Threatening Uveitis|A Pilot Study to Investigate Ustekinumab (StelaraTM) for the Treatment of Active Sight-Threatening Uveitis||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 6, 2014|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647152||82279|
NCT01648218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTHG.VGH.UBC|Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia|Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia|PTHG|Vancouver General Hospital|No|Terminated|August 2012|June 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|5|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 12, 2012||No|Poor enrollment|No||https://clinicaltrials.gov/show/NCT01648218||82197|
NCT01648608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TENBC|Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer|Study to Assessment the Efficacy and Safety of Joint TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Operable Breast Cancer||Tianjin Medical University|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Female|N/A|N/A|No|||August 2012|August 2, 2012|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648608||82174|
NCT01648868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 081232|Transcranial Magnetic Stimulation (rTMS) and Autism.|Transcranial Magnetic Stimulation (rTMS) and Autism.Implication of the Superior Temporal Sulcus in Normal and Abnormal Social Perception|TMSAUTISME|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2011|April 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648868||82154|
NCT01648881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 100505|Imaging of Dissection of the Descending Aorta|Dissection of Aorta: Descending Part, Imaging|DADI|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2011|December 2018|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|No|Probability Sample|Patients with dissection of the descending aorta|January 2016|January 14, 2016|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648881||82153|
NCT01649154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8580/DS/CE|Clinical Trial on Harmonic Focus Shears Versus Ligasure Small Jaw and Clamp-and-tie Technique for Total Thyroidectomy|||Ospedale Regina Apostolorum|No|Completed|April 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|120|||Both|N/A|N/A||||June 2012|July 20, 2012|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01649154||82133|
NCT01649167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MACSSD042010|Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia|Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia||Materno-Perinatal Hospital of the State of Mexico|No|Completed|February 2009|November 2010|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|55|Samples Without DNA|Serum|Female|16 Years|46 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women who had received medical attention during pregnancy at the HMPMP in Toluca, Mexico.|July 2012|July 24, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01649167||82132|
NCT01649193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LF001H|What is an Important Change in the Short Physical Performance Battery (SPPB)?|Determining the Minimal Important Difference of the Short Physical Performance Battery and 4m Gait Speed in Chronic Respiratory Disease Patients.||Royal Brompton & Harefield NHS Foundation Trust|No|Completed|March 2012|May 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|Samples With DNA|Blood taken and stored as whole blood, serum, and plasma.|Both|N/A|N/A|No|Probability Sample|All chronic respiratory disease patients referred for pulmonary rehabilitation.|November 2014|November 4, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01649193||82130|
NCT01649518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54497|A Measurement of Knee Osteoarthritis Usual Care|||Universitaire Ziekenhuizen Leuven||Recruiting|November 2012|||||N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1500|||Both|N/A|N/A|No|Non-Probability Sample|General Practice: Based on the electronic patient files of general practiotioners of the        MEDIDOC users-group (an electronic software package) a list will be generated of patients        diagnosed with knee osteoarthritis. A random sample of these patients will be addressed to        take part into the study by a questionnaire.        Orthopedic Surgery: Patients, consulting orthopedic surgeons for knee osteoarthritis will        receive a patient questionnaire.        Physiotherapy: Patients, recruited by general practitioners and orthopedic surgeons will        be asked about the care they received by their physiotherapist. Moreover physiotherapists        will be recruited by the national association of physiotherapists to complete a        questionnaire about the care they usually deliver.|June 2012|October 8, 2013|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01649518||82107|
NCT01626651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100870|A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants|An Open-Label, Sequential Design Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Subjects||Janssen Research & Development, LLC||Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|June 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01626651||83810|
NCT01615913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TE9512|Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole|Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine and Ketoconazole Formulation||Taiwan Biotech Co., Ltd.|Yes|Recruiting|April 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|18|||Both|25 Years|75 Years|No|||June 2012|June 6, 2012|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01615913||84631|
NCT01615926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSSRP-IC2012|Assessment of The Clinical Course of Dyspnea in Acute Heart Failure Patients|Assessment of The Clinical Course of Dyspnea and Its Association With Respiratory Rate in Patients With Acute Heart Failure Syndromes||Northwestern University|No|Terminated|June 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients who present to the Emergency Department with Acute Heart Failure|April 2013|April 30, 2013|June 7, 2012||No|Student related research project. Completion of allotted time.|No||https://clinicaltrials.gov/show/NCT01615926||84630|
NCT01617577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADDF-GCSF|Efficacy and Safety of Filgrastim in Alzheimer's Disease|Efficacy and Safety of Filgrastim as a Pro‐Cognitive Agent in Alzheimer's Disease|FFAD|University of South Florida|Yes|Completed|June 2009|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|55 Years|N/A|No|||June 2012|November 26, 2012|November 8, 2011|Yes|Yes||No|June 29, 2012|https://clinicaltrials.gov/show/NCT01617577||84504|
NCT01617876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LXH-EGC-1|Enhanced Magnifying Endoscopy for Diagnosis of Early Gastric Cancer|A Prospective Study on the Accuracy of Enhanced Magnifying Endoscopy for Differential Diagnosis of Small Focal Gastric Lesions Identified With White-light Endoscopy||Peking Union Medical College Hospital|No|Completed|March 2010|March 2012|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|282|Samples Without DNA|Biopsy of gastric lesions|Both|40 Years|85 Years|No|Non-Probability Sample|Patients who received surveillance endoscopy for EGC using a zoom endoscope were eligible        for inclusion.|June 2012|June 9, 2012|June 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01617876||84481|
NCT01648114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABFS-1|A Randomized Controlled Trial of an Antenatal Intervention to Increase Exclusive Breastfeeding|A Randomized Controlled Trial of an Antenatal Intervention to Increase Exclusive Breastfeeding|ABFS|The University of Hong Kong|No|Completed|August 2012|February 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|472|||Female|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 12, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01648114||82205|
NCT01648491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-204|Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use|Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use||William Beaumont Hospitals|No|Active, not recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|78 Years|82 Years|No|||July 2015|July 11, 2015|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648491||82183|
NCT01648504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00070166|Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy|Integration of an Electronic Education System Into Colonoscopy: Improving Education, Consent and Compliance of Patients at Colonoscopy With an Ipad-based Secure Video Intervention||Johns Hopkins University|No|Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2014|March 26, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01648504||82182|
NCT01648738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/04|Effectiveness of a Short, Intensive and Standardised Spa Therapy for Low Back Pain on Sick Leave Duration|Effectiveness of a Short, Intensive and Standardised Spa Therapy for Subacute and Chronic Low Back Pain on Return to Work for Patients in Sick Leave From 4 to 24 Weeks Duration : a Randomized Controlled Trial Using a Modified Zelen Method|ITILO|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|July 2012|March 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|60 Years|No|||December 2015|December 21, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648738||82164|
NCT01644968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-066A|Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer|Phase 1 Trial of a Monoclonal Antibody to OX40 in Patients With Advanced Cancer.||Providence Health & Services|No|Active, not recruiting|November 2003|January 2015|Anticipated|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644968||82408|
NCT01644981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.3 07.10.2011|Prospective Study on Plasma Pro-endothelin-1 in Predicting Bronchopulmonary Dysplasia|||University of Zurich||Completed|May 2012|December 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|Samples Without DNA|EDTA plasma|Both|N/A|4 Months|Accepts Healthy Volunteers|Probability Sample|VLBW infants|February 2014|February 24, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644981||82407|
NCT01646307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARISE-001|Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing PCI|Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing Percutaneous Coronary Intervention|ARISE|Beijing Anzhen Hospital|Yes|Recruiting|January 2012|June 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1000|||Both|65 Years|80 Years|No|||July 2012|July 18, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646307||82322|
NCT01646528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012SDU-QILU-G01|The Value of Black Spots in Diagnosing Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy|The Value of Mesenchymal Black Spots in Diagnosing Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy||Shandong University|Yes|Recruiting|June 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Taken biopsies during endoscopy|Both|18 Years|80 Years|No|Non-Probability Sample|Patients without any disease of heart, liver or kidney.|July 2012|July 19, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01646528||82305|
NCT01647685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39717.018.12|A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort|A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) in Atherosclerotic Tissue in Subjects With Peripheral Artery Disease.|DELIVER|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|May 2012|May 2013|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|21|||Both|18 Years|N/A|No|||May 2012|July 19, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01647685||82238|
NCT01647698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDWM-2012-07|Pilot Study to Determine if Working Memory Training Aids Cognitive Functioning in Patients With Parkinson's Disease|Beyond the Physical: Enhancing Psychosocial Functioning in Parkinson's Disease|PDWM|Nova Scotia Health Authority|No|Recruiting|October 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|N/A|No|||July 2012|May 5, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01647698||82237|
NCT01648231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116797|Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers|An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine (5mg) and Losartan (100mg) in Healthy Adult Male and Female Subjects Under Fasting Conditions||GlaxoSmithKline|No|Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2012|October 25, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01648231||82196|
NCT01648660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2032- 06/07|Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)|Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients for Two More Years (LUTEGA 2)||University of Jena|No|Completed|May 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|80|||Both|50 Years|N/A|No|||January 2013|January 9, 2013|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01648660||82170|
NCT01648894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 110125|Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer|Randomized Control Trial Comparing the Impact of a Lengthening of the Interval Between the Radiochemotherapy and Surgery (7 Weeks vs. 11 Weeks) on Complete Pathological Response in Rectal Cancer|GRECCAR6|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2012|April 2020|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|265|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648894||82152|
NCT01648907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070302|French Cohort of Undifferentiated Spondyloarthritis|French Cohort on Outcome of Recent Undifferentiated Spondyloarthritis|DESIR|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2007|May 2021|Anticipated|May 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|708|||Both|18 Years|50 Years|No|Non-Probability Sample|Patients presenting early inflammatory back pain of more than 3 months and less than 3        years|April 2015|April 20, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648907||82151|
NCT01649180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE0801|NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma|NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)|PrE0801|PrECOG, LLC.|Yes|Completed|July 2012|March 2016|Actual|January 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649180||82131|
NCT01644812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001-SMIJ-N|Lifestyle Interventions for Generalized Anxiety Disorder|Lifestyle Interventions for Generalized Anxiety Disorder||Southern Methodist University|No|Terminated|March 2012|||July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 16, 2013|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644812||82420|
NCT01617083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6119-128500|Antibiotic Treatment Trial for the PANDAS/PANS Phenotype|Antibiotic Treatment Trial for the PANDAS/PANS Phenotype|AZT|University of South Florida|Yes|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|4 Years|14 Years|No|||December 2014|February 3, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01617083||84542|
NCT01617096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-020|Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women|ASPIRE|International Partnership for Microbicides, Inc.|Yes|Completed|August 2012|August 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|3540|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 9, 2015|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617096||84541|
NCT01626911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAI-H|Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis||CRAI-H|Nanjing University School of Medicine|No|Recruiting|September 2011|||December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|70 Years|No|||December 2013|December 6, 2013|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01626911||83790|
NCT01626924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU 01-02-01|A Study of 2-Iminobiotin in Neonates With Perinatal Asphyxia|A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) in Neonates With ≥36 Weeks GA With Moderate to Severe Perinatal Asphyxia||Neurophyxia B.V.|Yes|Active, not recruiting|June 2012|March 2016|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|N/A|6 Hours|No|||December 2014|December 18, 2014|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626924||83789|
NCT01617616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFUBAHA01|Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects|Tilt Table and Autonomic Testing in Suspected POTS Subjects|POTS|Wake Forest Baptist Health|Yes|Active, not recruiting|March 2012|March 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|48|||Both|10 Years|21 Years|No|Probability Sample|Children between the ages of 10-21 years whose diagnostic workup for chronic unexplained        nausea has unexpectedly revealed underlying cardiovascular instability manifesting as        dysautonomia, primary defined as postural orthostatic tachycardia syndrome (POTS).|March 2013|March 27, 2013|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01617616||84501|
NCT01617889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK88|Healthy Term Infants Fed Milk-Based Formulas|Healthy Term Infants Fed Milk-Based Formulas With Different Fat Blends||Abbott Nutrition|Yes|Completed|March 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|17|||Both|53 Days|115 Days|Accepts Healthy Volunteers|||February 2013|February 14, 2013|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01617889||84480|
NCT01613794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011T012|Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis|Prospective Randomized Controlled, Open Label, Clinical Trial to Study if Rosuvastatin Use Improves the Coagulation Profile in Patients With Venous Thrombosis|START|Leiden University Medical Center|Yes|Recruiting|December 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|250|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01613794||84793|
NCT01648127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEF-MD-01|Pharmacokinetics of Ceftaroline in Normal and Obese Subjects|Pharmacokinetics of Ceftaroline in Normal and Obese Subjects||University of Illinois at Chicago|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 12, 2013|July 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01648127||82204|
NCT01648517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0132|Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy|||Yonsei University|No|Recruiting|July 2012|February 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|N/A|No|||March 2014|March 4, 2014|July 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01648517||82181|
NCT01648530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTX-12-470|Chronic Migraine Epidemiology and Outcomes Study|||Allergan|No|Completed|July 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|16789|||Both|N/A|N/A|No|Non-Probability Sample|Participants with migraine|January 2015|January 21, 2015|July 20, 2012||No||No|January 21, 2015|https://clinicaltrials.gov/show/NCT01648530||82180|
NCT01648751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO09090064|Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse|Impact of Vaginal Estrogen in the Treatment of Symptomatic Mild Pelvic Organ Prolapse With Pelvic Floor Physical Therapy||University of Pittsburgh|Yes|Recruiting|May 2012|December 2019|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|53|||Female|40 Years|80 Years|No|||January 2016|January 27, 2016|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648751||82163|
NCT01645254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRTC_Arge01|Phase 1b Malaria Clinical Trial Using Argemone Mexicana in Healthy Adults in Mali|Phase 1b Clinical Trial Using Argemone Mexicana in Healthy Adults Infected or Not Infected With Plasmodium Falciparum in Mali: Pharmacokinetics and Observational Study||University of Bamako|No|Active, not recruiting|September 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01645254||82386|
NCT01647165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120169|Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance|Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|October 4, 2014|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647165||82278|
NCT01646541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033042|Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery|Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery: Pilot, Screening Study||Duke University|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients seen in the cardiology, pulmonary hypertension, or cardiac surgery clinics at the        enrolling institutions|September 2014|August 5, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01646541||82304|
NCT01646866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15861|Early Detection of Autism Spectrum Disorder in Children|Early Detection of Autism Spectrum Disorder in Children||St. Louis University|No|Active, not recruiting|December 2010|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Saliva will be collected|Both|6 Months|36 Months|Accepts Healthy Volunteers|Non-Probability Sample|Biological siblings of children with a previous expert clinical diagnosis of Autism        Spectrum Disorder.|October 2015|October 1, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01646866||82280|
NCT01647997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lsne-128/01|Lactate Metabolism After an Endotoxin Challenge in Healthy Humans|Effects of an Acute Administration of Bacterial Endotoxin on Whole Body and Regional Lactate Metabolism in Healthy Male Volunteers||University of Lausanne|No|Completed|April 2002|December 2004|Actual|March 2004|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|14|||Male|18 Years|30 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647997||82214|
NCT01647958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D01292|The EndoGastric Solutions TEMPO Trial|Transoral Incisionless Fundoplication (TIF) Versus Medical Proton Pump Inhibitor (PPI) Management of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms|TEMPO|EndoGastric Solutions|No|Active, not recruiting|June 2012|November 2015|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01647958||82217|
NCT01647971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TGTX 1101-101|Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy||TG Therapeutics, Inc.|Yes|Active, not recruiting|August 2012|June 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647971||82216|
NCT01647984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RITMONUTRA 2012|Role of a Combination of Nutraceuticals (Ritmonutra) on Benign Supraventricular and Ventricular Arrhythmias|Study on the Role of a Combination of Nutraceuticals (Ritmonutra) With an Effect on Benign Supraventricular and Ventricular Arrhythmias in Subjects Free of a Specific Organic Heart Disease.||Federico II University|Yes|Completed|December 2012|December 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|1500|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 2, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01647984||82215|
NCT01648634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090202|Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy|NEBIDYS|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|March 2012|March 2021|Anticipated|December 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Male|10 Years|15 Years|No|||December 2015|December 15, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648634||82172|
NCT01648647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE DHM-AN-OR-2012/01|Copeptin in Aortic Valve Replacement|GE DHM-AN-OR-2012/01|CARE|Deutsches Herzzentrum Muenchen|No|Completed|May 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for surgical or transcatheter aortic valve replacement|July 2012|July 20, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648647||82171|
NCT01648920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AER-044|A Study to Explore the Utility of Fractional Exhaled Nitric Oxide (FeNO) Compared With Methacholine Challenge (MCC) Testing in the Assessment of Patients With Suspected But Undiagnosed Asthma|||Aerocrine AB|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|7 Years|N/A|No|Non-Probability Sample|Male and female subjects, approximately 7 years of age and above with suspected but        undiagnosed asthma that are scheduled to undergo Methacholine Challenge (MCC) testing as        part of the routine evaluation of suspected asthma.|April 2014|April 8, 2014|July 5, 2012||No||No|November 27, 2013|https://clinicaltrials.gov/show/NCT01648920||82150|
NCT01649206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTA-2012|Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules|Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study||Federico II University|Yes|Completed|January 2010|June 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|87 Years|No|||July 2012|July 25, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01649206||82129|
NCT01645137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Multi-NE-O|Effectiveness Of Osteopathic Manipulative Treatment In NICU: A Multicenter Clinical Trial|Effectiveness Of Osteopathic Manipulative Treatment In Neonatal Intensive Care Units: A Multicenter Randomized Clinical Trial||European Institute for Evidence Based Osteopathic Medicine||Completed|July 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|690|||Both|29 Weeks|37 Weeks|Accepts Healthy Volunteers|||April 2014|April 24, 2014|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01645137||82395|
NCT01645410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-VIN-057|Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions|Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single Oral Dose, Crossover BE Study of Atorvastatin Ca 40mg Tablets of Dr.Reddy's With Lipitor® 40 mg Tablets of Pfizer in Healthy Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|March 2009|May 2009|Actual|April 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|71|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01645410||82374|
NCT01617109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-09; 13-24HC|Optimizing Vitamin D Status During Initial Military Training|Optimizing Vitamin D Status During Initial Military Training: A Randomized, Double-blind, Placebo-controlled Trial||United States Army Research Institute of Environmental Medicine|No|Active, not recruiting|June 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1400|||Both|18 Years|42 Years|Accepts Healthy Volunteers|||August 2013|August 16, 2013|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01617109||84540|
NCT01617304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M201|Effects of Food Cooking on Diabetes-2 Risk Factors||Age-2|University of Copenhagen|Yes|Completed|December 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|100|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01617304||84525|
NCT01617317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU-09-330|H-IVIG Treatment for Severe H1N1 2009|Hyperimmune Intravenous Immunoglobulin Treatment for Severe H1N1 2009 Infection||The University of Hong Kong|Yes|Completed|January 2010|May 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|June 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01617317||84524|
NCT01614080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10.677|Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA|Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA in the Administered Rt-PA|OPHELIE|University Hospital, Lille|Yes|Completed|November 2011|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|700|||Both|18 Years|N/A|No|Probability Sample|Patients treated in routine by iv t-PA for acute ischaemic stroke|December 2014|December 18, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01614080||84771|
NCT01614093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00090751|Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia|Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia||University of Maryland|Yes|Completed|June 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|54 Years|No|||April 2014|April 14, 2014|March 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01614093||84770|
NCT01614379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-33818|Non-enhanced Magnetic Resonance Angiography of Diabetic Ischemic Lower Limbs|Non-enhanced Magnetic Resonance Angiography of Diabetic Ischemic Lower Limbs||Aarhus University Hospital|Yes|Withdrawn|June 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|Samples Without DNA|Blood sample less then 250ml to determine Hba1c (blood glucose level).|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Diabetic subjects with foot ulcers will be asked of interest to participate in the study,        when visiting the clinic in connection to their regular treatment at the clinic. Staff        physician Niels Ejskjaer is treating a large part of the patients and will after their        visit at the clinic ask the patients of participation, with stretch on that it's voluntary        and it has not effect of their regular treatment.        The healthy control subjects will be recruited from posters calling for participants to        contact the investigator on phone or mail. The posters will have information about the        project but information on the phone and invitation to a personal conversation with a        trusted friend will be offered, as it is to the diabetic patients.|April 2013|April 11, 2013|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614379||84748|
NCT01649024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESOT-TREM-2008|A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma|A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma||Azienda Ospedaliera Universitaria Senese|Yes|Active, not recruiting|May 2009|June 2013|Anticipated|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01649024||82142|
NCT01649310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Patricia|Whole Body Vibration in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of Whole Body Vibration Training in Chronic Obstructive Pulmonary Disease (COPD) Patients: a Randomized Controlled Trial||Universidade Federal de Pernambuco|Yes|Recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|21|||Both|50 Years|75 Years|No|||December 2014|December 1, 2014|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01649310||82121|
NCT01644656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01582|Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)|Non-invasive Diagnosis of Portal Hypertension by Acoustic Radiation Force Impulse (ARFI) Imaging of the Liver and Spleen in Patients With Chronic Liver Disease||VA Connecticut Healthcare System|No|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|18 Years|85 Years|No|||July 2015|July 22, 2015|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644656||82432|
NCT01644669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTPR-0009|Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System|A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx™ System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer||Xoft, Inc.|Yes|Recruiting|May 2012|December 2024|Anticipated|May 2024|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1000|||Female|40 Years|N/A|No|||January 2016|January 28, 2016|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644669||82431|
NCT01645995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/03|The Impact of Reformulated Foods on Cardiovascular Risk Factors|The Impact of Reformulated Product Consumption on Energy and Nutrient Intake, Body Composition, Vascular Function and Plasma Lipid and Glucose Concentrations|REFORM|University of Reading|Yes|Completed|March 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|50|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||December 2014|December 3, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645995||82346|
NCT01647425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTAK - 1109|Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer|Prevalence and Risk Factors for Persistent Tobacco or Alcohol Use Over the First Year of a First Lung or Head and Neck Cancer|ALTAK|Centre Oscar Lambret|No|Terminated|April 2012|September 2014|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|385|||Both|18 Years|N/A|No|Non-Probability Sample|patient with a first head and neck cancer or first lung cancer|August 2014|September 29, 2015|July 19, 2012||No|Low recruitment|No||https://clinicaltrials.gov/show/NCT01647425||82258|
NCT01647399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MD007075-01|Vitamin D, Steroids, and Asthma in African American Youth|AsthMaP 2: Vitamin D, Steroids, and Asthma in African American Youth|AsthMaP2|Children's Research Institute|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples With DNA|Blood, urine, tissue|Both|6 Years|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|AshMaP 2 subjects will be enrolled from all the sites in the Children's National Medical        Center city-wide pediatric and adolescent health systems sites, including primary care        offices (community and hospital-based), specialty clinics, Emergency Departments, and        inpatient units.|December 2015|December 3, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647399||82260|
NCT01647412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ8306|Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease|Growth Hormone and Nutrition Therapy in Juvenile Crohn's Disease, a Randomized Clinical Trial||Columbia University|Yes|Withdrawn|March 2012|||||Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|10 Years|17 Years|No|||April 2015|April 9, 2015|July 19, 2012|Yes|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT01647412||82259|
NCT01648244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|353757|The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes|The Use of a Computer Assisted Diabetes Decision Support (CADS) System to Improve Outcomes in Patients With Type 2 Diabetes Who Are Treated by Primary Care Providers|CADS|Walter Reed National Military Medical Center|Yes|Completed|March 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|N/A|N/A|No|||November 2015|November 24, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01648244||82195|
NCT01648257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116585|Relative Bioavailability Study of GSK1265744 Formulations|A Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 in Healthy Adult Subjects||ViiV Healthcare|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2013|February 28, 2013|July 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01648257||82194|
NCT01648270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202087|Disposition Effects of Cyclosporin on Buprenorphine|Influence of Cyclosporine on Buprenorphine Disposition and Effect|BUPCsa|Washington University School of Medicine|Yes|Active, not recruiting|April 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|29|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01648270||82193|
NCT01648283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201203105|CYP2B6 Polymorphisms in Methadone|Role of CYP2B6 Polymorphisms in Methadone Metabolism and Clearance||Washington University School of Medicine|Yes|Active, not recruiting|May 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 13, 2015|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648283||82192|
NCT01649531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0097|Two Implants Versus One Implant With a Cantilever - a Randomized Controlled Clinical Trial|||University of Zurich|No|Active, not recruiting|July 2012|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|34|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649531||82106|
NCT01649544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1008058|Comparison of Treatment of Atrial Fibrillation (AF) Between Surgical Ultrasonic Technology or Drug Therapy for Patients With AF Requiring Mitral Valve Surgery|Comparison of Treatment of Atrial Fibrillation (AF) Between Surgical Ultrasonic Technology (EPICOR) or Drug Therapy (Cordarone) for Patients With AF Requiring Mitral Valve Surgery|EPICAF|Centre Hospitalier Universitaire de Saint Etienne|No|Terminated|March 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|July 23, 2012||No|End of commercialization of the medical device|No||https://clinicaltrials.gov/show/NCT01649544||82105|
NCT01644838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyoscine & Promethazin|Effect of Hyoscine and Promethazine on Labor Pain|Principal Investigator||Mashhad University of Medical Sciences||Completed|August 2010|April 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|93|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644838||82418|
NCT01644851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMKC SS11-212e|Cognitive Training for Post Traumatic Stress Disorder: Effects on Cognitive, Emotional, and Brain Function|Cognitive Training for PTSD: Effects on Cognitive, Emotional, and Brain Function||University of Missouri, Kansas City|Yes|Active, not recruiting|July 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 4, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644851||82417|
NCT01637584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO08050307|Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans|Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans|NOSSTIP|University of Pittsburgh|Yes|Active, not recruiting|April 2010|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 13, 2012|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637584||82971|
NCT01617343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEP-OKS-01|The HEP-OKS Study - Hemifield Eye Patching and Optokinetic Stimulation to Treat Hemispatial Neglect in Stroke Patients|The HEP-OKS Pilot Study - a Randomized Controlled Trial of Hemifield Eye Patching and Optokinetic Stimulation to Treat Hemispatial Neglect in Stroke Patients||University of Luebeck|No|Completed|August 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|90 Years|No|||April 2014|April 7, 2014|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01617343||84522|
NCT01617330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DALLER|Controlled Exposure to Diesel Exhaust in Subjects With Allergic Rhinitis|Controlled Exposure to Diesel Exhaust in Subjects With Allergic Rhinitis|DALLER|University Hospital, Umeå|No|Completed|March 2001|February 2002|Actual|February 2002|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|14|||Both|20 Years|45 Years|No|||June 2012|June 11, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01617330||84523|
NCT01617590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMARD-RA|Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research|A 48-week, Multi-center, Randomized, Open-lable, Controlled Study to Assess the Response (ACR20) Using Different Disease-Modifying Antirheumatic Drugs Cycle Combination Regimen in Adult Patients With Active Rheumatoid Arthritis|DCCT|Shanxi Medical University|Yes|Recruiting|May 2012|May 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|75 Years|No|||June 2012|June 12, 2012|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01617590||84503|
NCT01617603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07.52.NRC|A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial|||Nestlé|Yes|Completed|April 2009|May 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|62|||Both|45 Years|75 Years|No|||July 2013|July 5, 2013|June 1, 2012||No||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01617603||84502|
NCT01614418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU_WKL_RFA1|Radiofrequency Ablation for Gastric Metaplasia and Dysplasia|Endoscopic Radiofrequency Ablation for Gastric Metaplasia and Dysplasia||The University of Hong Kong|No|Completed|September 2011|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2013|December 18, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01614418||84745|
NCT01614691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLR_12_03|Safety and Efficacy of SPARC1203 in Allergic Rhinitis|||Sun Pharma Advanced Research Company Limited|No|Completed|June 2012|March 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|159|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614691||84724|
NCT01614392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG-18844|Lower Extremity Muscle and Function in the Elderly: Study 2|Lower Extremity Muscle and Function in the Elderly: Study 2||Tufts University|No|Completed|September 2009|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|52|||Both|70 Years|85 Years|Accepts Healthy Volunteers|||June 2012|June 5, 2012|September 28, 2009||No||No||https://clinicaltrials.gov/show/NCT01614392||84747|
NCT01649050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2215|Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis|A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis||Novartis|No|Withdrawn|October 2016|March 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||August 2014|August 21, 2014|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01649050||82140|
NCT01649336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARRAY-162-112|A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer|||Array BioPharma|No|Active, not recruiting|July 2012|||March 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|July 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01649336||82120|
NCT01649349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110807|The Feasibility Study of Dual-Section Nasogastric Tube|The Feasibility Study of Dual-Section Nasogastric Tube in Dysphagia Patients||Changhua Christian Hospital||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|10|||Both|20 Years|80 Years|No|||July 2012|July 22, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01649349||82119|
NCT01644682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11045|Replacement of Insecticides to Control Visceral Leishmaniasis (VL)|Replacement of Insecticides to Control Visceral Leishmaniasis||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|3600|||Both|N/A|N/A|No|||July 2012|February 16, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644682||82430|
NCT01644994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFLuenCe - Meso|Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma|PhaseI Dose-Escalation /PhaseII Monocentric Open Trial for Evaluation of Safety and Efficacy of Intracavitary Cisplatin-Fibrin Localized Chemotherapy After Pleurectomy/Decortication or Extrapleural Pneumonectomy for the Treatment of Patients With Malignant Pleural Mesothelioma||University of Zurich|No|Recruiting|November 2012|August 2020|Anticipated|August 2020|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|54|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644994||82406|
NCT01645007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0025-12-NHR|Prevalence of Hepatitis B Infection in the Galilee Region, Israel|||Western Galilee Hospital-Nahariya|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Native Israeli Druze|June 2014|June 17, 2014|July 17, 2012||No|The study was not carried out due to lack of funding and budget problems|No||https://clinicaltrials.gov/show/NCT01645007||82405|
NCT01646008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Carbon dioxide Getafe|Correlation Between Carbon Dioxide Measured in End of Exhalation and Arterial Blood|Correlation Between Carbon Dioxide Measured in End of Exhalation and Arterial Blood in Chronic Obstructive Pulmonary Disease (COPD) in Intensive Care Unit With Nasal Cannula||Hospital Universitario Getafe|No|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|All adult COPD patients admitted to the ICU who consent|December 2015|December 2, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646008||82345|
NCT01646021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100848|Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy|A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy||Janssen Research & Development, LLC|Yes|Active, not recruiting|December 2012|November 2016|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|280|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646021||82344|
NCT01646034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N12OLG|High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer|High-dose Alkylating Chemotherapy in Oligo-metastatic Breast Cancer Harboring Homologous Recombination Deficiency|Oligo|The Netherlands Cancer Institute|No|Recruiting|September 2014|July 2019|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|86|||Female|18 Years|N/A|No|||January 2016|January 21, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01646034||82343|
NCT01647191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDu-001|Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China|Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China||Shanghai Mental Health Center|No|Active, not recruiting|July 2011|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|340|||Both|20 Years|N/A|No|||July 2012|July 18, 2012|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647191||82276|
NCT01647711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.121|A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations|A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations||Boehringer Ingelheim||Completed|July 2012|September 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|July 16, 2012||||No||https://clinicaltrials.gov/show/NCT01647711||82236|
NCT01647724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMD2TE|New Methods of Distribution of a Self Sampler Kit for Cervical Cancer Screening|Experimentation of New Organizational Models of Cervical Cancer Screening Programs, Upon the Use of HPV Test as First Level: Evaluation of the Methodologies Proposed of the Use of Self-sampling Devices to Recover Non-responders.|NMDSS2|Azienda Sanitaria Locale 4, Teramo|No|Not yet recruiting|September 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|15000|Samples Without DNA|vaginal washings|Female|35 Years|64 Years|No|Probability Sample|Involving 15000 women non-responders to previous calls in five different screening        programs in Italy (Rome, Bologna, Abruzzo region, Molise region, Veneto region).|May 2012|July 23, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647724||82235|
NCT01647737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHSU Lozenge Xerostomia Study|Green Tea Lozenges for the Management of Dry Mouth|A Natural Formulation for Patients Diagnosed With Xerostomia||Georgia Regents University|No|Completed|March 2011|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||March 2015|March 17, 2015|May 14, 2012||No||No|January 23, 2015|https://clinicaltrials.gov/show/NCT01647737||82234|
NCT01647750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5863|Study of Optimal Replacement of Thyroxine in the Elderly|Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) SORTED 1 - a Randomised Controlled Trial (Pilot Study), SORTED 2 - Qualitative Interviews, SORTED 3 - Retrospective Cohort|SORTED|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|August 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|48|||Both|80 Years|N/A|No|||October 2015|October 7, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01647750||82233|
NCT01648010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAS-4M-PR-H-127-1|Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer|An Open Label Study Evaluating Short Term Safety and Tolerability of Patients With MUSCLE INVASIVE BLADDER CANCER- for Intravesical Instillation Mitomycin c Mixed With Disposable Device Which Prevents Drug Drainage Out of the Patient's Bladder||UroGen Pharma Ltd.|No|Completed|November 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|7|||Both|45 Years|N/A|No|||December 2012|May 6, 2013|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01648010||82213|
NCT01648023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0181|Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin|Comparative, Prospective, Open-labeled, Randomized Phase II Study of Cisplatin/Gemcitabine in Combination With Irinotecan-loaded LC Bead Versus Cisplatin/Gemcitabine Alone in the Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma|DELTIC|University of Louisville|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648023||82212|
NCT01648673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HFHS-JHI Platform|Pilot Evaluation of the JHI Platform|Pilot Evaluation of the Janssen Healthcare Innovation Integrated Cardiovascular Rehabilitation Management Platform (JHI PLATFORM).||Henry Ford Health System|No|Active, not recruiting|August 2012|April 2017|Anticipated|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|500|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiology services.|July 2015|July 15, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648673||82169|
NCT01644890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A3105301|A Phase III Study of NK105 in Patients With Breast Cancer|A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer||Nippon Kayaku Co.,Ltd.|Yes|Active, not recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|414|||Female|20 Years|74 Years|No|||February 2016|February 23, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644890||82414|
NCT01618123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9437-MS-CTIL|Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit|The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)||Sheba Medical Center|No|Recruiting|October 2012|December 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|80 Years|No|Non-Probability Sample|All subjects admitted to the CPU with low to moderate probability for CAD and negative        troponin, will undergo the following tests upon arrival following clinical evaluation and        their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear        imaging or stress echocardiography. Except for EndoPAT testing, all other tests were        conducted according to the routine CPU protocol.|July 2014|July 6, 2014|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01618123||84462|
NCT01637324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSM VCT|Multidisciplinary Services to Enhance HIV Testing and Linkage to Care Among MSM|The Thai Red Cross AIDS Research Centre||Thai Red Cross AIDS Research Centre|No|Completed|May 2011|June 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|350|||Male|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|MSM with HIV negative and positive MSM in Thai Red Cross Bangkok Thailand, the Cipto        Mangunkusumo Hospital in Jakarta, and the Sanglah Hospital in Bali, Indonesia|July 2012|July 10, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637324||82991|
NCT01617902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBCS_01|Hyperbilirubinemia After Cardiac Surgery|Hyperbilirubinemia After Major Cardiac or Thoracic Aorta Surgery: Predictors and Clinical Significance||Asan Medical Center|Yes|Recruiting|June 2012|August 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing elective major cardiac or thoracic aorta surgery|June 2012|June 14, 2012|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01617902||84479|
NCT01617915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12127|Tumor Specific Plasma DNA|Tumor Specific Plasma DNA||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|October 2012|July 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6|||Both|18 Years|N/A|No|Non-Probability Sample|Breast and Lung cancer patients|September 2013|September 23, 2015|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01617915||84478|
NCT01613807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDRI 08-01|Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes|Phase 4 Humalog® Mix50/50(tm) for the Treatment of Insulin Requiring Gestational Diabetes||William Sansum Diabetes Center|Yes|Completed|October 2008|October 2010|Actual|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|44 Years|No|||June 2012|June 6, 2012|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613807||84792|
NCT01617629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAN-003X|Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study|An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study|CAN-003X|Prima BioMed Ltd|Yes|Completed|December 2011|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Female|18 Years|N/A|No|||June 2014|June 18, 2014|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617629||84500|
NCT01614405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAART Study|Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis|Randomized Controlled Pilot Study of Highly Active Anti-Retroviral Therapy for Patients With Primary Biliary Cirrhosis|HAART|University of Alberta|Yes|Completed|June 2012|August 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||December 2014|November 30, 2015|April 25, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614405||84746|
NCT01645020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20|Comparison Between Two Types of Meshes Used in Pelvic Organs Prolapse Procedures|Comparison Between Two Types of Meshes Used in Pelvic Organs Prolapse Procedures||Western Galilee Hospital-Nahariya|Yes|Recruiting|August 2008|June 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|240|||Female|N/A|N/A|No|Non-Probability Sample|women been operated at Western Galilee Hospital - Nahariya Israel|July 2012|July 18, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01645020||82404|
NCT01645267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20090162|Calcaneal Neck Lengthening Osteotomy With Artificial Bone Graft|Calcaneal Neck Lengthening Osteotomy - Allogen Bone Graft Material Versus a Hydroxyappatite / β- Tricalcium Phosphate Bone Substitute||Aarhus University Hospital|Yes|Active, not recruiting|October 2010|October 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|8 Years|20 Years|No|||July 2012|July 19, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01645267||82385|
NCT01645722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11090215|Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites|Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites|AMP-5|University of Pittsburgh|Yes|Active, not recruiting|July 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 2, 2016|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01645722||82366|
NCT01646554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-1207|Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases|BOS3: Randomized Phase II/III Trial Evaluating the Efficacy of FOLFOX Alone Versus FOLFOX Plus Aflibercept in K-ras Mutant as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer.|BOS3|European Organisation for Research and Treatment of Cancer - EORTC||Withdrawn|December 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||February 2015|February 19, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01646554||82303|
NCT01647178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00310|TORQ Clinical Study|The Influence of the TORQ Sternal Closure Assistance Device on Post-Operative Pain, Pulmonary Function and Quality of Life Compared to Traditional Manual Wire Closure: A Randomized Controlled Trial.|TORQClin|Kardium Inc.|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|N/A|No|||August 2015|August 31, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647178||82277|
NCT01647464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MBretention|Renal Retention of Microbubbles|Study of Whether There is Renal Retention of Lipid Microbubble Ultrasound Contrast Agents||Oregon Health and Science University|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients undergoing contrast echocardoigraphy|April 2014|April 5, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647464||82255|
NCT01647477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEREDIA - 1110|Interventional Study Collecting Quantitative and Qualitative Data About Patient With Non Treated Cancer|Determinants of the Consultation Delay in Cancers of the Upper Aero Digestive Tract|DEREDIA|Centre Oscar Lambret|No|Recruiting|December 2012|September 2016|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|2000|||Both|18 Years|N/A|No|||July 2012|March 6, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647477||82254|
NCT01647438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21HL113743-01|Translating a Heart Disease Lifestyle Intervention Into the Community|Translating a Heart Disease Lifestyle Intervention Into the Community||Northwestern University|No|Completed|August 2012|February 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|63|||Both|30 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|July 19, 2012||No||No|July 17, 2015|https://clinicaltrials.gov/show/NCT01647438||82257|
NCT01647451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8828-3842|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis||Novo Nordisk A/S|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|75 Years|No|||November 2013|November 7, 2013|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647451||82256|
NCT01648036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCA2011/001|Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot|Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot||University of Manitoba|Yes|Completed|July 2012|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||July 2014|July 9, 2014|July 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01648036||82211|
NCT01648296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND113344|Fatty Acid Radiotracer Comparison Study in Heart Failure Patients|Measurements of Myocardial Fatty Acid Metabolism With PET and [F-18]FluorbetaOx in Humans With Heart Failure With and Without Diabetes: Comparison With [C-11]Palmitate||Washington University School of Medicine|Yes|Active, not recruiting|August 2012|December 2014|Anticipated|June 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648296||82191|
NCT01649219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|64/2009|Intensity of Exercise and Glucose Metabolism||PreDiabEx|University of Oulu|No|Active, not recruiting|January 2010|June 2013|Anticipated|June 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|80|||Both|30 Years|70 Years|No|||July 2012|July 24, 2012|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01649219||82128|
NCT01649570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA-1472|Safety and Efficacy of Insulin Aspart in Type 2 Diabetes|An Open-labelled, Single-arm, Multi-centre, 6-month Study to Investigate the Safety and Efficacy of NovoRapid as Meal Time Insulin in Type 2 Diabetes Patients Treated on a Basal-bolus Regimen With NPH Human Insulin||Novo Nordisk A/S|No|Completed|March 2002|August 2003|Actual|August 2003|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|123|||Both|20 Years|N/A|No|||July 2012|July 24, 2012|November 25, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01649570||82103|
NCT01645436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUCIA|Physical Activity in Pediatric Cancer (PAPEC)|Physical Activity in Pediatric Cancer Patients With Solid Tumor Trial|PAPEC|Universidad Europea de Madrid|Yes|Recruiting|January 2013|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|60|||Both|4 Years|16 Years|No|||December 2014|December 1, 2014|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01645436||82372|
NCT01614002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONKODOC 01|A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region.||Onkovis GmbH|Yes|Completed|May 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|371|||Both|N/A|N/A|No|Probability Sample|Patients treated in practices, clinics, hospitals|June 2015|June 3, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01614002||84777|
NCT01614314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVCdressing|Dressing of Tunneled Central Venous Catheter|Dressing of Tunneled Central Venous Catheter: Preceptorship's Presence or Use of Auto-instructional Guide||University of Sao Paulo|No|Completed|August 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|35|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614314||84753|
NCT01614327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EY18280-04|Computer-based Screening for Diabetic Retinopathy|Phase 0 Observational Study of a Computer-based Screening Algorithm for Detection of Diabetic Retinopathy||VisionQuest Biomedical LLC|No|Recruiting|August 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|||Both|18 Years|65 Years|No|Probability Sample|Primary care clinics in the Southwest serving a Diabetic Community|December 2014|December 8, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01614327||84752|
NCT01617928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-629|A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors|A Phase 1 Study of Veliparib (ABT-888) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Solid Tumors||AbbVie|Yes|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|20 Years|N/A|No|||July 2013|July 9, 2013|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01617928||84477|
NCT01617941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGG492A2214|A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention|A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled, Study in Patients With Non-chronic Migraine to Assess the Efficacy, Safety and Tolerability of BID Oral Doses of BGG492 in Migraine Prevention.||Novartis|No|Withdrawn|May 2016|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||September 2014|September 29, 2014|June 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01617941||84476|
NCT01614067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF 11-07259|Delayed Start to Ovarian Stimulation|Delayed Start to Ovarian Stimulation Improves Oocyte Maturation and Quality: A Randomized Trial|DOS/DOR|University of California, San Francisco|No|Terminated|May 2012|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Female|18 Years|N/A|No|||July 2015|July 17, 2015|May 2, 2012|Yes|Yes|Slow enrollment resulted in withdraw of funding|No||https://clinicaltrials.gov/show/NCT01614067||84772|
NCT01613833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scu.Cyt.003|Serum and Synovium Protease Inhibitor Levels in Primary and Secondary Osteoarthritic Joints|||Scuderi, Gaetano J., M.D.|No|Recruiting|March 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|40|Samples With DNA|1. 2cc whole blood to be collected from patient on date of total knee arthroplasty        2. Joint aspirate harvested and collected intraoperatively during total knee arhtroplasty|Both|19 Years|65 Years|No|Non-Probability Sample|Patients undergoing total knee arthroplasty|June 2012|June 5, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613833||84790|
NCT01614119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002|Cerebral Responses During Exercise in Hypoxia|Evaluation of the Cerebral Responses to Exercise in Hypoxia|CERVOX|University Hospital, Grenoble|No|Completed|June 2010|July 2011|Actual|July 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 4, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01614119||84768|
NCT01614704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cancer et fertilité - 1104|Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility|Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility||Centre Oscar Lambret|No|Recruiting|October 2011|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Female|18 Years|37 Years|No|Non-Probability Sample|young female, treated for non metastatic breast cancer|August 2014|August 21, 2014|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01614704||84723|
NCT01614132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOA-07|Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults|Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-07)|NOA-07|University of Regensburg|No|Active, not recruiting|January 2009|July 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||June 2015|June 2, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01614132||84767|
NCT01645033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111009300|Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients|Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients||Yale University|Yes|Completed|April 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01645033||82403|
NCT01645280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100736|A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy||Janssen Research & Development, LLC|Yes|Completed|August 2012|May 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|274|||Both|18 Years|80 Years|No|||May 2015|May 26, 2015|June 6, 2012|Yes|Yes||No|December 12, 2014|https://clinicaltrials.gov/show/NCT01645280||82384|
NCT01645293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Koeln-1065|Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides|Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides|TECLA|University of Cologne|Yes|Not yet recruiting||||||Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||July 2012|July 17, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01645293||82383|
NCT01645306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Revacept/CS/02|Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)|Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups|Revacept/CS/02|AdvanceCor GmbH|Yes|Recruiting|March 2013|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|N/A|No|||September 2015|September 15, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01645306||82382|
NCT01645735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-25|Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus|A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus||Forest Laboratories|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||December 2015|December 24, 2015|July 9, 2012|Yes|Yes||No|September 29, 2014|https://clinicaltrials.gov/show/NCT01645735||82365|Small number of subjects enrolled
NCT01646580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPO_08_01|Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children|Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses||Ferrer Internacional S.A.|No|Terminated|October 2008|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Both|3 Months|10 Years|No|||July 2012|July 19, 2012|July 12, 2012||No|Low recruitment rate. with the final sample primary endpoint could be assessed.|No||https://clinicaltrials.gov/show/NCT01646580||82301|
NCT01647490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LM-003|Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position|Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position - Right Pace Study||Ospedale Santa Maria di Loreto Mare|No|Recruiting|April 2012|July 2015|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|408|||Both|18 Years|N/A|No|||July 2012|July 19, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647490||82253|
NCT01647763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EKSG11/042|Hemorrhoidal Artery Ligation and Rectoanal Repair Versus Stapled Hemorrhoidopexy|Hemorrhoidal Artery Ligation and Rectoanal Repair Versus Stapled Hemorrhoidopexy||Cantonal Hospital of St. Gallen|No|Recruiting|July 2011|December 2017|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|70 Years|No|||June 2015|June 29, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01647763||82232|
NCT01648309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAVIPSYCH-HMO-CTIL|Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation|Neuropsychological Testing in Patients Undergoing TAVI|TAVIPSYCH|Hadassah Medical Organization|No|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|60 Years|N/A|No|Non-Probability Sample|All patients with severe aortic stenosis that are candidates for TAVI|March 2013|March 19, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01648309||82190|
NCT01648686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110126|Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly|Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os (70 mg Weekly)|BOCOMEDEN|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|280|||Female|45 Years|70 Years|No|||April 2015|April 20, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648686||82168|
NCT01648933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOR10027|Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis|Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis|PARCS|Assistance Publique - Hôpitaux de Paris|No|Recruiting|July 2012|September 2014|Anticipated|February 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|18 Years|N/A|No|||August 2013|August 26, 2013|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01648933||82149|
NCT01644864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.37|Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?|Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance Therapy for Opioid Abstinence?|TAP|Thomas Jefferson University|Yes|Completed|July 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|110|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644864||82416|
NCT01644877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAS181-2-05|A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen|A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen|DAS181-2-05|Ansun Biopharma, Inc.|Yes|Recruiting|March 2014|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|129|||Both|12 Years|N/A|No|||February 2016|February 17, 2016|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644877||82415|
NCT01645189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1111C|Safety and Efficacy of Hunterase|To Evaluate the Safety and Efficacy of Hunterase(Idursulfase-beta) in Hunter Syndrome Patients < 6 Years of Age Receiving Idursulfase Enzyme Replacement Therapy|GC1111|Green Cross Corporation|No|Completed|July 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|N/A|5 Years|No|||July 2014|July 7, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01645189||82391|
NCT01645449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-VIN-095|Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|June 2010|August 2010|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01645449||82371|
NCT01645904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0418|A Social Media Approach to Improve Genetic Risk Communication Phase I|A Social Media Approach to Improve Genetic Risk Communication Phase I||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2013|||February 2017|Anticipated|Phase 1|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Anticipated|49|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants recruited from Lynch syndrome families enrolled in the Human Pedigree        Analysis Resource (HPAR), MDACC's hereditary cancer registry.|November 2015|November 6, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645904||82353|
NCT01646164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Effect of Dill seed|Effect of Dill Seed on Uterus Contractions Pattern|||Mashhad University of Medical Sciences||Completed|May 2009|August 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|100|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|pregnance women|July 2012|July 19, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646164||82333|
NCT01646190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 08-060|Fast-Track Colorectal Surgery in Senior Patients|Fast-Track Perioperative Care After Elective Colorectal Surgery in Senior Patients. Randomized Controlled Trial|FT-SS|University Hospital, Geneva|No|Recruiting|December 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|70 Years|N/A|No|||July 2012|July 20, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646190||82331|
NCT01617642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2197/REK|Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)|Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)||Nordlandssykehuset HF|No|Not yet recruiting|July 2012|December 2021|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|150|Samples With DNA|Serum and plasma. Urine samples. Pax tubes for RNA/DNA samples.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The group of patients with acute intermittent porphyria will be recruited from primary        care clinics and patient organizations.        The control group will be selected randomly from the same geographical area, matched for        gender and age|June 2012|June 8, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01617642||84499|
NCT01617655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12732|Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C Higher or Equal to 160mg/dL With Their Lipid-Modifying Therapy||Sanofi|Yes|Completed|June 2012|January 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|June 8, 2012|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01617655||84498|Manual reclassification was done by the Sponsor for the "other reasons" of non-completion of study as specified in the electronic case report form (eCRF).
NCT01617668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCL161A2201|A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer|A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer||Novartis|No|Completed|August 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|210|||Female|18 Years|N/A|No|||December 2014|December 1, 2014|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617668||84497|
NCT01617954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROMIS|PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score|PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score|PROMIS|Agendia|No|Completed|May 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|820|Samples With DNA|Patients have the option to agree to the storage of excess samples at Agendia.|Female|18 Years|90 Years|No|Probability Sample|Patients with an Intermediate Recurrence Score|January 2016|January 28, 2016|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617954||84475|
NCT01617967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALN-TTR02-002|Trial to Evaluate Safety and Tolerability of ALN-TTR02 in Transthyretin (TTR) Amyloidosis|A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis||Alnylam Pharmaceuticals|No|Completed|May 2012|January 2014|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|85 Years|No|||April 2014|April 22, 2014|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01617967||84474|
NCT01613820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000624|Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder|Combination of Anticholinergic and Glutamatergic Effects in Treatment-resistant Major Depressive Disorder. A Pilot Study||Massachusetts General Hospital|Yes|Enrolling by invitation|September 2015|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|15|||Both|18 Years|65 Years|No|||January 2015|January 26, 2015|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01613820||84791|
NCT01614444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMIRB# 12-0452|Acupressure and Stress Resilience|Using Complementary and Alternative Medicine (CAM) to Promote Stress Resilience in Those With Co-Occurring Mild TBI and PTSD||VA Eastern Colorado Health Care System||Active, not recruiting|June 2012|December 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||January 2016|January 13, 2016|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614444||84743|
NCT01614145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSF Aspergillus PCR|Diagnostic Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples|Diagnostic Study Evaluating the Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis||Heidelberg University|No|Enrolling by invitation|September 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Aspergillus DNA samples|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Immunocompromised patients at risk for invasive aspergillosis|December 2015|December 8, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614145||84766|
NCT01614743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROS-INC-12|A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea|A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea||DeNova Research|No|Active, not recruiting|June 2012|November 2014|Anticipated|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|65 Years|No|||September 2014|September 12, 2014|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614743||84720|
NCT01645319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSA29020050035I|Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma|A Prospective Observational Study Comparing the Effectiveness of Treatment Strategies for Open-Angle Glaucoma|RiGOR|Agency for Healthcare Research and Quality (AHRQ)|No|Completed|February 2011|July 2013|Actual|July 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||12|Actual|2597|||Both|18 Years|N/A|No|Non-Probability Sample|In the United States, the prevalence of open-angle glaucoma for all adults 40 years old        and older is estimated to be 1.86%. Open-angle glaucoma affects an estimated 2.22 million        people, and that will rise to 3.3 million in 2020 as the population ages in the United        States. Worldwide, it is estimated that 66.8 million people have glaucoma. Glaucoma of all        types is one of the leading causes of legal blindness in the country.|July 2012|January 7, 2014|October 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01645319|12 Months|82381|
NCT01645748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUHH-MO-02|Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer|Multicenter Phase II Study of Weekly Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck|TPSHNSCC|Chonnam National University Hospital|Yes|Completed|October 2008|March 2012|Actual|October 2011|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01645748||82364|
NCT01646047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20112190|Diabetes Visual Function Supplement Study|Effects of a Novel Dietary Supplement on Visual Function in Patients With Diabetes With and Without Early Diabetic Retinopathy|DiVFuSS|ZeaVision, LLC|Yes|Completed|May 2012|September 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Actual|70|||Both|18 Years|N/A|No|||January 2015|January 20, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01646047||82342|
NCT01646320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB102-129|Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin||AstraZeneca|No|Completed|September 2012|February 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|320|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646320||82321|
NCT01647204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09/H0502/93|Southampton Mealtime Assistance Study|Introduction of Mealtime Assistance Onto an Acute Medical Ward for Older People|SMAS|University Hospital Southampton NHS Foundation Trust.|No|Completed|November 2009|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|342|||Female|70 Years|N/A|No|||November 2014|November 3, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01647204||82275|
NCT01647776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1207|Screening and Risk Factors of Colon Neoplasia|Screening and Risk Factors of Colon Neoplasia||Case Comprehensive Cancer Center|No|Recruiting|April 2012|||May 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1600|Samples With DNA|Whole Blood, Urine, Stool samples, Colon polyps|Both|30 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Average-risk patients undergoing colonoscopy at screening endoscopy centers in the        University Hospitals of Cleveland system.|February 2016|February 16, 2016|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01647776||82231|
NCT01647789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCFG920X2101|A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer|A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer||Novartis|No|Completed|December 2012|February 2016|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Male|18 Years|N/A|No|||March 2016|March 5, 2016|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647789||82230|
NCT01648049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0309|Treatment of Insomnia and Depression in Elders (TIDE)|Treatment of Insomnia and Depression in Elders (TIDE)|TIDE|University of Alabama, Tuscaloosa|Yes|Active, not recruiting|June 2012|||March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|46|||Both|50 Years|100 Years|No|||November 2015|November 30, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01648049||82210|
NCT01648946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FSB|Transfusion Requirements in Critically Ill Oncologic Patient|Transfusion Requirements in Critical Clinical Oncologic Patients: a Phase 3 Randomized Controlled Clinical Trial (TRICCOP STUDY)|TRICCOP|Instituto do Cancer do Estado de São Paulo|Yes|Recruiting|June 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||November 2012|November 5, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01648946||82148|
NCT01649232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vpradtdcs0102012|ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation|Implications of Electrophysiological ADHD Endophenotypes to Predict Response to Transcranial Direct-Current Stimulation|tdcs&adhd|Spanish Foundation for Neurometrics Development|Yes|Completed|June 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|8 Years|68 Years|Accepts Healthy Volunteers|||April 2014|April 19, 2014|June 18, 2012|Yes|Yes||No|December 15, 2012|https://clinicaltrials.gov/show/NCT01649232||82127|
NCT01649557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-08-210|Multicenter, Open-label, Safety and Tolerability Study|A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients With Schizophrenia|STEP 210|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|August 2009|September 2011|Actual|August 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|244|||Both|18 Years|67 Years|No|||September 2015|September 29, 2015|July 20, 2012|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01649557||82104|
NCT01617850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100297|Efficacy of Physical Exercise in Cardiac Rehabilitation|||Aarhus University Hospital Skejby|No|Completed|April 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||May 2015|May 21, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01617850||84483|
NCT01646203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14549|A Study of IMC-TR1 in Patients With Advanced Solid Tumors|Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available||Eli Lilly and Company|No|Completed|July 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|June 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01646203||82330|
NCT01646463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K01AT005270|Pilot Trial of CenteringPregnancy With Mindfulness Skills|Integrative Stress Reduction for Maternal-Child Health||University of California, San Francisco|Yes|Active, not recruiting|January 2011|February 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|49|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 17, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646463||82310|
NCT01617694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0181|Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia|||Yonsei University|No|Completed|June 2011|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|65|||Female|20 Years|60 Years|No|||June 2012|June 11, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01617694||84495|
NCT01617980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIL-DOT-MOBI|Multimodal Hypoxia Imaging and Intensity Modulated Radiotherapy for Inoperable Non-small-cell Lung Cancer||HIL|German Cancer Research Center|No|Terminated|April 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|18 Years|N/A|No|||March 2014|March 14, 2014|April 10, 2012||No|Slow accrual|No||https://clinicaltrials.gov/show/NCT01617980||84473|
NCT01617993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AUX-002|Eeva™ Continued Access Study: Assessing the Usability of Eeva in a Clinical Setting|Eeva Continued Access Study.|CAS|Progyny, Inc.|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|31|||Female|18 Years|40 Years|No|Non-Probability Sample|Women in the United States who undergo IVF treatment and imaging of their embryos with        Eeva.|January 2014|January 9, 2014|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617993||84472|
NCT01614106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK0606|Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users|Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users||Columbia University|Yes|Active, not recruiting|January 2013|July 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|360|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 10, 2016|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01614106||84769|
NCT01614457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX11-770-110|Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation|KONDUCT|Vertex Pharmaceuticals Incorporated|Yes|Completed|July 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|70|||Both|6 Years|N/A|No|||January 2015|January 31, 2015|June 5, 2012|Yes|Yes||No|January 31, 2015|https://clinicaltrials.gov/show/NCT01614457||84742|
NCT01614769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0000-253|Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)|A Study to Assess the Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|10|||Both|18 Years|60 Years|No|||November 2015|November 19, 2015|June 6, 2012|No|Yes||No|January 2, 2014|https://clinicaltrials.gov/show/NCT01614769||84718|
NCT01614782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5823-002|A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Healthy Overweight/Obese Subjects and Patients With Type 2 Diabetes Mellitus||Merck Sharp & Dohme Corp.|No|Terminated|June 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01614782||84717|
NCT01614756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM134-002|A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis|A Two-Part, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of Subcutaneous and Intravenous Administration of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody; BMS-981164) in Healthy Subjects and Adult Subjects With Atopic Dermatitis||Bristol-Myers Squibb|No|Completed|July 2012|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|14||Actual|93|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01614756||84719|
NCT01646060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZM-11-01|Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw|Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw||Zynex Monitoring Solutions|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|10|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 17, 2012|November 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01646060||82341|
NCT01646333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT107964|A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease|A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease||Virginia Commonwealth University|No|Completed|July 2012|December 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01646333||82320|
NCT01646567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHP-141C-002|SHP-141C in Plaque Type Psoriasis|A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.||TetraLogic Pharmaceuticals|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|70 Years|No|||July 2014|July 10, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01646567||82302|
NCT01646346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110009173|4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer|A Pilot Study of Four-Dimensional Conformal Image Guided Accelerated Partial Breast Irradiation In The Treatment Of Stage 0 and l Breast Cancer||Yale University|No|Active, not recruiting|February 2012|January 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|50 Years|N/A|No|||January 2015|January 26, 2015|March 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01646346||82319|
NCT01647217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P012-01|Demodex Blepharitis Treatment Study|Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial|DBTS|Tissue Tech Inc.|Yes|Recruiting|February 2014|April 2015|Anticipated|January 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|15 Years|80 Years|No|||July 2014|July 15, 2014|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01647217||82274|
NCT01648322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC-627-02|Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy||Generon (Shanghai) Corporation Ltd.|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|232|||Female|18 Years|74 Years|No|||January 2015|January 26, 2015|April 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648322||82189|
NCT01648335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beyth01-CTIL-HMO|A Prospective Study of the Effect of Treatment of First Time Traumatic Shoulder Anterior Dislocation by Immobilization in External Rotation on the Incidence of Recurrent Dislocation|||Hadassah Medical Organization|No|Not yet recruiting||July 2013||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|2||||||Male|18 Years|29 Years|No|||March 2013|March 21, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01648335||82188|
NCT01648699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016351|Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain|Study on the Effectiveness and Safety of OROS Hydromorphone in Pain Management Among Patients With Cancer Pain||Janssen Pharmaceutica|No|Terminated|April 2010|September 2010|Actual|September 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|70 Years|No|||October 2013|October 1, 2013|July 20, 2012|Yes|Yes|the study was stopped due to non-availability of 4mg|No|March 15, 2013|https://clinicaltrials.gov/show/NCT01648699||82167|The study was prematurely terminated due to administrative reason.
NCT01617291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012051|Therapeutic Hypothermia After the Return of Spontaneous Circulation|Induction of Therapeutic Hypothermia in the Pre-hospital Setting After the Return on Spontaneous Circulation: A Randomized Controlled Study||University of California, San Francisco|Yes|Terminated|March 2013|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|May 27, 2012||No|A similar study was recently published with definitive results.|No||https://clinicaltrials.gov/show/NCT01617291||84526|
NCT01617551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RENO_01|Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones|Effect of Renal Denervation on NO-mediated Regulation of Salt- and Water Excretion, Vasoactive Hormones and Tubular Transport Proteins in Patients With Resistant Hypertension|RENO|Regional Hospital Holstebro|No|Recruiting|March 2012|June 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|30 Years|70 Years|No|||March 2014|March 1, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01617551||84506|
NCT01617564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W2010IM|Paracervical Block During II-trimester Abortion|Paracervical Block (PCB) During II-trimester Abortion- A Randomized Controlled Trial||Karolinska Institutet|Yes|Completed|May 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Female|18 Years|50 Years|No|||May 2015|May 15, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01617564||84505|
NCT01645150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-154/2012|Reduction of Cancer Related Fatigue in Patients During TKI Therapy|Pilot Study on the Effects of Strength Training on Cancer Related Fatigue in Cancer Patients During Tyrosine Kinase Inhibitor Therapy|RECAP|German Cancer Research Center|No|Completed|May 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|80 Years|No|||March 2016|March 21, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01645150||82394|
NCT01645163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPNPVW72/SAS|mHealth - A Novel Approach to Improve Child Nutrition in India|mHealth - A Novel Approach to Improve Child Nutrition in India|mHealth|Society for Applied Studies|No|Completed|November 2011|May 2014|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment|1||Anticipated|72|||Both|9 Months|11 Months|Accepts Healthy Volunteers|||November 2014|November 18, 2014|July 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01645163||82393|
NCT01645176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23784|Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee|Hydroxychloroquine/Atorvastatin in the Treatment of OA of the Knee||Stanford University|Yes|Active, not recruiting|May 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|40 Years|N/A|No|||February 2016|February 3, 2016|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01645176||82392|
NCT01645917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUPIR001|Durability of Pulmonary Vein Isolation Following Cryoablation for Treatment of Paroxysmal Atrial Fibrillation|SUstained PV Isolation With aRctic Front Advance|SUPIR|Medtronic Atrial Fibrillation Solutions|No|Completed|August 2012|November 2013|Actual|July 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645917||82352|
NCT01645930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16013|Phase 1 Pharmacokinetic Study of Oral IXAZOMIB Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma||Millennium Pharmaceuticals, Inc.|No|Active, not recruiting|December 2012|August 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645930||82351|
NCT01646216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00068967|Long Term Split Belt Treadmill Training for Stroke Recovery|Long Term Split Belt Treadmill Training for Stroke Recovery||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|June 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|20 Years|80 Years|No|||March 2015|March 31, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01646216||82329|
NCT01646801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMB PP CLD 2158|Study of NMB Drug Ejecting Balloon for Peripheral Arteries|The Use of NMB Drug Ejecting Balloon for Treatment of Patients With Peripheral Arterial Disease||N.M.B. Medical Applications Ltd||Not yet recruiting|January 2013|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2012|July 22, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01646801||82285|
NCT01618006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIF-11271|Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery|Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery|ASACABG|Hamilton Health Sciences Corporation|No|Completed|January 2012|August 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|18 Years|N/A|No|||March 2015|March 18, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01618006||84471|
NCT01613846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16037 / AN 33/11|Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)|Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma||Technische Universität München||Active, not recruiting|May 2012|March 2017|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|544|||Both|18 Years|85 Years|No|||March 2016|March 16, 2016|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01613846||84789|
NCT01613859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TSI-G-COstatus-12A-H|Measurement of Cardiac Output and Intravascular Volume Status in Children Using COstatus (SH)|Measurement of Cardiac Output and Intravascular Volume Status in Critically Ill Children Using an Ultrasound Dilution Method (COstatus)||Transonic Systems Inc.||Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|40|||Both|N/A|21 Years|No|Non-Probability Sample|Pediatric Patients (under 21 years of age) in the ICU|June 2012|June 4, 2012|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01613859||84788|
NCT01614158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|73/2009B02|Assessment of Visual Field-related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy|Pilot SINN; Assessment of Visual Field (vf)-Related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy (N-AION)|Pilot-SINN|University Hospital Tuebingen|No|Completed|April 2009|February 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|16|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with acute N-AION (less then 7 days); male and female > 18 years|May 2014|May 27, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01614158||84765|
NCT01615042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#228|Phase I Study of Lenalidomide in Patients With Acute Leukemia|Phase I Trial of High Dose Lenalidomide in Patients With Refractory/Relapsed Acute Leukemia as a Bridge to Bone Marrow Transplant||University of California, Davis|Yes|Recruiting|August 2012|August 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|80 Years|No|||January 2016|January 20, 2016|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615042||84697|
NCT01615341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DK088914-01A1|Study of Subclinical Viral Infection|Subclinical Viral Infection and Renal Allograft Injury||Seattle Children's Hospital|No|Recruiting|October 2011|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|If participant agrees, blood, tissue, and study data will be banked at Seattle Children's      Research Institute.|Both|1 Year|25 Years|No|Non-Probability Sample|Pediatric and young adult renal transplant recipients (1<25yrs) of their first kidney        transplant from Seattle Children's Hospital and University of Washington Medical Center.|June 2012|June 7, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615341||84675|
NCT01615029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR101391|Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma|An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma||Janssen Research & Development, LLC|Yes|Active, not recruiting|January 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615029||84698|
NCT01645787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI7400|Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients|Columbia SMA Project: 4-AP as a Potential SMA Therapeutic Agent and Biological Mechanisms of Action||Columbia University|No|Active, not recruiting|June 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|50 Years|No|||May 2015|May 13, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01645787||82361|
NCT01646073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-606|Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (Humira®) in Chinese Subjects With Moderate to Severe Plaque Psoriasis||AbbVie|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|425|||Both|18 Years|N/A|No|||January 2015|January 14, 2015|July 18, 2012||No||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01646073||82340|
NCT01646593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16339|Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy|An Open-label Expanded Access Program of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib||Bayer||No longer available||||||Phase 3|Expanded Access|N/A|||||||Both|18 Years|N/A||||December 2014|December 12, 2014|July 18, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01646593||82300|
NCT01646606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000029983|Monitoring OXYgen in Infants Hospitalized With Bronchiolitis: A Best Practices Trial (The MOXY Trial)|Monitoring OXYgen in Infants Hospitalized With Bronchiolitis: A Best Practices Trial (The MOXY Trial)||The Hospital for Sick Children|No|Recruiting|March 2012|October 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|32|||Both|6 Weeks|24 Months|No|||July 2015|July 17, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01646606||82299|
NCT01647503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|parathyroid tumorigenesis|Differentially Expressed Proteins in Sporadic Parathyroid Tumors|Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|July 2012|||September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|50|||Both|15 Years|65 Years|No|Non-Probability Sample|Patients visiting the hospital for hypercalcemia, bone pain, renal problems and other        symptoms related to primary hyperparathyroidim will be consider. Investigations and        clinical symptoms will be confirmed for primary hyperpathyroidism. Finally if patient        suggested for surgery then he will be included in the study|April 2014|April 15, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01647503||82252|
NCT01616836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011-2012|Optimizing Pain and Rehabilitation After Knee Arthroplasty|Optimizing Pain and Rehabilitation After Knee Arthroplasty - Randomized, Blinded Clinical Trial Comparing Continuous Femoral Nerve Block Versus Single Injection Femoral Nerve Block Versus Local Infiltration Analgesia|OPRA|Sunnybrook Health Sciences Centre|Yes|Active, not recruiting|September 2012|December 2015|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|100|||Both|18 Years|85 Years|No|||April 2015|April 7, 2015|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616836||84561|
NCT01617070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USC Kuvan Melatonin|Effects of Kuvan on Melatonin Secretion|Pilot Study to Evaluate Melatonin Secretion as a Marker of Decreased Serotonin in Individuals With PKU: Evaluation of the CNS Effects of Tetrahydrobiopterin||University of Southern California|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01617070||84543|
NCT01649583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120727|Feasibility Study of Dynasplint to Prevent Trismus in Head and Neck Cancer|A Feasibility Study to Evaluate Use of the Jaw Dynasplint System to Prevent Trismus in Patients With Head and Neck Cancer Receiving Primary or Adjuvant Radiation-Based Therapy||Vanderbilt University|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|40|||Both|21 Years|N/A|No|||June 2014|June 18, 2014|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649583||82102|
NCT01644903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 26737|Proteogenomic Monitoring and Assessment of Liver Transplant Recipients|Proteogenomic Monitoring and Assessment of Liver Transplant Recipients|"Mini-Liver"|Northwestern University|No|Recruiting|April 2010|December 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Urine Sample - One half cup of urine (100 mL) will be taken for research tests at each study      visit.      Blood Sample - About 1.5 tablespoons (20.5 mL) will be taken for research tests at each      study visit.      Liver Biopsy - A liver biopsy is a procedure to remove and examine a small piece of liver      tissue. For this study, an extra tissue sample will possibly be taken during your biopsy.      One additional needle pass may be made to collect the sample for this study.|Both|18 Years|N/A|No|Non-Probability Sample|The intention of our biomarker panel is to be broadly applicable to all patients with        liver transplant with the assumption that there are common underlying molecular mechanisms        of CKD and AR (and HCV) that can be detected hopefully at early stages of disease. We        therefore want to validate and test our biomarker panel in a broad collection of patient        types.        Patients co-infected with HIV will be excluded given the inherent immunological        differences in the HIV and non-HIV populations. In addition, recipients undergoing liver        transplant who have had or are undergoing combined organ transplantation (i.e. kidney,        heart, lung) will be excluded to remove the impact of another graft on defining the        proteogenomic signature in this population.|January 2016|January 12, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644903||82413|
NCT01644916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPD_HSRG_2010|"Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"|"Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"|COPD_HSRG|National University, Singapore|Yes|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|900|||Both|55 Years|90 Years|No|||April 2015|April 20, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644916||82412|
NCT01646476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01-075|Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction|Comparison of Efficacy of Covered Versus Uncovered Self-expandable Metallic Stents for Treatment of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Study||Samsung Medical Center|No|Recruiting|July 2012|November 2015|Anticipated|September 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|102|||Both|20 Years|80 Years|No|||August 2012|May 25, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01646476||82309|
NCT01647633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AkP 010112A|Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash|Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash on Patient-Perceived Breathing Comfort||Drexel University|No|Completed|May 2012|May 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2015|May 21, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647633||82242|
NCT01618019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYUH-C55|N-3 PUFA and Rheumatoid Arthritis in Korea|Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis||Hanyang University|No|Completed|November 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|109|||Both|18 Years|80 Years|No|||August 2012|August 30, 2012|June 8, 2012||No||No|June 17, 2012|https://clinicaltrials.gov/show/NCT01618019||84470|
NCT01618032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-002|Effects of Two Techniques of Mobilization in the Dorsiflexion on Patients With Chronic Ankle Instability|The Effects of Two Techniques of Mobilization in the Improvement of Dorsiflexion on Chronic Instability Ankles. A Double Blind Randomized Controlled Trial||CEU San Pablo University|Yes|Completed|November 2010|November 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|52|||Both|15 Years|40 Years|No|||November 2012|November 30, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01618032||84469|
NCT01613872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000557/1|The Effects of Mindfulness Based Stress Reduction on Patients With Traumatic Brain Injury|The Effects of Mindfulness Based Stress Reduction on Patients With Traumatic Brain Injury||Spaulding Rehabilitation Hospital|No|Completed|May 2012|June 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|8|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 30, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01613872||84787|
NCT01613885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-10042011-8546|Understanding and Diagnosing Allergic Disease in Twins|Understanding and Diagnosing Allergic Disease in Twins||Stanford University|No|Recruiting|August 2010|||December 2016|Anticipated|N/A|Observational|N/A||1|Anticipated|200|Samples With DNA|Blood|Both|N/A|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers are not specifically targeted. Healthy non-allergic study participants        may be found through the course of evaluation for the presence of allergies. Women,        minorities or children will not be excluded from this study.|November 2015|November 24, 2015|June 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01613885||84786|
NCT01613898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-09-7393-HC-CTIL|Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis|Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis|CTX|Sheba Medical Center|No|Recruiting|August 2010|June 2015|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|17|Samples Without DNA|Lipid and lipoprotein profiles|Both|10 Years|N/A|No|Probability Sample|PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS|June 2012|June 6, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01613898||84785|
NCT01614171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00053014|Growth Hormone for Osteoporosis Pseudoglioma Syndrome|Trial of Growth Hormone for Osteoporosis Pseudoglioma Syndrome|GHOPPG|University of Maryland|Yes|Not yet recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|4 Years|N/A|No|||January 2013|January 14, 2013|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614171||84764|
NCT01614184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI23922|Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer|Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Operable Breast Cancer||University of Utah|Yes|Withdrawn|May 2008|June 2013|Actual|June 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||July 2013|July 8, 2013|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614184||84763|
NCT01614197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2014-001|A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma|A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma||Therapeutic Advances in Childhood Leukemia Consortium|Yes|Recruiting|March 2015|December 2019|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|1 Year|21 Years|No|||November 2015|February 2, 2016|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614197||84762|
NCT01615354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25559|A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers|Single-Center, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Assess the Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel as Components of the Oral Contraceptive Microgynon®||Hoffmann-La Roche||Completed|July 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Investigator)|2||Actual|18|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615354||84674|
NCT01615328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bonion ACDF|Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™|Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™||Seoul National University Hospital|Yes|Completed|November 2011|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|85|||Both|20 Years|80 Years|No|||July 2014|July 13, 2014|June 6, 2012||No||No|September 15, 2013|https://clinicaltrials.gov/show/NCT01615328||84676|Our study was included relatively small samples and short follow-up periods with 77 patients and one year duration. the measurement bias could be presented by individually different extent of neck flexion and extension in dynamic radiographs.
NCT01646086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK093586|Weight Tracking and Weight Loss Outcomes: Establishing the Standard of Care|Weight Tracking and Weight Loss Outcomes: Establishing the Standard of Care|Tracking|University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2012|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|339|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646086||82339|
NCT01646359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2010-0046|Value of Pulse Pressure Variations and Corrected Flow Time in Esophageal Doppler as a Predictor of Fluid Responsiveness in Prone Position During Spinal Surgery|||Yonsei University|No|Completed|March 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|45|||Both|21 Years|69 Years|No|||July 2012|July 19, 2012|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01646359||82318|
NCT01646372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHRI-20120006|Does Instruction on Cognitive Aid Use Improve Performance and Retention of Skills?|Does Instruction on Cognitive Aid Use Improve Performance and Retention of Skills? A Simulation Based Randomized Controlled Trial||Ottawa Hospital Research Institute|No|Active, not recruiting|July 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|3||Anticipated|66|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|May 21, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01646372||82317|
NCT01646632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABR NL 24558.042.09|Exercise Intervention in Institutionalized Elderly People|Effects of Exercise on ADL Performance, Physical Fitness, and Care Dependency in Institutionalized Elderly People|BENENFIT|Hanze University|Yes|Active, not recruiting|October 2009|February 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|164|||Both|70 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 18, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01646632||82297|
NCT01648062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IISleepTrial12|Sleep Self-Regulation Using Mental Imagery|Using Mental Imagery to Deliver Self-Regulation Techniques That Target Sleep Initiation Behaviors and Pre-Sleep Arousal||University of Auckland, New Zealand|No|Completed|October 2008|April 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|104|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01648062||82209|
NCT01648959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0268-B|Intra Cranial EEG Activity During Dexmedetomidine Sedation|Intra Cranial EEG Activity During Dexmedetomidine Sedation.Comparing the Effects of Dexmedetomidine on the Cortical and the Sub Cortical(Hippocampus) Structures.||University Health Network, Toronto|No|Terminated|July 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|No|Probability Sample|Adults between 18 to 80 years of age, who are scheduled for elective removal of        intracranial (surface and depth) electrodes under conscious sedation|February 2015|February 9, 2015|July 13, 2012||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01648959||82147|
NCT01648972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOA-ggRCT1|Gastrografin in Postoperative Ileus|Randomised Double-blind Placebo-controlled Trial of Gastrografin in the Therapeutic Management of Prolonged Postoperative Ileus Following Elective Surgery.|GAP|University of Auckland, New Zealand|No|Completed|September 2012|July 2014|Actual|July 2014|Actual|Phase 2/Phase 3|Interventional|N/A|2||||||Both|18 Years|N/A|No|||July 2014|July 2, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01648972||82146|
NCT01649245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPIC Trial|Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C|Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial|HAPIC|MinaPharm Pharmaceuticals|Yes|Recruiting|August 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5000|||Both|18 Years|60 Years|No|||January 2013|January 12, 2013|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649245||82126|
NCT01649258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-11-5|Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy|A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response||University of Southern California|Yes|Recruiting|September 2012|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649258||82125|
NCT01649596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRMC120009|Impact of Expanded Peri Operative Warming|Impact of Expanded Peri Operative Warming for Patients Undergoing Elective Surgery||Genesys Regional Medical Center|Yes|Recruiting|August 2012|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 24, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649596||82101|
NCT01646229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC11-054(CC11-146)|Impact of Early Peri-operative Use of Polymyxin-B Hemoperfusion in Septic Patients Undergoing Emergent Abdominal Surgery|Impact of Early Per-operative Use of Polymyxin-B Hemoperfusion in Septic Patients Undergoing Emergent Abdominal Surgery||University Hospital, Geneva|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646229||82328|
NCT01647347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJB 1|PVP Iodine Effect on Post Debridement Bacteraemia|Effects of Ultrasonic Debridement With PVP-iodine Irrigation on Post-treatment Bacteraemia Compared to Ultrasonic Debridement With Water|PJB 1|University of Zurich|Yes|Completed|August 2012|November 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 20, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01647347||82264|
NCT01647919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01-10-STEV|Effects of cogniVida™ on Learning and Memory and in Comparison to Placebo After Long-term Supplementation|Effects of cogniVida™ on Learning and Memory and in Comparison to Placebo After Long-term Supplementation|MemIprov|DSM Nutritional Products, Inc.|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|88|||Both|50 Years|65 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01647919||82220|
NCT01648166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-1-0781|A Population-based Case-control Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens|A Population-based Case-control Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens||University of Kentucky|Yes|Active, not recruiting|January 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|1800|Samples With DNA|Blood, live lymphocytes, serum, plasma, radon test kit, urine, water, soil, toenails, and      hair.|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|This case-control study will be performed in Appalachian Kentucky, specifically the 5th        Congressional District of Kentucky and will include male and female subjects from the        subset of all histologically or cytologically confirmed primary carcinoma of the lung        (International Classification of Diseases-9, 162.2-162.9) over the age of 17 years old        that occur in the 5th District between October 17, 20011 and November 14, 2013.|January 2016|January 11, 2016|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01648166||82201|
NCT01614210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI57098|Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance|Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance|POWER PIINC|University of Utah|Yes|Active, not recruiting|August 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||November 2015|November 10, 2015|June 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01614210||84761|
NCT01614470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-770-111|Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation|A Phase 3, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Crossover Study With an Open-Label Period to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation|KONNECTION|Vertex Pharmaceuticals Incorporated|Yes|Completed|July 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|39|||Both|6 Years|N/A|No|||October 2014|October 23, 2014|June 5, 2012|Yes|Yes||No|October 23, 2014|https://clinicaltrials.gov/show/NCT01614470||84741|
NCT01614795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01971|Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma|A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors||National Cancer Institute (NCI)|Yes|Active, not recruiting|June 2012|||December 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|46|||Both|1 Year|30 Years|No|||February 2015|March 19, 2015|June 6, 2012|Yes|Yes||No|March 19, 2015|https://clinicaltrials.gov/show/NCT01614795||84716|
NCT01615640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02.08.2010 V.1.0|Diffusion Study on Patients With Osteosarcoma|Monitoring the Response of Osteosarcoma Under Neoadjuvant Chemotherapy: The Value of Dynamic Contrast Enhancement and Diffusion-weighted MRI||Klinikum Stuttgart|No|Recruiting|September 2010|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|||Both|N/A|N/A|No|Non-Probability Sample|German, Austrian and Swiss patients with an osteosarcoma will be entered into the study.|June 2012|June 7, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615640||84652|
NCT01615614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100812|A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants|A Phase I, Open-Label Study in Healthy Subjects, to Explore the Pharmacokinetics of Different Dosing Regimens of Rilpivirine in Combination With Rifabutin, at Steady-State||Janssen R&D Ireland|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2014|March 27, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615614||84654|
NCT01615627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JGH-12-058|Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain|Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain||Jewish General Hospital|No|Not yet recruiting||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12|||Both|18 Years|N/A|No|||June 2012|June 11, 2012|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615627||84653|
NCT01646099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00058220|Sun Protection of Kidney Transplant Recipients|Internet-Based Sun Protection Program for Kidney Transplantation Recipients||Northwestern University|No|Completed|November 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|335|||Both|18 Years|85 Years|No|||April 2015|April 21, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01646099||82338|
NCT01646385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801348|Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry|Long-term Safety and Efficacy of Etanercept in a UK Observational Cohort Study - a Retrospective Database Analysis of British Society of Rheumatology Biologics Registry (BSRBR) Data||Pfizer|No|Completed|February 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|6393|||Both|18 Years|N/A|No|Non-Probability Sample|adult patients with a diagnosis of rheumatoid arthritis|July 2014|July 7, 2014|April 12, 2012||No||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01646385||82316|
NCT01646619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC 1028A|Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy|A Multicenter Randomized Controlled Trial of Therapeutic Hypothermia Plus Magnesium Sulphate (MgSO4) Versus Therapeutic Hypothermia Plus Placebo in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy|MagCool|Hamad Medical Corporation|Yes|Recruiting|May 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|N/A|6 Hours|No|||April 2013|April 3, 2013|July 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646619||82298|
NCT01646645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-086|Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation||Memorial Sloan Kettering Cancer Center||Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|N/A|N/A|No|||October 2015|October 5, 2015|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646645||82296|
NCT01647230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011612CSPT|Cerebral Oxygenation and Spinal Anaesthesia in Elderly Patients With Hip Fracture|Observational Study of Cerebral Oxygenation and Spinal Anaesthesia in Elderly Patients With Hip Fracture||Hospital de Sabadell|Yes|Recruiting|February 2012|February 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|70 Years|N/A|No|Non-Probability Sample|Patients aged > 70 years old with hip fracture undergoing surgery under spinal        anaesthesia.|July 2012|July 24, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647230||82273|
NCT01647516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC01-202|Efficacy and Safety Study of RPC1063 in Ulcerative Colitis|||Celgene|Yes|Active, not recruiting|December 2012|December 2019|Anticipated|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|199|||Both|18 Years|65 Years|No|||June 2015|June 3, 2015|July 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01647516||82251|
NCT01640366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE/US/11/01/PIC|PICO Breast Reduction Clinical Study Looking at Incision Healing Complications|A Prospective, Randomized, Intra-patient, Comparative, Open, Multi-centre Study to Evaluate the Efficacy of a Single-Use NPWT System on the Prevention of Incision Healing Complications in Patients Undergoing Reduction Mammoplasty||Smith & Nephew Wound Management Inc|No|Completed|June 2012|July 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|N/A|No|||January 2016|January 8, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01640366||82759|
NCT01648985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|catwil00|Diabetes in Minor Stroke and TIA, Glucose Tolerance and Haemostasis, a Long-term-follow-up Study and Intervention With Yoga|Diabetes in Minor Stroke and TIA, Glucose Tolerance and Haemostasis, a Long-term-follow-up Study and Intervention With Yoga||Karolinska Institutet|No|Recruiting|May 2010|June 2018|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|85 Years|No|Probability Sample|Acute stroke and TIA patients screened from the stroke unit at Danderyd Hospital,        Stockholm, Sweden|August 2012|August 22, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01648985||82145|
NCT01645202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SK 107 -- 012/12 (II)|A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: The CHOICE Trial|A Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPIEN XT (The CHOICE Trial)|CHOICE|Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH|Yes|Active, not recruiting|March 2012|December 2018|Anticipated|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|75 Years|N/A|No|||March 2015|March 30, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01645202||82390|
NCT01645475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/247|Desmopressin Melt: Impact on Sleep and Daytime Functioning|Desmopressin Melt: Impact on Sleep and Daytime Functioning? A Prospective Study.|SLEEP|University Hospital, Ghent|No|Completed|April 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|6 Years|16 Years|No|||December 2014|December 4, 2014|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01645475||82370|
NCT01646814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL-ASA-005|Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects|A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects||PLx Pharma|Yes|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|247|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|July 18, 2012|Yes|Yes||No|June 18, 2015|https://clinicaltrials.gov/show/NCT01646814||82284|
NCT01646827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-11-290|An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia|An Open-label, Randomized, Parallel Arm, Bioavailability Trial of Aripiprazole IM Depot Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|May 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|37|||Both|18 Years|64 Years|No|||July 2014|July 1, 2014|June 18, 2012|Yes|Yes||No|April 30, 2014|https://clinicaltrials.gov/show/NCT01646827||82283|
NCT01648179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116595|A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects|A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects||GlaxoSmithKline|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|June 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01648179||82200|
NCT01648192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116681|Phase I Study of GW856553 (Losmapimod)|A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Losmapimod in Healthy Japanese Subjects.||GlaxoSmithKline|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|6||Actual|20|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01648192||82199|
NCT01648582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13439|A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus|The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea||Eli Lilly and Company|Yes|Completed|July 2012|December 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|789|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|July 16, 2012|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01648582||82176|
NCT01614483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSTAPAWP2YC|Efficacy of Yellow Cassava to Improve Vitamin A Status of Kenyan School Children|Efficacy of Yellow Cassava to Improve Vitamin A Status of Mildly Deficient Primary School Children in Kenya: a Randomized Controlled Trial|CASSAVITA|Wageningen University|Yes|Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|341|||Both|61 Months|13 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01614483||84740|
NCT01614496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PS09/01255|Rule-Based Closed Loop System for Type 1 Diabetes Control|||Corporacion Parc Tauli||Completed||||||N/A|Interventional|N/A|||||||Both|18 Years|65 Years||||June 2013|September 23, 2013|June 7, 2012||||No||https://clinicaltrials.gov/show/NCT01614496||84739|
NCT01614808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B7|Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor|Observational - Characterization of Urinary Metabolite Profiles in Wilms Tumor||Children's Oncology Group|No|Completed|June 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|90|Samples With DNA|Urine|Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with stage III, favorable-histology Wilms tumors and patients diagnosed        with stage III, favorable-histology Wilms tumors who have relapsed.|May 2015|May 6, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614808||84715|
NCT01615055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000568|Fluoxetine Prevention Trial|Prevention of Cognitive Decline After Chemotherapy, With Fluoxetine Treatment||University of California, Los Angeles|Yes|Not yet recruiting|June 2018|October 2020|Anticipated|October 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|376|||Both|21 Years|N/A|No|||February 2016|February 4, 2016|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615055||84696|
NCT01616472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116015|WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)|WEUKBRE5716: Quantifying the Burden of Steroid-related Damage in Systemic Lupus Erythematosus in the Hopkins Lupus Cohort||GlaxoSmithKline|No|Active, not recruiting|April 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||10|Anticipated|1|||Both|N/A|N/A|No|Non-Probability Sample|Cases and controls will be identified from the Hopkins Lupus Cohort, a prospective        longitudinal study of lupus activity, organ damage, and quality of life in patients with        SLE which has followed patients up since 1987. The cohort database is continually updated        and includes socio-demographic information, medical and reproductive history,        comorbidities, SLE complications, and treatment. Data, collected at each patient visit,        includes SLE clinical activity indices, laboratory data and treatment (medication and        dose).|March 2015|March 9, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616472||84588|
NCT01615887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU2570309B|Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis|Effects of Lisdexamfetamine on Bradyphrenia in Multiple Sclerosis||State University of New York at Buffalo||Completed|November 2009|August 2011|Actual|August 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|63|||Both|18 Years|55 Years|No|||June 2012|June 6, 2012|March 23, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615887||84633|
NCT01615900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/6-O|Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)|Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)|TELEGRAFT|Nantes University Hospital|Yes|Recruiting|February 2012|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|700|||Both|18 Years|N/A|No|||June 2012|June 7, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01615900||84632|
NCT01646398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851088|A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older|A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine||Pfizer|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|764|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 17, 2013|May 10, 2012||No||No|July 17, 2013|https://clinicaltrials.gov/show/NCT01646398||82315|
NCT01646411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300831|300 Antibody Diagnostic Test Kit|Phase I Study for Positive IgM Antibody Detection in New Diagnostic Test Kit for for Acute Phase Infection|Antibody 300|The Plasma Source|Yes|Enrolling by invitation|August 2012|July 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|300|Samples Without DNA|Serum collected in two 10ml sst and two 8ml edta venipuncture tubes.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with acute infection between the age of 18 and 70. Sex and race are random.|July 2012|July 19, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01646411||82314|
NCT01646671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A1305|Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients|A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension||Novartis|Yes|Completed|July 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Both|20 Years|N/A|No|||October 2015|October 2, 2015|July 18, 2012||No||No|July 8, 2015|https://clinicaltrials.gov/show/NCT01646671||82295|
NCT01647802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/EV-03|Cross-over Study of Three Modular Devices for Aid in Patient Standing and Transfer|Cross-over Study of Three Modular Devices for Aid in Patient Standing and Transfer|VTT|Centre Hospitalier Universitaire de Nīmes|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|6||Actual|30|||Both|75 Years|N/A|No|||March 2015|March 25, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647802||82229|
NCT01648348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01989|Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naïve Patients With Recurrent Glioblastoma Multiforme||National Cancer Institute (NCI)|Yes|Active, not recruiting|November 2012|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|128|||Both|18 Years|N/A|No|||November 2015|March 24, 2016|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648348||82187|
NCT01648452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120167|CNTF Implants for CNGB3 Achromatopsia|A Phase I/II Study of the NT-501 Intraocular Implant Releasing Ciliary Neurotrophic Factor (CNTF) in Participants With CNGB3 Achromatopsia|CNTF-CNGB3-1|National Institutes of Health Clinical Center (CC)|Yes|Active, not recruiting|July 2012|October 2015|Anticipated|March 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|July 20, 2012|Yes|Yes||No|January 9, 2014|https://clinicaltrials.gov/show/NCT01648452||82186|
NCT01648712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Necker|Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery|Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery||Hôpital Necker-Enfants Malades|Yes|Not yet recruiting|September 2012|March 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|74|||Both|N/A|5 Years|No|||August 2012|August 2, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648712||82166|
NCT01648725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/12|Hypnosis and Closed-Loop Anesthesia System|Influence of Hypnosis on the Propofol Requirement to Induce General Anesthesia|LoopHypnosis|Hopital Foch|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|97|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648725||82165|
NCT01644617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P07627|A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (P07627)|A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 Using an Environmental Exposure Chamber in Subjects With House Dust Induced Allergic Rhinitis/Rhinoconjunctivitis||Merck Sharp & Dohme Corp.|No|Completed|October 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|124|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644617||82435|
NCT01644929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOC.NSI.11.02|Rehabilitation Combined With Bihemispherictranscranial Direct Current Stimulation in Subacute Ischemic Stroke|Rehabilitation Combined With Bihemispherictranscranial Direct Current Stimulation in Subacute Ischemic Stroke to Increase Upper Limb Motor Recovery, a Randomised, Controlled, Double-blind Study|RECOMBINE|Ospedale Civico, Lugano|Yes|Recruiting|March 2013|October 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Anticipated|36|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644929||82411|
NCT01645215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-013-00CH1|Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors|Phase I Study of Safety and Pharmacokinetics of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors||Hutchison Medipharma Limited|Yes|Completed|January 2011|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||September 2013|September 29, 2013|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01645215||82389|
NCT01645566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS1330978|Task Focusing Strategy During a Simulated Cardiopulmonary Resuscitation|Impact of a Task Focusing Strategy on Perceived Stress Levels and Performance During a Simulated Cardiopulmonary Resuscitation: A Randomized Controlled Trial||University Hospital, Basel, Switzerland|No|Completed|December 2007|July 2008|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01645566||82369|
NCT01646242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP2012|Cold Snare Versus Double Biopsy Polypectomy Technique for Removal of Diminutive Colorectal Polyps|Cold Snare Versus Double Biopsy Polypectomy Technique for Removal of Diminutive Colorectal Polyps: a Prospective Randomized Trial||Kyunghee University Medical Center|Yes|Completed|July 2012|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|54|||Both|20 Years|N/A|No|||October 2014|October 13, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01646242||82327|
NCT01645943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/ 01595|Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities|Randomized Comparison Between Invasive and Conservative Strategies in Patients With Non-ST-segment Elevation Acute Coronary Syndrome and Comorbidities|MOSCA|University of Valencia|Yes|Completed|January 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|70 Years|N/A|No|||April 2014|March 27, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01645943||82350|
NCT01646489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPC3649-206|Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects|A Phase 1, Open-Label, Drug Interaction Study to Assess Safety, Tolerability, and Pharmacokinetics of Co-Administered Miravirsen and Telaprevir in Healthy Subjects||Santaris Pharma A/S|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 9, 2012|July 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01646489||82308|
NCT01647360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-699|Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment|A Post- Marketing, Prospective,Multicenter, Observational Program: Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment||Abbott|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|210|||Female|18 Years|45 Years|No|Probability Sample|Women with heavy menstrual bleeding|May 2013|May 27, 2013|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647360||82263|
NCT01647646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|97083|Real Life Effectiveness in Patients With Not Optimally Controlled Asthma|Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA||Far Eastern Memorial Hospital|Yes|Completed|March 2009|March 2012|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|80 Years|No|||July 2012|July 23, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647646||82241|
NCT01648205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IN-US-259-0128|Efficacy Study of Sodium Channel Blocker in LQT3 Patients|Ranolazine in LQT3 Patients||University of Rochester|Yes|Recruiting|September 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|21 Years|N/A|No|||December 2015|December 30, 2015|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648205||82198|
NCT01648595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Effect of Fentanyl|Effect of Fentanyl on Pain Severity and Duration of Labor|Principal Investigator||Mashhad University of Medical Sciences|Yes|Terminated|January 2006|September 2006||August 2006||Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2|||70|||Female|21 Years|37 Years||||January 2006|July 23, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01648595||82175|
NCT01649102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B04920108373|Impact of Catheter Design on Catheter Survival in Chronic Hemodialysis Patients|Impact of Catheter Design on Catheter Survival in Chronic Hemodialysis Patients||AZ Sint-Jan AV|Yes|Completed|March 2010|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|302|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01649102||82137|
NCT01614509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR-11-144|Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion|||Yeungnam University College of Medicine|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|30 Years|80 Years|No|||December 2012|December 3, 2012|June 5, 2012||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01614509||84738|The limitation of our study include short duration of follow up (6 months) and small populations of study enroll (45 patients)
NCT01614522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASLAN001-001|A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2|Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours Are Epidermal Growth Factor Receptor-2 (HER 2) Amplified or Co-expressing Epidermal Growth Factor Receptor-1 (HER-1) and HER-2.||Aslan Pharmaceuticals|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Both|21 Years|N/A|No|||January 2015|January 13, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01614522||84737|
NCT01615068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28257|An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)|An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study)).||Genentech, Inc.||Recruiting|June 2012|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Tissue and whole blood samples|Both|18 Years|N/A|No|Probability Sample|Patients with HER2 positive (HER2+) metastatic breast cancer|March 2016|March 1, 2016|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01615068||84695|
NCT01615367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K23MH091182-02|Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder|Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder|NEW Tx|Massachusetts General Hospital|Yes|Recruiting|May 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Female|18 Years|65 Years|No|||March 2016|March 15, 2016|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01615367||84673|
NCT01617057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P081235|Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis|Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis|OTOPHOS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|May 2012|July 2016|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|75 Years|No|||November 2015|December 8, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617057||84544|
NCT01617278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23474-P|I-Scan Versus High-definition White Light|A Randomized Controlled Trial Comparing High-definition White Light Colonoscopy to I-Scan Enhanced Colonoscopy for Adenoma Detection in a Population at Increased Risk of Colorectal Cancer. (A Pilot Study)||University of Calgary|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|150|||Both|18 Years|74 Years|Accepts Healthy Volunteers|||July 2013|July 3, 2013|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01617278||84527|
NCT01646684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230XDE04|Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer|Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer||Novartis|No|Active, not recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|N/A|No|||February 2016|February 28, 2016|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646684||82294|
NCT01646697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10110|Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery|Cytopathologic Margin Evaluation in Patients Undergoing Pancreatic Cancer Resection||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|November 2011|||June 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|80 Years|No|||July 2015|July 6, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646697||82293|
NCT01647243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20110181|Preoperative Strength Training in Patients With Total Knee Arthroplasty|Effect of Preoperative Strength Training on Postoperative Quadriceps Strength and Ability of Function in Patients With Total Knee Arthroplasty in Fast Track Regi||University of Aarhus|Yes|Recruiting|January 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||July 2012|July 20, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01647243||82272|
NCT01647256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VFCE-2011-004|Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions|Comparison of Nikkomycin Z Bioavailability After Single Dose Administration Under Fed (High Fat Meal) Compared to Fasting Conditions||University of Arizona|No|Terminated|July 2012|June 2013|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|5|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2013|September 16, 2013|July 16, 2012|Yes|Yes|Insufficient # subjects available for 2nd group; evaluating alternate study site|No||https://clinicaltrials.gov/show/NCT01647256||82271|
NCT01639547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-133|Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C|A Randomized, Open-lable, Multicenter, Parallel Group Study to Compare SVR Rate of Pegasys Plus Ribavirin for 48 Weeks vs. 36 Weeks in Patients With Chronic Hepatitis C||Chang Gung Memorial Hospital|No|Terminated|July 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|410|||Both|20 Years|70 Years|No|||July 2015|July 27, 2015|June 28, 2012||No|early termination due to difficult collection of patients|No||https://clinicaltrials.gov/show/NCT01639547||82820|
NCT01639833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVEUCV0140|A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery|A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery||Medtronic - MITG|Yes|Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||June 2014|June 3, 2014|July 11, 2012||No||No|June 3, 2014|https://clinicaltrials.gov/show/NCT01639833||82798|
NCT01649271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.134|Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.|Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab.||Boehringer Ingelheim||Active, not recruiting|July 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|13|||Both|18 Years|99 Years|No|||February 2016|February 26, 2016|July 23, 2012||||No||https://clinicaltrials.gov/show/NCT01649271||82124|
NCT01649284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1200.45|Afatinib Expanded Access Program|LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)||Boehringer Ingelheim||No longer available|July 2012|March 2014|Actual|March 2014|Actual|N/A|Expanded Access|N/A|||||||Both|18 Years|N/A|No|||March 2015|March 9, 2015|July 23, 2012||||||https://clinicaltrials.gov/show/NCT01649284||82123|
NCT01644630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0147|To Compare Cemented Versus Screw-retained Implant-supported Single Crowns With Customized Zirconia Abutments|A Randomized Controlled Clinical Trial Comparing Cemented Versus Screw-retained Implant-supported Single Crowns With Customized Zirconia Abutments||University of Zurich|No|Active, not recruiting|June 2012|||December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|34|||Both|18 Years|80 Years|No|||December 2015|December 1, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01644630||82434|
NCT01644942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8193|Identification in Obese Patients of the Mechanism Involved in Intramuscular Lipid Accumulation|Identification in Obese Patients of the Mechanisms Involved in Intramuscular Lipid Accumulation.||University Hospital, Montpellier|No|Completed|May 2008|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|33|||Male|40 Years|70 Years|No|||June 2013|June 17, 2013|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644942||82410|
NCT01645228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGH-P100133|Could Non-invasive Biochemical, Image or Physiological Index Predict Significant Coronary Arterial Stenosis in Symptomatic Adults?|Could Non-invasive Biochemical, Image or Physiological Index Predict Significant Coronary Arterial Stenosis in Symptomatic Adults?||Cathay General Hospital|Yes|Recruiting|August 2012|July 2013|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|120|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|population for a general health check-up|August 2012|August 14, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645228||82388|
NCT01645956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400012|Consistency in Individual Differences in Energy Intake Following Acute Exercise|Consistency in Individual Differences in Energy Intake Following Acute Exercise||The Miriam Hospital|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|28|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Relatively sedentary (exercising less than 60 minutes/week over the past 6 months)        overweight and obese (BMI: 25.0 to <35.0 kg/m2) women between the ages of 18 and 45.|July 2012|February 18, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645956||82349|
NCT01646255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1037|Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa||UCB Pharma|No|Completed|July 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|346|||Both|30 Years|N/A|No|||January 2016|January 29, 2016|July 18, 2012||No||No|October 8, 2015|https://clinicaltrials.gov/show/NCT01646255||82326|
NCT01646515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1102-063-352|Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure||ULTIMATE-SHF|Seoul National University Hospital|Yes|Terminated|December 2011|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|41|||Both|18 Years|90 Years|No|||April 2014|April 22, 2014|June 13, 2012||No|Substantial benefit was observed in the active treatment group|No||https://clinicaltrials.gov/show/NCT01646515||82306|
NCT01646502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00862|Treatment of Chronic Wound Biofilms|Treatment of Chronic Wound Staphylococcus Aureus Biofilms With Staphylococcus Epidermidis Esp Protein to Promote Healing||University of British Columbia|No|Withdrawn|July 2014|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|19 Years|N/A|No|||October 2014|October 3, 2014|July 18, 2012||No|Project was discontinued. Ran into difficulties with purification at the protein production    stage|No||https://clinicaltrials.gov/show/NCT01646502||82307|
NCT01646840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1701010|Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation|a Phase 1, Open-Label, Single Dose, Relative Bioavailability Study In Healthy Volunteers Comparing PF-04958242 Capsule Formulation To PF-04958242 Oral Solution In The Fasted State||Pfizer|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01646840||82282|
NCT01647932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEMI-IC-CLOR|Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure|Safety and Efficacy of the Combination of Loop Diuretics With Thiazide-type Diuretics in Patients With Decompensated Heart Failure: a Double-blind, Randomized, Placebo-controlled Trial (CLOROTIC Trial).|CLOROTIC|Spanish Society of Internal Medicine|No|Recruiting|October 2014|January 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01647932||82219|
NCT01649128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrePark|Screening for Preeclampsia With Various Markers in Low-risk Pregnancy Populations|Screening Models for Early Detection of Late-onset Preeclampsia With Various Markers in Low-risk Pregnancy Populations||CHA University|Yes|Completed|August 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|262|||Female|20 Years|39 Years|No|Probability Sample|low risk women who had not a risk factor of preeclampsia.|July 2012|July 24, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01649128||82135|
NCT01618097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032794|Evaluation of DVD and Internet Decision Aids for Hip and Knee Osteoarthritis: Focus on Health Literacy|Evaluation of DVD and Internet Decision Aids for Hip and Knee Osteoarthritis: Focus on Health Literacy||Duke University|No|Completed|January 2012|January 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|155|||Both|18 Years|N/A|No|||March 2015|March 4, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01618097||84464|
NCT01614561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-LT-CRE-2010/01|An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon|CEPHEUS Centralized Pan-Levant Survey on the Undertreatment of Hypercholesterolemia NIS-LT-CRE-2010/01 Version 1.0|CEPHEUS|AstraZeneca|No|Completed|August 2010|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|1000|None Retained|Blood specimens, serum, non-retained|Both|18 Years|N/A|No|Probability Sample|Patients attending out patient clinics in Jordan and Lebanon|June 2012|June 6, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01614561||84734|
NCT01616186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC# 12521|Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)|A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)||University of California, San Francisco|Yes|Withdrawn|July 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||April 2013|April 4, 2013|June 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01616186||84610|
NCT01616797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-24813|A Novel Neurobehavioral Intervention for Emotion Regulation in Anxiety and Depression Across the Lifespan|A Novel Neurobehavioral Intervention for Emotion Regulation in Anxiety and Depression||Stanford University|No|Recruiting|February 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|60 Years|No|||July 2015|July 15, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01616797||84564|
NCT01613989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/07|Total Hip Prosthesis Assisted by Computer|Total Hip Prosthesis Assisted by Computer Based on Pre-operative EOS Imaging|NAVEOS|University Hospital, Bordeaux|No|Active, not recruiting|June 2012|November 2014|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|78|||Both|40 Years|90 Years|No|||August 2014|August 20, 2014|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01613989||84778|
NCT01638988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-12-17|Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin|Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome (PCOS) and a Resistance to Insulin. Randomised Controlled Study||OVO R & D|No|Withdrawn|September 2013|December 2015|Anticipated|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|35 Years|No|||July 2015|July 24, 2015|July 9, 2012||No|Previous studies have been done regarding same condition|No||https://clinicaltrials.gov/show/NCT01638988||82863|
NCT01639001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A8081029|A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients|Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus||Pfizer|Yes|Active, not recruiting|September 2012|July 2017|Anticipated|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||March 2016|March 10, 2016|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639001||82862|
NCT01639261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN_BOSZT_01|A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT|Eine Phase II Studie über Interferon Gamma 1b Zur Behandlung Der steroidrefraktären Bronchiolitis Obliterans Nach Allogener SZT|IFN_BOSZT_01|University Hospital Regensburg|No|Active, not recruiting|July 2012|September 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01639261||82842|
NCT01648075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Universidad de Chile|Effect of the Consumption of Probiotics in the Reduction of Incidence of Carious Lesions in Preschool Children|Effect of the Consumption of Probiotics Lactobacilli Enriched Milk in the Reduction of Incidence of Carious Lesions in Preschool Children|Probiotics|University of Chile|No|Completed|July 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|261|||Both|2 Years|3 Years|No|||January 2014|January 20, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01648075||82208|
NCT01648088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|569-11-EP|Detection of Staph Colonization in Pre-op Arthroplasty Patients|Enhanced Detection of Staphylococcus Aureus Colonization in Patients Undergoing Prosthetic Joint Implantation.|Staph|University of Nebraska|No|Completed|September 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|234|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All patients undergoing prosthetic joint implantation.|March 2015|March 18, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01648088||82207|
NCT01644643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4280C00006|Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens|An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens||AstraZeneca||Completed|January 2013|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|345|||Both|18 Years|90 Years|No|||November 2015|November 10, 2015|June 28, 2012|Yes|Yes||No|September 28, 2015|https://clinicaltrials.gov/show/NCT01644643||82433|
NCT01644955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10151|Carboplatin in Treating Patients With Recurrent High-Grade Gliomas|Intracerebral Convection Enhanced Delivery of Carboplatin for Treatment of Recurrent High-grade Gliomas||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2012|||December 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|70 Years|No|||March 2016|March 17, 2016|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644955||82409|
NCT01645969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25647|A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265|A Follow-up Study to Evaluate the One-year Post Treatment Effects of Peginterferon Alfa-2a (PEGASYS) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study ML 22265||Hoffmann-La Roche||Completed|April 2011|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|65|||Both|18 Years|N/A|No|Probability Sample|Patients who received treatment and completed follow-up in study arm "A" of study ML22265|March 2016|March 1, 2016|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645969||82348|
NCT01646281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39854.068.12|Vernakalant Versus Flecainide: Atrial Contractility|Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation||Maastricht University Medical Center|Yes|Not yet recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|70|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646281||82324|
NCT01647373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0125-12|Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling|Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling.||Meir Medical Center|No|Not yet recruiting|July 2013|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|18 Years|90 Years|No|Non-Probability Sample|Patients at least 6 months after succesful retinal detachment surgery, with silicone        sponge scleral buckling, currently attached, and with IOL Master pre-surgery Axial Length        measurement .|July 2012|June 11, 2013|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647373||82262|
NCT01647659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115892|Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation|An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|15|||Both|18 Years|N/A|No|||December 2012|December 6, 2012|July 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01647659||82240|
NCT01647945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAH-70522|FK506 (Tacrolimus) in Pulmonary Arterial Hypertension|Single-Center Randomized Controlled Phase II Study of Safety and Efficacy of FK-506 (Tacrolimus) in Pulmonary Arterial Hypertension|TransformPAH|Stanford University|Yes|Terminated|July 2012|August 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|23|||Both|18 Years|70 Years|No|||January 2015|January 5, 2015|July 18, 2012|Yes|Yes|Prematurely stopped due to limited funding/slow patient recruitment in single academic center.    Follow-up multicenter phase IIb efficacy trial is planned.|No||https://clinicaltrials.gov/show/NCT01647945||82218|
NCT01648829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|449/2012/D|PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity|Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial|PORTO|University of Roma La Sapienza|No|Not yet recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|100|||Both|18 Years|80 Years|No|||March 2013|March 6, 2013|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01648829||82157|
NCT01648842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM10113|Vitamin D and Preeclampsia|Vitamin D Status in Pregnant Women With Preeclampsia|FEPED|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|April 2012|February 2016|Anticipated|December 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|3174|||Female|18 Years|N/A|No|Non-Probability Sample|Teh vitamin D status will be measured in a large population of french pregnant women (in        the first trimester) in order to evaluate the importance of the vitamin D deficency in        France and correlate this deficiency with preeclampsia|December 2015|December 15, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648842||82156|
NCT01649141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM57145|Trauma-Focused Cognitive Behavior Therapy for Youth: Effectiveness in a Community Setting|National Child Traumatic Stress Initiative: Community Treatment and Service Centers||Delaware Division of Prevention and Behavioral Health Services|No|Active, not recruiting|August 2006|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|110|||Both|7 Years|17 Years|No|||July 2012|July 20, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01649141||82134|
NCT01649453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10043P|A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test|A Prospective Study of Clinical Outcomes for the Pathwork® Tissue of Origin Test||Cedar Associates LLC|No|Terminated|May 2012|February 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|19|Samples With DNA|Tissue biopsy specimen.|Both|18 Years|N/A|No|Non-Probability Sample|Community and academic clinics|March 2013|March 4, 2013|July 23, 2012||No|Terminated by sponsor.|No||https://clinicaltrials.gov/show/NCT01649453||82112|
NCT01614262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0899|Examining The Role of CGM in T2DM|Examining the Role of Continuous Glucose Monitoring (CGM) in Non-Insulin Treated Type 2 Diabetes||University of North Carolina, Chapel Hill|No|Active, not recruiting|June 2012|December 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|70 Years|No|||July 2015|August 13, 2015|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01614262||84757|
NCT01614275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|059-11|Using Web-based Technology to Expand and Enhance Applied Behavioral Analysis Programs for Children With Autism in Military Families|Using Technology to Expand and Enhance Applied Behavioral Analysis Programs for Children With Autism in Military Families||University of Nebraska|No|Recruiting|May 2012|July 2015|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|50|||Both|18 Months|48 Months|No|||June 2012|June 14, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01614275||84756|
NCT01615393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28199|A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers|Prospective, Randomized, Single-blind, Cross-over, Comparative Study for Establishing Comparative Bioavailability of Copegus vs Vilona® in Healthy Volunteers||Hoffmann-La Roche||Completed|June 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615393||84671|
NCT01616810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB 04-227C|Lower Urinary Tract Symptoms Screening Questionnaire|Lower Urinary Tract Symptoms Screening Questionnaire Validation STudy|LUTS-2|St. Michael's Hospital, Toronto|No|Completed|January 2007|December 2011|Actual|October 2007|Actual|N/A|Observational|N/A||1|Actual|300|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants, 18 years of age and older with any gynecological symptoms other than        lower urinary tract symptoms or pelvic floor dysfunction|June 2012|June 8, 2012|August 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01616810||84563|
NCT01616823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB File # 10-232|Fetal HIV Transmission Risk and Duration of Membrane Rupture|Duration of Rupture of Membranes and Risk of Fetal Transmission of HIV in Optimally Managed HIV Positive Mothers||St. Michael's Hospital, Toronto|No|Completed|January 2009|December 2010|Actual|December 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|210|||Female|N/A|N/A|No|Probability Sample|Total of 210 women from two downtown Toronto, Ontario academic-affiliated hospitals|September 2011|June 8, 2012|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01616823||84562|
NCT01623102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WJP001|Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer|An Open-label Randomized Phase II Trial of Gemcitabine and Cisplatin With or Without Bevacizumab in EGFR Wild-type Non-squamous Non-small-cell Lung Cancer Patients||Sichuan Cancer Hospital and Research Institute|No|Recruiting|February 2013|December 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|70 Years|No|||February 2013|February 11, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623102||84082|
NCT01647269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 11/0226|A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome|A Randomised, Controlled, Crossover Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Severe Tourette Syndrome||University College, London|Yes|Completed|July 2011|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|20 Years|N/A|No|||March 2015|March 18, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01647269||82270|
NCT01647529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R733/17/2010|Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis|Intra-cameral Penetration of Ganciclovir Following Topical Administration of 0.15% Ganciclovir Gel (VIRGAN©) for CMV Anterior Uveitis / Endotheliitis|Virgan|Singapore National Eye Centre|Yes|Completed|July 2012|July 2014|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|21 Years|99 Years|No|||November 2015|November 16, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647529||82250|
NCT01647815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/PJ-02|Ultrasound Comparison of the Surface of the Subclavian and the Axillary Vein Versus the Surface of the Subclavian Vein|Ultrasound Comparison of the Surface of the Subclavian Vein (Arm in Abduction (90°) and External Rotation (90 °)) and the Surface of the Axillary Vein (Arms Along the Body) Versus the Surface of the Subclavian Vein (Arm Along the Body)|AnatoAbord|Centre Hospitalier Universitaire de Nīmes|No|Completed|August 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|50|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647815||82228|
NCT01647828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|59R5-002|A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer|A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer|ALPINE|OncoMed Pharmaceuticals, Inc.|Yes|Active, not recruiting|October 2012|September 2016|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|154|||Both|18 Years|90 Years|No|||March 2016|March 7, 2016|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647828||82227|
NCT01648465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 67/12|Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors|Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.||Hellenic Cooperative Oncology Group|No|Recruiting|July 2012|April 2017|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||September 2015|February 11, 2016|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01648465||82185|
NCT01648478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.705|IRAPs (Secreted Insulin Regulated AminoPeptidase): a New Insulin Sensitivity Biomarker|Evaluation of Plasma IRAP Secreted Protein as a New Insulin Sensitivity Biomarker, Using Hyperinsulinemic Euglycemic Clamp|IRAP|Hospices Civils de Lyon|No|Completed|June 2012|September 2012|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|21|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2014|September 10, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01648478||82184|
NCT01645241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEX005|Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation|Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation||Institut Universitari Dexeus|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||March 2013|October 24, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645241||82387|
NCT01645709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-201|Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee|CS-201: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intra-Articular Verapamil in the Treatment of JoinT Pain in Subjects With Osteoarthritis of the Knee||Calosyn Pharma, Inc.|No|Terminated|April 2012|||February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|81|||Both|35 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 26, 2014|July 17, 2012|Yes|Yes|Sponsor decision to terminate study|No|August 26, 2014|https://clinicaltrials.gov/show/NCT01645709||82367|
NCT01645696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDT-11-CGM002|Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics|Three-day, In-clinic, Clamp Evaluation of the BD 2nd Generation Continuous Glucose Sensor in Subjects With Type 1 Diabetes||Becton, Dickinson and Company|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|65 Years|No|||April 2013|April 19, 2013|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01645696||82368|
NCT01646853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSNT0415|Radiation Dose Study of Concurrent Chemoradiotherapy With Cisplatin Plus Fluorouracil in Oesophageal Cancer|||Simcere Pharmaceutical Co., Ltd||Not yet recruiting|August 2012|||December 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|1||Anticipated|500|||Both|18 Years|N/A|No|||July 2012|July 18, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01646853||82281|
NCT01647386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEP_MBT|Pilot Study Using Radiostereometric Analysis (RSA) to Evaluate the Fixation of the Tibial Components in the DePuy M.B.T. Revision Knee System|Pilot Study Using Radiostereometric Analysis (RSA) to Evaluate the Fixation of the Tibial Components in the DePuy M.B.T. Revision Knee System||Nova Scotia Health Authority|No|Active, not recruiting|September 2013|January 2017|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|||Both|N/A|N/A|No|Non-Probability Sample|Failed primary TKR|October 2015|October 7, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647386||82261|
NCT01647672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aesa|Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer|A Study to Assess the Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in the Treatment of Operable Breast Cancer||Tianjin Medical University|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|N/A|N/A|No|||July 2012|July 24, 2012|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647672||82239|
NCT01648621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEGH001 PIC COPD|Program of Integrated Care for Patients With Chronic Obstructive Pulmonary Disease and Multiple Comorbidities|Program of Integrated Care for Patients With Chronic Obstructive Pulmonary Disease and Multiple Comorbidities: A Randomized Controlled Trial|PICCOPD+|Toronto East General Hospital|Yes|Recruiting|August 2012|||April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|470|||Both|50 Years|N/A|No|||June 2015|June 10, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01648621||82173|
NCT01648855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI 11030|Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn|Consequences of Circulating Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn|ANGIODYS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|June 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|33|||Both|18 Years|N/A|No|Probability Sample|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age        from mother with preeclampsia|April 2015|April 20, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648855||82155|
NCT01649479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-I/2012/FC-01|Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome|Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome|MENT-APL-O|Centre Hospitalier Universitaire de Nīmes|No|Terminated|April 2013|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|20|||Female|18 Years|45 Years|No|||March 2015|March 24, 2015|July 23, 2012||No|Impossible to include patients at a correct rate; patients don't want to come back so they    refuse participation.|No||https://clinicaltrials.gov/show/NCT01649479||82110|
NCT01649492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54465|In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice|In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|September 2012|October 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 20, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649492||82109|
NCT01615094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5 R01 HL073355-06|Cardiac Health, Mood, & Neuroimmune Activation|BNP and Neuroimmune Characteristics of CHF and Depression (Competing Renewal)||University of California, San Diego|No|Completed|January 2011|February 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|456|Samples With DNA|blood|Both|18 Years|N/A|No|Non-Probability Sample|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B        patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml|March 2015|March 17, 2015|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01615094||84693|
NCT01622842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-076|Bioimpedance and Arterial Distension|Bioimpedance of Human Tissue of the Upper Arm and Arterial Distension|SenseC1|Sense A/S|No|Completed|September 2011|December 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|16|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Equal number of females and males. Large variations of BMI Large variations of BP|June 2012|June 21, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01622842||84101|
NCT01617863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-Med2-EM-2012|Hemodynamics During the Soccer Championship 2012|Central Hemodynamics, Arterial Stiffness, Heartrate and Endothelial Dysfunktion During the European Soccer Championship 2012||University of Schleswig-Holstein|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|180|Samples Without DNA|EDTA-Blood, Serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|primary care clinic, clinical employees, students|June 2012|July 2, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01617863||84482|
NCT01618136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7449-E044-101|An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors|An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors||Eisai Inc.|No|Active, not recruiting|January 2012|||November 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|41|||Both|18 Years|N/A|No|||November 2015|November 6, 2015|May 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618136||84461|
NCT01647282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314-12-FB|Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients|Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients||University of Nebraska|No|Active, not recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|85 Years|No|||December 2015|December 3, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647282||82269|
NCT01647295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-60|Social Interactions: Ocular Explorations and Pupillometry in Autism|Social Interactions: Ocular Explorations and Pupillometry in Autism|ISEOP|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|February 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|150|||Both|3 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Autistic children from the University Hospital of Tours Healthy children from the normal        population|February 2016|February 24, 2016|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647295||82268|
NCT01647542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-875_307|Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg Compared With Placebo in Asia Pacific Subjects With Type 2 Diabetes|GRAND-307|Takeda|Yes|Terminated|October 2012|March 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|393|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|July 19, 2012||No|Due to potential concerns about liver safety (See Detailed Description)|No|July 22, 2015|https://clinicaltrials.gov/show/NCT01647542||82249|
NCT01647555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESPACE|Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer|Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.||Centre Oscar Lambret|No|Active, not recruiting|November 2006|December 2014|Anticipated|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with epidermoid head and neck cancer locally advanced|August 2014|August 22, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647555||82248|
NCT01647841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 1111002615|Maternal Determinants of HIV-exposed and HIV-unexposed Fetal Growth, Birth Outcomes and Early Infant Growth|||Cornell University|No|Completed|April 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|218|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|HIV+ and HIV- women and their infants attending a semi-rural clinic and/or rural        dispensaries for their antenatal and early infancy care in north western Tanzania|September 2013|September 26, 2013|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01647841||82226|
NCT01648101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114855|Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.||GlaxoSmithKline|No|Terminated|August 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|76|||Both|18 Years|N/A|No|||December 2014|August 6, 2015|June 28, 2012||No|Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam|No|August 14, 2014|https://clinicaltrials.gov/show/NCT01648101||82206|RTG114855 was designed for registration of retigabine as add-on treatment of drug-resistant POS in South Korea/Taiwan/ Vietnam. GSK decided not to pursue registration in these countries and terminated the study early based on new safety information.
NCT01648998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-12|Fludrocortisone and Information Processing in Healthy Volunteers|The Effects of Fludrocortisone on Information Processing in Healthy Female Volunteers||Leiden University Medical Center|No|Completed|May 2012|December 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2014|February 23, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01648998||82144|
NCT01635998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1465|Adjunctive Renal Denervation to Modify Hypertension and Sympathetic Tone as Upstream Therapy in the Treatment of Atrial Fibrillation|Adjunctive Renal Denervation to Modify Hypertension and Sympathetic Tone as Upstream Therapy in the Treatment of Atrial Fibrillation|H-FIB|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|September 2012|September 2021|Anticipated|September 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|85 Years|No|||November 2015|November 30, 2015|July 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01635998||83093|
NCT01636778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116101|Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients|Non-randomised, Open Label, Multi-centre Phase II Study to Assess the Efficacy and Safety of SB-497115-GR in Thrombocytopenic Subjects With Chronic Hepatitis C and Compensated Liver Cirrhosis.||GlaxoSmithKline|No|Completed|July 2012|November 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|20 Years|74 Years|No|||September 2015|February 1, 2016|July 5, 2012||No||No|January 22, 2015|https://clinicaltrials.gov/show/NCT01636778||83033|
NCT01636791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GVC CBT vs RTW|CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care|Cognitive Behavior Therapy Versus a Return to Work Intervention for Sick-listed Patients With Common Mental Illness in Primary Care: a Randomized Clinical Trial|CBT vs RTW I|Karolinska Institutet|No|Completed|September 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|211|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636791||83032|
NCT01637935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-03-TL-OPI-524|Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes|Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes||Takeda|No|Completed|July 2004|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|193099|||Both|40 Years|N/A|No|Probability Sample|The study was conducted within Kaiser Permanente Northern California (KPNC), which        provides comprehensive healthcare services to approximately 3.2 million members. The        source population was identified from the KPNC diabetes registry, which was first        constructed in 1993 and has been updated annually since then. The registry identifies        patients primarily from four data sources: primary hospital discharge diagnoses of        diabetes mellitus (since 1971); two or more outpatient visit diagnoses of diabetes (since        1995); any prescription for a diabetes-related medication (since 1994); or any record of        an abnormal hemoglobin A1c (HbA1c) test (>6.7%) (since 1991).        The diabetes registry gathers data from a variety of KPNC electronic medical records (EMR)        to build and follow the registry cohort across time. These data include cancer registries,        pharmacy records, laboratory records, and inpatient and outpatient medical diagnoses.|December 2015|December 9, 2015|July 7, 2012||No||No|August 31, 2012|https://clinicaltrials.gov/show/NCT01637935||82944|
NCT01637688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Si262/2012|Growth and Plasma Amino Acids in Infants With CMPA and Treated With a Newly Innovated Amino Acid Formula|Growth and Plasma Amino Acid Levels in Infants With Cow's Milk Protein Allergy and Treated With a Newly Innovated Amino Acid Formula Compared to a Commercial Amino Acid Formula||Mahidol University|Yes|Recruiting|April 2013|||March 2016|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|74|||Both|N/A|6 Months|Accepts Healthy Volunteers|Non-Probability Sample|-  population who are diagnosed cow's milk protein allergy via a double-blind             placebo-controlled food challenge and consume either a newly innovated amino acid             formula or a commercial amino acid formula          -  population from a well-baby clinic|April 2015|April 30, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01637688||82963|
NCT01637701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PkEP-TURP-2004|Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate|Comparison of Pasmakinetic Enucleation of the Prostate With Bipolar Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hypertrophy Patients With Large Prostate||Fuzhou General Hospital|Yes|Completed|June 2004|December 2011|Actual|December 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Male|50 Years|70 Years|No|||July 2012|July 7, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01637701||82962|
NCT01637922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.57|Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone|Effect of Multiple Dosing With BI 201335 on the Safety, Pharmacokinetics and Pharmacodynamics of Steady-state Methadone and Buprenorphine/Naloxone in Subjects on Stable Addiction Management Therapy||Boehringer Ingelheim||Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|64 Years|No|||July 2015|July 3, 2015|July 9, 2012||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01637922||82945|
NCT01638182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3-018|Biocomparison Study|Comparison of Effects of Nutritional Doses Vitamin K1 and K2 on Carboxylation||Maastricht University Medical Center|No|Completed|March 2011|September 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|81|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638182||82925|
NCT01639092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC2012-1215|Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B|A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment|IN-US-0202|Asan Medical Center|Yes|Active, not recruiting|September 2012|June 2018|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|20 Years|75 Years|No|||June 2015|June 24, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639092||82855|
NCT01639105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/395|10 600 nm Ablative Fractional Laser Treatment of Scars: a Prospective Single Blinded Within Patient Controlled Randomized Trial|10 600 nm Ablative Fractional Laser Treatment of Scars: a Prospective Single Blinded Within Patient Controlled Randomized Trial||University Hospital, Ghent|No|Recruiting|February 2013|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639105||82854|
NCT01639118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SITUP-2012|Prospective Study Of A Size Tailored Approach To Repair Umbilical And Epigastric Primary Ventral Hernias|Prospective Observational Cohort Study Of A Size Tailored Approach To Repair Umbilical And Epigastric Primary Ventral Hernias|SITUP|Algemeen Ziekenhuis Maria Middelares|No|Terminated|March 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|11|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|community sample|November 2012|November 18, 2012|July 10, 2012||No|Perception of an increased incidence of C-Qur V-patch mesh infection, with need for removal,    compared to other meshes used for umbilical hernia repair.|No||https://clinicaltrials.gov/show/NCT01639118||82853|
NCT01639131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1214|Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma|A Multi-institutional Open Label, Trial Evaluating the Efficacy of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma With Methylated CHFR and/or Microsatellite Instability Phenotype||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2012|||August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639131||82852|
NCT01639924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120154|Evaluation of People With Gastrointestinal Disease|Evaluation of Patients With Gastrointestinal Disease||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|999999|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01639924||82791|
NCT01649505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6606|Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction|Intraoperative Use of Fibrin Glue Sealant Combined With Sharp Dissection Technique as a Preventative Measure for Seromas||OHSU Knight Cancer Institute|Yes|Terminated|January 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2|||Female|18 Years|N/A|No|||March 2013|March 13, 2013|July 20, 2012|Yes|Yes|Low patient enrollment and no clinical findings.|No|February 11, 2013|https://clinicaltrials.gov/show/NCT01649505||82108|Early termination due to low accrual; no participants were analyzed.
NCT01645124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FARM6YNXAN|Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)|A Large-scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events In Patients With Polycythemia Vera (PV)|CYTO-PV|Consorzio Mario Negri Sud|No|Terminated|May 2008|July 2012|Anticipated|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|365|||Both|18 Years|N/A|No|||May 2012|July 19, 2012|July 17, 2012||No|Low accrual rate not allowing planned sample size leads to a futility condition|No||https://clinicaltrials.gov/show/NCT01645124||82396|
NCT01645111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00261|An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion|An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion||Nationwide Children's Hospital|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|N/A|No|||February 2015|February 3, 2015|June 8, 2012||No||No|February 3, 2015|https://clinicaltrials.gov/show/NCT01645111||82397|
NCT01645384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01621/09-10|Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions|An Open-label, Randomized, Single Oral Dose, Two Way Crossover Bioequivalence Study of Atorvastatin Ca 40 mg Tablets of Dr.Reddy's With Lipitor® 40 mg Tablets of Pfizer in 74 Healthy, Adult, Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|May 2009|July 2009|Actual|June 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|69|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01645384||82376|
NCT01645839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEPOSEIN-1008|Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer (DEPOSEIN).|Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer. Randomized Phase III Study.|DEPOSEIN|Centre Oscar Lambret|Yes|Recruiting|August 2011|July 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|144|||Female|18 Years|N/A|No|||May 2015|May 27, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01645839||82358|
NCT01645852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMS 12052|A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection|A Randomized Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|June 2012|December 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Anticipated|114|||Both|18 Years|N/A|No|||August 2015|February 25, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01645852||82357|
NCT01637571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102718|Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain|The Effect of Dexilant Treatment on Esophageal Hypersensitivity in GERD Related Non Cardiac Chest Pain Patients|Dexilant|University of Iowa||Withdrawn||||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||July 2012|July 10, 2012|December 6, 2011|Yes|Yes|Sponsor could not fund|No||https://clinicaltrials.gov/show/NCT01637571||82972|
NCT01642264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL083540|Web-Based Respiratory Education About Tobacco and Health Phase II|Web-Based Respiratory Education About Tobacco and Health (WeBREATHe) Phase II|WeBREATHe II|Oregon Research Institute|No|Completed|March 2008|December 2010|Actual|November 2010|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|217|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642264||82614|
NCT01642550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RM-131-005|Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa|A Phase 2, Investigator-Initiated, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa||Rhythm Pharmaceuticals, Inc.|Yes|Completed|November 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Female|18 Years|45 Years|No|||January 2016|January 4, 2016|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642550||82593|
NCT01643057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMD-CS-0015|Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health|Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health||Wyss Institute at Harvard University|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|36|||Both|N/A|N/A|No|Non-Probability Sample|Infants currently inpatient in the Neonatal Intensive Care Unit at Beth Israel Deaconess        Medical Center.|September 2015|September 9, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01643057||82554|
NCT01636518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13117|Hybrid AF -- A Prospective Registry|Hybrid Procedure for the Treatment of Long Standing Persistent Atrial Fibrillation - A Prospective Registry||University of Kansas Medical Center|No|Withdrawn|July 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing standard of care procedures to treat Atrial Fibrillation at the        University of Kansas Hospital|April 2015|April 20, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636518||83053|
NCT01637714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probiotics for IBS|The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome|The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome: Double-blind, Randomized, Placebo-controlled Trial||Seoul National University Hospital||Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 17, 2013|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01637714||82961|
NCT01637948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKCTR-1145|Controlled Clinical Trial of Traditional Chinese Medicine Mouthrinse|Controlled Clinical Trial of Traditional Chinese Medicine Mouthrinse In Improving Oral Health in Orthodontic Patients||The University of Hong Kong|No|Completed|October 2010|January 2012|Actual|May 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|90|||Both|13 Years|35 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|January 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01637948||82943|
NCT01638494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|56/09|Calcium and Vitamin D Intakes in Children|||Federico II University|No|Completed|December 2008|February 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|184|||Both|3 Years|17 Years|No|||July 2012|July 9, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01638494||82901|
NCT01638507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP 126|An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System|Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm|RI-US|Medtronic Vascular|No|Completed|July 2012|June 2015|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|230|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|July 9, 2012|Yes|Yes||No|October 23, 2015|https://clinicaltrials.gov/show/NCT01638507||82900|
NCT01638806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NONSTEMI|Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction|Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction (NON-ST-Elevation Myocardial Infarction=NONSTEMI Trial)|NONSTEMI|Aarhus University Hospital Skejby|Yes|Recruiting|June 2012|June 2022|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|4500|||Both|18 Years|80 Years|No|||December 2015|December 17, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01638806||82877|
NCT01639079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REDES-EPS-LAT-SMK-5|Comparison of Internet Stop Smoking Intervention to Usual Care on Smoking Cessation at 6 Months|Smoking Cessation Through the Web: Latino Smokers Follow-Up Study|TC5Redes|University of California, San Francisco|No|Recruiting|June 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10000|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639079||82856|
NCT01639352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100650|Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma|Phase II Trial of SOM230 (Pasireotide LAR) in Patients With Unresectable Hepatocellular Carcinoma (HCC)||University of Miami|Yes|Active, not recruiting|July 2012|||December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639352||82835|
NCT01638845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/072/HP|Hip Fracture and Perineural Catheter|||University Hospital, Rouen|No|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|314|||Both|60 Years|N/A|No|||July 2015|July 29, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01638845||82874|
NCT01639430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSMC-tempger-1|Diagnostic Accuracy of Body Temperature Measurement in Geriatric Patients|Diagnostic Accuracy of Body Temperature Measurement in Geriatric Patients Presenting to the Emergency Department||Klinikum Nürnberg||Completed|May 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|427|||Both|75 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Consecutive patients >= 75 years presenting to the emergency department of an urban        university-affiliated hospital (80.000 attendees per year).|July 2012|July 11, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639430||82829|
NCT01639716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NG63900|Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers|Aggressive Non-Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers||Guler, Nil, M.D.|Yes|Completed|May 2011|June 2012|Actual|May 2012|Actual|N/A|Observational|N/A||7|Actual|58|Samples Without DNA|periperal blood sample|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|31 newly diagnosed non hodgkin lymphoma and 27 healthy controls. We studied IL-10 and IL-4        in lymphoma group and healthy group and observed patients till end of study. We analised        survival. We compared with IL-4 and IL-10 levels with prognostic factors.|July 2012|July 12, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01639716||82807|
NCT01639664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6233|COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2|COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of High Doses CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU|COMPACT-2|Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva|Yes|Recruiting|September 2013|December 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|14 Years|N/A|No|||September 2015|September 18, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01639664||82811|
NCT01639677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOK-2|Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity|Randomized Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity|LOK|Göteborg University|No|Completed|April 2000|August 2010|Actual|April 2001|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|20 Years|60 Years|No|||July 2012|July 10, 2012|September 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01639677||82810|
NCT01644825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MITO-11|Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer|MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer|MITO-11|National Cancer Institute, Naples|No|Active, not recruiting|December 2010|December 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|72|||Female|18 Years|75 Years|No|||October 2015|October 28, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644825||82419|
NCT01645423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-VIN-105|Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2009|September 2009|Actual|September 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|77|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01645423||82373|
NCT01645891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC02-2012-01|A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers|TCO2-2012-01 A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers||Electrochemical Oxygen Concepts, Inc.|No|Recruiting|April 2012|May 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|30 Years|90 Years|No|||August 2013|August 9, 2013|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645891||82354|
NCT01638091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSR-10-1167|Practice-Based Learning to Predict Polyp Histology at Colonoscopy|Practice-Based Learning to Predict Polyp Histology at Colonoscopy: A Demonstration Project in Community Practice||Stanford University|No|Completed|March 2011|||March 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|14|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 10, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01638091||82932|
NCT01645397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R10-06-013|Exhaled Nitric Oxide and Airway Caliber in Children With Asthma|Exhaled Nitric Oxide and Airway Caliber in Children With Asthma||Atlantic Health System|No|Completed|June 2011|August 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|6 Years|N/A|No|Non-Probability Sample|Children, six years of age or older, with asthma attending asthma clinic|January 2014|January 15, 2014|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01645397||82375|
NCT01645865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPC441|Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost|Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost||Elizabeth Glaser Pediatric AIDS Foundation|No|Completed|May 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|600|||Both|N/A|N/A|No|Non-Probability Sample|Potential participants are recruited from participating study sites.|November 2014|November 12, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645865||82356|
NCT01646424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-RTR-XXX-2012/1|Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)|Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination DPI in COPD||AstraZeneca|No|Completed|August 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|446|||Both|40 Years|N/A|No|Non-Probability Sample|Patients of both sexes ≥ 40 years of age, diagnosed with COPD (according to ICD-10        criteria) and receiving budesonide/formoterol fix dose combination treatment by means of        inhaler devices. The first prescription must be given at least 3 months prior to the study        start and patient inclusion.|October 2012|October 15, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01646424||82313|
NCT01641731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOTI_CMA_HULP|Specific Oral Tolerance Induction in Children Allergic to Cow's Milk Proteins|Efficacy and Safety of Specific Oral Tolerance Induction in Children Allergic to Cow's Milk Proteins According to Their Serum Specific IgE Level||Instituto de Investigación Hospital Universitario La Paz|No|Completed|March 2009|September 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|4 Years|N/A|No|||July 2012|July 12, 2012|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01641731||82655|
NCT01639846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD1202|Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis|A Single-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the Onset and Duration of Action of RX-10045 Ophthalmic Solution, 0.09% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis||C.T. Development America, Inc.||Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639846||82797|
NCT01640119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|aslav2|Correction of Metabolic Acidosis in End Stage Renal Disease (ESRD)|A Prospective, Controlled, Randomized, Multicentric Study: Correction of Metabolic Acidosis With Use of Bicarbonate in Chronic Renal Insufficiency (CKD3b-4)|UBI|Azienda Sanitaria ASL Avellino 2|Yes|Recruiting|July 2014|December 2017|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|728|||Both|18 Years|80 Years|No|||September 2014|September 17, 2014|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01640119||82777|
NCT01637103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-12-123|Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Light Therapy and Cognitive Therapy|Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Light Therapy and Cognitive Therapy||Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|September 2011|February 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|75 Years|No|||August 2014|August 5, 2014|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01637103||83008|
NCT01637116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PURIST|Profiling Urticaria for the Identification of Subtypes|Profiling Urticaria for the Identification of Subtypes|PURIST|Charite University, Berlin, Germany|No|Completed|July 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|195|||Both|18 Years|N/A|No|Non-Probability Sample|1. Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive             chronic spontaneous urticaria)          2. Patients with chronic spontaneous urticaria with a positive ASST, who also test             positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor             basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune             chronic spontaneous urticaria).          3. Patients with chronic spontaneous urticaria with a positive ASST, who test negative             in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies             (=autoreactive, non-autoimmune chronic spontaneous urticaria)|July 2015|July 27, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01637116||83007|
NCT01637467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0639A|Effect of Electrical Muscle Stimulation in Critically Ill Patients|The Effects of Electrical Muscle Stimulation (EMS) on Muscle Atrophy and Functional Outcomes in Critically Ill Patients; a Pilot Randomized Controlled Trial||University Health Network, Toronto|No|Completed|July 2012|October 2015|Actual|October 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||May 2015|February 5, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637467||82980|
NCT01637740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04072012MB|Pseudoexfoliation Syndrome in Myopes|Pseudoexfoliation Syndrome in Myopes Defined With Optical Low Coherence Reflectometry||General Hospital Sveti Duh||Completed|August 2009|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|5753|||Both|40 Years|N/A|No|Probability Sample|5753 eyes of cataract surgery patients ≥ 40 years old|July 2012|July 10, 2012|July 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01637740||82959|
NCT01638208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIG-VSL#3-IBS-NP|Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D|Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3.||Asian Institute of Gastroenterology, India|No|Not yet recruiting|August 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||July 2012|July 9, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01638208||82923|
NCT01638520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB 2012/02212|Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB)|Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB): a Randomized, Double-blind, Placebo-controlled, Proof-of-concept Clinical Trial||National University Hospital, Singapore|Yes|Recruiting|June 2012|June 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|56|||Both|21 Years|75 Years|No|||October 2014|October 14, 2014|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638520||82899|
NCT01638819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB2011Chez|Autologous Cord Blood Stem Cells for Autism|A Randomized, Blinded, Placebo-controlled, Crossover Study to Assess the Efficacy of Stem Cells From Autologous Umbilical Cord Blood to Improve Language and Behavior in Children With Autism||Sutter Health|Yes|Active, not recruiting|August 2012|April 2016|Anticipated|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|29|||Both|2 Years|7 Years|No|||March 2016|March 1, 2016|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638819||82876|
NCT01638832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-005|Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease|Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease||Johann Wolfgang Goethe University Hospitals|No|Recruiting|June 2012|December 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|572|||Both|18 Years|N/A|No|||June 2012|July 11, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01638832||82875|
NCT01639144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-024|Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing|Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing After Elective Foot and Ankle Surgery in Healthy Adults|PRP|UHZ Sports Medicine Institute|Yes|Completed|July 2012|March 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|515|||Both|18 Years|80 Years|No|||May 2015|May 21, 2015|July 10, 2012||No||No|April 6, 2015|https://clinicaltrials.gov/show/NCT01639144||82851|Originally intended to enroll more patients but due to apparent lack of effect of PRP treatment, enrollment was truncated to n = 250 per study group.
NCT01639417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.115|Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients|Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients||University of Michigan Cancer Center|Yes|Recruiting|May 2012|January 2017|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|40|||Both|18 Years|N/A|No|Probability Sample|Breast Cancer Survivors with and without Chronic Pain|December 2014|December 21, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01639417||82830|
NCT01639443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-055|Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy|Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy|No-show|VA Office of Research and Development|No|Active, not recruiting|July 2013|July 2017|Anticipated|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|180|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 6, 2016|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01639443||82828|
NCT01639742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTICE-001|European New Texture Implant Clinical Experience With Round Breast Implants|||Allergan|No|Active, not recruiting|June 2012|October 2017|Anticipated|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment|1||Actual|18|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 2, 2015|July 11, 2012|No|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT01639742||82805|
NCT01639391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-33|Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study|Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study|ALSCELL|Institut Pasteur|No|Recruiting|November 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2012|December 5, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639391||82832|
NCT01639404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPUCB|Umbilical Cord Blood Therapy for Children With Cerebral Palsy|Allogeneic Umbilical Cord Blood Therapy for Children With Cerebral Palsy||Bundang CHA Hospital|No|Completed|July 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|6 Months|20 Years|No|||August 2013|August 8, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639404||82831|
NCT01645878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hands on and hands off|Effect of Education on Breast Feeding on Primiparous Women|||Mashhad University of Medical Sciences|Yes|Terminated|January 2010|September 2011|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|136|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||January 2010|July 19, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01645878||82355|
NCT01638104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANX-042-C100|ANX-042 Healthy Volunteer Dose Escalation Study|ANX-042 Healthy Volunteer Dose Escalation Study||Anexon, Incorporated|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|12||Actual|30|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 17, 2013|July 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01638104||82931|
NCT01615120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G200712|Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer|Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy||GTx|Yes|Active, not recruiting|July 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Male|18 Years|N/A|No|||February 2016|February 5, 2016|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01615120||84691|
NCT01638676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-MEL-11-03|A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients|A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients||James Graham Brown Cancer Center|Yes|Recruiting|July 2012|June 2019|Anticipated|June 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|55|||Both|18 Years|N/A|No|||January 2016|February 29, 2016|June 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638676||82887|
NCT01646723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VALID1|Volunteers Adding Life in Dementia|Volunteers Adding Life in Dementia (VALID)|VALID|Queen's University|No|Recruiting|June 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|30|||Both|65 Years|N/A|No|||April 2015|April 21, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646723||82291|
NCT01642277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|204195|Bacterial Genomic Sequencing in Overactive Bladder|The Effect of Short Term Solifenacin for Overactive Bladder on the Female Urinary Microbiome||Loyola University|No|Completed|July 2012|August 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|134|||Female|18 Years|89 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|July 3, 2012|Yes|Yes||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01642277||82613|
NCT01639872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DA032533-01A1|Clozapine for Cannabis Use in Schizophrenia|Clozapine for Cannabis Use Disorder in Schizophrenia|CLOCS|Dartmouth-Hitchcock Medical Center|Yes|Recruiting|April 2013|December 2017|Anticipated|September 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|55 Years|No|||January 2016|January 20, 2016|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639872||82795|
NCT01636271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116740|SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)|SB-480848 in Major Adverse Cardiovascular Events - Integrated Phase III Summary of Efficacy and Safety||GlaxoSmithKline|No|Completed|October 2011|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|28855|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with clinical manifestations of cardiovascular disease (chronic coronary heart        disease (CHD) or post Acute Coronary Syndrome (ACS)) randomized into the STABILITY trial        (LPL100601) or the SOLID-TIMI 52 trial (SB-480848/033).|October 2014|October 30, 2014|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636271||83072|
NCT01637441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_24|Prosthetic Pelvic Organ Prolapse Repair|Randomized Study Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery in Cystocele Repair|PROSPERE|University Hospital, Lille|Yes|Completed|September 2012|November 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|262|||Female|45 Years|75 Years|No|||November 2015|November 3, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637441||82982|
NCT01637753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJ-Glioma 3.1.0 Version|Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma|Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Recurrent Malignant Glioma||Shandong Lanjin Pharmaceuticals Co.,Ltd|Yes|Recruiting|June 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|70 Years|No|||July 2012|July 8, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01637753||82958|
NCT01637987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|694-11-EP|Nurse PIV Insertion Success With and Without Assistive Devices in Patients 0-12 Months of Age|Nurse Peripheral Intravenous Catheter Insertion Success With and Without Assistive Devices in Patients 0-12 Months of Age||University of Nebraska|No|Enrolling by invitation|July 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|720|||Both|N/A|12 Months|No|||August 2012|August 6, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637987||82940|
NCT01637961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01982|Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus|A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus||National Cancer Institute (NCI)|Yes|Active, not recruiting|August 2012|||August 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Female|18 Years|N/A|No|||January 2015|June 22, 2015|July 8, 2012|Yes|Yes||No|April 29, 2015|https://clinicaltrials.gov/show/NCT01637961||82942|
NCT01637974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0050-CTIL|Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hysteroscopic Surgery|Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hysteroscopic Surgery - a Prospective Double Blind Randomized Study||Carmel Medical Center|No|Recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|130|||Female|18 Years|50 Years|No|||July 2015|July 30, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01637974||82941|
NCT01638221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ME10 0006|Comparison of Patient Perceived Pain and Satisfaction Between Lightweight and Heavyweight Mesh for Laparoscopic Inguinal Hernia Repair|Comparison of Patient Perceived Pain and Satisfaction Between Lightweight and Heavyweight Mesh for Laparoscopic Inguinal Hernia Repair||Genesys Regional Medical Center|Yes|Recruiting|July 2012|||July 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients over the age of 18 who are undergoing a unilateral repair of inguinal hernias        laparoscopically|July 2012|July 31, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638221||82922|
NCT01638533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01040|Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction|A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction||National Cancer Institute (NCI)|Yes|Recruiting|June 2012|||September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|February 11, 2016|July 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01638533||82898|
NCT01638546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01130|Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer||National Cancer Institute (NCI)|No|Active, not recruiting|June 2012|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||March 2016|March 9, 2016|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638546||82897|
NCT01639157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R21DA034095-01|Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine|Human Laboratory Study of the Impact of Buspirone Maintenance on the Reinforcing, Subjective and Performance Effects of Cocaine||University of Kentucky|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|July 10, 2012|No|Yes||No|December 4, 2015|https://clinicaltrials.gov/show/NCT01639157||82850|
NCT01639170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Federico II-0919|Abdominal Free Air After Surgery|Intra-abdominal Free Air on a Plain Radiograph After Surgery. Could it be a Finding That May Predict Gastrointestinal Perforation?||Federico II University||Recruiting|June 2011|||June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|600|||Both|18 Years|90 Years|No|||June 2012|July 16, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639170||82849|
NCT01639183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:227|Power Toothbrush Use in Nursing Homes to Eliminate Mouth and Body Inflammation|The Effects of Daily Power Toothbrushing on Caregiver Compliance and on Oral and Systemic Inflammation in a Nursing Home Population: A Randomized Controlled Trial||University of Manitoba|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|58|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 23, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639183||82848|
NCT01639729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP102|Effect of Delivery Route on PK of Sufentanil NanoTab|Effect of Delivery Route on the Pharmacokinetics of Sufentanil NanoTab® in Healthy Subjects||AcelRx Pharmaceuticals, Inc.|No|Completed|July 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|25|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2015|September 16, 2015|July 11, 2012|No|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01639729||82806|
NCT01639989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0028-12 HYMC|Doppler Assesment of Blood Flow in the Spiral Arteries|Pilot Study Which is Aiming at the Feasibility of Performing Doppler Studies of the Spiral Arteries||Hillel Yaffe Medical Center|No|Not yet recruiting|September 2012|September 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Female|18 Years|52 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women at 1st trimester|July 2012|July 12, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01639989||82787|
NCT01639755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENTICE-002|European New Texture Implant Clinical Experience With Shaped Breast Implants|||Allergan|No|Active, not recruiting|June 2012|October 2017|Anticipated|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment|1||Actual|19|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 2, 2015|July 11, 2012|No|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT01639755||82804|
NCT01637844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012019|Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV|Telbivudine in the Third Trimester of Pregnancy to Prevent Mother-to-infant Transmission of HBV||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yes|Completed|April 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|335|||Female|20 Years|40 Years|No|||November 2014|November 30, 2014|July 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637844||82951|
NCT01646138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120077|Influenza A 2009 H1N1 Challenge Study in Healthy Adults|Influenza A 2009 H1N1 Human Challenge Study in Healthy Adult Volunteers||National Institutes of Health Clinical Center (CC)||Completed|February 2012|December 2013|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|49|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 11, 2014|July 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01646138||82335|
NCT01646112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912126|Uncertain Genetic Test Results for Lynch Syndrome|Living in Lynch Syndrome Limbo: Exploring the Meaning of Uncertain Genetic Test Results||National Institutes of Health Clinical Center (CC)||Completed|April 2012|February 2016||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|40|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||February 2016|February 6, 2016|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646112||82337|
NCT01646125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAUY922A2207|An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations|A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment||Novartis|No|Completed|November 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||December 2015|December 16, 2015|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646125||82336|
NCT01639287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USG-3131-AR|Painless Synovitis in Patients With Longstanding Rheumatoid Arthritis|Correlation of "Painless" Synovitis With Clinical, Laboratory and Radiological (X-ray, Sonography) Finds in Patients With Longstanding Rheumatoid Arthritis (RA).||Federal University of São Paulo|Yes|Recruiting|July 2012|July 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Retrospective||2|Anticipated|60|Samples Without DNA|Serum|Female|18 Years|N/A|No|Non-Probability Sample|Federal University of São Paulo ambulatory (Unifesp) and basic helth unit|July 2012|July 11, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639287||82840|
NCT01639560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-005652|Varenicline for Light Smokers|Varenicline for Light Smokers|ChanLight|Mayo Clinic|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|224|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 14, 2016|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639560||82819|
NCT01636011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-808|Effect of Osteopathic Manipulative Medicine (OMM) on Pulmonary Function and Speech in Parkinson's Disease|Effect of Osteopathic Manipulative Medicine on Pulmonary Function and Speech in Parkinson's Disease||New York Institute of Technology||Active, not recruiting|February 2013|May 2016|Anticipated|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636011||83092|
NCT01636804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13211|Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads|Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads: Impact on Electrophysiological Profile||University of Kansas Medical Center|No|Completed|July 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|190|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that received either Quicksite or Quickflex leads at the University of Kansas        Hospital|August 2013|August 6, 2013|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636804||83031|
NCT01636817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8226-3612|A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics|A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics||Novo Nordisk A/S|No|Terminated|August 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|239|||Both|18 Years|75 Years|No|||November 2014|November 19, 2014|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636817||83030|
NCT01637727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDM.CTIL|Long Term Effects of Gestational Diabetes Mellitus in a Population of Parous Women|Long Term Effects of Gestational Diabetes Mellitus in a Population of Parous Women|GDM|Shaare Zedek Medical Center|No|Not yet recruiting|September 2012|||September 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|324||the women will undergo a physical examination which will include measurements of blood      pressure, height, weight and waist circumference.Blood samples will be obtained for      evaluation of fasting glucose level, HbA1c, lipid profile and kidney functions.|Female|20 Years|45 Years|No|Non-Probability Sample|The proposed research format is: a case control study using a historical cohort of women        diagnosed with GDM. The study group will include women who gave birth in Shaare Zedek        Medical Center between the years 2000 and 2010. Women with a GDM history will be        identified based on the gestational diabetes clinic files. Women without a history of GDM        who will be the control group will be identified from the Shaare Zedek Medical Center        birth registration records|July 2012|July 12, 2012|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01637727||82960|
NCT01637168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GGKEMS0910|Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders|Clinical Phase III, Randomized, Double-blind, Prospective Study, for Efficacy and Safety Evaluation of Panax Ginseng + Associations Compared to Ginkgo Biloba in Symptomatic Cognitive Function Disorder Treatment.||EMS|Yes|Not yet recruiting|November 2013|September 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|60 Years|No|||September 2013|September 24, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01637168||83003|
NCT01637493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JY062011A|Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients|Safety,Tolerability,Pharmacokinetics and Pharmacodynamics Phase 1 Study of Pegfilgrastim in Chemotherapy Patients||Hangzhou Jiuyuan Gene Engineering Co. Ltd.,|No|Recruiting|February 2012|June 2013|Anticipated|February 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|24|||Both|18 Years|70 Years|No|||July 2012|July 10, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01637493||82978|
NCT01638000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-EC-001|A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Are Previously Treated With Another Medicine But Were Not Satisfied With That Treatment|A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy|BEYOND|Astellas Pharma Inc|No|Completed|June 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1887|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638000||82939|
NCT01638234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200902026M|Effectiveness of Melatonin for Sleep Disturbances in Children With Atopic Dermatitis|Effectiveness of Melatonin Supplement in the Management of Sleep Disturbances in Children With Atopic Dermatitis||National Taiwan University Hospital|Yes|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|1 Year|18 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01638234||82921|
NCT01638247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 54|Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients|A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients|MALE|German Breast Group|Yes|Recruiting|August 2012|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|48|||Male|18 Years|85 Years|No|||February 2016|February 9, 2016|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638247||82920|
NCT01638260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-2-033|GLP-1 and Non-exercise Activity Thermogenesis in RHZ|Liraglutide With or Without NEAT in Type 2 Diabetes Mellitus; Effects on HbA1c, Weight, Blood Pressure, Quality of Life and Health Care Costs.||Maastricht University Medical Center|Yes|Terminated|October 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|22|||Both|40 Years|75 Years|No|||December 2013|December 16, 2013|July 9, 2012||No|Terminated because of insufficient number of subjects included.|No||https://clinicaltrials.gov/show/NCT01638260||82919|
NCT01638559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT iWITH|Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients|Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients|iWITH|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|August 2012|July 2017|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|88|||Both|N/A|18 Years|No|||September 2015|September 23, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638559||82896|
NCT01638572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200910002R|Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma|Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma||National Taiwan University Hospital|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|90|||Both|N/A|18 Years|No|Non-Probability Sample|From year 1990 to 2010, pediatric neuroblastoma patients treated at National University        Hospital, Taiwan|June 2012|July 8, 2012|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01638572||82895|
NCT01638858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lucentis_DME_ERG|Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)|A Prospective, Non-randomized, Mono-center, Cohort Study of Evaluate the Effects of 0.5mg Intraocular Ranibizumab (Lucentis)Injections on Retinal Function in Patients With Diabetic Macular Edema (DME) During Twelve Months||University of Luebeck||Completed|October 2011|||July 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|25|||Both|18 Years|N/A|No|||July 2014|July 4, 2014|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01638858||82873|
NCT01638871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1384|Internet-Based Osteoarthritis Pain Coping Skills Intervention|Internet-Based Osteoarthritis Pain Coping Skills Intervention|PainCOACH|University of North Carolina, Chapel Hill|No|Completed|October 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|113|||Both|18 Years|N/A|No|||February 2014|February 19, 2014|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01638871||82872|
NCT01638910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91773|Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects|A Multi-center, Open, Uncontrolled Phase 3 Study to Investigate the Efficacy and Safety of a 4-phasic Oral Contraceptive SH T00658ID Containing Estradiol Valerate and Dienogest in a 28-day Regimen for 13 Cycles in Healthy Female Subjects||Bayer|No|Completed|June 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|955|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||December 2014|December 16, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01638910||82869|
NCT01639482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P002712|Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram|||Massachusetts General Hospital|No|Completed|April 2010|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|64 Years|No|Probability Sample|Patients with Bipolar Depression|September 2014|September 15, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639482||82825|
NCT01640041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMF-CP-0004|Feasibility Study for Enhancing Gait Following Stroke With Implanted Microstimulators|Feasibility Study for Enhancing Gait Following Stroke With Implanted Microstimulators||The Alfred E. Mann Foundation for Scientific Research|No|Completed|May 2008|January 2010|Actual|December 2009|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|21 Years|N/A|No|||July 2012|July 11, 2012|June 22, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640041||82783|
NCT01614587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-10-004|Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition?|Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition?||Atlantic Health System|Yes|Active, not recruiting|March 2012|July 2014|Anticipated|February 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|DNA obtained from a buccal swab|Female|N/A|N/A|No|Probability Sample|Women suffering from pelvic organ prolapse|January 2014|January 27, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01614587||84732|
NCT01614860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KL2-2012NWAHF|Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels|Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels||Northwestern University|No|Completed|May 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|Samples Without DNA|Plasma storage for potential future studies with existing or novel biomarkers.|Both|18 Years|N/A|No|Probability Sample|Patients who present to the Emergency Department (ED) with signs and symptoms of AHF|September 2014|September 7, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01614860||84711|
NCT01638390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISUMAX-2012-1|Use of the Visumax™ Femtosecond Laser|Use of the Visumax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia||Carl Zeiss Meditec, Inc.|Yes|Active, not recruiting|July 2012|September 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|360|||Both|22 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638390||82909|
NCT01638403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09-15/ BF2.649 Harmony 1bis|Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.|Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy||Bioprojet|Yes|Completed|November 2010|July 2012|Actual|April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|N/A|No|||February 2013|February 8, 2013|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638403||82908|
NCT01646151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/033|A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|||Allergan|No|Completed|May 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2580|||Both|N/A|N/A|No|Non-Probability Sample|Subjects with POAG and OHT|May 2014|May 15, 2014|July 18, 2012|Yes|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01646151||82334|
NCT01639885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHIP trial|Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer|Chemo-Immunotherapy, Gemcitabine With Pegylated Interferon Alpha-2b (Peg-Intron) With and Without p53 Synthetic Long Peptide (p53 SLP) Vaccine, for Patients With Platinum Resistant Ovarian Cancer CHIP Trial|CHIP|Leiden University Medical Center|Yes|Completed|August 2011|||January 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Female|18 Years|N/A|No|||January 2014|January 6, 2014|April 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639885||82794|
NCT01639573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMPATH-1H SSc|Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis|Campath-1h as Immunoablative Therapy for Children and Adolescents With Treatment Refractory Systemic Sclerosis|CAMPATH-1H|Children's Hospital Los Angeles|Yes|Recruiting|April 2011|April 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|6|||Both|8 Years|18 Years|No|Probability Sample|Patients, 8 to18 years of age, will be included if they have a proven diagnosis of diffuse        cutaneous or systemic SSc as defined by the ACR criteria with evidence of active        inflammatory disease|January 2016|January 26, 2016|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639573||82818|
NCT01639859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.658|Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci|Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci|PROSTATE SSI|Hospices Civils de Lyon|No|Completed|October 2011|August 2013|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Male|18 Years|N/A|No|||September 2011|August 7, 2013|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01639859||82796|
NCT01636531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP27951|A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers|A Multi-center, Randomized Open-label, Single-dose, Parallel Group Investigation of the Relative Bioavailability, Tolerability and Dose-exposure Relationship of a High Concentration Liquid Formulation (HCLF) Versus a Lyophilized Formulation (LyoF) of RO4909832 (Gantenerumab) When Administered by su||Hoffmann-La Roche||Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Masking: Open Label|2||Actual|120|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636531||83052|
NCT01637129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00324|Transcranial Magnetic Stimulation in Children With Stroke|Transcranial Magnetic Stimulation in Children With Stroke|TMSCS|Nationwide Children's Hospital|Yes|Completed|May 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|6 Years|18 Years|No|||March 2014|March 31, 2014|June 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01637129||83006|
NCT01637142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12682|A Study of LY2140023 in Healthy Participants|An Absolute Bioavailability Study of LY2140023 and LY404039 in Healthy Subjects Using the Intravenous Tracer Method||Eli Lilly and Company||Completed|July 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|June 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01637142||83005|
NCT01637480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16882|Effects of Lumbopelvic Manipulation on Hip and Knee Neuromuscular Activity|Effects of Lumbopelvic Manipulation on Hip and Knee Neuromuscular Activity in People With and Without Patellofemoral Pain Syndrome||Texas Woman's University|Yes|Completed|July 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|January 9, 2015|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01637480||82979|
NCT01637779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0231-E|A Randomized Controlled Trial About Teaching Parents How to Manage Childhood Immunization Pain|A Randomized Clinical Trial to Evaluate the Impact of a Fact Sheet About Childhood Immunization Pain Management on Parental Knowledge||University of Toronto|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|120|||Female|15 Years|60 Years|No|||October 2013|October 26, 2013|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01637779||82956|
NCT01638273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLA5PR-102|PK Study of Pregabalin GLARS Tablet 150mg and IR Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects|A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg and Immediate Release Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects|GLA5PR-102|GL Pharm Tech Corporation|No|Completed|February 2014|November 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2014|November 11, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638273||82918|
NCT01638585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|August 2|Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia|Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase|August2|GWT-TUD GmbH|Yes|Terminated|June 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|May 14, 2012||No|recruition number was not reached|No||https://clinicaltrials.gov/show/NCT01638585||82894|
NCT01638884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A00031-38|Prospective Memory Imaging|Cerebral Substrates of Prospective Memory in Healthy Young Adults and Disruptions in Normal Aging and Alzheimer Disease: a Study in Anatomical, Functional and Diffusion Tensor MRI.|IMPRO|University Hospital, Caen|Yes|Recruiting|September 2010|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Anticipated|118|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 8, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01638884||82871|
NCT01638897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF4|DF4 Connector System Post-Approval Study|DF4 Connector System Post-Approval Study||Medtronic|No|Active, not recruiting|January 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1778|||Both|N/A|N/A|No|Non-Probability Sample|Patients intended to be implanted or are within 30 days post-implant of a DF4 Connector        System with a Medtronic DF4 lead. All subjects must meet Inclusion criteria and none of        the Exclusion criteria.|July 2015|July 24, 2015|July 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01638897||82870|
NCT01639495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMART-AF CA|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Continued Access||Biosense Webster, Inc.|No|Completed|July 2012|October 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Both|18 Years|N/A|No|||January 2015|January 7, 2015|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639495||82824|
NCT01640314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V58_32S|Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above|A Phase 3 Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects||Novartis|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 19, 2016|July 6, 2012||No||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01640314||82763|
NCT01646177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13685|A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)|A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period|UNCOVER-3|Eli Lilly and Company|Yes|Active, not recruiting|July 2012|August 2019|Anticipated|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|1346|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646177||82332|
NCT01646762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1182|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Trial of Nab-paclitaxel (Abraxane®) in Patients With Relapsed or Refractory Multiple Myeloma||Mayo Clinic|Yes|Completed|November 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2015|January 4, 2016|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01646762||82288|
NCT01646775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-186-SDR|The Effect of Epidural Fentanyl on Immune Function|The Effect of Perioperative Epidural Opioids on Inflammatory Cytokines and Immune Function||McGill University Health Center|No|Recruiting|July 2012|December 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|30|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01646775||82287|
NCT01646437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIPS-3|The International Polycap Study 3 (TIPS-3)|The International Polycap Study 3 (TIPS-3) is a Randomized Double-blind Placebo-controlled Trial for the Evaluation of a Polycap, Low Dose Aspirin and Vitamin D Supplementation in Primary Prevention|TIPS-3|Population Health Research Institute|Yes|Recruiting|June 2012|March 2020|Anticipated|June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|5000|||Both|55 Years|N/A|No|||May 2015|May 22, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01646437||82312|
NCT01646710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPNPVW48/SAS|Optifood, An Approach to Improve Nutrition|Optifood, An Approach to Improve Nutrition|Optifood|Society for Applied Studies|No|Completed|October 2011|May 2014|Actual|July 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment|1||Anticipated|36|||Both|9 Months|11 Months|Accepts Healthy Volunteers|||November 2014|November 18, 2014|July 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01646710||82292|
NCT01646736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T2WILN|Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis|Evaluation of Efficacy and Safety of Glucocorticosteroid Combined With Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of Patients With Lupus Nephritis.||Peking Union Medical College Hospital|Yes|Recruiting|July 2012|December 2013|Anticipated|July 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|65 Years|No|||July 2012|July 19, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01646736||82290|
NCT01640158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPI-1002-11|Broad-spectrum Cognitive Remediation: Effects of a Brain Plasticity-based Program in Mild Traumatic Brain Injury|BRAVE Trial: Broad-spectrum Cognitive Remediation Available to Veterans: Effects of a Brain Plasticity-based Program in Mild Traumatic Brain Injury (mTBI)|BRAVE|Posit Science Corporation|Yes|Recruiting|September 2013|February 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|50 Years|No|||November 2015|November 12, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01640158||82775|
NCT01636024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3740C00001|To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers||AstraZeneca||Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|73|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 19, 2013|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636024||83091|
NCT01640145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH98|Effect of Low Intensity Exercise and Protein Intake on Skeletal Muscle Protein Synthesis in Elderly|Impact of Acute Low Intensity Exercise and Protein Intake on Skeletal Muscle Protein Synthesis in Elderly: a Randomized Controlled Trial||Bispebjerg Hospital||Completed|July 2012|October 2014|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|30|||Male|65 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 5, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01640145||82776|
NCT01636830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR 001|The Incidence of Gingival Fissures _ a Crossover Single-blinded Randomized Clinical Trial|The Incidence of Gingival Fissures _ a Crossover Single-blinded Randomized||Federal University of Rio Grande do Sul|No|Completed|August 2011|March 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|35|||Both|14 Years|20 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636830||83029|
NCT01636843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8226-3613|A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate|A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate||Novo Nordisk A/S|No|Terminated|October 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|298|||Both|18 Years|75 Years|No|||November 2014|November 19, 2014|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636843||83028|
NCT01637454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGIMERIndia|TYPE 2 HEPATORENAL SYNDROME|NORADRENALINE VERSUS TERLIPRESSIN IN THE TREATMENT OF TYPE 2 HEPATORENAL SYNDROME:A RANDOMIZED STUDY|Type2 HRS|Postgraduate Institute of Medical Education and Research|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|70 Years|No|||July 2012|July 10, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01637454||82981|
NCT01638052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH IRB 2005-12645|Great Auricular Nerve Block for Tympanomastoid Surgery: Will the Addition of Clonidine Enhance the Duration of Analgesia?|Great Auricular Nerve Block for Children Undergoing Tympanomastoid Surgery: Does the Addition of Clonidine Increase the Duration of Postoperative Analgesia?||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|February 2006|April 2008|Actual|March 2008|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|56|||Both|1 Year|18 Years|No|||July 2012|March 19, 2013|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638052||82935|
NCT01637766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807009906|Intra-arterial Chemotherapy for Spinal Metastases|Selective Intra-arterial Chemotherapy in the Treatment Strategy of Metastatic Spinal Disease|SIAC|Weill Medical College of Cornell University|Yes|Recruiting|April 2012|||April 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||January 2016|January 16, 2016|July 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637766||82957|
NCT01638026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emc-0060-12-CTIL|Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG|Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG||HaEmek Medical Center, Israel|Yes|Recruiting|September 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|45 Years|No|||September 2015|September 3, 2015|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01638026||82937|
NCT01638013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-RAJ2|A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K|Extension Study of ASP015K - Open-Label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase IIb Study or Phase III Study of ASP015K||Astellas Pharma Inc|Yes|Recruiting|July 2012|September 2018|Anticipated|September 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|20 Years|N/A|No|||October 2015|October 5, 2015|July 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01638013||82938|
NCT01638286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-EPAC-101|Study to Evaluate a Pharmacokinetic Drug Interaction Between Eperisone Hydrochloride and Aceclofenac in Healthy Male Subjects|||Hanmi Pharmaceutical Company Limited|No|Completed|August 2012|April 2013|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||3|Actual|24|||Male|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Acute low back pain|March 2014|March 8, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638286||82917|
NCT01638299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3076823, V3.0|Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting|Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia and Hyperglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting||Animas Corporation|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 19, 2012|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638299||82916|
NCT01638598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1310.3|Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers (Placebo-controlled, Randomised and Double-blind Within Dose Groups)||Boehringer Ingelheim||Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|80|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 31, 2013|July 2, 2012||||No||https://clinicaltrials.gov/show/NCT01638598||82893|
NCT01638611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDU11656|A Study of Subcutaneous Doses of HIP2B in Healthy Male Subjects|A Randomized, Double-blind, Third Party (Sponsor) Open, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of HIP2B in Healthy Male Subjects|HIP2B|CureDM|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Male|19 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 28, 2012|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638611||82892|
NCT01638936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|983|BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma|A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma||Biotest Pharmaceuticals Corporation|Yes|Active, not recruiting|July 2012|November 2017|Anticipated|July 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638936||82867|
NCT01640327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V78_10S|Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above|A Phase 3, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Fluvirin®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects||Novartis|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 28, 2015|July 6, 2012||No||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01640327||82762|
NCT01639794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VES-IE-001|Vesitirim™ in Men Postmarketing Observational Study|An Irish Observational Study to Evaluate LUTS Storage Symptom Improvement in Men Being Treated With Vesitirim™ (Solifenacin)|VIM|Astellas Pharma Inc|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|12|||Male|35 Years|N/A|No|Non-Probability Sample|Patients will be identified from the Consultants routine clinics and the decision to treat        a patient with Vesitirim™ will be made by the treating physician prior to enrolment into        this non interventional study|January 2013|January 16, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01639794||82801|
NCT01640054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00029|A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis|(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia|OSKIRA-Asia-1X|AstraZeneca|Yes|Terminated|July 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|115|||Both|18 Years|N/A|No|||February 2014|February 27, 2014|July 2, 2012|Yes|Yes|AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to    Rigel Pharmaceuticals.|No|November 21, 2013|https://clinicaltrials.gov/show/NCT01640054||82782|Insufficient efficacy data was available for analysis due to sparse data collection and the early termination of the study.
NCT01646450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV20|First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients|An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation||Betta Pharmaceuticals Co.,Ltd.|Yes|Active, not recruiting|July 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|70 Years|80 Years|No|||September 2015|September 5, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01646450||82311|
NCT01647321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00069253|Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis|Evaluating the Effects of Functional Electrical Stimulation on Ambulation in Individuals With Secondary Progressive Multiple Sclerosis||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|July 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|No|||February 2016|February 22, 2016|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647321||82266|
NCT01647308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS 304801-CS4|Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes|A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus||Ionis Pharmaceuticals, Inc.|No|Terminated|July 2012|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|No|||July 2014|July 11, 2014|July 19, 2012|No|Yes|The study was terminated for business planning purposes. Assessments of APOCIIIRx in this    population will be explored in a larger efficacy study|No||https://clinicaltrials.gov/show/NCT01647308||82267|
NCT01647568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DVAMC-09-084|Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study|||Dallas VA Medical Center|No|Completed|December 2009|||March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|715|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to the GI lab for elective colonoscopy.|July 2012|July 19, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647568||82247|
NCT01647581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLNB-005-13F|Risk of Post-polypectomy Bleeding With Prophylactic Hemoclipping|Risk of Post-Polypectomy Bleeding With Prophylactic Hemoclipping||VA Office of Research and Development|Yes|Recruiting|September 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|1750|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647581||82246|
NCT01646749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL41371|Effects of Beef Protein Consumption on Energy Intake|Effects of Beef Protein Consumption on Energy Intake - The Protein Leverage Hypothesis||Maastricht University Medical Center|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01646749||82289|
NCT01647854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-1003-0034-5|Operation of a Mobile Telemedicine System in the EMS|Introduction and Operation of a Mobile Telemedicine System to Support Paramedics in the Emergency Medical Service||RWTH Aachen University|No|Completed|August 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|425|||Both|N/A|N/A|No|||September 2015|September 22, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01647854||82225|
NCT01636297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01NS073717-01|The Cyclical Lower-extremity Exercise for Parkinson's Trial|The Cyclical Lower-extremity Exercise for Parkinson's Trial|CYCLE|The Cleveland Clinic|No|Recruiting|June 2013|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|100|||Both|30 Years|75 Years|No|||January 2016|January 27, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636297||83070|
NCT01636284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JX594-IV-HEP021|A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer|A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)|FLASH|SillaJen, Inc.|Yes|Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|June 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636284||83071|
NCT01637155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-VIT-D|Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization|Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization|PK-VIT-D|Hospital Clinic of Barcelona|No|Not yet recruiting||||||Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01637155||83004|
NCT01636882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLA 008|Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks|A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total||Viralytics||Active, not recruiting|June 2012|March 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|67|||Both|18 Years|N/A|No|||July 2015|July 23, 2015|July 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636882||83025|
NCT01637181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL38160.078.11|Clinical Trial of Endovenous 940 and 1470 Laser Ablation for Treating Great Saphenous Veins|Comparative Randomized Clinical Trial of Endovenous 940 nm Laser Ablation Versus Endovenous 1470 nm Laser Ablation for Treatment of Great Saphenous Veins|COLA|Erasmus Medical Center||Completed|May 2012|December 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|142|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01637181||83002|
NCT01637194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 06-043|Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer|A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors||Fox Chase Cancer Center|Yes|Completed|November 2008|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|October 20, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637194||83001|
NCT01638962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110153|The Effect on Knee Joint Loads of Analgesic Use Compared With Exercise in Patients With Knee Osteoarthritis - An RCT|The Effect on Knee Joint Loads of Instruction in Analgesic Use Compared With NEUROMUSCULAR Exercise in Patients With Knee Osteoarthritis - A Single Blind RCT|EXERPHARMA|University of Southern Denmark|No|Active, not recruiting|August 2012|September 2016|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|70 Years|No|||August 2015|August 11, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01638962||82865|
NCT01638039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0105-11-HYMC|Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|330|||Both|N/A|65 Years|Accepts Healthy Volunteers|||July 2012|July 8, 2012|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01638039||82936|
NCT01638338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-2010-2318620|Risky Drinkers and the Web: a RCT Study in Region Friuli-Venezia Giulia.|Optimizing and Integrating the Delivery of Primary Care Services for Risky Drinkers in Region Friuli-Venezia Giulia|EFAR-FVG|Azienda Per I Servizi Sanitari N. 2 Isontina|No|Completed|November 2012|||December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|674|||Both|14 Years|N/A|No|||June 2015|June 22, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01638338||82913|
NCT01638312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUH-IRB-20110188|Development of Method of Fructose Identification in Urine to Detect the Viral Infection|The Development of Fast and Simple Method of Fructose Identification in Urine to Detect the Viral Infection in Early Stage||Kaohsiung Medical University Chung-Ho Memorial Hospital|Yes|Completed|June 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|50|None Retained|urine|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|the person who has HIV infection|September 2012|September 3, 2015|January 20, 2012||No||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01638312||82915|
NCT01638325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14771|A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants|A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of Single Subcutaneous Injections of Insulin Lispro With BioChaperone Excipient in Healthy Volunteers||Adocia|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|37|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||February 2013|June 13, 2014|July 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01638325||82914|
NCT01638624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Diskapi2012|The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury|The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury in Total Knee Arthroplasty||Diskapi Teaching and Research Hospital||Recruiting|June 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|40|||Both|18 Years|65 Years|No|||July 2012|July 11, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01638624||82891|
NCT01638923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|91774|Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding|A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled, 7 Cycle Duration (196 Days), Phase 3 Study to Investigate the Efficacy and Safety of Oral Estradiol Valerate / Dienogest Tablets for the Treatment of Heavy Menstrual Bleeding||Bayer|No|Completed|June 2012|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|339|||Female|18 Years|N/A|No|||July 2015|July 8, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01638923||82868|
NCT01639196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|338877-1|Brief Online Intervention for Chronic Pain|The Expressive Writing Paradigm: A Study of Therapeutic Effectiveness for Chronic Pain||University of Maryland|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||January 2013|January 11, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639196||82847|
NCT01639508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-097|Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity|A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity||Memorial Sloan Kettering Cancer Center||Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|68|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639508||82823|
NCT01640340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10118|Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)|Pilot Study on the Efficacy of an Ondansetron Versus Palonosetron-containing Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC).||Ohio State University Comprehensive Cancer Center|Yes|Completed|January 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|88 Years|No|||October 2013|October 13, 2013|July 10, 2012|Yes|Yes||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01640340||82761|
NCT01640353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300101|Sacroiliac Joint Fusion With iFuse Implant System (SIFI)|Sacroiliac Joint Fusion With iFuse Implant System (SIFI)|SIFI|SI-BONE, Inc.|No|Active, not recruiting|July 2012|December 2015|Anticipated|January 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|||Both|21 Years|70 Years|No|Non-Probability Sample|Subjects with SI joint pain due to degeneration or disruption of the SI joint|May 2015|May 8, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01640353||82760|
NCT01636193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115926|Drug Use Investigation for ROTARIX®|Drug Use Investigation for ROTARIX||GlaxoSmithKline||Completed|June 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1607|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Infants who receive Rotarix for the first time to prevent rotavirus gastroenteritis as        part of routine immunisation programme.|August 2015|August 13, 2015|June 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636193||83078|
NCT01646788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMB AVS HSR|Study of NMB Drug Ejecting Balloon for Arteriovenous Fistulae|||N.M.B. Medical Applications Ltd||Not yet recruiting|January 2013|January 2015|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2012|July 22, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01646788||82286|
NCT01647620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPOC-002|A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.|A Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics (PK), Pharmacodynamics (PD), PK/PD Characteristics and Safety of Multiple Once-daily Oral Dosing of DPOC-4088 in Healthy Young Male Subjects||Diakron Pharmaceuticals|No|Terminated|February 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2012|February 23, 2015|July 19, 2012||No|Diakron Pharmaceuticals couldn't fulfill the financial responsibility of the study|No||https://clinicaltrials.gov/show/NCT01647620||82243|
NCT01647880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOVING|MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)|Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis|MOVING|Charite University, Berlin, Germany|No|Recruiting|July 2013|April 2017|Anticipated|April 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|55 Years|No|||January 2016|January 20, 2016|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01647880||82223|
NCT01647594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-390|Pilot Study for Young Women's Intervention|Qualitative Assessment and Pilot Study for Young Women's Intervention|YWI Pilot|Dana-Farber Cancer Institute|Yes|Completed|March 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|93|||Female|18 Years|46 Years|No|||January 2013|January 4, 2013|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01647594||82245|
NCT01647607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFCI 12-101|Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer|Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer|Y&S|Dana-Farber Cancer Institute|Yes|Active, not recruiting|June 2012|August 2020|Anticipated|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|610|||Female|18 Years|45 Years|No|||January 2016|January 3, 2016|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01647607||82244|
NCT01647867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetLung - 1204|Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers|Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers|MetLung|Centre Oscar Lambret|No|Active, not recruiting|July 2012|July 2016|Anticipated|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|57|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01647867||82224|
NCT01636557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100842|A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis|A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis||Janssen Research & Development, LLC|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Both|18 Years|65 Years|No|||March 2016|March 11, 2016|July 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636557||83050|
NCT01636544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-45|Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity|Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity|INECOC|Institut Pasteur|No|Recruiting|June 2012|July 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|No|||April 2013|April 4, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636544||83051|
NCT01636570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD3HF|Vitamin D3 Supplementation for Heart Failure Patients|Double-Blind, Placebo-Controlled Trial of Vitamin D3 (Cholecalciferol) Supplementation for Heart Failure Patients||Saint Patrick Hospital|Yes|Completed|August 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|N/A|N/A|No|||May 2015|May 18, 2015|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636570||83049|
NCT01636895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SuNMaP-OR1|Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria|An Evaluation of Sulfadoxine-pyrimethamine Resistance and Effectiveness of IPTp in Nigeria|OR1|Malaria Consortium, UK|Yes|Recruiting|January 2011|February 2013|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|600|||Female|16 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636895||83024|
NCT01637506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H10-01195|Urine and Stool Analysis in Kidney Stone Disease|Correlation Between Excretion Metabolites in Urine and Bacterial Microflora in Patients With Urinary Stone Disease||University of British Columbia|Yes|Recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|Samples With DNA|De-identified and study coded urine and stool are collected, processed and analysed in the      research laboratory.|Both|19 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Subjects in the study group are seen at Vancouver General Hospital for their kidney stone        disease. Subjects in the control group do not have history or family history of kidney        stones and can join the study if they are eligible, wiling to participate, and can provide        their specimens at Vancouver General Hospital.|December 2015|December 10, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01637506||82977|
NCT01638975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC 2010 Lee|Response Inhibition Training for Individuals With Trichotillomania|Testing the Feasibility of Response Inhibition Enhancement Training for Individuals With Trichotillomania||University of Wisconsin, Milwaukee|No|Completed|October 2010|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|9 Years|17 Years|No|||January 2014|January 17, 2014|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01638975||82864|
NCT01643343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33060|Measurement of Joint Attention Fluency|Measurement of Joint Attention Fluency||The Vista School|No|Recruiting|October 2011|October 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|100|||Both|8 Months|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|July 2012|July 16, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643343||82532|
NCT01638351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110029RC|Resistance Training in Diabetic Elder Patients|Effects of Resistance Training on Muscle Dysfunction in Elderly Patients With Type 2 Diabetes Mellitus||National Taiwan University Hospital|No|Completed|December 2011|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|49|||Both|65 Years|80 Years|Accepts Healthy Volunteers|||November 2012|November 15, 2012|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01638351||82912|
NCT01639222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CW-2200-401-RD|Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants|A Two Period, One-sequence Open-label Study of a Newly Developed Calcium Carbonate-vitamin D3 Chewable Tablet Formulation (Calcium 500 mg and Vitamin D3 800) Dosed for Three Days to Investigate the Effect on Urine Calcium and Serum Parathyroid Hormone (PTH) as Measurements of Intestinal Calcium Absorption in Healthy Postmenopausal Women and Healthy Men Compared to Baseline.|Osteopro|Takeda|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|45 Years|70 Years|Accepts Healthy Volunteers|||August 2013|August 13, 2013|July 9, 2012||No||No|March 25, 2013|https://clinicaltrials.gov/show/NCT01639222||82845|
NCT01638637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGCPS-US11-002|Prospective Collection of Female and Male Specimens for PANTHER® System Testing|Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System||Gen-Probe, Incorporated|No|Completed|February 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|1492|Samples With DNA|urine|Both|16 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Symptomatic and asymptomatic subjects at least 16 years of age.|October 2013|October 16, 2013|February 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638637||82890|
NCT01638949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01493-38|Multi-modal Neuroimaging in Alzheimer's Disease|Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging|IMAP+|University Hospital, Caen|Yes|Recruiting|May 2012|||December 2021|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|8||Anticipated|295|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 8, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01638949||82866|
NCT01639209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REB #12-031|Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment|A Randomised Controlled Trial Comparing Pneumatic Retinopexy Versus Vitrectomy for the Management of Primary Retinal Detachment; Anatomical Success, Functional Success and Impact on Patient Quality of Life||St. Michael's Hospital, Toronto|No|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|176|||Both|N/A|N/A|No|||July 2015|July 30, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01639209||82846|
NCT01640067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT: 2009-014484-39|Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)|Intra-spinal Cord Delivery of Human Neural Stem Cells in ALS Patients: Proposal for a Phase I Study/ Trapianto Intramidollare di Cellule Staminali Neurali Umane Come Terapia Putativa Per la SLA: Proposta di un Trial Clinico di Fase I|hNSCALS|Azienda Ospedaliera Santa Maria, Terni, Italy|Yes|Completed|December 2011|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|18|||Both|20 Years|75 Years|No|||December 2015|December 29, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01640067||82781|
NCT01640912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RXI-109-1201|Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109|A Phase 1 Single Center, Randomized, Double-Blind, Ascending Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Pannus of Healthy Women Who Will Later Undergo Elective Abdominoplasty||RXi Pharmaceuticals, Corp.|Yes|Completed|June 2012|May 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Female|21 Years|50 Years|Accepts Healthy Volunteers|||September 2014|September 16, 2014|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640912||82717|
NCT01636206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118-DRY-400|Safety Study of Lifitegrast to Treat Dry Eye|A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)|SONATA|Shire|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||May 2014|May 7, 2014|July 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636206||83077|
NCT01647334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lung-START|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer||Lawson Health Research Institute|Yes|Terminated|January 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||February 2015|February 17, 2015|July 19, 2012||No|Poor accrual|No||https://clinicaltrials.gov/show/NCT01647334||82265|
NCT01648153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116378|Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM|A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.|T2DM|GlaxoSmithKline|No|Completed|August 2012|January 2014|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|3||Actual|37|||Both|18 Years|70 Years|No|||April 2014|April 24, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01648153||82202|
NCT01648140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115879|Dose Ranging of GSK2336805 in Combination Therapy|A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection|HAI115879|GlaxoSmithKline|No|Completed|August 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|286|||Both|18 Years|70 Years|No|||September 2015|September 10, 2015|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01648140||82203|
NCT01648543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2012-0042|Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs Angle|||Yonsei University|No|Recruiting|June 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|194|||Both|20 Years|N/A|No|||July 2012|July 23, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01648543||82179|
NCT01648764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11967|A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread|Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors||Eli Lilly and Company|No|Completed|September 2008|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||November 2012|November 28, 2012|July 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01648764||82162|
NCT01648777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-3289-10|Catheter Outcomes With Sternotomy Cardiac Operated|Cicatricial Analgesia Catheters Outcome on Bronchopulmonary Infection Number With Sternotomy Cardiac Operated|STERNOCAT|Assistance Publique - Hôpitaux de Paris|Yes|Completed|March 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1502|||Both|18 Years|N/A|No|||November 2013|April 23, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648777||82161|
NCT01636063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFPRF12-16|Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks|Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks|MIMI 11-15|Boston University|Yes|Recruiting|June 2012|||May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 5, 2012|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636063||83088|
NCT01636856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3604/11/022|Effects of Oropharyngeal Exercises on Patients With Primary Snore, Mild and Moderate Obstructive|Effects of Oropharyngeal Exercises on Snoring Intensity, Symptoms, Upper Airway Anatomy and Collapsability of Upper Airway Awake and Asleep in Patients With Primary Snoring and Mild to Moderate Obstructive Sleep Apnea|EOE|University of Sao Paulo|Yes|Recruiting|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|25 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 27, 2014|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636856||83027|
NCT01636869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|010/2555|Plasma Concentrations of Bupivacaine After Peri-articular Injection in Total Knee Arthroplasty|Plasma Concentrations of Bupivacaine After Spinal Anesthesia With Single Shot Femoral Nerve Block and Peri-articular Injection in Total Knee Arthroplasty||Mahidol University|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|43|||Both|30 Years|70 Years|No|||July 2014|July 25, 2014|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636869||83026|
NCT01636583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNL/CTC_LSFZn|Zinc Absorption From Fortified Water|Zinc Absorption From Enriched Drinking Water Compared With the Zinc Absorption From a Fortified Maize Pudding in Healthy Young Adults.||Swiss Federal Institute of Technology|No|Completed|June 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|18|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01636583||83048|
NCT01637207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10AR11|How Easy is it to Identify the Cricothyroid Membrane in Children? Can Ultrasound Imagine be Used to Aid Identification?|How Easy is it to Identify the Cricothyroid Membrane in Children? Can Ultrasound Imaging me Used to Aid Identification?||Great Ormond Street Hospital for Children NHS Foundation Trust|No|Not yet recruiting|August 2012|February 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|20|||Both|N/A|8 Years|No|||July 2012|July 10, 2012|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01637207||83000|
NCT01637220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110909|Role of Neutrophil Activation in Anaphylaxis to Curare|Role of Neutrophil Activation in Anaphylaxis to Curare|NASA|Assistance Publique - Hôpitaux de Paris|No|Completed|August 2012|December 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Non-Probability Sample|Selection of cases :          -  Any patient of age 18 and over:          -  Presenting with clinical signs compatible with a perioperative anaphylactic reaction             to neuromuscular blocking drugs, whatever the grade of the anaphylactic reaction          -  That was treated following the French Patient Management 2011 guidelines        Selection of controls:          -  Any patient of age 18 and over          -  Hospitalized for a surgical intervention necessitating a neuromuscular blocking drug             injection, without developing an anaphylactic reaction          -  That had been informed of the particulars of the study and that had consented to             participate in this study|January 2016|January 16, 2016|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01637220||82999|
NCT01637519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00383|Use of the PercSys MicroStent Device to Alleviate Ureteral Stone Symptoms and Hydronephrosis|Use of the PercSys MicroStent Device to Alleviate Ureteral Stone Symptoms and Hydronephrosis||University of British Columbia|Yes|Completed|August 2012|September 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|Samples With DNA|Urine|Both|19 Years|N/A|No|Non-Probability Sample|Patients that present with a unilateral, mid- or distal, ureteral stone that require stent        placement to relieve stone symptoms|December 2015|December 10, 2015|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01637519||82976|
NCT01643356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10203 Tufts|Interventions to Reduce Excess Weight Gain in Pregnancy|Interventions to Reduce Excess Weight Gain in Pregnancy in Overweight and Obese Mothers||Tufts University|No|Active, not recruiting|July 2012|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|75|||Female|18 Years|45 Years|No|||December 2014|December 5, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643356||82531|
NCT01639235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14-13934|Effects of Secondhand Smoke on Flight Attendant Health|Cardiopulmonary Effects of Secondhand Smoke Exposure on Flight Attendants|FAMRI|University of California, San Francisco|No|Recruiting|January 2005|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|2000|Samples With DNA|There is an optional blood draw blood portion to the research study. A sample is collected      from the interested flight attendant. The majority of the sample is processed and stored in      the FAMRI biorepository for future research purposes to identify biomarkers of      cardiovascular risk and secondhand smoke. The remainder of the sample is analyzed for the      flight attendant. A lipid profile is sent to the flight attendant participant.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This is a cross-sectional observational study of flight attendants exposed to secondhand        tobacco smoke.|December 2015|December 1, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01639235||82844|
NCT01639248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2076-CL-005|Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC|A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer||CASI Pharmaceuticals, Inc.|Yes|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Female|18 Years|N/A|No|||July 2015|November 10, 2015|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639248||82843|
NCT01639521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4B-10-5|Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer|Randomized Phase II Trial Of Adjuvant Chemotherapy For Urothelial Carcinoma Comparing GC To Dose-Dense MVAC||University of Southern California|Yes|Withdrawn|May 2013|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 27, 2014|July 10, 2012|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01639521||82822|
NCT01639807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEH/SLT/012/2011|Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP|A Prospective, Randomized, Controlled Clinical Trial Comparing Topical Medical Therapy With Selective Laser Trabeculoplasty in South Indian Population||Aurolab|No|Recruiting|October 2011|December 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|80 Years|No|||July 2012|July 11, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01639807||82800|
NCT01640080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100843|A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression|A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression||Janssen Research & Development, LLC||Completed|June 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|18 Years|64 Years|No|||April 2015|April 7, 2015|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640080||82780|
NCT01637857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACPM01|Oligo-antigenic Diet in the Treatment of Chronic Anal Fissures.|Oligo-antigenic Diet in the Treatment of Chronic Anal Fissures. Evidence for a Relationship Between Food Hypersensitivity and Anal Fissures||University of Palermo|Yes|Completed|January 2006|December 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|161|||Both|17 Years|N/A|No|||January 2013|January 10, 2013|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01637857||82950|
NCT01641224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1106E00524|A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome|A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome||University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|May 2012|May 2014|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|800|||Both|18 Years|70 Years|No|||May 2014|May 9, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01641224||82694|
NCT01647893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTB-001|Phase 1 Single Dose Escalation Study of CTB-001|A Phase 1 Clinical Study, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study of the Safety and Pharmacokinetic/Pharmacodynamic Profiles of CTB-001 Intravenously Administered in Healthy Male Subjects||Chem Tech Research Incorporation|No|Recruiting|July 2012|December 2012|Anticipated|November 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|4||Anticipated|33|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 19, 2012|July 17, 2012||||No||https://clinicaltrials.gov/show/NCT01647893||82222|
NCT01647906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL SLP001|Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)|A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)|SoFI|Valeant Pharmaceuticals International, Inc.|No|Enrolling by invitation|May 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|244|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Fecal Incontinence.|September 2014|January 23, 2015|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01647906||82221|
NCT01648803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB39530|Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease|Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease|APDMclinic|University of Rochester|No|Completed|January 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|N/A|N/A|No|Non-Probability Sample|The initial study population for this pilot study will consist of approximately 20 people.        The study will be comprised of approximately equal numbers of men and women. The gender        and ethnic origins of the patients seen in the University of Rochester Movement Disorders        Center (from which subjects will be recruited) are approximately 60% male and 40% female;        91% Caucasian, 1% African American, 1% Hispanic, and 0.5% Asian (6% Unknown). There are no        restrictions on gender or race, however non-english speaking patients will be excluded as        the consent form will initially only be available in English. Parkinson disease is        exceedingly rare in children and only adults will be enrolled for this study.|November 2015|November 9, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01648803||82159|
NCT01648556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI 2011_843_0002|Research of Predictive Factors to Immune Thrombopenic Purpura|Research of Predictive Factors to Immune Thrombopenic Purpura in Front of a Thrombopenia in Appearance Isolated in the Elderly|PREDI-PTI|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|September 2012|September 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|60 Years|N/A|No|||July 2015|July 28, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648556||82178|
NCT01648790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14686|A Study of Prasugrel in Healthy Participants|Relative Bioavailability of Prasugrel Orally Disintegrating Tablet Formulations and the Effect of Food on the Bioavailability of the Orally Disintegrating Tablet in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 30, 2013|July 20, 2012|No|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01648790||82160|
NCT01649037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-AKI-01|To Compare the Efficacy of Nor Adrenaline and Terlipressin vs Step up Terlipressin Therapy in Hepatorenal Syndrome'|A Randomised, Open Label Study to Compare the Efficacy of Nor Adrenaline and Terlipressin vs Step up Terlipressin Therapy in Hepatorenal Syndrome'||Institute of Liver and Biliary Sciences, India|No|Withdrawn|August 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|65 Years|No|||December 2013|August 11, 2015|July 21, 2012||No|lack of funds|No||https://clinicaltrials.gov/show/NCT01649037||82141|
NCT01636076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQMF149F2202|Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, 12-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of QMF149 (150 µg/160 µg o.d.) Compared With Salmeterol Xinafoate/Fluticasone Propionate (50 µg/500 µg b.i.d.) in Patients With Chronic Obstructive Pulmonary Disease||Novartis|Yes|Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|629|||Both|40 Years|N/A|No|||November 2014|November 13, 2014|July 5, 2012||No||No|September 10, 2014|https://clinicaltrials.gov/show/NCT01636076||83087|
NCT01636336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-p-001665|Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects|||Mclean Hospital|No|Suspended|September 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|45|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|June 21, 2012||No|Clinical studies are stopped, pending funding|No||https://clinicaltrials.gov/show/NCT01636336||83067|
NCT01636349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-088|Health Effects of Recreational Soccer in Type 2 Diabetic Men|Cardiovascular, Muscular Adaptations and Glycaemic Control to 6 Months of Recreational Soccer in Type 2 Diabetic Men||University of Copenhagen|Yes|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|22|||Male|35 Years|60 Years|No|||December 2012|December 6, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636349||83066|
NCT01636908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/128|Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.|Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.|ICK|VU University Medical Center|No|Recruiting|August 2011|||August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636908||83023|
NCT01636921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-0352 Phase II|Sorafenib and Thoracic Radiation for Non-Small Cell Lung Cancer|Phase II Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC)||M.D. Anderson Cancer Center|No|Withdrawn|January 2008|January 2011|Actual|January 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|July 5, 2012||No|Terminated with slow accrual in early phase of study.|No||https://clinicaltrials.gov/show/NCT01636921||83022|
NCT01637532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PITCH trial|Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer|Chemo-Immunotherapy: Observational Trial of Carboplatin-pegylated Liposomal Doxorubicin (PLD) or Doxorubicin Combination Chemotherapy With Tocilizumab, a Humanized Monoclonal Antibody Against the Human Interleukin-6 (IL-6) Receptor, and Pegylated Interferon Alpha (Peg-Intron) for Patients With Recurrent Ovarian Cancer.|PITCH|Leiden University Medical Center|Yes|Completed|February 2011|September 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|21|||Female|18 Years|N/A|No|||January 2016|January 25, 2016|April 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01637532||82975|
NCT01637792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|044119620|Randomized Controlled Trial Comparing Residual Renal Function in Patients Undergoing Three or Four Exchanges CAPD|Randomized Controlled Trial Comparing Residual Renal Function in Patients Undergoing Three or Four Exchanges CAPD||Shanghai Jiao Tong University School of Medicine|No|Completed|June 2004|August 2010|Actual|August 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|80 Years|No|||July 2012|July 8, 2012|July 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01637792||82955|
NCT01637805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-ZRP-201205001|Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer|Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With CEA Gene in Stage IV Gastric Cancer|AAV-DC-CTL|Tianjin Medical University Cancer Institute and Hospital||Active, not recruiting|May 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|30|||Both|18 Years|80 Years|No|||July 2012|March 7, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01637805||82954|
NCT01636479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED12318|Phase 1 Safety Testing of SAR405838|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer||Sanofi|No|Active, not recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|82|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01636479||83056|
NCT01643616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HV 2010 003|Ultrasound Guided Distal Sciatic Nerve Block - a Comparison With Nerve Stimulator Technique|Ultrasound Guided Distal Sciatic Nerve Block - a Randomised Comparison With Nerve Stimulator Technique||Helios Research Center|No|Completed|November 2010|September 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|75 Years|No|||August 2013|August 27, 2013|July 16, 2012||No||No|March 21, 2013|https://clinicaltrials.gov/show/NCT01643616||82511|
NCT01639534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM12941|Biomarkers of Ischemia: Xanthine, Hypoxanthine and Inosine Levels During Carotid Stenting Procedures|Biomarkers of Ischemia: Xanthine, Hypoxanthine and Inosine Levels During Carotid Stenting Procedures||Virginia Commonwealth University|No|Active, not recruiting|March 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|10|Samples Without DNA|An aliquot of each sample will be stored for potentialconfirmatory reanalysis in the future      at this or a contracted insitution.|Both|18 Years|N/A|No|Non-Probability Sample|Patients scheduled for Carotid Stenting Procedure at Virginia Commonwealth University|November 2013|November 26, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639534||82821|
NCT01639820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008.515|Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts|Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Randomized Multicenter Study With Evaluation of Medico-economic Impacts|SENTICOL2|Hospices Civils de Lyon|No|Completed|January 2009|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|267|||Female|18 Years|N/A|No|||December 2011|August 21, 2013|September 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01639820||82799|
NCT01640626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University Of Malaya|Impact of Health Education on School Children|The Impact of Health Education in Controlling Soil-transmitted Helminthiasis Among Orang Asli Schoolchildren||University of Malaya|Yes|Completed|July 2012|November 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|317|||Both|5 Years|14 Years|No|||June 2014|June 22, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640626||82739|
NCT01637636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VP-VEC-162-1112|Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.|An Open-label, Single-sequence Study in Two Cohorts of Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.||Vanda Pharmaceuticals|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2014|February 14, 2014|June 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01637636||82967|
NCT01638442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TST101|Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects|An Open-label, Randomized, Two-way Crossover Trial of the Effect of a High-Fat Meal on the Pharmacokinetics of Oral Tosedostat (CHR 2797) in Healthy Male Subjects|8265134|CTI BioPharma|No|Active, not recruiting|June 2012|September 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|18|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 18, 2012|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638442||82905|
NCT01638117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP-TRPV1_PI-02|Cumulative Irritation Test of PAC-14028 in Healthy Volunteers|Phase I Clinical Trial to Investigate the Cumulative Skin Irritation of PAC-14028 in Healthy Volunteers||Amorepacific Corporation|No|Completed|April 2012|||August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Actual|35|||Both|20 Years|59 Years|Accepts Healthy Volunteers|||January 2014|January 19, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638117||82930|
NCT01638130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B322201110320|Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers|Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers||Universitaire Ziekenhuizen Leuven|No|Recruiting|February 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a high-grade glioma and their caregivers|July 2012|July 11, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01638130||82929|
NCT01648569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreanAES003|Long-term Outcomes of Total Thyroidectomy Versus Less Than Total Thyroidectomy for Papillary Thyroid Microcarcinoma|Proper Extent of Surgery for Papillary Microcarcinoma||Korean Association of Endocrine Surgeons|Yes|Completed|January 2012|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2014|||Both|10 Years|60 Years|No|Non-Probability Sample|We evaluated 2014 patients with PTMC who underwent TT (n=1015) or LT (n=999) between March        1986 and December 2006 and for whom complete follow-up data were available for at least 5        years (median 11.8 years; range 5-26 years).|July 2012|July 23, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01648569||82177|
NCT01649089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0278|Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer|Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/&lt;2CM) Cervical Cancer||Gynecologic Oncology Group|Yes|Recruiting|October 2012|||October 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|600|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01649089||82138|
NCT01649063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vaginal delivery and cesarean|Comparing the Shape and Frequency of Uterine Contractions|Principle Investigator||Mashhad University of Medical Sciences|Yes|Completed|April 2010|July 2011|Actual|June 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|95|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|primiparous women|July 2012|July 24, 2012|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01649063||82139|
NCT01649362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105/04|Effects of Prefeeding Oral Stimulation on Feeding Performance in Preterm Infants|Effects of Prefeeding Oral Stimulation on Feeding Performance in Preterm Infants Born Between 26 and 33+6 Weeks' Gestational Age: a Case-control Study||Centre Hospitalier du Luxembourg|No|Completed|June 2011|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|101|||Both|N/A|N/A|No|||February 2014|February 9, 2014|July 18, 2012||No||No|October 29, 2013|https://clinicaltrials.gov/show/NCT01649362||82118|
NCT01644695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BARS|Review of Complex Recurrent Hernia Repair|Repair of Complex Recurrent Incisional Hernias With The Bony Anchoring Reinforcement System (BARS)|BARS|Institute For Advanced Reconstruction|Yes|Enrolling by invitation|October 2011|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Actual|85|||Both|18 Years|65 Years|No|Non-Probability Sample|Over 18 with Hernia. Included men and women, minorities, and non-english speakers.|September 2012|September 11, 2012|July 17, 2012|No|Yes||No|September 11, 2012|https://clinicaltrials.gov/show/NCT01644695||82429|
NCT01636375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI DAA/PA|Comparison of Muscle Atrophy After Direct Anterior & Posterior Total Hip Arthroplasty|The Influence of Operative Approach on Muscle Atrophy After Total Hip Arthroplasty: A Comparison of Anterior and Posterior Approaches||Northwell Health|No|Active, not recruiting|May 2012|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|19|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients undergoing Total Hip arthroplasty by one of the two fellowship trained        arthroplasty surgeons.|March 2016|March 21, 2016|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01636375||83064|
NCT01636362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MpT Ag 01|A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns|An Open, Non Controlled, Multi-centre, Clinical Investigation to Evaluate Efficacy in Partial Thickness (Superficial, Deep and Mixed) Second Degree Burns When Using a Soft Silicone, Silver Containing, Wound Contact Layer, Mepitel Ag.||Molnlycke Health Care AB|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|2 Years|N/A|No|||December 2013|September 29, 2014|June 26, 2012||No||No|August 26, 2014|https://clinicaltrials.gov/show/NCT01636362||83065|
NCT01636934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0347|Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy|A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer||M.D. Anderson Cancer Center|Yes|Active, not recruiting|July 2012|||July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|July 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636934||83021|
NCT01637818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R59|Long-term Follow-up of Lichtenstein's Operation Versus Mesh Plug Repair|Long-term Follow-up of a Randomized Clinical Trial of Lichtenstein's Operation Versus Mesh Plug for Inguinal Hernia Repair||University Hospital, Basel, Switzerland|No|Completed|September 1999|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|594|||Both|39 Years|N/A|No|||July 2012|July 11, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637818||82953|
NCT01638065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP1011|A Comprehensive Look at Vascular Access|A Comprehensive Look at Vascular Access: Utilizing a Near Infrared Vein Visualization Device For Vascular Access Planning, Attempts, and Post Access||Christie Medical Holdings, Inc.|No|Completed|May 2012|July 2013|Actual|March 2013|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|196|||Both|N/A|N/A|No|Probability Sample|Patients at a medical facility requiring IV access.|January 2014|January 30, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638065||82934|
NCT01638364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041/2012|Dopamine Release in the Human Brain Following Alcohol Administration|Imaging Alcohol Induced Dopamine Release in the Human Brain: a PET/[11C](+)PHNO Study||Centre for Addiction and Mental Health|No|Completed|January 2013|June 2015|Actual|June 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|8|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01638364||82911|
NCT01638650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP25607|A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients|To Determine the Effect of the Modified SQV/r (Saquinavir-boosted by Ritonavir) Regimen (500/100 mg for the 1st Week Followed by 1000/100 mg for the 2nd Week) on the QTc Interval, Pharmacokinetics, and Antiviral Activity in Treatment-naive HIV-1 Infected Patients||Hoffmann-La Roche||Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01638650||82889|
NCT01636232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPLAGH-2012026|Vitamin D and Critically Ill Patients|Vitamin D Levels and Risk of Infection, Assessment for Disease Severity, and Predictor of Mortality in the Chinese Intensive Care Units: a Prospective Cohort Study||Chinese PLA General Hospital|No|Completed|October 2011|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|234|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All the subjects were selected from among inpatients who were hospitalized between        October-December, 2011 in the Surgical ICU, Respiratory ICU, and Emergency ICU, Chinese        PLA General Hospital.|July 2012|July 9, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636232||83075|
NCT01636700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP2011|Tramadol Infiltration for Tonsillectomy|Comparative Study of Analgesic Effect and Serum IL-6 With Tramadol Infiltration or Intravenous After Tonsillectomy||Federal University of São Paulo|No|Withdrawn|October 2011|October 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|4 Years|12 Years|No|||February 2014|July 27, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636700||83039|
NCT01636713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114634|A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD|A 24-week Randomised, Double-blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|July 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|581|||Both|40 Years|N/A|No|||May 2014|May 22, 2014|July 5, 2012||No||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01636713||83038|
NCT01644110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POMINC(MPNSG02-12)|Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF|A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis|POMINC|University of Ulm|Yes|Recruiting|August 2013|January 2021|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01644110||82473|
NCT01644357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATENFAR-PROAR|Effect of a 12-month Pharmaceutical Care Program on Control of Severe Asthma|PROJECT IMPLEMENTATION OF PHARMACEUTICAL CARE IN SEVERE ASTHMA IN OUTPATIENT PHARMACY DEPARTMENT.||Federal University of Bahia|Yes|Recruiting|August 2008|||August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|40|||Both|18 Years|80 Years|No|||March 2013|March 4, 2013|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644357||82455|
NCT01644591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0875|Melanoma Gamma Knife|A Prospective Randomized Phase III Trial to Compare Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With >3 Brain Metastases From Melanoma||M.D. Anderson Cancer Center|Yes|Active, not recruiting|August 2012|||August 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644591||82437|
NCT01637597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201204080RIC|Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation|An Exploratory Study Of Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation Determined By Different Molecular Diagnostic Methods||National Taiwan University Hospital|No|Terminated|June 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|12|Samples With DNA|Blood and tumor tissue are being collected during the course of this study, to assess the      safety and tolerability and spectrum of side effects of the study drug. However, it is      possible that after completion of all study-related analyses, some volume of samples may      remain. These left-over samples could be a valuable resource for future research.      Before any left-over samples can be used for any research other than that specified in the      protocol, patient must sign an additional future use consent from indicating they give their      permission for these samples to be used in future research. By signing the main consent      form, patients are only giving their permission to use their samples for the study related      procedures.|Both|20 Years|N/A|No|Non-Probability Sample|Patients with locally advanced or metastatic NSCLC who are eligible to apply for Extended        Access Program of crizotinib must have ALK translocation detected by RT-PCR, IHC or FISH        analyses methods.|December 2014|December 29, 2014|June 28, 2012||No|Pfizer Taiwan has received approval letter for criziontinb on March and expect obtaining    license by May 2013.|No||https://clinicaltrials.gov/show/NCT01637597||82970|
NCT01637610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-67|Detection of PPROM With AmniSure PAMG-1 Rapid Immunoassay|Detection of Preterm Prelabour Rupture of Membranes With AmniSure Placental Alpha Macroglobulin-1 Rapid Immunoassay||University of Saskatchewan|No|Terminated|September 2011|January 2014|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|85|||Female|N/A|N/A|No|Probability Sample|All women presenting to assessment at the labour and delivery unit at RUH with suspected        PPROM between 16+0 and 36+6 weeks gestation.|July 2012|May 26, 2015|June 28, 2012||No|Lack of support with enrollment.|No||https://clinicaltrials.gov/show/NCT01637610||82969|
NCT01638455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Masimo-Noninvasive 1|Pulse CO-Oximetry Noninvasive Monitoring and Laboratory Measurements of Subject Blood Samples|Noninvasive Parameter Testing With Pulse CO-Oximetry and Measurement of Blood Constituents With In-Vitro Analyzers||Masimo Corporation|No|Recruiting|June 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10000|Samples With DNA|Blood samples, venous or capillary|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects from Outpatient clinics and health fairs|July 2012|July 10, 2012|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01638455||82904|
NCT01637870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109727|Negative Pressure Wound Therapy After Cesarean Delivery|Negative Pressure Wound Therapy to Prevent Post Operative Wound Complications Following Cesarean Delivery in Women at High Risk for Wound Complications||University of Iowa|No|Recruiting|August 2012|June 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|55 Years|No|||December 2012|December 6, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637870||82949|
NCT01648816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 10056|Interaction Between Genetic Factors and Maternal Stressors During Pregnancy in the Risk of Postpartum Depression|Interaction Between Genetic Factors and Maternal Stressors During Pregnancy in the Risk of Postpartum Depression|IGEDEPP|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|November 2011|November 2015|Anticipated|November 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3000|||Female|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|causasian mothers after pregnancy|March 2015|March 6, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01648816||82158|
NCT01649427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CERL080ADE27|Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients|Spartacus|Novartis|Yes|Completed|October 2012|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|76|||Both|18 Years|64 Years|No|||October 2015|October 23, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649427||82114|
NCT01644721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMUNISE_BHP_early MV|Trial of Additional Measles Vaccine to Reduce Child Mortality|A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau||Bandim Health Project|Yes|Recruiting|July 2012|May 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|3750|||Both|4 Months|6 Months|No|||August 2014|August 6, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644721||82427|
NCT01649375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457F2310|16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis|MEASURE2|Novartis|Yes|Active, not recruiting|October 2012|October 2018|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|220|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649375||82117|
NCT01649388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICT-14900-021012|Delayed Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion|Delayed Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion||University of Louisville|Yes|Active, not recruiting|May 2012|December 2030|Anticipated|December 2025|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|65 Years|No|||November 2015|December 15, 2015|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649388||82116|
NCT01644708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CeformedDSM1|Empowerment and Overweight - a Prospective Observational Study|Th Efficacy of Individual Empowerment on Overweight and Obese Patients - a Prospective Observational Study.|ADPB-EMPW|Azienda Per I Servizi Sanitari N. 2 Isontina|No|Completed|January 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|All adult persons with BMI equal or above 25|June 2013|June 6, 2013|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644708||82428|
NCT01636401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_EKL001|Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Daewoong Pharmaceutical Co. LTD.||Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|N/A|2||||||Both|40 Years|N/A|No|||August 2013|August 20, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636401||83062|
NCT01636609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0188|Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)|Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)||M.D. Anderson Cancer Center|Yes|Active, not recruiting|November 2012|||November 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|60 Years|N/A|No|||October 2015|October 28, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636609||83046|
NCT01636596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-166|Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease|Evaluating the Efficacy of Controlled Pulsatile Intravenous Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease- A Pilot Study||Louisiana State University Health Sciences Center Shreveport|Yes|Withdrawn|September 2013|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|95 Years|No|||March 2014|March 12, 2014|July 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636596||83047|
NCT01636622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0394|Study of Vemurafenib, Carboplatin, and Paclitaxel|Phase I Study of the Combination of Vemurafenib With Carboplatin and Paclitaxel in Patients With Advanced Malignancy||M.D. Anderson Cancer Center|No|Recruiting|July 2012|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|96|||Both|12 Years|N/A|No|||October 2015|October 26, 2015|July 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636622||83045|
NCT01636947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0869-225|A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)|A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC Regimes) With Broad Range of Tumor Types (KMEC Study)|KMEC|Merck Sharp & Dohme Corp.|Yes|Completed|December 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|494|||Both|21 Years|N/A|No|||July 2015|July 2, 2015|July 5, 2012|Yes|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT01636947||83020|
NCT01638377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079/2011|Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers|A Multi-site Study to Disseminate and Evaluate Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers||Centre for Addiction and Mental Health|No|Terminated|August 2012|March 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|65 Years|No|||April 2014|April 1, 2014|June 28, 2012||No|Recruitment proved to be extremely difficult.|No||https://clinicaltrials.gov/show/NCT01638377||82910|
NCT01638663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAFA-1-2012|Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)|Effect of Vasopressin Antagonism on Renal Sodium and Water Handling and Circulation During Inhibition of the Nitric Oxide System in Healthy Subjects||Regional Hospital Holstebro|Yes|Completed|May 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||October 2014|October 8, 2014|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01638663||82888|
NCT01636505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECK011170|The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol|||European Hospital|No|Not yet recruiting|September 2012|September 2013|Anticipated|February 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|200|||Female|18 Years|46 Years|No|||July 2012|July 9, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636505||83054|
NCT01636492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP19292|A Study of Bitopertin (RO4917838) in Healthy Male Volunteers|Single Oral Ascending Dose Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4917838 in Healthy Male Volunteers.||Hoffmann-La Roche||Completed|November 2005|August 2006|Actual|August 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|71|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636492||83055|
NCT01637051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-033|The Importance of Different Modularity of the Polyethylene Insert for Tibial Component Migration and Adaptive Bone Remodeling After Uncemented Total Knee Arthroplasty Using Trabecular Metal Technology (TMT) Zimmer NexGen®, (Monoblock vs. Modular Design)|The Importance of Different Modularity of the Polyethylene Insert for Tibial Component Migration and Adaptive Bone Remodeling After Uncemented Total Knee Arthroplasty Using Trabecular Metal Technology (TMT) Zimmer NexGen®, (Monoblock vs. Modular Design)||Rigshospitalet, Denmark|Yes|Active, not recruiting|July 2012|August 2025|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637051||83012|
NCT01637337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|89-01-01-2391|Laparoscopic Pyelolithotomy Versus Percutaneous Nephrolothotomy for Management of >3cm Renal Pelvis Stone|||Shiraz University of Medical Sciences||Recruiting|May 2012|||December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|16 Years|N/A|No|||July 2012|July 13, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01637337||82990|
NCT01637350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-WXN-201205001|Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes|The Effect of Blood Glucose to Different Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes||Tianjin Medical University Cancer Institute and Hospital|No|Enrolling by invitation|August 2012|December 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|75 Years|No|Non-Probability Sample|gastric cancer with type 2 diabetes,18~75 years old,without serious underlying diseases|August 2012|February 14, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637350||82989|
NCT01637376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134367|Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer|Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer||University of Arkansas|No|Withdrawn|July 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||January 2014|January 14, 2014|July 6, 2012|No|Yes|No participants were enrolled|No||https://clinicaltrials.gov/show/NCT01637376||82987|
NCT01637389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB_CPHS_2009-1-47|Evaluation of Safe-Water Programs in Baja California Sur, Mexico|A Stepped Wedge, Cluster-randomized Impact Evaluation of a Household UV-treatment and Safe Storage Drinking Water Intervention in Rural Baja California Sur, Mexico||University of California, Berkeley|No|Completed|July 2009|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1731|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 10, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637389||82986|
NCT01637623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0026|Study of Cardiovascular Disease and Obstructive Sleep Apnea|Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea|CVD/OSA|University of Wisconsin, Madison|Yes|Recruiting|June 2012|||February 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|21 Years|65 Years|No|||October 2015|October 9, 2015|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637623||82968|
NCT01638468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERFUSE|Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System|Pulmonary Embolism Removal With the AngioJet 6F Ultra SystEm (PERFUSE)|PERFUSE|Boston Scientific Corporation|Yes|Suspended|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|July 6, 2012||No|Slow Enrollment|No||https://clinicaltrials.gov/show/NCT01638468||82903|
NCT01638741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rehabilitation|The Need for Rehabilitation and the Connection With Attachment Styles Among Patients With Gynaecological Cancer|Rehabilitation and the Association With Attachment Styles Among Patients With Gynaecological Cancer||Odense University Hospital|No|Recruiting|September 2011|October 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Female|20 Years|75 Years|No|Non-Probability Sample|Study Population Description * Patients referred to Odense University Hospital outpatient        clinic with suspition for gynaecological cancer. The patients are from to Regions in        Danmark, Region Zealand and Region South Denmark.|April 2013|April 23, 2013|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01638741||82882|
NCT01638754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-074|Image Guided Mapping for Cardiac Pacing Intervention|Multi-Modality Imaging Assessment for Pacing Interventions in Heart Failure: Targeting Optimal Sites and Outcomes|MAPIT-TOO|Lawson Health Research Institute|No|Active, not recruiting|May 2011|December 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|41 Years|N/A|No|||July 2012|July 11, 2012|June 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01638754||82881|
NCT01649115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLPP 2012|The Healthy Lifestyles Passport Program: a Nutrition Education Program to Prevent Childhood Obesity|The Healthy Lifestyles Passport Program: a Randomized Control Trial of a Prenatal Maternal Education Program to Prevent Infant and Childhood Obesity (HLPP)|HLPP|Bronx-Lebanon Hospital Center Health Care System|No|Not yet recruiting|August 2012|August 2017|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|150|||Female|N/A|N/A|No|||August 2012|August 8, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01649115||82136|
NCT01649401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/LG-02|Efficacy of the PARI LC Sprint Sp Nebulizer for Acute Asthma Attack in Hospitalized Children Less Than 36 Months of Age|Efficacy of the PARI LC Sprint Sp Nebulizer for Acute Asthma Attack in Hospitalized Children Less Than 36 Months of Age|LC SPRINT Sp|Centre Hospitalier Universitaire de Nīmes|No|Recruiting|December 2012|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|6 Months|36 Months|No|||October 2015|October 19, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649401||82115|
NCT01644747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STICODEP|tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients|tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients: a Randomized, Double-blind, Placebo Controlled Study|STICODEP|Centre Hospitalier Universitaire de Besancon|No|Recruiting|July 2012|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||February 2015|February 27, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644747||82425|
NCT01645059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACI-CMM-2010-01|Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy|Observational, Cross-sectional, Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy (PRIMHER)|PRIMHER|Asociación Cacereña para la Investigación y el Desarrollo en Oncología Médica|No|Completed|July 2011|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|129|||Female|18 Years|N/A|No|Non-Probability Sample|Female patients with disseminated HER2+ breast cancer in first line treatment|November 2013|November 20, 2013|July 13, 2012||No||No|July 9, 2013|https://clinicaltrials.gov/show/NCT01645059||82401|
NCT01644734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.502|Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test|MATHS: Assessment of Health-status of Patients With COPD on MAintenance THerapy With Spiriva® HH Measured by CAT Test||Boehringer Ingelheim||Completed|November 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment|1||Actual|1328|||Both|N/A|N/A|No|||April 2014|April 30, 2014|July 17, 2012||||No|March 28, 2014|https://clinicaltrials.gov/show/NCT01644734||82426|
NCT01645046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008MMXX2CoA005|The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia|The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia: a Randomized, Double-blinded, Placebo-controlled, Multi-center Clinical Trial||Zhejiang University|Yes|Completed|October 2008|August 2009|Actual|June 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|294|||Both|18 Years|75 Years|No|||July 2012|July 18, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01645046||82402|
NCT01636154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUCMDFH9634|Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations|Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations:A Prospective Randomized Controlled Multi-site Clinical Trial About Fractions-based Herbal Combinations of Clearing Heat and Promoting Blood Circulation||Dongfang Hospital Affiliated to Beijing University of Chinese Medicine|Yes|Recruiting|January 2012|August 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|40 Years|75 Years|No|||September 2015|September 16, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01636154||83081|
NCT01636414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051114B|Reinfusion Drains vs Tranexamic Acid in Total Joint Arthroplasty|||OrthoCarolina Research Institute, Inc.|Yes|Active, not recruiting|May 2012|October 2015|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|234|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01636414||83061|
NCT01637233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARCH-Kirby CNS|MARCH Central Nervous System Substudy|Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N(t)RTI) or Boosted Protease Inhibitors (PI/r) in HIV-1 Infected Individuals With Stable, Well-controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of Combination Antiretroviral Therapy (cART).||Kirby Institute|Yes|Completed|June 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|28|Samples Without DNA|plasma and CSF|Both|18 Years|N/A|No|Probability Sample|participants in the MARCH main study who are eligible for the CNS substudy and provide        written informed consent for participation|January 2016|January 18, 2016|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01637233||82998|
NCT01637246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/017|A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy|||Allergan|No|Completed|April 2009|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4385|||Both|N/A|N/A|No|Non-Probability Sample|Patients with Primary Open Angle Glaucoma or Ocular Hypertension|August 2012|August 21, 2012|July 9, 2012||No||No|August 21, 2012|https://clinicaltrials.gov/show/NCT01637246||82997|
NCT01642797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120621|Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma|Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma: A Multicenter, Randomized, Controlled Trial||Shandong University|Yes|Not yet recruiting|August 2012|September 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|242|||Both|18 Years|80 Years|No|||July 2012|July 17, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642797||82574|
NCT01643031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6793|Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel|Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel|MATTIS-D|Rabin Medical Center|Yes|Not yet recruiting|August 2012|October 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|30 Years|80 Years|No|||June 2013|June 14, 2013|July 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643031||82556|
NCT01643044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34AA020056|Computer-delivered Screening and Brief Intervention for Alcohol Use in Pregnancy|Computer-delivered SBIRT for Alcohol Use in Pregnancy: Planning a Stage II Trial||Wayne State University|No|Completed|April 2011|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|48|||Female|18 Years|40 Years|No|||July 2014|July 7, 2014|July 13, 2012||No||No|July 7, 2014|https://clinicaltrials.gov/show/NCT01643044||82555|
NCT01636752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVIDENT Trial|Effectiveness of Internet-based Depression Treatment||EVIDENT|University of Luebeck|Yes|Active, not recruiting|July 2012|February 2017|Anticipated|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|65 Years|No|||May 2015|May 26, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636752||83035|
NCT01636765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|199201-003|Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale|||Allergan|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|104|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with facial erythema related to rosacea|September 2013|September 12, 2013|July 9, 2012|Yes|Yes||No|September 12, 2013|https://clinicaltrials.gov/show/NCT01636765||83034|
NCT01637402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF Protocol No. 12551|A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer|A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC)||University of California, San Francisco|Yes|Active, not recruiting|March 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Male|18 Years|N/A|No|||September 2015|October 1, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637402||82985|
NCT01636726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115733|WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction|WEUKBRE5554: IMI PROTECT (Work Package 2): Use of Long Acting beta2 Adrenoceptor Agonists and Acute Myocardial Infarction (AMI)||GlaxoSmithKline|No|Completed|March 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|Descriptive study - all patients included in the period of valid data collection. The        study period will be defined from Jan 1, 2002 to Dec 31, 2009.        Cohort and nested case-control studies - all patients who received at least one        prescription of an inhaled LABA, SABA, LAMA, or SAMA and with coded diagnosis of asthma        and / or COPD during the study period.|March 2015|March 26, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636726||83037|
NCT01636739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115927|Special Drug Use Investigation for ROTARIX®|Special Drug Use Investigation for ROTARIX||GlaxoSmithKline||Completed|July 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10982|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Infants who receive Rotarix for the first time to prevent rotavirus gastroenteritis.|October 2015|October 29, 2015|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636739||83036|
NCT01637064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADAPT|Dermatomyositis and Polymyositis Registry|Acthar Dermatomyositis and Polymyositis Treatment|ADAPT|Phoenix Neurological Associates, LTD|Yes|Enrolling by invitation|April 2013|||December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|100|None Retained|This is a retrospective and prospective study|Both|18 Years|85 Years|No|Non-Probability Sample|All sites chosen are well-established universities, academic centers or private practices        that specialize in neuromuscular diseases. These are physicians who have several myositis        patients and who are prescribing or would prescribe Acthar to myositis patients|November 2015|November 5, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637064||83011|
NCT01637363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-2-2-011|Psychoeducation to Sick-listed Individuals With Mental Health Problems|Psychoeducation to Sick-listed Individuals With Mental Health Problems||University of Aarhus|No|Active, not recruiting|September 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|400|||Both|18 Years|64 Years|No|||February 2014|May 28, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637363||82988|
NCT01638156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACRIN PA 4008|Cardiac MRI for Severe Aortic Stenosis|Arterial Stiffness and Wave Reflections as Determinants of Regression of Left Ventricular Hypertrophy and Fibrosis Assessed With Cardiac MRI After Aortic Valve Replacement for Severe Aortic Stenosis||American College of Radiology Imaging Network|Yes|Recruiting|June 2013|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|80|Samples Without DNA|Collecting three tubes of blood: 10-mL of blood for plasma sampling, 10-mL of serum, and a      microtube or other adequate sample for hematocrit measurements. Hematocrit measurements      within 24 hours prior to the cardiac MRI scan. Serum and plasma samples will be stored at      -80°C in 0.5 mL vials.|Both|18 Years|N/A|No|Non-Probability Sample|Patients who are 18 years of age or older with no contraindications to gadolinium        contrast-enhanced MRI of the heart who are able to have a cardiac MRI in the 21 days        before the AVR operation, have been diagnosed with severe symptomatic aortic stenosis        (estimated aortic valve area <1 cm2),1,2 and are scheduled for AVR between 0 and 28 days        after enrollment. Potential participants will have undergone a clinically indicated        pre-operative evaluation showing the absence of hemodynamically-significant CAD that would        require revascularization during the AVR operation.|August 2013|August 19, 2013|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638156||82927|
NCT01638169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920100239|The Contribution of Heels for Walking Quality Among Children With Muscular Dystrophy|||Alyn Pediatric & Adolecent Rehabilitation Center|Yes|Completed|May 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only||1|Actual|11|||Both|6 Years|15 Years|No|Non-Probability Sample|children with DMD age >6 yrs walk without heel strike|June 2015|June 22, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638169||82926|
NCT01639066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC2012-1208|Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B|A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment|IN-US-0205|Asan Medical Center|Yes|Active, not recruiting|September 2012|February 2018|Anticipated|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|20 Years|75 Years|No|||June 2015|June 24, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639066||82857|
NCT01638767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-10-03|NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles|Effect of Using the Nuvaring on the Level of Satisfaction, Stress on Users and on Coordinating In Vitro Fertilization (IVF) Cycles: Randomized Public Study||OVO R & D|No|Terminated|July 2012|July 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|7|||Female|18 Years|43 Years|No|||July 2015|July 24, 2015|July 6, 2012||No|Difficulty to recruit patient due to lack of eligible patient|No||https://clinicaltrials.gov/show/NCT01638767||82880|
NCT01638780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-3-092|Resveratrol and Type 2 Diabetes|Effect of Resveratrol on Insulin Sensitivity and Metabolic Profile in Type 2 Diabetics||Maastricht University Medical Center|No|Active, not recruiting|May 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Male|40 Years|70 Years|No|||September 2014|September 3, 2014|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01638780||82879|
NCT01649440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPLAGH-2012023(1)|Sepsis Metabolomics|Systemic Metabolic Changes of Sepsis Patients Revealed by an LC-MS/MS Based Metabolomic Approach||Chinese PLA General Hospital|Yes|Completed|July 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||5|Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All subjects were selected from among inpatients who were hospitalized between July 2010        and Mar 2012 in the Respiratory ICU, Surgical ICU, and Emergency ICU, Chinese People's        Liberation Army (CPLA) General Hospital.|January 2014|January 13, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649440||82113|
NCT01644760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2012/LM-01|Respiratory Variations in the Diameter of the Inferior Vena Cava With Spontaneous Ventilation|Respiratory Variations in the Diameter of the Inferior Vena Cava With Spontaneous Ventilation: A Physiological Study on Healthy Volunteers||Centre Hospitalier Universitaire de Nīmes|No|Completed|September 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|52|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 25, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644760||82424|
NCT01645332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS3233-0912|Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus|Role of DLBS3233 in the Treatment of Subjects With New Onset of Type 2 Diabetes Mellitus||Dexa Medica Group|No|Completed|July 2012|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|60 Years|No|||October 2014|October 7, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645332||82380|
NCT01645761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSHH Endonase 1|Additive Effect of Endonase on Eradication Rate of First Line Therapy for Helicobacter Pylori|Additive Effect of Endonase on Eradication Rate of the 7-day Standard Proton Pump Inhibitor-based Triple Therapy for Helicobacter Pylori||Chuncheon Sacred Heart Hospital|Yes|Completed|June 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|112|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01645761||82363|
NCT01645774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|interventional|Comparing Pain and Bruising of Subcutaneous Heparin Injection|||Mashhad University of Medical Sciences|Yes|Terminated|January 2011|June 2012|Actual|June 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|4||Actual|90|||Both|53 Years|69 Years|No|||June 2012|July 19, 2012|May 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01645774||82362|
NCT01636960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08556|A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)|An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol No. MK-4031 370 Also Known as SCH 54031, P08556)||Merck Sharp & Dohme Corp.|No|Active, not recruiting|December 2012|October 2016|Anticipated|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|20 Years|75 Years|No|||February 2016|February 3, 2016|July 5, 2012|No|Yes||No|January 26, 2015|https://clinicaltrials.gov/show/NCT01636960||83019|
NCT01636973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0027|Effects of Humidified Ventilation on Arterial Oxygenation and Respiratory Mechanics During One Lung Ventilation|||Yonsei University|Yes|Completed|March 2011|April 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|1||Actual|60|||Both|30 Years|75 Years|No|||July 2012|July 9, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636973||83018|
NCT01637545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B-1107-131-007|Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations|Phase 4 Study of Nasea(R)/Ramosetron Inj.as Anti-emetics in the Patients Undergoing Facial Bone Fracture Operations||Seoul National University Hospital|No|Terminated|December 2011|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|49|||Both|N/A|N/A|No|||May 2015|May 7, 2015|July 8, 2012||No|Principal Investigator is away on business|No||https://clinicaltrials.gov/show/NCT01637545||82974|
NCT01637558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DATiC|Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)|Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)|DATiC|University of Cape Town|No|Active, not recruiting|November 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|240|||Both|1 Month|12 Years|No|||August 2015|August 31, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01637558||82973|
NCT01643369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0123-02|The Sounds of Compassion: Testing How Specific Elements of Meditation Change Daily Life|The Sounds of Compassion: Testing How Specific Elements of Meditation Change Daily Life||University of Arizona|Yes|Completed|November 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|32|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 5, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643369||82530|
NCT01643382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HiRT 042918|Hyperglycemia in Renal Transplantation|Randomized Study of the Impact of Peri-operative Glucose Control on Short Term Renal Allograft Function After Transplantation|HiRT|University of California, San Francisco|Yes|Recruiting|August 2012|August 2020|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||December 2014|December 15, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643382||82529|
NCT01636219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-11-8709-OE-SMC|Cough Efficiency in Cystic Fibrosis|Cough Efficiency in Cystic Fibrosis||Sheba Medical Center|No|Completed|September 2012|August 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|100|||Both|8 Years|50 Years|No|Non-Probability Sample|Any CF patient visiting the pulmonary function laboratory, above 8 years old, who could        cooperate with spirometry and who had no exacerbation, upon signing agreement consent|February 2014|February 6, 2014|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636219||83076|
NCT01640379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TECHNPID|Technology Enhanced Community Health Nursing (TECH-N) Study|Technology Enhanced Community Health Nursing (TECH-N) to Prevent Recurrent Sexually Transmitted Infections After Pelvic Inflammatory Disease|TECH-N|Johns Hopkins University|Yes|Recruiting|July 2012|July 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|350|||Female|13 Years|25 Years|No|||January 2016|January 1, 2016|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640379||82758|
NCT01637415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22731|The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS)|The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS): Development and Psychometric Characteristics of a New Scale for the Prediction of Complicated Alcohol Withdrawal Syndrome.|PAWSS|Stanford University|No|Completed|May 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|409|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients at Stanford Hospital and Clinics selected medical & surgical inpatient        units (B2, B3, and C2), admitted directly from either Stanford ED or from any community or        outpatient setting.|January 2015|January 28, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01637415||82984|
NCT01637428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|727209-HMO-CTIL|The Use of Intermittent Pneumatic Compression Device for Symptomatic Relief in Patients With Post Thrombotic Syndrome|The Use of Intermittent Pneumatic Compression Device for Symptomatic Relief in Patients With Post Thrombotic Syndrome||Hadassah Medical Organization|Yes|Not yet recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|80 Years|No|||July 2012|July 15, 2012|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637428||82983|
NCT01637649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5-2-0120-60-668|Diaphragmatic Function in Stroke Patients.|Diaphragm Function Evaluation in Stroke Patients During Voluntary Cough Using Sonography||The Catholic University of Korea|Yes|Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|75|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Stroke patients from a university affiliated medical center|June 2013|June 17, 2013|July 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01637649||82966|
NCT01637883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|54-039-08-1-2|Benzydamine HCl for Postoperative Sore Throat|Efficacy of Benzydamine Hydrochloride Dripping at Endotracheal Tube Cuff for Prevention of Postoperative Sore Throat|POST|Prince of Songkla University|Yes|Recruiting|January 2011|August 2012|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|86|||Both|18 Years|65 Years|No|||July 2012|July 25, 2012|July 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01637883||82948|
NCT01637896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo000|A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation|A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation: the ELICOPTER Trial|ELICOPTER|Ospedale San Donato|No|Terminated|June 2010|July 2012|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|July 7, 2012||No|the study was halted after an interim analysis perfomed for a perceived excess of target    vessel revascularization in the DEB+BMS arm|No||https://clinicaltrials.gov/show/NCT01637896||82947|
NCT01638481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58802-LS|Chronology of Occult and Gross Coagulopathy in Burn Patients|Determining the Chronology of Occult and Gross Coagulopathy in Thermally Injured Patients: A Systems Biology Approach||Medstar Research Institute|No|Recruiting|July 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||5|Anticipated|85|||Both|18 Years|N/A|No|Non-Probability Sample|Burn injury patients will be enrolled in the study upon arrival at Trauma Center.|May 2015|May 1, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638481||82902|
NCT01638793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JWGUHMED1-006|Capnographic Monitoring of Propofol-sedation During Colonoscopy|Capnographic Monitoring of Propofol-sedation During Colonoscopy||Johann Wolfgang Goethe University Hospitals|No|Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|528|||Both|18 Years|N/A|No|||June 2012|October 24, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01638793||82878|
NCT01639651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02195112.7.0000.5505|The Acute Effect of a Mobilization With Movement Technique to Improve Internal Rotation of the Shoulder|Principal Investigator||Federal University of São Paulo|Yes|Completed|June 2012|August 2015|Actual|August 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|15 Years|18 Years|Accepts Healthy Volunteers|||September 2015|September 1, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01639651||82812|
NCT01639339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114054|Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis|BLISS-LN|GlaxoSmithKline|Yes|Recruiting|July 2012|March 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|464|||Both|18 Years|N/A|No|||February 2016|March 17, 2016|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639339||82836|
NCT01649466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ADE08|Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.|A Randomized Open-label Study to Compare Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Patients With Type 2 Diabetes Mellitus That do Not Reach Adequate Glycemic Control on Their Current Sulfonylurea Monotherapy.|BENEFIT|Novartis||Completed|August 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|162|||Both|18 Years|85 Years|No|||October 2013|October 28, 2013|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649466||82111|
NCT01644773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJHG12|Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)|Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)||St. Jude Children's Research Hospital|No|Recruiting|August 2012|September 2019|Anticipated|September 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|2 Years|21 Years|No|||February 2016|February 18, 2016|July 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01644773||82423|
NCT01645085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4300C00020|A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib|An Open-label, Single-center, Randomized, 4-way Crossover Study to Assess the Bioequivalence of R406 in Healthy Volunteers When 100 and 150mg of Fostamatinib Are Administered as the 13% Drug-loaded Tablet Versus the 38% Drug-loaded Tablet|Fosta BE|AstraZeneca||Completed|July 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|88|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 18, 2013|July 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01645085||82399|
NCT01645072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIIMS|Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy|Efficacy of Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy - A Randomized Controlled Trial||All India Institute of Medical Sciences, New Delhi|No|Recruiting|June 2011|October 2012|Anticipated|August 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|2 Years|15 Years|No|||July 2012|July 17, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01645072||82400|
NCT01645345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|022012|Fractional Ablative Radiofrequency for the Treatment of Acne Scars and Wrinkles|RF Pixel With Micro-Plasma Technology: Fractional Ablative Radiofrequency for the Treatment of Acne Scars and RF Pixel With Micro-Plasma Technology: Fractional Ablative Radiofrequency for the Treatment of Acne Scars and||Alma Lasers Inc.|No|Active, not recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 18, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01645345||82379|
NCT01636635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2765|Effect of Age and Weight Loss on Inflammation and Iron Homeostasis|Effect of Age and Weight Loss on Obesity-related Inflammation and Iron Homeostasis in Women|HEP|Tufts University|No|Completed|March 2011|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|44|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 12, 2015|January 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01636635||83044|
NCT01636648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|En_2012|Enable I Long-term Follow-up Study|Enable I Long-term Follow-up Study||Medtronic Cardiovascular|No|Active, not recruiting|August 2012|April 2020|Anticipated|December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who were enrolled and implanted during the previous investigational study named        "ATS 3f Enable™ Aortic Bioprosthesis Model 6000" (study number S2005).|October 2015|October 6, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636648||83043|
NCT01637259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MARCH-Kirby renal|MARCH Renal Substudy|Maraviroc Switch Collaborative Study Renal Substudy|MARCHrenal|Kirby Institute|Yes|Completed|June 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|76|||Both|18 Years|N/A|No|||January 2016|January 18, 2016|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01637259||82996|
NCT01637272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230X2203|Intra-patient Dose Escalation Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome|A Multi-center, Intra-patient Dose Escalation Phase II Study to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome||Novartis|No|Completed|January 2013|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01637272||82995|
NCT01638078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|429/2012/D|Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation|Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation - The TOP RACER Trial|TOP RACER|University of Roma La Sapienza|Yes|Not yet recruiting|January 2014|December 2017|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01638078||82933|
NCT01636245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO-EV71-3002|Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine|Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial||Sinovac Biotech Co., Ltd|Yes|Completed|July 2012|February 2013|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|1400|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||March 2013|March 13, 2013|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636245||83074|
NCT01636258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-340|FRESH Study (Fitness, Relaxation and Eating to Stay Healthy)|Diet, Exercise, Cooking, and Stress Management for Patients With Prediabetes: A Pilot Randomized Controlled Study|FRESH|The Cleveland Clinic|No|Completed|May 2012|December 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|27|||Female|18 Years|N/A|No|||May 2014|May 21, 2014|July 5, 2012||No||No|October 31, 2013|https://clinicaltrials.gov/show/NCT01636258||83073|
NCT01638195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KM11-002|A Safety Evaluation of Renal Denervation Using Focused Therapeutic Ultrasound on Patients With Refractory Hypertension|A Feasibility Study: A Safety Evaluation of Renal Denervation Using Focused Therapeutic Ultrasound on Patients With Refractory Hypertension||Kona Medical Inc.|No|Completed|June 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||April 2015|April 10, 2015|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01638195||82924|
NCT01637077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11C3|Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel|RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome||Academic and Community Cancer Research United|Yes|Active, not recruiting|January 2012|||June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|46|||Both|18 Years|N/A|No|||March 2015|February 11, 2016|March 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01637077||83010|
NCT01637090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30213|Everolimus in Treating Cutaneous T-cell Lymphoma|PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)|CTCL|Boston Medical Center|Yes|Recruiting|June 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2015|January 28, 2015|April 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637090||83009|
NCT01637662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2012-065|Natriuretic Peptide's Headache Inducing Characteristics and Effects on the Cerebral Blood Flow|Mechanisms and Biological Markers During Headache Induced by Natriuretic Peptides||Danish Headache Center|No|Completed|July 2012|||January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|6|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01637662||82965|
NCT01637675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STS-PH01|Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension|Clinical Study of Effects of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension|STS|The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|May 2013|December 2014|Anticipated|December 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|15 Years|70 Years|No|||March 2014|March 28, 2014|July 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01637675||82964|
NCT01637909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0305|Korean Life-Style Modification Effects on Blood Pressure|||Yonsei University|No|Completed|September 2011|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|85|||Both|20 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 10, 2015|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01637909||82946|
NCT01639365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-176|SmartTouch Catheter in Ablation of Ventricular Tachycardia|Usefulness of the SmartTouch Catheter to Assess the Areas of Myocardial Scar in Patients With Ventricular Tachycardia||Hospital Universitario Virgen de la Arrixaca|No|Active, not recruiting|July 2012|December 2015|Anticipated|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|Consecutive patients with ventricular arrhythmias due to ischemic heart disease or dilated        cardiomyopathy undergoing VT ablation|September 2015|September 4, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639365||82834|
NCT01639638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONDI 02 AR|Recurrent and Nonrecurrent Condyloma Treatment|Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma||Laboratorio Elea S.A.C.I.F. y A.|No|Terminated|June 2010|December 2014|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|132|||Female|18 Years|65 Years|No|||March 2015|March 11, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01639638||82813|
NCT01639378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REACH|Renal Artery Denervation in Chronic Heart Failure Study|Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure|REACH|Imperial College London|Yes|Recruiting|August 2012|||August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|90 Years|No|||February 2016|February 22, 2016|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639378||82833|
NCT01644786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-4-004|The Head and Neck TUMOR Biobank|STORAGE OF HEAD AND NECK TUMOR SAMPLES IN A BIOBANK FOR FUTURE GENOMIC-BASED RESEARCH AIMING AT IMPROVED OUTCOME PREDICTION "THE HEAD AND NECK TUMOR BIOBANK"||Maastricht Radiation Oncology|No|Recruiting|August 2012|August 2019|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|800|Samples With DNA|mucosal HNSCC oropharynx, hypopharynx, larynx, nasopharynx, oral cavity|Both|18 Years|N/A|No|Probability Sample|All new patients with (suspected) mucosal HNSCC who are scheduled for diagnostic        panendoscopy|February 2013|February 18, 2013|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644786||82422|
NCT01644799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A051202|Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma|A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma||Alliance for Clinical Trials in Oncology|No|Active, not recruiting|July 2013|||July 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||September 2015|September 18, 2015|July 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01644799||82421|
NCT01645098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00532|Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy|Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy||Nationwide Children's Hospital|No|Completed|August 2011|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|53|||Male|N/A|N/A|No|||February 2015|February 25, 2015|June 8, 2012|Yes|Yes||No|February 4, 2015|https://clinicaltrials.gov/show/NCT01645098||82398|
NCT01645358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222|Helmet Ventilation in Acute Hypercapnic Respiratory Failure|Hypercapnic Acute Respiratory Failure: Is the Helmet an Effective Interface?"||Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|No|Completed|July 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||October 2014|October 5, 2014|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01645358||82378|
NCT01645371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00028|Assessing a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation|Assessing the Content Validity of a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation||AstraZeneca|No|Completed|August 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|79|||Both|18 Years|84 Years|No|Non-Probability Sample|multi-speciality medical clinics ( family practice, neurology, internal medicine, pain        management)|October 2014|October 17, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01645371||82377|
NCT01645800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LYS-002|Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study|Effects of Lysozyme On Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study||Eisai Inc.|Yes|Completed|August 2012|March 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|408|||Both|20 Years|84 Years|No|||October 2015|October 20, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01645800||82360|
NCT01645826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00004379|Efficacy Study of Cardizem in Pulmonary Arterial Hypertension|Calcium Channel Blockers in Nitric Oxide Non-responder Pulmonary Arterial Hypertension.||University of South Florida|Yes|Recruiting|July 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2013|September 6, 2013|October 18, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01645826||82359|
NCT01636986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00930|A Prospective Study of Two Daily Disposable Contact Lenses|Impact of a Novel Silicone Hydrogel in Reducing Contact Lens-Related Dryness Symptoms in Existing Contact Lens Wearers||Alcon Research|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|43 Years|No|||November 2013|November 25, 2013|July 6, 2012|Yes|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01636986||83017|The study was not powered to detect differences in individual items.
NCT01637831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPAPIPF-02|CPAP Therapy in Patients With Idiopathic Pulmonary Fibrosis and Sleep Apnea|CPAP Therapy in Patients With Idiopathic Pulmonary Fibrosis and Obstructive Sleep Apnea. Does It Offer a Better Quality of Life and Sleep?||University of Crete|No|Completed|March 2010|September 2011|Actual|September 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|80 Years|No|||July 2012|July 10, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01637831||82952|
NCT01642524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPHR HIT|The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT)|The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial|TOPHR HIT|Sunnybrook Health Sciences Centre|No|Completed|April 2004|July 2011|Actual|January 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|114|||Both|16 Years|N/A|No|||July 2012|July 13, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642524||82595|
NCT01642537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TP000-147|Electroanatomical Mapping of Patients Undergoing Catheter Ablation Procedures Using Rhythmia Mapping System and Catheter|Electroanatomical Mapping of Patients Undergoing Catheter Ablation Procedures Using Rhythmia Mapping System and Catheter||Boston Scientific Corporation|No|Completed|November 2012|January 2015|Actual|December 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|7|||Both|18 Years|75 Years|No|||July 2015|July 24, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642537||82594|
NCT01640093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100859|A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Assess the Relative Bioavailability of 3 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|July 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640093||82779|
NCT01640106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-164-PED|Feasibility of Omega-3 Supplementation for Children With Language Impairments|Feasibility of Omega-3 Fatty Acid Supplementation for Children With Early Developmental Impairment in Language||McGill University Health Center|No|Recruiting|June 2012|September 2013|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|24 Months|42 Months|No|||July 2012|July 12, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01640106||82778|
NCT01606358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00214-37|Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer|IClyCO Influence of Chemotherapy (Carboplatin and Taxol) on the ex Vivo Expansion and Functional Capacity of Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer|IClyCO|Rennes University Hospital|No|Withdrawn||||May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|Samples Without DNA|The VGAMMA9VDELTA2 T cells will be isolated from peripheral blood mononuclear cells of      patients with ovarian cancer.|Female|18 Years|N/A|No|Non-Probability Sample|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol        chemotherapy.|August 2014|August 8, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606358||85364|
NCT01607151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12CRP12050342|Safety and Feasibility Study of Targeted Temperature Management After ICH|Safety and Feasibility of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage|TTM-ICH|Thomas Jefferson University|Yes|Active, not recruiting|January 2013|June 2016|Anticipated|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607151||85303|
NCT01607463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNUH 2012-04-014-001|The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Venous Cannulation|The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Venous Cannulation||Kyungpook National University|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|100|||Both|N/A|N/A|No|||May 2012|May 24, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01607463||85279|
NCT01608035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00693|Sciatic Perineural Versus Stump Catheter for Below Knee Amputation|Ultrasound Guided Sciatic Perineural Catheter vs Surgically Placed Sciatic Stump Catheter for Below Knee Amputations: Is There A Difference in Patient Outcomes||University of British Columbia|Yes|Recruiting|September 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|16 Years|90 Years|No|||March 2014|March 5, 2014|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01608035||85236|
NCT01608334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0162|Comparison of Intrathecal Fentanyl or Sufentanil in 1 mg Bupivacaine Spinal Anesthesia for TURP in Elderly Patients|||Yonsei University|No|Completed|August 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|56|||Male|65 Years|85 Years|Accepts Healthy Volunteers|||May 2012|May 29, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608334||85213|
NCT01608022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0014|A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus|||Yonsei University|No|Recruiting|July 2012|March 2015|Anticipated|March 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|49|||Both|20 Years|N/A|No|||March 2014|March 4, 2014|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01608022||85237|
NCT01608685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH-2010|Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients|Interferon Gamma Release Assays Versus Tuberculin Skin Testing for the Detection of Latent Tuberculosis Infection in Renal Transplant Recipients||Ligue Pulmonaire Genevoise|No|Completed|January 2010|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|205|||Both|18 Years|N/A|No|Non-Probability Sample|Patients followed by the Division of Nephrology after renal transplantation, and        undergoing routine annual check-ups, in stable clinical condition, aged above 18|May 2012|May 30, 2012|July 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01608685||85186|
NCT01609270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCV00008317|CardioRoot Post-Marketing Surveillance Registry|CardioRoot Post-Marketing Surveillance Registry|CardioRoot|Maquet Cardiovascular|No|Recruiting|October 2012|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||April 2015|April 21, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01609270||85141|
NCT01608997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0071-11-HYMC|Postoperative Multiparameter Outcomes During the Six Months After Rotator Cuff Repair|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|June 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|50|||Both|45 Years|75 Years|No|Non-Probability Sample|Candidates for rotator cuff repair due to shoulder pain and tears|May 2012|May 29, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01608997||85162|
NCT01606098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIRO4|The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer|The Role of Surgery of the Primary Tumour With Few or Absent Symptoms in Patients With Synchronous Unresectable Metastases of Colorectal Cancer, a Randomized Phase III Study. A Study of the Dutch Colorectal Cancer Group (DCCG)|CAIRO4|Dutch Colorectal Cancer Group|Yes|Recruiting|July 2012|August 2020|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606098||85384|
NCT01621503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT530P-120210|Prospective Comparative Clinical Study to Investigate the Use of the NON CONTACT TONO/PACHYMETER NT-530P|Prospective Comparative Clinical Study to Investigate the Use of the NON CONTACT TONO/PACHYMETER NT-530P||Nidek Co. LTD.|No|Completed|April 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|250|||Both|20 Years|N/A|No|||July 2012|June 26, 2013|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621503||84203|
NCT01621204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-EIBS-A-12|A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients|Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study||McMaster University|Yes|Recruiting|October 2012|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|74|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01621204||84226|
NCT01621217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOAC8.Version1|Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0|Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0|NOAC8|Lund University Hospital|No|Active, not recruiting|June 2012|||July 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||April 2015|September 2, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621217||84225|
NCT01621230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|052009-049|Effects of Bupivacaine Induced Motor Blockade During the Second Stage of Labor|A Randomized Double-blinded Trial of the Effects of Bupivacaine Induced Motor Blockade on the Second Stage of Labor|BUP|University of Texas Southwestern Medical Center|Yes|Recruiting|September 2009|October 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|310|||Female|16 Years|44 Years|Accepts Healthy Volunteers|||June 2012|June 15, 2012|February 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01621230||84224|
NCT01621490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-038|PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma|An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)|PD-1|Bristol-Myers Squibb|No|Recruiting|September 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Anticipated|160|||Both|18 Years|N/A|No|||January 2016|February 10, 2016|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01621490||84204|
NCT01621711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-01606|Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care|Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care|Linkage|University of California, San Francisco|Yes|Active, not recruiting|March 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|504|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01621711||84187|
NCT01622387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P38558|Radial Artery Versus Saphenous Vein Patency (RSVP) Trial - 10 Year Follow-up|Randomised, Controlled Trial Comparing Angiographic Patency of the Radial Artery Versus the Saphenous Vein Used as Free Aorto-coronary Grafts in Coronary Revascularisation (Radial Artery Versus Saphenous Vein Patency (RSVP) Trial) - 10-year Follow-up||Imperial College London|No|Withdrawn||||||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||August 2015|September 8, 2015|March 22, 2012||No|No funding|No||https://clinicaltrials.gov/show/NCT01622387||84135|
NCT01622010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:101|The Effects of DVD Education on Physical Activity and Self Management of Heart Failure|The Effects of DVD Education on Physical Activity and Self Management of Heart Failure: A Randomized Controlled Trial||University of Manitoba|No|Terminated|April 2013|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|May 22, 2012||No|There is a lower recruitment rate than projected. Patients are being screened to participate    in another study and with held from our recruitment.|No||https://clinicaltrials.gov/show/NCT01622010||84164|
NCT01618227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007P002509|Rehabilitation With or Without Static Progressive Splinting for Wrist Stiffness|A Prospective Randomized Trial of Rehabilitation With or Without Static Progressive Splinting for Wrist Stiffness||Massachusetts General Hospital|No|Completed|September 2008|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01618227||84454|
NCT01604928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-008|Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder|A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder|Blossom|Astellas Pharma Inc|No|Completed|April 2004|January 2005|Actual|January 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|260|||Both|18 Years|N/A|No|||July 2013|July 1, 2013|May 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01604928||85474|
NCT01604941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-203|Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy|A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy||Shire|Yes|Terminated|September 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|60 Years|No|||August 2014|July 22, 2015|May 22, 2012|No|Yes|This study was terminated due to treatment stop resulting in an inability to draw conclusions    from the data. Evaluation of nonclinical rat findings is ongoing.|No|June 4, 2015|https://clinicaltrials.gov/show/NCT01604941||85473|This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
NCT01604954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF 2011-088|Does Food Labeling Influence Long-term Food Intake and Eating-related Variables in Women?|Does Food Labeling Influence Long-term Food Intake and Eating-related Variables in Women?|MENU|Laval University|No|Completed|August 2011|April 2015|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject)|2||Actual|160|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01604954||85472|
NCT01605136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUV039|Phase III Confirmatory Study in Erythropoietic Protoporphyria|A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)||Clinuvel Pharmaceuticals Limited|Yes|Active, not recruiting|May 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605136||85458|
NCT01606618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B110797-30|Self-esteem and Neuro-urological Follow-up in Patients With Spina Bifida or Spinal Cord Injury|Analysis of Psychosocial Determinants of Observance of Monitoring Neuro-urological in Spina-bifida Adult Patients and in Spinal Cord Injury Patients: a Prospective, Comparative, Multicenter With Parallel Groups Study|ESTIME|Rennes University Hospital|No|Recruiting|January 2012|April 2017|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|330|||Both|18 Years|60 Years|No|Non-Probability Sample|Patient seen in university hospitals or in rehabilitation clinic|May 2015|May 26, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01606618||85344|
NCT01606917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OrebroCC|Interventions for Lifestyle Changes to Promote Weight Reduction, a Randomized Controlled Trial in Primary Health Care|Interventions for Lifestyle Changes to Promote Weight Reduction, a Randomized Controlled Trial in Primary Health Care|LÄTTA|Örebro County Council|No|Completed|October 2004|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|133|||Both|18 Years|70 Years|No|||May 2012|May 25, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606917||85321|
NCT01607164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPC-R|Healthy Mood Internet Recruitment Study|Depression Prevention and Management Project|DPC-R|University of California, San Francisco|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1226|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607164||85302|
NCT01607177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bariatric Prehabilitation|Do Text Message Reminders Increase Preoperative Exercise in Obesity Surgery Candidates?|Text Messaging to Improve Adherence to Prehabilitation in Patients Undergoing Bariatric Surgery: a Randomised Controlled Trial||University of Auckland, New Zealand||Completed|August 2012|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|102|||Both|20 Years|60 Years|No|||November 2013|November 12, 2013|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607177||85301|
NCT01607762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100831|A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics|Comparison of Single-Dose Plasma and Blood Concentrations of Aripiprazole, Olanzapine, Quetiapine, Paliperidone and Risperidone After Capillary and Venous Blood Sample Collection||Janssen Research & Development, LLC|No|Completed|February 2012|October 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|31|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||April 2013|April 8, 2013|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01607762||85257|
NCT01608373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAngUH4|The Effect of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation on Pain After Laparoscopic Cholecystectomy|Comparison of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation for Effective Pain Relief After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-blind, Placebo-controlled Study||Chung-Ang University Hospital|Yes|Recruiting|July 2011|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|83|||Both|18 Years|65 Years|No|||July 2011|August 1, 2013|May 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01608373||85210|
NCT01608646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOTTG270105|Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer|Study of Dihydropyrimidine Dehydrogenase for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer||Xijing Hospital|No|Recruiting|March 2012|August 2018|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||May 2012|May 28, 2012|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01608646||85189|
NCT01608347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAPAN|Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies|Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial|LMWH-APAN|Assiut University|Yes|Active, not recruiting|January 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|228|||Female|20 Years|40 Years|No|||May 2012|May 31, 2012|May 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01608347||85212|
NCT01608659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTXC-10-001|An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A|||Allergan|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|110|||Female|18 Years|N/A|No|Non-Probability Sample|Subjects treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin        Type A|June 2012|June 25, 2012|May 29, 2012|Yes|Yes||No|June 25, 2012|https://clinicaltrials.gov/show/NCT01608659||85188|
NCT01608672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-BTXC-11-004|Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®|||Allergan|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|207|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects treated for at least 5 years with BOTOX® for glabellar lines|November 2013|November 4, 2013|May 29, 2012|Yes|Yes||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01608672||85187|
NCT01605266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000021384|INSIGHT (Insight Into Nephrotic Syndrome)|INSIGHT (Insight Into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics)|INSIGHT|The Hospital for Sick Children|No|Recruiting|January 2011|January 2021|Anticipated|January 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood is drawn for DNA, serum, plasma, buffy coat and whole blood. Urine and toenail      clippings are also collected.|Both|1 Year|18 Years|No|Non-Probability Sample|Children with nephrotic syndrome. Children are recruited from Toronto and surrounding        region with additional sites added later.|March 2016|March 2, 2016|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01605266||85448|
NCT01605565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-01|Functional Analysis by Dynamic Imaging of the Respiratory Epithelium in Infants With Cystic Fibrosis|Analyse Fonctionnelle Par Imagerie Dynamique de l'épithélium Respiratoire Chez Des Nourrissons Atteints de Mucoviscidose||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|November 2011|November 2014|Anticipated|November 2013|Anticipated|N/A|Interventional|Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|N/A|6 Months|Accepts Healthy Volunteers|||May 2012|May 21, 2012|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01605565||85425|
NCT01605578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-48|Description of Abdominal and Gluteo-femoral Subcutaneous Adipose Tissue Cell Population in Women - GLUTAB|Description Des Populations Cellulaires Des Tissus Adipeux Sous-cutanés Abdominaux et glutéo-fémoraux Chez la Femme.||Institut National de la Santé Et de la Recherche Médicale, France||Recruiting|May 2012|May 2014|Anticipated|May 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01605578||85424|
NCT01621724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-00272-CT2014001|WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study|WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study||Cell Therapy Catapult|Yes|Recruiting|April 2012|September 2018|Anticipated|September 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|75 Years|No|||January 2016|January 20, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01621724||84186|
NCT01621737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111017|Antipsychotic Effects of Oxytocin|Antipsychotic Effects of Oxytocin||University of California, San Diego|No|Completed|June 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|102|||Both|21 Years|N/A|No|||December 2014|December 11, 2014|June 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621737||84185|
NCT01621997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD TRAINING|Different Retraining Methods vs Usual Care on the Prevention of Peritonitis in Peritoneal Dialysis|Retraining Via Operation Inspection or Verbal Education vs Usual Care on the Prevention of Peritonitis in Peritoneal Dialysis||Peking University First Hospital|No|Recruiting|January 2012|July 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|150|||Both|18 Years|80 Years|No|||February 2014|October 28, 2014|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621997||84165|
NCT01621750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300-08|Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|August 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2008|June 14, 2012|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621750||84184|
NCT01622023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1/2012|Timing of Intrauterine Insemination (IUI) 24 or 48 Hours After Spontaneous Luteinizing Hormone (LH) Peak|Timing of IUI 24 or 48 Hours After Spontaneous LH Peak: a Randomised Controlled Trial||Universitair Ziekenhuis Brussel|No|Completed|October 2010|June 2013|Actual|June 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|435|||Female|18 Years|39 Years|No|||July 2013|July 18, 2013|March 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01622023||84163|
NCT01622413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/001|Trial to Show Non-inferiority / Superiority of an Endoscopic Transforaminal Discectomy to Standard Microdiscectomy|Transforaminal Endoscopic Surgery Cost Outcome Research Trial|TESCORT|Joimax GmbH|No|Not yet recruiting|September 2013|||September 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|80 Years||||July 2013|July 26, 2013|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01622413||84133|
NCT01622400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-34|Efficacy of a Dedicated Therapeutic Education Program in Patients at High Cardiovascular Risk|Randomized Prospective Trial Evaluating the Efficacy of a Dedicated Therapeutic Education Program on the Blood Pressure and Other Cardiovascular Risk Factors Control in General Practice Patients at High Cardiovascular Risk||University Hospital, Lille|No|Active, not recruiting|September 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||November 2014|October 13, 2015|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01622400||84134|
NCT01605149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-16425|Type 1 Diabetes Mellitus Bone Mineral Density in Childhood and Adolescence|Type 1 DM Bone Mineral Density in Childhood and Adolescence||Creighton University|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|60|||Both|5 Years|18 Years|No|Non-Probability Sample|Children and adolescents with Type 1 DM|March 2014|March 25, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605149||85457|
NCT01605162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E7016-A001-201|Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma|Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma||Eisai Inc.||Active, not recruiting|March 2012|August 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605162||85456|
NCT01605175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|nviazis|Predictors of Mucosal Healing in Inflammatory Bowel Disease (IBD) Patients Treated With Anti-TNF|Predictors of Tissue Healing in Inflammatory Bowel Disease Patients Treated With Anti-TNF||Evangelismos Hospital|Yes|Completed|May 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|21|Samples With DNA|Whole blood Serum Bowel mucosal tissue|Both|N/A|N/A|No|Non-Probability Sample|Patients treated with anti-TNF in a tertiary hospital.|November 2015|November 15, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605175||85455|
NCT01605461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1241.22|Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers|Metabolite Profile, Excretion Balance and Pharmacokinetics of BI 207127 NA Combined With [14C]-BI 207127 NA in Healthy Adult Male Volunteers After an 800 mg Single Oral Solution Dose; a Phase I, Single-arm, Open-label Trial||Boehringer Ingelheim||Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|May 9, 2012||||No|January 21, 2016|https://clinicaltrials.gov/show/NCT01605461||85433|
NCT01605474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00026352|Patient Satisfaction of Cervical Ripening in an Outpatient Setting|Safety, Efficacy, and Patient Satisfaction of Cervical Ripening With Transcervical Use of the Foley Catheter in an Outpatient Setting||Cedars-Sinai Medical Center|Yes|Recruiting|April 2012|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01605474||85432|
NCT01605747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-12-13-02|Study of Culturelle in the Prophylaxis of Infection and Diarrhea|A Blinded Placebo Controlled Clinical Outcomes Study of Culturelle® in the Prophylaxis of Infection and Diarrhea||Shriners Hospitals for Children||Terminated|January 2011|December 2015|Anticipated|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|20|||Both|6 Months|18 Years|No|||November 2013|November 12, 2013|May 8, 2012||No|Study was stopped due to inavailability of subjects meeting eligibility criteria.|No||https://clinicaltrials.gov/show/NCT01605747||85411|
NCT01606930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-14352.4|A Pilot Study to Improve Patient-Doctor Communication|A Pilot Study to Improve Patient-Doctor Communication||Walter Reed National Military Medical Center|No|Completed|November 2010|November 2011|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|106|||Both|18 Years|80 Years|No|||May 2012|May 23, 2012|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01606930||85320|
NCT01606943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XJ201202|Clinical Profiles and Outcomes of Acute Aortic Dissection in the Chinese Patients|The Study of The Chinese Registry of Acute Aortic Dissection and Clinical Study of Acute Aortic Dissection in Chinese Patients|CPOAADCP|Xijing Hospital|Yes|Completed|January 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2000|||Both|18 Years|80 Years|No|Probability Sample|Chinese population suffering acute aortic dissection|May 2012|May 25, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01606943||85319|
NCT01607788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProLit|Prospective Liver Tumor (ProLiT) Database|Prospective Database of Liver Transplantation for Hepatocellular Carcinoma|ProLit|University of Geneva, Switzerland|No|Recruiting|November 2009|December 2017|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|All patients with hepatocellular carcinoma listed for liver transplantation at the        participating centers|May 2012|May 29, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607788||85255|
NCT01608048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CZheng2012QN180|Transcutaneous Electrical Acupoint Stimulation to Improve Pregnancy Rates for Women Undergoing in Vitro Fertilization|Transcutaneous Electrical Acupoint Stimulation to Improve Pregnancy Rates for Women Undergoing in Vitro Fertilization||Huazhong University of Science and Technology|Yes|Not yet recruiting|May 2014|February 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|384|||Female|18 Years|40 Years|No|||November 2012|March 29, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01608048||85235|
NCT01608061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FNMI-001|ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease|A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease|ADvance|Functional Neuromodulation Ltd|Yes|Active, not recruiting|May 2012|September 2018|Anticipated|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|45 Years|85 Years|No|||October 2015|October 27, 2015|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01608061||85234|
NCT01608360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ChungAngUH3|The Effect of Intravenous Lidocaine on Pain After Thyroidectomy|Intravenous Lidocaine for Effective Pain Relief After Thyroidectomy: a Prospective, Randomized, Double-blind, Placebo-controlled Study||Chung-Ang University Hospital|No|Recruiting|July 2011|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|56|||Both|18 Years|65 Years|No|||March 2014|March 17, 2014|May 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01608360||85211|
NCT01608074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIMBRIECTOMIE|Radical Fimbriectomy for Young BRCA Mutation Carriers|Radical Fimbriectomy for Young BRCA Mutation Carriers at Risk of Pelvic Serous Carcinoma|Fimbriectomy|Centre Oscar Lambret|Yes|Active, not recruiting|December 2011|December 2027|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|123|||Female|35 Years|N/A|No|||February 2016|February 15, 2016|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01608074||85233|
NCT01608386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBHKY2012-002-16|A Study of Anterior Approach Combined With Infrahepatic Inferior Vena Cava Clamping|Anterior Approach Combined With Infrahepatic Inferior Vena Cava Clamping Right Hepatic Resection for Large Hepatocellular Carcinoma: A Prospective Randomized Controlled Study|AA+IVC|Eastern Hepatobiliary Surgery Hospital|Yes|Enrolling by invitation|May 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|75 Years|No|||August 2015|August 5, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01608386||85209|
NCT01605019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol# 00007027|The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery|A Multi-Center Clinical Pilot-Study to Evaluate the Performance of CoSeal in Reducing Post-Op Bleeding, Air Micro Emboli, and Cardiac Tissue Adhesions in Patients With Left Ventricular Assist Devices (LVADs)||The Methodist Hospital System|No|Terminated|June 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 21, 2012||No|funding for study stopped|No||https://clinicaltrials.gov/show/NCT01605019||85467|
NCT01605279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NeoDobuta|Dobutamine Versus Placebo for Low Superior Vena Cava Flow in Newborns|Randomised Double Blind Clinical Trial of Dobutamine Versus Placebo for Low Superior Vena Cava Flow Treatment in Low Birth Weight Infants: Systematic Assessment of Cerebral and Systemic Hemodynamics Effects||Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz|Yes|Completed|September 2010|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|127|||Both|N/A|12 Hours|No|||March 2015|March 6, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605279||85447|
NCT01605305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOLFOX6-2008|Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer|Phase II Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer||Fudan University|Yes|Completed|September 2008|January 2012|Actual|January 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|75 Years|No|||May 2012|May 23, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605305||85445|
NCT01605318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-IMMU-130-02|Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer|A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.||Immunomedics, Inc.|No|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|104|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605318||85444|
NCT01621243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M402-103|M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer|A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer||Momenta Pharmaceuticals, Inc.|No|Recruiting|May 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|March 15, 2016|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621243||84223|
NCT01621256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NM-V-101|Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss|Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)||Nordmark Arzneimittel GmbH & Co. KG|No|Recruiting|May 2013|October 2016|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|115|||Both|18 Years|70 Years|No|||October 2015|October 26, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01621256||84222|
NCT01621269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DDE12|ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon|A 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta|ENGYNE|Novartis|No|Withdrawn|June 2013|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|No|||September 2014|September 29, 2014|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01621269||84221|
NCT01621516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCFTX 001|Measurement of the Pancreas Function in Patients With More Than One Pancreas After Liver and Small Bowel Transplantation|Measurement of ß-cell Function and Insulin Sensitivity in Non-diabetic Patients With En-bloc Liver, Pancreas and Small Bowel Transplant Using a Hyperglycemic Clamp||Katholieke Universiteit Leuven|No|Completed|June 2012|November 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|6|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Liver/small bowel transplant patients with partial or whole pancreas (n = 3):        Solitary small bowel transplant patients (n=3)          -  Insuline independen (no diabetes mellitus)          -  Maintenance IS with Tacrolimus/Azathioprine|November 2015|November 9, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621516||84202|
NCT01621763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|305-08|Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel 300 mg Tablets of Dr. Reddy's India and Plavix® 300 mg Tablets Under Fed Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|September 2008|September 2008|Actual|September 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2008|June 22, 2012|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621763||84183|
NCT01622426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBC-100790|Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy|Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy||Federico II University|No|Completed|October 2008|October 2011|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|1 Month|168 Months|No|||June 2012|June 18, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622426||84132|
NCT01618253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00017344|Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma|Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization||Medical College of Wisconsin|Yes|Withdrawn|June 2012|June 2016|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||September 2013|September 4, 2013|June 4, 2012||No|Closed due to poor accrual.|No||https://clinicaltrials.gov/show/NCT01618253||84452|
NCT01618266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/RET/009|Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion|||Allergan|No|Completed|November 2011|October 2014|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|375|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with Macular Oedema due to Retinal Vein Occlusion|February 2016|February 16, 2016|June 11, 2012|No|Yes||No|January 13, 2016|https://clinicaltrials.gov/show/NCT01618266||84451|
NCT01605786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pf PEBS-Ia-IIa|Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)|Phase I and IIa Trial for Assessment of Safety, Immunogenicity (Phase Ia) and Efficacy (Phase IIa) Against Sporozoite Challenge of P. Falciparum Pre-Erythrocytic and Blood Stage (PfPEBS-LSP) Malaria Vaccine Candidate|PEBS-POC1|Vac4All|Yes|Recruiting|May 2012|August 2013|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|36|||Both|18 Years|44 Years|Accepts Healthy Volunteers|||May 2012|May 22, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01605786||85408|
NCT01606059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW0919-1003|Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition|A Randomized, Open Label, 2-treatment, 2-sequence, Cross-over Study to Compare the Safety and Pharmacokinetics of DW-0919 and DW-0920 After Single Oral Administration in Healthy Male Volunteers|DW0919-1003|Daewon Pharmaceutical Co., Ltd.|Yes|Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 21, 2013|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606059||85387|
NCT01606046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|momo0910|Comparison of the Effects of Vapocoolant Spray and EMLA Cream on Pain During Needle Electromyography|Comparison of the Effects of Vapocoolant Spray and Topical Anesthetic Cream on Pain During Needle Electromyography: a Randomized Controlled Clinical Trial||The Catholic University of Korea|No|Completed|July 2011|August 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|99|||Both|19 Years|70 Years|No|||May 2012|June 19, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606046||85388|
NCT01608399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCTDEP|Clinical Trial of the Effectiveness of Metacognitive Therapy in the Treatment of Patients With Major Depressive Disorder|A Randomized Controlled Trial of the Effectiveness of Metacognitive Therapy (MCT) in the Treatment of Patients With Major Depressive Disorder (MDD)||Norwegian University of Science and Technology|No|Recruiting|March 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||October 2015|October 6, 2015|February 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01608399||85208|
NCT01607515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-205 ex 11/12|Non Invasive Measurement of Cardiac Index by Impedance Cardiography|Non Invasive Measurement of Cardiac Index by Impedance Cardiography||Medical University of Graz|No|Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|89|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01607515||85275|
NCT01607476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000118|Bridging Study of C11 PiB and F18 Flutemetamol Brain PET|Bridging Study of C11 PiB and F18 Flutemetamol Brain PET||Mayo Clinic|Yes|Completed|July 2012|March 2016|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|89|||Both|30 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 9, 2016|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607476||85278|
NCT01607775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-256M-MA|In-house Produced PMMA- Versus PEEK-cages|Clinical Characterization of In-house Produced PMMA-cages in Patients With Cervical Pathology|Palcage|Universitätsmedizin Mannheim|No|Completed|February 2009|February 2012|Actual|February 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||June 2012|June 4, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01607775||85256|
NCT01607489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23-356 ex 10/11|Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography|Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Pilot Study||Medical University of Graz|No|Active, not recruiting|June 2011|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|25|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01607489||85277|
NCT01607801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMBI-123|Effect of Reoperation for Recurrence After Open Umbilical Hernia Repair|Effect of Reoperation for Recurrence After Open Surgery for Small Umbilical Hernia With Sutured Mesh or Plastic Surgery. A National Hernia Database Study.|UMBI-REC|Koege Sygehus|Yes|Completed|January 2007|December 2010|Actual|December 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|4847|||Both|N/A|N/A|No|Non-Probability Sample|Danish patients undergoing umbilical hernia repair, mesh/non-mesh, under 2 cm. in the        study period 1. january 2007 to 31. december 2010.|May 2012|May 30, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01607801||85254|
NCT01609023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22235|An Observational Study of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With CD20-Positive B-Cell Chronic Lymphocytic Leukaemia|An Observational Phase IV Non Interventional Study Evaluating Further the Safety of Rituximab in Combination With Various Chemotherapies for the Treatment of Patients With CD20- Positive B-cell Chronic Lymphocytic Leukaemia in Greece||Hoffmann-La Roche||Completed|April 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|67|||Both|18 Years|N/A|No|Probability Sample|Patients with CD20-positive B-cell chronic lymphocytic leukaemia eligible for 1st line or        2nd line therapy|March 2016|March 1, 2016|May 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01609023||85160|
NCT01609036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22236|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma|An Observational Phase IV Non Interventional Study in Patients With Advanced Follicular Lymphoma (III-IV) Evaluating the Safety of Maintenance Therapy With Rituximab After 8 Cycles of Rituximab in Combination With Chemotherapy as Induction Therapy in Previously Untreated Patients in Greece.||Hoffmann-La Roche||Terminated|October 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|||Both|18 Years|N/A|No|Probability Sample|Patients with stage III-IV follicular lymphoma|March 2016|March 1, 2016|May 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01609036||85159|
NCT01605032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-434|Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma||Albert Einstein College of Medicine of Yeshiva University|Yes|Active, not recruiting|February 2012|||January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|72 Years|No|||January 2016|January 11, 2016|March 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01605032||85466|
NCT01605292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-8432|Radial Artery Access With Ultrasound Trial|Radial Artery Access With Ultrasound Trial|RAUST|University of California, Irvine|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|698|||Both|18 Years|N/A|No|||February 2015|February 25, 2015|January 26, 2012||No||No|December 29, 2014|https://clinicaltrials.gov/show/NCT01605292||85446|Blinding was not possible in this study. We cannot exclude a bias in the performance, measurement, or recording of the procedure or clinical data. Time to prepare the US probe was not included in the time to access.
NCT01601405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-023|Effect of Repeated Doses of YF476 on Stomach Acidity|Open Study of the Effect of Repeated Doses of YF476 on Pentagastrin-induced Gastric Acid Output in Healthy Volunteers||Trio Medicines Ltd.|No|Completed|October 2001|November 2001|Actual|November 2001|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|||Actual|10|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601405||85745|
NCT01621529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHB 09.01|Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer|Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer|VOSETEP|Centre Henri Becquerel|Yes|Completed|February 2010|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Female|18 Years|N/A|No|Probability Sample|patient with invasive non-lobular breast cancer, histologically proved|June 2012|June 15, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621529||84201|
NCT01621776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3842011|Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia|Comparison of Effectiveness of Glulisine and Lispro in Decreasing Post-Prandial Hyperglycemia in a Real-World Setting||University of Florida|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|107|||Both|9 Years|14 Years|No|||January 2013|September 12, 2013|June 11, 2012|Yes|Yes||No|June 21, 2013|https://clinicaltrials.gov/show/NCT01621776||84182|In the first year (Camp 2011) there were 2 arms, the Humalog and Apidra. In the second year (Camp 2012) there were 3 arms, the Humalog, Apidra, and Novolog. Therefore, there will be more participants in the Humalog and Apidra arms.
NCT01621789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 2146/11|Efficacy of Lutein, Zeaxanthine and Trypan Blue to Stain the Anterior Lens Capsule|A Descriptive Study to Evaluate the Efficacy of the Dye Compound of the Combination of Lutein, Zeaxanthin and Trypan Blue to Stain the Anterior Lens Capsule During Cataract Phacoemulsification.||Federal University of São Paulo|Yes|Completed|June 2012|May 2014|Actual|July 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|25|||Both|50 Years|90 Years|No|||March 2016|March 15, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621789||84181|
NCT01622036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MM-SL-PreMIO|Prevalence of Malnutrition in Oncology (PreMiO)|The PreMiO Study: The Prevalence of Malnutrition in Oncology.|PreMiO|University of Roma La Sapienza|No|Completed|June 2012|March 2015|Actual|November 2014|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|1978|||Both|18 Years|N/A|No|Probability Sample|Enrollment will be conducted at Italian ESMO-accredited centers and in other medical        oncological centers in Italy. Six-thousand patients have been considered an adequate        sample for a suitable estimation of the prevalence of malnutrition in Italian cancer        patients at first medical oncology visit. Patient recruitment will be ensured through        enrollment by 60 centers throughout the Italian national territory (North, Center, South        and Islands).|December 2015|December 1, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01622036||84162|
NCT01618279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|193_05/2012|Tryptase and Coronary Heart Disease|Evaluation of Tryptase as a Biomarker of Coronary Heart Disease||Niguarda Hospital|No|Recruiting|January 2013|September 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|350|Samples Without DNA|Venous blood|Both|18 Years|80 Years|No|Non-Probability Sample|Italian subjects in the acute phase of disease and follow up. The work will be on 4        patient populations:          1. sindrome coronary acute ST elevation on electrocardiogram          2. sindrome ACS without ST elevation on electrocardiogram (acute myocardial infarction             with ST-segment depression on electrocardiogram and unstable angina)          3. malattia critical coronary artery stenosis <50%          4. aneurismi aorta.|March 2016|March 1, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618279||84450|
NCT01618565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-1|Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Shoulder Dystocia Management|Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Theoretical Versus Hands-On Training of Shoulder Dystocia Management: a Randomized Trial||Ruhr University of Bochum|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|203|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 8, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618565||84428|
NCT01606072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDAVP|Perioperative Use of Desmopressin (DDAVP) in Breast Cancer|Perioperative Administration of Desmopressin to Subjects With Breast Cancer: A Phase IIa, Dose-Escalation Study||Laboratorio Elea S.A.C.I.F. y A.|No|Completed|November 2011|July 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|21|||Female|21 Years|60 Years|No|||August 2015|August 27, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01606072||85386|
NCT01606371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10837|A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|No|Completed|May 2007|October 2007|Actual|October 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|11||Actual|32|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606371||85363|
NCT01607190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4C-2012-02|Biomarkers of Diabetic Retinopathy Progression|Biomarkers of Diabetic Retinopathy Progression.||Association for Innovation and Biomedical Research on Light and Image|No|Active, not recruiting|November 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|35 Years|100 Years|No|Non-Probability Sample|Patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy|October 2015|October 7, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607190||85300|
NCT01607528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIC-2010|Influence of Probiotics on Infections in Cirrhosis|Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections|PIC|Medical University of Graz|Yes|Active, not recruiting|July 2012|September 2016|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01607528||85274|
NCT01607216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|37933|Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies|Prematurity and Respiratory Outcome Program: Single Center Study of Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies||University of Rochester|Yes|Completed|August 2011|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|276|Samples With DNA|Several types of biospecimens are to be collected:      Cord Blood Tracheal Aspirates Urine Stool Saliva Blood      DNA collection is optional.|Both|N/A|7 Days|No|Non-Probability Sample|Eligible subjects are limited to patients born at the Golisano Children's Hospital at the        University of Rochester Medical Center and at Women's and Children's Hospital, University        at Buffalo. All admissions to the participating Neonatal Intensive Care Units will be        screened for eligibility.|October 2015|October 26, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01607216||85298|
NCT01609010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML16865|A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma|Rituximab (Mabthera®) as Single Agent and in Combination With Interferon Alfa-2a (Roferon-A®), a Phase-III Randomized Trial in Patients With Follicular or Other CD20+ Low-grade (Indolent) Lymphoma||Hoffmann-La Roche||Completed|October 2002|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|313|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|May 29, 2012||No||No|May 23, 2014|https://clinicaltrials.gov/show/NCT01609010||85161|Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events, and information is presented by SOC as AE data by preferred term were not available within specified parameters (with 5% threshold).
NCT01608412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR19T|A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus|An Open-label Randomized Controlled Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus 3 Months After Kidney Transplantation.||Hospital de Clinicas de Porto Alegre|Yes|Recruiting|February 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2011|May 30, 2012|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01608412||85207|
NCT01609283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008415|A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis|A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis||Mayo Clinic|Yes|Active, not recruiting|May 2012|April 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 29, 2015|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609283||85140|
NCT01609296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10048613|IN.PACT Global Clinical Study|The IN.PACT Global Clinical Study for the Treatment of Comprehensive Superficial Femoral and/or Popliteal Artery Lesions Using the IN.PACT Admiral™ Drug-Eluting Balloon.||Medtronic Endovascular|No|Active, not recruiting|May 2012|December 2020|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1538|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01609296||85139|
NCT01600612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|salah-1|Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial|Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial||Sohag University|Yes|Recruiting|September 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|300|||Female|N/A|N/A|No|||May 2013|May 30, 2013|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01600612||85806|
NCT01605045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-00007|Screening for Coronary Artery Disease Using Fluoroscopy During Coronary Angiography|Efficacy of Fluoroscopy-save Function During Cardiac Catheterization||New York University School of Medicine|Yes|Completed|April 2012|September 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|50|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01605045||85465|
NCT01621594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120141|Evaluating New Radiation Techniques for Cardiovascular Imaging|Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography||National Institutes of Health Clinical Center (CC)||Recruiting|May 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|3000|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621594||84196|
NCT01621542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D8350004|Clinical Study of WT2725 in Patients With Advanced Malignancies|Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies||Sunovion|No|Recruiting|July 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|18 Years|N/A|No|||February 2016|February 12, 2016|June 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01621542||84200|
NCT01621802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115158|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age|Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)||GlaxoSmithKline||Completed|June 2012|November 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|9||Actual|4011|||Both|4 Years|6 Years|Accepts Healthy Volunteers|||February 2016|February 18, 2016|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621802||84180|
NCT01622049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#105118|Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome|Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome|TTTS|University of South Florida|No|Completed|October 2006|February 2009|Actual|February 2009|Actual|N/A|Observational|N/A||1|Actual|77|||Female|18 Years|55 Years|No|||November 2012|March 13, 2013|August 5, 2010|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01622049||84161|
NCT01622062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAB40|Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen|Verorab® Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years||Sanofi|No|Recruiting|June 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|600|||Both|N/A|50 Years|No|||February 2016|February 26, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622062||84160|
NCT01622075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AE-V-S-1001|A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent|A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent|PEPCAD|B. Braun Medical International Trading Company Ltd.|No|Completed|March 2011|April 2014|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|220|||Both|18 Years|80 Years|No|||July 2015|July 22, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01622075||84159|
NCT01622439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version1.1|Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma|Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma|VALFRID|Lund University Hospital|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|80 Years|No|||February 2016|February 16, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01622439||84131|
NCT01618292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-08-011|Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy|Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy||Atlantic Health System|Yes|Completed|January 2007|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|393|||Female|N/A|N/A|No|Non-Probability Sample|Women suffering from pelvic organ prolapse who underwent a robotic assisted laparoscopic        sacral colpopexy between January 2007 and August 2011.|January 2014|January 27, 2014|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618292||84449|
NCT01618305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1081|Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission|A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 28 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission: NICHD P1081||National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Recruiting|July 2013|||June 2019|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|394|||Female|16 Years|N/A|No|||March 2016|March 9, 2016|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618305||84448|
NCT01618578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHI2010|The Rubber Hand Illusion (RHI) in Patients With CRPS|Comparable Induction of the Rubber Hand Illusion (RHI) in Complex Regional Pain Syndrome Type 1 (CRPS 1) and Healthy Subjects||Ruhr University of Bochum|No|Completed|May 2010|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|69|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study sample consists of three groups:          1. Patients with CRPS of the upper limb type 1 ( n=24)          2. Patients with unilateral pain of the upper limb origin other than CRPS (n=21)          3. Healthy subjects, age and sex-matched to patients with CRPS Patients with unilateral             pain of the upper limb of origin other than CRPS serve as controls. Recruitment for             all CRPS and the majority of patients in the control group took place in the pain             clinic of the Bergmannsheil University Hospital in Bochum. The remaining patients             were recruited from the Neurological respectively Surgical department of the             Bergmannsheil University Hospital.|June 2012|June 24, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618578||84427|
NCT01607203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dr. Decleer Wim|Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist|Randomised Controlled Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist||AZ Jan Palfijn Gent|Yes|Completed|November 2011|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Female|N/A|38 Years|No|||February 2015|February 3, 2015|May 4, 2012||No||No|December 30, 2013|https://clinicaltrials.gov/show/NCT01607203||85299|
NCT01608087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1302.1|Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects|Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study||Boehringer Ingelheim||Completed|May 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment|3||Actual|91|||Male|21 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 15, 2013|May 22, 2012||||No||https://clinicaltrials.gov/show/NCT01608087||85232|
NCT01607840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15657-S|Effects of Transcranial Direct Current Stimulation in Individuals With Schizophrenia|Effects of Transcranial Direct Current Stimulation in Individuals With Schizophrenia||Johns Hopkins University|Yes|Completed|June 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|11|||Both|18 Years|79 Years|No|||August 2015|August 31, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607840||85251|
NCT01608698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R015532040|Comparison of Body Weight Change During Contraception With Belara and Yasmin|A Comparison of Body Weight Changing and Side Effects Between Treatment With 30 mcg Ethinylestradiol/2 mg Chlormadinone Acetate (Belara®) and 30 mcg Ethinylestradiol/3 mg Drospirenone (Yasmin®): A Randomized Control Trial||Mahidol University|No|Enrolling by invitation|June 2012|February 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|19 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 7, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01608698||85185|
NCT01608100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7B5-02-10A01-03|Evaluation of a New Cardiac Biomarker Assay|Design Validation Protocol for the Evaluation of ARCHITECT STAT High Sensitive Troponin I Assay||Abbott Diagnostics Division|No|Completed|June 2012|September 2014|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|1101|||Both|18 Years|N/A|No|||January 2015|March 4, 2015|May 21, 2012|Yes|Yes||No|December 3, 2014|https://clinicaltrials.gov/show/NCT01608100||85231|Some tube types and some time points may not have been obtained for each subject. Every attempt was made to collect all tube types within the time point windows described.
NCT01608724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1680L00008|The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus|A Multicenter, Single Arm, Cohort Study to Evaluate the Efficacy and Safety of Saxagliptin 5mg, Once Daily for 24 Weeks, in Patients With Type 2 Diabetes Mellitus|SUNSHINE|AstraZeneca|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2165|||Both|18 Years|99 Years|No|||December 2015|December 31, 2015|May 28, 2012||No||No|May 14, 2015|https://clinicaltrials.gov/show/NCT01608724||85183|This was a single-arm study and thus potential placebo effect was unable to be adjusted in any efficacy analyses.
NCT01608737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.8|A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection|A Phase III, Randomised, Double-blind and Placebo-controlled Study of Once Daily BI 201335 for 12 or 24 Weeks in Combination With Pegylated interferon-a and Ribavirin in Treatment-naive and Prior Relapser Patients With Genotype 1 Chronic Hepatitis C Infection||Boehringer Ingelheim||Withdrawn|September 2012|||October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|5||Actual|0|||Both|18 Years|70 Years|No|||February 2013|February 23, 2013|May 29, 2012||||No||https://clinicaltrials.gov/show/NCT01608737||85182|
NCT01608711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-1C4D4-12-3|A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002|An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002||Astellas Pharma Inc|No|Completed|May 2012|October 2015|Actual|October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|May 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01608711||85184|
NCT01600885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0807004092|The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects|The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects|GuaKet|Yale University|No|Completed|August 2008|July 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|19|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||October 2014|October 22, 2014|May 15, 2012|Yes|Yes||No|August 29, 2014|https://clinicaltrials.gov/show/NCT01600885||85785|
NCT01600898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100104|Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers|Screening and Risk Factors of Pulmonary Arterial Hypertension in BMPR2 Mutation Asymptomatic Carriers|DELPHI-2|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|asymptomatic BMPR2 mutation carriers.|March 2015|March 6, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600898||85784|
NCT01609309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLASS - 01|Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)|Multicenter Study on Comparison of Long-term Outcome Between Laparoscopic and Open Distal Subtotal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer||Nanfang Hospital of Southern Medical University|Yes|Active, not recruiting|September 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1056|||Both|19 Years|74 Years|No|||January 2015|January 26, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609309||85138|
NCT01609322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH086668|Exposure Therapy for Fear of Falling in Older Adults|Exposure Therapy for Fear of Falling in Older Adults||University of California, San Diego|Yes|Completed|August 2010|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|65 Years|N/A|No|||December 2013|December 19, 2013|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609322||85137|
NCT01601145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|146/2011|Effect of Probiotic on the Plaque pH. A Randomized Double Blind Interventional Study|||Università degli Studi di Sassari|No|Completed|January 2012|August 2012|Actual|July 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|192|||Both|6 Years|8 Years|No|||August 2012|August 21, 2012|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601145||85765|
NCT01622166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EA1/104/11|Art Therapy in Acute Schizophrenia|Art Therapy for Symptom Reduction in Acute Schizophrenia - a Randomised Controlled Trial (Kunsttherapie Zur Symptomreduktion Bei Akuter Schizophrenie - Eine Randomisierte Kontrollierte Pilotstudie)|KUSS|Charite University, Berlin, Germany|No|Completed|August 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|64 Years|No|||October 2014|October 22, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01622166||84152|
NCT01621815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SH-12-13|Variance of Video Games Playing Patterns Among Adolescents With Psychiatric Disorders|Variance of Video Games Playing Patterns Among Adolescents With Psychiatric Disorders: Diagnostical and Dynamic Meanings||Shalvata Mental Health Center|No|Completed|July 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|46|||Male|13 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621815||84179|
NCT01622088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223AS304|Phase 3 Extension Study of Dexpramipexole in ALS|An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis|ENVISION|Knopp Biosciences|Yes|Terminated|June 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|616|||Both|18 Years|80 Years|No|||November 2014|November 24, 2014|May 3, 2012|Yes|Yes|The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.|No||https://clinicaltrials.gov/show/NCT01622088||84158|
NCT01622101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B238|Thermogenic Properties of Zantrex-3|Acute Effects of Zantrex-3 on Energy Expenditure and Appetite Sensations|ZANTREX|University of Copenhagen|No|Completed|May 2007|August 2007|Actual|August 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|23|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622101||84157|
NCT01622452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|396/12 FTGM|Post Cardiac Surgery Neurocognitive Decline: Correlations Between Neuropsychological Tests and Functional MRI Techniques|Neurocognitive Deficits Related to Cardiac Surgery Intervention With Extracorporeal Circulation. Correlations Between Neuropsychological Tests and Functional MRI Techniques (Spectroscopy, Diffusion and Morphometry)|CardChNeuroMRI|Fondazione Toscana Gabriele Monasterio|No|Not yet recruiting|October 2013|October 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|35 Years|70 Years|No|Probability Sample|Patients undergoing elective valve surgery in Ospedale del Cuore, Fondazione G.        Monasterio, Massa, Italy and matching inclusion/exclusion criteria will prospectively        enter the study.|August 2013|August 14, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622452||84130|
NCT01618318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/WS/0049|Glasgow Asthma and Allergy Study|Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma|GLAAS|National Services for Health Improvement Ltd|No|Completed|June 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|105|||Both|18 Years|N/A|No|Non-Probability Sample|People with asthma, non smoker, aged 18 and over.|December 2013|December 4, 2013|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01618318||84447|
NCT01618591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDCRP-065|Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea|A Randomized, Double-Blind, Clinical Trial Evaluating Three Single Dose Regimens With Loperamide for Treatment of Ambulatory Watery Travelers' Diarrhea, and Azithromycin With and Without Loperamide for Treatment of Ambulatory Dysentery/Febrile Diarrhea|TrEAT TD|Uniformed Services University of the Health Sciences|Yes|Recruiting|September 2012|September 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|510|||Both|18 Years|N/A|No|||April 2015|April 19, 2015|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01618591||84426|
NCT01618864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Luxe01|Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea|Safety and Efficacy Evaluation of the Luxe™ Device for the Treatment of Facial Wrinkles and Rosacea||Syneron Medical|No|Completed|March 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||July 2014|July 20, 2014|June 11, 2012|Yes|Yes||No|June 10, 2014|https://clinicaltrials.gov/show/NCT01618864||84405|Small number of subjects analyzed for post-marketing study.
NCT01606631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNIL AR091723|Role of Beta-blockers in the Prevention on the Arisen of a Severe Sepsis (TESS)|Evaluation of the Protective Role of Beta-blockers Prescribed in a Chronic Way on the Arisen of a Severe Septic Syndrome or a Toxic Shock at Patients Having a Community Infection||Rennes University Hospital|No|Completed|September 2009|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|2444|Samples Without DNA|Non applicable.|Both|18 Years|N/A|No|Non-Probability Sample|Case : patients included in the study and admitted to the ICU either directly from UAA or        after a hospitalization in a specialty, for a severe sepsis or septic shock on their        infectious disease community.        Control : patients included in the study with an infectious disease community, admitted to        a specialty, and have not progressed to severe sepsis or septic shock before hospital        discharge.|April 2012|May 23, 2012|February 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606631||85343|
NCT01606644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBO Copenhagen study|Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue|Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue.||Rigshospitalet, Denmark|No|Recruiting|May 2010|April 2014|Anticipated|April 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|N/A|No|||May 2012|May 25, 2012|May 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01606644||85342|
NCT01606657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10012010|Irrigation Versus no Irrigation for Cutaneous Abscess|Is Routine Irrigation of Cutaneous Abscesses Necessary?||University of California, San Francisco|No|Completed|August 2010|April 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|201|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01606657||85341|
NCT01607255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-10-11S|Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)|Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method||VA Office of Research and Development|Yes|Recruiting|May 2013|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|480|||Both|45 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 22, 2015|May 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607255||85295|
NCT01607554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1201|Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer|A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression||New Mexico Cancer Care Alliance|Yes|Recruiting|April 2012|December 2019|Anticipated|May 2018|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|33|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|May 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607554||85272|
NCT01607827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-1066|Colorectal Polypectomy Upon Insertion And Withdrawal Or Upon Withdrawal Only?|Colorectal Polypectomy Upon Insertion And Withdrawal Or Upon Withdrawal Only?||University of Zurich|No|Completed|April 2004|April 2007|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 18, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607827||85252|
NCT01608113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 802/2011|Long-term Follow-up of Subfoveal Neovascular AMD|||Medical University of Vienna||Recruiting|September 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|70|||Both|18 Years|N/A|No|Probability Sample|Patients suffering on treatment naive subfoveal neovascular age-related macular        degeneration|May 2012|May 25, 2012|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01608113||85230|
NCT01608425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telesaar RH_3|Ulcer Monitoring in Diabetes Mellitus|Impact Assessment by Introducing Telemedicine Consultations for Treatment of Diabetic Patients With Foot Ulcers in Region of Southern Denmark - Randomized Prospective Study|Telesaar|Odense University Hospital|Yes|Recruiting|April 2011|November 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|N/A|N/A|No|||June 2013|June 4, 2013|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01608425||85206|
NCT01604538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|protocol_364|Italian Pulmonary Embolism Registry - IPER|Italian Pulmonary Embolism Registry|IPER|University Of Perugia|No|Completed|March 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1700|||Both|18 Years|N/A|No|Non-Probability Sample|consecutive patients with acute pulmonary embolism|May 2012|May 21, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604538||85504|
NCT01604551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4649|Membrane Shedding During Septic Shock|Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance||University Hospital, Strasbourg, France|No|Completed|May 2003|December 2011|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Patients with septic shock|May 2012|May 31, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604551||85503|
NCT01609049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27851|An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)|Open-label, Multicenter, Non-comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in Real Clinical Practice||Hoffmann-La Roche||Completed|December 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1496|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C and compensated liver cirrhosis initiating treatment        with Pegasys and ribavirin|March 2016|March 1, 2016|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01609049||85158|
NCT01609062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-008|Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome|A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)||BioMarin Pharmaceutical|Yes|Terminated|April 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|7 Years|N/A|No|||December 2015|December 24, 2015|May 24, 2012|Yes|Yes||No|November 12, 2015|https://clinicaltrials.gov/show/NCT01609062||85157|
NCT01601171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|345/11|The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome)|The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome)||Centre Hospitalier Universitaire Vaudois|No|Recruiting|March 2012|March 2022|Anticipated|March 2022|Anticipated|N/A|Observational|Observational Model: Cohort||2|Anticipated|2000|Samples With DNA|whole blood, serum/plasma, white blood cells, DNA|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Study participants will be a convenience sample of those patients with reproductive        disorders (and their family members) who are interested in participating in this genetic        study.|June 2015|June 23, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601171||85763|
NCT01600872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-TMU-PCOS-201112030|Oxidative Stress and Bisphenol A (BPA) Impact With Polycystic Ovary Syndrome (PCOS)|Oxidative Stress and BPA Impact With PCOS||Taipei Medical University WanFang Hospital|No|Recruiting|March 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Normal health control and Women with reproductive endocrine disturbance menstrual        irregularity, and/or polycystic ovary syndrome.|November 2013|November 4, 2013|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01600872||85786|
NCT01601418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-022|Effect of Single Doses of YF476 on Stomach Acidity|Double-blind, Placebo-controlled, Single-dose, 5-way Crossover Study of the Effect of YF476 (1, 5, 25 & 100 mg) on Pentagastrin-induced Gastric Acid Output in Healthy Volunteers||Trio Medicines Ltd.|No|Completed|October 2001|January 2002|Actual|January 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 16, 2012|May 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601418||85744|
NCT01621828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1879|Multimedia Information and Pre-operative Anxiety|A Prospective Randomised Controlled Trial of the Impact of Multimedia Information to Reduce Pre-operative Anxiety in Patients Undergoing Major Elective Surgery|MIPA|Imperial College London|No|Not yet recruiting|July 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|50|||Both|18 Years|90 Years|No|||June 2012|June 15, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621828||84178|
NCT01622114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B252|Evaluation of the Association Between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|Evaluation of the Association Between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women - A 6-Month Intervention|MENSTRALEAN|University of Copenhagen|No|Completed|September 2011|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|60|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622114||84156|
NCT01622127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/497|Progrip Ventral Study for Sublay Repair|Efficacy of Self-fixating Mesh in Ventral and Incisional Hernia Repair||University Hospital, Ghent|No|Recruiting|February 2012|August 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with primary ventral and incisional hernia repair.|December 2014|December 4, 2014|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622127||84155|
NCT01622140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-TBESC-TO1|Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis|Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis||Centers for Disease Control and Prevention|No|Recruiting|October 2012|September 2021|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|42647|||Both|N/A|N/A|No|Non-Probability Sample|Individuals at high risk for latent tuberculosis infection or at high risk for progression        to tuberculosis from health clinics, hospitals, or health departments at the 10        Tuberculosis Epidemiologic Studies Consortium sites within the United States: California        Department of Public Health, Denver Health and Hospital Authority, Duke University, Emory        University, Hawaii Department of Health, Maricopa County Department of Public Health,        Maryland Department of Public Health, Public Health Seattle-King County, University of        Florida Board of Trustees, and University of North Texas Health Science Center|January 2016|February 2, 2016|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01622140||84154|
NCT01622465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|403/2011|Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty|Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty: Randomized Controlled Trial||University of Campinas, Brazil|No|Completed|August 2011|April 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|14|||Both|60 Years|N/A|No|||December 2014|December 3, 2014|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01622465||84129|
NCT01622478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNSBCC001|Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes|Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Radiologically Positive Axillary Lymph Nodes|VSNBNAC|Gangnam Severance Hospital|Yes|Completed|December 2006|November 2009|Actual|June 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Female|20 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Advanced breast cancer patients with node-positive proved in preoperative imaging study|August 2012|August 14, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622478||84128|
NCT01618331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-149|Protein Supplementation and Exercise in Patients With FSH Muscular Dystrophy- a Randomized Placebo Controlled Study|The Effect of Protein Supplementation Doing Regular Exercise in Patients With Facioscapulohumeral Muscular Dystrophy - a Blinded RCT Study|FSHD|Rigshospitalet, Denmark|No|Completed|March 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|42|||Both|18 Years|65 Years|No|||June 2014|June 4, 2014|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01618331||84446|
NCT01618604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPM2012|QST in Context With Conditioned Pain Modulation|Quantitative Sensory Testing in Context With Conditioned Pain Modulation (CPM)|CPM|Ruhr University of Bochum|No|Completed|May 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy voluntary probands|December 2012|December 30, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618604||84425|
NCT01606670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1058|Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease|A Multicenter, Non-interventional Study With Neupro® to Evaluate the Perception of Pain Associated With Idiopathic Parkinson's Disease|NEUPAD|UCB Pharma|No|Completed|May 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|93|||Both|N/A|N/A|No|Non-Probability Sample|Patients with pain associated with idiopathic Parkinson´s Disease. Every consecutive,        eligible patient to be treated with Neupro® as per physician's decision.|April 2015|April 28, 2015|May 22, 2012|No|Yes||No|April 1, 2015|https://clinicaltrials.gov/show/NCT01606670||85340|
NCT01607814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cirrhosis and Oxidative Stress|Oxidative Stress and Haemostasis Abnormalities in Cirrhosis|Oxidative Stress and Haemostasis Abnormalities in Cirrhosis||University of Roma La Sapienza|Yes|Recruiting|November 2011|November 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|200|Samples Without DNA|Plasma, serum and urine samples|Both|18 Years|90 Years|No|Non-Probability Sample|Patients affected by cirrhosis of any etiology and severity|May 2012|May 30, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607814||85253|
NCT01607541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-01257|Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV|Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV|BCAP|New York University|Yes|Active, not recruiting|April 2012|April 2016|Anticipated|February 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|3400|||Both|18 Years|60 Years|No|||April 2015|April 15, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01607541||85273|
NCT01603758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201110042|Physiological Study of Human Cholesterol Metabolism and Excretion|Reverse Cholesterol Transport in Humans||Washington University School of Medicine|No|Not yet recruiting|September 2012|January 2016|Anticipated|July 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|130|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603758||85564|
NCT01608126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medial block II /nalos|Medial Cervical Block for Carotid Endarterectomy Comparison With Standard Method|A Comparison of Medial Cervical Plexus Block Versus Combined (Superficial and Deep) Cervical Plexus Block for Carotid Endarterectomy: A Prospective, Randomized Single Blind Study||Masaryk Hospital Krajská zdravotní a.s.|No|Completed|January 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|100|||Both|30 Years|90 Years|No|||May 2012|May 29, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01608126||85229|
NCT01608139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0574|Study of Curcumin, Vorinostat, and Sorafenib|Pilot Study of Curcumin, Vorinostat, and Sorafenib in Patients With Advanced Solid Tumors||M.D. Anderson Cancer Center|No|Withdrawn|November 2012|||November 2022|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||October 2012|October 17, 2012|May 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01608139||85228|
NCT01607853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LP0076-57|A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris|A Phase IIa Exploratory Study Evaluating the Anti-psoriatic Effect of Daivobet® Gel Applied Then Removed After 10 Minutes, Daivobet® Gel Applied Then Removed After 20 Minutes, Daivobet® Gel Applied for 24 Hours and Daivobet® Gel Vehicle Applied for 24 Hours||LEO Pharma|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)|1||Actual|24|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|May 23, 2012||No||No|November 4, 2013|https://clinicaltrials.gov/show/NCT01607853||85250|In this small exploratory trial the subjects received all 4 investigational products on small dermal test sites.Regarding Adverse Events, only local dermal reactions could be potentially attributed to a specific investigational product.
NCT01604252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28296|An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)|A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients||Genentech, Inc.||Active, not recruiting|June 2012|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|503|Samples With DNA|optional blood sample|Both|18 Years|N/A|No|Probability Sample|Patients treated for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome|March 2016|March 1, 2016|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604252||85526|
NCT01604265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GWMS0107|A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis|A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis.||GW Pharmaceuticals Ltd.|No|Completed|March 2002|August 2002|Actual|August 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|May 21, 2012||No||No|July 18, 2012|https://clinicaltrials.gov/show/NCT01604265||85525|
NCT01604837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03-074|The Optimal Oblique and Axial Angle of Fluoroscope for Superior Hypogastric Plexus Block|The Optimal Oblique and Axial Angle of Fluoroscope for Superior Hypogastric Plexus Block||Samsung Medical Center|Yes|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|268|||Both|20 Years|80 Years|No|Non-Probability Sample|Those undergoing abdominopelvic CT scan with pelvic malignancy or chronic pelvic pain with        constitutional disease|December 2013|December 24, 2013|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01604837||85481|
NCT01604824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R727-CL-1018|A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene|A Phase 2 Pilot Study With a Randomized Double-Blind Treatment Phase to Evaluate the Pharmacodynamics and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia and Gain-of-Function Mutations in 1 or Both Alleles of the PCSK9 Gene or Loss-of-Function Mutations in 1 or More Alleles of the Apolipoprotein B Gene||Regeneron Pharmaceuticals|No|Active, not recruiting|September 2012|September 2016|Anticipated|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|23|||Both|18 Years|70 Years|No|||January 2015|January 24, 2015|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01604824||85482|
NCT01601184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEVITEM|Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway|An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway||Centre Leon Berard|Yes|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|38|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01601184||85762|
NCT01606280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005003|Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation|Reporting of Amyloidosis Stem Cell Transplantation Outcomes||Mayo Clinic|No|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|400|||Both|18 Years|75 Years|No|Non-Probability Sample|Patient receiving transplantation|January 2014|January 20, 2014|March 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01606280||85370|
NCT01601158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GDDUCB|Umbilical Cord Blood Therapy for Children With Global Developmental Delay|Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Children With Global Developmental Delay||Bundang CHA Hospital|No|Completed|May 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|6 Months|15 Years|No|||January 2014|January 8, 2014|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01601158||85764|
NCT01601795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS-57/12|Sevoflurane and Isoflurane - During Cardiopulmonary Bypass With the MECC System (Minimized Extracorporeal Circuit)|Sevoflurane and Isoflurane - Cardioprotective Effects, Hemodynamic Stability and Pharmacokinetics During Cardiopulmonary Bypass With the MECC System||University Hospital, Basel, Switzerland|Yes|Completed|July 2012|January 2014|Actual|January 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 28, 2014|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01601795||85715|
NCT01601808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-021951-26|Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma|A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma|ViP|University of Liverpool|Yes|Recruiting|October 2011|October 2013|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2012|May 16, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01601808||85714|
NCT01621607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912478|Individual Differences in Reward and Impulse Control|Gene x Environment Interactions as Risk Factors for Addiction||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|120|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 13, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621607||84195|
NCT01621620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-JG-0044-CTIL|The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects|The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|August 2012|August 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 15, 2012|June 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01621620||84194|
NCT01621867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICL/CRO-1881|Repeated Application of Gene Therapy in CF Patients|A Randomised, Double-blind, Placebo-controlled Phase 2B Clinical Trial of Repeated Application of Gene Therapy in Patients With Cystic Fibrosis||Imperial College London|Yes|Completed|May 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|130|||Both|12 Years|N/A|No|||November 2012|October 21, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621867||84175|
NCT01621841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX2012/01|Analysis of Visual Pathways in Glaucoma Patients Using a 3tesla-MRI||ENVOL|University Hospital, Bordeaux|Yes|Completed|June 2012|November 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|114|||Both|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Glaucoma subjects are recruted in ophtalmologic departement|December 2013|December 18, 2013|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01621841||84177|
NCT01622153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021117|Electrical and Formocresol Pulpotomy in Primary Molars|A Prospective Study and Clinical Evaluation of Pre & Post Operative Treatment Comparison of Electrical and Formocresol Pulpotomy Procedures in Primary Molars of Children Undergoing General Anesthesia||University Hospital Case Medical Center|No|Active, not recruiting|June 2011|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|3 Years|8 Years|No|||June 2012|June 18, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622153||84153|
NCT01622491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICID-2012-H1N1-01|Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada|Effectiveness of the GSK Pandemic H1N1 Influenza Vaccines in Preventing Hospitalization for Influenza and Pneumonia in Manitoba, Canada||International Centre for Infectious Diseases, Canada|No|Not yet recruiting|June 2012|December 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|1860|||Both|6 Months|N/A|No|Non-Probability Sample|Any adult or child > 6 months of age who normally resides in Manitoba and who has been        continuously covered during the study period.|June 2012|June 18, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622491||84127|
NCT01618903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01362A|An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese|A Monocenter, Open-label, Two-way Randomized Cross-over Study to Evaluate the Bioequivalence of Levetiracetam Administered as a 45 Minutes Intravenous Infusion and Same Dosage Levetiracetam Oral Tablet (Part A); and a Randomized, Double-blind, Placebo-controlled, Parallel Study on the Safety, Tolerability and Pharmacokinetics of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of b.i.d. Dosing (Part B), in Chinese Healthy Volunteers||UCB Pharma|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||August 2012|August 2, 2012|June 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01618903||84402|
NCT01619176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acumicro|Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood|Non Inferiority Trial for the Study of Acupuncture on Rheumatoid Arthritis||Chinese Academy of Sciences|No|Completed|October 2012|||December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|15|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01619176||84381|
NCT01619189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC 2001|Cell Therapy in Failure Syndromes in Limbal Stem Cells|Thérapie Cellulaire au Cours Des Syndromes d'Insuffisance en Cellules Souches Limbiques|TC181|Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts|No|Active, not recruiting|June 2007|||December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||February 2015|February 3, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01619189||84380|
NCT01606995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15914|Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation|Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation|XANTUS|Bayer|No|Completed|June 2012|March 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6834|||Both|18 Years|N/A|No|Probability Sample|Patients with a diagnosis of non-valvular atrial fibrillation who start treatment with        rivaroxaban to prevent stroke or non-CNS systemic embolism|April 2015|April 21, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606995||85315|
NCT01607281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DiskapiTRH1|The Ability of Anesthesiologists Identifying Internal Jugular Vein Bilaterally by Anatomic Landmarks|The Ability of Anesthesiologists Identifying Internal Jugular Vein by Anatomic Landmark Technique||Diskapi Teaching and Research Hospital|No|Not yet recruiting|June 2012|July 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|22 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|the residents of anesthesiology clinics|May 2012|July 9, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01607281||85293|
NCT01607294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1002-005|A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes||Esperion Therapeutics|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|70 Years|No|||August 2015|August 27, 2015|April 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607294||85292|
NCT01604291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28268|An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C|Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients||Hoffmann-La Roche||Active, not recruiting|May 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|959|||Both|18 Years|N/A|No|Probability Sample|Chronic hepatitis C patients initiating Pegasys-based treatment|December 2015|December 31, 2015|May 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01604291||85523|
NCT01604304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.692|Flexible urétéroscopy Versus Extracorporeal Shockwave Lithotripsy in Renal Calculi|Flexible urétéroscopy Versus Extracorporeal Shockwave Lithotripsy in 5 to 20 mm Renal Calculi, Efficacity Prospective Randomized Trial|CALIX-1|Hospices Civils de Lyon|No|Completed|May 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||August 2014|August 26, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604304||85522|
NCT01604005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08_DOG07_93|PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma|PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention|PIT|Christie Hospital NHS Foundation Trust|No|Recruiting|July 2012|August 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|374|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604005||85545|
NCT01604278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2316|Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD|GLOW6|Novartis||Completed|May 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|449|||Both|40 Years|N/A|No|||November 2014|November 12, 2014|May 21, 2012||No||No|July 28, 2014|https://clinicaltrials.gov/show/NCT01604278||85524|
NCT01604564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-54228|Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients|KOPOF Registry (Patients Characteristics, Operative Data, Postoperative Outcome, Functional Postoperative Recovery ) of Patients in Which a Pouch Has Been Created Due to Colitis Ulcerosa (CU) or Familial Adenomatous Polyposis(FAP)|KOPOF|Universitaire Ziekenhuizen Leuven|No|Recruiting|May 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|N/A|N/A|No|Non-Probability Sample|Colitis Ulcerosa or Familial Adenomatous Polyposis Patients who have undergone a        restorative proctocolectomy with creation of an ileoanal pouche|July 2015|July 3, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604564||85502|
NCT01600651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0119|Diffuse Acute Respiratory Distress Syndrome (ARDS), Recruitment Maneuver, and sRAGE (DAMAGE Study)|Effects Of A Recruitment Maneuver On Plasma Levels of sRAGE, The Soluble Form of The Receptor For Advanced Glycation End Products, In Patients With Diffuse Acute Respiratory Distress Syndrome (ARDS)|DAMAGE|University Hospital, Clermont-Ferrand||Completed|April 2012|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||October 2013|October 1, 2013|April 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01600651||85803|
NCT01600625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0830|Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction|||Yonsei University|No|Completed|November 2011|March 2013|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|40 Years|80 Years|No|||March 2014|March 4, 2014|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01600625||85805|
NCT01606527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NHRC.2012.0013|NSAID RCT for Prevention of Altitude Sickness|Prospective, Double-blind, Randomized, Placebo-controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness||Naval Health Research Center|No|Not yet recruiting|July 2012|October 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2012|May 23, 2012|April 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606527||85351|
NCT01601431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12050|The Utility of Cap Colonoscopy in Increasing Adenoma Detection Rate|The Utility of Cap Colonoscopy in Increasing Adenoma Detection Rate||Texas Tech University Health Sciences Center|Yes|Completed|April 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|440|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01601431||85743|
NCT01601834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5261001|A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Pf-06273340 In Healthy Volunteers||Pfizer|No|Completed|May 2012|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|20|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01601834||85712|
NCT01602120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX28198|An Extension Study to Evaluate the Long-Term Safety of FCFD4514S in Patients With Geographic Atrophy|A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of FCFD4514S in Patients With Geographic Atrophy||Genentech, Inc.||Active, not recruiting|May 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|93|||Both|60 Years|89 Years|No|||March 2016|March 1, 2016|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01602120||85690|
NCT01622504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MVP005-CLN-001|Naloxone Nasal Spray Pharmacokinetic Study|A Phase I Single Dose, Open Label, Randomized, Three Period Crossover Pilot Study to Compare the Pharmacokinetics, Safety and Tolerability of MVP005 Intranasal Spray With Intranasal Administration of Naloxone Solution for Injection in Healthy Adult Subjects||Mitovie Pharma Ltd|No|Not yet recruiting|June 2012|August 2012|Anticipated|July 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|6|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 19, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01622504||84126|
NCT01618344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCH-13929|Smartphone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer|Use of a Smartphone Medication Reminder Application to Promote Adherence to Oral Medications by Adolescents and Young Adults(AYA) With Cancer||University of Utah|No|Recruiting|May 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 0|Observational|Time Perspective: Prospective||1|Anticipated|20|||Both|15 Years|29 Years|No|Non-Probability Sample|Primary care clinics for patients be treated for cancer.|February 2016|February 24, 2016|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01618344||84445|
NCT01618357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11155|Pre-Operative Radiation and Veliparib for Breast Cancer|Pre-Operative PARPi and Irradiation (POPI) in Women With an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer||Indiana University|Yes|Suspended|September 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Female|18 Years|N/A|No|||December 2015|December 2, 2015|January 20, 2012|No|Yes|Awaiting site initiation visit for transfer of coordinating center|No||https://clinicaltrials.gov/show/NCT01618357||84444|
NCT01618617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111028-SUS-REN-CTT-RA|Multistrain Probiotic for Functional Constipation|Dose-response Effectiveness of 6-week Multistrain Probiotic Supplementation on Whole Gut Transit Time, Quality of Life, and Gastrointestinal Symptoms in Adults With Functional Constipation||Renew Life Formulas Inc|No|Recruiting|June 2012|March 2013|Anticipated|March 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|81|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|November 29, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618617||84424|
NCT01618370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16216|Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases|Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases||Bayer|No|Completed|July 2012|February 2016|Actual|August 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|705|||Male|18 Years|N/A|No|||March 2016|March 9, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618370||84443|
NCT01618383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC11_0110|Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation|Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation|EnteroLarc|Nantes University Hospital|Yes|Recruiting|March 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|18|||Both|30 Years|80 Years|No|||December 2015|December 22, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618383||84442|
NCT01618630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-048|Amino Acid Supplementation in Recovery From Severe Burn|Amino Acid Supplementation in Recovery From Severe Burn|ExAA|The University of Texas Medical Branch, Galveston|Yes|Recruiting|May 2012|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|40|||Both|7 Years|17 Years|No|||June 2014|June 30, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01618630||84423|
NCT01607268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120574|Magnetic Resonance Spectroscopy in Autonomic Failure|Proton Magnetic Resonance Spectroscopy in Primary Autonomic Failure||Vanderbilt University|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|26|||Both|18 Years|80 Years|No|Non-Probability Sample|Primary autonomic failure patients will be recruited from patients already in the hospital        participating in the approved protocol "The Evaluation and Treatment of Autonomic        Failure." Prospective participants come from several sources including clinic patients,        former patients, referrals from other physicians, and subjects that read about the        Autonomic Dysfunction Center on the Vanderbilt website.|March 2016|March 7, 2016|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01607268||85294|
NCT01603459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ60201_3053_1|Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm|Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes||Merz Pharmaceuticals GmbH|Yes|Completed|May 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|155|||Both|18 Years|80 Years|No|||September 2015|September 10, 2015|April 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603459||85587|
NCT01604317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAB Neo 005|Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part I|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part I||University of Alabama at Birmingham|Yes|Recruiting|June 2012|February 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|182|||Both|N/A|1 Hour|No|||January 2016|January 12, 2016|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604317||85521|
NCT01604577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120595|Targeting Social Determinants to Improve Chronic Kidney Disease Care|Targeting Social Determinants to Improve Chronic Kidney Disease Care||Vanderbilt University|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|273|||Both|18 Years|80 Years|No|||July 2014|July 26, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604577||85501|
NCT01604850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0108|Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)|A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection|FUSION|Gilead Sciences|Yes|Completed|June 2012|May 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|202|||Both|18 Years|N/A|No|||May 2014|May 9, 2014|May 21, 2012|Yes|Yes||No|March 31, 2014|https://clinicaltrials.gov/show/NCT01604850||85480|
NCT01600638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA12-005|Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature|Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature||Zeltiq Aesthetics|No|Completed|April 2012|January 2013|Actual|October 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|February 4, 2013|April 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01600638||85804|
NCT01600664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006814ctil|The Effect of the Use of Computer Game- "My Diabetic Friend" in Children With Type 1 Diabetes|Randomized Controlled Trial to Evaluate the Effect of 3 Months Use With Interactive Computer Game- "My Diabetic Friend"-Comparing to Conventional Diabetes Education on Metabolic Control, Quality of Life and Diabetes Knowledge in Children With Type 1 Diabetes.||Rabin Medical Center|No|Completed|June 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|30|||Both|7 Years|11 Years|No|||May 2014|May 4, 2014|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01600664||85802|
NCT01600911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC0991003|Establish a Vegetable Signature Database From Human Metabolomics Responses|Establish a Vegetable Signature Database From Human Metabolomics Responses||National Health Research Institutes, Taiwan|No|Active, not recruiting|December 2010|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 17, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01600911||85783|
NCT01600924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFA-12-02|Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes|Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes|SAMBA|Metabolic Fitness Association, Italy|No|Active, not recruiting|October 2012|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|Samples Without DNA|Whole blood, plasma, serum and urine samples|Both|18 Years|75 Years|No|Probability Sample|Outpatients clinics|April 2015|April 7, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01600924||85782|
NCT01606826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SARP003|Severe Asthma Research Program|Severe Asthma Research Program|SARP|Milton S. Hershey Medical Center|Yes|Active, not recruiting|October 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|Samples With DNA|Blood: CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA Urine EBC Sputum: Supernatant, Cell      Pellet Bronch: BAl, Bronchial Brushings, Bronchial Biopsy|Both|6 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The target recruitment goal for each center is 75% adults (age 18 and older) and 25%        children age 6-17 years. Within the pediatric age group, an attempt will be made to enroll        equal numbers of children 6-11 and 12-17 years of age. Similarly, an attempt will be made        to enroll at least 50% females and 30% minorities.        Given the mission of SARP, a diverse sample of subjects with asthma is needed to gain        better understanding of asthma and its endotypes. Because there are a number of        respiratory disorders that may be confused with asthma or confound asthma assessment, SARP        enrollees must meet the eligibility criteria as outlined below.        Approximately 49 Health Control patients, matching the demographic characteristics of the        asthma patients, will also be recruited across the 7 site partnerships in order to        generate reference data for biospecimens collected from asthmatic patients.|April 2015|April 6, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606826||85328|
NCT01601444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-CG-504-CTIL|Detection of Pleural Effusion by Internal Thoracic Impedance Method|Detection of Pleural Effusion by Internal Thoracic Impedance Method||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2012|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Both|40 Years|90 Years|No|||May 2012|May 16, 2012|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01601444||85742|
NCT01601821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0468H-102012|Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids|An Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids With Further CSA Elimination In The Rapamune Arm With The Introduction Of MMF||Pfizer|No|Completed|April 2006|March 2008|Actual|March 2008|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|245|||Both|13 Years|18 Years|No|||April 2013|April 29, 2013|May 3, 2012|Yes|Yes||No|April 29, 2013|https://clinicaltrials.gov/show/NCT01601821||85713|
NCT01607060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lactulona|Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.|Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.||Federal University of São Paulo|No|Completed|September 2008|||April 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|N/A|No|||October 2012|January 5, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607060||85310|
NCT01607346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116158|An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures|An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures||GlaxoSmithKline|No|Recruiting|March 2013|February 2019|Anticipated|February 2019|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|February 4, 2016|May 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607346||85288|
NCT01627470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNAP-ITW|Comparison of Continuous Non-invasive Pressure Device Versus Invasive Pressure Measurement During Prehospital Emergency|Evaluation of a Continuous Non-invasive Arterial Pressure Device in Comparison With Invasive Pressure Measurement During Out-of-hospital Emergency||University of Schleswig-Holstein|No|Recruiting|August 2011|August 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|ICU Patients with established arterial pressure measurement|June 2012|June 22, 2012|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01627470||83747|
NCT01627483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUCPGMHip-09|Randomized Controlled Trial of Effects of Physician's Medication Reviews on Prescribing in Older Hip Fracture Patients|Improving Treatment With Fracture-preventing and Fall-risk-increasing Drugs in Older Hip Fracture Patients: Effects of Medication Reviews Performed by a Physician - a Randomized Controlled Trial||Sahlgrenska University Hospital, Sweden|No|Completed|April 2009|September 2010|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Both|65 Years|N/A|No|||June 2012|June 21, 2012|June 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627483||83746|
NCT01621880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012025|Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma|Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma|BRAIN|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Yes|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||December 2013|December 9, 2013|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621880||84174|
NCT01622179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLAGH OD 13|Outcome of Two Different Suture Methods for Achilles Tendon Rupture|Closed Achilles Tendon Rupture Treats by Two Different Suture Methods and the Outcome||Chinese PLA General Hospital|No|Recruiting|June 2012|June 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||February 2013|February 19, 2013|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01622179||84151|
NCT01622517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22227|Computed Tomography Perfusion (CTP) to Predict Response to Recanalization in Ischemic Stroke Project (CRISP)|Computed Tomography Perfusion (CTP) to Predict Response to Recanalization in Ischemic Stroke Project|CRISP|Stanford University|Yes|Recruiting|September 2011|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|acute ischemic stroke patients|May 2015|May 18, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622517||84125|
NCT01628679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01805|Physiotherapy Intervention for Provoked Vulvar Vestibulodynia|Physiotherapy Intervention for Provoked Vulvar Vestibulodynia||University of British Columbia|No|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Female|16 Years|40 Years|No|||December 2015|December 17, 2015|February 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01628679||83654|
NCT01628692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI444-062|Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus|A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy With Genotype 1 Chronic Hepatitis C||Bristol-Myers Squibb|No|Completed|July 2012|November 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|230|||Both|18 Years|N/A|No|||October 2015|October 29, 2015|June 25, 2012|Yes|Yes||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01628692||83653|
NCT01628978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-028-001|Verification of Appropriate Insertion Depth of Endotracheal Tube Placement|Verification of Appropriate Insertion Depth of Endotracheal Tube Placement in Infants and Young Children by Ultrasonography||Samsung Medical Center|No|Recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|60|||Both|1 Month|10 Years|No|Non-Probability Sample|Infants or young children (less than body weight of 20 kg) undergoing elective surgery        (general surgery, urology, plastic surgery, otolaryngologic surgery, cardiac surgery)        under general anesthesia with endotracheal intubation|November 2014|November 10, 2014|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01628978||83631|
NCT01607021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|beijing302-004|Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection|Pharmacogenomics Study on IL28B Genetic Variants for Prediction of Drug Response in Chinese Children With HCV Infection.||Beijing 302 Hospital|Yes|Recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|1 Year|18 Years|No|Probability Sample|200 children with chronic HCV infection who were seen at beijing 302 hospital(Beijing        China)between april 2012 and december 2012.|August 2015|August 14, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607021||85313|
NCT01604018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP005B|An Optional Two Year Follow Up Study to Study CP005A|An Optional Two Year Follow Up Study to Evaluate the Continued Efficacy of Cat-PAD ToleroMune Peptide Immunotherapy in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber||Circassia Limited|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|51|||Both|18 Years|65 Years|No|Non-Probability Sample|Subjects previously randomised in study CP005 and completed all dosing and PTC in CP005        and all visits in CP005A.|May 2012|May 23, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604018||85544|
NCT01604031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30087 TAIL|Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide|Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide|TAIL|Baylor College of Medicine|Yes|Terminated|February 2013|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|75 Years|No|||February 2016|February 5, 2016|May 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01604031||85543|
NCT01600677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0031272|Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions|Determining the Impact of a Medication Delivery Unit on Medication Adherence Immediately Following Hospitalization of Adults With Common Cardiac Conditions|EMMA-RCT|University of Pittsburgh|Yes|Terminated|May 2012|May 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|17|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|May 14, 2012||No|Terminated on 2/28/13, low enrollment; last participant med visit 5/13/13.|No||https://clinicaltrials.gov/show/NCT01600677||85801|
NCT01604590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101652, MUSC|Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme|Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease||Medical University of South Carolina|No|Completed|July 2012|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|18 Years|80 Years|No|Non-Probability Sample|Male and female subjects, 18-80 years old with progressive glioblastoma who receive        bevacizumab|March 2015|April 10, 2015|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604590||85500|
NCT01604863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGS1036-C1118|A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies|Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies||GlaxoSmithKline|No|Suspended|June 2012|July 2014|Anticipated|June 2014|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|54|||Both|18 Years|N/A|No|||October 2012|October 29, 2012|January 23, 2012|Yes|Yes|Study suspended prior to enrollment|No||https://clinicaltrials.gov/show/NCT01604863||85479|
NCT01601457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F7ORTHO-1506|Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction|A Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Efficacy and Safety of Activated Recombinant Coagulation Factor VII (rFVIIa, NovoSeven®) in Patients With Major Fractures of Pelvis or Pelvis and Acetabulum Undergoing Repair Surgery||Novo Nordisk A/S|No|Completed|September 2002|April 2004|Actual|April 2004|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|60 Years|No|||May 2012|May 21, 2012|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01601457||85741|
NCT01606293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0464|Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix|Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix||M.D. Anderson Cancer Center|No|Recruiting|May 2012|||May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Female|N/A|N/A|No|Non-Probability Sample|All patients who are members of the Facebook group found at the uniform resource locator        https://www.facebook.com/SmallCellCC through an online link.|December 2015|December 7, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606293||85369|
NCT01600937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFA-12-01|Italian Diabetes and Exercise Study 2|Italian Diabetes and Exercise Study 2 - A Long-term Behavioural Intervention for Adoption and Maintenance of a Physically Active Lifestyle|IDES-2|Metabolic Fitness Association, Italy|No|Active, not recruiting|October 2012|November 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|40 Years|80 Years|No|||April 2015|April 15, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01600937||85781|
NCT01600950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13831|A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus|Pharmacodynamics of LY2963016 Compared to LANTUS® in Subjects With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|60 Years|No|||October 2014|October 3, 2014|May 15, 2012|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01600950||85780|
NCT01607099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PicoPrep|Sodium Picosulfate Plus Magnesium Citrate Versus Macrogol 4000 in the Bowel Cleansing Procedure: a Comparison of Efficiency and Compatibility|Sodium Picosulfate Plus Magnesium Citrate Versus Macrogol 4000 in the Bowel Cleansing Procedure: a Comparison of Efficiency and Compatibility||Technische Universität München|No|Completed|September 2012|November 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|220|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607099||85307|
NCT01607112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116663|A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above||GlaxoSmithKline||Completed|July 2012|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|119|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|November 14, 2013|May 24, 2012|Yes|Yes||No|July 25, 2013|https://clinicaltrials.gov/show/NCT01607112||85306|
NCT01606813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39237EP|The Impact of Integrating an Internet Weight Control Program Into Primary Care|The Impact of Integrating an Internet Weight Control Program Into Primary Care||Milton S. Hershey Medical Center|Yes|Active, not recruiting|October 2012|April 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|611|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||February 2016|February 5, 2016|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606813||85329|
NCT01607073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 113666|Verapamil as Therapy for Children and Young Adults With Dravet Syndrome|Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome||Gillette Children's Specialty Healthcare|Yes|Completed|April 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|2 Years|25 Years|No|||March 2015|March 24, 2015|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01607073||85309|
NCT01607372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116392|A Study to Investigate the Safety, Pharmacodynamics and Efficacy Against Allergic Reactivity of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies|A Randomised, Double Blind, Placebo-controlled Study to Investigate the Safety, Pharmacodynamics and Efficacy Against Allergic Reactivity of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies||GlaxoSmithKline|No|Completed|April 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Both|18 Years|62 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01607372||85286|
NCT01607385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116511|A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.|A Single Blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Repeat Doses of GSK2330672 in Healthy Volunteers, Given Alone and With a Single Day of Dosing With GSK1614235||GlaxoSmithKline||Completed|May 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|March 7, 2013|May 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01607385||85285|
NCT01627496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSQLOP|Nutritional Status and Quality of Life in Older Adults|Nutritional Status and Quality of Life in Older Hospitalised Adults|NSQLOP|University of Surrey|No|Completed|September 2010|December 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|40|||Both|75 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hospitalised older adults (>75years)|July 2012|July 3, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01627496||83745|
NCT01627795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OS-MES-P2-01|Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment|A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study||Oshadi Drug Administration|No|Not yet recruiting|December 2015|December 2017|Anticipated|August 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Both|21 Years|N/A|No|||April 2015|April 21, 2015|June 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01627795||83722|
NCT01627782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100886|A Study of Ketamine in Patients With Treatment-resistant Depression|A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression||Janssen Research & Development, LLC||Completed|August 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|68|||Both|18 Years|64 Years|No|||January 2016|January 25, 2016|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01627782||83723|
NCT01628068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELIGIBLE|ELIGIBLE (Efficacy of Left atrIal Appendage Closure After GastroIntestinal BLEeding)|Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding|ELIGIBLE|Hospital Clinic of Barcelona|Yes|Recruiting|February 2012|July 2014|Anticipated|July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||June 2012|June 25, 2012|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628068||83701|
NCT01628081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9174-SG-CTIL|The Effect of Alga Dunaliella Bardawil on Psoriasis|A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis.||Sheba Medical Center|No|Recruiting|June 2012|July 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|75 Years|No|||June 2012|June 25, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01628081||83700|
NCT01628341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-3988|French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients|French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients|DIALOG|Novo Nordisk A/S|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Retrospective||1|Actual|4424|||Both|18 Years|N/A|No|Non-Probability Sample|Approximately 3811 patients with Type 1 or Type 2 diabetes are expected to be recruited.        Patients will be asked to complete 2 self-assessment questionnaires, one retrospective and        one prospective, to characterize severe hypoglycaemias during the last 12 months        (retrospective questionnaire) and severe/non-severe hypoglycaemias during the coming month        after inclusion (prospective questionnaire).|April 2014|April 29, 2014|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01628341||83680|
NCT01628354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHG|Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration|A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD.||University of Melbourne|Yes|Completed|February 2008|April 2010|Actual|April 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|20 Years|N/A|No|||June 2012|June 26, 2012|June 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628354||83679|
NCT01628991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|clinical trial|Behavioral Intervention Program and Vaginal Cones on SUI|Comparison of the Effect of Vaginal Cones and Behavioral Intervention Program on Urinary Stress Incontinence in Women||Mashhad University of Medical Sciences|Yes|Completed|April 2008|August 2009|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Female|25 Years|65 Years|Accepts Healthy Volunteers|||June 2012|June 26, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01628991||83630|
NCT01629251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAN02|Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes: Evaluation of Reduced Meal Bolusing|||University of Cambridge|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|12 Years|18 Years|No|||June 2012|June 25, 2012|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01629251||83610|
NCT01603160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00032162|Improving Emergency Department Management of Adults With Sickle Cell Disease|Improving Emergency Department Management of Adults With Sickle Cell Disease||Duke University|Yes|Completed|September 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|715|||Both|18 Years|N/A|No|Non-Probability Sample|Patient subjects will be recruited from the Duke University and Wake Forest Emergency        Departments. All ED attending and resident physicians and ED nurses will be invited to        complete the SCD Attitudes survey. Ten clinicians at Duke and 10 clinicians at Wake Forest        will be recruited to participate in the FMECA's.|March 2015|March 4, 2015|April 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01603160||85610|
NCT01603173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ipca/ARL/233|Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fasting Condition|A Randomized, Open Label, Two-Treatment, Two-Period, Two-Sequence, Crossover, Single Dose, Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg With Seroquel® 25 mg in Normal, Healthy, Adult, Human Subjects, Under Fasting Condition||IPCA Laboratories Ltd.|Yes|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|April 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01603173||85609|
NCT01604044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Meropur2009|Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.|||Catholic University of the Sacred Heart||Completed|May 2012|September 2013|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|579|||Female|35 Years|41 Years|Accepts Healthy Volunteers|||September 2014|September 4, 2014|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01604044||85542|
NCT01604057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZT-3201|Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass|A Parallel Group Study to Evaluate the Effect of Six Weeks of Treatment With Nasal Spray (NS) ZT-034, Compared to Subcutaneous (SC) Forteo and Placebo, on Bone Formation, as Assessed by Stimulation of Serum P1NP Levels in Postmenopausal Women With Low Bone Mass||Azelon Pharmaceuticals|No|Active, not recruiting|November 2011|July 2012|Anticipated|July 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|130|||Female|45 Years|N/A|No|||May 2012|May 21, 2012|May 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01604057||85541|
NCT01605409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLI196|Emergency Cardiopulmonary Bypass for Cardiac Arrest|Emergency Cardiopulmonary Bypass After Cardiac Arrest With Ongoing Cardiopulmonary Resuscitation - a Pilot Randomized Trial|ECPB4OHCA|Medical University of Vienna|No|Recruiting|November 2014|May 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||November 2015|November 29, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605409||85437|
NCT01600963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100807|A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis|A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)||Janssen Infectious Diseases BVBA|Yes|Withdrawn|March 2014|November 2022|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|April 24, 2012|Yes|Yes|PhIII program revised; TMC207-C210 cancelled|No||https://clinicaltrials.gov/show/NCT01600963||85779|
NCT01601197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27518|A Study of Two Injection Techniques to Reduce Pain in Infants Undergoing Immunization|A Study of Two Injection Techniques Added to Proven Strategies to Reduce Pain in One- to Twelve-month Old Infants Undergoing Immunization||University of Toronto|No|Recruiting|May 2012|May 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|1 Month|12 Months|Accepts Healthy Volunteers|||October 2012|October 23, 2012|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01601197||85761|
NCT01606306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 004|Individualized Therapy For Asthma in Toddlers|Individualized Therapy For Asthma in Toddlers|INFANT|Milton S. Hershey Medical Center|Yes|Completed|February 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|300|||Both|12 Months|59 Months|No|||April 2015|April 6, 2015|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606306||85368|
NCT01606319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AsthmaNet 005|Acetaminophen Versus Ibuprofen in Children With Asthma|Acetaminophen vs. Ibuprofen in Children With Asthma|AVICA|Milton S. Hershey Medical Center|Yes|Completed|February 2013|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|300|||Both|12 Months|59 Months|No|||March 2016|March 11, 2016|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606319||85367|
NCT01601847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL109293|Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy|Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy|D-Wheeze|Case Western Reserve University|Yes|Active, not recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|N/A|1 Year|No|||January 2016|January 8, 2016|May 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01601847||85711|
NCT01606267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant # 109947|Evaluation of Integrated Community Case Management in Ethiopia|Independent Prospective Evaluation of Integrated Community Case Management and Development and Implementation of a Method for Real-time Mortality Monitoring in the Oromia Region, Ethiopia||Johns Hopkins Bloomberg School of Public Health|No|Enrolling by invitation|December 2010|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|607770|||Both|N/A|N/A|Accepts Healthy Volunteers|||May 2012|May 24, 2012|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01606267||85371|
NCT01607125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14137A|Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Exploratory Study Investigating the Effects of [Vortioxetine] Lu AA21004 on Cognition and BOLD fMRI Signals in Subjects Remitted From Depression and Controls||H. Lundbeck A/S|No|Completed|July 2012|||September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|96|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 24, 2013|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607125||85305|
NCT01607086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111649|Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo|A Randomised, Double-blind Study in Healthy Volunteers to Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo||GlaxoSmithKline|No|Completed|July 2008|July 2008|Actual|July 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2012|May 24, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607086||85308|
NCT01607398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116571|ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease|A 12-week Randomised, Double-blind, Parallel-group Study to Evaluate the Anti-inflammatory Effects of ADOAIR® 50/250mcg Twice Daily Compared With Placebo Twice Daily in Japanese Subjects With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|40 Years|N/A|No|||March 2014|April 24, 2014|May 10, 2012||No||No|March 6, 2014|https://clinicaltrials.gov/show/NCT01607398||85284|
NCT01607684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAREMAG|Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis|Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis||Martin-Luther-Universität Halle-Wittenberg|No|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|50|||Both|50 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 3, 2012|May 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01607684||85263|
NCT01620320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|projet #10-011|Stress Echocardiography Versus Coronary Angiography for Left Main Stenosis Detection|Évaluation de l'Echographie de Stress Par Comparaison à la Coronarographie Comme Outil Non Invasif de détection de la resténose Intra endoprothèse du Tronc Commun|ESTRIE-TC|Université de Sherbrooke|No|Withdrawn|July 2010|July 2013|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients presenting to teaching hospital or stent from community hospitals to teaching        hospital and having left main angioplasty|June 2013|June 24, 2013|July 16, 2010||No|No Funding|No||https://clinicaltrials.gov/show/NCT01620320||84293|
NCT01627808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|656/11|Fluid Optimization in Liver Surgery|Study on Fluid Optimization in Liver Surgery Trough Vigileo/FloTac System Associated to Traditional Monitoring.||Catholic University of the Sacred Heart|No|Completed|September 2011|May 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|17|||Both|30 Years|70 Years|No|Non-Probability Sample|In this study were enrolled patients scheduled for elective major hepatic surgery.|June 2012|June 25, 2012|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01627808||83721|
NCT01628094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28266|ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment|Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability of the Combination of RO5466731, RO5190591, Ritonavir, and Copegus With or Without RO5024048 in HCV Genotype 1 Infected Patients Who Are Either Treatment Naïve or Null Responders to Previous Interferon-Based Treatment||Hoffmann-La Roche||Completed|June 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|110|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628094||83699|
NCT01628107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOE-11-03|A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin|A Phase 3, Open-Label, Multicenter, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|AiME - 03|Hospira, Inc.|No|Completed|July 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|414|||Both|18 Years|80 Years|No|||December 2015|December 22, 2015|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628107||83698|
NCT01628120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOE-11-04|A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin|A Phase 3, Open-Label, Multicenter, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|AiME - 04|Hospira, Inc.|No|Completed|May 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|173|||Both|18 Years|80 Years|No|||December 2015|December 22, 2015|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01628120||83697|
NCT01628705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CI-10808|Moderated-fat Diet Complemented With Green Tea Reduces oxLDL and Fat Mass in Obese Women|Moderated-fat Diet Complemented With Green Tea Reduces oxLDL and Fat Mass in Obese Women: A Randomized, Controlled Clinical Trial|GTRoxLDL|University of Guadalajara|Yes|Completed|April 2007|December 2007|Actual|December 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Female|18 Years|60 Years|No|||July 2012|July 19, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01628705||83652|
NCT01621425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 11.01|Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity|Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity|LEANDOC|Radboud University|No|Completed|June 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|25|Samples Without DNA|Blood samples for docetaxel concentration measurement (n=4)|Both|18 Years|N/A|No|Non-Probability Sample|20 female subjects who are diagnosed with breast and 20 male subjects with metas-tatic        castration-resistant prostate carcinoma and will receive docetaxel treatment according to        standard hospital protocol (TAC or PRODOC regimens)|August 2015|August 12, 2015|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01621425||84209|
NCT01603472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000028242|Markers of Bone Disease in Children on Parenteral Nutrition|Markers of Parenteral Nutrition (PN) Associated Metabolic Bone Disease in Children on Long-Term PN for Intestinal Failure.||The Hospital for Sick Children|No|Completed|May 2012|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|38|||Both|6 Weeks|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children on long term PN and childen not on PN.|July 2013|July 26, 2013|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01603472||85586|
NCT01603771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201104290|Neural Activation and Connectivity in Response to Exercise and Cognitive Training|Neural Activation and Connectivity in Response to Exercise and Cognitive Training|NAC|Washington University School of Medicine|No|Completed|June 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|55 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study population will include 24 adults, male and female, aged 55-75 years who meet        eligibility criteria for and are enrolled in the parent study, Combining Exercise and        Cognitive Training to Improve Everyday Function (EXACT), Unique Protocol ID 201102416.        Participants will be sedentary (not exercising regularly) but otherwise generally healthy.|August 2014|August 29, 2014|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01603771||85563|
NCT01604876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL3905802912|Effect of Bright Light on Mood and Sleep in Parkinson's Disease|Effect of Bright Light on Mood and Sleep in Parkinson's Disease|LightPD|VU University Medical Center|No|Recruiting|May 2012|October 2017|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|No|||June 2015|June 8, 2015|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01604876||85478|
NCT01605422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PC 2011 KRS|Meta-analyses of the Effect of Dietary Pulses on Acute Postprandial Metabolic Control|Effect of Dietary Pulses on Acute Postprandial Glycemia and Food Intake Regulation: A Systematic Review and Meta-analyses||University of Toronto|No|Active, not recruiting|October 2011|December 2015|Anticipated|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Probability Sample|Varied|May 2015|May 26, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01605422||85436|
NCT01605682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|28AI2|Multi Dose Effects of a Berry Extract Upon Moodand Cognition in Healthy Young Adults|Multi Dose Effects of a Berry Extract Upon Mood, Attention and Memory in Healthy Young Adults.||Northumbria University|No|Completed|July 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|36|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2012|May 21, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01605682||85416|
NCT01605968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS11176|A Comparative Efficacy and Safety Study Between Two Silver Containing Dressings In Post-Op Wound Healing|A Comparative Efficacy and Safety Study Between BCT Silver Bandage and Aquacel® Ag. Dressing In Obstetrical and Gynecological Post-Op Wound Healing||Bio-medical Carbon Technology Co., Ltd.|No|Terminated|June 2012|||October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Female|18 Years|70 Years|No|||February 2014|February 12, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01605968||85394|
NCT01606553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCA|Inspiratory Muscle Training in Patients With Chronic Heart Failure|The INCA Study: Inspiratory Muscle Training in Patients With Chronic Heart Failure|INCA|Parc de Salut Mar|No|Completed|October 2010|June 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01606553||85349|
NCT01606540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20120015|Non-steroid Antiinflammatory Drugs to Heal Colles Fracture|The Influence of Non-steroid Antiinflammatory Drugs (NSAID) to Heal Colles Fracture.||Northern Orthopaedic Division, Denmark|No|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|192|||Both|50 Years|80 Years|No|||January 2016|January 21, 2016|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01606540||85350|
NCT01607996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUG 02-0555|Effect of Epidural Anesthesia on Pancreatic Perfusion and Clinical Outcome in Patients With Severe Acute Pancreatitis|Phase 1 Study of Epidural Anesthesia on Pancreatic Perfusion and Clinical Outcome in Patients With Severe Acute Pancreatitis||University Hospital, Geneva|No|Completed|July 2005|November 2011|Actual|August 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|16 Years|90 Years|No|||May 2012|May 25, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01607996||85239|
NCT01608009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1627|[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer|Phase 1b Exploratory Study of [18F]Fluciclatide-PET as a Marker of Angiogenic Response to Combination Therapy With the Pan-VEGF Inhibitor, Pazopanib, and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer|PAZPET-1|Imperial College London|Yes|Active, not recruiting|July 2012|December 2016|Anticipated|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|17|||Female|18 Years|N/A|No|||September 2015|February 16, 2016|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01608009||85238|
NCT01607411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01390|A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model|A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model||GlaxoSmithKline|No|Completed|February 2012|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|55|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||July 2014|August 7, 2014|February 16, 2012|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01607411||85283|
NCT01607424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECOS|Specific Cognitive Remediation for Schizophrenia|Specific Versus General Cognitive Remediation for Schizophrenia|RECOS|Hôpital le Vinatier|No|Completed|December 2008|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|151|||Both|18 Years|45 Years|No|||September 2015|September 2, 2015|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01607424||85282|
NCT01607697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B300201213369|Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With PD|Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With Parkinson's Disease (PD)||University Hospital, Antwerp|No|Completed|March 2012|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|42|||Both|N/A|N/A|No|||June 2015|June 13, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607697||85262|
NCT01620333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1164|Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers|A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Characterizing the Pharmacokinetics and Pharmacodynamics of NN-X14Mix50 and NN-X14Mix70 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|February 2000|April 2000|Actual|April 2000|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||June 2012|June 13, 2012|June 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01620333||84292|
NCT01620619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKSMC 2010 - 4|The Role of Rotator Interval Closure in Bankart Lesion Repair|The Role of Rotator Interval Closure in Bankart Lesion Repair||University of Western Ontario, Canada|No|Recruiting|February 2010|||May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|142|||Both|15 Years|51 Years|No|||April 2014|April 24, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01620619||84270|
NCT01620892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOC-OM-Arthrex-001|Study of Patient Outcomes 5 Years After Partial Knee Replacement|Outcomes of Patients With Unicompartmental Arthritis of the Knee Five Years After Treatment With Partial Knee Replacement||Athens Orthopedic Clinic, P.A.|No|Enrolling by invitation|June 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|185|||Both|18 Years|N/A|No|Probability Sample|The potential study population consists of all patients who have undergone implantation of        a specific unicondylar knee arthroplasty device under the care of the principal        investigator between December, 2006 and December, 2008. This is a clinic-based sample of        consecutive cases.|May 2014|May 5, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620892||84250|
NCT01621126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000188|Neuromonitoring During the Latarjet Procedure|Neuromonitoring During the Latarjet Procedure||Massachusetts General Hospital|No|Suspended|June 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2012|June 15, 2012|June 7, 2012|Yes|Yes|Suspended pending registration on clinicaltrials.gov.|No||https://clinicaltrials.gov/show/NCT01621126||84232|
NCT01621438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1203-087-402|Clinical Implication of 3-vessel Fractional Flow Reserve (FFR)|Influence of Total Atherosclerotic Burden Assessed by 3-vessel Fractional Flow Reserve (FFR) on the Clinical Outcomes of the Patients With Multi-vessel Disease||Seoul National University Hospital|Yes|Active, not recruiting|May 2012|September 2016|Anticipated|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1136|||Both|N/A|N/A|No|Probability Sample|The patients with 3-vessel intermediate coronary artery disease (visually 30~70% stenosis        in coronary angiogram) whose FFR was measured at all 3-vessels due to their own clinical        needs.|September 2015|September 23, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01621438||84208|
NCT01603485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5271050|Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects|Open-Label, Randomized, Crossover Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-Release Lersivirine (UK-453,061) 500 mg in Healthy Subjects||Pfizer|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 18, 2012|May 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01603485||85585|
NCT01603784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102416|Combining Exercise and Cognitive Training to Improve Everyday Function|Combining Exercise and Cognitive Training to Improve Everyday Function|EXACT|Washington University School of Medicine|Yes|Completed|March 2010|June 2013|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|96|||Both|55 Years|75 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01603784||85562|
NCT01605110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRI-2011-02-BLEPH-00 BS|Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing|Effects of HBOT for Edema/Ecchymosis After Upper Eyelid Blepharoplasty (Single Site Study)|BLEPH|Restorix Research Institute, LLLP|Yes|Enrolling by invitation|August 2011|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|164|||Both|40 Years|85 Years|Accepts Healthy Volunteers|||December 2012|December 3, 2012|September 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01605110||85460|
NCT01605721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1101-054-347|Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)|||Seoul National University Hospital|Yes|Recruiting|May 2011|April 2015|Anticipated|April 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|2000|||Both|18 Years|N/A|No|||May 2012|May 21, 2012|July 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01605721||85413|
NCT01605734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ShandongCHI-002|TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma|Phase II Trail of TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma||Shandong Cancer Hospital and Institute|Yes|Not yet recruiting|July 2012|December 2015|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|75 Years|No|||May 2012|May 21, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01605734||85412|
NCT01605695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDAbs 12-002|Normal Human Plasma Level of iNOS Study|Determination of the Normal Human Plasma Level of Inducible Nitric Oxide Synthase (iNOS) Using the PliNOSa Test||Research & Diagnostic Antibodies|No|Completed|May 2012|September 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|Samples Without DNA|heparinized plasma samples|Both|18 Years|79 Years|Accepts Healthy Volunteers|Probability Sample|Reference values will be obtained from 100 plasma samples obtained from healthy normal        humans collected prospectively under an IRB approved protocol and informed consent after        blood donation for use in research. The 100 normal human plasma samples will be assayed        using the PliNOSa test.|November 2013|November 23, 2013|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01605695||85415|
NCT01605708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R846-AD-1105|Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis|Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Dose Study of the Clinical Activity, Safety, Tolerability and Pharmacokinetics of a Single IV Dose of REGN846 in Refractory Moderate-to-Severe Pruritus in Adult Patients With Moderate-to-Severe Atopic Dermatitis||Regeneron Pharmaceuticals|No|Terminated|June 2012|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||May 2013|September 27, 2013|October 12, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605708||85414|
NCT01605981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107EBR06|Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.|A Phase II, Non Randomized, Open Label, Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.|MACS1881|Novartis|Yes|Withdrawn|February 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||June 2014|June 5, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01605981||85393|
NCT01605994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN171-002|Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects|Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043||Bristol-Myers Squibb|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|11||Actual|115|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2014|June 26, 2014|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01605994||85392|
NCT01606592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POSE|Psychotherapy Outcome and Self-selection Effects in Panic Disorder|Phase 2/3 Study of Panic Control Treatment vs Panic-Focussed Psychodynamic Psychotherapy Under Randomized and Self-Selection Conditions||Region Skane|Yes|Recruiting|January 2010|June 2017|Anticipated|June 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|216|||Both|18 Years|60 Years|No|||August 2013|September 4, 2013|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01606592||85346|
NCT01606566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCIA202/10|A Study to Evaluate the Safety and Efficacy of PC-A11 in Patients With Recurrent Head and Neck Squamous Cell Carcinoma|An Open-label, Single Arm, Multi-centre, Phase II Study to Evaluate the Safety and Efficacy of PC-A11 With Superficial and Interstitial Laser Light Application in Patients With Recurrent Head and Neck Squamous Cell Carcinoma Unsuitable for Surgery and Radiotherapy||PCI Biotech AS|Yes|Terminated|April 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||June 2015|June 5, 2015|May 21, 2012|Yes|Yes|Business reasons|No||https://clinicaltrials.gov/show/NCT01606566||85348|
NCT01606579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRI-724-201|Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies|An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies||Prism Pharma Co., Ltd.|No|Completed|July 2012|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|49|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|May 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606579||85347|
NCT01606839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24-079 ex 11/12|Noninvasive Measurement of Cardiac Output in Pulmonary Hypertension Using Inert Gas Rebreathing|Noninvasive Measurement of Cardiac Output in Pulmonary Hypertension Using Inert Gas Rebreathing||Medical University of Graz|No|Completed|February 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|34|||Both|18 Years|N/A|No|Non-Probability Sample|The study population consists of patients undergoing diagnostic or follow-up right heart        cathereization.|February 2014|February 18, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606839||85327|
NCT01608321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPLD-001-11F|rTMS for the Treatment of Chronic Pain in GW1 Veterans|rTMS for the Treatment of Chronic Pain in GW1 Veterans|rTMS|VA Office of Research and Development|Yes|Terminated|September 2012|September 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|70 Years|No|||December 2015|December 8, 2015|May 25, 2012|No|Yes|Did not meet recruitment goals|No||https://clinicaltrials.gov/show/NCT01608321||85214|
NCT01608308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-12-0111|Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery|A Double Blind, Randomized, Placebo-controlled Study to Investigate the Effectiveness of IV Acetominophen Administered During Functional Endoscopic Sinus Surgery in Reducing the Use of Opiates to Treat Postoperative Pain|IVAPAP|The University of Texas Health Science Center, Houston|No|Completed|July 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|62|||Both|18 Years|68 Years|No|||September 2015|September 25, 2015|May 25, 2012|Yes|Yes||No|June 12, 2015|https://clinicaltrials.gov/show/NCT01608308||85215|
NCT01608581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|flaming fool|Development and Evaluation of an Adult Burn Prevention Program|Development and Evaluation of an Adult Burn Prevention Program||The University of Queensland|No|Completed|February 2010|April 2011|Actual|April 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|1637|||Male|16 Years|N/A|No|||June 2012|June 1, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01608581||85194|
NCT01608594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-063|Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma|Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-Α2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study||University of Pittsburgh|Yes|Recruiting|June 2013|October 2027|Anticipated|October 2018|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|May 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01608594||85193|
NCT01620645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSP-83727|The MRC/ABPI COPD Cohort v1.7|The Mechanisms of Inflammation and Immunity in COPD and Their Relationship to Exacerbations and Disease Progression.|COPDMAP|University College, London|Yes|Recruiting|February 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples With DNA|Blood, sputum and urine samples will be collected. Commercially available ELISA assays will      be be used to qualify inflammatory markers.      Quantitative bacterial culture will be performed on sputum samples. Bacterial and viral load      will be determined by polymerase chain reaction (PCR). Proteomics such as Cholesterol, BNP,      CRP by routine hospital assay techniques. Specific DNA sections will be selected from the      genome to identify/confirm genes believed to be associated with different COPD phenotypes by      molecular techniques.|Both|40 Years|N/A|No|Non-Probability Sample|Patients will be recruited from existing cohorts and may have participated in previously        approved studies.        Potential primary care patients will be identified from databases held in practices and        contacted, by the GP, by letter in the first instance. If the patient replies to the GP        that they are willing to participate in the research, then a telephone call will be made        by the research team to arrange a clinic visit.        Potential outpatient participants will be identified by the outpatient respiratory        physician and if willing to participate will be referred to the research team via        telephone call or referral letter.|June 2012|June 13, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620645||84268|
NCT01620632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|511-2011|Laparoscopy-assisted ERCP in Patients With Altered Gastric Anatome|Prospective Evaluation of the Clinical Utility of Laparoscopy-assisted ERCP in Patients With Altered Gastric Anatomy||University of Florida|No|Recruiting|December 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Those patients who have altered gastric anatomy that require a laparoscopy assisted ERCP|March 2016|March 9, 2016|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620632||84269|
NCT01620905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNLVPT08072806|Development of a CPR for Neck Manipulation|Development of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Cervical Spine Manipulation and Exercise||University of Nevada, Las Vegas|Yes|Completed|November 2008|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|82|||Both|18 Years|60 Years|No|||June 2012|June 13, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620905||84249|
NCT01621139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001937|A Pilot Clinical Trial to Evaluate the Effects of Acupuncture in Patients on Prolonged Mechanical Ventilation|A Pilot Prospective Randomized Study to Evaluate the Effects of Acupuncture in Patients on Prolonged Mechanical Ventilation||Mayo Clinic|No|Completed|January 2011|November 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||November 2013|November 12, 2013|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01621139||84231|
NCT01621451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PZ-1001-403-NS|Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?|Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?||Asan Medical Center|Yes|Enrolling by invitation|June 2012|June 2014|Anticipated|May 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|80 Years|No|||November 2012|November 20, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01621451||84207|
NCT01621685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND# 69,642|Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men|The Role of Age on the Human Cough Reflex|Capsaicin|University of South Florida|No|Completed|September 2004|September 2007|Actual|September 2007|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Male|19 Years|92 Years|Accepts Healthy Volunteers|||June 2012|June 15, 2012|August 5, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01621685||84189|
NCT01604343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100866|A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy||Janssen Research & Development, LLC|Yes|Active, not recruiting|August 2012|January 2017|Anticipated|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1670|||Both|18 Years|N/A|No|||March 2016|March 11, 2016|May 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01604343||85519|
NCT01604603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFH-TMU-RetroMcLab-201203022|The Clinical and Biochemical Characteristics in Women With Different Menstrual Pattern|||Taipei Medical University WanFang Hospital|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||4|Actual|470|||Female|13 Years|45 Years|No|Probability Sample|Patients had sufficient medical records (anthropometric, endocrine, metabolic, lipid        parameters) and age less than 45.|November 2013|November 4, 2013|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604603||85499|
NCT01604616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0032-12-ZIV|Short Term Postoperative Tamponade Using Perfluorocarbon Liquid for Giant Retinal Tears|Short Term Postoperative Tamponade Using Perfluorocarbon Liquid for Giant Retinal Tears||Ziv Hospital|Yes|Recruiting|January 1998|June 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|man and women above the age of 18 years|May 2012|May 22, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01604616||85498|
NCT01605123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFO152/SFB1052-C5|Longitudinal Assessment of Cardiovascular and Metabolic Parameters in Obese and Lean Children|Leipzig Artherobesity Childhood Cohort||University of Leipzig|No|Active, not recruiting|April 2007|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|200|Samples With DNA|Serum samples, samples from oral glucose tolerance tests (oGTT), EDTA/DNA samples, primary      cells (endothelial progenitor cells), peripheral blood mononuclear cells), urine|Both|6 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Obese children from our out-patient department in Leipzig, Germany Lean children        community-based from Leipzig|June 2014|June 12, 2014|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01605123||85459|
NCT01606033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPSY 0905|Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating|Psychological and Emotional Impacts of Participation in Oncologic Clinical Trials|IPSY|Centre Oscar Lambret|No|Active, not recruiting|March 2011|December 2014|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Anticipated|240|||Both|18 Years|N/A|No|||May 2012|March 6, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606033||85389|
NCT01606345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16722|Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma|Phase I Dose Escalation and Landmark Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (UTUC) Following Endoscopic Resection||H. Lee Moffitt Cancer Center and Research Institute|Yes|Active, not recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|May 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606345||85365|
NCT01606007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-169|Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.||AstraZeneca|Yes|Completed|July 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|1282|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|May 23, 2012|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01606007||85391|
NCT01606020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108128|Sleep Deprivation : Effects on Driving Performance and Central Fatigue|Effects of Sleep Deprivation on Driving Performance and Central Fatigue|PrivSom|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|September 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01606020||85390|
NCT01606332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC001|Indwelling Interscalene Nerve Catheters in Surgical Management of Idiopathic Adhesive Capsulitis|Indwelling Interscalene Nerve Catheters in Surgical Management of Idiopathic Adhesive Capsulitis||OAD Orthopaedics|No|Recruiting|June 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 10, 2013|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606332||85366|
NCT01607437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HowellFollowUp|Clinical Follow-up After ACL Reconstruction|10-year Follow-up After ACL Reconstruction With Howells Guide, Transtibial Drilling and Hamstrings Graft|Howell|Bergen Knee Group|No|Completed|February 2011|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|96|||Both|16 Years|50 Years|No|Non-Probability Sample|Patients reconstructed with Howells guide, hamstrings graft and transtibial drilling at        Haraldsplass Deaconess Hospital from 1999 to 2001.|May 2012|May 29, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01607437||85281|
NCT01607450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010002497|Modulation of Human Myocardial Metabolism by GLP-1 Dose Response|Modulation of Human Myocardial Metabolism by GLP-1 Dose Response||Indiana University|Yes|Completed|May 2010|December 2012|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|33|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 19, 2016|May 21, 2012|Yes|Yes||No|November 16, 2015|https://clinicaltrials.gov/show/NCT01607450||85280|This was a dose-finding study of myocardial responses to systemically infused GLP-1. After ascertaining no detectable response in controls with low dose, we completed mid dose studies. Finding an important difference there we did not do the high dose
NCT01606852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND 111693|Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients|Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients|PCS|University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|March 2013|July 2015|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|April 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01606852||85326|
NCT01606865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIANCA|Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery|Does Platelet Inhibition Predict Surgery Related Bleeding in Patients Undergoing Non-Cardiac Surgery During Dual Antiplatelet Therapy|BIANCA|Medical University of Graz|No|Completed|September 2010|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|207|||Both|N/A|N/A|No|Probability Sample|Patients taking Clopidogrel, Prasugrel, or Ticagrelor within at least 7 days|October 2014|October 22, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01606865||85325|
NCT01608620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC 2012 KRS EPI|Meta-analyses of Fructose-containing Sugars and Incident Cardiometabolic Disease|The Relation of Fructose-containing Sugars to Incident Cardiometabolic Disease: Systematic Reviews and Meta-analyses of Prospective Observational Studies to Provide Evidence-based Guidance for Nutrition Guidelines Development||University of Toronto|No|Active, not recruiting|May 2012|September 2016|Anticipated|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1|||Both|N/A|N/A|No|Probability Sample|Varied|May 2015|May 26, 2015|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01608620||85191|
NCT01608633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-001|Effects of Spray and Stretch on Postneedling Soreness and Sensitivity After Dry Needling of a Latent Myofascial Trigger Point.|||CEU San Pablo University||Completed|March 2012|||April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2013|September 3, 2013|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01608633||85190|
NCT01608607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCC 2012 KRS|Meta-analysis of Fructose-Containing Sugar Sweetened Beverages (SSBs) and Weight Change|Effect of Fructose-containing Sugar Sweetened Beverages (SSBs) on Body Weight: A Systematic Review and Meta-analysis of Controlled Feeding Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development||University of Toronto|No|Active, not recruiting|May 2012|October 2015|Anticipated|September 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|1|||Both|N/A|N/A|No|Probability Sample|Varied|May 2015|May 26, 2015|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01608607||85192|
NCT01608945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH112|Prospective Randomized Study of Glucocorticoids in the Impact of the Liver Function and the Prognosis After Hepatectomy of HCC|||Eastern Hepatobiliary Surgery Hospital||Suspended|April 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|60|May 2012|May 30, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01608945||85166|
NCT01608958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3000|Intravenous and Intramuscular Administration of Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage|Intravenous and Intramuscular Administration of Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage||Gynuity Health Projects|Yes|Active, not recruiting|May 2012|January 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|644|||Female|N/A|N/A|Accepts Healthy Volunteers|||February 2014|February 18, 2014|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01608958||85165|
NCT01609244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA-2010|Bilevel Versus Servoventilation in Complex Sleep Apnea|Bilevel Versus Servoventilation in Complex Sleep Apnea|CSA-FKKG|Krankenhaus Kloster Grafschaft|No|Completed|January 2010|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|80 Years|No|||January 2016|January 6, 2016|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01609244||85143|
NCT01620931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP27885|A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers|A Single-Center, Randomized, Observer-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5469754, a Humanized Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Adults||Hoffmann-La Roche||Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|36|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2013|February 4, 2013|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01620931||84247|
NCT01620944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-494|Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC|A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC||Bristol-Myers Squibb|No|Terminated|July 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|3|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|June 13, 2012|Yes|Yes|Business objectives have changed|No||https://clinicaltrials.gov/show/NCT01620944||84246|
NCT01620918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/341|Soft Tissue Responses Around Nanostructured Calcium-phosphate-coated Implant Abutments on Dental Implants: Histological, Genetic and Clinical Evaluation in Smokers and Non-smokers.|Soft Tissue Responses Around Nanostructured Calcium-phosphate-coated Implant Abutments on Dental Implants: Histological, Genetic and Clinical Evaluation in Smokers and Non-smokers.|STRANDI|University Ghent|No|Recruiting|August 2012|August 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 4, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620918||84248|
NCT01621152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000007|PRevention of Acute Kidney Injury Initiated With Electronic Surveillance Enhancement|Electronic Surveillance Sniffer for Early Detection and Intervention for Acute Kidney Injury: PRAISE Trial|PRAISE|Mayo Clinic|No|Active, not recruiting|June 2012|December 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|984|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621152||84230|
NCT01621698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN/2012/4036|Study of Use of Paravertebral Blocks for Pain Relief in Video Assisted Lung Surgery|Early Versus Late Paravertebral Block for Analgesia in Video Assisted Thoracoscopic Lung Resection.|ErLaPara|University Hospitals Bristol NHS Foundation Trust|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621698||84188|
NCT01621971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH-MI201106|Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients|Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery||Konkuk University Medical Center|Yes|Completed|January 2003|January 2004|Actual|January 2004|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|65 Years|No|||June 2012|June 18, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621971||84167|
NCT01622335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1491-952|Effect OF Nitrous Oxide On Acute Pain and Opioid Consumption, and Chronic Pain After Hysterectomy|Effect OF Nitrous Oxide On Acute Pain and Opioid Consumption, and Chronic||The Cleveland Clinic|No|Active, not recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|200|||Female|18 Years|65 Years|No|||February 2016|February 12, 2016|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622335||84139|
NCT01609140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC28210|A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease|A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease||Genentech, Inc.||Completed|May 2012|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|248|||Both|18 Years|80 Years|No|||March 2016|March 1, 2016|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609140||85151|
NCT01609413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#09-MAX-05-BIO-01b|The COMparison of CALcium Bioavailability Between AlgaeCal® and a Proprietary Supplement|A Human Crossover Study to Compare the Bioavailability of Calcium From AlgaeCal® Versus a Proprietary Calcium Dietary Supplement|COMCAL|SPRIM Advanced Life Sciences, SprimItalia|Yes|Completed|October 2009|April 2010|Actual|April 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Male|20 Years|50 Years|Accepts Healthy Volunteers|||May 2012|May 31, 2012|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01609413||85130|
NCT01605435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 814309|Ghrelin Dose Finding In Frail Elderly|Ghrelin In Frail Elderly Subcutaneous Dose Finding Study||University of Pennsylvania|No|Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|1||Actual|6|||Both|70 Years|N/A|No|||January 2013|January 15, 2013|May 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605435||85435|
NCT01605448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P-000411|Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment|Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment||Beth Israel Deaconess Medical Center|No|Completed|January 2010|January 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|60 Years|90 Years|No|||May 2012|May 21, 2012|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01605448||85434|
NCT01606904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|58/2012|The Effect of CBT- Based Weight Loss Program on Eating Behavior, Weight Loss Result and Risk for Coronary Heart Diseases and Type 2 Diabetes||CognObe|University of Oulu|No|Recruiting|May 2012|||September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|20 Years|65 Years|No|||May 2012|May 23, 2012|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01606904||85322|
NCT01606605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-05-025|Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma|Retrospective Analysis of Diffuse Large B-cell Lymphoma: Identification of Factors Associated With Treatment Resistance Via Gene Expression Profile||Samsung Medical Center|No|Completed|January 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|350|Samples With DNA|Parrafin-embedded tissue blocks|Both|15 Years|90 Years|No|Probability Sample|Patients with diffuse large B-cell lymphoma|January 2013|January 12, 2013|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01606605||85345|
NCT01606878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADVL1212|Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma|A Phase 1 Study of Crizotinib (IND#105573) in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma||Children's Oncology Group|Yes|Recruiting|March 2013|||April 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|65|||Both|1 Year|21 Years|No|||March 2016|March 24, 2016|May 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01606878||85324|
NCT01606891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01HD068990|NET-Works:Community Preschooler Obesity Prevention|Linking Primary Care, Communities and Families to Prevent Obesity Among Preschoolers|NET-Works|University of Minnesota - Clinical and Translational Science Institute|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label|2||Anticipated|500|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01606891||85323|
NCT01607138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-CTJ-224-CTIL|Speech and Swallowing Characteristics of Patients After Laryngectomy and the Effect on Quality of Life|Speech and Swallowing Characteristics of Patients After Laryngectomy and the Effect on Quality of Life||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|June 2012|December 2014|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|40|||Both|35 Years|80 Years|No|Probability Sample|40 adult patients, ages 35-80 y/o who underwent total laryngectomy and a trechea        esophageal puncture was performed for the use of voice prothesis.|May 2012|May 25, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01607138||85304|
NCT01607736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JBMP-VGTinOA-pilot|Pilot Study of Virtual Gait Training in Older Adults|Pilot Study of Effects of Virtual Gait Training on Walking Stability in Older Adults||University Hospital, Basel, Switzerland|No|Completed|May 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|12|||Both|65 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 29, 2012|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01607736||85259|
NCT01607749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GESA|Study for Asthma Education in Primary Schools|Asthma Educational Intervention on Physical Education Teachers in Primary Schools||Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Yes|Active, not recruiting|November 2011|July 2013|Anticipated|July 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|4506|||Both|10 Years|13 Years|Accepts Healthy Volunteers|||June 2012|June 17, 2012|November 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01607749||85258|
NCT01607710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEF003523.2|Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)|Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)|fMRI|Hartford Hospital|No|Completed|July 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|55|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of the Greater Hartford Connecticut area.|March 2013|September 4, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01607710||85261|
NCT01607723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8916|"NAVA-PAV" Study: a Cross-over Comparative Study of 2 Advanced Modes|Comparison of Two New Ventilatory Modes: NAVA vs PAV+: a Randomized Controlled Cross-over Study: the "NAVA-PAV" Study||University Hospital, Montpellier|No|Completed|May 2012|March 2014|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01607723||85260|
NCT01608984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPCON-12|Effects of Remote Ischemic PreConditioning in Off-pump Versus On-pump Coronary Artery Bypass Grafting(RIPCON)|Effects of Remote Ischemic PreConditioning in Off-pump Versus On-pump Coronary|RIPCON|Heinrich-Heine University, Duesseldorf|Yes|Recruiting|May 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|80 Years|No|||July 2013|July 15, 2013|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01608984||85163|
NCT01608971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007|Protamine in Cardiac Surgery and Haemostasis|The Effects of Heparin Level Based Versus Weight Based Protamine Dosing on Protamine Demand, Markers of Haemostasis, Blood Product Utilization and Perioperative Blood Loss in Patients Undergoing Extended Cardiac Surgery Cardiac Surgery|PROTT|Heart and Diabetes Center North-Rhine Westfalia|No|Completed|January 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|75 Years|No|Probability Sample|Patients undergoing complex cardiac surgery using cardiopulmonary bypass with mitral valve        repair/replacement and 2-4 coronary artery bypass grafting including the left thoracic        artery|November 2015|November 18, 2015|May 29, 2012||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01608971||85164|small study cohort
NCT01609231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0646-025|A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)|A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels||Merck Sharp & Dohme Corp.|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||January 2015|January 6, 2015|May 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609231||85144|
NCT01609257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LV03-105|Norovirus Bivalent-Vaccine Efficacy Study|Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease||LigoCyte Pharmaceuticals, Inc.|Yes|Completed|May 2012|February 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|132|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||May 2014|May 9, 2014|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01609257||85142|
NCT01605851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSO 11-05|GORE® Septal Occluder European Union Clinical Evaluation|GORE® Septal Occluder EU Clinical Evaluation: A Study to Evaluate Clinical Success and Performance in the Treatment of Transcatheter Closure of Patent Foramen Ovale (PFO)||W.L.Gore & Associates|No|Completed|May 2012|April 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|150|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01605851||85403|
NCT01620957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-55 Inserm|Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma|Analyse de l'activité cérébrale intrinsèque Pendant le Coma et Lors du Retour à la Conscience|ACI-Coma|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|153|||Both|18 Years|75 Years|No|Non-Probability Sample|We will analyse DMN functional and anatomical connectivity in severely brain-injured        patients in coma and during the first two month following brain injury. All patients will        be admitted from one of the four Critical Care Units of University Teaching Hospital of        Toulouse, France.|April 2015|April 24, 2015|April 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01620957||84245|
NCT01621165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12909|Prazosin as an Antimanic Agent in Severe Mania or Mixed States|Prazosin as an Antimanic Agent in Severe Mania or Mixed Episodes: a Double-blind, Placebo-controlled Study||Mclean Hospital||Withdrawn|March 2009|November 2009|Actual|November 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||June 2012|June 15, 2012|March 17, 2009||No|unable to recruit subjects given short length of stay in hospital|No||https://clinicaltrials.gov/show/NCT01621165||84229|
NCT01621178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13798|A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)|A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease|AWARD-7|Eli Lilly and Company|No|Active, not recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|576|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621178||84228|
NCT01621191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14614|An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)|An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia||Eli Lilly and Company|No|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|149|||Both|20 Years|74 Years|No|||January 2015|January 27, 2015|June 14, 2012|Yes|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01621191||84227|
NCT01621464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPAIN|Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study)|Closed Loop Stimulation for Neuromediated Syncope|SPAIN|Spanish Society of Cardiology|No|Active, not recruiting|May 2006|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|55|||Both|40 Years|N/A|No|||April 2014|April 11, 2014|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01621464||84206|
NCT01621477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAP3R|T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant|T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant||St. Jude Children's Research Hospital|No|Recruiting|August 2012|August 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|N/A|21 Years|No|||February 2016|February 15, 2016|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621477||84205|
NCT01621984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|274/21-9-2011|Therapeutic Riding and Neuromuscular Disease|The Evaluation of Therapeutic Riding in Children and Adolescent With Kinetic Deficits Because of Neuromuscular Disease.|TR NMD|University of Ioannina||Recruiting|June 2011|November 2015|Anticipated|November 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|30|||Both|4 Years|18 Years|No|||May 2015|May 26, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01621984||84166|
NCT01622361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBCSG012|Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer|A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer|NEST|Asan Medical Center|Yes|Recruiting|June 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Female|20 Years|N/A|No|||September 2013|September 26, 2013|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01622361||84137|
NCT01622374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aminpasha_CT0001|Effects of "Music for the Mind" on Pre-operative Anxiety in Dentistry|a Randomized Controlled Clinical Trial on the Effects of "Music for the Mind" on Pre-operative Anxiety in Dentistry||Azad University of Medical Sciences|Yes|Completed|January 2011|April 2011|Actual|March 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Both|17 Years|70 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622374||84136|
NCT01609153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMBINE|Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy|A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients. - COMBINE|COMBINE|Heinrich-Heine University, Duesseldorf|Yes|Recruiting|June 2012|August 2017|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|399|||Both|18 Years|65 Years|No|||July 2015|July 1, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01609153||85150|
NCT01609426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11021|Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome|Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome|NEPHROVIR-2|Assistance Publique - Hôpitaux de Paris|No|Recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only||1|Anticipated|420|Samples With DNA|DNA Peripheral Blood Mononuclear Cells Plasma|Both|6 Months|16 Years|No|Non-Probability Sample|Any children below 16 years of age with a first manifestation of idiopathic nephrotic        syndrome commencing or having commenced in the Paris area|February 2016|February 23, 2016|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01609426||85129|
NCT01609439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UAH-Oto-TT01|Preoperative Vitamin D for Post-thyroidectomy Hypocalcemia|Pre-operative Vitamin D Supplementation to Reduce Post-operative Hypocalcemia in Patients Undergoing Total Thyroidectomy: A Randomized Controlled Trial||University of Alberta|Yes|Not yet recruiting|August 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|110|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2012|May 29, 2012|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01609439||85128|
NCT01605760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|657898/2008|House Dust Mite SLIT in Elderly Patients|House Dust Mite Sublingual Immunotherapy: a Double-blind, Placebo Control Study in Elderly Patients.||Medical University of Silesia|Yes|Completed|January 2008|March 2012|Actual|January 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|111|||Both|60 Years|75 Years|No|||May 2012|May 21, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01605760||85410|
NCT01631786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR-THRUST-ARB-001|Synchrotron Imaging of Human Ovaries Ex Situ|Synchrotron Imaging of Human Ovaries Ex Situ||University of Saskatchewan|No|Completed|August 2011|June 2013|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|10|Samples With DNA|surgically removed human ovarian tissues and Formalin-fixed human ovarian tissues|Female|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients in the Saskatoon Health Region|September 2014|September 19, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631786||83416|
NCT01631799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A 40 2008|Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia|Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia. A Randomized, Controlled Trial||University of Rostock|No|Completed|October 2008|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|80 Years|No|||June 2012|June 27, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631799||83415|
NCT01632059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADSeS (PV3927)|Examination of ADMA Serum Level and DDAH II|Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value|ADSeS|Universitätsklinikum Hamburg-Eppendorf|No|Active, not recruiting|February 2012|June 2016|Anticipated|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|Samples With DNA|Whole blood|Both|18 Years|N/A|No|Non-Probability Sample|Patients > 18 y/o with sepsis and/or septical shock|December 2015|December 4, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01632059||83395|
NCT01632072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/928|The Undernourished Patient: Prevention and Treatment|The Undernourished Patient: Prevention and Treatment||University of Oslo|No|Completed|June 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||September 2015|September 14, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632072||83394|
NCT01632293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00068596|Evaluating Intervention Responsiveness in People With Multiple Sclerosis|Evaluating Intervention Responsiveness in People With Multiple Sclerosis||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Completed|April 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 22, 2016|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632293||83377|
NCT01631825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-08-002|A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients|An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa||Otsuka Pharmaceutical Co., Ltd.|No|Completed|October 2009|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|321|||Both|N/A|N/A|No|||February 2014|February 3, 2014|June 25, 2012||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01631825||83413|
NCT01632618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|160167|Trunk Muscle Training and Neuromuscular Electrical Stimulation to Improve Function in Older Adults With Chronic Low Back Pain|Trunk Muscle Training and Neuromuscular Electrical Stimulation to Improve Function in Older Adults With Chronic Low Back Pain||University of Delaware|No|Completed|May 2007|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment|||Actual|66|||Both|60 Years|85 Years|No|||June 2012|July 2, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632618||83352|
NCT01632579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14707|A Single Dose Study of LY3023703 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects||Eli Lilly and Company|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Anticipated|30|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|June 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632579||83355|
NCT01632592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p-000917|Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue|Abdominal Obesity, Cardiovascular Inflammation, and Effects of a Growth Hormone Releasing Hormone Analogue to Reduce Inflammation||Massachusetts General Hospital|Yes|Withdrawn|January 2014|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|June 27, 2012|Yes|Yes|No funding available|No||https://clinicaltrials.gov/show/NCT01632592||83354|
NCT01632878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-764|Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study|Omacor Plus Standard Therapies In Post MI Subjects Evaluation: The OPTIMISE Study||Abbott|No|Completed|July 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1695|||Both|18 Years|70 Years|No|Probability Sample|primary care clinic|December 2014|December 22, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632878||83332|
NCT01632891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5297|Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected|An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <350 Cells/mm3||AIDS Clinical Trials Group|Yes|Recruiting|July 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632891||83331|
NCT01633125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aau-1|Group Music Therapy for Chinese Prisoners|Group Music Therapy for Chinese Prisoners: A Randomized Controlled Trial||Aalborg University||Recruiting|April 2012|April 2014|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|192|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|July 3, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01633125||83313|
NCT01633424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-02|The "Stanford Integrated Psychosocial Assessment for Transplant" (SIPAT)|The "Stanford Integrated Psychosocial Assessment for Transplant" (SIPAT): Psychometric Characteristics of a New Scale for the Prediction of Post-transplant Psychosocial and Medical Outcomes.||Stanford University|No|Active, not recruiting|October 2011|||October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|600|||Both|18 Years|N/A|No|Non-Probability Sample|217 Stanford Hospital and Clinics patients fulfilled our criteria of being transplanted        with heart, liver, kidney or lung between 6/1/2008 and 7/31/2011 and having been evaluated        with SIPAT.|August 2013|August 27, 2013|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633424||83290|
NCT01633658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton 13|The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3|The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3 Compared to Native Vitamin D3: A Short Term Pharmacokinetic Study||Creighton University|No|Withdrawn|November 2012|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|0|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 27, 2013|July 2, 2012||No|Protocol has changed|No||https://clinicaltrials.gov/show/NCT01633658||83272|
NCT01633671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ana-ulm-ntprobnp-288/11|NT-proBNP as a Tool for the Detection of Acute Pulmonary Artery Embolism (APE)|NT-proBNP: a Useful Tool for the Detection of Acute Pulmonary Artery Embolism in Post-surgical Patients||University of Ulm|No|Completed|November 2008|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|44|||Both|N/A|N/A|No|Probability Sample|Patients after major surgery referred to the anesthesiologic ICU due to suspected acute        pulmonary embolism.|July 2012|July 4, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01633671||83271|
NCT01626898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01PS001570|HIV Prevention Among Latino MSM: Evaluation of a Locally Developed Intervention|HIV Prevention Among Latino MSM: Evaluation of a Locally Developed Intervention||Centers for Disease Control and Prevention|No|Completed|August 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|304|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 2, 2016|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626898||83791|
NCT01634217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012LS019|Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation|Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|November 2013|June 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|22|||Both|18 Years|75 Years|No|||February 2016|February 18, 2016|July 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01634217||83229|
NCT01634230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCR002-EmUse-001|Emergency Use of OCR-002 in Acute Liver Failure|Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure||Ocera Therapeutics|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|N/A|N/A|No|||June 2014|June 2, 2014|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01634230||83228|
NCT01634568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V81444-1PD-01|A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men|A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male Volunteers||Vernalis (R&D) Ltd|No|Completed|August 2011|February 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|49|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|June 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01634568||83202|
NCT01635127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USZ-DER-AAN-017|Efficacy Study of Canakinumab to Treat Urticaria|A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria|URTICANA|University of Zurich|Yes|Recruiting|June 2012|December 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|70 Years|No|||July 2012|February 3, 2014|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635127||83160|
NCT01635387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAAS-block dial|RAAS Inhibitor Drugs in Dialysis Patients|Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes||Second University of Naples|No|Active, not recruiting|February 2010|September 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|N/A|No|||July 2012|July 4, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01635387||83140|
NCT01635101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-APA-353|A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients|A Randomized, Placebo Controlled, Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients||Mallinckrodt|No|Active, not recruiting|June 2012|January 2016|Anticipated|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|2 Years|No|||January 2016|January 25, 2016|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01635101||83162|
NCT01635114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-12-10-RESV|Effect of resVida on Liver Fat Content|Evaluate the Effects of resVidaTM on Liver Fat Content, Body Fat Distribution and Insulin Sensitivity|resVida NAFL|University Hospital Tuebingen|Yes|Active, not recruiting|June 2012|December 2015|Anticipated|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 17, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635114||83161|
NCT01631552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-IMMU-132-01|Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers|A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers||Immunomedics, Inc.|No|Recruiting|February 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631552||83433|
NCT01631565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACO2012|Early Incorporation of Patient and Family to Attention and Care Program in Oncology Versus Standard of Care|Management of Symptoms in Patients With Advanced Lung Cancer: Early Incorporation of Patient and Family to Attention and Care Program in Oncology|PACO|Instituto Nacional de Cancerologia de Mexico|Yes|Recruiting|May 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|90 Years|No|||February 2016|February 22, 2016|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01631565||83432|
NCT01635660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANKIEL-VLS-2012-CAV|Out-of-Hospital Randomized Comparison of Video-assisted Endotracheal Intubation|Prospective, Randomized, Multicentre Evaluation of Different Video-assisted, for Emergency Use Designed Intubation Aids for Out-of-hospital Endotracheal Intubation. Comparison of C-MAC System PM (Karl Storz), AP Advance (Venner Medical), and King Vision (King Systems) at Four German HEMS.||University of Schleswig-Holstein|No|Completed|October 2011|June 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|N/A|No|||August 2015|August 1, 2015|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635660||83119|
NCT01635673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIBES|Effects of Whole Body Vibration Exercise on Metabolic Systems in Latino Boys|Effects of Whole Body Vibration Exercise on Metabolic Systems in Latino Boys|VIBES|University of Southern California|No|Completed|May 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Male|8 Years|10 Years|Accepts Healthy Volunteers|||May 2011|July 6, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635673||83118|
NCT01632085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5131|Comparison of Two Laryngoscopes: Single-use Device Laryngobloc ® (SU) Versus Reusable Handle With Disposable Metal Blade (R)|Comparison of Two Laryngoscopes: Single-use Device Laryngobloc ® (SU) Versus Reusable Handle With Disposable Metal Blade (R) : Quality of Laryngoscopy and Bacterial Contamination of the Handle|MUUR|University Hospital, Strasbourg, France|No|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|480|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01632085||83393|
NCT01631838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD157/11|Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome|Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome||Malaysia Palm Oil Board|No|Completed|May 2012|October 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|32|||Both|25 Years|60 Years|No|||December 2013|December 19, 2013|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631838||83412|
NCT01632930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.660|Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis|Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis||Hospices Civils de Lyon|No|Recruiting|July 2012|December 2021|Anticipated|July 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|900|||Male|18 Months|N/A|No|||April 2014|April 30, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632930||83328|
NCT01632605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|003/2008/1.0|The Vienna RAP Pilot Study|Rapamycin in Advanced Polycystic Kidney Disease Pilot Study|RAP|Medical University of Vienna|Yes|Completed|November 2009|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|May 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01632605||83353|
NCT01633164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133N110006|Re-Inventing Yourself After Spinal Cord Injury|Re-Inventing Yourself After SCI: A Site-Specific Randomized Clinical Trial||Craig Hospital|No|Recruiting|April 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 27, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01633164||83310|
NCT01633138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205010253|Performance-based Reinforcement to Enhance Cognitive Remediation Therapy|Pilot Study of Performance-based Reinforcement to Enhance Cognitive Remediation Therapy for Substance Users||Yale University|Yes|Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||July 2015|July 16, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01633138||83312|
NCT01633151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEDDIT-2012-1|Validation Study for an Unobtrusive Online Sleep Measurement System|Validation Study for an Unobtrusive Online Sleep Measurement System||Beddit.com Ltd|No|Completed|June 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|A group of 20 volunteers - 10 males, 10 females - is recruited so that their ages are        distributed evenly between 18 and 80.|September 2013|September 29, 2013|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01633151||83311|
NCT01633684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton 14|Type 1 Diabetes Mellitus Effect on Bone Mineral Density|Type 1 DM Effect on BMD: a Longitudinal Study in Adults||Creighton University|No|Completed|August 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|123|Samples Without DNA|We will be storing serum samples. No genetic tests will be performed on these.|Both|19 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who have Type 1 DM and their age and sex matched control and have been enrolled        in a study of Type 1 DM and bone and had a baseline DXA and pQCT during the last 4 years.        Persons that completed visit 1 for the previous study and had a DXA and pQCT done will be        invited back for repeat DXA and pQCT measurement. If a diabetic patient does not have an        age and sex matched control or their control does not want to be in the longitudinal study        a new age and sex matched control will be recruited.|October 2014|October 30, 2014|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633684||83270|
NCT01633944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EN3409-308|Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects|Phase 3, Double-Blind, Placebo-Controlled, Study to Evaluate the Analgesic Efficacy, Safety, and Tolerability of Buprenorphine HCl Buccal Film in Opioid-Naive Subjects With Chronic Lower Back Pain Requiring Opioid Analgesia||Endo Pharmaceuticals|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|752|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 2, 2012|Yes|Yes||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01633944||83250|
NCT01633957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYSU-XZ001|A Trial of Genotype-based Warfarin Initiation in Patients With Mechanical Prosthetic Heart Valve|Academic Leader，Head of Cardiac Surgery,Principal Investigator, Clinical Professor|SYSU-WARFA|First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|June 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||February 2016|February 20, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01633957||83249|
NCT01618396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSSJ001|Effects of Sedatives on Sublingual Microcirculation of Patients With Septic Shock|Effects of Sedatives on Sublingual Microcirculation of Patients With Septic Shock||Casa de Saúde São José|No|Completed|March 2011|August 2011|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2012|June 12, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618396||84441|
NCT01618409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43MD004048|PictureRx: An Intervention to Reduce Latino Health Disparities|PictureRx: An Intervention to Reduce Latino Health Disparities||PictureRx, LLC|No|Completed|March 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|200|||Both|18 Years|N/A|No|||June 2012|June 11, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618409||84440|
NCT01618929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP Protocol 1.0|Effects of Montelukast in Asthmatic Children With and Without Food Allergy|Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study||Hacettepe University|Yes|Recruiting|March 2013|April 2016|Anticipated|October 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|6 Years|18 Years|No|||August 2014|August 17, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01618929||84400|
NCT01618942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pressure algometer|To Measure Pain Perception With Electronic Pressure Algometer of Different Size Probes : a Healthy Subjects Research|To Measure Pain Perception With Electronic Pressure Algometer of Different Size Probes : a Healthy Subjects Research||Huazhong University of Science and Technology|Yes|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)|2||Actual|100|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|June 12, 2012||No||No|May 23, 2013|https://clinicaltrials.gov/show/NCT01618942||84399|There was no significant limitation in the study.
NCT01634594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0242|The Effect of Deliberate Hypotension on QTc, Tp-e Intervals and Heart Rate Variability|||Yonsei University|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|66|||Both|20 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01634594||83201|
NCT01634854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120660|A Study Comparing Vaginal Misoprostol and Intravenous Oxytocin for Induction of Labor|Randomized Comparison of Vaginal Misoprostol and Intravenous Oxytocin for Labor Induction in Multiparous Women||Vanderbilt University|No|Active, not recruiting|July 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|136|||Female|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 9, 2014|July 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01634854||83181|
NCT01634867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-03|Observational Study of Rapid Sequence Intubation (RSI) Drug Delivery Using Intraosseous (IO) and Intravenous (IV) Access in Pediatric Patients|A Pilot Study of Intubating Conditions Comparing Intraosseous Vascular Access With Peripheral Intravenous Access for Drug Delivery in Rapid Sequence Intubation Using Rocuronium as the Paralytic Agent||Vidacare Corporation|No|Withdrawn|September 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Both|N/A|N/A|No|Non-Probability Sample|patients in the emergency department with airway difficulties requiring rapid sequence        intubation.|December 2014|December 19, 2014|July 2, 2012||No|No subject enrollment.|No||https://clinicaltrials.gov/show/NCT01634867||83180|
NCT01635140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHE-BT001|Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children|Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children.||Children's Cancer Hospital Egypt 57357|Yes|Completed|May 2010|July 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|64|||Both|3 Years|18 Years|No|||July 2012|July 6, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01635140||83159|
NCT01635400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGT1A1-01|Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer|Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer||Zhejiang Cancer Hospital|Yes|Recruiting|June 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|18 Years|75 Years|No|||June 2012|July 6, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01635400||83139|
NCT01635335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH087232|Randomized Control Trial of Family-Based HIV Prevention for Latinos|A Randomized Controlled Trial of Family-Based HIV Prevention for Latino Youth|LatinoSTYLE|University of South Florida|Yes|Active, not recruiting|August 2010|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|640|||Both|14 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 8, 2015|June 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01635335||83144|
NCT01635348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10090070|Thinking, Walking Outcomes by Type of Exercise|Benefits of Two Types of Therapeutic Exercise on Gait and Cognition|2-STEP|University of Pittsburgh|Yes|Completed|January 2011|October 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|22|||Both|65 Years|N/A|Accepts Healthy Volunteers|||June 2012|July 28, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01635348||83143|
NCT01635361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12024|Understanding and Appraising the New Medicine Service in England|Understanding and Appraising the New Medicine Service in England|NMS|University of Nottingham|No|Completed|August 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|504|||Both|14 Years|N/A|No|||May 2015|May 27, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01635361||83142|
NCT01635686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_DWP422001|Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers|A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers||Daewoong Pharmaceutical Co. LTD.||Not yet recruiting|September 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind|2||Anticipated|38|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635686||83117|
NCT01635699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATUNI-1|Effect of Modified Fujita Technique Uvulopalatoplasty on Oxidative DNA Damage Levels in Patients With Obstructive Sleep Apnea SyndromE (OSAS)|Effect of Modified Fujita Technique Uvulopalatoplasty on Oxidative DNA Damage Levels in Patients With Obstructive Sleep Apnea SyndromE||Erzurum Regional Training & Research Hospital|No|Completed|June 2008|March 2011|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|Samples Without DNA|serum, whole blood|Both|18 Years|N/A|No|Probability Sample|Patients who underwent uvulopalatopharngoplasty (UPPP)for Obstructive sleep apnea syndrome        (OSAS) at the otolaryngology department of our hospital in Erzurum, Turkey.|July 2012|July 6, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635699||83116|
NCT01631578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|252399- HMO-CTIL|Improving the Reproductive Outcome of Poor Quality Ova by Injection of Autologous Somatic Mitochondria|Phase 1 Study of the Impact of Injecting an Autologous Somatic Mitochondrial Concentrate Into Poor Quality Ova.||Hadassah Medical Organization|No|Withdrawn|January 2012|August 2015|Actual|August 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|45 Years|No|||August 2015|August 19, 2015|May 24, 2012||No|PI moved from medical center|No||https://clinicaltrials.gov/show/NCT01631578||83431|
NCT01631812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-06-001|A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients|An Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa||Otsuka Pharmaceutical Co., Ltd.|No|Completed|December 2006|February 2010|Actual|February 2010|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|130|||Both|N/A|N/A|No|||February 2014|February 3, 2014|June 25, 2012||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01631812||83414|
NCT01632124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTX|Rituximab-induced Pulmonary Function Changes|Rituximab-induced Pulmonary Function Changes - an Observational Study in Patients With Rheumatoid Arthritis and Inflammatory Myositis||University of Zurich|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|Ambulatory patients at University Hospital|June 2012|June 28, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632124||83390|
NCT01633190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROTA 2010-2017|Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT)|Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT): Assessment of Hospitalizations and Emergency Department Visits - the Impact of Publicly Funded Vaccine Programs in Canada||Canadian Paediatric Society|No|Recruiting|March 2012|June 2018|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|2500|||Both|N/A|16 Years|No|Non-Probability Sample|Children age 0-16 admitted to the participating IMPACT hospitals (to December 31, 2017)        with confirmation of positive stool samples; and children age 0-5 years presenting to the        emergency departments (to December 31, 2014) of the participating IMPACT hospitals with a        diagnosis of gastroenteritis.|August 2015|August 5, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01633190||83308|
NCT01632904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18424-357|Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study|Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes||Incyte Corporation|No|Active, not recruiting|June 2012|June 2016|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|June 29, 2012|Yes|Yes||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01632904||83330|
NCT01633697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-131|Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease|Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease||University of Vermont|Yes|Recruiting|September 2012|November 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633697||83269|
NCT01633437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX157-112|Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers|A Phase I, Multiple-Dose, Randomized, Double-Blind, Oral Tyramine Pressor Response Study Comparing CX157 Tablets to Placebo in Healthy Male Volunteers|CX157-112|CeNeRx BioPharma Inc.|No|Completed|September 2010|October 2010|Actual|October 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||June 2012|June 29, 2012|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633437||83289|
NCT01633450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNL/CTC12-Reis|Zinc Absorption From Biofortified Rice|Bioavailability of Zinc From Rice Biofortified With 70Zn and Rice Extrinsically Labeled With 70Zn in Young Adults: a Randomized, Single-blind Study||Swiss Federal Institute of Technology||Completed|June 2012|October 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|16|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633450||83288|
NCT01634633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENFD-25-2012|Endometrial Nerve Fibers Detection in Patients With Different Gynecological Pathologies|Endometrial Nerve Fibers Detection in Patients With Different Gynecological Pathologies||Ain Shams Maternity Hospital|No|Recruiting|January 2011|December 2012|Anticipated|November 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|300|||Female|20 Years|60 Years|No|Probability Sample|The population of this study will be 300 patient undergoing laparoscopy or laparotomy for        different gynecological diseases namely, polycystic ovarian disease (PCOD), ovarian cysts        either benign or malignant, fibroid uterus, adenomyosis, endometrial hyperplasia and        endometrial carcinoma|July 2012|July 5, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634633||83198|
NCT01634906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37698.101.11|Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy|Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy|EBABAST|Sint Franciscus Gasthuis|No|Completed|July 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|55|||Both|18 Years|N/A|No|||March 2013|March 21, 2013|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634906||83177|
NCT01622855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT11158|Acute Intervention to Reduce Distress Following Sexual Assault|Prevention of Post-Rape Psychopathology and Drug Abuse||Medical University of South Carolina|No|Completed|March 1997|September 2005|Actual|September 2005|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|442|||Female|14 Years|90 Years|No|||April 2015|April 21, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622855||84100|
NCT01623128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14812|Prenatal Education Video Study|Prenatal Education Video Study|PEVS|University of Virginia|No|Completed|March 2010|July 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|522|||Female|15 Years|N/A|No|||December 2013|December 18, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623128||84080|
NCT01623115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12492|Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|ODYSSEY FH I|Sanofi|Yes|Completed|July 2012|December 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|486|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|June 15, 2012|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01623115||84081|Manual reclassification was done by the Sponsor for the "other reasons" of non-completion of study as specified in the electronic case report form (eCRF).
NCT01634607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNT-HIV 003.1|Bone Health and Vitamin D Status|Bone Health and Vitamin D Status in Thai HIV-1 Infected and Uninfected Adults (A Substudy of TNT-HIV 003: Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study)|BHVD|Thai Red Cross AIDS Research Centre|No|Recruiting|October 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|235|||Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|All participants are from the Anonymous Clinic of the Thai Red Cross AIDS Research Centre        (TRC-ARC, the HIV Netherlands Australia Thailand Research Collaboration (HIVNAT) and Queen        Savang Vadhana Memorial Hospital (QSV).|November 2015|November 2, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634607||83200|
NCT01634880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 11-37|Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies|Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies||The University of Texas Health Science Center at San Antonio|Yes|Withdrawn|July 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 25, 2013|July 3, 2012|Yes|Yes|Lack of accrual.|No||https://clinicaltrials.gov/show/NCT01634880||83179|
NCT01635426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASUOGRCT976|Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages|Aspirin Versus Clopidogrel Effect on Uterine Perfusion in Women With Unexplained Recurrent Pregnancy Loss With Decreased Uterine Artery Pulsatility Index: A Randomized Controlled Trial||Ain Shams University|Yes|Active, not recruiting|March 2012|December 2013|Anticipated|November 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|32|||Female|20 Years|35 Years|No|||August 2013|August 6, 2013|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635426||83137|
NCT01635439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWAFH2010-1|Prostin and Propess in Induction of Labor|Induction of Labour: A Comparison Between Propess Vaginal Delivery System and Prostin E2 Vaginal Suppositories, A Randomized Controlled Trial.||Ain Shams University|Yes|Completed|December 2010|December 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|40 Years|No|||January 2014|January 7, 2014|July 4, 2012||No||No|July 6, 2012|https://clinicaltrials.gov/show/NCT01635439||83136|
NCT01635413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008560|Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)|Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)|GET FIT|OHSU Knight Cancer Institute|Yes|Active, not recruiting|September 2012|||January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|466|||Female|50 Years|75 Years|No|||December 2015|December 2, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01635413||83138|
NCT01635725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMH 2012-08|New Bowel Preparation Scale for Measuring Colon Cleanliness|New Bowel Preparation Scale for Measuring the Cleansing of the Colon for Colonoscopy||Gastroenterology Services, Ltd.|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients already planning to have a colonoscopy in our office endoscopy suite.|October 2012|October 28, 2012|July 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01635725||83114|
NCT01635374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00030841|Per-Oral Endoscopic Esophagomyotomy (POEM)|Per-Oral Endoscopic Esophagomyotomy (POEM)|POEM|Northwestern University|No|Completed|July 2010|January 2014|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|400|||Both|18 Years|85 Years|No|||January 2015|January 5, 2015|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01635374||83141|
NCT01631604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fall-HMO-CTIL|Gait Characteristics Following a Fall|Quantification of Gait Parameters and Muscle Activation Patterns Following a Fall||Hadassah Medical Organization||Recruiting|June 2012|June 2014||June 2014||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Primary Purpose: Treatment|||||||Both|5 Years|N/A|Accepts Healthy Volunteers|||June 2012|July 5, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01631604||83429|
NCT01631591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|eosinophilic esophagitis|Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis|Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis|EE|University of South Florida|Yes|Completed|May 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|N/A||2|Actual|31|||Both|18 Years|N/A|No|Probability Sample|Male and female subjects, ages 18 years and older with findings of > 15 eosinophils per        high powered field by endoscopic esophageal biopsy. Patients should also have symptoms        consistent with eosinophilic esophagitis including dysphagia, heartburn, epigastric pain,        recurrent vomiting, or food impaction. The comparative group will include male and female        subjects, ages 18 years and older with a previous diagnosis of gastroesophageal reflux        with findings of < 15 eosinophils per high power field by endoscopic esophageal biopsy.|October 2014|October 6, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631591||83430|
NCT01632358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTAP311X2201|Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Assess Safety and Tolerability, Pharmacokinetics, and Explore Pharmacodynamics of TAP311 in Patients With Mixed Dyslipidaemia||Novartis|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|279|||Both|18 Years|80 Years|No|||November 2013|November 27, 2013|June 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632358||83372|
NCT01633177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0308112690000|Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes|Diabetes Prevention in the Vitamin D and Omega-3 Trial||Brigham and Women's Hospital|Yes|Active, not recruiting|September 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 2, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01633177||83309|
NCT01633463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emcap 2011|An Observational Study of Pain Assessment and Treatment Adequacy of Emergency Cancer Pain|A Prospective Observational Study of Assessment of Pain and Its Treatment Adequacy in Emergency Department at Tertiary Care Cancer Hospital.||Tata Memorial Hospital|No|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|100 ADULT CANCER PATIENTS REPORTING TO EMERGENCY DEPARTMENT WITH COMPLAINTS OF PAIN.|June 2012|July 3, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633463||83287|
NCT01634347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRPL-004|Memory Reconsolidation Blockade for Treating Drug Addiction|Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study||Douglas Mental Health University Institute|No|Recruiting|January 2012|||December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|45|||Both|18 Years|65 Years|No|||June 2014|June 23, 2014|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634347||83219|
NCT01634360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2007-E044-205|Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations|A 48-month Open Label Multi-centered Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 in Patients With Parkinson's Disease With "Wearing Off" Motor Fluctuations and "on" Period Dyskinesias||Eisai Inc.|No|Terminated|November 2004|June 2008|Actual|June 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|185|||Both|N/A|N/A|No|||January 2013|June 25, 2014|July 3, 2012|Yes|Yes|Due to termination of clinical program for Parkinson's Disease|No|October 23, 2012|https://clinicaltrials.gov/show/NCT01634360||83218|Due to early termination, no subjects completed this open-label extension study.
NCT01633970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28328|A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors||Genentech, Inc.||Recruiting|July 2012|September 2017|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|225|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|June 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01633970||83248|
NCT01634334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HL103684|Improving Household Air Quality in Homes With Children|Innovation for Smoke-Free Homes: Real-Time Feedback|ProjFreshAir|San Diego State University|Yes|Recruiting|May 2012|April 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 21, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634334||83220|
NCT01634919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2012-74|Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin|A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients With Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments||Seoul National University Boramae Hospital|No|Active, not recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|Samples With DNA|-  Liver tissue in frozen states        -  Whole blood including PBMC and sera|Both|20 Years|N/A|No|Probability Sample|Hospital-based cohort|December 2015|December 1, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634919||83176|
NCT01634386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-189|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fasting Conditions|An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Single-dose Bioequivalence Study of Quetiapine 25 mg Tablet [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 25 mg Tablet [Reference Formulation; AstraZeneca, USA] in Healthy Human Volunteers Under Fasting Condition.||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01634386||83216|
NCT01635179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glo-anaest-2012|Laryngeal View With Videolaryngoscopy|Laryngeal View With Intubation by Videolaryngoscopy With and Without Sellicks Maneuver.||Glostrup University Hospital, Copenhagen|Yes|Completed|April 2012|September 2012|Actual|July 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|1||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2013|April 24, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01635179||83156|
NCT01635192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProGlucose-1|Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System|Effects of Probiotic VSL#3 on Expression of Small Intestinal Mucosal Renin-angiotensin System and Glucose Absorption in Man - a Doubleblind, Randomized Parallel Arm Placebo Controlled Exploratory Study in Healthy Volunteers||Göteborg University|No|Completed|December 2011|July 2013|Actual|July 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2014|May 21, 2014|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01635192||83155|
NCT01623141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scinti/PressurePain2011|Correlation Between 3 Phase Bone Scintigraphy and Pressure Pain Thresholds in Patients With Complex Regional Pain Syndrome (CRPS)|Correlation Between 3 Phase Bone Scintigraphy and Pressure Pain Thresholds in Patients With CRPS||Ruhr University of Bochum|No|Completed|October 2010|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The study sample consists of three groups:          1. Patients with CRPS of one of the upper limb type 1 (n=18)          2. Patients with unilateral upper limb pain of other origin (n=17)          3. Healthy subjects (n=18)        All patients were recruited from the Department of Pain medicine and the Department of        nuclear medicine of the University Hospital Bergmannsheil|June 2012|June 18, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623141||84079|
NCT01623401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TR701-110|A Phase 1, Open-Label, 10 Day Safety Study|Phase 1, Open-Label, Ophthalmology and Neurology Safety Study of Oral 200 mg TR-701 FA Once Daily for 10 Days in Healthy Adults||Trius Therapeutics LLC|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2012|December 5, 2012|June 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623401||84059|
NCT01623414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMR-1950|Sunlight Exposure and Vitamin D Status of Children of South Asian Ethnicity Living in the UK|Sunlight Exposure and Vitamin D Status of Children of South Asian Ethnicity Living in the UK||University of Manchester|No|Completed|September 2012|October 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|131|||Both|12 Years|15 Years|Accepts Healthy Volunteers|Non-Probability Sample|Schoolchildren of South Asian ethnicity in Greater Manchester|February 2015|February 4, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01623414||84058|
NCT01634893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 11-71|Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors|A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors||The University of Texas Health Science Center at San Antonio|Yes|Completed|June 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634893||83178|
NCT01635153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DarDar 2-C CPHS 21592|Effects of a Protein Calorie Supplement in HIV-infected Women With Tuberculosis|Randomized Controlled Trial of a Protein-calorie Supplement for HIV-infected Women With Tuberculosis|DarDar|Dartmouth-Hitchcock Medical Center|Yes|Completed|May 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|151|||Female|18 Years|N/A|No|||February 2015|February 9, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01635153||83158|
NCT01631890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS- EUS-001|To Compare the Efficacy of Endoscopic Ultrasound Assisted Endoscopic Glue Injection and Conventional Endoscopic Injection Therapy for Prevention of Gastric Variceal Rebleed|Phase III Study of the Efficacy of Endoscopic Ultrasound (EUS) Assisted Endoscopic Glue Injection and Conventional Endoscopic Injection Therapy for Prevention of Gastric Variceal Rebleed||Institute of Liver and Biliary Sciences, India|No|Withdrawn|June 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|70 Years|No|||June 2012|November 7, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01631890||83408|
NCT01631903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZPV-200 EXT|Extension of Study ZPV-200|A Phase 2, Multi-Center, Five-Arm, Parallel Design, Randomized, Single-Blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Confirmed by Ultrasound||Repros Therapeutics Inc.|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|48|||Female|18 Years|47 Years|No|||November 2012|April 15, 2014|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631903||83407|
NCT01635738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TH-IRB-10-14|Probiotics and Allergic Diseases|Probiotics and Allergic Diseases|probiotics|GenMont Biotech Incorporation|Yes|Completed|December 2011|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|4||Actual|240|||Both|1 Year|18 Years|No|||August 2015|August 31, 2015|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635738||83113|
NCT01635712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNX-5422-CLN1-005|Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies|A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies||Esanex Inc.|No|Active, not recruiting|February 2014|June 2016|Anticipated|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|July 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01635712||83115|
NCT01631864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2207|Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects|A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects||Novartis|No|Completed|October 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|98|||Both|18 Years|N/A|No|||June 2015|July 11, 2015|June 27, 2012||No||No|July 11, 2015|https://clinicaltrials.gov/show/NCT01631864||83410|
NCT01631851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0102012121-B|Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder|||Yale University|No|Recruiting|May 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|9 Years|16 Years|No|||July 2014|July 7, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631851||83411|
NCT01632137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACU-RED-301|Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome|A Phase 3 Study to Determine the Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome||Acucela Inc.|No|Completed|June 2012|||June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|564|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632137||83389|
NCT01632631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2012/412|Patient-specific Virtual Reality Rehearsal Prior to EVAR: Influence on Technical and Non-technical Operative Performance|Patient-specific Virtual Reality Rehearsal Prior to EVAR: Influence on Technical and Non-technical Operative Performance. A Randomized Controlled Trial.||University Hospital, Ghent|No|Active, not recruiting|February 2013|October 2015|Anticipated|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Patients with an infrarenal aortic aneurysm suitable for endovascular exclusion. The        suitability for endovascular repair is based upon the physician's decision.|August 2015|August 11, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632631||83351|
NCT01632917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATX-101-12-32|Open-Label Pharmacokinetic Study of Final Formulations of ATX-101|Phase 1, Open-Label, Randomized, Safety and Pharmacokinetic Study of Two Final Formulations of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Injections in the Submental Fat||Kythera Biopharmaceuticals|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632917||83329|
NCT01633476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV-001|CMV Modulation of the Immune System in ANCA-associated Vasculitis|Does CMV Reactivation Cause Functional Impairment of CMV Specific CD4+ T-cells? The Potential for Valaciclovir to Prevent CMV-mediated Adverse Modulation of the Immune System in Patients With ANCA-associated Vasculitis|CANVAS|University of Birmingham|No|Recruiting|July 2013|August 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|16 Years|N/A|No|||December 2014|December 9, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633476||83286|
NCT01633489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL-REG-12|Lysosomal Acid Lipase (LAL) Deficiency Registry|An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency (Wolman Disease and Cholesteryl Ester Storage Disease) and Carriers of the Disorder||Alexion Pharmaceuticals|No|Recruiting|December 2012|||December 2027|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1000|||Both|N/A|N/A|No|Non-Probability Sample|All patients with a diagnosis of LAL Deficiency or carriers of the disorder.|March 2013|April 2, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633489|10 Years|83285|
NCT01633983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|khateb-HMO-CTIL|Methotrexate for Central Serous Chorioretinopathy Treatment Trial|Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy|MTX4CSC|Hadassah Medical Organization|No|Not yet recruiting|August 2012|July 2015|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|65 Years|No|||July 2012|July 18, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633983||83247|
NCT01634646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lyzme5-IRB26715/1|Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man|A Placebo-Controlled Pilot Study to Observe the Impact Lyzme5 Has on Cholesterol and Body Weight in Man|Lyzme5|All American Pharmaceutical|Yes|Terminated|May 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator)|1||Actual|19|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 12, 2013|July 3, 2012||No|Unable to recruit sufficient local qualifying volunteers for study.|No||https://clinicaltrials.gov/show/NCT01634646||83197|
NCT01634399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-190|Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions|An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover Single-dose Bioequivalence Study of Quetiapine 25 mg Tablet [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 25 mg Tablet [Reference Formulation; AstraZeneca, USA] in Healthy Human Volunteers Under Fed Condition.||Torrent Pharmaceuticals Limited||Completed||||||Phase 1|Interventional|N/A|||||||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 2, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01634399||83215|
NCT01623752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801317|Prospective Evaluation of the Radiographic Efficacy of Enbrel|A Prospective Evaluation Of The Radiographic Efficacy Of Etanercept In Patients With Rheumatoid Arthritis Or Psoriatic Arthritis.|PRERA|Pfizer|No|Enrolling by invitation|March 2012|April 2018|Anticipated|April 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|Only patients for whom the decision has already been made to initiate treatment with        Enbrel® can be enrolled in this observational trial. These patients must have a proven        diagnosis of Rheumatoid Arthritis or Psoriasis Arthritis|March 2016|March 9, 2016|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623752||84032|
NCT01624038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|huoepio|Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.|Phase 2 Study of Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.||Ain Shams University|Yes|Not yet recruiting|June 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|3 Years|18 Years|No|||June 2012|June 18, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01624038||84011|
NCT01623427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2012:037|The AVATAR Trial: Applying VAcuum To Accomplish Reduced Wound Infections|The AVATAR Trial: Applying VAcuum To Accomplish Reduced Wound Infections in Laparoscopic Pediatric Surgery|AVATAR|University of Manitoba|Yes|Terminated|August 2012|August 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|150|||Both|N/A|17 Years|No|||November 2015|November 30, 2015|June 11, 2012||No|Difficulty recruiting enough patients|No||https://clinicaltrials.gov/show/NCT01623427||84057|
NCT01623765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/458/B|Lung Cancer Diagnosis and Staging Using Ultrasound Guidance|Diagnosis and Staging of Lung Cancer Using Minimally Invasive Technique With Ultrasound Guidance||Singapore General Hospital|No|Recruiting|January 2010|||January 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1000|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with suspected lung cancer|June 2012|June 19, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623765||84031|
NCT01635751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLA5PR-101|A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects|A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects|GLA5PR-101|GL Pharm Tech Corporation|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 25, 2013|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635751||83112|
NCT01631643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3093513|One Touch® Verio®IQ European Clinical Outcomes Study|One Touch® Verio®IQ European Clinical Outcomes Study||LifeScan|No|Withdrawn|December 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|80 Years|No|||December 2012|December 6, 2012|June 25, 2012|Yes|Yes|Business decision to withdraw trial|No||https://clinicaltrials.gov/show/NCT01631643||83426|
NCT01632176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K01AA017630-04|Real Talk Brief Intervention Study|Real Talk Brief Intervention Study||Boston University|Yes|Recruiting|March 2014|February 2017|Anticipated|February 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|360|||Both|15 Years|19 Years|No|||January 2016|January 19, 2016|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632176||83386|
NCT01632163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12382|Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin||Sanofi|Yes|Completed|October 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632163||83387|
NCT01631617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120159|Effects of Treatments on Atopic Dermatitis|Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|113|||Both|2 Years|50 Years|Accepts Healthy Volunteers|||December 2015|January 1, 2016|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631617||83428|
NCT01631877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS- PVT-01|Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver|||Institute of Liver and Biliary Sciences, India|No|Recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|70 Years|No|||August 2015|August 11, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01631877||83409|
NCT01632150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA204-010|Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|Phase 2a Single-Arm Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma||Bristol-Myers Squibb|No|Active, not recruiting|June 2012|December 2016|Anticipated|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|18 Years|N/A|No|||December 2015|January 29, 2016|June 28, 2012|Yes|Yes||No|December 22, 2015|https://clinicaltrials.gov/show/NCT01632150||83388|
NCT01632956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-105|Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer|Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer: A Pilot Study||Memorial Sloan Kettering Cancer Center||Withdrawn|June 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Female|21 Years|80 Years|No|Probability Sample|Recruitment will be conducted by the MSKCC Research Study Assistant (RSA) with the        assistance of the treatment team and community partners. Patients of MSKCC and QCC will be        approached in clinic waiting rooms by the RSA. ACS Asian Initiatives and the Charles B        Wang Community Health Center are referral sites for this study.|February 2014|February 5, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632956||83326|
NCT01633216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11064|Poliovirus Vaccine Trial in Bangladesh|Assessment of the Immunogenicity of Three Doses of Bivalent, Trivalent or Type One Monovalent Oral Poliovirus Vaccines Provided at 2 or 4 Week Intervals||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|5||Actual|1000|||Both|6 Weeks|6 Weeks|Accepts Healthy Volunteers|||June 2012|January 6, 2013|June 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01633216||83306|
NCT01633502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DanShock-01|Danish Cardiogenic Shock Trial|Effects of Advanced Mechanical Circulatory Support in Patients With ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock. The Danish Cardiogenic Shock Trial|DanShock|Rigshospitalet, Denmark|Yes|Recruiting|December 2012|April 2018|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|N/A|No|||December 2012|December 13, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01633502||83284|
NCT01633710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDL-2009-01|Multicentre Study to Investigate the Performance of the Padd Device in the Assessment of Peripheral Arterial Disease|Protocol for a Multicentre Study to Investigate the Performance of the Padd Device in the Assessment of Peripheral Arterial Disease||University Hospitals, Leicester|No|Terminated|May 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|86|||Both|50 Years|N/A|No|Non-Probability Sample|Patients of 50 or over attending a vascular clinic at a major London hospital; patients of        70 years or over or 50-69 years with a history of diabetes, smoking, known peripheral        arterial disease or at least 2 risk factors (previous ischaemic event, hyperlipidaemia,        hypertension, family history of cardiovascular disease) from both primary and secondary        care.|June 2012|July 3, 2012|July 16, 2009||No|Redesigned sensor to be subjected to a new protocol|No||https://clinicaltrials.gov/show/NCT01633710||83268|
NCT01633723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA6886_IBS_I|Phase I Clinical Trial of DA-6886 in Healthy Male Subjects|A Phase I, Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Trial With Open-labelled Food Effect Study of Single Dose to Investigate the Safety, Tolerability and Pharmacokinetics of DA-6886 After Oral Administration in Healthy Male Subjects||Dong-A ST Co., Ltd.|Yes|Recruiting|August 2012|||December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633723||83267|
NCT01633996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2002-P-001899|Effectiveness of Acupuncture for Depressed Patients Taking Antidepressant Medications|Effectiveness of Acupuncture Augmentation on Treatment Resistant Depressed Patients||Massachusetts General Hospital|No|Completed|August 2007|April 2010|Actual|April 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|45|||Both|18 Years|65 Years|No|||July 2012|July 2, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01633996||83246|
NCT01634373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-08-111|Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets|An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Steady State Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 300 mg Tablet [Reference Formulation; AstraZeneca, USA] in Schizophrenic Patients.||Torrent Pharmaceuticals Limited|No|Completed||||||Phase 1|Interventional|N/A|||||||Both|25 Years|65 Years|No|||July 2012|July 2, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01634373||83217|
NCT01634412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F102|Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults|A Single-Dose, Open-Label, Randomized Study of the Comparative Pharmacokinetics of Sublingual TNX-102 2.4 mg at pH 3.5 and 7.1, Oral Cyclobenzaprine 5 mg Tablets, and Intravenous Cyclobenzaprine 2.4 mg in Healthy Adults||Tonix Pharmaceuticals, Inc.|No|Completed|June 2012|January 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01634412||83214|
NCT01623492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-052-435|Eisenmenger Quality Enhancement Research Initiative|Eisenmenger Quality Enhancement Research Initiative|ES-QuERI|Actelion|No|Active, not recruiting|July 2012|June 2018|Anticipated|April 2018|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Blood samples will be collected at Baseline and at each of the annual visits. In addition,      urine sampling will be performed at Baseline. An analysis of biomarkers will be performed at      a hospital core laboratory.|Both|18 Years|N/A|No|Non-Probability Sample|200 adult patients with Eisenmenger Syndrome recruited from approximately 50 US cardiology        practices.|March 2016|March 1, 2016|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01623492|3 Years|84052|
NCT01624064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSF CKDu Research|Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology|A Double Blind Clinical Trial to Examine the Renal Effects of an Angiotensin Converting Enzyme Inhibitor (Enalapril) in Adults With Chronic Kidney Disease of Uncertain Aetiology (CKDu)|CKDu|Ministry of Health, Sri Lanka|Yes|Not yet recruiting|August 2012|October 2013|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|70 Years|No|||June 2012|June 19, 2012|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01624064||84009|
NCT01631656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II-AM-Intendis-ROS|Combination Gel and Vascular ND in Mild to Moderate Rosacea|Combination Finacea Gel and Vascular Nd:Yag Laser Therapy for Mild to Moderate Rosacea||Wake Forest School of Medicine|No|Completed|July 2010|February 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||December 2015|December 9, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631656||83425|
NCT01635504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00990|HIV Posterior Cheek Enlargement|Posterior Cheek Enlargement in HIV: Anatomic Characterization and Treatment With Botulinum Toxin A||University of British Columbia|No|Completed|October 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|19 Years|N/A|No|||August 2015|August 20, 2015|June 4, 2012||No||No|May 27, 2015|https://clinicaltrials.gov/show/NCT01635504||83131|This was a pilot study with only 5 participants. This study can only serve as a guide for larger studies.
NCT01631916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HGNPE-66-2012|Corticosteroids in Community-acquired Pneumonia|Use of Corticosteroids in Children Hospitalized With Community-acquired Pneumonia||Hospital General de Niños Pedro de Elizalde|Yes|Withdrawn|November 2015|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|18 Years|No|||February 2016|February 26, 2016|June 26, 2012||No|Unable to find patients matching inclusion criteria|No||https://clinicaltrials.gov/show/NCT01631916||83406|
NCT01631669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|352511|Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification|Prophylaxis of Heterotopic Ossification (HO) in Wartime Extremity Injuries, a Randomized Clinical Trial||Walter Reed National Military Medical Center|No|Recruiting|May 2012|June 2018|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|18 Years|65 Years|No|||June 2012|June 29, 2012|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631669||83424|
NCT01632397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34MH095584-01|Pre-exposure Prophylaxis Adherence Intervention for MSM|Optimizing Antiretroviral-Based Prevention by Enhancing PrEP Adherence in MSM|PrEPare|Fenway Community Health|Yes|Completed|August 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|103|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|May 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632397||83369|
NCT01631630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120143|Piogliatazone for Alcohol Craving|Role of Proinflammatory Signaling in Alcohol Craving||National Institutes of Health Clinical Center (CC)||Completed|May 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|16|||Both|21 Years|65 Years|No|||May 2015|September 3, 2015|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631630||83427|
NCT01632644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU66384|Identifying Skin Biopsy Sites|Pilot Study of Skin Biopsy Sites: A Consensus Approach Based on Patient and Physician Interviews||Northwestern University|Yes|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|59|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Physicians will be recruited by email obtained through directories.        Patients will be those who have had biopsies at the Northwestern University Department of        Dermatology.|September 2014|September 3, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01632644||83350|
NCT01632943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10054637DOC|Single-arm Study of Symplicity™ Renal Denervation System in Patients With Uncontrolled HyperTensioN in India|A Prospective, Multi-center, Non-randomized, Controlled Trial in India to Evaluate Efficacy and Safety of Renal Denervation in the Treatment of Uncontrolled Hypertension|HTN-India|Medtronic Vascular|No|Terminated|October 2013|December 2014|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|June 29, 2012||No|Study Enrollment was stopped pending review of another study in the same therapeutic area.|No||https://clinicaltrials.gov/show/NCT01632943||83327|
NCT01632982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mobile631|Mobile Psychosocial Interventions for MMT Clients|Providing Psychosocial Interventions to Substance Abusers Via Mobile Technology|MobileMMT|National Development and Research Institutes, Inc.|No|Recruiting|July 2013|November 2016|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|219|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632982||83324|
NCT01633229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120010|Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications|A Phase I Study of Bone Marrow Stromal Cell Infusions to Treat Acute Graft Versus Host Disease, Marrow Failure and Tissue Injury After Allogeneic Stem Cell Transplantation||National Institutes of Health Clinical Center (CC)||Completed|November 2011|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||May 2015|May 28, 2015|June 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01633229||83305|
NCT01633749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-567|Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2012/2013. An Open-label, Baseline-controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age||Abbott|No|Completed|July 2012|July 2012|Actual|July 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 3, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633749||83265|
NCT01634022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004P002819|Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications|Effectiveness of Acupuncture on Treating Major Depressive Disorder||Massachusetts General Hospital|No|Completed|May 2005|November 2011|Actual|November 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|18 Years|65 Years|No|||July 2012|July 2, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01634022||83244|
NCT01633736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UoN-SWW-2|Targeted Hip Strength Training in Children With Cerebral Palsy (CP)|Targeted Hip Progressive Resistance Training to Improve Single Leg Balance and Walking in Children With Cerebral Palsy||University of Nottingham|No|Recruiting|December 2011|March 2013|Anticipated|March 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|20|||Both|7 Years|16 Years|No|||July 2012|July 3, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01633736||83266|
NCT01634009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-09038|Soy-Ready to Use Therapeutic Food (RUTF) in Severely Malnourished Children|Efficacy of Ready to Use Therapeutic Food Using Soy Protein Isolate in Under-5 Children With Severe Acute Malnutrition in Bangladesh||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Anticipated|260|||Both|6 Months|5 Years|No|||June 2012|March 24, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01634009||83245|
NCT01634958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6043-PG-PSC-192|Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma|A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma||Leti Pharma GmbH|Yes|Completed|October 2012|June 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|308|||Both|18 Years|70 Years|No|||November 2013|November 18, 2013|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634958||83173|
NCT01634971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-WUQ-201205001|External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD)|Phase II Study of External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent|EDIDPD|Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|May 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||January 2013|February 14, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634971||83172|
NCT01622907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HISTORIC AF 2011-10-11|Hybrid Staged Operating Room and Interventional Catheter Ablation for Atrial Fibrillation|European Multicenter Study Using Hybrid Staged Operating Room and Interventional Catheter Ablation Techniques to Treat Chronic AF|HISTORIC-AF|Azienda Ospedaliera Spedali Civili di Brescia|Yes|Recruiting|May 2012|April 2015|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|75 Years|No|Non-Probability Sample|Patients with Symptomatic Recurrent Persistent AF or Long Standing Persistent AF, defined        as persistent AF for greater than 1-year but less than 5 years duration (according to the        HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial        Fibrillation)|June 2012|June 15, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622907||84096|
NCT01623180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12EU01|A Randomized Clinical Evaluation of the BioFreedom™ Stent|A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding.|Leaders Free|Biosensors Europe SA|Yes|Active, not recruiting|December 2012|June 2016|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2456|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01623180||84076|
NCT01623778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HBV2012|Optimization of Antiviral Therapy of Chronic HBV Infection|Observation Study of Different Optimized Therapy Method of Patients With Chronic Hepatitis B||Changhai Hospital|No|Completed|January 2009|December 2011|Actual|December 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|67|Samples With DNA|Blood samples were retented at 12w,24w and 48w after optimized therapy|Both|16 Years|65 Years|No|Non-Probability Sample|cases of HBeAg-positive CHB with inadequate response to 24 weeks Peg interferon alpha-2a        were enrolled.|June 2012|June 19, 2012|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01623778||84030|
NCT01624077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJLT001|Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance|Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Promote Donor-specific Clinical Liver Transplantation Tolerance in Nanjing|Treg|Nanjing Medical University|Yes|Active, not recruiting|December 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||December 2014|February 21, 2015|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01624077||84008|
NCT01635517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIHF1203|Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure|Multicenter Tolvaptan Study For Uncontrolled Volume Overload in Japanese Acute Decompensated Heart faIlure Patients: A Prospective Observational Multicenter Cohort Study|MT FUJI|Translational Research Informatics Center, Kobe, Hyogo, Japan|No|Active, not recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|274|||Both|20 Years|N/A|No|Non-Probability Sample|Patients hospitalized for decompensated heart failure with fluid retention and serum        sodium levels of less than 140 mEq/L|March 2015|March 26, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635517||83130|
NCT01635790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35860.018.11|Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)|Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (The BRDME Study)|BRDME|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|June 2012|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|246|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01635790||83109|
NCT01635816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-11050|Immunogenicity of SA 14-14-2 JE Vaccine|A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Manufactured in a New Good Manufacturing Practices Facility and Non-inferiority With Respect to an Earlier Product.||International Centre for Diarrhoeal Disease Research, Bangladesh|Yes|Completed|May 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|1000|||Both|10 Months|12 Months|Accepts Healthy Volunteers|||July 2012|March 7, 2013|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635816||83107|
NCT01631682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-11-2-0092|Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders|Psychophysiology of Delayed Extinction and Reconsolidation in Humans||Massachusetts General Hospital|Yes|Completed|November 2010|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|199|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||May 2015|May 5, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631682||83423|
NCT01631929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|65-HGNPE-2012|Two Bag System for Hydration in Diabetes|Two Bag System vs. One Bag System for Hydration Patients With Diabetic Ketoacidosis||Hospital General de Niños Pedro de Elizalde|No|Terminated|August 2012|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|1 Year|18 Years|No|||August 2014|September 23, 2015|June 25, 2012||No|Monitoring Committee found significant & meaningful difference on main outcome|No|August 19, 2015|https://clinicaltrials.gov/show/NCT01631929||83405|
NCT01632657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0139-B|Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy|Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy||University Health Network, Toronto|Yes|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|80 Years|No|||February 2015|February 9, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632657||83349|
NCT01632371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE IDE NO. S00112|Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4|ISAR-DESIRE 4: Randomized Trial Of Scoring Balloon in Patients With Restenosis in "Limus"-Eluting Coronary Stents Undergoing Angioplasty With Paclitaxel-Coated Balloon|ISAR-DESIRE 4|Deutsches Herzzentrum Muenchen|No|Active, not recruiting|June 2012|December 2016|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01632371||83371|
NCT01632384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031550|The Effects of Smoking Withdrawal On Resting State Functional Connectivity|The Effects of Smoking Withdrawal on Resting State Functional Connectivity|SmokeAtt04|Duke University|No|Withdrawn|February 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 10, 2013|February 20, 2012||No|study close-out|No||https://clinicaltrials.gov/show/NCT01632384||83370|
NCT01633203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOCCHI 2009-01|Observational Study of Perioperative Chemotherapy in Gastric Cancer|Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery|PRECISO|Grupo Oncologico Cooperativo Chileno de Investigation|No|Active, not recruiting|August 2010|September 2018|Anticipated|March 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|61|||Both|19 Years|80 Years|No|Non-Probability Sample|Current diagnosis of T3-4 and/or N+ M0 (according to staging system of the American Joint        Committee on Cancer 2002) resectable gastric cancer. The resectability has to be confirmed        by a surgical oncologist and/or Oncological Committee.|March 2015|March 14, 2015|June 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01633203||83307|
NCT01633515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-12-0032-CTIL|Intralesional Cryosurgery for Basal Cell Carcinoma - a Feasibility Study|Intralesional Cryosurgery for the Treatment of Basal Cell Carcinoma of the Lower Extremities in the Elderly - a Feasibility Study||Carmel Medical Center|No|Recruiting|July 2012|July 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|60 Years|N/A|No|||December 2013|December 2, 2013|June 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01633515||83283|
NCT01633528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Royan-Emb-014|The Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy|To Evaluate the Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy in Frozen Embryo Transfer Cycles||Royan Institute|Yes|Completed|May 2012|October 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|18 Years|40 Years|No|||March 2012|May 21, 2013|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01633528||83282|
NCT01634425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROACT NSTEMI|Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT)|Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) Novel Proximal Pathways for Non ST Elevation Myocardial Infarction|PROACT|University of Alberta|No|Completed|November 2011|February 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|601|||Both|31 Years|N/A|No|||October 2015|October 19, 2015|October 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01634425||83213|
NCT01634698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEPHUCFF 06801|Relative-dose-response Test (RDR) Adaptation for Chronic Liver Disease|Responsiveness of RDR Test to Assess Hepatic Vitamin A Stores in Chronic Liver Disease||Universidade Federal do Rio de Janeiro|Yes|Completed|October 2007|December 2008|Actual|December 2007|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|178|||Both|20 Years|N/A|No|||May 2012|July 2, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01634698||83193|
NCT01634451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/R/AN/01|Development and Evaluation of Strategies to Improve Sedation Quality in InTensive Care|Development and Evaluation of Strategies to Improve Sedation Quality in InTensive Care|DESIST|University of Edinburgh|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|1637|||Both|16 Years|N/A|No|||June 2015|June 10, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01634451||83211|
NCT01634711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LC 1033, Version 3.0|Clinical Evaluation of a Resorbable PLLA Implant for Regeneration of the Anterior Cruciate Ligament (ACL)|A Prospective and Consecutive Clinical Evaluation of Soft Tissue Regeneration's L-C Ligament® in Primary ACL Reconstruction||Soft Tissue Regeneration, Inc.|No|Active, not recruiting|June 2013|April 2016|Anticipated|April 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|45 Years|No|||June 2014|June 18, 2014|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01634711||83192|
NCT01623193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABC Trial|The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study|The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery|ABC|Nova Scotia Health Authority|No|Recruiting|August 2012|||||Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|16 Years|N/A|No|||May 2014|May 13, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01623193||84075|
NCT01623791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ÇÜTFKHD|Random Urine Protein-creatinin Ratio to Predict Magnitude of Proteinuria|Random Urine Protein-creatinine Ratio to Predict Magnitude of Proteinuria in Different Severity of Pre-eclamptic Patients||Cukurova University|Yes|Recruiting|May 2011|June 2012|Anticipated|June 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|209|None Retained|URINE|Female|16 Years|50 Years|No|Probability Sample|Patients admitted to the University of Cukurova, School of Medicine, Department of        Obstetrics and Gynecology between May 2011- May 2012 for evaluation of possible        preclampsia and/or characterization of the severity of the preeclampsia were offered        participation of this study.|June 2012|June 19, 2012|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01623791||84029|
NCT01623804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EX-KOA-1206|Randomized Trial in knEe Osteoarthritis Using Low Intensity Ultrasound - Evaluating Feasibility (RELIEF)|Can Very Low Intensity Ultrasound Therapy Improve Pain in People With Knee Osteoarthritis? A Pilot Randomized Controlled Trial|RELIEF|McMaster University|Yes|Terminated|July 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|40 Years|N/A|No|||April 2015|April 7, 2015|May 31, 2012||No|funding to support alternate feasible recruitment strategy was not acquired|No||https://clinicaltrials.gov/show/NCT01623804||84028|
NCT01624909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSGY-201202025-3|China PEACE-Prospective AMI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Acute Myocardial Infarction||China National Center for Cardiovascular Diseases|Yes|Completed|December 2012|July 2015|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|4286|Samples With DNA|A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for      biomarker analysis and storage for future genetic studies;      A urine samples of 40mL will be collected at 1-month visit and 12-month visit for biomarker      analysis and storage.|Both|18 Years|N/A|No|Non-Probability Sample|In 40 hospitals of different levels in China, 4000 hospitalized patients with acute        myocardial infarction will be enrolled consecutively.|August 2015|August 27, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01624909||83944|
NCT01625182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720I2201|Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.|A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)||Novartis|Yes|Recruiting|December 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|176|||Both|18 Years|75 Years|No|||November 2015|November 5, 2015|June 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01625182||83923|
NCT01635530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T1/2012|Study of Lyme Neuroborreliosis|Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment||Turku University Hospital||Not yet recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||July 2012|July 6, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635530||83129|
NCT01635803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL35869.018.11|Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)|Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (The BRVO Study)|BRVO|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|June 2012|||June 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|296|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01635803||83108|
NCT01631955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAUTII&Schbc-UTI-QoL|Assessment of UTI Symptoms and Quality of Life According to Antibiotics Treatment in Acute Uncomplicated Cystitis|A Study of Quality of Life and Changes to Symptom Relief for Acute Uncomplicated Cystitis Treated With Antibiotics (Ciprobay); Prospective, Open-label, Multicenter, Observational Study||Soonchunhyang University Hospital||Completed|October 2009|October 2011|Actual|February 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|386|||Female|20 Years|65 Years|No|Probability Sample|Outpatient|June 2012|June 28, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631955||83403|
NCT01631968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERITR-COL|Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement|Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement||Parc de Salut Mar|No|Completed|September 2007|May 2012|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2948|||Both|18 Years|N/A|No|||June 2012|February 23, 2016|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01631968||83402|
NCT01631981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL11-007|PGL2001 Proof of Concept Study in Symptomatic Endometriosis|A Phase II, Multicentre, Randomised, Two-Arm, Parallel Group, Double-Blind, Placebo Controlled Study of the Steroid Sulfatase Inhibitor PGL2001 With Concomitant Administration of NETA (Norethisterone Acetate) for the Treatment of Symptoms Related to Endometriosis|AMBER|PregLem SA|No|Completed|June 2012|May 2014|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|162|||Female|18 Years|45 Years|No|||June 2014|June 2, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01631981||83401|
NCT01631942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7415-3986|A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects|A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects|explorer™2|Novo Nordisk A/S|No|Terminated|June 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|4|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||November 2014|November 12, 2014|June 28, 2012|No|Yes|See detailed description|No||https://clinicaltrials.gov/show/NCT01631942||83404|
NCT01632189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|040/2012|The Effect of Varenicline on D2/D3 Receptor Binding in Smokers|Investigating the Effects of Varenicline on D2/3 Receptor Binding in Brain of Tobacco-smokers: a PET/[11C](+)PHNO Study||Centre for Addiction and Mental Health|No|Completed|September 2012|August 2015|Actual|August 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|21 Years|45 Years|No|||January 2016|January 26, 2016|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632189||83385|
NCT01632969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-136|Improving End of Life Care in Head and Neck Cancer|Improving End of Life Care in Head and Neck Cancer||Memorial Sloan Kettering Cancer Center||Terminated|June 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Retrospective||1|Actual|2|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Deceased Head and Neck Surgery patients will be queried from Dataline and screened for        eligibility. Interviews with family members and next of kin of deceased patients treated        at MSKCC for noncutaneous squamous cell carcinomas of the upper aerodigestive tract will        be conducted via telephone, employing the survey instruments.|March 2015|March 4, 2015|June 29, 2012||No|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01632969||83325|
NCT01632670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-027|Functional Change in Endothelium After Cardiac cAtheterization, With and Without Music Therapy|FEAT: Functional Change in Endothelium After Cardiac cAtheterization, With and Without Music Therapy|FEAT|North Texas Veterans Healthcare System|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||October 2013|October 27, 2013|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01632670||83348|
NCT01632683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62199040|STorz Against Glidescope Effectiveness|Comparative Effectiveness of the C-MAC D-blade to Glidescope Videolaryngoscope in the Predicted Difficult Airway|STAGE|Oregon Health and Science University|Yes|Completed|May 2013|August 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|1100|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||October 2015|October 13, 2015|June 14, 2012||No||No|September 30, 2014|https://clinicaltrials.gov/show/NCT01632683||83347|
NCT01633541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2010.101|Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer|UMCC 2010.101 Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer||University of Michigan Cancer Center|Yes|Recruiting|March 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|52|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633541||83281|
NCT01633242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120090|Heart Imaging in Children With Muscular Dystrophy|A Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy||National Institutes of Health Clinical Center (CC)||Completed|February 2012|||||N/A|Observational|Time Perspective: Prospective|||Actual|2|||Both|8 Years|100 Years|No|||October 2015|November 3, 2015|June 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01633242||83304|
NCT01633255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120120|[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment|A Pilot, Open-label, Proof-of-Concept Study of the Use of [18F] Fluciclatide PET/CT Imaging in the Evaluation of Anti-AngiogenicTherapy in Renal Cancers||National Institutes of Health Clinical Center (CC)||Withdrawn|April 2012|April 2014|Actual|April 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|99 Years|No|||April 2014|November 18, 2015|June 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633255||83303|
NCT01633268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120139|Estimating Brain Biomechanics Using MRI|Estimation of Brain Biomechanics Using MRI||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|90|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|December 1, 2015|June 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01633268||83302|
NCT01634048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0592|The Effect of Protein-enriched Diet on Body Composition and Appetite|The Effect of Protein-enriched Diet on Body Composition and Appetite|Protein Rich|Imperial College London|Yes|Recruiting|July 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|25 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634048||83242|
NCT01634061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235D2101|Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients|Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.||Novartis|No|Completed|September 2012|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|43|||Male|18 Years|N/A|No|||September 2015|September 10, 2015|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01634061||83241|
NCT01633762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERA 2012|Eradication of Gut Microbiota|Eradication of Gut Microbiota - Effects on Postprandial Gut Hormone Secretion, Glucose Metabolism, Bone Metabolism and Gut Microbiome|ERA|University Hospital, Gentofte, Copenhagen|No|Completed|April 2012|April 2013|Actual|April 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|12|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01633762||83264|
NCT01634035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-001|Correlation Between Glycated Hemoglobin and Mean Plasma Glucose in Hemodialysis Patients|Correlation Between Glycated Hemoglobin and Mean Plasma Glucose in Hemodialysis Patients.||Northwell Health|No|Completed|March 2009|May 2009|Actual|May 2009|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Retrospective||1|Actual|159|None Retained|review of previous blood tests|Both|18 Years|N/A|No|Non-Probability Sample|all hemodialysis and diabetic population|July 2012|July 2, 2012|June 3, 2010||No||No||https://clinicaltrials.gov/show/NCT01634035||83243|
NCT01634438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001925|Heparin Dose for Radial Angiography|Low Versus High Dose Unfractionated Heparin in Patients Undergoing Angiography Via the Radial Artery||University of Alberta|No|Completed|July 2008|December 2010|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|49|||Both|18 Years|N/A|No|||July 2012|July 2, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01634438||83212|
NCT01635010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSIMVOP012|Obstructive Sleep Apnea in the Absence of Metabolic Syndrome|Obstructive Sleep Apnea in the Absence of Metabolic Syndrome: Pulse Wave Velocity, Inflammatory and Oxidative Stress Markers||Associação Fundo de Incentivo à Pesquisa|No|Completed|December 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Male|25 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01635010||83169|
NCT01666379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ForefootFenta vs.2|Pain Management After Forefoot Surgery|||Turku University Hospital|No|Completed|January 2009|November 2010|Actual|November 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|75 Years|No|||August 2012|August 10, 2012|July 19, 2012||||No||https://clinicaltrials.gov/show/NCT01666379||80838|
NCT01624610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMGI-DIETIBS|Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome|Comparing the Effectiveness of Two Diets to Control the Symptoms of Irritable Bowel Syndrome With Diarrhea (IBS-D): a Randomized, Controlled Trial and Gastrointestinal Microbiome Analysis||University of Michigan|No|Recruiting|July 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 12, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624610||83967|
NCT01625442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3132012|Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome|Effect of Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) on Metabolic Syndrome||Birjand University of Medical Sciences|Yes|Completed|January 2010|February 2012|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|732|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625442||83903|
NCT01631695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medasense002|Clinical Evaluation of Medasense Pain Monitor Performances|Evaluation of the Performances of Medasense Pain Monitor During General Anesthesia and Postoperative Recovery Compared to Pain Related Physiological Indicators and to Subjective Assessment of Pain by Anesthesiologist||Medasense Biometrics Ltd|No|Completed|November 2009|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|96|||Both|18 Years|70 Years|No|Probability Sample|Patients scheduled for elective surgeries under general anesthesia, healthy or suffering        from minor chronic diseases (ASA I-II)|October 2013|October 27, 2013|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01631695||83422|
NCT01631708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04609|Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?|Mi-Iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?|Mi-iron|Murdoch Childrens Research Institute|Yes|Recruiting|June 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01631708||83421|
NCT01666145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-11-13B|Advanced Image Guidance Utilized in Liver Surgery|Advanced Image Guidance for Ablation Probe Placement in Laparoscopic Liver Surgery: A Pilot Study||Carolinas Healthcare System|Yes|Completed|February 2012|February 2014|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|May 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01666145||80856|
NCT01666392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|#2232|﻿﻿Omega-3 Fatty Acid Supplementation in Older Adults|The Impact of ﻿﻿Omega-3 Fatty Acid Supplementation on Markers of Inflammation and Lean Body Mass in Older Adults||University of Memphis|No|Withdrawn|August 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2012|October 8, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01666392||80837|
NCT01632436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PIX 112|Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment|A Non-randomized Cohort Study With Matched Controls Investigating Pharmacokinetic Parameters and Safety of a Single Dose of Pixantrone With Metastatic Cancer and Moderate, Severe, or No Hepatic Impairment.|Hepatic|CTI BioPharma|No|Active, not recruiting|May 2012|February 2018|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|N/A|No|||June 2012|June 28, 2012|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632436||83366|
NCT01632410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMAC-12-NB-0227-12-CTIL|The Autonomic Nervous System State and Response to Different Stimuli Among Patients Post Stroke: A Follow-up Study|The Cardiac Autonomic Nervous System State and Response to Reflective, Motor and Cognitive Stimuli Among Patients Post Stroke: A Follow-up Study||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2012|December 2013|Anticipated|November 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Anticipated|100|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Post hemispheral ischemic stroke cognitively intact.|June 2012|July 2, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01632410||83368|
NCT01632423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/OPH/GLA/025|A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|||Allergan|No|Completed|February 2010|November 2010|Actual|November 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10337|||Both|N/A|N/A|No|Non-Probability Sample|Patients with open angle glaucoma or ocular hypertension|August 2012|August 21, 2012|June 25, 2012|Yes|Yes||No|August 21, 2012|https://clinicaltrials.gov/show/NCT01632423||83367|
NCT01632995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrEP Demonstration Project|Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics|Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|October 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|557|||Male|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 8, 2016|June 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632995||83323|
NCT01633008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120155|Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain|Acceptance and Commitment Therapy for Adolescents and Adults With Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study||National Institutes of Health Clinical Center (CC)||Completed|June 2012|February 2015|Actual|May 2014|Actual|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|12 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 21, 2016|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633008||83322|
NCT01635283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-002665|Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma|A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma||Jonsson Comprehensive Cancer Center|Yes|Active, not recruiting|January 2012|December 2019|Anticipated|August 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01635283||83148|
NCT01635894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1706|A Community Intervention Study of Female Pelvic Floor Condition and Knowledge of Pelvic Floor Exercises|A Community Intervention Study of Female Pelvic Floor Condition and Knowledge of Pelvic Floor Exercises||Plymouth Hospitals NHS Trust|No|Completed|April 2002|November 2005|Actual|November 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635894||83101|
NCT01633775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VESC#2007-056|Re-Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Secondary Surgical Management of Patients With Refractory Glaucoma|Re-Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Secondary Surgical Management of Patients With Refractory Primary Open Angle Glaucoma: a Three-year Comparative Study||Vanak Eye Surgery Center|Yes|Completed|December 2007|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|||Both|40 Years|N/A|No|Probability Sample|Patients with refractory primary open angle glaucoma and a history of failed        trabeculectomy with mitomycin C (MMC).|June 2012|July 3, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633775||83263|
NCT01663740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WV25651|An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls|A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir vs. Concurrent Untreated Matched Controls||Hoffmann-La Roche||Recruiting|January 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|37|||Male|20 Years|50 Years|No|Probability Sample|Adult male renal transplant recipients|August 2014|August 4, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663740||81023|
NCT01634464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06-CTS-02341|Role of Nutrition and Maternal Genetics on the Programming of Development of Fetal Adipose Tissue|The Role of Nutrition and Maternal Genetics on the Programming of Development of Fetal Adipose Tissue. Search for Markers of the Obesity Risk in Early Stages of Life|PREOBE|Universidad de Granada|No|Recruiting|March 2007|June 2013|Anticipated|October 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|300|Samples With DNA|Maternal blood and blood from the umbilical cord, serum, plasma, placental tissue, placental      tissue treated with RNAlater, saliva, oral mucosa, urine, faeces, human milk|Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|A total of 350 pregnant women aged between 18 and 42, with singleton pregnancies, were        recruited at 12 weeks of pregnancy at the Clinical University Hospital 'San Cecilio' and        "Mother-Infant" Hospital in the city of Granada, Spain|July 2012|July 5, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01634464||83210|
NCT01634724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NJGLHRMCSUN1|GnRH Agonist (GnRHa) Withdrawal at Late Stage of Long Protocol and the Incidence of Ovarian Hyper-stimulation|Study of Effect of GnRHa Withdrawal at Late Stage of Long Protocol on the Risk of Ovarian Hyper-stimulation in Patients With Polycystic Ovary (PCO) Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles||Nanjing University|Yes|Recruiting|July 2012|June 2013|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|96|||Female|23 Years|35 Years|No|||July 2012|July 7, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634724||83191|
NCT01666613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1883C00008|A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways|A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 When Administered Inhaled Via a New Dry Powder Inhaler and Via Turbuhaler™||AstraZeneca||Withdrawn|November 2012|March 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|0|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 18, 2012|August 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01666613||80820|
NCT01623505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIPRC-6614|Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling|Interventions for Cardiovascular Disease: "Real-World" Effectiveness of Combined Pharmacotherapy and Behavioural Counseling for Smoking Cessation|RW|Ottawa Heart Institute Research Corporation|Yes|Completed|June 2010|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1068|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 7, 2015|July 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01623505||84051|
NCT01625195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRSC-2012|Causal Relationships Between LC-omega-3-enriched Diet and Cognition|Causal Relationships Between LC-omega-3-enriched Diet and Cognition|MOP201109|Université de Sherbrooke|Yes|Recruiting|May 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01625195||83922|
NCT01625741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HYDRIC|Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy|Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy|HYDRIC|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Terminated|July 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|19 Years|N/A|No|||September 2015|September 28, 2015|June 6, 2012||No|Stopped by Principal Investigator decision|No||https://clinicaltrials.gov/show/NCT01625741||83880|
NCT01635842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11073|Informed Consent and Clinical Trials|Informed Consent and Clinical Trials: a Survey on the Patient's Level of Understanding||Azienda Usl di Bologna|No|Completed|June 2012|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects or legal representatives (care givers, parents) who have signed the ICF during        the last 30 days for participation in an interventional clinical trial|March 2015|March 2, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01635842||83105|
NCT01635855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110637|Belotero Post Approval Study|Belotero® Post Approval Study for the Treatment of Nasolabial Folds||Merz Pharmaceuticals, LLC|No|Completed|June 2012|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|117|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2014|July 3, 2014|July 5, 2012|Yes|Yes||No|April 2, 2014|https://clinicaltrials.gov/show/NCT01635855||83104|
NCT01665014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMI MM1|Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma|Efficacy and Safety of Double Autologous Hematopoietic Stem Cell Transplantation With Sequential Use of Total Marrow Irradiation and High-dose Melphalan in Multiple Myeloma||Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice|Yes|Not yet recruiting|August 2012|August 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||August 2012|August 16, 2012|August 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01665014||80942|
NCT01665027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSU-389049|Effect of Vacuum on Fetal and Maternal Complications During Difficult Caesarean Section|||Shahid Sadoughi University of Medical Sciences and Health Services||Completed|December 2010|January 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|108|||Female|15 Years|45 Years|No|||August 2012|August 14, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01665027||80941|
NCT01664052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17035|ESS505 Pre-hysterectomy Protocol|ESS505 Pre-hysterectomy Protocol: Safety and Short Term Effectiveness Study||Bayer||Completed|July 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|66|||Female|18 Years|N/A|No|||April 2014|April 2, 2014|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664052||80999|
NCT01632202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF2293|Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy|The Role of Seprafilm Bioresorbable Slurry in the Prevention of Intrauterine Synechiae in Patients Undergoing Hysteroscopic Myomectomy|Seprafilm|Columbia University|Yes|Recruiting|May 2012|||January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|328|||Female|18 Years|48 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632202||83384|
NCT01632215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEP 0223/09|Preoperative Gabapentine for Carpal Tunnel|Effect of Preoperative Gabapentine for Carpal Tunnel Syndrome||Federal University of São Paulo|No|Completed|March 2010|March 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|60 Years|No|||May 2014|May 19, 2014|June 28, 2012||No||No|February 24, 2014|https://clinicaltrials.gov/show/NCT01632215||83383|
NCT01632449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|109HV109|Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.|A Randomized, Single-Blind, Two-Period Crossover Study in Healthy Volunteers to Establish the Bioequivalence of BG00012 Supplied by Two Different Manufacturers.||Biogen|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|80|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 30, 2013|June 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632449||83365|
NCT01632462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-2012|A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease|A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease||Federico II University|Yes|Recruiting|September 2012|February 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||August 2014|August 10, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01632462||83364|
NCT01632696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPHM 1201|Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors|Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors||Peregrine Pharmaceuticals|No|Terminated|June 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|11|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|June 12, 2012|No|Yes|Sponsor decision|No||https://clinicaltrials.gov/show/NCT01632696||83346|
NCT01632709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DOD_PAP 12|Pathophysiology of Post Amputation Pain|Pathophysiology of Post Amputation Pain|PPAP|Rehabilitation Institute of Chicago|No|Completed|May 2012|December 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|June 11, 2012|Yes|Yes||No|June 1, 2015|https://clinicaltrials.gov/show/NCT01632709||83345|
NCT01633021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912149|Developing the Family Map: Looking at Communal Coping|Development of the Family Map: Examination of Communal Coping Across Disease Context||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|4000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|December 30, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633021||83321|
NCT01635907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 23811|Dovitinib in Neuroendocrine Tumors|A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma||Abramson Cancer Center of the University of Pennsylvania|Yes|Active, not recruiting|June 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|July 5, 2012|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01635907||83100|
NCT01635920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-004|A Comparison of Silicone Hydrogel Contact Lenses: AIR OPTIX® COLORS Versus AIR OPTIX® AQUA|A Comparison of Silicone Hydrogel Lenses: Colored Versus Non-Colored||Alcon Research|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|258|||Both|16 Years|N/A|No|||February 2014|February 18, 2014|July 5, 2012|Yes|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01635920||83099|
NCT01632007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-472/CCT-002|Double-blind Comparative Study of SYR-472|||Takeda|No|Completed|May 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|245|||Both|20 Years|N/A||||January 2014|January 13, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01632007||83399|
NCT01632020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|134190|Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth|Pilot Study: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth||University of Arkansas|No|Terminated|August 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|June 27, 2012|No|Yes|Inadequate accrual|No||https://clinicaltrials.gov/show/NCT01632020||83398|
NCT01664520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Turku University Hospital|Dexmedetomidine and Subarachnoid Haemorrhage|The Effects of Dexmedetomidine on Cerebral Autoregulation and Cerebral Oxygenation in Subarachnoid Haemorrhage Patients||Turku University Hospital|No|Recruiting|June 2013|||May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|15|||Both|18 Years|80 Years|No|||November 2014|November 14, 2014|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01664520||80980|
NCT01664741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA026823|Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging|Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging||Johns Hopkins University|Yes|Recruiting|April 2012|May 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|90|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 23, 2016|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664741||80963|
NCT01665625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XHDD 003|Regional Versus Systemic Chemotherapy in the Treatment of Unresectable Pancreatic Cancer|A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer||Fourth Military Medical University|Yes|Not yet recruiting|August 2012|February 2016|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||August 2012|August 10, 2012|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01665625||80896|
NCT01666132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METHOD|METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease|METHOD - Phase I/II Study of Intramyocardial Injection of Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease||Cardiocentro Ticino|No|Terminated|January 2011|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|June 27, 2011||No|Due to the slow recruitment process and the progress of newer cell types we decided to stop    the trial after the phase 1 (after 10 patients included)|No||https://clinicaltrials.gov/show/NCT01666132||80857|
NCT01666912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPI-12-0732|Postpartum Etonogestrel Implant for Adolescents|Etonogestrel-releasing Subdermal Implant for Adolescents in the Postpartum Period: a Randomized Controlled Trial|PPImplant|University of North Carolina, Chapel Hill|Yes|Active, not recruiting|August 2012|April 2015|Anticipated|April 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|96|||Female|14 Years|24 Years|Accepts Healthy Volunteers|||July 2014|July 10, 2014|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666912||80797|
NCT01624337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR # 1849|Malaria Prevention Cambodia|A Randomized, Double Blind, Placebo-controlled Clinical Trial of Monthly DHA-piperaquine for Malaria Prevention in Cambodia.|MPC|Armed Forces Research Institute of Medical Sciences, Thailand|Yes|Terminated|May 2012|March 2015|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|231|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 15, 2014|June 17, 2012||No|Medication safety concern|No||https://clinicaltrials.gov/show/NCT01624337||83988|
NCT01625455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110806|Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome|Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome||Vanderbilt University|No|Terminated|February 2012|||July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|7|||Both|18 Years|80 Years|No|||March 2016|March 18, 2016|June 19, 2012||No|Difficulty recruiting.|No||https://clinicaltrials.gov/show/NCT01625455||83902|
NCT01625468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056797|Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households|Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households||Emory University|No|Completed|June 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|500|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 7, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01625468||83901|
NCT01625481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP2-072-02|Seal-V Safety and Performance Study|Prospective, Single Arm, Open Label, Non-randomized Study to Evaluate The Safety and Performance of The Seal-V System||Sealantis Ltd.|No|Completed|July 2012|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||May 2014|May 26, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625481||83900|
NCT01626586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1200|Diabetes Adolescent and Family Group Therapy|Adjustment and Self-Management Intervention Groups for Youth With Type 1 Diabetes Mellitus||Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|80|||Both|10 Years|17 Years|No|||January 2016|January 26, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01626586||83815|
NCT01626599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PG-01|Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data|Pilot Study to Evaluate a Baseline Prototype Device Designed to Collect ECG (Electrocardiogram) and Accelerometer Data||Cyberonics, Inc.|No|Completed|June 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|147|||Both|5 Years|N/A|No|||September 2015|September 17, 2015|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626599||83814|
NCT01631721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NICHD_064734|Couple & Family Contexts|Affective Influences on Adolescent Sexual Risk Behavior: Couple & Family Contexts|CFC|New York University|Yes|Completed|November 2010|February 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2960|||Both|17 Years|19 Years|Accepts Healthy Volunteers|Probability Sample|Latino and African American adolescents currently involved in romantic relationships who        reside in the Bronx, New York.|March 2016|March 21, 2016|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01631721||83420|
NCT01665859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FH09|Risk Factors for Poor Outcome After Epigastric and Umbilical Hernia Repair|Nationwide Prospective Study of Surgical Risk Factors for Poor Outcome After Epigastric and Umbilical Hernia Repair||University Hospital Koge|No|Completed|January 2007|July 2012|Actual|January 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6783|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All elective umbilical or epigastric hernia repairs registered in tha Danish National        Hernia Database from January 1st 2007 to December 31st 2010|August 2012|August 13, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665859||80878|
NCT01663051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-018|Evaluation of the Zilver® Vena™ Venous Stent|Evaluation of the Zilver® Vena™ Venous Stent|VIVO EU|Cook||Active, not recruiting|November 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic iliofemoral venous outflow obstruction.|December 2015|January 29, 2016|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01663051||81076|
NCT01663064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-018|Zenith® p-Branch™: Single-Center Study|Zenith® p-Branch™: Single-Center Study|PBCT|Cook||Active, not recruiting|June 2012|January 2018|Anticipated|May 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01663064||81075|
NCT01632228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27819|A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma||Hoffmann-La Roche||Completed|June 2012|January 2016|Actual|January 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632228||83382|
NCT01632475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-006-F/U|Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia|Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia||Samsung Medical Center|Yes|Active, not recruiting|September 2011|September 2017|Anticipated|September 2017|Anticipated|Phase 1|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|9|||Both|4 Months|2 Years|No|Non-Probability Sample|Infants who enrolled in the study of phase 1 clinical trial to evaluate the safety and        efficacy of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia.        (NCT01297205)|May 2015|May 19, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01632475||83363|
NCT01632735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K01DA027754-03|Mobile Continuing Care Approach for Youth|Mobile Continuing Care Approach for Youth||Azusa Pacific University|Yes|Completed|February 2012|June 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|80|||Both|12 Years|24 Years|No|||July 2015|July 28, 2015|June 29, 2012||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01632735||83343|Pilot study limiting number of participants recruited.
NCT01663766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM-T-IMMU-115-03|Phase I Study of Milatuzumab for Graft Versus Host Disease|A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies||Immunomedics, Inc.|No|Active, not recruiting|December 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663766||81021|
NCT01632722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0166|Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets|A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases (APPROACH)||Yonsei University|No|Recruiting|June 2012|August 2018|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|218|||Both|20 Years|80 Years|No|||July 2015|July 14, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632722||83344|
NCT01633281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acupuncture 001|Acupuncture for Peripheral Neuropathy|A Study of Acupuncture for Bortezomib or Thalidomide -Induced Peripheral Neuropathy in Patients With Multiple Myeloma or Lymphoma||Singapore General Hospital|No|Terminated|June 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|21 Years|85 Years|No|||November 2015|November 18, 2015|June 29, 2012||No|poor recruitment and expiry of funding|No||https://clinicaltrials.gov/show/NCT01633281||83301|
NCT01632254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP-H|Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque|Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI, MRS and Ultrasound Imaging for Carotid Artery Plaque Dimension and Composition Assessment||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Recruiting|July 2009|June 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|30|||Both|N/A|N/A|No|Probability Sample|Patients with ≥70% carotid artery stenosis on clinical ultrasound duplex examination,        scheduled for endarterectomy in the Athero-Express study.|May 2012|July 19, 2012|October 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01632254||83380|
NCT01632501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCR1TS|Safety and Efficacy of the Percutaneous Intervention Performed With Devices of a Single-brand|Safety and Efficacy of the Percutaneous Intervention Performed With Devices of a Single-brand|Tsunami|Hospital Sao Lucas da PUCRS|Yes|Completed|January 2011|||March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|84|||Both|18 Years|N/A|No|||January 2011|July 2, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01632501||83361|
NCT01632761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001526|Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia|Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia in the Elderly||Brigham and Women's Hospital|Yes|Enrolling by invitation|November 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|2000|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632761||83341|
NCT01665001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALG ALL6|Personalized Therapy of Precursor Lymphoid Neoplasms|Optimization of the Treatment of Adults With Precursor Lymphoid Neoplasms With Adjustment of the Type and Intensity of the Therapy for Age, Status of Minimal Residual Disease, Genetic and Phenotypic Features||Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice|Yes|Not yet recruiting|August 2012|August 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|August 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01665001||80943|
NCT01665326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00001562|Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease|Determination of Cross-Reactive Immunological Material (CRIM) Status and Longitudinal Follow-up of Individuals With Pompe Disease||Duke University|Yes|Recruiting|September 2009|August 2019|Anticipated|August 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|N/A|18 Years|No|Non-Probability Sample|Study subjects will be babies/children with a confirmed diagnosis of infantile-onset Pompe        disease who are:          1. seen by the clinical staff of Duke Division of Medical Genetics, or          2. whose physician or parent contacts the Duke Division of Medical Genetics with the             wish to participate in this CRIM research study.|August 2015|August 18, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665326||80918|
NCT01666366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BITA Y vs In Situ|Comparison Between 2 Bilateral Internal Thoracic Artery Coronary Artery Bypass Grafting Configurations|Comparison of Bilateral Internal Thoracic Artery Revascularization Using in Situ or Y Graft Configurations: a Prospective Randomized Clinical, Functional and Angiographic Evaluation||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Completed|February 2003|March 2012|Actual|August 2006|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|75 Years|No|||August 2012|August 10, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01666366||80839|
NCT01666626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM64431|Ultrasound Stiffness Imaging in Crohn's Disease|Investigating Ultrasound Stiffness Imaging for Predicting Outcomes in Crohn's Disease||University of Michigan|Yes|Completed|September 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients with Crohn's disease, either:          -  hospitalized for small bowel obstruction, OR,          -  undergoing outpatient start of anti-tumor necrosis factor alpha|July 2015|July 29, 2015|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01666626||80819|
NCT01663025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC1HM|The Effects of Intra Operative Hand Reflexology for Patients Receiving Out Patient Vein Surgery|Evaluating The Effects Of Intra Operative Hand Reflexology on Pain and Anxiety During Out Patient Vein Surgery||The Whiteley Clinic|Yes|Completed|January 2013|February 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|100|||Both|18 Years|80 Years|No|||May 2014|May 16, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01663025||81078|
NCT01663038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|119HPS10F|Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination|Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers||Chong Kun Dang Pharmaceutical|No|Completed|December 2010|September 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|December 20, 2010||No||No||https://clinicaltrials.gov/show/NCT01663038||81077|
NCT01624922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSGY-201202025-4|China PEACE-Prospective PCI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Percutaneous Coronary Intervention||China National Center for Cardiovascular Diseases|Yes|Completed|December 2012|July 2015|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5185|Samples With DNA|A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for      biomarker analysis and storage for future genetic studies;      A urine samples of 40mL will be collected at 1-month visit and 12-month visit for biomarker      analysis and storage.|Both|18 Years|N/A|No|Non-Probability Sample|In 30 tertiary hospitals with capability of Percutaneous Coronary Intervention in China,        3000 hospitalized patients undergoing Percutaneous Coronary Intervention will be enrolled        consecutively.|August 2015|August 27, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01624922||83943|
NCT01625494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRBES_L_05887|Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy|A Prospective Open-label Multicentre Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg or Amlodipine 5 mg Monotherapy||Sanofi|No|Completed|May 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|158|||Both|18 Years|N/A|No|||January 2013|January 17, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625494||83899|
NCT01625507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RES0013109|The Alberta Diet: Effectiveness Study|The Alberta Diet: a Proposal for Its Implementation||University of Alberta|No|Completed|October 2012|December 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|35 Years|80 Years|No|||July 2015|August 9, 2015|June 19, 2012||No||No|November 18, 2014|https://clinicaltrials.gov/show/NCT01625507||83898|
NCT01626885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A002-A8|A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia|A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia||Mitsubishi Tanabe Pharma Corporation||Completed|May 2012|June 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|20 Years|64 Years|No|||January 2015|January 22, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01626885||83792|
NCT01622790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114580|Evaluation of the Bioequivalence of a Combined Formulated Tablet|An Evaluation of the Bioequivalence of a Combined Formulated Tablet (50mg/600mg/300mg Dolutegravir/Abacavir/Lamivudine) Compared to One Dolutegravir 50mg Tablet and One EPZICOM† (600mg/300mg Abacavir/Lamivudine) Tablet Administered Concurrently and the Effect of Food on Bioavailability of the Combined Formulation in Healthy Adult Subjects||ViiV Healthcare|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|66|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 11, 2012|May 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01622790||84105|
NCT01622803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KH0LEE|Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction|Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction||Samsung Medical Center|Yes|Recruiting|August 2011|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01622803||84104|
NCT01664754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003323|Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer|Phase I Dose Escalation Study of Carboplatin, Pemetrexed and Exemestane in Post-menopausal Women With Metastatic Non-squamous NSCLC||Jonsson Comprehensive Cancer Center|Yes|Recruiting|September 2012|||August 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|N/A|No|||March 2016|March 4, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664754||80962|
NCT01666639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0421-FSCP-Z256|Behavioral Exercise Therapy and Multidisciplinary Rehabilitation for Chronic Non-specific Low Back Pain|Behavioral Exercise Therapy to Optimize Inpatient Behavioral Orthopedic Rehabilitation for Chronic Non-specific Low Back Pain|VBT|University of Erlangen-Nürnberg|No|Completed|March 2011|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|351|||Both|18 Years|65 Years|No|||January 2014|January 26, 2014|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01666639||80818|
NCT01631994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|254286-5|Study to Evaluate the Efficacy of Oral Dissolving Metoclopramide Before Video Capsule Endoscopy|Title: A Prospective, Single Center, Randomized, Single Blinded Study to Evaluate the Efficacy of Oral Dissolving Metoclopramide Before Video Capsule Endoscopy.||Winthrop University Hospital|Yes|Completed|September 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|4|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01631994||83400|
NCT01663285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2012.038|Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)|Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)||University of Michigan Cancer Center|Yes|Terminated|September 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||November 2015|November 4, 2015|July 24, 2012|Yes|Yes|Low study participant enrollment.|No|September 11, 2014|https://clinicaltrials.gov/show/NCT01663285||81058|The study was terminated prematurely due to poor patient accrual. Study objectives were not analyzed.
NCT01663779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010421|Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters|Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters.||Yale University|No|Terminated|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|16 Years|N/A|No|||August 2015|August 5, 2015|August 8, 2012||No|Inability to recruit further.|No|March 30, 2015|https://clinicaltrials.gov/show/NCT01663779||81020|
NCT01633034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-329A|Tissue Collection for Understanding Intervertebral Disc Degeneration and Back Pain|Tissue Collection for Understanding Intervertebral Disc Degeneration and Back Pain||Northwell Health|No|Recruiting|January 2011|||December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|200|Samples Without DNA|Intervertebral disc tissue Spinal Ligament Tissue Blood serum|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects who meet inclusion criteria will be recruited from the patients undergoing        surgery at The North Shore University Hospital|September 2015|September 15, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633034||83320|
NCT01634477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNT-HIV 003|Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study|Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study|TNT-HIV|Thai Red Cross AIDS Research Centre|No|Recruiting|January 2010|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|816|||Both|30 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Thai HIV-infected patients with and without ART, and HIV negative patients from the Thai        Red Cross AIDS Research Centre and Queen Savang Memorial Hospital Institute during January        2010 - December 2014|November 2015|November 2, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634477||83209|
NCT01632527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|StemCells CL-N01-AMD|Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)|Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration||StemCells, Inc.|Yes|Completed|June 2012|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|50 Years|N/A|No|||September 2015|September 10, 2015|June 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632527||83359|
NCT01632306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14453|A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer|Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy||Eli Lilly and Company|No|Terminated|March 2013|June 2015|Actual|June 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|13|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|June 28, 2012|Yes|Yes|Study has been terminated due to slow enrollment.|No||https://clinicaltrials.gov/show/NCT01632306||83376|
NCT01664000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTIX 12-101|A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors||Cellceutix Corporation|Yes|Completed|October 2012|February 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664000||81003|
NCT01633073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLMA vs i-gel|A Comparison of the Laryngeal Mask Airway (LMA) Supreme and I-gel in Children|A Randomized Trial Comparing the Laryngeal Mask Airway-SupremeTM With the i-gelTM in Children||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|June 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|170|||Both|3 Months|11 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01633073||83317|
NCT01665846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H015|Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders|Neuroimaging Correlates of Monocyte/Macrophage Infiltration in HIV-infected Individuals: A Cross-sectional Pilot Study Using IV Ferumoxytol||University of Hawaii|No|Completed|July 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|4|||Both|19 Years|N/A|No|||August 2012|August 15, 2012|August 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01665846||80879|
NCT01633593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|deliriumBR2012|Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial|Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial||University of Sao Paulo|No|Terminated|August 2012|August 2018|Anticipated|December 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|19|||Both|60 Years|N/A|No|||December 2015|December 20, 2015|June 29, 2012||No|Difficulty in recruiting subjects for the trial.|No||https://clinicaltrials.gov/show/NCT01633593||83277|
NCT01633827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BWH-2012P000956|Combination Therapy to Treat Sleep Apnea|Combination Therapy for the Treatment of Obstructive Sleep Apnea||Brigham and Women's Hospital|No|Completed|August 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|79 Years|No|||July 2015|July 21, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633827||83259|
NCT01633840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-089M|New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges|New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges||Umeå University|No|Completed|September 2008|December 2010|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|2||Actual|275|||Both|8 Years|15 Years|Accepts Healthy Volunteers|||June 2012|June 29, 2012|June 20, 2012||||No||https://clinicaltrials.gov/show/NCT01633840||83258|
NCT01625208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027213|Supraclavicular Versus Combined Block for Ulnar and Median Distribution Hand Surgery|Standard Supraclavicular Block Versus Low-Volume Supraclavicular Block Plus Ulnar or Median Nerve Block for Hand Surgery in the Ulnar or Median Nerve Distribution||University of Alberta|No|Active, not recruiting|March 2012|December 2015|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|160|||Both|18 Years|80 Years|No|||April 2015|April 21, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625208||83921|
NCT01625221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1876, 1990, 2321|Feasibility Study of the Magnetic Anal Sphincter (FENIX System)|An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter||Torax Medical Incorporated|No|Active, not recruiting|December 2008|March 2016|Anticipated|March 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|19 Years|84 Years|No|||November 2015|November 2, 2015|June 19, 2012|Yes|Yes||No|November 26, 2013|https://clinicaltrials.gov/show/NCT01625221||83920|
NCT01626274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A_10-016|Long Term Vital Parameter Monitoring (LAVIMO)|Long Term Vital Parameter Monitoring Pilot Study to Evaluate Measurement Data Via In-ear Sensor in Comparison to Standard Polysomnography in Sleep Laboratory|LAVIMO|RWTH Aachen University|No|Completed|January 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|N/A|No|||November 2013|November 26, 2013|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626274||83839|
NCT01623089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/810/C|Identification of Asthma Phenotypes in Severe Asthmatics|Identification of Asthma Phenotypes in Severe Asthmatics||Singapore General Hospital|No|Recruiting|January 2011|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|500|||Both|21 Years|80 Years|No|Probability Sample|Respiratory or asthma clinic|June 2012|June 19, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623089||84083|
NCT01665638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100800|Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, 2-Way Cross-Over Study to Evaluate the Effect of Single Dose Canagliflozin on Kinetics of C-Peptide in Healthy Subjects||Janssen-Cilag International NV|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 6, 2013|August 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01665638||80895|
NCT01662713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002430|Optical Frequency Domain Imaging for Non-melanoma Skin Cancers|Optical Frequency Domain Imaging for Non-melanoma Skin Cancers|OFDI|Massachusetts General Hospital|No|Recruiting|November 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|90|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662713||81102|
NCT01635647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC050|A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso|A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children||University of Oxford|Yes|Completed|November 2012|September 2014|Actual|August 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|730|||Both|5 Months|17 Months|Accepts Healthy Volunteers|||February 2016|February 12, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635647||83120|
NCT01663519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFOUGSB-9725 Regional R&D|Effectiveness of Insoles Provided to Patients With Diabetes. A Longitudinal Randomized Controlled Study in Gothenburg|Effectiveness of Insoles Provided to Diabetic Patients at Risk to Develop Ulcers||Sahlgrenska University Hospital, Sweden|No|Completed|January 2008|July 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|114|||Both|18 Years|N/A|No|||October 2014|October 6, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663519||81040|
NCT01663532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31-12-291|Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia|A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|October 2012|September 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|340|||Both|18 Years|65 Years|No|||February 2015|February 12, 2015|August 9, 2012|Yes|Yes||No|December 19, 2014|https://clinicaltrials.gov/show/NCT01663532||81039|
NCT01632488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012SDU-QILU-G02|Assessment of Small Intestinal Bowel Epithelial Gaps in Irritable Bowel Syndrome|Assessment of Small Intestinal Bowel Epithelial Gaps in Patients With Irritable Bowel Syndrome by Confocal Laser Endomicroscopy||Shandong University|Yes|Recruiting|June 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|Samples With DNA|Taken biopsies during endoscopy|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with indications for colonoscopy in Qilu Hospital outpatient and inpatient        department.|June 2012|June 28, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632488||83362|
NCT01632748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMR-12-1004|Validation Study in Healthy Female Volunteers: A Comparison of Two Neurotech Vital Devices Set up to Provide Different Types of Electrical Stimulation|Validation Study in Healthy Female Volunteers: A Comparison of Two Neurotech Vital Devices Set up to Provide Different Types of Electrical Stimulation||Bio-Medical Research, Ltd.|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|September 20, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632748||83342|
NCT01635023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1532C00066|A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244|A Phase I, Single-center, Randomized, Open-label, Crossover Study to Compare the White (Current Phase II) and Blue (Planned Phase III) Capsule Formulations of AZD6244 Hyd-Sulfate in Healthy Male Subjects|AZD6244Formula|AstraZeneca||Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|27|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 24, 2012|June 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01635023||83168|
NCT01635270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|midP|Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma|Randomized Phase 2 Study Evaluating the Interest of Mid-position Strategy Versus ITV (Internal Target Volume) Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-resected Non-small Cell Lung Carcinoma (NSCLC).|midP|Centre Leon Berard|Yes|Recruiting|July 2012|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|No|||February 2015|February 10, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01635270||83149|
NCT01632098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-4384d|Economic Aspects of Extreme Obesity in Adolescent|Medical and Psychosocial Implications of Adolescent Extreme Obesity - Acceptance and Effects of Structured Care Study, Subproject 4|YES|University of Ulm|Yes|Active, not recruiting|July 2012|July 2021|Anticipated|July 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|429|||Both|14 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the general population through different healthcare- and        non healthcare settings to ascertain the inclusion of treatment-seeking and non        treatment-seeking individuals. Healthcare settings include university based obesity        clinics, physician offices and health insurance agencies. Non-healthcare settings include        schools, job centers, and employment agencies.|May 2015|May 11, 2015|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01632098||83392|
NCT01632800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMP 5.0|Sensory Effects of Rapidly-Changing Magnetic Fields|Sensory Effects of Rapidly-Changing Magnetic Fields||Weinberg Medical Physics LLC|Yes|Completed|August 2011|October 2011|Actual|October 2011|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 7, 2015|March 17, 2010||No||No||https://clinicaltrials.gov/show/NCT01632800||83338|
NCT01632813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Leuven-GID|Leuven Growing Into Deficit Follow-up Study|Neurocognitive Development in Children With Congenital Heart Disease: Growing Into Deficit|Leuven-GID|Katholieke Universiteit Leuven|No|Completed|July 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|172|||Both|84 Months|89 Months|Accepts Healthy Volunteers|Non-Probability Sample|Seven-year-old children with CHD and healthy seven-year-old control children|January 2016|January 7, 2016|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632813||83337|
NCT01632826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-4047-MM-009|Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma|A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma|PEXIUS|Celgene||Approved for marketing||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||April 2014|April 4, 2014|June 29, 2012|No|Yes||||https://clinicaltrials.gov/show/NCT01632826||83336|
NCT01633372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 39110-230|An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis|An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)||Incyte Corporation|No|Active, not recruiting|April 2012|January 2018|Anticipated|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|125|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633372||83294|
NCT01633385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO2012-02|Bronchial Inflammation in Patients With Bronchiolithis Obliterans|Lung Function and Bronchial Inflammation in Patients With Bronchiolithis Obliterans|FRABO-02|Johann Wolfgang Goethe University Hospitals|No|Completed|April 2012|December 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|37|Samples With DNA|blood, sputum cells, sputum supernatans|Both|6 Years|25 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients suffering from Bronchiolitis obliterans and controls|April 2013|April 3, 2013|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01633385||83293|
NCT01633606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAS-ICU-2012|Drawing the Line Between Medium Care and Intensive Care. A Prospective Observational Study Based on the Nursing Activities Score|Drawing the Line Between Medium Care and Intensive Care. A Prospective Observational Study Based on the Nursing Activities Score||Katholieke Universiteit Leuven|No|Completed|February 2013|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|N/A|N/A|No|Probability Sample|acute patients|January 2014|January 28, 2014|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633606||83276|
NCT01625234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X396-CLI-101|Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer|Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer||Xcovery Holding Company, LLC|No|Recruiting|June 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|February 2, 2016|June 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01625234||83919|
NCT01625247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-2008-0140|Drainage is Not Necessary Procedure After Laparoscopic Cholecystectomy Due to Severe Acute Cholecystitis|||Yonsei University|No|Recruiting|June 2009|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Both|18 Years|85 Years|No|||June 2012|June 20, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01625247||83918|
NCT01626612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-002297-22|De-escalation of Empirical Antimicrobial Therapy Study in Severe Sepsis|De-escalation of Empirical Antimicrobial Therapy Study in Severe Sepsis: A Randomized Clinical Trial (DEA Study)||Assistance Publique Hopitaux De Marseille|No|Completed|February 2012|July 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|N/A|No|||April 2015|April 20, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01626612||83813|
NCT01619475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A2ALL Core Protocol|Adult-to-Adult Living Donor Transplant Cohort Study|A2ALL: Adult-to-Adult Living Transplant Cohort Study|A2ALL-2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|February 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Anticipated|1900|Samples With DNA|To collect biosamples prior to, during, and after LDLT among all donors and recipients.      These biosamples include, liver biopsy,whole blood for genetic studies and DNA extraction,      plasma, serum and peripheral cells to be retained in the bio-repository.|Both|18 Years|N/A|No|Non-Probability Sample|The sample population will consist of the following:          -  Donors and LDLT and DDLT recipients enrolled in the original A2ALL cohort study.          -  Donors and LDLT recipients where the donation/transplant occurred during the period             of time that began with the end of enrollment into the original Cohort study (August             31, 2009) and ended with the opening of enrollment in the current core protocol; this             is referred to as the "Gap Era."          -  Prospective donors and LDLT recipients for donation/transplant surgery.          -  HCV-infected adult liver transplant recipients enrolled in the A2ALL-1 Cohort and             from those currently transplanted at the new A2ALL-2 centers (University of Toronto,             University of Pittsburgh, and Lahey Clinic).|May 2014|May 28, 2014|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01619475||84358|
NCT01666405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPC032012|Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence|A Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence||Uroplasty, Inc|No|Terminated|August 2012|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 28, 2015|August 10, 2012||No|business reasons|No||https://clinicaltrials.gov/show/NCT01666405||80836|
NCT01634789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2311014|A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women|A Phase 1, Open-label, Single-dose, Randomized, 4-treatment, 4- Period, Crossover, Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene (Bza) Compared With A Reference Tablet Formulation of Bza/Conjugated Estrogens (ce) in Healthy Postmenopausal Women||Pfizer|No|Terminated|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Actual|2|||Female|45 Years|64 Years|Accepts Healthy Volunteers|||January 2013|January 17, 2013|July 3, 2012|No|Yes|This study was terminated on 10 December 2012 due to low enrollment. The decision to terminate    the study was not based on safety or efficacy issues.|No||https://clinicaltrials.gov/show/NCT01634789||83186|
NCT01635322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0309|Sagittal Plane Correction With Pass-LP Device in Adult Deformity Patients|The Relationship Between Sagittal Plane Correction and Quality of Life in Adult Deformity Patients Treated With Posterior Instrumentation||Medicrea International|No|Active, not recruiting|July 2012|August 2017|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|125|||Both|21 Years|N/A|No|Non-Probability Sample|Adult with a lumbar or thoraco-lumbar spine deformity|July 2012|November 18, 2014|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01635322||83145|
NCT01632241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115471|Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)|A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)|EMBRACE|GlaxoSmithKline|Yes|Recruiting|February 2013|January 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|816|||Both|18 Years|N/A|No|||February 2016|March 17, 2016|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632241||83381|
NCT01633554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24190708|ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B|The Ability of Prediction of Fibrosis for ST-2 as a Non-invasive Marker in Chronic Hepatitis B||Turkiye Yuksek Ihtisas Education and Research Hospital|Yes|Recruiting|January 2011|September 2012|Anticipated|July 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|95|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|25 Healthy Volunteers 45 patients with chronic hepatitis B 25 patients with liver        cirrhosis|July 2012|July 3, 2012|July 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01633554||83280|
NCT01633788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|195263-006|A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction|||Allergan|No|Completed|July 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|232|||Both|40 Years|N/A|No|||April 2015|April 15, 2015|July 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633788||83262|
NCT01634074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11847|Reiterative Development and Evaluation Study of OSA Therapy System|A Multicenter, Prospective, Variable Duration, Reiterative Development and Evaluation Study of ApniCure's Therapy System(s) for the Treatment of Obstructive Sleep Apnea (OSA)||ApniCure, Inc.|No|Recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Probability Sample|Patients with known or suspected OSA|November 2013|November 21, 2013|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01634074||83240|
NCT01635582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:182|Home Based Computer Gaming Hand Exercise Regimen for People With Arthritis Affecting the Hands|Effects of Home Based Computer Gaming Hand Exercise Regimen in People With Rheumatoid Arthritis (RA) or Osteoarthritis (OA) -A Randomized Controlled Pilot Trial||University of Manitoba|No|Completed|June 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|30 Years|70 Years|No|||October 2014|October 11, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01635582||83125|
NCT01632111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fabry|Pulmonary Involvement in Patients With Fabry Disease|Impact of the Treatment With Agalsidase Alpha on Lung Function and on Pulmonary Involvement in Patients With Fabry Disease. A Multicenter, Retrospective Observational Study||University of Zurich|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|110|||Both|16 Years|N/A|No|Probability Sample|Ambulatory patients at University Hospital of Zurich with Fabry disease|May 2014|May 26, 2014|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632111||83391|
NCT01632332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1136|Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer|A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer||Mayo Clinic|Yes|Active, not recruiting|July 2012|||June 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|June 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632332||83374|
NCT01632540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-401|Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis|Investigation of the Real World Effectiveness of Beclomethasone Dipropionate (BDP) Nasal Aerosol in Perennial Allergic Rhinitis (PAR) Patients|BALANCE|Teva Pharmaceutical Industries|No|Completed|July 2012|February 2014|Actual|December 2013|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|824|||Both|12 Years|N/A|No|Non-Probability Sample|Male and female patients, at least 12 years of age, with a diagnosis of PAR for at least        one year and who are newly prescribed BDP nasal aerosol.|April 2014|April 14, 2014|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632540|6 Months|83358|
NCT01632553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1678|Cortisol Evaluation in Abuse Survivors|Longitudinal Measurement of Cortisol in Association With Mental Health and Experience of Domestic Violence and Abuse|CEASE|University of Bristol|No|Completed|August 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|214|Samples Without DNA|Saliva|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women referred to two specialist domestic violence agencies for community outreach support        or refuge accommodation by other agencies or self-referred. Non-abused friend and family        controls will be recruited through index participants and in local communities through        invitation letters displayed in public places in areas surrounding agencies sites.|December 2015|December 4, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632553||83357|
NCT01632566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14284|A Multiple-dose Study of LY3031207 in Healthy Participants|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3031207 in Healthy Subjects||Eli Lilly and Company|No|Terminated|June 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|90|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|June 25, 2012|No|Yes|Elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in some    participants.|No||https://clinicaltrials.gov/show/NCT01632566||83356|
NCT01633086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR99-IRB-273|A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy|A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy||China Medical University Hospital|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|30 Years|80 Years|No|||March 2015|March 11, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01633086||83316|
NCT01633099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DACOGENAML2003|Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients|The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients||Chinese Academy of Medical Sciences|Yes|Active, not recruiting|May 2012|July 2016|Anticipated|July 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|60 Years|N/A|No|||July 2012|July 4, 2012|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01633099||83315|
NCT01633112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720D2312|MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone|A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis||Novartis|No|Recruiting|August 2012|June 2023|Anticipated|June 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|1960|||Both|18 Years|65 Years|No|||March 2016|March 10, 2016|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633112||83314|
NCT01633398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASIAN HF Registry|ASIAN HF Registry, A Prospective Observational Study|Asian Sudden Cardiac Death in Heart Failure(ASIAN-HF) Prospective Observational Study|ASIANHF|National University Health System, Singapore|No|Recruiting|September 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|8000|||Both|18 Years|100 Years|No|Non-Probability Sample|This is a prospective, observational, multinational, multicenter Asian registry of        patients with Stage C HF, including both HFrEF (ejection fraction <40%) and HFpEF        (ejection fraction ≥50%).        This study population (Stage C HF) was selected in recognition of current recommendations        emphasizing that HF is a progressive, staged disease.13 29 The HFrEF population was        defined based on a recent meta-analysis showing that risk of death in HF increases        particularly as ejection fraction falls below 40%.3 The HFpEF population was defined        according to current guidelines.29 Patients with an ejection fraction in the range of 40%        to 50% represent an intermediate group which was not included since we aimed to study        distinct clinical phenotypes.29|October 2015|October 18, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01633398||83292|
NCT01626040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-008643|Evaluation of One-day Polyethylene Glycol Powder Solution for Colonoscopy in Children|Evaluation of One-day Polyethylene Glycol Powder Solution for Colonoscopy in Children||Children's Hospital of Philadelphia|No|Completed|June 2012|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|178||No biospecimens are to be retained|Both|1 Year|18 Years|No|Non-Probability Sample|children undergoing outpatient colonoscopy|January 2014|January 16, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626040||83857|
NCT01622816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETDRS2012|Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart|Prospective Determination of Agreement Between Standard ETDRS (Early Treatment Diabetic Retinopathy Study) Chart and Handheld Illuminated ETDRS Equivalent Chart in Eyes With Retinal Pathology||Wills Eye||Completed|March 2012|March 2014|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|70|||Both|18 Years|N/A|No|Probability Sample|Patients enrolled in clinical trials for various retinal diseases at the Wills Eye        Institute|February 2015|February 2, 2015|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01622816||84103|
NCT01622829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-602/2011|Activity on Prescription to Promote Physical Activity in Hospitalized Patients|Pilot Study on Physical Activity||Heidelberg University||Recruiting|February 2012|September 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|40 Years|75 Years|No|||June 2012|June 19, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622829||84102|
NCT01619228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT01546780|Skin Maturation in Premature Infants|Ontogeny of Skin Barrier Maturation in Premature Infants||Children's Hospital Medical Center, Cincinnati|No|Enrolling by invitation|April 2012|February 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|200|||Both|24 Weeks|43 Weeks|Accepts Healthy Volunteers|||June 2015|August 3, 2015|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01619228||84377|
NCT01634802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2073|Evaluation of Use of Clinical Decision Support System in HIV Care in Resource Constrained Settings|Evaluation of Use of Clinical Decision Support System for Early Detection of Immunological Treatment Failure Among HIV Patients in Resource Constrained Settings|CDSS|Kenya Medical Research Institute|No|Not yet recruiting|August 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Anticipated|1460|||Both|18 Months|N/A|No|||July 2012|July 5, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634802||83185|
NCT01634815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5244|Evaluation of Local Capillary Blood Lactate in Chronic Critical Ischemia of Lower Limb Before and After Revascularization|Evaluation of Local Capillary Blood Lactate in Chronic Critical Ischemia of Lower Limb Before and After Revascularization.|ELIT|University Hospital, Strasbourg, France|No|Recruiting|February 2013|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634815||83184|
NCT01634841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120066|Walnuts and Healthy Aging|Effect of Daily Ingestion of Walnuts for 2 Years on Age-related Cognitive Decline and Macular Degeneration in Healthy Elderly Subjects: A Randomized, Single Blind, Dual Center, Controlled Trial|WAHA|Loma Linda University|Yes|Active, not recruiting|April 2012|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|700|||Both|63 Years|79 Years|Accepts Healthy Volunteers|||January 2016|January 28, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01634841||83182|
NCT01635062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000905|The VALDIATE-D Study|Evaluating Hormonal Mechanisms for Vitamin D Receptor Agonist Therapy in Diabetes: The VALIDATE-D Study|VALIDATE-D|Brigham and Women's Hospital|Yes|Completed|September 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|70 Years|No|||February 2016|February 1, 2016|July 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01635062||83165|
NCT01635075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21DA031283|Acute Effects of Exercise in Smokers With Schizophrenia|Acute Effects of Exercise in Smokers With Schizophrenia||Brown University|No|Completed|June 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|30|||Both|18 Years|60 Years|No|||September 2015|September 25, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01635075||83164|
NCT01635088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P05285|Onset and Duration of Mometasone by Oscillometry and Spirometry|Onset and Duration of Action of Mometasone Inhalation Powder as Measured by Oscillometry Versus Spirometry||California Allergy and Asthma Medical Group, Inc.|No|Completed|June 2011|||December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|65 Years|No|||August 2013|August 30, 2013|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01635088||83163|
NCT01633294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|335/08 - 28/07/08|Antibiotic Prophylaxis in Prelabor Rupture of Membranes at Term|Antibiotic Prophylaxis in Prelabor Rupture of Membranes at Term - a Randomized Controlled Trial||Hospital de Santa Maria, Portugal|No|Completed|October 2008|January 2012|Actual|January 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|161|||Female|N/A|N/A|No|||June 2012|June 30, 2012|June 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01633294||83300|
NCT01633307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PERMI|Decrease the Frequency of Inappropriate Intravenous Lines in Internal Medicine|Effect of a Nationwide Teaching Program on the Frequency of Inappropriate Intravenous Lines in Internal Medicine: A Randomized Controlled Trial|PERMI|Hopital Lariboisière|Yes|Completed|January 2007|May 2007|Actual|April 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|59|||Both|N/A|N/A|No|||June 2012|July 3, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01633307||83299|
NCT01631773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nasal Polyp Study & Aspirin|A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only|A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only||University of South Florida|Yes|Completed|August 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|26|Samples With DNA|Nasal epithelial tissue will be collected from the inferior nasal turbinates of ten subjects      with nasal polyps and AERD disease and from the inferior turbinates of ten subjects with      nasal polyps but without AERD. A rhinoprobe™ will be used to collect this epithelial tissue.      These samples will be analyzed by miRNA assay to determine if there is a difference in      mircroRNA expression between the two subject groups.|Both|18 Years|70 Years|No|Non-Probability Sample|This study will be a prospective study design with a target sample size of 20. The        objective of conducting it as a prospective study is to confirm that the sampling        procedures and analysis methodology work as expected before attempting a larger study. We        propose to have 10 study participants with nasal polyps but without AERD and 10 study        participants with nasal polyps and AERD. If the results of this study are promising,        larger studies with sufficient power for statistical analysis will be considered.|October 2014|October 6, 2014|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01631773||83417|
NCT01634737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|235_09/2010|Crustacean Allergy and Dust Mites Sensitization|Crustacean Allergy and Sensitization to Dust Mites in Patients With Respiratory Allergy: Clinical Study and Analysis of Common and Peculiar Allergens||Niguarda Hospital|No|Completed|September 2010|October 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|Samples Without DNA|Blood for in vitro investigations|Both|18 Years|80 Years|No|Non-Probability Sample|Will be selected a group of patients (group A) consisted of 50 subjects with a history of        allergic reactions to shellfish, both slight localized to the oral cavity than severe        systemic, these patients will show positive IgE to the extract of whole shrimp. In this        group may also be included subjects with symptoms and circulating IgE positive for dust        mites, both symptomatic and asymptomatic|March 2014|March 6, 2014|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634737||83190|
NCT01632280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 P- 000121|Enhancement of Brain Circuit of Inhibitory Control in Obese Patients Undergoing Gastric Banding|"Neuroband": The Effect of Perioperative Enhancement of the Brain Circuit of Inhibitory Control in Obese Patients Undergoing Laparoscopic Adjustable Gastric Banding (LAGB)|"Neuroband"|Beth Israel Deaconess Medical Center|No|Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|55 Years|No|||November 2015|November 12, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01632280||83378|
NCT01632345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1439-007|A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)|Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients||Merck Sharp & Dohme Corp.|No|Active, not recruiting|October 2012|March 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Anticipated|320|||Both|18 Years|N/A|No|||February 2016|March 9, 2016|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01632345||83373|
NCT01632319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008P001357|Therapy for Undergraduate College Students Who Binge Drink and Are Depressed|Treatment for Excessive Alcohol Use and Depression in Students (TREADS)|TREADS|Massachusetts General Hospital|No|Recruiting|May 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|24 Years|No|||June 2012|June 29, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632319||83375|
NCT01632865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|415807818|Recanalization and Stenting for Non-acute Veterbrobasilar Artery Occlusion|Recanalization and Stenting for Subacute and Chronic Veterbrobasilar Artery Occlusion||Zhengzhou University|Yes|Recruiting|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|30 Years|N/A|No|||July 2015|July 15, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01632865||83333|
NCT01632839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LOCAL/2011/BF-03|Psychometric Validation of a French Version of the PISQ-R and a New Questionnaire About Sexuality|Psychometric Validation of a French Version of the PISQ-R and a New Questionnaire About Sexuality: Tools for Evaluating Sexuality in Patients With From Urinary Incontinence or Pelvic Organ Prolapse||Centre Hospitalier Universitaire de Nīmes|No|Active, not recruiting|January 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||8|Actual|298|||Female|18 Years|N/A|No|Non-Probability Sample|Patients undergoing vaginal, abdominal or urinary incontinence surgery.|February 2016|February 5, 2016|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01632839||83335|
NCT01632852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSLCT-AML-11-73|A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission|A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse||CSL Limited|Yes|Completed|July 2012|||August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|June 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01632852||83334|
NCT01633411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-0003.A|Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium|Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium||C2 Therapeutics, Inc.|Yes|Completed|December 2011|June 2014|Actual|May 2014|Actual|Phase 1|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|39|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Barrett's esophagus with or without dysplasia|April 2015|April 24, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01633411||83291|
NCT01633632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-16438/13-16721|Hatha Yoga for Smoking Cessation|Hatha Yoga as an Adjunct to Cognitive Behavioral Therapy for Smoking Cessation||Creighton University|No|Completed|August 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|67|||Both|19 Years|N/A|No|||December 2015|December 10, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633632||83274|
NCT01633645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26866138-LUC-2006|Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II, Open-Label Trial of Bortezomib (VELCADE®) in Combination With Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer||University Hospital of Crete|No|Completed|June 2009|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01633645||83273|
NCT01626287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB 2012-044|Reduction of Perineal Pain After Vaginal Birth With Black Tea: Pilot Randomized Study|||Fraser Health|Yes|Completed|November 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|43|||Female|19 Years|N/A|No|||October 2013|May 22, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626287||83838|
NCT01619215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSULDRCBSMH001|The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease|The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease||King Saud University|Yes|Recruiting|June 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|35|Samples With DNA|Blood (serum, plasma, and RNA isolate) Liver core biopsy Subcutaneous fat Visceral fat      Abdominal wall muscle|Both|18 Years|60 Years|No|Non-Probability Sample|NAFLD patients|January 2016|January 25, 2016|May 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01619215||84378|
NCT01634542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN28151|An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia|A Non-Interventional Prospective Cohort Study of Patients With Persistent Symptoms of Schizophrenia to Describe The Course and Burden of Illness||Hoffmann-La Roche||Completed|February 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1433|||Both|18 Years|N/A|No|Probability Sample|Patients with persistent symptoms of schizophrenia|March 2016|March 1, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634542||83204|
NCT01634555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14433|A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI|A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Irinotecan and Its Metabolite SN-38 When Coadministered With Folinic Acid and 5 Fluorouracil in Patients With Advanced Malignant Solid Tumors||Eli Lilly and Company|No|Active, not recruiting|October 2012|June 2016|Anticipated|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 3, 2012|Yes|Yes||No|June 12, 2014|https://clinicaltrials.gov/show/NCT01634555||83203|
NCT01634828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP00002762|Method for Improved Intraoperative Blood Loss Estimates|Method for Improved Intraoperative Blood Loss Estimates|EBL|University of Utah|No|Recruiting|July 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Elective surgical patients|July 2012|July 5, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634828||83183|
NCT01663207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta Cell - Protocol 1c|Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes|Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes||Foundation for the National Institutes of Health|No|Completed|May 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|20|||Both|30 Years|65 Years|No|Probability Sample|obese individuals with prediabetes|August 2012|July 14, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663207||81064|
NCT01663220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beta Cell - Protocol 1d|Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus|Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus||Foundation for the National Institutes of Health|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Anticipated|20|||Both|30 Years|65 Years|No|Probability Sample|obese individuals with type 2 diabetes mellitus|August 2013|August 13, 2013|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663220||81063|
NCT01663415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-UC-0001|A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer||Astellas Pharma Inc|No|Withdrawn|August 2012|October 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Male|N/A|N/A|No|||September 2012|September 14, 2012|August 9, 2012|No|Yes|A business decision was made to not initiate this study.|No||https://clinicaltrials.gov/show/NCT01663415||81048|
NCT01663428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-00776|Sup-ER Splint for Children With Birth Related Brachial Plexus Injury|Sup-ER Splinting: Does Early Passive Positioning in Supination and External Rotation in Children With Birth Related Brachial Plexus Injury Have Benefit?||University of British Columbia|No|Withdrawn|July 2012|August 2019|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|6 Weeks|8 Weeks|No|||August 2013|August 28, 2013|August 9, 2012||No|It was decided to change the study from a cohort to a randomized controlled trial.|No||https://clinicaltrials.gov/show/NCT01663428||81047|
NCT01663688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCT RS-3000|Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye|Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis||Nidek Co. LTD.|No|Completed|July 2012|August 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|279|||Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Normal subject eyes|January 2014|January 16, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01663688||81027|
NCT01664273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA 1201|Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer|Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer||Copenhagen University Hospital at Herlev|Yes|Terminated|July 2012|May 2015|Anticipated|May 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||June 2014|June 19, 2014|July 16, 2012||No|Production of the IMP (plasmid AMEP) has been terminated by the supplier (BioAlliance Pharma)|No||https://clinicaltrials.gov/show/NCT01664273||80983|
NCT01664247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-3944|The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification|The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification||Novo Nordisk A/S|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|346|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664247||80985|
NCT01664949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11002X-001|A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease|||Allergan|No|Completed|January 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|460|||Both|18 Years|N/A|No|||September 2015|September 8, 2015|August 10, 2012|Yes|Yes||No|May 22, 2015|https://clinicaltrials.gov/show/NCT01664949||80947|
NCT01664962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|920080002|Search for Genetic Basis of Vulvodynia|||Western Galilee Hospital-Nahariya||Completed|November 2008|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|168|||Female|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with Vulvodynia, Normal healthy controls|August 2012|August 13, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01664962||80946|
NCT01665274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCPCT1205/repeat|Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer|A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection|repeat|Harbin Medical University|Yes|Suspended|September 2013|December 2020|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|70 Years|No|||March 2015|March 29, 2015|August 5, 2012||No|we are working on a larger similar multicenter cinical trials as a participant.so in order to    avoid conflicts of interest, we have to suspended this project.|No||https://clinicaltrials.gov/show/NCT01665274||80922|
NCT01665287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300712FORVOS|Cerebral Oximetry in Newborns - Comparing INVOS 5100 and FORE-SIGHT Cerebral Oximeters|Cerebral Oximetry in Newborns - Comparing INVOS 5100 and FORE-SIGHT Cerebral Oximeters Absolute Values, Sensitivity for Low Oxygen Levels and Reproducibility..||Rigshospitalet, Denmark|No|Completed|August 2012|November 2012|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|||Both|N/A|2 Minutes|Accepts Healthy Volunteers|Non-Probability Sample|Term infants born by elective cesarian section.|January 2013|January 14, 2013|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665287||80921|
NCT01665261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2011-366-1|Newborn Screening for Congenital Heart Disease|Accuracy Assessment of 7 Clinical Indicators in Newborn Screening for Congenital Heart Disease|NSCHD|Children's Hospital of Fudan University|Yes|Completed|July 2012|February 2013|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6730|||Both|N/A|72 Hours|No|Probability Sample|All consecutive neonates including pre-mature neonates and symptomatic neonates) will be        recruited prospectively from two collaboration hospitals of the ongoing projects— "Key        Clinical Research Project Sponsored by Ministry of Health Screening, evaluation and        intervention of congenital heart disease in newborn infants(2010-239)"|March 2015|March 10, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01665261||80923|
NCT01665586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0927|Effective Dose of Dexmedetomidine for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia With or Without Fentanyl by Age Groups: Randomized Comparative Study|||Yonsei University|No|Completed|March 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|82|||Male|45 Years|85 Years|No|||July 2014|July 24, 2014|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01665586||80899|
NCT01634295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130HT11P|Efficacy and Safety of CKD-828 to Stage 2 Hypertension|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension||Chong Kun Dang Pharmaceutical|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634295||83223|
NCT01634308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA05-CP01|Efficacy and Safety of Bongros-BMP Compared to Bio-oss for Regeneration of Alveolar Bone Tissue After Maxillary Sinus Floor Augmentation|||Daewoong Pharmaceutical Co. LTD.||Completed|June 2010|June 2012|Actual|June 2012|Actual|Phase 3|Interventional|N/A|2||||||Both|40 Years|70 Years|No|||July 2012|July 12, 2012|July 3, 2012||||No||https://clinicaltrials.gov/show/NCT01634308||83222|
NCT01634321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_LP1M002P|The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty|The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study||Daewoong Pharmaceutical Co. LTD.||Completed|July 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|63|||Both|4 Years|9 Years|No|||August 2014|August 1, 2014|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634321||83221|
NCT01634620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AER-042|Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease|Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease||Aerocrine AB|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|200|||Both|40 Years|N/A|No|Non-Probability Sample|Patients from the UNC Hospital Outpatient Pulmonary Function Laboratory in Chapel Hill, NC        and approximately 3 to 6 outpatient clinics associated with UNC who meet the        inclusion/exclusion criteria|January 2014|January 15, 2014|July 3, 2012||No||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01634620||83199|
NCT01665989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000824|Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study|Improving Diabetes Outcomes Through Lifestyle Change (IDOLc) Translation Study|IDOLc|Massachusetts General Hospital|Yes|Completed|August 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|N/A|No|||September 2015|September 23, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01665989||80868|
NCT01666262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPO FLU VACCINE-01|Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais|Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais||Mahidol University|Yes|Completed|September 2009|January 2012|Actual|||Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|363|||Both|9 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|January 11, 2010||No||No||https://clinicaltrials.gov/show/NCT01666262||80847|
NCT01666847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21429|Milking the Umbilical Cord for Extreme Preterm Infants|Milking the Umbilical Cord for Extreme Preterm Infants||St. Louis University|Yes|Active, not recruiting|October 2012|March 2017|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|N/A|Accepts Healthy Volunteers|||September 2015|September 22, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666847||80802|
NCT01662622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK20120301|Minimal Alveolar Concentration of Sevoflurane Inducing Isoelectric Electroencephalogram|Minimal Alveolar Concentration of Sevoflurane Inducing Isoelectric Electroencephalogram||Huazhong University of Science and Technology|Yes|Completed|March 2012|July 2012|Actual|May 2012|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|45 Years|65 Years|No|||August 2012|August 12, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662622||81109|
NCT01666821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-E-1|A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population|A Population-based Study of Macular Choroidal Neovascularization Using Optical Coherence Tomography in a Chinese Population||Shanghai University of Traditional Chinese Medicine|Yes|Completed|May 2004|January 2009|Actual|September 2008|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|59|||Both|45 Years|N/A|Accepts Healthy Volunteers|Probability Sample|recruited 1813 adults citizens aged above 45 years by probability sampling from the Youyi        Street, Baoshan District, Shanghai, China for an epidemiologic survey. All participants        gave written informed consent, and this study was approved by the local Ethics Committee        in accordance with the Helsinki Declaration.|August 2012|August 14, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666821||80804|
NCT01662596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0044-12-HYMC|Detection of Risk Factors for Fetal Anomalies in a Rural Hospital Population|Detection of Risk Factors for Fetal Anomalies in a Rural Hospital Population||Hillel Yaffe Medical Center|Yes|Not yet recruiting|August 2012|August 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|320|||Female|N/A|N/A|No|Probability Sample|Pregnant women who address the emergency room, Ultrasound unit or foreign clinics.|August 2012|August 8, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662596||81111|
NCT01663233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2319|Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine|A Randomized, 8-week, Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 5 mg Monotherapy Treatment||Novartis|Yes|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|266|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|August 8, 2012||No||No|July 21, 2015|https://clinicaltrials.gov/show/NCT01663233||81062|
NCT01663454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|bhø_2011/2271|Working Memory Training in Children With Cerebral Palsy, a Pilot Study|Computer Based Working Memory Training in Children With Cerebral Palsy, a Pilot Study||Helse Stavanger HF|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|7 Years|8 Years|No|||October 2014|October 7, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663454||81045|
NCT01663441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL201-Ⅲ-2012|A Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11|Multicenter, Randomized Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11 to Prevent Chemotherapy-induced Thrombocytopenia in Cancer Patients Receiving Chemotherapy.||Beijing Northland Biotech. Co., Ltd.|Yes|Active, not recruiting|March 2015|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|300|||Both|18 Years|75 Years|No|||March 2015|March 23, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663441||81046|
NCT01663701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSSP-2|Simplified Severe Sepsis Protocol-2 (SSSP-2) in Zambia|Simplified Severe Sepsis Protocol-2 (SSSP-2): A Randomized Controlled Trial of a Bundled Intervention for Severe Sepsis at the University Teaching Hospital in Zambia|SSSP-2|Vanderbilt University|Yes|Not yet recruiting|August 2012|September 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|212|||Both|18 Years|N/A|No|||August 2012|August 12, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663701||81026|
NCT01664494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25281|An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer|A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer||Hoffmann-La Roche||Completed|April 2010|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|664|||Both|18 Years|N/A|No|Probability Sample|Patients metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced        gastric cancer or breast cancer receiving Xeloda|October 2015|October 1, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664494||80982|
NCT01664507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Croup_01|The Effect and Safety of Low Dose Nebulized Epinephrine in Croup|The Effect and Safety of Low Dose Nebulized Epinephrine in the Treatment of Croup||Seoul National University Hospital|Yes|Not yet recruiting|September 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|132|||Both|6 Months|5 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01664507||80981|
NCT01656174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DENVTS-US12-001|Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross|Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross||Gen-Probe, Incorporated|No|Completed|August 2012|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35035|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|volunteer blood donors from Puerto Rico|March 2015|March 19, 2015|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656174||81599|
NCT01664260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iklnac|Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder|Elucidation of Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder: An 8-week Multimodal Neuroimaging and Neurocognitive Study||Ewha Womans University|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|20 Years|65 Years|No|||September 2015|September 17, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664260||80984|
NCT01664975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|hnslblzlzx2011-3|Treatment of Peripheral T-cell Lymphoma|A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )||Zhengzhou University|No|Recruiting|August 2011|December 2019|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|14 Years|70 Years|No|||July 2015|July 15, 2015|August 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01664975||80945|
NCT01665573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120303009906|Cannabinoid Augmentation of Fear Response in Humans|Cannabinoid Augmentation of Fear Response in Humans||Yale University|Yes|Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Anticipated|75|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 25, 2015|July 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01665573||80900|
NCT01665300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1106-026-365|Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity|Usefulness of Myocardial Deformation Imaging in Breast Cancer Patients Treated With Trastuzumab for Early Detection of Myocardial Dysfunction||Seoul National University Hospital|No|Completed|July 2011|April 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|120|Samples With DNA|genetic susceptibility for HER2(+)cardiotoxicity|Female|18 Years|75 Years|No|Non-Probability Sample|The investigators evaluated serial echocardiograms (baseline, 3, 6, 9, and 12 months)from        120 consecutive female patients receiving trastuzumab as part of their treatment for        either early or advanced breast cancer.|April 2014|April 26, 2014|December 13, 2011||No||No||https://clinicaltrials.gov/show/NCT01665300||80920|
NCT01665833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNTAX|Impact of Coronary Anatomy on Angina Relief in Patients Undergoing Coronary Revascularization|A Retrospective Analysis Determining the Impact of Coronary Anatomy on Angina Relief in Patients Undergoing Coronary||North Texas Veterans Healthcare System||Completed|January 2003|December 2011|Actual|December 2011|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|4000000|||Both|N/A|N/A|No|Non-Probability Sample|We propose all patients between January 1, 2003 and December 31, 2011 who underwent an        uncomplicated coronary revascularization with PCI and/or CABG for chronic stable angina        within the VA. The data set that includes this information is the same as was used for        study 09-018 (VA-CAP Study).|August 2012|August 13, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665833||80880|
NCT01635166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT11/01|Multi-centre Study to Assess the Long-term Performance of the Deltamotion Cup System in Primary Hip Replacement Surgery|A Multi-centre, Prospective, Uncontrolled Post Market Clinical Follow-up Study (PMCFS) to Monitor the Survival and Performance of the DeltaMotion Cup System in Subjects Requiring a Total Hip Replacement||DePuy International|No|Recruiting|July 2012|March 2024|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|18 Years|75 Years|No|||July 2014|September 8, 2014|February 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01635166||83157|
NCT01635478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|emcap2011|A Observational Study of Assessment and Treatment Adequacy of Emergency Cancer Pain in Tertiary Cancer Hospital|A Prospective Observational Study of Assessment of Emergency Cancer Pain and Its Treatment Adequacy in Emergency Department of Tertiary Care Cancer Hospital.||Tata Memorial Hospital|Yes|Completed|April 2011|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|ADULT CANCER PATIENTS REPORTING TO EMERGENCY ROOM WITH COMPLAINTS PRIMARILY OF PAIN.|July 2012|July 4, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635478||83133|
NCT01635452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL10-014|A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (Ulipristal Acetate) as Pre-operative Treatment of Moderate to Severe Symptoms of Uterine Fibroids||PREMYA|PregLem SA|No|Active, not recruiting|May 2012|March 2016|Anticipated|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|1500|||Female|18 Years|N/A|No|Non-Probability Sample|The target study population will include women who have had a diagnosis of symptomatic        uterine fibroids and are initiating preoperative treatment with ESMYA.|January 2015|January 26, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01635452||83135|
NCT01635465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-LSF-201205001|Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer|A Randomised Controlled Phase II Trial of Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer.||Tianjin Medical University Cancer Institute and Hospital|Yes|Not yet recruiting|November 2016|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|120|||Female|18 Years|N/A|No|Probability Sample|120|July 2012|December 21, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01635465||83134|
NCT01666002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Onycho-2012|Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser|Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser||Stanford University|No|Recruiting|September 2011|November 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 22, 2012|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666002||80867|
NCT01666015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RF-CACICPES01|Exercise in Pediatric Autologous Stem Cell Transplant Patients|Exercise in Pediatric Autologous Stem Cell Transplant Patients: A Randomized Controlled Trial Protocol|SCORE|University of Calgary|Yes|Recruiting|June 2012|July 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|24|||Both|5 Years|18 Years|No|||July 2012|August 15, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01666015||80866|
NCT01662648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR013534|Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia||Janssen Pharmaceutica|No|Completed|June 2007|April 2009|Actual|April 2008|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1117|||Both|18 Years|N/A|No|||April 2014|April 17, 2014|August 8, 2012|Yes|Yes||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01662648||81107|
NCT01662635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCAN/CC/039/11|Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)|CLINICOPATHOLOGICAL FEATURES OF NON-SMALL CELL LUNG CANCER PATIENTS ASSOCIATED WITH THE CHOROMOSOME 2p (EML4-ALK) INVERSION IN MEXICAN POPULATION.|ALK|Instituto Nacional de Cancerologia de Mexico|No|Completed|February 2011|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|230|Samples With DNA|FISH studies were performed in 3-mm to 4-mm thick paraffin sections from 230 NSCLCs and 1      ALCL specimen with t(2;5) that was used as a positive control for the break-apart detection.      48 patients were analyzed for the presence of EML4-ALK gene fusion variants using the RNA      from frozen tissue sections|Both|18 Years|N/A|No|Non-Probability Sample|Mexican pupulation, with Non small-cell lung cancer.|September 2014|November 14, 2014|August 8, 2012||No||No|September 23, 2014|https://clinicaltrials.gov/show/NCT01662635||81108|There were no limitations in obtaining the planned number of samples. Two-hundred and thirty patients with advanced NSCLC were analyzed by FISH. Among the FISH tests performed, 30 were not evaluable due to scarce samples.
NCT01662921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APIDRL06229|Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes|Non-inferiority Trial Comparing Insulin Glulisine to Insulin Lispro as Part of a Basal-bolus Insulin Regimen for the Treatment of Gestational Diabetes.||William Sansum Diabetes Center|No|Active, not recruiting|April 2013|October 2017|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Female|18 Years|N/A|No|||May 2015|May 18, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662921||81086|
NCT01662934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUBH_GO_004|A Randomized, Sham Device Controlled, Single Blinded Trial of Portable Transcutaneous Electrical Nerve Stimulation and Heat Therapy Machine in Women With Dysmenorrhea|||Seoul National University Hospital|Yes|Active, not recruiting|August 2012|April 2013|Anticipated|April 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|118|||Female|20 Years|N/A|No|||March 2013|March 14, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662934||81085|
NCT01663467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH_YHK_TRT|Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy|Efficacy of Internet and Smartphone Application-delivered TRT||Seoul National University Hospital|No|Not yet recruiting|September 2014|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|20 Years|65 Years|No|||May 2014|May 13, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663467||81044|
NCT01663714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|104514|Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.|Phase II Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.||GlaxoSmithKline|Yes|Completed|February 2000|February 2012|Actual|February 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2013|March 14, 2013|August 9, 2012|Yes|Yes||No|September 20, 2012|https://clinicaltrials.gov/show/NCT01663714||81025|
NCT01663961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-059|A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178|An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of Digoxin in Healthy Subjects||Astellas Pharma Inc|No|Completed|September 2008|December 2008|Actual|December 2008|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|25|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01663961||81006|
NCT01656434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P06448|Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)|A Phase III, Randomized, Open-label, Active-controlled, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate - 17ß-estradiol) in Healthy, Sexually-active Women Aged 18-50 Years||Merck Sharp & Dohme Corp.|No|Terminated|November 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3173|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 12, 2015|July 31, 2012|Yes|Yes|Business reasons|No|February 9, 2015|https://clinicaltrials.gov/show/NCT01656434||81580|
NCT01664728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR016912|An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001|An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001||Janssen Research & Development, LLC|No|Completed|April 2007|September 2012|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|54|||Male|18 Years|N/A|No|||April 2013|April 18, 2013|August 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01664728||80964|
NCT01664715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL19775|A Randomized Trial of Recommendations for Exercise to Prevent Weight Regain|A Randomized Trial of Recommendations for Exercise to Prevent Weight Regain||University of Kansas Medical Center|Yes|Recruiting|August 2012|April 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|287|||Both|21 Years|55 Years|No|||December 2014|December 4, 2014|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664715||80965|
NCT01665313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|attention_SNUH|Comparison of Attention of Physician After Outpatient Clinic|Comparison of Performance, Attention, and Emotion of Physician Before and After Outpatient Clinic Session||Seoul National University Hospital|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|46|||Both|30 Years|59 Years|Accepts Healthy Volunteers|Probability Sample|physicians with outpatient clinic sessions in Seoul National University Hospital|July 2013|July 25, 2013|July 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01665313||80919|
NCT01665599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000023|A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel|A Phase 3, Open-label, Non-randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males||Ferring Pharmaceuticals|No|Completed|July 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|180|||Male|18 Years|75 Years|No|||December 2015|December 2, 2015|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665599||80898|
NCT01665612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FI-2012|The Clinical and Subjective Performance of Three Different MPDS With Silicon Hydrogel Lenses|The Evaluation of the Clinical and Subjective Performance of Three Different Contact Lens Care Solutions With Silicon Hydrogel Lenses||Finnsusp Ltd.|Yes|Completed|August 2012|||January 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|3||Actual|40|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01665612||80897|
NCT01635491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20100267|Gastrointestinal Transit Times and Motility in Healthy Volunteers Obtained by Motilis-3D-transit|Gastrointestinal Transit Times and Motility in Healthy Volunteers Obtained by Motilis-3D-transit||University of Aarhus|Yes|Completed|April 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy Volunteers|December 2012|December 6, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01635491||83132|
NCT01635764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-555|Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa|A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)|PIONEER (OLE)|AbbVie|No|Active, not recruiting|April 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|540|||Both|18 Years|99 Years|No|||January 2016|January 25, 2016|March 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01635764||83111|
NCT01635777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z015|Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)|||AB Foundation|No|Completed|July 2007|December 2010|Actual|October 2009|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|12 Years|65 Years|No|||July 2012|July 9, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635777||83110|
NCT01665742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNS-5|Anti-inflammatory Dietary Intervention in Overweight and Obese Adolescents|Novel Anti-inflammatory Dietary Intervention to Improve the Metabolic Phenotype of Overweight and Obese 13-18 Year Old Adolescents - Insights Into Potential Genetic Susceptibility||University College Dublin|No|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|13 Years|18 Years|No|||December 2014|December 5, 2014|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01665742||80887|
NCT01665755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/456/C|To Determine Optimal Time for Delivering Electrical Shocks to Cardiac Arrest Patients|A Multicenter Randomised Controlled Trial Comparing Shock Success With Synchronized Defibrillation (Compression Upstroke Versus Precompression) During Ongoing Mechanical Cardiopulmonary Resuscitation In The Emergency Department||Singapore General Hospital|Yes|Not yet recruiting|January 2016|June 2017|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|21 Years|N/A|No|||November 2015|November 17, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01665755||80886|
NCT01666535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REMICADEIBD4010|Infliximab IBD Influenza Vaccine Study|Effect of Influenza Vaccination Timing on Immune Response in Patients With Inflammatory Bowel Disease on Infliximab Therapy: A Randomized Equivalence Trial||University of Calgary|No|Not yet recruiting|August 2012|August 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|180|||Both|9 Years|60 Years|No|||August 2012|August 10, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01666535||80826|
NCT01666886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 12/30/243|Efficacy of Additional Titration During Oral Appliance Treatment for Sleep-disordered Breathing.|Efficacy of Additional Titration During Oral Appliance Treatment for Sleep-disordered Breathing.||University Hospital, Antwerp||Recruiting|August 2012|||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 19, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666886||80799|
NCT01662973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302-005|Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis|Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Primary Biliary Cirrhosis||Beijing 302 Hospital|Yes|Recruiting|October 2011|October 2013|Anticipated|October 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||May 2013|May 30, 2013|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01662973||81082|
NCT01662986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.478|Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2|A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 2)||Boehringer Ingelheim||Completed|August 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|79|||Both|40 Years|N/A|No|||July 2015|July 17, 2015|August 9, 2012||||No|April 24, 2015|https://clinicaltrials.gov/show/NCT01662986||81081|The original protocol planned to randomize 604 subjects. However this was not reached due to low patient enrollment.
NCT01662947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wrist BPM TMB-1117|Clinical Study of Wrist Blood Pressure Monitor in Conformance With the ANSI/AAMI SP10 Standard|Verify Wrist BPM TMB-1117 to Comply With ANSI/AAMI SP10|WristBPM01|BTS International|No|Completed|May 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 8, 2012|August 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01662947||81084|
NCT01662960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH R01 HD068565|Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke|Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke||Albert Einstein Healthcare Network|No|Enrolling by invitation|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|40 Years|80 Years|No|||June 2015|June 22, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662960||81083|
NCT01663480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAVA3|To Identify the Proportionality of Respiratory Work Under Different NAVA Level|Assessment of Patient-ventilator Breath Contribution (PVBC) During Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Acute Respiratory Failure||Southeast University, China|Yes|Completed|March 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|||Both|18 Years|80 Years|No|Probability Sample|patient with respiratery failure need mechinical ventilation, and will be tolerance short        time loe level support ventilation|July 2014|July 28, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663480||81043|
NCT01663727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO25632|Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer||Hoffmann-La Roche||Active, not recruiting|August 2012|January 2019|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|481|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 9, 2012|Yes|Yes||No|January 12, 2016|https://clinicaltrials.gov/show/NCT01663727||81024|The results represent the data up to primary completion date (30 Nov 2014).
NCT01663974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NFR-XXX-2012/1|Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar Disorder|Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar Disorder|POLARIS|AstraZeneca|No|Terminated|April 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|125|||Both|18 Years|N/A|No|Probability Sample|hospital/medico-psychological centre (CMP) [clinic] / private practice|March 2015|March 6, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01663974||81005|
NCT01663987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.477|Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1|A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 1)||Boehringer Ingelheim||Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|79|||Both|40 Years|N/A|No|||June 2015|June 17, 2015|August 9, 2012||||No|May 1, 2015|https://clinicaltrials.gov/show/NCT01663987||81004|The original protocol planned to randomize 604 subjects, however this was not reached due to low patient enrollment. All results are descriptive only.
NCT01656447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|26069|Scleroderma Registry & Repository at the Hospital for Special Surgery|The Scleroderma Registry & Repository||Hospital for Special Surgery, New York|No|Recruiting|August 2006|||January 2030|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Research bloods will be collected if the patient gives permission. These bloods can be      donated at the time of a patient's private visit with a physician at Hospital for Special      Surgery, or at an independent research visit.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All individuals older than 18 years of age who have Scleroderma|February 2016|February 17, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656447||81579|
NCT01656733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-057-6|Nicotine Replacement for Smoking Cessation During Pregnancy|Nicotine Replacement for Smoking Cessation During Pregnancy||University of Connecticut Health Center|Yes|Recruiting|December 2010|November 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|360|||Female|16 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 6, 2014|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656733||81557|
NCT01664988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|muscular relaxation|Effect of Muscular Relaxation and Breathing Technique on Blood Pressure in Pregnancy|||Mashhad University of Medical Sciences||Terminated|February 2010|February 2012|Actual|September 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Female|18 Years|40 Years|No|||August 2012|August 15, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01664988||80944|
NCT01657266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOPH155-0412/II|Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification|Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients||Laboratorios Sophia S.A de C.V.|Yes|Recruiting|December 2013|June 2014|Anticipated|May 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01657266||81516|
NCT01657825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0033|Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Warfarin in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657825||81473|
NCT01657578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 051043|Optimal Dosing of Omeprazole in Neonates|Optimal Dose and Population Pharmacokinetics of Omeprazole in Neonates With Gastroesophageal Reflux Disease (GERD)|OMEPRAZOLE-1|Assistance Publique - Hôpitaux de Paris|Yes|Completed|June 2007|February 2012|Actual|December 2010|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|55|||Both|35 Weeks|N/A|No|||July 2012|October 10, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657578||81492|
NCT01657591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17013|Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma|Phase I Study of Escalating Doses of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|July 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657591||81491|
NCT01657838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0040|Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects|A Phase 1, Randomized, Open-Label, Two-Arm, Parallel Group Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657838||81472|
NCT01634932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fe_Biofortified_Millet|Iron Absorption From Regular, Biofortified and Post-harvest Fortified Pearl Millet|Comparison of Iron Absorption From Regular-iron, Iron Biofortified, and Post-harvest Iron-fortified Pearl Millet Using Multiple Meals in Young Women||Swiss Federal Institute of Technology||Completed|July 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|22|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||November 2012|November 7, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634932||83175|
NCT01635205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPG 110082|Paraspinous Anesthetic Block for Non-Responsive Pelvic Pain|Efficacy of Paraspinous Anesthetic Block in Patients With Chronic Pelvic Pain Non-Responsive to Pharmacological Treatment||Hospital de Clinicas de Porto Alegre|Yes|Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||April 2014|April 23, 2014|December 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01635205||83154|
NCT01666288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000683|The Metabolomics of Anaphylaxis to Immunotherapy|The Metabolomics of Anaphylaxis to Immunotherapy||Massachusetts General Hospital|No|Recruiting|April 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|Samples With DNA|Plasma will be collected and retained from whole blood samples that are spun.|Both|18 Years|75 Years|No|Non-Probability Sample|Patients ages 18-75, undergoing routine outpatient subcutaneous environmental allergen        and/or venom immunotherapy|September 2015|September 21, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666288||80845|
NCT01666548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KEK-ZH-Nr. 2011-0394|Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects|Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects||University Children's Hospital, Zurich|No|Completed|February 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|89|Samples Without DNA|urine, native-blood, blood plasma, EDTA stabilized blood, heparin blood|Both|2 Months|17 Years|No|Probability Sample|children and youth from 2 months to 17 years in who had suffered from haemolytic uraemic        syndrome|September 2013|September 3, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01666548||80825|
NCT01654731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100109|Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis|Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy.|BEZURSO|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|69 Years|No|||October 2015|October 8, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01654731||81706|
NCT01662999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV181-191|Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants|A Single-dose, Open-label, Randomized, 3 Period, 3 Treatment Crossover Study to Evaluate the Pharmacokinetics of Saxagliptin 5 mg and Dapagliflozin 10 mg When Coadministered to Fasted Healthy Subjects||AstraZeneca|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|42|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 21, 2015|August 9, 2012|No|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01662999||81080|
NCT01663012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-24833|Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma|A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma||Stanford University|Yes|Completed|July 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|August 2, 2012|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01663012||81079|
NCT01663246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005.097|Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer|Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer||University of Michigan Cancer Center|Yes|Completed|April 2006|December 2008|Actual|October 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 14, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01663246||81061|
NCT01655420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20112124|Patient Reported Outcomes With LASIK: PROWL-2|Patient-Reported Outcomes With LASIK: PROWL-2|PROWL-2|Food and Drug Administration (FDA)|No|Completed|July 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|21 Years|84 Years|No|Non-Probability Sample|Individuals age of 21 to 84 years planning to undergo refractive surgery using LASIK for        myopia, hyperopia, or astigmatism|February 2014|February 13, 2014|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01655420||81657|
NCT01655667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015/11|Comorbidities and Healthcare Utilisation: Indicators for Improving COPD Diagnosis|Improving Diagnosis of COPD Through Characterisation of Comorbidities Present at, and Healthcare Utilisation Prior to, Diagnosis of COPD in UK. A Retrospective Primary Care Database.||Research in Real-Life Ltd|Yes|Completed|December 2010|June 2012|Actual|February 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|38859|||Both|40 Years|N/A|No|Non-Probability Sample|Subjects aged 40 years or older, with an electronically coded diagnosis of COPD made        between 1990 and 2009, a minimum of three years continuous practice data including two        years prior to and one year post diagnosis to ensure patients recieved COPD therapy post        diagnosis (defined as two or more prescriptions for COPD therapies in the 12 months post        diagnosis year 1). COPD therapies included short- and long-acting bronchodilators, inhaled        corticosteroids, theophylline and leukotriene receptor antagonists.|August 2012|August 1, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655667||81638|
NCT01655680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-855|A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers||AbbVie|Yes|Completed|May 2012|July 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|432|||Both|20 Years|65 Years|No|||April 2015|April 28, 2015|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655680||81637|
NCT01655940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB11-00256|Cerebral Oximeter Comparison Study|Comparison of the FORE-SITE and INVOS Cerebral Oximeters During Cardiac Surgery||Nationwide Children's Hospital|No|Completed|May 2011|December 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|N/A|N/A|No|Non-Probability Sample|Cardiac bypass patients having surgery at Nationwide Children's Hospital|July 2012|August 1, 2012|May 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01655940||81617|
NCT01656161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Debio 8206-SC-301|Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer|A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer||Debiopharm International SA|No|Completed|July 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Male|N/A|N/A|No|||August 2015|August 13, 2015|July 31, 2012||No||No|August 13, 2015|https://clinicaltrials.gov/show/NCT01656161||81600|
NCT01657019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD489-345|Open Label Extension in Adults With Binge Eating Disorder (BED)|A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder||Shire||Completed|August 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|604|||Both|18 Years|55 Years|No|||December 2014|November 10, 2015|August 1, 2012|Yes|Yes||No|October 5, 2015|https://clinicaltrials.gov/show/NCT01657019||81535|
NCT01657032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB2010|Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis|Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis: A Double Blind Randomized, Placebo- Controlled Trial||Medical University of Warsaw|Yes|Completed|August 2010|October 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|3 Months|5 Years|No|||January 2010|February 14, 2014|July 5, 2012||No||No|November 20, 2013|https://clinicaltrials.gov/show/NCT01657032||81534|A potential limitation of our study is the lack of perfect blinding. Patients received smectite or placebo in identical packages from the hospital pharmacy. After being dissolved in water, they were of different colors.
NCT01656746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09123|Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease|Single Incision Laparoscopic Surgery (SILS) for Colorectal Disease - A Novel Approach||Ohio State University Comprehensive Cancer Center|Yes|Completed|May 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|80 Years|No|||November 2013|November 4, 2013|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656746||81556|
NCT01656993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|55107|Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts|Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts||University of Utah|Yes|Not yet recruiting|October 2012|April 2014|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|45|||Both|N/A|12 Months|No|Probability Sample|Infants undergoing cardiac surgery involving aortopulmonary and/or cavopulmonary shunts        with planned aspirin treatment|August 2012|August 29, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01656993||81537|
NCT01657279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMH 09-020|Clinician JUdgment Versus Risk Score to Predict Stroke outComes: The JURASSIC Clinical Trial|Clinician JUdgment Versus Risk Score to Predict Stroke outComes:|JURASSIC|St. Michael's Hospital, Toronto|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|111|||Both|20 Years|75 Years|No|||October 2012|October 27, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01657279||81515|
NCT01657890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0041|Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects|A Phase 1, Open Label, Parallel Group, Single Dose Study to Evaluate the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects||Astellas Pharma Inc|No|Completed|June 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|28|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 31, 2015|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657890||81468|
NCT01654263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0034|A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine|A Phase IIb, Open-Label, Dose-Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine||National Institute of Allergy and Infectious Diseases (NIAID)||Active, not recruiting|October 2012|March 2016|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|884|||Both|55 Years|74 Years|Accepts Healthy Volunteers|||July 2015|August 27, 2015|July 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01654263||81742|
NCT01634659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-033|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses||Alcon Research|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|330|||Both|18 Years|N/A|No|||November 2013|November 27, 2013|July 3, 2012|Yes|Yes||No|September 27, 2013|https://clinicaltrials.gov/show/NCT01634659||83196|
NCT01634945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IZ70Z0_123900/1|Efficacy of Iron Fortified Complementary Food and IPT of Malaria in Young Children in Côte d'Ivoire|Aetiology, Prevention and Control of Anaemia in Sub-Saharan Africa - Work Package 2: Efficacy Study: Efficacy of 2 Iron Fortified Porridges and IPT for the Prevention of Anemia in Young Children in Côte d'Ivoire.||Swiss Federal Institute of Technology|Yes|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|5||Actual|629|||Both|12 Months|36 Months|No|||September 2013|September 23, 2013|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634945||83174|
NCT01635218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HJM2030/12-A|Homeopathic Treatment for Depression in Peri- and Postmenopausal Women|Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol|HOMDEP-MENOP|Hospital Juarez de Mexico|Yes|Completed|March 2012|March 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|133|||Female|40 Years|65 Years|No|||September 2014|September 30, 2014|June 30, 2012||No||No|September 8, 2014|https://clinicaltrials.gov/show/NCT01635218||83153|
NCT01666301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epo-Loc1|ESAs, Reticulocyte Dynamic and Hemoglobin Variability|Reticulocyte Dynamic and Related Hemoglobin Variability in Hemodialysis Patients Treated With Darbepoetin Alfa and C.E.R.A.: a Randomized Controlled Trial||Ospedale Regionale di Locarno||Completed|February 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666301||80844|
NCT01666314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C21013|Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer|A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer||Millennium Pharmaceuticals, Inc.|No|Completed|September 2012|November 2013|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|137|||Male|18 Years|N/A|No|||January 2014|January 31, 2014|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666314||80843|
NCT01666873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/526|Correlation Between Alignment of Lower Limb and Clinical Outcome After Total Knee Prosthesis.|Correlation Between Alignment of Lower Limb and Clinical Outcome After Total Knee Prosthesis.||University Hospital, Ghent|No|Recruiting|September 2012|May 2016|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|People who have osteoarthritis of the knee joint and receive a total knee prosthesis.|December 2014|December 4, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666873||80800|
NCT01666574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12029 (Period 2)|The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake|The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake.||Pennington Biomedical Research Center|No|Completed|August 2012|July 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|47|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666574||80823|
NCT01654770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SA-001|A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy|A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding||King Chulalongkorn Memorial Hospital|No|Completed|October 2010|March 2012|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654770||81705|
NCT01663259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2009.078|Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients|Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients||University of Michigan Cancer Center|Yes|Recruiting|June 2010|January 2021|Anticipated|June 2020|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01663259||81060|
NCT01655693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA2011/03/04|Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma|Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.|ReLive|Onxeo|Yes|Recruiting|June 2012|December 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|390|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01655693||81636|
NCT01655953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLR Salty Life 8 Study|Changes in Acid Base Status During High Salt Intake||SL8|DLR German Aerospace Center||Completed|July 2007|August 2007|Actual|||N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|8|||Male|19 Years|35 Years|Accepts Healthy Volunteers|||July 2012|August 1, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01655953||81616|
NCT01655966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RAIL002|Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c|Vitamin D in Addition to Pegylated Interferon and Ribavirin Compared to Pegylated Interferon and Ribavirin Alone in the Treatment of Chronic Hepatitis C Genotype 4.||Cairo University|Yes|Active, not recruiting|May 2012|April 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||January 2014|January 28, 2014|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655966||81615|
NCT01656187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|032011-007|Attenuation of Corticosteroid Induced Hippocampal Changes|Attenuation of Corticosteroid Induced Hippocampal Changes||University of Texas Southwestern Medical Center|Yes|Recruiting|January 2012|June 2017|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|65 Years|No|||February 2016|February 3, 2016|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656187||81598|
NCT01665651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kidney Yin/Yang replenishment|Kidney Yin/Yang Replenishment on Patients With Renal Osteodystrophy|Effect of Kidney Yin/Yang Replenishment on Bone Metabolism in Patients With Renal Osteodystrophy||Shanghai University of Traditional Chinese Medicine|Yes|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|300|||Both|20 Years|50 Years|Accepts Healthy Volunteers|||August 2012|May 19, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01665651||80894|
NCT01657292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBW-11|Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds|Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds||Birken AG|No|Completed|August 2012|July 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|N/A|No|||August 2015|August 28, 2015|July 29, 2012||No||No|July 31, 2015|https://clinicaltrials.gov/show/NCT01657292||81514|
NCT01657305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSH-12|Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites|Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Wound Healing of Split Thickness Skin Graft Donor Sites||Birken AG|No|Completed|August 2012|September 2014|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|N/A|No|||April 2015|April 2, 2015|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01657305||81513|
NCT01657006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9581-IG-CTIL|HeartTrends Heart Rate Variability (HRV) Algorithm for the Diagnosis of Myocardial Ischemia|HeartTrends HRV Algorithm for the Diagnosis of Myocardial Ischemia||Sheba Medical Center|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Both|21 Years|N/A|No|Non-Probability Sample|The study will prospectively enroll consecutive patients, without known ischemic heart        disease, referred by their physician for an exercise MPI.|March 2015|March 18, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01657006||81536|
NCT01654016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Detra-001-Ajd|Study of Antiinflammatory Effects of Detralex (Daflon)|Study of Antiinflammatory Effects of Detralex (Daflon) in Patients With Chronic Venous Disease||University Hospital Dubrava|No|Enrolling by invitation|August 2012|May 2016|Anticipated|February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|84|||Both|18 Years|N/A|No|||June 2015|June 11, 2015|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654016||81761|
NCT01662440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V49_23|Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects|A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects.||Novartis|No|Completed|August 2012|October 2013|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|661|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|August 2, 2012|Yes|Yes||No|October 6, 2014|https://clinicaltrials.gov/show/NCT01662440||81123|
NCT01634672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GERD|Prevalence of Gastroesophageal Reflux Disease in Peritoneal Dialysis and Hemodialysis Patients|Prevalence of Gastroesophageal Reflux Disease in Peritoneal Dialysis and Hemodialysis Patients||Konyang University Hospital|Yes|Active, not recruiting|July 2010|October 2012|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|N/A|N/A|No|Probability Sample|patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis over        1 year were enrolled|July 2012|July 5, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634672||83195|
NCT01634685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 032012-025|A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma|A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma||University of Texas Southwestern Medical Center|Yes|Active, not recruiting|August 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|99 Years|No|||February 2016|February 29, 2016|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01634685||83194|
NCT01635543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-01890|Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas|Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas||University of British Columbia|Yes|Withdrawn|October 2011|October 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|19 Years|70 Years|No|Non-Probability Sample|Men and women ages 19-70 years old with Crohn's disease and sexually active in the last 4        weeks.|October 2013|October 16, 2013|June 27, 2012||No|This study was terminated due to some challenges in recruitment process|No||https://clinicaltrials.gov/show/NCT01635543||83128|
NCT01635829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100830|A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir|A Phase I, Open-label, Randomized, 2-panel, Sequential Treatment Study in Healthy Subjects to Investigate the Potential Pharmacokinetic Interactions Between Multiple Doses of Phenytoin or Carbamazepine and Telaprevir at Steady-state||Janssen Infectious Diseases BVBA|No|Completed|May 2012|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 23, 2013|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635829||83106|
NCT01666561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12029 (Period 1)|The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake.|The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake.|Quaker A|Pennington Biomedical Research Center|No|Completed|August 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|48|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666561||80824|
NCT01666860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/740|Long-term Follow-up of the Anterior Lumbar Interbody Fusion Procedure.|Long-term Follow-up of the Anterior Lumbar Interbody Fusion Procedure.||University Hospital, Ghent|No|Completed|November 2010|July 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|56|||Both|N/A|N/A|No|Non-Probability Sample|Patients who have an Anterior Lumbar Interbody Fusion Procedure as treatment for        degenerative disc disease.|August 2012|August 16, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666860||80801|
NCT01666899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.032|Effect of Radiation on Tissue for Delayed Breast Reconstruction|Effect of Radiation on Tissue for Delayed Breast Reconstruction||University of Michigan Cancer Center|Yes|Active, not recruiting|October 2012|February 2017|Anticipated|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Female|18 Years|75 Years|No|||March 2016|March 18, 2016|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666899||80798|
NCT01662661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100881|A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants|A Phase I, Open-Label, Randomized, 2-way Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of a Single Oral Dose of JNJ-47910382 Formulated as a Tablet and as a Suspension||Janssen R&D Ireland|No|Completed|July 2012|September 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|August 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01662661||81106|
NCT01662674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-DMCL002|BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered in Healthy Male Volunteers||LG Life Sciences|No|Completed|October 2012|March 2013|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01662674||81105|
NCT01655095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMED-1478-12|Improving Bowel Preparation for the Colon Capsule|Improving Bowel Preparation for the Colon Capsule: Picosalax and Prucalopride vs. PEG and Prucalopride||Queen's University|Yes|Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|20|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2015|November 30, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655095||81682|
NCT01655433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VMXP-2490|Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients|VELOCITY: Pilot Study to Evaluate Ultrafast Hypothermia Before Reperfusion in Patients With Acute ST-Elevation Myocardial Infarction|VELOCITY|Velomedix, Inc.|Yes|Terminated|November 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|85 Years|No|||July 2014|July 24, 2014|July 30, 2012|Yes|Yes|Sponsor business decision, not safety related|No||https://clinicaltrials.gov/show/NCT01655433||81656|
NCT01655979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESA-AO-06-BR|Medium-term Bedrest Whey Protein (MEP)||MEP|DLR German Aerospace Center||Completed|August 2011|||April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01655979||81614|
NCT01656200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JEV SA14-14-2/T cell/01|A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2|A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2||Indian Institute of Science|No|Completed|May 2012|March 2014|Actual|October 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|17|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 10, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01656200||81597|
NCT01656460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 259|Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer|Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer||Brown University|Yes|Active, not recruiting|April 2012|March 2017|Anticipated|March 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|12|||Both|18 Years|N/A|No|||November 2015|November 17, 2015|July 24, 2012|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01656460||81578|
NCT01656759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12032202-IRB01|Use of a Novel Fibrin Sealant in Total Knee Arthroplasty|Use of a Novel Fibrin Sealant in Total Knee Arthroplasty: A Prospective Randomized Controlled Clinical Trial||Rush University Medical Center|Yes|Completed|May 2012|August 2015|Actual|December 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|73|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|June 14, 2012||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT01656759||81555|
NCT01665885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HAIS-SE|Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE)|HAIS-SE (Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling): A Randomized Trial Comparing Surface Versus Endovascular Cooling in Awake Stroke Patients Treated With Thrombolysis|HAIS-SE|University Hospital Heidelberg|No|Active, not recruiting|August 2012|November 2015|Anticipated|August 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|90 Years|No|||June 2013|February 16, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665885||80876|
NCT01665872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010007484|New Haven MOMS Partnership|New Haven Mental Health Outreach for MotherS (MOMS) Partnership||Yale University|No|Recruiting|September 2011|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Female|16 Years|N/A|No|||February 2016|February 1, 2016|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665872||80877|
NCT01657604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML V|Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study|Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy|TIGER|University of Jena|Yes|Recruiting|August 2012|December 2020|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|652|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657604||81490|
NCT01657877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01381|Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice|In Situ Study to Confirm the Anti-caries Potential of a 1.1365% w/w Sodium Monofluorophosphate (1500ppm F) Dentifrice||GlaxoSmithKline|No|Completed|May 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|August 2, 2012|Yes|Yes||No|June 19, 2014|https://clinicaltrials.gov/show/NCT01657877||81469|
NCT01666418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ10ON01|Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel|||University of Zurich||Active, not recruiting|August 2012|May 2015|Anticipated|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01666418||80835|
NCT01666652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-23|A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults|A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in a Non-Endemic Region|DPIV-001|U.S. Army Medical Research and Materiel Command|Yes|Active, not recruiting|September 2012|February 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|100|||Both|18 Years|39 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|August 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01666652||80817|
NCT01662739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Donida-1|Population-Based Stomach Cancer Registry|Creation of a Population-Based Stomach Cancer Registry in the Cremona Province Area in Italy. Study of the Epidemiology, the Risk Factors and Clinical, Histological and Biomolecular Features of the Pathology.|GCR|Medicina e Arte Onlus|Yes|Recruiting|January 2010|||December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Blood and Cancer Tissue Sample|Both|N/A|N/A|No|Non-Probability Sample|Gastric Cancer|August 2012|July 11, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662739||81100|
NCT01635231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-JMJ-2012-1|The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects|Effect of Thiazide, Amiloride and Hypertonic Saline on Sodium- and Water Channel Activity in the Nephron in Healthy Subjects Estimated by Urinary Biomarkers|THAM|Regional Hospital Holstebro|Yes|Completed|July 2012|November 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic|3||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 1, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01635231||83152|
NCT01635244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N015029-00|Hemodynamic Comparison of Tissue Aortic Valves|Trifecta Comparative Stress Hemodynamic Study (Randomized Comparison of Exercise Hemodynamics and Left Ventricular Remodeling With Aortic Bioprostheses After Aortic Valve Replacement for Aortic Stenosis)||University of Michigan|No|Active, not recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|60|||Both|18 Years|N/A|No|||May 2015|May 26, 2015|July 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01635244||83151|
NCT01635556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:128|Evaluation of a Modified Dialectical Behavior Therapy Program|Evaluation of a Modified Dialectical Behavior Therapy Program for Borderline Personality Disorder||University of Manitoba|Yes|Active, not recruiting|September 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|24|||Both|18 Years|65 Years|No|Non-Probability Sample|The participants will be selected from the community.|November 2014|December 1, 2014|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01635556||83127|
NCT01666340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Generation-100|Generation 100: How Exercise Affects Mortality and Morbidity in the Elderly: A Randomized Control Study|Generation 100: How Exercise Affects Mortality and Morbidity in the Elderly: A Randomized Control Study|GEN100|Norwegian University of Science and Technology|Yes|Active, not recruiting|August 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|4000|||Both|70 Years|76 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01666340||80841|
NCT01654458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVA-120243|A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer|A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer||Women's College Hospital|No|Recruiting|July 2012|||February 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|520|||Female|18 Years|N/A|No|||December 2015|December 7, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654458||81727|
NCT01654250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWP09-ADHD-300|NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Multicenter, Dose-optimized, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy Of Nwp09 In Pediatric Patients With Attention Deficit Hyperactivity Disorder (Adhd) In A Laboratory Classroom||Pfizer|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|6 Years|12 Years|No|||January 2016|January 4, 2016|April 27, 2012|Yes|Yes||No|January 4, 2016|https://clinicaltrials.gov/show/NCT01654250||81743|
NCT01655706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0117-A|Canadian Biomarker Integration Network for Depression Study|Integrated Biological Markers for the Prediction of Treatment Response in Depression|CAN-BIND|University Health Network, Toronto|No|Recruiting|March 2013|August 2018|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|132|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|July 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655706||81635|
NCT01655719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.097|Pioglitazone in Thyroid Cancers|Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene||University of Michigan|Yes|Recruiting|April 2012|||April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01655719||81634|
NCT01655732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rabia|Effect of Atraumatic Restorative Treatment on Streptococcus Mutans Count in Saliva of Pregnant Women|Effect of Atraumatic Restorative Treatment on Streptococcus Mutans Count in Saliva of Pregnant Women, A Randomized Control Trial|ART|Sheikh Zayed Federal Postgraduate Medical Institute|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|94|||Female|N/A|N/A|No|||August 2012|August 13, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655732||81633|
NCT01655108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUB-UnB TrichoGroup 1|Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients|BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA||Brasilia University Hospital|No|Active, not recruiting|March 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|65 Years|No|||September 2013|September 23, 2013|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01655108||81681|
NCT01655446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012131RB|Effects of RR and MT on Patient With Stroke|Randomized Trials of Robotic Rehabilitation, Mirror Therapy, and Dose-Matched Control Intervention for Upper-Limb Rehabilitation in Patients With Chronic Stroke: Comparative Efficacy and Clinimetric Study||National Taiwan University Hospital|No|Recruiting|August 2011|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|100|||Both|40 Years|75 Years|No|||July 2012|July 29, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01655446||81655|
NCT01664767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTUNIFE01|Effects of Sulfur Thermal Water Inhalation on Airway Oxidative Stress in COPD Patients|Placebo Controlled Study Evaluating the Modulatory Effects of Sulfur Thermal Water Inhalation on Superoxide Anion Levels in Exhaled Breath Condensate in COPD Patients||Università degli Studi di Ferrara|No|Completed|November 2011|June 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|50 Years|80 Years|No|||December 2013|December 27, 2013|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664767||80961|
NCT01665040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A5004|Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain|Precision Spectra™ Neurostimulator System for the Treatment of Chronic Intractable Pain of the Trunk and/or Limbs||Boston Scientific Corporation|No|Recruiting|August 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2013|November 6, 2013|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01665040||80940|
NCT01665053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2067|The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)|EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)||Boston Scientific Corporation|Yes|Active, not recruiting|November 2012|August 2018|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|1684|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 7, 2012|Yes|Yes||No|December 1, 2015|https://clinicaltrials.gov/show/NCT01665053||80939|
NCT01665066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KINECIG UNICT 526 /12 (Polosa)|Pharmacokinetic Profile of Toxic Substances and Nicotine in Electronic Cigarettes|Pharmacokinetic Profile of Toxic Substances and Nicotine in Electronic Cigarettes: a Randomised Cross-over Trial KINECIG|KINECIG|Universita degli Studi di Catania|No|Completed|May 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||December 2012|December 12, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01665066||80938|
NCT01665365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|30685|Long-term Clinical Outcome in Patients Undergoing Remote Ischemic Conditioning Before Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Follow-up Study|Long-term Clinical Outcome in Patients Undergoing Remote Ischemic Conditioning Before Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Follow-up Study||University of Aarhus|Yes|Active, not recruiting|February 2007|December 2015|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|251|||Both|18 Years|N/A|No|||August 2013|April 13, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665365||80915|
NCT01665378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051384|Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes|Impact of Pre-Pregnancy Micronutrient Supplementation on Maternal and Child Outcomes||Emory University|No|Active, not recruiting|October 2011|September 2017|Anticipated|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|5011|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||February 2016|February 17, 2016|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665378||80914|
NCT01666431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SZ10ON03|Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment|||University of Zurich||Terminated|June 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01666431||80834|
NCT01666158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-171-SDR|Prehabilitation for Esophageal Resection Surgery|Prehabilitation to Enhance Postoperative Functional Capacity Following Esophageal Resection||McGill University Health Center|Yes|Recruiting|January 2013|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|68|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666158||80855|
NCT01662453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01664|Risk Factors for Sudden Unexplained Death in Epilepsy|Risk Factors for Sudden Unexplained Death in Epilepsy (SUDEP)|SUDEP|New York University School of Medicine|No|Recruiting|June 2011|||June 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|400|Samples With DNA|If the family is willing to donate tissue, the family's permission is recorded in writing      and it is filed in the subject's study record. The family can contact Autism Tissue Program      (ATP) themselves or we will transfer the call to the ATP for them. The ATP has a 24/7 on      call duty in place to receive new donors. The ATP coordinator will facilitate the donation      process by coordinating with the family, medical examiner's office or hospital. The      coordinator will also communicate to the research assistant when the donation is complete.      In the case the participant does not want to donate tissue, but would like to donate other      DNA samples, they will be able to do so through the NYU Biorepository. The participant will      be consented, by research personnel, with the specific DNA collection consent form. Mucosal      swaps or blood samples will be collected if available, if neither is available, we will      collect hair or nails.|Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|The SUDEP group consists of epileptic patients who had a sudden unexplainable death        excluding trauma, drowning, status epilepticus, or other known cause, but there is often        evidence of an associated seizure.|October 2015|October 5, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01662453||81122|
NCT01662765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-003-UPS|Conservative Versus Surgical Treatment of Umbilical Pilonidal Disease|Conservative Versus Surgical Treatment of Umbilical Pilonidal Sinus Disease: A Prospective, Randomised, and Multicenter Clinical Trial||Medical Park Gaziantep Hospital|Yes|Completed|November 2003|May 2012|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|N/A|N/A|No|||August 2012|August 9, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662765||81098|
NCT01663103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0586|Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)|Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)||University of Colorado, Denver|Yes|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|38|||Both|18 Years|80 Years|No|||March 2016|March 8, 2016|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663103||81072|
NCT01634984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-ZHJ-201205001|The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer|The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|January 2012|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|500|||Female|N/A|N/A|No|Probability Sample|500 patients with breast cancer|January 2012|December 21, 2015|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01634984||83171|
NCT01634997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL2722|Evaluation of SCOUT DS Device in the Diagnosis of Diabetes|An Evaluation of the SCOUT DS Device. Random Capillary Glucose and Leicester Diabetes Risk Score for Screening Subjects at Risk for Type 2 Diabetes||VeraLight, Inc.|No|Recruiting|June 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|330|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects must be 18 years of age or older|July 2012|July 3, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634997||83170|
NCT01635569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01656|Clinical Outcomes in Pediatric Obsessive-Compulsive Disorder|Clinical Outcomes Following Group-based Family Cognitive-Behaviour Therapy in Pediatric Obsessive-Compulsive Disorder (OCD)||University of British Columbia|No|Recruiting|October 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|5 Years|18 Years|No|||November 2015|November 30, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01635569||83126|
NCT01635868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABSNOME|The Effect of Sutures Versus Mesh in Umbilical Hernia Repair|Long Term Recurrence and Chronic Pain After Repair for Small Umbilical or Epigastric Hernias. A Regional Cohort Study.|ABSNOME|Hvidovre University Hospital|No|Completed|December 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1313|||Both|18 Years|N/A|No|Non-Probability Sample|all patient having mesh or sutured repair of small (> 2 cm) umbilical or epigastric        hernias in the region of Zealand from 1th of January 2008 to 31th of December 2010.|February 2014|February 19, 2014|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635868||83103|
NCT01635881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2228|Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter|EMERGE: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm Percutaneous Transluminal Coronary Angioplasty (PTCA) Dilatation Catheter||Boston Scientific Corporation|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||October 2013|October 14, 2013|May 25, 2012|Yes|Yes||No|August 9, 2013|https://clinicaltrials.gov/show/NCT01635881||83102|
NCT01666600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NONK-3/NOA-12|NOA-12: BIBF1120 and R-RT in Glioblastoma|A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma||University Hospital Heidelberg|Yes|Recruiting|August 2012|September 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01666600||80821|
NCT01654471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WIQ-SNU|Validation of the Korean Version of the Walking Impairment Questionnaire in Patients With Peripheral Arterial Disease|Validation of the Korean Version of the Walking Impairment Questionnaire in Patients With Peripheral Arterial Disease||Seoul National University Hospital|Yes|Completed|August 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|47|||Both|19 Years|80 Years|No|Probability Sample|Patients with peripheral arterial disease|November 2014|November 19, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654471||81726|
NCT01664065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3720C00012|A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects|An Open-label, Nonrandomised, Phase I Study to Assess the Pharmacokinetics of Ceftaroline After Intravenous Administration of aSingle Dose of Ceftaroline Fosamil (200 mg) to Patients With End-stage Renal Disease Undergoing Haemodialysis When Compared to a Single Dose of Ceftaroline Fosamil (600 mg)||AstraZeneca||Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 16, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664065||80998|
NCT01655121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-501-11/12-1|Effect of High-protein High-fiber Diet in Patients With Autoimmune Hepatitis|Effect of a High-protein High-fiber Diet and Nutritional Status, Serum Ammonia Concentration and Plasma Cytokines in Patients With Autoimmune Hepatitis||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|No|Completed|January 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|20 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 18, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01655121||81680|
NCT01664559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRHR 5K12001259-12 - toradol|Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement|Pain Control for Intrauterine Device Placement: A Randomized, Double Blind Control Trial of Ketorolac Prior to Intrauterine Device Placement.||University of California, San Diego|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|June 28, 2012|No|Yes||No|July 22, 2015|https://clinicaltrials.gov/show/NCT01664559||80977|
NCT01664572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012A00458-35|Methodological Issues and Laser Speckle Contrast Imaging|Methodological Issues of Laser Speckle Contrast Imaging for Studying Microcirculation.|METHODO-LSCI|University Hospital, Angers|No|Recruiting|June 2012|July 2014|Anticipated|November 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|45|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Residents of France|August 2012|August 9, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01664572||80976|
NCT01665079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Propofol TCI obese|Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response|Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response.||Universidad del Desarrollo|Yes|Completed|April 2011|November 2011|Actual|November 2011|Actual|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|14|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01665079||80937|
NCT01665092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM103799|Rapid Administration of Carnitine in sEpsis|Phase 2 Study of Levo-Carnitine for Vasopressor Dependent Septic Shock|RACE|University of Mississippi Medical Center|Yes|Recruiting|January 2013|June 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|250|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|August 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665092||80936|
NCT01665391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1008FSGS03110|A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)|A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis|FSGS|Sanofi|Yes|Completed|August 2012|November 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665391||80913|
NCT01665664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0014-12-WOMC|Hypocaloric vs. Full Energy Enteral Feeding in Critically Ill Patients|Hypocaloric vs. Full Energy Enteral Feeding in Critically Ill Patients Guided by Indirect Calorimetry, a Prospective, Blinded, Randomized Controlled Trial.||Wolfson Medical Center|No|Not yet recruiting|September 2012|October 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665664||80893|
NCT01666171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALGB-A211201|Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32|Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32||National Cancer Institute (NCI)||Not yet recruiting|August 2012|||April 2013|Anticipated|N/A|Observational|N/A|||Anticipated|458|||Female|18 Years|74 Years|No|||January 2013|July 9, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666171||80854|
NCT01666184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T3212|Biomarkers Study in Pancreatic Cancer|Biomarkers Study in Pancreatic Cancer||National Health Research Institutes, Taiwan|No|Enrolling by invitation|September 2012|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|270|Samples With DNA|The specimen and clinical information will be collected and delivered to the laboratory of      Dr. Hui-Ju Ch'ang over NICR, NHRI, Tainan .|Both|20 Years|75 Years|No|Probability Sample|We expect to collect tissue samples from 270 pancreatic cancer patients of resectable        pancreatic cancer. Since the enrollment criteria are not limited to new patients, we        expect to enroll 67 patients a year. The patient enrollment will be completed in 4 years.        Clinical follow-up will be completed in another one year. Data analysis and correlation        study may be finished in the end of 5th year of this study.|August 2012|August 14, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666184||80853|
NCT01666444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-3003|VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||VentiRx Pharmaceuticals Inc.|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|290|||Female|18 Years|N/A|No|||January 2016|January 5, 2016|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666444||80833|
NCT01666678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16135|Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination|A Bioavailability Study of Naproxen Sodium and Diphenhydramine Hydrochloride Under Fasting Conditions and Naproxen Sodium and Diphenhydramine Hydrochloride Combination Under Fasting and Fed Conditions|Morpheus PK|Bayer|No|Completed|January 2012|March 2012|Actual|February 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Actual|32|||Both|18 Years|55 Years|No|||August 2014|August 20, 2014|August 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01666678||80815|
NCT01666665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-142|Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin|Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin||The University of Texas Medical Branch, Galveston|Yes|Recruiting|November 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|10 Years|19 Years|No|||February 2016|February 9, 2016|August 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01666665||80816|
NCT01662479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-025|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2012|||||N/A|N/A|N/A||||||||||||||November 13, 2012|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662479||81120|
NCT01662492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|191622-103|A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine|||Allergan|Yes|Recruiting|August 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|126|||Both|12 Years|17 Years|No|||January 2016|January 27, 2016|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662492||81119|
NCT01662752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/32/2012|Lymphatic Mapping for Sentinel Node Identification and Analysis|A Study to Assess Near Infrared Laparoscopy With Indocyanine Green (ICG) for Intraoperative Lymphatic Imaging and Sentinel Lymph Node Identification During Standard Surgical Resection for Colonic Cancer||Imperial College London|Yes|Completed|May 2013|October 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662752||81099|
NCT01662791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006817|Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth|Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth||Mayo Clinic|No|Completed|September 2012|March 2015|Actual|January 2015|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662791||81096|
NCT01635257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|080974|Accuracy of Multi-organ Ultrasound for the Diagnosis of Pulmonary Embolism|Accuracy of Multi-organ Ultrasound (Venous, Cardiac and Thoracic) for the Diagnosis of Pulmonary Embolism: Suspected Pulmonary Embolism Sonographic Assessment (SPES) Multicenter Prospective Study|SPES|Azienda Ospedaliero-Universitaria Careggi|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|357|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients more than 18 years presenting to three emergency departments with clinical        suspected pulmonary embolism. Clinical suspected pulmonary embolism is defined as new        onset or worsening dyspnea, chest pain, syncope or shock/Hypotension without an        alternative obvious cause|March 2013|March 14, 2013|July 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01635257||83150|
NCT01663506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28311|A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|April 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|23|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra        (tocilizumab)|November 2015|November 3, 2015|August 8, 2012|No|Yes||No|November 3, 2015|https://clinicaltrials.gov/show/NCT01663506||81041|
NCT01664013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT_IT_010|The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients|The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients||Chulalongkorn University||Recruiting|October 2012|||October 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||August 2013|August 18, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01664013||81002|
NCT01664533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25708|An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy|Prospective, Open-label, Multicenter, National, Non-interventional Phase IV Trial of the Effectiveness, Safety and Tolerability of Tarceva as Second-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC), After Failure of First-line Treatment With a Pemetrexed-containing Chemotherapy Regimen|TIME|Hoffmann-La Roche||Completed|September 2011|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|57|||Both|18 Years|N/A|No|Probability Sample|Patients with locally advanced or metastatic non-small cell lung cancer initiated on        second-line Tarceva therapy after first-line pemetrexed-containing chemotherapy.|November 2015|November 23, 2015|August 10, 2012||No||No|October 9, 2015|https://clinicaltrials.gov/show/NCT01664533||80979|
NCT01664546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Funsare - 001|Study of the Best Blastocyst Post Transfer by aCGH|Study of the Best Blastocyst Post Transfer by aCGH||University of Buenos Aires|No|Not yet recruiting|September 2012|September 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|Removed cells from human trophectoderm|Both|21 Years|50 Years|No|Non-Probability Sample|Adult patients who require IVF/ICSI procedure to achieve pregnancy|August 2012|August 14, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01664546||80978|
NCT01654224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO10110247|Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting|Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting||University of Pittsburgh|Yes|Completed|November 2011|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|205|||Both|65 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 6, 2015|July 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654224||81745|
NCT01663792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAMD-17-98-1-8207|Dietary Seaweed and Early Breast Cancer: A Randomized Trial|Dietary Seaweed and Early Breast Cancer: A Randomized Trial||University of South Carolina|No|Completed|October 2006|December 2007|Actual|December 2007|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|15|||Female|45 Years|68 Years|Accepts Healthy Volunteers|||January 2016|January 14, 2016|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663792||81019|
NCT01664806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0049|Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin|Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode and Thermal Injury to Tissue Adjacent to Port Sites||University of Colorado, Denver|No|Completed|November 2010|May 2012|Actual|August 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|40|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 18, 2013|August 10, 2012||No||No|January 25, 2013|https://clinicaltrials.gov/show/NCT01664806||80958|This is a pilot study with no funding so data is limited.
NCT01655992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2012-09 CBCSG011|A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)|A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer.||Fudan University|No|Active, not recruiting|January 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|386|||Female|18 Years|75 Years|No|||December 2015|December 24, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01655992||81613|
NCT01664780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARFI-UK Erlangen|Acoustic Radiation Force Impulse Imaging (ARFI) in Patients After Liver Transplantation|Acoustic Radiation Force Impulse Imaging (ARFI) in Patients After Liver Transplantation||University of Erlangen-Nürnberg Medical School|No|Recruiting|May 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|Patients after orthotopic liver transplantation|August 2012|August 13, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664780||80960|
NCT01664793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U01IP000321-01|From Innovation to Solutions: Childhood Influenza Vaccination Planning|From Innovation to Solutions: Autodialers, Use of Early Autumn Physicals and Vaccination Assessment as a Vital Sign to Increase Childhood Influenza Vaccination in Diverse Settings||University of Pittsburgh|No|Completed|October 2010|November 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|87665|||Both|6 Months|18 Years|Accepts Healthy Volunteers|||November 2014|November 21, 2014|August 2, 2012||No||No|May 27, 2014|https://clinicaltrials.gov/show/NCT01664793||80959|2 offices of 1 practice were randomized to each arm potentially causing carryover of the intervention.
NCT01665677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00021090|Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation|Phase II Study of Atorvastatin, Micro-dose Methotrexate and Tacrolimus Administered Only to Transplant Recipients for the Prophylaxis of Acute Graft-versus-host Disease Following Allogeneic Hematopoietic Cell Transplantation||Medical College of Wisconsin|Yes|Active, not recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2015|September 3, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665677||80892|
NCT01665898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IncheonSMH|Comparing Cold Biopsy Forceps Versus Cold Snare Biopsy for Colon Polyps|Randomized Controlled Trial Comparing Cold Biopsy Forceps Versus Cold Snare Biopsy for Colon Polyps||Incheon St.Mary's Hospital|Yes|Completed|August 2012|March 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|138|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01665898||80875|
NCT01665911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-I-086|An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy|An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy||Indiana University|No|Completed|August 2012|June 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)|5||Actual|28|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2015|February 3, 2015|August 7, 2012|Yes|Yes||No|August 5, 2014|https://clinicaltrials.gov/show/NCT01665911||80874|
NCT01666197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|853-P-401|Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain||Novartis|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|August 14, 2012||No||No|February 12, 2014|https://clinicaltrials.gov/show/NCT01666197||80852|
NCT01666210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTX-12-002|Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery|A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase II Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery||Ocular Therapeutix, Inc.|No|Completed|October 2012|August 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|21 Years|N/A|No|||November 2013|November 19, 2013|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666210||80851|
NCT01666457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-13949 Horner|Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the Neonatal ICU (NICU)|The Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the NICU||Ann & Robert H Lurie Children's Hospital of Chicago|No|Completed|September 2009|||September 2011|Actual|N/A|Observational|Time Perspective: Prospective||2|Actual|156|||Both|3 Months|5 Months|No|Non-Probability Sample|Convenience sample of NICU infants discharged home prior to the implementation of the        SOFFI will be compared to a convenience sample of NICU infants discharged home following        the implementation of the SOFFI.|August 2012|August 16, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01666457||80832|
NCT01666470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Chula-ARC 001/12|Quality of Life of Patients With a History of Drug Allergy in Thailand|Quality of Life of Patients With a History of Drug Allergy in Thailand||Chulalongkorn University|No|Recruiting|August 2012|October 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|Thai patients with a history of drug allergy|January 2016|January 31, 2016|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01666470||80831|
NCT01666691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZAF-201|An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects|Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 Weeks||Zafgen, Inc.|Yes|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|160|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 21, 2013|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01666691||80814|
NCT01662466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|072312-01|Effect of Testosterone Treatment on Embryo Quality|A Randomized Double Blind Control Trial of Transdermal Testosterone Supplementation vs Placebo on Follicular Development and Atresia, Oocyte and Embryo Quality Among Women With Diminished Ovarian Reserve Undergoing in Vitro Fertilization||Center for Human Reproduction|Yes|Recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Female|38 Years|44 Years|No|||January 2016|January 11, 2016|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662466||81121|
NCT01662505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1230.26|Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)|An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia||Boehringer Ingelheim||Completed|August 2012|May 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|August 8, 2012||||No||https://clinicaltrials.gov/show/NCT01662505||81118|
NCT01662778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1694|The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma|The Clinical Effect in Asthma of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols||Imperial College London|Yes|Completed|December 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|No|||August 2012|February 15, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662778||81097|
NCT01663350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VER-0007|Comparison of Aneuploidy Risk Evaluations|Performance of the Verinata Health Prenatal Aneuploidy Test Compared to Current Fetal Aneuploidy Screening Results and Pregnancy Outcomes in an 'All‐Risk' Population|CARE|Verinata Health, Inc.|No|Completed|July 2012|||July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3000|Samples With DNA|Plasma|Female|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of pregnant women at least 18 years of age, who meet the        study eligibility criteria. Women who plan or have already completed prenatal screening        for fetal aneuploidy during first and/or second trimester, will be recruited from approved        participating clinical centers.|July 2013|July 12, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01663350||81053|
NCT01662687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-SCSCL002|Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)|Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy||LG Life Sciences|No|Recruiting|February 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|276|||Both|20 Years|N/A|No|||August 2012|August 15, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662687||81104|
NCT01662700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FTM1202|Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand|An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand||Mahidol University|No|Recruiting|October 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||January 2013|January 24, 2013|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662700||81103|
NCT01664026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PWeb123|Efficacy of a Web-based Lifestyle Modification Program in Obese Patients With Cardiovascular Risk Factors|A 6-Month, Randomized Study to Evaluate the Efficacy of a Web-based Lifestyle Modification Program With and Without Telephone Counseling Support||Clínica Bazterrica|No|Active, not recruiting|August 2012|December 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|350|||Both|25 Years|70 Years|No|||August 2012|August 10, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01664026||81001|
NCT01664039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-244|An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®|Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma||Alcon Research|No|Completed|September 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|August 10, 2012|No|Yes||No|June 19, 2015|https://clinicaltrials.gov/show/NCT01664039||81000|
NCT01665339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Effect of preload on weight|Preload, Weight Management, Risk of Cardiovascular Disease|Effect of Preload on Body Weight and Cardiovascular Risks||Isfahan University of Medical Sciences|No|Completed|September 2011|December 2011|Actual|December 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01665339||80917|
NCT01663805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR21T|Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population|Effects of the Use of "de Novo" Everolimus for the Expression of Cytokines in Kidneys From Extended Criteria Donors and With Delayed Graft Function||Instituto de Urologia e Nefrologia|No|Recruiting|January 2012|June 2015|Anticipated|December 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|65 Years|No|||April 2012|August 9, 2012|April 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663805||81018|
NCT01654003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 09-044 B|Impact of Early Goal-directed Fluid Therapy in Septic Patients Undergoing Emergency Surgery|Impact of Early Goal-directed Fluid Therapy in Septic Patients Undergoing Emergency Surgery. A Prospective, Randomised, Open Trial||University Hospital, Geneva|Yes|Recruiting|April 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01654003||81762|
NCT01654237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|123ERGON|Musculoskeletal Complaints in an Industry|Factors That Influence the Prevalence of Musculoskeletal Complaints Among Workers in Different Sectors of an Industry|FIPMCAWMI|University of Sao Paulo General Hospital|Yes|Completed|October 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|185|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 31, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654237||81744|
NCT01664598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28124|An Extension Study of WA19926 of the Long-Term Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Completed|May 2012|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|49|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01664598||80974|
NCT01664611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNOLE 0306|Daily REmote Ischaemic Conditioning Following Acute Myocardial Infarction|The DREAM Study (Daily Remote Ischaemic Conditioning Following Acute Myocardial Infarction)|DREAM|University of Leicester|No|Recruiting|September 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|80 Years|No|||August 2012|December 4, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01664611||80973|
NCT01664624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROF-T2D_107|Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes|A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin||Takeda|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|80 Years|No|||January 2014|January 22, 2014|August 10, 2012|No|Yes||No|November 25, 2013|https://clinicaltrials.gov/show/NCT01664624||80972|
NCT01664585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12006|Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life|EXERCISE TRAINING WITH PHYSICALLY ACTIVE LIFESTYLE TO REDUCE HEADACHE AND INCREASE QUALITY OF LIFE. A Randomised Controlled Trial of the Effectiveness and Cost-effectiveness of Exercise Training and Physical Activity on Chronic Headache|HEADEX|UKK Institute|No|Active, not recruiting|September 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|120|||Female|18 Years|60 Years|No|||May 2015|May 26, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01664585||80975|
NCT01665404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28250|A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers|A Single-Center, Open-Label, One-Sequence, Crossover Study to Investigate the Effects of Multiple Doses of Fluvoxamine on the Pharmacokinetics of a Single Dose RO4917523 in Healthy Subjects||Hoffmann-La Roche||Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665404||80912|
NCT01665417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IC-IV08|Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma|Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|August 2012|July 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|70 Years|No|||July 2015|July 14, 2015|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01665417||80911|
NCT01665690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|29923-J|Washington State Community Expedited Partner Treatment (EPT) Trial|A Community-level RCT of Expedited Partner Treatment for Gonorrhea and Chlamydia||University of Washington|No|Completed|July 2007|August 2011|Actual|December 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|33222|||Both|14 Years|N/A|No|||August 2012|August 15, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665690||80891|
NCT01666223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-049|Effect of Bile Acids on GLP-1 Secretion|Effect of Bile Acids in the Gut on GLP-1 Secretion in Healthy Subjects and Patients With Type 2 Diabetes||University Hospital, Gentofte, Copenhagen|Yes|Completed|November 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|4||Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 21, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01666223||80850|
NCT01666483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P/473/CE/2011|Micro-laparoscopy and Single-port Hysterectomy|Micro-laparoscopic Versus Single-port Total Hysterectomy: a Randomized Trial.|MLPS/LESS|Catholic University of the Sacred Heart|Yes|Completed|May 2011|May 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|71|||Female|18 Years|75 Years|No|||August 2012|August 14, 2012|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01666483||80830|
NCT01666730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1212|Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer|A Phase II Study of Metformin Plus Modified FOLFOX 6 in Patients With Metastatic Pancreatic Cancer||Case Comprehensive Cancer Center|Yes|Recruiting|February 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666730||80811|
NCT01662518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bramets-01|DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)|A Safety and Efficacy Study to Assess DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)|DDS-25|Centro de Pesquisa Rubens Siqueira|No|Recruiting|July 2011|January 2015|Anticipated|November 2014|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||July 2014|July 22, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662518||81117|
NCT01662531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSL654_3002|A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B|A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B||CSL Behring||Completed|September 2012|||October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Male|N/A|11 Years|No|||November 2015|November 5, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662531||81116|
NCT01666704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MB121-010|Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis|A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Effects of BMS-823778 on Atherosclerotic Plaque Inflammation as Measured by Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET) in Patients With Atherosclerotic Cardiovascular Disease||Bristol-Myers Squibb|No|Withdrawn|April 2014|May 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|80 Years|No|||June 2013|June 19, 2013|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666704||80813|
NCT01666717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML4355_VOC|Characterization of Disease Related Changes in Inflammatory Bowel Disease Using Fecal Metabolite Profiling|Characterization of Disease Related Changes in Inflammatory Bowel Disease Using Fecal Metabolite Profiling||Katholieke Universiteit Leuven|No|Completed|August 2008|May 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|204|Samples With DNA|Fecal samples|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary care clinic|August 2012|August 16, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666717||80812|
NCT01662804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-116|Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors|Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors||Memorial Sloan Kettering Cancer Center||Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|13 Months|N/A|No|||November 2015|November 23, 2015|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01662804||81095|
NCT01663142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-API-02|Early Postoperative Recurrence in Crohn's Disease: Predictors of Research Targeting the Constitutional Mutation of IRGM|Early Postoperative Recurrence in Crohn's Disease: Predictors of Research Targeting the Constitutional Mutation of IRGM||Centre Hospitalier Universitaire de Nice|No|Recruiting|October 2010|December 2017|Anticipated|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Lesional tissue samples and healthy in cryotubes, taken from surgical specimens or biopsies.|Both|18 Years|N/A|No|Non-Probability Sample|Sick to benefit from ileal, colonic or ileocolic continuity with re Cohn proved a        complicated disease (stenosis or fistula) or resistant to medical treatment well led|May 2010|October 30, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01663142||81069|
NCT01663857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12517|A Study of LY2228820 for Recurrent Ovarian Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer||Eli Lilly and Company|No|Recruiting|September 2012|February 2018|Anticipated|February 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Anticipated|116|||Female|18 Years|N/A|No|||March 2016|March 8, 2016|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663857||81014|
NCT01663272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.105|A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer|A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer||University of Michigan Cancer Center|Yes|Active, not recruiting|July 2012|||January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|18 Years|N/A|No|||March 2016|March 18, 2016|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663272||81059|
NCT01663493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000955/1|Comparing Methods to Biopsy Pancreas Mass|Randomized Noninferiority Trial Comparing Diagnostic Yield of Cytopathologist-guided Versus 7 Passes During EUS-FNA of Solid Pancreatic Masses||Brigham and Women's Hospital|No|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|140|||Both|18 Years|100 Years|No|||October 2015|October 23, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663493||81042|
NCT01665352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTP054-201|A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin||vTv Therapeutics|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|186|||Both|18 Years|70 Years|No|||April 2015|April 14, 2015|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665352||80916|
NCT01663597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHTH-240512|Optical Biometry and Spherical Aberration in Ametropic and Emmetropic Eyes|Optical Biometry and Spherical Aberration in Ametropic and Emmetropic Eyes||Medical University of Vienna||Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|160|||Both|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants will be selected by the Department of Clinical Pharmacology|August 2013|August 28, 2013|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663597||81034|
NCT01655459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0800|Evaluation of the LMA Position Using Ultrasound in Pediatric Patients|||Yonsei University|No|Completed|January 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|100|||Both|1 Year|6 Years|No|Non-Probability Sample|Following Internal Review Board approval(4-2011-0800) and written informed consent, total        100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular        urologic surgeries were included in the study. Children with upper respiratory tract        infection, restricted mouth opening, congenital heart disease and those at risk for        aspiration were excluded.|July 2012|July 29, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01655459||81654|
NCT01663545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120182|Brain P-gp and Inflammation in People With Epilepsy|Positron Emission Tomography Measurement of Neuroinflammation and P-glycoprotein in Localization-Related Epilepsy||National Institutes of Health Clinical Center (CC)||Recruiting|July 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663545||81038|
NCT01664104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28336|An Observational Study to Evaluate RoActemra/Actemra (Tocilizumab) Treatment in a Real-Life Setting|CRP and BMI Study: Evaluation in Real Life of Clinical Remission Rate and Correlation Between CRP and BMI in Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis treated with RoActemra/Actemra according to routine        clinical practice.|March 2015|March 2, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01664104||80995|
NCT01664832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULMN_SIMV|Is Synchronization More Effective During Noninvasive Ventilation in Immediately Extubated Preterm Infants?|Is Synchronization More Effective During Noninvasive Ventilation in Immediately Extubated Preterm Infants?|N_SIMV|University of Ulm|No|Recruiting|July 2012|||September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|18|||Both|N/A|N/A|No|||June 2013|June 26, 2013|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01664832||80956|
NCT01665105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB2-101|Study on the Effect of Electroacupuncture at Both Zusanli and at Both Yanglingquan Acupoints on Cardiovascular Activity|Study on the Effect of Electroacupuncture at Both Zusanli and at Both Yanglingquan Acupoints on Autonomic Nerve Modulating Cardiovascular Activity , and Skin Blood Flow and Skin Temperature||China Medical University Hospital|No|Completed|July 2012|May 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|24|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 11, 2013|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01665105||80935|
NCT01665118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-TS05|The Trusculpt (Radio Frequency) Device For Thigh Circumference Reduction|The Cutera Trusculpt Device For Thigh Circumference Reduction||Cutera Inc.|No|Completed|August 2012|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 9, 2015|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665118||80934|
NCT01665131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUBTRACT 1|The Use of Subcutaneous Implantable Cardiac Defibrillators (ICDs) Following Extraction of Conventional ICDs|The Use of Subcutaneous Implantable Cardiac Defibrillators (ICDs) Following Extraction of Conventional ICDs|SUBTRACT|Guy's and St Thomas' NHS Foundation Trust|Yes|Not yet recruiting|November 2012|November 2015|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|90 Years|No|||August 2012|August 13, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01665131||80933|
NCT01665703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1213|Imaging Correlates of Renal Cell Carcinoma Biological Features|LCCC 1213: Defining Molecular and Functional Imaging Correlates of Renal Cell Carcinoma Biological Features||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|August 2012|August 2019|Anticipated|November 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|17|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01665703||80890|
NCT01665924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLPG0634-CL-104|Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects|Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects||Galapagos NV|No|Completed|July 2012|October 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|36|||Both|40 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 26, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01665924||80873|
NCT01665937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-072|STA-9090 in Patients With Advanced Hepatocellular Cancer|A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma||Massachusetts General Hospital|Yes|Completed|August 2010|March 2014|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2014|March 19, 2014|April 27, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01665937||80872|
NCT01666743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPT-MD-34|Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia|A Multicenter Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects With Community-Acquired Bacterial Pneumonia||Forest Laboratories|No|Withdrawn|November 2012|March 2014|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|65 Years|N/A|No|||February 2013|February 7, 2013|August 14, 2012|Yes|Yes|Change in strategy.|No||https://clinicaltrials.gov/show/NCT01666743||80810|
NCT01666756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11043|Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer|A Phase I Open Label Study Investigating the Combination of KD018 and Sorafenib (Nexavar) in Patients With Advanced Hepatocellular Carcinoma||City of Hope Medical Center|Yes|Active, not recruiting|May 2013|||December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|August 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01666756||80809|
NCT01662544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103-041|Heated High Flow Oxygen Use in Infants With Bronchiolitis and Hypoxia|Comparison of Heated Humidified High-flow Nasal Cannula (HHFNC) Versus Standard Nasal Cannula Oxygen Delivery on Respiratory Distress and Length of Stay in Infants With Bronchiolitis and Hypoxia|HHFNC|Children's Hospitals and Clinics of Minnesota|Yes|Recruiting|August 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|3 Months|18 Months|No|||April 2014|April 21, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662544||81115|
NCT01662830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MED 016|A Retrospective Chart Review of Three Medifast Weight Control Centers|Use of the Medifast Meal Replacement Program for Weight Loss in Obese Patients: A Restrospective Chart Review of Three Medifast Weight Control Centers (MWCC)||Medifast, Inc.|No|Completed|April 2010|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|446|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|This study was a systematic retrospective chart review of patients participating in the        Jump Start (5 & 1) Plan at three different MWCC locations in Texas during the years        2007-2010.|August 2012|August 8, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01662830||81093|
NCT01662817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13487|Major Depressive Disorder (MDD)|Effectiveness of Physicians' Education, Implementation and Follow up of Current Recommendations Regarding Screening for Major Depressive Disorder in High Risk Patients on Improving the Under-Recognition Rates of Depression in Primary Care||Eli Lilly and Company|No|Completed|September 2009|July 2010|Actual|July 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|525|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Primary Care Physicians are given the intervention of education to utilize on screened and        consented patient participants under the PCP care.|August 2012|August 8, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01662817||81094|
NCT01663363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STAR-110-IDMY|Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4IR™ Excimer Laser||Abbott Medical Optics|No|Completed|August 2012|July 2015|Actual|March 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|170|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|September 30, 2015|August 9, 2012|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01663363||81052|
NCT01663636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1144|SMS Mobile Technology for Vaccine Coverage and Acceptance|SMS Mobile Technology for Vaccine Coverage and Acceptance in Guatemalan Infants|Vaxtech|University of Colorado, Denver|No|Withdrawn|September 2012|June 2015|Actual|June 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|1 Month|12 Months|Accepts Healthy Volunteers|Non-Probability Sample|Infants under 12 months of age from Ministry of Health Clinics in Guatemala City|July 2015|July 24, 2015|August 8, 2012||No|not human subjects research, no subjects enrolled|No||https://clinicaltrials.gov/show/NCT01663636||81031|
NCT01665196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgG4RD-PET|18F-FDG PET/CT for IgG4-Related Disease|Evaluation of 18F-FDG PET/CT in Diagnosis and Response Assessment of Patients With IgG4-Related Disease||Peking Union Medical College Hospital|Yes|Recruiting|October 2010|March 2016|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|75 Years|No|||November 2014|November 1, 2014|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665196||80928|
NCT01665209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-455|Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets in Healthy Volunteers.||Ranbaxy Inc.|No|Completed|October 2006|December 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|24|||Both|19 Years|41 Years|Accepts Healthy Volunteers|||August 2012|August 13, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665209||80927|
NCT01663753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011.670/13|Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy|Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy|ERRICC|Hospices Civils de Lyon|No|Recruiting|January 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|148|||Female|18 Years|N/A|No|||January 2016|January 20, 2016|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663753||81022|
NCT01634516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HWU113821/UoE|Effectiveness of Mediterranean Diet Intervention in Pregnant Women|An Investigation of the Effectiveness of the Mediterranean Diet in Pregnant Women at Risk of Developing Allergy in Their Infants: Pilot Randomised Controlled Trial||Heriot-Watt University|Yes|Completed|May 2012|August 2014|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Female|16 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 30, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634516||83206|
NCT01634529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V158866-1Pa-01|Single and Multiple Ascending Dose Study of V158866 in Healthy Volunteers|A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of V158866 in Healthy Volunteers||Vernalis (R&D) Ltd|No|Completed|March 2011|July 2011|Actual|July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|July 21, 2011||No||No||https://clinicaltrials.gov/show/NCT01634529||83205|
NCT01663831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPP1032354|Repellents as Added Control Measure to Long Lasting Insecticidal Nets|Repellents as Added Control Measure to Long Lasting Insecticidal Nets to Target the Residual Transmission in Southeast Asia: a Step Forwards to Malaria Elimination|MalaResT|Institute of Tropical Medicine, Belgium|Yes|Completed|May 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|40000|||Both|2 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 31, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01663831||81016|
NCT01664117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28356|An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy|Study of Clinical Management and Profile of Patients With Rheumatoid Arthritis Treated With Biological Therapies in Monotherapy||Hoffmann-La Roche||Completed|June 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|210|||Both|18 Years|N/A|No|Probability Sample|Patients with moderate to severe rheumatoid arthritis|December 2015|December 1, 2015|August 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01664117||80994|
NCT01663558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23592103|Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV|Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV||United States Naval Medical Center, San Diego|No|Withdrawn|May 2015|May 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|0|||Male|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 14, 2015|August 9, 2012||No|funding not available|No||https://clinicaltrials.gov/show/NCT01663558||81037|
NCT01663571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-01293|STAT3 in T Cells: At The Crossroads of Inflammation and Cancer|STAT3 in T Cells: At The Crossroads of Inflammation and Cancer||New York University School of Medicine||Recruiting|May 2012|||April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Skin biopsy specimens from cutaneous T cell lymphoma (CTCL) patients and benign skin      conditions namely eczema, dermatitis and psoriasis will be obtained through a standard punch      biopsy procedure from the skin lesion. The investigators will assay the mRNA levels of the      transcription factors of the different T effector cells by qPCR.|Both|18 Years|N/A|No|Non-Probability Sample|Patients with Cutaneous T cell Lymphoma (CTCL), either newly diagnosed or with progression        of disease. Patients with Eczema, psoriasis and dermatitis are also eligible for the study|April 2015|April 13, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663571||81036|
NCT01664637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZP-102-CL-G004|Diabetic Gastroparesis Efficacy/Safety Study of TZP-102|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis|DIGEST|Tranzyme, Inc.|Yes|Terminated|August 2012|February 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|80 Years|No|||December 2012|December 18, 2012|August 10, 2012|Yes|Yes|Insufficient efficacy in planned interim futility analysis|No||https://clinicaltrials.gov/show/NCT01664637||80971|
NCT01665456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P141/03/2012|Assessing Childbirth-related Complications at the Community Level in Kenya|Assessing Childbirth-related Complications at the Community Level in Kenya: A Case Control Study Among Postpartum Women||Kenyatta National Hospital|Yes|Completed|August 2012|March 2014|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|585|None Retained|This was a two-arm study (Cases and controls). Random identification of cases through      cross-sectional survey was done. Then, a random sample of controls was drawn from the source      population from which the cases were selected (i.e. from same study base except that they      were not cases) through matching variables i.e. age and location. Individual matching of      controls to the characteristics of the cases was done. A total of 585 clients (women) were      recruited (294cases and 291 controls).|Female|15 Years|49 Years|Accepts Healthy Volunteers|Probability Sample|The study population consisted of women aged 15-49 years with a delivery within 12 months        preceding data collection date. A woman who reported having experienced a birth-related        complication was recruited as a case. A woman aged 15-49 years with a delivery within 12        months preceding data collection who report having experienced no complication during        child-birth was recruited as a control.|April 2014|April 25, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01665456||80909|
NCT01664819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0047247|Antioxidants for Prevention of Cataracts Follow-up Study|Antioxidants for Prevention of Cataracts Follow-up Study||University of California, San Francisco|No|Enrolling by invitation|July 2012|May 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|798|||Both|50 Years|65 Years|No|||December 2015|December 9, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664819||80957|
NCT01665144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBAF312A2304|Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.||Novartis||Active, not recruiting|December 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|1651|||Both|18 Years|60 Years|No|||January 2016|January 12, 2016|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665144||80932|
NCT01665430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28175|A Long-Term Extension Study to WA19926 of RoActemra/Actemra (Tocilizumab) in Patients With Early, Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients From Poland With Early, Moderate to Severe Rheumatoid Arthritis.||Hoffmann-La Roche||Completed|August 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01665430||80910|
NCT01666236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBPD952ABR01T|Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy|Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy.||Federal University of São Paulo|No|Withdrawn|September 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|50 Years|N/A|No|||August 2015|August 11, 2015|August 8, 2012||No|Lack of resources|No||https://clinicaltrials.gov/show/NCT01666236||80849|
NCT01666496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1208010715|An Interactive Game for HIV Prevention in Early Adolescents|An Interactive Video Game for HIV Prevention in Early Adolescents||Yale University|No|Active, not recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|333|||Both|11 Years|14 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01666496||80829|
NCT01663870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0450|Technology and Navigation to Improve Survivorship Care|Integrating Technology and Navigation to Improve Survivorship Care in Underserved Populations||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2013|||February 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Breast cancer survivors and stakeholders at LBJ General Hospital Cancer Survivorship        Clinic in Houston, Texas|January 2016|January 14, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663870||81013|
NCT01664169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A151201|Biomarkers in Plasma Specimens From Patients Treated on Study CALGB-80303|Validation of Circulating Biomarkers Using the Immunological Multiparameter Chip Technology (IMPACT) on Plasma Specimens Collected on CALGB 80303||Alliance for Clinical Trials in Oncology|No|Withdrawn||||||N/A|Observational|N/A|||Actual|0|||Both|18 Years|N/A|No|||August 2012|June 17, 2013|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664169||80990|
NCT01664663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLANET|Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy|Phase II Randomized Study on Locally Advanced Non Small Cell Lung Cancer Escalated Dose on Individual Basis Treatment With Radiochemotherapy|PLANET|Swedish Lung Cancer Study Group|Yes|Terminated|September 2011|October 2015|Anticipated|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|37|||Both|18 Years|80 Years|No|||December 2014|December 8, 2014|August 10, 2012||No|Safety analysis showed increased grade 5 toxicity in experimental arm.|No||https://clinicaltrials.gov/show/NCT01664663||80969|
NCT01663155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-455|Chest Imaging, Breath, and Biomarkers in a Screening Trial|A Clinical Trial to Develop Chest Imaging, Breath, and Biomarkers in a Screening Trial||The Cleveland Clinic|Yes|Completed|September 2008|May 2014|Actual|May 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1424|Samples With DNA|Blood draw includes 2 10 mL red top tubes for serum retrieval, and 2 7 mL EDTA tubes for      plasma and buffy coat retrieval|Both|40 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Primary care physicians or any other physician may refer potential candidates.        Additionally, subjects may see marketing materials and contact the research team directly.        There is no restriction to the area of residence of subjects.|July 2015|July 27, 2015|November 10, 2008|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663155||81068|
NCT01665222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAI-US-456|Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets in Healthy Volunteers.||Ranbaxy Inc.|No|Completed|October 2006|December 2006|Actual|October 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|26|||Both|20 Years|53 Years|Accepts Healthy Volunteers|||August 2012|August 13, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665222||80926|
NCT01665235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RenJiH-20120804|Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis|The Correlation Study Between Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis||RenJi Hospital|Yes|Recruiting|August 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||August 2012|August 14, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665235||80925|
NCT01634178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-CP-022|Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects|A Phase 1, Open-Label, Randomized, Two-Period, Two-Sequence Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a Single 30 mg Tablet of Apremilast (CC-10004) in Healthy Subjects||Celgene|No|Completed|February 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|46|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|July 5, 2012|July 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01634178||83232|
NCT01634191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-CP-024|Pharmacokinetics of Apremilast (CC-10004) in Healthy Elderly Subjects|An Open-Label, Single-Dose Study to Evaluate the Effects of Age and Sex on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects||Celgene|No|Completed|February 2012|April 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|36|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||June 2012|July 5, 2012|July 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01634191||83231|
NCT01634204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KiloCoach|Efficacy of a Web-based Weight Loss Program|Is the Support of a Web-based Weight Loss Program Effective in Supporting Self-initiated Weight Loss and Lifestyle Changes?||Charite University, Berlin, Germany|No|Active, not recruiting|September 2011|July 2013|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Both|30 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 5, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634204||83230|
NCT01663844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/934-31/4|New Clinical Applications for Internet-based Cognitive Behavior Therapy for Insomnia and Depression|New Clinical Applications for Internet-based Cognitive Behavior Therapy: An Adaptive Treatment Strategy to Decrease the Number of Failed Treatments, and a Combination Treatment for Insomnia and Depression.||Karolinska Institutet|No|Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|440|||Both|18 Years|N/A|No|||September 2015|September 1, 2015|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01663844||81015|
NCT01664143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WP28102|A Single-Center Study of RO5508887 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects||Hoffmann-La Roche||Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 1, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01664143||80992|
NCT01664078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-4601|A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)|A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)|INSPIRATION|Cordis Corporation|Yes|Active, not recruiting|July 2012|August 2018|Anticipated|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|190|||Both|20 Years|N/A|No|||December 2014|December 31, 2014|August 9, 2012|Yes|Yes||Yes||https://clinicaltrials.gov/show/NCT01664078||80997|
NCT01665170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178 S11 PF|Pilot Study on the Efficacy of Pascoflair in an Acute Stressful Situation (TSST)|A Randomized, Double Blind, Placebo-controlled Pilot Study on the Efficacy of Passiflora Incarnata L. in an Acute Stressful Situation||Pascoe Pharmazeutische Praeparate GmbH|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|August 1, 2012||No||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01665170||80930|
NCT01666249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMUPAN1011|Non-inferiority of Immunoglobulin Anti-RhD KamRho-D® Compared to Rhopphylac® in Postpartum Immunization of Rh-negative, Coombs Negative Women at Risk of Sensitization.|Phase III Study of the Evaluation of the Non-inferiority of Immunoglobulin Anti-RhD KamRho-D® (Panamerican) Compared to Rhopphylac® (CSL Behring)in Postpartum Immunization of Rh-negative, Coombs Negative Women at Risk of Sensitization.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Not yet recruiting|February 2013|February 2015|Anticipated|February 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|232|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 10, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01666249||80848|
NCT01665157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTUH201109018RD|Efficacy and Acceptability of Low-Residue Diet Package (Enimaclin®) as Diet Control Before Colonoscopy|A Randomized, Single-blinded, Comparative Study to Evaluate the Efficacy and the Acceptability of Low-residue Diet Package (Enimaclin®) as Diet Control Before Colonoscopy||National Taiwan University Hospital|Yes|Completed|November 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|180|||Both|20 Years|75 Years|No|||February 2014|February 18, 2014|February 27, 2012||No||No|February 21, 2013|https://clinicaltrials.gov/show/NCT01665157||80931|
NCT01665950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002545|Simvastatin Augmentation of Lithium Treatment in Bipolar Depression|Simvastatin Augmentation of Lithium Treatment in Bipolar Depression||Massachusetts General Hospital|Yes|Terminated|August 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|4|||Both|18 Years|65 Years|No|||April 2015|April 22, 2015|April 9, 2012|Yes|Yes|Lack of enrollment|No||https://clinicaltrials.gov/show/NCT01665950||80871|
NCT01665963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0042-12-HYMC|Efficacy of TopClosure(C)System in Healing Complicated Pacemaker Wounds|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||August 2012|August 14, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01665963||80870|
NCT01665976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25593|A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers|A Single Center, Randomized, Single Dose, Open-label, Four Period Cross-over Study to Investigate the Relative Bioavailability of RO4917838 and the Effect of Food Following Oral Administration in Healthy Subjects||Hoffmann-La Roche||Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|4||Actual|16|||Female|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01665976||80869|
NCT01662843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-07-FB-0204-HOSP|BRIPPED Scan for Evaluation of Emergency Department (ED) Patients With Shortness of Breath|BRIPPED Scan for Evaluation of Emergency Department Patients With Shortness of Breath|BRIPPED|Eastern Virginia Medical School|Yes|Completed|October 2011|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|104|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|A convenience sample of community subjects presenting to an Academic Hospital Emergency        Department (volume approx 60,000 patients per year).|August 2013|August 13, 2013|February 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01662843||81092|
NCT01662856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IG1101|Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery|A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Peripheral Vascular Surgery||Grifols Biologicals Inc.||Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|225|||Both|N/A|N/A|No|||December 2015|December 28, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662856||81091|
NCT01663168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN13074752|EARNEST Rifabutin Pharmacokinetics (PK) Substudy|Toxicity and Pharmacokinetics of Different Rifabutin Doses in HIV-infected Adults and Adolescents Taking Lopinavir / Ritonavir as Second-line Anti-retroviral Therapy (ART) (EARNEST Rifabutin PK Substudy)||Medical Research Council|No|Recruiting|December 2011|January 2014|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|12 Years|N/A|No|||August 2012|August 8, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01663168||81067|
NCT01663376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSC-MSCs-CLI|Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia|Effects of Adipose Tissue Derived Stem Cells Implantation in Patients With Critical Limb Ischemia||Biostar|No|Completed|January 2009|April 2011|Actual|March 2010|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|20 Years|80 Years|No|||March 2014|March 24, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663376||81051|
NCT01663662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PAF06621|The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study|The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Acute Decompensated Heart Failure-Pilot Study||University of Michigan|No|Withdrawn|August 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|99 Years|No|||December 2015|December 10, 2015|August 8, 2012|Yes|Yes|Lack of eligible patients|No||https://clinicaltrials.gov/show/NCT01663662||81029|
NCT01664182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01289|Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer|A Randomized Phase 2 Study of AMG 386 With or Without Continued Anti-vascular Endothelial Growth Factor (VEGF) Therapy in Patients With Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib||National Cancer Institute (NCI)|No|Active, not recruiting|August 2012|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664182||80989|
NCT01664195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOBLA0312IV-I|PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Eritromax (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Single Dose, Intravenous Administration in Healthy Subjects: a Randomized Study.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Not yet recruiting|February 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01664195||80988|
NCT01664676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-5236|Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients|A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients||University of Aarhus|Yes|Completed|December 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Male|20 Years|60 Years|No|||February 2014|February 27, 2014|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664676||80968|
NCT01664858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP/12/1/29062|Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease-2|Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease - 2 (CE-MARC2)|CE-MARC2|University of Leeds|Yes|Active, not recruiting|November 2012|March 2018|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|1200|||Both|30 Years|N/A|No|||March 2015|March 27, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664858||80954|
NCT01664871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC1110|Pharmacokinetics of Diammine Silver Fluoride|Characterization of Fluoride and Silver Pharmacokinetics of Diammine Silver Fluoride Applied Topically to Teeth of Adults||Universidad Peruana Cayetano Heredia|No|Completed|July 2011|September 2011|Actual|August 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|10 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664871||80953|
NCT01665248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV2012-03|Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina|Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina||CardioVascular Research Foundation, Korea|No|Terminated|August 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|21 Years|N/A|No|||July 2014|July 25, 2014|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665248||80924|
NCT01665547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lcpco|Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome|Adding L-carnitine in Clomiphene Resistant Pco Improves the Quality of Ovulation and the Pregnancy Outcome,a Randomized Clinical Trial||Woman's Health University Hospital, Egypt|Yes|Enrolling by invitation|July 2012|September 2013|Anticipated|August 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|157|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||September 2013|September 9, 2013|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665547||80902|
NCT01633853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-078|Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder|Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease||Capital Medical University|Yes|Completed|July 2012|September 2015|Actual|September 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|204|||Both|18 Years|75 Years|No|||January 2016|January 16, 2016|June 29, 2012||No||No|October 21, 2015|https://clinicaltrials.gov/show/NCT01633853||83257|
NCT01633619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUV0005|European Implant Cohort Study|European Implant Cohort Study|EICS|Centre Hospitalier Universitaire Vaudois|Yes|Not yet recruiting|January 2013|||January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|4000|||Both|18 Years|N/A|No|Probability Sample|All patient with hip, knee and shoulder prosthetic joint infection.|July 2012|July 3, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633619||83275|
NCT01633866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-1041|Pediatric Radio Frequency Coils Generic|Pediatric Radio Frequency Coil Development on Clinical and Research MR Scanners||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Observational|Time Perspective: Prospective||1|Anticipated|75|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy participants will be recruited by word-of-mouth, generally from within CCHMC.The        healthy participants could include children of faculty or staff members of CCHMC.Because        the healthy participants could include children of faculty or staff members, recruitment        will be consistent with CCHMC Research Policy.Patients will be recruited at the time of        their scheduled clinical scan.We are only using these participants to evaluate the safety        and feasibility of the use of the new coils in our patient population.For this reason, we        will not focus on the demographics of the participants.However, we will attempt to obtain        a broad anatomic size range to match that of the patient population for which the coils        were developed.|September 2015|September 11, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01633866||83256|
NCT01663818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TD 0009|Tack Optimized Balloon Angioplasty (TOBA) Study|Tack Optimized Balloon Angioplasty (TOBA) Study for Femoropopliteal Arteries Using the Tack-IT Endovascular Stapler|TOBA|Intact Vascular|Yes|Active, not recruiting|August 2012|February 2017|Anticipated|December 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|138|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01663818||81017|
NCT01664091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-254|Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT|An Evaluation of Cosmetic Results and Toxicity in the Use of Post-Mastectomy Immediate Reconstruction With a Tissue Expander and Acellular Dermal Matrix Followed by Radiation Therapy||Dana-Farber Cancer Institute|Yes|Active, not recruiting|October 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be invited to take part in this clinical trial because they have breast        cancer that was recently treated with mastectomy and the participant and their doctors        have decided that additional treatment with radiation therapy is the best course.|August 2015|August 4, 2015|June 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01664091||80996|
NCT01665729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-2-48|Diagnosis and Treatment of Minor Ischaemic Stroke According to the Etiology and Pathogenesis|Diagnosis and Treatment of Minor Ischaemic Stroke According to the Etiology and Pathogenesis||Third Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|June 2011|December 2015|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|1000|||Both|20 Years|79 Years|No|Probability Sample|patients with new emergence of minor ischaemic stroke ( one of two conditions: (1)        conscious patients with any of NIHSS score = 1,or (2) NIHSS ≤ 3 )|August 2012|August 14, 2012|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01665729||80888|
NCT01665716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL32242.041.10|Ovarian Ageing in Type 1 Diabetes Mellitus|Ovarian Ageing in Type 1 Diabetes Mellitus: the Role of Vascular Factors|OVADIA|UMC Utrecht|No|Completed|July 2011|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Actual|290|Samples Without DNA|serum|Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Part I: Premenopausal women diagnosed with DM-1 older than 18 years and registered at the        department for Endocrinology of in several Dutch hospitals.        Reference group: the Scheffer, Van Rooij, De Vet (SRV) cohort of normal fertile Caucasian        women (n=250), recruited in the period of 1990 till 2000.        For the substudy concerning EPCs will we recruite a control group of 20 healthy female        age-matched controls. We will recruite these women within the UMC Utrecht due to logistic        reasons.        Part II: Postmenopausal women diagnosed with DM-1 and registered at the department for        Endocrinology of several Dutch hospitals. Reference group:a selection of women from the        Prospect-EPIC cohort, who had experienced natural menopause|April 2014|April 10, 2014|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01665716||80889|
NCT01662557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807610|Treatment of Early Childhood Overweight in Primary Care: Pilot Study|Treatment of Early Childhood Overweight in Primary Care: Pilot Study||University of Pennsylvania|No|Completed|February 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||January 2011|August 14, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662557||81114|
NCT01662570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|807775|Beverage Choice and Lifestyle Modification in Overweight Youth|Beverage Choice and Lifestyle Modification in Overweight Youth||University of Pennsylvania|No|Completed|March 2008|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|65|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||November 2011|August 14, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662570||81113|
NCT01663181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|413/2009|Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study|Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study||Medical University of Vienna|No|Completed|May 2009|April 2010|Actual|February 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|109|||Female|18 Years|N/A|No|Non-Probability Sample|women, aged >= 18 years with pelvic floor dysfunction, undergoing diagnostic work-up at a        tertiary referral center for urogynecologic conditions|August 2012|August 8, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01663181||81066|
NCT01663389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112167|A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose|An Open Label, Non-Randomized, Single Dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects||GlaxoSmithKline|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01663389||81050|
NCT01663935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0023|Vision Response to Dopamine Replacement|Interventional Study of Levodopa Replacement on Retinal Function in Oculocutaneous Albinism||University of Wisconsin, Madison|No|Recruiting|August 2012|October 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|3 Years|N/A|No|||October 2015|October 9, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663935||81008|
NCT01663649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Deprexis_2|Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders|Evaluation of the Effectiveness of a Web-based Treatment Program for Depression (Deprexis) for the Reduction of Depressive Symptoms in Patients With Multiple Sclerosis and Epilepsy. A Randomized Controlled Trial||Universitätsklinikum Hamburg-Eppendorf|No|Completed|June 2012|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|180|||Both|18 Years|65 Years|No|||March 2015|March 24, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663649||81030|
NCT01663883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-210911|Optic Nerve Head Autoregulation During Changes in Arterial Blood Pressure|||Medical University of Vienna|Yes|Completed|February 2012|August 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|40|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 9, 2012|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01663883||81012|
NCT01663896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJM-CVD-0612|Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention|Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention Stage I (ILUMIEN I)|ILUMIEN I|St. Jude Medical|Yes|Completed|November 2012|October 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|418|||Both|18 Years|N/A|No|Non-Probability Sample|Elective or ad hoc PCI, stable angina, acute coronary syndrome|January 2016|January 7, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01663896||81011|
NCT01664221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOBLA0412IV-I|PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Eritromax (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Multiple Dose, Intravenous Administration in Healthy Subjects: a Randomized Parallel Study.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Not yet recruiting|February 2013|October 2013|Anticipated|October 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01664221||80987|
NCT01664234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECS 1178/2012|Oxygen Insuflation and ArterialDesaturation During Tracheal Intubation in Children|||Medical University of Vienna|No|Recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|48|||Both|1 Month|2 Years|No|||August 2012|August 10, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664234||80986|
NCT01664689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVD12|Intraoperative and Postoperative Outcomes of Three Ophthalmic Viscosurgical Devices During Phacoemulsification|||Iladevi Cataract and IOL Research Center||Completed|October 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|120|||Both|45 Years|80 Years|No|||August 2012|August 13, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664689||80967|
NCT01664897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0060|Pilot Phase II - Erlotinib for Acute Myeloid Leukemia (AML)|A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2013|||May 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||June 2015|June 9, 2015|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664897||80951|
NCT01664884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTINT|Internalized Stigma in Patients With Bipolar Disorder or Schizophrenia|Internalized Stigma in a Sample of Young Adults With Bipolar Disorder or Schizophrenia.|ESTINT|University of Sao Paulo|No|Recruiting|June 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|18 Years|40 Years|No|Non-Probability Sample|The group will consist of patients from the Institute of Psychiatry, Hospital das        Clinicas, Faculty of Medicine, University of São Paulo (HCFMUSP) diagnosed by DSM-IV-TR        bipolar disorder (in remission) or schizophrenia (absence of positive symptoms).|August 2012|August 15, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664884||80952|
NCT01665560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0505027690|Neural, Behavioral and Physiological Correlates of Feeding in Humans|Neural, Behavioral and Physiological Correlates of Feeding in Humans||Yale University|Yes|Completed|June 2005|July 2009|Actual|July 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|27|Samples With DNA|saliva samples were obtained and are stored using a coded ID in a secure part of our      facility|Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults in the New Haven, CT area.|August 2012|August 9, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01665560||80901|
NCT01633879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01HD062084|Addressing Proven Factors in HIV Prevention for Latino Youth|Health and Success: Addressing Proven Factors in HIV Prevention for Latino Youth||Education Development Center, Inc.|No|Enrolling by invitation|July 2009|July 2014|Anticipated|December 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|3400|||Both|10 Years|14 Years|Accepts Healthy Volunteers|||July 2012|July 3, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633879||83255|
NCT01633892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12010078|Use of Concentrated Endogenous Autologous Adipose Stromal Cells in Fat Grafts for Craniofacial Trauma|Use of Concentrated Endogenous Autologous Adipose Stromal Cells in Fat Grafts for Craniofacial Trauma|ARM5|University of Pittsburgh|Yes|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 2, 2014|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01633892||83254|
NCT01633905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_01|Electrophysiological Correlates of Emotional and Crossmodal Stimuli Processing Among Alcohol-dependent Participants|Electrophysiological Correlates of Emotional and Crossmodal Stimuli Processing Among Alcohol-dependent Participants : Exploration of the Peripheral Presentation Effect|ALCOLAT|University Hospital, Lille|No|Completed|December 2010|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|-  22 recently detoxified participants, diagnosed as alcohol-dependent on the basis of             DSM-IV criteria, free of any alcohol consumption during the last 15 days, and without             any other DSM-IV criteria          -  22 healthy controls paired for gender, age and educational level with             alcohol-dependent participants, without any alcohol consumption during the last three             days and without any psychiatric or neurological diagnosis.        All participants will be between 18 and 60 years of age, will be French-speaking and will        present a normal or corrected-to-normal auditory and visual acuity.|June 2015|June 16, 2015|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01633905||83253|
NCT01634243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|243-03-001|A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients|A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients||Otsuka Pharmaceutical Co., Ltd.|No|Completed|January 2005|May 2006|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Both|30 Years|79 Years|No|||February 2014|February 3, 2014|June 27, 2012||No||No|February 3, 2014|https://clinicaltrials.gov/show/NCT01634243||83227|
NCT01634256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INs-LF-CURCUMA|A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury|||Chonbuk National University Hospital|Yes|Completed|February 2011|January 2012|Actual|October 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|60|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|July 3, 2012||No||No|July 11, 2012|https://clinicaltrials.gov/show/NCT01634256||83226|
NCT01664650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20073XZSR3_003|Effects of Genistein in Postmenopausal Women With Metabolic Syndrome|Role of Genistein on Metabolic Syndrome in Post-menopausal Women||University of Messina|No|Completed|September 2008|January 2011|Actual|November 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|120|||Female|49 Years|67 Years|No|||August 2012|August 9, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01664650||80970|
NCT01665183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POLARIS2012-005|Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma|Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies||Polaris Group|No|Completed|September 2012|February 2016|Actual|February 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665183||80929|
NCT01664130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1812|High-Dose Stereotactic Radiation for Prostate Cancer|High-Dose Stereotactic Body Radiation Therapy in Treating Patients With Low-, Intermediate-, or High-Risk Localized Prostate Cancer||Case Comprehensive Cancer Center|Yes|Active, not recruiting|July 2012|||December 2014|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Male|18 Years|N/A|No|||February 2016|February 4, 2016|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664130||80993|
NCT01664845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGHKS12-CT3-16|Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance|Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance||Kaohsiung Veterans General Hospital.|No|Recruiting|August 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|20 Years|80 Years|No|||August 2012|August 13, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664845||80955|
NCT01666275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000448|The Metabolomics of Anaphylaxis|The Metabolomics of Anaphylaxis||Massachusetts General Hospital|No|Recruiting|March 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|12|Samples With DNA|We retain and freeze the plasma from blood after spinning down whole-blood samples.|Both|18 Years|75 Years|No|Non-Probability Sample|Patients ages 18-75, history of an allergic reaction to aspirin and referred for a        clinically indicated outpatient or inpatient aspirin desensitization procedure for aspirin        exacerbated respiratory disease (AERD)|September 2015|September 21, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666275||80846|
NCT01666509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CL-068-IV-01|Efficacy and Tolerability of Topical Rossoseq™ Compared to Vehicle in Rosacea Subtype 1 (Erythematotelangiectatic)|A Post Marketing Clinical Follow-up, Randomised, Double-blind Study Comparing the Efficacy and Tolerability of Topical Rossoseq™ With Vehicle in Rosacea Subtype 1 (Erythematotelangiectatic)||PBB Entrepreneur Ltd.|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|85 Years|No|||January 2013|January 4, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666509||80828|
NCT01666795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITP-006|Autoantibody Specificity and Response to IVIG in ITP|Autoantibody Specificity and Response to Intravenous Immunoglobulin G (IVIG) in Immune Thrombocytopenia (ITP): a Retrospective Cohort Study||Shandong University||Recruiting|February 2005|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|75 Years|No|Probability Sample|adult patients with severe ITP who underwent IVIG therapy and had platelet autoantibodies        assayed|August 2012|October 31, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666795||80806|
NCT01666808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00057680|FACBC Outcomes for Post Prostatectomy|Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy||Emory University|Yes|Recruiting|September 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|162|||Male|18 Years|95 Years|No|||October 2015|October 12, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666808||80805|
NCT01666769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00039552|Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation|Safety and Pharmacokinetics of Micafungin in Children Supported With Extracorporeal Membrane Oxygenation||Duke University|No|Recruiting|January 2013|December 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|50|||Both|N/A|18 Years|No|||February 2016|February 11, 2016|August 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01666769||80808|
NCT01666782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIC 1336-B12-1|Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy|A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy|IMMUNE|Rochester General Hospital|No|Active, not recruiting|August 2012|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|120|||Both|18 Years|64 Years|No|||May 2015|May 6, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666782||80807|
NCT01662869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YO28322|A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)|A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic Her2-Negative, Met-Positive Gastroesophageal Cancer (MetGastric)||Hoffmann-La Roche||Completed|November 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|564|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662869||81090|
NCT01662882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18F-AV-45-J05|A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)|An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)||Avid Radiopharmaceuticals||Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|48|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 16, 2013|August 7, 2012|No|Yes||No|July 16, 2013|https://clinicaltrials.gov/show/NCT01662882||81089|
NCT01662895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000005|High-Dose Deferoxamine in Intracerebral Hemorrhage|Futility Study of Deferoxamine in Intracerebral Hemorrhage|HI-DEF|Beth Israel Deaconess Medical Center|Yes|Suspended|March 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|324|||Both|18 Years|80 Years|No|||February 2014|February 25, 2014|July 30, 2012|Yes|Yes|Recruitment halted by DSMB due to increased incidence of ARDS). Modifications to minimize dug    toxicity with this high dose and the risk of ARDS are underway|No||https://clinicaltrials.gov/show/NCT01662895||81088|
NCT01663194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mgkaya-makpek|Neutrophil/Lymphocyte (N/L) Ratio and Long Term Follow-up in ST-elevation Myocardial Infarction|Observational Study of N/L Ratio in Patients With STEMI||TC Erciyes University|No|Completed|January 2000|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1034|Samples Without DNA|serum and plasma of blood|Both|18 Years|90 Years|No|Non-Probability Sample|STEMI patients who were admitted within 6 hours from symptom onset and who underwent        primary PCI were prospectively included in this study|August 2012|August 13, 2012|August 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663194||81065|
NCT01663402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11570|ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome||Sanofi|Yes|Recruiting|October 2012|February 2018|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|18600|||Both|40 Years|N/A|No|||February 2016|February 3, 2016|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663402||81049|
NCT01663675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5249|Trisomy 21 in Adulthood|Trisomy 21 in Adulthood. Evaluation of Health and Social State in Alsace (North-eastern France)||University Hospital, Strasbourg, France|No|Not yet recruiting|October 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Cases with trisomy 21 older than 18 years living in Alsace Region (North-eastern France)|August 2012|August 8, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663675||81028|
NCT01663948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14554|International Plastic Bronchitis Registry|International Plastic Bronchitis Registry||Virginia Commonwealth University|No|Recruiting|July 2012|July 2022|Anticipated|July 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Airway Casts|Both|N/A|N/A|No|Non-Probability Sample|The study is open to patients around the world suffering from Plastic bronchitis|November 2015|November 3, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663948||81007|
NCT01663909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Scoliosis|Pain Management Using Guided Imagery for Adolescents Post-spinal Fusion|The Efficacy of Guided Imagery on Pain, Anxiety, and Coping for Adolescents Post-spinal Fusion||St. Justine's Hospital|No|Completed|May 2010|December 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|11 Years|20 Years|No|||August 2012|August 9, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01663909||81010|
NCT01663922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 045|Boceprevir and Ucalm (St John&Apos;s Wort)|Phase I Evaluation of the Pharmacokinetics and Safety of Boceprevir and Ucalm (St John&Apos;s Wort) When Co-administered to Male and Female Healthy Volunteers.||St Stephens Aids Trust|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|17|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|August 3, 2012||No||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01663922||81009|
NCT01664702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSCL15253|Substrate Oxidation in Children in Response to High and Low Dairy Intake|Substrate Oxidation in Children in Response to Exercise With High and Low Dairy Intake||University of Kansas Medical Center|Yes|Completed|January 2005|December 2005|Actual|December 2005|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|24|||Both|10 Years|13 Years|Accepts Healthy Volunteers|||August 2012|August 13, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664702||80966|
NCT01664936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-050|Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes|Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes||Memorial Sloan Kettering Cancer Center||Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|MSKCC Clinics|March 2016|March 9, 2016|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01664936||80948|
NCT01664910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0265|CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies|Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies||M.D. Anderson Cancer Center|No|Recruiting|October 2012|||October 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|No|||February 2016|February 24, 2016|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664910||80950|
NCT01664923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDV3100-09|Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer|A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy|STRIVE|Medivation, Inc.||Active, not recruiting|July 2012|June 2018|Anticipated|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|396|||Male|18 Years|N/A|No|||May 2015|May 26, 2015|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01664923||80949|
NCT01665807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1203|A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine|A Time-Motion Study to Compare Self-vaccination With Intanza® Intradermal Influenza Vaccine to Nurse-administered Vaxigrip® Intramuscular Influenza Vaccine in Small Group Settings of Health Care Workers||Mount Sinai Hospital, Canada|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|868|||Both|18 Years|69 Years|Accepts Healthy Volunteers|||October 2013|October 24, 2013|August 13, 2012|Yes|Yes||No|July 31, 2013|https://clinicaltrials.gov/show/NCT01665807||80882|
NCT01633918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|166,02|FeetEnergy Approach to Increase Physical Activity and Reduce Screen Time in Adolescents|Integrating Internet-supported FeetEnergy Approach in Health Education Lessons to Increase Physical Activity and Reduce Screen Time in Adolescents|FeetEnergy|UKK Institute|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1291|||Both|13 Years|15 Years|Accepts Healthy Volunteers|||August 2014|December 7, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01633918||83252|
NCT01633931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR0038|Treatment of Adolescent Idiopathic Scoliosis Patients Using the Ellipse MAGEC System|Treatment of Adolescent Idiopathic Scoliosis Patients Using the Ellipse MAGEC System||Ellipse Technologies, Inc.|No|Active, not recruiting|March 2012|June 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|10 Years|15 Years|No|Non-Probability Sample|Patients diagnosed with Adolescent Idiopathic Diagnosis|January 2016|January 19, 2016|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633931||83251|
NCT01634269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT-2111 23 mm trial|Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis|||Medtronic Cardiovascular|Yes|Active, not recruiting|July 2012|September 2019|Anticipated|April 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|N/A|N/A|No|||October 2015|October 29, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634269||83225|
NCT01634282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|262-09-002|Along-term Study of OPC-262 in Patients With Type 2 Diabetes|A Long-term Clinical Study of OPC-262 in Patients With Type 2 Diabetes on Study (Extension From Study 262-09-001)||Kyowa Hakko Kirin Company, Limited|No|Completed|August 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|222|||Both|20 Years|74 Years|No|||January 2014|January 6, 2014|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634282||83224|
NCT01665469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lyc-2012-02|Effect of Tomato Extracted Lycopene on Postprandial Oxidation and inﬂammation in Healthy Weight Men and Women|||LycoRed Ltd.|No|Recruiting|November 2012|June 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||December 2012|December 19, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01665469||80908|
NCT01665482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PD155/11|Effects of Dietary Fats on Cardiovascular Health and Insulin Sensitivity in Subjects With Abdominal Obesity|Effects of Dietary Fats on Cardiovascular Health and Insulin Sensitivity in Subjects With Abdominal Obesity||Malaysia Palm Oil Board|Yes|Completed|March 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Actual|47|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 14, 2012|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01665482||80907|
NCT01666834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|zdyyicu3|Cross-section Survey of Mechanical Ventilation and Acute Respiratory Distress Syndrome in China|Southeast Univerity||Southeast University, China|No|Recruiting|January 2014|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|1000|||Both|18 Years|85 Years|No|Non-Probability Sample|A mixed group of critically ill patients who received mechanical ventilation|January 2014|January 24, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666834||80803|
NCT01666522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed116671002|Vitamin D and Physical Activity for Prevention of Sarcopenia in Osteoporosis|Effect of Vitamin D Supplementation and Physical Activity in Preventing Sarcopenia in Older Adults With Osteoporosis||Faculty of Medicine, University of Alexandria|Yes|Completed|April 2011|September 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|145|||Both|60 Years|N/A|No|||August 2012|August 10, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01666522||80827|
NCT01662583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ9354|Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children|Pragmatic Clinical Trial of Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children||Columbia University|No|Completed|September 2012|June 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|3||Actual|660|||Both|6 Months|9 Years|No|||July 2015|July 19, 2015|August 8, 2012||No||No|May 17, 2015|https://clinicaltrials.gov/show/NCT01662583||81112|
NCT01662609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-14882|Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer|Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|June 2007|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|75|||Both|30 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Individuals potentially at high-risk for developing pancreatic cancer.|October 2015|October 8, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01662609||81110|
NCT01662908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU176b-D-U211|A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis|A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis - Edoxaban Thrombus Reduction Imaging Study|eTRIS|Daiichi Sankyo Inc.|No|Completed|August 2012|March 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||March 2015|March 26, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662908||81087|
NCT01657981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-015|A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects|An Open Label Study to Evaluate the Pharmacokinetics of YM150 After a Single Oral Dose of C14-labeled YM150 in Healthy Male Subjects||Astellas Pharma Inc|No|Completed|February 2007|March 2007|Actual|March 2007|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|June 24, 2013|July 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657981||81461|
NCT01657994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-796-10|Combined Functional Electrical Stimulation & Robotic Gait Training for Children With Cerebral Palsy|Combined Functional Electrical Stimulation & Robotic Gait Training for Children With Cerebral Palsy||Children's Hospital Medical Center, Cincinnati|No|Recruiting|May 2012|September 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|11|||Both|5 Years|12 Years|No|||August 2012|August 1, 2012|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01657994||81460|
NCT01657396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|23068|Implementation and Evaluation of Revised Protocols for Oral Hygiene for Mechanically Ventilated Patients|Implementation and Evaluation of Revised Protocols for Oral Hygiene for Mechanically Ventilated Patients in Alberta Health Services Calgary Region - a Pilot Project.||University of Calgary|No|Completed|July 2012|November 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|150|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01657396||81506|
NCT01657682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARO-005|A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations|A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations||Arog Pharmaceuticals, Inc.|Yes|Active, not recruiting|October 2012|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||November 2015|November 3, 2015|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657682||81484|
NCT01657968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-10-72-321-12|Procalcitonin-guided Detection of Streptococcal Acute Tonsillitis|Procalcitonin-guided Detection of Streptococcal Acute Tonsillitis||Aarhus University Hospital|Yes|Recruiting|August 2012|March 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Patients with acute tonsillitis:        -  Oral temperature, streptococcal rapid antigen detection test, Tonsil surface swab for           microbiological culture and a blood sample (measuring the infection markers:           Procalcitonin, C-reactive protein, White blood cell count and Absolute neutrophile           count).      Healthy control patients:        -  Tonsil surface swab for microbiological culture.|Both|15 Years|40 Years|No|Probability Sample|Patients with acute tonsillitis aged 15 to 40 years consulting their general practitioner        with signs and symptoms of acute tonsillitis meeting to or more of Centors criteria.        Healthy control patients aged 15 to 40 years consulting their general practitioner in        other reason than infection.|January 2013|January 17, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01657968||81462|
NCT01654991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105031|Randomized Trial of Home Versus Clinic-Based STD Testing|A Randomized Trial of Home Versus Clinic-Based STD Testing Among Men||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Completed|June 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|200|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||October 2013|October 30, 2013|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01654991||81690|
NCT01655290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAD-1140-WIL-0020-I|Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI|Intraindividual Comparison of the Diagnostic Accuracy Using Gadobutrol (Gadovist®) Versus Gadobenat Dimeglumin (Multihance®) for Delayed Enhancement MRI of Myocardial Infarction.|Gadovit|Technische Universität München|No|Completed|August 2012|June 2014|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|80 Years|No|||March 2016|March 16, 2016|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655290||81667|
NCT01655264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-08-5641-MS-CTIL|Evaluation of the Gertner Tele-Motion-Rehabilitation System for Stroke Rehabilitation|Randomized Controlled Trial of Gertner Tele-Motion-Rehabilitation|GertnerTMR|Sheba Medical Center|No|Recruiting|July 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|24|||Both|18 Years|80 Years|No|||October 2012|October 10, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655264||81669|
NCT01655277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-202|Ultrasound Guided Adductor Canal Block Versus Femoral Nerve Block for Quadriceps Strength and Fall-risk|The Effects of Ultrasound Guided Adductor Canal Block Versus Femoral Nerve Block on Quadriceps Strength and Fall-risk: a Blinded Randomized Trial of Volunteers||St. Luke's-Roosevelt Hospital Center||Completed|February 2012|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|16|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655277||81668|
NCT01656369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rectal prolapse|Comparative Study Between Delorme Operation With or Without Postanal Repair in Treatment of Complete Rectal Prolapse|Comparative Study Between Delorme Operation With or Without Postanal Repair and Levatorplasty in Treatment of Complete Rectal Prolapse.||Mansoura University|Yes|Completed|January 2007|June 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|82|||Both|16 Years|64 Years|No|||January 2007|November 20, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01656369||81585|
NCT01656083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SM2010CHINA|The Compliance of Varenicline With Short-massage|The Compliance of Varenicline Usage and the Smoking Abstinence Rate Via Mobile Phone Text Messaging Combine With Varenicline: a Single-blind, Randomised Control Trial|CV-SM|China-Japan Friendship Hospital|Yes|Recruiting|May 2010|December 2012|Anticipated|July 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|220|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|In this research, professional biostatistical staffs adopt SAS program to divide groups in        the trial. The sample size is calculated based on drug compliance rate. Since lack of the        data related to varenicline combined SM intervention, the similar trials in the past are        taken as reference, but mostly based on the experiences of the investigator`s, the mean        treatment time for patients using Varenicline is 4 weeks, the proportion of patients who        use Varenicline for 4 weeks is about 40%; when combined SM intervention, it supposed to        increase to 60% . When use 80% power and 0.05 significance for calculation, the sample        size is 192, 96 for each group. Considering the drop rate is aobut 15%, 220 qualified        subjects are included in random group division.|July 2012|August 1, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656083||81606|
NCT01656655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTSDpar-2-hmo|Effect of Post Traumatic Stress Disorder on Parenting|Parenting With and Without PTSD: The Effect of Attachment, Symptoms and Posttraumatic Growth||Hadassah Medical Organization|Yes|Recruiting|May 2012|June 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with ptsd|August 2012|August 2, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656655||81563|
NCT01656668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC1036-001|Study of the Safety and Effectiveness of BC1036 Capsules to Treat Frequent Long-Term Cough|A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough||Respicopea Limited|No|Completed|July 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|288|||Both|18 Years|75 Years|No|||August 2013|August 1, 2013|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01656668||81562|
NCT01657539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UFPEL-PPGO0013|Effect of Probiotics Containing Yogurts on the Composition of Biofilms in Patients Under Orthodontic Treatment|Effects of Yogurt Containing Bifidobacterium Animalis Ssp. Lactis dn- 1173010 Probiotics in the Composition of Biofilms and Saliva of Orthodontic Patients: a Crossover, Double-blind, Randomized and Placebo Controlled Clinical Trial.||Federal University of Pelotas||Completed|August 2011|March 2013|Actual|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|30|||Both|14 Years|30 Years|Accepts Healthy Volunteers|||September 2013|September 17, 2013|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657539||81495|
NCT01657552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116010|Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects|A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects||GlaxoSmithKline|Yes|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|56|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||February 2013|May 16, 2013|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657552||81494|
NCT01658111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIT02012EEG|Robot-aided Therapy in Stroke Patients for Upper Limb Rehabilitation|Robot-aided Therapy in Acute Stroke Patients for the Upper Limb Rehabilitation With Long-term Follow-up.|MITEEG|IRCCS San Raffaele|No|Recruiting|July 2012|August 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|90 Years|No|||August 2012|August 31, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01658111||81451|
NCT01657851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116502|Bioequivalence - Duodart Against Avodart & Omnic|An Open-Label, Randomized, Single Dose Crossover Study to Determine the Bioequivalence of Duodart® 0.5mg/0.4mg (Capsule Formulation of Dutasteride 0.5mg and Tamsulosin Hydrochloride 0.4mg) Compared to Concomitant Dosing of Avodart® 0.5mg and Omnic® 0.4mg Commercial Capsules in Healthy Male Subjects.||GlaxoSmithKline|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2013|March 7, 2013|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657851||81471|
NCT01655134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00306-37|Biomarkers and Therapeutic Modelisation in Heart Failure|Home-based Assessment of Plasma Volume, Serum Potassium and Renal Function Variations in Patients With Heart Failure and Low Left Ventricular Ejection Fraction: Pilot Study BIOMIC. Biomarkers and Therapeutic Modelisation in Heart Failure|BIOMIC|Central Hospital, Nancy, France|No|Recruiting|November 2012|March 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|20|||Both|18 Years|N/A|No|||July 2013|March 20, 2014|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655134||81679|
NCT01658410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023552-90|Short-term Endothelin A Receptor Blockade in Patients With On-pump CABG|Short-term Endothelin A Receptor Blockade in Patients With On-pump Coronary Artery Bypass Grafting||Medical University of Vienna|Yes|Enrolling by invitation|July 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||August 2012|August 2, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01658410||81428|
NCT01659632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|gastric cancer alarm symptom|Gastric Cancer Screening and Alarm Symptoms in Early Gastric Cancer|Gastric Cancer Screening and Alarm Symptoms in Early Gastric Cancer||The Catholic University of Korea|No|Recruiting|April 2010|March 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|1000|||Both|15 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|gastric cancer patients in St.mary`s hospital|August 2012|August 6, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659632||81336|
NCT01656018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100803|A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants|Phase 1 Open Label Safety, Acceptability, Pharmacokinetic and ex Vivo Pharmacodynamic Study of TMC278 Long Acting (LA) Administered Intramuscularly to HIV-1 Seronegative Individuals||Janssen Research & Development, LLC|No|Recruiting|November 2012|February 2016|Anticipated|January 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|10||Anticipated|90|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|July 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656018||81611|
NCT01656252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrE0901|Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission|Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults With Acute Myeloid Leukemia (AML) in Complete Remission|PrE0901|PrECOG, LLC.|Yes|Active, not recruiting|July 2012|May 2016|Anticipated|March 2016|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|14|||Both|18 Years|70 Years|No|||March 2016|March 1, 2016|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656252||81593|
NCT01656265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ 197-008|Study of ARQ 197 in Hepatocellular Carcinoma (HCC)|Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma||Kyowa Hakko Kirin Company, Limited|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|N/A|No|||March 2015|March 2, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01656265||81592|
NCT01657422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7R01CA081495-04|PACE+: Counseling Adolescents for Exercise and Nutrition|PACE+: Counseling Adolescents for Exercise and Nutrition|PACEAdol|University of California, San Diego|No|Completed|August 2000|April 2006|Actual|November 2004|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|819|||Both|11 Years|15 Years|No|||August 2012|August 3, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01657422||81504|
NCT01656811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|051-306|A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma|An Efficacy, Safety, and Tolerability Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma||Sunovion|No|Completed|October 2001|July 2002|Actual|July 2002|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|146|||Both|4 Years|11 Years|No|||July 2012|July 31, 2012|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656811||81551|
NCT01654120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|high dose and lira 001|Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics|Liraglutide and Insulin-001 A Randomized Prospective Trial of Liraglutide Added to High-Dose Insulin Therapy vs. High-Dose Insulin Therapy Alone in Insulin-Resistant Patients With Type 2 Diabetes||Mountain Diabetes and Endocrine Center|No|Completed|December 2011|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|80 Years|No|||November 2013|April 16, 2015|December 16, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654120||81753|
NCT01653847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Novartis- Everolimus|Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens|Impact of Two Prednisone-free Maintenance Immunosuppressive Regimens With Reduced Dose FK506+Everolimus vs. Standard Dose Tacrolimus (FK506)+ Mycophenolate Mofetil (MMF) on Subpopulation of T and B Cells, Renal Allograft Function and Gene Expression Profiles in Renal Allograft Biopsies at 12 Months Post-transplant. Prospective Single Center Study in Recipients of Renal Transplant Allograft.||Northwestern University|No|Active, not recruiting|February 2013|May 2017|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|88|||Both|18 Years|70 Years|No|||May 2015|May 18, 2015|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01653847||81774|
NCT01654107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0220110199|Persistence-Targeted Smoking Cessation|Persistence-Targeted Smoking Cessation|PTSC|Rutgers, The State University of New Jersey|Yes|Completed|July 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||July 2015|August 17, 2015|July 19, 2012||No||No|August 17, 2015|https://clinicaltrials.gov/show/NCT01654107||81754|
NCT01655615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3427|Does Delaying Adolescent Substance Use Lead to Improved Cognitive Function and Reduce Risk for Addiction?|Co-venture: a Cluster Randomized Trial Investigating the Effects of Selective Intervention on Adolescent Cognitive Development and Addiction||St. Justine's Hospital|Yes|Active, not recruiting|September 2011|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|31|||Both|12 Years|18 Years|Accepts Healthy Volunteers|||May 2015|May 25, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01655615||81642|
NCT01655303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16057|Rate Control in Atrial Fibrillation|Oral Propranolol, Diltiazem, Metoprolol and Verapamil in Atrial Fibrillation Rate Control in Patients With Stable Hemodynamic Status||Tehran University of Medical Sciences||Completed|February 2011|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|90|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655303||81666|
NCT01655589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IV-01|VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents|VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration||Institute of Vision, Brasil||Recruiting|January 2008|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|74|||Both|50 Years|N/A|No|Non-Probability Sample|Eye clinic in Belo Horizonte, Brazil|July 2012|July 31, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655589||81644|
NCT01656382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-273|Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex|Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV||Medstar Research Institute|No|Completed|January 2007|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||July 2012|August 2, 2012|April 24, 2007|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656382||81584|
NCT01656681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WLM1-FMR-CT|Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects|A 64-week Pilot Trial to Evaluate the Effects of a Novel Nutraceutical on Weight Loss and Weight Loss Maintenance in Obese Subjects||MetaProteomics LLC|No|Active, not recruiting|May 2011|December 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|124|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 6, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656681||81561|
NCT01656967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-10-0604|AMBU AScope2 Fiberoptic Intubation Versus Fastrach Intubating LMA|Flexible Optical Intubation Via the AMBU Aura-I Versus Blind Intubation Via the Fastrach Single Use Intubating LMA - A Prospective Randomized Clinical Trial||The University of Texas Health Science Center, Houston|No|Completed|July 2010|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|66|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01656967||81539|
NCT01656629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00050448|Stem Cell Recruitment in Osteoporosis Therapy|||Johns Hopkins University||Completed|August 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|3||Actual|46|||Female|50 Years|80 Years|No|||November 2014|November 21, 2014|August 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656629||81565|
NCT01656642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GP28384|A Phase 1b Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma|A Phase Ib, Open-Label Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma||Genentech, Inc.||Recruiting|August 2012|June 2018|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|55|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656642||81564|
NCT01657253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOPH148-0512/III|Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye|A Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye||Laboratorios Sophia S.A de C.V.|Yes|Recruiting|November 2013|August 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01657253||81517|
NCT01657864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|117051|WEUSKOP6166: Lamotrigine and Aseptic Meningitis|WEUSKOP6166: Prevalence of Aseptic Meningitis Among Lamotrigine Users||GlaxoSmithKline|No|Completed|May 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|1|||Both|N/A|N/A|No|Non-Probability Sample|The study population for this study includes new user of lamotrigine. To be eligible for        this study, Patients were required to use lamotrigine for epilepsy or bipolar disorder.        Patients must have at least 180 days history on the database prior to the index of        lamotrigine use. Patients must have medical and pharmacy coverage throughout the study.|July 2012|August 2, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657864||81470|
NCT01663298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AWU|Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics|FGF2 Promoter Hypermethylation and Implant Wound Healing Among Smokers and Diabetics||University of North Carolina, Chapel Hill|No|Recruiting|August 2010|May 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|44|Samples With DNA|Gingival tissues, gingival crevicular fluid, saliva|Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients in the graduate periodontal clinic in the school of dentistry at the University        of North Carolina|January 2016|January 21, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01663298||81057|
NCT01659320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30MH085943-04|Open Treatment of Minocycline in Geriatric Depression|||Weill Medical College of Cornell University|Yes|Recruiting|March 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|55 Years|90 Years|No|||December 2014|December 18, 2014|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659320||81360|
NCT01659619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC12MISI0164|Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis|Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis : Randomized and Prospective Study||The Catholic University of Korea|No|Completed|April 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|114|||Both|N/A|N/A|No|||February 2013|February 20, 2013|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01659619||81337|
NCT01655147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100651|A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Abiraterone (JNJ-589485) Following Administration of Abiraterone Acetate (JNJ-212082) Tablets in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|January 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01655147||81678|
NCT01656564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120157|Clinical Outcomes in Persons With HIV Acquired Early in Life|Clinical Outcomes in Persons With HIV Acquired Early in Life (COPE)||National Institutes of Health Clinical Center (CC)||Recruiting|July 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|250|||Both|10 Years|N/A|Accepts Healthy Volunteers|||February 2016|March 2, 2016|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656564||81570|
NCT01657721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|245899|Working Memory Training in ADHD (The Engage Study)|Working Memory Training in Attention-Deficit/Hyperactivity Disorder: Neural Mechanisms of Change||University of Toronto|No|Recruiting|May 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 3, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01657721||81481|
NCT01658007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIR-MO-1101|Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma|Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma|SIR-MO-1101|Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|August 2012|April 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|38|||Both|N/A|30 Years|No|||September 2015|September 25, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01658007||81459|
NCT01657123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33088|Exercise Capacity and Recovery in Addison's Disease|Effect of Hydrocortisone Stress Dose on Exercise Capacity and Post-exercise Recovery in Patients With Addison's Disease||UMC Utrecht|Yes|Not yet recruiting|January 2013|January 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|50 Years|No|||August 2012|August 2, 2012|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657123||81527|
NCT01654133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0062|Visceral (Kidney and Abdominal Organ) Function After Fenestrated Endovascular Aneurysm Repair (FEVAR)|Evaluation of Visceral Function Following Fenestrated Endovascular Aortic Aneurysm Repair (FEVAR) Using Branch Stent-Grafts||University of North Carolina, Chapel Hill|Yes|Enrolling by invitation|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|160|||Both|18 Years|N/A|No|||December 2015|December 20, 2015|July 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654133||81752|
NCT01654354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neovist IIT|Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT|Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT||Seoul National University Hospital||Completed|July 2012|December 2013|Actual|November 2012|Actual|Phase 4|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|104|||Both|20 Years|75 Years|No|Non-Probability Sample|Subject who performed scheduled CT scan, mostly postoperative state of stomach cancer|January 2014|January 13, 2014|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01654354|8 Days|81735|
NCT01654627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGD001|Guided Bone Regeneration Using Synthetic Membrane|Horizontal Guided Bone Regeneration for Dental Implants Using Synthetic Membrane (Regenecures' AMCA GBR Dental Membrane) a Prospective, Randomized,Controlled Study.||RegeneCure, Ltd.|Yes|Recruiting|April 2013|June 2015|Anticipated|April 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|32|||Both|18 Years|65 Years|No|||August 2013|August 26, 2013|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01654627||81714|
NCT01656096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSD-Leipzig|Renal Sympathetic Denervation in Mild Refractory Hypertension|Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension||University of Leipzig|No|Recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|75 Years|No|||August 2013|August 5, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656096||81605|
NCT01656694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11018|A Single-Center, Epidemiological Study of the Survivorship of the DePuy Sigma HP Unicompartmental Knee Prosthesis|Two and Five-Year Survivorship of Unicompartmental Knee Arthroplasty Using DePuy Sigma HP Replacement||Mississippi Sports Medicine and Orthopaedic Center|No|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Since the first Sigma® HP Partial Knee System was introduced at MSMOC, over 1,000 have        been implanted in patients by the investigators of this study. The population used for        this study was the first patients of our clinic to receive this particular prosthesis. The        first replacement was implanted on August 21, 2008. By October 31, 2009, 300 patients had        received the Sigma® HP replacement. These 300 patients will be the subject population        whose data will be analyzed for the study upon their consent.|October 2014|October 30, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656694||81560|
NCT01656707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA08-263|Adaptive Treatment for Adolescent Cannabis Use Disorders|Adaptive Treatment for Adolescent Cannabis Use Disorders||University of Connecticut Health Center|Yes|Active, not recruiting|September 2011|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|172|||Both|13 Years|18 Years|No|||December 2015|December 9, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656707||81559|
NCT01656720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRL001-01/2011 (SEFI)|A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period|A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period||Norgine||Completed|February 2012|September 2014|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|417|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656720||81558|
NCT01656941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECHO|Genetic Determinants of Congenital Heart Disease Outcomes|The GECHO Trial: Genetic Determinants of Congenital Heart Disease Outcomes|GECHO|University of Michigan|No|Recruiting|March 2011|December 2019|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|800|Samples With DNA|Whole blood samples will be frozen and stored until DNA can be isolated. Eventually,      isolated DNA samples will be frozen and stored in a biorepository.|Both|N/A|30 Days|No|Non-Probability Sample|Neonates with d-transposition of the great arteries undergoing the arterial switch        procedure and neonates with single ventricle cardiac disease undergoing stage I surgical        palliation at the University of Michigan or other collaborating institutions.|December 2014|December 1, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01656941||81541|
NCT01656954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813558|Predicting Volume Response Study|Change in Stroke Volume During Passive Leg Raise Predicts Volume Challenge Response as Measured by Arterial Pressure Cardiac Output Monitor.|PVRS|University of Pennsylvania|No|Recruiting|August 2011|December 2013|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted to the Rhoads 5 SICU on the Trauma/Surgical Critical Service who        would be anticipated to receive IV fluids or blood as part of their treatment.|July 2012|August 2, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01656954||81540|
NCT01662154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031858|Neurometer vs Nerve Stimulator: Block Patients|Percutaneous Nerve Stimulation as a Means to Assess Nerve Block Effectiveness||University of Alberta|No|Active, not recruiting|July 2012|December 2015|Anticipated|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|60|||Both|18 Years|90 Years|No|||May 2015|May 21, 2015|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01662154||81144|
NCT01662167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1133-3069|Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy|Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy: a Clinical Trail||Hormozgan University of Medical Sciences||Completed|January 2008|December 2011|Actual|December 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|87|||Female|N/A|N/A|No|||August 2012|August 9, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01662167||81143|
NCT01654783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMUM-2012|Observational Study in the Management of Ulcerative Colitis With Oral 5-ASA|Observational Study on Clinical Practice in the Management of Ulcerative Colitis With Oral 5-Aminosalicylic Acid in Japan||Kyorin Pharmaceutical Co.,Ltd|No|Completed|September 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|5704|||Both|20 Years|N/A|No|Probability Sample|University, Main hospital, General Hospital, General Practitioner|February 2015|February 17, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01654783||81704|
NCT01663584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Natera014|Multi-disease Carrier Screening Test Validation|Collection of Blood Samples for Development of Multi-disease Carrier Testing||Natera, Inc.|No|Withdrawn|August 2012|||June 2013|Actual|N/A|Observational|N/A||1|Actual|0|Samples With DNA|De-identified samples may be retained for future research.|Both|18 Years|N/A|No|Non-Probability Sample|Study participation will be open to individuals who have tested positive for carrier        status of a specific genetic disease or mutation and are able to provide documentation of        their test results.|July 2013|July 12, 2013|August 9, 2012||No|Samples were not needed for test development, therefore subjects were not recruited or    enrolled|No||https://clinicaltrials.gov/show/NCT01663584||81035|
NCT01654796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001233|Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression|Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression|RAPID|Massachusetts General Hospital|Yes|Recruiting|April 2013|April 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|65 Years|No|||July 2015|July 13, 2015|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01654796||81703|
NCT01654809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BJCDPC-1|Safety and Immunogenicity Study of Split Influenza Virus Vaccine in Different Age Groups|Evaluation of Safety and Immunogenicity Among Different Age-groups Receiving Different Split Influenza Vaccines||Beijing Center for Disease Control and Prevention|No|Completed|August 2010|June 2011|Actual|February 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|3||Actual|900|||Both|6 Months|N/A|Accepts Healthy Volunteers|||July 2012|September 30, 2012|July 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01654809||81702|
NCT01656512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHE-ALL002|Zometa Study in Pediatric Acute Lymphoblastic Leukemia|Analysis of Outcome of Bisphosphonate Use in Children With ALL- "Case Controlled Study"||Children's Cancer Hospital Egypt 57357|Yes|Suspended|October 2011|August 2015|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|120|||Both|5 Years|18 Years|No|||August 2012|February 8, 2015|July 30, 2012||No|Study Exceed Budget|No||https://clinicaltrials.gov/show/NCT01656512||81574|
NCT01656525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP22431|A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients|A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients||Chugai Pharmaceutical|No|Completed|June 2012|June 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|28|||Both|50 Years|80 Years|No|||September 2014|September 17, 2014|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01656525||81573|
NCT01657136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Casilino0001|Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia|Comparison of Ivabradine and Beta-blockers Administration in the Treatment of Inappropriate Sinus Tachycardia|CIBIST|Policlinico Casilino ASL RMB|No|Recruiting|September 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||November 2015|November 9, 2015|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657136||81526|
NCT01658033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2012-11|Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients|Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer||Fudan University|No|Completed|May 2012|November 2014|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Female|18 Years|75 Years|No|||September 2015|September 8, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01658033||81457|
NCT01657695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/08_CE_UniRer|Hepatocellular Carcinoma Growth and Molecular Aggressiveness|"Integrated Molecular/Imaging Technology for Characterization of Biological Aggressiveness of HCC in Patients Candidate to Liver Transplant"|UniRer|University of Modena and Reggio Emilia|No|Completed|June 2008|August 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|78|Samples With DNA|We have designed custom arrays selecting those genes that, on the basis of literature and      our own data, will be most informative regarding molecular pathways of relevance for HCC      onset and progression and which have been already associated with decreased survival. These      genes belong to cell cycle, apoptosis, cell proliferation, cell signaling, hypoxia and      metastasis-prone pathways.|Both|18 Years|N/A|No|Non-Probability Sample|Cirrhotic patients, at first diagnosis of HCC and potential liver transplant candidates|September 2012|September 29, 2012|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01657695||81483|
NCT01654653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LB.05.01.1.4.0.70|Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients|A Phase , Prospective, Randomized, Open-label Study to Compare the Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG (Coronary Artery Bypass Grafting) Patients||Innogene Kalbiotech Pte. Ltd|No|Completed|July 2008|March 2009|Actual|March 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|45 Years|80 Years|No|||July 2012|July 27, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01654653||81712|
NCT01654367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jzhang2|Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer|The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition|esozao|Tianjin Medical University|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Female|N/A|N/A|No|||July 2012|July 26, 2012|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654367||81734|
NCT01654640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_Metformin|The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine|Phase 4 Study of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine||Seoul National University Hospital|Yes|Recruiting|July 2012|June 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01654640||81713|
NCT01654965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01220|Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer||National Cancer Institute (NCI)|No|Active, not recruiting|July 2012|||March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||October 2015|March 14, 2016|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01654965||81691|
NCT01655875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00053638|AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia|A Pilot Study of AMD3100 as a Sensitizing Agent in Myeloablative Allogeneic Blood and Marrow Transplantation for Chemotherapy Resistant Pediatric Acute Leukemia|BMTAMD3100|Emory University|Yes|Terminated|June 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|2 Years|22 Years|No|||April 2014|April 4, 2014|July 27, 2012|No|Yes|lack of patient enrollment|No||https://clinicaltrials.gov/show/NCT01655875||81622|
NCT01655888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MESOT-TREM-2012|The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma|A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012||Azienda Ospedaliera Universitaria Senese|Yes|Recruiting|July 2012|January 2015|Anticipated|January 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|18 Years|N/A|No|||July 2012|July 31, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655888||81621|
NCT01655901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|272112|Active Video Games and Appetite Control in Adolescents|Effects of Active Video Games on Energy Balance: a Randomized Crossover Study in Adolescents||Children's Hospital of Eastern Ontario|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|30|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||February 2015|February 2, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655901||81620|
NCT01656109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 146|Atazavanir/Ritonavir-based HAART in Children|The Study of Atazavanir/Ritonavir-based HAART in Thai HIV-infected Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|July 2011|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|6 Years|18 Years|No|||August 2014|August 25, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01656109||81604|
NCT01656421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPON 87610|Assessment of Risk in Chronic Airways Disease Evaluation|Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE)|ARCADE|Cardiff University|No|Active, not recruiting|May 2011|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|750|||Both|35 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|July 2015|July 27, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656421||81581|
NCT01661686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COPAC|Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures|A Randomized Comparison of a Fully Covered Self Expandable Metal Stent Versus a Partially Covered Self Expandable Metal Stent in Malignant Esophageal Strictures|COPAC|Foundation for Liver Research|No|Recruiting|July 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|98|||Both|18 Years|N/A|No|||December 2015|December 10, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01661686||81180|
NCT01661699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-416|Oxidative Stress in Obstructive Sleep Apnea: Correlation of Biomarkers and Nasal CPAP Compliance|Oxidative Stress in Obstructive Sleep Apnea: Correlation of Biomarkers and Nasal CPAP Compliance||Georgetown University|No|Completed|August 2011|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Both|18 Years|N/A|No|Non-Probability Sample|Those over 18 years suspected of having sleep apnea.|August 2014|August 26, 2014|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01661699||81179|
NCT01657240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOPH118-0112/III|Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis|Phase 3 Clinical Trial to Evaluate the Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis||Laboratorios Sophia S.A de C.V.|Yes|Suspended|November 2014|May 2015|Anticipated|April 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|300|||Both|6 Years|60 Years|No|||June 2013|June 3, 2013|July 19, 2012||No|Formula Reformulation|No||https://clinicaltrials.gov/show/NCT01657240||81518|
NCT01661712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOSATS2012-V1.0-01/08/2012|Continuous Transcutaneous Electrical Stimulation in Sleep Apnoea|Randomised, Double-blinded, Sham-controlled Cross-over Trial of Continuous Transcutaneous Electrical Stimulation of the Pharyngeal Dilator Muscles in Obstructive Sleep Apnoea|TESLA|Guy's and St Thomas' NHS Foundation Trust|Yes|Completed|March 2013|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|75 Years|No|||December 2015|December 21, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661712||81178|
NCT01661725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hualanbio-Meningococcal CT 001|Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001|Phase I Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine||Hualan Biological Engineering, Inc.|Yes|Completed|April 2006|May 2006|Actual|April 2006|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|60|||Both|2 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 6, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661725||81177|
NCT01663077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KBK2012|Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients|Clozapine Fixed Dose Steady State Plasma Levels and the Relationship to the Polymorphism of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in Clinically Stable Schizophrenic Adult Patients||Tirat Carmel Mental Health Center|No|Recruiting|October 2012|October 2016|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|65 Years|No|||November 2014|November 14, 2014|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01663077||81074|
NCT01655758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UParma2004crossover|24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension|The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs.||University of Parma|No|Completed|January 2002|February 2004|Actual|December 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|61|||Both|40 Years|70 Years|No|||July 2012|August 1, 2012|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01655758||81631|
NCT01656239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|483-009|Dose Range Finding Study of Fedovapagon in Men With Nocturia|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia||Vantia Ltd|No|Completed|August 2012|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|358|||Male|55 Years|N/A|No|||June 2014|June 18, 2014|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656239||81594|
NCT01656278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMAGINE-RA|An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis|Does an MRI-guided Treatment Strategy Reduce Disease Activity and Progression in Patients With Rheumatoid Arthritis (RA): a Randomised Controlled Trial|IMAGINE-RA|King Christian X´Hospital for Rheumatic Diseases|Yes|Active, not recruiting|March 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01656278||81591|
NCT01656304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-064|Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy|Phase II Trial of Bevacizumab in PSA Relapse Androgen Independent Prostate Cancer (AVF3952sn)||Barbara Ann Karmanos Cancer Institute|Yes|Completed|May 2007|June 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|July 30, 2012|Yes|Yes||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01656304||81590|There was a small sample size.
NCT01657435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09001|28mm Ceramic-on-Ceramic Total Hip Replacement Study|Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prothesis System|COC28|DePuy Orthopaedics|No|Recruiting|May 2012|January 2024|Anticipated|January 2024|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2015|December 14, 2015|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657435||81503|
NCT01657708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHA-0008-12|Implementation of Shared Decision Making Model in Psychiatric Rehabilitation Setting|||Shalvata Mental Health Center||Not yet recruiting|August 2012|||August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver)|1||Anticipated|140|||Both|18 Years|65 Years|No|||August 2012|August 2, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657708||81482|
NCT01653886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10017-P|Palatability (Energy I Pilot)|Palatability of Meals That Vary in Fat and Energy Density. A Pilot Study to the Behavioral Response to Short-Term (Two Day) Positive Energy Balance Through Overfeeding (ENERGY I)||Pennington Biomedical Research Center|No|Completed|October 2010|April 2011|Actual|February 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|16|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||February 2016|February 3, 2016|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653886||81771|
NCT01654666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIPC2012|Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting|Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting||Capital Medical University|Yes|Completed|July 2012|July 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|189|||Both|18 Years|80 Years|No|||October 2015|October 13, 2015|July 23, 2012||No||No|July 23, 2015|https://clinicaltrials.gov/show/NCT01654666||81711|
NCT01658020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW224-III-3|A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg|Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.|DW224-III-3|Dong Wha Pharmaceutical Co. Ltd.|No|Completed|August 2012|August 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|345|||Both|40 Years|N/A|No|||October 2014|October 2, 2014|July 25, 2012||No||No|September 1, 2014|https://clinicaltrials.gov/show/NCT01658020||81458|
NCT01653860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/683|Partner Violence and Anger Management|Partner Violence and Anger Management: a Randomised Controlled Study of the Effectiveness of Cognitive Behavioral Therapy||Norwegian University of Science and Technology|No|Recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|134|||Male|18 Years|N/A|No|||October 2015|October 23, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01653860||81773|
NCT01655355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rivk-001-HMO-CTIL|Revision of the Hip Joint - Prospective Study|||Hadassah Medical Organization|No|Not yet recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|45 Years|85 Years|No|Non-Probability Sample|Patients that underwent a revision of the hip replacement without removing the acetabular        implant.|July 2012|July 31, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655355||81662|
NCT01655368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEM|Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM)|Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM)|STEM|Heinrich-Heine University, Duesseldorf|No|Active, not recruiting|May 2012|October 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|512|||Both|18 Years|65 Years|No|||August 2015|August 17, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01655368||81661|
NCT01655004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BR05/14/12|Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD|Prospective Study of UDP-gluconoryltransferase (UGT) 2B17 Genotype as a Predictive Marker of Exemestane Pharmacokinetics and Pharmacodynamics in Asian Women With Hormone Receptor-positive Advanced Breast Cancer||National University Hospital, Singapore|Yes|Recruiting|August 2012|August 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|110|||Female|21 Years|N/A|No|||June 2015|June 17, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655004||81689|
NCT01655017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100503|Fibrosis a New Pathological Actor in Adipose Tissue|Fibrosis a New Pathological Actor in Adipose Tissue|fibrota|Assistance Publique - Hôpitaux de Paris|No|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|300|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|July 2, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01655017||81688|
NCT01655316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16062|Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control|||Tehran University of Medical Sciences|No|Completed|October 2010|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||November 2012|November 12, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655316||81665|
NCT01655329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MF 2012-1|Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image|Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image. AP Stands for Antero-Posterior. PA Stands for Postero-anterior.||Georgetown University|No|Completed|August 2012|February 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|There are two populations: the radiologists and the cases they will review. For cases,        these are sequential cases selected by database search using defined search criteria.|June 2014|June 9, 2014|July 30, 2012|Yes|Yes||No|February 2, 2014|https://clinicaltrials.gov/show/NCT01655329||81664|
NCT01656122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 167|Abacavir and Lamivudine PK in Children|Pharmacokinetics of Abacavir Once Daily vs. Twice Daily and Lamivudine Once Daily vs. Twice Daily in HIV-infected Thai Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|July 2012|July 2015|Actual|July 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|N/A|18 Years|No|||February 2016|February 18, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01656122||81603|
NCT01656135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONErgt11|Reference Group Trial for The ONE Study|Reference Group Trial for The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation||University of Regensburg|No|Completed|December 2012|December 2015|Actual|December 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|70|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656135||81602|
NCT01656395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1029-012|A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects With Persistent Asthma||Merck Sharp & Dohme Corp.|No|Terminated|August 2012|July 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|557|||Both|18 Years|65 Years|No|||July 2015|July 29, 2015|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656395||81583|
NCT01656408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8150-002|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150||Merck Sharp & Dohme Corp.|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|10||Actual|103|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656408||81582|
NCT01656148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FAME|FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra|Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra|FAME|University of Southern Denmark|Yes|Completed|June 2012|May 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|60 Years|No|||May 2014|May 9, 2014|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656148||81601|
NCT01661205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2012-1|Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)|Feasibility Trial of a Staged Epicardial & Endocardial Approach for Treatment of Patients With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation|Staged DEEP|AtriCure, Inc.|Yes|Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661205||81217|
NCT01656980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LJ-Glioma 3. 3.0 Version|Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma|Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma||Shandong Lanjin Pharmaceuticals Co.,Ltd|Yes|Not yet recruiting|August 2012|December 2014|Anticipated|August 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|236|||Both|18 Years|70 Years|No|||August 2012|August 2, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656980||81538|
NCT01654484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|33-001|A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT|A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension||Santen Inc.|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|8||Actual|60|||Both|18 Years|N/A|No|||October 2012|December 14, 2012|July 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654484||81725|
NCT01663311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-Ti-CDC01|Repetitive Transcranial Magnetic Stimulation With Double Cone Coil in Chronic Tinnitus|Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) With Double-Cone-Coil in Patients With Chronic Tinnitus (Ti-CDC)|Ti-CDC|University of Regensburg|No|Completed|July 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|70 Years|No|||April 2014|April 25, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01663311||81056|
NCT01655498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA003|A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE)|A Clinical Evaluation of the LivSure Vaginal Bowel Control (VBC) System for the Treatment of Fecal Incontinence in Women.|LIFE|Pelvalon, Inc.|No|Completed|August 2012|March 2014|Actual|January 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Female|19 Years|75 Years|No|||May 2015|May 22, 2015|July 24, 2012|Yes|Yes||No|April 1, 2015|https://clinicaltrials.gov/show/NCT01655498||81651|
NCT01655771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0083|TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects|A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects||Theravance Biopharma R & D, Inc.|No|Completed|August 2012|March 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655771||81630|
NCT01655784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120439|Framing Eighteen Coils in Cerebral Aneurysms Trial|Framing Eighteen Coils in Cerebral Aneurysms Trial: FEAT|FEAT|Vanderbilt University|Yes|Recruiting|August 2012|January 2019|Anticipated|August 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|660|||Both|18 Years|80 Years|No|||February 2015|February 26, 2015|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655784||81629|
NCT01656837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA029726-02|Family-Based Treatment for Parental Substance Abuse and Child Maltreatment|Family-Based Treatment for Parental Substance Abuse and Child Maltreatment||Medical University of South Carolina|No|Active, not recruiting|April 2011|July 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|6 Years|N/A|No|||April 2015|April 10, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656837||81549|
NCT01657734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53303|Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy|||Universitaire Ziekenhuizen Leuven||Recruiting|September 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated with glioblastoma treated with dendritic cell therapy|May 2011|August 1, 2012|September 7, 2011||No||No||https://clinicaltrials.gov/show/NCT01657734||81480|
NCT01654679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HydrosunWoundHealing|Impact of Preoperative Local Water-Filtered Infrared-A (wIRA) Irradiation on Postoperative Wound Healing|Impact of Preoperative Local Water-Filtered Infrared-A (wIRA) Irradiation on Postoperative Wound Healing - A Randomized Patient- and Observer Blinded Controlled Clinical Trial|Hydrosun|German Research Foundation|No|Completed|August 2008|July 2012|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|400|||Both|30 Years|80 Years|No|||September 2012|September 5, 2012|July 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01654679||81710|
NCT01653873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202077RIC|Imaging Parameters to Predict Future Vertebral Fracture in Osteoporosis|to Compare the Efficacy of Parameters From Different Imaging Modality in Predicting the Risk of Future Vertebral Compression Fracture in Osteoporotic Patients.||National Taiwan University Hospital|No|Recruiting|July 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Non-Probability Sample|all the patients received vertebroplasty treatment between 2005.01-2011.12|January 2014|January 23, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653873||81772|
NCT01654692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIBIT-M1|A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma|A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients With Unresectable Locally Advanced or Metastatic Malignant Melanoma|NIBIT-M1|Italian Network for Tumor Biotherapy|Yes|Completed|June 2010|September 2014|Actual|May 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|86|||Both|18 Years|N/A|No|||May 2015|May 12, 2015|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01654692||81709|
NCT01655381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28174|A Long-Term Extension Study of WA19926 on the Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open Label, Single Arm, Long-term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis||Hoffmann-La Roche||Completed|April 2012|March 2016|Actual|March 2016|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01655381||81660|
NCT01655628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120704|GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma|Autologous Cytokine-Induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma||Sun Yat-sen University|Yes|Recruiting|July 2012|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|60 Years|No|||July 2012|August 1, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01655628||81641|
NCT01655394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01607831337|Change of Nerve Conduction Properties in IVIg Dependent Neuropathies|Change of Nerve Conduction Properties in IVIg Dependent Neuropathies||University of Cologne|No|Active, not recruiting|October 2012|June 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|Serum|Both|18 Years|N/A|No|Probability Sample|patients with immune neuropathies|December 2014|December 11, 2014|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655394||81659|
NCT01655914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLS002|Safety and Pharmacokinetic Study of Sublingual Flumazenil (CRLS035) in Healthy Adults|Open Label, Randomized, Three-way Crossover Study to Assess the Safety and the Pharmacokinetics of Sublingual Flumazenil (CRLS035) in Healthy Adults||Coeruleus Ltd.||Completed|July 2010|August 2012|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 29, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655914||81619|
NCT01655927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT28072012FIRE|Efficacy of Tranexamic Acid in Brain Tumor Resections|PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS|COLFIRE|Colombian Foundation for Epilepsy and Neurological Disease|Yes|Recruiting|July 2012|||July 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|65 Years|No|||July 2012|July 31, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655927||81618|
NCT01661231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1106|Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe|BIOTRONIK - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar-18 Stents (BIOFLEX-I Europe)|BIOFLEX-I EU|Biotronik AG||Active, not recruiting|October 2012|October 2018|Anticipated|September 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|456|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661231||81215|
NCT01661244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RVH007|A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV568 in Healthy Volunteers||Respivert Ltd|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661244||81214|
NCT01661192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006971ctil|Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes|Open Label Study (Extension 001)to Evaluate Long Term Treatment Effect of the Safety, Tolerability and Efficacy of Intervenous ALPHA-1 ANTITRYSIN (AAT)Glasia™ in Type 1 Diabetes Mellitus (Extension to KAMADA AAt 008, PHASE I/II Study)|AAT Extension|Rabin Medical Center|No|Active, not recruiting|January 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|24|||Both|10 Years|25 Years|No|||November 2015|November 26, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661192||81218|
NCT01661452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F110510007|Development of Post Traumatic Stress Disorder After Natural Disaster|Development of Post Traumatic Stress Disorder After Natural Disaster||University of Alabama at Birmingham||Completed|June 2011|September 2013|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|629|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to UAB emergency room, outpatient trauma clinics and substance abuse        center.|November 2013|December 2, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661452||81198|
NCT01661751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hualanbio-Meningococcal CT 003|Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 003|Phase III Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine||Hualan Biological Engineering, Inc.|Yes|Completed|May 2006|August 2006|Actual|May 2006|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|900|||Both|2 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 6, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01661751||81175|
NCT01661946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QueensU|Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye|Systemic Absorption of Bevacizumab and Ranibizumab in Humans Treated for Diabetic Macular Edema||Queen's University|No|Completed|August 2012|August 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|10|||Both|18 Years|N/A|No|||August 2013|August 21, 2013|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661946||81160|
NCT01662726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C/24/2011|A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth|A Phase II, Open Label, Preoperative Study to Assess the Efficacy of the Novel Steroid Sulfatase Inhibitor Irosustat in Postmenopausal Women With Early Oestrogen Receptor Positive Breast Cancer|IPET|Imperial College London|No|Terminated|August 2012|December 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Female|18 Years|N/A|No|||August 2013|March 11, 2016|August 7, 2012||No|Recruitment challenging: lack of suitable pts; recruiting so soon after diagnosis; competing    studies. Funding ended despite extensions to grant.|No||https://clinicaltrials.gov/show/NCT01662726||81101|
NCT01663324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-Reg-multisite-rTMS-Tin-01|rTMS for the Treatment of Chronic Tinnitus: Optimization by Simulation of the Cortical Tinnitus Network|Repetitive Transcranial Magnetic Stimulation for the Treatment of Chronic Tinnitus: Optimization by Stimulation of the Cortical Tinnitus Network|Multisite rTMS|University of Regensburg|No|Completed|July 2012|January 2015|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01663324||81055|
NCT01655511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3461040|Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Crossover, Ascending Dose-Tolerance Study To Assess The Safety And Pharmacokinetics Of Tafamidis Doses Greater Than 120 Mg As Oral Solution In Healthy Volunteers||Pfizer|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|3||Actual|9|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01655511||81650|
NCT01655797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RFR-10276|Cognitive Behavior Therapy for Insomnia in Primary Care|Treating Insomnia in Primary Care: A Study of Effectiveness and Dissemination|TIRED|Uppsala University|No|Completed|May 2008|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||July 2012|July 30, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01655797||81628|
NCT01656031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21204 Phase 2|A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia|A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia||Comprehensive Cancer Center of Wake Forest University|Yes|Active, not recruiting|February 2005|||November 2008|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|120 Years|No|||October 2015|October 22, 2015|July 31, 2012|Yes|Yes||No|January 10, 2013|https://clinicaltrials.gov/show/NCT01656031||81610|
NCT01657149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0081-12-RMC|Influence of Manual Lymph Drainage During Hospitalization on Swelling, Function and Pain in Patients After Total Knee Replacement|Influence of Manual Lymph Drainage During Hospitalization on Swelling, Function and Pain in Patients After Total Knee Replacement - Randomized Control Trial.||Rabin Medical Center|Yes|Not yet recruiting|September 2012|September 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|85 Years|No|||January 2012|August 6, 2012|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01657149||81525|
NCT01657162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA058-05-005|Twenty Four Month Extension Study of BA058-05-003|An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003|ACTIVExtend|Radius Health, Inc.|No|Active, not recruiting|October 2012|||October 2016|Anticipated|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1200|||Female|N/A|N/A|No|||January 2015|January 14, 2015|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657162||81524|
NCT01658046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMES-COPD|Effects of Neuromuscular Electrical Stimulation as an Adjunct to Exercise Training in Stable Chronic Obstructive Pulmonary Disease (COPD)|Effects of Neuromuscular Electrical Stimulation as an Adjunct to Exercise Training in Stable COPD||Hacettepe University|Yes|Completed|July 2009|August 2011|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|27|||Both|35 Years|75 Years|No|||August 2012|August 3, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658046||81456|
NCT01654146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-022209-16|ICON8: Weekly Chemotherapy in Ovarian Cancer|An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|ICON8|Medical Research Council|Yes|Recruiting|June 2011|||June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1485|||Female|18 Years|N/A|No|||July 2012|July 26, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01654146||81751|
NCT01654380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12157|A Study of LY2605541 Versus Insulin Glargine on Blood Sugar|Comparison of the Effects of LY2605541 and Insulin Glargine on Endogenous Glucose Output and Peripheral Glucose Disposal in Healthy Subjects and Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|July 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Anticipated|24|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2013|October 18, 2013|July 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01654380||81733|
NCT01655641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|# WS2017115|Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery|Role of Tranexamic Acid for Reducing Blood Loss in Patients Undergoing Major Gastro-intestinal Surgery|TMGS|Tribhuvan University Teaching Hospital, Institute Of Medicine.|Yes|Active, not recruiting|July 2012|July 2014|Anticipated|June 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|118|||Both|16 Years|N/A|No|||October 2012|October 14, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01655641||81640|
NCT01655654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSWR-002-EHW|Prevalence, Awareness and Management of Hypertension in Acute Care Personnel|Prevalence, Awareness and Management of Hypertension in Acute Care Personnel||Providence Health & Services|No|Active, not recruiting|August 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2013|May 21, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655654||81639|
NCT01660698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.03.MET|Immune-modulatory Effect of Probiotic Strain on Grass Pollen Allergic Individuals|Immune-modulatory Effect of Candidate Probiotic Strain on Whole Blood Cells of Grass Pollen Allergic Individuals||Nestlé|Yes|Completed|May 2011|January 2012|Actual|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|65 Years|No|||July 2013|July 11, 2013|August 2, 2012||No||No|April 2, 2013|https://clinicaltrials.gov/show/NCT01660698||81256|
NCT01660711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH12-267|A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma|A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma||NorthShore University HealthSystem|Yes|Active, not recruiting|July 2012|July 2018|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|21|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660711||81255|
NCT01661270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11338|A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy|A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen|AFLAME|Sanofi|Yes|Completed|July 2012|July 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|332|||Both|18 Years|N/A|No|||October 2015|October 22, 2015|August 7, 2012|Yes|Yes||No|October 22, 2015|https://clinicaltrials.gov/show/NCT01661270||81212|
NCT01661491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206010476|Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis|Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis||Yale University|No|Recruiting|August 2012|December 2020|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples Without DNA|Fecal samples|Both|3 Months|4 Years|Accepts Healthy Volunteers|Non-Probability Sample|Infants and children up to the age of 4 with Cystic Fibrosis, and age-matched controls        without cystic fibrosis will be eligible for this study. Participants will be recruited        from the Cystic Fibrosis clinic and Primary Care Clinic of the Yale New Haven Hospital.|January 2015|January 20, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01661491||81195|
NCT01658163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prineo|Use of 2-octyl-cyanoacrylate Together With a Self-adhering Mesh|Use of 2 Octyl-cyanoacrylate Together With a Self-adhering Mesh for Skin Closure Following Abdominoplasty: An Open, Prospective, Controlled, Randomized Clinical Study||Medical University of Graz|Yes|Completed|June 2009|September 2011|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|2|||Both|18 Years|65 Years|No|Probability Sample|primary care clinic|January 2013|January 3, 2013|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01658163||81447|
NCT01661465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X110422001|Routine Clinical Screening for Substance Use Disorders in the Emergency Room Setting|Routine Clinical Screening for Substance Use Disorders in the Emergency Room Setting||University of Alabama at Birmingham|No|Terminated|May 2011|December 2013|Actual|December 2013|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|9212|||Both|19 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients presenting to University Hospital Emergency Department|March 2015|March 13, 2015|August 7, 2012||No|The Principal Investigator left the site.|No||https://clinicaltrials.gov/show/NCT01661465||81197|
NCT01663090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-254|Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas|Ferumoxytol-Enhanced Magnetic Resonance Imaging (MRI) in Pediatric and Adult Patients With Malignant Sarcoma: A Two-part Pilot Study for Safety and Efficacy in the Pediatric and Adult Populations||Dana-Farber Cancer Institute|Yes|Recruiting|September 2012|||September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|49|||Both|12 Years|N/A|No|||August 2015|August 3, 2015|July 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663090||81073|
NCT01663116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cx611-0101|Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients|"Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic Adipose-derived Mesenchymal Cells (eASCs) to Refractory Rheumatoid Arthritis (RA) Patients".||Cellerix|Yes|Completed|March 2011|January 2013|Actual|January 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|53|||Both|18 Years|N/A|No|||February 2013|March 5, 2013|August 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01663116||81071|
NCT01663337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39884|Sequence of Symptom Change During AUD or PTSD Treatment for Comorbid PTSD/AUD|Sequence of Symptom Change During AUD (Alcohol Use or Dependence) or PTSD (Posttraumatic Stress Disorder) Treatment for Comorbid PTSD/AUD||University of Washington|Yes|Recruiting|March 2013|November 2018|Anticipated|November 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|235|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01663337||81054|
NCT01656317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2189.|Rehabilitation of Patients After Subarachnoid Hemorrhage|Effect of Early Rehabilitation in Patients With Acute Subarachnoid Hemorrhage|SAH|Oslo University Hospital|Yes|Active, not recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|160|||Both|18 Years|N/A|No|||October 2014|October 17, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01656317||81589|
NCT01656577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912475|Pexacerfont for Stress-induced Food Craving|Pexacerfont for Reduction of Stress-Induced Food Craving and Eating in Humans||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|December 2019|Anticipated|December 2019|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|75|||Both|21 Years|65 Years|No|||June 2012|January 30, 2013|July 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656577||81569|
NCT01657448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYSEMS0112|Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria|Phase III, Prospective, Multicenter, Single-blind, Randomized, Superiority to Evaluate the Efficacy and Safety of Methenamine Association 250mg + Methylthioninium Chloride 20 mg Compared to Phenazopyridine 100 mg in Symptomatic Control of Dysuria||EMS|Yes|Not yet recruiting|January 2016|October 2016|Anticipated|July 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|316|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657448||81502|
NCT01657461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NV-SFR004|Solitaire With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial|Solitaire™ FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial|SWIFT PRIME|Medtronic - MITG|Yes|Completed|November 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|80 Years|No|||February 2015|February 25, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657461||81501|
NCT01654393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01352|Triage Nurse Initiated Radiographs According to OAR|Can Triage Nurse Initiated Radiographs in Accordance With the Ottawa Ankle Rule Shorten Emergency Department Length of Stay At a Tertiary Care Center?||Vancouver Coastal Health|No|Recruiting|July 2012|February 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research|2||Anticipated|142|||Both|19 Years|N/A|No|||September 2012|September 10, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654393||81732|
NCT01654159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOL2012|Assessment of Visual Function and Optics in Intraocular Lenses|Evaluating Subjective and Objective Performance of Instrumentation Used and Devices Implanted in Cataract Surgery||Aston University|No|Enrolling by invitation|September 2013|December 2024|Anticipated|December 2024|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|500|||Both|40 Years|85 Years|No|||January 2015|January 14, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01654159||81750|
NCT01654172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05/Q2401/146|Effect of Flavanol-rich Cocoa on Peripheral and Cerebral Blood Flow in Type 2 Diabetes|Effect of Flavanol-rich Cocoa on Peripheral and Cerebral Blood Flow in Type 2 Diabetes||University of Nottingham|Yes|Completed|September 2006|December 2008|Actual|December 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|18|||Both|35 Years|70 Years|No|||July 2012|July 30, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01654172||81749|
NCT01654406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMU-JIRB 201203007|Fractional CO2 Laser in the Treatment for Cesarian Scar|||Taipei Medical University WanFang Hospital||Recruiting|July 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|N/A|N/A|No|||July 2012|July 27, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01654406||81731|
NCT01655030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-BD-RCT|Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression|A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Creatine Monohydrate as Adjunctive Therapy for Bipolar Depression||University of Sao Paulo|No|Recruiting|July 2012|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|60 Years|No|||December 2015|December 1, 2015|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01655030||81687|
NCT01655342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Moran- HMO-CTIL|Assessment of the Effectiveness of Biodentine® in Pulpotomies Primary Teeth|Assessment of the Effectiveness of Biodentine® in Pulpotomies Primary Teeth.||Hadassah Medical Organization||Active, not recruiting|August 2012|||August 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|3 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|Healthy children attending the Pediatric Dentistry Clinic of the Hebrew        University-Hadassah School of Dental Medicine in Jerusalem|July 2015|August 19, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655342||81663|
NCT01655043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00050900|Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI|Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI||Northwestern University|Yes|Completed|September 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|20|||Both|19 Years|89 Years|No|||March 2015|March 30, 2015|July 30, 2012|Yes|Yes||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01655043||81686|The small number of subjects results in reduced statistical power; The cohort was selected from patients at a single medical center, potentially reducing generalizability
NCT01655056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|150-CL-006|A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YM150 in Healthy Caucasian and Japanese Male and Female Subjects||Astellas Pharma Inc|No|Completed|June 2006|November 2006|Actual|November 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|5||Actual|82|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||July 2012|June 24, 2013|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01655056||81685|
NCT01655407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lonza-ESS01|Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds|Evaluation of Autologous Engineered Skin Substitute (ESS-W) Compared to Meshed, Split-Thickness Autograft (AG) for Treatment of Deep Partial- and Full-Thickness Thermal Burn Wounds in Adult Patients||Amarantus BioScience Holdings, Inc.|Yes|Not yet recruiting|April 2016|July 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|40 Years|No|||October 2015|February 23, 2016|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655407||81658|
NCT01660438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TVT 112010|Urethral Length Measurement in Women Undergoing Suburethral Sling Operative Procedure|Prospective, Non-randomized, Observational Study of the Surgical Management of Suburethral Slings in Women With Stress Urinary Incontinence||Cantonal Hospital, Frauenfeld|Yes|Completed|August 2010|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|188|||Female|18 Years|N/A|No|Probability Sample|Women who have surgically-correctable stress urinary incontinence and undergo a        suburethral sling operative procedure.|August 2013|August 9, 2013|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660438||81276|
NCT01660451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16349|Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas|Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas|CHRONOS-1|Bayer|Yes|Active, not recruiting|November 2012|July 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|223|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|August 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01660451||81275|
NCT01660724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mulvarp2012|Ultrasound Guided Arterial Puncture|Ultrasound Guided Arterial Puncture: a Prospective, Blinded, Randomised Controlled Trial.||Odense University Hospital|No|Completed|July 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|238|||Both|16 Years|N/A|No|||August 2013|August 2, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01660724||81254|
NCT01660737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|180A12PALL|Observational Study With PASCALLERG ® in Patients With Hay Fever|Observational Study With PASCALLERG ® in Patients With Hay Fever||Pascoe Pharmazeutische Praeparate GmbH|No|Recruiting|February 2012|September 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|1 Year|N/A|No|Probability Sample|patients from natural practioners and doctors from Germany|August 2012|August 13, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01660737||81253|
NCT01657903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z6961385|Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion|A Placebo Controlled Study to Evaluate the Effectiveness of Experimental Foaming Gel Toothpastes Using an In-situ Erosion Remineralization Model||GlaxoSmithKline|No|Completed|November 2011|February 2012|Actual|February 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|56|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2014|January 22, 2015|August 2, 2012|Yes|Yes||No|January 16, 2014|https://clinicaltrials.gov/show/NCT01657903||81467|
NCT01661010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120181|The Clinical Study of Sex Chromosome Variants|The Clinical Study of Patients With Sex Chromosome Variants||National Institutes of Health Clinical Center (CC)||Recruiting|July 2012|||||N/A|Observational|N/A|||Anticipated|150|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661010||81232|
NCT01653769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BS11-000639|CoSeal for Hemostasis of Aortic Anastamoses|CoSeal for Hemostasis of Aortic Anastomoses: A Propensity-Matched Cohort Study||The Methodist Hospital System|Yes|Recruiting|June 2012|July 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|150|None Retained|Time perspective is both retrospective and prospective.|Both|N/A|N/A|No|Non-Probability Sample|Subjects for this study will be selected from patients undergoing cardio-thoracic surgery        requiring a large aortic anastomosis. Both the retrospective and prospective study        components will review the data of all procedures requiring a large aortic anastomosis in        order to compare those in which CoSeal® was used versus other materials/techniques.        For the retrospective arm of the study, pre-existing data will be collected from the        patient's medical records under a HIPAA Waiver of Authorization. For the prospective arm        of the study, patients will provide consent to collect their data.        Approximately 150 patients will be enrolled in this study. Specifically, consecutive        potential subjects will be evaluated for participation in this study according to the        inclusion and exclusion criteria.|July 2012|July 27, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01653769||81780|
NCT01658423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIFS-002|Maturity and Motor Fitness|EFFECT OF MATURITY ON SPRINT AND JUMP PERFORMANCES IN ADOLESCENT BOYS.|MMF|National Institute of Fitness and Sports in Kanoya|Yes|Completed|March 2011|March 2012|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|107|||Male|156 Months|167 Months|Accepts Healthy Volunteers|Non-Probability Sample|Junior high school students|August 2012|August 6, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658423||81427|
NCT01654029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCCI 93790|Patient Centred Communication Intervention|Patient Centred Communication Intervention|PCCI|University Health Network, Toronto|No|Completed|September 2010|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|N/A|N/A|No|||April 2014|April 23, 2014|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01654029||81760|
NCT01663129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-07e|Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study|Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS)|STOPP-CIS|Children's Hospital of Eastern Ontario|No|Active, not recruiting|January 2005|January 2017|Anticipated|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|406|||Both|1 Month|16 Years|No|Probability Sample|Children will be recruited into the study following a clinical diagnosis of        glucocorticoid-requiring leukemia, rheumatic disease or nephrotic syndrome, as determined        by the study collaborators in each of the three sub-specialties according to their usual        clinical practice. Potential participants will be identified by the attending physician        (oncologist, rheumatologist or nephrologist) who will then refer the patient to the site        bone designee. The bone designee (or his/her research assistant) will be responsible for        determining patient eligibility and for carrying out the requirements of the study.|February 2016|February 22, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01663129||81070|
NCT01656330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100867|A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers|Randomized, Parallel-Group, Open-Label Study to Assess the Effects of 3-Factor and 4-Factor Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban||Janssen Research & Development, LLC||Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|35|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 18, 2013|July 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656330||81588|
NCT01656590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ7305|High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease|High Protein Nutrition and Exercise Therapy (HPET) Plus Nocturnal Enteral Feeding (NEF) in Juvenile-onset Pompe Disease.||Columbia University|No|Withdrawn|October 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|8 Years|17 Years|No|||April 2015|April 9, 2015|August 1, 2012||No|PI left the institution|No||https://clinicaltrials.gov/show/NCT01656590||81568|
NCT01656850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PV0805|The Effect of Whole Almonds on Biomarkers of Cardiovascular Disease in Chinese Patients With Type 2 Diabetes|The Effect of Whole Almonds on Glucoregulation, Endothelial Function, Inflammation, Lipid Profile, and Oxidative Stress in Chinese Patients With Type 2 Diabetes||Taipei Medical University|Yes|Completed|November 2011|December 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|70 Years|No|||February 2016|February 16, 2016|January 13, 2012||No||No|October 19, 2015|https://clinicaltrials.gov/show/NCT01656850||81548|
NCT01656863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|00-15-12 HYMC|Oral Rehydration Therapy in Children With Mild to Moderate Dehydration|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Parents of children suffering dehydration reporting to pediatric emergency room|August 2012|August 2, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656863||81547|
NCT01657747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53580|Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer|Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer|S53580|Universitaire Ziekenhuizen Leuven|No|Completed|November 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|350|||Female|N/A|N/A|No|||September 2011|July 1, 2015|November 2, 2011||No||No||https://clinicaltrials.gov/show/NCT01657747||81479|
NCT01654432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0004-B|A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery|A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery||Women's College Hospital|No|Active, not recruiting|July 2011|December 2013|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|85 Years|No|||November 2013|November 15, 2013|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654432||81729|
NCT01654705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|223_PANTO_09|Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fasting Study|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate Equivalent to 40 mg of Pantoprazole) of Ohm Laboratories Inc. (a Subsidiary of Ranbaxy Pharmaceuticals Inc, USA) With PROTONIX® 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate Equivalent to 40 mg of Pantoprazole) of Wyeth Pharmaceuticals Inc. in Healthy, Adult, Male, Human Subjects Under Fasting Conditions.||Ranbaxy Inc.|No|Completed|September 2009|December 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|80|||Male|19 Years|43 Years|Accepts Healthy Volunteers|||June 2012|July 28, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01654705||81708|
NCT01654419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|006-2010|Comparison of the Quantity of Distal Movement of the Upper Canine and Molar|Comparison of the Quantity of Distal Movement of the Upper Canine and Molar Using Class II Elastics With and Without Sliding Jig in a Period of 3 Months||Universidad de Antioquia|Yes|Completed|March 2010|May 2012|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|13 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01654419||81730|
NCT01659554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI1246|A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers|A Phase II Combined Modality Protocol of Debulking Surgery With Heated Intraoperative Chemotherapy (HIPEC) Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancers|HIPEC|Columbia University|Yes|Terminated|March 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|18 Years|N/A|No|||March 2015|March 2, 2015|July 10, 2012|Yes|Yes|Principal Investigator left institution|No|November 3, 2014|https://clinicaltrials.gov/show/NCT01659554||81342|Zero participants analyzed due to early termination of study. Adverse Events could not be collected over the pre-specified Time Frame ("5 years") due to study termination
NCT01659567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25544|An Observational Study of Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C|Prospective Observational Study on Predictors of On-treatment Response and Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegylated Interferons in Georgia||Hoffmann-La Roche||Completed|April 2011|October 2015|Actual|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|530|||Both|18 Years|N/A|No|Probability Sample|Adult patients with chronic hepatitis C infection and naive to peginterferon/ribavirin        treatment|March 2016|March 1, 2016|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01659567||81341|
NCT01660152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11019|Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery|Analysis of Technique Comparison With a Vacuum Erection Device as Part of an Erectile Rehabilitation Program Following Robotic Radical Prostatectomy: A Randomized Comparison of Methodology||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|September 2011|||July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Male|N/A|70 Years|No|||July 2015|July 10, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660152||81296|
NCT01660464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD-Team-03|Guided Self-Help for Parents of Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|Guided Self-Help for Parents of Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD): A Feasibility and Effectiveness Study||University of Cologne|No|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|13 Years|18 Years|No|||April 2014|April 14, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660464||81274|
NCT01660763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IAP311|Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery|P3 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Knee or Hip Replacement Surgery||AcelRx Pharmaceuticals, Inc.|No|Completed|August 2012|May 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|419|||Both|18 Years|N/A|No|||September 2015|September 30, 2015|August 7, 2012|Yes|Yes||No|October 24, 2013|https://clinicaltrials.gov/show/NCT01660763||81251|
NCT01661218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCH20120530|Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients|Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients(CVCCP)|CVCCP|Beijing Huanxing Cancer Hospital|Yes|Enrolling by invitation|August 2012|September 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|3500|||Both|18 Years|N/A|No|Non-Probability Sample|All adult cancer patients with CVC and PICC placed at BeijingHCH and with written consent        for this study|August 2012|August 6, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661218||81216|
NCT01657929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IDRI-FPVPX-112|H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects||IDRI|Yes|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|5||Actual|105|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||February 2014|February 24, 2014|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657929||81465|
NCT01653795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMA-U vs SLMA (multiple sizes)|A Comparison of the Laryngeal Mask Airway (LMA) - Unique and LMA-Supreme in Children|A Randomized Trial Comparing the Laryngeal Mask Airway-Unique and Laryngeal Mask Airway-Supreme in Children||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|July 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|180|||Both|3 Months|11 Years|Accepts Healthy Volunteers|||November 2012|November 17, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653795||81778|
NCT01661478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X110721008|Healthcare Provider Attitudes Towards Patients With Substance Use Before and After Implementation of the SBIRT Model in the Emergency Room|Healthcare Provider Attitudes Towards Patients With Substance Use Before and After Implementation of the SBIRT Model in the Emergency Room||University of Alabama at Birmingham||Completed|September 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|200|||Both|19 Years|N/A|No|Non-Probability Sample|Personnel in the Emergency Medicine Department and the Department of Psychiatry|August 2012|August 7, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661478||81196|
NCT01661738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hualanbio-Meningococcal CT 002|Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002|Phase II Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine||Hualan Biological Engineering, Inc.|Yes|Completed|May 2006|June 2006|Actual|May 2006|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|360|||Both|2 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 6, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661738||81176|
NCT01653782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6411023|Cost Effectiveness of Medical Yoga Therapy on Low Back Pain|Cost Effectiveness of Early Interventions for Non-specific Low Back Pain: A Randomized Controlled Study Investigating Medical Yoga, Exercise Therapy and Evidence Based Advice|MYTH|Karolinska Institutet|No|Completed|September 2009|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|159|||Both|18 Years|60 Years|No|||February 2016|February 15, 2016|June 28, 2012||No||No|September 25, 2013|https://clinicaltrials.gov/show/NCT01653782||81779|Problems in recruiting eligible subject and drop outs especially in the control group resulted in a small number of subjects analysed.
NCT01654822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV2-HPV-001|AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections|Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load||Cesa Projects International|No|Active, not recruiting|August 2012|January 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Female|25 Years|40 Years|No|||November 2012|November 8, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01654822||81701|
NCT01654835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-587|A Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Low Systolic Blood Pressure|||The Cleveland Clinic|Yes|Active, not recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|711|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01654835||81700|
NCT01664156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC-OH-IRB 2012-004|Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet|Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial||The Korean Society of Ginseng|Yes|Completed|October 2012|March 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Female|16 Years|60 Years|No|||March 2014|March 12, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01664156||80991|
NCT01663610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012334314|Online Course Teachning Adults With ADHD How to Use a Smartphone|Online Course for Adults With ADHD or Subclinical ADHD Teaching How to Use a Smartphone as a Support in Their Everyday Life|VardagsSMART|Karolinska Institutet|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||May 2014|May 15, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01663610||81033|
NCT01663623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115466|Belimumab in Remission of VASculitis|A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis|BREVAS|GlaxoSmithKline|Yes|Active, not recruiting|March 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|August 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01663623||81032|
NCT01656876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRC-09-10-08|The Effects of Mirror Therapy on Upper Extremity in Stroke Patients|The Effects of Mirror Therapy on Upper Extremity in Stroke Patients||Taipei Medical University Hospital|No|Completed|September 2010|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|60|||Both|20 Years|75 Years|No|||November 2012|November 3, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01656876||81546|
NCT01657175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009 /117|Quality of Life After Oesophageal or Gastric Cancer Surgery|Quality of Life and Supportive Care Needs After Oesophageal or Gastric Cancer Surgery.||Region Skane|No|Recruiting|January 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||July 2013|July 5, 2013|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01657175||81523|
NCT01657474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFDFU002|Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Study of Amniotic Membrane Wound Graft With Weekly Versus BiWeekly Application In the Management of Diabetic Foot Ulcers||MiMedx Group, Inc.||Completed|September 2012|November 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657474||81500|
NCT01653899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00024049|Caspase Inhibition in Islet Transplantation|Improving Engraftment, Islet Survival and Metabolic Reserve in Clinical Islet Transplantation Using Caspase Inhibitor - IDN-6556||University of Alberta|Yes|Active, not recruiting|June 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|68 Years|No|||November 2015|November 30, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01653899||81770|
NCT01653912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKB116611|Dose-finding Study in Platinum-Resistant Ovarian Cancer|An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer||Accenture|No|Active, not recruiting|December 2012|September 2015|Anticipated|August 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Female|18 Years|N/A|No|||December 2014|December 18, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653912||81769|
NCT01654445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 2.2, Aug 28,2013|TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion|A Phase 2, Prospective, Two Cohort, Dose-escalation, Safety and Feasibility Study of Thrombolysis for Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion Using TNK-tPA|TEMPO-1|University of Calgary|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01654445||81728|
NCT01654718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|251_PANTO_08|Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fed Study|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate is Equivalent to 40 mg of Pantoprazole) of OHM Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceuticals Inc. USA) With PROTONIX® 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate is Equivalent to 40 mg of Pantoprazole) of Wyeth Laboratories in Healthy, Adult, Human, Male Subjects Under Fed Conditions.||Ranbaxy Inc.|No|Completed|October 2008|November 2009|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|20 Years|37 Years|Accepts Healthy Volunteers|||June 2012|July 28, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01654718||81707|
NCT01655069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|905-CL-077|A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076|An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects With Overactive Bladder (OAB)|LEOPARD|Astellas Pharma Inc|No|Completed|October 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|148|||Both|5 Years|17 Years|No|||July 2015|July 23, 2015|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655069||81684|
NCT01655082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V00116 TD 2 02|Nicotine Patch Safety Study|||Pierre Fabre Medicament||Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|160|||Both|18 Years|N/A|No|||December 2012|December 10, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655082||81683|
NCT01660165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 0139.0.314.000-09|Nutritional Status and Mental Health During Pregnancy and Postpartum: a Cohort Study in Rio de Janeiro, Brazil|Mental Health and Nutritional Status During Pregnancy and Postpartum: A Prospective Study With a Nested Clinical Trial||Universidade Federal do Rio de Janeiro|No|Completed|November 2009|July 2012|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|299|Samples With DNA|Fatty acids C-reactive protein Interleukin-6|Female|20 Years|40 Years|No|Non-Probability Sample|Pregnant women attending a health care center in the city of Rio de Janeiro, Brazil|January 2014|January 16, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01660165||81295|
NCT01660490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IO Image Quality|Development and Validation of Intraoperative Image-quality Criteria|Development and Validation of Intraoperative Image-quality Criteria A Retrospective Multicenter Case Series to Validate a Set of Intraoperative Image-quality Criteria||AO Clinical Investigation and Documentation|No|Completed|September 2012|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|No|Non-Probability Sample|All patients with a proximal femur fractures treated with ORIF between May 2010 and        December 2010|March 2014|March 18, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660490||81272|
NCT01660750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMyC 11-MM-01|A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma|A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma|11-MM-01|Academic Myeloma Consortium|No|Completed|January 2013|December 2015|Actual|August 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||January 2016|January 4, 2016|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01660750||81252|
NCT01661764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11165|Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention|Fatty Acid Desaturase Activity, Fish Oil and Colorectal Cancer Prevention||Vanderbilt University|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|6||Actual|142|||Both|40 Years|79 Years|No|||December 2015|December 7, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661764||81174|
NCT01661985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ostergotland CC|Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced|Study of Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Antibiotic Treatment||Ostergotland County Council, Sweden|No|Recruiting|February 2010|September 2016|Anticipated|August 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|160|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01661985||81157|
NCT01654523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00050426|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania||University of Michigan|Yes|Completed|January 2005|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|33|||Both|18 Years|60 Years|No|||July 2015|July 24, 2015|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01654523||81722|
NCT01654536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP060-401|A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)|A 6 Month Randomized, Open Label, Parallel Group, Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis||Sunovion|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|737|||Both|12 Years|N/A|No|||July 2014|July 23, 2014|July 27, 2012|Yes|Yes||No|June 25, 2014|https://clinicaltrials.gov/show/NCT01654536||81721|
NCT01654848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TransplanTUM-1|Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients|Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients: a Prospective Multivariate Analysis of Prognostic Factors and Haemostaseological Findings|HITOLT|CHIR-Net|No|Completed|January 2010|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|18 Years|75 Years|No|Non-Probability Sample|consecutive livertransplant recipients of our transplant center, organ allocation via        Eurotransplant Foundation, Leiden, The Netherlands; Laboratory investigations performed at        the Abteilung für Transfusionsmedizin am Institut für Immunologie und Transfusionsmedizin        der Universitätsmedizin Greifswald, Greifswald, Germany|July 2012|July 31, 2012|March 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01654848||81699|
NCT01654861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERMC 11-11|Safety and Efficacy Study of Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) for Patients With Metastatic Adenocarcinoma of the Pancreas|Evaluation of the Safety and Efficacy of Standard Dose Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) Treatment for Patients With Metastatic Adenocarcinoma of the Pancreas.||Eastern Regional Medical Center|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||November 2015|November 13, 2015|July 13, 2012||No||No|November 26, 2014|https://clinicaltrials.gov/show/NCT01654861||81698|
NCT01665495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|72/16/11|Drainage or Pericardiocentesis (DROP) Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention|Drainage or Pericardiocentesis Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention.|DROP|Maria Vittoria Hospital|Yes|Recruiting|December 2011|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|122|||Both|18 Years|90 Years|No|||August 2012|August 14, 2012|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01665495||80906|
NCT01665508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BYS-IT-75|Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease|Nebivolol for the Relief of Microvascular Angina in Women|NIRVANA|Massachusetts General Hospital|Yes|Completed|April 2013|May 2015|Actual|May 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|40 Years|80 Years|No|||August 2015|August 17, 2015|August 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665508||80905|
NCT01666028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP@home02|Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes|An Open-label, Three-centre, Randomised, Two-period Crossover Study to Assess the Safety, Efficacy and Utility of Automated Closed-loop Glucose Control in Comparison With Continuous Subcutaneous Insulin Infusion Combined With Continuous Glucose Monitoring in Adults With Type 1 Diabetes - A Combined Clinical Research Facility and Home Study|AP@home02|University of Cambridge|No|Completed|November 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01666028||80865|
NCT01666041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-201202|Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate|||Gachon University Gil Medical Center|Yes|Completed|January 2012|July 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|25 Years|80 Years|No|||August 2012|November 1, 2014|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01666041||80864|
NCT01657188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HDZNRW_KA_001_OO|Effects of Adaptive Servoventilation in Patients With Systolic Heart Failure and Sleep-Disordered Breathing|Effects of Adaptive Servoventilation in Patients With Systolic Heart Failure and Sleep-Disordered Breathing||Ruhr University of Bochum|No|Active, not recruiting|May 2009|March 2022|Anticipated|December 2021|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Probability Sample|Patients of a university hospital|May 2015|May 11, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01657188||81522|
NCT01657760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NURA-022-11F|Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics|Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics|CECDRAAD|VA Office of Research and Development|Yes|Recruiting|April 2014|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|60|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657760||81478|
NCT01658059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rcauhr-HMO-CTIL|Reducing Children's Anxiety Using Homeopathic Remedy Before Dental Treatment|Reducing Children's Anxiety Using Homeopathic Remedy Before Dental Treatment||Hadassah Medical Organization|No|Active, not recruiting|September 2012|December 2015|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|30|||Both|5 Years|12 Years|Accepts Healthy Volunteers|||March 2015|March 18, 2015|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01658059||81455|
NCT01653925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INAF-2010-H09-10-114|Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression|Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression||Centre Hospitalier Universitaire de Québec, CHU de Québec|Yes|Active, not recruiting|November 2010|November 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|120|||Male|35 Years|75 Years|No|||February 2016|February 3, 2016|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01653925||81768|
NCT01654185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2012-12|Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer|Phase II Study of Dimethyldiguanide Combined With AI Compared to AI in Postmenopausal HR(+) Metastatic Breast Cancer.||Fudan University|Yes|Active, not recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654185||81748|
NCT01659268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EERP-2012-LMASIMULATION|Performance of Baccalaureate Nursing Students in Insertion of Laryngeal Mask: a Trial in Mannequins|Performance of Nursing Students in the Insertion of Supraglottic Device (Laryngeal Mask): Randomized Controlled Trial on Mannequins.|LMANURSING|University of Sao Paulo|Yes|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|17|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|May 7, 2014|August 2, 2012||No||No|August 11, 2013|https://clinicaltrials.gov/show/NCT01659268||81364|The limitations of this study are due to the small number of participants in the sample, even after running wide dissemination workshop for print and electronic media with students nursing institution involved in research.
NCT01658904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120179|Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma|Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma||National Institutes of Health Clinical Center (CC)|No|Terminated|July 2012|April 2014|Actual|February 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|3|||Both|18 Years|75 Years|No|||December 2015|February 1, 2016|August 3, 2012|Yes|Yes|study closed prematurely because investigator left National Institutes of Health|No|October 14, 2015|https://clinicaltrials.gov/show/NCT01658904||81391|The study was closed prematurely because the investigator left the National Institutes of Health.
NCT01659580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T89-07-CAESA|Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina|Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic® (T89) in Patients With Chronic Stable Angina|CAESA|Tasly Pharmaceuticals, Inc.|Yes|Recruiting|August 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|960|||Both|20 Years|80 Years|No|||November 2015|November 16, 2015|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659580||81340|
NCT01659593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCOG-SEP|Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients|Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients. A Double Blind Randomized Multicenter Trial.|PROCOG-SEP|Central Hospital, Nancy, France|No|Recruiting|September 2012|June 2018|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|60 Years|No|||March 2016|March 7, 2016|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659593||81339|
NCT01659801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BunnyLens TR 70 EMS|Evaluation of the BunnyLens TR Intraocular Lens|Clinical Evaluation of the Toric BuunyLens TR Intra-ocular Lens||Hanita Lenses|Yes|Not yet recruiting||||||Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|40 Years|80 Years|No|||August 2012|August 5, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01659801||81323|
NCT01659814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009P000038|Dopamine Neurotransmission in Major Depression|Dopamine Neurotransmission in Major Depression||Mclean Hospital|No|Completed|March 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|71|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with Major Depressive Disorder and Healthy Controls|April 2014|April 22, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01659814||81322|
NCT01659827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIPF001|Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis|A Prospective, Randomized, Blinded, Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis||MiMedx Group, Inc.||Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|45|||Both|18 Years|N/A|No|||December 2013|December 10, 2013|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01659827||81321|
NCT01659840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|senhaodf|Efficacy of Red and Infrared Lasers in Treatment of Temporomandibular Disorders|Efficacy of Red and Infrared Lasers in Treatment of Temporomandibular Disorders - A Double-blind, Randomized, Parallel Clinical Trial|TMD|Federal University of São Paulo|Yes|Completed|September 2010|November 2010|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659840||81320|
NCT01660178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FDAAA|Profile of Newborn Undergoing Early Stimulation in a Neonatal Intensive Care Unit|Profile of Newborn Undergoing Early Stimulation in a Neonatal Intensive Care Unit.||Universidade Federal do Rio de Janeiro|No|Completed|January 2011|June 2011|Actual|||N/A|Observational|Time Perspective: Retrospective||1|||||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|newborns underwent early stimulation in a neonatal ICU|August 2012|August 7, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01660178||81294|
NCT01660477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0035|Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole|A Phase 1, Open-Label, Parallel Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Multiple Doses of Lopinavir/Ritonavir and the Effects of Lopinavir/Ritonavir on the Pharmacokinetics of Multiple Doses of Isavuconazole in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|68|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|August 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01660477||81273|
NCT01657331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ5050|Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)|A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma|SGN+Benda|Columbia University|Yes|Recruiting|July 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|71|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657331||81511|
NCT01657344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-009177|PECARN Emergency Care Registry|Improving the Quality of Pediatric Emergency Care Using an Electronic Medical Record Registry and Clinician Feedback||Children's Hospital of Philadelphia|No|Recruiting|January 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Anticipated|1300300|||Both|N/A|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study subjects are all patients (0-18 regardless of race, ethnicity, or gender and of        diagnosis or chronic health condition) who are registered to the ED in calendar year of        2011 and during a 36 month study period between 2012 and 2016; all licensed independent        practitioners who practice in the ED will also be study subjects.|November 2015|November 4, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657344||81510|
NCT01661023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912174|The Ghana Breast Health Study|A Multidisciplinary Study of Breast Cancer in Ghana||National Institutes of Health Clinical Center (CC)||Recruiting|July 2012|||||N/A|Observational|Time Perspective: Retrospective|||Anticipated|5000|||Female|18 Years|74 Years|No|||April 2015|April 22, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661023||81231|
NCT01661257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-10-038-002|Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy|Expression of T-cell Immunoglobulin- and Mucin-domain-containing Molecule 3 (TIM-3)and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy||Samsung Medical Center|Yes|Completed|October 2009|June 2011|Actual|June 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|20|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661257||81213|
NCT01654042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRINT-II-2012|Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II|Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (the PRINT II Study): a Randomized Controlled, Non-inferiority Trial Comparing 4-weekly With 12-weekly Testing and Dose-assessment|PRINT-II|McMaster University|No|Withdrawn|April 2014|October 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 18, 2014|July 21, 2012||No|No funding obtained|No||https://clinicaltrials.gov/show/NCT01654042||81759|
NCT01654289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0207|University of Wisconsin Meditation & Exercise Cold Study|Meditation or Exercise for Preventing Acute Respiratory Infection (MEPARI-2)|MEPARI-2|University of Wisconsin, Madison|Yes|Active, not recruiting|June 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|396|||Both|30 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01654289||81740|
NCT01654549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1391/3/27-573|Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis|The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-diabetic Subjects With Non-alcoholic Fatty Liver Disease||Tehran University of Medical Sciences|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|45 Years|No|||November 2012|November 21, 2012|July 27, 2012||No||No|October 20, 2012|https://clinicaltrials.gov/show/NCT01654549||81720|No limitations and Caveats
NCT01654874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIP-TcTx-P101b|99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404|99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404||Molecular Insight Pharmaceuticals, Inc.|No|Completed|July 2012|||February 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|6|||Male|21 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 23, 2015|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654874||81697|
NCT01654887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0428|A Randomized Controlled Trial of Lung Ultrasound Compared to Chest X-ray for Diagnosing Pneumonia in the Emergency Department|Comparative Effectiveness of Lung Ultrasound vs. Chest X-ray for the Diagnosis of Pneumonia in the Emergency Department||Icahn School of Medicine at Mount Sinai|Yes|Terminated|August 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|191|||Both|N/A|N/A|No|||December 2015|December 24, 2015|July 30, 2012||No|lack of resources|No||https://clinicaltrials.gov/show/NCT01654887||81696|
NCT01665521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12CRP12000001|Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain|Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain|HEART Pathway|Wake Forest Baptist Health|Yes|Active, not recruiting|September 2012|January 2016|Anticipated|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|282|||Both|21 Years|N/A|No|||December 2015|December 8, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01665521||80904|
NCT01665534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SS-011-RC|Inflammatory Response to Salt in Essential Hypertension|Procalcitonin and the Inflammatory Response to Salt in Essential Hypertension: a Randomised Cross-over Clinical Trial.||Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|No|Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|70 Years|No|||August 2012|August 12, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01665534||80903|
NCT01666054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-07-237|Comparison of Weaning on Pressure Support vs. Proportional Assist Ventilation: A Pilot Study|Is Respiratory Rate an Adequate Indicator of Respiratory Distress During Weaning? A Comparison of Weaning on Pressure Support vs. Proportional Assist Ventilation.||Lawson Health Research Institute|No|Completed|March 2009|July 2013|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666054||80863|
NCT01666067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMC-201110|Vascular and Metabolic Effects of Vytorin vs Simvastatin|||Gachon University Gil Medical Center|Yes|Completed|November 2011|November 2012|Actual|October 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|204|||Both|25 Years|80 Years|No|||August 2012|November 1, 2014|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01666067||80862|
NCT01657487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|099013-F|Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients|||Far Eastern Memorial Hospital|Yes|Recruiting|April 2010|December 2012|Anticipated|September 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|40 Years|80 Years|No|||August 2012|August 3, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657487||81499|
NCT01658072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11139|Analgesia After Total Hip Arthroplasty: Peri-Articular Injection Versus Epidural Patient Controlled Analgesia (PCA)|Analgesia After Total Hip Arthroplasty: Peri-Articular Injection Versus Epidural Patient Controlled Analgesia|PAI Hip|Hospital for Special Surgery, New York|Yes|Recruiting|February 2012|||February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|50 Years|80 Years|No|||July 2012|February 4, 2013|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658072||81454|
NCT01654198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815253|PET/CT in Psoriatic Arthritis|FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis||University of Pennsylvania|No|Recruiting|July 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|24|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients with psoriatic arthritis defined by CASPAR criteria and active joint disease.|December 2015|December 1, 2015|July 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01654198||81747|
NCT01654211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28297|A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers|A Three-Part Study Evaluating the Pharmacokinetics of Intravenous (IV) Danoprevir (DNV)/Oral Low-Dose Ritonavir (RTV), the Absolute Bioavailability of DNV With and Without Oral Low-Dose RTV, and the Effect of Oral Cyclosporine on IV DNV/Oral Low-Dose RTV in Healthy Adult Volunteers||Hoffmann-La Roche||Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Single Blind (Subject)|7||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|July 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654211||81746|
NCT01659294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Elliott|Diabetes Outcomes and Nurse Case Manager Study|Impact of Nurse Case Management on Diabetes-related Health Outcomes in a Specialty Care Setting: A Randomized Controlled Trial|DONCM|BCDiabetes.Ca|No|Completed|August 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|90 Years|No|||January 2016|January 26, 2016|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01659294||81362|
NCT01659307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11127DMcA-AS|The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury|The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury|ARENA|Belfast Health and Social Care Trust|Yes|Recruiting|September 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 14, 2016|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01659307||81361|
NCT01659281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WRAIR-1327|Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand|Efficacy of Artesunate-Mefloquine Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Trat Province, Thailand||Armed Forces Research Institute of Medical Sciences, Thailand|No|Completed|September 2007|May 2012|Actual|May 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|5 Years|70 Years|No|||August 2012|August 6, 2012|January 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01659281||81363|
NCT01660191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12943|A Study Comparing CoQ10 Levels While Taking 3 Different Statins|A Study Comparing the Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on Plasma Levels of CoQ10 (SPARQ)|SPARQ|University of Kansas Medical Center|No|Completed|December 2011|October 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|135|||Both|18 Years|70 Years|No|||February 2014|February 3, 2014|May 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01660191||81293|
NCT01660204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-148|Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections|Antibiotic Treatment of Community-acquired Pneumonia: a Prospective Comparison of Dutch Guideline Advices.|CAP-START|UMC Utrecht|No|Completed|February 2011|January 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|2283|||Both|18 Years|N/A|No|||April 2014|April 22, 2014|May 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01660204||81292|
NCT01659853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|US10219|Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea|A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea||Galderma Laboratories, L.P.|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|No|||March 2014|July 8, 2014|August 6, 2012|Yes|Yes||No|January 15, 2014|https://clinicaltrials.gov/show/NCT01659853||81319|A significant period effect was observed for CEA indicating there was carryover from period 1 to period 2. Therefore, as stated a priori in the protocol, only data from period 1 were used to analyze efficacy. All safety data are reported.
NCT01660776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01163-38|BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology|BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology|BMS_PD-L1|Rennes University Hospital|No|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||6|Anticipated|325|Samples Without DNA|Biomedical research on total blood at diagnosis.|Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Number of DLBCL patients : 40 Number of non-small cell lung cancer patients : 100 Number        of Hodgkin patients : 20 Number of metastatic breast cancer patients : 20 Number of        healthy volunteers : 140 Number of patients with immune thrombocytopenia (ITP) : 5|December 2015|December 17, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01660776||81250|
NCT01657357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THA after PAO|Routine Follow up After Total Hip Arthroplasty Prior Periacetabular Osteotomy|Routine Follow up After THA in PAO Patient||University of Aarhus|Yes|Completed|January 2012|October 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|||Both|N/A|N/A|No|Probability Sample|Patients, who despite a joint preserving procedure(periacetabular osteotomy PAO) ended up        with a total hip arthroplasty (THA).|January 2013|January 30, 2013|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01657357||81509|
NCT01653808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nipro-Elisio 210H|In Vivo Evaluation of the Nipro Elisio™ Dialyzer|In Vivo Evaluation of the Nipro Elisio™ Dialyzer||Nipro Europe N.V.|Yes|Completed|April 2009|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||November 2008|September 13, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653808||81777|
NCT01657617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-RAD-01|Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer|Stereotactic Body Radiation Therapy for Post-chemoradiation Residual Disease in Stage II/III Non-small Cell Lung Cancer||University of Kentucky|Yes|Completed|October 2007|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01657617||81489|
NCT01654055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1243803|International Prospective Study on Morphine-induced Adverse Drug Reactions in Emergency Departments.|International Multicentre Prospective Study on Morphine-induced Adverse Drug Reactions in Emergency Departments: Description and Predictive Factors.|EI-Morphinique|University Hospital, Toulouse|No|Completed|October 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1128|||Both|18 Years|N/A|No|Probability Sample|Patients aged 18 years or older who require treatment with morphine for pain control|December 2015|December 22, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654055||81758|
NCT01654068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-RAD-01|Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine|Conformal High Dose Intensity Modulated Radiation Therapy for Asymptomatic Metastatic Disease to the Thoracic and Lumbar Spine||University of Kentucky|Yes|Recruiting|December 2009|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||January 2016|January 14, 2016|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654068||81757|
NCT01654302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00061115|Efficacy and Safety of Synera in Osteoarthritis Pain|Efficacy and Safety of Synera in OA Pain||Northwestern University|No|Completed|September 2013|February 2015|Actual|September 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|40 Years|N/A|No|||April 2015|April 22, 2015|July 11, 2012|Yes|Yes||No|September 29, 2014|https://clinicaltrials.gov/show/NCT01654302||81739|
NCT01654562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHM-STATIN|The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia|A Repeated Measures Study of Simvastatin on Choroideremia: Simvastatin Intervention and Reversal in Choroideremia Patients and Age-matched Controls.||University of Alberta|No|Terminated|December 2012|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|October 14, 2014|July 27, 2012||No|The study has been terminated due to limited participant enrollment.|No||https://clinicaltrials.gov/show/NCT01654562||81719|
NCT01654575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|alexmed116662981|Methotrexate in Symptomatic Knee Osteoarthritis|Randomized Controlled Trial Using Methotrexate for Knee Osteoarthritis||Faculty of Medicine, University of Alexandria|Yes|Completed|July 2011|January 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|60 Years|N/A|No|||July 2012|July 28, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01654575||81718|
NCT01655537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COG-FM-HMO-CTIL|Cognitive Dysfunction in Fibromyalgia Patients|Cognitive Dysfunction in Fibromyalgia Patients: Specific Neuro-psychological Dysfunctions, Psychiatric Comorbidity and Integrative Assessments||Hadassah Medical Organization|No|Completed|July 2012|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|25|||Both|18 Years|70 Years|No|Non-Probability Sample|fibromyalgia patients|September 2013|September 16, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655537||81648|
NCT01655810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201102160|Vitamin D, Cardiovascular Disease, and African Americans|Vitamin D and Early Markers of Cardiovascular Disease in African Americans||Washington University School of Medicine|Yes|Recruiting|July 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|86|||Both|50 Years|70 Years|No|||July 2012|August 1, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01655810||81627|
NCT01665768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1228|Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma|A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|August 2012|July 2018|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|100 Years|No|||October 2015|October 30, 2015|July 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665768||80885|
NCT01665781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCIRB2012-0534|Erythropoietin in the Prevention of Acute Mountain Sickness|Randomized, Controlled Trial of Erythropoietin in the Prevention of Acute Mountain Sickness|EPO-AMS|University of Ulsan|Yes|Completed|August 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|39|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2013|March 16, 2013|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01665781||80884|
NCT01666327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-1303-E03|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease|An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacodynamics of a Single Oral Dose of MT-1303 in Subjects With Inflammatory Bowel Disease.||Mitsubishi Tanabe Pharma Corporation||Completed|June 2012|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||September 2014|September 4, 2014|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01666327||80842|
NCT01657773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wenzhouMC 001|Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm|Study of the Prevalence of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease.|NWC|Wenzhou Medical University|Yes|Completed|April 2012|July 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|2315|||Both|10 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population consisted entirely of outpatients. Patients were offered to perform        colonoscopy for CRC screening according to the American College of Gastroenterology        recommendations. Based on blood tests and abdomen B ultrasonography, patients without        NAFLD were regarded as healthy controls and those with NAFLD constituted the community        NAFLD cohort. Patients were included only if they had colonoscopy and conventional        inspections (blood routine, liver function test and abdomen B ultrasonography). Among them        who with history of colorectal cancers or polyps, other extraintestinal malignancies and        contraindications to colonoscopy were excluded. Besides, we excluded patients who had        viral hepatitis, cirrhosis, liver cancer or other liver disease.Patients who drank more        than 20g alcohol per day were also excluded.|August 2012|August 3, 2012|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01657773||81477|
NCT01653938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002083|A Trial of a CPR Video in Heart Failure Patients|A Randomized Controlled Trial of a CPR Video in Heart Failure Patients||Massachusetts General Hospital|No|Recruiting|April 2011|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|50|||Both|65 Years|N/A|No|||July 2012|July 30, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01653938||81767|
NCT01658891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1110-PR-0071|Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children|A SINGLE CENTRE, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, 2-WAY CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF CHF1535 50/6 NEXThaler® (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE AND FORMOTEROL FUMARATE) AND THE FREE COMBINATION OF LICENSED BECLOMETHASONE DIPROPIONATE AND FORMOTEROL FUMARATE IN ASTHMATIC CHILDREN ALREADY TREATED WITH INHALED CORTICOSTEROIDS||Chiesi Farmaceutici S.p.A.|No|Withdrawn|February 2014|February 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|5 Years|11 Years|No|||February 2013|February 18, 2013|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01658891||81392|
NCT01659255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-4059POE001|Phase I Study of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL|Phase I Dose-escalation Study to Investigate the Safety and Tolerability of ONO-4059 Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma and/or Chronic Lymphocytic Leukaemia.||Ono Pharmaceutical Co. Ltd|No|Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|90|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659255||81365|
NCT01659606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-950|Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita|Non-TBI and Alkylator-free Conditioning for Allogeneic Bone Marrow Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease||Children's Hospital Boston|Yes|Recruiting|July 2012|October 2032|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|30 Years|No|||September 2015|September 14, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659606||81338|
NCT01656473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|069-2011|Evaluating the Effectiveness of Motivational Interviewing and a Dialectical Therapy Skills- Based Intervention for Youth|CIHR Team in Innovations in Child and Youth Concurrent Disorders: Service Delivery and Treatment Subproject||Centre for Addiction and Mental Health|No|Completed|July 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|14 Years|18 Years|No|||July 2015|July 22, 2015|January 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01656473||81577|
NCT01660503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Tate & Lyle Teen Study|Dose Effects of SCF on Calcium Metabolism and GI Microflora in Adolescents|Dose Response Effects of Soluble Corn Fiber (SCF) on Calcium Metabolism and Gastrointestinal Microflora in Adolescents||Purdue University|No|Active, not recruiting|June 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|30|||Female|9 Years|13 Years|Accepts Healthy Volunteers|||March 2014|March 10, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660503||81271|
NCT01657045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRX-001|Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy|A Phase I Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Needle-free Dermal Injection to Cohorts of Adults Receiving Surgical Sternotomy Incisions||SironRX Therapeutics, Inc.|Yes|Recruiting|July 2012|July 2014|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|25|||Both|40 Years|80 Years|No|||July 2013|July 22, 2013|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657045||81533|
NCT01657318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AKMRC-12-004|Olivamine-containing Products in the Management of Patients With Nonhealing Lower Extremity Ulcers|A Prospective Observational Study on the Use of a Olivamine-containing Products in the Management of Patients With Compromised Nonhealing Lower Extremity Ulcers||De La Salle University Medical Center|No|Not yet recruiting|September 2012|September 2014|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Potential study subjects will be patients who are 18 years or older, has confirmed with        the informed consent. He/she has a non-healing lower extremity ulcers compromised due to        underlying factors such as peripheral arterial disease, diabetes, venous insufficiency,        and pressure. The ulcer must be between 1.0 cm2 and 10 cm2.|August 2012|August 3, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657318||81512|
NCT01657955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RGN0117|Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia|Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients|CLL|Shandong Lanjin Pharmaceuticals Co.,Ltd|Yes|Recruiting|January 2011|December 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|75 Years|No|||August 2012|August 3, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657955||81463|
NCT01657630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Accu-Chek Combo|Accu-Chek Combo in Young Patients|Evaluation of the Use of the Accu-Chek Combo System in Young Patients With Type 1 Diabetes||Rabin Medical Center|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|13|||Both|6 Months|6 Years|No|Non-Probability Sample|Young patients with type 1 Diabetes treated at the institute of Endocrinology and        Diabetes, Schneider Children's Medical Center, which is a tertiary hospital|March 2015|March 11, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657630||81488|
NCT01657916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R12-01-005|5-Year Objective and Subjective Results of a Mid-Urethral Sling|5-Year Objective and Subjective Results of a Mid-Urethral Sling||Atlantic Health System|Yes|Recruiting|June 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Female|18 Years|N/A|No|Probability Sample|women who suffered from stress urinary incontinence (leakage of urine will        laughing/coughing/sneezing/exercising)|August 2014|August 25, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657916||81466|
NCT01654588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AD-S|Different End Points for Bronchial Hyperactivity (BHR) Tests.|Different End Points for Bronchial Hyperactivity (BHR) Tests, What Comes First?||Wolfson Medical Center|No|Completed|September 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|501|||Both|1 Month|18 Years|No|Probability Sample|Patients referred for HRA trigger testing.|December 2014|December 10, 2014|July 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01654588||81717|
NCT01654601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DWCZP-I-1|A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg|Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients|DWCZP-I-1|Dong Wha Pharmaceutical Co. Ltd.|No|Completed|June 2012|August 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|28|||Both|20 Years|60 Years|No|||February 2014|February 13, 2014|July 25, 2012||No||No|December 17, 2013|https://clinicaltrials.gov/show/NCT01654601||81716|
NCT01654900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Heart90-HMO-CTIL|Mid-term Survival and Quality of Life of Elderly Patients Undergoing Open Heart Surgery|Mid -Term Survival and Quality of Life of Elderly Patients Undergoing Open Heart Surgery||Hadassah Medical Organization|No|Not yet recruiting|October 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|207|||Both|75 Years|N/A|No|Non-Probability Sample|All patients age >75 y who underwent open heart surgery between 2008-2011 at hadassah        medical center.|July 2012|July 31, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01654900||81695|
NCT01654315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0215|Robotic Brace Incorporating Electromyography for Moderate Affected Arm Impairment After Stroke|Robotic Brace Incorporating EMG for Moderate Affected Arm Impairment After Stroke||Ohio State University|No|Completed|March 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Both|35 Years|85 Years|No|||September 2015|September 15, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01654315||81738|
NCT01654913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/16|Influence of Oxygen on Non-invasive Measurement of Hemoglobin|Influence of the Inspired Oxygen Fraction on the Noninvasive Measurement of Hemoglobin Using Two Different Devices (Namely Pronto 7 and NBM-200)|Hb-O2|Hopital Foch|No|Completed|July 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|47|||Both|18 Years|N/A|No|||March 2015|March 25, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01654913||81694|
NCT01655225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13517|A Study of LY3023414 in Participants With Advanced Cancer|A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer||Eli Lilly and Company|No|Recruiting|July 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|130|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01655225||81672|
NCT01655524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSUAGE-MPI Trial|The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion|The Impact of Routine Administration of Aminophylline Following Regadenoson According to the ASSUAGE Protocol on the Accuracy of Regadenoson Stress Myocardial Perfusion Imaging: A Single-Blinded Cross-Over Clinical Trial|ASSUAGE-MPI|Rush University Medical Center|Yes|Suspended|July 2012|December 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|60|||Both|18 Years|N/A|No|||July 2012|March 14, 2014|July 26, 2012|Yes|Yes|Due to nationwide shortage of Aminophylline.|No||https://clinicaltrials.gov/show/NCT01655524||81649|
NCT01655823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTX-CINP-201|The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment|A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain|TTX-CINP-201|Wex Pharmaceuticals Inc.|Yes|Terminated|July 2012|December 2016|Anticipated|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|125|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|July 19, 2012|Yes|Yes|Interim analysis completed and decided to terminate and proceed to Phase 3 trial.|No||https://clinicaltrials.gov/show/NCT01655823||81626|
NCT01656343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-075|Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients|Belatacept and Risk of PTLD in US Renal Transplant Recipients||Bristol-Myers Squibb|No|Active, not recruiting|October 2011|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Adult, EBV seropositive, kidney only transplant recipients initiated on belatacept and        adult, EBV seropositive, kidney only transplant recipients initiated on CNIs reported to        the UNOS during the period of recruiting belatacept users|January 2016|January 28, 2016|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656343||81587|
NCT01665794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1088|Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma||University of Chicago|No|Recruiting|August 2012|December 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|92|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665794||80883|
NCT01666080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012OC065|Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)|Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)||Masonic Cancer Center, University of Minnesota|No|Recruiting|August 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|N/A|55 Years|No|||January 2016|January 21, 2016|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666080||80861|
NCT01666093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEWLI-Trial|Non-Healing Ulcers Without Critical Limb Ischemia|NON-HEALING ULCERS WITHOUT CRITICAL LIMB ISCHEMIA (NEWLI-Trial): A Single Center Pilot Trial on the Efficacy of an Endovascular Approach for Treatment of Non-healing Lower Limb Ulcers in Patients Presenting With a Mild to Moderate Peripheral Artery Disease|NEWLI|University Hospital, Geneva|No|Recruiting|August 2012|August 2015|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||August 2012|August 15, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01666093||80860|
NCT01666106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101102|Osteonecrosis of the Jaw (ONJ) Case Registry|Osteonecrosis of the Jaw (ONJ) Case Registry||Amgen|No|Recruiting|October 2012|September 2021|Anticipated|September 2021|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Probability Sample|Subjects with cancer and ONJ|March 2016|March 9, 2016|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01666106||80859|
NCT01666353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1208|PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy|PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|April 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|20|||Both|18 Years|N/A|No|||March 2015|March 17, 2015|May 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666353||80840|
NCT01658085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EO-0618|Budget Impact of Harmonic FOCUS in Thyroidectomy|Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease. A Randomized, Prospective Study|TIME|Hospital Universitari de Bellvitge|Yes|Active, not recruiting|February 2009|August 2012|Anticipated|March 2010|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|56|||Both|18 Years|80 Years|No|Probability Sample|Eligible patients met the following criteria: to have MNG, age between 18 and 80 and        consent to be included in the study.        Eligible patients were proposed to enter a randomized study with 2 arms in which we        compared the use of two harmonic scalpel devices: ACE14S and Harmonic Focus (Ethicon        Endo-Surgery, Cincinnati, OH, USA).|August 2012|August 1, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01658085||81453|
NCT01658098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|etamez|Prevalence of Postpartum Depression in Hospital Jose E. Gonzalez|Prevalence of Postpartum Depression in the Jose E. Gonzalez Hospital, Using the Edinburgh Postpartum Depression Scale||Hospital Universitario Dr. Jose E. Gonzalez|Yes|Not yet recruiting|September 2012|February 2013|Anticipated|November 2012|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|348|||Female|N/A|N/A|No|Probability Sample|348 patients on their 4th-6th week after delivery|July 2012|August 1, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01658098||81452|
NCT01653951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|shs250014|Comparative Effectiveness of Two Approaches to Diabetes Management in the Uninsured|Comparative Effectiveness of Two Community Based Diabetes Management Approaches||Summa Health System|Yes|Completed|August 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|64|||Both|25 Years|75 Years|No|||July 2015|July 16, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01653951||81766|
NCT01653964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004437|Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing|Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing|Split-Dose|Mayo Clinic|Yes|Active, not recruiting|July 2012|September 2016|Anticipated|April 2016|Anticipated|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|82|||Female|40 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653964||81765|
NCT01658657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1133|A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension|A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension||University of North Carolina, Chapel Hill|No|Completed|October 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|18 Years|N/A|No|||August 2015|August 17, 2015|July 31, 2012|Yes|Yes||No|June 3, 2015|https://clinicaltrials.gov/show/NCT01658657||81410|
NCT01659866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00059558|Antibiotic Prophylaxis for Transrectal Prostate Biopsy|Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP)||Northwestern University|No|Active, not recruiting|August 2012|August 2016|Anticipated|August 2015|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|540|||Male|30 Years|90 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01659866||81318|
NCT01659879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LBK-2010/12-1|Multimedia Based Information to Parents in a Pediatric Acute Ward: A Randomized Controlled Trial|Multimedia Based Information to Parents in a Pediatric Acute Ward: A Randomized Controlled Trial||Norwegian University of Science and Technology|No|Completed|January 2011|August 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|101|||Both|N/A|N/A|No|||April 2015|April 7, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01659879||81317|
NCT01656213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/LO/0087|Randomised Control Trial for Improving Functional Outcome From Stroke in End Stage Renal Disease Patients|Randomised Control Trial for Improving Functional Outcome From Stroke in End Stage Renal Disease Patients||Imperial College London|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||July 2012|February 15, 2016|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01656213||81596|
NCT01656226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISD-FPT-01-2012|Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis|A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis.||ISDIN|No|Active, not recruiting|July 2012|January 2014|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2012|October 10, 2013|July 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656226||81595|
NCT01657370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1602-007|A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine||Merck Sharp & Dohme Corp.|No|Completed|August 2012|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|195|||Both|18 Years|65 Years|No|||January 2015|January 23, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657370||81508|
NCT01656772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-020|Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study|Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study|VERSATILE|Stereotaxis|Yes|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|80 Years|No|||June 2015|June 4, 2015|July 30, 2012|Yes|Yes||No|May 20, 2015|https://clinicaltrials.gov/show/NCT01656772||81554|
NCT01656785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUMCHNM004|68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke|68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Angiogenesis Following Stroke|GRGDS|Peking Union Medical College Hospital|Yes|Recruiting|February 2012|March 2016|Anticipated|November 2015|Anticipated|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|30 Years|70 Years|No|||November 2014|November 1, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656785||81553|
NCT01653834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11162|Lymphocyte Reinfusion|Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas||Sidney Kimmel Comprehensive Cancer Center|Yes|Completed|July 2012|March 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2014|August 11, 2014|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653834||81775|
NCT01653821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIM-WROCPL-CORIDEA|Surgical Removal of Carotid Body in Patients With Systolic Heart Failure|Surgical Removal of Carotid Body in Patients With Systolic Heart Failure.|FIM|Noblewell|No|Completed|August 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||March 2015|March 27, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653821||81776|
NCT01654081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-LUN-90-MCC|A Protocol of Irinotecan for Carcinoma of the Lung|A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung||University of Kentucky|Yes|Withdrawn|October 2013|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||May 2014|May 28, 2014|July 27, 2012|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01654081||81756|
NCT01654926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF-HF-1|Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers|Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers||Clalit Health Services|No|Completed|December 2012|October 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Both|18 Years|N/A|No|Non-Probability Sample|HF patients|March 2015|March 8, 2015|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01654926||81693|
NCT01655212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMV-MM-1|Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial|Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial|CONCERT|Leiden University Medical Center|Yes|Terminated|June 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|N/A|12 Weeks|No|||June 2015|June 17, 2015|July 13, 2012||No|1 Indication for further investigations (brain ultrasound). 2 Change of study design to    efficacy study with historical control group.|No||https://clinicaltrials.gov/show/NCT01655212||81673|
NCT01655238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00324|Obesity Guidelines for Outpatient Surgery|Have NCH Obesity Guidelines Made an Impact? Differences in Anesthetizing the Obese Child in Outpatient Sites Versus Main OR at NCH.||Nationwide Children's Hospital|No|Completed|July 2012|December 2015|Actual|December 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|1327|||Both|N/A|N/A|No|Non-Probability Sample|Obese patients|January 2016|January 7, 2016|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655238||81671|
NCT01655550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GARC003501|The Impact of Oral Contrast in Multidetector CT of the Abdomen and Pelvis on Radiologist Confidence|The Impact of Oral Contrast in Multidetector CT of the Abdomen and Pelvis on Radiologist Confidence: A Randomized Controlled Trial||Hartford Hospital|No|Recruiting|June 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|216|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 1, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655550||81647|
NCT01656616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 4053X|Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis|Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis||Maine Medical Center|No|Not yet recruiting|August 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|||Both|N/A|N/A|No|Non-Probability Sample|EMS patients possibly exposed to cyanide via poisoning or smoke exposure.|August 2012|August 2, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656616||81566|
NCT01656889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|802-247-09-029|Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers|A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers||Healthpoint|Yes|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|447|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|August 1, 2012|Yes|Yes||No|January 19, 2016|https://clinicaltrials.gov/show/NCT01656889||81545|
NCT01656902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1202|Safety and Effectiveness Study to Evaluate NOVOCART® 3D Plus Compared to the Microfracture to Treat Articular Cartilage Defects of the Knee|A Prospective Randomized Controlled Multicenter Phase-III Clinical Study to Evaluate the Safety and Effectiveness of NOVOCART® 3D Plus Compared to the Standard Procedure Microfracture in the Treatment of Articular Cartilage Defects of the Knee|N3D|Tetec AG|Yes|Recruiting|January 2013|June 2019|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|261|||Both|18 Years|65 Years|No|||February 2014|February 10, 2014|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01656902||81544|
NCT01665820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study EM-05-012530|Auscultate Obese Patients Using Electronic and Traditional Stethoscopes|Study EM-05-012530 Benefit of Auscultation With 3M™ Littmann® 3200 Electronic Stethoscope to Diagnose Murmurs and Heart Pathologies in Overweight and Obese Patients With Increased Layers of Adipose Tissue||3M|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients greater or equal to 18 years of age, with a BMI greater than 30 and who have been        scheduled for an echocadiogram examination|June 2013|June 6, 2013|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01665820||80881|
NCT01666587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRAPC|Ischemia Reperfusion: Prostaglandins and Antioxidants|The Role of Prostaglandin and Anti-oxidant Availability on Recovery From Forearm Ischemia-reperfusion Injury in Humans||University of Essex|Yes|Recruiting|August 2012|August 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|4||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 15, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01666587||80822|
NCT01653977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC 09-044|Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery|Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery A Prospective, Randomised, Open Trial||University Hospital, Geneva|Yes|Recruiting|February 2010|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|250|||Both|18 Years|N/A|No|||August 2012|August 6, 2012|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01653977||81764|
NCT01657812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3869480|A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy|A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy||Anhui Medical University|Yes|Recruiting|July 2012|July 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|65 Years|No|||August 2012|August 3, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657812||81474|
NCT01658644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0392-BE|Put a Face to a Name (Part A): The Effects of Photographic Aids on Patient Satisfaction, Clinician Communication, and Quality of Care|Put a Face to a Name (Part A): The Effects of Photographic Aids on Patient Satisfaction,Clinician Communication, and Quality of Care|Face2Name|University Health Network, Toronto||Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|256|||Both|N/A|N/A|Accepts Healthy Volunteers|||August 2012|April 4, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658644||81411|
NCT01658917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120175|Collecting Solid Tumor Tissue to Identify New Treatments|Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets||National Institutes of Health Clinical Center (CC)||Recruiting|July 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|1000|||Both|16 Years|99 Years|No|||January 2016|January 23, 2016|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01658917||81390|
NCT01658930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CX5|Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early Stage Cervical Cancer (SHAPE)|A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-Risk Early Stage Cervical Cancer (SHAPE)||Canadian Cancer Trials Group|Yes|Recruiting|September 2012|September 2020|Anticipated|September 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|700|||Female|18 Years|N/A|No|||March 2016|March 22, 2016|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01658930||81389|
NCT01659892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MONT-CT5-PVFD-1|Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fed Conditions||Roxane Laboratories|No|Completed|August 2008|August 2008|Actual|August 2008|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659892||81316|
NCT01656005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANDA2|Beta Blocker Therapy in Moderate to Severe COPD|Evaluation of Effects of Chronic Dose Exposure to Cardioselective and Non-cardioselective Beta Blockers on Measures of Cardiopulmonary Function in Moderate to Severe COPD.|ANDA2|University of Dundee|No|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|18|||Both|40 Years|80 Years|No|||March 2015|March 4, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656005||81612|
NCT01657383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-02E|Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery|Surgical Outcomes Database for Faculty of Hepatopancreatico Biliary Surgery||Carolinas Healthcare System|Yes|Enrolling by invitation|April 2012|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|90 Years|No|Non-Probability Sample|Hepatopancreatico Biliary surgical patients.|February 2016|February 11, 2016|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657383||81507|
NCT01656486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-12-16EM|Stereotactic Radiation to Decrease Pancreatic Secretions|Utilization of Stereotactic Radiation in Patients With Pancreatic Fistula to Decrease Pancreatic Secretions||Carolinas Healthcare System|Yes|Completed|July 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|1|||Both|18 Years|70 Years|No|||February 2014|February 14, 2014|August 1, 2012|No|Yes||No|February 14, 2014|https://clinicaltrials.gov/show/NCT01656486||81576|
NCT01656499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML7245|Effect of AXOS on the Colon Metabolism in Healthy Volunteers|Effect of AXOS on the Colon Metabolism in Healthy Volunteers||Katholieke Universiteit Leuven|Yes|Completed|March 2011|September 2012|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01656499||81575|
NCT01657942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCa003|Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Cancer|Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Cancer: Feasibility Study||InSightec|No|Recruiting|July 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Male|55 Years|75 Years|No|||February 2016|February 1, 2016|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657942||81464|
NCT01654341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MID-Frail|Multi-Modal Intervention In Frail And Prefrail Older People With Type 2 Diabetes|A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF A MULTI-MODAL INTERVENTION IN FRAIL AND PREFRAIL OLDER PEOPLE WITH TYPE 2 DIABETES ON FRAILTY AND QUALITY OF LIFE: THE MID-Frail STUDY|MID-Frail|Hospital Universitario Getafe|No|Active, not recruiting|December 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|986|||Both|70 Years|N/A|No|||February 2016|March 22, 2016|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01654341||81736|
NCT01654094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHP-P6-1|Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns|A Multicenter, Prospective, Randomized Study to Compare Milliken Dressing P6 to Mafenide Acetate 5% Solution as a Split Thickness Skin Graft Cover Dressing in Burn Wound Patients.||Milliken Healthcare Products, LLC|No|Active, not recruiting|October 2012|October 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|80|||Both|18 Years|65 Years|No|||July 2014|July 14, 2014|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654094||81755|
NCT01654328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL nr.: 40730.091.12|Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy|Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy|INOVATIO|Radboud University|Yes|Terminated|August 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|256|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|July 21, 2012||No|slow inclusion|No||https://clinicaltrials.gov/show/NCT01654328||81737|
NCT01655563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000026524|Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation|A Pharmacogenetic Trial of Tacrolimus Dosing After Pediatric Transplantation||The Hospital for Sick Children|Yes|Terminated|September 2011|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|75|||Both|N/A|18 Years|No|||February 2016|February 25, 2016|July 27, 2012||No|Delays in reaching target recruitment|No||https://clinicaltrials.gov/show/NCT01655563||81646|
NCT01655576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLADRAINAGE|Effectiveness of Placental Drainage in the Third Stage of Labor: a Randomized Clinical Trial|Effectiveness of Placental Drainage in the Third Stage of Labor: a Randomized Clinical Trial|PLADRAINAGE|Instituto Materno Infantil Prof. Fernando Figueira|Yes|Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|226|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|June 4, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655576||81645|
NCT01655251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-098-CCMC|Video Discharge Instructions for Fever and ED Recidivism|Video Discharge Instructions for Fever and ED Recidivism||Connecticut Children's Medical Center|No|Completed|February 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|273|||Both|8 Weeks|18 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655251||81670|
NCT01656070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HLS02/2011-1.0-09-11-2010|Vitamin D Supplementation in HIV-infected Youth|Vitamin D Status and T Cell Phenotype in HIV-infected Youth Supplemented With Cholecalciferol: a Randomized Clinical Trial.||University of Milan|No|Completed|April 2011|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|N/A|30 Years|No|||August 2012|August 1, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656070||81607|
NCT01656928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRTLasti_nutr_kiga|Effects of a Pre-school-based Nutritional Intervention on Children's Eating Behavior and Anthropometric Parameters|Effects of a Pre-school-based Nutritional Intervention on Children's Eating Behavior and Anthropometric Parameters: a Cluster-randomized Trial||Heidelberg University|No|Completed|September 2008|April 2011|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|375|||Both|3 Years|7 Years|No|||July 2012|August 2, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01656928||81542|
NCT01666119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNX-201|An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects|An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects (BNX-201)||BioDelivery Sciences International|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|249|||Both|18 Years|65 Years|No|||July 2013|July 26, 2013|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666119||80858|
NCT01653990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCTC_2012001|Moxifloxacin_QT Study in Chinese Healthy Volunteer|A Single-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study to Assess the QT/QTc Interval After Administration of Single Oral Dose of 400mg Moxifloxacin in Healthy Chinese Subjects||Peking University Third Hospital|No|Recruiting|July 2012|October 2012|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 30, 2012|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653990||81763|
NCT01658124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISRCTN11225767|Haemorrhage Alleviation With Tranexamic Acid- Intestinal System|Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial|HALT-IT|London School of Hygiene and Tropical Medicine|Yes|Recruiting|January 2013|October 2017|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|8000|||Both|16 Years|N/A|No|||September 2015|September 7, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01658124||81450|
NCT01658384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNO-001|Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients|Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients|CogMS|Clinique Neuro-Outaouais|No|Completed|September 2011|March 2015|Actual|February 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with multiple sclerosis who are receiving Tysabri per indication.|March 2015|March 30, 2015|November 10, 2011||No||No||https://clinicaltrials.gov/show/NCT01658384||81430|
NCT01658397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P001066|The Effect of Calorie Deprivation on Adipose Tissue Distribution|The Effect of Calorie Deprivation on Adipose Tissue Distribution||Massachusetts General Hospital|No|Active, not recruiting|September 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|12|||Both|21 Years|45 Years|Accepts Healthy Volunteers|||February 2016|February 27, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658397||81429|
NCT01655472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-11-NR-0192-11-CTIL|Schizophrenia Imaging|Prospective Ultrasonographic and Magnetic Resonance Imaging (MRI) Assessment of General and Brain Fetal Development in Offspring of Schizophrenic Patients||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|July 2012|July 2015|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|80|||Female|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 31, 2012|June 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655472||81653|
NCT01656798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481313|Food Effect Study For New Formulation|An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study In Healthy Subjects Assessing The Pharmacokinetics And Safety Of Powder For Oral Suspension Of Sildenafil Citrate Administered Under Fasted And Fed Conditions||Pfizer|No|Completed|August 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 14, 2012|August 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01656798||81552|
NCT01655745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1209|Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer|LCCC 1209: Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) for Staging of Muscle-Invasive Bladder Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Recruiting|August 2012|August 2019|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|30|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01655745||81632|
NCT01657097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHINO97|Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge|Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge. Impact on Bronchial Hyperresponsiveness and the Effect of Intranasal Corticosteroid Treatment||University of Aarhus|No|Completed|February 1997|April 1997|Actual|April 1997|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|24|||Both|18 Years|N/A|No|||August 2012|August 3, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01657097||81529|
NCT01657110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRJ-006245|Pilot Study to Evaluate Tea Tree Oil Gel for Facial Acne|Uncontrolled, Open-label, Phase II Pilot Study to Evaluate the Efficacy, Tolerability and Acceptability of 200mg/g Tea Tree Oil Gel Applied Topically Twice Daily for the Treatment of Mild to Moderate Facial Acne||The University of Western Australia|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|16 Years|45 Years|No|||January 2015|January 27, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01657110||81528|
NCT01657643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120100395|Effect of Probiotics on Health-related Quality of Life in College Students With Upper Respiratory Infections|Effect of Lactobacillus Rhamnosus LGG® and Bifidobacterium Animalis Ssp Lactis BB-12® on Health-related Quality of Life in College Students With Upper Respiratory Infections||Rutgers, The State University of New Jersey|No|Completed|January 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|231|||Both|18 Years|25 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|July 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01657643||81487|
NCT01657656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R00HL089710|Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia|Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia||Harvard School of Public Health|Yes|Completed|October 2012|July 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|80 Years|No|||July 2014|July 29, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657656||81486|
NCT01654939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0794|Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease|Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease||Icahn School of Medicine at Mount Sinai|No|Withdrawn|October 2012|September 2015|Anticipated|September 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 25, 2015|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01654939||81692|
NCT01654614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|62/18.07.2012|Diagnostic Capacity of Keratoconus Match Index and Keratoconus Match Probability in Forme Fruste Keratoconus|Diagnostic Capacity of Keratoconus Match Index and Keratoconus Match Probability in Forme Fruste Keratoconus||Democritus University of Thrace|Yes|Completed|November 2011|July 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|All participants were recruited from the Outpatients Cornea service, in a consecutive if        eligible basis|November 2011|July 29, 2012|July 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01654614||81715|
NCT01655602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajH-005|Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation|Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation||Siriraj Hospital|Yes|Recruiting|July 2012|May 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|10|||Male|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 1, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01655602||81643|
NCT01655862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMA-BTX-12-001|A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie) Treated With OnabotulinumtoxinA|||Allergan|No|Active, not recruiting|July 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|62|||Both|16 Years|N/A|No|Non-Probability Sample|Patients with Cervical Dystonia (Dystonie)|January 2016|January 12, 2016|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655862||81623|
NCT01655836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.210|High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer|Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients||Thomas Jefferson University|Yes|Recruiting|October 2012|September 2019|Anticipated|September 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Male|18 Years|N/A|No|||November 2015|November 16, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01655836||81625|
NCT01655849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Z160-LSR-201|Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of Z160 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy||Zalicus|No|Completed|August 2012|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|141|||Both|18 Years|N/A|No|||December 2013|December 11, 2013|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01655849||81624|
NCT01656356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPO AVIAN FLU Vaccine-V02|Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers|Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers||Mahidol University|Yes|Completed|May 2012|||August 2012|Actual|Phase 1|Interventional|N/A|2||||||Both|18 Years|49 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01656356||81586|
NCT01657227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADE10 00032|Tertiary Prevention in Type II Diabetes Mellitus in Canary Islands Study|Effectiveness and Cost-effectiveness of Two Multi-component Interventions to Improve the Health Outcomes in People With Type 2 Diabetes Mellitus|INDICA|Servicio Canario de Salud|No|Active, not recruiting|January 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Anticipated|2880|||Both|18 Years|65 Years|No|||January 2013|May 18, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01657227||81519|
NCT01658137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIGEST-Pilot|Diet Intervention and GEnetic STudy (DIGEST-Pilot)|Dietary Intervention Trial to Understand the Mechanism Underlying the 9p21 Variant Interaction With High Fruits and Vegetable Consumption|DIGEST|McMaster University|No|Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||August 2012|August 1, 2012|July 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01658137||81449|
NCT01662414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|53653|Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease|Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function||Chulalongkorn University||Completed|April 2011|December 2012|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|38|||Both|30 Years|80 Years|No|||September 2013|September 27, 2013|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01662414||81125|
NCT01662427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6222012|Nocturnal Parkinson's Disease Symptoms Study Group|Nocturnal Parkinson's Disease Symptoms Study Group||Chulalongkorn University||Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|300|||Both|30 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Parkinson's disease patient and care givers|August 2013|August 18, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662427||81124|
NCT01658670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|608-11-FB|HEART Camp: Promoting Adherence to Exercise in Patients With Heart Failure|HEART Camp: Promoting Adherence to Exercise in Patients With Heart Failure|HEART Camp|University of Nebraska|Yes|Active, not recruiting|April 2012|March 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|246|||Both|19 Years|N/A|No|||December 2015|December 31, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658670||81409|
NCT01656538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I213|A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer|A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer||Canadian Cancer Trials Group|No|Recruiting|August 2012|August 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 22, 2016|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656538||81572|
NCT01656551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MILES-4|MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer|A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.|MILES-4|National Cancer Institute, Naples|No|Recruiting|July 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|550|||Both|70 Years|N/A|No|||November 2015|November 25, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01656551||81571|
NCT01656824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bv8/PK-2CTIL|Tissue Study of Bv8/PK-2 Inhibition in Human Cancer|Study of Human Primary Cancer Tissue Implanted in Mice Lacking Bv8/PH-2 in Their Bone Marrow-derived Cells||Rambam Health Care Campus|No|Recruiting|August 2012|October 2014|Anticipated|September 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|20|Samples With DNA|cancer tissues|Both|18 Years|85 Years|No|Non-Probability Sample|Patients diagnosed with pancreatic cancer and are candidates for whipple's procedure|November 2013|November 20, 2013|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01656824||81550|
NCT01657058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-147|Effects of Mode of Administration of Soluble Fibre Blend on Glycemia, Appetite & Sensory Parameters|The Effects of Different Modes of Administration of Soluble Fibre on Postprandial and Second Meal Blood Glucose Response, Appetite and Sensory Parameters in Healthy Individuals|FI-FORM|St. Michael's Hospital, Toronto|No|Active, not recruiting|July 2012|October 2014|Anticipated|December 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|5||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 6, 2014|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01657058||81532|
NCT01657071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YH14659-102|Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects|A Randomized, Open-label, Single Dose, 2-treatment, 2-period, 2-way Crossover Study to Assess the Pharmacokinetic Characteristics of YH14659, a Fixed Dose Combination Compared With Coadministration of Separate Constituents Under Fasted Conditions in Healthy Male Subjects||Yuhan Corporation|No|Completed|March 2012|April 2012|Actual|April 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||July 2012|August 2, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01657071||81531|
NCT01657084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012051485|Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask|Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask|EpiCapno|University of Aarhus|Yes|Recruiting|September 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|20|||Both|18 Years|80 Years|No|||September 2012|January 15, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01657084||81530|
NCT01657409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL003|Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome|Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome||Buddhist Tzu Chi General Hospital|No|Recruiting|August 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|90|||Both|20 Years|90 Years|No|||April 2014|April 3, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657409||81505|
NCT01657669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-01-12|Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results|Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results||Retina Research Institute, LLC|No|Active, not recruiting|October 2012|December 2015|Anticipated|November 2014|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 24, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657669||81485|
NCT01626820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116664|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in Adults Aged 18 Years and Older||GlaxoSmithKline||Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|113|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 8, 2013|June 21, 2012|Yes|Yes||No|August 8, 2013|https://clinicaltrials.gov/show/NCT01626820||83797|
NCT01622725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/223|Primary and Secondary Ventral Hernia Repair Using Long-term Resorbable Versus Non-resorbable Large Pore Synthetic Mesh.|Recurrence Rate After Primary and Secondary Ventral Hernia Repair Using Long-term Resorbable Versus Non-resorbable Large Pore Synthetic Mesh.|TIGR|University Hospital, Ghent|No|Recruiting|February 2013|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|268|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622725||84109|
NCT01622998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA7025|Self-directed Titrated Transdermal Nicotine Patch Versus Standard Treatment for Smoking Cessation|Self-directed Titrated Transdermal Nicotine Patch Versus Standard Treatment for Smoking Cessation in Smokers Motivated to Quit|STEP|Ottawa Heart Institute Research Corporation|Yes|Completed|January 2011|September 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|303|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 16, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622998||84090|
NCT01623271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000466|Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)|Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)||Massachusetts General Hospital|No|Terminated|May 2013|December 2014|Anticipated|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|80 Years|No|||July 2014|July 2, 2014|June 12, 2012|No|Yes|Due to limited population of research participants.|No||https://clinicaltrials.gov/show/NCT01623271||84069|
NCT01623596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFTY720DUS09|Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.|A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)|PREFERMS|Novartis|No|Completed|June 2012|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|881|||Both|18 Years|65 Years|No|||August 2015|August 21, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623596||84044|
NCT01623609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3820C00018|Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol|A Phase I, Randomised, Open-label, 3 Way Cross-over Study in Healthy Volunteers to Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial Formulation.||AstraZeneca|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|42|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2014|October 13, 2014|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623609||84043|
NCT01624155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11808|Increasing Contraception Utilization Among Women Prescribed Teratogenic Medications|Utilizing the Electronic Medical Record to Collaborate With a Community- Based Organization to Increase More Effective Contraception Utilization Among Women Prescribed Teratogenic Medications|TLC|University of California, San Diego|No|Recruiting|May 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|100|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||February 2013|February 20, 2013|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01624155||84002|
NCT01625286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3610C00002|Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients|A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status|BEECH|AstraZeneca|Yes|Recruiting|October 2012|August 2017|Anticipated|November 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|140|||Female|18 Years|130 Years|No|||February 2016|February 24, 2016|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01625286||83915|
NCT01626066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035444|Cathepsin Activatable Fluorescent Probe|A Phase I Study of the Safety and Activation of a Cathepsin-Activatable Fluorescent Cancer Specific Probe LUM015|LUM015|Duke University|Yes|Completed|June 2012|August 2015|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|15|||Both|18 Years|74 Years|No|||December 2015|December 8, 2015|June 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01626066||83855|
NCT01626300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200513884-2|The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens|The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens: A Randomized Placebo-controlled Clinical Trial||University of California, Davis|No|Completed|December 2007|June 2008|Actual|June 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|45|||Both|60 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy subjects > 60 years of age.|June 2012|June 21, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626300||83837|
NCT01626313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003001|UCLA FOCUS Family Resiliency Training Research Study|UCLA FOCUS (Families OverComing Under Stress) Family Resiliency Training Research Study|FOCUS|University of California, Los Angeles|No|Recruiting|December 2011|November 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|24|||Both|5 Years|N/A|No|||June 2012|June 20, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626313||83836|
NCT01618643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHT/2010/25|Aceto-whitening in the Assessment of Gastrointestinal Neoplasia|Acetowhitening Time as a Novel Objective Tool for the Diagnosis of High Risk Neoplasia in Barrett's Oesophagus||Portsmouth Hospitals NHS Trust|Yes|Recruiting|November 2010|November 2013|Anticipated|September 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|None Retained|Only pathology retained is for NHS purposes only. No separate tissue retained for the study|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing surveillance for Barrett's oesophagus|June 2012|June 13, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01618643||84422|
NCT01618656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202009714|Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal|FAAH-Inhibitor for Cannabis Dependence||Yale University|Yes|Suspended|June 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Male|18 Years|55 Years|No|||March 2016|March 18, 2016|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01618656||84421|
NCT01618669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3606-CL-3004|A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)|A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)|EXERRT|Astellas Pharma Inc|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|1147|||Both|18 Years|N/A|No|||January 2016|January 7, 2016|May 29, 2012|Yes|Yes||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01618669||84420|
NCT01639937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120158|Myocardial Perfusion and Scarring in Congenital Heart Disease|Quantitative Myocardial Perfusion, Myocardial Scarring and Their Contribution to Late Clinical Decompensation in Adults With Congenital Heart Disease||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|140|||Both|18 Years|80 Years|No|||March 2016|March 24, 2016|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01639937||82790|
NCT01639950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120160|Validating Pain Scales in Children and Young Adults|Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults With Chronic Illness and Their Parents||National Institutes of Health Clinical Center (CC)||Completed|June 2012|||||N/A|Observational|Time Perspective: Prospective|||Actual|189|||Both|6 Years|99 Years|Accepts Healthy Volunteers|||January 2016|January 22, 2016|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01639950||82789|
NCT01639976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0024-12|Doppler Flow Measurements in Patients With Misoprostol Treatment for Arrested Pregnancy|Testing the Connection Between the Existence of Endometrial Flows With Doppler Examination if the Treatment Cytotec Success in Women With Miss Abortion||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Female|18 Years|43 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women with miss abortion who choose treatment with cytotec|July 2012|July 12, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01639976||82788|
NCT01636388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYMC-553|Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma|A Multicenter Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation Followed by Adoptive Cellular Immunotherapy With Donor Derived Latent Membrane Protein (LMP) Specific-CTLs in Patients With Epstein-Barr Virus (EBV)Positive Refractory or Recurrent Hodgkin Lymphoma||New York Medical College|Yes|Recruiting|January 2013|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|N/A|45 Years|No|||March 2016|March 23, 2016|June 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636388||83063|
NCT01624324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aminoglycoside|Aminoglycoside Plasma Level Measurement in Neonates With Infection|Aminoglycoside Plasma Level Measurement in Neonates With Infection||Indonesia University|No|Recruiting|November 2010|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25||Plasma, Urine|Both|N/A|1 Month|No|Non-Probability Sample|neonates hospitalized in Perinatology Division, Pediatric Department, Cipto Mangunkusumo        Hospital with severe infection requiring an aminoglycoside therapy|July 2012|July 8, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624324||83989|
NCT01625429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABX-1201|Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer|A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer||Shanghai Cancer Hospital, China|No|Active, not recruiting|June 2012|June 2017|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|70 Years|No|||November 2012|November 8, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625429||83904|
NCT01625975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106309|Retrospective Eight Plate Study|A Retrospective Study to Assess the Outcome After Treatment With the Eight Plate System in Pediatric Patients||AO Clinical Investigation and Documentation|No|Completed|July 2012|December 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|138|||Both|18 Months|17 Years|No|Non-Probability Sample|Pediatric patients with an age range at implantation of the Eight Plate growth modulation        devices of 18 months to 17 years        Treatment with Eight Plate (Orthofix) of varus/valgus deformities of the knee and/or leg        length discrepancy due to any of the following:          -  Diseases or syndromes affecting the growth plate (eg, Blount's dis-ease)          -  Post-traumatic, affecting the growth plate          -  Post-infectious, affecting the growth plate          -  Idiopathic etiology|April 2014|April 7, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01625975||83862|
NCT01626222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001JDE49|4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer|A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research|MACS2096|Novartis|No|Completed|June 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|301|||Female|18 Years|N/A|No|||April 2015|April 26, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626222||83843|
NCT01626521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0033-12-HYMC|Value of Prothrombin Fragment F1+2 in the Diagnosis of Pulmonary Embolism in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|July 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Probability Sample|Patients admitted to hospital due to COPD exacerbation|June 2012|June 21, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01626521||83820|
NCT01626534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005164-15|Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome|Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome.||Assistance Publique Hopitaux De Marseille|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|125|||Both|18 Years|75 Years|No|||August 2014|August 27, 2014|March 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01626534||83819|
NCT01622751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-09-055|Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome|Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome||Samsung Medical Center|Yes|Completed|January 2007|June 2007|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|46|||Both|5 Years|12 Years|Accepts Healthy Volunteers|Probability Sample|The study population comprised 28 children with PWS and 18 controls. The enrolled children        with PWS were volunteers from a pool of approximately 100 children with PWS followed up at        the Samsung Medical Center. The controls were healthy children from several elementary and        middle schools located in the southern areas of Seoul.|June 2012|June 14, 2012|January 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01622751||84108|
NCT01623011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSAW|Can Shoulder Arthroscopy Work|What is the Clinical and Cost Effectiveness of Arthroscopic Sub-acromial Decompression Surgery?|CSAW|University of Oxford|Yes|Active, not recruiting|July 2012|April 2017|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|300|||Both|35 Years|75 Years|No|||June 2015|June 18, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623011||84089|
NCT01623284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-008772|PiB PET Scanning in Speech and Language Based Dementias|PiB PET Scanning in Speech and Language Based Dementias||Mayo Clinic|Yes|Completed|March 2010|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|168|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|June 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01623284||84068|
NCT01623622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC-58 (SHS) II-1|Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke|A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke||Asahi Kasei Pharma Corporation|No|Active, not recruiting|July 2012|||May 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Anticipated|270|||Both|20 Years|N/A|No|||February 2015|February 3, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623622||84042|
NCT01623869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01978|Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery|Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma||National Cancer Institute (NCI)||Completed|July 2012|February 2015|Actual|September 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|N/A|No|||June 2015|September 28, 2015|June 17, 2012|Yes|Yes||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01623869||84023|
NCT01624987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WB_2012|Intervention to Support the Reintegration of Former Combatants and Soldiers|||University of Konstanz|No|Enrolling by invitation|June 2012|February 2014|Anticipated|February 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|100|||Male|16 Years|70 Years|Accepts Healthy Volunteers|||July 2013|July 29, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01624987||83938|
NCT01625806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28236|A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers|A Single-Center, Open-Label, Parallel Study to Investigate the Effects of Multiple Doses of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of RO4602522 in Healthy Male Subjects||Hoffmann-La Roche||Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|2||Actual|34|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625806||83875|
NCT01621633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696B2203|A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers|A Single-dose, Open-label Parallel-group Study to Assess the Pharmacokinetics of LCZ696 in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects||Novartis|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|32|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2015|July 11, 2015|June 14, 2012||No||No|July 11, 2015|https://clinicaltrials.gov/show/NCT01621633||84193|
NCT01621893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KC-SCP-001|Evaluation of Subchondroplasty™ for Defects Associated With Bone Marrow Lesions|Prospective Efficacy Evaluation of Subchondroplasty™ for the Treatment of Defects Associated With Tibial Bone Marrow Lesions|SCP|Knee Creations, LLC||Recruiting|January 2012|||January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|70|||Both|40 Years|70 Years|No|Non-Probability Sample|Patients with bone marrow edema of the tibia|June 2012|June 15, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01621893||84173|
NCT01626664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROTOCOL 0761-009|KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)|Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)||Kyowa Hakko Kirin Pharma, Inc.|No|Active, not recruiting|June 2012|November 2016|Anticipated|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626664||83809|
NCT01626937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01382-39|Multicenter National Randomized Controlled Open Label Study Assessing Interest of Non Invasive Ventilation in out-of Hospital Setting During Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease Patients. VeNIS BPCO|Multicenter National Randomized Controlled Open Label Study Assessing Interest of Non Invasive Ventilation in out-of Hospital Setting During Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease Patients. VeNIS BPCO|VeNIS BPCO|Centre Hospitalier d'Agen||Not yet recruiting|June 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|398|||Both|18 Years|N/A|No|||January 2012|June 22, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626937||83788|
NCT01639690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-164|ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene|A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|July 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01639690||82809|
NCT01639703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-44-013|Hepatic Xenetix-CT Perfusion|Diagnostic Contribution of XENETIX® CT PERFUSION in Pre-therapeutical Assessment of Hepatocellular Carcinoma||Guerbet|No|Completed|April 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|96|||Both|18 Years|N/A|No|||December 2014|December 23, 2014|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01639703||82808|
NCT01640236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCDOS_PRO_110314_02|Flare Measurements in Human Radiation Therapy Patients|||ChromoLogic, LLC|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|All patients meeting the inclusion/exclusion criteria and receiving whole body irradiation        at the UCLA Radiation Oncology clinic|July 2014|July 14, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01640236||82769|
NCT01636089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00227-34|Bicarbonates Versus Saline for Contrast Induced Acute Kidney Injury Prevention in Intensive Care Unit||HYDRAREA|University Hospital, Caen||Completed|February 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|300|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01636089||83086|
NCT01640262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-066|Evaluation of Modern MRI in the Diagnosis of Prostate Cancer in a Danish Setup|Evaluation of Modern MRI in the Diagnosis of Prostate Cancer in a Danish Setup||Copenhagen University Hospital at Herlev|No|Completed|August 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|170|||Male|18 Years|N/A|No|Non-Probability Sample|-  Study 1 is offered to 140 patients with newly diagnosed localized prostate cancer and             is comparing mMRI to TRUS and DRE in the assessment of the clinical stage of prostate             cancer.          -  Study 2 is offered to 55 patients with newly diagnosed localized prostate cancer who             have undergone Brachytherapy and is comparing MRI to CT scan performed 4 weeks after             surgery in the evaluation of postoperative dosimetry (treatment effect).          -  Study 3 is offered to 55 patients scheduled for re-biopsy due to continuing suspicion             of prostate cancer after standard TRUS-guided biopsies with negative findings.             Standardised TRUS-guided re-biopsies as well as TRUS biopsies of any MRI-suspicious             lesion are performed in the same session and marked separately. The MRI-targeted             biopsies are compared to the standard TRUS-guided re-biopsies to see if             multiparametric MRI can detect prostate cancer invisible on transrectal ultrasound;             in order to improve detection rate.|May 2014|February 2, 2016|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01640262||82767|
NCT01625702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CGOG5001|Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer|||Peking University||Recruiting|June 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01625702||83883|
NCT01625988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ART-01|A Study of LY2951742 in Participants With Migraine|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine||Eli Lilly and Company|No|Completed|June 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|65 Years|No|||April 2014|April 14, 2014|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625988||83861|
NCT01626001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0631|Imaging Study Compare 4DCT Image|An Imaging Study to Compare Methods to Reduce 4DCT Image Acquisition Artifacts||M.D. Anderson Cancer Center|Yes|Completed|July 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|52|||Both|18 Years|N/A|No|||August 2014|November 16, 2015|June 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01626001||83860|
NCT01626235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRR-LUIT-01|AMPED Outcomes Registry of Post-ED Pain Management|Acute Management of Pain From the Emergency Department: A National, Emergency Department-Based Prospective Post-Intervention Registry of Non-Opioid and Opioid Management of Acute Pain|AMPED|Radnor Registry Research, Inc|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Time Perspective: Prospective||3|Actual|843|||Both|18 Years|N/A|No|Non-Probability Sample|at least 800 patients with specific musculoskeletal or visceral pain syndrome|March 2014|March 11, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626235||83842|
NCT01626547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ORHEO|Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology|Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology; Non-interventional, Observational, Prospective Study||Hospira, Inc.|No|Completed|December 2010|July 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|291|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chemotherapy-induced symptomatic anaemia. Patients suffer from solid        tumours, malignant lymphomas or multiple myeloma and have developed symptomatic anaemia        due to their chemotherapy.|July 2015|July 27, 2015|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01626547||83818|
NCT01626794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V210-062|A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)|A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX Made With the Varicella Enhanced Process (VEP)||Merck Sharp & Dohme Corp.|No|Withdrawn|July 2014|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|0|||Both|12 Months|23 Months|Accepts Healthy Volunteers|||January 2015|January 26, 2015|June 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626794||83799|
NCT01623635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004203-20|Intraperitoneal Atomization of Ropivacaine During Gynecologic Laparoscopic Surgery|Intraperitoneal Atomization of Ropivacaine During Gynecologic Laparoscopic Surgery: Impact on Pain, Opioid Use and Length of Recovery Room Stay||University of Padova|No|Recruiting|February 2012|||September 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|200|||Female|18 Years|75 Years|No|||February 2012|June 19, 2012|February 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623635||84041|
NCT01623882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041311|Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy System|Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Negative Pressure Wound Therapy System for Treatment of Non-responding Venous Stasis and Diabetic Lower Extremity Ulcers|OG/SNaP|Spiracur, Inc.|Yes|Recruiting|June 2012|December 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with lower extremity venous and diabetic ulcers.|April 2013|April 23, 2013|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623882||84022|
NCT01624168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBT Feasibility|Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults|Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults||Appalachian State University|Yes|Completed|January 2013|August 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|June 15, 2012||No||No|August 31, 2015|https://clinicaltrials.gov/show/NCT01624168||84001|None of the reported Serious Adverse Events or Adverse Events were determined to be a result of participation in the intervention.
NCT01624402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH096685|Ecosystem Focused Therapy in Post Stroke Depression|||Weill Medical College of Cornell University|Yes|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|160|||Both|50 Years|N/A|No|||December 2014|December 18, 2014|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624402||83983|
NCT01624675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100877|A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder|A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder||Janssen Pharmaceutical K.K.|No|Completed|September 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|39|||Both|5 Years|17 Years|No|||October 2015|October 13, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01624675||83962|
NCT01625546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0147-01|Whole Body Hyperthermia and Major Depression (MDD)|Whole Body Hyperthermia and Major Depression (MDD)||University of Arizona|Yes|Completed|July 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 6, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625546||83895|
NCT01621373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s54472|Exploratory Propofol Dose Finding Study In Neonates|Prospective Exploratory Dose-finding Study in Neonates Receiving a Single Intravenous Propofol Bolus for Endotracheal Intubation During (Semi-)Elective INSURE Procedure or Non-INSURE Procedures in Neonates|NEOPROP|Universitaire Ziekenhuizen Leuven|No|Completed|August 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|N/A|28 Days|No|||August 2012|May 28, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01621373||84213|
NCT01621386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00038169|Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)|A Study Comparing Measures of Ventilatory Heterogeneity (VH) in Asthma Patients||Duke University|No|Active, not recruiting|January 2013|March 2016|Anticipated|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|34|||Both|18 Years|65 Years|No|||October 2015|October 19, 2015|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01621386||84212|
NCT01618422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.286-T|Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou|A Randomized, Parallel, Controlled Study to Evaluate the Role of Directly Observed Therapy Short Course-Plus (DOTS-Plus) Versus DOTS for Retreatment of Relapsed Pulmonary TB in Guangzhou.||Chinese University of Hong Kong|Yes|Completed|March 2009|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|225|||Both|18 Years|90 Years|No|||November 2015|November 3, 2015|June 11, 2012||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01618422||84439|
NCT01626339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPUM/MDU/300/04/03|Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter|Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter||University of Malaya|Yes|Recruiting|April 2012|||June 2012|Anticipated|N/A|Interventional|N/A|||Anticipated|30|||Both|20 Years|90 Years|No|||June 2012|June 21, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626339||83834|
NCT01626677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CARTISTEM_CR_F/U|Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect|Long Term Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee||Medipost Co Ltd.|Yes|Completed|June 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||September 2014|January 6, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01626677||83808|
NCT01622868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01977|Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer|Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG||National Cancer Institute (NCI)|Yes|Recruiting|July 2012|||February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|143|||Both|18 Years|N/A|No|||November 2015|March 24, 2016|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01622868||84099|
NCT01640002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FR-473218|A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder|A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder||Hospital Universitário Professor Edgard Santos|Yes|Recruiting|May 2012|April 2013|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640002||82786|
NCT01640249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14372|A Study of LY3006072 in Healthy Participants|A Single Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3006072 in Healthy Subjects||Eli Lilly and Company|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 17, 2012|July 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640249||82768|
NCT01636128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA-UB-101|Urinary Biomarker Study With Sulindac and Difluoromethylornithine|A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)||Cancer Prevention Pharmaceuticals, Inc.|Yes|Withdrawn|March 2014|April 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||July 2014|July 28, 2014|July 2, 2012|Yes|Yes|Funding and staffing|No||https://clinicaltrials.gov/show/NCT01636128||83083|
NCT01636661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205M13901|Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis|Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis|tDCS|University of Minnesota - Clinical and Translational Science Institute|No|Completed|July 2012|December 2013|Actual|August 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|8 Years|17 Years|No|||October 2015|October 7, 2015|June 11, 2012||No||No|June 22, 2015|https://clinicaltrials.gov/show/NCT01636661||83042|
NCT01626014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012NTLS005|Interactive Educational Website for Women With Ovarian Cancer & Caregivers|Making End of Life Decision in Ovarian Cancer: When to Enter Hospice? A Prototype Interactive Computer Program for Patients and Providers||University of Minnesota - Clinical and Translational Science Institute|No|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|53|||Female|18 Years|N/A|No|||November 2015|November 30, 2015|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626014||83859|
NCT01626248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-001-TY|Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control|Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in a Natalizumab Treated Population With Active Control Assessment||Rocky Mountain MS Research Group, LLC|No|Completed|July 2012|April 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort||5|Actual|164|Samples Without DNA|serum|Both|18 Years|80 Years|No|Non-Probability Sample|Patients with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated at Rocky        Mountain Multiple Sclerosis Clinic, and who are currently undergoing disease modifying        therapy, natalizumab, glatiramer acetate injections, interferon beta 1a, or who are        beginning one of these disease modifying therapies.|June 2013|June 12, 2013|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626248||83841|
NCT01626560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|daptocina|The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin|Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin||Hospital Universitario Evangelico de Curitiba|No|Completed|July 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|80 Years|No|||March 2015|March 19, 2015|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01626560||83817|
NCT01626807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01CA163146-01A1|Evaluation of a Walking School Bus Program|Evaluation of a Walking School Bus Program: A Cluster Randomized Controlled Trial||Seattle Children's Hospital|Yes|Enrolling by invitation|December 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|770|||Both|7 Years|14 Years|Accepts Healthy Volunteers|||November 2015|November 16, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626807||83798|
NCT01624415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT - 190312|Subjective Image Quality in Stereoscopic Image Modifications||Stereopsis|Medical University of Vienna||Completed|June 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants will be selected by the Department of Clinical Pharmacology healthy        subjects, male and female, 18-35 years|June 2012|June 28, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624415||83982|
NCT01624688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001091|Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal|Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal||Massachusetts General Hospital|Yes|Active, not recruiting|July 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|June 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01624688||83961|
NCT01624701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/925/B|Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells|Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells: A Pilot Trial in Collaboration With the Massachusetts Institute of Technology||Singapore General Hospital|Yes|Terminated|March 2012|July 2016|Anticipated|July 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|12 Years|60 Years|No|||November 2015|November 26, 2015|March 20, 2012||No|Funding expired|No||https://clinicaltrials.gov/show/NCT01624701||83960|
NCT01625000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A002-A4|Safety and Efficacy of MP-214 in Patients With Schizophrenia|A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia||Mitsubishi Tanabe Pharma Corporation||Recruiting|May 2012|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|480|||Both|20 Years|64 Years|No|||February 2016|February 5, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625000||83937|
NCT01625013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF-SYNVISC-ONE 001|Synvisc-One for Younger, Active Patients With Osteoarthritis|Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)|SYNVISC-ONE|University of California, San Francisco|No|Recruiting|July 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|30 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|June 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625013||83936|
NCT01625299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-07-0223|Pilot Study of Diet and Behavior in Children With Autism|PILOT STUDY: The Physiological Basis for Dietary Protein Intolerance in Children With Autism||The University of Texas Health Science Center, Houston|Yes|Completed|October 2008|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|12|||Both|3 Years|12 Years|No|||June 2012|June 19, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625299||83914|
NCT01620840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB-LCM-2011|Lacosamid-i.v.-Register|Lacosamid-i.v.-Register|LCM|University of Schleswig-Holstein|Yes|Completed|June 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|130|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who are treated with Lacosamide i.v.-solution in routine clinical practice.|May 2015|May 27, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620840||84253|
NCT01621100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100659|Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients|A Prospective, Open-Label, Multicenter, Single-Arm, Interventional Study to Evaluate the Efficacy and Tolerability of Once-Daily Oros Hydromorphone for Cancer Pain Treatment in Korean Cancer Patients.||Janssen Korea, Ltd., Korea|No|Completed|December 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|106|||Both|20 Years|N/A|No|||September 2013|September 5, 2013|April 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621100||84234|
NCT01626352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRI LYM 75|Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy|Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy||SCRI Development Innovations, LLC|No|Active, not recruiting|August 2012|October 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|70 Years|N/A|No|||March 2016|March 2, 2016|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626352||83833|
NCT01626703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A102065_2012_2|Effect of Depressin Screening and Care Program at Community Health Center|||National Clinical Research Coordination Center, Seoul, Korea||Completed|June 2012|March 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|86|||Both|60 Years|N/A|No|||March 2016|March 9, 2016|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626703||83806|
NCT01626950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AO/INCA/2011/JPD|Living Conditions and Breast Cancer|Living Conditions and Breast Cancer||Centre Hospitalier Universitaire de Nīmes|No|Completed|May 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|684|||Female|N/A|N/A|No|Non-Probability Sample|This study is a case-control study concerning the female population suffering from breast        cancer in the Herault department of France. Only invasive cancers are taken into account.        For each case, we will have at least 2 controls, matched according to age +- 2 years.|March 2015|March 25, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626950||83787|
NCT01622881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0173|Analgesic Efficacy of Nefopam in Patients Undergoing Kidney Transplantation|Analgesic Efficacy of Nefopam in Patients Undergoing Kidney Transplantation : Randomized Controlled Study||Severance Hospital|No|Completed|June 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|98|||Both|20 Years|64 Years|No|||August 2013|August 18, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01622881||84098|
NCT01622894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008/067/HP|Genetics of Mendelian Forms of Young Onset Alzheimer Disease|Genetics of Mendelian Forms of Young Onset Alzheimer Disease. Identification of Novel Genetic Causes of AD Are of Importance in Completing the Mechanisms of the Amyloid Hypothesis. This Project is Useful to Promote the Guidelines on the Genetic Diagnosis of AD in France.|GMAJ|University Hospital, Rouen|Yes|Active, not recruiting|November 2009|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|Samples With DNA|samples with DNA|Both|18 Years|75 Years|No|Non-Probability Sample|cases of familial Alzheimer disease with age of onset under 65|January 2016|January 22, 2016|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622894||84097|
NCT01623739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITI 689_2010|Esthetic, Clinical and Radiographic Outcomes of Immediately Placed Implants (Type 1) and Early Placed Implants (Type 2)|Esthetic, Clinical and Radiographic Outcomes of Immediately Placed Implants (Type 1) and Early Placed Implants (Type 2)||The University of Texas Health Science Center at San Antonio|No|Active, not recruiting|December 2010|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 21, 2015|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01623739||84033|
NCT01640015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO197|The Effect of Eating Frequency on Blood Pressure|The Effect of Number of Eating Episodes Per Day on Blood Pressure. A Randomised Controlled Trial||Imperial College London|Yes|Not yet recruiting|August 2012|March 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|35 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640015||82785|
NCT01640028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Inno-6026|Exploratory Study of Intra and Inter-subject Variability in Sebum Excretion Rate|Exploratory Study of Intra and Inter-subject Variability in Sebum Excretion Rate||Innovaderm Research Inc.|No|Completed|July 2012|December 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Approximately 40 subjects, male or female, aged 18 years or older with a sebum excretion        rate (SER) of at least 4 at Day 0 on both sides of the forehead as measured with Sebutape,        will be included in this study.|January 2013|January 15, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640028||82784|
NCT01637298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIN Study|Biomarkers to Detect Anal Intraepithelial Neoplasia in Thai Men Who Have Sex With Men|The Thai Red Cross AIDS Research Centre||Thai Red Cross AIDS Research Centre|No|Completed|December 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|450|||Male|18 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|MSM with HIV negative and positive in Thailand|July 2012|July 10, 2012|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01637298||82993|
NCT01625715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCP-001|Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization|A Prospective, Randomized, Case Controlled, Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization in Children With Peanut Allergies.||Gordon Sussman Clinical Research|No|Active, not recruiting|January 2011|September 2012|Anticipated|June 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|6|||Both|8 Years|12 Years|No|||June 2012|June 20, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625715||83882|
NCT01625728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10529|Vocal Demands Among Classroom Teachers|A Comparison of Vocal Demands With Vocal Performance Among Classroom Teachers||Southern Illinois University Carbondale|No|Recruiting|June 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Participants in the experimental group: student teachers enrolled in teaching education        programs and active teachers. Participants in the control group: not enrolled in teaching        education programs and are not active teachers.|December 2015|December 9, 2015|March 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01625728||83881|
NCT01626261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-051|Examination of Implant´s Safety in an Electronic and Magnetic Field Environment|Study of Provocation Concerning Implants´Safety in Electronic and Magnetic Fields in Their Environment|FEMU|RWTH Aachen University|No|Recruiting|September 2009|December 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood (serum and plasma) urine|Both|18 Years|80 Years|No|Probability Sample|age between 18 and 80|April 2015|April 30, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626261||83840|
NCT01626573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39110-201|A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis|A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis||Incyte Corporation|No|Completed|March 2012|October 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|12||Actual|106|||Both|18 Years|75 Years|No|||March 2014|March 26, 2014|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626573||83816|
NCT01623024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAFLD-VITAMIN D 01|Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis|A Randomised Controlled Trial of Vitamin D Plus Plus Lifestyle Versus Lifestyle in Patients With Non-alcoholic Steatohepatitis:Effect on Liver Histology and Metabolic Parameters||University of Palermo|No|Not yet recruiting|September 2012|||September 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623024||84088|
NCT01623037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA12-006|Pilot Study on The Flanks of Asian Patients|PILOT STUDY OF NON-INVASIVE FAT LAYER REDUCTION IN THE FLANKS OF ASIAN PATIENTS WITH THE COOLCURVE+ APPLICATOR||Zeltiq Aesthetics|No|Completed|June 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2012|October 14, 2014|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01623037||84087|
NCT01626833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P090903|Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone|Severe Decrease of Growth Velocity in Children With Anorexia Nervosa. Therapeutic Trial of Growth Hormone|OREX|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2013|March 2022|Anticipated|March 2022|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|8 Years|203 Months|No|||March 2012|January 16, 2016|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626833||83796|
NCT01620008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mercer-9329|Delayed Cord Clamping and Infant Brain Study|Effects of Placental Transfusion on Early Brain Development|IBS|University of Rhode Island|No|Active, not recruiting|October 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|128|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 27, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01620008||84317|
NCT01620021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00003205|Feasibility of Wearable Sensors to Determine Gait Parameters|Feasibility of Wearable Sensors to Determine Gait Parameters||University of South Florida|Yes|Completed|April 2011|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Ten healthy volunteers with no history of gait and balance issues will be recruited to        participate in the study. The participants must be between 18 and 65 years of age.|May 2015|May 6, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01620021||84316|
NCT01620294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|triclosan-coated-suture2009|Abdominal Wall Closure With Triclosan-coated Suture|Abdomen Closure Using Triclosan Coated Absorbable Suture vs Uncoated Sutures of the Same Base Material|TCS09|University of Pecs|Yes|Completed|November 2009|November 2010|Actual|April 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1|||Both|18 Years|80 Years|No|||June 2012|June 14, 2012|May 10, 2010||No||No||https://clinicaltrials.gov/show/NCT01620294||84295|
NCT01620580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-SN-11-0465|Symptom Management Program for Hemodialysis Patients|Symptom Management Program for Hemodialysis Patients||The University of Texas Health Science Center, Houston|Yes|Completed|September 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 14, 2012|October 24, 2011||No||No||https://clinicaltrials.gov/show/NCT01620580||84273|
NCT01620593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTRC 10-21|Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer|Phase II, Randomized, Placebo Controlled, Double Blind, Prospective Study of Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer.||The University of Texas Health Science Center at San Antonio|Yes|Active, not recruiting|April 2011|May 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Male|18 Years|N/A|No|||November 2015|November 4, 2015|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01620593||84272|
NCT01620827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUP-FURS-2012|Hospital vs. Cell Phone Number Follow-Up Randomization Study|Study Subject Responsiveness to Follow-Up Phone Calls From a Hospital Landline as Compared With From a Private Cellular Phone Number|FURS|University of Pennsylvania|No|Recruiting|February 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|400|||Both|18 Years|N/A|No|||June 2012|July 3, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620827||84254|
NCT01622205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOTVED|GOThenburg Very Early Supported Discharged|Phase 2 Study of Very Early Supported Discharge From a Stroke Unit in|GOTVED|Göteborg University|No|Enrolling by invitation|May 2011|July 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Both|18 Years|N/A|No|||November 2015|November 2, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01622205||84149|
NCT01622218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor007112clit|The Impact of Medical Clowning on Pain and Stress Level in Pediatric Patients Undergoing Hernia Repair Surgery LAUGH Study.|The Impact of Medical Clowning on Pain and Stress Level in Pediatric Patients Undergoing Hernia Repair Surgery LAUGH Study||Soroka University Medical Center|No|Recruiting|August 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|4 Years|10 Years|No|||November 2014|November 30, 2014|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01622218||84148|
NCT01622231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116365|Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis|Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis||GlaxoSmithKline||Completed|June 2012|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|2 Years|14 Years|No|||May 2013|August 8, 2013|June 7, 2012|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01622231||84147|
NCT01625845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110007119|Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)|Targeting Systemic Inflammation to Concurrently Treat Late-Life Depression and Reduce Coronary Artery Disease Risk|INFLAMED|Indiana University|Yes|Completed|June 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|40 Years|N/A|No|||October 2015|October 30, 2015|June 19, 2012|Yes|Yes||No|May 28, 2015|https://clinicaltrials.gov/show/NCT01625845||83872|Missing data precluded analysis of two secondary outcome variables: IL-1α and IL-1β.Due to the very small sample of randomized patients, conclusions should not be drawn from the results of this pilot trial.
NCT01626092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS147|Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders|Treatment of High Risk, Inherited Lysosomal and Peroxisomal Disorders by Reduced-Intensity Hematopoietic Cell Transplantation and Low-Dose Total Body Irradiation With Marrow Boosting by Volumetric-Modulated Arc Therapy (VMAT)||Masonic Cancer Center, University of Minnesota|Yes|Completed|July 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|N/A|55 Years|No|||May 2014|May 15, 2014|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626092||83853|
NCT01622530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000991|Development of a Simulation Tool for Upper Extremity Prostheses|Development of a Simulation Tool for Upper Extremity Prostheses||University of South Florida|Yes|Recruiting|July 2010|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups will be studied: non-amputees and upper limb amputees. The subjects will be        recruited from around the community.|January 2016|January 12, 2016|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01622530||84124|
NCT01622543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I210|Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer|A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.||Canadian Cancer Trials Group|Yes|Active, not recruiting|August 2012|March 2017|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|109|||Both|18 Years|N/A|No|||April 2015|March 22, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01622543||84123|
NCT01626716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A102065_2012_1|Collaborative Care for Depressed Elderly in Korea|||National Clinical Research Coordination Center, Seoul, Korea||Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|60 Years|N/A|No|||March 2016|March 10, 2016|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626716||83805|
NCT01622608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0179|Adolescent Vaccination Kiosk Project|Adolescent Vaccination Kiosk Project||University of Colorado, Denver|No|Completed|August 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|42|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 20, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622608||84118|
NCT01623453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANTG-ASC-211|Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)|A Follow-up Study to Evaluate the Sustained Healing Effect the Patients Who Showed Complete Closure of Fistula the Previous ANTG-ASC-210 Study|ANTG|Anterogen Co., Ltd.|Yes|Active, not recruiting|September 2010|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|40|||Both|18 Years|N/A|No|Non-Probability Sample|• the patients with complete closure at week 8 after last injection in ANTG-ASC-210 trials|June 2012|June 17, 2012|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01623453||84055|
NCT01639768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB/0038|SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding|A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Birch in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen||HAL Allergy|Yes|Completed|July 2012|April 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|270|||Both|18 Years|60 Years|No|||May 2013|May 28, 2013|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01639768||82803|
NCT01639456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS151|CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission|A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy in Older Adults With Acute Myelogenous Leukemia in First Complete Remission||Masonic Cancer Center, University of Minnesota|Yes|Withdrawn|October 2013|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|75 Years|No|||March 2014|March 4, 2014|July 10, 2012|Yes|Yes|study was abandoned and a new study was written to replace this one|No||https://clinicaltrials.gov/show/NCT01639456||82827|
NCT01639781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGE-111-CH|Age-dependent Effects of Flavanols on Vascular Status|Age-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status After Acute and Chronic Application.||Heinrich-Heine University, Duesseldorf|No|Completed|November 2011|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|44|||Male|18 Years|80 Years|Accepts Healthy Volunteers|||December 2014|December 14, 2014|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01639781||82802|
NCT01636167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Astigmatism|Construction of Computerized Intraoperative Keratometer and Experimental Study|Construction of Computerized Intraoperative Keratometer and Experimental Study||Wenzhou Medical University|Yes|Completed|July 2011|May 2012|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|60|||Both|20 Years|80 Years|No|||July 2012|July 9, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01636167||83080|
NCT01636427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|STEMI Versus NSTEMI: Clinical and Angiographic Differences|STEMI Versus NSTEMI: a Mono Versus a Multivessel Disease?||Federico II University|No|Completed|January 2007|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|200|||Both|N/A|N/A|No|Probability Sample|Patients with acute myocardial infarction with or without ST segment elevation.|July 2012|July 17, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636427||83060|
NCT01637311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSNJ-POEM|Peroral Endoscopic Remyotomy for Failed Heller Myotomy|Peroral Endoscopic Remyotomy for Failed Heller Myotomy||Shanghai Zhongshan Hospital|Yes|Recruiting|January 2010|December 2014|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|80 Years|No|||May 2012|July 6, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01637311||82992|
NCT01626027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GY1154|Depression Care for Hospitalized Coronary Heart Disease Patients: Prospective Cohort Study|Depression Care for Hospitalized Coronary Heart Disease Patients: Bridging the Gap Between Guidelines and Reality|CDCare|Charite University, Berlin, Germany|No|Active, not recruiting|June 2012|August 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with confirmed Coronary Heart Disease (CHD) hospitalized in the coronary care        units of 2 University hospitals in Germany. Additionally, starting August 2012, patients        with confirmed CHD who receive ambulatory care at one of the cardiology clinics will also        be enrolled.|July 2015|July 29, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626027||83858|
NCT01622764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28015|89Zr-RO5323441 PET Imaging in Glioblastoma|89Zr-RO5323441 PET Imaging in Patients With Recurrent Glioblastoma Treated With Bevacizumab||University Medical Center Groningen|No|Withdrawn|September 2014|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 27, 2014|June 15, 2012||No|No funding from the sponsor|No||https://clinicaltrials.gov/show/NCT01622764||84107|
NCT01622777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSU001|The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study|Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Effect of Rosuvastatin in Diabetic Polyneuropathy||University of Guadalajara|Yes|Completed|February 2010|June 2011|Actual|January 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|34|||Both|35 Years|80 Years|No|||June 2012|June 18, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622777||84106|
NCT01623050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNS-005|Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium|SinuSys Patency of Maxillary Sinus Ostia Study||SinuSys Corporation|No|Completed|April 2012|September 2014|Actual|June 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|75 Years|No|||October 2014|October 30, 2014|June 13, 2012||No||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01623050||84086|
NCT01623063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EIFMUSP|Histomorphometry Analysis in Fertile and Infertile Patients|Histomorphometry Analysis in Fertile and Infertile Patients||University of Sao Paulo|No|Recruiting|January 2012|August 2012|Anticipated|June 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|40|||Female|18 Years|41 Years|Accepts Healthy Volunteers|||June 2012|June 18, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623063||84085|
NCT01623297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECRIP|Confusion in the Elderly After Colon Surgery|Cognitive Changes After Surgery in the Elderly: Does Minimally Invasive Surgery Influence the Incidence of Postoperative Cognitive Changes Compared to Open Colon Surgery?||New York Hospital Queens|No|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|52|Samples Without DNA|Plasma samples stored up to 7 months then expired and discarded|Both|65 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients newly diagnosed with colon adenocarcinoma will be contacted after being scheduled        for surgery at New York Hospital Queens.|June 2012|June 15, 2012|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01623297||84067|
NCT01620853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASI-ALK-F|Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)|Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)||Applied Spectral Imaging Ltd.|No|Completed|May 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Both|20 Years|90 Years|No|Probability Sample|Patients having non-small cell lung cancer (NSCLC)|February 2015|February 5, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620853||84252|
NCT01620866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BET-study|A Eye Movement Desensitization Reprocessing (EMDR) Study in Bipolar Traumatized Patients|A Controlled, Single-blind Pilot Study of EMDR in Bipolar, Subsyndromal Patients With Trauma|BET|FIDMAG Germanes Hospitalàries|No|Completed|November 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||June 2012|June 18, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01620866||84251|
NCT01621113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D-732-12|Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury|Restoring Lost Functions After Spinal Cord Injury: Combination Therapy With Dalfampridine and Locomotor Training for Persons With Chronic, Motor Incomplete Spinal Cord Injury||Kessler Foundation|Yes|Recruiting|June 2012|October 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|46|||Both|18 Years|70 Years|No|||December 2012|December 27, 2012|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01621113||84233|
NCT01621399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-1601-01|Safety and Efficacy Study to Treat Bacterial Vaginosis|A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis||Medicis Global Service Corporation|No|Completed|May 2012|December 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|651|||Female|18 Years|N/A|No|||August 2013|August 20, 2013|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01621399||84211|
NCT01621412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSAD-VIH-2011|HIV Disclosure and Medication Adherence, a Pilot Study|HIV Disclosure and Medication Adherence, a Pilot Study|RSAD-VIH-11|Policlinique Médicale Universitaire|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients enrolled in the adherence-enhancing program at ther pharmacy of Department of        Ambulatory Care and Community Medicine in Lausanne|December 2015|December 21, 2015|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01621412||84210|
NCT01621906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-039|18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain|Pilot Study of 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain||Memorial Sloan Kettering Cancer Center||Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01621906||84172|
NCT01625572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAPPro|Ultrasound-assisted Bilateral Transversus Abdominis Plane Block for Open Prostatectomy|Ultrasound-assisted Bilateral Transversus Abdominis Plane Block for Open Prostatectomy|TAPPro|Charite University, Berlin, Germany|No|Recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|66|||Male|18 Years|N/A|No|||February 2015|February 6, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625572||83893|
NCT01625832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|067/11|Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study)|Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study)||University Hospital Inselspital, Berne|No|Completed|September 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|35|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01625832||83873|
NCT01626118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IND3-10-06|Study of Indomethacin Capsules to Treat Pain Following Bunionectomy|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Indomethacin Nanoformulation Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy||Iroko Pharmaceuticals, LLC|No|Completed|May 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|373|||Both|18 Years|65 Years|No|||February 2014|February 17, 2014|June 20, 2012|Yes|Yes||No|December 11, 2013|https://clinicaltrials.gov/show/NCT01626118||83851|
NCT01626365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHBahk_DLT_thermosoftening|Thermosoftening of Double-lumen Tube to Reduce Sore Throat|The Effect of Double-lumen Tube Thermosoftening Before Intubation to Reduce Hoarseness and Sore Throat||Seoul National University Hospital||Completed|May 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|154|||Both|20 Years|75 Years|No|||December 2012|December 16, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626365||83832|
NCT01626105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPTIH No. 1|Personalized Prediction of Tolerance and Immunogenicity in Hemophilia|Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity|PPTIH|Los Angeles Orthopaedic Hospital|No|Not yet recruiting|June 2012|June 2014|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|55|Samples With DNA|A core laboratory exists for this study and will house a Biorepository containing the      following:        1. White blood cells        2. Blood plasma|Male|2 Years|N/A|No|Non-Probability Sample|Fifty five patients with severe or moderately severe hemophilia A who have received        replacement therapy with a Factor VIII product representing only a single primary amino        acid sequence.|July 2012|July 25, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626105||83852|
NCT01626378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-237-007|Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)|A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)||TauRx Therapeutics Ltd|Yes|Active, not recruiting|August 2013|January 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|220|||Both|N/A|79 Years|No|||March 2015|March 19, 2015|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626378||83831|
NCT01626391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-237-008|Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease|A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy||TauRx Therapeutics Ltd|Yes|Terminated|September 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|9|||Both|N/A|90 Years|No|||June 2014|June 10, 2014|June 20, 2012|Yes|Yes|This study has been terminated for administrative reasons only.|No|April 28, 2014|https://clinicaltrials.gov/show/NCT01626391||83830|Early termination leading to small numbers of subjects analyzed
NCT01623154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBT-1l-202|POCone-UBiT-IR300 Pediatric Comparison Study|A Prospective, Multi-Center, Open-Label Study to Compare the POCone® With the UBiT®-IR300 in Measurement of 13CO2/12CO2 Ratio in Breath Samples Collected From Pediatric Subjects Ages 3 to 17 Years With Upper Gastrointestinal Signs and Symptoms||Otsuka America Pharmaceutical|No|Completed|July 2012|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|99|||Both|3 Years|18 Years|No|||January 2015|February 2, 2015|June 15, 2012|Yes|Yes||No|April 29, 2014|https://clinicaltrials.gov/show/NCT01623154||84078|
NCT01623167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120150|Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia|Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|January 2024|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|121|||Both|2 Years|N/A|No|||January 2016|January 13, 2016|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623167||84077|
NCT01623466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ATI-CL21|Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches|A Randomized, Open-Label, Parallel Group Study To Evaluate Pharmacokinetic Profile, Wearability And Safety of Two Progestin-Only Patches Containing Different Doses Of Levonorgestrel (LNG)|ATI-CL21|Agile Therapeutics|No|Active, not recruiting|June 2012|September 2012|Anticipated|September 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623466||84054|
NCT01623479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GMA-LTS-10-001|An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes|||Allergan|No|Completed|November 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|585|||Both|18 Years|N/A|No|Non-Probability Sample|Subjects with hypotrichosis of the eyelashes|August 2012|August 16, 2012|June 18, 2012|Yes|Yes||No|August 16, 2012|https://clinicaltrials.gov/show/NCT01623479||84053|
NCT01639469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-342|Telemedicine Intervention to Improve Physical Function|A Telemedicine Intervention to Improve Physical Function in Patients With PD||VA Office of Research and Development|No|Active, not recruiting|January 2013|April 2017|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|158|||Both|40 Years|N/A|No|||December 2015|December 4, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639469||82826|
NCT01640275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00030861|Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia|The Effect of Isoflurane Versus Propofol Anesthesia on Alzheimers Disease CSF Markers|MAD-PIA|Duke University|No|Completed|March 2012|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Actual|105|||Both|18 Years|N/A|No|||March 2015|August 3, 2015|June 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640275||82766|
NCT01636180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1.0, 2009-06-06|Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.|Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.|REL-0609|Fundacja Ośrodek Badań Medycznych|No|Withdrawn|March 2012|||May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|April 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636180||83079|
NCT01636440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|070/12|Reliability of Measuring Conditioned Pain Modulation With the Nociceptive Withdrawal Reflex|Reliability of Measuring Conditioned Pain Modulation With the Nociceptive Withdrawal Reflex||University Hospital Inselspital, Berne|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|39|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 18, 2013|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636440||83059|
NCT01637012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.0, 2011-12-01|Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease|Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease. Study With Angiography and OCT Follow-up.|ALEX OCT|Balton Sp.zo.o.|No|Completed|February 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|N/A|No|||March 2014|March 12, 2014|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637012||83015|
NCT01637025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|621101|Oxidized Cellulose hEmostAsis evaluatioN|A Prospective, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Traumastem as an Adjunct to Hemostasis for Tissue Bleeding in Open Cardiac, Intra-abdominal (Including Retroperitoneal) and Pelvic Surgery|OCEAN|Baxter Healthcare Corporation||Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|111|||Both|N/A|N/A|No|||January 2013|January 23, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637025||83014|
NCT01626846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NF Survey 2012|How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem|Cognitive Impairments, Self-Esteem & Academic Performance in Teenagers With Neurofibromatosis Type 1||John Jay High School|No|Recruiting|June 2012|September 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|||Both|14 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Teenagers aged 14-17 years with NF1|June 2012|June 22, 2012|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626846||83795|
NCT01626859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A002-A11|A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia|A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)||Mitsubishi Tanabe Pharma Corporation||Completed|May 2012|August 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|38|||Both|20 Years|64 Years|No|||June 2014|June 3, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01626859||83794|
NCT01626872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A002-A5|Long-Term Study of MP-214 in Patients With Schizophrenia|Long-Term Extension Study of MP-214 in Patients With Schizophrenia||Mitsubishi Tanabe Pharma Corporation||Recruiting|June 2012|||||Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|240|||Both|20 Years|64 Years|No|||February 2016|February 5, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01626872||83793|
NCT01623323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-FLU-CS-3204|Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps|A 3-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps||Optinose US Inc.|No|Completed|September 2013|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|719|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 14, 2012|Yes|Yes||No|February 2, 2016|https://clinicaltrials.gov/show/NCT01623323||84065|
NCT01623648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCCCBI 017-2007-104|High Protein Breakfast on Appetite, Postprandial Glycemia and Weight Loss in T2D|Effect of Whey Protein vs Other Proteins in the Breakfast on Appetite, Overall Postprandial Glycemia and Weight Loss, in Obese Diabetic Individuals|HPB|Hospital de Clinicas Caracas|Yes|Active, not recruiting|February 2013|August 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|58|||Both|30 Years|70 Years|Accepts Healthy Volunteers|||September 2015|January 15, 2016|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623648||84040|
NCT01623895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUCH-R-0701|Pharmacogenetic Study in Patients Received Iron Chelating Agent|Pharmacogenetic Study in Patients Received Iron Chelating Agent||Seoul National University Hospital|No|Completed|December 2007|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|Candidate genes exhibit polymorphisms and encodes proteins that are involved in the      pharmacokinetics and pharmacodynamics of deferasirox.      Candidate genes : MRP2, BCRP, UGT1A subfamily|Both|N/A|21 Years|No|Non-Probability Sample|Patients who received deferasirox because of transfusion associated iron overload|December 2013|July 11, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01623895||84021|
NCT01623908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110618GD|Bone Loss Treatment From Adjuvant Zoledronate Efficacy|An Open,Multicentre,Prospective Study of Adjuvant Zoledronate Treatment in Osteoporosis Women With Breast Cancer|BLAZE|First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|July 2011|June 2017|Anticipated|June 2014|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|18 Years|N/A|No|||October 2012|October 17, 2012|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01623908||84020|
NCT01624181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZIM-KF2111207AK0|Fast Identification of Pathogen in the Setting of Hospital-acquired Pneumonia Using Ion Mobility Spectrometry|Identification of Microbes Through Detection of Pathogen Specific Volatile Compound Patterns, Using Multi-capillary Column Coupled Ion Mobility Spectrometry (MCC-IMS) in the Setting of Hospital-acquired Pneumonia||University of Göttingen|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|Samples Without DNA|aspiration samples from the respiratory system (tracheal secretion sample, BAL)|Both|18 Years|90 Years|No|Non-Probability Sample|patients will be recruited from two intensive care units of the university hospital.|January 2013|January 9, 2013|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01624181||84000|
NCT01625052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A.653|Determination of the Optimal Approach to Select the Best Size of BASKA Mask to Use in Male Patients|Determination of the Optimal Approach to Select the Best Size of BASKA Mask to Use in Male Patients||University College Hospital Galway|No|Completed|January 2012|June 2012|Actual|June 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|16 Years|85 Years|No|||December 2012|December 22, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01625052||83933|
NCT01625325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1131-4384a|Identification and Characterization of Youth With Extreme Obesity|Medical and Psychosocial Implications of Adolescent Extreme Obesity - Acceptance and Effects of Structured Care Study, Subproject 1|YES|University of Ulm|Yes|Completed|July 2012|December 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|429|Samples With DNA|Samples of fasting plasma, serum, DNA, and urine will be retained.|Both|14 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the general population through different healthcare- and        non healthcare settings to ascertain the inclusion of treatment-seeking and non        treatment-seeking individuals. Healthcare settings include university based obesity        clinics, physician offices and health insurance agencies. Non-healthcare settings include        schools, job centers, and employment agencies.|May 2015|May 12, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625325||83912|
NCT01625858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THLD-4-12|Evaluation of Supraglottic Airway Devices in Children and Comparison to Historic Control|Prospective Evaluation of Pediatric Supraglottic Airways in Anesthetized Children||University Hospital Inselspital, Berne|Yes|Completed|May 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|250|||Both|N/A|18 Years|Accepts Healthy Volunteers|Probability Sample|patients of both genders, ages 0-18 years, ASA physical status I-III, scheduled at the        University Hospital of Bern for elective surgery under general anesthesia in supine        position with planned operation time <4 hours and planned airway management including a        supraglottic airway.|September 2014|September 1, 2014|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01625858||83871|
NCT01625871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vivax|Artemether/Lumefantrine and Vivax Malaria|Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan||University of Khartoum|Yes|Completed|September 2011|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|38|||Both|5 Years|80 Years|No|||January 2013|January 16, 2013|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01625871||83870|
NCT01626131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-Exercise|Exercise: A Novel Treatment for Combat Post Traumatic Stress Disorder|Exercise: A Novel Treatment for Combat PTSD||INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Terminated|October 2011|January 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|65 Years|No|||April 2013|April 24, 2013|June 20, 2012||No|The funding agency, DoD, determined that the study could not meet its enrollment numbers by    the end of the grant.|No||https://clinicaltrials.gov/show/NCT01626131||83850|
NCT01626690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0823|Prospective Trial of the Effect of Preoperative Forced-air Warming on Perioperative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients|Prospective Randomized Control Trial of the Effect of Preoperative Forced-air Warming on Perioperative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients||University of Wisconsin, Madison||Terminated|May 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|55 Years|85 Years|No|||December 2014|October 1, 2015|June 12, 2012|Yes|Yes|Surgeons change in preference for perioperative warming.|No||https://clinicaltrials.gov/show/NCT01626690||83807|
NCT01626404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TC-060112|Screening for Advanced Heart Failure Treatment (SEE-HF)|Screening for Advanced Heart Failure Treatment (SEE-HF)|SEE-HF|Thoratec Europe Ltd|No|Active, not recruiting|October 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|99|||Both|18 Years|80 Years|No|Non-Probability Sample|Outpatients with CRT and/or ICD, EF </= 40% and in NYHA III-IV|January 2016|January 4, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626404||83829|
NCT01622634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPHIT|Effect of a High-Protein Diet and/or High-Intensity Training on Metabolic Syndrome|The E-PHIT Study: Eggs, Protein, and High-Intensity Training: A Diabetes Prevention Program for Women|EPHIT|University of Georgia|No|Completed|February 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|49|||Female|30 Years|65 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622634||84116|
NCT01622920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMET|Preliminary Clinical Study of Ultrasound to Measure Enamel Thickness|Preliminary Clinical Study of Ultrasound to Measure Enamel Thickness|UMET|University of Leeds|No|Completed|November 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2013|March 15, 2013|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01622920||84095|
NCT01640288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037791|Imaging Regional Lung Defect Severity|Human Lung Regional Ventilation Defect Severity Measured by Fluorine-19 Gas MRI|DIAL1001004|Duke University|Yes|Recruiting|January 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 19, 2015|July 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640288||82765|
NCT01636674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SJ-82|18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer|Value of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography and Molecular Tumor Characterisation in Preoperative Staging og Postoperative Control of Colon Cancer|COLOPET1|Naestved Hospital|No|Active, not recruiting|July 2009|March 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|66|||Both|18 Years|N/A|No|||July 2012|July 9, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01636674||83041|
NCT01636999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-007|Comparing Sedara to Butorphanol in Early Labor|Comparing Pain Relief in Early Labor: Nitrous Oxide Versus Butorphonol Study||West Penn Allegheny Health System|Yes|Not yet recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|100|||Female|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 9, 2012|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636999||83016|
NCT01637285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1111005|A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers|A Phase 1, Randomized, Open-label, Parallel-group Study To Evaluate The Pharmacokinetics Of Pf-04856883 (Cvx-096) Following Subcutaneous Administration In Healthy Volunteers||Pfizer|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|49|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2015|July 30, 2015|June 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01637285||82994|
NCT01637038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-06-010-001|The Effect of Remote Ischemic Postconditioning on Liver Graft and Renal Function in Patients Undergoing Living-related Liver Transplantation|The Effect of Remote Ischemic Postconditioning on Liver Graft and Renal Function in Patients Undergoing Living-related Liver Transplantation||Samsung Medical Center|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|80|||Both|20 Years|70 Years|No|||December 2013|December 24, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01637038||83013|
NCT01641965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC 111/11|Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients|Impact of Early Non-invasive Ventilation in Amyotrophic Lateral Sclerosis Patients: a Randomized Controlled Trial||Hospital Universitari de Bellvitge|Yes|Completed|April 2012|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|18 Years|80 Years|No|||February 2016|February 19, 2016|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01641965||82637|
NCT01641978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GLASGOW GETAFE|INTEROBSERVER CORRELATION OF GLASGOW COMA SCORE|INTEROBSERVER CORRELATION OF GLASGOW COMA SCORE||Hospital Universitario Getafe|No|Completed|January 2012|January 2013|Actual|January 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|125|||Both|18 Years|N/A|No|Non-Probability Sample|neurologic patients|June 2011|February 1, 2013|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01641978||82636|
NCT01641991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0024|Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule|A Randomized Trial for the Assessment of Immunogenicity and Safety of Four Different Dosing Regimens of BioThrax® for Post-Exposure Prophylaxis for Anthrax in Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|July 2012|June 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|328|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 24, 2014|July 5, 2012|Yes|Yes||No|April 17, 2014|https://clinicaltrials.gov/show/NCT01641991||82635|
NCT01623076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU-022012-084|A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis|A Longitudinal Study of Patients Diagnosed With or at Increased Risk for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder||University of Texas Southwestern Medical Center|No|Recruiting|June 2012|||June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|150|Samples With DNA|Patients will donate serum, plasma, DNA, RNA and white blood cells.|Both|6 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients previously diagnosed with Neuromyelitis Optica, Neuromyelitis Optica Spectrum        Disorder, Transverse Myelitis and Optic Neuritis will be recruited to take part in a        longitudinal study of their disease.|September 2013|September 5, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623076||84084|
NCT01623310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-FLU-CS-3203|Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps|A 12-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps||Optinose US Inc.|No|Completed|September 2013|October 2015|Actual|August 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|223|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623310||84066|
NCT01623661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBP-JMJ-2012-2|Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease|Effect of Intravenous Sodium Chloride on Urinary Biomarkers for Measurement of Sodium- and Water Channel Activity in the Nephron in Healthy Subject an Patients With Chronic Kidney Disease. A Case Control Study|CASE|Regional Hospital Holstebro|Yes|Completed|December 2011|June 2013|Actual|April 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|47|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||March 2014|March 3, 2014|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623661||84039|
NCT01623921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-08-WAA-026911-TLV|Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma|||Tel-Aviv Sourasky Medical Center||Not yet recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|80 Years|No|||June 2012|June 19, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01623921||84019|
NCT01624194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-12132011-8827|Intranasal Oxytocin Treatment for Social Deficits in Children With Autism|Double-blind, Randomized, Placebo Controlled Trial of Intranasal Oxytocin Treatment for Social Deficits in Children With Autism.||Stanford University|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|6 Years|12 Years|No|||December 2015|December 2, 2015|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624194||83999|
NCT01625065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Medi-3889-10|Study of Medication Compliance - a Comparison of Patients in Pain Management and Pre-surgical Patients|Toxicological Analyses of Blood and Urine Samples in Pain Patients and Pre-surgical Control Patients to Investigate Incidences of Concealed and Feigned Substances||Ruhr University of Bochum|No|Completed|May 2010|October 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|343||serum, urine|Both|18 Years|80 Years|No|Non-Probability Sample|pain management and surgical outpatient department of a University hospital|June 2012|June 20, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625065||83932|
NCT01625078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C.A.657|Observational Study of Baska Mask, a New Supraglottic Airway Device in Children|Observational Study of Baska Mask, a New Supraglottic Airway Device in Children||University College Hospital Galway|No|Completed|March 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|8 Years|16 Years|No|||May 2014|May 28, 2014|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01625078||83931|
NCT01625026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCABSGS|Obeticholic Acid in Bariatric and Gallstone Disease|Effects of Obeticholic Acid on Hepatic Fatty Acid/Triglyceride Metabolism and Hepatobiliary Detoxification/Elimination in Morbidly Obese and Gallstone Patients|OCABSGS|Sahlgrenska University Hospital, Sweden|No|Recruiting|September 2013|September 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|40|||Both|20 Years|65 Years|No|||February 2016|February 18, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625026||83935|
NCT01625039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1|Impact of Employee Wellness Programme|The Impact of an Employee Wellness Programme in Clothing/Textile Manufacturing Companies: A Randomised Control Trial||University of Cape Town|No|Completed|January 2008|November 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||June 2012|June 20, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01625039||83934|
NCT01625338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0109|Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies|An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies||Gilead Sciences|Yes|Completed|June 2012|December 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|534|||Both|18 Years|N/A|No|||October 2015|October 9, 2015|June 7, 2012|Yes|Yes||No|October 9, 2015|https://clinicaltrials.gov/show/NCT01625338||83911|There were no limitations affecting the analysis or results.
NCT01625585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBEWashU 2012|Single Balloon Enterosocpy Obscure Gastrointestinal Bleeding Bleed|LONG-TERM OUTCOMES AFTER SINGLE-BALLOON ENTEROSCOPY IN PATIENTS WITH OBSCURE GASTROINTESTINAL BLEEDING||Washington University School of Medicine|No|Completed|May 2011|||March 2012|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|147|||Both|18 Years|N/A|No|Non-Probability Sample|All patients who underwent SBE at Washington University Medical Center/ Barnes Jewish        Hospital prior to 1/1/2011 were eligible for inclusion. There was no control group as this        was a retrospective cohort study.|October 2013|October 14, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625585||83892|
NCT01625884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CTR-XXX-2012/1|Observational Study to Understand Patients' and Physicians' Attitudes to Statins in TurkeY|Observational Study to Understand Patients' and Physicians' Attitudes to Statins in TurkeY|STAY|AstraZeneca|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|500|||Both|N/A|N/A|No|Non-Probability Sample|Patients > 18 years of age, diagnosed with hypercholesterolemia and prescribed with at        least one statin irrespective of its type and/or dose. The inclusion period will last 6        months, on which consecutive patients attending the outpatient Family Physicians or        Cardiologists office will be invited to participate.|January 2014|January 8, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625884||83869|
NCT01625897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A002-A7|A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia|A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia||Mitsubishi Tanabe Pharma Corporation||Completed|May 2012|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|125|||Both|20 Years|74 Years|No|||April 2015|April 17, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625897||83868|
NCT01626417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 007|Evaluation of Transfer Kinematics and Kinetics in Patients Chronic Post-stroke Using the Tibion Bionic Leg|A Prospective, Experimental Study to Evaluate Transfer Kinematics and Kinetics of Chronic Post-stroke Patients With Tibion Bionic Leg||Tibion Bionics, Inc.|No|Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|30 Years|N/A|No|||November 2012|November 13, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01626417||83828|
NCT01626729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1101007870|Facts-Up-Front Versus Traffic-Light Food Labels|Facts-Up-Front Versus Traffic-Light Food Labels: A Randomized Controlled Trial||Yale University|No|Completed|May 2011|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|703|||Both|18 Years|N/A|No|||June 2012|June 20, 2012|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01626729||83804|
NCT01622621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000805|Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer|Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC)||Mayo Clinic|No|Recruiting|May 2012|March 2020|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|96|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622621||84117|
NCT01622647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-Z078-1611|The Effect of Nasal Continuous Positive Airway Pressure (N-CPAP) on Arterial pCO2 During Spinal Anesthesia|The Effect of Nasal Continuous Positive Airway Pressure (N-CPAP) on Arterial pCO2 During Spinal Anesthesia With Intravenous Sedation for Total Knee Arthroplasty||Mednax Center for Research, Education and Quality|No|Completed|July 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|21 Years|69 Years|No|||September 2013|September 5, 2013|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01622647||84115|
NCT01623817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-09-067|Effectiveness of Vancomycin Loading Therapy|Effectiveness of Vancomycin Loading Therapy||Samsung Medical Center|Yes|Not yet recruiting|June 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|20 Years|75 Years|No|||June 2012|June 19, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623817||84027|
NCT01624090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120151|Mithramycin for Lung, Esophagus, and Other Chest Cancers|Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum||National Institutes of Health Clinical Center (CC)||Suspended|June 2012|December 2018|Anticipated|August 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|13|||Both|18 Years|99 Years|No|||November 2015|December 15, 2015|June 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624090||84007|
NCT01640301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2498.00|Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant|Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML||Fred Hutchinson Cancer Research Center|Yes|Recruiting|December 2012|||March 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|55|||Both|N/A|N/A|No|||January 2016|January 25, 2016|November 29, 2011|No|Yes||No||https://clinicaltrials.gov/show/NCT01640301||82764|
NCT01636687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2309|Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis|JUNCTURE|Novartis|Yes|Active, not recruiting|October 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|182|||Both|18 Years|N/A|No|||April 2015|April 1, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636687||83040|
NCT01639014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F02695 LP 2 05|Effect of F2695 on Functional Recovery After Ischemic Stroke|Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study|LIFE|Pierre Fabre Medicament|No|Completed|July 2012|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|532|||Both|18 Years|80 Years|No|||March 2014|March 31, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639014||82861|
NCT01638715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOBIO Study|A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action|A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action||Medical University of Vienna|No|Recruiting|May 2012|||June 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|200|||Both|18 Years|75 Years|No|||October 2015|October 14, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01638715||82884|
NCT01639274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-PP-09|Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD)|Prevalence of Chronic Obstructive Pulmonary Disease in HIV-patient Population|HIV and COPD|Centre Hospitalier Universitaire de Nice|No|Completed|January 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|639|||Both|18 Years|N/A|No|||November 2013|November 7, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639274||82841|
NCT01623336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/0468|BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C|Safety and Efficacy of BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C: Randomized, Multicentric Study With Blinded Analysis|BIP48II/III|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Yes|Recruiting|January 2012|December 2016|Anticipated|August 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|740|||Both|18 Years|70 Years|No|||November 2011|June 15, 2012|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623336||84064|
NCT01620034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106-2010|Lung Stereotactic Body Radiotherapy (SBRT) Delivered Over 4 Days Versus 11 Days|A Randomized Study of Stereotactic Body Radiotherapy (SBRT) for Lung Tumours Delivered Over 4 Days Versus 11 Days||Sunnybrook Health Sciences Centre|No|Active, not recruiting|May 2010|||August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01620034||84315|
NCT01620307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB:100-2433C|Rapamune Improves Outcomes of Severe H1N1 Pneumonia|Adjuvant Treatment With a mTOR Inhibitor, Rapamune Improves Outcomes of Severe H1N1 Pneumonia With Acute Respiratory Failure||Chang Gung Memorial Hospital|Yes|Completed|June 2009|December 2011|Actual|July 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|38|||Both|20 Years|90 Years|No|||June 2012|June 14, 2012|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01620307||84294|
NCT01620606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHRMC13744|Managing Childhood Abdominal Pain|Parent Training to Address Pediatric Functional Abdominal Pain|MCAP|University of Washington|Yes|Active, not recruiting|September 2011|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|300|||Both|7 Years|12 Years|No|||October 2015|October 5, 2015|February 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01620606||84271|
NCT01625091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U01AA020797-01|Clinical Trial to Reduce Drinking in Women With HIV|Pharmacotherapy for Alcohol Consumption in HIV Infected Women: Randomized Trial|WHATIF|University of Florida|Yes|Recruiting|December 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 30, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625091||83930|
NCT01625351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADIANT|A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas|A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas||St. Jude Children's Research Hospital|No|Recruiting|July 2012|July 2021|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|2 Years|21 Years|No|||November 2015|November 16, 2015|June 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01625351||83910|
NCT01625598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|001|Computer Detection of Diabetic Retinopathy Compared to Clinical Examination|A Multicenter Masked Study to Compare Analysis of the Detection Program IDx-DR Against Standard of Care Clinical Examination by Ophthalmologists to Differentiate Levels of Diabetic Retinopathy and Diabetic Macular Edema|CDDR|IDx LLC||Completed|April 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|No|Probability Sample|Persons with diabetes, eighteen years of age or older, who have been referred to an        ophthalmologists for a dilated eye examination to detect diabetic retinopathy.|April 2014|April 21, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01625598||83891|
NCT01626144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35099EP|Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles|Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles||Milton S. Hershey Medical Center|No|Recruiting|September 2011|January 2017|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples With DNA|Whole blood, serum, urine|Female|18 Years|N/A|No|Non-Probability Sample|Post-menopausal breast cancer patients in the breast oncology clinic at the Penn State        Hershey Cancer Institute (PSHCI).|June 2012|June 21, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626144||83849|
NCT01626430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A004/11|Acute Effects of Tocotrienols on Insulin Sensitivity and Metabolic Risk Markers in Individuals at Risk for Metabolic Syndrome|Acute Effects of Tocotrienols on Insulinaemic and Inflammatory Responses in Metabolic Syndrome Subjects||Malaysia Palm Oil Board|Yes|Completed|January 2012|December 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|30|||Both|20 Years|60 Years|No|||October 2015|October 5, 2015|June 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01626430||83827|
NCT01626742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BL01|A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study|A Randomized Double Blinded Controlled Trial of an Oral Nutritional Supplement Containing AN 777 in Older Hospitalized Patients||Abbott Nutrition|Yes|Completed|May 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|652|||Both|65 Years|N/A|No|||April 2015|April 24, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626742||83803|
NCT01623206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDAVP-R01-02|Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding|Prospective, Open-labelled, Phase II Study, of the Administration of Desmopressin in Patients With Colorectal Cancer, With or Without Metastasis, With Rectal Bleeding, Before Treatment With Surgery and/or Chemotherapy and/or Radiotherapy.||Laboratorio Elea S.A.C.I.F. y A.|No|Recruiting|April 2013|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|80 Years|No|||January 2016|January 19, 2016|May 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01623206||84074|
NCT01623518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLU004|A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1|A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1||University of Oxford|Yes|Completed|June 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|December 1, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01623518||84050|
NCT01624350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COVPERP0200|A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas|MASERATI 100 - A Prospective, Multi-center, Post-mArket, Single-arm obsERvATIonal Study to Collect Clinical Outcome Data on the Use of Permacol™ Collagen Paste in the Treatment of Anorectal Fistulas||Medtronic - MITG|Yes|Completed|September 2012|June 2015|Actual|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects who meet the eligibility criteria that are planned to undergo surgical        treatment for anorectal fistulas with Permacol™ Collagen Paste and agree to 12 months of        follow-up.|June 2015|June 25, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01624350||83987|
NCT01636453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP 5038 (IDE # G120050)|The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms|The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms||Penumbra Inc.|Yes|Active, not recruiting|September 2012|February 2017|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|120|||Both|18 Years|N/A|No|||March 2016|March 14, 2016|July 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01636453||83058|
NCT01641744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-703|Efficacy of Group Attachment Based Intervention for Vulnerable Families|Birth to Three: A Pragmatic Clinical Trial for Child Maltreatment Prevention||Albert Einstein College of Medicine of Yeshiva University|No|Recruiting|August 2012|May 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|N/A|36 Months|Accepts Healthy Volunteers|||January 2015|January 12, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641744||82654|
NCT01638728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC 2012-039|Change of Depth in a RAE Tube: Tube Fixation at the Midline or Angle and in a Neutral or Neck Extended Position|||Kyung Hee University Hospital at Gangdong||Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|90 Years|No|Probability Sample|adult patients who are scheduled for elective surgery under general anesthesia|January 2014|January 23, 2014|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01638728||82883|
NCT01639586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00167-34|Comparison for the Patient With Alzheimer Disease the Impact of Three Different Groups of Patient Care|Comparaison du Service Rendu à la Personne Atteinte d'Une Maladie d'Alzheimer et de l'Aidant Par Trois Types de Prises en Charge (Plateforme, Accueil de Jour et Groupe contrôle|COMPARSE|Centre Hospitalier Universitaire de Nice|No|Recruiting|August 2011|April 2013|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|360|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|March 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01639586||82817|
NCT01639027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Drotaverine in labor|Drotaverine to Shorten the Length of Labor|Use of Antispasmodic Drotaverine to Shorten the Length of Labor in Nulliparous Women||Ain Shams Maternity Hospital|Yes|Completed|May 2012|January 2013|Actual|December 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|352|||Female|18 Years|35 Years|No|||January 2013|January 17, 2013|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639027||82860|
NCT01619748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH-16309|Peripheral Vascular Function in Obstructive Sleep Apnoea|Effects of Obstructive Sleep Apnoea and Its Treatment on Macrovascular and Microvascular Function||Sheffield Teaching Hospitals NHS Foundation Trust|No|Completed|June 2012|June 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|45|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients and controls living in and around Sheffield, UK|August 2013|August 6, 2013|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01619748||84337|
NCT01624220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0190|Spinal Stereotactic Body Radiation Therapy|A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy||M.D. Anderson Cancer Center|No|Recruiting|June 2012|||June 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|57|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|June 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01624220||83997|
NCT01624441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00950|Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer|A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer||National Cancer Institute (NCI)||Active, not recruiting|August 2012|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|June 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01624441||83980|
NCT01624740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7001|High Rate Spinal Cord Stimulation (SCS) for Chronic Pain|Precision Plus™ High-Rate Subperception SCS for the Treatment of Chronic Intractable Pain||Boston Scientific Corporation|No|Completed|June 2012|December 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||December 2014|March 9, 2015|June 15, 2012|Yes|Yes||No|December 18, 2014|https://clinicaltrials.gov/show/NCT01624740||83957|
NCT01624753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/245/Cfcfm|Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases|Clinical Utility of Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases||Singapore General Hospital|No|Recruiting|May 2012|April 2017|Anticipated|April 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|21 Years|90 Years|No|||November 2014|November 26, 2014|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01624753||83956|
NCT01624766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1043|Anakinra or Denosumab and Everolimus in Advanced Cancer|A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies||M.D. Anderson Cancer Center|No|Recruiting|June 2012|||June 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|147|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|June 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01624766||83955|
NCT01625611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1011007710|Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors|Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors||Yale University|Yes|Recruiting|February 2011|June 2018|Anticipated|June 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|97|||Both|21 Years|50 Years|No|||January 2016|January 4, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625611||83890|
NCT01625624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KFG-122X-02|Evaluating the Effects of Food Products on Energy and Performance|Effect of Food Products on Perceived Energy and Task Performance||Mondelēz International, Inc.|No|Completed|June 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|48|||Both|20 Years|35 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01625624||83889|
NCT01625910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1107M02462|For the Health of Our Children--Clinic Based Treatment of Childhood Obesity|For the Health of Our Children--Clinic Based Treatment of Childhood Obesity: The Feasibility of Recruitment and the Effectiveness of a Low-intensity Stage||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|September 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||November 2015|November 2, 2015|April 10, 2012||No||No|April 9, 2013|https://clinicaltrials.gov/show/NCT01625910||83867|There were no adverse events during this 3-month trial comparing a parent-based behavioral intervention with usual care.
NCT01626157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAAVED11A0|A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)|A Novel Assay to Quantify Treatment Response in CF||National Jewish Health|No|Enrolling by invitation|May 2011|January 2018|Anticipated|January 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|120|||Both|18 Years|N/A|No|Probability Sample|Adult CF patients > 18 years of age undergoing treatment for acute pulmonary exacerbation|March 2016|March 22, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626157||83848|
NCT01626443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MI-DCI|Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions|||Lo.Li.Pharma s.r.l||Recruiting||||||Phase 4|Interventional|N/A|2||||||Female|14 Years|40 Years|No|||June 2012|October 18, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01626443||83826|
NCT01626456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALK9072-003EXT|A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)|A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia||Alkermes, Inc.|No|Completed|June 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|478|||Both|18 Years|70 Years|No|||May 2015|May 15, 2015|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626456||83825|
NCT01626755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLATA|Prevention of Phantom Limb Pain After Transtibial Amputation|Prevention of Phantom Limb Pain After Transtibial Amputation (PLATA) - Randomized, Double-blind, Controlled, Multi-center Trial Comparing Optimized Intravenous Pain Control vs Optimized Intravenous Pain Control Plus Nerve Block.|PLATA|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Recruiting|August 2013|October 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||October 2015|October 19, 2015|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626755||83802|
NCT01623531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fibrinogenstudy0911|Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery|The Use of Fibrinogen Concentrate in High-Risk Cardiac Surgery. A Prospective, Double-blinded, Randomized, Controlled Study||Nova Scotia Health Authority|Yes|Recruiting|February 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|222|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623531||84049|
NCT01624935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-02408|Clinical Trial of Interpersonal Therapy for Survivors of the Sichuan Earthquake|Randomized Controlled Clinical Trial of Interpersonal Therapy for Survivors of the Sichuan Earthquake||University of California, San Francisco|Yes|Completed|July 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|February 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01624935||83942|
NCT01636466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00059278|The Everolimus-Transplant Exit Strategy Trial (E-TEST)|Zortress (Everolimus) to Prevent Alloantibody Formation in Patients With Late Stage Renal Allograft Failure: The Everolimus-Transplant Exit Strategy Trial (E-TEST)|E-TEST|Emory University|Yes|Terminated|June 2013|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|75 Years|No|||May 2015|May 26, 2015|July 5, 2012|Yes|Yes|Feasibility|No|May 26, 2015|https://clinicaltrials.gov/show/NCT01636466||83057|
NCT01638689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-019363-11|A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram|A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram||Karolinska Institutet||Completed|September 2010|July 2012|Actual|February 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||July 2012|July 11, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01638689||82886|
NCT01638702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-086-BMB|Study of Complication Rates Associated With PICC for Left vs Right|Assessment of Impact of Choice of Arm for Access on Rate of Complications in Peripherally Inserted Central Venous Catheters||McGill University Health Center|Yes|Completed|October 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|203|||Both|18 Years|80 Years|No|||March 2016|March 14, 2016|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01638702||82885|
NCT01639898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10 015|POEMS Syndrome Treatment With Lenalidomide|Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.|POEMS|University Hospital, Limoges|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|N/A|No|||March 2015|March 8, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01639898||82793|
NCT01619488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0082295|Laparoscopic Adjustable Gastric Banding in Adolescents|Laparoscopic Adjustable Gastric Banding for Treatment of Morbid Obesity in Adolescents||Nemours Children's Clinic|Yes|Active, not recruiting|August 2007|December 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|14 Years|17 Years|No|||July 2014|July 17, 2014|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01619488||84357|
NCT01623375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN1250-4000|A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects|A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects||Novo Nordisk A/S|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 18, 2015|June 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01623375||84061|
NCT01623960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|THD-HAEM-QoL|Quality of Life in Adult Patients With Severe Haemophilia in Turkey|A Nationwide Multicenter Study on the Quality of Life in Adult Patients With Severe Haemophilia in Turkey|TurkHaemQoL|Turkish Society of Hematology|Yes|Not yet recruiting|October 2012|February 2014|Anticipated|October 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|500|||Male|18 Years|N/A|No|Non-Probability Sample|Adult male patient with severe haemophilia followed at 10 different haemophilia centers in        Turkey|June 2012|June 17, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01623960||84016|
NCT01624207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROYAL|The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg|A Multi-center, Randomized, Open-labeled Clinical Trial to Evaluate Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg in Korean Patients With Hypercholesterolemia||Seoul National University Hospital|Yes|Completed|March 2010|April 2011|Actual|January 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|376|||Both|20 Years|79 Years|No|||December 2013|December 15, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624207||83998|
NCT01624233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13976|A Study in Japanese Participants With Moderate-to-Severe Psoriasis|A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis|UNCOVER-J|Eli Lilly and Company|No|Active, not recruiting|June 2012|December 2016|Anticipated|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|90|||Both|20 Years|N/A|No|||December 2014|December 8, 2014|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624233||83996|
NCT01624454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS-CRAP|Optimal Bowel Cleansing Trial|Osmotic or Large Volume Lavage for Optimal Bowel Preparation - a Single-blind Randomized Trial||Helse Stavanger HF|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|380|||Both|18 Years|80 Years|No|||June 2012|May 7, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624454||83979|
NCT01624467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14472|A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors|A Study to Determine Whether Necitumumab (IMC-11F8) Monotherapy Affects the Corrected QT (QTc) Interval in Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Completed|August 2012|June 2015|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|75|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|May 24, 2012|Yes|Yes||No|December 21, 2015|https://clinicaltrials.gov/show/NCT01624467||83978|
NCT01624480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C10953/1100|Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy|A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy||Teva Pharmaceutical Industries|No|Completed|July 2012|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|40|||Both|6 Years|17 Years|No|||December 2015|December 8, 2015|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624480||83977|
NCT01624779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KOR-01|Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury|The Effect of Intrathecal Transplantation of Autologous Adipose Tissue Derived Mesenchymal Stem Cells in the Patients With Spinal Cord Injury, Phase I Clinical Study||Bukwang Pharmaceutical|No|Completed|April 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|19 Years|70 Years|No|||June 2012|February 11, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624779||83954|
NCT01624792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0171|Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2|Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2||Texas A&M University|No|Recruiting|October 2011|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|77|||Both|45 Years|N/A|Accepts Healthy Volunteers|||September 2015|September 30, 2015|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01624792||83953|
NCT01624805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0334|Horse ATG in Patients With AA or Low/Int-1 Risk MDS|Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)||M.D. Anderson Cancer Center|No|Recruiting|June 2012|||June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|N/A|No|||December 2015|December 21, 2015|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624805||83952|
NCT01625364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01NR010544-05|Comparison of Asthma Programs for Schools|Comparison of Asthma Programs for Schools|CAPS|University of Texas at Austin|Yes|Completed|September 2009|September 2014|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|432|||Both|9 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 6, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625364||83909|
NCT01625637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103008127-2|Tobacco Approach Avoidance Training for Adolescent Smokers-2|Tobacco Approach Avoidance Training for A Smoking Cessation in Adolescent Smokers- Study 2|AAT-2|Yale University|Yes|Completed|May 2012|August 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|66|||Both|13 Years|18 Years|No|||August 2013|January 17, 2014|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625637||83888|
NCT01625923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACG-SP-002-2012|A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis|A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis||University of Michigan|No|Active, not recruiting|January 2013|||January 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||July 2015|July 24, 2015|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625923||83866|
NCT01626170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARST12B6|Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma|Observational - Identifying and Validating Novel Mechanisms of Radiation Resistance in Rhabdomyosarcoma||Children's Oncology Group|No|Recruiting|June 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|20|||Both|N/A|N/A|No|Non-Probability Sample|Patients with rhabdomyosarcoma enrolled on COG-D9902.|November 2015|November 6, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626170||83847|
NCT01622660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-191|Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy|Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy||Memorial Sloan Kettering Cancer Center||Terminated|June 2012|February 2016|Actual|February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||February 2016|February 3, 2016|June 15, 2012|Yes|Yes|Safety reasons|No||https://clinicaltrials.gov/show/NCT01622660||84114|
NCT01622673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0518-247|A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)|A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen||Merck Sharp & Dohme Corp.|No|Completed|June 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|27|||Both|18 Years|N/A|No|||February 2015|February 6, 2015|June 15, 2012|No|Yes||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01622673||84113|
NCT01622933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-021|Multiple Antigen-Engineered DC Vaccine for Melanoma|A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients||University of Pittsburgh|Yes|Active, not recruiting|June 2012|October 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|June 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01622933||84094|
NCT01624103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000261-21|Comfort Score During Ultrasound Guided Supraclavicular Brachial Plexus Block Placement in Elderly Patients|Influence of Anesthetic Volume on Comfort Score During US-SCB Placement in Elderly Patients|US-SCB|Šarić, Jadranka Pavičić, M.D.|No|Recruiting|November 2012|November 2015|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|65 Years|N/A|No|||March 2015|March 2, 2015|June 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624103||84006|
NCT01624948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001AUS184T|Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients|Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection||University of California, San Francisco|No|Completed|September 2012|November 2015|Actual|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|75 Years|No|||March 2016|March 3, 2016|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624948||83941|
NCT01624961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TUCHMI-001|Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults|Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults||Sanaria Inc.|Yes|Completed|June 2012|February 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|5||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||April 2015|April 9, 2015|June 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01624961||83940|
NCT01641484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANOXICOL-1102|Study of a Predictor for Cervix Cancer|Study Evaluating Predictive Value of Local Control at 19.8 (MRI and TEP Scan) for Patient With Stade I to IIIB Cervix Carcinoma Treated by Radiotherapy|ANOXICOL|Centre Oscar Lambret|No|Terminated|January 2012|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Female|18 Years|65 Years|No|||February 2016|February 15, 2016|July 6, 2012||No|unreached recruitment objectives|No||https://clinicaltrials.gov/show/NCT01641484||82674|
NCT01638429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25182|Role of Methane in Glycemic Control|Methane Production and Glycemic Regulation in Pre-diabetic Subjects: Role of Methane in Glycemic Control||Cedars-Sinai Medical Center|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||April 2014|April 1, 2014|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01638429||82906|
NCT01640171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rvaf-2012|Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival|Topical Lidocaine Gel With and Without Subconjunctival Lidocaine Injection for Intravitreal Injection: a Within-patient Study||Retina Vitreous Associates of Florida|No|Completed|July 2012|October 2013|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|57|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|July 11, 2012||No||No|November 30, 2013|https://clinicaltrials.gov/show/NCT01640171||82774|Most patients were treated with subconjunctival anesthetic prior to the study.
NCT01623388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-5649|Epigenetic Modifications of Diabetes Mellitus Type I|Epigenetic Modifications Induced by Glycemic Variability||Scripps Translational Science Institute||Withdrawn|January 2013|||January 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|0|Samples With DNA|Whole blood|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Type I Diabetic|January 2014|January 7, 2014|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01623388||84060|
NCT01623700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U-11-001|Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients|A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients||Uppsala University|No|Active, not recruiting|January 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|78000|||Both|N/A|N/A|No|Non-Probability Sample|Patients previously enrolled into the SWEDEHEART (RIKS-HIA/SCAAR/SEPHIA) registry from 1        Jan 2006 to 1 July 2010 with an event of ACS and observed during the index hospitalization        following enrollment.|May 2011|June 15, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01623700||84036|
NCT01623687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUllmark Apr -12|Bone Forming at Prosthetic Surfaces. Fingerprint2|Bone Forming at Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study||Uppsala University|No|Recruiting|August 2011|March 2015|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|26|||Both|50 Years|69 Years|No|||April 2014|April 3, 2014|January 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01623687||84037|
NCT01623973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-MDTR, Brazil|Impact of Restriction of the Non Paretic Upper Limb Rehabilitation of Patients a With Stroke:Randomized Clinical Trial|Impact of the Restriction of the Non Paretic Upper Limb in Rehabilitation of Patients Post-stroke:Randomized Clinical Trial||Universidade Federal de Pernambuco|Yes|Completed|March 2011|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|21 Years|70 Years|No|||June 2012|June 19, 2012|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01623973||84015|
NCT01624246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CXL-PK-04|Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance|A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance||Forest Laboratories|No|Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|55 Years|No|||October 2013|October 11, 2013|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624246||83995|
NCT01624259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11377|A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes|A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)|AWARD-6|Eli Lilly and Company|No|Completed|June 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|599|||Both|18 Years|N/A|No|||October 2014|October 3, 2014|June 18, 2012|Yes|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01624259||83994|
NCT01624493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GYN12-154 / ANZGOG-1103|BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients|Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse||Hoosier Cancer Research Network|Yes|Withdrawn|October 2012|October 2014|Actual|July 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||December 2015|December 21, 2015|June 15, 2012|No|Yes|Phase I was conducted Australia. Phase II not conducted and no US pts enrolled.|No||https://clinicaltrials.gov/show/NCT01624493||83976|
NCT01624506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2776|Observational Study of Anti-Reflux Surgery|Observational Study of Anti-Reflux Surgery: Clinical Experience With the LINX Reflux Management System and Fundoplication||Torax Medical Incorporated|No|Completed|January 2010|January 2015|Actual|January 2015|Actual|N/A|Observational|N/A||3|Actual|734|||Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing antireflux surgery for the treatment of GERD|September 2014|March 3, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624506||83975|
NCT01624818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|268289|Active With Heart Disease|Coping With Physical Activity and Psychosocial Challenges in Children With Heart Disease at Geilomo Childrens Hospital||Oslo University Hospital||Not yet recruiting|March 2013|December 2015|Anticipated|December 2014|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|48|||Both|6 Years|12 Years|No|||June 2012|June 20, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01624818||83951|
NCT01625377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001HFR02|A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients|Etude Nationale Multicentrique, randomisée, en Ouvert, évaluant l'efficacité et la tolérance de l'évérolimus associé au mycophénolate Sodique, en Comparaison à un Traitement Standard Associant Tacrolimus et mycophénolate Sodique Chez Des Patients Adultes transplantés hépatiques de Novo|SIMCER|Novartis|Yes|Completed|December 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|191|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625377||83908|
NCT01625650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|New England IRB 02-021|Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study|The Corrona Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions Sub-study: The Corrona CERTAIN Sub-study|CERTAIN|The Consortium of Rheumatology Researchers of North America, Inc.|No|Completed|October 2010|May 2015|Actual|May 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2795|Samples With DNA|Blood tests: at each study blood is obtained to examine, lipid levels with direct ( non      fasting) LDL, a high sensitivity CRP as well as toxicity monitoring labs including a      complete blood count and a comprehensive panel. During the baseline visit DNA is collected      upon consent - to allow future genetic and pharmacogenetic studies- and also serology      markers and immunoglobulin levels. During the first three visits RNA serum and plasma for      storage and future experiments are collected.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Ppproximately 3,000 subjects from 100 sites will participate in this Sub-study and that        approximately 30, and up to 200, subjects from this site will be enrolled.|February 2016|February 18, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625650|1 Year|83887|
NCT01625936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02812|CRLX101 Plus Bevacizumab in Advanced RCC|Phase 1b Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|June 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment|||Anticipated|22|||Both|18 Years|N/A|No|||October 2015|October 16, 2015|June 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625936||83865|
NCT01626183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B8|Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia|Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL||Children's Oncology Group|No|Active, not recruiting|June 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|RNA|Both|N/A|N/A|No|Non-Probability Sample|pediatric patients with diagnosed or relapsed T-ALL|May 2015|May 4, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626183||83846|
NCT01626482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEU-003|Effect of Kinesio Tape in Muscle Fatigue Measured by Biering-Sorensen Test|||CEU San Pablo University||Completed|September 2011|May 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 30, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01626482||83823|
NCT01626768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DF4-Imaging-2012|Medtronic Market-Released DF4 Lead Imaging|||Medtronic Cardiac Rhythm Disease Management|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|37|||Both|19 Years|N/A|No|Non-Probability Sample|Patients followed at participating centers.|July 2013|July 16, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01626768||83801|
NCT01622686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R43MD005805|PlainLanguageRx: Improving Medication Labels to Reduce Health Disparities|PlainLanguageRx: Improving Medication Labels to Reduce Health Disparities||PictureRx, LLC|No|Completed|November 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|470|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|June 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01622686||84112|
NCT01622946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-024410-59|The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach|The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach. A Prospective, Double Blind, Placebo-controlled Clinical Trial.||Universitaire Ziekenhuizen Leuven||Recruiting|April 2012|||December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|80|||Both|18 Years|N/A|No|||April 2012|June 18, 2012|June 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01622946||84093|
NCT01623219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00055554|Community-Based Telemedicine to Reduce Risk to Georgia Veterans With Post Traumatic Stress Disorder|Community-Based Telemedicine to Reduce Risk to Georgia Veterans With PTSD||Emory University|No|Withdrawn|March 2012|||January 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|June 12, 2012||No|Unable to recruit|No||https://clinicaltrials.gov/show/NCT01623219||84073|
NCT01625754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|279-2011|The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease|The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease||Sunnybrook Health Sciences Centre|No|Active, not recruiting|November 2011|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|129|Samples With DNA|Whole blood for ApoE4 genotyping|Both|50 Years|75 Years|No|Probability Sample|Patients with coronary artery disease participating in a cardiac rehabilitation exercise        program|November 2015|November 26, 2015|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01625754||83879|
NCT01638416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZICRCDJC006|Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial|A Multi-centre Randomised Double Blinded Phase III Trial of the Effect of Standard Issue Red Blood Cell Blood Units on Mortality Compared to Freshest Available Red Blood Cell Units|TRANSFUSE|Australian and New Zealand Intensive Care Research Centre|Yes|Recruiting|October 2012|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|5000|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638416||82907|
NCT01639300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNC-002|Safety Study of GNbAC1 in Multiple Sclerosis Patients|Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1||GeNeuro Innovation SAS|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||April 2014|April 17, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639300||82839|
NCT01639313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCA_CMR_MA|Comparison of Nexfin Pulse Contour Analysis and Cardiac Magnetic Resonance Imaging for the Measurement of Cardiac Output|Is Arterial Pulse Contour Analysis Using Nexfin a New Option in the Non-invasive Measurement of Cardiac Output? - A Pilot Study||Universitätsmedizin Mannheim||Completed|June 2011|November 2011|Actual|November 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|18 Years|N/A|No|Probability Sample|Hemodynamically stable patients undergoing CMR|July 2012|July 9, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01639313||82838|
NCT01636310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2005-p-002454|Multiple Cigarette Induced Changes in Hormone Function, Mood States and Behavior|||Mclean Hospital|No|Suspended|December 2005|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|72|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|June 21, 2012||No|Clinical studies stopped, pending funding|No||https://clinicaltrials.gov/show/NCT01636310||83069|
NCT01636323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-p-002456|Smoked Nicotine Induced Changes in Hormone Function, Mood States and Behaviors|||Mclean Hospital|No|Suspended|December 2008|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|300|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||January 2013|January 14, 2013|June 21, 2012||No|Clinical studies stopped, pending funding|No||https://clinicaltrials.gov/show/NCT01636323||83068|
NCT01623713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YPLT20111123|Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia|A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia||Jiangsu Hansoh Pharmaceutical Co., Ltd.|Yes|Completed|June 2012|November 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|260|||Both|18 Years|65 Years|No|||November 2013|November 17, 2013|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01623713||84035|
NCT01623440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10152|Food Reward in Native American Women|Neural Correlates of Food Reward in Native American Women||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|November 2009|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01623440||84056|
NCT01623986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLS STP-9000010|Correlation of Measurements From Mespere Venus 1000 System & Echocardiography to Estimate Right Atrial Pressure|Technical Correlation of a Noninvasive Estimation of Central Venous Pressure From the Mespere Venus 1000 System and the Inferior Vena Cava From Echocardiography, to Estimate Right Atrial Pressure||Mespere Lifesciences Inc.|No|Completed|March 2013|September 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|45|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients referred to St. Michael's Hospital echocardiography lab|August 2014|August 14, 2014|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01623986||84014|
NCT01624012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EETTMK:23/2011|Non-invasive Ventilation With Neurally Adjusted Ventilatory Assist Versus Nasal Continuous Airway Pressure in Premature Infants|Non-invasive Ventilation With Neurally Adjusted Ventilatory Assist (NIV NAVA) Versus Nasal Continuous Airway Pressure (NCPAP) in Premature Infants|NIV NAVA|University of Oulu|No|Recruiting|August 2011|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|48 Hours|No|||December 2014|December 29, 2014|June 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01624012||84013|
NCT01624025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0222|A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin|||Yonsei University|No|Recruiting|July 2012|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|20 Years|N/A|No|||March 2014|March 4, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01624025||84012|
NCT01624844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG 2012-001|Predictive Value of Ultrasound Measurement of the Dural Sac Volume on the Sensory Level in Spinal Anesthesia|Predictive Value of an Ultrasound Model of Measurement of the Dural Sac Volume on the Sensory Level Obtained by Spinal Anesthesia||Centre hospitalier de l'Université de Montréal (CHUM)|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|45|||Both|18 Years|80 Years|No|||June 2014|June 5, 2014|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01624844||83949|
NCT01624519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10H-821002|Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate in the Intensive Care Unit|Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate in the Intensive Care Unit||University of California, Los Angeles|Yes|Not yet recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|18 Years|N/A|No|||June 2012|June 18, 2012|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624519||83974|
NCT01624532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1109_P2|A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109|A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects|GC1109|Green Cross Corporation|Yes|Suspended|November 2011|November 2016|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Anticipated|299|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2016|February 24, 2016|March 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01624532||83973|
NCT01624831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U. Az IRB 11-0567-02|Social Cognition in Longstanding Psychosis|Social Cognition in Longstanding Psychosis||University of Arizona|No|Terminated|November 2011|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9|||Both|18 Years|75 Years|No|Non-Probability Sample|Individuals with longstanding psychotic disorder (i.e., 5 years or longer in duration)|November 2015|November 30, 2015|November 7, 2011||No|Lack of funding|No||https://clinicaltrials.gov/show/NCT01624831||83950|
NCT01625663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202004|Heart and Muscle Metabolism in Barth Syndrome|Heart and Skeletal Muscle Metabolism, Energetics and Function in Barth Syndrome||Washington University School of Medicine|Yes|Recruiting|June 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|Samples With DNA|Serum, skin biopsy, breath|Male|8 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children and adults ages 8-13 yrs with Barth syndrome and healthy controls.|December 2015|December 7, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625663||83886|
NCT01625676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIC-2012|Study of Modified Constraint-Induced Aphasia Therapy Schedule to Treat Patients Following Sub-acute Stroke|Constraint-Induced Aphasia Therapy Following Sub-acute Stroke: A Modified Therapy Schedule|MCIAT|NRZ Magdeburg Median Kliniken GmbH & Co|No|Completed|August 2004|December 2011|Actual|October 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|100|||Both|34 Years|84 Years|No|||June 2012|June 19, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01625676||83885|
NCT01625949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMR project 80/3/2010-BMS|Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery|Study of Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery|COAT|All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|March 2011|September 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||June 2012|June 22, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01625949||83864|
NCT01626469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P002805|Eye Blood Flow and the Kidney|Eye Blood Flow and the Kidney||Brigham and Women's Hospital|No|Recruiting|May 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|75 Years|No|||November 2015|November 12, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01626469||83824|
NCT01626196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIT MOV 1002|Evaluation of the Main Determinants of Patient Acceptability of the Bowel Cleansing Procedure, and of Success of Bowel Cleansing and Caecal Intubation|Multicentre, Observational, Prospective Study, Conducted on Italian Out-patients Undergoing Colonoscopy, for the Evaluation of the Main Determinants of the Patient's Acceptability of Bowel Cleansing Procedure, and of the Success of Bowel Cleansing and Caecal Intubation||Norgine|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Consecutive patients invited for routine colonoscopy were invited to participate in hte        study.|July 2012|July 10, 2012|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626196||83845|
NCT01626495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-007706|Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma|CHP 959 - A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leukemia and Lymphoma|Pedi CART19|University of Pennsylvania|Yes|Active, not recruiting|August 2011|September 2016|Anticipated|August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|1 Year|24 Years|No|||March 2016|March 10, 2016|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626495||83822|
NCT01626508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IACOBELLI PHRC IR 2011|Prospective Evaluation in Older Premature, Untreated Breast Milk and Milk Processed by the Breast-milk Bank|Directed Donation of Untreated Milk or Milk Processed by the Breast-milk : Prospective Evaluation in Older Premature|ADiLL|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|April 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|90|Samples Without DNA|blood sample milk|Both|N/A|12 Hours|No|Probability Sample|for both groups, the gestational age at birth must be less than 33 weeks gestation and at        the time of inclusion the child must be hospitalized in neonatal resuscitation|January 2013|January 4, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01626508||83821|
NCT01623544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RWE-000015|Asthma Comparative Effectiveness Study|A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol Combination (BFC) and Fluticasone Propionate/Salmeterol Combination (FSC) Among Asthma Patients|Asthma CER|AstraZeneca|No|Completed|June 2012|September 2012|Actual|July 2012|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|6086|||Both|12 Years|64 Years|No|Non-Probability Sample|Health plan members with asthma aged 12 to 64 years receiving two or more prescriptions        for BFC or FSC during 6/1/2007-9/30/2010 who are naive to ICS/LABA combination therapy.|February 2013|February 22, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01623544||84048|
NCT01623557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC045|A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates|A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS|VAC045|University of Oxford|No|Completed|April 2012|November 2012|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||February 2015|February 12, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01623557||84047|
NCT01623830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00056442|Targeting Reconsolidation to Prevent Return of Fear|Targeting Memory Reconsolidation to Prevent the Return of Fear in a Pilot RCT||Emory University|No|Active, not recruiting|July 2012|June 2016|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01623830||84026|
NCT01624623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|W81XWH-08-2-0174, A-15214.3|Daily Target Guided Radiation Therapy Using the Calypso 4D Localization System in Patients Who Have Had a Prostatectomy for Prostate Cancer|Post-prostatectomy Daily Target Guided Radiotherapy Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study||U.S. Army Medical Research Acquisition Activity|Yes|Active, not recruiting|March 2010|August 2016|Anticipated|May 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Male|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will include high risk patients referred for adjuvant or salvage radiation        therapy after radical prostatectomy based upon the presence of unfavorable characteristics        after prostatectomy, which include positive surgical margins, extracapsular extension of        disease, or immediately detectable PSA.|September 2015|September 9, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624623||83966|
NCT01624636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLFG316A2201|Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).|A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration||Novartis||Terminated|December 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Both|55 Years|90 Years|No|||June 2014|June 10, 2014|May 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624636||83965|
NCT01626053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASMART-01|The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes|The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes|ASMART|KRJG Services Inc.|No|Completed|March 2009|June 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|182|||Both|18 Years|N/A|No|||June 2012|June 21, 2012|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01626053||83856|
NCT01626625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NONUNISTEM1|Mesenchymal Stem Cells; Donor and Role in Management and Reconstruction of Nonunion Fracture|||Indonesia University|Yes|Recruiting|April 2010|January 2016|Anticipated|April 2015|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|10|||Both|18 Years|55 Years|No|||June 2012|June 22, 2012|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01626625||83812|
NCT01638143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3-017|Bio-equivalence Study|Comparison of Bioavailability of Three Different Vitamin K2 Formulations||Maastricht University Medical Center|No|Completed|November 2010|August 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|24|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 10, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01638143||82928|
NCT01639599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|haloperidol|Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients|Phase 4 Study of Optimal Dose of Haloperidol||The Catholic University of Korea|Yes|Completed|March 2012|May 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|150|||Female|20 Years|65 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|July 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639599||82816|
NCT01639612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00031192|Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma|A Pilot Safety Study of the Administration of Bone Marrow Derived Stem Cells (ALD-451) in WHO Grade IV Malignant Glioma||Duke University|Yes|Active, not recruiting|June 2012|||May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|10|||Both|18 Years|N/A|No|||March 2015|March 5, 2015|June 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01639612||82815|
NCT01623726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAISM-001|Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia|Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia: a Double-blind Randomized Clinical Trial||University of Sao Paulo|No|Withdrawn|August 2012|August 2014|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|59 Years|No|||December 2013|December 13, 2013|June 8, 2012||No|To be submitted for grant application|No||https://clinicaltrials.gov/show/NCT01623726||84034|
NCT01624857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120618|Statin for Depression in Patients Undergoing Coronary Artery Bypass Graft|Perioperative Statin for Depression in Patients Undergoing Coronary Artery Bypass Surgery|Stress CABG|China National Center for Cardiovascular Diseases|Yes|Recruiting|June 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|18 Years|N/A|No|||May 2012|August 13, 2013|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01624857||83948|
NCT01625104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1998-0080|Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI|Randomized Trial of Aggressive Process of Care Quality Improvement Intervention to Decrease Door to Balloon Time in Primary PCI for Acute Myocardial Infarction|RAPID-PCI|University of Michigan|No|Completed|September 2003|December 2006|Actual|February 2006|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|882|||Both|N/A|N/A|No|Probability Sample|All patients diagnosed with an STEMI at participating sites in a large, regional registry        of consecutive percutaneous coronary interventions were included.|June 2012|June 20, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625104||83929|
NCT01625117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DFG_2011|Mental Health and Aggression in Congolese Ex-combatants|||University of Konstanz|No|Completed|May 2011|September 2012|Actual|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|38|||Male|16 Years|35 Years|No|||June 2013|June 25, 2013|January 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01625117||83928|
NCT01625143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AALL12B7|Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia|Molecular Taxonomy of Pediatric Cancer||Children's Oncology Group|No|Active, not recruiting|June 2012|||August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|40|Samples With DNA|Archived bone marrow samples|Both|N/A|21 Years|No|Non-Probability Sample|Diagnosis of B-cell acute lymphoblastic leukemia|May 2015|May 4, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01625143||83926|
NCT01625689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAIV-BD-01|Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine|Assessment of the Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine Among Children Aged 24 Through 59 Months in Bangladesh||PATH|Yes|Completed|June 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|309|||Both|24 Months|59 Months|Accepts Healthy Volunteers|||June 2012|May 15, 2015|June 14, 2012||No||No|April 28, 2015|https://clinicaltrials.gov/show/NCT01625689||83884|
NCT01625962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-BRI|Brain Indices of Risk for Posttraumatic Stress Disorder (PTSD) After Mild Traumatic Brain Injury (mTBI)|Brain Indices of Risk for Posttraumatic Stress Disorder After Mild Traumatic Brain Injury||INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Active, not recruiting|October 2011|September 2015|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|50 Years|No|Probability Sample|Service members who have sustained mild TBI or extracranial injury (ECI), warranting        evacuation from OEF/OIF/OND theatre to Walter Reed National Military Medical Center|August 2015|August 6, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01625962||83863|
NCT01626209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120Z2102|A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors|A Phase I Study of BKM120, Administered Orally in Adult Chinese Patients With Advanced Solid Tumors||Novartis|Yes|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|N/A|No|||February 2015|February 5, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01626209||83844|
NCT01623232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-07-11S|MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly|MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly|CCTA #0005|VA Office of Research and Development|Yes|Withdrawn|October 2012|June 2014|Anticipated|November 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention|4||Actual|0|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 25, 2012|June 15, 2012|Yes|Yes|FDA hold on the project|No||https://clinicaltrials.gov/show/NCT01623232||84072|
NCT01623245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11714|Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy|Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy|Amylo|French Cardiology Society|Yes|Active, not recruiting|June 2012|June 2017|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|260|Samples With DNA|10 mL of whole blood in EDTA tube|Both|18 Years|N/A|No|Non-Probability Sample|The study population is that of patients with hypertrophic cardiomyopathy in France whose        origin has not yet been determined.|July 2014|July 8, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01623245||84071|
NCT01624363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0906-23|Prevalence of Pancreatic Cysts During Routine Endoscopic Ultra Sound|Prevalence of Pancreatic Cysts During Routine EUS||Indiana University|Yes|Active, not recruiting|September 2009|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients were identified on the day of scheduled endoscopy.|March 2015|March 24, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624363||83986|
NCT01624376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLX105-004-001-001|Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease|A Randomized, Double-blind, Placebo-controlled Phase I/IIa Study in Patients With Abdominal or Perianal Fistulizing Crohn's Disease to Explore the Safety, Tolerability and Preliminary Efficacy of Locally Administered DLX105.||Delenex Therapeutics AG|No|Completed|June 2012|August 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|65 Years|No|||February 2014|February 3, 2014|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01624376||83985|
NCT01624649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100744|A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors|Prospective Follow-Up Observational Study to Examine the Progression of ADHD Drug Treatment and to Analyze Associated Factors||Janssen Korea, Ltd., Korea|No|Completed|February 2012|April 2014|Actual|April 2014|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|289|||Both|6 Years|15 Years|No|Non-Probability Sample|Children and adolescents of age between 6 and 15 years (in Korean age) who are dianosed        with ADHD by K-SADS-PL but have never received any of methylphenidate or atomoxetine        within 3 months prior to screening.|June 2015|June 8, 2015|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624649||83964|
NCT01626638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00818-33|Confocal Micro-endoscopy in Head and Neck Cancer/Micro Endoscopie Confocale (MEC)Oto-Rhino-Laryngologie (ORL)|Clinical Evaluation of Confocal Microscopy in Head and Neck Cancer|MEC ORL|Gustave Roussy, Cancer Campus, Grand Paris|No|Recruiting|February 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01626638||83811|
NCT01639040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R668-AD-1121|Study to Assess the Safety of REGN668 (SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Safety of REGN668 Administered Concomitantly With Topical Corticosteroids to Patients With Moderate-to-Severe Atopic Dermatitis||Regeneron Pharmaceuticals|Yes|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||February 2013|September 27, 2013|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639040||82859|
NCT01639911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS054|MLN8237 and Pazopanib in Combination for Solid Tumors|Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors||University of Illinois at Chicago|Yes|Recruiting|August 2013|September 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|March 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639911||82792|
NCT01640184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-079|Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients|Study of the Efficacy and Safety on the Ultrasonic Ablation Treatment for Secondary Hyperthyroidism in Chronic Kidney Disease Patients.||Capital Medical University|Yes|Completed|August 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|84|||Both|18 Years|75 Years|No|||October 2015|October 21, 2015|July 9, 2012||No||No|October 21, 2015|https://clinicaltrials.gov/show/NCT01640184||82773|
NCT01640197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22P4|Chronic Resveratrol Supplementation in Healthy Humans|The Effects of Chronic Trans- Resveratrol Supplementation on Aspects of Cognitive Performance, Mood, Sleep, Health and Cerebral Blood Flow in Healthy, Young Humans.||Northumbria University||Completed|February 2011|June 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|60|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|October 17, 2012|July 10, 2012||No||No|September 11, 2012|https://clinicaltrials.gov/show/NCT01640197||82772|
NCT01640210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00666-35|Technical Evaluation Of JewelPUMP In Type 1 Diabetic Patients Treated With Extern Insulin Pump|TECHNICAL EVALUATION OF JEWELPUMP IN TYPE 1 DIABETIC PATIENTS TREATED WITH EXTERN INSULIN PUMP|DIABELOOP|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|November 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||December 2011|July 12, 2012|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01640210||82771|
NCT01624272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H1325072291220|Respiratory Muscle Training in Institutionalized Elderly Population|The Effectiveness of Pranayama Breathing Exercises vs. Threshold Inspiratory Muscle Trainer to Improve Respiratory Muscle Function in an Institutionalized Frail Elderly Population||University of Valencia|No|Completed|November 2008|February 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|71|||Both|65 Years|N/A|No|||March 2014|March 23, 2014|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01624272||83993|
NCT01624285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-003311|Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer|A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)||Jonsson Comprehensive Cancer Center|Yes|Recruiting|July 2012|||June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|356|||Both|19 Years|N/A|No|||February 2016|February 29, 2016|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624285||83992|
NCT01624545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|218/10|To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation|To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation - a Prospective, Randomized, Controlled Trial|TOSCAN|University Hospital Inselspital, Berne|Yes|Recruiting|June 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624545||83972|
NCT01624558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00049358|Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient|Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient||Johns Hopkins University|No|Withdrawn|July 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Both|2 Years|16 Years|Accepts Healthy Volunteers|||September 2014|September 9, 2014|June 11, 2012||No|Measurement device not performing to standard in study environment|No||https://clinicaltrials.gov/show/NCT01624558||83971|
NCT01624870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advance-II|CoreValve Advance-II Study: Prospective International Post-market Study|CoreValve Advance-II Study: Best Practices Investigation of Patients Implanted With the Medtronic CoreValve Bioprosthesis.|Advance-II|Medtronic Cardiovascular|No|Completed|October 2011|March 2014|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|21 Years|N/A|No|Non-Probability Sample|Patients with aortic stenosis and at elevated surgical risk are eligible to be included in        the study.|October 2015|October 26, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01624870||83947|
NCT01625130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1296|Effect of Sulforaphane-rich Broccoli Sprout Homogenate on Ozone Induced Inflammation Through Modulation of NRF2|Down Regulation of Oxidant Induced Airway Inflammation Through Modulation of NRF2|BroccOz|University of North Carolina, Chapel Hill|No|Completed|October 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Actual|16|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625130||83927|
NCT01625390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15534|A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150|A Phase 2/3, Multicenter, Open-label Clinical Study to Assess the Safety and Efficacy of BAY86-6150 in Subjects With Hemophilia A or B With Inhibitors, Composed of 2 Parts (A & B). Part A: Sequential Cohorts of Four Dose Levels of the Modified rFVIIa BAY86-6150 Assessed in a Non-controlled Dose Response Design in Acutely Bleeding Subjects and for PK/ PD in an Intra-individual Crossover Design Compared With One Fixed Dose of Eptacog Alfa in Non-bleeding Subjects. Part B: Confirmatory Study to Further Investigate the Efficacy and Safety of BAY86-6150||Bayer|Yes|Completed|June 2012|March 2014|Actual|March 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|10|||Male|12 Years|62 Years|No|||June 2015|June 4, 2015|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625390||83907|
NCT01622699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TcB AmaliaCC|Implementation of a Transcutaneous Bilirubinometer|Implementation of a Transcutaneous Bilirubinometer in Jaundiced Newborns: a Randomised Controlled Trial||Princess Amalia Children's Clinic|No|Recruiting|October 2013|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|210|||Both|N/A|8 Days|No|||October 2015|October 21, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01622699||84111|
NCT01622959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|use of ACUPUNCTURE in ED|Use of ACUPUNCTURE in Emergency Departement|Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in Emergency Department (ED)||University of Monastir|Yes|Recruiting|June 2013|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 11, 2013|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622959||84092|
NCT01624116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RT2011|Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes|A Comparison of Four Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetic Patients and the Effect of Add-On Acarbose on Glycaemic Excursions During Ramadan Fasting||Services Hospital, Lahore|No|Completed|August 2011|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|161|||Both|N/A|N/A|No|||June 2012|June 19, 2012|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01624116||84005|
NCT01624129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011_0023|New Serological Markers for Eosinophilic Esophagitis|||Technische Universität München|No|Recruiting|January 2011|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|80 Years|No|Non-Probability Sample|primary care clinic|February 2011|June 16, 2012|February 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01624129||84004|
NCT01624142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110271|Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders|A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia|TAUSSIG|Amgen|No|Active, not recruiting|June 2012|March 2020|Anticipated|March 2020|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Both|12 Years|80 Years|No|||June 2015|June 25, 2015|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624142||84003|
NCT01624974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1029-011|Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011 AM2)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study of MK-1029 in Adult Subjects With Persistent Asthma Who Remain Uncontrolled While Being Maintained on Montelukast||Merck Sharp & Dohme Corp.|No|Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|107|||Both|18 Years|65 Years|No|||May 2015|May 7, 2015|June 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624974||83939|
NCT01625260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-801-01-12|A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer|A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer||Altor Bioscience Corporation|Yes|Recruiting|April 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|June 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01625260||83917|
NCT01625273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB/205/2010|Supplementation of Infant Formula With Synbiotics|Supplementation of Infant Formula With the Synbiotics (Lactobacillus Paracasei Ssp. Paracasei Strain F19 and Fructo- and Galactooligosaccharides).||Arla Foods|No|Active, not recruiting|January 2010|February 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|N/A|28 Days|Accepts Healthy Volunteers|||June 2012|June 23, 2015|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625273||83916|
NCT01625520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-023128-26|SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer|Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression||Federico II University|Yes|Recruiting|February 2012|||May 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|19|||Both|18 Years|80 Years|No|||June 2012|June 20, 2012|May 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625520||83897|
NCT01622192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH 16290|A Comparison Between the Repeatability of Probing Pocket Depths Achieved With Manual and Automated Periodontal Probes|A Comparison Between the Repeatability of Probing Pocket Depths Achieved With Manual and Automated Periodontal Probes||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|April 2012|August 2012|Anticipated|June 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Anticipated|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2012|June 18, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01622192||84150|
NCT01639053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1007|Sientra Post-Approval Study|U.S. Postapproval Study of Sientra Silicone Gel Breast Implants||Sientra, Inc.|No|Active, not recruiting|April 2012|March 2025|Anticipated|March 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Women who receive Sientra Silicone Gel Breast Implants for augmentation, revision        augmentation, reconstruction, and revision reconstruction. Control participants are        candidates for and undergo aesthetic surgery other than implantation with Silicone Gel        Breast implants.|February 2015|February 4, 2015|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01639053||82858|
NCT01639326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-IRI-2011-134|Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1|Phase II Randomized Pharmacogenetic Study to Evaluate the Efficacy and Safety of FOLFIRI Schedule With High Doses of Irinotecan (FOLFIRI-AD) in Patients With Metastatic Colorectal Cancer According to UGT1A Genotype 1.|FOLFIRI-AD|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|July 2012|September 2018|Anticipated|July 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|96|||Both|18 Years|75 Years|No|||June 2012|May 6, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01639326||82837|
NCT01640223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00726-35|Creation of a Patient Database for Silicon Patient Simulation, Glucose Sensor Variability and Pharmacokinetic Study of Debiotech Jewelpump|SEMI-CLOSED LOOP "FOR THE CONTROL OF BLOOD GLUCOSE IN DIABETIC SUBJECTS DIABELOOP First CLINICAL PROJECT: Under Project 3 (UP3), CREATING A DATABASE|DiabeloopWP3|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|No|Completed|March 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2014|October 24, 2014|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01640223||82770|
NCT01636102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V71_32S|Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above|A Phase II Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Agrippal®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects||Novartis|No|Completed|July 2012|July 2012|Actual|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|126|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 2, 2015|July 5, 2012||No||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01636102||83085|
NCT01624051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sawyer - Lung - CCI|A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer|A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy||AHS Cancer Control Alberta|No|Recruiting|July 2014|September 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||September 2014|September 26, 2014|April 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01624051||84010|
NCT01624298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TFCBTRCTDCOF|Randomized Control Trial on Trauma Focused CBT in Zambia|A Randomized Control Trial to Determine the Effectiveness of Trauma Focused Cognitive Behavioral (TF-CBT) Among Children in Lusaka, Zambia||Johns Hopkins Bloomberg School of Public Health|Yes|Recruiting|August 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|250|||Both|5 Years|18 Years|Accepts Healthy Volunteers|||July 2013|July 22, 2013|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624298||83991|
NCT01624571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-GRCL001|Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO|A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection||LG Life Sciences|Yes|Completed|March 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|147|||Both|20 Years|N/A|No|||October 2012|February 26, 2013|June 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01624571||83970|
NCT01624883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSGY-201202025-1|China PEACE-Retrospective AMI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction||China National Center for Cardiovascular Diseases|Yes|Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|18000|||Both|N/A|N/A|No|Probability Sample|Using a stratified two-stage cluster sampling design, 175 hospitals will be selected from        different regions in China, and 13,900 AMI inpatient cases will be selected in 2011, and        6,950 in 2001 and 2006 separately, from these sample hospitals.|June 2014|June 29, 2014|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01624883||83946|
NCT01625156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-00949|Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery|A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors||National Cancer Institute (NCI)||Completed|May 2012|October 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||May 2015|October 19, 2015|June 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01625156||83925|
NCT01625403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHCHESTCCU01|Recombinant BNP on Heart and Renal Function in Acute Heart Failure|Effect of Recombinant BNP on Heart and Renal Function in Acute Decompensated Heart Failure Patients With Acute Renal Injury||Shanghai Chest Hospital|No|Recruiting|July 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||August 2012|August 5, 2012|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625403||83906|
NCT01625416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42937 C|Trauma Survivors Outcomes and Support Study IV|Integrating Information Technology Advancements Into Early PTSD Interventions|TSOS IV|University of Washington|No|Recruiting|July 2012|January 2019|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|120|||Both|14 Years|N/A|No|||June 2012|January 14, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625416||83905|
NCT01626781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIO-LQ-0111|A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer|A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer|PROCAPP|AIO-Studien-gGmbH||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2013|October 21, 2013|June 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01626781||83800|
NCT01623258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-20010|A Prospective Randomized Study Comparing Sentinel Lymph Node (SLN) Evaluation With Standard Pathological Evaluation for the Staging of Colon Carcinoma|||Walter Reed Army Medical Center|No|Completed|December 2002|August 2011|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|34|||Both|18 Years|N/A|No|Probability Sample|Up to 150 male or female military healthcare beneficiaries over the age of 18 years        presenting at the Walter Reed Army Medical Center (WRAMC) General Surgery clinic with the        diagnosis of biopsy-proven, primary, non-metastatic (Clinical Stage I,II or III) colon        carcinoma will be enrolled. Subjects with colonic masses clinically consistent with colon        cancer, and eventually confirmed by pathology, will also be enrolled.|June 2012|June 18, 2012|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623258||84070|
NCT01623570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CREA022011|Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP|Prospective Randomized Open Label Study to Compare the Efficacy and Safety of Ovarian Stimulation With Pergoveris® and Menopur® in Women With Severe Luteinizing Hormone (LH) and Follicular Stimulating Hormone (FSH) Deficiency.||Centro Riproduzione e Andrologia|No|Completed|March 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|25 Years|36 Years|No|||June 2012|June 17, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01623570||84046|
NCT01623583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-02-02-NVO-MI|Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias|A Randomized Controlled Study of the Effect of a Needle Phobia or Apprehension Intervention With or Without Synera® on Conversion From Central Venous Catheters to Arteriovenous Fistula or Graft||Davita Clinical Research|No|Terminated|April 2014|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|10|||Both|18 Years|N/A|No|||April 2015|April 14, 2015|May 31, 2012|No|Yes|limited qualifying patient population|No||https://clinicaltrials.gov/show/NCT01623583||84045|
NCT01623843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIRST-01|Femoroacetabular Impingement RandomiSed Controlled Trial|Femoroacetabular Impingement RandomiSed Controlled Trial (FIRST)|FIRST|McMaster University|Yes|Recruiting|September 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|220|||Both|18 Years|50 Years|No|||November 2015|November 5, 2015|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01623843||84025|
NCT01623856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANHL12B1|Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients|Observational - Candidate Gene Variants and Childhood/Adolescent Non-Hodgkin Lymphoma: A Preliminary Investigation||Children's Oncology Group|No|Completed|June 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|483|||Both|N/A|20 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients diagnosed with lymphoblastic lymphoma (LL) or Burkitt lymphoma ( BL) enrolled on        the Children Oncology Group (COG) protocols 5961, A5971, or ANHL01P1.|May 2015|May 6, 2015|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01623856||84024|
NCT01624389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101-1074A1|Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study|Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study|Alzheimer's|Chang Gung Memorial Hospital|Yes|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|1||Anticipated|200|||Both|55 Years|90 Years|Accepts Healthy Volunteers|||January 2012|June 17, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01624389||83984|
NCT01624662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPN-FLU-NP-3102|Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety|A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety||Optinose US Inc.|No|Completed|October 2013|October 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|323|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01624662||83963|
NCT01625533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120601|Safety and Efficacy Study of Dual-axis Rotational Versus Standard Coronary Angiography|Randomized Study on the Safety and Efficacy of Dual-axis Rotational Versus Standard Coronary Angiography||General Hospital of Chinese Armed Police Forces|Yes|Completed|June 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|576|||Both|18 Years|N/A|No|Probability Sample|Patients undergoing diagnostic coronary angiography at the General Hospital of Chinese        People's Armed Police Forces.|June 2015|June 3, 2015|June 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01625533||83896|
NCT01625767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1103008127-1|Tobacco Approach Avoidance Training for Adolescent Smokers-1|Tobacco Approach Avoidance Training for Smoking Cessation in Adolescent Smokers-Study 1|AAT-1|Yale University|Yes|Completed|September 2011|March 2012|Actual|March 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Actual|40|||Both|13 Years|18 Years|No|||August 2013|August 19, 2013|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01625767||83878|
NCT01625780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00027444|Comparing Ilioinguinal Single-shot and Three-layer Blocks|A New Approach to Ilio-inguinal Nerve Blocks: 3-layer Injection vs Conventional Ultrasound-guided Single-shot Approach||University of Alberta|No|Terminated|April 2012|March 2016|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|32|||Both|N/A|16 Years|No|||November 2015|November 24, 2015|April 12, 2012||No|Not a significant difference in outcomes between groups|No||https://clinicaltrials.gov/show/NCT01625780||83877|
NCT01625793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0166-02|Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes|Inflammation, Stress and Social Behavior: Using Ecological Assessments and Model Systems to Enhance Relevance to Health Outcomes||University of Arizona|Yes|Withdrawn|June 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|0|||Both|21 Years|65 Years|No|||July 2013|July 18, 2013|June 11, 2012||No|New medication coming on the market, made study obsolete.|No||https://clinicaltrials.gov/show/NCT01625793||83876|
NCT01639625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300CX02AR01|Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application|Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External Endocavitary Brachytherapy + Concurrent Hemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation||Laboratorio Elea S.A.C.I.F. y A.|No|Active, not recruiting|May 2011|June 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|18|||Female|21 Years|70 Years|No|||March 2015|January 19, 2016|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01639625||82814|
NCT01636037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156/2011|Antipsychotic Augmentation With L-Dopa|Augmentation of Antipsychotics With L-Dopa (Sinemet)||Centre for Addiction and Mental Health|Yes|Completed|September 2012|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|55 Years|No|||March 2016|March 11, 2016|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636037||83090|
NCT01636050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CST-002|Effect of Squat Training on Body Composition, Muscular Strength and Motor Fitness for Youth- Randamized Trial|Phase 1 Study of Child Exercise Training|CET|National Institute of Fitness and Sports in Kanoya|Yes|Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|2|||Both|12 Years|15 Years|Accepts Healthy Volunteers|||July 2012|July 9, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636050||83089|
NCT01636115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISU-IRB-101-001|Validation of Muscle Strength Testing for Pectoralis Major|Validation of Muscle Strength Testing for Pectoralis Major||National Science Council, Taiwan||Completed|May 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|24|||Male|17 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Students in University.|December 2012|December 5, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01636115||83084|
NCT01636141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OLT1177-01|Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects|A Phase 1, Randomized, Dose Escalation, Single Center, Safety Study of Single and Multi-Dose, Topically Applied OLT1177 Gel in Healthy Subjects||Olatec Industries LLC|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 5, 2012|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01636141||83082|
NCT01624311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAN6104|Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants|Hypothermia Treatment in Hyperammonemia and Encephalopathy||Columbia University|Yes|Completed|August 2007|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|N/A|30 Days|No|||May 2015|May 28, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01624311||83990|
NCT01624584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008970|A Study Comparing Two Treatments for Child With Anxiety|A Randomized-controlled Study Comparing Two Treatments for Children With Anxiety Disorders||Mayo Clinic|No|Completed|June 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|15|||Both|7 Years|17 Years|No|||April 2015|April 8, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01624584||83969|
NCT01624597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|065095|A Randomized Controlled Trial to Improve Teen Driving|A Randomized Controlled Trial to Improve Teen Driving||University of Iowa|Yes|Active, not recruiting|June 2011|August 2017|Anticipated|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|153|||Both|14 Years|17 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01624597||83968|
NCT01624896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSGY-201202025-2|China PEACE-Retrospective CathPCI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Coronary Catheterization and Percutaneous Coronary Intervention||China National Center for Cardiovascular Diseases|Yes|Completed|April 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|12000|||Both|N/A|N/A|No|Probability Sample|Using a stratified two-stage cluster sampling design, 70 hospitals will be selected from        different regions in China, and 7,000 PCI inpatient cases will be selected in 2011, and        3,500 in 2001 and 2006 separately, from these sample hospitals.|June 2014|June 29, 2014|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01624896||83945|
NCT01625169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HS-09-00698|Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma|Antiretroviral Drug Concentrations and HIV Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART (Highly Active Antiretroviral Therapy) Therapy: Etravirine (ETR) Pharmacokinetics (PK) in Breast Milk and Plasma||University of Southern California|No|Completed|April 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Female|18 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 11, 2014|June 12, 2012|Yes|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01625169||83924|
NCT01622712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/823|Evaluation of Mesh Integration and Mesh Contraction After Open Preperitoneal Inguinal Hernia Repair Using a Memory Ring Containing Device|Evaluation of Mesh Integration and Mesh Contraction After Open Preperitoneal Inguinal Hernia Repair Using a Memory Ring Containing Device.|REBOUND|University Hospital, Ghent|No|Recruiting|February 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Male|18 Years|N/A|No|||December 2014|December 4, 2014|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622712||84110|
NCT01622972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10050|Mode of Action of Moviprep|Mode of Action of Moviprep:Impact on Distribution of Intestinal Fluid and Colonic Microbiota||University of Nottingham|No|Completed|September 2011|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 11, 2014|June 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01622972||84091|
NCT01681511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICET-001|A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.|A Randomized Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter Attached to an Antimicrobial Anti-Reflux Device for Reduction of Catheter-Associated Urinary Tract Infection||Innovative Chemical and Environmental Technologies, Inc|Yes|Terminated|May 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|July 29, 2012|Yes|Yes|Business Reasons|No|October 29, 2013|https://clinicaltrials.gov/show/NCT01681511||79677|Study could not be completed for business reasons.
NCT01652287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3U01AT003600-02S1|Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children|Yogurt Beverages as a Vehicle to Deliver High Dose Probiotics||Georgetown University|Yes|Completed|February 2013|July 2014|Actual|July 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|60|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||March 2015|March 24, 2015|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01652287||81894|
NCT01652534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M012010|Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease|Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease||Northwestern University|No|Recruiting|June 2011|August 2015|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|15|||Both|18 Years|85 Years|No|||March 2015|March 11, 2015|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01652534||81875|
NCT01652573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1010007548|Calcitonin for Treating X-linked Hypophosphatemia|Calcitonin for Treating X-linked Hypophosphatemia||Yale University|Yes|Recruiting|March 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||February 2015|February 26, 2015|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652573||81872|
NCT01652586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0008|Sedation Regimen in Patients Undergoing Cardiac Electrophysiology Study and Ablation : a Comparison Between Dexmedetomidine-remifentanil and Midazolam-remifentanil Combinations|||Yonsei University|No|Completed|April 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|20 Years|70 Years|No|||July 2012|July 27, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652586||81871|
NCT01653093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-07042|3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer|Imaging of the Prostate Gland Using High Field Strength 3T MRI||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|September 2007|||December 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|170|||Male|N/A|N/A|No|||September 2014|September 25, 2014|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653093||81832|
NCT01653353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSVDNH|Swiss Study on Vitamin D and Calcium in Nursing Homes|Swiss Study on Vitamin D and Calcium in Nursing Homes||University of Zurich|No|Completed|July 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|71|||Both|N/A|N/A|No|||October 2013|October 1, 2013|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01653353||81812|
NCT01653626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUACTEK01|A Study to Measure the Effectiveness of an Intervention Package Aiming to Decrease Perinatal Mortality and Increase Institution-based Obstetric Care Among Indigenous Populations in Guatemala|A Matched Pair Cluster-randomized Implementation Study to Measure the Effectiveness of an Intervention Package Aiming to Decrease Perinatal Mortality and Increase Institution-based Obstetric Care Among Indigenous Populations in Guatemala||Hospital San Juan de Dios Guatemala|Yes|Recruiting|July 2012|December 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|1||Anticipated|1|||Female|10 Years|49 Years|No|||July 2012|July 30, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01653626||81791|
NCT01649986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|450/2012/D|Nutraceuticals to Improve Lipid Profile in European Countries|Additive Effects of Nutraceuticals to Non-pharmacologic Intervention to Improve Lipid Profile in the Real World Clinical Practice in European Countries - The PIN (Portugul Italy Nutraceutical) Study|PIN|University of Roma La Sapienza|No|Not yet recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||March 2013|March 6, 2013|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649986||82071|
NCT01653600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SENS-FP-2-LifeStent Arm|Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease|Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial)|SENS-FP-2|Korea University Guro Hospital|Yes|Not yet recruiting|September 2012|August 2015|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|346|||Both|20 Years|85 Years|No|||July 2012|July 27, 2012|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01653600||81793|
NCT01653613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECOG-E2L10T1|Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia|Genomic Analysis of Adolescent and Young Adult Acute Lymphoblastic Leukemia||National Cancer Institute (NCI)||Not yet recruiting|August 2010|||February 2013|Anticipated|N/A|Observational|N/A|||Anticipated|400|||Both|16 Years|39 Years|No|||July 2012|July 9, 2013|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653613||81792|
NCT01650558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00043360; DAIDS ES-10822|Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi|Randomized, Open-label Controlled Trial of Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on Anti-retroviral Therapy in Malawi|TSCQ|University of Maryland|Yes|Recruiting|November 2012|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1500|||Both|18 Years|N/A|No|||June 2015|June 15, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01650558||82027|
NCT01642303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Listening comprehension|The Effect of Vodcasting on Listening Comprehension|||Mashhad University of Medical Sciences|Yes|Terminated|January 2010|January 2012|Actual|June 2010|Actual|Phase 2/Phase 3|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|106|||Male|18 Years|21 Years|Accepts Healthy Volunteers|||January 2010|July 17, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642303||82612|
NCT01642316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|reading comprehension|The Effect of Washback on Reading Comprehension|||Mashhad University of Medical Sciences|Yes|Terminated|October 2008|October 2009|Actual|October 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|130|||Both|18 Years|22 Years|Accepts Healthy Volunteers|||October 2008|July 23, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642316||82611|
NCT01650519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPI-CL-017|A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery|A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery||Cumberland Pharmaceuticals|No|Completed|September 2012|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||July 2014|July 8, 2014|July 24, 2012|Yes|Yes||No|April 15, 2014|https://clinicaltrials.gov/show/NCT01650519||82030|
NCT01650779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGAL19412|A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta|Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The INFORM Study)||Sanofi|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Male|N/A|N/A|No|||June 2014|June 9, 2014|July 24, 2012|No|Yes||No|June 9, 2014|https://clinicaltrials.gov/show/NCT01650779||82010|This is considered to be an exploratory study for the following reasons: it was based on a small number of participants and has been designed as an open-label, single-arm study as opposed to a two-arm crossover design.
NCT01651052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-03|Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000|Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000||Edwards Lifesciences|Yes|Active, not recruiting|July 2011|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||March 2016|March 17, 2016|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01651052||81989|
NCT01651260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5156-I|Assessment of an Endotracheal Tube Securement Device|Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device||Hollister Incorporated|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|65|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|July 16, 2012||No||No|March 18, 2014|https://clinicaltrials.gov/show/NCT01651260||81973|Adult subjects in respiratory insufficiency in ICU setting were intubated with only four ET tube sizes: 7.0, 7.5, 8.0 and 8.5 mm. No other sizes were represented in the sample population.
NCT01652001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Xerostomia-2012|Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity|Effectiveness of Malic Acid 1% in Patients With Xerostomia Induced by Drugs. Determination of Salivary Mucins and Buffering Capacity||Universidad de Granada|Yes|Recruiting|January 2011|January 2014|Anticipated|January 2013|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|185|||Both|18 Years|80 Years|No|||July 2012|July 24, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01652001||81916|
NCT01652014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|021002|Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies|Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options||Rutgers, The State University of New Jersey|No|Suspended|January 2014|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|18 Years|65 Years|No|||June 2013|June 28, 2013|July 20, 2012|Yes|Yes|Funding unavailable|No||https://clinicaltrials.gov/show/NCT01652014||81915|
NCT01652027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSC-MS-11-0202|Hemophilia Inhibitor Previously Untreated Patient Study|Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia|HIPS|The University of Texas Health Science Center, Houston|Yes|Recruiting|July 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|Samples With DNA|Plasma samples, lymphocyte cell lines, Genomic DNA, RNA|Both|N/A|N/A|No|Non-Probability Sample|Patients with severe hemophilia A who have not previously been treated with Factor VIII        concentrates.|November 2015|November 30, 2015|June 3, 2011||No||No||https://clinicaltrials.gov/show/NCT01652027||81914|
NCT01652300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUMS|The Effect of Oral Health Education in Pregnancy|Oral Health Education in Pregnancy Promotes Knowledge,Attitude and Performance of Pregnant Women About Oral Health.||Gonabad University of Medical Sciences|Yes|Completed|June 2008|December 2008|Actual|December 2008|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|142|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 27, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01652300||81893|
NCT01652859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLC166.2|An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects|An Open-label, Randomized, Balanced, Crossover Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects||Taiwan Liposome Company|No|Completed|February 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|36|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||November 2013|November 25, 2013|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01652859||81850|
NCT01653366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D11282|Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway|Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway||Dartmouth-Hitchcock Medical Center|Yes|Active, not recruiting|December 2012|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|35|||Female|18 Years|N/A|No|||June 2012|January 14, 2016|July 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653366||81811|
NCT01653639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15495|Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222|Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A to Compare the Bioavailability of 2 Different Strengths of Kogenate FS (BAY14-2222)||Bayer|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|18|||Male|18 Years|65 Years|No|||January 2014|January 8, 2014|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653639||81790|
NCT01649752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stem cells and implantation|Role of Stem Cells in Improving Implantation Rates in ICSI Patients|Phase I Study of Role of Stem Cells in Improving Implantation Rates in ICSI Patients||Kasr El Aini Hospital|Yes|Recruiting|April 2015|October 2015|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|20 Years|40 Years|No|||July 2012|June 27, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649752||82089|
NCT01649765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114055|Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy|A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus|PLUTO|GlaxoSmithKline|Yes|Recruiting|September 2012|January 2027|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|5 Years|17 Years|No|||March 2016|March 10, 2016|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649765||82088|
NCT01649999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|015K-CL-RAJ1|A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects|A Phase 2b Study of ASP015K -Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Subjects -||Astellas Pharma Inc|No|Completed|February 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|281|||Both|20 Years|75 Years|No|||July 2013|July 25, 2013|July 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01649999||82070|
NCT01650298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|60039204/C|Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation|Pilot Study: Tailored Anticoagulation for Noncontinuous AF|TACTIC AF|St. Jude Medical|Yes|Enrolling by invitation|January 2013|June 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|200|||Both|18 Years|N/A|No|||November 2015|November 1, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650298||82047|
NCT01651351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|471201|GLASSIA Infusion Rate Study|A Phase 4 Double-Blind Study to Assess the Safety and Tolerability of Intravenous Administration of GLASSIA in Healthy Adult Volunteers||Baxalta US Inc.|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2014|June 26, 2015|July 23, 2012|Yes|Yes||No|April 29, 2014|https://clinicaltrials.gov/show/NCT01651351||81966|Simultaneous infusion of GLASSIA and placebo did not allow adverse events (AEs) to be unquestionably ascribed to either one. Any observed AE which was assessed by the investigator as related to treatment was conservatively attributed to GLASSIA.
NCT01649973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SeoulNUBH-B-1003-096-012|Study for Appropriate Operating Table Height for Endotracheal Intubation Under Direct Laryngoscopy|Study for Appropriate Operating Table Height for Endotracheal Intubation Under Direct Laryngoscopy||National Medical Center, Seoul|Yes|Completed|March 2010|March 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|8|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|certificated anesthesiologists|January 2014|January 2, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649973||82072|
NCT01650831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-MBI-0212|Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection|Clinical Study to Evaluate the Equivalence of the Modified BreathID Compared to Currently Approved BreathID System in Detection of H.Pylori Infection||Exalenz Bioscience LTD.|Yes|Completed|October 2012|January 2013|Actual|November 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|1||Actual|113|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 24, 2012|Yes|Yes||No|May 28, 2013|https://clinicaltrials.gov/show/NCT01650831||82006|
NCT01649960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007896|Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial|Role of Exercise and Low-Dose Rapamycin on Age-Associated Impairments in Older Adults With Coronary Artery Disease: Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial|CARE|Mayo Clinic|Yes|Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|60 Years|N/A|No|||April 2015|December 30, 2015|July 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01649960||82073|
NCT01650220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INTRuST-CV Markers|Cardiovascular Risk Markers in Veterans With Post Traumatic Stress Disorder|Cardiovascular Risk Markers in Veterans With PTSD|CVMarkers|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|Yes|Terminated|April 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|13|Samples With DNA|For the assessment of CVD risk, high-sensitivity CRP (hs-CRP) measurements will be used.      Standard assays detect 1,000 fold increases in CRP in response to infection or inflammation;      these high levels cannot be used to stratify with respect to CVD risk. Hs-CRP, however,      measurement can detect CRP levels as low as 0.5 mg/L. Though mainly used for research      purposes, high-sensitivity IL-6 assays are also able to discriminate IL-6 levels within the      normal range for CVD risk stratification. Both CRP and IL-6 levels will be analyzed as      continuous quantitative traits.      Though no DNA analysis is planned for this study, subjects are asked if they are willing to      have their samples banked for future research.|Both|28 Years|38 Years|No|Non-Probability Sample|OIF and OEF veterans within the VASDHS, who are between 28 and 38 years of age inclusively|April 2013|April 25, 2013|June 20, 2012||No|The funding agency, DoD, determined that the study could not meet its enrollment numbers by    the end of the grant|No||https://clinicaltrials.gov/show/NCT01650220||82053|
NCT01650233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00028889|Improving Wellness for Young Men|Improving Wellness for Young Men||Johns Hopkins University|No|Completed|August 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|41|||Male|N/A|N/A|Accepts Healthy Volunteers|||July 2012|July 23, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01650233||82052|
NCT01650532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIUC_IRB_12362|Stretching and Yoga Exercise Study|The Effects of an 8-Week Yoga Intervention on Cognition and Functional Fitness in Older Adults|SAYExercise|University of Illinois at Urbana-Champaign|No|Completed|May 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|118|||Both|55 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 18, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01650532||82029|
NCT01650792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01NS064905|Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS)|CHADSS: Chagas Disease Scan Study|CLINICS|Federal University of Bahia|No|Recruiting|July 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||September 2015|September 2, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650792||82009|
NCT01651065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110766|Micro-Clinic Obesity and Metabolic Risk Prevention Program|Micro-Clinic Obesity and Metabolic Risk Prevention Program: A Randomized-Control Trial of a Social-Network Based Intervention||Microclinic International|No|Completed|June 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|919|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651065||81988|
NCT01651273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV201-008|A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia|A Site and Subject Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS 852927 in Patients With Primary Hypercholesterolemia on a Stable Dose of Statin Therapy||Bristol-Myers Squibb|No|Terminated|November 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|97|||Both|18 Years|75 Years|No|||August 2013|August 2, 2013|July 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01651273||81972|
NCT01651806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12021202|Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty|Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty, a Randomized-clinical Trial.||Rush University Medical Center|Yes|Completed|May 2012|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|65|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2015|October 27, 2015|May 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01651806||81931|
NCT01651819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROAND2012|Urological Physical Therapy in HTLV-1 With Urinary Symptoms|TREATMENT OF NEUROGENIC BLADDER IN PATIENTS INFECTED WITH HUMAN T-LYMPHOTROPIC VIRUS 1|UROHTLV|Hospital Universitário Professor Edgard Santos|No|Enrolling by invitation|March 2012|July 2017|Anticipated|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651819||81930|
NCT01651780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol No. TMC-BIV-11-02|Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH|Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)|BRAVO-2/3|The Medicines Company|Yes|Completed|October 2012|August 2015|Actual|August 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|868|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651780||81933|
NCT01652040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B7867-W|Resistance Training and Testosterone After Spinal Cord Injury|Effects of Evoked Resistance Training and Testosterone After Spinal Cord Injury||VA Office of Research and Development|No|Active, not recruiting|July 2012|June 2017|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|24|||Male|18 Years|50 Years|No|||January 2016|January 12, 2016|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01652040||81913|
NCT01652053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP 2010-001|A Pilot Study of the InterCushion Disc Nucleus Prosthesis (DNP) in Patients Receiving Discectomy|A Pilot Clinical Study to Assess the Safety and Effectiveness of the InterCushion Disc Nucleus Prosthesis in Patients Receiving Discectomy||Vertebral Technologies, Inc.|No|Recruiting|January 2012|June 2018|Anticipated|January 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|21 Years|60 Years|No|||January 2016|January 12, 2016|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01652053||81912|
NCT01652313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13496A|Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women|A Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women||H. Lundbeck A/S|No|Completed|May 2012|||June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652313||81892|
NCT01652326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPittsburgh 0031860|Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome|Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome||University of Pittsburgh|No|Completed|July 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|792|||Both|18 Years|N/A|No|Non-Probability Sample|hospitalized inpatients|January 2016|January 12, 2016|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01652326||81891|
NCT01652339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL-LDV-101|Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects|||Hanlim Pharm. Co., Ltd.|No|Completed|July 2012|December 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|40|||Male|20 Years|40 Years|Accepts Healthy Volunteers|||March 2013|March 25, 2013|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01652339||81890|
NCT01653106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11055|Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients|A Randomized Study to Compare the Effect of Short- and Long-Term Schedules of Cryotherapy on the Incidence and Severity of Mucositis in High-Dose Melphalan||Ohio State University Comprehensive Cancer Center|Yes|Completed|April 2012|March 2015|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||March 2015|March 31, 2015|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653106||81831|
NCT01653652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.31. NRC|Effect of a Probiotic on Seasonal Allergic Rhinitis Symptoms|Mitigation of Seasonal Allergic Rhinitis Symptoms in Adults by Probiotic Intervention||Nestlé|Yes|Completed|April 2012|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|65 Years|No|||November 2013|November 19, 2013|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653652||81789|
NCT01649778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115232|Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma|PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib|PRINCIPAL|Novartis|No|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|700|None Retained|Not applicable. This is a Non-interventional study collecting prospective observational      data.|Both|18 Years|99 Years|No|Non-Probability Sample|This observational studies plans to recruit from cliinics that are prescribing pazopanib        to patients as part local standard of practice.|March 2016|March 22, 2016|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649778||82087|
NCT01650597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100707|A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants|A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects||Janssen-Cilag International NV|No|Completed|August 2011|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|29|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||May 2014|May 6, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650597||82024|
NCT01650285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 246|Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL)|Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL) Following Radical Prostatectomy||Brown University|Yes|Terminated|January 2013|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Male|18 Years|N/A|No|||June 2015|June 9, 2015|July 24, 2012|Yes|Yes||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01650285||82048|
NCT01651364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-27036|A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence|A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence||Baylor College of Medicine|Yes|Completed|July 2011|October 2011|Actual|October 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|11|||Both|18 Years|55 Years|No|||July 2012|July 25, 2012|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651364||81965|
NCT01651377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28454|Pramipexole as a Treatment for Cocaine Dependence|Pramipexole as a Treatment for Cocaine Dependence||Baylor College of Medicine|Yes|Completed|October 2011|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|10|||Both|18 Years|55 Years|No|||July 2014|July 18, 2014|February 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651377||81964|
NCT01650272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajH-006|Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia|An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA||Siriraj Hospital|Yes|Recruiting|June 2012|April 2013|Anticipated|February 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|N/A|No|||July 2012|July 25, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650272||82049|
NCT01650545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI001|Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients|A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation||University of Maryland|Yes|Completed|June 2012|April 2015|Actual|April 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|June 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650545||82028|
NCT01650805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AP24534-12-301|Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)|A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase||Ariad Pharmaceuticals|Yes|Terminated|June 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|307|||Both|18 Years|N/A|No|||October 2014|November 5, 2014|July 18, 2012|Yes|Yes|Study terminated based on evaluation of safety data.|Yes|October 15, 2014|https://clinicaltrials.gov/show/NCT01650805||82008|Trial was discontinued early.
NCT01651078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAASR|Laser Ablation After Stereotactic Radiosurgery|Laser Ablation After Stereotactic Radiosurgery|LAASR|Monteris Medical|Yes|Active, not recruiting|July 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|44|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with radiographic evidence of lesion regrowth following prior treatment with        radiosurgery (regardless of the process being suspected recurrent or progressive brain        metastasis versus radionecrosis).|January 2016|January 27, 2016|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651078||81987|
NCT01651286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001283|Nasal Mask Ventilation During the Induction of General Anesthesia|Determination of the Efficacy of Nasal Mask Ventilation During the Induction of General Anesthesia||Massachusetts General Hospital|No|Recruiting|June 2012|August 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|52|||Both|18 Years|65 Years|No|||July 2012|July 24, 2012|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01651286||81971|
NCT01651572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2633Pbis|Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia|Assessment of Post-operative Residual Curarization (PORC) Incidence in Patients Undergoing Surgery With General Anaesthesia; Comparison Between Cisatracurium and Rocuronium. A Randomised, Single-blind Phase 4 Study.||Azienda Ospedaliera di Padova|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|120|||Both|18 Years|80 Years|No|||March 2014|March 9, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01651572||81949|
NCT01651585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P070708|In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir|In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial|CYMEVAL2|Assistance Publique - Hôpitaux de Paris|Yes|Completed|July 2011|July 2015|Actual|May 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||July 2015|July 20, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651585||81948|
NCT01652625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Peking University|Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis|Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis||Peking University|Yes|Completed|March 2010|March 2011|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|227|||Both|18 Years|65 Years|No|||July 2012|July 25, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652625||81868|
NCT01651793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Study of cocoa-like beverages|Effect of Phytochemicals From Theobroma Cacao on Mental Energy|Effect of Phytochemicals From Theobroma Cacao on Mental Energy||University of Georgia|No|Recruiting|July 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|5||Anticipated|25|||Both|18 Years|34 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651793||81932|
NCT01652599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE12-010|Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT|Eltrombopag and High-dose Dexamethasone as First Line Treatment for Immune Thrombocytopenia||Hospital Universitario Dr. Jose E. Gonzalez|No|Completed|June 2012|November 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||January 2014|January 3, 2014|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652599||81870|
NCT01652872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110226|Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease|Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease|START-CKD|Amgen|Yes|Active, not recruiting|July 2011|October 2017|Anticipated|October 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|756|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652872||81849|
NCT01653119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP-004|Peking and Rotterdam on Mission to Reduce Coronary Artery Disease|Peking and Rotterdam on Mission to Reduce Coronary Artery Disease|PROMISS|Peking University Third Hospital|Yes|Recruiting|April 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|40 Years|N/A|No|||March 2012|July 26, 2012|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653119||81830|
NCT01653379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2MD-7H-2A|A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism|A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis||Deltanoid Pharmaceuticals|No|Completed|August 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|42|||Both|18 Years|N/A|No|||July 2014|July 23, 2014|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653379||81810|
NCT01650311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-239|Investigating Serotonin Signalling in IBD Patients|Investigating Serotonin Signalling in IBD Patients|IBD|McMaster University|No|Recruiting|July 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|60|Samples With DNA|Samples will be collected from inflamed and non-inflamed regions, spanning the distal colon      to distal ileum.|Both|19 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|All potential participants will be included only if they meet the stringent inclusion        criteria in place. Only when their eligibility is confirmed the potential participants        will be approached for consent prior to endoscopy. For healthy subjects, they will be        screened and consented from the colorectal screening list, also prior to endoscopy.|January 2013|January 21, 2013|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01650311||82046|
NCT01650584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S00231|Evaluation of Ocular Comfort With ISTA Tears vs Systane|||Bausch & Lomb Incorporated|No|Completed|June 2012|||December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||April 2014|April 4, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650584||82025|
NCT01650844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42495|School-Based Telemedicine Enhanced Asthma Management|School-Based Telemedicine Enhanced Asthma Management: A Randomized Control Trial Using Novel Technology to Improve Preventive Asthma Care|SB-TEAM|University of Rochester|Yes|Recruiting|August 2012|July 2018|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|3 Years|10 Years|No|||September 2015|September 15, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650844||82005|
NCT01651117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-407|Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control|Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control||VA Office of Research and Development|No|Recruiting|September 2012|March 2018|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Anticipated|698|||Both|30 Years|75 Years|No|||January 2016|January 29, 2016|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651117||81984|
NCT01651390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1105|Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis.|BIOLUX RCT - Clinical Performance of the Pantera LUX Paclitaxel Releasing Balloon Versus the Drug Eluting Orsiro Hybrid Stent System in Patients With In-stent Restenosis - a Randomized Controlled Trial|BIOLUX-RCT|Biotronik AG|Yes|Active, not recruiting|June 2012|August 2016|Anticipated|January 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|231|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651390||81963|
NCT01650571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5024-A|Evaluation of a 'Hand-Held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (SMH/UHN)|Evaluation of a 'Hand-Held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (SMH/UHN)|SMH/UHN|University Health Network, Toronto|No|Enrolling by invitation|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|18 Years|N/A|No|Non-Probability Sample|20 patients with wounds resulting from general abdominal surgery will be entered into this        trial, based on statistical power-based calculations for sample size determined in        collaboration with the UHN Biostatistics Group (assuming one wound per patient).|December 2014|December 9, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650571||82026|
NCT01651611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-28386|Intervention Study to Increase Smoking Cessation Rates Among Public Housing Residents|Health Advocates as a Vehicle to Improve Treatment for Smokers in Public Housing||Boston University|Yes|Recruiting|September 2011|August 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|79 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651611||81946|
NCT01651624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D65C09002710007|Screening for Colorectal Cancer With FOBT, Virtual Colonoscopy and Optical Colonoscopy. A Randomized Clinical Trial in the Florence District|Comparison Between Faecal Occult Blood Test (FOBT), Computed Tomographic Colonography (CTC) With Computer Aided Diagnosis (CAD) and Colonoscopy as a Primary Screening Test for Colorectal Cancer. Validation of a Teleradiology Model. Biological Banking in Subjects Recruited for Colonoscopy or CTC.|SAVE|Cancer Prevention and Research Institute, Italy|Yes|Recruiting|December 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|4||Anticipated|14000|||Both|55 Years|64 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01651624||81945|
NCT01651845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5003-A|Evaluation of a 'Hand-held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (JDRTC/UHN)|Evaluation of a 'Hand-held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (JDRTC/UHN)|JDRTC/UHN|University Health Network, Toronto|No|Enrolling by invitation|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Non-Probability Sample|The study will be conducted at the Judy Dan Research and Treatment Centre in Toronto.        Patients of the JDRTC typically present with diabetic foot ulcers. Eighty new patients        with wounds will be entered into this trial, based on statistical power-based calculations        for sample size determined in collaboration with the UHN Biostatistics Group (assuming one        wound per patient).|May 2015|May 18, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651845||81928|
NCT01650818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEC641|Aerobic Exercise Training in Amyotrophic Lateral Sclerosis|Exercise traiNing in Amyotrophic Lateral Sclerosis: a ranDomized Trial Comparing Home-based Aerobic endUrance tRAiNing vs. Usual physiCal Therapy intErvention|ENDURANCE|Fondazione Salvatore Maugeri|Yes|Recruiting|January 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|80 Years|No|||September 2013|September 8, 2013|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650818||82007|
NCT01651091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAT-30072012-T|Effects of Meditation Awareness Training on Psychosocial Functioning in Prison Participants|Effects of Meditation Awareness Training on Psychosocial Functioning in Prison Participants: A Randomized Controlled Trial||Nottingham Trent University|Yes|Not yet recruiting|March 2013|||November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|102|||Male|18 Years|65 Years||||August 2012|August 6, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651091||81986|
NCT01651299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BTG-PR005-001|Copperhead Envenomation Observational Study|Observational Study of Recovery From Copperhead Snake Envenomation||BTG International Inc.|No|Completed|July 2012|April 2013|Actual|November 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Males and non-pregnant females at least 18 yrs of age with evidence of copperhead        envenomation on an extremity distal to the knee or elbow that present for care at a health        care facility within 24 hours of envenomation.|September 2012|May 10, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651299||81970|
NCT01651312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-CL-007|A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178|An Open-label Study to Evaluate the Pharmacokinetics of YM178 After Single Oral Administration of 14C-labeled YM178 in Healthy Male Volunteers||Astellas Pharma Inc|No|Completed|January 2003|February 2003|Actual|February 2003|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|4|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 4, 2013|July 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01651312||81969|
NCT01651598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1313.2|Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients|Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of Multiple Rising Doses of BI 144807 Powder for Oral Drinking Solution Over a Period of 14 Days in Otherwise Healthy Controlled Asthmatic Subjects in a Randomised, Double-blind, Placebo-controlled Trial||Boehringer Ingelheim||Completed|July 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|57|||Both|18 Years|55 Years|No|||October 2013|October 31, 2013|July 23, 2012||||No||https://clinicaltrials.gov/show/NCT01651598||81947|
NCT01652105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rubenschouten1|Randomized Trial of Preoperative Diets Before Bariatric Surgery|Comparison of Preoperative Diets Before Bariatric Surgery: a Randomized Controlled Trial||Lievensberg Ziekenhuis|No|Not yet recruiting|September 2012|June 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|60 Years|No|||August 2012|August 6, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652105||81908|
NCT01652378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 122011-052|Pharmacologic MRI in Cocaine Addiction|Pharmacologic MRI in Cocaine-addiction|phMRI|University of Texas Southwestern Medical Center|No|Recruiting|August 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|30|||Both|21 Years|64 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with cocaine addiction will be recruited from patients requesting treatment for        addiction at the Dallas VA Medical Center and Homeward Bound,Inc. Recently using cocaine        patients and healthy controls will be recruited from flyers and internet ads.|June 2012|May 29, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652378||81887|
NCT01652352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|105880|Experimental Evaluation of Wheelchair-Mounted Robotic Arms|HRI: Maximizing Manipulation of Persons With Disabilities Using a Smart Wheelchair-Mounted Robotic System|HRI|University of South Florida|Yes|Completed|August 2010|July 2011|Actual|July 2011|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|20|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Candidates will be recruited from University of South Florida facilities and through        channels of normal operation of the Center for Assistive and Rehabilitation Robotic        Technologies laboratory, its group members, and students.        Included candidate sources are primary and specialist care facilities in the Tampa Bay        area, affiliates of USF, CARRT, and the College of Engineering, contacts of said        organizations, and the general community.|July 2012|July 27, 2012|September 13, 2010||No||No||https://clinicaltrials.gov/show/NCT01652352||81889|
NCT01652365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19371-106|Feasibility and Impact of Malaria Rapid Diagnostic Tests in the African Retail Sector|Evaluation of the Feasibility and Impact of Introducing Malaria Rapid Diagnostic Tests in the Retail Sector: A Randomized Controlled Trial in Eastern Uganda||Harvard School of Public Health|No|Completed|March 2011|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|2800|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 27, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01652365||81888|
NCT01652612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0301|Positive End-expiratory Pressure and Alveolar Recruitment for One Lung Ventilation|Effects of Positive End-expiratory Pressure and Alveolar Recruitment on the Oxygenation and Respiratory Mechanics During One-lung Ventilation in the Supine Position||Yonsei University|Yes|Completed|August 2011|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|3||Actual|99|||Both|20 Years|75 Years|No|||July 2013|July 3, 2013|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01652612||81869|
NCT01652885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN2728-AD-203|Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis|An Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment in Adolescents With Atopic Dermatitis||Anacor Pharmaceuticals, Inc.||Completed|July 2012|November 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|23|||Both|12 Years|17 Years|No|||February 2014|February 12, 2014|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652885||81848|
NCT01652898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOP LDLA202.101|A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers|A Single Centre Prospective, Randomized, Double Blind, Crossover, Three-treatment Periods PK, PD, Safety and Tolerability Study to Compare Bolus Administration of AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers After a Pilot Phase of AOP LDLA202 Safety and Local Tolerability Assessment.||AOP Orphan Pharmaceuticals AG|No|Completed|July 2012|August 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 4, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01652898||81847|
NCT01650012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHASE-1|Eplerenone in Hemodialysis Trial|Pilot Trial of Hemodialysis Patient Aldosterone antagoniSm With Eplerenone Trial|PHASE|McMaster University|No|Completed|March 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|158|||Both|18 Years|N/A|No|||September 2015|September 24, 2015|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650012||82069|
NCT01650324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBPR108-101|A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects||National Health Research Institutes, Taiwan|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|32|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||February 2014|August 15, 2014|July 19, 2012|Yes|Yes||No|May 20, 2014|https://clinicaltrials.gov/show/NCT01650324||82045|
NCT01650337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|mFit-UCLA|mFit: The Mobile Fitness Project|Randomized Trial of a Smartphone Application for Weight Loss in Primary Care|mFIT|University of California, Los Angeles|Yes|Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Supportive Care|2||Actual|212|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 2, 2013|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650337||82044|
NCT01650610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPNEC001|Gait Training With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Study Protocol|Gait Training Associated With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Study Protocol||University of Sao Paulo|No|Recruiting|July 2012|July 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|50 Years|85 Years|No|||November 2012|November 6, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01650610||82023|
NCT01650857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HannoverMS PH-Reha001|Pulmonary Hypertension: Efficacy of a 3 Week Inpatient Rehabilitation on Physical Condition, Body Composition and Health Related Quality of Life|Pulmonary Hypertension: Efficacy of a 3 Week Inpatient Pulmonary Rehabilitation on Physical Condition, Body Composition and Health Related Quality of Life - an Observational Study||Hannover Medical School|No|Recruiting|April 2010|December 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with pulmonary hypertension in World Heart Organization functional classification        classes (FC) II and III|August 2015|August 19, 2015|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01650857||82004|
NCT01651403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-174-0144|Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection|A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection||Gilead Sciences|Yes|Recruiting|December 2012|June 2019|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|11 Years|No|||December 2015|December 24, 2015|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651403||81962|
NCT01651637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1011-PR-0059|First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome|A First in Human Clinical Study on the Safety and Tolerability of Two Escalating Single Doses of CHF 5633 (Synthetic Surfactant) in Preterm Neonates With Respiratory Distress Syndrome||Chiesi Farmaceutici S.p.A.|Yes|Completed|October 2012|||January 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|27 Weeks|34 Weeks|No|||July 2015|July 27, 2015|April 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01651637||81944|
NCT01642901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11F.612|Zoledronic Acid in Acute Spinal Cord Injury|Zoledronic Acid to Prevent Bone Loss After Acute Spinal Cord Injury||Thomas Jefferson University|Yes|Recruiting|May 2012|May 2018|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|65 Years|No|||October 2015|October 8, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642901||82566|
NCT01651104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V70_39S|Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects|A Phase 2, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine (Fluad®), Formulation 2012/2013, When Administered to Elderly Subjects||Novartis|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|63|||Both|65 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 3, 2014|July 24, 2012||No||No|July 11, 2013|https://clinicaltrials.gov/show/NCT01651104||81985|
NCT01651325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0042|Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Dextromethorphan in Healthy Adult Subjects||Astellas Pharma Inc|No|Completed|May 2012|May 2012|Actual|May 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|July 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01651325||81968|
NCT01651858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_SDF001|Nurigra Chewable Tablet in Healthy Adult Male Volunteers|Nurigra Chewable Tablet in Healthy Adult Male Volunteers||Daewoong Pharmaceutical Co. LTD.|Yes|Completed|February 2012|March 2012|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|52|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651858||81927|
NCT01651338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|accupuncture|Quality of Life and Acupuncture on Chronic Pain: A Randomized Study Before and After Performing|Islamic Azad University and Dr Sadre Nabavi Clinic||Islamic Azad University, Tehran|Yes|Terminated|January 2009|January 2010|Actual|August 2009|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|150|||Both|17 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|July 17, 2012||No|This study was completed.|No||https://clinicaltrials.gov/show/NCT01651338||81967|
NCT01652144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I194|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma||Canadian Cancer Trials Group|No|Completed|August 2012|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||February 2015|February 13, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652144||81905|
NCT01651832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01GY1143|Supportive Cancer Care Networkers (SCAN)|Supportive Cancer Care Networkers - a Prospective Randomized Controlled Multi-center Trial|SCAN|Martin-Luther-Universität Halle-Wittenberg|No|Recruiting|July 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|700|||Both|18 Years|85 Years|No|||December 2014|December 1, 2014|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651832||81929|
NCT01652118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05059079727|Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis|Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin|Claprum|Zekai Tahir Burak Women's Health Research and Education Hospital|No|Recruiting|October 2011|January 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention|2||Anticipated|250|||Both|N/A|2 Days|No|||July 2012|July 26, 2012|July 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01652118||81907|
NCT01652937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|227RA201|BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs|A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BIIB057 in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs|EMBRACE|Biogen|Yes|Withdrawn|August 2012|March 2014|Anticipated|February 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|0|||Female|18 Years|N/A|No|||October 2012|September 12, 2013|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01652937||81844|
NCT01653145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 10017|Positive Energy I Through Overfeeding|Behavioral Response to Short-term (Two-day) Positive Energy Balance Through Overfeeding (ENERGY I)||Pennington Biomedical Research Center|No|Completed|July 2010|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|3||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653145||81828|
NCT01653132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P00304|Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism|Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism||Beth Israel Deaconess Medical Center|No|Completed|March 2012|September 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|90 Years|No|||January 2015|January 26, 2015|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653132||81829|
NCT01653405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDP 12-249|Improving Anticoagulation Control in VISN 1|Improving Anticoagulation Control in VISN 1||VA Office of Research and Development|No|Withdrawn|October 2014|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|0|||Both|21 Years|N/A|No|||May 2014|May 9, 2014|July 6, 2012||No|Study design changed, no longer an experimental design.|No||https://clinicaltrials.gov/show/NCT01653405||81808|
NCT01653431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HC12381|Transcranial Direct Current Stimulation to Enhance Cognition in Mild Cognitive Impairment|||The University of New South Wales||Recruiting|January 2013|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|85 Years|Accepts Healthy Volunteers|||July 2015|July 21, 2015|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653431||81806|
NCT01652079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-485|CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer|A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer||Massachusetts General Hospital|Yes|Recruiting|April 2012|||April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Female|18 Years|N/A|No|||January 2014|January 22, 2014|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652079||81910|
NCT01652092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012OC055|Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies|Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|September 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|30|||Both|N/A|50 Years|No|||January 2016|January 22, 2016|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652092||81909|
NCT01653392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBS.AVA.010 / NHRC.2012.0003|BioThrax® (Anthrax) Vaccine in Pregnancy Registry|BioThrax® (Anthrax) Vaccine in Pregnancy Registry||Emergent BioSolutions|No|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|580|||Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Active duty female service members who received one or more doses of BioThrax® while        pregnant, with the onset of pregnancy defined as the first day of the last menstrual        period (LMP) All live born infants born to women who join the registry.|October 2015|October 23, 2015|July 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653392||81809|
NCT01649791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 136908|Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia|A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)||Roswell Park Cancer Institute|No|Completed|January 2010|October 2014|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||October 2014|October 23, 2014|July 23, 2012|No|Yes||No|December 26, 2013|https://clinicaltrials.gov/show/NCT01649791||82086|This trial did not reach full accrual.
NCT01650025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAIIO|Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90°|Effects of the Probiotic Preparation VSL#3 on the Metabolic, Endocrine, Lipidomic and Inflammatory Parameters as Well as Variation of the Microbiota in Pediatric Patients With Body Mass Index >90°|VAIIO|Bambino Gesù Hospital and Research Institute|Yes|Completed|August 2012|December 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Actual|48|||Both|6 Years|12 Years|No|||November 2012|April 1, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650025||82068|
NCT01650870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SplitDose Cryst. Lactulose|Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults|A Single Center, Randomized, Single-blind Pilot Study to Determine the Safety, Efficacy, and Patient Preference of Split-Dose Regimen of Crystalline Lactulose for Cleansing of the Colon as a Preparation for Colonoscopy in Adults||Benaroya Research Institute|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||August 2014|August 7, 2014|July 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01650870||82003|
NCT01651156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|156-12-809-01|Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema|Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Phase 3 Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Patients With Cardiac Edema Based on the Conventional Therapy||Otsuka Beijing Research Institute|No|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|244|||Both|20 Years|85 Years|No|||December 2013|December 25, 2013|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651156||81981|
NCT01651416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QA389|Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana|An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana.||Centre for Global Health Research, Ghana|Yes|Completed|July 2012|July 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|2400|||Both|3 Months|59 Months|No|||September 2015|September 17, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651416||81961|
NCT01651910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2012/73/FHMS|The Pain and Unmet Needs Study|A Prospective Longitudinal Survey Exploring the Unmet Needs of Cancer Patients in Pain.||University of Surrey|No|Terminated|July 2012|February 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|162|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will be recruited from patients attending St Luke's Cancer Centre at the        Royal Surrey County Hospital, Guildford, Surrey, UK. An audit is already being carried out        at the centre, to determine the amount of patients who have pain. Patients who have pain        who have completed the audit and are willing to take part in research will be screened for        the trial. In order to ensure that sufficient numbers of patients in the trial have        controlled pain, uncontrolled pain and breakthrough pain, when 104 participants have been        recruited into one of these specific pain groups then people will no longer be approached        who have that type of pain.|November 2012|April 9, 2014|July 25, 2012||No|Recruitment issues, interim analysis indicated a reduced sample size of 162 was acceptable.|No||https://clinicaltrials.gov/show/NCT01651910||81923|
NCT01651650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1113-PR-0074|An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device||NEXThalerPIF|Chiesi Farmaceutici S.p.A.|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|41|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01651650||81943|
NCT01642693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-007|Histological Change of The Dentinal-Pulp Complex and Root Resorption|Histological Changes of The Dentinal-Pulp Complex and Root Resorption in Maxillary Premolars With Intrusive Orthodontic Movements Under a Low Power Laser Effect||Universidad de Antioquia|Yes|Completed|June 2006|May 2009|Actual|May 2008|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|34|||Both|13 Years|23 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642693||82582|
NCT01652131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REF.343|Behaviour of Intravenous Solutions in Obese Patients Under General Anesthesia|Colloid Volume Kinetics in Morbidly Obese Patients Under General Anaesthesia||National Institute of Medical Sciences and Nutrition, Salvador Zubiran|Yes|Recruiting|May 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|12|||Both|18 Years|70 Years|No|||November 2012|November 18, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652131||81906|
NCT01652391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|211/2010BO1_1|Modulation of Cognitive Control by Transcranial Direct Current Stimulation|Modulation of Cognitive Control in Healthy and Depressed Subjects by Transcranial Direct Current Stimulation||University Hospital Tuebingen|No|Completed|July 2011|December 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|44|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||December 2013|December 29, 2013|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652391||81886|
NCT01652638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPBLA0312SC-I|PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|February 2013|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652638||81867|
NCT01652950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REC REF 061/2010|Study Comparing the Effectiveness of Incentives on Physical Activity Behavior in a Health Insured Population|A Prospective, Randomized, Study Comparing the Effectiveness of Different Types of Incentives in Increasing Physical Activity Behaviour on the Vitality Health Promotion Programme|PAIS|University of Cape Town|No|Completed|July 2010|October 2011|Actual|June 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|6||Actual|10907|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01652950||81843|
NCT01653171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-221|Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy|Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy.|PRUE|Pontificia Universidad Catolica de Chile|Yes|Completed|July 2012|November 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|5||Actual|230|||Both|18 Years|N/A|No|||December 2013|December 8, 2013|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653171||81826|
NCT01653457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC11-387|Randomised Controlled Trial of Memantine in Fibromyalgia|Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial||Aragon Institute of Health Sciences|No|Not yet recruiting|September 2012|May 2013|Anticipated|October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||July 2012|July 30, 2012|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01653457||81804|
NCT01653444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC1119_P1|Evaluate the Safety and Exploratory Efficacy of GC1119|Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119(Recombinant Human α-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients||Green Cross Corporation|No|Recruiting|July 2012|||February 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|16 Years|N/A|No|||January 2012|July 30, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01653444||81805|
NCT01652911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00028097|A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation|A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation||University of Alberta|Yes|Active, not recruiting|June 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|68 Years|No|||November 2015|November 30, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01652911||81846|
NCT01652924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Anestesia002|Efficacy of Mechanical Ventilation With Facial Mask to Reduce Gastric Insufflation|Efficacy and Safety of Pressure-controlled Ventilation Compared With Manual Ventilation to Reduce Gastric Insufflation During Induction of Anesthesia in Children: Controlled Trial Randomized, Double-blind||Universidad de Antioquia|Yes|Recruiting|May 2012|August 2012|Anticipated|August 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|1 Month|14 Years|Accepts Healthy Volunteers|||July 2012|July 27, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01652924||81845|
NCT01649804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28146|A Long-Term Safety Extension Study of WA19926 in Patients With Rheumatoid Arthritis|A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG-TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS||Hoffmann-La Roche||Completed|July 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649804||82085|
NCT01650350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 275|Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer|Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer: A Phase II Brown University Oncology Group Research Project||Brown University|Yes|Terminated|November 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|July 24, 2012|Yes|Yes|Study stopped 10/24/13 secondary to lack of patients/slow enrollment|No|August 14, 2014|https://clinicaltrials.gov/show/NCT01650350||82043|
NCT01651429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D12AP00241|Predicting Cognitive Resilience Against Sleep Loss|Multimodal Neuroimaging to Predict Cognitive Resilience Against Sleep Loss||Mclean Hospital|No|Completed|April 2013|June 2014|Actual|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|48|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||June 2014|June 13, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01651429||81960|
NCT01651130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-04|Carbetocin at Elective Cesarean Delivery Part 3|Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study Part 3||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|6||Actual|40|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651130||81983|
NCT01651923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEPBLA0312IV-I|PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|February 2013|April 2013|Anticipated|April 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 10, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651923||81922|
NCT01652183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KA08/180|Paracetamol for Catheter Related Bladder Discomfort|THE EFFECT OF INTRAOPERATIVE PARACETAMOL ON CATHETER-RELATED BLADDER DISCOMFORT: A PROSPECTIVE, RANDOMISED, DOUBLE-BLIND STUDY||Baskent University|Yes|Completed|October 2008|November 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|18 Years|65 Years|No|||July 2012|July 26, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652183||81902|
NCT01652196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU 11182|Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer|A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|November 2012|||September 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|70|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652196||81901|
NCT01642927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University_of_Minnesota|Pulse Wave Analysis in Advanced Heart Failure|Pulse Wave Analysis in Advanced Heart Failure Patients Before and After Ventricular Assist Device|PWA-HF|University of Minnesota - Clinical and Translational Science Institute|No|Enrolling by invitation|February 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||7|Anticipated|350|||Both|18 Years|N/A|No|Non-Probability Sample|Advanced heart failure patients, eligible for or currently treated with LVAD, outpatient        cardiology clinic or inpatient heart failure service patients|March 2016|March 17, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01642927||82564|
NCT01652157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CFFC-OB-11|Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)|A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors||AbbVie||Recruiting|July 2012|July 2022|Anticipated|July 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|N/A|99 Years|No|Non-Probability Sample|Cystic fibrosis patients who are active in the Cystic Fibrosis Patient Registry|March 2016|March 1, 2016|July 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01652157||81904|
NCT01652404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN01|PROcalcitonin to SHORTen Antibiotics Duration in PEDiatricICU Patients (ProShort-Ped) Trial|PROcalcitonin to SHORTen Antibiotics Duration in PEDiatricICU Patients (ProShort-Ped) Trial|ProShort-Ped|Hunan Children's Hospital|No|Recruiting|March 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|1 Month|15 Years|No|||July 2012|July 27, 2012|August 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01652404||81885|
NCT01652651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5383|Risk and Resilience Factors in Learning Disabilities Population|The Contribution of Risk and Resilience Factors in Learning Disabilities Population to Academic and Emotional Development||Rabin Medical Center||Recruiting|May 2009|December 2013|Anticipated|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|70|||Both|11 Years|15 Years|Accepts Healthy Volunteers|||June 2012|July 25, 2012|June 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01652651||81866|
NCT01652664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-008|Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients|A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients||Alcon Research|No|Completed|September 2012|March 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|184|||Both|2 Months|17 Years|No|||June 2015|June 30, 2015|July 26, 2012|Yes|Yes||No|March 31, 2015|https://clinicaltrials.gov/show/NCT01652664||81865|
NCT01652963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UEA-6345832-MED1|Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills|Evaluating a Picture-based Computerised Assessment and Training Paradigm for Cognitive Behaviour Therapy Skills in Adults With Intellectual Disabilities||University of East Anglia|Yes|Recruiting|July 2012|August 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|2||Anticipated|132|||Both|18 Years|80 Years|No|||November 2012|November 20, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652963||81842|
NCT01653158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A4021003|CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies|A Phase 1b Dose Escalation, Open-label Study Of CP-751,871 In Combination With Docetaxel In Advanced Non-hematologic Malignancies||Pfizer|No|Completed|March 2005|February 2009|Actual|February 2009|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|46|||Both|18 Years|N/A|No|||October 2013|October 4, 2013|July 26, 2012|No|Yes||No|January 18, 2013|https://clinicaltrials.gov/show/NCT01653158||81827|
NCT01649843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endoscopycenter-POEM|Clinical Impact of Peroral Endoscopic Myotomy for Esophageal Achalasia|Clinical Impact of Peroral Endoscopic Myotomy for Esophageal Achalasia||Shanghai Zhongshan Hospital|Yes|Recruiting|August 2010|December 2014|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|450|||Both|6 Years|90 Years|No|||July 2012|July 22, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01649843||82082|
NCT01653704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120008-01H|Learning Crisis Resource Management: Practicing Versus Observational Role in Simulation Training|Learning Crisis Resource Management: Practicing Versus Observational Role in Simulation Training||Ottawa Hospital Research Institute|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|42|||Both|N/A|N/A|No|||May 2014|May 12, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01653704||81785|
NCT01653418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208046|Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation|A Phase II Study of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) as Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation for Multiple Myeloma|V-BEAM|Washington University School of Medicine|No|Terminated|September 2012|December 2013|Actual|August 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||October 2014|October 8, 2014|July 23, 2012|Yes|Yes|Due to the high rate of morbidity and mortality|No|September 26, 2014|https://clinicaltrials.gov/show/NCT01653418||81807|2 early deaths caused a concern for safety and resulted in suspension of enrollment in May 2013. After a review of the data, the investigators determined that this regimen had unexpected toxicity & the trial was closed to enrollment in June 2013.
NCT01653678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002880|Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)|Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension||Brigham and Women's Hospital|Yes|Active, not recruiting|November 2011|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01653678||81787|
NCT01653665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJSEB001|Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?|Does GM-CSF Restore Effective Neutrophil Function in Critically Ill Patients?|GMCSF|Newcastle-upon-Tyne Hospitals NHS Trust|Yes|Completed|August 2012|February 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|70|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01653665||81788|
NCT01650038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 2011_005|Transplantation of Faeces in Ulcerative Colitis; Restoring Nature's Homeostasis|Transplantation of Faeces in Ulcerative Colitis; Restoring Nature's Homeostasis.|TURN|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Yes|Completed|May 2011|December 2014|Actual|August 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||December 2014|December 28, 2014|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01650038||82067|
NCT01650623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USPNEC002|Gait Training With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Randomised Controlled Trial|Gait Training Associated With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Randomised Controlled Trial||University of Sao Paulo|No|Recruiting|July 2012|July 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|85 Years|No|||November 2012|November 6, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01650623||82022|
NCT01650636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100771|Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process|Patient-Partner Stress Management Effects on CFS Symptoms and Neuroimmune Process||University of Miami|Yes|Active, not recruiting|October 2010|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|150|||Both|21 Years|75 Years|No|||December 2015|December 17, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650636||82021|
NCT01680107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRC-01|D-cycloserine Augmented CBT for Panic Disorder|The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial||University of Oxford|Yes|Recruiting|October 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|65 Years|No|||November 2015|December 2, 2015|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01680107||79785|
NCT01651143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT12339|Proof of Biological Activity of SAR100842 in Systemic Sclerosis|Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis||Sanofi|No|Completed|January 2013|April 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 26, 2016|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651143||81982|
NCT01680562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1126/2009|In-vivo Optical Coherence Tomography Imaging in Dermatooncology|Improving Diagnosis of Skin Cancer Patients Via Optical Coherence Tomography and Teledermatology- A Pilot Study||Medical University of Vienna|No|Active, not recruiting|January 2010|December 2012|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|37|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Skin tumor patients with subsequent excision and histopathological analysis at the        department of dermatology, Medical University of Vienna|September 2012|September 4, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01680562||79750|
NCT01680848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E1157|Assessment of Caries Diagnosis and Caries Treatment in Dental PBRN Japan|||Dental PBRN Japan|No|Active, not recruiting|May 2010|February 2015|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|200|||Both|24 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants are dentists who work in outpatient dental practices who have affiliated with        Dental PBRN Japan|September 2012|September 4, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680848||79728|
NCT01652209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMC-BD-CT-P-003|RELIEF(A Randomized,Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial inFarction)|A Multi-center, Open-label, Comparison and a Parallel Group Study (3 Groups) Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, in Order to Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI(Autologous Human Bone Marrow Derived Mesenchymal Stem Cells) in AMI Patients, and to Observe the Efficacy of the Second Cell Treatment.||Pharmicell Co., Ltd.|Yes|Recruiting|October 2013|||December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|135|||Both|20 Years|70 Years|No|||January 2015|January 30, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652209||81900|
NCT01681147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 2012-16|Barriers to Adherence to Recommended Follow-up in Women With a History of Gestational Diabetes|Barriers to Adherence to Recommended Follow-up in Women With a History of Gestational Diabetes||Joslin Diabetes Center|No|Active, not recruiting|June 2012|December 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Female|21 Years|45 Years|No|||April 2015|April 1, 2015|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01681147||79705|
NCT01643499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0033|Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies|A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies||University of Chicago|No|Recruiting|March 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|July 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01643499||82520|
NCT01643785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSHH Endonase2|Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection|Additive Effect of Endonase on the Efficacy of Bismuth-containing Quadruple Therapy as Second-line Treatment for Helicobacter Pylori Infection||Chuncheon Sacred Heart Hospital|Yes|Terminated|June 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|N/A|No|||January 2014|January 20, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01643785||82498|
NCT01652170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP12-001|The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis|The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis in Children, Adolescents, and Young Adults Presenting to the Emergency Department|APPY1|Venaxis, Inc.|Yes|Completed|January 2013|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|2201|Samples Without DNA|Surplus plasma samples will be retrieved by the Sponsor for future development of protein      biomarkers.|Both|2 Years|20 Years|No|Non-Probability Sample|Children, adolescents and young adults 2 to 20 years old.|March 2014|March 20, 2014|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652170||81903|
NCT01652417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P 110118|Treatment of Renal Sarcoidosis by Methylprednisolone Bolus|Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis|CORTICOIDOSE|Assistance Publique - Hôpitaux de Paris|No|Terminated|October 2012|November 2015|Actual|November 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||October 2015|February 24, 2016|May 16, 2012||No|insufficient recruitment|No||https://clinicaltrials.gov/show/NCT01652417||81884|
NCT01652677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TMS-001|Navigation Repetitive Transcranial Magnetic Stimulation in Stroke Rehabilitation|Randomized Controlled Single-blind Research "Navigation Repetitive Transcranial Magnetic Stimulation in Stroke Rehabilitation"|NTMSR|Russian Academy of Medical Sciences|Yes|Completed|January 2012|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||April 2015|April 30, 2015|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652677||81864|
NCT01652690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110132|Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Prolia® in Routine Clinical Practice|Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice||Amgen|No|Completed|June 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|600|||Female|N/A|N/A|No|Non-Probability Sample|Postmenopausal women with OP who receive an injection of Prolia® and meet the        inclusion/exclusion criteria will be eligible to participate in the study.|February 2016|February 22, 2016|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652690||81863|
NCT01653717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-1169|CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)|Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL)||M.D. Anderson Cancer Center|No|Active, not recruiting|June 2013|June 2017|Anticipated|June 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|80 Years|No|||April 2015|April 2, 2015|July 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653717||81784|
NCT01649856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MO28107|A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma|A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)||Hoffmann-La Roche||Active, not recruiting|August 2012|September 2016|Anticipated|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|572|||Both|18 Years|80 Years|No|||December 2015|January 15, 2016|July 23, 2012|Yes|Yes||No|January 15, 2016|https://clinicaltrials.gov/show/NCT01649856||82081|
NCT01650077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProAcTyon - 1203|Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria|Early Assessment of Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria: Retrospective Study of Feasibility|ProAcTyon|Centre Oscar Lambret|No|Active, not recruiting|September 2012|December 2014|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|134|||Both|18 Years|N/A|No|Probability Sample|Patients with soft tissue sarcoma treated with at least 2 cycles of Yondelis after failure        or intolerance to doxorubicin/ifosfamide|August 2014|August 22, 2014|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01650077||82064|
NCT01650064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAMOS|Latin America Hip Fracture Mortality Study|Latin America Hip Fracture Mortality Study|LAMOS|AO Clinical Investigation and Documentation|No|Active, not recruiting|January 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|60 Years|N/A|No|Non-Probability Sample|Patients with surgically-treated hip fracture in Latin America|July 2015|July 14, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01650064||82065|
NCT01653691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-002148|Laser Therapy for Treating Hypertrophic Burn Scars in Children|Tunable-Dye Laser Therapy to Ameliorate Hypertrophic Scarring in Burned Children|LaserTherapy|Massachusetts General Hospital|No|Not yet recruiting|May 2012|January 2015|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|9 Years|21 Years|No|||July 2012|July 30, 2012|July 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653691||81786|
NCT01649817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28258|A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)|Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION II Study)||Hoffmann-La Roche||Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|183|||Both|18 Years|N/A|No|Probability Sample|Rheumatoid arthritis patients suitable for treatment with RoActemra/Actemra according to        SPC|March 2016|March 1, 2016|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649817||82084|
NCT01650051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AM-PHN-004|Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)|A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)||Amneal Pharmaceuticals, LLC|Yes|Completed|February 2012|February 2014|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|424|||Female|18 Years|N/A|No|||June 2014|June 25, 2014|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650051||82066|
NCT01650363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTSURG|CAM in Post Surgical Management in Cardiothoracic Surgery|Effect of Complementary and Alternative Medical Methods on the Post Operative Recovery Following Cardio-thoracic Surgery- a Pragmatic, Randomized,Single Blinded, Placebo Controlled Study||Shaare Zedek Medical Center|No|Not yet recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2012|July 23, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01650363||82042|
NCT01650376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS22810034|Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer|Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients||Swedish Medical Center|No|Active, not recruiting|August 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|52|||Female|18 Years|N/A|No|||June 2015|June 4, 2015|July 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650376||82041|
NCT01650883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VitD3USFstudy|A Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients|A Randomized Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients||University of South Florida|No|Completed|March 2009|April 2011|Actual|April 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650883||82002|
NCT01650896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CADIS-2012|Prospective Randomised Controlled Trial of Delirium Management by Geriatric Medicine Versus General Medicine|Prospective Randomised Controlled Trial of Delirium Management The Central Coast Australia Delirium Intervention Study (CADIS|CADIS|Central Coast Local Health District|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|65 Years|N/A|No|||July 2012|July 24, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01650896||82001|
NCT01651169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-04-49-16359|Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD)|Evaluating the Effect of Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Comorbid With Attention Deficit Disorder With Hyperactivity(ADHD) in TMS Unit, Neurcognitive Lab, Iranian National Center for Addiction Studies (INCAS), in 2012. A Randomized, Controlled Trial|ADHD|Tehran University of Medical Sciences|Yes|Enrolling by invitation|September 2012|March 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|30|||Both|18 Years|70 Years|No|||November 2014|November 15, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651169||81980|
NCT01680341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN5401-3941|Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine|A Trial Comparing the Efficacy and Safety of Two Different Titration Algorithms for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®: SIMPLE vs. STEPWISE)|BOOST®|Novo Nordisk A/S|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|272|||Both|18 Years|N/A|No|||November 2015|November 24, 2015|August 31, 2012|Yes|Yes||No|October 16, 2015|https://clinicaltrials.gov/show/NCT01680341||79767|
NCT01651663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARB-M1/P01-11|A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold|Double-blind, Randomized, Placebo-controlled Clinical Study Investigating Efficacy and Safety of Arbidol (Umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold.|ARBITR|Pharmstandard|No|Recruiting|September 2011|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|840|||Both|18 Years|65 Years|No|||July 2013|July 26, 2013|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01651663||81942|
NCT01681173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DDS-FKZ 232/11/08|OPTIFIT-Optimal Fiber Trial for Diabetes Prevention|Investigation of the Effect of Insoluble Dietary Fiber on Carbohydrate and Lipid Metabolism and the Prevention of Diabetes Mellitus Type 2 in Subjects With Impaired Glucose Tolerance||German Institute of Human Nutrition|No|Completed|May 2010|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||February 2015|February 4, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681173||79703|
NCT01681160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|86/116|Study of Maggot Therapy in Diabetic Foot Ulcers|Maggot Therapy in Diabetic Foot Ulcers|MDT|Kerman Medical University|Yes|Completed|January 2009|June 2011|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|128|||Both|40 Years|90 Years|No|||September 2012|September 7, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01681160||79704|
NCT01643512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111282|Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members|Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members||University of California, San Diego|No|Recruiting|August 2011|August 2013|Anticipated|August 2013|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Cross-Sectional||1|Anticipated|500|Samples With DNA|serum, plasma, urine, stool, DNA|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Twins and first degree relatives (sibling-sibling or offspring-parent).|July 2012|July 17, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643512||82519|
NCT01652976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA180-359|Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma|Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma|FOLFOX-D|University of Florida|Yes|Recruiting|July 2012|June 2018|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 15, 2015|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652976||81841|
NCT01653184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Omega 20120660|Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration|The Effect of Oral Supplementation With Omega-3 Fatty Acids on Serum Omega-3 Levels in Patients With Age-related Macular Degeneration: A Randomized Controlled Trial.||Wills Eye|No|Active, not recruiting|July 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|55 Years|N/A|No|||November 2013|November 6, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01653184||81825|
NCT01653197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813606-3|Evive Health Randomized Controlled Trials|Evive Health Randomized Controlled Trials||University of Pennsylvania|No|Not yet recruiting|August 2012|August 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|30000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 26, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653197||81824|
NCT01653470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA216-003|Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors|A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors||Bristol-Myers Squibb|No|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|95|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|July 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653470||81803|
NCT01653483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116213|Aura Adolescent PK Study GSK2829332|A Randomized, Double-blind, Placebo-controlled, Repeat Dose, 2-period Incomplete Block Crossover Safety and Pharmacokinetic Study of Umeclidinium in Adolescent Asthma Subjects||GlaxoSmithKline|No|Withdrawn|September 2012|March 2013|Anticipated|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|17 Years|Accepts Healthy Volunteers|||November 2012|November 8, 2012|July 23, 2012|Yes|Yes|FDA advised that study is no longer required|No||https://clinicaltrials.gov/show/NCT01653483||81802|
NCT01678352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-136|Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas|A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas||University of Pittsburgh|Yes|Recruiting|October 2012|September 2017|Anticipated|September 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|27|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678352||79919|
NCT01650090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EP-ILC-201|Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma|Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma||Eleison Pharmaceuticals LLC.|No|Active, not recruiting|August 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|50|||Both|13 Years|N/A|No|||January 2016|January 19, 2016|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650090||82063|
NCT01650415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPEPO|Erythropoietin Therapy for Children With Cerebral Palsy|Random Control Trial to Evaluate the Safety and Efficacy of Erythropoietin Therapy for Children With Cerebral Palsy -Patient, Principle Investigator, Observer Blind||Bundang CHA Hospital|No|Not yet recruiting|September 2014|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|4 Months|4 Years|No|||March 2014|March 31, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650415||82038|
NCT01649830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012012|Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma|Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma||Sun Yat-sen University|Yes|Recruiting|July 2012|August 2022|Anticipated|August 2021|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|290|||Both|18 Years|60 Years|No|||December 2015|December 10, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01649830||82083|
NCT01650649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USWM-LX1-1005-2|Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects||US WorldMeds LLC|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|60 Years|No|||January 2013|January 15, 2013|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650649||82020|
NCT01650909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Redox Sub-study of PKU-016|The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU|The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical Phenylketonuria||Stanford University||Withdrawn|July 2012|||||Phase 3|Observational|Time Perspective: Prospective||1|Actual|0|Samples With DNA|Blood and urine will be collected to anaylze redox biomarkers|Both|8 Years|N/A|No|Probability Sample|Children 8+ and adults, any gender or ethic background, diagnosed with classical        phenylketonuria and participating in PKU-016.|April 2014|April 21, 2014|July 24, 2012|Yes|Yes|Withdrawn due to no funding|No||https://clinicaltrials.gov/show/NCT01650909||82000|
NCT01650922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSBRN0004|Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples|Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples||Stanford University||Completed|September 2005|September 2008|Actual|September 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|4|Samples With DNA|the investigators will sample a single blood sample or buccal swab and if obtained at the      time of diagnosis, brain tumor biopsy.|Both|N/A|24 Years|No|Non-Probability Sample|Pediatric cancer patients diagnosed with brain tumors|July 2012|July 25, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650922||81999|
NCT01679171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHRC-2012-01|One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically Ventilated|One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically Ventilated|SENIOREA|University Hospital, Angers|Yes|Recruiting|September 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|75 Years|N/A|No|Non-Probability Sample|All patients aged 75 and over admitted in one of the participating ICU and requiring        mechanical ventilation will be recruited for this study|February 2013|February 28, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01679171||79857|
NCT01679509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LESS-A|Study of Laparoendoscopic Single Site Adnexal Surgery for Benign Ovarian and Tubal Disease|Prospective Randomized Comparison of Single-port and Three-port Laparoscopic Adnexal Surgery||Asan Medical Center|No|Recruiting|September 2012|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|330|||Female|20 Years|70 Years|No|||September 2012|September 3, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679509||79831|
NCT01679483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FloSeal-LND|Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer|THE ROLE OF FLOSEAL IN THE PREVENTION OF LYMPHOCELE AND LYMPHATIC ASCITES AFTER LYMPH NODE DISSECTION FOR GYNECOLOGIC CANCER: A RANDOMIZED CONTROLLED TRIAL||Asan Medical Center|No|Recruiting|September 2012|||July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|200|||Female|20 Years|N/A|No|||September 2012|September 3, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679483||79833|
NCT01679496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK 2011/1951|Fat Quality on Blood Lipids and Immune Response||NoMa|Oslo and Akershus University College of Applied Sciences|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|180|||Both|25 Years|70 Years|No|||February 2015|February 3, 2015|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01679496||79832|
NCT01679821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|538/2010-CEP|Prevalence of Signs and Symptoms of TMD in Patients Wearing Double Complete Dentures, RPD and in Dentistry Students.|Prevalence of Signs and Symptoms of Temporomandibular Disorders (TMD) in Patients Wearing Double Complete Dentures, Removable Partial Dentures and Dentistry Students at State University of West of Paraná - UNIOESTE||Universidade Estadual do Oeste do Paraná|Yes|Completed|December 2010|August 2011|Actual|March 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|210|None Retained|The sample consisted of 210 individuals, aged 19-90 years (average 44.5 years) of both      genders, divided into 3 groups:      Group 1 - seventy dental students of State University of West of Paraná - UNIOESTE; Group 2      - seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture      (partially edentulous); Group 3 - seventy patients with double complete dentures treated in      Center for Dental Specialties of Cascavel - PR.      Students in orthodontic treatment or with less than one year after the end of orthodontic      treatment were excluded from the research. Patients wearing a complete denture in one      maxillary and a removable partial denture in another maxillary, and patients wearing just      one complete denture were not included in the research.|Both|19 Years|90 Years|Accepts Healthy Volunteers|Probability Sample|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients        treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially        edentulous) and seventy patients with double complete dentures treated in Center for        Dental Specialties of Cascavel, Paraná, Brazil.|September 2012|September 5, 2012|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01679821||79807|
NCT01680094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLEAR0001|Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART|The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 From The Latent Reservoir (CLEAR) Study|CLEAR|University of Aarhus|Yes|Completed|September 2012|January 2014|Actual|September 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01680094||79786|
NCT01651676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI2011_843_0006|Estimation of the VQ11 Auto-questionnaire, to Follow Patients With Chronic Obstructive Pulmonary Disease|Evaluation of the VQ11 Auto-questionnaire of Quality of Life in Pneumology Investigation, During the Implementation of a Long-acting Bronchodilator Treatment of Patients With COPD.|EPIC|Centre Hospitalier Universitaire, Amiens|Yes|Recruiting|July 2012|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|250|||Both|18 Years|80 Years|No|||April 2013|April 22, 2013|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01651676||81941|
NCT01681758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AICU2012-007|An Assessment of Pulse Pressure Variation to Guide Fluid Therapy in Cardiac Surgery Patients|A Before-and-after Assessment of Pulse Pressure Variation Guided Fluid Therapy in Cardiac Surgery Patients Receiving Mandatory Mechanical Ventilation||Austin Health|No|Completed|January 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|104|||Both|18 Years|90 Years|No|||July 2013|July 9, 2013|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01681758||79658|
NCT01681771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORSS-221791|Internet Cognitive Behavioural Therapy to Patients With Heart Failure and Depression|Internet Cognitive Behavioural Therapy to Patients With Heart Failure and Depression A Randomised Controlled Study of Short and Long Term Effects on Depressive Symptoms||University Hospital, Linkoeping|No|Completed|February 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01681771||79657|
NCT01681485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCC(QEH)/HKBU/NSCLC2012|Survey on Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer|The Changing Pattern of Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer in Hong Kong: A Longitudinal Survey||Hong Kong Baptist University|Yes|Terminated|June 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|49|||Both|18 Years|N/A|No|Non-Probability Sample|All newly suspected or diagnosed NSCLC patients from Department of Cardiothoracic Surgery        who are going to have resection will be invited to participate in this study. Two        interviews will be provided: pre- and post-operations in In-patient and Out-patient        Departments of Cardiothoracic Surgery, respectively, for investigating the changing of TCM        syndromes of individual patients, and its correlation with quality of life. Patients who        are eligible for the study will be continuously followed for two years if their diagnoses        of NSCLC are confirmed by postoperative pathological evaluation.|July 2015|July 31, 2015|June 12, 2012||No|Inability to recruit adequate number of patients|No||https://clinicaltrials.gov/show/NCT01681485||79679|
NCT01644058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UDEM-EE-2012b|Immediate Loading Of Dental Implants: A Pilot Clinical Study|Immediate Loading Of Dental Implants In Mandible Full-Arch: A Pilot Clinical Study On Patients Satisfaction, Quality Of Life And Implant Success||Université de Montréal|Yes|Completed|June 2011|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|July 16, 2012||No||No|August 26, 2013|https://clinicaltrials.gov/show/NCT01644058||82477|Phase-I clinical trial with small sample size and a pre-post design with no control group.
NCT01652716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB118|Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes|A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus|DURATION-NEO-1|AstraZeneca|No|Completed|January 2013|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|377|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 26, 2012|Yes|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01652716||81861|
NCT01652989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U54CA153459|PILI at Work a 5-Year Controlled Intervention Trial: Testing DVD Versus Group Delivery of a Weight-Loss Maintenance Intervention in Native Hawaiian- Serving Worksites|5-Year Controlled Intervention Trial: Testing DVD Versus Group Delivery of a Weight-Loss Maintenance Intervention in Native Hawaiian- Serving Worksites|P@W|University of Hawaii|Yes|Completed|September 2010|May 2015|Actual|April 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||July 2012|November 30, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652989||81840|
NCT01653210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16272|Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes|Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes||University of Virginia|No|Completed|August 2012|September 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|15|Samples Without DNA|At each follow-up visit #3-13, blood will be taken to sample estradiol, progesterone,      luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone and      sex-hormone binding globulin (SHBG). At the end of study visit #14, a hemoglobin A1c will be      measured.|Female|18 Years|55 Years|No|Probability Sample|Fifteen premenopausal women with menstrual cycles, 18-55 years of age, who have been        diagnosed as type 1 diabetic for at least 2 years. Actively using a current insulin pump        for the past 6 months with pre-defined parameters for glucose goal, carbohydrate ratio,        and insulin sensitivity factor. Use of medication or intervention that significantly        alters the menstrual cycle such as oral contraceptives, depoprovera, or intrauterine        device (IUD)is prohibited.|December 2013|December 10, 2013|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653210||81823|
NCT01678053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-090H|Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas|A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma||Massachusetts Eye and Ear Infirmary|Yes|Recruiting|September 2012|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2012|September 11, 2012|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678053||79942|
NCT01678625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EH12-158|Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade|Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade||NorthShore University HealthSystem Research Institute|No|Terminated|June 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|18 Years|80 Years|No|Non-Probability Sample|Patients presenting for elective surgical procedures under general anesthesia with an        expected duration greater than 60 minutes will be enrolled in this study.|March 2015|March 11, 2015|August 28, 2012||No|Company making the device no longer in existence. Did not finish supplying data to research    team|No||https://clinicaltrials.gov/show/NCT01678625||79898|
NCT01678599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSF/DNDi-CD-PCR-01|Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease|Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia|PCR|Drugs for Neglected Diseases|No|Active, not recruiting|April 2011|April 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|220|||Both|18 Years|60 Years|No|||August 2012|August 30, 2012|March 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01678599||79900|
NCT01678612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODEHRdR|Efficacy of Copper in Reducing Health-Acquired Infections in a Pediatric Intensive Care Unit|Efficacy of Copper in Reducing Health-Acquired Infections and Microbial Burden as Measured on High Touch Surfaces in a Pediatric Intensive Care Unit. A Controlled Clinical Trial.||Codelco|No|Completed|November 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1012|||Both|N/A|180 Months|No|||April 2014|April 9, 2014|August 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01678612||79899|
NCT01650389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1100570/1|Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination|Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV Infected Mothers|MVA(TB)029|University of Cape Town|Yes|Completed|October 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|248|||Both|N/A|96 Hours|No|||September 2015|September 29, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01650389||82040|
NCT01650402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-155S-2|Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People|Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People||University of Connecticut Health Center|Yes|Recruiting|December 2011|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|75 Years|N/A|No|||December 2013|December 9, 2013|December 14, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650402||82039|
NCT01679184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XM-One|XM-One Study for Living Donor Program|XM-One Study for Living Donor Program||University of Miami|No|Terminated|June 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|Samples Without DNA|A total of 6 teaspoons of blood will be drawn.|Both|18 Years|75 Years|No|Probability Sample|Living donor kidney transplant recipients|November 2015|November 10, 2015|August 31, 2012||No|Lack of staff to enroll patients in this study|No||https://clinicaltrials.gov/show/NCT01679184||79856|
NCT01679535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOMEDI-12-049|A Nutrition/Hygiene Education Program for the Prevention of Child Malnutrition in Rural Kenya|A Nutrition/Hygiene Education Program for the Prevention of Child Malnutrition in Rural Kenya||University of New Mexico|No|Completed|November 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|246|||Both|1 Month|6 Months|Accepts Healthy Volunteers|||February 2015|February 4, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01679535||79829|
NCT01679522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LESS-E|Feasibility Study of Laparoendoscopic Single Site Surgical Staging for Endometrial Cancer|Prospective Randomized Comparison of Single-port and Four-port Laparoscopic Staging Operation for Endometrial Cancer|LESS-E|Asan Medical Center|No|Recruiting|September 2012|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|108|||Female|20 Years|N/A|No|||September 2012|September 8, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679522||79830|
NCT01680133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-3-037|Regulation of Tissue Lipolysis by Insulin in Type 2 Diabetes|Regulation of Lipolysis by Insulin in Skeletal Muscle and Adipose Tissue in Type 2 Diabetes||Maastricht University Medical Center||Completed|June 2007|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|Samples With DNA|adipose tissue and skeletal muscle biopsies|Male|45 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|Healthy normoglycemic men and type 2 diabetic men|October 2012|October 11, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01680133||79783|
NCT01679834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25724|An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C|A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers||Hoffmann-La Roche||Recruiting|November 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|7500|||Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C infection|March 2016|March 1, 2016|September 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01679834||79806|
NCT01679847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSZL201001|Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.|||Dalian Holley Kingkong Pharmaceutical Co., Ltd|Yes|Not yet recruiting|September 2012|June 2013|Anticipated|April 2013|Anticipated|Phase 1|Observational|Observational Model: Case-Only||1|Anticipated|8|Samples Without DNA|Plasma and Cerebrospinal fluid|Both|N/A|N/A|No|Non-Probability Sample|malignant patients|September 2012|September 7, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679847||79805|
NCT01680120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CUH07/03/2012|Dose Finding Study for Continuous Spinal Anaesthesia|Determination of the Minimum Local Anaesthetic Needed for Operative Fixation of Fractured Neck of Femur With Continuous Spinal Anaesthesia||Cork University Hospital|No|Not yet recruiting|September 2012|December 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|60 Years|N/A|No|||September 2012|September 2, 2012|March 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680120||79784|
NCT01680861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110126|Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium|Randomized, Open-Label Trial of Tacrolimus/Everolimus vs. Tacrolimus/Enteric-Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection and Chronic Allograft Injury in Adult, Primary Kidney Transplantation||University of Miami|Yes|Completed|November 2012|December 2014|Actual|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|18 Years|75 Years|No|||January 2015|January 22, 2015|March 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680861||79727|
NCT01680874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0462|Probiotics for Clostridium Difficile Infection in Older Adults|A Pilot Study to Examine the Role of Probiotics for Improving Outcomes of C. Difficile|PICO|University of Wisconsin, Madison|Yes|Completed|February 2013|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680874||79726|
NCT01680328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4011|Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations|Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations||Novo Nordisk A/S|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Actual|82|||Both|18 Years|74 Years|No|||July 2014|July 15, 2014|August 31, 2012||No||No|December 6, 2013|https://clinicaltrials.gov/show/NCT01680328||79768|
NCT01682031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 107807|Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy|Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck||Roswell Park Cancer Institute|Yes|Terminated|June 2009|June 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|18|||Both|18 Years|N/A|No|||August 2014|August 8, 2014|September 5, 2012|Yes|Yes|Due to a lack of funding|No|June 26, 2014|https://clinicaltrials.gov/show/NCT01682031||79637|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.
NCT01644071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTC-A_12-023|Serotonergic System and Violent Video Games|Genetic-pharmacological Neuroimaging of the Serotonergic System in Violent Video Games|Serogen|RWTH Aachen University|No|Completed|February 2012|June 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|1||Actual|47|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||September 2015|September 28, 2015|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01644071||82476|
NCT01681706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIDES|HIV Indicator Diseases Across Europe Study|HIV Indicator Diseases Across Europe Study|HIDES|University of Copenhagen|No|Recruiting|February 2012|June 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|14000|||Both|18 Years|64 Years|No|Probability Sample|Participants between the age of 18 and 64 years old, presenting with 1 of the 11 indicator        diseases surveyed|September 2012|September 5, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01681706||79662|
NCT01682005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116829|Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination|Clinical and Cost Impact of Complete and Incomplete Rotavirus Vaccination||GlaxoSmithKline||Completed|August 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||7|Actual|1|||Both|N/A|5 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children less than 5 years old continuously enrolled in commercial insurance or Medicaid        from birth, and received both medical and pharmacy benefits.|August 2014|August 28, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682005||79639|
NCT01682265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRD 11/6-Q|Stretta In Reflux Uncontrolled by IPP|Stretta In Reflux Uncontrolled by Intake of Inhibitors of Protons Pump (IPP).- The SIRUP Trial- Multicentric, Randomized, Double Blind, Prospective Study|SIRUP|Nantes University Hospital|Yes|Recruiting|March 2012|December 2018|Anticipated|June 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682265||79619|
NCT01678365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|043-07-EMC|Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children|Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children||HaEmek Medical Center, Israel|Yes|Completed|July 2008|October 2009|Actual|October 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|1 Year|14 Years|No|||September 2012|September 3, 2012|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01678365||79918|
NCT01678742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-06-007-002|Effects of Jeju Red Horsehead Fish-based, High Protein Diet on Satiety and Incretin Hormones in Diabetes Patients|Effects of Jeju Red Horsehead Fish-based, High Protein Diet on Satiety and Incretin Hormones in Diabetes Patients||Jeju National University Hospital|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|20 Years|79 Years|No|||March 2015|March 31, 2015|August 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01678742||79889|
NCT01679262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2007-0407|Determination of the Optimal Size of Oropharyngeal Airway; Correlation With External Body Measurements|||Yonsei University|No|Completed|May 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|149|||Both|20 Years|70 Years|No|||August 2012|August 31, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679262||79850|
NCT01679275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54683|Pre-operative Cerebral Oxygenation in Neonates With Congenital Heart Disease|Longitudinal Pre-operative Measurements of Cerebral Oxygenation Using Near Infrared Spectroscopy in Neonates With Congenital Heart Disease.|CHD-NIRS|Universitaire Ziekenhuizen Leuven|No|Recruiting|October 2012|December 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|75|||Both|N/A|1 Month|No|||December 2015|December 7, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679275||79849|
NCT01678963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR-002|Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)|Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.||Ohr Pharmaceutical Inc.|No|Completed|November 2012|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|142|||Both|50 Years|N/A|No|||June 2015|June 11, 2015|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678963||79873|
NCT01650662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYCLE (IRFMN_5635)|CYCLosporinE A in Reperfused Acute Myocardial Infarction|CYCLosporinE A in Reperfused Acute Myocardial Infarction Prospective, Controlled, Randomized, Multicentre Trial to Examine Whether a Single i.v. Bolus of Cyclosporine A Before PCI Can Reduce Myocardial Reperfusion Injury in Patients With STEMI.|CYCLE|Mario Negri Institute for Pharmacological Research|Yes|Completed|January 2012|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|410|||Both|18 Years|N/A|No|||October 2013|April 15, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650662||82019|
NCT01679548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LESS-H|Study of Laparoendoscopic Single Site Hysterectomy in Benign and Preinvasive Uterine Disease|Prospective Randomized Comparison of Single-port and Three-port Laparoscopic Assisted Vaginal Hysterectomy||Asan Medical Center|No|Recruiting|September 2012|||July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|424|||Female|20 Years|70 Years|No|||September 2012|September 10, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679548||79828|
NCT01680354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUH_ASTIGMATISM|Surgical Correction of Astigmatism|Comparative Study of Surgical Laser Correction of Astigmatism||Aarhus University Hospital|No|Withdrawn|September 2012|||September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|20 Years|50 Years|No|||April 2014|April 30, 2014|September 4, 2012||No|Institution changed surgical method to small incision lenticule extraction. Study never    started.|No||https://clinicaltrials.gov/show/NCT01680354||79766|
NCT01680601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12KH253|Remote Ischaemic Preconditioning in Children Undergoing Cardiac Surgery|Effect of Remote Ischaemic Preconditioning in Cardiac Dysfunction and End-organ Injury Following Cardiac Surgery With Cardiopulmonary Bypass in Children.||NHS Greater Glasgow and Clyde|No|Completed|January 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|51|||Both|N/A|16 Years|No|||April 2015|April 17, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01680601||79747|
NCT01678664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFCD 1104|Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors|Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors|EVACEL|Federation Francophone de Cancerologie Digestive|Yes|Recruiting|October 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|72|||Both|18 Years|N/A|No|||January 2013|January 2, 2013|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01678664||79895|
NCT01678677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116647|A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers||GlaxoSmithKline||Completed|August 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|10||Actual|272|||Both|50 Years|70 Years|Accepts Healthy Volunteers|||June 2014|August 28, 2014|August 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678677||79894|
NCT01679574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pcolcm|Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome|Letrozole Versus Clomiphene Citrate Plus Metformin in the First Treatment of Infertility in Patients With Polycystic Ovarian Syndrome|PCO|Assiut University|No|Completed|January 2009|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Female|18 Years|35 Years|No|||September 2012|September 6, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679574||79826|
NCT01679587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16370|Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)|Multicenter, Randomized, Single-blind, Placebo-controlled, Combined 2-fold Cross-over and Group-comparison, Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses of BAY85 3934 in Subjects With Chronic Kidney Disease (CKD)||Bayer|No|Completed|September 2012|July 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|4||Actual|48|||Both|18 Years|79 Years|No|||April 2015|April 2, 2015|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679587||79825|
NCT01680380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00008533|Tracking Breathing During Sleep With Non-contact Sensors|Tracking Breathing During Sleep With Non-contact Sensors||Oregon Health and Science University|No|Recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|21 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the PI's department (OHSU faculty, Ph.D. students) by        email and the investigators' personal acquaintances. Participants must be age 21-100 and        have no self-reported sleep breathing problems.|October 2015|October 22, 2015|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680380||79764|
NCT01680575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEPACA-OVCA|Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer|Development of a Risk Model Predicting Chemotherapy-induced Grade 3-4 Neutropenia by Paclitaxel/Carboplatin in Epithelial Ovarian Cancer: Prospective Observational Study for Model Development and Retrospective Study for Validation of Developed Model||Asan Medical Center|No|Recruiting|September 2012|||July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|750|||Female|20 Years|80 Years|No|Probability Sample|Training cohort (prospective cohort): Patients with epithelial ovarian cancer who        underwent staging operation or debulking surgery at university hospital and who are        planned to receive adjuvant chemotherapy with paclitaxel and carboplatin.        Validation cohort (retrospective cohort): Patients with epithelial ovarian cancer who        received adjuvant chemotherapy with paclitaxel and carboplatin after staging operation or        debulking operation.|September 2012|September 8, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680575||79749|
NCT01680588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAV4-01|Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease|A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers||Navidea Biopharmaceuticals|No|Active, not recruiting|August 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|70|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||November 2013|November 26, 2013|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680588||79748|
NCT01677832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201201062RIB|Executive Functions and Self-Regulation Among Children With and Without ADHD in Germany and Taiwan|Neuronal Correlates of Executive Functions and Self-Regulation Among Children and Adolescents With and Without ADHD in Germany and Taiwan||National Taiwan University Hospital|Yes|Recruiting|January 2012|December 2014|Anticipated|||N/A|Observational|N/A||4|Anticipated|180|||Both|10 Years|14 Years|No|Non-Probability Sample|Participants will be recruited respectively in Germany and Taiwan using the same        standardized procedures according to the protocol. Children and adolescents with and        without ADHD between the ages 10 to 14, with an IQ full score ≥ 80, will participate in        this study. Participants with ADHD have to meet the criteria of ICD-10 (WHO, 1991) before        enrolment. They are diagnosed with ADHD combined subtype and have no comorbid disorders.        None of the controls are clinically diagnosed with any disorders and take any medication.        Both samples should be matched according to the variables: gender, IQ, and socio-economic        status (SES).|August 2012|August 30, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677832||79959|
NCT01678131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7009-048|Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)|A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-7009 in Chronic Hepatitis C Patients||Merck Sharp & Dohme Corp.|No|Completed|October 2012|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|31|||Both|18 Years|65 Years|No|||December 2015|December 22, 2015|August 30, 2012|No|Yes||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01678131||79936|
NCT01678703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2trimabort.CTIL|Comparison of Laminaria and Misoprostol for Cervical Preparation Before Second Trimester Surgical Abortion|Randomized Controlled Study: Comparison of Laminaria and Misoprostol for Cervical Preparation Before Second Trimester Surgical Abortion||Wolfson Medical Center|Yes|Completed|November 2007|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|15 Years|45 Years|No|||July 2012|August 30, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01678703||79892|
NCT01678716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AED ARTS/IFPRI-S-01|Impact of Behavior Change Communications and Market-based Approach to Delivering Micronutrient Powders on Stunting, Infant Feeding Practices and Anemia in Bangladesh|1) Impact Evaluation of Behavior Change Communication and Micronutrient Supplementation Interventions on Infant and Young Child Feeding (IYCF) Practices and on Childhood Stunting and Anaemia 2) Evaluation of the Public Health Impact of a Market-based Approach to Improving Diet Quality of Infants and Young Children Through the Use of Sprinkles in Bangladesh||International Food Policy Research Institute|No|Completed|April 2010|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|8800|||Both|N/A|60 Months|Accepts Healthy Volunteers|||February 2016|February 29, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01678716||79891|
NCT01644084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2009-0061|A Comparison Between 5% Albumin and 6% Hydroxyethyl Starch 130/0.4 in Priming Solution for Cardiopulmonary Bypass and Post-bypass Maintenance Fluid in High-risk Patients|||Yonsei University|No|Completed|June 2009|April 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|54|||Both|20 Years|80 Years|No|||July 2012|July 18, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01644084||82475|
NCT01682018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMC126908|The Value of Bronchoscopic Lung Volume Reduction by Endobronchial Valves in Patients With Single Lung Transplantation and Overinflation of the Native Lung|Clinical Trial to Evaluate the Value of Bronchoscopic Lung Volume Reduction by Endobronchial Valves in Patients With Single Lung Transplantation and Overinflation of the Native Lung||Rabin Medical Center|No|Not yet recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|65 Years|No|||July 2012|September 7, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682018||79638|
NCT01682278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REK2012/331|Prospective Cohort Study of Health Complaints|Amalgam Removal in Patients With Health Complaints Attributed to Amalgam Restorations: A Prospective Cohort Study||Uni Research|Yes|Recruiting|September 2012|June 2021|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|305|Samples Without DNA|Serum|Both|20 Years|70 Years|No|Non-Probability Sample|The study population will be selected from primary care clinics and dental clinics in        Norway.|August 2015|August 12, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682278||79618|
NCT01682291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|450-B/2012/D|Prehypertension and Dietary Supplements - The PYRAMIDS Study|Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications|PYRAMIDS|University of Roma La Sapienza|Yes|Not yet recruiting|January 2014|December 2017|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|500|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682291||79617|
NCT01678066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001561|A Prospective Study to Bilaterally Compare a Non-Invasive Cardiac Output Monitor|A Prospective Study to Bilaterally Compare a New FDA-Approved Non-Invasive Cardiac Output Monitor in Children Undergoing General Anesthesia||Massachusetts General Hospital|No|Not yet recruiting|September 2012|February 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|1 Month|8 Years|No|Non-Probability Sample|Pediatric patients who will undergo general anesthesia in the operating room from age 1        month old to 8 years old with all types of medical conditions who are having lower        abdominal and lower extremity surgery in this study so that the additional 8 EKG leads        placed on the patients do not interfere with the surgical site or patient positioning.|August 2012|August 31, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678066||79941|
NCT01678755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-608|A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers||AbbVie|Yes|Completed|August 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|157|||Both|20 Years|55 Years|No|||March 2015|March 4, 2015|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678755||79888|
NCT01678781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-678|Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide|Open International Study on Quality of Life in IBS Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide||Abbott|No|Completed|July 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|607|||Both|18 Years|N/A|No|Non-Probability Sample|Primary care clinic, community sample|September 2013|September 6, 2013|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01678781||79887|
NCT01678976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-104|Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers|Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|March 2002|April 2002|Actual|April 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 19, 2014|August 31, 2012||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01678976||79872|
NCT01678989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4946498|Evaluation of Brain MRI and Clinical Characteristics of Adolescents With Bipolar Disorder and Children of Parents With Bipolar Disorder|||Turkish Psychiatry Association|No|Recruiting|July 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||3|Anticipated|60|||Both|12 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|In this study, the cranial MRI findings and clinical features in adolescents with bipolar        disorder and the same age and sex matched children who have parents with BD and healthy        controls were investigated.|August 2012|September 4, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678989||79871|
NCT01679210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIH 2R01DK064902-06A1|Study of a Postpartum Diabetes Prevention Program for Hispanic Women|Estudio PARTO: Proyecto pAra Reducir Diabetes Tipo dOs / Project Aiming to Reduce Type twO Diabetes||University of Massachusetts, Amherst|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 15, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01679210||79854|
NCT01679223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081512|Incorporation of AlloMaxTM in Breast Reconstruction Ver8-15-12|Objective Evaluation of Collagen Deposition in AlloMaxTM Acellular Dermal Matrix in Breast Reconstruction Version 8-15-12||University of Nevada, Las Vegas|No|Recruiting|February 2014|November 2018|Anticipated|November 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||3|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients (18 - 70 yrs) scheduled for immediate two stage breast reconstruction with        AlloMaxTM are potential subjects for this study|January 2015|January 8, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679223||79853|
NCT01678950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAM2012|MostCare Versus Echo-Doppler for Cardiac Output Measurement|Comparison Between MostCare and Echo-Doppler for Cardiac Output Measurement: an Observational Study|PRAM|Azienda Ospedaliera Universitaria Senese|Yes|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|400|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in Intensive Care Unit, under different clinical conditions|June 2014|June 24, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678950||79874|
NCT01681199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AZYY-XNK-2012001|Fluvastatin AmelIorates aTHerosclerosis Study|The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease|FAITH|Beijing Anzhen Hospital|No|Recruiting|July 2012|August 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|45 Years|70 Years|No|||September 2012|September 5, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681199||79701|
NCT01682044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 83106|Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma|Phase II Clinical Trial of Rituximab in Combination With Pegfilgrastim in Patients With Indolent B-Cell (CD-20-Positive) Lymphoma||Roswell Park Cancer Institute|Yes|Active, not recruiting|April 2007|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|19 Years|N/A|No|||November 2015|November 20, 2015|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682044||79636|
NCT01678690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HR-11-001|An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors|An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors||InnoPharmax Inc.|No|Completed|August 2012|April 2014|Actual|April 2014|Actual|Phase 0|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|18 Years|N/A|No|||May 2014|May 19, 2014|August 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678690||79893|
NCT01679236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2006-0279|Pilot Study on Mindfulness for Tobacco and Alcohol in University Students|Pilot Study on Mindfulness for Tobacco and Alcohol in University Students||University of Wisconsin, Madison|Yes|Completed|September 2006|September 2009|Actual|September 2007|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|55|||Both|18 Years|29 Years|No|||May 2014|May 19, 2014|August 31, 2012||No||No|May 19, 2014|https://clinicaltrials.gov/show/NCT01679236||79852|Participants were not blinded to their respective treatment conditions.Attrition reduced power and generalizability.
NCT01680159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-650-24|A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis|||Mitsubishi Tanabe Pharma Corporation|No|Completed|July 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|51|||Both|16 Years|75 Years|No|||April 2015|April 9, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01680159||79781|
NCT01680900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|816164|Vilazodone for Menopausal Hot Flashes|Vilazodone for Menopausal Hot Flashes: A Proof in Principle Study||University of Pennsylvania|No|Completed|November 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Female|45 Years|60 Years|No|||December 2014|January 13, 2015|August 28, 2012|Yes|Yes||No|December 4, 2014|https://clinicaltrials.gov/show/NCT01680900||79724|
NCT01681186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14893|A Study of LY2940680 in Healthy Participants|A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects||Eli Lilly and Company|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|6||Anticipated|38|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 11, 2013|September 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681186||79702|
NCT01681498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-010|Fetal Electrocardiogram Extraction-Pilot Study|Fetal Electrocardiogram Extraction-Pilot Study||Huntleigh Healthcare Ltd|No|Terminated|May 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Female|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Prenatal care clinic|September 2014|September 1, 2014|August 30, 2012||No|Indeterminate performance during the first half of the trial.|No||https://clinicaltrials.gov/show/NCT01681498||79678|
NCT01681212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-202|Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma|Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Previously Untreated Unresectable or Metastatic Melanoma||Bristol-Myers Squibb|No|Completed|October 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|20 Years|N/A|No|||June 2015|June 9, 2015|September 5, 2012|Yes|Yes||No|May 22, 2015|https://clinicaltrials.gov/show/NCT01681212||79700|This study was discontinued due to severe liver toxicity.
NCT01678417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FL or MCL 131I-rituximab RIT|131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma|A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Follicular or Mantle Cell Lymphoma||Korea Cancer Center Hospital|No|Recruiting|June 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|29|||Both|20 Years|N/A|No|||August 2012|September 4, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678417||79914|
NCT01679249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01249|Blood Volume Analysis and Related Outcomes in Hemodialysis|Blood Volume Analysis and Related Outcomes in Hemodialysis||VA New York Harbor Healthcare System|No|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|21 Years|N/A|No|Non-Probability Sample|Subjects will be recruited from the pool of patients at the Dialysis Center at the        Department of Veteran Affairs New York Harbor Healthcare System who are currently        undergoing dialysis for treatment of chronic kidney disease.|September 2012|September 6, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679249||79851|
NCT01644097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0084|Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy|A Phase II Feasibility and Correlative Study of Probiotic Supplementation in Cancer Patients Receiving Chemotherapy or Tyrosine Kinase Inhibitors (TKIs)||Stanford University|Yes|Withdrawn|November 2012|||September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|July 12, 2012||No|issues with obtaining study product|No||https://clinicaltrials.gov/show/NCT01644097||82474|
NCT01678079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000033463|Encapsulated Calcium Absorption in Pregnancy|Bioavailability and Acceptability of Enteric-Coated Microencapsulated Calcium During Pregnancy: A Randomized Crossover Trial in Bangladesh (Encapsulated Calcium Absorption in Pregnancy)|ENCAP|The Hospital for Sick Children|No|Completed|February 2013|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|61|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||November 2014|November 17, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678079||79940|
NCT01678092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|011394|Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis|Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis|OXAD|Stanford University|Yes|Completed|May 2004|December 2006|Actual|December 2006|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|8|||Both|4 Years|25 Years|No|||November 2015|November 24, 2015|August 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678092||79939|
NCT01680172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001156|Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer|Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer||Mayo Clinic|No|Terminated|August 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 29, 2016|September 4, 2012||No|Slow enrollment|No|January 29, 2016|https://clinicaltrials.gov/show/NCT01680172||79780|The study was terminated due to slow accrual rate. Data analysis limited to 5 participants.
NCT01681810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11030131|Oral Nitrite in Adults With Metabolic Syndrome and Hypertension|An Open-Label Study of Oral Nitrite in Adults With Metabolic Syndrome and Hypertension|ONTX|University of Pittsburgh|No|Recruiting|October 2012|||June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|60 Years|No|||February 2016|February 18, 2016|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681810||79654|
NCT01679041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20112015|High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment|A Phase II Study of High Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Transplant for Multiple Sclerosis That Failed at Least Two Lines of Therapy||Texas Oncology Cancer Center|Yes|Terminated|November 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|60 Years|No|||November 2013|November 21, 2013|August 29, 2012|No|Yes|Insufficient accruals; PI leaving site|No||https://clinicaltrials.gov/show/NCT01679041||79867|
NCT01651767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100760|Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382|A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Caucasian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens||Janssen R&D Ireland|No|Terminated|August 2012|June 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|11|||Both|18 Years|70 Years|No|||May 2014|May 9, 2014|July 25, 2012||No|Because of many competing trials using the same mechanism of action, but being further    advanced in development|No||https://clinicaltrials.gov/show/NCT01651767||81934|
NCT01679197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCRU 2834|Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy|Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy||University of Michigan|No|Active, not recruiting|October 2012|||May 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|5 Years|N/A|No|||January 2016|January 8, 2016|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01679197||79855|
NCT01681784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200901031R|Studies of Biomarkers in Female Lower Urinary Tract Symptoms|Studies of Biomarkers in Different Urodynamic Diagnoses of Female Patients With Lower Urinary Tract Symptoms||National Taiwan University Hospital|Yes|Recruiting|January 2009|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Patients' voided urine|Female|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Female patients with lower urinary tract symptoms and underwent urodynamic studies|March 2009|September 7, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681784||79656|
NCT01678105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCOG-2012-DOVE|A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands|A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)|DOVE|Ontario Clinical Oncology Group (OCOG)|Yes|Completed|November 2012|September 2015|Actual|September 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|21|||Both|18 Years|N/A|No|||September 2015|September 16, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01678105||79938|
NCT01678404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZL 131I-rituximab RIT|131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma|A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma||Korea Cancer Center Hospital|No|Recruiting|October 2011|September 2016|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|20 Years|N/A|No|||August 2012|September 4, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01678404||79915|
NCT01679886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 11066|Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women|Comparison of the Diagnostic Performances of 82Rubidium Positron Emission Tomography and Conventional Scintigraphy With CZT Cameras for Detection of Myocardial Ischemia in a Population of Overweighed Patients and Women|RUBIS|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|September 2012|March 2017|Anticipated|December 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|313|||Both|18 Years|N/A|No|||February 2016|February 15, 2016|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679886||79802|
NCT01652807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-028-DEBL|Yoga for Stress and Mental Health|An 8-Week Hatha Yoga Intervention for Stress and Mental Health||Southern Methodist University|No|Completed|February 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|52|||Female|25 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 12, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652807||81854|
NCT01680627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-8442|The Effect of Computerized Alcohol Screening and Brief Intervention (CASI) on Alcohol Consumption in Adolescent Patients in the Emergency Department||CASI|University of California, Irvine||Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|12 Years|17 Years||Non-Probability Sample|EMERGENCY DEPARTMENT|September 2012|September 6, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680627||79745|
NCT01681797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC/11/13|Fluorescence Angiography: Planning and Monitoring of Perforator Flaps|Fluorescence Angiography With Fluobeam™ Camera (Fluoptics Company): Planning and Monitoring of Perforator Flaps|AFLU|University Hospital, Grenoble|Yes|Recruiting|August 2012|July 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|40|||Both|18 Years|N/A|No|||November 2015|December 1, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01681797||79655|
NCT01682057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-01|A Multicenter Study to Evaluate the ROX Anastomotic Coupler System (ACS) In Patients With Severe Hypertension|A Prospective, Non-Randomized, Open Label, Multi-Center Study to Evaluate the ROX Anastomotic Coupler System (ACS) in Patients With Severe Hypertension||ROX Medical, Inc.|No|Completed|October 2011|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|85 Years|No|||January 2015|January 27, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682057||79635|
NCT01682070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP/0036|SUBLIVAC FIX Phleum Pratense DT/DRF|A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Phleum Pratense in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Grass Pollen||HAL Allergy|Yes|Completed|September 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|266|||Both|18 Years|60 Years|No|||May 2013|May 28, 2013|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682070||79634|
NCT01681225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P-000242|EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures|EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures (EPVent2)|EPVent2|Beth Israel Deaconess Medical Center|Yes|Recruiting|September 2012|September 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|16 Years|N/A|No|||December 2015|December 24, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681225||79699|
NCT01681524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMS747158-302|Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI|A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)||Lantheus Medical Imaging|Yes|Withdrawn|November 2012|May 2014|Anticipated|February 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|N/A|No|||April 2013|May 29, 2013|August 28, 2012|Yes|Yes|delayed study start|No||https://clinicaltrials.gov/show/NCT01681524||79676|
NCT01678144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-040|Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation|Evaluation of the Safety and Performance of the Medtentia Mitral Valve Repair System When Used in Adults Undergoing Mitral Valve Repair Surgery||Medtentia International Ltd Oy|Yes|Recruiting|June 2011|November 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|230|||Both|18 Years|85 Years|No|||July 2014|July 3, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678144||79935|
NCT01679028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T89-10-JP|Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese|Single- and Multiple- Dose-Escalation Study to Investigate the Safety and Tolerability of T89 in Japanese Healthy Volunteers||Tasly Pharmaceuticals, Inc.|No|Completed|August 2012|February 2013|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|6||Actual|20|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 16, 2014|August 24, 2012|Yes|Yes||No|May 6, 2014|https://clinicaltrials.gov/show/NCT01679028||79868|
NCT01649947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031105|Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II|Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)||Rutgers, The State University of New Jersey|No|Recruiting|December 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 10, 2015|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01649947||82074|
NCT01680393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BBH290511BRAINshoulderscd|Sequential Compression Device (SCD) for Stabilizing Hemodynamics in the Beach Chair Position|Stabilizing Cerebral and Circulatory Hemodynamics During Shoulder Surgery in the Beach Chair Position Using Sequential Compression Device (SCD) or TED Stockings Compared to a Control Group||Bispebjerg Hospital|No|Recruiting|May 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|3||Anticipated|60|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|February 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01680393||79763|
NCT01680913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U/S spinals|Does Ultrasound Guidance Improve Time to Perform a Spinal or Number of Attempts in Obese Patients?|Does Ultrasound Guidance Improve Time to Perform a Spinal or Number of Attempts in Obese Patients? A Randomized Controlled Study.||University of Saskatchewan|No|Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|67|||Both|18 Years|85 Years|No|||February 2013|December 1, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01680913||79723|
NCT01634490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|013908|Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy|||Federico II University|No|Completed|October 2008|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|300|||Both|1 Month|12 Months|No|Probability Sample|We prospectively evaluated otherwise healthy infants (1-12 months of age at the diagnosis)        visit one the Pediatric Gastroenterology and Allergology Centre because of the necessity        of a diagnostic oral food challenge for cow's milk proteins. Children were in stable        clinical condition without signs of CMA already on exclusion diet with an hypoallergenic        formula for a period of 7-15 days as presented by the general paediatrician, immediately        the symptoms appear and before being attended at the Center for diagnosis of CMA.|July 2012|July 5, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634490||83208|
NCT01679899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BoneGlyc|Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability|Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR|BoneGlyc|Centro de Diabetes Curitiba Ltda|No|Completed|December 2012|October 2015|Actual|October 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Female|40 Years|75 Years|No|||February 2016|February 9, 2016|September 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01679899||79801|
NCT01681537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-202|Lenalidomide Plus Chemotherapy for AML|A Phase I Study of Lenalidomide Plus Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients With Acute Myelogenous Leukemia||Massachusetts General Hospital|Yes|Completed|September 2012|December 2015|Actual|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|18 Years|70 Years|No|||March 2016|March 15, 2016|September 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681537||79675|
NCT01679626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-06|Airway Manoeuvers - Implications for Airway Management?|The Effect of Cricoid Pressure and Backward Upward Rightward Pressure on Airway Dimensions - Implications for Airway Management?||Catharina Ziekenhuis Eindhoven|Yes|Completed|June 2011|July 2011|Actual|July 2011|Actual|N/A|Observational|N/A||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|200 consecutive adult patients scheduled for elective surgery requiring endotracheal        intubation.|September 2012|September 6, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679626||79822|
NCT01678638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-225-01|Timing of Inguinal Hernia Repair in Premature Infants|Timing of Inguinal Hernia Repair in Premature Infants: A Randomized Trial||Vanderbilt University|Yes|Recruiting|June 2013|June 2018|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|N/A|37 Weeks|No|||May 2015|May 26, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678638||79897|
NCT01678651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAD-NB-08-2012-01|Embryo Kinetics and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH|Embryo Kinetcis From Embryos Deriving From Egg Donation Cycle With Different Stimulation Protocol: Recombinant FSH vs Human FSH||IVI Madrid|No|Terminated|August 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||March 2015|February 23, 2016|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678651||79896|
NCT01651546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11029|Intermittent Catheterization Acceptance Test|Development and Psychometric Validation of a Scale Assessing "the Acceptance" of Clean Intermittent Self Catheterization in a Neurological and no Neurological Population With Indication to Self Catheterization.|I-CAT|Assistance Publique - Hôpitaux de Paris|No|Completed|March 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|200|||Both|18 Years|N/A|No|||June 2015|June 12, 2015|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651546||81951|
NCT01679860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PTCL-062006-004234-33|Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma|Intensive Chemo-immunotherapy as First-line Treatment in Adult Patients With Peripheral T-cell Lymphoma (PTCL)|PTCL-06|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Yes|Completed|November 2006|August 2012|Actual|December 2011|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|60 Years|No|||September 2012|September 3, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01679860||79804|
NCT01679873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBV-001-HD|Abstract' Content and GPs' Confidence in the Conclusion|Impact of Reporting Funding Sources and Conflicts of Interest in RCTs' Abstracts on General Practitioners' Confidence: a 3-arms Randomized Controlled Trial.|ACOPI|Hotel Dieu Hospital|No|Completed|October 2012|January 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|3||Actual|354|||Both|N/A|N/A|No|||December 2013|December 20, 2013|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01679873||79803|
NCT01680146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC 12-3-030|Impact of Fat Co-ingestion With Protein on the Post-prandial Anabolic Response in Elderly Men|Impact of Fat Co-ingestion With Protein on the Post-prandial Anabolic Response in Elderly Men (Pro-Fat Study)|Pro-Fat|Maastricht University Medical Center|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|24|||Male|55 Years|85 Years|Accepts Healthy Volunteers|||November 2014|November 27, 2014|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680146||79782|
NCT01678118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-028|Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care|Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care||Memorial Sloan Kettering Cancer Center||Active, not recruiting|April 2011|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Participants will also be recruited from Heritage Health Center, located at 1727 Amsterdam        Ave, which serves a large proportion to low income, minority patients in Harlem, New York.        Also, from the Ralph Lauren Center for Cancer Care and Cancer Prevention (RLCCCP), a        community based Center for the prevention, diagnosis, and treatment of cancer located at        1919 Madison Avenue.|October 2015|October 9, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678118||79937|
NCT01679002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIA-2093-110|Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers|Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers||Bial - Portela C S.A.|No|Completed|October 2003|December 2003|Actual|December 2003|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||December 2014|December 31, 2014|August 31, 2012||No||No|November 28, 2014|https://clinicaltrials.gov/show/NCT01679002||79870|
NCT01679015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL-001|Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes|Concomitant Dry Eye in Patients With Ocular Allergy: an Under Recognized and Poorly Managed Syndrome||Schwartz Laser Eye Center|No|Active, not recruiting|August 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|250|||Both|18 Years|N/A|No|Probability Sample|Patients will be screened from existing patient database.|January 2013|January 4, 2013|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01679015||79869|
NCT01652820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GECP 00-08 / TAX.ES1.209|Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer|Randomized Phase II Trial Using Concomitant Chemoradiation Plus Induction or Consolidation Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer Patients|GECP0008|Spanish Lung Cancer Group|Yes|Completed|October 2001|December 2007|Actual|July 2006|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Both|18 Years|N/A|No|||July 2012|July 27, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01652820||81853|
NCT01653067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STORM-2011|STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma|A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial|STORM|University Hospital Heidelberg|Yes|Recruiting|September 2012|July 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|88|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653067||81834|
NCT01653314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DW_MGV001|Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers|A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Megavec 400 mg (Imatinib Mesylate) Under Fasted Conditions in Healthy Male Subjects||Daewoong Pharmaceutical Co. LTD.||Completed|January 2012|March 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|40|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01653314||81815|
NCT01649687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-VGH-201001|Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells|Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells||National Yang Ming University|Yes|Completed|May 2012|January 2014|Actual|January 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|20 Years|70 Years|No|||September 2014|September 11, 2014|April 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01649687||82094|
NCT01649700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SB-VGH-201101|Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells|Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells||National Yang Ming University|No|Completed|October 2011|May 2013|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|20 Years|40 Years|No|||September 2014|September 11, 2014|April 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01649700||82093|
NCT01649934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01634|The Use of Implementation Intentions to Increase the Appointment Attendance of OEF/OIF Veterans|The Use of Implementation Intentions to Increase the Appointment Attendance of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans||VA Connecticut Healthcare System|No|Recruiting|June 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|60|||Both|22 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 22, 2015|July 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01649934||82075|
NCT01650194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9785-CL-0011|A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients|A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (Formerly MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients||Astellas Pharma Inc|No|Active, not recruiting|July 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Male|N/A|N/A|No|||March 2016|March 11, 2016|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650194||82055|
NCT01650207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCH-110410|Acupuncture for Hemiplegic Shoulder Pain|||Changhua Christian Hospital||Completed|July 2011|June 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|60|||Both|18 Years|N/A|No|||July 2012|July 25, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01650207||82054|
NCT01649713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fluval AB-H-YL2012|Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season|Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 ugHA/Strain/0.5mL) in Adult and Elderly Subjects||Omninvest Vaccine Manufacturing, Researching and Trading Ltd.|No|Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 11, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649713||82092|
NCT01681238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZZD-025|Goal-directed Therapy in High-risk Surgery|A Randomized Study of Goal-directed Therapy in the Elderly High-risk Patients Undergoing Total Hip Replacement||Guangzhou First Municipal People’s Hospital|Yes|Active, not recruiting|September 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|70 Years|N/A|No|||September 2012|September 5, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681238||79698|
NCT01677845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-00867|Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer|Phase I Study of Hypo-Fractionated Radiation Therapy (HRT) for Localized Prostate Cancer||New York University School of Medicine|Yes|Recruiting|May 2012|July 2022|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Male|18 Years|N/A|No|||September 2015|September 11, 2015|August 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01677845||79958|
NCT01678430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OMB114578|A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment|A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL|RIAltO|University of Liverpool|Yes|Recruiting|December 2011|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|670|||Both|18 Years|N/A|No|||August 2012|October 12, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678430||79913|
NCT01678729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0049-12-ZIV|Does Pupil Size Matters in Refractive Surgery?|||Ziv Hospital||Active, not recruiting|January 2009|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|myopic patiens who did refractive surgery|August 2012|September 4, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678729||79890|
NCT01679561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILRIFRM|Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial|Phase 4 Study of the Efficacy of Intralipid Treatment in Patients With Recurrent Implantation Failure and Miscarriages With High Peripheral and Uterine Natural Killer Cells|ILRIFRM|Woman's Health University Hospital, Egypt|Yes|Recruiting|February 2012|December 2013|Anticipated|August 2012|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Anticipated|380|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|August 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01679561||79827|
NCT01651559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P7BH|The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients|A Double Blind Controlled Clinical Trial Comparing The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients Undergoing Phototherapy||Ahava Dead Sea Laboratories|No|Enrolling by invitation|November 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|70 Years|No|Non-Probability Sample|Volunteers aged 18-70 diagnosed with moderate to severe chronic stable plaque type        Psoriasis for at least 6 months and candidates for phototherapy treatment.|November 2012|November 14, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01651559||81950|
NCT01652066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00225-36|Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults|Effect of a Mixture of Probiotics ( Lactobacillus Gasseri PA16/8,Bifidobacterium Longum SP07/3, Bifidobacterium Bifidum MF 20/5) on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adult|PROBIMMUNE|Merck Medication Familiale|No|Completed|May 2011|December 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|430|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 25, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652066||81911|
NCT01680367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06043|Wound Dressings For Split-Thickness Skin Graft Donor Sites in Patients Undergoing Surgery|A Comparative Study of Dressings for Split-Thickness Skin Graft Donor Sites.||Ohio State University Comprehensive Cancer Center|Yes|Completed|November 2008|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|69|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680367||79765|
NCT01680614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-8155|The Efficacy of Computerized Alcohol Screening and Intervention (CASI) in At-Risk Emergency Department and Trauma Patients||CASI|University of California, Irvine||Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|18 Years|N/A||Probability Sample|Emergency Department|September 2012|September 6, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680614||79746|
NCT01680887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|814643|A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence|A Phase II, Randomized, Double-Blind Trial of Varenicline for the Treatment of Cocaine Dependence||University of Pennsylvania|Yes|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680887||79725|
NCT01652547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230X2404|A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma|A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma||Novartis|No|Completed|November 2012|April 2015|Actual|April 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 20, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01652547||81874|
NCT01652560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTDS-01|Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy|Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy|BIBC|Xijing Hospital|No|Recruiting|June 2012|September 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|75 Years|No|Non-Probability Sample|Breast cancer patients of vascular endocrine surgery department in Xijing Hospital|July 2012|July 25, 2012|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01652560||81873|
NCT01652833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101121|European Physician Survey of EGFR Inhibitor Prescribing Patterns|Survey of Oncologists in Europe to Evaluate Their Knowledge of KRAS Testing||Amgen|No|Completed|March 2012|November 2014|Actual|November 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||3|Actual|453|||Both|18 Years|N/A|No|Probability Sample|Physician's satisfying all of the eligibility criteria are eligible to be enrolled in the        survey|February 2016|February 29, 2016|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01652833||81852|
NCT01652846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHR9-Temp|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|July 2012|||||N/A|N/A|N/A||||||||||||||July 31, 2013|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652846||81851|
NCT01653080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-0361|MRI in Diagnosing Solid Tumors of the Eye and Orbit|Dynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit.||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|June 2004|||December 2020|Anticipated|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|N/A|No|||September 2014|September 25, 2014|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653080||81833|
NCT01653327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1022|Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer|Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer||Dartmouth-Hitchcock Medical Center|Yes|Recruiting|June 2010|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|10|||Both|18 Years|N/A|No|||February 2014|November 11, 2015|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653327||81814|
NCT01653340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE100112|A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine|A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine|rCM HF-SCS|University of Roma La Sapienza|No|Completed|May 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||February 2014|February 17, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01653340||81813|
NCT01649726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01390-41|Comparison of Two Strategies to Realize Apnea Test for the Diagnostic of Brain Death in Potential Organ Donors (CPAPNEE STUDY)|||Poitiers University Hospital||Recruiting||||December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2|||208|||Both|18 Years|70 Years|No|||March 2013|March 27, 2013|July 23, 2012||||No||https://clinicaltrials.gov/show/NCT01649726||82091|
NCT01649739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMCVAR1234|Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost|||Rabin Medical Center|Yes|Not yet recruiting|September 2012|January 2014|Anticipated|May 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|70 Years|No|||July 2012|July 24, 2012|July 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01649739||82090|
NCT01650246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDEA594-305|Open-Label Lesinurad Monotherapy Extension Study in Gout|A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout||Ardea Biosciences, Inc.|Yes|Completed|August 2012|August 2014|Actual|April 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|143|||Both|18 Years|85 Years|No|||March 2015|March 23, 2015|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650246||82051|
NCT01650259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1218.95|Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus|Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus||Boehringer Ingelheim||Active, not recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|3300|||Both|N/A|N/A|No|Non-Probability Sample|3300|January 2016|January 29, 2016|July 24, 2012||||No||https://clinicaltrials.gov/show/NCT01650259||82050|
NCT01634750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120207|Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)|A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)||National Institutes of Health Clinical Center (CC)||Completed|September 2012|May 2013|Actual|||Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|70 Years|No|||February 2016|March 8, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634750||83189|
NCT01634763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378X1101|Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)|A Phase I, Multicenter, Open-label Dose Escalation Study of LDK378, Administered Orally in Japanese Patients With Tumors Characterized by Genetic Alterations in ALK||Novartis||Completed|June 2012|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634763||83188|
NCT01634776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-0358|Behavioral, Genetic, and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans|Behavioral, Genetic, and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans.||University of North Carolina, Chapel Hill|No|Completed|February 2009|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|66|||Both|16 Months|16 Months|Accepts Healthy Volunteers|||March 2013|March 4, 2013|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634776||83187|
NCT01682083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115532|A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.|COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection|COMBI-AD|GlaxoSmithKline|Yes|Active, not recruiting|January 2013|July 2018|Anticipated|October 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|852|||Both|18 Years|N/A|No|||January 2016|February 4, 2016|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682083||79633|
NCT01678157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|314-11FB|Use of Strattice Mesh in Paraesophageal Hernia Surgery|Use of Strattice in the Laparoscopic Suture Closure of a Paraesophageal Hernia|Strattice|University of Nebraska|Yes|Completed|March 2012|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|19 Years|N/A|No|Non-Probability Sample|Adults over 19 years of age with paraesophageal hernia greater than 5 cm.|December 2015|December 3, 2015|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678157||79934|
NCT01678378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12020646|School Health Center Healthy Adolescent Relationship Program|School Health Center Healthy Adolescent Relationship Program|SHARP|University of Pittsburgh|Yes|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1012|||Both|14 Years|19 Years|No|||April 2015|April 24, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678378||79917|
NCT01678391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.065-1|Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy|Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy||California Pacific Medical Center Research Institute|No|Active, not recruiting|August 2012|March 2016|Anticipated|June 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01678391||79916|
NCT01669837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-IFA-06|An Efficiency/Safety Study of Surgical Tissue Glue to Treat Inguinal Hernias|Cyanoacrylate Fixation for Laparoscopic Repair of Inguinal Hernias: a Prospective, Multicenter Registry||be Medical|No|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a primary inguinal hernia|July 2015|July 15, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01669837||80572|
NCT01670409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUMC-ECA-001|Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer|A Phase II Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy in Patients With Esophageal Squamous Cell Carcinoma||Shantou University Medical College|No|Completed|August 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|85|||Both|18 Years|75 Years|No|||August 2015|August 27, 2015|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01670409||80528|
NCT01670110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-007405|Pasireotide LAR in Severe Polycystic Liver Disease|A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease|SOM230|Mayo Clinic|Yes|Recruiting|August 2012|December 2018|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|48|||Both|18 Years|N/A|No|||April 2015|April 6, 2015|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670110||80551|
NCT01670123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MH091260|Development of a Personalized Real-time Intervention for Bipolar Disorder|Development of a Personalized Real-time Intervention for Bipolar Disorder|PRISM|University of California, San Diego|No|Completed|July 2010|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|90|||Both|18 Years|N/A|No|||July 2014|July 24, 2014|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670123||80550|
NCT01670682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-gyn-03|Ischia Spinous Fascia Fixation Procedure Versus Modified Total Pelvic Floor Reconstructive Surgery for Pelvic Organ Prolapse Stage III|A Prospective，Multicenter Pilot Study to Compare Ischia Spinous Fascia Fixation Procedure With Modified Total Pelvic Floor Reconstruction Surgery For Pelvic Organ Prolapse Stage III||Peking Union Medical College Hospital|No|Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Female|55 Years|80 Years|No|||August 2012|August 18, 2012|February 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01670682||80507|
NCT01670695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IgG4RD-Cohort|Cohort Study of IgG4RD|Cohort Study of Patients With IgG4-Related Disease||Peking Union Medical College Hospital|Yes|Recruiting|August 2012|March 2014|Anticipated|January 2014|Anticipated|Phase 0|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|blood samples (serum and plasma, with DNA)|Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients with newly diagnosed IgG4-related disease.|August 2012|August 20, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01670695||80506|
NCT01671020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-115|Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects|Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects||Boryung Pharmaceutical Co., Ltd|Yes|Recruiting|June 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Anticipated|16|||Both|20 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671020||80481|
NCT01671644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AUX-005|Eeva™ Pregnancy Investigational Clinical Study: A Postmarket Follow-Up Study|Eeva™ Pregnancy Investigational Clinical Study: A Postmarket Follow-Up Study|EPIC|Progyny, Inc.|No|Completed|February 2013|October 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|104|||Female|N/A|N/A|No|Non-Probability Sample|Patients undergoing in vitro fertilization treatment who provide informed consent and plan        to undergo Day 3 embryo transfer.|October 2015|October 19, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671644||80434|
NCT01671618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202009791|Point-of-Care Focused Cardiac Ultrasound in Assessing the Thoracic Aorta|A Prospective Study on Point-of-Care Focused Cardiac Ultrasound in Assessing for Thoracic Aortic Dimensions, Dilation, and Aneurysm in Correlation With CT Angiogram in Suspected Cases of Pathology||Yale University|No|Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|210|||Both|18 Years|N/A|No|Probability Sample|Patients 18 years of age or older presenting to an urban, academic, and level I emergency        department with estimated volume of approximately 90,000 patients per year.|August 2012|August 20, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671618||80436|
NCT01671852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01653|Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy|A Randomized Controlled Trial of Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy|Nasonex OSA|Children's & Women's Health Centre of British Columbia|No|Withdrawn|May 2012|July 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|3 Years|16 Years|No|||July 2015|July 28, 2015|July 5, 2012||No|Could not obtain funding.|No||https://clinicaltrials.gov/show/NCT01671852||80418|
NCT01672112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/02076|Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain|Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain||Tan Tock Seng Hospital|Yes|Completed|July 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|21 Years|70 Years|No|||May 2015|May 13, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672112||80398|
NCT01672359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20090985|Evaluating Whole Foods Supplementation on Cognition|The Effect of Whole-Food Dietary Supplementation on Cognitive and Immune Functioning and Quality of Life in Healthy Older Adults||University of Miami|No|Completed|May 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|97|||Both|60 Years|N/A|Accepts Healthy Volunteers|||August 2014|August 4, 2014|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01672359||80379|
NCT01672619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|npa - 777 - 12|Nautilus: Dynamic Craniotomy; New Surgical Technique and Preliminary Results|Nautilus: Dynamic Craniotomy; New Surgical Technique and Preliminary Results|Nautilus|Nucleo de Plastica Avancada|Yes|Completed|June 2010|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|10|||Both|6 Months|13 Years|No|Probability Sample|children with craniosynostoses|June 2010|August 22, 2012|August 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01672619||80359|
NCT01672632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 26040|Fat Cell Size and Overfeeding and Etopic Study|Fat Cell Size and Overfeeding and Etopic Study|EAT|Pennington Biomedical Research Center|Yes|Active, not recruiting|May 2008|May 2016|Anticipated|February 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||November 2015|November 18, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01672632||80358|
NCT01679743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120199|GRN1005 for Brain Metastases From Breast or Lung Cancer|A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|99 Years|No|||August 2014|January 30, 2016|September 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01679743||79813|
NCT01680003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT11-03|Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy and Safety of HEPAR-P Capsule for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD)|Hepar-P|Nova Laboratories Sdn Bhd|No|Recruiting|September 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|80 Years|No|||April 2013|April 10, 2013|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01680003||79793|
NCT01680783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1391|Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure|Mechanical Ventilation in Patients With \Respiratory Failure: A Comparison of Face Mask and Non Invasive Ventilation Via a Helmet Device||University of Chicago|Yes|Recruiting|September 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|100 Years|No|||January 2016|January 4, 2016|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680783||79733|
NCT01681082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SE-2012-0539|Psychological Effects of Tai Chi Training|Psychological Effects of Tai Chi Training||University of Wisconsin, Madison||Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|161|||Both|18 Years|23 Years|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01681082||79710|
NCT01681095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIC# 2012-125|Custodiol-HTK Solution as a Cardioplegic Agent|Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial||William Beaumont Hospitals|Yes|Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|110|||Both|18 Years|N/A|No|||June 2014|June 24, 2014|August 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681095||79709|
NCT01681394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBMCS-CTNS-01|Effect of a Polyphenol-rich Cocoa Extract on Peripheral Blood Mononuclear Cells Gene Expression|Effect of the Administration of a Polyphenol-rich Cocoa Extract on Peripheral Blood Mononuclear Cells Gene Expression in Humans||Technological Centre of Nutrition and Health, Spain|No|Completed|June 2012|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|25|||Male|20 Years|35 Years|Accepts Healthy Volunteers|||July 2013|July 2, 2013|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681394||79686|
NCT01681966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNP-IL102|A Single-dose Open-Label Study to Assess the Safety and Preliminary Efficacy of PRF 110 in Open Herniorrhaphy Surgery|A Single-dose, Open-Label, Multi-center Study to Assess the Safety and Preliminary Efficacy of PRF 110 (Formerly LNP) in Open Herniorrhaphy Surgery||PainReform LTD|No|Recruiting|September 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|18 Years|N/A|No|||November 2015|November 22, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681966||79642|
NCT01681979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114593|WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes|WEUSRTP4850: Phase II: Asthma Treatment in Pregnancy and the Frequency of Adverse Pregnancy Outcomes||GlaxoSmithKline|No|Completed|July 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1|||Female|11 Years|50 Years|No|Non-Probability Sample|The study population will consist of all eligible pregnancies identified from the source        population where the female is considered to have asthma. The source population will be        all pregnancies identified on the GPRD that started and ended between 1 January 2000 and        31 December 2010.|September 2014|September 29, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01681979||79641|
NCT01681693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6113|Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans|Effect of Genetic Variants in MATE1 and OCT3 Transporters on the Pharmacodynamics of Metformin in African Americans With Type II Diabetes Mellitus.|#6113|University of California, San Francisco|Yes|Completed|February 2010|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|33|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 21, 2014|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681693||79663|
NCT01669278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA-Endo001|Evaluation of Office-Based Sheathed Flexible Nasopharyngoscopy|Evaluation of Office-Based Sheathed Flexible Nasopharyngoscopy: A Randomized Controlled Trial||University of Alberta|No|Not yet recruiting|September 2012|||September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Anticipated|76|||Both|17 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 17, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01669278||80615|
NCT01681992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115649|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life|Immunogenicity and Safety Study of GSK Biologicals' Priorix® Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life||GlaxoSmithKline||Completed|October 2012|August 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|4536|||Both|12 Months|15 Months|Accepts Healthy Volunteers|||March 2016|March 14, 2016|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681992||79640|
NCT01670149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12072|Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea|A Randomised Placebo Controlled Trial of "Follow on" Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea|RAPID|University of Nottingham|Yes|Recruiting|December 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|180|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670149||80548|
NCT01670422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABT-1233-RV|Risk Factors Associated With Recurrence and Life-threatening Complications for CSOJ|Risk Factors Associated With Recurrence and Life-threatening Complications for Patients Hospitalized With Chronic Suppurative Osteomyelitis of the Jaw||West China College of Stomatology|No|Completed|January 1980|May 2009|Actual|January 2009|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|322|||Both|1 Month|83 Years|No|Non-Probability Sample|Patients with a diagnosis of CSOJ who were admitted to our hospital from 1980 to 2009 were        investigated. Ultimately, 322 patients were enrolled in the study of life-threatening        complications.Patients were divided into four classes according to their age (years): <6,        6-18, 19-65, >65.|August 2012|August 21, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01670422||80527|
NCT01670708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-RY-BX-0003|HOPE Demonstration Field Experiment Multisite Evaluation|Multisite Evaluation of the Honest Opportunity With Enforcement Demonstration Field Experiment||RTI International|No|Active, not recruiting|August 2012|March 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|1600|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||March 2015|March 11, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01670708||80505|
NCT01670721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFLIBL06266|Colorectal Cancer Metastatic|A Multicenter, Single Arm, Open Label Clinical Trial Evaluating Safety and Health Related Quality of Life of Aflibercept in Combination With Irinotecan/5FU Chemotherapy (FOLFIRI) in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen|AFEQT|Sanofi|No|Completed|August 2012|June 2015|Actual|June 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|183|||Both|18 Years|N/A|No|||August 2015|August 3, 2015|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670721||80504|
NCT01671033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 09902-006|Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring|Muscle Relaxation With Biofeedback Via Internet for Panic disorder-a Randomized Pilot Study||Chimei Medical Center|Yes|Terminated|February 2010|January 2011|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|20 Years|60 Years|No|||April 2010|August 22, 2012|August 20, 2012||No|The drop-out rate was too high.|No||https://clinicaltrials.gov/show/NCT01671033||80480|
NCT01671904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28440|A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia|A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia||Genentech, Inc.||Recruiting|January 2014|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Anticipated|100|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|August 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01671904||80414|
NCT01671891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCRC-NM-1001|Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer|Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer||Fudan University|Yes|Recruiting|February 2012|February 2013|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|Samples With DNA|whole blood|Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|rectal cancer diagnosed with stage II-IV|August 2012|August 21, 2012|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01671891||80415|
NCT01672151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|jsxys456|Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia|Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia|ITP|First Affiliated Hospital of Suzhou Medical College|Yes|Completed|November 2011|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|35|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|35 patients using rapamycin therapy were observed before and after treatment,who did not        response to any other administrations including prednisone and immunosuppressive drugs,        even splenectomy .|August 2012|August 23, 2012|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672151||80395|
NCT01671865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00065256|Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy|Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|No|Recruiting|March 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will include a group of adults with facioscapulohumeral muscular dystrophy and        a group of adults who do not have facioscapulohumeral muscular dystrophy.|May 2014|May 14, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671865||80417|
NCT01671878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIl1244|Glucose and Insulin Responses to Test Foods|Characterization of the Postprandial Glucose and Insulin Responses to Test Foods in Lean and Overweight Subjects||Mondelēz International, Inc.|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|May 6, 2013|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671878||80416|
NCT01672125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASMC-12-EG-449-CTIL|Effect of Upper Limb Posture on Limb Volume as Expressed in Circumference Measurement in Healthy Women and in Women With Breast Cancer Related Lymphedema|Effect of Upper Limb Posture on Limb Volume as Expressed in Circumference Measurement in Healthy Women and in Women With Breast Cancer Related Lymphedema||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|November 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|45|||Female|40 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|women who have completed breast cancer treatments, with a diagnosis of unilateral arm        lymphedema, in the intensive phase and in the maintenance phase of lymphedema treatment,        15 healthy women adjusted in age and BMI.|August 2012|August 23, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672125||80397|
NCT01680523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KGOG 1029|Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)|A Randomized Controlled Trial Comparing Radical Hysterectomy Plus Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)||Asan Medical Center|Yes|Recruiting|September 2012|||July 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|409|||Female|20 Years|75 Years|No|||September 2012|September 8, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680523||79753|
NCT01681121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADX-N05 202|A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy|A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy||Jazz Pharmaceuticals|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|70 Years|No|||September 2014|September 15, 2014|September 5, 2012|Yes|Yes||No|September 4, 2014|https://clinicaltrials.gov/show/NCT01681121||79707|
NCT01681407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMC-07411-CTIL|Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications|Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.|MIRPROT|HaEmek Medical Center, Israel|Yes|Terminated|November 2011|February 2014|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|17|Samples With DNA|Subjects and patients will be asked to give blood samples at 4 points of time for the lab      processing: micro-RNA and proteome profiling/|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients at community or hospital settings. Patients were clinically evaluated for        suspected depression.|June 2015|June 18, 2015|September 5, 2012||No|Insufficient microRNA for the analysis|No||https://clinicaltrials.gov/show/NCT01681407||79685|
NCT01681420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10849|Improving Blood Safety and HIV Testing in Brazil|Improving Blood Safety and HIV Testing in Brazil: a Randomized Controlled Trial||Blood Systems Research Institute|Yes|Recruiting|March 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|12000|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 11, 2013|February 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01681420||79684|
NCT01681680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6112|Effect of Genetic Variation in the Transporter OCT2, MATE1 and MATE2-K on the PKPD of Metformin|Effect of Genetic Variation in the Transporter OCT2, MATE1 and MATE2-K on the Pharmacokinetics and Pharmacodynamics of Metformin|#6112|University of California, San Francisco|Yes|Completed|October 2010|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|41|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2014|June 30, 2014|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681680||79664|
NCT01681433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GU12-159|OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone|The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159||Hoosier Cancer Research Network|Yes|Active, not recruiting|December 2012|December 2017|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|72|||Male|18 Years|N/A|No|||March 2016|March 3, 2016|September 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681433||79683|
NCT01681446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCI IFNa miR-26|The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC|The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With Hepatocellular Carcinoma: a Muti-center Randomized Clinical Trail.||Fudan University|No|Recruiting|August 2012|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|506|||Both|18 Years|75 Years|No|||February 2016|February 2, 2016|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01681446||79682|
NCT01669291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MLFC-003|Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation|Effect of GnRH Antagonist Protocol vs Agonist Long Protocol During Controlled Hyperstimulation (COH)for Assisted Reproduction on IVF Outcome, Peak Estradiol Level, and Duration of Stimulation.||Main Line Fertility Center|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Female|21 Years|40 Years|Accepts Healthy Volunteers|||June 2014|June 3, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01669291||80614|
NCT01669512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC048|Adjuvanting Viral Vectored Malaria Vaccines With Matrix M|Safety and Immunogenicity of ChAd63 ME-TRAP / MVA ME-TRAP Heterologous Prime Boost Malaria Vaccination Adjuvanted With Matrix M™||University of Oxford|No|Completed|August 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|23|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2015|January 6, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669512||80597|
NCT01670448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE12.231|PECBLOCK for the Treatment of Pain After Breast Surgery|The Pectoral Nerve Block (PECBLOCK) for the Treatment of Pain After Breast Cancer Surgery.|PECBLOC|Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Completed|January 2014|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|128|||Female|18 Years|85 Years|No|||July 2015|August 31, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670448||80525|
NCT01670734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POP12671|Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects|An Open-Label, Pharmacokinetic and Tolerability Study of SAR236553/REGN727 Given as a Single SC Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function||Sanofi|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|25|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||June 2013|June 27, 2013|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670734||80503|
NCT01670747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201208|Evaluation of the Lung Recruitment and End-expiratory Lung Collapse in Acute Respiratory Distress Syndrome (ARDS)|Evaluation of the Lung Recruitment and End-expiratory Lung Collapse in Patients With Acute Respiratory Distress Syndrome||Policlinico Hospital|No|Completed|September 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to ICU with diagnosis of ARDS who required mechanical ventilation|March 2015|March 18, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01670747||80502|
NCT01671046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27944|An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection|Prospective Multicenter Observational Trial to Evaluate Correlation Between Liver Biopsy and Transient Elastography in Liver Fibrosis Assessment and Correlation Between Viral Kinetics and Transient Elastography Evolution During Hepatitis C Treatment in a Population of Chronic HCV Infected Patients||Hoffmann-La Roche||Completed|July 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|123|Samples With DNA|Biopsy of the liver|Both|18 Years|N/A|No|Probability Sample|Patients with chronic hepatitis C|March 2016|March 1, 2016|August 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01671046||80479|
NCT01671059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28314|A Non-Interventional Study Evaluating Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)|A Multi-Center, Non-inteRventional Study in rheumatOid Arthritis patientS Treated With Tocilizumab in Serbia- ACROSS; (Part of Global Umbrella Project)||Hoffmann-La Roche||Completed|July 2012|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|80|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra        (tocilizumab)|March 2016|March 1, 2016|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671059||80478|
NCT01671072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KS-TGC-01-2B|Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis|A Placebo Controlled, Single-blind, Randomized, Multi-center Phase 2B Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis||Kolon Life Science|Yes|Completed|July 2011|January 2013|Actual|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||January 2015|January 21, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671072||80477|
NCT01671371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110009227|Point-of-Care Ultrasound in the Emergency Department Evaluation of Syncope|A Randomized, Prospective Study on Point-of-Care Focused Cardiac Ultrasound in Patients Presenting to the Emergency Department With Syncope||Yale University|No|Recruiting|July 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|150|||Both|18 Years|N/A|No|||August 2012|August 20, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01671371||80455|
NCT01672177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOE2010-T2-2-107|Self Care for Older Persons in Singapore: An Intervention Study|Self Care for Older Persons in Singapore: An Intervention Study|SCOPE|National University, Singapore|No|Completed|August 2011|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|400|||Both|55 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 15, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01672177||80393|
NCT01672190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09389|Lessening Incontinence by Learning Yoga||LILY|University of California, San Francisco|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|40 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01672190||80392|
NCT01672164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DAIT CTOT-14|Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients|Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Liver Transplant Recipients|CTOT-14|National Institute of Allergy and Infectious Diseases (NIAID)|Yes|Active, not recruiting|August 2012|September 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|202|Samples With DNA|whole blood, plasma, serum, urine supernatant, urine pellet and tissue|Both|18 Years|N/A|No|Non-Probability Sample|Liver Transplant Recipients|March 2016|March 3, 2016|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01672164||80394|
NCT01672411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|propsa12|Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer|Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates, %p2psa and Prostate Health Index in the Detection of Prostate Cancer and in Predicting Aggressive Disease: a Prospective Study||University Of Perugia|No|Completed|April 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|250|||Male|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Urological outpatient clinics of one tertiary university high volume department of urology|February 2013|February 23, 2013|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672411||80375|
NCT01672138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TANTRA_TCAI|Pulmonary Vein Antrum Isolation (PVAI) Plus Isolation of Complex Fractionated Atrial Electrograms (CAFE) and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation|PVAI Plus Isolation of CAFEs and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation|TANTRA|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|February 2013|December 2018|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|186|||Both|18 Years|80 Years|No|||May 2015|May 19, 2015|August 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672138||80396|
NCT01672658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUSTU58913|Traditional Balance vs Vibrotactile Feedback Training for Vestibular Rehabilitation|Standard Vestibular Rehabilitation Training (VRT) vs. Sensory Kinetics Balance System (SKBS) + VRT on Balance and Functional Outcomes in the Mild Traumatic Brain Injury (mTBI) Population.||Rehabilitation Institute of Chicago|No|Completed|January 2012|November 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|75 Years|No|||November 2014|November 3, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01672658||80356|
NCT01672385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG039474-01|Improving Transition Outcomes Through Accessible Health IT and Caregiver Support|Improving Transition Outcomes Through Accessible Health IT and Caregiver Support||University of Michigan|Yes|Enrolling by invitation|August 2012|||August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1692|||Both|50 Years|N/A|No|||April 2015|April 30, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672385||80377|
NCT01680809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CWCT-001|Compliance of Compression Therapy in Healed Venous Ulcerations|Compliance of Compression Therapy in Healed Venous Ulcerations||University Hospital Case Medical Center|No|Not yet recruiting|September 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|18 Years|N/A|No|||September 2012|September 4, 2012|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680809||79731|
NCT01681108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06304|Childhood Obesity-A Study of Intervention|Childhood Obesity-A Study of Intervention||Winthrop University Hospital|Yes|Completed|June 2006|December 2011|Actual|December 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|8 Years|16 Years|No|||September 2012|September 6, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01681108||79708|
NCT01680549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L12-078|Pain Control With Total Knee Replacement|Pain Control With Total Knee Replacement: Does Gabapentin Affect Narcotic Usage and Functional Outcome? A Randomized Controlled Trial.|L12-078|Texas Tech University Health Sciences Center|No|Completed|September 2012|February 2016|Actual|February 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|50|||Both|25 Years|N/A|Accepts Healthy Volunteers|||February 2016|February 23, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680549||79751|
NCT01680822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0662|Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease|Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease in the University of Illinois Hospital & Health Sciences System||University of Illinois at Chicago|No|Completed|September 2012|||November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who were seeking or receiving medical care for NTM disease at UIC Medical Center        that satisfy the inclusion and exclusion criteria of study are eligible to participation.|November 2014|November 16, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01680822||79730|
NCT01680835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-1001|EverFlex Post Approval Study|The US StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the EverfLex NitInol STent System Post Approval Study|DURABILITY PAS|Medtronic Endovascular|No|Recruiting|September 2012|April 2019|Anticipated|April 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|113|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680835||79729|
NCT01681134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FKC-016|A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers|A Comparison of Effects of Short-Term Steady State Low Dose Exposure of Extended Release (Advagraf®) and Immediate Release (Prograf®) Formulations of Tacrolimus on Renal Perfusion and Function in Healthy Male Volunteers||Astellas Pharma Inc|No|Completed|July 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|19|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||November 2012|November 6, 2012|September 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681134||79706|
NCT01673360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR1102|Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices|Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices|CAPTURE|American Medical Systems|No|Recruiting|September 2012|December 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|5000|||Female|18 Years|N/A|No|Non-Probability Sample|All patients planned to receive at least one (1) target AMS market approved female pelvic        health product will be considered for inclusion in the registry.|August 2014|August 12, 2014|August 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01673360||80302|
NCT01673373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|iCAST™ RX-ARAS-001|Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension|ARTISAN: iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension|ARTISAN|Atrium Medical Corporation|Yes|Recruiting|October 2012|December 2020|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|138|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|August 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673373||80301|
NCT01669850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-12-07-002|Clipped Versus Handsewn Arteriovenous Fistula Anastomosis|The Safety and Effectiveness of Clipped Technique vs. Hand-Sewn Technique for Anastomosis in Arteriovenous Fistulas||Gundersen Lutheran Medical Foundation|No|Terminated|August 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||September 2015|September 4, 2015|August 16, 2012||No|minimal accrual|No||https://clinicaltrials.gov/show/NCT01669850||80571|
NCT01669863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MHH-6208|Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)|Awake Extracorporeal Membrane Oxygenation (ECMO) for Acute Respiratory Failure A Non-controlled, Single-center, Investigator-initiated Prove-of-concept Study||Hannover Medical School|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|75 Years|No|||March 2015|April 22, 2015|August 15, 2012||No||No|March 17, 2015|https://clinicaltrials.gov/show/NCT01669863||80570|
NCT01670136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-1646|Pharmacokinetics of Sildenafil in Premature Infants|Pharmacokinetics of Sildenafil in Premature Infants||University of North Carolina, Chapel Hill|Yes|Recruiting|February 2013|May 2016|Anticipated|May 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|41|||Both|N/A|364 Days|No|||March 2016|March 17, 2016|August 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01670136||80549|
NCT01669876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCP-009|Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease|3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease|ASAP|Rock Creek Pharmaceuticals, Inc.|No|Terminated|August 2012|February 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|85|||Both|65 Years|90 Years|No|||April 2015|April 28, 2015|August 17, 2012||No|Administrative status of active ingredient anatabine|No||https://clinicaltrials.gov/show/NCT01669876||80569|
NCT01670461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEP-10-171-01-PCSM|FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer|FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer|FACE|Children's Research Institute|No|Completed|January 2009|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|60|||Both|14 Years|90 Years|Accepts Healthy Volunteers|||May 2015|May 19, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670461||80524|
NCT01670760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-DTT-BS-01|Zero Heat Flux Thermometry System Comparison Trial|3M(TM)SpotOn(TM) Temperature Monitoring System Thermometry Trial||Arizant Healthcare|No|Not yet recruiting|August 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|20|||Both|N/A|17 Years|No|||August 2012|August 17, 2012|August 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01670760||80501|
NCT01670773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAT-1004-103|A Study of CAT-1004 Biomarkers in Healthy Subjects|A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004||Catabasis Pharmaceuticals|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||October 2012|October 29, 2012|August 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01670773||80500|
NCT01671384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Valproate and SMA|Valproate and Levocarnitine in Children With Spinal Muscular Atrophy|Randomized Placebo Controlled Trial of Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Aged 2-15 Years||All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|August 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|2 Years|15 Years|No|||December 2015|December 31, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01671384||80454|
NCT01671657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AUX-008|US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)|US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)|US EPIC|Progyny, Inc.|No|Active, not recruiting|January 2013|June 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|100|||Female|N/A|N/A|No|Non-Probability Sample|Patients undergoing in vitro fertilization treatment who provide informed consent and plan        to undergo Day 3 embryo transfer.|October 2015|October 19, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671657||80433|
NCT01681823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC12192-12CTIL|Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA|Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA||EcoNugenics|Yes|Recruiting|June 2013|August 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|21 Years|N/A|No|||January 2016|January 19, 2016|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01681823||79653|
NCT01672671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNNP 001|BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy|Identification of BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy||Russian Academy of Medical Sciences|No|Completed|August 2011|November 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|75 Years|No|||November 2015|November 1, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01672671||80355|
NCT01672398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R18HS019625-01A1|Trial of the CarePartner Program for Improving the Quality of Transition Support|Trial of the CarePartner Program for Improving the Quality of Transition Support||University of Michigan|Yes|Enrolling by invitation|August 2012|||June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|844|||Both|21 Years|N/A|No|||April 2015|April 30, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672398||80376|
NCT01673204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUH-TNFR|Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy|||Seoul National University Hospital||Recruiting|October 2012|||April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|2||Anticipated|276|||Both|19 Years|80 Years|No|||February 2014|February 12, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01673204||80314|
NCT01672944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16448|Evaluating Biobanking Educational Tools|Evaluating Biobanking Educational Tools||H. Lee Moffitt Cancer Center and Research Institute|No|Active, not recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|339|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 12, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01672944||80334|
NCT01680315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH2012|Calorie Anticipation and Food Intake|Differences in Physiological Responses of Satiety and Reward After (in)Consistent Calorie Cues.||Uppsala University|No|Completed|May 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|12|||Female|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|September 3, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01680315||79769|
NCT01672567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/05|Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease|Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease: A Randomized, Controlled, Crossover Trial||Griffin Hospital|No|Completed|October 2010|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|34|||Both|35 Years|75 Years|No|||August 2012|August 22, 2012|August 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01672567||80363|
NCT01672840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/03|Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension|Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension|DARC|Griffin Hospital|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|75 Years|No|||December 2014|December 31, 2014|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01672840||80342|
NCT01673100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|178-09-FB|Physical Activity Telehealth Intervention After Percutaneous Coronary Procedures|Physical Activity Telehealth Intervention After Percutaneous Coronary Procedures||University of Nebraska|Yes|Completed|March 2011|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|50|||Both|19 Years|N/A|No|||December 2014|December 1, 2014|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01673100||80322|
NCT01669525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|811129|Placental Growth and Adverse Pregnancy Outcomes|Placental Growth and Maternal Serum Biomarkers in the Prediction of Adverse Pregnancy Outcome||University of Pennsylvania|No|Active, not recruiting|November 2009|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1200|Samples Without DNA|Maternal serum will be collected. Placental biopsies may be collected.|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Singleton pregnancies presenting for Sequential Screen prior to 14 weeks gestation|April 2013|April 3, 2013|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01669525||80596|
NCT01669538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815789|Effect of Galantamine on Short-term Abstinence|Repurposing Cholinesterase Inhibitors for Smoking Cessation.|GAL-K|University of Pennsylvania|No|Recruiting|August 2012|March 2018|Anticipated|February 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|60 Years|No|||September 2015|September 23, 2015|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669538||80595|
NCT01669551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPenn 815656|A Phase 1 Feasbility Study Of Volume Intracardiac Echo In Assessment Of Patients With Structural And Valvular Heart Disease Undergoing Percutaneous Transcatheter Therapy|A Phase 1 Feasbility Study Of Volume Intracardiac Echo In Assessment Of Patients With Structural And Valvular Heart Disease Undergoing Percutaneous Transcatheter Therapy||University of Pennsylvania|No|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with structural or valvular heart disease|August 2012|December 8, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669551||80594|
NCT01669564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R18HS018932-01A1|Functional Assessment Screening Patient Reported Information|Functional Assessment Screening Patient Reported Information|FAST-PRI|University of Pittsburgh|Yes|Completed|February 2013|August 2015|Actual|August 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|666|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 1, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669564||80593|
NCT01670162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VGFT-OD-1220|On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)|On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.|ROLL|Tennessee Retina|No|Active, not recruiting|August 2012|January 2016|Anticipated|November 2015|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|50 Years|N/A|No|||October 2014|October 27, 2014|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670162||80547|
NCT01670435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15029|Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance|Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance||Bayer|No|Completed|May 2007|October 2010|Actual|June 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|3274|||Both|7 Years|N/A|No|Non-Probability Sample|Patients who received Ciproxan as a first-line treatment were eligible for the study,        among those with sepsis, secondary infection due to trauma, burn, or surgical wound,        pneumonia, peritonitis, cholecystitis, cholangitis, and anthrax as the indications of this        drug.|August 2012|August 27, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01670435||80526|
NCT01671085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14938|A Study of LY3015014 in Healthy Participants With High Cholesterol|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Subjects With Elevated LDL-C on a Stable Statin Therapy||Eli Lilly and Company|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2013|April 30, 2013|August 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01671085||80476|
NCT01671397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|041923|Women's Health Project for Women Wanting to Lose Weight|Intervention Study in Women Wanting to Lose Weight (Women's Health Project)||Texas Tech University Health Sciences Center|No|Completed|September 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|70 Years|No|||April 2014|April 30, 2014|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671397||80453|
NCT01671670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CB518501-3|Acupuncture for Patients With Function Dyspepsia|Phase III Study of Acupuncture for Patients With Functional Dyspepsia||Chengdu University of Traditional Chinese Medicine|Yes|Completed|September 2012|November 2014|Actual|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||November 2014|November 25, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671670||80432|
NCT01681264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2013P-001510|Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance|Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance||Massachusetts General Hospital|Yes|Recruiting|November 2013|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||December 2015|December 2, 2015|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681264||79696|
NCT01671917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOM 10042|Evaluation of an Educational Program Associated With Exercises (EDEX) Before Total Knee Arthroplasty|Evaluation of an Educational Program Associated With Exercises (EDEX) Before Total Knee Arthroplasty|EDEX|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2012|October 2018|Anticipated|April 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|50 Years|85 Years|No|||December 2015|December 21, 2015|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671917||80413|
NCT01677858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-002|A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (CHAMPION 1)|A Phase 1/2, Multicenter, Single-arm, Nonrandomized, Open-label and Dose-escalation Study of Weekly Carfilzomib and Dexamethasone (Cd-qw) for Patients With Progressive Multiple Myeloma.||Onyx Pharmaceuticals|Yes|Active, not recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|123|||Both|18 Years|N/A|No|||October 2015|October 21, 2015|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677858||79957|
NCT01678170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-LPF-201205001|Clinical Application of Breast Blood-oxygen Functional Imaging Technology|Clinical Application of Breast Blood-oxygen Functional Imaging Technology||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|September 2012|December 2016|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Female with breast lump, received breast ultrasound and mammography|May 2012|December 21, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678170||79933|
NCT01672957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27844|ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)|Prospective, Open-label, Non-interventional Study for the Follow-up of Renal Function in de Novo Kidney Transplant Patients Treated With Immunosuppressive Therapy Containing CellCept in Routine Clinical Practice (ORANGE Study)||Hoffmann-La Roche||Completed|September 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|129|||Both|18 Years|N/A|No|Probability Sample|Renal allograft transplant patients initiated on combined immunosuppressive treatment        containing mycophenolate mofetil (CellCept)|March 2016|March 1, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01672957||80333|
NCT01672970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28212|A Non-Interventional Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis|Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With Tocilizumab.||Hoffmann-La Roche||Completed|July 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|291|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra        (tocilizumab)|December 2015|December 1, 2015|August 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672970||80332|
NCT01678443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2361.00|Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies|A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies||Fred Hutchinson Cancer Research Center|No|Active, not recruiting|December 2012|||September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678443||79912|
NCT01651871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210D1526|Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis|A Phase 2, Multicenter, Parallel-Group, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Combination Study Of S-555739 And Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis||Shionogi Inc.||Completed|July 2012|May 2013|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|779|||Both|18 Years|64 Years|No|||May 2013|May 30, 2013|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651871||81926|
NCT01651884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00015784|Effects of tDCS Versus HD-tDCS for Stroke Rehabilitation|High Definition-transcranial Direct Current Stimulation (HD-tDCS) for Stroke Rehabilitation|tDCS- Aphasia|Soterix Medical|No|Completed|March 2012|January 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment|2||||||Both|25 Years|80 Years|No|||August 2015|August 25, 2015|July 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651884||81925|
NCT01672333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOX protocol|Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma|Phase 2 Study of Response Rate and Side Effects of Preoperative Chemotherapy With Docetaxel, Oxaliplatin and Capcitabine (TOX) in Patients With Locally Advanced Operable Gastric Adenocarcinoma|TOX|Milad Hospital|Yes|Completed|June 2008|||March 2011|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|70 Years|No|||March 2014|March 18, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01672333||80381|
NCT01672866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-321-0105|Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)|A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2), in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)||Gilead Sciences|Yes|Active, not recruiting|December 2012|December 2023|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|222|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672866||80340|
NCT01672879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-321-0106|Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH|A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)|NASH|Gilead Sciences|Yes|Active, not recruiting|October 2012|February 2024|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|259|||Both|18 Years|65 Years|No|||August 2015|August 25, 2015|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672879||80339|
NCT01673113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001380|Characterization of Transient Alterations of Cutaneous Sensory Nerve Function by Cryolipolysis|||Massachusetts General Hospital|No|Completed|December 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2013|October 21, 2013|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673113||80321|
NCT01673386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-951-12-205|A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma|A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects With Metastatic Renal Cell Carcinoma|TAURUS|AVEO Pharmaceuticals, Inc.|No|Completed|July 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|August 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673386||80300|
NCT01669304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-002814|Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness|Pharmacologic Dissection of Vestibular Migraine and Chronic Subjective Dizziness: A Double-Blind Parallel Group Trial Comparing Response to Verapamil Versus Sertraline||Mayo Clinic|No|Completed|August 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|32|||Both|18 Years|N/A|No|||August 2015|August 20, 2015|August 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01669304||80613|
NCT01669317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 12004|Mechanisms Underlying the Sleep Promoting Effect of Cherry Juice Standardized to Its Proanthocyanidin Content|Mechanisms Underlying the Sleep Promoting Effect of Cherry Juice Standardized to Its Proanthocyanidin Content|CHERRY JUICE|Pennington Biomedical Research Center|No|Completed|June 2014|October 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|65 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669317||80612|
NCT01669889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28421|A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome|A Multi-center, Non-drug Study to Explore the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome.||Hoffmann-La Roche||Completed|January 2013|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|38|||Male|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|High functioning (IQ >70) male adult individuals with Autistic Disorder or Asperger's        Syndrome and age and IQ matched healthy male volunteers|March 2016|March 1, 2016|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01669889||80568|
NCT01670175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC# 12083|Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors|A Phase I Study of Sirolimus in Combination With Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults With Relapsed and Refractory Solid Tumors||University of California, San Francisco|Yes|Active, not recruiting|August 2012|November 2015|Anticipated|September 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Both|N/A|25 Years|No|||August 2015|August 7, 2015|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670175||80546|
NCT01680926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Almased100|Metabolic Activation With Almased for Type 2 Diabetes Patients|Protein-rich Meal Replacement Significantly Reduces Weight, HbA1c and Daily Insulin Requirement Long-term in Patients With Type 2 Diabetes Mellitus and >100 U Insulin Per Day|Almased100|West German Center of Diabetes and Health|No|Completed|July 2009|October 2011|Actual|February 2011|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|22|||Both|35 Years|75 Years|No|||September 2012|September 9, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680926||79722|
NCT01681251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2009:135|Goal Directed Therapy for Patients Undergoing Major Vascular Surgery|Goal Directed Therapy for Patients Undergoing Major Vascular Surgery||University of Manitoba|No|Completed|August 2010|October 2013|Actual|June 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|85 Years|No|||November 2013|November 7, 2013|May 18, 2011||No||No||https://clinicaltrials.gov/show/NCT01681251||79697|
NCT01681277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1314.2|Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d. for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)||Boehringer Ingelheim||Completed|September 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment|4||Actual|48|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 10, 2013|September 5, 2012||||No||https://clinicaltrials.gov/show/NCT01681277||79695|
NCT01681550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8-Kamoi|A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years|Effect of Incretin-based Therapy Combined With Insulin on HbA1c, Hypoglycemia and Chronic Diabetic Complications in Type 2 Diabetic Patients||Nagaoka Red Cross Hospital|Yes|Not yet recruiting|October 2012|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|500|||Both|20 Years|95 Years|No|||September 2012|September 8, 2012|September 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01681550||79674|
NCT01682096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PI09/90513|Pilot Safety Study of Coronary CTA for the Diagnosis of Acute Coronary Syndrome in the Emergency Room|Usefulness of Coronary CTA for the Diagnosis of Acute Coronary Syndrome in the Emergency Room.||Hospital Clinic of Barcelona|No|Completed|January 2010|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|150|||Both|35 Years|N/A|No|||October 2013|October 15, 2013|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682096||79632|
NCT01677871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILBS-ATT-01|Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease|Study of Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease||Institute of Liver and Biliary Sciences, India|No|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|75 Years|No|||December 2013|December 16, 2013|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677871||79956|
NCT01677884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-005559-15|Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy|Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy in Hepatic Metastases of Metastatic Colorectal Cancer: a Phase II Multicentric Study With Patients in Progression After First Line Systemic Chemotherapy|BEVIAC|Gustave Roussy, Cancer Campus, Grand Paris|Yes|Terminated|November 2012|February 2016|Anticipated|February 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|75 Years|No|||November 2015|November 25, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677884||79955|
NCT01678183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BU IRB H-30045|Financial Incentives for Medication Adherence|Financial Incentives for Medication Adherence|FIMA|Boston Medical Center|No|Completed|September 2012|January 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|74|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678183||79932|
NCT01678456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFNET_A7|Prospective Registration and Assessment of Serious Adverse Events Within the AFNET|Prospective Registration and Independent Assessment of Incidence, Clinical Relevance and Outcome of Serious Adverse Events (SAE) Registered in the German Competence Network on Atrial Fibrillation|AFNET A7|German Atrial Fibrillation Network|No|Completed|February 2004|December 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|13000|||Both|18 Years|N/A|No|Non-Probability Sample|Real-life population Patients with atrial fibrilation documented within the last 12 months        before enrollment|August 2012|August 19, 2013|September 14, 2005||No||No||https://clinicaltrials.gov/show/NCT01678456||79911|
NCT01678469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A001138-33|Lipophilic Micronutrients, Adipokines and Gestational Diabetes Mellitus|Lipophilic Micronutrients, Adipokines and Gestational Diabetes Mellitus|2011-23|Assistance Publique Hopitaux De Marseille||Recruiting|November 2011|May 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Female|18 Years|N/A|No|||July 2015|July 1, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678469||79910|
NCT01651897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111580|Delirium in the Emergency Department and Its Extension Into Hospitalization||DELINEATE|Vanderbilt University|No|Recruiting|February 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|Samples Without DNA|15-30 cc of blood|Both|65 Years|N/A|No|Non-Probability Sample|We will enroll 150 delirious ED patients and a random selection of 150 non-delirious ED        patients who are hospitalized and reassess their delirium status daily throughout their        hospitalization.|July 2012|July 26, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651897||81924|
NCT01652430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-0159|Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder|Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder||VA Eastern Colorado Health Care System|No|Completed|October 2010|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|78|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Probability Sample|The sample for the current project will be recruited from the group of veterans receiving        or eligible to receive outpatient mental health services at the Denver VA Medical Center        who have served in combat who may or may not have a diagnosis of PTSD.|July 2012|January 6, 2015|December 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01652430||81883|
NCT01672580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lempira_Phase2|Social Network Interventions in Rural Honduras|Diffusion of Health Interventions Across Social Networks in Honduran Villages||Harvard University|No|Completed|August 2012|October 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|6||Actual|5773|||Both|15 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 18, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01672580||80362|
NCT01672853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-321-0102|Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)|A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)||Gilead Sciences|Yes|Active, not recruiting|February 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|235|||Both|18 Years|70 Years|No|||August 2015|August 20, 2015|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672853||80341|
NCT01672892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RTOG 1203|Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer|A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)||Radiation Therapy Oncology Group|Yes|Recruiting|November 2012|||June 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|281|||Female|18 Years|N/A|No|||November 2015|November 14, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01672892||80338|
NCT01672905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDR0000738979|PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802|Evaluation of PSA Antibody on E9802: Confirmation and Concordance||National Cancer Institute (NCI)||Not yet recruiting|November 2012|||December 2012|Anticipated|N/A|Observational|N/A|||Anticipated|20|||Male|18 Years|N/A|No|||August 2012|August 23, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01672905||80337|
NCT01673126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/201|Transcranial Direct Current Stimulation in Patients With Disorders of Consciousness|Transcranial Direct Current Stimulation in Patients With Disorders of Consciousness: a Sham-controlled Randomised Double Blind Study|tDCS in DOC|University Hospital of Liege|No|Completed|January 2010|December 2011|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|55|||Both|15 Years|75 Years|No|||May 2014|May 12, 2014|August 14, 2012||No||No|December 18, 2013|https://clinicaltrials.gov/show/NCT01673126||80320|
NCT01673139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/978b|Effect of 3 Years of Exercise in Patients With Atrial Fibrillation|Effect of 3 Years of Exercise in Patients With Atrial Fibrillation - A Generation 100 Substudy||Norwegian University of Science and Technology|No|Active, not recruiting|September 2012|January 2026|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|150|||Both|70 Years|75 Years|No|||January 2016|January 20, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673139||80319|
NCT01669005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 324/06|The Utility of Multiplex PCR for Detection of DNA in Neutropenic Patients With Hematological Malignancies|Obtaining Early Diagnosis and Prognosis in Urgent Sepsis (OEDIPUS) Study|MedIso|Centre Hospitalier Universitaire Vaudois|No|Completed|November 2007|December 2008|Actual|December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|Samples With DNA|3 ml of EDTA-blood|Both|N/A|N/A|No|Non-Probability Sample|Patients hospitalized in the bone marrow transplant unit in the study period|August 2012|August 17, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669005||80636|
NCT01669577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1081/09|Independent Predictors of Mortality in Polytrauma Patients|Independent Predictors of Mortality in Polytrauma Patients: a Prospective, Observational, Longitudinal Study||University of Sao Paulo|Yes|Completed|October 2010|August 2014|Actual|June 2013|Actual|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|N/A|No|Probability Sample|Severe trauma patients evaluated at trauma scene|January 2015|January 8, 2015|August 8, 2012||No||No|December 24, 2014|https://clinicaltrials.gov/show/NCT01669577||80592|single center trial, majority of TBI and male patients
NCT01669590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00050933|Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle|Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle||University of Utah|Yes|Active, not recruiting|December 2011|January 2017|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|28|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|young and older healthy humans|December 2014|December 3, 2014|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01669590||80591|
NCT01669902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28247|An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis|HAQIMONO a Non-interventional National Multicenter Study, Observing RA Patients Treated With Tocilizumab in Mono-therapy, i.e. Without Combination With DMARD||Hoffmann-La Roche||Completed|April 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|107|||Both|18 Years|N/A|No|Probability Sample|Patients with active moderate to severe rheumatoid arthritis unable to use methotrexate|October 2015|October 21, 2015|August 13, 2012|No|Yes||No|October 21, 2015|https://clinicaltrials.gov/show/NCT01669902||80567|
NCT01670786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GPPOT-02|Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion|Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion||Grupo de Pesquisa em Pleura e Oncologia Toracica|No|Completed|January 2010|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||May 2014|May 12, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01670786||80499|
NCT01670799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INST 1115|Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Pilot Trial to Study the Availability and Effect of Post-OP IV Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Cells Retrieved From the Peritoneal Cavity||New Mexico Cancer Care Alliance|Yes|Active, not recruiting|March 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 0|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Female|18 Years|N/A|No|||January 2016|January 15, 2016|August 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01670799||80498|
NCT01680640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHM MED1071|Investigation of Synbiotic Treatment in NAFLD|Investigation of the Effects of a Synbiotic on Liver Fat, Disease Biomarkers and Intestinal Microbiota in Non-alcoholic Fatty Liver Disease|INSYTE|University Hospital Southampton NHS Foundation Trust.|No|Recruiting|December 2013|||April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01680640||79744|
NCT01681290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBX129801-DN-201|Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects With Mild to Moderate Diabetic Peripheral Neuropathy||Cebix Incorporated|No|Completed|October 2012|January 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|65 Years|No|||January 2015|January 28, 2015|September 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681290||79694|
NCT01681563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCO|Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia|A Single-arm Multi-center Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia||Niguarda Hospital|No|Active, not recruiting|September 2011|June 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|65 Years|N/A|No|||December 2015|December 23, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01681563||79673|
NCT01681836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11120134|Oral Nitrite and Nitrate in Healthy Normal Volunteer Adults|An Open-Label Study of Oral Nitrite and Nitrate in Healthy Normal Volunteer Adults||University of Pittsburgh|No|Recruiting|October 2012|||||Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|1||Anticipated|10|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 30, 2013|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681836||79652|
NCT01682109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 11.05|Palatability Testing of a New Paediatric Formulation of Valacyclovir|Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children|VALID-0|Radboud University|No|Recruiting|September 2012|July 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|70|||Both|4 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 25, 2016|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682109||79631|
NCT01677897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MetAb-Pro|Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients|Impact of the Addition of Metformin to Abiraterone in Pre-docetaxel Metastatic Castration-resistant Prostate Cancer Patients Progressing on Abiraterone Treatment (MetAb-Pro): a Phase II Pilot Study|MetAb-Pro|Kantonsspital Graubünden|Yes|Recruiting|August 2013|April 2015|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Male|18 Years|90 Years|No|||September 2014|September 9, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01677897||79954|
NCT01677910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LX1606.1-301-CS|TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)|A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy||Lexicon Pharmaceuticals|Yes|Active, not recruiting|October 2012|||March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|105|||Both|18 Years|N/A|No|||April 2015|April 29, 2015|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677910||79953|
NCT01678209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 11-0161|Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach|Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|October 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|144|||Both|7 Years|17 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678209||79930|
NCT01678196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE 12-024|Helping Families Help Veterans With PTSD and Alcohol Abuse: An RCT of VA-CRAFT|Helping Families Help Veterans With PTSD and Alcohol Abuse: An RCT of VA-CRAFT||VA Office of Research and Development|No|Active, not recruiting|May 2013|April 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|66|||Both|18 Years|80 Years|No|||January 2016|January 27, 2016|August 29, 2012||No||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01678196||79931|
NCT01678846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LSHTM_6183|Good Schools Study|The Good Schools Study: Cluster Randomised Controlled Trial of a Program to Prevent Violence Against Children in Schools|GSS|London School of Hygiene and Tropical Medicine|No|Completed|June 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3820|||Both|N/A|N/A|No|||June 2015|December 17, 2015|August 24, 2012||No||No|October 8, 2015|https://clinicaltrials.gov/show/NCT01678846||79882|
NCT01652703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110231|A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Stable Statin Therapy in Japanese Subjects With Hypercholesterolemia and High Cardiovascular Risk|AMG145|Amgen|Yes|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|6||Actual|310|||Both|20 Years|80 Years|No|||September 2015|September 3, 2015|July 26, 2012|Yes|Yes||No|September 3, 2015|https://clinicaltrials.gov/show/NCT01652703||81862|
NCT01672593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120818|Glue Sealing for Patients With Low-Output ECFs|A Randomized Controlled Trial to Evaluate Endoscopy Assisted Fibrin Glue Application in the Treatment of Low-Output ECFs|Glue-sealing|Jinling Hospital, China|Yes|Recruiting|May 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|65 Years|No|||March 2014|March 10, 2014|August 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672593||80361|
NCT01672606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSA ROC|Effect of Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea|Effect of Partial Neuromuscular Blockade by Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea-before and After Three Month CPAP Treatment. A Non-randomized, Non-blinded Study.||Karolinska University Hospital|Yes|Completed|May 2012|February 2016|Actual|February 2016|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|11|||Male|18 Years|70 Years|No|||February 2016|February 26, 2016|June 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01672606||80360|
NCT01673152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RG 4/2011|The Effect of the Oligofructose Supplementation on Body Weight in Overweight and Obese Children|The Effect of the Oligofructose Supplementation on Body Weight in Overweight and Obese Children: a Randomized, Double Blind, Placebo-controlled Trial||Medical University of Warsaw|Yes|Completed|February 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|96|||Both|7 Years|18 Years|Accepts Healthy Volunteers|||January 2014|January 15, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01673152||80318|
NCT01669018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSPS-1-10-72-366-12|Ultrasound Guided Blockade of the Lumbar Plexus - the Supra Sacral Parallel Shift|The Supra Sacral Parallel Shift (SSPS) - Ultrasound Guided Blockade of the Lumbar Plexus|SSPS|University of Aarhus|No|Completed|August 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 30, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669018||80635|
NCT01669330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NW20012011|Laparoscopic Nissen Versus Anterior Partial Fundoplication|Comparison of Laparoscopic Nissen Versus Anterior Partial Fundoplication ad Modum Watson, A Prospective Randomized Trial||Region Skane|No|Completed|January 2001|January 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||April 2014|April 9, 2014|November 22, 2011||No||No||https://clinicaltrials.gov/show/NCT01669330||80611|
NCT01669603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16241|Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)|Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)|EPIARR|University of Virginia|No|Active, not recruiting|August 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|160|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669603||80590|
NCT01669616|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VL-2723|Point of Service Diabetes Screening Evaluation|Point of Service Diabetes Screening Evaluation|POSSE|VeraLight, Inc.|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|667|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Attendees of Blue Cross Blue Shield Wellness Event|January 2013|January 13, 2013|July 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669616||80589|
NCT01670474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROCOPrt-PA|Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA|Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial|PROCOPrt-PA|Centre Hospitalier du Centre du Valais|Yes|Recruiting|January 2011|November 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|240|||Both|18 Years|79 Years|No|||August 2012|August 20, 2012|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01670474||80523|
NCT01680653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012PG-T1D001|Testing State of the Art Remote Glucose Monitoring at Diabetes Camp|Pilot Study in Testing State of the Art Remote Glucose Monitoring at Diabetes Camp||Stanford University|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|4||Actual|20|||Both|7 Years|21 Years|No|||March 2015|March 31, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01680653||79743|
NCT01680666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-8943|A Prospective Trial of Ultrasound Versus Landmark Guided Central Venous Access in the Pediatric Population|A Prospective Randomized Trial of Ultrasound Versus Landmark Guided Central Venous Access in Children||Stanford University|No|Completed|May 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|N/A|18 Years|No|||January 2015|January 26, 2015|August 28, 2012||No||No|January 26, 2015|https://clinicaltrials.gov/show/NCT01680666||79742|
NCT01680939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSAS-HHSC2012|Investigating the Safety of Post-surgical Analgesics in Children With Obstructive Sleep Apnea|Investigating the Safety of Morphine and Ibuprofen in Children Post-adenotonsillectomy for Obstructive Sleep Apnea||Hamilton Health Sciences Corporation|Yes|Recruiting|May 2012|||December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|1 Year|10 Years|Accepts Healthy Volunteers|||May 2013|May 24, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680939||79721|
NCT01680952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0920|Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients|||Yonsei University|No|Completed|September 2012|January 2016|Actual|January 2016|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|158|||Both|20 Years|N/A|No|||March 2016|March 7, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680952||79720|
NCT01681576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2222|Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension|A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension||Novartis|No|Completed|August 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|72|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|August 30, 2012|Yes|Yes||No|July 10, 2015|https://clinicaltrials.gov/show/NCT01681576||79672|
NCT01681849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00000857|Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder|Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder||Emory University|Yes|Active, not recruiting|July 2009|July 2016|Anticipated|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|144|||Female|18 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 4, 2015|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681849||79651|
NCT01681862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R21HS020982-01A1|Insights for Community Health|Insights for Community Health||New York University School of Medicine|Yes|Completed|September 2012|July 2015|Actual|July 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681862||79650|
NCT01681875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U54DA031659|Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes|Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes|P1S1|University of Pittsburgh|Yes|Completed|June 2013|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|7||Anticipated|840|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|August 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681875||79649|
NCT01678222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120190|The COX-2 Gene and the Immune System|The Role of Functionally Relevant Cyclooxygenase-2 (COX-2) Gene Single Nucleotide Polymorphisms -765G> C and 8473T> C in Lymphocyte Differentiation||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|August 2012|||||N/A|Observational|Time Perspective: Prospective|||Actual|117|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678222||79929|
NCT01678235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glulisine_Aspart|Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus|The Impact Of Insulin Glulisine In Comparison With Aspart On Postprandial Glycemia After The High-Glycemic Index Meal In Children With Type 1 Diabetes - Cross-Over Double-Blind, Randomized Clinical Trial.||Medical University of Warsaw|No|Completed|September 2011|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|64|||Both|10 Years|18 Years|No|||August 2012|October 6, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01678235||79928|
NCT01678508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOPHO ALL2000 TPMT and outcome|Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia|Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia - Influence on Cure Rates and Risk of Second Cancer||Rigshospitalet, Denmark|No|Completed|January 2002|February 2012|Actual|July 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1020|Samples With DNA|whole blood stored for a subset of patients|Both|1 Year|15 Years|No|Probability Sample|The study cohort is based on patients enrolled in the NOPHO ALL2000 protocol.|September 2012|September 4, 2012|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01678508||79907|
NCT01679093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-002701-40|Antagonism Research Between Antiemetics Agents (Droperidol, Dexametasone, Ondansetron) and Acetaminophen in Thyroidectomy's Post-operative Analgesia.|Antagonism Research Between Antiemetics Agents (Droperidol, Dexametasone, Ondansetron) and Acetaminophen in Thyroidectomy's Post-operative Analgesia.|ANPATHY|University Hospital, Lille|Yes|Completed|June 2009|June 2011|Actual|January 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|66|||Both|18 Years|70 Years|No|||March 2012|August 31, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679093||79863|
NCT01678482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1|Clinical and Usability Study to Determine Safety and Efficacy of the Clear Device for Acne Treatment|Clinical and Usability Study to Determine Safety and Efficacy of the Clear Device for the Treatment of Mild to Moderate Inflammatory Acne.||Home Skinovations Ltd.|No|Completed|November 2011|April 2012|Actual|April 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|50|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 31, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678482||79909|
NCT01678495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-SPM-2011-63|Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic Stroke|Sonothrombolysis Potentiated by Microbubbles as a Novel Treatment of Acute Ischemic Stroke: a Prospective Randomized Pilot Study||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|August 2012|July 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|N/A|No|||August 2015|August 7, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678495||79908|
NCT01679691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCHE-BoneT001|The Effect of Epidural Anesthesia on the Intra-operative and Post-operative Amount of Bleeding Following Lower Limb Salvage Surgery|The Effect of Epidural Anesthesia on the Intra-operative and Post-operative Amount of Bleeding Following Lower Limb Salvage Surgery||Children's Cancer Hospital Egypt 57357|Yes|Suspended|September 2011|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|45|||Both|5 Years|18 Years|No|||September 2012|January 11, 2016|August 12, 2012||No|Till IRB renewal|No||https://clinicaltrials.gov/show/NCT01679691||79817|
NCT01652443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0488|Relationships and Health in the OEF/OIF Veteran Population|Relationships and Health in the OEF/OIF Veteran Population||VA Eastern Colorado Health Care System|No|Enrolling by invitation|April 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|65|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|OEF/OIF Veterans receiving or eligible to receive care at the VA|January 2016|January 22, 2016|December 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01652443||81882|
NCT01672918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120184|Fluorodeoxyglucose Imaging Studies to Detect Lymphoma|Use of Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography for the Evaluation of Autoimmune Lymphoproliferative Syndrome Lymphadenopathy Suggestive of Lymphoma||National Institutes of Health Clinical Center (CC)||Withdrawn|August 2012|February 2015||||N/A|Observational|Time Perspective: Prospective|||Actual|0|||Both|5 Years|N/A|No|||February 2015|March 3, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01672918||80336|
NCT01673165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gerber7747|Fortified Skimmed Mother's Milk in the Management of Chylothorax|A Comparison of the Effectiveness of Fortified Skimmed Mother's Milk Versus Specialized Formula in the Management of Chylous Effusion in Infants Following Cardiothoracic Surgery||Oregon Health and Science University|No|Completed|June 2012|September 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|N/A|12 Months|No|||October 2014|October 13, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673165||80317|
NCT01669031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oftalmo_Glaucoma_002|Randomized Controlled Trial on Visual Field Training|Effect of Exposure to Computer Simulated Visual Field Testing on Variability and Reliability of Test Results: A Randomized Controlled Trial||Oftalmologia Hospital Sotero del Rio|Yes|Recruiting|August 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Anticipated|200|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669031||80634|
NCT01669343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI Host Factors|Aromatase Inhibitor Host Factors Study|Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Active, not recruiting|September 2012|December 2015|Anticipated|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Female|N/A|N/A|No|||October 2015|October 19, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01669343||80610|
NCT01669928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1749|Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control|Hellenic Anglo Research Into Morning Or Evening Antihypertensive Drug deliverY Trial|HARMONY|Imperial College London|No|Completed|April 2012|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|80 Years|No|||February 2015|September 8, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01669928||80565|
NCT01670188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004676|SCD Use to Prevent DVT in Patients With PICC Lines|Sequential Pneumatic Compression to Prevent PICC-related Upper Extremity Venous Thrombosis in Critically Ill Neurological Patients||Mayo Clinic|No|Enrolling by invitation|August 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|102|||Both|18 Years|N/A|No|||May 2014|April 6, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01670188||80545|
NCT01680185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAPT-NODAT_9march2012|Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation|Treat-To-Target Trial of Continuous Subcutaneous, Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation (SAPT-NODAT)|SAPT-NODAT|Medical University of Vienna|No|Active, not recruiting|August 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|85|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01680185||79779|
NCT01680978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC25445|A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease|A SINGLE CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSSOVER, PHASE II STUDY TO ASSESS THE EFFECT OF ALEGLITAZAR ON CARDIAC ENERGETICS AND FUNCTION IN PATIENTS WITH UNCOMPLICATED TYPE 2 DIABETES MELLITUS AND NO HISTORY OF CORONARY ARTERY DISEASE WHO ARE DRUG-NAÏVE OR TREATED WITH STABLE METFORMIN MONOTHERAPY||Hoffmann-La Roche||Completed|October 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Endpoint Classification: Pharmacodynamics Study, Masking: Double Blind (Subject, Investigator)|2||Actual|18|||Both|40 Years|70 Years|No|||March 2016|March 1, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680978||79718|
NCT01681303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IWW-0004|Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients.|||Chang Gung Memorial Hospital||Completed|January 2009|December 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|85 Years|No|||August 2013|August 3, 2013|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681303||79693|
NCT01682122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIUH12-037|Frequency and Persistence of Wide Pulse Pressure in the Neonatal Population|Evaluation of the Frequency and Persistence of Wide Pulse Pressure in the Neonatal Population||Staten Island University Hospital|Yes|Not yet recruiting|August 2012|||August 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|196|||Both|N/A|72 Hours|Accepts Healthy Volunteers|Probability Sample|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age.|September 2012|September 7, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01682122||79630|
NCT01682135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14139|A Study in Participants With Advanced Solid Tumors|Phase I Study of Ramucirumab in Patients With Advanced Solid Tumors||Eli Lilly and Company|No|Completed|November 2012|March 2015|Actual|March 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||March 2015|March 19, 2015|September 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01682135||79629|
NCT01677923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-2-1|Obesity in Children and Adolescents: Associated Risks and Early Intervention|Phase 3: Effect of Diet, Physical Activity and Insulin Sensitizer Metformin on Obesity and Associated Risks in Children and Adolescents.|OCA|Lithuanian University of Health Sciences|Yes|Completed|May 2013|December 2015|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|182|||Both|10 Years|18 Years|No|||March 2016|March 2, 2016|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677923||79952|
NCT01677936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Raisin DM 002|Study of Raisins Versus Alternative Snacks in Patients With Type 2 Diabetes Mellitus|A Randomized, Unblinded, Single Research Site, Comparator Study of Raisins Versus Alternative Snacks on Glycemic Control and Other Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus||Louisville Metabolic and Atherosclerosis Research Center|No|Completed|June 2012|January 2014|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|18 Years|N/A|No|||March 2014|March 22, 2014|August 21, 2012|Yes|Yes||No|February 2, 2014|https://clinicaltrials.gov/show/NCT01677936||79951|This study was limited by being an un-blinded, single site study of modest size.
NCT01678521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZentiPTX3|Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients|Effect of LDL-apheresis on Pentraxin3 Plasma Levels in Hypercholesterolemic Patients With Coronary Artery Disease||Universita di Verona|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|12|Samples Without DNA|serum and plasma|Both|18 Years|75 Years|No|Non-Probability Sample|Hypercholesterolemic patients with documented CAD, on cronic fortnightly HELP-apheresis        treatment.|December 2014|December 18, 2014|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01678521||79906|
NCT01678534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMASCIS-01/2011|Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial|Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue. Safety Assessment. A Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial.(AMASCIS-01/2011)|AMASCIS-01|Instituto de Investigación Hospital Universitario La Paz|Yes|Recruiting|September 2014|June 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|60 Years|80 Years|No|||January 2015|February 5, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678534||79905|
NCT01678547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RoboSTROKE|Robot Walking Rehabilitation in Stroke Patients|Effect of Robot Assisted Treatment on Gait Performace in Stroke Patients||IRCCS San Raffaele|No|Recruiting|September 2012|September 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2014|February 12, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678547||79904|
NCT01679327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WY0524|Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer|Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer||Chinese Academy of Medical Sciences|No|Recruiting|March 2012|September 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|August 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01679327||79845|
NCT01679340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOXSP|A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery|Phase Ⅱ Study of S-1 Combined With Oxaliplatin (SOX)Verse S-1 Combined With Cisplatin(SP) in Adjuvant Chemotherapy After D2 Surgery||Peking University|Yes|Recruiting|April 2011|June 2018|Anticipated|March 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|160|||Both|18 Years|N/A|No|||May 2015|May 17, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01679340||79844|
NCT01679353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0278|Comparison of Analgesic Effect of Magnesium Added to Ropivacaine and Ropivacaine Alone in Caudal Analgesia on Postoperative Pain Control in Pediatric Patients Undergoing Inguinal Hernia Repair|||Yonsei University|No|Completed|September 2012|January 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|80|||Both|2 Years|6 Years|No|||June 2014|June 10, 2014|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01679353||79843|
NCT01679366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0054-11-ZIV|The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients|The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients||Ziv Hospital|Yes|Completed|October 2012|October 2013|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|57|||Both|18 Years|N/A|No|||November 2011|October 21, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01679366||79842|
NCT01679379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASU-07-2012|Wound Infection in Obese Women After Cesarean Delivery|Surgical Site Infection in Obese Women After Cesarean Section; A Randomized Controlled Trial of Absorbable Versus Non Absorbable Sutures for Skin Closure.||Ain Shams University|Yes|Completed|July 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Female|18 Years|35 Years|No|||May 2013|May 23, 2013|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679379||79841|
NCT01681459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2011-060|Effects of Lipids on Gastric Emptying, Satiety Hormones, and Appetite in Severe Overweight|Effects of Lipids on Gastric Emptying, Satiety Hormones, and Appetite in Severe Overweight||Hvidovre University Hospital|Yes|Completed|January 2012|January 2015|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|20|Samples Without DNA|Plasma|Male|25 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|10 lean subjects and 10 severely obese subjects|February 2016|February 18, 2016|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681459||79681|
NCT01681472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISO-CC-002|PK/PD Investigation of Modufolin® in Plasma, Tumor and Adjacent Mucosa in Patients With Colon Cancer|A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin® (60 or 200 mg/m2) Compared to Levoleucovorin (60 or 200 mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer||Isofol Medical AB|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Actual|32|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|September 5, 2012||No||No|May 21, 2015|https://clinicaltrials.gov/show/NCT01681472||79680|
NCT01672645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3771001|A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.|A Phase 1, Randomized, Double Blind, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Efficacy Of Multiple Ascending Dose Levels Of Pf-05402536 And Pf-06413367 In Healthy Adult Smokers||Pfizer|No|Completed|June 2012|December 2015|Actual|December 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|277|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2016|January 25, 2016|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01672645||80357|
NCT01672931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0034-12 HYMC|The Association Between Overweight and Oocyte Diameter in Women Undergoing Vitro Fertilization|||Hillel Yaffe Medical Center|Yes|Not yet recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|||Female|18 Years|45 Years|No|Probability Sample|Women undergoing IVF treatments|August 2012|August 22, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01672931||80335|
NCT01669044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB[2012]260|Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients|Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|May 2012|December 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|80|||Both|18 Years|N/A|No|Probability Sample|Postoperative patients of major abdominal surgery|August 2012|August 20, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669044||80633|
NCT01669668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207113|Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)|Radiofrequency Ablation Under Ideal Conditions in Hepatocellular Carcinoma||Washington University School of Medicine|No|Withdrawn|December 2014|December 2018|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|69 Years|No|||July 2014|July 15, 2014|August 16, 2012||No|Lack of referrals.|No||https://clinicaltrials.gov/show/NCT01669668||80585|
NCT01669356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNsupplESO|The Effect of Parenteral Nutrition Supplement on Esophagectomy Patients|The Effect of Parenteral Nutrition Supplement Versus Enteral Nutrition Alone on Nutrition Status After Esophagectomy: A Prospective Randomized Controlled Trial||Shanghai Zhongshan Hospital|No|Completed|July 2012|March 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|80 Years|No|||March 2014|March 30, 2014|August 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01669356||80609|
NCT01669369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lithium-5010|Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma|A Prospected Randomized Multicenter Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma|Li2CO3|Sun Yat-sen University|Yes|Recruiting|January 2013|December 2023|Anticipated|December 2023|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|400|||Both|8 Years|70 Years|No|||December 2015|December 7, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669369||80608|
NCT01669629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-005199|Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear|Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear||Johnson & Johnson Vision Care, Inc.|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|183|||Both|18 Years|45 Years|No|||May 2015|May 5, 2015|August 16, 2012|No|Yes||No|December 9, 2013|https://clinicaltrials.gov/show/NCT01669629||80588|
NCT01669642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201112017|Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children|Mean Effective Dose of Rapidly Administered Ketamine for Brief Pediatric Procedural Sedation||Washington University School of Medicine|Yes|Completed|April 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|112|||Both|2 Years|17 Years|No|||November 2014|November 19, 2014|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669642||80587|
NCT01669915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010P-000769|A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline|A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline|VITAL-Cog|Brigham and Women's Hospital|No|Enrolling by invitation|August 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|3226|||Both|60 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 11, 2016|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01669915||80566|
NCT01679912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110109|A Call Center During HAE Attacks (SOS HAE)|Hereditary Angioedema : Interest From the Use of a Call Center During the Attacks.|SOS AOH|Assistance Publique - Hôpitaux de Paris|Yes|Active, not recruiting|March 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||January 2015|January 15, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01679912||79800|
NCT01680432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|033/11|Effect of the Consumption of a Cheese Enriched With Probiotic Organisms in Improving Symptoms of Constipation|Effect of the Consumption of a Cheese Enriched With Probiotic Organisms (Bifidobacterium Lactis Bi-07) in Improving Symptoms of Constipation: a Randomized Controlled Trial||Centro Universitário Univates|Yes|Completed|January 2012|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|30|||Female|20 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01680432||79760|
NCT01681589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00685|Relationship Between Attention and Emotional Regulation Post-Traumatic Brain Injury (TBI)|Relationship Between Attention and Emotional Regulation Post-TBI: Probing Neural Circuitry With Transcranial Direct Current Stimulation||New York University School of Medicine|No|Recruiting|August 2012|December 2016|Anticipated|October 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|40|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 16, 2016|August 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681589||79671|
NCT01681888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biofeedback2012|Surface EMG Biofeedback for Children With Cerebral Palsy|Clinical Trial of Surface EMG Biofeedback for Children With Cerebral Palsy and Associated Movement Disorders||University of Southern California|No|Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|N/A|21 Years|No|||May 2015|May 28, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01681888||79648|
NCT01677949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011LS158|Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia|A Phase II Trial Investigating Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia||Masonic Cancer Center, University of Minnesota|Yes|Recruiting|December 2013|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|49|||Both|N/A|60 Years|No|||October 2015|October 9, 2015|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677949||79950|
NCT01677962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101778|A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma||Medical University of South Carolina|Yes|Active, not recruiting|August 2012|||September 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677962||79949|
NCT01678248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0048-12-ZIV|The Effectiveness of Intravitreal Avastin Injection for CRVO|The Effectiveness of Intravitreal Avastin Injection for CRVO||Ziv Hospital|Yes|Recruiting|January 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|68|||Both|18 Years|N/A|No|Probability Sample|patients who suffer from CRVO and were injected by bevazicumab intravitrealy|August 2012|August 29, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01678248||79927|
NCT01678261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|19668|X-chromosome Inactivation, Epigenetics and the Transcriptome|X-chromosome Inactivation, Epigenetics and the Transcriptome||University of Aarhus|No|Active, not recruiting|September 2012|January 2016|Anticipated|October 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||13|Anticipated|395|Samples With DNA|Whole blood      Serum      White cells      Tissue|Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Individuals with sex chromosome syndromes will be recruited from out-patient clinics        Controls will be recruited from the general population|June 2015|December 14, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678261||79926|
NCT01677975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ultrasound in melanomas|The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma|||Rigshospitalet, Denmark|No|Enrolling by invitation|September 2012|||||N/A|Interventional|N/A|1||||||Both|18 Years|N/A|No|||August 2012|August 31, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677975||79948|
NCT01678274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|35202|Prospective Characterization of the Heart, Aorta and Blood Pressure in Turner Syndrome. Association With Aortic Dissection.|Prospective Characterization of the Heart, Aorta and Blood Pressure in Women With Turner Syndrome. Association With Aortic Dissection.|TSCORII|University of Aarhus|No|Recruiting|December 2013|October 2016|Anticipated|February 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|170|Samples With DNA|Blood Serum|Female|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females with Turner Syndrome previously participating in our study number 2001024 are        recruited from out-patient clinics.        Controls are healthy volunteers recruited from the general population by advertisement.|June 2015|June 26, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678274||79925|
NCT01679418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PONV_thyroidsurgery|Impact of Drains on Postoperative Nausea and Vomiting After Thyroid Surgery|Randomized Controlled Trial on the Impact of Postoperative Drainage on Nausea and Vomiting After Thyroid- and Parathyroid Surgery|PONTS|Kantonsspital Liestal|Yes|Completed|November 2007|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|139|||Both|18 Years|95 Years|No|||August 2012|February 24, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01679418||79838|
NCT01679431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-114997|Metabolic Determinants of the Progression of Aortic Stenosis|Metabolic Determinants of the Progression of Aortic Stenosis - PROGRESSA Study|PROGRESSA|Laval University|No|Recruiting|April 2005|January 2018|Anticipated|January 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples With DNA|Fasting blood sample (serum, lithium-heparin, EDTA) and white cells - Tissue (explanted      aortic valves)|Both|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Cohort will be selected at primary care clinic|October 2015|October 30, 2015|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01679431||79837|
NCT01678859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFC 1|Cervical Mucus - the Biochemical and Molecular Properties in Fertile and Subfertile Women (C-MIS Study)|Cervical Mucus - the Biochemical and Molecular Properties in Fertile and Subfertile Women|C-MIS|Merrion Fertility Clinic|No|Recruiting|August 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|90|Samples With DNA|cervical mucus serum|Female|18 Years|42 Years|Accepts Healthy Volunteers|Non-Probability Sample|gyanecological outpatient department|September 2013|September 5, 2013|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678859||79881|
NCT01678872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS1/002/11|A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration|A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration||Oxford BioMedica|Yes|Enrolling by invitation|August 2012|November 2027|Anticipated|November 2027|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|21|||Both|50 Years|N/A|No|||May 2014|May 28, 2014|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678872||79880|
NCT01679106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-559|The Effects of Continuous Transversus Abdominis Plane (TAP) Catheters on Postoperative Pain After Renal Transplantation|||The Cleveland Clinic|No|Active, not recruiting|August 2012|December 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|174|||Both|18 Years|80 Years|No|||February 2014|February 21, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679106||79862|
NCT01679392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2011-030|A Study Investigating Properties of the Transversus Abdominis Plane Block|Transversus Abdominis Plane Block: A Placebo-controlled Study in Healthy Volunteers||Hillerod Hospital, Denmark|Yes|Completed|August 2012|May 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|16|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2015|March 19, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01679392||79840|
NCT01679405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIBW 2992|BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer|Open-label, Uncontrolled, Multicenter Phase I/Ib Trial to Investigate Safety and Efficacy of BIBW 2992 and Standard Gemcitabine/Cisplatin in Chemo-naïve Patients With Advanced Biliary Tract Adenocarcinoma||Johannes Gutenberg University Mainz|No|Recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||November 2014|November 27, 2014|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01679405||79839|
NCT01679730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMH-100126-F|Changes of Microbiota in Irritable Bowel Syndrome Patients|||Far Eastern Memorial Hospital|Yes|Recruiting|June 2012|||April 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|20 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Irritable bowel syndrome patients|September 2012|March 9, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01679730||79814|
NCT01681719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ERGOFORCE1|Ergospirometric Values and WBV in Elderly|Whole Body Vibration as Alternative for Improve the Ergospirometric Values in Elderly: a Randomized Clinical Trial|EVAWIE|Universidade Federal de Pernambuco|Yes|Completed|January 2011|||December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Actual|25|||Both|60 Years|74 Years|Accepts Healthy Volunteers|||September 2012|September 5, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01681719||79661|
NCT01681732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38403|A Pilot Study of Personalized Medicine for Pediatric Asthma|A Pilot Study of Personalized Medicine for Pediatric Asthma||Milton S. Hershey Medical Center|No|Recruiting|September 2012|||September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|6 Years|17 Years|No|||September 2012|September 7, 2012|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681732||79660|
NCT01681745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MYO-0535|Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects|Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects||MyoScience, Inc|No|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681745||79659|
NCT01673178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B2901011|Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus|A Phase 1, Placebo-controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Iv Doses Of Pf-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin||Pfizer|No|Completed|October 2012|September 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|107|||Both|30 Years|70 Years|No|||January 2015|January 28, 2015|August 22, 2012|No|Yes||No|January 6, 2015|https://clinicaltrials.gov/show/NCT01673178||80316|
NCT01673191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCA2012|A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus|A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus||Retinal Consultants of Arizona|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2014|April 1, 2015|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673191||80315|
NCT01679639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP25561|A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers|An Open-label, Fixed-sequence, Three-period, Single Group Study to Investigate the Effects of Rifampicin as an OATP1B1 Inhibitor and a CYP2C8 Inducer on the Pharmacokinetics of Aleglitazar in Healthy Subjects||Hoffmann-La Roche||Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01679639||79821|
NCT01669941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STOPMiP-KENYA|Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya|Intermittent Screening and Treatment (IST) or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya: a Randomized Controlled Trial|STOP MiP KENYA|Kenya Medical Research Institute|Yes|Active, not recruiting|August 2012|December 2015|Anticipated|October 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|1554|||Female|N/A|N/A|No|||August 2015|August 5, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01669941||80564|
NCT01670201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MxT Ag 01|An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Adequacy of a New Donor Site Dressing in Surgical Burn Patients.||Molnlycke Health Care AB|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|7 Years|N/A|No|||February 2013|September 3, 2014|June 12, 2012||No||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01670201||80544|
NCT01680445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HOS-01-011|Telephone Interview Study for Men and Women With Osteoarthritis|Observational Telephone Interview Study for Men and Women With Osteoarthritis||Health Outcomes Solutions|Yes|Completed|March 2011|May 2011|Actual|April 2011|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|23|||Both|40 Years|80 Years|No|Non-Probability Sample|US residents|September 2012|September 4, 2012|October 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01680445||79759|
NCT01680705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SIESS-2012|Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery|Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery||University of Calgary|No|Completed|July 2012|September 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|75|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01680705||79739|
NCT01680406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-CGH-6338|Ethiopia Antimalarial in Vivo Efficacy Study 2012|Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection||Centers for Disease Control and Prevention|Yes|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|398|||Both|1 Year|N/A|No|||January 2015|January 14, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01680406||79762|
NCT01680419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R44MH088063-02|Mission Reconnect: Promoting Resilience and Reintegration of Post-Deployment Veterans and Their Families|Mission Reconnect: Promoting Resilience and Reintegration of Post-Deployment Veterans and Their Families||Collinge and Associates, Inc.|No|Completed|September 2012|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|4||Actual|320|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 31, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01680419||79761|
NCT01681602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-3-2011-128|Effect of Physical Exercise in Alzheimer Patients|Preserving Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise|ADEX|Rigshospitalet, Denmark|Yes|Completed|January 2012|June 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|200|||Both|50 Years|90 Years|No|||November 2014|November 28, 2014|April 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01681602||79670|
NCT01681901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-06010|Ultrasound in Detecting Lymph Node Metastasis in Older Patients Undergoing Breast Sonography|Lymph Node Evaluation in the Axilla of Symptomatic Older Women During Breast Sonography.||Ohio State University Comprehensive Cancer Center|Yes|Withdrawn|June 2006|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|0|||Female|55 Years|N/A|No|Non-Probability Sample|Inclusion Criteria:          -  Patients referred for a breast ultrasound          -  Patients who have had a mammogram with a Breast Imaging Reporting and Data System             (BIRADS) of >= 4          -  Patients who are undiagnosed for breast cancer|October 2015|October 6, 2015|September 5, 2012||No|no accrual|No||https://clinicaltrials.gov/show/NCT01681901||79647|
NCT01682148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-99-52120-162|Neuro Muscular Junction Study|A Phase III Prospective, Multi-center, Randomised, Evaluator-blinded Study to Compare Neuromuscular Junction (NMJ) Targeted Technique for Dysport® Injections in Upper Limb Spasticity Post Stroke or Traumatic Brain Injury to the Technique Used in Current Clinical Practice|NMJ|Ipsen|No|Terminated|September 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|101|||Both|18 Years|N/A|No|||April 2015|April 28, 2015|September 6, 2012|No|Yes|The study was terminated early due to slow recruitment.|No||https://clinicaltrials.gov/show/NCT01682148||79628|
NCT01682161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100740|A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate|An Open-Label, Comparative Study of Immediate or Delayed Switch to Paliperidone Palmitate in Patients Unsatisfied With Current Oral Atypical Antipsychotics to Evaluate the Evolution of Medication Satisfaction and Adherence||Janssen Korea, Ltd., Korea|No|Completed|January 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|154|||Both|20 Years|65 Years|No|||July 2014|July 31, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682161||79627|
NCT01677988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101822|Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma|Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Capecitabine With Concurrent Limited Field Radiation Therapy in Patients With Localized Pancreatic Head Adenocarcinoma||Medical University of South Carolina|Yes|Terminated|July 2012|||October 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|80 Years|No|||July 2015|December 11, 2015|August 29, 2012||No|Study was terminated due to low accrual.|No|October 28, 2015|https://clinicaltrials.gov/show/NCT01677988||79947|
NCT01678560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01648|Remote Monitoring in Obstructive Sleep Apnea|Remote Monitoring in Obstructive Sleep Apnea Management in Military Veterans||VA Connecticut Healthcare System|No|Recruiting|January 2014|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|2||Anticipated|220|||Both|18 Years|90 Years|No|||December 2014|December 8, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678560||79903|
NCT01679132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|360039|CVRx Barostim Hypertension Pivotal Trial|CVRx Barostim Hypertension Pivotal Trial||CVRx, Inc.|Yes|Active, not recruiting|January 2013|September 2017|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|310|||Both|21 Years|80 Years|No|||October 2015|October 26, 2015|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01679132||79860|
NCT01679782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FVIE_FA1|Involvement of Nervous System in Muscle Weakness in COPD Patients|Phase 1 Impact of Nocturnal Desaturations on Central Motor Drive in COPD Patients: A New Insight on the Systemic Effects of the Disease.|DesCoM-1|5 Santé|Yes|Completed|July 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Actual|137|Samples With DNA|whole blood|Both|40 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two groups of COPD patients and one group with healthy sedentary subjects|March 2015|March 9, 2015|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679782||79810|
NCT01679795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TDILA|Vascular Effect of Tibolone Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery|||Federal University of Minas Gerais||Completed|February 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679795||79809|
NCT01678885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC27007 Energy Balance|Assessment of Energy Balance|Assessment of Energy Balance||Pennington Biomedical Research Center|No|Completed|May 2007|December 2009|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|65 Years|No|||September 2014|September 19, 2014|August 31, 2012||No||No|December 20, 2012|https://clinicaltrials.gov/show/NCT01678885||79879|Accelerometers can underestimate TEE by 30%-60%. The IDEEA™ has been validated in controlled conditions, and this study builds upon evidence of its utility in free-living conditions.
NCT01678898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PB-102-F01|Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients|A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients||Protalix|No|Active, not recruiting|October 2012|January 2016|Anticipated|December 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678898||79878|
NCT01679119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL 11/0475|Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy|A Randomised Phase II Trial of Inotuzumab Ozogamicin Plus Rituximab & CVP (IO-R-CVP) vs Gemcitabine Plus Rituximab & CVP (Gem-R-CVP) for the First Line Treatment of Patients With DLBCL Who Are Not Suitable for Anthracycline Containing Chemotherapy|INCA|University College, London|Yes|Recruiting|October 2013|October 2018|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|132|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01679119||79861|
NCT01680276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/104/13|Clinical and Cost Effectiveness of Positive Behaviour Support: a Trial|Clinical and Cost Effectiveness of Staff Training in Positive Behaviour Support (PBS) for Treating Challenging Behaviour in People With Intellectual Disability: A Cluster Randomised Controlled Trial|PBS|University College, London|Yes|Active, not recruiting|November 2012|November 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|246|||Both|18 Years|N/A|No|||June 2015|June 22, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01680276||79772|
NCT01677819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201109027RD|Inhibition Control of Children and Adolescents With ADHD|Inhibition Control of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder||National Taiwan University Hospital|Yes|Completed|November 2011|March 2012|Actual|||N/A|Observational|N/A||1|Actual|60|||Both|10 Years|18 Years|No|Non-Probability Sample|We will recruit 60 children and adolescents, aged 10 to 18, who are diagnosed with ADHD at        the Department of Psychiatry, National Taiwan University Hospital.|August 2012|August 30, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677819||79960|
NCT01669382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Med2UKEr1/2012|Angio-Seal® vs. Exo-Seal® for Closure of Arterial Puncture Sites|ACCESS: A Randomized, Multicenter, Single-Blinded Trial to Compare the Extrafemoral Closure Device Exo-Seal® and the Collagen-based Intravascular Device Angio-SealTM for Arterial Puncture Site Closure.||University Hospital Erlangen|Yes|Completed|January 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|304|||Both|18 Years|N/A|No|||February 2015|February 2, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01669382||80607|
NCT01669655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AK99|Plasma Profile of Exclusively Breastfed Infants|Plasma Profile of Exclusively Breastfed Infants||Abbott Nutrition|No|Completed|June 2012|December 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Actual|56|Samples With DNA|Blood sample; Human Milk sample|Both|6 Weeks|16 Weeks|Accepts Healthy Volunteers|Non-Probability Sample|Breastfeeding infants and their mothers|January 2015|January 19, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669655||80586|
NCT01679652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHC-1-2012|The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension|The Effects of Nebivolol on the NO-system in Patients With Essential|NEBI|Regional Hospital Holstebro|Yes|Completed|August 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|40 Years|70 Years|No|||March 2014|March 1, 2014|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01679652||79820|
NCT01679665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT012|Systems Biology of Vaccination for EV71 Vaccine in Humans|Systems Biology of Vaccination for EV71 Vaccine in Chinese Healthy Children Aged From 2 to 5 Years Old||Jiangsu Province Centers for Disease Control and Prevention|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|72|||Both|2 Years|5 Years|No|||May 2013|May 7, 2013|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01679665||79819|
NCT01679925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P111010|Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years|Qualitative Assessment of the Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years|PUPSY|Assistance Publique - Hôpitaux de Paris|No|Completed|October 2012|February 2015|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Female|6 Years|8 Years|No|Non-Probability Sample|The study will be offered to all children and families who visit in a day hospital in the        pediatric endocrinology department of Robert Debré Hospital for further assessment of        early puberty.|July 2012|March 25, 2015|July 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01679925||79799|
NCT01680198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oct2010PENNYStudy|Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)|Effect of Paricalcitol on Endothelial Function in Chronic Kidney Disease (CKD) Patients (the PENNY Study)|PENNY|Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy|Yes|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|88|||Both|18 Years|80 Years|No|||October 2012|October 1, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01680198||79778|
NCT01680991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YP25623|A Study of RO5072759 (GA101) in Patients With CD20+-Malignant Lymphoma|A Multi-center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease.||Hoffmann-La Roche||Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680991||79717|
NCT01680679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13-0210|Influenza Immunization of Children in India|Influenza Immunization of Children in India||University of Colorado, Denver|Yes|Active, not recruiting|May 2012|||March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|3600|||Both|6 Months|10 Years|Accepts Healthy Volunteers|||January 2016|January 5, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680679||79741|
NCT01680965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17071|Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease|Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease||H. Lee Moffitt Cancer Center and Research Institute|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||February 2016|February 4, 2016|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680965||79719|
NCT01681615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASA-ST-OS|Challenge Test for Acetylsalicylic Acid Hypersensitivity|Challenge Test for Acetylsalicylic Acid Hypersensitivity||Helse Stavanger HF|No|Not yet recruiting|September 2012|December 2013|Anticipated|March 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Anticipated|50|||Both|18 Years|60 Years|No|||September 2012|September 12, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01681615||79669|
NCT01681628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uganda2012|Community Self-help Using Thought Field Therapy in a Traumatised Population in Uganda: a Randomised Trial|Effectiveness of Thought Field Therapy Provided by Community Workers to a Traumatised Population in Uganda: a Randomised Trial||Thought Field Therapy Foundation (UK) Ltd|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|256|||Both|18 Years|N/A|No|||January 2015|January 17, 2015|September 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01681628||79668|
NCT01681914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100803|Assessment of the Effectiveness of New Clinical Guidelines for Differential Diagnosis and Management of Common HIV/AIDS-related Conditions in Mozambique|Assessment of the Effectiveness of New Clinical Guidelines for Differential Diagnosis and Management of Common HIV/AIDS-related Conditions in Mozambique: A Country-specific Public Health Evaluation." (CDC)||Vanderbilt University|No|Completed|April 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|492|||Both|18 Years|N/A|No|Non-Probability Sample|The study population will consist of HIV-infected adult Mozambicans (age 18 years or over)        who receive ambulatory care at the Centro de Saúde (Health Center) of the 3 participating        health districts (Inhassunge, Namacurra and Maganja da Costa) in Zambézia Province. All 3        health centers have been providing ART for more than three years.|April 2013|August 9, 2013|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01681914||79646|
NCT01682187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8660|A Dose-Escalation Study in Participants With Recurrent Malignant Glioma|Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma||Eli Lilly and Company|No|Active, not recruiting|December 2005|December 2015|Anticipated|May 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|N/A|No|||April 2015|April 13, 2015|September 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01682187||79625|
NCT01678300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000100|Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)|Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)||Beth Israel Deaconess Medical Center|No|Completed|August 2012|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|70|||Both|18 Years|80 Years|No|Non-Probability Sample|The population of this study will be adults with diagnosed Ulcerative Colitis who have        been prescribed topical mesalamine (Rowasa/Canasa) for treatment of their ulcerative        colitis.|November 2015|November 13, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01678300||79923|
NCT01679444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-003693|MRS Probe Study of Alcohol|Magnetic Resonance Spectroscopy Probe Study of Alcohol Use||Mayo Clinic|No|Completed|August 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01679444||79836|
NCT01679756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EAES 7625|INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer|INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer: a Randomized Clinical Trial. (IN EXTREMO Study)|INEXTREMO|Ospedale Misericordia e Dolce|Yes|Not yet recruiting|March 2013|June 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|384|||Both|18 Years|80 Years|No|||September 2012|September 1, 2012|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01679756||79812|
NCT01679769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-455|Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B|Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic||Peking University First Hospital|Yes|Completed|May 2012|November 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Time Perspective: Prospective||1|Actual|818|Samples Without DNA|liver biopsy samples and blood samples|Both|18 Years|75 Years|No|Non-Probability Sample|patients with chronic hepatitis B or compensated cirrhosis due to chronic hepatits B virus        (HBV) infection|November 2015|November 4, 2015|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01679769|2 Weeks|79811|
NCT01680029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PM001|PBASE-system Acute Migraine Clinical Investigation|A Clinical Investigation to Evaluate the Safety and Performance of the PBASE-system When Used in the Treatment of Acute Migraine Episodes of Moderate to Severe Intensity||Chordate Medical|No|Terminated|January 2013|||||N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|65 Years|No|||November 2013|November 8, 2013|September 3, 2012||No|Too slow recruitment rate|No||https://clinicaltrials.gov/show/NCT01680029||79791|
NCT01680016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V49_24|A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults|A Phase IIIb, Randomized, Open-label Study Comparing Two Different Rabies Vaccine Post-exposure Schedules (Zagreb 2-1-1 and Rabipur® Essen 1-1-1-1-1) in Chinese Children and Older Adults||Novartis|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|644|||Both|6 Years|N/A|Accepts Healthy Volunteers|||April 2014|April 22, 2014|September 3, 2012||No||No|January 7, 2014|https://clinicaltrials.gov/show/NCT01680016||79792|
NCT01680536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSAT 046|A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study||CINAMMON|St Stephens Aids Trust||Completed|November 2012|February 2016|Actual|November 2015|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|18 Years|65 Years|No|||February 2016|February 26, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680536||79752|
NCT01680796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTKI258AU012T|Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma|Phase I, Open Label, Clinical Study to Determine the Maximum Tolerated Dose (MTD) of Oral Dovitinib (TKI258) When Given in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Patients||University of Florida|Yes|Withdrawn|February 2013|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 18, 2013|August 29, 2012|No|Yes|The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily    treated multiple myeloma.|No||https://clinicaltrials.gov/show/NCT01680796||79732|
NCT01679600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CardioRobot|Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise|Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise: A Randomised Controlled Pilot Trial||Bern University of Applied Sciences|Yes|Completed|August 2012|April 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||July 2015|July 30, 2015|August 29, 2012||No||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01679600||79824|
NCT01679613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1199.161|Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers|Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)||Boehringer Ingelheim||Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|34|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 26, 2014|September 3, 2012||||No|November 14, 2014|https://clinicaltrials.gov/show/NCT01679613||79823|
NCT01679054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Roche-TR116582|Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong|Cost-minimization Analysis of Xeloda® vs 5-fluorouracil-based Treatment for Gastric Cancer Patients in Hong Kong||Chinese University of Hong Kong|No|Completed|October 2011|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|58|||Both|18 Years|N/A|No|Non-Probability Sample|CDARS data will be accessed at respective sites to identify patients with aGC who have        completed either EOX or EOF regimens.|August 2012|August 31, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679054||79866|
NCT01679288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECO-AAA|Screening for Abdominal Aortic Aneurysm and Abdominal Aortic Atherosclerosis by Hand-Held Ultrasonography|Feasibility of Hand-Held-Ultrasonography in Primary Care in the Screening of Abdominal Aortic Aneurysm and Abdominal Aortic Atheromatosis.|ECO-AAA|Consorci d'Atenció Primària de Salut de l'Eixample|Yes|Completed|January 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|106|||Male|50 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 15, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01679288||79848|
NCT01679678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MWPH-2012-08-01|A Study, Performed in Subjects With Post Traumatic-post Surgical Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily Regimen|A Double Blind, Randomized, Controlled Study, Performed in Subjects With Post Traumatic-post Surgical Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of Polyheal-2 vs PolyHeal in Once Daily Regimen||MediWound Ltd|No|Not yet recruiting|November 2012|December 2013|Anticipated|November 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||August 2012|September 1, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01679678||79818|
NCT01679938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SALUD-2009-01-114027|A Child Care-based Obesity Prevention Intervention|Prevention of Obesity in Children: An Intervention Based on Child Care Centers Belonging to the Mexican Institute of Social Security||Instituto Nacional de Salud Publica, Mexico|Yes|Active, not recruiting|May 2011|November 2012|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|640|||Both|2 Years|4 Years|Accepts Healthy Volunteers|||September 2012|September 3, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01679938||79798|
NCT01680211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OL-S-OB-LP/03-12|Safety and Efficacy Study of Herbal Supplements in Prediabetic and Mild to Moderate Hyperlipidemic Patients|Efficacy and Safety Study of Herbal Supplements (SR-L-01, SR-B-01 and SI-S-01) in the Management of Prediabetes and Mild to Moderate Hyperlipidemia||Olive Lifesciences Pvt Ltd|Yes|Completed|April 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|4||Actual|40|||Both|18 Years|65 Years|No|||September 2012|September 3, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01680211||79777|
NCT01680458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0561022|Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication|Special Investigation Of Fluconazole For Pediatric Subjects|DREAM|Pfizer|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|N/A|6 Years|No|Probability Sample|The patients whom an investigator involving A0561022 prescribes the fluconazole        (Diflucan).|November 2015|November 4, 2015|September 4, 2012|No|Yes||No|November 4, 2015|https://clinicaltrials.gov/show/NCT01680458||79758|
NCT01681017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN HBB Study|Global Network Implementation of Helping Babies Breathe (HBB)|Global Network for Women's and Children's Health Research Does Implementation of HELPING BABIES BREATHE (HBB) Save Lives?||NICHD Global Network for Women's and Children's Health|Yes|Completed|September 2012|December 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|70704|||Both|16 Years|N/A|No|||October 2015|October 13, 2015|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01681017||79715|
NCT01681004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|300103|Investigation of Sacroiliac Fusion Treatment (INSITE)|INSITE Investigation of Sacroiliac Fusion Treatment|INSITE|SI-BONE, Inc.|No|Active, not recruiting|September 2012|December 2016|Anticipated|February 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|21 Years|70 Years|No|||June 2015|June 3, 2015|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01681004||79716|
NCT01681316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DH20120703|Danhong Injection in the Treatment of Chronic Stable Angina|A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Chronic Stable Angina||China Academy of Chinese Medical Sciences|Yes|Recruiting|December 2012|||December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|870|||Both|18 Years|70 Years|No|||March 2016|March 17, 2016|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681316||79692|
NCT01681329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOP-82771-12-04|Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder|Improving Outcomes for Adults With Generalized Anxiety Disorder: Combining Cognitive-Behavioral Treatment and Interpretation Modification Training|CBT+IMT-GAD|Concordia University|No|Recruiting|September 2012|March 2017|Anticipated|March 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681329||79691|
NCT01681927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|220488-4|Study of Idiopathic Edema|Study of Idiopathic Edema||Winthrop University Hospital|No|Recruiting|November 2011|May 2018|Anticipated|May 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Anticipated|75|||Female|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with idiopathic edema|December 2015|December 9, 2015|August 8, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01681927||79645|
NCT01682174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-05775|Glycaemic Response to a Liquid Meal Tolerance Test|Effects of Dehydrated Vegetable Powder on Glycaemic Responses to a Liquid Meal Tolerance Test (LMTT)||Mondelēz International, Inc.|No|Completed|September 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|13|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682174||79626|
NCT01678001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRZ IIT - 2011 - 009|Treatment of Plantar Fasciitis With Xeomin|Treatment of Plantar Fasciitis With Xeomin: A Randomized, Placebo-Controlled, Double-Blinded, Prospective Study|Xeomin|Rothman Institute Orthopaedics|No|Recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2014|September 23, 2014|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678001||79946|
NCT01678287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0052|Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults|A Phase 1, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Dosing of ASP1941 and to Explore the Effect of ASP1941 on Glucose Levels in Healthy Adult Subjects (18 to 45 Years and ≥ 65 Years)||Astellas Pharma Inc|No|Completed|November 2007|January 2008|Actual|January 2008|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|4||Actual|65|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 30, 2012|August 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678287||79924|
NCT01678586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-001795|Effect of Acupuncture and Pain Medication on Radicular Pain Using QST|Effect of Acupuncture and Pain Medication on Radicular Pain Using QST||Massachusetts General Hospital|Yes|Recruiting|December 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Anticipated|100|||Both|18 Years|75 Years|No|||December 2015|December 2, 2015|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678586||79901|
NCT01678911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIC_Dep_CPP_2012|Efficacy of Gralise® for Chronic Pelvic Pain|Efficacy of Gralise® for Chronic Pelvic Pain||Rehabilitation Institute of Chicago|Yes|Terminated|August 2012|June 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|N/A|No|||June 2015|June 26, 2015|August 31, 2012|Yes|Yes|Study ended due to difficulties in recruitment and low enrollment.|No|May 20, 2015|https://clinicaltrials.gov/show/NCT01678911||79877|This study was terminated early due to low recruitment. Therefore, the data presented represents a very small sample, with low 'n's in each group. The data tables represent all available data for the small sample.
NCT01678924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|214868-007|A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia|||Allergan|Yes|Terminated|January 2013|September 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|282|||Both|18 Years|80 Years|No|||October 2015|October 20, 2015|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678924||79876|
NCT01670981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABI 55-1202-1|An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)|MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TRANSENDOCARDIAL INJECTION OF IXMYELOCEL-T IN SUBJECTS WITH HEART FAILURE DUE TO ISCHEMIC DILATED CARDIOMYOPATHY (IDCM).|ixCELL DCM|Vericel Corporation|Yes|Active, not recruiting|October 2012|February 2017|Anticipated|February 2016|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|114|||Both|30 Years|86 Years|No|||March 2016|March 22, 2016|August 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670981||80484|
NCT01670994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-ALT-801-01-11|A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma|A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma||Altor Bioscience Corporation|Yes|Active, not recruiting|August 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|66|||Both|18 Years|N/A|No|||December 2015|December 8, 2015|August 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01670994||80483|
NCT01679145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE2597/141;ZI1119/31;WI709/101|Learning and Relapse Risk in Alcohol Dependence|Learning Mechanisms as Predictors of Treatment Outcome in Alcohol- Dependent Patients|LeAD|Technische Universität Dresden|No|Active, not recruiting|January 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|225|Samples With DNA|liver encymes|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Detoxified alcohol- dependent patients and age- and gender matched healthy controls living        in Germany|December 2015|December 1, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679145|1 Year|79859|
NCT01679158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR600|MOTIVATE Weight Loss Study|Evaluating MOTIlity, Hormonal Impact, Satiety, and Weight Changes With VArying Procedural TEchniques Utilizing the Incisionless Operating Platform for the Treatment of Primary Obesity|MOTIVATE|USGI Medical|Yes|Completed|February 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|21 Years|60 Years|No|||April 2015|April 1, 2015|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679158||79858|
NCT01680042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck-023|Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy|Phase 1 Study of Phenytoin Mucoadhesive Paste for Wound Healing After Oral Biopsy||hahid Beheshti University of Medical Sciences|Yes|Recruiting|October 2012|||March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||October 2012|October 1, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01680042||79790|
NCT01680055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Aplastic Anemia 1|Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors|||Shandong University||Recruiting|February 2009|November 2012|Anticipated|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|70|||Both|16 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Patients With Aplastic Anemia|September 2012|September 3, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01680055||79789|
NCT01680289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Adhesive1|Influence of the Number of Layers of a One Bottle Adhesive on the Longevity of Composite Restorations in Primary Molars|Influence of the Number of Layers of a One Bottle Adhesive on the Longevity of Composite Resin Restorations in Primary Molars - Randomized Controlled Clinical Study.||Universidade Federal do Rio de Janeiro|No|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|5 Years|8 Years|Accepts Healthy Volunteers|||September 2012|November 25, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01680289||79771|
NCT01680081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2011-0064|Adenosine-induced Stress Dynamic Myocardial Perfusion Imaging With Dual-source CT|||Yonsei University|No|Recruiting|August 2011|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|152|||Both|40 Years|80 Years|No|||March 2014|March 4, 2014|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01680081||79787|
NCT01680302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/978b-2|Effect of 3 Years of Exercise on Development of Atrial Fibrillation|Effect of 3 Years of Exercise on Development of Atrial Fibrillation - A "Generation 100" Substudy||Norwegian University of Science and Technology|No|Active, not recruiting|September 2012|December 2025|Anticipated|December 2025|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|4000|||Both|70 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 20, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680302||79770|
NCT01679067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALT-HIV|Gut Associated Lymphatic Tissue (GALT) in HIV (Human Immunodeficiency Virus)- Infected Patients|Phase IV Longitudinal Study of Gut Associated Lymphatic Tissue (GALT) in HIV (Human Immunodeficiency Virus)- Infected Patients Before and During Antiretroviral Therapy (ART)||University of Cologne|No|Completed|June 2011|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|Samples With DNA|Endoscopic biopsies, PBMC|Both|18 Years|65 Years|No|Non-Probability Sample|prospective longitudinal non- controlled phase IV study, 30 patients|January 2016|January 12, 2016|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01679067||79865|
NCT01679301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HRC-1216-SimGoSleep-SS|Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator|Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator||Philips Respironics|No|Recruiting|September 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|20|||Both|21 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from the Principal Investigator's clinic, as well as the        Philips Respironics Home Healthcare Research Registry. This study is designed to allow        both continuous and pulsed dose nocturnal oxygen users to participate.|October 2012|October 22, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01679301||79847|
NCT01679951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100734|A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate|A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Dose Range Finding Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy||Janssen Research & Development, LLC|Yes|Terminated|October 2012|July 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|272|||Both|18 Years|80 Years|No|||April 2015|April 13, 2015|September 3, 2012|Yes|Yes|The decision was made to prematurely discontinue this trial due to lack of efficacy.|No||https://clinicaltrials.gov/show/NCT01679951||79797|
NCT01680692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12094|Continuous Femoral and Tibial Nerve Blocks in TKA Patients|A Prospective, Randomized Study Comparing Continuous Femoral and Tibial Nerve Blocks vs. Continuous Femoral and Single Shot Sciatic Nerve Block in Total Knee Arthroplasties.||Texas Tech University Health Sciences Center|No|Terminated|August 2012|March 2014|Actual|March 2014|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||October 2013|May 5, 2014|August 29, 2012||No|Principal Investigator left institution--no subjects completed the study|No||https://clinicaltrials.gov/show/NCT01680692||79740|
NCT01680718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Behavioral Neuropeptides|Neuropeptides and Social Behavior|Neuropeptides and Social Behavior||University of California, Los Angeles|No|Completed|October 2012|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|160|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01680718||79738|
NCT01681030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|400-12-002|The Fibrin Pad Cardiovascular Study|A Randomized, Controlled, Comparative Phase II Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery||Ethicon, Inc.|Yes|Completed|August 2012|September 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|42|||Both|18 Years|N/A|No|||September 2014|September 9, 2014|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681030||79714|
NCT01681043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120001|Sleep Investigation in Respirator Treated ICU Patients: the Importance of Intensive Environment|||Vejle Hospital|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|19|||Both|18 Years|N/A|No|||March 2015|March 24, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01681043||79713|
NCT01681342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRACHY-HDR|Sparing of Organs at Risk in High Dose Rate Brachytherapy|Prospective Study on the Sparing of Organs at Risk in High Dose Rate Brachytherapy for Cervix Cancer||Centre Oscar Lambret|No|Completed|June 2011|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|24|||Female|18 Years|75 Years|No|Non-Probability Sample|Patients with indication of HDR brachytherapy in cervix carcinoma of stage IB to II.        After realization of external radiation therapy done (60 Gy in IMRT)|July 2013|July 24, 2013|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681342||79690|
NCT01678313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL004|Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels|COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level||Buddhist Tzu Chi General Hospital|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|140|||Male|40 Years|N/A|No|||July 2014|July 2, 2014|August 29, 2012||No||No|April 8, 2014|https://clinicaltrials.gov/show/NCT01678313||79922|
NCT01678573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100668|A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants|A Single-Dose, Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Pharmacokinetics of Abiraterone in Chinese Healthy Male Subjects||Janssen Research & Development, LLC|Yes|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2013|September 5, 2013|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678573||79902|
NCT01670370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSPH-001|Trial of GemOx±R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma|Randomized Controlled Trial of GemOx±R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma||The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|January 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|60 Years|N/A|No|||August 2012|August 19, 2012|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670370||80531|
NCT01678937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1783-011|Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents|Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents||Northwestern University|No|Completed|September 2007|September 2008|Actual|May 2008|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|31|Samples With DNA|Blood tests: Monotherapy patients        1. Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low           cells).        2. Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to           process antigens (CD83; CD205); markers that have been shown to induce regulatory T           cells (ILT3; ILT4).        3. Soluble HLA G      Blood tests: Conversion patients        1. Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low           cells).        2. Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to           process antigens (CD83; CD205); markers that have been shown to induce regulatory T           cells (ILT3; ILT4),        3. Soluble HLA G, and        4. Liver function and drug levels.      Blood tests: Healthy controls (same tests as Monotherapy Group)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Liver transplant patients converting on stable IS monotherapy or undergoing conversion to        rapamycin or MMF monotherapy.|April 2015|April 14, 2015|July 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01678937||79875|
NCT01671332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO11508|Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer|Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy||University of Wisconsin, Madison|Yes|Active, not recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||May 2015|May 8, 2015|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671332||80458|
NCT01671306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1037|The Association Between Monocyte Subsets and Coronary Collateral Development in Diabetes Mellitus|The Association Between Monocyte Subsets and Coronary Collateral Development in Diabetes Mellitus||Samsun Education and Research Hospital|No|Completed|January 2011|October 2011|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|83|||Both|30 Years|80 Years|No|Non-Probability Sample|The study population consisted of 83 consecutive type 2 diabetic patients who have        undergone coronary angiography because of stable symptoms and signs of coronary artery        disease. The main inclusion criterion was the presence of >95% stenosis of at least one        major coronary artery in their first coronary angiogram.|August 2012|August 22, 2012|August 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01671306||80460|
NCT01671319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO10104|Dose Dense TC + Pegfilgrastim Support for Breast Cancer|Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer|ddTC|University of Wisconsin, Madison|Yes|Completed|June 2011|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|41|||Female|18 Years|N/A|No|||July 2013|July 2, 2013|August 5, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671319||80459|
NCT01679457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-001010/1; McLean|Assessing Models of Exposure Therapy|Assessing Models of Exposure Therapy||Mclean Hospital|Yes|Enrolling by invitation|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01679457||79835|
NCT01679470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-LC-001|Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors|A Pilot Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors||Nanospectra Biosciences, Inc.|Yes|Active, not recruiting|October 2012|July 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|August 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01679470||79834|
NCT01679808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GK-18|Pressure Dependent Tracheal Obstruction in Copd Patients|Pressure Dependent Tracheal Obstruction in Copd Patients|PDTO|LHL Helse|Yes|Completed|August 2004|August 2011|Actual|August 2006|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|104|||Both|N/A|N/A|No|Non-Probability Sample|Patients (both sexes) in a pulmonary rehabilitation clinic|September 2012|September 3, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679808||79808|
NCT01680068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012815b|Air Tamponade in Macular Hole Surgery|Air Tamponade in Macular Hole Surgery||Helse Stavanger HF|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|N/A|N/A|No|||December 2013|December 4, 2013|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01680068||79788|
NCT01672086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|344-01|Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System|Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System||StelKast, Inc.|No|Active, not recruiting|August 2012|August 2022|Anticipated|August 2022|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|320|||Both|18 Years|N/A|No|Non-Probability Sample|All patients treated with the Stelkast Surpass Acetabular System at the participating        siteswill be included in the evaluation.|November 2014|November 17, 2014|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672086||80400|
NCT01679080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TreatOI|The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta|The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta||University of Aarhus|No|Recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|80|||Both|22 Years|70 Years|No|||December 2015|December 3, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01679080||79864|
NCT01679314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC-001|Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment|A Prospective, Single Site, Randomized, Controlled, Parallel Group Study in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Stage III and IV Using AlphaCore or Sham (Control, Not Active) as a Prophylactic Treatment||ElectroCore LLC|Yes|Completed|July 2012|May 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|54|||Both|40 Years|75 Years|No|||October 2013|October 4, 2013|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01679314||79846|
NCT01680224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HD071900|Effectiveness Trial of a Dissonance-Based Obesity Prevention Program|Effectiveness Trial of a Dissonance-Based Obesity Prevention Program|Project Health|Oregon Research Institute|Yes|Active, not recruiting|September 2012|August 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|360|||Both|17 Years|23 Years|Accepts Healthy Volunteers|||October 2015|October 15, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01680224||79776|
NCT01680237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BoSPmA|Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia|Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia||Ruhr University of Bochum|No|Recruiting|October 2011|December 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|18 Years|65 Years|No|||October 2015|October 29, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01680237||79775|
NCT01680471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ECho2012|A Study on the Effects of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery|Comparative Study on the Effects of Capacities of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery : a Randomized Double- Blinded Trial||Korea University Anam Hospital|Yes|Completed|July 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|90|||Both|1 Year|13 Years|No|||January 2013|January 3, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01680471||79757|
NCT01680731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39146|3D Ultrasound in Women With Vacuum or Forceps Deliveries|3-Dimension Ultrasound Findings in Women Who Have Undergone Vacuum Versus Forceps-Assisted Vaginal Deliveries|VADUS|University of Rochester|No|Completed|October 2011|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||4|Actual|45|||Female|18 Years|45 Years|No|Non-Probability Sample|Forty primiparous subjects with a history of a singleton pregnancy who have undergone a        term vacuum assisted vaginal delivery, forceps assisted vaginal delivery, spontaneous        vaginal delivery, or elective primary cesarean section or spontaneous vaginal delivery        with 10 subjects in each group.|February 2014|February 19, 2014|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680731||79737|
NCT01680744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R38OT22183|The Effect of Therapeutic Hypothermia on Deceased Donor Renal Graft Outcomes - a Randomized Controlled Trial From the Region 5 Donor Management Goals Workgroup|||University of California, San Francisco|Yes|Completed|May 2012|November 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|370|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01680744||79736|
NCT01681368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120191|Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer|Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal||National Institutes of Health Clinical Center (CC)|No|Completed|August 2012|April 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 5, 2012|Yes|Yes||No|January 21, 2015|https://clinicaltrials.gov/show/NCT01681368||79688|
NCT01681381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I-LOVE-IT2|Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization|A Prospective, Open Label, Randomized Study to Evaluate Safety And Effectiveness Of The Tivoli® Biodegradable Polymer Rapamycin-Eluting Stent and The FIREBIRD2® Rapamycin-Eluting Coronary CoCr Stent For Treatment Coronary Revascularization||Essen Technology (Beijing) Co., Ltd.|Yes|Recruiting|September 2012|September 2018|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2790|||Both|18 Years|N/A|No|||November 2012|February 20, 2013|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01681381||79687|
NCT01681355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLU.1.C/A|Gastrointestinal Tolerance Study of a New Infant Formula|Open-label Study to Evaluate the Gastrointestinal Tolerance of a New Infant Formula in Healthy, Term, Asian Infants|BOOGIE|Danone Asia Pacific Holdings Pte, Ltd.|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|50|||Both|N/A|17 Weeks|Accepts Healthy Volunteers|||January 2013|January 8, 2013|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01681355||79689|
NCT01678326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012.061-2-JSha|EUS-Guided Rendezvous or Direct Interventions Versus Advanced ERCP Techniques for Biliary Access and Therapy|Endoscopic Ultrasound Guided Rendezvous or Direct Interventions Versus Advanced ERCP Techniques for Biliary Access and Therapy||California Pacific Medical Center Research Institute|No|Recruiting|August 2012|September 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|230|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01678326||79921|
NCT01678339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CIT-XXX-2012/1|Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients|Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients|HEALTH-DB ACS|AstraZeneca|No|Withdrawn|September 2012|December 2012|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|All patients discharged alive from an hospitalization for Acute Myocardial Infarction        (AMI) between January, 1st 2008 and December, 31st 2010 (inclusion period) will be        included into analysis. The discharge date will be defined as "inclusion date".|October 2012|October 2, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01678339||79920|
NCT01670383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNUHEM-Repository-12-0001|Repository for Sepsis and Postresuscitation Samples|Repository for Samples Collected From Sepsis and Postresuscitation Patients in Emergency Intensive Care Unit||Seoul National University Hospital|Yes|Recruiting|July 2006|January 2021|Anticipated|December 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|500|Samples Without DNA|Patients sera at ICU admission, day-1, day-3 and day-7 are stored in deep freezer.|Both|16 Years|N/A|No|Probability Sample|Sepsis patients admitted to ICU Postresuscitation patients admitted to ICU|March 2016|March 3, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01670383||80530|
NCT01670396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZS-XN-ISR|Genetics Study of In-stent Restenosis|G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents|ISR|Shanghai Zhongshan Hospital|Yes|Recruiting|March 2012|September 2012|Anticipated|August 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|300|Samples With DNA|whole blood|Both|18 Years|N/A|No|Probability Sample|Hospitalized patients|August 2012|August 19, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01670396||80529|
NCT01670669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRU-USA-24|Prucalopride in Paediatric Subjects, With Functional Faecal Retention|An Open-label Follow-up Study of 0.01 mg/kg/Day to 0.03 mg/kg/Day Prucalopride (R108512) Oral Solution in Paediatric Subjects, Aged >= 4 to <= 12 Years With Functional Faecal Retention (FFR), Who Participated in the PRU-USA-12.||Movetis||Completed|November 1998|July 1999|Actual|July 1999|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|4 Years|12 Years||||August 2012|August 20, 2012|July 31, 2012||||||https://clinicaltrials.gov/show/NCT01670669||80508|
NCT01671345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 12-050|An Educational Intervention for Type 2 Diabetes Patients|A Randomized Trial of an Educational Intervention in Type 2 Diabetes Patients|ACTIVet|VA Office of Research and Development|No|Recruiting|November 2013|November 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01671345||80457|
NCT01671579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00061688|Comparison of Bowel Ultrasound & MR Enterography in the Follow-up of Previously Diagnosed Pediatric Small Bowel Crohn Disease|Comparison of Bowel Ultrasound & MR Enterography in the Follow-up of Previously Diagnosed Pediatric Sm. Bowel Crohn Disease.||Children's Hospital Medical Center, Cincinnati|Yes|Recruiting|March 2012|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|10 Years|18 Years|No|||January 2016|January 26, 2016|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671579||80439|
NCT01671592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-052|Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)|Safety and Feasibility Evaluation of the MRI-based Tracking of Alpha-type-1 Dendritic Cell Vaccines in Patients With Colorectal Cancer||University of Pittsburgh|Yes|Completed|January 2013|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|6|||Both|18 Years|N/A|No|||December 2015|December 23, 2015|August 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01671592||80438|
NCT01671566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUCHUmU01|Interval Training in Adults With Congenital Heart Disease a Randomized Trial|Effect of Home Based Interval Training on Exercise Capacity and Quality of Life in Adults With Congenital Heart Disease - a Randomized Controlled Multicenter Trial||Umeå University|No|Completed|September 2012|March 2016|Actual|March 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|2||Actual|26|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671566||80440|
NCT01671826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LGT-2012|Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years|Prospective, Observational, Multicenter Trial Evaluating Autologous Stem Cell Transplantation for Myeloma Patients Over the Age of 65|LATMM|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|55|||Both|18 Years|N/A|No|Non-Probability Sample|Newly diagnosed myeloma patients over 65 years of age and a measurable disease.|June 2015|June 23, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671826||80420|
NCT01672346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZODIAC_TCAI|PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation|Pulmonary Vein (PV) Reconnection After Pulmonary Vein Antrm Isolation (PVAI) at Different Power Settings and Adenosine Provocation|ZODIAC|Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|May 2013|December 2016|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|188|||Both|18 Years|80 Years|No|||May 2015|May 19, 2015|August 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672346||80380|
NCT01679964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MISP40301|Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study|A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen|TaISENWITCH|Lin, Hsi-Hsun, M.D.|No|Recruiting|July 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|20 Years|N/A|No|||September 2012|September 5, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01679964||79796|
NCT01679977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOBIL|Vibrational-proprioceptive Resistance Exercise Training Versus Neuromuscular Electrical Stimulation Training in Elderly People With Muscle Weakness||MOBIL|Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation|No|Completed|June 2008|March 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|150|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||March 2016|March 4, 2016|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01679977||79795|
NCT01679990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PLX 1204-01|Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)|A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel- Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects With Intermittent Claudication (IC)||Pluristem Ltd.||Recruiting|October 2012|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Anticipated|150|||Both|45 Years|85 Years|No|||February 2016|February 2, 2016|September 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01679990||79794|
NCT01680250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SILVER|Sirolimus for Massive Polycystic Liver|An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver|SILVER|Seoul National University Hospital|No|Recruiting|September 2011|August 2015|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|65 Years|No|||September 2012|September 3, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01680250||79774|
NCT01680484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEK 10/117-13|Bitter Chocolate or Orange Juice for Non-reactive Non-stress Test (NST) Patterns|Bitter Chocolate Versus Orange Juice for Non-reactive Non-stress Test (NST) Patterns: A Randomized Prospective Controlled Study||Dr. Sami Ulus Children's Hospital||Completed|February 2011|January 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|3||Actual|180|||Female|18 Years|45 Years|No|||September 2012|September 6, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01680484||79756|
NCT01680497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/MED/FIL/018|Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds|||Allergan|No|Completed|June 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 5, 2015|September 4, 2012||No||No|June 5, 2015|https://clinicaltrials.gov/show/NCT01680497||79755|
NCT01681056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1134-1994|Efficacy Study of Autosuggestion for Quality of Life of Geriatric Patients|Quality of Life and Psycho-Neuro-Endocrine-Immunology Pathway of Geriatric Patients: A Trial of Autosuggestion|ESAQoGe|Indonesia University|Yes|Completed|August 2010|February 2012|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|51|||Both|60 Years|N/A|No|||October 2012|October 2, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01681056||79712|
NCT01681069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INQ/009712|Efficacy and Safety of IQP-VV-102 in Weight Management|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-VV-102 in Reducing Body Weight in Overweight and Obese Subjects||InQpharm Group|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|120|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 5, 2015|September 4, 2012||No||No|September 1, 2015|https://clinicaltrials.gov/show/NCT01681069||79711|
NCT01681940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-04|Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis|A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis||Zymenex A/S|No|Completed|January 2012|September 2013|Actual|August 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Both|5 Years|21 Years|No|||September 2012|February 9, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01681940||79644|
NCT01681953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rhLAMAN-05|A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis.||Zymenex A/S|Yes|Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|5 Years|35 Years|No|||February 2015|February 9, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01681953||79643|
NCT01681641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUHN-0211-AH|Managing Changes in Life After Deep Brain Stimulation for Parkinson's Disease|Managing Changes in Life After Deep Brain Stimulation for Parkinson's Disease - Designing and Developing a Targeted Nursing Program to Patients and Spouses.||University of Aarhus|No|Recruiting|February 2011|July 2014|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|N/A|N/A|No|||September 2012|September 7, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01681641||79667|
NCT01681654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENHANCE10001991|Exercise and Nutrition for Head and Neck Cancer Patients|Exercise and Nutrition for Head and Neck Cancer Patients: A Patient Oriented, Clinic-Supported Randomized Controlled Trial|ENHANCE|University of Calgary|No|Recruiting|June 2012|December 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|4||Anticipated|80|||Both|18 Years|N/A|No|||September 2012|September 5, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01681654||79666|
NCT01678014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DBSAN|Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa|Phase 1 Study of Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia||Ruijin Hospital|Yes|Recruiting|April 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|60 Years|No|||September 2012|September 1, 2012|August 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678014||79945|
NCT01678027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCSTS04-103|Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication|Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study||National Cancer Center, Korea||Recruiting|November 2004|||February 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|1810|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 3, 2014|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01678027||79944|
NCT01678040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000031585|Ventricular Volume as Assessed by Cardiac Magnetic Resonance|MRI Assessment of the Effect of Preload on Ventricular Volumes and Function in Healthy Adult Volunteers||The Hospital for Sick Children|No|Active, not recruiting|May 2012|December 2012|Anticipated|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Staff from the Heart Centre at The Hospital for Sick Children will be sent an email        notifying them of the study. They will be invited to obtain the particulars of the study        by replying to Dr. Daryl Schantz or Dr. Lars Grosse-Wortmann. If they agree to participate        Dr. Schantz will obtain written informed consent.|August 2012|August 30, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01678040||79943|
NCT01671007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.136|GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)|GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)||Boehringer Ingelheim||Recruiting|August 2012|January 2020|Anticipated|January 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|18875|||Both|18 Years|N/A|No|Non-Probability Sample|patients with non-valvular AF|March 2016|March 21, 2016|August 20, 2012||||No||https://clinicaltrials.gov/show/NCT01671007||80482|
NCT01671358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU-00010|Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms|Comparison of Contamination Rates of Medication Storage Cabinets Between Isolation and Non-isolation Rooms With Methicillin-resistant Staphylococcus Aureus (MRSA)||West Virginia University|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|400|||Both|N/A|N/A|Accepts Healthy Volunteers|Probability Sample|Inaptients at an academic medical center|June 2015|June 1, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01671358||80456|
NCT01671631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FORECAST|The Diastolic Pressure Gradient for Patients With Acute Coronary Syndrome: Evaluation of Non Culprit Lesions||FORECAST|University Magna Graecia|No|Recruiting||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|40 Years|80 Years|No|Probability Sample|Patients with Acute Coronary Syndrome and multivessel coronary artery disease.|August 2012|August 22, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671631||80435|
NCT01671605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090846|Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation|Mechanisms of CKD-Induced Foam Cell Formation||Vanderbilt University|Yes|Completed|February 2013|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||3|Actual|100|||Both|18 Years|N/A|No|Probability Sample|Patients with ESRD on hemodialysis (CKD stage V) (ESRD-HD)        Patients with CKD not on dialysis (CKD III-IV)        Controls with normal kidney function (Control)|April 2015|April 1, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671605||80437|
NCT01671839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-01-1004|Study of the Cabochon System for Improvement in the Appearance of Cellulite|Pivotal Study of the Cabochon System for Improvement in the Appearance of Cellulite||Cabochon Aesthetics, Inc.|Yes|Completed|August 2012|December 2015|Actual|September 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|55|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||December 2015|December 17, 2015|August 17, 2012|Yes|Yes||No|July 25, 2014|https://clinicaltrials.gov/show/NCT01671839||80419|
NCT01672099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-3-037|Effects of Dairy on Vitamin K-status|The Effects of a Vitamin K-enriched Dairy Product on Vitamin K-status||Maastricht University Medical Center|No|Completed|September 2010|April 2012|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|45 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 21, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01672099||80399|
NCT01672372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20091119|The Effect of Methylated Vitamin B Complex on Depression|The Effect of Methylated Vitamin B Complex on Depression||University of Miami|Yes|Completed|January 2011|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|N/A|No|||August 2014|August 4, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672372||80378|
NCT01679704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GIS.2012|Determination of Glycemic Index (GI) of Ten Food Products|Determination of Glycemic Index (GI) of Ten Food Products||Danone Asia Pacific Holdings Pte, Ltd.|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|15|||Female|21 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 1, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01679704||79816|
NCT01679717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H4/2012|Postoperative Therapy After Interposition Arthroplasty in CMC1|Postoperative Therapy After Interposition Arthroplasty in CMC1||Diakonhjemmet Hospital|Yes|Recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|20 Years|N/A|No|||May 2015|May 4, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01679717||79815|
NCT01680263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K Homayouni|Kinesiotaping in Treatment of Pes Anserinus Tendino-bursitis|Kinesiotaping in Treatment of Pes Anserinus Tendino-bursitis||Shiraz University of Medical Sciences|No|Completed|February 2012|July 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|20 Years|70 Years|No|||September 2012|September 3, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01680263||79773|
NCT01680510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9373-YR-CTIL|The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil|The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa||Sheba Medical Center|Yes|Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||November 2015|November 22, 2015|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01680510||79754|
NCT01680757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS-001 PLACE III|Study of Left Atrial Appendage Closure in Patients With Atrial Fibrillation - III|Multicenter Registry of Permanent Ligation Approximation Closure Exclusion of the Left Atrial Appendage in Patients With Atrial Fibrillation III (PLACE III)|PLACE III|University of California, San Francisco|No|Withdrawn|September 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|0|||Both|21 Years|N/A|No|||February 2013|February 21, 2013|August 28, 2012|No|Yes|This study has been withdrawn prior to enrollment|No||https://clinicaltrials.gov/show/NCT01680757||79735|
NCT01680770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-566B|Use of Ultrasonography to Determine Fluid-responsiveness for Shock in a Population of Intensive Care Unit Patients|Use of Ultrasonography to Determine Fluid-responsiveness for Shock in a Population of Intensive Care Unit Patients||University of Chicago|Yes|Recruiting|July 2010|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|124|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Intensive Care Unit Patients|June 2015|June 3, 2015|June 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01680770||79734|
NCT01681667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3003|Tablet vs. Liquid Suspension Ibuprofen in the Relief of Pain|Tablet vs. Liquid Suspension Ibuprofen in the Relief of Pain||Albany Medical College|Yes|Recruiting|September 2013|May 2015|Anticipated|May 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|100|||Both|12 Years|65 Years|No|||March 2014|March 10, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01681667||79665|
NCT01682226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-153|Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies|Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies||Memorial Sloan Kettering Cancer Center||Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|2 Years|70 Years|Accepts Healthy Volunteers|||January 2016|January 4, 2016|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682226||79622|
NCT01682239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC 023/2012|Effects of Right Ventricular Pacemaker Lead Position Assessed by MRI|Effects of Different Right Ventricular Lead Positioning on Cardiac Contraction Measured by Cardiac MRI: a Pilot Trial||Medical University of Vienna|Yes|Enrolling by invitation|September 2012|August 2015|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|24|||Both|18 Years|90 Years|No|||September 2012|September 7, 2012|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682239||79621|
NCT01682200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PaspaPharma-04|Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne|An Open Label Pilot Clinical Trial on the Efficacy and Safety of ProOxy Facial Spray (Topical 15% Oxygen Solution) in the Treatment of Moderate Facial Acne Vulgaris Among Filipino Patients||Medivet Pty Ltd|No|Completed|October 2009|September 2011|Actual|March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 7, 2012|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01682200||79624|
NCT01682213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-124|Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation|A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation||Memorial Sloan Kettering Cancer Center||Recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|16 Years|N/A|No|||March 2016|March 2, 2016|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682213||79623|
NCT01682252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01201000247|Analysis of Blood During Surgery for Musculoskeletal Tumors|Cellular Analysis of Blood Suctioned During Surgery for Musculoskeletal Tumors||Rutgers, The State University of New Jersey|No|Terminated|May 2012|February 2016|Actual|November 2015|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|34|||Both|18 Years|90 Years|No|Probability Sample|all patients undergoing orthopedic surgery for remival of musculoskeletal tumors under        general anesthesia|February 2016|February 8, 2016|September 5, 2012||No|investigators felt sufficient data has been collected|No||https://clinicaltrials.gov/show/NCT01682252||79620|
NCT01669824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12557|Pharmacy Based Pharmacoepidemiological Observational Study With Aspirin Protect 100 mg|Tolerability, Compliance and Indications of Aspirin Protect 100 mg in Longterm Use (12 Months) Under Everyday's Conditions - Data Collection With Questionnaires Handed Out in Pharmacies to Aspirin Protect 100 mg Consumers||Bayer|No|Completed|August 2007|May 2009|Actual|||N/A|Observational|Time Perspective: Prospective||1|Actual|4235|||Both|N/A|N/A|No|Non-Probability Sample|Patients who buy Aspirin protect 100 mg with or without prescription in German pharmacies        and who are willing to participate in the study.|August 2012|August 17, 2012|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01669824||80573|
NCT01671410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.398|Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines|A Randomized, Open Label Clinical Trial of Buprenorphine in the Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines or Are Breastfeeding|MOPPlus|Thomas Jefferson University|Yes|Recruiting|August 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|N/A|N/A|No|||February 2016|February 4, 2016|August 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671410||80452|
NCT01671956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Immune/BRT/UC-01|Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis||Immune Pharmaceuticals|No|Recruiting|July 2015|November 2016|Anticipated|October 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|70 Years|No|||February 2016|February 12, 2016|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01671956||80410|
NCT01671969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VLCD1|Very Low Calorie Diet for Diabetic Kidney Disease|||Indiana University|No|Completed|March 2012|March 2014|Actual|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|March 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671969||80409|
NCT01673022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204008493|Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging|Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging for Detecting Metastatic Endometrial and Cervical Cancer|FIRES|Indiana University|Yes|Recruiting|May 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|640|||Female|18 Years|N/A|No|||March 2015|March 26, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673022||80328|
NCT01673256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DETECT AF|DEtermining Accuracy and TrEnding CharacTerization of AF|DEtermining Accuracy and TrEnding CharacTerization of AF||St. Jude Medical|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Care Clinic|March 2015|March 16, 2015|August 22, 2012||No||No|January 5, 2015|https://clinicaltrials.gov/show/NCT01673256||80310|
NCT01672203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UKK-PostLE|Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Incidence in Patients With Central Versus Peripheral Embolism|Incidence of CTEPH in Dependence of Thrombus Location in Patients With Acute Pulmonary Embolism and Index Fibrinolysis||University of Cologne|Yes|Recruiting|January 2009|November 2012|Anticipated|October 2012|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|500|||Both|18 Years|90 Years|No|Probability Sample|Patients who were hospitalized for acute pulmonary embolism at the University Hospital of        Cologne.|August 2012|August 23, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01672203||80391|
NCT01672450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI56809|A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma|A Phase I Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma||University of Utah|Yes|Completed|September 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||July 2015|July 7, 2015|August 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672450||80372|
NCT01672424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11090441|Ultrasound Assessment of Gastric Emptying|Ultrasound Assessment of Gastric Emptying Following the Addition of a High Protein Drink vs Ice Chips During Labor||University of Pittsburgh|Yes|Completed|May 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|18|||Female|14 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|All women of childbearing age (including children aged 14 years and above) who request        epidural analgesia at Magee-Womens Hospital of UPMC will be eligible to participate in the        study. The racial, gender and ethnic characteristics of the proposed subject population        reflects the demographics of Pittsburgh and the surrounding area and/or the patient        population of the University of Pittsburgh Medical Center Health System. Every attempt        will be made to recruit subjects in respective proportion to these demographics.|February 2013|February 1, 2013|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672424||80374|
NCT01669980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P903-24|Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)|A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)||Forest Laboratories|Yes|Completed|October 2012|August 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|2 Months|18 Years|No|||October 2015|October 5, 2015|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669980||80561|
NCT01673230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00364-39|Hemodynamic Indices Predictive of a Beneficial Response to Fluid Expansion in Case of Hemodynamic Failure After Cardiac Surgery With Altered Preoperative Ejection Fraction (LVEF≤45%)|Hemodynamic Indices Predictive of a Beneficial Response to Fluid Expansion in Case of Hemodynamic Failure After Cardiac Surgery With Altered Preoperative Ejection Fraction (LVEF≤45%): Sensibility and Specificity of Respiratory Variations of Pulse Pressure (∆PP), Photoplethysmography (∆POP), Perfusion Index (PVI), Before and After Fluid Expansion.|ALTERVOL|Rennes University Hospital||Recruiting|September 2012|May 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|80|||Both|18 Years|N/A|No|||September 2015|September 11, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673230||80312|
NCT01669083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116741|Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing|A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing||GlaxoSmithKline|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||April 2013|May 2, 2013|August 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01669083||80630|
NCT01669096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116777|Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342|Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 in Healthy Adults||GlaxoSmithKline||Completed|August 2012|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2014|November 13, 2014|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669096||80629|
NCT01669421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20100844|Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.|Effect of a Higher Dose of Alpha-1 Antitrypsin Augmentation Therapy on Lung Inflammation in Subjects With Alpha-1 Antitrypsin Deficiency.||University of Miami|No|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||September 2015|September 25, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669421||80604|
NCT01676220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12347|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy|6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs With a 6-month Safety Extension Period|EDITION III|Sanofi|No|Completed|August 2012|March 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|878|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|August 28, 2012|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01676220||80083|
NCT01676233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY12335|Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus|A Randomized, Open-label, 2-treatment Crossover Study of a New Formulation of Insulin Glargine Comparing to Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus on Treatment With Basal-bolus Insulin||Sanofi|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|20 Years|N/A|No|||August 2013|August 16, 2013|August 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01676233||80082|
NCT01676246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Flpmetab2008|Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine|Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine After Intravenous, Single Dose and Chronic Oral Administration in Healthy Subjects Genotyped for NAT2, UGT1A1 and GSTP1||University Medicine Greifswald|No|Completed|May 2008|June 2009|Actual|May 2009|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|36|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676246||80081|
NCT01676480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2009-102|The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving Androgen Deprivation Therapy|The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving ADT||Rigshospitalet, Denmark|Yes|Completed|September 2009|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 3, 2012|January 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01676480||80063|
NCT01676493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODE-OS+T-(2-17)-SPK-1|A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural Pain|A Multicenter, Open-Label, Safety and Pharmacokinetic Study of Oral Codeine Sulfate Administration in Pediatric Subjects 2 Years Old Through 17 Years Old With Post-procedural Pain||Roxane Laboratories|No|Terminated|August 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|2 Years|17 Years|No|||February 2014|February 12, 2014|August 24, 2012||No|Decision to stop study due to low recruitment.|No||https://clinicaltrials.gov/show/NCT01676493||80062|
NCT01676792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100CT221|SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma|A Pilot Study to Assess the Efficacy & Safety of Topical SR-T100 Gel in the Treatment of Human Vulva Pre-cancerous Lesions (Vulvar Intraepithelial Neoplasia; VIN) & Cutaneous Condyloma(External Genital Warts; EGWs)||National Cheng-Kung University Hospital|No|Completed|April 2011|October 2013|Actual|April 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|20 Years|N/A|No|||April 2014|April 21, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676792||80039|
NCT01670487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEB-02|Vapocoolant (Pain Ease Medium Stream) for Intravenous Lines in Emergency Department Patients|Prospective,Randomized,Blinded, Comparative,Efficacy and Safety Trial of Vapocoolant (Pain Ease Medium Stream) for Intravenous Cannulation in Emergency Department Patients.||The Cleveland Clinic|Yes|Completed|October 2012|December 2014|Actual|November 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|302|||Both|18 Years|80 Years|No|||December 2014|December 5, 2014|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670487||80522|
NCT01677611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIG 35|Effects of Resveratrol in Patients With Type 2 Diabetes|Effects of Resveratrol in Patients With Type 2 Diabetes: The RED Trial|RED|Khoo Teck Puat Hospital|Yes|Completed|December 2008|March 2012|Actual|September 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|10|||Male|40 Years|69 Years|No|||August 2012|August 31, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677611||79976|
NCT01671098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06301998|Sinonasal Gas Exchange Dynamics|Sinonasal Gas Exchange Dynamics The Aerodynamic Theory of the Sinonasal Interface||Louisiana State University Health Sciences Center Shreveport|No|Completed|August 2013|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||3|Actual|12|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adult patients who had balloon sinuplasty of traditional endoscopic uncinectomy for        treatment of chronic maxillary sinusitis|August 2015|August 18, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671098||80475|
NCT01671111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD602-301|Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)|A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)||Shire||Terminated|August 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|6 Years|N/A|No|||August 2014|July 10, 2015|August 16, 2012|No|Yes|This study was terminated due to treatment stop resulting in an inability to draw conclusions    from the data. Evaluation of nonclinical rat findings is ongoing.|No|July 10, 2015|https://clinicaltrials.gov/show/NCT01671111||80474|This study was terminated early due to non-clinical safety results. Not all participants completed the study. The available efficacy data were analyzed as specified in the statistical analysis plan; however, no efficacy conclusions were drawn.
NCT01671709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|615/10|Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671709||80429|
NCT01671722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|616/10|Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|February 2010|March 2010|Actual|March 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671722||80428|
NCT01672710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GW093066|Gulf War Illness: Evaluation of an Innovative Detoxification Program|Pilot Study of Application of the Hubbard Detoxification Program to Veterans With Gulf War Illness||University at Albany|Yes|Completed|April 2010|December 2015|Actual|November 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|N/A|N/A|No|||December 2015|December 9, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01672710||80352|
NCT01672723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Opioids and Social Cognition|Neuropharmacological Basis of Social Connection: The Role of Opioids|Neuropharmacological Basis of Social Connection: The Role of Opioids||University of California, Los Angeles|No|Completed|October 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|34|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||December 2015|December 10, 2015|August 20, 2012|No|Yes||No|May 29, 2015|https://clinicaltrials.gov/show/NCT01672723||80351|
NCT01669161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Mt-St-01|Paired Vagus Nerve Stimulation (VNS) With Rehabilitation for Upper Limb Function Improvement After Stroke|A Proof-of-Concept Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Rehabilitation for Improved Upper Limb Function After Stroke (MicroTransponder's Vivistim System)||MicroTransponder Inc.|Yes|Completed|February 2013|December 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|80 Years|No|||December 2015|December 10, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01669161||80624|
NCT01669174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBYM338X2204|BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia|A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia||Novartis|Yes|Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|67|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 16, 2015|March 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669174||80623|
NCT01672463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCI57337|Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients|Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients|OKN-007|Oklahoma Medical Research Foundation|Yes|Recruiting|December 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||October 2015|October 13, 2015|August 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672463||80371|
NCT01669109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-4957-BO|Hatha Yoga for Patients With Colorectal Cancer|Hatha Yoga for Patients With Colorectal Cancer - a Randomized Controlled Trial|YoCo|Universität Duisburg-Essen|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|54|||Both|18 Years|N/A|No|||January 2014|January 9, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669109||80628|
NCT01672697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12005-TriHealth|Physical Therapy for Women With Obstetric Trauma and Anal Incontinence|Effects of Physical Therapy on Pelvic Floor Symptoms and Quality of Life in Postpartum Women Following Severe Perineal Trauma: a Randomized Controlled Trial||TriHealth Inc.|No|Active, not recruiting|July 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|65|||Female|18 Years|N/A|No|||April 2015|July 9, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672697||80353|
NCT01670253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120069|Reduction of Starvation Time Prior to Gastroscopy|Randomized, Double-blind, Controlled, Parallel-group Study Reduction of Starvation Time Prior to Gastroscopy|RETIME|Odense University Hospital|No|Not yet recruiting|August 2012|January 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Diagnostic|2||Anticipated|600|||Both|18 Years|N/A|No|||August 2012|August 21, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01670253||80540|
NCT01670526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLIN-003-10S|Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI|Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI|RIVET|VA Office of Research and Development|Yes|Active, not recruiting|January 2013|December 2016|Anticipated|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 29, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01670526||80519|
NCT01670539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-22930|Home Telemonitoring for Patients With Lung Cancer|PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca|HTPLC|West Virginia University|Yes|Recruiting|June 2010|May 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|70|||Both|45 Years|90 Years|No|||August 2012|August 21, 2012|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01670539||80518|
NCT01659658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C16011|Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis|A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis||Millennium Pharmaceuticals, Inc.|Yes|Recruiting|December 2012|April 2020|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|248|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659658||81334|
NCT01659944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZGD04112|Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults|A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adult Subjects.||Sanofi|No|Completed|May 2012|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||March 2015|March 19, 2015|August 6, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01659944||81312|
NCT01675999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P100131|Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer|PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer|ECKINOXE|Assistance Publique - Hôpitaux de Paris|Yes|Recruiting|May 2012|February 2021|Anticipated|May 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|186|||Both|18 Years|76 Years|No|||January 2012|January 14, 2016|February 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675999||80100|
NCT01669954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJ1 09/0329|Determination of Optimum Age for DXA Screening for Osteoporosis in HIV - The Probono 1 Study|Prospective Study to Determine the Optimum Age for Routine DEXA Screening for Osteopenia/Osteoporosis in People With HIV Infection|Probono1|King's College London|No|Completed|February 2009|June 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|440|Samples Without DNA|Plasma and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|A randomly recruited numbers of HIV uninfected controls and HIV patients aged 18 years or        above, equally matched for age, and gender.|August 2012|August 17, 2012|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01669954||80563|
NCT01670214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIYAYESH CLINIC 1|Pulsed Electromagnetic Field Therapy in the Refractory Migraine|A Randomized, Placebo-control of Pulsed Electromagnetic Field Therapy as Preventive Treatment of Refractory Migraine||Niyayesh Clinic|Yes|Completed|January 2012|October 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|30|||Both|17 Years|55 Years|No|||August 2012|February 15, 2016|January 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670214||80543|
NCT01670227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01MH77331-2|ParentCorps: Promoting Healthy Development in Children From Low Income Communities|Preventing Conduct Problems in Poor Urban Preschoolers|ParentCorps|New York University School of Medicine|No|Completed|September 2005|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|1050|||Both|4 Years|N/A|No|||March 2016|March 1, 2016|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01670227||80542|
NCT01670500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-258|Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa|A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations||Dana-Farber Cancer Institute|Yes|Recruiting|October 2012|June 2018|Anticipated|June 2018|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670500||80521|
NCT01670825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|373481-3|Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia|Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia||Johns Hopkins University|No|Completed|August 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01670825||80496|
NCT01670812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSPH-CLL-001|Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia|Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia||The First Affiliated Hospital with Nanjing Medical University|Yes|Recruiting|January 2012|June 2014|Anticipated|June 2013|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|80 Years|No|||August 2012|August 19, 2012|August 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670812||80497|
NCT01671137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PrevenDAR|Probiotic for the Prevention of Functional Disorders in Childhood|A Randomized Controlled Trial of Lactobacillus Rhamnosus Strain GG for The Prevention of Functional Abdominal Pain Children After Acute Gastroenteritis||University of Bari|Yes|Not yet recruiting|September 2012|September 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|400|||Both|3 Years|16 Years|No|||August 2012|August 20, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01671137||80472|
NCT01671423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4372|Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis|Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis||Albert Einstein Healthcare Network|Yes|Recruiting|August 2012|June 2015|Anticipated|March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|100|||Both|18 Years|70 Years|No|||January 2015|January 30, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671423||80451|
NCT01672476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A657-BR-CT-L301|A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension|fimasartan|Boryung Pharmaceutical Co., Ltd|Yes|Recruiting|March 2012|March 2013|Anticipated|November 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|275|||Both|20 Years|75 Years|No|||August 2012|September 4, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01672476||80370|
NCT01673269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E12053-A|Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD|Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD||Texas Tech University Health Sciences Center|Yes|Completed|July 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Both|18 Years|80 Years|No|||November 2013|November 25, 2013|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673269||80309|
NCT01669122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01333|Pharmacokinetic Study of 4 mg Nicotine Lozenge.|A Randomized, Cross-Over, Single Dose Pharmacokinetic Study of 4mg Nicotine Lozenges.||GlaxoSmithKline|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|40|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2014|January 12, 2015|August 16, 2012||No||No|July 18, 2013|https://clinicaltrials.gov/show/NCT01669122||80627|
NCT01669135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M19-12-21-2010|Spinal Anesthesia for Cesarean Delivery is Associated With Decreases in Regional Cerebral Oxygen Saturation as Assessed by Near- Infrared Spectroscopy|||University of Athens|No|Completed|December 2010|August 2012|Actual|May 2012|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|34|||Female|18 Years|48 Years|No|||August 2012|August 17, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01669135||80626|
NCT01669707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BeijingCH001|Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)|Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)||Beijing Chest Hospital|Yes|Recruiting|April 2011|August 2013|Anticipated|April 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2012|August 17, 2012|August 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669707||80582|
NCT01669434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|369-12-FB|Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery|Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study||University of Nebraska|No|Enrolling by invitation|June 2015|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|19 Years|90 Years|No|||November 2015|November 30, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669434||80603|
NCT01669720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG C261|Adjuvant Aflibercept for Metastatic Colorectal Cancer|BrUOG C261:Single Agent Adjuvant Aflibercept for Patients With Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study|C261|Brown University|Yes|Terminated|December 2012|January 2016|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|August 7, 2012|Yes|Yes|Lack of efficacy and enrollment|No|January 8, 2016|https://clinicaltrials.gov/show/NCT01669720||80581|
NCT01669993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0273|Factors Predictive of Adverse Postoperative Outcomes in Children Undergoing Tonsillectomy|Factors Predictive of Adverse Postoperative Outcomes in Children Undergoing||Children's Hospital Medical Center, Cincinnati|Yes|Enrolling by invitation|May 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|N/A|17 Years|No|Non-Probability Sample|Children undergoing adenotonsillectomy in the United States|August 2012|August 17, 2012|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01669993||80560|
NCT01670006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAM5397|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2012|||||N/A|N/A|N/A||||||||||||||January 28, 2016|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670006||80559|
NCT01659671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007/449-31/3, Ö 21-2007|RCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea||SKUP3|Karolinska University Hospital|Yes|Completed|June 2007|May 2014|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|18 Years|N/A|No|||December 2014|December 12, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659671||81333|
NCT01669395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-021|Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial|Early Homebased Rehabilitation for Patients With Severe Heart Failure - An Intersectoral Randomized Controlled Trial||University Hospital, Gentofte, Copenhagen|No|Not yet recruiting|September 2012|July 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||August 2012|August 16, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669395||80606|
NCT01670240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004268-31|Adalimumab in the Treatment of Chronic Pouchitis|Adalimumab (Humira) in the Treatment of Chronic Pouchitis|ADAP|Odense University Hospital|Yes|Completed|August 2012|January 2016|Actual|September 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|August 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670240||80541|
NCT01670513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DPSI-IDP-118-P2-01|A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118|A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118|IDP-118|Dow Pharmaceutical Sciences|No|Active, not recruiting|June 2012|July 2013|Anticipated|May 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|65 Years|No|||April 2013|April 23, 2013|May 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670513||80520|
NCT01670838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Kuopio UH|Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients|Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients|SAHHEART|Kuopio University Hospital|Yes|Recruiting|July 2012|November 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Non-Probability Sample|Study material consists of 200 consecutive aSAH-patients treated in Kuopio University        Hospital and Turku University Hospital.|February 2015|February 27, 2015|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01670838||80495|
NCT01670851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISIS.11.01.06.BS/SC|Perineal Reconstruction Following eLAPE and Simultaneous Stoma Sublay Reinforcement|Perineal Reconstruction Following Extralevator Abdominoperineal Excision of Rectum and Simultaneous Stoma Sublay Reinforcement|PRESSUR|University Hospitals, Leicester|No|Completed|March 2013|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|patients with low rectal carcinoma|December 2015|December 7, 2015|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01670851||80494|
NCT01671150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Endotoxin 2|Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms|Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms||University of California, Los Angeles|Yes|Completed|March 2011|August 2013|Actual|August 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 16, 2014|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671150||80471|
NCT01671163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|endoscopic fiducial placement|Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiotherapy|EUS-Guided Fiducial Placement for Stereotactic Body Radiotherapy||University of Florida|No|Recruiting|July 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|All subjects who are currently scheduled to undergo fiducial placement at the University        of Florida in Gainesville as medically indicated.|March 2016|March 9, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01671163||80470|
NCT01671176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wide04262012|Wide Diameter Bone Anchored Implant Study|A Clinical Study of the Oticon Medical Ponto 4.5mm Wide Implant||Oticon Medical|No|Completed|May 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||April 2015|April 9, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01671176||80469|
NCT01671436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMIT-1042|Meditation for Depression|Central Meditation and Imagery Therapy for Depression|CMIT|University of California, Los Angeles|Yes|Completed|September 2012|March 2014|Actual|November 2013|Actual|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|18 Years|65 Years|No|||March 2014|March 30, 2014|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671436||80450|
NCT01671124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fer-01|The Study of Antidepressant Properties and Safety of Fer-01(Soline®) on the Patients With Depression|Phase IIa Study of Antidepression Use Natural Plants Extracted of Soline Capsule.||Taipei Medical University Hospital|Yes|Recruiting|September 2012|November 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|20 Years|60 Years|No|Probability Sample|community sample, residents of Taiwan|August 2012|September 9, 2012|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671124||80473|
NCT01671449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMC-ONCGI-1202|S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer|Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer|SOPP|Asan Medical Center|No|Completed|December 2012|October 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|338|||Both|18 Years|N/A|No|||November 2015|November 26, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01671449||80449|
NCT01672229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#229|Bortezomib in Patients With Chronic Graft Versus Host Disease|A Pilot Study Of Weekly Subcutaneous Bortezomib In Patients With Steroid-Refractory Or -Dependent Chronic Graft Versus Host Disease||University of California, Davis|Yes|Active, not recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672229||80389|
NCT01672736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMHOSI906-MM001|A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma|A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma||University Health Network, Toronto|Yes|Active, not recruiting|September 2012|December 2018|Anticipated|June 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|75|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672736||80350|
NCT01673061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HN 4405|Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage|Vapocoolant Spray as a Novel Local Anesthetic for Cutaneous Abscess Incision and Drainage||Albert Einstein Healthcare Network|Yes|Terminated|August 2012|August 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|21|||Both|18 Years|N/A|No|||June 2014|June 20, 2014|August 14, 2012||No|Vapocoolant was not effective in controlling/preventing pain during an abscess incision and    drainage when compared with Lidocaine.|No||https://clinicaltrials.gov/show/NCT01673061||80325|
NCT01673035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HA-X|Internet Treatment for Health Anxiety|Cognitive Behavior Therapy vs. Behavioral Stress Management for Severe Health Anxiety: a Randomized Controlled Trial of Two Internet-based Treatments|HA-X|Karolinska Institutet|No|Completed|September 2012|December 2015|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|178|||Both|18 Years|N/A|No|||March 2016|March 2, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673035||80327|
NCT01673048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3ESINFemur|Modification of ESIN-osteosynthesis in a Femoral Fracture Model and Its Transmission to Clinical Practice|From Bench to Bedside: Modification of Elastic Stable Intramedullary Nailing With a 3rd Nail in a Femoral Spiral Fracture Model and Its Transmission to Clinical Practice|ESIN|University of Luebeck|No|Completed|January 2009|December 2012|Actual|October 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|3 Years|17 Years|No|||February 2014|February 13, 2014|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01673048||80326|
NCT01669148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007p-001197|Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography|Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography||Massachusetts General Hospital|No|Active, not recruiting|November 2007|October 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|600|||Female|35 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 16, 2012|April 30, 2010||No||No||https://clinicaltrials.gov/show/NCT01669148||80625|
NCT01669733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE5112|The Effects of Perioperative Music Therapy on Women Undergoing Breast Biopsy Surgery|The Effects of Perioperative Music Therapy on Women Undergoing Breast Biopsy Surgery||Case Comprehensive Cancer Center|No|Completed|August 2012|August 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|201|||Female|19 Years|N/A|No|||August 2015|August 21, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669733||80580|
NCT01669746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA-0006931|A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)|A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia||Aderans Research Institute|No|Completed|June 2012|||April 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 9, 2013|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669746||80579|
NCT01670019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037462|Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression|A Randomized, Blinded, Comparison of Asenapine and Placebo as Adjunctive Treatment in Patients With Non-Psychotic Major Depressive Disorder Incompletely Responsive to Antidepressant Monotherapy||Duke University|No|Completed|October 2012|June 2014|Actual|May 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|46|||Both|18 Years|65 Years|No|||August 2015|August 31, 2015|August 17, 2012|Yes|Yes||No|June 29, 2015|https://clinicaltrials.gov/show/NCT01670019||80558|
NCT01670292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRiSM Study|Patient Response to Spinal Manipulation|Patient Response to Spinal Manipulation|PRiSM|Palmer College of Chiropractic|Yes|Completed|September 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|82|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 4, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01670292||80537|
NCT01670565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12006|Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis|Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.||Hospital for Special Surgery, New York|Yes|Active, not recruiting|August 2012|February 2016|Anticipated|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||February 2016|February 17, 2016|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01670565||80516|
NCT01670578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KNEEJECT|Platelet-rich Plasma vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology|Platelet-rich Plasma (PRP) vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology: a Randomized Double-blind Controlled Trial|PRP|Istituto Ortopedico Rizzoli|Yes|Completed|February 2009|May 2014|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|192|||Both|18 Years|80 Years|No|||May 2014|September 3, 2014|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01670578||80515|
NCT01660308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105045RC|Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia|Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia||National Taiwan University Hospital|No|Recruiting|June 2011|||June 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|40|||Both|20 Years|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with tumor induced osteomalacia and people without osteomalacia|September 2014|September 9, 2014|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01660308||81286|
NCT01669681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UF 8871|Cobra (Severe Asthma)Medical-economic|Medical Economic Evaluation of the Care of the Severe Asthma : Cohort COBRA|Cobra|University Hospital, Montpellier|Yes|Recruiting|December 2011|January 2016|Anticipated|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|130|||Both|18 Years|N/A|No|Non-Probability Sample|The recruited patients are patients already included in the observationnelle cohort COBRA        in the centers of Marseille, Montpelier or Nice, classified GINA 4 and agreeing to        participate.|April 2013|December 30, 2014|April 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01669681||80584|
NCT01671462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDX-11-EUHPV|European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System|European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System||Becton, Dickinson and Company|No|Completed|August 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|N/A||1|Actual|1365|||Female|N/A|N/A|No|Non-Probability Sample|The study includes retrospectively (residual, frozen) collected SurePath or PreservCyt        vials and prospectively collected BD cervical brushes in BD transport medium, and SurePath        or PreservCyt vials from subjects who meet the inclusion criteria below.|February 2014|February 19, 2014|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01671462||80448|
NCT01671748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-SUR-5323|MIST Ultrasound Therapy Compared to United Kingdom Standard Care for the Treatment of Non-healing Venous Leg Ulcers|Pragmatic Randomised Controlled Trial of MIST Ultrasound Therapy Compared to UK Standard Care for the Treatment of Non-healing Venous Leg Ulcers.||Cardiff and Vale University Health Board|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|August 21, 2012||No||No|June 4, 2015|https://clinicaltrials.gov/show/NCT01671748||80426|Difference in treatment frequency between the groups which could potentially bias results.Standard deviation proved to be larger than estimated from the available literature which resulted in the study having reduced statistical power.
NCT01671475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDEEG|Putting Electroencephalography (EEG) in the Emergency Department|Impact of microEEG on Clinical Management and Outcomes of Emergency Department (ED) Patients With Altered Mental Status||Bio-Signal Group Corp.|Yes|Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|149|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01671475||80447|
NCT01671488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BrUOG 276|A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer|BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer|276|Brown University|Yes|Active, not recruiting|April 2013|May 2018|Anticipated|December 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|25|||Both|18 Years|N/A|No|||February 2016|February 23, 2016|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01671488||80446|
NCT01671735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRP 12-440|VA Diabetes Prevention: Epidemiology of Pre-Diabetes and Implementation Pilot|VA Diabetes Prevention: Epidemiology of Pre-Diabetes and Implementation Pilot||VA Office of Research and Development|No|Withdrawn|September 2012|August 2013|Anticipated|July 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|85 Years|No|||October 2012|October 12, 2012|August 20, 2012||No|Not considered a clinical trial because both treatment protocols have been approved as usual    care|No||https://clinicaltrials.gov/show/NCT01671735||80427|
NCT01672489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P000370|Objective Assessment of the Effects of Shift Work on Drowsiness and Driving Impairment in Hospital Staff|Objective Assessment of the Effects of Shift Work on Drowsiness and Driving Impairment in Hospital Staff||Brigham and Women's Hospital|No|Active, not recruiting|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort||1|Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in this study include shift workers who undertake extended duration shifts        (16 hours or longer) or night shifts (e.g. resident physicians, nursing staff and allied        health staff, police, firefighters, etc.).|August 2015|August 6, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01672489||80369|
NCT01672749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EOS TROLLEY|Evaluation of a Modern System to Allow for Growth in Children With Scoliosis Versus a Conventional Treatment|Evaluation of a Growth Guiding Construct vs. Standard Dual Growing Rods and VEPTR for the Treatment of Early Onset Scoliosis Patients: A Prospective Multi-center Cohort Study With a Matched Historical Control||AO Clinical Investigation and Documentation|Yes|Recruiting|June 2015|April 2027|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|51|||Both|5 Years|10 Years|No|Non-Probability Sample|One third of the patients will be recruited in designated investigation sites using the        TROLLEY system. For each trolley patient one to two comparative matched pairs will be        generated from mining the database of the Chest Wall and Spine Deformity Study Group        (CWSDSG) and the Growing Spine Study Group (GSSG).|July 2015|July 14, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01672749||80349|
NCT01673334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15779|Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms|Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms||University of Virginia|Yes|Active, not recruiting|September 2011|||July 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|40|||Both|18 Years|90 Years|No|||August 2012|August 24, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673334||80304|
NCT01669226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V01-2009-03|First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer|A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)|AICE|Shanghai Gynecologic Oncology Group|Yes|Recruiting|April 2009|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Female|18 Years|75 Years|No|||May 2015|October 30, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01669226||80619|
NCT01673308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-MDS-PI-0722|Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome|Salvage in Patients With Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Lenalidomide as a Second-line Therapy|VIOLET|Ulsan University Hospital|No|Active, not recruiting|August 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673308||80306|
NCT01673321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|27226|Protein Concentrations in Yogurt and Satiety, Food Intake and Glycemia in Healthy Men|Effect of Varied Protein Concentrations in Greek Yogurt on Glycemic Response, Satiety and Next Meal Food Intake in Healthy Young Men||University of Toronto|No|Completed|February 2012|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|5||Actual|20|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673321||80305|
NCT01669447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSouza|Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis|Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis.||University of Campinas, Brazil|No|Not yet recruiting|September 2012|December 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|20|||Both|50 Years|N/A|No|||August 2012|August 20, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669447||80602|
NCT01669187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OU-4824|The Effects of Pre-operative Physical Therapy Education|Phase 1 of the The Effects of Pre-operative Physical Therapy Education and Exercise on Patient Outcomes Post Breast Cancer Surgery: a Randomized Controlled Trial||Oakland University|No|Withdrawn|December 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|0|||Both|18 Years|N/A|No|||April 2014|April 9, 2014|July 20, 2012||No|Study withdrawn.|No||https://clinicaltrials.gov/show/NCT01669187||80622|
NCT01669460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-5041-C|Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy|A Phase II, Open Label Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy||University Health Network, Toronto|Yes|Completed|July 2012|||July 2013|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|20|||Male|18 Years|85 Years|No|||December 2013|December 18, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669460||80601|
NCT01669759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMR101-IRB2-151|The Study in the Correlation Between the Severity of Post-stroke Fatigue and the Severity of qi Deficiency and Blood Stasis|The Study in the Correlation Between the Severity of Post-stroke Fatigue and the Severity of qi Deficiency and Blood Stasis in Chinese Medicine.||China Medical University Hospital|No|Recruiting|July 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||1|Anticipated|90|||Both|40 Years|80 Years|No|Non-Probability Sample|Patients with post-stroke fatigue were enrolled from the departments of neurological,        neurosurgical, and rehabilitation in China Medical University Hospital (Taichung, Taiwan),        their Brief Fatigue Inventory-Taiwan form score ≥ 4, and stroke onset more than 3 months.|August 2012|August 20, 2012|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669759||80578|
NCT01670032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.06. SPR. 18216|Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo|A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo||NovaBay Pharmaceuticals, Inc.|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|328|||Both|2 Years|N/A|No|||August 2014|August 8, 2014|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670032||80557|
NCT01670045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28216|A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab||Hoffmann-La Roche||Completed|March 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|43|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiating treatment with RoActemra/Actemra|February 2016|February 1, 2016|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670045||80556|
NCT01670305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0272.0.251.000-10|Photodynamic Therapy and Periodontal Therapy. A Clinical, Microbiological and Immunoenzymatic Analysis|Photodynamic Therapy and Periodontal Therapy. A Clinical, Microbiological and Immunoenzymatic Analysis.||Paulista University|Yes|Completed|February 2011|March 2013|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|75|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||September 2013|September 10, 2013|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01670305||80536|
NCT01669057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2011-366|Study on Clinical Prognosis, Risk Factors and Genetic Basis of Congenital Heart Disease|Case-control Study on Environmental and Genetic Factors of Congenital Heart Disease|SCPRFGBCHD|Children's Hospital of Fudan University|Yes|Completed|October 2011|August 2014|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|6000|Samples With DNA|whole blood|Both|N/A|3 Years|Accepts Healthy Volunteers|Non-Probability Sample|The population is from two ongoing projects— "Key Clinical Research Project Sponsored by        Ministry of Health Screening, evaluation and intervention of congenital heart disease in        newborn infants(2010-239)" and "Health and Public Welfare Research Project Sponsored by        Ministry of Health of China Screening and evaluation of congenital heart disease in        children of under 3 years old in the countryside(20102006)"|March 2015|March 9, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669057||80632|
NCT01669694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-317|Pelvic Floor Physical Therapy-Biomarkers Project|Women's Urology Center-Physical Therapy-Biomarkers Project||William Beaumont Hospitals|No|Completed|October 2011|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|59|Samples With DNA|serum and urine|Female|18 Years|100 Years|No|Non-Probability Sample|Women in the Beaumont Women's Urology Center who have pelvic pain and are starting pelvic        floor PT in our center.|October 2015|October 13, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01669694||80583|
NCT01669967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R11-132|The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin|The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin||Lawson Health Research Institute|No|Completed|September 2011|December 2015|Actual|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)|2||Actual|34|||Both|18 Years|80 Years|No|||March 2016|March 19, 2016|June 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01669967||80562|
NCT01670890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|pumch-neurosurgery-01|Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas|Efficacy and Safety of Salvage Treatment With Dose-dense TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas: a Multicentre,Prospective Clinical Study||Peking Union Medical College Hospital|Yes|Recruiting|August 2012|||August 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|No|||August 2012|August 21, 2012|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01670890||80491|
NCT01671228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V4_01_JUN_12|Developing and Evaluating the Yorkshire Dialysis Decision Aid|Development of a Patient Decision Aid (PtDA) to Facilitate Renal Patients Informed Decisions About Dialysis Treatments|YoDDA|University of Leeds|Yes|Completed|January 2011|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|4||Actual|488|||Both|18 Years|N/A|No|||April 2014|April 30, 2014|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01671228||80466|
NCT01671761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-19|Normative Data of Brain Network Activation in Adolescents and Young Adults|Establishment of Normative Data of Brain Network Activation (BNA) Using Evoked Response Potentials in Adolescents and Young Adults||ElMindA Ltd|No|Completed|August 2012|July 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|43|||Both|15 Years|24 Years|Accepts Healthy Volunteers|Non-Probability Sample|Experimental subjects will include males and females recruited from the New York City        metropolitan area, Clinilabs Ltd. Clinical Research's database and from referrals.|April 2015|April 8, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671761||80425|
NCT01671982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTER|ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment|Tenofovir Pharmacokinetics in HIV-infected Thai Adults With Moderate Renal Function Impairment Receiving Either a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based or Lopinavir/Ritonavir-based Antiretroviral Therapy|ALTER|Institut de Recherche pour le Developpement|No|Completed|August 2012|May 2015|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||May 2015|May 28, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01671982||80408|
NCT01671995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTIMAL|Optimising Congestive Heart Failure Outpatient Clinic Project|Optimising Congestive Heart Failure Outpatient Clinic Project (OPTIMAL)|OPTIMAL|Karolinska Institutet|No|Completed|January 1996|June 2001|Actual|June 2001|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|208|||Both|60 Years|N/A|No|||August 2012|August 21, 2012|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01671995||80407|
NCT01672008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOX-100-ORIENT201|NOX-100 for Preventing Hypotension During Hemodialysis|A Phase IIa Study of Safety and Efficacy of NOX-100 for Preventing Hypotension in Patients During Hemodialysis Sessions||Medinox, Inc.|Yes|Completed|August 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|62|||Both|20 Years|80 Years|No|||December 2015|December 30, 2015|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672008||80406|
NCT01672242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00052656|Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)|Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)||University of Maryland|Yes|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|6|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||April 2014|April 25, 2014|August 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672242||80388|
NCT01672502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMW-2010-FP-00521|Fire Fighter Fatigue Management Program: Operation Fight Fatigue|Fire Fighter Fatigue Management Program: Operation Fight Fatigue||Brigham and Women's Hospital|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|620|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 15, 2016|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01672502||80368|
NCT01672775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGS-16C3F-12-2|A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology|A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology||Astellas Pharma Inc|No|Active, not recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|8||Actual|34|||Both|18 Years|N/A|No|||February 2016|February 5, 2016|August 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672775||80347|
NCT01672788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1276.7|Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets|Bioequivalence of Empagliflozin/Metformin (850 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)||Boehringer Ingelheim||Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|August 22, 2012||||No|June 26, 2015|https://clinicaltrials.gov/show/NCT01672788||80346|
NCT01669265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLTI-1113|Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer|Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer|SOLO-1|SOLTI Breast Cancer Research Group|No|Completed|June 2012|August 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|701|||Female|N/A|N/A|No|Non-Probability Sample|Patients with cT1-3, N0 breast cancer, who had intraoperative SLN evaluation by OSNA assay        with a complete axillary lymph node dissection.|November 2014|November 17, 2014|May 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01669265||80616|
NCT01669239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLTI-1002|Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer|OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet®) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer|OptiHER-Heart|SOLTI Breast Cancer Research Group|Yes|Active, not recruiting|June 2013|November 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|83|||Female|18 Years|74 Years|No|||January 2015|January 9, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01669239||80618|
NCT01669252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOLTI-1007|Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer|A Phase II, Open-label, Single-arm, Exploratory Pharmacogenomic Study of Single Agent Eribulin (HALAVEN®) as Neoadjuvant Treatment for Operable Stage I-II HER2 Non-overexpressing Breast Cancer.|NeoEribulin|SOLTI Breast Cancer Research Group|Yes|Completed|August 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|163|||Both|18 Years|N/A|No|||August 2015|August 5, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01669252||80617|
NCT01673282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP1065|Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy|A Non-interventional, Observational Study Evaluating Changes in Drug Load and Seizure Frequency Using Vimpat (Lacosamide) in Daily Clinical Practice in Combination Therapy With Sodium Channel Blocking Anti-epileptic Drugs (AEDs) or Non Sodium Channel Blocking AEDs|VICTOS|UCB Pharma|No|Completed|July 2012|July 2015|Actual|July 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|315|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients with focal epilepsy with or without secondary generalization.|July 2015|July 27, 2015|August 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01673282||80308|
NCT01673295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P1200_11|RING - Rituximab for Lupus Nephritis With Remission as a Goal|RING - Rituximab for Lupus Nephritis With Remission as a Goal, an Investigator-initiated Randomized International Open Multicentric Study|RING|Université Catholique de Louvain|Yes|Recruiting|November 2014|November 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|194|||Both|15 Years|N/A|No|||May 2015|May 27, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673295||80307|
NCT01669473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1U19HS021093-01|A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use|A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use||Northwestern University|Yes|Recruiting|June 2013|September 2017|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|600|||Both|18 Years|90 Years|No|||August 2015|August 11, 2015|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01669473||80600|
NCT01669772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA-9701 trial|Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Volunteers|Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Males and Female Subjects||The Catholic University of Korea|Yes|Completed|March 2012|December 2013|Actual|February 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|20 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 2, 2014|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01669772||80577|
NCT01669785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTP-002|NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study|NUPRO Sensodyne Prophylaxis Paste With NovaMin for the Treatment of Dentin Hypersensitivity.||Dentsply International|No|Completed|March 2012|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|139|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||August 2014|August 20, 2014|June 8, 2012|Yes|Yes||No|February 20, 2014|https://clinicaltrials.gov/show/NCT01669785||80576|
NCT01670058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM103-074|Pattern Of Use Of Belatacept In US Transplant Recipients|Pattern Of Use Of Belatacept In US Transplant Recipients||Bristol-Myers Squibb|No|Active, not recruiting|January 2012|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|5000|||Both|N/A|N/A|No|Non-Probability Sample|The cohort for the analyses of all transplants includes all organ transplant recipients        who are reported with Belatacept at transplant|January 2016|January 27, 2016|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670058||80555|
NCT01670331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STH16575|Psychological Preparation Prior to Bariatric Surgery|Psychological Preparation Prior to Bariatric Surgery: A Feasibility Study||Sheffield Teaching Hospitals NHS Foundation Trust|No|Recruiting|March 2013|June 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 23, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01670331||80534|
NCT01670318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPECIALIST Registry|Study Examining the PROMUS Element Everolimus-eluting Stent in Multi-center Coronary Intervention of Complex Arterial Lesion Subsets|Study Examining the PROMUS Element Everolimus-eluting Stent in Multi-center Coronary Intervention of Complex Arterial Lesion Subsets|SPECIALIST|The PCI Guideline Research Society|Yes|Recruiting|August 2012|December 2015|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|800|||Both|20 Years|85 Years|No|||August 2012|August 21, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01670318||80535|
NCT01670617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSU2011-03B|DeNovo NT Natural Tissue Graft Stratified Knee Study|A Stratified, Post-Market Study of DeNovo NT for the Treatment of Femoral and Patellar Articular Cartilage Lesions of the Knee||Zimmer Orthobiologics, Inc.|No|Recruiting|March 2012|December 2021|Anticipated|December 2018|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|254|||Both|18 Years|55 Years|No|||July 2015|July 21, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01670617||80512|
NCT01678794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-003284|CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function|Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function||Mayo Clinic|Yes|Recruiting|February 2012|April 2017|Anticipated|April 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01678794||79886|
NCT01678807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8237-008|Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)|Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)||Merck Sharp & Dohme Corp.|No|Completed|October 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|195|||Both|12 Years|17 Years|No|||January 2016|January 19, 2016|August 31, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01678807||79885|
NCT01671189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMMC-MCK-2012|Automated SMS-Based Appointment Validation Tool|An Automated SMS-Based Reminder and Rescheduling Tool to Improve Appointment Adherence Rates and Glycemic Control Among Diabetes Patients in San Mateo County||Medic Mobile|No|Not yet recruiting|October 2012|December 2013|Anticipated|October 2013|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2012|August 22, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671189||80468|
NCT01671215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC120026CTIL|Endometrial and Myometrial Changes, With and Without Fibroids|Endometrial and Myometrial Changes, With and Without Fibroids||Meir Medical Center|No|Withdrawn|August 2012|||August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|20 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|women at the age of 20-45|April 2012|April 14, 2015|August 20, 2012||No|no enrollment|No||https://clinicaltrials.gov/show/NCT01671215||80467|
NCT01671501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P0048609_Satre|Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients|Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients||University of California, San Francisco|Yes|Active, not recruiting|March 2013|August 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|600|||Both|18 Years|N/A|No|||June 2015|June 8, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671501||80445|
NCT01671514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSD IRB 111680|Effects of Dark Chocolate on Exercise Capacity, and Mitochondrial Structure and Function|Effects of Epicatechin-enriched Dark Chocolate on Mitochondrial Function and Exercise Capacity in Patients With Both Diabetes and Heart Failure and in Sedentary Individuals||University of California, San Diego|Yes|Completed|July 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|21|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671514||80444|
NCT01671774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GM-IMAB-001-04|Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer|Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus or the Gastro-esophageal Junction.|PILOT|Ganymed Pharmaceuticals AG|Yes|Completed|August 2012|October 2014|Actual|October 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||December 2015|December 14, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671774||80424|
NCT01672021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02243|Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients|Initial Assessment of 18FDG-PET/MRI in Determining the Extent of Systemic Disease in Breast Cancer Patients.||New York University School of Medicine|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|125|||Both|20 Years|80 Years|No|||July 2015|July 30, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672021||80405|
NCT01672255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SSRI and Exercise|Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)|Hypoglycemia Associated Autonomic Failure in Type 1 DM, SSRI and Exercise||University of Maryland|Yes|Recruiting|October 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|64|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 30, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01672255||80387|
NCT01672515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-RIPC-cerebral infarction|Protective Effects of Remote Limb Ischemic Preconditioning on Acute Cerebral Infarction|Phase 2 Study of Remote Limb Ischemic Preconditioning on Acute Cerebral Infarction||Capital Medical University|Yes|Not yet recruiting|October 2012|||October 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|40 Years|80 Years|Accepts Healthy Volunteers|||August 2012|August 22, 2012|August 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672515||80367|
NCT01672762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0122|A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients|Phase 3 Study of ASP1941 - A Long-term Administration Study in Subjects With Type 2 Diabetes Mellitus (T2DM)||Astellas Pharma Inc|No|Completed|June 2012|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|174|||Both|20 Years|N/A|No|||January 2016|January 19, 2016|August 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01672762||80348|
NCT01672801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P-000186|Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT|Using Nimodipine, a Calcium Channel Blocker, to Prevent LH Surge in Women Undergoing Controlled Ovarian Stimulation and Intrauterine Insemination: a Double-blinded, Randomized Controlled Study|NIMO|Boston IVF|Yes|Completed|September 2012|October 2015|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|22|||Female|25 Years|40 Years|Accepts Healthy Volunteers|||July 2015|January 11, 2016|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672801||80345|
NCT01669499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZonMW 11510009|Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009|Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study||UMC Utrecht|Yes|Recruiting|January 2012|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|411|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669499||80598|
NCT01669200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC12024|Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment|Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment||Pennington Biomedical Research Center|No|Recruiting|August 2012|October 2014|Anticipated|August 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|50 Years|N/A|No|||June 2014|June 6, 2014|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669200||80621|
NCT01669213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSAhn_ramosetron_hypotension|Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension|Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension After Spinal Anesthesia||Seoul National University Hospital||Active, not recruiting|August 2012|August 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Anticipated|100|||Both|20 Years|70 Years|No|||August 2012|August 17, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01669213||80620|
NCT01669798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033060|BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer|Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma||Duke University|No|Recruiting|February 2013|January 2018|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01669798||80575|
NCT01670084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC1184|Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia|A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage||Mayo Clinic|Yes|Withdrawn|December 2012|September 2017|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||October 2015|October 29, 2015|August 17, 2012|Yes|Yes|No Accrual|No||https://clinicaltrials.gov/show/NCT01670084||80553|
NCT01670071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100817|A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia|A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia||Johnson & Johnson Taiwan Ltd|No|Terminated|January 2013|June 2015|Actual|June 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|17|||Both|20 Years|60 Years|No|||September 2015|September 25, 2015|August 17, 2012||No|The study was terminated due to insufficient sample size and protocol compliance issue.|No||https://clinicaltrials.gov/show/NCT01670071||80554|
NCT01670344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10308644 Final 2.5|Evaluation of an Innovative Medical Device Supporting Orthopedic Surgical Interventions|Virtual Implant Planning System - A Method to Support Image-guided Surgical Interventions|VIPS|Siemens Healthcare QT|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01670344||80533|
NCT01670643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-11-116|Reading Performance With a Video Magnifier|The Effect of Video Camera Magnifier Use on Reading||Massachusetts Eye and Ear Infirmary|No|Completed|January 2010|February 2011|Actual|April 2010|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|120|||Both|40 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy|August 2012|August 20, 2012|December 6, 2010||No||No||https://clinicaltrials.gov/show/NCT01670643||80510|
NCT01670656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08257|A Study to Evaluate the Effect of Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)|A Multicenter, Randomized, Partially Blinded, Placebo-controlled Clinical Trial to Evaluate the Effect on Primary Dysmenorrhea of Vaginal Rings With an Average Daily Release of 700 μg Nomegestrol Acetate (NOMAC) and 300 μg Estradiol (E2), or 900 μg Nomegestrol Acetate (NOMAC) and 300 μg Estradiol (E2), or 100 μg Etonogestrel (ENG) and 300 μg E2, or 125 μg Etonogestrel (ENG) and 300 μg E2. Protocol MK-8175A/MK-8342B 057 (Abbreviated as P057), Also Known as SCH900121/SCH900432 08257 (Abbreviated as P08257)||Merck Sharp & Dohme Corp.|No|Completed|January 2013|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|439|||Female|18 Years|50 Years|No|||September 2015|September 24, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670656||80509|
NCT01678820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0431D-266|A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)|A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy||Merck Sharp & Dohme Corp.|No|Terminated|October 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|299|||Both|18 Years|79 Years|No|||October 2014|October 16, 2014|August 31, 2012|Yes|Yes|Merck terminated the study for business reasons in November 2013.|No|October 16, 2014|https://clinicaltrials.gov/show/NCT01678820||79884|Study was terminated for business reasons in November 2013.
NCT01678833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|999912480|Understanding Drug Abuse Treatment Outcomes|Neural Mechanistic Explanations for Differential Drug Abuse Treatment Outcomes||National Institutes of Health Clinical Center (CC)||Completed|July 2012|March 2016||||N/A|Observational|N/A|||Anticipated|18|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||March 2016|March 8, 2016|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01678833||79883|
NCT01670864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|QTW2012|Promoting Smoking Cessation in the Community Via Quit to Win Contest 2012|Promoting Smoking Cessation in the Community Via Quit to Win Contest 2012: Aa Cluster Randomized Controlled Trial of 18 Districts in Hong Kong||The University of Hong Kong|Yes|Completed|July 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|1193|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2013|July 22, 2013|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670864||80493|
NCT01670877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209135|Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer|A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer||Washington University School of Medicine|No|Recruiting|December 2012|November 2020|Anticipated|December 2018|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|70|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670877||80492|
NCT01670552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIPEMS1111|Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients|Parallel Study, Double-blind, Randomized, to Compare the Safety of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients.||EMS|Yes|Not yet recruiting|February 2016|April 2017|Anticipated|January 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|206|||Both|18 Years|65 Years|No|||November 2015|November 9, 2015|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670552||80517|
NCT01671254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|POT2-FMR-CT|Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation|A Double-blind, Placebo-controlled Trial of a Dietary Supplement Containing Citrus Bioflavonoids and Vitamin E at 2 Doses in Conjunction With Fish Oil Supplementation in Hyperlipidemic Subjects||MetaProteomics LLC|No|Recruiting|August 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|3||Anticipated|72|||Both|18 Years|72 Years|Accepts Healthy Volunteers|||August 2012|August 20, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671254||80464|
NCT01671800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20548|Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating|Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis Associated Symptomatic Sweating, or Residual Limb Hyperhidrosis in Amputees||Henry M. Jackson Foundation for the Advancement of Military Medicine|No|Completed|September 2008|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||January 2013|January 8, 2013|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671800||80422|
NCT01671787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-320-0101|A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B|A Phase 1b Randomized, Open Label, Active-Controlled Study to Assess the Safety, Viral Kinetics, and Anti-HBV Activity of GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B (CHB) Infection||Gilead Sciences|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|51|||Both|18 Years|65 Years|No|||May 2014|May 8, 2014|August 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01671787||80423|
NCT01672034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/477|Impact of Laparoscopic Gastric Bypass Surgery and Weight Reduction on Lower Esophageal Sphincter (LES)|Impact of Laparoscopic Gastric Bypass Surgery and Weight Reduction an Lower Esophageal Sphincter. A Study of Morbidly Obese Patients Before and After Surgery.||Örebro University, Sweden|No|Withdrawn|November 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|60 Years|No|Non-Probability Sample|The initial measurements were made on a group of male and female patients 18-60 years with        BMI > 35, ASA-classification 1-3 planned for laparoscopic bariatric surgery.|November 2014|November 4, 2014|August 21, 2012||No|no patient enrolled|No||https://clinicaltrials.gov/show/NCT01672034||80404|
NCT01672268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A001113-38|Interest of Cardiac Computed Tomography to Optimize and Improve the Procedure of TAVI|Interest of Cardiac Computed Tomography (CT) to Optimize and Improve the Procedure of Transcatheter Aortic Valve Implantation (TAVI)|CT-TAVI|University Hospital, Grenoble|Yes|Completed|February 2012|November 2014|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|18 Years|N/A|No|||April 2012|November 24, 2014|April 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01672268||80386|
NCT01672528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-CAD-5351|Patient Reported Outcome Measures for Ablation of Cardiac Arrhythmias|A Multicentre, Prospective Observational Study to Develop, Evaluate and Validate Patient Reported Outcome Measures (PROMs) for Patients Treated With Cardiac Ablation for Symptomatic Cardiac Arrhythmias||Cardiff and Vale University Health Board|No|Active, not recruiting|September 2012|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|630|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiac arrhythmia clinic|February 2016|February 1, 2016|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01672528||80366|
NCT01673074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UPCC 02507|HPPH and PDT for Pleural Malignancy|A Phase 1 Trial of Photodynamic Therapy With HPPH in Patients With Pleural Malignancy||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|November 2007|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Primary Purpose: Treatment|||Anticipated|37|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|August 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673074||80324|
NCT01677793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201105115RC|Developmental Trajectory of Brain Structural Connectivity and Cognitive Function From Childhood to Adulthood|Developmental Trajectory of Brain Structural Connectivity and Cognitive Function From Childhood to Adulthood||National Taiwan University Hospital|Yes|Recruiting|January 2012|December 2014|Anticipated|||N/A|Observational|N/A||1|Anticipated|140|||Both|8 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|The sample consists of 140 healthy volunteers (70 males and 70 females). The ranges of age        are 8-21 (around 5 males and 5 females in each age group). They will be recruited from        schools and colleges.|August 2012|August 31, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677793||79962|
NCT01673672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYT003-QbG10 12|CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma|A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)||Cytos Biotechnology AG|Yes|Terminated|November 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|365|||Both|18 Years|65 Years|No|||May 2014|May 13, 2014|August 23, 2012|Yes|Yes|primary endpoint missed|No||https://clinicaltrials.gov/show/NCT01673672||80279|
NCT01673685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010090|Trial of Portable Oxygen Cylinders Versus Battery Powered Portable Oxygen Concentrators|Randomised Crossover Trial of Portable Oxygen Cylinders Versus Battery Powered Portable Oxygen Concentrators||The Queen Elizabeth Hospital|Yes|Recruiting|October 2010|||October 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|85 Years|No|||August 2012|August 23, 2012|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673685||80278|
NCT01673698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|The REDUCE Pivotal Trial|A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects|A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects||ReShape Medical, Inc.|Yes|Completed|August 2012|September 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|326|||Both|21 Years|60 Years|No|||November 2015|November 2, 2015|August 15, 2012|Yes|Yes||No|August 25, 2015|https://clinicaltrials.gov/show/NCT01673698||80277|There are no overall limitations and caveats.
NCT01669486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1514|The Pain in Intensive Care Unit: Different Rating System Comparing|The Pain in Intensive Care Unit: An Experimental Research to Compare Behavioural Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT)|ICPain|Università degli Studi dell'Insubria|Yes|Completed|June 2012|April 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|85 Years|No|Non-Probability Sample|Adult male and female Critically ill patients Mechanically ventilated patients|April 2013|April 22, 2013|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669486||80599|
NCT01670097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0001|Dexamethasone Dyspnea Study|A Preliminary Study of Dexamethasone for Dyspnea in Cancer Patients||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2013|||December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2015|June 16, 2015|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670097||80552|
NCT01674231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|321900-2|The Effects Grapes on Health Indices|Pilot Study: The Effects of Whole Grapes on Markers of Health||University of California, Davis|No|Completed|August 2012|April 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 3, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674231||80236|
NCT01670357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA6034_DES_II|Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome|Placebo Controlled, Dose-Response, Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of DA-6034 Eye Drops in Patients With Dry Eye Syndrome|DES|Dong-A ST Co., Ltd.|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|20 Years|N/A|No|||September 2014|September 29, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01670357||80532|
NCT01674764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCI-POEM|Surgical Treatment for Spinal Cord Injury|Prognostic Factors and Therapeutic Effects of Surgical Treatment for Traumatic Spinal Column Injury With Spinal Cord Injury: A Prospective, Observational European Multi-center Study.|SCI-POEM|AOSpine Europe|Yes|Recruiting|November 2012|March 2017|Anticipated|November 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|The study will enroll 300 patients with anticipated 1:2 ratio of early vs. late surgery.        This CIP is not limited to cervical spinal cord injuries, does not consider a diagnostic        MRI as mandatory and will be conducted in a European setting where patients are generally        transported more swiftly to the treating institution when compared to other geographic        regions in the world.|January 2016|January 15, 2016|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01674764||80195|
NCT01675037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1122602|Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy|Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy||University Hospital, Toulouse|No|Recruiting|July 2012|July 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|None Retained|Whole blood, and urine|Both|6 Months|N/A|No|Non-Probability Sample|All patients over 6 months-old with obstructive hydrocephalus who are referred for planned        endoscopic third ventriculocisternostomy to department of neurosurgery in University        Hospital of Toulouse, France.|March 2015|March 25, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675037||80174|
NCT01670266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONO-9054IOU002|Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma|A Double-masked, Placebo-controlled, Dose-escalation Study and Double-masked, Two-sequence, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-9054 in Patients With Ocular Hypertension or Mild Open-Angle Glaucoma||Ono Pharmaceutical Co. Ltd|No|Completed|August 2012|||May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|60|||Both|18 Years|80 Years|No|||May 2013|May 31, 2013|August 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01670266||80539|
NCT01670279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-12-291|Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder|A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder||Otsuka Pharmaceutical Development & Commercialization, Inc.|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|18|||Both|70 Years|85 Years|No|||January 2016|January 5, 2016|August 7, 2012|No|Yes||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01670279||80538|Cohort 3 was not initiated based on the safety/tolerability results from Cohorts 1 and 2.
NCT01671241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LossPreventionTotalBodyWrap|Heat Loss Prevention in Very Preterm Infants in Delivery Rooms: A Multicenter, Randomized, Controlled Trial of Polyethylene Occlusive Total Body Skin Wrapping|||University of Padova|Yes|Recruiting|January 2011|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|80|||Both|N/A|3 Minutes|No|||August 2012|August 22, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01671241||80465|
NCT01671527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3142012|Insights Into Deep Brain Stimulation (DBS) for Cervical Dystonia|Pathophysiological Insights Into STN DBS for Primary Cervical Dystonia||University of Florida|Yes|Recruiting|August 2012|April 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|70|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be recruited from the University of Florida Center for Movement Disorders &        Neurorestoration out-patient population, patient care meetings, the UFMDC research        database, and during the course of normal clinical care. Additionally, we plan to enroll        subjects from other DBS centers. Patients who are diagnosed with primary (or predominantly        primary) cervical dystonia and are candidates for DBS surgery, or who have already had DBS        surgery, will be identified as candidates for this research study.        Control subjects will be recruited via advertising flyers in the local community.|January 2016|January 21, 2016|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671527||80443|
NCT01671540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_Kine_IPV|Effects of IPV Assessed With Functional Imaging|Evaluation of the Effects of Intrapulmonary Percussive Ventilation Using Functional Respiratory Imaging|IPV|University Hospital, Antwerp|Yes|Recruiting|September 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|30 Years|N/A|No|||May 2015|May 27, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671540||80442|
NCT01671553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COSH-SmokefreeTeen|Helping Smokers to Quit Via the Smoke-free Teen Contest 2011: A Randomized Controlled Trial|Helping Smokers to Quit Via the Smoke-free Teen Contest 2011: A Randomized Controlled Trial||The University of Hong Kong|Yes|Recruiting|October 2011|October 2012|Anticipated|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|269|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 20, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671553||80441|
NCT01672060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010s0569|BC Healthy Connections Project|A Scientific Evaluation of the Nurse-Family Partnership (NFP) Program in British Columbia|BCHCP|Simon Fraser University|Yes|Recruiting|October 2013|October 2018|Anticipated|October 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|1040|||Female|N/A|24 Years|No|||May 2015|May 20, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672060||80402|
NCT01672047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PURCP201103|Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients|Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients|EVIDENCE|Peking University People's Hospital|Yes|Recruiting|April 2012|December 2015|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|75 Years|No|||August 2012|August 29, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672047||80403|
NCT01672281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|vbx|vibroX-training in Endurance Trained Men|Influence of vibroX-training on the Power-duration-relationship and Maximal Force in Relation to Conventional Resistance Training in Endurance Trained Men||University of Zurich|No|Completed|November 2011|December 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|30|||Male|18 Years|35 Years|No|||May 2013|May 13, 2013|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01672281||80385|
NCT01672814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VED-001|Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus|A Randomized, Controlled Study of the Vedera™ KXS Microwave System With Corneal Collagen Cross-Linking Compared With Corneal Collagen Cross-Linking Alone for Eyes With Keratoconus||Cornea and Laser Eye Institute|No|Recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 22, 2015|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01672814||80344|
NCT01673347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-182|Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe|Allograft Knee Meniscal Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe|MTP|William Beaumont Hospitals|Yes|Active, not recruiting|September 2010|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2015|August 26, 2015|August 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673347||80303|
NCT01677520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12.08.004|Investigation of Stem Cells in Human Lipoaspirate|Investigation of Adipose-Derived Stem Cells in Human Lipoaspirate||University of Nevada, Las Vegas|No|Recruiting|March 2011|August 2018|Anticipated|August 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|240|Samples Without DNA|Cells from lipoaspirate maximum of 20 days|Both|18 Years|70 Years|No|Non-Probability Sample|Primary Care Clinic|January 2015|January 8, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01677520||79983|
NCT01677806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JNMGH20120821|Safety and Efficacy Study of Percutaneous Vertebroplasty for Painful Acute Osteoporotic Spine Fractures|Investigational Percutaneous Vertebroplasty Efficacy and Safety Trial||Jinan Military General Hospital|Yes|Enrolling by invitation|October 2012|December 2014|Anticipated|October 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|50 Years|N/A|No|||September 2014|September 9, 2014|August 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677806||79961|
NCT01673711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011NTUC092|Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer|Correlation of [D10] Phenanthrene Metabolism With Bronchoepitheial Dysplasia and Metaplasia in Smokers at High Risk for Lung Cancer||University of Minnesota - Clinical and Translational Science Institute|Yes|Recruiting|July 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|350|||Both|18 Years|N/A|No|||January 2014|August 21, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01673711||80276|
NCT01669811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D961UC00002|Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)|A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of D961H 20 mg Twice Daily Oral Administration and D961H 20 mg Once Daily Oral Administration in Patients With Refractory Reflux Esophagitis||AstraZeneca||Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1398|||Both|20 Years|N/A|No|||August 2015|August 19, 2015|August 17, 2012||No||No|May 18, 2015|https://clinicaltrials.gov/show/NCT01669811||80574|
NCT01674244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09594|Integrative Exercise for Post-Deployment Stress|Integrative Exercise for Post-Deployment Stress||Northern California Institute of Research and Education|Yes|Active, not recruiting|March 2013|August 2015|Anticipated|August 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|65 Years|No|||April 2015|April 14, 2015|August 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01674244||80235|
NCT01674491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPS_201106|Effects of Black Soy Peptide Supplementation on Blood Pressure|Effects of Black Soy Peptide Supplementation on Blood Pressure and Oxidative Stress:A Randomized Controlled Trial||Yonsei University|Yes|Completed|July 2011|March 2012|Actual|September 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|100|||Both|30 Years|65 Years|No|||August 2012|August 27, 2012|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01674491||80216|
NCT01674777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1941-CL-0071|A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941|A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of ASP1941||Astellas Pharma Inc|No|Completed|October 2010|December 2010|Actual|December 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label|3||Actual|30|||Male|20 Years|44 Years|Accepts Healthy Volunteers|||August 2012|August 27, 2012|August 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01674777||80194|
NCT01675050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00056045|A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain|A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain||University of Michigan|Yes|Recruiting|August 2012|August 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|8 Years|18 Years|No|||August 2012|August 29, 2012|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675050||80173|
NCT01675063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UM HUM 63973|Minimally Invasive Cardiac Output Monitoring Device|Development of a Minimally Invasive Cardiac Output Monitoring Device for Critically Ill Patients||University of Michigan|No|Active, not recruiting|August 2012|January 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|75|||Both|18 Years|N/A|No|||August 2015|August 16, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675063||80172|
NCT01675297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HL_RSNP_401|Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis|For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis||Hanlim Pharm. Co., Ltd.|No|Recruiting|July 2011|March 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1170|||Both|19 Years|N/A|No|||January 2013|January 17, 2013|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675297||80154|
NCT01670903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-8336-DS-CTIL|The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients|the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients||Sheba Medical Center|No|Recruiting|May 2011|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|150|||Both|50 Years|80 Years|No|Probability Sample|medically treated hypertensive patients, ages 50-80|August 2012|August 19, 2012|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01670903||80490|
NCT01670916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHNEO-NEC01|Probiotics to Prevent NEC - a Historical Control Study|Probiotics to Prevent NEC Stage II+ in Very Preterm Infants - a Historical Control Study||Rigshospitalet, Denmark||Completed|March 2010|June 2013|Actual|April 2013|Actual|Phase 4|Observational|Observational Model: Case Control||2|Actual|714|||Both|N/A|3 Days|No|Non-Probability Sample|Newborn infants admitted for special or intensive care|September 2013|September 30, 2013|August 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01670916||80489|
NCT01670929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PPROURM|Preconceptional Progesterone Treatment in Women With Unexplained Recurrent Miscarriage, a Randomized Double-blind Controlled Trial|Phase 4 Preconceptional Progesterone in Patients With Recurrent Unexplained Miscarriages||Woman's Health University Hospital, Egypt|Yes|Completed|September 2012|March 2014|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|1||Actual|400|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||August 2014|August 4, 2014|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01670929||80488|
NCT01671280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A0661207|Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Azithromycin Iv|RESCUE|Pfizer|No|Active, not recruiting|September 2012|May 2016|Anticipated|November 2015|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|400|||Both|N/A|N/A|No|Probability Sample|The patients whom an investigator involviong A0661207 prescribes the Zithromac IV.|February 2016|February 17, 2016|August 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01671280||80462|
NCT01671293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FONIS SA10I20017|Multicomponent Telecare Model for Supporting Prediabetes Patients|Remote Care Model for Supporting Prediabetes Patients|MTELECAREP|Pontificia Universidad Catolica de Chile|No|Completed|September 2011|March 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Both|20 Years|64 Years|No|||June 2015|June 25, 2015|August 20, 2012||No||No|January 7, 2015|https://clinicaltrials.gov/show/NCT01671293||80461|
NCT01676376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11016|The eMESH 1 Feasibility Study|A Multi-center, International Study of External Saphenous Vein Support Using eSVS® Mesh in CABG Surgery: The eMESH I Study|eMESH 1|Kips Bay Medical, Inc.|Yes|Recruiting|August 2012|June 2020|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|21 Years|85 Years|No|||February 2015|February 17, 2015|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676376||80071|
NCT01671813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17024|Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly|Pilot Study of Brentuximab Vedotin in CD30 Positive EBV Positive Diffuse Large B-Cell Lymphomas of the Elderly||H. Lee Moffitt Cancer Center and Research Institute|No|Withdrawn|March 2013|July 2013|Actual|July 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||July 2013|July 24, 2013|August 21, 2012|No|Yes|Terminated by pharmaceutical sponsor - no accrual|No||https://clinicaltrials.gov/show/NCT01671813||80421|
NCT01672073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROX005|Analysis of the Arterial Pressure Wave Form Through the Proxima Device|An Open, Non-randomised, Study to Provide Data on the Arterial Pressure Wave Form Obtained Through the Proxima 3 in Patients Who Require the Insertion of an Arterial Line||Sphere Medical Ltd.|No|Completed|January 2013|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|N/A|No|Non-Probability Sample|Patients treated in the Intensive Care or High Dependency Units who require an arterial        line to be inserted as standard care|August 2013|August 8, 2013|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672073||80401|
NCT01672294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIR 11-347|Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness|Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness||VA Office of Research and Development|No|Active, not recruiting|June 2013|April 2016|Anticipated|December 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|418|||Both|18 Years|99 Years|No|||February 2016|February 8, 2016|May 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01672294||80384|
NCT01672541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIPC-6161|Dating Matters: Strategies to Promote Healthy Teen Relationships|Randomized Controlled Trial of the "Dating Matters: Strategies to Promote Healthy Teen Relationships" Comprehensive Approach|DM|Centers for Disease Control and Prevention|No|Enrolling by invitation|August 2012|June 2021|Anticipated|June 2021|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|30000|||Both|N/A|N/A|No|||February 2015|February 2, 2015|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01672541||80365|
NCT01672827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-067-021|Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images|A Study to Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images.||GE Healthcare|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|1||Actual|276|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2013|December 18, 2013|August 22, 2012|Yes|Yes||No|August 14, 2013|https://clinicaltrials.gov/show/NCT01672827||80343|
NCT01673087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH093486-01A1|Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures|Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures||University of Michigan|No|Recruiting|October 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|350|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||November 2015|November 19, 2015|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673087||80323|
NCT01677533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EDU 08-428-2|Program for Research on the Outcomes of VA Education|Program for Research on the Outcomes of VA Education: Controlled Study of Panel Management and Microsystem Education Interventions to Improve Outcomes in Hypertension and Smoking Cessation|PROVE|VA New York Harbor Healthcare System|Yes|Active, not recruiting|September 2009|May 2014|Anticipated|September 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Anticipated|38000|||Both|N/A|N/A|Accepts Healthy Volunteers|||December 2013|December 19, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01677533||79982|
NCT01673399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000278-49|Oxytocin Antagonist in Patients With Repeated Failure of Implantation|Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.||AZ Jan Palfijn Gent|Yes|Recruiting|February 2012|||December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|290|||Female|18 Years|38 Years|No|||March 2015|March 27, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01673399||80299|
NCT01673724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKL001|Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease|Effect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized Study||Sandoz Korea|No|Recruiting|February 2012|June 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|30 Years|N/A|No|||September 2012|September 3, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01673724||80275|
NCT01674023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|No.518|MicroRNA Expression Profile in Human Vitreous of Patients With Various Vitreoretinal Diseases Requiring Vitrectomy|||Kyorin University|No|Completed|August 2012|||December 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|8|Samples Without DNA|3ml of blood serum and 1ml of vitreous|Both|N/A|N/A|No|Non-Probability Sample|Pateints undergoing vitrectomy for various vitreoretinal disesases|March 2015|March 31, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674023||80252|
NCT01674257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MICA-V1.3|Metabolic Imaging in Carotid Atherosclerosis|An Investigation of the Role of 18F-Sodium Fluoride and 18F-Flurodeoxyglucose PET CT and USPIO Enhanced MRI in Imaging Carotid Artery Inflammation and Mineralization.|MICA|University of Edinburgh|No|Recruiting|January 2013|September 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Blood and excised carotid atheroma|Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for carotid endarterectomy for symptomatic carotid artery stenosis.|March 2013|March 5, 2013|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674257||80234|
NCT01674270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEG_PRE-OP_001|Degarelix Neo-Adjuvant Radical Prostatectomy Trial|Phase II Randomized Open Label Study of Neo-Adjuvant Degarelix vs. LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy||University Health Network, Toronto|Yes|Completed|August 2012|November 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|35|||Male|18 Years|75 Years|No|||December 2015|December 21, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674270||80233|
NCT01673945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P69/CE/2011|FV-EUS Endoscope Versus CLA-EUS for EUS-FNA of Solid Lesions|Forward Viewing US Endoscope Versus Standard Viewing US Endoscope in the Performance of EUS-guided Fine Needle Aspiration of Solid Lesions of the Gastrointestinal Tract and of Adjacent Organs: A Prospective Randomized Controlled Study||Catholic University of the Sacred Heart|No|Recruiting|June 2012|July 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|124|||Both|18 Years|80 Years|No|||July 2012|August 24, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01673945||80258|
NCT01674803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIO-RESORT|Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)|Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion: Randomized Multicenter Trial in an All Comers Population Treated Within thE NeThErlands 3 (TWENTE 3)|BIO-RESORT|Cardio Research Enschede BV|Yes|Enrolling by invitation|December 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|3540|||Both|18 Years|N/A|No|||July 2015|July 27, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01674803||80192|
NCT01674504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|741/09|Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|January 2010|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|63|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674504||80215|
NCT01674517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|742/09|Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|February 2010|February 2010|Actual|February 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|35|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||August 2012|August 24, 2012|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674517||80214|
NCT01674790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Priming Study|Combined Effects of Aerobic Exercise and Cognitive Training on Cognition After Stroke|Exploring Potential Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition After Stroke.||Nova Scotia Health Authority|No|Recruiting|September 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|N/A|No|||October 2014|October 29, 2014|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674790||80193|
NCT01675076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UOHI-05|Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events|A Randomized Controlled Trial to Investigate Whether a Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at the Time of Device Surgery, in Patients With Moderate to High Risk of Arterial Thrombo-embolic Events, Leads to a Reduction in the Incidence of Clinically Significant Hematoma|BRUISECONTROL2|Ottawa Heart Institute Research Corporation|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|846|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675076||80171|
NCT01675635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYC11-CN-304|OxyNorm Capsules in Post-Operative Pain Study|A Double-blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety, of Oxycodone Immediate-release Capsules Versus Morphine Immediate-release Tablets in Hospitalized Patients With Moderate to Severe Pain Following Surgery.||Mundipharma (China) Pharmaceutical Co. Ltd|Yes|Completed|July 2011|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|65 Years|No|||August 2015|August 11, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01675635||80128|
NCT01670591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21-12050/2008|Effects of Prevention in School (PS): a Swedish School-wide Positive Behavior Support Program at the Primary Prevention Level|||Karolinska Institutet|No|Completed|January 2009|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|3207|||Both|10 Years|15 Years|Accepts Healthy Volunteers|||August 2012|August 20, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01670591||80514|
NCT01670604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KAH012|Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures|The Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures: Effect on Acid-Base Status and Renal Functions||Kasr El Aini Hospital|Yes|Recruiting|January 2012|||March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|40|||Both|18 Years|80 Years|No|||August 2012|August 20, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01670604||80513|
NCT01676142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012082RC|Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation|Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation||National Taiwan University Hospital|No|Recruiting|January 2011|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|200|||Both|18 Years|N/A|No|Probability Sample|1. Patients with NTM pulmonary infection: diagnosed by NTM guidelines by American             Thoracic Society(ATS)          2. Patients with NTM pulmonary colonization: Patients are not fulfilling the ATS             diagnostic criteria but having at least one set of positive sputum for NTM             (colonization).          3. Patients have pulmonary infiltrates, not related by NTM: three sets of respiratory             specimens that are negative for NTM.|June 2011|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676142||80089|
NCT01676155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110822RC|The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis|The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis||National Taiwan University Hospital|No|Recruiting|September 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|400|||Both|20 Years|N/A|Accepts Healthy Volunteers|Probability Sample|1. Patients with tuberculosis: microbiology or pathology proven tuberculosis infection          2. Patients with latent tuberculosis infection are defined by interferon-gamma release             assay          3. Patients without tuberculosis and latent tuberculosis are defi=ed by negative             findings in above-mentioned results|June 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676155||80088|
NCT01676389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-760|Osteopathic Manual Medicine Treatment in Autism|Osteopathic Manual Medicine Treatment in Autism, A Pilot Study|OMMA|New York Institute of Technology|No|Completed|January 2013|May 2015|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|3|||Both|3 Years|11 Years|No|||September 2014|January 19, 2016|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01676389||80070|
NCT01676662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD 1004|Solace European Confirmatory Trial|An Evaluation of the Solace Bladder Control System in the Treatment of Female Subjects With Stress Urinary Incontinence|SOLECT|Solace Therapeutics, Inc.|No|Active, not recruiting|September 2012|April 2016|Anticipated|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|60|||Female|18 Years|N/A|No|||August 2014|August 7, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01676662||80049|
NCT01676402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VRC 703|Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years|Open-Label, Randomized Phase 1b Study of the Safety & Immunogenicity of Investigational Seasonal Influenza DNA Vaccine Followed by TIV Administered Intradermally (ID) or Intramuscularly (IM) in Healthy Adults 18-70 Years||National Institute of Allergy and Infectious Diseases (NIAID)|No|Completed|August 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|6||Actual|316|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 17, 2014|August 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01676402||80069|
NCT01672307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MFL University|Minoxidil 2% for Eyebrow Enhancement|Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study||Mae Fah Luang University Hospital|No|Completed|September 2012|March 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2013|June 18, 2013|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01672307||80383|
NCT01672320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P000809|Outcomes of Robotic Total Hip Arthroplasty|Outcomes of Robotic Total Hip Arthroplasty: A Prospective Study||Massachusetts General Hospital|No|Withdrawn|January 2013|January 2023|Anticipated|January 2023|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|||Both|20 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adults requiring a total hip arthroplasty procedure.|November 2013|November 4, 2013|August 10, 2012||No|No patients will be recruited at Massachsetts General hospital. IRB approval changed to core    center.|No||https://clinicaltrials.gov/show/NCT01672320||80382|
NCT01672554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D1443C00030|Clinical Benefits of Seroquel XR in Anxiety Disorder|Open Label, Non-randomised, Single Arm, Phase IIIB Switch Study: Evaluating the Clinical Benefits of Quetiapine XR in Patients With Schizophrenia and Anxiety Disorder.||Corporation de Recherche en Neuropsycho Pharmacologie de Quebec|No|Active, not recruiting|December 2008|October 2013|Anticipated|April 2012|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|65 Years|No|||August 2012|August 22, 2012|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01672554||80364|
NCT01677494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/068/HP|Collagen Markers in Heart Failure and Preserved Ejection Fraction|To Assess the 12-month Prognostic Significance of Left Ventricular Collagen Markers in Patients With Heart Failure and Preserved Ejection Fraction.|COLLAG4|University Hospital, Rouen|No|Terminated|September 2010|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|84|Samples Without DNA|Proteomics|Both|18 Years|85 Years|Accepts Healthy Volunteers|Probability Sample|heart failure with preserved ejection fraction|September 2014|September 1, 2014|December 2, 2010||No|lack of recruitment|No||https://clinicaltrials.gov/show/NCT01677494||79985|
NCT01677507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00052276|Glaucoma Biomarkers|Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance||University of Michigan||Recruiting|August 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|150|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 20, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01677507||79984|
NCT01673412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AOL02-DR-LOK|Research of Prognostic Factors Associated With Healing of Venous Leg Ulcers|Research of Prognostic Factors Associated With Healing of Venous Leg Ulcers||Centre Hospitalier Universitaire, Amiens|No|Completed|January 2003|December 2008|Actual|June 2008|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|104|||Both|50 Years|N/A|No|||August 2012|August 23, 2012|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01673412||80298|
NCT01674036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GZFD00111/GZFD00211|Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men|A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Oral Doses of Genz-682452 With a Pilot Investigation of Food Effect in Healthy Adult Male Subjects.||Sanofi|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|63|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2014|March 17, 2014|August 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01674036||80251|
NCT01673763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240179|Post-ERCP Pancreatitis Prevention by Stent Insertion|Study to Reduce Incidence of Post-ERCP Pancreatitis by Stent Insertion in the Main Pancreatic Duct After Unintended Cannulation of the Main Pancreatic Duct|PEPSI|Technische Universität München|Yes|Recruiting|July 2010|December 2012|Anticipated|October 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Anticipated|603|||Both|18 Years|N/A|No|||August 2012|August 27, 2012|October 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01673763||80272|
NCT01673971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAJ1201|Optical Tomographic Imaging of Infantile Hemangiomas|Optical Tomographic Imaging of Infantile Hemangiomas||Columbia University|Yes|Active, not recruiting|May 2012|January 2017|Anticipated|January 2016|Anticipated|N/A|Observational|Observational Model: Cohort||2|Actual|15|||Both|N/A|7 Years|No|Non-Probability Sample|All subjects will be recruited verbally from the pediatric dermatology faculty practices,        clinics and inpatient services at CUMC/NYP (MSCHONY). In accordance with CUMC policy,        researchers will not approach a patient for recruitment until that patient has been        informed of the study by their treating physician who has ascertained the patient's        willingness to discuss the study with the investigators.|January 2016|January 28, 2016|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01673971||80256|
NCT01673958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUC-011|Stair Descending vs. Stair Ascending Exercise|The Effect of Stair Descending and Stair Ascending Exercise on Muscle Strength and Performance: the SmartEscalator Device||European University Cyprus|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|12|||Male|60 Years|70 Years|No|||August 2012|August 24, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673958||80257|
NCT01674543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESQ-002|Clinical Symptoms of Schizophrenia and Physical Exercise|Schizophrenia and Physical Exercise: Effect of 20 Weeks of Training in Symptoms and Concentration in Serum IGF-1 and BDNF||Federal University of São Paulo|Yes|Completed|February 2010|March 2013|Actual|December 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|47|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 11, 2014|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01674543||80212|
NCT01675089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0776/11|Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation|A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation||University of Sao Paulo General Hospital|Yes|Completed|July 2012|May 2014|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|N/A|No|||March 2013|May 16, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01675089||80170|
NCT01675336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-11-129-PST2Taiwan|Genetics of Periodontal Diseases in Chinese (Taiwan)|The Association Between Interleukin-1 Gene Variations and Adult Chronic Periodontal Disease in Chinese (Taiwan))||Kaohsiung Medical University|No|Active, not recruiting|August 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|400|||Both|35 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|All study subjects will be selected from a pre-existing patient database in Taiwan. All        chronic periodontitis cases and controls will be subjects who were at least 35 years old        at time of enrollment.        Classification of chronic periodontitis will be based on the extent of periodontal tissue        destruction with consideration of tooth loss.|August 2012|August 28, 2012|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675336||80151|
NCT01675349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6062 -PR-PRI-195|Biological Standardization of Chenopodium Album Allergen Extract|Biological Standardization of Chenopodium Album Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units||Laboratorios Leti, S.L.|No|Completed|November 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|48|||Both|18 Years|60 Years|No|||August 2012|May 22, 2014|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675349||80150|
NCT01675609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-100-0015|Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects|A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects||Eye Therapies, LLC|No|Completed|August 2012|||October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|57|||Both|40 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 28, 2014|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675609||80130|
NCT01675622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYC10-CN-303|Immediate-Release Oxycodone Capsules Study in Cancer Pain|A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine Tablets for the Treatment of Chinese Patients With Cancer Pain.||Mundipharma (China) Pharmaceutical Co. Ltd|Yes|Completed|December 2010|July 2012|Actual|June 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|80 Years|No|||August 2015|August 11, 2015|April 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01675622||80129|
NCT01675908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356090|Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression|Multicenter Randomized Trial Comparing Covered Metal and Plastic Stents for Preoperative Biliary Decompression in Pancreatic Cancer||Florida Hospital|Yes|Recruiting|July 2010|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|19 Years|N/A|No|||November 2015|November 24, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675908||80107|
NCT01670630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS201202|A Comparison of a Sheathed to a Standard Speculum for Visualization of the Cervix|A Comparison of a Novel Sheathed Speculum to a Standard Speculum for Visualization of the Cervix||Florida Hospital|No|Completed|July 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|136|||Female|18 Years|50 Years|No|||February 2013|February 28, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01670630||80511|
NCT01671267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRMA06|Implementation of Physical Exercise at the Workplace (IRMA06) - Slaughterhouse Workers|Implementation of Physical Exercise at the Workplace (IRMA06) - Slaughterhouse Workers|IRMA|National Research Centre for the Working Environment, Denmark|No|Completed|August 2012|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|66|||Both|18 Years|67 Years|Accepts Healthy Volunteers|||January 2014|January 26, 2014|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01671267||80463|
NCT01670942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB#1024157|Hypobaria and Traumatic Pneumothorax|The Effects of Hypobaric Conditions on Small, Traumatic Pneumothoraces||Intermountain Health Care, Inc.|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with unilateral pneumothorax of traumatic etiology that has been treated with        oxygen, observation, or tube thoracostomy|April 2014|April 25, 2014|August 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01670942||80487|
NCT01670955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASUTH/08/2012|The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients|A Prospective Phase II/III Randomized, Blinded Study to Demonstrate the Safety and Effectiveness of Jobelyn ( a Herbal Preparation ) in Pre-operative Management of Anaemia in Gynaecological Patients||Lagos State University|Yes|Recruiting|September 2012|February 2013|Anticipated|November 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|45|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 1, 2012|August 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01670955||80486|
NCT01670968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV RCTS|HIV Reverse Cholesterol Transport Study|The Effect of Antiretroviral Therapy and HIV on Reverse Cholesterol Transport in Blood( HIV Reverse Cholesterol Transport Study- HIV RCTS)|HIV RCTS|University College Dublin|No|Recruiting|September 2009|June 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Individuals starting antiretroviral therapy at the Mater Misericordiae University        Hospital, Dublin, and Chelsea and Westminister Hospital, London|January 2013|January 25, 2013|August 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01670968||80485|
NCT01676168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201205098RIC|To Study Gene Expression of Postburn Hypertrophic Scar|To Study Gene Expression of Postburn Hypertrophic Scar||National Taiwan University Hospital|No|Recruiting|July 2012|||July 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|Samples With DNA|Hypertrophic scar from post-burn patient|Both|20 Years|80 Years|No|Non-Probability Sample|The patient have hypertrophic scar.|August 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676168||80087|
NCT01676701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14598|Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)|Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate||Eli Lilly and Company|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|No|||January 2014|January 7, 2014|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676701||80046|
NCT01676675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JSVCT011|A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults|A Single Center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Trial for Safety and Preliminary Immunogenicity of a Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults, on Day 0 and 21 Intramuscularly||Jiangsu Province Centers for Disease Control and Prevention|No|Withdrawn|August 2012|March 2013|Anticipated|January 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|8||Actual|0|||Both|12 Years|60 Years|No|||March 2013|March 14, 2013|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676675||80048|
NCT01676714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCDCC#231|Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer|Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy||University of California, Davis|Yes|Active, not recruiting|February 2013|October 2016|Anticipated|October 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676714||80045|
NCT01676922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27768|An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)|Prospective Non-interventional Study to Collect Data on the Use of Avastin and Conventional Chemotherapy for the Treatment of Previously Untreated Metastatic Colorectal Cancer in Patients >/= 70 Years||Hoffmann-La Roche||Completed|August 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|256|||Both|70 Years|N/A|No|Probability Sample|Patients >/= 70 years of age with previously untreated metastatic colorectal cancer        suitable to receive chemotherapy with or without Avastin|March 2016|March 1, 2016|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01676922||80029|
NCT01676935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-427|This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease|Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985||AbbVie|No|Terminated|August 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|349|||Both|55 Years|90 Years|No|||March 2014|March 21, 2014|August 29, 2012|Yes|Yes|Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.|No||https://clinicaltrials.gov/show/NCT01676935||80028|
NCT01677221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Acleara-01|Effects of Acleara Needle Insert on Acne|A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris||Theravant Corporation|No|Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|14 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 9, 2013|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677221||80006|
NCT01677481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIL/IMRC/RP/TP/10/2010|Randomized Evaluation of Vascular Entry Site and Radiation Exposure: REVERE Trial|Randomized Evaluation of Vascular Entry Site and Radiation Exposure: REVERE Trial.|REVERE|Total Cardiovascular Solutions|No|Completed|February 2011|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|1500|||Both|18 Years|90 Years|No|Probability Sample|Patients referred for diagnostic coronary angiography|March 2016|March 11, 2016|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01677481||79986|
NCT01677234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01797|Wrist NIBP During Elective Cesarean Delivery|Comparison of Arm and Forearm Blood Pressure During Elective Cesarean Delivery||University of British Columbia|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|71|||Female|19 Years|N/A|No|Non-Probability Sample|Women having an elective cesarean delivery at BC Women's Hospital in Vancouver, British        Columbia.|July 2013|July 2, 2013|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677234||80005|
NCT01673737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCD12739|A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer|A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma||Sanofi|No|Completed|August 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|75|||Both|18 Years|N/A|No|||April 2015|April 9, 2015|August 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673737||80274|
NCT01674049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|081025|Nutrient Timing Following Resistance Exercise|Nutrient Timing Following Resistance Exercise in Young Overweight and Obese Young Men With a Family History of Diabetes||George Washington University|Yes|Completed|October 2010|May 2011|Actual|May 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|11|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2012|August 28, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674049||80250|
NCT01671930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 08-4-057|Maastricht Biomarker CT Study|Maastricht Biomarker CT Study. Relation Between Cardiovascular Biomarkers and Coronary Atherosclerosis in Patients Undergoing Multi Detector Cardiac Computed Tomography.||Maastricht University Medical Center|No|Completed|April 2007|January 2014|Actual|January 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|5000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients that were refered to undergo cardiac computed tomography by their cardiologist,        to exclude coronary artery disease. Location: tertiary academic hospital.|May 2014|May 26, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671930||80412|
NCT01673984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A-97-52014-181|GP Extended Action Triptorelin|A Phase IV, Randomised, Open-label, Multi-centre Study to Assess the Impact on Disease Control, Safety, Patient and Clinician Experience of Changing Patients With Advanced Prostate Cancer From a 3-monthly LHRH Agonist to 6-monthly Injections of Decapeptyl® SR 22.5 MG|GREAT|Ipsen|No|Terminated|August 2012|February 2014|Actual|February 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|27|||Male|18 Years|N/A|No|||July 2015|August 28, 2015|August 23, 2012||No|The study was discontinued prematurely by the sponsor due to non-medical reasons|No|July 10, 2015|https://clinicaltrials.gov/show/NCT01673984||80255|
NCT01673997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P-643/09|Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metoprolol Succinate Extended-Release Tablets 200mg of Dr. Reddy's Laboratories Limited, India Comparing With That of TOPROL-XL® (Containing Metoprolol Succinate) Extended-Release Tablets 200mg of AstraZeneca LP Wilmington, DE in Healthy, Adult, Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|December 2010|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||January 2011|September 24, 2012|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673997||80254|
NCT01674010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELND005-BPD201|Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder||Transition Therapeutics Ireland Limited|Yes|Terminated|August 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|309|||Both|18 Years|65 Years|No|||October 2015|October 15, 2015|August 24, 2012|Yes|Yes|Business Decision|No|September 14, 2015|https://clinicaltrials.gov/show/NCT01674010||80253|
NCT01674530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DRL-USG01-L/2012|Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation|A,Randomized , Double-blind,Double -Dummy Placebo-controlled,Parallel -Group, Multicenter Study to Evaluate the Clinical Equivalence of Lubiprostone 24 mcg Capsules ( Dr. Reddy's Laboratories Ltd.) With AMITIZA® (Lubiprostone ) 24 mcg Capsules ( Sucampo Pharmaceuticals, Inc. ) in the Treatment of Chronic Idiopathic Constipation||Dr. Reddy's Laboratories Limited|No|Completed|October 2012|March 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|909|||Both|18 Years|N/A|No|||August 2012|April 2, 2014|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674530||80213|
NCT01674842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-283|Cisplatin + RT for Triple Negative Breast Cancer|A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer||Dana-Farber Cancer Institute|Yes|Recruiting|October 2012|October 2018|Anticipated|January 2017|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01674842||80189|
NCT01674816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE12.006|Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration|(Étude de la cinématique Tridimensionnelle du Genou et Guidage Chirurgical Minimalement Effractifs Par Recalage Rigide échographique)||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|October 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01674816||80191|
NCT01674829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHA CTP 1101|A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)|A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)||CHABiotech CO., Ltd|Yes|Recruiting|September 2012|April 2016|Anticipated|February 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|12|||Both|55 Years|N/A|No|||August 2012|October 22, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01674829||80190|
NCT01675102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBMT-42204420|Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)|Allogeneic HSCT in 17p- CLL in First or Second Partial or Complete Remission at Transplant: a Non-interventional Prospective Study.|17p-CLL NIS|European Group for Blood and Marrow Transplantation|No|Recruiting|August 2010|||June 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|41|||Both|18 Years|69 Years|No|Probability Sample|eligible patients from EBMT centres|October 2014|October 2, 2014|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675102||80169|
NCT01675362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4228|Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury?|A Randomized Controlled Trial for Evaluating Protective Effects of Antioxidants (Selenium and Vitamins A, C and E), Calcium Channel Blocker (Verapamil) and Angiotensin Receptor Blocker (Losartan) Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury|SWL|Mansoura University|Yes|Completed|August 2012|October 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|4||Actual|160|||Both|18 Years|60 Years|No|||October 2014|October 8, 2014|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675362||80149|
NCT01675375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS 004|Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain|Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain||FORSIGHT Vision3|Yes|Completed|March 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|125|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2013|February 1, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675375||80148|
NCT01675284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-AI-11|A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine|A Phase I, Prospective, Randomized, Open Label, Observer-Blind, Single Center Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Produced in Madin-Darby Canine Kidney (MDCK) Cells||Medigen Biotechnology Corporation|No|Completed|August 2012|May 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Actual|36|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||October 2013|October 23, 2013|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01675284||80155|
NCT01675544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-16350|PRospective Evaluation of Electrocardiographic Voltage Changes and Six Minute Walk Test for Predicting Readmissions in Heart Failure (PREEMT-HF Study)||PREEMT-HF|Creighton University|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|46|||Both|19 Years|N/A|No|Non-Probability Sample|Patients admitted with acute decompensated heart failure|November 2015|November 27, 2015|August 28, 2012||No||No|September 25, 2014|https://clinicaltrials.gov/show/NCT01675544||80135|
NCT01675856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AUGIB|Urgent vs. Early Endoscopy in High Risk Patients With Upper Gastrointestinal Bleeding (UGIB)|Urgent vs. Early Endoscopy in High Risk Patients With UGIB||Chinese University of Hong Kong|No|Recruiting|July 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|516|||Both|18 Years|N/A|No|||February 2016|February 24, 2016|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675856||80111|
NCT01675869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R34MH095911|Executive Function/Metacognitive Training for At-Risk Preschoolers|Executive Function/Metacognitive Training for At-Risk Preschoolers|ETAM|Children's Hospital Medical Center, Cincinnati|No|Active, not recruiting|July 2012|June 2016|Anticipated|June 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|70|||Both|3 Years|5 Years|No|||May 2015|July 27, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01675869||80110|
NCT01675882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VIPES|Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy|A Double-blind, Placebo-controlled, Randomized Trial to Study the Viaskin Peanut's Efficacy and Safety for Treating Peanut Allergy in Children and Adults.|VIPES|DBV Technologies|Yes|Completed|August 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|221|||Both|6 Years|55 Years|No|||September 2015|September 28, 2015|August 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675882||80109|
NCT01676740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMCHI0112|Iron and Vitamin Adminstration Prior to Joint Replacement to Prevent Transfusion|Randomized Ttrial to Establish the Efficacy of Hematinic Agents in Patietns With Mild Anemia Undergoing Total Hip or Knee Replacement in Avoiding Blood Transfusion||Meir Medical Center|No|Not yet recruiting|November 2012|February 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|120|||Both|18 Years|N/A|No|||August 2012|August 31, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676740||80043|
NCT01676727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Advance-DA|ADVANCE Direct Aortic|CoreValve® ADVANCE Direct Aortic Study|ADVANCE DA|Medtronic Cardiovascular||Completed|September 2012|August 2015|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|21 Years|N/A|No|Probability Sample|Patients with severe aortic stenosis who are scheduled for an elective transcatheter        aortic valve implantation and who are selected (e.g. because of an calcified femoral        artery) to receive the CoreValve® device via direct aortic access.|October 2015|October 26, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676727||80044|
NCT01676688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AlfaDom|Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home|Safety Study of Alfalastin (Human Alpha-1 Antitrypsin, 33.33 mg/ml) Administered at Home to Patients Suffering From Severe Forms of Primary Deficiency in Alpha-1 Antitrypsin, Phenotype PIZZ or PISZ, With Pulmonary Emphysema.||Laboratoire français de Fractionnement et de Biotechnologies|No|Completed|January 2012|October 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Both|18 Years|N/A|No|Probability Sample|Patients above 18 y.o, suffering from severe forms of primary alpha-1 antitrypsin        deficiency, phenotype PiZZ or PiSZ with pulmonary emphysema, currently treated , once a        week, as per routine practice by ALFALASTIN® at home or in out-of-hospital location.|August 2012|November 8, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676688||80047|
NCT01676948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CACZ885G2402|An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|β-SPECIFIC 4Pa|Novartis||Withdrawn|January 2013|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|0|||Both|2 Years|20 Years|No|||October 2015|October 13, 2015|August 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01676948||80027|
NCT01676961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 10-02429|Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy|Phase II Trial Evaluating the Efficacy and Safety of Romiplostim (Nplate) Treatment of Chemotherapy Induced Thrombocytopenia in Patients With Multiple Myeloma||New York University School of Medicine|Yes|Terminated|January 2013|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|5|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|August 29, 2012|No|Yes|PI left the institution|No||https://clinicaltrials.gov/show/NCT01676961||80026|
NCT01677247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BE-Glimepiride|Bioequivalence Study of 4 mg Glimepiride Tablet|Bioequivalence Study of Two Formulations of Glimepiride Tablet in Healthy Subjects||Dexa Medica Group|No|Completed|February 2011|March 2011|Actual|March 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677247||80004|
NCT01677546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bolus-calculator|Bolus Calculator and Wireless Communication With Blood Glucose Meter in Management of Type 1 Diabetes Mellitus (T1DM).|The Impact of Insulin Pump Bolus Calculator and Wireless Communication With Blood Glucose Meter on Metabolic Control in Children With Type 1 Diabetes Mellitus - Randomised Control Trial||Medical University of Warsaw|No|Completed|January 2011|July 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Actual|156|||Both|7 Years|18 Years|No|||August 2012|August 29, 2012|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01677546||79981|
NCT01677559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210123|Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies|Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies||Washington University School of Medicine|No|Recruiting|May 2013|June 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|39|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01677559||79980|
NCT01673750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIVBI|Body Image in Youth With HIV|Body Image in Youth With HIV||St. Jude Children's Research Hospital|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|146|||Both|16 Years|23 Years|No|Non-Probability Sample|Patients with documented HIV infection between the ages of 16 and 24 who are willing and        able to consent.|April 2014|April 11, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01673750||80273|
NCT01671943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICMBC-01|Cryotherapy for Breast Cancer Trial|Evaluation of Safety and Feasibility of ICE-SENSE3TM , a Cryotherapy Device for Office-based Ultrasound- Guided Treatment of Breast Cancer|ICE-BREACCER|IceCure Medical Ltd.|No|Completed|August 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Female|N/A|N/A|No|||February 2015|February 5, 2015|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01671943||80411|
NCT01674296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFHNRC018|Seasonal Patterns of Stress, Diet and Physical Activity - Life in All Seasons (LENAS)|Seasonality of Stress, Diet, and Physical Activity in Mid-Life Women|LENAS|USDA Grand Forks Human Nutrition Research Center|Yes|Active, not recruiting|June 2012|June 2016|Anticipated|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|54|Samples With DNA|Serum, Plasma, Buffy Coat, Urine, Saliva|Female|40 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Middle-aged females|November 2015|November 20, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674296||80231|
NCT01674283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVO-12-08|Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization|Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization||OVO R & D|No|Withdrawn|October 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|40 Years|No|||July 2015|July 24, 2015|August 23, 2012||No|Uterine contractility not possible to visualize with our ultrasound machines|No||https://clinicaltrials.gov/show/NCT01674283||80232|
NCT01675128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120187|ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer|A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|N/A|No|||April 2014|October 22, 2014|August 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675128||80167|
NCT01675115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BNG-1-PIIIB|Efficacy of BNG-1 to Treat Acute Ischemic Stroke|A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Compare the Functional Outcome and Safety of Treatment With BNG-1 in Combination With Aspirin With That of Aspirin Alone in Ischemic Stroke Recovery|BNG-1|Chang Gung Memorial Hospital|Yes|Completed|August 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|20 Years|65 Years|No|||July 2015|July 27, 2015|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01675115||80168|
NCT01675388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1006008466|Hypothermia During ECMO to Decrease Brain Injury|Hypothermia as Neuroprotection During ECMO: Is Brain MRI a Biomarker of Outcomes?||Sood, Beena G., MD, MS|No|Withdrawn|August 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|N/A|28 Days|No|||November 2014|November 17, 2014|August 24, 2012||No|No funding|No||https://clinicaltrials.gov/show/NCT01675388||80147|
NCT01675674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RHE-001|Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics|Unrecognized Mucopolysaccharidosis I, II, IVA, and VI in the Pediatric Rheumatology Population||National MPS Society|Yes|Terminated|September 2011|March 2014|Anticipated|March 2014|Anticipated|N/A|Observational|N/A||1|Anticipated|3000|||Both|6 Months|18 Years|No|Non-Probability Sample|For the prospective study, subjects will be drawn from all children (aged 6 months to 18        years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric        hand, or skeletal dysplasia clinic), with at least ONE "highly suspicious" symptom or at        least TWO "less suspicious" symptoms that may be indicative of an MPS disorder (see        inclusion criteria).        For the retrospective chart review, subjects will be drawn from all children who were 6        months to 18 years of age at the time of first presentation to selected clinics (pediatric        rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE "highly        suspicious" symptom or at least TWO "less suspicious" symptoms that may be indicative of        an MPS disorder (see inclusion criteria).|May 2013|May 23, 2013|August 23, 2012||No|Funding withdrawn due to insufficient enrollment rate|No||https://clinicaltrials.gov/show/NCT01675674||80125|
NCT01675557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Creighton15|Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney Disease Patients on Chronic Hemodialysis|Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney||Creighton University|No|Completed|September 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|30|||Both|20 Years|65 Years|No|||February 2015|February 24, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675557||80134|
NCT01675570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTD1201|A Study of RX-10045 in the Treatment of Dry Eye Disease|A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease||C.T. Development America, Inc.|Yes|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||February 2013|February 7, 2013|August 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675570||80133|
NCT01675583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WoundImager-2012-01|Laser Speckle Imaging for Wound Perfusion Monitoring (WoundImager)|Laser Speckle Imaging for Wound Perfusion Monitoring (WoundImager)||CW Optics, Inc.||Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|20|||Both|21 Years|N/A|No|Non-Probability Sample|Adult patients who have chronic lower extremity wounds will be recruited from the patient        population at Winchester Medical Center for enrollment in the study.|June 2013|June 28, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675583||80132|
NCT01675596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-14|The SOLACE-AU Clinical Trial|A Multicentre, Non-Randomised Controlled Study of the Safety, Performance, Quality of Life and Cost Effectiveness Outcomes of the Edwards SAPIEN XT™ Transcatheter Heart Valve in an Australian Population|SOLACE-AU|Edwards Lifesciences|Yes|Recruiting|April 2012|November 2018|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|70 Years|N/A|No|||June 2014|June 27, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675596||80131|
NCT01675895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DİLEKLEVOBUPİVACAİNE|Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration|Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration: Randomized Controlled Trial||Diskapi Teaching and Research Hospital|No|Completed|July 2009|July 2011|Actual|July 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|40|||Male|40 Years|80 Years|No|||December 2012|December 17, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01675895||80108|
NCT01676753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC# 12951|Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression|A Phase I/Ib Dose-escalation Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumor Malignancies and Assessment of MYC Oncogene Overexpression||University of California, San Francisco|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|85 Years|No|||March 2014|March 24, 2014|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676753||80042|
NCT01677000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP Infection Registry|CPP Bone Infection Registry|Clinical Priority Program: Bone Infection; Use of a Registry on Infection to Improve Patient Outcomes and Research Efforts|CPP Infection|AO Clinical Investigation and Documentation|Yes|Recruiting|June 2012|June 2018|Anticipated|June 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|blood samples nasal and wound specimen|Both|18 Years|130 Years|No|Non-Probability Sample|patients with diagnosis of Staphylococcus aureus bone infection|January 2016|January 4, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677000||80023|
NCT01676974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COMBAT|Carriage Of Multiresistant Bacteria After Travel|Impact of International Travel on the Emergence and Spread of Antimicrobial Resistance in The Netherlands|COMBAT|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Active, not recruiting|November 2012|June 2016|Anticipated|November 2013|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Anticipated|2000|Samples With DNA|Fecal Swab|Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Travelers and their family members not planning to travel|January 2014|January 14, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676974||80025|
NCT01676987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ach-ALN-04(7/07)|Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma|Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma:a Randomized, Double-blind, Multicenter, Controlled Clinical Trial.|Ach-ALN|Ache Laboratorios Farmaceuticos S.A.|Yes|Completed|April 2009|June 2011|Actual|September 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|77 Years|No|||August 2012|August 30, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676987||80024|
NCT01677572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|221AD103|Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease|A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease||Biogen|Yes|Active, not recruiting|October 2012|October 2019|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|9||Actual|197|||Both|50 Years|90 Years|No|||February 2016|February 19, 2016|August 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01677572||79979|
NCT01673425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 604-2010|Evaluating Immune Response to Seasonal FluMist in Healthy Adults|Evaluating Immune Response to Seasonal FluMist in Healthy Adults||National Center for Occupational Health and Infection Control|No|Terminated|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Both|20 Years|49 Years|Accepts Healthy Volunteers|||August 2014|September 2, 2014|August 21, 2012|Yes|Yes|Low accrual(4 completed subjects over 2 months)& inconclusive nasal wash assays.|No|July 29, 2014|https://clinicaltrials.gov/show/NCT01673425||80297|
NCT01673438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALDOXORUBICIN-P1-MTD-02|Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors|An Open-Label Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL Administered as Infusions Every 3 Weeks in Subjects With Advanced Solid Tumors||CytRx|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||April 2014|April 18, 2014|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673438||80296|
NCT01673464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ELM-12|A Prospective Study of Brain Network Activation (BNA) Changes in High School Athletes Following Concussion|A Prospective Study of Brain Network Activation (BNA) Changes in High School Athletes Following Concussion||ElMindA Ltd|No|Completed|August 2012|June 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|126|||Both|13 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|High school (13-18 yrs) athletes from American football, soccer, and lacrosse who meet the        inclusion/exclusion criteria will be recruited into the study. We expect that between        10-20 participants will sustain a concussion during the period of the study and complete        the post-concussion protocol.|April 2015|April 8, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01673464||80294|
NCT01672216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|101/12 ethics comm. Giessen|Multicenter Randomized Controlled Trial to Compare the Outcome of Conservative Triple Target Treatment With EMG-Biofeedback in Chronic Obstipation|Triple Target Treatment (3T) Combining Amplitude Modulated Middle Frequency (AM-MF) Stimulation With Electromyography (EMG)EMG-Biofeedback Versus EMG-Biofeedback in Chronic Obstipation|3T-CO|University of Giessen|Yes|Recruiting|August 2012|May 2015|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||September 2013|September 20, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01672216||80390|
NCT01672437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nyfødt -DP -269|NewPreBP: Project Newborn -Preparation for Birth and Parenthood|NewPreBP: Project Newborn -Preparation for Birth and Parenthood. A Large Interdisciplinary Randomised Trial on the Effect of Birth and Parent Preparation|NewPreBP|University of Southern Denmark|Yes|Active, not recruiting|November 2012|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|2350|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 25, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01672437||80373|
NCT01674569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X82-OPH-102|Pilot Study of X-82 in Patients With Wet AMD|A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)||Tyrogenex|No|Completed|October 2012|February 2015|Actual|February 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|50 Years|N/A|No|||March 2016|March 8, 2016|August 23, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01674569||80210|
NCT01674582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version1.0|Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters|Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters.||Lund University Hospital|No|Recruiting|October 2012|February 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|150|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|January 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674582||80209|
NCT01674556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1601|Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer|Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification||Haukeland University Hospital|No|Completed|February 2012|January 2015|Actual|January 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|N/A|N/A|No|||September 2015|September 23, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01674556||80211|
NCT01674868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAN SpauldingRH|Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke|Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke|FLAN|Spaulding Rehabilitation Hospital|No|Withdrawn|April 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|85 Years|No|||June 2015|June 14, 2015|August 24, 2012||No|unable to find patients meeting inclusion/exclusion criteria|No||https://clinicaltrials.gov/show/NCT01674868||80187|
NCT01674881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPoS-1|The Effectiveness of Mindfulness on Chronic Pain in Breast Cancer Survivors|A Randomized Controlled Trial of Mindfulness-based Cognitive Therapy (MBCT) on Chronic Pain in Women Treated for Breast Cancer||University of Aarhus|No|Completed|September 2012|January 2015|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|130|||Female|18 Years|N/A|No|||August 2013|April 13, 2015|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01674881||80186|
NCT01675401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEC 12-3-040|Body Weight and Vascular Function|Vascular Function Markers: Differences Between Lean and Abdominally Overweight / Obese Men and Effects of Weight Loss||Maastricht University Medical Center|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|75|||Male|18 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 28, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01675401||80146|
NCT01675687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK-12-098-VK ID by EC Vienna|Web Based Follow up Intervention in Obesity Treatment for Women|Effects on Self-efficacy, Sustainability and Drop Out Rate Using Web Based Follow up Intervention in Obesity Treatment for Women||FEM Süd|No|Completed|August 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|84|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675687||80124|
NCT01675973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-259-0112|A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine|A Phase 1, Parallel-group, Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Ranolazine ER in Subjects With Severe Renal Impairment as Compared to Healthy Subjects With Normal Renal Function||Gilead Sciences||Terminated|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|July 26, 2012|No|Yes|Study met stopping criteria specified within protocol.|No||https://clinicaltrials.gov/show/NCT01675973||80102|
NCT01675986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GABAPAC|Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score|||Poitiers University Hospital||Recruiting||||January 2014|Anticipated|Phase 2|Interventional|N/A|3||||||Both|18 Years|75 Years|No|||February 2012|March 27, 2013|February 7, 2012||||No||https://clinicaltrials.gov/show/NCT01675986||80101|
NCT01675310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Conacyt 151819|Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women|EFFECTIVITY OF MEDICAL NUTRITION THERAPY PLUS TRANSGESTATIONAL METFORMIN FOR PREVENTING THE INCIDENCE OF GESTATIONAL DIABETES MELLITUS IN HIGH RISK MEXICAN WOMEN.||Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes|Yes|Completed|January 2012|March 2015|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|90|||Female|18 Years|50 Years|No|||March 2015|March 23, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675310||80153|
NCT01675323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00073951|Glutamate, Hyperarousal and Restless Legs Syndrome|Glutamate, Hyperarousal and Restless Legs Syndrome||Johns Hopkins University|No|Active, not recruiting|August 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|70|Samples With DNA|Whole blood and urine (female participants only)|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Subjects with RLS and healthy subjects, 18 years of age or older, matched for age, gender,        race, and educational level. Both men and women will be included.|October 2015|October 13, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01675323||80152|
NCT01675921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-P-000674/1|Implementation of ACT Through Facebook for Teenagers With Asthma|Implementation of ACT Through Facebook for Teenagers With Asthma||Massachusetts General Hospital|No|Active, not recruiting|September 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|120|||Both|14 Years|17 Years|No|||February 2014|February 4, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675921||80106|
NCT01675934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO00017208|Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes|Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes||Medical College of Wisconsin|No|Withdrawn|February 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|0|||Both|18 Years|100 Years|Accepts Healthy Volunteers|||January 2016|January 6, 2016|August 28, 2012||No|PI has left institution|No||https://clinicaltrials.gov/show/NCT01675934||80105|
NCT01677013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUACH-721002|Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus|Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Selective Type 2 Diabetes Mellitus||Peking University Aerospace Centre Hospital|Yes|Recruiting|May 2011|May 2016|Anticipated|May 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|500|||Both|30 Years|70 Years|No|||January 2015|January 26, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677013||80022|
NCT01677260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR. 143/EQL/2009|Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet|A Combined Single Dose Study Under Fasting Condition And Multiple Doses Study Under Normal Diabetic Meal Comparing the Bioavailability of Two Formulations of 500 mg Metformin Hydrochloride Extended Release Tablets.||Dexa Medica Group|No|Completed|October 2009|January 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677260||80003|
NCT01677585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S2288|Post-Approval Study of PROMUS Element™ in China|PROMUS Element™ China Post-Approval Study|PEChina|Boston Scientific Corporation|No|Enrolling by invitation|August 2012|May 2020|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|2000|||Both|18 Years|N/A|No|Non-Probability Sample|All subjects who are candidates for coronary artery stenting, signed the informed consent        form and eligible to receive a PROMUS Element stent will be evaluated for enrollment in        this study.|September 2014|November 6, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677585||79978|
NCT01673451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E2006-A001-002|2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of E2006 in Healthy Adult and Elderly Subjects||Eisai Inc.||Completed|August 2012|July 2013|Actual|May 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||October 2013|October 10, 2013|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673451||80295|
NCT01674062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO17929|A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer.|An Exploratory Single-arm Study to Evaluate the Effect of Pertuzumab in Combination With Herceptin on Response Rate in Patients With HER2-positive Metastatic Breast Cancer||Hoffmann-La Roche||Active, not recruiting|May 2006|December 2017|Anticipated|February 2008|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|95|||Female|18 Years|N/A|No|||September 2015|September 24, 2015|August 24, 2012|No|Yes||No|August 11, 2015|https://clinicaltrials.gov/show/NCT01674062||80249|
NCT01674075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001141|Lidocaine Serum Levels in Healthy Adult Volunteers: a Pilot Evaluation of the J-Tip Delivery System|||Massachusetts General Hospital|No|Completed|September 2012|||February 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|10|||Both|18 Years|59 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers over the age of 18.|July 2013|July 10, 2013|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01674075||80248|
NCT01673243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XPD12-110 SMOBAN|Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting|Tobacco Trials at St. Jude: Parent Willingness to Participate Among Families of Children With Cancer, Sickle Cell Disease, or Survivors of Childhood Cancer||St. Jude Children's Research Hospital|No|Completed|September 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|88|||Both|N/A|N/A|No|Non-Probability Sample|For the purposes of this protocol, the term "parent" includes biological parents,        step-parents, and legal guardians.        The primary study population will consist of parents of St. Jude Children's Research        Hospital (SJCRH) patients with a diagnosis of (1) cancer or (2) sickle cell disease (to        include genotypes HbSS, HbSC, HbSβ°thal, HbSβ+thal, HbSD, HbSO, Hb S/HPFH, HbSE), or (3)        will be a surviving cancer patient.|March 2015|March 4, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01673243||80311|
NCT01674855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DA3031_NP_III|Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia|Randomized, Open, Multi-Center, Phase III Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy|PEG-G-CSF|Dong-A ST Co., Ltd.|No|Completed|February 2012|May 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|74|||Both|18 Years|70 Years|No|||September 2014|September 29, 2014|January 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01674855||80188|
NCT01674595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AV-X-01|An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy||ALK-Abelló A/S|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|93|||Both|18 Years|65 Years|No|||April 2013|April 29, 2013|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01674595||80208|
NCT01672684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BRSADJ0023|Phase I: At-Home Support for Rural Women Using Group Video Calling|At-Home Support for Rural Women Using Group Video Calling||Stanford University|No|Completed|October 2012|June 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|34|||Female|21 Years|N/A|No|||October 2014|October 15, 2014|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01672684||80354|
NCT01675141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120192|Lenalidomide Maintenance Therapy for Multiple Myeloma|Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study||National Institutes of Health Clinical Center (CC)||Active, not recruiting|August 2012|April 2018|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|99 Years|No|||March 2016|March 18, 2016|August 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675141||80166|
NCT01675414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Grant 2037|Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)|Understanding Gastrointestinal Conditions in Children With ASD||Massachusetts General Hospital|No|Completed|September 2008|February 2011|Actual|June 2010|Actual|N/A|Observational|Observational Model: Cohort||1|Actual|131|||Both|2 Years|17 Years|No|Probability Sample|131 nonselected subjects with ASD|August 2012|August 29, 2012|April 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01675414||80145|
NCT01675700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122975|Topical Nitrates for Myofascial Trigger Points|||GF Strong Rehabilitation Centre|No|Completed|January 2009|December 2009|Actual|July 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|19 Years|65 Years|No|||August 2012|August 28, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01675700||80123|
NCT01676181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/333-31/4|ATT Compared With ATE in OSAS Children|Randomised Surgical Intervention Study Between Adenotonsillectomy and Adenotonsillotomy in Children With Obstructive Sleep Apnea Syndrome|RCT ATE/ATT|Karolinska University Hospital|Yes|Active, not recruiting|November 2011|August 2022|Anticipated|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|2 Years|6 Years|No|||February 2016|February 25, 2016|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01676181||80086|
NCT01675648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lofex00428|Lofexidine for Inpatient Opiate Detox in Singapore|A Double-blind Randomised Controlled Clinical Trial of Lofexidine Versus Diazepam in the Management of the Opioid Withdrawal Syndrome During Inpatient Detoxification in Singapore||Institute of Mental Health, Singapore|Yes|Completed|August 2012|July 2015|Actual|July 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|112|||Both|21 Years|55 Years|No|||August 2015|August 26, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01675648||80127|
NCT01675661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-0053|Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment|Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)|ACCENT|Medical University of South Carolina|Yes|Completed|January 2014|August 2015|Actual|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|50 Years|No|||September 2015|September 22, 2015|August 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675661||80126|
NCT01676207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|007/12|Prevalence of Extracardiac Coronary Collateral Supply Via the Internal Mammary Arteries|Prevalence of Extracardiac Coronary Collateral Supply Via the Internal Mammary Arteries||University Hospital Inselspital, Berne|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|120|||Both|18 Years|N/A|No|Non-Probability Sample|Patients electively referred for coronary angiography|January 2014|January 15, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676207||80084|
NCT01676415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18369|Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Role of Short Term Systemic Corticosteroid Therapy in the Management of Chronic Rhinosinusitis Without Nasal Polyps||Northwestern University||Recruiting|August 2012|June 2017|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||July 2015|July 17, 2015|August 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676415||80068|
NCT01676194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012~A00269-34|Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma|Efficacy of Transarterial Chemoembolization With DC-BeadsR Prior to Liver Transplantation for Hepatocellular Carcinoma on Patient Survival : A Prosepctive Multicentre and Randomized Study|CATCH|Rennes University Hospital|Yes|Active, not recruiting|August 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|140|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676194||80085|
NCT01676428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/106|A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases|A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases|FASTRACK|Peter MacCallum Cancer Centre, Australia|Yes|Active, not recruiting|May 2012|November 2015|Anticipated|November 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||April 2015|May 6, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01676428||80067|
NCT01676441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cerecellgram-spine|Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury|A Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Patients With Chronic Spinal Cord Injury.||Pharmicell Co., Ltd.|No|Recruiting|August 2008|May 2016|Anticipated|October 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|32|||Both|16 Years|65 Years|No|||August 2012|October 28, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01676441||80066|
NCT01676766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM 64388|Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease|Novel Quantification Methods for Fundus Flavoprotein Fluorescence and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease||University of Michigan|No|Recruiting|September 2012|February 2014|Anticipated|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|5 Years|18 Years|No|Non-Probability Sample|We will perform an observational clinical study of 25 pediatric patients with Stargardt        Disease recruited from the retinal degeneration clinic at the University of Michigan who        have two mutations in ABCA4.|September 2012|September 19, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01676766||80041|
NCT01677273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B299|The Effect of Hydrolyzed Casein on Energy Expenditure and Subjective Appetite|The Effect of Hydrolyzed Casein on Energy Expenditure and Subjective Appetite|HerKulES|University of Copenhagen|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|3||Actual|33|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 26, 2013|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677273||80002|
NCT01677286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31546|Safety and Effect of Doxycycline in Patients With Amyloidosis|A Phase II Study of Doxycycline in Patients With Amyloidosis||Boston University|No|Active, not recruiting|July 2012|December 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2015|January 2, 2015|August 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677286||80001|
NCT01677299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCPOC10|Study Assessing the PK of EFB0027 (Metformin Delayed-release) and Effect on Circulating Glucose and GI Hormone Concentrations in Subjects With T2DM|A RANDOMIZED, CROSSOVER STUDY ASSESSING THE EFFECTS OF PH 6.5 ENTERIC COATING OF METFORMIN HCL TABLETS ON PHARMACOKINETICS AND CHANGES IN CIRCULATING GLUCOSE AND GASTROINTESTINAL HORMONE CONCENTRATIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS||Elcelyx Therapeutics, Inc.|No|Completed|May 2012|September 2012|Actual|September 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|24|||Both|19 Years|70 Years|No|||May 2014|May 15, 2014|August 23, 2012|Yes|Yes||No|February 12, 2014|https://clinicaltrials.gov/show/NCT01677299||80000|
NCT01677598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100140|A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries|A Study to Evaluate Ustekinumab in Clinical Practice in Patients With Plaque Psoriasis in Asia-Pacific Countries|MARCOPOLO|Johnson & Johnson Pte Ltd|No|Completed|December 2011|November 2013|Actual|November 2013|Actual|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|169|||Both|18 Years|N/A|No|Non-Probability Sample|Patients at least 18 years of age with a diagnosis of plaque psoriasis, according to the        dermatologists' clinical judgment|January 2016|January 25, 2016|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01677598||79977|
NCT01671683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUH 10|Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer|A Phase II Study of Additional Four-week Chemotherapy With Capecitabine During the Resting Periods After Six-week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer||Chungnam National University|No|Completed|July 2010|September 2011|Actual|||N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|44|||Both|20 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients of our hospital|August 2012|August 21, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671683||80431|
NCT01671696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CardiacMRI|Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy|Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy: A Cardiac Magnetic Resonance and Biomarker Imaging and Serological Biomarker Study||Connecticut Children's Medical Center|No|Recruiting|September 2011|May 2014|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||1|Anticipated|80|||Both|9 Years|35 Years|No|Non-Probability Sample|Survivors of childhood cancer who were treated with anthracyclines and are greater than 2        years from their last cycle of chemotherapy|May 2011|August 21, 2012|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01671696||80430|
NCT01674309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FFCD 1102|First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis|Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis||Federation Francophone de Cancerologie Digestive|Yes|Recruiting|April 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|65|||Both|18 Years|N/A|No|||August 2012|October 6, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01674309||80230|
NCT01674322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100885|A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants|An Open-Label Phase 1 Study to Determine the Pharmacokinetics, Metabolism, and Routes of Excretion of (14C) Radiolabeled PCI-32765 in Healthy Male Subjects||Janssen Research & Development, LLC|No|Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Male|30 Years|55 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01674322||80229|
NCT01674608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICF|TEAM: Trial of Early Activity and Mobilization|TEAM: An Multi-centre Observational Study of Early Activity and Mobilization in Australia and New Zealand|TEAM|Australian and New Zealand Intensive Care Research Centre|No|Completed|July 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|192|||Both|18 Years|N/A|No|Non-Probability Sample|Intensive care unit patients|May 2015|May 4, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01674608||80207|
NCT01672996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GE-145-004|Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers|A Phase 1/2, Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Contrast-Enhanced Abdominal Computed Tomography in Healthy Volunteers||GE Healthcare|No|Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|66|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||April 2014|May 13, 2014|August 9, 2012|Yes|Yes||No|January 17, 2014|https://clinicaltrials.gov/show/NCT01672996||80330|
NCT01673009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0512-25|Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas||Indiana University|Yes|Completed|May 2006|August 2012|Actual|December 2011|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|36|||Both|3 Years|65 Years|No|||August 2012|August 24, 2012|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673009||80329|
NCT01672983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-536|A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection|A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection||AbbVie|No|Completed|July 2012|May 2014|Actual|May 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Actual|110|||Both|18 Years|75 Years|No|||October 2015|October 27, 2015|July 27, 2012||No||No|October 27, 2015|https://clinicaltrials.gov/show/NCT01672983||80331|
NCT01673217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 127008|Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma||Roswell Park Cancer Institute|No|Completed|April 2009|June 2013|Actual|October 2011|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Female|18 Years|N/A|No|||January 2014|January 10, 2014|August 22, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01673217||80313|
NCT01669070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115441|A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)|An Open Label, Part-randomised, Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate (FF) When Administered as FF Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subjects||GlaxoSmithKline|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01669070||80631|
NCT01669408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreCOOL 1|Prehospital COOLing 1 (PreCOOL 1)|A Randomized Controlled Trial Evaluating Cold Infusions for Prehospital Induction of Cooling in Awake Stroke Patients (PreCOOL 1)|PreCOOL|University Hospital Heidelberg|No|Recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||June 2013|June 21, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01669408||80605|
NCT01675947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3368-12056|Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy|Multi-Center, Randomized, Single Masked Phase 2 Study of Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration|Sirolimus|National Eye Institute (NEI)|Yes|Terminated|February 2012|February 2016|Anticipated|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|52|||Both|55 Years|N/A|No|||December 2015|December 8, 2015|August 28, 2012|Yes|Yes|On May 30, 2014, study injections were discontinued at the request of the DSMC. No further    recruitment will occur.|No||https://clinicaltrials.gov/show/NCT01675947||80104|
NCT01675960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|112909|Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children|A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children||Gillette Children's Specialty Healthcare|Yes|Active, not recruiting|April 2012|October 2020|Anticipated|October 2019|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|1 Month|16 Years|No|||February 2016|February 8, 2016|May 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01675960||80103|
NCT01676454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vasopressin Study|Serum Vasopressin Levels and Severe Hemorrhagic Shock|Determination of Serum Vasopressin Levels and Correlation With Life-threatening Complications in Adults With Severe Hemorrhagic Shock.||Poudre Valley Health System|No|Withdrawn|November 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted to Medical Center of the Rockies with minor injuries.|December 2015|December 30, 2015|August 21, 2012||No|Study closed without enrollment .|No||https://clinicaltrials.gov/show/NCT01676454||80065|
NCT01676779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DC-MEL|mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma|Randomized Controlled Phase II Clinical Trial on mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Patients Who Are Disease-free Following the Local Treatment of Macrometastases.|DC-MEL|Universitair Ziekenhuis Brussel|No|Active, not recruiting|October 2012|September 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|N/A|No|||December 2015|December 30, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01676779||80040|
NCT01677039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531004|Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation|An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Ethanol 20% and 40% on the Bioavailability a Controlled Release Formulation of Oxycodone 20 Mg With Sequestered Naltrexone 2.4 Mg in Healthy Volunteers||Pfizer|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|19|||Both|21 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|August 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01677039||80020|
NCT01676467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENA002|Sample Collection in Smoking Asthma|A Sample Collection Protocol for Disease Profiling of Smoking Asthma.||Respivert Ltd|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||6|Actual|23|Samples With DNA|serum sputum|Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be selected by advertisements from the general population and primary care.|January 2013|January 7, 2013|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01676467||80064|
NCT01677052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STR-148|THERMOCOOL® SMARTTOUCH™ Registry|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Atrial Fibrillation- Registry||Biosense Webster, Inc.|Yes|Completed|August 2012|August 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|426|||Both|18 Years|N/A|No|Non-Probability Sample|Target enrollment for this registry is 650 subjects. Of the 650 subjects enrolled, at        least 250 will have paroxysmal atrial fibrillation.|September 2014|September 24, 2014|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01677052||80019|
NCT01677065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4531007|A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers|An Open-label, Single-dose, Randomized, Two-way Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers||Pfizer|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|Phase 1|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|14|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adult volunteers|October 2012|October 22, 2012|August 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01677065||80018|
NCT01677312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|356077|Trial Comparing 19 and 25-gauge EUS-FNA Needles|Multi-Center Randomized Trial Comparing 19 and 25-gauge Needles for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) of Solid Pancreatic Mass Lesions|EUS-FNA|Florida Hospital|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|109|||Both|19 Years|N/A|No|||March 2013|March 12, 2013|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01677312||79999|
NCT01677325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2006-65|The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine|The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine||Fudan University|Yes|Completed|January 2007|January 2008|Actual|January 2007|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Actual|40|||Male|18 Years|65 Years|No|||September 2012|September 4, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01677325||79998|
NCT01677026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP-004|Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache|Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache||Autonomic Technologies, Inc.|No|Active, not recruiting|September 2012|September 2020|Anticipated|September 2020|Anticipated|N/A|Observational [Patient Registry]|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|N/A|N/A|No|Non-Probability Sample|Subjects who meet the CE marked labeling for cluster headache for the ATI Neurostimulation        System.|March 2016|March 8, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677026|5 Years|80021|
NCT01673490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114785|Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia|A Pivotal, Open-label Trial Assessing the Safety and Efficacy of the 0.5 mg Dutasteride and 0.4 mg Tamsulosin Combination Once Daily for Six Months in Patients With Benign Prostatic Hyperplasia|FDC114785|GlaxoSmithKline|No|Terminated|June 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|59|||Male|50 Years|N/A|No|||October 2015|November 16, 2015|June 28, 2012||No|The sole investigative site refused to accept the amended protocol and declined to continue    the study. There was no safety signal nor any other reason.|No|October 8, 2015|https://clinicaltrials.gov/show/NCT01673490||80293|
NCT01673503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20100111|A Prospective Study of Femtosecond Laser Intracorneal Lensectomi|A Prospective Study of Femtosecond Laser Intracorneal Lensectomi in Treatment of Moderate to High Myopia||Odense University Hospital|Yes|Completed|May 2011|||||Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2|||35|||Both|25 Years|45 Years|Accepts Healthy Volunteers|||January 2013|January 23, 2013|August 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01673503||80292|
NCT01673776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FEMO|Multimodal Approach to Improve the Outcome of Patients With a Proximal Femoral Fracture|Can a Multimodal Approach Improve the Outcome of Patients With a Proximal Femoral Fracture?|FEMO|Technische Universität München|Yes|Recruiting|March 2012|||March 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|132|||Both|60 Years|N/A|No|Probability Sample|Patients with proximal femoral fractures (femoral neck fractures or pertrochanteric        femoral fractures)|March 2013|March 14, 2013|August 20, 2012||||No||https://clinicaltrials.gov/show/NCT01673776||80271|
NCT01641432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPI-1002-2011|Computerized Attention Training for Individuals With Acquired Brain Injury|Computerized Cognitive Treatment of Vigilance Deficits in Individuals With Acquired Brain Injury||Posit Science Corporation||Completed|July 2011|||July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|27|||Both|21 Years|80 Years|No|||July 2014|July 21, 2014|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01641432||82678|
NCT01641939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BO27952|A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer|A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction||Hoffmann-La Roche||Active, not recruiting|September 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|3||Actual|415|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641939||82639|
NCT01641666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08599|Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)|An Open-Label Study to Assess the Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Any Interferon Plus Ribavirin in Vietnam||Merck Sharp & Dohme Corp.|No|Withdrawn|May 2014|September 2016|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2015|September 7, 2015|July 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01641666||82660|
NCT01642498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH-02|A Multicenter Study to Evaluate the ROX Arteriovenous Coupler in Patients With Treatment-Resistant Hypertension|ROX CONTROL HTN Study: A Prospective, Randomized, Open-Label, Multicenter Study to Evaluate the ROX Coupler in Patients With Resistant Hypertension||ROX Medical, Inc.|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||September 2015|September 28, 2015|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01642498||82597|
NCT01642238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0732|Antithrombotic Effects of Ticagrelor Versus Clopidogrel|Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin When Administered With Bivalirudin||Icahn School of Medicine at Mount Sinai|No|Completed|July 2012|April 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2014|January 16, 2014|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642238||82616|
NCT01633060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120F2303|A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi|A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment|BELLE-3|Novartis|Yes|Recruiting|October 2012|March 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|420|||Female|18 Years|N/A|No|||January 2016|January 4, 2016|June 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01633060||83318|
NCT01633346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUL-TOC-2010-01|Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients|Regulation of the Immune System in Response to the Treatment With Tocilizumab in RA Patients||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|June 2010|October 2015|Anticipated|July 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with RA who are going to commence treatment with Ro-Actemra® (Tocilizumab). All        patients initiating treatment will be considered for the study if they fulfill all        inclusion/exclusion criteria.|January 2013|April 13, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01633346||83296|
NCT01643018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MK-001-CH|Laparoscopic Versus Open Surgery for the Management of Cystic Echinococcosis of the Liver|Laparoscopic Versus Open Conservative Surgery for the Management of Cystic Echinococcosis of the Liver: Prospective, Randomized, and Controlled Clinical Trial of Efficacy and Safety||Medical Park Gaziantep Hospital|Yes|Completed|November 2006|May 2012|Actual|November 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|350|||Both|18 Years|90 Years|No|||July 2012|July 16, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01643018||82557|
NCT01633567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0538|Culturally Targeted & Individually Tailored Smoking Cessation Study: LGBT Smokers|||University of Illinois at Chicago|No|Active, not recruiting|May 2012|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 7, 2015|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01633567||83279|
NCT01633801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BambinoGHRI|Use of High Flows in Pediatric Cardiac Surgical Patients|Use of High Flow Ventilation in Pediatric Cardiac Surgical Patients||Bambino Gesù Hospital and Research Institute|No|Recruiting|August 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|N/A|18 Months|No|||August 2012|August 21, 2012|June 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01633801||83261|
NCT01642004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-017|Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)|An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)||Bristol-Myers Squibb|Yes|Active, not recruiting|September 2012|January 2017|Anticipated|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|352|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|July 9, 2012|Yes|Yes||No|February 19, 2016|https://clinicaltrials.gov/show/NCT01642004||82634|
NCT01642017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11GENE06|Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria|Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria|VOTRAGE|Institut Claudius Regaud|No|Recruiting|March 2015|December 2016|Anticipated|October 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|75 Years|N/A|No|||September 2014|March 26, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642017||82633|
NCT01657513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-001|TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis|Production of Antibodies Against Tnf-alfa Blockers in Patients With Psoriasis||University Hospital, Gentofte, Copenhagen|No|Recruiting|June 2012|||July 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|75 Years|No|||August 2012|August 3, 2012|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01657513||81497|
NCT01657526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116018|Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Healthy Adults||GlaxoSmithKline||Completed|August 2012|November 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|48|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||December 2013|December 12, 2013|August 2, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01657526||81496|
NCT01643187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APE-001|Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children|Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children From the Takalik Abaj||Association for the Study and Prevention of HIV/AIDS|No|Not yet recruiting|July 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1000|||Both|6 Months|72 Months|No|||July 2012|July 16, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01643187||82544|
NCT01643200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IP110|Safety and Feasibility of the Zotarolimus Stent in Treating Males With Erectile Dysfunction (ED)|The Medtronic Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males With Sub-optimal Response to PDE5 Inhibitors|ZEN|Medtronic Endovascular|Yes|Terminated|October 2009|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Male|18 Years|N/A|No|||January 2016|January 25, 2016|July 16, 2012|Yes|Yes|Sponsor chose not to pursue indication for erectile dysfunction|No||https://clinicaltrials.gov/show/NCT01643200||82543|
NCT01644045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-1003-0034-4|Prehospital Emergency Care of Obstructive Respiratory Emergencies With the Use of Teleconsultation|Prehospital Emergency Care of Obstructive Respiratory Emergencies With the Use of Teleconsultation||RWTH Aachen University|No|Completed|August 2012|September 2015|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|17|||Both|N/A|N/A|No|||September 2015|September 21, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01644045||82478|
NCT01644487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV-10302|Self-Expanding Nitinol Stent Versus Balloon Angioplasty Alone for the Below The Knee Arteries(SENS-BTK)|Efficacy of Self-Expanding Nitinol Stent Versus Balloon Angioplasty Alone for the Below The Knee Arteries Following Successful Balloon Angioplasty Trial (Korean Vascular Intervention Multicenter Study)|SENS-BTK|Korea University Guro Hospital||Recruiting|July 2012|July 2018|Anticipated|July 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|232|||Both|20 Years|80 Years|No|||November 2015|November 6, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644487||82445|
NCT01640860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCESO|Concurrent Chemoradiotherapy With Docetaxel and Cisplatin in Esophageal Cancer|A Phase II Study of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin in Inoperable Esophageal Cancer||Chonnam National University Hospital|Yes|Completed|December 2007|December 2011|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|36|||Both|18 Years|75 Years|No|Non-Probability Sample|advanced esophageal cancer diagosed at Chonnam National University Hospital|July 2012|July 16, 2012|January 7, 2008||No||No||https://clinicaltrials.gov/show/NCT01640860||82721|
NCT01641159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTN-0052|Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence|A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence (BRAC)|BRAC|University of Cincinnati|Yes|Completed|August 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|62|||Both|18 Years|N/A|No|||December 2014|December 18, 2014|July 10, 2012|Yes|Yes||No|December 9, 2014|https://clinicaltrials.gov/show/NCT01641159||82699|
NCT01640821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-ASSS-MTL-10-001|Dissemination of the "Choisir de Maigrir?" Program|Dissemination of the "Choisir de Maigrir?" Program in Health and Social Service Centers in Québec: Evaluation of Its Implementation and Impact on Lifestyle Habits and Well-being|CHOIX-CSSS|Laval University|No|Completed|September 2010|June 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|328|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 11, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640821||82724|
NCT01640834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14576|Study of LY2409021 in Participants With Type 1 Diabetes|Pilot Study of the Effects of LY2409021 in Patients With Type 1 Diabetes Mellitus||Eli Lilly and Company|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Anticipated|30|||Both|18 Years|65 Years|No|||September 2012|September 20, 2012|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640834||82723|
NCT01640847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106-10-201|MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases|Phase II Trial of Phillips MRI-Guided High Intensity Focused Ultrasound (Sonalleve) and Lyso-thermosensitive Liposomal Doxorubicin (ThermoDox) for Palliation of Painful Bone Metastases||Celsion||Withdrawn|July 2012|July 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2016|March 4, 2016|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640847||82722|
NCT01641692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116402|A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma|A Multi-national, Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study With GSK 573719 as Monotherapy in Adult Subjects With Asthma||GlaxoSmithKline|No|Completed|May 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|350|||Both|18 Years|N/A|No|||July 2014|August 18, 2014|May 31, 2012|Yes|Yes||No|May 8, 2014|https://clinicaltrials.gov/show/NCT01641692||82658|
NCT01641705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-01|Analysis of Respiratory Mechanics in Patients With Rheumatoid Arthritis|Analysis of Respiratory Mechanics in Patients With Rheumatoid Arthritis: Effect of Duration of Disease||Hospital Universitario Pedro Ernesto|No|Recruiting|July 2010|July 2013|Anticipated|December 2012|Anticipated|N/A|Observational|Time Perspective: Cross-Sectional||5|Anticipated|90|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Non-Probability Sample|The control group will consist of healthy subjects, nonsmokers, who had no episode of        respiratory infection thirty days before the examinations.        The group of patients with rheumatoid arthritis will be comprised of individuals treated        at the Department of Rheumatology (Hospital Universitártio Pedro Ernesto) nonsmokers, who        had no episode of respiratory infection thirty days before the examinations.|July 2012|July 16, 2012|March 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01641705||82657|
NCT01642225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20120052|Desensitization Protocol for Deceased Donor List|Desensitization Protocol for Deceased Donor List||University of Miami|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|180|||Both|7 Years|75 Years|No|Probability Sample|Approximately 100 subjects are expected to participate from 2007 to current, and another        100 subjects are expected to participate during the next 12-month period.|October 2014|October 17, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01642225||82617|
NCT01642251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01985|Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer|Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer||National Cancer Institute (NCI)|Yes|Active, not recruiting|September 2012|||January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|168|||Both|18 Years|N/A|No|||January 2016|March 22, 2016|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642251||82615|
NCT01644604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MDT2-11-07|Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension|The Clinical Study of Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension|HTN-J|Medtronic Vascular|Yes|Active, not recruiting|July 2012|April 2017|Anticipated|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|41|||Both|20 Years|80 Years|No|||October 2015|October 23, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01644604||82436|
NCT01633047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAAE 01430812.1.0000.5505|Electrostimulation in Anterior Cruciate Ligament Reconstruction|Effects of Low Frequency Neuromuscular Electrical Stimulation Applied to the Quadriceps in the Production of Knee Extension Strength and Control of Edema After Anterior Cruciate Ligament Reconstruction||Federal University of São Paulo|No|Completed|June 2015|July 2015|Actual|July 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2015|July 16, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01633047||83319|
NCT01633320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CPP 2012-021 B|Non-invasive Assessment of Immediate Postoperative Analgesia Using Analgesia/Nociception Index (ANI)|Non-invasive Assessment of Immediate Postoperative Analgesia Using Analgesia/Nociception Index (ANI): A Prospective and Observational Study||Hôpital Edouard Herriot|Yes|Completed|July 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|75 Years|No|Non-Probability Sample|Adult patients underoing surgical or endoscopic procedures performed on general anesthesia|November 2012|November 13, 2012|June 28, 2012||No||No|August 6, 2012|https://clinicaltrials.gov/show/NCT01633320||83298|
NCT01633333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WMCO2_KG|Water Exchange Versus Carbon Dioxide for Colonoscopy|Water Exchange Versus Carbon Dioxide Insufflation to Improve Colonoscopy Screening - a Randomized Controlled Trial||Sorlandet Hospital HF|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|2||Actual|473|||Both|50 Years|80 Years|Accepts Healthy Volunteers|||February 2014|February 11, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633333||83297|
NCT01634126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01CA154982|Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening|Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening|MY-FIT|Kaiser Permanente|Yes|Active, not recruiting|August 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|3000|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||April 2015|April 2, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01634126||83236|
NCT01634139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.445|Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma||Boehringer Ingelheim||Completed|July 2012|December 2015|Actual|June 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|403|||Both|6 Years|11 Years|No|||January 2016|January 6, 2016|July 3, 2012||||No||https://clinicaltrials.gov/show/NCT01634139||83235|
NCT01634152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.446|Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma||Boehringer Ingelheim||Completed|July 2012|May 2015|Actual|May 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|401|||Both|6 Years|11 Years|No|||December 2015|December 22, 2015|July 3, 2012||||No|November 17, 2015|https://clinicaltrials.gov/show/NCT01634152||83234|
NCT01634165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14676|A Study of LY2963016 in Healthy Participants|Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus® in Healthy Subjects Following Two Single Subcutaneous Doses||Eli Lilly and Company|No|Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|24|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|July 2, 2012|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01634165||83233|
NCT01634503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GX-188E-SN|Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3|A Single Center, Open-label, Dose-escalating, Phase Ι Study to Evaluate the Safety of GX-188E Administered by Electroporation (EP) in DNA-based Therapeutic Vaccine for Patients With Cervical Intraepithelial Neoplasia Grade 3 (CIN 3)|CIN3|Genexine, Inc.|No|Completed|November 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Female|20 Years|50 Years|No|||February 2014|February 14, 2014|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01634503||83207|
NCT01642329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProACS|Portuguese Registry on Acute Coronary Syndromes|Portuguese Registry on Acute Coronary Syndromes|ProACS|Portuguese Society of Cardiology|No|Recruiting|January 2002|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|50000|None Retained|no samples retained|Both|18 Years|N/A|No|Probability Sample|All adult patients with Acute Coronary Syndrome (ACS) with <48 hours of evolution,        admitted to Portuguese Hospitals.|September 2015|October 22, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642329||82610|
NCT01642342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0C-11-3|Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors|A First-In-Human Phase I Study of sEphB4-HSA in Patients With Advanced Solid Tumors With Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).||University of Southern California|Yes|Recruiting|September 2012|January 2017|Anticipated|January 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|138|||Both|18 Years|N/A|No|||July 2015|July 6, 2015|July 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642342||82609|
NCT01642862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CYPCEL-1103|Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration|A Phase I, Randomized, Open Label, Mono-centered, Prospective Study to Evaluate the Pharmacokinetics of Different Formulations and Doses of Simvastatin in Healthy Subjects and in Subjects With Celiac Disease in Remission||University of Zurich|Yes|Terminated|July 2012|February 2014|Actual|July 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|12|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||May 2015|June 2, 2015|July 10, 2012||No|Low recruitment rate|No||https://clinicaltrials.gov/show/NCT01642862||82569|
NCT01657786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2008-0075|Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting|||Yonsei University|Yes|Completed|May 2008|April 2009|Actual|February 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|198|||Both|20 Years|90 Years|No|||August 2012|August 3, 2012|July 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01657786||81476|
NCT01657799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M10-897|A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)|A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer||AbbVie|Yes|Completed|October 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|307|||Both|18 Years|99 Years|No|||January 2016|January 22, 2016|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657799||81475|
NCT01643798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1F30DA033748|Role of the Supraspinal Opioidergic Circuit in Prefrontal TMS-Induced Analgesia|Role of the Supraspinal Opioidergic Circuit in Prefrontal TMS-Induced Analgesia||Medical University of South Carolina|No|Completed|January 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|15|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2012|March 10, 2014|June 22, 2012||No||No|November 18, 2013|https://clinicaltrials.gov/show/NCT01643798||82497|
NCT01644032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-1003-0034-3|Telemedically Supported Analgesia in the Emergency Medical Service|Telemedically Supported Analgesia in the Emergency Medical Service||RWTH Aachen University|No|Completed|August 2012|September 2015|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|106|||Both|N/A|N/A|No|||September 2015|September 21, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01644032||82479|
NCT01644513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCMM-AMD-105|Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients|Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal Anti-VEGF Injections (Bevacizumab or Ranibizumab) to Evaluate the Association Between Genetic Load and Response to Therapy/Treatment Burden|EVERGREEN|Sequenom, Inc.|No|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|196|None Retained|Remnant samples of DNA will be destroyed after analysis is complete.|Both|55 Years|N/A|No|Probability Sample|Patients with age-related macular degeneration treated with anti-VEGF therapy|July 2012|February 11, 2013|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644513||82443|
NCT01644253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16009|Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab or Idelalisib in Chronic Lymphocytic Leukemia|A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU 016 in Combination With Rituximab, in Combination With Obinutuzumab, or in Combination With Rituximab and Idelalisib in Patients With Chronic Lymphocytic Leukemia||Emergent Product Development Seattle LLC|No|Recruiting|September 2012|March 2017|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|93|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644253||82462|
NCT01644279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|429-2005|Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle|Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle||University of Florida|Yes|Active, not recruiting|March 2006|October 2016|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|63|Samples With DNA|Skeletal muscle biopsy; plasma, serum, urine.|Both|20 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Young (age 20-35 years; N =20), old high-functioning, (age 70-99 years; N = 25), and old        low-functioning (age 70-99 years; N = 20) subjects.|October 2015|October 22, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01644279||82461|
NCT01641172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TASTY-01|Taste, Smell and Chemotherapy (TASTY)|Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy|TASTY|University Medical Center Groningen|No|Recruiting|June 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|140|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||October 2015|October 1, 2015|January 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01641172||82698|
NCT01640561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU-MSU-UGANDA-2012|Enhancing Ugandan HIV-Affected Child Development With Caregiver Training|Enhancing Ugandan HIV-Affected Child Development With Caregiver Training|MISC|Johns Hopkins Bloomberg School of Public Health|No|Recruiting|January 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|1 Year|5 Years|Accepts Healthy Volunteers|||July 2012|July 11, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01640561||82744|
NCT01641679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL37266.031.11|PET Evaluation of Recurrent Differentiated Thyroid Cancer|Recurrent Differentiated Thyroid Cancer: Towards Personalized Treatment Based on Evaluation of Tumor Characteristics With PET (THYROPET|THYROPET|The Netherlands Cancer Institute|No|Not yet recruiting|August 2012|January 2016|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|100 patients with a history of DTC treated with total thyroidectomy and ablation who now        have a suspicion of recurrence outside the neck based on a raised Tg and a negative neck        ultrasound|June 2014|June 16, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641679||82659|
NCT01641471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF 12-476|Evaluation of Electrical Nerve Stimulation (TENS) Therapy for Pain Relief Following Total Knee Arthroplasty (TKA)|Prospective Evaluation of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Relief Following Total Knee Arthroplasty (TKA)||The Cleveland Clinic|No|Completed|December 2012|June 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|116|||Both|18 Years|85 Years|No|||February 2016|February 11, 2016|June 19, 2012|Yes|Yes||No|February 11, 2016|https://clinicaltrials.gov/show/NCT01641471||82675|
NCT01641952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27953|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-TNF Agent|Non-interventional, Prospective, Multicenter Study to Assess Efficacy and Safety of MabtheRA (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One Anti-TNF Agent - FAST 2 SWITCH Program||Hoffmann-La Roche||Completed|October 2011|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|505|||Both|18 Years|N/A|No|Probability Sample|Patients with active rheumatoid arthritis and an inadequate response or intolerant to one        prior anti-TFN therapy initiated on treatment with MabThera/Rituxan|March 2016|March 1, 2016|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01641952||82638|
NCT01632774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAR|Analysis of Risk Factors for Death After Blunt Traumatic Rupture of the Thoracic Aorta|Analysis of Risk Factors for Death After Blunt Traumatic Rupture of the Thoracic Aorta||University of Zurich|No|Completed|January 1990|December 2003|Actual|December 2003|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|85|||Both|16 Years|N/A|No|Probability Sample|Hospitalized patients Patients who died at the scene|June 2012|July 2, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632774||83340|
NCT01640951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAIN457A2304E1|Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies|Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies||Novartis|Yes|Active, not recruiting|September 2012|May 2017|Anticipated|May 2017|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|675|||Both|18 Years|N/A|No|||March 2016|March 23, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640951||82715|
NCT01633359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRAVEL-CAD|The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients|The Randomly Controlled Clinical Trial of the Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients|VSEL-CAD|Beijing Anzhen Hospital|Yes|Not yet recruiting|July 2012|May 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 4, 2012|May 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01633359||83295|
NCT01633580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/019|D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists|Follicular Phase Endocrine Characteristics During Ovarian Stimulation and GnRH Antagonist Co-treatment for IVF; Randomized Trial Comparing Corifollitropin Alfa (Elonva) Initiated on Cycle Day 2 or 4.||Universitair Ziekenhuis Brussel|No|Completed|December 2011|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|67|||Female|18 Years|36 Years|No|||December 2014|December 2, 2014|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01633580||83278|
NCT01633814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1133919|Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women|Influence of Hormone Replacement on Neural Cardiovascular Control in Postmenopausal Women||University of Missouri-Columbia|Yes|Recruiting|September 2011|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Anticipated|30|||Female|18 Years|80 Years|Accepts Healthy Volunteers|||June 2013|June 25, 2013|June 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01633814||83260|
NCT01641497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOMOGYN - 1105|Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer|Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer of 70 Years Old Women : Contribution of Oncogeriatric Evaluation to the Study of Acute Toxicity|TOMOGYN|Centre Oscar Lambret|Yes|Recruiting|May 2012|March 2017|Anticipated|May 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|60|||Both|70 Years|N/A|No|||February 2016|February 11, 2016|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01641497||82673|
NCT01641757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arsalanmalik|Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy,|Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy, A Randomized Control Trial||University of the Punjab|Yes|Enrolling by invitation|May 2012|October 2012|Anticipated|July 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|160|||Both|N/A|N/A|No|||July 2012|July 17, 2012|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641757||82653|
NCT01642875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PerOsEnteral1|Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy|Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial||Medical University of Warsaw|No|Active, not recruiting|July 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|96|||Both|18 Years|N/A|No|||June 2012|July 16, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01642875||82568|
NCT01657565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ED209|Appendectomy in Children Performed by Residents in the Era of Laparoscopic Surgery|Appendectomy in Children Performed by Residents in the Era of Laparoscopic Surgery||Odense University Hospital|No|Completed|January 2006|January 2011|Actual|January 2011|Actual|N/A|Observational|Time Perspective: Retrospective||2|Actual|390|||Both|N/A|15 Years|No|Non-Probability Sample|children 0-15 years of age having an appendectomy|August 2012|August 3, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01657565||81493|
NCT01643811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1210552-1|Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients|Effect of Gastrectomy and Anastomosis on Chronic Metabolic Disease Such as Diabetes and Hypertension in Early Gastric Cancer Patients||National Cancer Center, Korea|Yes|Completed|April 2012|February 2016|Actual|February 2016|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|159|||Both|20 Years|80 Years|No|Probability Sample|patients diagnosed as early gastric cancer|March 2016|March 23, 2016|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01643811||82496|
NCT01643824|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCCCTS-12-622|Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma|A Phase II Study Using Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma||National Cancer Center, Korea|No|Recruiting|June 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|135|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01643824||82495|
NCT01640587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU1201|Compare the Effectiveness Between Existing Treatment and New Treatment|Randomized Open-label Trial of Comparison Between DHA-Piperaquine and Mefloquine Artesunate Combinations 3 Day-regimens for the Treatment of Uncomplicated Plasmodium Falciparum Malaria|RMA|University of Oxford|No|Recruiting|November 2013|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|5 Years|N/A|No|||March 2014|March 24, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640587||82742|
NCT01640574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMRU1102|Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)|Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax||University of Oxford|No|Recruiting|July 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|900|||Both|6 Months|N/A|No|||August 2013|August 28, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640574||82743|
NCT01640886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP2012-A|Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA|Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA||MicroPhage, Inc.|No|Terminated|June 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|764|Samples Without DNA|Retention of de-identified blood culture specimens only.|Both|18 Years|N/A|No|Non-Probability Sample|Hospital patients with Gram positive blood cultures determined to be positive with the        following bottle types:          1. bioMerieux BacT/Alert Standard Aerobic and Anaerobic          2. bioMerieux BacT/Alert FAN Aerobic and FAN Anaerobic|January 2013|January 14, 2013|July 12, 2012||No|Results did not meet study requirements.|No||https://clinicaltrials.gov/show/NCT01640886||82719|
NCT01641146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-000617|An HIV Intervention for Black Men at Risk - The Enhanced Sexual Health Intervention for Men (ES-HIM)|An HIV Intervention for Black Men at Risk|ES-HIM|University of California, Los Angeles|Yes|Completed|December 2008|May 2011|Actual|September 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|118|||Male|18 Years|N/A|Accepts Healthy Volunteers|||December 2011|July 11, 2012|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01641146||82700|
NCT01641458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SG 343/12|Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients|Pharmacogenetics and Therapeutic Drug Monitoring for the Optimization of Fluoropyrimidine Treatment in Patients With Advanced Colorectal Cancer|FLOXTOX2|Cantonal Hospital of St. Gallen|Yes|Completed|October 2012|November 2015|Actual|November 2015|Actual|Phase 4|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|37|||Both|18 Years|N/A|No|||January 2016|January 31, 2016|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01641458||82676|
NCT01632046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOKID 04 EU|Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children|Randomized, Long-Term Administration of pH-Neutral PD Solutions Containing Lactate (BALANCE) or Bicarbonate (BICAVERA) in Children|BIOKID|Heidelberg University|Yes|Completed|March 2004|March 2007|Actual|March 2007|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|42|||Both|1 Month|21 Years|No|||June 2012|June 28, 2012|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632046||83396|
NCT01632267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10003|Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm|A Retrospective Analysis of Outcomes in Outpatients With Major Depressive Disorder (MDD) in a Staff Model HMO: Pharmacogenetic Algorithm for Psychotropic Pharmacotherapeutic Applications|UHS|Assurex Health Inc.|No|Completed|January 2011|September 2011|Actual|April 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|104|Samples With DNA|Buccal samples|Both|18 Years|65 Years|No|Probability Sample|Subjects under the care of a psychiatrist at Union Health Services, Chicago, IL|February 2013|December 4, 2015|June 27, 2012||No||No|February 14, 2013|https://clinicaltrials.gov/show/NCT01632267||83379|
NCT01641718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TISTA|Use of Human Fibrin Glue Versus Staples for Mesh Fixation in Laparoscopic Transabdominal Preperitoneal Hernioplasty|Use of Human Fibrin Glue (Tisseel) Versus Staples for Mesh Fixation in Laparoscopic Transabdominal Preperitoneal Hernioplasty (TISTA)|TISTA|Cantonal Hospital of St. Gallen|No|Active, not recruiting|January 2013|July 2016|Anticipated|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention|4||Anticipated|82|||Male|18 Years|80 Years|No|||June 2015|June 29, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01641718||82656|
NCT01632787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VSofM 4-2012|Utility of a Survey Instrument to Predict Benefit From a Novel Treatment for Vertical Heterophoria|Utility of a Survey Instrument to Predict Benefit From a Novel Treatment for Vertical Heterophoria|VH|Vision Specialists of Birmingham|No|Recruiting|April 2012|April 2017|Anticipated|April 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients presenting to the Emergency Department at St. Joseph Mercy Hospital with        complaint of non-traumatic exacerbation of chronic headaches of previously unknown        etiology.|December 2015|December 8, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01632787||83339|
NCT01641263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIA-RO1-AG026364|Promoting Sleep and Healthy Aging Research Study (PRO-SHARE)|Aging: Sleep and Inflammatory Mechanism in Depression Prevention|PRO-SHARE|University of California, Los Angeles|Yes|Recruiting|July 2012|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|300|||Both|60 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01641263||82691|
NCT01641276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|02621512.3.0000.5461|Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma|Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma|THBC-HSL2|Hospital Sirio-Libanes|Yes|Completed|April 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic|2||Actual|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|September 10, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641276||82690|
NCT01640639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|430/2012/D|THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure|Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial|THUNDER|University of Roma La Sapienza|Yes|Recruiting|July 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|March 6, 2013|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01640639||82738|
NCT01640925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1211-0239|Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit|Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit||The Methodist Hospital System|No|Completed|July 2012|September 2014|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|350|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|July 5, 2012||No||No|April 15, 2015|https://clinicaltrials.gov/show/NCT01640925||82716|
NCT01641237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01299|Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions|The Effect of Fluoride in an Experimental Dentifrice on Remineralization of Erosive Lesions In-Situ||GlaxoSmithKline|No|Completed|March 2012|May 2012|Actual|May 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|72|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2014|July 17, 2014|July 12, 2012|Yes|Yes||No|May 30, 2013|https://clinicaltrials.gov/show/NCT01641237||82693|
NCT01641770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BK83|Oral Nutritional Supplementation in Hospital Patients|Oral Nutritional Supplementation in Hospital Patients||Abbott Nutrition|Yes|Completed|October 2010|October 2011|Actual|July 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|212|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01641770||82652|
NCT01642030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1203|Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance|Analgesic Effects and Abuse Liability of Intravenous Hydromorphone and Buprenorphine in Pain-free Opioid Dependent Participants||Johns Hopkins University|No|Recruiting|August 2013|May 2017|Anticipated|May 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|55 Years|No|||February 2015|February 25, 2015|July 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01642030||82632|
NCT01642615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR_207|Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents|A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years||Takeda|No|Completed|July 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|63|||Both|12 Years|17 Years|No|||May 2015|May 8, 2015|July 12, 2012|Yes|Yes||No|May 8, 2015|https://clinicaltrials.gov/show/NCT01642615||82588|
NCT01643447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EHBH-RCT-2012-001|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)|A Prospective Randomized Trial Comparing Ulinastatin's Drug Protection in Hepatocellular Carcinoma(HCC)Patients'Postoperative Hepatic Failure||Eastern Hepatobiliary Surgery Hospital|Yes|Recruiting|May 2012|April 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|200|||Both|35 Years|55 Years|No|||July 2012|July 17, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643447||82524|
NCT01662401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMH IRB 2008-13399|Postoperative Pain Control in Children Undergoing Laparoscopic Appendectomy: Peripheral Nerve Block Versus Local Anesthetic|Postoperative Pain Control in Children Undergoing Laparoscopic Appendectomy: Comparison of Peripheral Nerve Blocks to Local Anesthetic||Ann & Robert H Lurie Children's Hospital of Chicago|Yes|Completed|May 2008|||January 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|66|||Both|6 Years|18 Years|No|||August 2012|June 28, 2013|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662401||81126|
NCT01644292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:069|Enhancing Participation In the Community by Improving Wheelchair Skills: Phase 2|Enhancing Participation In the Community by Improving Wheelchair Skills (EPIC WheelS): Phase 2|EPIC WheelS|University of Manitoba|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|2|||Both|50 Years|N/A|No|||January 2014|February 12, 2015|July 13, 2012||No||No|August 12, 2013|https://clinicaltrials.gov/show/NCT01644292||82460|
NCT01644565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-07|Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea|A Phase 1 Dose Escalating Study of Two Enterotoxigenic Escherichia Coli Prototype Adhesin-based Vaccines With or Without Modified Heat-labile Enterotoxin by Intradermal or Transcutaneous Immunization||U.S. Army Medical Research and Materiel Command|Yes|Active, not recruiting|August 2012|November 2017|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|9||Anticipated|57|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||October 2015|October 30, 2015|July 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01644565||82439|
NCT01644578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-005887|Prospective Use of Real-time MRI|Prospective Use of Real-time MRI||Mayo Clinic|No|Recruiting|October 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|90 Years|No|||November 2015|November 5, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644578||82438|
NCT01640873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8655-002|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002 AM1)|A Randomized Double-Blind Placebo-Controlled Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Subjects With Type 2 Diabetes||Merck Sharp & Dohme Corp.|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|65 Years|No|||January 2015|January 19, 2015|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640873||82720|
NCT01641445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA007850-21|Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms|Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms|IMPACT|Brown University|Yes|Recruiting|July 2012|August 2016|Anticipated|May 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|160|||Both|14 Years|24 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641445||82677|
NCT01641211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1008|ENLaCE Pilot Study|Using MEDUCATION to Improve Asthma Medication Device Technique||University of North Carolina, Chapel Hill|No|Completed|July 2012|April 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|92|||Both|8 Years|16 Years|No|||April 2013|April 8, 2013|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01641211||82695|
NCT01632514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USaoPauloGH 8624|Vitamin D Deficiency and Postoperative Hypocalcemia|Correction of Vitamin D Deficiency to Prevent Postoperative Hypocalcemia After Thyroidectomy||University of Sao Paulo General Hospital|No|Active, not recruiting|June 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|90|||Both|18 Years|N/A|No|||December 2014|December 5, 2014|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01632514||83360|
NCT01644370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 102|Children With HIV and Asthma (CHIVAS)|Allergen Specific T Effector and T Regulatory Cell Response to Common Aeroallergens Following Immune Restoration in HIV-infected Children||The HIV Netherlands Australia Thailand Research Collaboration|No|Completed|September 2011|December 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|20|||Both|2 Years|18 Years|Accepts Healthy Volunteers|||February 2016|February 19, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644370||82454|
NCT01641250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28085|A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia|Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML).||Hoffmann-La Roche||Completed|August 2012|February 2015|Actual|February 2015|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641250||82692|
NCT01641510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRAISE-GENE|PRAsugrel or clopIdogrel in Acute Coronary SyndromE Patients With CYP2C19 Polymorphism Before Percutaneous Coronary Intervention|Phase 3 Study Comparing the Efficacy and Safety of Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.|PRAISE-GENE|Dong-A University|Yes|Recruiting|October 2013|January 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|70|||Both|20 Years|80 Years|No|||January 2016|January 11, 2016|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01641510||82672|
NCT01642355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPACT-2012-400|Prevention Trial to Achieve Cardiovascular Targets|Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets|IMPACT|New York University School of Medicine|Yes|Recruiting|June 2012|June 2017|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|400|||Both|21 Years|N/A|No|||April 2015|April 13, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01642355||82608|
NCT01642602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TAK-390MR_206|Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents|A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease||Takeda|No|Completed|July 2012|January 2014|Actual|January 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|104|||Both|12 Years|17 Years|No|||July 2014|July 14, 2014|July 12, 2012|Yes|Yes||No|July 13, 2014|https://clinicaltrials.gov/show/NCT01642602||82589|
NCT01642849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|03-07996-FB|Effect of Diet Composition on Weight Change and Metabolic Parameters|Effect of Diet Composition on Weight Change and Metabolic Parameters||University of Tennessee|No|Recruiting|January 2009|June 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|24|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||July 2012|July 13, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01642849||82570|
NCT01662180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRORAILS trial|Predicting Ovarian Response in Artificial Insemination With Low Stimulation|Predicting Ovarian Response in Artificial Insemination With Low Stimulation||Isala|No|Recruiting|December 2012|March 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|510|Samples With DNA|blood sample tested for FSH, E2 and AMH|Both|18 Years|45 Years|Accepts Healthy Volunteers|Probability Sample|Subfertile couples presenting at fertility clinics with an indication for IUI in        stimulated cycles|December 2012|December 12, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01662180||81142|
NCT01644305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3849|Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.|||Ankara Education and Research Hospital||Active, not recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|||||Female|25 Years|35 Years||Probability Sample|Hospital Endocrinology Outpatient Clinic|July 2012|July 18, 2012|July 17, 2012||||No||https://clinicaltrials.gov/show/NCT01644305||82459|
NCT01644318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3848|CXCL9 and CXCL11 Levels in Patients With Autoimmune Thyroiditis and Habitual Abortions|||Ankara Education and Research Hospital||Active, not recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|||||Female|20 Years|40 Years||Probability Sample|Endocrinology Outpatient Clinic|July 2012|July 18, 2012|July 17, 2012||||No||https://clinicaltrials.gov/show/NCT01644318||82458|
NCT01635296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28023|A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia|A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML)||Hoffmann-La Roche||Completed|July 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|43|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01635296||83147|
NCT01640600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105008516|Yale Pink and Blue Kids: Effects of Exposure During Pregnancy to Nicotine or Antidepressants in 4-8 Year Old Children|Yale Pink and Blue Kids: Effects of in Utero Exposure to Nicotine and Selective Serotonin Reuptake Inhibitors in 4-8 Year Old Children|PABKids|Yale University|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control||3|Actual|61|Samples With DNA|We will be collecting saliva from mothers and their children in order to look at certain      genes that may be related to developmental outcomes.|Both|4 Years|65 Years|No|Probability Sample|Each subject is a previous study participant known to this research team who has agreed to        be contacted about future studies. We will review only their research records and not        medical records in order to determine eligibility. There are no subjects for whom the        ability to give informed consent can be questioned. All of the subjects were at least the        age of 18 at the time of their initial PAB participation between 2005-2008, and thus are        at least age 20 at the present time. All subjects are English speaking.        These are women who participated in the PAB Study (HIC #12394) and delivered a singleton        birth (no twins or triplets) between 2005-2008. We are inviting them and their children        (now aged 4-8) to participate.|January 2016|January 4, 2016|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640600||82741|
NCT01640613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00147-36|Anterior Ultrasound-guided Cervical Plexus Block for Carotid Endarterectomy|Anterior Approach Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Endarterectomy||Hôpital Edouard Herriot|No|Completed|April 2012|October 2013|Actual|October 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|116|||Both|18 Years|N/A|No|Non-Probability Sample|patients undergoing carotid endarterectomy under regional anaesthesia|March 2014|March 5, 2014|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01640613||82740|
NCT01641185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPI|Ion Prostate Irradiation|Hypofractionated Ion Irradiation (Carbon Ions Versus Protons) of the Prostate|IPI|Heidelberg University|Yes|Completed|May 2012|December 2015|Actual|December 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|92|||Male|40 Years|80 Years|No|||May 2014|December 5, 2015|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01641185||82697|
NCT01641198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-069-CERES-D|Osseous Healing Around 3 Types of Mandibular Implants|Étude Clinique Prospective Sur l'évaluation quantifiée de la guérison Osseuse Autour de 3 Types d'Implants 12 Mois et 15 Ans ou Plus Suite à la Mise en Bouche de prothèses Dentaires complètes Fixes visées Sur Implants Mandibulaires. Prospective Superiority Trial of the Quantitative Alveolar Osseous Healing Around 3 Types of Implants 12 Months and 15 Years or More After Insertion of Complete Fixed Dental Prostheses on Mandibular Implants.||Université de Montréal|Yes|Completed|March 1992|September 2013|Actual|April 1997|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|1||Actual|58|||Both|25 Years|56 Years|No|||August 2014|August 11, 2014|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01641198||82696|
NCT01643889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100893|A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single- and Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Subjects||Janssen Research & Development, LLC||Completed|July 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|44|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||June 2013|June 21, 2013|July 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01643889||82490|
NCT01643902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28242|Safety of Intravenous Thrombolytics in Stroke on Awakening|Safety of Intravenous Thrombolytics in Stroke on Awakening|SAIL-ON|Johns Hopkins University|Yes|Recruiting|January 2013|December 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|January 16, 2014|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643902||82489|
NCT01644123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090361|Reliability of an Algorithm to Diagnose Spasticity|Inter-Rater Reliability of a Spasticity Diagnosis Algorithm||Vanderbilt University|No|Completed|April 2013|January 2016|Actual|January 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|72|||Both|18 Years|100 Years|Accepts Healthy Volunteers|Non-Probability Sample|Nursing home residents|January 2016|January 25, 2016|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01644123||82472|
NCT01640652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/06|MenPF-1 - A New Vaccine Against Meningococcal Disease|A Phase I, Single Centre, Open-label Dose-escalation Study to Assess the Safety and Immunogenicity of Three Doses of 25µg or 50 µg of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine MenPF-1||University of Oxford|Yes|Active, not recruiting|August 2012|March 2016|Anticipated|July 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|52|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||August 2015|August 18, 2015|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01640652||82737|
NCT01641523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NEU02|Controlled Study in Cranioplasty Reconstruction|Multicenter Prospective Controlled Study in Cranioplasty Reconstruction||Azienda Ospedaliero-Universitaria di Parma|Yes|Completed|January 2007|September 2011|Actual|January 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|91|||Both|14 Years|75 Years|No|Probability Sample|consecutive patients,in different italian centres, requiring cranioplasty|August 2015|August 18, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01641523||82671|
NCT01641536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HB110_HB_I_EP|Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients|An Open-label, Dose-escalating Clinical Study to Evaluate the Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation (EP) in an Add-on Therapy With Entecavir in Chronic Hepatitis B Patients||Genexine, Inc.|No|Completed|November 2011|April 2013|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|20 Years|60 Years|No|||June 2013|June 19, 2013|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01641536||82670|
NCT01641549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 1.01|Surgery Versus Fibrinolytic Therapy for Left-sided Prosthetic Heart Valve Thrombosis|Surgery Compared to Fibrinolytic Therapy for Symptomatic Patients With Left-sided Prosthetic Heart Valve Thrombosis|SAFE-PVT|All India Institute of Medical Sciences, New Delhi|Yes|Not yet recruiting|January 2013|January 2017|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|70 Years|No|||July 2012|July 16, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01641549||82669|
NCT01641783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YL2012-03|Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients|To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial||The Third Affiliated Hospital of Harbin Medical University|Yes|Not yet recruiting|July 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|75 Years|No|||July 2012|July 13, 2012|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641783||82651|
NCT01642043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p001126|Point-of-Care Ultrasound in Greater Trochanteric Pain Syndrome|Point-of-Care Ultrasound in Greater Trochanteric Pain Syndrome (GTPS)||Massachusetts General Hospital|No|Active, not recruiting|June 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Outpatient rheumatology clinic|April 2015|April 13, 2015|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642043||82631|
NCT01642056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120161|EPI-743 for Metabolism or Mitochondrial Disorders|Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction||National Institutes of Health Clinical Center (CC)||Recruiting|June 2012|April 2018|Anticipated|April 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|1||Anticipated|20|||Both|2 Years|11 Years|No|||December 2015|January 9, 2016|July 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642056||82630|
NCT01642368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PBRC 11026|The Optimum Omega-3 (003) Diet Study|The Optimum Omega -3 (003) Diet Study||Pennington Biomedical Research Center|No|Active, not recruiting|June 2012|September 2020|Anticipated|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|72|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|July 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01642368||82607|
NCT01642628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17006|The Effect of Mirror Education for Women Undergoing Mastectomy|The Effect of Pre-Operative Education and Self-Reflection on Anxiety, Body Image, Depression and Emotional Well-Being of Women Undergoing Mastectomy||Texas Woman's University|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|19|||Female|18 Years|N/A|No|||March 2014|March 28, 2014|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01642628||82587|
NCT01642641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0332|Different Surgical Modalities in the Treatment of Periodontitis|The Efficacy of Different Surgical Modalities in the Treatment of Periodontitis. A Single-Centre Randomised Controlled Trial||University College, London|No|Active, not recruiting|January 2013|December 2018|Anticipated|December 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|48|||Both|30 Years|N/A|Accepts Healthy Volunteers|||February 2015|December 4, 2015|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642641||82586|
NCT01661959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007HSGAIS|Adolescent Idiopathic Scoliosis Outcomes Database Registry|Scoliosis Outcomes Database Registry|AIS|Setting Scoliosis Straight Foundation|No|Enrolling by invitation|January 2005|||December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|4121|||Both|10 Years|21 Years|No|Non-Probability Sample|Patients who present to the investigator's clinic, who meet the inclusion criteria will be        offered enrollment in the study.|December 2013|December 20, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01661959||81159|
NCT01661972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037688|Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer|X-TRAP: Phase I/II Study of Capecitabine Plus Aflibercept in Metastatic Colorectal Cancer|X-TRAP|Duke University|Yes|Active, not recruiting|August 2012|August 2017|Anticipated|August 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 15, 2016|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661972||81158|
NCT01662193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|190136|Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients|Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients||Isfahan University of Medical Sciences|Yes|Recruiting|February 2012|||February 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|120|||Both|30 Years|N/A|No|||August 2012|August 10, 2012|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01662193||81141|
NCT01658150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-0679|Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder|A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade||Icahn School of Medicine at Mount Sinai|No|Recruiting|September 2012|July 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|36|||Both|18 Years|60 Years|No|||October 2015|October 8, 2015|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658150||81448|
NCT01644331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00037557|Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure|The Targeting Acute Congestion With Tolvaptan In Congestive Heart Failure Study|TACTICS-HF|Duke University|Yes|Completed|October 2012|February 2016|Actual|February 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|257|||Both|18 Years|N/A|No|||March 2016|March 10, 2016|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644331||82457|
NCT01635309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTA-VISION|Coronary CT Angiography to Predict Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN (CTA -VISION) Study|Coronary CT Angiography to Predict Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN (CTA -VISION) Study|CTA-VISION|McMaster University|Yes|Completed|May 2007|November 2014|Actual|November 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|987|||Both|45 Years|N/A|No|Non-Probability Sample|International non cardiac surgical patients|April 2015|April 27, 2015|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635309||83146|
NCT01635608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MRI-probe drugs|Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water|Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water||University Medicine Greifswald|No|Completed|April 2011|||July 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 4, 2012|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01635608||83123|
NCT01644526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CVM-HVS-Phase I|A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement|A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement||CreatiVasc Medical LLC|Yes|Recruiting|April 2009|April 2014|Anticipated|January 2014|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|1||Anticipated|12|||Both|18 Years|N/A|No|||January 2013|January 29, 2013|April 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01644526||82442|
NCT01644539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL 35991.041.11|Brain Activity and Hormonal Changes During Food Administration|Functional MRI of Satiety, the Interaction Between Gastric and Oral Stimulation and Related Hormones in Healthy Men||UMC Utrecht|No|Completed|July 2011|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Actual|16|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01644539||82441|
NCT01635946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0043|Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Atorvastatin||Astellas Pharma Inc|No|Completed|August 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01635946||83097|
NCT01635959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-GEG-XXX-2012/1|Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt|Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt|GERD Q NIS|AstraZeneca|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|3170|||Both|18 Years|N/A|No|Non-Probability Sample|Community patients|October 2014|October 2, 2014|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635959||83096|
NCT01635972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9766-CL-0044|Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Bupropion||Astellas Pharma Inc|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|24|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01635972||83095|
NCT01640899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRR120709|Insoles Effect on Pain and Daily Activities|The Effect of Shoe Insoles on Pain and Daily Activities and the Relation Between Satisfaction With Insoles and Use: A pre-and Post-intervention Survey||Centre for Rehabilitation Research, Örebro|No|Completed|August 2010|November 2011|Actual|January 2011|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|89|||Both|18 Years|N/A|No|||July 2012|July 12, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640899||82718|
NCT01631747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DK10-014|Maternal-Offspring Metabolics:Family Intervention Trial|Maternal-Offspring Metabolics:Family Intervention Trial (MOMFIT)|MOMFIT|Northwestern University|Yes|Active, not recruiting|November 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|281|||Female|18 Years|45 Years|No|||January 2016|January 21, 2016|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01631747||83419|
NCT01631760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biomarkers in Asthma|Identification of Plasma miRNAs as Potential Biomarkers in Asthma Exacerbation|Identification of Plasma miRNAs as Potential Biomarkers in Asthma Exacerbation||University of South Florida|No|Withdrawn|October 2011|||February 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|0|||Both|5 Years|85 Years|No|Non-Probability Sample|Both genders of any racial or ethnic group, age 5-85 are eligible. The subjects should not        have participated in any other experimental study in the last 30 days.|October 2014|October 6, 2014|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01631760||83418|
NCT01632033|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PL 2012/14|Functional Evaluation With Questionnaire in Patients Investigated for Suspected Peripheral Artery Disease|Estimation de la capacité Fonctionnelle a la Marche Par Questionnaire Clinique Chez Des Patients adressés Pour Bilan artériel Des Membres inférieurs: Etude WELCH-bis|WELCH-bis|University Hospital, Angers|Yes|Completed|July 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|150|||Both|18 Years|N/A|No|Non-Probability Sample|Patients referred for arterial leower limb investigations|July 2015|July 16, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01632033||83397|
NCT01644383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HIV-NAT 109|Meaning of Life in HIV-infected Youths|Meaning in Life of Youth Infected With HIV||The HIV Netherlands Australia Thailand Research Collaboration|No|Active, not recruiting|February 2011|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|48|||Both|16 Years|24 Years|No|||February 2016|February 19, 2016|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644383||82453|
NCT01640392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 U01SP001573-01|MyLife MyStyle Evaluation Project|Evaluating Locally Developed Homegrown HIV Prevention Interventions|MLMS|Los Angeles County Department of Public Health|No|Recruiting|April 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|528|||Male|18 Years|29 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640392||82757|
NCT01640964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRLX030X2201|An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension|An Exploratory Study to Investigate the Haemodynamic Effects of Serelaxin (RLX030) in Patients With Compensated Cirrhosis and Portal Hypertension||Novartis|No|Completed|April 2013|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|47|||Both|18 Years|75 Years|No|||March 2016|March 11, 2016|June 21, 2012||No||No|December 14, 2015|https://clinicaltrials.gov/show/NCT01640964||82714|
NCT01641562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4192910|Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction|Diagnosis and Prediction of Subclinical Cardiac Dysfunction Induced by Therapy With Taxanes in Patients With Breast Cancer|CARDIOTAX|Carol Davila University of Medicine and Pharmacy|Yes|Recruiting|January 2012|January 2017|Anticipated|October 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples With DNA|Biomarkers: brain natriuretic peptides, troponin T, markers of myocardial fibrosis (β cross      laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6,      IL 10, TNFalpha).      Markers of the oxidative stress: concentration of carbonyl in plasmatic proteins, and the      antioxidant capacity of plasma.      Genetic tests of susceptibility to cardiotoxicity: genomic DNA extraction kit/DNA      quantification tests/PCR tests.|Both|18 Years|80 Years|No|Probability Sample|Study will include 60 patients with early breast cancer, scheduled to receive taxanes, in        monotherapy (30 patients) or associated to anthracyclines (30 patients), with doses        according to the stage of the disease.|January 2016|January 27, 2016|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01641562||82668|
NCT01641796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-12-13|Expanded Access WR 279396 Topical Cream Treatment for Uncomplicated Cutaneous Leishmaniasis|WR 279,396 (Paromomycin + Gentamicin Topical Cream) Treatment Protocol for Individuals With Uncomplicated Cutaneous Leishmaniasis|WR279396RX|U.S. Army Medical Research and Materiel Command||Available||||||N/A|Expanded Access|N/A|||||||Both|N/A|N/A||||July 2015|July 8, 2015|June 18, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01641796||82650|
NCT01642069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B9|Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia|Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia||Children's Oncology Group|No|Recruiting|July 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|100|||Both|N/A|30 Years|No|Non-Probability Sample|Patients diagnosed with acute megakaryoblastic leukemia.|November 2015|November 5, 2015|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01642069||82629|
NCT01642082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GOG-0229N|Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer|A PHASE II EVALUATION OF DALANTERCEPT, A NOVEL SOLUBLE RECOMBINANT ACTIVIN RECEPTOR-LIKE KINASE 1 (ALK-1) INHIBITOR RECEPTOR-FUSION PROTEIN, IN THE TREATMENT OF RECURRENT OR PERSISTENT ENDOMETRIAL CARCINOMA||Gynecologic Oncology Group||Active, not recruiting|September 2012|||November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|N/A|No|||January 2016|January 7, 2016|July 15, 2012|Yes|Yes||No|January 7, 2016|https://clinicaltrials.gov/show/NCT01642082||82628|
NCT01642888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TESEC-05|A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI|A Phase III Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI (PPD)||Statens Serum Institut|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|1190|||Both|N/A|65 Years|Accepts Healthy Volunteers|||April 2015|April 16, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01642888||82567|
NCT01643135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|si248/2012|Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid|Reduction Perioperative Bleeding in Laminectomy With Instrumentation or More Than or Equal to 3 Levels Laminectomy: The Comparison Between Placebo, and Double Doses of Tranexamic Acid (15 mg/kg and 15 mg/kg)||Mahidol University|No|Completed|June 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|78|||Both|18 Years|65 Years|No|||December 2013|December 17, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643135||82548|
NCT01658683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201200579-01|The Efficacy and Economics of Exercise Maintenance Post-Cardiac Rehabilitation|Ecologically Optimizing Exercise Maintenance in Men and Women Post-Cardiac Rehabilitation: A Randomized Controlled Trial of Efficacy With Economics|ECOPCR|Ottawa Heart Institute Research Corporation|No|Recruiting|October 2012|April 2018|Anticipated|April 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Anticipated|604|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658683||81408|
NCT01658943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01993|Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy|Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy|S1115|National Cancer Institute (NCI)|Yes|Completed|August 2012|June 2015|Actual|June 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|137|||Both|18 Years|N/A|No|||July 2015|February 10, 2016|August 3, 2012|Yes|Yes||No|February 10, 2016|https://clinicaltrials.gov/show/NCT01658943||81388|
NCT01644344|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RI1211:135|A Prospective Trial Comparing the Cost of Post Operative X-rays for Fractures Treated With Stable Internal Fixation|Pilot Study for a Randomized Control Trial Comparing the Cost of a Simplified Post-Operative Radiographic (SPOR) Protocol for Fractures With Stable Internal Fixation Treated at Health Sciences Centre|SPOR|University of Manitoba||Completed|January 2012|August 2012|Actual|August 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|39|||Both|17 Years|N/A|No|||March 2012|October 3, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01644344||82456|
NCT01644552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|kmerrill|Positive Angle Kappa|Positive Angle Kappa: a Sign in Aniridia||University of Minnesota - Clinical and Translational Science Institute|Yes|Completed|August 2010|September 2011|Actual|September 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|16|||Both|1 Month|85 Years|Accepts Healthy Volunteers|Non-Probability Sample|patients with aniridia|July 2012|July 18, 2012|February 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01644552||82440|
NCT01635595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Cardia AdCa UNIBO|Nodal Status in Adenocarcinoma of the Esophagus an Cardia|AdCa of the Esophagus and Cardia (ADEC): Relationship Between Nodal Metastasization and the Presence Absence of Intestinal Metaplasia in the Esophagus and Stomach||University of Bologna|No|Completed|January 2006|December 2011|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|194|||Both|N/A|N/A|No|Non-Probability Sample|Patients with a preoperative diagnosis of adenocarcinoma of the distal esophagus and        cardia who underwent surgery up to December 2011, which fully adhered to the pre and        postoperative protocol, including endoscopic gastric mucosa sampling.|July 2012|July 24, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635595||83124|
NCT01635933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-005|A Comparison of AIR OPTIX® COLORS Versus FRESHLOOK® COLORBLENDS|A Comparison of a Colored Silicone Hydrogel Lens Versus a Colored HEMA Lens||Alcon Research|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|370|||Both|16 Years|N/A|No|||April 2014|April 25, 2014|July 5, 2012|Yes|Yes||No|February 18, 2014|https://clinicaltrials.gov/show/NCT01635933||83098|
NCT01635985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D2340C00012|A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways|A Phase I, Single Centre, Open, Partly Randomised, Crossover Study in Healthy Subjects to Evaluate AZD5423 Absolute Pulmonary Bioavailability When Administered Inhaled Via a New Dry Powder Inhaler, Turbuhaler, Spira Nebulizer and I-neb AAD System||AstraZeneca||Completed|August 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|6||Actual|18|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 13, 2015|July 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01635985||83094|
NCT01643629|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/HPL-AGA/11-12/001A|A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia|A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA)||Kasiak Research Pvt. Ltd.|Yes|Active, not recruiting|January 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|50 Years|No|||July 2012|July 24, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01643629||82510|
NCT01643642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P09.146/NL29380.058.09|Cost- Effectiveness Study of Brief Interventions for Mood and Anxiety Disorders|A Efficacy and Cost-effectiveness Study of a Brief Interventions for Mood and Anxiety Disorders: Brief Intake, Treatment and Routine Outcome Monitoring (ROM)|K&K|Leiden University Medical Center|No|Completed|March 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2013|June 10, 2013|September 8, 2011||No||No||https://clinicaltrials.gov/show/NCT01643642||82509|
NCT01644136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-11017|Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer|A Pilot Clinical Trial for the Prevention of Postoperative Lymphoceles Using Absorbable Micorporous Polysaccharide Hemosphere Particles During Robotic Assisted Prostatectomy With Lymph Node Dissection||Ohio State University Comprehensive Cancer Center|Yes|Recruiting|July 2011|||July 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|100|||Male|N/A|N/A|No|||July 2012|July 16, 2012|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644136||82471|
NCT01644396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M13-279|An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation|An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation||AbbVie||Completed|May 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|N/A|No|||September 2014|September 22, 2014|May 7, 2012||No||No|September 9, 2014|https://clinicaltrials.gov/show/NCT01644396||82452|
NCT01640405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-12-01|Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells|Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.|VISNU-1|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|350|||Both|18 Years|70 Years|No|||November 2015|November 17, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01640405||82756|
NCT01640418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL40299.068.12|Prevention of Sacral Pressure Ulcers With Preventive Dressings||SACRESS|Maastricht University Medical Center|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|253|||Both|18 Years|N/A|No|||July 2015|July 20, 2015|July 11, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640418||82755|
NCT01640665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GC0212|Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors|Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors||Yale University|Yes|Recruiting|July 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|N/A|No|||July 2012|July 10, 2012|June 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640665||82736|
NCT01641315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC5502|Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins|Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins for Post-exposure Rabies Treatment||Queen Saovabha Memorial Institute|No|Recruiting|September 2015|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|75|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641315||82687|
NCT01642095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AREN12B8|Studying Biomarkers in Samples From Younger Patients With Kidney Cancer|Focal Adhesion Kinase Expression in Pediatric Renal Tumors||Children's Oncology Group|No|Withdrawn|August 2012|||September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|0|||Both|N/A|N/A|No|Probability Sample||February 2014|February 14, 2014|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01642095||82627|
NCT01642654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|yula01|Water Exercise and Vascular Function in Elderly|Nitrite Levels and Vascular Function in Elderly Women Submitted to Water Exercise: a Randomised Controlled Trial||Universidade Federal do Rio Grande do Norte|Yes|Completed|May 2010|September 2010|Actual|September 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|60 Years|80 Years|Accepts Healthy Volunteers|||March 2012|July 16, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01642654||82585|
NCT01642667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROUK|Pharmacoinvasive Therapy With Prourokinase|The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay||Suzhou Landing Pharmaceuticals|Yes|Completed|November 2008|December 2010|Actual|November 2009|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|197|||Both|N/A|75 Years|No|||July 2012|July 26, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642667||82584|
NCT01642680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0010|Optimal Timing of Physical Activity in Cancer Treatment|Optimal Timing of a Tailored Physical Activity Program During Chemotherapeutic Cancer Treatment to Reduce Long-term Cardiovascular Morbidity|ACT|University Medical Center Groningen|No|Recruiting|January 2013|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|206|||Both|18 Years|80 Years|No|||October 2015|October 1, 2015|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01642680||82583|
NCT01654276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MSA-FEB-137|Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome|Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome||University of Texas Southwestern Medical Center|No|Recruiting|May 2012|May 2019|Anticipated|May 2019|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|21 Years|N/A|No|||February 2015|February 3, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01654276||81741|
NCT01654497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111827|Dexanabinol in Patients With Brain Cancer|A Phase I, Sequential Cohort, Open-Label, Dose-escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients With Brain Cancer||University of California, San Diego|Yes|Active, not recruiting|June 2012|December 2015|Anticipated|September 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|N/A|No|||November 2015|November 19, 2015|July 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01654497||81724|
NCT01654510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HUM00017734|A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder|A Systems Level Intervention for Unemployed Persons With Social Anxiety||University of Michigan|Yes|Completed|April 2008|March 2012|Actual|March 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|165|||Both|18 Years|60 Years|No|||July 2012|July 30, 2012|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01654510||81723|
NCT01635036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AUX-001|Eeva 12-well Dish Study|Eeva 12-well Dish Study|NDS|Progyny, Inc.|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|17|||Female|18 Years|N/A|No|Probability Sample|Women in the United States who undergo IVF treatment|January 2014|January 9, 2014|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01635036||83167|
NCT01642810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H2012:179|Online Acceptance-based Behavioural Treatment for Fibromyalgia|Online Acceptance-Based Behavioural Treatment for Fibromyalgia||University of Manitoba|Yes|Completed|September 2012|August 2015|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01642810||82573|
NCT01643070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XELOX-RT|Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases|Randomized Phase II Trial of Preoperative Chemoradiation With or Without Induction Chemotherapy In Patients With Locally Advanced Or Borderlinely Resectable Rectal Cancer With Resectable Synchronous Liver Metastases||Asan Medical Center|Yes|Active, not recruiting|January 2010|December 2016|Anticipated|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|38|||Both|20 Years|75 Years|No|||January 2016|January 11, 2016|November 1, 2011||No||No||https://clinicaltrials.gov/show/NCT01643070||82553|
NCT01635621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD0001|A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Olokizumab Administered Subcutaneously to Subjects With Moderate to Severe Crohn's Disease||UCB Pharma|No|Withdrawn|June 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|65 Years|No|||October 2012|October 29, 2012|July 3, 2012|Yes|Yes|Study was withdrawn due to delay in timelines. There were no safety concerns regarding the    study or the compound in the decision to withdraw the trial.|No||https://clinicaltrials.gov/show/NCT01635621||83122|
NCT01635634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CuFib|Cupping in Fibromyalgia|Randomized Controlled Pilot Trial: The Effectiveness of Cupping in Patients With Fibromyalgia|CuFib|Universität Duisburg-Essen|No|Completed|June 2012|March 2015|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|141|||Both|18 Years|75 Years|No|||April 2015|April 21, 2015|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01635634||83121|
NCT01643655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSC-MSCs-AVN|Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head||Biostar|No|Active, not recruiting|May 2012|July 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|15|||Both|18 Years|70 Years|No|||March 2014|March 24, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643655||82508|
NCT01643915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UIC-ODP-2|Behavior Management Using Audiovisual Tools|Behavior Management Using Audiovisual Tools in Pediatric Dental Patients||Universitat Internacional de Catalunya|No|Recruiting|September 2012|September 2015|Anticipated|July 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label|3||Anticipated|224|||Both|4 Years|9 Years|Accepts Healthy Volunteers|||May 2014|May 26, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643915||82488|
NCT01643928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3281004|Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)|Extension Study Evaluating Treatment With PF-05280586 Versus Rituximab In Subjects With Active Rheumatoid Arthritis Who Have Participated In Other PF-05280586 Clinical Trials||Pfizer|Yes|Active, not recruiting|August 2012|March 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|157|||Both|18 Years|N/A|No|||January 2016|January 20, 2016|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643928||82487|
NCT01643941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3451011|Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years|A Phase 1/2 Placebo-controlled, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 3 Ascending Dose Levels of a 4-antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to < 86 Years||Pfizer|Yes|Completed|August 2012|March 2014|Actual|May 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|5||Actual|284|||Both|65 Years|85 Years|Accepts Healthy Volunteers|||July 2014|July 25, 2014|July 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643941||82486|
NCT01644149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJ-500-07|Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe|A Randomized Controlled Clinical Trial Assessing the Immunologic Response to an FDA-approved Influenza Vaccine Delivered Using an FDA-Cleared Jet Injection Vaccine Delivery Device or a Needle and Syringe||PharmaJet, Inc.|No|Completed|January 2012|February 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|83|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||March 2013|March 14, 2013|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644149||82470|
NCT01640977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NUVA.P1001|A Prospective Non-concurrent Controlled Evaluation of Open and MAS® PLIF|A Prospective Non-current Concurrent Controlled Evaluation of Open and MAS® PLIF for the Treatment of Symptomatic Lumbar Degenerative Conditions||NuVasive|No|Completed|June 2012|September 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|67|||Both|18 Years|N/A|No|Non-Probability Sample|Existing clinic patients|April 2015|April 29, 2015|July 9, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01640977||82713|
NCT01641289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAKMAL1201|Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria|Paracetamol Effect on Oxidative Stress and Renal Function in Severe Falciparum Malaria With Intravascular Haemolysis: A Randomised Controlled Clinical Trial||University of Oxford|No|Active, not recruiting|July 2012|December 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|62|||Both|12 Years|N/A|No|||March 2016|March 16, 2016|May 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01641289||82689|
NCT01641302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0287.|The Effect of Pneumoperitoneum and Trendelenburg Position on Intracranial Pressure: Ultrasonographic Measurement of Optic Nerve Sheath Diameter|||Yonsei University|No|Completed|June 2012|August 2013|Actual|August 2013|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|20|||Both|20 Years|90 Years|No|Non-Probability Sample|Patients undergoing robot-assisted laparoscopic prostatectomy under general anesthesia|August 2013|August 5, 2013|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01641302||82688|
NCT01641341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-108|Irritable Bowel Syndrome Evaluation and Treatment in Primary Care|Irritable Bowel Syndrome Evaluation and Treatment in Primary Care||American Academy of Family Physicians|No|Completed|November 2010|March 2012|Actual|March 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|65 Years|No|||June 2014|June 23, 2014|May 9, 2011||No||No||https://clinicaltrials.gov/show/NCT01641341||82685|
NCT01641354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-20080179|Comparison of Two Surgical Techniques to Treat Knock Knees in Children|Reversible Hemiepiphysiodesis in Children - Stapling Versus Eight Plate||Aarhus University Hospital|Yes|Active, not recruiting|May 2009|June 2013|Anticipated|July 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|14|||Both|8 Years|15 Years|No|||July 2012|July 12, 2012|June 7, 2010||No||No||https://clinicaltrials.gov/show/NCT01641354||82684|
NCT01641809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116482|Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine|A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects||ViiV Healthcare|No|Active, not recruiting|August 2012|December 2020|Anticipated|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|244|||Both|18 Years|N/A|No|||October 2015|February 4, 2016|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641809||82649|
NCT01641367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACTG A5288|A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure|Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)|MULTI-OCTAVE|AIDS Clinical Trials Group|Yes|Recruiting|October 2012|April 2018|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|500|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|June 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641367||82683|
NCT01642108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Ohara|Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus|The Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Glycemic Control and Inappropriate Glucagon Secretion in Non-obese Japanese Patients With Type 2 Diabetes.||Niigata Medical Center|No|Recruiting|July 2012|June 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|20 Years|90 Years|Accepts Healthy Volunteers|||August 2012|August 19, 2012|June 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642108||82626|
NCT01641822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-205-0170|Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects With Cystic Fibrosis|AZLI CAT|Gilead Sciences|Yes|Completed|November 2012|January 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|90|||Both|6 Years|N/A|No|||April 2015|April 9, 2015|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641822||82648|
NCT01641835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-2012-1 NORM-cc|Optical Coherence Tomography (OCT) Data Collection Study|Optical Coherence Tomography (OCT) Data Collection Study "S-2012-1 Norm-cc"||Heidelberg Engineering GmbH|Yes|Completed|July 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|322|||Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|No eye disease.|July 2013|July 3, 2013|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01641835||82647|
NCT01642381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AA 020077-01A1|Component Analysis for Motivational Interviewing|Component Analysis for Motivational Interviewing||Northwell Health|Yes|Active, not recruiting|May 2012|March 2017|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|65 Years|No|||December 2015|December 30, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642381||82606|
NCT01642394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRONIK11/036|Impact of Self-care Education Program in Patients With Type 2 Diabetes in Primary Care in the Basque Country|Impact of Self-care Education Program "Active Patient" in Metabolic Control, Cardiovascular Risk and Quality of Life in Patients With Type 2 Diabetes in Primary Care in the Basque Country: Randomized Clinical Trial of 2 Years of Follow up||Osakidetza|No|Enrolling by invitation|September 2011|June 2015|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|556|||Both|18 Years|80 Years|No|||March 2014|March 6, 2014|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01642394||82605|
NCT01642407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A1481298|Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension|A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension||Pfizer|No|Recruiting|August 2012|November 2018|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|1 Year|17 Years|No|||March 2016|March 24, 2016|June 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642407||82604|
NCT01642420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEMPROG 2012|Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression|Quantitative Electroencephalography, Cerebrospinal Fluid Biomarkers, Linear CT Analyses and Timed Up and GO Dual Task as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression.|DEMPROG|Roskilde County Hospital|No|Recruiting|April 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|115|Samples Without DNA|Cerebrospinalfluid (CSF) CSF is analysed to find Alzheimer Disease biomarkers|Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with MCI and AD will be recruitted among consectutively refered patients in a        memory clinic. Participation is voluntary Healthy control persons will be recuitted by        posters and notices|September 2012|September 12, 2012|April 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642420||82603|
NCT01655160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100-4548B|Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke|Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke: Outcomes in Brain and Movement Reorganization, Sensorimotor and Daily Functions, and Measures of Physiological Markers.||Chang Gung Memorial Hospital|No|Completed|August 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|2|||Both|18 Years|75 Years|No|||June 2015|June 4, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01655160||81677|
NCT01655485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|255769-1|Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder|Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder(ASD) Undergoing Medical Imaging Procedures||Medical College of Wisconsin|Yes|Completed|October 2011|July 2013|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|32|||Both|4 Years|16 Years|Accepts Healthy Volunteers|||August 2013|August 6, 2013|October 11, 2011||No||No||https://clinicaltrials.gov/show/NCT01655485||81652|
NCT01635049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-AUX-004|Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromosome Screening Results|Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromosome Screening Results,Implantation and Live Birth|CCS|Progyny, Inc.|No|Completed|June 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|110|||Female|N/A|43 Years|No|Non-Probability Sample|Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical        need by the clinical site reproductive endocrinologist.|January 2015|January 12, 2015|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01635049||83166|
NCT01643083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HKU_RD1|Rifaximin for Functional Dyspepsia|Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial||The University of Hong Kong|No|Completed|January 2013|May 2015|Actual|May 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|95|||Both|18 Years|70 Years|No|||November 2015|November 30, 2015|July 15, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01643083||82552|
NCT01643096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90-04-27-15366|The Effect of Thyme and Sumac on the Thermic Effect of Food and Comparison Between Warm and Cold Temperament People|||Tehran University of Medical Sciences|Yes|Not yet recruiting|August 2012|August 2014|Anticipated|August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|2||Anticipated|40|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 16, 2012|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01643096||82551|
NCT01643395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0122|VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures|VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures|VOLCANO|University Hospital, Clermont-Ferrand||Completed|September 2010|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|99|||Both|18 Years|70 Years|No|||February 2014|February 14, 2014|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01643395||82528|
NCT01643668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-128|Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation|Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation||Massachusetts General Hospital|Yes|Active, not recruiting|July 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|34|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|June 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643668||82507|
NCT01643954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-08108|Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at The James|Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at Ohio State University/The James.||Ohio State University Comprehensive Cancer Center|Yes|Active, not recruiting|September 2008|December 2035|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|2||Anticipated|4000|||Male|18 Years|N/A|No|||December 2013|December 19, 2013|May 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01643954||82485|
NCT01640678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|METC2012_052|Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients|Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|No|Active, not recruiting|June 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|10|||Both|18 Years|N/A|No|||August 2013|August 2, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640678||82735|
NCT01640704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3Ui8HS11046|Impact of Computerized Reminders on Blood Pressure Documentation and Control|||Agency for Healthcare Research and Quality (AHRQ)||Completed|July 2003|February 2005|Actual|February 2005|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double-Blind|||||||Both|20 Years|N/A||||July 2012|July 13, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640704||82733|
NCT01640990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115387|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers|A Single-centre, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Slow Intravenous Infusion of GW328267X in Healthy Volunteers||GlaxoSmithKline|No|Completed|November 2011|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label|2||Actual|3|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||July 2012|July 26, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640990||82712|
NCT01641055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/572|A Study of the Effects of Fish Protein Intake on Glucose Homeostasis and Inflammation in Overweight and Obese Adults.|A 8 wk Study to Compare the Effects of Proteins and Peptides From Various Fish Species (Salmon, Herring, Cod) on Glucose Homeostasis and Inflammatory Markers in Overweight and Obese Adults.||University of Bergen|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|94|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||December 2013|December 19, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641055||82707|
NCT01641068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|7750|Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms|Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study||University of Washington|No|Recruiting|September 2012|||September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|15|||Female|21 Years|90 Years|No|||January 2016|January 20, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641068||82706|
NCT01641380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DepoText|Meaningful Use of Technology to Improve Health Care Delivery|Meaningful Use of Technology to Improve Health Care Delivery for Urban Adolescents: Focus on Teen Pregnancy Prevention (DepoText Study)|DepoText|Johns Hopkins University|No|Active, not recruiting|January 2011|July 2013|Anticipated|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Supportive Care|2||Actual|100|||Female|13 Years|21 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01641380||82682|
NCT01642134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MEIX-VALV-001|Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI|PHASE IV Study of Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After Percutaneous Aortic Valve Implantation. Multicenter Randomized Clinical Trial|AUREA|Hospital de Meixoeiro|Yes|Recruiting|April 2013|April 2017|Anticipated|January 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||July 2015|February 24, 2016|June 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01642134||82624|
NCT01642121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAML12B10|Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia|Observational - Rapid Identification of Leukemia Stem Cells Associated With AML1-ETO and Inv(16) Through Characterization of Oncogene-Induced Changes in Cell-Surface Antigen Profiles on Hematopoietic Stem Cells||Children's Oncology Group|No|Recruiting|August 2012|||January 2100|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|bone marrow|Both|N/A|30 Years|No|Non-Probability Sample|childhood acute myeloid leukemia (AML) patients|November 2015|November 5, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642121||82625|
NCT01642706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8969|Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments|Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments||University Hospital, Montpellier|No|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|Samples Without DNA|Comparison of Bregs levels      Lymphocytes will be analyzed from :        -  circulating blood        -  serum        -  articular serum        -  synovial membrane|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients and controls will be recruited in the Immuno-rheumatology Service of the        University Hospital of Montpellier.        They will be recruited during consultations or hospitalizations, when a blood sample is        planned within the framework of their usual follow-up.|November 2015|November 19, 2015|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642706||82581|
NCT01655173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dnr 52-6104|Cognitive Behavioural Therapy (CBT) and Recreational Activity for Autism Spectrum Disorders (ASD)|Cognitive Behavioural Therapy and Recreational Activity for Adults With Autism Spectrum Disorders. A Randomized Controlled Trial.||Karolinska Institutet|No|Completed|August 2005|September 2011|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||June 2014|June 17, 2014|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01655173||81676|
NCT01655186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1202|A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus|||Reata Pharmaceuticals, Inc.||Withdrawn|September 2012|October 2013|Anticipated|October 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|30 Years|N/A|No|||October 2012|October 19, 2012|July 30, 2012|Yes|Yes|IDMC recommendation for safety concerns|No||https://clinicaltrials.gov/show/NCT01655186||81675|
NCT01642823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PEDSEYE0002|Cancer Biology of Retinoblastoma|Cancer Biology of Retinoblastoma||Stanford University|Yes|Recruiting|July 2012|December 2017|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|20|Samples With DNA|retinoblastoma tumor tissue sample|Both|N/A|5 Years|No|Non-Probability Sample|Retinoblastoma patients undergoing surgical removal of part or all of their tumor, with or        without the remainder of the eye|June 2015|June 30, 2015|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642823||82572|
NCT01642836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|spo47512|Clinic, Family & Community Collaboration to Treat Overweight and Obese Children (Stanford GOALS)|Clinic, Family & Community Collaboration to Treat Overweight and Obese Children|Stanford GOALS|Stanford University|Yes|Active, not recruiting|July 2012|April 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|7 Years|11 Years|Accepts Healthy Volunteers|||January 2014|January 23, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01642836||82571|
NCT01643681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KSC-MSCs-LIDD|Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration||Biostar|No|Recruiting|July 2012|April 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|8|||Both|19 Years|70 Years|No|||March 2014|March 24, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643681||82506|
NCT01643694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004566|Individualized Electronic Intervention to Promote Work Engagement|Randomized Controlled Trial Evaluating the Effect of An Individualized Electronic Intervention to Promote Resilience, Meaning, and Engagement for Physicians||Mayo Clinic|No|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|288|||Both|30 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 27, 2013|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01643694||82505|
NCT01643408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|100EUSA12|A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy|Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.||Jazz Pharmaceuticals|Yes|Completed|November 2012|December 2013|Actual|August 2013|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|1 Year|30 Years|No|||May 2014|May 8, 2014|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643408||82527|
NCT01644409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USQ-9yr|Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up|Urgent-SQ Implant in Treatment of Overactive Bladder Syndrome: Nine-year Follow-up Study||Radboud University|Yes|Completed|January 2012|July 2012|Actual|May 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|8|||Both|18 Years|N/A|No|Non-Probability Sample|Refractory overactive bladder syndrome that have an Urgent-SQ tibial nerve implant|July 2012|July 18, 2012|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644409||82451|
NCT01640431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fisio2011|Lumbar Segmental Stabilization and TENS in Lumbar Disc Herniation|Lumbar Segmental Stabilization and TENS in Lumbar Disc Herniation: a Randomized Clinical Trial||University of Sao Paulo General Hospital|Yes|Recruiting|March 2011|July 2013|Anticipated|August 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|25 Years|55 Years|No|||July 2012|July 12, 2012|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01640431||82754|
NCT01640444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTD-12-02|Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)|Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells|VISNU-2|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|No|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|240|||Both|18 Years|70 Years|No|||November 2015|November 17, 2015|June 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01640444||82753|
NCT01640470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|232262|A Multi-Site Trial of the Impact of Assistive Technology With Assistance Users and Their Caregivers|A Multi-Site Trial of the Impact of Assistive Technology With Individuals With Mobility Limitations and Their Caregivers.|CATS|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal|Yes|Active, not recruiting|December 2011|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|240|||Both|55 Years|N/A|No|||February 2016|February 18, 2016|November 21, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640470||82751|
NCT01640691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLUW001A|Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults|A Clinical Study to Evaluate the Immunogenicity and Safety of Pandemic Influenza Vaccine, AdimFlu-W (H5N1), in Healthy Adults||Adimmune Corporation|Yes|Recruiting|July 2012|||April 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|30|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640691||82734|
NCT01640717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALX-MCD-501|A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)|A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)||Alexion Pharmaceuticals|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|15|||Both|N/A|N/A|No|Non-Probability Sample|All patients who received only intravenous cPMP under named-patient use will be eligible|February 2016|February 17, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640717||82732|
NCT01641003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cancer stem cells.ctil|Isolation and Characterization of Cancer Stem Cells Using iFP Technique|Isolation and Characterization of Cancer Stem Cells Using iFP Technique||Rambam Health Care Campus|No|Not yet recruiting|July 2012|June 2015|Anticipated|June 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|Samples of fresh tumors taken after surgery without compromising final histology diagnosis.      These specimens will be used to isolate and grow cancer stem cells.|Both|18 Years|N/A|No|Non-Probability Sample|Patients newly diagnosed with GBM, Pancreas or Breast cancer who are planed to undergo        surgery.|July 2012|July 11, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01641003||82711|
NCT01641016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BREATHER (PENTA 16)|BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection|BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection|BREATHER|PENTA Foundation|Yes|Active, not recruiting|April 2011|June 2016|Anticipated|June 2014|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|8 Years|24 Years|No|||July 2013|February 27, 2015|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641016||82710|
NCT01641328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRI_Farb_001|Cognitive Activation Therapy for MCI: A Randomized Control Study|Phase 1 Study of Cognitive Activation Behavioral Therapy for MCI: A Randomized Waitlist-Control and Delayed Active-Control Study|FarbMCI2012|Rotman Research Institute at Baycrest|No|Not yet recruiting|October 2012|July 2013|Anticipated|March 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|50 Years|N/A|No|||July 2012|July 13, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641328||82686|
NCT01641614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REQ:690|Beating Versus Arrested Heart for Mitral Valve Replacement|Clinical and Ultramicroscopic Myocardial Randomized Study of On-Pump Beating Heart Mitral Valve Replacement|BAHMVR|Federal University of Bahia|Yes|Completed|April 2010|January 2012|Actual|March 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|34|||Both|18 Years|60 Years|No|||July 2012|July 17, 2012|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01641614||82664|
NCT01641627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010_05|Preventive Effect of Proprioceptive Stimulation on Muscle Atrophy|Phase 2 Randomized Clinical Trial, Efficy of a Proprioceptive Stimulation Device in Term of Prevention of Muscle Atrophy of the Calf After Total Knee Replacement|PrevAtrophy|University Hospital, Lille|Yes|Completed|March 2012|March 2015|Actual|December 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|34|||Both|18 Years|80 Years|No|||April 2015|April 8, 2015|May 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01641627||82663|
NCT01642147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KY2012-183|Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy|Cerebral Hyperemia During Emergence From General Anesthesia for Craniotomy of Patients With Brain Tumor||Huashan Hospital|Yes|Completed|November 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|25 Years|60 Years|No|||May 2013|May 15, 2013|July 8, 2012||No||No|March 9, 2013|https://clinicaltrials.gov/show/NCT01642147||82623|The study population was not homogenous according to tumor size and location.
NCT01642160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-008195|Continous Positive Airway Pressure (CPAP) Compliance Study|ICAN (Improvement in CPAP Adherence Via the Net) Study|ICAN|Mayo Clinic|No|Completed|July 2012|November 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|90 Years|No|||March 2013|March 5, 2013|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642160||82622|
NCT01641575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CO-101-011|A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin|A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.||Clovis Oncology, Inc.|No|Terminated|July 2012|June 2013|Actual|May 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|N/A|No|||March 2014|March 8, 2014|July 9, 2012|No|Yes|Registrational study did not meet endpoint so entire program (including CO-101-011) was    terminated.|No||https://clinicaltrials.gov/show/NCT01641575||82667|
NCT01641588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1497|Are You Sitting Down: Cognitive Exectutive Function Task Comparison Between Seated and Standing Positions|Are You Sitting Down: Cognitive Exectutive Function Task Comparison Between Seated and Standing Positions Using Assessments From CNS Vital Signs Test Battery|sitstandcef|University of Southampton|Yes|Completed|March 2012|March 2012|Actual|March 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|19|||Male|21 Years|40 Years|Accepts Healthy Volunteers|||July 2012|July 12, 2012|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01641588||82666|
NCT01642719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01HL095799-01A2|Chronic Moderate Sleep Restriction in Older Adults|Chronic Moderate Sleep Restriction in Older Long Sleepers and Older Average Sleepers|MSSS|University of California, Los Angeles|Yes|Recruiting|July 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|200|||Both|60 Years|80 Years|Accepts Healthy Volunteers|||July 2012|July 17, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642719||82580|
NCT01642433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071/2011|Prazosin for Smoking Cessation|Prazosin as a Novel Treatment for Smoking Cessation||Centre for Addiction and Mental Health|No|Terminated|July 2012|September 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642433||82602|
NCT01642940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-11|Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study|Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study||University of Patras|No|Completed|June 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|75 Years|No|||January 2013|January 21, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01642940||82563|
NCT01643213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A7006|Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector|Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector|RESCUE|Boston Scientific Corporation|No|Completed|July 2012|February 2015|Actual|February 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|27|||Both|18 Years|N/A|No|||December 2015|December 3, 2015|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643213||82542|
NCT01655199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CODEX-20819|Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease|Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase III: Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD|CODEx|Laval University|Yes|Recruiting|September 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|1||Anticipated|40|||Both|50 Years|80 Years|No|||September 2013|September 17, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01655199||81674|
NCT01642563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISS-2007646931|Italian Platelet Technology Assessment Study|A Multi-center, Single-blind, Randomized, Parallel, Non Inferiority Study to Separately Investigate the Effect of Standard Platelets Versus Platelets Prepared With Two Commercial Procedures of Pathogen Reduction Technologies (PRT) on Bleeding Incidence and Severity in Thrombocytopenic Recipients|IPTAS|Centro Nazionale Sangue|Yes|Terminated|October 2010|March 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|456|||Both|18 Years|N/A|No|||September 2014|July 27, 2015|July 13, 2012||No|Patient enrolment below planned schedule|No||https://clinicaltrials.gov/show/NCT01642563||82592|
NCT01642576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZCHOENFU|Comparing Effects of Diet, With or Without Exercise, on Sexual, Urinary and Endothelial Function, Inflammatory Profile and Quality of Life in Obese Men|Comparing Effects of Diet, With or Without Exercise, on Sexual, Urinary and Endothelial Function, Inflammatory Profile and Quality of Life in Obese Men||Changi General Hospital|No|Completed|July 2010|April 2014|Actual|April 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|90|||Male|30 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 27, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01642576||82591|
NCT01642589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA52|Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea|Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Versus Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) in Subjects 11 to 55 Years of Age in South Korea||Sanofi|No|Completed|July 2012|June 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|300|||Both|11 Years|55 Years|Accepts Healthy Volunteers|||November 2013|November 8, 2013|July 13, 2012|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01642589||82590|
NCT01643421|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|II+EPAP|Effect of a Program of Deep Inspiration Combined to Expiratory Positive Airway Pressure in Asthmatic|Effects of a Program of Deep Inspiration Combined to Expiratory Positive Airway in Quality of Life and Heart Rate Variability||Federal University of Health Science of Porto Alegre|Yes|Completed|January 2011|July 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|14|||Both|20 Years|80 Years|No|||August 2014|August 7, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01643421||82526|
NCT01643707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPROVE Brady|Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)|Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)|IMPROVE Brady|Medtronic Cardiac Rhythm Disease Management|No|Recruiting|July 2012|November 2020|Anticipated|November 2020|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|14850|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with possible sinus node dysfunction|March 2014|March 6, 2014|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01643707||82504|
NCT01643967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHI-OZO-01-10|Clinical Trial to Evaluate the Efficacy and Safety of the Use of Ozone Versus Sunflower Oil in Treating Diabetic Foot|Clinical Trial, Open, Phase III, Multicenter, Randomized to Evaluate the Efficacy and Safety of the Use of Ozone Released by Philozon Medplus Device Versus Conventional Therapy in Treating Patients With Diabetic Foot.|PHIOZO0110|Philozon Geradores de Ozonio LTDA|Yes|Recruiting|June 2012|January 2013|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01643967||82484|
NCT01644422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/HPL-AGA/11-12/001B|Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant|A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant||Kasiak Research Pvt. Ltd.|Yes|Active, not recruiting|January 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|30|||Male|18 Years|50 Years|No|||July 2012|July 24, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644422||82450|
NCT01640457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAG-G-H-1102|Safety and Efficacy With NOVOCART® Disc Plus (ADCT) for the Treatment of Degenerative Disc Disease in Lumbar Spine|A Prospective Randomized Multicentre Phase I/II Clinical Trial to Evaluate Safety and Efficacy of NOVOCART® Disc Plus Autologous Disc Chondrocyte Transplantation (ADCT) in the Treatment of Nucleotomized and Degenerative Lumbar Discs to Avoid Secondary Disease|NDisc|Tetec AG|Yes|Recruiting|August 2012|January 2021|Anticipated|January 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|60 Years|No|||October 2015|October 29, 2015|May 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01640457||82752|
NCT01640730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KLT-NSCLC-004|Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer|An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment||KangLaiTe USA|Yes|Terminated|May 2012|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2014|January 15, 2014|June 15, 2012|Yes|Yes|poor enrollment|No||https://clinicaltrials.gov/show/NCT01640730||82731|
NCT01640496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0542|Vitamin D Treatment in Ulcerative Colitis|Vitamin D Treatment in Ulcerative Colitis|Vitamin D|University of Chicago|No|Withdrawn|July 2012|December 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01640496||82749|
NCT01640756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P11-001|AqueSys Microfistula Implant in Refractory Glaucoma|A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma||AqueSys, Inc.|No|Completed|July 2012|April 2015|Actual|November 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|45 Years|N/A|No|||January 2016|January 11, 2016|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640756||82729|
NCT01640509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 08 06|Synchrotron Radiation to the Treatment of Intracranial Tumors|A Phase I-II Synchrotron Radiation Application to the Treatment of Intracranial Tumors|ESRF|University Hospital, Grenoble|Yes|Recruiting|June 2012|June 2019|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|18 Years|N/A|No|||November 2013|November 8, 2013|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01640509||82748|
NCT01641029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11H-770351|Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis|Surveillance and Risk Factor Analysis of Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis in the United States||Olive View-UCLA Education & Research Institute|No|Completed|July 2013|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|720|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients will be recruited from ten U.S. university-affiliated medical center emergency        departments participating in a CDC-collaborative emerging infections sentinel network,        EMERGEncy ID NET. Patients presenting with symptoms of acute uncomplicated pyelonephritis        will be enrolled by treating physicians or study coordinators.|April 2015|April 23, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641029||82709|
NCT01641042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115524|Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years||GlaxoSmithKline||Completed|September 2012|March 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|86|||Both|1 Year|17 Years|Accepts Healthy Volunteers|||August 2015|August 31, 2015|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641042||82708|
NCT01642173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-005460|Assessment of Coronary Plaque Composition Using Optical Coherence Tomography|Assessment of Coronary Plaque Composition Using Optical Coherence Tomography During Chronic Inhibition of Lp-PLa2 Activity||Mayo Clinic|Yes|Completed|October 2010|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|41|||Both|18 Years|85 Years|No|||August 2015|August 13, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01642173||82621|
NCT01641601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-08620|Prehospital Cervical Ripening Before Induction and the Maternal Experience|Randomized Controlled Trial of Prehospital Cervical Ripening With an Outpatient Transcervical Foley Balloon and the Duration of Induction and Maternal Satisfaction|"PRIME"|University of California, San Francisco|No|Recruiting|July 2012|||July 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Female|15 Years|50 Years|No|||December 2014|December 2, 2014|July 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01641601||82665|
NCT01641848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-SJA-002|INBONE™ Total Ankle Prosthesis With Long Talar Stem|Limited Enrollment of the INBONE™ Total Ankle Prosthesis With Long Talar Stem||Wright Medical Technology|Yes|Terminated|December 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||August 2013|May 6, 2014|June 3, 2011|Yes|Yes|Lack of patient enrollment|No||https://clinicaltrials.gov/show/NCT01641848||82646|
NCT01642732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.008|Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer|A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer||University of Michigan Cancer Center|Yes|Terminated|October 2012|August 2014|Actual|August 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Male|18 Years|N/A|No|||December 2015|December 8, 2015|March 24, 2012|Yes|Yes|Lack of accrual and funding expires in June, 2014.|No|November 13, 2014|https://clinicaltrials.gov/show/NCT01642732||82579|Only one patient was enrolled to the trial and consent was withdrawn prior to treatment therefore the primary objective could not be analyzed.
NCT01642953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJIRB-MED-MDB-12-002|Early Recovery After Gastric Cancer Surgery|Prospective Clinical Study for Early Recovery After Gastric Cancer Surgery||Ajou University School of Medicine|No|Recruiting|July 2012|August 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|109|||Both|N/A|65 Years|No|||July 2012|July 18, 2012|July 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01642953||82562|
NCT01643226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KXL-002|Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus||Avedro, Inc.|No|Active, not recruiting|July 2012|July 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|226|||Both|12 Years|N/A|No|||December 2015|December 23, 2015|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643226||82541|
NCT01643239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|94-1052B|Effects of Forms of Modified CIT on Upper Extremity Performance in Cerebral Palsy|Effects of Forms of Modified Constraint-induced Therapy on Functional Performance of Upper Extremity in Children With Cerebral Palsy With Asymmetric Motor Impairments: A Follow up Study of Kinematic and Clinical Analyses||Chang Gung Memorial Hospital|No|Completed|August 1996|||September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Actual|60|||Both|4 Years|10 Years|No|||February 2013|February 27, 2013|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01643239||82540|
NCT01656044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCCWFU 99212|Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer|The Effect of Negative Pressure Therapy on Incisional Surgical Site Infections||Comprehensive Cancer Center of Wake Forest University|No|Recruiting|June 2012|||June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|264|||Both|18 Years|N/A|No|||February 2015|July 27, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656044||81609|
NCT01643109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-294|Constraint Induced Movement Therapy (CIMT)- Neuroimaging Predictors of Positive Response to Constraint|Childhood Hemiplegic CP Integrated Neuroscience Discovery Network (CP-NET) Theme IIIa: Constraint Induced Movement Therapy (CIMT)- Neuroimaging Predictors of Positive Response to Constraint|OBI_CIMT|Holland Bloorview Kids Rehabilitation Hospital|Yes|Completed|March 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|26|||Both|7 Years|16 Years|No|||January 2016|January 11, 2016|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01643109||82550|
NCT01643434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0758/09|Resistant Hypertension Optimal Treatment|Multicenter Study of Patients With Hypertension Resistant to Patient Identification and Standardization of Therapeutic|ReHOT|Instituto do Coracao|Yes|Recruiting|August 2012|July 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2000|||Both|18 Years|75 Years|No|||June 2013|June 6, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01643434||82525|
NCT01644188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11569|Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)|A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy||Sanofi|Yes|Completed|August 2012|July 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|720|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 16, 2012|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01644188||82467|Reported results are from first step analysis conducted after all participants completed 52 weeks visit.
NCT01644162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/LO/1777|Ventilator Monitoring in Early Exacerbation Detection|Use of Ventilator Monitoring for Early Detection of Exacerbations of Chronic Lung Disease||ResMed|No|Completed|July 2012|January 2014|Actual|January 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|30|||Both|18 Years|N/A|No|||March 2012|October 15, 2014|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644162||82469|
NCT01644175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11568|Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy||Sanofi|Yes|Completed|July 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|316|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 16, 2012|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01644175||82468|
NCT01640483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC/2012/455|Differential Efficacy of Supportive and Interpretative Psychodynamic Techniques for Dependent and Self-critical Depressive Patients|Differential Efficacy of Supportive and Interpretative Psychodynamic Techniques for Dependent and Self-critical Depressive Patients: an Experimental Single Case Design.|PsychodynDep|University Ghent|No|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|9|||Both|18 Years|60 Years|No|||June 2015|June 3, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01640483||82750|
NCT01640743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|42501/2009|Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation|Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation: a Randomized Study|EVERTWIST|IRCCS Policlinico S. Matteo|Yes|Completed|March 2010|April 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|58|||Both|18 Years|75 Years|No|||March 2015|March 24, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01640743||82730|
NCT01644461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/HPL-FR/11-12/002B|A Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Facial Wrinkles(Nasolabial Folds)|A Prospective, Multicentric, Open Label, Bio-Interventional, Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment of Facial Wrinkles (Nasolabial Folds)||Kasiak Research Pvt. Ltd.|Yes|Active, not recruiting|April 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|40 Years|No|||July 2012|July 24, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644461||82447|
NCT01640522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO07050143|Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms|Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma|CaSSY|University of Pittsburgh|No|Completed|January 2008|December 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|261|||Both|18 Years|N/A|No|||July 2012|December 23, 2015|September 16, 2010||No||No||https://clinicaltrials.gov/show/NCT01640522||82747|
NCT01640769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAPIT-CRT|Imaging Study of Allocation of Pacing Targets in Cardiac Resynchronization Therapy|MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy||Lawson Health Research Institute|Yes|Not yet recruiting|August 2012|December 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|328|||Both|18 Years|N/A|No|||July 2012|July 11, 2012|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01640769||82728|
NCT01641861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE542161|A Comparative Study of Papacarie® and the Conventional Method for Dental Caries Treatment|Study of Papacarie® for Caries Removal.||Khon Kaen University|No|Completed|August 2012|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|488|||Both|7 Years|8 Years|Accepts Healthy Volunteers|||December 2015|February 3, 2016|July 9, 2012||No||No|December 6, 2015|https://clinicaltrials.gov/show/NCT01641861||82645|The limitations: First, the long duration of the trial caused participants to lost to follow up. Second, the operator and patients could not be blinded from the treatment status because of the apparent difference in the intervention techniques.
NCT01641874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16399E|The McKenzie System With Arthritic Knees: Do Some Knees Respond to Specific Exercise More Than General or no Exercise|The McKenzie System's Derangement Classification in Osteoarthritic Knees: Efficacy of McKenzie Treatment Versus Evidence Based Care: A Randomised Controlled Trial||Lawson Health Research Institute|No|Completed|November 2009|August 2012|Actual|May 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|180|||Both|N/A|N/A|No|||September 2015|September 10, 2015|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01641874||82644|
NCT01641887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-MGH-Hur-GERD|Decision Aid for Gastroesophageal Reflux Disease Management|Personalized Decision Aid for the Management of Gastroesophageal Reflux Disease||Massachusetts General Hospital|No|Not yet recruiting|January 2014|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients who have GERD who have not yet had endoscopy.|April 2013|April 1, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01641887||82643|
NCT01642472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PGL11-024|PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata|A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding|PEARLext2|PregLem SA|Yes|Completed|July 2012|April 2015|Actual|March 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|64|||Female|18 Years|N/A|No|||December 2015|January 7, 2016|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01642472||82599|
NCT01642745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS-A-522|Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness|Mannitol and Methacholine Responsiveness: Effects of Deep Inhalations||University of Saskatchewan|No|Completed|November 2011|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|20|||Both|18 Years|65 Years|No|||October 2013|December 10, 2013|January 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642745||82578|
NCT01642446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20125010Y|Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension|A Randomized Control Clinical Trial Between Precise Hepatectomy and Combined Interventional Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension||Sun Yat-sen University|Yes|Recruiting|January 2013|June 2022|Anticipated|June 2022|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|360|||Both|18 Years|65 Years|No|||November 2015|November 17, 2015|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642446||82601|
NCT01643252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KXL-003|Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery||Avedro, Inc.|No|Withdrawn|July 2012|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|12 Years|N/A|No|||December 2015|December 23, 2015|July 16, 2012|Yes|Yes|This study was withdrawn for business reasons.|No||https://clinicaltrials.gov/show/NCT01643252||82539|
NCT01643265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTI2012-CS02|Effect of Whey and Albumin Protein on Plasma Levels of Amino Acids|Effect of Whey and Albumin Protein on Plasma Levels of Amino Acids||Metabolic Technologies Inc.|No|Completed|July 2012|September 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|8|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|February 13, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643265||82538|
NCT01643525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00069985|Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke|A NonRandomized, Multicenter, NonSig Risk Study With a NonInv, Passive PressureWave Method of Diagnosing Cerebral Anomalies to Develop a Diag. Algorithm for Cerebral Isch and to Test Sens./Spec. of This Algorithm in Determining Isch Stroke||Jan Medical, Inc.|No|Terminated|June 2012|December 2012|Actual|December 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|29|||Both|18 Years|90 Years|Accepts Healthy Volunteers|||June 2015|June 2, 2015|June 29, 2012|Yes|Yes|Insufficient Subject Recruitment|No|June 2, 2015|https://clinicaltrials.gov/show/NCT01643525||82518|
NCT01643538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|69924|Social Goals and Individual Incentives to Promote Walking in Older Adults|Social Goals and Individual Incentives to Promote Walking in Older Adults (Way to Walk II)||University of Pennsylvania|No|Completed|August 2012|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|94|||Both|65 Years|N/A|No|||February 2014|March 4, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643538||82517|
NCT01643837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHS-799|Mastalgia Treatment: Is There a Role for Osteopathic Manipulative Treatment|Mastalgia Treatment: Is There a Role for Osteopathic Manipulative Treatment?||New York Institute of Technology|No|Not yet recruiting|February 2016|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|87|||Female|18 Years|N/A|No|||January 2016|January 19, 2016|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01643837||82494|
NCT01656057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GALINKUR|The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion|The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion||University Hospital, Gentofte, Copenhagen|No|Completed|July 2012|April 2014|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|6||Actual|10|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 10, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01656057||81608|
NCT01643122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15849|Validation Study for Endometriosis PRO|Validation Study to Assess Psychometric Properties of a Newly Developed Patient Reported Outcome Tool for Endometriosis|VALEPRO|Bayer|No|Completed|August 2012|September 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|275|||Female|18 Years|45 Years|No|Non-Probability Sample|Women with endometriosis confirmed by laparoscopy|October 2014|October 10, 2014|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01643122||82549|
NCT01643460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0812-57|Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts|Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts||Indiana University|No|Recruiting|September 2009|January 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 11, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01643460||82523|
NCT01643980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PESAPRO-2012|Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies|Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies|PESAPRO|Puerta de Hierro University Hospital|No|Recruiting|July 2012|June 2016|Anticipated|May 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|254|||Female|18 Years|N/A|No|||October 2015|October 20, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01643980||82483|
NCT01643993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RMA-2012-01|Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer|Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer: A Randomized Controlled Trial||Reproductive Medicine Associates of New Jersey|No|Completed|May 2012|November 2014|Actual|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|300|||Female|18 Years|43 Years|Accepts Healthy Volunteers|||January 2015|January 21, 2015|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01643993||82482|
NCT01644435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/HPL-AS/11-12/004|A Pilot Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Acne Scarring|A Prospective, Multicentric, Open Label, Bio Interventional, Phase I, Phase II Pilot Study to Evaluate the Safety and Efficacy of Autologous Human Platelet Lysate (HPL) for Treatment of Acne Scarring||Kasiak Research Pvt. Ltd.|Yes|Completed|May 2012|October 2012|Actual|October 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|40 Years|No|||October 2012|October 12, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644435||82449|
NCT01644448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KRPL/HPL-FR/11-12/002A|A Study to Determine the Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Dark Circles|A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate (HPL) for Treatment of Periorbital Hyperpigmentation (Dark Circles)||Kasiak Research Pvt. Ltd.|Yes|Active, not recruiting|March 2012|November 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|20|||Both|18 Years|55 Years|No|||July 2012|July 24, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01644448||82448|
NCT01640782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITACA-S|Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach|Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen|ITACA-S|Mario Negri Institute for Pharmacological Research|Yes|Completed|February 2005|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1100|||Both|18 Years|75 Years|No|||December 2013|July 17, 2014|July 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01640782||82727|
NCT01640795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP001|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|June 2010|||||N/A|N/A|N/A||||||||||||||July 12, 2012|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01640795||82726|
NCT01640808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIK-333-05|Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC|NIK-333 (Peretinoin) Phase ⅢStudy Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus (HCV)-Positive Hepatocellular Carcinoma(HCC）, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study||Kowa Company, Ltd.||Active, not recruiting|April 2012|March 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|600|||Both|20 Years|N/A|No|||February 2015|March 23, 2015|July 10, 2012||||No||https://clinicaltrials.gov/show/NCT01640808||82725|
NCT01641081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAC-MD-21|Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma|Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover Study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients With Mild to Moderate Asthma||Forest Laboratories|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|174|||Both|18 Years|N/A|No|||February 2013|February 13, 2013|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641081||82705|
NCT01641393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR-005|Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.|A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis||Forest Laboratories|Yes|Completed|June 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|96|||Both|12 Years|N/A|No|||March 2014|March 13, 2014|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01641393||82681|
NCT01642186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-211|Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)|A Randomized Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|84|||Both|12 Years|N/A|No|||August 2015|August 13, 2015|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642186||82620|
NCT01642199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01DK095771-01|Lay Health Coaches for Weight Loss: Peers Versus Mentors|A Randomized Trial Testing Lay Health Coaches for Obesity Treatment||The Miriam Hospital|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|272|||Both|40 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 31, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01642199||82619|
NCT01642485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPL-01-11|Food and Insulin Effect on QT/QTC Interval of ECG|Evaluation of the Effect of Different Foods, Carbohydrate Meal, and a Euglycaemic Insulin Clamp on the QT/QTc Interval Using a Single Dose of Moxifloxacin as a Positive Control in Healthy Male and Female, Caucasian and Japanese Volunteers|C11035|Richmond Pharmacology Limited|No|Completed|July 2011|September 2011|Actual|September 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|32|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||August 2014|August 19, 2014|June 19, 2012||No||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01642485||82598|Our findings based on the confirmatory and concentration-effect analysis suggest that any difference between ethnicities was most likely attributable to differences in plasma concentrations and not differences in sensitivity to moxifloxacin.
NCT01642459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0107|The Outcomes of Arteriovenous Fistula Cannulated From Different Direction.|The Outcomes of Arteriovenous Fistula (AVF) Cannulated From Different Direction in Maintenance Hemodialysis Patients.||Capital Medical University|Yes|Terminated|September 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|10|||Both|18 Years|85 Years|No|||May 2015|May 19, 2015|July 12, 2012||No|The patients enrolled are limited.|No||https://clinicaltrials.gov/show/NCT01642459||82600|
NCT01642966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PATRASCARDIOLOGY-12|Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention|Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.||University of Patras|No|Completed|September 2012|September 2012|Actual|September 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|74 Years|No|||January 2013|January 21, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01642966||82561|
NCT01643278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01165|Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic|Phase I Study of Dasatinib in Combination With Ipilimumab for Patients With Advanced Gastrointestinal Stromal Tumor and Other Sarcomas||National Cancer Institute (NCI)||Recruiting|July 2012|||December 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|39|||Both|18 Years|N/A|No|||July 2015|January 26, 2016|July 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01643278||82537|
NCT01643551|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1204M12861|Neuron Specific Enolase in Ventricular Assist Device Recipients|Neuron Specific Enolase in Ventricular Assist Device Recipients|NSE-LVAD|University of Minnesota - Clinical and Translational Science Institute|No|Completed|June 2012|July 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Cardiovascular Surgical candidates from outpatient cardiology clinic or inpatient service.|December 2014|December 16, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643551||82516|
NCT01643564|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111M06547|Cytokine Profiling Post-Heart Transplant|Cytokine Profiling of Cardiac Transplant Recipients||University of Minnesota - Clinical and Translational Science Institute|No|Terminated|November 2011|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Actual|34|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Cardiology Clinic and inpatient service. Normal controls are volunteers from within the        community.|January 2014|January 6, 2014|July 16, 2012||No|Subject Recruitment|No||https://clinicaltrials.gov/show/NCT01643564||82515|
NCT01643850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMCS110X2201|MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS)|A Phase II Randomized, Double -Blind, Placebo Controlled Study Followed by Open Label Dosing to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)||Novartis|No|Recruiting|April 2012|November 2017|Anticipated|November 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|18|||Both|18 Years|N/A|No|||January 2016|January 6, 2016|March 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643850||82493|
NCT01643863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28202|A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (MONACO)|A Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (TCZ)||Hoffmann-La Roche||Terminated|August 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1|||Both|18 Years|N/A|No|Probability Sample|Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra in        monotherapy|March 2016|March 1, 2016|July 16, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01643863||82492|
NCT01656603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6637-01|Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation|A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients||New York Blood Center|Yes|Recruiting|February 2012|December 2020|Anticipated|December 2019|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|9999|||Both|N/A|N/A|No|||March 2016|March 9, 2016|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01656603||81567|
NCT01643720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MMC1013010kCTIL|Emotion Regulation in Preschoolers With Autism and Their Parents|Emotion Regulation in Preschoolers With Autism and Their Parents||Meir Medical Center|No|Completed|November 2010|May 2011|Actual|May 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|80|Samples Without DNA|Saliva used for cortisol and oxytocin extraction|Both|3 Years|6 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants in the study group will be recrutied from psychiatric clinics, after a        diagnosis of ASD has been made, and from special education kindergartens.        participants in the comparison group will be recruited by adds suggesting participiation        in the study that were published in variose cities and on the internet.|September 2013|April 7, 2015|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01643720||82503|
NCT01643174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT retro|Predictors of Mortality and Morbidity in the Surgical Management of Primary Tumors of the Spine|Predictors of Mortality and Morbidity in the Surgical Management of Primary Tumors of the Spine: A Multi-center Retrospective Cohort Study With a Cross-Sectional Survival Check|PT|AOSpine International|No|Completed|February 2012|May 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|1600|||Both|18 Years|N/A|No|Probability Sample|Retrospective chart review and selection|June 2013|June 19, 2013|April 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01643174||82545|
NCT01643733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-133-SDR|Study on Fistuloplasty Using Flow Measurement Guidance|Confirmation of Clinical Effectiveness and Safety of Use of Transonics in Determining Success of Intervention in Dialysis Fistulae||McGill University Health Center|Yes|Recruiting|October 2012|August 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|50|||Both|16 Years|90 Years|No|||March 2016|March 22, 2016|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01643733||82502|
NCT01643746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 12.048|Evaluation of Luminal Expansion Following Stenting of Femoro-popliteal Occlusive Disease|C-arm CT Evaluation of Luminal Expansion in Stenting Severe Femoro-popliteal Atherosclerotic Disease: Supera Versus LifeStent||Centre hospitalier de l'Université de Montréal (CHUM)|No|Not yet recruiting|March 2013|March 2015|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||March 2013|March 12, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643746||82501|
NCT01644201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Wharton Study No. 05|A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics|A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a Highly Viscous Non-starch Polysaccharide (PolyGlycopleX® - PGX®), on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics Enrolled in a Medically Supervised Weight Management Program.||InovoBiologic Inc.|No|Recruiting|October 2012|||January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|75 Years|No|||October 2012|February 14, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01644201||82466|
NCT01644214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PessaryProtocol|Timing of Pessary Follow-up for Pelvic Organ Prolapse|Timing of Pessary Follow-up for Pelvic Organ Prolapse: Patient Preference and Complication Rates||St. Michael's Hospital, Toronto|No|Not yet recruiting|September 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Female|18 Years|N/A|No|||June 2012|July 16, 2012|June 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01644214||82465|
NCT01641406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAC CCAM 11-01|"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"|"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"|NACprotocol|Auxilio Mutuo Cancer Center|Yes|Recruiting|March 2011|March 2013|Anticipated|January 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|60|||Female|18 Years|N/A|No|||July 2012|July 12, 2012|July 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641406||82680|
NCT01641419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-30398|Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg|Randomized, Controlled Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg||Baylor College of Medicine|No|Withdrawn|July 2012|December 2014|Actual|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|64 Years|No|||March 2015|March 13, 2015|July 11, 2012||No|Inability to recruit subjects at our hospital due to change in surgical patient population.    Not worth to continue.|No||https://clinicaltrials.gov/show/NCT01641419||82679|
NCT01641640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0110|Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection|NEUTRINO|Gilead Sciences|Yes|Completed|June 2012|April 2013|Actual|January 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|328|||Both|18 Years|N/A|No|||April 2014|April 8, 2014|July 9, 2012|Yes|Yes||No|February 25, 2014|https://clinicaltrials.gov/show/NCT01641640||82662|
NCT01641900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH092638|Effects of Eszopiclone on Sleep and Memory in Schizophrenia|Sleep-dependent Memory Processing in Schizophrenia||Massachusetts General Hospital|No|Recruiting|July 2012|June 2015|Anticipated|June 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 1, 2015|January 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641900||82642|
NCT01642212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPI-101-06|OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension|Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension||Shire|No|Completed|July 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|93|||Both|11 Years|40 Years|No|||March 2014|November 3, 2015|July 13, 2012|Yes|Yes||No|September 30, 2015|https://clinicaltrials.gov/show/NCT01642212||82618|
NCT01642979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNH-2012|Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria|Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria|PNH-2012|Institute of Hematology & Blood Diseases Hospital|Yes|Active, not recruiting|July 2012|July 2017|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|120|||Both|18 Years|N/A|No|||January 2013|January 1, 2013|July 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01642979||82560|
NCT01642992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-11-060|Korean Coronary Bifurcation Stenting (COBIS) Registry II|Korean Coronary Bifurcation Stenting (COBIS) Registry II||Samsung Medical Center||Completed|January 2011|April 2012|Actual|April 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|2873|||Both|18 Years|N/A|No|Probability Sample|Patients with coronary bifurcation lesion treated with drug-eluting stents|January 2013|January 9, 2013|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01642992||82559|
NCT01643291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00335|Ultrasound Use for Difficult Lumbar Punctures in Pediatric Oncology Patients|Ultrasound Imaging Facilitates Lumbar Punctures in Pediatric Oncology Patients With Difficult Surface Landmarks and/or a History of Difficult Lumbar Puncture||Nationwide Children's Hospital|No|Terminated|July 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|N/A|N/A|No|||February 2015|February 4, 2015|July 12, 2012||No|We were unable to recruit subjects for this study.|No||https://clinicaltrials.gov/show/NCT01643291||82536|
NCT01643304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16384|A Swedish Questionnaire Study to Investigate the Perception of Menstrual Bleedings|A Swedish Cross-sectional Study With Questionnaire to Investigate Perception of Menstrual Bleeding||Bayer|No|Completed|May 2012|June 2012|Actual|||N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|1547|||Female|40 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects included in the SIFO (Swedish institute of market research) volontary subject        pool.|November 2013|November 20, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643304||82535|
NCT01643577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00044436|Acupuncture Treatment for Gastroparesis: a Pilot Study|Acupuncture Treatment for Gastroparesis: a Pilot Study||Johns Hopkins University|No|Recruiting|November 2011|November 2013|Anticipated|November 2013|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||July 2012|July 16, 2012|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01643577||82514|
NCT01643590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JTCS-004|Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.|A Phase II Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of JVS-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure|STOP-HF|Juventas Therapeutics, Inc.|Yes|Active, not recruiting|July 2012|November 2014|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|N/A|No|||February 2014|February 6, 2014|July 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643590||82513|
NCT01643876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMD-UdeM-EE-2012a|The Effect of Palatal Brushing on Denture Stomatitis|Phase-I Clinical Trial on the Effect of Palatal Brushing on Denture Stomatitis||Université de Montréal|Yes|Completed|July 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|48|||Both|18 Years|N/A|No|||December 2013|December 23, 2013|July 16, 2012||No||No|July 23, 2013|https://clinicaltrials.gov/show/NCT01643876||82491|One group pre-test post-test study. External validity limitations
NCT01656915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHDR1212|Ex Vivo LPS Stimulation in Healthy and Compromised Subjects|Ex Vivo LPS Stimulation in Healthy and Compromised Subjects||TNO|Yes|Completed|June 2012|October 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control||2|Actual|36|Samples Without DNA|Blood samples will be obtained for standard clinical chemistry, heamatology, cytokines and      ex vivo LPS stimulation.|Male|35 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|In total, 36 male subjects will participate in the study. The study will be conducted in        two different subject groups (one healthy and one compromised group), each consisting of        18 subjects.|June 2013|June 18, 2013|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01656915||81543|
NCT01657201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYP1018|Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)|A Randomized, Open-label, Two-Treatment, Two-Period, Two-Sequence, Cross-over Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend) in Healthy Male Volunteers||Samyang Biopharmaceuticals Corporation|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|59|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||December 2012|December 20, 2012|July 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01657201||81521|
NCT01643148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCQ|The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer|Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini|leptin|Materno-Perinatal Hospital of the State of Mexico|No|Completed|January 2011|July 2012|Actual|October 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|88|None Retained|serum|Female|40 Years|60 Years|No|Probability Sample|Cross-sectional prospective study conducted at the Maternal-Perinatal Hospital "Mónica        Pretelini" (HMPMP), State of Mexico Health Institute (ISEM), Toluca, Mexico, from January        to October 2011.|July 2012|July 17, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643148||82547|
NCT01643161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005721|Guided Self-Help for Functional Neurological Symptoms|Guided Self-Help for Functional Neurological Symptoms: A Randomized Controlled Efficacy Trial||Mayo Clinic|No|Terminated|April 2012|August 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|33|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|July 16, 2012||No|Slow accrual.|No||https://clinicaltrials.gov/show/NCT01643161||82546|
NCT01643486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012 iTouch|Development of a 'Phosphate Counting Program'|Development of a 'Phosphate Counting Program' on an iTouch to Simplify Self-management of Dietary Phosphate by Patients With End Stage Renal Disease(ESRD) Treated With Peritoneal Dialysis||Ottawa Hospital Research Institute|No|Recruiting|June 2012|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|90 Years|No|||May 2015|May 21, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643486||82521|
NCT01643759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP08-CN-002|Norspan Transdermal Patches Study in Osteoarthritis Patients|A Single Dose PK Study of BTDS 5, 10, and 20 in Chinese Osteoarthritis Patients||Mundipharma (China) Pharmaceutical Co. Ltd|No|Completed|July 2009|||March 2010|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|20 Years|60 Years|No|||July 2015|July 7, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01643759||82500|
NCT01643473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|s14-00414|Tailored Approaches to Improve Medication Adherence|Tailored Approaches to Improve Medication Adherence||New York University School of Medicine|Yes|Recruiting|April 2013|September 2017|Anticipated|July 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2015|December 22, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643473||82522|
NCT01644227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sebastian-1|Dual Mobility Cup in Total Hip Arthroplasty Preventing Dislocation in Patients at Risk|Dual Mobility Cup in Total Hip Arthroplasty Preventing Dislocation in Patients at Risk||Sundsvall Hospital|No|Completed|June 2012|July 2012|Actual|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|34|||Both|N/A|N/A|No|Non-Probability Sample|All patients operated with an cemented dual mobility cups at Sundsvall hospital between        2009-2012.        Indications for surgery are recurrent dislocation and patients at risk for dislocation        mainly due to comorbidity, neuromuscular, psychiatric or cognitive disorders.|October 2015|October 28, 2015|June 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01644227||82464|
NCT01640548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28372|A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis|A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis||Hoffmann-La Roche||Completed|September 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|320|||Both|18 Years|N/A|No|Probability Sample|Patients treated with a biologic in monotherapy for rheumatoid arthritis|February 2016|February 1, 2016|July 6, 2012||No||No|August 12, 2015|https://clinicaltrials.gov/show/NCT01640548||82745|
NCT01644006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-1003-0034-1|Telemedical Support in Prehospital Emergency Care of Acute Coronary Syndrome|Telemedical Support in Prehospital Emergency Care of Acute Coronary Syndromes||RWTH Aachen University|No|Completed|August 2012|September 2015|Actual|July 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|39|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01644006||82481|
NCT01640535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MOLZ-301|Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients|Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial||Hanmi Pharmaceutical Company Limited|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|283|||Both|15 Years|N/A|No|||April 2013|April 4, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01640535||82746|
NCT01641133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115992|Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™|Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™||GlaxoSmithKline||Completed|September 2012|May 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|457|||Both|6 Weeks|12 Weeks|Accepts Healthy Volunteers|||December 2014|December 11, 2014|July 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01641133||82701|
NCT01641653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0120110037|Does Preop Midazolam Maintain Blood Glucose Norms in the Non Diabetic Perioperative Period|Does the Administration of Preop Midazolam Assist in Maintaining Blood Glucose Norms in Non-diabetic Patient During the Perioperative Period||Rutgers, The State University of New Jersey|No|Completed|June 2011|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|18 Years|80 Years|No|||November 2014|September 29, 2015|December 8, 2011||No||No|October 2, 2014|https://clinicaltrials.gov/show/NCT01641653||82661|
NCT01641913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001344|Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients|Determination of Intestinal Permeability and Response to Treatment in Patients With Eosinophilic Esophagitis||Mayo Clinic|No|Completed|August 2012|February 2014|Actual|January 2014|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|80 Years|No|||June 2014|June 20, 2014|July 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01641913||82641|
NCT01641926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P08450|A Study of the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Participants With Chronic Hepatitis B (P08450)|A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450)||Merck Sharp & Dohme Corp.|No|Terminated|November 2012|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|402|||Both|18 Years|N/A|No|||February 2016|February 16, 2016|July 11, 2012|Yes|Yes|This study was terminated early due to poor recruitment|No||https://clinicaltrials.gov/show/NCT01641926||82640|
NCT01642511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMSN001|Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative|Phase II Trail of Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative|IMSLNB-EBCP|Shandong Cancer Hospital and Institute|No|Recruiting|January 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|4|||Female|18 Years|80 Years|No|||August 2013|August 24, 2013|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01642511||82596|
NCT01642758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HQK-P2-THAL|Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon|An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia|LB-04-THAL|Boston University|Yes|Completed|May 2012|January 2013|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|16 Years|50 Years|No|||March 2013|March 13, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01642758||82577|
NCT01642771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EBC protocol 1.1|Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer|A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer||China Breast Cancer Clinical Study Group|Yes|Recruiting|June 2012|May 2020|Anticipated|December 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|636|||Female|18 Years|70 Years|No|||June 2014|June 25, 2014|July 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01642771||82576|
NCT01642784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2.0, 2011-11-24|Complete Infarct Related Artery Revascularization in Acute Myocardial Infarction|Complete Infarct Related Artery Revascularization in Acute Myocardial Infarction Registry(CORAMIreg)|CORAMIreg|Fundacja Ośrodek Badań Medycznych|No|Completed|November 2011|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Study population will comprise of approx. 200 patients (males and females) with the        diagnosis of STEMI or NSTEMI and at least two independent critical lesions in infarct        related artery (one of which is considered as target/culprit lesion that have caused the        myocardial infarction and requires immediate PCI). Patients enrolled to the registry must        meet all the eligibility criteria.|July 2013|July 2, 2013|June 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01642784||82575|
NCT01643005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1105008508|A Couple-Based Relationship Strengthening HIV Intervention for Young Parents|Pilot Phase of Couples-Based Intervention to Reduce HIV/STD Risk (Concurrency, Number of Partners, Unprotected Sex), Strengthen Relationships, and Improve Parenting Among Young Parenting Heterosexual Couples||Yale University|Yes|Not yet recruiting|August 2012|July 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Both|14 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 16, 2012|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01643005||82558|
NCT01643317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Catharina_Project_SCAN|Screening Cardiovascular Patients for Aortic Aneurysms|Screening Cardiovascular Patients for Aortic Aneurysms|SCAN|Catharina Ziekenhuis Eindhoven|No|Recruiting|July 2012|||July 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1|||Both|55 Years|N/A|No|Non-Probability Sample|Patients with peripheral arterial disease or carotid arterial disease|May 2013|May 23, 2013|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01643317||82534|
NCT01643330|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CELL-004|A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure|A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure|CUPID-2b|Celladon Corporation|Yes|Completed|July 2012|February 2016|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|250|||Both|18 Years|80 Years|No|||February 2016|February 25, 2016|July 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643330||82533|
NCT01643603|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-204|Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies|Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|May 2012|December 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|May 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01643603||82512|
NCT01634087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INCB 39110-250|A Study of Escalating Doses of INCB039110 Administered Orally in Patients With Plaque Psoriasis|A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of Escalating Doses of Oral INCB039110 in Subjects With Stable, Chronic Plaque Psoriasis||Incyte Corporation|No|Completed|June 2012|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|8||Actual|50|||Both|18 Years|75 Years|No|||November 2013|November 26, 2013|July 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01634087||83239|
NCT01634100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1245.83|Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid|A Randomised, Open-label, Three-way Crossover Trial to Investigate the Effect of Rifampicin and Probenecid on Empagliflozin Pharmacokinetics in Healthy Male and Female Subjects||Boehringer Ingelheim||Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|18|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||June 2014|June 27, 2014|July 3, 2012||||No|May 16, 2014|https://clinicaltrials.gov/show/NCT01634100||83238|
NCT01634113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.443|Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma|A Phase II/III, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution (2.5 µg and 5 µg) Administered Once Daily in the Afternoon Via Respimat® Inhaler for 12 Weeks in Patients 1 to 5 Years Old With Persistent Asthma||Boehringer Ingelheim||Completed|July 2012|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|102|||Both|1 Year|5 Years|No|||June 2015|June 3, 2015|April 16, 2012||||No|June 3, 2015|https://clinicaltrials.gov/show/NCT01634113||83237|
NCT01657214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TED12337|Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients|Phase I, Dose Escalation Study of Safety, Pharmacokinetic and Pharmacodynamic of SAR125844 Administered Weekly as Intravenous Infusion in Asian Adult Patients With Advanced Malignant Solid Tumors|SARMETA|Sanofi|No|Completed|September 2012|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|70|||Both|20 Years|N/A|No|||February 2016|February 16, 2016|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01657214||81520|
NCT01657500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-10-20|Life 4°C Versus Optisol in Corneal Storage Media|A Randomized, Prospective, Double Masked Clinical Trial of Life 4°C Versus Optisol GS Corneal Storage Media||University Hospital Case Medical Center|Yes|Active, not recruiting|June 2011|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Anticipated|76|||Both|30 Years|85 Years|No|||July 2012|August 3, 2012|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01657500||81498|
NCT01642914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIN-MD-04|Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating|Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Chronic Constipation and Prominent Abdominal Bloating at Baseline||Forest Laboratories|No|Completed|August 2012|August 2013|Actual|May 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|487|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2013|September 30, 2013|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01642914||82565|
NCT01644240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0095|A Phase 1, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects||Theravance Biopharma R & D, Inc.|No|Completed|September 2012|December 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|5||Actual|16|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||December 2014|December 1, 2014|July 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01644240||82463|
NCT01643772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OXYC09-CN-102|OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study|OxyNorm® Capsules (Immediate-Release) PK Study||Mundipharma (China) Pharmaceutical Co. Ltd|No|Completed|May 2011|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|30 Years|60 Years|No|||August 2015|August 26, 2015|November 17, 2011||No||No||https://clinicaltrials.gov/show/NCT01643772||82499|
NCT01644019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|005-1003-0034-2|Prehospital Telemedical Support in Acute Stroke|Prehospital Telemedical Support in Acute Stroke||RWTH Aachen University|No|Completed|August 2012|September 2015|Actual|July 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Both|18 Years|N/A|No|||September 2015|September 21, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01644019||82480|
NCT01644500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11991|A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus|The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus||Eli Lilly and Company|Yes|Completed|July 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|807|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 17, 2012|Yes|Yes||No|August 3, 2015|https://clinicaltrials.gov/show/NCT01644500||82444|
NCT01644474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC11716|Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia|A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia|ODYSSEY MONO|Sanofi|Yes|Completed|July 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|18 Years|N/A|No|||October 2015|October 7, 2015|July 17, 2012|Yes|Yes||No|August 20, 2015|https://clinicaltrials.gov/show/NCT01644474||82446|Due to administrative error in the automated process (which was detected after database lock), planned dose up­titration criteria for LDL­C levels was changed from ≥100 mg/dL to ≥70 mg/dL.
NCT01641094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETIM|Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms|Effect of Telaprevir in Triple Therapy on Intrahepatic Immunological Mechanisms.|ETIM|Foundation for Liver Research|Yes|Completed|May 2012|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|Whole Blood|Both|18 Years|70 Years|No|Non-Probability Sample|Patients with chronic hepatitis C, genotype 1|March 2015|March 10, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641094||82704|
NCT01641107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAL1811|Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.|Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.|LAL1811|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|October 2014|November 2019|Anticipated|November 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|44|||Both|18 Years|N/A|No|||July 2015|July 29, 2015|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01641107||82703|
NCT01641120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-12-002|Assessing Tolerability of Avonex Intramuscular Injections|Assessing Tolerability of Avonex Intramuscular Injections With a 25 Gauge Needle Versus 30 Gauge Needle||Saint Francis Care|No|Completed|May 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|65 Years|No|||December 2015|December 18, 2015|July 6, 2012|No|Yes||No|July 13, 2015|https://clinicaltrials.gov/show/NCT01641120||82702|
NCT01697644|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHRETARD/NL/21|Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation|Growth Hormone Treatment of Children After Intrauterine Growth Retardation||Novo Nordisk A/S|No|Completed|October 1990|May 2005|Actual|May 2005|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|75|||Both|3 Years|11 Years|No|||September 2012|October 2, 2012|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697644||78438|
NCT01697657|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN304-1375|Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes|A Randomised, Open Label, Cross-over, Multi-centre, Multinational Trial Comparing the Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir and NPH Insulin in Well Controlled Subjects With Type 1 Diabetes on a Basal-bolus Regimen||Novo Nordisk A/S|No|Completed|September 2001|November 2002|Actual|November 2002|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697657||78437|
NCT01698242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10030801|The Congestive Heart Failure Adherence Redesign Trial|Reduction in Hospitalizations in Low-Income Patients With Heart Failure|CHART|Rush University Medical Center|Yes|Active, not recruiting|May 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|320|||Both|18 Years|N/A|No|||May 2015|May 4, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01698242||78393|
NCT01698567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|38402|Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)|Antithrombin III Supplementation for Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass.||University of Rochester|Yes|Terminated|July 2012|March 2016|Actual|March 2016|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|6|||Both|N/A|180 Days|No|||March 2016|March 21, 2016|September 4, 2012|Yes|Yes|Challenges enrolling subjects in study|No||https://clinicaltrials.gov/show/NCT01698567||78368|
NCT01698541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GenTac-12|Generic Tacrolimus in the Elderly - Prograf® vs Tacni®|Generic Tacrolimus in the Elderly - Prograf® vs Tacni®|GenTac|University of Oslo School of Pharmacy|No|Completed|February 2013|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Both|60 Years|N/A|No|||December 2014|December 2, 2014|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01698541||78370|
NCT01698814|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-028|A Six-Week Safety Study of an Investigational Ophthalmic Solution|A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily||Alcon Research|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|518|||Both|2 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 27, 2014|September 27, 2012|Yes|Yes||No|January 21, 2014|https://clinicaltrials.gov/show/NCT01698814||78349|
NCT01699126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|98-2167B|The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome|The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome||Chang Gung Memorial Hospital|Yes|Recruiting|May 2010|August 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|120|||Both|18 Years|N/A|No|||August 2012|October 16, 2012|August 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699126||78325|
NCT01699386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AH73|Growth of Infants Fed an Elemental Medical Food|Growth of Infants Fed an Elemental Medical Food||Abbott Nutrition|No|Completed|April 1999|December 2000|Actual|December 2000|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|N/A|9 Days|Accepts Healthy Volunteers|||October 2012|October 2, 2012|October 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01699386||78305|
NCT01699412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0712.1.146.000-08|Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease|Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients||Grupo de Estudos Multicentricos em Onco-Hematologia|No|Completed|August 2008|August 2012|Actual|July 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|12 Years|N/A|No|||September 2012|September 30, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01699412||78303|
NCT01695226|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUMC MEC 04-038|Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer|Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer||Maastricht University Medical Center|No|Completed|February 2004|||July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||||||Female|18 Years|74 Years|No|||September 2012|September 25, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695226||78623|
NCT01695681|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1943 (REK)|Screen-detected Coeliac Disease, a Population Based Study|Screen-detected Coeliac Disease. Prevalence and Impact on Gastrointestinal Symptoms and Quality of Life||University Hospital of North Norway|No|Active, not recruiting|October 2012|December 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|30 Years|87 Years|No|||January 2016|January 8, 2016|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695681||78588|
NCT01692717|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALHHYP0512OR-I|Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Lorsatana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A. In Healthy Subjects|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|February 2013|May 2013|Anticipated|May 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692717||78816|
NCT01695915|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DV-Rect-UL|Diurnal Variation in Rectal Diameter|Diurnal Variation in Rectal Diameter Measured by Transabdominal Ultrasound in Healthy and Constipated Children.||Vejle Hospital|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|30|||Both|4 Years|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|Constipated children are recruited from the outpatient clinic at Kolding pediatric        department. A list of patients which have been given the diagnose constipation are drawn        from the computer and reviewed. Children between 4-12 years who fulfill the Rome III        criteria of constipation and have been taking PEG maintenance treatment at least 1 month,        are contacted by telephone for possible participation in the study.        Healthy participants without constipation or other diseases affecting the gastrointestinal        tract were recruited among the employees of the Department of Pediatrics at Kolding        Hospital.        Written informed consent was obtained from both parents before any procedures were        initiated.|November 2012|November 15, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695915||78570|
NCT01696214|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARCTC-09|A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial|SAPS:Smoking Asthmatics Pilot Study:|SAPS|University of California, San Diego|Yes|Recruiting|October 2012|September 2016|Anticipated|September 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|50 Years|No|||June 2013|June 11, 2013|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696214||78547|
NCT01689077|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TTH48|Time-differentiated Therapeutic Hypothermia|Time-differentiated Treatment With Mild Therapeutic Hypothermia Following Cardiac Arrest, a Multi Center Study.|TTH48|University of Aarhus|No|Recruiting|January 2013|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|340|||Both|18 Years|80 Years|No|||September 2012|June 17, 2015|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689077||79096|
NCT01696760|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-10055|Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology|Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology||Ohio State University Comprehensive Cancer Center|Yes|Completed|October 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|12|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|September 27, 2012|Yes|Yes||No|June 4, 2014|https://clinicaltrials.gov/show/NCT01696760||78505|Overall patient compliance for the study was low
NCT01697358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1665|Spinal Cord Stimulation for Predominant Low Back Pain|Prospective, Randomized Study of Multicolumn Implantable Lead Stimulation for Predominant Low Back Pain|PROMISE|MedtronicNeuro|No|Active, not recruiting|January 2013|||April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01697358||78460|
NCT01697345|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MelissaDahir|Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy|Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy||Creighton University|No|Completed|February 2013|May 2013|Actual|April 2013|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Female|50 Years|N/A|No|||December 2013|December 18, 2013|September 26, 2012||No||No|August 15, 2013|https://clinicaltrials.gov/show/NCT01697345||78461|Limitations of this pilot study included the narrow time frame for enrollment, the exclusion of surgically menopausal women under the age of 50, and symptoms of recurrent Gardnerella vaginalis.
NCT01697670|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UC1001|Photodynamic Therapy for Ulcerative Colitis|A Multicenter, Open Phase II Study to Assess the Effect and Safety of "Low Dose" Photodynamic Therapy in Patients With Moderate to Severe Active Distal Ulcerative Colitis||University of Zurich|Yes|Recruiting|September 2012|December 2012|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|7|||Both|18 Years|N/A|No|||September 2012|November 2, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697670||78436|
NCT01697683|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-0005-A|Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy|Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy|ProVIP|Mount Sinai Hospital, Canada|Yes|Completed|May 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|86|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2014|March 20, 2014|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697683||78435|
NCT01697943|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-44-563|Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Quality of Life in Patients Undergoing Total Gastrectomy|A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Roux-En-Y Pouch Reconstruction and Conventional Roux-En-Y Reconstruction in Patients Undergoing Total Gastrectomy.|GCQOL02|Fudan University|No|Recruiting|May 2012|May 2017|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|20 Years|75 Years|No|||October 2012|October 15, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697943||78416|
NCT01698255|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P30MH085943-05|Psychotherapy for Late Life Depression|Psychotherapy for Late Life Depression|ENGAGE-II|Weill Medical College of Cornell University|Yes|Recruiting|March 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|60 Years|N/A|No|||December 2014|December 18, 2014|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01698255||78392|
NCT01698580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPPesq 0145/11|Multifactorial Falls Prevention Program - Brazil|Effectiveness of a Multifactorial Falls Prevention Program in Community-dwelling Older People When Compared to Usual Care: A Randomized, Controlled Trial||University of Sao Paulo|Yes|Recruiting|January 2013|December 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|612|||Both|60 Years|N/A|No|||September 2013|September 30, 2013|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01698580||78367|
NCT01698840|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-31433|Effect of Vitamin D in Diets of Preterm Infants|An Evaluation of the Effects of Two Levels of Vitamin D in Infants Fed Preterm or Transitional Formula on Serum 25-Hydroxyvitamin D and Bone Status in Preterm Infants: A Double-Blind, Randomized Controlled Trial||Baylor College of Medicine|No|Recruiting|January 2013|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|50|||Both|N/A|N/A|No|||January 2016|January 13, 2016|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01698840||78347|
NCT01699139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC101-2314-B-182A-111|The Effect of Positional Device on the Obstructive Sleep Apnea in Patients With Ischemic Stroke|The Effect of Positional Device on the Obstructive Sleep Apnea in Patients With Ischemic Stroke||Chang Gung Memorial Hospital|Yes|Completed|August 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|13|||Both|18 Years|N/A|No|||August 2012|February 9, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01699139||78324|
NCT01695239|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13731|A Study of Ixekizumab in Participants With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis|SPIRIT-P1|Eli Lilly and Company|Yes|Active, not recruiting|December 2012|August 2017|Anticipated|December 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|412|||Both|18 Years|N/A|No|||September 2015|September 3, 2015|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695239||78622|
NCT01695460|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20120052|A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine|A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine||Aalborg University|Yes|Completed|September 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|65 Years|No|||December 2015|December 28, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695460||78605|
NCT01695473|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC# 115516|Neoadjuvant BKM120 in High-risk Prostate Cancer|A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer||University of California, San Francisco|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Male|18 Years|85 Years|No|||October 2015|October 1, 2015|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695473||78604|
NCT01692730|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00040730|Web Assisted Tobacco Intervention With Community Colleges|Web Assisted Tobacco Intervention With Community Colleges|WATI|University of Rochester|Yes|Recruiting|October 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1440|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|February 17, 2016|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692730||78815|
NCT01695928|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESWT2|Effect of Shock Waves on Tooth Movement and Miniscrew Stability|Effect of Low-energy Extracorporeal Shock Waves on Orthodontic Tooth Movement and Miniscrew Stability||Medical University of Vienna|Yes|Completed|September 2012|January 2014|Actual|December 2013|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 9, 2015|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695928||78569|
NCT01695941|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01712|Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma|A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma||National Cancer Institute (NCI)|Yes|Recruiting|August 2012|||August 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||October 2015|December 31, 2015|September 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01695941||78568|
NCT01696227|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00279|Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children|Targeted Pathogen Replacement With Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children|Nissle 1917|Nationwide Children's Hospital|No|Completed|July 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|50|Samples Without DNA|Bacteria recovered from samples will be retained|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with urinary catheters that will be getting them removed|October 2014|October 13, 2014|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696227||78546|
NCT01696500|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPB-01-07/C-01|Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.||Nihon Pharmaceutical Co., Ltd|No|Completed|October 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|N/A|No|||October 2013|July 1, 2014|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01696500||78525|
NCT01697124|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-20952|The Children in Action Feasibility Study|The Children in Action Feasibility Study|CIA|Baylor College of Medicine|Yes|Completed|September 2007|August 2009|Actual|August 2009|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|274|||Both|3 Years|5 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01697124||78478|
NCT01697111|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15457|Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis|A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (β-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis||Bayer|No|Completed|October 2012|December 2014|Actual|March 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|312|||Female|20 Years|N/A|No|||January 2016|February 16, 2016|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697111||78479|
NCT01697709|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6623|Quetiapine Pharmacotherapy for Cannabis Dependence|Quetiapine Pharmacotherapy for Cannabis Dependence|QUEST|New York State Psychiatric Institute|Yes|Recruiting|October 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697709||78433|
NCT01697696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNVA237A2319|Long Term Safety Study of NVA237 vs QAB149 in COPD Patients|A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation||Novartis|No|Completed|October 2012|November 2014|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|511|||Both|40 Years|N/A|No|||February 2016|February 17, 2016|September 28, 2012|Yes|Yes||No|November 10, 2015|https://clinicaltrials.gov/show/NCT01697696||78434|
NCT01697956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BDP-AR-307|Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA)-Axis in Pediatric Subjects (6 to 11 Years of Age) With Perennial Allergic Rhinitis (PAR)||Teva Pharmaceutical Industries|No|Completed|October 2012|February 2013|Actual|February 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|99|||Both|6 Years|11 Years|No|||September 2015|September 10, 2015|September 28, 2012|Yes|Yes||No|July 27, 2015|https://clinicaltrials.gov/show/NCT01697956||78415|
NCT01697969|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M-12-047|Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients|Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%||Alcon Research|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|17|||Both|18 Years|N/A|No|||July 2014|July 30, 2014|September 27, 2012|Yes|Yes||No|July 30, 2014|https://clinicaltrials.gov/show/NCT01697969||78414|The lack of concurrent control made it difficult to discriminate changes caused by PATADAY® from that caused by other factors, such as observer or patient expectation. Open-labeled design increased the bias from the observer or patient expectation.
NCT01698593|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RS#2009-1356|Bupivacaine Digital Blocks: How Long is the Pain Relief and Temperature Elevation?|Bupivacaine Digital Blocks: How Long is the Pain Relief and Temperature Elevation?||Lalonde, Donald H., M.D.||Completed|July 2009|July 2010|Actual|July 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|1||Actual|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2012|October 2, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698593||78366|
NCT01698866|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-004968-30|Low Grade Lymphoma|Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment.|EVACC-B|Central Hospital, Nancy, France|Yes|Recruiting|July 2012|July 2015|Anticipated|July 2014|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|40|||Both|18 Years|N/A|No|||July 2012|October 1, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01698866||78345|
NCT01699152|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TG02-102|Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma||Tragara Pharmaceuticals, Inc.|No|Active, not recruiting|September 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||September 2015|September 10, 2015|October 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01699152||78323|
NCT01698853|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192837|Difference Between Central and Peripheral Arterial Blood Oxygen Saturation With Different CPB Strategy|The Difference Between Central and Peripheral Arterial Blood Oxygen Saturation in Patients Undergoing Cardiac Surgery With Different Cardiopulmonary Bypass Strategy||Xijing Hospital|No|Not yet recruiting|October 2012|May 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|patient undergoing totally thoracoscopic cardiac surgery with cardiopulmonary bypass|September 2012|September 29, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01698853||78346|
NCT01699165|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1202-2|Efficacy and Safety of Nasal Filters on Seasonal Allergic Rhinitis (Hay Fever)|Efficacy and Safety of Nasal Filters on Seasonal Allergic Rhinitis in a Double-blinded Randomized Placebo-controlled Crossover Pilot Study||University of Aarhus|Yes|Completed|December 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|24|||Both|18 Years|65 Years|No|||April 2013|April 18, 2013|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01699165||78322|
NCT01699178|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAR-12010|Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men|Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men||Clarus Therapeutics, Inc.|No|Active, not recruiting|August 2012|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|182|||Male|18 Years|75 Years|No|||December 2013|December 17, 2013|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699178||78321|
NCT01699425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJA201205|Multicentric Comparative Randomized Study of the Single-incision Sling Ajust® Versus Suburethral Transobturator Slings.|Multicentric Comparative Randomized Study of the Single-incision Sling Ajust® Versus Suburethral Transobturator Slings.||Hospital Universitari Vall d'Hebron Research Institute||Active, not recruiting|March 2013|March 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|140|||Female|18 Years|90 Years|No|||September 2015|September 21, 2015|September 22, 2012||||No||https://clinicaltrials.gov/show/NCT01699425||78302|
NCT01699438|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SMR-2268|Mesalazine Treatment in IBS (The MIBS Study)|Mesalazine Treatment in IBS, a Double-blind Placebo-controlled Phase II Intervention Study in Adult Patients|MIBS|Göteborg University|Yes|Recruiting|April 2012|December 2016|Anticipated|September 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01699438||78301|
NCT01699451|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004718|DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida|DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida||Mayo Clinic|No|Enrolling by invitation|September 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|This study will establish a repository of stored DNA, RNA, monocyte, lymphocyte and skin      fibroblast samples from people with ALS and ALS-FTD, subjects with a family history of ALS      who do not have ALS or ALS-FTD, and subjects with no personal history of ALS or dementia, to      support future translational and basic research studies on ALS and related neurodegenerative      disorders.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Eligible patients will be female or male, > or = 18 years of age. ALS and control subjects        will meet eligibility criteria. Control subjects will be similar in age to ALS patients.        No special classes of subjects are specifically sought or excluded from the protocol.|December 2015|December 31, 2015|September 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01699451||78300|
NCT01699464|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AR-12286-CS206|A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months|Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months||Aerie Pharmaceuticals|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|211|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699464||78299|
NCT01699477|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-04/2008|Safety Study Using Transcranial MR Guided Focused Ultrasound in the Treatment of Neuropathic Pain|MR-Guided Functional Ultrasound-Neurosurgery|FUS-CLT|University Children's Hospital, Zurich|Yes|Recruiting|August 2008|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|30|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01699477||78298|
NCT01695252|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN12CP071|Measuring and Monitoring Patient Informed Clinical Outcomes In Psychological Therapy Supervision|Measuring and Monitoring Patient Informed Clinical Outcomes In Psychological Therapy Supervision - A Stepped Wedge Cluster Randomised Controlled Trial|MEMOS|NHS Greater Glasgow and Clyde|No|Not yet recruiting|October 2012|September 2014|Anticipated|||N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment|2||Anticipated|470|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695252||78621|
NCT01696279|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPD405-207|A Comparison of Lanthanum Carbonate and Calcium Carbonate in Children|A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 Years to <18 Years With Chronic Kidney Disease on Dialysis||Shire|No|Recruiting|February 2013|June 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|10 Years|17 Years|No|||February 2016|February 1, 2016|September 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01696279||78542|
NCT01696292|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-04-3435-JL-CTIL|Evaluation of Mental Flexibility Through Language Tests in Adolescents With Frontal Brain Damage and in Healthy Children in Ages 8-17|||Sheba Medical Center|No|Completed|August 2004|March 2010|Actual|March 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|20|||Both|8 Years|17 Years|No|Non-Probability Sample|A group of children ages 8-17 with frontal lobe damage, who are treated at the children        rehabilitation center at sheba medical center|September 2012|September 28, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696292||78541|
NCT01696240|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1202-005-396|A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]|Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]||Seoul National University Hospital|Yes|Recruiting|September 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||February 2013|February 22, 2013|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696240||78545|
NCT01696513|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU66710|Effect of Subcision and Suction on Acne Scars|Pilot Split Face Randomized, Evaluator Blinded Study on the Effect of Subcision and Suctioning With a Microdermabrasion Device on Rolling Acne Scars||Northwestern University|No|Active, not recruiting|September 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 11, 2016|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01696513||78524|
NCT01696253|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1206M15384|Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study|Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study||University of Minnesota - Clinical and Translational Science Institute|No|Active, not recruiting|September 2012|August 2014|Anticipated|August 2014|Anticipated|N/A|Observational|Observational Model: Case-Only||2|Anticipated|360|Samples Without DNA|First morning clean catch urine sample.|Both|1 Year|N/A|No|Probability Sample|A family is eligible for this multi-center feasibility study if a firm diagnosis of AS in        a family member has been made by skin biopsy, kidney biopsy, or molecular genetic        analysis.        In order to enhance identification of subjects with early stage AS (normalbuminuria or MA)        and subjects with untreated proteinuria, investigators at each recruitment site will        contact all known AS families in their databases, seeking at-risk children whose disease        status is unknown. The family populations to be queried at each site are estimated in the        table below:|June 2014|June 19, 2014|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01696253||78544|
NCT01696773|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012H0189|Carotenoid and Flavonoid Absorption From Red and Tangerine-Type Tomatoes|Enhancing Bioavailability and Nutritional Quality of Processed Tomato Products||Ohio State University|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|12|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||July 2015|July 6, 2015|September 27, 2012||No||No|October 14, 2014|https://clinicaltrials.gov/show/NCT01696773||78504|
NCT01696786|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0903010292|Oocyte Cryopreservation|Oocyte Cryopreservation||Weill Medical College of Cornell University||Active, not recruiting|June 2009|October 2017|Anticipated|October 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|250|||Female|N/A|42 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696786||78503|
NCT01696799|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|079-2951-109|Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years|A Multi-Center, Randomized Comparative Study of the Pharmacokinetics of Econazole Nitrate 1% Foam and Econazole Nitrate 1% Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years||AmDerma|No|Completed|September 2011|August 2012|Actual|April 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|42|||Both|12 Years|18 Years|No|||September 2012|September 28, 2012|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696799||78502|
NCT01696812|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DELAS-201209|Web-based International Multi-Center Clinical Study for Parkinson's Disease|Web-based International Multi-Center Clinical Study for Parkinson's Disease; the Evaluation of Clinical Outcome Based on the Electrode Position Estimated From the Fused Images of Preoperative MRI and Postoperative CT After Bilateral STN DBS||Seoul National University Hospital|Yes|Not yet recruiting|November 2014|December 2020|Anticipated|December 2016|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Anticipated|136|||Both|20 Years|70 Years|No|||November 2014|November 25, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01696812||78501|
NCT01689363|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|API-H001-CLN-A2|Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)|A Randomized, Double-Blinded, Negative- and Positive-Controlled Study for Evaluation of the Allergenicity of Amphadase® in Healthy Volunteers Using Intradermal Skin Test|H001-A2|Amphastar Pharmaceuticals, Inc.|Yes|Completed|September 2012|December 2012|Actual|November 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening|1||Actual|263|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2013|February 22, 2013|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689363||79074|
NCT01689376|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16040|Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)|Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)||Bayer||No longer available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|99 Years||||February 2016|February 4, 2016|July 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689376||79073|
NCT01697384|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|301|Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer|Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer||Endo Pharmaceuticals|No|Completed|April 2000|October 2004|Actual|August 2003|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|138|||Male|45 Years|N/A|No|||September 2012|September 27, 2012|July 13, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697384||78458|
NCT01697371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5120022|Proton Therapy in the Treatment of Liver Metastases|Phase I-II Trial of Stereotactic Body Proton Therapy for Patients With Liver Metastases||Loma Linda University|Yes|Recruiting|September 2012|September 2020|Anticipated|September 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|35|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01697371||78459|
NCT01697982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00033340|Pilot Study of Living With Hope Program|Living With Hope: Pilot Study of Patient-Centered Hope Intervention for Persons Receiving Palliative Care Services||University of Alberta|No|Completed|September 2012|July 2014|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|19|||Both|18 Years|N/A|No|||December 2014|December 2, 2014|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01697982||78413|
NCT01698268|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-213|Study of Transverse Abdominis Plane (TAP) Block in Children Undergoing Hydrocelectomy and/or Hernia Repair Surgery|The Efficacy of Transverse Abdominis Plane (TAP) Block in Children Undergoing Hydrocelectomy and/or Hernia Repair|TAP|William Beaumont Hospitals|Yes|Completed|February 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|2 Years|8 Years|No|||June 2015|June 2, 2015|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01698268||78391|
NCT01698281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AEZS-108-049|Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer|A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.||AEterna Zentaris|No|Terminated|December 2012|October 2014|Anticipated|August 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|7|||Female|18 Years|N/A|No|||May 2013|January 14, 2014|September 21, 2012|No|Yes|Poor recruitment|No||https://clinicaltrials.gov/show/NCT01698281||78390|
NCT01698294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I 216812|Biomarkers in Post-Menopausal Women Receiving Flaxseed|A Pilot Study of the Flaxseed Effects on Hormones and Lignans: Role of Race, Genes, and Gut Microbiome||Roswell Park Cancer Institute|Yes|Recruiting|December 2012|||July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|250|||Female|45 Years|75 Years|Accepts Healthy Volunteers|||December 2015|December 8, 2015|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01698294||78389|
NCT01698606|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|103011|FOR HEALTH: A Family-oriented Healthy Eating, Activity and Lifestyle Intervention for Overweight Preschool Children|FOR HEALTH: A Family-ORiented Healthy Eating, Activity and Lifestyle Training With Hands-on Experience for Overweight and Obese Preschool Children and Their Families - a Pilot Trial.|FOR HEALTH|Lawson Health Research Institute|No|Recruiting|January 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|28|||Both|2 Years|6 Years|No|||May 2015|May 29, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698606||78365|
NCT01698879|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICOG-07|Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment|Treatment of de Novo Acute Myeloid Leukemia With the Combination of Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin (Mylotarg ®), Associated or Not Priming With G-CSF. Prospective Study of Efficacy and Toxicity||Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias|No|Active, not recruiting|October 2009|February 2013|Anticipated|December 2012|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|70 Years|No|||October 2012|October 1, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01698879||78344|
NCT01698892|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12_0208|Comparison of Respiratory Tolerance to I.V. Versus Sublingual Sedation During Bronchoscopy. (TORSIV)|Comparison of Respiratory Tolerance to I.V. Versus Sublingual Sedation During Bronchoscopy.|TORSIV|Nantes University Hospital|Yes|Completed|October 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|85|||Both|18 Years|80 Years|No|||June 2015|June 5, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698892||78343|
NCT01699191|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProCeDo|Probiotics for the Treatment of Irritable Bowel Syndrome in Celiac Patients||ProCel|University of Bari|No|Not yet recruiting|October 2012|January 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|No|||October 2012|October 2, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699191||78320|
NCT01695486|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-4778-BO|Sedation Monitoring During Open Muscle Biopsy in Children|||University Hospital, Essen|No|Completed|October 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|30|||Both|12 Months|18 Years|No|Non-Probability Sample|children aged 1-18 years undergoing open muscle biopsy as diagnostic procedure|September 2014|September 15, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695486||78603|
NCT01695720|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VisionScope VSI-001|Clinical Efficacy Study Comparing VisionScope Imaging (VSI) to Magnetic Resonance Imaging (MRI) in Injuries of the Knee|Trial Comparing VisionScope Imaging (VSI) With Magnetic Resonance Imaging (MRI) in the Diagnosis of Suggestive Clinical Symptoms for Meniscus and Articular Cartilage Injuries in the Knee|VSI-001|VisionScope Technologies|No|Completed|June 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|105|||Both|18 Years|75 Years|No|||May 2013|May 29, 2013|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695720||78585|
NCT01695993|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCCS1202|Alternative Approaches for Nausea Control|Alternative Approaches for Nausea Control||University of Rochester|Yes|Recruiting|November 2012|May 2017|Anticipated|February 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|3||Anticipated|252|||Female|18 Years|N/A|No|||December 2015|December 4, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695993||78564|
NCT01696006|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMCCV 2012-04|Perfusion CT Registry||Perfusion CT|Asan Medical Center||Recruiting|September 2012|December 2019|Anticipated|September 2018|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|20 Years|N/A|No|Non-Probability Sample|General hospital|January 2016|January 3, 2016|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696006||78563|
NCT01688817|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMKP-2008|The Magnitude of Effect of PCP Counseling on Participation Rate and Sedation Rate in Colonoscopy-based Screening Program|The Magnitude of Effect of Physician's Counseling on Participation Rate and Utilization of Sedation in Colonoscopy-based Colorectal Cancer Screening Program||Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology|No|Completed|May 2008|May 2010|Actual|December 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|600|||Both|50 Years|65 Years|No|||September 2012|September 24, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688817||79116|
NCT01688830|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1321.1|Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate|Randomised, Double-blind, Placebo-controlled Phase I Study in Healthy Male Volunteers. to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 655075 (Part 1) and to Explore the Dose of BI 655075 Effective to Reverse Dabigatran Anticoagulant Activity (Part 2)||Boehringer Ingelheim||Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|3||Actual|145|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||January 2016|January 15, 2016|September 17, 2012||||No|November 13, 2015|https://clinicaltrials.gov/show/NCT01688830||79115|There is only one group of subjects in study part 3 receiving active treatment. However, AE table displays the AEs occurring in different phases separately.
NCT01688505|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BPV-Hallym|Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function|Multicenter Retrospective Study of Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function|BPV-COG|Hallym University Medical Center|No|Recruiting|May 2012|February 2013|Anticipated|February 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|140|||Both|60 Years|80 Years|No|Non-Probability Sample|Outpatients of stroke clinic in secondary or tertiary hospitals|September 2012|September 19, 2012|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01688505||79140|
NCT01688518|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCR-07-01-101|Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers|Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers||CRI Lifetree|Yes|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||January 2013|January 2, 2013|September 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01688518||79139|
NCT01695967|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 3 03Mar2012|Turbinate Cauterization in Pediatric Patients With Nasal Obstruction|Turbinate Cauterization in Pediatric Patients With Nasal Obstruction A Randomized Prospective Trial||Eastern Virginia Medical School|No|Recruiting|August 2012|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|110|||Both|3 Years|16 Years|No|||August 2015|August 11, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695967||78566|
NCT01695980|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|version 4 25Jun2012|Laryngeal Mask Airway in Pediatric Adenotonsillectomy|Laryngeal Mask Airway in Pediatric Adenotonsillectomy|LMA|Eastern Virginia Medical School|No|Recruiting|August 2012|June 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|2 Years|16 Years|No|||August 2015|August 11, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695980||78565|
NCT01696266|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INS-4019|An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes|An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes||Novo Nordisk A/S|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Actual|29304|||Both|18 Years|N/A|No|Non-Probability Sample|Insulin-treated patients with Type 1 or Type 2 diabetes mellitus. Patients should be        ambulatory, literate, have used insulin for at least 12 months, and be over 18 years of        age to be able to participate in the study.|January 2015|January 9, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696266||78543|
NCT01697761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHACU-201202|Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease|Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease and Its Regulation Mechanism to the Immune Homeostasis Mediated by Th17/Treg Cells||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Completed|September 2012|November 2014|Actual|August 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|92|||Both|18 Years|70 Years|No|||September 2012|November 19, 2014|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697761||78430|
NCT01697774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAZ-012-0001RG|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2012|||||N/A|N/A|N/A||||||||||||||May 14, 2014|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697774||78429|
NCT01697137|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6 R39OT22056-01-01|Patient and Physician Intervention to Increase Organ Donation|Patient and Physician Intervention to Increase Organ Donation in Primary Care Settings|DECIDE|Case Western Reserve University|No|Completed|September 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|916|||Both|15 Years|78 Years|Accepts Healthy Volunteers|||February 2015|February 19, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697137||78477|
NCT01697397|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLP-2012-001|Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol|A Feasibility Study For Monitoring And Recording Gastrointestinal Myoelectric Activity In Subjects With Suspected Or Diagnosed Irritable Bowel Syndrome (Lbs) And Reports Of GI Pain And Asymptomatic Subjects Without Lbs And GI Pain||G-Tech Corporation|No|Completed|July 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|88|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Irritable bowel syndrome, functional bowel disorder.|August 2015|August 11, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697397||78457|
NCT01697410|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012A080204018;2007015|Continuos Terlipressin Infusion in Septic Shock|A Multicenter,Prospective,Randomized,Controlled,Double Blind Study in China to Evaluate the Effect of Terlipressin in Patients With Septic Shock||First Affiliated Hospital, Sun Yat-Sen University|Yes|Recruiting|January 2013|January 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1000|||Both|16 Years|N/A|No|||December 2014|December 25, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697410||78456|
NCT01697735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WZ medical college|The Therapeutic Effects of Statins and Berberine on the Hyperlipemia|The Therapeutic Effects of Combination of Statins With Berberine on the Patients With Hyperlipemia:a Single-center, Open Clinical Trial||Wenzhou Medical University|No|Terminated|September 2012|June 2015|Anticipated|June 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|24|||Both|20 Years|75 Years|No|||December 2014|December 24, 2014|September 28, 2012|Yes|Yes|Because of lack of participants and funds|No||https://clinicaltrials.gov/show/NCT01697735||78431|
NCT01697722|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BA21|Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy|A Retrospective Evaluation of Effectiveness and Cost-effectiveness of Extrafine HFA-BDP Compared With Combination ICS/LABA Therapy in the Management of Asthma in a Representative Population of UK Primary Care Patients|QvarvsCombo|Research in Real-Life Ltd|Yes|Completed|January 1991|February 2010|Actual|June 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||3|Actual|815377|||Both|5 Years|80 Years|No|Non-Probability Sample|Primary care asthma patients who were receiving ICS therapy (any of BDP, extrafine        BDP-HFA, BUD or FP as pMDI or BAI) who, at an index prescription date, underwent either:        (i) an increase in ICS as extrafine HFA-BDP (pMDI or BAI); (ii) a change to combination        therapy with a separate LABA pMDI or BAI (no change in drug, device or daily        BDP-equivalent dose) (iii) a change to combination therapy via a fixed-combination inhaler        (with no increase in daily BDP-equivalent dose).|October 2012|October 3, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697722||78432|
NCT01697995|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGA-11J08|Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI|Diagnostic and Prognostic Value of the Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI in Patients With Known or Suspected Coronary Artery Disease (CAD).|RVuptakeLexi|University of Arizona|No|Enrolling by invitation|January 2013|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Case Control||2|Anticipated|650|||Both|18 Years|89 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Retrospective population (approximately 300 charts to be reviewed)               -  Patients with MPI and 2D Echocardiogram within one month of the stress testing                  in calendar year 2010 at University Medical Center, Tucson AZ.               -  18 years or older          2. Prospective population (approximately 350 subjects to be recruited)               -  Patients scheduled for MPI at University Medical Center, Tucson AZ, and invited                  to participate in this study.               -  18 years to 89 years old|November 2015|November 3, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01697995||78412|
NCT01698619|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AconcaguaIron|Hemodynamic Changes in Altitude Adaptation|Hemodynamic Changes in Altitude Adaptation||Goethe University|No|Recruiting|August 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|12|||Both|20 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|healthy volunteers taking part in an expedition to Mount Aconcagua|September 2012|October 2, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01698619||78364|
NCT01698905|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107A2408|Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)|A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib|ENESTop|Novartis|No|Active, not recruiting|December 2012|January 2019|Anticipated|January 2019|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|164|||Both|N/A|N/A|No|||December 2015|December 20, 2015|October 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01698905||78342|
NCT01699204|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H08-02288|Diesel Exhaust and Mechanism of Asthma|Effects of Diesel Exhaust on Airways||University of British Columbia|No|Completed|September 2007|October 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|26|||Both|19 Years|49 Years|Accepts Healthy Volunteers|||October 2012|October 1, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699204||78319|
NCT01699490|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSC 101-2314-B-006 -064 -MY3|Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder|Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder||National Cheng-Kung University Hospital|Yes|Recruiting|August 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|65 Years|No|||September 2014|September 26, 2014|September 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01699490||78297|
NCT01695265|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AC26392COPD|Feel Breathe, Restriction Device Ventilatory Nasal (COPD)|Feel Breathe, Restriction Device Ventilatory Nasal (COPD)|BreatheCOPD|University of Cadiz|No|Active, not recruiting|February 2012|||June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Anticipated|15|||Both|40 Years|70 Years|No|||May 2013|May 15, 2013|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695265||78620|
NCT01695291|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|6574|Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD|A Randomized, Placebo-controlled Trial of Minocycline Added to Serotonin Reuptake Inhibitors in Pediatric OCD: Examining the Effects on Clinical Symptoms and on Brain Glutamate Levels Using MRS Imaging||New York State Psychiatric Institute|Yes|Recruiting|May 2012|February 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|45|||Both|8 Years|20 Years|No|||March 2015|August 31, 2015|September 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01695291||78618|
NCT01695759|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EPOBLA1011|Evaluation Of Clinical Efficacy And Immunogenicity Of Eritromax® Produced By Lab Blau Pharmaceutical S / A. Compared To The Product Eprex®, Produced By The Laboratory Janssen-Cilag, In Patients With Anemia Secondary To Chronic Kidney Disease|||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.||Not yet recruiting|March 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|210|||Both|18 Years|60 Years|No|||September 2012|September 27, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695759||78582|
NCT01696032|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SGI-110-02|SGI-110 in Combination With Carboplatin in Ovarian Cancer|A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer|SGI-110|Astex Pharmaceuticals|No|Active, not recruiting|September 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|116|||Female|18 Years|N/A|No|||December 2015|December 28, 2015|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696032||78561|
NCT01696838|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHACU-201201|Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With fMRI|Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With Functional Magnetic Resonance Imaging(fMRI)||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Completed|September 2012|November 2014|Actual|April 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|November 19, 2014|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696838||78499|
NCT01697449|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML21889|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)|||Hoffmann-La Roche||Completed|March 2009|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|191|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic colorectal cancer initiated on Avastin in combination with        chemotherapy|September 2015|September 15, 2015|September 28, 2012||No||No|September 15, 2015|https://clinicaltrials.gov/show/NCT01697449||78453|
NCT01688557|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Innovations in colonoscopy|Trial on Innovative Technologies in Colonoscopy|Prospective Randomised Trial Comparing New Technologies of Endoscopic Bowel Visualisation With Conventional Colonoscopy.|RCT-IC|Jagiellonian University|No|Recruiting|September 2012|December 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|600|||Both|40 Years|65 Years|No|||September 2012|September 19, 2012|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01688557||79136|
NCT01696539|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Spartacus01|Steps for PRosTAte Cancer Health and Survival (SPaRTACuS): Pilot Study of a Walking Intervention to Improve Health and Quality of Life in Prostate Cancer Patients|Pilot Intervention Study of the Impact of Sustainable Daily Physical Activity on Health and Quality of Life in a Cohort of Men With Prostate Cancer in Sweden: Steps for PRosTAte Cancer Health and Survival (SPaRTACuS)||Örebro University, Sweden|Yes|Completed|March 2010|May 2010|Actual|May 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|42|||Male|40 Years|80 Years|No|||September 2012|September 27, 2012|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01696539||78522|
NCT01698047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCF-12-001142|Building Resiliency and Increasing Community Hope|Building Resiliency and Increasing Community Hope|BRICH|University of California, Los Angeles|Yes|Completed|October 2012|June 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|168|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 3, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01698047||78408|
NCT01699243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0990|Continuous Noninvasive Method for Estimating and Predicting Maternal and Fetal Hemodynamic Changes During Regional Anesthesia|A Continuous, Noninvasive Method for Estimating and Predicting Maternal and Fetal Hemodynamic Changes During Regional Anesthesia||University of Colorado, Denver|No|Active, not recruiting|September 2012|December 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|14 Years|44 Years|No|Non-Probability Sample|All pregnant females undergoing regional anesthesia for labor or fetal intervention at the        University of Colorado Hospital and Children's Hospital Colorado.|December 2015|December 3, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699243||78316|
NCT01696357|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5RO1NR11169|Automated Device for Asthma Monitoring|Developing an Automated Symptom Monitoring Device for Adolescents With Asthma|ADAM|University of Rochester|Yes|Completed|September 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|84|||Both|13 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Adolescents between the ages of 13-17 who received care at Strong Memorial Hospital,        Rochester NY.|December 2014|December 8, 2014|September 18, 2012||No||No|December 2, 2014|https://clinicaltrials.gov/show/NCT01696357||78536|
NCT01698021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Projet 12-081|Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome|Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome|QUANTUM|Université de Sherbrooke|No|Recruiting|June 2013|November 2013|Anticipated|November 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|18 Years|N/A|No|Probability Sample|All consecutive patients presenting to the emergency department or being hospitalized for        any reason in which we suspect an acute coronary syndrome.|September 2012|June 25, 2013|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01698021||78410|
NCT01698333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|122-0551-202|Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression|An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment||Therapeutics, Inc.|No|Completed|March 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|18 Years|N/A|No|||November 2013|November 25, 2013|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01698333||78386|
NCT01698632|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USF IRB Pro00009001|International Ovarian Tumour Analysis (IOTA) Phase 5|A Multicentre Study to Examine the Short and Long Term Outcomes of the Conservative Management of Benign-looking Adnexal Masses and the Pre-operative Characterisation of Ovarian Tumours|IOTA-5|University of South Florida|No|Enrolling by invitation|September 2012|September 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|N/A|No|Non-Probability Sample|Women being seen at the University of South Florida South Tampa Center|March 2015|March 11, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01698632||78363|
NCT01698008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|396-12-FB|Effect of Mobile Phone Telemedicine on Diabetes Care|Effect of Mobile Phone Telemedicine on Diabetes Care||University of Nebraska|Yes|Not yet recruiting|December 2012|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|19 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01698008||78411|
NCT01698307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RP1202|Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy|A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease|REACT2|University of Western Ontario, Canada|No|Enrolling by invitation|March 2014|September 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|1200|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01698307||78388|
NCT01698320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ABS-AS-307|Safety Study of Albuterol Spiromax® in Subjects With Asthma|A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma||Teva Pharmaceutical Industries|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|364|||Both|12 Years|N/A|No|||August 2015|August 12, 2015|September 14, 2012|Yes|Yes||No|July 13, 2015|https://clinicaltrials.gov/show/NCT01698320||78387|
NCT01696552|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/7613|Patient-specific Positioning Guides (PSPG) Technique Versus Conventional Technique in Total Knee Arthroplasty|Patient-specific Positioning Guides (PSPG) Technique Versus Conventional Technique in Total Knee Arthroplasty - a Prospective Randomized Study.||Oslo University Hospital|No|Recruiting|September 2011|May 2020|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2012|September 27, 2012|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01696552||78521|
NCT01697423|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-003565-18|Comparative Assessment of Intra-articular Knee Injections of Platelet-rich Plasma (PRP) and Hyaluronic Acid in the Treatment of Knee Osteoarthritis|Comparative Assessment of Intra-articular Knee Injections of Platelet-rich Plasma (PRP) and Hyaluronic Acid in the Treatment of Knee Osteoarthritis||Assistance Publique Hopitaux De Marseille|Yes|Recruiting|October 2012|December 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|75 Years|No|||November 2015|November 9, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697423||78455|
NCT01697436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28307|A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets|A Bioequivalence Study of Ribavirin Oral Solution (RO0209963) Versus the Reference Ribavirin Tablets (Copegus) Following Oral Administration in Healthy Adult Subjects||Hoffmann-La Roche||Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Masking: Open Label|4||Actual|40|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697436||78454|
NCT01698931|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AGEE-1259|Efficacy of Repaglinide in Subjects With Type 2 Diabetes|Efficacy of Repaglinide Compared to Glyburide and Placebo on Hepatic Glucose Metabolism in Type 2 Diabetic Subjects Treated With Diet or With Antidiabetic Oral Agents. A Randomized, Open, Cross-over Single-centre Placebo-controlled Trial||Novo Nordisk A/S|No|Completed|April 2002|March 2003|Actual|March 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|9|||Both|40 Years|75 Years|No|||October 2012|October 1, 2012|October 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01698931||78340|
NCT01698944|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GHDADULT-1112|Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency|Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency||Novo Nordisk A/S|No|Terminated|May 2001|November 2002|Actual|November 2002|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|12 Years|25 Years|No|||October 2012|October 3, 2012|October 1, 2012|Yes|Yes|The trial was prematurely terminated due to low recruitment|No||https://clinicaltrials.gov/show/NCT01698944||78339|
NCT01695772|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28419|A Study of Avastin (Bevacizumab) in Combination With 5-FU Based Doublet Chemotherapy in Patients With Colorectal Cancer And Previously Untreated Unresectable Liver-Only Metastases|A Multi-center, Single-arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer||Hoffmann-La Roche||Active, not recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|75 Years|No|||March 2016|March 1, 2016|September 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01695772||78581|
NCT01696318|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1134-6977|Program for Cardiovascular Prevention and Randomized Clinical Trial|Management Models for Cardiovascular Risk Reduction in Primary for Brazil: Developing a Program for Cardiovascular Prevention and Randomized Clinical Trial||Federal University of Rio Grande do Sul|Yes|Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|256|||Both|40 Years|N/A|No|||January 2016|January 14, 2016|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01696318||78539|
NCT01696565|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PH-CP002-2|PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy|PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy||PhytoHealth Corporation|No|Completed|December 2001|October 2003|Actual|October 2003|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|32|||Both|20 Years|75 Years|No|||September 2012|September 27, 2012|March 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01696565||78520|
NCT01697462|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML22585|An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)|Evaluation of Safety and Efficacy of Xeloda in Metastatic Colorectal Carcinoma||Hoffmann-La Roche||Completed|July 2009|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|258|||Both|18 Years|N/A|No|Probability Sample|Patients with metastatic colorectal cancer|November 2015|December 16, 2015|September 28, 2012||No||No|December 16, 2015|https://clinicaltrials.gov/show/NCT01697462||78452|
NCT01698359|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RRK4571|Evaluation of Ultrasound Probe for Use in Bladder Radiotherapy|Evaluation of Ultrasound Probe for Use in Adaptive Bladder Radiotherapy||University Hospital Birmingham NHS Foundation Trust|No|Not yet recruiting|November 2012|October 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|5|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers from within the staff of the Radiotherapy, Medical Physics and Oncology        departments at the Queen Elizabeth Hospital|September 2012|September 28, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01698359||78384|
NCT01689155|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTA57|Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children|Post-licensure Safety Surveillance Study of Menactra® Vaccine When Administered As a 2-dose Schedule to Children 9 Months Through 23 Months of Age.||Sanofi|No|Enrolling by invitation|August 2012|April 2016|Anticipated|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|122|||Both|9 Months|23 Months|Accepts Healthy Volunteers|Non-Probability Sample|Participants at age 9 to 23 months at the time of receipt of the first dose of Menactra        vaccine according to routine clinical practice during the study period.|July 2015|July 14, 2015|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689155||79090|
NCT01689168|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ROSE004|Chiropractic Treatment With Counseling Versus Counseling Alone for Promoting Smoking Cessation|Chiropractic Treatment With Counseling Versus Counseling Alone for Promoting Smoking Cessation: A Randomized Clinical Trial||Southern California University of Health Sciences|Yes|Terminated|March 2012|May 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|19|||Both|18 Years|N/A|Accepts Healthy Volunteers|||May 2015|May 18, 2015|June 5, 2012||No|Funding ran out|No||https://clinicaltrials.gov/show/NCT01689168||79089|
NCT01698957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UA Doppler 2012|Maternal Uterine Artery Doppler Study|A Simple Technique to Modify Maternal Uterine Artery Perfusion.||Mednax Center for Research, Education and Quality|No|Recruiting|September 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women greater than or equal to 18 weeks gestation and 18 years old eligible for        an ultrasound without fetal or uterine anomalies|April 2015|April 27, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698957||78338|
NCT01698970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NU098|Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease|Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease||Danone Research|No|Completed|February 2004|March 2010|Actual|March 2007|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind|2||Actual|122|||Both|18 Years|N/A|No|||October 2012|October 2, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698970||78337|
NCT01689610|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IOM-02240|Non-interventional Study With Nab-Paclitaxel (Abraxane®)|Nabucco - Non-Interventional Study to Investigate Efficacy and Safety of Nab-Paclitaxel in Patients With Metastatic Breast Cancer|Nabucco|iOMEDICO AG|No|Active, not recruiting|April 2012|April 2016|Anticipated|March 2016|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|700|||Female|18 Years|N/A|No|Non-Probability Sample|Adult female patients with metastatic breast cancer|March 2016|March 11, 2016|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01689610||79055|
NCT01688206|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BP28179|A Study of RO5520985 in Patients With Locally Advanced or Metastatic Solid Tumors|An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors.||Hoffmann-La Roche||Recruiting|October 2012|September 2019|Anticipated|September 2019|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|117|||Both|18 Years|N/A|No|||February 2016|February 1, 2016|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01688206||79163|
NCT01688219|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|45896566645469|Immune Response in the SAPHO Syndrome|Immune Mechanisms During SAPHO Syndrome and Treatment by Etarnecept||Assistance Publique - Hôpitaux de Paris||Completed|November 2005|May 2008|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|39|||Both|1 Year|70 Years|Accepts Healthy Volunteers|Probability Sample|SAPHO syndrome patients|October 2007|September 18, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688219||79162|
NCT01696370|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/0216|Trimetazidine Therapy in Hypertrophic Cardiomyopathy|A Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic Cardiomyopathy||University College, London|Yes|Recruiting|April 2012|April 2014|Anticipated|April 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|N/A|No|||August 2011|February 27, 2013|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696370||78535|
NCT01696578|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCTF5S2P4D1|Effectiveness of Combined Intervention Approaches in the Treatment of Affective Disorders and Chronic Pain in War Victims|Effectiveness of Combined Intervention Approaches in the Treatment of Affective Disorders and Chronic Pain in Victims of Torture and Massive Violence in Kosovo: A Randomized Controlled Trial||Rehabilitation and Research Centre for Torture Victims|Yes|Completed|January 2012|April 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|No|||April 2014|April 23, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01696578||78519|
NCT01698918|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001Y24135|Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer|An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer|Bolero-4|Novartis|No|Active, not recruiting|March 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|202|||Female|18 Years|N/A|No|||April 2015|April 22, 2015|October 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01698918||78341|
NCT01699217|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CML0912|Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase|Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.|CML0912|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|June 2013|November 2019|Anticipated|November 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|No|Non-Probability Sample|Treatment decision is at the discretion of the investigator and must not be made on the        basis of this observational study. Patients should have their treatment initiated in        accordance with the summary of product characteristics.|February 2015|February 22, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699217||78318|
NCT01699503|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AG040220-01A1|Indiana University Dementia Screening Trial|Indiana University Dementia Screening Trial: The IU CHOICE Study|IU-CHOICE|Indiana University|Yes|Recruiting|October 2012|July 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|4000|||Both|65 Years|N/A|No|||August 2015|August 27, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01699503||78296|
NCT01695733|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201010722|Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy|Influenza Vaccination Response in Patients With Non-Hematological Malignancies||Washington University School of Medicine|No|Terminated|September 2011|September 2013|Actual|September 2013|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|21|||Both|18 Years|N/A|No|||December 2014|December 4, 2014|September 26, 2012|No|Yes|no longer had funding to continue|No||https://clinicaltrials.gov/show/NCT01695733||78584|
NCT01695746|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25476|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia|Efficacy of C.E.R.A. for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV , Not on Dialysis , Treated According to Routine Clinical Practice||Hoffmann-La Roche||Completed|August 2011|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|108|||Both|18 Years|65 Years|No|Probability Sample|Patients with stage III-IV chronic kidney disease not on dialysis receiving treatment with        Mircera for chronic renal anemia|November 2015|November 2, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695746||78583|
NCT01697150|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JDRF 22-2011-649 SB|Outpatient Control-to-Range: System and Monitoring Testing|Systems Approach to Closed-Loop Control of Type 1 Diabetes at Home||William Sansum Diabetes Center|No|Active, not recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|21 Years|65 Years|No|||July 2013|July 22, 2013|April 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697150||78476|
NCT01698034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-00943|Volunteering and Cardiovascular Risk in Adolescents|How Volunteer Programs Affect Health and Well-being in Low-income Youth||University of British Columbia|No|Completed|September 2011|January 2012|Actual|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|106|||Both|N/A|N/A|Accepts Healthy Volunteers|||October 2012|October 2, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01698034||78409|
NCT01698645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP070/12|Patient Satisfaction and Quality of Life Impact - PecFent®|A Spanish , Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)|Qualipec|Archimedes Development Ltd|No|Recruiting|September 2012|||December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients with breakthrough pain|July 2013|July 10, 2013|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698645||78362|
NCT01698658|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-201|Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer|Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner||Barbara Ann Karmanos Cancer Institute|Yes|Recruiting|October 2012|||April 2017|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|100|||Female|18 Years|89 Years|No|||February 2016|February 11, 2016|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01698658||78361|
NCT01699516|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB33982|Non-invasive Contrast Enhanced Ultrasound Sonography in Intestinal Acute Graft-vs-Host Disease|A Prospective Study on Qualitative and Quantitative Non-invasive Evaluation of Intestinal Acute Graft-vs-host Disease by Contrast Enhanced Ultrasound Sonography||University of Pisa|No|Recruiting|January 2008|||May 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|32|||Both|22 Years|66 Years|Accepts Healthy Volunteers|Probability Sample|In the setting of allogenic transplant: intestinal acute graft vs host disease (GVHD),        stomach GVHD, neutropenic enterocolitis.|October 2012|October 1, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699516||78295|
NCT01696331|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|25318|Text Messaging for Adherence in Adolescent Liver Transplant Recipients|Impact of Text Messaging on Adherence in Adolescent Liver Transplant Patients||Stanford University|No|Active, not recruiting|September 2012|December 2016|Anticipated|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|42|||Both|12 Years|25 Years|No|||November 2015|November 24, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696331||78538|
NCT01697163|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSIRES0067|De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors|Pilot Study to Identify the Mechanism of De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) in NSCLC With EGFR Mutation.||Severance Hospital|No|Not yet recruiting|October 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|155|Samples With DNA|DNA extracted from FFPE tissue sample|Both|20 Years|80 Years|No|Probability Sample|NSCLC patient with EGFR mutation|September 2012|September 26, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01697163||78475|
NCT01698671|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCV00010173|InterGard Synergy Post-Marketing Surveillance Study|InterGard Synergy Post-Marketing Surveillance Study||Maquet Cardiovascular|No|Active, not recruiting|October 2012|May 2014|Anticipated|October 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|50|||Both|N/A|N/A|No|||November 2013|November 24, 2013|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698671||78360|
NCT01695317|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-001624-36|Effect of Acetyl-L-carnitine in Migraine|Effect of Acetyl-L-carnitine in Migraine - a Randomized, Double-blind Placebo Controlled Study|ALCAR|Norwegian University of Science and Technology|Yes|Completed|April 2013|September 2014|Actual|July 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|72|||Both|18 Years|65 Years|No|||January 2015|January 21, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695317||78616|
NCT01697787|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CM/CRUN0012|Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso|Efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso||Centre Muraz|No|Completed|October 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|6 Months|90 Years|No|||July 2015|July 29, 2015|September 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01697787||78428|
NCT01697800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1247|A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract|A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|September 2012|September 2016|Anticipated|September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|21 Years|N/A|No|||May 2014|May 12, 2014|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697800||78427|
NCT01697813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LAZ-012-0002RG|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|September 2012|||||N/A|N/A|N/A||||||||||||||May 14, 2014|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697813||78426|
NCT01698684|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TA-501|Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction||VIVUS, Inc.|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|440|||Male|18 Years|N/A|No|||October 2014|October 21, 2014|September 25, 2012|Yes|Yes||No|October 15, 2014|https://clinicaltrials.gov/show/NCT01698684||78359|
NCT01695304|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCEZID-6369|Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya|Pilot Intervention Trial of Ceramic Water Filters to Reduce the Burden of Cryptosporidium in Household Drinking Water in Rural Kenya.||Centers for Disease Control and Prevention|No|Not yet recruiting|February 2013|||August 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|240|||Both|4 Months|10 Months|Accepts Healthy Volunteers|||April 2013|April 18, 2013|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695304||78617|
NCT01688232|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI11033|The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer|Colorectal Cancer: a Prospective Multicentric Study of the in Situ Immune Infiltrate for the Identification of the Patients at High Risk of Relapse|IMMUCOL|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2012|October 2017|Anticipated|October 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|459|Samples With DNA|The pathologist of each center will choose a tumor block containing the core of the tumor      and the invasive margin. Three tissue sections of 4 microns of this tumor block will be cut      and deposited on glass slides for the immunohistochemical analyses. Four tissue sections of      4 microns will be cut and deposited in a safe lock eppendorf tube for a DNA extraction. If      biopsies for diagnostic purpose are available in the laboratory of pathology for the same      patient, one tissue section of 4 microns of each biopsy will be cut and deposited on a glass      slide|Both|18 Years|N/A|No|Non-Probability Sample|Adult patient with newly diagnosed colorectal cancer.|October 2015|October 5, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688232||79161|
NCT01696058|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.52|Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®|A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]||Boehringer Ingelheim||Completed|September 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1137|||Both|40 Years|N/A|No|||November 2014|November 13, 2014|September 26, 2012||||No|September 5, 2014|https://clinicaltrials.gov/show/NCT01696058||78559|
NCT01696071|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|205.441|Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication|A Randomised, Double- Blind, 2 Way Cross-over Study to Determine 24-hour FEV1-time Profile of Inhaled Tiotropium, Delivered Via the Respimat Inhaler, After 4 Weeks of Once Daily [5 mcg in the Evening (2 Actuations of 2.5 mcg)] or Twice Daily [2.5 mcg in the Morning and Evening (2 Actuations of 1.25 mcg)] Administration in Patients With Moderate Persistent Asthma.||Boehringer Ingelheim||Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|98|||Both|18 Years|75 Years|No|||July 2014|July 24, 2014|September 26, 2012||||No|June 18, 2014|https://clinicaltrials.gov/show/NCT01696071||78558|
NCT01696630|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|XENON|A Study Which Compares the Efficacy of Xenon and Desflurane in Association With a Thoracic Epidural Analgesia|Phase II Study, Randomized, Monocentric, Single-blind, Comparing the Efficacy of Gases Xenon and Desflurane , in Association With a Thoracic Epidural Analgesia in Maintenance Phase of a Colorectal Oncologic Surgery||Centre Leon Berard|Yes|Completed|October 2012|February 2013|Actual|January 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Actual|31|||Both|18 Years|N/A|No|||September 2014|September 11, 2014|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01696630||78515|
NCT01696591|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-CR-007-F/U|The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD|The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD||Samsung Medical Center|Yes|Recruiting|March 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|14|||Both|50 Years|75 Years|No|Non-Probability Sample|The patients, who were administered with NEUROSTEM®-AD in the earlier part of the Phase I        study, will be compared with the patients, who have similar demographics and disease        characteristics as the subjects in the test group but have not been treated with        NEUROSTEM®-AD.|September 2012|September 27, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01696591||78518|
NCT01696604|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116715|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects|A Single-center, Randomized, Blinded, Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in Single and Repeat Doses, With and Without Food, in Healthy Male Subjects||GlaxoSmithKline|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|10||Actual|17|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2012|March 7, 2013|September 27, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01696604||78517|
NCT01696851|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-10-8276-GZ-CTIL|Physiological and Psycho-social Variables of People With SCI Participating in Competitive Rugby in Wheelchairs|||Sheba Medical Center|No|Not yet recruiting|September 2012|||September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Non-Probability Sample|Wheelchair rugby players with SCI with four limbs paralyzed playing and practicing        regularly. Season lasts about six months.        Belonging to this group are training and playing regularly twice a week about 3 hours at a        time, total of 6 hours per week under the supervision of two coaches who attend every        practice and game.|September 2012|September 27, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01696851||78498|
NCT01695278|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00068025|A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community|Coaching for Control: A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community|C4C|Northwestern University|No|Completed|September 2012|August 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|16|||Both|18 Years|N/A|No|||November 2014|November 19, 2014|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695278||78619|
NCT01695499|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BAL-Biomarker-ICU Study|Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung Infiltrates|Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, Beta D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Real-time qPCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL)and Blood Samples of Intensive Care Unit Patients With Pulmonary Infiltrates||Heidelberg University|No|Enrolling by invitation|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Only fungal DNA investigated|Both|18 Years|100 Years|No|Probability Sample|Immunocompromised patients on the intensive care unit with lun infiltrates and one of the        following underlying conditions:          -  Underlying malignancy          -  Antineoplastic chemotherapy          -  Neutropenia          -  Allogeneic hematopoietic stem cell transplantation          -  Solid organ transplantation          -  Retransplantation          -  Acute or chronic immunological rejection or graft-versus-host-disease          -  Treatment with immunosuppressive agents (calcineurin inhibitors, OKT3, etc)          -  Profound systemic corticosteroid therapy prior to ICU admission          -  COPD Gold III/IV          -  Advanced liver cirrhosis and ICU treatment for more than 7 days          -  Hemodialysis, renal failure          -  CMV infection          -  HIV infection; CD4 cellcount          -  Post splenectomy          -  Post cardiac surgery          -  Diabetes mellitus          -  mechanical ventilation for more than 21 days          -  ICU-based steroid therapy and corticosteroid treatment for more than 7 days          -  Malnutrition          -  Severe burn wounds|December 2015|December 8, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695499||78602|
NCT01696305|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyalobarrier_P3|Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy|Prospective, Randomized, Double Blind, Multicenter Study for Hyalobarrier ® to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG® After Thyroidectomy||Green Cross Corporation|No|Completed|December 2012|February 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|198|||Both|18 Years|79 Years|No|||February 2014|February 27, 2014|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696305||78540|
NCT01698346|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|cev001|Pertussis (Tdap) Vaccination in Pregnancy|Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants||Universiteit Antwerpen|No|Active, not recruiting|February 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|100|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||July 2015|July 14, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01698346||78385|
NCT01698372|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCI VAC Study|Negative Pressure Dressing After Saphenous Vein Harvest|Negative Pressure Dressing to Decrease the Incidence of Leg Wound Complications After CABG||University of Calgary|No|Completed|September 2012|March 2015|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|64|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01698372||78383|
NCT01699230|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0120|Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis?|Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis?|CORONOMEGA3|University Hospital, Clermont-Ferrand||Recruiting|March 2011|May 2013|Anticipated|May 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|30|||Male|50 Years|N/A|No|||October 2012|October 1, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01699230||78317|
NCT01695512|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Heidelberg|Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients|Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, 1->3-β-D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL) and Blood Samples of Hematological High Risk Patients and to Detect Point Mutations Conferring Azole Resistance||Heidelberg University|No|Enrolling by invitation|August 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|200|Samples With DNA|Only fungal DNA is retained and investigated|Both|18 Years|100 Years|Accepts Healthy Volunteers|Probability Sample|Patients suffering from acute leukemia and pts after allogeneic stem cell transplantation        with febrile neutropenia and lung infiltrates diagnosed in a chest CT scan suggestive for        fungal infection will be investigated after pts`s informed consent in a multicentre,        prospective trial|December 2015|December 8, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695512||78601|
NCT01699256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008-58-0028|Enhanced Implementation of Low Back Pain Guidelines in General Practice|Enhanced Implementation of Low Back Pain Guidelines in General Practice: A Cluster Randomized Trial||University of Aarhus|No|Active, not recruiting|October 2012|February 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1101|||Both|18 Years|65 Years|No|||July 2015|December 2, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01699256||78315|
NCT01699542|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM00049674|WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture|A Multi-Center, Prospective, Randomized (RCT) Study Comparing WallFlex® Esophageal Fully Covered (FC) Metal Stent to Bougie Dilation for the Treatment of Refractory Anastomotic Esophageal Strictures||Boston Scientific Corporation|No|Recruiting|April 2013|June 2017|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|44|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 20, 2015|October 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699542||78293|
NCT01699555|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GNC-001|First-in-Human Study With GNbAC1 in Healthy Volunteers|Randomized Placebo-Controlled First-in-Human Study With GNbAC1||GeNeuro Innovation SAS|No|Completed|July 2011|August 2012|Actual|March 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|33|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 4, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01699555||78292|
NCT01699568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Erico1|Stability of Implants With Different Surface Treatment: Randomized Clinical Trial|Stability of Implants With Different Surface Treatment: Randomized Clinical Trial||University of Sao Paulo|No|Active, not recruiting|February 2012|||July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|42|||Both|30 Years|60 Years|No|||February 2013|February 14, 2013|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699568||78291|
NCT01689896|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00070640|Testosterone and Pain Sensitivity|Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome||Johns Hopkins University|No|Withdrawn|August 2012|March 2015|Actual|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Male|18 Years|N/A|No|||March 2015|March 30, 2015|September 11, 2012||No|Difficult to obtain placebo|No||https://clinicaltrials.gov/show/NCT01689896||79033|
NCT01689909|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH095776-01A1|Reducing Suicidal Ideation Through Insomnia Treatment|Reducing Suicidal Ideation Through Insomnia Treatment|REST-IT|Georgia Regents University|Yes|Recruiting|September 2012|April 2017|Anticipated|April 2017|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|138|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689909||79032|
NCT01698697|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN248-1494|Comparison of Two Insulin Aspart Formulations in Healthy Volunteers|A Single Centre, Randomized, Balanced Double-blind, Cross-Over Trial Investigating the Bioequivalence of a Continuous Subcutaneous Infusion of a Marketed NovoRapid Formulation Containing 100 U/ml and a New NovoRapid Formulation Containing 200 U/ml in Healthy Male Volunteers||Novo Nordisk A/S|No|Completed|September 2002|October 2002|Actual|October 2002|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|24|||Male|18 Years|50 Years|No|||September 2012|October 2, 2012|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01698697||78358|
NCT01699529|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10058715DOC|Multi-electrode Radiofrequency Renal Denervation System Feasibility Study|Multi-electrode Radiofrequency Renal Denervation System Feasibility Study||Medtronic Vascular|Yes|Active, not recruiting|September 2012|August 2016|Anticipated|March 2014|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|18 Years|80 Years|No|||October 2015|October 26, 2015|September 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01699529||78294|
NCT01687920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|15481|Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets|Single Center, Randomized, Open-label, 5-fold Crossover Study in Healthy Male Subjects to Investigate the Pharmacokinetic Dose Proportionality of BAY94-8862 Given as 5 Different Single Oral IR Tablet Doses (1.25, 2.5, 5.0, 7.5 and 10 mg)||Bayer|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label|5||Actual|25|||Male|18 Years|46 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01687920||79185|
NCT01687933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Virtual Reality System|The Effect of Virtual Reality Glasses on Labor Pain|Principal Investigator||Mashhad University of Medical Sciences|Yes|Completed|February 2011|August 2012|Actual|July 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|30|||Female|18 Years|29 Years|Accepts Healthy Volunteers|||August 2012|September 15, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01687933||79184|
NCT01696097|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112011665|The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults|The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults (S31)|S31|Purdue University|No|Completed|April 2012|October 2014|Actual|February 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|19|||Both|40 Years|75 Years|No|||August 2015|August 13, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696097||78556|
NCT01696396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110232|AMG 181 in Subjects With Moderate to Severe Crohn's Disease|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease||Amgen|Yes|Active, not recruiting|December 2012|March 2019|Anticipated|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|4||Actual|254|||Both|18 Years|65 Years|No|||December 2015|December 19, 2015|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696396||78533|
NCT01697241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20120109|Effect of Exercise as Non-surgical Treatments on Time to Total Hip Replacement Surgery|The Effect of Education and Supervised Exercise vs. Education Alone on Time to Total Hip Replacement in Patients With Hip Osteoarthritis Considered Eligible for Surgery|HipSPORT|University of Southern Denmark|No|Recruiting|March 2013|September 2016|Anticipated|January 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|40 Years|N/A|No|||December 2014|December 15, 2014|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01697241||78469|
NCT01696617|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|031-KOC-1108i|Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder|Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder||Seoul National University Hospital|Yes|Recruiting|February 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|65 Years|No|||December 2015|December 7, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01696617||78516|
NCT01696864|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9471-GZ-CTIL|Remote Rehabilitation Via the Internet to Patients After a Stroke - Physical Rehabilitation Using Biofeedback Systems to Improve Upper Extremity Function|||Sheba Medical Center|No|Not yet recruiting|September 2012|||September 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|45|||Both|30 Years|80 Years|No|||September 2012|September 27, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01696864||78497|
NCT01696877|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J1265|A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer|A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a GM-CSF-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy||Sidney Kimmel Comprehensive Cancer Center|Yes|Active, not recruiting|September 2012|April 2018|Anticipated|April 2018|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|29|||Male|21 Years|N/A|No|||December 2015|December 21, 2015|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696877||78496|
NCT01697176|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPTION|Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques|A 1-year Prospective, Multicenter, Non-Randomized, Observational, Study to Evaluate Optimal Improvement of Vein Graft Patency Long Term by the Implementation of Novel Endoscopic Harvesting Techniques|OPTION|Cardiopulmonary Research Science and Technology Institute|No|Completed|August 2010|August 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Primary Isolated CABG|September 2012|October 21, 2014|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01697176||78474|
NCT01696019|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Byrd-ARG2007|Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders|A Pilot Randomized Intervention Study of Physical Exercise and Social Engagement in Chinese Elders|SCIBHI|University of South Florida|No|Completed|July 2008|September 2009|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|120|||Both|60 Years|79 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696019||78562|
NCT01696825|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-182|Comparison of Absorption of Vaginal Diazepam Using Different Delivery Systems|COMPARISON OF ABSORPTION OF VAGINAL DIAZEPAM USING DIFFERENT DELIVERY SYSTEMS||William Beaumont Hospitals|Yes|Terminated|October 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|3|||Female|18 Years|55 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696825||78500|
NCT01698385|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RADIEL|Prevention of Gestational Diabetes Through Lifestyle Modification|Prevention of Gestational Diabetes Through Lifestyle Modification (RADIEL) - a Randomized Controlled Multi-centre Intervention Study|RADIEL|Helsinki University|Yes|Completed|February 2008|February 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|750|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||January 2015|January 14, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01698385||78382|
NCT01698710|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-178|Endoscopic Abraxane Injection Into Pancreatic Cysts|EUS Guided Injection of Albumin Bound Paclitaxel Into Pancreatic Cysts||Massachusetts General Hospital|Yes|Completed|November 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|5|||Both|18 Years|N/A|No|||September 2014|September 17, 2014|October 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01698710||78357|
NCT01698983|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011H0055|Ex Vivo Stimulation of Whole Blood as a Means to Determine Glucocorticoid Sensitivity to Mild-to-Moderate and Refractory Asthmatics|Ex Vivo Stimulation of Whole Blood as a Means to Determine Glucocorticoid Sensitivity to Mild-to-Moderate and Refractory Asthmatics||Ohio State University|No|Terminated|June 2011|October 2012|Actual|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|14|||Both|18 Years|N/A|No|Probability Sample|clinic|October 2012|October 30, 2012|October 1, 2012||No|data not as expected|No||https://clinicaltrials.gov/show/NCT01698983||78336|
NCT01698996|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102928|A Randomized Blinded Trial of Abscess Management With Packing vs No Packing|A Randomized Blinded Trial of Abscess Management With Packing vs No Packing||Lawson Health Research Institute|No|Withdrawn|March 2013|||March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698996||78335|
NCT01699269|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0125|Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging|Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging: Peritumoral Glial Cell Infiltration Quantitative Method|TeDi-C2|University Hospital, Clermont-Ferrand||Completed|April 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Screening|1||Actual|10|||Both|18 Years|85 Years|No|||July 2014|July 4, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01699269||78314|
NCT01695343|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KB001A-05|Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment|A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas Aeruginosa|KB001-A|KaloBios Pharmaceuticals|Yes|Completed|December 2012|December 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|182|||Both|12 Years|50 Years|No|||January 2015|January 12, 2015|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695343||78614|
NCT01689922|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JPNI-2|The Effectiveness of Anti-Gravity Treadmill Training|The Effectiveness of Anti-Gravity Treadmill Training in Patients After Lumbar Microdiscectomy and Fusion Surgeries||Justin Parker Neurological Institute|No|Recruiting|June 2012|June 2017|Anticipated|January 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|120|||Both|18 Years|65 Years|No|Probability Sample|Patients undergoing one-level microdiscectomy or fusion surgeries|August 2015|August 31, 2015|June 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01689922||79031|
NCT01695525|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12945|Influence of Yoga in Patients With Neurocardiogenic Syncope|Neurocardiogenic Syncope and the Role That Yoga Plays in People With Autonomic Dysfunction|SYNC - YOGA|University of Kansas Medical Center|No|Completed|June 2012|March 2015|Actual|March 2015|Actual|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|60 Years|No|||June 2015|June 27, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01695525||78600|
NCT01695785|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-079|Perception of Physical Exertion in Healthy Weight and Obese Adolescents|Perception of Physical Exertion in Healthy Weight and Obese Adolescents: A Pilot Study||University of Vermont|No|Active, not recruiting|June 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|40|||Both|13 Years|18 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy weight and obese adolescents from the community|September 2015|September 9, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695785||78580|
NCT01696045|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA184-178|Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma|Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma||Bristol-Myers Squibb|Yes|Recruiting|November 2012|July 2017|Anticipated|July 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|12 Years|17 Years|No|||January 2016|March 11, 2016|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696045||78560|
NCT01696929|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00000405|An Open-Label Trial of Tocilizumab in Schizophrenia|An Open-Label Trial of Tocilizumab in Schizophrenia||Georgia Regents University|No|Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|50 Years|No|||September 2015|September 3, 2015|September 24, 2012||No||No|August 5, 2015|https://clinicaltrials.gov/show/NCT01696929||78492|
NCT01696942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|36497|Cimzia Versus Mesalamine for Crohn's Recurrence|Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine||Milton S. Hershey Medical Center|Yes|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696942||78491|
NCT01696903|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SKARV-GLH-001|Evaluation of a Novel Pancreaticojejunostomy Technique for Pancreaticoduodenectomy|Clinical Randomized Trial Investigating a Novel Pancreaticojejunostomy Technique for Pancreaticoduodenectomy in Patients With a High Risk for Postoperative Pancreatic Fistula||Karolinska Institutet|No|Recruiting|September 2011|September 2015|Anticipated|April 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|N/A|N/A|No|||October 2013|March 30, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01696903||78494|
NCT01696916|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sentec2012|Development of the Partial Pressure of Carbon Dioxide During Exercise and at Night in Patients With Chronic Obstructive Pulmonary Disease (COPD) IV|Development of the Partial Pressure of Carbon Dioxide During 6-min Walking Test and at Night in Patients With Chronic Obstructive Pulmonary Disease IV||Klinikum Berchtesgadener Land der Schön-Kliniken|No|Completed|March 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|75|||Both|30 Years|75 Years|No|||April 2014|April 14, 2014|February 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01696916||78493|
NCT01696890|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEMAHF2|Integration of Follow-up by First and Second Line Practitioners by Telemonitoring in Heart Failure.|Integration of Follow-up by First and Second Line Practitioners Facilitated by Telemonitoring Versus Stand-alone Telemonitoring in Patients With Severe Heart Failure|TEMA-HF2|Jessa Hospital|Yes|Terminated|October 2011|December 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|60 Years|90 Years|No|||April 2015|April 6, 2015|March 29, 2012||No|lack of inclusions, sudden withdrawal of study coordinator|No||https://clinicaltrials.gov/show/NCT01696890||78495|
NCT01697215|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|111128-PIP|Novel Device to Assess Endotracheal Tube Migration|Novel Device (AirWave™) to Assess Endotracheal Tube Migration.||The Cleveland Clinic||Completed|April 2012|||June 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|N/A|No|Non-Probability Sample|MICU Based|September 2012|September 28, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01697215||78471|
NCT01697189|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EISD-109378-FWF|An Educational Intervention to Promote Safe Driving|An Educational Intervention to Promote Safe and Economic Truck Driving||Finnish Institute of Occupational Health|No|Completed|August 2010|May 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|54|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|November 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01697189||78473|
NCT01697202|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GoteborgU|Fatigue in Rheumatoid Arthritis - Longitudinal Study|Fatigue in Rheumatoid Arthritis - Longitudinal Study||Göteborg University|No|Completed|November 2011|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|67|||Both|20 Years|65 Years|No|Probability Sample|Persons with RA at the Rheumatology clinic at Sahlgrenska University hospital Gothenburg,        Sweden|February 2014|February 19, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01697202||78472|
NCT01697514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14492|A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma|A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma||Eli Lilly and Company|No|Withdrawn|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|12 Months|21 Years|No|||August 2013|August 26, 2013|September 28, 2012|No|Yes|Trial stopped early for poor accrual.|No||https://clinicaltrials.gov/show/NCT01697514||78448|
NCT01697475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AJPM 12-0206-126R|Text-Messaging to Motivate Walking in Older African Americans|An Motivational Text Messaging Walking Program for Older African Americans||Georgetown University|No|Completed|October 2010|August 2011|Actual|July 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|36|||Both|60 Years|85 Years|No|||September 2011|September 27, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01697475||78451|
NCT01698060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXA01-001subA|Immunogenicity of ND1.1 by Delivery Directly to the Ileum|An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of ND1.1 by Delivery Directly to the Ileum Using the InteliSite® Companion Capsule in Healthy Adult Males|ICC H5|Vaxart|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|12|||Male|18 Years|49 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|September 29, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01698060||78407|
NCT01698086|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1114|Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial)|Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most?||University of Colorado, Denver|No|Recruiting|October 2012|June 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|88|||Both|18 Years|60 Years|No|||January 2016|January 27, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01698086||78405|
NCT01698099|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APP001|Diagnostic Accuracy of Serum Bilirubin in the Prediction of Perforated Appendicitis|Diagnostic Accuracy of Serum Bilirubin in the Prediction of Perforated Appendicitis||University Hospital Tuebingen|No|Completed|May 2009|September 2012|Actual|August 2011|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|500|||Both|16 Years|95 Years|No|Probability Sample|patients undergoing appendectomy for suspected appendicitis|September 2012|September 27, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01698099||78404|
NCT01698398|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-092|The Increase Study. Effect of Incremental Versus Fixed Pump on Peak Oxygen Consumption in Heart Failure Patients Supported With a Continuous Flow Left Venticular Assist Device|The Increase Study. Effect of Incremental Versus Fixed Pump on Peak Oxygen Consumption in Heart Failure Patients Supported With a Continuous Flow Left Venticular Assist Device.||Rigshospitalet, Denmark||Completed|October 2012|||January 2013|Actual|N/A|Interventional|Allocation: Randomized, Masking: Double Blind (Subject, Investigator)|1||||||Both|18 Years|N/A||||October 2012|February 10, 2014|October 2, 2012||||No||https://clinicaltrials.gov/show/NCT01698398||78381|
NCT01698723|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEV-RIBA|A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus|A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus|HEVRibavirin|All India Institute of Medical Sciences, New Delhi|Yes|Recruiting|September 2012|June 2014|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|40|||Both|12 Years|N/A|No|||September 2012|September 29, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01698723||78356|
NCT01699282|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHU-0121|Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education|Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education.|EDUCA|University Hospital, Clermont-Ferrand||Recruiting|July 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|186|||Both|18 Years|N/A|No|||October 2012|October 1, 2012|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01699282||78313|
NCT01695096|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ibnsinaH|High Versus Free Humidity Incubators; A Randomized Clinical Trial|High Versus Free Humidity Incubators; A Randomized Clinical Trial||Ibn Sina Hospital|Yes|Recruiting|October 2012|March 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Health Services Research|2||Anticipated|284|||Female|18 Years|33 Years|Accepts Healthy Volunteers|||April 2015|April 5, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01695096||78633|
NCT01695577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OUSHIOA2012|Vestibular Rehabilitation and Balance Training After Traumatic Brain Injury|Vestibular Rehabilitation and Balance Training for Patients With Dizziness and Balance Problems After Traumatic Brain Injury.|VRTBI2012|Oslo University Hospital|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|65|||Both|16 Years|60 Years|No|||January 2016|January 8, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01695577||78596|
NCT01689935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-P-002352|Reduced Side-Effects Of Photodynamic Therapy For The Treatment Of Moderate To Severe Acne (i-PDT)|A Pilot Clinical Trial To Reduce Side-Effects Of Photodynamic Therapy For The Treatment Of Moderate To Severe Acne|i-PDT|Massachusetts General Hospital|Yes|Active, not recruiting|November 2009|December 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Anticipated|35|||Both|14 Years|50 Years|Accepts Healthy Volunteers|||May 2013|May 16, 2013|October 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01689935||79030|
NCT01695538|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12946|Yoga and Rate and Duration of Inappropriate Sinus Tachycardia (IST) Episodes|The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Inappropriate Sinus Tachycardia|YOGA STAR|University of Kansas Medical Center|No|Withdrawn|December 2011|November 2015|Actual|November 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|60 Years|No|||November 2015|November 13, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01695538||78599|
NCT01695798|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIPV|IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi.|Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants.|MIPV|Aga Khan University|Yes|Completed|October 2012|October 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|840|||Both|9 Months|12 Months|Accepts Healthy Volunteers|||January 2014|January 14, 2014|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695798||78579|
NCT01696084|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLTR0310-301|Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia|Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML|301|Celator Pharmaceuticals|Yes|Active, not recruiting|November 2012|December 2016|Anticipated|March 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|60 Years|75 Years|No|||February 2016|February 23, 2016|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696084||78557|
NCT01696422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEN-01-IB|Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine|Phase II, Step-wise, Randomized, Double-blind, Controlled Clinical Trial for Safety and Immunogenicity Evaluation of a Lyophilized Formulation of Dengue 1,2,3,4 (Attenuated) Vaccine in Healthy Adults||Butantan Institute|Yes|Active, not recruiting|October 2013|December 2018|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|5||Actual|300|||Both|18 Years|59 Years|Accepts Healthy Volunteers|||January 2016|January 13, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696422||78531|
NCT01696409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Vitamin D and Gene Expression|The Effect Of Vitamin D On Measures Of Bone Health And Gene Expression|The Effect of Vitamin D on Measures of Bone Health and Gene Expression||Boston Medical Center|No|Completed|July 2009|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|11|Samples With DNA|Buffy coat has been retained from whole blood.|Both|18 Years|70 Years|Accepts Healthy Volunteers|Probability Sample|Healthy Students from Boston University Medical School|September 2012|October 1, 2012|June 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696409||78532|
NCT01696656|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gutadjuvant1|Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency|Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency||University of Sao Paulo|No|Completed|September 2012|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|37|||Both|18 Years|90 Years|No|Non-Probability Sample|Adults with short bowel syndrome secondary to trauma, Crohn´s disease, mesenteric        thrombosis, radiation enteritis and other conditions, suffering from intestinal        insufficiency and undergoing home-parenteral or enteral nutrition.|September 2012|September 28, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696656||78513|
NCT01697566|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-0739|An Endometrial Cancer Chemoprevention Study of Metformin|An Endometrial Cancer Chemoprevention Study of Metformin Versus No Treatment in Women With a Body Mass Index (BMI) >/= 35 kg.m2 and Hyperinsulinemia||M.D. Anderson Cancer Center|No|Active, not recruiting|May 2013|||May 2019|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|100|||Female|50 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 4, 2016|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697566||78444|
NCT01697228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-00352|The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM|The Effects of Vitamin D Supplementation on Glycemic Control and Proinflammatory Markers Involved in Microvascular Complications in Adolescents With Type 1 Diabetes.||Children's Hospital Los Angeles|Yes|Not yet recruiting|October 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|26|||Both|13 Years|21 Years|No|||October 2012|October 1, 2012|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697228||78470|
NCT01697527|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000153|Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies|Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies||Jonsson Comprehensive Cancer Center|Yes|Recruiting|November 2012|||October 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|16 Years|N/A|No|||March 2016|March 4, 2016|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697527||78447|
NCT01697540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KMUHIRB-2012-05-05(I)|Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan|||Kaohsiung Medical University Chung-Ho Memorial Hospital||Recruiting|September 2012|||August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|N/A|N/A|No|Non-Probability Sample|HIV/AIDS group|September 2015|September 3, 2015|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697540||78446|
NCT01697488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27765|An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)|Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer||Hoffmann-La Roche||Recruiting|February 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|1190|||Both|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary        peritoneal cancer with indication for first-line carboplatin/paclitaxel chemotherapy in        combination with Avastin. In the second study phase recruitment focusses on patients >/=        70 years.|March 2016|March 1, 2016|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697488||78450|
NCT01697501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28470|A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253|Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study||Hoffmann-La Roche||Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|88|||Both|18 Years|N/A|No|||October 2015|December 1, 2015|September 28, 2012||No||No|June 10, 2015|https://clinicaltrials.gov/show/NCT01697501||78449|
NCT01698112|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PreDiabetes Flax|Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?|Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?||University of Colorado, Colorado Springs|No|Completed|July 2006|June 2009|Actual|June 2009|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|25|||Both|50 Years|65 Years|No|||September 2012|September 27, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01698112||78403|
NCT01697826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ND1210132-34|Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections|A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections||Daswani, Bhart, M.D.|No|Completed|April 2011|September 2011|Actual|September 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|73|||Female|18 Years|65 Years|No|||September 2012|October 1, 2012|September 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01697826||78425|
NCT01697839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X05392|Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients|Correlation Between Serum Vitamin D Levels and the Incidence of Peripheral Neuropathy Among Multiple Myeloma Patients Who Have Previously Received Treatment With Bortezomib or Thalidomide||Oncotherapeutics|No|Completed|June 2012|August 2015|Actual|August 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|110|Samples Without DNA|whole blood, serum, white blood cells, red blood cells|Both|18 Years|N/A|No|Non-Probability Sample|community sample|April 2015|March 8, 2016|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01697839||78424|
NCT01698073|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0241|Effect of a Culturally-based Intervention on Sexual Risky Behavior Among Young American Indian Adolescents|Teen Pregnancy Prevention Among Native Youth of the Northern Plains|COL/AS+|University of Colorado, Denver|No|Completed|September 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|167|||Both|10 Years|12 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01698073||78406|
NCT01698736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK 1540/2012|ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration|ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration||Medical University of Vienna|Yes|Completed|October 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|14|||Both|18 Years|N/A|No|||February 2013|February 28, 2013|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01698736||78355|
NCT01699009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WCCR-MIG2|A Nutritional Intervention for Migraines-2|A Nutritional Intervention for Migraines-2|WCCR-MIG2|Physicians Committee for Responsible Medicine|Yes|Completed|October 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|24|||Both|18 Years|100 Years|No|||May 2014|October 19, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699009||78334|
NCT01695109|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|702/2008|The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers|The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers||Medical University of Vienna|No|Completed|November 2010|March 2012|Actual|February 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|16|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 26, 2012|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01695109||78632|
NCT01695356|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VISUV-melasma|Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma|A Double Blind Randomized Study Comparing the Ultraviolet (UV) Photoprotection With UV Plus Visible Light Photoprotection in the Treatment of Melasma.||Universidad Autonoma de San Luis Potosí|No|Completed|September 2012|November 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|68|||Female|25 Years|60 Years|No|||December 2014|December 1, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695356||78613|
NCT01695382|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0592|Apoyo Con Carino: Patient Navigation for Palliative Care|Apoyo Con Carino: Patient Navigation to Improve Palliative Care Outcomes for Latinos With Advanced Cancer||University of Colorado, Denver|No|Recruiting|August 2012|May 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Anticipated|240|||Both|18 Years|90 Years|No|||December 2015|December 9, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695382||78611|
NCT01695590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRLX93936-0002|Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma|Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma||Prolexys Pharmaceuticals|No|Recruiting|March 2012|September 2014|Anticipated|March 2014|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||May 2013|May 31, 2013|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695590||78595|
NCT01690481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-09242009-4020|The Effects of High and Low Blood Glucose Values on the Brain in Children With Type 1 Diabetes Mellitus|Neurocognitive and Neuroanatomical Studies in Young Children With Type 1 Diabetes Mellitus||Stanford University|No|Active, not recruiting|December 2006|December 2016|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|3 Years|10 Years|Accepts Healthy Volunteers|Non-Probability Sample|Children between ages 3 to 10 with and without type 1 diabetes mellitus|September 2012|September 20, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01690481||78988|
NCT01695811|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLAK-15615|Femtosecond Laser-Assisted Keratoplasty|Femtosecond Laser-Assisted Keratoplasty|FLAK|University of Michigan|No|Completed|November 2007|December 2013|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|24|||Both|18 Years|N/A|No|Probability Sample|subjects indicated for corneal transplant surgery|January 2015|January 16, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695811||78578|
NCT01696110|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYNH20120001|BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.|Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT):a Randomised Controlled Trial|BRIGHT|Shenyang Northern Hospital|Yes|Completed|August 2012|July 2014|Actual|July 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|2194|||Both|18 Years|80 Years|No|||September 2014|September 30, 2014|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01696110||78555|
NCT01696383|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDG-11-257|Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia|Assessing the Efficacy of DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination), as a Replacement Therapy in Glaucoma Patients in Russia, Previously on Prior Prostaglandin Analogue or Beta-blocker Monotherapy||Alcon Research|No|Withdrawn|February 2013|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||February 2013|February 6, 2013|September 27, 2012|No|Yes|Management decision|No||https://clinicaltrials.gov/show/NCT01696383||78534|
NCT01696435|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-001881|VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL|VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL|VITAL-DEP|Brigham and Women's Hospital|Yes|Active, not recruiting|July 2010|October 2017|Anticipated|October 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|25875|||Both|50 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 1, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01696435||78530|
NCT01696448|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVR-2012-01|The BANGALORE Study; Combination of Berberine, Lipoic Acid, and Picrorhiza|Changes in Appetite, Weight, Body Composition, Endothelial Function and Biomarkers in Patients With the Cardiometabolic Syndrome: Comparison of a Combination of Berberine, Lipoic Acid, and Picrorhiza (CAR-191) Versus Placebo (The "BANGALORE" Study)|CAR-191|Carmel Biosciences|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|28|||Both|18 Years|80 Years|No|||November 2014|November 10, 2014|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01696448||78529|
NCT01696669|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS-21|Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults|Phase 2, Open-label, Uncontrolled, Multicenter and Prospective Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults||Grupo Espanol de Investigacion en Sarcomas|Yes|Active, not recruiting|April 2010|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|43|||Both|N/A|40 Years|No|||August 2015|August 17, 2015|June 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01696669||78512|
NCT01696981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01757|Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial||National Cancer Institute (NCI)||Active, not recruiting|November 1993|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|154900|||Both|55 Years|74 Years|No|||February 2016|February 22, 2016|September 28, 2012|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01696981||78488|
NCT01696955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01640|Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery|A Randomized Phase II Trial of ARQ 197 (Tivantinib) /Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer||National Cancer Institute (NCI)|No|Active, not recruiting|August 2012|||May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696955||78490|
NCT01696968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01756|Screening for Lung Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial||National Cancer Institute (NCI)||Active, not recruiting|November 1993|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|154901|||Both|55 Years|74 Years|No|||February 2016|February 22, 2016|September 28, 2012|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01696968||78489|
NCT01697579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0517-029|Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)|A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy||Merck Sharp & Dohme Corp.|No|Recruiting|December 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Anticipated|227|||Both|N/A|11 Years|No|||February 2016|February 24, 2016|September 28, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697579||78443|
NCT01697553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I11 001|Home-Based Technologies Coupled to Teleassistance Service in the Elderly|Home-Based Technologies Coupled to Teleassistance Service: Efficacy for Preventing Falls at Home in Frail Elderly Population Losing Autonomy|DOMOLIM|University Hospital, Limoges|No|Recruiting|October 2012|June 2016|Anticipated|October 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|1200|||Both|65 Years|N/A|No|||April 2015|April 1, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697553||78445|
NCT01697852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITDCVP54|The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention|Cluster Randomised Trial to Compare Effectiveness of the Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) to LLINs Alone for Malaria Prevention in Muleba District, Kagera Region, Tanzania||London School of Hygiene and Tropical Medicine|Yes|Recruiting|January 2011|December 2012|Anticipated|November 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|22300|||Both|6 Months|14 Years|Accepts Healthy Volunteers|||October 2012|October 2, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01697852||78423|
NCT01697865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|061217B|Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction|Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction: A Prospective, Randomized Investigation||OrthoCarolina Research Institute, Inc.|Yes|Recruiting|October 2012|October 2019|Anticipated|October 2018|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|42|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01697865||78422|
NCT01698125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/2498/REK nord|Autonomic Cardiovascular Control for Elderly Surgery Patients|Autonomic Cardiovascular Control for Elderly Surgery Patients||Oslo University Hospital|No|Terminated|October 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|3|Samples With DNA|Serum. Plasma. Saliva.|Both|65 Years|N/A|No|Non-Probability Sample|Patients scheduled for abdominal surgery at Oslo University Hospital.|April 2014|April 14, 2014|September 27, 2012||No|Practical circumstances made it too difficult to carry out as planned.|No||https://clinicaltrials.gov/show/NCT01698125||78402|
NCT01698138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/1151|Prevention of Bladder Dysfunction in Acute Spinal Cord Injury|Prevention of Bladder Dysfunction in Acute Spinal Cord Injury. A Double-blind, Randomized, Placebo-controlled Study to Explore the Effect of Early Treatment With Onabotulinumtoxin A on Development of Detrusor Overactivity|BOT-SCI|Oslo University Hospital|No|Recruiting|September 2012|September 2016|Anticipated|September 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|80 Years|No|||May 2014|May 15, 2014|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01698138||78401|
NCT01698411|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-57|Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders|Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders|HATS|Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|October 2012|January 2014|Anticipated|January 2014|Anticipated|N/A|Observational|Observational Model: Cohort||1|Anticipated|305|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|adult with chronic complain of insomnia|July 2012|January 30, 2013|July 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01698411||78380|
NCT01699022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A09-109|Pharmacokinetic and Pharmacodynamic Study of Cyclofem|Pharmacokinetic and Pharmacodynamic Study of Cyclofem||Sun Pharmaceutical Industries Limited|No|Completed|June 2010|December 2011|Actual|July 2011|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|17|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|September 28, 2012|Yes|Yes||No|December 12, 2012|https://clinicaltrials.gov/show/NCT01699022||78333|
NCT01699295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13460|Physical Activity and Academic Achievement Across the Curriculum (A+PAAC)|Physical Activity and Academic Achievement Across the Curriculum (A+PAAC)|A+PAAC|University of Kansas Medical Center|No|Completed|September 2011|June 2015|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|584|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||January 2016|January 9, 2016|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699295||78312|
NCT01699308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pfizer/WS935852|Growth Hormone and Brain Functioning After Traumatic Brain Injury|Growth Hormone and Brain Functioning After Traumatic Brain Functioning|GH|University of Kentucky|Yes|Recruiting|December 2009|April 2014|Anticipated|April 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|15|||Both|18 Years|55 Years|No|||May 2013|May 13, 2013|October 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699308||78311|
NCT01695122|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|327/11|Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma|Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma||Instituto do Cancer do Estado de São Paulo|No|Completed|September 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|14|||Both|N/A|65 Years|No|||February 2016|February 22, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695122||78631|
NCT01695369|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CV-12-54|Evaluation of Comfilcon A and Senofilcon A Lenses|Clinical Comfort Evaluation of Biofinity and Acuvue Oasys Lenses||Coopervision, Inc.|No|Completed|August 2012|August 2012|Actual|August 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Actual|61|||Both|18 Years|N/A|No|||February 2014|February 3, 2014|September 26, 2012|Yes|Yes||No|November 1, 2013|https://clinicaltrials.gov/show/NCT01695369||78612|
NCT01695395|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF-01GY1134|Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder|Mental Health Care Provision for Adults With Mental Retardation and a Psychiatric Diagnosis|MEMENTA|Technische Universität Dresden|Yes|Completed|February 2012|July 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|371|||Both|18 Years|65 Years|No|Probability Sample|The study population are adults with mild or moderate intellectual disability.|February 2015|February 10, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695395||78610|
NCT01686724|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R324A120358|Study of the Collaborative Life Skills Program|Efficacy of the Collaborative Life Skills Program||University of California, San Francisco|No|Recruiting|September 2012|June 2016|Anticipated|November 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|504|||Both|7 Years|11 Years|No|||May 2014|May 8, 2014|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01686724||79277|
NCT01696123|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMU-1391|Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine|||hahid Beheshti University of Medical Sciences||Completed|January 2011|August 2012|Actual|January 2012|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|125|||Both|50 Years|N/A|No|||September 2012|September 27, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01696123||78554|
NCT01696136|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RDC-2010.01|Multi-electrode PulmonarY Vein Isolation Versus Single Tip Wide Area Catheter Ablation for Paroxysmal Atrial Fibrillation (PAF)|Multi-electrode PulmonarY Vein Isolation Versus Single Tip Wide Area Catheter Ablation for PAF a Randomized Multinational Multicenter Trial|MYSTIC-PAF|R&D Cardiologie|No|Completed|January 2011|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696136||78553|
NCT01696643|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2402-006|Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain||Cubist Pharmaceuticals LLC||Terminated|October 2012|October 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1407|||Both|18 Years|80 Years|No|||January 2016|January 5, 2016|September 21, 2012|Yes|Yes|A review of blinded data indicates that the number of participant exposures needed to reach    ICH standards has been met|No|July 14, 2015|https://clinicaltrials.gov/show/NCT01696643||78514|
NCT01696201|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pregnancy outcomes|Effect of Physical Exercise Program on Outcomes and Level of Depression|Effect of a Supervised Exercise Program During Whole Pregnancy on Outcomes and Level of Depression. A Randomized Controlled Trial||Technical University of Madrid|Yes|Recruiting|October 2009|June 2015|Anticipated|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|160|||Female|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|November 13, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01696201||78548|
NCT01696461|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|09-PLEX|A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor|A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies||Center for International Blood and Marrow Transplant Research|Yes|Active, not recruiting|May 2013|September 2016|Anticipated|July 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|64|||Both|18 Years|65 Years|No|||January 2016|January 26, 2016|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696461||78528|
NCT01696682|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZSchest2012001|The Optimal Width of Gastric Conduit for Minimally Invasive Esophagectomy: Wide or Narrow?|Study on the Difference of Anastomotic Leakage Ratio Between Wide and Narrow Gastric Conduit During Minimally Invasive Esophagectomy||Fudan University|No|Recruiting|September 2012|December 2014|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Anticipated|200|||Both|N/A|N/A|No|||February 2013|February 7, 2013|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01696682||78511|
NCT01696695|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27791|AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer|Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)||Hoffmann-La Roche||Completed|July 2011|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|882|||Both|18 Years|N/A|No|Probability Sample|Patients with newly diagnosed colorectal cancer who have started first-line capecitabine        (Xeloda) based chemotherapy alone or in combination with bevacizumab (Avastin)|March 2016|March 1, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696695||78510|
NCT01696994|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01758|Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial||National Cancer Institute (NCI)||Active, not recruiting|November 1993|||May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|78216|||Female|55 Years|74 Years|No|||February 2016|February 22, 2016|September 28, 2012|Yes|Yes||No|August 30, 2013|https://clinicaltrials.gov/show/NCT01696994||78487|
NCT01697254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00018979|The CARRA Registry|The CARRA Registry|CARRA Registry|Duke University|No|Completed|August 2009|October 2015|Actual|October 2015|Actual|N/A|Observational [Patient Registry]|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|9587|Samples With DNA|Specimens currently being collected from subjects with juvenile dermatomyositis JDM),      systemic juvenile idiopathic arthritis (sJIA), and localized scleroderma.|Both|N/A|N/A|No|Non-Probability Sample|Subjects will be recruited from the patient population of a CARRA Registry site.|November 2015|November 16, 2015|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01697254|10 Years|78468|
NCT01697267|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RITAZAREM|Rituximab Vasculitis Maintenance Study|An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis|RITAZAREM|Cambridge University Hospitals NHS Foundation Trust|Yes|Recruiting|April 2013|December 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|190|||Both|15 Years|N/A|No|||December 2015|December 15, 2015|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697267||78467|
NCT01697891|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MU12-530|A Pilot Study of ALTENS in Improving Dysphagia Induced by IMRT for Head and Neck Cancers|Effectiveness of Acupuncture-like Transcutaneous Nerve Stimulation (ALTENS) in Improving Dysphagia and Associated Symptoms of Chemotherapy and/or Intensity Modulated Radiation Therapy (IMRT) for Head and Neck Cancers: A Pilot Study||McMaster University|No|Enrolling by invitation|October 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|35|||Both|18 Years|N/A|No|||October 2012|October 1, 2012|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697891||78420|
NCT01697878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011P001333|Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery|Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery: A Randomized Controlled Trial||Massachusetts General Hospital|No|Completed|March 2012|March 2016|Actual|July 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|45|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01697878||78421|
NCT01698151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-20110163|Prognosis and Treatment of COPD in Primary Care-use of Biomarkers|Prognosis and Treatment of COPD in Primary Care-use of Biomarkers|PROTECCT-M|University of Southern Denmark|No|Recruiting|October 2012|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|2000|||Both|40 Years|100 Years|No|Non-Probability Sample|Patients in primary care on the Fyn island, Denmark|March 2016|March 7, 2016|September 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01698151||78400|
NCT01698450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK: 2012-0027|Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders|MR-Guided Functional Ultrasound-Neurosurgery for Movement Disorders||University Children's Hospital, Zurich|Yes|Completed|November 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|10|||Both|18 Years|80 Years|No|||October 2014|October 8, 2014|July 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01698450||78377|
NCT01698463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17664|Prescribe Exercise for Prevention of Falls and Fractures: A Family Health Team Approach|Tailored Exercise for Fall and Fracture Prevention in Older Adults: A Family Health Team Approach|PEPTEAM|University of Waterloo|No|Completed|January 2012|July 2012|Actual|June 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|11|||Both|65 Years|N/A|No|||October 2012|October 2, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01698463||78376|
NCT01698424|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PET/CT Amino Acids|PET/CT of Skeletal Muscle Amino Acid Kinetics|||University of California, San Francisco|No|Completed|June 2013|September 2014|Actual|August 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|12|Samples Without DNA|Biopsies will be taken from upper thigh, Muscle tissue|Female|65 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Healthy women|January 2015|January 9, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01698424||78379|
NCT01698437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AG2010/026,ZH 2010-0543/3|Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Brain Tumors|MR-guided Ultrasound-Neurosurgery for the Treatment of Malignant Brain Tumors|FUS-Tumor|University Children's Hospital, Zurich|Yes|Recruiting|February 2011|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01698437||78378|
NCT01699035|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H133B080031|Survey on Return to Work After Stroke|Survivor Perspective on Critical Factors to Return to Work After Stroke||Rehabilitation Institute of Chicago|No|Completed|February 2012|September 2014|Actual|December 2012|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|715|||Both|18 Years|N/A|No|Non-Probability Sample|stroke survivors|September 2014|September 10, 2014|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699035||78332|
NCT01699321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1903|FITShop: Promoting Physical Activity in Black Barbershops|Promoting Physical Activity in Black Barbershops|FITShop|University of North Carolina, Chapel Hill|Yes|Completed|July 2012|August 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|628|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 15, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699321||78310|
NCT01699334|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8011-170712|Effectiveness of an Educational Video Following Acute Whiplash Trauma|Effectiveness of an Educational Video Following Acute Whiplash Trauma: A Randomized Controlled Trial||University of Aarhus|Yes|Recruiting|October 2012|May 2016|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|60 Years|No|||January 2014|January 20, 2014|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01699334||78309|
NCT01695135|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100010|A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy|A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy||Janssen Research & Development, LLC|No|Active, not recruiting|August 2012|June 2018|Anticipated|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|214|||Male|18 Years|N/A|No|||March 2016|March 11, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695135||78630|
NCT01695408|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INSIGHTS-IPF|Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis|Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.|INSIGHTS-IPF|Technische Universität Dresden|No|Recruiting|October 2012|April 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|750|||Both|18 Years|N/A|No|Probability Sample|Patients with Idiopathic Pulmonary Fibrosis (confirmed diagnosis according to current        ATS/ERS guidelines)|June 2015|June 16, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695408||78609|
NCT01687595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-400-02|Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Subjects With Recurrent Genital Herpes|A Phase 2a Multicenter, Double-blinded, Randomized Trial to Evaluate The Effect of HerpV on Viral Shedding in Adults With Recurrent Genital Herpes||Agenus, Inc.|Yes|Completed|October 2012|January 2015|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|80|||Both|18 Years|50 Years|No|||January 2015|January 12, 2015|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687595||79210|
NCT01695837|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5P20RR016464-11/8|Live Well: A Practical and Effective Low-Intensity Dietary Counseling Intervention for Use in Primary Care Patients With Dyslipidemia|||University of Nevada, Las Vegas|No|Completed|July 2011|June 2012|Actual|May 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|61|||Both|21 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695837||78576|
NCT01696149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|87-4520|Effects of High and Low Frequency TENS on Sympathetic Skin Response and Skin Temperature|The Effects of High and Low Frequency Transcutaneous Electrical Nerve Stimulation on Sympathetic Skin Response and Skin Temperature||Shiraz University of Medical Sciences|Yes|Completed|March 2010|June 2011|Actual|February 2011|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Basic Science|1||Actual|15|||Both|20 Years|30 Years|No|||September 2012|September 27, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01696149||78552|
NCT01696162|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|413|Conventional Home Exercise Programs Versus Electronic Home Exercise Versus Artificial Intelligence "Virtual Therapy" for Anterior Knee Pain|Conventional Home Exercise Programs Versus Electronic Home Exercise Versus Artificial Intelligence "Virtual Therapy" for Anterior Knee Pain: a Prospective Randomized Comparative Trial.||Simpletherapy|Yes|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|85|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||June 2014|June 15, 2014|September 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01696162||78551|
NCT01696474|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAD0111|Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease|Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease|CAD0111|Gruppo Italiano Malattie EMatologiche dell'Adulto|No|Recruiting|December 2012|March 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|25|||Both|18 Years|N/A|No|||April 2015|April 21, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696474||78527|
NCT01696708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C12-49|Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease|Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease|PRO-MH2|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Recruiting|December 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|50|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|April 30, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01696708||78509|
NCT01696721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-103|PPCR: Registry for Pedi Patients Treated With Proton RT|Pediatric Proton Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Proton Radiation Therapy||Massachusetts General Hospital|No|Recruiting|July 2012|||December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|5000|||Both|N/A|21 Years|No|Non-Probability Sample|Pediatric patients age <22 treated with proton beam radiation therapy|February 2016|February 25, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696721||78508|
NCT01697007|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TaMoVac II|A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique|A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique|TaMoVac II|Muhimbili University of Health and Allied Sciences|Yes|Completed|November 2012|June 2015|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|3||Actual|198|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||June 2015|June 26, 2015|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01697007||78486|
NCT01697280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1952-Ped-ERC-11|Polio NID and Routine EPI Integration Trial Pakistan|Improving Routine Immunization Coverage Through Educational Messages Delivered During Polio NIDs in Pakistan: A Cluster Randomized Trial||Aga Khan University|Yes|Completed|April 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research|4||Actual|4560|||Both|3 Months|14 Months|Accepts Healthy Volunteers|||January 2014|January 15, 2014|April 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01697280||78466|
NCT01697293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-269|Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer|A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer||Albert Einstein College of Medicine of Yeshiva University|Yes|Recruiting|January 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|56|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697293||78465|
NCT01697592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-015|Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)|A Phase III, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of Addition of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Oral Antihyperglycemic Agent Monotherapy||Merck Sharp & Dohme Corp.|Yes|Completed|October 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|10||Actual|585|||Both|20 Years|N/A|No|||September 2015|September 29, 2015|September 28, 2012|Yes|Yes||No|September 29, 2015|https://clinicaltrials.gov/show/NCT01697592||78442|
NCT01697605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBGJ398X1101|A Phase I Study of Oral BGJ398 in Asian Patients|A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway||Novartis||Recruiting|October 2012|December 2018|Anticipated|December 2018|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|22|||Both|18 Years|N/A|No|||March 2016|March 5, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01697605||78441|
NCT01698164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2008BAI57B04|Multi-centre Clinical Trial on Hormone Replacement Treatment in China|Multi-centre Clinical Trial on Hormone Replacement Treatment in China||Peking Union Medical College Hospital||Recruiting|December 2008|||October 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|1200|||Female|40 Years|60 Years|No|||September 2012|September 28, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01698164||78399|
NCT01698177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|240293|Optimizing Influenza Vaccination in Surgical Oncology Patients|Optimizing Influenza Vaccination in Surgical Oncology Patients||Stony Brook University|No|Recruiting|October 2011|July 2013|Anticipated|June 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Anticipated|204|||Both|18 Years|N/A|No|||April 2013|April 18, 2013|August 11, 2011|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01698177||78398|
NCT01698190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBUGI-2012|Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions|Comparing the Overall Efficacy of Endoscopic Ultrasound Fine Needle Aspiration Versus Fine Needle Biopsy in the Diagnosis of Solid Lesions: A Multicenter, Randomized Clinical Trial||Stony Brook University|No|Recruiting|December 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic|2||Anticipated|400|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01698190||78397|
NCT01698476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRETB-2012|Immune Reconstitution in Tuberculosis Disease|Immune Reconstitution in Tuberculosis Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate|IRETB|Karolinska Institutet|Yes|Completed|September 2012|August 2015|Actual|August 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|390|||Both|18 Years|75 Years|No|||February 2016|February 4, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01698476||78375|
NCT01698489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00074308|The Very Large Database of Lipids (VLDL)||VLDL|Johns Hopkins University|No|Enrolling by invitation|April 2011|||April 2013|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|2859333|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients clinically referred for VAP density gradient ultracentrifugation.|October 2015|October 14, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698489||78374|
NCT01698502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EXINT2_FD|Physical Training and the Incretin Effect|Does Physical Training Effect the Incretin Effect|EXINT2|University of Copenhagen|No|Completed|August 2012|June 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Cross-Sectional||2|Actual|21|Samples Without DNA|Human plasma samples.|Male|20 Years|30 Years|Accepts Healthy Volunteers|Non-Probability Sample|Danish University Students from University of Copenhagen,|March 2014|March 24, 2014|September 26, 2012||No||No|December 10, 2013|https://clinicaltrials.gov/show/NCT01698502||78373|
NCT01698749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PoojaBansal 13|Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema|Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema||Postgraduate Institute of Medical Education and Research|No|Completed|December 2011|February 2012|Actual|January 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|61|||Both|20 Years|72 Years|Accepts Healthy Volunteers|||September 2012|September 29, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01698749||78354|
NCT01698762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0172|IADAPT-Third Phase|IADAPT-Third Phase||M.D. Anderson Cancer Center|No|Active, not recruiting|March 2013|||March 2018|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|828|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Harris County Hospital District (HCHD) and Kelsey-Seybold patients in rheumatology,        internal medicine and family practice clinics.|December 2015|December 14, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698762||78353|
NCT01699048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HREVS|The Comparative Effectiveness of Hybrid Revascularization (MIDCAB Then PCI) With DES Versus Multivessel DES PCI or CABG|Prospective, Single-center, Randomized Trial, Intended to Compare Three Revascularization Strategies in Patients With Multi-vessel Coronary Artery Disease|HREVS|Russian Academy of Medical Sciences|No|Recruiting|April 2012|December 2018|Anticipated|December 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Anticipated|150|||Both|18 Years|75 Years|No|||October 2012|October 4, 2012|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699048||78331|
NCT01699347|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0059-CTIL|Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432|Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432|OK432|Carmel Medical Center|Yes|Recruiting|September 2012|January 2016|Anticipated|January 2014|Anticipated|Phase 4|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|5|||Both|1 Year|18 Years|No|||November 2013|November 28, 2013|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01699347||78308|
NCT01695148|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHU IRB 4150|Efficacy of β-carotene Biofortified Maize in Reducing Vitamin A Deficiency Among Children|Efficacy of β-carotene Biofortified Maize in Improving Vitamin A Status and Reducing the Prevalence of Vitamin A Deficiency Among Children in Rural Zambia||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|August 2012|June 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1228|||Both|4 Years|8 Years|Accepts Healthy Volunteers|||February 2014|February 5, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695148||78629|
NCT01695161|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZ-MPS-2012-01|Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.|Corneal-Compensated Intraocular Pressure, Corneal Hysteresis and Corneal Resistance Factor Measurements Performed With the Ocular Response Analyzer and Their Correlation to Conventional Goldmann Applanation Tonometry.|MPSORA|Johannes Gutenberg University Mainz|No|Recruiting|September 2012|||September 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|75|||Both|12 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|25 eyes of MPS patients 25 eyes of Fabry patients 25 eyes of healthy age matched controls        (a difference of ± 5 years in the mean between both groups is accepted)|February 2013|February 28, 2013|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695161||78628|
NCT01695174|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-006516|A Pilot Study of Xifaxan to Treat Patients With PSC|A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis|PSC|Mayo Clinic|No|Completed|August 2012|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|75 Years|No|||October 2014|October 12, 2014|September 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01695174||78627|
NCT01695187|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NB-001-010|NB-001 Treatment of Recurrent Herpes Labialis|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 Treatment of Recurrent Herpes Labialis||NanoBio Corporation|Yes|Active, not recruiting|October 2012|July 2013|Anticipated|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|362|||Both|18 Years|N/A|No|||June 2013|June 13, 2013|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695187||78626|
NCT01695200|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSRB: 2011/00028|Omega-3 Fatty Acids in Autism Spectrum Disorders|The Role of Omega-3 Fatty Acids in the Management of Singaporean Children With Autism Spectrum Disorders||National Healthcare Group, Singapore|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|5 Years|18 Years|No|||April 2013|April 30, 2013|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01695200||78625|
NCT01688440|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05.018|ETCare: Safety and Preliminary Efficacy Trial|"ETCare": A Phase II, Safety and Preliminary Efficacy Trial||Intermountain Health Care, Inc.|No|Completed|June 2005|September 2005|Actual|September 2005|Actual|Phase 0|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|10|||Both|N/A|N/A|No|||September 2012|September 18, 2012|May 12, 2008||No||No||https://clinicaltrials.gov/show/NCT01688440||79145|
NCT01695850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSRF09101501|A Double-blinded,Double-dummy Clinical Trial of Chinese Herbal Medicine (MaZiRenWan) for Functional Constipation|Chinese Herbal Medicine (MaZhiRenWan) for Functional Constipation: a Prospective, Double-blinded, Double-dummy, Randomized Controlled Study||Hong Kong Baptist University|Yes|Recruiting|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|291|||Both|18 Years|65 Years|No|||March 2015|March 21, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695850||78575|
NCT01696175|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PALVOS|PICU Admission Lactate and Central Venous Oxymetry Study|Lactate Levels and Venous Oxygen Saturation in Children Admitted to a Dutch PICU|PALVOS|Radboud University|No|Recruiting|September 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|500|||Both|N/A|16 Years|No|Non-Probability Sample|Al children admitted to a PICU <= 16 years equipped with an arterial and central venous        catheter in situ at admission or inserted within < 12 hours after admission to the PICU.|October 2012|October 3, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01696175||78550|
NCT01696487|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fru1.0|Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.|Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.||Medical University of Vienna|Yes|Completed|February 2012|February 2014|Actual|February 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|4||Actual|10|||Both|18 Years|85 Years|Accepts Healthy Volunteers|||September 2015|September 24, 2015|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01696487||78526|
NCT01696734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0261|Treatment Protocol for the Compassionate Use of Domperidone|Treatment Protocol for the Compassionate Use of Domperidone||M.D. Anderson Cancer Center|No|Recruiting|October 2012|||October 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|16 Years|N/A|No|||November 2015|November 4, 2015|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01696734||78507|
NCT01696747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GpCRC-GpR 2-5|Gastroparesis Registry 2|GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients|GpR2|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Yes|Recruiting|July 2012|December 2017|Anticipated|August 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|500|Samples With DNA|plasma serum DNA|Both|18 Years|N/A|No|Non-Probability Sample|This study will enroll patients with gastroparesis and delayed gastric emptying. These        patients can have either diabetic, idiopathic, or post-Nissen fundoplication        gastroparesis. In addition, patients with symptoms similar to gastroparesis, but with        normal gastric emptying will be enrolled as a reference group.|March 2016|March 18, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696747||78506|
NCT01697059|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RIH408212|Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis|Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis||Rhode Island Hospital|No|Completed|September 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|73|||Both|5 Years|18 Years|No|||May 2015|May 4, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01697059||78483|
NCT01697046|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIS# 39550|A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection|A Pilot Study of the Safety, Acceptability, Behavior Impact, and HIV Seroincidence Among High Risk Men Who Have Sex With Men With Access to Isentress 400 mg BID + Truvada Once Daily for Peri-exposure Chemoprophylaxis for HIV Infection Chemoprophylaxis for HIV Infection|PERIEP|Projeto Praça Onze|No|Not yet recruiting|November 2012|March 2014|Anticipated|March 2014|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|65|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 26, 2012|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697046||78484|
NCT01697020|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INV298|Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions|A SINGLE CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE OF AN ORAL MERCAPTOPURINE SUSPENSION 100 mg / 5 mL VERSUS AN ORAL MERCAPTOPURINE TABLET 50 mg (PURINETHOL®) IN AT LEAST 62 HEALTHY MALE SUBJECTS UNDER FASTING CONDITIONS||Nova Laboratories Limited|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|70|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||November 2013|November 28, 2013|September 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697020||78485|
NCT01697319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOR-006|Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation|A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation||BioMarin Pharmaceutical|Yes|Terminated|August 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|5 Years|N/A|No|||December 2015|December 8, 2015|September 17, 2012|Yes|Yes||No|October 12, 2015|https://clinicaltrials.gov/show/NCT01697319||78463|
NCT01697618|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANA/DCD/046|Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes|A Randomised, Double-blind, Single Centre, Two-way Cross-over Trial Comparing the Pharmacokinetics, Pharmacodynamics and Safety of the Biphasic Insulin Aspart 30 and Insulin Mixtard 30/70 After Multiple Dosing With a Twice Daily Dose Regimen in Type 2 Diabetic Patients||Novo Nordisk A/S|No|Completed|April 1997|November 1998|Actual|November 1998|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|13|||Both|40 Years|75 Years|No|||September 2012|October 2, 2012|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697618||78440|
NCT01697631|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIASP-1409|Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes|Comparison of Biphasic Insulin Aspart 30 Twice Daily and Biphasic Insulin Aspart 30 Twice Daily Plus Lunchtime Injection of Insulin Aspart Treatment Efficiency in Overall Glycemic Control and Postprandial Glycemic Excursions. A Multi-center, Randomized, Open-label, Two-armed Parallel Group Trial in Subjects With Type 2 Diabetes Previously Treated With Conventional Biphasic Human Insulin 30/70||Novo Nordisk A/S|No|Completed|July 2002|April 2003|Actual|April 2003|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|131|||Both|18 Years|N/A|No|||September 2012|September 28, 2012|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697631||78439|
NCT01697904|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU 052011-044|Trial of a Limited Versus Traditional Oxygen Strategy During Resuscitation in Premature Newborns|Randomized Trial of a Limited Versus Traditional Oxygen Strategy During Resuscitation in Premature Newborns||University of Texas Southwestern Medical Center|No|Completed|August 2010|January 2011|Actual|January 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|88|||Both|N/A|N/A|No|||September 2012|October 1, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01697904||78419|
NCT01698203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5277|Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy|Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA)||University Hospital, Strasbourg, France|No|Recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|2||Anticipated|92|||Both|18 Years|80 Years|No|||October 2014|October 27, 2014|September 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01698203||78396|
NCT01698515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OHARA_1898|Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy|Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy||Johns Hopkins University|No|Recruiting|August 2012|December 2017|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|18 Years|75 Years|No|Non-Probability Sample|20 subjects with RA, who are starting TNF inhibitors based on the decision of their        treating rheumatologist, will be recruited from the clinic. Patients will be starting        commercially available anti-TNF agents that have already been authorized for insurance        coverage. We are not requesting anti-TNFs or other drugs specifically for patients        enrolled in this study from Janssen or any other pharmaceutical company. Patients will        also continue on their background MTX and corticosteroids if they are taking these agents,        and MTX will be required for patients taking Infliximab or Golimumab as per approved        indication. No medications will be supplied through the study.|August 2015|August 31, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698515||78372|
NCT01698229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111012024|Collection of Cerebrospinal Fluid in Healthy Children|Collection of Cerebrospinal Fluid in Healthy Children||Weill Medical College of Cornell University|No|Terminated|December 2011|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|32|Samples Without DNA|5 mL of cerebrospinal fluid (CSF) will be collected in this study at one time point.|Both|2 Years|8 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects will be healthy controls (children ages 2 years to 8 years) undergoing a lumbar        puncture at New York Presbyterian Hospital, for clinical care purposes. They will be        inpatients and outpatients.|December 2015|December 18, 2015|August 15, 2012||No|Study interest shifted|No||https://clinicaltrials.gov/show/NCT01698229||78394|
NCT01698775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3102-019|A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)|A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects With Type 2 Diabetes Mellitus With Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control||Merck Sharp & Dohme Corp.|Yes|Completed|October 2012|January 2016|Actual|January 2016|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|213|||Both|30 Years|N/A|No|||January 2016|February 1, 2016|October 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01698775||78352|
NCT01699061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARQ197-A-U-159|Effect of Tivantinib on the QTC Interval in Cancer Subjects|A PHASE 1 SINGLE-BLIND, SINGLE-SEQUENCE STUDY ASSESSING THE EFFECT OF TIVANTINIB ON THE QTC INTERVAL IN CANCER SUBJECTS||Daiichi Sankyo Inc.|No|Completed|July 2012|May 2013|Actual|January 2013|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|38|||Both|18 Years|N/A|No|||September 2013|September 30, 2013|October 1, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01699061||78330|
NCT01699074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|182629|Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes|Acute Dose Response Effects of Korean White Ginseng (Panax Ginseng C.A. Meyer) on Cardiovascular Disease Risk Factors in Individuals With Metabolic Syndrome or Type 2 Diabetes|KWG|St. Michael's Hospital, Toronto||Completed|May 2013|January 2014|Actual|September 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|30|||Both|18 Years|75 Years|No|||April 2014|April 14, 2014|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01699074||78329|
NCT01699087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-10-084|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|August 2012|||||N/A|N/A|N/A||||||||||||||August 4, 2015|September 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01699087||78328|
NCT01699100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SF11024|Reduction of Plantar Pressure in Neuropathic Diabetic Foot Patients Using Insoles With Removable Pegs Design|Reduction of Plantar Pressure in Neuropathic Diabetic Foot Patients Using Offloading Technique: Insoles With Peg Assist Design||Taichung Veterans General Hospital|Yes|Completed|September 2011|May 2012|Actual|May 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|26|||Both|N/A|N/A|No|||October 2012|October 2, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01699100||78327|
NCT01699113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|05-021|Effects of YF476 and Rabeprazole on Gastric Function|Effects of YF476, a Gastrin Antagonist, and Rabeprazole, a Proton Pump Inhibitor, Alone and in Combination, on Gastric Function in Healthy Subjects||Trio Medicines Ltd.|No|Completed|August 2006|June 2007|Actual|June 2007|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|||Actual|32|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|October 2, 2012|September 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01699113||78326|
NCT01699360|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H3110-81072700|The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients|The Biomarker for CYP3A-mediated Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients||Central South University|No|Recruiting|September 2012|December 2013|Anticipated|September 2013|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 30, 2012|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01699360||78307|
NCT01699373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UGSA/2010|A Trial on Ultrasound-assisted Spinal Anaesthesia|A Randomised Controlled Trial on Ultrasound-assisted Spinal Anaesthesia||Changi General Hospital|No|Completed|April 2011|May 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|170|||Both|21 Years|80 Years|No|||February 2013|February 27, 2013|September 30, 2012||No||No|February 27, 2013|https://clinicaltrials.gov/show/NCT01699373||78306|Baseline characteristics not equal
NCT01695434|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GA-SWI 24|A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months|A Prospective, Observational, Single-blinded, Longitudinal MRI Study of Effect of Glatiramer Acetate on Iron Deposition in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months|GASWI|University at Buffalo|No|Completed|June 2012|February 2013|Actual|February 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|MS patients from the Baird MS Center, The Jacobs Neurological Institute, Department of        Neurology, State University at Buffalo, NY, USA who are also taking Copaxone as their        disease modifying therapy.        Healthy controls from the general population.|March 2013|March 21, 2013|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695434||78607|
NCT01688453|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-46|Overweight Management and Social Inequalities|Reduction of Inequalities in Overweight and Obesity Management Care Access Among High School Adolescents|PRALIMAP-INES|Institut National de la Santé Et de la Recherche Médicale, France|Yes|Active, not recruiting|September 2012|September 2016|Anticipated|September 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|1689|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||February 2016|February 12, 2016|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01688453||79144|
NCT01688466|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120197|Pomalidomide for Chronic Graft-versus-Host Disease|A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD||National Institutes of Health Clinical Center (CC)||Recruiting|August 2012|July 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|35|||Both|18 Years|75 Years|No|||January 2016|January 22, 2016|September 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688466||79143|
NCT01695876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110246|A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects|||Amgen||Completed|October 2012|October 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|58|||Both|25 Years|55 Years|Accepts Healthy Volunteers|||January 2015|March 2, 2015|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695876||78573|
NCT01695889|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEMA-1|Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?|A Case-control Study of Exposure to General Anesthesia and a Diagnosis of Alzheimer´s Disease Later in Life.|DEMA|University Hospital, Linkoeping|No|Active, not recruiting|May 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||1|Actual|877|||Both|N/A|N/A|No|Non-Probability Sample|Cases from a regional Alzheimer´s disease record. Matched controls from the national        population register.|March 2016|March 24, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695889||78572|
NCT01696188|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12D.328|A Study Comparing Two Methods of Placing an Interscalene Nerve Catheter for Postoperative Pain Control in Patients Who Undergo Open Shoulder Surgery.|Comparison of In-Plane vs. Out-of-Plane Ultrasound-Guided Approach for Interscalene Nerve Catheters: a Prospective, Randomized Trial||Thomas Jefferson University|No|Completed|July 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|84|||Both|18 Years|N/A|No|||October 2015|October 14, 2015|September 13, 2012||No||No|August 4, 2015|https://clinicaltrials.gov/show/NCT01696188||78549|
NCT01696526|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BMBF 0315668|Bioefficiency of of Conventional Fish and Vitamin D Fortified Fish|Bioefficiency of of Conventional Fish and Vitamin D Fortified Fish in Healthy Volunteers||Martin-Luther-Universität Halle-Wittenberg|Yes|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research|2||Actual|53|||Both|18 Years|N/A|Accepts Healthy Volunteers|||December 2012|December 19, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01696526||78523|
NCT01688765|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001796|Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis|Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis||Mclean Hospital|No|Not yet recruiting|October 2012|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|200|||Both|18 Years|45 Years|Accepts Healthy Volunteers|Non-Probability Sample|First episode psychosis patients Healthy controls|September 2012|September 17, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688765||79120|
NCT01697085|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SBMM|Effects of Sea Buckthorn Oil on Mucous Membranes|Effects of Sea Buckthorn Oil on Mucous Membranes|SBMM|Aromtech Ltd.||Completed|October 2012|May 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|116|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||January 2016|January 27, 2016|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01697085||78481|
NCT01697098|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Dexa WHH|Dexamethasone for Preterm Labour|Dexamethasone Dosing Interval: 12 or 24 Hours Apart? A Randomized,Clinical Trial|PTL|Assiut University|Yes|Completed|January 2012|August 2012|Actual|July 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|200|||Female|20 Years|40 Years|No|||September 2012|September 28, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01697098||78480|
NCT01697072|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20070622|First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma|RILOMET-1|Amgen|Yes|Terminated|October 2012|August 2015|Actual|November 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|609|||Both|18 Years|99 Years|No|||January 2016|January 18, 2016|September 26, 2012|Yes|Yes|All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data    Monitoring Committee safety review of study 20070622.|No||https://clinicaltrials.gov/show/NCT01697072||78482|
NCT01697332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hyperpolarized xenon|Functional Applications of Hyperpolarized 129Xe MRI|Functional Applications of Hyperpolarized 129Xe MRI||Brigham and Women's Hospital|Yes|Recruiting|January 2013|November 2016|Anticipated|October 2016|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|100|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||January 2016|January 12, 2016|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01697332||78462|
NCT01697306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 70/06|The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer|The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus-Calmette Guerin (BCG) Instillation Therapy on the Quality of Life in Non-muscle-invasive Bladder Cancer (NMIBC) Patients: Results of a Prospective, Randomised Phase II Trial.||Azienda Ospedaliera San Giovanni Battista|No|Completed|September 2006|May 2012|Actual|March 2011|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|120|||Both|18 Years|85 Years|No|||September 2012|September 27, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01697306||78464|
NCT01697917|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-44-562|Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction|A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction|GCQOL01|Fudan University|No|Recruiting|May 2012|May 2017|Anticipated|May 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|140|||Both|20 Years|75 Years|No|||September 2012|October 1, 2012|September 29, 2012||||No||https://clinicaltrials.gov/show/NCT01697917||78418|
NCT01697930|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-168|A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)|A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)||Memorial Sloan Kettering Cancer Center||Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|50|||Both|21 Years|90 Years|No|||February 2016|February 8, 2016|September 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01697930||78417|
NCT01698216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Consta_Sustenna|Switching From Consta® to Sustenna® in Patients With Schizophrenia|Switching From Risperidone Long Acting Injection (Consta®) to Paliperidone Palmitate (Sustenna®) in Patients With Schizophrenia and Its Influence on Subjective Well-Being: A Prospective Observational Study||Seoul National University Hospital|Yes|Completed|December 2011|May 2015|Actual|May 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|50|||Both|18 Years|65 Years|No|Non-Probability Sample|Patients with schizophrenia who would be switched to Paliperidone Palmitate from        Risperidone Long Acting Injection|December 2015|December 7, 2015|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01698216||78395|
NCT01698528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHS 2012-18|Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration|Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration||Joslin Diabetes Center|Yes|Completed|October 2012|October 2015|Actual|October 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|October 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01698528||78371|
NCT01698554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|192024-046|Bimatoprost in the Treatment of Eyelash Hypotrichosis|||Allergan|No|Completed|November 2012|March 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|464|||Both|18 Years|N/A|No|||January 2015|January 27, 2015|October 1, 2012|Yes|Yes||No|January 27, 2015|https://clinicaltrials.gov/show/NCT01698554||78369|
NCT01698788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dr.poojabansal|Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema|Role of Intraoperative Dexamethasone Implant in Improving Outcome of Taut Posterior Hyaloid Removal in Diabetic Macular Edema||Postgraduate Institute of Medical Education and Research|No|Completed|May 2011|February 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|5|||Both|60 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 29, 2012|March 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01698788||78351|
NCT01698801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-5013-MM-025|A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma|A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma||Celgene|Yes|Active, not recruiting|October 2012|June 2018|Anticipated|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|20 Years|N/A|No|||January 2016|January 15, 2016|October 1, 2012|No|Yes||No|November 25, 2014|https://clinicaltrials.gov/show/NCT01698801||78350|
NCT01698827|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastrotubes5A|Replacement Gastrostomy Tubes: Technical and Clinical Comparison of Five Commercial Models|Replacement Gastrostomy Tubes: Technical and Clinical Comparison of Five Commercial Models||University of Sao Paulo|No|Completed|January 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||5|Actual|100|||Both|18 Years|90 Years|No|Probability Sample|Adults on long-term nutritional care requiring prolonged gastrostomy feeding via        percutaneous endoscopic gastrostomy|September 2012|September 29, 2012|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01698827||78348|
NCT01699399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DTCRD101(2)-E-03|Comparing Water Exchange, Water Immersion and Air Insufflation Methods During Colonoscopy With the Option of on Demand Sedation|A Randomized, Controlled Trial Comparing Water Exchange, Water Immersion and Air Insufflation Methods During Colonoscopy With the Option of on Demand Sedation||Dalin Tzu Chi General Hospital|No|Recruiting|August 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Diagnostic|3||Anticipated|225|||Both|20 Years|80 Years|No|||July 2014|July 29, 2014|September 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01699399||78304|
NCT01695213|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Symax DEXA study|RCT Comparing the DEXA Results of the HA-Omnifit Versus the Symax Uncemented Hip Stem|A Randomized Comparative Study to Evaluate the Performance and Confirm the Safety of the Diocom Hip Syhstem in Cementless Hip Arthroplasty||Maastricht University Medical Center|No|Completed|April 2003|July 2009|Actual|July 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|75 Years|No|||September 2012|September 25, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695213||78624|
NCT01695447|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZEH-LL-CX-004-02|Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy|Randomised Controlled Trail of Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy After Pancreaticoduodenectomy||Zhejiang University||Recruiting|January 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||September 2012|September 27, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01695447||78606|
NCT01689064|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-24588|Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection|Comparison of the Posterior Septectomy and Stamm Approach to Endoscopic Pituitary Adenoma Resection: A Randomized, Single-blind Trial||University of Calgary|No|Completed|September 2012|June 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|55|||Both|18 Years|N/A|No|||December 2014|December 1, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01689064||79097|
NCT01695642|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LASIK_00049051|Long-term LASIK Follow up Study|Long-term Outcomes After Laser in Situ Keratomileusis (LASIK): Mechanical Microkeratome vs Femtosecond Laser|LASIK|University of Michigan|No|Active, not recruiting|June 2011|December 2016|Anticipated|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|All subjects who had LASIK surgery for correction of myopia or myopic astigmatism at the        Kellogg Eye Center with either the microkeratome or femtosecond laser for LASIK flap        creation between 2002 to 2005.|January 2016|January 26, 2016|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695642||78591|
NCT01695902|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-001564-77|Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding|A Multiple Center, Randomised, Parallel Group, Single-blind Clinical Trial, to Assess the Therapeutic Equivalence in Terms of Efficacy and Safety of Test Product (Levosert) and Reference Product (Mirena®) in Patients With Menorrhagia - Phase III (Therapeutic Equivalence).|LVS-20|Uteron Pharma S.A.|No|Completed|December 2007|September 2011|Actual|January 2010|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|280|||Female|18 Years|N/A|No|||September 2012|September 27, 2012|September 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01695902||78571|
NCT01688778|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2011-158|Telemedicine as a Means to Achieving Good Diabetes Control Among Patients With Type 2 Diabetes|The Copenhagen Rehabilitation Trial Part 2: Telemedicine as a Means to Achieve Good Diabetes Control Among Patients With Type 2 Diabetes||Bispebjerg Hospital|No|Active, not recruiting|June 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|165|||Both|30 Years|75 Years|No|||March 2014|March 27, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688778||79119|
NCT01690884|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120477|Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake|Ticagrelor and Adenosine Uptake. Phase II Study Comparing the Effects of Ticagrelor vs Dipyridamole on Adenosine Uptake||Vanderbilt University|No|Active, not recruiting|August 2012|September 2016|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|3||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||July 2015|July 13, 2015|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01690884||78957|
NCT01686841|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZA12-003|A Pilot Clinical Trial Investigating the Effect of Cutaneous Cooling on Sebum Production|PILOT STUDY OF NON-INVASIVE FAT LAYER REDUCTION IN THE FLANKS OF ASIAN PATIENTS WITH THE COOLCURVE+ APPLICATOR||Zeltiq Aesthetics|No|Recruiting|September 2012|September 2013|Anticipated|August 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|28|||Male|18 Years|25 Years|Accepts Healthy Volunteers|||September 2012|March 26, 2013|September 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01686841||79268|
NCT01687140|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCT003135|The Use of D-Cycloserine to Augment CBT for Pediatric OCD|The Use of D-Cycloserine to Augment Intensive Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder|DCS|University of California, Los Angeles|Yes|Recruiting|July 2012|July 2014|Anticipated|July 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|7 Years|17 Years|No|||September 2012|September 13, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687140||79245|
NCT01687452|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00015-36|Microparticles, Vector of Genetic Information During HIV Infection|Microparticles, Vector of Genetic Information During HIV Infection ?||Assistance Publique Hopitaux De Marseille|No|Completed|March 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Actual|15|||Male|30 Years|50 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|March 31, 2011||No||No||https://clinicaltrials.gov/show/NCT01687452||79221|
NCT01687686|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER-12-01|Differential Effects of Lipids on Cardiovascular Diseases: A CALIBER Study|Differential Effects of Total Cholesterol, Non-HDL Cholesterol and Triglycerides on Initial Presentation of Specific Cardiovascular Diseases (a CALIBER Study)||University College, London|Yes|Active, not recruiting|January 2001|December 2012|Anticipated|March 2010|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|175872|||Both|30 Years|N/A|No|Non-Probability Sample|The cohort used in the present analysis was drawn from patients registered with 225 GPRD        general practices in England which consented to data linkage, covering approximately 5% of        the UK population. We used an open cohort design, where participants joined the cohort        when they met the inclusion criteria at any point between 1st January 2001 and 25th March        2010, the date of the last GPRD data submission. Patients were included in cohort if,        prior to study entry, they were aged 30 to 100, had at least one year of electronic health        record data which meet General Practice Research Database data quality standards, and had        no record indicating any cardiovascular disease phenotypes. Patients were followed up        until the date of an initial presentation of one of our cardiovascular endpoints or were        censored on the date of leaving the practice or the date of last data submission from        their practice.|September 2012|September 18, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687686||79203|
NCT01687972|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00043795|INSORB Versus Subcuticular Sutures at Cesarean Section|A Randomized Controlled Trial of Skin Closure at Cesarean Section: INSORB Absorbable Staples Versus Subcuticular Sutures||Johns Hopkins University|No|Recruiting|May 2011|June 2013|Anticipated|March 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|450|||Female|16 Years|50 Years|No|||September 2012|September 14, 2012|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01687972||79181|
NCT01687985|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BLI801-202|A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults|A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults||Braintree Laboratories|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||July 2014|July 14, 2014|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687985||79180|
NCT01688284|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UNKTRPL|The Role of Uterine NK Cells and T Cell Cytokines in Recurrent Miscarriage|The Role of Uterine NK Cells and T Cell Cytokines in Recurrent Miscarriage.||Woman's Health University Hospital, Egypt|Yes|Completed|March 2010|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|2||Actual|500|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 18, 2012|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688284||79157|
NCT01694342|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ramona 1.0|Telomere Parameters in Patients With Nonalcoholic Fatty Liver|Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver|telomereFL|Meir Medical Center|No|Not yet recruiting|September 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|30|||Both|18 Years|75 Years|Accepts Healthy Volunteers|Probability Sample|Individuals - over 18 years old that were diagnosed with nonalcoholic fatty liver and are        on follow-up in our liver unit|July 2012|September 26, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694342||78691|
NCT01694641|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TL-SET|Embryo Selection by Time Lapse Monitoring for Single Embryo Transfer ("SET")|Time Lapse Embryo Monitoring Versus Standard Embryo Monitoring for Selection for Single Blastocyst Transfer||Kaali Institute IVF Center|No|Recruiting|January 2012|March 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|50|||Female|18 Years|36 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01694641||78668|
NCT01694654|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SFT-1|Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura.|Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. A Multicenter Study.||University of Zurich|Yes|Recruiting|September 2012|December 2016|Anticipated|December 2015|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|300|Samples With DNA|Tumor specimen (operative resectate)|Both|16 Years|N/A|No|Non-Probability Sample|Histologically proven diagnosis of SFTP between 2000 and 2011.|June 2015|June 25, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694654||78667|
NCT01688726|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A00977|Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid Deficiency|Evaluation of SYSTANE® BALANCE on Conjunctival Staining (CS) Visual Performance (VP) and Tear Film Kinetics (TFK) in Dry Eye Subjects With Lipid Deficiency||Alcon Research|No|Completed|December 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|91|||Both|18 Years|N/A|No|||November 2014|November 18, 2014|September 17, 2012||No||No|November 11, 2014|https://clinicaltrials.gov/show/NCT01688726||79123|
NCT01689012|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU68255|The Effect of Facial Exercise on the Appearance of Aging|A Pilot Study of the Efficacy of a Facial Exercise Program||Northwestern University|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|27|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||March 2015|March 2, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01689012||79101|
NCT01689051|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-Sivertsen|Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus|||University Hospital, Gentofte, Copenhagen|No|Completed|March 2012|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|20|||Male|18 Years|75 Years|Accepts Healthy Volunteers|||January 2014|January 30, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01689051||79098|
NCT01689324|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Td540|Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents|Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) as a Booster in Japanese Adolescents||Sanofi|No|Completed|September 2012|May 2013|Actual|November 2012|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|43|||Both|11 Years|12 Years|Accepts Healthy Volunteers|||February 2014|February 19, 2014|September 17, 2012|Yes|Yes||No|November 7, 2013|https://clinicaltrials.gov/show/NCT01689324||79077|
NCT01689584|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IC 2011-11|COsegregation of VARiants in the BRCA1/2 Genes|Study of Family COsegregation of VARiants in the BRCA1/2 Genes to Validate Their Use in Genetic|COVAR|Institut Curie|No|Recruiting|April 2012|December 2027|Anticipated|December 2022|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|2000|||Both|18 Years|N/A|No|||September 2014|September 5, 2014|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01689584||79057|
NCT01690039|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|090/12|Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis|Prospective Clinical Study About the Influence of Polymorphisms in the ATP6V1 Gene of the Vacuolar-type H+-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis in Patients With Recurrent Nephrolithiasis.||University Hospital Inselspital, Berne|No|Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|300|Samples With DNA|Blood|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients suffered from at least one kidney stone episode.|December 2015|December 15, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01690039||79022|
NCT01690052|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9999|Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva|Efficacy of Cevimeline vs. Pilocarpine in the Secretion of Saliva||University of Kentucky|No|Completed|January 2009|July 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|21 Years|N/A|No|||August 2014|August 5, 2014|April 6, 2011|Yes|Yes||No|December 16, 2012|https://clinicaltrials.gov/show/NCT01690052||79021|There are limitations that affected this study. This is a pilot study with a relative low number of patients.
NCT01690351|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3291015|A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State|A Phase 1, Open Label, Single Dose, Bioavailability Study In Healthy Volunteers Comparing PF-05089771 TS Oral Dispersion To PF-05089771 TS Capsule||Pfizer|No|Completed|September 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||December 2012|December 10, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01690351||78998|
NCT01690585|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/123/HP|Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65|Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65|FerHem|University Hospital, Rouen|No|Recruiting|January 2013|June 2016|Anticipated|January 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|116|||Both|65 Years|N/A|No|||September 2015|September 14, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690585||78980|
NCT01690598|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VeTo|Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status|Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown BRCA Status||Vejle Hospital|Yes|Completed|November 2012|February 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Female|18 Years|N/A|No|||June 2015|June 9, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01690598||78979|
NCT01690897|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H12-01659|Mindfulness-Based Treatment for Women With Sexual Interest/Desire Concerns: The MIND Group|||University of British Columbia||Recruiting|January 2013|January 2018|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|64|||Female|19 Years|65 Years|No|||June 2015|June 11, 2015|August 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01690897||78956|
NCT01690910|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RCAY 40|Effects of Mobility Devices on Nursing Compliance With Mobility Protocols|Effects of Mobility Devices on Nursing Compliance With Mobility Protocols.|EMS|Saint Joseph Mercy Health System|No|Recruiting|September 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01690910||78955|
NCT01686854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMCM01|Effectiveness of Cognitive Behavioral Therapy vs. Prescriptive Diet in Short and Medium-term Control of Body Weight|"Terapia Dell'obesità: Studio Randomizzato Per la Valutazione Dell'Efficacia Della Terapia Cognitivo-comportamentale Versus Dietoterapia Prescrittiva Nel Controllo a Breve e Medio Termine Del Peso Corporeo e Del Rischio Cardiovascolare."||IRCCS Policlinico S. Matteo|Yes|Active, not recruiting|March 2007|January 2013|Anticipated|January 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|163|||Both|18 Years|65 Years|No|||September 2012|September 13, 2012|May 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01686854||79267|
NCT01686867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COCINAS|Feasibility Intervention Trial of Two Types of Improved Cookstoves in Three Developing Countries|Feasibility Intervention Trial of Two Types of Improved Cookstoves in Three Developing Countries||Johns Hopkins Bloomberg School of Public Health|No|Completed|April 2012|May 2014|Actual|May 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|137|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||April 2015|April 1, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01686867||79266|
NCT01687153|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADC-044|A Study of Brain Aging in Vietnam War Veterans|Effects of Traumatic Brain Injury and Post Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans Using Alzheimer's Disease Neuroimaging Initiative (ADNI)|DOD-ADNI|University of Southern California|Yes|Recruiting|October 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||6|Anticipated|420|Samples With DNA|blood, urine, cerobrospinal fluid|Both|50 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|Vietnam Veterans|February 2016|February 29, 2016|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01687153||79244|
NCT01687465|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIHR granted glaucoma RCT|A Trial to Compare the Laser Treatment (SLT vs. ALT) in Glaucoma Patients|A Randomized Clinical Trial of Selective Laser Trabeculoplasty (SLT) in Open Angle Glaucoma Who Had Been Previously Treated With Complete SLT|SLTRepeat|Lawson Health Research Institute|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|144|||Both|18 Years|N/A|No|||July 2015|July 13, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687465||79220|
NCT01687478|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|13702|A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression|A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression||Eli Lilly and Company|No|Terminated|September 2012|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|176|||Both|18 Years|65 Years|No|||February 2016|February 4, 2016|September 7, 2012|Yes|Yes|Interim assessment: Lack of efficacy|No||https://clinicaltrials.gov/show/NCT01687478||79219|
NCT01687699|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|dohas01|Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients|||Dialysis Outcomes Heart Failure Aldactone Study Group||Completed|April 2008|||December 2008|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|157|||Both|30 Years|N/A||||September 2012|September 14, 2012|September 12, 2012||||No||https://clinicaltrials.gov/show/NCT01687699||79202|
NCT01687712|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FIN3002|A Phase III Study to Compare Efficacy and Safety of AFOLIA vs. Gonal-f® in Infertile Women 35 to 42 Years of Age Undergoing in Vitro Fertilization (IVF)|A Phase III Investigator- and Assessor-blinded 1:1 Randomized, Parallel-group Multicenter Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA Pen vs. Gonal-f® RFF Pen) in Normal Ovulatory Women 35 to 42 Years of Age Undergoing in Vitro Fertilization (IVF)|FIN3002|Finox AG|No|Active, not recruiting|December 2013|April 2017|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|1100|||Female|35 Years|42 Years|No|||February 2016|February 10, 2016|September 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687712||79201|
NCT01688297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VXA02-001|Safety Study of an Oral Vaccine to Prevent Seasonal Influenza|A Randomized Phase 1 Double-Blinded Placebo Controlled Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant Administered Orally to Healthy Volunteers Age 18-49 Years||Vaxart|No|Completed|September 2012|January 2014|Actual|January 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|37|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||December 2014|December 8, 2014|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01688297||79156|
NCT01688310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO11080657|A Randomized Controlled Trial of Open Surgical vs. Minimally-invasive Voluntary Adult Male Circumcision|A Randomized Controlled Trial of Open Surgical vs. Minimally-invasive Voluntary Adult Male Circumcision||Universidade Católica de Moçambique|Yes|Completed|August 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|200|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2013|June 30, 2013|August 27, 2012||No||No|June 7, 2013|https://clinicaltrials.gov/show/NCT01688310||79155|
NCT01688570|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UL1RR031973-02|Mechanisms of Neuromuscular Fatigue Post Stroke|Mechanisms of Neuromuscular Fatigue Post Stroke||Medical College of Wisconsin|No|Completed|August 2011|May 2015|Actual|May 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|27|||Both|18 Years|N/A|Accepts Healthy Volunteers|||November 2015|November 4, 2015|September 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01688570||79135|
NCT01688856|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01HD068588|Contralaterally Controlled FES of Arm & Hand for Subacute Stroke Rehabilitation|Optimizing Contralaterally Controlled FES for Acute Upper Limb Hemiplegia||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|No|Recruiting|July 2012|June 2017|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|108|||Both|21 Years|80 Years|No|||March 2016|March 21, 2016|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688856||79113|
NCT01694355|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sor0089-12-ctil|The Impact of Severe Vitamin D Deficiency and Its Correction on Bone Mineral Density (BMD) in Postmenopausal Women||Vitamin D|Soroka University Medical Center|No|Recruiting|September 2012|||October 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|1||Anticipated|30|||Female|55 Years|70 Years|Accepts Healthy Volunteers|||May 2015|May 26, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694355||78690|
NCT01694667|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00068694|Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder|Effectiveness of Omega-3 Fatty Acids for the Reduction of Hyperactivity in Children With Autism Spectrum Disorder||Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Yes|Completed|September 2012|May 2013|Actual|December 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|57|||Both|5 Years|8 Years|No|||June 2014|June 16, 2014|March 26, 2012|Yes|Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01694667||78666|
NCT01694680|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NWT-02/Human 4|Intervention Trial in Early Age-related Macular Degeneration|Intervention Study to Assess the Effect of Daily Consumption of a Lutein-enriched-egg Beverage on Maintenance of Visual Function in Subjects With Early Signs of Age-related Macular Degeneration|I-TEAM|Newtricious R&D BV|No|Active, not recruiting|October 2012|April 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|120|||Both|50 Years|N/A|No|||March 2016|March 22, 2016|September 25, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01694680||78665|
NCT01688739|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101267|Ascending Single Doses of AMG 334 in Healthy Subjects and Migraine Patients|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and Migraine Patients||Amgen|No|Completed|March 2012|August 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|60|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||January 2014|January 8, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688739||79122|
NCT01689038|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F17464 PO 1 02|Brain Imaging Study of F17464|||Pierre Fabre Medicament||Completed|November 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||February 2013|February 13, 2013|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01689038||79099|
NCT01689597|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18501|Epidural Morphine for Analgesia After Traumatic Vaginal Delivery|Efficacy of Two Doses of Epidural Morphine for Analgesia After Traumatic Vaginal Delivery: a Randomized, Double Blinded, Placebo-controlled Pilot Study||Lawson Health Research Institute||Not yet recruiting|September 2012|January 2013|Anticipated|January 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|30|||Female|18 Years|40 Years|No|||September 2012|September 20, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689597||79056|
NCT01693211|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1118|Prospective Evaluation of Circularity and Diameter of Femtosecond Laser Versus Manual Anterior Capsulotomy in Singapore National Eye Centre|Prospective Evaluation of Circularity and Diameter of Femtosecond Laser Versus Manual Anterior Capsulotomy in Singapore National Eye Centre|1118|Technolas Perfect Vision GmbH|No|Completed|September 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|N/A|No|||June 2014|June 30, 2014|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01693211||78778|
NCT01693224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DMID 10-0051|Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa|Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects in Cape Town, South Africa||Tuberculosis Clinical Diagnostics Research Consortium|No|Active, not recruiting|April 2011|February 2013|Anticipated|February 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|512|||Both|18 Years|N/A|No|||September 2012|September 23, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01693224||78777|
NCT01693692|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0092|Phase 2 Study of TD-9855 to Treat Fibromyalgia|A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)||Theravance Biopharma Antibiotics, Inc.|No|Completed|November 2012|April 2014|Actual|January 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|392|||Both|18 Years|65 Years|No|||September 2014|September 8, 2014|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693692||78741|
NCT01693705|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0053-12-HYMC|Outcome Evaluation of Patients After Percutaneous Tracheostomy Due to Respiratory Failure in an Intensive Care Unit|||Hillel Yaffe Medical Center|No|Not yet recruiting|October 2012|April 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|55|||Both|18 Years|80 Years|No|Probability Sample|Patients with respiratory failure who were mechanically ventilated in the critical care        unit|September 2012|September 24, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693705||78740|
NCT01693991|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|258431|Randomized Controlled Trial of the Meaning-Making Intervention (MMi)|Randomized Controlled Trial of the Meaning-Making Intervention (MMi) in Patients Newly Diagnosed With Advanced Cancer: A Pilot Study||Jewish General Hospital|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|3||Actual|60|||Both|N/A|N/A|No|||July 2014|July 9, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01693991||78718|
NCT01694212|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MZJ-2106|Preoperative Topic Diclofenac as a Prevention of Postoperative Macular Edema in Patients With Diabetic Retinopathy|Effect of Perioperative Topical Diclofenac on Intraocular Inflammation After Cataract Surgery and the Incidence of Postoperative Macular Edema in Patients With Diabetic Retinopathy||Eye Clinic Medic Zuljan Jukic|No|Enrolling by invitation|October 2012|September 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|120|||Both|60 Years|90 Years|No|||September 2012|September 26, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694212||78701|
NCT01694225|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCC-BRE-12-Adherence|Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors|Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors||James Graham Brown Cancer Center|Yes|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|120|||Female|18 Years|N/A|No|||January 2016|March 2, 2016|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694225||78700|
NCT01686607|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|9463-CL-1401|Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents|A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents|MYCOS|Astellas Pharma Inc|No|Active, not recruiting|October 2012|November 2020|Anticipated|April 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|35000|||Both|N/A|N/A|No|Non-Probability Sample|Patients treated with parenteral antifungals in tertiary referral centers across the        United States.|March 2016|March 3, 2016|September 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01686607||79286|
NCT01686620|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3-201|A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)|A Randomized, Parallel Group Trial Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes Using Basal-bolus Insulin Injection Therapy||Biodel|No|Completed|August 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|132|||Both|18 Years|N/A|No|||July 2015|July 22, 2015|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686620||79285|
NCT01686880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRYPHON|Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver|Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver|TRYPHON|Jules Bordet Institute|No|Terminated|September 2012|January 2015|Actual|January 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|N/A|No|||June 2015|June 30, 2015|September 11, 2012|Yes|Yes|poor recruitment and an unexpected low treatment rate|No||https://clinicaltrials.gov/show/NCT01686880||79265|
NCT01687166|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDM00048665|Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|ZERO-AF|Boston Scientific Corporation|No|Active, not recruiting|October 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|552|||Both|18 Years|N/A|No|||March 2016|March 3, 2016|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687166||79243|
NCT01687179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAIL-1100|Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis|Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus|SAIL|Brigham and Women's Hospital|Yes|Recruiting|September 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|18|||Female|18 Years|85 Years|No|||January 2015|January 28, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01687179||79242|
NCT01687491|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AXA_2012|Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome|Comparison of Anti-Xa Activity in the Treatment With Enoxaparin in ACS Admitted to the Emergency. Randomized Clinical Trial ENOXA ® Versus LOVENOX ®|AXA|Les Laboratoires des Médicaments Stériles|Yes|Completed|July 2012|October 2014|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|179|||Both|20 Years|N/A|No|||September 2012|November 2, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687491||79218|
NCT01687725|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD-TRH|Renal Denervation in Treatment Resistant Hypertension|Renal Denervation in Treatment Resistant Hypertension||University of Erlangen-Nürnberg Medical School|No|Recruiting|November 2010|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|85 Years|No|Non-Probability Sample|treatment resistant hypertensive adults|October 2015|October 8, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687725||79200|
NCT01687738|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0992|Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention|Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention||University of North Carolina, Chapel Hill|No|Recruiting|August 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|496|||Both|21 Years|N/A|No|||December 2015|December 2, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687738||79199|
NCT01687998|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11949|A Study of Evacetrapib in High-Risk Vascular Disease|Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes|ACCELERATE|Eli Lilly and Company|Yes|Active, not recruiting|October 2012|May 2016|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|12000|||Both|18 Years|N/A|No|||January 2016|January 25, 2016|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687998||79179|
NCT01689441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001755|Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis|Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis||Brigham and Women's Hospital|No|Completed|February 2013|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|67|||Both|18 Years|N/A|No|||November 2014|November 3, 2014|September 18, 2012||No||No|October 27, 2014|https://clinicaltrials.gov/show/NCT01689441||79068|
NCT01689675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00049927|Pain Management Following Musculoskeletal Injury|Pain Management Following Musculoskeletal Injury||Johns Hopkins University|No|Recruiting|January 2012|December 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|200|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01689675||79050|
NCT01689688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KobeU-001|Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography|Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography|HEAL|Kobe University|Yes|Recruiting|September 2012|October 2015|Anticipated|September 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who are percutaenous coronary intervention and stenting and eligible to receive        dual antiplatelet therapy at least more than 6 month.|September 2013|September 6, 2013|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01689688||79049|
NCT01694368|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-285|Intracoronary Imaging With NIRS-IVUS to Characterize Arterial Plaques|Multimodality Advanced Intracoronary Imaging With Near-infrared Spectroscopy and Intravascular Ultrasound to Characterize Coronary Artery Plaques Before and After Percutaneous Intervention|NIRS-IVUS|Spectrum Health Hospitals|No|Recruiting|November 2011|July 2025|Anticipated|July 2025|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Coronary Artery Disease Patients|November 2015|November 18, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694368||78689|
NCT01694381|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TS01-01|Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor|Phase 1 Trial of Mutant proUK, M5, and Its Inhibitor, C1-inhibitor||TSI, LLC|Yes|Suspended|September 2015|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|50|Samples Without DNA|plasma samples.|Male|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Community sample|January 2015|January 9, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694381||78688|
NCT01691053|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MN0511_1|Mineralocorticoid Receptor Antagonists in End Stage Renal Disease|Phase II Trial to Evaluate the Efficacy and Safety of Spironolactone in Hemodialysis Patients|MiREnDa|Wuerzburg University Hospital|Yes|Recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|N/A|No|||February 2014|February 14, 2014|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691053||78944|
NCT01689350|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012ZX09506001-004|A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment|Prospective Study Based on Genetic Polymorphisms Related to Individual Variations of Side Effects of Cyclophosphamide in Systemic Lupus Erythematosus Treatment|SLE|Sun Yat-sen University|Yes|Completed|October 2012|March 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|92|||Both|12 Years|60 Years|Accepts Healthy Volunteers|||August 2014|August 27, 2014|September 17, 2012|Yes|Yes||No|June 10, 2014|https://clinicaltrials.gov/show/NCT01689350||79075|The sample size is too small to evaluate the significance of the cyclophosphamide (CPA) medication based on genotypes. We need to enroll more SLE patients in the following study.
NCT01693237|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-084080|Improving Patient Outcome in Group Therapy for Eating Disorders|Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial|F-EAT|Psychotherapeutic Center Stolpegard|Yes|Active, not recruiting|August 2012|December 2014|Anticipated|August 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|159|||Both|18 Years|N/A|No|||February 2014|February 25, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01693237||78776|
NCT01693471|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEARCH-2012|Survey on the Effect of Health Related Quality of Life (QOL) Associated With Compliance of Carbocisteine in Asthma Patients|Survey on the Effect of Health Related QOL Associated With Compliance of Carbocisteine in Asthma Patients Study (SEARCH Study)||Kyorin Pharmaceutical Co.,Ltd|No|Completed|September 2012|January 2013|Actual|December 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|179|||Both|20 Years|N/A|No|Probability Sample|General Practitioner|February 2013|February 27, 2013|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01693471||78758|
NCT01689389|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-NFR-SER-2012/1|Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study|Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France|TBD|AstraZeneca|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Actual|2292|||Both|18 Years|130 Years|No|Probability Sample|Hospital, clinic|December 2015|December 14, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689389||79072|
NCT01689818|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201012130RB|Long-term Follow-up of Functional Performance and Exercise Efficacy in Community-dwelling Elderly With Insomnia|Long-term Follow-up of Functional Performance and Exercise Efficacy in Community-dwelling Elderly With Insomnia||National Taiwan University Hospital|Yes|Recruiting|August 2011|July 2014|Anticipated|July 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|250|||Both|65 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 20, 2012|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01689818||79039|
NCT01693458|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TZ.08.0147|Positive Change Agents Program-Tanzania (Evaluation)|Enabling People Living With HIV/AIDS (PHA) to Serve as Change Agents for HIV Prevention||Harvard School of Public Health|Yes|Completed|April 2011|September 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1046|||Both|18 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 16, 2015|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01693458||78759|
NCT01690065|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAMN107AKR07T|Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML|Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia|NICE-BORA|Ulsan University Hospital|No|Recruiting|September 2012|December 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|46|||Both|18 Years|65 Years|No|||September 2012|September 21, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01690065||79020|
NCT01690364|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-05-090-001|Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery|Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery||Samsung Medical Center|No|Completed|July 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|2||Actual|74|||Both|20 Years|75 Years|No|||December 2013|December 24, 2013|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01690364||78997|
NCT01690611|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|366151-1|Visual Feedback to Improve Balance During Walking|Sensory Treadmill to Improve of Balance During Walking||Temple University|No|Recruiting|June 2011|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|76|||Both|65 Years|N/A|No|||April 2015|April 2, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690611||78978|
NCT01690624|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1315.1|BI 836858 Dose Escalation in Refractory or Relapsed Acute Myeloid Leukemia|A Phase I, Open Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia.||Boehringer Ingelheim||Recruiting|September 2012|October 2016|Anticipated|April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|36|||Both|18 Years|N/A|No|||March 2016|March 7, 2016|September 13, 2012||||No||https://clinicaltrials.gov/show/NCT01690624||78977|
NCT01686633|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116863|An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.|A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents||GlaxoSmithKline|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1040|||Both|12 Years|N/A|No|||May 2014|July 10, 2014|September 13, 2012|Yes|Yes||No|April 3, 2014|https://clinicaltrials.gov/show/NCT01686633||79284|
NCT01686646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01361|Effects of Two Doses of a Common Cold Treatment on Alertness|Effects of Two Doses of a Common Cold Treatment on Cognitive Function||GlaxoSmithKline|No|Completed|November 2011|November 2012|Actual|November 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|240|||Both|18 Years|N/A|No|||July 2014|November 20, 2014|September 13, 2012||No||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01686646||79283|
NCT01688323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC1208|Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer|Identification of Predictors of Tolerance to Chemoradiotherapy in Elderly Patients With Head and Neck Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Suspended|July 2012|July 2016|Anticipated|July 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|3|Samples With DNA|Whole Blood|Both|65 Years|N/A|No|Non-Probability Sample|Elderly (65 and older) patients with Head and Neck Cancer|November 2015|November 23, 2015|September 14, 2012||No|Subject population inadequate for timely enrollment|No||https://clinicaltrials.gov/show/NCT01688323||79154|
NCT01688583|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100728|The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement|The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement: Multicenter, Prospective, Open-label, Observational Study||Janssen Korea, Ltd., Korea||Completed|December 2011|March 2013|Actual|March 2013|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|410|||Both|20 Years|N/A|No|Non-Probability Sample|Patients who complain of chronic pain and have pain inadequately controlled by previous        treatment with narcotic analgesics (eg, tramadols, codeines, morphines, oxycodone), and        are judged to require Fentanyl matrix administration will participate in this study.|November 2013|November 20, 2013|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688583||79134|
NCT01688869|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-12-03A|Mild Traumatic Brain Injury Registry|Mild Traumatic Brain Injury Registry|mTBI|Carolinas Healthcare System|Yes|Completed|April 2012|January 2015|Actual|January 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|40|Samples With DNA|Blood samples will be obtained in the emergency room and processed for future analysis.      Depending on the blood volume obtained, up to two citrate, two EDTA, and one Paxgene tube      will be collected.|Both|16 Years|60 Years|No|Non-Probability Sample|Patients who are seen in the CMC emergency department who have a clearly defined history        of traumatic brain injury that produced at least transient alteration in consciousness, or        change in mood, together with one or more persistent symptom lasting longer than one hour        after impact. Symptoms can include head pain, nausea, dizziness, disequilibrium,        confusion, amnesia, or irritability. All patients must be awake and alert (GCS 13 to 15),        and must be enrolled within 72 hours of the injury.|February 2015|February 9, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688869||79112|
NCT01689181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-39|Apathy in Schizophrenia|L'Apathie Dans la schizophrénie: étude Neuropsychologique et Anatomique||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|June 2012|September 2013|Anticipated|June 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Anticipated|60|||Both|20 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|schizophrenic patients:          -  outpatients of the Corentin Celton psychiatric service          -  inpatients of the Corentin Celton Day Hospital Unit        healthy volunteers: community|September 2012|September 17, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01689181||79088|
NCT01689454|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EG48BSept12|ISM1 Versus EmbrioGen Media for Embryo Culture With Previous Failure Implantation in ART Treatments|Prospective Randomized Controlled Trail to Assess the Efficacy of EmbryoGen Culture Medium to Improve Ongoing Pregnancy and Implantation Rates in IVF Treatments of Patients With a Previous History of Implantation Failure||Biogenesi|No|Enrolling by invitation|September 2012|September 2013|Anticipated|June 2013|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Female|N/A|N/A|No|Probability Sample|Infertile couple with an indication for standard IVF or intracytoplasmic sperm injection.        Moreover all couples had previous implantation failures after ART treatment (minimun 2        maximun 4 embryo replacements).|September 2012|September 17, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01689454||79067|
NCT01689467|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KD-FR-FVE|Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise|||Chonbuk National University Hospital|Yes|Recruiting|June 2012|December 2013|Anticipated|September 2012|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|60|||Both|19 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689467||79066|
NCT01689701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKU-EG-ECKL|Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis|||Chonbuk National University Hospital|Yes|Completed|August 2011|April 2012|Actual|August 2011|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|54|||Both|19 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01689701||79048|
NCT01694966|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CB-17-01/06|The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy|The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy||Cosmo Technologies Ltd|Yes|Recruiting|September 2013|June 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening|3||Anticipated|1270|||Both|50 Years|75 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694966||78643|
NCT01691599|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INFINITI|Infection Rates Following Internal Fixation of Open and Closed Tibia Fractures in India|Infection Rates Following Internal Fixation of Open and Closed Tibia Fractures in India (INFINITI): a Prospective Multi-center Observational Study.||AO Clinical Investigation and Documentation|No|Completed|August 2012|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|800|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with open or closed tibia fractures|June 2015|June 23, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01691599||78902|
NCT01691612|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001029|Role of the Isomerase Pin-1 in the Development and Treatment of Asthma|Role of the Isomerase Pin-1 in the Development and Treatment of Asthma|Pin1|Brigham and Women's Hospital|No|Active, not recruiting|March 2013|December 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|55 Years|No|||September 2015|September 21, 2015|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691612||78901|
NCT01692951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-306|Free Fatty Acid Metabolite Biomarkers for Cancer|||The Cleveland Clinic|No|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|1176|Samples Without DNA|Blood will be sampled for FFA metabolites|Both|18 Years|80 Years|No|Non-Probability Sample|Prostate cancer occurs only in men; conversely, breast cancer is almost exclusively a        disease of women. The non-cancer control patients for each type of cancer will be of the        same sex. We propose to study roughly comparable numbers of prostate and breast cancer        patients (and controls). Colon and lung cancers occur at similar rates in men and women.        We thus expect that about half of our total enrollment will be female.|May 2014|May 14, 2014|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692951||78798|
NCT01692964|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0615|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|October 2012|||||N/A|N/A|N/A||||||||||||||May 8, 2013|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01692964||78797|
NCT01689090|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HypNOCOX|Diameter Changes of Retinal Vessels During Hypoxia|Diameter Changes of Retinal Vessels During Hypoxia||University of Aarhus|No|Recruiting|November 2012|June 2016|Anticipated|May 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|60|||Both|20 Years|65 Years|Accepts Healthy Volunteers|||August 2015|August 17, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01689090||79095|
NCT01689103|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1AA020253|Therapeutic Alliances in Alcoholism Treatment|||State University of New York at Buffalo|Yes|Active, not recruiting|August 2012|March 2016|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|166|||Both|18 Years|65 Years|No|||November 2014|November 17, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01689103||79094|
NCT01689116|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|402-C-1006|Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers|A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.||Reata Pharmaceuticals, Inc.||Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|179|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|April 9, 2013|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689116||79093|
NCT01689831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JHP - 42023|Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)|Dose Comparison Study of Tuberculin Purified Protein Derivative (PPD)With Standard Tuberculin Purified Protein Derivative.||JHP Pharmaceuticals LLC|No|Recruiting|May 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Diagnostic|2||Anticipated|168|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 18, 2012|July 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689831||79038|
NCT01690078|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10-1634|Functional Modeling of the Pediatric Airway|Predictive Modeling for Treatment of Upper Airway Obstruction in Young Children||University of North Carolina, Chapel Hill|Yes|Enrolling by invitation|April 2011|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||3|Anticipated|45|||Both|N/A|17 Years|No|Non-Probability Sample|Children < 18 years of age with a diagnosis of either Pierre Robin Sequence, Micrognathia        or Subglottic Stenosis.        Clinically indicated control data will be collected from CT scans of neck and        maxillofacial CT scans performed on children < 18 years of age|May 2015|May 29, 2015|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01690078||79019|
NCT01690091|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NT13034|Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes|Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes|CARMET|Institute for Clinical and Experimental Medicine|Yes|Recruiting|November 2012|December 2016|Anticipated|May 2016|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|40 Years|70 Years|No|||March 2016|March 3, 2016|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690091||79018|
NCT01690377|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004-093|Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients|Plasmacytoid Dendritic Cells in Vaccination of Stage IV Melanoma Patients: a Phase I Study||Radboud University|No|Completed|February 2008|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||November 2014|November 29, 2014|February 5, 2008||No||No||https://clinicaltrials.gov/show/NCT01690377||78996|
NCT01690637|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDC-NCIRD-6330|Panama and El Salvador Children's Oseltamivir Study|Efficacy of Early Oseltamivir Phosphate Treatment at Hospital Admission to Reduce Severity of Illness Among Children Aged Less Than 10 Years Hospitalized With Influenza in El Salvador and Panama|PECOS|Centers for Disease Control and Prevention|Yes|Terminated|September 2012|November 2013|Actual|November 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|721|||Both|N/A|9 Years|No|||June 2014|June 30, 2014|September 17, 2012|Yes|Yes|Slower than anticipated participant accrual|No||https://clinicaltrials.gov/show/NCT01690637||78976|
NCT01687751|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FHREB 2012-057|Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients|Dexmedetomidine Compared to Midazolam for Symptom Control in Advanced Cancer Patients: A Pilot Randomized Controlled Trial (RCT)||Fraser Health|No|Withdrawn|November 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|0|||Both|19 Years|N/A|No|||January 2013|May 22, 2015|August 29, 2012||No|Study design determined to be not likely feasible|No||https://clinicaltrials.gov/show/NCT01687751||79198|
NCT01688336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCCC 1105|FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer|Phase II Single Arm Clinical Trial of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer||UNC Lineberger Comprehensive Cancer Center|Yes|Active, not recruiting|January 2012|February 2017|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Both|18 Years|N/A|No|||January 2015|January 30, 2015|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01688336||79153|
NCT01688596|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|40708|Injection of Local Anesthetic to Trocar Insertion Sites After Laparoscopy|Infiltration of Bupivacaine Local Anesthetic to Trocar Insertion Sites After Laparoscopic Hysterectomy: A Randomized, Double-Blind, Placebo-Controlled Trial||Milton S. Hershey Medical Center|Yes|Active, not recruiting|September 2012|January 2013|Anticipated|December 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|140|||Female|18 Years|80 Years|No|||September 2012|September 16, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01688596||79133|
NCT01688882|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQGE031X2202|Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment||Novartis|Yes|Terminated|January 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|20|||Both|20 Years|80 Years|No|||October 2015|October 14, 2015|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688882||79111|
NCT01689194|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRCST-L-0007|Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer|A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)||Seoul National University Hospital||Recruiting|February 2013|February 2016|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|53|||Both|18 Years|75 Years|No|||February 2013|May 23, 2014|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01689194||79087|
NCT01689207|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4910C00001|To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)|A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI)||AstraZeneca||Completed|September 2012|December 2014|Actual|December 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|4||Actual|124|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01689207||79086|
NCT01690221|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VEN307-AF-001|Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures|A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure||Ventrus Biosciences, Inc|No|Completed|October 2012|January 2014|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|434|||Both|18 Years|75 Years|No|||January 2014|January 22, 2014|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01690221||79008|
NCT01690234|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-C-2008-112|Early Coordinated Multidisciplinary Intervention to Prevent Sickness Absence and Labor Market Exclusion in Patients With Low Back Pain.|Early Coordinated Multidisciplinary Intervention to Prevent Sickness Absence and Labor Market Exclusion in Patients With Low Back Pain. A Randomized Controlled Trial|TIKI|Back and Rehabilitation Center, Copenhagen|No|Recruiting|September 2009|October 2014|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|770|||Both|18 Years|65 Years|No|||September 2012|September 19, 2012|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690234||79007|
NCT01691313|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRX-VN-002|Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm|Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Doses of Vanoxerine for Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm|COR-ART|Laguna Pharmaceuticals, Inc.|Yes|Completed|November 2012|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|104|||Both|18 Years|N/A|No|||November 2015|November 18, 2015|September 20, 2012||No||No|October 15, 2015|https://clinicaltrials.gov/show/NCT01691313||78924|
NCT01689129|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12449|Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus|A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period|EDITION JP I|Sanofi|No|Completed|September 2012|April 2014|Actual|October 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|243|||Both|18 Years|N/A|No|||June 2014|June 6, 2014|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01689129||79092|
NCT01692977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00993-38|What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate?|Orienting Oneself in a Healing Garden: What Elements of the Design Are Used as Landmarks by Patients With Alzheimer's Disease ?|JAZ-TOP|Central Hospital, Nancy, France|No|Completed|August 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|77|||Both|65 Years|90 Years|Accepts Healthy Volunteers|||July 2015|July 29, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01692977||78796|
NCT01689415|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-4-2012-102|Renal Denervation Hypertension After Stroke|Pilot Study in Renal Denervation in Patients With Stroke and Uncontrolled Hypertension|REHEARSE|Bispebjerg Hospital|No|Terminated|September 2012|November 2014|Anticipated|January 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Non-Probability Sample|Patients in the study population must be 18+ years old and have a clinical verified stroke        within the last year and treatment resistant hypertension at 150 mm Hg or higher systolic        at consultation. The patients Modified Ranking Scale must be between 0-2.|July 2014|July 15, 2014|September 18, 2012||No|Based on results from SYMPLICITY HTN-3|No||https://clinicaltrials.gov/show/NCT01689415||79070|
NCT01689623|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100873|A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants|A Phase I, 2-Panel, Open-Label Study in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and the HMG-CoA Reductase Inhibitors Atorvastatin and Simvastatin||Janssen Research & Development, LLC|No|Completed|June 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|36|||Both|19 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 1, 2013|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01689623||79054|
NCT01689636|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.1|Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients|CLINICAL STUDY OF A SINGLE-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND BIODISTRIBUTION OF TECHNETIUM Tc 99m EC20 IN NORMAL VOLUNTEERS AND OVARIAN CANCER PATIENTS||Endocyte||Completed|August 2000|July 2002|Actual|||Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|8|||Female|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 17, 2012|September 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689636||79053|
NCT01689844|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA00051935|Randomized Trial of Tailored Dietary Advice to Lower Blood Pressure|Five Plus Nuts and Beans Trial|FivePlus|Johns Hopkins University|Yes|Enrolling by invitation|April 2012|March 2015|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|120|||Both|21 Years|N/A|No|||September 2012|September 18, 2012|April 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01689844||79037|
NCT01690117|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIA5-2512FSB552|German Adaptation of REACH II|German Adaptation of Resources to Enhance Alzheimer`s Caregiver Health|DeREACH|University of Leipzig|No|Recruiting|October 2012|December 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|158|||Both|N/A|N/A|No|||January 2014|January 21, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01690117||79016|
NCT01690390|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BD-IV-43|Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease|An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease||Betta Pharmaceuticals Co.,Ltd.|Yes|Recruiting|September 2012|July 2016|Anticipated|December 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|75 Years|No|||December 2013|December 26, 2014|September 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01690390||78995|
NCT01690650|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Oxygen - HH 527|Neonatal Cerebral Oxygenation After Exposure to Oxygen Evaluated With the INVOS Oximeter|Oxygenation of the Neonatal Brain - a Study Using the INVOS Oximeter||Copenhagen University Hospital, Hvidovre|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|33|||Both|N/A|4 Weeks|No|||November 2013|November 6, 2013|June 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01690650||78975|
NCT01687777|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC07/90208|Mensenchymal Stem Cell (MSC) Included in OrthADAPT Membrane for Rotator Cuff Tears Repair|Treatment of Rotator Cuff Tears Using Autologous Bone Marrow Mensenchymal Stem Cell Transplantation.|msctendonrep|Hospital San Carlos, Madrid|No|Recruiting|May 2010|December 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|10|||Both|55 Years|80 Years|No|||September 2012|September 18, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687777||79196|
NCT01688011|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Connect® MDS/AML Registry|Connect® MDS/AML Disease Registry|Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry||Celgene|No|Recruiting|December 2013|December 2025|Anticipated|December 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|1500|Samples With DNA|Perform molecular and cellular correlative studies on blood/bone marrow and oral epithelial      cell samples.|Both|18 Years|N/A|No|Non-Probability Sample|Approximately 1,500 patients across approximately 150 sites throughout the US will be        enrolled in the Connect® MDS and AML Registry. Sites will include both community-based and        academic centers that are representative of where patients with MDS and AML are diagnosed        and treated. To best capture the distribution of sites with regard to the settings of        where MDS and AML patients are typically treated in routine practice, approximately 70-80%        of the sites will be community hematology/ oncology clinics and approximately 20-30% will        be academic-based institutions.|November 2015|November 10, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688011||79178|
NCT01688024|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052685|Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis|Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis||Li, Zhiping, M.D.|Yes|Recruiting|September 2012|September 2019|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Anticipated|130|||Both|18 Years|N/A|No|||May 2015|May 29, 2015|September 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688024||79177|
NCT01688037|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NBI-98854-1201|NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder||Neurocrine Biosciences|No|Completed|September 2012|October 2013|Actual|September 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|109|||Both|18 Years|85 Years|No|||October 2014|October 10, 2014|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688037||79176|
NCT01688349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110906|Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome|Comparative Study of Subcutaneous and Visceral Adipose Tissue in Patients Affected by Cushing Syndrome Versus 2 Controls Population|LIPOCUSH|Assistance Publique - Hôpitaux de Paris|No|Recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Basic Science|3||Anticipated|4|||Both|18 Years|N/A|No|||December 2015|December 21, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01688349||79152|
NCT01688609|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01970|Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer|Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer||National Cancer Institute (NCI)||Completed|July 2012|||December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Female|20 Years|N/A|No|||December 2013|March 20, 2014|September 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688609||79132|
NCT01688622|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KoreaSO_Exercise|Glypican4 and CTRP5 in Metabolic Syndrome and the Effect of Exercise on These Adipokines|Effects of Exercise on Glypican4,CTRP3,5 and RBP4 Levels and Circulating Levels of These Adipokines in the Subjects With or Without Metabolic Syndrome||Korea University|Yes|Completed|July 2012|September 2012|Actual|September 2012|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|90|||Both|20 Years|80 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01688622||79131|
NCT01688895|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 08-0959-04|Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact|Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact||Icahn School of Medicine at Mount Sinai|Yes|Recruiting|July 2012|December 2019|Anticipated|September 2019|Anticipated|N/A|Observational|Observational Model: Cohort||3|Anticipated|150|Samples With DNA|DNA extracted from peripheral blood sample or buccal (inside cheek) sampling for DNA      analysis; whole blood in ACD anti-coagulant to establish a lymphoid cell line, red blood      cells and plasma for biochemical assays.|Both|N/A|N/A|No|Non-Probability Sample|Subjects will be recruited from the following resources:          1. Patients followed by one of the Investigators          2. The American Porphyria Foundation (APF)          3. The Rare Diseases Clinical Research Network (RDCRN) Contact Registry          4. Non-study Physician referrals          5. Self-referrals, including family members of individuals diagnosed with Porphyria             (proband) and other individuals who may have heard about the study from other             subjects or prospective subjects.          6. Medical Records Review|September 2015|September 22, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688895||79110|
NCT01689948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC12_0080|Alzheimer Disease : Rehabilitation's Intervention at Home|Alzheimer Disease : Rehabilitation's Intervention at Home. A Preliminary Pilot Study.|pré MATAPA|Nantes University Hospital|No|Terminated|October 2012|September 2014|Actual|May 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|17|||Both|65 Years|N/A|Accepts Healthy Volunteers|||October 2014|October 14, 2014|September 18, 2012||No|difficulties of recruitment|No||https://clinicaltrials.gov/show/NCT01689948||79029|
NCT01690767|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|17770|A Study to Assess the Ability of 2% Lidocaine Gel to Reduce the Discomfort of Urethral Catheterization|A Randomized Blinded Controlled Trial of 2% Lidocaine Gel Compared to Standard of Care in Children Undergoing Urethral Catheterization||Lawson Health Research Institute|No|Completed|December 2011|December 2014|Actual|December 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|133|||Both|N/A|24 Months|No|||March 2015|March 25, 2015|February 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01690767||78966|
NCT01691079|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09621|Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes|Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes|STAMINA|University of California, San Francisco|No|Completed|December 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|20|||Both|13 Years|N/A|Accepts Healthy Volunteers|||December 2014|December 1, 2014|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691079||78942|
NCT01688843|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BSC-CDM00048360|Safety and Performance Study of the INGEVITY Lead|INGEVITY(TM) Active Fixation and Passive Fixation Pace/ Sense Lead Clinical Study||Boston Scientific Corporation|No|Active, not recruiting|October 2012|January 2019|Anticipated|January 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|1030|||Both|18 Years|N/A|No|||May 2015|May 18, 2015|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688843||79114|
NCT01688791|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8109-001|A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)|A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Alone or in Combination in Adult Subjects With Advanced Cancers||Endocyte|No|Terminated|December 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|37|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|September 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01688791||79118|
NCT01688804|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R03DK095740-01|Reducing Sedentary Time in Obese Adults|A Mobile Health Approach to Reducing Sedentary Time in Bariatric Surgery Patients||The Miriam Hospital|No|Completed|February 2013|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||September 2012|March 19, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688804||79117|
NCT01690156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Probeposition|Trial on the Effects of Ultrasound Probe Position on Ultrasound-guided Nerve Blocks|Double Blinded Randomized Control Trial on the Effects of Ultrasound Probe Position on Ultrasound-guided Nerve Blocks||University of New Mexico|No|Recruiting|August 2012|April 2013|Anticipated|March 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|62|||Both|18 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy volunteers naiive to ultrasound techniques|September 2012|September 20, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01690156||79013|
NCT01689857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1004-048-004|Clinical Trial to Evaluate the Safety and Efficacy of Scarclinic™ Thin in Surgical Scars|Phase 4 Study of Scarclinic™ Thin That Treats Surgical Scars.||Seoul National University Hospital|No|Completed|October 2010|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|55 Years|No|||April 2013|April 12, 2013|September 13, 2012||No||No|December 3, 2012|https://clinicaltrials.gov/show/NCT01689857||79036|
NCT01689870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LUD2012-005|Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma|Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma||Ludwig Institute for Cancer Research|No|Withdrawn|March 2014|August 2014|Anticipated|June 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|0|||Both|18 Years|N/A|No|||March 2014|March 31, 2014|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689870||79035|
NCT01690104|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Rifa-BP|The Effect of PXR Activation on Blood Pressure Regulation|The Effect of PXR Activation on Blood Pressure Regulation||University of Oulu|No|Completed|August 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|22|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||September 2012|December 29, 2014|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01690104||79017|
NCT01690130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Brain Stimulation Lab / MUSC|Transcranial Magnetic Stimulation Effects on Nicotine Craving|Transcranial Magnetic Stimulation Effects on Nicotine Craving||Medical University of South Carolina|No|Recruiting|June 2009|||June 2014|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01690130||79015|
NCT01690143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CTO 101669|Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation|Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma||University of Alabama at Birmingham|Yes|Recruiting|May 2012|||November 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|70 Years|No|||January 2016|January 5, 2016|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01690143||79014|
NCT01690403|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|INT12291|Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients|An Open-label, Non-randomized, Single Sequence, Two Periods, Four-treatment, Three Parallel Groups Pharmacokinetic Interaction Study of Repeated Oral Doses (Daily or Weekly Regimen) of Rifapentine on ATRIPLA™ (Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate) Given to HIV+ Patients||Sanofi|No|Completed|December 2012|March 2014|Actual|March 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|3||Actual|25|||Both|18 Years|55 Years|No|||February 2015|February 26, 2015|September 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01690403||78994|
NCT01690416|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|sloth2|Conventional vs Ultrasound Guided Arteria Cannulation.|Conventional vs Ultrasound Guided Arteria Cannulation||Aarhus University Hospital Skejby|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|40|||Both|20 Years|90 Years|No|||May 2015|May 11, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01690416||78993|
NCT01690663|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|815628|Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%|Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25% in Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block, a Randomized, Placebo Controlled Prospective Clinical Trial|Dex Dose|University of Pennsylvania|Yes|Recruiting|September 2012|September 2013|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|80|||Both|18 Years|70 Years|No|||June 2013|June 18, 2013|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01690663||78974|
NCT01688648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-07-098-001|Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft|The Comparison of Antiarrhythmic and Myocardial Protective Effect Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft||Samsung Medical Center|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)|4||Actual|160|||Both|20 Years|80 Years|No|||October 2014|October 24, 2014|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01688648||79129|
NCT01688050|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-004|TRANSFIX Zenith® Transection Clinical Study|TRANSFIX - Zenith® TX2® Low Profile Endovascular Graft for Blunt Thoracic Aortic Injury|TRANSFIX|Cook||Active, not recruiting|January 2013|May 2019|Anticipated|June 2014|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|50|||Both|16 Years|N/A|No|||October 2015|October 15, 2015|September 14, 2012|Yes|Yes||No|October 15, 2015|https://clinicaltrials.gov/show/NCT01688050||79175|
NCT01688908|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201202014|Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)|Efficacy of Endoscopy Screening on Esophageal Cancer in a High Risk Region of Rural China: a Randomized Controlled Trial|ESECC|Peking University|Yes|Recruiting|January 2012|December 2022|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening|2||Anticipated|32000|||Both|45 Years|69 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688908||79109|
NCT01689220|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SP-02L03|A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea|A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea||Solasia Pharma K.K.|No|Completed|September 2012|September 2014|Actual|January 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|20 Years|N/A|No|||September 2014|September 3, 2014|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01689220||79085|
NCT01689233|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-237-005|Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease||TauRx Therapeutics Ltd|Yes|Active, not recruiting|November 2012|May 2016|Anticipated|April 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|700|||Both|N/A|89 Years|No|||June 2014|January 8, 2015|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689233||79084|
NCT01689246|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRx-237-015|Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease||TauRx Therapeutics Ltd|Yes|Active, not recruiting|February 2013|February 2016|Anticipated|November 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|833|||Both|N/A|89 Years|No|||August 2014|August 27, 2014|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689246||79083|
NCT01689480|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1108153|Prospective Study for 24-months of Physical Training Introduced in Lifestyle of Patients With FSHD : Tolerance, Sustainability and Efficiency of Unsupervised Training Program.|Prospective Study for 24-months of Physical Training Introduced in Lifestyle of Patients With Facioscapulohumeral Dystrophy : Tolerance, Sustainability and Efficiency of Unsupervised Training Program.|FSHD2|Centre Hospitalier Universitaire de Saint Etienne|No|Completed|December 2011|September 2015|Actual|September 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|15|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with facioscapulohumeral dystrophy and who have participated to the FSHD1 study|December 2015|December 8, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689480||79065|
NCT01689714|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.4|Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma|A MULTI-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FOLATESCAN (TECHNETIUM Tc 99m EC20) IN PATIENTS WITH SUSPECTED OVARIAN CARCINOMA OR RECURRENT ENDOMETRIAL CARCINOMA||Endocyte|Yes|Completed|August 2003|August 2005|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|16|||Female|18 Years|N/A|No|||September 2012|September 17, 2012|September 9, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01689714||79047|
NCT01690494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAK0206|Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders|Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders, An Effectiveness Trial|PACT|Columbia University||Recruiting|June 2013|||July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|480|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 2, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690494||78987|
NCT01690507|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CN301-XYK-001|Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）|Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML）||Chinese PLA General Hospital|No|Completed|November 2012|January 2016|Actual|May 2015|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|55 Years|75 Years|No|||February 2016|February 23, 2016|September 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01690507||78986|
NCT01687283|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114219|Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma|A Multicenter, Randomized, Single Blind, Active Controlled, Parallel Group Study to Determine Efficacy and Safety of Nebulized Fluticasone Propionate 1mg BID Compared With Nebulized Budesonide 2mg BID Administered for 12 Weeks in Chinese Adult and Adolescent Patients With Severe Persistent Asthma||GlaxoSmithKline|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|316|||Both|17 Years|70 Years|No|||June 2014|July 3, 2014|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01687283||79234|
NCT01687296|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114220|Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma|A Multicentre, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Determine the Efficacy and Safety of Nebulized Fluticasone Propionate 1mg Twice Daily Compared With Oral Prednisone Administered for 7 Days to Chinese Pediatric and Adolescent Subjects (Aged 4 to 16 Years) With an Acute Exacerbation of Asthma||GlaxoSmithKline|No|Completed|November 2012|June 2013|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|261|||Both|4 Years|16 Years|No|||November 2013|November 21, 2013|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01687296||79233|
NCT01691092|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1111009365|PET Imaging of mGLuR5 With Drug Challenge|PET Imaging of mGluR5 With Drug Challenge||Yale University|No|Recruiting|June 2012|June 2022|Anticipated|October 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|100|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||October 2015|October 19, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01691092||78941|
NCT01689428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EG48Asept12|Ism1 Versus EmbryoGen Media for Embryo Culture in Previous Pregnancy Loss Cases|Prospective Randomized Controlled Trail to Assess the Efficacy of EmbryoGen Culture Medium to Improve Ongoing Pregnancy and Implantation Rates in IVF Treatments of Patients With a Previous History of Pregnancy Loss||Biogenesi|No|Enrolling by invitation|September 2012|September 2013|Anticipated|June 2013|Anticipated|Phase 3|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Female|N/A|N/A|No|Probability Sample|Infertile couple with an indication for standard IVF or intracytoplasmic sperm injection.        Moreover all couples had at least a previous miscarriage and/or biochemical pregnancy        experience after ART treatment.|September 2012|September 17, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01689428||79069|
NCT01689402|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-2-2012-009|MRI for the Early Evaluation of Acute Intracerebral Hemorrhage|MRI for Early Identification of Underlying Pathology in Patients With Acute Intracerebral Hemorrhage||Bispebjerg Hospital|No|Recruiting|April 2012|||April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|Patients admitted with CT-demonstrated Intracerebral Hemorrhage (ICH) within 72 hours        after symptom onset.|July 2014|July 15, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689402||79071|
NCT01686672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0467|Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis|Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis|Be In Charge|Children's Hospital Medical Center, Cincinnati|No|Completed|October 2012|October 2014|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|4 Years|9 Years|No|||October 2014|October 17, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686672||79281|
NCT01689649|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017830|A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy|Open Flexible Dose Optimisation Trial Assessing Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Who Are Treatment Naive or Have Failed One Anti-Epileptic Drug Treatment in Monotherapy||Johnson & Johnson Pte Ltd|No|Completed|May 2008|January 2010|Actual|January 2010|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|139|||Both|5 Years|18 Years|No|||April 2013|April 26, 2013|August 23, 2012|No|Yes||No|October 22, 2012|https://clinicaltrials.gov/show/NCT01689649||79052|
NCT01689883|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001592|Improving Recovery After Stroke Via Electrical Stimulation of Proprioceptors|Improving Recovery After Stroke Via Electrical Stimulation of Proprioceptors||Spaulding Rehabilitation Hospital|No|Active, not recruiting|August 2011|December 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||March 2015|March 9, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01689883||79034|
NCT01686659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NACHO|Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management|Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management|NACHO|Society for the Advancement of Blood Management, Inc|Yes|Recruiting|September 2012|March 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|470|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|August 29, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686659||79282|
NCT01686893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AN3547|Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients With COPD|STIT-1 Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients With COPD|STIT-1|Medical University Innsbruck|No|Recruiting|February 2009|March 2013|Anticipated|February 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|30 Years|80 Years|No|||September 2012|September 18, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686893||79264|
NCT01687504|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PK-PTBHIV01|Pharmacokinetics of Anti-TB Drugs in HIV/TB Co-infected Children in Ghana|Pharmacokinetics and Safety of the WHO Recommended Increased Dosages of the First-line Anti-TB Medications in Children With TB and HIV/TB Coinfection||The Miriam Hospital|Yes|Recruiting|October 2012|May 2017|Anticipated|May 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|106|Samples With DNA|EDTA plasma for analysis of drug concentrations Whole blood DNA for for genotyping of drug      metabolizing enzymes and transporters|Both|3 Months|14 Years|No|Non-Probability Sample|Children aged 3 months to 14 years old with active tuberculosis with or with HIV        coinfection|September 2012|October 10, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687504||79217|
NCT01689259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNX-CY-F103|Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults|A Single-Dose, Open-Label, Randomized, Parallel-Design Study of the Comparative Pharmacokinetics and Safety of TNX-102 2.4 mg SL Tablets (With Phosphate) at 2.4 mg and 4.8 mg, TNX-102-A 2.4 mg SL Tablets (Without Phosphate) at 2.4 mg and Cyclobenzaprine 5 mg Oral Tablets in Healthy Adults.||Tonix Pharmaceuticals, Inc.|No|Completed|September 2012|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|24|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2014|September 24, 2014|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01689259||79082|
NCT01688921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PJ-501-12-2|Jet Injection for Influenza|Jet Injection for Influenza: A Randomized Controlled Clinical Trial to Demonstrate Non Inferiority of Jet Injection vs. Needle and Syringe for Administration of Trivalent Inactivated Influenza Vaccine|JIFI|PharmaJet, Inc.|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1250|||Both|18 Years|64 Years|Accepts Healthy Volunteers|||October 2014|October 16, 2014|September 17, 2012|Yes|Yes||No|September 15, 2014|https://clinicaltrials.gov/show/NCT01688921||79108|
NCT01689493|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APHM 2010-A00933-36|Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation|Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation||Hôpital de la Timone|No|Completed|May 2011|August 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|800|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01689493||79064|
NCT01689727|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.7|Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors|A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors||Endocyte||Completed|September 2002|||September 2004|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|September 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689727||79046|
NCT01689740|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MP-9|Randomized, Double-blind, Active-placebo Controlled Study of MDMA-assisted Psychotherapy in People With Chronic PTSD|A Randomized, Double-Blind, Active Placebo-Controlled Phase 2 Pilot Study of MDMA-assisted Psychotherapy in People With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)||Multidisciplinary Association for Psychedelic Studies|No|Active, not recruiting|October 2013|May 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|10|||Both|18 Years|N/A|No|||November 2015|March 14, 2016|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689740||79045|
NCT01689961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-469|Be Healthy in Pregnancy (BHIP) With Nutrition and Exercise|Be Healthy in Pregnancy (BHIP) With Nutrition and Exercise|BHIP|McMaster University|No|Recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|350|||Female|18 Years|60 Years|No|||March 2014|March 13, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01689961||79028|
NCT01690247|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Beijing302-008|Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance|Human Umbilical Cord Mesenchymal Stem Cell Induce Liver Allografts Tolerance||Beijing 302 Hospital|Yes|Recruiting|February 2012|February 2015|Anticipated|February 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|70 Years|No|||May 2013|May 30, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690247||79006|
NCT01687010|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCT001|Diagnostic and Prognostic Value of Combination Biomarkers in the Critically Ill Patient With Sepsis.|||Southeast University, China||Recruiting|March 2012|October 2012|Anticipated|||N/A|Observational|Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Critically ill patients|August 2012|September 17, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687010||79255|
NCT01687023|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-P-001597|A Wearable System to Monitor Tai Chi Practice|A Wearable System to Monitor Tai Chi Practice||Spaulding Rehabilitation Hospital|No|Active, not recruiting|July 2011|September 2015|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|24|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Healthy Tai Chi practitioners in a wide range of proficiency|November 2014|November 20, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687023||79254|
NCT01687036|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoolLoop First|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System||AFreeze GmbH|Yes|Completed|September 2012|June 2013|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||January 2016|January 8, 2016|July 18, 2012||No||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01687036||79253|
NCT01688414|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAR0083|Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer|Utility of Fluorescence and Photoacoustic Imaging Intraoperatively to Assist With Robotic Assisted Minimally Invasive Surgery||Stanford University||Withdrawn|September 2012|||September 2015|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|0|||Both|18 Years|85 Years|No|||July 2014|July 25, 2014|September 12, 2012||No|PI left Stanford|No||https://clinicaltrials.gov/show/NCT01688414||79147|
NCT01688427|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RO1HD07177101|Perinatal Nurse Home Visiting Enhanced With mHealth Technology|Perinatal Nurse Home Visiting Enhanced With mHealth Technology||Johns Hopkins University|Yes|Recruiting|October 2012|January 2017|Anticipated|January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|800|||Female|15 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01688427||79146|
NCT01691664|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-02|Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer|Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer||Capital Medical University|No|Recruiting|September 2012|June 2017|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01691664||78897|
NCT01691898|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO27834|A Safety and Efficacy Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab (MabThera/Rituxan) or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab and Polatuzumab Vedotin Combined With Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)|A Randomized, Open Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma||Genentech, Inc.||Recruiting|September 2012|June 2019|Anticipated|June 2019|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|246|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691898||78879|
NCT01690169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9927-3909|Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects|Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects||Novo Nordisk A/S|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|45|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 23, 2013|September 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01690169||79012|
NCT01690689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALCR-120412-01|Investigation of a Customized Femoral Resurfacing Implant|Investigation of a Customized Femoral Resurfacing Implant (Episealer® Knee Condyle Device) to Assess the Safety Profile and Performance for 2 Years Post-operatively|Knee100|Episurf Medical AB|Yes|Recruiting|December 2012|February 2018|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|26|||Both|30 Years|65 Years|No|||February 2015|February 23, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01690689||78972|
NCT01689142|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFC12512|Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus|A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period|EDITION JP II|Sanofi|No|Completed|September 2012|June 2014|Actual|November 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|240|||Both|18 Years|N/A|No|||June 2014|June 4, 2014|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01689142||79091|
NCT01690429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SOMNOcheck-2012|Arousal Analysis by Pulse Wave Amplitude in Patients With Obstructive Sleep Apnea|Arousalanalyse Mittels Pulswellenamplitude Bei Patienten Mit Obstruktiver Schlafapnoe||Institut für Pneumologie Hagen Ambrock eV|No|Completed|June 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|26|||Both|20 Years|70 Years|No|||November 2013|November 13, 2013|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690429||78992|
NCT01686906|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIIOS-BL-2012|Isolated Bowman Layer Graft for Reducing and Stabilizing Advanced Keratoconus|Mid-stromal Isolated Bowman Layer Graft Implantation to Reduce and Stabilize Advanced Keratoconus||Netherlands Institute for Innovative Ocular Surgery||Recruiting|January 2011|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|16 Years|N/A|No|||June 2015|June 2, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686906||79263|
NCT01690676|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Epi2012|Effect of an Apple Polyphenol Extract on Brachial Artery Flow-mediated Vasodilatory Function|The Effect of an Apple Polyphenol Extract Rich in Epicatechin and Flavan-3-ol Oligomers (Evesse™ EPC) on Brachial Artery Flow-mediated Vasodilatory Function (FMD)in Volunteer Subjects||Danisco|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|57|||Both|40 Years|65 Years|Accepts Healthy Volunteers|||April 2014|April 7, 2014|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01690676||78973|
NCT01687517|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110115|Efficacy and Safety of Influenza Vaccine During Sarcoidosis|Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis.|SARCOVAC|Assistance Publique - Hôpitaux de Paris|Yes|Completed|October 2012|October 2014|Actual|June 2013|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|190|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||April 2015|April 20, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01687517||79216|
NCT01687764|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HCPA11-0249|Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children|Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children: a Randomized Clinical Trial||Hospital de Clinicas de Porto Alegre||Recruiting|August 2011|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|90|||Both|7 Years|11 Years|No|||September 2012|September 14, 2012|October 26, 2011||No||No||https://clinicaltrials.gov/show/NCT01687764||79197|
NCT01687530|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REGO01/12|Evaluation of the Safety and Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Femoral Fractures|Randomised Controlled Trial to Evaluate the Safety Performance and Initial Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Proximal (Subtrochanteric) Femoral Fractures||RegeneCure, Ltd.|Yes|Not yet recruiting||||||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|65 Years|No|||August 2013|August 26, 2013|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01687530||79215|
NCT01689506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VOLU-011-C P4|Fluid Resuscitation in Patients Suffering From Burns Injury|Prospective Randomised Controlled Open-label Explorative Multi-centre Pilot Trial of Volulyte®-Supplemented Versus Albumin-supplemented Fluid Resuscitation for Major Burns||Fresenius Kabi|Yes|Terminated|December 2012|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|11|||Both|18 Years|80 Years|No|||June 2014|June 25, 2014|September 18, 2012||No|Study stopped due to low recruitment|No||https://clinicaltrials.gov/show/NCT01689506||79063|
NCT01689753|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P2009/021|Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia|Prevention of Tunneled Cuffed Hemodialysis Catheter-Related Dysfunction and Bacteremia by the TEGO® Connector: A Single-Center Randomized Controlled Trial||Erasme University Hospital|No|Completed|March 2009|March 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|66|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01689753||79044|
NCT01689974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S12-02746|Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma|Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma||New York University School of Medicine|Yes|Terminated|January 2013|March 2015|Actual|March 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|19 Years|80 Years|No|||July 2015|July 30, 2015|September 18, 2012|Yes|Yes|single agent ipi will be replaced by the combination of ipi and nivo|No||https://clinicaltrials.gov/show/NCT01689974||79027|
NCT01690260|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-20040019|Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment|Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.||Northern Orthopaedic Division, Denmark|No|Active, not recruiting|September 2004|December 2015|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|20 Years|70 Years|No|||April 2015|April 9, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690260||79005|
NCT01690273|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8206212|STRETCHING IN ANKYLOSING SPONDYLITIS|BENEFITIAL EFFECTS OF A STRETCHING EXERCISE PROGRAM FOR PATIENTS WITH ANKYLOSING SPONDYLITIS - A RANDOMIZED CONTROLLED TRIAL||University of Sao Paulo|No|Completed|July 2012|June 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|40|||Both|N/A|N/A|No|||February 2014|February 12, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01690273||79004|
NCT01690520|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2603.00|Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes|Multi-center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies||Fred Hutchinson Cancer Research Center|Yes|Recruiting|December 2012|||October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|160|||Both|6 Months|45 Years|No|||November 2015|November 20, 2015|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01690520||78985|
NCT01690780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R-11-340|Oral Morphine Versus Ibuprofen|Oral Morphine Versus Ibuprofen for Post-fracture Pain Management in Children: a Randomized Controlled Study||Lawson Health Research Institute|No|Completed|September 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|183|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||July 2014|July 15, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01690780||78965|
NCT01686737|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012210|Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer Patients|Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer Patients|IFaB|Universität Duisburg-Essen|No|Withdrawn|November 2012|July 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|0|||Female|18 Years|N/A|No|||February 2013|February 4, 2013|September 12, 2012||No|Recruitment problems|No||https://clinicaltrials.gov/show/NCT01686737||79276|
NCT01688128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1207/162-001|Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)|An Open-label, Controlled, Cross-over Trial of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) in Mild Cognitive Impairment|U-SMART|Seoul National University Bundang Hospital|Yes|Active, not recruiting|August 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|55 Years|90 Years|No|||September 2015|September 19, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01688128||79169|
NCT01688141|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Shelton|A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease|A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease||University Hospitals, Leicester|Yes|Active, not recruiting|January 2010|July 2017|Anticipated|January 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|28304|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|November 20, 2009||No||No||https://clinicaltrials.gov/show/NCT01688141||79168|
NCT01688154|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|306724|Ability of Grape Seed Proanthocyanidins to Reduce Postprandial Triglycerides in Humans|Ability of Grape Seed Proanthocyanidins to Reduce Postprandial Triglycerides in Humans||Technological Centre of Nutrition and Health, Spain|No|Completed|February 2013|June 2013|Actual|May 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|16|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||July 2013|July 2, 2013|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688154||79167|
NCT01692392|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PECCAR-1|Health-related Quality of Life in Patients Undergoing Surgery for Pectus Carinatum|Short and Long-term Effects of Surgical Repair of Pectus Carinatum - A Questionnaire Study of Health-related Quality of Life, Persisten Post-surgical Pain and Sensory Disturbances.|HRQoL|University of Aarhus|No|Completed|September 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|40|||Both|10 Years|55 Years|No|Probability Sample|All patients referred to the Department of Cardiothoracic and Vascular Surgery, Aarhus        University Hospital, Skejby for the purpose of surgery for pectus carinatum from May 1,        2012 to May 1, 2013 are invited to participated in the study|September 2012|August 4, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01692392||78841|
NCT01692405|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0086-12-EMC|Semi-automatic Download of Prostate Biopsy Cores While Keeping the Orientation, Unfolding and Unity of the Sample|Semi-automatic Download of Prostate Biopsy Cores While Keeping the Orientation, Unfolding and Unity of the Sample||UC Care, Ltd.|No|Not yet recruiting|October 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|3||Anticipated|100|||Male|18 Years|N/A|No|||September 2012|September 20, 2012|September 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01692405||78840|
NCT01692418|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/0246|Preoperative Intravenous Iron to Treat Anaemia in Major Surgery|A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Anaemia Undergoing Major Open Abdominal Surgery|PREVENTT|University College, London|Yes|Recruiting|January 2014|August 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|N/A|No|||April 2015|April 17, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01692418||78839|
NCT01690182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F/11/2010|MRI Study of Stomach Volumes and Satiety|Effects of Test Meal Volume and Energy Density on Gastric Volumes and Satiety Assessed by MRI||University of Nottingham|No|Completed|December 2010|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|18|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2012|December 17, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01690182||79011|
NCT01689662|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.3|Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma|A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma||Endocyte||Completed|August 2002|July 2003|Actual|||Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|40|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|September 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689662||79051|
NCT01690442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAD2056|HIV Prevention for Injecting Drug Users in Kazakhstan|Couples Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan||Columbia University|Yes|Completed|May 2008|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|600|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2014|February 25, 2014|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690442||78991|
NCT01690455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML25701|An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice|Non-interventional Study to Assess the Efficacy of Mircera for Renal Anemia Correction in Dialysis Patients in Everyday Clinical Practice in Poland.||Hoffmann-La Roche||Completed|July 2011|June 2015|Actual|June 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|247|||Both|18 Years|N/A|No|Probability Sample|Patients with renal anemia and on dialysis therapy|March 2016|March 1, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690455||78990|
NCT01686919|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/966|Effect of Milk-free Diet on Weight and Irritable Bowel Syndrome in Morbid Obesity|Effect of Milk-free Diet on Weight and Irritable Bowel Syndrome in Morbid Obesity||Norwegian University of Science and Technology|No|Withdrawn|December 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|70 Years|No|||January 2015|January 20, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686919||79262|
NCT01686685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|begin1HMO-CTIL|Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months|Study of Correlation Between Expression of Proteins That Are Essential for Embryonic Brain Development and Neurodevelopmental Outcomes at 2 Years of Age in Premature Infants.|ASD-CXCR4|Hadassah Medical Organization|No|Recruiting|September 2013|December 2018|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|400|Samples Without DNA|blood samples. expression of proteins or RNA will be determined from the blood.|Both|N/A|1 Day|Accepts Healthy Volunteers|Non-Probability Sample|neonatal intensive care units newborn ward|September 2012|April 19, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686685||79280|
NCT01686932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLAF237ADE07|Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function|Multicentric Cross-over Trial to Assess the Glycemic Profiles on 8 Weeks of Vildagliptin and Sitagliptin Treatment, Each, in Type-2 Diabetic Patients With a Pre-existing Cardiovascular Disease Pre-treated With Insulin, Using a PROBE-design|CGM-VISIT|Novartis|No|Completed|November 2012|September 2014|Actual|September 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|51|||Both|40 Years|80 Years|No|||February 2016|February 2, 2016|September 13, 2012||No||No|August 31, 2015|https://clinicaltrials.gov/show/NCT01686932||79261|
NCT01687192|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/18|Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.|Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy.|PRIMAVERA|University Hospital, Bordeaux|No|Active, not recruiting|October 2012|November 2016|Anticipated|May 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|37|||Female|9 Years|18 Years|No|||July 2015|July 30, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687192||79241|
NCT01687205|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-011|Coital Pharmacokinetics/Pharmacodynamics (PK/PD) of Tenofovir Gel|Phase 1 Evaluation of the Impact of Coitus on Pharmacokinetics and Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing||CONRAD|Yes|Completed|November 2012|November 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|31|||Both|21 Years|46 Years|Accepts Healthy Volunteers|||December 2015|December 14, 2015|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687205||79240|
NCT01687218|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MTN-017|Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel|A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel||CONRAD|Yes|Completed|June 2013|May 2015|Actual|May 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label|6||Actual|195|||Male|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 4, 2015|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687218||79239|
NCT01686945|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN9924-3991|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes||Novo Nordisk A/S|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|107|||Male|18 Years|64 Years|Accepts Healthy Volunteers|||April 2013|April 15, 2013|September 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01686945||79260|
NCT01687231|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00012374|Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets|A Randomized Pilot Study Comparing Infection Rates in Myeloablative Allogeneic Stem Cell Transplant Patients Receiving a Non-Neutropenic Diet or a Neutropenic Diet||Duke University|Yes|Completed|April 2009|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|47|||Both|20 Years|70 Years|No|||May 2013|May 8, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687231||79238|
NCT01688362|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1016|Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears|Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Thickness Rotator Cuff Tears. A Randomized, Prospective, Double Blinded Trial.||University of North Carolina, Chapel Hill|No|Terminated|November 2012|May 2014|Actual|May 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|12|||Both|18 Years|65 Years|No|||February 2016|February 9, 2016|September 14, 2012|No|Yes|Did not meet target enrollment deadlines.|No||https://clinicaltrials.gov/show/NCT01688362||79151|
NCT01688635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14973|A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants|Comparative Pharmacokinetics and Pharmacodynamics of LY2963016 and US-Approved Lantus® After Single-Dose Subcutaneous Administration to Healthy Subjects||Eli Lilly and Company|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|91|||Both|21 Years|65 Years|Accepts Healthy Volunteers|||October 2014|October 3, 2014|September 17, 2012|No|Yes||No|October 3, 2014|https://clinicaltrials.gov/show/NCT01688635||79130|
NCT01690793|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|acute asthma|Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma|Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma|acute asthma|University of South Florida|No|Completed|February 2009|February 2011|Actual|December 2010|Actual|N/A|Observational|N/A||1|Actual|30|Samples With DNA|Samples of blood will be secured in the Division of Allergy/Immunology at the University of      South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be      appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20      degrees Celsius. GENETICS SAMPLES ARE OPTIONAL|Both|18 Years|85 Years|No|Probability Sample|The Asthma Control Test score of less than 18.        Asthma control test consists of five questions, scored 1-5 each.|May 2015|May 27, 2015|August 5, 2010||No||No||https://clinicaltrials.gov/show/NCT01690793||78964|
NCT01686750|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA032059|Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations|A Cluster Randomized Trial of Integrated Care Centers to Improve Access to HIV Prevention, Testing, and Treatment Services Among High-Risk Vulnerable Populations in India||Johns Hopkins University|Yes|Recruiting|October 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|49000|||Both|18 Years|N/A|No|||March 2016|March 16, 2016|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686750||79275|
NCT01687049|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REALITY|Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance|A Prospective Study of Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance||Sunnybrook Health Sciences Centre|No|Not yet recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Male|19 Years|90 Years|No|||November 2012|November 6, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687049||79252|
NCT01687309|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116439|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2586184 Following a Single Dose of 800mg and Repeat Oral Tablet Doses of 800mg b.d and the Effect of Food and Gender on the Pharmacokinetics of Oral GSK2586184 in Healthy Subjects|JAK116439|GlaxoSmithKline|No|Completed|April 2012|July 2012|Actual|July 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|19|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|May 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01687309||79232|
NCT01687322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|lieb004-CTIL-HMO|Long Term Follow-Up After Patients Underwent Total Hip Replacement|||Hadassah Medical Organization|No|Active, not recruiting|January 2013|||January 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|150|||Both|28 Years|85 Years|No|Probability Sample|men and women than underwent total hup replacment|March 2013|March 19, 2013|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01687322||79231|
NCT01687608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AskBio009-101|Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B|A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B||Baxalta US Inc.|Yes|Recruiting|September 2012|November 2029|Anticipated|November 2019|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Male|18 Years|75 Years|No|||February 2016|February 17, 2016|August 27, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687608||79209|
NCT01688167|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110290|Increasing Availability and Acceptability of Circumcision in Zambia|Increasing Availability and Acceptability of Circumcision in Zambia||University of Miami|No|Completed|January 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|3||Actual|1468|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2015|July 8, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01688167||79166|
NCT01683942|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NesherMimouni|A New Reproducible Method of Measuring C/D Ratio of Digital Stereo Images of Optic Disc|A New Reproducible Method of Measuring C/D Ratio of Digital Stereo Images of Optic Disc||Meir Medical Center|No|Completed|August 2012|||||N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Actual|250|||Both|N/A|N/A|No|Probability Sample|500 consecutive digitalized optic disc photos of 250 patients attending the Glaucoma        Service between 1996-2012 will be extracted from a database of optic disc photos at the        Glaucoma Service of the Ophthalmology Department, Meir Medical Center, Kfar Saba, Israel.|September 2012|September 10, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01683942||79490|
NCT01684228|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0271-10-RMB-CTIL|Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease|Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease||Rambam Health Care Campus|No|Completed|August 2010|September 2012|Actual|September 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|37|Samples Without DNA|exhaled breath|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Hemodialysis patients|May 2015|May 6, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684228||79468|
NCT01690195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M11-428|Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease|Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793||AbbVie|No|Terminated|September 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|343|||Both|55 Years|90 Years|No|||March 2014|March 21, 2014|September 19, 2012|Yes|Yes|Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.|No||https://clinicaltrials.gov/show/NCT01690195||79010|
NCT01690208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2012.136-T|Evaluation of Morbidities, Endpoints and Reaching Targets in Diabetic Patients Managed by a Diabetes Specialist Team|Evaluation of Morbidities, Endpoints and Reaching Targets in Diabetic Patients Managed by an All-encompassing Program Led by a Diabetes Specialist Team|EMERALD|Asia Diabetes Foundation|Yes|Recruiting|May 2012|December 2017|Anticipated|July 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|600|||Both|18 Years|70 Years|No|||August 2015|August 6, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690208||79009|
NCT01690702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GBG 68|Study of Nab-Paclitaxel in High Risk Early Breast Cancer|Adjuvant Phase III Trial to Compare Intense Dose-dense Adjuvant Treatment With EnPC to Dose Dense, Tailored Therapy With dtEC-dtD for Patients With High-risk Early Breast Cancer (GAIN-2)|GAIN-2|German Breast Group|Yes|Recruiting|September 2012|December 2020|Anticipated|January 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|2886|||Female|18 Years|N/A|No|||February 2016|February 9, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01690702||78971|
NCT01690715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSL 2012/06|Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery|Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery|HSL2012-06|Hospital Sirio-Libanes|Yes|Recruiting|July 2012|||||N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|50|||Both|N/A|N/A|No|Non-Probability Sample|Patients diagnosed with hepatocellular carcinoma confirmed by imaging or histological        specimen underwent surgical resection with curative intent with the presence of venous        outflow obstruction, either by direct tumor invasion or thrombosis, on portal vein or one        of its main vessels.|September 2012|September 19, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690715||78970|
NCT01690468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-17035|Triciribine and Carboplatin in Ovarian Cancer|Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research||Prescient Therapeutics, Ltd.|No|Active, not recruiting|September 2014|May 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Female|18 Years|N/A|No|||May 2015|May 26, 2015|September 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01690468||78989|
NCT01686698|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-VSL-2012-124|Effect of VSL#3 on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis|Study of the Effect of VSL#3 on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Recruiting|March 2013|March 2016|Anticipated|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|August 28, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686698||79279|
NCT01690728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBR-001|Effect of Physical Activity on Weight Loss and Cardiovascular Risk Factors After Gastric Bypass|Effect of Physical Activity on Weight Loss and Cardiovascular Risk Factors After Gastric Bypass||Hospital of South West Denmark|Yes|Enrolling by invitation|October 2012|September 2015|Anticipated|September 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|25 Years|60 Years|No|||September 2012|September 19, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01690728||78969|
NCT01687543|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ProENT11|Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients|Probiotics for Reduction of Colonisation With Clostridium Difficile in Antibiotic Treated Intensive Care Patients|ProbiEnt|Region Skane|No|Active, not recruiting|June 2012|December 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|250|||Both|18 Years|N/A|No|||October 2015|October 27, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01687543||79214|
NCT01687790|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12030005|The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease|The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease.||University of Pittsburgh|No|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|60|||Female|18 Years|N/A|No|||December 2014|December 2, 2014|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687790||79195|
NCT01688063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU49554|Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type|A Pilot Study of Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type||Northwestern University|Yes|Enrolling by invitation|July 2011|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Anticipated|250|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Up to 350 subjects who meet the inclusion/exclusion criteria for either study Part A, Part        B or both will be consented and enrolled with the goal of having 100 subjects complete        Part A and 250 subjects complete Part B. Subjects will be recruited from the Dermatology        Clinic at Northwestern University and other Northwestern University clinics.|January 2016|January 11, 2016|August 15, 2011||No||No||https://clinicaltrials.gov/show/NCT01688063||79174|
NCT01688076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU56722|Treatment of Forehead/Glabellar Rhytide Complex With Botulinum Toxin A Injection|Treatment of Forehead/Glabellar Rhytide Complex With Botulinum Toxin A Injection: Impact of Muscle Contraction on Onset of Action, Efficacy, and Duration of Treatment||Northwestern University|No|Active, not recruiting|January 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|25|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||January 2016|January 11, 2016|April 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01688076||79173|
NCT01688674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009/HD11/16712 U|Dextrose Infusion by Burettes Versus Dextrose Boluses in Prevention of Neonatal Hypoglycemia|Dextrose Boluses Versus Dextrose Infusions by Burettes in Prevention of Hypoglycemia Among Preterms Admitted at Mulago Hospital: An Open Label Randomized Clinical Trial||Makerere University|Yes|Terminated|February 2012|April 2012|Actual|April 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|140|||Both|N/A|24 Hours|Accepts Healthy Volunteers|||September 2012|September 17, 2012|September 17, 2012|Yes|Yes|There was more benefit from the infusion arm compared to the bolus arm.|No||https://clinicaltrials.gov/show/NCT01688674||79127|
NCT01688934|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VND2001|Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee|A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee||Purdue Pharma LP|Yes|Completed|September 2012|August 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|230|||Both|40 Years|80 Years|No|||December 2013|December 4, 2013|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688934||79107|
NCT01688947|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VND2002|Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)|A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)||Purdue Pharma LP|No|Completed|September 2012|April 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|105|||Both|21 Years|90 Years|No|||May 2014|May 9, 2014|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688947||79106|
NCT01686763|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEI 1147|Endothelin-1 and Methabolites Concentrations in Mycrodialysis and Cerebrospinal Fluid in Subarachnoid Hemorrhage Patients|||University of Turin, Italy||Completed|January 2004|||December 2008|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|35|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with subarachnoid hemorrhage at high risk for vasospasm according to Fisher scale        admitted to the ICU were consecutively studied.|December 2009|March 15, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686763||79274|
NCT01687062|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EK2012N31|Iron Absorption From Tef-injera in Women of Reproductive Age|Iron Absorption From Tef-injera in Women of Reproductive Age||Swiss Federal Institute of Technology|No|Completed|September 2012|October 2013|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|40|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||October 2013|October 11, 2013|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687062||79251|
NCT01687335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A00631-40|Impact on the Nutritional State and the Quality of Life|Conformity With European Recommendations Concerning the Nutritional Care of the Cancerous Patients Benefiting From a Treatment by Chemotherapy Impact on the Nutritional State and the Quality of Life||Assistance Publique Hopitaux De Marseille|No|Recruiting|September 2011|February 2015|Anticipated|September 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|85 Years|No|Non-Probability Sample|cancerous patients benefiting from a treatment by chemotherapy|August 2014|August 29, 2014|October 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01687335||79230|
NCT01687621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OCAVS|Omphalitis Community Based Algorithm Validation Study|Omphalitis Community Based Algorithm Validation Study|OCAVS|Boston University|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|1009|||Both|N/A|10 Days|Accepts Healthy Volunteers|Non-Probability Sample|Neonate between day 1-10 of life presenting to Livingstone and Mazabuka district hospitals        and community health centers in Southern Province, Zambia|July 2015|July 20, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01687621||79208|
NCT01687634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P3018725|Home Visiting for Low Income, Pregnant Women|Home Visiting for Low Income, Pregnant Women||University of California, Los Angeles|No|Active, not recruiting|October 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Anticipated|125|||Female|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 8, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01687634||79207|
NCT01687842|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P110911|Social Cognition and Turner Syndrome|Social Cognition and Turner Syndrome|COGNITUR|Assistance Publique - Hôpitaux de Paris|No|Recruiting|March 2013|March 2017|Anticipated|March 2017|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||1|Anticipated|160|Samples With DNA|Buccal DNA samples will be collected in the patient and her mother|Female|8 Years|18 Years|No|Probability Sample|Turner syndrome patients|February 2016|February 24, 2016|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01687842||79191|
NCT01687855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|wzmcwyl|Dynamic Alterations of Tongue in Sleep Apnoea Hypopnea Syndrome During Sleep|Observation of the Change in Soft Tissue in OSAH||Wenzhou Medical University|Yes|Completed|February 2003|May 2006|Actual|May 2006|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|41|||Male|40 Years|55 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects are recruited prospectively from the Tenth Hospital Affiliated to Tongji        University of Shanghai,with varying degrees of symptoms of OSAHS (daytime sleepiness,        snoring and/or nocturnal apneas).|September 2012|September 18, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687855||79190|
NCT01688752|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012NTLS086|Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia|Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia, A Pilot Study||University of Minnesota - Clinical and Translational Science Institute|No|Withdrawn||||||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples With DNA|Fasting blood samples will be obtained for lipids (total cholesterol, triglycerides, LDL-      cholesterol, HDL-cholesterol) insulin, glucose, inflammatory cytokines (CRP, IL-6, oxidized      LDL), leptin, adiponectin, insulin-like growth factor 1 (IGF-1), thyroid, and gonadal      function.|Both|7 Years|21 Years|Accepts Healthy Volunteers|Non-Probability Sample|Study entry is open to patients regardless of gender or ethnic background. While there        will be every effort to seek out and include females and minority patients, the patient        population is expected to be no different than the general pediatric oncology population        seen at the participating institutions.|August 2014|August 21, 2014|September 17, 2012||No|Funding unavailable|No||https://clinicaltrials.gov/show/NCT01688752||79121|
NCT01684241|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB_0001-01|RBL001/RBL002 Phase I Clinical Trial|Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intranodal Administration of an RNA-based Cancer Vaccine Targeting Two Tumor-associated Antigens in Patients With Advanced Melanoma|MERIT|Biontech RNA Pharmaceuticals GmbH|Yes|Completed|June 2012|July 2015|Actual|May 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|18 Years|N/A|No|||July 2015|July 21, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684241||79467|
NCT01690754|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRD_IRB_2011_03_002|Evaluating the Effectiveness of Interactive SMS Reminders on TB Treatment Outcomes|Monitoring Patient Compliance With Tuberculosis Treatment Regimens||Interactive Research and Development|No|Completed|March 2011|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|2207|||Both|15 Years|N/A|No|||March 2015|March 18, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01690754||78967|
NCT01686711|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SYR-322-4833/CCT-901|A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322|A Phase 4, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of AD-4833 When Orally Administered Once Daily as add-on to SYR-322 Versus SYR-322 Alone in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With SYR-322 in Addition to Diet and/or Exercise Therapy||Takeda|No|Completed|September 2012|December 2013|Actual|December 2013|Actual|Phase 4|Interventional|Intervention Model: Parallel Assignment, Primary Purpose: Treatment|3||Actual|207|||Both|20 Years|N/A|No|||May 2014|May 16, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01686711||79278|
NCT01690741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISK-N101|Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies||Immune System Key Ltd|Yes|Recruiting|December 2013|June 2016|Anticipated|December 2015|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|48|||Both|18 Years|N/A|No|||March 2015|March 23, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690741||78968|
NCT01686971|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0044-12rmb.ctil|The Needs of Cancer Survivors|The Needs of Cancer Survivors||Rambam Health Care Campus|No|Not yet recruiting|November 2012|November 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|150|||Both|18 Years|80 Years|No|Non-Probability Sample|Oncology patients at the end of theier treatment. The patients will consist from 2 most        common cancer diseases:Breast cancer and colon cancer.|September 2012|September 24, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686971||79258|
NCT01687257|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0125|Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation|A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation||Gilead Sciences|Yes|Completed|July 2012|October 2015|Actual|January 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 12, 2012|Yes|Yes||No|January 27, 2016|https://clinicaltrials.gov/show/NCT01687257||79236|There were no limitations affecting the analysis or results.
NCT01686958|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PMI-10246|Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer|Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer||Profound Medical Inc.|Yes|Active, not recruiting|March 2013|April 2019|Anticipated|March 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Male|65 Years|75 Years|No|||October 2015|October 23, 2015|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686958||79259|
NCT01687244|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rAd-IFN-CS-002|Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer|A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer||FKD Therapies Oy|Yes|Completed|September 2012|January 2016|Actual|October 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|N/A|No|||March 2015|February 2, 2016|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687244||79237|
NCT01687803|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200614442-2|Evaluating the Health Benefits of Physical Activity Recommendations in the Dietary Guidelines|Evaluating the Health Benefits of Physical Activity Recommendations in the Dietary Guidelines|FL52|USDA, Western Human Nutrition Research Center|No|Completed|October 2006|September 2011|Actual|September 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|2||Actual|37|||Female|42 Years|52 Years|Accepts Healthy Volunteers|||September 2012|September 13, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687803||79194|
NCT01688089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3109001|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-103: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.|NOCOS|Orion Corporation, Orion Pharma|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)|3||Actual|67|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||September 2014|September 18, 2014|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01688089||79172|
NCT01688375|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E25071969F|The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice|The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice After Endoscopic or Surgical Treatment||University Clinical Centre of Kosova|No|Not yet recruiting|December 2012|December 2013|Anticipated|July 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|54|||Both|19 Years|80 Years|No|||September 2012|October 1, 2012|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688375||79150|
NCT01688661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KHNMC 2012-074|The Effects of Age and Gender on the Advantage of Sniffing Position for Laryngoscopic View|||Kyung Hee University Hospital at Gangdong||Completed|August 2012|March 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||1|Actual|200|||Both|18 Years|90 Years|No|Probability Sample|adult patients who are scheduled for elective surgery under general anesthesia|April 2013|April 23, 2013|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01688661||79128|
NCT01689272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0111RK00337|Functional Reserve Estimation of Donor Kidney|Improving of Morphological,Clinical Biochemical and Instrumental Functional Reserve Estimation of Donor Kidney||Republican Scientific Center for Emergency Medicine|Yes|Completed|May 2011|December 2013|Actual|September 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|60|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||February 2015|February 10, 2015|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689272||79081|
NCT01690832|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|595/2012/D|Fenoldopam for Prevention of Acute Kidney Injury|Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial|FANCY|University of Roma La Sapienza|Yes|Active, not recruiting|September 2012|December 2014|Anticipated|December 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690832||78961|
NCT01686776|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3.00 # amended version 1.1|A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA|A Prospective Validation Study in Healthy Volunteers, Patients With Acute Inflammation and Patients Scheduled for Major Abdominal Surgery||Karolinska Institutet|No|Recruiting|September 2012|June 2014|Anticipated|June 2014|Anticipated|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|48|||Both|40 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 16, 2013|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686776||79273|
NCT01686789|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC08-064|Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4|Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4||King Abdulaziz Medical City|Yes|Completed|January 2011|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|70 Years|No|||February 2016|February 23, 2016|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686789||79272|
NCT01687075|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Create|CRE8 in All Comers Patients|||Tel-Aviv Sourasky Medical Center|No|Not yet recruiting|October 2012|October 2014|Anticipated|October 2013|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2012|September 13, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687075||79250|
NCT01687088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MJM/Olfactory/002|Smell Sensitivity in Chronic Migraine: A Case-Control Study|Olfactory Acuity in Chronic Migraine: A Case-Control Study||Thomas Jefferson University|No|Completed|July 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|100|||Both|18 Years|N/A|No|Non-Probability Sample|Male and female subjects, over age 18 years who meet criteria for diagnosis of chronic        migraine Controls will be age and sex-matched and will have no history of migraine|October 2014|October 21, 2014|September 13, 2012||No||No|July 14, 2014|https://clinicaltrials.gov/show/NCT01687088||79249|
NCT01687348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000817-36|Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy|Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy.||Assistance Publique Hopitaux De Marseille|No|Completed|November 2012|December 2015|Actual|November 2015|Actual|Phase 3|Interventional|Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||September 2015|January 22, 2016|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01687348||79229|
NCT01688180|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Yonghua Gao|The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis|The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis||The First Affiliated Hospital of Guangzhou Medical University|Yes|Recruiting|December 2012|May 2014|Anticipated|May 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Anticipated|160|||Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Adults with non-CF bronchiectasis attending the First Affiliated Hospital of Guangzhou        Medical College,Guangzhou,Guangdong,China|August 2013|August 6, 2013|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688180||79165|
NCT01688193|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-ESNP-102|Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male|Randomized, Open, 2-way Cross Over, Single Dose Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male||Hanmi Pharmaceutical Company Limited|No|Completed|October 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Actual|68|||Male|20 Years|50 Years|Accepts Healthy Volunteers|Probability Sample|healthy korean male|January 2013|January 4, 2013|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688193||79164|
NCT01687868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0351|Evaluation of Efficacy and Safety of General Anesthesia Using Dexmedetomidine With Sevoflurane in Patients Undergoing Arthroscopic Shoulder Surgery: Preliminary Study|||Yonsei University|Yes|Completed|July 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|19|||Both|20 Years|N/A|No|||March 2014|March 4, 2014|September 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01687868||79189|
NCT01688479|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Calendula trial|Trial Comparing Calendula Officinalis With Aqueous Cream "Essex" to Treat Skin Reactions From Radiotherapy of Breast Cancer|Randomized, Blinded Phase III Trial Comparing Calendula Officinalis Cream With Standard Aqueous Cream "Essex" for Treatment of Skin Reactions Caused by Postoperative Radiotherapy of Breast Cancer||Karolinska University Hospital|No|Completed|February 2011|September 2012|Actual|March 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|420|||Female|18 Years|N/A|No|||September 2015|September 16, 2015|September 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01688479||79142|
NCT01692444|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CHUBX 2011/34|Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease|Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease|FIBROCHIR|University Hospital, Bordeaux|No|Recruiting|April 2013|April 2016|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Anticipated|45|Samples Without DNA|Lung tissue form surgery such as lobectomy or pneumonectomy,whole blood sample for      fibrocytes analysis|Both|40 Years|N/A|No|Non-Probability Sample|Controls and COPD patients will be recruited during surgical visit or hospitalization in        thoracic surgery department before surgery.|November 2014|November 12, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692444||78837|
NCT01684514|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1-2012-089 sub-1|Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment|Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment||Herlev Hospital|Yes|Completed|October 2012|February 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Anticipated|36|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2015|February 17, 2015|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01684514||79446|
NCT01684774|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0070-12-HYMC|Comparison Between Ultrasound-guided and Landmark-guided Ankle Blocks|||Hillel Yaffe Medical Center|No|Not yet recruiting|December 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|N/A|No|Probability Sample|Adult ASA I-III (American Society of Anesthesiologists classification) patients undergoing        orthopedic foot operation with osteotomy|September 2012|September 12, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684774||79426|
NCT01686997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Elegance01|Effect of Long Biliopancreatic Limb RYGB on Weight Loss and Comorbidities|'Effect of Long biLiopancrEatic Limb lenGth in lAparoscopic Roux-eN-Y Gastric Bypass on Weight Loss and Comorbidities in Patients With Morbid obEsity: a Prospective Randomized Control Trial'|Elegance|Rijnstate Hospital|No|Active, not recruiting|July 2012|December 2018|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|280|||Both|18 Years|65 Years|No|||March 2014|May 18, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686997||79256|
NCT01686984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/381|Influence of Inspiratory Flow Pattern on Exchange of Carbon Dioxide in Humans Without Primary Lung Disease|Influence of Inspiratory Flow Pattern on Exchange of Carbon Dioxide in Humans Without Primary Lung Disease||Region Skane|No|Completed|September 2012|May 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|8|||Both|18 Years|N/A|No|||May 2015|May 13, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686984||79257|
NCT01687270|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-334-0126|Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant||Gilead Sciences|No|Completed|November 2012|August 2014|Actual|December 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|September 12, 2012|Yes|Yes||Yes|December 11, 2014|https://clinicaltrials.gov/show/NCT01687270||79235|
NCT01687816|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S53729|Nasal Specimen Collection Study in Patients With ILI and/or ARI in an Outpatient Setting|Prospective, Nasal Specimen Collection Study in Patients Presenting With Influenza Like Illness and/or Acute Respiratory Infection in an Outpatient Setting||Universitaire Ziekenhuizen Leuven|Yes|Active, not recruiting|February 2012|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Actual|300|Samples With DNA|Nasal swabs of left and right nostril|Both|N/A|N/A|No|Probability Sample|Patients with ILI will present with a sudden onset of symptoms and at least one of the        following four symptoms: fever or feverishness, malaise, headache, myalgia and at least        one of the following three respiratory symptoms: cough, sore throat, shortness of breath.        Patients with ARI will present with a sudden onset of symptoms and at least one of the        following four respiratory symptoms: cough, sore throat, shortness of breath, coryza and        the GP`s judgment that the illness is due to an infection.|September 2012|September 13, 2012|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01687816||79193|
NCT01687556|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|04-2005-043-0|EGCG Improves Acne by Modulating Molecular Targets|Epigallocatechin-3-Gallate Improves Acne in Humans by Modulating Intracellular Molecular Targets and Inhibiting P. Acnes|EGCG|Seoul National University Hospital|No|Completed|July 2005|June 2006|Actual|June 2006|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|35|||Both|15 Years|40 Years|No|||September 2012|September 13, 2012|July 23, 2010||No||No||https://clinicaltrials.gov/show/NCT01687556||79213|
NCT01687569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P12-05774|Glycaemic Responses to Cracker Snacks|Effects of Added Spice Flour on Glycaemic Responses to a Cracker Snack||Mondelēz International, Inc.|No|Completed|September 2012|October 2012|Actual|October 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|3||Actual|27|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||May 2013|May 7, 2013|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01687569||79212|
NCT01688388|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-001 Single Fraction IORT|Single Fraction Intraoperative Radiotherapy|Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial||St. Joseph Hospital of Orange|No|Recruiting|February 2012|February 2022|Anticipated|February 2015|Anticipated|Phase 1/Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|200|||Female|41 Years|N/A|No|||October 2014|October 14, 2014|September 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01688388||79149|
NCT01688687|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD-2012-01|Conventional Biopsies vs pCLE for Diagnosis of Superficial Gastric Neoplasia|The Accuracy of Probe-based Confocal Endomicroscopy Versus Conventional Biopsies for the Diagnosis of Superficial Gastric Neoplasias|pCLE|Soonchunhyang University Hospital|Yes|Completed|February 2012|||September 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|63|Samples Without DNA|Endscopic resection specimens of gastric neoplasia. Speciments were obtained either by      endoscopic mucosal resection or endoscopic submucosal dissection.|Both|18 Years|85 Years|No|Probability Sample|Consecutive patients referred to a tertiary medical center for endoscopic resection of        gastric superficial lesions.|September 2012|September 19, 2012|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01688687||79126|
NCT01688960|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R910-ST-1114|Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies|A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies||Regeneron Pharmaceuticals|No|Completed|October 2012|November 2014|Actual|November 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|48|||Both|18 Years|N/A|No|||March 2015|March 16, 2015|September 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688960||79105|
NCT01690533|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16515|Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease|Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease||Bayer|No|Completed|May 2008|July 2013|Actual|December 2010|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|497|||Both|20 Years|N/A|No|Non-Probability Sample|Patients with secondary infection of chronic respiratory disease (excluding acute        bronchitis patients who have been determined to be without chronic respiratory tract        disease based on their medical history, x-ray findings, and/or other findings)|September 2014|September 16, 2014|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690533||78984|
NCT01690806|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OTO: OTO12-0447R|Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy|Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.||Università degli Studi dell'Aquila|Yes|Completed|January 2008|March 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|328|||Both|N/A|75 Years|No|Probability Sample|patients undergoing thyroid surgery for benign and malignant thyroidal disease|August 2011|September 25, 2012|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690806||78963|
NCT01687101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SDS/STPAIN/01|STOPAIN in the Treatment of a Single Migraine Attack|A Study to Evaluate the Efficacy and Tolerability of STOPAIN in the Treatment of a Single Migraine Attack||Thomas Jefferson University|No|Completed|May 2012|May 2013|Actual|May 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|32|||Both|18 Years|65 Years|No|||April 2015|April 7, 2015|September 13, 2012||No||No|February 19, 2015|https://clinicaltrials.gov/show/NCT01687101||79248|
NCT01687361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00449-34|Can Branched Chain Amino Acids Supplementation Reduce Muscle Damage Induced by Neuromuscular Electrical Stimulation? A Combined Functional and Metabolic Non-invasive Investigation in Healthy Humans|Can Branched Chain Amino Acids Supplementation Reduce Muscle Damage Induced by Neuromuscular Electrical Stimulation ? A Combined Functional and Metabolic Non-invasive Investigation in Healthy Humans.||Assistance Publique Hopitaux De Marseille|No|Completed|June 2012|January 2014|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|20|||Male|18 Years|35 Years|Accepts Healthy Volunteers|||August 2014|August 29, 2014|June 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01687361||79228|
NCT01687374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HvH-2011-545-1|Parathyroid Hormone for the Treatment of Humerus Fractures|Phase IV Study of the Effect of Parathyroid Hormone on Fractures of the Humerus||Hvidovre University Hospital|Yes|Recruiting|March 2012|December 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|72|||Both|65 Years|85 Years|No|||September 2012|September 13, 2012|March 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01687374||79227|
NCT01687647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-A01380-41|Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure|Interest of Morphometric Analysis of Sputum Cytology for Lung Cancer Screening in Workers Highly Exposed to Asbestos - Exploratory Analysis of Biomarkers Predictive for Lung Cancer|AMORCE-CBP|University Hospital, Caen|No|Enrolling by invitation|September 2012|December 2019|Anticipated|March 2015|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|1||Anticipated|1000|||Both|56 Years|N/A|No|||April 2014|April 8, 2014|August 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01687647||79206|
NCT01687400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201210102|Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Genomic Predictors of Decitabine Response in AML/MDS||Washington University School of Medicine|No|Recruiting|February 2013|January 2019|Anticipated|April 2018|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|125|||Both|18 Years|N/A|No|||November 2015|November 30, 2015|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687400||79225|
NCT01687881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CEH-K34KSF-AHUS|Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option in Cervicogenic Headache|Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option in Cervicogenic Headache? A Randomized Controlled Clinical Trial.||University Hospital, Akershus|Yes|Completed|September 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|19|||Both|18 Years|70 Years|No|||December 2015|December 30, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687881||79188|
NCT01687894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CNUH-2012-074|Vasopressin to Prevent Hypotension During Beach Chair Surgery|Clinical Trials of Vasopressin for Prevention of Hypotension During Shoulder Surgery in Beach Chair Position Under General Anesthesia||Chonnam National University Hospital|No|Recruiting|May 2012|December 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|60|||Both|18 Years|70 Years|No|Non-Probability Sample|Patients undergoing shoulder surgery in the beach chair position under the general        anesthesia|September 2012|September 15, 2012|September 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01687894||79187|
NCT01687907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|18/2.9.2009, 178/13/03/03/2009|The Effects of Music on Fear of Childbirth and Outcome of Delivery|A Randomized Longitudinal Trial About the Effects of Music on Fear of Childbirth and Outcome of Delivery|MUUSA|Helsinki University Central Hospital||Recruiting|October 2009|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|800|||Female|N/A|N/A|No|||September 2012|September 15, 2012|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01687907||79186|
NCT01692145|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KCT1204|A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes|A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes||Kissei Pharmaceutical Co., Ltd.|No|Completed||||||Phase 2|Interventional|Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||||||Both|20 Years|N/A|No|||May 2014|May 29, 2014|September 20, 2012||||No||https://clinicaltrials.gov/show/NCT01692145||78860|
NCT01688492|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-120|Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer|A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|57|||Male|18 Years|N/A|No|||September 2015|September 18, 2015|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688492||79141|
NCT01692158|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOBLA0512SC-I|Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose|Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Subcutaneous Administration.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Not yet recruiting|March 2013|November 2013|Anticipated|November 2013|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|36|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692158||78859|
NCT01692431|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12/EE/011|The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity|The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity|FOFA|University of East Anglia|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|28|||Male|35 Years|55 Years|Accepts Healthy Volunteers|||October 2013|October 14, 2013|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692431||78838|
NCT01692171|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ENOBLA0612IV-I|Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration|Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Intravenous Administration.||L.A.L Clinica Pesquisa e Desenvolvimento Ltda.|Yes|Completed|September 2013|March 2014|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 3, 2016|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692171||78858|
NCT01692457|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100823|A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Golimumab (Simponi) Among Adult Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis||Janssen Pharmaceutica|No|Withdrawn|July 2013|July 2016|Anticipated|July 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Adult Filipino patients with rheumatoid arthritis, psoriatic arthritis and ankylosing        spondylitis; and who are on the approved product label of golimumab.|November 2015|November 30, 2015|September 21, 2012||No|The company decided to cancel the study in conformity with Philippine FDA Circular 2013-004|No||https://clinicaltrials.gov/show/NCT01692457||78836|
NCT01693250|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEENS-2012|iStart Smart for Teens for Healthy Weight Management|Phase 1 Study of Fitbit and Apps on Healthy Weight Management in Obese Teens in Primary Care Clinics||University of California, San Francisco|No|Not yet recruiting|May 2015|December 2016|Anticipated|December 2015|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|60|||Both|13 Years|18 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01693250||78775|
NCT01687829|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|F20120913|Macular Hole Surgery With and Without Internal Limiting Membrane Peeling：A Systematic Review and Meta-analysis|Macular Hole Surgery With and Without Internal Limiting Membrane Peeling：A Systematic Review and Meta-analysis||Wenzhou Medical University||Recruiting|January 2013|May 2014|Anticipated|April 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Anticipated|400|||Both|18 Years|80 Years|No|Probability Sample|patients were scheduled to undergo macular hole surgery and randomized to with and without        internal limiting membrane (ILM) peeling|February 2014|February 12, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687829||79192|
NCT01687582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL-DIAB-02|Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients|Clinical and Histopathological Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|No|Recruiting|January 2012|March 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|20 Years|75 Years|No|||September 2012|September 13, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687582||79211|
NCT01688115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPAD2012|Reduction of Preoperative Anxiety in Children: Clickamico Project 2nd Phase|Reduction of Preoperative Anxiety in Children: Clickamico Project 2nd Phase||University of Florence|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|40|||Both|6 Years|11 Years|No|||October 2015|October 28, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01688115||79170|
NCT01688973|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01641|Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery|Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma||National Cancer Institute (NCI)|No|Active, not recruiting|August 2012|||April 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|78|||Both|N/A|N/A|No|||November 2015|March 22, 2016|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688973||79104|
NCT01689285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCN-AKF 11.04|Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir|Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of VZV and HSV Infections in Children, Phase I (VALID-I)|VALID-I|Radboud University|No|Completed|December 2013|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label|2||Actual|16|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2015|September 2, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01689285||79080|
NCT01688102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MPO-0787|The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile|The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile||Rockefeller University|No|Active, not recruiting|September 2012|||July 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01688102||79171|
NCT01689766|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EC20.9|Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma|A Screening Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma||Endocyte||Completed|November 2003|||November 2007|Actual|Phase 2|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|150|||Both|18 Years|N/A|No|||September 2012|September 17, 2012|September 9, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689766||79043|
NCT01689987|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8296|Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma||OHSU Knight Cancer Institute|Yes|Active, not recruiting|October 2012|||April 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|September 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01689987||79026|
NCT01690286|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100915|Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers|An Open-Label Study to Assess the Effects of Repeated Twice-Daily Doses of Ketoconazole on the Steady-State Pharmacokinetics of JNJ-38518168 in Healthy Subjects||Janssen Research & Development, LLC||Completed|October 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2013|July 15, 2013|September 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01690286||79003|
NCT01690299|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CC-10004-PSOR-010|Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis|A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo in Subjects With Moderate to Severe Plaque Psoriasis||Celgene|Yes|Active, not recruiting|October 2012|April 2016|Anticipated|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|250|||Both|18 Years|N/A|No|||December 2015|December 4, 2015|September 19, 2012|Yes|Yes||No|July 2, 2015|https://clinicaltrials.gov/show/NCT01690299||79002|
NCT01690819|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PROLABI|Protective Ventilatory Strategy in Severe Acute Brain Injury|Protective Ventilatory Strategy in Severe Acute Brain Injury: Randomized Multi-center Controlled Trial|PROLABI|University of Turin, Italy|Yes|Recruiting|October 2013|March 2016|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|524|||Both|18 Years|N/A|No|||January 2014|January 10, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690819||78962|
NCT01690559|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16516|Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution|||Bayer|No|Completed|April 2010|January 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|704|||Both|7 Years|N/A|No|Non-Probability Sample|Patients who received Ciproxan iv administration without dilution in the daily practice        among those with sepsis, secondary infection due to trauma, burn, or surgical wound,        pneumonia, peritonitis, cholecystitis, cholangitis, and anthrax as the indications of this        drug.|September 2012|September 19, 2012|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690559||78982|
NCT01686815|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CILO522DUSXXT|Cross-Sectional Iloperidone IVGTT|Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)||Massachusetts General Hospital|No|Recruiting|October 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||3|Anticipated|60|Samples Without DNA|Samples will be retained to test IL-6 and other inflammatory markers.|Both|18 Years|65 Years|No|Non-Probability Sample|Subjects will include 60 outpatients between the ages of 18-65 with schizophrenia,        schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS,        delusional disorder or paranoid disorder. 60 subjects will be screened and 45 will enter        the cross-sectional study (15 olanzapine, 15 iloperidone, 15 risperidone-treated subjects        matched for BMI).|April 2015|April 15, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686815||79270|
NCT01687114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HNRC2785|Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products|Urinary Proanthocyanidin (PAC) A2 as a Biomarker of Compliance to Intake of Cranberry Products - A Pilot Study||Tufts University|No|Completed|September 2012|April 2014|Actual|March 2013|Actual|N/A|Interventional|Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|5|||Female|20 Years|40 Years|Accepts Healthy Volunteers|||December 2014|December 10, 2014|September 13, 2012||No||No|November 13, 2014|https://clinicaltrials.gov/show/NCT01687114||79247|
NCT01687387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IPH2102-201|Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)|Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission|EFFIKIR|Innate Pharma|Yes|Active, not recruiting|October 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|150|||Both|60 Years|80 Years|No|||February 2016|February 23, 2016|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01687387||79226|
NCT01687413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201207059|Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer|Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) Trial for Oropharynx Malignancy|ADEPT|Washington University School of Medicine|No|Recruiting|January 2013|October 2021|Anticipated|October 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|496|||Both|21 Years|N/A|No|||March 2016|March 15, 2016|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687413||79224|
NCT01687660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012CB518501-2|Acupuncture for Migraine Prophylaxis|A Continuous Study on Abiding Effect of Acupuncture for Migraine Treatment|AMP|Chengdu University of Traditional Chinese Medicine|Yes|Recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|249|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|October 22, 2013|August 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687660||79205|
NCT01691391|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/323|Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET|Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET||VU University Medical Center||Recruiting|January 2012|||January 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|25|||Both|18 Years|N/A|No|Probability Sample|Patients with histopathologically confirmed advanced CRC with K-Ras wild type, aged ≥ 18        years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR        antibody monotherapy (3rd line palliative treatment).|June 2015|June 2, 2015|May 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01691391||78918|
NCT01691703|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COM.12|Combined Technique for Difficult Intubation|Combined Technique Using Videolaryngoscopy and Bonfils for a Difficult Airway Intubation||Catharina Ziekenhuis Eindhoven|No|Completed|August 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)|1||Actual|40|||Both|18 Years|N/A|No|||February 2013|February 19, 2013|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01691703||78894|
NCT01691716|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRJ-00014|The Efficacy of Tendoactive, Eccentric Training, and the Combination of Both as a Treatment of Achilles Tendinopathy|A Prospective Randomized Study Comparing the Therapeutic Effect of Tendoactive®, Eccentric Training, and a Combination of Both as a Treatment of Achilles Tendinopathy|Tendoactive|Bioiberica||Completed|April 2012|September 2013|Actual|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|100|||Both|18 Years|70 Years|No|||February 2014|February 25, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01691716||78893|
NCT01691950|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO1934|Investigating Lower Limb Trauma|Investigating the Outcomes of Lower-limb Trauma Patients||Imperial College London|No|Completed|April 2012|February 2014|Actual|February 2014|Actual|N/A|Observational|Observational Model: Cohort||3|Actual|30|||Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Participants who have been treated following lower limb trauma at the Imperial College NHS        Trust sites will be recruited for this study.|March 2013|December 11, 2014|April 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01691950||78875|
NCT01688531|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RD.03.SPR.40183E|A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients|A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients||Galderma R&D|No|Active, not recruiting|August 2012|September 2013|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science|1||Actual|38|||Both|18 Years|35 Years|No|||September 2013|September 16, 2013|September 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01688531||79138|
NCT01688544|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08-112|Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism|Phase 1 Study to Evaluate the Effect of CYP Polymorphism and Gender on the Pharmacokinetics and Pharmacodynamics of Ilaprazole After Multiple Dosing||Inje University|Yes|Completed|January 2009|December 2011|Actual|December 2011|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|27|||Both|20 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 19, 2012|December 6, 2011||No||No||https://clinicaltrials.gov/show/NCT01688544||79137|
NCT01694602|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-064|Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II|Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase 2|3MH-2|The University of Texas Medical Branch, Galveston|No|Completed|November 2012|June 2015|Actual|June 2015|Actual|Phase 2|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|8|Samples Without DNA|Spot urine samples.|Both|18 Years|N/A|No|Non-Probability Sample|We will conduct a longitudinal study (repeated measures design) in 30 newly diagnosed        nonsmall cell lung cancer (NSCLC) patients who are not candidates for curative resection.|July 2015|July 1, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694602||78671|
NCT01688401|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|J11164|Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).|Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).||Sidney Kimmel Comprehensive Cancer Center|Yes|Recruiting|January 2013|||December 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|5|||Both|1 Month|17 Years|No|||November 2015|November 17, 2015|September 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688401||79148|
NCT01689298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-05|Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment|Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|January 2010|August 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 17, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01689298||79079|
NCT01689519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28141|A Phase III Study Comparing Vemurafenib vs Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With Metastatic Melanoma|A Phase III Double-blind, Placebo-controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma|coBRIM|Hoffmann-La Roche||Active, not recruiting|January 2013|December 2017|Anticipated|December 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|495|||Both|18 Years|N/A|No|||October 2015|October 1, 2015|September 18, 2012|Yes|Yes||No|July 1, 2015|https://clinicaltrials.gov/show/NCT01689519||79062|
NCT01689532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100876|A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine|A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously as Monotherapy, in Japanese Subjects With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine||Janssen Pharmaceutical K.K.|Yes|Completed|November 2012|March 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|121|||Both|20 Years|N/A|No|||February 2016|February 16, 2016|September 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01689532||79061|
NCT01689779|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P001852|High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status|Effect of High-dose Cholecalciferol Supplementation on Perioperative Vitamin D Status in Colorectal Surgery Patients||Massachusetts General Hospital|Yes|Active, not recruiting|January 2013|||December 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||December 2014|December 11, 2014|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01689779||79042|
NCT01690000|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-AKA|Treatment of Osteopenia With Melatonin|Treatment of Osteopenia With Melatonin: Effects on BMD, Muscle Strength and Quality of Life|MelaOst|University of Aarhus|Yes|Completed|November 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|82|||Female|55 Years|75 Years|Accepts Healthy Volunteers|||April 2013|June 3, 2014|June 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01690000||79025|
NCT01690312|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-09-002|Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy|Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.||Nutrasource Diagnostics Inc.|No|Completed|September 2012|February 2014|Actual|December 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|36|||Both|18 Years|70 Years|No|||February 2014|February 6, 2014|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01690312||79001|
NCT01690546|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00036909|Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence|An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL®) in Opioid Addiction|BUP/NXT-VIVI|Duke University|Yes|Completed|September 2012|February 2015|Actual|February 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|35|||Both|18 Years|65 Years|No|||June 2015|June 8, 2015|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01690546||78983|
NCT01686802|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102923|Post-operative Oral Morphine Versus Ibuprofen|Oral Morphine Versus Ibuprofen for Post-operative Pain Management in Children: a Randomized Controlled Study||Lawson Health Research Institute|No|Recruiting|September 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|150|||Both|5 Years|17 Years|Accepts Healthy Volunteers|||March 2016|March 2, 2016|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01686802||79271|
NCT01694823|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CS-ACI2012001|Safety and Efficacy Study of Cells Sheet-Autologous Chondrocyte Implantation to Treat Articular Cartilage Defects|A Prospective Open-label Multi-center Study to Demonstrate the Safety and Efficacy of Cells Sheet-Autologous Chondrocyte Implantation（CS-ACI）for the Treatment of Articular Cartilage Defects|CS-ACI|Fourth Military Medical University|Yes|Recruiting|April 2012|June 2015|Anticipated|July 2013|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|50 Years|No|||September 2012|September 28, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694823||78654|
NCT01695070|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1133-4541|Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies|A Pilot Study of Maternally Administered Melatonin to Decrease the Level of Oxidative Stress in Human Pregnancies Affected by Intrauterine Growth Restriction.||Monash University|No|Completed|September 2012|November 2014|Actual|October 2014|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Female|18 Years|45 Years|No|||November 2014|November 14, 2014|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01695070||78635|
NCT01691144|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/355B|Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project|Follow-up of Gynecological Cancer Patients. Their Needs and Expectations. A Cooperation Project.||University of Oslo|No|Recruiting|September 2012|December 2015|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||2|Anticipated|200|||Female|19 Years|N/A|No|Non-Probability Sample|Newly treated gynecological cancer patients and patients treated 2-3 years ago|June 2015|June 11, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01691144||78937|
NCT01691404|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL4077208112|Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO)|Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure in Untreated (Pre)Hypertensive Subjects||Wageningen University|No|Completed|September 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|38|||Both|30 Years|80 Years|Accepts Healthy Volunteers|||November 2012|April 22, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01691404||78917|
NCT01687946|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RESOLVE - WP2|Explorative Study on the Molecular Pathology of Lung Fibrosis by Combination of Clinical Assessment and System Biology|Pilot Investigation on the Combined Use of Established Clinical Criteria and Systems Biology for Progressive Pulmonary Fibrosis||Medical University of Vienna|No|Completed|June 2010|August 2014|Actual|December 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|80|Samples With DNA|Transbronchial biopsies and Video-assisted throracoscopic biopsies|Both|18 Years|90 Years|Accepts Healthy Volunteers|Non-Probability Sample|The participants are chosen from patients lists of participating center.|March 2016|March 15, 2016|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01687946||79183|
NCT01688245|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRO12080344|A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults|A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults|TRAC|University of Pittsburgh|Yes|Completed|November 2012|May 2015|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|765|||Both|18 Years|25 Years|No|||May 2015|May 26, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688245||79160|
NCT01688258|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GUD-PCR|New Multiplex Real-time PCR for Genital Ulcer Disease|A Prospective, Open Labeled, Multicenter, Diagnostic Study on the Detection of T. Pallidum, H. Ducreyi and HSV Type 1 and 2 From Genital, Anal and Oropharyngeal Ulcers With a New Multiplex Real-time Polymerase Chain Reaction||University of Zurich||Recruiting|January 2012|July 2013|Anticipated|July 2013|Anticipated|N/A|Observational|Time Perspective: Prospective||1|Anticipated|50|||Both|18 Years|N/A|No|Non-Probability Sample|Patient with genital, anal or oropharyngeal ulcers|August 2012|September 18, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688258||79159|
NCT01693497|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gestalt therapy for PTSD|Comparison of Cognitive Processing Therapy (CPT) and Dialogical Exposure Therapy (DET) for Posttraumatic Stress Disorder|Comparison of a Gestalt-based Approach to PTSD Therapy With Cognitive Processing Therapy||Ludwig-Maximilians - University of Munich|No|Completed|September 2002|April 2012|Actual|September 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|150|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01693497||78756|
NCT01693757|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3|Functional Outcome Anterior Cruciate Ligament Reconstruction|Comparison of Functional Outcome Measures of Anterior Cruciate Ligament Reconstruction Using Either Patellar Tendon or Hamstring Tendon Grafts and Controls in Competitive Soccer Players: A Randomized Trial||University of Social Welfare and Rehabilitation Science|Yes|Completed|January 2010|March 2011|Actual|January 2011|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|63|||Male|21 Years|30 Years|Accepts Healthy Volunteers|Probability Sample|The patients with ACL deficiency were invited to participate in a randomized trial        comparing ACLR with either a BPTB or STG graft.|September 2012|September 24, 2012|May 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01693757||78736|
NCT01694329|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GSK114180|Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada|Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada|Nunavik2|Centre Hospitalier Universitaire de Québec, CHU de Québec|No|Active, not recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1420|||Both|N/A|5 Years|Accepts Healthy Volunteers|Probability Sample|Children of Nunavik born between 2006 and 2010, who have been exposed to PHiD-CV in        combination with PCV-7 or PCV-13|October 2015|October 19, 2015|June 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01694329||78692|
NCT01688700|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NimoESCC|Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma|A Prospective, Single Arm, Multicenter, Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma||Zhejiang Cancer Hospital|Yes|Recruiting|September 2012|September 2017|Anticipated|September 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||September 2012|September 19, 2012|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01688700||79125|
NCT01688986|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120194|Environmental Polymorphisms Registry Health and Exposures Survey|Environmental Polymorphisms Registry Health and Exposures Survey||National Institutes of Health Clinical Center (CC)||Enrolling by invitation|August 2012|||||N/A|Observational|Time Perspective: Retrospective|||Actual|9000|||Both|18 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 24, 2016|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01688986||79103|
NCT01688999|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120205|Cabozantinib for Advanced Urothelial Cancer|A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma||National Institutes of Health Clinical Center (CC)||Active, not recruiting|September 2012|August 2017|Anticipated|March 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|64|||Both|18 Years|99 Years|No|||April 2015|March 8, 2016|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01688999||79102|
NCT01689311|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-06|In Vitro Myometrial Contractions in Laboring and Non-laboring Women|In Vitro Myometrial Contractions in Laboring and Non-laboring Women: Oxytocin is Superior to Other Uterotonic Agents||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|No|Completed|March 2009|August 2012|Actual|August 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|53|||Female|N/A|N/A|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01689311||79078|
NCT01689545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA022962|Prevention for Positives: An RCT Among Vietnamese HIV-positive IDU|Prevention for Positives: A Randomized Controlled Trial Among Vietnamese HIV-positive Injecting Drug Users||Johns Hopkins Bloomberg School of Public Health|Yes|Completed|December 2007|April 2013|Actual|April 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|2175|||Male|18 Years|N/A|No|||May 2014|June 4, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01689545||79060|
NCT01689805|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FLG-255-AR|Clinical Importance of Filaggrin Gene Mutation for Treatment Outcome in Atopic Dermatitis|Do Mutations in the Filaggrin Gene Have Clinical Importance for the Treatment Outcome in Atopic Dermatitis?||Helsinki University Central Hospital|No|Recruiting|June 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|800|Samples With DNA|Serum samples are collected to investigate if the patient has a mutation in the filaggrin      gene.|Both|18 Years|N/A|No|Probability Sample|Patients with atopic dermatitis who are followed-up at the Skin and Allergy Hospital in        Helsinki for at least one year can be included in the study.        The control population consists of non-atopic persons without any other skin disease        (samples for the control population are applied for from a sample collection of the        National institute for health and welfare).|September 2012|September 18, 2012|June 23, 2011||No||No||https://clinicaltrials.gov/show/NCT01689805||79040|
NCT01690013|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-41-0666|Life Quality and Health in Patients With Klinefelter Syndrome|Life Quality and Health in Patients With Klinefelter Syndrome - a Questionnaire Survey||University of Aarhus|No|Completed|September 2012|July 2014|Actual|January 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|452|||Male|18 Years|N/A|No|Non-Probability Sample|Klinefelter patients is recruited from endocrinology, genetics and fertility clinics in        Denmark.        An age-, educational, and zipcode-matched control group was created from Statistics        Denmark by extracting five randomly selected men for each KS subject|September 2012|May 31, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01690013||79024|
NCT01690026|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Project Options|Facilitating Adolescent Self-Change for Alcohol Problems|||University of California, San Diego|No|Recruiting|October 2012|September 2017|Anticipated|September 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|9400|||Both|14 Years|19 Years|Accepts Healthy Volunteers|||May 2015|May 27, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690026||79023|
NCT01690325|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WSG-AM05|Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)|Molecular Imaging for Response Assessment of Bevacizumab + Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer||West German Study Group|No|Recruiting|September 2012|September 2022|Anticipated|August 2017|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|94|||Female|18 Years|65 Years|No|||June 2015|June 18, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01690325||79000|
NCT01690858|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10/6-K|Multicentric Prospective Study of Genetic and Physiopathology Concerning Dysregulation of Complement During Repeated Fetal Abortions|Multicentric Prospective Study of Genetic and Physiopathology Concerning Dysregulation of Complement During Repeated Fetal Abortions||Nantes University Hospital|No|Completed|May 2011|May 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|60|Samples With DNA|blood samples|Female|18 Years|40 Years|Accepts Healthy Volunteers|Non-Probability Sample|Females with medical history of repeated foetal losses and females without medical history        of repeated foetal losses as controls.|October 2014|October 14, 2014|November 29, 2011||No||No||https://clinicaltrials.gov/show/NCT01690858||78959|
NCT01690871|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235ZIC01|A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa|A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa||Novartis|Yes|Withdrawn|September 2012|January 2015|Anticipated|January 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||August 2013|August 1, 2013|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01690871||78958|
NCT01686828|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|43007-B|T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin|Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men|T-IR|University of Washington|Yes|Active, not recruiting|June 2013|December 2017|Anticipated|June 2017|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Male|25 Years|55 Years|Accepts Healthy Volunteers|||March 2016|March 1, 2016|September 12, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686828||79269|
NCT01687127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H11-03009|Impact of High-dose Folic Acid Supplementation on Pathways Linked to DNA Formation|Metabolic Consequences of High-Dose Folic Acid Supplementation on Kinetics of 1-Carbon Metabolism||University of British Columbia|No|Not yet recruiting|October 2015|December 2018|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|25|||Female|20 Years|35 Years|Accepts Healthy Volunteers|||April 2015|April 24, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01687127||79246|
NCT01687426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-150-0001|Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension|A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension||Eye Therapies, LLC|No|Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|15|||Both|18 Years|N/A|No|||December 2012|December 21, 2012|September 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687426||79223|
NCT01687439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NSCLC0901|Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)|Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer||Fudan University|No|Completed|December 2008|October 2009|Actual|October 2009|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|15|||Both|18 Years|N/A|No|||September 2012|September 18, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01687439||79222|
NCT01687673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCSF CC# 124511|Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma|Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma||University of California, San Francisco|Yes|Active, not recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Both|18 Years|85 Years|No|||December 2015|December 3, 2015|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01687673||79204|
NCT01687959|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BEZM-LC-postERCP|Timing of Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiography for Acute Biliary Pancreatitis|Prospective Randomized Clinical Study for Timing of Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiography for Acute Biliary Pancreatitis||Bezmialem Vakif University|No|Active, not recruiting|September 2012|August 2015|Anticipated|June 2015|Anticipated|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|60|||Both|N/A|N/A|Accepts Healthy Volunteers|||January 2015|January 27, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01687959||79182|
NCT01688271|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24882|Simulation-Based Training for Ultrasound-Guided Perineural Catheter Insertion|A Prospective Study to Determine the Efficacy of Simulation-based Training on Practicing Anesthesiologists' Acquisition of Ultrasound-guided Perineural Catheter Insertion Skills||VA Palo Alto Health Care System|Yes|Completed|August 2012|July 2014|Actual|July 2014|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|32|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Active board certificated (American Board of Anesthesiologists) Anesthesiologists in        practice ten years or more.|October 2014|October 27, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01688271||79158|
NCT01694316|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-24890|Use of a Novel Neuroplasticity-based Neurobehavioral Intervention for PTSD|Use of a Novel Neuroplasticity-based Neurobehavioral Intervention for PTSD - A Nationwide, Online Study||Stanford University|No|Recruiting|September 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|40|||Both|18 Years|65 Years|No|||July 2015|July 15, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694316||78693|
NCT01694056|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL39991.081.12|Soy Protein Intake and the Metabolic Syndrome|Soy Protein Intake and the Metabolic Syndrome: Reducing Inflammation to Improve Insulin Resistance and Glucose Homeostasis|SOY|Wageningen University|Yes|Completed|September 2012|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention|2||Actual|15|||Female|45 Years|70 Years|Accepts Healthy Volunteers|||January 2013|January 3, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01694056||78713|
NCT01694628|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPCRC Pilot Grant|e-Counseling for COPD|Psychosocial-Behavioral Therapy for Patients With Advanced COPD and Depression|CLIMB|University of Washington|No|Recruiting|September 2012|July 2014|Anticipated|May 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|70|||Both|40 Years|N/A|No|||November 2012|November 29, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694628||78669|
NCT01688713|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ZhejiangCH-LCBM-1202|Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer|||Zhejiang Cancer Hospital|Yes|Recruiting|August 2012|September 2015|Anticipated|February 2015|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Both|18 Years|75 Years|No|||September 2012|September 19, 2012|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01688713||79124|
NCT01689025|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN8828-4002|An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)|A Randomised, Placebo-controlled, Double-blind, Multiple-dose, Dose-escalation Trial Investigating the Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus||Novo Nordisk A/S|No|Terminated|September 2012|February 2014|Actual|February 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|64 Years|No|||April 2014|April 7, 2014|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01689025||79100|
NCT01689337|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR700692_007|A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Trial to Investigate the Efficacy and Safety of 30 mcg and 100 mcg AS902330 Given as One Cycle of Three Intra-articular Knee Injections Once a Week for Three Weeks as an Adjunct Treatment to Patients Following Microfracture Surgery for Cartilage Injury of the Knee.||EMD Serono|No|Terminated|April 2013|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|1|||Both|18 Years|60 Years|No|||July 2015|August 14, 2015|September 17, 2012|Yes|Yes|The study was discontinued due to low recruitment.|No|July 8, 2015|https://clinicaltrials.gov/show/NCT01689337||79076|Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.
NCT01689558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20111220|Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer|Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma||Cancer Hospital of Guizhou Province|Yes|Recruiting|December 2011|January 2017|Anticipated|January 2015|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|1||Anticipated|60|||Both|18 Years|70 Years|No|||March 2013|March 11, 2013|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01689558||79059|
NCT01689571|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCD-1202-PR-0080|A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics|A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma|CHF6001_POC2|Chiesi Farmaceutici S.p.A.|No|Completed|October 2012|April 2013|Actual|April 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|60 Years|No|||May 2013|May 8, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01689571||79058|
NCT01689792|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NOR-01/2011 (PDR)|A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)|A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)||Norgine|No|Completed|November 2011|December 2013|Actual|January 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|2||Actual|398|||Both|40 Years|80 Years|No|||December 2013|March 30, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01689792||79041|
NCT01690338|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSA-NMB-001|A Study of Residual Curarization Incidence in China|A Perspective, Multicentre, Randomized，Blind Study of Residual Curarization Incidence in China||Peking University First Hospital|Yes|Recruiting|October 2012|December 2014|Anticipated|October 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|3||Anticipated|6090|||Both|18 Years|N/A|No|||May 2013|May 22, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01690338||78999|
NCT01690572|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DEBT|Drug Eluting Balloon for Prevention of Constrictive Remodeling|Drug Coated Balloon (DCB) for the Prevention of Constrictive Remodeling and Restenosis in Small Vessel Coronary Disease||Herz-Zentrums Bad Krozingen|No|Recruiting|October 2012|April 2017|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01690572||78981|
NCT01690845|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10712010|Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis|Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study|MARS in HH|Medical University of Vienna|Yes|Recruiting|June 2012|||September 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|September 16, 2012||||No||https://clinicaltrials.gov/show/NCT01690845||78960|
NCT01694537|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBS1033|The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers|The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers||Indonesia University|Yes|Recruiting|July 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|20|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 25, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01694537||78676|
NCT01693614|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBKM120Z2402|Safety and Efficacy of BKM120 in Relapsed and Refractory NHL|An Open-label Phase II Study of BKM120 in Patients With Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma||Novartis|No|Active, not recruiting|February 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|72|||Both|18 Years|N/A|No|||February 2016|February 8, 2016|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693614||78747|
NCT01693367|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLS 5.0|Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation|A Multi-Center Randomized Controlled Pilot Study of Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation||AO Clinical Investigation and Documentation|No|Terminated|September 2012|December 2014|Actual|December 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|5|||Both|21 Years|120 Years|No|||January 2016|January 4, 2016|September 20, 2012||No|The medical device has been withdrawn from the market due to technical issues.|No||https://clinicaltrials.gov/show/NCT01693367||78766|
NCT01693926|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|286/12|Effect of Physical Activity an Stress in Children|Effect of Physical Activity an Stress in Children||University of Lausanne Hospitals|No|Active, not recruiting|September 2012|December 2015|Anticipated|June 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|7 Years|10 Years|Accepts Healthy Volunteers|||December 2014|December 12, 2014|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01693926||78723|
NCT01693952|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00322-41|Sepsis in Neutropenic Patients: Autologous Stem Cell Transplantation as Model: a Transcriptomic Approach|Sepsis in Neutropenic Patients: Autologous Stem Cell Transplantation as Model: a Transcriptomic Approach.||Assistance Publique Hopitaux De Marseille|No|Recruiting|May 2012|December 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|24|||Both|18 Years|N/A|No|||August 2014|August 29, 2014|May 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01693952||78721|
NCT01694459|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|596-2012-D|DEDICA (Dose of HEparin During Coronary Angioplasty) Trial|Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial)|DEDICA|San Filippo Neri General Hospital|No|Recruiting|January 2010|December 2012|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|1000|||Both|18 Years|N/A|No|||September 2012|September 26, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694459||78682|
NCT01694472|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-RXB-201205002|Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors|Phase 1 Study of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors||Tianjin Medical University Cancer Institute and Hospital||Active, not recruiting|July 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|15|||Both|18 Years|80 Years|No|||September 2012|December 21, 2015|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694472||78681|
NCT01691911|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVES-123|Preconditioning Shields Against Vascular Events in Surgery|Preconditioning Shields Against Vascular Events in Surgery. A Multi-Centre Trial of Preconditioning Against Adverse Events in Major Vascular Surgery|SAVES|Mid Western Regional Hospital, Ireland|Yes|Completed|February 2012|November 2014|Actual|November 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|200|||Both|18 Years|N/A|No|||June 2015|June 2, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01691911||78878|
NCT01692132|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017521|A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation|A Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation||Janssen Pharmaceutica|No|Withdrawn|February 2013|December 2014|Anticipated|February 2014|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Filipino patients with chronic constipation|November 2015|November 30, 2015|September 20, 2012||No|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|No||https://clinicaltrials.gov/show/NCT01692132||78861|
NCT01692106|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TBD|A Clinical Study of Per Oral Endoscopic Myotomy (POEM) in Patients Suffering From Achalasia|A Clinical Study of Per Oral Endoscopic Myotomy (POEM) in Patients Suffering From Achalasia.|POEM|McMaster University|No|Completed|November 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|10|||Both|18 Years|70 Years|No|||September 2015|September 22, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01692106||78863|
NCT01692119|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PHARM-CHF|Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure|Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure (PHARM-CHF): A Randomized Controlled Trial|PHARM-CHF|Federal Union of German Associations of Pharmacists|Yes|Active, not recruiting|October 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care|2||Actual|254|||Both|60 Years|N/A|No|||January 2016|January 6, 2016|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692119||78862|
NCT01667003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|G1209|BIOFLOW-III Sweden Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Sweden||Biotronik ApS|No|Active, not recruiting|August 2012|December 2015|Anticipated|December 2014|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|406|||Both|18 Years|N/A|No|Non-Probability Sample|All-comers patient population with all subjects requiring coronary revascularization with        a Drug Eluting Stent (DES)|September 2015|September 7, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667003||80790|
NCT01667224|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TgBio-TG1022-001|Efficacy and Safety of Actiponin on Antiobesity in Obese Korean Subjects.|Actiponin Supplementation Reduces Abdominal Fat Area, Weight, Body Fat Mass and BMI in Obese Korean Subjects.||Chonbuk National University Hospital|Yes|Completed|October 2009|October 2010|Actual|August 2010|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|80|||Both|19 Years|65 Years|Accepts Healthy Volunteers|||March 2014|March 16, 2014|August 14, 2012||No||No|March 16, 2014|https://clinicaltrials.gov/show/NCT01667224||80773|
NCT01694901|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Smart-Outcome|Optimization of the Anesthetic Regimen Using the SmartPilot® System and Influence on Different Outcome Parameters - a Pilot Study.|Optimization of the Anesthetic Regimen Using the SmartPilot® System and Influence on Different Outcome Parameters - a Pilot Study. A Single- Center Prospective Randomized Controlled Pilot Study.||Charite University, Berlin, Germany|No|Recruiting|May 2013|June 2016|Anticipated|March 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Male/female patients scheduled for elective surgery (general/abdominal surgery;        traumatological/orthopedic surgery, gynecology, urology) in general anesthesia at Charité        - Universitaetsmedizin Berlin, Campus Mitte and Campus Virchow-Klinikum|February 2016|February 1, 2016|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694901||78648|
NCT01690988|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201206071|The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial|The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial|PODCAST|Washington University School of Medicine|Yes|Recruiting|February 2014|February 2018|Anticipated|February 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Anticipated|600|||Both|60 Years|N/A|No|||December 2015|December 23, 2015|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01690988||78949|
NCT01691261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B4711001|A Study Of Implantation Of Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration|Phase 1, Open-label, Safety And Feasibility Study Of Implantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe) Living Tissue Equivalent) In Subjects With Acute Wet Age Related Macular Degeneration and Recent Rapid Vision Decline||Pfizer|Yes|Active, not recruiting|June 2015|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|60 Years|N/A|No|||February 2016|February 23, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01691261||78928|
NCT01691274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B5311002|A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Parallel Group Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of Pf-04895162 In Healthy Subjects||Pfizer|No|Completed|October 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science|2||Actual|10|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 26, 2013|September 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01691274||78927|
NCT01691547|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116415|A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects|A Randomized, Double-blind, Single Dose, Four Way Cross-over Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol Following Single Inhaled Doses of Umeclidinium/Vilanterol Blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in Healthy Subjects||GlaxoSmithKline|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|4||Actual|44|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||May 2013|May 9, 2013|September 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01691547||78906|
NCT01691833|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01-11-09A|The Effect of Hypovitaminosis D and Vitamin D Supplementation on Fracture Nonunion Rates|The Effect of Hypovitaminosis D and Vitamin D Supplementation on Fracture Nonunion Rates|VitD|Carolinas Healthcare System|Yes|Active, not recruiting|February 2011|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|880|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01691833||78884|
NCT01692860|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1109011319|Effects of Milk Protein Concentrate on Overall Health During Weight Loss in Overweight/Obese Adults|Effects of Milk Protein Concentrate on Blood Pressure, Inflammation, Muscle Health During Weight Loss in Overweight/Obese Adults|S28|Purdue University|No|Completed|January 2012|January 2015|Actual|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|48|||Both|35 Years|65 Years|Accepts Healthy Volunteers|||November 2015|November 3, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692860||78805|
NCT01692314|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BIOVASC 2009|Effect of Resistance Training on Microvascular, Hemodynamic and Physical Parameters in Obese Adolescents|Effect of Resistance Training on Microvascular Reactivity, Endothelial Function, Inflammatory Markers, Body Composition, Blood Pressure, Heart Rate and Physical Fitness in Obese Adolescents||Rio de Janeiro State University|No|Completed|June 2010|May 2012|Actual|September 2010|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Actual|20|||Both|13 Years|17 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01692314||78847|
NCT01693380|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BUTANTAN|Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza|Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza the in São Paulo, 2009|Xo_Gripe|Butantan Institute|Yes|Completed|May 2009|November 2009|Actual|June 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|1742|||Both|6 Years|18 Years|Accepts Healthy Volunteers|||September 2012|September 24, 2012|September 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01693380||78765|
NCT01693406|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0629|Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers|Breast Milk and Infant Growth and Body Composition Among Healthy Mothers, Obese Mothers, and Mothers With Diabetes|MIG|University of Colorado, Denver|No|Recruiting|August 2012|December 2016|Anticipated|June 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|160|Samples Without DNA|Human Milk, Plasma, Urine and Stool|Female|20 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|We will recruit pregnant women in the Denver Colorado area who plan to deliver their        infant at the University of Colorado Hospital, and plan to exclusively breastfeed their        infant for at least 5 months.|February 2016|February 1, 2016|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01693406||78763|
NCT01693419|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-1201|S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer|A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer||Hallym University Medical Center|No|Recruiting|August 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|28|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693419||78762|
NCT01693627|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/133|Cemented Marathon/Corail Versus Pinnacle/Corail|Cemented Marathon/Corail Versus Pinnacle/Corail. Comparison of Polyethylene Wear, Component Migration and Periprosthetic Bone Mineral Density. A Randomised Study of 48 Hips Using Radiostereometry and Dual-energy X-ray Absorptiometry||Haukeland University Hospital|Yes|Active, not recruiting|January 2012|January 2022|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Actual|61|||Both|30 Years|70 Years|No|||February 2016|February 23, 2016|March 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693627||78746|
NCT01693913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YMCAAtlantaWeightLoss|Cognitive-behavioral Weight Loss Treatment|Effects of a Cognitive-behavioral Weight Loss Treatment||YMCA of Metropolitan Atlanta|No|Withdrawn|October 2012|April 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Female|21 Years|60 Years|Accepts Healthy Volunteers|||December 2013|December 27, 2013|September 21, 2012||No|IRB approval canceled|No||https://clinicaltrials.gov/show/NCT01693913||78724|
NCT01694160|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/107 D|Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria|Consultant in Neprhology. MD. PhD.||Oslo University Hospital|No|Not yet recruiting|January 2013|January 2015|Anticipated|January 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|70 Years|No|||September 2012|September 26, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694160||78705|
NCT01691677|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MC/PR/1400/007/11|beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study|Multicentre, Randomized, Double-blind, Parallel Group, Placebo-Controlled Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate Suspension for Inhalation 800 µg Twice Daily vs. Placebo Added to Antibiotic Therapy in Patients With Acute Rhinosinusitis|CLEAR|Chiesi Farmaceutici S.p.A.|No|Completed|January 2013|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|166|||Both|18 Years|65 Years|No|||January 2015|January 19, 2015|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01691677||78896|
NCT01691924|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIBSP-PBF-2012-38|Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers|Randomized, Double Blind, Placebo Controlled "First In-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|No|Completed|October 2012|October 2013|Actual|October 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)|2||Actual|56|||Male|18 Years|45 Years|Accepts Healthy Volunteers|||March 2016|March 7, 2016|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01691924||78877|
NCT01691937|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TJMZK20120302|Continuous Paravertebral Block on Postoperative Pain After Hepatectomy|Continuous Right Thoracic Paravertebral Block on Postoperative Pain After Right Lobe Hepatectomy||Huazhong University of Science and Technology|Yes|Completed|September 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|70 Years|No|||August 2013|August 12, 2013|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01691937||78876|
NCT01683409|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14734|A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease||Eli Lilly and Company|No|Completed|August 2012|November 2014|Actual|September 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|5||Actual|129|||Both|18 Years|N/A|No|||January 2015|January 16, 2015|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683409||79531|
NCT01683721|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12023|Post-Market Observational Study of the WINX Sleep Therapy for the Treatment of Obstructive Sleep Apnea (OSA)|The UNMASK Study: A Post-Market Longitudinal Observational Study of the WinxTM Sleep Therapy System for the Treatment of Obstructive Sleep Apnea (OSA)|UNMASK|ApniCure, Inc.|No|Recruiting|September 2012|February 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Probability Sample|Subjects with obstructive sleep apnea (OSA)|September 2013|September 3, 2013|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683721||79507|
NCT01683734|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Nephro11-021-1|Assessing Renal Function in Patients With an Antibiotic Laden Spacer|Nephrotoxicity Following 2-Stage Exchange With Associated Antibiotic Laden Spacer in Patients With Infected Total Hip/Knee Arthroplasty||Central DuPage Hospital|No|Recruiting|May 2012|||December 2019|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Non-Probability Sample|patients with an infected hip or knee arthroplasty scheduled to undergo a 2-stage        resection surgery|February 2015|February 3, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01683734||79506|
NCT01683708|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Symbiotic2012|Effectiveness Of Symbiotic Therapy In Jaundiced Patients|Effectiveness of Perioperative Symbiotic Therapy to Reduce Infectious Morbidity in Jaundiced Patients: a Randomized Controlled Trial||Azienda Ospedaliera Ordine Mauriziano di Torino|No|Active, not recruiting|November 2008|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|20|||Both|18 Years|80 Years|No|Probability Sample|Jaundiced patients scheduled for hepato-biliary pancreatic surgery|September 2012|September 10, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01683708||79508|
NCT01667042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-000304|Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough|Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough||Mayo Clinic|No|Completed|August 2012|June 2015|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|7|||Both|18 Years|N/A|No|Probability Sample|All consecutive adult patients seen at the Mayo Clinic in Florida with a confirmed        diagnosis of systemic sclerosis (SSc) will be eligible.|January 2016|January 7, 2016|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01667042||80787|
NCT01667289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LMTG 12-01|Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma|A Randomized Phase II Study of Comparing Radiotherapy Alone With Concurrent Chemoradiation in Patients With Low Risk NK/T-cell Lymphoma||Fudan University|No|Terminated|June 2012|June 2017|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|75 Years|No|||March 2013|March 2, 2013|August 13, 2012||No|unexpected high grade of mucositis observed|No||https://clinicaltrials.gov/show/NCT01667289||80768|
NCT01667263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1132-6877|Therapeutic Efficacy and Mechanism Study of Retinoid Acid on Immune Thrombocytopenia Patients|Clinical Study on Therapeutic Efficacy and Mechanism of All-trance-retinoid Acid in Refractory Immune Thrombocytopenia Patients||Peking University People's Hospital|Yes|Active, not recruiting|June 2011|June 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 17, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667263||80770|
NCT01694914|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0908018|Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium|Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium||Centre Hospitalier Universitaire de Saint Etienne|No|Completed|January 2012|February 2014|Actual|February 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|122|||Both|18 Years|N/A|No|||January 2015|January 29, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694914||78647|
NCT01694927|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIT-2012-ACF-001|Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients|Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients|MSC-SCI|Clinica las Condes, Chile|No|Enrolling by invitation|January 2012|June 2014|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|2 Years|65 Years|No|||July 2013|July 2, 2013|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694927||78646|
NCT01691001|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2011-0430|Effect of Dexmedetomidine on Sevoflurane Requirements and Emergence Agitation in Children Undergoing Ambulatory Surgery|||Yonsei University|No|Completed|August 2011|March 2012|Actual|March 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|40|||Male|1 Year|5 Years|No|||September 2012|September 18, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01691001||78948|
NCT01691014|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1801347|Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents|Formation Of Antibodies And Subsequent Prediction Of Clinical Response In Patients With Rheumatoid Arthritis Treated With Four Tnf Blocking Agents||Pfizer|No|Terminated|April 2013|January 2015|Actual|January 2015|Actual|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Actual|80|||Both|18 Years|N/A|No|Non-Probability Sample|patients with Rheumatoid Arthritis (RA)|March 2015|March 23, 2015|September 12, 2012||No|The study was terminated on 10DEC2014 due to the inability to enroll the planned number of    patients. There were no safety concerns.|No||https://clinicaltrials.gov/show/NCT01691014||78947|
NCT01691287|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rmc006444ctil|MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes|MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes||Rabin Medical Center|No|Completed|October 2012|December 2013|Actual|December 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|23|||Both|12 Years|17 Years|No|||April 2014|April 30, 2014|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01691287||78926|
NCT01691560|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RH01426|Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity|A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity||GlaxoSmithKline|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|140|||Both|18 Years|55 Years|No|||July 2013|May 1, 2014|September 20, 2012|Yes|Yes||No|May 1, 2014|https://clinicaltrials.gov/show/NCT01691560||78905|
NCT01691573|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EU01|European Pediatric Catheter Ablation Registry|European Pediatric Catheter Ablation Registry|EUROPA|A.O. Ospedale Papa Giovanni XXIII|No|Recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|||||Both|N/A|18 Years|No|Probability Sample|European pediatric population|September 2012|September 24, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01691573||78904|
NCT01692639|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5313|Acute Acetaminophen Ingestion: Does Repeated Acetaminophen Blood Test Have an Interest?|Acute Acetaminophen Ingestion: Does Repeated Acetaminophen Blood Test Have an Interest?||University Hospital, Strasbourg, France|No|Terminated|May 2013|November 2015|Actual|November 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|4|||Both|18 Years|N/A|No|Non-Probability Sample|Patients over 18 years with acute paracetamol ingestion admitted in a group of 8 emergency        departments of the region Alsace, France (Strasbourg Hautepierre and Nouvel Hôpital Civil,        Haguenau, Saverne,Wissembourg, Colmar, Sélestat, Mulhouse) and with a single dose of        paracetamol over 4 grams.|March 2016|March 2, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01692639||78822|
NCT01693146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UN4484|STIT-2: Evaluation of Safety and Efficacy of Short-time TNI® Treatment in Patients With COPD and Hypercapnia|Evaluation of Safety and Efficacy of Short-time TNI® Treatment in Patients With COPD and Hypercapnia Acute Testing of Oxygen Demand Using TNI® vs. Standard Insufflation in COPD Patients With Hypercapnia at Rest|STIT-2|Medical University Innsbruck|No|Recruiting|December 2011|December 2013|Anticipated|December 2013|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|30|||Both|30 Years|85 Years|No|||September 2012|September 25, 2012|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01693146||78783|
NCT01693159|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Uni-HD-2010-33-40-1003|Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades|Randomized Controlled Multicenter Trial to Evaluate the Effects of Ethyl-2-cyanoacrylate on Pain Intensity and Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades During Radioimmunotherapy|SUPPORT|National Center for Tumor Diseases, Heidelberg|No|Recruiting|May 2011|November 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||August 2013|May 19, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01693159||78782|
NCT01693393|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|COLO400BDE02T|Low Dose Cyclosporin A in Primary Sjögren Syndrome|A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome|CYPRESS|Charite University, Berlin, Germany|Yes|Completed|March 2010|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|75 Years|No|||July 2015|July 27, 2015|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01693393||78764|
NCT01693640|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-280|A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome|A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Mucocutaneous Manifestations of Behcet's Syndrome||New York University School of Medicine|No|Recruiting|June 2012|February 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Female|18 Years|N/A|No|||January 2016|January 29, 2016|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693640||78745|
NCT01693653|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML27874|Tocilizumab for the Treatment of Behcet's Syndrome|Tocilizumab for the Treatment of Behcet's Syndrome||New York University School of Medicine|Yes|Terminated|September 2012|November 2013|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|N/A|No|||September 2014|September 30, 2014|September 19, 2012|Yes|Yes|low enrollment|No||https://clinicaltrials.gov/show/NCT01693653||78744|
NCT01693939|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FT-FS200-001|Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap|A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap||Durrie Vision|No|Completed|February 2012|April 2012|Actual|April 2012|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|30|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2013|January 24, 2013|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693939||78722|
NCT01691365|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FMHS|Effects of Antioxidants and B Vitamins Supplements on Inflammation in Obese Diabetic Patients|Oxidative Damage and Inflammation in Obese Diabetic Emirati Subjects Supplemented With Antioxidants and B-vitamins: a Randomized Placebo-controlled Trail||United Arab Emirates University|No|Completed|September 2008|June 2011|Actual|December 2009|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|100|||Both|18 Years|N/A|No|||September 2012|September 19, 2012|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691365||78920|
NCT01691690|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB12-00097|Analgesic Effect of IV Acetaminophen in Tonsillectomies|Analgesic Effect of Single Dose Intravenous Acetaminophen in Pediatric Patients Undergoing Tonsillectomy||Nationwide Children's Hospital|No|Active, not recruiting|October 2012|June 2016|Anticipated|March 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|240|||Both|2 Years|9 Years|No|||January 2016|January 14, 2016|May 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01691690||78895|
NCT01683149|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16963|Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies|Phase I, Traditional 3+3, Trial of PO Sorafenib and Topotecan in Refractory or Recurrent Pediatric Solid Malignancies||H. Lee Moffitt Cancer Center and Research Institute|No|Completed|January 2013|January 2016|Actual|January 2016|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|13|||Both|3 Years|18 Years|No|||March 2016|March 3, 2016|September 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01683149||79551|
NCT01683396|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|X052160|Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand|A Phase 2 Proof-of-Concept Study of Gevokizumab in Active Inflammatory, Erosive Osteoarthritis of the Hand||XOMA (US) LLC|No|Completed|July 2012|February 2014|Actual|February 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|87|||Both|18 Years|N/A|No|||March 2014|March 3, 2014|September 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683396||79532|
NCT01683968|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RE11/027|Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis|Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis||King Abdullah International Medical Research Center|Yes|Recruiting|September 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|216|||Both|14 Years|N/A|No|Non-Probability Sample|Adult patient admitted to the hospital with vaso-occlusive crisis|September 2012|September 12, 2012|September 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01683968||79488|
NCT01683981|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|f-91-138|Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate|Exercise Capacity and Quality of Life in Patients With Idiopathic Pulmonary Hypertension and Eisenmenger Syndrome Receiving Short Term Oral L-Citrulline Malate||Masih Daneshvari Hospital|Yes|Recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 0|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|25|||Both|15 Years|70 Years|No|||September 2012|August 8, 2013|September 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01683981||79487|
NCT01683955|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TEAHIPS|Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty|Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty||Henry Ford Health System|No|Recruiting|January 2013|May 2014|Anticipated|March 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|228|||Both|18 Years|N/A|No|||February 2014|February 24, 2014|September 8, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01683955||79489|
NCT01667575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|rjkls2012004|Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori|||Shanghai Jiao Tong University School of Medicine|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|180|||Both|18 Years|75 Years|No|||June 2013|June 1, 2013|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667575||80746|
NCT01667848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCHE0909|Warmed, Humidified Carbon Dioxide Insufflation vs Standard Carbon Dioxide in Laparoscopic Cholecystectomy|Warmed, Humidified Carbon Dioxide Insufflation vs Standard Carbon Dioxide in Laparoscopic Cholecystectomy: a Double-blinded Randomized Controlled Trial||Ludwig Boltzmann Institute for Operative Laparoscopy|No|Completed|July 2011|September 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|148|||Both|18 Years|N/A|No|||May 2014|May 4, 2014|July 27, 2012||No||No|September 30, 2013|https://clinicaltrials.gov/show/NCT01667848||80725|
NCT01667861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NL25853.068.09/MEC09-2-112|Risk Factors for Glaucoma in Musicians|Risk Factors for Glaucoma in Musicians||Maastricht University Medical Center|No|Completed|October 2011|January 2015|Actual|February 2014|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|40|||Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|(Professional) musicians, who play in symphony or wind orchestras.|May 2015|May 22, 2015|August 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01667861||80724|
NCT01668121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3103012|Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers|Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers, Two Batches of Symbicort Turbuhaler and Budesonide/Formoterol Easyhaler: Randomised, Double-blind, Double-dummy, Single Centre, Single Dose, Crossover Study in Healthy Subjects|REFLI|Orion Corporation, Orion Pharma|No|Completed|August 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||August 2012|November 22, 2012|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01668121||80704|
NCT01694940|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF4597|North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)|North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)|NAMDC|Columbia University|No|Recruiting|December 2010|December 2025|Anticipated|December 2025|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|1000|Samples With DNA|Any type of tissue sample can be stored in the biorepository.|Both|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with known mitochondrial disorders. People at risk of carrying a mitochondrial        DNA mutation Patients with abnormal mitochondrial function|May 2015|May 6, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694940||78645|
NCT01694953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAI5453|The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)|The Rare Disease Clinical Research Network Natural History Study of MNGIE|NAHIM|Columbia University|No|Recruiting|February 2013|June 2020|Anticipated|June 2020|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|20|||Both|5 Years|N/A|No|Non-Probability Sample|Male or female, At least 5 years of age, with Thymidine Phosphorylase defect|February 2015|February 10, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694953||78644|
NCT01691027|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C1000-R|Visuomotor Rehabilitation Training|Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas|VRT|VA Office of Research and Development|No|Completed|July 2013|December 2015|Actual|July 2015|Actual|Phase 0|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|4|||Both|55 Years|95 Years|No|||February 2016|February 16, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01691027||78946|
NCT01691040|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SNOXH94C201|Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer|Phase IIa Study to Characterize the Effects of the Spiegelmer® NOX H94 on Anemia of Chronic Disease in Patients With Cancer||NOXXON Pharma AG|No|Completed|September 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||June 2014|June 25, 2014|September 4, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691040||78945|
NCT01692054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IIA5-2511DSM220|Risk and Protective Factors of Children and Adolescents Who Were Hospitalized Due to Alcohol Intoxication|Prediction and Detection of Intermediate and Long-term Developmental Hazards in Adolescents After Alcohol Intoxication|RiScA|Technische Universität Dresden|No|Completed|June 2012|June 2013|Actual|May 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|Actual|394|||Both|20 Years|N/A|No|Probability Sample|young adults living in Germany who were hospitalized due to alcohol intoxication        (experimental group) or other medical conditions (control group) 5 to 12 years ago|May 2014|May 20, 2014|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692054||78867|
NCT01692327|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Biovasc-02|Study About High Fat Meal and Postprandial Lipemia|Evaluating the Effect of Lipid Overload in Endothelial Function and Microvascular Reactivity in Young Obese Women||Rio de Janeiro State University|Yes|Completed|September 2012|July 2014|Actual|December 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|3||Actual|60|||Female|19 Years|40 Years|Accepts Healthy Volunteers|||November 2014|November 4, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01692327||78846|
NCT01692873|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PACAomics / IPC 2011-004|Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors|Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004|PACAomics|Institut Paoli-Calmettes|No|Recruiting|February 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 25, 2016|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01692873||78804|
NCT01692886|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B1851015|A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China|A Phase 3, Randomized, Active-controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13vPnC Vaccine Compared With a 7vPnC in Healthy Infants in China||Pfizer|Yes|Completed|August 2012|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|1674|||Both|42 Days|77 Days|Accepts Healthy Volunteers|||July 2014|July 15, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01692886||78803|
NCT01692899|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRB1800007|Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice|Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice|MAINTAIN|Pfizer|No|Completed|June 2011|September 2011|Actual|September 2011|Actual|Phase 4|Observational|Time Perspective: Retrospective||3|Actual|780|||Both|18 Years|N/A|No|Non-Probability Sample|RA defined by the 1987 ACR criteria [18]; first TNFα inhibitor prescribed in the        previously mentioned period; TNFα inhibitor prescribed as first-line biotherapy; and        patients had undergone at least one evaluation in the center after treatment initiation.        Patients were excluded if: they had previously received another biotherapy; the TNFα        inhibitor was prescribed in an RCT; or they refused to participate.|September 2012|September 24, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692899||78802|
NCT01693172|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|118/12|Effect of an Early Mobilization Program on Outcomes After Major Cancer Surgery|Effect of an Early Mobilization Program After Surgery on Functional Recovery and Clinical Complications in Patients Undergoing Major Cancer Surgey : a Randomized Controlled Trial||Instituto do Cancer do Estado de São Paulo|No|Recruiting|December 2014|January 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|108|||Both|18 Years|N/A|No|||August 2015|August 27, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01693172||78781|
NCT01693185|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160048|Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy|Remifentanil Only vs. Combination Group Midazolam + Meperidine During Elective Colonoscopy|remifentanil|Konkuk University Medical Center|No|Completed|December 2012|August 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|19 Years|65 Years|No|||May 2014|May 16, 2014|September 17, 2012||No||No|February 2, 2014|https://clinicaltrials.gov/show/NCT01693185||78780|
NCT01695044|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSMA ADC 2301|A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)|A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer||Progenics Pharmaceuticals, Inc.|No|Completed|September 2012|February 2015|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|119|||Male|18 Years|N/A|No|||March 2015|March 10, 2015|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695044||78637|
NCT01691118|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0229|A Trial of Fimasartan for Early Diastolic Heart Failure|Fimasartan for Improvement of Diastolic Dysfunction in Hypertensive Patients|FINE|Asan Medical Center|No|Completed|September 2012|August 2015|Actual|August 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|60|||Both|40 Years|80 Years|No|||December 2015|December 29, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01691118||78939|
NCT01691378|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0127|Window to Hope-Evaluating a Psychological Treatment for Hopelessness Among Veterans With Traumatic Brain Injury|Window to Hope-Evaluating a Psychological Treatment for Hopelessness Among Veterans With Traumatic Brain Injury|WtoH|VA Eastern Colorado Health Care System|No|Recruiting|January 2012|June 2015|Anticipated|January 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|90|||Both|18 Years|89 Years|No|||November 2014|November 24, 2014|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01691378||78919|
NCT01682850|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-005820|Pulmonary Rehabilitation Before Lung Cancer Resection|Pulmonary Rehabilitation Before Lung Cancer Resection||Mayo Clinic|Yes|Enrolling by invitation|August 2013|October 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|154|||Both|40 Years|100 Years|No|||January 2016|March 17, 2016|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01682850||79574|
NCT01682863|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CQVA149A2340|A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB in Patients With COPD Who Have Moderate to Severe Airflow Limitation|A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB in Patients With COPD Who Have Moderate to Severe Airflow Limitation||Novartis|Yes|Completed|October 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|614|||Both|40 Years|N/A|No|||January 2015|January 2, 2015|September 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01682863||79573|
NCT01683747|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110376|Single Dose Enteral Tranexamic Acid in Critically Ill Patients|Single Dose Enteral Tranexamic Acid for the Reduction of Morbidity in Hospitalized Critically Ill Patients||San Diego Veterans Healthcare System|Yes|Terminated|June 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|4|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 9, 2012|No|Yes|Lower than anticipated enrollment|No||https://clinicaltrials.gov/show/NCT01683747||79505|
NCT01692743|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HP-00049230|Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)|Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)|TELE-IBD|University of Maryland|Yes|Active, not recruiting|September 2012|July 2016|Anticipated|July 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|3||Actual|349|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01692743||78814|
NCT01684254|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2007-P-000837|An In-Shoe Device to Monitor Toe-Walking in Children With Cerebral Palsy|An In-Shoe Device to Monitor Toe-Walking in Children With Cerebral Palsy||Spaulding Rehabilitation Hospital||Active, not recruiting|May 2010|December 2015|Anticipated|September 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|45|||Both|5 Years|17 Years|No|Probability Sample|Children diagnosed with CP|July 2015|July 20, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01684254||79466|
NCT01667601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HSEARS20121211001|Mindfulness-based Illness Management Program for Schizophrenia|The Effectiveness of a Mindfulness-based Illness Management Program for Chinese Patients With Schizophrenia: An Randomised Controlled Trial|MBPP|The Hong Kong Polytechnic University|Yes|Active, not recruiting|May 2013|February 2017|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|108|||Both|18 Years|60 Years|No|||August 2015|August 17, 2015|August 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01667601||80744|
NCT01667900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12925|A Study of Dulaglutide in Chinese Participants|Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM||Eli Lilly and Company|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|8||Actual|58|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||February 2016|February 8, 2016|August 15, 2012|No|Yes||No|June 9, 2015|https://clinicaltrials.gov/show/NCT01667900||80721|
NCT01667913|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Hip Fracture study 7/7-12|Reliability of 6-Minutes Walking Test in Hip Fracture Patients|The Relative and Absolute Reliability of 6-Minutes Walking Test in Hip Fracture Patients||Lolland Community, Denmark|No|Terminated|September 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|1||Actual|20|||Both|60 Years|N/A|No|||November 2013|November 13, 2013|August 15, 2012||No|Due to low inclusion rate we terminated this study with n=20 participants instead of n=50.|No||https://clinicaltrials.gov/show/NCT01667913||80720|
NCT01691300|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-2177A|C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT|C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment|ACTMM|Chang Gung Memorial Hospital|Yes|Completed|May 2011|November 2015|Actual|May 2015|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|30|||Both|20 Years|N/A|No|||November 2015|November 11, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01691300||78925|
NCT01691586|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCU.DHL.001|Patient Perspective on Remote Monitoring of Cardiovascular Implantable Electronic Devices|Remote Monitoring of Heart Failure Patients With Cardiovascular Implantable Electronic Device: The Patient Perspective|REMOTE-CIED|UMC Utrecht|No|Recruiting|April 2013|December 2017|Anticipated|December 2017|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|600|||Both|18 Years|85 Years|No|Probability Sample|Heart failure patients implanted with a first-time ICD/CRT-D device at one of the        participating centers.|May 2015|May 27, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01691586||78903|
NCT01691846|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC28035|A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone|A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR PLUS METFORMIN COMBINATION THERAPY COMPARED WITH PLACEBO PLUS METFORMIN IN PATIENTS WITH T2D INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY||Hoffmann-La Roche||Completed|October 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|200|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691846||78883|
NCT01692340|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OSU-09105|Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans|Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans.||Ohio State University Comprehensive Cancer Center|Yes|Completed|February 2012|November 2013|Actual|November 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|12|||Both|21 Years|70 Years|Accepts Healthy Volunteers|||September 2015|September 4, 2015|September 20, 2012||No||No|February 10, 2015|https://clinicaltrials.gov/show/NCT01692340||78845|
NCT01692652|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0463|Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate|||Yonsei University|No|Completed|August 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|98|||Both|20 Years|80 Years|No|||February 2014|February 17, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692652||78821|
NCT01692665|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1-2012-0031|Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction|||Yonsei University|No|Withdrawn|November 2012|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|20 Years|80 Years|No|Probability Sample|stage 3 or stage 4 meibomiang gland dysfunction patients|February 2014|February 17, 2014|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01692665||78820|
NCT01692912|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRC-05-2011|Psoriatic Arthritis Treat to Target vs. Usual Care|A Trial of Active Psoriatic Arthritis (PsA): Randomizing to Treat to a Target vs. Usual Care|PRC-05-2011|Pope Research Corporation|No|Recruiting|October 2012|||November 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care|2||Anticipated|230|||Both|18 Years|N/A|No|||November 2013|November 13, 2013|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692912||78801|
NCT01694485|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20110166|AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis|A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis||Amgen|Yes|Active, not recruiting|November 2012|November 2019|Anticipated|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|5||Actual|359|||Both|18 Years|65 Years|No|||March 2016|March 3, 2016|September 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01694485||78680|
NCT01694498|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|000030|Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial Investigating the Efficacy and Safety of Two Different Dose Levels of Desmopressin for the Treatment of Nocturia in Adult Men|NOC|Ferring Pharmaceuticals|No|Completed|September 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|183|||Male|20 Years|N/A|No|||August 2013|August 22, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01694498||78679|
NCT01695057|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1B-10-10|Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer|A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer||University of Southern California|Yes|Withdrawn|October 2012|October 2015|Anticipated|October 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Female|18 Years|N/A|No|||January 2014|January 27, 2014|September 24, 2012|Yes|Yes|Lack of funding|No||https://clinicaltrials.gov/show/NCT01695057||78636|
NCT01691131|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Unopar|Effects of Two Training Protocols in Patients With Chronic Obstructive Pulmonary Disease|Effects of Two Training Protocols in Physical Activity in Daily Life and Balance in Patients With COPD: Land Versus Water||Universidade Norte do Paraná|No|Recruiting|July 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|50 Years|N/A|No|||September 2012|September 21, 2012|April 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01691131||78938|
NCT01682577|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PR.122/EQL/2008|Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition|Bioequivalence Study of 4 mg Perindopril Tablets Produced by PT Dexa Medica in Comparison With the Reference Tablets (Prexum® 4 mg, Servier)Under Fasting Condition||Dexa Medica Group|No|Completed|September 2008|December 2008|Actual|November 2008|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|18|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 6, 2012|September 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01682577||79595|
NCT01683422|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5110324|Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer|A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)||Loma Linda University|Yes|Recruiting|December 2011|December 2020|Anticipated|December 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|43|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|February 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01683422||79530|
NCT01692197|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2009-0570|E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes|A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes||M.D. Anderson Cancer Center|No|Active, not recruiting|February 2013|||February 2019|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||July 2015|July 16, 2015|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01692197||78856|
NCT01692470|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100849|A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Rilpivirine Hydrochloride Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection||Janssen Pharmaceutica|No|Withdrawn|June 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|0|||Both|18 Years|N/A|No|Non-Probability Sample|Filipino anti-retroviral (ARV) naive patients with human immunodeficiency virus type 1        (HIV-1) infection and who are using rilpivirine upon its local registration|November 2015|November 30, 2015|September 21, 2012|Yes|Yes|The company decided to cancel this study in conformity with Philippines FDA Circular 2013-004|No||https://clinicaltrials.gov/show/NCT01692470||78835|
NCT01692756|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0706|Early Treatment for Acute ACL Tear|Early Anti-inflammatory Treatment in Patients With Acute ACL Tear|AAA|University of Kentucky|Yes|Active, not recruiting|March 2013|November 2015|Anticipated|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Anticipated|68|||Both|14 Years|33 Years|No|||December 2014|December 10, 2014|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01692756||78813|
NCT01692990|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LL-spec1|Study on the Effect of Fish Oil and Appetite|Study on the Effect of Fish Oil and Appetite||University of Copenhagen|No|Completed|October 2011|November 2011|Actual|November 2011|Actual|Phase 0|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Actual|20|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||September 2012|November 9, 2012|May 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01692990||78795|
NCT01676259|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SLSG12D-P2|A Phase II Study of siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer|A Phase II, Randomized, Open Label Study of Single Dose siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer||Silenseed Ltd|Yes|Not yet recruiting|June 2016|June 2018|Anticipated|June 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|124|||Both|18 Years|N/A|No|||December 2015|December 17, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676259||80080|
NCT01676532|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000025631|Feasibility Study on the Model School Pediatric Health Initiative Pilot Project|Feasibility Study on the Model School Pediatric Health Initiative Pilot Project||The Hospital for Sick Children|No|Recruiting|January 2012|January 2015|Anticipated|January 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|N/A|12 Years|Accepts Healthy Volunteers|Non-Probability Sample|All students of Sprucecourt Public School as well as the fourteen surrounding inner city        public schools and their siblings. All children attending the on-site Parenting and Family        Literacy Centre.|January 2015|January 23, 2015|August 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01676532||80059|
NCT01691326|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC49|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)||Sanofi|No|Completed|September 2012|February 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|60|||Both|6 Months|8 Years|Accepts Healthy Volunteers|||March 2014|March 12, 2014|September 19, 2012|Yes|Yes||No|January 24, 2014|https://clinicaltrials.gov/show/NCT01691326||78923|
NCT01691859|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115666|MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects|MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial||GlaxoSmithKline|Yes|Active, not recruiting|September 2012|April 2018|Anticipated|April 2018|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|150|||Both|18 Years|N/A|No|||December 2015|February 4, 2016|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691859||78882|
NCT01692067|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PT075819|Deployment Health in Regular Military Women|Combat, Sexual Assault and Post-Traumatic Stress in OIF/OEF Military Women|DHRMS|Iowa City Veterans Affairs Medical Center|Yes|Active, not recruiting|April 2009|January 2013|Anticipated|January 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||4|Anticipated|754|||Both|18 Years|60 Years|Accepts Healthy Volunteers|Non-Probability Sample|Women and Men who have or are currently serving in the USA regular military.|September 2012|September 20, 2012|July 28, 2011||No||No||https://clinicaltrials.gov/show/NCT01692067||78866|
NCT01691872|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116247|Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects|An Open-label, Single Centre, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects||GlaxoSmithKline|No|Withdrawn|October 2012|October 2012|Anticipated|October 2012|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Male|20 Years|45 Years|Accepts Healthy Volunteers|||November 2015|November 9, 2015|September 13, 2012||No|Development plan of retigabine XR in Japan was readjusted.|No||https://clinicaltrials.gov/show/NCT01691872||78881|
NCT01692080|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DU Protocol #10-11|Implementation of an Asthma Program to Improve Asthma Identification and Education in Children|Implementation of an Asthma Program to Improve Asthma Identification and Education in Children||Duquesne University|Yes|Completed|January 2010|December 2012|Actual|December 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||1|Actual|231|||Both|5 Years|17 Years|Accepts Healthy Volunteers|Non-Probability Sample|Two screenings will be held prior to each camp, at two separate locations, for a total of        six screenings per year. Screenings will be held at different locations throughout the        city of Pittsburgh in an effort to increase identification and recruitment for subsequent        camps. All children will be invited to participate in screenings, regardless of        participation in the study. All children, ages 5-17 years, will be included in our study        pending informed consent and assent. Camps will take place three times each year. All        children will be invited to participate in camps, regardless of participation in the        study. All children, ages 5-17 years will be included in our study pending informed        consent and assent.|August 2013|August 5, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01692080||78865|
NCT01692353|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RJRT-CSD0806|Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers|Evaluation of Cardiovascular Disease Biomarkers in Exclusive Smokers and Exclusive Moist Snuff Consumers||R.J. Reynolds Tobacco Company|No|Completed|September 2008|April 2009|Actual|February 2009|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||3|Actual|168|Samples Without DNA|Biospecimens to be retained include: serum, plasma, and urine.|Male|26 Years|49 Years|Accepts Healthy Volunteers|Non-Probability Sample|Subjects were selected from a community sample of male smokers, moist snuff consumers and        non-tobacco consumers. Target enrollment was 60 subjects/cohort (N=180).        The age-stratification for each of the three cohorts was as follows:          -  Ages 26 to 31: n=15          -  Ages 32 to 37: n=15          -  Ages 38 to 43: n=15          -  Ages 44 to 49: n=15|February 2016|February 15, 2016|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01692353||78844|
NCT01692366|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ARD12888|Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly|A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly||Sanofi|No|Completed|November 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|8|||Both|20 Years|N/A|No|||September 2014|September 19, 2014|September 10, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01692366||78843|
NCT01692678|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR017269|A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma|Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma||Xian-Janssen Pharmaceutical Ltd.|No|Recruiting|August 2012|February 2019|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|141|||Both|15 Years|N/A|No|||March 2016|March 11, 2016|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01692678||78819|
NCT01694173|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STEM CELL PGI|Tissue Distribution of F18-FDG Labelled Autologous Bone Marrow Derived Stem Cells in Patients With Type 2 DM|Tissue Distribution of F18-FDG Labelled Autologous Bone Marrow Derived Stem Cells in Patients With Type 2 Diabetes Mellitus||Postgraduate Institute of Medical Education and Research|Yes|Recruiting|December 2010|February 2013|Anticipated|August 2012|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|28|||Both|30 Years|70 Years|No|||September 2012|September 28, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694173||78704|
NCT01686009|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UBC Dept of EM|Intra-nasal Ketamine for Analgesia in the Emergency Department|Intra-nasal Ketamine for Analgesia in the Emergency Department|INKA|Lions Gate Hospital|No|Completed|October 2012|January 2013|Actual|January 2013|Actual|Phase 4|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|40|||Both|6 Years|N/A|No|||February 2013|February 3, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686009||79331|
NCT01686022|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NRCT_G04|Grass Sensitisation and Allergic Rhinitis in Thai Patients|The Study of Allergens From Grass and Weed Which Are Causes of Allergic Rhinitis in Thai Patients||Mahidol University|No|Recruiting|October 2012|March 2014|Anticipated|November 2013|Anticipated|N/A|Observational|N/A||1|Anticipated|185|Samples Without DNA|Serum|Both|10 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Allergy Clinic|April 2013|April 27, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686022||79330|
NCT01694784|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1338|Understanding and Discouraging Overuse of Potentially Harmful Screening Tests|Understanding and Discouraging Overuse of Potentially Harmful Screening Tests||University of North Carolina, Chapel Hill|Yes|Active, not recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|775|||Both|50 Years|85 Years|Accepts Healthy Volunteers|||August 2014|August 9, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01694784||78657|
NCT01694797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|642/09|Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metoprolol Succinate Extended-Release Tablets 50 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of TOPROL-XL® (Containing Metoprolol Succinate) Extended-Release Tablets 50 mg of AstraZeneca LP Wilmington, DE in Healthy, Adult, Human Subjects Under Fasting Conditions||Dr. Reddy's Laboratories Limited|Yes|Completed|January 2011|January 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||November 2010|September 27, 2012|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694797||78656|
NCT01694810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NI-AC002|Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers|A Phase 1 Multiple Dose, Single-Center, Observer-Blind Parallel Group Study Evaluating Safety and Cutaneous Tolerability of NVN1000 Topical Gel in Healthy Volunteers||Novan, Inc.|No|Completed|September 2012|November 2012|Actual|November 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|4||Anticipated|60|||Both|18 Years|N/A|Accepts Healthy Volunteers|||January 2014|January 10, 2014|September 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694810||78655|
NCT01686568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004590|Omega-3 Fatty Acids and Insulin Sensitivity|Dietary Omega-3 Fatty Acids as a Therapeutic Strategy in Insulin Resistant Humans||Mayo Clinic|No|Completed|December 2012|June 2015|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||June 2015|June 16, 2015|September 11, 2012|Yes|Yes||No|June 16, 2015|https://clinicaltrials.gov/show/NCT01686568||79289|
NCT01682876|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V59_57|Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.|A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age.||Novartis|No|Completed|October 2012|May 2014|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|715|||Both|2 Years|10 Years|Accepts Healthy Volunteers|||February 2015|February 20, 2015|September 7, 2012|Yes|Yes||No|June 6, 2014|https://clinicaltrials.gov/show/NCT01682876||79572|
NCT01692210|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PA12-0524|The Effect of Dexmedetomidine of the Immune System|The Effect of Dexmedetomidine on Immunological Parameters of Women Undergoing Breast Cancer Surgery||M.D. Anderson Cancer Center|Yes|Completed|September 2012|February 2015|Actual|February 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|20|Samples With DNA|15cc of blood drawn prior or at the moment of anesthesia induction and the morning after      surgery.|Female|18 Years|N/A|No|Probability Sample|Women undergoing unilateral mastectomy for malignancy at MD Anderson Cancer Center in        Houston, Texas.|January 2016|January 5, 2016|September 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01692210||78855|
NCT01692483|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100856|Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer|Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Metastatic Advanced Prostate Cancer||Janssen Pharmaceutica|No|Withdrawn|July 2013|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Male|18 Years|N/A|No|Non-Probability Sample|Male Filipino patients with advanced metastatic castration resistant prostate cancer|November 2015|November 30, 2015|September 21, 2012|Yes|Yes|Sponsor determined study is not required according to PFDA Circular 2013-004|No||https://clinicaltrials.gov/show/NCT01692483||78834|
NCT01692496|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GEIS-30|Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial|Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists||Grupo Espanol de Investigacion en Sarcomas|No|Active, not recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|52|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01692496||78833|
NCT01692509|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIV related practices|Non Invasive Ventilation (NIV) Related Practices, Monitoring of the NIV Treatment Effect and of the Patient's Comfort|Observation of Non Invasive Ventilation (NIV) Related Practices, Monitoring of the NIV Treatment Effect and of the Patient's Comfort During NIV||University of Lausanne Hospitals|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|30|||Both|18 Years|N/A|No|Non-Probability Sample|Adult patients hospitalized in the CHUV intensive care unit who require non invasive        ventilation because of respiratory failure.|June 2015|June 7, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692509||78832|
NCT01694043|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8927B|The Effect of Watching a Television Show on the Liking of Snack Foods|The Effect of Perceived Healthy and Unhealthy Commercials on Intake of Perceived Healthy and Unhealthy Snack Foods in Normal Weight, College-Aged, Dietary Restrained Women||University of Tennessee|No|Active, not recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Anticipated|48|||Female|18 Years|30 Years|Accepts Healthy Volunteers|||January 2016|January 26, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01694043||78714|
NCT01694303|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB-24519|Computerized Interventions for College Students' Cognitive Functioning and Mental Well-being|Computerized Interventions for College Students' Cognitive Functioning and Mental Well-being||Stanford University|No|Completed|September 2012|September 2013|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Actual|38|||Both|18 Years|30 Years|Accepts Healthy Volunteers|||July 2015|July 15, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694303||78694|
NCT01693003|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCMPALABAtrial|Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD|Randomized, Open-label, Crossover Clinical Trial to Assess the Effects of Indacaterol 150 µg d.o. Compared to Tiotropium Bromide 5 µg d.o. on Dyspnea, Dynamic Pulmonary Hyperinflation and Exercise Tolerance in Patients With Moderate COPD||Irmandade Santa Casa de Misericórdia de Porto Alegre|No|Completed|March 2013|October 2013|Actual|October 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|40 Years|N/A|No|||January 2014|January 6, 2014|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01693003||78794|
NCT01676545|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-10-122-PST2China|Genetics of Periodontal Diseases in Chinese|||Shanghai Stomatological Disease Center||Active, not recruiting|July 2011|||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|||||Both|35 Years|N/A||Non-Probability Sample|All study subjects will be selected from a pre-existing patient database in Shanghai. All        chronic periodontitis cases and controls will be subjects who were at least 35 years old        at time of enrollment.        Classification of chronic periodontitis will be based on the extent of periodontal tissue        destruction with consideration of tooth loss.|August 2012|August 30, 2012|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01676545||80058|
NCT01676558|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DLBCL_131I-rituximab RIT|A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)|A Phase II Study of 131I-rituximab for Elderly or Poor Performance Status Patients With Diffuse Large B Cell Lymphoma (DLBCL) or for Adult Patients With Relapsed or Refractory DLBCL||Korea Cancer Center Hospital|No|Recruiting|June 2012|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|24|||Both|20 Years|N/A|No|||August 2012|November 13, 2012|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01676558||80057|
NCT01676831|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813320(UPCC03411)|Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)|A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma||Abramson Cancer Center of the University of Pennsylvania|Yes|Completed|February 2012|January 2015|Actual|January 2015|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||January 2015|January 13, 2015|July 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01676831||80036|
NCT01691339|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRC50|Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.|Safety and Immunogenicity Among Adults of Fluzone®, Influenza Virus Vaccines 2012-2013 Formulation (Intradermal and Intramuscular Route)||Sanofi|No|Completed|September 2012|February 2013|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|4||Actual|200|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 29, 2013|September 19, 2012|Yes|Yes||No|August 29, 2013|https://clinicaltrials.gov/show/NCT01691339||78922|
NCT01691625|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JR-01|Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer|Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer||Capital Medical University|No|Recruiting|September 2012|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|50|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01691625||78900|
NCT01691638|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ILI-11-127-PST2Europe|Genetics of Periodontal Diseases in European Caucasians|||University of Kiel||Active, not recruiting||||||N/A|Observational|Observational Model: Case Control, Time Perspective: Retrospective||2|||||Both|35 Years|N/A||Non-Probability Sample|All study subjects will be selected from pre-existing patient databases in Germany and the        Netherlands. All chronic periodontitis cases and controls will be subjects who were at        least 35 years old at time of enrollment. Classification of chronic periodontitis will be        based on extent of alveolar bone loss with consideration of tooth loss.|September 2012|September 24, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01691638||78899|
NCT01691885|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|116601|RELOVAIR® Lung Deflation Study|A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and Arterial Stiffness in Adults With Chronic Obstructive Pulmonary Disease (COPD)||GlaxoSmithKline||Completed|November 2012|July 2014|Actual|July 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|45|||Both|40 Years|N/A|No|||August 2014|March 26, 2015|August 30, 2012|No|Yes||No|March 26, 2015|https://clinicaltrials.gov/show/NCT01691885||78880|
NCT01692093|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCRG_KM110329|KM110329 in Adult Patients With Atopic Dermatitis|KM110329 in Adult Patients With Atopic Dermatitis : a Randomised, Double-blind, Placebo-controlled, Multicenter Trial||Kyunghee University Medical Center|Yes|Recruiting|September 2012|September 2014|Anticipated|June 2014|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|66|||Both|18 Years|65 Years|No|||November 2013|November 12, 2013|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692093||78864|
NCT01693666|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|22009|Lifestyle Intervention Forever: Healthy Weight for Pregnancy and Birth (Pilot Study)|Lifestyle Intervention Forever: Healthy Weight for Pregnancy and Birth (Pilot Study)||St. Louis University|No|Completed|September 2012|July 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|30|||Female|18 Years|40 Years|Accepts Healthy Volunteers|||September 2015|September 30, 2015|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01693666||78743|
NCT01693965|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00601-42|Clinical Course and Changes in the Respiratory Microbiota Based on Antibiotic Treatment in Patients With Cystic Fibrosis|Clinical Course and Changes in the Respiratory Microbiota Based on Antibiotic Treatment in Patients With Cystic Fibrosis||Assistance Publique Hopitaux De Marseille|No|Recruiting|January 2013|February 2016|Anticipated|September 2015|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Anticipated|10|||Both|11 Years|N/A|No|||August 2014|August 29, 2014|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01693965||78720|
NCT01694186|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PSV-FAI-001|Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert|A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye||pSivida Corp.|No|Active, not recruiting|June 2013|March 2018|Anticipated|March 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|129|||Both|18 Years|N/A|No|||October 2015|October 20, 2015|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694186||78703|
NCT01694524|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|febrile seizure and infection|Nervous System Infections Among Patients With Febrile Seizure|Nervous System Infections Among Patients With Febrile Seizure : Retrospective Cohort Review of Consecutive Patients Admitted in 7 Pediatric Emergency Departments in Ile-de-France Between 2007 and 2011||Hôpital Armand Trousseau|No|Completed|June 2013|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|1200|||Both|3 Months|5 Years|No|Non-Probability Sample|This was a retrospective cohort review of consecutive patients admitted in 7 pediatric        emergency departments in Ile-de-France between 2007 and 2011. All clinically well-apparent        children 3 to 11 months of age with a first simple febrile seizure were included in the        study. All children between 3 months and 5 years with a complex febrile seizure were        included|May 2014|May 19, 2014|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694524||78677|
NCT01686321|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DSHNHL-2010-1|Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma|Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients ("Slow Go") With Aggressive CD20-positive B-cell|B-R-ENDA|University of Göttingen|Yes|Recruiting|May 2012|October 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|60 Years|N/A|No|||February 2013|February 21, 2013|July 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01686321||79308|
NCT01686581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAF/AGN/NS/CM/002|An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine|||Allergan|No|Active, not recruiting|July 2015|September 2016|Anticipated|September 2016|Anticipated|Phase 4|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|644|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with chronic migraine prescribed BOTOX® for the prophylaxis of headaches|February 2016|February 18, 2016|September 13, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01686581||79288|
NCT01686308|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIRCAT|The Effect of Cataract on Photoentrainment of the Circadian Rhythm in Humans|The Effect of Cataract on Photoentrainment of the Circadian Rhythm in Humans|CIRCAT|Glostrup University Hospital, Copenhagen|Yes|Completed|February 2011|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|76|||Both|18 Years|N/A|No|||February 2015|February 9, 2015|November 30, 2011||No||No||https://clinicaltrials.gov/show/NCT01686308||79309|
NCT01682590|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quenot IDEAL-ICU|I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus deLayed in Intensive Care Unit)|Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial|IDEAL-ICU|Centre Hospitalier Universitaire Dijon|Yes|Recruiting|July 2012|||||Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Anticipated|864|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|September 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01682590||79594|
NCT01691417|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Sleeves-Bickel|Pneumatic Sleeves and Congestive Heart Failure|The Impact of Intermittent Sequential Pneumatic Compression (ISPC) Leg Sleeves on Cardiac Performance in Patients With Congestive Heart Failure|Sleeves-Bickel|Western Galilee Hospital-Nahariya||Completed||||||N/A|Interventional|N/A|2||||||Both|N/A|N/A|No|||September 2012|September 19, 2012|September 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01691417||78916|
NCT01691729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A739|Comparison Study of 3 Ostomy Products|A Randomized, Multicenter, Cross-Over Study Comparing the Performance of Three Ostomy Accessory Products||ConvaTec Inc.|No|Active, not recruiting|September 2012|December 2013|Anticipated|November 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|6||Actual|26|||Both|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|November 13, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01691729||78892|
NCT01692184|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AVL-292-004|Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292|A Phase 1, Two-part Study to Investigate the Safety and Pharmacokinetics of AVL-292 Following Multiple Oral Doses and to Evaluate the Effect of Food on the Pharmacokinetics of AVL-292 Following a Single Oral Dose in Healthy Adult Subjects||Celgene Corporation|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|6||Anticipated|54|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||March 2016|March 24, 2016|September 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01692184||78857|
NCT01693770|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BM-MRgFUS|Primary Pain Palliation in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound|Primary Pain Palliation and Local Tumor Control in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound||University of Roma La Sapienza|Yes|Enrolling by invitation|January 2011|February 2015|Anticipated|January 2015|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|90 Years|No|||June 2014|June 17, 2014|September 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01693770||78735|
NCT01693783|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-02877|Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer|A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies||National Cancer Institute (NCI)|Yes|Active, not recruiting|December 2012|||December 2015|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|27|||Female|18 Years|N/A|No|||November 2015|February 4, 2016|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693783||78734|
NCT01693796|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-A01118-31|Evaluation of Thyroid Exposure to Radiation Doses During Paediatric Cardiac Catheterisations Performed for Diagnosis or the Treatment of Congenital Heart Disease|Evaluation of Thyroid Exposure to Radiation Doses During Paediatric Cardiac Catheterisations Performed for Diagnosis or the Treatment of Congenital Heart Disease||Assistance Publique Hopitaux De Marseille|No|Completed|March 2011|April 2015|Actual|April 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|500|||Both|N/A|18 Years|No|||August 2015|August 20, 2015|April 5, 2011||No||No||https://clinicaltrials.gov/show/NCT01693796||78733|
NCT01676272|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|soluble 102|Multi Center Site , Controlled Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograft|Proposal for a Multi- Center Site Randomized, Prospective Controlled Head-to-head Clinical Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograf||Soluble Systems, LLC|No|Enrolling by invitation|July 2012|November 2015|Anticipated|November 2015|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|90 Years|No|Probability Sample|Study population includes Diabetic patients with type 1 or type 2 Diabetes with foot        ulcers|November 2015|November 16, 2015|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676272||80079|
NCT01676519|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Arezzo007|Impact of Critical Limb Ischemia on Long Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization|||Ospedale San Donato|No|Completed|July 2002|December 2011|Actual|May 2007|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|764|||Both|18 Years|N/A|No|Probability Sample|consecutive diabetic patients undergoing percutaneous coronary intervention|August 2012|August 30, 2012|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01676519||80060|
NCT01677130|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FOV application|Standardized Application of High Frequency Oscillatory Ventilation in the Acute Respiratory Distress Syndrome (ARDS)|||Southeast University, China||Not yet recruiting|August 2012|August 2014|Anticipated|||N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|N/A|No|Probability Sample|patients of ARDS age> 18 years|August 2012|August 30, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677130||80013|
NCT01692379|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|REVASCAT|Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours|RandomizEd Trial of reVascularizAtion With Solitaire FR® Device Versus Best mediCal Therapy in the Treatment of Acute Stroke Due to anTerior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset|REVASCAT|Fundacio Ictus Malaltia Vascular|Yes|Terminated|November 2012|December 2015|Actual|March 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|206|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|September 20, 2012||No|Following DSMB advice after first interim analysis (n=174)|No||https://clinicaltrials.gov/show/NCT01692379||78842|
NCT01691651|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RECUNIFESP-87051|Botulinum Toxin A for the Treatment of Keratoconus|Botulinum Toxin Type A for Keratoconus||Federal University of São Paulo|Yes|Completed|September 2012|October 2014|Actual|October 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Both|10 Years|40 Years|No|||October 2014|October 18, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01691651||78898|
NCT01692925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NN7008-4015|Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A|Multi-centre, Open-labelled Trial Investigating the Pharmacokinetics of Four Lots of Turoctocog Alfa in Subjects With Haemophilia A||Novo Nordisk A/S|No|Completed|December 2012|March 2013|Actual|March 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|15|||Male|18 Years|N/A|No|||November 2014|November 18, 2014|September 21, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01692925||78800|
NCT01693198|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0172-12-MMC|Cyanobacteria Allergy in Lake Kineret|Cyanobacteria Allergy in Lake Kineret||Meir Medical Center|Yes|Not yet recruiting|November 2012|November 2014|Anticipated|November 2014|Anticipated|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|200|||Both|18 Years|N/A|No|||September 2012|September 23, 2012|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01693198||78779|
NCT01693432|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-1202|Docetaxel and S-1 for Advanced Esophageal Cancer|A Phase II Study of Docetaxel and S-1 as First-line Chemotherapy in Patients With Advanced Esophageal Cancer||Hallym University Medical Center|No|Recruiting|November 2011|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|37|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693432||78761|
NCT01693978|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34DA032689-01A1|Contingency Outcomes in Prolonged Exposure|Incentivizing Adherence to Prolonged Exposure With Substance Users|COPE|Johns Hopkins University|No|Active, not recruiting|September 2012|August 2015|Anticipated|May 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|125|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01693978||78719|
NCT01694199|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RBI.2012.003.P.2|A Multicenter, Randomized, Sham-Controlled, Double-Blinded Study to Evaluate the Analgesic Efficacy and Safety of Pulsed Radiofrequency Energy (PRFE) in Bunionectomy Surgery for the Treatment of Post-Operative Pain|||Regenesis Biomedical, Inc.|Yes|Terminated|September 2012|December 2012|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Actual|139|||Both|18 Years|75 Years|No|||January 2013|November 3, 2014|September 24, 2012|Yes|Yes|IDMC recommendation|No||https://clinicaltrials.gov/show/NCT01694199||78702|
NCT01694511|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2-2188|Endoscopic Detection of Dysplasia in Barrett's Esophagus|High Resolution Magnifying Endoscopy and Contrast Enhanced Imaging Versus Standard White Light Endoscopy for the Detection of Dysplasia in Barrett's Esophagus. A Prospective Blinded Cross-over Study.||Göteborg University|No|Completed|November 2009|January 2013|Actual|November 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic|2||Actual|111|||Both|20 Years|80 Years|No|||February 2014|February 7, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01694511||78678|
NCT01694836|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|603-PG-PSC-191|Depigoid Birch 5000 Longterm Study in Adults and Adolescents|Multicenter, Placebo-controlled, Long-term Study of Depigoid Birch 5000 in Adults and Adolescents With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma||Leti Pharma GmbH|Yes|Active, not recruiting|September 2012|July 2018|Anticipated|May 2018|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|634|||Both|12 Years|70 Years|No|||July 2014|July 11, 2014|August 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01694836||78653|
NCT01695083|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P091119|Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients|Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients|FIRM|Assistance Publique - Hôpitaux de Paris|No|Active, not recruiting|October 2012|June 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|blood, liver biopsy|Both|18 Years|N/A|No|Non-Probability Sample|morbidly obese patients undergoing bariatric surgery|October 2015|November 3, 2015|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695083||78634|
NCT01686594|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT 2012-000212-28|PUVA Maintenance Therapy in Mycosis Fungoides|A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB|M_PUVA_2012|Medical University of Graz|No|Recruiting|February 2013|October 2021|Anticipated|October 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|82|||Both|18 Years|82 Years|No|||November 2015|November 24, 2015|May 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01686594||79287|
NCT01691430|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1112009472|A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents|A Randomized, Controlled Trial of Cranberry Capsules for UTI Prevention in Nursing Home Residents||Yale University|No|Active, not recruiting|August 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|190|||Female|65 Years|N/A|Accepts Healthy Volunteers|||October 2015|October 22, 2015|August 9, 2012||No||No||https://clinicaltrials.gov/show/NCT01691430||78915|
NCT01693263|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-0269|Outcome of BCF Access in Hemodialysis Patients|A Clinical and Computational Study to Improve Brachiocephalic Fistula (BCF) Outcomes|BCF|University of Chicago|No|Recruiting|October 2011|December 2018|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|250|Samples With DNA|Whole Blood Viscosity (WBV), Hematocrit, and ADMA: WBV will be measured by Brookfield      Programmable DV-II+ cone plate viscometer. ADMA will be measured by ADMA ELISA kit. The      samples will be collected every 6 months on all subjects and frozen to be run in aliquots of      50.      Cephalic Vein and Arterial Tissue Samples: During placement of BCF vein and arterial tissue      are excised during anastomosis to create the fistula. After the tissue is removed from the      vein and artery a small portion of each will be removed and collected for research from this      discarded material. The cephalic vein and arterial samples will be collected and preserved      in a tissue bank for later review by light and electron microscopy in a subsequent study.|Both|21 Years|N/A|No|Non-Probability Sample|Subjects for consideration in the study will be those referred from the out-patient        nephrology clinic at the University of Chicago or a dialysis unit affiliated with DaVita        Dialysis for a primary AVF. Eligible patients are those who are evaluated at the        University of Chicago or Weiss Hospital by a transplant or vascular surgeon. If the        treating surgeon determines that the patient will have an attempted BCF, these patients        will be eligible to participate in this study. The research team will be notified of a        potential subject.|November 2015|November 4, 2015|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01693263||78774|
NCT01694069|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24255|Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis|Continuous Infusion Piperacillin-Tazobactam for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis|PIPE-CF|West Virginia University|No|Terminated|September 2012|December 2014|Anticipated|March 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|6|||Both|8 Years|N/A|No|||March 2014|March 14, 2014|September 19, 2012||No|Recruitment was not sufficient to complete the study|No||https://clinicaltrials.gov/show/NCT01694069||78712|
NCT01676285|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0010/11|Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis|Effect of Metoprolol Succinate in Cardiac Remodeling Related to Nonalcoholic Cirrhosis. Randomized Study.|CARE Cirrhosis|University of Sao Paulo|Yes|Completed|January 2012|March 2014|Actual|September 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|125|||Both|18 Years|60 Years|No|||September 2014|September 9, 2014|August 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01676285||80078|
NCT01676298|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|01001686|Spartan FRX Project Reproducibility Study|Study of the Analytical Reproducibility of the Spartan FRX CYP2C19 *2,*3 and *17 Genotyping System.||Spartan Bioscience Inc.|No|Completed|August 2012|November 2012|Actual|September 2012|Actual|N/A|Observational|Time Perspective: Prospective||1|Actual|8|||Both|16 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|8 Individuals with predetermined CYP2C19 *2,*3 and *17 genotypes|December 2012|December 3, 2012|August 28, 2012||No||No|November 6, 2012|https://clinicaltrials.gov/show/NCT01676298||80077|
NCT01677143|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SUS2012CMR01|Pre-emptive Local Anaesthesia in Gynecological Laparoscopy|Pre-emptive Local Anaesthesia in Gynecological Laparoscopy||Helse Stavanger HF|No|Completed|February 2013|September 2013|Actual|September 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|2||Actual|24|||Female|18 Years|N/A|Accepts Healthy Volunteers|||November 2014|November 20, 2014|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01677143||80012|
NCT01677156|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CDX000015|A Registry to Evaluate Patterns of Care Associated With the Use of Corus® CAD in Real World Clinical Care Settings|The PRESET Registry: A Registry to Evaluate Patterns of Care Associated With the Use of Corus® CAD in Real World Clinical Care Settings|PRESET|CardioDx|No|Completed|August 2012|October 2015|Actual|September 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|713|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Patients presenting to their primary clinician's office with chest pain suggestive of        obstructive coronary artery disease.|January 2016|January 26, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677156||80011|
NCT01692704|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ONK-USZ-003|Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy|Downstaging of Unresectable Intrahepatic or Hilar Cholangiocellular Carcinoma by Selective Intra-arterial Floxuridine and Systemic Cisplatin and Gemcitabine. A Dose Finding Single Center Phase IIa Study||University of Zurich|Yes|Completed|April 2012|March 2016|Actual|March 2016|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|12|||Both|18 Years|N/A|No|||March 2016|March 24, 2016|June 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01692704||78817|
NCT01684475|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CJH1 Trial|A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE|A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE||Alexandra Marine and General Hospital|No|Recruiting|September 2012|September 2013|Anticipated|September 2013||Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|1||Anticipated|21|||Both|40 Years|85 Years|No|||September 2012|September 12, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01684475||79449|
NCT01692691|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-10|Dacarbazine and Carmustine in Metastatic Melanoma|Phase II Trial of Sequenced Chemotherapy With Dacarbazine and Carmustine With Neulasta® Support in Previously Treated Metastatic Melanoma||Western Regional Medical Center|No|Terminated|August 2012|October 2014|Actual|October 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|1|||Both|18 Years|N/A|No|||January 2016|January 1, 2016|August 29, 2012|Yes|Yes|Low enrollment|No|January 1, 2016|https://clinicaltrials.gov/show/NCT01692691||78818|
NCT01693445|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HMC-HO-GI-1203|S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer|Dose Finding Study of S-1, Oxaliplatin, and Irinotecan Combination Chemotherapy for Patients With Inoperable Advanced or Metastatic Gastrointestinal Cancers||Hallym University Medical Center|No|Completed|June 2012|August 2014|Actual|February 2014|Actual|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|22|||Both|18 Years|N/A|No|||September 2012|February 18, 2016|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693445||78760|
NCT01693679|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Telbivudine|Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis|||Sun Yat-sen University|Yes|Active, not recruiting|September 2012|||April 2014|Anticipated|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|120|||Both|18 Years|75 Years|No|||September 2012|September 24, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693679||78742|
NCT01685541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HHSA29010007|Evaluation of Computer Generated After Visit Summaries|Evaluation of Computer Generated After Visit Summaries to Support Patient-Centered Care||Baylor College of Medicine|No|Completed|December 2010|June 2012|Actual|January 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|272|||Both|21 Years|N/A|No|||September 2012|September 13, 2012|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685541||79367|
NCT01685554|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Norm-Arh-2012|Normothermiс Cardiopulmonary Bypass Increases Cerebral Oxygenation During Valve Surgery|Normothermiс Cardiopulmonary Bypass Increases Cerebral Oxygenation During Combined Valve Surgery: Single Center, Randomized Trial||Northern State Medical University|No|Completed|March 2010|December 2011|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|40|||Both|18 Years|80 Years|No|||October 2012|October 17, 2012|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01685554||79366|
NCT01685801|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VX12-770-113|Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function|A Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis, Residual CFTR Function, and FEV1 ≥40% Predicted||Vertex Pharmaceuticals Incorporated|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|4||Actual|24|||Both|12 Years|N/A|No|||April 2015|April 30, 2015|September 6, 2012|Yes|Yes||No|April 30, 2015|https://clinicaltrials.gov/show/NCT01685801||79347|
NCT01685775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|U1111-1114-7386|Needlescopic Versus Transvaginal/Transumbilical Cholecystectomy|Needlescopic Versus Transvaginal/Transumbilical Cholecystectomy: a Randomized Clinical Trial|NATCH|University of Witten/Herdecke|No|Completed|February 2010|December 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|40|||Female|18 Years|80 Years|No|||October 2013|October 12, 2013|September 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01685775||79349|
NCT01685788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUL - FaBeR - Stroke - Meyer|Study of Sensory Deficits in the Upper Limb After Stroke|Prospective Longitudinal Study: Sensory Deficits in the Upper Limb After Stroke.||Universitaire Ziekenhuizen Leuven|Yes|Recruiting|October 2012|March 2015|Anticipated|March 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|stroke patients|December 2014|December 9, 2014|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01685788||79348|
NCT01691443|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DCIC 11 17|Functional Assessment of a Vibration Feedback on the Gripping Pressure in the Territory of the Median Nerve|Preliminary Study of the Substitution of Sensory Deficits of the Hand by a Medical Device Embedded : a Functional Assessment of Vibration Feedback on the Gripping Pressure in the Territory of the Median Nerve.|TEXIGLOVE|University Hospital, Grenoble|Yes|Terminated|April 2013|March 2015|Actual|March 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research|1||Anticipated|20|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||March 2015|March 13, 2015|July 12, 2012||No|Technical problem with one of the medical device used for the study.|No||https://clinicaltrials.gov/show/NCT01691443||78914|
NCT01691456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|539-10|Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|January 2011|February 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|45|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691456||78913|
NCT01691157|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11/NI/0026 version 3.1|Exercise in the Physiotherapy Management of Shoulder Impingement|The Effectiveness of Exercise in the Physiotherapy Management of Subacromial Impingement Syndrome|EaSI|University of Ulster|Yes|Recruiting|September 2012|May 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|94|||Both|18 Years|N/A|No|||October 2012|October 11, 2012|August 8, 2012||No||No||https://clinicaltrials.gov/show/NCT01691157||78936|
NCT01693016|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MASIMO 2012|Validation of Non-invasive Hemoglobin (SpHb) Measurement in Children|Validation of Non-invasive Hb-measurement (SpHb) in Children With the Masimo@ Radical 7||Johannes Gutenberg University Mainz|No|Completed|September 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|81|||Both|N/A|8 Years|No|||March 2014|March 23, 2014|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01693016||78793|
NCT01693042|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-01-01REPEAT|Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure|Randomized Controlled Trial to Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Total and SHFM-predicted Mortality in Patients With Chronic Post-infarction Heart Failure|REPEAT|Johann Wolfgang Goethe University Hospitals|Yes|Recruiting|November 2013|January 2022|Anticipated|November 2020|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|676|||Both|18 Years|80 Years|No|||September 2015|September 8, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01693042||78791|
NCT01691963|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|M12-1233|Epiglottic Downfolding During Endotracheal Intubation|Epiglottic Downfolding During Endotracheal Intubation - An Alternative Technique to Improve Glottic Exposure and Facilitate Intubation?||Catharina Ziekenhuis Eindhoven|Yes|Withdrawn|April 2013|January 2016|Actual|January 2016|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|0|||Both|18 Years|N/A|No|||January 2016|January 27, 2016|September 19, 2012||No|Main investigators (Pieters/van Zundert) changed institutions. Therefore, they were not able    to start the study and decided to withdraw the study for now.|No||https://clinicaltrials.gov/show/NCT01691963||78874|
NCT01693289|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|elsharkwy t|Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome|Phase 1 Study of Efficacy of Combined Metformin-letrozole in Comparison With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome||Zagazig University||Completed|January 2012|July 2012|Actual|June 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|146|||Female|18 Years|35 Years|No|||September 2012|September 25, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01693289||78772|
NCT01693523|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-0587|Minocycline Study in Pancreatic Cancer Patients|A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden for Pancreatic Cancer Patients||M.D. Anderson Cancer Center|Yes|Active, not recruiting|January 2013|||January 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|76|||Both|18 Years|N/A|No|||November 2015|November 12, 2015|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693523||78754|
NCT01693510|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BHIP-DFC|Be Healthy in Pregnancy (B-HIP): A Trial to Study Nutrition and Exercise Approaches for Healthy Pregnancy|Be Healthy in Pregnancy (B-HIP): A Randomized Clinical Trial (RCT) to Study Nutrition and Exercise Approaches for Healthy Pregnancy|BHIP|McMaster University|No|Recruiting|July 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|110|||Female|18 Years|N/A|No|||March 2014|March 13, 2014|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693510||78755|
NCT01693809|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0127/11|The Effects of Caffeine on Vestibular Evoked Myogenic Potentials in Healthy Subjects|The Effects of Caffeine on Vestibular Evoked Myogenic Potentials in Healthy||Hospital do Servidor Publico Estadual|Yes|Active, not recruiting|January 2012|January 2013|Anticipated|October 2012|Anticipated|Phase 4|Interventional|Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening|1||Anticipated|25|||Both|20 Years|40 Years|Accepts Healthy Volunteers|||September 2012|September 29, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693809||78732|
NCT01694082|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1207010596|Brief Web-Based Alcohol Reduction Intervention for Undergraduates|Randomized, Controlled Trial of a Brief, Web-Based Alcohol Reduction Intervention for Undergraduates||Yale University|No|Completed|October 2012|June 2014|Actual|November 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|4||Actual|207|||Both|18 Years|24 Years|Accepts Healthy Volunteers|||June 2014|June 12, 2014|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01694082||78711|
NCT01676857|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU00030121|Chemokine Mechanisms in Chronic Pelvic Pain|Chemokine Mechanisms in Chronic Pelvic Pain||Northwestern University|No|Recruiting|May 2010|June 2017|Anticipated|June 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|264|Samples With DNA|Expressed prostatic secretions, urine with or without cells, blood for cells and plasma|Male|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The Study population will include 176 adult patients diagnosed with CPPS (equal numbers of        CPPS IIIa and CPPS IIIb) and 88 adult comparator controls, at least 18 years of age,        recruited from Northwestern urology clinical site practices. All CPPS participants will be        male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had        been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise        the patient population.|January 2016|January 6, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676857||80034|
NCT01677429|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9520-AC-CTIL|The Assessment and Treatment of Balance Impairment Using Virtual Reality (VR) in Panic Disorder Patients|||Sheba Medical Center|No|Not yet recruiting|June 2015|September 2016|Anticipated|June 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|80|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||June 2015|June 23, 2015|August 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01677429||79990|
NCT01684488|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RPCGA-YRI-21003|Trial of the Youth Readiness Intervention|A Feasibility Trial of the Youth Readiness Intervention: A Group Psychosocial Intervention for War-affected Youth in Sierra Leone|YRI|Harvard School of Public Health|No|Completed|April 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|4||Actual|443|||Both|15 Years|24 Years|No|||July 2015|July 21, 2015|March 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01684488||79448|
NCT01692938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPT1001|Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO|Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO||Optos, PLC.|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Actual|32|||Both|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Twenty-four subjects, 12 without retinal disease (Cohort 1) and 12 with retinal disease        (Cohort 2) will be recruited. Any subjects that do not comply with or complete the study        protocol will be replaced to ensure that a total of 24 subjects complete the protocol.        Subjects will be screened and recruited based on the Inclusion/Exclusion criteria outlined        within this protocol. Subjects fulfilling the stated criteria and who are willing to        comply must sign an informed consent prior form to study participation.|September 2015|October 28, 2015|September 21, 2012||No||No|July 19, 2013|https://clinicaltrials.gov/show/NCT01692938||78799|
NCT01685034|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMCSD.2012.0148|Allergy Immunotherapy in the Management of Eosinophilic Esophagitis|Evaluation of the Clinical, Endoscopic and Histologic Effects of Environmental Allergy Immunotherapy in the Treatment of Eosinophilic Esophagitis|AIMEE|United States Naval Medical Center, San Diego|Yes|Withdrawn||||||N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||September 2014|September 24, 2014|September 5, 2012|Yes|Yes|I was deployed to Afghanistan prior to IRB approval, so the study was halted (before it    started).|No||https://clinicaltrials.gov/show/NCT01685034||79406|
NCT01685281|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AL011|Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder|Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder||Alcobra Ltd.|No|Completed|August 2013|December 2013|Actual|December 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|55 Years|No|||January 2014|January 13, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685281||79387|
NCT01685567|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SRM-2012-02|Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure|INVESTIGATION of FLOW ALTERED, SHORT TRANSCERVICAL CAROTID ARTERY STENTING in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE With Filter.|ROADSTER|Silk Road Medical|Yes|Recruiting|November 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Anticipated|283|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|September 10, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01685567||79365|
NCT01694238|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stoma-Const|A Randomized Trial on the Technical Aspects of Stoma Construction.|Circular, Mesh Enforced or Cruciate Incision in the Abdominal Wall Fascia for coloStomy Construction - A Randomised Trial||Sahlgrenska University Hospital, Sweden||Recruiting|June 2013|September 2017|Anticipated|September 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|240|||Both|N/A|N/A|No|||August 2015|August 19, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694238||78699|
NCT01690923|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MA000-1442|Nasal Pillows vs. Nasal Masks at High CPAP Pressure|Nasal Pillows at High CPAP Pressure||ResMed|Yes|Completed|August 2011|December 2012|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|90 Years|No|||September 2014|October 7, 2014|September 16, 2012||No||No|September 26, 2014|https://clinicaltrials.gov/show/NCT01690923||78954|This study only included established CPAP users.
NCT01686048|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Ambrosia|The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel|||Meir Medical Center||Completed|April 2015|April 2015|Actual|April 2015|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|120|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients refered for allergic evaluation|October 2015|October 6, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686048||79329|
NCT01686061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MUS6020100920|Blepharospasm Patient Survey for Patients With Blepharospasm|Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm||Merz Pharmaceuticals, LLC|No|Completed|September 2012|April 2013|Actual|April 2013|Actual|N/A|Observational|N/A||1|Actual|124|||Both|18 Years|81 Years|No|Non-Probability Sample|Patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA or        onabotulinumtoxinA treatment.|April 2014|April 7, 2014|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01686061||79328|
NCT01692535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|106/12|Evaluation of Video Laryngoscopes in Difficult Airway|Multicenter Study Evaluating Video Laryngoscopes: The Swiss Video-Intubation Trial (SWIVIT I)|SWIVIT I|University Hospital Inselspital, Berne|No|Completed|January 2013|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|6||Actual|720|||Both|18 Years|N/A|Accepts Healthy Volunteers|||June 2015|June 10, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692535||78830|
NCT01692548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|110084|Neurofeedback Intervention on the Development of ADHD in Children at Risk|Effect of Neurofeedback Intervention on the Development of ADHD in Children at Risk: a Comparative Study.||Hospital de Clinicas de Porto Alegre|Yes|Completed|May 2012|December 2012|Actual|August 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|36|||Both|6 Years|10 Years|Accepts Healthy Volunteers|||May 2013|May 1, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01692548||78829|
NCT01691742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035126|MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery|Double-Blind Randomized Controlled Trial of MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery in Women Receiving Routine Docusate Sodium|MVP|Duke University|Yes|Completed|September 2012|April 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Actual|131|||Female|19 Years|N/A|No|||October 2014|May 15, 2015|September 18, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01691742||78891|
NCT01693276|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCC-GI-01|Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer|Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer||University of Cincinnati|No|Terminated|September 2012|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|3|||Both|18 Years|N/A|No|||October 2015|October 23, 2015|September 19, 2012|Yes|Yes|Slow accrual|No||https://clinicaltrials.gov/show/NCT01693276||78773|
NCT01693055|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1207/162-004|Safety and Efficacy Evaluation of UltheraTM in Treatment of Baggy Eyelid|Safety and Efficacy Evaluation of UltheraTM in Treatment of Baggy Eyelid,Phase 4.||Seoul National University Hospital|No|Completed|September 2012|February 2013|Actual|February 2013|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Female|20 Years|50 Years|Accepts Healthy Volunteers|||April 2014|April 4, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01693055||78790|
NCT01693302|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|06-0994|Timing of Meal Insulin Boluses for Optimal Postprandial Glycemic Control in Type 1 Diabetes|Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control in Patients With Type 1 Diabetes||University of Colorado, Denver|No|Completed|August 2007|May 2009|Actual|May 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|23|||Both|12 Years|30 Years|No|||September 2012|September 21, 2012|September 9, 2009||No||No||https://clinicaltrials.gov/show/NCT01693302||78771|
NCT01693536|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RO783|Can Primary Care Change Elderly Physical Activity and Salt Intake? An Australian Pilot Trial|Effective Change of Behaviour of the Elderly in Normal General Practice|ECOBEING|Health HQ|No|Completed|October 2008|December 2010|Actual|July 2009|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|85|||Both|75 Years|95 Years|Accepts Healthy Volunteers|||September 2012|September 22, 2012|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01693536||78753|
NCT01693549|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HE 11B/11|Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes|Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes||Hellenic Cooperative Oncology Group|No|Recruiting|September 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|84|||Female|18 Years|75 Years|No|||September 2015|September 23, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693549||78752|
NCT01693822|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICR-CTSU/2011/10033|A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy|A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy|A-PREDICT|Institute of Cancer Research, United Kingdom|Yes|Recruiting|October 2012|September 2016|Anticipated|October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|99|||Both|18 Years|N/A|No|||April 2013|April 12, 2013|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01693822||78731|
NCT01693835|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-42|"Cancersensor": Circadian Rhythms|Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : the Circadian Rhythms of Urinary Excretion of Modified Nucleosides.||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|August 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|60|Samples With DNA|Saliva (exfoliated oral mucosa cells) and urine|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients with metastatic colorectal cancer treated at the Department of Medical Oncology        of Paul Brousse Hospital|April 2015|June 5, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01693835||78730|
NCT01694095|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAIN-002-10-2010|Evolution and Risk Factors Associated With Geographic Atrophy Progression|Characterization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration|GAIN|Institut de la Macula y la Retina|Yes|Completed|December 2009|August 2013|Actual|August 2013|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|96|||Both|50 Years|N/A|No|Non-Probability Sample|Patients with geographic atrophy|March 2015|March 23, 2015|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01694095||78710|
NCT01676870|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011/1230|Exercise in Prevention of Metabolic Syndrome|Exercise in Prevention of Metabolic Syndrome|EX-MET|Norwegian University of Science and Technology|No|Recruiting|January 2012|March 2017|Anticipated|February 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Anticipated|750|||Both|30 Years|70 Years|No|||November 2015|November 25, 2015|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01676870||80033|
NCT01677780|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NP28366|An Extension Study of RO5045337 in Patients Participating in Previous Cancer Studies|A Multi-center, Open Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-sponsored Phase 1 Cancer Studies.||Hoffmann-La Roche||Active, not recruiting|November 2012|November 2016|Anticipated|November 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment|1||Actual|11|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|August 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01677780||79963|
NCT01684501|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-P-000951|Comparing Active and Passive Ankle-foot Prostheses|Comparing Active and Passive Ankle-foot Prostheses||Spaulding Rehabilitation Hospital|No|Completed|June 2010|June 2011|Actual|June 2011|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|6|||Both|18 Years|64 Years|No|Non-Probability Sample|Adults with history of traumatic unilateral transtibial amputation|September 2012|September 12, 2012|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01684501||79447|
NCT01684748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|arbfat|Angiotensin II Blockade and Inflammation in Obesity|Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity|ARB|Virginia Polytechnic Institute and State University|Yes|Completed|February 2009|August 2011|Actual|August 2011|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|20|||Both|18 Years|75 Years|No|||January 2015|January 8, 2015|September 6, 2012||No||No|May 29, 2014|https://clinicaltrials.gov/show/NCT01684748||79428|
NCT01685047|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR-12-014-ID-HV|A Clinical Evaluation of ST Changes in a Group of Patients Having Ventricular Arrhythmias|A Clinical Evaluation of ST Changes in a Group of Patients Having Ventricular Arrhythmias|inSighT|St. Jude Medical|No|Active, not recruiting|December 2012|December 2015|Anticipated|September 2015|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|470|||Both|18 Years|N/A|No|Non-Probability Sample|Patient is implanted with SJM ICD and has or is at high risk of CAD|October 2015|October 21, 2015|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01685047||79405|
NCT01685294|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R01MH095230-01|Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression|Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression||Brown University|Yes|Completed|December 2011|October 2014|Actual|October 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|181|||Both|18 Years|N/A|No|||January 2016|January 12, 2016|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01685294||79386|
NCT01685307|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRONUTRIAL|Impact of Cooking Process on Meat Protein Digestion and Metabolism|||Institut National de la Recherche Agronomique|Yes|Recruiting|February 2012|||September 2012|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Anticipated|48|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||September 2012|September 11, 2012|March 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01685307||79385|
NCT01694004|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB #121111|Nutrient Sensing in the Duodenum|Duodenal Lipid Sensing and Nutrient Absorption||Vanderbilt University|No|Enrolling by invitation|November 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|20|Samples With DNA|Plasma|Both|18 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|Residents within and near Nashville, TN|March 2016|March 2, 2016|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694004||78717|
NCT01690936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|055-022|Metabolic Effects of Almond in the Longer-term Study|Effects of Chronic Almond Consumption at Meals or as Snacks on Appetite, Intake, Body Weight, Glycemia, Insulinemia and Lipids in Healthy Adults.|MEAL|Purdue University|Yes|Completed|October 2010|June 2012|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|5||Actual|150|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||May 2013|May 28, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690936||78953|
NCT01694550|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OVGU-Kar-011|QT Interval in Patients With Pacemaker Dependency|Corrected QT Interval in Patients With Pacemaker Dependency (QT-TENDENCY-Study)|QT-TENDENCY|University of Magdeburg|Yes|Recruiting|March 2012|April 2015|Anticipated|April 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|180|None Retained|No biospecimen are necessary for the study and this issue is irrelevant.|Both|18 Years|75 Years|No|Non-Probability Sample|The study will enroll 180 patients after an implantation of cardioverter/defibrillator or        pacemaker based on a standard guideline indication. The point of enrolment for all        patients is the time at which the patient signs and dates the ICF during the hospital stay        in the context of implantation.|March 2015|March 7, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694550||78675|
NCT01692561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WFMCMRI 001|MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters|Study Title: Brain Transmitters/Metabolites, Magnetic Resonance Spectroscopy, and Brain Connectivity: Diagnostic Strategies to Study the Effects of Non-Pharmacologic Therapies for Dysautonomia and Chronic Nausea||Wake Forest Baptist Health|Yes|Recruiting|August 2012|June 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||4|Anticipated|18|||Both|9 Years|18 Years|Accepts Healthy Volunteers|Probability Sample|A combination of male and female subjects who are healthy or ahve dysautonomia/|March 2013|March 28, 2013|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01692561||78828|
NCT01692769|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|102632|Trial Of Normal Saline Versus Ringer's Lactate In Paediatric Trauma Patients|Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate||Lawson Health Research Institute|No|Recruiting|May 2013|December 2014|Anticipated|August 2014|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|50|||Both|1 Year|17 Years|No|||July 2013|July 2, 2013|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01692769||78812|
NCT01693068|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EMR 200066-007|Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma|A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma||EMD Serono||Completed|December 2012|January 2016|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|194|||Both|18 Years|N/A|No|||February 2016|February 11, 2016|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693068||78789|
NCT01693081|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VR040/2/003|Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease|A Clinic-Based, Phase IIa, Double-Blind, Placebo- Controlled, Ascending-Dose, Multicentre Study of Safety, Tolerability, Efficacy and Pharmacokinetics of VR040 in Parkinson's Disease|VR040/2/003|South Glasgow University Hospitals NHS Trust|Yes|Completed|March 2007|July 2009|Actual|July 2007|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|47|||Both|30 Years|90 Years|No|||September 2012|September 25, 2012|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693081||78788|
NCT01693315|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AMA0076-201|Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma|A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma||Amakem, NV|No|Completed|September 2012|July 2013|Actual|July 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Actual|82|||Both|30 Years|85 Years|No|||July 2013|July 16, 2013|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693315||78770|
NCT01693328|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP057/11|Patient Satisfaction and Quality of Life Impact - PecFent®|A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)|Qualipec|Archimedes Development Ltd|No|Recruiting|September 2012|||March 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|300|||Both|18 Years|N/A|No|Non-Probability Sample|Cancer patients with breakthrough pain|January 2014|January 14, 2014|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693328||78769|
NCT01693575|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|APX-2012MMC|Use of APX 100 Device for Small-pupil Cataract Surgery and Intraoperative Floppy-iris Syndrome|Use of APX 100 Device for Expansion of Small Pupil in Cataract Surgery and Management of Intraoperative Floppy-iris Syndrome||Meir Medical Center|No|Completed|September 2012|January 2015|Actual|January 2015|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|6|||Both|18 Years|N/A|No|||September 2012|April 15, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01693575||78750|
NCT01693848|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-58|"Cancersensor" Metastasis Resection|Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring, of Cancer Therapy: Impact of Surgical Resection of Metastasis on Urinary Excretion of Modified Nucleosides.||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|45|Samples Without DNA|Urine|Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic colorectal cancer treated at the Department of Medical Oncology        of Paul Brousse Hospital|June 2015|June 24, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01693848||78729|
NCT01694108|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EudraCT2010-021979-85|Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.|Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. A Prospective, Randomised, Clinical Trial.||Rigshospitalet, Denmark|Yes|Completed|September 2012|January 2015|Actual|January 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|2||Actual|4262|||Both|N/A|7 Days|No|||December 2015|December 3, 2015|September 22, 2012||No||No|December 3, 2015|https://clinicaltrials.gov/show/NCT01694108||78709|The allocation was planned to be stratified by sex, study site, and prematurity, however, due to a programming error the allocation was stratified only by prematurity.
NCT01694693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IM101-364|Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study|Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study||Bristol-Myers Squibb|No|Not yet recruiting|January 2018|December 2018|Anticipated|December 2018|Anticipated|N/A|Observational|Time Perspective: Retrospective||1|Anticipated|1000|||Both|18 Years|N/A|No|Non-Probability Sample|Patients included in SFR's ORA Registry|February 2016|February 19, 2016|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694693||78664|
NCT01694706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1220.59|Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir|Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of a Single Oral Dose of 240 mg Faldaprevir in an Open-label, Randomised, Three-way Cross-over Trial in Healthy Subjects||Boehringer Ingelheim||Completed|September 2012|December 2012|Actual|December 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|15|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2015|July 3, 2015|September 24, 2012||||No|July 3, 2015|https://clinicaltrials.gov/show/NCT01694706||78663|
NCT01677169|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TNI-UIC-01|Effect of Noni Juice on Lipid Peroxidation-derived DNA Adducts in Heavy Smokers|Double Blind, Randomized, Placebo-controlled Clinical Trial of the Effect of Noni Juice on Lipid Peroxidation-derived DNA Adducts in Current Heavy Smokers||Tahitian Noni International, Inc.|Yes|Completed|September 2000|August 2006|Actual|November 2005|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|3||Actual|317|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 30, 2012|August 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01677169||80010|
NCT01673932|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCB-IS-01|Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke|Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke||China Spinal Cord Injury Network|Yes|Recruiting|October 2012|July 2017|Anticipated|December 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|12|||Both|35 Years|65 Years|No|||July 2015|July 28, 2015|August 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01673932||80259|
NCT01685060|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLDK378A2201|LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib|A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib||Novartis|Yes|Active, not recruiting|November 2012|January 2016|Anticipated|January 2016|Anticipated|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|141|||Both|18 Years|N/A|No|||January 2016|January 24, 2016|September 4, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01685060||79404|
NCT01684761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol Number 2012-00|Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis|A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis|Abili-T|Opexa Therapeutics, Inc.|Yes|Active, not recruiting|August 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|180|||Both|18 Years|60 Years|No|||July 2015|July 7, 2015|September 11, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01684761||79427|
NCT01685580|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RB 11.095 préOVNI|Non-Invasive Ventilation Preoperative Lung Resection Surgery|Evaluation of Non-Invasive Ventilation Preoperative Lung Resection Surgery|préOVNI|University Hospital, Brest|Yes|Recruiting|October 2012|February 2017|Anticipated|February 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01685580||79364|
NCT01693718|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12141B|A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer|A Multicenter Phase II Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer||University of Chicago|Yes|Completed|March 2003|September 2004|Actual|September 2003|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|||Actual|44|||Both|59 Years|N/A|No|||September 2013|September 4, 2013|August 20, 2010|No|Yes||No||https://clinicaltrials.gov/show/NCT01693718||78739|
NCT01694849|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GFT505-212-7|Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)|A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).||Genfit|Yes|Completed|September 2012|December 2015|Actual|February 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|270|||Both|18 Years|75 Years|No|||January 2016|January 13, 2016|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694849||78652|
NCT01691976|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2017|Mild Cognitive Impairment in Men Following Androgen Deprivation|Mild Cognitive Impairment in Men Following Androgen Deprivation Therapy for Prostate Cancer: a Longitudinal fMRI and qEEG Pilot Study.||Imperial College London|No|Not yet recruiting|October 2012|March 2014|Anticipated|September 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label|3||Anticipated|10|||Male|50 Years|90 Years|Accepts Healthy Volunteers|||October 2012|October 16, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01691976||78873|
NCT01691170|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|USP01|Comparison of Two Protocols for Patellofemoral Pain Syndrome|Quadriceps Femoris Strengthening Versus Hamstring Stretching for Patellofemoral Pain Syndrome: A Randomized Clinical Trial.|PFPS|University of Sao Paulo||Completed|March 2008|September 2011|Actual|February 2011|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|20|||Both|18 Years|40 Years|No|||September 2012|September 21, 2012|September 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01691170||78935|
NCT01691183|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0705|Reliability of Hertel Exophthalmometer Measurements|Reliability of Hertel Exophthalmometer Measurements||University of North Carolina, Chapel Hill|No|Completed|May 2012|June 2012|Actual|June 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|85|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|150 consecutive adult patients of both sexes and all ages will be recruited by David        Chesnutt MD from the UNC Eye Clinic. Patients taken from a pool of patients already        scheduled for appointments.|September 2012|September 21, 2012|June 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01691183||78934|
NCT01692574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|813829|Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)|Treatment of Obesity in Depressed Individuals: A Randomized Controlled Trial|TODI|University of Pennsylvania|Yes|Recruiting|August 2012|||March 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|90|||Both|18 Years|70 Years|No|||September 2012|March 20, 2014|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692574||78827|
NCT01692587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201011804|Does Protein Restriction Inhibit Prostrate Cancer Growth|Does Protein Restriction Inhibit Prostrate Cancer Growth||Washington University School of Medicine|Yes|Completed|January 2011|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|65|||Male|N/A|N/A|No|||June 2015|June 1, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01692587||78826|
NCT01692782|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SEP360-201|Adult Attention Deficit Hyperactivity Disorder|A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)||Sunovion|Yes|Completed|December 2012|December 2013|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|341|||Both|18 Years|55 Years|No|||January 2015|January 9, 2015|September 18, 2012|Yes|Yes||No|November 17, 2014|https://clinicaltrials.gov/show/NCT01692782||78811|
NCT01693029|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HX575-307|Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa|Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease|ACCESS|Sandoz|Yes|Completed|September 2012|March 2015|Actual|May 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|437|||Both|18 Years|N/A|No|||May 2015|May 20, 2015|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693029||78792|
NCT01693094|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012P002281|A Randomized Trial Measuring the Effect of Decision Aids on Patients' Satisfaction, Conflict of Decision-making and Clinical Outcome|||Massachusetts General Hospital||Enrolling by invitation|September 2012|||December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|126|||Both|18 Years|N/A|No|||August 2015|August 4, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01693094||78787|
NCT01693341|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CT-tsaiac1943|A Caregiver-mediated Intervention Improves the Functional Ability of Home-living Chronic Stroke Patients|Caregiver-mediated Intervention in Home-living Chronic Stroke Patients||Asia University|Yes|Completed|October 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|50|||Both|18 Years|85 Years|No|||March 2013|March 28, 2013|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693341||78768|
NCT01693562|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CD-ON-MEDI4736-1108|A Phase 1/2 Study to Evaluate MEDI4736|A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors||MedImmune LLC|No|Recruiting|August 2012|July 2018|Anticipated|July 2017|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|1038|||Both|18 Years|99 Years|No|||March 2016|March 2, 2016|September 14, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01693562||78751|
NCT01693861|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C11-59|"Cancersensor" Chemotherapy|Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : Effect of Chemotherapy on Cancerous Proliferation Based on the Dynamic Excretion of Urinary Nucleosides.||Institut National de la Santé Et de la Recherche Médicale, France|No|Recruiting|October 2012|August 2015|Anticipated|August 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|30|Samples With DNA|Urine and exfoliated oral mucosa cells|Both|18 Years|N/A|No|Non-Probability Sample|Patients with metastatic colorectal cancer treated at the Department of Medical Oncology        of Paul Brousse Hospital|April 2015|April 24, 2015|September 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01693861||78728|
NCT01693874|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AT007064|Mindfulness-based Stress Reduction and Cognitive Function in Stress and Aging|Mindfulness-based Stress Reduction and Cognitive Function in Stress and Aging||Washington University School of Medicine|Yes|Completed|October 2011|June 2014|Actual|June 2014|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|103|||Both|65 Years|N/A|No|||July 2014|July 21, 2014|March 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01693874||78727|
NCT01694394|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ASSERT-II|Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor|Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patient With Cardiovascular Risk Factors (ASSERT-II)|ASSERT-II|Population Health Research Institute|Yes|Active, not recruiting|December 2012|October 2016|Anticipated|July 2016|Anticipated|Phase 4|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|250|Samples Without DNA|Blood will be collected for NT-ProBNP and hs-Troponin-T|Both|65 Years|N/A|No|Non-Probability Sample|Patients at increased risk of atrial fibrillation and cardiovascular events but without        prior history of atrial fibrillation or implanted pacemaker or defibrillator|September 2015|September 21, 2015|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694394||78687|
NCT01694979|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|L12-020|Pelvic Floor Activity and Breathing in Women|Effect Of Variations In Forced Expiration Effort On Pelvic Floor Activation In Asymptomatic Women||Kitani, Lenore, PT|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Actual|18|||Female|18 Years|35 Years|Accepts Healthy Volunteers|Non-Probability Sample|Convenience sample from a University student, faculty and staff population.|September 2012|September 26, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694979||78642|
NCT01691066|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1110009256|Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder|Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder||Yale University||Active, not recruiting|September 2012|September 2015|Anticipated|September 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|12 Months|15 Months|No|||July 2015|July 1, 2015|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01691066||78943|
NCT01677442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NTEA001|Nonintubated Thoracic Epidural Anesthesia Versus Double-lumen Intubated Anesthesia in Video-assisted Thoracic Surgery|Nonintubated Thoracic Epidural Anesthesia Versus Double-lumen Intubated Anesthesia in Video-assisted Thoracic Surgery||Guangzhou Institute of Respiratory Disease|Yes|Recruiting|July 2011|July 2015|Anticipated|July 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|500|||Both|18 Years|65 Years|No|||April 2012|August 31, 2012|May 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01677442||79989|
NCT01668953|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IMPROVE-001|Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)|Impact of Platelet Rich Plasma Over Alternative Therapies in Patients With Lateral Epicondylitis|IMPROVE|McMaster University|Yes|Recruiting|August 2012|January 2017|Anticipated|January 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|4||Anticipated|100|||Both|18 Years|N/A|No|||March 2016|March 15, 2016|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668953||80640|
NCT01693484|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ICGVA-OS CALCIS 2012|Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures|Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures Requiring Extensile Lateral Incision||Louisiana State University Health Sciences Center Shreveport|No|Terminated|April 2013|March 2015|Actual|March 2015|Actual|Phase 2/Phase 3|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|13|||Both|18 Years|65 Years|No|||March 2016|March 2, 2016|September 20, 2012||No|Resource availability|No||https://clinicaltrials.gov/show/NCT01693484||78757|
NCT01685320|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PressureCara|Force and Pressure Distribution Using Macintosh and GlideScope Laryngoscopes in Normal Airway: an in Vivo Study|Force and Pressure Distribution Using Macintosh and GlideScope Laryngoscopes in Normal Airway: an in Vivo Study||Campus Bio-Medico University|Yes|Completed|January 2011|December 2011|Actual|October 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|30|||Both|18 Years|65 Years|No|||March 2013|March 13, 2013|September 7, 2012||No||No|February 8, 2013|https://clinicaltrials.gov/show/NCT01685320||79384|Patients studied were classified with “normal airways”, while difficult intubations were not considered.We excluded patients with CL grade 2 or greater.We employed only the Macintosh size 3 blade to avoid additional variables.
NCT01694251|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KUH1160027|Mitral Valve Area Using 3-dimensional Transesophageal Echocardiography|Determination of Mitral Valve Area After Mitral Valve Repair Surgery for Mitral Stenosis Using 3-dimensional Transesophageal Echocardiography|MVA|Konkuk University Medical Center|Yes|Completed|December 2011|March 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Actual|86|||Both|18 Years|N/A|No|Probability Sample|mitral valve repair mitral stenosis|September 2012|September 23, 2012|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694251||78698|
NCT01694264|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|H-1112-073-390|Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα|A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFα Treatment||Seoul National University Hospital|No|Recruiting|September 2012|August 2015|Anticipated|August 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|128|||Both|16 Years|85 Years|No|||April 2013|April 18, 2013|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694264||78697|
NCT01694563|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CP2011-1|ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal AF|AtriCure Synergy Ablation Lesions for Non-Paroxysmal Forms of Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery|ABLATE PAS|AtriCure, Inc.|No|Active, not recruiting|September 2012|November 2018|Anticipated|November 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|365|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with a history of non-paroxysmal forms of atrial fibrillation (AF), persistent or        longstanding persistent, who are undergoing an elective open cardiac surgical procedure.|December 2015|December 29, 2015|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694563||78674|
NCT01694576|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NPC-N23-RCT|NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation|Adjuvant Chemotherapy or Not for NPC Patients Staged N2-3M0 After Concurrent Chemotherapy :a Phase Ⅱ Study||Jiangsu Cancer Institute & Hospital|Yes|Terminated|September 2012|October 2015|Anticipated|September 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|10|||Both|18 Years|65 Years|No|||June 2015|June 12, 2015|September 17, 2012|Yes|Yes|slow patient enrollment|No||https://clinicaltrials.gov/show/NCT01694576||78673|
NCT01691469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|540-10|Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.||Dr. Reddy's Laboratories Limited|No|Completed|January 2011|February 2011|Actual|January 2011|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691469||78912|
NCT01691755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BC28034|A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy|A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NAÏVE TO ANTI-HYPERGLYCEMIC THERAPY||Hoffmann-La Roche||Completed|November 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|196|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691755||78890|
NCT01691989|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WC28325|A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy|A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PHASE III STUDY TO ASSESS THE EFFICACY,SAFETY AND TOLERABILITY OF ALEGLITAZAR ADDED TO A SU OR ADDED TO A SU IN COMBINATION WITH MET IN PATIENTS WITH T2D INADEQUATELY CONTROLLED WITH SU MONOTHERAPY OR WITH SU + METFORMIN COMBINATION THERAPY||Hoffmann-La Roche||Completed|December 2012|September 2013|Actual|September 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|197|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691989||78872|
NCT01692223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-167|A Safety Study Assessing the Effects of Receiving Genome Sequencing Results|Personal Genomics: A Safety Study Assessing the Effects of Receiving Genome Sequencing Results||Memorial Sloan Kettering Cancer Center||Active, not recruiting|September 2012|August 2016|Anticipated|August 2016|Anticipated|N/A|Observational|Observational Model: Family-Based, Time Perspective: Prospective||3|Actual|8|Samples With DNA|Participants will be recruited from cohorts of patients whose DNA samples are being examined      with WGS/WES as part of efforts to identify novel cancer susceptibility alleles.      Participants will be derived from the following protocols: 09-068 and 96-051.|Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Participants will be recruited from cohorts of patients whose DNA samples are being        examined with WGS/WES as part of efforts to identify novel cancer susceptibility alleles.        Participants will be derived from the following protocols: 09-068 and 96-051. We will also        recruit an additional group of participants (up to 100) from the general public (with or        without a cancer history) who have not had their genomes or exomes sequenced to        participate in focus groups to inform us about their perceptions of the hypothetical        utility of learning of incidental results from their genome or exomes.|August 2015|August 6, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692223||78854|
NCT01692522|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|093/12|Comparison of the Laryngeal Mask Ambu Aura-i Versus AirQ in Children|Comparison of the Pediatric Intubation on Laryngeal Masks Ambu Aira-i and AirQ for Simulated Blind Intubation in Anesthetized Children||University Hospital Inselspital, Berne|No|Completed|October 2012|August 2014|Actual|August 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)|2||Anticipated|80|||Both|N/A|16 Years|Accepts Healthy Volunteers|||August 2014|August 14, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692522||78831|
NCT01692600|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0095-CE|Optical Coherence Tomography for Monitoring Late Oral Radiation Toxicity After Radiotherapy of Head and Neck Cancer Patients|Optical Coherence Tomography for Monitoring Late Oral Radiation Toxicity After Radiotherapy of Head and Neck Cancer Patients||University Health Network, Toronto|No|Completed|June 2012|June 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|20|||Both|18 Years|N/A|Accepts Healthy Volunteers|Probability Sample|The study population are selected from the patients who have received radiation as a        treatment for head and neck cancer and have developed late radiation toxicity in their        oral tissue. This population is selected among the patients who can open their mouth more        than 2 centimeters (so that the imaging probe can be inserted into their oral cavity)|May 2015|May 7, 2015|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01692600||78825|
NCT01692795|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CALIBER_EH3|Cardiovascular Medication Use Before First Myocardial Infarction|Cardiovascular Medication Prescriptions Before First Myocardial Infarction in Patients With and Without Previously Diagnosed Atherosclerotic Disease: an Analysis of Linked Prospectively Collected Electronic Healthcare Records||London School of Hygiene and Tropical Medicine|Yes|Completed|September 2009|September 2013|Actual|September 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|17000|||Both|18 Years|N/A|No|Non-Probability Sample|The study population is comprised of patients with a first myocardial infarction who are        registered at those General Practice Research Database (GPRD) practices that agreed to the        linkage with the MINAP database, and whose practices are "up to standard" according to        GPRD criteria. Practices taking part in the GPRD are chosen to be representative of all        United Kingdom (UK) practices, and 98% of people in the UK are registered with a General        Practitioner (GP). Therefore the GPRD should be a representative sample of the UK        population.|October 2015|October 1, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692795||78810|
NCT01693354|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MID-INT01|Mid-HDF Randomized Controlled Study on Outcome|Mid-dilution Hemodiafiltration International Randomized Prospective Study on Incident Patients Focused on Outcome|MILESTONE|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Yes|Recruiting|September 2012|September 2018|Anticipated|September 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|800|||Both|18 Years|N/A|No|||February 2016|February 19, 2016|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01693354||78767|
NCT01693588|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|341-2012|Study of a Multimodality Pain Management Protocol on Postoperative Neurosurgical Pain|The Effect of a Multimodality Pain Management Protocol on Postoperative Neurosurgical Pain||University of Florida|No|Completed|October 2012|August 2013|Actual|August 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|94|||Both|18 Years|N/A|No|||January 2014|January 13, 2014|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01693588||78749|
NCT01694407|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A11-117|Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine|A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine||CONRAD|No|Completed|February 2013|December 2013|Actual|December 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention|4||Actual|48|||Female|18 Years|50 Years|Accepts Healthy Volunteers|||March 2015|March 31, 2015|July 17, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01694407||78686|
NCT01694719|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2930|Cognitive Control Training as an Adjunct to Behavioral Activation Therapy in the Treatment of Depression|||Boston University|No|Recruiting|September 2012|October 2013|Anticipated|October 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|26|||Both|18 Years|65 Years|No|||September 2012|September 26, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694719||78662|
NCT01694992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11.0121|Very Early Rehabilitation in Acute Ischemic Stroke|Randomized Clinical Trial of Very Early Rehabilitation Compared With Conventional Rehabilitation in Acute Ischemic Stroke in the Vascular Unit of the Hospital de Clínicas de Porto Alegre - HCPA|VERIS-Brazil|Hospital de Clinicas de Porto Alegre|Yes|Recruiting|March 2012|August 2015|Anticipated|December 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|184|||Both|18 Years|N/A|No|||September 2012|September 25, 2012|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694992||78641|
NCT01695005|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14547|A Study of LY3039478 in Participants With Advanced Cancer|A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer||Eli Lilly and Company|No|Recruiting|October 2012|August 2017|Anticipated|August 2017|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|182|||Both|18 Years|N/A|No|||December 2015|December 18, 2015|September 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01695005||78640|
NCT01673646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSOM230C1202|Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism|A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism||Novartis|No|Active, not recruiting|October 2012|May 2016|Anticipated|May 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|33|||Both|18 Years|N/A|No|||October 2015|October 12, 2015|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01673646||80281|
NCT01673659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRG-NY-12-008|A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 Mcg/Actuation Compared With Nasonex® Nasal Spray 50 Mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)|||Perrigo Company|No|Completed|August 2012|October 2012|Actual|October 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|1220|||Both|12 Years|65 Years|No|||September 2013|September 23, 2013|August 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01673659||80280|
NCT01667146|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ANZIC-RC/AD002 Version 8|A Multi-centre Trial of an Open Lung Strategy Including Permissive Hypercapnia, Alveolar Recruitment and Low Airway Pressure in Patients With Acute Respiratory Distress Syndrome|A Multi-centre Randomised Controlled Trial of an Open Lung Strategy Including Permissive Hypercapnia, Alveolar Recruitment and Low Airway Pressure in Patients With Acute Respiratory Distress Syndrome.|PHARLAP|Australian and New Zealand Intensive Care Research Centre|No|Recruiting|October 2012|January 2019|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|340|||Both|16 Years|N/A|No|||December 2015|December 7, 2015|August 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01667146||80779|
NCT01693731|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5K23DEO21779|Oral Health in Breast Cancer Survivors on Aromatase Inhibitors|Oral Health in Breast Cancer Survivors on Aromatase Inhibitors||University of Michigan|Yes|Completed|April 2012|March 2015|Actual|March 2015|Actual|N/A|Observational|Time Perspective: Cross-Sectional||2|Actual|300|Samples With DNA|Each patient will have 5ml of blood collected at the visit. Saliva, and urine will also be      collected at the study visit.|Female|N/A|N/A|Accepts Healthy Volunteers|Non-Probability Sample|This study will have a sample of 300 postmenopausal women; 150 healthy women and 150 with        early breast cancer using Aromatase Inhibitors|May 2015|May 18, 2015|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01693731||78738|
NCT01693744|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LNiyaz|Pseudoexfoliation and Chronic Kidney Disease|The Relationship Between Pseudoexfoliation and Chronic Kidney Disease||Corum State Hospital|Yes|Completed|October 2011|April 2012|Actual|||N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||3|Actual|358|||Both|40 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|Patients from nephrology clinic|September 2012|September 24, 2012|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01693744||78737|
NCT01694862|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Integra Initiative|Benefits and Costs of Integrating Sexual-Reproductive Health and HIV Services in Kenya and Swaziland|Integra Initiative to Assess the Benefits and Costs of Integrating Sexual and Reproductive Health and HIV Services in Kenya and Swaziland|Integra|London School of Hygiene and Tropical Medicine|No|Active, not recruiting|January 2009|June 2013|Anticipated|December 2012|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|4763|||Female|15 Years|49 Years|No|||September 2012|September 25, 2012|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01694862||78651|
NCT01690949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|601-0005|Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers|Single-blind Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers||Pulmatrix Inc.|No|Completed|August 2012|April 2013|Actual|April 2013|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||July 2013|July 18, 2013|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01690949||78952|
NCT01691196|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Baxter/UIC Ref#2012-04881|Inflammation in Peritoneal Dialysis Patients: Effect of Obesity|Inflammation in Peritoneal Dialysis Patients: Effect of Obesity||University of Illinois at Chicago|Yes|Recruiting|September 2012|September 2017|Anticipated|September 2017|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||1|Anticipated|50|Samples Without DNA|Blood Collection: Venous blood after overnight fast will include: (1) heparinized tube      (green top) for whole blood (WB) cultures; (2) EDTA tube (lavender top) for CBC and      measurement of cytokines and adipokines, and (3) serum-separator (red top) for determination      of lipid panel, glucose, insulin, and hemoglobin A1c. Glucose and insulin will be used to      calculate HOMA-IR (index of insulin resistance).      Collection of peritoneal dialysis effluent (PDE): To minimize variability, 2.5% glucose      peritoneal dialysis (PD) solution and 4h dwell time will be used for all patients on test      day. Immediately after collection, PDE will be chilled before further processing.|Both|18 Years|N/A|No|Non-Probability Sample|Patients undergoing peritoneal dialysis|May 2015|May 27, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01691196||78933|
NCT01691768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPRISA008|Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services|Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa||Centre for the AIDS Programme of Research in South Africa|Yes|Completed|October 2012|December 2015|Actual|April 2015|Actual|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|382|||Female|18 Years|N/A|Accepts Healthy Volunteers|||January 2016|January 27, 2016|July 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01691768||78889|
NCT01692002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRO2020 - Imperial College Lon|Oral Propionate to Treat and Prevent Diabetes|Development of Orally Administered Sodium Propionate to Treat and Prevent Diabetes||Imperial College London|Yes|Not yet recruiting|January 2013|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|104|||Both|18 Years|70 Years|Accepts Healthy Volunteers|||September 2012|September 20, 2012|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01692002||78871|
NCT01692236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120200|Brain Imaging for HIV-Associated Thinking and Mood Disorders|Neurovascular Magnetic Resonance Imaging in the Assessment of HIV-Associated Neurocognitive Disorders||National Institutes of Health Clinical Center (CC)||Recruiting|September 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|80|||Both|25 Years|61 Years|Accepts Healthy Volunteers|||June 2015|June 10, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692236||78853|
NCT01692613|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|A139/12|Endomicroscopy, IBS and Food Intolerance|Confocal Endomicrosopy for the Detection of Food Intolerance in Patients With Irritable Bowel Syndrome||University of Schleswig-Holstein|Yes|Completed|September 2012|September 2014|Actual|September 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||1|Actual|60|Samples Without DNA|-  duodenal biopsies        -  duodenal fluid|Both|18 Years|80 Years|Accepts Healthy Volunteers|Probability Sample|-  N=50 patients with unexplained bloating and diarrhoea with suspicion of food             intolerance and negative testing with routine methods          -  N=10 patients with Lactose intolerance          -  N=10 patients with Fructose intolerance          -  N=10 volunteers with Barrett's esophagus who need evaluation for possible dysplasia             in the Barrett's mucosa with confocal endomicrosopy but no symptoms of bloating and             abdominal pain (n=10) to serve as healthy controls for allergy testing|June 2015|June 2, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692613||78824|
NCT01692808|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|JP2012042|Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease|Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease.||St. Justine's Hospital|Yes|Completed|October 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|5||Actual|20|||Both|10 Years|18 Years|No|||November 2015|November 2, 2015|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01692808||78809|
NCT01692821|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|OPHT-180312|Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation|Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation||Medical University of Vienna|Yes|Completed|June 2012|January 2013|Actual|December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|3||Actual|30|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||January 2013|January 29, 2013|June 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01692821||78808|
NCT01693601|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GCO 12-1225|Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)|Panobinostat and Ruxolitinib In MyElofibrosis (PRIME STUDY) - Phase I/II Study of Combination Oral JAK2 Tyrosine Kinase Inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) Therapy in Patients With Myelofibrosis|PRIME|Icahn School of Medicine at Mount Sinai|Yes|Recruiting|January 2013|August 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|58|||Both|18 Years|N/A|No|||January 2016|January 13, 2016|September 14, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693601||78748|
NCT01694121|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH096657|Evaluating a Structural and Behavioral HIV Risk Reduction Program for Black Men|Evaluating a Structural and Behavioral HIV Risk Reduction Program for Black Men|MEN Count|University of California, San Diego|Yes|Recruiting|March 2013|May 2017|Anticipated|May 2017|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|504|||Male|18 Years|40 Years|Accepts Healthy Volunteers|||March 2016|March 13, 2016|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01694121||78708|
NCT01694433|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1 RO1 AR053542-01A2|"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"|Innate Immunity in Acne Vulgaris||University of California, Los Angeles|No|Active, not recruiting|February 2013|December 2014|Anticipated|January 2014|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|54|||Both|18 Years|N/A|Accepts Healthy Volunteers|||February 2013|October 18, 2013|September 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01694433||78684|
NCT01694732|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SAVE RB11-135|Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease|Efficacy of Varenicline Associated With Intensive Counselling Versus Placebo of Varenicline Associated With Intensive Counselling on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD). A Multicenter Randomized Double-blind Trial|SAVE|University Hospital, Brest|Yes|Completed|August 2012|November 2015|Actual|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|83|||Both|18 Years|N/A|No|||February 2016|February 10, 2016|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694732||78661|
NCT01695018|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PKUSSOM20120711|Early Diagnosis of Oral Cancer by Detecting p16 Methylation|A Multicentral Prospective Study on Prediction of Malignant Progression of Oral Epithelial Dysplasia With p16 Methylation||Peking University|Yes|Completed|February 2009|||March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|180|Samples With DNA|Oral mucosal biopsy tissues were formalin fixed , paraffin embedded , sliced and      hematoxylin-eosin (HE) staining.|Both|25 Years|78 Years|No|Probability Sample|180 patients with mild or moderate oral epithelial dysplasia were selected. 81 of them        were from Peking University of Stomatology and 68 were from Capital Medical University        School of Stomatology and other 31 were from Fourth Military Medical University School of        Stomatology.All of the patients with OED had been diagnosed pathologically by at least two        senior pathologists using the criteria from '2005 WHO Classification System' and The oral        tissue pathology diagnostic criteria (oral histopathology Edition Sixth).All cases        involved primary lesions without any LASER, radiation therapy or chemotherapy.|September 2014|September 24, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01695018||78639|
NCT01668693|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0600-E-905-JH|ERA Test in Patients With Recurrent Implantation Failure|The Endometrial Receptivity Array (ERA) as Diagnosis and Personalized Embryo Transfer (pET) as Treatment in Patients With Receptive Implantation Failure (RIF).|ERA|Igenomix|No|Recruiting|January 2010|December 2016|Anticipated|April 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|150|||Female|20 Years|38 Years|Accepts Healthy Volunteers|||October 2015|October 16, 2015|August 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01668693||80660|
NCT01668706|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MD098SCW01|Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts|Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts||National Health Research Institutes, Taiwan|No|Recruiting|March 2009|December 2013|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||4|Anticipated|600|Samples With DNA|plasma, DNA and urine|Both|20 Years|65 Years|Accepts Healthy Volunteers|Non-Probability Sample|1. Normal control group:             Healthy adults will be recruited from community.          2. Methadone Maintenance treatment group Study subjects will be enrolled only in the             methadone clinic.          3. Buprenorphine/Naloxone treatment group Subjects will be enrolled only in the clinic.          4. Drug-free ex-addict group Subjects will be recruited from the therapeutic communities             and halfway house of Operation Dawn.|August 2012|August 16, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668706||80659|
NCT01694017|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|10465|Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy|Economic Evaluation of Treatment of HIV With Zidovudine/Stavudine and Tenofovir Regimen: A Cost Effectiveness Study||Tufts University|Yes|Completed|November 2012|August 2014|Actual|August 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|68|||Both|18 Years|N/A|No|||November 2014|November 20, 2014|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01694017||78716|
NCT01694030|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|University of Southampton: LO6|Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study|Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study||University of Southampton|No|Not yet recruiting|November 2012|December 2014|Anticipated|December 2014|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|2||Anticipated|100|||Both|18 Years|N/A|No|||September 2012|September 24, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01694030||78715|
NCT01694277|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AB11002|A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib|A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment||AB Science|Yes|Recruiting|April 2012|December 2015|Anticipated|January 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|208|||Both|18 Years|N/A|No|||August 2013|August 13, 2013|August 22, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694277||78696|
NCT01694290|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|24308|Chemical Ice Packs for Cooling Hyperthermic Patients|Randomized Controlled Trial Assessing Effectiveness of Chemical Cold Packs Used on Various Skin Surfaces for Cooling Hyperthermic Patients||Stanford University|Yes|Recruiting|August 2012|||July 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|10|||Male|18 Years|N/A|Accepts Healthy Volunteers|||September 2012|September 24, 2012|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694290||78695|
NCT01694589|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|071108|A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer|A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer||Rutgers, The State University of New Jersey|No|Withdrawn|November 2012|July 2014|Actual|June 2014|Actual|Phase 0|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||December 2014|December 10, 2014|September 24, 2012|Yes|Yes|Lack of accrual|No||https://clinicaltrials.gov/show/NCT01694589||78672|
NCT01691209|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|16200|Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis|An Investigator-blinded, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a Topical Medical Device in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin|Phoenix|Bayer|No|Withdrawn|October 2013|June 2014|Anticipated|April 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|0|||Both|18 Years|60 Years|No|||August 2013|August 9, 2013|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01691209||78932|
NCT01691482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114956|A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium|A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects With Chronic Obstructive Pulmonary Disease||GlaxoSmithKline||Completed|July 2012|February 2013|Actual|February 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|56|||Both|40 Years|N/A|No|||March 2014|April 17, 2014|September 20, 2012|Yes|Yes||No|June 12, 2013|https://clinicaltrials.gov/show/NCT01691482||78911|
NCT01691781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012p0001961|The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study|The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study|RAAS-PARC|Brigham and Women's Hospital|Yes|Recruiting|October 2012|||December 2016|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|80 Years|Accepts Healthy Volunteers|||February 2016|February 1, 2016|September 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01691781||78888|
NCT01692015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLS21|Diet and Hereditary Haemorrhagic Telangiectasia|A Questionnaire Study on Diet and Hereditary Haemorrhagic Telangiectasia||Imperial College London|No|Active, not recruiting|April 2011|September 2016|Anticipated|September 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Anticipated|150|||Both|18 Years|N/A|No|||September 2012|May 28, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01692015||78870|
NCT01692249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AFRETH 2|Efficacy and Safety of Spa Treatment in Chronic Shoulder Pain Due to Rotator Cuff Tendinopathy|Spa Therapy in the Treatment of Chronic Shoulder Pain Due to Rotator Cuff Tendinopathy: ROTATHERM, a Large Randomized Multicentre Trial|ROTATHERM|Association Francaise pour la Recherche Thermale|Yes|Completed|March 2009|May 2011|Actual|April 2010|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|186|||Both|20 Years|80 Years|No|||September 2012|September 24, 2012|September 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01692249||78852|
NCT01692626|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|WVU21011|1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX|1% Topical Pimecrolimus Cream for the Prevention of Rash Associated With the Use of the EGFR Antagonist, Cetuximab||West Virginia University|Yes|Recruiting|February 2012|July 2015|Anticipated|June 2015|Anticipated|Phase 2|Interventional|Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care|1||Anticipated|20|||Both|18 Years|N/A|No|||January 2014|January 6, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01692626||78823|
NCT01692834|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99752|A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers|A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers ; An Open-label, Subject-blind, Laboratory-blind, Single-dose (5 mg/kg Infusion), Randomised, Two-period Crossover Tolerability Study Carried Out in Healthy Male and Female Subjects||NeuroVive Pharmaceutical AB|No|Completed|June 2009|January 2010|Actual|January 2010|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)|2||Actual|65|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||July 2014|July 31, 2014|September 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01692834||78807|
NCT01694134|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8833|Assessment of the Efficacy of an Intradiscal Injection of Corticoids in Modic I Discopathies.|Assessment of the Efficacy of an Intradiscal Injection of Corticoids in Modic I Discopathies.|MODISC|University Hospital, Montpellier|No|Recruiting|July 2012|September 2017|Anticipated|February 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|80 Years|No|||December 2014|December 3, 2014|September 22, 2012||No||No||https://clinicaltrials.gov/show/NCT01694134||78707|
NCT01694420|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035447|Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet|Treatment of Acute HIV Infection With the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate, A Pilot Study of Response to Therapy and HIV Pathogenesis|PHI04|Duke University|No|Active, not recruiting|September 2012|February 2017|Anticipated|October 2015|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|75 Years|No|||January 2016|January 11, 2016|September 21, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694420||78685|
NCT01694446|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Glucose 090428B|Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose|Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose|glucose|University Health Network, Toronto|No|Completed|September 2011|January 2013|Actual|January 2013|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|14|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||March 2015|March 6, 2015|September 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01694446||78683|
NCT01694745|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EUROPAIN Survey|EUROpean Pain Audit In Neonates|European Survey of Sedation and Analgesia Practices for Newborns Admitted to Intensive Care Units|EUROPAINsurvey|Hôpital Armand Trousseau|No|Completed|October 2012|June 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6489|||Both|N/A|45 Weeks|No|Non-Probability Sample|-  All neonates up to a corrected age of 44 weeks post conception. That means, for             example, that a baby of 40 weeks gestational age can be included up to 28 days (4             weeks) of post natal age or that a baby of 32 weeks gestational age can be included             up to 12 weeks of post natal age.          -  The aim of including all neonates is to both ensure a generalization of the findings             to all ventilated and non ventilated neonates admitted to intensive care units and to             obtain a clear description of practices across Europe.|February 2013|January 22, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694745||78660|
NCT01694758|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NIS-CME-XXX-2012/1|OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA|OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)|OPTIMISE|AstraZeneca||Completed|November 2012|March 2014|Actual|March 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|733|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with diabetes type 2|August 2014|August 13, 2014|September 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01694758||78659|
NCT01691352|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Stoma Closure_Wound Infection|Wick vs. No Wick: Does Method of Closure Affect Rate of Wound Infection?|Prospective, Randomized Controlled Trial of Wound Management After Ostomy Closure||Children's Healthcare of Atlanta|No|Withdrawn|January 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment|2||Actual|0|||Both|N/A|18 Years|No|||December 2014|December 16, 2014|September 20, 2012||No|lack of sufficient population for recruitment|No||https://clinicaltrials.gov/show/NCT01691352||78921|
NCT01668992|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|21050|Impact Evaluation of a Family-based Intervention With Burmese Migrant and Displaced Children and Families in Tak Province, Thailand|Impact Evaluation of a Family-based Intervention With Burmese Migrant and Displaced Children and Families in Tak Province, Thailand||International Rescue Committee|No|Active, not recruiting|September 2011|August 2013|Anticipated|May 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|1000|||Both|8 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 16, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668992||80637|
NCT01666925|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC046|Efficacy of Malaria Vaccines in Kenyan Adults|Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection.||University of Oxford|Yes|Completed|March 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|120|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666925||80796|
NCT01666938|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CSE-1410/2011|Telephone Counselling to Promote Physical Activity in Diabetes Mellitus People|The Use of a Telephone Counselling as a Strategy to Promote Physical Activity in Diabetes Mellitus People||University of Sao Paulo||Completed|April 2012|November 2012|Actual|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|26|||Both|18 Years|80 Years|No|||March 2013|March 23, 2013|August 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01666938||80795|
NCT01694875|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HPVGPS-US12-001|Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System|Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens||Gen-Probe, Incorporated|No|Completed|October 2012|November 2012|Actual|November 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Anticipated|2200|||Female|21 Years|N/A|Accepts Healthy Volunteers|Probability Sample|Samples from subjects who attended colposcopy from the Adjunct Study and subjects who had        positive APTIMA HPV Assay results in the APTIMA HPV Assay TIGRIS System Study or the        APTIMA HPV Assay PANTHER System Study.|November 2012|November 12, 2012|September 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01694875||78650|
NCT01690962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCRM DN-1|A Nutritional Intervention for Diabetic Neuropathy|A Nutritional Intervention for Diabetic Neuropathy||Physicians Committee for Responsible Medicine|Yes|Completed|November 2012|February 2014|Actual|February 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|15|||Both|18 Years|65 Years|No|||September 2014|September 2, 2014|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01690962||78951|
NCT01691222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|90/12|Tracheostomy in ICU With a Double Lumen Endotracheal Tube|Percutaneous Tracheostomy in Intensive Care Unit With a Dedicated Double Lumen Endotracheal Tube||University of Genova|Yes|Recruiting|July 2012|June 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|30|||Both|18 Years|82 Years|No|||July 2013|July 2, 2013|August 30, 2012||No||No||https://clinicaltrials.gov/show/NCT01691222||78931|
NCT01691495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115280|ARIXTRA® Adherence in SVT Patients.|ARIXTRA® Physician Adherence to the Prescribing Information in Isolated Superficial Vein Thrombosis (SVT) Patients.||GlaxoSmithKline|No|Completed|October 2012|August 2014|Actual|August 2014|Actual|N/A|Observational|Time Perspective: Retrospective||1|Actual|1|||Both|18 Years|N/A|No|Non-Probability Sample|Up to 12 clinical sites representative of geographical regions of several EU countries,        targeting physician adherence to prescribing in approximately 840 patients with SVT.|March 2015|March 26, 2015|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01691495||78910|
NCT01691508|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115575|Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma|MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects With Severe Refractory Asthma||GlaxoSmithKline|Yes|Completed|October 2012|December 2013|Actual|December 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|135|||Both|12 Years|N/A|No|||December 2015|January 28, 2016|September 20, 2012|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT01691508||78909|
NCT01691794|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AI424-452|Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients|A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety of Atazanavir (ATV) Capsule Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected, Antiretroviral Naive and Experienced Pediatric Subjects Greater Than or Equal to 6 Years to Less Than 18 Years||Bristol-Myers Squibb|No|Completed|November 2012|October 2014|Actual|October 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|108|||Both|6 Years|17 Years|No|||February 2016|February 8, 2016|September 21, 2012|Yes|Yes||No|October 27, 2015|https://clinicaltrials.gov/show/NCT01691794||78887|
NCT01692028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GRH-PN01|Identification of the Region of Vitamin D Responsiveness|A Novel Approach Localizes the Association of Vitamin D Status With Insulin Resistance to One Region of the 25(OH)D Continuum.|GRH-PN01|Creighton University|No|Completed|February 2012|February 2012|Actual|February 2012|Actual|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional||1|Actual|4116|||Both|18 Years|95 Years|Accepts Healthy Volunteers|Non-Probability Sample|Healthy adults living in or near Calgary and associated with the oil and gas industries|September 2012|September 21, 2012|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01692028||78869|
NCT01692275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010-0782|Assessment of Chiropractic Treatment for Low Back Pain and Smoking Cessation in Military Active Duty Personnel.|Assessment of Chiropractic Treatment for Low Back Pain and Smoking Cessation in Military Active Duty Personnel||RAND|Yes|Active, not recruiting|September 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|750|||Both|18 Years|50 Years|No|||December 2015|December 8, 2015|September 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01692275||78850|
NCT01692262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D3610C00003|Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.|A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)|PYRUS|AstraZeneca||Completed|November 2012|June 2014|Actual|June 2014|Actual|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening|3||Actual|59|||Male|18 Years|N/A|No|||June 2014|June 18, 2014|September 19, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01692262||78851|
NCT01693107|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Version 20120423|Atrial Fibrillation Force Contact Ablation Study|The Canadian Atrial Fibrillation Force Contact Ablation Study|CAFCAS|Lawson Health Research Institute|No|Not yet recruiting|September 2012|January 2015|Anticipated|December 2013|Anticipated|Phase 1/Phase 2|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|18 Years|N/A|No|Non-Probability Sample|Patients with symptomatic paroxysmal atrial fibrillation who have failed antiarrhythmic        medications and scheduled for a pulmonary vein isolation procedure.|September 2012|September 21, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01693107||78786|
NCT01692847|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SD-05163-BBN-IGS|Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes|Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes (VitalCare - Guardian Version 2)||Philips Healthcare|Yes|Recruiting|October 2012|January 2016|Anticipated|December 2015|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|No|Non-Probability Sample|The investigators plan to observe a non-probability, convenience sample of patients which        will consist primarily of acutely ill hospitalized adult patients (at least 18 years of        age). Study participants will be recruited from all eligible patients during the        enrollment period who are having vital signs monitoring performed as Standard of Care.|November 2015|November 26, 2015|September 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01692847||78806|
NCT01693887|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ITRFUN4056|Treatment Method Research of Invasive Pulmonary Fungal Infection|A Comparative Study About Empirical Therapy and Preemptive Therapy to Invasive Pulmonary Fungal Infection ICU Patients in China|4056|West China Hospital|Yes|Terminated|August 2012|November 2013|Actual|November 2013|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|7|||Both|18 Years|N/A|No|Probability Sample|suspected Pulmonary invasive fungal Infection in ICU patients with Mechanical Ventilation|December 2015|December 10, 2015|September 21, 2012||No|The study difficulty is more serious than expected. The budget isn't enough.|No||https://clinicaltrials.gov/show/NCT01693887||78726|
NCT01693900|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2011-285|A Study to Compare the Ultrasound-guided Fascia Iliaca Compartment Block (FICB) to Surgeon-placed Fascia Iliaca Compartment Block for Post-operative Pain Control in Patients Undergoing an Anterior Hip Replacement Surgery.|EFFICACY OF FASCIA ILIACA BLOCK VERSUS INTRAOPERATIVE NERVE INFILTRATION DURING ANTERIOR HIP REPLACEMENT SURGERY||William Beaumont Hospitals|Yes|Completed|August 2012|January 2015|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|50|||Both|18 Years|65 Years|No|||March 2015|March 5, 2015|August 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01693900||78725|
NCT01694147|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|99-3957B|EVLWI Exhibits Pulmonary and Systemic Permeability in Sepsis Related ALI/ARDS|Extravascular Lung Water Index Exhibits Pulmonary and Systemic Permeability in Patients With Sepsis Related Acute Lung Injury/Acute Respiratory Distress Syndrome.||Chang Gung Memorial Hospital|Yes|Recruiting|July 2011|January 2017|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|60|Samples Without DNA|To measure the relationship between endothelial injury (serum TM, vWF, VEGF, TIE-2 increase      and imbalance of ANG-1/ANG-2) and vascular permeability and EVLWI in patients, 20ml      peripheral blood will be sampling retented on day 1 and day 3 after including.|Both|20 Years|N/A|No|Probability Sample|Septic patients receiving endotracheal mechanical ventilation for hypoxemic acute        respiratory failure were eligible if the following criteria were met for no more than 48        hours before enrollment: ratio of partial pressure of arterial oxygen over fraction of        inspired oxygen (PaO2:FIO2) no greater than 300 mm Hg at time of enrollment, recent        appearance of bilateral pulmonary infiltrates consistent with edema, and no clinical        evidence of left atrial hypertension (pulmonary-capillary wedge pressure _18 mm Hg, when        available).|September 2012|July 27, 2015|September 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01694147||78706|
NCT01694771|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1222.51|Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®|A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]||Boehringer Ingelheim||Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment|2||Actual|1134|||Both|40 Years|N/A|No|||August 2014|August 25, 2014|September 25, 2012||||No|July 23, 2014|https://clinicaltrials.gov/show/NCT01694771||78658|
NCT01695031|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1R34HL109296-01A1|Feasibility of an ED Initiated Online Asthma Management Program for Urban Teens|Feasibility of an ED-initiated Online Asthma Management Program for Urban Teens (Puff City-ED)|PuffCityED|Henry Ford Health System|Yes|Completed|October 2012|March 2015|Actual|March 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver)|2||Actual|126|||Both|13 Years|19 Years|No|||March 2015|March 30, 2015|September 12, 2012||No||No||https://clinicaltrials.gov/show/NCT01695031||78638|
NCT01691105|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1205010297|Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers|Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers||Yale University|No|Active, not recruiting|August 2013|August 2016|Anticipated|August 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|2||Actual|1044|||Both|18 Years|N/A|No|||January 2016|January 11, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01691105||78940|
NCT01668797|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|331-10-232|Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia|EQUATOR|Otsuka Pharmaceutical Development & Commercialization, Inc.|Yes|Completed|October 2012|February 2015|Actual|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|524|||Both|18 Years|65 Years|No|||July 2015|July 20, 2015|August 16, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01668797||80652|
NCT01668810|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RISSCH4255|The Third Survey of Prescription Pattern of Psychotropic Drugs in China|The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder||Peking University|Yes|Recruiting|July 2012|July 2013|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Ecologic or Community, Time Perspective: Prospective||10|Anticipated|7000|||Both|18 Years|65 Years|No|Probability Sample|schizophrenia, depression and bipolar disorder patients|July 2012|August 17, 2012|August 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01668810||80651|
NCT01666951|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LCP-Tacro 2019|Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant|Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacro™ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients||Veloxis Pharmaceuticals|No|Completed|November 2012|May 2013|Actual|March 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|36|||Both|18 Years|70 Years|No|||June 2015|June 30, 2015|August 14, 2012|Yes|Yes||No|May 19, 2015|https://clinicaltrials.gov/show/NCT01666951||80794|
NCT01666977|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|20101128|Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer|A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer||Amgen|Yes|Completed|August 2012|November 2015|Actual|November 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|36|||Both|18 Years|95 Years|No|||November 2015|November 23, 2015|August 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01666977||80792|
NCT01694615|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NA_00052081|Cryoprobe Transbronchial Lung Biopsy in Lung Transplant Patients|Prospective Controlled Study of Transbronchial Cryoprobe Versus Forceps Biopsy for Acute Rejection in Lung Transplantation||Johns Hopkins University|Yes|Completed|November 2011|September 2015|Actual|September 2015|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|30|||Both|18 Years|99 Years|No|||February 2016|February 4, 2016|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01694615||78670|
NCT01694888|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Documentation Skill|Midwifery Students' Performance Before and After Teaching Fundamentals of Documentation|||Mashhad University of Medical Sciences|No|Completed|June 2011|July 2011|Actual|July 2011|Actual|Phase 2/Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|27|||Female|21 Years|22 Years|Accepts Healthy Volunteers|||April 2011|September 25, 2012|September 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01694888||78649|
NCT01690975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B3551001|Benzonatate Dose Tolerance Study|A Phase I, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Tolerability of Benzonatate Following Single Dose Administration in Healthy Volunteers||Pfizer||Completed|July 2012|August 2012|Actual|August 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science|2||Actual|9|||Both|18 Years|55 Years|Accepts Healthy Volunteers|||September 2012|September 19, 2012|July 5, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01690975||78950|
NCT01691235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-1293|SIMpill Medication Dispensing Device in the Treatment of HCV|Evaluation of the SIMpill Medication Dispensing Device in the Treatment of Chronic Hepatitis C|SIMpill HCV|University of Chicago|No|Withdrawn|September 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|0|Samples With DNA|A blood draw (about 1 tablespoon) if the medication is not working for a subject. This blood      draw is another way for the study team to measure adherence to the therapy. This blood draw      will be taken only once at the time HCV in the blood return to high levels. This blood draw      will measure HCV resistance.|Both|18 Years|70 Years|No|Probability Sample|Subjects will be recruited from the outpatient/inpatient Liver GI clinic at the University        of Chicago Medical Center|October 2014|October 6, 2014|September 17, 2012||No|No subjects enrolled due to delay in device production|No||https://clinicaltrials.gov/show/NCT01691235||78930|
NCT01691248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5119-001|Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation|A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation|DEFLECT-1|Merck Sharp & Dohme Corp.|Yes|Completed|October 2012|April 2015|Actual|April 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|611|||Both|18 Years|N/A|No|||May 2014|April 27, 2015|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01691248||78929|
NCT01691521|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115588|Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma|MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma||GlaxoSmithKline|Yes|Completed|October 2012|January 2014|Actual|January 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|580|||Both|12 Years|N/A|No|||December 2015|January 28, 2016|September 20, 2012|Yes|Yes||No|November 5, 2015|https://clinicaltrials.gov/show/NCT01691521||78908|
NCT01691534|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NC-003-(C-J-Pa-Z)|Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)|A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Plus PA-824 Plus Pyrazinamide Plus Clofazimine, TMC207 Plus PA-824 Plus Pyrazinamide, TMC207 Plus PA-824 Plus Clofazimine Alone, TMC207 Plus Pyrazinamide Plus Clofazimine, Pyrazinamide Alone, and Clofazimine Alone; in Adult Patients With Newly Diagnosed, Smear-Positive Pulmonary Tuberculosis.|NC-003|Global Alliance for TB Drug Development|No|Active, not recruiting|September 2012|July 2013|Anticipated|June 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|7||Anticipated|105|||Both|18 Years|65 Years|No|||April 2013|April 11, 2013|September 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01691534||78907|
NCT01691807|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|113603|Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma|An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma||GlaxoSmithKline|No|Active, not recruiting|January 2013|February 2016|Anticipated|February 2016|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|30|||Both|18 Years|N/A|No|||December 2014|January 5, 2015|September 13, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01691807||78886|
NCT01691820|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115639|A Study in Adolescent Females to Explore Cytomegalovirus Infection|A Study in Adolescent Females to Explore Cytomegalovirus Infection||GlaxoSmithKline||Active, not recruiting|October 2012|March 2017|Anticipated|November 2016|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening|2||Anticipated|363|||Female|10 Years|17 Years|Accepts Healthy Volunteers|||October 2015|October 26, 2015|September 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01691820||78885|
NCT01692041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HeHe|Effect of an add-on Treatment With Ivy Leaves Dry Extract on Lung Function in Bronchial Asthma|Tolerance and Effect of an add-on Treatment With a Cough Medicine Containing Ivy Leaves Dry Extract on Lung Function in Children With Bronchial Asthma|HeHe|Technische Universität Dresden|Yes|Recruiting|April 2012|December 2013|Anticipated|December 2013|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|2||Anticipated|30|||Both|6 Years|12 Years|No|||September 2012|September 24, 2012|May 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01692041||78868|
NCT01692288|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|K7051-07-03|Evaluation of the Effectiveness of a Home Visiting Program for New Parents in New Mexico|Evaluation of the Effectiveness of the First Born® Program for New Parents in Santa Fe County, New Mexico||RAND|No|Enrolling by invitation|September 2012|||December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|280|||Both|N/A|2 Months||||May 2014|May 8, 2014|September 14, 2012||No||No||https://clinicaltrials.gov/show/NCT01692288||78849|
NCT01692301|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CLCZ696A2216|Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension|A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension||Novartis|Yes|Completed|December 2012|April 2015|Actual|April 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|454|||Both|60 Years|N/A|No|||October 2015|October 5, 2015|September 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01692301||78848|
NCT01693120|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VICTORY AF|Evaluation of the Phased Radio Frequency Ablation System|Evaluation of Multielectrode Phased RF Technology in Persistent Atrial Fibrillation|VICTORY-AF|Medtronic Atrial Fibrillation Solutions|Yes|Recruiting|November 2013|December 2017|Anticipated|March 2017|Anticipated|Phase 3|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|300|||Both|18 Years|75 Years|No|||December 2015|December 3, 2015|September 19, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01693120||78785|
NCT01693133|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EFDFU003|Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers|A Multicenter, Prospective, Randomized, Controlled, Comparative Parallel Study of Dehydrated Human Amnion/Chorion Membrane (dHACM) Wound Graft in the Management of Diabetic Foot Ulcers||MiMedx Group, Inc.|Yes|Recruiting|July 2012|December 2016|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|84|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|September 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01693133||78784|
NCT01659463|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0347.0243.000-10|Resin Infiltratration on the Sealing of Proximal Early Caries|Resin Infiltration on Teh Sealing of Proximal Early Caries Lesins: a Randomized Trial||Universidade Federal de Santa Maria|No|Recruiting|April 2011|September 2013|Anticipated|September 2012|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|39|||Both|9 Years|N/A|Accepts Healthy Volunteers|||August 2012|August 21, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659463||81349|
NCT01658735|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB_00052918|Comparison of Electrotherapies for Chronic Low Back Pain|Electrical Stimulation for Chronic Non-specific Low Back Pain in a Working-Age Population: A 12-Week Double Blinded Randomized Controlled Trial||University of Utah|Yes|Completed|July 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|113|||Both|18 Years|65 Years|No|||February 2015|February 24, 2015|July 30, 2012||No||No|February 9, 2015|https://clinicaltrials.gov/show/NCT01658735||81404|Participant enrollment was based on chronic pain VAS score of >= 5.0 (0-10 scale). High baseline VAS scores did not translate to a priori hypothesized high ODI scores, resulting in study being underpowered to detect differences in primary outcomes.
NCT01658748|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N1112-I|A Pilot Study of Deep Brain Stimulation of the Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder|A Pilot Study to Examine Deep Brain Stimulation (DBS) in the Basolateral Nucleus (BLn) of the Amygdala for the Management of Symptoms in Veterans With Chronic and Treatment-Refractory Combat-related Post-Traumatic Stress Disorder (PTSD)|ADIP|VA Office of Research and Development|Yes|Withdrawn|January 2013|December 2015|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Male|25 Years|65 Years|No|||May 2013|May 28, 2013|July 28, 2012|||Funding not finalized|No||https://clinicaltrials.gov/show/NCT01658748||81403|
NCT01658761|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|KyorinEye008|Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes|Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes||Kyorin University|No|Completed|September 1998|March 2012|Actual|February 2011|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|1||Actual|64|||Both|30 Years|90 Years|No|||August 2012|August 1, 2012|July 28, 2012||No||No||https://clinicaltrials.gov/show/NCT01658761||81402|
NCT01659437|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|T9-370-1|WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8|Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection)||University Medical Center Groningen|Yes|Recruiting|December 2012|January 2018|Anticipated|January 2017|Anticipated|Phase 2/Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|415|||Both|5 Years|N/A|No|||January 2015|January 2, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01659437||81351|
NCT01660373|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISSBRIL0080|Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome|Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study|TE-CLOT|Pusan National University Yangsan Hospital|Yes|Recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|18 Years|80 Years|No|||December 2012|December 16, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01660373||81281|
NCT01660646|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1205|Determining the Impact of Enhanced Case Finding on Tuberculosis Notification in The Gambia|A Cluster Randomised Trial to Assess the Impact of an Enhanced Case Finding Strategy on Tuberculosis Notification in The Gambia|ECF|Medical Research Council Unit, The Gambia|No|Completed|June 2012|October 2015|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Actual|650000|||Both|N/A|N/A|No|||April 2015|November 12, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01660646||81260|
NCT01661439|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PCTRPL|Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome|A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)||Woman's Health University Hospital, Egypt|Yes|Recruiting|March 2012|June 2014|Anticipated|June 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|316|||Female|18 Years|40 Years|Accepts Healthy Volunteers|Probability Sample|patients with recurrent pregnancy losses either two or more recurrent miscarriages or        intrauterine fetal deathes after 20 weeks of gestation with positive antiphospholipid        antibodies in medium to high titer in two occasions 6 weeks apart.|March 2012|June 20, 2014|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661439||81199|
NCT01661634|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ULA01|Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure|Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]|TRUE-AHF|Cardiorentis|Yes|Active, not recruiting|July 2012|February 2016|Anticipated|November 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|2152|||Both|18 Years|85 Years|No|||February 2016|February 2, 2016|July 31, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661634||81184|
NCT01695655|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Neovasc-6281|Neovascularization Patterns in Corneal Graft Rejection|Neovascularization Patterns in Corneal Graft Rejection||University of Michigan|No|Active, not recruiting|November 2007|December 2016|Anticipated|December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|60|||Both|18 Years|99 Years|No|Probability Sample|subjects with indications of corneal transplant|January 2016|January 26, 2016|September 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01695655||78590|
NCT01659645|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00052551|Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast|Amino Acid Transport Imaging of Breast Carcinoma Via Anti-3-[18F]FACBC PET-CT: A Pilot Study||Emory University|Yes|Active, not recruiting|August 2012|||August 2016|Anticipated|Phase 0|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|12|||Female|18 Years|85 Years|No|||January 2016|January 19, 2016|August 1, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659645||81335|
NCT01660256|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|037E-11-003|Confirmatory Study of OPC-12759 Ophthalmic Solution|Confirmatory Study of OPC-12759 Ophthalmic Solution in Patients With Dry Eye||Otsuka Pharmaceutical Co., Ltd.|No|Completed|August 2012|May 2013|Actual|March 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|3||Actual|209|||Both|20 Years|N/A|No|||June 2013|June 9, 2013|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660256||81288|
NCT01660854|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TIP4|Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites|Re-exposure of Previously Immunized and Challenged Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites|TIP4|Radboud University|Yes|Completed|July 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|21|||Both|18 Years|35 Years|Accepts Healthy Volunteers|||July 2012|February 12, 2013|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01660854||81244|
NCT01661088|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.007|A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients|A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer||University of Michigan Cancer Center|Yes|Recruiting|June 2011|June 2017|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|31|||Both|18 Years|N/A|No|||November 2015|November 16, 2015|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661088||81226|
NCT01661322|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08093|Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke|Safety and Efficacy of Intensive Versus Guideline Antiplatelet Therapy in High Risk Patients With Recent Ischaemic Stroke or Transient Ischaemic Attack: a Randomised Controlled Trial|TARDIS|University of Nottingham|Yes|Recruiting|April 2009|September 2017|Anticipated|September 2017|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Anticipated|4100|||Both|50 Years|N/A|No|||June 2014|June 16, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01661322||81208|
NCT01662297|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Quetiapine-Trazodone Insomnia|Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans|Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans: an Open (e.g. Unblinded) Randomized Stay-Switch Pilot Trial||VA Connecticut Healthcare System|Yes|Enrolling by invitation|July 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|122|||Both|18 Years|N/A|No|||August 2012|August 10, 2012|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01662297||81134|
NCT01658280|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PAN-001|Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies|Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial.||Azienda Ospedaliero, Universitaria Ospedali Riuniti|No|Completed|August 2012|July 2015|Actual|May 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic|2||Actual|253|||Both|18 Years|N/A|No|||February 2016|February 2, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658280||81438|
NCT01658540|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESREFO09|Drug Eluting Balloon (DEB) and Long Lesions of Superficial Femoral Artery (SFA) Ischemic Vascular Disease|Safety and Efficacy of the Drug Eluting Balloon (DEB) for the Treatment of the Superficial Femoral Artery (SFA) Ischemic Vascular Disease in Symptomatic Patients Presenting With Long Lesions: a Pilot Study|DEB-SFA-LONG|Ettore Sansavini Health Science Foundation|No|Active, not recruiting|October 2012|December 2016|Anticipated|May 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|105|||Both|N/A|N/A|No|Non-Probability Sample|Patients affected by lower extremities artery disease (LEAD) and referred to the        participating centres for the endovascular treatment of de novo or restenotic lesions (no        in stent restenosis) in the superficial femoral and proximal popliteal arteries will be        considered for the study|February 2015|February 24, 2015|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658540||81418|
NCT01659164|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012/333-31|Psychological Treatment for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Psychological Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) - Pilot Evaluation of a New Treatment Manual Based on CBT and DBT||Karolinska Institutet|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|65 Years|No|||April 2015|April 1, 2015|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659164||81372|
NCT01659125|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEF003581HI|Effectiveness and Neuropsychological Predictors of Guided Self-Help for Obsessive-Compulsive Disorder (OCD)|Effectiveness and Neuropsychological Predictors of Guided Self-Help for OCD||Hartford Hospital|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|N/A|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|26|||Both|18 Years|69 Years|No|||December 2015|December 2, 2015|August 3, 2012||No||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01659125||81375|
NCT01659138|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ACT12688|Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC)|FUSCIA|Sanofi|Yes|Terminated|August 2012|June 2014|Actual|June 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|93|||Both|18 Years|70 Years|No|||November 2015|November 3, 2015|August 3, 2012|Yes|Yes|The study was early terminated due to slow recruitment. Not linked to any safety concern.|No||https://clinicaltrials.gov/show/NCT01659138||81374|
NCT01660061|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EV 77/11|Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome|Monitoring Anticoagulant Therapy With Vitamin-K Antagonists in Patients With Antiphospholipid Syndrome||Johann Wolfgang Goethe University Hospitals|No|Completed|July 2011|December 2014|Actual|June 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Anticipated|150|Samples Without DNA|Plasma samples.|Both|18 Years|90 Years|No|Non-Probability Sample|Patients with antiphospholipid syndrome requiring long-term treatment with vitamin-K        antagonists (N=40) Pateints without antiphospholipid antibodies treated with vitamin-K        antagonists (N=100)|April 2015|April 14, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660061||81303|
NCT01660074|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|FP202|Glycemic Index and Glycemic Response of Food and Products|Glycemic Index and Glycemic Response of Food and Products That Produced in Taiwan|GI|National Pingtung University Science and Technology|Yes|Completed|July 2008|June 2010|Actual|June 2010|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|10|||Both|20 Years|30 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01660074||81302|
NCT01660386|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CCEMD014|Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"|An Open-label, Randomized, Four-way Cross-over, Single Dose Study to Compare the Different Effect of DPP-4 Inhibitors and Sulfonylurea on the Beta Cell Function by Using "Biphase-Hyperglycemic Clamp"||Shanghai Jiao Tong University School of Medicine|Yes|Recruiting|July 2012|March 2013|Anticipated|December 2012|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label|4||Anticipated|12|||Male|20 Years|30 Years|Accepts Healthy Volunteers|||December 2012|December 13, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01660386||81280|
NCT01660659|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SCC 1284|Indoor Air Pollution (IAP) Carriage Study|Use of Biomass Briquettes: Its Effect on Indoor Air Pollution and on Pneumococcal Nasopharyngeal Carriage. A Randomized Clinical Trial||Medical Research Council Unit, The Gambia|No|Completed|January 2012|August 2015|Actual|June 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)|2||Actual|500|||Both|2 Months|8 Months|Accepts Healthy Volunteers|||April 2015|October 23, 2015|May 18, 2012||No||No||https://clinicaltrials.gov/show/NCT01660659||81259|
NCT01661660|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-PP-01|Ecological Assessment of Autonomy and Apathy|Ecological Assessment of Autonomy and Apathy in Alzheimer Patients at Mild and Moderate Stages, as Welle as in Healthy Control Particpants|Dem@Care|Centre Hospitalier Universitaire de Nice|No|Recruiting|September 2012|September 2016|Anticipated|September 2012|Actual|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)|3||Anticipated|150|||Both|65 Years|N/A|Accepts Healthy Volunteers|||March 2016|March 21, 2016|July 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01661660||81182|
NCT01652729|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|BCB120|Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus|A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus|DURATION-NEO-2|AstraZeneca|No|Completed|February 2013|April 2014|Actual|April 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|365|||Both|18 Years|N/A|No|||July 2015|July 31, 2015|July 26, 2012|Yes|Yes||No|April 3, 2015|https://clinicaltrials.gov/show/NCT01652729||81860|
NCT01652742|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1283.34|Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX|Pharmacokinetics and Pharmacodynamics of BI 135585 XX Administered as Oral Dose in Healthy Male Volunteers (Open-label, Single-dose Trial)||Boehringer Ingelheim||Completed|July 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|9|||Male|18 Years|55 Years|Accepts Healthy Volunteers|||March 2013|March 6, 2013|July 26, 2012||||No||https://clinicaltrials.gov/show/NCT01652742||81859|
NCT01661907|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PUCRP201101|Anesthesia-analgesia Methods and Postoperative Delirium|Effects of Two Different Anesthesia-analgesia Methods on the Incidence of Postoperative Delirium: a Multicenter, Randomized Controlled Trial||Peking University First Hospital|Yes|Completed|November 2011|June 2015|Actual|May 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|1800|||Both|60 Years|90 Years|No|||October 2015|October 28, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01661907||81163|
NCT01661920|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CAPTIME|Suitability of Antibiotic Treatment for CAP|Suitability of Antibiotic Treatment for Community-acquired Pneumonia|CAPTIME|Hospital Galdakao-Usansolo|No|Completed|January 2012|April 2014|Actual|March 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|602|||Both|18 Years|N/A|No|||August 2015|August 19, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01661920||81162|
NCT01662128|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|xeloda|Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer|Randomized Controlled Trials of Efficacy and Safety With Xeloda as Sequential Adjuvant Therapy After Chemotherapy of Anthracycline and/or Taxane in Breast Cancer of Triple Negative or HER-2 Positive or Axillary Lymph Node Metastasis ≥4||Tianjin Medical University|Yes|Recruiting|June 2012|June 2022|Anticipated|June 2014|Anticipated|Phase 2/Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|600|||Female|N/A|N/A|No|||August 2012|August 7, 2012|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662128||81146|
NCT01695668|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Lotemax_00045815|Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%|Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol|Lotemax_BMT|University of Michigan|No|Completed|August 2011|February 2015|Actual|September 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|75|||Both|18 Years|N/A|No|||August 2015|August 24, 2015|September 25, 2012||No||No|January 16, 2015|https://clinicaltrials.gov/show/NCT01695668||78589|
NCT01659957|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01AA017865|Couples Therapy for Alcoholic Patients|Behavioral Couples Group Therapy for Alcholic Patients: Clinical and Cost Outcomes|CALM|Harvard University|Yes|Completed|November 2010|November 2014|Actual|November 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|285|||Both|18 Years|65 Years|No|||March 2015|March 19, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659957||81311|
NCT01660243|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MT-9938-A01|Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis||Toray Industries, Inc|No|Terminated|September 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|4||Actual|45|||Both|18 Years|N/A|No|||February 2016|February 18, 2016|August 2, 2012|Yes|Yes|This study has been terminated because of insufficient patient recruitment.|No||https://clinicaltrials.gov/show/NCT01660243||81289|
NCT01660867|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Bronchiolitis_1|Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department|Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department||Seoul National University Hospital||Active, not recruiting|August 2012|August 2013|Anticipated|August 2013|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|336|||Both|3 Months|24 Months|No|||August 2012|August 8, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01660867||81243|
NCT01660880|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-1205-094-410|Validation of Receptor Occupancy Simulation|||Seoul National University Hospital|No|Recruiting|December 2012|April 2014|Anticipated|December 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Cross-Sectional||1|Anticipated|20|||Both|20 Years|55 Years|No|Non-Probability Sample|Patients with schizophrenia who is in the steady sate of antipsychotic treatment|May 2013|May 18, 2013|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01660880||81242|
NCT01661101|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1160.143|Management of Myocardial Injury After Noncardiac Surgery Trial|A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery|MANAGE|Population Health Research Institute|Yes|Recruiting|January 2013|April 2017|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|3200|||Both|45 Years|N/A|No|||March 2016|March 9, 2016|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661101||81225|
NCT01661855|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RILISE-07-2013|A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD|A Pilot Study of Riluzole vs. Placebo in the Treatment of Children and Adolescents With Autism Spectrum Disorders|RILISE|Anagnostou, Evdokia, M.D.|Yes|Active, not recruiting|September 2013|March 2016|Anticipated|September 2015|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|6 Years|17 Years|No|||February 2016|February 9, 2016|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01661855||81167|
NCT01661335|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0413|Efficacy of Aprepitant (Emend®) in Children|Efficacy of Aprepitant (Emend®) in Children Receiving Highly Emetogenic Chemotherapy||University of Oklahoma|Yes|Recruiting|June 2012|October 2015|Anticipated|October 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Anticipated|50|||Both|6 Months|20 Years|No|||December 2014|December 2, 2014|June 18, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661335||81207|
NCT01658306|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D111107003111008|Clinical Trial on Remote Ischemic Preconditioning and Cerebral Small Vessel Disease|A Random Controlled, Double-Blind Clinical Trial: Remote Ischemic Preconditioning and Cerebral Small Vessel Disease|RIPC-SVD|Capital Medical University|Yes|Completed|July 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|30|||Both|40 Years|80 Years|No|||November 2014|November 25, 2014|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01658306||81436|
NCT01658553|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114655|A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212|A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors||GlaxoSmithKline|No|Completed|September 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|1||Actual|35|||Both|18 Years|N/A|No|||May 2014|February 12, 2015|June 28, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01658553||81417|
NCT01658293|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB100-25|Thermal Stimulation for Stroke Patients|Facilitation of Sensory and Motor Recovery by Means of Heat and Cold-water Stimulation on the Paretic Upper Limb of After Stroke: One Year Follow up|TSSP|Buddhist Tzu Chi General Hospital|Yes|Recruiting|July 2011|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|30 Years|80 Years|No|||August 2012|August 6, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658293||81437|
NCT01659151|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MCC-16992|Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma|A Phase II Clinical Trial of Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma||H. Lee Moffitt Cancer Center and Research Institute|No|Recruiting|July 2012|August 2016|Anticipated|August 2016|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|30|||Both|18 Years|N/A|No|||December 2015|December 7, 2015|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659151||81373|
NCT01659450|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Low energy density diet|Low Energy Dense, Weight Maintenance, Risk of Cardiovascular Disease|Low Energy Density Diet and Weight Loss Maintenance||Isfahan University of Medical Sciences|No|Completed|January 2011|November 2011|Actual|November 2011|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research|2||Actual|35|||Both|40 Years|70 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01659450||81350|
NCT01660984|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120178|Natural History Study of Children and Young Adults With Medullary Thyroid Cancer|Longitudinal Assessment and Natural History Study of Children and Young Adults With Medullary Thyroid Carcinoma||National Institutes of Health Clinical Center (CC)||Recruiting|July 2012|||||N/A|Observational|Time Perspective: Prospective|||Anticipated|90|||Both|1 Year|99 Years|Accepts Healthy Volunteers|||February 2016|February 20, 2016|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01660984||81234|
NCT01659736|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|DIEF003523.1|Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder|Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder||Hartford Hospital|No|Completed|May 2012|December 2014|Actual|December 2014|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|26|||Both|18 Years|N/A|No|||December 2015|December 2, 2015|May 25, 2012|Yes|Yes||No|April 8, 2015|https://clinicaltrials.gov/show/NCT01659736||81328|
NCT01659749|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00002447a|Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria|Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria (PKU) or Maple Syrup Urine Disease (MSUD).||Emory University|Yes|Completed|June 1995|June 2000|Actual|June 2000|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|35|||Female|12 Years|N/A|Accepts Healthy Volunteers|||December 2015|December 9, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659749||81327|
NCT01660087|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SERC/1121480001|Diagnosis of Lung Cancer From Exhaled Breath With Silicon Biophotonic Device|Diagnosis of Lung Cancer From Exhaled Breath With Silicon Biophotonic Device.||National University Hospital, Singapore|No|Active, not recruiting|April 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|80|||Both|21 Years|N/A|Accepts Healthy Volunteers|||July 2012|August 6, 2012|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660087||81301|
NCT01660997|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|120180|MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma|MLN9708 and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study||National Institutes of Health Clinical Center (CC)||Withdrawn|July 2012|March 2014|Actual|March 2014|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|0|||Both|18 Years|N/A|No|||March 2014|October 24, 2014|August 7, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660997||81233|
NCT01652755|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N-H-Y|Plasma Cystatin C and Acute Kidney Injury|Use of Cystatin C in Predicting AKI in Patients Undergone Cardiopulmonary Bypass Surgery||Jinhua Central Hospital|No|Recruiting|April 2011|May 2013|Anticipated|May 2013|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Anticipated|100|||Both|18 Years|80 Years|No|Non-Probability Sample|patients undergone cardiopulmonary bypass surgery|August 2012|August 3, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652755||81858|
NCT01652768|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE1310|PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors|PRESENCE Project: An Early Palliative Care Intervention for Patients With Malignant Brain Tumors and Their Primary Caregivers||Case Comprehensive Cancer Center|No|Terminated|December 2011|August 2013|Actual|August 2013|Actual|N/A|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|1|||Both|18 Years|N/A|Accepts Healthy Volunteers|||August 2013|August 28, 2013|July 26, 2012||No|Research Cancelled|No||https://clinicaltrials.gov/show/NCT01652768||81857|
NCT01661673|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EVP-0962-002|Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease|Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease||FORUM Pharmaceuticals Inc|No|Completed|November 2012|||October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|5||Actual|52|||Both|45 Years|85 Years|Accepts Healthy Volunteers|||January 2014|January 10, 2014|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661673||81181|
NCT01661933|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AU/3/BOBD012|Desensitising Celiac Disease Patients With the Human Hookworm|Combining Necator Americanus With Trace Gluten to Restore Tolerance in Coeliac Disease: a Pilot Clinical and a Detailed in Vitro Immunological Study.|NaCeD|The Prince Charles Hospital|Yes|Completed|August 2012|March 2014|Actual|March 2014|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention|1||Actual|12|||Both|18 Years|N/A|No|||October 2014|October 10, 2014|August 6, 2012|Yes|Yes||No|September 21, 2014|https://clinicaltrials.gov/show/NCT01661933||81161|Open study. Small number. Historical controls.
NCT01695954|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NYU 11-01787|Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz|THE EFFECT OF EFAVIRENZ AND RITONAVIR-BOOSTED DARUNAVIR ON THE PHARMACOKINETICS OF THE HMG CoA REDUCTASE INHIBITOR PITAVASTATIN||New York University School of Medicine|Yes|Active, not recruiting|May 2012|October 2012|Anticipated|October 2012|Anticipated|Phase 1|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label|2||Actual|28|||Both|18 Years|60 Years|Accepts Healthy Volunteers|||September 2012|September 27, 2012|September 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01695954||78567|
NCT01659970|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28195|PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer|A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)||Hoffmann-La Roche||Completed|June 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|152|||Both|18 Years|N/A|No|Probability Sample|Patients with locally advanced or metastatic squamous NSCLC initiating 2nd line treatment        with Tarceva|March 2016|March 1, 2016|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01659970||81310|
NCT01660295|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMEX839BDE07|Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects|An Open-label, Single Center, Parallel-group Study to Compare the Single- and Repeated-dose Pharmacokinetics of Stepwise Increasing Doses of Subcutaneous Certoparin (3000 IU o.d., 3000 IU b.i.d., 8000 IU o.d., and 8000 IU b.i.d.) in Subjects With Severe Renal Insufficiency and Healthy Subjects||Novartis||Completed|December 2011|||June 2012|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|32|||Both|21 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 5, 2012|December 20, 2011||No||No||https://clinicaltrials.gov/show/NCT01660295||81287|
NCT01660568|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-07-043|Gemcitabine in NK/T Cell Lymphoma|Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma||Samsung Medical Center||Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||1|Actual|20|||Both|15 Years|N/A|No|Non-Probability Sample|relapsed or refractory NK/T cell lymphoma treated with gemcitabine conatining treatment|August 2012|February 11, 2013|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660568||81266|
NCT01660893|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SR 3-01|Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth|A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults||St. Renatus, LLC|No|Terminated|August 2012|September 2012|Actual|September 2012|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Actual|26|||Both|18 Years|N/A|No|||May 2015|May 15, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660893||81241|
NCT01661569|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3035/002|A Randomised Controlled Trial to Investigate the Effects of a Mindfulness Smartphone App on Well-being in the Workplace|A Randomised Controlled Trial to Investigate the Effects of the Headspace Mindfulness Smartphone App on Psychological Well-being and Biological Indicators of Stress in the Workplace||University College, London|No|Not yet recruiting|August 2012|January 2013|Anticipated|January 2013|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|120|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661569||81189|
NCT01661868|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-170|Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer|Phase II Study of Single Agent Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer With No Prior PARP Exposure or Prior PARP Inhibitor Exposure||Dana-Farber Cancer Institute|Yes|Withdrawn|August 2012|August 2012|Actual|August 2012|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Female|18 Years|N/A|No|||August 2012|August 18, 2012|October 24, 2011|Yes|Yes|Drug not available.|No||https://clinicaltrials.gov/show/NCT01661868||81166|
NCT01662063|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ML28338|A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open Label Long Term Extension Study of WA22762 and NA25220 to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis||Genentech, Inc.||Completed|August 2012|June 2014|Actual|June 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|218|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01662063||81151|
NCT01658319|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CASE2Y10|Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies|Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies||Case Comprehensive Cancer Center|Yes|Completed|May 2011|May 2015|Actual|February 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Both|18 Years|N/A|No|||August 2015|August 12, 2015|July 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01658319||81435|
NCT01658800|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAX161-01C|Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49|Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49||VaxInnate Corporation|Yes|Completed|September 2012|December 2013|Actual|September 2013|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention|1||Actual|275|||Both|18 Years|49 Years|Accepts Healthy Volunteers|||March 2015|March 5, 2015|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01658800||81399|
NCT01658813|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-09|5-FU Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer|Phase II Trial of Chemoimmunotherapy With 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer||Western Regional Medical Center|No|Completed|July 2012|July 2014|Actual|July 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|18|||Both|18 Years|N/A|No|||June 2015|June 1, 2015|August 2, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658813||81398|
NCT01658826|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AIC316-01-II-02|Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes|A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.||AiCuris Anti-infective Cures GmbH|No|Terminated|October 2012|July 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|91|||Both|18 Years|N/A|No|||August 2012|July 8, 2014|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658826||81397|
NCT01658839|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|C-12-009|Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients|An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients||Alcon Research|No|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|25|||Both|2 Months|17 Years|No|||July 2014|June 28, 2015|August 3, 2012|Yes|Yes||No|June 24, 2014|https://clinicaltrials.gov/show/NCT01658839||81396|
NCT01659476|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-01|Bronchodilating and Bronchoprotective Effects of Deep Inspirations|Bronchodilating and Bronchoprotective Effects of Deep Inspirations in Asthma, Cough Variant Asthma and Chronic Cough With Normal Airway Sensitivity and Sensory-Mechanical Responses to High-Dose Methacholine in Healthy Normal Subjects||Queen's University|No|Recruiting|October 2012|August 2017|Anticipated|August 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science|4||Anticipated|36|||Both|18 Years|65 Years|Accepts Healthy Volunteers|||February 2016|February 9, 2016|July 30, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659476||81348|
NCT01660425|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ADHD-TEAM-02|Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Support|Enhancement of Psychosocial Functioning, Quality of Life, Satisfaction With Medication and Medication Compliance of Methylphenidate Treatment by Psychosocial Intervention and Support||University of Cologne|No|Active, not recruiting|May 2012|March 2015|Anticipated|December 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|100|||Both|6 Years|12 Years|No|||March 2014|March 12, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660425||81277|
NCT01651689|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajH-003|Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia|Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia|ThaiScalpBx|Siriraj Hospital|Yes|Enrolling by invitation|October 2010|May 2013|Anticipated|April 2013|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|50|Samples Without DNA|scalp biopsy specimen|Both|18 Years|N/A|No|Non-Probability Sample|Thai patients who have alopecia and on scadule for hair transplantation|July 2012|July 25, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651689||81940|
NCT01661426|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SU-07262012-10669|Weight Loss Diet Study: Low Carb vs Low Fat|Weight Loss Diet Study: Low Carbohydrate vs. Low Fat and Genotype Predisposition||Stanford University|No|Completed|April 2012|March 2013|Actual|March 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|61|||Both|18 Years|50 Years|Accepts Healthy Volunteers|||March 2013|March 27, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661426||81200|
NCT01661647|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CE 12.005|3D Kinematic Assessment of the Human Knee During Physical and Daily Life Activities|(Étude de la cinématique Tridimensionnelle du Genou Humain Lors de Gestes Sportifs et de la Vie Courante)||Centre hospitalier de l'Université de Montréal (CHUM)|Yes|Not yet recruiting|September 2016|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Anticipated|10|||Both|N/A|N/A|No|||January 2016|January 11, 2016|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01661647||81183|
NCT01652222|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CONEM-BETA-FPM/SAR-0111|Experimental Study to Validate the "Therapeutic Game" CONEM-BETA|Experimental Study to Validate the "Therapeutic Game" CONEM-BETA||Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|No|Completed|January 2012|August 2012|Actual|July 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|3||Actual|101|||Both|18 Years|N/A|Accepts Healthy Volunteers|||July 2014|July 8, 2014|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01652222||81899|
NCT01652456|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ALTAKRA - 1205|Alcohol and Tobacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support|Alcohol and TObacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support||Centre Oscar Lambret|No|Withdrawn|October 2012|October 2014|Anticipated|October 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|0|||Both|18 Years|60 Years|No|||August 2014|August 21, 2014|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652456||81881|
NCT01653275|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-136S-1|Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover|Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover|MedSD|University of Connecticut Health Center|Yes|Recruiting|April 2012|December 2014|Anticipated|December 2014|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|20|||Female|65 Years|N/A|Accepts Healthy Volunteers|||July 2012|July 26, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653275||81818|
NCT01653002|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RLK-Epi-1|Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging|||University Hospital, Essen|No|Recruiting|February 2012|||February 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|||Both|18 Years|90 Years|No|Probability Sample|Patients with proven or suspcted lung cancer and enlarged mediastinal or hilar lymph nodes|May 2014|May 21, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01653002||81839|
NCT01653223|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|statin2|Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery|A Study of Simvastatin on Myocardial Protection and Cardiac Function Undergoing Cardiac Surgery With Cardiopulmonary Bypass||Sun Yat-sen University|Yes|Recruiting|January 2013|December 2020|Anticipated|December 2018|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|3||Anticipated|369|||Both|18 Years|N/A|No|||March 2015|March 13, 2015|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653223||81822|
NCT01653236|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|3034-108|Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection|Pilot Study to Determine the Efficacy and Safety of Combining Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection||Theodor Bilharz Research Institute|No|Recruiting|December 2013|December 2015|Anticipated|December 2015|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|40|||Both|18 Years|N/A|No|||December 2014|December 25, 2014|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653236||81821|
NCT01695694|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00040309|Violence and HIV Risk Among Women|HIV Risk Reduction for Women Reporting Intimate Partner Violence|VHRW|University of Rochester|No|Completed|September 2012|October 2013|Actual|October 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Anticipated|120|||Female|18 Years|49 Years|No|||February 2014|February 17, 2014|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01695694||78587|
NCT01695707|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RSRB00041078|Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients|Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients||University of Rochester|Yes|Withdrawn|March 2013|June 2014|Anticipated|January 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|55 Years|No|||December 2014|December 1, 2014|September 26, 2012||No|Insufficient Funding.|No||https://clinicaltrials.gov/show/NCT01695707||78586|
NCT01660581|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Regent Vsel|Intracardiac CD133+ Cells in Patients With No-option Resistant Angina|A Randomized, Prospective, Double-blind Study to Evaluate Intracardiac Injections of Bone Marrow, Autologous CD133+ Cells (Electromechanical Mapping Based) in Patients With Resistant Angina and no Effective Revascularization Option. Regent Vsel Study.|Regent Vsel|Medical University of Silesia|No|Recruiting|June 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||August 2013|February 12, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660581||81265|
NCT01661582|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MIDAS|Myocardial Ischaemia After Exposure to Diesel Exhaust|Myocardial Ischaemia After Exposure to Diesel Exhaust|MIDAS|University of Edinburgh|No|Recruiting|October 2012|August 2015|Anticipated|February 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science|2||Anticipated|24|||Male|18 Years|60 Years|Accepts Healthy Volunteers|||December 2014|December 2, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661582||81188|
NCT01662089|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SirirajH-004|The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement|A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Oral Chelated Zinc Supplement||Siriraj Hospital|Yes|Recruiting|January 2012|December 2012|Anticipated|October 2012|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Female|18 Years|N/A|No|||August 2012|August 7, 2012|August 5, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01662089||81149|
NCT01662076|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000027444|Homeopathic Treatment of Fatigue in Children Receiving Chemotherapy|A Feasibility Pilot Trial of Individualized Homeopathic Treatment of Fatigue in Children Receiving Chemotherapy||The Hospital for Sick Children|No|Completed|August 2012|May 2014|Actual|May 2014|Actual|Phase 3|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label|1||Actual|9|||Both|2 Years|18 Years|No|||May 2015|May 19, 2015|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01662076||81150|
NCT01659489|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SHEBA-12-9605-RM-CTIL|ADnexal TOrsion Markers Study|Blood and Serum Markers in Patients Operated for Suspected Ovarian Torsion|ATOMS|Sheba Medical Center|No|Recruiting|August 2012|||December 2016|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|200|Samples Without DNA|Serum will be frozen for evaluation|Female|18 Years|45 Years|No|Probability Sample|200 women undergoing laparoscopy for suspected ovarian torsion in a tertiary referral        center|December 2014|December 17, 2014|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01659489||81347|
NCT01659502|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TLH-207|Investigator's Initiated Phase II Study for Pancreatic Cancer Patients|||Tiltan Pharma Ltd.||Not yet recruiting|December 2013|||October 2014|Anticipated|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|18 Years|N/A|No|||December 2013|December 4, 2013|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01659502||81346|
NCT01658579|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PDY12777|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin|A 16-week, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine Versus Lantus in Patients With Type 1 Diabetes Mellitus||Sanofi|No|Completed|August 2012|May 2013|Actual|May 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Actual|59|||Both|18 Years|70 Years|No|||May 2015|May 7, 2015|July 26, 2012|Yes|Yes||No|March 24, 2015|https://clinicaltrials.gov/show/NCT01658579||81416|
NCT01660412|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|31337|Does Alkalinization Reduce Perceived Pain Levels During Sentinel Lymph Node Imaging?|Does Alkalinization of Technetium-99m Sulfur Colloid Reduce Perceived Pain Levels During Non-breast Sentinel Lymphoscintigraphy?|buffering SLN|University of Arkansas|Yes|Active, not recruiting|August 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|N/A|No|||January 2016|January 26, 2016|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660412||81278|
NCT01660672|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LVT1R01NS074409|Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria|A Dose-Escalation, Safety And Feasibility Study Of Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria|LVT1|University of Rochester|Yes|Completed|January 2013|July 2013|Actual|July 2013|Actual|Phase 1/Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|7|||Both|2 Years|6 Years|No|||October 2014|October 16, 2014|July 19, 2012||No||No|August 11, 2014|https://clinicaltrials.gov/show/NCT01660672||81258|
NCT01659762|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB00051454|A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.|A Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stromal (MSC) Cells in Adults With Moderate to Severe Crohn's Disease.|EPIC/MSC/IBD|Emory University|Yes|Completed|July 2012|||July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|18 Years|65 Years|No|||January 2016|January 13, 2016|August 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659762||81326|
NCT01659775|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LG-SCSCL001|Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)|A Multicenter, Randomized, Open-label, Paralleled-group, Active-controlled, Phase IV Study to Evaluate the Efficacy and Safety of Sancuso Patch (Granisetron) in Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic (HE) Chemotherapy||LG Life Sciences|No|Completed|August 2011|November 2012|Actual|November 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|389|||Both|20 Years|N/A|No|||January 2012|July 23, 2013|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01659775||81325|
NCT01659788|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CoEnzyme Q10-HMO-CTIL|Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age|Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age||Hadassah Medical Organization|No|Not yet recruiting|September 2012|September 2014|Anticipated|September 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Anticipated|100|||Female|38 Years|43 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01659788||81324|
NCT01661179|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|D4200C00098|Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma|A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma||AstraZeneca|No|Completed|November 2012|July 2014|Actual|December 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|16|||Both|20 Years|N/A|No|||May 2015|May 29, 2015|July 17, 2012|Yes|Yes||No|December 8, 2014|https://clinicaltrials.gov/show/NCT01661179||81219|
NCT01651702|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|0067-12-RMC|Comparison of Carto Versus Ensite 3D Electroanatomical Mapping Systems for Arrhythmias Ablations|Comparative Study of Two 3D Electroanatomical Mapping Systems for Ablations of Different Complex Arrhythmias||Rabin Medical Center|No|Suspended|July 2015|October 2016|Anticipated|July 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|70|||Both|18 Years|80 Years|No|||November 2014|November 4, 2014|July 23, 2012||No|Poor recruit rate|No||https://clinicaltrials.gov/show/NCT01651702||81939|
NCT01660685|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|39952EP|Effects of Journaling on Weight Loss|Effects of Journaling on Weight Loss||Milton S. Hershey Medical Center|No|Completed|August 2012|January 2013|Actual|January 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|100|||Both|21 Years|65 Years|No|||January 2013|January 31, 2013|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01660685||81257|
NCT01652469|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ETOP3-12|Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.|A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor|EMPHASIS|European Thoracic Oncology Platform|Yes|Completed|August 2012|December 2015|Actual|December 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|81|||Both|18 Years|N/A|No|||January 2016|January 22, 2016|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01652469||81880|
NCT01649661|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-125|MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk|Epidemiology of MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk||Memorial Sloan Kettering Cancer Center||Active, not recruiting|July 2012|July 2016|Anticipated|July 2016|Anticipated|N/A|Observational|Observational Model: Case-Crossover, Time Perspective: Prospective||2|Anticipated|420|Samples Without DNA|Blood sample collected at time of MRI for serum hormone analysis Postmenopausal women only|Female|21 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|The proposed study will involve cancer-free women who are undergoing breast MRI screening        at MSKCC.|August 2015|August 14, 2015|July 19, 2012||No||No||https://clinicaltrials.gov/show/NCT01649661||82096|
NCT01649674|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PRECOL2011-1|Comparison of Bowel Cleansing Regimens Prior to Colonoscopy|PRECOL2011-1: Sodium Picophosphate and Magnesium Citrate Versus Polyethylene Glycol as Evacuating Treatment Prior to Colonoscopy: Phase IV Randomized Trial.|PRECOL2011-1|National Cancer Institute, Naples|No|Active, not recruiting|November 2011|December 2016|Anticipated|July 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|525|||Both|18 Years|N/A|No|||November 2015|November 27, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649674||82095|
NCT01653015|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RC1-274129|Live Versus Inactivated Influenza Vaccine Study in Hutterite Children|A Randomized Controlled Trial of Live Attenuated Vaccine Versus Trivalent Inactivated Vaccine in Hutterite Children||McMaster University|No|Active, not recruiting|November 2012|December 2015|Anticipated|December 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|3800|||Both|N/A|N/A|Accepts Healthy Volunteers|||July 2015|July 2, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653015||81838|
NCT01653249|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|130662|A Phase I Clinical Trial of an HPV Therapeutic Vaccine|A Phase I Clinical Trial of an HPV Therapeutic Vaccine||University of Arkansas|Yes|Completed|August 2012|July 2015|Actual|July 2015|Actual|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label|1||Anticipated|60|||Female|18 Years|50 Years|No|||July 2015|July 15, 2015|July 26, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01653249||81820|
NCT01661114|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UMCC 2011.036|A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers|A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers||University of Michigan Cancer Center|Yes|Active, not recruiting|July 2011|July 2016|Anticipated|December 2014|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|39|||Both|18 Years|N/A|No|||January 2016|January 5, 2016|July 24, 2012|Yes|Yes||No|January 5, 2016|https://clinicaltrials.gov/show/NCT01661114||81224|
NCT01661348|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Prevena-Smith|The Use of the Prevena Incision Management System to Reduce Post-operative Cesarean Delivery Wound Complications|Reduction of Post Operative Wound Complications in Patients Undergoing Cesarean Delivery With the Use of the Prevena Incision Management System||University of Oklahoma|No|Withdrawn|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|0|||Female|18 Years|45 Years|No|Probability Sample|All eligible patients will be approached for consent to participate in the study prior to        surgical procedure.|October 2013|October 15, 2013|July 26, 2012||No|Did not receive funding.|No||https://clinicaltrials.gov/show/NCT01661348||81206|
NCT01661881|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-168|Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma|A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma||Dana-Farber Cancer Institute|Yes|Active, not recruiting|August 2012|August 2019|Anticipated|May 2015|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|23|||Both|18 Years|69 Years|No|||August 2015|August 7, 2015|July 15, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01661881||81165|
NCT01662102|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SPI-ZEV-12-302|Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)|An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy||Spectrum Pharmaceuticals, Inc|No|Terminated|September 2012|July 2013|Actual|July 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1|||Both|18 Years|75 Years|No|||December 2015|December 4, 2015|August 3, 2012|Yes|Yes|Sponsor decision|No|October 16, 2015|https://clinicaltrials.gov/show/NCT01662102||81148|
NCT01662310|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CR100427|An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia|Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study||Janssen Research & Development, LLC|Yes|Completed|June 2011|April 2013|Actual|April 2013|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|3||Actual|201|||Both|18 Years|N/A|No|||September 2014|September 15, 2014|March 29, 2012|Yes|Yes||No|April 30, 2014|https://clinicaltrials.gov/show/NCT01662310||81133|Independent Data Monitoring Committee (IDMC) conducted an interim analysis after 61st relapse in double-blind (DB) phase and DB phase completed on 09-Nov-2012 based on positive results of interim analysis.
NCT01659216|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2004T004A|The Long-term Efficacy of Electrical Pudendal Nerve Stimulation for the Urgency-Frequency Syndrome in Women|The Long-term Efficacy of Electrical Pudendal Nerve Stimulation for the Urgency-Frequency Syndrome in Women||Shanghai Institute of Acupuncture, Moxibustion and Meridian|Yes|Completed|January 2002|May 2012|Actual|March 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|90|||Female|27 Years|81 Years|No|Probability Sample|female UFS patients with ≥50% symptom improvement at the end of EPNS treatment|August 2012|August 6, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659216||81368|
NCT01659515|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S-11-0001|Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria|Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria||U.S. Army Medical Research and Materiel Command||Available||||||N/A|Expanded Access|N/A|||||||Both|18 Years|N/A||||October 2015|October 28, 2015|August 3, 2012|Yes|Yes||||https://clinicaltrials.gov/show/NCT01659515||81345|
NCT01660100|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|LIBERATION|Outcome of Atrial Fibrillation Ablation After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation|Freedom From Atrial Arrhythmia in Atrial Fibrillation Patients After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation||Texas Cardiac Arrhythmia Research Foundation|No|Recruiting|July 2012|December 2018|Anticipated|December 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|400|||Both|18 Years|N/A|No|||March 2016|March 8, 2016|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01660100||81300|
NCT01660113|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TRIA-FAN-064|[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]||[Redacted]||Withheld|March 2012|||||N/A|N/A|N/A||||||||||||||February 5, 2013|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01660113||81299|
NCT01660399|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CIH-CHP-201205001|Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy|Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial||Tianjin Medical University Cancer Institute and Hospital|Yes|Recruiting|August 2012|December 2016|Anticipated|November 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|300|||Both|18 Years|N/A|No|||August 2012|December 21, 2015|August 5, 2012||No||No||https://clinicaltrials.gov/show/NCT01660399||81279|
NCT01650935|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|114|Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria|Study of the Effects of DASH Style Diet and Oxalate Restricted Diet on Urinary Supersaturation Which is a Major Predisposing Factor for Nephrolithiasis||hahid Beheshti University of Medical Sciences|Yes|Completed|September 2012|April 2013|Actual|February 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|48|||Both|18 Years|70 Years|No|||April 2013|April 15, 2013|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650935||81998|
NCT01651182|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TXA Liver - PK|Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection|Open Label, Non-Randomized, Study to Evaluate the Pharmacokinetics of Tranexamic Acid in Patients Undergoing Major Liver Resection||Sunnybrook Health Sciences Centre|No|Completed|March 2014|February 2015|Actual|February 2015|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Actual|24|||Both|18 Years|N/A|No|||September 2015|September 17, 2015|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651182||81979|
NCT01660126|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GN11GE272|Thyroid Hormone Replacement for Subclinical Hypothyroidism|Multi-modal Effects of Thyroid Hormone Replacement for Untreated Older Adults With Subclinical Hypothyroidism; a Randomised Placebo-controlled Trial|TRUST|NHS Greater Glasgow and Clyde|Yes|Recruiting|May 2014|February 2017|Anticipated|November 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|540|||Both|65 Years|N/A|No|||July 2015|July 1, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660126||81298|
NCT01660139|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|STU67142|Use of Alternative Medicine Among Outpatients in Dermatology and Primary Care Clinics|Use of Alternative Medicine Among Outpatients in Dermatology and Primary Care Clinics||Northwestern University|No|Recruiting|July 2012|October 2015|Anticipated|October 2015|Anticipated|N/A|Observational|Time Perspective: Prospective||2|Anticipated|400|||Both|18 Years|N/A|Accepts Healthy Volunteers|Non-Probability Sample|Patients attending clinic appointments in dermatology and primary care clinics.|May 2015|May 13, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01660139||81297|
NCT01651949|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|V503-003|Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)|A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women||Merck Sharp & Dohme Corp.|No|Completed|October 2012|August 2014|Actual|August 2014|Actual|Phase 3|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|3||Actual|2520|||Both|16 Years|26 Years|Accepts Healthy Volunteers|||August 2015|August 4, 2015|July 25, 2012|Yes|Yes||No|February 24, 2015|https://clinicaltrials.gov/show/NCT01651949||81920|
NCT01651936|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|8457-010|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Subjects With Active Rheumatoid Arthritis and an Inadequate Response or Intolerance for Anti-TNF-α Therapy||Merck Sharp & Dohme Corp.|No|Terminated|August 2012|October 2013|Actual|October 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|56|||Both|18 Years|N/A|No|||October 2015|October 8, 2015|July 25, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651936||81921|
NCT01652235|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|07-003|Zenith® p-Branch® and Zenith® Fenestrated AAA Endovascular Graft Clinical Study|Study Assessing Safety and Effectiveness of Perivisceral Aortic Aneurysm Treatment With the Zenith® Fenestrated AAA Endovascular Graft and the Zenith® p-Branch® and the Effects on Organ and Extremity Perfusion|FENP|Cook|Yes|Recruiting|July 2008|April 2023|Anticipated|October 2018|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|40|||Both|18 Years|N/A|No|||February 2016|February 9, 2016|July 17, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652235||81898|
NCT01652482|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GO28074|A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer|A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer||Genentech, Inc.||Completed|October 2012|November 2014|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment|2||Actual|135|||Both|18 Years|N/A|No|||March 2016|March 1, 2016|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01652482||81879|
NCT01658436|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CBEZ235F2201|BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.|A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.||Novartis|Yes|Completed|November 2012|July 2015|Actual|July 2015|Actual|Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|31|||Both|18 Years|N/A|No|||October 2015|October 5, 2015|July 6, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658436||81426|
NCT01658956|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Institut Jules Bordet|Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia|A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia|PAPALDO|Jules Bordet Institute|No|Recruiting|July 2012|July 2015|Anticipated|July 2015|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Anticipated|142|||Female|N/A|N/A|No|||January 2015|January 5, 2015|July 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01658956||81387|
NCT01653028|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NCI-2012-01991|Alisertib in Treating Patients With Advanced or Metastatic Sarcoma|Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma||National Cancer Institute (NCI)||Suspended|August 2012|||February 2016|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|72|||Both|18 Years|N/A|No|||October 2015|February 2, 2016|July 26, 2012|Yes|Yes|Temporarily stopped for assessment.|No||https://clinicaltrials.gov/show/NCT01653028||81837|
NCT01653262|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|N01395|Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)|An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b||UCB Pharma|No|Completed|July 2012|November 2013|Actual|November 2013|Actual|Phase 3|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|29|||Both|16 Years|N/A|No|||July 2015|July 13, 2015|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01653262||81819|
NCT01653535|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|5R01DA016903|Multisite Prevention of Conduct Problems (Fast Track)|Multisite Prevention of Conduct Problems||Duke University|No|Active, not recruiting|March 1991|December 2020|Anticipated|December 2020|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention|2||Actual|891|||Both|6 Years|8 Years|Accepts Healthy Volunteers|||August 2015|August 28, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01653535||81798|
NCT01653548|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Pro00035922|Evaluating a Novel Method of Generalizing Emotion Regulation|Evaluating a Novel Method of Generalizing Emotion Regulation|EMOGEN|Duke University|No|Recruiting|August 2012|September 2016|Anticipated|March 2016|Anticipated|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science|3||Anticipated|250|||Both|18 Years|55 Years|No|||August 2015|August 6, 2015|July 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01653548||81797|
NCT01661127|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PNUHDM-psoriasis|Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis|Phase 0 Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis||Pusan National University Hospital|No|Recruiting|June 2012|December 2015|Anticipated|June 2015|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|10|Samples Without DNA|Peripheral blood and 18-F-FDG PET/CT images|Both|18 Years|N/A|No|Non-Probability Sample|Patients of diagnosed with psoriasis in Pusan National University Hospital|November 2014|November 3, 2014|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661127||81223|
NCT01661361|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|S54585|Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices|Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices||Universitaire Ziekenhuizen Leuven|No|Not yet recruiting|September 2012|December 2012|Anticipated|December 2012|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|15|Samples Without DNA|blood samples|Both|18 Years|N/A|No|Non-Probability Sample|Adult patients admitted for catheter related infection with methicillin-resistant        coagulase-negative staphylococci (MR-CNS) and treated with systemic vancomycin in        combination with vancomycin antibiotic lock via central venous port device.|August 2012|August 8, 2012|July 20, 2012||No||No||https://clinicaltrials.gov/show/NCT01661361||81205|
NCT01661374|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM14433|The Effect of Humidification on Mucus Rheology|The Effect of Humidification on Mucus Rheology||Virginia Commonwealth University|No|Completed|July 2012|April 2014|Actual|April 2014|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Prospective||2|Actual|18|Samples With DNA|Sputum|Both|40 Years|90 Years|No|Non-Probability Sample|Primary Care Clinic,ICU, Pulmonary Clinic|December 2014|December 9, 2014|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01661374||81204|
NCT01661894|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|11-363|Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly|Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly|3ECog|Duke-NUS Graduate Medical School|No|Completed|April 2012|April 2014|Actual|April 2014|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|82|||Both|60 Years|70 Years|Accepts Healthy Volunteers|||July 2014|July 24, 2014|May 17, 2012||No||No||https://clinicaltrials.gov/show/NCT01661894||81164|
NCT01658852|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Gastrectomy-MDZ-001|Effects and Safety of Metronidazole in Patients With Gastrectomy|||The Catholic University of Korea||Active, not recruiting|May 2011|May 2014|Anticipated|May 2014|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|170|||Both|18 Years|70 Years|No|||August 2012|August 6, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01658852||81395|
NCT01659177|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|14511|A Study of LY2140023 in Healthy Participants|The Effect of Food on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects After Administration of the Commercial Tablet Formulation of LY2140023||Eli Lilly and Company|No|Withdrawn|August 2012|September 2012|Anticipated|September 2012|Anticipated|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science|2||Actual|0|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2012|September 28, 2012|August 3, 2012|No|Yes|The decision to stop the trial was based on efficacy results in the overall schizophrenia    patient population.|No||https://clinicaltrials.gov/show/NCT01659177||81371|
NCT01662323|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TOPHU01|Study to Improve the Treatment of Patients With Heart Failure by General Practitioners|Therapy OPtimization Heart Failure Utrecht|TOPHU|Julius Center|No|Completed|June 2009|June 2012|Actual|June 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment|2||Actual|683|||Both|18 Years|N/A|No|||November 2012|November 13, 2012|August 2, 2012||No||No||https://clinicaltrials.gov/show/NCT01662323||81132|
NCT01659190|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|I10028|The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage?|The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage?|LINIPOCHE|University Hospital, Limoges|No|Completed|August 2012|December 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|136|||Both|N/A|36 Months|No|||June 2012|January 10, 2014|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659190||81370|
NCT01659229|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|63214040|Fluoroscopic Analysis of PFC CR 150 Versus Standard PFC CR Total Knee Arthroplasty Implants in Deep Flexion|Fluoroscopic Analysis Comparing the Dynamic Flexion of 2 Different Knee Arthroplasty Implants||Singapore General Hospital|No|Active, not recruiting|October 2011|December 2012|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|12|||Both|50 Years|95 Years|No|Non-Probability Sample|All patients who underwent total knee replacement surgery who received either the PFC CR        150 knee implants or the PFC CR standard knee implant|August 2012|August 16, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659229||81367|
NCT01659242|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YK 01-2012|Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study|Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis Patients With Active Disease Despite Methotrexate: an Ultrasound and Magnetic Resonance Imaging Study||Singapore General Hospital|No|Terminated|July 2012|||December 2012|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment|2||Actual|1|||Both|21 Years|65 Years|No|||November 2014|November 26, 2014|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01659242||81366|
NCT01659528|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CMC-11-0028-CTIL|Establishing Nomograms of Penile Length and Width Throughout the Weeks of Pregnancy|Establishing Nomograms of Penile Length and Width Throughout the Weeks of Pregnancy - A Prospective Descriptive Study.||Carmel Medical Center|No|Withdrawn|July 2012|July 2014|Anticipated|July 2014|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|0|||Female|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|Pregnant women addressing for routine ultrasound scan at the ultrasound unit.|January 2013|January 31, 2013|August 5, 2012||No|A similar article was already published by another investigator.|No||https://clinicaltrials.gov/show/NCT01659528||81344|
NCT01650948|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|SQNM-AMD-106|Genetic Load and Phenotype in Aggressive AMD|Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.|RPED Genetics|Sequenom, Inc.|No|Completed|July 2012|December 2013|Actual|December 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||2|Actual|100|Samples With DNA|DNA samples and remnants will be destroyed after analysis.|Both|50 Years|N/A|No|Probability Sample|Patients with AMD who are or have been treated with anti-VEGF therapy|January 2014|January 16, 2014|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650948||81997|
NCT01650961|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|YSJeon_palonosetron_QTc|The Effect of Palonosetron on the QTc Interval During Perioperative Period|The Effect of Palonosetron on the QTc Interval During Perioperative Period||Seoul National University Hospital||Completed|July 2012|February 2013|Actual|December 2012|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention|2||Actual|100|||Both|20 Years|N/A|No|||August 2013|August 6, 2013|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650961||81996|
NCT01651195|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|189/13/03/00/11|Probiotics and Infections in Conscripts in Military Service|Probiotic and Respiratory and Gastrointestinal Tract Infections in Finnish Military Conscripts - a Randomized and Placebo-controlled Double-blinded Study||Helsinki University Central Hospital||Active, not recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention|2||Anticipated|900|||Both|18 Years|40 Years|Accepts Healthy Volunteers|||January 2016|January 7, 2016|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651195||81978|
NCT01651481|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HM-MOLZ-102|Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination|Open-label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics and Safety of Singulair (10 mg) and Xyzal (5 mg) in Free Combination and Fixed-dose Combination as HCP1102 in Healthy Male Volunteers||Hanmi Pharmaceutical Company Limited|No|Completed|July 2012|December 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|28|||Male|20 Years|55 Years|Accepts Healthy Volunteers|||August 2013|August 12, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651481||81956|
NCT01651442|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01MH091053-01|Sequenced Therapies for Comorbid and Primary Insomnias|Sequenced Therapies for Comorbid and Primary Insomnias||National Jewish Health|Yes|Recruiting|June 2011|||February 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|4||Anticipated|224|||Both|21 Years|N/A|No|||April 2015|April 24, 2015|June 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01651442||81959|
NCT01651455|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MAESTRALE|Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000|Maintaining Lung Function in Cystic Fibrosis Patients: Evaluation and Comparison Between Two Decades in a Retrospective Monocentric Observational Study|MAESTRALE|Chiesi Farmaceutici S.p.A.|Yes|Completed|September 2012|June 2013|Actual|March 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Retrospective||2|Actual|92|||Both|10 Years|15 Years|No|Probability Sample|Patients affected with Pseudomonas A. living in the N-E area of Italy.|July 2013|July 30, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651455||81958|
NCT01651468|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|HEMOFIX- HMO-CTIL|The Effect of the Nutraceutical "Hemofix" on the Coagulation System|Phase 1 Study of the Nutraceutical "Hemofix" Safety and Effect on the Coagulation System||Hadassah Medical Organization|No|Not yet recruiting|September 2012|December 2013|Anticipated|February 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Anticipated|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||July 2012|July 28, 2012|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651468||81957|
NCT01651962|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0412|Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement|Intravenous Terbutaline to Facilitate Epidural Catheter Placement for Parturients With Labor Pain||University of Arizona|No|Recruiting|August 2012|December 2015|Anticipated|July 2015|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|3||Anticipated|250|||Female|18 Years|53 Years|No|||January 2015|January 15, 2015|July 20, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651962||81919|
NCT01652248|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|08/H1307/47|Pacemaker Upgrade to Cardiac Resynchronisation Therapy in Patients With Left Ventricular Dysfunction Dependant Upon Right Ventricular Pacing|Pacemaker Upgrade to Cardiac Resynchronisation Therapy in Patients With Left Ventricular Dysfunction Dependant Upon Right Ventricular Pacing.|PRE-Empt|University of Leeds|No|Completed|April 2008|May 2012|Actual|December 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention|2||Actual|50|||Both|18 Years|N/A|No|||December 2015|December 1, 2015|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01652248||81897|
NCT01653041|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRAD001ABR26T|Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors|Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors||Hospital do Rim e Hipertensão|No|Active, not recruiting|August 2012|August 2015|Anticipated|August 2014|Actual|Phase 4|Interventional|Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|100|||Both|18 Years|N/A|No|||March 2015|March 20, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653041||81836|
NCT01653561|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2012-08|A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer|A Multi-institutional, Open-label, Single Arm Study of Apatinib in Non-triple-negative Metastatic Breast Cancer||Fudan University|Yes|Completed|November 2011|October 2012|Actual|October 2012|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|20|||Female|18 Years|70 Years|No|||August 2013|December 2, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01653561||81796|
NCT01653574|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Fudan BR2012-10|A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer|A Single-Institutional, Phase II, Open-label, Single Arm Trial of Famitinib Malate in in HER2-negative Metastatic Breast Cancer||Fudan University|Yes|Completed|May 2012|November 2013|Actual|November 2013|Actual|Phase 2|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|28|||Female|18 Years|70 Years|No|||March 2013|December 1, 2013|July 10, 2012||No||No||https://clinicaltrials.gov/show/NCT01653574||81795|
NCT01649635|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CABAZ_L_06003|Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer|A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context.|PROSPECTA|Sanofi|No|Active, not recruiting|July 2012|June 2016|Anticipated|January 2014|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|45|||Male|18 Years|N/A|No|||July 2015|July 7, 2015|July 20, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01649635||82098|
NCT01649648|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NMRC/EDG/1032/2, EDG09nov061|Autologous Cord Blood Cells for Brain Injury in Term Newborns|Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy: Phase I Study of Feasibility and Safety||National University Hospital, Singapore|No|Recruiting|September 2011|September 2015|Anticipated|September 2013|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|10|||Both|N/A|3 Days|No|||April 2012|July 24, 2012|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649648||82097|
NCT01661387|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Protocol 0918-400|A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency|A European, Multi-Centre, Multi-Country, Post-Authorisation, Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency||Shire|No|Recruiting|August 2012|||August 2017|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||2|Anticipated|1656|||Both|N/A|N/A|No|Non-Probability Sample|Patients with chronic adrenal insufficiency (primary or secondary) who are receiving        Plenadren or other glucocorticoid replacement therapies at endocrinology centres in        certain European countries as part of their routine clinical care. Approximately 20 sites        are planned for enrollment.|November 2015|November 30, 2015|August 6, 2012||No||No||https://clinicaltrials.gov/show/NCT01661387||81203|
NCT01661400|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|201209088|Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors|Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors|ASCR|Washington University School of Medicine|No|Recruiting|October 2012|February 2020|Anticipated|February 2017|Anticipated|Phase 0|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|3||Anticipated|12|||Both|1 Year|21 Years|No|||May 2015|May 14, 2015|July 30, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01661400||81202|
NCT01661595|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-153|The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue|The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue.||The University of Texas Medical Branch, Galveston|Yes|Completed|November 2012|June 2015|Actual|June 2015|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment|3||Actual|30|||Both|50 Years|60 Years|Accepts Healthy Volunteers|||December 2015|December 3, 2015|August 7, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01661595||81187|
NCT01658332|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-A00135-38|Circulating Tumor Cells in Lung Cancer|Circulating Tumor Cells Identification in Advanced Stage Non-small Cell Lung Cancer|CIRCUBRONCH|Central Hospital, Nancy, France|No|Terminated|June 2012|December 2017|Anticipated|December 2017|Anticipated|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic|1||Actual|59|||Both|N/A|N/A|No|||July 2015|July 29, 2015|June 16, 2012||No|unavailability of the investigator due to an overloaded planning|No||https://clinicaltrials.gov/show/NCT01658332||81434|
NCT01658865|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NE-EM-001|Assessment of Esophageal Motility With Transnasal Endoscopy|||The Catholic University of Korea||Recruiting|July 2011|October 2012|Anticipated|September 2012|Anticipated|N/A|Observational|Observational Model: Case-Only, Time Perspective: Prospective||1|Anticipated|40|||Both|18 Years|70 Years|Accepts Healthy Volunteers|Non-Probability Sample|Patients with esophageal motility disorder Healthy volunteer|August 2012|August 3, 2012|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01658865||81394|
NCT01659203|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-100|Proton or Photon RT for Retroperitoneal Sarcomas|Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) With Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas||Massachusetts General Hospital|Yes|Recruiting|December 2012|||December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|80|||Both|18 Years|N/A|No|||January 2016|January 19, 2016|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659203||81369|
NCT01650428|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|UCL/09/0176|Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery|A Phase II, Multicentre, Open-Label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients With MRI Defined High-Risk Cancer of the Rectum|BACCHUS|University College, London|Yes|Active, not recruiting|April 2013|December 2017|Anticipated|October 2017|Anticipated|Phase 2|Interventional|Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|60|||Both|18 Years|75 Years|No|||May 2015|September 9, 2015|July 16, 2012||No||No||https://clinicaltrials.gov/show/NCT01650428||82037|
NCT01650441|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|PML_DOC_1102|Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients|OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN ASTHMATIC PATIENTS.||University Hospital, Antwerp|No|Completed|April 2012|June 2013|Actual|June 2013|Actual|Phase 2|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|31|||Both|18 Years|N/A|No|||May 2015|May 27, 2015|June 29, 2012||No||No||https://clinicaltrials.gov/show/NCT01650441||82036|
NCT01659541|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IRB 15-00014|Stimulation With Wire Leads to Restore Cough|Spinal Cord Stimulation With Wire Leads to Restore Cough||Case Western Reserve University|Yes|Recruiting|April 2015|August 2019|Anticipated|February 2019|Anticipated|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Anticipated|16|||Both|18 Years|75 Years|No|||January 2016|January 28, 2016|May 23, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659541||81343|
NCT01651208|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1RC1MD004327|Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations|Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations||University of Miami|No|Completed|January 2010|June 2012|Actual|November 2011|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research|2||Actual|452|||Both|N/A|N/A|No|||August 2014|August 5, 2014|July 24, 2012||No||No|May 14, 2014|https://clinicaltrials.gov/show/NCT01651208||81977|
NCT01651494|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-0009|Influenza Antiviral DAS-181-F04 in Healthy Adults|A Phase 1 Clinical Study With Influenza Antiviral DAS181-F04: Double-Blind, Randomized, Placebo-Controlled, Multi Dose Study in Healthy Adults||National Institute of Allergy and Infectious Diseases (NIAID)||Completed|August 2012|September 2012|Actual|September 2012|Actual|Phase 1|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|9|||Both|18 Years|45 Years|Accepts Healthy Volunteers|||May 2013|November 7, 2013|July 12, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01651494||81955|
NCT01651715|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ESTUAR001|Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections|Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Study Evaluating the Efficacy and Safety of Early Self-Treatment of Viral Upper Respiratory Tract Infections With Homeopathic Oral Antibodies to the TLR3 FYW Peptide (TAO1)|ESTUAR|Theranor s.p.r.l|No|Completed|September 2012|August 2013|Actual|August 2013|Actual|Phase 1/Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|232|||Both|18 Years|N/A|No|||August 2013|August 5, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651715||81938|
NCT01652495|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2012-000866-40|Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection|Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy|TPESP2011-12|Istituto Ortopedico Rizzoli|No|Completed|March 2012|May 2013|Actual|May 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment|2||Actual|44|||Both|18 Years|70 Years|No|||August 2014|August 23, 2014|July 21, 2012|No|Yes||No|March 22, 2014|https://clinicaltrials.gov/show/NCT01652495||81878|
NCT01652261|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EORTC-20101-23101|Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)|Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group|H11|European Organisation for Research and Treatment of Cancer - EORTC|Yes|Withdrawn|May 2013|March 2022|Anticipated|March 2020|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|60 Years|No|||June 2014|June 13, 2014|July 18, 2012||No|Study closed due to lack of recruitment|No||https://clinicaltrials.gov/show/NCT01652261||81896|
NCT01653587|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|ISCMM-01|AngioSeal Versus Radial Approach in Acute Coronary Syndrome|Randomized Trial Between the Transfemoral Approach With AngioSeal and the Transradial Approach to Prevent Vascular Access Complications in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Submitted To Early Invasive Strategy|ARISE|Irmandade Santa Casa Misericórdia Marília|No|Active, not recruiting|July 2012|March 2016|Anticipated|March 2015|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care|2||Actual|240|||Both|18 Years|N/A|No|||March 2015|March 2, 2015|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653587||81794|
NCT01658696|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VAC047|Efficacy of Candidate Malaria Vaccines in Senegalese Adults|Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection||University of Oxford|Yes|Completed|August 2012|February 2013|Actual|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention|2||Actual|120|||Male|18 Years|50 Years|Accepts Healthy Volunteers|||December 2013|December 11, 2013|July 31, 2012||No||No||https://clinicaltrials.gov/show/NCT01658696||81407|
NCT01649921|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|IFN_sepsis|The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis|The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis, a Randomised Double-blind Placebo-controlled Pilot (Phase IIIb) Study||Radboud University|Yes|Recruiting|November 2012|December 2016|Anticipated|December 2016|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|20|||Both|18 Years|N/A|No|||April 2014|April 11, 2014|July 23, 2012||No||No||https://clinicaltrials.gov/show/NCT01649921||82076|
NCT01650181|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GAS-399-11/11/1|Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis|Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|Yes|Completed|November 2011|June 2014|Actual|March 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|2||Actual|50|||Both|18 Years|65 Years|No|||August 2014|August 18, 2014|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01650181||82056|
NCT01650506|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|AAAF3743|Study of Erlotinib and Metformin in Triple Negative Breast Cancer|Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer||Columbia University|Yes|Active, not recruiting|July 2012|September 2016|Anticipated|June 2016|Anticipated|Phase 1|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Female|18 Years|79 Years|No|||March 2016|March 17, 2016|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01650506||82031|
NCT01661413|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|1000030743|Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy|Chemotherapy-induced Nausea and Vomiting in Children Receiving Intrathecal Methotrexate With/Without Vincristine||The Hospital for Sick Children|No|Recruiting|July 2012|||December 2013|Anticipated|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Anticipated|100|||Both|4 Years|18 Years|No|Non-Probability Sample|Receiving intrathecal methotrexate in the context of maintenance therapy for acute        lymphoblastic leukemia and as dosed by age per protocol. Patients will also receive their        protocol driven maintenance chemotherapy which includes oral 6 mercaptopurine and may        include IV vincristine and an oral steroid pulse (prednisone or dexamethasone). Oral        methotrexate is typically held the weeks that patients receive intrathecal methotrexate        during maintenance therapy.|July 2013|July 26, 2013|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01661413||81201|
NCT01661608|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TPR41122|Gastric Restriction Using the EndoSurgical Operating System|Gastric Restriction Using the EndoSurgical Operating System||USGI Medical|Yes|Terminated|December 2008|January 2010|Actual|January 2010|Actual|N/A|Interventional|Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science|1||Actual|32|||Both|20 Years|60 Years|Accepts Healthy Volunteers|||August 2012|August 7, 2012|August 7, 2012|No|Yes|FDA indicated study should have had prior IDE submission & approval|No||https://clinicaltrials.gov/show/NCT01661608||81186|
NCT01661621|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|TCGHUROL002|Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1|Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers||Buddhist Tzu Chi General Hospital|No|Completed|August 2012|August 2013|Actual|August 2013|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|395|||Male|40 Years|N/A|No|||June 2014|June 23, 2014|August 2, 2012||No||No|April 21, 2014|https://clinicaltrials.gov/show/NCT01661621||81185|
NCT01658358|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|EGF114081|ErbB2 Positive Metastatic Breast Cancer|A Phase I/II Study of Lapatinib (Tykerb) Plus Liposomal Doxorubicin Hydrochloride ( Lipo-Dox) for Patients With ErbB2 Positive Metastatic Breast Cancer||China Medical University Hospital|No|Terminated|July 2012|September 2014|Anticipated|September 2014|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|15|||Female|18 Years|75 Years|No|||February 2013|February 26, 2013|August 1, 2012||No||No||https://clinicaltrials.gov/show/NCT01658358||81432|
NCT01658371|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRE-2008.180|Preference of Genetic Polymorphism and Pharmacokinetics|Preference of CYP450 2B6 516 G>T Polymorphism and Pharmacokinetics of Plasma Efavirenz in A Group of HIV Infected Southern Chinese||Chinese University of Hong Kong|No|Completed|May 2008|June 2010|Actual|December 2009|Actual|N/A|Observational|Time Perspective: Cross-Sectional||1|Actual|100|||Both|N/A|N/A|No|Non-Probability Sample|Southern Chinese HIV patients|August 2012|August 2, 2012|February 27, 2012||No||No||https://clinicaltrials.gov/show/NCT01658371||81431|
NCT01658592|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|NAc-VC DBS for alcohol addict|Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule for Severe Alcohol Addiction|Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule as a Novel Treatment in Severe Alcohol Addiction||Tang-Du Hospital|Yes|Recruiting|July 2012|March 2014|Anticipated|March 2014|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment|4||Anticipated|20|||Both|18 Years|50 Years|No|||August 2012|August 2, 2012|July 26, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01658592||81415|
NCT01658605|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|115393|A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis|A Phase II, 20-week, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Proof of Concept Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis||GlaxoSmithKline||Withdrawn|February 2013|December 2014|Anticipated|February 2013|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Actual|0|||Both|18 Years|N/A|No|||June 2013|June 20, 2013|May 24, 2012||No|Study CCX115383 has been terminated prior to enrolment of any patients. A decision was made by    GSK to delay pursuit of this indication as the biology evolves.|No||https://clinicaltrials.gov/show/NCT01658605||81414|
NCT01658878|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CA209-040|Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Subjects With Advanced Liver Cancer|A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic Therapy||Bristol-Myers Squibb|Yes|Recruiting|September 2012|July 2018|Anticipated|December 2016|Anticipated|Phase 1/Phase 2|Interventional|Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|6||Anticipated|600|||Both|18 Years|N/A|No|||November 2015|March 11, 2016|August 3, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01658878||81393|
NCT01650701|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|RV-FOL-GELARC-0683|A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma|A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.|RELEVANCE|The Lymphoma Academic Research Organisation|Yes|Active, not recruiting|February 2012|June 2024|Anticipated|June 2024|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|1031|||Both|18 Years|N/A|No|||March 2015|March 30, 2015|July 24, 2012|No|Yes||No||https://clinicaltrials.gov/show/NCT01650701||82016|
NCT01650974|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|E-1205-154-002|High Flow Nasal OXygen Therapy in High Risk Patients of Hypoxia Undergoing Diagnostic BRONCHOscopy|High Flow Nasal OXygen Therapy in High Risk Patients of Hypoxia Undergoing Diagnostic BRONCHOscopy: A Prospective, Randomized, Controlled Study|HFNOT|Seoul National University Hospital|Yes|Recruiting|July 2012|June 2016|Anticipated|June 2016|Anticipated|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care|3||Anticipated|152|||Both|19 Years|N/A|No|||December 2015|December 16, 2015|July 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01650974||81995|
NCT01650675|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|R01DA029050|Indirect Assessment and Intervention for Perinatal Drug Use|Indirect Assessment and Intervention for Perinatal Drug Use||Wayne State University|No|Completed|June 2012|May 2015|Actual|November 2014|Actual|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening|2||Actual|500|||Female|18 Years|45 Years|No|||December 2015|December 7, 2015|July 13, 2012||No||No||https://clinicaltrials.gov/show/NCT01650675||82018|
NCT01650688|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|4-2012-0315|Difference in Grades of Epiblepharon According to Positional Changes and General Anesthesia|||Yonsei University|No|Active, not recruiting|July 2012|September 2012|Anticipated|July 2012|Actual|N/A|Observational|Observational Model: Case-Only, Time Perspective: Retrospective||1|Anticipated|63|||Both|1 Year|12 Years|No|Non-Probability Sample|Subjects with epiblepharon which needed surgical correction|July 2012|July 23, 2012|July 15, 2012||No||No||https://clinicaltrials.gov/show/NCT01650688||82017|
NCT01651741|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|911029-1|Effects of Seaweeds Combined With Probiotics on Intestinal Function of Healthy Subjects|Effects of Seaweeds Combined With Probiotics on Intestinal Function of Healthy Subjects: a Randomized, Double-blind, Placebo-controlled, Waiting-list Clinical Trial||Korea Institute of Planning & Evalution for Technology of Food, Agriculture, Forestry & Fisherie|Yes|Completed|May 2012|July 2013|Actual|July 2013|Actual|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention|2||Actual|40|||Both|18 Years|75 Years|Accepts Healthy Volunteers|||September 2013|September 20, 2013|July 25, 2012||No||No||https://clinicaltrials.gov/show/NCT01651741||81936|
NCT01651975|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|200917127|Evaluation of Two Different Thickening Products in Patients With Dysphagia|Evaluation of Two Different Thickening Products in Patients With Dysphagia||University of California, Davis|No|Completed|November 2009|April 2011|Actual|April 2011|Actual|Phase 4|Interventional|Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care|1||Actual|100|||Both|18 Years|N/A|No|||April 2013|April 22, 2013|January 24, 2012||No||No||https://clinicaltrials.gov/show/NCT01651975||81918|
NCT01651728|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|48/PT02.FK/ETIK/2012|Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients|Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients: A Study of Immunological, Inflammatory, and Coagulation Responses in Relation to Reduce Mortality During Hospitalization||Indonesia University|Yes|Recruiting|July 2012|September 2013|Anticipated|August 2013|Anticipated|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment|2||Anticipated|200|||Both|60 Years|N/A|No|||August 2012|August 2, 2012|July 24, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01651728||81937|
NCT01652274|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|B 30 2 FTH 0 20 00 00/136|Level of Knowledge and Habitual Concepts of Turkish Parents on Child Passenger Safety|"Too Small for a Car Seat". An Unnoticed Obstacle to the Proper Use of Car Seats!||Fatih University|Yes|Completed|June 2012|August 2012|Actual|August 2012|Actual|N/A|Observational|Observational Model: Case Control, Time Perspective: Cross-Sectional||2|Actual|98|||Both|18 Years|50 Years|Accepts Healthy Volunteers|Non-Probability Sample|The study will be done on mothers and fathers of babies brought to the first. control.|August 2012|August 16, 2012|July 21, 2012||No||No||https://clinicaltrials.gov/show/NCT01652274||81895|
NCT01653054|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|Merck IISP 40090/MMC11-01-050E|Anal Dysplasia in Patients With Inflammatory Bowel Disease|The Incidence of Abnormal Anal Pap Smears in Patients With Inflammatory Bowel Disease|HPVIBD|Montefiore Medical Center|No|Recruiting|October 2011|June 2013|Anticipated|June 2013|Anticipated|N/A|Interventional|Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic|2||Anticipated|40|||Both|18 Years|65 Years|No|||June 2012|July 27, 2012|July 26, 2012||No||No||https://clinicaltrials.gov/show/NCT01653054||81835|
NCT01652781|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|VZ-MDS-PI-0267|5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome|A Randomized, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of 5-day Azacitidine for Patients With Lower-risk Myelodysplastic Syndrome||Seoul St. Mary's Hospital|Yes|Recruiting|March 2012|December 2016|Anticipated|June 2016|Anticipated|Phase 2|Interventional|Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Anticipated|92|||Both|18 Years|80 Years|No|||November 2015|November 18, 2015|July 11, 2012||No||No||https://clinicaltrials.gov/show/NCT01652781||81856|
NCT01659008|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-01-FB-0003|Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding|Estradiol Versus Tranexamic Acid on the Amount and Duration of Acute Cyclic Heavy Menstrual Bleeding||Eastern Virginia Medical School|Yes|Recruiting|June 2012|March 2016|Anticipated|December 2015|Anticipated|N/A|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment|2||Anticipated|100|||Female|18 Years|45 Years|No|||February 2015|February 13, 2015|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659008||81384|
NCT01659021|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|GS-US-312-0119|Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia||Gilead Sciences|Yes|Active, not recruiting|December 2012|March 2017|Anticipated|January 2015|Actual|Phase 3|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment|2||Actual|261|||Both|18 Years|N/A|No|||November 2015|November 5, 2015|August 3, 2012|Yes|Yes||No||https://clinicaltrials.gov/show/NCT01659021||81383|
NCT01658982|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|12-004215|Cardiopulmonary Exercise Testing in Cirrhotic Patients: a Pilot Study|Cardiopulmonary Exercise Testing in Cirrhotic Patients: a Pilot Study||Mayo Clinic|No|Completed|August 2012|July 2013|Actual|June 2013|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Prospective||1|Actual|6|||Both|18 Years|N/A|No|Non-Probability Sample|pre liver transpalnt patietns with cirrhosis and end stage liver disease|November 2013|November 27, 2013|August 3, 2012||No||No||https://clinicaltrials.gov/show/NCT01658982||81386|
NCT01659333|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|2010/10|The Association Between Arterial Stiffness and Assessment of Hydration State in Peritoneal Dialysis Patients|Volume Status in Peritoneal Dialysis Patients With Using Different Determining Methods.||TC Erciyes University|No|Completed|January 2011|February 2012|Actual|January 2012|Actual|N/A|Observational|Observational Model: Cohort, Time Perspective: Cross-Sectional||2|Actual|60|||Both|18 Years|65 Years|No|Non-Probability Sample|We evaluated 60 patients' hydration states were measured by bioimpedance spectroscopy        methods. Patients were assigned to normo and hypervolemic groups according to Body        composition monitor(BCM) results. Also, normalized calf resistivity (nRho) was calculated        from resistance at 5 Khz and the levels of NT-proBNP were measured in all study patients.        The analyses of arterial stiffness were performed by using the pulse wave velocity (PWV)        technique on the patients. Additionally, all patients underwent conventional        echocardiography and their left ventricular diastolic functions were evaluated. The        patients were grouped using the BCM method because, according to the literature, this        method is the only one that can classify subjects in terms of volume conditions.|August 2012|August 4, 2012|August 4, 2012||No||No||https://clinicaltrials.gov/show/NCT01659333||81359|
NCT01662115|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|CRS-2012-05|Nicotine Gum Recovery After Colorectal Surgery|Does Nicotine Gum Enhance Bowel Recovery After Colorectal Surgery?||Cleveland Clinic Florida|No|Completed|August 2012|June 2014|Actual|June 2014|Actual|Phase 4|Interventional|Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment|3||Actual|7|||Both|18 Years|85 Years|No|||December 2015|December 11, 2015|August 7, 2012||No||No||https://clinicaltrials.gov/show/NCT01662115||81147|
NCT01662349|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|MOE - 121|Safety Study of Plasma Treatment System to Treat Back Acne|A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Back Acne||Moe Medical Devices||Terminated|August 2012|||June 2013|Actual|N/A|Interventional|Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment|1||Actual|8|||Both|18 Years|40 Years|No|||March 2016|March 21, 2016|August 2, 2012|Yes|Yes|The study was stopped due to other research priorities.|No||https://clinicaltrials.gov/show/NCT01662349||81130|
NCT01662336|ClinicalTrials.gov processed this data on March 24, 2016|03/24/2016|P13-566|Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program|Real Life Effectiveness of KASA: A Prospective Observational Cohort Study||AbbVie|No|Active, not recruiting|June 2012|September 2016|Anticipated|September 2016|Anticipated|N/A|Observational